




APPROVED DRUG PRODUCTS

WITH

**THERAPEUTIC
EQUIVALENCE
EVALUATIONS**

43rd EDITION

**THE PRODUCTS IN THIS LIST HAVE BEEN APPROVED UNDER
SECTION 505 OF THE FEDERAL FOOD, DRUG, AND COSMETIC ACT.**

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
FOOD AND DRUG ADMINISTRATION
OFFICE OF MEDICAL PRODUCTS AND TOBACCO
CENTER FOR DRUG EVALUATION AND RESEARCH
OFFICE OF GENERIC DRUGS
OFFICE OF GENERIC DRUG POLICY

2023

APPROVED DRUG PRODUCTS with THERAPEUTIC EQUIVALENCE EVALUATIONS

The products in this list have been approved under section 505 of the Federal Food, Drug, and Cosmetic Act. This volume is current through December 31, 2022.

43rd EDITION



U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
FOOD AND DRUG ADMINISTRATION
OFFICE OF MEDICAL PRODUCTS AND TOBACCO
CENTER FOR DRUG EVALUATION AND RESEARCH
OFFICE OF GENERIC DRUGS
OFFICE OF GENERIC DRUG POLICY

2023

**FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUG EVALUATION AND RESEARCH**

**APPROVED DRUG PRODUCTS
With
Therapeutic Equivalence Evaluations**

CONTENTS

PAGE

PREFACE TO FORTY THIRD EDITION.....	iv
1.0 INTRODUCTION	vi
1.1 Content and Exclusion.....	vi
1.2 Therapeutic Equivalence-Related Terms	vii
1.3 Further Guidance on Bioequivalence	ix
1.4 Reference Listed Drug and Reference Standard	x
1.5 General Policies and Legal Status	xi
1.6 Practitioner/User Responsibilities	xi
1.7 Therapeutic Equivalence Evaluations Codes	xii
1.8 Description of Certain Special Situations	xx
1.9 Therapeutic Equivalence Code Change for a Drug Entity	xxiii
1.10 Change of the Therapeutic Equivalence Evaluation for a Single Product	xxiii
1.11 Discontinued Section	xxiv
1.12 Changes to the Orange Book	xxiv
1.13 Availability of the Edition.....	xxv
2.0 HOW TO USE THE DRUG PRODUCTS LISTS	2-1
2.1 Key Sections for Using the Drug Product Lists	2-1
2.2 Drug Product Illustration	2-3
2.3 Therapeutic Equivalence Evaluations Illustration	2-4
DRUG PRODUCT LISTS	
Prescription Drug Product List	3-1
OTC Drug Product List	4-1
Drug Products with Approval under Section 505 of the FD&C Act Administered by the Center for Biologics Evaluation and Research List	5-1
Discontinued Drug Product List	6-1
Orphan Products Designations and Approvals List	7-1
Drug Products Which Must Demonstrate in vivo Bioavailability Only if Product Fails to Achieve Adequate Dissolution	8-1
APPENDICES	
A. Product Name Index	A-1
B. Product Name Index Listed by Applicant	B-1
C. Uniform Terms	C-1
PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	AD1
A. Patent and Exclusivity Lists	ADA1
B. Patent and Exclusivity Terms	ADB1

**FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUG EVALUATION AND RESEARCH**

**APPROVED DRUG PRODUCTS
With
Therapeutic Equivalence Evaluations**

PREFACE TO FORTY THIRD EDITION

The publication, *Approved Drug Products With Therapeutic Equivalence Evaluations* (the List, commonly known as the Orange Book), identifies drug products approved on the basis of safety and effectiveness by the Food and Drug Administration (FDA) under the Federal Food, Drug, and Cosmetic Act (the FD&C Act). The main criterion for the inclusion of any product is that the product is the subject of an application with an approval that has not been withdrawn for safety or effectiveness reasons. Inclusion of products in the Orange Book is independent of any current regulatory action being taken administratively or judicially against a drug product. In addition, the Orange Book contains therapeutic equivalence evaluations for approved multisource prescription drug products. These evaluations have been prepared to serve as public information and advice to state health agencies, prescribers, and pharmacists to promote public education in the area of drug product selection and to foster containment of health care costs. Therapeutic equivalence evaluations in this publication are not official FDA actions affecting the legal status of products under the FD&C Act.

Background of the Publication. To contain drug costs, virtually every state has adopted laws and/or regulations that encourage the substitution of drug products. These state laws generally require either that substitution be limited to drugs on a specific list (the positive formulary approach) or that it be permitted for all drugs except those prohibited by a particular list (the negative formulary approach). Because of the number of requests in the late 1970s for FDA assistance in preparing both positive and negative formularies, it became apparent that FDA could not serve the needs of each state on an individual basis. The Agency also recognized that providing a single list based on common criteria would be preferable to evaluating drug products on the basis of differing definitions and criteria in various state laws. As a result, on May 31, 1978, the Commissioner of the Food and Drug Administration sent a letter to officials of each state announcing FDA's intent to provide a list of all prescription drug products that are approved by FDA for safety and effectiveness, along with therapeutic equivalence determinations for multisource prescription products.

The Orange Book was distributed as a proposal in January 1979. It included only currently marketed prescription drug products approved by FDA through new drug applications (NDAs) and abbreviated new drug applications (ANDAs) under the provisions of Section 505 of the FD&C Act and FDA regulations at that time.

The therapeutic equivalence evaluations in the Orange Book reflect FDA's application of specific criteria to the multisource prescription drug products listed in the Orange Book and approved under Section 505 of the FD&C Act. These evaluations are presented in the form of code letters that indicate the basis for the evaluation made. An explanation of the codes appears in the *Introduction*.

A complete discussion of the background and basis of FDA's therapeutic equivalence evaluation policy was published in the *Federal Register* on January 12, 1979 (44 FR 2932). The final rule, which includes FDA's responses to the public comments on the proposal, was published in the *Federal Register* on October 31, 1980 (45 FR 72582). The first publication of the Orange Book in October 1980, concurrent with finalization of the rule, incorporated appropriate revisions. Each subsequent edition has included new approvals and made appropriate changes in data.

On September 24, 1984, the President signed into law the Drug Price Competition and Patent Term Restoration Act of 1984 (Hatch-Waxman Amendments). The Hatch-Waxman Amendments amended the FD&C Act to establish, among other things, the 505(b)(2) and 505(j) approval pathways. The Hatch-Waxman Amendments require that FDA, among other things, make publicly available a list of approved drug products with monthly supplements. The Orange Book and its monthly Cumulative Supplements satisfy this requirement. The *Addendum* to this publication identifies drugs that have qualified under the FD&C Act for periods of exclusivity and provides patent information concerning the approved drug products in the Orange Book. The *Addendum* also provides additional information that may be helpful to those submitting an NDA under section 505(b) of the FD&C Act or an ANDA under section 505(j) of the FD&C Act to the Agency.

The Agency intends to use this publication to further its objective of obtaining input and comment on the publication itself and related Agency procedures. Therefore, if you have comments on how the publication can be improved, please send them to the Central Document Room, Attn: Director, Division of Orange Book Publication and Regulatory Assessment (DOBPR), Office of Generic Drug Policy, Center for Drug Evaluation and Research, Food and Drug Administration, 5901-B Amundson Rd., Beltsville, MD 20705-1266. Comments received are publicly available to the extent allowable under the Freedom of Information Act and FDA regulations.

1.0 INTRODUCTION

1.1 Content and Exclusion

The Orange Book is composed of four parts: (1) approved prescription drug products with therapeutic equivalence evaluations; (2) approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs; (3) drug products with approval under Section 505 of the FD&C Act administered by the Center for Biologics Evaluation and Research; and (4) a cumulative list of approved products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn from sale for safety or effectiveness reasons, or have had their approvals withdrawn for other than safety or effectiveness reasons subsequent to being discontinued from marketing.¹ This publication also includes indices of prescription and OTC drug products by proprietary name (brand name or trade name) or, if no proprietary name exists, established name of the active ingredient and by applicant name, which have been abbreviated for this publication. Established names for active ingredients generally conform to compendial names or *United States Adopted Names* (USAN) as described in 21 CFR 299.4(e). A list of uniform terms is provided in Appendix C.

The *Addendum* contains patent and exclusivity information for the Prescription, OTC, Discontinued Drug Product Lists, and for the Drug Products with Approval under Section 505 of the FD&C Act Administered by the Center for Biologics Evaluation and Research. The publication may include additional information that the Agency deems appropriate to disseminate.

Prior to the 6th Edition, the publication had excluded OTC drug products and drug products with approval under Section 505 of the FD&C Act administered by the Center for Biologics Evaluation and Research. The Hatch-Waxman Amendments required the Agency to begin publishing an up-to-date list of all marketed drug products, OTC as well as prescription, that have been approved for safety and effectiveness and for which NDAs are required.

Under the FD&C Act, some drug products are given tentative approvals. The Agency will not include drug products with tentative approvals in the Orange Book because a drug product that is granted tentative approval is not an approved drug product. Tentative approval lists by month are available on FDA's website Drugs@FDA. When the tentative approval becomes a final approval through a subsequent action letter to the applicant, the Agency will list the drug product and the date of approval in the appropriate approved drug product list. In addition, we note that Section 505(x) of the FD&C Act affects the date of approval for certain drug products subject to scheduling under the Controlled Substances Act. For these drug products subject to scheduling, the Agency will list the drug product on FDA's website Drugs@FDA upon approval under section 505(c) of the FD&C Act, and will list the drug product in the Orange Book upon the date of approval as determined under Section 505(x).

¹ Generally, newly approved products are added to the Active Section of the Orange Book (i.e., the Prescription Drug Product List or the Over-the-Counter Drug Product List), depending on the dispensing requirements (prescription or OTC) or approval authority, unless the Division of Orange Book Publication and Regulatory Assessment is otherwise notified before publication. See Section 1.12.

The Orange Book identifies the application holder of a drug product and does not identify distributors or repackagers.

1.2 Therapeutic Equivalence-Related Terms

Pharmaceutical Equivalents. Pharmaceutical equivalents are drug products in identical dosage forms and route(s) of administration that contain identical amounts of the identical active drug ingredient, i.e., the same salt or ester of the same therapeutic moiety, or, in the case of modified-release dosage forms that require a reservoir or overage or such forms as prefilled syringes where the residual volume may vary, that deliver identical amounts of the active drug ingredient over the identical dosing period; do not necessarily contain the same inactive ingredients; and meet the identical compendial or other applicable standard of identity, strength, quality, and purity, including potency and, where applicable, content uniformity, disintegration times, and/or dissolution rates.² They may differ in characteristics such as shape, scoring configuration, release mechanisms, packaging, excipients (including colors, flavors, preservatives), expiration date/time, and, within certain limits, labeling.

Pharmaceutical Alternatives. Pharmaceutical alternatives are drug products that contain the identical therapeutic moiety, or its precursor, but not necessarily in the same amount or dosage form, or the same salt or ester (e.g., tetracycline hydrochloride, 250 mg capsules vs. tetracycline phosphate complex, 250 mg capsules; quinidine sulfate, 200 mg tablets vs. quinidine sulfate, 200 mg capsules).³ Each such drug product individually meets either the identical or its own respective compendial or other applicable standard of identity, strength, quality, and purity, including potency and, where applicable, content uniformity, disintegration times, and/or dissolution rates.⁴ Different dosage forms and strengths within a product line by a single manufacturer are pharmaceutical alternatives, as are extended-release products when compared with immediate-release or standard-release formulations of the same active ingredient.

Therapeutic Equivalents. Approved drug products are considered to be therapeutic equivalents if they are pharmaceutical equivalents for which bioequivalence has been demonstrated, and they can be expected to have the same clinical effect and safety profile when administered to patients under the conditions specified in the labeling.⁵

FDA classifies as therapeutically equivalent those drug products that meet the following general criteria: (1) they are approved as safe and effective; (2) they are pharmaceutical equivalents in that they (a) contain identical amounts of the identical active drug ingredient in the identical dosage form and route of administration, and (b) meet compendial or other applicable standards of strength, quality, purity, and identity; (3) they are bioequivalent in that (a) they do not present a known or potential bioequivalence problem, and they meet an acceptable *in vitro* standard, or (b) if they do present such a known or potential problem, they are shown to meet an appropriate bioequivalence standard; (4) they are adequately labeled; and (5) they are manufactured in compliance with Current Good Manufacturing Practice regulations. The concept of therapeutic equivalence applies only to drug products containing the identical active ingredient(s) and does not encompass a comparison of different therapeutic agents used for the same

² 21 CFR 314.3(b).

³ See 21 CFR 314.3(b).

⁴ 21 CFR 314.3(b).

⁵ 21 CFR 314.3(b).

condition (e.g., meperidine hydrochloride vs. morphine sulfate for the treatment of pain). Any drug product in the Orange Book repackaged and/or distributed by other than the applicant is considered to be therapeutically equivalent to the applicant's drug product even if the applicant's drug product is single source or coded as non-equivalent (e.g., **BN**). Distributors or repackagers of an applicant's drug product are not identified in the Orange Book.

FDA considers drug products to be therapeutically equivalent if they meet the criteria outlined above, even though they may differ in certain other characteristics such as shape, scoring configuration, release mechanisms, packaging, excipients (including colors, flavors, preservatives), expiration date/time, certain aspects of labeling (e.g., the presence of specific pharmacokinetic information), and storage conditions. When such differences are important in the care of a particular patient, it may be appropriate for the prescribing physician to require that a specific product be dispensed as a medical necessity. With this limitation, however, FDA believes that products classified as therapeutically equivalent can be substituted with the full expectation that the substituted product can be expected to have the same clinical effect and safety profile as the prescribed product when administered to patients under the conditions specified in the labeling.

Strength. Strength refers to the amount of drug substance contained in, delivered, or deliverable from a drug product, which includes: (1)(a) the total quantity of drug substance in mass or units of activity in a dosage unit or container closure (e.g., weight/unit dose, weight/volume or weight/weight in a container closure, or units/volume or units/weight in a container closure); and/or, as applicable, (b) the concentration of the drug substance in mass or units of activity per unit volume or mass (e.g., weight/weight, weight/volume, or units/volume); or (2) such other criteria the Agency establishes for determining the amount of drug substance contained in, delivered, or deliverable from a drug product if the weights and measures described in clause (1)(a) do not apply (e.g., certain drug-device combination products for which the amount of drug substance is emitted per use or unit time).⁶ Note that if the criteria the Agency establishes for determining and expressing the amount of drug substance in a product evolves over time, the Agency generally does not intend to revise the expressions of strength for drug products already included in the Orange Book, but rather intends to apply the criteria prospectively to drug products added to the Orange Book.

Although the strength of drug products in the Orange Book is generally expressed in terms of the amount of drug substance (active ingredient) in the drug product, it is sometimes expressed in terms of the amount of the active moiety.⁷ For example, certain drug products included in the Orange Book include a designation of "EQ" next to their expression of strength. This "EQ" designation generally is used in connection with salt drug products to indicate that the strength of such drug product is being expressed in terms of the equivalent strength of the active moiety (e.g., "EQ 200 MG BASE"), rather than in terms of the strength of the active ingredient.

Bioavailability. Bioavailability is the rate and extent to which the active ingredient or active moiety is absorbed from a drug product and becomes available at the site of drug action. For drug products that are not intended to be absorbed into the bloodstream, bioavailability may be assessed

⁶ 21 CFR 314.3(b).

⁷ Active moiety is the molecule or ion, excluding those appended portions of the molecule that cause the drug to be an ester, salt (including a salt with hydrogen or coordination bonds), or other noncovalent bonds (such as a complex, chelate, or clathrate) of the molecule, responsible for the physiological or pharmacological action of the drug substance. 21 CFR 314.3(b).

by scientifically valid measurements intended to reflect the rate and extent to which the active ingredient or active moiety becomes available at the site of drug action.⁸

Bioequivalence. Bioequivalence is the absence of a significant difference in the rate and extent to which the active ingredient or active moiety in pharmaceutical equivalents or pharmaceutical alternatives becomes available at the site of drug action when administered at the same molar dose under similar conditions in an appropriately designed study.⁹ Section 505(j)(8)(B) of the FD&C Act describes certain conditions under which a test drug and reference listed drug (RLD)(see Section 1.4) shall be considered bioequivalent:

- (i) the rate and extent of absorption of the [test] drug do not show a significant difference from the rate and extent of absorption of the [reference] listed drug when administered at the same molar dose of the therapeutic ingredient under similar experimental conditions in either a single dose or multiple doses; or
- (ii) the extent of absorption of the [test] drug does not show a significant difference from the extent of absorption of the [reference] listed drug when administered at the same molar dose of the therapeutic ingredient under similar experimental conditions in either a single dose or multiple doses and the difference from the [reference] listed drug in the rate of absorption of the drug is intentional, is reflected in its proposed labeling, is not essential to the attainment of effective body drug concentrations on chronic use, and is considered medically insignificant for the drug.

Where these above methods are not applicable (e.g., for drug products that are not intended to be absorbed into the bloodstream), other scientifically valid *in vivo* or *in vitro* test methods to demonstrate bioequivalence may be appropriate.

For example, bioequivalence may sometimes be demonstrated using an *in vitro* bioequivalence standard, especially when such an *in vitro* test has been correlated with human *in vivo* bioavailability data. In other situations, bioequivalence may sometimes be demonstrated through comparative clinical trials or pharmacodynamic studies.¹⁰

1.3 Further Guidance on Bioequivalence

FDA's regulations and guidance documents provide additional information regarding bioequivalence and bioavailability, including methodologies and statistical criteria used to establish the bioequivalence of drug products.¹¹

⁸ 21 CFR 314.3(b).

⁹ 21 CFR 314.3(b).

¹⁰ 21 CFR 320.24.

¹¹ We note that prior to the 36th edition of the Orange Book, the Preface to the Orange Book included a section entitled "Statistical Criteria for Bioequivalence." Please see FDA's regulations and guidance documents for additional information regarding bioequivalence and bioavailability. See generally 21 CFR part 320. See FDA Drugs guidance Web page at <https://www.fda.gov/drugs/guidance-compliance-regulatory-information/guidances-drugs> and FDA Drugs guidance (Product-Specific Guidances for Generic Drug Development) Web page at <https://www.fda.gov/drugs/guidances-drugs/product-specific-guidances-generic-drug-development>.

1.4 Reference Listed Drug and Reference Standard

A reference listed drug is the listed drug¹² identified by FDA as the drug product upon which an applicant relies in seeking approval of its ANDA.¹³ FDA's general practice is to designate as RLDs drug products that have been approved for safety and effectiveness under section 505(c) of the FD&C Act. For an ANDA based on an approved suitability petition (a petitioned ANDA), the reference listed drug generally is the listed drug referenced in the approved suitability petition.¹⁴

A reference standard is the drug product selected by FDA that an applicant seeking approval of an ANDA must use in conducting an *in vivo* bioequivalence study required for approval.¹⁵ FDA generally selects a single reference standard that ANDA applicants must use in *in vivo* bioequivalence testing. Ordinarily, FDA will select the reference listed drug as the reference standard. However, in some instances, the reference listed drug and the reference standard may be different. For example, where the reference listed drug has been withdrawn from sale for reasons other than safety or effectiveness, FDA may select an ANDA that is therapeutically equivalent to this reference listed drug as the reference standard.

FDA identifies reference listed drugs in the Prescription Drug Product, OTC Drug Product, and Discontinued Drug Product Lists. Listed drugs identified as reference listed drugs represent drug products upon which an applicant can rely in seeking approval of an ANDA. FDA intends to update periodically the reference listed drugs identified in the Prescription Drug Product, OTC Drug Product, and Discontinued Drug Product Lists, as appropriate.

If FDA has not designated a reference listed drug for a drug product the applicant intends to duplicate, the potential applicant may submit a controlled correspondence to the Office of Generic Drugs to ask FDA to designate a reference listed drug for that drug product. Section 1.7, *Therapeutic Equivalence Evaluations Codes (products meeting necessary bioequivalence requirements)* explains the character coding system (e.g., **AB**, **AB1**, **AB2**, **AB3**...) for multisource prescription drug products listed under the same heading with two or more reference listed drugs.

FDA also identifies reference standards in the Prescription Drug Product and OTC Drug Product Lists. Listed drugs identified as reference standards represent FDA's best judgment at this time as to the appropriate comparator for purposes of conducting any *in vivo* bioequivalence studies required for approval.

A potential applicant should consult Agency guidance related to referencing approved drug products in ANDA submissions for information on submitting a request for selection of a reference standard. FDA may, on its own initiative, select a new reference standard when doing so will help to ensure that applications for generic drugs may be submitted and evaluated, e.g., in the event that the listed drug currently selected as the reference standard has been withdrawn from sale.

¹² A "listed drug" is a new drug product that has been approved under section 505(c) of the FD&C Act for safety and effectiveness or under section 505(j) of the FD&C Act, which has not been withdrawn or suspended under section 505(e)(1) through (5) or section 505(j)(6) of the FD&C Act, and which has not been withdrawn from sale for what FDA has determined are reasons of safety or effectiveness. Listed drug status is evidenced by the drug product's identification in the current edition of FDA's "Approved Drug Products With Therapeutic Equivalence Evaluations" (the list) as an approved drug. A drug product is deemed to be a listed drug on the date of approval for the NDA or ANDA for that drug product (21 CFR 314.3(b)).

¹³ 21 CFR 314.3(b).

¹⁴ 21 CFR 314.94(a)(3)(i).

¹⁵ 21 CFR 314.3(b).

If an applicant has a question related to the appropriate reference standard, it is recommended that an applicant planning to conduct an *in vivo* bioequivalence study submit a controlled correspondence to the Office of Generic Drugs.

1.5 General Policies and Legal Status

The Orange Book contains public information and advice. It does not mandate the drug products that are purchased, prescribed, dispensed, or substituted for one another, nor does it, conversely, mandate the products that should be avoided. To the extent that the Orange Book sets forth FDA's evaluations of the therapeutic equivalence of drug products that have been approved, it contains FDA's advice to the public, to practitioners, and to the states regarding drug product selection. These evaluations do not constitute determinations that any product is in violation of the FD&C Act or that any product is preferable to any other. Therapeutic equivalence evaluations are a scientific judgment based upon evidence, while generic substitution may involve social and economic policy administered by the states, e.g., reducing the cost of drugs to consumers. To the extent that the Orange Book identifies drug products approved under Section 505 of the FD&C Act, it sets forth information that the Agency is required to publish and that the public is entitled to under the Freedom of Information Act. Exclusion of a drug product from the Orange Book does not necessarily mean that the drug product is in violation of Section 505 of the FD&C Act, that such a product is not safe or effective, or that such a product is not therapeutically equivalent to other drug products. Rather, the exclusion may be based on the fact that FDA has not evaluated the safety, effectiveness, and quality of the drug product.

1.6 Practitioner/User Responsibilities

Professional care and judgment should be exercised in using the Orange Book. Evaluations of therapeutic equivalence for prescription drugs are based on scientific and medical evaluations by FDA. Products evaluated as therapeutically equivalent can be expected, in the judgment of FDA, to have the same clinical effect and safety profile when administered to patients under the conditions specified in the labeling. However, these products may differ in other characteristics that are not required by statute or regulation to be the same, such as shape, scoring configuration, release mechanisms, packaging, excipients (including colors, flavors, preservatives), expiration date/time, and, in some instances, labeling. If products with such differences are substituted for each other, there is a potential for patient confusion, e.g., due to differences in color or shape of tablets, inability to provide a given dose using a partial tablet if the proper scoring configuration is not available, or decreased patient acceptance of certain products because of flavor. There may also be patient-specific allergic reactions in rare cases due to a coloring or a preservative ingredient.

FDA evaluation of therapeutic equivalence in no way relieves practitioners of their professional responsibilities in prescribing and dispensing such products with due care and with appropriate information to individual patients. In those circumstances where the characteristics of a specific product, other than its active ingredient, are important in the therapy of a particular patient, the practitioner's prescribing of that product may be appropriate. Pharmacists must also be familiar with the different characteristics of therapeutically equivalent products, e.g., expiration dates/times and labeling directions for storage of the different products

(particularly for reconstituted products), so they can properly advise patients when one product is substituted for another.

Multisource and single-source drug products. In the Orange Book, FDA has evaluated for therapeutic equivalence only multisource prescription drug products approved under Section 505 of the FD&C Act, which in most instances means those pharmaceutical equivalents available (i.e., not on the Discontinued Drug Product list) from more than one manufacturer. For such products, a therapeutic equivalence code generally is included and product information is highlighted in bold face and underlined. Those products with approved applications that are single source (i.e., there is only one approved product available for that active ingredient, dosage form, route of administration, and strength) are also included in the Orange Book, but no therapeutic equivalence code is included with such products. Any drug product in the Orange Book repackaged and/or distributed by the applicant or some other person authorized by the applicant (e.g., an authorized generic) is considered to be therapeutically equivalent to the applicant's drug product even if the applicant's drug product is single source or coded as non-equivalent (e.g., **BN**). Distributors or repackagers of an applicant's drug product are not identified in the Orange Book. The details of therapeutic equivalence codes and the policies underlying them are discussed in Section 1.7, *Therapeutic Equivalence Evaluations Codes*.

Products in the Orange Book are identified by the names of the holders of approved applications (applicants) who may not necessarily be the manufacturer of the product. There are numerous entities other than the applicant that may be involved in the development, manufacturing, and/or marketing of a product. Products listed in the Orange Book are identified by the applicant's name (firm name on the Form FDA 356h in the application). Where the applicant's name does not appear on the label, a person wishing to relate a specific product to the applicant name in the Orange Book may refer to FDA's NDC Directory¹⁶ and match its search terms to information on the label, such as the NDC Code if available.

Every product in the Orange Book is subject at all times to regulatory action. From time to time, approved products may be found in violation of one or more provisions of the FD&C Act. In such circumstances, the Agency may commence appropriate enforcement action to correct the violation, if necessary, by securing removal of the product from the market by voluntary recall, seizure, or other enforcement actions. Such regulatory actions are, however, independent of the inclusion of a product in the Orange Book. The main criterion for inclusion of a product is that it has an NDA or ANDA that has been approved and that has not been withdrawn for safety or effectiveness reasons. FDA believes that retention of a violative product in the Orange Book will not have any significant adverse health consequences, because other legal mechanisms are available to the Agency to prevent the product's actual marketing. FDA may, however, change a product's therapeutic equivalence rating if the circumstances giving rise to the violation change or otherwise call into question the Agency's assessment of whether a product meets the criteria for therapeutic equivalence.

1.7 Therapeutic Equivalence Evaluations Codes

Generally, prescription drug products that the Agency considers multisource have been assigned a therapeutic equivalence code. The coding system for therapeutic equivalence evaluations is designed to allow users to determine quickly whether the Agency has evaluated a particular approved

¹⁶ <https://www.fda.gov/drugs/drug-approvals-and-databases/national-drug-code-directory>.

prescription drug product (e.g., a particular strength of an approved drug that is not on the Discontinued Drug Product list) as therapeutically equivalent to other pharmaceutically equivalent prescription drug products (first letter) and to provide additional information on the basis of FDA's evaluations (second letter). With some exceptions (e.g., therapeutic equivalence evaluations for certain 505(b)(2) applications), the therapeutic equivalence evaluation date is the same as the approval date.

The two basic categories into which multisource drugs have been placed are indicated by the first letter of the relevant therapeutic equivalence code as follows:

A Drug products that FDA considers to be therapeutically equivalent to other pharmaceutically equivalent products, i.e., drug products for which:

- (1) there are no known or suspected bioequivalence problems. These are designated **AA, AN, AO, AP, or AT**, depending on the dosage form; or
- (2) actual or potential bioequivalence problems have been resolved with adequate *in vivo* and/or *in vitro* evidence supporting bioequivalence. These are designated **AB**.

B Drug products that FDA at this time, considers not to be therapeutically equivalent to other pharmaceutically equivalent products, i.e.,

drug products for which actual or potential bioequivalence problems have not been resolved by adequate evidence of bioequivalence. Often the problem is with specific dosage forms rather than with the active ingredients. These are designated **BC, BD, BE, BN, BP, BR, BS, BT, BX, or B***.

Individual drug products have been evaluated as therapeutically equivalent to the reference product in accordance with the definitions and policies outlined below:

"A" CODES

Drug products that are considered to be therapeutically equivalent to other pharmaceutically equivalent products.

"A" products are those for which there are no known or suspected bioequivalence problems or for which actual or potential bioequivalence problems have been resolved with adequate *in vivo* and/or *in vitro* evidence supporting bioequivalence. Drug products designated with an "A" code fall under one of two main policies:

- (1) for those active ingredients or dosage forms for which no *in vivo* bioequivalence issue is known or suspected, the information necessary to show bioequivalence between pharmaceutically equivalent products is either presumed and considered self-evident (based on other information in the application for some dosage forms (e.g., solutions)), or satisfied by a showing that an acceptable *in vitro* approach is met. A therapeutically equivalent rating is assigned such products so long as they are manufactured in accordance with Current Good Manufacturing Practice regulations and meet the other requirements of their approved applications (these are designated **AA, AN, AO, AP, or AT**, depending on the dosage form, as described below); or

- (2) for those Drug Efficacy Study Implementation (DESI) drug products containing active ingredients or dosage forms that have been identified by FDA as having actual or potential bioequivalence problems, and for post-1962 drug products presenting a potential bioequivalence problem, an evaluation of therapeutic equivalence is assigned to pharmaceutical equivalents only if the approved application contains adequate scientific evidence establishing through *in vivo* and/or *in vitro* studies the bioequivalence of the product to a selected reference product (these products are designated as **AB**).

There are some general principles that may affect the substitution of pharmaceutically equivalent products in specific cases. Prescribers and dispensers of drugs should be alert to these principles so as to deal appropriately with situations that require professional judgment and discretion.

There may be labeling differences among pharmaceutically equivalent products that require attention on the part of the health professional (e.g., pharmaceutically equivalent powders to be reconstituted for administration as oral or injectable liquids may vary with respect to their expiration time or storage conditions after reconstitution). FDA's determination that such products are therapeutically equivalent is applicable only when each product is reconstituted, stored, and used under the conditions specified in its labeling.

The Agency may use notes in this publication to point out special situations, such as potential differences between two drug products that have been evaluated as bioequivalent and otherwise therapeutically equivalent, when they should be brought to the attention of health professionals. These notes are contained in Section 1.8, *Description of Certain Special Situations*. For example, in certain instances, there may be variations among therapeutically equivalent products in their use or in conditions of administration. When such variations may, in the Agency's opinion, affect prescribing or substitution decisions by health professionals, a note may be added to Section 1.8.

For example, occasionally a situation may arise in which changes in a listed drug product after its approval (for example, a change in dosing interval) may have an impact on the substitutability of already approved generic versions of that product that were rated by the Agency as therapeutically equivalent to the listed product. When such changes in the listed drug product are considered by the Agency to have a significant impact on therapeutic equivalence, the Agency will change the therapeutic equivalence ratings for other versions of the drug product unless the manufacturers of those other versions of the product provide additional information to assure equivalence under the changed conditions. Pending receipt of the additional data, the Agency may add a note to Section 1.8, or, in rare cases, may even change the therapeutic equivalence rating.

In some cases (e.g., Isolyte® S w/ Dextrose 5% in Plastic Container and Plasma-Lyte® 148 and Dextrose 5% in Plastic Container), closely related products are listed as containing the same active ingredients, but in somewhat different amounts. In determining which of these products are pharmaceutically equivalent, generally the Agency has considered products to be pharmaceutically equivalent with labeled strengths of an ingredient that do not vary by more than 1%.

Different salts, esters or other noncovalent derivatives (such as a complex, chelate, or clathrate) of the same active moiety are regarded as different active ingredients. For the purpose of this publication, products containing such different active ingredients are considered pharmaceutical

alternatives and, thus, not therapeutically equivalent. Anhydrous and hydrated entities, as well as different polymorphs, are considered to be the same active ingredient and are expected to meet the same standards for identity to be considered pharmaceutical equivalents and therapeutic equivalents.

The codes in this book are not intended to preclude health care professionals from converting pharmaceutically different concentrations into pharmaceutical equivalents using accepted professional practice.

Where package size variations have therapeutic implications, products so packaged have not been considered pharmaceutically equivalent. For example, some oral contraceptives are supplied in 21-tablet and 28-tablet packets; the 28-tablet packets contain 7 placebo or iron tablets. These two packaging configurations are not regarded as pharmaceutically equivalent; thus, they are not designated as therapeutically equivalent.

Preservatives and other inactive ingredients may differ among some therapeutically equivalent drug products. These differences do not affect FDA's evaluation of therapeutic equivalence except in cases where these components may influence bioequivalence or routes of administration.

The specific sub-codes for those drugs evaluated as therapeutically equivalent and the policies underlying these sub-codes follow:

AA Products in conventional dosage forms not presenting bioequivalence problems

Multisource drug products coded as **AA** contain active ingredients and are in dosage forms that are not regarded as presenting either actual or potential bioequivalence problems or drug quality or standards issues. However, all oral dosage forms must, nonetheless, meet an appropriate *in vitro* bioequivalence standard that is acceptable to the Agency in order to be approved.

AB, AB1, AB2, AB3... Products meeting necessary bioequivalence requirements

Multisource drug products listed under the same heading (i.e., identical active ingredient(s), dosage form, and route(s) of administration) and having the same strength (see Section 1.2, *Therapeutic Equivalence-Related Terms, Strength*) generally will be coded **AB** if data and information are submitted demonstrating bioequivalence.

In certain instances, a number is added to the end of the **AB** code to make a three character code (i.e., **AB1**, **AB2**, **AB3**, etc.). Three-character codes generally are assigned only in situations when more than one reference listed drug of the same strength has been designated under the same heading. If a study is submitted that demonstrates bioequivalence to a reference listed drug product, the generic product will be given the same three-character code as the reference listed drug it was compared against. For example, Adalat® CC and Procardia XL®, extended-release tablets, are listed under the active ingredient nifedipine. These drug products, listed under the same heading, are not bioequivalent to each other. Adalat® CC and Procardia XL® have been assigned ratings of **AB1** and **AB2**, respectively. Generic drug products deemed by FDA to be bioequivalent to Adalat® CC and Procardia XL® have been approved. As a result, the generic drug products bioequivalent to Adalat® CC have been assigned a rating of **AB1** and those bioequivalent to Procardia XL® have been assigned a rating of **AB2**. (The assignment of an **AB1** or **AB2** rating to a specific product does not imply product preference.) Even though drug products of distributors and/or repackagers are not included in the Orange Book, they are considered

therapeutically equivalent to the applicant's drug product if the applicant's drug product is rated either with an **AB** or three-character code or is single source in the Orange Book. Drugs coded as **AB** under a heading are considered therapeutically equivalent only to other drugs coded as **AB** under that heading. Drugs coded with a three-character code under a heading are considered therapeutically equivalent only to other drugs coded with the same three-character code under that heading.

AN Solutions and powders for aerosolization

Uncertainty regarding the therapeutic equivalence of aerosolized products arises primarily because of differences in the drug delivery system. Solutions and powders intended for aerosolization that are marketed for use in general-use delivery systems are considered to be pharmaceutically and therapeutically equivalent and are coded **AN**. Those products that are compatible only with a specific delivery system or those products that are packaged in and with a specific delivery system are coded **BN**, unless they have met an appropriate bioequivalence standard and are otherwise determined to be therapeutically equivalent. Solutions or suspensions in a specific delivery system will be coded **AN** if the bioequivalence standard is based upon *in vitro* methodology. If bioequivalence needs to be demonstrated by *in vivo* methodology, then the drug products will be coded **AB**.

AO Injectable oil solutions

The absorption of drugs in injectable (parenteral) oil solutions may vary substantially with the type of oil employed as a vehicle and the concentration of the active ingredient. Injectable oil solutions are therefore considered to be pharmaceutically and therapeutically equivalent only when the active ingredient, its concentration, and the type of oil used as a vehicle are all identical.

AP Injectable aqueous solutions and, in certain instances, intravenous non-aqueous solutions

It should be noted that even though injectable (parenteral) products under a specific listing may be evaluated as therapeutically equivalent, there may be important differences among the products in the general category, Injectable; Injection. For example, historically some injectable products that are rated therapeutically equivalent are labeled for different routes of administration. In addition, some products evaluated as therapeutically equivalent may have different preservatives or no preservatives at all. Injectable products available as dry powders for reconstitution, concentrated sterile solutions for dilution, or sterile solutions ready for injection are pharmaceutical alternative drug products. They are not rated as therapeutically equivalent (AP) to each other even if these pharmaceutical alternative drug products are designed to produce the same concentration prior to injection and are similarly labeled. Consistent with accepted professional practice, it is the responsibility of the prescriber, dispenser, or individual administering the product to be familiar with a product's labeling to assure that it is given only by the route(s) of administration stated in the labeling.

Certain commonly used large volume intravenous products in glass containers are not included in the Orange Book (e.g., dextrose injection 5%, dextrose injection 10%, sodium chloride injection 0.9%) since these

products are on the market without FDA approval and FDA has not published conditions for marketing such parenteral products under approved NDAs. When packaged in plastic containers, however, FDA regulations require approved applications prior to marketing. Approval then depends on, among other things, the extent of the available safety data involving the specific plastic component of the product. All large volume parenteral products are manufactured under similar standards, regardless of whether they are packaged in glass or plastic. Thus, FDA has no reason to believe that the packaging container of large volume parenteral drug products that are pharmaceutically equivalent would have any effect on their therapeutic equivalence.

Consistent with the definition of strength included in Section 1.2, *Therapeutic Equivalence-Related Terms*, the strength of parenteral drug products generally is identified by both the total drug content and the concentration of drug substance in a container approved by FDA.¹⁷ In the past, the strength of liquid parenteral drug products in the Orange Book has not been fully displayed. Rather, the strength of liquid parenteral drug products in the Orange Book has been displayed in terms of concentration, expressed as x mg/mL. Generally, the amount of dry powder or lyophilized powder in a container is identified as the strength, expressed as x mg/vial.

However, FDA subsequently realized that the format of the Orange Book with respect to parenteral solutions should be changed to reflect that each strength of a drug is considered to be a separate listed drug. The Orange Book generally displays the strength of new approvals of parenteral solutions. Previously (i.e., prior to 2003), we would have displayed only the concentration of an approved parenteral solution, e.g. 1 mg/mL. For example, if this application had a 125 mL and 250 mL container approved, we would now display two product strengths, listing both total drug content and concentration of drug substance in the relevant approved container, e.g. 125 mg/125 mL (1 mg/mL) and 250 mg/250 mL (1 mg/mL).

AT Topical products

There are a variety of topical dosage forms available for dermatologic, ophthalmic, otic, rectal, and vaginal administration, including creams, gels, lotions, oils, ointments, pastes, solutions, sprays, suppositories, and inserts. Even though different topical dosage forms may contain the same active ingredient and potency, these dosage forms are not considered pharmaceutically equivalent. Therefore, they are not considered therapeutically equivalent. All solutions and DESI drug products containing the same active ingredient in the same topical dosage form for which a waiver of *in vivo* bioequivalence has been granted, or the application contains adequate scientific evidence establishing through an *in vitro* approach the bioequivalence of the product to a selected reference product, and for which chemistry and manufacturing processes are adequate to demonstrate bioequivalence, are considered therapeutically equivalent and coded **AT**. Pharmaceutically equivalent topical products that raise questions of bioequivalence and for which a waiver of *in vivo* bioequivalence has not been granted, including all post-1962 non-solution topical drug products, are coded **AB** when supported by adequate *in vivo* bioequivalence data, and **BT** in the absence of such data.

¹⁷ The strengths of certain parenteral drug products, including contrast agents, may be expressed as a percentage.

"B" CODES

Drug products that FDA, at this time, considers not to be therapeutically equivalent to other pharmaceutically equivalent products.

"B" products, for which actual or potential bioequivalence problems have not been resolved by adequate evidence of bioequivalence, often have a problem with specific dosage forms rather than with the active ingredients. Drug products designated with a "B" code fall under one of three main policies:

- (1) the drug products contain active ingredients or are manufactured in dosage forms that have been identified by the Agency as having documented bioequivalence problems or a significant potential for such problems and for which no adequate studies demonstrating bioequivalence have been submitted to FDA; or
- (2) the quality standards are inadequate or FDA has an insufficient basis to determine therapeutic equivalence; or
- (3) the drug products are under regulatory review.

The specific coding definitions and policies for the "B" sub-codes are as follows:

B* Drug products requiring further FDA investigation and review to determine therapeutic equivalence

The code **B*** is assigned to products previously assigned an **A** or **B** code when FDA receives new information that raises a significant question regarding therapeutic equivalence that can be resolved only through further Agency investigation and/or review of data and information submitted by the applicant. The **B*** code signifies that the Agency will take no position regarding the therapeutic equivalence of the product until the Agency completes its investigation and review.

BC Extended-release dosage forms (capsules, injectables and tablets)

Extended-release tablets are formulated in such a manner as to make the contained drug substance available over an extended period of time following ingestion.

Although bioavailability studies have been conducted on these dosage forms, they may be subject to bioavailability differences, primarily because applicants developing extended-release products for the same active ingredient rarely employ the same formulation approach. FDA, therefore, does not consider different extended-release dosage forms containing the same active ingredient in equal strength to be therapeutically equivalent unless equivalence between individual products in both rate and extent has been specifically demonstrated through appropriate bioequivalence studies. Extended-release products for which such bioequivalence data have not been submitted are coded **BC**, while those for which such data are available have been coded **AB**.

BD Active ingredients and dosage forms with documented bioequivalence problems

The **BD** code denotes products containing active ingredients with known bioequivalence problems and for which adequate studies have not been

submitted to FDA demonstrating bioequivalence. Where studies showing bioequivalence have been submitted, the product has been coded **AB**.

BE Delayed-release oral dosage forms

Where the drug may be destroyed or inactivated by the gastric juice or where it may irritate the gastric mucosa, the use of "enteric" coatings is indicated. Such coatings are intended to delay the release of the medication until the tablet has passed through the stomach. Drug products in delayed-release dosage forms containing the same active ingredients are subject to significant differences in absorption. Unless otherwise specifically noted, the Agency considers different delayed-release products containing the same active ingredients as presenting a potential bioequivalence problem and codes these products **BE** in the absence of *in vivo* studies showing bioequivalence. If adequate *in vivo* studies have demonstrated the bioequivalence of specific delayed-release products, such products are coded **AB**.

BN Products in aerosol-nebulizer drug delivery systems

This code applies to drug solutions or powders that are marketed only as a component of, or as compatible with, a specific drug delivery system. There may, for example, be significant differences in the dose of drug and particle size delivered by different products of this type. Therefore, the Agency does not consider different metered aerosol dosage forms containing the same active ingredient(s) in equal strengths to be therapeutically equivalent unless the drug products meet an appropriate bioequivalence standard; such products are coded **AB**.

BP Active ingredients and dosage forms with potential bioequivalence problems

FDA's bioequivalence regulations (21 CFR 320.33) contain criteria and procedures for determining whether a specific active ingredient in a specific dosage form has a potential for causing a bioequivalence problem. It is FDA's policy to consider an ingredient meeting these criteria as having a potential bioequivalence problem even in the absence of positive data demonstrating inequivalence. Pharmaceutically equivalent products containing these ingredients in oral dosage forms are coded **BP** until adequate bioequivalence data are submitted, after which such products are coded **AB**. Injectable suspensions containing an active ingredient suspended in an aqueous or oleaginous vehicle have also been coded **BP**. Injectable suspensions are subject to bioequivalence problems because differences in particle size, polymorphic structure of the suspended active ingredient, or the suspension formulation can significantly affect the rate of release and absorption. FDA does not consider pharmaceutical equivalents of these products bioequivalent without adequate evidence of bioequivalence; such products would be coded **AB**.

BR Suppositories or enemas that deliver drugs for systemic absorption

The absorption of active ingredients from suppositories or enemas that are intended to have a systemic effect (as distinct from suppositories administered for local effect) can vary significantly from product to product. Therefore, FDA considers pharmaceutically equivalent systemic suppositories or enemas bioequivalent only if *in vivo* evidence of bioequivalence is available. In those cases where *in vivo* evidence is

available, the products are coded **AB**. If such evidence is not available, the products are coded **BR**.

BS Products having drug standard deficiencies

If the drug standards for an active ingredient in a particular dosage form are found by FDA to be deficient so as to prevent an FDA evaluation of either pharmaceutical or therapeutic equivalence, all drug products containing that active ingredient in that dosage form are coded **BS**. For example, if the standards permit a wide variation in pharmacologically active components of the active ingredient such that pharmaceutical equivalence is in question, all products containing that active ingredient in that dosage form are coded **BS**.

BT Topical products with bioequivalence issues

This code applies mainly to post-1962 dermatologic, ophthalmic, otic, rectal, and vaginal products for topical administration, including creams, gels, lotions, oils, ointments, pastes, solutions, sprays, suppositories, and inserts not intended for systemic drug absorption. Topical products evaluated as having acceptable clinical performance, but that are not bioequivalent to other pharmaceutically equivalent products or that lack sufficient evidence of bioequivalence, will be coded **BT**.

BX Drug products for which the data are insufficient to determine therapeutic equivalence

The code **BX** is assigned to specific drug products for which the data that have been reviewed by the Agency are insufficient to determine therapeutic equivalence under the policies stated in this document. In these situations, the drug products are presumed to be therapeutically inequivalent until the Agency has determined that there is adequate information to make a full evaluation of therapeutic equivalence.

1.8 Description of Certain Special Situations

Certain drugs listed in the Orange Book present special situations that merit further discussion. The following are descriptions of certain examples of those special situations:

Amino Acid and Protein Hydrolysate Injections. These products differ in the amount and kinds of amino acids they contain and, therefore, are not considered pharmaceutical equivalents. For this reason, these products are not considered therapeutically equivalent. At the same time, the Agency believes that it is appropriate to point out that where nitrogen balance is the sole therapeutic objective and individual amino acid content is not a consideration, pharmaceutical alternatives with the same total amount of nitrogen content may be expected to have the same clinical effect and safety profile when administered to patients under the conditions specified in the labeling.

Gaviscon®. Gaviscon® is an OTC product that has been marketed since September 1970. The active ingredients in this product, aluminum hydroxide and magnesium trisilicate, were reviewed by the Agency's OTC Antacid Panel and were considered to be safe and effective ingredients (Category I) by that Panel. However, the tablet failed to pass the antacid test that is required of all antacid products. The Agency, therefore, placed the tablet in Category III for lack of effectiveness. A full NDA with clinical studies was

submitted by Marion Laboratories, Inc., and approved by FDA on December 9, 1983. Gaviscon®'s activity in treating reflux acidity is made possible by the physical-chemical properties of the inactive ingredients, sodium bicarbonate and alginic acid. Therefore, *all ANDAs that cite Gaviscon® tablets as the reference listed drug must contain the inactive ingredients sodium bicarbonate and alginic acid.* A full NDA will be required to support the effectiveness of the drug product if different inactive ingredients are to be substituted for sodium bicarbonate or alginic acid or if different proportions of these ingredients are to be used.

Levothyroxine Sodium.¹⁸ Because there are multiple reference listed drugs for levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character therapeutic equivalence codes may be potentially confusing and inadequate for these drug products. Looking at the Orange Book listing alone for a product identified as a reference listed drug or reference standard, it may be difficult to determine to which therapeutic equivalence code the reference listed drugs and/or reference standard designation corresponds. For example, Unithroid 0.3 mg strength has been assigned the therapeutic equivalence codes AB1, AB2, and AB3 and it is identified as the reference listed drug and reference standard, but it is unclear that the reference listed drug and reference standard designations are associated with the AB1 therapeutic equivalence code.

Accordingly, FDA provides the following chart, which identifies (1) a reference listed drug for each therapeutic equivalence code in the Orange Book and (2) the reference standard products in the Active Section of the Orange Book.¹⁹

- Therapeutic equivalence has been established between products that have the same AB+number therapeutic equivalence code (i.e. AB1, AB2, AB3 or AB4).
- More than one therapeutic equivalence code may apply to some products. One common therapeutic equivalence code indicates therapeutic equivalence between products. For example, Unithroid has been assigned therapeutic equivalence codes AB1, AB2, and AB3, and therefore, Unithroid tablets are considered therapeutically equivalent to other levothyroxine sodium products of the same strength with these therapeutic equivalence codes.

TE Code	Proprietary Name	Applicant	Strength	App'l No	RLD	RS
AB1	UNITHROID	STEVENS J	0.3 MG	N021210	RLD	RS
AB2	SYNTHROID	ABBVIE	0.3 MG	N021402	RLD	RS

¹⁸ In previous editions of the Orange Book, FDA provided a chart outlining therapeutic equivalence codes for all 0.025 mg levothyroxine sodium drug products in the Active Section of the Orange Book. FDA has decided, for ease of review, to revise the chart to identify the NDAs for the reference listed drugs for each therapeutic equivalence code (i.e., AB1, AB2, AB3, and AB4), and their corresponding reference standards, which are identified in 0.2 and 0.3 mg strengths.

¹⁹ The chart is current as of the date of publication of the annual edition. See the most current monthly cumulative supplement for updates to this information available at <https://www.fda.gov/media/72973/download>. Please consult the Active Section for information on other strengths.

AB3	LEVOXYL	KING PHARMS	0.2 MG	N021301	RLD	RS
AB4	THYRO-TABS	ALVOGEN INC	0.3 MG	N021116	RLD	–
AB4	LEVOTHYROXINE SODIUM ²⁰	MYLAN	0.3 MG	A076187	–	RS

Patent Certification(s) and Reference Standard for ANDAs Duplicating a Drug Product Approved in a Petitioned ANDA. To submit an ANDA for a generic drug that is not the same as its reference listed drug because it has one different active ingredient in a fixed-combination drug product, or has a different route of administration, dosage form, or strength than that of the reference listed drug, an applicant first must obtain permission from FDA through what is known as a suitability petition pursuant to Section 505(j)(2)(C) of the FD&C Act. A petitioned ANDA relies on the reference listed drug described in the suitability petition. An ANDA seeking approval of a drug that is the same as a drug product approved in a petitioned ANDA should use as its reference listed drug, the reference listed drug that served as the basis for the approved suitability petition, and use the drug product approved in the petitioned ANDA as its reference standard for conducting an *in vivo* bioequivalence study required for approval. However, the reference listed drug for any such ANDA is generally the listed drug referenced in the approved suitability petition. The ANDA must include appropriate patent certification(s) and an exclusivity statement with respect to the reference listed drug that served as the basis for the approved suitability petition.²¹ (This concept also generally applies to an ANDA applicant that utilizes a reference standard that is not a reference listed drug, as such an application must include appropriate patent certification(s) and an exclusivity statement with respect to the reference listed drug.)

Waived exclusivity. If an NDA submitted under Section 505(b) of the FD&C Act qualifies for exclusivity under the FD&C Act, the exclusivity is generally listed in the Patent and Exclusivity Section of the Orange Book. If a drug product has received this exclusivity, FDA will not accept for review and/or will not approve, as applicable, other applications blocked by the relevant exclusivity. If the listed drug is also protected by one or more patents, the approval date for an ANDA or 505(b)(2) application that relies on the listed drug will be determined based on an analysis of the applicant's patent certification(s) or statement(s) for each relevant patent and the effect of relevant exclusivity listed in the Orange Book. However, the

²⁰ Alvogen, Inc's tablets (NDA 021116) (previously known as Levothroid) previously was listed in the Discontinued Drug Product List section of the Orange Book. It is the RLD for therapeutic equivalents identified with the AB4 code. During this time, Mylan's levothyroxine product (ANDA 076187) was selected as the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. It remains the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. If an ANDA that uses Mylan's levothyroxine product as its reference standard is approved, the ANDA will receive an AB4 rating. The ANDA applicant also may obtain an AB rating for its product to the other reference listed drugs (i.e., Unithroid, Synthroid, and Levoxyl) by submitting supplements that demonstrate that the generic product is bioequivalent to these other reference listed drugs and satisfies all other therapeutic equivalence criteria with respect to these reference listed drugs. See Letter from Janet Woodcock, M.D., Director, Center for Drug Evaluation and Research, FDA to Teri Nataline, Principal Consultant, Lachman Consultant Services, Inc., Docket No. FDA-2015-P-0403 (May 27, 2016).

²¹ If after approval of a suitability petition and before approval of an ANDA submitted pursuant to the approved petition, a drug product is approved in an NDA for the change described in the petition, the suitability petition and the listed drug identified in the petition can no longer be the basis of submission for such ANDA. Under these circumstances, an applicant seeking approval for a drug product with the change approved in the suitability petition must submit a new ANDA that identifies the drug product approved under such NDA as the RLD and comply with applicable regulatory requirements. See 21 CFR 314.93(f)(2).

holder of the NDA may waive its exclusivity as to any or all applications that might otherwise be blocked by such exclusivity. If an NDA holder waives its exclusivity, qualified applications may be accepted for review and/or approved, as applicable. An NDA for which the holder has waived its exclusivity as to all applications will be coded with a "W" in the Patent and Exclusivity Section of the Orange Book. The applicant whose product might otherwise be blocked by this exclusivity should indicate in the exclusivity statement in its application that the holder of the listed drug has waived its exclusivity.

1.9 Therapeutic Equivalence Code Change for a Category of Multisource Drug Products

The Agency will use the following procedures when, in response to a petition or on its own initiative, it is considering a change in the therapeutic equivalence code for approved multisource drug products. Such changes will generally occur when the Agency becomes aware of new scientific information affecting the therapeutic equivalence of an entire category of multisource drug products in the Orange Book (e.g., information concerning the active ingredient or the dosage form), rather than information concerning a single drug product within the category. These procedures will be used when a change in therapeutic equivalence code is under consideration for all drug products found in the Prescription Drug Product List under a specific active ingredient and dosage form. The change may be from the code signifying that the drug does not present a bioequivalence problem (e.g., **AA**) to a code signifying an actual or potential bioequivalence problem (e.g., **BP**), or vice versa. This procedure does not apply to a change of a particular product code (e.g., a change from **BP** to **AB** or from **AB** to **BX**).

Before making a change in a therapeutic equivalence code for an entire category of multisource drug products as described above, the Agency will announce in the *Introduction* to the Cumulative Supplement that it is considering the change and will invite comments. Comments, along with scientific data, may be sent to the Director, Office of Bioequivalence, Office of Generic Drugs, Center for Drug Evaluation and Research, Food and Drug Administration, Central Document Room, 5901-B Ammendale Rd., Beltsville, MD 20705-1266.

The comment period will generally be 60 days in length, and the closing date for comments will be listed in the description of the proposed change for each drug entity.

The most useful type of scientific data submitted to support comments is generally an *in vivo* bioavailability/bioequivalence study conducted on batches of the subject drug products. Comments including scientific data from an *in vivo* bioavailability/bioequivalence study should present a full description of the analytical procedures and equipment used, a validation of the analytical methodology, including the standard curve, a description of the method of calculating results, and a description of the pharmacokinetic and statistical models used in analyzing the data. Anecdotal or testimonial information is the least useful to the Agency, and submission of comments based on such information is discouraged. However, when there is supporting published or unpublished scientific literature, copies should be submitted with comments.

1.10 Change of the Therapeutic Equivalence Evaluation for a Single Product

The procedure described in Section 1.9 does not apply to a change in a single drug product code. For example, a change in a single drug product's

code from **BP** to **AB** as a result of the submission of an acceptable bioequivalence study ordinarily will not be the subject of notice and comment in the Cumulative Supplement. Likewise, a change in a single drug product's code from **AB** to **BX** (e.g., as a result of new information raising a significant question as to bioequivalence) does not require notice and comment. The Agency's responsibility to provide the public with the Agency's most current information related to therapeutic equivalence may require a change in a drug product's code prior to any formal notice and opportunity for the applicant to be heard. The publication in the *Federal Register* of a proposal to withdraw approval of a drug product will ordinarily result in a change in a product's code from **AB** to **BX** if this action has not already been taken.

We recognize that certain drug products approved in 505(b)(2) applications may not have therapeutic equivalence codes, and that FDA may undertake therapeutic equivalence evaluations with respect to such drug products. A person seeking to have a therapeutic equivalence rating for a drug product approved in a 505(b)(2) application may petition the Agency through the citizen petition procedure (see 21 CFR 10.25(a) and 21 CFR 10.30).

1.11 Discontinued Section

Those drug products in the discontinued section of the Orange Book (Discontinued Drug Product List) for which a determination has been made that the products were not withdrawn for safety or effectiveness reasons have been annotated with a footnote following the product strength: "***Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons***". The determinations listed in the Orange Book are only reflective of determinations made since 1995 and published in the Federal Register. The identification of these drug products in the Discontinued Drug Product List should avoid the submission of multiple citizen petitions requesting a determination for the same drug product.

Generally, approved products are added to the Discontinued Drug Product List when the applicant notifies the Division of Orange Book Publication and Regulatory Assessment (DOBPR) of the products' not-marketed status. Products may also be added to the Discontinued Drug Product List if annual reports or other submissions to the Agency indicate the product is not being marketed or as a result of other Agency administrative actions.²² Changes to the Orange Book are not affected by the drug registration and listing requirements of Section 510 of the FD&C Act.

1.12 Changes to the Orange Book

Every effort is made to ensure the Annual Edition is current and accurate. Applicants are requested to inform DOBPR of any changes or corrections, including any change in ownership or a product's marketing status that would result in the product being moved to the Discontinued Drug Product List. FDA notes that under Section 506I(a) of the FD&C Act, application holders must notify the Agency in writing 180 days prior to withdrawing a drug product from sale, or if 180 days is not practicable, not later than the date of withdrawal from sale. Furthermore, Section 506I(b) of the FD&C Act requires that application holders notify the Agency in writing within 180 days of approval of a drug product if such drug product will not be available for sale within 180 days of approval. A request to include a newly approved product in the Discontinued Drug Product List, rather than parts 1 or 2 of the Orange Book (as discussed in Section 1.1), must be

²² See, e.g., Section 506I(d) of the FD&C Act.

submitted to DOBPRA by the end of the month in which the product is approved to ensure that the product is not included in the "Active Section" of the next published Orange Book update. The Prescription Drug Product List and the Over-the-Counter (OTC) Drug Product List are collectively referred to as the "Active Section."

In addition, DOBPRA generally will act on requests to change a proprietary name for a listed drug only after approval of a supplement for the relevant change in proprietary name. To the extent that conventions for describing product identification information (i.e., active ingredients, dosage forms, routes of administration, product names, applicants, strengths) evolve over time, the Agency generally does not intend to revise such information for drug products already listed in the Orange Book, but rather intends to apply the change prospectively to drug products as they are added to the Orange Book.

You can contact DOBPRA by email at orangebook@fda.hhs.gov.

1.13 Availability of the Edition

The Annual Edition and current monthly Cumulative Supplement are available in a Portable Document Format (PDF) at the [Orange Book](#) home page by clicking on Publications. An annual subscription of the PDF format may be obtained from the U.S. Government Publishing Office, <https://www.gpo.gov/>.

2.0 HOW TO USE THE DRUG PRODUCT LISTS

2.1 Key Sections for Using the Drug Product Lists

This publication contains illustrations, along with Drug Product Lists, indices, and lists of abbreviations and terms which facilitate their use.

Illustrations. The annotated *Drug Product Illustration* (see Section 2.2) and the *Therapeutic Equivalence Evaluations Illustration* (see Section 2.3) are offered to provide further clarification. These depict the format found in the Prescription Drug Product List (the only list in which therapeutic equivalence evaluation codes are displayed).

Drug Product Lists. The Prescription and OTC Drug Product Lists, arranged alphabetically by active ingredient(s), contain product identification information (active ingredients, dosage forms, routes of administration, product names, applicants, strengths) for single and multiple ingredient drug products. Also shown are the application number and drug product number (FDA internal computer data use only) and approval dates for those drug products approved on or after January 1, 1982. The application number preceded by "N" is a New Drug Application (NDA or commonly the innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or commonly the generic).

The Discontinued Drug Product List, arranged alphabetically by active ingredient(s), contains product identification information (active ingredients, dosage forms, routes of administration, product names, applicants, strengths).

If a prescription drug product is available from more than one source (multisource), a therapeutic equivalence code will appear in front of the applicant's name. If a product is therapeutically equivalent to one or more products or to an appropriate reference, it will be designated with a code beginning with "A" and the entry will be underlined and printed in bold font for emphasis.

Active ingredient headings for multiple ingredient (combination) drug products are arranged alphabetically. For purposes of this publication, this alphabetical sort takes precedence over United States Pharmacopeia official monograph order (i.e., Reserpine, Hydralazine Hydrochloride, Hydrochlorothiazide). For example, product information labeled as Reserpine, Hydrochlorothiazide and Hydralazine Hydrochloride appears under the active ingredient heading *Hydralazine Hydrochloride; Hydrochlorothiazide; Reserpine*. A cross-reference to the product information (for prescription and OTC products) appears for each additional active ingredient in the product. For combination drug products, the ingredient strengths are separated by semicolons and appear in the same relative sequence as the ingredients in the heading. Available strengths of the dosage form from an applicant appear on separate lines.

To use the Drug Product Lists, determine by alphabetical order the ingredient under which the product information is listed, using the Product Name Index, if necessary. Then, find the ingredient in the applicable Drug Product List. Proceed to the dosage form and route of administration and

compare products within that ingredient heading only. Therapeutic equivalence or inequivalence for prescription products is determined on the basis of the therapeutic equivalence codes provided within that specific dosage form and route heading. The OTC Drug Product List, Discontinued Drug Product List, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List have their data arranged similarly.

The Discontinued Drug Product List contains approved products that have never been marketed, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons, are for military use, or have had their approvals withdrawn for other than safety or efficacy reasons subsequent to being discontinued from marketing. All products having a "@" in the December Cumulative Supplement of the previous Edition List have been added to the Discontinued Drug Product List appearing in this Edition. In addition, approved drug products that are not in the commercial distribution channel e.g., approved drug products in applications for export only are also listed in the Discontinued Drug Product List.

Product Name Index (*Prescription and OTC Drug Product Lists*). This is an index of drug products by trade name or established name of the active ingredient, if no trade name exists. The second term of each entry indicates the active ingredient name under which product information can be found in the appropriate Drug Product List. For those drug products with multiple active ingredients, only the first active ingredient (in alphabetical order) will appear. OTC products are so designated.

Product Name Index Listed by Applicant (*Prescription and OTC Drug Product Lists*). This is an index that cross-references applicants to drug products. The bolded and underlined entry represents the applicant name abbreviation used in this publication. Each complete applicant name that is represented by the abbreviated name is marked with an asterisk (*). Listed under each complete applicant name is the first alphabetically arranged ingredient under which product information can be found in the appropriate Drug Product List.

OTC products are so designated. To use the Drug Product Lists, determine by alphabetical order the ingredient under which the product information is listed, using the Product Name Index, if appropriate.

Uniform Terms. To improve readability, uniform terms are used to designate dosage forms, routes of administration, and abbreviations used to express strengths. These terms are listed in Appendix C. In some cases, the terms used may differ from those used in product labels and other labeling.

2.2 DRUG PRODUCT ILLUSTRATION

SINGLE INGREDIENT

ACTIVE INGREDIENT	MEPERIDINE HYDROCHLORIDE								
DOSAGE FORM; ROUTE OF ADMINISTRATION	INJECTABLE; INJECTION								
TRADE OR GENERIC NAMES	HEXANON								
REFERENCE LISTED DRUG* (+)	AP +! PAGE PHARMA	25MG/ML	N013111	001	AUG	22,	1983		
REFERENCE STANDARD * (!)	AP +!	50MG/ML	N013111	002	AUG	22,	1983		
	AP +!	75MG/ML	N013111	003	AUG	22,	1983		
	AP +!	100MG/ML	N013111	004	JAN	04,	1989		
	MEPERIDINE HCL								
THERAPEUTIC EQUIVALENCE (TE)	AP DAVIS PHARM	25MG/ML	A064890	001	FEB	29,	1987		
CODE FOR MULTISOURCE PRODUCT	AP	50MG/ML	A064890	002	FEB	29,	1987		
	AP	75MG/ML	A064890	003	FEB	29,	1987		
	AP	100MG/ML	A064890	004	MAR	08,	1992		
SINGLE SOURCE PRODUCT (NO TE CODE)	! TIMOKIM LLC	10MG/ML	A099225	001	DEC	12,	1995		
	AP JOHNSON MED	25MG/ML	A099226	001	NOV	27,	1993		
	! KENDRA PHARM	150MG/ML	A079444	001	OCT	31,	1999		
APPLICANT									
AVAILABLE STRENGTH(S) OF A PRODUCT									
APPLICATION NUMBER									
PRODUCT NUMBER IS FOR FDA INTERNAL COMPUTER DATA USE ONLY									
APPROVAL DATE									

*NOTE: REFERENCE LISTED DRUG AND REFERENCE STANDARD ARE DISCUSSED IN THE PREFACE SECTION 1.4


MULTIPLE INGREDIENTS WITH PRODUCT INFORMATION

ALPHABETICALLY SORTED BY									
ACTIVE INGREDIENT	HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; RESERPINE								
PRODUCT INFORMATION	TABLET; ORAL								
	HYDROCHLOROTHIAZIDE, RESERPINE AND HYDRALAZINE HCL								
	REINWALD LABS 25MG; 15MG; 0.1MG	A069808	001	JAN	18,	1982			

THIS EXAMPLE IS FOR PURPOSE OF ILLUSTRATION ONLY. IT DOES NOT REPRESENT ACTUAL PRODUCTS FROM THE PRESCRIPTION DRUG PRODUCT LIST.

2.3 THERAPEUTIC EQUIVALENCE EVALUATIONS ILLUSTRATION

DRUG PRODUCTS CODED **AB** (OR ANY CODE BEGINNING WITH AN "A") UNDER AN INGREDIENT AND DOSAGE FORM HEADING ARE CONSIDERED THERAPEUTICALLY EQUIVALENT ONLY TO OTHER PRODUCTS CODED **AB** (OR ANY CODE BEGINNING WITH AN "A") AND **NOT** TO THOSE CODED **BP** (OR ANY CODE BEGINNING WITH "B") AND ANY PRODUCTS NOT LISTED. DRUG PRODUCTS CODED **BP** (OR ANY CODE BEGINNING WITH A "B") ARE **NOT** CONSIDERED THERAPEUTICALLY EQUIVALENT TO ANY OTHER PRODUCT. FOR A COMPLETE EXPLANATION OF THE **TE** CODES REFER TO SECTION 1.7 OF THE *INTRODUCTION*.



NOTE: BOLD FONT AND UNDERLINING DENOTES MULTISOURCE PRODUCTS WHICH ARE CONSIDERED THERAPEUTICALLY EQUIVALENT.

THIS EXAMPLE IS FOR PURPOSES OF ILLUSTRATION ONLY. IT DOES NOT REPRESENT ACTUAL PRODUCTS FROM THE PRESCRIPTION DRUG PRODUCT LIST.

PRESCRIPTION DRUG PRODUCT LIST

3-1 (of 474)

ABACAVIR SULFATE

SOLUTION; ORAL

ABACAVIR SULFATE

AA	AUROBINDO PHARMA LTD	EQ 20MG BASE/ML	A077950 001	Mar 14, 2018
AA	HETERO LABS LTD III	EQ 20MG BASE/ML	A201107 001	Sep 26, 2016

ZIAGEN

AA	+! VIIV HLTHCARE	EQ 20MG BASE/ML	N020978 001	Dec 17, 1998

TABLET; ORAL

ABACAVIR SULFATE

AB	AUROBINDO PHARMA LTD	EQ 300MG BASE	A077844 001	Dec 17, 2012
AB	CIPLA	EQ 300MG BASE	A078119 001	Nov 21, 2017
AB	HETERO LABS LTD III	EQ 300MG BASE	A091560 001	Sep 13, 2013
AB	MYLAN PHARMS INC	EQ 300MG BASE	A091294 001	Jun 18, 2012
AB	STRIDES PHARMA	EQ 300MG BASE	A091050 001	Oct 28, 2016

ZIAGEN

AB	+! VIIV HLTHCARE	EQ 300MG BASE	N020977 001	Dec 17, 1998

ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE

TABLET; ORAL

TRIUMEQ

+!	VIIV HLTHCARE	EQ 600MG BASE; EQ 50MG BASE; 300MG	N205551 001	Aug 22, 2014

TABLET, FOR SUSPENSION; ORAL

TRIUMEQ PD

+!	VIIV HLTHCARE	EQ 60MG BASE; EQ 5MG BASE; 30MG	N215413 001	Mar 30, 2022

ABACAVIR SULFATE; LAMIVUDINE

TABLET; ORAL

ABACAVIR SULFATE AND LAMIVUDINE

AB	AUROBINDO PHARMA LTD	EQ 600MG BASE; 300MG	A090159 001	Nov 15, 2018
AB	CIPLA	EQ 600MG BASE; 300MG	A091144 001	Mar 28, 2017
AB	LAURUS	EQ 600MG BASE; 300MG	A216332 001	Jul 25, 2022
AB	LUPIN LTD	EQ 600MG BASE; 300MG	A204990 001	Mar 28, 2017

EPZICOM

AB	+! VIIV HLTHCARE	EQ 600MG BASE; 300MG	N021652 001	Aug 02, 2004

ABACAVIR SULFATE; LAMIVUDINE; ZIDOVUDINE

TABLET; ORAL

ABACAVIR SULFATE, LAMIVUDINE AND ZIDOVUDINE

AB	LUPIN LTD	EQ 300MG BASE; 150MG; 300MG	A202912 001	Dec 05, 2013

TRIZIVIR

AB	+! VIIV HLTHCARE	EQ 300MG BASE; 150MG; 300MG	N021205 001	Nov 14, 2000

ABALOPARATIDE

SOLUTION; SUBCUTANEOUS

TYMLOS

+!	RADIUS HEALTH INC	3.12MG/1.56ML (2MG/ML)	N208743 001	Apr 28, 2017

ABEMACICLIB

TABLET; ORAL

VERZENIO

+	ELI LILLY AND CO	50MG	N208716 001	Sep 28, 2017
+		100MG	N208716 002	Sep 28, 2017
+		150MG	N208716 003	Sep 28, 2017
+!		200MG	N208716 004	Sep 28, 2017

ABIRATERONE ACETATE

TABLET; ORAL

ABIRATERONE ACETATE

AB	AMNEAL PHARMS	250MG	A208327 001	Jan 07, 2019
AB		500MG	A208327 002	Dec 23, 2020
AB	APOTEX	250MG	A208453 001	Oct 31, 2018
AB	DR REDDYS	250MG	A208416 001	May 18, 2020
AB	GLENMARK PHARMS	250MG	A209227 001	Oct 16, 2019
AB		500MG	A209227 002	May 19, 2022
AB	HIKMA	250MG	A208339 001	Oct 31, 2018
AB	MSN	250MG	A210686 001	Jul 10, 2019
AB	MYLAN	250MG	A208446 001	Oct 31, 2018
AB		500MG	A208446 002	Dec 14, 2020
AB	NOVUGEN	250MG	A215947 001	Jan 05, 2022
AB		500MG	A215947 002	Jan 05, 2022
AB	QILU	250MG	A212462 001	Sep 27, 2019
AB		500MG	A212462 002	Jun 25, 2021
AB	RISING	250MG	A208371 001	Feb 25, 2019

PRESCRIPTION DRUG PRODUCT LIST

3-2 (of 474)

ABIRATERONE ACETATE

TABLET; ORAL

ABIRATERONE ACETATE

<u>AB</u>	TEVA PHARMS USA	<u>250MG</u>	<u>A208432</u>	<u>001</u>	Oct 31, 2018
<u>AB</u>	WOCKHARDT BIO AG	<u>250MG</u>	<u>A208380</u>	<u>001</u>	Feb 27, 2019
<u>ZYTIGA</u>					
<u>AB</u>	+	JANSSEN BIOTECH	<u>250MG</u>	<u>N202379</u>	<u>001</u> Apr 28, 2011
<u>AB</u>	+	!	<u>500MG</u>	<u>N202379</u>	<u>002</u> Apr 14, 2017
YONSA					
	+	!	SUN PHARM	N210308	001 May 22, 2018

ABROCITINIB

TABLET; ORAL

CIBINQO

+	PFIZER	50MG	N213871	001	Jan 14, 2022
+		100MG	N213871	002	Jan 14, 2022
+	!	200MG	N213871	003	Jan 14, 2022

ACALABRUTINIB

CAPSULE; ORAL

CALQUENCE

+	!	ASTRAZENECA	100MG	N210259	001 Oct 31, 2017

ACALABRUTINIB MALEATE

TABLET; ORAL

CALQUENCE

+	!	ASTRAZENECA	EQ 100MG BASE	N216387	001 Aug 03, 2022

ACAMPROSATE CALCIUM

TABLET, DELAYED RELEASE; ORAL

ACAMPROSATE CALCIUM

<u>AB</u>	!	GLENMARK GENERICS	<u>333MG</u>	<u>A202229</u>	<u>001</u> Jul 16, 2013
<u>AB</u>		MYLAN	<u>333MG</u>	<u>A200142</u>	<u>001</u> Mar 11, 2014
<u>AB</u>		ZYDUS PHARMS	<u>333MG</u>	<u>A205995</u>	<u>001</u> May 26, 2017

ACARBOSE

TABLET; ORAL

ACARBOSE

<u>AB</u>		EMCURE PHARMS LTD	<u>25MG</u>	<u>A202271</u>	<u>001</u> Feb 07, 2012
<u>AB</u>			<u>50MG</u>	<u>A202271</u>	<u>002</u> Feb 07, 2012
<u>AB</u>			<u>100MG</u>	<u>A202271</u>	<u>003</u> Feb 07, 2012
<u>AB</u>		HIKMA	<u>25MG</u>	<u>A078470</u>	<u>001</u> May 07, 2008
<u>AB</u>			<u>50MG</u>	<u>A078470</u>	<u>002</u> May 07, 2008
<u>AB</u>			<u>100MG</u>	<u>A078470</u>	<u>003</u> May 07, 2008
<u>AB</u>		IMPAX LABS	<u>25MG</u>	<u>A078441</u>	<u>001</u> May 14, 2009
<u>AB</u>			<u>50MG</u>	<u>A078441</u>	<u>002</u> May 14, 2009
<u>AB</u>			<u>100MG</u>	<u>A078441</u>	<u>003</u> May 14, 2009
<u>AB</u>	!	STRIDES PHARMA	<u>25MG</u>	<u>A090912</u>	<u>001</u> Jul 27, 2011
<u>AB</u>			<u>50MG</u>	<u>A090912</u>	<u>002</u> Jul 27, 2011
<u>AB</u>			<u>100MG</u>	<u>A090912</u>	<u>003</u> Jul 27, 2011
<u>AB</u>		VIRTUS PHARM	<u>25MG</u>	<u>A091343</u>	<u>001</u> Oct 17, 2013
<u>AB</u>			<u>50MG</u>	<u>A091343</u>	<u>002</u> Oct 17, 2013
<u>AB</u>			<u>100MG</u>	<u>A091343</u>	<u>003</u> Oct 17, 2013
<u>AB</u>		WATSON LABS	<u>25MG</u>	<u>A077532</u>	<u>001</u> May 07, 2008
<u>AB</u>			<u>50MG</u>	<u>A077532</u>	<u>002</u> May 07, 2008
<u>AB</u>			<u>100MG</u>	<u>A077532</u>	<u>003</u> May 07, 2008

ACEBUTOLOL HYDROCHLORIDE

CAPSULE; ORAL

ACEBUTOLOL HYDROCHLORIDE

<u>AB</u>	!	AMNEAL PHARM	<u>EQ 200MG BASE</u>	<u>A075047</u>	<u>001</u> Dec 30, 1999
<u>AB</u>	!		<u>EQ 400MG BASE</u>	<u>A075047</u>	<u>002</u> Dec 30, 1999
<u>AB</u>		ANI PHARMS	<u>EQ 200MG BASE</u>	<u>A074007</u>	<u>001</u> Oct 18, 1995
<u>AB</u>			<u>EQ 400MG BASE</u>	<u>A074007</u>	<u>002</u> Oct 18, 1995

ACETAMINOPHEN

SOLUTION; INTRAVENOUS

ACETAMINOPHEN

<u>AP</u>		ASPIRO	<u>1GM/100ML (10MG/ML)</u>	<u>A216617</u>	<u>001</u> Jul 27, 2022
<u>AP</u>		BAXTER HLTHCARE CORP	<u>1GM/100ML (10MG/ML)</u>	<u>A214331</u>	<u>001</u> Sep 17, 2021
<u>AP</u>		EUGIA PHARMA	<u>1GM/100ML (10MG/ML)</u>	<u>A210969</u>	<u>001</u> Oct 21, 2020
<u>AP</u>		HIKMA	<u>1GM/100ML (10MG/ML)</u>	<u>A202605</u>	<u>001</u> Jun 13, 2016
<u>AP</u>		MYLAN	<u>1GM/100ML (10MG/ML)</u>	<u>A213255</u>	<u>001</u> Aug 07, 2020
<u>AP</u>	!	SANDOZ INC	<u>1GM/100ML (10MG/ML)</u>	<u>A204052</u>	<u>001</u> Mar 22, 2016
<u>AP</u>		ZYDUS PHARMS	<u>1GM/100ML (10MG/ML)</u>	<u>A216467</u>	<u>001</u> Oct 25, 2022

PRESCRIPTION DRUG PRODUCT LIST

3-3 (of 474)

ACETAMINOPHEN

SOLUTION; INTRAVENOUS

ACETAMINOPHEN

+	!	B BRAUN MEDICAL INC	500MG/50ML (10MG/ML)	N204957	001	Feb 18, 2021
+	!		1GM/100ML (10MG/ML)	N204957	002	Feb 18, 2021
		FRESENIUS KABI USA	1GM/100ML (10MG/ML)	N204767	001	Oct 28, 2015
+	!	HIKMA	1GM/100ML (10MG/ML)	N206968	001	Jun 03, 2022

ACETAMINOPHEN; BENZHYDROCODONE HYDROCHLORIDE

TABLET; ORAL

APADAZ

+		KVK TECH INC	325MG; EQ 4.08MG BASE	N208653	002	Jan 04, 2019
+			325MG; EQ 6.12MG BASE	N208653	001	Feb 23, 2018
+	!		325MG; EQ 8.16MG BASE	N208653	003	Jan 04, 2019

ACETAMINOPHEN; BUTALBITAL

CAPSULE; ORAL

BUTALBITAL AND ACETAMINOPHEN

AA		GRANULES	300MG; 50MG	A213115	001	Nov 22, 2019
AA	!	MAYNE PHARMA INC	300MG; 50MG	A207313	001	Dec 27, 2017

TABLET; ORAL

ALLZITAL

AA	!	LARKEN LABS INC	325MG; 25MG	A203484	001	Dec 04, 2015

BUTALBITAL AND ACETAMINOPHEN

AA		AACE PHARMS	300MG; 50MG	A214955	001	Aug 16, 2022
AA		ALVOGEN	300MG; 50MG	A207635	001	Jun 05, 2017
AA		LARKEN LABS INC	325MG; 50MG	A203484	002	Dec 04, 2015
AA	!	LGM PHARMA	300MG; 50MG	A090956	001	Aug 23, 2011
AA		MIKART	300MG; 50MG	A207386	001	Nov 15, 2016
AA		RISE PHARMA	300MG; 50MG	A214088	001	Apr 07, 2022
AA			325MG; 25MG	A214088	002	Apr 07, 2022
AA			325MG; 50MG	A214088	003	Apr 07, 2022

BUTAPAP

AA	!	MIKART	325MG; 50MG	A089987	001	Oct 26, 1992

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

AA		AUROLIFE PHARMA LLC	325MG; 50MG; 40MG	A204733	001	Sep 26, 2018
AA		GRANULES	300MG; 50MG; 40MG	A213321	001	Apr 08, 2020
AA		LANNETT CO INC	300MG; 50MG; 40MG	A212082	001	Dec 17, 2019
AA			325MG; 50MG; 40MG	A212083	001	Dec 17, 2019
AA	!	LGM PHARMA	300MG; 50MG; 40MG	A040885	001	Nov 16, 2009
AA		MAYNE PHARMA INC	300MG; 50MG; 40MG	A210817	001	Dec 17, 2019
AA	!		325MG; 50MG; 40MG	A089007	001	Mar 17, 1986
AA		NOVAST LABS	300MG; 50MG; 40MG	A215047	001	Nov 17, 2021
AA		NUVO PHARMS INC	300MG; 50MG; 40MG	A207118	001	Oct 28, 2016
AA		SENORES PHARMS	300MG; 50MG; 40MG	A214087	001	Aug 13, 2021
AA			325MG; 50MG; 40MG	A214087	002	Aug 13, 2021
AA		TARO PHARM INDS LTD	300MG; 50MG; 40MG	A213046	001	Jul 01, 2020
AA		XSPIRE PHARMA	300MG; 50MG; 40MG	A206615	001	Aug 04, 2017

SOLUTION; ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

!		MIKART	325MG/15ML; 50MG/15ML; 40MG/15ML	A040387	001	Jan 31, 2003

TABLET; ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

AA		ABHAI LLC	325MG; 50MG; 40MG	A211106	001	Sep 26, 2018
AA	+	ACTAVIS LABS UT INC	325MG; 50MG; 40MG	A088616	001	Nov 09, 1984
AA		GRANULES	325MG; 50MG; 40MG	A040864	001	Dec 01, 2008
AA		LANNETT CO INC	325MG; 50MG; 40MG	A200243	001	Sep 13, 2012
AA		LGM PHARMA	325MG; 50MG; 40MG	A209587	001	Oct 31, 2018
AA		MIKART	325MG; 50MG; 40MG	A089175	001	Jan 21, 1987
AA	!	STRIDES PHARMA	325MG; 50MG; 40MG	A040511	001	Aug 27, 2003
AA			325MG; 50MG; 40MG	A203647	001	Sep 21, 2020

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE

AB		HIKMA	300MG; 50MG; 40MG; 30MG	A215138	002	Jan 26, 2022
AB			325MG; 50MG; 40MG; 30MG	A215138	001	Jan 26, 2022
AB		LGM PHARMA	300MG; 50MG; 40MG; 30MG	A076560	002	Jul 19, 2012
AB			325MG; 50MG; 40MG; 30MG	A076560	001	Jun 10, 2004
AB		NOSTRUM LABS INC	325MG; 50MG; 40MG; 30MG	A075929	001	Apr 22, 2002
AB		STRIDES PHARMA	325MG; 50MG; 40MG; 30MG	A204649	001	Jul 08, 2020

PRESCRIPTION DRUG PRODUCT LIST

3-4 (of 474)

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

FIORICET W/ CODEINE

AB	+!	ACTAVIS LABS UT INC	325MG; 50MG; 40MG; 30MG	<u>N020232</u>	<u>001</u>	Jul 30, 1992

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE; ORAL

TREZIX

		XSPIRE PHARMA	320.5MG; 30MG; 16MG	A204785	001	Nov 26, 2014

TABLET; ORAL

ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE

		LARKEN LABS INC	325MG; 30MG; 16MG	A204209	001	Sep 30, 2016

ACETAMINOPHEN; CODEINE PHOSPHATE

SOLUTION; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

AA		AKORN	<u>120MG/5ML; 12MG/5ML</u>	<u>A040119</u>	<u>001</u>	Apr 26, 1996

AA		CHARTWELL	<u>120MG/5ML; 12MG/5ML</u>	<u>A089450</u>	<u>001</u>	Oct 27, 1992

AA	!	PHARM ASSOC	<u>120MG/5ML; 12MG/5ML</u>	<u>A087508</u>	<u>001</u>	

TABLET; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

AA		AMNEAL PHARMS NY	<u>300MG; 30MG</u>	<u>A040779</u>	<u>001</u>	May 29, 2008

AA		AUROLIFE PHARMA LLC	<u>300MG; 15MG</u>	<u>A202800</u>	<u>001</u>	Apr 15, 2013

AA			<u>300MG; 30MG</u>	<u>A202800</u>	<u>002</u>	Apr 15, 2013

AA			<u>300MG; 60MG</u>	<u>A202800</u>	<u>003</u>	Apr 15, 2013

AA		ELITE LABS INC	<u>300MG; 15MG</u>	<u>A212418</u>	<u>001</u>	Sep 10, 2019

AA			<u>300MG; 30MG</u>	<u>A212418</u>	<u>002</u>	Sep 10, 2019

AA			<u>300MG; 60MG</u>	<u>A212418</u>	<u>003</u>	Sep 10, 2019

AA		EYWA	<u>300MG; 15MG</u>	<u>A211610</u>	<u>001</u>	Jun 27, 2019

AA			<u>300MG; 30MG</u>	<u>A211610</u>	<u>002</u>	Jun 27, 2019

AA			<u>300MG; 60MG</u>	<u>A211610</u>	<u>003</u>	Jun 27, 2019

AA		NOSTRUM LABS INC	<u>300MG; 15MG</u>	<u>A088629</u>	<u>002</u>	Mar 06, 1985

AA			<u>300MG; 30MG</u>	<u>A088629</u>	<u>003</u>	Mar 06, 1985

AA	+!		<u>300MG; 60MG</u>	<u>A088629</u>	<u>001</u>	Mar 06, 1985

AA	!	SPECGX LLC	<u>300MG; 15MG</u>	<u>A040419</u>	<u>001</u>	May 31, 2001

AA	!		<u>300MG; 30MG</u>	<u>A040419</u>	<u>002</u>	May 31, 2001

AA			<u>300MG; 60MG</u>	<u>A040419</u>	<u>003</u>	May 31, 2001

AA		SUN PHARM INDS LTD	<u>300MG; 30MG</u>	<u>A085868</u>	<u>001</u>	

AA			<u>300MG; 60MG</u>	<u>A087083</u>	<u>001</u>	

ACETAMINOPHEN; HYDROCODONE BITARTRATE

SOLUTION; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA	!	CHARTWELL	<u>325MG/15ML; 7.5MG/15ML</u>	<u>A040482</u>	<u>001</u>	Sep 25, 2003

AA		EYWA	<u>325MG/15ML; 7.5MG/15ML</u>	<u>A211023</u>	<u>001</u>	Mar 08, 2019

AA		GENUS	<u>325MG/15ML; 7.5MG/15ML</u>	<u>A040894</u>	<u>001</u>	Jul 19, 2011

AA		PHARM ASSOC	<u>325MG/15ML; 7.5MG/15ML</u>	<u>A040838</u>	<u>001</u>	May 10, 2013

AA		VISTAPHARM	<u>325MG/15ML; 7.5MG/15ML</u>	<u>A200343</u>	<u>001</u>	Jan 25, 2012

!		MIKART	300MG/15ML; 10MG/15ML	A040881	001	Feb 25, 2010

!		PHARM ASSOC	325MG/15ML; 10MG/15ML	A040834	001	Apr 18, 2008

TABLET; ORAL

ANEXSIA 5/325

AA	!	SPECGX LLC	<u>325MG; 5MG</u>	<u>A040409</u>	<u>001</u>	Oct 20, 2000

ANEXSIA 7.5/325

AA	!	SPECGX LLC	<u>325MG; 7.5MG</u>	<u>A040405</u>	<u>001</u>	Sep 08, 2000

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA		ABHAI LLC	<u>300MG; 5MG</u>	<u>A209036</u>	<u>001</u>	Jun 21, 2017

AA			<u>300MG; 7.5MG</u>	<u>A209036</u>	<u>002</u>	Jun 21, 2017

AA			<u>300MG; 10MG</u>	<u>A209036</u>	<u>003</u>	Jun 21, 2017

AA			<u>325MG; 5MG</u>	<u>A209037</u>	<u>001</u>	Jun 21, 2017

AA			<u>325MG; 7.5MG</u>	<u>A209037</u>	<u>002</u>	Jun 21, 2017

AA			<u>325MG; 10MG</u>	<u>A209037</u>	<u>003</u>	Jun 21, 2017

AA		AMNEAL PHARMS	<u>300MG; 10MG</u>	<u>A207137</u>	<u>001</u>	Nov 29, 2016

AA		AMNEAL PHARMS NY	<u>300MG; 5MG</u>	<u>A206869</u>	<u>001</u>	Jun 23, 2017

AA			<u>325MG; 5MG</u>	<u>A040736</u>	<u>001</u>	Aug 25, 2006

AA			<u>325MG; 7.5MG</u>	<u>A040746</u>	<u>002</u>	May 10, 2016

AA			<u>325MG; 10MG</u>	<u>A040746</u>	<u>001</u>	Aug 25, 2006

AA		ASCENT PHARMS INC	<u>325MG; 5MG</u>	<u>A211487</u>	<u>002</u>	Nov 07, 2018

AA			<u>325MG; 7.5MG</u>	<u>A211487</u>	<u>003</u>	Nov 07, 2018

AA			<u>325MG; 10MG</u>	<u>A211487</u>	<u>004</u>	Nov 07, 2018

AA		AUROLIFE PHARMA LLC	<u>300MG; 5MG</u>	<u>A207709</u>	<u>001</u>	Sep 13, 2018

AA			<u>300MG; 7.5MG</u>	<u>A207709</u>	<u>002</u>	Sep 13, 2018

AA			<u>300MG; 10MG</u>	<u>A207709</u>	<u>003</u>	Sep 13, 2018

AA			<u>325MG; 5MG</u>	<u>A201013</u>	<u>001</u>	Apr 11, 2012

PRESCRIPTION DRUG PRODUCT LIST

3-5 (of 474)

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA		325MG;7.5MG	A201013	002	Apr 11, 2012	
AA		325MG;10MG	A201013	003	Apr 11, 2012	
AA	!	CHARTWELL	300MG;5MG	A040658	001	Jan 19, 2006
AA	!		300MG;7.5MG	A040658	002	Mar 24, 2006
AA	!		300MG;10MG	A040658	003	Jun 23, 2004
AA			325MG;7.5MG	A040432	001	Jan 22, 2003
AA		EPIC PHARMA LLC	325MG;5MG	A203863	001	Mar 30, 2018
AA			325MG;7.5MG	A203863	002	Mar 30, 2018
AA			325MG;10MG	A203863	003	Mar 30, 2018
AA		NOVEL LABS INC	300MG;5MG	A206142	001	Nov 14, 2016
AA			300MG;7.5MG	A206142	002	Nov 14, 2016
AA			300MG;10MG	A206142	003	Nov 14, 2016
AA			325MG;5MG	A206245	001	Dec 01, 2016
AA			325MG;7.5MG	A206245	002	Dec 01, 2016
AA			325MG;10MG	A206245	003	Dec 01, 2016
AA		PRINSTON INC	325MG;5MG	A214928	001	Dec 30, 2021
AA			325MG;7.5MG	A214928	002	Dec 30, 2021
AA			325MG;10MG	A214928	003	Dec 30, 2021
AA		RHODES PHARMS	300MG;5MG	A207808	001	Mar 30, 2018
AA			300MG;7.5MG	A207808	002	Mar 30, 2018
AA			300MG;10MG	A207808	003	Mar 30, 2018
AA			325MG;5MG	A202991	001	Apr 12, 2016
AA			325MG;7.5MG	A202991	002	Apr 12, 2016
AA			325MG;10MG	A202991	003	Apr 12, 2016
AA		SPECGX LLC	300MG;5MG	A206718	001	Mar 31, 2017
AA			300MG;7.5MG	A206718	002	Mar 31, 2017
AA			300MG;10MG	A206718	003	Mar 31, 2017
AA	!		325MG;10MG	A040400	001	Jul 26, 2000
AA		STRIDES PHARMA	325MG;5MG	A040655	001	Jan 19, 2006
AA			325MG;5MG	A202935	002	Jun 15, 2016
AA			325MG;7.5MG	A040656	001	Jan 19, 2006
AA			325MG;7.5MG	A202935	003	Jun 15, 2016
AA			325MG;10MG	A040355	001	May 31, 2000
AA			325MG;10MG	A202935	004	Jun 15, 2016
AA		SUN PHARM INDS INC	325MG;5MG	A090118	001	Dec 23, 2008
AA			325MG;7.5MG	A090118	002	Dec 23, 2008
AA			325MG;10MG	A090118	003	Dec 23, 2008
AA		TRIS PHARMA INC	300MG;5MG	A202214	004	Mar 15, 2016
AA			300MG;7.5MG	A202214	005	Mar 15, 2016
AA			300MG;10MG	A202214	006	Mar 15, 2016
AA			325MG;5MG	A202214	001	Mar 27, 2013
AA			325MG;7.5MG	A202214	002	Mar 27, 2013
AA			325MG;10MG	A202214	003	Mar 27, 2013
AA		WES PHARMA INC	300MG;5MG	A207509	001	Oct 29, 2018
AA			300MG;7.5MG	A207509	002	Oct 29, 2018
AA			300MG;10MG	A207509	003	Oct 29, 2018
AA			325MG;5MG	A210211	001	Oct 30, 2017
AA			325MG;7.5MG	A210211	002	Oct 30, 2017
AA			325MG;10MG	A210211	003	Oct 30, 2017
AA	!	ASCENT PHARMS INC	325MG;2.5MG	A211487	001	Nov 07, 2018

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

SOLUTION; ORAL

OXYCODONE AND ACETAMINOPHEN

<u>AA</u>	!	ABHAI LLC	<u>325MG/5ML; 5MG/5ML</u>	<u>A211499</u>	<u>001</u>	Dec 31, 2018
<u>AA</u>		NOSTRUM LABS INC	<u>325MG/5ML; 5MG/5ML</u>	<u>A201448</u>	<u>001</u>	Aug 26, 2021
		MIKART	<u>300MG/5ML; 10MG/5ML</u>	<u>A202142</u>	<u>001</u>	Nov 27, 2018

TABLET; ORAL

OXYCET

<u>AA</u>		SPECGX LLC	<u>325MG; 5MG</u>	<u>A087463</u>	<u>001</u>	Dec 07, 1983

OXYCODONE AND ACETAMINOPHEN

~~CHLORDANE AND NORTHRINONE~~						
<u>AA</u>	ABHAI LLC	<u>325MG;2.5MG</u>	<u>A210644</u>	<u>001</u>	Feb 09, 2018	
<u>AA</u>		<u>325MG;5MG</u>	<u>A210644</u>	<u>002</u>	Feb 09, 2018	
<u>AA</u>		<u>325MG;7.5MG</u>	<u>A210644</u>	<u>003</u>	Feb 09, 2018	
<u>AA</u>		<u>325MG;10MG</u>	<u>A210644</u>	<u>004</u>	Feb 09, 2018	
<u>AA</u>	ACTAVIS ELIZABETH	<u>325MG;2.5MG</u>	<u>A201447</u>	<u>001</u>	Apr 12, 2013	
<u>AA</u>		<u>325MG;5MG</u>	<u>A201447</u>	<u>002</u>	Apr 12, 2013	
<u>AA</u>		<u>325MG;7.5MG</u>	<u>A201447</u>	<u>003</u>	Apr 12, 2013	
<u>AA</u>		<u>325MG;10MG</u>	<u>A201447</u>	<u>004</u>	Apr 12, 2013	
<u>AA</u>	ALVOGEN	<u>325MG;5MG</u>	<u>A202677</u>	<u>003</u>	Mar 08, 2016	

PRESCRIPTION DRUG PRODUCT LIST

3-6 (of 474)

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL

OXYCODONE AND ACETAMINOPHEN

<u>AA</u>		<u>325MG; 7.5MG</u>	<u>A202677</u>	<u>001</u>	Jul 26, 2012
<u>AA</u>		<u>325MG; 10MG</u>	<u>A202677</u>	<u>002</u>	Jul 26, 2012
<u>AA</u>	AMNEAL PHARMS	<u>325MG; 5MG</u>	<u>A040777</u>	<u>001</u>	Nov 27, 2007
<u>AA</u>	AMNEAL PHARMS NY	<u>325MG; 7.5MG</u>	<u>A040778</u>	<u>002</u>	Jun 27, 2014
<u>AA</u>		<u>325MG; 10MG</u>	<u>A040778</u>	<u>001</u>	Nov 27, 2007
<u>AA</u>	ASCENT PHARMS INC	<u>325MG; 2.5MG</u>	<u>A207419</u>	<u>001</u>	Mar 22, 2017
<u>AA</u>		<u>325MG; 5MG</u>	<u>A207419</u>	<u>002</u>	Mar 22, 2017
<u>AA</u>		<u>325MG; 7.5MG</u>	<u>A207419</u>	<u>003</u>	Mar 22, 2017
<u>AA</u>		<u>325MG; 10MG</u>	<u>A207419</u>	<u>004</u>	Mar 22, 2017
<u>AA</u>	AUROLIFE PHARMA LLC	<u>325MG; 2.5MG</u>	<u>A201972</u>	<u>001</u>	Jul 15, 2013
<u>AA</u>		<u>325MG; 5MG</u>	<u>A201972</u>	<u>002</u>	Jul 15, 2013
<u>AA</u>		<u>325MG; 7.5MG</u>	<u>A201972</u>	<u>003</u>	Jul 15, 2013
<u>AA</u>		<u>325MG; 10MG</u>	<u>A201972</u>	<u>004</u>	Jul 15, 2013
<u>AA</u>	CHARTWELL	<u>325MG; 5MG</u>	<u>A207834</u>	<u>001</u>	Aug 15, 2019
<u>AA</u>		<u>325MG; 7.5MG</u>	<u>A207834</u>	<u>002</u>	Aug 15, 2019
<u>AA</u>		<u>325MG; 10MG</u>	<u>A207834</u>	<u>003</u>	Aug 15, 2019
<u>AA</u>	EPIC PHARMA LLC	<u>325MG; 5MG</u>	<u>A203864</u>	<u>001</u>	Jul 02, 2018
<u>AA</u>		<u>325MG; 7.5MG</u>	<u>A203864</u>	<u>002</u>	Jul 02, 2018
<u>AA</u>		<u>325MG; 10MG</u>	<u>A203864</u>	<u>003</u>	Jul 02, 2018
<u>AA</u>	MAYNE PHARMA INC	<u>325MG; 2.5MG</u>	<u>A090177</u>	<u>001</u>	Oct 20, 2008
<u>AA</u>		<u>325MG; 5MG</u>	<u>A090177</u>	<u>002</u>	Oct 20, 2008
<u>AA</u>		<u>325MG; 7.5MG</u>	<u>A090177</u>	<u>003</u>	Oct 20, 2008
<u>AA</u>		<u>325MG; 10MG</u>	<u>A090177</u>	<u>004</u>	Oct 20, 2008
<u>AA</u>	NOVEL LABS INC	<u>325MG; 2.5MG</u>	<u>A204407</u>	<u>001</u>	Feb 24, 2017
<u>AA</u>		<u>325MG; 5MG</u>	<u>A204407</u>	<u>002</u>	Feb 24, 2017
<u>AA</u>		<u>325MG; 7.5MG</u>	<u>A204407</u>	<u>003</u>	Feb 24, 2017
<u>AA</u>		<u>325MG; 10MG</u>	<u>A204407</u>	<u>004</u>	Feb 24, 2017
<u>AA</u>	RHODES PHARMS	<u>325MG; 5MG</u>	<u>A201278</u>	<u>001</u>	Aug 28, 2014
<u>AA</u>		<u>325MG; 7.5MG</u>	<u>A201278</u>	<u>002</u>	Aug 28, 2014
<u>AA</u>		<u>325MG; 10MG</u>	<u>A201278</u>	<u>003</u>	Aug 28, 2014
<u>AA</u>	SPECGX LLC	<u>325MG; 7.5MG</u>	<u>A040545</u>	<u>001</u>	Jun 30, 2004
<u>AA</u>		<u>325MG; 10MG</u>	<u>A040545</u>	<u>002</u>	Jun 30, 2004
<u>AA</u>	SUN PHARM INDS INC	<u>325MG; 2.5MG</u>	<u>A090535</u>	<u>001</u>	Dec 26, 2013
<u>AA</u>		<u>325MG; 5MG</u>	<u>A090535</u>	<u>002</u>	Dec 26, 2013
<u>AA</u>		<u>325MG; 7.5MG</u>	<u>A090535</u>	<u>003</u>	Dec 26, 2013
<u>AA</u>		<u>325MG; 10MG</u>	<u>A090535</u>	<u>004</u>	Dec 26, 2013
<u>AA</u>	WES PHARMA INC	<u>325MG; 5MG</u>	<u>A207510</u>	<u>001</u>	Mar 21, 2018
<u>AA</u>		<u>325MG; 7.5MG</u>	<u>A207510</u>	<u>002</u>	Mar 21, 2018
<u>AA</u>		<u>325MG; 10MG</u>	<u>A207510</u>	<u>003</u>	Mar 21, 2018

PERCOCET

<u>AA</u>	!	VINTAGE PHARMS LLC	<u>325MG; 2.5MG</u>	<u>A040330</u>	<u>001</u>	Jun 25, 1999
<u>AA</u>	!		<u>325MG; 5MG</u>	<u>A040330</u>	<u>002</u>	Jun 25, 1999
<u>AA</u>	!		<u>325MG; 7.5MG</u>	<u>A040330</u>	<u>003</u>	Nov 23, 2001
<u>AA</u>	!		<u>325MG; 10MG</u>	<u>A040330</u>	<u>004</u>	Nov 23, 2001

OXYCODONE AND ACETAMINOPHEN

!	MIKART	300MG; 2.5MG	A040608	001	Dec 30, 2005
!		300MG; 5MG	A040608	002	Dec 30, 2005
!		300MG; 7.5MG	A040608	003	Dec 30, 2005
!		300MG; 10MG	A040608	004	Dec 30, 2005

ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE

TABLET; ORAL

TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN

<u>AB</u>	ALKEM LABS LTD	<u>325MG; 37.5MG</u>	<u>A202076</u>	<u>001</u>	Mar 30, 2012
<u>AB</u>	AMNEAL PHARMS	<u>325MG; 37.5MG</u>	<u>A090485</u>	<u>001</u>	Dec 09, 2009
<u>AB</u>	AUROBINDO PHARMA	<u>325MG; 37.5MG</u>	<u>A207152</u>	<u>001</u>	Mar 22, 2017
<u>AB</u>	MICRO LABS LTD	<u>325MG; 37.5MG</u>	<u>A201952</u>	<u>001</u>	Dec 14, 2012
	INDIA				
<u>AB</u>	RISING	<u>325MG; 37.5MG</u>	<u>A077858</u>	<u>001</u>	Sep 26, 2008
<u>AB</u>	SUN PHARM INDS INC	<u>325MG; 37.5MG</u>	<u>A077184</u>	<u>001</u>	Dec 16, 2005
<u>AB</u>	ZYDUS PHARMS USA	<u>325MG; 37.5MG</u>	<u>A090460</u>	<u>001</u>	Sep 06, 2012
	INC				

ULTRACET

<u>AB</u>	+	JANSSSEN PHARMS	<u>325MG; 37.5MG</u>	<u>N021123</u>	<u>001</u>	Aug 15, 2001

PRESCRIPTION DRUG PRODUCT LIST

3-7 (of 474)

ACETAZOLAMIDE

CAPSULE, EXTENDED RELEASE; ORAL

ACETAZOLAMIDE

<u>AB</u>	ACCORD HLTHCARE	<u>500MG</u>	<u>A207659</u>	<u>001</u>	Oct 18, 2018
<u>AB</u>	ALEMBIC PHARMS	<u>500MG</u>	<u>A210423</u>	<u>001</u>	Feb 19, 2019
<u>AB</u>	! CADILA	<u>500MG</u>	<u>A205301</u>	<u>001</u>	Jan 16, 2019
<u>AB</u>	HERITAGE PHARMA	<u>500MG</u>	<u>A040904</u>	<u>001</u>	Dec 10, 2008
<u>AB</u>	MICRO LABS LTD	<u>500MG</u>	<u>A207401</u>	<u>001</u>	Oct 01, 2020
	INDIA				
<u>AB</u>	NOSTRUM LABS INC	<u>500MG</u>	<u>A204691</u>	<u>001</u>	Mar 29, 2016
<u>AB</u>	NOVAST LABS	<u>500MG</u>	<u>A203434</u>	<u>001</u>	Sep 30, 2016

TABLET; ORAL

ACETAZOLAMIDE

<u>AB</u>	APPCO	<u>125MG</u>	<u>A211372</u>	<u>001</u>	Feb 22, 2021
<u>AB</u>		<u>250MG</u>	<u>A211372</u>	<u>002</u>	Feb 22, 2021
<u>AB</u>	BRECKENRIDGE	<u>125MG</u>	<u>A207503</u>	<u>001</u>	Apr 30, 2020
<u>AB</u>		<u>250MG</u>	<u>A207503</u>	<u>002</u>	Apr 30, 2020
<u>AB</u>	CHARTWELL MOLECULAR	<u>250MG</u>	<u>A084840</u>	<u>001</u>	
<u>AB</u>	EYWA PHARMA	<u>125MG</u>	<u>A211556</u>	<u>001</u>	Oct 18, 2019
<u>AB</u>		<u>250MG</u>	<u>A211556</u>	<u>002</u>	Oct 18, 2019
<u>AB</u>	HERITAGE PHARMA	<u>125MG</u>	<u>A205530</u>	<u>001</u>	Oct 27, 2016
<u>AB</u>		<u>250MG</u>	<u>A205530</u>	<u>002</u>	Oct 27, 2016
<u>AB</u>	MANKIND PHARMA	<u>125MG</u>	<u>A214282</u>	<u>001</u>	Oct 07, 2020
<u>AB</u>		<u>250MG</u>	<u>A214282</u>	<u>002</u>	Oct 07, 2020
<u>AB</u>	NOVITIUM PHARMA	<u>125MG</u>	<u>A210588</u>	<u>001</u>	Oct 17, 2019
<u>AB</u>		<u>250MG</u>	<u>A210588</u>	<u>002</u>	Oct 17, 2019
<u>AB</u>	RUBICON	<u>125MG</u>	<u>A215101</u>	<u>001</u>	Aug 19, 2021
<u>AB</u>		<u>250MG</u>	<u>A215101</u>	<u>002</u>	Aug 19, 2021
<u>AB</u>	STRIDES PHARMA	<u>125MG</u>	<u>A209734</u>	<u>001</u>	Nov 20, 2017
<u>AB</u>		<u>250MG</u>	<u>A209734</u>	<u>002</u>	Nov 20, 2017
<u>AB</u>	TARO	<u>125MG</u>	<u>A040195</u>	<u>001</u>	May 28, 1997
<u>AB</u>	!	<u>250MG</u>	<u>A040195</u>	<u>002</u>	May 28, 1997

ACETAZOLAMIDE SODIUM

INJECTABLE; INJECTION

ACETAZOLAMIDE SODIUM

<u>AP</u>	EMCURE PHARMS LTD	<u>EQ 500MG BASE/VIAL</u>	<u>A202693</u>	<u>001</u>	Dec 19, 2014
<u>AP</u>	HIKMA	<u>EQ 500MG BASE/VIAL</u>	<u>A040089</u>	<u>001</u>	Feb 28, 1995
<u>AP</u>	MYLAN ASI	<u>EQ 500MG BASE/VIAL</u>	<u>A200880</u>	<u>001</u>	May 09, 2012
<u>AP</u>	! XGEN PHARMS	<u>EQ 500MG BASE/VIAL</u>	<u>A040784</u>	<u>001</u>	Dec 10, 2008
<u>AP</u>	ZYDUS PHARMS	<u>EQ 500MG BASE/VIAL</u>	<u>A206533</u>	<u>001</u>	Apr 15, 2019

ACETIC ACID, GLACIAL

SOLUTION; IRRIGATION, URETHRAL

ACETIC ACID 0.25% IN PLASTIC CONTAINER

<u>AT</u>	B BRAUN	<u>250MG/100ML</u>	<u>N018161</u>	<u>001</u>	
<u>AT</u>	BAXTER HLTHCARE	<u>250MG/100ML</u>	<u>N018523</u>	<u>001</u>	Feb 19, 1982
<u>AT</u>	+! ICU MEDICAL INC	<u>250MG/100ML</u>	<u>N017656</u>	<u>001</u>	

SOLUTION/DROPS; OTIC

ACETIC ACID

<u>AT</u>	RISING	<u>2%</u>	<u>A207280</u>	<u>001</u>	Mar 09, 2018
<u>AT</u>	SAPTALIS PHARMS	<u>2%</u>	<u>A040607</u>	<u>001</u>	Feb 24, 2005
<u>AT</u>	TARO	<u>2%</u>	<u>A088638</u>	<u>001</u>	Sep 06, 1984

VOSOL

<u>AT</u>	! AKORN	<u>2%</u>	<u>N012179</u>	<u>001</u>	

ACETIC ACID, GLACIAL; HYDROCORTISONE

SOLUTION/DROPS; OTIC

HYDROCORTISONE AND ACETIC ACID

<u>AT</u>	COSETTE	<u>2%:1%</u>	<u>A040609</u>	<u>001</u>	Feb 06, 2006
<u>AT</u>	TARO PHARM INDS LTD	<u>2%:1%</u>	<u>A088759</u>	<u>001</u>	Mar 04, 1985

VOSOL HC

<u>AT</u>	+! AKORN	<u>2%:1%</u>	<u>N012770</u>	<u>001</u>	

ACETOHYDROXAMIC ACID

TABLET; ORAL

LITHOSTAT

	+! MISSION PHARMA	250MG	N018749	001	May 31, 1983

PRESCRIPTION DRUG PRODUCT LIST

3-8 (of 474)

ACETYLCHOLINE CHLORIDE

FOR SOLUTION;OPHTHALMIC

MIOCHOL-E

+! BAUSCH AND LOMB

20MG/VIAL

N020213 001 Sep 22, 1993

ACETYLCYSTEINE

INJECTABLE;INTRAVENOUS

ACETADOTEAP +! CUMBERLAND PHARMS6GM/30ML (200MG/ML)N021539 001 Jan 23, 2004ACETYLCYSTEINEAP AKORN6GM/30ML (200MG/ML)A203173 001 Mar 24, 2015AP ASPEN6GM/30ML (200MG/ML)A213693 001 Feb 03, 2022AP EUGIA PHARMA6GM/30ML (200MG/ML)A207358 001 Feb 29, 2016AP FRESENIUS KABI USA6GM/30ML (200MG/ML)A200644 001 Nov 07, 2012AP INDOCO6GM/30ML (200MG/ML)A215620 001 Feb 23, 2022AP SAGENT PHARMS INC6GM/30ML (200MG/ML)A091684 001 Oct 31, 2017AP ZYDUS PHARMS6GM/30ML (200MG/ML)A208166 001 Jul 20, 2018

SOLUTION;INHALATION, ORAL

ACETYLCYSTEINEAN ALVOGEN10%A204674 001 Feb 11, 2014AN20%A203853 001 Jun 21, 2012AN ! AM REGENT10%A072489 001 Jul 28, 1995AN !20%A072547 001 Jul 28, 1995AN HOSPIRA10%A073664 001 Aug 30, 1994AN20%A074037 001 Aug 30, 1994ACITRETIN

CAPSULE;ORAL

ACITRETINAB BARR LABS INC10MGA091455 001 Apr 04, 2013AB25MGA091455 002 Apr 04, 2013AB IMPAX LABS INC10MGA202552 001 Dec 23, 2015AB17.5MGA202552 002 Dec 23, 2015AB22.5MGA202552 003 Dec 23, 2015AB25MGA202552 004 Dec 23, 2015AB MYLAN10MGA202148 001 Sep 10, 2015AB25MGA202148 002 Sep 10, 2015AB SIGMAPHARM LABS LLC10MGA204633 001 May 22, 2015AB17.5MGA204633 002 May 22, 2015AB22.5MGA204633 003 May 22, 2015AB !25MGA204633 004 May 22, 2015AB TEVA PHARMS USA17.5MGA202897 001 Apr 04, 2013AB22.5MGA202897 002 Apr 04, 2013ACRIDINIUM BROMIDE

POWDER, METERED;INHALATION

TUDORZA PRESSAIR

+! COVIS

0.4MG/INH

N202450 001 Jul 23, 2012

ACRIDINIUM BROMIDE; FORMOTEROL FUMARATE

POWDER, METERED;INHALATION

DUAKLIR PRESSAIR

+! COVIS

0.4MG/INH;0.012MG/INH

N210595 001 Mar 29, 2019

ACYCLOVIR

CAPSULE;ORAL

ACYCLOVIRAB ! APOTEX200MGA075677 001 Sep 28, 2005AB CADILA200MGA204313 001 Mar 25, 2016AB CADILA PHARMS LTD200MGA201445 001 Mar 06, 2014AB CARLSBAD TECHNOLOGY200MGA206261 001 Aug 16, 2017AB HERITAGE PHARMS200MGA074889 001 Oct 31, 1997AB KENTON200MGA075090 001 Jan 26, 1999AB TEVA200MGA074578 001 Apr 22, 1997AB YILING200MGA212173 001 Sep 14, 2020

CREAM;TOPICAL

ACYCLOVIRAB AMNEAL5%A208766 001 Nov 09, 2020AB ! PADAGIS ISRAEL5%A208702 001 Feb 04, 2019ZOVIRAXAB + BAUSCH5%N021478 001 Dec 30, 2002

OINTMENT;TOPICAL

ACYCLOVIRAB ALEMBIC PHARMS5%A209000 001 Apr 06, 2018AB AMNEAL PHARMS5%A204605 001 Jun 18, 2014

PRESCRIPTION DRUG PRODUCT LIST

3-9 (of 474)

ACYCLOVIR

OINTMENT; TOPICAL

ACYCLOVIR

<u>AB</u>	APOTEX	<u>5%</u>	<u>A210774</u>	<u>001</u>	Sep 06, 2019
<u>AB</u>	CADILA	<u>5%</u>	<u>A205974</u>	<u>001</u>	Mar 15, 2019
<u>AB</u>	CHARTWELL RX	<u>5%</u>	<u>A212495</u>	<u>001</u>	Apr 07, 2020
<u>AB</u>	CIPLA	<u>5%</u>	<u>A211794</u>	<u>001</u>	Jan 18, 2019
<u>AB</u>	COSETTE	<u>5%</u>	<u>A205591</u>	<u>001</u>	Nov 13, 2017
<u>AB</u>	FOUGERA PHARMS INC	<u>5%</u>	<u>A206633</u>	<u>001</u>	May 11, 2016
<u>AB</u>	GLENMARK PHARMS SA	<u>5%</u>	<u>A205510</u>	<u>001</u>	Jul 31, 2017
<u>AB</u>	MACLEODS PHARMS LTD	<u>5%</u>	<u>A212444</u>	<u>001</u>	May 19, 2021
<u>AB</u>	MYLAN PHARMS INC	<u>5%</u>	<u>A202459</u>	<u>001</u>	Apr 03, 2013
<u>AB</u>	TARO	<u>5%</u>	<u>A205469</u>	<u>001</u>	Dec 21, 2016
<u>AB</u>	TORRENT	<u>5%</u>	<u>A209971</u>	<u>001</u>	Jan 11, 2019
<u>AB</u>	XIROMED	<u>5%</u>	<u>A201501</u>	<u>001</u>	Jan 29, 2020

ZOVIRAX

<u>AB</u>	<u>+</u> ! BAUSCH	<u>5%</u>	<u>N018604</u>	<u>001</u>	Mar 29, 1982

SUSPENSION; ORAL

ACYCLOVIR

<u>AB</u>	ACTAVIS MID ATLANTIC	<u>200MG/5ML</u>	<u>A074738</u>	<u>001</u>	Apr 28, 1997
<u>AB</u>	AKORN	<u>200MG/5ML</u>	<u>A077026</u>	<u>001</u>	Jun 07, 2005
<u>AB</u>	HERITAGE PHARMS INC	<u>200MG/5ML</u>	<u>A212718</u>	<u>001</u>	Apr 23, 2020
<u>AB</u>	HETERO LABS LTD III	<u>200MG/5ML</u>	<u>A215669</u>	<u>001</u>	Jul 01, 2022
<u>AB</u>	NOVITIUM PHARMA	<u>200MG/5ML</u>	<u>A212252</u>	<u>001</u>	Jul 10, 2020
<u>AB</u>	RUBICON	<u>200MG/5ML</u>	<u>A215724</u>	<u>001</u>	Aug 18, 2022
<u>AB</u>	VISTAPHARM	<u>200MG/5ML</u>	<u>A213951</u>	<u>001</u>	Jan 11, 2021

ZOVIRAX

<u>AB</u>	<u>+</u> ! MYLAN	<u>200MG/5ML</u>	<u>N019909</u>	<u>001</u>	Dec 22, 1989

TABLET; BUCCAL

SITAVIG

+! EPI HLTH

50MG

N203791 001 Apr 12, 2013

TABLET; ORAL

ACYCLOVIR

<u>AB</u>	APOTEX INC	<u>400MG</u>	<u>A077309</u>	<u>001</u>	Sep 29, 2005
<u>AB</u>		<u>800MG</u>	<u>A077309</u>	<u>002</u>	Sep 29, 2005
<u>AB</u>	CADILA PHARMS LTD	<u>400MG</u>	<u>A202168</u>	<u>001</u>	Nov 15, 2013
<u>AB</u>		<u>800MG</u>	<u>A202168</u>	<u>002</u>	Nov 15, 2013
<u>AB</u>	CARLSBAD	<u>400MG</u>	<u>A075382</u>	<u>001</u>	Apr 30, 1999
<u>AB</u>		<u>800MG</u>	<u>A075382</u>	<u>002</u>	Apr 30, 1999
<u>AB</u>	HERITAGE PHARMS	<u>400MG</u>	<u>A074891</u>	<u>001</u>	Oct 31, 1997
<u>AB</u>		<u>800MG</u>	<u>A074891</u>	<u>002</u>	Oct 31, 1997
<u>AB</u>	HETERO LABS LTD V	<u>400MG</u>	<u>A203834</u>	<u>001</u>	Oct 29, 2013
<u>AB</u>	<u>!</u>	<u>800MG</u>	<u>A203834</u>	<u>002</u>	Oct 29, 2013
<u>AB</u>	SQUARE PHARMS	<u>400MG</u>	<u>A209366</u>	<u>001</u>	Oct 07, 2019
<u>AB</u>		<u>800MG</u>	<u>A209366</u>	<u>002</u>	Oct 07, 2019
<u>AB</u>	STRIDES PHARMA	<u>400MG</u>	<u>A074946</u>	<u>001</u>	Nov 19, 1997
<u>AB</u>		<u>800MG</u>	<u>A074946</u>	<u>002</u>	Nov 19, 1997
<u>AB</u>	TEVA	<u>400MG</u>	<u>A074556</u>	<u>002</u>	Apr 22, 1997
<u>AB</u>		<u>800MG</u>	<u>A074556</u>	<u>003</u>	Apr 22, 1997
<u>AB</u>	YILING	<u>400MG</u>	<u>A210401</u>	<u>001</u>	Mar 07, 2018
<u>AB</u>		<u>800MG</u>	<u>A210401</u>	<u>002</u>	Mar 07, 2018
<u>AB</u>	ZYDUS PHARMS	<u>400MG</u>	<u>A204314</u>	<u>001</u>	Aug 19, 2014
<u>AB</u>		<u>800MG</u>	<u>A204314</u>	<u>002</u>	Aug 19, 2014

ACYCLOVIR SODIUM

INJECTABLE; INJECTION

ACYCLOVIR SODIUM

<u>AP</u>	EUGIA PHARMA	<u>EQ 50MG BASE/ML</u>	<u>A203701</u>	<u>001</u>	Oct 11, 2013
<u>AP</u>	<u>!</u> FRESENIUS KABI USA	<u>EQ 50MG BASE/ML</u>	<u>A074930</u>	<u>001</u>	May 13, 1998
<u>AP</u>	ZYDUS PHARMS	<u>EQ 50MG BASE/ML</u>	<u>A206535</u>	<u>001</u>	Aug 31, 2018

ACYCLOVIR; HYDROCORTISONE

CREAM; TOPICAL

XERESE

+! BAUSCH

5%; 1%

N022436 001 Jul 31, 2009

ADAGRASIB

TABLET; ORAL

KRAZATI

+! MIRATI THERAPS

200MG

N216340 001 Dec 12, 2022

PRESCRIPTION DRUG PRODUCT LIST

3-10 (of 474)

ADAPALENE

CREAM; TOPICAL

ADAPALENE

AB	FOUGERA PHARMS	0.1%	A090824	001	Jun 30, 2010

DIFFERIN

AB	+! GALDERMA LABS LP	0.1%	N020748	001	May 26, 2000

GEL; TOPICAL

ADAPALENE

AB	ACTAVIS MID	0.3%	A201000	001	Oct 27, 2014

ATLANTIC

AB	ALEOR	0.3%	A213508	001	Jun 18, 2020

DERMACEUTICALS

AB	TARO	0.3%	A208322	001	Jun 23, 2016

DIFFERIN

AB	+! GALDERMA LABS LP	0.3%	N021753	001	Jun 19, 2007

LOTION; TOPICAL

DIFFERIN

	+! GALDERMA LABS LP	0.1%	N022502	001	Mar 17, 2010

SOLUTION; TOPICAL

ADAPALENE

AB	CALL INC	0.1%	A203981	001	Sep 23, 2016

AB		0.1%	A204593	001	Jan 05, 2016

ADAPALENE; BENZOYL PEROXIDE

GEL; TOPICAL

ADAPALENE AND BENZOYL PEROXIDE

AB	ACTAVIS LABS UT INC	0.3%; 2.5%	A209641	001	Jun 22, 2022

AB	ALEOR	0.3%; 2.5%	A214185	001	Aug 04, 2022

DERMACEUTICALS

AB	GLENMARK PHARMS LTD	0.1%; 2.5%	A208108	001	Nov 08, 2019

AB	PADAGIS ISRAEL	0.1%; 2.5%	A205033	001	Jan 23, 2018

AB		0.3%; 2.5%	A212464	001	May 31, 2022

AB	TARO	0.1%; 2.5%	A206959	001	Jan 24, 2018

AB		0.3%; 2.5%	A209148	001	Oct 17, 2018

AB	ZYDUS PHARMS	0.3%; 2.5%	A214553	001	Jun 03, 2022

EPIDUO

AB	+! GALDERMA LABS LP	0.1%; 2.5%	N022320	001	Dec 08, 2008

EPIDUO FORTE

AB	+! GALDERMA LABS	0.3%; 2.5%	N207917	001	Jul 15, 2015

ADEFOVIR DIPIVOXIL

TABLET; ORAL

ADEFOVIR DIPIVOXIL

AB	APOTEX	10MG	A205459	001	Jul 06, 2018

AB	SIGMAPHARM LABS LLC	10MG	A202051	001	Aug 29, 2013

HEPSERA

AB	+! GILEAD	10MG	N021449	001	Sep 20, 2002

ADENOSINE

INJECTABLE; INJECTION

ADENOSINE

AP	! AKORN	3MG/ML	A078076	001	Oct 31, 2008

AP	FRESENIUS KABI USA	3MG/ML	A077133	001	Apr 27, 2005

AP		3MG/ML	A205568	001	Apr 16, 2018

AP	GLAND PHARMA LTD	3MG/ML	A077283	001	Jun 14, 2007

AP		3MG/ML	A206778	001	Feb 16, 2018

AP	HIKMA	3MG/ML	A076404	001	Jun 16, 2004

AP		3MG/ML	A076500	001	Jun 16, 2004

AP	MYLAN LABS LTD	3MG/ML	A078686	001	May 13, 2009

SOLUTION; INTRAVENOUS

ADENOSINE

AP	AKORN	60MG/20ML (3MG/ML)	A090450	001	Oct 02, 2014

AP		90MG/30ML (3MG/ML)	A090450	002	Oct 02, 2014

AP	EMCURE PHARMS LTD	60MG/20ML (3MG/ML)	A202313	001	Sep 15, 2014

AP		90MG/30ML (3MG/ML)	A202313	002	Sep 15, 2014

AP	EUGIA PHARMA	60MG/20ML (3MG/ML)	A205331	001	Nov 02, 2017

AP		90MG/30ML (3MG/ML)	A205331	002	Nov 02, 2017

AP	FRESENIUS KABI USA	60MG/20ML (3MG/ML)	A077897	001	Nov 27, 2017

AP		90MG/30ML (3MG/ML)	A077897	002	Nov 27, 2017

AP	HOSPIRA	60MG/20ML (3MG/ML)	A203883	001	Mar 24, 2014

AP		90MG/30ML (3MG/ML)	A203883	002	Mar 24, 2014

AP	MYLAN ASI	60MG/20ML (3MG/ML)	A090212	001	Mar 28, 2014

AP		90MG/30ML (3MG/ML)	A090212	002	Mar 28, 2014

AP	! TEVA PHARMS USA	60MG/20ML (3MG/ML)	A077425	001	Aug 29, 2013

PRESCRIPTION DRUG PRODUCT LIST

3-11 (of 474)

ADENOSINE

SOLUTION; INTRAVENOUS

ADENOSINE

AP	!	<u>90MG/30ML (3MG/ML)</u>	<u>A077425</u>	<u>002</u>	Aug 29, 2013

AFAMELANOTIDE

IMPLANT; SUBCUTANEOUS

SCENESSE

+	!	CLIVUNEL INC	16MG	N210797	001	Oct 08, 2019

AFATINIB DIMALEATE

TABLET; ORAL

GILOTRIF

+		BOEHRINGER	EQ 20MG BASE	N201292	001	Jul 12, 2013

INGELHEIM

+			EQ 30MG BASE	N201292	002	Jul 12, 2013

+	!		EQ 40MG BASE	N201292	003	Jul 12, 2013

AIR POLYMER-TYPE A

FOAM; INTRAUTERINE

EXEM FOAM KIT

+	!	GISKIT	10ML	N212279	001	Nov 07, 2019

ALBENDAZOLE

TABLET; ORAL

ALBENDAZOLE

AB		ACTAVIS ELIZABETH	<u>200MG</u>	<u>A208094</u>	<u>001</u>	May 20, 2019

AB		CIPLA LTD	<u>200MG</u>	<u>A210434</u>	<u>001</u>	Sep 21, 2018

AB	!	DR REDDYS	<u>200MG</u>	<u>A211034</u>	<u>001</u>	Jan 26, 2021

AB		EDENBRIDGE PHARMS	<u>200MG</u>	<u>A211117</u>	<u>001</u>	May 14, 2019

AB		MSN	<u>200MG</u>	<u>A213435</u>	<u>001</u>	Jan 21, 2021

AB		STRIDES PHARMA	<u>200MG</u>	<u>A210011</u>	<u>001</u>	Dec 07, 2018

AB		ZYDUS PHARMS	<u>200MG</u>	<u>A208979</u>	<u>001</u>	Dec 14, 2018

ALBUMIN HUMAN

INJECTABLE; INJECTION

OPTISON

+	!	GE HEALTHCARE	10MG/ML	N020899	001	Dec 31, 1997

ALBUTEROL SULFATE

AEROSOL, METERED; INHALATION

ALBUTEROL SULFATE

AB1		CIPLA	<u>EQ 0.09MG BASE/INH</u>	<u>A209959</u>	<u>001</u>	Apr 08, 2020

AB1		SANDOZ INC	<u>EQ 0.09MG BASE/INH</u>	<u>A207085</u>	<u>001</u>	Jun 01, 2021

PROVENTIL-HFA

AB1	+	!	KINDEVA	<u>EQ 0.09MG BASE/INH</u>	<u>N020503</u>	Aug 15, 1996

ALBUTEROL SULFATE

AB2		LUPIN	<u>EQ 0.09MG BASE/INH</u>	<u>A209954</u>	<u>001</u>	Aug 24, 2020

PROAIR HFA

AB2	+	!	TEVA BRANDED PHARM	<u>EQ 0.09MG BASE/INH</u>	<u>N021457</u>	Oct 29, 2004

VENTOLIN HFA

BX	+	!	GLAXOSMITHKLINE	EQ 0.09MG BASE/INH	N020983	001	Apr 19, 2001

POWDER, METERED; INHALATION

PROAIR DIGIHALER

+		TEVA BRANDED PHARM	EQ 0.09MG BASE/INH	N205636	002	Dec 21, 2018

PROAIR RESPICLICK

+	!	TEVA BRANDED PHARM	EQ 0.09MG BASE/INH	N205636	001	Mar 31, 2015

SOLUTION; INHALATION

ACCUNE

AN	+	!	MYLAN SPECIALITY LP	<u>EQ 0.021% BASE</u>	<u>N020949</u>	<u>002</u>	Apr 30, 2001

ALBUTEROL SULFATE

AN		AKORN	<u>EQ 0.5% BASE</u>	<u>A074543</u>	<u>001</u>	Jan 15, 1998

AN		LUOXIN AUROVITAS	<u>EQ 0.083% BASE</u>	<u>A206224</u>	<u>001</u>	Oct 17, 2017

AN		NEPHRON	<u>EQ 0.021% BASE</u>	<u>A076355</u>	<u>002</u>	Mar 31, 2010

AN	!		<u>EQ 0.042% BASE</u>	<u>A076355</u>	<u>001</u>	Jun 28, 2004

AN	!		<u>EQ 0.083% BASE</u>	<u>A074880</u>	<u>001</u>	Sep 17, 1997

AN	!		<u>EQ 0.5% BASE</u>	<u>A075664</u>	<u>001</u>	Jun 26, 2001

AN		RITEDOSE CORP	<u>EQ 0.021% BASE</u>	<u>A214531</u>	<u>001</u>	Dec 28, 2021

AN			<u>EQ 0.042% BASE</u>	<u>A214531</u>	<u>002</u>	Dec 28, 2021

AN			<u>EQ 0.083% BASE</u>	<u>A077839</u>	<u>001</u>	Dec 16, 2008

AN		SUN PHARM	<u>EQ 0.083% BASE</u>	<u>A207857</u>	<u>001</u>	Jul 21, 2017

AN		WATSON LABS	<u>EQ 0.021% BASE</u>	<u>A077772</u>	<u>001</u>	Sep 25, 2007

AN			<u>EQ 0.042% BASE</u>	<u>A077772</u>	<u>002</u>	Sep 25, 2007

PRESCRIPTION DRUG PRODUCT LIST

3-12 (of 474)

ALBUTEROL SULFATE

SYRUP; ORAL

ALBUTEROL SULFATE

<u>AA</u>	AKORN	<u>EQ 2MG BASE/5ML</u>	<u>A074749</u>	<u>001</u>	Jan 30, 1998
<u>AA</u>	AMNEAL PHARMS	<u>EQ 2MG BASE/5ML</u>	<u>A079241</u>	<u>001</u>	May 12, 2010
<u>AA</u>	CHARTWELL MOLECULAR	<u>EQ 2MG BASE/5ML</u>	<u>A078105</u>	<u>001</u>	Dec 27, 2006
<u>AA</u>	CHARTWELL RX	<u>EQ 2MG BASE/5ML</u>	<u>A077788</u>	<u>001</u>	Jun 26, 2007
<u>AA</u>	COSETTE	<u>EQ 2MG BASE/5ML</u>	<u>A074454</u>	<u>001</u>	Sep 25, 1995
<u>AA</u>	QUAGEN	<u>EQ 2MG BASE/5ML</u>	<u>A212197</u>	<u>001</u>	Sep 06, 2019
<u>AA</u>	! TEVA	<u>EQ 2MG BASE/5ML</u>	<u>A073419</u>	<u>001</u>	Mar 30, 1992

TABLET; ORAL

ALBUTEROL SULFATE

<u>AB</u>	AIZANT	<u>EQ 2MG BASE</u>	<u>A210948</u>	<u>001</u>	Mar 15, 2019
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A210948</u>	<u>002</u>	Mar 15, 2019
<u>AB</u>	AMNEAL PHARMS CO	<u>EQ 2MG BASE</u>	<u>A208804</u>	<u>001</u>	May 21, 2018
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A208804</u>	<u>002</u>	May 21, 2018
<u>AB</u>	MYLAN	<u>EQ 2MG BASE</u>	<u>A072894</u>	<u>002</u>	Jan 17, 1991
<u>AB</u>	!	<u>EQ 4MG BASE</u>	<u>A072894</u>	<u>001</u>	Jan 17, 1991
<u>AB</u>	RISING	<u>EQ 2MG BASE</u>	<u>A207046</u>	<u>001</u>	Jun 29, 2018
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A207046</u>	<u>002</u>	Jun 29, 2018
<u>AB</u>	SUN PHARM INDUSTRIES	<u>EQ 2MG BASE</u>	<u>A072637</u>	<u>002</u>	Dec 05, 1989
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A072637</u>	<u>001</u>	Dec 05, 1989
<u>AB</u>	VIRTUS PHARM	<u>EQ 2MG BASE</u>	<u>A211397</u>	<u>001</u>	Oct 26, 2018
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A211397</u>	<u>002</u>	Oct 26, 2018
<u>AB</u>	ZYDUS PHARMS	<u>EQ 2MG BASE</u>	<u>A208884</u>	<u>001</u>	Oct 22, 2020
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A208884</u>	<u>002</u>	Oct 22, 2020

ALBUTEROL SULFATE; IPRATROPIUM BROMIDE

SOLUTION; INHALATION

ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE

<u>AN</u>	CIPLA	<u>EQ 0.083% BASE; 0.017%</u>	<u>A077559</u>	<u>001</u>	Dec 31, 2007
<u>AN</u>	! NEPHRON	<u>EQ 0.083% BASE; 0.017%</u>	<u>A076749</u>	<u>001</u>	Dec 31, 2007
<u>AN</u>	RITEDOSE CORP	<u>EQ 0.083% BASE; 0.017%</u>	<u>A202496</u>	<u>001</u>	Oct 01, 2012
<u>AN</u>	SUN PHARM	<u>EQ 0.083% BASE; 0.017%</u>	<u>A207875</u>	<u>001</u>	Aug 07, 2017

SPRAY, METERED; INHALATION

COMBIVENT RESPIMAT

+	!	BOEHRINGER	EQ 0.1MG BASE/INH; 0.02MG/INH	N021747	001	Oct 07, 2011
		INGELHEIM				

ALCLOMETASONE DIPROPIONATE

CREAM; TOPICAL

ALCLOMETASONE DIPROPIONATE

<u>AB</u>	!	FOUGERA PHARMS	<u>0.05%</u>	<u>A076973</u>	<u>001</u>	Jul 12, 2005
<u>AB</u>		GLENMARK GENERICS	<u>0.05%</u>	<u>A079061</u>	<u>001</u>	Jun 23, 2009
<u>AB</u>		TARO	<u>0.05%</u>	<u>A076587</u>	<u>001</u>	Sep 15, 2005

OINTMENT; TOPICAL

ALCLOMETASONE DIPROPIONATE

<u>AB</u>	!	FOUGERA PHARMS	<u>0.05%</u>	<u>A076884</u>	<u>001</u>	Jul 18, 2005
<u>AB</u>		GLENMARK GENERICS	<u>0.05%</u>	<u>A079227</u>	<u>001</u>	Jul 30, 2009
<u>AB</u>		TARO	<u>0.05%</u>	<u>A076730</u>	<u>001</u>	Jul 29, 2004

ALCOHOL

SOLUTION; INTRA-ARTERIAL

ABLYSINOL

+	BPI LABS	99% (1ML)	N207987	001	Jun 21, 2018
+	!	99% (5ML)	N207987	002	Jun 21, 2018

ALECTINIB HYDROCHLORIDE

CAPSULE; ORAL

ALECENSA

+	!	HOFFMANN-LA ROCHE	EQ 150MG BASE	N208434	001	Dec 11, 2015

ALENDRONATE SODIUM

SOLUTION; ORAL

ALENDRONATE SODIUM

!	HIKMA	EQ 70MG BASE/75ML	A090520	001	Feb 25, 2013

TABLET; ORAL

ALENDRONATE SODIUM

<u>AB</u>	APOTEX	<u>EQ 5MG BASE</u>	<u>A077982</u>	<u>001</u>	Aug 04, 2008
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077982</u>	<u>002</u>	Aug 04, 2008
<u>AB</u>		<u>EQ 35MG BASE</u>	<u>A077982</u>	<u>003</u>	Aug 04, 2008
<u>AB</u>		<u>EQ 70MG BASE</u>	<u>A077982</u>	<u>004</u>	Aug 04, 2008
<u>AB</u>	AUROBINDO PHARMA	<u>EQ 10MG BASE</u>	<u>A090124</u>	<u>001</u>	Aug 04, 2008
<u>AB</u>		<u>EQ 35MG BASE</u>	<u>A090124</u>	<u>002</u>	Aug 04, 2008

PRESCRIPTION DRUG PRODUCT LIST

3-13 (of 474)

ALENDRONATE SODIUM

TABLET; ORAL

ALENDRONATE SODIUM

<u>AB</u>		<u>EQ 70MG BASE</u>	<u>A090124</u>	<u>003</u>	Aug 04, 2008
<u>AB</u>	CIPLA	<u>EQ 5MG BASE</u>	<u>A076768</u>	<u>001</u>	Aug 04, 2008
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A076768</u>	<u>002</u>	Aug 04, 2008
<u>AB</u>		<u>EQ 35MG BASE</u>	<u>A076768</u>	<u>003</u>	Aug 04, 2008
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A076768</u>	<u>004</u>	Aug 04, 2008
<u>AB</u>		<u>EQ 70MG BASE</u>	<u>A076768</u>	<u>005</u>	Aug 04, 2008
<u>AB</u>	HANGZHOU BINJIANG	<u>EQ 5MG BASE</u>	<u>A090258</u>	<u>001</u>	Sep 24, 2009
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A090258</u>	<u>002</u>	Sep 24, 2009
<u>AB</u>		<u>EQ 35MG BASE</u>	<u>A090258</u>	<u>003</u>	Sep 24, 2009
<u>AB</u>		<u>EQ 70MG BASE</u>	<u>A090258</u>	<u>004</u>	Sep 24, 2009
<u>AB</u>	SUN PHARM	<u>EQ 5MG BASE</u>	<u>A090022</u>	<u>001</u>	Sep 10, 2008
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A090022</u>	<u>002</u>	Sep 10, 2008
<u>AB</u>		<u>EQ 35MG BASE</u>	<u>A090022</u>	<u>003</u>	Sep 10, 2008
<u>AB</u>		<u>EQ 70MG BASE</u>	<u>A090022</u>	<u>004</u>	Sep 10, 2008
<u>AB</u>	WATSON LABS	<u>EQ 35MG BASE</u>	<u>A076984</u>	<u>001</u>	Aug 04, 2008
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A076984</u>	<u>002</u>	Aug 04, 2008
<u>AB</u>		<u>EQ 70MG BASE</u>	<u>A076984</u>	<u>003</u>	Aug 04, 2008

FOSAMAX

<u>AB</u>	+! ORGANON	<u>EQ 70MG BASE</u>	<u>N020560</u>	<u>005</u>	Oct 20, 2000
TABLET, EFFERVESCENT; ORAL					
BINOSTO					
	+! ASCEND THERAPS US	EQ 70MG BASE	N202344	001	Mar 12, 2012

ALENDRONATE SODIUM; CHOLECALCIFEROL

TABLET; ORAL

FOSAMAX PLUS D

+	ORGANON LLC	EQ 70MG BASE; 2,800 IU	N021762	001	Apr 07, 2005
+		EQ 70MG BASE; 5,600 IU	N021762	002	Apr 26, 2007

ALFENTANIL HYDROCHLORIDE

INJECTABLE; INJECTION

ALFENTA

<u>AP</u>	+! AKORN	<u>EQ 0.5MG BASE/ML</u>	<u>N019353</u>	<u>001</u>	Dec 29, 1986
<u>ALFENTANIL</u>					
<u>AP</u>	HOSPIRA	<u>EQ 0.5MG BASE/ML</u>	<u>A075221</u>	<u>001</u>	Oct 28, 1999

ALFUZOSIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

ALFUZOSIN HYDROCHLORIDE

<u>AB</u>	APOTEX INC	<u>10MG</u>	<u>A079013</u>	<u>001</u>	Jul 18, 2011
<u>AB</u>	AUROBINDO PHARMA LTD	<u>10MG</u>	<u>A079060</u>	<u>001</u>	Aug 30, 2012
<u>AB</u>	INVAGEN PHARMS	<u>10MG</u>	<u>A090284</u>	<u>001</u>	Jan 17, 2012
<u>AB</u>	SUN PHARM	<u>10MG</u>	<u>A079057</u>	<u>001</u>	Jul 18, 2011
<u>AB</u>	UNICHEM	<u>10MG</u>	<u>A203192</u>	<u>001</u>	Jan 28, 2016

UROXATRAL

<u>AB</u>	+! CONCORDIA	<u>10MG</u>	<u>N021287</u>	<u>001</u>	Jun 12, 2003

ALISKIREN HEMIFUMARATE

TABLET; ORAL

ALISKIREN HEMIFUMARATE

<u>AB</u>	ANCHEN PHARMS	<u>EQ 150MG BASE</u>	<u>A206665</u>	<u>001</u>	Mar 22, 2019
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A206665</u>	<u>002</u>	Mar 22, 2019
<u>TEKTURNA</u>					
<u>AB</u>	+ NODEN PHARMA	<u>EQ 150MG BASE</u>	<u>N021985</u>	<u>001</u>	Mar 05, 2007
<u>AB</u>	+!	<u>EQ 300MG BASE</u>	<u>N021985</u>	<u>002</u>	Mar 05, 2007

ALITRETINOIN

GEL; TOPICAL

PANRETIN

+	CONCORDIA	EQ 0.1% BASE	N020886	001	Feb 02, 1999

ALLOPURINOL

TABLET; ORAL

ALLOPURINOL

<u>AB</u>	ACCORD HLTHCARE	<u>100MG</u>	<u>A203154</u>	<u>001</u>	May 06, 2013
<u>AB</u>	!	<u>300MG</u>	<u>A203154</u>	<u>002</u>	May 06, 2013
<u>AB</u>	CHARTWELL	<u>100MG</u>	<u>A077353</u>	<u>001</u>	Sep 08, 2005
<u>AB</u>		<u>300MG</u>	<u>A077353</u>	<u>002</u>	Sep 08, 2005
<u>AB</u>	HARMAN FINOCHEM	<u>100MG</u>	<u>A214443</u>	<u>001</u>	Mar 07, 2022
<u>AB</u>		<u>300MG</u>	<u>A214443</u>	<u>002</u>	Mar 07, 2022
<u>AB</u>	INDOCO	<u>100MG</u>	<u>A204467</u>	<u>001</u>	Jul 28, 2016
<u>AB</u>		<u>300MG</u>	<u>A204467</u>	<u>002</u>	Jul 28, 2016

PRESCRIPTION DRUG PRODUCT LIST

3-14 (of 474)

ALLOPURINOL

TABLET; ORAL

ALLOPURINOL

<u>AB</u>	IPCA LABS LTD	<u>100MG</u>	<u>A090637</u>	<u>001</u>	Mar 16, 2011
<u>AB</u>		<u>300MG</u>	<u>A090637</u>	<u>002</u>	Mar 16, 2011
<u>AB</u>	MYLAN	<u>100MG</u>	<u>A018659</u>	<u>001</u>	Oct 24, 1986
<u>AB</u>		<u>300MG</u>	<u>A018659</u>	<u>002</u>	Oct 24, 1986
<u>AB</u>	NORTHSTAR HLTHCARE	<u>100MG</u>	<u>A078253</u>	<u>001</u>	Sep 11, 2007
<u>AB</u>		<u>300MG</u>	<u>A078253</u>	<u>002</u>	Sep 11, 2007
<u>AB</u>	SUN PHARM INDUSTRIES	<u>100MG</u>	<u>A071450</u>	<u>002</u>	Jan 09, 1987
<u>AB</u>		<u>300MG</u>	<u>A071450</u>	<u>001</u>	Jan 09, 1987
<u>AB</u>	UNICHEM	<u>100MG</u>	<u>A211820</u>	<u>001</u>	Mar 12, 2019
<u>AB</u>		<u>300MG</u>	<u>A211820</u>	<u>002</u>	Mar 12, 2019
<u>AB</u>	VINTAGE PHARMS	<u>100MG</u>	<u>A075798</u>	<u>001</u>	Jun 27, 2003
<u>AB</u>		<u>300MG</u>	<u>A075798</u>	<u>002</u>	Jun 27, 2003
<u>AB</u>	WATSON LABS	<u>100MG</u>	<u>N018832</u>	<u>002</u>	Sep 28, 1984
<u>AB</u>		<u>300MG</u>	<u>N018877</u>	<u>001</u>	Sep 28, 1984
<u>AB</u>	ZYDUS PHARMS	<u>100MG</u>	<u>A210117</u>	<u>001</u>	Oct 12, 2017
<u>AB</u>		<u>300MG</u>	<u>A210117</u>	<u>002</u>	Oct 12, 2017

LOPURIN

<u>AB</u>	DR REDDYS LA	<u>100MG</u>	<u>A071586</u>	<u>001</u>	Apr 02, 1987
<u>AB</u>		<u>300MG</u>	<u>A071587</u>	<u>001</u>	Apr 02, 1987

ZYLOPRIM

<u>AB</u>	+	CASPER PHARMA LLC	<u>100MG</u>	<u>N016084</u>	<u>001</u>
<u>AB</u>	+		<u>300MG</u>	<u>N016084</u>	<u>002</u>
	+			N016084	003 Aug 04, 2022

ALLOPURINOL SODIUM

INJECTABLE; INJECTION

ALLOPURINOL SODIUM

<u>AP</u>	GLAND PHARMA LTD	<u>EQ 500MG BASE/VIAL</u>	<u>A212363</u>	<u>001</u>	Jan 26, 2022
<u>AP</u>	HIKMA	<u>EQ 500MG BASE/VIAL</u>	<u>A076870</u>	<u>001</u>	Aug 26, 2004

ALOPRIM

<u>AP</u>	+	MYLAN	<u>EQ 500MG BASE/VIAL</u>	<u>N020298</u>	<u>001</u> May 17, 1996

ALMOTRIPTAN MALATE

TABLET; ORAL

ALMOTRIPTAN MALATE

<u>AB</u>	AJANTA PHARMA LTD	<u>EQ 6.25MG BASE</u>	<u>A205523</u>	<u>001</u>	Mar 03, 2016
<u>AB</u>	!	<u>EQ 12.5MG BASE</u>	<u>A205523</u>	<u>002</u>	Mar 03, 2016
<u>AB</u>	MYLAN	<u>EQ 6.25MG BASE</u>	<u>A205171</u>	<u>001</u>	Nov 09, 2015
<u>AB</u>		<u>EQ 12.5MG BASE</u>	<u>A205171</u>	<u>002</u>	Nov 09, 2015
<u>AB</u>	TEVA PHARMS USA	<u>EQ 6.25MG BASE</u>	<u>A078027</u>	<u>001</u>	Jul 07, 2015
<u>AB</u>		<u>EQ 12.5MG BASE</u>	<u>A078027</u>	<u>002</u>	Jul 07, 2015

ALOGLIPTIN BENZOATE

TABLET; ORAL

NESINA

+	TAKEDA PHARMS USA	EQ 6.25MG BASE	N022271	001	Jan 25, 2013
+		EQ 12.5MG BASE	N022271	002	Jan 25, 2013
+	!	EQ 25MG BASE	N022271	003	Jan 25, 2013

ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE

TABLET; ORAL

KAZANO

+	TAKEDA PHARMS USA	EQ 12.5MG BASE; 500MG	N203414	001	Jan 25, 2013
+	!	EQ 12.5MG BASE; 1GM	N203414	002	Jan 25, 2013

ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

OSENI

+	TAKEDA PHARMS USA	EQ 12.5MG BASE; EQ 30MG BASE	N022426	005	Jan 25, 2013
+		EQ 25MG BASE; EQ 15MG BASE	N022426	001	Jan 25, 2013
+		EQ 25MG BASE; EQ 30MG BASE	N022426	002	Jan 25, 2013
+	!	EQ 25MG BASE; EQ 45MG BASE	N022426	003	Jan 25, 2013

ALOSETRON HYDROCHLORIDE

TABLET; ORAL

ALOSETRON HYDROCHLORIDE

<u>AB</u>	AMNEAL PHARMS	<u>EQ 0.5MG BASE</u>	<u>A206647</u>	<u>001</u>	Dec 22, 2016
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A206647</u>	<u>002</u>	Dec 22, 2016
<u>AB</u>	HIKMA	<u>EQ 0.5MG BASE</u>	<u>A200652</u>	<u>001</u>	May 04, 2015
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A200652</u>	<u>002</u>	May 04, 2015
<u>AB</u>	MANKIND PHARMA	<u>EQ 0.5MG BASE</u>	<u>A213614</u>	<u>001</u>	Sep 09, 2020
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A213614</u>	<u>002</u>	Sep 09, 2020

PRESCRIPTION DRUG PRODUCT LIST

3-15 (of 474)

ALOSETRON HYDROCHLORIDE

TABLET; ORAL

ALOSETRON HYDROCHLORIDE

AB	RISING	<u>EQ 0.5MG BASE</u>	<u>A209180 001</u>	Jan 14, 2019
AB		<u>EQ 1MG BASE</u>	<u>A209180 002</u>	Jan 14, 2019
<u>LOTROXEX</u>				
AB	+ SEBELA IRELAND LTD	<u>EQ 0.5MG BASE</u>	<u>N021107 002</u>	Dec 23, 2003
AB	+!	<u>EQ 1MG BASE</u>	<u>N021107 001</u>	Feb 09, 2000

ALPELISIB

TABLET; ORAL

PIQRAY

+	NOVARTIS	50MG	N212526 001	May 24, 2019
+		150MG	N212526 002	May 24, 2019
+	!	200MG	N212526 003	May 24, 2019

VIJOICE

+	NOVARTIS	50MG	N215039 001	Apr 05, 2022
+		125MG	N215039 002	Apr 05, 2022
+	!	200MG	N215039 003	Apr 05, 2022

ALPHA-TOCOPHEROL ACETATE; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL;
FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE
HYDROCHLORIDE; VITAMIN A PALMITATE; VITAMIN K

SOLUTION; INTRAVENOUS

INFUVITE ADULT

+	SANDOZ CANADA INC	2 IU/ML; 40MG/ML; 12MCG/ML; 40 IU/ML; 1MCG/ML; 3MG/ML; 120MCG/ML; 8MG/ML; 1.2MG/ML; 0.72MG/ML; 1.2MG/ML; 660 IU/ML; 0.03MG/ML	N021163 001	May 18, 2000
+	!	2 IU/ML; 40MG/ML; 12MCG/ML; 40 IU/ML; 1MCG/ML; 3MG/ML; 120MCG/ML; 8MG/ML; 1.2MG/ML; 0.72MG/ML; 1.2MG/ML; 660 IU/ML; 30MCG/ML	N021163 002	Jun 16, 2003

ALPRAZOLAM

CONCENTRATE; ORAL

ALPRAZOLAM

!	HIKMA	1MG/ML	A074312 001	Oct 31, 1993

TABLET; ORAL

ALPRAZOLAM

AB	ACTAVIS ELIZABETH	<u>0.25MG</u>	<u>A074342 001</u>	Oct 31, 1993
AB		<u>0.5MG</u>	<u>A074342 002</u>	Oct 31, 1993
AB		<u>1MG</u>	<u>A074342 003</u>	Oct 31, 1993
AB		<u>2MG</u>	<u>A074342 004</u>	Oct 31, 1993
AB	APOTEX INC	<u>0.25MG</u>	<u>A077741 001</u>	Jan 19, 2007
AB		<u>0.5MG</u>	<u>A077741 002</u>	Jan 19, 2007
AB		<u>1MG</u>	<u>A077741 003</u>	Jan 19, 2007
AB		<u>2MG</u>	<u>A077741 004</u>	Jan 19, 2007
AB	AUROBINDO PHARMA	<u>0.25MG</u>	<u>A203346 001</u>	Jul 31, 2015
AB		<u>0.5MG</u>	<u>A203346 002</u>	Jul 31, 2015
AB		<u>1MG</u>	<u>A203346 003</u>	Jul 31, 2015
AB		<u>2MG</u>	<u>A203346 004</u>	Jul 31, 2015
AB	BRECKENRIDGE	<u>0.25MG</u>	<u>A207507 001</u>	Jul 09, 2018
AB		<u>0.5MG</u>	<u>A207507 002</u>	Jul 09, 2018
AB		<u>1MG</u>	<u>A207507 003</u>	Jul 09, 2018
AB		<u>2MG</u>	<u>A207507 004</u>	Jul 09, 2018
AB	NATCO	<u>0.25MG</u>	<u>A200739 001</u>	Apr 15, 2015
AB		<u>0.5MG</u>	<u>A200739 002</u>	Apr 15, 2015
AB		<u>1MG</u>	<u>A200739 003</u>	Apr 15, 2015
AB		<u>2MG</u>	<u>A200739 004</u>	Apr 15, 2015
AB	NOVITIUM PHARMA	<u>0.25MG</u>	<u>A074174 001</u>	Oct 19, 1993
AB		<u>0.5MG</u>	<u>A074174 002</u>	Oct 19, 1993
AB		<u>1MG</u>	<u>A074174 003</u>	Oct 19, 1993
AB		<u>2MG</u>	<u>A074174 004</u>	Oct 19, 1993
AB	SANDOZ	<u>0.25MG</u>	<u>A074112 001</u>	Dec 29, 1995
AB		<u>0.5MG</u>	<u>A074112 002</u>	Dec 29, 1995
AB		<u>1MG</u>	<u>A074112 003</u>	Dec 29, 1995
AB		<u>2MG</u>	<u>A074909 001</u>	Mar 25, 1998
AB	STRIDES PHARMA	<u>0.25MG</u>	<u>A090248 001</u>	Sep 17, 2010
AB		<u>0.5MG</u>	<u>A090248 002</u>	Sep 17, 2010
AB		<u>1MG</u>	<u>A090248 003</u>	Sep 17, 2010
AB		<u>2MG</u>	<u>A090248 004</u>	Sep 17, 2010
AB	SUN PHARM	<u>0.25MG</u>	<u>A090082 001</u>	Jun 17, 2010
AB		<u>0.5MG</u>	<u>A090082 002</u>	Jun 17, 2010
AB		<u>1MG</u>	<u>A090082 003</u>	Jun 17, 2010

PRESCRIPTION DRUG PRODUCT LIST

3-16 (of 474)

ALPRAZOLAM

TABLET; ORAL

ALPRAZOLAM

<u>AB</u>		<u>2MG</u>	<u>A090082</u>	<u>004</u>	Jun 17, 2010

XANAX

<u>AB</u>	+	UPJOHN	<u>0.25MG</u>	<u>N018276</u>	<u>001</u>	
<u>AB</u>	+		<u>0.5MG</u>	<u>N018276</u>	<u>002</u>	
<u>AB</u>	+	!	<u>1MG</u>	<u>N018276</u>	<u>003</u>	
<u>AB</u>	+		<u>2MG</u>	<u>N018276</u>	<u>004</u>	Nov 27, 1985

TABLET, EXTENDED RELEASE; ORAL

ALPRAZOLAM

<u>AB</u>		ACTAVIS ELIZABETH	<u>0.5MG</u>	<u>A078056</u>	<u>001</u>	Feb 13, 2007
<u>AB</u>			<u>1MG</u>	<u>A078056</u>	<u>002</u>	Feb 13, 2007
<u>AB</u>			<u>2MG</u>	<u>A078056</u>	<u>003</u>	Feb 13, 2007
<u>AB</u>			<u>3MG</u>	<u>A078056</u>	<u>004</u>	Feb 13, 2007
<u>AB</u>		AMNEAL PHARMS NY	<u>0.5MG</u>	<u>A078387</u>	<u>001</u>	May 30, 2008
<u>AB</u>			<u>1MG</u>	<u>A078387</u>	<u>002</u>	May 30, 2008
<u>AB</u>			<u>2MG</u>	<u>A078387</u>	<u>003</u>	May 30, 2008
<u>AB</u>			<u>3MG</u>	<u>A078387</u>	<u>004</u>	May 30, 2008
<u>AB</u>		ANCHEN PHARMS	<u>0.5MG</u>	<u>A078469</u>	<u>001</u>	Sep 29, 2011
<u>AB</u>			<u>1MG</u>	<u>A078469</u>	<u>002</u>	Sep 29, 2011
<u>AB</u>			<u>2MG</u>	<u>A078469</u>	<u>003</u>	Sep 29, 2011
<u>AB</u>			<u>3MG</u>	<u>A078469</u>	<u>004</u>	Sep 29, 2011
<u>AB</u>		APOTEX INC	<u>0.5MG</u>	<u>A078449</u>	<u>001</u>	Nov 12, 2008
<u>AB</u>			<u>1MG</u>	<u>A078449</u>	<u>004</u>	Dec 23, 2015
<u>AB</u>			<u>2MG</u>	<u>A078449</u>	<u>002</u>	Nov 12, 2008
<u>AB</u>			<u>3MG</u>	<u>A078449</u>	<u>003</u>	Nov 12, 2008
<u>AB</u>		AUROBINDO PHARMA	<u>0.5MG</u>	<u>A090871</u>	<u>001</u>	Jun 07, 2011
<u>AB</u>			<u>1MG</u>	<u>A090871</u>	<u>002</u>	Jun 07, 2011
<u>AB</u>			<u>2MG</u>	<u>A090871</u>	<u>003</u>	Jun 07, 2011
<u>AB</u>			<u>3MG</u>	<u>A090871</u>	<u>004</u>	Jun 07, 2011

XANAX XR

<u>AB</u>	+	UPJOHN	<u>0.5MG</u>	<u>N021434</u>	<u>001</u>	Jan 17, 2003
<u>AB</u>	+		<u>1MG</u>	<u>N021434</u>	<u>002</u>	Jan 17, 2003
<u>AB</u>	+		<u>2MG</u>	<u>N021434</u>	<u>003</u>	Jan 17, 2003
<u>AB</u>	+	!	<u>3MG</u>	<u>N021434</u>	<u>004</u>	Jan 17, 2003

TABLET, ORALLY DISINTEGRATING; ORAL

ALPRAZOLAM

<u>AB</u>		ACTAVIS ELIZABETH	<u>0.25MG</u>	<u>A078561</u>	<u>001</u>	Mar 16, 2010
<u>AB</u>			<u>0.5MG</u>	<u>A078561</u>	<u>002</u>	Mar 16, 2010
<u>AB</u>			<u>1MG</u>	<u>A078561</u>	<u>003</u>	Mar 16, 2010
<u>AB</u>			<u>2MG</u>	<u>A078561</u>	<u>004</u>	Mar 16, 2010
<u>AB</u>		PAR PHARM	<u>0.25MG</u>	<u>A078088</u>	<u>001</u>	Jan 09, 2009
<u>AB</u>			<u>0.5MG</u>	<u>A078088</u>	<u>002</u>	Jan 09, 2009
<u>AB</u>	!		<u>1MG</u>	<u>A078088</u>	<u>003</u>	Jan 09, 2009
<u>AB</u>			<u>2MG</u>	<u>A078088</u>	<u>004</u>	Jan 09, 2009

ALPROSTADIL

INJECTABLE; INJECTION

ALPROSTADIL

<u>AP</u>		HIKMA	<u>0.5MG/ML</u>	<u>A074815</u>	<u>001</u>	Jan 20, 1998
<u>AP</u>		TEVA PHARMS USA	<u>0.5MG/ML</u>	<u>A075196</u>	<u>001</u>	Apr 30, 1999

CAVERJECT

<u>AP</u>	+	PFIZER	<u>0.01MG/VIAL</u>	<u>N020379</u>	<u>001</u>	Jul 06, 1995
<u>AP</u>	+	!	<u>0.02MG/VIAL</u>	<u>N020379</u>	<u>002</u>	Jul 06, 1995
<u>AP</u>	+	!	<u>0.04MG/VIAL</u>	<u>N020379</u>	<u>004</u>	May 19, 1997

EDEX

<u>AP</u>	+	AUXILIUM PHARMS LLC	<u>0.01MG/VIAL</u>	<u>N020649</u>	<u>002</u>	Jun 12, 1997
<u>AP</u>	+		<u>0.02MG/VIAL</u>	<u>N020649</u>	<u>003</u>	Jun 12, 1997
<u>AP</u>	+	!	<u>0.04MG/VIAL</u>	<u>N020649</u>	<u>004</u>	Jun 12, 1997

PROSTIN VR PEDIATRIC

<u>AP</u>	+	!	PFIZER	<u>0.5MG/ML</u>	<u>N018484</u>	<u>001</u>	
			CAVERJECT IMPULSE				
			PFIZER	0.01MG/VIAL	N021212	001	Jun 11, 2002
				0.02MG/VIAL	N021212	002	Jun 11, 2002

EDEX

+	!	AUXILIUM PHARMS LLC	0.01MG/VIAL	N020649	005	Jul 30, 1998
+	!		0.02MG/VIAL	N020649	006	Jul 30, 1998
+	!		0.04MG/VIAL	N020649	007	Jul 30, 1998

SUPPOSITORY; URETHRAL

MUSE

+	!	MYLAN SPECIALITY LP	0.25MG	N020700	002	Nov 19, 1996
+	!		0.5MG	N020700	003	Nov 19, 1996

PRESCRIPTION DRUG PRODUCT LIST

3-17 (of 474)

ALPROSTADIL

SUPPOSITORY; URETHRAL

MUSE

+!

1MG

N020700 004 Nov 19, 1996

ALVIMOPAN

CAPSULE; ORAL

ALVIMOPAN**AB** WATSON LABS TEVA **12MG****A208295 001** Dec 19, 2019ENTEREG**AB** +! CUBIST PHARMS **12MG****N021775 001** May 20, 2008AMANTADINE HYDROCHLORIDE

CAPSULE; ORAL

AMANTADINE HYDROCHLORIDE**AB** ALEMBIC PHARMS **100MG****A208966 001** Jun 21, 2017**AB** ! BIONPHARMA INC **100MG****A078720 001** May 29, 2008**AB** HERITAGE PHARMA **100MG****A209171 001** Jun 12, 2017**AB** HUMANWELL PURACAP **100MG****A214580 001** Dec 20, 2022**AB** NOVELGENIX THERAPS **100MG****A210129 001** Mar 02, 2020**AB** RUBICON **100MG****A212044 001** May 21, 2020**AB** SANDOZ **100MG****A071293 001** Feb 18, 1987**AB** STRIDES PHARMA **100MG****A211354 001** Feb 18, 2022**AB** UPSHER SMITH LABS **100MG****A070589 001** Aug 05, 1986**AB** ZYDUS PHARMS **100MG****A208278 001** May 31, 2016

BX STRIDES PHARMA 100MG

A209047 001 Jun 07, 2017

CAPSULE, EXTENDED RELEASE; ORAL

GOCOVRI

+ ADAMAS OPERATIONS

EQ 68.5MG BASE

N208944 001 Aug 24, 2017

+!

EQ 137MG BASE

N208944 002 Aug 24, 2017

SYRUP; ORAL

AMANTADINE HYDROCHLORIDE**AA** ! AKORN **50MG/5ML****A074170 001** Oct 28, 1994**AA** ! CHARTWELL RX **50MG/5ML****A074028 001** Jun 28, 1993**AA** ! CMP PHARMA INC **50MG/5ML****A075819 001** Sep 11, 2002**AA** NOVELGENIX THERAPS **50MG/5ML****A214178 001** Aug 20, 2021**AA** ! PHARM ASSOC **50MG/5ML****A074509 001** Jul 17, 1995

TABLET; ORAL

AMANTADINE HYDROCHLORIDE**AB** ALEMBIC PHARMS **100MG****A214284 001** Oct 15, 2020**AB** NOVELGENIX THERAPS **100MG****A210215 001** Mar 10, 2020**AB** ! UPSHER SMITH LABS **100MG****A076186 001** Dec 16, 2002**AB** WATSON LABS INC **100MG****A208096 001** Dec 15, 2016

BX STRIDES PHARMA 100MG

A209035 001 Jun 09, 2017

TABLET, EXTENDED RELEASE; ORAL

OSMOLEX ER

+ ADAMAS OPERATIONS

EQ 129MG BASE

N209410 001 Feb 16, 2018

+

EQ 193MG BASE

N209410 002 Feb 16, 2018

AMBRISENTAN

TABLET; ORAL

AMBRISENTAN**AB** APOTEX **5MG****A210701 001** May 19, 2022**AB** **10MG****A210701 002** May 19, 2022**AB** AUROBINDO PHARMA **5MG****A216531 001** Jul 21, 2022**AB** **10MG****A216531 002** Jul 21, 2022**AB** CIPLA **5MG****A210715 001** Apr 26, 2019**AB** **10MG****A210715 002** Apr 26, 2019**AB** MYLAN **5MG****A208441 001** Mar 28, 2019**AB** **10MG****A208441 002** Mar 28, 2019**AB** PAR PHARM INC **5MG****A209509 001** Apr 10, 2019**AB** **10MG****A209509 002** Apr 10, 2019**AB** SIGMAPHARM LABS LLC **5MG****A208354 001** Apr 10, 2019**AB** **10MG****A208354 002** Apr 10, 2019**AB** SUN PHARM **5MG****A210784 001** Mar 28, 2019**AB** **10MG****A210784 002** Mar 28, 2019**AB** WATSON LABS INC **5MG****A208252 001** Mar 28, 2019**AB** **10MG****A208252 002** Mar 28, 2019**AB** ZYDUS PHARMS **5MG****A210058 001** Mar 28, 2019**AB** **10MG****A210058 002** Mar 28, 2019LETAIRIS**AB** + GILEAD **5MG****N022081 001** Jun 15, 2007**AB** +! **10MG****N022081 002** Jun 15, 2007

PRESCRIPTION DRUG PRODUCT LIST

3-18 (of 474)

AMCINONIDE

CREAM; TOPICAL

AMCINONIDE

AB	!	GENUS LIFESCIENCES	0.1%	A076065	001	May 15, 2003
AB		TARO PHARM INDS	0.1%	A076229	001	May 31, 2002

LOTION; TOPICAL

AMCINONIDE

!	ANDA REPOSITORY	0.1%	A076329	001	Nov 06, 2002

OINTMENT; TOPICAL

AMCINONIDE

AB	!	ANDA REPOSITORY	0.1%	A076096	001	Nov 19, 2002
AB		TARO PHARM INDS	0.1%	A076367	001	Mar 19, 2003

AMIFAMPRIDINE PHOSPHATE

TABLET; ORAL

FIRDAPSE

+	CATALYST PHARMS	EQ 10MG BASE	N208078	001	Nov 28, 2018

AMIFOSTINE

INJECTABLE; INJECTION

AMIFOSTINE

AP		SUN PHARM	500MG/VIAL	A077126	001	Mar 14, 2008

ETHYOL

AP	+	CLINIGEN	500MG/VIAL	N020221	001	Dec 08, 1995

AMIKACIN SULFATE

INJECTABLE; INJECTION

AMIKACIN SULFATE

AP	!	EMCURE PHARMS LTD	EQ 250MG BASE/ML	A204040	001	Dec 12, 2013
AP		FRESENIUS KABI USA	EQ 50MG BASE/ML	A205605	001	Dec 09, 2015
AP			EQ 250MG BASE/ML	A205604	001	Dec 09, 2015
AP	!	HIKMA	EQ 50MG BASE/ML	A063313	001	Apr 11, 1994
AP			EQ 250MG BASE/ML	A063315	001	Apr 11, 1994
AP		SAGENT PHARMS INC	EQ 250MG BASE/ML	A203323	001	May 12, 2016
AP		TEVA PHARMS USA	EQ 250MG BASE/ML	A064045	002	Sep 28, 1993

SUSPENSION, LIPOSOMAL; INHALATION

ARIKAYCE KIT

+	INSMED INC	EQ 590MG BASE/8.4ML	N207356	001	Sep 28, 2018

AMILORIDE HYDROCHLORIDE

TABLET; ORAL

AMILORIDE HYDROCHLORIDE

AB	!	PAR PHARM	5MG	A070346	001	Jan 22, 1986
AB		SIGMAPHARM LABS LLC	5MG	A079133	001	Jan 30, 2009

MIDAMOR

AB	+	PADAGIS US	5MG	N018200	001	

AMILORIDE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

AB		BARR	EQ 5MG ANHYDROUS; 50MG	A071111	001	May 10, 1988
AB	!	RISING	EQ 5MG ANHYDROUS; 50MG	A073209	001	Oct 31, 1991

AMINO ACIDS

INJECTABLE; INJECTION

AMINO ACIDS

B BRAUN	15% (150GM/1000ML)	A091112	001	Apr 13, 2012
	15% (300GM/2000ML)	A091112	002	Apr 13, 2012
AMINOSYN II 10% IN PLASTIC CONTAINER				
ICU MEDICAL INC	10% (10GM/100ML)	N020015	001	Dec 19, 1991
AMINOSYN II 15% IN PLASTIC CONTAINER				
ICU MEDICAL INC	15% (15GM/100ML)	N020041	001	Dec 19, 1991
AMINOSYN-PF 10%				
ICU MEDICAL INC	10% (10GM/100ML)	N019492	002	Oct 17, 1986
AMINOSYN-PF 7%				
ICU MEDICAL INC	7% (7GM/100ML)	N019398	001	Sep 06, 1985
CLINISOL 15% SULFITE FREE IN PLASTIC CONTAINER				
BAXTER HLTHCARE	15% (15GM/100ML)	A020512	001	Aug 30, 1996
FREAMINE HBC 6.9%				
B BRAUN	6.9% (6.9GM/100ML)	N016822	006	May 17, 1983
FREAMINE III 10%				
B BRAUN	10% (10GM/100ML)	N016822	005	
FREAMINE III 8.5%				
B BRAUN	8.5% (8.5GM/100ML)	N016822	004	

PRESCRIPTION DRUG PRODUCT LIST

3-19 (of 474)

AMINO ACIDS

INJECTABLE; INJECTION

HEPATAMINE 8%

B BRAUN 8% (8GM/100ML)

N018676 001 Aug 03, 1982

PREMASOL 10% IN PLASTIC CONTAINER

BAXTER HLTHCARE 10% (10GM/100ML)

A075880 002 Jun 19, 2003

PREMASOL 6% IN PLASTIC CONTAINER

BAXTER HLTHCARE 6% (6GM/100ML)

A075880 001 Jun 19, 2003

PROSOL 20% SULFITE FREE IN PLASTIC CONTAINER

+! BAXTER HLTHCARE 20% (20GM/100ML)

N020849 001 Aug 26, 1998

TRAVASOL 10% IN PLASTIC CONTAINER

BAXTER HLTHCARE 10% (10MG/100ML)

N018931 003 Aug 23, 1984

TRAVASOL 5.5% IN PLASTIC CONTAINER

BAXTER HLTHCARE 5.5% (5.5GM/100ML)

N018931 001 Aug 23, 1984

TRAVASOL 8.5% IN PLASTIC CONTAINER

BAXTER HLTHCARE 8.5% (8.5GM/100ML)

N018931 002 Aug 23, 1984

TROPHAMINE

+! B BRAUN 6% (6GM/100ML)

N019018 001 Jul 20, 1984

TROPHAMINE 10%

+! B BRAUN 10% (10GM/100ML)

N019018 003 Sep 07, 1988

AMINO ACIDS; CALCIUM ACETATE; GLYCERIN; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

PROCALAMINE

B BRAUN 3%; 26MG/100ML; 3GM/100ML; 54MG/100ML; 41MG/100ML; 150MG/100ML; 200MG/100ML; 120MG/100ML

N018582 001 May 08, 1982

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

CLINIMIX E 2.75/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER

+! BAXTER HLTHCARE 2.75%; 33MG/100ML; 10GM/100ML; 51MG/100ML; 261MG/100ML; 217MG/100ML; 112MG/100ML

N020678 002 Mar 26, 1997

CLINIMIX E 2.75/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER

+! BAXTER HLTHCARE 2.75%; 33MG/100ML; 25GM/100ML; 51MG/100ML; 261MG/100ML; 217MG/100ML; 112MG/100ML

N020678 005 Mar 26, 1997

CLINIMIX E 2.75/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER

+! BAXTER HLTHCARE 2.75%; 33MG/100ML; 5GM/100ML; 51MG/100ML; 261MG/100ML; 217MG/100ML; 112MG/100ML

N020678 001 Mar 26, 1997

CLINIMIX E 4.25/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER

+! BAXTER HLTHCARE 4.25%; 33MG/100ML; 10GM/100ML; 51MG/100ML; 261MG/100ML; 297MG/100ML; 77MG/100ML

N020678 009 Mar 26, 1997

CLINIMIX E 4.25/20 SULFITE FREE W/ ELECT IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER

+! BAXTER HLTHCARE 4.25%; 33MG/100ML; 20GM/100ML; 51MG/100ML; 261MG/100ML; 297MG/100ML; 77MG/100ML

N020678 011 Mar 26, 1997

CLINIMIX E 4.25/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER

+! BAXTER HLTHCARE 4.25%; 33MG/100ML; 25GM/100ML; 51MG/100ML; 261MG/100ML; 297MG/100ML; 77MG/100ML

N020678 012 Mar 26, 1997

CLINIMIX E 4.25/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER

+! BAXTER HLTHCARE 4.25%; 33MG/100ML; 5GM/100ML; 51MG/100ML; 261MG/100ML; 297MG/100ML; 77MG/100ML

N020678 008 Mar 26, 1997

CLINIMIX E 5/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER

+! BAXTER HLTHCARE 5%; 33MG/100ML; 10GM/100ML; 51MG/100ML; 261MG/100ML; 340MG/100ML; 59MG/100ML

N020678 016 Mar 26, 1997

CLINIMIX E 5/15 SULFITE FREE W/ ELECT IN DEXTROSE 15% W/ CALCIUM IN PLASTIC CONTAINER

+! BAXTER HLTHCARE 5%; 33MG/100ML; 15GM/100ML; 51MG/100ML; 261MG/100ML; 340MG/100ML; 59MG/100ML

N020678 017 Mar 26, 1997

CLINIMIX E 5/20 SULFITE FREE W/ ELECT IN 20% DEXTROSE W/ CALCIUM IN PLASTIC CONTAINER

+! BAXTER HLTHCARE 5%; 33MG/100ML; 20GM/100ML; 51MG/100ML; 261MG/100ML; 340MG/100ML; 59MG/100ML

N020678 018 Mar 26, 1997

CLINIMIX E 5/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER

+! BAXTER HLTHCARE 5%; 33MG/100ML; 25GM/100ML; 51MG/100ML; 261MG/100ML; 340MG/100ML; 59MG/100ML

N020678 019 Mar 26, 1997

CLINIMIX E 5/35 SULFITE FREE W/ ELECT IN DEXTROSE 35% W/ CALCIUM IN PLASTIC CONTAINER

+! BAXTER HLTHCARE 5%; 33MG/100ML; 35GM/100ML; 51MG/100ML; 261MG/100ML; 340MG/100ML; 59MG/100ML

N020678 021 Mar 26, 1997

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM GLYCEROPHOSPHATE; SOYBEAN OIL

EMULSION; INTRAVENOUS

KABIVEN IN PLASTIC CONTAINER

+ FRESenius KABI USA 3.3%; 29MG/100ML; 9.8GM/100ML; 96MG/100ML; 174MG/100ML; 239MG/100ML; 147MG/100ML; 3.9GM/100ML (1026ML)

N200656 004 Aug 25, 2014

+ 3.3%; 29MG/100ML; 9.8GM/100ML; 96MG/100ML; 174MG/100ML; 239MG/100ML; 147MG/100ML; 3.9

N200656 005 Aug 25, 2014

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM ACETATE;
SODIUM GLYCEROPHOSPHATE; SOYBEAN OIL

EMULSION; INTRAVENOUS

KABIVEN IN PLASTIC CONTAINER

	GM/100ML (1540ML)				
+	3.3%;29MG/100ML;9.8GM/100ML;96MG/100ML; 174MG/100ML;239MG/100ML;147MG/100ML;3.9 GM/100ML (2053ML)	N200656	006	Aug 25,	2014
+	3.3%;29MG/100ML;9.8GM/100ML;96MG/100ML; 174MG/100ML;239MG/100ML;147MG/100ML;3.9 GM/100ML (2566ML)	N200656	007	Aug 25,	2014

PERIKABIVEN IN PLASTIC CONTAINER

+	FRESENIUS KABI USA	2.4%;20MG/100ML;6.8GM/100ML;68MG/100ML; 124MG/100ML;170MG/100ML;105MG/100ML;3.5 GM/100ML (1440ML)	N200656 001	Aug 25, 2014
+		2.4%;20MG/100ML;6.8GM/100ML;68MG/100ML; 124MG/100ML;170MG/100ML;105MG/100ML;3.5 GM/100ML (1920ML)	N200656 002	Aug 25, 2014
+		2.4%;20MG/100ML;6.8GM/100ML;68MG/100ML; 124MG/100ML;170MG/100ML ;105MG/100ML;3.5GM/100ML (2400ML)	N200656 003	Aug 25, 2014

AMINO ACIDS; DEXTROSE

INJECTABLE; INJECTION

CLINIMIX 2.75/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	2.75%;10GM/100ML	N020734	002	Sep 29, 1997
CLINIMIX 2.75/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	2.75%;25GM/100ML	N020734	005	Sep 29, 1997
CLINIMIX 2.75/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	2.75%;5GM/100ML	N020734	001	Sep 29, 1997
CLINIMIX 4.25/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	4.25%;10GM/100ML	N020734	008	Sep 29, 1997
CLINIMIX 4.25/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	4.25%;20GM/100ML	N020734	010	Sep 29, 1997
CLINIMIX 4.25/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	4.25%;25GM/100ML	N020734	011	Sep 29, 1997
CLINIMIX 4.25/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	4.25%;5GM/100ML	N020734	007	Sep 29, 1997
CLINIMIX 5/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	5%;10GM/100ML	N020734	014	Sep 29, 1997
CLINIMIX 5/15 SULFITE FREE IN DEXTROSE 15% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	5%;15GM/100ML	N020734	015	Sep 29, 1997
CLINIMIX 5/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	5%;20GM/100ML	N020734	016	Sep 29, 1997
CLINIMIX 5/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	5%;25GM/100ML	N020734	017	Sep 29, 1997
CLINIMIX 5/35 SULFITE FREE IN DEXTROSE 35% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	5%;35GM/100ML	N020734	018	Sep 29, 1997

AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; POTASSIUM CHLORIDE; SODIUM ACETATE

INJECTABLE; INJECTION

FREAMINE III 8.5% W/ ELECTROLYTES
B BRAUN 8.5%;110MG/100ML;230MG/100ML;10MG/100ML N016822 007 Jul 01, 1988
;440MG/100ML;690MG/100ML

AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

FREAMINE III 3% W/ ELECTROLYTES				
B BRAUN	3%;54MG/100ML;40MG/100ML;150MG/100ML;20		N016822	003
	0MG/100ML;120MG/100ML			

AMINOCAPROIC ACID

INJECTABLE; INJECTION

<u>AMINOCAPROIC ACID</u>			
<u>AP</u>	LUITPOLD	250MG/ML	<u>A071192 001</u> Dec 01, 1987
<u>AMINOCAPROIC ACID IN PLASTIC CONTAINER</u>			

<u>AP</u>	<u>!</u>	HOSPIRA	<u>250MG/ML</u>	<u>A070010</u>	<u>001</u>	Mar 09, 1987
SOLUTION:ORAL						

SOLUTION: ORAL

<u>AMICAR</u>			
AA	+!	AKORN	0.25GM/ML
			N015230 002

<u>AMINOCAPROIC ACID</u>					
<u>AA</u>	AMNEAL	<u>0.25GM/ML</u>	<u>A212780</u>	<u>001</u>	Aug 23, 2019
<u>AA</u>	ANNORA PHARMA	<u>0.25GM/ML</u>	<u>A216464</u>	<u>001</u>	Nov 04, 2022
<u>AA</u>	AUROBINDO PHARMA	<u>0.25GM/ML</u>	<u>A216804</u>	<u>001</u>	Sep 26, 2022
<u>AA</u>	BELCHER	<u>0.25GM/ML</u>	<u>A213825</u>	<u>001</u>	Apr 08, 2021

PRESCRIPTION DRUG PRODUCT LIST

3-21 (of 474)

AMINOCAPROIC ACID

SOLUTION; ORAL

AMINOCAPROIC ACID

<u>AA</u>	CARNEGIE	<u>0.25GM/ML</u>	<u>A214140</u>	<u>001</u>	Jan 26, 2021
<u>AA</u>	FLORIDA	<u>0.25GM/ML</u>	<u>A215510</u>	<u>001</u>	Mar 23, 2022
<u>AA</u>	TULEX PHARMS INC	<u>0.25GM/ML</u>	<u>A212494</u>	<u>001</u>	Aug 11, 2020
<u>AA</u>	VISTAPHARM	<u>0.25GM/ML</u>	<u>A212814</u>	<u>001</u>	Feb 26, 2020

TABLET; ORAL

AMICAR

<u>AB</u>	+	AKORN	<u>500MG</u>	<u>N015197</u>	<u>001</u>	
<u>AB</u>	+		<u>1GM</u>	<u>N015197</u>	<u>002</u>	Jun 24, 2004

AMINOCAPROIC ACID

<u>AB</u>		AMNEAL	<u>500MG</u>	<u>A212492</u>	<u>001</u>	Nov 26, 2019
<u>AB</u>		ANI PHARMS	<u>500MG</u>	<u>A211629</u>	<u>001</u>	Dec 14, 2020
<u>AB</u>		CARNEGIE	<u>500MG</u>	<u>A213928</u>	<u>001</u>	Feb 12, 2021
<u>AB</u>			<u>1GM</u>	<u>A213928</u>	<u>002</u>	Feb 12, 2021
<u>AB</u>		MSN	<u>500MG</u>	<u>A212938</u>	<u>001</u>	Nov 06, 2020
<u>AB</u>		OPTIMUS	<u>500MG</u>	<u>A213944</u>	<u>001</u>	Sep 14, 2022
<u>AB</u>			<u>1GM</u>	<u>A213944</u>	<u>002</u>	Sep 14, 2022
<u>AB</u>		SUNNY	<u>500MG</u>	<u>A209060</u>	<u>001</u>	Nov 27, 2018
<u>AB</u>	!		<u>1GM</u>	<u>A209060</u>	<u>002</u>	Nov 27, 2018

AMINOLEVULINIC ACID HYDROCHLORIDE

FOR SOLUTION; ORAL

GLEOLAN

+! NXDC

1.5GM/VIAL

N208630 001 Jun 06, 2017

GEL; TOPICAL

AMELUZ

+! BIOFRONTERA

10%

N208081 001 May 10, 2016

SOLUTION; TOPICAL

LEVULAN

+! DUSA

20%

N020965 001 Dec 03, 1999

AMINOPHYLLINE

INJECTABLE; INJECTION

AMINOPHYLLINE

! HOSPIRA

25MG/ML

A087242 001 Oct 26, 1983

AMINOSALICYLIC ACID

GRANULE, DELAYED RELEASE; ORAL

PASER

! EUROCEPT PHARMS

4GM/PACKET

A074346 001 Jun 30, 1994

AMIODARONE HYDROCHLORIDE

INJECTABLE; INJECTION

AMIODARONE HYDROCHLORIDE

<u>AP</u>		ACELLA	<u>50MG/ML</u>	<u>A077610</u>	<u>001</u>	Oct 30, 2008
<u>AP</u>			<u>50MG/ML</u>	<u>A077834</u>	<u>001</u>	Oct 30, 2008
<u>AP</u>	!	FRESENIUS KABI USA	<u>50MG/ML</u>	<u>A075761</u>	<u>001</u>	Oct 15, 2002
<u>AP</u>	!	GLAND PHARMA LTD	<u>50MG/ML</u>	<u>A077161</u>	<u>001</u>	Apr 20, 2005
<u>AP</u>		HIKMA FARMACEUTICA	<u>50MG/ML</u>	<u>A077234</u>	<u>001</u>	Feb 25, 2008
<u>AP</u>		HOSPIRA	<u>50MG/ML</u>	<u>A203884</u>	<u>001</u>	Nov 25, 2013
<u>AP</u>	!	MYLAN INSTITUTIONAL	<u>50MG/ML</u>	<u>A076217</u>	<u>001</u>	Oct 15, 2002
		NEXTERONE				
	+	! BAXTER HLTHCARE	150MG/100ML (1.5MG/ML)	N022325	002	Nov 16, 2010
	+	!	360MG/200ML (1.8MG/ML)	N022325	003	Nov 16, 2010

TABLET; ORAL

AMIODARONE HYDROCHLORIDE

<u>AB</u>		AUROBINDO PHARMA LTD	<u>200MG</u>	<u>A204742</u>	<u>001</u>	Jun 03, 2016
<u>AB</u>		MAYNE PHARMA INC	<u>100MG</u>	<u>A075389</u>	<u>002</u>	Dec 28, 2017
<u>AB</u>			<u>200MG</u>	<u>A075389</u>	<u>001</u>	Jan 25, 2001
<u>AB</u>			<u>400MG</u>	<u>A075389</u>	<u>003</u>	Dec 28, 2017
<u>AB</u>		MURTY PHARMS	<u>100MG</u>	<u>A077069</u>	<u>003</u>	Oct 04, 2016
<u>AB</u>			<u>200MG</u>	<u>A077069</u>	<u>001</u>	Apr 08, 2005
<u>AB</u>			<u>400MG</u>	<u>A077069</u>	<u>002</u>	Apr 08, 2005
<u>AB</u>		RUBICON	<u>100MG</u>	<u>A078578</u>	<u>002</u>	Feb 26, 2021
<u>AB</u>			<u>200MG</u>	<u>A078578</u>	<u>001</u>	Nov 06, 2008
<u>AB</u>			<u>400MG</u>	<u>A078578</u>	<u>003</u>	Feb 26, 2021
<u>AB</u>		TARO	<u>100MG</u>	<u>A075424</u>	<u>002</u>	Dec 18, 2002
<u>AB</u>	!		<u>200MG</u>	<u>A075424</u>	<u>001</u>	Mar 30, 2001
<u>AB</u>			<u>400MG</u>	<u>A076362</u>	<u>001</u>	Nov 29, 2002
<u>AB</u>		TEVA PHARMS	<u>200MG</u>	<u>A074739</u>	<u>001</u>	Nov 30, 1998
<u>AB</u>		UNICHEM	<u>200MG</u>	<u>A213446</u>	<u>001</u>	Jul 21, 2020
<u>AB</u>		ZYDUS PHARMS USA	<u>100MG</u>	<u>A079029</u>	<u>002</u>	Jan 06, 2023

PRESCRIPTION DRUG PRODUCT LIST

3-22 (of 474)

AMIODARONE HYDROCHLORIDE

TABLET; ORAL

AMIODARONE HYDROCHLORIDE

INC

<u>AB</u>		<u>200MG</u>	<u>A079029</u>	<u>001</u>	Sep 16, 2008
<u>AB</u>		<u>400MG</u>	<u>A079029</u>	<u>003</u>	Jan 06, 2023
	<u>PACERONE</u>				
<u>AB</u>	UPSHER SMITH LABS	<u>100MG</u>	<u>A075135</u>	<u>002</u>	Apr 12, 2005
<u>AB</u>		<u>200MG</u>	<u>A075135</u>	<u>001</u>	Apr 30, 1998
<u>AB</u>		<u>400MG</u>	<u>A075135</u>	<u>003</u>	Jul 02, 2020
	AMIODARONE HYDROCHLORIDE				
	TARO	300MG	A076362	002	Dec 02, 2003

AMISULPRIDE

SOLUTION; INTRAVENOUS

BARHEMSYS

+	!	ACACIA	5MG/2ML (2.5MG/ML)	N209510	001	Feb 26, 2020
+	!		10MG/4ML (2.5MG/ML)	N209510	002	Sep 01, 2020

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

AMITRIPTYLINE HYDROCHLORIDE

<u>AB</u>		ACCORD HLTHCARE	<u>10MG</u>	<u>A202446</u>	<u>001</u>	Jun 04, 2014
<u>AB</u>			<u>25MG</u>	<u>A202446</u>	<u>002</u>	Jun 04, 2014
<u>AB</u>			<u>50MG</u>	<u>A202446</u>	<u>003</u>	Jun 04, 2014
<u>AB</u>			<u>75MG</u>	<u>A202446</u>	<u>004</u>	Jun 04, 2014
<u>AB</u>			<u>100MG</u>	<u>A202446</u>	<u>005</u>	Jun 04, 2014
<u>AB</u>			<u>150MG</u>	<u>A202446</u>	<u>006</u>	Jun 04, 2014
<u>AB</u>		LEADING	<u>10MG</u>	<u>A216243</u>	<u>001</u>	Jun 06, 2022
<u>AB</u>			<u>25MG</u>	<u>A216243</u>	<u>002</u>	Jun 06, 2022
<u>AB</u>			<u>50MG</u>	<u>A216243</u>	<u>003</u>	Jun 06, 2022
<u>AB</u>			<u>75MG</u>	<u>A216243</u>	<u>004</u>	Jun 06, 2022
<u>AB</u>			<u>100MG</u>	<u>A216243</u>	<u>005</u>	Jun 06, 2022
<u>AB</u>			<u>150MG</u>	<u>A216243</u>	<u>006</u>	Jun 06, 2022
<u>AB</u>		MANKIND PHARMA	<u>10MG</u>	<u>A213999</u>	<u>001</u>	Feb 19, 2021
<u>AB</u>			<u>25MG</u>	<u>A213999</u>	<u>002</u>	Feb 19, 2021
<u>AB</u>			<u>50MG</u>	<u>A213999</u>	<u>003</u>	Feb 19, 2021
<u>AB</u>			<u>75MG</u>	<u>A213999</u>	<u>004</u>	Feb 19, 2021
<u>AB</u>			<u>100MG</u>	<u>A213999</u>	<u>005</u>	Feb 19, 2021
<u>AB</u>			<u>150MG</u>	<u>A213999</u>	<u>006</u>	Feb 19, 2021
<u>AB</u>	+	SANDOZ	<u>10MG</u>	<u>A085968</u>	<u>004</u>	
<u>AB</u>	+	!	<u>25MG</u>	<u>A085968</u>	<u>002</u>	
<u>AB</u>	+		<u>50MG</u>	<u>A085968</u>	<u>001</u>	
<u>AB</u>	+		<u>75MG</u>	<u>A085968</u>	<u>006</u>	
<u>AB</u>	+		<u>100MG</u>	<u>A085968</u>	<u>003</u>	
<u>AB</u>	+		<u>150MG</u>	<u>A085968</u>	<u>005</u>	
<u>AB</u>		SUN PHARM INDS INC	<u>10MG</u>	<u>A089399</u>	<u>002</u>	Jul 14, 1987
<u>AB</u>			<u>25MG</u>	<u>A089399</u>	<u>001</u>	Jul 14, 1987
<u>AB</u>			<u>50MG</u>	<u>A089399</u>	<u>003</u>	Jul 14, 1987
<u>AB</u>			<u>75MG</u>	<u>A089399</u>	<u>004</u>	Jul 14, 1987
<u>AB</u>			<u>100MG</u>	<u>A089399</u>	<u>005</u>	Jul 14, 1987
<u>AB</u>			<u>150MG</u>	<u>A089399</u>	<u>006</u>	Jul 14, 1987
<u>AB</u>		UNICHEM	<u>10MG</u>	<u>A214548</u>	<u>001</u>	May 19, 2021
<u>AB</u>			<u>25MG</u>	<u>A214548</u>	<u>002</u>	May 19, 2021
<u>AB</u>			<u>50MG</u>	<u>A214548</u>	<u>003</u>	May 19, 2021
<u>AB</u>			<u>75MG</u>	<u>A214548</u>	<u>004</u>	May 19, 2021
<u>AB</u>			<u>100MG</u>	<u>A214548</u>	<u>005</u>	May 19, 2021
<u>AB</u>			<u>150MG</u>	<u>A214548</u>	<u>006</u>	May 19, 2021
<u>AB</u>		ZYDUS PHARMS	<u>10MG</u>	<u>A210086</u>	<u>001</u>	Oct 06, 2017
<u>AB</u>			<u>25MG</u>	<u>A210086</u>	<u>002</u>	Oct 06, 2017
<u>AB</u>			<u>50MG</u>	<u>A210086</u>	<u>003</u>	Oct 06, 2017
<u>AB</u>			<u>75MG</u>	<u>A210086</u>	<u>004</u>	Oct 06, 2017
<u>AB</u>			<u>100MG</u>	<u>A210086</u>	<u>005</u>	Oct 06, 2017
<u>AB</u>			<u>150MG</u>	<u>A210086</u>	<u>006</u>	Oct 06, 2017

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET; ORAL

CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE

<u>AB</u>		MICRO LABS	<u>EQ 12.5MG BASE;5MG</u>	<u>A211925</u>	<u>001</u>	Feb 02, 2022
<u>AB</u>			<u>EQ 25MG BASE;10MG</u>	<u>A211925</u>	<u>002</u>	Feb 02, 2022
<u>AB</u>		MYLAN PHARMS INC	<u>EQ 12.5MG BASE;5MG</u>	<u>A071297</u>	<u>002</u>	Dec 10, 1986
<u>AB</u>	!		<u>EQ 25MG BASE;10MG</u>	<u>A071297</u>	<u>001</u>	Dec 10, 1986

PRESCRIPTION DRUG PRODUCT LIST

3-23 (of 474)

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET; ORAL

PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE

MYLAN	10MG; 2MG	A071443	002	Nov 10, 1988
	10MG; 4MG	A071443	003	Nov 10, 1988
!	25MG; 2MG	A071443	004	Nov 10, 1988
!	25MG; 4MG	A071443	005	Nov 10, 1988
!	50MG; 4MG	A071443	001	Nov 10, 1988

AMLODIPINE BENZOATE

SUSPENSION; ORAL

KATERZIA

+! AZURITY	EQ 1MG BASE/ML	N211340	001	Jul 08, 2019

AMLODIPINE BESYLATE

SOLUTION; ORAL

NORLIQVA

+! CMP DEV LLC	EQ 1MG BASE/ML	N214439	001	Feb 24, 2022

TABLET; ORAL

AMLODIPINE BESYLATE

AB	ACCORD HLTHCARE	EQ 2.5MG BASE	A202553	001	Apr 29, 2013
AB		EQ 5MG BASE	A202553	002	Apr 29, 2013
AB		EQ 10MG BASE	A202553	003	Apr 29, 2013
AB	ALKEM	EQ 2.5MG BASE	A078925	001	May 04, 2009
AB		EQ 5MG BASE	A078925	002	May 04, 2009
AB		EQ 10MG BASE	A078925	003	May 04, 2009
AB	APOTEX	EQ 2.5MG BASE	A076719	001	May 23, 2007
AB		EQ 5MG BASE	A076719	002	May 23, 2007
AB		EQ 10MG BASE	A076719	003	May 23, 2007
AB	AUROBINDO PHARMA	EQ 2.5MG BASE	A078021	001	Jul 17, 2007
AB		EQ 5MG BASE	A078021	002	Jul 17, 2007
AB		EQ 10MG BASE	A078021	003	Jul 17, 2007
AB	CHARTWELL RX	EQ 2.5MG BASE	A076692	001	Jul 20, 2007
AB		EQ 5MG BASE	A076692	002	Jul 20, 2007
AB		EQ 10MG BASE	A076692	003	Jul 20, 2007
AB	CHINA RESOURCES	EQ 2.5MG BASE	A090752	003	May 16, 2016
AB		EQ 5MG BASE	A090752	001	Apr 15, 2011
AB		EQ 10MG BASE	A090752	002	Apr 15, 2011
AB	CIPLA	EQ 2.5MG BASE	A077073	001	Sep 26, 2007
AB		EQ 5MG BASE	A077073	002	Sep 26, 2007
AB		EQ 10MG BASE	A077073	003	Sep 26, 2007
AB	EPIC PHARMA LLC	EQ 2.5MG BASE	A078552	001	Apr 08, 2009
AB		EQ 5MG BASE	A078552	002	Apr 08, 2009
AB		EQ 10MG BASE	A078552	003	Apr 08, 2009
AB	INVAGEN PHARMS	EQ 2.5MG BASE	A077955	001	Aug 28, 2007
AB		EQ 2.5MG BASE	A206367	001	Dec 10, 2015
AB		EQ 5MG BASE	A077955	002	Aug 28, 2007
AB		EQ 5MG BASE	A206367	002	Dec 10, 2015
AB		EQ 10MG BASE	A077955	003	Aug 28, 2007
AB		EQ 10MG BASE	A206367	003	Dec 10, 2015
AB	LUPIN	EQ 2.5MG BASE	A078043	001	Jul 12, 2007
AB		EQ 5MG BASE	A078043	002	Jul 12, 2007
AB		EQ 10MG BASE	A078043	003	Jul 12, 2007
AB	ORBION PHARMS	EQ 2.5MG BASE	A078453	001	Jul 02, 2009
AB		EQ 5MG BASE	A078453	002	Jul 02, 2009
AB		EQ 10MG BASE	A078453	003	Jul 02, 2009
AB	OXFORD PHARMS	EQ 2.5MG BASE	A078414	001	Apr 07, 2010
AB		EQ 5MG BASE	A078414	002	Apr 07, 2010
AB		EQ 10MG BASE	A078414	003	Apr 07, 2010
AB	POLYGEN PHARMS	EQ 2.5MG BASE	A207821	001	Jul 11, 2016
AB		EQ 5MG BASE	A207821	002	Jul 11, 2016
AB		EQ 10MG BASE	A207821	003	Jul 11, 2016
AB	STRIDES PHARMA	EQ 2.5MG BASE	A077516	001	Jul 11, 2007
AB		EQ 5MG BASE	A077516	002	Jul 11, 2007
AB		EQ 10MG BASE	A077516	003	Jul 11, 2007
AB	SUN PHARM INDS LTD	EQ 2.5MG BASE	A077974	001	Jul 09, 2007
AB		EQ 5MG BASE	A077974	002	Jul 09, 2007
AB		EQ 10MG BASE	A077974	003	Jul 09, 2007
AB	TEVA	EQ 2.5MG BASE	A076846	001	Jun 28, 2007
AB		EQ 5MG BASE	A076846	002	Jun 28, 2007
AB		EQ 10MG BASE	A076846	003	Jun 28, 2007
AB	UNICHEM	EQ 2.5MG BASE	A203245	001	Oct 21, 2013
AB		EQ 5MG BASE	A203245	002	Oct 21, 2013

PRESCRIPTION DRUG PRODUCT LIST

3-24 (of 474)

AMLODIPINE BESYLATE

TABLET; ORAL

AMLODIPINE BESYLATE

<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A203245</u>	<u>003</u>	Oct 21, 2013
<u>AB</u>	ZYDUS PHARMS USA	<u>EQ 2.5MG BASE</u>	<u>A078226</u>	<u>001</u>	Jul 09, 2007
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078226</u>	<u>002</u>	Jul 09, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078226</u>	<u>003</u>	Jul 09, 2007
<u>NORVASC</u>					
<u>AB</u>	+	<u>EQ 2.5MG BASE</u>	<u>N019787</u>	<u>001</u>	Jul 31, 1992
<u>AB</u>	+	<u>EQ 5MG BASE</u>	<u>N019787</u>	<u>002</u>	Jul 31, 1992
<u>AB</u>	+	<u>EQ 10MG BASE</u>	<u>N019787</u>	<u>003</u>	Jul 31, 1992

AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM

TABLET; ORAL

AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM

<u>AB</u>	APOTEX	<u>EQ 5MG BASE;EQ 10MG BASE</u>	<u>A205199</u>	<u>001</u>	Nov 18, 2019
<u>AB</u>		<u>EQ 5MG BASE;EQ 20MG BASE</u>	<u>A205199</u>	<u>002</u>	Nov 18, 2019
<u>AB</u>		<u>EQ 5MG BASE;EQ 40MG BASE</u>	<u>A205199</u>	<u>003</u>	Nov 18, 2019
<u>AB</u>		<u>EQ 5MG BASE;EQ 80MG BASE</u>	<u>A205199</u>	<u>004</u>	Nov 18, 2019
<u>AB</u>		<u>EQ 10MG BASE;EQ 10MG BASE</u>	<u>A205199</u>	<u>005</u>	Nov 18, 2019
<u>AB</u>		<u>EQ 10MG BASE;EQ 20MG BASE</u>	<u>A205199</u>	<u>006</u>	Nov 18, 2019
<u>AB</u>		<u>EQ 10MG BASE;EQ 40MG BASE</u>	<u>A205199</u>	<u>007</u>	Nov 18, 2019
<u>AB</u>		<u>EQ 10MG BASE;EQ 80MG BASE</u>	<u>A205199</u>	<u>008</u>	Nov 18, 2019
<u>AB</u>	DR REDDYS	<u>EQ 2.5MG BASE;EQ 10MG BASE</u>	<u>A203874</u>	<u>001</u>	Mar 07, 2014
<u>AB</u>		<u>EQ 2.5MG BASE;EQ 20MG BASE</u>	<u>A203874</u>	<u>002</u>	Mar 07, 2014
<u>AB</u>		<u>EQ 2.5MG BASE;EQ 40MG BASE</u>	<u>A203874</u>	<u>003</u>	Mar 07, 2014
<u>AB</u>		<u>EQ 5MG BASE;EQ 10MG BASE</u>	<u>A203874</u>	<u>004</u>	Mar 07, 2014
<u>AB</u>		<u>EQ 5MG BASE;EQ 20MG BASE</u>	<u>A203874</u>	<u>005</u>	Mar 07, 2014
<u>AB</u>		<u>EQ 5MG BASE;EQ 40MG BASE</u>	<u>A203874</u>	<u>006</u>	Mar 07, 2014
<u>AB</u>		<u>EQ 5MG BASE;EQ 80MG BASE</u>	<u>A203874</u>	<u>007</u>	Mar 07, 2014
<u>AB</u>		<u>EQ 10MG BASE;EQ 10MG BASE</u>	<u>A203874</u>	<u>008</u>	Mar 07, 2014
<u>AB</u>		<u>EQ 10MG BASE;EQ 20MG BASE</u>	<u>A203874</u>	<u>009</u>	Mar 07, 2014
<u>AB</u>		<u>EQ 10MG BASE;EQ 40MG BASE</u>	<u>A203874</u>	<u>010</u>	Mar 07, 2014
<u>AB</u>		<u>EQ 10MG BASE;EQ 80MG BASE</u>	<u>A203874</u>	<u>011</u>	Mar 07, 2014
<u>AB</u>	MYLAN	<u>EQ 5MG BASE;EQ 10MG BASE</u>	<u>A200465</u>	<u>004</u>	Nov 29, 2013
<u>AB</u>		<u>EQ 5MG BASE;EQ 20MG BASE</u>	<u>A200465</u>	<u>005</u>	Nov 29, 2013
<u>AB</u>		<u>EQ 5MG BASE;EQ 40MG BASE</u>	<u>A200465</u>	<u>006</u>	Nov 29, 2013
<u>AB</u>		<u>EQ 5MG BASE;EQ 80MG BASE</u>	<u>A200465</u>	<u>007</u>	Nov 29, 2013
<u>AB</u>		<u>EQ 10MG BASE;EQ 10MG BASE</u>	<u>A200465</u>	<u>008</u>	Nov 29, 2013
<u>AB</u>		<u>EQ 10MG BASE;EQ 20MG BASE</u>	<u>A200465</u>	<u>009</u>	Nov 29, 2013
<u>AB</u>		<u>EQ 10MG BASE;EQ 40MG BASE</u>	<u>A200465</u>	<u>010</u>	Nov 29, 2013
<u>AB</u>		<u>EQ 10MG BASE;EQ 80MG BASE</u>	<u>A200465</u>	<u>011</u>	Nov 29, 2013
<u>AB</u>	ZYDUS PHARMS	<u>EQ 2.5MG BASE;EQ 10MG BASE</u>	<u>A207762</u>	<u>001</u>	Jan 11, 2019
<u>AB</u>		<u>EQ 2.5MG BASE;EQ 20MG BASE</u>	<u>A207762</u>	<u>002</u>	Jan 11, 2019
<u>AB</u>		<u>EQ 2.5MG BASE;EQ 40MG BASE</u>	<u>A207762</u>	<u>003</u>	Jan 11, 2019
<u>AB</u>		<u>EQ 5MG BASE;EQ 10MG BASE</u>	<u>A207762</u>	<u>004</u>	Jan 11, 2019
<u>AB</u>		<u>EQ 5MG BASE;EQ 20MG BASE</u>	<u>A207762</u>	<u>005</u>	Jan 11, 2019
<u>AB</u>		<u>EQ 5MG BASE;EQ 40MG BASE</u>	<u>A207762</u>	<u>006</u>	Jan 11, 2019
<u>AB</u>		<u>EQ 5MG BASE;EQ 80MG BASE</u>	<u>A207762</u>	<u>007</u>	Jan 11, 2019
<u>AB</u>		<u>EQ 10MG BASE;EQ 10MG BASE</u>	<u>A207762</u>	<u>008</u>	Jan 11, 2019
<u>AB</u>		<u>EQ 10MG BASE;EQ 20MG BASE</u>	<u>A207762</u>	<u>009</u>	Jan 11, 2019
<u>AB</u>		<u>EQ 10MG BASE;EQ 40MG BASE</u>	<u>A207762</u>	<u>010</u>	Jan 11, 2019
<u>AB</u>		<u>EQ 10MG BASE;EQ 80MG BASE</u>	<u>A207762</u>	<u>011</u>	Jan 11, 2019
<u>CADUET</u>					
<u>AB</u>	+	<u>EQ 2.5MG BASE;EQ 10MG BASE</u>	<u>N021540</u>	<u>009</u>	Jul 29, 2004
<u>AB</u>	+	<u>EQ 2.5MG BASE;EQ 20MG BASE</u>	<u>N021540</u>	<u>010</u>	Jul 29, 2004
<u>AB</u>	+	<u>EQ 2.5MG BASE;EQ 40MG BASE</u>	<u>N021540</u>	<u>011</u>	Jul 29, 2004
<u>AB</u>	+	<u>EQ 5MG BASE;EQ 10MG BASE</u>	<u>N021540</u>	<u>001</u>	Jan 30, 2004
<u>AB</u>	+	<u>EQ 5MG BASE;EQ 20MG BASE</u>	<u>N021540</u>	<u>002</u>	Jan 30, 2004
<u>AB</u>	+	<u>EQ 5MG BASE;EQ 40MG BASE</u>	<u>N021540</u>	<u>003</u>	Jan 30, 2004
<u>AB</u>	+	<u>EQ 5MG BASE;EQ 80MG BASE</u>	<u>N021540</u>	<u>004</u>	Jan 30, 2004
<u>AB</u>	+	<u>EQ 10MG BASE;EQ 10MG BASE</u>	<u>N021540</u>	<u>005</u>	Jan 30, 2004
<u>AB</u>	+	<u>EQ 10MG BASE;EQ 20MG BASE</u>	<u>N021540</u>	<u>006</u>	Jan 30, 2004
<u>AB</u>	+	<u>EQ 10MG BASE;EQ 40MG BASE</u>	<u>N021540</u>	<u>007</u>	Jan 30, 2004
<u>AB</u>	+	<u>EQ 10MG BASE;EQ 80MG BASE</u>	<u>N021540</u>	<u>008</u>	Jan 30, 2004

AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

CAPSULE; ORAL

AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE

<u>AB</u>	APOTEX	<u>EQ 2.5MG BASE;10MG</u>	<u>A091431</u>	<u>001</u>	Dec 30, 2013
<u>AB</u>		<u>EQ 5MG BASE;10MG</u>	<u>A091431</u>	<u>002</u>	Dec 30, 2013
<u>AB</u>		<u>EQ 5MG BASE;20MG</u>	<u>A091431</u>	<u>003</u>	Dec 30, 2013
<u>AB</u>		<u>EQ 5MG BASE;40MG</u>	<u>A091431</u>	<u>004</u>	Dec 30, 2013

PRESCRIPTION DRUG PRODUCT LIST

3-25 (of 474)

AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

CAPSULE;ORAL

AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE

AB		EQ 10MG BASE;20MG	A091431	005	Dec 30, 2013	
AB		EQ 10MG BASE;40MG	A091431	006	Dec 30, 2013	
AB	AUROBINDO PHARMA LTD	EQ 2.5MG BASE;10MG	A202239	001	Sep 05, 2012	
AB		EQ 5MG BASE;10MG	A202239	002	Sep 05, 2012	
AB		EQ 5MG BASE;20MG	A202239	003	Sep 05, 2012	
AB		EQ 5MG BASE;40MG	A202239	004	Sep 05, 2012	
AB		EQ 10MG BASE;20MG	A202239	005	Sep 05, 2012	
AB		EQ 10MG BASE;40MG	A202239	006	Sep 05, 2012	
AB	DR REDDYS LABS INC	EQ 2.5MG BASE;10MG	A077183	001	Apr 15, 2010	
AB		EQ 5MG BASE;10MG	A077183	002	Apr 15, 2010	
AB		EQ 5MG BASE;20MG	A077183	003	Apr 15, 2010	
AB		EQ 5MG BASE;40MG	A090149	001	Jul 05, 2011	
AB		EQ 10MG BASE;20MG	A077183	004	Apr 15, 2010	
AB		EQ 10MG BASE;40MG	A090149	002	Jul 05, 2011	
AB	LUPIN PHARMS	EQ 2.5MG BASE;10MG	A078466	001	Feb 05, 2010	
AB		EQ 5MG BASE;10MG	A078466	002	Feb 05, 2010	
AB		EQ 5MG BASE;20MG	A078466	003	Feb 05, 2010	
AB		EQ 5MG BASE;40MG	A078466	005	Jul 05, 2011	
AB		EQ 10MG BASE;20MG	A078466	004	Feb 05, 2010	
AB		EQ 10MG BASE;40MG	A078466	006	Jul 05, 2011	
AB	WATSON LABS	EQ 2.5MG BASE;10MG	A077890	001	Oct 14, 2010	
AB		EQ 5MG BASE;10MG	A077890	002	Oct 14, 2010	
AB		EQ 5MG BASE;20MG	A077890	003	Oct 14, 2010	
AB		EQ 10MG BASE;20MG	A077890	004	Oct 14, 2010	
AB	WATSON LABS INC	EQ 5MG BASE;40MG	A090364	001	Jul 05, 2011	
AB		EQ 10MG BASE;40MG	A090364	002	Jul 05, 2011	
LOTREL						
AB	+	NOVARTIS	EQ 2.5MG BASE;10MG	N020364	002	Mar 03, 1995
AB	+		EQ 5MG BASE;10MG	N020364	003	Mar 03, 1995
AB	+		EQ 5MG BASE;20MG	N020364	004	Mar 03, 1995
AB	+		EQ 5MG BASE;40MG	N020364	007	Apr 11, 2006
AB	+		EQ 10MG BASE;20MG	N020364	005	Jun 20, 2002
AB	+		EQ 10MG BASE;40MG	N020364	006	Apr 11, 2006

AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

TABLET;ORAL

OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE

AB	PAR PHARM INC	EQ 5MG BASE;12.5MG;20MG	A206137	001	Oct 26, 2016	
AB		EQ 5MG BASE;12.5MG;40MG	A206137	002	Oct 26, 2016	
AB		EQ 5MG BASE;25MG;40MG	A206137	003	Oct 26, 2016	
AB		EQ 10MG BASE;12.5MG;40MG	A206137	004	Oct 26, 2016	
AB		EQ 10MG BASE;25MG;40MG	A206137	005	Oct 26, 2016	
AB	TEVA PHARMS USA	EQ 5MG BASE;12.5MG;20MG	A202491	001	Nov 03, 2016	
AB		EQ 5MG BASE;12.5MG;40MG	A202491	002	Nov 03, 2016	
AB		EQ 5MG BASE;25MG;40MG	A202491	003	Nov 03, 2016	
AB		EQ 10MG BASE;12.5MG;40MG	A202491	004	Nov 03, 2016	
AB		EQ 10MG BASE;25MG;40MG	A202491	005	Nov 03, 2016	
AB	TORRENT	EQ 5MG BASE;12.5MG;20MG	A203580	001	Oct 26, 2016	
AB		EQ 5MG BASE;12.5MG;40MG	A203580	002	Oct 26, 2016	
AB		EQ 5MG BASE;25MG;40MG	A203580	003	Oct 26, 2016	
AB		EQ 10MG BASE;12.5MG;40MG	A203580	004	Oct 26, 2016	
AB		EQ 10MG BASE;25MG;40MG	A203580	005	Oct 26, 2016	
TRIBENZOR						
AB	+	COSETTE	EQ 5MG BASE;12.5MG;20MG	N200175	001	Jul 23, 2010
AB	+		EQ 5MG BASE;12.5MG;40MG	N200175	002	Jul 23, 2010
AB	+		EQ 5MG BASE;25MG;40MG	N200175	003	Jul 23, 2010
AB	+		EQ 10MG BASE;12.5MG;40MG	N200175	004	Jul 23, 2010
AB	+		EQ 10MG BASE;25MG;40MG	N200175	005	Jul 23, 2010

AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET;ORAL

AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE

AB	AUROBINDO PHARMA	EQ 5MG BASE;12.5MG;160MG	A206180	001	Dec 19, 2017
AB		EQ 5MG BASE;25MG;160MG	A206180	002	Dec 19, 2017
AB		EQ 10MG BASE;12.5MG;160MG	A206180	003	Dec 19, 2017
AB		EQ 10MG BASE;25MG;160MG	A206180	004	Dec 19, 2017
AB		EQ 10MG BASE;25MG;320MG	A206180	005	Dec 19, 2017
AB	LUPIN LTD	EQ 5MG BASE;12.5MG;160MG	A200797	001	Jun 03, 2015
AB		EQ 5MG BASE;25MG;160MG	A200797	002	Jun 03, 2015
AB		EQ 10MG BASE;12.5MG;160MG	A200797	003	Jun 03, 2015

PRESCRIPTION DRUG PRODUCT LIST

3-26 (of 474)

AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET; ORAL

AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE

<u>AB</u>		<u>EQ 10MG BASE;25MG;160MG</u>	<u>A200797</u>	<u>004</u>	Jun 03, 2015
<u>AB</u>		<u>EQ 10MG BASE;25MG;320MG</u>	<u>A200797</u>	<u>005</u>	Jun 03, 2015
<u>AB</u>	STRIDES PHARMA	<u>EQ 5MG BASE;12.5MG;160MG</u>	<u>A201087</u>	<u>001</u>	Jun 01, 2015
<u>AB</u>		<u>EQ 5MG BASE;25MG;160MG</u>	<u>A201087</u>	<u>002</u>	Jun 01, 2015
<u>AB</u>		<u>EQ 10MG BASE;12.5MG;160MG</u>	<u>A201087</u>	<u>003</u>	Jun 01, 2015
<u>AB</u>		<u>EQ 10MG BASE;25MG;160MG</u>	<u>A201087</u>	<u>004</u>	Jun 01, 2015
<u>AB</u>		<u>EQ 10MG BASE;25MG;320MG</u>	<u>A201087</u>	<u>005</u>	Jun 01, 2015
<u>EXFORGE HCT</u>					
<u>AB</u>	+	NOVARTIS	<u>EQ 5MG BASE;12.5MG;160MG</u>	<u>N022314</u>	<u>001</u> Apr 30, 2009
<u>AB</u>	+		<u>EQ 5MG BASE;25MG;160MG</u>	<u>N022314</u>	<u>002</u> Apr 30, 2009
<u>AB</u>	+		<u>EQ 10MG BASE;12.5MG;160MG</u>	<u>N022314</u>	<u>003</u> Apr 30, 2009
<u>AB</u>	+		<u>EQ 10MG BASE;25MG;160MG</u>	<u>N022314</u>	<u>004</u> Apr 30, 2009
<u>AB</u>	+	!	<u>EQ 10MG BASE;25MG;320MG</u>	<u>N022314</u>	<u>005</u> Apr 30, 2009

AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL

TABLET; ORAL

AMLODIPINE AND OLMESARTAN MEDOXOMIL

AB		AJANTA PHARMA LTD	EQ 5MG BASE;20MG	A207216	001	Oct 28, 2016
AB			EQ 5MG BASE;40MG	A207216	002	Oct 28, 2016
AB			EQ 10MG BASE;20MG	A207216	003	Oct 28, 2016
AB			EQ 10MG BASE;40MG	A207216	004	Oct 28, 2016
AB		ALEMBIC PHARMS	EQ 5MG BASE;20MG	A207073	001	Jul 17, 2017
AB			EQ 5MG BASE;40MG	A207073	002	Jul 17, 2017
AB			EQ 10MG BASE;20MG	A207073	003	Jul 17, 2017
AB			EQ 10MG BASE;40MG	A207073	004	Jul 17, 2017
AB		ALKEM LABS LTD	EQ 5MG BASE;20MG	A209042	001	Aug 14, 2017
AB			EQ 5MG BASE;40MG	A209042	002	Aug 14, 2017
AB			EQ 10MG BASE;20MG	A209042	003	Aug 14, 2017
AB			EQ 10MG BASE;40MG	A209042	004	Aug 14, 2017
AB		AUROBINDO PHARMA	EQ 5MG BASE;20MG	A206906	001	May 15, 2017
AB			EQ 5MG BASE;40MG	A206906	002	May 15, 2017
AB			EQ 10MG BASE;20MG	A206906	003	May 15, 2017
AB			EQ 10MG BASE;40MG	A206906	004	May 15, 2017
AB		GLENMARK PHARMS LTD	EQ 5MG BASE;20MG	A207807	001	Jul 05, 2017
AB			EQ 5MG BASE;40MG	A207807	002	Jul 05, 2017
AB			EQ 10MG BASE;20MG	A207807	003	Jul 05, 2017
AB			EQ 10MG BASE;40MG	A207807	004	Jul 05, 2017
AB		MACLEODS PHARMS LTD	EQ 5MG BASE;20MG	A206884	001	Oct 26, 2016
AB			EQ 5MG BASE;40MG	A206884	003	Oct 26, 2016
AB			EQ 10MG BASE;20MG	A206884	002	Oct 26, 2016
AB			EQ 10MG BASE;40MG	A206884	004	Oct 26, 2016
AB		MICRO LABS	EQ 5MG BASE;20MG	A207435	001	Nov 02, 2017
AB			EQ 5MG BASE;40MG	A207435	002	Nov 02, 2017
AB			EQ 10MG BASE;20MG	A207435	003	Nov 02, 2017
AB			EQ 10MG BASE;40MG	A207435	004	Nov 02, 2017
AB		ZYDUS PHARMS	EQ 5MG BASE;20MG	A207771	001	Sep 22, 2017
AB			EQ 5MG BASE;40MG	A207771	002	Sep 22, 2017
AB			EQ 10MG BASE;20MG	A207771	003	Sep 22, 2017
AB			EQ 10MG BASE;40MG	A207771	004	Sep 22, 2017
AZOR						
AB	+	COSETTE	EQ 5MG BASE;20MG	N022100	001	Sep 26, 2007
AB	+		EQ 5MG BASE;40MG	N022100	002	Sep 26, 2007
AB	+		EQ 10MG BASE;20MG	N022100	003	Sep 26, 2007
AB	+	!	EQ 10MG BASE;40MG	N022100	004	Sep 26, 2007

AMLODIPINE BESYLATE; PERINDOPRIL ARGININE

TABLET; ORAL

PRESTALIA

+	ADHERA	EQ 2.5MG BASE;3.5MG	N205003	001	Jan 21, 2015
+		EQ 5MG BASE;7MG	N205003	002	Jan 21, 2015
+	!	EQ 10MG BASE;14MG	N205003	003	Jan 21, 2015

AMLODIPINE BESYLATE; TELMISARTAN

TABLET; ORAL

TELMISARTAN AND AMLODIPINE

AB		LUPIN LTD	EQ 5MG BASE;40MG	A201586	001	Jan 08, 2014
AB			EQ 5MG BASE;80MG	A201586	003	Jan 08, 2014
AB			EQ 10MG BASE;40MG	A201586	002	Jan 08, 2014
AB			EQ 10MG BASE;80MG	A201586	004	Jan 08, 2014
AB		MYLAN	EQ 5MG BASE;40MG	A202516	001	Aug 26, 2014
AB			EQ 5MG BASE;80MG	A202516	003	Aug 26, 2014

PRESCRIPTION DRUG PRODUCT LIST

3-27 (of 474)

AMLODIPINE BESYLATE; TELMISARTAN

TABLET; ORAL

TELMISARTAN AND AMLODIPINE

<u>AB</u>		<u>EQ 10MG BASE;40MG</u>	<u>A202516</u>	<u>002</u>	Aug 26, 2014
<u>AB</u>	!	<u>EQ 10MG BASE;80MG</u>	<u>A202516</u>	<u>004</u>	Aug 26, 2014

AMLODIPINE BESYLATE; VALSARTAN

TABLET; ORAL

AMLODIPINE BESYLATE AND VALSARTAN

<u>AB</u>		<u>EQ 5MG BASE;160MG</u>	<u>A202713</u>	<u>001</u>	Apr 03, 2015
<u>AB</u>		<u>EQ 5MG BASE;320MG</u>	<u>A202713</u>	<u>003</u>	Apr 03, 2015
<u>AB</u>		<u>EQ 10MG BASE;160MG</u>	<u>A202713</u>	<u>002</u>	Apr 03, 2015
<u>AB</u>		<u>EQ 10MG BASE;320MG</u>	<u>A202713</u>	<u>004</u>	Apr 03, 2015
<u>AB</u>	AUROBINDO PHARMA	<u>EQ 5MG BASE;160MG</u>	<u>A206512</u>	<u>001</u>	Apr 22, 2016
<u>AB</u>		<u>EQ 5MG BASE;320MG</u>	<u>A206512</u>	<u>002</u>	Apr 22, 2016
<u>AB</u>		<u>EQ 10MG BASE;160MG</u>	<u>A206512</u>	<u>003</u>	Apr 22, 2016
<u>AB</u>		<u>EQ 10MG BASE;320MG</u>	<u>A206512</u>	<u>004</u>	Apr 22, 2016
<u>AB</u>	HETERO LABS	<u>EQ 5MG BASE;160MG</u>	<u>A205137</u>	<u>001</u>	Sep 16, 2016
<u>AB</u>		<u>EQ 5MG BASE;320MG</u>	<u>A205137</u>	<u>003</u>	Sep 16, 2016
<u>AB</u>		<u>EQ 10MG BASE;160MG</u>	<u>A205137</u>	<u>002</u>	Sep 16, 2016
<u>AB</u>		<u>EQ 10MG BASE;320MG</u>	<u>A205137</u>	<u>004</u>	Sep 16, 2016
<u>AB</u>	LUPIN	<u>EQ 5MG BASE;160MG</u>	<u>A090245</u>	<u>001</u>	Mar 30, 2015
<u>AB</u>		<u>EQ 5MG BASE;320MG</u>	<u>A090245</u>	<u>003</u>	Mar 30, 2015
<u>AB</u>		<u>EQ 10MG BASE;160MG</u>	<u>A090245</u>	<u>002</u>	Mar 30, 2015
<u>AB</u>		<u>EQ 10MG BASE;320MG</u>	<u>A090245</u>	<u>004</u>	Mar 30, 2015
<u>AB</u>	MYLAN	<u>EQ 5MG BASE;160MG</u>	<u>A090483</u>	<u>001</u>	Mar 30, 2015
<u>AB</u>		<u>EQ 5MG BASE;320MG</u>	<u>A090483</u>	<u>003</u>	Mar 30, 2015
<u>AB</u>		<u>EQ 10MG BASE;160MG</u>	<u>A090483</u>	<u>002</u>	Mar 30, 2015
<u>AB</u>		<u>EQ 10MG BASE;320MG</u>	<u>A090483</u>	<u>004</u>	Mar 30, 2015
<u>AB</u>	NOVEL LABS INC	<u>EQ 5MG BASE;160MG</u>	<u>A202829</u>	<u>001</u>	Mar 30, 2015
<u>AB</u>		<u>EQ 5MG BASE;320MG</u>	<u>A202829</u>	<u>003</u>	Mar 30, 2015
<u>AB</u>		<u>EQ 10MG BASE;160MG</u>	<u>A202829</u>	<u>002</u>	Mar 30, 2015
<u>AB</u>		<u>EQ 10MG BASE;320MG</u>	<u>A202829</u>	<u>004</u>	Mar 30, 2015
<u>AB</u>	STRIDES PHARMA	<u>EQ 5MG BASE;160MG</u>	<u>A090011</u>	<u>001</u>	Mar 28, 2013
<u>AB</u>		<u>EQ 5MG BASE;320MG</u>	<u>A090011</u>	<u>003</u>	Mar 28, 2013
<u>AB</u>		<u>EQ 10MG BASE;160MG</u>	<u>A090011</u>	<u>002</u>	Mar 28, 2013
<u>AB</u>		<u>EQ 10MG BASE;320MG</u>	<u>A090011</u>	<u>004</u>	Mar 28, 2013
<u>EXFORGE</u>					
<u>AB</u>	+	<u>EQ 5MG BASE;160MG</u>	<u>N021990</u>	<u>002</u>	Jun 20, 2007
<u>AB</u>	+	<u>EQ 5MG BASE;320MG</u>	<u>N021990</u>	<u>004</u>	Jun 20, 2007
<u>AB</u>	+	<u>EQ 10MG BASE;160MG</u>	<u>N021990</u>	<u>003</u>	Jun 20, 2007
<u>AB</u>	+	<u>EQ 10MG BASE;320MG</u>	<u>N021990</u>	<u>005</u>	Jun 20, 2007

AMMONIA N-13

INJECTABLE; INTRAVENOUS

AMMONIA N 13

<u>AP</u>	3D IMAGING DRUG	<u>30mCi-300mCi/8ML (3.75-37.5mCi/ML)</u>	<u>A203779</u>	<u>001</u>	Oct 19, 2015	
<u>AP</u>	BIOMEDCL RES FDN	<u>48.75mCi-487.5mCi/13ML (3.75-37.5mCi/ML)</u>	<u>A204352</u>	<u>001</u>	May 01, 2015	
<u>AP</u>	BRIGHAM WOMENS HOSP	<u>30mCi-300mCi/8ML (3.75-37.5mCi/ML)</u>	<u>A203783</u>	<u>001</u>	Oct 30, 2014	
<u>AP</u>	CARDINAL HLTH 414	<u>30mCi-300mCi/8ML (3.75-37.5mCi/ML)</u>	<u>A203700</u>	<u>001</u>	Feb 25, 2013	
<u>AP</u>	DECATUR	<u>30mCi-300mCi/8ML (3.75-37.5mCi/ML)</u>	<u>A204465</u>	<u>001</u>	Oct 23, 2014	
<u>AP</u>	ESSENTIAL ISOTOPES	<u>3.75mCi-260mCi/ML</u>	<u>A205687</u>	<u>001</u>	Dec 17, 2015	
<u>AP</u>	+	<u>FEINSTEIN</u>	<u>30mCi-300mCi/8ML (3.75-37.5mCi/ML)</u>	<u>N022119</u>	<u>001</u>	Aug 23, 2007
<u>AP</u>	GEN HOSP	<u>30mCi-300mCi/8ML (3.75-37.5mCi/ML)</u>	<u>A207025</u>	<u>001</u>	Feb 03, 2016	
<u>AP</u>	IONETIX	<u>22.5mCi-225mCi/6ML (3.75-37.5mCi/ML)</u>	<u>A210524</u>	<u>001</u>	Dec 21, 2018	
<u>AP</u>	JOHNS HOPKINS UNIV	<u>30mCi-300mCi/8ML (3.75-37.5mCi/ML)</u>	<u>A204514</u>	<u>001</u>	Aug 19, 2014	
<u>AP</u>	KREITCHMAN PET CTR	<u>30mCi-300mCi/8ML (3.75-37.5mCi/ML)</u>	<u>A203938</u>	<u>001</u>	Dec 09, 2013	
<u>AP</u>	MCPRF	<u>30mCi-300mCi/8ML (3.75-37.5mCi/ML)</u>	<u>A203321</u>	<u>001</u>	Feb 25, 2013	
<u>AP</u>	METHODIST	<u>3.75mCi-260mCi/ML</u>	<u>A215083</u>	<u>001</u>	Jul 09, 2021	
<u>AP</u>	MIDWEST MEDCL	<u>30mCi-300mCi/8ML (3.75-37.5mCi/ML)</u>	<u>A204457</u>	<u>001</u>	Nov 18, 2015	
<u>AP</u>	MIPS CRF	<u>30mCi-300mCi/8ML (3.75-37.5mCi/ML)</u>	<u>A204535</u>	<u>001</u>	Nov 20, 2014	
<u>AP</u>	NCM USA BRONX LLC	<u>3.75mCi-260mCi/ML</u>	<u>A204515</u>	<u>001</u>	Feb 04, 2015	
<u>AP</u>	NUKEMED	<u>30mCi-300mCi/8ML (3.75-37.5mCi/ML)</u>	<u>A204455</u>	<u>001</u>	Apr 23, 2015	
<u>AP</u>	PETNET	<u>30mCi-300mCi (3.75-37.5mCi/ML)</u>	<u>A204510</u>	<u>001</u>	Nov 02, 2015	
<u>AP</u>	PRECISION NUCLEAR	<u>3.75mCi-260mCi/ML</u>	<u>A204547</u>	<u>001</u>	Aug 14, 2015	
<u>AP</u>	SHERTECH LABS LLC	<u>3.75mCi-260mCi/ML</u>	<u>A204366</u>	<u>001</u>	Sep 19, 2014	
<u>AP</u>	SOFIE	<u>18.8mCi-188mCi/5ML (3.75-37.5mCi/ML)</u>	<u>A204667</u>	<u>001</u>	Apr 22, 2015	
<u>AP</u>	!	<u>3.75mCi-260mCi/ML</u>	<u>A203543</u>	<u>001</u>	Dec 14, 2012	
<u>AP</u>	UCLA BIOMEDICAL	<u>30mCi-300mCi/8ML (3.75-37.5mCi/ML)</u>	<u>A203812</u>	<u>001</u>	Jun 27, 2013	
<u>AP</u>	UCSF RODIOPHARM	<u>30mCi-300mCi/8ML (3.75-37.5mCi/ML)</u>	<u>A204496</u>	<u>001</u>	Mar 28, 2014	
<u>AP</u>	UNIV ALABAMA BIRM	<u>15mCi-150mCi/4ML (3.75-37.5mCi/ML)</u>	<u>A211698</u>	<u>001</u>	Nov 03, 2022	
<u>AP</u>	UNIV TX SW MEDCTR	<u>30mCi-300mCi/8ML (3.75-37.5mCi/ML)</u>	<u>A209507</u>	<u>001</u>	Nov 01, 2019	
<u>AP</u>	UNIV WISCONSIN	<u>30mCi-300mCi/8ML (3.75-37.5mCi/ML)</u>	<u>A211740</u>	<u>001</u>	Sep 09, 2020	

PRESCRIPTION DRUG PRODUCT LIST

3-28 (of 474)

AMMONIA N-13

INJECTABLE; INTRAVENOUS

AMMONIA N 13

<u>AP</u>	WA UNIV SCH MED	<u>30mCi-300mCi/8ML (3.75-37.5mCi/ML)</u>	<u>A204506</u>	<u>001</u>	Feb 07, 2014
<u>AP</u>	WISCONSIN	<u>3.75mCi-260mCi/ML</u>	<u>A204356</u>	<u>001</u>	Dec 18, 2014

AMMONIUM CHLORIDE

INJECTABLE; INJECTION

AMMONIUM CHLORIDE IN PLASTIC CONTAINER

!	HOSPIRA	5MEQ/ML	A088366	001	Jun 13, 1984

AMMONIUM LACTATE

CREAM; TOPICAL

AMMONIUM LACTATE

<u>AB</u>	!	PADAGIS ISRAEL	<u>EQ 12% BASE</u>	<u>A075774</u>	<u>001</u>	May 01, 2002
<u>AB</u>		TARO	<u>EQ 12% BASE</u>	<u>A075883</u>	<u>001</u>	Apr 10, 2003

LOTION; TOPICAL

AMMONIUM LACTATE

<u>AB</u>	!	PADAGIS ISRAEL	<u>EQ 12% BASE</u>	<u>A075570</u>	<u>001</u>	Jun 23, 2004
<u>AB</u>		TARO	<u>EQ 12% BASE</u>	<u>A076216</u>	<u>001</u>	May 28, 2004

AMOXAPINE

TABLET; ORAL

AMOXAPINE

	WATSON LABS	25MG	A072691	002	Aug 28, 1992
		50MG	A072691	003	Aug 28, 1992
		100MG	A072691	004	Aug 28, 1992
!		150MG	A072691	001	Aug 28, 1992

AMOXICILLIN

CAPSULE; ORAL

AMOXICILLIN

<u>AB</u>		AUROBINDO	<u>250MG</u>	<u>A065271</u>	<u>001</u>	Nov 09, 2005
<u>AB</u>			<u>500MG</u>	<u>A065271</u>	<u>002</u>	Nov 09, 2005
<u>AB</u>		CHARTWELL	<u>250MG</u>	<u>A062058</u>	<u>001</u>	
<u>AB</u>			<u>500MG</u>	<u>A062058</u>	<u>002</u>	
<u>AB</u>		HIKMA PHARMS	<u>250MG</u>	<u>A065291</u>	<u>001</u>	Feb 05, 2007
<u>AB</u>			<u>500MG</u>	<u>A065291</u>	<u>002</u>	Feb 05, 2007
<u>AB</u>		MICRO LABS	<u>250MG</u>	<u>A207471</u>	<u>001</u>	Jun 24, 2022
<u>AB</u>			<u>500MG</u>	<u>A207471</u>	<u>002</u>	Jun 24, 2022
<u>AB</u>		SANDOZ	<u>250MG</u>	<u>A064076</u>	<u>001</u>	Sep 30, 1994
<u>AB</u>			<u>500MG</u>	<u>A064076</u>	<u>002</u>	Sep 30, 1994
<u>AB</u>		TEVA	<u>250MG</u>	<u>A061926</u>	<u>001</u>	
<u>AB</u>	!		<u>500MG</u>	<u>A061926</u>	<u>003</u>	

AMOXIL

<u>AB</u>		US ANTIBIOTICS	<u>250MG</u>	<u>A062216</u>	<u>001</u>	
<u>AB</u>			<u>500MG</u>	<u>A062216</u>	<u>004</u>	

FOR SUSPENSION; ORAL

AMOXICILLIN

<u>AB</u>		AUROBINDO	<u>200MG/5ML</u>	<u>A065334</u>	<u>001</u>	Dec 28, 2006
<u>AB</u>			<u>400MG/5ML</u>	<u>A065334</u>	<u>002</u>	Dec 28, 2006
<u>AB</u>		AUROBINDO PHARMA LTD	<u>125MG/5ML</u>	<u>A204030</u>	<u>001</u>	Sep 15, 2014
<u>AB</u>			<u>250MG/5ML</u>	<u>A204030</u>	<u>002</u>	Sep 15, 2014
<u>AB</u>		DAVA PHARMS INC	<u>125MG/5ML</u>	<u>A062927</u>	<u>001</u>	Nov 25, 1988
<u>AB</u>			<u>250MG/5ML</u>	<u>A062927</u>	<u>002</u>	Nov 25, 1988
<u>AB</u>		HIKMA	<u>125MG/5ML</u>	<u>A065322</u>	<u>002</u>	Jun 19, 2006
<u>AB</u>			<u>200MG/5ML</u>	<u>A065325</u>	<u>002</u>	Jun 19, 2006
<u>AB</u>			<u>250MG/5ML</u>	<u>A065322</u>	<u>001</u>	Jun 19, 2006
<u>AB</u>			<u>400MG/5ML</u>	<u>A065325</u>	<u>001</u>	Jun 19, 2006
<u>AB</u>		SANDOZ	<u>125MG/5ML</u>	<u>A065387</u>	<u>001</u>	Mar 26, 2007
<u>AB</u>			<u>200MG/5ML</u>	<u>A065378</u>	<u>001</u>	Mar 26, 2007
<u>AB</u>			<u>250MG/5ML</u>	<u>A065387</u>	<u>002</u>	Mar 26, 2007
<u>AB</u>			<u>400MG/5ML</u>	<u>A065378</u>	<u>002</u>	Mar 26, 2007
<u>AB</u>		TEVA	<u>200MG/5ML</u>	<u>A065119</u>	<u>001</u>	Dec 04, 2002
<u>AB</u>	!		<u>250MG/5ML</u>	<u>A061931</u>	<u>002</u>	
<u>AB</u>	!		<u>400MG/5ML</u>	<u>A065119</u>	<u>002</u>	Dec 04, 2002
<u>AB</u>		WOCKHARDT BIO AG	<u>400MG/5ML</u>	<u>A065319</u>	<u>002</u>	Jun 18, 2007

AMOXICILLIN PEDIATRIC

<u>AB</u>		TEVA	<u>50MG/ML</u>	<u>A061931</u>	<u>003</u>	Dec 01, 1982

AMOXIL

<u>AB</u>		US ANTIBIOTICS	<u>50MG/ML</u>	<u>A062226</u>	<u>005</u>	
<u>AB</u>			<u>125MG/5ML</u>	<u>A062226</u>	<u>001</u>	
<u>AB</u>			<u>250MG/5ML</u>	<u>A062226</u>	<u>002</u>	

PRESCRIPTION DRUG PRODUCT LIST

3-29 (of 474)

AMOXICILLIN

FOR SUSPENSION; ORAL

LAROTID

<u>AB</u>	US ANTIBIOTICS	<u>125MG/5ML</u>	<u>A062226</u>	<u>003</u>	
<u>AB</u>		<u>250MG/5ML</u>	<u>A062226</u>	<u>004</u>	

TABLET; ORAL

AMOXICILLIN

<u>AB</u>	AUROBINDO	<u>500MG</u>	<u>A065256</u>	<u>001</u>	Nov 09, 2005
<u>AB</u>		<u>875MG</u>	<u>A065256</u>	<u>002</u>	Nov 09, 2005
<u>AB</u>	HIKMA	<u>875MG</u>	<u>A065255</u>	<u>001</u>	Mar 29, 2006
<u>AB</u>	SANDOZ	<u>500MG</u>	<u>A065228</u>	<u>001</u>	Jul 13, 2005
<u>AB</u>		<u>875MG</u>	<u>A065228</u>	<u>002</u>	Jul 13, 2005
<u>AB</u>	TEVA	<u>500MG</u>	<u>A065056</u>	<u>001</u>	Sep 18, 2000
<u>AB</u>	!	<u>875MG</u>	<u>A065056</u>	<u>002</u>	Sep 18, 2000

TABLET, CHEWABLE; ORAL

AMOXICILLIN

	TEVA	125MG	A064013	002	Sep 11, 1995
	!	250MG	A064013	001	Dec 22, 1992

AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE

CAPSULE, TABLET, CAPSULE, DELAYED REL PELLETS; ORAL

LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN (COPACKAGED)

<u>AB</u>	!	RISING	<u>500MG;500MG;30MG</u>	<u>A206006</u>	<u>001</u>	Oct 07, 2016
<u>AB</u>		SANDOZ INC	<u>500MG;500MG;30MG</u>	<u>A202588</u>	<u>001</u>	Mar 04, 2014

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

<u>AB</u>	AUROBINDO PHARMA	<u>125MG/5ML;EQ 31.25MG BASE/5ML</u>	<u>A209371</u>	<u>001</u>	Apr 19, 2019
<u>AB</u>		<u>250MG/5ML;EQ 62.5MG BASE/5ML</u>	<u>A209371</u>	<u>002</u>	Apr 19, 2019
<u>AB</u>	AUROBINDO PHARMA LTD	<u>200MG/5ML;EQ 28.5MG BASE/5ML</u>	<u>A201090</u>	<u>001</u>	Dec 20, 2011
<u>AB</u>		<u>400MG/5ML;EQ 57MG BASE/5ML</u>	<u>A201090</u>	<u>002</u>	Dec 20, 2011
<u>AB</u>		<u>600MG/5ML;EQ 42.9MG BASE/5ML</u>	<u>A201091</u>	<u>001</u>	Dec 20, 2011
<u>AB</u>	HIKMA PHARMS	<u>200MG/5ML;EQ 28.5MG BASE/5ML</u>	<u>A065191</u>	<u>002</u>	Jan 25, 2005
<u>AB</u>		<u>400MG/5ML;EQ 57MG BASE/5ML</u>	<u>A065191</u>	<u>001</u>	Jan 25, 2005
<u>AB</u>		<u>600MG/5ML;EQ 42.9MG BASE/5ML</u>	<u>A065373</u>	<u>001</u>	Nov 09, 2007
<u>AB</u>	MICRO LABS LTD INDIA	<u>200MG/5ML;EQ 28.5MG BASE/5ML</u>	<u>A205187</u>	<u>001</u>	May 21, 2021
<u>AB</u>		<u>400MG/5ML;EQ 57MG BASE/5ML</u>	<u>A205187</u>	<u>002</u>	May 21, 2021
<u>AB</u>	SANDOZ	<u>200MG/5ML;EQ 28.5MG BASE/5ML</u>	<u>A065066</u>	<u>001</u>	Jun 05, 2002
<u>AB</u>		<u>400MG/5ML;EQ 57MG BASE/5ML</u>	<u>A065066</u>	<u>002</u>	Jun 05, 2002
<u>AB</u>	SANDOZ INC	<u>200MG/5ML;EQ 28.5MG BASE/5ML</u>	<u>A065098</u>	<u>001</u>	Dec 16, 2002
<u>AB</u>		<u>400MG/5ML;EQ 57MG BASE/5ML</u>	<u>A065098</u>	<u>002</u>	Dec 16, 2002
<u>AB</u>		<u>600MG/5ML;EQ 42.9MG BASE/5ML</u>	<u>A065358</u>	<u>001</u>	Aug 13, 2007
<u>AB</u>	TEVA	<u>200MG/5ML;EQ 28.5MG BASE/5ML</u>	<u>A065089</u>	<u>001</u>	May 25, 2004
<u>AB</u>	!	<u>400MG/5ML;EQ 57MG BASE/5ML</u>	<u>A065089</u>	<u>002</u>	May 25, 2004
<u>AB</u>	!	<u>600MG/5ML;EQ 42.9MG BASE/5ML</u>	<u>A065162</u>	<u>001</u>	Mar 12, 2004
<u>AB</u>	WOCKHARDT BIO AG	<u>250MG/5ML;EQ 62.5MG BASE/5ML</u>	<u>A065431</u>	<u>001</u>	Nov 25, 2008
<u>AB</u>		<u>600MG/5ML;EQ 42.9MG BASE/5ML</u>	<u>A065420</u>	<u>001</u>	Dec 02, 2013

AUGMENTIN '125'

<u>AB</u>	+	US ANTIBIOTICS	<u>125MG/5ML;EQ 31.25MG BASE/5ML</u>	<u>N050575</u>	<u>001</u>	Aug 06, 1984

AUGMENTIN '250'

<u>AB</u>	+	!	US ANTIBIOTICS	<u>250MG/5ML;EQ 62.5MG BASE/5ML</u>	<u>N050575</u>	<u>002</u>	Aug 06, 1984

AUGMENTIN ES-600

<u>AB</u>	+	US ANTIBIOTICS	<u>600MG/5ML;EQ 42.9MG BASE/5ML</u>	<u>N050755</u>	<u>001</u>	Jun 22, 2001

TABLET; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

<u>AB</u>	AUROBINDO PHARMA LTD	<u>250MG;EQ 125MG BASE</u>	<u>A091569</u>	<u>001</u>	Jan 20, 2012	
<u>AB</u>		<u>500MG;EQ 125MG BASE</u>	<u>A091569</u>	<u>002</u>	Jan 20, 2012	
<u>AB</u>		<u>875MG;EQ 125MG BASE</u>	<u>A091568</u>	<u>001</u>	Jan 20, 2012	
<u>AB</u>	HIKMA PHARMS	<u>875MG;EQ 125MG BASE</u>	<u>A203824</u>	<u>001</u>	Aug 23, 2016	
<u>AB</u>	MICRO LABS LTD INDIA	<u>250MG;EQ 125MG BASE</u>	<u>A205707</u>	<u>001</u>	Dec 30, 2016	
<u>AB</u>		<u>500MG;EQ 125MG BASE</u>	<u>A205707</u>	<u>002</u>	Dec 30, 2016	
<u>AB</u>		<u>875MG;EQ 125MG BASE</u>	<u>A204755</u>	<u>003</u>	Dec 30, 2016	
<u>AB</u>	!	SANDOZ	<u>250MG;EQ 125MG BASE</u>	<u>A065189</u>	<u>001</u>	Aug 23, 2005
<u>AB</u>		<u>500MG;EQ 125MG BASE</u>	<u>A065064</u>	<u>001</u>	Mar 15, 2002	
<u>AB</u>	!		<u>875MG;EQ 125MG BASE</u>	<u>A065063</u>	<u>001</u>	Mar 14, 2002
<u>AB</u>	!	SANDOZ INC	<u>500MG;EQ 125MG BASE</u>	<u>A065117</u>	<u>001</u>	Nov 27, 2002
<u>AB</u>		<u>875MG;EQ 125MG BASE</u>	<u>A065093</u>	<u>001</u>	Nov 21, 2002	
<u>AB</u>	TEVA	<u>500MG;EQ 125MG BASE</u>	<u>A065101</u>	<u>001</u>	Oct 30, 2002	
<u>AB</u>	TEVA PHARMS USA	<u>875MG;EQ 125MG BASE</u>	<u>A065096</u>	<u>001</u>	Oct 29, 2002	

PRESCRIPTION DRUG PRODUCT LIST

3-30 (of 474)

AMOXICILLIN; CLAVULANATE POTASSIUM

TABLET; ORAL

AUGMENTIN '875'

AB	+	US ANTIBIOTICS	875MG;EQ 125MG BASE	N050720 001	Feb 13, 1996
		TABLET, CHEWABLE; ORAL			
		AMOXICILLIN AND CLAVULANATE POTASSIUM			
		TEVA	200MG;EQ 28.5MG BASE	A065205 001	Feb 09, 2005
		!	400MG;EQ 57MG BASE	A065205 002	Feb 09, 2005
		TABLET, EXTENDED RELEASE; ORAL			
		AMOXICILLIN AND CLAVULANATE POTASSIUM			
		!	SANDOZ 1GM;EQ 62.5MG BASE	A090227 001	Apr 21, 2010

AMOXICILLIN; OMEPRAZOLE MAGNESIUM; RIFABUTIN

CAPSULE, DELAYED RELEASE; ORAL

TALICIA

+	!	REDHILL	250MG;EQ 10MG BASE;12.5MG	N213004 001	Nov 01, 2019

AMPHETAMINE

TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE; ORAL

ADZENYS XR-ODT

+		NEOS THERAPS	EQ 3.1MG BASE	N204326 001	Jan 27, 2016
+			EQ 6.3MG BASE	N204326 002	Jan 27, 2016
+			EQ 9.4MG BASE	N204326 003	Jan 27, 2016
+			EQ 12.5MG BASE	N204326 004	Jan 27, 2016
+			EQ 15.7MG BASE	N204326 005	Jan 27, 2016
+	!		EQ 18.8MG BASE	N204326 006	Jan 27, 2016

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

ADDERALL XR 10

AB	+	TAKEDA PHARMS USA	2.5MG;2.5MG;2.5MG;2.5MG	N021303 001	Oct 11, 2001

ADDERALL XR 15

AB	+	TAKEDA PHARMS USA	3.75MG;3.75MG;3.75MG;3.75MG	N021303 006	May 22, 2002

ADDERALL XR 20

AB	+	TAKEDA PHARMS USA	5MG;5MG;5MG;5MG	N021303 002	Oct 11, 2001

ADDERALL XR 25

AB	+	TAKEDA PHARMS USA	6.25MG;6.25MG;6.25MG;6.25MG	N021303 004	May 22, 2002

ADDERALL XR 30

AB	+	!	TAKEDA PHARMS USA	7.5MG;7.5MG;7.5MG;7.5MG	N021303 003	Oct 11, 2001

ADDERALL XR 5

AB	+	TAKEDA PHARMS USA	1.25MG;1.25MG;1.25MG;1.25MG	N021303 005	May 22, 2002

DETROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB		ASCENT PHARMS INC	1.25MG;1.25MG;1.25MG;1.25MG	A214959 001	Sep 29, 2021
AB			2.5MG;2.5MG;2.5MG;2.5MG	A214959 002	Sep 29, 2021
AB			3.75MG;3.75MG;3.75MG;3.75MG	A214959 003	Sep 29, 2021
AB			5MG;5MG;5MG;5MG	A214959 004	Sep 29, 2021
AB			6.25MG;6.25MG;6.25MG;6.25MG	A214959 005	Sep 29, 2021
AB			7.5MG;7.5MG;7.5MG;7.5MG	A214959 006	Sep 29, 2021

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB		ACTAVIS ELIZABETH	1.25MG;1.25MG;1.25MG;1.25MG	A077302 001	Jun 22, 2012
AB			2.5MG;2.5MG;2.5MG;2.5MG	A077302 002	Jun 22, 2012
AB			3.75MG;3.75MG;3.75MG;3.75MG	A077302 003	Jun 22, 2012
AB			5MG;5MG;5MG;5MG	A077302 004	Jun 22, 2012
AB			6.25MG;6.25MG;6.25MG;6.25MG	A077302 005	Jun 22, 2012
AB			7.5MG;7.5MG;7.5MG;7.5MG	A077302 006	Jun 22, 2012
AB		ANI PHARMS	1.25MG;1.25MG;1.25MG;1.25MG	A205401 001	Jan 22, 2019
AB			3.75MG;3.75MG;3.75MG;3.75MG	A205401 003	Jan 22, 2019
AB			5MG;5MG;5MG;5MG	A205401 004	Jan 22, 2019
AB			6.25MG;6.25MG;6.25MG;6.25MG	A205401 005	Jan 22, 2019
AB			7.5MG;7.5MG;7.5MG;7.5MG	A205401 006	Jan 22, 2019
AB		ELITE LABS INC	1.25MG;1.25MG;1.25MG;1.25MG	A212037 001	Dec 11, 2019
AB			2.5MG;2.5MG;2.5MG;2.5MG	A212037 002	Dec 11, 2019
AB			3.75MG;3.75MG;3.75MG;3.75MG	A212037 003	Dec 11, 2019
AB			5MG;5MG;5MG;5MG	A212037 004	Dec 11, 2019
AB			6.25MG;6.25MG;6.25MG;6.25MG	A212037 005	Dec 11, 2019
AB			7.5MG;7.5MG;7.5MG;7.5MG	A212037 006	Dec 11, 2019
AB		IMPAX LABS	1.25MG;1.25MG;1.25MG;1.25MG	A076852 001	Feb 16, 2016
AB			2.5MG;2.5MG;2.5MG;2.5MG	A076852 002	Feb 16, 2016
AB			3.75MG;3.75MG;3.75MG;3.75MG	A076852 003	Feb 16, 2016
AB			5MG;5MG;5MG;5MG	A076852 004	Feb 16, 2016
AB			6.25MG;6.25MG;6.25MG;6.25MG	A076852 005	Feb 16, 2016
AB			7.5MG;7.5MG;7.5MG;7.5MG	A076852 006	Feb 16, 2016
AB		RHODES PHARMS	1.25MG;1.25MG;1.25MG;1.25MG	A210651 001	May 17, 2019

PRESCRIPTION DRUG PRODUCT LIST

3-31 (of 474)

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB		2.5MG;2.5MG;2.5MG;2.5MG	A210651	002	May 17, 2019
AB		3.75MG;3.75MG;3.75MG;3.75MG	A210651	003	May 17, 2019
AB		5MG;5MG;5MG;5MG	A210651	004	May 17, 2019
AB		6.25MG;6.25MG;6.25MG;6.25MG	A210651	005	May 17, 2019
AB		7.5MG;7.5MG;7.5MG;7.5MG	A210651	006	May 17, 2019
AB	SPECGX LLC	1.25MG;1.25MG;1.25MG;1.25MG	A211547	001	Apr 22, 2019
AB		2.5MG;2.5MG;2.5MG;2.5MG	A211547	002	Apr 22, 2019
AB		3.75MG;3.75MG;3.75MG;3.75MG	A211547	003	Apr 22, 2019
AB		5MG;5MG;5MG;5MG	A211547	004	Apr 22, 2019
AB		6.25MG;6.25MG;6.25MG;6.25MG	A211547	005	Apr 22, 2019
AB		7.5MG;7.5MG;7.5MG;7.5MG	A211547	006	Apr 22, 2019
AB	SUN PHARM INDUSTRIES	1.25MG;1.25MG;1.25MG;1.25MG	A211715	001	May 17, 2019
AB		2.5MG;2.5MG;2.5MG;2.5MG	A211715	002	May 17, 2019
AB		3.75MG;3.75MG;3.75MG;3.75MG	A211715	003	May 17, 2019
AB		5MG;5MG;5MG;5MG	A211715	004	May 17, 2019
AB		6.25MG;6.25MG;6.25MG;6.25MG	A211715	005	May 17, 2019
AB		7.5MG;7.5MG;7.5MG;7.5MG	A211715	006	May 17, 2019
	MYDAYIS				
+	TAKEDA PHARMS USA	3.125MG;3.125MG;3.125MG;3.125MG	N022063	001	Jun 20, 2017
+		6.25MG;6.25MG;6.25MG;6.25MG	N022063	002	Jun 20, 2017
+		9.375MG;9.375MG;9.375MG;9.375MG	N022063	003	Jun 20, 2017
+	!	12.5MG;12.5MG;12.5MG;12.5MG	N022063	004	Jun 20, 2017

TABLET; ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB	ACTAVIS ELIZABETH	1.25MG;1.25MG;1.25MG;1.25MG	A206340	001	Feb 05, 2016
AB		1.875MG;1.875MG;1.875MG;1.875MG	A206340	002	Feb 05, 2016
AB		2.5MG;2.5MG;2.5MG;2.5MG	A206340	003	Feb 05, 2016
AB		3.125MG;3.125MG;3.125MG;3.125MG	A206340	004	Feb 05, 2016
AB		3.75MG;3.75MG;3.75MG;3.75MG	A206340	005	Feb 05, 2016
AB		5MG;5MG;5MG;5MG	A206340	006	Feb 05, 2016
AB		7.5MG;7.5MG;7.5MG;7.5MG	A206340	007	Feb 05, 2016
AB	ALVOGEN	1.25MG;1.25MG;1.25MG;1.25MG	A207388	001	Jul 28, 2017
AB		1.875MG;1.875MG;1.875MG;1.875MG	A207388	002	Jul 28, 2017
AB		2.5MG;2.5MG;2.5MG;2.5MG	A207388	003	Jul 28, 2017
AB		3.125MG;3.125MG;3.125MG;3.125MG	A207388	004	Jul 28, 2017
AB		3.75MG;3.75MG;3.75MG;3.75MG	A207388	005	Jul 28, 2017
AB		5MG;5MG;5MG;5MG	A207388	006	Jul 28, 2017
AB		7.5MG;7.5MG;7.5MG;7.5MG	A207388	007	Jul 28, 2017
AB	ASCENT PHARMS INC	1.25MG;1.25MG;1.25MG;1.25MG	A213709	001	Apr 22, 2021
AB		1.875MG;1.875MG;1.875MG;1.875MG	A213709	002	Apr 22, 2021
AB		2.5MG;2.5MG;2.5MG;2.5MG	A213709	003	Apr 22, 2021
AB		3.125MG;3.125MG;3.125MG;3.125MG	A213709	004	Apr 22, 2021
AB		3.75MG;3.75MG;3.75MG;3.75MG	A213709	005	Apr 22, 2021
AB		5MG;5MG;5MG;5MG	A213709	006	Apr 22, 2021
AB		7.5MG;7.5MG;7.5MG;7.5MG	A213709	007	Apr 22, 2021
AB	AUROLIFE PHARMA LLC	1.25MG;1.25MG;1.25MG;1.25MG	A202424	001	Nov 27, 2013
AB		1.875MG;1.875MG;1.875MG;1.875MG	A202424	002	Nov 27, 2013
AB		2.5MG;2.5MG;2.5MG;2.5MG	A202424	003	Nov 27, 2013
AB		3.125MG;3.125MG;3.125MG;3.125MG	A202424	004	Nov 27, 2013
AB		3.75MG;3.75MG;3.75MG;3.75MG	A202424	005	Nov 27, 2013
AB		5MG;5MG;5MG;5MG	A202424	006	Nov 27, 2013
AB		7.5MG;7.5MG;7.5MG;7.5MG	A202424	007	Nov 27, 2013
AB	BARR	1.25MG;1.25MG;1.25MG;1.25MG	A040422	001	Feb 11, 2002
AB		1.875MG;1.875MG;1.875MG;1.875MG	A040422	005	Mar 19, 2003
AB		2.5MG;2.5MG;2.5MG;2.5MG	A040422	002	Feb 11, 2002
AB		3.125MG;3.125MG;3.125MG;3.125MG	A040422	006	Mar 19, 2003
AB		3.75MG;3.75MG;3.75MG;3.75MG	A040422	007	Mar 19, 2003
AB		5MG;5MG;5MG;5MG	A040422	003	Feb 11, 2002
AB	!	7.5MG;7.5MG;7.5MG;7.5MG	A040422	004	Feb 11, 2002
AB	ELITE LABS INC	1.25MG;1.25MG;1.25MG;1.25MG	A211352	001	Dec 07, 2018
AB		1.875MG;1.875MG;1.875MG;1.875MG	A211352	002	Dec 07, 2018
AB		2.5MG;2.5MG;2.5MG;2.5MG	A211352	003	Dec 07, 2018
AB		3.125MG;3.125MG;3.125MG;3.125MG	A211352	004	Dec 07, 2018
AB		3.75MG;3.75MG;3.75MG;3.75MG	A211352	005	Dec 07, 2018
AB		5MG;5MG;5MG;5MG	A211352	006	Dec 07, 2018
AB		7.5MG;7.5MG;7.5MG;7.5MG	A211352	007	Dec 07, 2018
AB	EPIC PHARMA LLC	1.25MG;1.25MG;1.25MG;1.25MG	A040444	001	Jun 19, 2002
AB		1.875MG;1.875MG;1.875MG;1.875MG	A040444	005	Nov 03, 2014

PRESCRIPTION DRUG PRODUCT LIST

3-32 (of 474)

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

TABLET; ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB		2.5MG;2.5MG;2.5MG;2.5MG	A040444	002	Jun 19, 2002
AB		3.125MG;3.125MG;3.125MG;3.125MG	A040444	006	Nov 03, 2014
AB		3.75MG;3.75MG;3.75MG;3.75MG	A040444	007	Nov 03, 2014
AB		5MG;5MG;5MG;5MG	A040444	003	Jun 19, 2002
AB		7.5MG;7.5MG;7.5MG;7.5MG	A040444	004	Jun 19, 2002
AB	GRANULES	1.25MG;1.25MG;1.25MG;1.25MG	A215771	001	Dec 28, 2021
AB		1.875MG;1.875MG;1.875MG;1.875MG	A215771	002	Dec 28, 2021
AB		2.5MG;2.5MG;2.5MG;2.5MG	A215771	003	Dec 28, 2021
AB		3.125MG;3.125MG;3.125MG;3.125MG	A215771	004	Dec 28, 2021
AB		3.75MG;3.75MG;3.75MG;3.75MG	A215771	005	Dec 28, 2021
AB		5MG;5MG;5MG;5MG	A215771	006	Dec 28, 2021
AB		7.5MG;7.5MG;7.5MG;7.5MG	A215771	007	Dec 28, 2021
AB	NUVO PHARM	1.25MG;1.25MG;1.25MG;1.25MG	A209799	001	Dec 28, 2017
AB		1.875MG;1.875MG;1.875MG;1.875MG	A209799	002	Dec 28, 2017
AB		2.5MG;2.5MG;2.5MG;2.5MG	A209799	003	Dec 28, 2017
AB		3.125MG;3.125MG;3.125MG;3.125MG	A209799	004	Dec 28, 2017
AB		3.75MG;3.75MG;3.75MG;3.75MG	A209799	005	Dec 28, 2017
AB		5MG;5MG;5MG;5MG	A209799	006	Dec 28, 2017
AB		7.5MG;7.5MG;7.5MG;7.5MG	A209799	007	Dec 28, 2017
AB	RHODES PHARMS	1.25MG;1.25MG;1.25MG;1.25MG	A213111	001	Jan 13, 2021
AB		1.875MG;1.875MG;1.875MG;1.875MG	A213111	002	Jan 13, 2021
AB		2.5MG;2.5MG;2.5MG;2.5MG	A213111	003	Jan 13, 2021
AB		3.125MG;3.125MG;3.125MG;3.125MG	A213111	004	Jan 13, 2021
AB		3.75MG;3.75MG;3.75MG;3.75MG	A213111	005	Jan 13, 2021
AB		5MG;5MG;5MG;5MG	A213111	006	Jan 13, 2021
AB		7.5MG;7.5MG;7.5MG;7.5MG	A213111	007	Jan 13, 2021
AB	SANDOZ	1.25MG;1.25MG;1.25MG;1.25MG	A040439	004	Sep 27, 2002
AB		2.5MG;2.5MG;2.5MG;2.5MG	A040439	001	Jun 14, 2002
AB		5MG;5MG;5MG;5MG	A040439	002	Jun 14, 2002
AB		7.5MG;7.5MG;7.5MG;7.5MG	A040439	003	Jun 14, 2002
AB	SPECGX LLC	1.25MG;1.25MG;1.25MG;1.25MG	A040440	001	Oct 07, 2003
AB		1.875MG;1.875MG;1.875MG;1.875MG	A040440	002	Oct 07, 2003
AB		2.5MG;2.5MG;2.5MG;2.5MG	A040440	003	Oct 07, 2003
AB		3.125MG;3.125MG;3.125MG;3.125MG	A040440	004	Oct 07, 2003
AB		3.75MG;3.75MG;3.75MG;3.75MG	A040440	005	Oct 07, 2003
AB		5MG;5MG;5MG;5MG	A040440	006	Oct 07, 2003
AB		7.5MG;7.5MG;7.5MG;7.5MG	A040440	007	Oct 07, 2003
AB	SUN PHARM INDUSTRIES	1.25MG;1.25MG;1.25MG;1.25MG	A040480	001	Sep 09, 2003
AB		1.875MG;1.875MG;1.875MG;1.875MG	A040480	002	Sep 09, 2003
AB		2.5MG;2.5MG;2.5MG;2.5MG	A040480	003	Sep 09, 2003
AB		3.125MG;3.125MG;3.125MG;3.125MG	A040480	004	Sep 09, 2003
AB		3.75MG;3.75MG;3.75MG;3.75MG	A040480	005	Sep 09, 2003
AB		5MG;5MG;5MG;5MG	A040480	006	Sep 09, 2003
AB		7.5MG;7.5MG;7.5MG;7.5MG	A040480	007	Sep 09, 2003
AB	USPHARMA WINDLAS	1.25MG;1.25MG;1.25MG;1.25MG	A210293	001	Apr 03, 2020
AB		1.875MG;1.875MG;1.875MG;1.875MG	A210293	002	Apr 03, 2020
AB		2.5MG;2.5MG;2.5MG;2.5MG	A210293	003	Apr 03, 2020
AB		3.75MG;3.75MG;3.75MG;3.75MG	A210293	004	Apr 03, 2020
AB		5MG;5MG;5MG;5MG	A210293	005	Apr 03, 2020
AB		7.5MG;7.5MG;7.5MG;7.5MG	A210293	006	Apr 03, 2020
AB	ZYDUS PHARMS	1.25MG;1.25MG;1.25MG;1.25MG	A207340	001	Oct 31, 2017
AB		1.875MG;1.875MG;1.875MG;1.875MG	A207340	002	Oct 31, 2017
AB		2.5MG;2.5MG;2.5MG;2.5MG	A207340	003	Oct 31, 2017
AB		3.125MG;3.125MG;3.125MG;3.125MG	A207340	004	Oct 31, 2017
AB		3.75MG;3.75MG;3.75MG;3.75MG	A207340	005	Oct 31, 2017
AB		5MG;5MG;5MG;5MG	A207340	006	Oct 31, 2017
AB		7.5MG;7.5MG;7.5MG;7.5MG	A207340	007	Oct 31, 2017

AMPHETAMINE SULFATE

TABLET; ORAL

AMPHETAMINE SULFATE

AA	ALKEM LABS LTD	5MG	A213720	001	Oct 27, 2020
AA		10MG	A213720	002	Oct 27, 2020
AA	AMNEAL PHARMS	5MG	A211139	001	Sep 26, 2018
AA		10MG	A211139	002	Sep 26, 2018
AA	AUROLIFE PHARMA LLC	5MG	A211639	001	Apr 17, 2019
AA		10MG	A211639	002	Apr 17, 2019
AA	BIONPHARMA INC	5MG	A212919	001	Nov 22, 2019

PRESCRIPTION DRUG PRODUCT LIST

3-33 (of 474)

AMPHETAMINE SULFATE

TABLET; ORAL

AMPHETAMINE SULFATE

<u>AA</u>		<u>10MG</u>	<u>A212919</u>	<u>002</u>	Nov 22, 2019
<u>AA</u>	CEROVENE INC	<u>5MG</u>	<u>A212582</u>	<u>001</u>	Feb 04, 2020
<u>AA</u>		<u>10MG</u>	<u>A212582</u>	<u>002</u>	Feb 04, 2020
<u>AA</u>	EPIC PHARMA LLC	<u>5MG</u>	<u>A213980</u>	<u>001</u>	Oct 27, 2020
<u>AA</u>		<u>10MG</u>	<u>A213980</u>	<u>002</u>	Oct 27, 2020
<u>AA</u>	GRANULES	<u>5MG</u>	<u>A212619</u>	<u>001</u>	Aug 05, 2019
<u>AA</u>		<u>10MG</u>	<u>A212619</u>	<u>002</u>	Aug 05, 2019
<u>AA</u>	PRINSTON INC	<u>5MG</u>	<u>A211861</u>	<u>001</u>	Mar 11, 2020
<u>AA</u>		<u>10MG</u>	<u>A211861</u>	<u>002</u>	Mar 11, 2020
<u>AA</u>	RHODES PHARMS	<u>5MG</u>	<u>A213852</u>	<u>001</u>	Sep 07, 2021
<u>AA</u>		<u>10MG</u>	<u>A213852</u>	<u>002</u>	Sep 07, 2021
<u>AA</u>	RISE PHARMA	<u>5MG</u>	<u>A212901</u>	<u>001</u>	May 22, 2020
<u>AA</u>		<u>10MG</u>	<u>A212901</u>	<u>002</u>	May 22, 2020
<u>AA</u>	SPECGX LLC	<u>5MG</u>	<u>A213583</u>	<u>001</u>	Jan 22, 2021
<u>AA</u>		<u>10MG</u>	<u>A213583</u>	<u>002</u>	Jan 22, 2021
<u>AA</u>	SUN PHARM INDS INC	<u>5MG</u>	<u>A214574</u>	<u>001</u>	Jan 27, 2021
<u>AA</u>		<u>10MG</u>	<u>A214574</u>	<u>002</u>	Jan 27, 2021

EVEKEO

<u>AA</u>	ARBOR PHARMS LLC	<u>5MG</u>	<u>A200166</u>	<u>001</u>	Aug 09, 2012
<u>AA</u>	!	<u>10MG</u>	<u>A200166</u>	<u>002</u>	Aug 09, 2012

TABLET, ORALLY DISINTEGRATING; ORAL

EVEKEO ODT

+	AZURITY	5MG	N209905	001	Jan 30, 2019
+		10MG	N209905	002	Jan 30, 2019
+		15MG	N209905	003	Jan 30, 2019
+	!	20MG	N209905	004	Jan 30, 2019

AMPHETAMINE; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE

SUSPENSION, EXTENDED RELEASE; ORAL

DYANA VEL XR

+	!	TRIS PHARMA INC	2MG/ML; EQ 0.5MG BASE/ML	N208147	001	Oct 19, 2015

TABLET, EXTENDED RELEASE; ORAL

DYANA VEL XR 10

+	TRIS PHARMA INC	8MG; EQ 2MG BASE	N210526	002	Nov 04, 2021

DYANA VEL XR 15

+	TRIS PHARMA INC	12MG; EQ 3MG BASE	N210526	003	Nov 04, 2021

DYANA VEL XR 20

+	!	TRIS PHARMA INC	16MG; EQ 4MG BASE	N210526	004	Nov 04, 2021

DYANA VEL XR 5

+	TRIS PHARMA INC	4MG; EQ 1MG BASE	N210526	001	Nov 04, 2021

AMPHOTERICIN B

INJECTABLE; INJECTION

AMPHOTERICIN B

!	XGEN PHARMS	50MG/VIAL	A063206	001	Apr 29, 1992

INJECTABLE, LIPID COMPLEX; INJECTION

ABELCET

+	!	LEADIANT BIOSCI INC	5MG/ML	N050724	001	Nov 20, 1995

INJECTABLE, LIPOSOMAL; INJECTION

AMBISOME

<u>AB</u>	+	!	ASTELLAS	<u>50MG/VIAL</u>	<u>N050740</u>	<u>001</u>	Aug 11, 1997

AMPHOTERICIN B

<u>AB</u>	EUGIA PHARMA	<u>50MG/VIAL</u>	<u>A214010</u>	<u>001</u>	Nov 17, 2022

<u>AB</u>	SPII	<u>50MG/VIAL</u>	<u>A212514</u>	<u>001</u>	Dec 14, 2021

AMPICILLIN SODIUM

INJECTABLE; INJECTION

AMPICILLIN SODIUM

<u>AP</u>	ACS DOBFAR SPA	<u>EQ 10GM BASE/VIAL</u>	<u>A090889</u>	<u>001</u>	Apr 03, 2013
<u>AP</u>	ANTIBIOTICE	<u>EQ 250MG BASE/VIAL</u>	<u>A090354</u>	<u>001</u>	Dec 28, 2009
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A090354</u>	<u>002</u>	Dec 28, 2009
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A090354</u>	<u>003</u>	Dec 28, 2009
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A090354</u>	<u>004</u>	Dec 28, 2009
<u>AP</u>	EUGIA PHARMA	<u>EQ 250MG BASE/VIAL</u>	<u>A065499</u>	<u>002</u>	Aug 17, 2010
<u>AP</u>	SPECLTS	<u>EQ 500MG BASE/VIAL</u>	<u>A065499</u>	<u>003</u>	Aug 17, 2010
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A065499</u>	<u>004</u>	Aug 17, 2010
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065499</u>	<u>005</u>	Aug 17, 2010
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A065493</u>	<u>001</u>	Aug 17, 2010
<u>AP</u>	HQ SPECLT PHARMA	<u>EQ 250MG BASE/VIAL</u>	<u>A062772</u>	<u>006</u>	Apr 15, 1993
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A062772</u>	<u>007</u>	Apr 15, 1993

PRESCRIPTION DRUG PRODUCT LIST

3-34 (of 474)

AMPICILLIN SODIUM

INJECTABLE; INJECTION

AMPICILLIN SODIUM

AP		<u>EQ 1GM BASE/VIAL</u>	<u>A062772</u>	<u>001</u>	Apr 15, 1993
AP		<u>EQ 2GM BASE/VIAL</u>	<u>A062772</u>	<u>003</u>	Apr 15, 1993
AP		<u>EQ 10GM BASE/VIAL</u>	<u>A063142</u>	<u>001</u>	Apr 15, 1993
AP	ISTITUTO BIO ITA SPA	<u>EQ 10GM BASE/VIAL</u>	<u>A201404</u>	<u>001</u>	Dec 20, 2013
AP		<u>EQ 250MG BASE/VIAL</u>	<u>A062719</u>	<u>001</u>	May 12, 1987
AP		<u>EQ 500MG BASE/VIAL</u>	<u>A062719</u>	<u>003</u>	May 12, 1987
AP		<u>EQ 1GM BASE/VIAL</u>	<u>A062719</u>	<u>002</u>	May 12, 1987
AP		<u>EQ 2GM BASE/VIAL</u>	<u>A062797</u>	<u>002</u>	Jul 12, 1993
AP	MYLAN LABS LTD	<u>EQ 1GM BASE/VIAL</u>	<u>A201025</u>	<u>003</u>	Apr 09, 2014
AP		<u>EQ 2GM BASE/VIAL</u>	<u>A201025</u>	<u>004</u>	Apr 09, 2014
AP		<u>EQ 10GM BASE/VIAL</u>	<u>A202198</u>	<u>001</u>	Apr 07, 2014
AP	SAGENT PHARMS INC	<u>EQ 125MG BASE/VIAL</u>	<u>A090583</u>	<u>001</u>	Nov 27, 2015
AP		<u>EQ 250MG BASE/VIAL</u>	<u>A090583</u>	<u>002</u>	Nov 27, 2015
AP		<u>EQ 500MG BASE/VIAL</u>	<u>A090583</u>	<u>003</u>	Nov 27, 2015
AP		<u>EQ 1GM BASE/VIAL</u>	<u>A090583</u>	<u>004</u>	Nov 27, 2015
AP		<u>EQ 2GM BASE/VIAL</u>	<u>A090583</u>	<u>005</u>	Nov 27, 2015
AP		<u>EQ 10GM BASE/VIAL</u>	<u>A090581</u>	<u>001</u>	Oct 20, 2015
AP	! SANDOZ	<u>EQ 125MG BASE/VIAL</u>	<u>A061395</u>	<u>001</u>	
AP	!	<u>EQ 250MG BASE/VIAL</u>	<u>A061395</u>	<u>002</u>	
AP	!	<u>EQ 500MG BASE/VIAL</u>	<u>A061395</u>	<u>003</u>	
AP	!	<u>EQ 1GM BASE/VIAL</u>	<u>A061395</u>	<u>004</u>	
AP	!	<u>EQ 2GM BASE/VIAL</u>	<u>A061395</u>	<u>005</u>	
AP	!	<u>EQ 10GM BASE/VIAL</u>	<u>A061395</u>	<u>006</u>	

POWDER; INTRAVENOUS

AMPICILLIN SODIUM

AP	! SANDOZ	<u>EQ 1GM BASE/VIAL</u>	<u>A062738</u>	<u>001</u>	Feb 19, 1987
AP	!	<u>EQ 2GM BASE/VIAL</u>	<u>A062738</u>	<u>002</u>	Feb 19, 1987

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE; INJECTION

AMPICILLIN AND SULBACTAM

AP	ACS DOBFAR	<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A065406</u>	<u>001</u>	Dec 22, 2009
AP		<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A065406</u>	<u>002</u>	Dec 22, 2009
AP		<u>EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL</u>	<u>A065403</u>	<u>001</u>	Dec 23, 2009
AP	ANTIBIOTICE	<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A201406</u>	<u>001</u>	Dec 07, 2015
AP		<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A201406</u>	<u>002</u>	Dec 07, 2015
AP	ASTRAL	<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A090579</u>	<u>001</u>	Jan 08, 2016
AP		<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A090579</u>	<u>002</u>	Jan 08, 2016
AP		<u>EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL</u>	<u>A090578</u>	<u>001</u>	Jan 11, 2016
AP	EUGIA PHARMA SPECLTS	<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A090349</u>	<u>001</u>	Sep 20, 2010
AP		<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A090349</u>	<u>002</u>	Sep 20, 2010
AP		<u>EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL</u>	<u>A090339</u>	<u>001</u>	Sep 20, 2010
AP	HIKMA	<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A065074</u>	<u>001</u>	Mar 19, 2002
AP		<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A065074</u>	<u>002</u>	Mar 19, 2002
AP		<u>EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL</u>	<u>A065076</u>	<u>001</u>	Mar 19, 2002
AP	HQ SPECLT PHARMA	<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A065176</u>	<u>001</u>	Nov 30, 2005
AP		<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A065176</u>	<u>002</u>	Nov 30, 2005
AP		<u>EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL</u>	<u>A065188</u>	<u>001</u>	Nov 25, 2005
AP	ISTITUTO BIO ITA SPA	<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A065222</u>	<u>001</u>	Nov 29, 2005
AP		<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A065222</u>	<u>002</u>	Nov 29, 2005
AP		<u>EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL</u>	<u>A065314</u>	<u>001</u>	Nov 27, 2006
AP	MYLAN LABS LTD	<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A201024</u>	<u>001</u>	Apr 07, 2014
AP		<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A201024</u>	<u>002</u>	Apr 07, 2014
AP		<u>EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL</u>	<u>A202197</u>	<u>001</u>	Apr 07, 2014
AP	SANDOZ	<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A065241</u>	<u>001</u>	Jul 25, 2006
AP		<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A065310</u>	<u>001</u>	Jul 25, 2006
AP		<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A065241</u>	<u>002</u>	Jul 25, 2006
AP		<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A065310</u>	<u>002</u>	Jul 25, 2006
AP		<u>EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL</u>	<u>A065240</u>	<u>001</u>	Jul 25, 2006
<u>UNASYN</u>					
AP	! PFIZER	<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>A062901</u>	<u>002</u>	Feb 27, 1992
AP	!	<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A062901</u>	<u>001</u>	Nov 23, 1988
AP	+	<u>EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>N050608</u>	<u>002</u>	Dec 31, 1986
AP	+	<u>EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL</u>	<u>N050608</u>	<u>001</u>	Dec 31, 1986
AP	+	<u>EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL</u>	<u>N050608</u>	<u>005</u>	Dec 10, 1993

PRESCRIPTION DRUG PRODUCT LIST

3-35 (of 474)

AMPICILLIN/AMPICILLIN TRIHYDRATE

CAPSULE; ORAL

AMPICILLIN TRIHYDRATE

! SANDOZ

EQ 500MG BASE

A064082 002 Aug 29, 1995

ANAGRELIDE HYDROCHLORIDE

CAPSULE; ORAL

AGRYLINAB TAKEDA PHARMS USAEQ 0.5MG BASEN020333 001 Mar 14, 1997ANAGRELIDE HYDROCHLORIDEAB IMPAX LABSEQ 0.5MG BASEA076910 001 Apr 18, 2005ABEQ 1MG BASEA076910 002 Apr 18, 2005AB IVAX SUB TEVA
PHARMSEQ 0.5MG BASEA076468 001 Apr 18, 2005AB !EQ 1MG BASEA076468 002 Apr 18, 2005AB TORRENTEQ 0.5MG BASEA209151 001 Jun 30, 2017ABEQ 1MG BASEA209151 002 Jun 30, 2017ANASTROZOLE

TABLET; ORAL

ANASTROZOLEAB ACCORD HLTHCARE1MGA090568 001 Jun 28, 2010AB BEIJING YILING1MGA206037 001 Nov 09, 2018AB CIPLA1MGA091164 001 Jun 28, 2010AB EUGIA PHARMA1MGA212434 001 Jul 24, 2020AB KENTON1MGA078944 001 Jun 28, 2010AB NATCO PHARMA LTD1MGA079220 001 Jun 28, 2010AB TEVA PHARMS1MGA078058 001 Jun 28, 2010AB ZYDUS PHARMS USA
INC1MGA078921 001 Jun 28, 2010ARIMIDEXAB +! ANI PHARMS1MGN020541 001 Dec 27, 1995ANGIOTENSIN II ACETATE

SOLUTION; INTRAVENOUS

GIAPREZA

+! LA JOLLA PHARMA

EQ 0.5MG BASE/ML (EQ 0.5MG BASE/ML)

N209360 003 Dec 23, 2021

+!

EQ 2.5MG BASE/ML (EQ 2.5MG BASE/ML)

N209360 001 Dec 21, 2017

ANIDULAFUNGIN

POWDER; INTRAVENOUS

ERAXIS

+! VICURON HOLDINGS

50MG/VIAL

N021632 001 Feb 17, 2006

+!

100MG/VIAL

N021632 002 Nov 14, 2006

APALUTAMIDE

TABLET; ORAL

ERLEADA

+! JANSSEN BIOTECH

60MG

N210951 001 Feb 14, 2018

APIXABAN

TABLET; ORAL

APIXABANAB ACCORD HLTHCARE2.5MGA210180 001 Jul 28, 2020AB5MGA210180 002 Jul 28, 2020AB INDOCO2.5MGA209898 001 Sep 11, 2020AB5MGA209898 002 Sep 11, 2020ELIQUISAB + BRISTOL MYERS
SQUIBB2.5MGN202155 001 Dec 28, 2012AB +!5MGN202155 002 Dec 28, 2012APOMORPHINE HYDROCHLORIDE

FILM; SUBLINGUAL

KYNMOBI

+ SUNOVION PHARMS INC

10MG

N210875 001 May 21, 2020

+

15MG

N210875 002 May 21, 2020

+

20MG

N210875 003 May 21, 2020

+

25MG

N210875 004 May 21, 2020

+!

30MG

N210875 005 May 21, 2020

INJECTABLE; SUBCUTANEOUS

APOKYNAP +! MDD US30MG/3ML (10MG/ML)N021264 002 Apr 20, 2004APOMORPHINE HYDROCHLORIDEAP SAGE CHEMS30MG/3ML (10MG/ML)A212025 001 Feb 23, 2022

PRESCRIPTION DRUG PRODUCT LIST

3-36 (of 474)

APRACLOINIDINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

APRACLOINIDINE HYDROCHLORIDE

<u>AT</u>	AKORN	<u>EQ 0.5% BASE</u>	<u>A077764</u>	<u>001</u>	Mar 12, 2009	
<u>IOPIDINE</u>						
<u>AT</u>	+!	IMPRIMIS PHARMS USA	<u>EQ 0.5% BASE</u>	<u>N020258</u>	<u>001</u>	Jul 30, 1993
	+!		EQ 1% BASE	N019779	001	Dec 31, 1987

APREMILAST

TABLET;ORAL

APREMILAST

<u>AB</u>		ALKEM LABS LTD	<u>10MG</u>	<u>A211761</u>	<u>001</u>	Sep 21, 2021
<u>AB</u>			<u>20MG</u>	<u>A211761</u>	<u>002</u>	Sep 21, 2021
<u>AB</u>			<u>30MG</u>	<u>A211761</u>	<u>003</u>	Sep 21, 2021
<u>AB</u>		TEVA PHARMS USA INC	<u>10MG</u>	<u>A211897</u>	<u>001</u>	Aug 18, 2022
<u>AB</u>			<u>20MG</u>	<u>A211897</u>	<u>002</u>	Aug 18, 2022
<u>AB</u>			<u>30MG</u>	<u>A211897</u>	<u>003</u>	Aug 18, 2022
<u>OTEZLA</u>						
<u>AB</u>	+	AMGEN INC	<u>10MG</u>	<u>N205437</u>	<u>001</u>	Mar 21, 2014
<u>AB</u>	+		<u>20MG</u>	<u>N205437</u>	<u>002</u>	Mar 21, 2014
<u>AB</u>	+!		<u>30MG</u>	<u>N205437</u>	<u>003</u>	Mar 21, 2014

APREPITANT

CAPSULE;ORAL

APREPITANT

<u>AB</u>		GLENMARK PHARMS SA	<u>40MG</u>	<u>A207777</u>	<u>001</u>	Oct 12, 2017
<u>AB</u>			<u>80MG</u>	<u>A207777</u>	<u>002</u>	Oct 12, 2017
<u>AB</u>			<u>125MG</u>	<u>A207777</u>	<u>003</u>	Oct 12, 2017
<u>AB</u>		SANDOZ	<u>40MG</u>	<u>A090999</u>	<u>001</u>	Sep 24, 2012
<u>AB</u>			<u>80MG</u>	<u>A090999</u>	<u>002</u>	Sep 24, 2012
<u>AB</u>			<u>125MG</u>	<u>A090999</u>	<u>003</u>	Sep 24, 2012
<u>AB</u>		TORRENT	<u>40MG</u>	<u>A211835</u>	<u>001</u>	Oct 21, 2020
<u>AB</u>			<u>80MG</u>	<u>A211835</u>	<u>002</u>	Oct 21, 2020
<u>AB</u>			<u>125MG</u>	<u>A211835</u>	<u>003</u>	Oct 21, 2020
<u>EMEND</u>						
<u>AB</u>	+	MERCK	<u>80MG</u>	<u>N021549</u>	<u>001</u>	Mar 26, 2003
<u>AB</u>	+!		<u>125MG</u>	<u>N021549</u>	<u>002</u>	Mar 26, 2003
EMULSION;INTRAVENOUS						
APONVIE						
	+!	HERON THERAPS INC	32MG/4.4ML (7.2MG/ML)	<u>N216457</u>	<u>001</u>	Sep 16, 2022
CINVANTI						
	+!	HERON THERAPS INC	130MG/18ML (7.2MG/ML)	<u>N209296</u>	<u>001</u>	Nov 09, 2017
FOR SUSPENSION;ORAL						
EMEND						
	+!	MSD MERCK CO	125MG/KIT	<u>N207865</u>	<u>001</u>	Dec 17, 2015

ARFORMOTEROL TARTRATE

SOLUTION;INHALATION

ARFORMOTEROL TARTRATE

<u>AN</u>		ALEMBIC PHARMS	<u>EQ 0.015MG BASE/2ML</u>	<u>A214779</u>	<u>001</u>	May 10, 2022
<u>AN</u>		CIPLA	<u>EQ 0.015MG BASE/2ML</u>	<u>A207306</u>	<u>001</u>	Jun 22, 2021
<u>AN</u>		LUPIN	<u>EQ 0.015MG BASE/2ML</u>	<u>A213068</u>	<u>001</u>	Feb 07, 2022
<u>AN</u>		MANKIND PHARMA	<u>EQ 0.015MG BASE/2ML</u>	<u>A216128</u>	<u>001</u>	Nov 15, 2022
<u>AN</u>		SLATE RUN PHARMA	<u>EQ 0.015MG BASE/2ML</u>	<u>A213762</u>	<u>001</u>	Jun 22, 2021
<u>AN</u>		SLAYBACK PHARMA LLC	<u>EQ 0.015MG BASE/2ML</u>	<u>A216815</u>	<u>001</u>	Nov 25, 2022
<u>AN</u>		SUN PHARM	<u>EQ 0.015MG BASE/2ML</u>	<u>A215385</u>	<u>001</u>	May 26, 2022
<u>AN</u>		TEVA PHARMS USA	<u>EQ 0.015MG BASE/2ML</u>	<u>A200293</u>	<u>001</u>	Nov 09, 2021

BROVANA

<u>AN</u>	+!	LUPIN	<u>EQ 0.015MG BASE/2ML</u>	<u>N021912</u>	<u>001</u>	Oct 06, 2006

ARGATROBAN

INJECTABLE;INJECTION

ARGATROBAN

<u>AP</u>		AMNEAL PHARMS CO	<u>250MG/2.5ML (100MG/ML)</u>	<u>A206698</u>	<u>001</u>	Jan 26, 2018
<u>AP</u>		CAPLIN	<u>50MG/50ML (1MG/ML)</u>	<u>A214235</u>	<u>001</u>	Jan 21, 2021
<u>AP</u>		FRESENIUS KABI USA	<u>250MG/2.5ML (100MG/ML)</u>	<u>N201811</u>	<u>001</u>	Mar 23, 2015
<u>AP</u>	+!	HIKMA PHARM CO LTD	<u>50MG/50ML (1MG/ML)</u>	<u>N203049</u>	<u>002</u>	Sep 30, 2016
<u>AP</u>	+!		<u>250MG/2.5ML (100MG/ML)</u>	<u>N203049</u>	<u>001</u>	Jan 05, 2012
<u>AP</u>		HOSPIRA	<u>250MG/2.5ML (100MG/ML)</u>	<u>A204120</u>	<u>001</u>	Sep 21, 2016
<u>AP</u>		MYLAN INSTITUTIONAL	<u>250MG/2.5ML (100MG/ML)</u>	<u>A202626</u>	<u>001</u>	Jun 30, 2014
<u>AP</u>	+!	NOVARTIS	<u>250MG/2.5ML (100MG/ML)</u>	<u>N020883</u>	<u>001</u>	Jun 30, 2000
<u>AP</u>		PAR STERILE PRODUCTS	<u>250MG/2.5ML (100MG/ML)</u>	<u>A091665</u>	<u>001</u>	Jun 30, 2014

PRESCRIPTION DRUG PRODUCT LIST

3-37 (of 474)

ARGATROBAN

INJECTABLE; INTRAVENOUS

ARGATROBAN IN SODIUM CHLORIDEAP + GLAND PHARMA LTD 125MG/125ML (1MG/ML)A205570 001 May 22, 2017AP +! SANDOZ 125MG/125ML (1MG/ML)N022485 001 May 09, 2011

SOLUTION; INTRAVENOUS

ARGATROBAN IN SODIUM CHLORIDE

+! ACCORD HLTHCARE 50MG/50ML (1MG/ML)

N212035 001 Jun 07, 2021

EUGIA PHARMA 50MG/50ML (1MG/ML)

N209552 001 Nov 27, 2018

SPECLTS

ARGININE HYDROCHLORIDE

INJECTABLE; INJECTION

R-GENE 10

+! PHARMACIA AND 10GM/100ML

N016931 001

UPJOHN

ARIPIPIRAZOLE

FOR SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR

ABILIFY MAINTENA KIT

+ OTSUKA PHARM CO LTD 300MG/VIAL

N202971 001 Feb 28, 2013

+ 300MG

N202971 003 Sep 29, 2014

+! 400MG/VIAL

N202971 002 Feb 28, 2013

+ 400MG

N202971 004 Sep 29, 2014

SOLUTION; ORAL

ARIPIPIRAZOLEAA ! AMNEAL PHARMS 1MG/MLA203906 001 Aug 14, 2015AA APOTEX INC 1MG/MLA204094 001 Sep 30, 2015AA AUROBINDO PHARMA 1MG/MLA210479 001 Jan 29, 2019

LTD

AA GLASSHOUSE PHARMS 1MG/MLA215595 001 Oct 25, 2022AA LANNETT CO INC 1MG/MLA204171 001 Aug 14, 2015AA RUBICON 1MG/MLA216351 001 Oct 27, 2022AA VISTAPHARM 1MG/MLA212870 001 Dec 26, 2019

TABLET; ORAL

ABILIFYAB + OTSUKA 2MGN021436 006 Nov 15, 2002AB + 5MGN021436 005 Nov 15, 2002AB +! 10MGN021436 001 Nov 15, 2002AB + 15MGN021436 002 Nov 15, 2002AB + 20MGN021436 003 Nov 15, 2002AB + 30MGN021436 004 Nov 15, 2002ARIPIPIRAZOLEAB ACCORD HLTHCARE 2MGA206251 001 Dec 07, 2016AB 5MGA206251 002 Dec 07, 2016AB 10MGA206251 003 Dec 07, 2016AB 15MGA206251 004 Dec 07, 2016AB 20MGA206251 005 Dec 07, 2016AB 30MGA206251 006 Dec 07, 2016AB AJANTA PHARMA LTD 2MGA206174 001 Sep 12, 2016AB 5MGA206174 002 Sep 12, 2016AB 10MGA206174 003 Sep 12, 2016AB 15MGA206174 004 Sep 12, 2016AB 20MGA206174 005 Sep 12, 2016AB 30MGA206174 006 Sep 12, 2016AB ALEMBIC PHARMS 2MGA202101 001 Apr 28, 2015AB 5MGA202101 002 Apr 28, 2015AB 10MGA202101 003 Apr 28, 2015AB 15MGA202101 004 Apr 28, 2015AB 20MGA202101 005 Apr 28, 2015AB 30MGA202101 006 Apr 28, 2015AB ALKEM LABS LTD 2MGA207105 001 Feb 21, 2019AB 5MGA207105 002 Feb 21, 2019AB 10MGA207105 003 Feb 21, 2019AB 15MGA207105 004 Feb 21, 2019AB 20MGA207105 005 Feb 21, 2019AB 30MGA207105 006 Feb 21, 2019AB AMNEAL PHARMS 2MGA204838 001 Jun 17, 2016AB 5MGA204838 002 Jun 17, 2016AB 10MGA204838 003 Jun 17, 2016AB 15MGA204838 004 Jun 17, 2016AB 20MGA204838 005 Jun 17, 2016AB 30MGA204838 006 Jun 17, 2016AB APOTEX INC 2MGA078583 001 Jul 24, 2015

PRESCRIPTION DRUG PRODUCT LIST

3-38 (of 474)

ARIPIRAZOLE

TABLET; ORAL

ARIPIRAZOLE

<u>AB</u>		<u>5MG</u>	<u>A078583</u>	<u>002</u>	Jul 24, 2015
<u>AB</u>		<u>10MG</u>	<u>A078583</u>	<u>003</u>	Jul 24, 2015
<u>AB</u>		<u>15MG</u>	<u>A078583</u>	<u>004</u>	Jul 24, 2015
<u>AB</u>		<u>20MG</u>	<u>A078583</u>	<u>005</u>	Jul 24, 2015
<u>AB</u>		<u>30MG</u>	<u>A078583</u>	<u>006</u>	Jul 24, 2015
<u>AB</u>	AUROBINDO PHARMA	<u>2MG</u>	<u>A203908</u>	<u>001</u>	Oct 08, 2015
<u>AB</u>		<u>5MG</u>	<u>A203908</u>	<u>002</u>	Oct 08, 2015
<u>AB</u>		<u>10MG</u>	<u>A203908</u>	<u>003</u>	Oct 08, 2015
<u>AB</u>		<u>15MG</u>	<u>A203908</u>	<u>004</u>	Oct 08, 2015
<u>AB</u>		<u>20MG</u>	<u>A203908</u>	<u>005</u>	Oct 08, 2015
<u>AB</u>		<u>30MG</u>	<u>A203908</u>	<u>006</u>	Oct 08, 2015
<u>AB</u>	BOSCOGEN	<u>2MG</u>	<u>A091279</u>	<u>001</u>	Jan 09, 2017
<u>AB</u>		<u>5MG</u>	<u>A091279</u>	<u>002</u>	Jan 09, 2017
<u>AB</u>		<u>10MG</u>	<u>A091279</u>	<u>003</u>	Jan 09, 2017
<u>AB</u>		<u>15MG</u>	<u>A091279</u>	<u>004</u>	Jan 09, 2017
<u>AB</u>		<u>20MG</u>	<u>A091279</u>	<u>005</u>	Jan 09, 2017
<u>AB</u>		<u>30MG</u>	<u>A091279</u>	<u>006</u>	Jan 09, 2017
<u>AB</u>	HETERO LABS LTD V	<u>2MG</u>	<u>A205064</u>	<u>001</u>	Apr 28, 2015
<u>AB</u>		<u>5MG</u>	<u>A205064</u>	<u>002</u>	Apr 28, 2015
<u>AB</u>		<u>10MG</u>	<u>A205064</u>	<u>003</u>	Apr 28, 2015
<u>AB</u>		<u>15MG</u>	<u>A205064</u>	<u>004</u>	Apr 28, 2015
<u>AB</u>		<u>20MG</u>	<u>A205064</u>	<u>005</u>	Apr 28, 2015
<u>AB</u>		<u>30MG</u>	<u>A205064</u>	<u>006</u>	Apr 28, 2015
<u>AB</u>	MACLEODS PHARMS LTD	<u>2MG</u>	<u>A204111</u>	<u>001</u>	Oct 07, 2016
<u>AB</u>		<u>5MG</u>	<u>A204111</u>	<u>002</u>	Oct 07, 2016
<u>AB</u>		<u>10MG</u>	<u>A204111</u>	<u>003</u>	Oct 07, 2016
<u>AB</u>		<u>15MG</u>	<u>A204111</u>	<u>004</u>	Oct 07, 2016
<u>AB</u>		<u>20MG</u>	<u>A204111</u>	<u>005</u>	Oct 07, 2016
<u>AB</u>		<u>30MG</u>	<u>A204111</u>	<u>006</u>	Oct 07, 2016
<u>AB</u>	ORBION PHARMS	<u>2MG</u>	<u>A202683</u>	<u>001</u>	May 23, 2017
<u>AB</u>		<u>5MG</u>	<u>A202683</u>	<u>002</u>	May 23, 2017
<u>AB</u>		<u>10MG</u>	<u>A202683</u>	<u>003</u>	May 23, 2017
<u>AB</u>		<u>15MG</u>	<u>A202683</u>	<u>004</u>	May 23, 2017
<u>AB</u>		<u>20MG</u>	<u>A202683</u>	<u>005</u>	May 23, 2017
<u>AB</u>		<u>30MG</u>	<u>A202683</u>	<u>006</u>	May 23, 2017
<u>AB</u>	PRINSTON INC	<u>2MG</u>	<u>A205363</u>	<u>001</u>	Dec 04, 2017
<u>AB</u>		<u>5MG</u>	<u>A205363</u>	<u>002</u>	Dec 04, 2017
<u>AB</u>		<u>10MG</u>	<u>A205363</u>	<u>003</u>	Dec 04, 2017
<u>AB</u>		<u>15MG</u>	<u>A205363</u>	<u>004</u>	Dec 04, 2017
<u>AB</u>		<u>20MG</u>	<u>A205363</u>	<u>005</u>	Dec 04, 2017
<u>AB</u>		<u>30MG</u>	<u>A205363</u>	<u>006</u>	Dec 04, 2017
<u>AB</u>	SCIEGEN PHARMS INC	<u>2MG</u>	<u>A206383</u>	<u>001</u>	Sep 29, 2016
<u>AB</u>		<u>5MG</u>	<u>A206383</u>	<u>002</u>	Sep 29, 2016
<u>AB</u>		<u>10MG</u>	<u>A206383</u>	<u>003</u>	Sep 29, 2016
<u>AB</u>		<u>15MG</u>	<u>A206383</u>	<u>004</u>	Sep 29, 2016
<u>AB</u>		<u>20MG</u>	<u>A206383</u>	<u>005</u>	Sep 29, 2016
<u>AB</u>		<u>30MG</u>	<u>A206383</u>	<u>006</u>	Sep 29, 2016
<u>AB</u>	TORRENT	<u>2MG</u>	<u>A201519</u>	<u>001</u>	Apr 28, 2015
<u>AB</u>		<u>10MG</u>	<u>A201519</u>	<u>003</u>	Apr 28, 2015
<u>AB</u>		<u>5MG</u>	<u>A201519</u>	<u>002</u>	Apr 28, 2015
<u>AB</u>		<u>15MG</u>	<u>A201519</u>	<u>004</u>	Apr 28, 2015
<u>AB</u>		<u>20MG</u>	<u>A201519</u>	<u>005</u>	Apr 28, 2015
<u>AB</u>		<u>30MG</u>	<u>A201519</u>	<u>006</u>	Apr 28, 2015
<u>AB</u>	UNICHEM	<u>2MG</u>	<u>A203025</u>	<u>001</u>	Dec 01, 2021
<u>AB</u>		<u>5MG</u>	<u>A203025</u>	<u>002</u>	Dec 01, 2021
<u>AB</u>		<u>10MG</u>	<u>A203025</u>	<u>003</u>	Dec 01, 2021
<u>AB</u>		<u>15MG</u>	<u>A203025</u>	<u>004</u>	Dec 01, 2021
<u>AB</u>		<u>20MG</u>	<u>A203025</u>	<u>005</u>	Dec 01, 2021
<u>AB</u>		<u>30MG</u>	<u>A203025</u>	<u>006</u>	Dec 01, 2021
ABILIFY MYCITE KIT					
+	OTSUKA	2MG	N207202	001	Nov 13, 2017
+	!	5MG	N207202	002	Nov 13, 2017
+		10MG	N207202	003	Nov 13, 2017
+		15MG	N207202	004	Nov 13, 2017
+		20MG	N207202	005	Nov 13, 2017
+		30MG	N207202	006	Nov 13, 2017
TABLET, ORALLY DISINTEGRATING; ORAL					
<u>ARIPIRAZOLE</u>					
<u>AB</u>	!	ALEMBIC PHARMS	<u>10MG</u>	<u>A202102</u>	<u>001</u> Apr 28, 2015

PRESCRIPTION DRUG PRODUCT LIST

3-39 (of 474)

ARIPIRAZOLE

TABLET, ORALLY DISINTEGRATING; ORAL

ARIPIRAZOLE

<u>AB</u>		<u>15MG</u>	<u>A202102</u>	<u>002</u>	Apr 28, 2015
<u>AB</u>	ORBION PHARMS	<u>10MG</u>	<u>A202547</u>	<u>001</u>	Dec 11, 2017
<u>AB</u>		<u>15MG</u>	<u>A202547</u>	<u>002</u>	Dec 11, 2017
<u>AB</u>	SCIEGEN PHARMS INC	<u>10MG</u>	<u>A207240</u>	<u>001</u>	Apr 18, 2018
<u>AB</u>		<u>15MG</u>	<u>A207240</u>	<u>002</u>	Apr 18, 2018
<u>AB</u>	SQUARE PHARMS	<u>10MG</u>	<u>A090165</u>	<u>001</u>	Aug 28, 2018
<u>AB</u>		<u>15MG</u>	<u>A090165</u>	<u>002</u>	Aug 28, 2018
		20MG	A090165	003	Aug 28, 2018
		30MG	A090165	004	Aug 28, 2018

ARIPIRAZOLE LAUROXIL

SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR

ARISTADA

+	ALKERMES INC	441MG/1.6ML (275.63MG/ML)	N207533	001	Oct 05, 2015
+		662MG/2.4ML (275.83MG/ML)	N207533	002	Oct 05, 2015
+	!	882MG/3.2ML (275.63MG/ML)	N207533	003	Oct 05, 2015
+		1064MG/3.9ML (272.82MG/ML)	N207533	004	Jun 05, 2017
	ARISTADA INITIO KIT				
+	ALKERMES INC	675MG/2.4ML	N209830	001	Jun 29, 2018

ARMODAFINIL

TABLET; ORAL

ARMODAFINIL

<u>AB</u>	AUROBINDO PHARMA LTD	<u>50MG</u>	<u>A206069</u>	<u>001</u>	Mar 06, 2018
<u>AB</u>		<u>150MG</u>	<u>A206069</u>	<u>002</u>	Mar 06, 2018
<u>AB</u>		<u>200MG</u>	<u>A206069</u>	<u>004</u>	Dec 07, 2018
<u>AB</u>		<u>250MG</u>	<u>A206069</u>	<u>003</u>	Mar 06, 2018
<u>AB</u>	LUPIN LTD	<u>50MG</u>	<u>A200751</u>	<u>001</u>	Nov 28, 2016
<u>AB</u>		<u>150MG</u>	<u>A200751</u>	<u>003</u>	Nov 28, 2016
<u>AB</u>		<u>200MG</u>	<u>A200751</u>	<u>004</u>	Nov 28, 2016
<u>AB</u>		<u>250MG</u>	<u>A200751</u>	<u>005</u>	Nov 28, 2016
<u>AB</u>	MYLAN PHARMS INC	<u>50MG</u>	<u>A200043</u>	<u>001</u>	Jun 01, 2012
<u>AB</u>		<u>100MG</u>	<u>A200043</u>	<u>004</u>	May 09, 2019
<u>AB</u>		<u>150MG</u>	<u>A200043</u>	<u>002</u>	Jun 01, 2012
<u>AB</u>		<u>200MG</u>	<u>A200043</u>	<u>005</u>	May 09, 2019
<u>AB</u>		<u>250MG</u>	<u>A200043</u>	<u>003</u>	Jun 01, 2012
<u>AB</u>	NATCO PHARMA LTD	<u>50MG</u>	<u>A202768</u>	<u>001</u>	Nov 28, 2016
<u>AB</u>		<u>100MG</u>	<u>A202768</u>	<u>004</u>	Sep 28, 2017
<u>AB</u>		<u>150MG</u>	<u>A202768</u>	<u>002</u>	Nov 28, 2016
<u>AB</u>		<u>200MG</u>	<u>A202768</u>	<u>005</u>	Sep 28, 2017
<u>AB</u>		<u>250MG</u>	<u>A202768</u>	<u>003</u>	Nov 28, 2016

NUVIGIL

<u>AB</u>	+	CEPHALON	<u>50MG</u>	<u>N021875</u>	<u>001</u>	Jun 15, 2007
<u>AB</u>	+		<u>150MG</u>	<u>N021875</u>	<u>003</u>	Jun 15, 2007
<u>AB</u>	+		<u>200MG</u>	<u>N021875</u>	<u>005</u>	Mar 26, 2009
<u>AB</u>	+	!	<u>250MG</u>	<u>N021875</u>	<u>004</u>	Jun 15, 2007

ARSENIC TRIOXIDE

INJECTABLE; INJECTION

ARSENIC TRIOXIDE

<u>AP</u>	AMNEAL	<u>1MG/ML</u>	<u>A210739</u>	<u>001</u>	Jan 25, 2021
<u>AP</u>		<u>2MG/ML</u>	<u>A210739</u>	<u>002</u>	Aug 19, 2021
<u>AP</u>	AMRING PHARMS	<u>1MG/ML</u>	<u>A210802</u>	<u>001</u>	Nov 13, 2018
<u>AP</u>	EUGIA PHARMA	<u>2MG/ML</u>	<u>A214011</u>	<u>001</u>	Oct 15, 2021
<u>AP</u>	!	FRESENIUS KABI USA	<u>A208231</u>	<u>001</u>	Aug 31, 2018
<u>AP</u>	GLAND PHARMA LTD	<u>1MG/ML</u>	<u>A215059</u>	<u>002</u>	Apr 22, 2022
<u>AP</u>		<u>2MG/ML</u>	<u>A215059</u>	<u>001</u>	Oct 07, 2021
<u>AP</u>	INGENUS PHARMS LLC	<u>1MG/ML</u>	<u>A209315</u>	<u>001</u>	Nov 15, 2018
<u>AP</u>	NEXUS PHARMS	<u>1MG/ML</u>	<u>A209780</u>	<u>001</u>	Nov 15, 2018
<u>AP</u>	SANDOZ INC	<u>2MG/ML</u>	<u>A215359</u>	<u>001</u>	Dec 02, 2021
<u>AP</u>	STI PHARMA LLC	<u>1MG/ML</u>	<u>A209873</u>	<u>001</u>	May 06, 2019
<u>AP</u>	ZYDUS PHARMS	<u>1MG/ML</u>	<u>A206228</u>	<u>001</u>	Nov 13, 2018
<u>AP</u>		<u>2MG/ML</u>	<u>A206228</u>	<u>002</u>	Aug 30, 2019

TRISENOX

<u>AP</u>	+	!	CEPHALON	<u>2MG/ML</u>	<u>N021248</u>	<u>002</u>	Oct 13, 2017

PRESCRIPTION DRUG PRODUCT LIST

3-40 (of 474)

ARTEMETHER; LUMEFANTRINE

TABLET; ORAL

COARTEM

+! NOVARTIS

20MG; 120MG

N022268 001 Apr 07, 2009

ARTESUNATE

POWDER; INTRAVENOUS

ARTESUNATE

+! AMIVAS

110MG/VIAL

N213036 001 May 26, 2020

ARTICAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

ORABLOC

+ PIERREL

4%; EQ 0.009MG BASE/1.8ML (EQ 0.005MG
BASE/ML)

N022466 001 Feb 26, 2010

+!

4%; EQ 0.018MG BASE/1.8ML (EQ 0.01MG
BASE/ML)

N022466 002 Feb 26, 2010

SEPTOCAINE

+! DEPROCO

4%; EQ 0.0085MG BASE/1.7ML (4%; EQ
0.005MG BASE/ML)

N020971 002 Mar 30, 2006

+!

4%; EQ 0.017MG BASE/1.7ML (4%; EQ 0.01MG
BASE/ML)

N020971 001 Apr 03, 2000

ASCIMINIB HYDROCHLORIDE

TABLET; ORAL

SCSEMBLIX

+ NOVARTIS

EQ 20MG BASE

N215358 001 Oct 29, 2021

+!

EQ 40MG BASE

N215358 002 Oct 29, 2021

ASCORBIC ACID

SOLUTION; INTRAVENOUS

ASCOR

+! MCGUFF

25,000MG/50ML (500MG/ML)

N209112 001 Oct 02, 2017

ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K

INJECTABLE; INTRAVENOUS

INFUVITE PEDIATRIC

+! SANDOZ CANADA INC

80MG/VIAL; 0.02MG/VIAL; 400
IU/VIAL; 0.001MG/VIAL; 5MG/VIAL; 0.14MG/VIAL;
17MG/VIAL; 1MG/VIAL; 1.4MG/VIAL; 1.2MG/
VIAL; 7 IU/VIAL; 2,300 IU/VIAL; 0.2MG/VIAL

N021265 001 Feb 21, 2001

INFUVITE PEDIATRIC (PHARMACY BULK PACKAGE)

+! SANDOZ CANADA INC

80MG/VIAL; 0.02MG/VIAL; 400
IU/VIAL; 0.001MG/VIAL; 5MG/VIAL; 0.14MG/VIAL;
17MG/VIAL; 1MG/VIAL; 1.4MG/VIAL; 1.2MG/
VIAL; 7 IU/VIAL; 2,300 IU/VIAL; 0.2MG/VIAL

N021265 002 Jan 29, 2004

ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE

FOR SOLUTION; ORAL

MOVIPREPAA +! SALIX PHARMS 4.7GM; 100GM; 1.015GM; 5.9GM; 2.691GM; 7.5GM N021881 001 Aug 02, 2006PEG-3350, SODIUM SULFATE, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM ASCORBATE AND ASCORBICAA NOVEL LABS INC 4.7GM; 100GM; 1.015GM; 5.9GM; 2.691GM; 7.5GM A090145 001 Jan 25, 2012

PLENVU

+! SALIX

7.54GM; 140GM; 2.2GM; 48.11GM; 5.2GM; 9GM

N209381 001 May 04, 2018

ASENAPINE

SYSTEM; TRANSDERMAL

SECUADO

+! HISAMITSU

3.8MG/24HR

N212268 001 Oct 11, 2019

+

5.7MG/24HR

N212268 002 Oct 11, 2019

+

7.6MG/24HR

N212268 003 Oct 11, 2019

ASENAPINE MALEATE

TABLET; SUBLINGUAL

ASENAPINE MALEATEAB ALEMBIC PHARMS EQ 2.5MG BASE A206098 003 Jul 19, 2021AB EQ 5MG BASE A206098 001 Dec 10, 2020AB EQ 10MG BASE A206098 002 Dec 10, 2020AB BRECKENRIDGE EQ 2.5MG BASE A205960 001 Dec 10, 2020AB EQ 5MG BASE A205960 003 Mar 08, 2021AB EQ 10MG BASE A205960 002 Dec 10, 2020AB SIGMAPHARM LABS LLC EQ 5MG BASE A206107 001 Dec 10, 2020AB EQ 10MG BASE A206107 002 Dec 10, 2020SAPHRISAB + ALLERGAN EQ 2.5MG BASE N022117 003 Mar 12, 2015

PRESCRIPTION DRUG PRODUCT LIST

3-41 (of 474)

ASENAPINE MALEATE

TABLET;SUBLINGUAL

SAPHRIS

AB	+	<u>EQ 5MG BASE</u>	<u>N022117</u>	<u>001</u>	Aug 13, 2009
AB	+	<u>EQ 10MG BASE</u>	<u>N022117</u>	<u>002</u>	Aug 13, 2009

ASPIRIN

CAPSULE, EXTENDED RELEASE;ORAL

DURLAZA

+	ESPERO	162.5MG	N200671	001	Sep 04, 2015

ASPIRIN; BUTALBITAL; CAFFEINE

CAPSULE;ORAL

BUTALBITAL, ASPIRIN AND CAFFEINE

AA	NOSTRUM LABS INC	<u>325MG;50MG;40MG</u>	<u>A078149</u>	<u>001</u>	Jun 13, 2007

LANORINAL

AA	!	LANNETT	<u>325MG;50MG;40MG</u>	<u>A086996</u>	<u>002</u>	Oct 11, 1985

TABLET;ORAL

BUTALBITAL, ASPIRIN AND CAFFEINE

!	STRIDES PHARMA	325MG;50MG;40MG	A204195	001	Sep 22, 2016

ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE;ORAL

BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE

AB	LGM PHARMA	<u>325MG;50MG;40MG;30MG</u>	<u>A075231</u>	<u>001</u>	Nov 30, 2001

AB	!	STEVENS J	<u>325MG;50MG;40MG;30MG</u>	<u>A074951</u>	<u>001</u>	Aug 31, 1998

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET;ORAL

ORPHENGESIC

GALT PHARMS	385MG;30MG;25MG	A075141	001	May 29, 1998

ORPHENGESIC FORTE

!	GALT PHARMS	770MG;60MG;50MG	A075141	002	May 29, 1998

ASPIRIN; DIPYRIDAMOLE

CAPSULE, EXTENDED RELEASE;ORAL

ASPIRIN AND DIPYRIDAMOLE

AB	AMNEAL PHARMS	<u>25MG;200MG</u>	<u>A206392</u>	<u>001</u>	Mar 08, 2016

AB	BARR	<u>25MG;200MG</u>	<u>A078804</u>	<u>001</u>	Aug 14, 2009

AB	DR REDDYS	<u>25MG;200MG</u>	<u>A209048</u>	<u>001</u>	Oct 10, 2018

AB	!	GLENMARK PHARMS SA	<u>25MG;200MG</u>	<u>A210318</u>	<u>001</u>	May 24, 2019

AB	MICRO LABS	<u>25MG;200MG</u>	<u>A209929</u>	<u>001</u>	Aug 11, 2021

AB	PAR PHARM INC	<u>25MG;200MG</u>	<u>A207944</u>	<u>001</u>	Jan 18, 2017

AB	SANDOZ INC	<u>25MG;200MG</u>	<u>A206739</u>	<u>001</u>	Jan 18, 2017

AB	ZYDUS PHARMS	<u>25MG;200MG</u>	<u>A206753</u>	<u>001</u>	Aug 29, 2017

ASPIRIN; HYDROCODONE BITARTRATE

TABLET;ORAL

HYDROCODONE BITARTRATE AND ASPIRIN

!	LGM PHARMA	500MG;5MG	A205479	001	May 28, 2021

ASPIRIN; OXYCODONE HYDROCHLORIDE

TABLET;ORAL

OXYCODONE AND ASPIRIN

AA	EPIC PHARMA LLC	<u>325MG;4.8355MG</u>	<u>A040910</u>	<u>001</u>	Jul 16, 2020

PERCODAN

AA	+	ENDO PHARMS	<u>325MG;4.8355MG</u>	<u>N007337</u>	<u>007</u>	Aug 05, 2005

ATAZANAVIR SULFATE

CAPSULE;ORAL

ATAZANAVIR SULFATE

AB	AMNEAL	<u>EQ 150MG BASE</u>	<u>A209717</u>	<u>002</u>	Jun 01, 2020

AB		<u>EQ 200MG BASE</u>	<u>A209717</u>	<u>003</u>	Jun 01, 2020

AB		<u>EQ 300MG BASE</u>	<u>A209717</u>	<u>004</u>	Jun 01, 2020

AB	AUROBINDO PHARMA	<u>EQ 100MG BASE</u>	<u>A204806</u>	<u>001</u>	Jun 25, 2018

AB		<u>EQ 150MG BASE</u>	<u>A204806</u>	<u>002</u>	Jun 25, 2018

AB		<u>EQ 200MG BASE</u>	<u>A204806</u>	<u>003</u>	Jun 25, 2018

AB		<u>EQ 300MG BASE</u>	<u>A204806</u>	<u>004</u>	Jun 25, 2018

AB	CIPLA	<u>EQ 100MG BASE</u>	<u>A200626</u>	<u>001</u>	Aug 09, 2018

AB		<u>EQ 150MG BASE</u>	<u>A200626</u>	<u>002</u>	Aug 09, 2018

AB		<u>EQ 200MG BASE</u>	<u>A200626</u>	<u>003</u>	Aug 09, 2018

AB		<u>EQ 300MG BASE</u>	<u>A200626</u>	<u>004</u>	Aug 09, 2018

AB	HETERO LABS LTD III	<u>EQ 150MG BASE</u>	<u>A212278</u>	<u>001</u>	Feb 02, 2022

AB		<u>EQ 200MG BASE</u>	<u>A212278</u>	<u>002</u>	Feb 02, 2022

AB		<u>EQ 300MG BASE</u>	<u>A212278</u>	<u>003</u>	Feb 02, 2022

AB	LAURUS	<u>EQ 150MG BASE</u>	<u>A212579</u>	<u>001</u>	Apr 30, 2021

PRESCRIPTION DRUG PRODUCT LIST

3-42 (of 474)

ATAZANAVIR SULFATE

CAPSULE; ORAL

ATAZANAVIR SULFATE

<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A212579</u>	<u>002</u>	Apr 30, 2021
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A212579</u>	<u>003</u>	Apr 30, 2021
<u>AB</u>	TEVA PHARMS USA	<u>EQ 100MG BASE</u>	<u>A091673</u>	<u>001</u>	Apr 22, 2014
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A091673</u>	<u>002</u>	Apr 22, 2014
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A091673</u>	<u>003</u>	Apr 22, 2014
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A091673</u>	<u>004</u>	Apr 22, 2014

REYATAZ

<u>AB</u>	+	BRISTOL MYERS SQUIBB	<u>EQ 200MG BASE</u>	<u>N021567</u>	<u>003</u>	Jun 20, 2003
<u>AB</u>	+	!	<u>EQ 300MG BASE</u>	<u>N021567</u>	<u>004</u>	Oct 16, 2006

POWDER; ORAL

REYATAZ

	+	BRISTOL MYERS SQUIBB	<u>EQ 50MG BASE/PACKET</u>	<u>N206352</u>	<u>001</u>	Jun 02, 2014

ATAZANAVIR SULFATE; COBICISTAT

TABLET; ORAL

EVOTAZ

	+	BRISTOL	<u>EQ 300MG BASE; 150MG</u>	<u>N206353</u>	<u>001</u>	Jan 29, 2015

ATENOLOL

TABLET; ORAL

ATENOLOL

<u>AB</u>	ALVOGEN	<u>25MG</u>	<u>A072304</u>	<u>002</u>	Jul 31, 1992
<u>AB</u>		<u>50MG</u>	<u>A072304</u>	<u>003</u>	Jul 18, 1988
<u>AB</u>		<u>100MG</u>	<u>A072304</u>	<u>001</u>	Jul 15, 1988
<u>AB</u>	AUROBINDO PHARMA	<u>25MG</u>	<u>A078512</u>	<u>001</u>	Oct 31, 2007
<u>AB</u>		<u>50MG</u>	<u>A078512</u>	<u>002</u>	Oct 31, 2007
<u>AB</u>		<u>100MG</u>	<u>A078512</u>	<u>003</u>	Oct 31, 2007
<u>AB</u>	HLTHCARE	<u>25MG</u>	<u>A073026</u>	<u>002</u>	May 01, 1992
<u>AB</u>		<u>50MG</u>	<u>A073026</u>	<u>003</u>	Sep 17, 1991
<u>AB</u>		<u>100MG</u>	<u>A073026</u>	<u>001</u>	Sep 17, 1991
<u>AB</u>	IPCA LABS LTD	<u>25MG</u>	<u>A077877</u>	<u>001</u>	Dec 27, 2006
<u>AB</u>		<u>50MG</u>	<u>A077877</u>	<u>002</u>	Dec 27, 2006
<u>AB</u>		<u>100MG</u>	<u>A077877</u>	<u>003</u>	Dec 27, 2006
<u>AB</u>	MYLAN	<u>25MG</u>	<u>A073457</u>	<u>002</u>	Apr 26, 1999
<u>AB</u>		<u>50MG</u>	<u>A073457</u>	<u>003</u>	Jan 24, 1992
<u>AB</u>		<u>100MG</u>	<u>A073457</u>	<u>001</u>	Jan 24, 1992
<u>AB</u>	TEVA	<u>25MG</u>	<u>A074056</u>	<u>003</u>	Jul 19, 2004
<u>AB</u>		<u>50MG</u>	<u>A074056</u>	<u>001</u>	Jan 18, 1995
<u>AB</u>		<u>100MG</u>	<u>A074056</u>	<u>002</u>	Jan 18, 1995
<u>AB</u>	UNICHEM	<u>25MG</u>	<u>A213136</u>	<u>001</u>	Nov 21, 2019
<u>AB</u>		<u>50MG</u>	<u>A213136</u>	<u>002</u>	Nov 21, 2019
<u>AB</u>		<u>100MG</u>	<u>A213136</u>	<u>003</u>	Nov 21, 2019
<u>AB</u>	UNIQUE	<u>25MG</u>	<u>A077443</u>	<u>001</u>	Sep 13, 2006
<u>AB</u>		<u>50MG</u>	<u>A077443</u>	<u>002</u>	Sep 13, 2006
<u>AB</u>		<u>100MG</u>	<u>A077443</u>	<u>003</u>	Sep 13, 2006
<u>AB</u>	ZYDUS PHARMS USA	<u>25MG</u>	<u>A076900</u>	<u>001</u>	Jan 28, 2005
<u>AB</u>		<u>50MG</u>	<u>A076900</u>	<u>002</u>	Jan 28, 2005
<u>AB</u>		<u>100MG</u>	<u>A076900</u>	<u>003</u>	Jan 28, 2005

TENORMIN

<u>AB</u>	+	ALMATICA	<u>25MG</u>	<u>N018240</u>	<u>004</u>	Apr 09, 1990
<u>AB</u>	+		<u>50MG</u>	<u>N018240</u>	<u>001</u>	
<u>AB</u>	+	!	<u>100MG</u>	<u>N018240</u>	<u>002</u>	

ATENOLOL; CHLORTHALIDONE

TABLET; ORAL

ATENOLOL AND CHLORTHALIDONE

<u>AB</u>	ALVOGEN	<u>50MG; 25MG</u>	<u>A072302</u>	<u>002</u>	May 31, 1990
<u>AB</u>		<u>100MG; 25MG</u>	<u>A072302</u>	<u>001</u>	May 31, 1990
<u>AB</u>	NOVITIUM PHARMA	<u>50MG; 25MG</u>	<u>A215560</u>	<u>001</u>	Oct 25, 2021
<u>AB</u>		<u>100MG; 25MG</u>	<u>A215560</u>	<u>002</u>	Oct 25, 2021
<u>AB</u>	UNICHEM	<u>50MG; 25MG</u>	<u>A213302</u>	<u>001</u>	Nov 25, 2020
<u>AB</u>		<u>100MG; 25MG</u>	<u>A213302</u>	<u>002</u>	Nov 25, 2020
<u>AB</u>	WATSON LABS	<u>50MG; 25MG</u>	<u>A073665</u>	<u>001</u>	Jul 02, 1992
<u>AB</u>		<u>100MG; 25MG</u>	<u>A073665</u>	<u>002</u>	Jul 02, 1992
<u>AB</u>	ZYDUS PHARMS	<u>50MG; 25MG</u>	<u>A210028</u>	<u>001</u>	Mar 08, 2019
<u>AB</u>		<u>100MG; 25MG</u>	<u>A210028</u>	<u>002</u>	Mar 08, 2019

TENORETIC 100

<u>AB</u>	+	ALMATICA	<u>100MG; 25MG</u>	<u>N018760</u>	<u>001</u>	Jun 08, 1984

PRESCRIPTION DRUG PRODUCT LIST

3-43 (of 474)

ATENOLOL; CHLORTHALIDONE

TABLET; ORAL

TENORETIC 50

AB	+	ALMATICA	50MG; 25MG	<u>N018760</u>	<u>002</u>	Jun 08, 1984

ATOGEPAANT

TABLET; ORAL

QULIPTA

+	ABEVIE INC	10MG	N215206	001	Sep 28, 2021
+		30MG	N215206	002	Sep 28, 2021
+	!	60MG	N215206	003	Sep 28, 2021

ATOMOXETINE HYDROCHLORIDE

CAPSULE; ORAL

ATOMOXETINE HYDROCHLORIDE

AB		APOTEX	<u>10MG</u>	<u>A078983</u>	<u>001</u>	May 30, 2017
AB			<u>18MG</u>	<u>A078983</u>	<u>002</u>	May 30, 2017
AB			<u>25MG</u>	<u>A078983</u>	<u>003</u>	May 30, 2017
AB			<u>40MG</u>	<u>A078983</u>	<u>004</u>	May 30, 2017
AB			<u>60MG</u>	<u>A078983</u>	<u>005</u>	May 30, 2017
AB			<u>80MG</u>	<u>A078983</u>	<u>006</u>	May 30, 2017
AB			<u>100MG</u>	<u>A078983</u>	<u>007</u>	May 30, 2017
AB		AUROBINDO PHARMA	<u>10MG</u>	<u>A079016</u>	<u>001</u>	May 30, 2017
AB			<u>18MG</u>	<u>A079016</u>	<u>002</u>	May 30, 2017
AB			<u>25MG</u>	<u>A079016</u>	<u>003</u>	May 30, 2017
AB			<u>40MG</u>	<u>A079016</u>	<u>004</u>	May 30, 2017
AB			<u>60MG</u>	<u>A079016</u>	<u>005</u>	May 30, 2017
AB			<u>80MG</u>	<u>A079016</u>	<u>006</u>	May 30, 2017
AB			<u>100MG</u>	<u>A079016</u>	<u>007</u>	May 30, 2017
AB		DR REDDYS	<u>10MG</u>	<u>A090609</u>	<u>001</u>	Feb 23, 2018
AB			<u>18MG</u>	<u>A090609</u>	<u>002</u>	Feb 23, 2018
AB			<u>25MG</u>	<u>A090609</u>	<u>003</u>	Feb 23, 2018
AB			<u>40MG</u>	<u>A090609</u>	<u>004</u>	Feb 23, 2018
AB			<u>60MG</u>	<u>A090609</u>	<u>005</u>	Feb 23, 2018
AB			<u>80MG</u>	<u>A090609</u>	<u>006</u>	Feb 23, 2018
AB			<u>100MG</u>	<u>A090609</u>	<u>007</u>	Feb 23, 2018
AB		GLENMARK PHARMS LTD	<u>10MG</u>	<u>A079019</u>	<u>001</u>	May 30, 2017
AB			<u>18MG</u>	<u>A079019</u>	<u>002</u>	May 30, 2017
AB			<u>25MG</u>	<u>A079019</u>	<u>003</u>	May 30, 2017
AB			<u>40MG</u>	<u>A079019</u>	<u>004</u>	May 30, 2017
AB			<u>60MG</u>	<u>A079019</u>	<u>005</u>	May 30, 2017
AB			<u>80MG</u>	<u>A079019</u>	<u>006</u>	May 30, 2017
AB			<u>100MG</u>	<u>A079019</u>	<u>007</u>	May 30, 2017
AB		HETERO LABS LTD V	<u>10MG</u>	<u>A202682</u>	<u>001</u>	Mar 11, 2021
AB			<u>18MG</u>	<u>A202682</u>	<u>002</u>	Mar 11, 2021
AB			<u>25MG</u>	<u>A202682</u>	<u>003</u>	Mar 11, 2021
AB			<u>40MG</u>	<u>A202682</u>	<u>004</u>	Mar 11, 2021
AB			<u>60MG</u>	<u>A202682</u>	<u>005</u>	Mar 11, 2021
AB			<u>80MG</u>	<u>A202682</u>	<u>006</u>	Mar 11, 2021
AB			<u>100MG</u>	<u>A202682</u>	<u>007</u>	Mar 11, 2021
AB		TEVA PHARMS USA	<u>10MG</u>	<u>A079022</u>	<u>001</u>	May 30, 2017
AB			<u>18MG</u>	<u>A079022</u>	<u>002</u>	May 30, 2017
AB			<u>25MG</u>	<u>A079022</u>	<u>003</u>	May 30, 2017
AB			<u>40MG</u>	<u>A079022</u>	<u>004</u>	May 30, 2017
AB			<u>60MG</u>	<u>A079022</u>	<u>005</u>	May 30, 2017
AB			<u>80MG</u>	<u>A079022</u>	<u>006</u>	May 30, 2017
AB			<u>100MG</u>	<u>A079022</u>	<u>007</u>	May 30, 2017
AB		ZYDUS PHARMS USA INC	<u>18MG</u>	<u>A079017</u>	<u>001</u>	Sep 17, 2010
AB			<u>25MG</u>	<u>A079017</u>	<u>002</u>	Sep 17, 2010
AB			<u>40MG</u>	<u>A079017</u>	<u>003</u>	Sep 17, 2010
AB			<u>60MG</u>	<u>A079017</u>	<u>004</u>	Sep 17, 2010
AB			<u>80MG</u>	<u>A079017</u>	<u>005</u>	Sep 17, 2010
AB			<u>100MG</u>	<u>A079017</u>	<u>006</u>	Sep 17, 2010
<u>STRATTERA</u>						
AB	+	LILLY	<u>10MG</u>	<u>N021411</u>	<u>002</u>	Nov 26, 2002
AB	+		<u>18MG</u>	<u>N021411</u>	<u>003</u>	Nov 26, 2002
AB	+		<u>25MG</u>	<u>N021411</u>	<u>004</u>	Nov 26, 2002
AB	+		<u>40MG</u>	<u>N021411</u>	<u>005</u>	Nov 26, 2002
AB	+	!	<u>60MG</u>	<u>N021411</u>	<u>006</u>	Nov 26, 2002
AB	+		<u>80MG</u>	<u>N021411</u>	<u>007</u>	Feb 14, 2005
AB	+		<u>100MG</u>	<u>N021411</u>	<u>008</u>	Feb 14, 2005

PRESCRIPTION DRUG PRODUCT LIST

3-44 (of 474)

ATORVASTATIN CALCIUM

TABLET; ORAL

ATORVASTATIN CALCIUM

<u>AB</u>	ACCORD HLTHCARE	<u>EQ 10MG BASE</u>	<u>A207687 001</u>	Mar 30, 2018
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A207687 002</u>	Mar 30, 2018
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A207687 003</u>	Mar 30, 2018
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A207687 004</u>	Mar 30, 2018
<u>AB</u>	AGNITIO	<u>EQ 10MG BASE</u>	<u>A214969 001</u>	Sep 02, 2021
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A214969 002</u>	Sep 02, 2021
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A214969 003</u>	Sep 02, 2021
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A214969 004</u>	Sep 02, 2021
<u>AB</u>	ALKEM LABS LTD	<u>EQ 10MG BASE</u>	<u>A209288 001</u>	Dec 21, 2018
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A209288 002</u>	Dec 21, 2018
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A209288 003</u>	Dec 21, 2018
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A209288 004</u>	Dec 21, 2018
<u>AB</u>	APOTEX INC	<u>EQ 10MG BASE</u>	<u>A090548 001</u>	May 29, 2012
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A090548 002</u>	May 29, 2012
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A090548 003</u>	May 29, 2012
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A090548 004</u>	May 29, 2012
<u>AB</u>	BIOCON PHARMA	<u>EQ 10MG BASE</u>	<u>A216436 001</u>	Nov 23, 2022
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A216436 002</u>	Nov 23, 2022
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A216436 003</u>	Nov 23, 2022
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A216436 004</u>	Nov 23, 2022
<u>AB</u>	DR REDDYS	<u>EQ 10MG BASE</u>	<u>A214659 001</u>	Jul 14, 2021
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A214659 002</u>	Jul 14, 2021
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A214659 003</u>	Jul 14, 2021
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A214659 004</u>	Jul 14, 2021
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 10MG BASE</u>	<u>A091650 001</u>	Jul 17, 2012
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A091650 002</u>	Jul 17, 2012
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A091650 003</u>	Jul 17, 2012
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A202357 001</u>	Jul 17, 2012
<u>AB</u>	GRAVITI PHARMS	<u>EQ 10MG BASE</u>	<u>A209912 001</u>	Jun 18, 2018
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A209912 002</u>	Jun 18, 2018
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A209912 003</u>	Jun 18, 2018
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A209912 004</u>	Jun 18, 2018
<u>AB</u>	INVAGEN PHARMS	<u>EQ 10MG BASE</u>	<u>A204846 001</u>	Jan 09, 2017
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A204846 002</u>	Jan 09, 2017
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A204846 003</u>	Jan 09, 2017
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A204846 004</u>	Jan 09, 2017
<u>AB</u>	LANNETT CO INC	<u>EQ 10MG BASE</u>	<u>A091624 001</u>	Apr 05, 2013
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A091624 002</u>	Apr 05, 2013
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A091624 003</u>	Apr 05, 2013
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A091624 004</u>	Apr 05, 2013
<u>AB</u>	LEPU PHARM	<u>EQ 10MG BASE</u>	<u>A216848 001</u>	Nov 03, 2022
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A216848 002</u>	Nov 03, 2022
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A216848 003</u>	Nov 03, 2022
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A216848 004</u>	Nov 03, 2022
<u>AB</u>	LUPIN LTD	<u>EQ 10MG BASE</u>	<u>A204991 001</u>	Mar 06, 2019
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A204991 002</u>	Mar 06, 2019
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A204991 003</u>	Mar 06, 2019
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A204991 004</u>	Mar 06, 2019
<u>AB</u>	MICRO LABS LTD INDIA	<u>EQ 10MG BASE</u>	<u>A205945 001</u>	Nov 07, 2019
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A205945 002</u>	Nov 07, 2019
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A205945 003</u>	Nov 07, 2019
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A205945 004</u>	Nov 07, 2019
<u>AB</u>	MSN	<u>EQ 10MG BASE</u>	<u>A211933 001</u>	Feb 08, 2019
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A211933 002</u>	Feb 08, 2019
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A211933 003</u>	Feb 08, 2019
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A211933 004</u>	Feb 08, 2019
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 10MG BASE</u>	<u>A091226 001</u>	May 29, 2012
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A091226 002</u>	May 29, 2012
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A091226 003</u>	May 29, 2012
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A091226 004</u>	May 29, 2012
<u>AB</u>	SANDOZ INC	<u>EQ 10MG BASE</u>	<u>A077575 001</u>	May 29, 2012
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A077575 002</u>	May 29, 2012
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077575 003</u>	May 29, 2012
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A077575 004</u>	May 29, 2012
<u>AB</u>	SCIEGEN PHARMS INC	<u>EQ 10MG BASE</u>	<u>A205519 001</u>	May 19, 2016
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A205519 002</u>	May 19, 2016
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A205519 003</u>	May 19, 2016
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A205519 004</u>	May 19, 2016
<u>AB</u>	SUN PHARM INDS LTD	<u>EQ 10MG BASE</u>	<u>A076477 001</u>	Nov 30, 2011

PRESCRIPTION DRUG PRODUCT LIST

3-45 (of 474)

ATORVASTATIN CALCIUM

TABLET; ORAL

ATORVASTATIN CALCIUM

<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A076477</u>	<u>002</u>	Nov 30, 2011
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A076477</u>	<u>003</u>	Nov 30, 2011
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A076477</u>	<u>004</u>	Nov 30, 2011
<u>AB</u>	TEVA PHARMS USA	<u>EQ 10MG BASE</u>	<u>A205300</u>	<u>001</u>	Mar 27, 2017
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A205300</u>	<u>002</u>	Mar 27, 2017
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A205300</u>	<u>003</u>	Mar 27, 2017
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A205300</u>	<u>004</u>	Mar 27, 2017
<u>AB</u>	UMEDICA LABS PVT LTD	<u>EQ 10MG BASE</u>	<u>A213853</u>	<u>001</u>	Aug 19, 2020
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A213853</u>	<u>002</u>	Aug 19, 2020
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A213853</u>	<u>003</u>	Aug 19, 2020
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A213853</u>	<u>004</u>	Aug 19, 2020
<u>AB</u>	ZYDUS PHARMS	<u>EQ 10MG BASE</u>	<u>A206536</u>	<u>001</u>	Nov 20, 2018
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A206536</u>	<u>002</u>	Nov 20, 2018
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A206536</u>	<u>003</u>	Nov 20, 2018
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A206536</u>	<u>004</u>	Nov 20, 2018

LIPITOR

<u>AB</u>	+	UPJOHN	<u>EQ 10MG BASE</u>	<u>N020702</u>	<u>001</u>	Dec 17, 1996
<u>AB</u>	+		<u>EQ 20MG BASE</u>	<u>N020702</u>	<u>002</u>	Dec 17, 1996
<u>AB</u>	+		<u>EQ 40MG BASE</u>	<u>N020702</u>	<u>003</u>	Dec 17, 1996
<u>AB</u>	+	!	<u>EQ 80MG BASE</u>	<u>N020702</u>	<u>004</u>	Apr 07, 2000

ATORVASTATIN CALCIUM; EZETIMIBE

TABLET; ORAL

LYPQOZET

SCOV3

!

EQ 10MG BASE;10MG	A206084	001	Apr 26, 2017
EQ 20MG BASE;10MG	A206084	002	Apr 26, 2017
EQ 40MG BASE;10MG	A206084	003	Apr 26, 2017
EQ 80MG BASE;10MG	A206084	004	Apr 26, 2017

ATOVAQUONE

SUSPENSION; ORAL

ATOVAQUONE

<u>AB</u>	ABHAI LLC	<u>750MG/5ML</u>	<u>A210510</u>	<u>001</u>	May 31, 2019
<u>AB</u>	ABON PHARMS LLC	<u>750MG/5ML</u>	<u>A214272</u>	<u>001</u>	Oct 25, 2021
<u>AB</u>	AMNEAL PHARMS	<u>750MG/5ML</u>	<u>A202960</u>	<u>001</u>	Mar 18, 2014
<u>AB</u>	APOTEX	<u>750MG/5ML</u>	<u>A209750</u>	<u>001</u>	Oct 11, 2017
<u>AB</u>	BIONPHARMA INC	<u>750MG/5ML</u>	<u>A212918</u>	<u>001</u>	Mar 30, 2021
<u>AB</u>	CHARTWELL RX	<u>750MG/5ML</u>	<u>A207833</u>	<u>001</u>	Apr 28, 2017
<u>AB</u>	GLENMARK PHARMS	<u>750MG/5ML</u>	<u>A209685</u>	<u>001</u>	Nov 21, 2018
<u>AB</u>	HETERO LABS LTD III	<u>750MG/5ML</u>	<u>A210692</u>	<u>001</u>	Oct 11, 2018
<u>AB</u>	LUPIN LTD	<u>750MG/5ML</u>	<u>A209105</u>	<u>001</u>	Sep 11, 2018
<u>MEPRON</u>					
<u>AB</u>	<u>+</u> GLAXOSMITHKLINE LLC	<u>750MG/5ML</u>	<u>N020500</u>	<u>001</u>	Feb 08, 1995

ATOVAQUONE; PROGUANIL HYDROCHLORIDE

TABLET; ORAL

ATOVAQUONE AND PROGUANIL HYDROCHLORIDE

<u>AB</u>	GLENMARK GENERICS	<u>62.5MG;25MG</u>	<u>A091211</u>	<u>002</u>	Apr 06, 2015
<u>AB</u>		<u>250MG;100MG</u>	<u>A091211</u>	<u>001</u>	Jan 12, 2011
<u>AB</u>	MYLAN	<u>62.5MG;25MG</u>	<u>A202362</u>	<u>001</u>	May 27, 2014
<u>AB</u>		<u>250MG;100MG</u>	<u>A202362</u>	<u>002</u>	May 27, 2014

MALARONE

<u>AB</u>	+	!	GLAXOSMITHKLINE	<u>250MG;100MG</u>	<u>N021078</u>	<u>001</u>	Jul 14, 2000
<u>AB</u>	+		GLAXOSMITHKLINE	<u>62.5MG;25MG</u>	<u>N021078</u>	<u>002</u>	Jul 14, 2000

ATACURIUM BESYLATE

INJECTABLE; INJECTION

ATACURIUM BESYLATE

<u>AP</u>		EUGIA PHARMA	<u>10MG/ML</u>	<u>A206011</u>	<u>001</u>	Apr 08, 2015
<u>AP</u>	!	HIKMA	<u>10MG/ML</u>	<u>A074901</u>	<u>001</u>	Jul 18, 1997
<u>AP</u>		HOSPIRA INC	<u>10MG/ML</u>	<u>A090761</u>	<u>001</u>	Oct 18, 2012
<u>AP</u>		MEITHEAL	<u>10MG/ML</u>	<u>A091489</u>	<u>001</u>	Feb 17, 2012

ATACURIUM BESYLATE PRESERVATIVE FREE

<u>MINORION DESTROYED PRESERVATIVE FREE</u>					
<u>AP</u>	EUGIA PHARMA	<u>10MG/ML</u>	<u>A206010</u>	<u>001</u>	Apr 08, 2015
<u>AP</u>	! HIKMA	<u>10MG/ML</u>	<u>A074900</u>	<u>001</u>	Jul 18, 1997
<u>AP</u>	HOSPIRA INC	<u>10MG/ML</u>	<u>A090782</u>	<u>001</u>	Oct 18, 2012
<u>AP</u>	MEITHEAL	<u>10MG/ML</u>	<u>A091488</u>	<u>001</u>	Feb 17, 2012

PRESCRIPTION DRUG PRODUCT LIST

3-46 (of 474)

ATROPINE

SOLUTION; INTRAMUSCULAR

ATROPEN

+	!	MMT	EQ 0.25MG SULFATE/0.3ML	N017106	004	Sep 17, 2004
+	!		EQ 0.5MG SULFATE/0.7ML	N017106	003	Jun 19, 2003
+	!		EQ 1MG SULFATE/0.7ML	N017106	002	Jun 19, 2003
+	!		EQ 2MG SULFATE/0.7ML	N017106	001	

ATROPINE SULFATE

SOLUTION; INTRAVENOUS

ATROPINE SULFATE

<u>AP</u>		ACCORD HLTHCARE	<u>0.25MG/5ML (0.05MG/ML)</u>	<u>A212868</u>	<u>001</u>	Jul 26, 2021
<u>AP</u>	+	!	<u>0.4MG/ML (0.4MG/ML)</u>	<u>N214652</u>	<u>001</u>	Sep 29, 2020
<u>AP</u>			<u>0.5MG/5ML (0.1MG/ML)</u>	<u>A212868</u>	<u>002</u>	Jul 26, 2021
<u>AP</u>			<u>1MG/10ML (0.1MG/ML)</u>	<u>A212868</u>	<u>003</u>	Jul 26, 2021
<u>AP</u>	+	!	<u>1MG/ML (1MG/ML)</u>	<u>N214652</u>	<u>002</u>	Sep 29, 2020
<u>AP</u>		AM REGENT	<u>0.4MG/ML (0.4MG/ML)</u>	<u>A216120</u>	<u>001</u>	May 26, 2022
<u>AP</u>			<u>1MG/ML (1MG/ML)</u>	<u>A216120</u>	<u>002</u>	May 26, 2022
<u>AP</u>		AMNEAL	<u>0.5MG/5ML (0.1MG/ML)</u>	<u>A215342</u>	<u>001</u>	Jan 26, 2022
<u>AP</u>	+	!	<u>0.25MG/5ML (0.05MG/ML)</u>	<u>N021146</u>	<u>002</u>	Jul 09, 2001
<u>AP</u>	+	!	<u>0.5MG/5ML (0.1MG/ML)</u>	<u>N021146</u>	<u>001</u>	Jul 09, 2001
<u>AP</u>	+	!	<u>1MG/10ML (0.1MG/ML)</u>	<u>N021146</u>	<u>003</u>	Jul 09, 2001
<u>AP</u>		INTL MEDICATION SYS	<u>1MG/10ML (0.1MG/ML)</u>	<u>A212461</u>	<u>001</u>	Oct 05, 2020
<u>AP</u>		MEDEFIL INC	<u>1MG/10ML (0.1MG/ML)</u>	<u>A214970</u>	<u>001</u>	Nov 04, 2022

SOLUTION; INTRAVENOUS, INTRAMUSCULAR, SUBCUTANEOUS, INTRAOSSEOUS, ENDOTRACHEAL

ATROPINE SULFATE

<u>AP</u>		ACCORD HLTHCARE	<u>8MG/20ML (0.4MG/ML)</u>	<u>A213424</u>	<u>001</u>	Mar 19, 2021
<u>AP</u>	+	!	<u>8MG/20ML (0.4MG/ML)</u>	<u>N209260</u>	<u>001</u>	Jan 26, 2018
<u>AP</u>		HIKMA	<u>8MG/20ML (0.4MG/ML)</u>	<u>A213561</u>	<u>001</u>	Dec 01, 2021

SOLUTION/DROPS; OPHTHALMIC

ATROPINE SULFATE

<u>AT</u>	+	!	<u>AKORN</u>	<u>1%</u>	<u>N206289</u>	<u>001</u>	Jul 18, 2014
<u>AT</u>			<u>AMNEAL</u>	<u>1%</u>	<u>A214752</u>	<u>001</u>	Jul 14, 2022
<u>AT</u>			<u>APOTEX INC</u>	<u>1%</u>	<u>A215624</u>	<u>001</u>	Nov 26, 2021
	+	!	BAUSCH AND LOMB INC	1%	N213581	001	Mar 15, 2022
			ISOPTO ATROPINE				
	+	!	ALCON LABS INC	1%	N208151	001	Dec 01, 2016

ATROPINE SULFATE; DIFENOXIN HYDROCHLORIDE

TABLET; ORAL

MOTOFEN

+	!	SEBELA IRELAND LTD	0.025MG; 1MG	N017744	002	

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

SOLUTION; ORAL

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

!		HIKMA	0.025MG/5ML; 2.5MG/5ML	A087708	001	May 03, 1982

TABLET; ORAL

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

<u>AA</u>		ANI PHARMS	<u>0.025MG; 2.5MG</u>	<u>A086727</u>	<u>001</u>	
<u>AA</u>		BAYSHORE PHARMS LLC	<u>0.025MG; 2.5MG</u>	<u>A210819</u>	<u>001</u>	Nov 13, 2018
<u>AA</u>		CHARTWELL RX	<u>0.025MG; 2.5MG</u>	<u>A207128</u>	<u>001</u>	Oct 21, 2020
<u>AA</u>		LANNETT	<u>0.025MG; 2.5MG</u>	<u>A085372</u>	<u>001</u>	
<u>AA</u>		LEADING	<u>0.025MG; 2.5MG</u>	<u>A213413</u>	<u>001</u>	Feb 20, 2020
<u>AA</u>		MYLAN	<u>0.025MG; 2.5MG</u>	<u>A085762</u>	<u>001</u>	
<u>AA</u>		SPECGX LLC	<u>0.025MG; 2.5MG</u>	<u>A213335</u>	<u>001</u>	Oct 06, 2020
<u>AA</u>		UPSHER SMITH LABS	<u>0.025MG; 2.5MG</u>	<u>A210571</u>	<u>001</u>	Aug 31, 2018
<u>AA</u>		WINDER LABS LLC	<u>0.025MG; 2.5MG</u>	<u>A211362</u>	<u>001</u>	Jan 27, 2021

LOMOTIL

<u>AA</u>	+	!	PFIZER	<u>0.025MG; 2.5MG</u>	<u>N012462</u>	<u>001</u>

ATROPINE; PRALIDOXIME CHLORIDE

INJECTABLE; INTRAMUSCULAR

DUODOTE

+	!	MMT	2.1MG/0.7ML; 600MG/2ML	N021983	001	Sep 28, 2006

AURANOFIN

CAPSULE; ORAL

RIDAURA

+	!	SEBELA IRELAND LTD	3MG	N018689	001	May 24, 1985

PRESCRIPTION DRUG PRODUCT LIST

3-47 (of 474)

AVACOPAN

CAPSULE; ORAL

TAVNEOS

+	!	CHEMOCENTRYX	10MG	N214487	001	Oct 07, 2021

AVANAFIL

TABLET; ORAL

STENDRA

+		METUCHEN PHARMS	50MG	N202276	001	Apr 27, 2012
+			100MG	N202276	002	Apr 27, 2012
+	!		200MG	N202276	003	Apr 27, 2012

AVAPRITINIB

TABLET; ORAL

AYVAKIT

+		BLUEPRINT MEDICINES	25MG	N212608	004	Jun 16, 2021
+			50MG	N212608	005	Jun 16, 2021
+			100MG	N212608	001	Jan 09, 2020
+			200MG	N212608	002	Jan 09, 2020
+	!		300MG	N212608	003	Jan 09, 2020

AVATROMBOPAG MALEATE

TABLET; ORAL

DOPTELET

+	!	AKARX INC	EQ 20MG BASE	N210238	001	May 21, 2018

AVIBACTAM SODIUM; CEFTAZIDIME

POWDER; INTRAVENOUS

AVYCAZ

+	!	ALLERGAN	EQ 0.5GM BASE; 2GM/VIAL	N206494	001	Feb 25, 2015

AXITINIB

TABLET; ORAL

INLYTA

+		PF PRISM CV	1MG	N202324	001	Jan 27, 2012
+	!		5MG	N202324	002	Jan 27, 2012

AZACITIDINE

POWDER; INTRAVENOUS, SUBCUTANEOUS

AZACITIDINE

AP		ACCORD HLTHCARE	100MG/VIAL	A207475	001	Jul 02, 2018
AP		ACTAVIS LLC	100MG/VIAL	N208216	001	Apr 29, 2016
AP		AMNEAL	100MG/VIAL	A211549	001	Feb 03, 2022
AP		CIPLA	100MG/VIAL	A209540	001	May 04, 2018
AP		DR REDDYS	100MG/VIAL	A201537	001	Sep 16, 2013
AP		EUGIA PHARMA	100MG/VIAL	A215066	001	Dec 30, 2022
AP		EUROHLTH INTL SARL	100MG/VIAL	A209337	001	Jun 08, 2020
AP		MEITHEAL	100MG/VIAL	A212128	001	Nov 02, 2020
AP		NATCO PHARMA LTD	100MG/VIAL	A207234	001	Jun 23, 2017
AP		SHILPA MEDICARE	100MG/VIAL	A207518	001	Sep 29, 2016

VIDAZA

AP	+	!	BRISTOL-MYERS	100MG/VIAL	N050794	001	May 19, 2004

TABLET; ORAL

ONUREG

+		BRISTOL	200MG	N214120	001	Sep 01, 2020
+	!		300MG	N214120	002	Sep 01, 2020

AZATHIOPRINE

TABLET; ORAL

AZASAN

AB		AAIPHARMA LLC	25MG	A075252	002	Feb 03, 2003
AB			50MG	A075252	001	Jun 07, 1999
AB			75MG	A075252	003	Feb 03, 2003
AB			100MG	A075252	004	Feb 03, 2003

AZATHIOPRINE

AB		ALKEM LABS LTD	25MG	A208687	001	Mar 27, 2020
AB			50MG	A208687	002	Mar 27, 2020
AB			75MG	A208687	003	Mar 27, 2020
AB			100MG	A208687	004	Mar 27, 2020
AB		AMNEAL	50MG	A074069	001	Feb 16, 1996
AB			75MG	A074069	002	Nov 02, 2021
AB			100MG	A074069	003	Nov 02, 2021
AB		RISING	50MG	A075568	001	Dec 13, 1999
AB		ZYDUS PHARMS USA	25MG	A077621	002	Sep 05, 2008
AB			50MG	A077621	001	Mar 15, 2007
AB			75MG	A077621	003	Sep 05, 2008

PRESCRIPTION DRUG PRODUCT LIST

3-48 (of 474)

AZATHIOPRINE

TABLET; ORAL

AZATHIOPRINE

AB		100MG	A077621 004	Sep 05, 2008

IMURAN

AB	+ !	SEBELA IRELAND LTD	50MG	N016324 001

AZATHIOPRINE SODIUM

INJECTABLE; INJECTION

AZATHIOPRINE SODIUM

! HIKMA

EQ 100MG BASE/VIAL

A074419 001 Mar 31, 1995

AZELAIC ACID

AEROSOL, FOAM; TOPICAL

FINACEA

AB	+ !	LEO PHARMA AS	15%	N207071 001	Jul 29, 2015

CREAM; TOPICAL

AZELEX

+! ALMIRALL

20%

N020428 001 Sep 13, 1995

GEL; TOPICAL

AZELAIC ACID

AB		ACTAVIS LABS UT INC	15%	A208011 001	Nov 19, 2018

AB		ENCUBE	15%	A208724 001	Nov 19, 2018

AB		GLENMARK PHARMS	15%	A204637 001	Nov 19, 2018

AB		TARO	15%	A210549 001	Aug 23, 2019

FINACEA

AB	+ !	LEO PHARMA AS	15%	N021470 001	Dec 24, 2002

AZELASTINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

AZELASTINE HYDROCHLORIDE

AT		ALEMBIC PHARMS	0.05%	A209620 001	Mar 20, 2019

AT		APOTEX INC	0.05%	A078621 001	Aug 03, 2009

AT		GLAND PHARMA LTD	0.05%	A210092 001	Feb 25, 2020

AT	!	SANDOZ INC	0.05%	A202305 001	May 31, 2012

AT		SOMERSET THERAPS	0.05%	A207411 001	Mar 29, 2019

LLC

AT		SUN PHARM	0.05%	A078738 001	Jun 21, 2010

SPRAY, METERED; NASAL

AZELASTINE HYDROCHLORIDE

AB		AKORN	0.137MG/SPRAY	A207610 001	May 17, 2019

AB		ALKEM LABS LTD	0.137MG/SPRAY	A208156 001	Aug 18, 2017

AB		AMNEAL	0.137MG/SPRAY	A204660 001	Aug 28, 2017

AB	!	APOTEX INC	0.137MG/SPRAY	A077954 001	Apr 30, 2009

AB		AUROBINDO PHARMA	0.137MG/SPRAY	A212289 001	May 08, 2020

LTD

AB		BRECKENRIDGE	0.137MG/SPRAY	A090176 001	Jul 28, 2015

AB		HIKMA	0.137MG/SPRAY	A091444 001	Oct 24, 2014

AB		PADAGIS ISRAEL	0.2055MG/SPRAY	A202743 001	May 08, 2014

AB		SUN PHARM	0.137MG/SPRAY	A090423 001	May 23, 2012

AB		UPSHER SMITH LABS	0.137MG/SPRAY	A202609 001	Mar 17, 2017

AB		ZYDUS PHARMS	0.137MG/SPRAY	A091409 001	Aug 14, 2017

AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE

SPRAY, METERED; NASAL

AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE

AB		APOTEX	0.137MG/SPRAY; 0.05MG/SPRAY	A207712 001	Apr 28, 2017

AB		PADAGIS ISRAEL	0.137MG/SPRAY; 0.05MG/SPRAY	A208111 001	Feb 18, 2021

DYMISTA

AB	+ !	MYLAN SPECIALITY LP	0.137MG/SPRAY; 0.05MG/SPRAY	N202236 001	May 01, 2012

AZILSARTAN KAMEDOXOMIL

TABLET; ORAL

EDARBI

+ AZURITY

EQ 40MG MEDOXOMIL

N200796 001 Feb 25, 2011

+!

EQ 80MG MEDOXOMIL

N200796 002 Feb 25, 2011

AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE

TABLET; ORAL

EDARBYCLOR

+ AZURITY

EQ 40MG MEDOXOMIL; 12.5MG

N202331 001 Dec 20, 2011

+!

EQ 40MG MEDOXOMIL; 25MG

N202331 002 Dec 20, 2011

PRESCRIPTION DRUG PRODUCT LIST

3-49 (of 474)

AZITHROMYCIN

FOR SUSPENSION; ORAL

AZITHROMYCIN

<u>AB</u>	AMNEAL	<u>EQ 100MG BASE/5ML</u>	<u>A205666</u>	<u>001</u>	Jul 19, 2018
<u>AB</u>		<u>EQ 200MG BASE/5ML</u>	<u>A205666</u>	<u>002</u>	Jul 19, 2018
<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 100MG BASE/5ML</u>	<u>A209201</u>	<u>001</u>	Oct 09, 2018
<u>AB</u>		<u>EQ 200MG BASE/5ML</u>	<u>A209201</u>	<u>002</u>	Oct 09, 2018
<u>AB</u>	EPIC PHARMA LLC	<u>EQ 100MG BASE/5ML</u>	<u>A207531</u>	<u>001</u>	Apr 09, 2018
<u>AB</u>		<u>EQ 200MG BASE/5ML</u>	<u>A207531</u>	<u>002</u>	Apr 09, 2018
<u>AB</u>	PLIVA	<u>EQ 100MG BASE/5ML</u>	<u>A065246</u>	<u>002</u>	Jul 05, 2006
<u>AB</u>		<u>EQ 200MG BASE/5ML</u>	<u>A065246</u>	<u>001</u>	Jul 05, 2006
<u>AB</u>	ZYDUS	<u>EQ 100MG BASE/5ML</u>	<u>A211147</u>	<u>001</u>	Jul 31, 2018
<u>AB</u>		<u>EQ 200MG BASE/5ML</u>	<u>A211147</u>	<u>002</u>	Jul 31, 2018

ZITHROMAX

<u>AB</u>	+ PFIZER	<u>EQ 100MG BASE/5ML</u>	<u>N050710</u>	<u>001</u>	Oct 19, 1995
<u>AB</u>	+!	<u>EQ 200MG BASE/5ML</u>	<u>N050710</u>	<u>002</u>	Oct 19, 1995
	+!	EQ 1GM BASE/PACKET	N050693	001	Sep 28, 1994

INJECTABLE; INJECTION

AZITHROMYCIN

<u>AP</u>	EUGIA PHARMA	<u>EQ 500MG BASE/VIAL</u>	<u>A203294</u>	<u>001</u>	Jun 19, 2015
<u>AP</u>	FRESENIUS KABI USA	<u>EQ 500MG BASE/VIAL</u>	<u>A065179</u>	<u>001</u>	Dec 13, 2005
<u>AP</u>	GLAND PHARMA LTD	<u>EQ 500MG BASE/VIAL</u>	<u>A065501</u>	<u>001</u>	Nov 09, 2009
<u>AP</u>	HAINAN POLY PHARM	<u>EQ 500MG BASE/VIAL</u>	<u>A203412</u>	<u>001</u>	Oct 09, 2018
<u>AP</u>	HOSPIRA	<u>EQ 500MG BASE/VIAL</u>	<u>A065500</u>	<u>001</u>	Jun 26, 2009
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A065511</u>	<u>001</u>	Jun 26, 2009
<u>AP</u>	SUN PHARM INDS LTD	<u>EQ 500MG BASE/VIAL</u>	<u>A090923</u>	<u>001</u>	Apr 02, 2013

ZITHROMAX

<u>AP</u>	+! PFIZER	<u>EQ 500MG BASE/VIAL</u>	<u>N050733</u>	<u>001</u>	Jan 30, 1997
	SOLUTION/DROPS; OPHTHALMIC				
	AZASITE				
	+! THEA PHARMA	1%	N050810	001	Apr 27, 2007

TABLET; ORAL

AZITHROMYCIN

<u>AB</u>	ACI	<u>EQ 250MG BASE</u>	<u>A215772</u>	<u>001</u>	Jul 15, 2022
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A215773</u>	<u>001</u>	Jul 12, 2022
<u>AB</u>	ALEMBIC PHARMS	<u>EQ 250MG BASE</u>	<u>A211791</u>	<u>001</u>	Jan 28, 2020
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A211792</u>	<u>001</u>	Jan 28, 2020
<u>AB</u>		<u>EQ 600MG BASE</u>	<u>A211793</u>	<u>001</u>	Jan 27, 2020
<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 250MG BASE</u>	<u>A207370</u>	<u>001</u>	Jul 05, 2018
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A207398</u>	<u>001</u>	Jul 05, 2018
<u>AB</u>	BIONPHARMA INC	<u>EQ 250MG BASE</u>	<u>A210000</u>	<u>001</u>	Feb 26, 2019
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A210001</u>	<u>001</u>	Feb 26, 2019
<u>AB</u>		<u>EQ 600MG BASE</u>	<u>A209999</u>	<u>001</u>	Dec 26, 2018
<u>AB</u>	CHARTWELL RX	<u>EQ 250MG BASE</u>	<u>A065404</u>	<u>001</u>	Feb 11, 2008
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065405</u>	<u>001</u>	Feb 11, 2008
<u>AB</u>		<u>EQ 600MG BASE</u>	<u>A065302</u>	<u>003</u>	Feb 11, 2008
<u>AB</u>	CSPC OUYI	<u>EQ 250MG BASE</u>	<u>A208250</u>	<u>001</u>	Apr 17, 2019
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A208249</u>	<u>001</u>	Oct 25, 2018
<u>AB</u>		<u>EQ 600MG BASE</u>	<u>A207566</u>	<u>001</u>	Sep 24, 2018
<u>AB</u>	LUPIN LTD	<u>EQ 250MG BASE</u>	<u>A065398</u>	<u>001</u>	May 15, 2015
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065399</u>	<u>001</u>	May 15, 2015
<u>AB</u>		<u>EQ 600MG BASE</u>	<u>A065400</u>	<u>001</u>	May 15, 2015
<u>AB</u>	PLIVA	<u>EQ 250MG BASE</u>	<u>A065225</u>	<u>001</u>	Nov 14, 2005
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065223</u>	<u>001</u>	Nov 14, 2005
<u>AB</u>	!	<u>EQ 600MG BASE</u>	<u>A065218</u>	<u>001</u>	Nov 14, 2005
<u>AB</u>	SANDOZ	<u>EQ 250MG BASE</u>	<u>A065211</u>	<u>001</u>	Nov 14, 2005
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065212</u>	<u>001</u>	Nov 14, 2005
<u>AB</u>		<u>EQ 600MG BASE</u>	<u>A065209</u>	<u>001</u>	Nov 14, 2005
<u>AB</u>	SUNSHINE	<u>EQ 250MG BASE</u>	<u>A209045</u>	<u>001</u>	Dec 07, 2018
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A209044</u>	<u>001</u>	Dec 07, 2018
<u>AB</u>		<u>EQ 600MG BASE</u>	<u>A209043</u>	<u>001</u>	Dec 06, 2018
<u>AB</u>	TEVA	<u>EQ 500MG BASE</u>	<u>A065193</u>	<u>001</u>	Nov 14, 2005
<u>AB</u>	YUNG SHIN PHARM	<u>EQ 250MG BASE</u>	<u>A211317</u>	<u>001</u>	Jul 26, 2022
<u>AB</u>		<u>EQ 600MG BASE</u>	<u>A211068</u>	<u>001</u>	May 08, 2020

ZITHROMAX

<u>AB</u>	+ PFIZER	<u>EQ 250MG BASE</u>	<u>N050711</u>	<u>001</u>	Jul 18, 1996
<u>AB</u>	+	<u>EQ 500MG BASE</u>	<u>N050784</u>	<u>001</u>	May 24, 2002

PRESCRIPTION DRUG PRODUCT LIST

3-50 (of 474)

AZTREONAM

FOR SOLUTION; INHALATION

CAYSTON

+! GILEAD

75MG/VIAL

N050814 001 Feb 22, 2010

INJECTABLE; INJECTION

AZACTAMAP +! BRISTOL MYERS
SQUIBB1GM/VIALN050580 002 Dec 31, 1986AP +!2GM/VIALN050580 003 Dec 31, 1986AZTREONAMAP FRESenius KABI USA1GM/VIALA065439 002 Jun 18, 2010AP2GM/VIALA065439 003 Jun 18, 2010AP HOSPIRA1GM/VIALA206517 001 Nov 08, 2021AP2GM/VIALA206517 002 Nov 08, 2021

FRESenius KABI USA 500MG/VIAL

A065439 001 Jun 18, 2010BACITRACIN

OINTMENT; OPHTHALMIC

BACITRACIN

! PADAGIS US

500 UNITS/GM

A061212 001

BACITRACIN ZINC; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE

! PADAGIS US

400 UNITS/GM; 1%; EQ 3.5MG BASE/GM; 10,000
UNITS/GM

A062166 002

BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONEAT AKORN400 UNITS/GM; 1%; EQ 3.5MG BASE/GM; 10,000
UNITS/GMA065213 001 Jul 25, 2012AT ! BAUSCH AND LOMB400 UNITS/GM; 1%; EQ 3.5MG BASE/GM; 10,000
UNITS/GMA064068 001 Oct 30, 1995BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

LUMI-SPORYNAT + CASPER PHARMA LLCEQ 400 UNITS/GM; EQ 3.5MG BASE/GM; EQ
10,000 UNITS/GMN050417 001NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINCAT AKORN400 UNITS/GM; EQ 3.5MG BASE/GM; 10,000
UNITS/GMA065088 001 Feb 06, 2004AT ! BAUSCH AND LOMB400 UNITS/GM; EQ 3.5MG BASE/GM; 10,000
UNITS/GMA064064 001 Oct 30, 1995AT PADAGIS US400 UNITS/GM; EQ 3.5MG BASE/GM; 10,000
UNITS/GMA060764 002BACITRACIN ZINC; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

BACITRACIN ZINC AND POLYMYXIN B SULFATEAT AKORN500 UNITS/GM; 10,000 UNITS/GMA064028 001 Jan 30, 1995AT ! BAUSCH AND LOMB500 UNITS/GM; 10,000 UNITS/GMA064046 001 Jan 26, 1995AT PADAGIS US500 UNITS/GM; 10,000 UNITS/GMA065022 001 Feb 27, 2002BACLOFEN

GRANULES; ORAL

LYVISPAH

+ AMNEAL

5MG/PACKET

N215422 001 Nov 22, 2021

+

10MG/PACKET

N215422 002 Nov 22, 2021

+!

20MG/PACKET

N215422 003 Nov 22, 2021

INJECTABLE; INTRATHECAL

BACLOFENAP AMNEAL0.05MG/MLA091193 001 May 03, 2016AP0.5MG/MLA091193 002 May 03, 2016AP2MG/MLA091193 003 May 03, 2016AP MAIA PHARMS INC0.05MG/MLA210777 001 Jan 15, 2021AP0.5MG/MLA210048 001 Sep 11, 2019AP1MG/MLA210315 001 Jul 30, 2019AP2MG/MLA210048 002 Sep 11, 2019AP MYLAN LABS LTD0.5MG/MLA209592 001 Mar 21, 2018AP1MG/MLA209594 001 Mar 06, 2018AP2MG/MLA209592 002 Mar 21, 2018GABLOFENAP +! PIRAMAL CRITICAL0.05MG/MLN022462 001 Nov 19, 2010AP +!0.5MG/MLN022462 002 Nov 19, 2010AP +!1MG/MLN022462 004 Jun 22, 2012

PRESCRIPTION DRUG PRODUCT LIST

3-51 (of 474)

BACLOFEN

INJECTABLE; INTRATHECAL

GABLOFEN

AP	+	2MG/ML	N022462	003	Nov 19, 2010

LIORESAL

AP	+	AMNEAL	0.05MG/ML	N020075	003	Nov 07, 1996

AP	+	0.5MG/ML	N020075	001	Jun 17, 1992

AP	+	2MG/ML	N020075	002	Jun 17, 1992

SOLUTION; ORAL

OZOBAX

+	METACEL PHARMS LLC	5MG/5ML	N208193	001	Sep 18, 2019

SUSPENSION; ORAL

FLEQSUVY

+	AZURITY	25MG/5ML	N215602	001	Feb 04, 2022

TABLET; ORAL

BACLOFEN

AB	AUROBINDO PHARMA LTD	10MG	A214099	001	Jul 13, 2021

AB		20MG	A214099	002	Jul 13, 2021

AB	BEXIMCO PHARMS USA	10MG	A214114	001	Jul 16, 2021

AB		20MG	A214114	002	Jul 16, 2021

AB	EYWA PHARMA	5MG	A211555	003	Nov 30, 2021

AB		10MG	A211555	001	Feb 01, 2019

AB		20MG	A211555	002	Feb 01, 2019

AB	IMPAX	5MG	A077971	003	Jul 07, 2021

AB		10MG	A077971	001	Oct 26, 2007

AB		20MG	A077971	002	Oct 26, 2007

AB	INNOGENIX	5MG	A212378	003	Apr 30, 2021

AB		10MG	A212378	001	Oct 09, 2020

AB		20MG	A212378	002	Oct 09, 2020

AB	IVAX SUB TEVA PHARMS	10MG	A072234	001	Jul 21, 1988

AB	!	20MG	A072235	001	Jul 21, 1988

AB	KARTHA	5MG	A214374	001	Mar 05, 2021

AB		10MG	A214374	002	Mar 05, 2021

AB		20MG	A214374	003	Mar 05, 2021

AB	LANNETT CO INC	5MG	A077241	003	Sep 22, 2021

AB		10MG	A077241	002	Jul 06, 2007

AB		20MG	A077241	001	Dec 20, 2005

AB	MANKIND PHARMA	5MG	A215885	001	Jan 25, 2022

AB		10MG	A215885	002	Jan 25, 2022

AB		20MG	A215885	003	Jan 25, 2022

AB	NORTHSTAR HLTHCARE	10MG	A078401	002	Sep 18, 2009

AB		20MG	A078401	001	Sep 18, 2009

AB	OXFORD PHARMS	10MG	A077088	002	Oct 31, 2007

AB		20MG	A077088	001	Oct 31, 2007

AB	RUBICON	5MG	A209102	001	Nov 28, 2017

AB		10MG	A209102	002	Nov 28, 2017

AB		20MG	A209102	003	Nov 28, 2017

AB	UNICHEM	10MG	A212067	001	Jul 09, 2020

AB		20MG	A212067	002	Jul 09, 2020

AB	UPSHER SMITH LABS	10MG	A074584	001	Aug 19, 1996

AB		20MG	A074584	002	Aug 19, 1996

AB	VINTAGE PHARMS	10MG	A077068	002	Aug 30, 2005

AB		20MG	A077068	001	Aug 30, 2005

AB	ZYDUS	5MG	A211659	003	Apr 17, 2020

AB		10MG	A211659	001	Nov 23, 2018

AB		20MG	A211659	002	Nov 23, 2018

AB		20MG	A211659	002	Nov 23, 2018

AB		20MG	A211659	002	Nov 23, 2018

AB		20MG	A211659	002	Nov 23, 2018

AB		20MG	A211659	002	Nov 23, 2018

AB		20MG	A211659	002	Nov 23, 2018

AB		20MG	A211659	002	Nov 23, 2018

AB		20MG	A211659	002	Nov 23, 2018

AB		20MG	A211659	002	Nov 23, 2018

AB		20MG	A211659	002	Nov 23, 2018

AB		20MG	A211659	002	Nov 23, 2018

AB		20MG	A211659	002	Nov 23, 2018

AB		20MG	A211659	002	Nov 23, 2018

AB		20MG	A211659	002	Nov 23, 2018

AB		20MG	A211659	002	Nov 23, 2018

AB		20MG	A211659	002	Nov 23, 2018

AB		20MG	A211659	002	Nov 23, 2018

AB		20MG	A211659	002	Nov 23, 2018

AB		20MG	A211659	002	Nov 23, 2018

AB		20MG	A211659	002	Nov 23, 2018

AB		20MG	A211659	002	Nov 23, 2018

AB		20MG	A211659	002	Nov 23, 2018

BALOXAVIR MARBOXIL

FOR SUSPENSION; ORAL

XOFLUZA

+	GENENTECH INC	2MG/ML	N214410	001	Nov 23, 2020

TABLET; ORAL

XOFLUZA

+	GENENTECH INC	20MG	N210854	001	Oct 24, 2018

+		40MG	N210854	002	Oct 24, 2018

+		80MG	N210854	003	Mar 18, 2021

PRESCRIPTION DRUG PRODUCT LIST

3-52 (of 474)

BALSALAZIDE DISODIUM

CAPSULE; ORAL

BALSALAZIDE DISODIUM

AB	APOTEX INC	750MG	A077883	001	Dec 28, 2007
AB	HIKMA	750MG	A077806	001	Dec 28, 2007

COLAZAL

AB	+ !	VALEANT PHARMS INTL	750MG	N020610	001	Jul 18, 2000

BARICITINIB

TABLET; ORAL

OLUMIANT

+	ELI LILLY AND CO	1MG	N207924	002	Oct 08, 2019
+		2MG	N207924	001	May 31, 2018
+ !		4MG	N207924	003	May 10, 2022

BARIUM SULFATE

FOR SUSPENSION; ORAL

E-Z-HD

+ !	BRACCO	98% (334GM/BOT)	N208036	001	Jan 11, 2016

E-Z-PAQUE

+ !	BRACCO	96% (169GM/BOT)	N208036	002	Apr 07, 2017

VARIBAR THIN LIQUID

+ !	BRACCO	81% (120GM/BOT)	N208036	004	Apr 30, 2019

PASTE; ORAL

VARIBAR PUDDING

	BRACCO	40%	N208844	001	Oct 14, 2016

SUSPENSION; ORAL

ENTERO VU 24%

+ !	BRACCO	24% (144GM/600ML)	N208143	008	May 29, 2020

LIQUID E-Z-PAQUE

+ !	BRACCO	60% (213GM/BOT)	N208143	003	Mar 01, 2017

READI-CAT 2

+ !	BRACCO	2% (9GM/BOT)	N208143	001	Jan 15, 2016

READI-CAT 2 SMOOTHIE

+ !	BRACCO	2% (9GM/BOT)	N208143	002	Jan 15, 2016

TAGITOL V

+ !	BRACCO	40% (8GM/BOT)	N208143	005	Aug 04, 2017

VARIBAR HONEY

+ !	BRACCO	40% (100GM/250ML)	N208143	007	Mar 26, 2018

VARIBAR NECTAR

+ !	BRACCO	40% (96GM/240ML)	N208143	004	Jul 07, 2017

VARIBAR THIN HONEY

+ !	BRACCO	40% (100GM/250ML)	N208143	006	Jan 23, 2018

BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED

TABLET; ORAL

DUAVEE

+ !	WYETH PHARMS	EQ 20MG BASE; 0.45MG	N022247	001	Oct 03, 2013

BECLOMETHASONE DIPROPIONATE

AEROSOL, METERED; INHALATION

QVAR REDHALER

+	NORTON WATERFORD	0.04MG/INH	N207921	001	Aug 03, 2017

+		0.08MG/INH	N207921	002	Aug 03, 2017

AEROSOL, METERED; NASAL

QNASL

+	TEVA BRANDED PHARM	0.04MG/ACTUATION	N202813	002	Dec 17, 2014

+ !		0.08MG/ACTUATION	N202813	001	Mar 23, 2012

BECLOMETHASONE DIPROPIONATE MONOHYDRATE

SPRAY, METERED; NASAL

BECONASE AQ

+ !	GLAXOSMITHKLINE	EQ 0.042MG DIPROP/SPRAY	N019389	001	Jul 27, 1987

BEDAQUILINE FUMARATE

TABLET; ORAL

SIRTURO

+	JANSSEN THERAP	EQ 20MG BASE	N204384	002	May 27, 2020

+ !		EQ 100MG BASE	N204384	001	Dec 28, 2012

PRESCRIPTION DRUG PRODUCT LIST

3-53 (of 474)

BELINOSTAT

POWDER; INTRAVENOUS

BELEODAQ

+! ACROTECH BIOPHARMA 500MG/VIAL

N206256 001 Jul 03, 2014

BELUMOSUDIL MESYLATE

TABLET; ORAL

REZUROCK

+! KADMON PHARMS LLC EQ 200MG BASE

N214783 001 Jul 16, 2021

BELZUTIFAN

TABLET; ORAL

WELIREG

+! MERCK SHARP DOHME 40MG

N215383 001 Aug 13, 2021

BEMPEDOIC ACID

TABLET; ORAL

NEXLETOL

+! ESPERION THERAPS INC 180MG

N211616 001 Feb 21, 2020

BEMPEDOIC ACID; EZETIMIBE

TABLET; ORAL

NEXLIZET

+! ESPERION THERAPS INC 180MG; 10MG

N211617 001 Feb 26, 2020

BENAZEPRIL HYDROCHLORIDE

TABLET; ORAL

BENAZEPRIL HYDROCHLORIDE

<u>AB</u>	AMNEAL PHARMS	<u>5MG</u>	<u>A076820</u>	<u>001</u>	Feb 03, 2006
<u>AB</u>		<u>10MG</u>	<u>A076820</u>	<u>002</u>	Feb 03, 2006
<u>AB</u>		<u>20MG</u>	<u>A076820</u>	<u>003</u>	Feb 03, 2006
<u>AB</u>		<u>40MG</u>	<u>A076820</u>	<u>004</u>	Feb 03, 2006
<u>AB</u>	ANNORA PHARMA	<u>5MG</u>	<u>A077128</u>	<u>001</u>	Mar 08, 2006
<u>AB</u>		<u>10MG</u>	<u>A077128</u>	<u>002</u>	Mar 08, 2006
<u>AB</u>		<u>20MG</u>	<u>A077128</u>	<u>003</u>	Mar 08, 2006
<u>AB</u>		<u>40MG</u>	<u>A077128</u>	<u>004</u>	Mar 08, 2006
<u>AB</u>	AUROBINDO PHARMA	<u>10MG</u>	<u>A078212</u>	<u>001</u>	May 22, 2008
<u>AB</u>		<u>20MG</u>	<u>A078212</u>	<u>002</u>	May 22, 2008
<u>AB</u>	!	<u>40MG</u>	<u>A078212</u>	<u>003</u>	May 22, 2008
<u>AB</u>	CADILA	<u>5MG</u>	<u>A078848</u>	<u>001</u>	May 23, 2008
<u>AB</u>		<u>10MG</u>	<u>A078848</u>	<u>002</u>	May 23, 2008
<u>AB</u>		<u>20MG</u>	<u>A078848</u>	<u>003</u>	May 23, 2008
<u>AB</u>		<u>40MG</u>	<u>A078848</u>	<u>004</u>	May 23, 2008
<u>AB</u>	CHARTWELL RX	<u>5MG</u>	<u>A076402</u>	<u>001</u>	Feb 11, 2004
<u>AB</u>		<u>10MG</u>	<u>A076402</u>	<u>002</u>	Feb 11, 2004
<u>AB</u>		<u>20MG</u>	<u>A076402</u>	<u>003</u>	Feb 11, 2004
<u>AB</u>		<u>40MG</u>	<u>A076402</u>	<u>004</u>	Feb 11, 2004
<u>AB</u>	HERITAGE PHARMA	<u>5MG</u>	<u>A076267</u>	<u>001</u>	Feb 11, 2004
<u>AB</u>		<u>10MG</u>	<u>A076267</u>	<u>002</u>	Feb 11, 2004
<u>AB</u>		<u>20MG</u>	<u>A076267</u>	<u>003</u>	Feb 11, 2004
<u>AB</u>		<u>40MG</u>	<u>A076267</u>	<u>004</u>	Feb 11, 2004
<u>AB</u>	PRINSTON INC	<u>5MG</u>	<u>A076118</u>	<u>001</u>	Feb 11, 2004
<u>AB</u>		<u>10MG</u>	<u>A076118</u>	<u>002</u>	Feb 11, 2004
<u>AB</u>		<u>20MG</u>	<u>A076118</u>	<u>003</u>	Feb 11, 2004
<u>AB</u>		<u>40MG</u>	<u>A076118</u>	<u>004</u>	Feb 11, 2004
<u>AB</u>	SUN PHARM INDS LTD	<u>5MG</u>	<u>A076344</u>	<u>001</u>	Feb 11, 2004
<u>AB</u>		<u>10MG</u>	<u>A076344</u>	<u>002</u>	Feb 11, 2004
<u>AB</u>		<u>20MG</u>	<u>A076344</u>	<u>003</u>	Feb 11, 2004
<u>AB</u>		<u>40MG</u>	<u>A076344</u>	<u>004</u>	Feb 11, 2004
<u>AB</u>	TEVA	<u>5MG</u>	<u>A076211</u>	<u>001</u>	Feb 11, 2004
<u>AB</u>		<u>10MG</u>	<u>A076211</u>	<u>002</u>	Feb 11, 2004
<u>AB</u>		<u>20MG</u>	<u>A076211</u>	<u>003</u>	Feb 11, 2004
<u>AB</u>		<u>40MG</u>	<u>A076211</u>	<u>004</u>	Feb 11, 2004
<u>LOTENSIN</u>					
<u>AB</u>	+	VALIDUS PHARMS	<u>10MG</u>	<u>N019851</u>	<u>002</u> Jun 25, 1991
<u>AB</u>	+		<u>20MG</u>	<u>N019851</u>	<u>003</u> Jun 25, 1991
<u>AB</u>	+		<u>40MG</u>	<u>N019851</u>	<u>004</u> Jun 25, 1991

PRESCRIPTION DRUG PRODUCT LIST

3-54 (of 474)

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

AB	ANI PHARMS	<u>5MG; 6.25MG</u>	<u>A076342</u>	<u>001</u>	Feb 11, 2004
AB		<u>10MG; 12.5MG</u>	<u>A076342</u>	<u>002</u>	Feb 11, 2004
AB		<u>20MG; 12.5MG</u>	<u>A076342</u>	<u>003</u>	Feb 11, 2004
AB		<u>20MG; 25MG</u>	<u>A076342</u>	<u>004</u>	Feb 11, 2004
AB	SANDOZ	<u>5MG; 6.25MG</u>	<u>A076631</u>	<u>001</u>	Feb 11, 2004
AB		<u>10MG; 12.5MG</u>	<u>A076631</u>	<u>002</u>	Feb 11, 2004
AB		<u>20MG; 12.5MG</u>	<u>A076631</u>	<u>003</u>	Feb 11, 2004
AB		<u>20MG; 25MG</u>	<u>A076631</u>	<u>004</u>	Feb 11, 2004
<u>LOTENSIN HCT</u>					
AB	+ VALIDUS PHARMS	<u>10MG; 12.5MG</u>	<u>N020033</u>	<u>002</u>	May 19, 1992
AB	+	<u>20MG; 12.5MG</u>	<u>N020033</u>	<u>004</u>	May 19, 1992
AB	+	<u>20MG; 25MG</u>	<u>N020033</u>	<u>003</u>	May 19, 1992

BENDAMUSTINE HYDROCHLORIDE

POWDER; IV (INFUSION)

BENDAMUSTINE HYDROCHLORIDE

AP	ACCORD HLTHCARE	<u>25MG/VIAL</u>	<u>A205574</u>	<u>001</u>	Dec 07, 2022
AP		<u>100MG/VIAL</u>	<u>A205574</u>	<u>002</u>	Dec 07, 2022
AP	DR REDDYS	<u>25MG/VIAL</u>	<u>A205376</u>	<u>001</u>	Dec 07, 2022
AP		<u>100MG/VIAL</u>	<u>A205376</u>	<u>002</u>	Dec 07, 2022
<u>TREANDA</u>					
AP	+! CEPHALON	<u>25MG/VIAL</u>	<u>N022249</u>	<u>002</u>	May 01, 2009
AP	+	<u>100MG/VIAL</u>	<u>N022249</u>	<u>001</u>	Mar 20, 2008

SOLUTION; INTRAVENOUS

BENDAMUSTINE HYDROCHLORIDE

+	APOTEX	100MG/4ML (25MG/ML)	N215033	001	Dec 07, 2022
+	BAXTER HLTHCARE	100MG/4ML (25MG/ML)	N216078	001	Dec 15, 2022
	CORP				
+	HOSPIRA	25MG/ML (25MG/ML)	N211530	001	Dec 15, 2022
+		100MG/4ML (25MG/ML)	N211530	002	Dec 15, 2022
+		200MG/8ML (25MG/ML)	N211530	003	Dec 15, 2022

VIVIMUSTA

+	SLAYBACK PHARMA LLC	100MG/4ML (25MG/ML)	N212209	001	Dec 07, 2022

SOLUTION; IV (INFUSION)

BELRAPZO

+	EAGLE PHARMS	100MG/4ML (25MG/ML)	N205580	001	May 15, 2018

BENDEKA

+	EAGLE PHARMS	100MG/4ML (25MG/ML)	N208194	001	Dec 07, 2015

BENOXINATE HYDROCHLORIDE; FLUORESCCEIN SODIUM

SOLUTION/DROPS; OPHTHALMIC

ALTAFLUOR BENOX

+	ALTAIRE PHARMS INC	0.4%; 0.25%	N208582	001	Dec 14, 2017

FLUORESCCEIN SODIUM AND BENOXINATE HYDROCHLORIDE

+	BAUSCH LOMB IRELAND	0.4%; 0.3%	N211039	001	Mar 09, 2020

BENZNIDAZOLE

TABLET; ORAL

BENZNIDAZOLE

+	CHEMO RESEARCH SL	12.5MG	N209570	001	Aug 29, 2017
+		100MG	N209570	002	Aug 29, 2017

BENZONATATE

CAPSULE; ORAL

BENZONATATE

AA	ACELLA	<u>100MG</u>	<u>A091310</u>	<u>001</u>	Jan 16, 2015
AA		<u>200MG</u>	<u>A091310</u>	<u>002</u>	Jan 16, 2015
AA	ALEMBIC LABS	<u>100MG</u>	<u>A040682</u>	<u>001</u>	Jul 30, 2007
AA		<u>200MG</u>	<u>A040682</u>	<u>002</u>	Jul 30, 2007
AA	ASCENT PHARMS INC	<u>100MG</u>	<u>A211518</u>	<u>001</u>	Feb 22, 2019
AA		<u>150MG</u>	<u>A211518</u>	<u>002</u>	Feb 22, 2019
AA		<u>200MG</u>	<u>A211518</u>	<u>003</u>	Feb 22, 2019
AA	BIONPHARMA INC	<u>100MG</u>	<u>A081297</u>	<u>001</u>	Jan 29, 1993
AA		<u>200MG</u>	<u>A081297</u>	<u>002</u>	Oct 30, 2007
AA	CHARTWELL RX	<u>100MG</u>	<u>A210562</u>	<u>001</u>	Nov 09, 2018
AA		<u>150MG</u>	<u>A210562</u>	<u>002</u>	Nov 09, 2018
AA		<u>200MG</u>	<u>A210562</u>	<u>003</u>	Nov 09, 2018
AA	CSPC-NBP PHARM	<u>100MG</u>	<u>A202765</u>	<u>002</u>	Aug 25, 2017
AA		<u>200MG</u>	<u>A202765</u>	<u>001</u>	Jul 31, 2015
AA	PURACAP PHARM LLC	<u>100MG</u>	<u>A206948</u>	<u>001</u>	Dec 19, 2018
AA		<u>200MG</u>	<u>A206948</u>	<u>002</u>	Dec 19, 2018
AA	STRIDES PHARMA	<u>100MG</u>	<u>A091133</u>	<u>001</u>	Jul 30, 2015

PRESCRIPTION DRUG PRODUCT LIST

3-55 (of 474)

BENZONATATE

CAPSULE; ORAL

BENZONATATE

<u>AA</u>			<u>200MG</u>	<u>A091133</u>	<u>002</u>	Jul 30, 2015
<u>AA</u>	!	THEPHARMANETWORK LLC	<u>100MG</u>	<u>A040627</u>	<u>001</u>	Mar 30, 2007
<u>AA</u>	!		<u>150MG</u>	<u>A040627</u>	<u>003</u>	Sep 24, 2014
<u>AA</u>	!		<u>200MG</u>	<u>A040627</u>	<u>002</u>	Jul 25, 2007
<u>AA</u>		ZYDUS PHARMS USA	<u>100MG</u>	<u>A040597</u>	<u>001</u>	Jun 08, 2007
<u>AA</u>			<u>200MG</u>	<u>A040597</u>	<u>002</u>	Jun 08, 2007

TESSALON

<u>AA</u>	+	PFIZER	<u>100MG</u>	<u>N011210</u>	<u>001</u>	

BENZOYL PEROXIDE

CREAM; TOPICAL

EPSOLAY

	+	!	GALDERMA LABS LP	5%	N214510	001	Apr 22, 2022

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

GEL; TOPICAL

ACANYA

<u>AB</u>	+	!	BAUSCH	<u>2.5%;EQ 1.2% BASE</u>	<u>N050819</u>	<u>001</u>	Oct 23, 2008

BENZACLIN

<u>AB</u>	+	!	BAUSCH	<u>5%;EQ 1% BASE</u>	<u>N050756</u>	<u>001</u>	Dec 21, 2000

CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE

<u>AB</u>			ACTAVIS LABS UT INC	<u>2.5%;EQ 1.2% BASE</u>	<u>A205128</u>	<u>001</u>	Jun 19, 2015
<u>AB</u>			ENCUBE	<u>5%;1.2%</u>	<u>A212433</u>	<u>001</u>	Apr 28, 2021
<u>AB</u>			GLENMARK PHARMS	<u>5%;EQ 1% BASE</u>	<u>A209252</u>	<u>001</u>	Mar 14, 2019
<u>AB</u>			MYLAN PHARMS INC	<u>5%;EQ 1% BASE</u>	<u>A065443</u>	<u>001</u>	Aug 11, 2009
<u>AB</u>			PADAGIS ISRAEL	<u>2.5%;EQ 1.2% BASE</u>	<u>A205397</u>	<u>001</u>	Sep 09, 2019
<u>AB</u>				<u>5%;EQ 1% BASE</u>	<u>A202440</u>	<u>001</u>	Sep 21, 2015
<u>AB</u>	!			<u>5%;1.2%</u>	<u>A090979</u>	<u>001</u>	Jun 26, 2012
<u>AB</u>			TARO	<u>2.5%;EQ 1.2% BASE</u>	<u>A206575</u>	<u>001</u>	Aug 19, 2019
<u>AB</u>				<u>5%;EQ 1% BASE</u>	<u>A208776</u>	<u>001</u>	May 25, 2018
<u>AB</u>			TARO PHARMS	<u>5%;1.2%</u>	<u>A206218</u>	<u>001</u>	Dec 15, 2017
<u>AB</u>			ZYDUS PHARMS	<u>5%;1.2%</u>	<u>A210794</u>	<u>001</u>	Dec 28, 2018

DUAC

<u>AB</u>	+		STIEFEL	<u>5%;1.2%</u>	<u>N050741</u>	<u>001</u>	Aug 26, 2002
			ONEXTON				
	+	!	BAUSCH	3.75%;EQ 1.2% BASE	N050819	002	Nov 24, 2014

BENZOYL PEROXIDE; ERYTHROMYCIN

GEL; TOPICAL

BENZAMYCIN

<u>AB</u>	+	!	VALEANT INTL	<u>5%;3%</u>	<u>N050557</u>	<u>001</u>	Oct 26, 1984

ERYTHROMYCIN AND BENZOYL PEROXIDE

<u>AB</u>			LYNE	<u>5%;3%</u>	<u>A065385</u>	<u>001</u>	Sep 18, 2015

BENZOYL PEROXIDE; TRETINOIN

CREAM; TOPICAL

TWYNEO

	+	!	GALDERMA LABS LP	3%;0.1%	N214902	001	Jul 26, 2021

BENZPHETAMINE HYDROCHLORIDE

TABLET; ORAL

BENZPHETAMINE HYDROCHLORIDE

<u>AA</u>			CHARTWELL	<u>50MG</u>	<u>A090473</u>	<u>002</u>	Sep 15, 2010
<u>AA</u>			EPIC PHARMA LLC	<u>50MG</u>	<u>A090346</u>	<u>001</u>	Dec 15, 2015
<u>AA</u>	!		KVK TECH	<u>50MG</u>	<u>A090968</u>	<u>001</u>	Jul 20, 2010
			CHARTWELL	25MG	A090473	001	Sep 15, 2010

BENZTROPINE MESYLATE

INJECTABLE; INJECTION

BENZTROPINE MESYLATE

<u>AP</u>			FRESENIUS KABI USA	<u>1MG/ML</u>	<u>A090233</u>	<u>001</u>	Jul 28, 2009
<u>AP</u>			HIKMA	<u>1MG/ML</u>	<u>A209442</u>	<u>001</u>	Oct 14, 2021
<u>AP</u>	!		HIKMA FARMACEUTICA	<u>1MG/ML</u>	<u>A090287</u>	<u>001</u>	Aug 31, 2009
<u>AP</u>			NAVINTA LLC	<u>1MG/ML</u>	<u>A091525</u>	<u>001</u>	Feb 05, 2013

TABLET; ORAL

BENZTROPINE MESYLATE

<u>AA</u>	!		ASPEN GLOBAL INC	<u>0.5MG</u>	<u>A204713</u>	<u>001</u>	Apr 14, 2015
<u>AA</u>	!			<u>1MG</u>	<u>A204713</u>	<u>002</u>	Apr 14, 2015
<u>AA</u>	!			<u>2MG</u>	<u>A204713</u>	<u>003</u>	Apr 14, 2015
<u>AA</u>			CHARTWELL RX	<u>1MG</u>	<u>A081265</u>	<u>002</u>	Jan 23, 1992
<u>AA</u>				<u>2MG</u>	<u>A081265</u>	<u>001</u>	Jan 23, 1992
<u>AA</u>			EPIC PHARMA LLC	<u>0.5MG</u>	<u>A072264</u>	<u>001</u>	Feb 27, 1989

PRESCRIPTION DRUG PRODUCT LIST

3-56 (of 474)

BENZTROPINE MESYLATE

TABLET; ORAL

BENZTROPINE MESYLATE

<u>AA</u>		<u>1MG</u>	<u>A072265</u>	<u>001</u>	Feb 27, 1989
<u>AA</u>		<u>2MG</u>	<u>A072266</u>	<u>001</u>	Feb 27, 1989
<u>AA</u>	INVAGEN PHARMS	<u>0.5MG</u>	<u>A090294</u>	<u>001</u>	Mar 29, 2010
<u>AA</u>		<u>1MG</u>	<u>A090294</u>	<u>002</u>	Mar 29, 2010
<u>AA</u>		<u>2MG</u>	<u>A090294</u>	<u>003</u>	Mar 29, 2010
<u>AA</u>	LEADING	<u>0.5MG</u>	<u>A090168</u>	<u>001</u>	Nov 28, 2012
<u>AA</u>		<u>1MG</u>	<u>A090168</u>	<u>002</u>	Nov 28, 2012
<u>AA</u>		<u>2MG</u>	<u>A090168</u>	<u>003</u>	Nov 28, 2012
<u>AA</u>	PLIVA	<u>0.5MG</u>	<u>A089058</u>	<u>001</u>	Aug 10, 1988
<u>AA</u>		<u>1MG</u>	<u>A089059</u>	<u>001</u>	Aug 10, 1988
<u>AA</u>		<u>2MG</u>	<u>A089060</u>	<u>001</u>	Aug 10, 1988
<u>AA</u>	VINTAGE	<u>0.5MG</u>	<u>A040715</u>	<u>001</u>	Aug 27, 2007
<u>AA</u>		<u>1MG</u>	<u>A040715</u>	<u>002</u>	Aug 27, 2007
<u>AA</u>		<u>2MG</u>	<u>A040715</u>	<u>003</u>	Aug 27, 2007

BEPOTASTINE BESILATE

SOLUTION/DROPS; OPHTHALMIC

BEPOTASTINE BESILATE

<u>AT</u>	APOTEX	<u>1.5%</u>	<u>A206066</u>	<u>001</u>	Mar 05, 2019	
<u>AT</u>	MYLAN	<u>1.5%</u>	<u>A206220</u>	<u>001</u>	Mar 18, 2019	
<u>BEPREVE</u>						
<u>AT</u>	+!	BAUSCH AND LOMB INC	<u>1.5%</u>	<u>N022288</u>	<u>001</u>	Sep 08, 2009

BEROTRALSTAT HYDROCHLORIDE

CAPSULE; ORAL

ORLADEYO

+	BIOCRYST	EQ 110MG BASE	N214094	001	Dec 03, 2020
+	!	EQ 150MG BASE	N214094	002	Dec 03, 2020

BESIFLOXACIN HYDROCHLORIDE

SUSPENSION/DROPS; OPHTHALMIC

BESIVANCE

+	!	BAUSCH AND LOMB	EQ 0.6% BASE	N022308	001	May 28, 2009

BETAINE

FOR SOLUTION; ORAL

BETAINE

<u>AB</u>	ETON	<u>1GM/SCOOPFUL</u>	<u>A210508</u>	<u>001</u>	Jan 28, 2022
<u>AB</u>	NOVITIUM PHARMA	<u>1GM/SCOOPFUL</u>	<u>A214864</u>	<u>001</u>	Nov 23, 2021
<u>CYSTADANE</u>					
<u>AB</u>	+! RECORDATI RARE	<u>1GM/SCOOPFUL</u>	<u>N020576</u>	<u>001</u>	Oct 25, 1996

BETAMETHASONE ACETATE; BETAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE

<u>AB</u>	AM REGENT	<u>3MG/ML;EQ 3MG BASE/ML</u>	<u>A090747</u>	<u>001</u>	Jul 31, 2009
<u>CELESTONE SOLUSPAN</u>					
<u>AB</u>	+!	ORGANON	<u>3MG/ML;EQ 3MG BASE/ML</u>	<u>N014602</u>	<u>001</u>

BETAMETHASONE DIPROPIONATE

CREAM; TOPICAL

BETAMETHASONE DIPROPIONATE

<u>AB</u>		ACTAVIS MID ATLANTIC	<u>EQ 0.05% BASE</u>	<u>A070885</u>	<u>001</u>	Feb 03, 1987
<u>AB</u>		COSETTE	<u>EQ 0.05% BASE</u>	<u>A210217</u>	<u>001</u>	Oct 12, 2018
<u>AB</u>	+!	FOUGERA PHARMS	<u>EQ 0.05% BASE</u>	<u>N019137</u>	<u>001</u>	Jun 26, 1984
<u>AB</u>		TARO	<u>EQ 0.05% BASE</u>	<u>A073552</u>	<u>001</u>	Apr 30, 1992
<u>AB</u>		ZYDUS PHARMS	<u>EQ 0.05% BASE</u>	<u>A208885</u>	<u>001</u>	Jan 11, 2019

CREAM, AUGMENTED; TOPICAL

BETAMETHASONE DIPROPIONATE

<u>AB</u>		FOUGERA PHARMS	<u>EQ 0.05% BASE</u>	<u>A076215</u>	<u>001</u>	Dec 09, 2003
<u>AB</u>	!	GLENMARK GENERICS	<u>EQ 0.05% BASE</u>	<u>A078930</u>	<u>001</u>	Sep 23, 2008
<u>AB</u>		PADAGIS ISRAEL	<u>EQ 0.05% BASE</u>	<u>A076592</u>	<u>001</u>	Dec 09, 2003
<u>AB</u>		TARO	<u>EQ 0.05% BASE</u>	<u>A076543</u>	<u>001</u>	Dec 09, 2003

GEL, AUGMENTED; TOPICAL

BETAMETHASONE DIPROPIONATE

<u>AB</u>	!	FOUGERA PHARMS	<u>EQ 0.05% BASE</u>	<u>A075276</u>	<u>001</u>	May 13, 2003
<u>AB</u>		TARO	<u>EQ 0.05% BASE</u>	<u>A076508</u>	<u>001</u>	Dec 02, 2003

LOTION; TOPICAL

BETAMETHASONE DIPROPIONATE

<u>AB</u>		COSETTE	<u>EQ 0.05% BASE</u>	<u>A071467</u>	<u>001</u>	Aug 10, 1987
<u>AB</u>	!	FOUGERA PHARMS INC	<u>EQ 0.05% BASE</u>	<u>A070275</u>	<u>001</u>	Aug 12, 1985
<u>AB</u>		PADAGIS US	<u>EQ 0.05% BASE</u>	<u>A072538</u>	<u>001</u>	Jan 31, 1990

PRESCRIPTION DRUG PRODUCT LIST

3-57 (of 474)

BETAMETHASONE DIPROPIONATE

LOTION, AUGMENTED; TOPICAL

BETAMETHASONE DIPROPIONATE

AB	AKORN	EQ 0.05% BASE	A208849 001	Oct 11, 2019
AB	FOUGERA PHARMS	EQ 0.05% BASE	A077111 001	May 21, 2007
AB	PAI HOLDINGS PHARM	EQ 0.05% BASE	A206389 001	Feb 13, 2018
AB	! TARO	EQ 0.05% BASE	A077477 001	May 21, 2007

OINTMENT; TOPICAL

BETAMETHASONE DIPROPIONATE

AB	ACTAVIS MID ATLANTIC	EQ 0.05% BASE	A071012 001	Feb 03, 1987
AB	CADILA	EQ 0.05% BASE	A214048 001	Jul 14, 2020
AB	+ ! FOUGERA PHARMS INC	EQ 0.05% BASE	N019141 001	Sep 04, 1984
AB	PADAGIS ISRAEL	EQ 0.05% BASE	A215847 001	Apr 12, 2022
AB	TARO	EQ 0.05% BASE	A074271 001	Sep 15, 1994
AB	TASMAN PHARMA	EQ 0.05% BASE	A215186 001	Feb 18, 2022

OINTMENT, AUGMENTED; TOPICAL

BETAMETHASONE DIPROPIONATE

AB	ACTAVIS MID ATLANTIC	EQ 0.05% BASE	A074304 001	Aug 31, 1995
AB	FOUGERA PHARMS	EQ 0.05% BASE	A075373 001	Jun 22, 1999
AB	LUPIN LTD	EQ 0.05% BASE	A209106 001	Dec 18, 2019
AB	PAI HOLDINGS PHARM	EQ 0.05% BASE	A206118 001	Nov 09, 2017
AB	TARO	EQ 0.05% BASE	A076753 001	Oct 12, 2004

DIPROLENE

AB	+ ! ORGANON	EQ 0.05% BASE	N018741 001	Jul 27, 1983

SPRAY; TOPICAL

SERNIVO

+ !	PRIMUS PHARMS	EQ 0.05% BASE/SPRAY	N208079 001	Feb 05, 2016

BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE

AEROSOL, FOAM; TOPICAL

ENSTILAR				
+ !	LEO PHARMA AS	0.064%; 0.005%	N207589 001	Oct 16, 2015

CREAM; TOPICAL

WYNZORA				
+ !	MC2	0.064%; 0.005%	N213422 001	Jul 20, 2020

OINTMENT; TOPICAL

CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE

AB	PADAGIS ISRAEL	0.064%; 0.005%	A200174 001	Dec 12, 2014
AB	TOLMAR	0.064%; 0.005%	A201615 001	Jan 14, 2013

TACLONEX

AB	+ ! LEO PHARMA AS	0.064%; 0.005%	N021852 001	Jan 09, 2006

SUSPENSION; TOPICAL

CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE

AB	TARO PHARMS	0.064%; 0.005%	A213269 001	Sep 02, 2020
AB	TOLMAR	0.064%; 0.005%	A210765 001	May 11, 2020

CALCIPOTRIENE AND BETHAMETHASONE DIPROPIONATE

AB	PADAGIS ISRAEL	0.064%; 0.005%	A212367 001	Sep 11, 2020

TACLONEX

AB	+ ! LEO PHARMA AS	0.064%; 0.005%	N022185 001	May 09, 2008

BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE

CREAM; TOPICAL

CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE

AB	ACTAVIS MID ATLANTIC	EQ 0.05% BASE; 1%	A076002 001	Aug 02, 2002
AB	FOUGERA PHARMS	EQ 0.05% BASE; 1%	A075502 001	Jun 05, 2001
AB	GLENMARK PHARMS	EQ 0.05% BASE; 1%	A202894 001	Oct 30, 2015
AB	TARO	EQ 0.05% BASE; 1%	A075673 001	May 29, 2001

LOTRISONE

AB	+ ! ORGANON	EQ 0.05% BASE; 1%	N018827 001	Jul 10, 1984

LOTION; TOPICAL

CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE

AB	FOUGERA PHARMS	EQ 0.05% BASE; 1%	A076516 001	Jun 16, 2005
AB	! TARO	EQ 0.05% BASE; 1%	A076493 001	Jul 28, 2004

BETAMETHASONE VALERATE

AEROSOL, FOAM; TOPICAL

BETAMETHASONE VALERATE

AB	PADAGIS ISRAEL	0.12%	A078337 001	Nov 26, 2012
AB	TARO	0.12%	A208204 001	May 24, 2017

LUXIQ

AB	+ ! MYLAN	0.12%	N020934 001	Feb 28, 1999

PRESCRIPTION DRUG PRODUCT LIST

3-58 (of 474)

BETAMETHASONE VALERATE

CREAM; TOPICAL

BETA-VAL

AB	COSETTE	EQ 0.1% BASE	N018642 001	Mar 24, 1983

BETAMETHASONE VALERATE

AB	+! FOUGERA PHARMS INC	EQ 0.1% BASE	N018861 001	Aug 31, 1983

DERMABET

AB	TARO	EQ 0.1% BASE	A072041 001	Jan 06, 1988

VALNAC

AB	ACTAVIS MID ATLANTIC	EQ 0.1% BASE	A070050 001	Oct 10, 1984

LOTION; TOPICAL

BETAMETHASONE VALERATE

AB	ANIMA	EQ 0.1% BASE	A070052 001	Jul 31, 1985

AB	+! FOUGERA PHARMS INC	EQ 0.1% BASE	N018866 001	Aug 31, 1983

OINTMENT; TOPICAL

BETA-VAL

AB	COSETTE	EQ 0.1% BASE	A070069 001	Dec 19, 1985

BETAMETHASONE VALERATE

AB	ACTAVIS MID ATLANTIC	EQ 0.1% BASE	A070051 001	Oct 10, 1984

AB	+! FOUGERA PHARMS INC	EQ 0.1% BASE	N018865 001	Aug 31, 1983

BETAXOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

BETAXOLOL HYDROCHLORIDE

AT	ACELLA	EQ 0.5% BASE	A078694 001	Nov 16, 2009

AT	AKORN	EQ 0.5% BASE	A075386 001	Jun 30, 2000

AT	MEDIMETRIKS PHARMS	EQ 0.5% BASE	A075630 001	Apr 12, 2001

BETOPTIC

AT	+! SANDOZ INC	EQ 0.5% BASE	N019270 001	Aug 30, 1985

SUSPENSION/DROPS; OPHTHALMIC

BETOPTIC S

+! NOVARTIS	EQ 0.25% BASE	N019845 001	Dec 29, 1989

TABLET; ORAL

BETAXOLOL HYDROCHLORIDE

AB	EPIC PHARMA	10MG	A075541 001	Oct 22, 1999

AB	!	20MG	A075541 002	Oct 22, 1999

AB	KVK TECH	10MG	A078962 001	Jun 27, 2008

AB		20MG	A078962 002	Jun 27, 2008

BETHANECHOL CHLORIDE

TABLET; ORAL

BETHANECHOL CHLORIDE

AA	AIPING LIFE SCI	5MG	A040728 002	Oct 26, 2007

AA		10MG	A040728 003	Oct 26, 2007

AA		25MG	A040728 004	Oct 26, 2007

AA		50MG	A040728 001	Oct 26, 2007

AA	! AMNEAL PHARM	5MG	A040855 001	Nov 21, 2007

AA	!	10MG	A040855 002	Nov 21, 2007

AA	!	25MG	A040855 003	Nov 21, 2007

AA	!	50MG	A040855 004	Nov 21, 2007

AA	UPSHER SMITH LABS	5MG	A040633 001	Jun 01, 2005

AA		10MG	A040634 001	Jun 01, 2005

AA		25MG	A040635 001	Jun 01, 2005

AA		50MG	A040636 001	Jun 01, 2005

DUVOID

AA	CHARTWELL RX	10MG	A086262 001	

AA		25MG	A086263 001	

AA		50MG	A085882 003	

BEXAROTENE

CAPSULE; ORAL

BEXAROTENE

AB	AMNEAL PHARMS NY	75MG	A210105 001	Sep 04, 2018

AB	ANI PHARMS	75MG	A209861 001	May 08, 2018

AB	BIONPHARMA INC	75MG	A203174 001	Aug 12, 2014

AB	HIKMA	75MG	A203663 001	Jun 16, 2020

AB	TEVA PHARMS USA	75MG	A209931 001	Jan 14, 2021

AB	UPSHER SMITH LABS	75MG	A209886 001	Jul 25, 2018

TARGRETIN

AB	+! VALEANT LUXEMBOURG	75MG	N021055 001	Dec 29, 1999

PRESCRIPTION DRUG PRODUCT LIST

3-59 (of 474)

BEXAROTENE

GEL; TOPICAL

BEXAROTENE

AB	AMNEAL	1%	A215398	001	Apr 27, 2022

TARGRETIN

AB	+! BAUSCH	1%	N021056	001	Jun 28, 2000

BICALUTAMIDE

TABLET; ORAL

BICALUTAMIDE

AB	ACCORD HLTHCARE	50MG	A078917	001	Jul 06, 2009

AB	APOTEX INC	50MG	A200274	001	May 21, 2015

AB	KENTON	50MG	A091011	001	Jun 10, 2015

AB	SANDOZ	50MG	A078575	001	Jul 06, 2009

AB	SUN PHARM	50MG	A079110	001	Jul 06, 2009

AB	WATSON LABS TEVA	50MG	A078634	001	Aug 28, 2009

AB	ZYDUS PHARMS USA	50MG	A079089	001	Jul 06, 2009

CASODEX

AB	+! ANI PHARMS	50MG	N020498	001	Oct 04, 1995

BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE

TABLET; ORAL

BIKTARVY

+	GILEAD SCIENCES INC	EQ 30MG BASE; 120MG; EQ 15MG BASE	N210251	002	Oct 07, 2021

+		EQ 50MG BASE; 200MG; EQ 25MG BASE	N210251	001	Feb 07, 2018

BIMATOPROST

IMPLANT; OPHTHALMIC

DURYSTA

+	ALLERGAN INC	10MCG	N211911	001	Mar 04, 2020

SOLUTION/DROPS; OPHTHALMIC

BIMATOPROST

AT	! ALEMBIC PHARMS	0.03%	A210263	001	Apr 12, 2019

AT	APOTEX INC	0.03%	A090449	001	Jul 20, 2015

AT	EUGIA PHARMA	0.03%	A205537	001	Oct 06, 2022

AT	GLAND PHARMA LTD	0.03%	A210126	001	Mar 22, 2019

AT	LUPIN LTD	0.03%	A203991	001	Feb 20, 2015

AT	MICRO LABS	0.03%	A202505	001	Sep 08, 2020

AT	SANDOZ INC	0.03%	A202565	001	May 05, 2015

AT	SOMERSET THERAPS	0.03%	A207601	001	Jun 19, 2019

LLCLUMIGAN

+	ALLERGAN	0.01%	N022184	001	Aug 31, 2010

SOLUTION/DROPS; TOPICAL

BIMATOPROST

AT	AKORN	0.03%	A203051	001	Oct 09, 2018

AT	ALEMBIC PHARMS	0.03%	A210515	001	Jan 21, 2020

AT	APOTEX INC	0.03%	A201894	001	Dec 01, 2014

AT	SANDOZ INC	0.03%	A202719	001	Apr 19, 2016

LATISSE

AT	+! ALLERGAN	0.03%	N022369	001	Dec 24, 2008

BINIMETINIB

TABLET; ORAL

MEKTOVI

+	ARRAY BIOPHARMA INC	15MG	N210498	001	Jun 27, 2018

BISMUTH SUBCITRATE POTASSIUM; METRONIDAZOLE; TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL

PYLERA

+	ALLERGAN	140MG; 125MG; 125MG	N050786	001	Sep 28, 2006

BISMUTH SUBSALICYLATE; METRONIDAZOLE; TETRACYCLINE HYDROCHLORIDE

TABLET, CHEWABLE, TABLET, CAPSULE; ORAL

BISMUTH SUBSALICYLATE, METRONIDAZOLE AND TETRACYCLINE HYDROCHLORIDE

!	AILEX PHARMS LLC	262.4MG, N/A, N/A; N/A, 250MG, N/A; N/A, N/A, 500MG	A202584	001	Nov 30, 2018

BISOPROLOL FUMARATE

TABLET; ORAL

BISOPROLOL FUMARATE

AB	ALEMBIC LABS	5MG	A204891	001	Jan 11, 2017

AB		10MG	A204891	002	Jan 11, 2017

AB	AUROBINDO PHARMA	5MG	A077910	001	Dec 27, 2006

AB		10MG	A077910	002	Dec 27, 2006

PRESCRIPTION DRUG PRODUCT LIST

3-60 (of 474)

BISOPROLOL FUMARATE

TABLET; ORAL

BISOPROLOL FUMARATE

<u>AB</u>	CADILA	<u>5MG</u>	<u>A215680</u>	<u>001</u>	Jul 25, 2022
<u>AB</u>		<u>10MG</u>	<u>A215680</u>	<u>002</u>	Jul 25, 2022
<u>AB</u>	NOVITIUM PHARMA	<u>5MG</u>	<u>A215563</u>	<u>001</u>	Oct 29, 2021
<u>AB</u>		<u>10MG</u>	<u>A215563</u>	<u>002</u>	Oct 29, 2021
<u>AB</u>	RUBICON	<u>5MG</u>	<u>A075643</u>	<u>001</u>	Nov 16, 2000
<u>AB</u>		<u>10MG</u>	<u>A075643</u>	<u>002</u>	Nov 16, 2000
<u>AB</u>	UNICHEM	<u>5MG</u>	<u>A078635</u>	<u>001</u>	Aug 18, 2009
<u>AB</u>	!	<u>10MG</u>	<u>A078635</u>	<u>002</u>	Aug 18, 2009
<u>AB</u>	UNITED RES LABS	<u>5MG</u>	<u>A075474</u>	<u>001</u>	Oct 25, 2002
<u>AB</u>		<u>10MG</u>	<u>A075474</u>	<u>002</u>	Oct 25, 2002

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE

<u>AB</u>	CADILA	<u>2.5MG; 6.25MG</u>	<u>A215666</u>	<u>001</u>	Nov 04, 2022
<u>AB</u>		<u>5MG; 6.25MG</u>	<u>A215666</u>	<u>002</u>	Nov 04, 2022
<u>AB</u>		<u>10MG; 6.25MG</u>	<u>A215666</u>	<u>003</u>	Nov 04, 2022
<u>AB</u>	EDENBRIDGE PHARMS	<u>2.5MG; 6.25MG</u>	<u>A212678</u>	<u>001</u>	Jul 09, 2020
<u>AB</u>		<u>5MG; 6.25MG</u>	<u>A212678</u>	<u>002</u>	Jul 09, 2020
<u>AB</u>		<u>10MG; 6.25MG</u>	<u>A212678</u>	<u>003</u>	Jul 09, 2020
<u>AB</u>	EPIC PHARMA	<u>2.5MG; 6.25MG</u>	<u>A075579</u>	<u>001</u>	Sep 25, 2000
<u>AB</u>		<u>5MG; 6.25MG</u>	<u>A075579</u>	<u>002</u>	Sep 25, 2000
<u>AB</u>		<u>10MG; 6.25MG</u>	<u>A075579</u>	<u>003</u>	Sep 25, 2000
<u>AB</u>	GLENMARK PHARMS LTD	<u>2.5MG; 6.25MG</u>	<u>A215995</u>	<u>001</u>	Jan 26, 2022
<u>AB</u>		<u>5MG; 6.25MG</u>	<u>A215995</u>	<u>002</u>	Jan 26, 2022
<u>AB</u>		<u>10MG; 6.25MG</u>	<u>A215995</u>	<u>003</u>	Jan 26, 2022
<u>AB</u>	MYLAN	<u>2.5MG; 6.25MG</u>	<u>A075768</u>	<u>001</u>	Sep 25, 2000
<u>AB</u>		<u>5MG; 6.25MG</u>	<u>A075768</u>	<u>002</u>	Sep 25, 2000
<u>AB</u>		<u>10MG; 6.25MG</u>	<u>A075768</u>	<u>003</u>	Sep 25, 2000
<u>AB</u>	NOVITIUM PHARMA	<u>2.5MG; 6.25MG</u>	<u>A215562</u>	<u>001</u>	Nov 04, 2021
<u>AB</u>		<u>5MG; 6.25MG</u>	<u>A215562</u>	<u>002</u>	Nov 04, 2021
<u>AB</u>		<u>10MG; 6.25MG</u>	<u>A215562</u>	<u>003</u>	Nov 04, 2021
<u>AB</u>	UNICHEM	<u>2.5MG; 6.25MG</u>	<u>A079106</u>	<u>001</u>	Jul 28, 2010
<u>AB</u>		<u>5MG; 6.25MG</u>	<u>A079106</u>	<u>002</u>	Jul 28, 2010
<u>AB</u>		<u>10MG; 6.25MG</u>	<u>A079106</u>	<u>003</u>	Jul 28, 2010
<u>AB</u>	<u>ZIAC</u>				
<u>AB</u>	+	TEVA BRANDED PHARM	<u>2.5MG; 6.25MG</u>	<u>N020186</u>	<u>003</u> Mar 26, 1993
<u>AB</u>	+		<u>5MG; 6.25MG</u>	<u>N020186</u>	<u>001</u> Mar 26, 1993
<u>AB</u>	+	!	<u>10MG; 6.25MG</u>	<u>N020186</u>	<u>002</u> Mar 26, 1993

BIVALIRUDIN

INJECTABLE; INTRAVENOUS

ANGIOMAX

<u>AP</u>	+	SANDOZ INC	<u>250MG/VIAL</u>	<u>N020873</u>	<u>001</u> Dec 15, 2000

BIVALIRUDIN

<u>AP</u>		ACCORD HLTHCARE	<u>250MG/VIAL</u>	<u>A206551</u>	<u>001</u> Nov 22, 2017
<u>AP</u>		DR REDDYS	<u>250MG/VIAL</u>	<u>A201577</u>	<u>001</u> May 26, 2017
<u>AP</u>		EUGIA PHARMA	<u>250MG/VIAL</u>	<u>A205962</u>	<u>001</u> Jul 27, 2018
<u>AP</u>		FRESENIUS KABI USA	<u>250MG/VIAL</u>	<u>A090189</u>	<u>001</u> Oct 28, 2016
<u>AP</u>		HAINAN POLY PHARM	<u>250MG/VIAL</u>	<u>A213078</u>	<u>001</u> May 28, 2021
<u>AP</u>		HOSPIRA	<u>250MG/VIAL</u>	<u>A090811</u>	<u>001</u> Jul 14, 2015
<u>AP</u>			<u>250MG/VIAL</u>	<u>A090816</u>	<u>001</u> Jul 14, 2015
<u>AP</u>		MEITHEAL	<u>250MG/VIAL</u>	<u>A091602</u>	<u>001</u> Jul 16, 2018
<u>AP</u>		MYLAN INSTITUTIONAL	<u>250MG/VIAL</u>	<u>A202471</u>	<u>001</u> Jun 01, 2018
<u>AP</u>		SHUANGCHENG	<u>250MG/VIAL</u>	<u>A210031</u>	<u>001</u> Oct 23, 2019

SOLUTION; INTRAVENOUS

ANGIOMAX RTU

	+	MAIA PHARMS INC	250MG/50ML (5MG/ML)	N211215	001 Jul 25, 2019

BLEOMYCIN SULFATE

INJECTABLE; INJECTION

BLEOMYCIN SULFATE

<u>AP</u>	!	FRESENIUS KABI USA	<u>EQ 15 UNITS BASE/VIAL</u>	<u>A065185</u>	<u>001</u> Jan 28, 2008
<u>AP</u>	!		<u>EQ 30 UNITS BASE/VIAL</u>	<u>A065185</u>	<u>002</u> Jan 28, 2008
<u>AP</u>		HIKMA	<u>EQ 15 UNITS BASE/VIAL</u>	<u>A065042</u>	<u>002</u> Oct 17, 2001
<u>AP</u>			<u>EQ 30 UNITS BASE/VIAL</u>	<u>A065042</u>	<u>001</u> Oct 17, 2001
<u>AP</u>		HOSPIRA	<u>EQ 15 UNITS BASE/VIAL</u>	<u>A065031</u>	<u>001</u> Mar 10, 2000
<u>AP</u>			<u>EQ 30 UNITS BASE/VIAL</u>	<u>A065031</u>	<u>002</u> Mar 10, 2000
<u>AP</u>		MEITHEAL	<u>EQ 15 UNITS BASE/VIAL</u>	<u>A205030</u>	<u>001</u> Apr 20, 2018
<u>AP</u>			<u>EQ 30 UNITS BASE/VIAL</u>	<u>A205030</u>	<u>002</u> Apr 20, 2018
<u>AP</u>		TEVA PHARMS USA	<u>EQ 15 UNITS BASE/VIAL</u>	<u>A065033</u>	<u>001</u> Jun 27, 2000

PRESCRIPTION DRUG PRODUCT LIST

3-61 (of 474)

BLEOMYCIN SULFATE

INJECTABLE; INJECTION

BLEOMYCIN SULFATE

<u>AP</u>		<u>EQ 30 UNITS BASE/VIAL</u>	<u>A065033</u>	<u>002</u>	Jun 27, 2000

BORTEZOMIB

INJECTABLE; INTRAVENOUS, SUBCUTANEOUS

BORTEZOMIB

<u>AP</u>	ACCORD HLTHCARE	<u>3.5MG/VIAL</u>	<u>A204405</u>	<u>001</u>	Jul 26, 2022
<u>AP</u>	APOTEX	<u>3.5MG/VIAL</u>	<u>A205533</u>	<u>001</u>	May 02, 2022
<u>AP</u>	BAXTER HLTHCARE CORP	<u>3.5MG/VIAL</u>	<u>A213823</u>	<u>001</u>	May 02, 2022
<u>AP</u>	DR REDDYS	<u>3.5MG/VIAL</u>	<u>A202963</u>	<u>001</u>	Jul 26, 2022
<u>AP</u>	EUGIA PHARMA	<u>3.5MG/VIAL</u>	<u>A212825</u>	<u>001</u>	May 02, 2022
<u>AP</u>	FRESENIUS KABI USA	<u>3.5MG/VIAL</u>	<u>A209659</u>	<u>001</u>	May 02, 2022
<u>AP</u>	HOSPIRA	<u>3.5MG/VIAL</u>	<u>A208460</u>	<u>001</u>	Jul 26, 2022
<u>AP</u>	JIANGSU HANSON PHARM	<u>3.5MG/VIAL</u>	<u>A215011</u>	<u>001</u>	Jul 26, 2022
<u>AP</u>	MEITHEAL	<u>3.5MG/VIAL</u>	<u>A212958</u>	<u>001</u>	Jul 26, 2022
<u>AP</u>	MSN	<u>3.5MG/VIAL</u>	<u>A209622</u>	<u>001</u>	Jul 26, 2022
<u>AP</u>	PHARMASCIENCE INC	<u>3.5MG/VIAL</u>	<u>A208392</u>	<u>001</u>	May 02, 2022
<u>AP</u>	QILU PHARM HAINAN	<u>3.5MG/VIAL</u>	<u>A210824</u>	<u>001</u>	May 02, 2022
<u>AP</u>	SANDOZ INC	<u>3.5MG/VIAL</u>	<u>A203654</u>	<u>001</u>	Jul 26, 2022
<u>AP</u>	WAVERLEY PHARMA INC	<u>3.5MG/VIAL</u>	<u>A211898</u>	<u>001</u>	Oct 11, 2022
<u>AP</u>	ZYDUS PHARMS	<u>3.5MG/VIAL</u>	<u>A210204</u>	<u>001</u>	May 02, 2022

VELCADE

<u>AP</u>	<u>+</u> !	TAKEDA PHARMS USA	<u>3.5MG/VIAL</u>	<u>N021602</u>	<u>001</u>	May 13, 2003

POWDER; INTRAVENOUS

BORTEZOMIB

	DR REDDYS	3.5MG/VIAL	N206927	001	Oct 04, 2019
	FRESENIUS KABI USA	3.5MG/VIAL	N205004	001	Nov 06, 2017

POWDER; INTRAVENOUS, SUBCUTANEOUS

BORTEZOMIB

<u>+</u> !	HOSPIRA	1MG/VIAL	N209191	001	May 02, 2022
<u>+</u> !		2.5MG/VIAL	N209191	002	May 02, 2022

SOLUTION; INTRAVENOUS

BORTEZOMIB

<u>+</u> !	ACCORD HLTHCARE	2.5MG/ML (2.5MG/ML)	N215441	001	Jul 26, 2022
<u>+</u> !		3.5MG/1.4ML (2.5MG/ML)	N215441	002	Jul 26, 2022
<u>+</u> !	MAIA PHARMS INC	3.5MG/1.4ML (2.5MG/ML)	N215331	002	Jul 27, 2022

BOSENTAN

TABLET; ORAL

BOSENTAN

<u>AB</u>		HIKMA	<u>62.5MG</u>	<u>A208695</u>	<u>001</u>	Apr 26, 2019
<u>AB</u>			<u>125MG</u>	<u>A208695</u>	<u>002</u>	Apr 26, 2019
<u>AB</u>		PAR PHARM INC	<u>62.5MG</u>	<u>A205699</u>	<u>001</u>	Apr 26, 2019
<u>AB</u>			<u>125MG</u>	<u>A205699</u>	<u>002</u>	Apr 26, 2019
<u>AB</u>		SUN PHARM	<u>62.5MG</u>	<u>A209324</u>	<u>001</u>	Apr 26, 2019
<u>AB</u>			<u>125MG</u>	<u>A209324</u>	<u>002</u>	Apr 26, 2019
<u>AB</u>		WATSON LABS INC	<u>62.5MG</u>	<u>A207110</u>	<u>001</u>	Apr 26, 2019
<u>AB</u>			<u>125MG</u>	<u>A207110</u>	<u>002</u>	Apr 26, 2019
<u>AB</u>		ZYDUS PHARMS	<u>62.5MG</u>	<u>A207760</u>	<u>001</u>	Apr 26, 2019
<u>AB</u>			<u>125MG</u>	<u>A207760</u>	<u>002</u>	Apr 26, 2019

TRACLEER

<u>AB</u>	<u>+</u>	ACTELION	<u>62.5MG</u>	<u>N021290</u>	<u>001</u>	Nov 20, 2001
<u>AB</u>	<u>+</u> !		<u>125MG</u>	<u>N021290</u>	<u>002</u>	Nov 20, 2001

TABLET, FOR SUSPENSION; ORAL

TRACLEER

<u>+</u> !	ACTELION	32MG	N209279	001	Sep 05, 2017

BOSUTINIB MONOHYDRATE

TABLET; ORAL

BOSULIF

<u>+</u> !	PF PRISM CV	EQ 100MG BASE	N203341	001	Sep 04, 2012
<u>+</u>		EQ 400MG BASE	N203341	003	Oct 27, 2017
<u>+</u>		EQ 500MG BASE	N203341	002	Sep 04, 2012

BREMELANOTIDE ACETATE

SOLUTION; SUBCUTANEOUS

VYLEESI (AUTOINJECTOR)

<u>+</u> !	PALATIN TECHNOLOGIES	EQ 1.75MG BASE/0.3ML (EQ 1.75MG BASE/0.3 ML)	N210557	001	Jun 21, 2019

PRESCRIPTION DRUG PRODUCT LIST

3-62 (of 474)

BRETYLIUM TOSYLATE

INJECTABLE; INJECTION

BRETYLIUM TOSYLATE

! BRECKENRIDGE

50MG/ML

A204386 001 Dec 21, 2018

BREXANOLONE

SOLUTION; INTRAVENOUS

ZULRESSO

+! SAGE THERAP

100MG/20ML (5MG/ML)

N211371 001 Jun 17, 2019

BREXPIRAZOLE

TABLET; ORAL

BREXPIRAZOLEAB TEVA PHARMS USA INC0.25MGA213692 001 Aug 11, 2022AB 0.5MGA213692 002 Aug 11, 2022AB 1MGA213692 003 Aug 11, 2022AB 2MGA213692 004 Aug 11, 2022AB 3MGA213692 005 Aug 11, 2022AB 4MGA213692 006 Aug 11, 2022AB ZYDUS PHARMS 0.25MGA213660 001 Jan 10, 2023AB 0.5MGA213660 002 Jan 10, 2023AB 1MGA213660 003 Jan 10, 2023AB 2MGA213660 004 Jan 10, 2023AB 3MGA213660 005 Jan 10, 2023AB 4MGA213660 006 Jan 10, 2023REXULTIAB + OTSUKA 0.25MGN205422 001 Jul 10, 2015AB + 0.5MGN205422 002 Jul 10, 2015AB + 1MGN205422 003 Jul 10, 2015AB +! 2MGN205422 004 Jul 10, 2015AB + 3MGN205422 005 Jul 10, 2015AB + 4MGN205422 006 Jul 10, 2015BRIGATINIB

TABLET; ORAL

ALUNBRIG

+ TAKEDA PHARMS USA

30MG

N208772 001 Apr 28, 2017

+ 90MG

N208772 002 Apr 28, 2017

+! 180MG

N208772 003 Oct 02, 2017

BRILLIANT BLUE G

SOLUTION; OPHTHALMIC

TISSUEBLUE

+! DUTCH OPHTHALMIC

0.025%

N209569 001 Dec 20, 2019

BRIMONIDINE TARTRATE

GEL; TOPICAL

BRIMONIDINE TARTRATEAB PADAGIS ISRAEL EQ 0.33% BASEA209158 001 Sep 23, 2021MIRVASOAB +! GALDERMA LABS LP EQ 0.33% BASEN204708 001 Aug 23, 2013

SOLUTION/DROPS; OPHTHALMIC

ALPHAGAN PAB +! ALLERGAN 0.1%N021770 001 Aug 19, 2005BRIMONIDINE TARTRATEAB APOTEX 0.1%A078480 001 Dec 21, 2022ALPHAGAN PAT +! ALLERGAN 0.15%N021262 001 Mar 16, 2001BRIMONIDINE TARTRATEAT AKORN 0.2%A076439 001 Mar 14, 2006AT APOTEX 0.15%A078479 001 Jan 31, 2022AT ! BAUSCH AND LOMB 0.2%A076260 001 May 28, 2003AT INDOCO 0.2%A091691 001 Nov 18, 2014AT SANDOZ INC 0.2%A076254 001 Sep 16, 2003AT 0.2%A078075 001 Jan 30, 2008AT SOMERSET THERAPS 0.2%A208992 001 Mar 11, 2019

LLC

QOLIANAAT +! SANDOZ INC 0.15%N021764 001 May 22, 2006

PRESCRIPTION DRUG PRODUCT LIST

3-63 (of 474)

BRIMONIDINE TARTRATE; BRINZOLAMIDE

SUSPENSION/DROPS;OPHTHALMIC

SIMBRINZA

+! ALCON LABS INC 0.2%;1%

N204251 001 Apr 19, 2013

BRIMONIDINE TARTRATE; TIMOLOL MALEATE

SOLUTION/DROPS;OPHTHALMIC

BRIMONIDINE TARTRATE AND TIMOLOL MALEATEAB AKORN 0.2%;EQ 0.5% BASEA091086 001 Oct 31, 2022AB APOTEX INC 0.2%;EQ 0.5% BASEA091442 001 Apr 20, 2022AB SANDOZ INC 0.2%;EQ 0.5% BASEA091087 001 Apr 04, 2022AB UPSHER SMITH LABS 0.2%;EQ 0.5% BASEA215598 001 Dec 12, 2022AB WATSON LABS TEVA 0.2%;EQ 0.5% BASEA201949 001 Oct 04, 2022COMBIGANAB +! ALLERGAN 0.2%;EQ 0.5% BASEN021398 001 Oct 30, 2007BRINCIDOFOVIR

SUSPENSION;ORAL

TEMBEXA

+! EMERGENT BIODEFENSE 10MG/ML

N214460 001 Jun 04, 2021

TABLET;ORAL

TEMBEXA

+! EMERGENT BIODEFENSE 100MG

N214461 001 Jun 04, 2021

BRINZOLAMIDE

SUSPENSION/DROPS;OPHTHALMIC

AZOPTAB +! NOVARTIS 1%N020816 001 Apr 01, 1998BRINZOLAMIDEAB BAUSCH AND LOMB 1%A204884 001 Aug 18, 2021AB WATSON LABS INC 1%A209406 001 Nov 27, 2020BRIVARACETAM

SOLUTION;INTRAVENOUS

BRIVIACT

+! UCB INC 50MG/5ML (10MG/ML)

N205837 001 May 12, 2016

SOLUTION;ORAL

BRIVIACT

+! UCB INC 10MG/ML

N205838 001 May 12, 2016

TABLET;ORAL

BRIVARACETAMAB AUROBINDO PHARMA LTD 50MGA214848 001 Jan 06, 2023AB 100MGA214848 002 Jan 06, 2023AB LUPIN LTD 10MGA214918 001 Dec 20, 2022AB 25MGA214918 002 Dec 20, 2022AB 50MGA214918 003 Dec 20, 2022AB 75MGA214918 004 Dec 20, 2022AB 100MGA214918 005 Dec 20, 2022BRIVIACTAB + UCB INC 10MGN205836 001 May 12, 2016AB + 25MGN205836 002 May 12, 2016AB + 50MGN205836 003 May 12, 2016AB + 75MGN205836 004 May 12, 2016AB +! 100MGN205836 005 May 12, 2016BROMFENAC SODIUM

SOLUTION/DROPS;OPHTHALMIC

BROMFENAC SODIUMAT2 ! AKORN EQ 0.09% ACIDA203395 001 Jan 22, 2014AT2 ALEMBIC PHARMS EQ 0.09% ACIDA210560 001 Jun 21, 2019AT2 EUGIA PHARMA EQ 0.09% ACIDA204813 001 Mar 18, 2022AT2 GLAND PHARMA LTD EQ 0.09% ACIDA211029 001 Mar 17, 2020

BROMSITE

+! SUN PHARM EQ 0.075% ACID

N206911 001 Apr 08, 2016

PROLENSA

+! BAUSCH AND LOMB EQ 0.07% ACID

N203168 001 Apr 05, 2013

BROMOCRIPTINE MESYLATE

CAPSULE;ORAL

BROMOCRIPTINE MESYLATEAB ! MYLAN EQ 5MG BASEA077226 001 Apr 04, 2005AB ZYDUS PHARMS USA EQ 5MG BASEA078899 001 Jul 30, 2008

INC

PRESCRIPTION DRUG PRODUCT LIST

3-64 (of 474)

BROMOCRIPTINE MESYLATE

CAPSULE; ORAL

PARLODEL

AB	+	VALIDUS PHARMS	<u>EQ 5MG BASE</u>	<u>N017962</u>	<u>002</u>	Mar 01, 1982

TABLET; ORAL

BROMOCRIPTINE MESYLATE

AB	!	PADAGIS US	<u>EQ 2.5MG BASE</u>	<u>A077646</u>	<u>001</u>	Oct 01, 2008
AB		SANDOZ INC	<u>EQ 2.5MG BASE</u>	<u>A074631</u>	<u>001</u>	Jan 13, 1998

PARLODEL

AB	+	VALIDUS PHARMS	<u>EQ 2.5MG BASE</u>	<u>N017962</u>	<u>001</u>	

CYCLOSET

	+	VEROSCIENCE	EQ 0.8MG BASE	N020866	001	May 05, 2009

BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SYRUP; ORAL

BROMFED-DM

AA	!	WOCKHARDT BIO AG	<u>2MG/5ML; 10MG/5ML; 30MG/5ML</u>	<u>A088811</u>	<u>001</u>	Jun 07, 1985

BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE

AA		ACELLA	<u>2MG/5ML; 10MG/5ML; 30MG/5ML</u>	<u>A203375</u>	<u>001</u>	Sep 20, 2016
AA		ALKEM LABS LTD	<u>2MG/5ML; 10MG/5ML; 30MG/5ML</u>	<u>A210647</u>	<u>001</u>	Jul 14, 2020
AA		BRECKENRIDGE	<u>2MG/5ML; 10MG/5ML; 30MG/5ML</u>	<u>A203997</u>	<u>001</u>	Sep 30, 2020
AA		CHARTWELL MOLECULAR	<u>2MG/5ML; 10MG/5ML; 30MG/5ML</u>	<u>A213125</u>	<u>001</u>	Apr 17, 2020
AA		EYWA	<u>2MG/5ML; 10MG/5ML; 30MG/5ML</u>	<u>A211170</u>	<u>001</u>	Jun 16, 2020
AA		MAYNE PHARMA INC	<u>2MG/5ML; 10MG/5ML; 30MG/5ML</u>	<u>A207676</u>	<u>001</u>	Dec 04, 2018
AA		PADAGIS US	<u>2MG/5ML; 10MG/5ML; 30MG/5ML</u>	<u>A205292</u>	<u>001</u>	Jul 15, 2014
AA		PHARM ASSOC	<u>2MG/5ML; 10MG/5ML; 30MG/5ML</u>	<u>A202940</u>	<u>001</u>	Jul 21, 2014
AA		TARO	<u>2MG/5ML; 10MG/5ML; 30MG/5ML</u>	<u>A205112</u>	<u>001</u>	Feb 27, 2017

BUDESONIDE

AEROSOL, FOAM; RECTAL

UCERIS

	+	SALIX	2MG/ACTUATION	N205613	001	Oct 07, 2014

CAPSULE, DELAYED RELEASE; ORAL

BUDESONIDE

AB		AMNEAL PHARMS	<u>3MG</u>	<u>A206200</u>	<u>001</u>	Jul 31, 2017
AB		AUROBINDO PHARMA USA	<u>3MG</u>	<u>A090410</u>	<u>001</u>	May 16, 2011
AB		MAYNE PHARMA	<u>3MG</u>	<u>A206623</u>	<u>001</u>	Apr 08, 2016
AB		RISING	<u>3MG</u>	<u>A207367</u>	<u>001</u>	Apr 07, 2017
AB		ZYDUS PHARMS	<u>3MG</u>	<u>A206134</u>	<u>001</u>	May 04, 2017

ENTOCORT EC

AB	+	PADAGIS US	<u>3MG</u>	<u>N021324</u>	<u>001</u>	Oct 02, 2001

ORTIKOS

	+	SUN PHARM INDS INC	6MG	N211929	001	Jun 13, 2019
	+		9MG	N211929	002	Jun 13, 2019

TARPEYO

	+	CALLIDITAS	4MG	N215935	001	Dec 15, 2021

POWDER, METERED; INHALATION

PULMICORT FLEXHALER

	+	ASTRAZENECA	0.08MG/INH	N021949	001	Jul 12, 2006

	+		0.16MG/INH	N021949	002	Jul 12, 2006

SUSPENSION; INHALATION

BUDESONIDE

AN		CIPLA	<u>0.25MG/2ML</u>	<u>A205710</u>	<u>001</u>	Nov 16, 2017
AN			<u>0.5MG/2ML</u>	<u>A205710</u>	<u>002</u>	Nov 16, 2017
AN			<u>1MG/2ML</u>	<u>A205710</u>	<u>003</u>	Nov 16, 2017
AN		IMPAX LABS INC	<u>0.25MG/2ML</u>	<u>A078404</u>	<u>001</u>	Jul 31, 2012
AN			<u>0.5MG/2ML</u>	<u>A078404</u>	<u>002</u>	Jul 31, 2012
AN		LUPIN	<u>0.5MG/2ML</u>	<u>A210897</u>	<u>001</u>	Nov 09, 2018
AN		NEPHRON	<u>0.25MG/2ML</u>	<u>A078202</u>	<u>001</u>	Mar 30, 2009
AN			<u>0.5MG/2ML</u>	<u>A078202</u>	<u>002</u>	Mar 30, 2009
AN		SANDOZ INC	<u>0.25MG/2ML</u>	<u>A201966</u>	<u>003</u>	Sep 27, 2013
AN			<u>0.5MG/2ML</u>	<u>A201966</u>	<u>002</u>	Sep 27, 2013
AN			<u>1MG/2ML</u>	<u>A201966</u>	<u>001</u>	Sep 27, 2013
AN		SUN PHARM	<u>0.25MG/2ML</u>	<u>A211922</u>	<u>001</u>	Apr 14, 2021
AN			<u>0.5MG/2ML</u>	<u>A211922</u>	<u>002</u>	Apr 14, 2021
AN			<u>1MG/2ML</u>	<u>A211922</u>	<u>003</u>	Apr 14, 2021
AN		TEVA PHARMS	<u>0.25MG/2ML</u>	<u>A077519</u>	<u>001</u>	Nov 18, 2008
AN			<u>0.5MG/2ML</u>	<u>A077519</u>	<u>002</u>	Nov 18, 2008
AN		TEVA PHARMS USA	<u>1MG/2ML</u>	<u>A204548</u>	<u>001</u>	Mar 08, 2016

PULMICORT RESPULES

AN	+	ASTRAZENECA	<u>0.25MG/2ML</u>	<u>N020929</u>	<u>001</u>	Aug 08, 2000
AN	+		<u>0.5MG/2ML</u>	<u>N020929</u>	<u>002</u>	Aug 08, 2000
AN	+		<u>1MG/2ML</u>	<u>N020929</u>	<u>003</u>	Aug 08, 2000

PRESCRIPTION DRUG PRODUCT LIST

3-65 (of 474)

BUDESONIDE

TABLET, EXTENDED RELEASE; ORAL

BUDESONIDE

AB	ACTAVIS LABS FL INC	9MG	A205457 001	Jul 03, 2018
AB	MYLAN	9MG	A208851 001	Sep 17, 2020

UCERIS

AB	+! SALIX	9MG	N203634 001	Jan 14, 2013

BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE

AEROSOL, METERED; INHALATION

BREYNA

AB	MYLAN	0.08MG/INH; 0.0045MG/INH	A211699 001	Mar 15, 2022
AB		0.16MG/INH; 0.0045MG/INH	A211699 002	Mar 15, 2022

SYMBICORT

AB	+! ASTRAZENECA	0.08MG/INH; 0.0045MG/INH	N021929 001	Jul 21, 2006
AB	+!	0.16MG/INH; 0.0045MG/INH	N021929 002	Jul 21, 2006

BUDESONIDE; FORMOTEROL FUMARATE; GLYCOPYRROLATE

AEROSOL, METERED; INHALATION

BREZTRI AEROSPHERE

+!	ASTRAZENECA AB	0.16MG/INH; 0.0048MG/INH; 0.009MG/INH	N212122 001	Jul 23, 2020

BUMETANIDE

INJECTABLE; INJECTION

BUMETANIDE

AP	ATHENEX INC	0.25MG/ML	A074441 001	Jan 27, 1995
AP	GLAND PHARMA LTD	0.25MG/ML	A216434 001	May 26, 2022
AP	HOSPIRA	0.25MG/ML	A074332 001	Oct 31, 1994
AP	MSN	0.25MG/ML	A215364 001	Aug 04, 2022
AP	! WEST-WARD PHARMS	0.25MG/ML	A079196 001	Apr 30, 2008

INT

TABLET; ORAL

BUMETANIDE

AB	AMNEAL PHARMS CO	0.5MG	A209724 001	Oct 18, 2017
AB		1MG	A209724 002	Oct 18, 2017
AB		2MG	A209724 003	Oct 18, 2017
AB	HERITAGE PHARMA	0.5MG	A074225 001	Apr 24, 1995
AB		1MG	A074225 002	Apr 24, 1995
AB		2MG	A074225 003	Apr 24, 1995
AB	SANDOZ	0.5MG	A074700 001	Nov 21, 1996
AB		1MG	A074700 002	Nov 21, 1996
AB	!	2MG	A074700 003	Nov 21, 1996
AB	UPSHER SMITH LABS	0.5MG	A209916 001	Jan 23, 2018
AB		1MG	A209916 002	Jan 23, 2018
AB		2MG	A209916 003	Jan 23, 2018
AB	ZYDUS PHARMS	0.5MG	A202900 001	Apr 30, 2018
AB		1MG	A202900 002	Apr 30, 2018
AB		2MG	A202900 003	Apr 30, 2018

BUMEX

AB	+ VALIDUS PHARMS	0.5MG	N018225 002	Feb 28, 1983
AB	+	1MG	N018225 001	Feb 28, 1983
AB	+	2MG	N018225 003	Jun 14, 1985

BUMETANIDE

BX	RISING	0.5MG	A212019 001	Dec 12, 2019
BX		1MG	A212019 002	Dec 12, 2019
BX		2MG	A212019 003	Dec 12, 2019

BUPIVACAINE

INJECTABLE, LIPOSOMAL; INJECTION

EXPAREL

+!	PACIRA PHARMS INC	133MG/10ML (13.3MG/ML)	N022496 001	Oct 28, 2011
+!		266MG/20ML (13.3MG/ML)	N022496 002	Oct 28, 2011

SOLUTION, EXTENDED RELEASE; INFILTRATION

POSIMIR

+!	INNOCOLL	660MG/5ML (132MG/ML)	N204803 001	Feb 01, 2021

BUPIVACAINE HYDROCHLORIDE

IMPLANT; IMPLANTATION

XARACOLL

+!	INNOCOLL PHARMS	100MG	N209511 001	Aug 28, 2020

INJECTABLE; INJECTION

BUPIVACAINE HYDROCHLORIDE

AP	EUGIA PHARMA	0.25%	A207183 001	May 13, 2016
AP		0.5%	A207183 002	May 13, 2016
AP	HIKMA PHARMS	0.25%	A205141 001	Feb 11, 2021

PRESCRIPTION DRUG PRODUCT LIST

3-66 (of 474)

BUPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

BUPIVACAINE HYDROCHLORIDE

AP		0.5%	<u>A205141</u>	<u>002</u>	Feb 11, 2021
AP	HOSPIRA	0.25%	<u>A070583</u>	<u>001</u>	Feb 17, 1987
AP		0.25%	<u>A070590</u>	<u>001</u>	Feb 17, 1987
AP		0.5%	<u>A070584</u>	<u>001</u>	Feb 17, 1986
AP		0.5%	<u>A070597</u>	<u>001</u>	Mar 03, 1987
AP		0.5%	<u>A070609</u>	<u>001</u>	Mar 03, 1987
AP		0.75%	<u>A070585</u>	<u>001</u>	Mar 03, 1987

BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE

AP	EUGIA PHARMA	0.25%	<u>A203895</u>	<u>001</u>	Nov 05, 2013
AP		0.5%	<u>A203895</u>	<u>002</u>	Nov 05, 2013
AP		0.75%	<u>A203895</u>	<u>003</u>	Nov 05, 2013
AP	HIKMA PHARMS	0.25%	<u>A204842</u>	<u>001</u>	Feb 11, 2021
AP		0.5%	<u>A204842</u>	<u>002</u>	Feb 11, 2021
AP		0.75%	<u>A204842</u>	<u>003</u>	Feb 11, 2021

MARCAINE HYDROCHLORIDE

AP	+!	HOSPIRA	0.25%	<u>N016964</u>	<u>001</u>
AP	+!		0.5%	<u>N016964</u>	<u>006</u>

MARCAINE HYDROCHLORIDE PRESERVATIVE FREE

AP	+!	HOSPIRA	0.25%	<u>N016964</u>	<u>012</u>
AP	+!		0.5%	<u>N016964</u>	<u>005</u>
AP	+!		0.75%	<u>N016964</u>	<u>009</u>

SENSORCAINE

AP		FRESENIUS KABI USA	0.25%	<u>A070552</u>	<u>001</u>	May 21, 1986
AP	+		0.25%	<u>N018304</u>	<u>001</u>	
AP			0.5%	<u>A070553</u>	<u>001</u>	May 21, 1986
AP	+		0.5%	<u>N018304</u>	<u>002</u>	
AP			0.75%	<u>A070554</u>	<u>001</u>	May 21, 1986
AP	+		0.75%	<u>N018304</u>	<u>003</u>	

INJECTABLE; SPINAL

BUPIVACAINE HYDROCHLORIDE

AP		B BRAUN MEDICAL INC	0.75%	<u>A209087</u>	<u>001</u>	Apr 02, 2019
AP		BAXTER HLTHCARE	0.75%	<u>A207266</u>	<u>001</u>	Jul 25, 2016
		CORP				
AP		HOSPIRA	0.75%	<u>A071810</u>	<u>001</u>	Dec 11, 1987
AP		HUONS	0.75%	<u>A212822</u>	<u>001</u>	Dec 30, 2019

MARCAINE

AP	+!	HOSPIRA	0.75%	<u>N018692</u>	<u>001</u>	May 04, 1984

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE

INJECTABLE; INJECTION

BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE

AP	!	HOSPIRA	0.5%; 0.005MG/ML	<u>A071168</u>	<u>001</u>	Jun 16, 1988
AP			0.5%; 0.005MG/ML	<u>A071170</u>	<u>001</u>	Jun 16, 1988
	!		0.25%; 0.005MG/ML	A071165	001	Jun 16, 1988
			0.25%; 0.005MG/ML	A071167	001	Jun 16, 1988

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

MARCAINE HYDROCHLORIDE W/ EPINEPHRINE

AP	+!	HOSPIRA	0.25%; 0.0091MG/ML	<u>N016964</u>	<u>004</u>
AP	+!		0.5%; 0.0091MG/ML	<u>N016964</u>	<u>008</u>

MARCAINE HYDROCHLORIDE W/ EPINEPHRINE PRESERVATIVE FREE

AP	+!	HOSPIRA	0.25%; 0.0091MG/ML	<u>N016964</u>	<u>013</u>
AP	+!		0.5%; 0.0091MG/ML	<u>N016964</u>	<u>007</u>
AP	+!		0.75%; 0.0091MG/ML	<u>N016964</u>	<u>010</u>

SENSORCAINE

AP		FRESENIUS KABI USA	0.25%; 0.0091MG/ML	<u>A070966</u>	<u>001</u>	Oct 13, 1987
AP			0.25%; 0.0091MG/ML	<u>A070967</u>	<u>001</u>	Oct 13, 1987
AP			0.5%; 0.0091MG/ML	<u>A070968</u>	<u>001</u>	Oct 13, 1987
AP	+		0.5%; 0.0091MG/ML	<u>N018304</u>	<u>004</u>	Sep 02, 1983
AP	+		0.75%; 0.0091MG/ML	<u>N018304</u>	<u>005</u>	Sep 02, 1983

BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE

	!	SEPTODONT	0.5%; 0.0091MG/ML	A077250	001	Sep 27, 2006

BUPIVACAINE; MELOXICAM

SOLUTION, EXTENDED RELEASE; PERIARTICULAR

ZYNRELEF KIT

	+!	HERON THERAPS INC	200MG/7ML (29.25MG/ML); 6MG/7ML (0.88MG/ML)	N211988	002	May 12, 2021
	+!		400MG/14ML (29.25MG/ML); 12MG/14ML (0.88MG/ML)	N211988	004	May 12, 2021

PRESCRIPTION DRUG PRODUCT LIST

3-67 (of 474)

BUPRENORPHINE

FILM, EXTENDED RELEASE; TRANSDERMAL

BUPRENORPHINE

<u>AB</u>	ALVOGEN	<u>5MCG/HR</u>	<u>A207490</u>	<u>001</u>	May 17, 2022
<u>AB</u>		<u>10MCG/HR</u>	<u>A207490</u>	<u>002</u>	May 17, 2022
<u>AB</u>		<u>15MCG/HR</u>	<u>A207490</u>	<u>003</u>	May 17, 2022
<u>AB</u>		<u>20MCG/HR</u>	<u>A207490</u>	<u>004</u>	May 17, 2022
<u>AB</u>	AMNEAL	<u>5MCG/HR</u>	<u>A211586</u>	<u>001</u>	Apr 14, 2020
<u>AB</u>		<u>7.5MCG/HR</u>	<u>A211586</u>	<u>002</u>	Apr 14, 2020
<u>AB</u>		<u>10MCG/HR</u>	<u>A211586</u>	<u>003</u>	Apr 14, 2020
<u>AB</u>		<u>15MCG/HR</u>	<u>A211586</u>	<u>004</u>	Apr 14, 2020
<u>AB</u>		<u>20MCG/HR</u>	<u>A211586</u>	<u>005</u>	Apr 14, 2020
<u>AB</u>	AVEVA	<u>5MCG/HR</u>	<u>A210272</u>	<u>001</u>	Sep 23, 2021
<u>AB</u>		<u>7.5MCG/HR</u>	<u>A210272</u>	<u>002</u>	Sep 23, 2021
<u>AB</u>		<u>10MCG/HR</u>	<u>A210272</u>	<u>003</u>	Sep 23, 2021
<u>AB</u>		<u>15MCG/HR</u>	<u>A210272</u>	<u>004</u>	Sep 23, 2021
<u>AB</u>		<u>20MCG/HR</u>	<u>A210272</u>	<u>005</u>	Sep 23, 2021
<u>AB</u>	WATSON LABS TEVA	<u>5MCG/HR</u>	<u>A204937</u>	<u>001</u>	Nov 20, 2018
<u>AB</u>		<u>7.5MCG/HR</u>	<u>A204937</u>	<u>005</u>	Jun 29, 2021
<u>AB</u>		<u>10MCG/HR</u>	<u>A204937</u>	<u>002</u>	Nov 20, 2018
<u>AB</u>		<u>15MCG/HR</u>	<u>A204937</u>	<u>003</u>	Nov 20, 2018
<u>AB</u>		<u>20MCG/HR</u>	<u>A204937</u>	<u>004</u>	Nov 20, 2018

BUTRANS

<u>AB</u>	+	PURDUE PHARMA LP	<u>5MCG/HR</u>	<u>N021306</u>	<u>001</u>	Jun 30, 2010
<u>AB</u>	+		<u>7.5MCG/HR</u>	<u>N021306</u>	<u>005</u>	Jun 30, 2014
<u>AB</u>	+		<u>10MCG/HR</u>	<u>N021306</u>	<u>002</u>	Jun 30, 2010
<u>AB</u>	+		<u>15MCG/HR</u>	<u>N021306</u>	<u>004</u>	Jul 25, 2013
<u>AB</u>	+		<u>20MCG/HR</u>	<u>N021306</u>	<u>003</u>	Jun 30, 2010

SOLUTION, EXTENDED RELEASE; SUBCUTANEOUS

SUBLOCADE

+	INDIVIOR INC	100MG/0.5ML (100MG/0.5ML)	N209819	001	Nov 30, 2017
+	!	300MG/1.5ML (200MG/ML)	N209819	002	Nov 30, 2017

BUPRENORPHINE HYDROCHLORIDE

FILM; BUCCAL

BELBUCA

+	BDSI	EQ 0.075MG BASE	N207932	001	Oct 23, 2015
+		EQ 0.15MG BASE	N207932	002	Oct 23, 2015
+		EQ 0.3MG BASE	N207932	003	Oct 23, 2015
+		EQ 0.45MG BASE	N207932	004	Oct 23, 2015
+		EQ 0.6MG BASE	N207932	005	Oct 23, 2015
+		EQ 0.75MG BASE	N207932	006	Oct 23, 2015
+	!	EQ 0.9MG BASE	N207932	007	Oct 23, 2015

INJECTABLE; INJECTION

BUPRENEX

<u>AP</u>	+	INDIVIOR INC	<u>EQ 0.3MG BASE/ML</u>	<u>N018401</u>	<u>001</u>	

BUPRENORPHINE HYDROCHLORIDE

<u>AP</u>	AM REGENT	<u>EQ 0.3MG BASE/ML</u>	<u>A078331</u>	<u>001</u>	Mar 27, 2007
<u>AP</u>	HIKMA	<u>EQ 0.3MG BASE/ML</u>	<u>A076931</u>	<u>001</u>	Mar 02, 2005
<u>AP</u>	HOSPIRA	<u>EQ 0.3MG BASE/ML</u>	<u>A074137</u>	<u>001</u>	Jun 03, 1996
<u>AP</u>	PAR STERILE PRODUCTS	<u>EQ 0.3MG BASE/ML</u>	<u>A206586</u>	<u>001</u>	Jul 28, 2015

TABLET; SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE

<u>AB</u>	ACTAVIS ELIZABETH	<u>EQ 2MG BASE</u>	<u>A090819</u>	<u>001</u>	Feb 19, 2015
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A090819</u>	<u>002</u>	Feb 19, 2015
<u>AB</u>	ETHYPHARM	<u>EQ 2MG BASE</u>	<u>A090622</u>	<u>001</u>	Sep 24, 2010
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A090622</u>	<u>002</u>	Sep 24, 2010
<u>AB</u>	HIKMA	<u>EQ 2MG BASE</u>	<u>A078633</u>	<u>001</u>	Oct 08, 2009
<u>AB</u>	!	<u>EQ 8MG BASE</u>	<u>A078633</u>	<u>002</u>	Oct 08, 2009
<u>AB</u>	RHODES PHARMS	<u>EQ 2MG BASE</u>	<u>A207276</u>	<u>001</u>	Mar 27, 2017
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A207276</u>	<u>002</u>	Mar 27, 2017
<u>AB</u>	RUBICON	<u>EQ 2MG BASE</u>	<u>A090279</u>	<u>001</u>	Jun 10, 2015
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A090279</u>	<u>002</u>	Jun 10, 2015
<u>AB</u>	SUN PHARM	<u>EQ 2MG BASE</u>	<u>A201760</u>	<u>001</u>	Jan 29, 2016
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A201760</u>	<u>002</u>	Jan 29, 2016

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

FILM; BUCCAL, SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE

<u>AB</u>	ALVOGEN	<u>EQ 2MG BASE; EQ 0.5MG BASE</u>	<u>A205954</u>	<u>001</u>	Jan 24, 2019
<u>AB</u>		<u>EQ 4MG BASE; EQ 1MG BASE</u>	<u>A205954</u>	<u>002</u>	Jan 24, 2019
<u>AB</u>		<u>EQ 8MG BASE; EQ 2MG BASE</u>	<u>A205954</u>	<u>003</u>	Jan 24, 2019
<u>AB</u>		<u>EQ 12MG BASE; EQ 3MG BASE</u>	<u>A205954</u>	<u>004</u>	Jan 24, 2019

PRESCRIPTION DRUG PRODUCT LIST

3-68 (of 474)

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

FILM;BUCCAL, SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE

<u>AB</u>	AVEVA	<u>EQ 8MG BASE;EQ 2MG BASE</u>	<u>A212756 001</u>	Jun 02, 2022
<u>AB</u>		<u>EQ 12MG BASE;EQ 3MG BASE</u>	<u>A212756 002</u>	Jun 02, 2022
<u>AB</u>	DR REDDYS LABS SA	<u>EQ 2MG BASE;EQ 0.5MG BASE</u>	<u>A205299 001</u>	Jun 14, 2018
<u>AB</u>		<u>EQ 4MG BASE;EQ 1MG BASE</u>	<u>A205806 001</u>	Jun 14, 2018
<u>AB</u>		<u>EQ 8MG BASE;EQ 2MG BASE</u>	<u>A205299 002</u>	Jun 14, 2018
<u>AB</u>		<u>EQ 12MG BASE;EQ 3MG BASE</u>	<u>A205806 002</u>	Jun 14, 2018
<u>AB</u>	MYLAN TECHNOLOGIES	<u>EQ 2MG BASE;EQ 0.5MG BASE</u>	<u>A211785 001</u>	Apr 17, 2020
<u>AB</u>		<u>EQ 4MG BASE;EQ 1MG BASE</u>	<u>A211785 002</u>	Apr 17, 2020
<u>AB</u>		<u>EQ 8MG BASE;EQ 2MG BASE</u>	<u>A207607 001</u>	Jun 14, 2018
<u>AB</u>		<u>EQ 12MG BASE;EQ 3MG BASE</u>	<u>A207607 002</u>	Jun 14, 2018
<u>SUBOXONE</u>				
<u>AB</u>	+ INDIVIOR INC	<u>EQ 2MG BASE;EQ 0.5MG BASE</u>	<u>N022410 001</u>	Aug 30, 2010
<u>AB</u>	+	<u>EQ 4MG BASE;EQ 1MG BASE</u>	<u>N022410 003</u>	Aug 10, 2012
<u>AB</u>	+	<u>EQ 8MG BASE;EQ 2MG BASE</u>	<u>N022410 002</u>	Aug 30, 2010
<u>AB</u>	+	<u>EQ 12MG BASE;EQ 3MG BASE</u>	<u>N022410 004</u>	Aug 10, 2012

TABLET;SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE

<u>AB</u>	ACTAVIS ELIZABETH	<u>EQ 2MG BASE;EQ 0.5MG BASE</u>	<u>A091422 001</u>	Feb 22, 2013
<u>AB</u>		<u>EQ 8MG BASE;EQ 2MG BASE</u>	<u>A091422 002</u>	Feb 22, 2013
<u>AB</u>	ALKEM LABS LTD	<u>EQ 2MG BASE;EQ 0.5MG BASE</u>	<u>A214930 001</u>	Jun 15, 2021
<u>AB</u>		<u>EQ 8MG BASE;EQ 2MG BASE</u>	<u>A214930 002</u>	Jun 15, 2021
<u>AB</u>	AMNEAL PHARMS	<u>EQ 2MG BASE;EQ 0.5MG BASE</u>	<u>A203136 001</u>	Feb 22, 2013
<u>AB</u>		<u>EQ 8MG BASE;EQ 2MG BASE</u>	<u>A203136 002</u>	Feb 22, 2013
<u>AB</u>	ETHYPHARM USA CORP	<u>EQ 2MG BASE;EQ 0.5MG BASE</u>	<u>A204431 001</u>	Oct 16, 2015
<u>AB</u>		<u>EQ 8MG BASE;EQ 2MG BASE</u>	<u>A204431 002</u>	Oct 16, 2015
<u>AB</u>	HIKMA	<u>EQ 2MG BASE;EQ 0.5MG BASE</u>	<u>A203326 001</u>	Jun 27, 2014
<u>AB</u>	!	<u>EQ 8MG BASE;EQ 2MG BASE</u>	<u>A203326 002</u>	Jun 27, 2014
<u>AB</u>	LANNETT CO INC	<u>EQ 2MG BASE;EQ 0.5MG BASE</u>	<u>A205022 001</u>	Sep 19, 2016
<u>AB</u>		<u>EQ 8MG BASE;EQ 2MG BASE</u>	<u>A205022 002</u>	Sep 19, 2016
<u>AB</u>	RHODES PHARMS	<u>EQ 2MG BASE;EQ 0.5MG BASE</u>	<u>A205601 001</u>	Mar 30, 2020
<u>AB</u>		<u>EQ 8MG BASE;EQ 2MG BASE</u>	<u>A205601 002</u>	Mar 30, 2020
<u>AB</u>	SPECGX LLC	<u>EQ 2MG BASE;EQ 0.5MG BASE</u>	<u>A207000 001</u>	Dec 13, 2017
<u>AB</u>		<u>EQ 8MG BASE;EQ 2MG BASE</u>	<u>A207000 002</u>	Dec 13, 2017
<u>AB</u>	SUN PHARM	<u>EQ 2MG BASE;EQ 0.5MG BASE</u>	<u>A201633 001</u>	Aug 05, 2016
<u>AB</u>		<u>EQ 8MG BASE;EQ 2MG BASE</u>	<u>A201633 002</u>	Aug 05, 2016
<u>AB</u>	WES PHARMA INC	<u>EQ 2MG BASE;EQ 0.5MG BASE</u>	<u>A209069 001</u>	Jul 17, 2020
<u>AB</u>		<u>EQ 8MG BASE;EQ 2MG BASE</u>	<u>A209069 002</u>	Jul 17, 2020
<u>ZUBSOLV</u>				
	+ OREXO US INC	EQ 0.7MG BASE;EQ 0.18MG BASE	N204242 006	Oct 04, 2016
	+	EQ 1.4MG BASE;EQ 0.36MG BASE	N204242 001	Jul 03, 2013
	+	EQ 2.9MG BASE;EQ 0.71MG BASE	N204242 005	Jun 04, 2015
	+	EQ 5.7MG BASE;EQ 1.4MG BASE	N204242 002	Jul 03, 2013
	+	EQ 8.6MG BASE;EQ 2.1MG BASE	N204242 003	Dec 11, 2014
	+	EQ 11.4MG BASE;EQ 2.9MG BASE	N204242 004	Dec 11, 2014

BUPROPION HYDROBROMIDE

TABLET, EXTENDED RELEASE;ORAL

APLENZIN

+	BAUSCH	174MG	N022108 001	Apr 23, 2008
+		348MG	N022108 002	Apr 23, 2008
+	!	522MG	N022108 003	Apr 23, 2008

BUPROPION HYDROCHLORIDE

TABLET;ORAL

BUPROPION HYDROCHLORIDE

<u>AB</u>	ALEMBIC PHARMS	<u>75MG</u>	<u>A203013 001</u>	Jun 08, 2018
<u>AB</u>		<u>100MG</u>	<u>A203013 002</u>	Jun 08, 2018
<u>AB</u>	APNAR PHARMA LP	<u>75MG</u>	<u>A075584 001</u>	Feb 07, 2000
<u>AB</u>		<u>100MG</u>	<u>A075584 002</u>	Feb 07, 2000
<u>AB</u>	APOTEX INC	<u>75MG</u>	<u>A076143 001</u>	Jan 17, 2006
<u>AB</u>	!	<u>100MG</u>	<u>A076143 002</u>	Jan 17, 2006
<u>AB</u>	CADILA PHARMS LTD	<u>75MG</u>	<u>A208606 001</u>	Jan 16, 2020
<u>AB</u>		<u>100MG</u>	<u>A208606 002</u>	Jan 16, 2020
<u>AB</u>	HERITAGE PHARMA	<u>75MG</u>	<u>A206975 001</u>	Aug 19, 2016
<u>AB</u>		<u>100MG</u>	<u>A206975 002</u>	Aug 19, 2016
<u>AB</u>	INVAGEN PHARMS	<u>75MG</u>	<u>A207389 001</u>	Sep 18, 2017
<u>AB</u>		<u>100MG</u>	<u>A207389 002</u>	Sep 18, 2017
<u>AB</u>	MICRO LABS	<u>75MG</u>	<u>A207403 001</u>	Apr 17, 2020
<u>AB</u>		<u>100MG</u>	<u>A207403 002</u>	Apr 17, 2020

PRESCRIPTION DRUG PRODUCT LIST

3-69 (of 474)

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

BUPROPION HYDROCHLORIDE

<u>AB1</u>	ACTAVIS LABS FL INC	<u>100MG</u>	<u>A079095</u>	<u>001</u>	Mar 24, 2009
<u>AB1</u>		<u>150MG</u>	<u>A079095</u>	<u>002</u>	Mar 24, 2009
<u>AB1</u>		<u>200MG</u>	<u>A079095</u>	<u>003</u>	Mar 24, 2009
<u>AB1</u>	ANCHEN PHARMS	<u>100MG</u>	<u>A091459</u>	<u>001</u>	Jun 09, 2011
<u>AB1</u>		<u>150MG</u>	<u>A091459</u>	<u>002</u>	Jun 09, 2011
<u>AB1</u>		<u>200MG</u>	<u>A091459</u>	<u>003</u>	Jun 09, 2011
<u>AB1</u>	EPIC PHARMA	<u>100MG</u>	<u>A075932</u>	<u>001</u>	Nov 25, 2003
<u>AB1</u>		<u>150MG</u>	<u>A075932</u>	<u>002</u>	Mar 22, 2004
<u>AB1</u>		<u>200MG</u>	<u>A075932</u>	<u>003</u>	Jun 22, 2005
<u>AB1</u>	IMPAX LABS	<u>100MG</u>	<u>A075913</u>	<u>001</u>	Jan 28, 2004
<u>AB1</u>		<u>150MG</u>	<u>A075913</u>	<u>002</u>	Mar 22, 2004
<u>AB1</u>	INVAGEN PHARMS	<u>100MG</u>	<u>A206674</u>	<u>001</u>	Feb 09, 2016
<u>AB1</u>		<u>150MG</u>	<u>A206674</u>	<u>002</u>	Feb 09, 2016
<u>AB1</u>		<u>200MG</u>	<u>A206674</u>	<u>003</u>	Feb 09, 2016
<u>AB1</u>	PRINSTON INC	<u>100MG</u>	<u>A202304</u>	<u>001</u>	May 26, 2015
<u>AB1</u>		<u>150MG</u>	<u>A202304</u>	<u>002</u>	May 26, 2015
<u>AB1</u>		<u>200MG</u>	<u>A202304</u>	<u>003</u>	May 26, 2015
<u>AB1</u>	SCIEGEN PHARMS INC	<u>100MG</u>	<u>A205794</u>	<u>001</u>	Mar 01, 2016
<u>AB1</u>		<u>150MG</u>	<u>A205794</u>	<u>002</u>	Mar 01, 2016
<u>AB1</u>		<u>200MG</u>	<u>A205794</u>	<u>003</u>	Mar 01, 2016
<u>AB1</u>	SUN PHARM	<u>100MG</u>	<u>A078866</u>	<u>001</u>	Apr 06, 2010
<u>AB1</u>		<u>150MG</u>	<u>A078866</u>	<u>002</u>	Apr 06, 2010
<u>AB1</u>		<u>200MG</u>	<u>A078866</u>	<u>003</u>	Apr 06, 2010
<u>AB1</u>	YICHANG HUMANWELL	<u>100MG</u>	<u>A211347</u>	<u>001</u>	Oct 16, 2018
<u>AB1</u>		<u>150MG</u>	<u>A211347</u>	<u>002</u>	Oct 16, 2018
<u>AB1</u>		<u>200MG</u>	<u>A211347</u>	<u>003</u>	Oct 16, 2018

WELLBUTRIN SR

<u>AB1</u>	+	GLAXOSMITHKLINE	<u>100MG</u>	<u>N020358</u>	<u>002</u>	Oct 04, 1996
<u>AB1</u>	+		<u>150MG</u>	<u>N020358</u>	<u>003</u>	Oct 04, 1996
<u>AB1</u>	+	!	<u>200MG</u>	<u>N020358</u>	<u>004</u>	Jun 14, 2002

BUPROPION HYDROCHLORIDE

<u>AB2</u>	!	ACTAVIS LABS FL INC	<u>150MG</u>	<u>A079094</u>	<u>001</u>	Mar 24, 2009
<u>AB2</u>		ANCHEN PHARMS	<u>150MG</u>	<u>A091520</u>	<u>001</u>	Jun 09, 2011
<u>AB2</u>		IMPAX LABS	<u>150MG</u>	<u>A075914</u>	<u>001</u>	May 27, 2004
<u>AB2</u>		SANDOZ INC	<u>150MG</u>	<u>A077475</u>	<u>001</u>	Mar 12, 2008
<u>AB2</u>		SCIEGEN PHARMS INC	<u>150MG</u>	<u>A206122</u>	<u>001</u>	Aug 17, 2016
<u>AB2</u>		YICHANG HUMANWELL	<u>150MG</u>	<u>A216766</u>	<u>001</u>	Jan 09, 2023
<u>AB3</u>		ACCORD HLTHCARE	<u>150MG</u>	<u>A210497</u>	<u>001</u>	Oct 31, 2018
<u>AB3</u>			<u>300MG</u>	<u>A210497</u>	<u>002</u>	Oct 31, 2018
<u>AB3</u>		ACTAVIS LABS FL INC	<u>150MG</u>	<u>A077715</u>	<u>001</u>	Nov 26, 2008
<u>AB3</u>		ANBISON LAB	<u>150MG</u>	<u>A207224</u>	<u>001</u>	Jun 30, 2017
<u>AB3</u>			<u>300MG</u>	<u>A207224</u>	<u>002</u>	Jun 30, 2017
<u>AB3</u>		ANCHEN PHARMS	<u>150MG</u>	<u>A077284</u>	<u>001</u>	Dec 14, 2006
<u>AB3</u>			<u>300MG</u>	<u>A077284</u>	<u>002</u>	Dec 14, 2006
<u>AB3</u>		GRANULES	<u>150MG</u>	<u>A215568</u>	<u>001</u>	Feb 02, 2022
<u>AB3</u>			<u>300MG</u>	<u>A215568</u>	<u>002</u>	Feb 02, 2022
<u>AB3</u>		GRAVITI PHARMS	<u>150MG</u>	<u>A211020</u>	<u>001</u>	Jan 28, 2019
<u>AB3</u>			<u>300MG</u>	<u>A211020</u>	<u>002</u>	Jan 28, 2019
<u>AB3</u>		INVAGEN PHARMS	<u>150MG</u>	<u>A206556</u>	<u>001</u>	Aug 26, 2016
<u>AB3</u>			<u>300MG</u>	<u>A206556</u>	<u>002</u>	Aug 26, 2016
<u>AB3</u>		LUPIN LTD	<u>150MG</u>	<u>A090693</u>	<u>001</u>	Apr 06, 2017
<u>AB3</u>			<u>300MG</u>	<u>A090693</u>	<u>002</u>	Apr 06, 2017
<u>AB3</u>		SCIEGEN PHARMS INC	<u>150MG</u>	<u>A207479</u>	<u>001</u>	Apr 12, 2017
<u>AB3</u>			<u>300MG</u>	<u>A207479</u>	<u>002</u>	Apr 12, 2017
<u>AB3</u>		SINOTHERAPEUTICS INC	<u>150MG</u>	<u>A208652</u>	<u>001</u>	Aug 21, 2017
<u>AB3</u>			<u>300MG</u>	<u>A208652</u>	<u>002</u>	Aug 21, 2017
<u>AB3</u>		SUN PHARM	<u>150MG</u>	<u>A200216</u>	<u>001</u>	Nov 30, 2020
<u>AB3</u>			<u>300MG</u>	<u>A203650</u>	<u>001</u>	Dec 31, 2020
<u>AB3</u>		TWI PHARMS	<u>150MG</u>	<u>A210081</u>	<u>001</u>	Nov 03, 2017
<u>AB3</u>			<u>300MG</u>	<u>A210081</u>	<u>002</u>	Nov 03, 2017
<u>AB3</u>		WATSON LABS INC	<u>150MG</u>	<u>A077285</u>	<u>001</u>	Nov 26, 2008
<u>AB3</u>			<u>300MG</u>	<u>A077285</u>	<u>002</u>	Aug 15, 2008
<u>AB3</u>		WOCKHARDT LTD	<u>150MG</u>	<u>A202189</u>	<u>001</u>	Nov 21, 2012
<u>AB3</u>			<u>300MG</u>	<u>A202189</u>	<u>002</u>	Jan 28, 2022
<u>AB3</u>		YICHANG HUMANWELL	<u>150MG</u>	<u>A210015</u>	<u>001</u>	Jun 14, 2018
<u>AB3</u>			<u>300MG</u>	<u>A210015</u>	<u>002</u>	Jun 14, 2018
<u>AB3</u>		ZHEJIANG JUTAI PHARM	<u>150MG</u>	<u>A211200</u>	<u>002</u>	Apr 29, 2020
<u>AB3</u>			<u>300MG</u>	<u>A211200</u>	<u>001</u>	Sep 05, 2019

PRESCRIPTION DRUG PRODUCT LIST

3-70 (of 474)

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

BUPROPION HYDROCHLORIDE

AB3	ZYDUS PHARMS	150MG	A201567 002	Jul 23, 2018
AB3		300MG	A201567 001	Jan 17, 2014
<u>WELLBUTRIN XL</u>				
AB3	+	BAUSCH	N021515 001	Aug 28, 2003
AB3	+	!	N021515 002	Aug 28, 2003
FORFIVO XL				
	+	ALMATICA	N022497 001	Nov 10, 2011

BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE

TABLET, EXTENDED RELEASE;ORAL

AUVELITY

+	AXSOME	105MG;45MG	N215430 001	Aug 18, 2022

BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

CONTRAVE

+	NALPROPION	90MG;8MG	N200063 001	Sep 10, 2014

BUSPIRONE HYDROCHLORIDE

TABLET;ORAL

BUSPIRONE HYDROCHLORIDE

AB	ACCORD HLTHCARE	5MG	A202557 001	Dec 30, 2014
AB		7.5MG	A202557 002	Dec 30, 2014
AB		10MG	A202557 003	Dec 30, 2014
AB	!	15MG	A202557 004	Dec 30, 2014
AB		30MG	A202557 005	Dec 30, 2014
AB	AMNEAL PHARMS CO	5MG	A208829 001	May 24, 2017
AB		7.5MG	A208829 002	May 24, 2017
AB		10MG	A208829 003	May 24, 2017
AB		15MG	A208829 004	May 24, 2017
AB		30MG	A208829 005	May 24, 2017
AB	AUROBINDO PHARMA LTD	5MG	A078246 001	Feb 27, 2009
AB		7.5MG	A078246 005	Feb 21, 2020
AB		10MG	A078246 002	Feb 27, 2009
AB		15MG	A078246 003	Feb 27, 2009
AB		30MG	A078246 004	Feb 27, 2009
AB	EPIC PHARMA LLC	5MG	A208972 001	Apr 16, 2019
AB		7.5MG	A208972 002	Apr 16, 2019
AB		10MG	A208972 003	Apr 16, 2019
AB		15MG	A208972 004	Apr 16, 2019
AB		30MG	A208972 005	Apr 16, 2019
AB	HERITAGE PHARMA	5MG	A204582 001	Sep 18, 2015
AB		10MG	A204582 002	Sep 18, 2015
AB		15MG	A204582 003	Sep 18, 2015
AB		30MG	A204582 004	Sep 18, 2015
AB	IMPAX LABS INC	5MG	A074253 001	Mar 28, 2001
AB		10MG	A074253 002	Mar 28, 2001
AB		15MG	A074253 003	Mar 13, 2002
AB	INVENTIA HLTHCARE	5MG	A209696 001	May 03, 2018
AB		7.5MG	A209696 002	May 03, 2018
AB		10MG	A209696 003	May 03, 2018
AB		15MG	A209696 004	May 03, 2018
AB		30MG	A209696 005	May 03, 2018
AB	MYLAN	5MG	A076008 003	Mar 01, 2002
AB		7.5MG	A076008 002	Jul 08, 2013
AB		10MG	A076008 004	Mar 01, 2002
AB		15MG	A076008 005	Mar 28, 2001
AB		30MG	A076008 001	Jun 28, 2001
AB	OXFORD PHARMS	5MG	A075388 001	May 09, 2002
AB		10MG	A075388 002	May 09, 2002
AB		15MG	A075388 003	May 09, 2002
AB		30MG	A078302 001	Dec 17, 2007
AB	RUBICON	5MG	A075521 001	Apr 05, 2002
AB		7.5MG	A075521 004	Mar 16, 2021
AB		10MG	A075521 002	Apr 05, 2002
AB		15MG	A075521 003	Apr 05, 2002
AB		30MG	A075521 005	Mar 16, 2021
AB	STRIDES PHARMA	5MG	A202330 001	Aug 25, 2014
AB		7.5MG	A202330 005	Feb 17, 2017
AB		10MG	A202330 002	Aug 25, 2014

PRESCRIPTION DRUG PRODUCT LIST

3-71 (of 474)

BUSPIRONE HYDROCHLORIDE

TABLET; ORAL

BUSPIRONE HYDROCHLORIDE

<u>AB</u>		<u>15MG</u>	<u>A202330</u>	<u>003</u>	Aug 25, 2014
<u>AB</u>		<u>30MG</u>	<u>A202330</u>	<u>004</u>	Aug 25, 2014
<u>AB</u>	TEVA	<u>5MG</u>	<u>A075022</u>	<u>001</u>	Feb 28, 2002
<u>AB</u>		<u>10MG</u>	<u>A075022</u>	<u>002</u>	Feb 28, 2002
<u>AB</u>		<u>15MG</u>	<u>A075022</u>	<u>003</u>	Feb 28, 2002
<u>AB</u>		<u>30MG</u>	<u>A075022</u>	<u>004</u>	Mar 25, 2004
<u>AB</u>	UNICHEM	<u>5MG</u>	<u>A210907</u>	<u>001</u>	Nov 14, 2019
<u>AB</u>		<u>10MG</u>	<u>A210907</u>	<u>002</u>	Nov 14, 2019
<u>AB</u>		<u>15MG</u>	<u>A210907</u>	<u>003</u>	Nov 14, 2019
<u>AB</u>		<u>30MG</u>	<u>A210907</u>	<u>004</u>	Nov 14, 2019
<u>AB</u>	YILING	<u>5MG</u>	<u>A202087</u>	<u>001</u>	Dec 16, 2015
<u>AB</u>		<u>10MG</u>	<u>A202087</u>	<u>002</u>	Dec 16, 2015
<u>AB</u>		<u>15MG</u>	<u>A202087</u>	<u>003</u>	Dec 16, 2015
<u>AB</u>		<u>30MG</u>	<u>A202087</u>	<u>004</u>	Dec 16, 2015
<u>AB</u>	ZYDUS PHARMS	<u>5MG</u>	<u>A078888</u>	<u>001</u>	Feb 07, 2014
<u>AB</u>		<u>10MG</u>	<u>A078888</u>	<u>002</u>	Feb 07, 2014
<u>AB</u>		<u>15MG</u>	<u>A078888</u>	<u>003</u>	Feb 07, 2014
<u>AB</u>		<u>30MG</u>	<u>A078888</u>	<u>004</u>	Feb 07, 2014

BUSULFAN

INJECTABLE; INJECTION

BUSULFAN

<u>AP</u>	ACCORD HLTHCARE INC	<u>6MG/ML</u>	<u>A210148</u>	<u>001</u>	Feb 22, 2019
<u>AP</u>	AM REGENT	<u>6MG/ML</u>	<u>A202259</u>	<u>001</u>	Dec 22, 2015
<u>AP</u>	AMNEAL	<u>6MG/ML</u>	<u>A209580</u>	<u>001</u>	Dec 18, 2017
<u>AP</u>	APOTEX	<u>6MG/ML</u>	<u>A210448</u>	<u>001</u>	May 07, 2019
<u>AP</u>	ARTHUR GRP	<u>6MG/ML</u>	<u>A205106</u>	<u>001</u>	Sep 21, 2018
<u>AP</u>	HOSPIRA	<u>6MG/ML</u>	<u>A205672</u>	<u>001</u>	Jul 31, 2018
<u>AP</u>	MEITHEAL	<u>6MG/ML</u>	<u>A212127</u>	<u>001</u>	Oct 23, 2020
<u>AP</u>	MYLAN INSTITUTIONAL	<u>6MG/ML</u>	<u>A208536</u>	<u>001</u>	Nov 20, 2017
<u>AP</u>	NEXUS PHARMS	<u>6MG/ML</u>	<u>A207794</u>	<u>001</u>	Jan 14, 2019
<u>AP</u>	PHARMASCIENCE INC	<u>6MG/ML</u>	<u>A207050</u>	<u>001</u>	Mar 24, 2017
<u>AP</u>	SHILPA	<u>6MG/ML</u>	<u>A210931</u>	<u>001</u>	Apr 18, 2019

BUSULFEX

<u>AP</u>	+! OTSUKA PHARM	<u>6MG/ML</u>	<u>N020954</u>	<u>001</u>	Feb 04, 1999
TABLET; ORAL					
MYLERAN					
	+! WOODWARD SPECL	2MG	N009386	001	

BUTENAFINE HYDROCHLORIDE

CREAM; TOPICAL

MENTAX

+! MYLAN	1%	N020524	001	Oct 18, 1996

BUTOCONAZOLE NITRATE

CREAM; VAGINAL

GYNAZOLE-1

! PADAGIS ISRAEL	2%	A200923	001	May 18, 2012

BUTORPHANOL TARTRATE

INJECTABLE; INJECTION

BUTORPHANOL TARTRATE

<u>AP</u>	HIKMA	<u>2MG/ML</u>	<u>A075046</u>	<u>001</u>	Aug 12, 1998
<u>AP</u>	HIKMA FARMACEUTICA	<u>1MG/ML</u>	<u>A078400</u>	<u>001</u>	May 01, 2009
<u>AP</u>		<u>2MG/ML</u>	<u>A078400</u>	<u>002</u>	May 01, 2009

BUTORPHANOL TARTRATE PRESERVATIVE FREE

<u>AP</u>	HIKMA	<u>1MG/ML</u>	<u>A075045</u>	<u>001</u>	Aug 12, 1998
<u>AP</u>		<u>2MG/ML</u>	<u>A075045</u>	<u>002</u>	Aug 12, 1998
<u>AP</u>	! HOSPIRA	<u>1MG/ML</u>	<u>A074626</u>	<u>001</u>	Jan 23, 1997
<u>AP</u>	!	<u>2MG/ML</u>	<u>A074626</u>	<u>002</u>	Jan 23, 1997

SPRAY, METERED; NASAL

BUTORPHANOL TARTRATE

<u>AB</u>	APOTEX INC	<u>1MG/SPRAY</u>	<u>A075499</u>	<u>001</u>	Dec 04, 2002
<u>AB</u>	HIKMA	<u>1MG/SPRAY</u>	<u>A075824</u>	<u>001</u>	Mar 12, 2002
<u>AB</u>	! RISING	<u>1MG/SPRAY</u>	<u>A075759</u>	<u>001</u>	Aug 08, 2001

PRESCRIPTION DRUG PRODUCT LIST

3-72 (of 474)

CABAZITAXEL

SOLUTION; INTRAVENOUS

CABAZITAXEL

AP	ACCORD HLTHCARE	<u>60MG/1.5ML (40MG/ML)</u>	<u>A207693</u>	<u>001</u>	Oct 26, 2022

JEVTANA KIT

AP	+! SANOFI AVENTIS US	<u>60MG/1.5ML (40MG/ML)</u>	<u>N201023</u>	<u>001</u>	Jun 17, 2010

CABERGOLINE

TABLET; ORAL

CABERGOLINE

AB	! INGENUS PHARMS LLC	<u>0.5MG</u>	<u>A204735</u>	<u>001</u>	Aug 01, 2018

AB	IVAX SUB TEVA	<u>0.5MG</u>	<u>A077750</u>	<u>001</u>	Mar 07, 2007

PHARMS

AB	STRIDES PHARMA	<u>0.5MG</u>	<u>A076310</u>	<u>001</u>	Dec 29, 2005

CABOTEGRAVIR

SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR

APRETUDE

+!	VIIV HLTHCARE	600MG/3ML (200MG/ML)	N215499	001	Dec 20, 2021

CABOTEGRAVIR SODIUM

TABLET; ORAL

VOCABRIA

+!	VIIV HLTHCARE	EQ 30MG BASE	N212887	001	Jan 21, 2021

CABOTEGRAVIR; RILPIVIRINE

SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR

CABENUVA KIT

+!	VIIV HLTHCARE	400MG/2ML (200MG/ML); 600MG/2ML (300MG/ML)	N212888	001	Jan 21, 2021

+!		600MG/3ML (200MG/ML); 900MG/3ML (300MG/ML)	N212888	002	Jan 21, 2021

CABOZANTINIB S-MALATE

CAPSULE; ORAL

COMETRIQ

+!	EXELIXIS	EQ 20MG BASE	N203756	001	Nov 29, 2012

+		EQ 80MG BASE	N203756	002	Nov 29, 2012

TABLET; ORAL

CABOMETYX

+	EXELIXIS INC	EQ 20MG BASE	N208692	001	Apr 25, 2016

+		EQ 40MG BASE	N208692	002	Apr 25, 2016

+!		EQ 60MG BASE	N208692	003	Apr 25, 2016

CAFFEINE CITRATE

SOLUTION; INTRAVENOUS

CAFCIT

AP	+! HIKMA	<u>EQ 30MG BASE/3ML (EQ 10MG BASE/ML)</u>	<u>N020793</u>	<u>001</u>	Sep 21, 1999

CAFFEINE CITRATE

AP	AM REGENT	<u>EQ 30MG BASE/3ML (EQ 10MG BASE/ML)</u>	<u>A077906</u>	<u>001</u>	May 15, 2007

AP	EUGIA PHARMA	<u>EQ 30MG BASE/3ML (EQ 10MG BASE/ML)</u>	<u>A205013</u>	<u>001</u>	Sep 22, 2015

AP	EXELA PHARMA	<u>EQ 30MG BASE/3ML (EQ 10MG BASE/ML)</u>	<u>A077233</u>	<u>001</u>	Sep 21, 2006

SCIENCE

AP	FRESENIUS KABI USA	<u>EQ 30MG BASE/3ML (EQ 10MG BASE/ML)</u>	<u>A077997</u>	<u>001</u>	Jul 20, 2007

AP	MICRO LABS	<u>EQ 30MG BASE/3ML (EQ 10MG BASE/ML)</u>	<u>A207400</u>	<u>001</u>	Dec 14, 2017

AP	SAGENT PHARMS	<u>EQ 30MG BASE/3ML (EQ 10MG BASE/ML)</u>	<u>A090827</u>	<u>001</u>	Aug 29, 2012

SOLUTION; ORAL

CAFFEINE CITRATE

AA	! EXELA PHARMA	<u>EQ 30MG BASE/3ML (EQ 10MG BASE/ML)</u>	<u>A077304</u>	<u>001</u>	Sep 21, 2006

AA	FRESENIUS KABI USA	<u>EQ 30MG BASE/3ML (EQ 10MG BASE/ML)</u>	<u>A078002</u>	<u>001</u>	Jan 31, 2008

AA	MICRO LABS	<u>EQ 30MG BASE/3ML (EQ 10MG BASE/ML)</u>	<u>A213202</u>	<u>001</u>	Dec 16, 2019

AA	SAGENT PHARMS	<u>EQ 30MG BASE/3ML (EQ 10MG BASE/ML)</u>	<u>A091102</u>	<u>001</u>	Aug 29, 2012

AA	SUN PHARM	<u>EQ 30MG BASE/3ML (EQ 10MG BASE/ML)</u>	<u>A090357</u>	<u>001</u>	Sep 30, 2009

CAFFEINE; ERGOTAMINE TARTRATE

SUPPOSITORY; RECTAL

MIGERGOT

+!	COSETTE	100MG; 2MG	A086557	001	Oct 04, 1983

TABLET; ORAL

ERGOTAMINE TARTRATE AND CAFFEINE

!	MIKART	100MG; 1MG	A040590	001	Sep 16, 2005

PRESCRIPTION DRUG PRODUCT LIST

3-73 (of 474)

CALCIFEDIOL

CAPSULE, EXTENDED RELEASE; ORAL

RAYALDEE

+! EIRGEN

0.03MG

N208010 001 Jun 17, 2016

CALCIPOTRIENE

AEROSOL, FOAM; TOPICAL

SORILUX

+! MAYNE PHARMA

0.005%

N022563 001 Oct 06, 2010

CREAM; TOPICAL

CALCIPOTRIENEAB GLENMARK PHARMS0.005%A205772 001 Jun 09, 2015AB TOLMAR0.005%A200935 001 May 30, 2012DOVONEXAB +! LEO PHARMA AS0.005%N020554 001 Jul 22, 1996

OINTMENT; TOPICAL

CALCIPOTRIENEAB ! GLENMARK PHARMS INC0.005%A090633 001 Mar 24, 2010DOVONEXAB + LEO PHARMA AS0.005%N020273 001 Dec 29, 1993

SOLUTION; TOPICAL

CALCIPOTRIENEAT AKORN0.005%A077579 001 Nov 19, 2009AT COSETTE0.005%A078468 001 Mar 24, 2011AT FOUGERA PHARMS0.005%A078305 001 May 06, 2008AT NOVEL LABS INC0.005%A207163 001 Dec 26, 2017AT ! TOLMAR0.005%A077029 001 Nov 20, 2009CALCITONIN SALMON

INJECTABLE; INJECTION

CALCITONIN-SALMONAP CUSTOPHARM INC200 IU/MLA212416 001 May 14, 2021AP PAR STERILE200 IU/MLA209358 001 Nov 10, 2021

PRODUCTS

MIACALCINAP +! MYLAN IRELAND LTD200 IU/MLN017808 002 Mar 29, 1991

SPRAY, METERED; NASAL

CALCITONIN-SALMON

! APOTEX INC

200 IU/SPRAY

A076396 001 Nov 17, 2008

CALCITRIOL

CAPSULE; ORAL

CALCITRIOLAB AMNEAL PHARMS0.25MCGA203289 002 Jun 14, 2017AB0.5MCGA203289 001 Jun 14, 2017AB BIONPHARMA INC0.25MCGA091174 001 May 24, 2013AB0.5MCGA091174 002 May 24, 2013AB HIKMA0.25MCGA076917 001 Mar 27, 2006AB STRIDES PHARMA0.25MCGA091356 001 Dec 12, 2014AB0.5MCGA091356 002 Dec 12, 2014AB SUN PHARM0.25MCGA204556 001 Feb 21, 2019AB0.5MCGA204556 002 Feb 21, 2019AB TEVA0.25MCGA075765 001 Oct 12, 2001AB0.5MCGA075765 002 Oct 12, 2001ROCALTRONAB + VALIDUS PHARMS0.25MCGN018044 001AB +!0.5MCGN018044 002

INJECTABLE; INJECTION

CALCITRIOLAP ! AKORN0.001MG/MLA078066 001 Jan 29, 2008AP GLAND PHARMA LTD0.001MG/MLA211030 001 Feb 03, 2020

OINTMENT; TOPICAL

VECTICAL

+! GALDERMA LABS LP

3MCG/GM

N022087 001 Jan 23, 2009

SOLUTION; ORAL

CALCITRIOLAA ELYSIUM1MCG/MLA209798 001 Nov 21, 2018AA HIKMA1MCG/MLA076242 001 Jul 18, 2003ROCALTRONAA +! VALIDUS PHARMS1MCG/MLN021068 001 Nov 20, 1998

PRESCRIPTION DRUG PRODUCT LIST

3-74 (of 474)

CALCIUM ACETATE

CAPSULE; ORAL

CALCIUM ACETATE

AB	CHARTWELL RX	667MG	A091312 001	Jun 01, 2012
AB	HERITAGE PHARMS INC	667MG	A202315 001	Jun 29, 2015
AB	HIKMA	667MG	A077728 001	Feb 26, 2008
AB	INVAGEN PHARMS	667MG	A203135 001	Feb 07, 2013
AB	LUPIN LTD	667MG	A202127 001	Jul 09, 2015
AB	NOSTRUM LABS INC	667MG	A203179 001	Oct 26, 2015
AB	SUVEN PHARMS	667MG	A211038 001	Feb 21, 2020

PHOSLO GELCAPS

AB	+ !	FRESENIUS MEDCL	667MG	N021160 003	Apr 02, 2001
SOLUTION; ORAL					
PHOSLYRA					
	+ !	FRESENIUS MEDCL	667MG/5ML	N022581 001	Apr 18, 2011
TABLET; ORAL					

CALCIUM ACETATE

AB	!	CHARTWELL MOLECULAR	667MG	A202420 001	Feb 05, 2013
AB		HERITAGE PHARMS INC	667MG	A202885 001	Jan 22, 2015
AB		PADAGIS US	667MG	A091561 001	Apr 13, 2011

CALCIUM CHLORIDE

INJECTABLE; INJECTION

CALCIUM CHLORIDE 10%

AP		AM REGENT	100MG/ML	A209088 001	Jul 27, 2017
AP		INTL MEDICATION SYS	100MG/ML	A203477 001	May 09, 2018
AP		MEDEFIL INC	100MG/ML	A211553 001	May 01, 2019

CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER

AP	+ !	HOSPIRA	100MG/ML	N021117 001	Jan 28, 2000

CALCIUM CHLORIDE; DEXTROSE; GLUTATHIONE DISULFIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

SOLUTION; IRRIGATION

BSS PLUS

+ !	ALCON	0.154MG/ML; 0.92MG/ML; 0.184MG/ML; 0.2MG/M L; 0.38MG/ML; 2.1MG/ML; 7.14MG/ML; 0.42MG/M L	N018469 001

CALCIUM CHLORIDE; DEXTROSE; LACTIC ACID; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

PRISMASOL B22GK 4/0 IN PLASTIC CONTAINER

+ !	BAXTER HLTHCARE CORP	N/A/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.0 5GM/1000ML; 0.314GM/1000ML; 2.21GM/1000ML ; 7.07GM/1000ML (5000ML)	N021703 011	Oct 10, 2008

PRISMASOL BGK 0/2.5 IN PLASTIC CONTAINER

+ !	BAXTER HLTHCARE CORP	3.68GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; N/A/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703 006	Oct 25, 2006

PRISMASOL BGK 2/0 IN PLASTIC CONTAINER

+ !	BAXTER HLTHCARE CORP	N/A/1000ML; 20GM/1000ML; 5.4GM/1000ML; 2.0 3GM/1000ML; 0.157GM/1000ML; 3.09GM/1000ML ; 6.46GM/1000ML (5000ML)	N021703 002	Oct 25, 2006

PRISMASOL BGK 2/3.5 IN PLASTIC CONTAINER

+ !	BAXTER HLTHCARE CORP	5.15GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 2.03GM/1000ML; 0.157GM/1000ML; 3.09GM/100 0ML; 6.46GM/1000ML (5000ML)	N021703 003	Oct 25, 2006

PRISMASOL BGK 4/0/1.2 IN PLASTIC CONTAINER

+ !	BAXTER HLTHCARE CORP	N/A/1000ML; 20GM/1000ML; 5.4GM/1000ML; 2.4 4GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML ; 6.46GM/1000ML (5000ML)	N021703 015	Oct 10, 2008

PRISMASOL BGK 4/2.5 IN PLASTIC CONTAINER

+ !	BAXTER HLTHCARE CORP	3.68GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 3.09GM/100 0ML; 6.46GM/1000ML (5000ML)	N021703 004	Oct 25, 2006

PRISMASOL BK 0/0/1.2 IN PLASTIC CONTAINER

+ !	BAXTER HLTHCARE CORP	N/A/1000ML; N/A/1000ML; 5.4GM/1000ML; 2.44 GM/1000ML; N/A/1000ML; 3.09GM/1000ML; 6.46 GM/1000ML (5000ML)	N021703 014	Oct 10, 2008

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL

DELFLX W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

AT	+ !	FRESENIUS MEDCL	25.7MG/100ML; 1.5GM/100ML; 15.2MG/100ML; 5 67MG/100ML; 392MG/100ML	N018883 001	Nov 30, 1984

DELFLX W/ DEXTROSE 1.5% LOW MAGNESIUM IN PLASTIC CONTAINER

AT	+ !	FRESENIUS MEDCL	25.7MG/100ML; 1.5GM/100ML; 5.08MG/100ML;	N018883 004	Nov 30, 1984

PRESCRIPTION DRUG PRODUCT LIST

3-75 (of 474)

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL

DELFLX W/ DEXTROSE 1.5% LOW MAGNESIUM IN PLASTIC CONTAINER

538MG/100ML; 448MG/100ML

DELFLX W/ DEXTROSE 1.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER

AT	+	FRESENIUS MEDCL	18.4MG/100ML; 1.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N020171	001	Aug 19, 1992

DELFLX W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

AT	+	FRESENIUS MEDCL	25.7MG/100ML; 2.5GM/100ML; 15.2MG/100ML; 567MG/100ML; 392MG/100ML	N018883	002	Nov 30, 1984

DELFLX W/ DEXTROSE 2.5% LOW MAGNESIUM IN PLASTIC CONTAINER

AT	+	FRESENIUS MEDCL	25.7MG/100ML; 2.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N018883	005	Nov 30, 1984

DELFLX W/ DEXTROSE 2.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER

AT	+	FRESENIUS MEDCL	18.4MG/100ML; 2.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N020171	002	Aug 19, 1992

DELFLX W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

AT	+	FRESENIUS MEDCL	25.7MG/100ML; 4.25GM/100ML; 15.2MG/100ML; 567MG/100ML; 392MG/100ML	N018883	003	Nov 30, 1984

DELFLX W/ DEXTROSE 4.25% LOW MAGNESIUM IN PLASTIC CONTAINER

AT	+	FRESENIUS MEDCL	25.7MG/100ML; 4.25GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N018883	006	Nov 30, 1984

DELFLX W/ DEXTROSE 4.25% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER

AT	+	FRESENIUS MEDCL	18.4MG/100ML; 4.25GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N020171	003	Aug 19, 1992

DIANEAL LOW CALCIUM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

AT	+	BAXTER HLTHCARE	18.3MG/100ML; 1.5GM/100ML; 5.08MG/100ML; 38MG/100ML; 448MG/100ML	N020183	001	Dec 04, 1992

DIANEAL LOW CALCIUM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

AT	+	BAXTER HLTHCARE	18.3MG/100ML; 2.5GM/100ML; 5.08MG/100ML; 38MG/100ML; 448MG/100ML	N020183	002	Dec 04, 1992

DIANEAL LOW CALCIUM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

AT	+	BAXTER HLTHCARE	18.3MG/100ML; 4.25GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N020183	004	Dec 04, 1992

DIANEAL LOW CALCIUM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

AT	+	BAXTER HLTHCARE	18.3MG/100ML; 1.5GM/100ML; 5.08MG/100ML; 38MG/100ML; 448MG/100ML	N017512	012	Jan 10, 1989

DIANEAL LOW CALCIUM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

AT	+	BAXTER HLTHCARE	18.3MG/100ML; 2.5GM/100ML; 5.08MG/100ML; 38MG/100ML; 448MG/100ML	N017512	013	Jul 11, 1990

DIANEAL LOW CALCIUM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

AT	+	BAXTER HLTHCARE	18.3MG/100ML; 3.5GM/100ML; 5.08MG/100ML; 38MG/100ML; 448MG/100ML	N017512	014	Jul 11, 1990

DIANEAL LOW CALCIUM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

AT	+	BAXTER HLTHCARE	18.3MG/100ML; 4.25GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N017512	015	Jul 11, 1990

DIANEAL PD-2 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

AT	+	BAXTER HLTHCARE	25.7MG/100ML; 1.5GM/100ML; 5.08MG/100ML; 38MG/100ML; 448MG/100ML	N017512	004	

AT	+		25.7MG/100ML; 1.5GM/100ML; 5.08MG/100ML; 38MG/100ML; 448MG/100ML	N020163	001	Dec 04, 1992

DIANEAL PD-2 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

AT	+	BAXTER HLTHCARE	25.7MG/100ML; 2.5GM/100ML; 5.08MG/100ML; 38MG/100ML; 448MG/100ML	N017512	005	

AT	+		25.7MG/100ML; 2.5GM/100ML; 5.08MG/100ML; 38MG/100ML; 448MG/100ML	N020163	002	Dec 04, 1992

DIANEAL PD-2 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

AT	+	BAXTER HLTHCARE	25.7MG/100ML; 4.25GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N017512	006	

AT	+		25.7MG/100ML; 4.25GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N020163	003	Dec 04, 1992

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE; INTRATHECAL

ELLIOTTS B SOLUTION

+	+	LUKARE MEDICAL LLC	0.2MG/ML; 0.8MG/ML; 0.3MG/ML; 0.3MG/ML; 1.9MG/ML; 7.3MG/ML; 0.2MG/ML	N020577	001	Sep 27, 1996

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

AP	+	ICU MEDICAL INC	20MG/100ML; 5GM/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML	N017608	001	

DEXTROSE 5% IN LACTATED RINGER'S IN PLASTIC CONTAINER

AP		B BRAUN	20MG/100ML; 5GM/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML	N019634	003	Feb 24, 1988

PRESCRIPTION DRUG PRODUCT LIST

3-76 (of 474)

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

LACTATED RINGER'S AND DEXTROSE 5% IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	<u>20MG/100ML; 5GM/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML</u>	<u>N016679 001</u>	

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	<u>20MG/100ML; 5GM/100ML; 254MG/100ML; 600MG/100ML; 310MG/100ML</u>	<u>N019367 006</u>	Apr 05, 1985

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	<u>20MG/100ML; 5GM/100ML; 179MG/100ML; 600MG/100ML; 310MG/100ML</u>	<u>N019367 004</u>	Apr 05, 1985

AP		<u>20MG/100ML; 5GM/100ML; 328MG/100ML; 600MG/100ML; 310MG/100ML</u>	<u>N019367 005</u>	Apr 05, 1985

AP	+ ICU MEDICAL INC	<u>20MG/100ML; 5GM/100ML; 179MG/100ML; 600MG/100ML; 310MG/100ML</u>	<u>N019685 002</u>	Oct 17, 1988

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	<u>20MG/100ML; 5GM/100ML; 254MG/100ML; 600MG/100ML; 310MG/100ML</u>	<u>N019367 007</u>	Apr 05, 1985

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	<u>20MG/100ML; 5GM/100ML; 328MG/100ML; 600MG/100ML; 310MG/100ML</u>	<u>N019367 008</u>	Apr 05, 1985

DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER

	B BRAUN	<u>10MG/100ML; 2.5GM/100ML; 15MG/100ML; 300MG/100ML; 160MG/100ML</u>	<u>N019634 001</u>	Feb 24, 1988

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

	BAXTER HLTHCARE	<u>20MG/100ML; 5GM/100ML; 105MG/100ML; 600MG/100ML; 310MG/100ML</u>	<u>N019367 002</u>	Apr 05, 1985

		<u>20MG/100ML; 5GM/100ML; 179MG/100ML; 600MG/100ML; 310MG/100ML</u>	<u>N019367 003</u>	Apr 05, 1985

POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

	BAXTER HLTHCARE	<u>20MG/100ML; 5GM/100ML; 105MG/100ML; 600MG/100ML; 310MG/100ML</u>	<u>N019367 001</u>	Apr 05, 1985

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

TPN ELECTROLYTES IN PLASTIC CONTAINER

	+! HOSPIRA	<u>16.5MG/ML; 25.4MG/ML; 74.6MG/ML; 121MG/ML; 16.1MG/ML</u>	<u>N018895 001</u>	Jul 20, 1984

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

SOLUTION; IRRIGATION

BALANCED SALT

AT	B BRAUN	<u>0.48MG/ML; 0.3MG/ML; 0.75MG/ML; 3.9MG/ML; 6.4MG/ML; 1.7MG/ML</u>	<u>A091387 001</u>	Feb 03, 2010

BSS

AT	+! ALCON	<u>0.48MG/ML; 0.3MG/ML; 0.75MG/ML; 3.9MG/ML; 6.4MG/ML; 1.7MG/ML</u>	<u>N020742 001</u>	Dec 10, 1997

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

INJECTABLE; INJECTION

PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER

	+! BAXTER HLTHCARE CORP	<u>N/A/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 2.21GM/1000ML; 6.95GM/1000ML; 0.187GM/100ML (5000ML)</u>	<u>N207026 002</u>	Jan 13, 2015

PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER

	+! BAXTER HLTHCARE CORP	<u>3.68GM/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.34GM/1000ML; 0.187GM/1000ML</u>	<u>N207026 001</u>	Jan 13, 2015

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

SOLUTION; PERFUSION, CARDIAC

CARDIOPLEGIC IN PLASTIC CONTAINER

AT	BAXTER HLTHCARE	<u>17.6MG/100ML; 325.3MG/100ML; 119.3MG/100ML; 643MG/100ML</u>	<u>A075323 001</u>	Apr 21, 2000

AT	FRESENIUS KABI USA	<u>17.6MG/100ML; 325.3MG/100ML; 119.3MG/100ML; 643MG/100ML</u>	<u>A214623 001</u>	Feb 18, 2022

PLEGISOL IN PLASTIC CONTAINER

AT	+! HOSPIRA	<u>17.6MG/100ML; 325.3MG/100ML; 119.3MG/100ML; 643MG/100ML</u>	<u>N018608 001</u>	Feb 26, 1982

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

RINGER'S IN PLASTIC CONTAINER

AP	B BRAUN	<u>33MG/100ML; 30MG/100ML; 860MG/100ML</u>	<u>N020002 001</u>	Apr 17, 1992

AP	BAXTER HLTHCARE	<u>33MG/100ML; 30MG/100ML; 860MG/100ML</u>	<u>N016693 001</u>	

AP	ICU MEDICAL INC	<u>33MG/100ML; 30MG/100ML; 860MG/100ML</u>	<u>N018251 001</u>	

PRESCRIPTION DRUG PRODUCT LIST

3-77 (of 474)

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

SOLUTION; IRRIGATION

RINGER'S IN PLASTIC CONTAINER

AT	B BRAUN	<u>33MG/100ML; 30MG/100ML; 860MG/100ML</u>	<u>N018156</u>	<u>001</u>	
AT	BAXTER HLTHCARE	<u>33MG/100ML; 30MG/100ML; 860MG/100ML</u>	<u>N018495</u>	<u>001</u>	Feb 19, 1982
AT	ICU MEDICAL INC	<u>33MG/100ML; 30MG/100ML; 860MG/100ML</u>	<u>N017635</u>	<u>001</u>	

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

LACTATED RINGER'S IN PLASTIC CONTAINER

AP	B BRAUN	<u>20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML</u>	<u>N019632</u>	<u>001</u>	Feb 29, 1988
AP	+! BAXTER HLTHCARE	<u>20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML</u>	<u>N016682</u>	<u>001</u>	
AP	FRESENIUS KABI USA	<u>20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML</u>	<u>A209338</u>	<u>001</u>	Jan 28, 2019
AP	ICU MEDICAL INC	<u>20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML</u>	<u>N017641</u>	<u>001</u>	

SOLUTION; IRRIGATION

LACTATED RINGER'S IN PLASTIC CONTAINER

AT	+! B BRAUN	<u>20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML</u>	<u>N018681</u>	<u>001</u>	Dec 27, 1982
AT	BAXTER HLTHCARE	<u>20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML</u>	<u>N018494</u>	<u>001</u>	Feb 19, 1982
AT	+!	<u>20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML</u>	<u>N018921</u>	<u>001</u>	Apr 03, 1984
AT	+! ICU MEDICAL INC	<u>20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML</u>	<u>N019416</u>	<u>001</u>	Jan 17, 1986

CALCIUM GLUCONATE

SOLUTION; INTRAVENOUS

CALCIUM GLUCONATE

AP	+! FRESENIUS KABI USA	<u>1GM/10ML (100MG/ML)</u>	<u>N208418</u>	<u>001</u>	Jun 15, 2017
AP	NIVAGEN PHARMS INC	<u>1GM/10ML (100MG/ML)</u>	<u>A213071</u>	<u>001</u>	Oct 14, 2022
	+! FRESENIUS KABI USA	5GM/50ML (100MG/ML)	N208418	002	Jun 15, 2017
	+!	10GM/100ML (100MG/ML)	N208418	003	Jun 15, 2017

CALCIUM GLUCONATE IN SODIUM CHLORIDE

	+! FRESENIUS KABI USA	1GM/50ML (20MG/ML)	N208418	004	Jun 17, 2021
	+!	2GM/100ML (20MG/ML)	N208418	005	Jun 17, 2021
	+! HQ SPCLT PHARMA	1GM/50ML (20MG/ML)	N210906	001	Oct 29, 2018
	+!	1GM/100ML (10MG/ML)	N210906	003	Jun 04, 2021
	+!	2GM/100ML (20MG/ML)	N210906	002	Oct 29, 2018

CALCIUM OXYBATE; MAGNESIUM OXYBATE; POTASSIUM OXYBATE; SODIUM OXYBATE

SOLUTION; ORAL

XYWAV

	+! JAZZ	0.234GM/ML; 0.096GM/ML; 0.13GM/ML; 0.04GM/ML	N212690	001	Jul 21, 2020

CANAGLIFLOZIN

TABLET; ORAL

INVOKANA

	+ JANSSEN PHARMS	100MG	N204042	001	Mar 29, 2013
	+!	300MG	N204042	002	Mar 29, 2013

CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE

TABLET; ORAL

INVOKAMET

	+ JANSSEN PHARMS	50MG; 500MG	N204353	001	Aug 08, 2014
	+	50MG; 1GM	N204353	002	Aug 08, 2014
	+	150MG; 500MG	N204353	003	Aug 08, 2014
	+!	150MG; 1GM	N204353	004	Aug 08, 2014

TABLET, EXTENDED RELEASE; ORAL

INVOKAMET XR

	+ JANSSEN PHARMS	50MG; 500MG	N205879	001	Sep 20, 2016
	+	50MG; 1GM	N205879	002	Sep 20, 2016
	+	150MG; 500MG	N205879	003	Sep 20, 2016
	+!	150MG; 1GM	N205879	004	Sep 20, 2016

CANDESARTAN CILEXETIL

TABLET; ORAL

ATACAND

AB	+ ANI PHARMS	<u>4MG</u>	<u>N020838</u>	<u>001</u>	Jun 04, 1998
AB	+	<u>8MG</u>	<u>N020838</u>	<u>002</u>	Jun 04, 1998
AB	+	<u>16MG</u>	<u>N020838</u>	<u>003</u>	Jun 04, 1998
AB	+!	<u>32MG</u>	<u>N020838</u>	<u>004</u>	Jun 04, 1998

PRESCRIPTION DRUG PRODUCT LIST

3-78 (of 474)

CANDESARTAN CILEXETIL

TABLET; ORAL

CANDESARTAN CILEXETIL

<u>AB</u>	ALEMBIC PHARMS	<u>4MG</u>	<u>A210302</u>	<u>001</u>	Dec 04, 2018
<u>AB</u>		<u>8MG</u>	<u>A210302</u>	<u>002</u>	Dec 04, 2018
<u>AB</u>		<u>16MG</u>	<u>A210302</u>	<u>003</u>	Dec 04, 2018
<u>AB</u>		<u>32MG</u>	<u>A209119</u>	<u>001</u>	Jun 20, 2017
<u>AB</u>	MACLEODS PHARMS LTD	<u>4MG</u>	<u>A203813</u>	<u>001</u>	Dec 05, 2016
<u>AB</u>		<u>8MG</u>	<u>A203813</u>	<u>002</u>	Dec 05, 2016
<u>AB</u>		<u>16MG</u>	<u>A203813</u>	<u>003</u>	Dec 05, 2016
<u>AB</u>		<u>32MG</u>	<u>A203813</u>	<u>004</u>	Dec 05, 2016
<u>AB</u>	MYLAN	<u>4MG</u>	<u>A078702</u>	<u>001</u>	May 03, 2013
<u>AB</u>		<u>8MG</u>	<u>A078702</u>	<u>002</u>	May 03, 2013
<u>AB</u>		<u>16MG</u>	<u>A078702</u>	<u>003</u>	May 03, 2013
<u>AB</u>		<u>32MG</u>	<u>A078702</u>	<u>004</u>	May 03, 2013
<u>AB</u>	ZYDUS PHARMS	<u>4MG</u>	<u>A091390</u>	<u>001</u>	Aug 23, 2017
<u>AB</u>		<u>8MG</u>	<u>A091390</u>	<u>002</u>	Aug 23, 2017
<u>AB</u>		<u>16MG</u>	<u>A091390</u>	<u>003</u>	Aug 23, 2017
<u>AB</u>		<u>32MG</u>	<u>A091390</u>	<u>004</u>	Aug 23, 2017

CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL

ATACAND HCT

<u>AB</u>	+	ANI PHARMS	<u>16MG; 12.5MG</u>	<u>N021093</u>	<u>001</u>	Sep 05, 2000
<u>AB</u>	+		<u>32MG; 12.5MG</u>	<u>N021093</u>	<u>002</u>	Sep 05, 2000
<u>AB</u>	+	!	<u>32MG; 25MG</u>	<u>N021093</u>	<u>003</u>	May 16, 2008

CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE

<u>AB</u>	DR REDDYS LABS LTD	<u>16MG; 12.5MG</u>	<u>A202965</u>	<u>001</u>	Jun 03, 2013
<u>AB</u>		<u>32MG; 12.5MG</u>	<u>A202965</u>	<u>002</u>	Jun 03, 2013
<u>AB</u>		<u>32MG; 25MG</u>	<u>A202965</u>	<u>003</u>	Jun 03, 2013
<u>AB</u>	MACLEODS PHARMS LTD	<u>16MG; 12.5MG</u>	<u>A204100</u>	<u>001</u>	Feb 27, 2015
<u>AB</u>		<u>32MG; 12.5MG</u>	<u>A204100</u>	<u>002</u>	Feb 27, 2015
<u>AB</u>		<u>32MG; 25MG</u>	<u>A204100</u>	<u>003</u>	Feb 27, 2015
<u>AB</u>	MYLAN	<u>16MG; 12.5MG</u>	<u>A090704</u>	<u>001</u>	Dec 04, 2012
<u>AB</u>		<u>32MG; 12.5MG</u>	<u>A090704</u>	<u>002</u>	Dec 04, 2012
<u>AB</u>		<u>32MG; 25MG</u>	<u>A090704</u>	<u>003</u>	Dec 04, 2012
<u>AB</u>	PRINSTON INC	<u>16MG; 12.5MG</u>	<u>A207455</u>	<u>001</u>	Apr 11, 2018
<u>AB</u>		<u>32MG; 12.5MG</u>	<u>A207455</u>	<u>002</u>	Apr 11, 2018
<u>AB</u>		<u>32MG; 25MG</u>	<u>A207455</u>	<u>003</u>	Apr 11, 2018
<u>AB</u>	ZYDUS PHARMS	<u>16MG; 12.5MG</u>	<u>A203466</u>	<u>001</u>	Nov 27, 2017
<u>AB</u>		<u>32MG; 12.5MG</u>	<u>A203466</u>	<u>002</u>	Nov 27, 2017
<u>AB</u>		<u>32MG; 25MG</u>	<u>A203466</u>	<u>003</u>	Nov 27, 2017

CANGRELOR

POWDER; INTRAVENOUS

KENGREAL

+	!	CHIESI	50MG/VIAL	N204958	001	Jun 22, 2015

CANNABIDIOL

SOLUTION; ORAL

EPIDIOLEX

+	!	GW RES LTD	100MG/ML	N210365	001	Sep 28, 2018

CAPECITABINE

TABLET; ORAL

CAPECITABINE

<u>AB</u>	ACCORD HLTHCARE	<u>150MG</u>	<u>A202593</u>	<u>001</u>	Apr 23, 2015
<u>AB</u>		<u>500MG</u>	<u>A202593</u>	<u>002</u>	Apr 23, 2015
<u>AB</u>	ALKEM LABS LTD	<u>150MG</u>	<u>A207652</u>	<u>001</u>	Nov 24, 2017
<u>AB</u>		<u>500MG</u>	<u>A207652</u>	<u>002</u>	Nov 24, 2017
<u>AB</u>	DR REDDYS	<u>150MG</u>	<u>A204345</u>	<u>001</u>	Dec 04, 2020
<u>AB</u>		<u>500MG</u>	<u>A204345</u>	<u>002</u>	Dec 04, 2020
<u>AB</u>	EUGIA PHARMA	<u>150MG</u>	<u>A210604</u>	<u>001</u>	Apr 17, 2018
<u>AB</u>		<u>500MG</u>	<u>A210604</u>	<u>002</u>	Apr 17, 2018
<u>AB</u>	HIKMA	<u>150MG</u>	<u>A200483</u>	<u>001</u>	Jul 14, 2016
<u>AB</u>		<u>500MG</u>	<u>A200483</u>	<u>002</u>	Jul 14, 2016
<u>AB</u>	MSN	<u>150MG</u>	<u>A209365</u>	<u>001</u>	Jul 02, 2018
<u>AB</u>		<u>500MG</u>	<u>A209365</u>	<u>002</u>	Jul 02, 2018
<u>AB</u>	RELIANCE LIFE	<u>150MG</u>	<u>A211724</u>	<u>001</u>	Apr 27, 2020
<u>AB</u>		<u>500MG</u>	<u>A211724</u>	<u>002</u>	Apr 27, 2020
<u>AB</u>	RISING	<u>150MG</u>	<u>A090943</u>	<u>001</u>	Aug 08, 2014
<u>AB</u>		<u>500MG</u>	<u>A090943</u>	<u>002</u>	Aug 08, 2014
<u>AB</u>	SHILPA	<u>150MG</u>	<u>A207456</u>	<u>001</u>	Dec 12, 2016
<u>AB</u>		<u>500MG</u>	<u>A207456</u>	<u>002</u>	Dec 12, 2016

PRESCRIPTION DRUG PRODUCT LIST

3-79 (of 474)

CAPECITABINE

TABLET; ORAL

CAPECITABINE

AB	SUN PHARM	150MG	A204668 001	Jun 21, 2019
AB		500MG	A204668 002	Jun 21, 2019
AB	TEVA PHARMS USA	150MG	A091649 001	Sep 16, 2013
AB		500MG	A091649 002	Sep 16, 2013

XELODA

AB	+	HOFFMANN LA ROCHE	150MG	N020896 001	Apr 30, 1998
AB	+	!	500MG	N020896 002	Apr 30, 1998

CAPMATINIB HYDROCHLORIDE

TABLET; ORAL

TABRECTA

+	NOVARTIS PHARM	EQ 150MG BASE	N213591 001	May 06, 2020
+	!	EQ 200MG BASE	N213591 002	May 06, 2020

CAPSAICIN

PATCH; TOPICAL

QUTENZA

+	!	AVERITAS	8%	N022395 001	Nov 16, 2009

CAPTOPRIL

TABLET; ORAL

CAPTOPRIL

AB	AJANTA PHARMA LTD	12.5MG	A212809 001	Dec 13, 2019
AB		25MG	A212809 002	Dec 13, 2019
AB		50MG	A212809 003	Dec 13, 2019
AB		100MG	A212809 004	Dec 13, 2019
AB	ANNORA PHARMA	12.5MG	A074737 001	Oct 28, 1998
AB		25MG	A074737 002	Oct 28, 1998
AB		50MG	A074737 003	Oct 28, 1998
AB		100MG	A074737 004	Oct 28, 1998
AB	BOSCOGEN	12.5MG	A074677 004	May 30, 1997
AB		25MG	A074677 002	May 30, 1997
AB		50MG	A074677 001	May 30, 1997
AB		100MG	A074677 003	May 30, 1997
AB	HIKMA INTL PHARMS	12.5MG	A074505 001	Feb 13, 1996
AB		25MG	A074505 002	Feb 13, 1996
AB		50MG	A074505 003	Feb 13, 1996
AB	!	100MG	A074505 004	Feb 13, 1996
AB	PRINSTON INC	12.5MG	A074477 001	Feb 13, 1996
AB		25MG	A074477 002	Feb 13, 1996
AB		50MG	A074477 003	Feb 13, 1996
AB		100MG	A074477 004	Feb 13, 1996
AB	WOCKHARDT	12.5MG	A074532 001	Mar 28, 1997
AB		25MG	A074532 002	Mar 28, 1997
AB		50MG	A074532 003	Mar 28, 1997
AB		100MG	A074532 004	Mar 28, 1997

CARBACHOL

SOLUTION; INTRAOCULAR

MIOSTAT

+	!	ALCON	0.01%	N016968 001

CARBAMAZEPINE

CAPSULE, EXTENDED RELEASE; ORAL

CARBAMAZEPINE

AB	APOTEX INC	100MG	A078986 001	Nov 25, 2011
AB		200MG	A078986 002	Nov 25, 2011
AB		300MG	A078986 003	Nov 25, 2011
AB	NOSTRUM LABS INC	100MG	A076697 001	May 20, 2011
AB		200MG	A076697 002	May 20, 2011
AB		300MG	A076697 003	May 20, 2011
AB	TARO	100MG	A201106 001	Jun 21, 2013
AB		200MG	A201106 002	Jun 21, 2013
AB		300MG	A201106 003	Jun 21, 2013
AB	TEVA PHARMS	100MG	A078592 001	Sep 20, 2012
AB		200MG	A078592 002	Sep 20, 2012
AB		300MG	A078592 003	Sep 20, 2012

CARBATROL

AB	+	TAKEDA PHARMS USA	100MG	N020712 003	Sep 30, 1997
AB	+		200MG	N020712 001	Sep 30, 1997
AB	+	!	300MG	N020712 002	Sep 30, 1997

PRESCRIPTION DRUG PRODUCT LIST

3-80 (of 474)

CARBAMAZEPINE

CAPSULE, EXTENDED RELEASE;ORAL

EQUETRO

+ VALIDUS PHARMS

100MG

N021710 001 Dec 10, 2004

+

200MG

N021710 002 Dec 10, 2004

+!

300MG

N021710 003 Dec 10, 2004

SUSPENSION;ORAL

CARBAMAZEPINE**AB** NOVITIUM PHARMA100MG/5MLA214277 001 Oct 06, 2022**AB** WOCKHARDT BIO AG100MG/5MLA075714 001 Jun 05, 2002TEGRETOL**AB** +! NOVARTIS100MG/5MLN018927 001 Dec 18, 1987TERIL**AB** TARO100MG/5MLA076729 001 Sep 20, 2004

TABLET;ORAL

CARBAMAZEPINE**AB** APOTEX INC200MGA075948 001 Feb 27, 2002**AB** TARO200MGA074649 001 Oct 03, 1996**AB** TORRENT PHARMS100MGA077272 001 Dec 07, 2005**AB**200MGA077272 002 Dec 07, 2005**AB** UMEDICA LABS PVT LTD100MGA207798 001 Apr 15, 2020**AB**200MGA207798 002 Apr 15, 2020**AB** UNICHEM200MGA213284 001 Aug 22, 2022EPITOL**AB** TEVA200MGA070541 001 Sep 17, 1986TEGRETOL**AB** +! NOVARTIS200MGN016608 001

CARBAMAZEPINE

TORRENT PHARMS

300MG

A077272 003 Dec 07, 2005

400MG

A077272 004 Dec 07, 2005

TABLET, CHEWABLE;ORAL

CARBAMAZEPINE**AB** TARO PHARM INDS100MGA075687 001 Oct 24, 2000**AB** TORRENT PHARMS100MGA075712 001 Jul 05, 2001EPITOL**AB** TEVA100MGA073524 001 Jul 29, 1992

CARBAMAZEPINE

! TARO PHARM INDS

200MG

A075687 002 Jul 29, 2002

TABLET, EXTENDED RELEASE;ORAL

CARBAMAZEPINE**AB** ANBISON LAB100MGA212948 001 Sep 30, 2021**AB**200MGA212948 002 Sep 30, 2021**AB**400MGA212948 003 Sep 30, 2021**AB** CSPC OUYI100MGA213311 001 Apr 13, 2021**AB**200MGA213311 002 Apr 13, 2021**AB**400MGA213311 003 Apr 13, 2021**AB** TARO100MGA078115 001 Mar 31, 2009**AB**200MGA078115 002 Mar 31, 2009**AB**400MGA078115 003 Mar 31, 2009**AB** UMEDICA LABS PVT LTD100MGA216594 001 Aug 18, 2022**AB**200MGA216594 002 Aug 18, 2022**AB**400MGA216594 003 Aug 18, 2022**AB** UNIQUE PHARM100MGA211623 001 Apr 24, 2020**AB**200MGA211623 002 Apr 24, 2020**AB**400MGA211623 003 Apr 24, 2020**AB** ZHEJIANG JIUZHOU100MGA215591 001 Mar 31, 2022**AB**200MGA215591 002 Mar 31, 2022**AB**400MGA215591 003 Mar 31, 2022**AB** ZYDUS PHARMS100MGA205571 001 Feb 07, 2019**AB**200MGA205571 002 Feb 07, 2019**AB**400MGA205571 003 Feb 07, 2019TEGRETOL-XR**AB** + NOVARTIS100MGN020234 001 Mar 25, 1996**AB** +200MGN020234 002 Mar 25, 1996**AB** +!400MGN020234 003 Mar 25, 1996

PRESCRIPTION DRUG PRODUCT LIST

3-81 (of 474)

CARBIDOPA

TABLET; ORAL

CARBIDOPA

<u>AB</u>	ALVOGEN	<u>25MG</u>	<u>A204291</u>	<u>001</u>	Jan 08, 2016
<u>AB</u>	AUROBINDO PHARMA	<u>25MG</u>	<u>A211055</u>	<u>001</u>	Oct 21, 2019
<u>AB</u>	EDENBRIDGE PHARMS	<u>25MG</u>	<u>A205304</u>	<u>001</u>	Feb 17, 2016
<u>AB</u>	NOVEL LABS INC	<u>25MG</u>	<u>A204763</u>	<u>001</u>	Oct 20, 2017
<u>AB</u>	ZYDUS PHARMS	<u>25MG</u>	<u>A209910</u>	<u>001</u>	May 07, 2018

LODOSYN

<u>AB</u>	+!	ATON	<u>25MG</u>	<u>N017830</u>	<u>001</u>

CARBIDOPA; ENTACAPONE; LEVODOPA

TABLET; ORAL

CARBIDOPA, LEVODOPA AND ENTACAPONE

<u>AB</u>	RISING	<u>12.5MG;200MG;50MG</u>	<u>A213212</u>	<u>001</u>	Jan 25, 2022
<u>AB</u>		<u>18.75MG;200MG;75MG</u>	<u>A213212</u>	<u>002</u>	Jan 25, 2022
<u>AB</u>		<u>25MG;200MG;100MG</u>	<u>A213212</u>	<u>003</u>	Jan 25, 2022
<u>AB</u>		<u>31.25MG;200MG;125MG</u>	<u>A213212</u>	<u>004</u>	Jan 25, 2022
<u>AB</u>		<u>37.5MG;200MG;150MG</u>	<u>A213212</u>	<u>005</u>	Jan 25, 2022
<u>AB</u>		<u>50MG;200MG;200MG</u>	<u>A213212</u>	<u>006</u>	Jan 25, 2022
<u>AB</u>	SUN PHARM	<u>25MG;200MG;100MG</u>	<u>A079085</u>	<u>001</u>	May 10, 2012
<u>AB</u>		<u>37.5MG;200MG;150MG</u>	<u>A079085</u>	<u>002</u>	May 10, 2012

STALEVO 100

<u>AB</u>	+	ORION PHARMA	<u>25MG;200MG;100MG</u>	<u>N021485</u>	<u>002</u>	Jun 11, 2003

STALEVO 125

<u>AB</u>	+	ORION PHARMA	<u>31.25MG;200MG;125MG</u>	<u>N021485</u>	<u>006</u>	Aug 29, 2008

STALEVO 150

<u>AB</u>	+	ORION PHARMA	<u>37.5MG;200MG;150MG</u>	<u>N021485</u>	<u>003</u>	Jun 11, 2003

STALEVO 200

<u>AB</u>	+	ORION PHARMA	<u>50MG;200MG;200MG</u>	<u>N021485</u>	<u>004</u>	Aug 02, 2007

STALEVO 50

<u>AB</u>	+	ORION PHARMA	<u>12.5MG;200MG;50MG</u>	<u>N021485</u>	<u>001</u>	Jun 11, 2003

STALEVO 75

<u>AB</u>	+	ORION PHARMA	<u>18.75MG;200MG;75MG</u>	<u>N021485</u>	<u>005</u>	Aug 29, 2008

CARBIDOPA; LEVODOPA

CAPSULE, EXTENDED RELEASE; ORAL

RYTARY

+	IMPAX LABS INC	23.75MG;95MG	N203312	001	Jan 07, 2015
+		36.25MG;145MG	N203312	002	Jan 07, 2015
+		48.75MG;195MG	N203312	003	Jan 07, 2015
+		61.25MG;245MG	N203312	004	Jan 07, 2015

SUSPENSION; ENTERAL

DUOPA

+	ABBVIE INC	4.63MG/ML;20MG/ML	N203952	001	Jan 09, 2015

TABLET; ORAL

CARBIDOPA AND LEVODOPA

<u>AB</u>	ACTAVIS ELIZABETH	<u>10MG;100MG</u>	<u>A074260</u>	<u>001</u>	Sep 03, 1993
<u>AB</u>		<u>25MG;100MG</u>	<u>A074260</u>	<u>002</u>	Sep 03, 1993
<u>AB</u>	!	<u>25MG;250MG</u>	<u>A074260</u>	<u>003</u>	Sep 03, 1993
<u>AB</u>	APOTEX INC	<u>10MG;100MG</u>	<u>A077120</u>	<u>001</u>	Jun 02, 2008
<u>AB</u>		<u>25MG;100MG</u>	<u>A077120</u>	<u>002</u>	Jun 02, 2008
<u>AB</u>		<u>25MG;250MG</u>	<u>A077120</u>	<u>003</u>	Jun 02, 2008
<u>AB</u>	AUROBINDO PHARMA LTD	<u>10MG;100MG</u>	<u>A216537</u>	<u>001</u>	Nov 28, 2022
<u>AB</u>		<u>25MG;100MG</u>	<u>A216537</u>	<u>002</u>	Nov 28, 2022
<u>AB</u>		<u>25MG;250MG</u>	<u>A216537</u>	<u>003</u>	Nov 28, 2022
<u>AB</u>	MAYNE PHARMA	<u>10MG;100MG</u>	<u>A073618</u>	<u>001</u>	Aug 28, 1992
<u>AB</u>		<u>25MG;100MG</u>	<u>A073589</u>	<u>001</u>	Aug 28, 1992
<u>AB</u>		<u>25MG;250MG</u>	<u>A073607</u>	<u>001</u>	Aug 28, 1992
<u>AB</u>	MYLAN	<u>10MG;100MG</u>	<u>A090324</u>	<u>001</u>	Sep 28, 2009
<u>AB</u>		<u>25MG;100MG</u>	<u>A090324</u>	<u>002</u>	Sep 28, 2009
<u>AB</u>		<u>25MG;250MG</u>	<u>A090324</u>	<u>003</u>	Sep 28, 2009
<u>AB</u>	RUBICON	<u>10MG;100MG</u>	<u>A216505</u>	<u>001</u>	Sep 21, 2022
<u>AB</u>		<u>25MG;100MG</u>	<u>A216505</u>	<u>002</u>	Sep 21, 2022
<u>AB</u>		<u>25MG;250MG</u>	<u>A216505</u>	<u>003</u>	Sep 21, 2022
<u>AB</u>	SCIEGEN PHARMS INC	<u>10MG;100MG</u>	<u>A214092</u>	<u>001</u>	May 07, 2021
<u>AB</u>		<u>25MG;100MG</u>	<u>A214092</u>	<u>002</u>	May 07, 2021
<u>AB</u>		<u>25MG;250MG</u>	<u>A214092</u>	<u>003</u>	May 07, 2021
<u>AB</u>	SUN PHARM INDS	<u>10MG;100MG</u>	<u>A078536</u>	<u>001</u>	Oct 28, 2008
<u>AB</u>		<u>25MG;100MG</u>	<u>A078536</u>	<u>002</u>	Oct 28, 2008
<u>AB</u>		<u>25MG;250MG</u>	<u>A078536</u>	<u>003</u>	Oct 28, 2008

PRESCRIPTION DRUG PRODUCT LIST

3-82 (of 474)

CARBIDOPA; LEVODOPA

TABLET; ORAL

SINEMET

<u>AB</u>	+	ORGANON	<u>10MG;100MG</u>	<u>N017555</u>	<u>001</u>	
<u>AB</u>	+		<u>25MG;100MG</u>	<u>N017555</u>	<u>003</u>	
<u>AB</u>	+		<u>25MG;250MG</u>	<u>N017555</u>	<u>002</u>	
DHIVY						
	+	AVION PHARMS	25MG;100MG	N214869	001	Nov 12, 2021

TABLET, EXTENDED RELEASE; ORAL

CARBIDOPA AND LEVODOPA

<u>AB</u>		ACCORD HLTHCARE	<u>25MG;100MG</u>	<u>A202323</u>	<u>001</u>	Feb 08, 2013
<u>AB</u>			<u>50MG;200MG</u>	<u>A202323</u>	<u>002</u>	Feb 08, 2013
<u>AB</u>		ALEMBIC PHARMS	<u>25MG;100MG</u>	<u>A210341</u>	<u>001</u>	Jun 05, 2019
<u>AB</u>			<u>50MG;200MG</u>	<u>A210341</u>	<u>002</u>	Jun 05, 2019
<u>AB</u>		APOTEX	<u>25MG;100MG</u>	<u>A076212</u>	<u>001</u>	Jun 16, 2004
<u>AB</u>			<u>50MG;200MG</u>	<u>A076212</u>	<u>002</u>	Jun 16, 2004
<u>AB</u>		IMPAX LABS	<u>25MG;100MG</u>	<u>A076521</u>	<u>001</u>	May 14, 2004
<u>AB</u>			<u>50MG;200MG</u>	<u>A076521</u>	<u>002</u>	May 14, 2004
<u>AB</u>		MYLAN	<u>25MG;100MG</u>	<u>A075091</u>	<u>002</u>	Apr 21, 2000
<u>AB</u>			<u>50MG;200MG</u>	<u>A075091</u>	<u>001</u>	Sep 30, 1999
<u>AB</u>		SCIEGEN PHARMS INC	<u>25MG;100MG</u>	<u>A214091</u>	<u>001</u>	Oct 05, 2021
<u>AB</u>			<u>50MG;200MG</u>	<u>A214091</u>	<u>002</u>	Oct 05, 2021
<u>AB</u>		SUN PHARM INDS	<u>25MG;100MG</u>	<u>A077828</u>	<u>001</u>	Aug 23, 2007
<u>AB</u>	!		<u>50MG;200MG</u>	<u>A077828</u>	<u>002</u>	Aug 23, 2007

TABLET, ORALLY DISINTEGRATING; ORAL

CARBIDOPA AND LEVODOPA

<u>AB</u>		SUN PHARM	<u>10MG;100MG</u>	<u>A078690</u>	<u>001</u>	Jul 31, 2009
<u>AB</u>			<u>25MG;100MG</u>	<u>A078690</u>	<u>002</u>	Jul 31, 2009
	!		25MG;250MG	A078690	003	Jul 31, 2009

CARBINOXAMINE MALEATE

SOLUTION; ORAL

CARBINOXAMINE MALEATE

!	MIKART	4MG/5ML	A040458	001	Apr 25, 2003

SUSPENSION, EXTENDED RELEASE; ORAL

KARBINAL ER

+	!	AYTU	4MG/5ML	N022556	001	Mar 28, 2013

TABLET; ORAL

CARBINOXAMINE MALEATE

<u>AA</u>		INVAGEN PHARMS	<u>4MG</u>	<u>A090435</u>	<u>001</u>	Apr 15, 2010
<u>AA</u>	!	MIKART	<u>4MG</u>	<u>A040442</u>	<u>001</u>	Mar 19, 2003
<u>AA</u>		MISSION PHARMACAL CO	<u>4MG</u>	<u>A090756</u>	<u>001</u>	May 27, 2011
	!	MIKART	6MG	A207484	001	May 31, 2016

CARBOPLATIN

INJECTABLE; INTRAVENOUS

CARBOPLATIN

<u>AP</u>		ACCORD HLTHCARE	<u>50MG/5ML (10MG/ML)</u>	<u>A206775</u>	<u>001</u>	Feb 09, 2017
<u>AP</u>			<u>150MG/15ML (10MG/ML)</u>	<u>A206775</u>	<u>002</u>	Feb 09, 2017
<u>AP</u>			<u>450MG/45ML (10MG/ML)</u>	<u>A206775</u>	<u>003</u>	Feb 09, 2017
<u>AP</u>			<u>600MG/60ML (10MG/ML)</u>	<u>A206775</u>	<u>004</u>	Feb 09, 2017
<u>AP</u>		AKORN	<u>50MG/5ML (10MG/ML)</u>	<u>A090475</u>	<u>001</u>	Jul 29, 2009
<u>AP</u>			<u>150MG/15ML (10MG/ML)</u>	<u>A090475</u>	<u>002</u>	Jul 29, 2009
<u>AP</u>			<u>450MG/45ML (10MG/ML)</u>	<u>A090475</u>	<u>003</u>	Jul 29, 2009
<u>AP</u>			<u>600MG/60ML (10MG/ML)</u>	<u>A091268</u>	<u>002</u>	Jul 28, 2010
<u>AP</u>		EUGIA PHARMA	<u>50MG/5ML (10MG/ML)</u>	<u>A205487</u>	<u>001</u>	Mar 28, 2016
<u>AP</u>			<u>150MG/15ML (10MG/ML)</u>	<u>A205487</u>	<u>002</u>	Mar 28, 2016
<u>AP</u>			<u>450MG/45ML (10MG/ML)</u>	<u>A205487</u>	<u>003</u>	Mar 28, 2016
<u>AP</u>			<u>600MG/60ML (10MG/ML)</u>	<u>A205487</u>	<u>004</u>	Aug 03, 2020
<u>AP</u>		FRESENIUS KABI USA	<u>450MG/45ML (10MG/ML)</u>	<u>A077247</u>	<u>003</u>	Oct 21, 2004
<u>AP</u>			<u>450MG/45ML (10MG/ML)</u>	<u>A077266</u>	<u>003</u>	Feb 15, 2006
<u>AP</u>			<u>600MG/60ML (10MG/ML)</u>	<u>A077266</u>	<u>004</u>	Feb 15, 2006
<u>AP</u>		GLAND PHARMA LTD	<u>50MG/5ML (10MG/ML)</u>	<u>A207324</u>	<u>001</u>	Feb 15, 2017
<u>AP</u>			<u>150MG/15ML (10MG/ML)</u>	<u>A207324</u>	<u>002</u>	Feb 15, 2017
<u>AP</u>			<u>450MG/45ML (10MG/ML)</u>	<u>A207324</u>	<u>003</u>	Feb 15, 2017
<u>AP</u>			<u>600MG/60ML (10MG/ML)</u>	<u>A207324</u>	<u>004</u>	Feb 15, 2017
<u>AP</u>		HIKMA	<u>50MG/5ML (10MG/ML)</u>	<u>A077244</u>	<u>001</u>	Oct 15, 2004
<u>AP</u>			<u>150MG/15ML (10MG/ML)</u>	<u>A077244</u>	<u>002</u>	Oct 15, 2004
<u>AP</u>			<u>450MG/45ML (10MG/ML)</u>	<u>A077244</u>	<u>003</u>	Oct 15, 2004
<u>AP</u>			<u>600MG/60ML (10MG/ML)</u>	<u>A077244</u>	<u>004</u>	Jan 20, 2006
<u>AP</u>	!	HOSPIRA	<u>50MG/5ML (10MG/ML)</u>	<u>A076517</u>	<u>001</u>	Oct 14, 2004
<u>AP</u>	!		<u>150MG/15ML (10MG/ML)</u>	<u>A076517</u>	<u>002</u>	Oct 14, 2004
<u>AP</u>	!		<u>450MG/45ML (10MG/ML)</u>	<u>A076517</u>	<u>003</u>	Oct 14, 2004

PRESCRIPTION DRUG PRODUCT LIST

3-83 (of 474)

CARBOPLATIN

INJECTABLE; INTRAVENOUS

CARBOPLATIN

<u>AP</u>	!	<u>600MG/60ML (10MG/ML)</u>	<u>A077059</u>	<u>001</u>	Nov 23, 2004
<u>AP</u>	NOVAST LABS	<u>50MG/5ML (10MG/ML)</u>	<u>A208487</u>	<u>001</u>	Apr 26, 2017
<u>AP</u>		<u>150MG/15ML (10MG/ML)</u>	<u>A208487</u>	<u>002</u>	Apr 26, 2017
<u>AP</u>	PHARMACHEMIE BV	<u>50MG/5ML (10MG/ML)</u>	<u>A077269</u>	<u>001</u>	Oct 14, 2004
<u>AP</u>		<u>150MG/15ML (10MG/ML)</u>	<u>A077269</u>	<u>002</u>	Oct 14, 2004
<u>AP</u>		<u>450MG/45ML (10MG/ML)</u>	<u>A077269</u>	<u>003</u>	Oct 14, 2004
<u>AP</u>		<u>600MG/60ML (10MG/ML)</u>	<u>A077269</u>	<u>004</u>	Dec 28, 2007
<u>AP</u>	SANDOZ INC	<u>50MG/5ML (10MG/ML)</u>	<u>A078280</u>	<u>001</u>	May 08, 2008
<u>AP</u>		<u>150MG/15ML (10MG/ML)</u>	<u>A078280</u>	<u>002</u>	May 08, 2008
<u>AP</u>		<u>450MG/45ML (10MG/ML)</u>	<u>A078280</u>	<u>003</u>	May 08, 2008
<u>AP</u>	SUN PHARM	<u>50MG/5ML (10MG/ML)</u>	<u>A077926</u>	<u>001</u>	Sep 19, 2008
<u>AP</u>		<u>150MG/15ML (10MG/ML)</u>	<u>A077926</u>	<u>002</u>	Sep 19, 2008
<u>AP</u>		<u>450MG/45ML (10MG/ML)</u>	<u>A077926</u>	<u>003</u>	Sep 19, 2008
<u>AP</u>	TEYRO LABS	<u>50MG/5ML (10MG/ML)</u>	<u>A077861</u>	<u>001</u>	Jan 18, 2007
<u>AP</u>		<u>150MG/15ML (10MG/ML)</u>	<u>A077861</u>	<u>002</u>	Jan 18, 2007
<u>AP</u>		<u>450MG/45ML (10MG/ML)</u>	<u>A077861</u>	<u>003</u>	Jan 18, 2007
<u>AP</u>		<u>600MG/60ML (10MG/ML)</u>	<u>A077861</u>	<u>004</u>	Jan 18, 2007
	! ACCORD HLTHCARE	1GM/100ML (10MG/ML)	A206775	005	Apr 06, 2020

CARBOPROST TROMETHAMINE

INJECTABLE; INJECTION

CARBOPROST TROMETHAMINE

<u>AP</u>	AMNEAL	<u>EQ 0.25MG BASE/ML</u>	<u>A215337</u>	<u>001</u>	Jan 27, 2022
<u>AP</u>	DR REDDYS	<u>EQ 0.25MG BASE/ML</u>	<u>A211941</u>	<u>001</u>	Jul 02, 2019
<u>AP</u>	LONG GROVE PHARMS	<u>EQ 0.25MG BASE/ML</u>	<u>A214499</u>	<u>001</u>	Aug 09, 2022
<u>AP</u>	SUNNY	<u>EQ 0.25MG BASE/ML</u>	<u>A213118</u>	<u>001</u>	Mar 25, 2021

HEMABATE

<u>AP</u>	+! PFIZER	<u>EQ 0.25MG BASE/ML</u>	<u>N017989</u>	<u>001</u>	

CARFILZOMIB

POWDER; INTRAVENOUS

CARFILZOMIB

<u>AP</u>	DR REDDYS	<u>60MG/VIAL</u>	<u>A209422</u>	<u>001</u>	Sep 09, 2019
	<u>KYPROLIS</u>				
<u>AP</u>	+! ONYX THERAP	<u>60MG/VIAL</u>	<u>N202714</u>	<u>001</u>	Jul 20, 2012
	+	10MG/VIAL	N202714	003	Jun 07, 2018
	+	30MG/VIAL	N202714	002	Jun 03, 2016

CARGLUMIC ACID

TABLET, FOR SUSPENSION; ORAL

CARBAGLU

<u>AB</u>	+! RECORDATI RARE	<u>200MG</u>	<u>N022562</u>	<u>001</u>	Mar 18, 2010

CARGLUMIC ACID

<u>AB</u>	NAVINTA LLC	<u>200MG</u>	<u>A213395</u>	<u>001</u>	Jun 22, 2022
<u>AB</u>	NOVITIUM PHARMA	<u>200MG</u>	<u>A213729</u>	<u>001</u>	Oct 13, 2021

CARIPRAZINE HYDROCHLORIDE

CAPSULE; ORAL

VRAYLAR

	+! ALLERGAN	EQ 1.5MG BASE	N204370	001	Sep 17, 2015
	+	EQ 3MG BASE	N204370	002	Sep 17, 2015
	+	EQ 4.5MG BASE	N204370	003	Sep 17, 2015
	+	EQ 6MG BASE	N204370	004	Sep 17, 2015

CARISOPRODOL

TABLET; ORAL

CARISOPRODOL

<u>AA</u>	ACCELRX LABS	<u>350MG</u>	<u>A040576</u>	<u>001</u>	Jun 07, 2005
<u>AA</u>	AUROBINDO PHARMA	<u>350MG</u>	<u>A040792</u>	<u>001</u>	Aug 06, 2009
<u>AA</u>	CHARTWELL RX	<u>350MG</u>	<u>A040245</u>	<u>001</u>	Sep 08, 1997
<u>AA</u>	MLV	<u>350MG</u>	<u>A211789</u>	<u>001</u>	Oct 20, 2021
<u>AA</u>	NATCO	<u>350MG</u>	<u>A090988</u>	<u>001</u>	Oct 28, 2014
<u>AA</u>	NOSTRUM LABS INC	<u>350MG</u>	<u>A207237</u>	<u>002</u>	Sep 21, 2020
<u>AA</u>	NOVAST LABS	<u>350MG</u>	<u>A040823</u>	<u>001</u>	Oct 22, 2008
<u>AA</u>	ORIENT PHARMA CO LTD	<u>350MG</u>	<u>A205085</u>	<u>001</u>	Oct 28, 2014
<u>AA</u>	OXFORD PHARMS	<u>350MG</u>	<u>A040188</u>	<u>001</u>	Mar 07, 1997
<u>AA</u>	SCIEGEN PHARMS INC	<u>350MG</u>	<u>A203374</u>	<u>001</u>	Jan 27, 2014
<u>AA</u>	WANBANG BIOPHARMS	<u>350MG</u>	<u>A081025</u>	<u>001</u>	Apr 13, 1989
<u>AA</u>	WATSON LABS	<u>350MG</u>	<u>A087499</u>	<u>001</u>	Apr 20, 1982
<u>AA</u>	WILSHIRE PHARMS INC	<u>350MG</u>	<u>A205126</u>	<u>002</u>	Jul 08, 2015

PRESCRIPTION DRUG PRODUCT LIST

3-84 (of 474)

CARISOPRODOL

TABLET; ORAL

SOMA

AA	+	MYLAN SPECIALITY LP	350MG	<u>N011792</u>	<u>001</u>	

CARISOPRODOL

AB		AUROBINDO PHARMA	250MG	<u>A040792</u>	<u>002</u>	Nov 08, 2016

AB		NOSTRUM LABS INC	250MG	<u>A207237</u>	<u>001</u>	May 11, 2017

AB		WILSHIRE PHARMS INC	250MG	<u>A205126</u>	<u>001</u>	Jul 08, 2015

SOMA

AB	+	MYLAN SPECIALITY LP	250MG	<u>N011792</u>	<u>004</u>	Sep 13, 2007

CARMUSTINE

IMPLANT; INTRACRANIAL

GLIADEL

+! AZURITY

7.7MG

N020637 001 Sep 23, 1996

INJECTABLE; INJECTION

BICNU

AP	+	AVET LIFESCIENCES	100MG/VIAL	<u>N017422</u>	<u>001</u>	

CARMUSTINE

AP		AMNEAL	100MG/VIAL	<u>A211229</u>	<u>001</u>	Oct 16, 2018

AP		DR REDDYS	100MG/VIAL	<u>A213207</u>	<u>001</u>	Oct 22, 2020

AP		HENGRUI PHARMA	100MG/VIAL	<u>A211202</u>	<u>001</u>	Mar 12, 2021

AP		INGENUS PHARMS LLC	100MG/VIAL	<u>A211011</u>	<u>001</u>	Jun 21, 2022

AP		MEITHEAL	100MG/VIAL	<u>A213460</u>	<u>001</u>	Aug 02, 2021

AP		NAVINTA LLC	100MG/VIAL	<u>A210179</u>	<u>001</u>	Sep 11, 2018

AP		STI PHARMA LLC	100MG/VIAL	<u>A209278</u>	<u>001</u>	Apr 02, 2019

Carmustine

AP		ACCORD HLTHCARE	100MG/VIAL	<u>A214117</u>	<u>001</u>	Dec 27, 2022

POWDER; INTRAVENOUS

CARMUSTINE

+! ACCORD HLTHCARE

50MG/VIAL

N215000 001 May 16, 2022

+!

300MG/VIAL

N215000 002 May 16, 2022

CARTEOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

CARTEOLOL HYDROCHLORIDE

! SANDOZ INC

1%

A075476 001 Jan 03, 2000

CARVEDILOL

TABLET; ORAL

CARVEDILOL

AB		AUROBINDO PHARMA	3.125MG	<u>A078332</u>	<u>001</u>	Sep 05, 2007

AB			6.25MG	<u>A078332</u>	<u>002</u>	Sep 05, 2007

AB			12.5MG	<u>A078332</u>	<u>003</u>	Sep 05, 2007

AB			25MG	<u>A078332</u>	<u>004</u>	Sep 05, 2007

AB		BEXIMCO USA	3.125MG	<u>A078384</u>	<u>001</u>	Sep 05, 2007

AB			6.25MG	<u>A078384</u>	<u>002</u>	Sep 05, 2007

AB			12.5MG	<u>A078384</u>	<u>003</u>	Sep 05, 2007

AB			25MG	<u>A078384</u>	<u>004</u>	Sep 05, 2007

AB		CHARTWELL MOLECULAR	3.125MG	<u>A077474</u>	<u>001</u>	Sep 05, 2007

AB			6.25MG	<u>A077474</u>	<u>002</u>	Sep 05, 2007

AB			12.5MG	<u>A077474</u>	<u>003</u>	Sep 05, 2007

AB			25MG	<u>A077474</u>	<u>004</u>	Sep 05, 2007

AB		DR REDDYS LABS LTD	3.125MG	<u>A076649</u>	<u>001</u>	Sep 05, 2007

AB			6.25MG	<u>A076649</u>	<u>002</u>	Sep 05, 2007

AB			12.5MG	<u>A076649</u>	<u>003</u>	Sep 05, 2007

AB			25MG	<u>A076649</u>	<u>004</u>	Sep 05, 2007

AB		GLENMARK GENERICS	3.125MG	<u>A078251</u>	<u>001</u>	Sep 05, 2007

AB			6.25MG	<u>A078251</u>	<u>002</u>	Sep 05, 2007

AB			12.5MG	<u>A078251</u>	<u>003</u>	Sep 05, 2007

AB			25MG	<u>A078251</u>	<u>004</u>	Sep 05, 2007

AB		LUPIN	3.125MG	<u>A078217</u>	<u>001</u>	Sep 05, 2007

AB			6.25MG	<u>A078217</u>	<u>002</u>	Sep 05, 2007

AB			12.5MG	<u>A078217</u>	<u>003</u>	Sep 05, 2007

AB			25MG	<u>A078217</u>	<u>004</u>	Sep 05, 2007

AB		MYLAN	3.125MG	<u>A077316</u>	<u>001</u>	Sep 05, 2007

AB			6.25MG	<u>A077316</u>	<u>002</u>	Sep 05, 2007

AB			12.5MG	<u>A077316</u>	<u>003</u>	Sep 05, 2007

AB			25MG	<u>A077316</u>	<u>004</u>	Sep 05, 2007

AB		RUBICON	3.125MG	<u>A078165</u>	<u>001</u>	Sep 05, 2007

AB			6.25MG	<u>A078165</u>	<u>002</u>	Sep 05, 2007

AB			12.5MG	<u>A078165</u>	<u>003</u>	Sep 05, 2007

AB			25MG	<u>A078165</u>	<u>004</u>	Sep 05, 2007

AB		SANDOZ	3.125MG	<u>A078227</u>	<u>001</u>	Sep 05, 2007

PRESCRIPTION DRUG PRODUCT LIST

3-85 (of 474)

CARVEDILOL

TABLET; ORAL

CARVEDILOL

<u>AB</u>		<u>6.25MG</u>	<u>A078227</u>	<u>002</u>	Sep 05, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A078227</u>	<u>003</u>	Sep 05, 2007
<u>AB</u>		<u>25MG</u>	<u>A078227</u>	<u>004</u>	Sep 05, 2007
<u>AB</u>	SUN PHARM INDS LTD	<u>3.125MG</u>	<u>A076989</u>	<u>001</u>	Sep 05, 2007
<u>AB</u>		<u>6.25MG</u>	<u>A076989</u>	<u>002</u>	Sep 05, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A076989</u>	<u>003</u>	Sep 05, 2007
<u>AB</u>		<u>25MG</u>	<u>A076989</u>	<u>004</u>	Sep 05, 2007
<u>AB</u>	TARO	<u>3.125MG</u>	<u>A077780</u>	<u>001</u>	Sep 05, 2007
<u>AB</u>		<u>6.25MG</u>	<u>A077780</u>	<u>002</u>	Sep 05, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A077780</u>	<u>003</u>	Sep 05, 2007
<u>AB</u>		<u>25MG</u>	<u>A077780</u>	<u>004</u>	Sep 05, 2007
<u>AB</u>	TEVA	<u>3.125MG</u>	<u>A076373</u>	<u>001</u>	Sep 05, 2007
<u>AB</u>		<u>6.25MG</u>	<u>A076373</u>	<u>002</u>	Sep 05, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A076373</u>	<u>003</u>	Sep 05, 2007
<u>AB</u>		<u>25MG</u>	<u>A076373</u>	<u>004</u>	Sep 05, 2007
<u>AB</u>	ZYDUS PHARMS USA INC	<u>3.125MG</u>	<u>A077614</u>	<u>004</u>	Sep 05, 2007
<u>AB</u>		<u>6.25MG</u>	<u>A077614</u>	<u>001</u>	Sep 05, 2007
<u>AB</u>		<u>12.5MG</u>	<u>A077614</u>	<u>002</u>	Sep 05, 2007
<u>AB</u>		<u>25MG</u>	<u>A077614</u>	<u>003</u>	Sep 05, 2007
<u>COREG</u>					
<u>AB</u>	+ WOODWARD	<u>3.125MG</u>	<u>N020297</u>	<u>004</u>	May 29, 1997
<u>AB</u>	+	<u>6.25MG</u>	<u>N020297</u>	<u>003</u>	Sep 14, 1995
<u>AB</u>	+!	<u>12.5MG</u>	<u>N020297</u>	<u>002</u>	Sep 14, 1995
<u>AB</u>	+	<u>25MG</u>	<u>N020297</u>	<u>001</u>	Sep 14, 1995

CARVEDILOL PHOSPHATE

CAPSULE, EXTENDED RELEASE; ORAL

CARVEDILOL PHOSPHATE

<u>AB</u>	IMPAX LABS INC	<u>10MG</u>	<u>A204717</u>	<u>001</u>	May 07, 2018
<u>AB</u>		<u>20MG</u>	<u>A204717</u>	<u>002</u>	May 07, 2018
<u>AB</u>		<u>40MG</u>	<u>A204717</u>	<u>003</u>	May 07, 2018
<u>AB</u>		<u>80MG</u>	<u>A204717</u>	<u>004</u>	May 07, 2018
<u>AB</u>	SUN PHARM INDUSTRIES	<u>10MG</u>	<u>A090132</u>	<u>001</u>	Oct 25, 2017
<u>AB</u>		<u>20MG</u>	<u>A090132</u>	<u>002</u>	Oct 25, 2017
<u>AB</u>		<u>40MG</u>	<u>A090132</u>	<u>003</u>	Oct 25, 2017
<u>AB</u>		<u>80MG</u>	<u>A090132</u>	<u>004</u>	Oct 25, 2017
<u>COREG CR</u>					
<u>AB</u>	+ WOODWARD	<u>10MG</u>	<u>N022012</u>	<u>001</u>	Oct 20, 2006
<u>AB</u>	+	<u>20MG</u>	<u>N022012</u>	<u>002</u>	Oct 20, 2006
<u>AB</u>	+!	<u>40MG</u>	<u>N022012</u>	<u>003</u>	Oct 20, 2006
<u>AB</u>	+	<u>80MG</u>	<u>N022012</u>	<u>004</u>	Oct 20, 2006

CASIMERSEN

SOLUTION; INTRAVENOUS

AMONDYS 45

+! SAREPTA THERAPS INC 100MG/2ML (50MG/ML) N213026 001 Feb 25, 2021

CASPOFUNGIN ACETATE

POWDER; INTRAVENOUS

CANCIDAS

<u>AP</u>	+! MERCK	<u>50MG/VIAL</u>	<u>N021227</u>	<u>001</u>	Jan 26, 2001
<u>AP</u>	+!	<u>70MG/VIAL</u>	<u>N021227</u>	<u>002</u>	Jan 26, 2001
<u>CASPOFUNGIN ACETATE</u>					
<u>AP</u>	FRESENIUS KABI USA	<u>50MG/VIAL</u>	<u>N206110</u>	<u>001</u>	Dec 30, 2016
<u>AP</u>		<u>70MG/VIAL</u>	<u>N206110</u>	<u>002</u>	Dec 30, 2016
<u>AP</u>	GLAND	<u>50MG/VIAL</u>	<u>A207092</u>	<u>001</u>	Sep 29, 2017
<u>AP</u>		<u>70MG/VIAL</u>	<u>A207092</u>	<u>002</u>	Sep 29, 2017
<u>AP</u>	HENGRUI PHARMA	<u>50MG/VIAL</u>	<u>A200833</u>	<u>001</u>	Jun 28, 2018
<u>AP</u>		<u>70MG/VIAL</u>	<u>A200833</u>	<u>002</u>	Jun 28, 2018
<u>AP</u>	UBI	<u>50MG/VIAL</u>	<u>A211263</u>	<u>001</u>	Oct 01, 2021
<u>AP</u>		<u>70MG/VIAL</u>	<u>A211263</u>	<u>002</u>	Oct 01, 2021

CEDAZURIDINE; DECITABINE

TABLET; ORAL

INQOVI

+! OTSUKA 100MG; 35MG N212576 001 Jul 07, 2020

PRESCRIPTION DRUG PRODUCT LIST

3-86 (of 474)

CEFACLOL

CAPSULE; ORAL

CEFACLOL

<u>AB</u>	HIKMA	<u>EQ 250MG BASE</u>	<u>A065350</u>	<u>001</u>	Apr 03, 2007
<u>AB</u>	!	<u>EQ 500MG BASE</u>	<u>A065350</u>	<u>002</u>	Apr 03, 2007
<u>AB</u>	YUNG SHIN PHARM	<u>EQ 250MG BASE</u>	<u>A065146</u>	<u>001</u>	Jan 22, 2004
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A065146</u>	<u>002</u>	Jan 22, 2004

FOR SUSPENSION; ORAL

CEFACLOL

	YUNG SHIN PHARM	EQ 125MG BASE/5ML	A065412	001	Feb 17, 2012
		EQ 187MG BASE/5ML	A065412	002	Feb 17, 2012
		EQ 250MG BASE/5ML	A065412	003	Feb 17, 2012
!		EQ 375MG BASE/5ML	A065412	004	Feb 17, 2012

TABLET, EXTENDED RELEASE; ORAL

CEFACLOL

	TEVA	EQ 375MG BASE	A065058	001	Sep 04, 2002
!		EQ 500MG BASE	A065058	002	Sep 04, 2002

CEFADROXIL/CEFADROXIL HEMIHYDRATE

CAPSULE; ORAL

CEFADROXIL

<u>AB</u>	AUROBINDO PHARMA	<u>EQ 500MG BASE</u>	<u>A065352</u>	<u>001</u>	Jan 25, 2007
<u>AB</u>	HIKMA	<u>EQ 500MG BASE</u>	<u>A065311</u>	<u>001</u>	Feb 07, 2006
<u>AB</u>	LUPIN	<u>EQ 500MG BASE</u>	<u>A065392</u>	<u>001</u>	May 29, 2007
<u>AB</u>	! TEVA PHARMS	<u>EQ 500MG BASE</u>	<u>A065282</u>	<u>001</u>	Jan 20, 2006

FOR SUSPENSION; ORAL

CEFADROXIL

<u>AB</u>	AUROBINDO	<u>EQ 250MG BASE/5ML</u>	<u>A065349</u>	<u>001</u>	Apr 25, 2013
<u>AB</u>		<u>EQ 500MG BASE/5ML</u>	<u>A065349</u>	<u>002</u>	Apr 25, 2013
<u>AB</u>	HIKMA PHARMS	<u>EQ 250MG BASE/5ML</u>	<u>A091036</u>	<u>001</u>	Nov 28, 2012
<u>AB</u>		<u>EQ 500MG BASE/5ML</u>	<u>A091036</u>	<u>002</u>	Nov 28, 2012
<u>AB</u>	LUPIN	<u>EQ 250MG BASE/5ML</u>	<u>A065396</u>	<u>001</u>	Feb 21, 2008
<u>AB</u>	!	<u>EQ 500MG BASE/5ML</u>	<u>A065396</u>	<u>002</u>	Feb 21, 2008

TABLET; ORAL

CEFADROXIL

<u>AB</u>	HIKMA	<u>EQ 1GM BASE</u>	<u>A065260</u>	<u>001</u>	Mar 30, 2006
<u>AB</u>	! TEVA PHARMS	<u>EQ 1GM BASE</u>	<u>A062774</u>	<u>001</u>	Apr 08, 1987

CEFAZOLIN SODIUM

INJECTABLE; INJECTION

CEFAZOLIN SODIUM

<u>AP</u>	ACS DOBFAR	<u>EQ 500MG BASE/VIAL</u>	<u>A065303</u>	<u>001</u>	Oct 22, 2008
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A065303</u>	<u>002</u>	Oct 22, 2008
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A065306</u>	<u>001</u>	Oct 22, 2008
<u>AP</u>	! HIKMA FARMACEUTICA	<u>EQ 500MG BASE/VIAL</u>	<u>A065047</u>	<u>001</u>	Sep 18, 2001
<u>AP</u>	!	<u>EQ 1GM BASE/VIAL</u>	<u>A065047</u>	<u>002</u>	Sep 18, 2001
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A065143</u>	<u>001</u>	Oct 18, 2004
<u>AP</u>	QILU	<u>EQ 1GM BASE/VIAL</u>	<u>A203661</u>	<u>001</u>	Dec 28, 2015
<u>AP</u>	!	<u>EQ 10GM BASE/VIAL</u>	<u>A209217</u>	<u>001</u>	Oct 17, 2018
<u>AP</u>	SANDOZ	<u>EQ 500MG BASE/VIAL</u>	<u>A062831</u>	<u>001</u>	Dec 09, 1988
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A062831</u>	<u>002</u>	Dec 09, 1988
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A065345</u>	<u>001</u>	May 09, 2007
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A062831</u>	<u>003</u>	Sep 25, 1992

ANCEF IN PLASTIC CONTAINER

!	BAXTER HLTHCARE	EQ 20MG BASE/ML	A063002	002	Mar 28, 1991

CEFAZOLIN AND DEXTROSE

+	! B BRAUN	EQ 1GM BASE/VIAL	N050779	002	Jul 27, 2000
+		EQ 2GM BASE/VIAL	N050779	003	Jan 13, 2012

CEFAZOLIN SODIUM

!	ACS DOBFAR	EQ 20GM BASE/VIAL	A065306	002	Aug 18, 2014
	QILU	EQ 2GM BASE/VIAL	A203661	002	Mar 11, 2022
!	SAMSON MEDCL	EQ 100GM BASE/VIAL	A065141	001	Nov 29, 2006
!		EQ 300GM BASE/VIAL	A065141	002	Nov 29, 2006

POWDER; INTRAVENOUS

CEFAZOLIN SODIUM

+	! HIKMA	EQ 2GM BASE/VIAL	N216109	001	Oct 07, 2022
+		EQ 3GM BASE/VIAL	N216109	002	Oct 07, 2022

SOLUTION; INTRAVENOUS

CEFAZOLIN IN PLASTIC CONTAINER

+	! BAXTER HLTHCARE	EQ 1GM BASE/50ML (EQ 20MG BASE/ML)	N207131	002	Feb 01, 2021
+	!	EQ 2GM BASE/100ML (EQ 20MG BASE/ML)	N207131	001	Aug 07, 2015

PRESCRIPTION DRUG PRODUCT LIST

3-87 (of 474)

CEFDINIR

CAPSULE; ORAL

CEFDINIR

<u>AB</u>	ALKEM LABS LTD	<u>300MG</u>	<u>A210220</u>	<u>001</u>	Feb 19, 2021
<u>AB</u>	AUROBINDO PHARMA	<u>300MG</u>	<u>A065434</u>	<u>001</u>	Jan 07, 2008
<u>AB</u>	LUPIN	<u>300MG</u>	<u>A065264</u>	<u>001</u>	May 19, 2006
<u>AB</u>	ORCHID HLTHCARE	<u>300MG</u>	<u>A065418</u>	<u>001</u>	Jul 18, 2007
<u>AB</u>	! SANDOZ	<u>300MG</u>	<u>A065330</u>	<u>001</u>	Apr 06, 2007
<u>AB</u>	TEVA PHARMS	<u>300MG</u>	<u>A065368</u>	<u>001</u>	May 09, 2007

FOR SUSPENSION; ORAL

CEFDINIR

<u>AB</u>	ALKEM LABS LTD	<u>125MG/5ML</u>	<u>A210534</u>	<u>001</u>	Feb 19, 2021
<u>AB</u>		<u>250MG/5ML</u>	<u>A210534</u>	<u>002</u>	Feb 19, 2021
<u>AB</u>	AUROBINDO PHARMA	<u>125MG/5ML</u>	<u>A065473</u>	<u>001</u>	Dec 14, 2007
<u>AB</u>	! LUPIN	<u>250MG/5ML</u>	<u>A065473</u>	<u>002</u>	Dec 14, 2007
<u>AB</u>		<u>125MG/5ML</u>	<u>A065259</u>	<u>001</u>	May 31, 2006
<u>AB</u>		<u>250MG/5ML</u>	<u>A065259</u>	<u>002</u>	May 07, 2007
<u>AB</u>	ORCHID HLTHCARE	<u>125MG/5ML</u>	<u>A065429</u>	<u>001</u>	Jul 18, 2007
<u>AB</u>		<u>250MG/5ML</u>	<u>A065429</u>	<u>002</u>	Jul 18, 2007
<u>AB</u>	SANDOZ	<u>125MG/5ML</u>	<u>A065337</u>	<u>001</u>	Apr 06, 2007
<u>AB</u>		<u>250MG/5ML</u>	<u>A065337</u>	<u>002</u>	Apr 06, 2007
<u>AB</u>	TEVA PHARMS	<u>125MG/5ML</u>	<u>A065332</u>	<u>001</u>	May 04, 2007
<u>AB</u>		<u>250MG/5ML</u>	<u>A065332</u>	<u>002</u>	May 04, 2007

CEFEPIME HYDROCHLORIDE

INJECTABLE; INJECTION

CEFEPIME HYDROCHLORIDE

<u>AP</u>	ACS DOBFAR	<u>EQ 1GM BASE/VIAL</u>	<u>A065441</u>	<u>001</u>	Mar 20, 2008
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065441</u>	<u>002</u>	Mar 20, 2008
<u>AP</u>	ASTRAL	<u>EQ 1GM BASE/VIAL</u>	<u>A212721</u>	<u>001</u>	Jul 21, 2020
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A212721</u>	<u>002</u>	Jul 21, 2020
<u>AP</u>	QILU	<u>EQ 500MG BASE/VIAL</u>	<u>A203704</u>	<u>001</u>	Feb 01, 2016
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A203704</u>	<u>002</u>	Feb 01, 2016
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A203704</u>	<u>003</u>	Feb 01, 2016
<u>AP</u>	SAGENT PHARMS INC	<u>EQ 1GM BASE/VIAL</u>	<u>A091048</u>	<u>001</u>	Jan 04, 2017
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A091048</u>	<u>002</u>	Jan 04, 2017

MAXIPIIME

<u>AP</u>	+! HOSPIRA INC	<u>EQ 500MG BASE/VIAL</u>	<u>N050679</u>	<u>001</u>	Jan 18, 1996
<u>AP</u>	+!	<u>EQ 1GM BASE/VIAL</u>	<u>N050679</u>	<u>002</u>	Jan 18, 1996
<u>AP</u>	+!	<u>EQ 2GM BASE/VIAL</u>	<u>N050679</u>	<u>003</u>	Jan 18, 1996

CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER

B BRAUN

EQ 1GM BASE/VIAL

N050821 001 May 06, 2010

EQ 2GM BASE/VIAL

N050821 002 May 06, 2010

CEFEPIME IN PLASTIC CONTAINER

+! BAXTER HLTHCARE

EQ 1GM BASE/50ML (EQ 20MG BASE/ML)

N050817 001 Aug 05, 2008

+!

EQ 2GM BASE/100ML (EQ 20MG BASE/ML)

N050817 002 Aug 05, 2008

POWDER; INTRAVENOUS

CEFEPIME HYDROCHLORIDE IN PLASTIC CONTAINER

SAMSON MEDCL

EQ 100GM BASE

A209408 001 Aug 21, 2018

CEFIDEROCOL SULFATE TOSYLATE

POWDER; INTRAVENOUS

FETROJA

+! SHIONOGI INC

EQ 1GM BASE/VIAL

N209445 001 Nov 14, 2019

CEFIXIME

CAPSULE; ORAL

CEFIXIME

<u>AB</u>	ALKEM LABS LTD	<u>400MG</u>	<u>A210574</u>	<u>001</u>	Oct 09, 2018

SUPRAX

<u>AB</u>	+! LUPIN LTD	<u>400MG</u>	<u>N203195</u>	<u>001</u>	Jun 01, 2012

FOR SUSPENSION; ORAL

CEFIXIME

<u>AB</u>	ALKEM LABS LTD	<u>100MG/5ML</u>	<u>A211775</u>	<u>001</u>	Feb 19, 2021
<u>AB</u>		<u>200MG/5ML</u>	<u>A211775</u>	<u>002</u>	Feb 19, 2021
<u>AB</u>	AUROBINDO PHARMA LTD	<u>100MG/5ML</u>	<u>A204835</u>	<u>001</u>	Apr 14, 2015
<u>AB</u>		<u>200MG/5ML</u>	<u>A204835</u>	<u>002</u>	Apr 14, 2015
<u>AB</u>	BELCHER	<u>100MG/5ML</u>	<u>A206938</u>	<u>001</u>	Feb 06, 2017
<u>AB</u>		<u>200MG/5ML</u>	<u>A206938</u>	<u>002</u>	Feb 06, 2017
<u>AB</u>		<u>500MG/5ML</u>	<u>A206939</u>	<u>001</u>	Feb 06, 2017

SUPRAX

<u>AB</u>	+! LUPIN LTD	<u>500MG/5ML</u>	<u>N202091</u>	<u>001</u>	Feb 20, 2013
<u>AB</u>	! LUPIN PHARMS	<u>200MG/5ML</u>	<u>A065355</u>	<u>001</u>	Apr 10, 2007

PRESCRIPTION DRUG PRODUCT LIST

3-88 (of 474)

CEFIXIMETABLET, CHEWABLE; ORAL
SUPRAX

LUPIN LTD	100MG	A065380	001	Oct 25, 2010
	150MG	A065380	002	Oct 25, 2010
!	200MG	A065380	003	Oct 25, 2010

CEFOTAXIME SODIUM

INJECTABLE; INJECTION

CEFOTAXIME

! HIKMA	EQ 500MG BASE/VIAL	A065072	001	Nov 20, 2002
!	EQ 1GM BASE/VIAL	A065072	002	Nov 20, 2002
!	EQ 2GM BASE/VIAL	A065072	003	Nov 20, 2002
!	EQ 10GM BASE/VIAL	A065071	001	Nov 20, 2002

CEFOTETAN DISODIUM

INJECTABLE; INJECTION

CEFOTAN

AP + PAI HOLDINGS PHARM	<u>EQ 1GM BASE/VIAL</u>	<u>N050588</u>	<u>001</u>	Dec 27, 1985
AP +	<u>EQ 2GM BASE/VIAL</u>	<u>N050588</u>	<u>002</u>	Dec 27, 1985

CEFOTETAN

AP ! FRESenius KABI USA	<u>EQ 1GM BASE/VIAL</u>	<u>A065374</u>	<u>001</u>	Aug 09, 2007
AP !	<u>EQ 2GM BASE/VIAL</u>	<u>A065374</u>	<u>002</u>	Aug 09, 2007

CEFOXITIN SODIUM

INJECTABLE; INJECTION

CEFOXITIN

AP ! ACS DOBFAR	<u>EQ 1GM BASE/VIAL</u>	<u>A065414</u>	<u>001</u>	Jun 12, 2009
AP !	<u>EQ 2GM BASE/VIAL</u>	<u>A065414</u>	<u>002</u>	Jun 12, 2009
AP !	<u>EQ 10GM BASE/VIAL</u>	<u>A065415</u>	<u>001</u>	May 19, 2010
AP HIKMA	<u>EQ 1GM BASE/VIAL</u>	<u>A065051</u>	<u>001</u>	Sep 11, 2000
AP	<u>EQ 2GM BASE/VIAL</u>	<u>A065051</u>	<u>002</u>	Sep 11, 2000
AP	<u>EQ 10GM BASE/VIAL</u>	<u>A065050</u>	<u>001</u>	Sep 11, 2000
AP HIKMA FARMACEUTICA	<u>EQ 1GM BASE/VIAL</u>	<u>A065238</u>	<u>001</u>	Mar 12, 2010
AP	<u>EQ 2GM BASE/VIAL</u>	<u>A065238</u>	<u>002</u>	Mar 12, 2010
AP	<u>EQ 10GM BASE/VIAL</u>	<u>A065239</u>	<u>001</u>	Mar 02, 2010

CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER

AP +! B BRAUN	<u>EQ 1GM BASE/VIAL</u>	<u>N065214</u>	<u>001</u>	Mar 10, 2006
AP +!	<u>EQ 2GM BASE/VIAL</u>	<u>N065214</u>	<u>002</u>	Mar 10, 2006

POWDER; INTRAVENOUS

CEFOXITIN IN PLASTIC CONTAINER

SAMSON MEDCL	EQ 100GM BASE	A200938	001	Nov 16, 2015

CEFPODOXIME PROXETIL

FOR SUSPENSION; ORAL

CEFPODOXIME PROXETIL

AUROBINDO PHARMA LTD	EQ 50MG BASE/5ML	A065409	001	Jun 08, 2007
!	EQ 100MG BASE/5ML	A065409	002	Jun 08, 2007

TABLET; ORAL

CEFPODOXIME PROXETIL

AB ALKEM LABS LTD	<u>EQ 100MG BASE</u>	<u>A210568</u>	<u>001</u>	May 18, 2022
AB	<u>EQ 200MG BASE</u>	<u>A210568</u>	<u>002</u>	May 18, 2022
AB AUROBINDO PHARMA	<u>EQ 100MG BASE</u>	<u>A065370</u>	<u>001</u>	Jun 11, 2007
AB	<u>EQ 200MG BASE</u>	<u>A065370</u>	<u>002</u>	Jun 11, 2007
AB ORCHID HLTHCARE	<u>EQ 100MG BASE</u>	<u>A065388</u>	<u>001</u>	Nov 14, 2007
AB	<u>EQ 200MG BASE</u>	<u>A065388</u>	<u>002</u>	Nov 14, 2007
AB SANDOZ	<u>EQ 100MG BASE</u>	<u>A065462</u>	<u>001</u>	May 28, 2008
AB !	<u>EQ 200MG BASE</u>	<u>A065462</u>	<u>002</u>	May 28, 2008

CEFPROZIL

FOR SUSPENSION; ORAL

CEFPROZIL

AB APOTEX INC	<u>125MG/5ML</u>	<u>A065351</u>	<u>001</u>	Feb 29, 2012
AB	<u>250MG/5ML</u>	<u>A065351</u>	<u>002</u>	Feb 29, 2012
AB AUROBINDO PHARMA	<u>125MG/5ML</u>	<u>A065381</u>	<u>001</u>	Jan 30, 2007
AB	<u>250MG/5ML</u>	<u>A065381</u>	<u>002</u>	Jan 30, 2007
AB LUPIN	<u>125MG/5ML</u>	<u>A065261</u>	<u>001</u>	Dec 19, 2005
AB !	<u>250MG/5ML</u>	<u>A065261</u>	<u>002</u>	Dec 19, 2005

TABLET; ORAL

CEFPROZIL

AB APOTEX INC	<u>250MG</u>	<u>A065327</u>	<u>001</u>	Mar 26, 2008
AB	<u>500MG</u>	<u>A065327</u>	<u>002</u>	Mar 26, 2008
AB AUROBINDO PHARMA	<u>250MG</u>	<u>A065340</u>	<u>001</u>	May 24, 2007
AB	<u>500MG</u>	<u>A065340</u>	<u>002</u>	May 24, 2007

PRESCRIPTION DRUG PRODUCT LIST

3-89 (of 474)

CEFPROZIL

TABLET; ORAL

CEFPROZIL

<u>AB</u>	CHARTWELL RX	<u>250MG</u>	<u>A065235</u>	<u>001</u>	Nov 14, 2005
<u>AB</u>		<u>500MG</u>	<u>A065235</u>	<u>002</u>	Nov 14, 2005
<u>AB</u>	LUPIN	<u>250MG</u>	<u>A065276</u>	<u>001</u>	Dec 08, 2005
<u>AB</u>	!	<u>500MG</u>	<u>A065276</u>	<u>002</u>	Dec 08, 2005
<u>AB</u>	TEVA	<u>250MG</u>	<u>A065208</u>	<u>001</u>	Dec 06, 2005
<u>AB</u>		<u>500MG</u>	<u>A065208</u>	<u>002</u>	Dec 06, 2005

CEFTAROLINE FOSAMIL

POWDER; INTRAVENOUS

TEFLARO

+	!	ALLERGAN	400MG/VIAL	N200327	001	Oct 29, 2010
+	!		600MG/VIAL	N200327	002	Oct 29, 2010

CEFTAZIDIME

INJECTABLE; INJECTION

CEFTAZIDIME

<u>AP</u>	ACS DOBFAR	<u>1GM/VIAL</u>	<u>A062640</u>	<u>002</u>	Nov 20, 1985
<u>AP</u>		<u>2GM/VIAL</u>	<u>A062640</u>	<u>003</u>	Nov 20, 1985
<u>AP</u>		<u>6GM/VIAL</u>	<u>A062640</u>	<u>004</u>	Feb 03, 1992

FORTAZ

<u>AP</u>	+	!	PAI HOLDINGS PHARM	<u>500MG/VIAL</u>	<u>N050578</u>	<u>001</u>	Jul 19, 1985
<u>AP</u>	+	!		<u>1GM/VIAL</u>	<u>N050578</u>	<u>002</u>	Jul 19, 1985
<u>AP</u>	+	!		<u>2GM/VIAL</u>	<u>N050578</u>	<u>003</u>	Jul 19, 1985
<u>AP</u>	+	!		<u>6GM/VIAL</u>	<u>N050578</u>	<u>004</u>	Jul 19, 1985

TAZICEF

<u>AP</u>	HOSPIRA	<u>500MG/VIAL</u>	<u>A062662</u>	<u>001</u>	Mar 06, 1986
<u>AP</u>		<u>1GM/VIAL</u>	<u>A062662</u>	<u>002</u>	Mar 06, 1986
<u>AP</u>		<u>1GM/VIAL</u>	<u>A064032</u>	<u>001</u>	Oct 31, 1993
<u>AP</u>		<u>2GM/VIAL</u>	<u>A062662</u>	<u>003</u>	Mar 06, 1986
<u>AP</u>		<u>2GM/VIAL</u>	<u>A064032</u>	<u>002</u>	Oct 31, 1993
<u>AP</u>		<u>6GM/VIAL</u>	<u>A062662</u>	<u>004</u>	Mar 06, 1986

CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM

POWDER; INTRAVENOUS

ZERBAXA

+	!	CUBIST PHARMS LLC	EQ 1GM BASE/VIAL; EQ 0.5GM BASE/VIAL	N206829	001	Dec 19, 2014

CEFTRIAXONE SODIUM

INJECTABLE; INJECTION

CEFTRIAXONE

<u>AP</u>	ACS DOBFAR	<u>EQ 500MG BASE/VIAL</u>	<u>A065329</u>	<u>001</u>	Jul 24, 2008
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A065329</u>	<u>002</u>	Jul 24, 2008
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065329</u>	<u>003</u>	Jul 24, 2008
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A065328</u>	<u>001</u>	Jul 24, 2008
<u>AP</u>	QILU	<u>EQ 10GM BASE/VIAL</u>	<u>A209218</u>	<u>001</u>	Oct 17, 2018
<u>AP</u>	! SANDOZ	<u>EQ 10GM BASE/VIAL</u>	<u>A065168</u>	<u>001</u>	May 17, 2005
<u>AP</u>	! SANDOZ INC	<u>EQ 1GM BASE/VIAL</u>	<u>A065204</u>	<u>001</u>	May 03, 2005
<u>AP</u>	!	<u>EQ 2GM BASE/VIAL</u>	<u>A065204</u>	<u>002</u>	May 03, 2005
<u>AP</u>	WOCKHARDT	<u>EQ 1GM BASE/VIAL</u>	<u>A065180</u>	<u>001</u>	May 12, 2006

CEFTRIAXONE AND DEXTROSE IN DUPLEX CONTAINER

<u>AP</u>	+	!	B BRAUN	<u>EQ 1GM BASE/VIAL</u>	<u>N050796</u>	<u>001</u>	Apr 20, 2005
<u>AP</u>	+	!		<u>EQ 2GM BASE/VIAL</u>	<u>N050796</u>	<u>002</u>	Apr 20, 2005

CEFTRIAXONE SODIUM

<u>AP</u>	ASTRAL	<u>EQ 10GM BASE/VIAL</u>	<u>A091117</u>	<u>001</u>	Jan 20, 2017
<u>AP</u>	HIKMA	<u>EQ 10GM BASE/VIAL</u>	<u>A090701</u>	<u>001</u>	Oct 04, 2017

CEFTRIAXONE

	SAMSON MEDCL	EQ 100GM BASE/VIAL	A090057	001	Apr 25, 2014

CEFTRIAXONE IN PLASTIC CONTAINER

!	BAXTER HLTHCARE	EQ 20MG BASE/ML	A065224	001	Aug 23, 2005
!		EQ 40MG BASE/ML	A065224	002	Aug 23, 2005

INJECTABLE; INTRAMUSCULAR, INTRAVENOUS

CEFTRIAXONE

<u>AP</u>	AKORN	<u>EQ 250MG BASE/VIAL</u>	<u>A065305</u>	<u>001</u>	Jan 11, 2008
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A065305</u>	<u>002</u>	Jan 11, 2008
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A065305</u>	<u>003</u>	Jan 11, 2008
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A065305</u>	<u>004</u>	Jan 11, 2008
<u>AP</u>	ASTRAL	<u>EQ 250MG BASE/VIAL</u>	<u>A091049</u>	<u>001</u>	Jun 11, 2018
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A091049</u>	<u>002</u>	Jun 11, 2018
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A091049</u>	<u>003</u>	Jun 11, 2018
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A091049</u>	<u>004</u>	Jun 11, 2018
<u>AP</u>	HIKMA FARMACEUTICA	<u>EQ 250MG BASE/VIAL</u>	<u>A065342</u>	<u>001</u>	Jan 10, 2008

PRESCRIPTION DRUG PRODUCT LIST

3-90 (of 474)

CEFTRIAXONE SODIUM

INJECTABLE; INTRAMUSCULAR, INTRAVENOUS

CEFTRIAXONE

AP		<u>EQ 500MG BASE/VIAL</u>	<u>A065342 002</u>	Jan 10, 2008
AP		<u>EQ 1GM BASE/VIAL</u>	<u>A065342 003</u>	Jan 10, 2008
AP		<u>EQ 2GM BASE/VIAL</u>	<u>A065342 004</u>	Jan 10, 2008
AP	QILU	<u>EQ 250MG BASE/VIAL</u>	<u>A203702 001</u>	Jun 29, 2016
AP		<u>EQ 500MG BASE/VIAL</u>	<u>A203702 002</u>	Jun 29, 2016
AP		<u>EQ 1GM BASE/VIAL</u>	<u>A203702 003</u>	Jun 29, 2016
AP		<u>EQ 2GM BASE/VIAL</u>	<u>A203702 004</u>	Jun 29, 2016
AP	! SANDOZ	<u>EQ 250MG BASE/VIAL</u>	<u>A065169 001</u>	May 09, 2005
AP	!	<u>EQ 500MG BASE/VIAL</u>	<u>A065169 002</u>	May 09, 2005
AP	!	<u>EQ 1GM BASE/VIAL</u>	<u>A065169 003</u>	May 09, 2005
AP	!	<u>EQ 2GM BASE/VIAL</u>	<u>A065169 004</u>	May 09, 2005
AP	WOCKHARDT	<u>EQ 250MG BASE/VIAL</u>	<u>A065391 001</u>	Apr 12, 2007
AP		<u>EQ 500MG BASE/VIAL</u>	<u>A065391 002</u>	Apr 12, 2007
AP		<u>EQ 2GM BASE/VIAL</u>	<u>A065391 003</u>	Apr 12, 2007

CEFUROXIME AXETIL

TABLET; ORAL

CEFUROXIME AXETIL

AB	ALKEM LABS LTD	<u>EQ 250MG BASE</u>	<u>A065496 001</u>	Jun 07, 2010
AB		<u>EQ 500MG BASE</u>	<u>A065496 002</u>	Jun 07, 2010
AB	APOTEX	<u>EQ 250MG BASE</u>	<u>A065069 001</u>	Oct 02, 2002
AB		<u>EQ 500MG BASE</u>	<u>A065069 002</u>	Oct 02, 2002
AB	AUROBINDO PHARMA	<u>EQ 125MG BASE</u>	<u>A065308 001</u>	Mar 29, 2006
AB		<u>EQ 250MG BASE</u>	<u>A065308 002</u>	Mar 29, 2006
AB		<u>EQ 500MG BASE</u>	<u>A065308 003</u>	Mar 29, 2006
AB	CHARTWELL RX	<u>EQ 125MG BASE</u>	<u>A065166 001</u>	Jul 29, 2005
AB		<u>EQ 250MG BASE</u>	<u>A065166 002</u>	Jul 29, 2005
AB		<u>EQ 500MG BASE</u>	<u>A065166 003</u>	Jul 29, 2005
AB	LUPIN	<u>EQ 250MG BASE</u>	<u>A065135 001</u>	Jul 25, 2003
AB	!	<u>EQ 500MG BASE</u>	<u>A065135 002</u>	Jul 25, 2003
AB	ORCHID HLTHCARE	<u>EQ 125MG BASE</u>	<u>A065359 001</u>	Feb 15, 2008
AB		<u>EQ 250MG BASE</u>	<u>A065359 002</u>	Feb 15, 2008
AB		<u>EQ 500MG BASE</u>	<u>A065359 003</u>	Feb 15, 2008

CEFUROXIME SODIUM

INJECTABLE; INJECTION

CEFUROXIME AND DEXTROSE IN DUPLEX CONTAINER

AP	+! B BRAUN	<u>EQ 750MG BASE/VIAL</u>	<u>N050780 001</u>	Feb 21, 2001
AP	+!	<u>EQ 1.5GM BASE/VIAL</u>	<u>N050780 002</u>	Feb 21, 2001

CEFUROXIME SODIUM

AP	ACS DOBFAR SPA	<u>EQ 1.5GM BASE/VIAL</u>	<u>A064125 002</u>	May 30, 1997
AP		<u>EQ 7.5GM BASE/VIAL</u>	<u>A064124 001</u>	May 30, 1997
AP	HIKMA FARMACEUTICA	<u>EQ 1.5GM BASE/VIAL</u>	<u>A065048 002</u>	Jan 09, 2004
AP		<u>EQ 7.5GM BASE/VIAL</u>	<u>A065046 001</u>	Jan 09, 2004

ZINACEF

AP	+! PAI HOLDINGS PHARM	<u>EQ 1.5GM BASE/VIAL</u>	<u>N050558 003</u>	Oct 19, 1983
AP	+!	<u>EQ 7.5GM BASE/VIAL</u>	<u>N050558 004</u>	Oct 23, 1986

INJECTABLE; INTRAMUSCULAR, INTRAVENOUS

CEFUROXIME SODIUM

AB	ACS DOBFAR SPA	<u>EQ 750MG BASE/VIAL</u>	<u>A064125 001</u>	May 30, 1997
AB	HIKMA FARMACEUTICA	<u>EQ 750MG BASE/VIAL</u>	<u>A065048 001</u>	Jan 09, 2004

ZINACEF

AB	+! PAI HOLDINGS PHARM	<u>EQ 750MG BASE/VIAL</u>	<u>N050558 002</u>	Oct 19, 1983

CELECOXIB

CAPSULE; ORAL

CELEBREX

AB	+ UPJOHN	<u>50MG</u>	<u>N020998 004</u>	Dec 15, 2006
AB	+	<u>100MG</u>	<u>N020998 001</u>	Dec 31, 1998
AB	+	<u>200MG</u>	<u>N020998 002</u>	Dec 31, 1998
AB	+!	<u>400MG</u>	<u>N020998 003</u>	Aug 29, 2002

CELECOXIB

AB	ALEMBIC PHARMS	<u>50MG</u>	<u>A204519 001</u>	Aug 21, 2015
AB		<u>100MG</u>	<u>A204519 002</u>	Aug 21, 2015
AB		<u>200MG</u>	<u>A204519 003</u>	Aug 21, 2015
AB		<u>400MG</u>	<u>A204519 004</u>	Aug 21, 2015
AB	APOTEX INC	<u>50MG</u>	<u>A204197 001</u>	Jun 02, 2015
AB		<u>100MG</u>	<u>A204197 002</u>	Jun 02, 2015
AB		<u>200MG</u>	<u>A204197 003</u>	Jun 02, 2015
AB	AUROBINDO PHARMA	<u>50MG</u>	<u>A206827 001</u>	Feb 01, 2016
AB		<u>100MG</u>	<u>A206827 002</u>	Feb 01, 2016

PRESCRIPTION DRUG PRODUCT LIST

3-91 (of 474)

CELECOXIB

CAPSULE; ORAL

CELECOXIB

<u>AB</u>		<u>200MG</u>	<u>A206827</u>	<u>003</u>	Feb 01, 2016
<u>AB</u>		<u>400MG</u>	<u>A206827</u>	<u>004</u>	Feb 01, 2016
<u>AB</u>	CADILA PHARMS LTD	<u>50MG</u>	<u>A208701</u>	<u>001</u>	Nov 14, 2019
<u>AB</u>		<u>100MG</u>	<u>A208701</u>	<u>002</u>	Nov 14, 2019
<u>AB</u>		<u>200MG</u>	<u>A208701</u>	<u>003</u>	Nov 14, 2019
<u>AB</u>		<u>400MG</u>	<u>A208701</u>	<u>004</u>	Nov 14, 2019
<u>AB</u>	CIPLA	<u>50MG</u>	<u>A207446</u>	<u>001</u>	Sep 23, 2015
<u>AB</u>		<u>100MG</u>	<u>A207446</u>	<u>002</u>	Sep 23, 2015
<u>AB</u>		<u>200MG</u>	<u>A207446</u>	<u>003</u>	Sep 23, 2015
<u>AB</u>		<u>400MG</u>	<u>A207446</u>	<u>004</u>	Sep 23, 2015
<u>AB</u>	CSPC OUYI	<u>50MG</u>	<u>A210071</u>	<u>001</u>	Jan 23, 2018
<u>AB</u>		<u>100MG</u>	<u>A210071</u>	<u>002</u>	Jan 23, 2018
<u>AB</u>		<u>200MG</u>	<u>A210071</u>	<u>003</u>	Jan 23, 2018
<u>AB</u>	LUPIN LTD	<u>50MG</u>	<u>A202240</u>	<u>001</u>	Oct 29, 2014
<u>AB</u>		<u>100MG</u>	<u>A202240</u>	<u>002</u>	Jun 09, 2015
<u>AB</u>		<u>200MG</u>	<u>A202240</u>	<u>003</u>	Jun 09, 2015
<u>AB</u>		<u>400MG</u>	<u>A202240</u>	<u>004</u>	Jun 09, 2015
<u>AB</u>	MACLEODS PHARMS LTD	<u>50MG</u>	<u>A204590</u>	<u>001</u>	Mar 16, 2016
<u>AB</u>		<u>100MG</u>	<u>A204590</u>	<u>002</u>	Mar 16, 2016
<u>AB</u>		<u>200MG</u>	<u>A204590</u>	<u>003</u>	Mar 16, 2016
<u>AB</u>		<u>400MG</u>	<u>A204590</u>	<u>004</u>	Mar 16, 2016
<u>AB</u>	MICRO LABS	<u>50MG</u>	<u>A204776</u>	<u>001</u>	Apr 30, 2018
<u>AB</u>		<u>100MG</u>	<u>A204776</u>	<u>002</u>	Apr 30, 2018
<u>AB</u>		<u>200MG</u>	<u>A204776</u>	<u>003</u>	Apr 30, 2018
<u>AB</u>		<u>400MG</u>	<u>A204776</u>	<u>004</u>	Apr 30, 2018
<u>AB</u>	MYLAN	<u>50MG</u>	<u>A078857</u>	<u>001</u>	May 30, 2014
<u>AB</u>		<u>100MG</u>	<u>A078857</u>	<u>002</u>	Feb 11, 2015
<u>AB</u>		<u>200MG</u>	<u>A078857</u>	<u>003</u>	Feb 11, 2015
<u>AB</u>		<u>400MG</u>	<u>A078857</u>	<u>004</u>	Feb 11, 2015
<u>AB</u>	NANJING	<u>200MG</u>	<u>A213598</u>	<u>001</u>	May 13, 2020
<u>AB</u>	QINGDAO BAHEAL PHARM	<u>50MG</u>	<u>A208856</u>	<u>001</u>	Aug 07, 2019
<u>AB</u>		<u>100MG</u>	<u>A208856</u>	<u>002</u>	Aug 07, 2019
<u>AB</u>		<u>200MG</u>	<u>A208856</u>	<u>003</u>	Aug 07, 2019
<u>AB</u>		<u>400MG</u>	<u>A208856</u>	<u>004</u>	Aug 07, 2019
<u>AB</u>	SCIEGEN PHARMS INC	<u>50MG</u>	<u>A205129</u>	<u>001</u>	Dec 03, 2020
<u>AB</u>		<u>100MG</u>	<u>A205129</u>	<u>002</u>	Dec 03, 2020
<u>AB</u>		<u>200MG</u>	<u>A205129</u>	<u>003</u>	Dec 03, 2020
<u>AB</u>		<u>400MG</u>	<u>A205129</u>	<u>004</u>	Dec 03, 2020
<u>AB</u>	TEVA	<u>50MG</u>	<u>A076898</u>	<u>001</u>	May 30, 2014
<u>AB</u>		<u>100MG</u>	<u>A076898</u>	<u>002</u>	May 30, 2014
<u>AB</u>		<u>200MG</u>	<u>A076898</u>	<u>003</u>	May 30, 2014
<u>AB</u>		<u>400MG</u>	<u>A076898</u>	<u>004</u>	May 30, 2014
<u>AB</u>	TIANJIN TIANYAO	<u>50MG</u>	<u>A207872</u>	<u>001</u>	Feb 25, 2020
<u>AB</u>		<u>100MG</u>	<u>A207872</u>	<u>002</u>	Feb 25, 2020
<u>AB</u>		<u>200MG</u>	<u>A207872</u>	<u>003</u>	Feb 25, 2020
<u>AB</u>		<u>400MG</u>	<u>A207872</u>	<u>004</u>	Feb 25, 2020
<u>AB</u>	TORRENT	<u>50MG</u>	<u>A207677</u>	<u>001</u>	Dec 23, 2015
<u>AB</u>		<u>100MG</u>	<u>A207677</u>	<u>002</u>	Dec 23, 2015
<u>AB</u>		<u>200MG</u>	<u>A207677</u>	<u>003</u>	Dec 23, 2015
<u>AB</u>		<u>400MG</u>	<u>A207677</u>	<u>004</u>	Dec 23, 2015
<u>AB</u>	UMEDICA LABS PVT LTD	<u>50MG</u>	<u>A210628</u>	<u>001</u>	Nov 27, 2019
<u>AB</u>		<u>100MG</u>	<u>A210628</u>	<u>002</u>	Nov 27, 2019
<u>AB</u>		<u>200MG</u>	<u>A210628</u>	<u>003</u>	Nov 27, 2019
<u>AB</u>		<u>400MG</u>	<u>A210628</u>	<u>004</u>	Nov 27, 2019
<u>AB</u>	WATSON LABS INC	<u>50MG</u>	<u>A200562</u>	<u>001</u>	Feb 11, 2015
<u>AB</u>		<u>100MG</u>	<u>A200562</u>	<u>002</u>	Feb 11, 2015
<u>AB</u>		<u>200MG</u>	<u>A200562</u>	<u>003</u>	Feb 11, 2015
<u>AB</u>		<u>400MG</u>	<u>A200562</u>	<u>004</u>	Feb 11, 2015
<u>AB</u>	YILING	<u>50MG</u>	<u>A211412</u>	<u>001</u>	Mar 06, 2020
<u>AB</u>		<u>100MG</u>	<u>A211412</u>	<u>002</u>	Mar 06, 2020
<u>AB</u>		<u>200MG</u>	<u>A211412</u>	<u>003</u>	Mar 06, 2020
<u>AB</u>		<u>400MG</u>	<u>A211412</u>	<u>004</u>	Mar 06, 2020
BX	AMNEAL PHARMS	50MG	A208833	001	May 31, 2018
BX		100MG	A208833	002	May 31, 2018
BX		200MG	A208833	003	May 31, 2018
BX		400MG	A208833	004	May 31, 2018

PRESCRIPTION DRUG PRODUCT LIST

3-92 (of 474)

CELECOXIB; TRAMADOL HYDROCHLORIDE

TABLET; ORAL

SEGLENTIS

+! KOWA PHARMS

56MG; 44MG

N213426 001 Oct 15, 2021

CENOBAIMATE

TABLET; ORAL

XCOPRI

+! SK LIFE

12.5MG

N212839 001 Mar 10, 2020

+

25MG

N212839 002 Mar 10, 2020

+

50MG

N212839 003 Mar 10, 2020

+

100MG

N212839 004 Mar 10, 2020

+

150MG

N212839 005 Mar 10, 2020

+

200MG

N212839 006 Mar 10, 2020

CEPHALEXIN

CAPSULE; ORAL

CEPHALEXINAB ALKEM LABS LTDEQ 250MG BASEA090836 001 Dec 20, 2010ABEQ 500MG BASEA090836 002 Dec 20, 2010AB AUROBINDO PHARMAEQ 250MG BASEA065253 001 Nov 16, 2005ABEQ 500MG BASEA065253 002 Nov 16, 2005AB BELCHER PHARMSEQ 250MG BASEA062713 001 Jul 15, 1988ABEQ 500MG BASEA062713 002 Jul 15, 1988AB CHARTWELL RXEQ 250MG BASEA065152 001 Feb 24, 2005ABEQ 500MG BASEA065152 002 Feb 24, 2005AB HIKMAEQ 250MG BASEA065215 001 Jan 24, 2006ABEQ 500MG BASEA065215 002 Jan 24, 2006AB LUPINEQ 250MG BASEA065229 001 Nov 25, 2005ABEQ 500MG BASEA065229 002 Nov 25, 2005AB ORCHID HLTHCAREEQ 250MG BASEA065248 001 Jun 28, 2005ABEQ 500MG BASEA065248 002 Jun 28, 2005AB TEVAEQ 250MG BASEA062702 001 Feb 13, 1987ABEQ 500MG BASEA062702 002 Feb 13, 1987

! ALKEM LABS LTD

EQ 333MG BASE

A090836 003 Mar 29, 2013

!

EQ 750MG BASE

A090836 004 Mar 29, 2013

FOR SUSPENSION; ORAL

CEPHALEXINAB ALKEM LABS LTDEQ 125MG BASE/5MLA210221 001 Mar 26, 2019ABEQ 250MG BASE/5MLA210221 002 Mar 26, 2019AB LUPINEQ 125MG BASE/5MLA065234 001 Aug 17, 2005ABEQ 250MG BASE/5MLA065234 002 Aug 17, 2005AB TEVAEQ 125MG BASE/5MLA062703 001 Feb 13, 1987AB !EQ 250MG BASE/5MLA062703 002 Feb 13, 1987AB YUNG SHIN PHARMEQ 125MG BASE/5MLA065336 001 Jul 25, 2007ABEQ 250MG BASE/5MLA065336 002 Jul 25, 2007

TABLET; ORAL

CEPHALEXIN

TEVA

EQ 250MG BASE

A063023 001 Jan 12, 1989

!

EQ 500MG BASE

A063024 001 Jan 12, 1989

CERITINIB

TABLET; ORAL

ZYKADIA

+! NOVARTIS

150MG

N211225 001 Mar 18, 2019

CETIRIZINE HYDROCHLORIDE

SOLUTION; INTRAVENOUS

QUZYTIR

+! JDP

10MG/ML (10MG/ML)

N211415 001 Oct 04, 2019

SOLUTION/DROPS; OPHTHALMIC

ZERVIAE

+! EYEVANCE

EQ 0.24% BASE

N208694 001 May 30, 2017

SYRUP; ORAL

CETIRIZINE HYDROCHLORIDEAA AMNEAL PHARMS5MG/5MLA090766 001 Oct 07, 2009AA BAJAJ5MG/5MLA090191 001 Nov 12, 2009AA BRECKENRIDGE5MG/5MLA078488 001 Oct 06, 2008AA CHARTWELL MOLECULAR5MG/5MLA078876 001 May 11, 2012AA ! PADAGIS US5MG/5MLA078398 001 Jun 17, 2008AA TARO5MG/5MLA076601 001 Jun 20, 2008AA TEVA PHARMS5MG/5MLA077279 001 May 27, 2008

PRESCRIPTION DRUG PRODUCT LIST

3-93 (of 474)

CETRORELIX ACETATE

POWDER; SUBCUTANEOUS

CETRORELIX ACETATE

AP	AKORN	<u>EQ 0.25MG BASE/VIAL</u>	<u>A215737</u>	<u>001</u>	Aug 12, 2022

CETROTIDE

AP	+! EMD SERONO INC	<u>EQ 0.25MG BASE/VIAL</u>	<u>N021197</u>	<u>001</u>	Aug 11, 2000

CEVIMELINE HYDROCHLORIDE

CAPSULE; ORAL

CEVIMELINE HYDROCHLORIDE

AB	HIKMA	<u>30MG</u>	<u>A091591</u>	<u>001</u>	Jul 08, 2013

AB	NOVEL LABS INC	<u>30MG</u>	<u>A204746</u>	<u>001</u>	Dec 30, 2016

AB	RISING	<u>30MG</u>	<u>A203775</u>	<u>001</u>	Jun 04, 2014

EVOXAC

AB	+! COSETTE	<u>30MG</u>	<u>N020989</u>	<u>002</u>	Jan 11, 2000

CHENODIOL

TABLET; ORAL

CHENODIOL

!	LGM PHARMA	250MG	A091019	001	Oct 22, 2009

CHLORAMBUCIL

TABLET; ORAL

LEUKERAN

+	!	WOODWARD SPECL	2MG	N010669	002

CHLORAMPHENICOL SODIUM SUCCINATE

INJECTABLE; INJECTION

CHLORAMPHENICOL SODIUM SUCCINATE

!	FRESENIUS KABI USA	EQ 1GM BASE/VIAL	A062365	001	Aug 25, 1982

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE; ORAL

CHLORDIAZEPOXIDE HYDROCHLORIDE

AB	BARR	<u>5MG</u>	<u>A084768</u>	<u>001</u>	

AB		<u>10MG</u>	<u>A083116</u>	<u>001</u>	

AB	!	<u>25MG</u>	<u>A084769</u>	<u>001</u>	

AB	CHARTWELL RX	<u>5MG</u>	<u>A084678</u>	<u>001</u>	

AB		<u>10MG</u>	<u>A084041</u>	<u>001</u>	

AB		<u>25MG</u>	<u>A084679</u>	<u>002</u>	

LIBRIUM

AB	+	BAUSCH	<u>25MG</u>	<u>A085475</u>	<u>001</u>

AB	+	VALEANT PHARM INTL	<u>5MG</u>	<u>A085461</u>	<u>001</u>

AB	+		<u>10MG</u>	<u>A085472</u>	<u>001</u>

CHLORDIAZEPOXIDE HYDROCHLORIDE; CLIDINIUM BROMIDE

CAPSULE; ORAL

CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDE

AB	ALKEM LABS LTD	<u>5MG; 2.5MG</u>	<u>A214065</u>	<u>001</u>	Apr 26, 2021

AB	AMNEAL	<u>5MG; 2.5MG</u>	<u>A215555</u>	<u>001</u>	Oct 25, 2021

AB	CHARTWELL RX	<u>5MG; 2.5MG</u>	<u>A213530</u>	<u>001</u>	Oct 20, 2020

AB	COREPHARMA	<u>5MG; 2.5MG</u>	<u>A215453</u>	<u>001</u>	Jul 29, 2022

AB	DR REDDYS	<u>5MG; 2.5MG</u>	<u>A214698</u>	<u>001</u>	May 10, 2021

AB	MICRO LABS	<u>5MG; 2.5MG</u>	<u>A215835</u>	<u>001</u>	Jul 19, 2022

AB	MISEMER	<u>5MG; 2.5MG</u>	<u>A210579</u>	<u>001</u>	Jul 29, 2020

AB	NUVO PHARMS INC	<u>5MG; 2.5MG</u>	<u>A211421</u>	<u>001</u>	Jul 07, 2020

LIBRAX

AB	+! BAUSCH	<u>5MG; 2.5MG</u>	<u>N012750</u>	<u>001</u>	

CHLORHEXIDINE GLUCONATE

SOLUTION; DENTAL

CHLORHEXIDINE GLUCONATE

AT	BAJAJ	<u>0.12%</u>	<u>A075561</u>	<u>001</u>	Nov 14, 2000

AT	LYNE	<u>0.12%</u>	<u>A074291</u>	<u>001</u>	Dec 28, 1995

AT	PHARM ASSOC	<u>0.12%</u>	<u>A074522</u>	<u>001</u>	Dec 15, 1995

AT	WOCKHARDT BIO AG	<u>0.12%</u>	<u>A075006</u>	<u>001</u>	Mar 03, 2004

AT	XTTRIUM	<u>0.12%</u>	<u>A077789</u>	<u>001</u>	Jun 18, 2009

PERIDEX

AT	+! 3M	<u>0.12%</u>	<u>N019028</u>	<u>001</u>	Aug 13, 1986

PERIOGARD

AT	COLGATE-PALMOLIVE	<u>0.12%</u>	<u>A203212</u>	<u>001</u>	Jan 28, 2016

CO

PRESCRIPTION DRUG PRODUCT LIST

3-94 (of 474)

CHLOROPROCAINE HYDROCHLORIDE

GEL;OPHTHALMIC

IHEEZO

+! HARROW EYE 3%

N216227 001 Sep 27, 2022

INJECTABLE; INJECTION

CHLOROPROCAINE HYDROCHLORIDE**AP** HIKMA **2%****A040273 001** Sep 09, 1998**AP** **3%****A040273 002** Sep 09, 1998NESACAINE**AP** + FRESENIUS KABI USA **2%****N009435 002**NESACAINE-MPF**AP** +! FRESENIUS KABI USA **2%****N009435 006** May 02, 1996**AP** +! **3%****N009435 007** May 02, 1996

NESACAINE

+! FRESENIUS KABI USA 1%

N009435 001

SOLUTION; INTRATHECAL

CLOROTEKAL

+ B BRAUN MEDICAL INC 50MG/5ML (10MG/ML)

N208791 001 Sep 26, 2017

CHLOROQUINE PHOSPHATE

TABLET; ORAL

CHLOROQUINE PHOSPHATE**AA** IMPAX LABS **250MG****A080880 001****AA** **500MG****A040516 001** Aug 29, 2003**AA** IPCA LABS LTD **250MG****A090610 001** Dec 03, 2009**AA** **500MG****A090249 001** Dec 03, 2009**AA** ! NATCO PHARMA LTD **250MG****A091621 001** Jan 21, 2011**AA** ! **500MG****A090612 001** Jan 21, 2011**AA** SUVEN PHARMS **500MG****A214756 001** Sep 03, 2021CHLOROTHIAZIDE

SUSPENSION; ORAL

DIURIL

+! SALIX PHARMS 250MG/5ML

N011870 001

CHLOROTHIAZIDE SODIUM

INJECTABLE; INJECTION

CHLOROTHIAZIDE SODIUM**AP** AM REGENT **EQ 500MG BASE/VIAL****A202561 001** Apr 22, 2013**AP** FRESENIUS KABI USA **EQ 500MG BASE/VIAL****A090896 001** Oct 16, 2009**AP** RK PHARMA **EQ 500MG BASE/VIAL****A202493 001** Jun 18, 2014**AP** SAGENT PHARMS INC **EQ 500MG BASE/VIAL****A202462 001** May 29, 2015**AP** SUN PHARM **EQ 500MG BASE/VIAL****A091546 001** Jul 26, 2011DIURIL**AP** +! AKORN **EQ 500MG BASE/VIAL****N011145 005**CHLORPHENIRAMINE MALEATE; CODEINE PHOSPHATE

TABLET, EXTENDED RELEASE; ORAL

TUXARIN ER

MAINPOINTE 8MG; 54.3MG

N206323 001 Jun 22, 2015

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION; ORAL

HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE

! PADAGIS US 4MG/5ML; 5MG/5ML; 60MG/5ML

A204627 001 Apr 29, 2014

CHLORPHENIRAMINE POLISTIREX; HYDROCODONE POLISTIREX

SUSPENSION, EXTENDED RELEASE; ORAL

HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX

! TRIS PHARMA INC EQ 8MG MALEATE/5ML; EQ 10MG BITARTRATE/5ML

A091632 001 Oct 01, 2010

CHLORPROMAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

CHLORPROMAZINE HYDROCHLORIDE

! GENUS 30MG/ML

A214542 001 Jun 02, 2021

! 100MG/ML

A214542 002 Jun 02, 2021

INJECTABLE; INJECTION

CHLORPROMAZINE HYDROCHLORIDE**AP** EUGIA PHARMA **25MG/ML****A211816 001** Jul 07, 2020**AP** +! WEST-WARD PHARMS **25MG/ML****A083329 001**

INT

TABLET; ORAL

CHLORPROMAZINE HYDROCHLORIDE**AB** GLENMARK PHARMS LTD **10MG****A212144 001** Mar 23, 2021**AB** **25MG****A212144 002** Mar 23, 2021

PRESCRIPTION DRUG PRODUCT LIST

3-95 (of 474)

CHLORPROMAZINE HYDROCHLORIDE

TABLET; ORAL

CHLORPROMAZINE HYDROCHLORIDE

<u>AB</u>		<u>50MG</u>	<u>A212144</u>	<u>003</u>	Mar 23, 2021
<u>AB</u>		<u>100MG</u>	<u>A212144</u>	<u>004</u>	Mar 23, 2021
<u>AB</u>		<u>200MG</u>	<u>A212144</u>	<u>005</u>	Mar 23, 2021
<u>AB</u>	LANNETT CO INC	<u>10MG</u>	<u>A212996</u>	<u>001</u>	Jan 22, 2021
<u>AB</u>		<u>25MG</u>	<u>A212996</u>	<u>002</u>	Jan 22, 2021
<u>AB</u>		<u>50MG</u>	<u>A212996</u>	<u>003</u>	Jan 22, 2021
<u>AB</u>		<u>100MG</u>	<u>A212996</u>	<u>004</u>	Jan 22, 2021
<u>AB</u>		<u>200MG</u>	<u>A212996</u>	<u>005</u>	Jan 22, 2021
<u>AB</u>	MSN	<u>25MG</u>	<u>A214827</u>	<u>001</u>	Jan 27, 2022
<u>AB</u>		<u>50MG</u>	<u>A214827</u>	<u>002</u>	Jan 27, 2022
<u>AB</u>		<u>100MG</u>	<u>A214827</u>	<u>003</u>	Jan 27, 2022
<u>AB</u>		<u>200MG</u>	<u>A214827</u>	<u>004</u>	Jan 27, 2022
<u>AB</u>	SUN PHARM	<u>10MG</u>	<u>A214256</u>	<u>001</u>	Oct 26, 2020
<u>AB</u>		<u>25MG</u>	<u>A214256</u>	<u>002</u>	Oct 26, 2020
<u>AB</u>		<u>50MG</u>	<u>A214256</u>	<u>003</u>	Oct 26, 2020
<u>AB</u>		<u>100MG</u>	<u>A214256</u>	<u>004</u>	Oct 26, 2020
<u>AB</u>		<u>200MG</u>	<u>A214256</u>	<u>005</u>	Oct 26, 2020
<u>AB</u>	TEVA PHARMS	<u>10MG</u>	<u>A215659</u>	<u>001</u>	Oct 25, 2021
<u>AB</u>		<u>25MG</u>	<u>A215659</u>	<u>002</u>	Oct 25, 2021
<u>AB</u>		<u>50MG</u>	<u>A215659</u>	<u>003</u>	Oct 25, 2021
<u>AB</u>		<u>100MG</u>	<u>A215659</u>	<u>004</u>	Oct 25, 2021
<u>AB</u>		<u>200MG</u>	<u>A215659</u>	<u>005</u>	Oct 25, 2021
<u>AB</u>	+ UPSHER SMITH LABS	<u>10MG</u>	<u>A083386</u>	<u>001</u>	
<u>AB</u>	+!	<u>25MG</u>	<u>A084112</u>	<u>001</u>	
<u>AB</u>	+	<u>50MG</u>	<u>A084113</u>	<u>001</u>	
<u>AB</u>	+!	<u>100MG</u>	<u>A084114</u>	<u>001</u>	
<u>AB</u>	+	<u>200MG</u>	<u>A084115</u>	<u>001</u>	
<u>AB</u>	ZAMEER PHARMS	<u>10MG</u>	<u>A212630</u>	<u>001</u>	Nov 29, 2021
<u>AB</u>		<u>25MG</u>	<u>A212630</u>	<u>002</u>	Nov 29, 2021
<u>AB</u>		<u>50MG</u>	<u>A212630</u>	<u>003</u>	Nov 29, 2021
<u>AB</u>		<u>100MG</u>	<u>A212630</u>	<u>004</u>	Nov 29, 2021
<u>AB</u>		<u>200MG</u>	<u>A212630</u>	<u>005</u>	Nov 29, 2021
<u>AB</u>	ZYDUS	<u>10MG</u>	<u>A213368</u>	<u>001</u>	Jan 17, 2020
<u>AB</u>		<u>25MG</u>	<u>A213368</u>	<u>002</u>	Jan 17, 2020
<u>AB</u>		<u>50MG</u>	<u>A213368</u>	<u>003</u>	Jan 17, 2020
<u>AB</u>		<u>100MG</u>	<u>A213368</u>	<u>004</u>	Jan 17, 2020
<u>AB</u>		<u>200MG</u>	<u>A213368</u>	<u>005</u>	Jan 17, 2020
BX	AMNEAL PHARMS CO	10MG	A209755	001	Sep 10, 2018
BX		25MG	A209755	002	Sep 10, 2018
BX		50MG	A209755	003	Sep 10, 2018
BX		100MG	A209755	004	Sep 10, 2018
BX		200MG	A209755	005	Sep 10, 2018

CHLORTHALIDONE

TABLET; ORAL

CHLORTHALIDONE

<u>AB</u>	AJANTA PHARMA LTD	<u>25MG</u>	<u>A214129</u>	<u>001</u>	Nov 27, 2020
<u>AB</u>		<u>50MG</u>	<u>A214129</u>	<u>002</u>	Nov 27, 2020
<u>AB</u>	ALEMBIC PHARMS	<u>25MG</u>	<u>A216262</u>	<u>001</u>	Aug 26, 2022
<u>AB</u>		<u>50MG</u>	<u>A216262</u>	<u>002</u>	Aug 26, 2022
<u>AB</u>	ALKEM LABS LTD	<u>25MG</u>	<u>A213412</u>	<u>001</u>	Feb 11, 2020
<u>AB</u>		<u>50MG</u>	<u>A213412</u>	<u>002</u>	Feb 11, 2020
<u>AB</u>	AMNEAL PHARMS CO	<u>25MG</u>	<u>A207204</u>	<u>001</u>	Jul 01, 2019
<u>AB</u>		<u>50MG</u>	<u>A207204</u>	<u>002</u>	Jul 01, 2019
<u>AB</u>	APPCO	<u>25MG</u>	<u>A210742</u>	<u>001</u>	Oct 12, 2018
<u>AB</u>		<u>50MG</u>	<u>A210742</u>	<u>002</u>	Oct 12, 2018
<u>AB</u>	CHARTWELL RX	<u>25MG</u>	<u>A211063</u>	<u>001</u>	Feb 26, 2019
<u>AB</u>		<u>50MG</u>	<u>A211063</u>	<u>002</u>	Feb 26, 2019
<u>AB</u>	INVENTIA	<u>25MG</u>	<u>A211320</u>	<u>001</u>	Feb 09, 2022
<u>AB</u>		<u>50MG</u>	<u>A211320</u>	<u>002</u>	Feb 09, 2022
<u>AB</u>	MANKIND PHARMA	<u>25MG</u>	<u>A215587</u>	<u>001</u>	Aug 04, 2022
<u>AB</u>		<u>50MG</u>	<u>A215587</u>	<u>002</u>	Aug 04, 2022
<u>AB</u>	+ MYLAN	<u>25MG</u>	<u>A086831</u>	<u>002</u>	
<u>AB</u>	+!	<u>50MG</u>	<u>A086831</u>	<u>001</u>	
<u>AB</u>	NOVAST LABS	<u>25MG</u>	<u>A206904</u>	<u>001</u>	Mar 30, 2017
<u>AB</u>		<u>50MG</u>	<u>A206904</u>	<u>002</u>	Mar 30, 2017
<u>AB</u>	SUN PHARM INDUSTRIES	<u>25MG</u>	<u>A089286</u>	<u>002</u>	Jul 21, 1986
<u>AB</u>		<u>50MG</u>	<u>A089286</u>	<u>001</u>	Jul 21, 1986
<u>AB</u>	TAGI	<u>25MG</u>	<u>A212878</u>	<u>001</u>	Feb 24, 2022

PRESCRIPTION DRUG PRODUCT LIST

3-96 (of 474)

CHLORTHALIDONE

TABLET; ORAL

CHLORTHALIDONE

<u>AB</u>		<u>50MG</u>	<u>A212875</u>	<u>001</u>	Feb 24, 2022
<u>AB</u>	UMEDICA LABS PVT LTD	<u>25MG</u>	<u>A207222</u>	<u>001</u>	May 24, 2018
<u>AB</u>		<u>50MG</u>	<u>A207222</u>	<u>002</u>	May 24, 2018
<u>AB</u>	UNICHEM	<u>25MG</u>	<u>A211627</u>	<u>001</u>	Aug 06, 2019
<u>AB</u>		<u>50MG</u>	<u>A211627</u>	<u>002</u>	Aug 06, 2019
<u>AB</u>	ZYDUS PHARMS	<u>25MG</u>	<u>A207813</u>	<u>001</u>	May 10, 2019
<u>AB</u>		<u>50MG</u>	<u>A207813</u>	<u>002</u>	May 10, 2019
THALITONE					
BX	+! CASPER PHARMA LLC	25MG	N019574	002	Feb 12, 1992
	+	15MG	N019574	001	Dec 20, 1988

CHLORZOXAZONE

TABLET; ORAL

CHLORZOXAZONE

<u>AA</u>	AUROBINDO PHARMA LTD	<u>500MG</u>	<u>A089853</u>	<u>001</u>	May 04, 1988
<u>AA</u>	COREPHARMA	<u>500MG</u>	<u>A214941</u>	<u>002</u>	Oct 20, 2022
<u>AA</u>	MAYNE PHARMA	<u>500MG</u>	<u>A211849</u>	<u>002</u>	Jul 21, 2020
<u>AA</u>	! MIKART	<u>250MG</u>	<u>A207483</u>	<u>001</u>	Jun 24, 2016
<u>AA</u>	NOVITIUM PHARMA	<u>500MG</u>	<u>A212254</u>	<u>001</u>	Sep 12, 2019
<u>AA</u>	SENORES PHARMS	<u>250MG</u>	<u>A215158</u>	<u>001</u>	Jul 29, 2021
<u>AA</u>	! WATSON LABS	<u>500MG</u>	<u>A089859</u>	<u>001</u>	May 04, 1988
<u>AB</u>	COREPHARMA	<u>375MG</u>	<u>A214941</u>	<u>001</u>	Oct 20, 2022
<u>AB</u>		<u>750MG</u>	<u>A214941</u>	<u>003</u>	Oct 20, 2022
<u>AB</u>	I3 PHARMS	<u>375MG</u>	<u>A212053</u>	<u>001</u>	Sep 14, 2020
<u>AB</u>		<u>750MG</u>	<u>A212053</u>	<u>002</u>	Sep 14, 2020
<u>AB</u>	MAYNE PHARMA	<u>375MG</u>	<u>A211849</u>	<u>001</u>	Jul 21, 2020
<u>AB</u>		<u>750MG</u>	<u>A211849</u>	<u>003</u>	Jul 21, 2020
<u>AB</u>	! MIKART	<u>375MG</u>	<u>A040861</u>	<u>001</u>	Jun 01, 2010
<u>AB</u>	!	<u>750MG</u>	<u>A040861</u>	<u>002</u>	Jun 01, 2010
<u>AB</u>	NOVITIUM PHARMA	<u>375MG</u>	<u>A212253</u>	<u>001</u>	Nov 27, 2019
<u>AB</u>		<u>750MG</u>	<u>A212253</u>	<u>002</u>	Nov 27, 2019
<u>AB</u>	PAR PHARM INC	<u>375MG</u>	<u>A212743</u>	<u>002</u>	Apr 29, 2021
<u>AB</u>		<u>750MG</u>	<u>A212743</u>	<u>001</u>	Nov 02, 2020
<u>AB</u>	RISING	<u>375MG</u>	<u>A213126</u>	<u>001</u>	Apr 05, 2022
<u>AB</u>		<u>500MG</u>	<u>A213126</u>	<u>002</u>	Apr 05, 2022
<u>AB</u>		<u>750MG</u>	<u>A213126</u>	<u>003</u>	Apr 05, 2022
<u>AB</u>	TEVA PHARMS USA INC	<u>375MG</u>	<u>A212898</u>	<u>001</u>	Jun 17, 2020
<u>AB</u>		<u>750MG</u>	<u>A212898</u>	<u>002</u>	Jun 17, 2020

CHOLESTYRAMINE

POWDER; ORAL

CHOLESTYRAMINE

<u>AB</u>	AJANTA PHARMA LTD	<u>EQ 4GM RESIN/PACKET</u>	<u>A211119</u>	<u>001</u>	Apr 06, 2020
<u>AB</u>		<u>EQ 4GM RESIN/SCOOPFUL</u>	<u>A211119</u>	<u>002</u>	Apr 06, 2020
<u>AB</u>	ALKEM LABS LTD	<u>EQ 4GM RESIN/PACKET</u>	<u>A211856</u>	<u>001</u>	Oct 19, 2021
<u>AB</u>		<u>EQ 4GM RESIN/SCOOPFUL</u>	<u>A211856</u>	<u>002</u>	Oct 19, 2021
<u>AB</u>	ANI PHARMS	<u>EQ 4GM RESIN/PACKET</u>	<u>A074554</u>	<u>001</u>	Oct 02, 1996
<u>AB</u>		<u>EQ 4GM RESIN/SCOOPFUL</u>	<u>A074554</u>	<u>002</u>	Oct 02, 1996
<u>AB</u>	! EPIC PHARMA	<u>EQ 4GM RESIN/PACKET</u>	<u>A074557</u>	<u>001</u>	Aug 15, 1996
<u>AB</u>		<u>EQ 4GM RESIN/SCOOPFUL</u>	<u>A074557</u>	<u>002</u>	Aug 15, 1996
<u>AB</u>	PAR PHARM	<u>EQ 4GM RESIN/PACKET</u>	<u>A077204</u>	<u>001</u>	Aug 26, 2005
<u>AB</u>		<u>EQ 4GM RESIN/SCOOPFUL</u>	<u>A077204</u>	<u>002</u>	Aug 26, 2005
<u>AB</u>	TAGI	<u>EQ 4GM RESIN/PACKET</u>	<u>A209597</u>	<u>001</u>	Mar 09, 2021
<u>AB</u>		<u>EQ 4GM RESIN/SCOOPFUL</u>	<u>A209597</u>	<u>002</u>	Mar 09, 2021
<u>AB</u>	ZYDUS PHARMS	<u>EQ 4GM RESIN/SCOOPFUL</u>	<u>A202901</u>	<u>001</u>	Jul 02, 2018

CHOLESTYRAMINE LIGHT

<u>AB</u>	ALKEM LABS LTD	<u>EQ 4GM RESIN/PACKET</u>	<u>A211799</u>	<u>001</u>	Oct 19, 2021
<u>AB</u>		<u>EQ 4GM RESIN/SCOOPFUL</u>	<u>A211799</u>	<u>002</u>	Oct 19, 2021
<u>AB</u>	! EPIC PHARMA	<u>EQ 4GM RESIN/PACKET</u>	<u>A074558</u>	<u>001</u>	Aug 15, 1996
<u>AB</u>		<u>EQ 4GM RESIN/SCOOPFUL</u>	<u>A074558</u>	<u>002</u>	Aug 15, 1996
<u>AB</u>	PAR PHARM	<u>EQ 4GM RESIN/PACKET</u>	<u>A077203</u>	<u>001</u>	Aug 26, 2005
<u>AB</u>		<u>EQ 4GM RESIN/SCOOPFUL</u>	<u>A077203</u>	<u>002</u>	Aug 26, 2005
<u>AB</u>	TAGI	<u>EQ 4GM RESIN/PACKET</u>	<u>A209599</u>	<u>001</u>	Nov 12, 2020
<u>AB</u>		<u>EQ 4GM RESIN/SCOOPFUL</u>	<u>A209599</u>	<u>002</u>	Nov 12, 2020
<u>AB</u>	ZYDUS PHARMS	<u>EQ 4GM RESIN/SCOOPFUL</u>	<u>A202902</u>	<u>001</u>	Apr 25, 2017

LOCHOLEST

<u>AB</u>	CHARTWELL RX	<u>EQ 4GM RESIN/PACKET</u>	<u>A074561</u>	<u>001</u>	Aug 15, 1996
<u>AB</u>		<u>EQ 4GM RESIN/SCOOPFUL</u>	<u>A074561</u>	<u>002</u>	Aug 15, 1996

PRESCRIPTION DRUG PRODUCT LIST

3-97 (of 474)

CHOLESTYRAMINE

POWDER; ORAL

LOCHOLEST LIGHT

AB	CHARTWELL RX	<u>EQ 4GM RESIN/PACKET</u>	<u>A074562</u>	<u>001</u>	Aug 15, 1996
AB		<u>EQ 4GM RESIN/SCOOPFUL</u>	<u>A074562</u>	<u>002</u>	Aug 15, 1996

PREVALITE

AB	UPSHER SMITH LABS	<u>EQ 4GM RESIN/PACKET</u>	<u>A073263</u>	<u>001</u>	Feb 22, 1996
AB		<u>EQ 4GM RESIN/SCOOPFUL</u>	<u>A073263</u>	<u>002</u>	Oct 30, 1997

CHOLIC ACID

CAPSULE; ORAL

CHOLBAM

+	TRAVERE	50MG	N205750	001	Mar 17, 2015
+	!	250MG	N205750	002	Mar 17, 2015

CHOLINE C-11

INJECTABLE; INTRAVENOUS

CHOLINE C-11

AP	DECATUR	<u>4-33.1mCi/ML</u>	<u>A206319</u>	<u>001</u>	Nov 13, 2015
AP	+	MCPRF	<u>4-33.1mCi/ML</u>	<u>N203155</u>	<u>001</u>
AP	WA UNIV SCH MED	<u>4-33.1mCi/ML</u>	<u>A208413</u>	<u>001</u>	Jan 10, 2017

CHOLINE FENOFIBRATE

CAPSULE, DELAYED RELEASE; ORAL

FENOFIBRIC ACID

AB	ACTAVIS ELIZABETH	<u>EQ 45MG FENOFIBRIC ACID</u>	<u>A200920</u>	<u>001</u>	Oct 07, 2015
AB		<u>EQ 135MG FENOFIBRIC ACID</u>	<u>A200920</u>	<u>002</u>	Oct 07, 2015
AB	ALEMBIC PHARMS	<u>EQ 45MG FENOFIBRIC ACID</u>	<u>A208705</u>	<u>001</u>	May 12, 2017
AB		<u>EQ 135MG FENOFIBRIC ACID</u>	<u>A208705</u>	<u>002</u>	May 12, 2017
AB	ANCHEN PHARMS	<u>EQ 45MG FENOFIBRIC ACID</u>	<u>A201573</u>	<u>002</u>	Jul 18, 2013
AB		<u>EQ 135MG FENOFIBRIC ACID</u>	<u>A201573</u>	<u>001</u>	Jul 18, 2013
AB	AUROBINDO PHARMA LTD	<u>EQ 45MG FENOFIBRIC ACID</u>	<u>A212598</u>	<u>001</u>	Jul 25, 2019
AB		<u>EQ 135MG FENOFIBRIC ACID</u>	<u>A212598</u>	<u>002</u>	Jul 25, 2019
AB	GRAVITI PHARMS	<u>EQ 45MG FENOFIBRIC ACID</u>	<u>A211626</u>	<u>001</u>	Jul 18, 2019
AB		<u>EQ 135MG FENOFIBRIC ACID</u>	<u>A211626</u>	<u>002</u>	Jul 18, 2019
AB	IMPAX LABS INC	<u>EQ 45MG FENOFIBRIC ACID</u>	<u>A200264</u>	<u>001</u>	Sep 07, 2016
AB		<u>EQ 135MG FENOFIBRIC ACID</u>	<u>A200264</u>	<u>002</u>	Sep 07, 2016
AB	LUPIN LTD	<u>EQ 45MG FENOFIBRIC ACID</u>	<u>A200750</u>	<u>001</u>	Dec 04, 2013
AB		<u>EQ 135MG FENOFIBRIC ACID</u>	<u>A200750</u>	<u>002</u>	Dec 04, 2013
AB	MICRO LABS	<u>EQ 45MG FENOFIBRIC ACID</u>	<u>A213450</u>	<u>001</u>	Jun 16, 2020
AB		<u>EQ 135MG FENOFIBRIC ACID</u>	<u>A213450</u>	<u>002</u>	Jun 16, 2020
AB	TWI PHARMS	<u>EQ 45MG FENOFIBRIC ACID</u>	<u>A210469</u>	<u>001</u>	Jul 05, 2019
AB		<u>EQ 135MG FENOFIBRIC ACID</u>	<u>A210469</u>	<u>002</u>	Jul 05, 2019
AB	YICHANG HUMANWELL	<u>EQ 45MG FENOFIBRIC ACID</u>	<u>A212562</u>	<u>001</u>	Dec 23, 2020
AB		<u>EQ 135MG FENOFIBRIC ACID</u>	<u>A212562</u>	<u>002</u>	Dec 23, 2020

TRILIPIX

AB	+	ABBVIE	<u>EQ 45MG FENOFIBRIC ACID</u>	<u>N022224</u>	<u>001</u>	Dec 15, 2008
AB	+	!	<u>EQ 135MG FENOFIBRIC ACID</u>	<u>N022224</u>	<u>002</u>	Dec 15, 2008

CHROMIC CHLORIDE

INJECTABLE; INJECTION

CHROMIC CHLORIDE IN PLASTIC CONTAINER

+	!	HOSPIRA	EQ 0.004MG CHROMIUM/ML	N018961	001	Jun 26, 1986

CICLESONIDE

AEROSOL, METERED; INHALATION

ALVESCO

+	!	COVIS	0.08MG/INH	N021658	002	Jan 10, 2008
+	!		0.16MG/INH	N021658	003	Jan 10, 2008

AEROSOL, METERED; NASAL

ZETONNA

+	!	COVIS	0.037MG/INH	N202129	001	Jan 20, 2012

SPRAY, METERED; NASAL

OMNARIS

+	!	COVIS	0.05MG/SPRAY	N022004	001	Oct 20, 2006

CICLOPIROX

CREAM; TOPICAL

CICLOPIROX

AB	COSETTE	<u>0.77%</u>	<u>A078463</u>	<u>001</u>	Dec 20, 2010
AB	FOUGERA PHARMS	<u>0.77%</u>	<u>A076435</u>	<u>001</u>	Dec 29, 2004
AB	GLENMARK PHARMS	<u>0.77%</u>	<u>A090273</u>	<u>001</u>	Nov 10, 2009
AB	PADAGIS ISRAEL	<u>0.77%</u>	<u>A077364</u>	<u>001</u>	Mar 03, 2006
AB	TARO	<u>0.77%</u>	<u>A076790</u>	<u>001</u>	Apr 12, 2005

PRESCRIPTION DRUG PRODUCT LIST

3-98 (of 474)

CICLOPIROX

CREAM; TOPICAL

LOPROX

AB	+ !	MEDIMETRIKS PHARMS	0.77%	N018748	001	Dec 30, 1982

GEL; TOPICAL

CICLOPIROX

AB		FOUGERA PHARMS	0.77%	A077896	001	Jun 10, 2008
AB	!	GLENMARK GENERICS	0.77%	A091595	001	Feb 29, 2012
AB		PADAGIS US	0.77%	A078266	001	Jan 07, 2009

SHAMPOO; TOPICAL

CICLOPIROX

AT		ACTAVIS MID	1%	A090490	001	Nov 24, 2009
		ATLANTIC				
AT		FOUGERA PHARMS	1%	A090146	001	May 25, 2010
AT		PADAGIS US	1%	A078594	001	Feb 16, 2010
AT		PAI HOLDINGS PHARM	1%	A209975	001	Apr 05, 2018
AT		TARO	1%	A090269	001	Feb 23, 2011

LOPROX

AT	+ !	BAUSCH	1%	N021159	001	Feb 28, 2003

SOLUTION; TOPICAL

CICLOPIROX

AT		ACELLA	8%	A078172	001	Sep 18, 2007
AT		AKORN	8%	A078270	001	Sep 18, 2007
AT		CHARTWELL RX	8%	A078046	001	Sep 18, 2007
AT		COSETTE	8%	A078233	001	Sep 18, 2007
AT		PADAGIS US	8%	A077623	001	Sep 18, 2007
AT		RISING	8%	A078124	001	Sep 18, 2007
AT		TARO PHARM INDS	8%	A078144	001	Sep 18, 2007

PENLAC

AT	+ !	VALEANT BERMUDA	8%	N021022	001	Dec 17, 1999

SUSPENSION; TOPICAL

CICLOPIROX

AB		FOUGERA PHARMS	0.77%	A076422	001	Aug 06, 2004
AB		PADAGIS ISRAEL	0.77%	A077676	001	Dec 15, 2006
AB		TARO	0.77%	A077092	001	Aug 10, 2005

LOPROX

AB	+ !	MEDIMETRIKS PHARMS	0.77%	N019824	001	Dec 30, 1988

CIDOFOVIR

INJECTABLE; INJECTION

CIDOFOVIR

AP		EMCURE PHARMS LTD	EQ 75MG BASE/ML	A202501	001	Jul 26, 2012
AP	!	MYLAN INSTITUTIONAL	EQ 75MG BASE/ML	A201276	001	Jun 27, 2012

CILASTATIN SODIUM; IMIPENEM

POWDER; INTRAVENOUS

IMIPENEM AND CILASTATIN

AP		ACS DOBFAR	EQ 500MG BASE/VIAL; 500MG/VIAL	A090577	002	Dec 21, 2011
AP		HQ SPCLT PHARMA	EQ 500MG BASE/VIAL; 500MG/VIAL	A207594	001	Dec 12, 2019

PRIMAXIN

AP	+ !	MERCK	EQ 500MG BASE/VIAL; 500MG/VIAL	N050587	002	Nov 26, 1985
		IMIPENEM AND CILASTATIN				
	!	ACS DOBFAR	EQ 250MG BASE/VIAL; 250MG/VIAL	A090577	001	Dec 21, 2011

CILASTATIN SODIUM; IMIPENEM; RELEBACTAM

POWDER; INTRAVENOUS

RECARBRIO

	+ !	MSD MERCK CO	EQ 500MG	N212819	001	Jul 16, 2019
			BASE/VIAL; 500MG/VIAL; 250MG/VIAL			

CILOSTAZOL

TABLET; ORAL

CILOSTAZOL

AB		APOTEX INC	50MG	A077030	001	Dec 10, 2004
AB			100MG	A077030	002	Dec 10, 2004
AB		CASI PHARMS INC	50MG	A077310	001	Nov 08, 2005
AB			100MG	A077021	001	Nov 23, 2004
AB		CHARTWELL RX	50MG	A077831	002	Sep 24, 2012
AB			100MG	A077831	001	Sep 24, 2012
AB		SLATE RUN PHARMA	50MG	A077208	002	Mar 29, 2006
AB			100MG	A077208	001	Mar 29, 2006
AB	!	TEVA	50MG	A077027	001	Nov 24, 2004
AB	!		100MG	A077027	002	Nov 24, 2004

PRESCRIPTION DRUG PRODUCT LIST

3-99 (of 474)

CIMETIDINE

TABLET; ORAL

CIMETIDINE

AB	MYLAN	<u>200MG</u>	<u>A074246</u>	<u>001</u>	May 17, 1994
AB		<u>300MG</u>	<u>A074246</u>	<u>002</u>	May 17, 1994
AB		<u>400MG</u>	<u>A074246</u>	<u>003</u>	May 17, 1994
AB	!	<u>800MG</u>	<u>A074246</u>	<u>004</u>	May 17, 1994
AB	PLIVA	<u>800MG</u>	<u>A074566</u>	<u>001</u>	Feb 27, 1997
AB	TEVA	<u>200MG</u>	<u>A074151</u>	<u>001</u>	May 17, 1994
AB		<u>300MG</u>	<u>A074151</u>	<u>002</u>	May 17, 1994
AB		<u>400MG</u>	<u>A074151</u>	<u>003</u>	May 17, 1994
AB		<u>800MG</u>	<u>A074463</u>	<u>001</u>	May 17, 1994

CIMETIDINE HYDROCHLORIDE

SOLUTION; ORAL

CIMETIDINE HYDROCHLORIDE

AA	!	AKORN	<u>EQ 300MG BASE/5ML</u>	<u>A074664</u>	<u>001</u>	Oct 28, 1997
AA		PHARM ASSOC	<u>EQ 300MG BASE/5ML</u>	<u>A074553</u>	<u>001</u>	Jan 27, 1997
AA		WOCKHARDT BIO AG	<u>EQ 300MG BASE/5ML</u>	<u>A074757</u>	<u>001</u>	Oct 17, 1997

CINACALCET HYDROCHLORIDE

TABLET; ORAL

CINACALCET HYDROCHLORIDE

AB	ACCORD HLTHCARE	<u>EQ 30MG BASE</u>	<u>A211892</u>	<u>001</u>	May 15, 2020	
AB		<u>EQ 60MG BASE</u>	<u>A211892</u>	<u>002</u>	May 15, 2020	
AB		<u>EQ 90MG BASE</u>	<u>A211892</u>	<u>003</u>	May 15, 2020	
AB	ACME LABS	<u>EQ 30MG BASE</u>	<u>A213325</u>	<u>001</u>	May 18, 2020	
AB		<u>EQ 60MG BASE</u>	<u>A213325</u>	<u>002</u>	May 18, 2020	
AB		<u>EQ 90MG BASE</u>	<u>A213325</u>	<u>003</u>	May 18, 2020	
AB	ALKEM LABS LTD	<u>EQ 30MG BASE</u>	<u>A210570</u>	<u>001</u>	May 17, 2019	
AB		<u>EQ 60MG BASE</u>	<u>A210570</u>	<u>002</u>	May 17, 2019	
AB		<u>EQ 90MG BASE</u>	<u>A210570</u>	<u>003</u>	May 17, 2019	
AB	AUROBINDO PHARMA LTD	<u>EQ 30MG BASE</u>	<u>A206125</u>	<u>001</u>	Mar 08, 2018	
AB		<u>EQ 60MG BASE</u>	<u>A206125</u>	<u>002</u>	Mar 08, 2018	
AB		<u>EQ 90MG BASE</u>	<u>A206125</u>	<u>003</u>	Mar 08, 2018	
AB	CIPLA	<u>EQ 30MG BASE</u>	<u>A208915</u>	<u>001</u>	Mar 08, 2018	
AB		<u>EQ 60MG BASE</u>	<u>A208915</u>	<u>002</u>	Mar 08, 2018	
AB		<u>EQ 90MG BASE</u>	<u>A208915</u>	<u>003</u>	Mar 08, 2018	
AB	DR REDDYS	<u>EQ 30MG BASE</u>	<u>A208368</u>	<u>001</u>	Sep 18, 2020	
AB		<u>EQ 60MG BASE</u>	<u>A208368</u>	<u>002</u>	Sep 18, 2020	
AB		<u>EQ 90MG BASE</u>	<u>A208368</u>	<u>003</u>	Sep 18, 2020	
AB	HETERO LABS LTD V	<u>EQ 30MG BASE</u>	<u>A209403</u>	<u>001</u>	Oct 07, 2020	
AB		<u>EQ 60MG BASE</u>	<u>A209403</u>	<u>002</u>	Oct 07, 2020	
AB		<u>EQ 90MG BASE</u>	<u>A209403</u>	<u>003</u>	Oct 07, 2020	
AB	PIRAMAL HLTHCARE UK	<u>EQ 30MG BASE</u>	<u>A210207</u>	<u>001</u>	Aug 01, 2018	
AB		<u>EQ 60MG BASE</u>	<u>A210207</u>	<u>002</u>	Aug 01, 2018	
AB		<u>EQ 90MG BASE</u>	<u>A210207</u>	<u>003</u>	Aug 01, 2018	
AB	STRIDES PHARMA	<u>EQ 30MG BASE</u>	<u>A209226</u>	<u>001</u>	Apr 30, 2018	
AB		<u>EQ 60MG BASE</u>	<u>A209226</u>	<u>002</u>	Apr 30, 2018	
AB		<u>EQ 90MG BASE</u>	<u>A209226</u>	<u>003</u>	Apr 30, 2018	
AB	SUN PHARM	<u>EQ 30MG BASE</u>	<u>A207008</u>	<u>001</u>	Oct 11, 2018	
AB		<u>EQ 60MG BASE</u>	<u>A207008</u>	<u>002</u>	Oct 11, 2018	
AB		<u>EQ 90MG BASE</u>	<u>A207008</u>	<u>003</u>	Oct 11, 2018	
AB	WATSON LABS TEVA	<u>EQ 30MG BASE</u>	<u>A204377</u>	<u>001</u>	Dec 27, 2018	
AB		<u>EQ 60MG BASE</u>	<u>A204377</u>	<u>002</u>	Dec 27, 2018	
AB		<u>EQ 90MG BASE</u>	<u>A204377</u>	<u>003</u>	Dec 27, 2018	
<u>SENSIPAR</u>						
AB	+	AMGEN	<u>EQ 30MG BASE</u>	<u>N021688</u>	<u>001</u>	Mar 08, 2004
AB	+		<u>EQ 60MG BASE</u>	<u>N021688</u>	<u>002</u>	Mar 08, 2004
AB	+	!	<u>EQ 90MG BASE</u>	<u>N021688</u>	<u>003</u>	Mar 08, 2004

CIPROFLOXACIN

FOR SUSPENSION; ORAL

CIPRO

+	BAYER HLTHCARE	250MG/5ML	N020780	001	Sep 26, 1997
+	!	500MG/5ML	N020780	002	Sep 26, 1997

INJECTABLE; INJECTION

CIPROFLOXACIN

AP	!	BAXTER HLTHCARE CORP	<u>200MG/20ML (10MG/ML)</u>	<u>A078062</u>	<u>001</u>	Apr 29, 2008
AP	!		<u>400MG/40ML (10MG/ML)</u>	<u>A078062</u>	<u>002</u>	Apr 29, 2008
AP		HIKMA FARMACEUTICA	<u>200MG/20ML (10MG/ML)</u>	<u>A076717</u>	<u>001</u>	Dec 22, 2009
AP			<u>400MG/40ML (10MG/ML)</u>	<u>A076717</u>	<u>002</u>	Dec 22, 2009

PRESCRIPTION DRUG PRODUCT LIST

3-100 (of 474)

CIPROFLOXACIN

INJECTABLE; INJECTION

CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>	BAXTER HLTHCARE CORP	<u>200MG/100ML</u>	<u>A078024</u>	<u>001</u>	Mar 18, 2008
<u>AP</u>		<u>400MG/200ML</u>	<u>A078024</u>	<u>002</u>	Mar 18, 2008
<u>AP</u>	HIKMA FARMACEUTICA	<u>400MG/200ML</u>	<u>A078431</u>	<u>001</u>	Nov 18, 2009
<u>AP</u>	! HOSPIRA	<u>200MG/100ML</u>	<u>A077753</u>	<u>001</u>	Mar 18, 2008
<u>AP</u>	!	<u>400MG/200ML</u>	<u>A077753</u>	<u>002</u>	Mar 18, 2008
<u>AP</u>	INFORLIFE	<u>200MG/100ML</u>	<u>A078252</u>	<u>001</u>	Mar 18, 2008
<u>AP</u>		<u>400MG/200ML</u>	<u>A078252</u>	<u>002</u>	Mar 18, 2008

INJECTABLE, SUSPENSION; OTIC

OTIPRIO

+	! ALK ABELLO	6% (60MG/ML)	N207986	001	Dec 10, 2015

CIPROFLOXACIN HYDROCHLORIDE

OINTMENT; OPHTHALMIC

CILOXAN

+	! NOVARTIS	EQ 0.3% BASE	N020369	001	Mar 30, 1998

SOLUTION/DROPS; OPHTHALMIC

CILOXAN

<u>AT</u>	+	! NOVARTIS	<u>EQ 0.3% BASE</u>	<u>N019992</u>	<u>001</u>	Dec 31, 1990

CIPROFLOXACIN HYDROCHLORIDE

<u>AT</u>		AKORN	<u>EQ 0.3% BASE</u>	<u>A076555</u>	<u>001</u>	Dec 11, 2008
<u>AT</u>		ALTAIRE PHARMS INC	<u>EQ 0.3% BASE</u>	<u>A204613</u>	<u>001</u>	May 03, 2018
<u>AT</u>		FDC LTD	<u>EQ 0.3% BASE</u>	<u>A077568</u>	<u>001</u>	Jun 30, 2008
<u>AT</u>		PAI HOLDINGS PHARM	<u>EQ 0.3% BASE</u>	<u>A076754</u>	<u>001</u>	Jun 09, 2004
<u>AT</u>		RISING	<u>EQ 0.3% BASE</u>	<u>A077689</u>	<u>001</u>	Dec 13, 2006
<u>AT</u>		WATSON LABS INC	<u>EQ 0.3% BASE</u>	<u>A076673</u>	<u>001</u>	Jan 21, 2005

SOLUTION/DROPS; OTIC

CETRAXAL

+	! WRASER PHARMS	EQ 0.2% BASE	N021918	001	May 01, 2009

TABLET; ORAL

CIPRO

<u>AB</u>	+	BAYER HLTHCARE	<u>EQ 250MG BASE</u>	<u>N019537</u>	<u>002</u>	Oct 22, 1987
<u>AB</u>	+	!	<u>EQ 500MG BASE</u>	<u>N019537</u>	<u>003</u>	Oct 22, 1987

CIPROFLOXACIN HYDROCHLORIDE

<u>AB</u>		AUROBINDO PHARMA	<u>EQ 250MG BASE</u>	<u>A077859</u>	<u>001</u>	Apr 26, 2007
<u>AB</u>			<u>EQ 500MG BASE</u>	<u>A077859</u>	<u>002</u>	Apr 26, 2007
<u>AB</u>			<u>EQ 750MG BASE</u>	<u>A077859</u>	<u>003</u>	Apr 26, 2007
<u>AB</u>		CARLSBAD	<u>EQ 250MG BASE</u>	<u>A076126</u>	<u>002</u>	Jun 09, 2004
<u>AB</u>			<u>EQ 500MG BASE</u>	<u>A076126</u>	<u>003</u>	Jun 09, 2004
<u>AB</u>			<u>EQ 750MG BASE</u>	<u>A076126</u>	<u>004</u>	Jun 09, 2004
<u>AB</u>		CHARTWELL	<u>EQ 250MG BASE</u>	<u>A076896</u>	<u>001</u>	Nov 04, 2004
<u>AB</u>			<u>EQ 500MG BASE</u>	<u>A076896</u>	<u>002</u>	Nov 04, 2004
<u>AB</u>			<u>EQ 750MG BASE</u>	<u>A076896</u>	<u>003</u>	Nov 04, 2004
<u>AB</u>		DR REDDYS LABS LTD	<u>EQ 100MG BASE</u>	<u>A075593</u>	<u>002</u>	Jun 09, 2004
<u>AB</u>			<u>EQ 250MG BASE</u>	<u>A075593</u>	<u>003</u>	Jun 09, 2004
<u>AB</u>			<u>EQ 500MG BASE</u>	<u>A075593</u>	<u>004</u>	Jun 09, 2004
<u>AB</u>			<u>EQ 750MG BASE</u>	<u>A075593</u>	<u>001</u>	Jun 09, 2004
<u>AB</u>		HIKMA	<u>EQ 250MG BASE</u>	<u>A076558</u>	<u>002</u>	Jun 09, 2004
<u>AB</u>			<u>EQ 500MG BASE</u>	<u>A076558</u>	<u>003</u>	Jun 09, 2004
<u>AB</u>			<u>EQ 750MG BASE</u>	<u>A076558</u>	<u>004</u>	Jun 09, 2004
<u>AB</u>		IVAX SUB TEVA PHARMS	<u>EQ 250MG BASE</u>	<u>A076089</u>	<u>002</u>	Jun 09, 2004
<u>AB</u>			<u>EQ 500MG BASE</u>	<u>A076089</u>	<u>003</u>	Jun 09, 2004
<u>AB</u>			<u>EQ 750MG BASE</u>	<u>A076089</u>	<u>004</u>	Jun 09, 2004
<u>AB</u>		RISING	<u>EQ 500MG BASE</u>	<u>A075817</u>	<u>003</u>	Jun 09, 2004
<u>AB</u>		TARO	<u>EQ 100MG BASE</u>	<u>A076912</u>	<u>001</u>	Feb 18, 2005
<u>AB</u>			<u>EQ 250MG BASE</u>	<u>A076912</u>	<u>002</u>	Oct 06, 2004
<u>AB</u>			<u>EQ 500MG BASE</u>	<u>A076912</u>	<u>003</u>	Oct 06, 2004
<u>AB</u>			<u>EQ 750MG BASE</u>	<u>A076912</u>	<u>004</u>	Oct 06, 2004
<u>AB</u>		UNIQUE	<u>EQ 250MG BASE</u>	<u>A076639</u>	<u>001</u>	Sep 10, 2004
<u>AB</u>			<u>EQ 500MG BASE</u>	<u>A076639</u>	<u>002</u>	Sep 10, 2004
<u>AB</u>			<u>EQ 750MG BASE</u>	<u>A076639</u>	<u>003</u>	Sep 10, 2004
<u>AB</u>		WATSON LABS	<u>EQ 100MG BASE</u>	<u>A076794</u>	<u>001</u>	Feb 10, 2005
<u>AB</u>			<u>EQ 250MG BASE</u>	<u>A076794</u>	<u>002</u>	Jun 09, 2004
<u>AB</u>			<u>EQ 500MG BASE</u>	<u>A076794</u>	<u>003</u>	Jun 09, 2004
<u>AB</u>			<u>EQ 750MG BASE</u>	<u>A076794</u>	<u>004</u>	Jun 09, 2004
<u>AB</u>		YILING	<u>EQ 250MG BASE</u>	<u>A208921</u>	<u>001</u>	Jun 22, 2018
<u>AB</u>			<u>EQ 500MG BASE</u>	<u>A208921</u>	<u>002</u>	Jun 22, 2018

PRESCRIPTION DRUG PRODUCT LIST

3-101 (of 474)

CIPROFLOXACIN HYDROCHLORIDE; FLUOCINOLONE ACETONIDE

SOLUTION/DROPS;OTIC

OTOVEL

+! LABORATORIOS SALVAT EQ 0.3% BASE;0.025%

N208251 001 Apr 29, 2016

CIPROFLOXACIN HYDROCHLORIDE; HYDROCORTISONE

SUSPENSION/DROPS;OTIC

CIPRO HC

+! NOVARTIS EQ 0.2% BASE;1%

N020805 001 Feb 10, 1998

CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

CIPROFLOXACIN EXTENDED RELEASEAB ! ANCHEN PHARMS 425.2MG;EQ 574.9MG BASEA078166 001 Nov 27, 2007AB DR REDDYS LABS LTD 425.2MG;EQ 574.9MG BASEA077701 001 Mar 26, 2007

! ANCHEN PHARMS 212.6MG;EQ 287.5MG BASE

A078166 002 Nov 27, 2007

CIPROFLOXACIN; DEXAMETHASONE

SUSPENSION/DROPS;OTIC

CIPRODEXAB +! NOVARTIS 0.3%;0.1%N021537 001 Jul 18, 2003CIPROFLOXACIN AND DEXAMETHASONEAB DR REDDYS 0.3%;0.1%A205548 001 Aug 10, 2020AB SUN PHARM 0.3%;0.1%A210470 001 Aug 30, 2022CISATRACURIUM BESYLATE

INJECTABLE;INJECTION

CISATRACURIUM BESYLATEAP EUGIA PHARMA EQ 2MG BASE/MLA209144 001 May 08, 2020AP FRESENIUS KABI USA EQ 2MG BASE/MLA203183 001 Feb 26, 2015AP HENGRUI PHARMA EQ 2MG BASE/MLA209334 001 Aug 30, 2017AP HIKMA EQ 10MG BASE/MLA203078 001 Jun 28, 2022AP HOSPIRA EQ 2MG BASE/MLA203236 001 Mar 30, 2018AP EQ 2MG BASE/MLA203238 001 Mar 30, 2018AP EQ 10MG BASE/MLA203236 002 Mar 30, 2018AP MEITHEAL EQ 2MG BASE/MLA211668 001 Apr 25, 2019AP EQ 2MG BASE/MLA211669 001 Apr 25, 2019AP EQ 10MG BASE/MLA211668 002 Apr 25, 2019AP PIRAMAL CRITICAL EQ 2MG BASE/MLA215516 001 May 24, 2022AP EQ 2MG BASE/MLA215517 001 Dec 14, 2022AP EQ 10MG BASE/MLA215516 002 May 24, 2022AP SAGENT PHARMS INC EQ 2MG BASE/MLA201836 001 Nov 06, 2020AP EQ 2MG BASE/MLA201851 001 Nov 06, 2020AP EQ 10MG BASE/MLA201836 002 Nov 06, 2020AP SANDOZ INC EQ 2MG BASE/MLA200159 001 Feb 03, 2012AP SOMERSET EQ 2MG BASE/MLA209132 001 Apr 24, 2019AP ZYDUS PHARMS EQ 2MG BASE/MLA212171 001 Nov 04, 2019AP EQ 10MG BASE/MLA212171 002 Nov 04, 2019CISATRACURIUM BESYLATE PRESERVATIVE FREEAP EUGIA PHARMA EQ 2MG BASE/MLA209665 001 Oct 27, 2020AP FRESENIUS KABI USA EQ 2MG BASE/MLA203182 001 Feb 26, 2015AP EQ 10MG BASE/MLA203182 002 Feb 26, 2015AP HENGRUI PHARMA EQ 2MG BASE/MLA204960 001 Jan 27, 2017AP EQ 10MG BASE/MLA204960 002 Sep 19, 2017AP SANDOZ INC EQ 2MG BASE/MLA200154 001 Feb 03, 2012AP EQ 10MG BASE/MLA200154 002 Feb 03, 2012AP SOMERSET THERAPS EQ 2MG BASE/MLA206791 001 Feb 20, 2019LLC EQ 10MG BASE/MLA206791 002 Feb 20, 2019NIMBEXAP +! ABBVIE EQ 2MG BASE/MLN020551 001 Dec 15, 1995NIMBEX PRESERVATIVE FREEAP +! ABBVIE EQ 2MG BASE/MLN020551 003 Dec 15, 1995AP +! EQ 10MG BASE/MLN020551 002 Dec 15, 1995CISPLATIN

INJECTABLE;INJECTION

CISPLATINAP ACCORD HLTHCARE 1MG/MLA206774 001 Aug 18, 2015AP ! FRESENIUS KABI USA 1MG/MLA074735 001 Jul 16, 1999AP GLAND PHARMA LTD 1MG/MLA207323 001 Mar 17, 2017AP HIKMA 1MG/MLA075036 001 Nov 07, 2000AP + HQ SPCLT PHARMA 1MG/MLN018057 004 Nov 08, 1988AP PHARMACHEMIE BV 1MG/MLA074656 001 May 16, 2000

+! HQ SPCLT PHARMA 50MG/VIAL

N018057 002

PRESCRIPTION DRUG PRODUCT LIST

3-102 (of 474)

CITALOPRAM HYDROBROMIDE

CAPSULE;ORAL

CITALOPRAM HYDROBROMIDE

+! ALMATICA

EQ 30MG BASE

N215428 001 Jan 31, 2022

SOLUTION;ORAL

CITALOPRAM HYDROBROMIDE**AA** AUROBINDO PHARMAEQ 10MG BASE/5ML**A077812 001** Aug 28, 2006**AA** CHARTWELL MOLECULAREQ 10MG BASE/5ML**A077629 001** Jun 14, 2006**AA** HETERO LABS LTD IIIEQ 10MG BASE/5ML**A201450 001** Dec 15, 2015**AA** ! HIKMAEQ 10MG BASE/5ML**A077043 001** Dec 13, 2004

TABLET;ORAL

CELEXA**AB** + ALLERGANEQ 10MG BASE**N020822 001** Apr 27, 2000**AB** +EQ 20MG BASE**N020822 002** Jul 17, 1998**AB** +!EQ 40MG BASE**N020822 003** Jul 17, 1998CITALOPRAM HYDROBROMIDE**AB** AMNEAL PHARMS NYEQ 10MG BASE**A077289 001** Nov 30, 2006**AB**EQ 20MG BASE**A077289 002** Nov 30, 2006**AB**EQ 40MG BASE**A077289 003** Nov 30, 2006**AB** APOTEX INCEQ 10MG BASE**A077046 001** Nov 24, 2004**AB** AUROBINDOEQ 10MG BASE**A077031 001** Oct 28, 2004**AB**EQ 20MG BASE**A077031 002** Oct 28, 2004**AB**EQ 40MG BASE**A077031 003** Oct 28, 2004**AB** CHARTWELL MOLECULAREQ 10MG BASE**A077044 001** Nov 05, 2004**AB**EQ 20MG BASE**A077044 002** Nov 05, 2004**AB**EQ 40MG BASE**A077044 003** Nov 05, 2004**AB** COSETTEEQ 10MG BASE**A077048 001** Nov 16, 2004**AB**EQ 20MG BASE**A077048 002** Nov 16, 2004**AB**EQ 40MG BASE**A077048 003** Nov 16, 2004**AB** DR REDDYS LABS LTDEQ 10MG BASE**A077038 001** Oct 28, 2004**AB**EQ 20MG BASE**A077038 002** Oct 28, 2004**AB**EQ 40MG BASE**A077038 003** Oct 28, 2004**AB** EPIC PHARMAEQ 10MG BASE**A077045 003** Apr 29, 2005**AB**EQ 20MG BASE**A077045 002** Apr 29, 2005**AB**EQ 40MG BASE**A077045 001** Apr 29, 2005**AB** GLENMARK GENERICSEQ 10MG BASE**A077654 001** Feb 27, 2009**AB**EQ 20MG BASE**A077654 002** Feb 27, 2009**AB**EQ 40MG BASE**A077654 003** Feb 27, 2009**AB** INVAGEN PHARMSEQ 10MG BASE**A077534 001** Oct 03, 2006**AB**EQ 20MG BASE**A077534 002** Oct 03, 2006**AB**EQ 40MG BASE**A077534 003** Oct 03, 2006**AB** MYLANEQ 10MG BASE**A077042 001** Nov 05, 2004**AB**EQ 20MG BASE**A077042 002** Nov 05, 2004**AB**EQ 40MG BASE**A077042 003** Nov 05, 2004**AB** TORPHARMEQ 20MG BASE**A077046 002** Nov 24, 2004**AB**EQ 40MG BASE**A077046 003** Nov 24, 2004**AB** TORRENT PHARMSEQ 10MG BASE**A078216 001** Mar 27, 2007**AB**EQ 20MG BASE**A078216 002** Mar 27, 2007**AB**EQ 40MG BASE**A078216 003** Mar 27, 2007CITRIC ACID; GLUCONOLACTONE; MAGNESIUM CARBONATE

SOLUTION;IRRIGATION

RENACIDIN

+! UNITED GUARDIAN

6.602GM/100ML;198MG/100ML;3.177GM/100ML

N019481 001 Oct 02, 1990

CITRIC ACID; LACTIC ACID; POTASSIUM BITARTRATE

GEL;VAGINAL

PHEXXI

+! EVOFEM INC

1%;1.8%;0.4%

N208352 001 May 22, 2020

CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE

FOR SOLUTION;ORAL

SODIUM PICOSULFATE, MAGNESIUM OXIDE AND ANHYDROUS CITRIC ACID

! HETERO LABS LTD V

12GM/PACKET;3.5GM/PACKET;10MG/PACKET

A212789 001 Jul 18, 2022

SOLUTION;ORAL

CLENPIQ

+! FERRING PHARMS INC

12GM/BOT;3.5GM/BOT;10MG/BOT

N209589 001 Nov 28, 2017

PRESCRIPTION DRUG PRODUCT LIST

3-103 (of 474)

CITRIC ACID; UREA C-13

FOR SOLUTION, TABLET, FOR SOLUTION; ORAL

IDKIT:HP

+! MERIDIAN BIOSCIENCE 4GM; 75MG

N021314 001 Dec 17, 2002

CLADRIBINE

INJECTABLE; INJECTION

CLADRIBINE**AP** ! FRESenius KABI USA1MG/MLA076571 001 Apr 22, 2004**AP** HIKMA1MG/MLA075405 001 Feb 28, 2000**AP** HISUN PHARM1MG/MLA210856 001 Nov 25, 2019

HANGZHOU

TABLET; ORAL

MAVENCLAD

+! EMD SERONO INC

10MG

N022561 001 Mar 29, 2019

CLARITHROMYCIN

FOR SUSPENSION; ORAL

CLARITHROMYCIN**AB** SANDOZ125MG/5MLA065283 002 Sep 04, 2007**AB** !250MG/5MLA065283 003 Sep 04, 2007

TABLET; ORAL

CLARITHROMYCIN**AB** ALEMBIC PHARMS250MGA210459 001 Jan 31, 2022**AB**500MGA210459 002 Jan 31, 2022**AB** ! AUROBINDO250MGA065489 001 Jul 25, 2012**AB** !500MGA065489 002 Jul 25, 2012**AB** CHARTWELL250MGA065384 001 Aug 20, 2007**AB**500MGA065384 002 Aug 20, 2007**AB** HEC PHARM250MGA203584 001 Sep 28, 2015**AB**500MGA203584 002 Sep 28, 2015**AB** SANDOZ250MGA065144 001 Oct 18, 2005**AB**500MGA065136 001 Aug 25, 2005**AB** STRIDES PHARMA250MGA202710 001 Jun 10, 2013**AB**500MGA202710 002 Jun 10, 2013**AB** TEVA250MGA065155 001 May 31, 2005**AB**500MGA065155 002 May 31, 2005

TABLET, EXTENDED RELEASE; ORAL

CLARITHROMYCIN**AB** ACTAVIS LABS FL INC500MGA065145 001 Jun 24, 2004**AB** ! MAYNE PHARMA500MGA065154 001 May 18, 2005**AB** SUNSHINE500MGA208987 001 Jul 09, 2018CLASCOTERONE

CREAM; TOPICAL

WINLEVI

+! SUN PHARM

1%

N213433 001 Aug 26, 2020

CLEMASTINE FUMARATE

SYRUP; ORAL

CLEMASTINE FUMARATE

! GENUS

EQ 0.5MG BASE/5ML

A073399 001 Jun 30, 1994

TABLET; ORAL

CLEMASTINE FUMARATE

! TEVA

2.68MG

A073283 001 Jan 31, 1992

CLEVIDIPINE

EMULSION; INTRAVENOUS

CLEVIPREX

+! CHIESI

25MG/50ML (0.5MG/ML)

N022156 001 Aug 01, 2008

+!

50MG/100ML (0.5MG/ML)

N022156 002 Aug 01, 2008

CLINDAMYCIN HYDROCHLORIDE

CAPSULE; ORAL

CLEOCIN HYDROCHLORIDE**AB** + PFIZEREQ 75MG BASEN050162 001**AB** +EQ 150MG BASEN050162 002**AB** +!EQ 300MG BASEN050162 003 Apr 14, 1988CLINDAMYCIN HYDROCHLORIDE**AB** AUROBINDO PHARMAEQ 150MG BASEA065442 001 Aug 26, 2009**AB**EQ 300MG BASEA065442 002 Aug 26, 2009**AB** CHARTWELL MOLECULAREQ 75MG BASEA065243 002 Aug 12, 2005**AB**EQ 150MG BASEA063029 001 Sep 20, 1989**AB**EQ 300MG BASEA063029 002 Aug 05, 2005**AB** EPIC PHARMA LLCEQ 150MG BASEA065194 001 Mar 22, 2004**AB**EQ 300MG BASEA065194 002 Mar 22, 2004

PRESCRIPTION DRUG PRODUCT LIST

3-104 (of 474)

CLINDAMYCIN HYDROCHLORIDE

CAPSULE; ORAL

CLINDAMYCIN HYDROCHLORIDE

AB	MICRO LABS	<u>EQ 75MG BASE</u>	<u>A207402</u>	<u>001</u>	Nov 05, 2018
AB		<u>EQ 150MG BASE</u>	<u>A207402</u>	<u>002</u>	Nov 05, 2018
AB		<u>EQ 300MG BASE</u>	<u>A207402</u>	<u>003</u>	Nov 05, 2018
AB	SUN PHARM INDS LTD	<u>EQ 150MG BASE</u>	<u>A065061</u>	<u>001</u>	Feb 02, 2001
AB		<u>EQ 300MG BASE</u>	<u>A065061</u>	<u>002</u>	Feb 02, 2001
AB	ZYDUS PHARMS USA	<u>EQ 75MG BASE</u>	<u>A065217</u>	<u>001</u>	Jan 31, 2005
AB		<u>EQ 150MG BASE</u>	<u>A065217</u>	<u>002</u>	Jan 31, 2005
AB		<u>EQ 300MG BASE</u>	<u>A065217</u>	<u>003</u>	Jan 31, 2005

CLINDAMYCIN PALMITATE HYDROCHLORIDE

FOR SOLUTION; ORAL

CLEOCIN

AA	! PFIZER	<u>EQ 75MG BASE/5ML</u>	<u>A062644</u>	<u>001</u>	Apr 07, 1986

CLINDAMYCIN PALMITATE HYDROCHLORIDE

AA	ALEMBIC LABS	<u>EQ 75MG BASE/5ML</u>	<u>A206958</u>	<u>001</u>	May 05, 2017
AA	AMNEAL PHARMS	<u>EQ 75MG BASE/5ML</u>	<u>A203513</u>	<u>001</u>	Mar 13, 2014
AA	AUROBINDO PHARMA LTD	<u>EQ 75MG BASE/5ML</u>	<u>A202409</u>	<u>001</u>	Apr 30, 2013
AA	HERITAGE PHARMS INC	<u>EQ 75MG BASE/5ML</u>	<u>A207047</u>	<u>001</u>	May 11, 2018
AA	LYNE	<u>EQ 75MG BASE/5ML</u>	<u>A201821</u>	<u>001</u>	Aug 28, 2012
AA	PADAGIS US	<u>EQ 75MG BASE/5ML</u>	<u>A090902</u>	<u>001</u>	Jul 07, 2010

CLINDAMYCIN PHOSPHATE

AEROSOL, FOAM; TOPICAL

CLINDAMYCIN PHOSPHATE

AT	GLENMARK PHARMS LTD	<u>1%</u>	<u>A210778</u>	<u>001</u>	Sep 20, 2021
AT	PADAGIS ISRAEL	<u>1%</u>	<u>A090785</u>	<u>001</u>	Mar 31, 2010
AT	TARO PHARM INDS LTD	<u>1%</u>	<u>A210004</u>	<u>001</u>	Mar 11, 2020

EVOCLIN

AT	+! MYLAN	<u>1%</u>	<u>N050801</u>	<u>001</u>	Oct 22, 2004

CREAM; VAGINAL

CLEOCIN

AB	+! PFIZER	<u>EQ 2% BASE</u>	<u>N050680</u>	<u>002</u>	Mar 02, 1998

CLINDAMYCIN PHOSPHATE

AB	FOUGERA PHARMS	<u>EQ 2% BASE</u>	<u>A065139</u>	<u>001</u>	Dec 27, 2004
	CLINDESSE				
	+! PADAGIS US	EQ 2% BASE	N050793	001	Nov 30, 2004

GEL; TOPICAL

CLEOCIN T

AB1	+! PFIZER	<u>EQ 1% BASE</u>	<u>N050615</u>	<u>001</u>	Jan 07, 1987

CLINDAMYCIN PHOSPHATE

AB1	AMNEAL	<u>EQ 1% BASE</u>	<u>A215219</u>	<u>001</u>	Nov 03, 2022
AB1	ENCUBE	<u>EQ 1% BASE</u>	<u>A212438</u>	<u>001</u>	Mar 11, 2021
AB1	FOUGERA PHARMS	<u>EQ 1% BASE</u>	<u>A064160</u>	<u>001</u>	Jan 28, 2000
AB1	GLENMARK PHARMS LTD	<u>EQ 1% BASE</u>	<u>A214251</u>	<u>001</u>	Feb 10, 2021
AB1	PADAGIS ISRAEL	<u>EQ 1% BASE</u>	<u>A212104</u>	<u>001</u>	Dec 31, 2020
AB1	SOLARIS PHARMA CORP	<u>EQ 1% BASE</u>	<u>A211872</u>	<u>001</u>	Jul 29, 2020
AB1	TARO PHARMS	<u>EQ 1% BASE</u>	<u>A214052</u>	<u>001</u>	Nov 10, 2020

CLINDAGEL

AB2	+! BAUSCH	<u>EQ 1% BASE</u>	<u>N050782</u>	<u>001</u>	Nov 27, 2000

CLINDAMYCIN PHOSPHATE

AB2	AMNEAL	<u>EQ 1% BASE</u>	<u>A214668</u>	<u>001</u>	Aug 05, 2022
AB2	SOLARIS PHARMA CORP	<u>EQ 1% BASE</u>	<u>A212842</u>	<u>001</u>	Aug 13, 2021

GEL; VAGINAL

XACIATO

	+! DARE	EQ 2% BASE	N215650	001	Dec 07, 2021

INJECTABLE; INJECTION

CLEOCIN PHOSPHATE

AP	PFIZER	<u>EQ 150MG BASE/ML</u>	<u>A062803</u>	<u>001</u>	Oct 16, 1987
AP	+!	<u>EQ 150MG BASE/ML</u>	<u>N050441</u>	<u>001</u>	

CLINDAMYCIN PHOSPHATE

AP	ALMAJECT	<u>EQ 150MG BASE/ML</u>	<u>A062800</u>	<u>001</u>	Jul 24, 1987
AP		<u>EQ 150MG BASE/ML</u>	<u>A062943</u>	<u>001</u>	Sep 29, 1988
AP	FRESENIUS KABI USA	<u>EQ 150MG BASE/ML</u>	<u>A065346</u>	<u>001</u>	Mar 29, 2007
AP		<u>EQ 150MG BASE/ML</u>	<u>A065347</u>	<u>001</u>	May 09, 2007
AP	HIKMA	<u>EQ 150MG BASE/ML</u>	<u>A062889</u>	<u>001</u>	Apr 25, 1988
AP		<u>EQ 150MG BASE/ML</u>	<u>A065206</u>	<u>001</u>	Sep 24, 2004
AP	SAGENT PHARMS INC	<u>EQ 150MG BASE/ML</u>	<u>A090108</u>	<u>001</u>	Sep 30, 2011
AP		<u>EQ 150MG BASE/ML</u>	<u>A090109</u>	<u>001</u>	Sep 30, 2011

PRESCRIPTION DRUG PRODUCT LIST

3-105 (of 474)

CLINDAMYCIN PHOSPHATE

INJECTABLE; INJECTION

CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER

<u>AP</u>	AKORN	<u>EQ 6MG BASE/ML</u>	<u>A203048</u>	<u>001</u>	Apr 04, 2013
<u>AP</u>		<u>EQ 12MG BASE/ML</u>	<u>A203048</u>	<u>002</u>	Apr 04, 2013
<u>AP</u>		<u>EQ 18MG BASE/ML</u>	<u>A203048</u>	<u>003</u>	Apr 04, 2013
<u>AP</u>	BAXTER HLTHCARE CORP	<u>EQ 6MG BASE/ML</u>	<u>A208084</u>	<u>001</u>	Jun 28, 2017
<u>AP</u>		<u>EQ 12MG BASE/ML</u>	<u>A208084</u>	<u>002</u>	Jun 28, 2017
<u>AP</u>		<u>EQ 18MG BASE/ML</u>	<u>A208084</u>	<u>003</u>	Jun 28, 2017
<u>AP</u>	! SANDOZ INC	<u>EQ 6MG BASE/ML</u>	<u>A201692</u>	<u>001</u>	May 31, 2012
<u>AP</u>	!	<u>EQ 12MG BASE/ML</u>	<u>A201692</u>	<u>002</u>	May 31, 2012
<u>AP</u>	!	<u>EQ 18MG BASE/ML</u>	<u>A201692</u>	<u>003</u>	May 31, 2012

CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%

+! ABRAXIS PHARM EQ 900MG BASE/100ML

N050635 001 Dec 22, 1989

LOTION; TOPICAL

CLEOCIN T

<u>AB</u>	+! PFIZER	<u>EQ 1% BASE</u>	<u>N050600</u>	<u>001</u>	May 31, 1989

CLINDAMYCIN PHOSPHATE

<u>AB</u>	ENCUBE	<u>EQ 1% BASE</u>	<u>A215607</u>	<u>001</u>	Jan 18, 2022
<u>AB</u>	FOUGERA PHARMS	<u>EQ 1% BASE</u>	<u>A065067</u>	<u>001</u>	Jan 31, 2002
<u>AB</u>	PADAGIS ISRAEL	<u>EQ 1% BASE</u>	<u>A214604</u>	<u>001</u>	Mar 08, 2021
<u>AB</u>	TARO PHARMS	<u>EQ 1% BASE</u>	<u>A214526</u>	<u>001</u>	Jun 28, 2021

SOLUTION; INTRAVENOUS

CLINDAMYCIN PHOSPHATE IN 0.9% SODIUM CHLORIDE

+! BAXTER HLTHCARE EQ 300MG BASE/50ML (EQ 6MG BASE/ML)
CORP

N208083 001 Apr 20, 2017

+! EQ 600MG BASE/50ML (EQ 12MG BASE/ML)

N208083 002 Apr 20, 2017

+! EQ 900MG BASE/50ML (EQ 18MG BASE/ML)

N208083 003 Apr 20, 2017

SOLUTION; TOPICAL

CLINDA-DERM

<u>AT</u>	PADAGIS US	<u>EQ 1% BASE</u>	<u>A063329</u>	<u>001</u>	Sep 30, 1992

CLINDAMYCIN PHOSPHATE

<u>AT</u>	CADILA	<u>EQ 1% BASE</u>	<u>A208767</u>	<u>001</u>	Jul 16, 2018
<u>AT</u>	ENCUBE ETHICALS	<u>EQ 1% BASE</u>	<u>A209914</u>	<u>001</u>	Jan 28, 2019
<u>AT</u>	FOUGERA PHARMS INC	<u>EQ 1% BASE</u>	<u>A064159</u>	<u>001</u>	Jun 05, 1997
<u>AT</u>	GLASSHOUSE PHARMS	<u>EQ 1% BASE</u>	<u>A209846</u>	<u>001</u>	Feb 08, 2018
<u>AT</u>	! PADAGIS US	<u>EQ 1% BASE</u>	<u>A064050</u>	<u>001</u>	Nov 30, 1995
<u>AT</u>	PAI HOLDINGS PHARM	<u>EQ 1% BASE</u>	<u>A206945</u>	<u>001</u>	Dec 30, 2016
<u>AT</u>	TARO PHARM INDS	<u>EQ 1% BASE</u>	<u>A065184</u>	<u>001</u>	Mar 31, 2004

SUPPOSITORY; VAGINAL

CLEOCIN

+! PFIZER 100MG

N050767 001 Aug 13, 1999

SWAB; TOPICAL

CLINDAMYCIN PHOSPHATE

<u>AT</u>	AKORN	<u>EQ 1% BASE</u>	<u>A065513</u>	<u>001</u>	Jun 17, 2010
<u>AT</u>	! PADAGIS US	<u>EQ 1% BASE</u>	<u>A065049</u>	<u>001</u>	May 25, 2000

CLINDETS

<u>AT</u>	PADAGIS US	<u>EQ 1% BASE</u>	<u>A064136</u>	<u>001</u>	Sep 30, 1996

CLINDAMYCIN PHOSPHATE; TRETINOIN

GEL; TOPICAL

CLINDAMYCIN PHOSPHATE AND TRETINOIN

<u>AB1</u>	ACTAVIS MID ATLANTIC	<u>1.2%; 0.025%</u>	<u>A202564</u>	<u>001</u>	Jun 12, 2015

ZIANA

<u>AB1</u>	+! BAUSCH	<u>1.2%; 0.025%</u>	<u>N050802</u>	<u>001</u>	Nov 07, 2006

CLINDAMYCIN PHOSPHATE AND TRETINOIN

<u>AB2</u>	SOLARIS PHARMA CORP	<u>1.2%; 0.025%</u>	<u>A212845</u>	<u>001</u>	Feb 10, 2022

VELTIN

<u>AB2</u>	+! ALMIRALL	<u>1.2%; 0.025%</u>	<u>N050803</u>	<u>001</u>	Jul 16, 2010

CLOBAZAM

FILM; ORAL

SYMPAZAN

+ OTTER PHARMS

N210833 001 Nov 01, 2018

+ 10MG

N210833 002 Nov 01, 2018

+! 20MG

N210833 003 Nov 01, 2018

SUSPENSION; ORAL

CLOBAZAM

<u>AB</u>	ACCORD HLTHCARE	<u>2.5MG/ML</u>	<u>A216008</u>	<u>001</u>	Sep 06, 2022
<u>AB</u>	ALKEM LABS LTD	<u>2.5MG/ML</u>	<u>A213039</u>	<u>001</u>	May 06, 2021
<u>AB</u>	AMNEAL	<u>2.5MG/ML</u>	<u>A210039</u>	<u>001</u>	Oct 22, 2018
<u>AB</u>	AUROBINDO PHARMA	<u>2.5MG/ML</u>	<u>A214404</u>	<u>001</u>	Mar 24, 2022

PRESCRIPTION DRUG PRODUCT LIST

3-106 (of 474)

CLOBAZAM

SUSPENSION; ORAL

CLOBAZAM

LTD

<u>AB</u>	BIONPHARMA INC	<u>2.5MG/ML</u>	<u>A208819</u>	<u>001</u>	Oct 22, 2018
<u>AB</u>	CHARTWELL MOLECULAR	<u>2.5MG/ML</u>	<u>A213110</u>	<u>001</u>	Apr 24, 2020
<u>AB</u>	HETERO LABS LTD III	<u>2.5MG/ML</u>	<u>A209796</u>	<u>001</u>	Feb 24, 2020
<u>AB</u>	LUPIN LTD	<u>2.5MG/ML</u>	<u>A210546</u>	<u>001</u>	Dec 28, 2018
<u>AB</u>	MYLAN	<u>2.5MG/ML</u>	<u>A211259</u>	<u>001</u>	Oct 22, 2018
<u>AB</u>	TARO	<u>2.5MG/ML</u>	<u>A210978</u>	<u>001</u>	Apr 15, 2019
<u>AB</u>	UPSHER SMITH LABS	<u>2.5MG/ML</u>	<u>A210569</u>	<u>001</u>	Oct 22, 2018
<u>AB</u>	VISTAPHARM	<u>2.5MG/ML</u>	<u>A210746</u>	<u>001</u>	Jul 10, 2019

ONFI

<u>AB</u>	<u>+</u> !	LUNDBECK PHARMS LLC	<u>2.5MG/ML</u>	<u>N203993</u>	<u>001</u>	Dec 14, 2012

TABLET; ORAL

CLOBAZAM

<u>AB</u>	ALKEM LABS LTD	<u>10MG</u>	<u>A212714</u>	<u>001</u>	Sep 06, 2019
<u>AB</u>		<u>20MG</u>	<u>A212714</u>	<u>002</u>	Sep 06, 2019
<u>AB</u>	AMNEAL PHARMS CO	<u>10MG</u>	<u>A209718</u>	<u>001</u>	Oct 22, 2018
<u>AB</u>		<u>20MG</u>	<u>A209718</u>	<u>002</u>	Oct 22, 2018
<u>AB</u>	BIONPHARMA INC	<u>10MG</u>	<u>A208825</u>	<u>001</u>	Oct 22, 2018
<u>AB</u>		<u>20MG</u>	<u>A208825</u>	<u>002</u>	Oct 22, 2018
<u>AB</u>	BRECKENRIDGE	<u>10MG</u>	<u>A209308</u>	<u>001</u>	Oct 22, 2018
<u>AB</u>		<u>20MG</u>	<u>A209308</u>	<u>002</u>	Oct 22, 2018
<u>AB</u>	HETERO LABS LTD III	<u>10MG</u>	<u>A209795</u>	<u>001</u>	Oct 22, 2018
<u>AB</u>		<u>20MG</u>	<u>A209795</u>	<u>002</u>	Oct 22, 2018
<u>AB</u>	LUPIN LTD	<u>10MG</u>	<u>A210545</u>	<u>001</u>	Dec 14, 2018
<u>AB</u>		<u>20MG</u>	<u>A210545</u>	<u>002</u>	Dec 14, 2018
<u>AB</u>	MICRO LABS	<u>10MG</u>	<u>A211711</u>	<u>001</u>	Jan 30, 2019
<u>AB</u>		<u>20MG</u>	<u>A211711</u>	<u>002</u>	Jan 30, 2019
<u>AB</u>	MSN	<u>10MG</u>	<u>A213404</u>	<u>001</u>	May 11, 2021
<u>AB</u>		<u>20MG</u>	<u>A213404</u>	<u>002</u>	May 11, 2021
<u>AB</u>	PIRAMAL HLTHCARE UK	<u>10MG</u>	<u>A209808</u>	<u>001</u>	Oct 22, 2018
<u>AB</u>		<u>20MG</u>	<u>A209808</u>	<u>002</u>	Oct 22, 2018
<u>AB</u>	UPSHER SMITH LABS	<u>10MG</u>	<u>A209687</u>	<u>001</u>	Oct 22, 2018
<u>AB</u>		<u>20MG</u>	<u>A209687</u>	<u>002</u>	Oct 22, 2018
<u>AB</u>	ZYDUS PHARMS	<u>10MG</u>	<u>A211449</u>	<u>001</u>	Oct 22, 2018
<u>AB</u>		<u>20MG</u>	<u>A211449</u>	<u>002</u>	Oct 22, 2018

ONFI

<u>AB</u>	<u>+</u>	LUNDBECK PHARMS LLC	<u>10MG</u>	<u>N202067</u>	<u>002</u>	Oct 21, 2011
<u>AB</u>	<u>+</u> !		<u>20MG</u>	<u>N202067</u>	<u>003</u>	Oct 21, 2011

CLOBAZAM

	ALKEM LABS LTD	5MG	A212714	003	Dec 21, 2020

CLOBETASOL PROPIONATE

AEROSOL, FOAM; TOPICAL

CLOBETASOL PROPIONATE

<u>AB1</u>	ALEOR	<u>0.05%</u>	<u>A215838</u>	<u>001</u>	Apr 21, 2022
	DERMACEUTICALS				
<u>AB1</u>	GLENMARK PHARMS LTD	<u>0.05%</u>	<u>A210809</u>	<u>001</u>	Feb 15, 2019
<u>AB1</u>	PADAGIS ISRAEL	<u>0.05%</u>	<u>A077763</u>	<u>001</u>	Mar 10, 2008
<u>AB1</u>	TARO	<u>0.05%</u>	<u>A208779</u>	<u>001</u>	Oct 04, 2018

OLUX

<u>AB1</u>	<u>+</u> !	MYLAN	<u>0.05%</u>	<u>N021142</u>	<u>001</u>	May 26, 2000

CLOBETASOL PROPIONATE

<u>AB2</u>	GLENMARK PHARMS LTD	<u>0.05%</u>	<u>A211450</u>	<u>001</u>	Sep 09, 2019
<u>AB2</u>	PADAGIS ISRAEL	<u>0.05%</u>	<u>A201402</u>	<u>001</u>	Aug 14, 2012

OLUX E

<u>AB2</u>	<u>+</u> !	MYLAN	<u>0.05%</u>	<u>N022013</u>	<u>001</u>	Jan 12, 2007

CREAM; TOPICAL

CLOBETASOL PROPIONATE

<u>AB1</u>	ALEOR	<u>0.05%</u>	<u>A213291</u>	<u>001</u>	Jan 27, 2020
	DERMACEUTICALS				
<u>AB1</u>	AMNEAL	<u>0.05%</u>	<u>A211256</u>	<u>001</u>	Dec 26, 2018
<u>AB1</u>	AUROBINDO PHARMA USA	<u>0.05%</u>	<u>A075338</u>	<u>001</u>	Feb 09, 2001
<u>AB1</u>	COSETTE	<u>0.05%</u>	<u>A074139</u>	<u>001</u>	Aug 03, 1994
<u>AB1</u>	ENCUBE	<u>0.05%</u>	<u>A212982</u>	<u>001</u>	Aug 28, 2020
<u>AB1</u>	FOUGERA PHARMS INC	<u>0.05%</u>	<u>A074392</u>	<u>001</u>	Sep 30, 1996
<u>AB1</u>	GLENMARK PHARMS	<u>0.05%</u>	<u>A209095</u>	<u>001</u>	May 10, 2018
<u>AB1</u>	LUPIN LTD	<u>0.05%</u>	<u>A210208</u>	<u>001</u>	Jan 30, 2018
<u>AB1</u>	PAI HOLDINGS PHARM	<u>0.05%</u>	<u>A209974</u>	<u>001</u>	Apr 17, 2018
<u>AB1</u>	RISING	<u>0.05%</u>	<u>A211401</u>	<u>001</u>	Jan 11, 2019

PRESCRIPTION DRUG PRODUCT LIST

3-107 (of 474)

CLOBETASOL PROPIONATE

CREAM; TOPICAL

CLOBETASOL PROPIONATE

AB1	TARO	0.05%	<u>A074249</u>	<u>001</u>	Jul 08, 1996
AB1	TORRENT	0.05%	<u>A211836</u>	<u>001</u>	Dec 30, 2019
AB1	XIROMED	0.05%	<u>A210034</u>	<u>001</u>	Jun 15, 2018
AB1	ZYDUS PHARMS	0.05%	<u>A211074</u>	<u>001</u>	Oct 15, 2018

CORMAX

AB1	! AKORN	0.05%	<u>A074220</u>	<u>001</u>	May 16, 1997

CLOBETASOL PROPIONATE (EMOLLIENT)

AB2	ANI PHARMS	0.05%	<u>A075733</u>	<u>001</u>	Aug 22, 2001
AB2	! FOUGERA PHARMS	0.05%	<u>A075430</u>	<u>001</u>	May 26, 1999
AB2	PAI HOLDINGS PHARM	0.05%	<u>A209411</u>	<u>001</u>	Aug 21, 2017
AB2	TARO	0.05%	<u>A075633</u>	<u>001</u>	May 17, 2000
IMPOYZ					
	+! PRIMUS PHARMS	0.025%	N209483	001	Nov 28, 2017

GEL; TOPICAL

CLOBETASOL PROPIONATE

AB	! FOUGERA PHARMS	0.05%	<u>A075368</u>	<u>001</u>	Feb 15, 2000
AB	PADAGIS US	0.05%	<u>A075027</u>	<u>001</u>	Oct 31, 1997
AB	PAI HOLDINGS PHARM	0.05%	<u>A208881</u>	<u>001</u>	Mar 06, 2017
AB	TARO	0.05%	<u>A075279</u>	<u>001</u>	May 28, 1999

EMBELINE

AB	AKORN	0.05%	<u>A076141</u>	<u>001</u>	Apr 12, 2002

LOTION; TOPICAL

CLOBETASOL PROPIONATE

AB	ACTAVIS MID ATLANTIC	0.05%	<u>A078223</u>	<u>001</u>	Dec 04, 2008
AB	CADILA	0.05%	<u>A205249</u>	<u>001</u>	Sep 24, 2019
AB	LUPIN LTD	0.05%	<u>A209147</u>	<u>001</u>	Sep 22, 2017
AB	PAI HOLDINGS PHARM	0.05%	<u>A208667</u>	<u>001</u>	Nov 29, 2016
AB	TARO	0.05%	<u>A200302</u>	<u>001</u>	Jul 02, 2012

CLOBEX

AB	+! GALDERMA LABS LP	0.05%	<u>N021535</u>	<u>001</u>	Jul 24, 2003
IMPEKLO					
	+! MYLAN	0.05%	N213691	001	May 19, 2020

OINTMENT; TOPICAL

CLOBETASOL PROPIONATE

AB	ALEOR	0.05%	<u>A211800</u>	<u>001</u>	Mar 04, 2019
DERMACEUTICALS					
AB	AUROBINDO PHARMA USA	0.05%	<u>A075057</u>	<u>001</u>	Aug 12, 1998
AB	COSETTE	0.05%	<u>A074089</u>	<u>001</u>	Feb 16, 1994
AB	ENCUBE	0.05%	<u>A211295</u>	<u>001</u>	Nov 15, 2019
AB	! FOUGERA PHARMS	0.05%	<u>A074407</u>	<u>001</u>	Feb 23, 1996
AB	GLENMARK PHARMS	0.05%	<u>A208933</u>	<u>001</u>	Mar 20, 2017
AB	NOVEL LABS INC	0.05%	<u>A208841</u>	<u>001</u>	May 04, 2018
AB	PAI HOLDINGS PHARM	0.05%	<u>A208589</u>	<u>001</u>	Jan 23, 2019
AB	TARO	0.05%	<u>A074248</u>	<u>001</u>	Jul 12, 1996
AB	XIROMED	0.05%	<u>A209701</u>	<u>001</u>	Apr 17, 2018
AB	ZYDUS PHARMS	0.05%	<u>A210199</u>	<u>001</u>	Oct 27, 2017

EMBELINE

AB	AKORN	0.05%	<u>A074221</u>	<u>001</u>	Mar 31, 1995

SHAMPOO; TOPICAL

CLOBETASOL PROPIONATE

AB	ACTAVIS MID ATLANTIC	0.05%	<u>A078854</u>	<u>001</u>	Jun 07, 2011
AB	AKORN	0.05%	<u>A209871</u>	<u>001</u>	Oct 27, 2017
AB	ALEOR	0.05%	<u>A213290</u>	<u>001</u>	May 18, 2020
DERMACEUTICALS					
AB	AMNEAL	0.05%	<u>A214895</u>	<u>001</u>	Jun 14, 2021
AB	PADAGIS ISRAEL	0.05%	<u>A090974</u>	<u>001</u>	Aug 09, 2012
AB	TARO PHARMS	0.05%	<u>A214867</u>	<u>001</u>	Mar 25, 2021

CLOBEX

AB	+! GALDERMA LABS	0.05%	<u>N021644</u>	<u>001</u>	Feb 05, 2004

SOLUTION; TOPICAL

CLOBETASOL PROPIONATE

AT	ALEOR	0.05%	<u>A212881</u>	<u>001</u>	Oct 21, 2019
DERMACEUTICALS					
AT	COSETTE	0.05%	<u>A074331</u>	<u>001</u>	Dec 15, 1995
AT	FOUGERA PHARMS	0.05%	<u>A075391</u>	<u>001</u>	Feb 08, 1999
AT	GLENMARK PHARMS LTD	0.05%	<u>A210190</u>	<u>001</u>	Apr 18, 2018
AT	MACLEODS PHARMS LTD	0.05%	<u>A209361</u>	<u>001</u>	Oct 25, 2017
AT	NOVEL LABS INC	0.05%	<u>A206075</u>	<u>001</u>	Nov 23, 2015

PRESCRIPTION DRUG PRODUCT LIST

3-108 (of 474)

CLOBETASOL PROPIONATE

SOLUTION; TOPICAL

CLOBETASOL PROPIONATE

AT	QUAGEN	<u>0.05%</u>	<u>A211240</u>	<u>001</u>	Feb 17, 2022
AT	SAPTALIS PHARMS	<u>0.05%</u>	<u>A211494</u>	<u>001</u>	Oct 02, 2019
AT	TARO	<u>0.05%</u>	<u>A075224</u>	<u>001</u>	Nov 16, 1998
AT		<u>0.05%</u>	<u>A075363</u>	<u>001</u>	Dec 29, 2000

EMBELINE

AT	! AKORN	<u>0.05%</u>	<u>A074222</u>	<u>001</u>	Dec 06, 1995

SPRAY; TOPICAL

CLOBETASOL PROPIONATE

AT	ALEOR	<u>0.05%</u>	<u>A211191</u>	<u>001</u>	Oct 02, 2019
	DERMACEUTICALS				
AT	GLENMARK PHARMS	<u>0.05%</u>	<u>A209004</u>	<u>001</u>	Mar 26, 2018
AT	LUPIN LTD	<u>0.05%</u>	<u>A208125</u>	<u>001</u>	Mar 26, 2018
AT	PADAGIS US	<u>0.05%</u>	<u>A090898</u>	<u>001</u>	Jun 16, 2011
AT	TARO	<u>0.05%</u>	<u>A208842</u>	<u>001</u>	Mar 26, 2018
AT	ZYDUS PHARMS	<u>0.05%</u>	<u>A206378</u>	<u>001</u>	Feb 16, 2017

CLOBEX

AT	+! GALDERMA LABS LP	<u>0.05%</u>	<u>N021835</u>	<u>001</u>	Oct 27, 2005

CLOCORTOLONE PIVALATE

CREAM; TOPICAL

CLOCORTOLONE PIVALATE

AB	TARO	<u>0.1%</u>	<u>A206370</u>	<u>001</u>	Apr 21, 2020

CLODERM

AB	+! EPI HLTH	<u>0.1%</u>	<u>N017765</u>	<u>001</u>	

CLOFARABINE

SOLUTION; INTRAVENOUS

CLOFARABINE

AP	ABON PHARMS LLC	<u>20MG/20ML (1MG/ML)</u>	<u>A204029</u>	<u>001</u>	May 09, 2017
AP	ACCORD HLTHCARE	<u>20MG/20ML (1MG/ML)</u>	<u>A212034</u>	<u>001</u>	Feb 22, 2019
AP	AMNEAL	<u>20MG/20ML (1MG/ML)</u>	<u>A208857</u>	<u>001</u>	Nov 06, 2017
AP	DR REDDYS	<u>20MG/20ML (1MG/ML)</u>	<u>A205375</u>	<u>001</u>	Nov 06, 2017
AP	EUGIA PHARMA	<u>20MG/20ML (1MG/ML)</u>	<u>A212457</u>	<u>001</u>	Oct 03, 2022
AP	GLAND PHARMA LTD	<u>20MG/20ML (1MG/ML)</u>	<u>A207831</u>	<u>001</u>	Oct 31, 2018
AP	MEITHEAL	<u>20MG/20ML (1MG/ML)</u>	<u>A213461</u>	<u>001</u>	Oct 23, 2020
AP	MSN	<u>20MG/20ML (1MG/ML)</u>	<u>A209775</u>	<u>001</u>	Dec 06, 2017
AP	MYLAN LABS LTD	<u>20MG/20ML (1MG/ML)</u>	<u>A208860</u>	<u>001</u>	Nov 06, 2017

CLOLAR

AP	+! GENZYME	<u>20MG/20ML (1MG/ML)</u>	<u>N021673</u>	<u>001</u>	Dec 28, 2004

CLOMIPHENE CITRATE

TABLET; ORAL

CLOMIPHENE CITRATE

!	COSETTE	50MG	A075528	001	Aug 30, 1999

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE; ORAL

ANAFRANIL

AB	+! SPECGX LLC	<u>25MG</u>	<u>N019906</u>	<u>001</u>	Dec 29, 1989
AB	+	<u>50MG</u>	<u>N019906</u>	<u>002</u>	Dec 29, 1989
AB	+	<u>75MG</u>	<u>N019906</u>	<u>003</u>	Dec 29, 1989

CLOMIPRAMINE HYDROCHLORIDE

AB	AJANTA PHARMA LTD	<u>25MG</u>	<u>A213897</u>	<u>001</u>	Oct 02, 2020
AB		<u>50MG</u>	<u>A213897</u>	<u>002</u>	Oct 02, 2020
AB		<u>75MG</u>	<u>A213897</u>	<u>003</u>	Oct 02, 2020
AB	ALEMBIC PHARMS	<u>25MG</u>	<u>A211822</u>	<u>001</u>	Aug 04, 2021
AB		<u>50MG</u>	<u>A211822</u>	<u>002</u>	Aug 04, 2021
AB		<u>75MG</u>	<u>A211822</u>	<u>003</u>	Aug 04, 2021
AB	AMNEAL PHARMS CO	<u>25MG</u>	<u>A208632</u>	<u>001</u>	Oct 31, 2018
AB		<u>50MG</u>	<u>A208632</u>	<u>002</u>	Oct 31, 2018
AB		<u>75MG</u>	<u>A208632</u>	<u>003</u>	Oct 31, 2018
AB	JUBILANT CADISTA	<u>25MG</u>	<u>A212218</u>	<u>001</u>	Oct 21, 2019
AB		<u>50MG</u>	<u>A212218</u>	<u>002</u>	Oct 21, 2019
AB		<u>75MG</u>	<u>A212218</u>	<u>003</u>	Oct 21, 2019
AB	LEADING	<u>25MG</u>	<u>A211364</u>	<u>001</u>	Feb 07, 2020
AB		<u>50MG</u>	<u>A211364</u>	<u>002</u>	Feb 07, 2020
AB		<u>75MG</u>	<u>A211364</u>	<u>003</u>	Feb 07, 2020
AB	LUPIN LTD	<u>25MG</u>	<u>A209294</u>	<u>001</u>	Nov 21, 2018
AB		<u>50MG</u>	<u>A209294</u>	<u>002</u>	Nov 21, 2018
AB		<u>75MG</u>	<u>A209294</u>	<u>003</u>	Nov 21, 2018
AB	MANKIND PHARMA	<u>25MG</u>	<u>A211767</u>	<u>001</u>	Apr 08, 2019
AB		<u>50MG</u>	<u>A211767</u>	<u>002</u>	Apr 08, 2019

PRESCRIPTION DRUG PRODUCT LIST

3-109 (of 474)

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE; ORAL

CLOMIPRAMINE HYDROCHLORIDE

<u>AB</u>		<u>75MG</u>	<u>A211767</u>	<u>003</u>	Apr 08, 2019
<u>AB</u>	MICRO LABS	<u>25MG</u>	<u>A213219</u>	<u>001</u>	Jun 22, 2020
<u>AB</u>		<u>50MG</u>	<u>A213219</u>	<u>002</u>	Jun 22, 2020
<u>AB</u>		<u>75MG</u>	<u>A213219</u>	<u>003</u>	Jun 22, 2020
<u>AB</u>	MYLAN	<u>25MG</u>	<u>A074947</u>	<u>001</u>	Apr 30, 1998
<u>AB</u>		<u>50MG</u>	<u>A074947</u>	<u>002</u>	Apr 30, 1998
<u>AB</u>		<u>75MG</u>	<u>A074947</u>	<u>003</u>	Apr 30, 1998
<u>AB</u>	SANDOZ	<u>25MG</u>	<u>A074364</u>	<u>001</u>	Mar 29, 1996
<u>AB</u>		<u>25MG</u>	<u>A074953</u>	<u>001</u>	Jun 25, 1997
<u>AB</u>		<u>50MG</u>	<u>A074364</u>	<u>002</u>	Mar 29, 1996
<u>AB</u>		<u>50MG</u>	<u>A074953</u>	<u>002</u>	Jun 25, 1997
<u>AB</u>		<u>75MG</u>	<u>A074364</u>	<u>003</u>	Mar 29, 1996
<u>AB</u>		<u>75MG</u>	<u>A074953</u>	<u>003</u>	Jun 25, 1997
<u>AB</u>	TARO	<u>25MG</u>	<u>A074694</u>	<u>001</u>	Dec 31, 1996
<u>AB</u>		<u>50MG</u>	<u>A074694</u>	<u>002</u>	Dec 31, 1996
<u>AB</u>		<u>75MG</u>	<u>A074694</u>	<u>003</u>	Dec 31, 1996
<u>AB</u>	TULEX PHARMS INC	<u>25MG</u>	<u>A210653</u>	<u>001</u>	Apr 03, 2020
<u>AB</u>		<u>50MG</u>	<u>A210653</u>	<u>002</u>	Apr 03, 2020
<u>AB</u>		<u>75MG</u>	<u>A210653</u>	<u>003</u>	Apr 03, 2020
<u>AB</u>	UNIQUE	<u>25MG</u>	<u>A212285</u>	<u>001</u>	Aug 07, 2020
<u>AB</u>		<u>50MG</u>	<u>A212285</u>	<u>002</u>	Aug 07, 2020
<u>AB</u>		<u>75MG</u>	<u>A212285</u>	<u>003</u>	Aug 07, 2020
<u>AB</u>	VGYAAN	<u>25MG</u>	<u>A213221</u>	<u>001</u>	Jun 22, 2020
<u>AB</u>		<u>50MG</u>	<u>A213221</u>	<u>002</u>	Jun 22, 2020
<u>AB</u>		<u>75MG</u>	<u>A213221</u>	<u>003</u>	Jun 22, 2020
<u>AB</u>	ZYDUS PHARMS	<u>25MG</u>	<u>A208961</u>	<u>001</u>	Dec 27, 2017
<u>AB</u>		<u>50MG</u>	<u>A208961</u>	<u>002</u>	Dec 27, 2017
<u>AB</u>		<u>75MG</u>	<u>A208961</u>	<u>003</u>	Dec 27, 2017

CLONAZEPAM

TABLET; ORAL

CLONAZEPAM

<u>AB</u>	ACCORD HLTHCARE	<u>0.5MG</u>	<u>A077147</u>	<u>001</u>	May 02, 2005
<u>AB</u>		<u>1MG</u>	<u>A077147</u>	<u>002</u>	May 02, 2005
<u>AB</u>		<u>2MG</u>	<u>A077147</u>	<u>003</u>	May 02, 2005
<u>AB</u>	ACTAVIS ELIZABETH	<u>0.5MG</u>	<u>A074869</u>	<u>001</u>	Oct 31, 1996
<u>AB</u>		<u>1MG</u>	<u>A074869</u>	<u>002</u>	Oct 31, 1996
<u>AB</u>		<u>2MG</u>	<u>A074869</u>	<u>003</u>	Oct 31, 1996
<u>AB</u>	PRINSTON INC	<u>0.5MG</u>	<u>A077856</u>	<u>001</u>	Jun 28, 2006
<u>AB</u>		<u>1MG</u>	<u>A077856</u>	<u>002</u>	Jun 28, 2006
<u>AB</u>		<u>2MG</u>	<u>A077856</u>	<u>003</u>	Jun 28, 2006
<u>AB</u>	RUBICON	<u>0.5MG</u>	<u>A075468</u>	<u>001</u>	Oct 06, 2000
<u>AB</u>		<u>1MG</u>	<u>A075468</u>	<u>002</u>	Oct 06, 2000
<u>AB</u>		<u>2MG</u>	<u>A075468</u>	<u>003</u>	Oct 06, 2000
<u>AB</u>	SANDOZ	<u>0.5MG</u>	<u>A074979</u>	<u>001</u>	Aug 29, 1997
<u>AB</u>		<u>1MG</u>	<u>A074979</u>	<u>002</u>	Aug 29, 1997
<u>AB</u>		<u>2MG</u>	<u>A074979</u>	<u>003</u>	Aug 29, 1997
<u>AB</u>	TEVA	<u>0.5MG</u>	<u>A074569</u>	<u>001</u>	Sep 10, 1996
<u>AB</u>		<u>1MG</u>	<u>A074569</u>	<u>002</u>	Sep 10, 1996
<u>AB</u>		<u>2MG</u>	<u>A074569</u>	<u>003</u>	Sep 10, 1996

KLONOPIN

<u>AB</u>	+	CHEPLAPHARM	<u>0.5MG</u>	<u>N017533</u>	<u>001</u>
<u>AB</u>	+	!	<u>1MG</u>	<u>N017533</u>	<u>002</u>
<u>AB</u>	+		<u>2MG</u>	<u>N017533</u>	<u>003</u>

TABLET, ORALLY DISINTEGRATING; ORAL

CLONAZEPAM

<u>AB</u>	ALEMBIC PHARMS	<u>0.125MG</u>	<u>A211033</u>	<u>001</u>	Jun 28, 2019
<u>AB</u>		<u>0.25MG</u>	<u>A211033</u>	<u>002</u>	Jun 28, 2019
<u>AB</u>		<u>0.5MG</u>	<u>A211033</u>	<u>003</u>	Jun 28, 2019
<u>AB</u>		<u>1MG</u>	<u>A211033</u>	<u>004</u>	Jun 28, 2019
<u>AB</u>		<u>2MG</u>	<u>A211033</u>	<u>005</u>	Jun 28, 2019
<u>AB</u>	BARR	<u>0.125MG</u>	<u>A077194</u>	<u>001</u>	Aug 10, 2005
<u>AB</u>		<u>0.25MG</u>	<u>A077194</u>	<u>002</u>	Aug 10, 2005
<u>AB</u>		<u>0.5MG</u>	<u>A077194</u>	<u>003</u>	Aug 10, 2005
<u>AB</u>		<u>1MG</u>	<u>A077194</u>	<u>004</u>	Aug 10, 2005
<u>AB</u>		<u>2MG</u>	<u>A077194</u>	<u>005</u>	Aug 10, 2005
<u>AB</u>	PAR PHARM	<u>0.125MG</u>	<u>A077171</u>	<u>001</u>	Aug 03, 2005
<u>AB</u>		<u>0.25MG</u>	<u>A077171</u>	<u>002</u>	Aug 03, 2005
<u>AB</u>		<u>0.5MG</u>	<u>A077171</u>	<u>003</u>	Aug 03, 2005
<u>AB</u>	!	<u>1MG</u>	<u>A077171</u>	<u>004</u>	Aug 03, 2005

PRESCRIPTION DRUG PRODUCT LIST

3-110 (of 474)

CLONAZEPAM

TABLET, ORALLY DISINTEGRATING; ORAL

CLONAZEPAM

<u>AB</u>		<u>2MG</u>	<u>A077171</u>	<u>005</u>	Aug 03, 2005
<u>AB</u>	SUN PHARM INDS INC	<u>0.125MG</u>	<u>A078654</u>	<u>001</u>	Aug 27, 2014
<u>AB</u>		<u>0.25MG</u>	<u>A078654</u>	<u>002</u>	Aug 27, 2014
<u>AB</u>		<u>0.5MG</u>	<u>A078654</u>	<u>003</u>	Aug 27, 2014
<u>AB</u>		<u>1MG</u>	<u>A078654</u>	<u>004</u>	Aug 27, 2014
<u>AB</u>		<u>2MG</u>	<u>A078654</u>	<u>005</u>	Aug 27, 2014

CLONIDINE

SYSTEM; TRANSDERMAL

CATAPRES-TTS-1

<u>AB</u>	+	LAVIPHARM	<u>0.1MG/24HR</u>	<u>N018891</u>	<u>001</u>	Oct 10, 1984

CATAPRES-TTS-2

<u>AB</u>	+	LAVIPHARM	<u>0.2MG/24HR</u>	<u>N018891</u>	<u>002</u>	Oct 10, 1984

CATAPRES-TTS-3

<u>AB</u>	+	LAVIPHARM	<u>0.3MG/24HR</u>	<u>N018891</u>	<u>003</u>	Oct 10, 1984

CLONIDINE

<u>AB</u>	ACTAVIS LABS UT INC	<u>0.1MG/24HR</u>	<u>A090873</u>	<u>001</u>	May 06, 2014
<u>AB</u>		<u>0.2MG/24HR</u>	<u>A090873</u>	<u>002</u>	May 06, 2014
<u>AB</u>		<u>0.3MG/24HR</u>	<u>A090873</u>	<u>003</u>	May 06, 2014
<u>AB</u>	AVEVA	<u>0.1MG/24HR</u>	<u>A076157</u>	<u>001</u>	Aug 18, 2009
<u>AB</u>		<u>0.2MG/24HR</u>	<u>A076157</u>	<u>002</u>	Aug 18, 2009
<u>AB</u>		<u>0.3MG/24HR</u>	<u>A076157</u>	<u>003</u>	Aug 18, 2009
<u>AB</u>	MAYNE PHARMA	<u>0.1MG/24HR</u>	<u>A079090</u>	<u>001</u>	Aug 20, 2010
<u>AB</u>		<u>0.2MG/24HR</u>	<u>A079090</u>	<u>002</u>	Aug 20, 2010
<u>AB</u>		<u>0.3MG/24HR</u>	<u>A079090</u>	<u>003</u>	Aug 20, 2010
<u>AB</u>	MYLAN TECHNOLOGIES	<u>0.1MG/24HR</u>	<u>A076166</u>	<u>001</u>	Jul 16, 2010
<u>AB</u>		<u>0.2MG/24HR</u>	<u>A076166</u>	<u>002</u>	Jul 16, 2010
<u>AB</u>		<u>0.3MG/24HR</u>	<u>A076166</u>	<u>003</u>	Jul 16, 2010

TABLET, EXTENDED RELEASE; ORAL

NEXICLON XR

ATHENA

EQ 0.17MG BASE

N022500 001 Dec 03, 2009

CLONIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

CLONIDINE HYDROCHLORIDE

<u>AP</u>	FRESENIUS KABI USA	<u>1MG/10ML (0.1MG/ML)</u>	<u>A200673</u>	<u>001</u>	Jul 08, 2011
<u>AP</u>		<u>5MG/10ML (0.5MG/ML)</u>	<u>A200673</u>	<u>002</u>	Jul 08, 2011
<u>AP</u>	HIKMA FARMACEUTICA	<u>1MG/10ML (0.1MG/ML)</u>	<u>A200300</u>	<u>001</u>	Jan 26, 2011
<u>AP</u>	!	<u>5MG/10ML (0.5MG/ML)</u>	<u>A200300</u>	<u>002</u>	Jan 26, 2011
<u>AP</u>	XGEN PHARMS	<u>1MG/10ML (0.1MG/ML)</u>	<u>A203167</u>	<u>001</u>	Oct 29, 2013
<u>AP</u>		<u>5MG/10ML (0.5MG/ML)</u>	<u>A203167</u>	<u>002</u>	Oct 29, 2013
<u>AP</u>	ZYDUS PHARMS	<u>1MG/10ML (0.1MG/ML)</u>	<u>A202601</u>	<u>001</u>	Feb 20, 2014
<u>AP</u>		<u>5MG/10ML (0.5MG/ML)</u>	<u>A202601</u>	<u>002</u>	Feb 20, 2014

DURACLON

<u>AP</u>	+	MYLAN INSTITUTIONAL	<u>1MG/10ML (0.1MG/ML)</u>	<u>N020615</u>	<u>001</u>	Oct 02, 1996

TABLET; ORAL

CLONIDINE HYDROCHLORIDE

<u>AB</u>	ACTAVIS ELIZABETH	<u>0.1MG</u>	<u>A070974</u>	<u>001</u>	Dec 16, 1986
<u>AB</u>		<u>0.2MG</u>	<u>A070975</u>	<u>001</u>	Dec 16, 1986
<u>AB</u>		<u>0.3MG</u>	<u>A070976</u>	<u>001</u>	Dec 16, 1986
<u>AB</u>	ALEMBIC PHARMS LTD	<u>0.1MG</u>	<u>A091368</u>	<u>001</u>	Dec 06, 2011
<u>AB</u>		<u>0.2MG</u>	<u>A091368</u>	<u>002</u>	Dec 06, 2011
<u>AB</u>		<u>0.3MG</u>	<u>A091368</u>	<u>003</u>	Dec 06, 2011
<u>AB</u>	AUROBINDO PHARMA LTD	<u>0.1MG</u>	<u>A070886</u>	<u>002</u>	Aug 31, 1988
<u>AB</u>		<u>0.2MG</u>	<u>A070886</u>	<u>001</u>	Aug 31, 1988
<u>AB</u>		<u>0.3MG</u>	<u>A070886</u>	<u>003</u>	Aug 31, 1988
<u>AB</u>	CHARTWELL MOLECULES	<u>0.1MG</u>	<u>A071785</u>	<u>002</u>	Apr 05, 1988
<u>AB</u>		<u>0.2MG</u>	<u>A071785</u>	<u>003</u>	Apr 05, 1988
<u>AB</u>		<u>0.3MG</u>	<u>A071785</u>	<u>001</u>	Apr 05, 1988
<u>AB</u>	IMPAX LABS	<u>0.1MG</u>	<u>A078099</u>	<u>001</u>	Aug 27, 2009
<u>AB</u>		<u>0.2MG</u>	<u>A078099</u>	<u>002</u>	Aug 27, 2009
<u>AB</u>		<u>0.3MG</u>	<u>A078099</u>	<u>003</u>	Aug 27, 2009
<u>AB</u>	PRINSTON INC	<u>0.1MG</u>	<u>A077901</u>	<u>001</u>	Mar 09, 2007
<u>AB</u>		<u>0.2MG</u>	<u>A077901</u>	<u>002</u>	Mar 09, 2007
<u>AB</u>		<u>0.3MG</u>	<u>A077901</u>	<u>003</u>	Mar 09, 2007
<u>AB</u>	UNICHEM	<u>0.1MG</u>	<u>A078895</u>	<u>001</u>	Aug 26, 2009
<u>AB</u>		<u>0.2MG</u>	<u>A078895</u>	<u>002</u>	Aug 26, 2009
<u>AB</u>	!	<u>0.3MG</u>	<u>A078895</u>	<u>003</u>	Aug 26, 2009
<u>AB</u>	URL LABS	<u>0.1MG</u>	<u>A070923</u>	<u>003</u>	Sep 04, 1987
<u>AB</u>		<u>0.2MG</u>	<u>A070923</u>	<u>002</u>	Sep 04, 1987

PRESCRIPTION DRUG PRODUCT LIST

3-111 (of 474)

CLONIDINE HYDROCHLORIDE

TABLET;ORAL

CLONIDINE HYDROCHLORIDE

<u>AB</u>		<u>0.3MG</u>	<u>A070923</u>	<u>001</u>	Sep 04, 1987
<u>AB</u>	YUNG SHIN PHARM	<u>0.1MG</u>	<u>A202297</u>	<u>001</u>	Jun 13, 2013
<u>AB</u>		<u>0.2MG</u>	<u>A202297</u>	<u>002</u>	Jun 13, 2013
<u>AB</u>		<u>0.3MG</u>	<u>A202297</u>	<u>003</u>	Jun 13, 2013

TABLET, EXTENDED RELEASE;ORAL

CLONIDINE HYDROCHLORIDE

<u>AB1</u>	ACTAVIS ELIZABETH	<u>0.1MG</u>	<u>A203320</u>	<u>001</u>	May 15, 2015
<u>AB1</u>	AJANTA PHARMA LTD	<u>0.1MG</u>	<u>A209686</u>	<u>001</u>	Nov 20, 2017
<u>AB1</u>	AMNEAL PHARMS NY	<u>0.1MG</u>	<u>A210052</u>	<u>001</u>	Nov 20, 2017
<u>AB1</u>	ANCHEN PHARMS	<u>0.1MG</u>	<u>A202984</u>	<u>001</u>	Sep 30, 2013
<u>AB1</u>	JUBILANT GENERICS	<u>0.1MG</u>	<u>A210338</u>	<u>001</u>	Jan 29, 2018
<u>AB1</u>	LUPIN LTD	<u>0.1MG</u>	<u>A209285</u>	<u>001</u>	Oct 23, 2017
<u>AB1</u>	NOVAST LABS	<u>0.1MG</u>	<u>A209675</u>	<u>001</u>	Mar 05, 2019
<u>AB1</u>	XIAMEN LP PHARM CO	<u>0.1MG</u>	<u>A209757</u>	<u>001</u>	Nov 20, 2017

KAPVAY

<u>AB1</u>	+! CONCORDIA PHARMS INC	<u>0.1MG</u>	<u>N022331</u>	<u>003</u>	Sep 28, 2010

CLONIDINE HYDROCHLORIDE

<u>AB2</u>	ACTAVIS ELIZABETH	<u>0.1MG</u>	<u>A202792</u>	<u>001</u>	May 15, 2015

CLOPIDOGREL BISULFATE

TABLET;ORAL

CLOPIDOGREL BISULFATE

<u>AB</u>	ACCORD HLTHCARE	<u>EQ 75MG BASE</u>	<u>A202925</u>	<u>001</u>	Mar 27, 2013
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A202925</u>	<u>002</u>	Mar 27, 2013
<u>AB</u>	ACME LABS	<u>EQ 75MG BASE</u>	<u>A078004</u>	<u>001</u>	May 17, 2012
<u>AB</u>	AMNEAL PHARMS	<u>EQ 75MG BASE</u>	<u>A203751</u>	<u>001</u>	Apr 11, 2014
<u>AB</u>	APOTEX INC	<u>EQ 75MG BASE</u>	<u>A076274</u>	<u>001</u>	May 17, 2012
<u>AB</u>	!	<u>EQ 300MG BASE</u>	<u>A076274</u>	<u>002</u>	Mar 04, 2014
<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 75MG BASE</u>	<u>A090540</u>	<u>001</u>	May 17, 2012
<u>AB</u>	DR REDDYS	<u>EQ 75MG BASE</u>	<u>A076273</u>	<u>001</u>	Jan 14, 2008
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 300MG BASE</u>	<u>A091023</u>	<u>001</u>	May 17, 2012
<u>AB</u>	GRAVITI PHARMS	<u>EQ 75MG BASE</u>	<u>A204359</u>	<u>001</u>	Feb 02, 2017
<u>AB</u>	MACLEODS PHARMS LTD	<u>EQ 75MG BASE</u>	<u>A202928</u>	<u>001</u>	Feb 10, 2014
<u>AB</u>	POLYGEN PHARMS	<u>EQ 75MG BASE</u>	<u>A213351</u>	<u>001</u>	Jul 17, 2020
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A213351</u>	<u>002</u>	Jul 17, 2020
<u>AB</u>	PRINSTON INC	<u>EQ 75MG BASE</u>	<u>A206376</u>	<u>001</u>	May 07, 2018
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A206376</u>	<u>002</u>	May 07, 2018
<u>AB</u>	SCIEGEN PHARMS INC	<u>EQ 75MG BASE</u>	<u>A204165</u>	<u>001</u>	Sep 15, 2014
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A204165</u>	<u>002</u>	Sep 15, 2014
<u>AB</u>	SUN PHARM	<u>EQ 75MG BASE</u>	<u>A090494</u>	<u>001</u>	May 17, 2012
<u>AB</u>	TEVA	<u>EQ 75MG BASE</u>	<u>A076999</u>	<u>001</u>	May 17, 2012
<u>AB</u>	TORRENT PHARMS LTD	<u>EQ 75MG BASE</u>	<u>A090844</u>	<u>001</u>	May 17, 2012

PLAVIX

<u>AB</u>	+ SANOFI AVENTIS US	<u>EQ 75MG BASE</u>	<u>N020839</u>	<u>001</u>	Nov 17, 1997
<u>AB</u>	+	<u>EQ 300MG BASE</u>	<u>N020839</u>	<u>002</u>	Sep 20, 2007

CLORAZEPATE DIPOTASSIUM

TABLET;ORAL

CLORAZEPATE DIPOTASSIUM

<u>AB</u>	AUROBINDO PHARMA	<u>3.75MG</u>	<u>A071858</u>	<u>002</u>	Jul 17, 1987
<u>AB</u>		<u>7.5MG</u>	<u>A071858</u>	<u>003</u>	Jul 17, 1987
<u>AB</u>	!	<u>15MG</u>	<u>A071858</u>	<u>001</u>	Jul 17, 1987
<u>AB</u>	COREPHARMA	<u>3.75MG</u>	<u>A215566</u>	<u>001</u>	Jun 14, 2022
<u>AB</u>		<u>7.5MG</u>	<u>A215566</u>	<u>002</u>	Jun 14, 2022
<u>AB</u>		<u>15MG</u>	<u>A215566</u>	<u>003</u>	Jun 14, 2022
<u>AB</u>	NOVITIUM PHARMA	<u>3.75MG</u>	<u>A213730</u>	<u>001</u>	Jun 16, 2022
<u>AB</u>		<u>7.5MG</u>	<u>A213730</u>	<u>002</u>	Jun 16, 2022
<u>AB</u>		<u>15MG</u>	<u>A213730</u>	<u>003</u>	Dec 16, 2022
<u>AB</u>	TARO	<u>3.75MG</u>	<u>A075731</u>	<u>003</u>	Apr 27, 2000
<u>AB</u>		<u>7.5MG</u>	<u>A075731</u>	<u>002</u>	Apr 27, 2000
<u>AB</u>		<u>15MG</u>	<u>A075731</u>	<u>001</u>	Apr 27, 2000

TRANXENE

<u>AB</u>	+ KEY THERAP	<u>7.5MG</u>	<u>N017105</u>	<u>007</u>	

PRESCRIPTION DRUG PRODUCT LIST

3-112 (of 474)

CLOTRIMAZOLE

CREAM; TOPICAL

CLOTRIMAZOLE

AB	FOUGERA PHARMS	1%	A078338 001	Sep 02, 2008
AB	GLENMARK PHARMS	1%	A090219 001	Aug 03, 2010
AB	! TARO	1%	A072640 001	Aug 31, 1993

SOLUTION; TOPICAL

CLOTRIMAZOLE

AT	NOVITIUM PHARMA	1%	A209815 001	Feb 14, 2019
AT	! TARO	1%	A074580 001	Jul 29, 1996
AT	TASMAN PHARMA	1%	A212281 001	Jul 25, 2019
AT	TEVA	1%	A073306 001	Feb 28, 1995

TROCHE/LOZENGE; ORAL

CLOTRIMAZOLE

AB	! HIKMA	10MG	A076387 001	Jul 29, 2004
AB	PADAGIS US	10MG	A076763 001	Oct 28, 2005

CLOZAPINE

SUSPENSION; ORAL

VERSACLOZ

+! TASMAN PHARMA 50MG/ML

N203479 001 Feb 06, 2013

TABLET; ORAL

CLOZAPINE

AB	ACCORD HLTHCARE	25MG	A202873 001	Nov 25, 2015
AB		100MG	A202873 002	Nov 25, 2015
AB	AUROBINDO PHARMA	25MG	A206433 001	Nov 29, 2016
AB		50MG	A206433 002	Nov 29, 2016
AB		100MG	A206433 003	Nov 29, 2016
AB		200MG	A206433 004	Nov 29, 2016
AB	IVAX SUB TEVA PHARMS	25MG	A074949 001	Nov 26, 1997
AB		50MG	A074949 004	Apr 25, 2005
AB		50MG	A076809 003	Dec 16, 2005
AB		100MG	A074949 002	Nov 26, 1997
AB		100MG	A076809 002	Dec 16, 2005
AB		200MG	A076809 001	Dec 16, 2005
AB	MAYNE PHARMA	25MG	A203807 001	Sep 17, 2015
AB		50MG	A203807 003	Aug 22, 2017
AB		100MG	A203807 002	Sep 17, 2015
AB		200MG	A203807 004	Aug 22, 2017
AB	MYLAN	25MG	A075417 001	May 27, 1999
AB		50MG	A075417 004	Apr 15, 2010
AB		100MG	A075417 002	May 27, 1999
AB		200MG	A075417 005	Apr 15, 2010
AB	SUN PHARM INDS INC	25MG	A075713 001	Nov 15, 2002
AB		50MG	A075713 003	Aug 19, 2005
AB		100MG	A075713 002	Nov 15, 2002
AB		200MG	A075713 004	Nov 07, 2017

CLOZARIL

AB	+ HERITAGE LIFE	25MG	N019758 001	Sep 26, 1989
AB	+	50MG	N019758 003	May 20, 2019
AB	+!	100MG	N019758 002	Sep 26, 1989
AB	+	200MG	N019758 004	May 20, 2019

CLOZAPINE

IVAX SUB TEVA PHARMS 12.5MG

A074949 003 Jul 31, 2003

TABLET, ORALLY DISINTEGRATING; ORAL

CLOZAPINE

AB	BARR LABS INC	25MG	A090308 001	Nov 25, 2015
AB	!	100MG	A090308 002	Nov 25, 2015
AB	MYLAN	25MG	A201824 002	Sep 15, 2015
AB		100MG	A201824 003	Sep 15, 2015
	BARR LABS INC	12.5MG	A090308 003	Apr 09, 2018
	TEVA PHARMS USA	150MG	A203039 001	Nov 25, 2015
		200MG	A203039 002	Nov 25, 2015

COBICISTAT

TABLET; ORAL

TYBOST

+! GILEAD SCIENCES INC 150MG

N203094 001 Sep 24, 2014

PRESCRIPTION DRUG PRODUCT LIST

3-113 (of 474)

COBICISTAT; DARUNAVIR

TABLET; ORAL

PREZCOBIX

+! JANSSEN PRODS

150MG; 800MG

N205395 001 Jan 29, 2015

COBICISTAT; DARUNAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE

TABLET; ORAL

SYM TUZA

+! JANSSEN PRODS

150MG; 800MG; 200MG; EQ 10MG BASE

N210455 001 Jul 17, 2018

COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE

TABLET; ORAL

GENVOYA

+! GILEAD SCIENCES INC

150MG; 150MG; 200MG; EQ 10MG BASE

N207561 001 Nov 05, 2015

COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL

STRIBILD

+! GILEAD SCIENCES INC

150MG; 150MG; 200MG; 300MG

N203100 001 Aug 27, 2012

COBIMETINIB FUMARATE

TABLET; ORAL

COTELLIC

+! GENENTECH INC

EQ 20MG BASE

N206192 001 Nov 10, 2015

COCAINE HYDROCHLORIDE

SOLUTION; NASAL

GOPRELTO

+! GENUS LIFESCIENCES

4%

N209963 001 Dec 14, 2017

NUMBRINO

+! CODY LABS INC

4%

N209575 001 Jan 10, 2020

CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETH HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE**AA** ! PHARM ASSOC 10MG/5ML; 5MG/5ML; 6.25MG/5ML **A040660 001** Dec 07, 2006PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE**AA** AKORN 10MG/5ML; 5MG/5ML; 6.25MG/5ML **A040674 001** Dec 23, 2014PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE**AA** AMNEAL PHARMS 10MG/5ML; 5MG/5ML; 6.25MG/5ML **A200963 001** Aug 26, 2015CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE**AA** +! ACTAVIS MID 10MG/5ML; 6.25MG/5ML **A088763 001** Oct 31, 1984

ATLANTIC

AA AKORN 10MG/5ML; 6.25MG/5ML **A040151 001** Aug 26, 1997**AA** AMNEAL PHARMS 10MG/5ML; 6.25MG/5ML **A200894 001** Apr 24, 2013**AA** NOSTRUM LABS INC 10MG/5ML; 6.25MG/5ML **A090180 001** Mar 17, 2010**AA** QUAGEN 10MG/5ML; 6.25MG/5ML **A214238 001** Oct 08, 2020**AA** TRIS PHARMA INC 10MG/5ML; 6.25MG/5ML **A200386 001** Jun 29, 2012**AA** WOCKHARDT BIO AG 10MG/5ML; 6.25MG/5ML **A088875 001** Dec 17, 1984PROMETHAZINE WITH CODEINE**AA** PHARM ASSOC 10MG/5ML; 6.25MG/5ML **A040650 001** Jan 31, 2006CODEINE PHOSPHATE; PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

SYRUP; ORAL

TRIACIN-C

! STI PHARMA LLC

10MG/5ML; 30MG/5ML; 1.25MG/5ML

A088704 001 Mar 22, 1985

CODEINE SULFATE

TABLET; ORAL

CODEINE SULFATE**AB** + HIKMA 15MG **N022402 001** Jul 16, 2009**AB** + 30MG **N022402 002** Jul 16, 2009**AB** +! 60MG **N022402 003** Jul 16, 2009**AB** LANNETT CO INC 15MG **A203046 001** Jun 13, 2014**AB** 30MG **A203046 002** Jun 13, 2014**AB** 60MG **A203046 003** Jun 13, 2014COLCHICINE

CAPSULE; ORAL

MITIGARE

+! HIKMA INTL PHARMS

0.6MG

N204820 001 Sep 26, 2014

SOLUTION; ORAL

GLOPERBA

+! SCILEX PHARMS

0.6MG/5ML

N210942 001 Jan 30, 2019

PRESCRIPTION DRUG PRODUCT LIST

3-114 (of 474)

COLCHICINE

TABLET; ORAL

COLCHICINE

AB	ALKEM LABS LTD	<u>0.6MG</u>	<u>A211250</u>	<u>001</u>	Feb 08, 2019
AB	AMNEAL PHARMS	<u>0.6MG</u>	<u>A204711</u>	<u>001</u>	Sep 28, 2016
AB	AUROBINDO PHARMA LTD	<u>0.6MG</u>	<u>A215444</u>	<u>001</u>	Jan 06, 2022
AB	DR REDDYS	<u>0.6MG</u>	<u>A209876</u>	<u>001</u>	Sep 06, 2019
AB	GRANULES	<u>0.6MG</u>	<u>A210425</u>	<u>001</u>	Feb 05, 2020
AB	HETERO LABS LTD V	<u>0.6MG</u>	<u>A208993</u>	<u>001</u>	Aug 13, 2021
AB	MYLAN	<u>0.6MG</u>	<u>A209470</u>	<u>001</u>	Sep 16, 2019
AB	PAR PHARM INC	<u>0.6MG</u>	<u>A203976</u>	<u>001</u>	Aug 12, 2021
AB	STRIDES PHARMA	<u>0.6MG</u>	<u>A209173</u>	<u>001</u>	Mar 10, 2022
AB	WATSON LABS INC	<u>0.6MG</u>	<u>A204461</u>	<u>001</u>	Jul 31, 2019
AB	ZYDUS PHARMS	<u>0.6MG</u>	<u>A211519</u>	<u>001</u>	Feb 19, 2019

COLCRYS

AB	+ TAKEDA PHARMS USA	<u>0.6MG</u>	<u>N022352</u>	<u>001</u>	Jul 29, 2009
	COLCHICINE				
	ZYDUS PHARMS	0.3MG	A211519	002	Nov 14, 2019

COLCHICINE; PROBENECID

TABLET; ORAL

COL-PROBENECID

AB	+ WATSON LABS	<u>0.5MG;500MG</u>	<u>A084279</u>	<u>001</u>	
	<u>PROBENECID AND COLCHICINE</u>				
AB	NOVAST LABS	<u>0.5MG;500MG</u>	<u>A040618</u>	<u>001</u>	May 13, 2008

COLESEVELAM HYDROCHLORIDE

FOR SUSPENSION; ORAL

COLESEVELAM HYDROCHLORIDE

AB	ALKEM LABS LTD	<u>3.75GM/PACKET</u>	<u>A210316</u>	<u>001</u>	May 06, 2019
AB	GLENMARK PHARMS LTD	<u>3.75GM/PACKET</u>	<u>A202190</u>	<u>002</u>	Jul 16, 2018

WELCHOL

AB	+ COSETTE	<u>3.75GM/PACKET</u>	<u>N022362</u>	<u>002</u>	Oct 02, 2009
	COLESEVELAM HYDROCHLORIDE				
	GLENMARK PHARMS LTD	1.875GM/PACKET	A202190	001	Jul 16, 2018

TABLET; ORAL

COLESEVELAM HYDROCHLORIDE

AB	ALKEM LABS LTD	<u>625MG</u>	<u>A209038</u>	<u>001</u>	Oct 05, 2018
AB	BEIJING TIDE PHARM	<u>625MG</u>	<u>A206036</u>	<u>001</u>	Oct 14, 2021
AB	BIONPHARMA INC	<u>625MG</u>	<u>A208670</u>	<u>001</u>	Sep 13, 2019
AB	DR REDDYS	<u>625MG</u>	<u>A210889</u>	<u>001</u>	Oct 05, 2018
AB	GLENMARK PHARMS LTD	<u>625MG</u>	<u>A203480</u>	<u>001</u>	May 18, 2018
AB	IMPAX LABS INC	<u>625MG</u>	<u>A091600</u>	<u>001</u>	May 16, 2018
AB	INVENTIA	<u>625MG</u>	<u>A212050</u>	<u>001</u>	Dec 04, 2020
AB	SPH	<u>625MG</u>	<u>A213456</u>	<u>001</u>	Jan 21, 2022
AB	ZHEJIANG JINGXIN	<u>625MG</u>	<u>A209946</u>	<u>001</u>	Jul 15, 2020
AB	ZYDUS PHARMS	<u>625MG</u>	<u>A207765</u>	<u>001</u>	Oct 07, 2019

WELCHOL

AB	+ COSETTE	<u>625MG</u>	<u>N021176</u>	<u>001</u>	May 26, 2000

COLESTIPOL HYDROCHLORIDE

GRANULE; ORAL

COLESTID

AB	+ PFIZER	<u>5GM/SCOOPFUL</u>	<u>N017563</u>	<u>003</u>	Sep 22, 1995
AB	+	<u>5GM/PACKET</u>	<u>N017563</u>	<u>004</u>	Sep 22, 1995

COLESTIPOL HYDROCHLORIDE

AB	IMPAX LABS	<u>5GM/SCOOPFUL</u>	<u>A077277</u>	<u>001</u>	May 02, 2006
AB		<u>5GM/PACKET</u>	<u>A077277</u>	<u>002</u>	May 02, 2006

FLAVORED COLESTID

+ PFIZER**+**

5GM/PACKET

N017563 001

5GM/SCOOPFUL

N017563 002

TABLET; ORAL

COLESTID

AB	+ PFIZER	<u>1GM</u>	<u>N020222</u>	<u>001</u>	Jul 19, 1994

COLESTIPOL HYDROCHLORIDE

AB	! IMPAX LABS	<u>1GM</u>	<u>A077510</u>	<u>001</u>	Oct 24, 2006
AB	ZYDUS PHARMS	<u>1GM</u>	<u>A215223</u>	<u>001</u>	Mar 10, 2022

PRESCRIPTION DRUG PRODUCT LIST

3-115 (of 474)

COLISTIMETHATE SODIUM

INJECTABLE; INJECTION

COLISTIMETHATE SODIUM

AP	EMCURE PHARMS LTD	<u>EQ 150MG BASE/VIAL</u>	<u>A202359</u>	<u>001</u>	Sep 28, 2012
AP	FRESENIUS KABI USA	<u>EQ 150MG BASE/VIAL</u>	<u>A065364</u>	<u>001</u>	Apr 17, 2008
AP	NEXUS PHARMS	<u>EQ 150MG BASE/VIAL</u>	<u>A065177</u>	<u>001</u>	Mar 19, 2004
AP	SAGENT PHARMS INC	<u>EQ 150MG BASE/VIAL</u>	<u>A201365</u>	<u>001</u>	Feb 19, 2014
AP	XELLIA PHARMS APS	<u>EQ 150MG BASE/VIAL</u>	<u>A205356</u>	<u>001</u>	May 29, 2015
AP	XGEN PHARMS	<u>EQ 150MG BASE/VIAL</u>	<u>A064216</u>	<u>001</u>	Feb 26, 1999

COLY-MYCIN M

AP	+ ! PAR STERILE PRODUCTS	<u>EQ 150MG BASE/VIAL</u>	<u>N050108</u>	<u>002</u>	

COLISTIN SULFATE; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; THONZONIUM BROMIDE

SUSPENSION/DROPS; OTIC

COLY-MYCIN S

+ !	ENDO PHARMS INC	EQ 3MG BASE/ML; 10MG/ML; EQ 3.3MG BASE/ML; 0.5MG/ML	N050356	001	

CONIVAPTAN HYDROCHLORIDE

INJECTABLE; INTRAVENOUS

VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER

+ !	CUMBERLAND PHARMS	20MG/100ML (0.2MG/ML)	N021697	002	Oct 08, 2008

COPANLISIB DIHYDROCHLORIDE

POWDER; INTRAVENOUS

ALIQOPA

+ !	BAYER HEALTHCARE	60MG/VIAL	N209936	001	Sep 14, 2017

COPPER

INTRAUTERINE DEVICE; INTRAUTERINE

PARAGARD T 380A

+ !	COOPERSURGICAL	309MG/COPPER	N018680	001	Nov 15, 1984

COPPER CU-64 DOTATATE

SOLUTION; INTRAVENOUS

DETECTNET

+ !	RADIOMEDIX	4mL (1mCi/ML)	N213227	001	Sep 03, 2020

CORTICOTROPIN

INJECTABLE; INJECTION

ACTHAR GEL

+ !	MALLINCKRODT ARD	80 UNITS/ML	N008372	008	

PURIFIED CORTROPHIN GEL

+ !	ANI PHARMS	80 UNITS/ML	N008975	002	

CORTISONE ACETATE

TABLET; ORAL

CORTISONE ACETATE

!	HIKMA INTL PHARMS	25MG	A080776	002	

COSYNTROPIN

INJECTABLE; INJECTION

CORTROSYN

AP	+ ! AMPHASTAR PHARMS INC	<u>0.25MG/VIAL</u>	<u>N016750</u>	<u>001</u>	

COSYNTROPIN

AP	MYLAN INSTITUTIONAL	<u>0.25MG/VIAL</u>	<u>A090574</u>	<u>001</u>	Dec 17, 2009
AP	SANDOZ	<u>0.25MG/VIAL</u>	<u>A202147</u>	<u>001</u>	Jun 29, 2012

CRISABOROLE

OINTMENT; TOPICAL

EUCRISA

+ !	ANACOR PHARMS INC	2%	N207695	001	Dec 14, 2016

CRIZOTINIB

CAPSULE; ORAL

XALKORI

+	PF PRISM CV	200MG	N202570	001	Aug 26, 2011
+ !		250MG	N202570	002	Aug 26, 2011

CROFELEMER

TABLET, DELAYED RELEASE; ORAL

MYTESI

+ !	NAPO PHARMS INC	125MG	N202292	001	Dec 31, 2012

PRESCRIPTION DRUG PRODUCT LIST

3-116 (of 474)

CROMOLYN SODIUM

CONCENTRATE; ORAL

CROMOLYN SODIUM

<u>AA</u>	AILEX PHARMS LLC	<u>100MG/5ML</u>	<u>A209264</u>	<u>001</u>	Oct 16, 2017
<u>AA</u>	MICRO LABS LTD	<u>100MG/5ML</u>	<u>A202745</u>	<u>001</u>	Apr 04, 2013
	INDIA				
<u>AA</u>	RISING	<u>100MG/5ML</u>	<u>A202583</u>	<u>001</u>	Oct 27, 2011

GASTROCROM

<u>AA</u>	+! MYLAN SPECIALITY LP	<u>100MG/5ML</u>	<u>N020479</u>	<u>001</u>	Feb 29, 1996

SOLUTION; INHALATION

CROMOLYN SODIUM

<u>AN</u>	AILEX PHARMS LLC	<u>10MG/ML</u>	<u>A209453</u>	<u>001</u>	Oct 16, 2017
<u>AN</u>	FERA PHARMS LLC	<u>10MG/ML</u>	<u>A075437</u>	<u>001</u>	Apr 21, 2000
<u>AN</u>	MICRO LABS	<u>10MG/ML</u>	<u>A213658</u>	<u>001</u>	Apr 29, 2022
<u>AN</u>	! TEVA PHARMS	<u>10MG/ML</u>	<u>A075271</u>	<u>001</u>	Jan 18, 2000
<u>AN</u>	WOCKHARDT BIO AG	<u>10MG/ML</u>	<u>A075346</u>	<u>001</u>	Oct 25, 1999

SOLUTION/DROPS; OPHTHALMIC

CROMOLYN SODIUM

<u>AT</u>	! AKORN	<u>4%</u>	<u>A074706</u>	<u>001</u>	Apr 29, 1998
<u>AT</u>	SANDOZ INC	<u>4%</u>	<u>A075282</u>	<u>001</u>	Jun 16, 1999

CROTAMITON

LOTION; TOPICAL

CROTAN

<u>AT</u>	MARNEL PHARMS	<u>10%</u>	<u>A087204</u>	<u>001</u>	

EURAX

<u>AT</u>	+! JOURNEY	<u>10%</u>	<u>N009112</u>	<u>003</u>	

CUPRIC CHLORIDE

INJECTABLE; INJECTION

CUPRIC CHLORIDE

<u>AP</u>	EXELA PHARMA	<u>EQ 0.4MG COPPER/ML</u>	<u>A212071</u>	<u>001</u>	Oct 31, 2022

CUPRIC CHLORIDE IN PLASTIC CONTAINER

<u>AP</u>	+! HOSPIRA	<u>EQ 0.4MG COPPER/ML</u>	<u>N018960</u>	<u>001</u>	Jun 26, 1986

CUPRIC SULFATE

INJECTABLE; INJECTION

CUPRIC SULFATE

!	AM REGENT	EQ 0.4MG COPPER/ML	A216324	001	Dec 16, 2022

CUPRIC SULFATE; MANGANESE SULFATE; SELENIOUS ACID; ZINC SULFATE

SOLUTION; INTRAVENOUS

MULTRY'S

+!	AM REGENT	EQ 60MCG COPPER/ML; EQ 3MCG BASE/ML; EQ 6MCG SELENIUM/ML; EQ 1000MCG BASE/ML (1ML)	N209376	003	Jun 30, 2021

TRALEMENT

+!	AM REGENT	EQ 0.3MG COPPER/ML; EQ 55MCG BASE/ML; EQ 60MCG SELENIUM/ML; EQ 3MG BASE/ML (1ML)	N209376	001	Jul 02, 2020
+!		EQ 0.3MG COPPER/ML; EQ 55MCG BASE/ML; EQ 60MCG SELENIUM/ML; EQ 3MG BASE/ML (5ML)	N209376	002	Dec 02, 2020

CYANOCOBALAMIN

INJECTABLE; INJECTION

CYANOCOBALAMIN

<u>AP</u>	+! AM REGENT	<u>1MG/ML</u>	<u>A080737</u>	<u>001</u>	
<u>AP</u>	EUGIA PHARMA	<u>1MG/ML</u>	<u>A213874</u>	<u>001</u>	Dec 08, 2020
<u>AP</u>	GLAND PHARMA LTD	<u>1MG/ML</u>	<u>A214390</u>	<u>001</u>	Sep 24, 2020
<u>AP</u>	MYLAN LABS LTD	<u>1MG/ML</u>	<u>A204829</u>	<u>001</u>	Jun 05, 2017
<u>AP</u>	SAGENT PHARMS INC	<u>1MG/ML</u>	<u>A215107</u>	<u>001</u>	Nov 15, 2022
<u>AP</u>	SANDOZ INC	<u>1MG/ML</u>	<u>A212915</u>	<u>001</u>	Jan 04, 2021
<u>AP</u>	SOLA PHARMS	<u>1MG/ML</u>	<u>A215417</u>	<u>001</u>	Apr 15, 2022
<u>AP</u>	SOMERSET THERAPS LLC	<u>1MG/ML</u>	<u>A206503</u>	<u>001</u>	Dec 11, 2015
<u>AP</u>		<u>1MG/ML</u>	<u>A209429</u>	<u>001</u>	Dec 18, 2018
<u>AP</u>	VITRUVIAS THERAP	<u>1MG/ML</u>	<u>A209255</u>	<u>001</u>	Dec 18, 2018
<u>AP</u>	WEST-WARD PHARMS INT	<u>1MG/ML</u>	<u>A080515</u>	<u>002</u>	
<u>AP</u>	ZYDUS PHARMS	<u>1MG/ML</u>	<u>A214655</u>	<u>001</u>	Apr 15, 2022

DODEX

<u>AP</u>	ACCORD HLTHCARE	<u>1MG/ML</u>	<u>A083022</u>	<u>001</u>	

VIBISONE

<u>AP</u>	+! FRESENIUS KABI USA	<u>1MG/ML</u>	<u>A080557</u>	<u>003</u>	

SPRAY, METERED; NASAL

NASCOBAL

+!	ENDO PHARMS INC	0.5MG/SPRAY	N021642	001	Jan 31, 2005

PRESCRIPTION DRUG PRODUCT LIST

3-117 (of 474)

CYCLOBENZAPRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

AMRIX

<u>AB</u>	+	TEVA PHARMS INTL	<u>15MG</u>	<u>N021777</u>	<u>001</u>	Feb 01, 2007
<u>AB</u>	+	!	<u>30MG</u>	<u>N021777</u>	<u>002</u>	Feb 01, 2007

CYCLOBENZAPRINE HYDROCHLORIDE

<u>AB</u>		APOTEX	<u>15MG</u>	<u>A206703</u>	<u>001</u>	Jul 24, 2018
<u>AB</u>			<u>30MG</u>	<u>A206703</u>	<u>002</u>	Jul 24, 2018
<u>AB</u>		TWI PHARMS INC	<u>15MG</u>	<u>A091281</u>	<u>001</u>	Jan 31, 2013
<u>AB</u>			<u>30MG</u>	<u>A091281</u>	<u>002</u>	Jan 31, 2013

TABLET; ORAL

CYCLOBENZAPRINE HYDROCHLORIDE

<u>AB</u>		ACTAVIS LABS FL INC	<u>5MG</u>	<u>A071611</u>	<u>002</u>	Feb 03, 2006
<u>AB</u>			<u>7.5MG</u>	<u>A071611</u>	<u>003</u>	Feb 03, 2006
<u>AB</u>			<u>10MG</u>	<u>A071611</u>	<u>001</u>	May 03, 1989
<u>AB</u>		ALEMBIC LABS	<u>5MG</u>	<u>A078218</u>	<u>002</u>	Jun 19, 2015
<u>AB</u>			<u>7.5MG</u>	<u>A078218</u>	<u>003</u>	Nov 03, 2020
<u>AB</u>			<u>10MG</u>	<u>A078218</u>	<u>001</u>	Apr 18, 2008
<u>AB</u>		ANDA REPOSITORY	<u>5MG</u>	<u>A073541</u>	<u>002</u>	Apr 06, 2006
<u>AB</u>			<u>10MG</u>	<u>A073541</u>	<u>001</u>	May 23, 1995
<u>AB</u>		AUROBINDO PHARMA	<u>5MG</u>	<u>A078643</u>	<u>001</u>	Sep 26, 2008
<u>AB</u>			<u>10MG</u>	<u>A078643</u>	<u>002</u>	Sep 26, 2008
<u>AB</u>		INVAGEN PHARMS	<u>5MG</u>	<u>A090478</u>	<u>001</u>	Jul 23, 2010
<u>AB</u>			<u>10MG</u>	<u>A090478</u>	<u>002</u>	Jul 23, 2010
<u>AB</u>		JUBILANT CADISTA	<u>5MG</u>	<u>A077563</u>	<u>001</u>	Apr 19, 2006
<u>AB</u>			<u>7.5MG</u>	<u>A077563</u>	<u>003</u>	Aug 25, 2017
<u>AB</u>			<u>10MG</u>	<u>A077563</u>	<u>002</u>	Apr 19, 2006
<u>AB</u>		KVK TECH	<u>5MG</u>	<u>A078048</u>	<u>001</u>	Feb 28, 2011
<u>AB</u>			<u>10MG</u>	<u>A078048</u>	<u>002</u>	Feb 28, 2011
<u>AB</u>		OXFORD PHARMS	<u>5MG</u>	<u>A077209</u>	<u>002</u>	Feb 03, 2006
<u>AB</u>			<u>10MG</u>	<u>A077209</u>	<u>001</u>	Oct 04, 2005
<u>AB</u>		PRINSTON INC	<u>5MG</u>	<u>A077797</u>	<u>001</u>	Feb 28, 2007
<u>AB</u>			<u>10MG</u>	<u>A077797</u>	<u>002</u>	Feb 28, 2007
<u>AB</u>		RUBICON	<u>5MG</u>	<u>A208170</u>	<u>001</u>	May 31, 2017
<u>AB</u>			<u>7.5MG</u>	<u>A208170</u>	<u>002</u>	May 31, 2017
<u>AB</u>	!		<u>10MG</u>	<u>A208170</u>	<u>003</u>	May 31, 2017
<u>AB</u>		SUN PHARM INDS LTD	<u>5MG</u>	<u>A078722</u>	<u>001</u>	May 12, 2008
<u>AB</u>			<u>7.5MG</u>	<u>A078722</u>	<u>002</u>	May 12, 2008
<u>AB</u>			<u>10MG</u>	<u>A078722</u>	<u>003</u>	May 12, 2008
<u>AB</u>		UNICHEM	<u>5MG</u>	<u>A213324</u>	<u>001</u>	Jul 06, 2020
<u>AB</u>			<u>7.5MG</u>	<u>A213324</u>	<u>002</u>	Jul 06, 2020
<u>AB</u>			<u>10MG</u>	<u>A213324</u>	<u>003</u>	Jul 05, 2020

CYCLOPENTOLATE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

AKPENTOLATE

<u>AT</u>		AKORN	<u>1%</u>	<u>A040164</u>	<u>001</u>	Jan 13, 1997
<u>AT</u>			<u>2%</u>	<u>A040165</u>	<u>001</u>	Jan 13, 1997

CYCLOGYL

<u>AT</u>	+	ALCON LABS INC	<u>0.5%</u>	<u>A084109</u>	<u>001</u>	
<u>AT</u>	+	!	<u>1%</u>	<u>A084110</u>	<u>001</u>	
<u>AT</u>	+	!	<u>2%</u>	<u>A084108</u>	<u>001</u>	

CYCLOPENTOLATE HYDROCHLORIDE

<u>AT</u>		AKORN	<u>0.5%</u>	<u>A205937</u>	<u>001</u>	Dec 09, 2015

PENTOLAIR

<u>AT</u>		BAUSCH AND LOMB	<u>1%</u>	<u>A040075</u>	<u>001</u>	Apr 29, 1994

CYCLOPENTOLATE HYDROCHLORIDE; PHENYLEPHRINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

CYCLOMYDRIL

!	ALCON LABS INC	0.2%; 1%	<u>A084300</u>	<u>001</u>		

CYCLOPHOSPHAMIDE

CAPSULE; ORAL

CYCLOPHOSPHAMIDE

<u>AB</u>		ALEMBIC PHARMS	<u>25MG</u>	<u>A215892</u>	<u>001</u>	Nov 10, 2022
<u>AB</u>			<u>50MG</u>	<u>A215892</u>	<u>002</u>	Nov 10, 2022
<u>AB</u>		ANIMA	<u>25MG</u>	<u>A209872</u>	<u>001</u>	May 07, 2018
<u>AB</u>			<u>50MG</u>	<u>A209872</u>	<u>002</u>	May 07, 2018
<u>AB</u>		CIPLA	<u>25MG</u>	<u>A211608</u>	<u>001</u>	Jan 18, 2019
<u>AB</u>			<u>50MG</u>	<u>A211608</u>	<u>002</u>	Jan 18, 2019
<u>AB</u>	+	HIKMA	<u>25MG</u>	<u>N203856</u>	<u>001</u>	Sep 16, 2013
<u>AB</u>	+	!	<u>50MG</u>	<u>N203856</u>	<u>002</u>	Sep 16, 2013

PRESCRIPTION DRUG PRODUCT LIST

3-118 (of 474)

CYCLOPHOSPHAMIDE

INJECTABLE; INJECTION

CYCLOPHOSPHAMIDE

<u>AP</u>	AMNEAL	<u>500MG/VIAL</u>	<u>A210046</u>	<u>001</u>	May 25, 2018
<u>AP</u>		<u>1GM/VIAL</u>	<u>A210046</u>	<u>002</u>	May 25, 2018
<u>AP</u>		<u>2GM/VIAL</u>	<u>A210046</u>	<u>003</u>	May 25, 2018
<u>AP</u>	! BAXTER HLTHCARE	<u>500MG/VIAL</u>	<u>A040745</u>	<u>001</u>	May 21, 2008
<u>AP</u>	!	<u>1GM/VIAL</u>	<u>A040745</u>	<u>002</u>	May 21, 2008
<u>AP</u>	!	<u>2GM/VIAL</u>	<u>A040745</u>	<u>003</u>	May 21, 2008
<u>AP</u>	HENGRUI PHARMA	<u>500MG/VIAL</u>	<u>A204555</u>	<u>001</u>	Oct 31, 2014
<u>AP</u>		<u>1GM/VIAL</u>	<u>A204555</u>	<u>002</u>	Oct 31, 2014
<u>AP</u>		<u>2GM/VIAL</u>	<u>A204555</u>	<u>003</u>	Oct 31, 2014
<u>AP</u>	XELLIA PHARMS APS	<u>500MG/VIAL</u>	<u>A211757</u>	<u>001</u>	Oct 18, 2022
<u>AP</u>		<u>1GM/VIAL</u>	<u>A211757</u>	<u>002</u>	Oct 18, 2022
<u>AP</u>		<u>2GM/VIAL</u>	<u>A211757</u>	<u>003</u>	Oct 18, 2022

SOLUTION; INTRAVENOUS

CYCLOPHOSPHAMIDE

+	! EUGIA PHARMA	500MG/2.5ML (200MG/ML)	N210735	001	Aug 25, 2021
	SPECLTS				
+	!	1GM/5ML (200MG/ML)	N210735	002	Aug 25, 2021
+	! INGENUS PHARMS LLC	500MG/2.5ML (200MG/ML)	N212501	001	Jul 30, 2020
+	!	1GM/5ML (200MG/ML)	N212501	002	Jul 30, 2020
+	!	2GM/10ML (200MG/ML)	N212501	003	Nov 19, 2021

TABLET; ORAL

CYTOXAN

+	BAXTER HLTHCARE	25MG	N012141	002	
+	!	50MG	N012141	001	

CYCLOSERINE

CAPSULE; ORAL

SEROMYCIN

!	CEROVENE INC	250MG	A060593	001	

CYCLOSPORINE

CAPSULE; ORAL

CYCLOSPORINE

<u>AB1</u>	APOTEX	<u>25MG</u>	<u>A210721</u>	<u>001</u>	Jul 10, 2019
<u>AB1</u>		<u>50MG</u>	<u>A210721</u>	<u>002</u>	Jul 10, 2019
<u>AB1</u>		<u>100MG</u>	<u>A210721</u>	<u>003</u>	Jul 10, 2019
<u>AB1</u>	IVAX SUB TEVA	<u>25MG</u>	<u>A065110</u>	<u>003</u>	Mar 29, 2005
	PHARMS				
<u>AB1</u>		<u>50MG</u>	<u>A065110</u>	<u>001</u>	Mar 29, 2005
<u>AB1</u>		<u>100MG</u>	<u>A065110</u>	<u>002</u>	Mar 29, 2005
<u>AB1</u>	MAYNE PHARMA	<u>25MG</u>	<u>A065044</u>	<u>002</u>	Dec 20, 2000
<u>AB1</u>		<u>100MG</u>	<u>A065044</u>	<u>001</u>	Dec 20, 2000
<u>AB1</u>	SANDOZ	<u>25MG</u>	<u>A065017</u>	<u>002</u>	Jan 13, 2000
<u>AB1</u>		<u>100MG</u>	<u>A065017</u>	<u>001</u>	Jan 13, 2000
<u>AB1</u>	STRIDES PHARMA	<u>25MG</u>	<u>A216046</u>	<u>001</u>	Aug 02, 2022
<u>AB1</u>		<u>50MG</u>	<u>A216046</u>	<u>002</u>	Aug 02, 2022
<u>AB1</u>		<u>100MG</u>	<u>A216046</u>	<u>003</u>	Aug 02, 2022

GENGRAF

<u>AB1</u>	ABEVIE	<u>25MG</u>	<u>A065003</u>	<u>001</u>	May 12, 2000
<u>AB1</u>		<u>100MG</u>	<u>A065003</u>	<u>003</u>	May 12, 2000

NEORAL

<u>AB1</u>	+	NOVARTIS	<u>25MG</u>	<u>N050715</u>	<u>001</u>	Jul 14, 1995
<u>AB1</u>	+	!	<u>100MG</u>	<u>N050715</u>	<u>002</u>	Jul 14, 1995

CYCLOSPORINE

<u>AB2</u>	APOTEX	<u>25MG</u>	<u>A065040</u>	<u>001</u>	May 09, 2002
<u>AB2</u>		<u>100MG</u>	<u>A065040</u>	<u>002</u>	May 09, 2002

SANDIMMUNE

<u>AB2</u>	+	NOVARTIS	<u>25MG</u>	<u>N050625</u>	<u>001</u>	Mar 02, 1990
<u>AB2</u>	+	!	<u>100MG</u>	<u>N050625</u>	<u>002</u>	Mar 02, 1990
BX	+	50MG	N050625	003	Nov 23, 1992	

EMULSION; OPHTHALMIC

CYCLOSPORINE

<u>AB</u>	CYCLOSPORINE	MYLAN	<u>0.05%</u>	<u>A205894</u>	<u>001</u>	Feb 02, 2022
	<u>RESTASIS</u>					
<u>AB</u>	+!	ALLERGAN	<u>0.05%</u>	<u>N050790</u>	<u>001</u>	Dec 23, 2002
	RESTASIS MULTIDOSE					
	+!	ALLERGAN	0.05%	N050790	002	Oct 27, 2016
	VERKAZIA					
	+!	SANTEN	0.1%	N214965	001	Jun 23, 2021

PRESCRIPTION DRUG PRODUCT LIST

3-119 (of 474)

CYCLOSPORINE

INJECTABLE; INJECTION

CYCLOSPORINE

<u>AP</u>	HIKMA	<u>50MG/ML</u>	<u>A065004</u>	<u>001</u>	Oct 29, 1999
<u>AP</u>	PADAGIS US	<u>50MG/ML</u>	<u>A065151</u>	<u>001</u>	Oct 07, 2003

SANDIMMUNE

<u>AP</u>	+! NOVARTIS	<u>50MG/ML</u>	<u>N050573</u>	<u>001</u>	Nov 14, 1983
SOLUTION; OPHTHALMIC					
CEQUA					
	+! SUN PHARM	0.09%	N210913	001	Aug 14, 2018
SOLUTION; ORAL					

CYCLOSPORINE

<u>AB1</u>	ABBVIE	<u>100MG/ML</u>	<u>A065025</u>	<u>001</u>	Mar 03, 2000
<u>AB1</u>	IVAX SUB TEVA PHARMS	<u>100MG/ML</u>	<u>A065078</u>	<u>001</u>	Mar 25, 2005

NEORAL

<u>AB1</u>	+! NOVARTIS	<u>100MG/ML</u>	<u>N050716</u>	<u>001</u>	Jul 14, 1995

CYCLOSPORINE

<u>AB2</u>	WOCKHARDT BIO AG	<u>100MG/ML</u>	<u>A065133</u>	<u>001</u>	Sep 17, 2004

SANDIMMUNE

<u>AB2</u>	+! NOVARTIS	<u>100MG/ML</u>	<u>N050574</u>	<u>001</u>	Nov 14, 1983

CYPROHEPTADINE HYDROCHLORIDE

SYRUP; ORAL

CYPROHEPTADINE HYDROCHLORIDE

<u>AA</u>	ANDA REPOSITORY	<u>2MG/5ML</u>	<u>A204823</u>	<u>001</u>	Dec 27, 2016
<u>AA</u>	CHARTWELL MOLECULAR	<u>2MG/5ML</u>	<u>A203191</u>	<u>001</u>	Jul 13, 2017
<u>AA</u>	ELYSIUM	<u>2MG/5ML</u>	<u>A209108</u>	<u>001</u>	Oct 16, 2018
<u>AA</u>	! LYNE	<u>2MG/5ML</u>	<u>A040668</u>	<u>001</u>	Jun 28, 2006
<u>AA</u>	PHARM ASSOC	<u>2MG/5ML</u>	<u>A091295</u>	<u>001</u>	Mar 28, 2013
<u>AA</u>	QUAGEN	<u>2MG/5ML</u>	<u>A212423</u>	<u>001</u>	May 22, 2019

TABLET; ORAL

CYPROHEPTADINE HYDROCHLORIDE

<u>AA</u>	APPCO	<u>4MG</u>	<u>A206553</u>	<u>001</u>	Nov 29, 2016
<u>AA</u>	BEXIMCO PHARMS USA	<u>4MG</u>	<u>A206676</u>	<u>001</u>	Apr 12, 2019
<u>AA</u>	BOSCOGEN	<u>4MG</u>	<u>A040644</u>	<u>001</u>	May 30, 2006
<u>AA</u>	ELYSIUM	<u>4MG</u>	<u>A207555</u>	<u>001</u>	Jan 31, 2017
<u>AA</u>	+! HERITAGE PHARMA	<u>4MG</u>	<u>A087056</u>	<u>001</u>	
<u>AA</u>	MOUNTAIN	<u>4MG</u>	<u>A040537</u>	<u>001</u>	Sep 30, 2003
<u>AA</u>	NOVAST LABS	<u>4MG</u>	<u>A205087</u>	<u>001</u>	Sep 23, 2015
<u>AA</u>	QUAGEN	<u>4MG</u>	<u>A212491</u>	<u>001</u>	Feb 24, 2021
<u>AA</u>	RISING	<u>4MG</u>	<u>A207783</u>	<u>001</u>	Dec 29, 2016
<u>AA</u>	STRIDES PHARMA	<u>4MG</u>	<u>A209172</u>	<u>001</u>	Apr 11, 2018
<u>AA</u>	ZYDUS PHARMS	<u>4MG</u>	<u>A208938</u>	<u>001</u>	May 19, 2017

CYSTEAMINE BITARTRATE

CAPSULE; ORAL

CYSTAGON

+	MYLAN	EQ 50MG BASE	N020392	001	Aug 15, 1994
+	!	EQ 150MG BASE	N020392	002	Aug 15, 1994

CAPSULE, DELAYED RELEASE; ORAL

PROCYSBI

+	HORIZON	EQ 25MG BASE	N203389	001	Apr 30, 2013
+	!	EQ 75MG BASE	N203389	002	Apr 30, 2013

GRANULE, DELAYED RELEASE; ORAL

PROCYSBI

+	HORIZON	EQ 75MG BASE/PACKET	N213491	001	Feb 14, 2020
+	!	EQ 300MG BASE/PACKET	N213491	002	Feb 14, 2020

CYSTEAMINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

CYSTADROPS

+	RECORDATI RARE	EQ 0.37% BASE	N211302	001	Aug 19, 2020

CYSTARAN

+	LEADIANT BIOSCI INC	EQ 0.44% BASE	N200740	001	Oct 02, 2012

CYSTEINE HYDROCHLORIDE

SOLUTION; INTRAVENOUS

ELCYS

+	EXELA PHARMA	500MG/10ML (50MG/ML)	N210660	001	Apr 16, 2019

PRESCRIPTION DRUG PRODUCT LIST

3-120 (of 474)

CYTARABINE

INJECTABLE; INJECTION

CYTARABINE

AP	!	FRESENIUS KABI USA	<u>100MG/ML</u>	<u>A076512</u>	<u>001</u>	Jan 15, 2004
AP		GLAND PHARMA LTD	<u>100MG/VIAL</u>	<u>A211937</u>	<u>001</u>	Dec 23, 2019
AP			<u>2GM/VIAL</u>	<u>A211938</u>	<u>001</u>	Dec 23, 2019
AP		HIKMA	<u>100MG/VIAL</u>	<u>A071471</u>	<u>001</u>	Aug 02, 1989
AP	!	HOSPIRA	<u>20MG/ML</u>	<u>A071868</u>	<u>001</u>	Jun 04, 1990
AP	!		<u>20MG/ML</u>	<u>A072168</u>	<u>001</u>	Aug 31, 1990
AP	!		<u>20MG/ML</u>	<u>A072945</u>	<u>001</u>	Feb 28, 1994
AP			<u>100MG/ML</u>	<u>A075383</u>	<u>001</u>	Nov 22, 1999
AP		MEITHEAL	<u>20MG/ML</u>	<u>A208485</u>	<u>001</u>	Feb 28, 2022
AP			<u>100MG/ML</u>	<u>A205696</u>	<u>001</u>	Jul 17, 2018
AP		RISING	<u>20MG/ML</u>	<u>A200915</u>	<u>001</u>	Dec 13, 2011
AP			<u>100MG/ML</u>	<u>A201784</u>	<u>001</u>	Jan 30, 2012
AP	!	WEST-WARD PHARMS	<u>2GM/VIAL</u>	<u>A074245</u>	<u>002</u>	Aug 31, 1994
		INT				
	!	HIKMA	500MG/VIAL	A071472	001	Aug 02, 1989
	!	WEST-WARD PHARMS	1GM/VIAL	A074245	001	Aug 31, 1994
		INT				

CYTARABINE; DAUNORUBICIN

POWDER; INTRAVENOUS

VYXEOS

+! CELATOR PHARMS 100MG; 44MG

N209401 001 Aug 03, 2017

DABIGATRAN ETEXILATE MESYLATE

CAPSULE; ORAL

DABIGATRAN ETEXILATE MESYLATE

AB		ALKEM LABS LTD	<u>EQ 75MG BASE</u>	<u>A208040</u>	<u>001</u>	Mar 11, 2020
AB			<u>EQ 150MG BASE</u>	<u>A208040</u>	<u>002</u>	Mar 11, 2020
AB		HETERO LABS LTD III	<u>EQ 75MG BASE</u>	<u>A207961</u>	<u>001</u>	May 06, 2020
AB			<u>EQ 150MG BASE</u>	<u>A207961</u>	<u>002</u>	May 06, 2020
<u>PRADAXA</u>						
AB	+	BOEHRINGER	<u>EQ 75MG BASE</u>	<u>N022512</u>	<u>001</u>	Oct 19, 2010
		INGELHEIM				
AB	+!		<u>EQ 150MG BASE</u>	<u>N022512</u>	<u>002</u>	Oct 19, 2010
	+		EQ 110MG BASE	N022512	003	Nov 20, 2015
PELLETS; ORAL						
PRADAXA						
	+	BOEHRINGER	EQ 20MG BASE/PACKET	N214358	001	Jun 21, 2021
		INGELHEIM				
	+		EQ 30MG BASE/PACKET	N214358	002	Jun 21, 2021
	+		EQ 40MG BASE/PACKET	N214358	003	Jun 21, 2021
	+		EQ 50MG BASE/PACKET	N214358	004	Jun 21, 2021
	+		EQ 110MG BASE/PACKET	N214358	005	Jun 21, 2021
	+!		EQ 150MG BASE/PACKET	N214358	006	Jun 21, 2021

DABRAFENIB MESYLATE

CAPSULE; ORAL

TAFINLAR

+ NOVARTIS EQ 50MG BASE

N202806 001 May 29, 2013

+! EQ 75MG BASE

N202806 002 May 29, 2013

DACARBAZINE

INJECTABLE; INJECTION

DACARBAZINE

AP	!	FRESENIUS KABI USA	<u>200MG/VIAL</u>	<u>A075371</u>	<u>002</u>	Aug 27, 1999
AP		HIKMA	<u>200MG/VIAL</u>	<u>A075812</u>	<u>001</u>	Jun 15, 2001
AP			<u>500MG/VIAL</u>	<u>A075812</u>	<u>002</u>	Oct 31, 2002
AP		HOSPIRA	<u>200MG/VIAL</u>	<u>A075940</u>	<u>001</u>	Oct 18, 2001
AP		TEVA PHARMS USA	<u>200MG/VIAL</u>	<u>A075259</u>	<u>002</u>	Aug 27, 1998
AP	!		<u>500MG/VIAL</u>	<u>A075259</u>	<u>001</u>	Sep 22, 2000
	!	FRESENIUS KABI USA	100MG/VIAL	A075371	001	Aug 27, 1999

DACOMITINIB

TABLET; ORAL

VIZIMPRO

+ PFIZER

15MG

N211288 001 Sep 27, 2018

+ 30MG

N211288 002 Sep 27, 2018

+! 45MG

N211288 003 Sep 27, 2018

PRESCRIPTION DRUG PRODUCT LIST

3-121 (of 474)

DACTINOMYCIN

INJECTABLE; INJECTION

COSMEGEN

AP	+!	RECORDATI RARE	0.5MG/VIAL	N050682 001	
<u>DACTINOMYCIN</u>					
AP		EUGIA PHARMA	0.5MG/VIAL	A203385 001	Nov 09, 2017
AP		HISUN PHARM HANGZHOU	0.5MG/VIAL	A207232 001	Jul 16, 2019
AP		MEITHEAL	0.5MG/VIAL	A213463 001	Nov 13, 2020
AP		XGEN PHARMS	0.5MG/VIAL	A203999 001	May 20, 2019

DALBAVANCIN HYDROCHLORIDE

POWDER; INTRAVENOUS

DALVANCE

+!	ALLERGAN	EQ 500MG BASE/VIAL	N021883 001	May 23, 2014

DALFAMPRIDINE

TABLET, EXTENDED RELEASE; ORAL

AMPYRA

AB	+!	ACORDA	10MG	N022250 001	Jan 22, 2010
<u>DALFAMPRIDINE</u>					
AB		ACCORD HLTHCARE	10MG	A206863 001	Jul 11, 2018
AB		ACTAVIS LABS FL INC	10MG	A206836 001	Jan 23, 2017
AB		ALKEM LABS LTD	10MG	A206765 001	Jul 30, 2018
AB		AUROBINDO PHARMA	10MG	A206811 001	Jan 23, 2017
AB		MICRO LABS	10MG	A210158 001	Mar 11, 2019
AB		SUN PHARM	10MG	A208292 001	May 21, 2019

DALFOPRISTIN; QUINUPRISTIN

INJECTABLE; INTRAVENOUS

SYNERCID

+!	KING PHARMS	350MG/VIAL; 150MG/VIAL	N050748 001	Sep 21, 1999

DALTEPARIN SODIUM

INJECTABLE; SUBCUTANEOUS

FRAGMIN

+	PFIZER	2,500IU/0.2ML (12,500IU/ML)	N020287 001	Dec 22, 1994
+		5,000IU/0.2ML (25,000IU/ML)	N020287 003	Mar 18, 1996
+		7,500IU/0.3ML (25,000IU/ML)	N020287 005	Apr 04, 2002
+		10,000IU/ML (10,000IU/ML)	N020287 004	Jan 30, 1998
+		10,000IU/4ML (2,500IU/ML)	N020287 012	Mar 15, 2022
+		12,500IU/0.5ML (25,000IU/ML)	N020287 009	May 01, 2007
+		15,000IU/0.6ML (25,000IU/ML)	N020287 010	May 01, 2007
+		18,000IU/0.72ML (25,000IU/ML)	N020287 011	May 01, 2007
+!		95,000IU/3.8ML (25,000IU/ML)	N020287 006	Apr 04, 2002

DANAZOL

CAPSULE; ORAL

DANAZOL

AB		BARR	50MG	A074582 003	May 29, 1998
AB			100MG	A074582 002	May 29, 1998
AB	!		200MG	A074582 001	Aug 09, 1996
AB		LANNETT CO INC	50MG	A077246 002	Apr 19, 2007
AB			100MG	A077246 003	Apr 19, 2007
AB			200MG	A077246 001	Sep 28, 2005

DANTROLENE SODIUM

CAPSULE; ORAL

DANTRIUM

AB	+	PAR STERILE PRODUCTS	25MG	N017443 001	
AB	+		50MG	N017443 003	
AB	+!		100MG	N017443 002	

DANTROLENE SODIUM

AB		ELITE LABS INC	25MG	A076686 001	Oct 24, 2005
AB			50MG	A076686 002	Oct 24, 2005
AB			100MG	A076686 003	Oct 24, 2005
AB		IMPAX LABS	25MG	A076856 001	Mar 01, 2005
AB			50MG	A076856 002	Mar 01, 2005
AB			100MG	A076856 003	Mar 01, 2005

FOR SUSPENSION; INTRAVENOUS

RYANODEX

+!	EAGLE PHARMS	250MG/VIAL	N205579 001	Jul 22, 2014

PRESCRIPTION DRUG PRODUCT LIST

3-122 (of 474)

DANTROLENE SODIUM

INJECTABLE; INJECTION

DANTRUM

AP	+	!	PAR STERILE PRODUCTS	20MG/VIAL	N018264	001	

DANTROLENE SODIUM

AP			HIKMA	20MG/VIAL	A204762	001	Jun 19, 2017

REVONTO

AP			USWM	20MG/VIAL	A078378	001	Jul 24, 2007

DAPAGLIFLOZIN

TABLET; ORAL

FARXIGA

+			ASTRAZENECA AB	5MG	N202293	001	Jan 08, 2014
+	!			10MG	N202293	002	Jan 08, 2014

DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

XIGDUO XR

+			ASTRAZENECA AB	2.5MG; 1GM	N205649	005	Jul 28, 2017
+				5MG; 500MG	N205649	001	Oct 29, 2014
+				5MG; 1GM	N205649	002	Oct 29, 2014
+				10MG; 500MG	N205649	003	Oct 29, 2014
+	!			10MG; 1GM	N205649	004	Oct 29, 2014

DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE

TABLET; ORAL

QTERN

+			ASTRAZENECA AB	5MG; EQ 5MG BASE	N209091	002	May 02, 2019
+	!			10MG; EQ 5MG BASE	N209091	001	Feb 27, 2017

DAPSONE

GEL; TOPICAL

ACZONE

AB	+	!	ALLERGAN	5%	N021794	001	Jul 07, 2005

AB	+	!	ALMIRALL	7.5%	N207154	001	Feb 24, 2016

DAPSONE

AB			COSETTE	5%	A210178	001	Mar 31, 2022

AB			MYLAN	7.5%	A213847	001	Feb 04, 2022

AB			TARO	5%	A209506	001	Oct 16, 2017

AB			TARO PHARMS	7.5%	A210191	001	Jun 26, 2019

AB			TORRENT	7.5%	A214722	001	Feb 10, 2022

TABLET; ORAL

DAPSONE

AB			ACTAVIS LLC	25MG	A204380	001	Mar 23, 2017

AB				100MG	A204380	002	Mar 23, 2017

AB			ALVOGEN	25MG	A205429	001	Jan 07, 2016

AB				100MG	A205429	002	Jan 07, 2016

AB	+		EVEREST LIFE SCI	25MG	A086841	001	

AB	+	!		100MG	A086842	001	

AB			NOSTRUM LABS INC	25MG	A203887	001	May 06, 2016

AB				100MG	A203887	002	May 06, 2016

AB			NOVITIUM PHARMA	25MG	A206505	001	Dec 01, 2016

AB				100MG	A206505	002	Dec 01, 2016

AB			RISING	100MG	A207165	001	May 08, 2019

DAPTOMYCIN

POWDER; INTRAVENOUS

CUBICIN

AP	+	!	CUBIST PHARMS LLC	500MG/VIAL	N021572	002	Sep 12, 2003

DAPTOMYCIN

AP			ACCORD HLTHCARE	350MG/VIAL	A212667	001	Jul 12, 2019

AP				500MG/VIAL	A211961	001	Jun 24, 2019

AP			ASPIRO	350MG/VIAL	A216445	001	Dec 23, 2022

AP				500MG/VIAL	A216413	001	Sep 23, 2022

AP			BE PHARMS	350MG/VIAL	A213425	001	Aug 20, 2020

AP				500MG/VIAL	A212513	001	Jun 26, 2019

AP			DR REDDYS	350MG/VIAL	A211403	001	Aug 31, 2020

AP				500MG/VIAL	A208375	001	May 01, 2019

AP			EUGIA PHARMA	500MG/VIAL	A213171	001	Sep 02, 2021

AP			FRESENIUS KABI USA	500MG/VIAL	A206077	001	Apr 11, 2018

AP			HAINAN POLY PHARM	500MG/VIAL	A215890	001	Aug 18, 2022

AP			HANGZHOU ZHONGMEI	500MG/VIAL	A215215	001	Nov 26, 2021

AP			HENGRUI PHARMA	500MG/VIAL	A212022	001	Aug 22, 2019

AP			MEITHEAL	350MG/VIAL	A213786	001	Jun 29, 2021

PRESCRIPTION DRUG PRODUCT LIST

3-123 (of 474)

DAPTOMYCIN

POWDER; INTRAVENOUS

DAPTOMYCIN

<u>AP</u>		<u>500MG/VIAL</u>	<u>A213623</u>	<u>001</u>	Jun 29, 2021
<u>AP</u>	MYLAN LABS LTD	<u>500MG/VIAL</u>	<u>A205037</u>	<u>001</u>	Jun 05, 2018
<u>AP</u>	QILU PHARM HAINAN	<u>500MG/VIAL</u>	<u>A215316</u>	<u>001</u>	Aug 24, 2021
<u>AP</u>	+! SAGENT PHARMS INC	<u>350MG/VIAL</u>	<u>N208385</u>	<u>001</u>	Sep 12, 2017
<u>AP</u>		<u>500MG/VIAL</u>	<u>A207104</u>	<u>001</u>	Nov 15, 2019
<u>AP</u>	TEVA PHARMS USA	<u>500MG/VIAL</u>	<u>A091039</u>	<u>001</u>	Mar 25, 2016
<u>AP</u>	XELLIA PHARMS APS	<u>500MG/VIAL</u>	<u>A206005</u>	<u>001</u>	Jun 15, 2016
	+! HOSPIRA	350MG/VIAL	N210282	001	Jun 21, 2021
	+!	500MG/VIAL	N210282	002	Jun 21, 2021
	+! XELLIA PHARMS APS	350MG/VIAL	N209949	001	Oct 20, 2017

DARIDOREXANT HYDROCHLORIDE

TABLET; ORAL

QUVIVIQ

+	IDORSIA	EQ 25MG BASE	N214985	001	Apr 07, 2022
+	!	EQ 50MG BASE	N214985	002	Apr 07, 2022

DARIFENACIN HYDROBROMIDE

TABLET, EXTENDED RELEASE; ORAL

DARIFENACIN

<u>AB</u>	MACLEODS PHARMS LTD	<u>EQ 7.5MG BASE</u>	<u>A207302</u>	<u>001</u>	Jul 28, 2017
<u>AB</u>	!	<u>EQ 15MG BASE</u>	<u>A207302</u>	<u>002</u>	Jul 28, 2017

DARIFENACIN HYDROBROMIDE

<u>AB</u>	ALEMBIC PHARMS	<u>EQ 7.5MG BASE</u>	<u>A207681</u>	<u>001</u>	Dec 08, 2017
<u>AB</u>		<u>EQ 15MG BASE</u>	<u>A207681</u>	<u>002</u>	Dec 08, 2017
<u>AB</u>	AUROBINDO PHARMA	<u>EQ 7.5MG BASE</u>	<u>A206743</u>	<u>001</u>	Sep 19, 2016
<u>AB</u>		<u>EQ 15MG BASE</u>	<u>A206743</u>	<u>002</u>	Sep 19, 2016
<u>AB</u>	CIPLA	<u>EQ 7.5MG BASE</u>	<u>A207664</u>	<u>001</u>	Sep 01, 2016
<u>AB</u>		<u>EQ 15MG BASE</u>	<u>A207664</u>	<u>002</u>	Sep 01, 2016
<u>AB</u>	POLYGEN PHARMS	<u>EQ 7.5MG BASE</u>	<u>A211045</u>	<u>001</u>	Jan 06, 2020
<u>AB</u>		<u>EQ 15MG BASE</u>	<u>A211045</u>	<u>002</u>	Jan 06, 2020
<u>AB</u>	TORRENT	<u>EQ 7.5MG BASE</u>	<u>A205209</u>	<u>001</u>	Nov 17, 2016
<u>AB</u>		<u>EQ 15MG BASE</u>	<u>A205209</u>	<u>002</u>	Nov 17, 2016

DAROLUTAMIDE

TABLET; ORAL

NUBEQA

+	BAYER HEALTHCARE	300MG	N212099	001	Jul 30, 2019

DARUNAVIR

SUSPENSION; ORAL

PREZISTA

+	JANSSEN PRODS	100MG/ML	N202895	001	Dec 16, 2011

TABLET; ORAL

DARUNAVIR

<u>AB</u>	LUPIN LTD	<u>600MG</u>	<u>A202073</u>	<u>001</u>	Sep 29, 2022
<u>AB</u>		<u>800MG</u>	<u>A202073</u>	<u>002</u>	Sep 29, 2022
<u>AB</u>	TEVA PHARMS USA	<u>600MG</u>	<u>A202118</u>	<u>001</u>	Nov 21, 2017

PREZISTA

<u>AB</u>	+	JANSSEN PRODS	<u>600MG</u>	<u>N021976</u>	<u>002</u>	Feb 25, 2008
<u>AB</u>	+!		<u>800MG</u>	<u>N021976</u>	<u>006</u>	Nov 09, 2012
	+		75MG	N021976	004	Dec 18, 2008
	+		150MG	N021976	005	Dec 18, 2008

DASATINIB

TABLET; ORAL

SPRYCEL

+	BRISTOL MYERS SQUIBB	20MG	N021986	001	Jun 28, 2006
+		50MG	N021986	002	Jun 28, 2006
+		70MG	N021986	003	Jun 28, 2006
+		80MG	N021986	005	Oct 28, 2010
+	!	100MG	N021986	004	May 30, 2008
+		140MG	N021986	006	Oct 28, 2010

DASIGLUCAGON HYDROCHLORIDE

SOLUTION; SUBCUTANEOUS

ZEGALOGUE

+	ZEALAND PHARMA	EQ 0.6MG BASE/0.6ML (EQ 0.6MG BASE/0.6ML)	N214231	001	Mar 22, 2021

ZEGALOGUE (AUTOINJECTOR)

+	ZEALAND PHARMA	EQ 0.6MG BASE/0.6ML (EQ 0.6MG BASE/0.6ML)	N214231	002	Mar 22, 2021

PRESCRIPTION DRUG PRODUCT LIST

3-124 (of 474)

DAUNORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

CERUBIDINE

<u>AP</u>	<u>!</u>	HIKMA	<u>EQ 20MG BASE/VIAL</u>	<u>A064103</u>	<u>001</u>	Feb 03, 1995

DAUNORUBICIN HYDROCHLORIDE

<u>AP</u>		FRESENIUS KABI USA	<u>EQ 20MG BASE/VIAL</u>	<u>A065000</u>	<u>001</u>	May 25, 1999
<u>AP</u>	<u>+</u>	HIKMA	<u>EQ 5MG BASE/ML</u>	<u>N050731</u>	<u>001</u>	Jan 30, 1998
<u>AP</u>		HISUN PHARM	<u>EQ 5MG BASE/ML</u>	<u>A208759</u>	<u>001</u>	Apr 12, 2019
		HANGZHOU				
<u>AP</u>		TEVA PHARMS USA	<u>EQ 5MG BASE/ML</u>	<u>A065035</u>	<u>001</u>	Jan 24, 2000
		FRESENIUS KABI USA	EQ 5MG BASE/VIAL	A065034	001	Nov 20, 2001

DECITABINE

INJECTABLE; INTRAVENOUS

DECITABINE

<u>AP</u>	<u>!</u>	ACCORD HLTHCARE	<u>50MG/VIAL</u>	<u>A203475</u>	<u>001</u>	Feb 27, 2017
<u>AP</u>		CHEMI SPA	<u>50MG/VIAL</u>	<u>A206033</u>	<u>001</u>	Sep 22, 2017
<u>AP</u>		DR REDDYS	<u>50MG/VIAL</u>	<u>A203131</u>	<u>001</u>	Jul 11, 2013
<u>AP</u>		EUGIA PHARMA	<u>50MG/VIAL</u>	<u>A214569</u>	<u>001</u>	Sep 20, 2021
<u>AP</u>		GLAND	<u>50MG/VIAL</u>	<u>A205539</u>	<u>001</u>	Nov 23, 2020
<u>AP</u>		JIANGSU HANSON	<u>50MG/VIAL</u>	<u>A213472</u>	<u>001</u>	Apr 15, 2022
		PHARM				
<u>AP</u>		LUPIN LTD	<u>50MG/VIAL</u>	<u>A210756</u>	<u>001</u>	Nov 09, 2018
<u>AP</u>		MEITHEAL	<u>50MG/VIAL</u>	<u>A212959</u>	<u>001</u>	Jul 02, 2021
<u>AP</u>		MSN	<u>50MG/VIAL</u>	<u>A212265</u>	<u>001</u>	Aug 28, 2019
<u>AP</u>		NIVAGEN PHARMS INC	<u>50MG/VIAL</u>	<u>A212117</u>	<u>001</u>	Dec 07, 2020
<u>AP</u>		NOVAST LABS	<u>50MG/VIAL</u>	<u>A210984</u>	<u>001</u>	Sep 16, 2019
<u>AP</u>		PHARMASCIENCE INC	<u>50MG/VIAL</u>	<u>A204607</u>	<u>001</u>	May 31, 2017
<u>AP</u>		QILU PHARM HAINAN	<u>50MG/VIAL</u>	<u>A212826</u>	<u>001</u>	Apr 12, 2021
<u>AP</u>		SAGENT PHARMS INC	<u>50MG/VIAL</u>	<u>A207100</u>	<u>001</u>	Mar 16, 2018
<u>AP</u>		SANDOZ INC	<u>50MG/VIAL</u>	<u>A202969</u>	<u>001</u>	Aug 28, 2014
<u>AP</u>		WOCKHARDT BIO AG	<u>50MG/VIAL</u>	<u>A209056</u>	<u>001</u>	Apr 09, 2019
<u>AP</u>		ZYDUS PHARMS	<u>50MG/VIAL</u>	<u>A214486</u>	<u>001</u>	Nov 19, 2021

POWDER; INTRAVENOUS

DECITABINE

<u>+</u>	<u>!</u>	SUN PHARM	50MG/VIAL	N205582	001	Jan 28, 2014

DEFERASIROX

GRANULE; ORAL

DEFERASIROX

<u>AB</u>		ALKEM LABS LTD	<u>90MG</u>	<u>A213374</u>	<u>001</u>	Jul 14, 2020
<u>AB</u>			<u>180MG</u>	<u>A213374</u>	<u>002</u>	Jul 14, 2020
<u>AB</u>			<u>360MG</u>	<u>A213374</u>	<u>003</u>	Jul 14, 2020
<u>AB</u>		ANNORA PHARMA	<u>180MG</u>	<u>A216229</u>	<u>001</u>	Sep 22, 2022
<u>AB</u>			<u>360MG</u>	<u>A216229</u>	<u>002</u>	Sep 22, 2022
<u>AB</u>		AUCTA	<u>90MG</u>	<u>A214559</u>	<u>001</u>	Mar 09, 2021
<u>AB</u>			<u>180MG</u>	<u>A214559</u>	<u>002</u>	Mar 09, 2021
<u>AB</u>			<u>360MG</u>	<u>A214559</u>	<u>003</u>	Mar 09, 2021
<u>AB</u>		CIPLA	<u>90MG</u>	<u>A215026</u>	<u>001</u>	Feb 23, 2022
<u>AB</u>			<u>180MG</u>	<u>A215026</u>	<u>002</u>	Feb 23, 2022
<u>AB</u>			<u>360MG</u>	<u>A215026</u>	<u>003</u>	Feb 23, 2022
<u>AB</u>		MSN	<u>90MG</u>	<u>A214650</u>	<u>003</u>	Apr 20, 2022
<u>AB</u>			<u>180MG</u>	<u>A214650</u>	<u>001</u>	Mar 17, 2021
<u>AB</u>			<u>360MG</u>	<u>A214650</u>	<u>002</u>	Mar 17, 2021
<u>AB</u>		TEVA PHARMS USA	<u>90MG</u>	<u>A214180</u>	<u>001</u>	Nov 19, 2021
<u>AB</u>			<u>180MG</u>	<u>A214180</u>	<u>002</u>	Nov 19, 2021
<u>AB</u>			<u>360MG</u>	<u>A214180</u>	<u>003</u>	Nov 19, 2021

JADENU SPRINKLE

<u>AB</u>	<u>+</u>	NOVARTIS	<u>90MG</u>	<u>N207968</u>	<u>001</u>	May 18, 2017
<u>AB</u>	<u>+</u>		<u>180MG</u>	<u>N207968</u>	<u>002</u>	May 18, 2017
<u>AB</u>	<u>+</u>	<u>!</u>	<u>360MG</u>	<u>N207968</u>	<u>003</u>	May 18, 2017

TABLET; ORAL

DEFERASIROX

<u>AB</u>		ACTAVIS ELIZABETH	<u>90MG</u>	<u>A208697</u>	<u>001</u>	Dec 13, 2019
<u>AB</u>			<u>180MG</u>	<u>A208697</u>	<u>002</u>	Dec 13, 2019
<u>AB</u>			<u>360MG</u>	<u>A208697</u>	<u>003</u>	Dec 13, 2019
<u>AB</u>		ALEMBIC PHARMS	<u>90MG</u>	<u>A211824</u>	<u>001</u>	Nov 20, 2019
<u>AB</u>			<u>180MG</u>	<u>A211824</u>	<u>003</u>	Jun 15, 2020
<u>AB</u>			<u>360MG</u>	<u>A211824</u>	<u>002</u>	Nov 20, 2019
<u>AB</u>		ALKEM LABS LTD	<u>90MG</u>	<u>A210555</u>	<u>001</u>	Mar 30, 2020
<u>AB</u>			<u>180MG</u>	<u>A210555</u>	<u>003</u>	Jul 02, 2020
<u>AB</u>			<u>360MG</u>	<u>A210555</u>	<u>002</u>	Mar 30, 2020
<u>AB</u>		ANNORA PHARMA	<u>90MG</u>	<u>A214341</u>	<u>001</u>	May 14, 2021
<u>AB</u>			<u>180MG</u>	<u>A214341</u>	<u>002</u>	May 14, 2021

PRESCRIPTION DRUG PRODUCT LIST

3-125 (of 474)

DEFERASIROX

TABLET; ORAL

DEFERASIROX

<u>AB</u>		<u>360MG</u>	<u>A214341</u>	<u>003</u>	May 14, 2021
<u>AB</u>	CELLTRION	<u>90MG</u>	<u>A212669</u>	<u>001</u>	May 27, 2021
<u>AB</u>		<u>180MG</u>	<u>A212669</u>	<u>002</u>	May 27, 2021
<u>AB</u>		<u>360MG</u>	<u>A212669</u>	<u>003</u>	May 27, 2021
<u>AB</u>	CIPLA	<u>90MG</u>	<u>A211852</u>	<u>001</u>	Feb 11, 2020
<u>AB</u>		<u>180MG</u>	<u>A211852</u>	<u>003</u>	Jun 15, 2020
<u>AB</u>		<u>360MG</u>	<u>A211852</u>	<u>002</u>	Feb 11, 2020
<u>AB</u>	MSN	<u>90MG</u>	<u>A210945</u>	<u>001</u>	Nov 20, 2019
<u>AB</u>		<u>180MG</u>	<u>A210945</u>	<u>003</u>	Jun 16, 2020
<u>AB</u>		<u>360MG</u>	<u>A210945</u>	<u>002</u>	Nov 20, 2019
<u>AB</u>	PIRAMAL HLTHCARE UK	<u>90MG</u>	<u>A212995</u>	<u>001</u>	Dec 30, 2019
<u>AB</u>		<u>180MG</u>	<u>A212995</u>	<u>003</u>	Jun 15, 2020
<u>AB</u>		<u>360MG</u>	<u>A212995</u>	<u>002</u>	Dec 30, 2019
<u>AB</u>	SUN PHARM	<u>90MG</u>	<u>A211641</u>	<u>001</u>	Jan 02, 2020
<u>AB</u>		<u>180MG</u>	<u>A211641</u>	<u>003</u>	Jun 15, 2020
<u>AB</u>		<u>360MG</u>	<u>A211641</u>	<u>002</u>	Jan 02, 2020
<u>AB</u>	ZYDUS PHARMS	<u>90MG</u>	<u>A211383</u>	<u>001</u>	Nov 20, 2019
<u>AB</u>		<u>180MG</u>	<u>A211383</u>	<u>003</u>	Jun 15, 2020
<u>AB</u>		<u>360MG</u>	<u>A211383</u>	<u>002</u>	Nov 20, 2019

JADENU

<u>AB</u>	+	NOVARTIS PHARMS CORP	<u>90MG</u>	<u>N206910</u>	<u>001</u>	Mar 30, 2015
<u>AB</u>	+		<u>180MG</u>	<u>N206910</u>	<u>002</u>	Mar 30, 2015
<u>AB</u>	+		<u>360MG</u>	<u>N206910</u>	<u>003</u>	Mar 30, 2015

TABLET, FOR SUSPENSION; ORAL

DEFERASIROX

<u>AB</u>	ACTAVIS ELIZABETH	<u>125MG</u>	<u>A203560</u>	<u>001</u>	Jan 26, 2016
<u>AB</u>		<u>250MG</u>	<u>A203560</u>	<u>002</u>	Jan 26, 2016
<u>AB</u>		<u>500MG</u>	<u>A203560</u>	<u>003</u>	Jan 26, 2016
<u>AB</u>	ALEMBIC PHARMS	<u>125MG</u>	<u>A210060</u>	<u>001</u>	Nov 20, 2019
<u>AB</u>		<u>250MG</u>	<u>A210060</u>	<u>002</u>	Nov 20, 2019
<u>AB</u>		<u>500MG</u>	<u>A210060</u>	<u>003</u>	Nov 20, 2019
<u>AB</u>	ALKEM LABS LTD	<u>125MG</u>	<u>A210519</u>	<u>001</u>	Nov 20, 2019
<u>AB</u>		<u>250MG</u>	<u>A210519</u>	<u>002</u>	Nov 20, 2019
<u>AB</u>		<u>500MG</u>	<u>A210519</u>	<u>003</u>	Nov 20, 2019
<u>AB</u>	BIONPHARMA INC	<u>125MG</u>	<u>A210920</u>	<u>001</u>	Nov 20, 2019
<u>AB</u>		<u>250MG</u>	<u>A210920</u>	<u>002</u>	Nov 20, 2019
<u>AB</u>		<u>500MG</u>	<u>A210920</u>	<u>003</u>	Nov 20, 2019
<u>AB</u>	ICHNOS	<u>125MG</u>	<u>A209433</u>	<u>001</u>	Jan 06, 2020
<u>AB</u>		<u>250MG</u>	<u>A209433</u>	<u>002</u>	Jan 06, 2020
<u>AB</u>		<u>500MG</u>	<u>A209433</u>	<u>003</u>	Jan 06, 2020
<u>AB</u>	MSN	<u>125MG</u>	<u>A209878</u>	<u>001</u>	Nov 20, 2019
<u>AB</u>		<u>250MG</u>	<u>A209878</u>	<u>002</u>	Nov 20, 2019
<u>AB</u>		<u>500MG</u>	<u>A209878</u>	<u>003</u>	Nov 20, 2019
<u>AB</u>	SUN PHARM	<u>125MG</u>	<u>A209782</u>	<u>001</u>	Nov 20, 2019
<u>AB</u>		<u>250MG</u>	<u>A209782</u>	<u>002</u>	Nov 20, 2019
<u>AB</u>		<u>500MG</u>	<u>A209782</u>	<u>003</u>	Nov 20, 2019
<u>AB</u>	TEVA PHARMS USA	<u>125MG</u>	<u>A207124</u>	<u>001</u>	Sep 23, 2022
<u>AB</u>		<u>250MG</u>	<u>A207124</u>	<u>002</u>	Sep 23, 2022
<u>AB</u>		<u>500MG</u>	<u>A207124</u>	<u>003</u>	Sep 23, 2022

EXJADE

<u>AB</u>	+	NOVARTIS	<u>125MG</u>	<u>N021882</u>	<u>001</u>	Nov 02, 2005
<u>AB</u>	+		<u>250MG</u>	<u>N021882</u>	<u>002</u>	Nov 02, 2005
<u>AB</u>	+		<u>500MG</u>	<u>N021882</u>	<u>003</u>	Nov 02, 2005

DEFERIPRONE

SOLUTION; ORAL

FERRIPROX

+! CHIESI

100MG/ML

N208030 001 Sep 09, 2015

TABLET; ORAL

DEFERIPRONE

<u>AB</u>	HIKMA	<u>500MG</u>	<u>A213239</u>	<u>001</u>	Mar 29, 2021
<u>AB</u>		<u>1GM</u>	<u>A213239</u>	<u>002</u>	Feb 08, 2022
<u>AB</u>	TARO PHARM INDS LTD	<u>500MG</u>	<u>A208800</u>	<u>001</u>	Feb 08, 2019

FERRIPROX

<u>AB</u>	+	CHIESI	<u>500MG</u>	<u>N021825</u>	<u>001</u>	Oct 14, 2011
<u>AB</u>	+		<u>1GM</u>	<u>N021825</u>	<u>002</u>	Jul 25, 2019
	+		1GM	N212269	001	May 19, 2020

PRESCRIPTION DRUG PRODUCT LIST

3-126 (of 474)

DEFEROXAMINE MESYLATE

INJECTABLE; INJECTION

DEFEROXAMINE MESYLATE

AP	FRESENIUS KABI USA	<u>500MG/VIAL</u>	<u>A078718</u>	<u>001</u>	Sep 15, 2009
AP		<u>2GM/VIAL</u>	<u>A078718</u>	<u>002</u>	Sep 15, 2009
AP	GLAND PHARMA LTD	<u>500MG/VIAL</u>	<u>A207384</u>	<u>001</u>	Sep 29, 2017
AP		<u>2GM/VIAL</u>	<u>A207384</u>	<u>002</u>	Sep 29, 2017
AP	HOSPIRA	<u>500MG/VIAL</u>	<u>A076019</u>	<u>001</u>	Mar 17, 2004
AP	!	<u>2GM/VIAL</u>	<u>A076019</u>	<u>002</u>	Mar 17, 2004
AP	WEST-WARD PHARMS INT	<u>500MG/VIAL</u>	<u>A078086</u>	<u>001</u>	May 30, 2007
AP		<u>2GM/VIAL</u>	<u>A078086</u>	<u>002</u>	May 30, 2007
<u>DESFERAL</u>					
AP	+! NOVARTIS	<u>500MG/VIAL</u>	<u>N016267</u>	<u>001</u>	

DEFIBROTIDE SODIUM

SOLUTION; INTRAVENOUS

DEFITELIO

+!	JAZZ PHARMS INC	200MG/2.5ML (80MG/ML)	N208114	001	Mar 30, 2016

DEFLAZACORT

SUSPENSION; ORAL

EMFLAZA

+!	PTC THERAP	22.75MG/ML	N208685	001	Feb 09, 2017

TABLET; ORAL

EMFLAZA

+	PTC THERAP	6MG	N208684	001	Feb 09, 2017
+		18MG	N208684	002	Feb 09, 2017
+		30MG	N208684	003	Feb 09, 2017
+!		36MG	N208684	004	Feb 09, 2017

DEGARELIX ACETATE

POWDER; SUBCUTANEOUS

FIRMAGON

+	FERRING	EQ 80MG BASE/VIAL	N022201	001	Dec 24, 2008
+!		EQ 120MG BASE/VIAL	N022201	002	Dec 24, 2008

DELAFLOXACIN MEGLUMINE

POWDER; INTRAVENOUS

BAXDELA

+!	MELINTA	EQ 300MG BASE/VIAL	N208611	001	Jun 19, 2017

TABLET; ORAL

BAXDELA

+!	MELINTA	EQ 450MG BASE	N208610	001	Jun 19, 2017

DEMECLOXYCLINE HYDROCHLORIDE

TABLET; ORAL

DEMECLOXYCLINE HYDROCHLORIDE

AB	AKORN	<u>150MG</u>	<u>A065389</u>	<u>001</u>	Dec 01, 2008
AB		<u>300MG</u>	<u>A065389</u>	<u>002</u>	Dec 01, 2008
AB	AMNEAL PHARM	<u>150MG</u>	<u>A065425</u>	<u>001</u>	Feb 27, 2008
AB	!	<u>300MG</u>	<u>A065425</u>	<u>002</u>	Feb 27, 2008
AB	EPIC PHARMA LLC	<u>150MG</u>	<u>A065447</u>	<u>001</u>	Aug 18, 2015
AB		<u>300MG</u>	<u>A065447</u>	<u>002</u>	Aug 18, 2015

DEOXYCHOLIC ACID

SOLUTION; SUBCUTANEOUS

DEOXYCHOLIC ACID

AP	SLAYBACK PHARMA LLC	<u>20MG/2ML (10MG/ML)</u>	<u>A212296</u>	<u>001</u>	Apr 02, 2021
AP	+! KYBELLA				
AP	+! KYTHERA BIOPHARMS	<u>20MG/2ML (10MG/ML)</u>	<u>N206333</u>	<u>001</u>	Apr 29, 2015

DESFLURANE

LIQUID; INHALATION

DESFLURANE

AN	SHANGHAI HENGRUI	<u>100%</u>	<u>A208234</u>	<u>001</u>	Feb 26, 2018
<u>SUPRANE</u>					
AN	+! BAXTER HLTHCARE	<u>100%</u>	<u>N020118</u>	<u>001</u>	Sep 18, 1992

DESIPRAMINE HYDROCHLORIDE

TABLET; ORAL

DESIPRAMINE HYDROCHLORIDE

AB	ACTAVIS TOTOWA	<u>10MG</u>	<u>A074430</u>	<u>001</u>	Feb 09, 1996
AB		<u>25MG</u>	<u>A071601</u>	<u>001</u>	Jun 05, 1987
AB		<u>50MG</u>	<u>A071588</u>	<u>001</u>	Jun 05, 1987
AB		<u>75MG</u>	<u>A071602</u>	<u>001</u>	Oct 05, 1987
AB		<u>100MG</u>	<u>A071766</u>	<u>001</u>	Oct 05, 1987

PRESCRIPTION DRUG PRODUCT LIST

3-127 (of 474)

DESIPRAMINE HYDROCHLORIDE

TABLET; ORAL

DESIPRAMINE HYDROCHLORIDE

<u>AB</u>		<u>150MG</u>	<u>A074430</u>	<u>002</u>	Feb 09, 1996
<u>AB</u>	ALEMBIC PHARMS	<u>10MG</u>	<u>A209785</u>	<u>001</u>	Jul 07, 2021
<u>AB</u>		<u>25MG</u>	<u>A209785</u>	<u>002</u>	Jul 07, 2021
<u>AB</u>		<u>50MG</u>	<u>A209785</u>	<u>003</u>	Jul 07, 2021
<u>AB</u>		<u>75MG</u>	<u>A209785</u>	<u>004</u>	Jul 07, 2021
<u>AB</u>		<u>100MG</u>	<u>A209785</u>	<u>005</u>	Jul 07, 2021
<u>AB</u>		<u>150MG</u>	<u>A209785</u>	<u>006</u>	Jul 07, 2021
<u>AB</u>	AMNEAL PHARMS CO	<u>10MG</u>	<u>A208105</u>	<u>001</u>	Mar 17, 2016
<u>AB</u>		<u>25MG</u>	<u>A208105</u>	<u>002</u>	Mar 17, 2016
<u>AB</u>		<u>50MG</u>	<u>A208105</u>	<u>003</u>	Mar 17, 2016
<u>AB</u>		<u>75MG</u>	<u>A208105</u>	<u>004</u>	Mar 17, 2016
<u>AB</u>		<u>100MG</u>	<u>A208105</u>	<u>005</u>	Mar 17, 2016
<u>AB</u>		<u>150MG</u>	<u>A208105</u>	<u>006</u>	Mar 17, 2016
<u>AB</u>	HERITAGE PHARMS	<u>10MG</u>	<u>A207433</u>	<u>001</u>	May 05, 2016
<u>AB</u>		<u>25MG</u>	<u>A207433</u>	<u>002</u>	May 05, 2016
<u>AB</u>		<u>50MG</u>	<u>A207433</u>	<u>003</u>	May 05, 2016
<u>AB</u>		<u>75MG</u>	<u>A207433</u>	<u>004</u>	May 05, 2016
<u>AB</u>		<u>100MG</u>	<u>A207433</u>	<u>005</u>	May 05, 2016
<u>AB</u>		<u>150MG</u>	<u>A207433</u>	<u>006</u>	May 05, 2016
<u>AB</u>	NOVAST LABS	<u>10MG</u>	<u>A204963</u>	<u>001</u>	Dec 26, 2017
<u>AB</u>		<u>25MG</u>	<u>A204963</u>	<u>002</u>	Dec 26, 2017
<u>AB</u>		<u>50MG</u>	<u>A204963</u>	<u>003</u>	Dec 26, 2017
<u>AB</u>		<u>75MG</u>	<u>A204963</u>	<u>004</u>	Dec 26, 2017
<u>AB</u>		<u>100MG</u>	<u>A204963</u>	<u>005</u>	Dec 26, 2017
<u>AB</u>		<u>150MG</u>	<u>A204963</u>	<u>006</u>	Dec 26, 2017
<u>AB</u>	SANDOZ	<u>10MG</u>	<u>A072099</u>	<u>001</u>	May 24, 1988
<u>AB</u>		<u>25MG</u>	<u>A072100</u>	<u>001</u>	May 24, 1988
<u>AB</u>		<u>50MG</u>	<u>A072101</u>	<u>001</u>	May 24, 1988
<u>AB</u>		<u>75MG</u>	<u>A072102</u>	<u>001</u>	Jun 20, 1988
<u>AB</u>		<u>100MG</u>	<u>A072103</u>	<u>001</u>	Jun 20, 1988
<u>AB</u>		<u>150MG</u>	<u>A072104</u>	<u>001</u>	Jun 20, 1988
<u>NORPRAMIN</u>					
<u>AB</u>	+	<u>10MG</u>	<u>N014399</u>	<u>007</u>	Feb 11, 1982
<u>AB</u>	+	<u>25MG</u>	<u>N014399</u>	<u>001</u>	
<u>AB</u>	+	<u>50MG</u>	<u>N014399</u>	<u>003</u>	
<u>AB</u>	+	<u>75MG</u>	<u>N014399</u>	<u>004</u>	
<u>AB</u>	+	<u>100MG</u>	<u>N014399</u>	<u>005</u>	
<u>AB</u>	+	<u>150MG</u>	<u>N014399</u>	<u>006</u>	

DESLORATADINE

TABLET; ORAL

CLARINEX

<u>AB</u>	+	ORGANON	<u>5MG</u>	<u>N021165</u>	<u>001</u>	Dec 21, 2001

DESLORATADINE

<u>AB</u>		BELCHER PHARMS	<u>5MG</u>	<u>A078355</u>	<u>001</u>	Apr 19, 2012
<u>AB</u>		DR REDDYS LABS LTD	<u>5MG</u>	<u>A078365</u>	<u>001</u>	Mar 08, 2011
<u>AB</u>		LUPIN PHARMS	<u>5MG</u>	<u>A078352</u>	<u>001</u>	Oct 25, 2010
<u>AB</u>		ORBION PHARMS	<u>5MG</u>	<u>A078357</u>	<u>001</u>	Feb 19, 2010

TABLET, ORALLY DISINTEGRATING; ORAL

DESLORATADINE

	REDDYS	2.5MG	A078367	001	Jul 12, 2010
!		5MG	A078367	002	Jul 12, 2010

DESLORATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

CLARINEX-D 12 HOUR

+	ORGANON LLC	2.5MG; 120MG	N021313	001	Feb 01, 2006

DESLORATADINE AND PSEUDOEPHEDRINE SULFATE 24 HOUR

!	DR REDDYS LABS LTD	5MG; 240MG	A078366	001	Apr 26, 2011

DESMOPRESSIN ACETATE

INJECTABLE; INJECTION

DDAVP

<u>AP</u>	+	FERRING PHARMS INC	<u>0.004MG/ML</u>	<u>N018938</u>	<u>001</u>	Mar 30, 1984

DESMOPRESSIN ACETATE

<u>AP</u>		AM REGENT	<u>0.004MG/ML</u>	<u>A091374</u>	<u>001</u>	Feb 14, 2019
<u>AP</u>		DR REDDYS	<u>0.004MG/ML</u>	<u>A215961</u>	<u>001</u>	Aug 19, 2022
<u>AP</u>		GLAND PHARMA LTD	<u>0.004MG/ML</u>	<u>A216922</u>	<u>001</u>	Nov 16, 2022
<u>AP</u>		SAGENT PHARMS INC	<u>0.004MG/ML</u>	<u>A204695</u>	<u>001</u>	Aug 22, 2017
<u>AP</u>			<u>0.004MG/ML</u>	<u>A204751</u>	<u>001</u>	Aug 22, 2017
<u>AP</u>		SUN PHARM INDS LTD	<u>0.004MG/ML</u>	<u>A091280</u>	<u>001</u>	Jan 25, 2013

PRESCRIPTION DRUG PRODUCT LIST

3-128 (of 474)

DESMOPRESSIN ACETATE

INJECTABLE; INJECTION

DESMOPRESSIN ACETATE

<u>AP</u>	TEVA PHARMS USA	<u>0.004MG/ML</u>	<u>A074888</u>	<u>001</u>	Oct 15, 1997
<u>AP</u>	UBI	<u>0.004MG/ML</u>	<u>A210218</u>	<u>001</u>	Feb 14, 2020
<u>AP</u>		<u>0.004MG/ML</u>	<u>A210223</u>	<u>001</u>	Sep 17, 2020

SPRAY, METERED; NASAL

DESMOPRESSIN ACETATE

<u>AB</u>	! BAUSCH	<u>0.01MG/SPRAY</u>	<u>A074830</u>	<u>001</u>	Jan 25, 1999
<u>DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION)</u>					
<u>AB</u>	APOTEX INC	<u>0.01MG/SPRAY</u>	<u>A076703</u>	<u>001</u>	Jan 27, 2005
<u>AB</u>	! SUN PHARM	<u>0.01MG/SPRAY</u>	<u>A078271</u>	<u>001</u>	Dec 23, 2013
<u>AB</u>	ZYDUS PHARMS	<u>0.01MG/SPRAY</u>	<u>A091345</u>	<u>001</u>	Oct 03, 2017

TABLET; ORAL

DDAVP

<u>AB</u>	+ FERRING PHARMS INC	<u>0.1MG</u>	<u>N019955</u>	<u>001</u>	Sep 06, 1995
<u>AB</u>	+!	<u>0.2MG</u>	<u>N019955</u>	<u>002</u>	Sep 06, 1995

DESMOPRESSIN ACETATE

<u>AB</u>	ABHAI LLC	<u>0.1MG</u>	<u>A210371</u>	<u>001</u>	Jan 28, 2019
<u>AB</u>		<u>0.2MG</u>	<u>A210371</u>	<u>002</u>	Jan 28, 2019
<u>AB</u>	ACTAVIS LABS FL INC	<u>0.1MG</u>	<u>A076470</u>	<u>001</u>	Jul 01, 2005
<u>AB</u>		<u>0.2MG</u>	<u>A076470</u>	<u>002</u>	Jul 01, 2005
<u>AB</u>	APOTEX INC	<u>0.1MG</u>	<u>A077414</u>	<u>001</u>	Mar 07, 2006
<u>AB</u>		<u>0.2MG</u>	<u>A077414</u>	<u>002</u>	Mar 07, 2006
<u>AB</u>	GLENMARK PHARMS LTD	<u>0.1MG</u>	<u>A201831</u>	<u>001</u>	May 28, 2015
<u>AB</u>		<u>0.2MG</u>	<u>A201831</u>	<u>002</u>	May 28, 2015
<u>AB</u>	HERITAGE PHARMA	<u>0.1MG</u>	<u>A207880</u>	<u>001</u>	May 26, 2017
<u>AB</u>		<u>0.2MG</u>	<u>A207880</u>	<u>002</u>	May 26, 2017
<u>AB</u>	NOVAST LABS	<u>0.1MG</u>	<u>A208357</u>	<u>001</u>	Jun 06, 2019
<u>AB</u>		<u>0.2MG</u>	<u>A208357</u>	<u>002</u>	Jun 06, 2019

TABLET; SUBLINGUAL

NOCDURNA

	+ FERRING PHARMS INC	0.0277MG	N022517	001	Jun 21, 2018
	+!	0.0553MG	N022517	002	Jun 21, 2018

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-28

BEKYREE

<u>AB</u>	LUPIN LTD	<u>0.15MG,N/A;0.02MG,0.01MG</u>	<u>A202226</u>	<u>001</u>	Aug 12, 2015

CYCLESSA

<u>AB</u>	+! ASPEN GLOBAL INC	<u>0.1MG,0.125MG,0.15MG;0.025MG,0.025MG,0.025MG</u>	<u>N021090</u>	<u>001</u>	Dec 20, 2000

DESOGESTREL AND ETHINYL ESTRADIOL

<u>AB</u>	! DURAMED PHARMS BARR	<u>0.15MG;0.03MG</u>	<u>A075256</u>	<u>002</u>	Aug 12, 1999
<u>AB</u>	MYLAN LABS LTD	<u>0.15MG,N/A;0.02MG,0.01MG</u>	<u>A202296</u>	<u>001</u>	Aug 30, 2013
<u>AB</u>	NAARI PTE LTD	<u>0.15MG,N/A;0.02MG,0.01MG</u>	<u>A209170</u>	<u>001</u>	Jun 05, 2017
<u>AB</u>	NOVAST LABS	<u>0.15MG;0.03MG</u>	<u>A091234</u>	<u>001</u>	Jul 12, 2013
<u>AB</u>	WATSON LABS	<u>0.15MG;0.03MG</u>	<u>A076915</u>	<u>001</u>	Jul 29, 2005

ENSKYCE

<u>AB</u>	LUPIN LTD	<u>0.15MG;0.03MG</u>	<u>A201887</u>	<u>001</u>	Mar 07, 2013

ISIBLOOM

<u>AB</u>	XIROMED	<u>0.15MG;0.03MG</u>	<u>A202789</u>	<u>001</u>	Aug 12, 2015

KALLIGA

<u>AB</u>	AUROBINDO PHARMA	<u>0.15MG;0.03MG</u>	<u>A207081</u>	<u>001</u>	May 17, 2017

KARIVA

<u>AB</u>	! BARR	<u>0.15MG,N/A;0.02MG,0.01MG</u>	<u>A075863</u>	<u>001</u>	Apr 05, 2002

KIMIDESS

<u>AB</u>	VINTAGE PHARMS	<u>0.15MG,N/A;0.02MG,0.01MG</u>	<u>A076681</u>	<u>001</u>	Apr 30, 2015

PIMTREA

<u>AB</u>	NOVAST LABS	<u>0.15MG,N/A;0.02MG,0.01MG</u>	<u>A091247</u>	<u>001</u>	Aug 01, 2013

SIMLIYA

<u>AB</u>	AUROBINDO PHARMA	<u>0.15MG,N/A;0.02MG,0.01MG</u>	<u>A206853</u>	<u>001</u>	Mar 22, 2017

VELIVET

<u>AB</u>	DURAMED PHARMS BARR	<u>0.1MG,0.125MG,0.15MG;0.025MG,0.025MG,0.025MG</u>	<u>A076455</u>	<u>001</u>	Feb 24, 2004

VIORELE

<u>AB</u>	GLENMARK GENERICS	<u>0.15MG,N/A;0.02MG,0.01MG</u>	<u>A091346</u>	<u>001</u>	Apr 02, 2012

VOLNEA

<u>AB</u>	XIROMED	<u>0.15MG,N/A;0.02MG,0.01MG</u>	<u>A202689</u>	<u>001</u>	Sep 09, 2016

PRESCRIPTION DRUG PRODUCT LIST

3-129 (of 474)

DESONIDE

AEROSOL, FOAM; TOPICAL

VERDESO

+! ALMIRALL

0.05%

N021978 001 Sep 19, 2006

CREAM; TOPICAL

DESONIDEAB ALEOR 0.05%A214396 001 Dec 08, 2022

DERMACEUTICALS

AB CADILA 0.05%A210198 001 Nov 20, 2019AB COSETTE 0.05%A074027 001 Sep 28, 1992AB GLENMARK PHARMS 0.05%A209729 001 Jul 24, 2017AB +! PADAGIS US 0.05%N017010 001AB TARO 0.05%A073548 001 Jun 30, 1992DESOWENAB GALDERMA LABS LP 0.05%N019048 001 Dec 14, 1984

GEL; TOPICAL

DESONIDE

! CINTEX SVCS

0.05%

A202470 001 May 11, 2020

LOTION; TOPICAL

DESONIDEAB ALEOR 0.05%A213632 001 Aug 24, 2020

DERMACEUTICALS

AB FOUGERA PHARMS 0.05%A075860 001 Mar 19, 2002AB GLENMARK PHARMS 0.05%A209494 001 Sep 26, 2017AB PAI HOLDINGS PHARM 0.05%A207855 001 Sep 28, 2017AB TARO 0.05%A202161 001 Oct 31, 2014DESOWENAB ! GALDERMA LABS LP 0.05%A072354 001 Jan 24, 1992

OINTMENT; TOPICAL

DESONIDEAB AKORN 0.05%A208836 001 Mar 27, 2017AB ALEOR 0.05%A212473 001 Oct 23, 2019

DERMACEUTICALS

AB ENCUBE ETHICALS 0.05%A210998 001 Jan 30, 2019AB FOUGERA PHARMS 0.05%A075751 001 Mar 12, 2001AB GLENMARK PHARMS LTD 0.05%A209996 001 Sep 15, 2017AB +! PADAGIS US 0.05%N017426 001AB PAI HOLDINGS PHARM 0.05%A212002 001 Mar 12, 2019AB TARO 0.05%A074254 001 Aug 03, 1994DESOWENAB GALDERMA LABS LP 0.05%A071425 001 Jun 15, 1988DESOXIMETASONE

CREAM; TOPICAL

DESOXIMETASONEAB ACTAVIS MID 0.25%A205082 001 Sep 04, 2015

ATLANTIC

AB CADILA 0.25%A205620 001 Sep 28, 2018AB COSETTE 0.25%A209595 001 Mar 04, 2020AB FOUGERA PHARMS 0.25%A078369 001 Jun 29, 2010AB LUPIN 0.05%A208163 001 Jan 10, 2017AB 0.25%A208164 001 Jan 09, 2017AB PADAGIS ISRAEL 0.25%A076510 001 Jul 01, 2003AB RISING 0.05%A210980 001 Dec 21, 2018AB 0.25%A205594 001 Jul 02, 2018TOPICORTAB ! TARO PHARM INDS LTD 0.05%A073210 001 Nov 30, 1990AB ! 0.25%A073193 001 Nov 30, 1990

GEL; TOPICAL

DESOXIMETASONEAB AKORN 0.05%A090727 001 Mar 10, 2011AB PADAGIS US 0.05%A077552 001 Jan 09, 2006AB RISING 0.05%A204675 001 Aug 12, 2016TOPICORTAB ! TARO PHARM INDS LTD 0.05%A074904 001 Jul 14, 1998

OINTMENT; TOPICAL

DESOXIMETASONEAB ACTAVIS MID 0.25%A204965 001 Nov 07, 2016

ATLANTIC

AB AKORN 0.25%A201005 001 Apr 24, 2014AB CADILA 0.25%A205206 001 Sep 19, 2017AB COSETTE 0.25%A206740 001 Dec 23, 2016AB FOUGERA PHARMS 0.25%A078657 001 Sep 28, 2012AB ! GLENMARK GENERICS 0.25%A202838 001 Sep 20, 2013

PRESCRIPTION DRUG PRODUCT LIST

3-130 (of 474)

DESOXIMETASONE

OINTMENT; TOPICAL

DESOXIMETASONE

AB	LUPIN	<u>0.05%</u>	<u>A208044</u>	<u>001</u>	Dec 12, 2016
AB		<u>0.25%</u>	<u>A208104</u>	<u>001</u>	Dec 01, 2016
AB	NOVEL LABS INC	<u>0.25%</u>	<u>A206792</u>	<u>001</u>	May 10, 2016
AB	PADAGIS ISRAEL	<u>0.25%</u>	<u>A077770</u>	<u>001</u>	Apr 20, 2015
AB	PAI HOLDINGS PHARM	<u>0.25%</u>	<u>A208101</u>	<u>001</u>	Feb 25, 2016
AB	RISING	<u>0.25%</u>	<u>A204272</u>	<u>001</u>	Nov 30, 2016
AB	THE J MOLNER	<u>0.05%</u>	<u>A209973</u>	<u>001</u>	Oct 23, 2018

TOPICORT

AB	+ !	TARO PHARM INDS LTD	<u>0.05%</u>	<u>N018594</u>	<u>001</u>	Jan 17, 1985

SPRAY; TOPICAL

DESOXIMETASONE

AT	LUPIN	<u>0.25%</u>	<u>A208124</u>	<u>001</u>	Mar 16, 2018
AT	PADAGIS ISRAEL	<u>0.25%</u>	<u>A206441</u>	<u>001</u>	Jan 20, 2017

TOPICORT

AT	+ !	TARO PHARMS	<u>0.25%</u>	<u>N204141</u>	<u>001</u>	Apr 11, 2013

DESVENLAFAXINE

TABLET, EXTENDED RELEASE; ORAL

DESVENLAFAXINE

+	ALEMBIC PHARMS LTD	50MG	N204150	001	Mar 04, 2013
+ !		100MG	N204150	002	Mar 04, 2013

DESVENLAFAXINE SUCCINATE

TABLET, EXTENDED RELEASE; ORAL

DESVENLAFAXINE SUCCINATE

AB	ACTAVIS LABS FL	EQ 25MG BASE	A204065	001	Jul 29, 2016
AB		EQ 50MG BASE	A204065	002	Jul 29, 2016
AB		EQ 100MG BASE	A204065	003	Jul 29, 2016
AB	ALEMBIC PHARMS	EQ 25MG BASE	A204003	003	Sep 14, 2018
AB		EQ 50MG BASE	A204003	001	Jun 29, 2015
AB		EQ 100MG BASE	A204003	002	Jun 29, 2015
AB	HIKMA	EQ 25MG BASE	A204082	002	Aug 28, 2017
AB		EQ 50MG BASE	A204082	001	Feb 16, 2016
AB		EQ 100MG BASE	A204083	001	Feb 16, 2016
AB	INTELLIPHARMACEUTIC S	EQ 50MG BASE	A204805	001	May 07, 2019
AB		EQ 100MG BASE	A204805	002	May 07, 2019
AB	LUPIN LTD	EQ 25MG BASE	A204172	003	Apr 13, 2022
AB		EQ 50MG BASE	A204172	001	Jun 29, 2015
AB		EQ 100MG BASE	A204172	002	Jun 29, 2015
AB	RUBICON	EQ 50MG BASE	A204028	001	Jun 29, 2015
AB		EQ 100MG BASE	A204028	002	Jun 29, 2015
AB	YICHANG HUMANWELL	EQ 25MG BASE	A210014	003	Oct 13, 2020
AB		EQ 50MG BASE	A210014	001	Oct 01, 2018
AB		EQ 100MG BASE	A210014	002	Oct 01, 2018
AB	ZYDUS PHARMS	EQ 25MG BASE	A204020	003	Nov 30, 2022
AB		EQ 50MG BASE	A204020	001	Oct 11, 2017
AB		EQ 100MG BASE	A204020	002	Oct 11, 2017
PRISTIQ					
AB	+ PF PRISM CV	EQ 25MG BASE	N021992	003	Aug 20, 2014
AB	+	EQ 50MG BASE	N021992	001	Feb 29, 2008
AB	+	EQ 100MG BASE	N021992	002	Feb 29, 2008

DEUCRAVACITINIB

TABLET; ORAL

SOTYKTU

+ !	BRISTOL	6MG	N214958	001	Sep 09, 2022

DEUTETRABENAZINE

TABLET; ORAL

AUSTEDO

+	TEVA BRANDED PHARM	6MG	N208082	001	Apr 03, 2017
+		9MG	N208082	002	Apr 03, 2017
+ !		12MG	N208082	003	Apr 03, 2017

DEXAMETHASONE

CONCENTRATE; ORAL

DEXAMETHASONE INTENSOL

!	HIKMA	1MG/ML	A088252	001	Sep 01, 1983

ELIXIR; ORAL

DEXAMETHASONE

AA	!	ANIMA	<u>0.5MG/5ML</u>	<u>A084754</u>	<u>001</u>

PRESCRIPTION DRUG PRODUCT LIST

3-131 (of 474)

DEXAMETHASONE

ELIXIR; ORAL

DEXAMETHASONE

AA	CHARTWELL MOLECULAR	<u>0.5MG/5ML</u>	<u>A091188</u>	<u>001</u>	May 11, 2011
AA	LYNE	<u>0.5MG/5ML</u>	<u>A090891</u>	<u>001</u>	Jul 12, 2011
	IMPLANT; INTRAVITREAL				
	OZURDEX				
	+! ALLERGAN	0.7MG	N022315	001	Jun 17, 2009
	INSERT; OPHTHALMIC				
	DEXTENZA				
	+! OCULAR THERAPEUTIX	0.4MG	N208742	001	Nov 30, 2018
	SOLUTION; ORAL				
	DEXAMETHASONE				
	+! HIKMA	0.5MG/5ML	A088248	001	Sep 01, 1983
	SUSPENSION; INTRAOCULAR				
	DEXYCU KIT				
	+! EYEPOINT PHARMS	9%	N208912	001	Feb 09, 2018
	SUSPENSION/DROPS; OPHTHALMIC				
	MAXIDEX				
	+! NOVARTIS	0.1%	N013422	001	

TABLET; ORAL

DEXAMETHASONE

AB	AMNEAL	<u>2MG</u>	<u>A216295</u>	<u>001</u>	Sep 08, 2022
AB		<u>4MG</u>	<u>A215106</u>	<u>001</u>	Oct 14, 2021
AB		<u>6MG</u>	<u>A215106</u>	<u>002</u>	Oct 14, 2021
AB	+ HIKMA	<u>1.5MG</u>	<u>A084610</u>	<u>001</u>	
AB	+!	<u>2MG</u>	<u>A087916</u>	<u>001</u>	Aug 26, 1982
AB	+	<u>4MG</u>	<u>A084612</u>	<u>001</u>	
AB	+!	<u>6MG</u>	<u>A088316</u>	<u>001</u>	Sep 15, 1983
AB	LARKEN LABS INC	<u>1.5MG</u>	<u>A201270</u>	<u>001</u>	Jul 17, 2017
AB	NOVITIUM PHARMA	<u>1.5MG</u>	<u>A215604</u>	<u>001</u>	Aug 08, 2022
AB		<u>4MG</u>	<u>A215604</u>	<u>002</u>	Aug 08, 2022
AB		<u>6MG</u>	<u>A215604</u>	<u>003</u>	Aug 08, 2022
AB	PRASCO	<u>4MG</u>	<u>A080399</u>	<u>002</u>	Apr 20, 2022
BP	ALVOGEN	0.5MG	A088481	002	Apr 28, 1983
BP		0.75MG	A088481	003	Apr 28, 1983
BP		4MG	A088481	004	Apr 28, 1983
BP		6MG	A088481	001	Nov 28, 1983
BP	+ HIKMA	0.5MG	A084611	001	
BP	+	0.75MG	A084613	001	
BP	+!	1MG	A088306	001	Sep 15, 1983
BP	XSPIRE PHARMA	1.5MG	A088237	001	Apr 28, 1983
	HEMADY				
	+! DEXCEL	20MG	N211379	001	Oct 03, 2019

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

DEXAMETHASONE SODIUM PHOSPHATE

AP	AMNEAL	<u>EQ 4MG PHOSPHATE/ML</u>	<u>A208689</u>	<u>001</u>	Aug 22, 2018
AP	EUGIA PHARMA	<u>EQ 4MG PHOSPHATE/ML</u>	<u>A206781</u>	<u>001</u>	Dec 01, 2015
AP		<u>EQ 10MG PHOSPHATE/ML</u>	<u>A210966</u>	<u>001</u>	Jun 05, 2020
AP		<u>EQ 10MG PHOSPHATE/ML</u>	<u>A210967</u>	<u>001</u>	Jun 07, 2019
AP	+! FRESENIUS KABI USA	<u>EQ 4MG PHOSPHATE/ML</u>	<u>A084916</u>	<u>001</u>	
AP		<u>EQ 4MG PHOSPHATE/ML</u>	<u>A203129</u>	<u>001</u>	Sep 30, 2015
AP	!	<u>EQ 10MG PHOSPHATE/ML</u>	<u>A040572</u>	<u>001</u>	Apr 22, 2005
AP		<u>EQ 10MG PHOSPHATE/ML</u>	<u>A209192</u>	<u>001</u>	Jul 06, 2018
AP	GLAND PHARMA LTD	<u>EQ 4MG PHOSPHATE/ML</u>	<u>A215654</u>	<u>001</u>	Aug 04, 2021
AP	MYLAN LABS LTD	<u>EQ 4MG PHOSPHATE/ML</u>	<u>A040803</u>	<u>001</u>	Aug 29, 2008
AP		<u>EQ 10MG PHOSPHATE/ML</u>	<u>A040802</u>	<u>001</u>	Aug 29, 2008
AP	SOMERSET	<u>EQ 4MG PHOSPHATE/ML</u>	<u>A207521</u>	<u>001</u>	Jun 08, 2018
AP	SOMERSET THERAPS	<u>EQ 10MG PHOSPHATE/ML</u>	<u>A211036</u>	<u>001</u>	May 10, 2019
AP	LLC				
AP	WEST-WARD PHARMS	<u>EQ 4MG PHOSPHATE/ML</u>	<u>A084282</u>	<u>001</u>	
AP	INT				
AP	!	<u>EQ 10MG PHOSPHATE/ML</u>	<u>A087702</u>	<u>001</u>	Sep 07, 1982

DEXAMETHASONE SODIUM PHOSPHATE PRESERVATIVE FREE

AP	AMNEAL	<u>EQ 10MG PHOSPHATE/ML</u>	<u>A208690</u>	<u>001</u>	Aug 22, 2018
AP	! FRESENIUS KABI USA	<u>EQ 10MG PHOSPHATE/ML</u>	<u>A040491</u>	<u>001</u>	Apr 11, 2003
AP	SOMERSET THERAPS	<u>EQ 10MG PHOSPHATE/ML</u>	<u>A207442</u>	<u>001</u>	Apr 19, 2018
	LLC				
	SOLUTION/DROPS; OPHTHALMIC, OTIC				
	DEXAMETHASONE SODIUM PHOSPHATE				
	! BAUSCH AND LOMB	EQ 0.1% PHOSPHATE	A040069	001	Jul 26, 1996

PRESCRIPTION DRUG PRODUCT LIST

3-132 (of 474)

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

MAXITROL

AT	+!	NOVARTIS	<u>0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM</u>	<u>N050065</u>	<u>002</u>	

NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE

AT		BAUSCH AND LOMB	<u>0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM</u>	<u>A064063</u>	<u>001</u>	Jul 25, 1994

AT		PADAGIS US	<u>0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM</u>	<u>A062938</u>	<u>001</u>	Jul 31, 1989

SUSPENSION/DROPS;OPHTHALMIC

DEXASPORIN

AT		BAUSCH AND LOMB	<u>0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML</u>	<u>A064135</u>	<u>001</u>	Sep 13, 1995

MAXITROL

AT	+!	IMPRIMIS PHARMS USA	<u>0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML</u>	<u>N050023</u>	<u>002</u>	

AT		SANDOZ INC	<u>0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML</u>	<u>A062341</u>	<u>001</u>	May 22, 1984

DEXAMETHASONE; TOBRAMYCIN

OINTMENT;OPHTHALMIC

TOBRADEX

+!	NOVARTIS	0.1%;0.3%	N050616	001	Sep 28, 1988

SUSPENSION/DROPS;OPHTHALMIC

TOBRADEX

AB	+!	NOVARTIS	<u>0.1%;0.3%</u>	<u>N050592</u>	<u>001</u>	Aug 18, 1988

TOBRAMYCIN AND DEXAMETHASONE

AB		AMNEAL	<u>0.1%;0.3%</u>	<u>A212991</u>	<u>001</u>	Jul 15, 2021

AB		BAUSCH AND LOMB	<u>0.1%;0.3%</u>	<u>A064134</u>	<u>001</u>	Oct 27, 1999

AB		PADAGIS US	<u>0.1%;0.3%</u>	<u>A212715</u>	<u>001</u>	Feb 11, 2022

TOBRADEX ST

+!	EYEVANCE	0.05%;0.3%	N050818	001	Feb 13, 2009

DEXCHLORPHENIRAMINE MALEATE

SYRUP;ORAL

DEXCHLORPHENIRAMINE MALEATE

AA	+!	PAI HOLDINGS PHARM	<u>2MG/5ML</u>	<u>A088251</u>	<u>001</u>	Mar 23, 1984

POLMON

AA		CAPELLON PHARMS LLC	<u>2MG/5ML</u>	<u>A202520</u>	<u>001</u>	Jul 16, 2018

DEXLANSOPRAZOLE

CAPSULE, DELAYED RELEASE;ORAL

DEXILANT

AB	+	TAKEDA PHARMS USA	<u>30MG</u>	<u>N022287</u>	<u>001</u>	Jan 30, 2009

AB	+!		<u>60MG</u>	<u>N022287</u>	<u>002</u>	Jan 30, 2009

DEXLANSOPRAZOLE

AB		PAR PHARM INC	<u>30MG</u>	<u>A202294</u>	<u>002</u>	Jun 16, 2022

AB			<u>60MG</u>	<u>A202294</u>	<u>001</u>	Apr 19, 2017

AB		TWI PHARMS	<u>30MG</u>	<u>A202666</u>	<u>001</u>	Sep 16, 2022

AB			<u>60MG</u>	<u>A202666</u>	<u>002</u>	Sep 16, 2022

DEXMEDETOMIDINE HYDROCHLORIDE

FILM;BUCCAL, SUBLINGUAL

IGALMI

+!	BIOXCEL	EQ 0.12MG BASE	N215390	001	Apr 05, 2022

+!		EQ 0.18MG BASE	N215390	002	Apr 05, 2022

INJECTABLE;INJECTION

DEXMEDETOMIDINE HYDROCHLORIDE

AP		ACCORD HLTHCARE	<u>EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)</u>	<u>A204023</u>	<u>001</u>	Feb 09, 2016

AP		ACTAVIS INC	<u>EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)</u>	<u>A204686</u>	<u>001</u>	Oct 17, 2016

AP		AKORN	<u>EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)</u>	<u>A202585</u>	<u>001</u>	Nov 24, 2014

AP		AMNEAL PHARMS CO	<u>EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)</u>	<u>A207551</u>	<u>001</u>	May 20, 2020

AP			<u>EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)</u>	<u>A207551</u>	<u>002</u>	May 20, 2020

AP		BAXTER HLTHCARE CORP	<u>EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)</u>	<u>A208532</u>	<u>001</u>	Aug 21, 2018

AP			<u>EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)</u>	<u>A208532</u>	<u>002</u>	Aug 21, 2018

AP		EUGIA PHARMA	<u>EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)</u>	<u>A205867</u>	<u>001</u>	Mar 17, 2016

AP			<u>EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)</u>	<u>A210321</u>	<u>001</u>	Dec 07, 2020

AP			<u>EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)</u>	<u>A210321</u>	<u>002</u>	Dec 07, 2020

AP		FRESENIUS KABI USA	<u>EQ 80MCG BASE/20ML (EQ 4MCG BASE/ML)</u>	<u>A208129</u>	<u>001</u>	Nov 29, 2018

AP			<u>EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)</u>	<u>A201072</u>	<u>001</u>	Sep 18, 2015

AP			<u>EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)</u>	<u>A208129</u>	<u>002</u>	Nov 29, 2018

AP			<u>EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)</u>	<u>A208129</u>	<u>003</u>	Nov 29, 2018

AP		GLAND	<u>EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)</u>	<u>A202126</u>	<u>001</u>	Aug 20, 2015

AP		GLAND PHARMA LTD	<u>EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)</u>	<u>A209307</u>	<u>001</u>	Jun 03, 2020

AP			<u>EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)</u>	<u>A209307</u>	<u>002</u>	Jun 03, 2020

AP		HENGRI PHARMA	<u>EQ 80MCG BASE/20ML (EQ 4MCG BASE/ML)</u>	<u>A209065</u>	<u>002</u>	Jun 12, 2020

AP			<u>EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)</u>	<u>A209065</u>	<u>001</u>	Sep 19, 2017

AP			<u>EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)</u>	<u>A209065</u>	<u>003</u>	Jun 12, 2020

AP			<u>EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)</u>	<u>A209065</u>	<u>004</u>	Jun 12, 2020

PRESCRIPTION DRUG PRODUCT LIST

3-133 (of 474)

DEXMEDETOMIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

DEXMEDETOMIDINE HYDROCHLORIDE

AP	HIKMA	<u>EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)</u>	<u>A205046</u>	<u>001</u>	Apr 26, 2017
AP		<u>EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)</u>	<u>A206407</u>	<u>001</u>	Jan 30, 2020
AP		<u>EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)</u>	<u>A206407</u>	<u>002</u>	Jan 30, 2020
AP	MEITHEAL	<u>EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)</u>	<u>A204843</u>	<u>001</u>	Jan 18, 2019
AP	MYLAN INSTITUTIONAL	<u>EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)</u>	<u>A202881</u>	<u>001</u>	Aug 18, 2014
AP	MYLAN LABS LTD	<u>EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)</u>	<u>A212571</u>	<u>001</u>	Aug 27, 2020
AP		<u>EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)</u>	<u>A212571</u>	<u>002</u>	Aug 27, 2020
AP	PAR STERILE PRODUCTS	<u>EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)</u>	<u>A203972</u>	<u>001</u>	Aug 18, 2014
AP		<u>EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)</u>	<u>A208266</u>	<u>001</u>	Sep 15, 2020
AP		<u>EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)</u>	<u>A208266</u>	<u>002</u>	Sep 15, 2020
AP	SANDOZ INC	<u>EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)</u>	<u>A091465</u>	<u>001</u>	Jun 14, 2016
AP	SLAYBACK PHARMA LLC	<u>EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)</u>	<u>A212791</u>	<u>001</u>	Dec 04, 2019
AP		<u>EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)</u>	<u>A212791</u>	<u>002</u>	Dec 04, 2019
AP	TAGI	<u>EQ 80MCG BASE/20ML (EQ 4MCG BASE/ML)</u>	<u>A212857</u>	<u>001</u>	Nov 23, 2020
AP		<u>EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)</u>	<u>A212857</u>	<u>002</u>	Nov 23, 2020
AP		<u>EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)</u>	<u>A212857</u>	<u>003</u>	Nov 23, 2020
AP	TEVA PHARMS USA	<u>EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)</u>	<u>A205272</u>	<u>001</u>	Nov 28, 2017
AP	ZYDUS PHARMS	<u>EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)</u>	<u>A206798</u>	<u>001</u>	Feb 27, 2018

PRECEDEX

AP	+	HOSPIRA	<u>EQ 80MCG BASE/20ML (EQ 4MCG BASE/ML)</u>	<u>N021038</u>	<u>004</u>	Nov 14, 2014
AP	+		<u>EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)</u>	<u>N021038</u>	<u>001</u>	Dec 17, 1999
AP	+		<u>EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)</u>	<u>N021038</u>	<u>002</u>	Mar 13, 2013
AP	+		<u>EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)</u>	<u>N021038</u>	<u>003</u>	Mar 13, 2013
	+		EQ 1MG BASE/250ML (EQ 4MCG BASE/ML)	N021038	005	Jan 31, 2020

SOLUTION; INTRAVENOUS

DEXMEDETOMIDINE HYDROCHLORIDE

+	!	HQ SPCLT PHARMA	EQ 1MG BASE/10ML (EQ 100MCG BASE/ML)	N206628	002	Oct 21, 2015
+			EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML)	N206628	003	Jun 22, 2018
+			EQ 400MCG BASE/4ML (EQ 100MCG BASE/ML)	N206628	001	Oct 21, 2015
+			EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML)	N206628	004	Jun 22, 2018

DEXMETHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

DEXMETHYLPHENIDATE HYDROCHLORIDE

AB	ADARE PHARMS INC	<u>5MG</u>	<u>A210279</u>	<u>001</u>	Oct 09, 2018
AB		<u>10MG</u>	<u>A210279</u>	<u>002</u>	Oct 09, 2018
AB		<u>15MG</u>	<u>A210279</u>	<u>003</u>	Oct 09, 2018
AB		<u>20MG</u>	<u>A210279</u>	<u>004</u>	Oct 09, 2018
AB		<u>25MG</u>	<u>A210279</u>	<u>005</u>	Oct 09, 2018
AB		<u>30MG</u>	<u>A210279</u>	<u>006</u>	Oct 09, 2018
AB		<u>35MG</u>	<u>A210279</u>	<u>007</u>	Oct 09, 2018
AB		<u>40MG</u>	<u>A210279</u>	<u>008</u>	Oct 09, 2018
AB	ASCENT PHARMS INC	<u>5MG</u>	<u>A215523</u>	<u>001</u>	Dec 08, 2021
AB		<u>10MG</u>	<u>A215523</u>	<u>002</u>	Dec 08, 2021
AB		<u>15MG</u>	<u>A215523</u>	<u>003</u>	Dec 08, 2021
AB		<u>20MG</u>	<u>A215523</u>	<u>004</u>	Dec 08, 2021
AB		<u>25MG</u>	<u>A215523</u>	<u>005</u>	Dec 08, 2021
AB		<u>30MG</u>	<u>A215523</u>	<u>006</u>	Dec 08, 2021
AB		<u>35MG</u>	<u>A215523</u>	<u>007</u>	Dec 08, 2021
AB		<u>40MG</u>	<u>A215523</u>	<u>008</u>	Dec 08, 2021
AB	GRANULES	<u>5MG</u>	<u>A213813</u>	<u>001</u>	Sep 09, 2020
AB		<u>10MG</u>	<u>A213813</u>	<u>002</u>	Sep 09, 2020
AB		<u>15MG</u>	<u>A213813</u>	<u>003</u>	Sep 09, 2020
AB		<u>20MG</u>	<u>A213813</u>	<u>004</u>	Sep 09, 2020
AB		<u>25MG</u>	<u>A213813</u>	<u>005</u>	Sep 09, 2020
AB		<u>30MG</u>	<u>A213813</u>	<u>006</u>	Sep 09, 2020
AB		<u>35MG</u>	<u>A213813</u>	<u>007</u>	Sep 09, 2020
AB		<u>40MG</u>	<u>A213813</u>	<u>008</u>	Sep 09, 2020
AB	IMPAX LABS INC	<u>5MG</u>	<u>A079108</u>	<u>001</u>	Aug 05, 2015
AB		<u>10MG</u>	<u>A079108</u>	<u>002</u>	Aug 05, 2015
AB		<u>15MG</u>	<u>A079108</u>	<u>003</u>	May 19, 2014
AB		<u>20MG</u>	<u>A079108</u>	<u>004</u>	Dec 21, 2015
AB		<u>25MG</u>	<u>A203614</u>	<u>001</u>	Jul 05, 2017
AB		<u>30MG</u>	<u>A079108</u>	<u>005</u>	Nov 21, 2013
AB		<u>35MG</u>	<u>A203614</u>	<u>002</u>	Jul 05, 2017
AB	INTELLIPHARMACEUTICS	<u>5MG</u>	<u>A078992</u>	<u>001</u>	Nov 23, 2021
AB		<u>10MG</u>	<u>A078992</u>	<u>002</u>	Nov 23, 2021
AB		<u>15MG</u>	<u>A078992</u>	<u>003</u>	Nov 18, 2013

PRESCRIPTION DRUG PRODUCT LIST

3-134 (of 474)

DEXMETHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

DEXMETHYLPHENIDATE HYDROCHLORIDE

<u>AB</u>		<u>30MG</u>	<u>A078992</u>	<u>004</u>	Nov 18, 2013
<u>AB</u>		<u>20MG</u>	<u>A078992</u>	<u>005</u>	Nov 23, 2021
<u>AB</u>		<u>40MG</u>	<u>A078992</u>	<u>006</u>	Nov 23, 2021
<u>AB</u>	PAR PHARM INC	<u>5MG</u>	<u>A202842</u>	<u>001</u>	Nov 30, 2016
<u>AB</u>		<u>10MG</u>	<u>A202842</u>	<u>002</u>	Nov 30, 2016
<u>AB</u>		<u>15MG</u>	<u>A202842</u>	<u>003</u>	Nov 30, 2016
<u>AB</u>		<u>20MG</u>	<u>A202842</u>	<u>004</u>	Nov 30, 2016
<u>AB</u>		<u>25MG</u>	<u>A202842</u>	<u>005</u>	Nov 30, 2016
<u>AB</u>		<u>30MG</u>	<u>A202842</u>	<u>006</u>	Nov 30, 2016
<u>AB</u>		<u>35MG</u>	<u>A202842</u>	<u>007</u>	Nov 30, 2016
<u>AB</u>		<u>40MG</u>	<u>A202842</u>	<u>008</u>	Nov 30, 2016
<u>AB</u>	SUN PHARM INDS INC	<u>5MG</u>	<u>A206734</u>	<u>001</u>	Nov 05, 2021
<u>AB</u>		<u>10MG</u>	<u>A206734</u>	<u>002</u>	Nov 05, 2021
<u>AB</u>		<u>15MG</u>	<u>A206734</u>	<u>003</u>	Nov 05, 2021
<u>AB</u>		<u>20MG</u>	<u>A206734</u>	<u>004</u>	Nov 05, 2021
<u>AB</u>		<u>25MG</u>	<u>A206734</u>	<u>005</u>	Nov 05, 2021
<u>AB</u>		<u>30MG</u>	<u>A206734</u>	<u>006</u>	Nov 05, 2021
<u>AB</u>		<u>35MG</u>	<u>A206734</u>	<u>007</u>	Nov 05, 2021
<u>AB</u>		<u>40MG</u>	<u>A206734</u>	<u>008</u>	Nov 05, 2021
<u>AB</u>	TEVA PHARMS USA	<u>5MG</u>	<u>A078908</u>	<u>001</u>	Nov 19, 2013
<u>AB</u>		<u>10MG</u>	<u>A078908</u>	<u>002</u>	Nov 19, 2013
<u>AB</u>		<u>15MG</u>	<u>A078908</u>	<u>004</u>	May 19, 2014
<u>AB</u>		<u>20MG</u>	<u>A078908</u>	<u>003</u>	Nov 19, 2013
<u>AB</u>		<u>25MG</u>	<u>A202731</u>	<u>001</u>	Jul 05, 2017
<u>AB</u>		<u>30MG</u>	<u>A202731</u>	<u>003</u>	May 19, 2014
<u>AB</u>		<u>35MG</u>	<u>A202731</u>	<u>004</u>	Jul 05, 2017
<u>AB</u>		<u>40MG</u>	<u>A202731</u>	<u>002</u>	Nov 19, 2013

FOCALIN XR

<u>AB</u>	+	NOVARTIS	<u>5MG</u>	<u>N021802</u>	<u>001</u>	May 26, 2005
<u>AB</u>	+		<u>10MG</u>	<u>N021802</u>	<u>002</u>	May 26, 2005
<u>AB</u>	+		<u>15MG</u>	<u>N021802</u>	<u>004</u>	Aug 01, 2006
<u>AB</u>	+		<u>20MG</u>	<u>N021802</u>	<u>003</u>	May 26, 2005
<u>AB</u>	+		<u>25MG</u>	<u>N021802</u>	<u>008</u>	Apr 21, 2011
<u>AB</u>	+		<u>30MG</u>	<u>N021802</u>	<u>005</u>	Oct 23, 2009
<u>AB</u>	+		<u>35MG</u>	<u>N021802</u>	<u>007</u>	Apr 21, 2011
<u>AB</u>	+		<u>40MG</u>	<u>N021802</u>	<u>006</u>	Aug 11, 2010

TABLET;ORAL

DEXMETHYLPHENIDATE HYDROCHLORIDE

<u>AB</u>	ABHAI INC	<u>2.5MG</u>	<u>A206931</u>	<u>001</u>	Dec 04, 2015
<u>AB</u>		<u>5MG</u>	<u>A206931</u>	<u>002</u>	Dec 04, 2015
<u>AB</u>		<u>10MG</u>	<u>A206931</u>	<u>003</u>	Dec 04, 2015
<u>AB</u>	ALKEM LABS LTD	<u>2.5MG</u>	<u>A212631</u>	<u>001</u>	Jul 19, 2019
<u>AB</u>		<u>5MG</u>	<u>A212631</u>	<u>002</u>	Jul 19, 2019
<u>AB</u>		<u>10MG</u>	<u>A212631</u>	<u>003</u>	Jul 19, 2019
<u>AB</u>	CEDIPROF INC	<u>5MG</u>	<u>A209211</u>	<u>001</u>	Sep 19, 2018
<u>AB</u>		<u>10MG</u>	<u>A209211</u>	<u>002</u>	Sep 19, 2018
<u>AB</u>	NOVEL LABS INC	<u>2.5MG</u>	<u>A204534</u>	<u>001</u>	Dec 04, 2015
<u>AB</u>		<u>5MG</u>	<u>A204534</u>	<u>002</u>	Dec 04, 2015
<u>AB</u>		<u>10MG</u>	<u>A204534</u>	<u>003</u>	Dec 04, 2015
<u>AB</u>	RHODES PHARMS	<u>2.5MG</u>	<u>A208756</u>	<u>001</u>	Nov 20, 2017
<u>AB</u>		<u>5MG</u>	<u>A208756</u>	<u>002</u>	Nov 20, 2017
<u>AB</u>		<u>10MG</u>	<u>A208756</u>	<u>003</u>	Nov 20, 2017
<u>AB</u>	SUN PHARM INDUSTRIES	<u>2.5MG</u>	<u>A201231</u>	<u>001</u>	Sep 24, 2015
<u>AB</u>		<u>5MG</u>	<u>A201231</u>	<u>002</u>	Sep 24, 2015
<u>AB</u>		<u>10MG</u>	<u>A201231</u>	<u>003</u>	Sep 24, 2015
<u>AB</u>	TRIS PHARMA INC	<u>2.5MG</u>	<u>A207901</u>	<u>001</u>	Aug 26, 2016
<u>AB</u>		<u>5MG</u>	<u>A207901</u>	<u>002</u>	Aug 26, 2016
<u>AB</u>		<u>10MG</u>	<u>A207901</u>	<u>003</u>	Aug 26, 2016

FOCALIN

<u>AB</u>	+	NOVARTIS	<u>2.5MG</u>	<u>N021278</u>	<u>001</u>	Nov 13, 2001
<u>AB</u>	+		<u>5MG</u>	<u>N021278</u>	<u>002</u>	Nov 13, 2001
<u>AB</u>	+		<u>10MG</u>	<u>N021278</u>	<u>003</u>	Nov 13, 2001

PRESCRIPTION DRUG PRODUCT LIST

3-135 (of 474)

DEXMETHYLPHENIDATE HYDROCHLORIDE; SERDEXMETHYLPHENIDATE CHLORIDE

CAPSULE; ORAL

AZSTARYS

+	COMMAVE THERAP	EQ 5.2MG BASE;EQ 26.1MG BASE	N212994	001	May 07, 2021
+		EQ 7.8MG BASE;EQ 39.2MG BASE	N212994	002	May 07, 2021
+	!	EQ 10.4MG BASE;EQ 52.3MG BASE	N212994	003	May 07, 2021

DEXRAZOXANE HYDROCHLORIDE

INJECTABLE; INJECTION

DEXRAZOXANE HYDROCHLORIDE

<u>AP</u>	!	EUGIA PHARMA	<u>EQ 250MG BASE/VIAL</u>	<u>A200752</u>	<u>001</u>	Oct 19, 2011
<u>AP</u>	!		<u>EQ 500MG BASE/VIAL</u>	<u>A200752</u>	<u>002</u>	Oct 19, 2011
<u>AP</u>		GLAND	<u>EQ 250MG BASE/VIAL</u>	<u>A207321</u>	<u>002</u>	Dec 16, 2019
<u>AP</u>			<u>EQ 500MG BASE/VIAL</u>	<u>A207321</u>	<u>001</u>	Nov 28, 2016
<u>AP</u>		HIKMA	<u>EQ 250MG BASE/VIAL</u>	<u>A076068</u>	<u>001</u>	Sep 28, 2004
<u>AP</u>			<u>EQ 500MG BASE/VIAL</u>	<u>A076068</u>	<u>002</u>	Sep 28, 2004

DEXTROAMPHETAMINE

SYSTEM; TRANSDERMAL

XELSTRYM

+	NOVEN PHARMS INC	4.5MG/9HR	N215401	001	Mar 22, 2022
+		9MG/9HR	N215401	002	Mar 22, 2022
+		13.5MG/9HR	N215401	003	Mar 22, 2022
+	!	18MG/9HR	N215401	004	Mar 22, 2022

DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

DEXEDRINE

<u>AB</u>	+	IMPAX LABS INC	<u>5MG</u>	<u>N017078</u>	<u>001</u>	
<u>AB</u>	+		<u>10MG</u>	<u>N017078</u>	<u>002</u>	
<u>AB</u>	+	!	<u>15MG</u>	<u>N017078</u>	<u>003</u>	

DEXTROAMPHETAMINE SULFATE

<u>AB</u>		ACTAVIS ELIZABETH	<u>5MG</u>	<u>A203901</u>	<u>001</u>	Nov 30, 2012
<u>AB</u>			<u>10MG</u>	<u>A203901</u>	<u>002</u>	Nov 30, 2012
<u>AB</u>			<u>15MG</u>	<u>A203901</u>	<u>003</u>	Nov 30, 2012
<u>AB</u>		SPECGX LLC	<u>5MG</u>	<u>A076353</u>	<u>001</u>	May 06, 2003
<u>AB</u>			<u>10MG</u>	<u>A076353</u>	<u>002</u>	May 06, 2003
<u>AB</u>			<u>15MG</u>	<u>A076353</u>	<u>003</u>	May 06, 2003
<u>AB</u>		STRIDES PHARMA	<u>5MG</u>	<u>A205673</u>	<u>001</u>	Oct 31, 2017
<u>AB</u>			<u>10MG</u>	<u>A205673</u>	<u>002</u>	Oct 31, 2017
<u>AB</u>			<u>15MG</u>	<u>A205673</u>	<u>003</u>	Oct 31, 2017

SOLUTION; ORAL

DEXTROAMPHETAMINE SULFATE

<u>AA</u>	!	OUTLOOK PHARMS	<u>5MG/5ML</u>	<u>A040776</u>	<u>001</u>	Jan 29, 2008
<u>AA</u>		TRIS PHARMA INC	<u>5MG/5ML</u>	<u>A203644</u>	<u>001</u>	May 29, 2013

TABLET; ORAL

DEXTROAMPHETAMINE SULFATE

<u>AA</u>		ARBOR PHARMS LLC	<u>5MG</u>	<u>A090533</u>	<u>002</u>	Oct 25, 2011
<u>AA</u>			<u>10MG</u>	<u>A090533</u>	<u>004</u>	Oct 25, 2011
<u>AA</u>		AUROLIFE PHARMA LLC	<u>5MG</u>	<u>A202893</u>	<u>001</u>	Jul 31, 2013
<u>AA</u>			<u>10MG</u>	<u>A202893</u>	<u>002</u>	Jul 31, 2013
<u>AA</u>		AVANTHI INC	<u>5MG</u>	<u>A203548</u>	<u>001</u>	Nov 23, 2015
<u>AA</u>			<u>10MG</u>	<u>A203548</u>	<u>002</u>	Nov 23, 2015
<u>AA</u>		BARR	<u>5MG</u>	<u>A040361</u>	<u>001</u>	Jan 31, 2001
<u>AA</u>	!		<u>10MG</u>	<u>A040361</u>	<u>002</u>	Jan 31, 2001
<u>AA</u>		NOVEL LABS INC	<u>5MG</u>	<u>A204330</u>	<u>001</u>	Mar 16, 2016
<u>AA</u>			<u>10MG</u>	<u>A204330</u>	<u>002</u>	Mar 16, 2016
<u>AA</u>		NUVO PHARM	<u>5MG</u>	<u>A210059</u>	<u>001</u>	Oct 18, 2017
<u>AA</u>			<u>10MG</u>	<u>A210059</u>	<u>002</u>	Oct 18, 2017
<u>AA</u>		SPECGX LLC	<u>5MG</u>	<u>A040436</u>	<u>001</u>	Jan 29, 2002
<u>AA</u>			<u>10MG</u>	<u>A040436</u>	<u>002</u>	Jan 29, 2002
<u>AA</u>		TRIS PHARMA INC	<u>5MG</u>	<u>A206095</u>	<u>001</u>	Aug 18, 2022
<u>AA</u>			<u>10MG</u>	<u>A206095</u>	<u>002</u>	Aug 18, 2022
		ARBOR PHARMS LLC	2.5MG	A090533	001	Oct 25, 2011
			7.5MG	A090533	003	Oct 25, 2011
			15MG	A090533	005	Oct 25, 2011
			20MG	A090533	006	Oct 25, 2011
			30MG	A090533	007	Oct 25, 2011

PRESCRIPTION DRUG PRODUCT LIST

3-136(of 474)

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETHAZINE DM

AA	!	SLATE RUN PHARMA	15MG/5ML; 6.25MG/5ML	A040649	001	Feb 14, 2006

PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE

AA		AMNEAL PHARMS	15MG/5ML; 6.25MG/5ML	A090575	001	Feb 08, 2011

AA		TRIS PHARMA INC	15MG/5ML; 6.25MG/5ML	A091687	001	Jun 28, 2012

PROMETHAZINE W/ DEXTROMETHORPHAN

AA		WOCKHARDT BIO AG	15MG/5ML; 6.25MG/5ML	A088864	001	Jan 04, 1985

DEXTROMETHORPHAN HYDROBROMIDE; QUINIDINE SULFATE

CAPSULE; ORAL

DEXTROMETHORPHAN HYDROBROMIDE AND QUINIDINE SULFATE

AB		ACTAVIS ELIZABETH	20MG; 10MG	A202934	001	Oct 10, 2017

NUDEXTA

AB	+	AVANIR PHARMS	20MG; 10MG	N021879	001	Oct 29, 2010

DEXTROSE

INJECTABLE; INJECTION

DEXTROSE 10% IN PLASTIC CONTAINER

AP	+	B BRAUN	10GM/100ML	N019626	004	Feb 02, 1988

AP	+	BAXTER HLTHCARE	10GM/100ML	N016694	001	

AP		FRESENIUS KABI USA	10GM/100ML	A209448	001	Jul 16, 2018

AP	+	ICU MEDICAL INC	10GM/100ML	N018080	001	

DEXTROSE 5% IN PLASTIC CONTAINER

AP	+	B BRAUN	50MG/ML	N016730	002	

AP	+		5GM/100ML	N016730	001	

AP	+		5GM/100ML	N019626	002	Feb 02, 1988

AP	+	BAXTER HLTHCARE	50MG/ML	N016673	003	Oct 30, 1985

AP	+		50MG/ML	N020179	002	Dec 07, 1992

AP	+		5GM/100ML	N016673	001	

AP	+		5GM/100ML	N020179	001	Dec 07, 1992

AP		FRESENIUS KABI USA	50MG/ML	A207449	001	Oct 21, 2016

AP	+	HOSPIRA	5GM/100ML	N019466	001	Jul 15, 1985

AP	+		5GM/100ML	N019479	001	Sep 17, 1985

AP	+	ICU MEDICAL INC	50MG/ML	N016367	002	

DEXTROSE 50%

AP	+	HOSPIRA	500MG/ML	N019445	001	Jun 03, 1986

AP		INTL MEDICATION SYS	500MG/ML	A203451	001	Mar 26, 2021

DEXTROSE 50% IN PLASTIC CONTAINER

AP	+	BAXTER HLTHCARE	50GM/100ML	N020047	001	Jul 02, 1991

AP	+	ICU MEDICAL INC	50GM/100ML	N018563	001	Mar 23, 1982

DEXTROSE 70% IN PLASTIC CONTAINER

AP	+	B BRAUN	70GM/100ML	N019626	005	Feb 18, 2015

AP	+	BAXTER HLTHCARE	70GM/100ML	N020047	003	Jul 02, 1991

AP	+	ICU MEDICAL INC	70GM/100ML	N018561	001	Mar 23, 1982

AP	+		70GM/100ML	N019893	001	Dec 26, 1989

DEXTROSE 20% IN PLASTIC CONTAINER

+		ICU MEDICAL INC	20GM/100ML	N018564	001	Mar 23, 1982

DEXTROSE 25%

+		HOSPIRA	250MG/ML	N019445	002	Nov 23, 1998

DEXTROSE 30% IN PLASTIC CONTAINER

+		ICU MEDICAL INC	30GM/100ML	N019345	001	Jan 26, 1985

DEXTROSE 40% IN PLASTIC CONTAINER

+		ICU MEDICAL INC	40GM/100ML	N018562	001	Mar 23, 1982

DEXTROSE; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

NORMOSOL-M AND DEXTROSE 5% IN PLASTIC CONTAINER

		ICU MEDICAL INC	5GM/100ML; 21MG/100ML; 128MG/100ML; 234MG/100ML	N017610	001	

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE

INJECTABLE; INJECTION

ISOLYTE P IN DEXTROSE 5% IN PLASTIC CONTAINER

		B BRAUN	5GM/100ML; 31MG/100ML; 130MG/100ML; 26MG/100ML; 320MG/100ML	N019873	001	Jun 10, 1993

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

DEXTROSE 5% AND ELECTROLYTE NO. 48 IN PLASTIC CONTAINER

		BAXTER HLTHCARE	5GM/100ML; 31MG/100ML; 141MG/100ML; 20MG/100ML; 12MG/100ML; 260MG/100ML	N017484	001	

PRESCRIPTION DRUG PRODUCT LIST

3-137 (of 474)

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM LACTATE; SODIUM PHOSPHATE, MONOBASIC ANHYDROUS

INJECTABLE; INJECTION

IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER

ICU MEDICAL INC

5GM/100ML; 30MG/100ML; 141MG/100ML; 15MG/100ML; 260MG/100ML; 25MG/100ML

N019513 001 May 08, 1986

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE; INJECTION

NORMOSOL-R AND DEXTROSE 5% IN PLASTIC CONTAINER

ICU MEDICAL INC

5GM/100ML; 30MG/100ML; 37MG/100ML; 222MG/100ML; 526MG/100ML; 502MG/100ML

N017609 001

DEXTROSE; POTASSIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5% AND POTASSIUM CHLORIDE 0.075%

AP FRESenius KABI USA

5GM/100ML; 75MG/100ML

A212346 001 Sep 10, 2020

DEXTROSE 5% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER

AP + BAXTER HLTHCARE

5GM/100ML; 75MG/100ML

N017634 004

DEXTROSE 5% AND POTASSIUM CHLORIDE 0.15%

AP FRESenius KABI USA

5GM/100ML; 150MG/100ML

A212346 002 Sep 10, 2020

DEXTROSE 5% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER

AP + BAXTER HLTHCARE

5GM/100ML; 150MG/100ML

N017634 001

DEXTROSE 5% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

AP + BAXTER HLTHCARE

5GM/100ML; 300MG/100ML

N017634 002

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% IN PLASTIC CONTAINER

AP B BRAUN

5GM/100ML; 150MG/100ML

N019699 004 Sep 29, 1989

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% IN PLASTIC CONTAINER

AP B BRAUN

5GM/100ML; 300MG/100ML

N019699 006 Sep 29, 1989

DEXTROSE 5% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER

+ BAXTER HLTHCARE

5GM/100ML; 224MG/100ML

N017634 003

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER

ICU MEDICAL INC

5GM/100ML; 149MG/100ML

N018371 001

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 10MEQ

AP BAXTER HLTHCARE

5GM/100ML; 75MG/100ML; 200MG/100ML

N018037 006 Apr 13, 1982

AP BAXTER HLTHCARE

5GM/100ML; 150MG/100ML; 200MG/100ML

N018037 007 Apr 13, 1982

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 15MEQ (K)

AP BAXTER HLTHCARE

5GM/100ML; 224MG/100ML; 200MG/100ML

N018037 004

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ

AP BAXTER HLTHCARE

5GM/100ML; 150MG/100ML; 200MG/100ML

N018037 008 Apr 13, 1982

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ (K)

AP BAXTER HLTHCARE

5GM/100ML; 300MG/100ML; 200MG/100ML

N018037 001

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 30MEQ

AP BAXTER HLTHCARE

5GM/100ML; 224MG/100ML; 200MG/100ML

N018037 005 Apr 13, 1982

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 40MEQ

AP BAXTER HLTHCARE

5GM/100ML; 300MG/100ML; 200MG/100ML

N018037 009 Apr 13, 1982

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ

AP BAXTER HLTHCARE

5GM/100ML; 75MG/100ML; 200MG/100ML

N018037 002

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ (K)

AP BAXTER HLTHCARE

5GM/100ML; 150MG/100ML; 200MG/100ML

N018037 003

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER

AP BAXTER HLTHCARE

5GM/100ML; 75MG/100ML; 330MG/100ML

N018629 005 Mar 23, 1982

AP BAXTER HLTHCARE

5GM/100ML; 150MG/100ML; 330MG/100ML

N018629 002 Mar 23, 1982

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 15MEQ IN PLASTIC CONTAINER

AP BAXTER HLTHCARE

5GM/100ML; 224MG/100ML; 330MG/100ML

N018629 003 Mar 23, 1982

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER

AP BAXTER HLTHCARE

5GM/100ML; 150MG/100ML; 330MG/100ML

N018629 004 Mar 23, 1982

AP BAXTER HLTHCARE

5GM/100ML; 300MG/100ML; 330MG/100ML

N018629 006 Mar 23, 1982

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER

AP BAXTER HLTHCARE

5GM/100ML; 224MG/100ML; 330MG/100ML

N018629 007 Mar 23, 1982

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER

AP BAXTER HLTHCARE

5GM/100ML; 300MG/100ML; 330MG/100ML

N018629 008 Mar 23, 1982

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 5MEQ IN PLASTIC CONTAINER

AP BAXTER HLTHCARE

5GM/100ML; 75MG/100ML; 330MG/100ML

N018629 001 Mar 23, 1982

DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 20MEQ (K) IN PLASTIC CONTAINER

AP BAXTER HLTHCARE

5GM/100ML; 300MG/100ML; 450MG/100ML

N018008 010

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

AP B BRAUN

5GM/100ML; 75MG/100ML; 200MG/100ML

N019630 008 Feb 17, 1988

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER

AP B BRAUN

5GM/100ML; 75MG/100ML; 330MG/100ML

N019630 014 Feb 17, 1988

PRESCRIPTION DRUG PRODUCT LIST

3-138 (of 474)

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDEINJECTABLE; INJECTION

<u>POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER</u>	
AP	B BRAUN 5GM/100ML;75MG/100ML;450MG/100ML N019630 020 Feb 17, 1988
<u>POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>	
AP	B BRAUN 5GM/100ML;75MG/100ML;900MG/100ML N019630 026 Feb 17, 1988
<u>POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER</u>	
AP	B BRAUN 5GM/100ML;150MG/100ML;200MG/100ML N019630 010 Feb 17, 1988
<u>POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER</u>	
AP	B BRAUN 5GM/100ML;150MG/100ML;330MG/100ML N019630 016 Feb 17, 1988
<u>POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER</u>	
AP	B BRAUN 5GM/100ML;150MG/100ML;450MG/100ML N019630 022 Feb 17, 1988
<u>POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>	
AP	B BRAUN 5GM/100ML;150MG/100ML;900MG/100ML N019630 028 Feb 17, 1988
<u>POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER</u>	
AP	B BRAUN 5GM/100ML;300MG/100ML;200MG/100ML N019630 012 Feb 17, 1988
<u>POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER</u>	
AP	B BRAUN 5GM/100ML;300MG/100ML;330MG/100ML N019630 018 Feb 17, 1988
<u>POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER</u>	
AP	B BRAUN 5GM/100ML;300MG/100ML;450MG/100ML N019630 024 Feb 17, 1988
<u>POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>	
AP	B BRAUN 5GM/100ML;300MG/100ML;900MG/100ML N019630 030 Feb 17, 1988
<u>POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45%</u>	
AP	FRESENIUS KABI USA 5GM/100ML;149MG/100ML;450MG/100ML A213523 005 Oct 11, 2022
<u>POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER</u>	
AP	BAXTER HLTHCARE 5GM/100ML;75MG/100ML;450MG/100ML N018008 005 Apr 28, 1982
AP	5GM/100ML;150MG/100ML;450MG/100ML N018008 006 Apr 28, 1982
AP	+! ICU MEDICAL INC 5GM/100ML;74.5MG/100ML;450MG/100ML N018362 009 Jul 05, 1983
AP	+! 5GM/100ML;149MG/100ML;450MG/100ML N018362 005 Mar 28, 1988
<u>POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER</u>	
AP	BAXTER HLTHCARE 5GM/100ML;150MG/100ML;450MG/100ML N018008 007 Apr 28, 1982
AP	+! ICU MEDICAL INC 5GM/100ML;149MG/100ML;450MG/100ML N018362 010 Jul 05, 1983
<u>POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>	
AP	BAXTER HLTHCARE 5GM/100ML;150MG/100ML;900MG/100ML N019308 005 Apr 05, 1985
AP	+! ICU MEDICAL INC 5GM/100ML;149MG/100ML;900MG/100ML N019691 005 Mar 24, 1988
<u>POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER</u>	
AP	BAXTER HLTHCARE 5GM/100ML;224MG/100ML;450MG/100ML N018008 008 Apr 28, 1982
AP	+! ICU MEDICAL INC 5GM/100ML;224MG/100ML;450MG/100ML N018362 002
<u>POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER</u>	
AP	BAXTER HLTHCARE 5GM/100ML;300MG/100ML;450MG/100ML N018008 009 Apr 28, 1982
AP	+! ICU MEDICAL INC 5GM/100ML;298MG/100ML;450MG/100ML N018362 003
<u>POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>	
AP	BAXTER HLTHCARE 5GM/100ML;300MG/100ML;900MG/100ML N019308 007 Apr 05, 1985
AP	+! ICU MEDICAL INC 5GM/100ML;298MG/100ML;900MG/100ML N019691 009 Mar 24, 1988
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER	
	B BRAUN 10GM/100ML;37MG/100ML;200MG/100ML N019630 031 Feb 17, 1988
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER	
	B BRAUN 10GM/100ML;37MG/100ML;450MG/100ML N019630 037 Feb 17, 1988
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER	
	B BRAUN 10GM/100ML;37MG/100ML;900MG/100ML N019630 043 Feb 17, 1988
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER	
	B BRAUN 5GM/100ML;37MG/100ML;110MG/100ML N019630 001 Feb 17, 1988
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER	
	B BRAUN 5GM/100ML;37MG/100ML;200MG/100ML N019630 007 Feb 17, 1988
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER	
	B BRAUN 5GM/100ML;37MG/100ML;330MG/100ML N019630 013 Feb 17, 1988
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER	
	B BRAUN 5GM/100ML;37MG/100ML;450MG/100ML N019630 019 Feb 17, 1988
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER	
	B BRAUN 5GM/100ML;37MG/100ML;900MG/100ML N019630 025 Feb 17, 1988
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER	
	B BRAUN 10GM/100ML;75MG/100ML;200MG/100ML N019630 032 Feb 17, 1988
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER	
	B BRAUN 10GM/100ML;75MG/100ML;450MG/100ML N019630 038 Feb 17, 1988
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER	
	B BRAUN 10GM/100ML;75MG/100ML;900MG/100ML N019630 044 Feb 17, 1988
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER	
	B BRAUN 3.3GM/100ML;75MG/100ML;300MG/100ML N019630 049 May 07, 1992
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER	
	B BRAUN 5GM/100ML;75MG/100ML;110MG/100ML N019630 002 Feb 17, 1988
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER	
	B BRAUN 10GM/100ML;110MG/100ML;200MG/100ML N019630 033 Feb 17, 1988

PRESCRIPTION DRUG PRODUCT LIST

3-139 (of 474)

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 0.11% IN	DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN	PLASTIC CONTAINER	
B BRAUN	10GM/100ML; 110MG/100ML; 450MG/100ML	N019630 039	Feb 17, 1988
POTASSIUM CHLORIDE 0.11% IN	DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN	PLASTIC CONTAINER	
B BRAUN	10GM/100ML; 110MG/100ML; 900MG/100ML	N019630 045	Feb 17, 1988
POTASSIUM CHLORIDE 0.11% IN	DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN	PLASTIC CONTAINER	
B BRAUN	3.3GM/100ML; 110MG/100ML; 300MG/100ML	N019630 050	May 07, 1992
POTASSIUM CHLORIDE 0.11% IN	DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN	PLASTIC CONTAINER	
B BRAUN	5GM/100ML; 110MG/100ML; 110MG/100ML	N019630 003	Feb 17, 1988
POTASSIUM CHLORIDE 0.11% IN	DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN	PLASTIC CONTAINER	
B BRAUN	5GM/100ML; 110MG/100ML; 200MG/100ML	N019630 009	Feb 17, 1988
POTASSIUM CHLORIDE 0.11% IN	DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN	PLASTIC CONTAINER	
B BRAUN	5GM/100ML; 110MG/100ML; 330MG/100ML	N019630 015	Feb 17, 1988
POTASSIUM CHLORIDE 0.11% IN	DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN	PLASTIC CONTAINER	
B BRAUN	5GM/100ML; 110MG/100ML; 450MG/100ML	N019630 021	Feb 17, 1988
POTASSIUM CHLORIDE 0.11% IN	DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN	PLASTIC CONTAINER	
B BRAUN	5GM/100ML; 110MG/100ML; 900MG/100ML	N019630 027	Feb 17, 1988
POTASSIUM CHLORIDE 0.15% IN	DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN	PLASTIC CONTAINER	
B BRAUN	10GM/100ML; 150MG/100ML; 200MG/100ML	N019630 034	Feb 17, 1988
POTASSIUM CHLORIDE 0.15% IN	DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN	PLASTIC CONTAINER	
B BRAUN	10GM/100ML; 150MG/100ML; 450MG/100ML	N019630 040	Feb 17, 1988
POTASSIUM CHLORIDE 0.15% IN	DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN	PLASTIC CONTAINER	
B BRAUN	10GM/100ML; 150MG/100ML; 900MG/100ML	N019630 046	Feb 17, 1988
POTASSIUM CHLORIDE 0.15% IN	DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN	PLASTIC CONTAINER	
B BRAUN	3.3GM/100ML; 150MG/100ML; 300MG/100ML	N019630 051	May 07, 1992
POTASSIUM CHLORIDE 0.15% IN	DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN	PLASTIC CONTAINER	
B BRAUN	5GM/100ML; 150MG/100ML; 110MG/100ML	N019630 004	Feb 17, 1988
POTASSIUM CHLORIDE 0.22% IN	DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN	PLASTIC CONTAINER	
B BRAUN	10GM/100ML; 220MG/100ML; 200MG/100ML	N019630 035	Feb 17, 1988
POTASSIUM CHLORIDE 0.22% IN	DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN	PLASTIC CONTAINER	
B BRAUN	10GM/100ML; 220MG/100ML; 450MG/100ML	N019630 041	Feb 17, 1988
POTASSIUM CHLORIDE 0.22% IN	DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN	PLASTIC CONTAINER	
B BRAUN	10GM/100ML; 220MG/100ML; 900MG/100ML	N019630 047	Feb 17, 1988
POTASSIUM CHLORIDE 0.22% IN	DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN	PLASTIC CONTAINER	
B BRAUN	3.3GM/100ML; 220MG/100ML; 300MG/100ML	N019630 052	May 07, 1992
POTASSIUM CHLORIDE 0.22% IN	DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN	PLASTIC CONTAINER	
B BRAUN	5GM/100ML; 220MG/100ML; 110MG/100ML	N019630 005	Feb 17, 1988
POTASSIUM CHLORIDE 0.22% IN	DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN	PLASTIC CONTAINER	
B BRAUN	5GM/100ML; 220MG/100ML; 200MG/100ML	N019630 011	Feb 17, 1988
POTASSIUM CHLORIDE 0.22% IN	DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN	PLASTIC CONTAINER	
B BRAUN	5GM/100ML; 220MG/100ML; 330MG/100ML	N019630 017	Feb 17, 1988
POTASSIUM CHLORIDE 0.22% IN	DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN	PLASTIC CONTAINER	
B BRAUN	5GM/100ML; 220MG/100ML; 450MG/100ML	N019630 023	Feb 17, 1988
POTASSIUM CHLORIDE 0.22% IN	DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN	PLASTIC CONTAINER	
B BRAUN	5GM/100ML; 220MG/100ML; 900MG/100ML	N019630 029	Feb 17, 1988
POTASSIUM CHLORIDE 0.3% IN	DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN	PLASTIC CONTAINER	
B BRAUN	10GM/100ML; 300MG/100ML; 200MG/100ML	N019630 036	Feb 17, 1988
POTASSIUM CHLORIDE 0.3% IN	DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN	PLASTIC CONTAINER	
B BRAUN	10GM/100ML; 300MG/100ML; 450MG/100ML	N019630 042	Feb 17, 1988
POTASSIUM CHLORIDE 0.3% IN	DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN	PLASTIC CONTAINER	
B BRAUN	10GM/100ML; 300MG/100ML; 900MG/100ML	N019630 048	Feb 17, 1988
POTASSIUM CHLORIDE 0.3% IN	DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN	PLASTIC CONTAINER	
B BRAUN	3.3GM/100ML; 300MG/100ML; 300MG/100ML	N019630 053	May 07, 1992
POTASSIUM CHLORIDE 0.3% IN	DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN	PLASTIC CONTAINER	
B BRAUN	5GM/100ML; 300MG/100ML; 110MG/100ML	N019630 006	Feb 17, 1988
POTASSIUM CHLORIDE 10MEQ IN	DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN	PLASTIC CONTAINER	
BAXTER HLTHCARE	5GM/100ML; 75MG/100ML; 900MG/100ML	N019308 004	Apr 05, 1985
	5GM/100ML; 150MG/100ML; 900MG/100ML	N019308 002	Apr 05, 1985
POTASSIUM CHLORIDE 20MEQ IN	DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN	PLASTIC CONTAINER	
+ ICU MEDICAL INC	5GM/100ML; 149MG/100ML; 225MG/100ML	N018365 001	
POTASSIUM CHLORIDE 20MEQ IN	DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN	PLASTIC CONTAINER	
BAXTER HLTHCARE	5GM/100ML; 300MG/100ML; 900MG/100ML	N019308 003	Apr 05, 1985
POTASSIUM CHLORIDE 30MEQ IN	DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN	PLASTIC CONTAINER	
BAXTER HLTHCARE	5GM/100ML; 224MG/100ML; 900MG/100ML	N019308 006	Apr 05, 1985
POTASSIUM CHLORIDE 5MEQ IN	DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN	PLASTIC CONTAINER	
BAXTER HLTHCARE	5GM/100ML; 150MG/100ML; 450MG/100ML	N018008 004	
POTASSIUM CHLORIDE 5MEQ IN	DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN	PLASTIC CONTAINER	
BAXTER HLTHCARE	5GM/100ML; 150MG/100ML; 900MG/100ML	N019308 001	Apr 05, 1985

PRESCRIPTION DRUG PRODUCT LIST

3-140 (of 474)

DEXTROSE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	B BRAUN	2.5GM/100ML;450MG/100ML	N019631	004	Feb 24, 1988
AP	+! BAXTER HLTHCARE	2.5GM/100ML;450MG/100ML	N016697	001	
AP	FRESENIUS KABI USA	2.5GM/100ML;450MG/100ML	A211190	001	Dec 20, 2019
<u>DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER</u>					
AP	B BRAUN	5GM/100ML;200MG/100ML	N019631	007	Feb 24, 1988
<u>DEXTROSE 5% AND SODIUM CHLORIDE 0.225%</u>					
AP	FRESENIUS KABI USA	5GM/100ML;225MG/100ML	A211221	001	Sep 15, 2020
<u>DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER</u>					
AP	+! ICU MEDICAL INC	5GM/100ML;225MG/100ML	N017606	001	
<u>DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER</u>					
AP	FRESENIUS KABI USA	5GM/100ML;300MG/100ML	A211194	001	Aug 26, 2020
AP	+! ICU MEDICAL INC	5GM/100ML;300MG/100ML	N017799	001	
<u>DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER</u>					
AP	B BRAUN	5GM/100ML;330MG/100ML	N019631	008	Feb 24, 1988
<u>DEXTROSE 5% AND SODIUM CHLORIDE 0.45%</u>					
AP	FRESENIUS KABI USA	5GM/100ML;450MG/100ML	A211276	001	Sep 15, 2020
<u>DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER</u>					
AP	B BRAUN	5GM/100ML;450MG/100ML	N019631	009	Feb 24, 1988
AP	+ ICU MEDICAL INC	5GM/100ML;450MG/100ML	N017607	001	
<u>DEXTROSE 5% AND SODIUM CHLORIDE 0.9%</u>					
AP	FRESENIUS KABI USA	5GM/100ML;900MG/100ML	A211211	001	Sep 14, 2020
<u>DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>					
AP	B BRAUN	5GM/100ML;900MG/100ML	N019631	010	Feb 24, 1988
AP	+! ICU MEDICAL INC	5GM/100ML;900MG/100ML	N017585	001	
<u>DEXTROSE 5% IN SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER</u>					
AP	BAXTER HLTHCARE	5GM/100ML;200MG/100ML	N016689	001	
<u>DEXTROSE 5% IN SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER</u>					
AP	BAXTER HLTHCARE	5GM/100ML;330MG/100ML	N016687	001	
<u>DEXTROSE 5% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER</u>					
AP	BAXTER HLTHCARE	5GM/100ML;450MG/100ML	N016683	001	
<u>DEXTROSE 5% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>					
AP	BAXTER HLTHCARE	5GM/100ML;900MG/100ML	N016678	001	
<u>DEXTROSE 10% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER</u>					
	B BRAUN	10GM/100ML;110MG/100ML	N019631	011	Feb 24, 1988
<u>DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER</u>					
	B BRAUN	10GM/100ML;200MG/100ML	N019631	012	Feb 24, 1988
<u>DEXTROSE 10% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER</u>					
	B BRAUN	10GM/100ML;330MG/100ML	N019631	013	Feb 24, 1988
<u>DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER</u>					
	B BRAUN	10GM/100ML;450MG/100ML	N019631	014	Feb 24, 1988
<u>DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>					
	B BRAUN	10GM/100ML;900MG/100ML	N019631	015	Feb 24, 1988
<u>DEXTROSE 2.5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER</u>					
	B BRAUN	2.5GM/100ML;110MG/100ML	N019631	001	Feb 24, 1988
<u>DEXTROSE 2.5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER</u>					
	B BRAUN	2.5GM/100ML;200MG/100ML	N019631	002	Feb 24, 1988
<u>DEXTROSE 2.5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER</u>					
	B BRAUN	2.5GM/100ML;330MG/100ML	N019631	003	Feb 24, 1988
<u>DEXTROSE 2.5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>					
	B BRAUN	2.5GM/100ML;900MG/100ML	N019631	005	Feb 24, 1988
<u>DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER</u>					
	B BRAUN	3.3GM/100ML;300MG/100ML	N019631	016	Jan 19, 1990
<u>DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER</u>					
	B BRAUN	5GM/100ML;110MG/100ML	N019631	006	Feb 24, 1988

DIATRIZOATE MEGLUMINE

SOLUTION; URETHRAL

CYSTOGRAFIN

+ BRACCO 30%

N010040 018

CYSTOGRAFIN DILUTE

+ BRACCO 18%

N010040 022 Nov 09, 1982

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM

SOLUTION; ORAL, RECTAL

DIATRIZOATE MEGLUMINE AND DIATRIZOATE SODIUM

AA	GUARDIAN DRUG	66%;10%	A214201	001	Jun 27, 2022
<u>GASTROGRAFIN</u>					
AA	+! BRACCO	66%;10%	N011245	003	
<u>MD-GASTROVIEW</u>					
AA	LIEBEL-FLARSHEIM	66%;10%	A087388	001	

PRESCRIPTION DRUG PRODUCT LIST

3-141 (of 474)

DIAZEPAM

CONCENTRATE; ORAL

DIAZEPAM

AA	!	CHARTWELL MOLECULAR	<u>5MG/ML</u>	<u>A204433</u>	<u>001</u>	Apr 14, 2014

DIAZEPAM INTENSOL

AA	!	HIKMA	<u>5MG/ML</u>	<u>A071415</u>	<u>001</u>	Apr 03, 1987

GEL; RECTAL

DIASTAT

+	!	BAUSCH	2.5MG/0.5ML (5MG/ML)	N020648	001	Jul 29, 1997

DIASTAT ACUDIAL

+	!	BAUSCH	10MG/2ML (5MG/ML)	N020648	007	Sep 15, 2005

+	!		20MG/4ML (5MG/ML)	N020648	006	Sep 15, 2005

INJECTABLE; INJECTION

DIAZEPAM

AP	!	BELOTECA INC	<u>10MG/2ML (5MG/ML)</u>	<u>A210363</u>	<u>001</u>	Mar 18, 2019

AP			<u>50MG/10ML (5MG/ML)</u>	<u>A211998</u>	<u>001</u>	Dec 26, 2019

AP		FRESENIUS KABI USA	<u>10MG/2ML (5MG/ML)</u>	<u>A214745</u>	<u>001</u>	Nov 10, 2022

AP		HIKMA	<u>10MG/2ML (5MG/ML)</u>	<u>A070313</u>	<u>001</u>	Dec 16, 1985

AP		HOSPIRA	<u>10MG/2ML (5MG/ML)</u>	<u>A072079</u>	<u>001</u>	Dec 20, 1988

AP	!		<u>50MG/10ML (5MG/ML)</u>	<u>A071583</u>	<u>001</u>	Oct 13, 1987

SOLUTION; ORAL

DIAZEPAM

AA		CHARTWELL MOLECULAR	<u>5MG/5ML</u>	<u>A206477</u>	<u>001</u>	Jun 24, 2016

AA	!	HIKMA	<u>5MG/5ML</u>	<u>A070928</u>	<u>001</u>	Apr 03, 1987

SPRAY; NASAL

VALTOCO

+		NEURELIS INC	5MG/SPRAY	N211635	001	Jan 10, 2020

+			7.5MG/SPRAY	N211635	002	Jan 10, 2020

+	!		10MG/SPRAY	N211635	003	Jan 10, 2020

TABLET; ORAL

DIAZEPAM

AB		IVAX SUB TEVA	<u>2MG</u>	<u>A071307</u>	<u>001</u>	Dec 10, 1986

PHARMS

AB			<u>5MG</u>	<u>A071321</u>	<u>001</u>	Dec 10, 1986

AB			<u>10MG</u>	<u>A071322</u>	<u>001</u>	Dec 10, 1986

AB		MAYNE PHARMA	<u>2MG</u>	<u>A071134</u>	<u>001</u>	Feb 03, 1987

AB			<u>5MG</u>	<u>A071135</u>	<u>001</u>	Feb 03, 1987

AB			<u>10MG</u>	<u>A071136</u>	<u>001</u>	Feb 03, 1987

AB		MYLAN	<u>2MG</u>	<u>A070325</u>	<u>002</u>	Sep 04, 1985

AB			<u>5MG</u>	<u>A070325</u>	<u>003</u>	Sep 04, 1985

AB			<u>10MG</u>	<u>A070325</u>	<u>001</u>	Sep 04, 1985

AB		STRIDES PHARMA	<u>2MG</u>	<u>A077749</u>	<u>001</u>	Mar 31, 2006

AB			<u>5MG</u>	<u>A077749</u>	<u>002</u>	Mar 31, 2006

AB			<u>10MG</u>	<u>A077749</u>	<u>003</u>	Mar 31, 2006

VALIUM

AB	+	WAYLIS THERAP	<u>2MG</u>	<u>N013263</u>	<u>002</u>	

AB	+		<u>5MG</u>	<u>N013263</u>	<u>004</u>	

AB	+	!	<u>10MG</u>	<u>N013263</u>	<u>006</u>	

DIAZOXIDE

SUSPENSION; ORAL

DIAZOXIDE

AB		E5 PHARMA INC	<u>50MG/ML</u>	<u>A211050</u>	<u>001</u>	Dec 20, 2019

AB		NOVITIUM PHARMA	<u>50MG/ML</u>	<u>A210799</u>	<u>001</u>	Jul 08, 2020

PROGLYCEM

AB	+	!	TEVA BRANDED PHARM	<u>50MG/ML</u>	<u>N017453</u>	<u>001</u>

DICHLORPHENAMIDE

TABLET; ORAL

DICHLORPHENAMIDE

AB		TORRENT	<u>50MG</u>	<u>A215924</u>	<u>001</u>	Dec 29, 2022

KEVEYIS

AB	+	!	XERIS	<u>50MG</u>	<u>N011366</u>	<u>002</u>

DICLOFENAC EPOLAMINE

SYSTEM; TOPICAL

FLECTOR

+	!	INST BIOCHEM	1.3%	N021234	001	Jan 31, 2007

LICART

+	!	IBSA INST BIO	1.3%	N206976	001	Dec 19, 2018

PRESCRIPTION DRUG PRODUCT LIST

3-142 (of 474)

DICLOFENAC POTASSIUM

CAPSULE; ORAL

DICLOFENAC POTASSIUM

AB	AUROBINDO PHARMA LTD	25MG	A213875	001	Oct 19, 2021
AB	BIONPHARMA INC	25MG	A204648	001	Feb 23, 2016
AB	STRIDES PHARMA	25MG	A210078	001	Dec 03, 2019

ZIPSOR

AB	+! ASSERTIO	25MG	N022202	001	Jun 16, 2009

FOR SOLUTION; ORAL

CAMBIA

AB	+! ASSERTIO	50MG	N022165	001	Jun 17, 2009

DICLOFENAC POTASSIUM

AB	ALKEM LABS LTD	50MG	A216635	001	Jul 20, 2022
AB	ANNORA PHARMA	50MG	A215375	001	Mar 04, 2022
AB	PAR FORM	50MG	A202964	001	May 02, 2016

TABLET; ORAL

CATAFLAM

AB	AMICI	25MG	A076561	002	Jul 21, 2021
AB		50MG	A076561	001	Mar 18, 2004

DICLOFENAC POTASSIUM

AB	NOVAST LABS	50MG	A215585	001	Oct 08, 2021
AB	! RK PHARMA	50MG	A075463	001	Jul 26, 1999
AB	RUBICON	25MG	A075229	002	Sep 16, 2021
AB		50MG	A075229	001	Nov 20, 1998
AB	TEVA	50MG	A075219	001	Aug 06, 1998
AB	UMEDICA LABS PVT LTD	50MG	A215750	001	May 11, 2022

DICLOFENAC SODIUM

GEL; TOPICAL

DICLOFENAC SODIUM

AB	ACTAVIS MID ATLANTIC	3%	A206493	001	Dec 02, 2015
AB	ALEOR DERMACEUTICALS	3%	A212351	001	Jul 27, 2022
AB	GLENMARK PHARMS LTD	3%	A208301	001	Sep 13, 2016
AB	PADAGIS ISRAEL	3%	A210893	001	Jul 27, 2018
AB	! TARO	3%	A206298	001	Apr 28, 2016
AB	TOLMAR	3%	A200936	001	Oct 28, 2013
	CIPLA	1%	A209903	001	Aug 03, 2018

SOLUTION; TOPICAL

DICLOFENAC SODIUM

AB	ALEOR DERMACEUTICALS	2%	A212506	001	Nov 29, 2022
AB	AMNEAL	2%	A208198	001	Aug 18, 2022
AB	APOTEX	2%	A207714	001	May 06, 2022
AB	LUPIN PHARMS	2%	A208021	001	Sep 20, 2022
AB	TARO	2%	A208098	001	Sep 29, 2022

PENNSAID

AB	+! HORIZON	2%	N204623	001	Jan 16, 2014

DICLOFENAC SODIUM

AT	AKORN	1.5%	A206655	001	Jan 28, 2021
AT	AMNEAL PHARMS	1.5%	A206116	001	Sep 02, 2016
AT	CADILA	1.5%	A206411	001	Apr 17, 2018
AT	LUPIN LTD	1.5%	A204132	001	Aug 20, 2015
AT	NOVEL LABS INC	1.5%	A205878	001	Dec 09, 2015
AT	PAI HOLDINGS PHARM	1.5%	A202769	001	Jul 08, 2015
AT	! TARO	1.5%	A203818	001	Nov 26, 2014
AT	WATSON LABS INC	1.5%	A202852	001	Nov 24, 2014

SOLUTION/DROPS; OPHTHALMIC

DICLOFENAC SODIUM

AT	ALTAIRE PHARMS INC	0.1%	A203383	001	Nov 16, 2015
AT	! BAUSCH AND LOMB	0.1%	A078792	001	Dec 28, 2007
AT	RISING	0.1%	A078553	001	Dec 28, 2007
AT	SANDOZ INC	0.1%	A078031	001	Feb 06, 2008

TABLET, DELAYED RELEASE; ORAL

DICLOFENAC SODIUM

AB	ACTAVIS ELIZABETH	50MG	A074514	001	Mar 26, 1996
AB		75MG	A074514	002	Mar 26, 1996
AB	CARLSBAD	25MG	A075185	002	Nov 13, 1998
AB		50MG	A075185	003	Nov 13, 1998
AB		75MG	A075185	001	Nov 13, 1998
AB	! UNIQUE	25MG	A090066	001	Dec 01, 2010

PRESCRIPTION DRUG PRODUCT LIST

3-143 (of 474)

DICLOFENAC SODIUM

TABLET, DELAYED RELEASE; ORAL

DICLOFENAC SODIUM

<u>AB</u>	!		<u>50MG</u>	<u>A090066</u>	<u>002</u>	Dec 01, 2010
<u>AB</u>	!		<u>75MG</u>	<u>A077863</u>	<u>003</u>	Jun 08, 2007

TABLET, EXTENDED RELEASE; ORAL

DICLOFENAC SODIUM

<u>AB</u>	!	DEXCEL LTD	<u>100MG</u>	<u>A076201</u>	<u>001</u>	Nov 06, 2002
<u>AB</u>		RICONPHARMA LLC	<u>100MG</u>	<u>A216275</u>	<u>001</u>	Sep 23, 2022
<u>AB</u>		VPNA	<u>100MG</u>	<u>A075492</u>	<u>001</u>	Feb 11, 2000

DICLOFENAC SODIUM; MISOPROSTOL

TABLET, DELAYED RELEASE; ORAL

ARTHROTEC

<u>AB</u>	+	PFIZER	<u>50MG; 0.2MG</u>	<u>N020607</u>	<u>001</u>	Dec 24, 1997
<u>AB</u>	+	!	<u>75MG; 0.2MG</u>	<u>N020607</u>	<u>002</u>	Dec 24, 1997

DICLOFENAC SODIUM AND MISOPROSTOL

<u>AB</u>		ACTAVIS LABS FL INC	<u>50MG; 0.2MG</u>	<u>A201089</u>	<u>001</u>	Jul 09, 2012
<u>AB</u>			<u>75MG; 0.2MG</u>	<u>A201089</u>	<u>002</u>	Jul 09, 2012
<u>AB</u>		AMNEAL PHARMS	<u>50MG; 0.2MG</u>	<u>A203995</u>	<u>001</u>	Nov 25, 2016
<u>AB</u>			<u>75MG; 0.2MG</u>	<u>A203995</u>	<u>002</u>	Nov 25, 2016
<u>AB</u>		MICRO LABS	<u>50MG; 0.2MG</u>	<u>A204355</u>	<u>001</u>	Jul 15, 2021
<u>AB</u>			<u>75MG; 0.2MG</u>	<u>A204355</u>	<u>002</u>	Jul 15, 2021
<u>AB</u>		SANDOZ	<u>50MG; 0.2MG</u>	<u>A200158</u>	<u>001</u>	May 09, 2013
<u>AB</u>			<u>75MG; 0.2MG</u>	<u>A200158</u>	<u>002</u>	May 09, 2013
<u>AB</u>		YUNG SHIN PHARM	<u>50MG; 0.2MG</u>	<u>A205143</u>	<u>001</u>	Feb 19, 2020
<u>AB</u>			<u>75MG; 0.2MG</u>	<u>A205143</u>	<u>002</u>	Feb 19, 2020

DICLOXACILLIN SODIUM

CAPSULE; ORAL

DICLOXACILLIN SODIUM

<u>AB</u>		AUROBINDO PHARMA	<u>EQ 250MG BASE</u>	<u>A216845</u>	<u>001</u>	Sep 23, 2022
<u>AB</u>			<u>EQ 500MG BASE</u>	<u>A216845</u>	<u>002</u>	Sep 23, 2022
<u>AB</u>		TEVA	<u>EQ 250MG BASE</u>	<u>A062286</u>	<u>001</u>	Jun 03, 1982
<u>AB</u>	!		<u>EQ 500MG BASE</u>	<u>A062286</u>	<u>002</u>	Jun 03, 1982

DICYCLOMINE HYDROCHLORIDE

CAPSULE; ORAL

DICYCLOMINE HYDROCHLORIDE

<u>AB</u>		AUROBINDO PHARMA	<u>10MG</u>	<u>A040319</u>	<u>001</u>	Sep 07, 1999
<u>AB</u>	!	USA				
<u>AB</u>	!	LANNETT	<u>10MG</u>	<u>A084285</u>	<u>001</u>	
<u>AB</u>		TWI PHARMS	<u>10MG</u>	<u>A217054</u>	<u>001</u>	Dec 27, 2022
<u>AB</u>		WATSON LABS	<u>10MG</u>	<u>A085082</u>	<u>001</u>	Jun 19, 1986
<u>AB</u>		WEST WARD	<u>10MG</u>	<u>A040204</u>	<u>001</u>	Feb 28, 1997

INJECTABLE; INJECTION

BENTYL

<u>AP</u>	+	!	ALLERGAN	<u>10MG/ML</u>	<u>N008370</u>	<u>001</u>	Oct 15, 1984
			<u>BENTYL PRESERVATIVE FREE</u>				
<u>AP</u>	+	!	ALLERGAN	<u>10MG/ML</u>	<u>N008370</u>	<u>002</u>	Oct 15, 1984

DICYCLOMINE HYDROCHLORIDE

<u>AP</u>		AKORN	<u>10MG/ML</u>	<u>A207084</u>	<u>001</u>	May 04, 2018
<u>AP</u>		AM REGENT	<u>10MG/ML</u>	<u>A208353</u>	<u>001</u>	Feb 17, 2017
<u>AP</u>		FOSUN PHARMA	<u>10MG/ML</u>	<u>A210979</u>	<u>001</u>	Jul 02, 2018
<u>AP</u>		FRESENIUS KABI USA	<u>10MG/ML</u>	<u>A210257</u>	<u>001</u>	Jan 25, 2019
<u>AP</u>		NEXUS PHARMS	<u>10MG/ML</u>	<u>A206468</u>	<u>001</u>	Feb 01, 2019
<u>AP</u>		SLATE RUN PHARMA	<u>10MG/ML</u>	<u>A207076</u>	<u>001</u>	Nov 02, 2018

DICYCLOMINE HYDROCHLORIDE (PRESERVATIVE FREE)

<u>AP</u>		HIKMA	<u>10MG/ML</u>	<u>A040465</u>	<u>001</u>	Jun 30, 2003

SYRUP; ORAL

DICYCLOMINE HYDROCHLORIDE

<u>AA</u>	!	GENERICS	<u>10MG/5ML</u>	<u>A040169</u>	<u>001</u>	Mar 24, 2005
<u>AA</u>		HIKMA	<u>10MG/5ML</u>	<u>A212286</u>	<u>001</u>	May 22, 2020
<u>AA</u>		NOVITIUM PHARMA	<u>10MG/5ML</u>	<u>A214721</u>	<u>001</u>	Apr 23, 2021

TABLET; ORAL

DICYCLOMINE HYDROCHLORIDE

<u>AB</u>		COREPHARMA	<u>20MG</u>	<u>A216760</u>	<u>001</u>	Nov 28, 2022
<u>AB</u>		HIKMA PHARMS	<u>20MG</u>	<u>A040161</u>	<u>001</u>	Oct 01, 1996
<u>AB</u>		LANNETT	<u>20MG</u>	<u>A040230</u>	<u>001</u>	Feb 26, 1999
<u>AB</u>		RUBICON	<u>20MG</u>	<u>A216736</u>	<u>001</u>	Dec 14, 2022
<u>AB</u>	!	WATSON LABS	<u>20MG</u>	<u>A085223</u>	<u>001</u>	Jul 30, 1986

PRESCRIPTION DRUG PRODUCT LIST

3-144 (of 474)

DIENOGEST; ESTRADIOL VALERATE

TABLET; ORAL

NATAZIA

+! BAYER HLTHCARE N/A, 2MG, 3MG, N/A, N/A; 3MG, 2MG, 2MG, 1MG, N/A N022252 001 May 06, 2010

DIETHYLPROPION HYDROCHLORIDE

TABLET; ORAL

DIETHYLPROPION HYDROCHLORIDE**AA** AVANTHI INC **25MG** **A201212 001** Dec 22, 2010**AA** ! LANNETT CO INC **25MG** **A200177 001** Jul 18, 2011

TABLET, EXTENDED RELEASE; ORAL

DIETHYLPROPION HYDROCHLORIDE**AB** ! LANNETT CO INC **75MG** **A091680 001** Oct 24, 2011DIFELIKEFALIN ACETATE

SOLUTION; INTRAVENOUS

KORSUVA

+! CARA THERAP EQ 0.065MG BASE/1.3ML (EQ 0.05MG BASE/ML) N214916 001 Aug 23, 2021

DIFLORASONE DIACETATE

CREAM; TOPICAL

DIFLORASONE DIACETATE

BX ! ANI PHARMS 0.05% A076263 001 Dec 20, 2002

BX ! TARO 0.05% A075508 001 Apr 24, 2000

OINTMENT; TOPICAL

DIFLORASONE DIACETATE**AB** FOUGERA PHARMS **0.05%** **A075374 001** Apr 27, 1999**AB** RISING **0.05%** **A207440 001** Feb 27, 2017**AB** ! TARO **0.05%** **A075331 001** May 14, 1999**AB** THE J MOLNER **0.05%** **A210753 001** Jun 12, 2018DIFLUNISAL

TABLET; ORAL

DIFLUNISAL**AB** HERITAGE PHARMA **500MG** **A202845 001** Mar 08, 2012**AB** ! TEVA **500MG** **A073673 001** Jul 31, 1992**AB** ZYDUS PHARMS **500MG** **A203547 001** Jun 16, 2017DIFLUPREDNATE

EMULSION; OPHTHALMIC

DIFLUPREDNATE**AB** AMNEAL **0.05%** **A211526 001** Nov 17, 2021**AB** CIPLA **0.05%** **A211776 001** Aug 09, 2021**AB** DR REDDYS **0.05%** **A214894 001** Nov 16, 2022DUREZOL**AB** +! NOVARTIS **0.05%** **N022212 001** Jun 23, 2008DIGOXIN

ELIXIR; ORAL

DIGOXIN**AA** AMICI **0.05MG/ML** **A215209 001** Mar 11, 2022**AA** +! HIKMA **0.05MG/ML** **N021648 001** Aug 26, 2004**AA** NOVITIUM PHARMA **0.05MG/ML** **A213000 001** Oct 04, 2019

INJECTABLE; INJECTION

DIGOXIN**AP** SANDOZ INC **0.25MG/ML** **A040481 001** Aug 21, 2003**AP** WEST-WARD PHARMS **0.25MG/ML** **A083391 001**

INT

LANOXIN**AP** +! COVIS **0.25MG/ML** **N009330 002**

LANOXIN PEDIATRIC

+! COVIS 0.1MG/ML N009330 004

TABLET; ORAL

DIGOXIN**AB** AUROBINDO PHARMA LTD **0.0625MG** **A214982 001** Feb 08, 2022**AB** **0.125MG** **A214982 002** Feb 08, 2022**AB** **0.25MG** **A214982 003** Feb 08, 2022**AB** HIKMA INTL PHARMS **0.125MG** **A077002 002** Oct 30, 2007**AB** **0.25MG** **A077002 001** Oct 30, 2007**AB** IMPAX LABS **0.125MG** **A078556 001** Jul 20, 2009**AB** **0.25MG** **A078556 002** Jul 20, 2009**AB** NOVITIUM PHARMA **0.0625MG** **A215307 003** Aug 25, 2022**AB** **0.125MG** **A215307 001** Nov 22, 2021**AB** **0.25MG** **A215307 002** Nov 22, 2021

PRESCRIPTION DRUG PRODUCT LIST

3-145 (of 474)

DIGOXIN

TABLET; ORAL

DIGOXIN

<u>AB</u>	RISING	<u>0.125MG</u>	<u>A040282</u>	<u>001</u>	Dec 23, 1999
<u>AB</u>		<u>0.25MG</u>	<u>A040282</u>	<u>002</u>	Dec 23, 1999
<u>AB</u>	STEVENS J	<u>0.125MG</u>	<u>A076268</u>	<u>001</u>	Jul 26, 2002
<u>AB</u>		<u>0.25MG</u>	<u>A076268</u>	<u>002</u>	Jul 26, 2002
<u>AB</u>	SUN PHARM INDS INC	<u>0.125MG</u>	<u>A076363</u>	<u>001</u>	Jan 31, 2003
<u>AB</u>		<u>0.25MG</u>	<u>A076363</u>	<u>002</u>	Jan 31, 2003

LANOXIN

<u>AB</u>	+	CONCORDIA	<u>0.0625MG</u>	<u>N020405</u>	<u>001</u>	Sep 30, 1997
<u>AB</u>	+		<u>0.125MG</u>	<u>N020405</u>	<u>002</u>	Sep 30, 1997
<u>AB</u>	+	!	<u>0.25MG</u>	<u>N020405</u>	<u>004</u>	Sep 30, 1997

DIHYDROERGOTAMINE MESYLATE

INJECTABLE; INJECTION

DIHYDROERGOTAMINE MESYLATE

<u>AP</u>	HIKMA	<u>1MG/ML</u>	<u>A040453</u>	<u>001</u>	Jun 09, 2003
<u>AP</u>	!	HIKMA PHARMS	<u>A206621</u>	<u>001</u>	Sep 15, 2017
<u>AP</u>	PADAGIS US	<u>1MG/ML</u>	<u>A040475</u>	<u>001</u>	Apr 28, 2003
<u>AP</u>	PROVEPHARM SAS	<u>1MG/ML</u>	<u>A212046</u>	<u>001</u>	Jan 07, 2020
<u>AP</u>	SAGENT PHARMS INC	<u>1MG/ML</u>	<u>A207264</u>	<u>001</u>	Jul 11, 2018

SPRAY, METERED; NASAL

DIHYDROERGOTAMINE MESYLATE

<u>AB</u>	CIPLA	<u>0.5MG/SPRAY</u>	<u>A212907</u>	<u>001</u>	May 20, 2020
<u>AB</u>	HIKMA	<u>0.5MG/SPRAY</u>	<u>A211393</u>	<u>001</u>	Feb 28, 2020

MIGRANAL

<u>AB</u>	+	!	BAUSCH	<u>0.5MG/SPRAY</u>	<u>N020148</u>	<u>001</u>	Dec 08, 1997
			TRUDHESA				
			+	!	IMPEL PHARMS	0.725MG/SPRAY	N213436 001 Sep 02, 2021

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

DILTIAZEM HYDROCHLORIDE

<u>AB1</u>	GLENMARK PHARMS LTD	<u>60MG</u>	<u>A212317</u>	<u>001</u>	Mar 22, 2021
<u>AB1</u>		<u>90MG</u>	<u>A212317</u>	<u>002</u>	Mar 22, 2021
<u>AB1</u>		<u>120MG</u>	<u>A212317</u>	<u>003</u>	Mar 22, 2021
<u>AB1</u>	MAYNE PHARMA INTL	<u>60MG</u>	<u>A215775</u>	<u>001</u>	May 05, 2022
<u>AB1</u>		<u>90MG</u>	<u>A215775</u>	<u>002</u>	May 05, 2022
<u>AB1</u>		<u>120MG</u>	<u>A215775</u>	<u>003</u>	May 05, 2022
<u>AB1</u>	MYLAN	<u>60MG</u>	<u>A074910</u>	<u>001</u>	May 02, 1997
<u>AB1</u>		<u>90MG</u>	<u>A074910</u>	<u>002</u>	May 02, 1997
<u>AB1</u>	!	<u>120MG</u>	<u>A074910</u>	<u>003</u>	May 02, 1997
<u>AB2</u>	ACCORD HLTHCARE	<u>120MG</u>	<u>A206997</u>	<u>001</u>	Apr 28, 2020
<u>AB2</u>		<u>180MG</u>	<u>A206997</u>	<u>002</u>	Apr 28, 2020
<u>AB2</u>		<u>240MG</u>	<u>A206997</u>	<u>003</u>	Apr 28, 2020
<u>AB2</u>	AMTA	<u>120MG</u>	<u>A216304</u>	<u>001</u>	Aug 08, 2022
<u>AB2</u>		<u>180MG</u>	<u>A216304</u>	<u>002</u>	Aug 08, 2022
<u>AB2</u>		<u>240MG</u>	<u>A216304</u>	<u>003</u>	Aug 08, 2022
<u>AB2</u>	APOTEX	<u>120MG</u>	<u>A074943</u>	<u>003</u>	Dec 19, 2000
<u>AB2</u>		<u>180MG</u>	<u>A074943</u>	<u>002</u>	Dec 19, 2000
<u>AB2</u>	!	<u>240MG</u>	<u>A074943</u>	<u>001</u>	Aug 06, 1998

CARDIZEM CD

<u>AB3</u>	+	BAUSCH	<u>120MG</u>	<u>N020062</u>	<u>001</u>	Aug 10, 1992
<u>AB3</u>	+		<u>180MG</u>	<u>N020062</u>	<u>002</u>	Dec 27, 1991
<u>AB3</u>	+		<u>240MG</u>	<u>N020062</u>	<u>003</u>	Dec 27, 1991
<u>AB3</u>	+		<u>300MG</u>	<u>N020062</u>	<u>004</u>	Dec 27, 1991
<u>AB3</u>	+	!	<u>360MG</u>	<u>N020062</u>	<u>005</u>	Aug 24, 1999

CARTIA XT

<u>AB3</u>	ACTAVIS LABS FL INC	<u>120MG</u>	<u>A074752</u>	<u>002</u>	Jul 09, 1998
<u>AB3</u>		<u>180MG</u>	<u>A074752</u>	<u>001</u>	Jul 09, 1998
<u>AB3</u>		<u>240MG</u>	<u>A074752</u>	<u>003</u>	Jul 09, 1998
<u>AB3</u>		<u>300MG</u>	<u>A074752</u>	<u>004</u>	Jul 09, 1998

DILTIAZEM HYDROCHLORIDE

<u>AB3</u>	ACTAVIS ELIZABETH	<u>360MG</u>	<u>A202463</u>	<u>001</u>	Dec 07, 2012
<u>AB3</u>	NOVAST LABS	<u>120MG</u>	<u>A208783</u>	<u>001</u>	Jun 14, 2019
<u>AB3</u>		<u>180MG</u>	<u>A208783</u>	<u>002</u>	Jun 14, 2019
<u>AB3</u>		<u>240MG</u>	<u>A208783</u>	<u>003</u>	Jun 14, 2019
<u>AB3</u>		<u>300MG</u>	<u>A208783</u>	<u>004</u>	Jun 14, 2019
<u>AB3</u>		<u>360MG</u>	<u>A208783</u>	<u>005</u>	Jun 14, 2019
<u>AB3</u>	PAR PHARM	<u>120MG</u>	<u>A074984</u>	<u>001</u>	Dec 20, 1999
<u>AB3</u>		<u>180MG</u>	<u>A074984</u>	<u>002</u>	Dec 20, 1999
<u>AB3</u>		<u>240MG</u>	<u>A074984</u>	<u>003</u>	Dec 20, 1999

PRESCRIPTION DRUG PRODUCT LIST

3-146 (of 474)

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

DILTIAZEM HYDROCHLORIDE

<u>AB3</u>		<u>300MG</u>	<u>A074984</u>	<u>004</u>	Dec 20, 1999
<u>AB3</u>	SUN PHARM	<u>120MG</u>	<u>A203023</u>	<u>001</u>	Jun 08, 2017
<u>AB3</u>		<u>180MG</u>	<u>A203023</u>	<u>002</u>	Jun 08, 2017
<u>AB3</u>		<u>240MG</u>	<u>A203023</u>	<u>003</u>	Jun 08, 2017
<u>AB3</u>		<u>300MG</u>	<u>A203023</u>	<u>004</u>	Jun 08, 2017
<u>AB3</u>		<u>360MG</u>	<u>A090492</u>	<u>005</u>	Oct 28, 2011
<u>AB3</u>		<u>360MG</u>	<u>A203023</u>	<u>005</u>	Jun 08, 2017
<u>AB3</u>	TWI PHARMS	<u>120MG</u>	<u>A205231</u>	<u>001</u>	Aug 30, 2018
<u>AB3</u>		<u>180MG</u>	<u>A205231</u>	<u>002</u>	Aug 30, 2018
<u>AB3</u>		<u>240MG</u>	<u>A205231</u>	<u>003</u>	Aug 30, 2018
<u>AB3</u>		<u>300MG</u>	<u>A205231</u>	<u>004</u>	Aug 30, 2018
<u>AB3</u>		<u>360MG</u>	<u>A205231</u>	<u>005</u>	Aug 30, 2018
<u>AB3</u>	VALEANT PHARMS NORTH	<u>120MG</u>	<u>A075116</u>	<u>001</u>	Dec 23, 1999
<u>AB3</u>		<u>180MG</u>	<u>A075116</u>	<u>002</u>	Dec 23, 1999
<u>AB3</u>		<u>240MG</u>	<u>A075116</u>	<u>003</u>	Dec 23, 1999
<u>AB3</u>		<u>300MG</u>	<u>A075116</u>	<u>004</u>	Dec 23, 1999
<u>AB3</u>	ZYDUS PHARMS	<u>120MG</u>	<u>A206534</u>	<u>001</u>	Aug 08, 2017
<u>AB3</u>		<u>180MG</u>	<u>A206534</u>	<u>002</u>	Aug 08, 2017
<u>AB3</u>		<u>240MG</u>	<u>A206534</u>	<u>003</u>	Aug 08, 2017
<u>AB3</u>		<u>300MG</u>	<u>A206534</u>	<u>004</u>	Aug 08, 2017
<u>AB3</u>		<u>360MG</u>	<u>A206534</u>	<u>005</u>	Aug 08, 2017
<u>AB4</u>	SANDOZ	<u>120MG</u>	<u>A091022</u>	<u>001</u>	Sep 28, 2012
<u>AB4</u>		<u>180MG</u>	<u>A091022</u>	<u>002</u>	Sep 28, 2012
<u>AB4</u>		<u>240MG</u>	<u>A091022</u>	<u>003</u>	Sep 28, 2012
<u>AB4</u>		<u>300MG</u>	<u>A091022</u>	<u>004</u>	Sep 28, 2012
<u>AB4</u>		<u>360MG</u>	<u>A091022</u>	<u>005</u>	Sep 28, 2012
<u>AB4</u>		<u>420MG</u>	<u>A091022</u>	<u>006</u>	Sep 28, 2012
<u>AB4</u>	SUN PHARM	<u>120MG</u>	<u>A090421</u>	<u>001</u>	Nov 15, 2010
<u>AB4</u>		<u>180MG</u>	<u>A090421</u>	<u>002</u>	Nov 15, 2010
<u>AB4</u>		<u>240MG</u>	<u>A090421</u>	<u>003</u>	Nov 15, 2010
<u>AB4</u>		<u>300MG</u>	<u>A090421</u>	<u>004</u>	Nov 15, 2010
<u>AB4</u>		<u>360MG</u>	<u>A090421</u>	<u>005</u>	Nov 15, 2010
<u>AB4</u>	ZYDUS PHARMS	<u>120MG</u>	<u>A206641</u>	<u>001</u>	Aug 11, 2017
<u>AB4</u>		<u>180MG</u>	<u>A206641</u>	<u>002</u>	Aug 11, 2017
<u>AB4</u>		<u>240MG</u>	<u>A206641</u>	<u>003</u>	Aug 11, 2017
<u>AB4</u>		<u>300MG</u>	<u>A206641</u>	<u>004</u>	Aug 11, 2017
<u>AB4</u>		<u>360MG</u>	<u>A206641</u>	<u>005</u>	Aug 11, 2017
<u>AB4</u>		<u>420MG</u>	<u>A206641</u>	<u>006</u>	Aug 11, 2017
<u>TAZTIA XT</u>					
<u>AB4</u>	ACTAVIS LABS FL INC	<u>120MG</u>	<u>A075401</u>	<u>001</u>	Apr 10, 2003
<u>AB4</u>		<u>180MG</u>	<u>A075401</u>	<u>002</u>	Apr 10, 2003
<u>AB4</u>		<u>240MG</u>	<u>A075401</u>	<u>003</u>	Apr 10, 2003
<u>AB4</u>		<u>300MG</u>	<u>A075401</u>	<u>004</u>	Apr 10, 2003
<u>AB4</u>		<u>360MG</u>	<u>A075401</u>	<u>005</u>	Apr 10, 2003
<u>TIAZAC</u>					
<u>AB4</u>	+	<u>120MG</u>	<u>N020401</u>	<u>001</u>	Sep 11, 1995
<u>AB4</u>	+	<u>180MG</u>	<u>N020401</u>	<u>002</u>	Sep 11, 1995
<u>AB4</u>	+	<u>240MG</u>	<u>N020401</u>	<u>003</u>	Sep 11, 1995
<u>AB4</u>	+	<u>300MG</u>	<u>N020401</u>	<u>004</u>	Sep 11, 1995
<u>AB4</u>	+	<u>360MG</u>	<u>N020401</u>	<u>005</u>	Sep 11, 1995
<u>AB4</u>	+	<u>420MG</u>	<u>N020401</u>	<u>006</u>	Oct 16, 1998
INJECTABLE; INJECTION					
<u>DILTIAZEM HYDROCHLORIDE</u>					
<u>AP</u>	AKORN	<u>5MG/ML</u>	<u>A075086</u>	<u>001</u>	Apr 09, 1998
<u>AP</u>	! ATHENEX INC	<u>5MG/ML</u>	<u>A074617</u>	<u>001</u>	Feb 28, 1996
<u>AP</u>	HIKMA FARMACEUTICA	<u>5MG/ML</u>	<u>A202651</u>	<u>001</u>	Aug 09, 2012
<u>AP</u>	HOSPIRA	<u>5MG/ML</u>	<u>A074941</u>	<u>001</u>	Apr 15, 1998
<u>AP</u>	WEST-WARD PHARMS INT	<u>5MG/ML</u>	<u>A078538</u>	<u>001</u>	Dec 17, 2008
	! HOSPIRA	100MG/VIAL	A075853	001	Dec 17, 2002
TABLET; ORAL					
<u>CARDIZEM</u>					
<u>AB</u>	+	<u>30MG</u>	<u>N018602</u>	<u>001</u>	Nov 05, 1982
<u>AB</u>	+	<u>60MG</u>	<u>N018602</u>	<u>002</u>	Nov 05, 1982
<u>AB</u>	+	<u>90MG</u>	<u>N018602</u>	<u>003</u>	Dec 08, 1986
<u>AB</u>	+	<u>120MG</u>	<u>N018602</u>	<u>004</u>	Dec 08, 1986
<u>DILTIAZEM HYDROCHLORIDE</u>					
<u>AB</u>	EDENBRIDGE PHARMS	<u>30MG</u>	<u>A211596</u>	<u>001</u>	Nov 18, 2019
<u>AB</u>		<u>60MG</u>	<u>A211596</u>	<u>002</u>	Nov 18, 2019

PRESCRIPTION DRUG PRODUCT LIST

3-147 (of 474)

DILTIAZEM HYDROCHLORIDE

TABLET; ORAL

DILTIAZEM HYDROCHLORIDE

<u>AB</u>		<u>90MG</u>	<u>A211596</u>	<u>003</u>	Nov 18, 2019
<u>AB</u>		<u>120MG</u>	<u>A211596</u>	<u>004</u>	Nov 18, 2019
<u>AB</u>	SCIEGEN PHARMS INC	<u>30MG</u>	<u>A216521</u>	<u>001</u>	Sep 23, 2022
<u>AB</u>		<u>60MG</u>	<u>A216521</u>	<u>002</u>	Sep 23, 2022
<u>AB</u>		<u>90MG</u>	<u>A216521</u>	<u>003</u>	Sep 23, 2022
<u>AB</u>		<u>120MG</u>	<u>A216521</u>	<u>004</u>	Sep 23, 2022
<u>AB</u>	TEVA	<u>30MG</u>	<u>A074185</u>	<u>001</u>	May 31, 1995
<u>AB</u>		<u>60MG</u>	<u>A074185</u>	<u>002</u>	May 31, 1995
<u>AB</u>		<u>90MG</u>	<u>A074185</u>	<u>003</u>	May 31, 1995
<u>AB</u>		<u>120MG</u>	<u>A074185</u>	<u>004</u>	May 31, 1995

TABLET, EXTENDED RELEASE; ORAL

CARDIZEM LA

<u>AB</u>	+	BAUSCH	<u>120MG</u>	<u>N021392</u>	<u>001</u>	Feb 06, 2003
<u>AB</u>	+		<u>180MG</u>	<u>N021392</u>	<u>002</u>	Feb 06, 2003
<u>AB</u>	+		<u>240MG</u>	<u>N021392</u>	<u>003</u>	Feb 06, 2003
<u>AB</u>	+		<u>300MG</u>	<u>N021392</u>	<u>004</u>	Feb 06, 2003
<u>AB</u>	+		<u>360MG</u>	<u>N021392</u>	<u>005</u>	Feb 06, 2003
<u>AB</u>	+		<u>420MG</u>	<u>N021392</u>	<u>006</u>	Feb 06, 2003

DILTIAZEM HYDROCHLORIDE

<u>AB</u>		ACTAVIS LABS FL INC	<u>120MG</u>	<u>A077686</u>	<u>006</u>	Mar 15, 2010
<u>AB</u>			<u>180MG</u>	<u>A077686</u>	<u>005</u>	Mar 15, 2010
<u>AB</u>			<u>240MG</u>	<u>A077686</u>	<u>004</u>	Mar 15, 2010
<u>AB</u>			<u>300MG</u>	<u>A077686</u>	<u>003</u>	Mar 15, 2010
<u>AB</u>			<u>360MG</u>	<u>A077686</u>	<u>002</u>	Mar 15, 2010
<u>AB</u>			<u>420MG</u>	<u>A077686</u>	<u>001</u>	Mar 15, 2010

DIMENHYDRINATE

INJECTABLE; INJECTION

DIMENHYDRINATE

!	FRESENIUS KABI USA	50MG/ML	A040519	001	Jun 23, 2004

DIMERCAPROL

INJECTABLE; INJECTION

BAL

+	AKORN	10%	N005939	001	

DIMETHYL FUMARATE

CAPSULE, DELAYED RELEASE; ORAL

DIMETHYL FUMARATE

<u>AB</u>		ACCORD HLTHCARE	<u>120MG</u>	<u>A210499</u>	<u>001</u>	Sep 24, 2020
<u>AB</u>			<u>240MG</u>	<u>A210499</u>	<u>002</u>	Sep 24, 2020
<u>AB</u>		ALKEM LABS LTD	<u>120MG</u>	<u>A210440</u>	<u>001</u>	Sep 24, 2020
<u>AB</u>			<u>240MG</u>	<u>A210440</u>	<u>002</u>	Sep 24, 2020
<u>AB</u>		AMNEAL	<u>120MG</u>	<u>A210402</u>	<u>001</u>	Sep 24, 2020
<u>AB</u>			<u>240MG</u>	<u>A210402</u>	<u>002</u>	Sep 24, 2020
<u>AB</u>		AUROBINDO PHARMA	<u>120MG</u>	<u>A210385</u>	<u>001</u>	Dec 22, 2022
<u>AB</u>			<u>240MG</u>	<u>A210385</u>	<u>002</u>	Dec 22, 2022
<u>AB</u>		CIPLA	<u>120MG</u>	<u>A210305</u>	<u>001</u>	Sep 24, 2020
<u>AB</u>			<u>240MG</u>	<u>A210305</u>	<u>002</u>	Sep 24, 2020
<u>AB</u>		GLENMARK PHARMS LTD	<u>120MG</u>	<u>A210309</u>	<u>001</u>	Oct 06, 2020
<u>AB</u>			<u>240MG</u>	<u>A210309</u>	<u>002</u>	Oct 06, 2020
<u>AB</u>		HETERO LABS LTD III	<u>120MG</u>	<u>A210500</u>	<u>001</u>	Sep 24, 2020
<u>AB</u>			<u>240MG</u>	<u>A210500</u>	<u>002</u>	Sep 24, 2020
<u>AB</u>		LUPIN	<u>120MG</u>	<u>A210226</u>	<u>001</u>	Oct 05, 2020
<u>AB</u>			<u>240MG</u>	<u>A210226</u>	<u>002</u>	Oct 05, 2020
<u>AB</u>		MSN	<u>120MG</u>	<u>A210460</u>	<u>001</u>	Sep 24, 2020
<u>AB</u>			<u>240MG</u>	<u>A210460</u>	<u>002</u>	Sep 24, 2020
<u>AB</u>		MYLAN	<u>120MG</u>	<u>A210531</u>	<u>001</u>	Aug 17, 2020
<u>AB</u>			<u>240MG</u>	<u>A210531</u>	<u>002</u>	Aug 17, 2020
<u>AB</u>		PRINSTON INC	<u>120MG</u>	<u>A210414</u>	<u>001</u>	Oct 18, 2022
<u>AB</u>			<u>240MG</u>	<u>A210414</u>	<u>002</u>	Oct 18, 2022
<u>AB</u>		TWI PHARMS	<u>120MG</u>	<u>A210382</u>	<u>001</u>	Oct 14, 2020
<u>AB</u>			<u>240MG</u>	<u>A210382</u>	<u>002</u>	Oct 14, 2020

TECFIDERA

<u>AB</u>	+	BIOGEN INC	<u>120MG</u>	<u>N204063</u>	<u>001</u>	Mar 27, 2013
<u>AB</u>	+		<u>240MG</u>	<u>N204063</u>	<u>002</u>	Mar 27, 2013

PRESCRIPTION DRUG PRODUCT LIST

3-148 (of 474)

DIMETHYL SULFOXIDE

SOLUTION; INTRAVESICAL

RIMSO-50

+! MYLAN INSTITUTIONAL 50%

N017788 001

DINOPROSTONE

GEL; ENDOCERVICAL

PREPIDIL

+! PFIZER 0.5MG/3GM

N019617 001 Dec 09, 1992

INSERT, EXTENDED RELEASE; VAGINAL

CERVIDIL

+! FERRING PHARMS INC 10MG

N020411 001 Mar 30, 1995

DIPHENHYDRAMINE HYDROCHLORIDE

ELIXIR; ORAL

DIPHENHYDRAMINE HYDROCHLORIDE

! PHARM ASSOC 12.5MG/5ML

A087513 001 Feb 10, 1982

INJECTABLE; INJECTION

DIPHENHYDRAMINE HYDROCHLORIDEAP APP PHARMS 50MG/MLA040466 001 May 28, 2002AP MICRO LABS 50MG/MLA205723 001 Aug 22, 2018AP MYLAN INSTITUTIONAL 50MG/MLA040498 001 Jul 12, 2005AP +! WEST-WARD PHARMS 50MG/MLA080817 002

INT

DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREEAP FRESENIUS KABI USA 50MG/MLA091526 001 Mar 26, 2013DIPYRIDAMOLE

INJECTABLE; INJECTION

DIPYRIDAMOLEAP ! CHARTWELL 5MG/MLA074939 001 Apr 13, 1998

INJECTABLE

AP FRESENIUS KABI USA 5MG/MLA074956 001 Sep 30, 1998AP HIKMA 5MG/MLA074521 001 Oct 18, 1996

TABLET; ORAL

DIPYRIDAMOLEAB ANI PHARMS 25MGA086944 002 Apr 16, 1991AB 50MGA086944 001 Feb 25, 1992AB 75MGA086944 003 Feb 25, 1992AB BARR 25MGA087184 001 Oct 03, 1990AB 50MGA087716 001 Oct 03, 1990AB 75MGA087717 001 Oct 03, 1990AB IMPAX LABS 25MGA040782 001 Jul 18, 2007AB 50MGA040782 002 Jul 18, 2007AB 75MGA040782 003 Jul 18, 2007AB MURTY PHARMS 25MGA040733 001 Feb 13, 2007AB 50MGA040733 002 Feb 13, 2007AB 75MGA040733 003 Feb 13, 2007AB OXFORD PHARMS 25MGA040542 001 Apr 21, 2006AB 50MGA040542 002 Apr 21, 2006AB 75MGA040542 003 Apr 21, 2006AB ZYDUS PHARMS USA 25MGA040874 001 Jan 28, 2008

INC

AB 50MGA040874 002 Jan 28, 2008AB 75MGA040874 003 Jan 28, 2008PERSANTINEAB + BOEHRINGER 25MGN012836 003 Dec 22, 1986

INGELHEIM

AB + 50MGN012836 004 Feb 06, 1987AB +! 75MGN012836 005 Feb 06, 1987DIROXIMEL FUMARATE

CAPSULE, DELAYED RELEASE; ORAL

VUMERITY

+! BIOGEN INC 231MG

N211855 001 Oct 29, 2019

DISOPYRAMIDE PHOSPHATE

CAPSULE; ORAL

DISOPYRAMIDE PHOSPHATEAB MAYNE PHARMA EQ 100MG BASEA070173 001 May 31, 1985AB EQ 150MG BASEA070173 002 May 31, 1985AB TEVA EQ 100MG BASEA070101 001 Feb 22, 1985AB EQ 150MG BASEA070102 001 Feb 22, 1985NORPACEAB + PFIZER EQ 100MG BASEN017447 001AB +! EQ 150MG BASEN017447 002

PRESCRIPTION DRUG PRODUCT LIST

3-149 (of 474)

DISOPYRAMIDE PHOSPHATE

CAPSULE, EXTENDED RELEASE;ORAL

NORPACE CR

+ PFIZER

EQ 100MG BASE

N018655 001 Jul 20, 1982

+!

EQ 150MG BASE

N018655 002 Jul 20, 1982

DISULFIRAM

TABLET;ORAL

DISULFIRAMAB ALVOGEN250MGA091681 001 Aug 08, 2013AB CHARTWELL MOLECULES250MGA091563 001 Dec 31, 2012AB500MGA091563 002 Dec 31, 2012AB HIKMA250MGA202652 001 Feb 05, 2014AB !500MGA202652 002 Feb 05, 2014AB SIGMAPHARM LABS LLC250MGA091619 001 Mar 28, 2011AB500MGA091619 002 Mar 28, 2011DIVALPROEX SODIUM

CAPSULE, DELAYED REL PELLETS;ORAL

DEPAKOTEAB +! ABBVIEEQ 125MG VALPROIC ACIDN019680 001 Sep 12, 1989DIVALPROEX SODIUMAB AJANTA PHARMA LTDEQ 125MG VALPROIC ACIDA213181 001 Mar 02, 2020AB DR REDDYS LABS LTDEQ 125MG VALPROIC ACIDA078979 001 Jan 23, 2009AB ZYDUS PHARMS USAEQ 125MG VALPROIC ACIDA078919 001 Jan 27, 2009

INC

TABLET, DELAYED RELEASE;ORAL

DEPAKOTEAB + ABBVIEEQ 125MG VALPROIC ACIDN018723 003 Oct 26, 1984AB +EQ 250MG VALPROIC ACIDN018723 001 Mar 10, 1983AB +!EQ 500MG VALPROIC ACIDN018723 002 Mar 10, 1983DIVALPROEX SODIUMAB ACTAVIS LABS FL INCEQ 500MG VALPROIC ACIDA079080 001 Feb 25, 2011AB APOTEXEQ 125MG VALPROIC ACIDA077615 003 Jul 29, 2008ABEQ 250MG VALPROIC ACIDA077615 002 Jul 29, 2008ABEQ 500MG VALPROIC ACIDA077615 001 Jul 29, 2008AB AUROBINDO PHARMAEQ 125MG VALPROIC ACIDA090554 001 Apr 21, 2011

LTD

ABEQ 250MG VALPROIC ACIDA090554 002 Apr 21, 2011ABEQ 500MG VALPROIC ACIDA090554 003 Apr 21, 2011AB

CELLTRION

EQ 125MG VALPROIC ACIDA077296 001 Jul 31, 2008ABEQ 250MG VALPROIC ACIDA077296 002 Jul 31, 2008ABEQ 500MG VALPROIC ACIDA077296 003 Jul 31, 2008AB

DR REDDYS LABS LTD

EQ 125MG VALPROIC ACIDA078755 001 Jul 29, 2008ABEQ 250MG VALPROIC ACIDA078755 002 Jul 29, 2008ABEQ 500MG VALPROIC ACIDA078755 003 Jul 29, 2008AB

INVATECH

EQ 125MG VALPROIC ACIDA078290 003 Jul 29, 2008ABEQ 250MG VALPROIC ACIDA078290 002 Jul 29, 2008ABEQ 500MG VALPROIC ACIDA078290 001 Jul 29, 2008AB

LUPIN

EQ 125MG VALPROIC ACIDA078790 001 Jul 29, 2008ABEQ 250MG VALPROIC ACIDA078790 002 Jul 29, 2008ABEQ 500MG VALPROIC ACIDA078790 003 Jul 29, 2008AB

ORBION PHARMS

EQ 125MG VALPROIC ACIDA078853 001 Nov 25, 2008ABEQ 250MG VALPROIC ACIDA078853 002 Nov 25, 2008ABEQ 500MG VALPROIC ACIDA078853 003 Nov 25, 2008AB

PRINSTON INC

EQ 125MG VALPROIC ACIDA090210 001 Nov 30, 2009ABEQ 250MG VALPROIC ACIDA090210 002 Nov 30, 2009ABEQ 500MG VALPROIC ACIDA090210 003 Nov 30, 2009AB

SUN PHARM INDS

EQ 125MG VALPROIC ACIDA078597 001 Jul 29, 2008ABEQ 250MG VALPROIC ACIDA078597 002 Jul 29, 2008ABEQ 500MG VALPROIC ACIDA078597 003 Jul 29, 2008AB

UNICHEM LABS LTD

EQ 125MG VALPROIC ACIDA079163 001 Apr 05, 2011ABEQ 250MG VALPROIC ACIDA079163 002 Apr 05, 2011ABEQ 500MG VALPROIC ACIDA079163 003 Apr 05, 2011AB

UPSHER SMITH LABS

EQ 125MG VALPROIC ACIDA078182 001 Jul 29, 2008ABEQ 250MG VALPROIC ACIDA078182 002 Jul 29, 2008ABEQ 500MG VALPROIC ACIDA078182 003 Jul 29, 2008AB

ZYDUS PHARMS USA

EQ 125MG VALPROIC ACIDA077100 001 Mar 05, 2009

INC

ABEQ 250MG VALPROIC ACIDA077100 002 Mar 05, 2009ABEQ 500MG VALPROIC ACIDA077100 003 Mar 05, 2009

PRESCRIPTION DRUG PRODUCT LIST

3-150 (of 474)

DIVALPROEX SODIUM

TABLET, EXTENDED RELEASE;ORAL

DEPAKOTE ER

<u>AB</u>	+	ABBVIE	<u>EQ 250MG VALPROIC ACID</u>	<u>N021168</u>	<u>002</u>	May 31, 2002
<u>AB</u>	+	!	<u>EQ 500MG VALPROIC ACID</u>	<u>N021168</u>	<u>001</u>	Aug 04, 2000

DIVALPROEX SODIUM

<u>AB</u>		AMNEAL PHARMS	<u>EQ 250MG VALPROIC ACID</u>	<u>A203730</u>	<u>001</u>	May 29, 2015
<u>AB</u>			<u>EQ 500MG VALPROIC ACID</u>	<u>A203730</u>	<u>002</u>	May 29, 2015
<u>AB</u>		AUROBINDO PHARMA LTD	<u>EQ 250MG VALPROIC ACID</u>	<u>A202419</u>	<u>001</u>	Jun 02, 2014
<u>AB</u>			<u>EQ 500MG VALPROIC ACID</u>	<u>A202419</u>	<u>002</u>	Jun 02, 2014
<u>AB</u>		DR REDDYS LABS LTD	<u>EQ 250MG VALPROIC ACID</u>	<u>A090161</u>	<u>001</u>	Mar 15, 2012
<u>AB</u>		LUPIN LTD	<u>EQ 250MG VALPROIC ACID</u>	<u>A209286</u>	<u>001</u>	Oct 18, 2019
<u>AB</u>			<u>EQ 500MG VALPROIC ACID</u>	<u>A209286</u>	<u>002</u>	Oct 18, 2019
<u>AB</u>		MYLAN	<u>EQ 250MG VALPROIC ACID</u>	<u>A077567</u>	<u>001</u>	Jan 29, 2009
<u>AB</u>			<u>EQ 500MG VALPROIC ACID</u>	<u>A077567</u>	<u>002</u>	Jan 29, 2009
<u>AB</u>		REDDYS	<u>EQ 500MG VALPROIC ACID</u>	<u>A090070</u>	<u>001</u>	Mar 12, 2012
<u>AB</u>		UNICHEM	<u>EQ 250MG VALPROIC ACID</u>	<u>A214643</u>	<u>001</u>	Feb 25, 2022
<u>AB</u>			<u>EQ 500MG VALPROIC ACID</u>	<u>A214643</u>	<u>002</u>	Feb 25, 2022
<u>AB</u>		WOCKHARDT	<u>EQ 250MG VALPROIC ACID</u>	<u>A078705</u>	<u>002</u>	Feb 10, 2009
<u>AB</u>			<u>EQ 500MG VALPROIC ACID</u>	<u>A078705</u>	<u>001</u>	Aug 04, 2009
<u>AB</u>		ZYDUS PHARMS USA INC	<u>EQ 250MG VALPROIC ACID</u>	<u>A078239</u>	<u>001</u>	Feb 27, 2009
<u>AB</u>			<u>EQ 500MG VALPROIC ACID</u>	<u>A078239</u>	<u>002</u>	Aug 04, 2009

DOBUTAMINE HYDROCHLORIDE

INJECTABLE;INJECTION

DOBUTAMINE HYDROCHLORIDE

<u>AP</u>		HAINAN POLY	<u>EQ 12.5MG BASE/ML</u>	<u>A216131</u>	<u>001</u>	Dec 21, 2022
<u>AP</u>		HIKMA	<u>EQ 12.5MG BASE/ML</u>	<u>A074277</u>	<u>001</u>	Oct 31, 1994
<u>AP</u>	!	HOSPIRA	<u>EQ 12.5MG BASE/ML</u>	<u>A074086</u>	<u>001</u>	Nov 29, 1993

DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>	+	!	BAXTER HLTHCARE	<u>EQ 50MG BASE/100ML</u>	<u>N020255</u>	<u>001</u>	Oct 19, 1993
<u>AP</u>	+	!		<u>EQ 100MG BASE/100ML</u>	<u>N020255</u>	<u>003</u>	Oct 19, 1993
<u>AP</u>	+	!		<u>EQ 200MG BASE/100ML</u>	<u>N020255</u>	<u>004</u>	Oct 19, 1993
<u>AP</u>	+	!		<u>EQ 400MG BASE/100ML</u>	<u>N020255</u>	<u>005</u>	Oct 19, 1993
<u>AP</u>	+	!	HOSPIRA	<u>EQ 50MG BASE/100ML</u>	<u>N020201</u>	<u>003</u>	Oct 19, 1993
<u>AP</u>	+	!		<u>EQ 100MG BASE/100ML</u>	<u>N020201</u>	<u>002</u>	Oct 19, 1993
<u>AP</u>	+	!		<u>EQ 200MG BASE/100ML</u>	<u>N020201</u>	<u>001</u>	Oct 19, 1993
<u>AP</u>	+	!		<u>EQ 400MG BASE/100ML</u>	<u>N020201</u>	<u>006</u>	Jul 07, 1994

DOCETAXEL

INJECTABLE;INJECTION

DOCETAXEL

<u>AP</u>	+	+	ACCORD HLTHCARE	<u>20MG/ML (20MG/ML)</u>	<u>N201195</u>	<u>003</u>	Apr 20, 2012
<u>AP</u>	+	+		<u>80MG/4ML (20MG/ML)</u>	<u>N201195</u>	<u>004</u>	Apr 20, 2012
<u>AP</u>	+	+		<u>160MG/8ML (20MG/ML)</u>	<u>N201195</u>	<u>005</u>	Apr 20, 2012
<u>AP</u>			ACTAVIS LLC	<u>20MG/ML (20MG/ML)</u>	<u>N203551</u>	<u>001</u>	Apr 12, 2013
<u>AP</u>				<u>80MG/4ML (20MG/ML)</u>	<u>N203551</u>	<u>002</u>	Apr 12, 2013
<u>AP</u>				<u>160MG/8ML (20MG/ML)</u>	<u>N203551</u>	<u>004</u>	Sep 21, 2015
<u>AP</u>			AMNEAL	<u>20MG/ML (20MG/ML)</u>	<u>A209640</u>	<u>001</u>	Jan 19, 2018
<u>AP</u>				<u>80MG/4ML (20MG/ML)</u>	<u>A209640</u>	<u>002</u>	Jan 19, 2018
<u>AP</u>				<u>160MG/8ML (20MG/ML)</u>	<u>A209640</u>	<u>003</u>	Jan 19, 2018
<u>AP</u>			DR REDDYS	<u>20MG/ML (20MG/ML)</u>	<u>A204193</u>	<u>001</u>	Nov 05, 2014
<u>AP</u>				<u>80MG/4ML (20MG/ML)</u>	<u>A204193</u>	<u>002</u>	Nov 05, 2014
<u>AP</u>			EUGIA PHARMA	<u>20MG/2ML (10MG/ML)</u>	<u>A214575</u>	<u>001</u>	Jun 25, 2021
<u>AP</u>				<u>80MG/8ML (10MG/ML)</u>	<u>A214575</u>	<u>002</u>	Jun 25, 2021
<u>AP</u>				<u>160MG/16ML (10MG/ML)</u>	<u>A214575</u>	<u>003</u>	Jun 25, 2021
<u>AP</u>			GLAND PHARMA LTD	<u>20MG/2ML (10MG/ML)</u>	<u>A213510</u>	<u>001</u>	Jul 01, 2021
<u>AP</u>				<u>80MG/8ML (10MG/ML)</u>	<u>A213510</u>	<u>002</u>	Jul 01, 2021
<u>AP</u>				<u>160MG/16ML (10MG/ML)</u>	<u>A213510</u>	<u>003</u>	Jul 01, 2021
<u>AP</u>			HENG Rui PHARMA	<u>20MG/ML (20MG/ML)</u>	<u>A207252</u>	<u>001</u>	Aug 09, 2017
<u>AP</u>				<u>80MG/4ML (20MG/ML)</u>	<u>A207252</u>	<u>002</u>	Aug 09, 2017
<u>AP</u>				<u>160MG/8ML (20MG/ML)</u>	<u>A207252</u>	<u>003</u>	Aug 09, 2017
<u>AP</u>			HIKMA	<u>20MG/ML (20MG/ML)</u>	<u>A204490</u>	<u>001</u>	Jan 14, 2021
<u>AP</u>				<u>80MG/4ML (20MG/ML)</u>	<u>A204490</u>	<u>002</u>	Jan 14, 2021
<u>AP</u>	+	!	HOSPIRA INC	<u>20MG/2ML (10MG/ML)</u>	<u>N022234</u>	<u>001</u>	Mar 08, 2011
<u>AP</u>	+	!		<u>80MG/8ML (10MG/ML)</u>	<u>N022234</u>	<u>002</u>	Mar 08, 2011
<u>AP</u>	+	!		<u>160MG/16ML (10MG/ML)</u>	<u>N022234</u>	<u>003</u>	Mar 08, 2011
<u>AP</u>			INGENUS PHARMS LLC	<u>80MG/8ML (10MG/ML)</u>	<u>A207563</u>	<u>002</u>	Aug 31, 2017
<u>AP</u>				<u>160MG/16ML (10MG/ML)</u>	<u>A207563</u>	<u>003</u>	Aug 31, 2017
<u>AP</u>			MEITHEAL	<u>20MG/2ML (10MG/ML)</u>	<u>A209634</u>	<u>001</u>	Aug 24, 2018
<u>AP</u>				<u>80MG/8ML (10MG/ML)</u>	<u>A209634</u>	<u>002</u>	Aug 24, 2018
<u>AP</u>				<u>160MG/16ML (10MG/ML)</u>	<u>A209634</u>	<u>003</u>	Aug 24, 2018

PRESCRIPTION DRUG PRODUCT LIST

3-151 (of 474)

DOCETAXEL

INJECTABLE; INJECTION

DOCETAXEL

<u>AP</u>	MYLAN LABS LTD	<u>20MG/2ML (10MG/ML)</u>	<u>A210072</u>	<u>001</u>	Jul 02, 2018
<u>AP</u>		<u>80MG/8ML (10MG/ML)</u>	<u>A210848</u>	<u>001</u>	Jul 06, 2018
<u>AP</u>		<u>160MG/8ML (20MG/ML)</u>	<u>A208137</u>	<u>001</u>	Apr 01, 2019
<u>AP</u>		<u>160MG/16ML (10MG/ML)</u>	<u>A208859</u>	<u>001</u>	Apr 30, 2018
<u>AP</u>	SANDOZ	<u>20MG/2ML (10MG/ML)</u>	<u>N201525</u>	<u>001</u>	Jun 29, 2011
<u>AP</u>		<u>80MG/8ML (10MG/ML)</u>	<u>N201525</u>	<u>002</u>	Jun 29, 2011
<u>AP</u>		<u>160MG/16ML (10MG/ML)</u>	<u>N201525</u>	<u>003</u>	Jun 29, 2011
<u>AP</u>	SHILPA	<u>20MG/ML (20MG/ML)</u>	<u>A210327</u>	<u>001</u>	May 16, 2019
<u>AP</u>	+	<u>20MG/ML (20MG/ML)</u>	<u>N205934</u>	<u>001</u>	Dec 22, 2015
<u>AP</u>		<u>80MG/4ML (20MG/ML)</u>	<u>A210327</u>	<u>002</u>	May 16, 2019
<u>AP</u>	+	<u>80MG/4ML (20MG/ML)</u>	<u>N205934</u>	<u>002</u>	Dec 22, 2015
<u>AP</u>		<u>160MG/8ML (20MG/ML)</u>	<u>A210327</u>	<u>003</u>	May 16, 2019
<u>AP</u>	+	<u>160MG/8ML (20MG/ML)</u>	<u>N205934</u>	<u>003</u>	Dec 22, 2015
<u>AP</u>	SUN PHARM	<u>20MG/ML (20MG/ML)</u>	<u>N022534</u>	<u>003</u>	Jan 08, 2019
<u>AP</u>		<u>80MG/4ML (20MG/ML)</u>	<u>N022534</u>	<u>004</u>	Jan 08, 2019
<u>AP</u>		<u>160MG/8ML (20MG/ML)</u>	<u>N022534</u>	<u>005</u>	Jan 08, 2019
<u>TAXOTERE</u>					
<u>AP</u>	+	<u>20MG/ML (20MG/ML)</u>	<u>N020449</u>	<u>003</u>	Aug 03, 2010
<u>AP</u>	+	<u>80MG/4ML (20MG/ML)</u>	<u>N020449</u>	<u>004</u>	Aug 02, 2010
<u>AP</u>	+	<u>160MG/8ML (20MG/ML)</u>	<u>N020449</u>	<u>005</u>	Apr 13, 2012
DOCETAXEL					
	ACTAVIS LLC	140MG/7ML (20MG/ML)	N203551	003	Apr 12, 2013
	+ HOSPIRA INC	20MG/ML (20MG/ML)	N022234	004	Jun 23, 2016
	+	80MG/4ML (20MG/ML)	N022234	005	Jun 23, 2016
	+	160MG/8ML (20MG/ML)	N022234	007	Jan 24, 2017
SOLUTION; INTRAVENOUS					
DOCETAXEL					
	+	20MG/2ML (10MG/ML)	N215813	001	Nov 22, 2022
	+	80MG/8ML (10MG/ML)	N215813	002	Nov 22, 2022
	+	160MG/16ML (10MG/ML)	N215813	003	Nov 22, 2022

DOFETILIDE

CAPSULE; ORAL

DOFETILIDE

<u>AB</u>	AUROBINDO PHARMA LTD	<u>0.125MG</u>	<u>A210740</u>	<u>001</u>	Jan 22, 2019
<u>AB</u>		<u>0.25MG</u>	<u>A210740</u>	<u>002</u>	Jan 22, 2019
<u>AB</u>		<u>0.5MG</u>	<u>A210740</u>	<u>003</u>	Jan 22, 2019
<u>DOFETILIDE</u>					
<u>AB</u>	ACCORD HLTHCARE	<u>0.125MG</u>	<u>A213338</u>	<u>001</u>	Jun 19, 2020
<u>AB</u>		<u>0.25MG</u>	<u>A213338</u>	<u>002</u>	Jun 19, 2020
<u>AB</u>		<u>0.5MG</u>	<u>A213338</u>	<u>003</u>	Jun 19, 2020
<u>AB</u>	BIONPHARMA INC	<u>0.125MG</u>	<u>A208625</u>	<u>001</u>	Apr 10, 2018
<u>AB</u>		<u>0.25MG</u>	<u>A208625</u>	<u>002</u>	Apr 10, 2018
<u>AB</u>		<u>0.5MG</u>	<u>A208625</u>	<u>003</u>	Apr 10, 2018
<u>AB</u>	GRANULES	<u>0.125MG</u>	<u>A212750</u>	<u>001</u>	Oct 14, 2021
<u>AB</u>		<u>0.25MG</u>	<u>A212750</u>	<u>002</u>	Oct 14, 2021
<u>AB</u>		<u>0.5MG</u>	<u>A212750</u>	<u>003</u>	Oct 14, 2021
<u>AB</u>	MAYNE PHARMA INC	<u>0.125MG</u>	<u>A207058</u>	<u>001</u>	Jun 06, 2016
<u>AB</u>		<u>0.25MG</u>	<u>A207058</u>	<u>002</u>	Jun 06, 2016
<u>AB</u>		<u>0.5MG</u>	<u>A207058</u>	<u>003</u>	Jun 06, 2016
<u>AB</u>	MSN	<u>0.125MG</u>	<u>A213220</u>	<u>001</u>	Jan 29, 2020
<u>AB</u>		<u>0.25MG</u>	<u>A213220</u>	<u>002</u>	Jan 29, 2020
<u>AB</u>		<u>0.5MG</u>	<u>A213220</u>	<u>003</u>	Jan 29, 2020
<u>AB</u>	SIGMAPHARM LABS LLC	<u>0.125MG</u>	<u>A207746</u>	<u>001</u>	Mar 26, 2018
<u>AB</u>		<u>0.25MG</u>	<u>A207746</u>	<u>002</u>	Mar 26, 2018
<u>AB</u>		<u>0.5MG</u>	<u>A207746</u>	<u>003</u>	Mar 26, 2018
<u>AB</u>	STRIDES PHARMA	<u>0.125MG</u>	<u>A208519</u>	<u>001</u>	Oct 09, 2018
<u>AB</u>		<u>0.25MG</u>	<u>A208519</u>	<u>002</u>	Oct 09, 2018
<u>AB</u>		<u>0.5MG</u>	<u>A208519</u>	<u>003</u>	Oct 09, 2018
<u>AB</u>	SUN PHARM	<u>0.125MG</u>	<u>A210466</u>	<u>001</u>	Oct 09, 2018
<u>AB</u>		<u>0.25MG</u>	<u>A210466</u>	<u>002</u>	Oct 09, 2018
<u>AB</u>		<u>0.5MG</u>	<u>A210466</u>	<u>003</u>	Oct 09, 2018
<u>TIKOSYN</u>					
<u>AB</u>	+	<u>0.125MG</u>	<u>N020931</u>	<u>001</u>	Oct 01, 1999
<u>AB</u>	+	<u>0.25MG</u>	<u>N020931</u>	<u>002</u>	Oct 01, 1999
<u>AB</u>	+	<u>0.5MG</u>	<u>N020931</u>	<u>003</u>	Oct 01, 1999

PRESCRIPTION DRUG PRODUCT LIST

3-152 (of 474)

DOLASETRON MESYLATE

TABLET; ORAL

ANZEMET

+! VALIDUS PHARMS

50MG

N020623 001 Sep 11, 1997

DOLUTEGRAVIR SODIUM

TABLET; ORAL

TIVICAY

+ VIIV HLTHCARE

EQ 10MG BASE

N204790 002 Jun 09, 2016

+

EQ 25MG BASE

N204790 003 Jun 09, 2016

+!

EQ 50MG BASE

N204790 001 Aug 12, 2013

TABLET, FOR SUSPENSION; ORAL

TIVICAY PD

+! VIIV HLTHCARE

EQ 5MG BASE

N213983 001 Jun 12, 2020

DOLUTEGRAVIR SODIUM; LAMIVUDINE

TABLET; ORAL

DOVATO

+! VIIV HLTHCARE

EQ 50MG BASE; 300MG

N211994 001 Apr 08, 2019

DOLUTEGRAVIR SODIUM; RILPIVIRINE HYDROCHLORIDE

TABLET; ORAL

JULUCA

+! VIIV HLTHCARE

EQ 50MG BASE; EQ 25MG BASE

N210192 001 Nov 21, 2017

DONEPEZIL HYDROCHLORIDE

SYSTEM; TRANSDERMAL

ADLARITY

+ CORIUM

5MG/DAY

N212304 001 Mar 11, 2022

+!

10MG/DAY

N212304 002 Mar 11, 2022

TABLET; ORAL

ARICEPTAB + EISAI INC5MGN020690 002 Nov 25, 1996AB +!10MGN020690 001 Nov 25, 1996AB +!23MGN022568 001 Jul 23, 2010DONEPEZIL HYDROCHLORIDEAB ACI5MGA078662 001 May 31, 2011AB10MGA078662 002 May 31, 2011AB ALEMBIC PHARMS LTD5MGA201724 001 Feb 25, 2013AB10MGA201724 002 Feb 25, 2013AB AUROBINDO5MGA090056 001 May 31, 2011AB10MGA090056 002 May 31, 2011AB CADILA5MGA090100 001 Oct 24, 2012AB10MGA090100 002 Oct 24, 2012AB CADILA PHARMS LTD5MGA204609 001 Sep 19, 2017AB10MGA204609 002 Sep 19, 2017AB CHARTWELL RX5MGA090425 001 May 31, 2011AB10MGA090425 002 May 31, 2011AB CIPLA LTD5MGA077518 001 May 31, 2011AB10MGA077518 002 May 31, 2011AB DEXCEL23MGA203713 001 Feb 19, 2016AB DR REDDYS23MGA202723 001 Jul 24, 2013AB DR REDDYS LABS LTD5MGA201001 001 May 31, 2011AB10MGA201001 002 May 31, 2011AB HETERO LABS LTD V5MGA203034 001 Jan 30, 2015AB10MGA203034 002 Jan 30, 2015AB INDICUS PHARMA5MGA201634 001 Jun 13, 2012AB10MGA201634 002 Jun 13, 2012AB JUBILANT GENERICS5MGA090768 001 May 31, 2011AB10MGA090768 002 May 31, 2011AB LUPIN LTD23MGA202782 001 Oct 30, 2015AB MACLEODS PHARMS LTD5MGA201146 001 Aug 17, 2012AB10MGA201146 002 Aug 17, 2012AB23MGA202631 001 Jan 22, 2014AB PRINSTON INC5MGA200292 001 May 31, 2011AB10MGA200292 002 May 31, 2011AB RISING5MGA202114 001 Jul 05, 2013AB10MGA202114 002 Jul 05, 2013AB SCIEGEN PHARMS INC5MGA203907 001 Oct 29, 2014AB10MGA203907 002 Oct 29, 2014AB STRIDES PHARMA5MGA090551 001 May 31, 2011AB10MGA090551 002 May 31, 2011AB SUN PHARM INDS5MGA090493 001 May 31, 2011AB10MGA090493 002 May 31, 2011

PRESCRIPTION DRUG PRODUCT LIST

3-153 (of 474)

DONEPEZIL HYDROCHLORIDE

TABLET; ORAL

DONEPEZIL HYDROCHLORIDE

AB	TORRENT PHARMS	5MG	A090686	001	May 31, 2011
AB		10MG	A090686	002	May 31, 2011
AB	TWI PHARMS	23MG	A203104	001	Oct 29, 2014
AB	ZYDUS PHARMS	23MG	A203162	001	Aug 31, 2017

TABLET, ORALLY DISINTEGRATING; ORAL

DONEPEZIL HYDROCHLORIDE

AB	HISUN PHARM HANGZHOU	5MG	A205269	001	Jul 27, 2018
AB		10MG	A205269	002	Jul 27, 2018
AB	MACLEODS PHARMS LTD	5MG	A201787	001	Dec 14, 2012
AB		10MG	A201787	002	Dec 14, 2012
AB	SANDOZ	5MG	A091198	001	May 10, 2011
AB	!	10MG	A091198	002	May 10, 2011

DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

NAMZARIC

+	ALLERGAN	10MG; 7MG	N206439	003	Jul 18, 2016
+		10MG; 14MG	N206439	001	Dec 23, 2014
+		10MG; 21MG	N206439	004	Jul 18, 2016
+	!	10MG; 28MG	N206439	002	Dec 23, 2014

DOPAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DOPAMINE HYDROCHLORIDE

AP	HIKMA INTL PHARMS	40MG/ML	A207707	001	Apr 11, 2018
AP		80MG/ML	A207707	002	Apr 11, 2018
AP	+! HOSPIRA	40MG/ML	N018132	001	
AP	+!	80MG/100ML	N018132	002	Feb 04, 1982
AP	+!	80MG/ML	N018132	004	Jul 09, 1982
AP	+!	160MG/100ML	N018132	003	Feb 04, 1982

DOPAMINE HYDROCHLORIDE AND DEXTROSE 5%

AP	+! B BRAUN	80MG/100ML	N019099	002	Oct 15, 1986
AP	+!	320MG/100ML	N019099	004	Oct 15, 1986

DOPAMINE HYDROCHLORIDE AND DEXTROSE 5% IN PLASTIC CONTAINER

AP	+! B BRAUN	160MG/100ML	N019099	003	Oct 15, 1986

DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	+! BAXTER HLTHCARE	80MG/100ML	N019615	001	Mar 27, 1987
AP	+!	160MG/100ML	N019615	002	Mar 27, 1987
AP	+!	320MG/100ML	N019615	003	Mar 27, 1987
AP	+! HOSPIRA	80MG/100ML	N018826	001	Sep 30, 1983
AP	+!	160MG/100ML	N018826	002	Sep 30, 1983
AP	+!	320MG/100ML	N018826	003	Sep 30, 1983

DOPAMINE HYDROCHLORIDE AND DEXTROSE 5% IN PLASTIC CONTAINER

+	B BRAUN	40MG/100ML	N019099	001	Oct 15, 1986

DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER

+	BAXTER HLTHCARE	640MG/100ML	N019615	004	Mar 27, 1987

DORAVIRINE

TABLET; ORAL

PIFELTRO

+	MSD MERCK CO	100MG	N210806	001	Aug 30, 2018

DORAVIRINE; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL

DELSTRIGO

+	MSD MERCK CO	100MG; 300MG; 300MG	N210807	001	Aug 30, 2018

DORZOLAMIDE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE

AT	AKORN	EQ 2% BASE	A077846	001	Oct 28, 2008
AT	ALEMBIC PHARMS	EQ 2% BASE	A212639	001	Aug 09, 2019
AT	BAUSCH AND LOMB	EQ 2% BASE	A090143	001	Jun 25, 2009
AT	FDC LTD	EQ 2% BASE	A205294	001	Jan 24, 2019
AT	GLAND PHARMA LTD	EQ 2% BASE	A215660	001	Jan 27, 2022
AT	INDOCO	EQ 2% BASE	A202053	001	Sep 11, 2014
AT	!	EQ 2% BASE	A204778	001	Nov 08, 2019
AT	SANDOZ INC	EQ 2% BASE	A078748	001	Nov 06, 2008
AT		EQ 2% BASE	A078981	001	Apr 13, 2009

PRESCRIPTION DRUG PRODUCT LIST

3-154 (of 474)

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS;OPHTHALMIC

COSOPT

AT	+!	THEA PHARMA	<u>EQ 2% BASE;EQ 0.5% BASE</u>	<u>N020869</u>	<u>001</u>	Apr 07, 1998

COSOPT PF

AT	+!	THEA PHARMA	<u>EQ 2% BASE;EQ 0.5% BASE</u>	<u>N202667</u>	<u>001</u>	Feb 01, 2012

DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE

AT		AKORN	<u>EQ 2% BASE;EQ 0.5% BASE</u>	<u>A077847</u>	<u>001</u>	Oct 28, 2008
AT			<u>EQ 2% BASE;EQ 0.5% BASE</u>	<u>A203058</u>	<u>001</u>	Sep 22, 2014
AT		ALEMBIC PHARMS	<u>EQ 2% BASE;EQ 0.5% BASE</u>	<u>A213099</u>	<u>001</u>	May 04, 2021
AT		BAUSCH AND LOMB	<u>EQ 2% BASE;EQ 0.5% BASE</u>	<u>A090037</u>	<u>001</u>	Jul 14, 2009
AT		EUGIA PHARMA	<u>EQ 2% BASE;EQ 0.5% BASE</u>	<u>A207629</u>	<u>001</u>	May 14, 2021
AT			<u>EQ 2% BASE;EQ 0.5% BASE</u>	<u>A207630</u>	<u>001</u>	Jul 24, 2018
AT		FDC LTD	<u>EQ 2% BASE;EQ 0.5% BASE</u>	<u>A205295</u>	<u>001</u>	Jun 13, 2019
AT		GLAND PHARMA LTD	<u>EQ 2% BASE;EQ 0.5% BASE</u>	<u>A215520</u>	<u>001</u>	Sep 19, 2022
AT		INDOCO	<u>EQ 2% BASE;EQ 0.5% BASE</u>	<u>A202054</u>	<u>001</u>	Sep 03, 2014
AT		MICRO LABS	<u>EQ 2% BASE;EQ 0.5% BASE</u>	<u>A204777</u>	<u>001</u>	May 28, 2020
AT			<u>EQ 2% BASE;EQ 0.5% BASE</u>	<u>A215936</u>	<u>001</u>	Jan 25, 2022
AT		SANDOZ	<u>EQ 2% BASE;EQ 0.5% BASE</u>	<u>A078749</u>	<u>001</u>	Nov 06, 2008
AT		SANDOZ INC	<u>EQ 2% BASE;EQ 0.5% BASE</u>	<u>A090604</u>	<u>001</u>	Nov 18, 2009
AT		SOMERSET	<u>EQ 2% BASE;EQ 0.5% BASE</u>	<u>A207523</u>	<u>001</u>	Jun 25, 2019
AT		TEVA PHARMS	<u>EQ 2% BASE;EQ 0.5% BASE</u>	<u>A078704</u>	<u>001</u>	Sep 28, 2009

DOXAPRAM HYDROCHLORIDE

INJECTABLE; INJECTION

DOPRAM

AP	+!	HIKMA	<u>20MG/ML</u>	<u>N014879</u>	<u>001</u>	

DOXAPRAM HYDROCHLORIDE

AP		CHARTWELL INJECTABLE	<u>20MG/ML</u>	<u>A076266</u>	<u>001</u>	Jan 10, 2003

DOXAZOSIN MESYLATE

TABLET; ORAL

CARDURA

AB	+!	VIATRIS	<u>EQ 1MG BASE</u>	<u>N019668</u>	<u>001</u>	Nov 02, 1990
AB	+		<u>EQ 2MG BASE</u>	<u>N019668</u>	<u>002</u>	Nov 02, 1990
AB	+		<u>EQ 4MG BASE</u>	<u>N019668</u>	<u>003</u>	Nov 02, 1990
AB	+		<u>EQ 8MG BASE</u>	<u>N019668</u>	<u>004</u>	Nov 02, 1990

DOXAZOSIN MESYLATE

AB		ACCORD HLTHCARE	<u>EQ 1MG BASE</u>	<u>A202824</u>	<u>001</u>	Jun 11, 2014
AB			<u>EQ 2MG BASE</u>	<u>A202824</u>	<u>002</u>	Jun 11, 2014
AB			<u>EQ 4MG BASE</u>	<u>A202824</u>	<u>003</u>	Jun 11, 2014
AB			<u>EQ 8MG BASE</u>	<u>A202824</u>	<u>004</u>	Jun 11, 2014
AB		APOTEX	<u>EQ 1MG BASE</u>	<u>A075580</u>	<u>001</u>	Oct 18, 2000
AB			<u>EQ 2MG BASE</u>	<u>A075580</u>	<u>002</u>	Oct 18, 2000
AB			<u>EQ 4MG BASE</u>	<u>A075580</u>	<u>003</u>	Oct 18, 2000
AB			<u>EQ 8MG BASE</u>	<u>A075580</u>	<u>004</u>	Oct 18, 2000
AB		PHARMGEN	<u>EQ 1MG BASE</u>	<u>A212727</u>	<u>001</u>	Mar 15, 2022
AB			<u>EQ 2MG BASE</u>	<u>A212727</u>	<u>002</u>	Mar 15, 2022
AB			<u>EQ 4MG BASE</u>	<u>A212727</u>	<u>003</u>	Mar 15, 2022
AB			<u>EQ 8MG BASE</u>	<u>A212727</u>	<u>004</u>	Mar 15, 2022
AB		PLIVA	<u>EQ 1MG BASE</u>	<u>A075750</u>	<u>001</u>	Jun 08, 2001
AB			<u>EQ 2MG BASE</u>	<u>A075750</u>	<u>002</u>	Jun 08, 2001
AB			<u>EQ 4MG BASE</u>	<u>A075750</u>	<u>003</u>	Jun 08, 2001
AB			<u>EQ 8MG BASE</u>	<u>A075750</u>	<u>004</u>	Jun 08, 2001
AB		TEVA	<u>EQ 1MG BASE</u>	<u>A075536</u>	<u>001</u>	Oct 18, 2000
AB			<u>EQ 2MG BASE</u>	<u>A075536</u>	<u>002</u>	Oct 18, 2000
AB			<u>EQ 4MG BASE</u>	<u>A075536</u>	<u>003</u>	Oct 18, 2000
AB			<u>EQ 8MG BASE</u>	<u>A075536</u>	<u>004</u>	Oct 18, 2000
AB		UPSHER SMITH LABS	<u>EQ 1MG BASE</u>	<u>A209013</u>	<u>001</u>	Apr 17, 2018
AB			<u>EQ 2MG BASE</u>	<u>A209013</u>	<u>002</u>	Apr 17, 2018
AB			<u>EQ 4MG BASE</u>	<u>A209013</u>	<u>003</u>	Apr 17, 2018
AB			<u>EQ 8MG BASE</u>	<u>A209013</u>	<u>004</u>	Apr 17, 2018
AB		ZYDUS PHARMS	<u>EQ 1MG BASE</u>	<u>A208719</u>	<u>001</u>	Jul 07, 2017
AB			<u>EQ 2MG BASE</u>	<u>A208719</u>	<u>002</u>	Jul 07, 2017
AB			<u>EQ 4MG BASE</u>	<u>A208719</u>	<u>003</u>	Jul 07, 2017
AB			<u>EQ 8MG BASE</u>	<u>A208719</u>	<u>004</u>	Jul 07, 2017
BX		HERITAGE PHARMA	<u>EQ 1MG BASE</u>	<u>A205210</u>	<u>001</u>	Feb 13, 2018
BX			<u>EQ 2MG BASE</u>	<u>A205210</u>	<u>002</u>	Feb 13, 2018
BX			<u>EQ 4MG BASE</u>	<u>A205210</u>	<u>003</u>	Feb 13, 2018
BX			<u>EQ 8MG BASE</u>	<u>A205210</u>	<u>004</u>	Feb 13, 2018

PRESCRIPTION DRUG PRODUCT LIST

3-155 (of 474)

DOXAZOSIN MESYLATE

TABLET, EXTENDED RELEASE; ORAL

CARDURA XL

+ VIATRIS

EQ 4MG BASE

N021269 001 Feb 22, 2005

+!

EQ 8MG BASE

N021269 002 Feb 22, 2005

DOXEPIH HYDROCHLORIDE

CAPSULE; ORAL

DOXEPIH HYDROCHLORIDE

<u>AB</u>	AJANTA PHARMA LTD	<u>EQ 10MG BASE</u>	<u>A212624 001</u>	Sep 13, 2019
<u>AB</u>		<u>EQ 25MG BASE</u>	<u>A212624 002</u>	Sep 13, 2019
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A212624 003</u>	Sep 13, 2019
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A212624 004</u>	Sep 13, 2019
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A212624 005</u>	Sep 13, 2019
<u>AB</u>	ALEMBIC PHARMS	<u>EQ 10MG BASE</u>	<u>A215076 001</u>	Apr 21, 2021
<u>AB</u>		<u>EQ 25MG BASE</u>	<u>A215076 002</u>	Apr 21, 2021
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A215076 003</u>	Apr 21, 2021
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A215076 004</u>	Apr 21, 2021
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A215076 005</u>	Apr 21, 2021
<u>AB</u>	AMNEAL PHARMS CO	<u>EQ 10MG BASE</u>	<u>A207482 001</u>	Jun 28, 2017
<u>AB</u>		<u>EQ 25MG BASE</u>	<u>A207482 002</u>	Jun 28, 2017
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A207482 003</u>	Jun 28, 2017
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A207482 004</u>	Jun 28, 2017
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A207482 005</u>	Jun 28, 2017
<u>AB</u>	APPCO	<u>EQ 10MG BASE</u>	<u>A214908 001</u>	Apr 01, 2021
<u>AB</u>		<u>EQ 25MG BASE</u>	<u>A214908 002</u>	Apr 01, 2021
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A214908 003</u>	Apr 01, 2021
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A214908 004</u>	Apr 01, 2021
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A214908 005</u>	Apr 01, 2021
<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 10MG BASE</u>	<u>A211603 001</u>	Mar 27, 2019
<u>AB</u>		<u>EQ 25MG BASE</u>	<u>A211603 002</u>	Mar 27, 2019
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A211603 003</u>	Mar 27, 2019
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A211603 004</u>	Mar 27, 2019
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A211603 005</u>	Mar 27, 2019
<u>AB</u>	CHARTWELL RX	<u>EQ 10MG BASE</u>	<u>A210268 001</u>	Sep 04, 2020
<u>AB</u>		<u>EQ 25MG BASE</u>	<u>A210268 002</u>	Sep 04, 2020
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A210268 003</u>	Sep 04, 2020
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A210268 004</u>	Sep 04, 2020
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A210268 005</u>	Sep 04, 2020
<u>AB</u>	CONTRACT PHARMACAL	<u>EQ 10MG BASE</u>	<u>A213474 001</u>	Jul 28, 2020
<u>AB</u>		<u>EQ 25MG BASE</u>	<u>A213474 002</u>	Jul 28, 2020
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A213474 003</u>	Jul 28, 2020
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A213474 004</u>	Jul 28, 2020
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A213474 005</u>	Jul 28, 2020
<u>AB</u>	EDENBRIDGE PHARMS	<u>EQ 150MG BASE</u>	<u>A213796 001</u>	Apr 19, 2022
<u>AB</u>	EPIC PHARMA LLC	<u>EQ 10MG BASE</u>	<u>A210675 001</u>	Oct 16, 2020
<u>AB</u>		<u>EQ 25MG BASE</u>	<u>A210675 002</u>	Oct 16, 2020
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A210675 004</u>	Mar 03, 2022
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A210675 005</u>	Mar 03, 2022
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A210675 003</u>	Oct 16, 2020
<u>AB</u>	JUBILANT CADISTA	<u>EQ 10MG BASE</u>	<u>A215483 001</u>	Mar 14, 2022
<u>AB</u>		<u>EQ 25MG BASE</u>	<u>A215483 002</u>	Mar 14, 2022
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A215483 003</u>	Mar 14, 2022
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A215483 004</u>	Mar 14, 2022
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A215483 005</u>	Mar 14, 2022
<u>AB</u>	LEADING	<u>EQ 10MG BASE</u>	<u>A211619 001</u>	Mar 09, 2021
<u>AB</u>		<u>EQ 25MG BASE</u>	<u>A211619 002</u>	Mar 09, 2021
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A211619 003</u>	Mar 09, 2021
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A211619 004</u>	Mar 09, 2021
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A211619 005</u>	Mar 09, 2021
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A211618 001</u>	Mar 01, 2021
<u>AB</u>	MANKIND PHARMA	<u>EQ 10MG BASE</u>	<u>A215710 001</u>	Feb 09, 2022
<u>AB</u>		<u>EQ 25MG BASE</u>	<u>A215710 002</u>	Feb 09, 2022
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A215710 003</u>	Feb 09, 2022
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A215710 004</u>	Feb 09, 2022
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A215710 005</u>	Feb 09, 2022
<u>AB</u>	MSN	<u>EQ 10MG BASE</u>	<u>A215113 001</u>	Jun 24, 2022
<u>AB</u>		<u>EQ 25MG BASE</u>	<u>A215113 002</u>	Jun 24, 2022
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A215113 003</u>	Jun 24, 2022
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A215113 004</u>	Jun 24, 2022
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A215113 005</u>	Jun 24, 2022
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 10MG BASE</u>	<u>A070791 002</u>	May 13, 1986

PRESCRIPTION DRUG PRODUCT LIST

3-156 (of 474)

DOXEPIN HYDROCHLORIDE

CAPSULE; ORAL

DOXEPIN HYDROCHLORIDE

<u>AB</u>	!	<u>EQ 25MG BASE</u>	<u>A070791</u>	<u>003</u>	May 13, 1986
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A070791</u>	<u>001</u>	May 13, 1986
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A070791</u>	<u>004</u>	May 13, 1986
<u>AB</u>	!	<u>EQ 100MG BASE</u>	<u>A070791</u>	<u>005</u>	May 13, 1986
<u>AB</u>	!	<u>EQ 150MG BASE</u>	<u>A071422</u>	<u>006</u>	Nov 09, 1987
<u>AB</u>	TARO PHARM INDS LTD	<u>EQ 10MG BASE</u>	<u>A213063</u>	<u>001</u>	Jul 01, 2020
<u>AB</u>		<u>EQ 25MG BASE</u>	<u>A213063</u>	<u>002</u>	Jul 01, 2020
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A213063</u>	<u>003</u>	Jul 01, 2020
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A213063</u>	<u>004</u>	Jul 01, 2020
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A213063</u>	<u>005</u>	Jul 01, 2020

CONCENTRATE; ORAL

DOXEPIN HYDROCHLORIDE

<u>AA</u>	!	<u>EQ 10MG BASE/ML</u>	<u>A074721</u>	<u>001</u>	Dec 29, 1998
<u>AA</u>	XTRIUM LABS INC	<u>EQ 10MG BASE/ML</u>	<u>A071918</u>	<u>001</u>	Jul 20, 1988

CREAM; TOPICAL

ZONALON

+! MYLAN

5%

N020126 001 Apr 01, 1994

TABLET; ORAL

DOXEPIN HYDROCHLORIDE

<u>AB</u>	ACTAVIS ELIZABETH	<u>EQ 3MG BASE</u>	<u>A201951</u>	<u>001</u>	Jul 26, 2013
<u>AB</u>		<u>EQ 6MG BASE</u>	<u>A201951</u>	<u>002</u>	Jul 26, 2013
<u>AB</u>	RK PHARMA	<u>EQ 3MG BASE</u>	<u>A202337</u>	<u>001</u>	Jan 20, 2016
<u>AB</u>		<u>EQ 6MG BASE</u>	<u>A202337</u>	<u>002</u>	Jan 20, 2016
<u>AB</u>	STRIDES PHARMA	<u>EQ 3MG BASE</u>	<u>A202510</u>	<u>001</u>	Jul 24, 2020
<u>AB</u>		<u>EQ 6MG BASE</u>	<u>A202510</u>	<u>002</u>	Jul 24, 2020

SILENOR

<u>AB</u>	+	<u>EQ 3MG BASE</u>	<u>N022036</u>	<u>001</u>	Mar 17, 2010
<u>AB</u>	+!	<u>EQ 6MG BASE</u>	<u>N022036</u>	<u>002</u>	Mar 17, 2010

DOXERCALCIFEROL

CAPSULE; ORAL

DOXERCALCIFEROL

<u>AB</u>	AVET	<u>0.5MCG</u>	<u>A205360</u>	<u>001</u>	Sep 15, 2020
<u>AB</u>		<u>1MCG</u>	<u>A205360</u>	<u>002</u>	Sep 15, 2020
<u>AB</u>		<u>2.5MCG</u>	<u>A205360</u>	<u>003</u>	Sep 15, 2020
<u>AB</u>	RISING	<u>0.5MCG</u>	<u>A201518</u>	<u>001</u>	Sep 09, 2016
<u>AB</u>		<u>1MCG</u>	<u>A201518</u>	<u>002</u>	Sep 09, 2016
<u>AB</u>		<u>2.5MCG</u>	<u>A201518</u>	<u>003</u>	Sep 09, 2016

HECTOROL

<u>AB</u>	+	<u>0.5MCG</u>	<u>N020862</u>	<u>002</u>	Apr 23, 2004
<u>AB</u>	+	<u>1MCG</u>	<u>N020862</u>	<u>003</u>	Jul 13, 2009
<u>AB</u>	+!	<u>2.5MCG</u>	<u>N020862</u>	<u>001</u>	Jun 09, 1999

INJECTABLE; INJECTION

DOXERCALCIFEROL

<u>AP</u>	AMNEAL	<u>2MCG/ML (2MCG/ML)</u>	<u>A208974</u>	<u>001</u>	May 24, 2017
<u>AP</u>		<u>4MCG/2ML (2MCG/ML)</u>	<u>A208974</u>	<u>002</u>	May 24, 2017
<u>AP</u>	EUGIA PHARMA	<u>2MCG/ML (2MCG/ML)</u>	<u>A213717</u>	<u>001</u>	Jan 24, 2022
<u>AP</u>		<u>4MCG/2ML (2MCG/ML)</u>	<u>A213717</u>	<u>002</u>	Jan 24, 2022
<u>AP</u>	GLAND PHARMA LTD	<u>4MCG/2ML (2MCG/ML)</u>	<u>A210452</u>	<u>001</u>	Sep 26, 2019
<u>AP</u>	HIKMA	<u>4MCG/2ML (2MCG/ML)</u>	<u>A091101</u>	<u>001</u>	Aug 30, 2013
<u>AP</u>	+	<u>4MCG/2ML (2MCG/ML)</u>	<u>N208614</u>	<u>001</u>	Jul 24, 2018
<u>AP</u>	LUPIN LTD	<u>4MCG/2ML (2MCG/ML)</u>	<u>A210801</u>	<u>001</u>	Nov 01, 2018
<u>AP</u>	MEITHEAL	<u>4MCG/2ML (2MCG/ML)</u>	<u>A211670</u>	<u>001</u>	Feb 07, 2020
<u>AP</u>	SANDOZ INC	<u>4MCG/2ML (2MCG/ML)</u>	<u>A091333</u>	<u>001</u>	May 05, 2014
<u>AP</u>		<u>4MCG/2ML (2MCG/ML)</u>	<u>A200926</u>	<u>001</u>	Feb 04, 2014

HECTOROL

<u>AP</u>	+	<u>2MCG/ML (2MCG/ML)</u>	<u>N021027</u>	<u>002</u>	Apr 06, 2000
<u>AP</u>	+!	<u>4MCG/2ML (2MCG/ML)</u>	<u>N021027</u>	<u>001</u>	Apr 06, 2000

DOXORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

DOXORUBICIN HYDROCHLORIDE

<u>AP</u>	ACTAVIS INC	<u>2MG/ML</u>	<u>A203622</u>	<u>001</u>	Jun 27, 2014
<u>AP</u>		<u>200MG/100ML</u>	<u>A203622</u>	<u>002</u>	Jun 27, 2014
<u>AP</u>	AMNEAL	<u>20MG/VIAL</u>	<u>A208888</u>	<u>001</u>	Feb 17, 2017
<u>AP</u>		<u>50MG/VIAL</u>	<u>A208888</u>	<u>002</u>	Feb 17, 2017
<u>AP</u>	FRESENIUS KABI USA	<u>2MG/ML</u>	<u>A063277</u>	<u>001</u>	Oct 26, 1995
<u>AP</u>	GLAND PHARMA LTD	<u>2MG/ML</u>	<u>A209825</u>	<u>001</u>	Aug 11, 2017
<u>AP</u>	HIKMA	<u>2MG/ML</u>	<u>A062975</u>	<u>001</u>	Mar 17, 1989
<u>AP</u>	!	<u>10MG/VIAL</u>	<u>A062921</u>	<u>001</u>	Mar 17, 1989

PRESCRIPTION DRUG PRODUCT LIST

3-157 (of 474)

DOXORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

DOXORUBICIN HYDROCHLORIDE

<u>AP</u>	!		<u>20MG/VIAL</u>	<u>A062921</u>	<u>002</u>	Mar 17, 1989
<u>AP</u>	!		<u>50MG/VIAL</u>	<u>A062921</u>	<u>003</u>	Mar 17, 1989
<u>AP</u>			<u>200MG/100ML</u>	<u>A064097</u>	<u>001</u>	Sep 13, 1994
<u>AP</u>		MYLAN LABS LTD	<u>50MG/VIAL</u>	<u>A200170</u>	<u>002</u>	Oct 28, 2011
<u>AP</u>	+	PFIZER	<u>2MG/ML</u>	<u>N050629</u>	<u>001</u>	Dec 23, 1987
<u>AP</u>	+		<u>200MG/100ML</u>	<u>N050629</u>	<u>002</u>	May 03, 1988
<u>AP</u>		PHARMACHEMIE BV	<u>2MG/ML</u>	<u>A063336</u>	<u>001</u>	Feb 28, 1995
<u>AP</u>			<u>10MG/VIAL</u>	<u>A063097</u>	<u>001</u>	May 21, 1990
<u>AP</u>			<u>20MG/VIAL</u>	<u>A063097</u>	<u>002</u>	May 21, 1990
<u>AP</u>			<u>50MG/VIAL</u>	<u>A063097</u>	<u>003</u>	May 21, 1990
<u>AP</u>			<u>200MG/100ML</u>	<u>A063336</u>	<u>004</u>	Feb 28, 1995
<u>AP</u>		SAGENT PHARMS	<u>2MG/ML</u>	<u>A091495</u>	<u>001</u>	Mar 18, 2013
<u>AP</u>		SUN PHARM INDS	<u>2MG/ML</u>	<u>A091418</u>	<u>001</u>	Feb 15, 2012
	+	PFIZER	150MG/75ML	N050629	003	Mar 28, 2011

INJECTABLE, LIPOSOMAL; INJECTION

DOXIL (LIPOSOMAL)

<u>AB</u>	+	BAXTER HLTHCARE CORP	<u>20MG/10ML (2MG/ML)</u>	<u>N050718</u>	<u>001</u>	Nov 17, 1995
<u>AB</u>	+		<u>50MG/25ML (2MG/ML)</u>	<u>N050718</u>	<u>002</u>	Jun 13, 2000
<u>DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL)</u>						
<u>AB</u>		AYANA PHARMA LTD	<u>20MG/10ML (2MG/ML)</u>	<u>A207228</u>	<u>001</u>	Oct 12, 2021
<u>AB</u>			<u>50MG/25ML (2MG/ML)</u>	<u>A207228</u>	<u>002</u>	Oct 12, 2021
<u>AB</u>		CELERITY PHARMS	<u>20MG/10ML (2MG/ML)</u>	<u>A212219</u>	<u>001</u>	Oct 19, 2022
<u>AB</u>			<u>50MG/25ML (2MG/ML)</u>	<u>A212219</u>	<u>002</u>	Oct 19, 2022
<u>AB</u>		DR REDDYS	<u>20MG/10ML (2MG/ML)</u>	<u>A208657</u>	<u>001</u>	May 15, 2017
<u>AB</u>			<u>50MG/25ML (2MG/ML)</u>	<u>A208657</u>	<u>002</u>	May 15, 2017
<u>AB</u>	!	SUN PHARM	<u>20MG/10ML (2MG/ML)</u>	<u>A203263</u>	<u>001</u>	Feb 04, 2013
<u>AB</u>	!		<u>50MG/25ML (2MG/ML)</u>	<u>A203263</u>	<u>002</u>	Feb 04, 2013
<u>AB</u>		ZYDUS	<u>20MG/10ML (2MG/ML)</u>	<u>A212299</u>	<u>001</u>	Sep 10, 2020
<u>AB</u>			<u>50MG/25ML (2MG/ML)</u>	<u>A212299</u>	<u>002</u>	Sep 10, 2020

DOXYCYCLINE

CAPSULE; ORAL

DOXYCYCLINE

<u>AB</u>		ALEMBIC PHARMS	<u>EQ 75MG BASE</u>	<u>A209165</u>	<u>001</u>	Jul 28, 2017
<u>AB</u>			<u>EQ 100MG BASE</u>	<u>A209165</u>	<u>002</u>	Jul 28, 2017
<u>AB</u>		COSETTE	<u>EQ 50MG BASE</u>	<u>A204446</u>	<u>001</u>	May 28, 2015
<u>AB</u>			<u>EQ 75MG BASE</u>	<u>A204446</u>	<u>002</u>	May 28, 2015
<u>AB</u>			<u>EQ 100MG BASE</u>	<u>A204446</u>	<u>003</u>	May 28, 2015
<u>AB</u>		LUPIN LTD	<u>EQ 50MG BASE</u>	<u>A204234</u>	<u>001</u>	Mar 05, 2014
<u>AB</u>			<u>EQ 75MG BASE</u>	<u>A204234</u>	<u>002</u>	Mar 05, 2014
<u>AB</u>			<u>EQ 100MG BASE</u>	<u>A204234</u>	<u>003</u>	Mar 05, 2014
<u>AB</u>		MAYNE PHARMA INC	<u>EQ 50MG BASE</u>	<u>A209396</u>	<u>001</u>	Sep 29, 2017
<u>AB</u>			<u>EQ 75MG BASE</u>	<u>A209396</u>	<u>002</u>	Sep 29, 2017
<u>AB</u>			<u>EQ 100MG BASE</u>	<u>A209396</u>	<u>003</u>	Sep 29, 2017
<u>AB</u>		STRIDES PHARMA	<u>EQ 50MG BASE</u>	<u>A065055</u>	<u>001</u>	Dec 01, 2000
<u>AB</u>			<u>EQ 100MG BASE</u>	<u>A065055</u>	<u>002</u>	Dec 01, 2000
<u>AB</u>	!		<u>EQ 150MG BASE</u>	<u>A065055</u>	<u>003</u>	Jul 15, 2005
<u>AB</u>		SUN PHARM INDS LTD	<u>EQ 50MG BASE</u>	<u>A065053</u>	<u>001</u>	Nov 22, 2000
<u>AB</u>			<u>EQ 75MG BASE</u>	<u>A065053</u>	<u>003</u>	Sep 10, 2003
<u>AB</u>	!		<u>EQ 100MG BASE</u>	<u>A065053</u>	<u>002</u>	Nov 22, 2000
<u>AB</u>		ZYDUS PHARMS	<u>EQ 50MG BASE</u>	<u>A205115</u>	<u>001</u>	Feb 18, 2016
<u>AB</u>			<u>EQ 75MG BASE</u>	<u>A205115</u>	<u>002</u>	Feb 18, 2016
<u>AB</u>			<u>EQ 100MG BASE</u>	<u>A205115</u>	<u>003</u>	Feb 18, 2016

MONODOX

<u>AB</u>	+	CHARTWELL RX	<u>EQ 50MG BASE</u>	<u>N050641</u>	<u>002</u>	Feb 10, 1992
<u>AB</u>	+		<u>EQ 75MG BASE</u>	<u>N050641</u>	<u>003</u>	Oct 18, 2006
<u>AB</u>	+		<u>EQ 100MG BASE</u>	<u>N050641</u>	<u>001</u>	Dec 29, 1989
<u>AB</u>	+		<u>EQ 150MG BASE</u>	<u>N050641</u>	<u>004</u>	Feb 17, 2022
		ORACEA				
	+	GALDERMA LABS LP	40MG	N050805	001	May 26, 2006

FOR SUSPENSION; ORAL

DOXYCYCLINE

<u>AB</u>		CHARTWELL	<u>EQ 25MG BASE/5ML</u>	<u>A065454</u>	<u>001</u>	Jul 16, 2008
<u>AB</u>		LUPIN LTD	<u>EQ 25MG BASE/5ML</u>	<u>A201678</u>	<u>001</u>	Mar 18, 2013

VIBRAMYCIN

<u>AB</u>	+	PFIZER	<u>EQ 25MG BASE/5ML</u>	<u>N050006</u>	<u>001</u>	

TABLET; ORAL

DOXYCYCLINE

<u>AB</u>		HERITAGE PHARMS	<u>EQ 50MG BASE</u>	<u>A091605</u>	<u>001</u>	Dec 20, 2011

PRESCRIPTION DRUG PRODUCT LIST

3-158 (of 474)

DOXYCYCLINE

TABLET; ORAL

DOXYCYCLINE

<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A091605</u>	<u>002</u>	Dec 20, 2011
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A091605</u>	<u>003</u>	Dec 20, 2011
<u>AB</u>	!	<u>EQ 150MG BASE</u>	<u>A091605</u>	<u>004</u>	Dec 20, 2011
<u>AB</u>	LANNETT CO INC	<u>EQ 50MG BASE</u>	<u>A065285</u>	<u>001</u>	Dec 08, 2005
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A065285</u>	<u>003</u>	Jul 30, 2008
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A065285</u>	<u>002</u>	Dec 08, 2005
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A065285</u>	<u>004</u>	Jul 30, 2008
<u>AB</u>	STRIDES PHARMA	<u>EQ 50MG BASE</u>	<u>A065070</u>	<u>001</u>	Dec 15, 2000
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A065070</u>	<u>003</u>	Dec 30, 2002
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A065070</u>	<u>002</u>	Dec 15, 2000
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A065070</u>	<u>004</u>	Jul 14, 2005
<u>AB</u>	SUN PHARM INDS LTD	<u>EQ 50MG BASE</u>	<u>A065356</u>	<u>001</u>	May 31, 2006
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A065356</u>	<u>002</u>	May 31, 2006
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A065356</u>	<u>003</u>	May 31, 2006
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A065356</u>	<u>004</u>	Jul 29, 2010
<u>AB</u>	ZYDUS PHARMS	<u>EQ 50MG BASE</u>	<u>A209582</u>	<u>001</u>	Sep 28, 2017
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A209582</u>	<u>002</u>	Sep 28, 2017
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A209582</u>	<u>003</u>	Sep 28, 2017
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A209582</u>	<u>004</u>	Sep 28, 2017

DOXYCYCLINE CALCIUM

SUSPENSION; ORAL

VIBRAMYCIN

+! PFIZER

EQ 50MG BASE/5ML

N050480 001

DOXYCYCLINE HYCLATE

CAPSULE; ORAL

DOXYCYCLINE HYCLATE

<u>AB</u>	ACTAVIS LABS FL INC	<u>EQ 50MG BASE</u>	<u>A062031</u>	<u>002</u>	Oct 13, 1982
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A062031</u>	<u>001</u>	
<u>AB</u>	ALEMBIC PHARMS	<u>EQ 50MG BASE</u>	<u>A210527</u>	<u>001</u>	Jun 13, 2018
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A210527</u>	<u>002</u>	Jun 13, 2018
<u>AB</u>	AMNEAL PHARMS	<u>EQ 100MG BASE</u>	<u>A207289</u>	<u>001</u>	Jun 27, 2016
<u>AB</u>	CADILA	<u>EQ 50MG BASE</u>	<u>A207774</u>	<u>001</u>	May 31, 2018
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A207774</u>	<u>002</u>	May 31, 2018
<u>AB</u>	CHANGZHOU PHARM	<u>EQ 100MG BASE</u>	<u>A209402</u>	<u>001</u>	Oct 07, 2019
<u>AB</u>	CHARTWELL	<u>EQ 50MG BASE</u>	<u>A062500</u>	<u>001</u>	Sep 11, 1984
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A062500</u>	<u>002</u>	Sep 11, 1984
<u>AB</u>	HIKMA INTL PHARMS	<u>EQ 50MG BASE</u>	<u>A062396</u>	<u>002</u>	Nov 07, 1984
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A062396</u>	<u>001</u>	May 07, 1984
<u>AB</u>	SUN PHARM INDUSTRIES	<u>EQ 50MG BASE</u>	<u>A062676</u>	<u>002</u>	Jul 10, 1986
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A062676</u>	<u>001</u>	Jul 10, 1986

VIBRAMYCINAB +! PFIZEREQ 100MG BASEN050007 002

INJECTABLE; INJECTION

DOXY 100

<u>AP</u>	!	FRESENIUS KABI USA	<u>EQ 100MG BASE/VIAL</u>	<u>A062475</u>	<u>001</u>	Dec 09, 1983

DOXY 200

<u>AP</u>	!	FRESENIUS KABI USA	<u>EQ 200MG BASE/VIAL</u>	<u>A062475</u>	<u>002</u>	Dec 09, 1983

DOXYCYCLINE

<u>AP</u>	!	HIKMA	<u>EQ 100MG BASE/VIAL</u>	<u>A062569</u>	<u>001</u>	Mar 09, 1988
<u>AP</u>		MYLAN LABS LTD	<u>EQ 100MG BASE/VIAL</u>	<u>A091406</u>	<u>001</u>	Aug 21, 2012
<u>AP</u>		ZYDUS PHARMS	<u>EQ 100MG BASE/VIAL</u>	<u>A207757</u>	<u>001</u>	Sep 28, 2017
<u>AP</u>			<u>EQ 200MG BASE/VIAL</u>	<u>A207757</u>	<u>002</u>	Sep 28, 2017

DOXYCYCLINE HYCLATE

<u>AP</u>		PAR STERILE PRODUCTS	<u>EQ 100MG BASE/VIAL</u>	<u>A216690</u>	<u>001</u>	Dec 07, 2022
<u>AP</u>		WEST-WARD PHARMS INT	<u>EQ 100MG BASE/VIAL</u>	<u>A062992</u>	<u>001</u>	Feb 16, 1989
<u>AP</u>			<u>EQ 200MG BASE/VIAL</u>	<u>A062992</u>	<u>002</u>	Feb 16, 1989

TABLET; ORAL

ACTICLATE

<u>AB</u>	+	ALMIRALL	<u>EQ 75MG BASE</u>	<u>N205931</u>	<u>001</u>	Jul 25, 2014
<u>AB</u>	+!		<u>EQ 150MG BASE</u>	<u>N205931</u>	<u>002</u>	Jul 25, 2014

DOXYCYCLINE HYCLATE

<u>AB</u>		ACELLA	<u>EQ 100MG BASE</u>	<u>A210664</u>	<u>001</u>	Mar 16, 2020
<u>AB</u>		ACTAVIS LABS FL INC	<u>EQ 100MG BASE</u>	<u>A062421</u>	<u>001</u>	Feb 02, 1983
<u>AB</u>		AJANTA PHARMA LTD	<u>EQ 75MG BASE</u>	<u>A211584</u>	<u>001</u>	Jun 01, 2020
<u>AB</u>			<u>EQ 150MG BASE</u>	<u>A211584</u>	<u>002</u>	Jun 01, 2020
<u>AB</u>		ALEMBIC PHARMS	<u>EQ 20MG BASE</u>	<u>A210537</u>	<u>001</u>	Mar 03, 2020

PRESCRIPTION DRUG PRODUCT LIST

3-159 (of 474)

DOXYCYCLINE HYCLATE

TABLET; ORAL

DOXYCYCLINE HYCLATE

AB		EQ 50MG BASE	A210536	002	Sep 14, 2021
AB		EQ 75MG BASE	A211744	001	Jun 30, 2020
AB		EQ 150MG BASE	A211744	002	Jun 30, 2020
AB	APOTEX	EQ 75MG BASE	A209243	001	Apr 15, 2019
AB		EQ 150MG BASE	A209243	002	Apr 15, 2019
AB	CADILA	EQ 100MG BASE	A207773	001	Oct 30, 2017
AB	CARIBE HOLDINGS	EQ 50MG BASE	A062269	003	Oct 05, 1983
AB	!	EQ 100MG BASE	A062269	002	Nov 08, 1982
AB	CHANGZHOU PHARM	EQ 100MG BASE	A211343	001	Oct 09, 2019
AB	CHARTWELL	EQ 50MG BASE	A062505	002	Jul 27, 2021
AB		EQ 100MG BASE	A062505	001	Sep 11, 1984
AB	!	EQ 20MG BASE	A065277	001	Nov 10, 2005
AB	EPIC PHARMA LLC	EQ 20MG BASE	A065182	001	May 13, 2005
AB		EQ 75MG BASE	A214207	001	Dec 16, 2020
AB		EQ 150MG BASE	A214207	002	Dec 16, 2020
AB	HIKMA INTL PHARMS	EQ 100MG BASE	A065095	001	Jul 02, 2003
AB	LARKEN LABS	EQ 20MG BASE	A065287	001	Feb 28, 2006
AB	LUPIN LTD	EQ 75MG BASE	A208818	001	Sep 27, 2017
AB		EQ 150MG BASE	A208818	002	Sep 27, 2017
AB	MAYNE PHARMA INC	EQ 75MG BASE	A208765	001	Jun 14, 2017
AB		EQ 150MG BASE	A208765	002	Jun 14, 2017
AB	NOVEL LABS INC	EQ 100MG BASE	A207558	001	Sep 06, 2017
AB	SUN PHARM INDUSTRIES	EQ 20MG BASE	A065134	001	May 13, 2005
AB		EQ 100MG BASE	A062677	001	Jul 10, 1986

TABLET, DELAYED RELEASE; ORAL

DORYX

AB	+	MAYNE PHARMA	EQ 50MG BASE	N050795	006	Dec 19, 2014
AB	+		EQ 75MG BASE	N050795	001	May 06, 2005
AB	+		EQ 100MG BASE	N050795	002	May 06, 2005
AB	+		EQ 150MG BASE	N050795	003	Jun 20, 2008
AB	+	!	EQ 200MG BASE	N050795	005	Apr 11, 2013

DOXYCYCLINE HYCLATE

AB		ACTAVIS ELIZABETH	EQ 50MG BASE	A090134	003	May 22, 2018
AB			EQ 75MG BASE	A090134	001	Dec 14, 2011
AB			EQ 100MG BASE	A090134	002	Dec 14, 2011
AB			EQ 200MG BASE	A090134	004	May 22, 2018
AB		ALEMBIC PHARMS	EQ 75MG BASE	A213075	001	Jan 03, 2022
AB			EQ 100MG BASE	A213075	002	Jan 03, 2022
AB			EQ 150MG BASE	A213075	003	Jan 03, 2022
AB			EQ 200MG BASE	A213075	004	Jan 03, 2022
AB		HERITAGE PHARMS	EQ 75MG BASE	A200856	001	Apr 30, 2013
AB			EQ 100MG BASE	A200856	002	Apr 30, 2013
AB			EQ 150MG BASE	A200856	003	Apr 30, 2013
AB			EQ 200MG BASE	A200856	004	Nov 13, 2018
AB		PRINCETON INC	EQ 50MG BASE	A207494	003	Feb 19, 2019
AB			EQ 150MG BASE	A207494	001	Nov 15, 2016
AB			EQ 200MG BASE	A207494	002	Nov 15, 2016

DORYX

+ MAYNE PHARMA EQ 80MG BASE N050795 004 Apr 11, 2013

DORYX MPC

+ MAYNE PHARMA EQ 60MG BASE N050795 007 May 20, 2016

+! EQ 120MG BASE N050795 008 May 20, 2016

DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE

TABLET, DELAYED RELEASE; ORAL

DICLEGIS

AB	+	!	DUCHESNAY	10MG;10MG	N021876	001	Apr 08, 2013

DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE

AB		ACTAVIS LABS FL INC	10MG;10MG	A205811	001	Aug 19, 2016
AB		MYLAN PHARMS INC	10MG;10MG	A207825	001	Jul 06, 2020
AB		PAR PHARM INC	10MG;10MG	A208518	001	Dec 06, 2017

TABLET, EXTENDED RELEASE; ORAL

BONJESTA

+! DUCHESNAY 20MG;20MG N209661 001 Nov 07, 2016

PRESCRIPTION DRUG PRODUCT LIST

3-160 (of 474)

DRONABINOL

CAPSULE; ORAL

DRONABINOL

<u>AB</u>	AKORN	<u>2.5MG</u>	<u>A079217</u>	<u>001</u>	Jun 20, 2014
<u>AB</u>		<u>5MG</u>	<u>A079217</u>	<u>002</u>	Jun 20, 2014
<u>AB</u>		<u>10MG</u>	<u>A079217</u>	<u>003</u>	Jun 20, 2014
<u>AB</u>	ASCENT PHARMS INC	<u>2.5MG</u>	<u>A207421</u>	<u>001</u>	Feb 07, 2020
<u>AB</u>		<u>5MG</u>	<u>A207421</u>	<u>002</u>	Feb 07, 2020
<u>AB</u>		<u>10MG</u>	<u>A207421</u>	<u>003</u>	Feb 07, 2020
<u>AB</u>	SVC PHARMA	<u>2.5MG</u>	<u>A078292</u>	<u>001</u>	Jun 27, 2008
<u>AB</u>		<u>5MG</u>	<u>A078292</u>	<u>002</u>	Jun 27, 2008
<u>AB</u>		<u>10MG</u>	<u>A078292</u>	<u>003</u>	Jun 27, 2008

MARINOL

<u>AB</u>	+	ALKEM LABS LTD	<u>2.5MG</u>	<u>N018651</u>	<u>001</u>	May 31, 1985
<u>AB</u>	+	!	<u>5MG</u>	<u>N018651</u>	<u>002</u>	May 31, 1985
<u>AB</u>	+		<u>10MG</u>	<u>N018651</u>	<u>003</u>	May 31, 1985

SOLUTION; ORAL

SYNDROS

+	!	BENUVIA OPERATIONS	5MG/ML	N205525	001	Mar 23, 2017

DRONEDARONE HYDROCHLORIDE

TABLET; ORAL

MULTAQ

+	!	SANOFI AVENTIS US	EQ 400MG BASE	N022425	001	Jul 01, 2009

PROPERIDOL

INJECTABLE; INJECTION

PROPERIDOL

<u>AP</u>		AM REGENT	<u>2.5MG/ML</u>	<u>A072123</u>	<u>001</u>	Oct 24, 1988
<u>AP</u>		EUROHLTH INTL SARL	<u>2.5MG/ML</u>	<u>A208197</u>	<u>001</u>	Dec 14, 2017
<u>AP</u>		HOSPIRA	<u>2.5MG/ML</u>	<u>A071981</u>	<u>001</u>	Feb 29, 1988

INAPSINE

<u>AP</u>	+	!	AKORN	<u>2.5MG/ML</u>	<u>N016796</u>	<u>001</u>

DROSPIRENONE

TABLET; ORAL

SLYND

+	!	EXELTIS USA INC	4MG	N211367	001	May 23, 2019

TABLET, CHEWABLE; ORAL

DROSPIRENONE

+	!	EXELTIS USA INC	3.5MG	N216285	001	Jun 29, 2022

DROSPIRENONE; ESTETROL

TABLET; ORAL

NEXTSTELLIS

+	!	MAYNE PHARMA	3MG; 14.2MG	N214154	001	Apr 15, 2021

DROSPIRENONE; ESTRADIOL

TABLET; ORAL

ANGELIQ

+		BAYER HLTHCARE	0.25MG; 0.5MG	N021355	001	Feb 29, 2012

+	!		0.5MG; 1MG	N021355	002	Sep 28, 2005

DROSPIRENONE; ETHINYL ESTRADIOL

TABLET; ORAL

DROSPIRENONE AND ETHINYL ESTRADIOL

<u>AB</u>		BARR	<u>3MG; 0.02MG</u>	<u>A078515</u>	<u>001</u>	Mar 30, 2009
<u>AB</u>		GLENMARK PHARMS LTD	<u>3MG; 0.02MG</u>	<u>A204296</u>	<u>001</u>	Aug 17, 2015
<u>AB</u>		HETERO LABS	<u>3MG; 0.02MG</u>	<u>A211944</u>	<u>001</u>	Mar 22, 2019
<u>AB</u>		HLTHCARE	<u>3MG; 0.02MG</u>	<u>A203291</u>	<u>001</u>	Jul 18, 2017
<u>AB</u>		MYLAN LABS LTD	<u>3MG; 0.02MG</u>	<u>A202594</u>	<u>001</u>	Oct 22, 2015
<u>AB</u>		WATSON LABS	<u>3MG; 0.02MG</u>	<u>A078833</u>	<u>001</u>	Nov 28, 2011

LO-ZUMANDIMINE

<u>AB</u>		AUROBINDO PHARMA LTD	<u>3MG; 0.02MG</u>	<u>A209632</u>	<u>001</u>	Feb 27, 2018

LORYNA

<u>AB</u>		XIROMED	<u>3MG; 0.02MG</u>	<u>A079221</u>	<u>001</u>	Mar 28, 2011

MELAMISA

<u>AB</u>		NOVAST LABS	<u>3MG; 0.02MG</u>	<u>A202016</u>	<u>001</u>	Jan 26, 2016

NIKKI

<u>AB</u>		LUPIN LTD	<u>3MG; 0.02MG</u>	<u>A201661</u>	<u>001</u>	May 27, 2014

YAZ

<u>AB</u>	+	!	BAYER HLTHCARE	<u>3MG; 0.02MG</u>	<u>N021676</u>	<u>001</u>	Mar 16, 2006

PRESCRIPTION DRUG PRODUCT LIST

3-161 (of 474)

DROSPIRENONE; ETHINYL ESTRADIOL

TABLET; ORAL-28

DROSPIRENONE AND ETHINYL ESTRADIOL

AB	BARR	<u>3MG;0.03MG</u>	<u>A077527</u>	<u>001</u>	May 09, 2008
AB	GLENMARK PHARMS LTD	<u>3MG;0.03MG</u>	<u>A204848</u>	<u>001</u>	Mar 25, 2016
AB	HETERO LABS	<u>3MG;0.03MG</u>	<u>A213034</u>	<u>001</u>	Jan 24, 2020
AB	LUPIN LTD	<u>3MG;0.03MG</u>	<u>A201663</u>	<u>001</u>	Dec 18, 2012
AB	MAYNE PHARMA	<u>3MG;0.03MG</u>	<u>A090081</u>	<u>001</u>	Sep 07, 2010
AB	MYLAN LABS LTD	<u>3MG;0.03MG</u>	<u>A202131</u>	<u>001</u>	May 04, 2015
AB	NAARI PTE LTD	<u>3MG;0.03MG</u>	<u>A207245</u>	<u>001</u>	Nov 22, 2016

SYEDA

AB	XIROMED	<u>3MG;0.03MG</u>	<u>A090114</u>	<u>001</u>	Mar 28, 2011

YAEAL

AB	NOVAST LABS	<u>3MG;0.03MG</u>	<u>A202015</u>	<u>001</u>	Nov 19, 2014

YASMIN

AB	+! BAYER HLTHCARE	<u>3MG;0.03MG</u>	<u>N021098</u>	<u>001</u>	May 11, 2001

ZUMANDIMINE

AB	AUROBINDO PHARMA LTD	<u>3MG;0.03MG</u>	<u>A209407</u>	<u>001</u>	Mar 26, 2018

DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM

TABLET; ORAL

BEYAZ

AB	+! BAYER HLTHCARE	<u>3MG,N/A:0.02MG,N/A:0.451MG,0.451MG</u>	<u>N022532</u>	<u>001</u>	Sep 24, 2010

DROSPIRENONE, ETHINYL ESTRADIOL AND LEVOMEFOLATE CALCIUM

AB	LUPIN LTD	<u>3MG,N/A:0.02MG,N/A:0.451MG,0.451MG</u>	<u>A205947</u>	<u>001</u>	Jun 13, 2018
AB	WATSON LABS INC	<u>3MG,N/A:0.02MG,N/A:0.451MG,0.451MG</u>	<u>A203593</u>	<u>001</u>	Oct 11, 2016
AB		<u>3MG,N/A:0.03MG,N/A:0.451MG,0.451MG</u>	<u>A203594</u>	<u>001</u>	Oct 11, 2016

SAFYRAL

AB	+! BAYER HLTHCARE	<u>3MG,N/A:0.03MG,N/A:0.451MG,0.451MG</u>	<u>N022574</u>	<u>001</u>	Dec 16, 2010

TYDEMY

AB	LUPIN LTD	<u>3MG,N/A:0.03MG,N/A:0.451MG,0.451MG</u>	<u>A205948</u>	<u>001</u>	Dec 12, 2017

DROXIDOPA

CAPSULE; ORAL

DROXIDOPA

AB	AJANTA PHARMA LTD	<u>100MG</u>	<u>A214391</u>	<u>001</u>	Feb 18, 2021
AB		<u>200MG</u>	<u>A214391</u>	<u>002</u>	Feb 18, 2021
AB		<u>300MG</u>	<u>A214391</u>	<u>003</u>	Feb 18, 2021
AB	ALKEM LABS LTD	<u>100MG</u>	<u>A213911</u>	<u>001</u>	Feb 18, 2021
AB		<u>200MG</u>	<u>A213911</u>	<u>002</u>	Feb 18, 2021
AB		<u>300MG</u>	<u>A213911</u>	<u>003</u>	Feb 18, 2021
AB	ANNORA	<u>100MG</u>	<u>A211726</u>	<u>002</u>	Aug 09, 2021
AB		<u>200MG</u>	<u>A211726</u>	<u>003</u>	Aug 09, 2021
AB		<u>300MG</u>	<u>A211726</u>	<u>001</u>	Feb 18, 2021
AB	AUROBINDO PHARMA LTD	<u>100MG</u>	<u>A214387</u>	<u>001</u>	Feb 18, 2021
AB		<u>200MG</u>	<u>A214387</u>	<u>002</u>	Feb 18, 2021
AB		<u>300MG</u>	<u>A214387</u>	<u>003</u>	Feb 18, 2021
AB	BIONPHARMA INC	<u>100MG</u>	<u>A213033</u>	<u>001</u>	Apr 28, 2021
AB		<u>200MG</u>	<u>A213033</u>	<u>002</u>	Apr 28, 2021
AB		<u>300MG</u>	<u>A213033</u>	<u>003</u>	Apr 28, 2021
AB	HIKMA	<u>100MG</u>	<u>A212835</u>	<u>001</u>	Feb 18, 2021
AB		<u>200MG</u>	<u>A212835</u>	<u>002</u>	Feb 18, 2021
AB		<u>300MG</u>	<u>A212835</u>	<u>003</u>	Feb 18, 2021
AB	LUPIN PHARMS	<u>100MG</u>	<u>A211652</u>	<u>001</u>	Feb 18, 2021
AB		<u>200MG</u>	<u>A211652</u>	<u>002</u>	Feb 18, 2021
AB		<u>300MG</u>	<u>A211652</u>	<u>003</u>	Feb 18, 2021
AB	MSN PHARMS INC	<u>100MG</u>	<u>A211741</u>	<u>001</u>	Feb 18, 2021
AB		<u>200MG</u>	<u>A211741</u>	<u>002</u>	Feb 18, 2021
AB		<u>300MG</u>	<u>A211741</u>	<u>003</u>	Feb 18, 2021
AB	SCIEGEN PHARMS INC	<u>100MG</u>	<u>A214017</u>	<u>001</u>	Feb 18, 2021
AB		<u>200MG</u>	<u>A214017</u>	<u>002</u>	Feb 18, 2021
AB		<u>300MG</u>	<u>A214017</u>	<u>003</u>	Feb 18, 2021
AB	SLATE RUN PHARMA	<u>100MG</u>	<u>A215265</u>	<u>001</u>	Nov 01, 2021
AB		<u>200MG</u>	<u>A215265</u>	<u>002</u>	Nov 01, 2021
AB		<u>300MG</u>	<u>A215265</u>	<u>003</u>	Nov 01, 2021
AB	SUN PHARM	<u>100MG</u>	<u>A214384</u>	<u>001</u>	Feb 18, 2021
AB		<u>200MG</u>	<u>A214384</u>	<u>002</u>	Feb 18, 2021
AB		<u>300MG</u>	<u>A214384</u>	<u>003</u>	Feb 18, 2021
AB	TRIS PHARMA INC	<u>100MG</u>	<u>A214543</u>	<u>001</u>	May 05, 2021
AB		<u>200MG</u>	<u>A214543</u>	<u>002</u>	May 05, 2021
AB		<u>300MG</u>	<u>A214543</u>	<u>003</u>	May 05, 2021
AB	UPSHER SMITH LABS	<u>100MG</u>	<u>A213661</u>	<u>001</u>	Feb 18, 2021

PRESCRIPTION DRUG PRODUCT LIST

3-162 (of 474)

DROXIDOPA

CAPSULE; ORAL

DROXIDOPA

<u>AB</u>		<u>200MG</u>	<u>A213661</u>	<u>002</u>	Feb 18, 2021
<u>AB</u>		<u>300MG</u>	<u>A213661</u>	<u>003</u>	Feb 18, 2021
<u>AB</u>	ZYDUS PHARMS	<u>100MG</u>	<u>A211818</u>	<u>001</u>	Feb 18, 2021
<u>AB</u>		<u>200MG</u>	<u>A211818</u>	<u>002</u>	Feb 18, 2021
<u>AB</u>		<u>300MG</u>	<u>A211818</u>	<u>003</u>	Feb 18, 2021

NORTHERA

<u>AB</u>	+	LUNDBECK NA LTD	<u>100MG</u>	<u>N203202</u>	<u>001</u>	Feb 18, 2014
<u>AB</u>	+		<u>200MG</u>	<u>N203202</u>	<u>002</u>	Feb 18, 2014
<u>AB</u>	+		<u>300MG</u>	<u>N203202</u>	<u>003</u>	Feb 18, 2014

DULOXETINE HYDROCHLORIDE

CAPSULE, DELAYED REL PELLETS; ORAL

CYMBALTA

<u>AB</u>	+	LILLY	<u>EQ 20MG BASE</u>	<u>N021427</u>	<u>001</u>	Aug 03, 2004
<u>AB</u>	+		<u>EQ 30MG BASE</u>	<u>N021427</u>	<u>002</u>	Aug 03, 2004
<u>AB</u>	+		<u>EQ 60MG BASE</u>	<u>N021427</u>	<u>004</u>	Aug 03, 2004

DULOXETINE HYDROCHLORIDE

<u>AB</u>		ACTAVIS ELIZABETH	<u>EQ 20MG BASE</u>	<u>A090776</u>	<u>001</u>	Dec 17, 2013
<u>AB</u>			<u>EQ 30MG BASE</u>	<u>A090776</u>	<u>002</u>	Dec 17, 2013
<u>AB</u>			<u>EQ 60MG BASE</u>	<u>A090776</u>	<u>003</u>	Dec 17, 2013
<u>AB</u>		AJANTA PHARMA LTD	<u>EQ 20MG BASE</u>	<u>A208706</u>	<u>001</u>	Jan 06, 2017
<u>AB</u>			<u>EQ 30MG BASE</u>	<u>A208706</u>	<u>002</u>	Jan 06, 2017
<u>AB</u>			<u>EQ 40MG BASE</u>	<u>A208706</u>	<u>004</u>	Mar 11, 2019
<u>AB</u>			<u>EQ 60MG BASE</u>	<u>A208706</u>	<u>003</u>	Jan 06, 2017
<u>AB</u>		ALEMBIC PHARMS	<u>EQ 20MG BASE</u>	<u>A202949</u>	<u>001</u>	Jun 09, 2014
<u>AB</u>			<u>EQ 30MG BASE</u>	<u>A202949</u>	<u>002</u>	Jun 09, 2014
<u>AB</u>			<u>EQ 60MG BASE</u>	<u>A202949</u>	<u>003</u>	Jun 09, 2014
<u>AB</u>		ALKEM LABS LTD	<u>EQ 20MG BASE</u>	<u>A203197</u>	<u>001</u>	Aug 26, 2015
<u>AB</u>			<u>EQ 30MG BASE</u>	<u>A203197</u>	<u>002</u>	Aug 26, 2015
<u>AB</u>			<u>EQ 60MG BASE</u>	<u>A203197</u>	<u>003</u>	Aug 26, 2015
<u>AB</u>		ANCHEN PHARMS	<u>EQ 20MG BASE</u>	<u>A090780</u>	<u>001</u>	Oct 28, 2015
<u>AB</u>			<u>EQ 30MG BASE</u>	<u>A090780</u>	<u>002</u>	Oct 28, 2015
<u>AB</u>			<u>EQ 60MG BASE</u>	<u>A090780</u>	<u>003</u>	Oct 28, 2015
<u>AB</u>		APOTEX	<u>EQ 20MG BASE</u>	<u>A202045</u>	<u>001</u>	Jun 11, 2014
<u>AB</u>			<u>EQ 30MG BASE</u>	<u>A202045</u>	<u>002</u>	Jun 11, 2014
<u>AB</u>			<u>EQ 60MG BASE</u>	<u>A202045</u>	<u>003</u>	Jun 11, 2014
<u>AB</u>		AUROBINDO PHARMA LTD	<u>EQ 20MG BASE</u>	<u>A090778</u>	<u>001</u>	Dec 11, 2013
<u>AB</u>			<u>EQ 30MG BASE</u>	<u>A090778</u>	<u>002</u>	Dec 11, 2013
<u>AB</u>			<u>EQ 60MG BASE</u>	<u>A090778</u>	<u>003</u>	Dec 11, 2013
<u>AB</u>		BRECKENRIDGE	<u>EQ 20MG BASE</u>	<u>A203088</u>	<u>001</u>	Jun 11, 2014
<u>AB</u>			<u>EQ 30MG BASE</u>	<u>A203088</u>	<u>002</u>	Jun 11, 2014
<u>AB</u>			<u>EQ 40MG BASE</u>	<u>A203088</u>	<u>004</u>	May 18, 2018
<u>AB</u>			<u>EQ 60MG BASE</u>	<u>A203088</u>	<u>003</u>	Jun 11, 2014
<u>AB</u>		CSPC OUYI	<u>EQ 20MG BASE</u>	<u>A211310</u>	<u>001</u>	Oct 16, 2018
<u>AB</u>			<u>EQ 30MG BASE</u>	<u>A211310</u>	<u>002</u>	Oct 16, 2018
<u>AB</u>			<u>EQ 60MG BASE</u>	<u>A211310</u>	<u>003</u>	Oct 16, 2018
<u>AB</u>		HETERO LABS LTD III	<u>EQ 20MG BASE</u>	<u>A204343</u>	<u>001</u>	Aug 03, 2016
<u>AB</u>			<u>EQ 30MG BASE</u>	<u>A204343</u>	<u>002</u>	Aug 03, 2016
<u>AB</u>			<u>EQ 60MG BASE</u>	<u>A204343</u>	<u>003</u>	Aug 03, 2016
<u>AB</u>		INVENTIA	<u>EQ 20MG BASE</u>	<u>A202336</u>	<u>001</u>	Oct 28, 2015
<u>AB</u>			<u>EQ 30MG BASE</u>	<u>A202336</u>	<u>002</u>	Oct 28, 2015
<u>AB</u>			<u>EQ 60MG BASE</u>	<u>A202336</u>	<u>003</u>	Oct 28, 2015
<u>AB</u>		LUPIN LTD	<u>EQ 20MG BASE</u>	<u>A090694</u>	<u>001</u>	Dec 11, 2013
<u>AB</u>			<u>EQ 30MG BASE</u>	<u>A090694</u>	<u>002</u>	Dec 11, 2013
<u>AB</u>			<u>EQ 40MG BASE</u>	<u>A090694</u>	<u>003</u>	Dec 11, 2013
<u>AB</u>			<u>EQ 60MG BASE</u>	<u>A090694</u>	<u>004</u>	Dec 11, 2013
<u>AB</u>		MACLEODS PHARMS LTD	<u>EQ 20MG BASE</u>	<u>A204815</u>	<u>001</u>	Mar 23, 2017
<u>AB</u>			<u>EQ 30MG BASE</u>	<u>A204815</u>	<u>002</u>	Mar 23, 2017
<u>AB</u>			<u>EQ 60MG BASE</u>	<u>A204815</u>	<u>003</u>	Mar 23, 2017
<u>AB</u>		MARKSANS PHARMA	<u>EQ 20MG BASE</u>	<u>A090723</u>	<u>001</u>	Dec 11, 2013
<u>AB</u>			<u>EQ 30MG BASE</u>	<u>A090723</u>	<u>002</u>	Dec 11, 2013
<u>AB</u>			<u>EQ 60MG BASE</u>	<u>A090723</u>	<u>003</u>	Dec 11, 2013
<u>AB</u>		PRINSTON INC	<u>EQ 20MG BASE</u>	<u>A206653</u>	<u>001</u>	May 18, 2017
<u>AB</u>			<u>EQ 30MG BASE</u>	<u>A206653</u>	<u>002</u>	May 18, 2017
<u>AB</u>			<u>EQ 60MG BASE</u>	<u>A206653</u>	<u>003</u>	May 18, 2017
<u>AB</u>		QINGDAO BAHEAL PHARM	<u>EQ 20MG BASE</u>	<u>A210599</u>	<u>001</u>	Apr 17, 2019
<u>AB</u>			<u>EQ 30MG BASE</u>	<u>A210599</u>	<u>002</u>	Apr 17, 2019
<u>AB</u>			<u>EQ 60MG BASE</u>	<u>A210599</u>	<u>003</u>	Apr 17, 2019

PRESCRIPTION DRUG PRODUCT LIST

3-163 (of 474)

DULOXETINE HYDROCHLORIDE

CAPSULE, DELAYED REL PELLETS; ORAL

DULOXETINE HYDROCHLORIDE

AB	SUN PHARM	<u>EQ 20MG BASE</u>	<u>A090745 001</u>	Dec 11, 2013
AB		<u>EQ 30MG BASE</u>	<u>A090745 002</u>	Dec 11, 2013
AB		<u>EQ 60MG BASE</u>	<u>A090745 003</u>	Dec 11, 2013
AB	SUNSHINE	<u>EQ 20MG BASE</u>	<u>A212328 001</u>	Feb 11, 2021
AB		<u>EQ 30MG BASE</u>	<u>A212328 002</u>	Feb 11, 2021
AB		<u>EQ 60MG BASE</u>	<u>A212328 003</u>	Feb 11, 2021
AB	TORRENT	<u>EQ 20MG BASE</u>	<u>A090774 001</u>	Dec 11, 2013
AB		<u>EQ 30MG BASE</u>	<u>A090774 002</u>	Dec 11, 2013
AB		<u>EQ 60MG BASE</u>	<u>A090774 003</u>	Dec 11, 2013
AB	ZYDUS HLTHCARE	<u>EQ 20MG BASE</u>	<u>A090739 001</u>	Jan 08, 2014
AB		<u>EQ 30MG BASE</u>	<u>A090739 002</u>	Jan 08, 2014
AB		<u>EQ 60MG BASE</u>	<u>A090739 003</u>	Jan 08, 2014
AB	ZYDUS PHARMS	<u>EQ 20MG BASE</u>	<u>A090728 001</u>	Jan 08, 2014
AB		<u>EQ 30MG BASE</u>	<u>A090728 002</u>	Jan 08, 2014
AB		<u>EQ 60MG BASE</u>	<u>A090728 003</u>	Jan 08, 2014
	DRIZALMA SPRINKLE			
	+ SUN PHARM	EQ 30MG BASE	N212516 002	Jul 19, 2019
	+	EQ 40MG BASE	N212516 003	Jul 19, 2019
	+!	EQ 60MG BASE	N212516 004	Jul 19, 2019

DUTASTERIDE

CAPSULE; ORAL

AVODART

AB	+! WOODWARD	<u>0.5MG</u>	<u>N021319 001</u>	Nov 20, 2001
	<u>DUTASTERIDE</u>			
AB	ACELLA	<u>0.5MG</u>	<u>A206373 001</u>	Mar 17, 2016
AB	AMNEAL PHARMS	<u>0.5MG</u>	<u>A203118 001</u>	Nov 20, 2015
AB	ASCENT PHARMS INC	<u>0.5MG</u>	<u>A206574 001</u>	Oct 21, 2016
AB	AUROBINDO PHARMA LTD	<u>0.5MG</u>	<u>A202660 001</u>	Nov 20, 2015
AB	BARR	<u>0.5MG</u>	<u>A090095 001</u>	Dec 21, 2010
AB	BIONPHARMA INC	<u>0.5MG</u>	<u>A200899 001</u>	Nov 20, 2015
AB	CADILA	<u>0.5MG</u>	<u>A204373 001</u>	Oct 04, 2017
AB	HUMANWELL PURACAP	<u>0.5MG</u>	<u>A209909 001</u>	Nov 21, 2017
AB	MARKSANS PHARMA	<u>0.5MG</u>	<u>A204376 001</u>	Apr 07, 2017
AB	STRIDES PHARMA	<u>0.5MG</u>	<u>A204262 001</u>	Nov 20, 2015
AB	VINTAGE	<u>0.5MG</u>	<u>A202421 001</u>	Nov 20, 2015

DUTASTERIDE; TAMSULOSIN HYDROCHLORIDE

CAPSULE; ORAL

DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE

AB	ANCHEN PHARMS	<u>0.5MG; 0.4MG</u>	<u>A202509 001</u>	Feb 26, 2014
AB	ZYDUS PHARMS	<u>0.5MG; 0.4MG</u>	<u>A207769 001</u>	May 24, 2018
	<u>JALYN</u>			
AB	+! WOODWARD	<u>0.5MG; 0.4MG</u>	<u>N022460 001</u>	Jun 14, 2010

DUVELISIB

CAPSULE; ORAL

COPIKTRA

+	SECURA	15MG	N211155 001	Sep 24, 2018
+		25MG	N211155 002	Sep 24, 2018

DYCLONINE HYDROCHLORIDE

SOLUTION; TOPICAL

DYCLOPRO

!	NOVOCOL INC	0.5%	A200480 001	Nov 20, 2018
!		1%	A200480 002	Nov 20, 2018

ECHOTHIOPHATE IODIDE

FOR SOLUTION; OPHTHALMIC

PHOSPHOLINE IODIDE

+	FERA PHARMS LLC	0.125%	N011963 001	

ECONAZOLE NITRATE

AEROSOL, FOAM; TOPICAL

ECOZA

+	RESILIA PHARMS	1%	N205175 001	Oct 24, 2013

CREAM; TOPICAL

ECONAZOLE NITRATE

AB	! PADAGIS ISRAEL	<u>1%</u>	<u>A076479 001</u>	Jun 23, 2004
AB	PAI HOLDINGS PHARM	<u>1%</u>	<u>A076574 001</u>	Dec 17, 2004
AB	TARO	<u>1%</u>	<u>A076005 001</u>	Nov 26, 2002

PRESCRIPTION DRUG PRODUCT LIST

3-164 (of 474)

EDARAVONE

SOLUTION; INTRAVENOUS

RADICAVA

+! MITSUBISHI TANABE 30MG/100ML (0.3MG/ML)
 +! 60MG/100ML (0.6MG/ML)

N209176 001 May 05, 2017
 N209176 002 Nov 15, 2018

SUSPENSION; ORAL

RADICAVA ORS

+! MITSUBISHI TANABE 105MG/5ML

N215446 001 May 12, 2022

EDETATE CALCIUM DISODIUM

INJECTABLE; INJECTION

CALCIUM DISODIUM VERSENATE

+! BAUSCH 200MG/ML

N008922 001

EDOXABAN TOSYLATE

TABLET; ORAL

SAVAYSA

+ DAIICHI SANKYO INC EQ 15MG BASE
 + EQ 30MG BASE
 +! EQ 60MG BASE

N206316 001 Jan 08, 2015
 N206316 002 Jan 08, 2015
 N206316 003 Jan 08, 2015

EFAVIRENZ

CAPSULE; ORAL

EFAVIRENZAB AUROBINDO PHARMA50MGA078064 001 Dec 15, 2017AB 200MGA078064 003 Dec 15, 2017SUSTIVAAB + BRISTOL MYERS 50MGN020972 001 Sep 17, 1998

SQUIBB

AB +! 200MGN020972 003 Sep 17, 1998

EFAVIRENZ

AUROBINDO PHARMA

100MG

A078064 002 Dec 15, 2017

TABLET; ORAL

EFAVIRENZAB AUROBINDO PHARMA600MGA077673 001 Sep 21, 2018

LTD

AB CIPLA 600MGA204766 001 Jun 15, 2018AB ! HETERO LABS LTD III 600MGA078886 001 Apr 27, 2018AB STRIDES PHARMA 600MGA204869 001 Mar 12, 2018EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL

ATRIPLAAB +! GILEAD SCIENCES 600MG; 200MG; 300MGN021937 001 Jul 12, 2006EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATEAB AUROBINDO PHARMA 600MG; 200MG; 300MGA203041 001 Sep 04, 2018AB CIPLA 600MG; 200MG; 300MGA206894 001 Jun 03, 2019AB HETERO LABS LTD V 600MG; 200MG; 300MGA203053 001 Jan 24, 2022AB LAURUS 600MG; 200MG; 300MGA213541 001 Dec 22, 2021AB MACLEODS PHARMS LTD 600MG; 200MG; 300MGA204287 001 Sep 13, 2021AB TEVA PHARMS USA 600MG; 200MG; 300MGA091215 001 Nov 09, 2018EFAVIRENZ; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL

EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATEAB LAURUS 400MG; 300MG; 300MGA213038 001 May 14, 2020AB 600MG; 300MG; 300MGA212786 001 May 14, 2020SYMFIAB +! MYLAN LABS LTD 600MG; 300MG; 300MGN022142 001 Mar 22, 2018SYMFI LOAB +! MYLAN 400MG; 300MG; 300MGN208255 001 Feb 05, 2018EFINACONAZOLE

SOLUTION; TOPICAL

EFINACONAZOLEAB NIVAGEN PHARMS INC 10%A211969 001 Jun 21, 2021AB TEVA PHARMS USA 10%A211827 001 Dec 16, 2020JUBLIAAB +! BAUSCH 10%N203567 001 Jun 06, 2014

PRESCRIPTION DRUG PRODUCT LIST

3-165 (of 474)

ELAGOLIX SODIUM

TABLET; ORAL

ORILISSA

+ ABBVIE INC

EQ 150MG BASE

N210450 001 Jul 23, 2018

+!

EQ 200MG BASE

N210450 002 Jul 23, 2018

ELAGOLIX SODIUM, ESTRADIOL, NORETHINDRONE ACETATE; ELAGOLIX SODIUM

CAPSULE; ORAL

ORIAHNN (COPACKAGED)

+! ABBVIE INC

EQ 300MG BASE, 1MG, 0.5MG; EQ 300MG BASE

N213388 001 May 29, 2020

ELBASVIR; GRAZOPREVRIS

TABLET; ORAL

ZEPATIER

+! MSD SUB MERCK

50MG; 100MG

N208261 001 Jan 28, 2016

ELETRIPTAN HYDROBROMIDE

TABLET; ORAL

ELETRIPTAN HYDROBROMIDE**AB** AJANTA PHARMA LTDEQ 20MG BASEA205186 001 Aug 29, 2017**AB**EQ 40MG BASEA205186 002 Aug 29, 2017**AB** AUROBINDO PHARMAEQ 20MG BASEA210708 001 Jan 15, 2019**AB**EQ 40MG BASEA210708 002 Jan 15, 2019**AB** BEXIMCO PHARMS USAEQ 20MG BASEA215467 001 Jul 13, 2022**AB**EQ 40MG BASEA215467 002 Jul 13, 2022**AB** MYLANEQ 20MG BASEA205152 001 Aug 11, 2017**AB**EQ 40MG BASEA205152 002 Aug 11, 2017**AB** TEVA PHARMS USAEQ 20MG BASEA202040 001 Jun 27, 2017**AB**EQ 40MG BASEA202040 002 Jun 27, 2017**AB** ZYDUS PHARMSEQ 20MG BASEA206409 001 Jun 16, 2017**AB**EQ 40MG BASEA206409 002 Jun 16, 2017RELPAK**AB** + UPJOHNEQ 20MG BASEN021016 001 Dec 26, 2002**AB** +!EQ 40MG BASEN021016 002 Dec 26, 2002ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR

TABLET; ORAL

TRIKAFTA (COPACKAGED)

+ VERTEX PHARMS INC

50MG, 37.5MG, 25MG; 75MG

N212273 002 Jun 08, 2021

+!

100MG, 75MG, 50MG; 150MG

N212273 001 Oct 21, 2019

ELIGLUSTAT TARTRATE

CAPSULE; ORAL

CERDELGA**AB** +! GENZYME CORPEQ 84MG BASEN205494 001 Aug 19, 2014ELIGLUSTAT TARTRATE**AB** AIZANTEQ 84MG BASEA212463 001 Sep 08, 2021ELTROMBOPAG OLAMINE

FOR SUSPENSION; ORAL

PROMACTA KIT

+ NOVARTIS

EQ 12.5MG ACID/PACKET

N207027 002 Sep 27, 2018

+!

EQ 25MG ACID/PACKET

N207027 001 Aug 24, 2015

TABLET; ORAL

PROMACTA

+ NOVARTIS

EQ 12.5MG ACID

N022291 004 Oct 20, 2011

+

EQ 25MG ACID

N022291 001 Nov 20, 2008

+

EQ 50MG ACID

N022291 002 Nov 20, 2008

+!

EQ 75MG ACID

N022291 003 Sep 08, 2009

ELUXADOLINE

TABLET; ORAL

VIBERZI

+ ALLERGAN HOLDINGS

75MG

N206940 001 May 27, 2015

+!

100MG

N206940 002 May 27, 2015

EMPAGLIFLOZIN

TABLET; ORAL

EMPAGLIFLOZIN**AB** ZYDUS PHARMS10MGA212138 001 Aug 03, 2022**AB**25MGA212138 002 Aug 03, 2022JARDIANCE**AB** + BOEHRINGER10MGN204629 001 Aug 01, 2014

INGELHEIM

AB +!25MGN204629 002 Aug 01, 2014

PRESCRIPTION DRUG PRODUCT LIST

3-166 (of 474)

EMPAGLIFLOZIN; LINAGLIPTIN

TABLET; ORAL

GLYXAMBI

+	BOEHRINGER	10MG; 5MG	N206073	001	Jan 30, 2015
	INGELHEIM				
+	!	25MG; 5MG	N206073	002	Jan 30, 2015

EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

TRIJARDY XR

+	BOEHRINGER	5MG; 2.5MG; 1GM	N212614	001	Jan 27, 2020
	INGELHEIM				
+		10MG; 5MG; 1GM	N212614	002	Jan 27, 2020
+		12.5MG; 2.5MG; 1GM	N212614	003	Jan 27, 2020
+	!	25MG; 5MG; 1GM	N212614	004	Jan 27, 2020

EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE

TABLET; ORAL

SYNJARDY

+	BOEHRINGER	5MG; 500MG	N206111	001	Aug 26, 2015
	INGELHEIM				
+		5MG; 1GM	N206111	002	Aug 26, 2015
+		12.5MG; 500MG	N206111	003	Aug 26, 2015
+	!	12.5MG; 1GM	N206111	004	Aug 26, 2015

TABLET, EXTENDED RELEASE; ORAL

SYNJARDY XR

+	BOEHRINGER	5MG; 1GM	N208658	001	Dec 09, 2016
	INGELHEIM				
+		10MG; 1GM	N208658	002	Dec 09, 2016
+		12.5MG; 1GM	N208658	003	Dec 09, 2016
+	!	25MG; 1GM	N208658	004	Dec 09, 2016

EMTRICITABINE

CAPSULE; ORAL

EMTRICITABINE

AB	CIPLA	200MG	A091168	001	Jul 02, 2018

EMTRIVA

AB	+	!	GILEAD	200MG	N021500	001	Jul 02, 2003

SOLUTION; ORAL

EMTRIVA

+	!	GILEAD	10MG/ML	N021896	001	Sep 28, 2005

EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE

TABLET; ORAL

ODEFSEY

+	!	GILEAD SCIENCES INC	200MG; EQ 25MG BASE; EQ 25MG BASE	N208351	001	Mar 01, 2016

EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL

COMPLERA

+	!	GILEAD SCIENCES INC	200MG; EQ 25MG BASE; 300MG	N202123	001	Aug 10, 2011

EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE

TABLET; ORAL

DESCOVY

+		GILEAD SCIENCES INC	120MG; EQ 15MG BASE	N208215	002	Jan 07, 2022
+	!		200MG; EQ 25MG BASE	N208215	001	Apr 04, 2016

EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL

EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE

AB	HETERO LABS LTD III	200MG; 300MG	A201806	001	Oct 07, 2021

EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE

AB	AMNEAL PHARMS CO	100MG; 150MG	A209721	001	Aug 22, 2018
AB		133MG; 200MG	A209721	002	Aug 22, 2018
AB		167MG; 250MG	A209721	003	Aug 22, 2018
AB		200MG; 300MG	A209721	004	Aug 22, 2018
AB	APOTEX	200MG; 300MG	A208740	001	Jun 16, 2021
AB	AUROBINDO PHARMA	200MG; 300MG	A090513	001	Jan 26, 2018
AB	CIPLA	200MG; 300MG	A090958	001	Apr 02, 2021
AB	LAURUS	200MG; 300MG	A212114	001	Jul 26, 2019
AB	LUPIN LTD	200MG; 300MG	A204131	001	Jun 04, 2021
AB	MACLEODS PHARMS LTD	200MG; 300MG	A203442	001	May 15, 2020
AB	MYLAN	200MG; 300MG	A206436	001	Apr 09, 2018
AB	STRIDES PHARMA	200MG; 300MG	A091055	001	Jan 13, 2021
AB	TEVA PHARMS USA	200MG; 300MG	A090894	001	Jun 08, 2017
AB	ZYDUS PHARMS	100MG; 150MG	A212689	002	Jul 01, 2021

PRESCRIPTION DRUG PRODUCT LIST

3-167 (of 474)

EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL

EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE

<u>AB</u>		<u>133MG;200MG</u>	<u>A212689</u>	<u>003</u>	Jul 01, 2021
<u>AB</u>		<u>167MG;250MG</u>	<u>A212689</u>	<u>004</u>	Jul 01, 2021
<u>AB</u>		<u>200MG;300MG</u>	<u>A212689</u>	<u>001</u>	Feb 28, 2020
<u>TRUVADA</u>					
<u>AB</u>	+	GILEAD	<u>100MG;150MG</u>	<u>N021752</u>	<u>002</u> Mar 10, 2016
<u>AB</u>	+		<u>133MG;200MG</u>	<u>N021752</u>	<u>003</u> Mar 10, 2016
<u>AB</u>	+		<u>167MG;250MG</u>	<u>N021752</u>	<u>004</u> Mar 10, 2016
<u>AB</u>	+	!	<u>200MG;300MG</u>	<u>N021752</u>	<u>001</u> Aug 02, 2004

ENALAPRIL MALEATE

SOLUTION; ORAL

ENALAPRIL MALEATE

<u>AB</u>		ALKEM LABS LTD	<u>1MG/ML</u>	<u>A213714</u>	<u>001</u> Mar 30, 2022
<u>AB</u>		ANNORA PHARMA	<u>1MG/ML</u>	<u>A214467</u>	<u>001</u> Feb 24, 2022
<u>AB</u>		BIONPHARMA INC	<u>1MG/ML</u>	<u>A212408</u>	<u>001</u> Aug 10, 2021
<u>EPANED</u>					
<u>AB</u>	+	!	AZURITY	<u>1MG/ML</u>	<u>N208686</u> <u>001</u> Sep 20, 2016

TABLET; ORAL

ENALAPRIL MALEATE

<u>AB</u>		HERITAGE PHARMA	<u>2.5MG</u>	<u>A075479</u>	<u>001</u> Aug 22, 2000
<u>AB</u>			<u>5MG</u>	<u>A075479</u>	<u>002</u> Aug 22, 2000
<u>AB</u>			<u>10MG</u>	<u>A075479</u>	<u>003</u> Aug 22, 2000
<u>AB</u>			<u>20MG</u>	<u>A075479</u>	<u>004</u> Aug 22, 2000
<u>AB</u>		PRINSTON INC	<u>2.5MG</u>	<u>A213273</u>	<u>001</u> Jul 07, 2022
<u>AB</u>			<u>5MG</u>	<u>A213273</u>	<u>002</u> Jul 07, 2022
<u>AB</u>			<u>10MG</u>	<u>A213273</u>	<u>003</u> Jul 07, 2022
<u>AB</u>			<u>20MG</u>	<u>A213273</u>	<u>004</u> Jul 07, 2022
<u>AB</u>		SANDOZ INC	<u>2.5MG</u>	<u>A075496</u>	<u>001</u> Aug 22, 2000
<u>AB</u>			<u>5MG</u>	<u>A075496</u>	<u>002</u> Aug 22, 2000
<u>AB</u>			<u>10MG</u>	<u>A075459</u>	<u>001</u> Aug 22, 2000
<u>AB</u>			<u>20MG</u>	<u>A075459</u>	<u>002</u> Aug 22, 2000
<u>AB</u>		TARO	<u>2.5MG</u>	<u>A075657</u>	<u>001</u> Jan 23, 2001
<u>AB</u>			<u>5MG</u>	<u>A075657</u>	<u>002</u> Jan 23, 2001
<u>AB</u>			<u>10MG</u>	<u>A075657</u>	<u>003</u> Jan 23, 2001
<u>AB</u>			<u>20MG</u>	<u>A075657</u>	<u>004</u> Jan 23, 2001
<u>AB</u>		WOCKHARDT LTD	<u>2.5MG</u>	<u>A075483</u>	<u>001</u> Aug 22, 2000
<u>AB</u>			<u>5MG</u>	<u>A075483</u>	<u>002</u> Aug 22, 2000
<u>AB</u>			<u>10MG</u>	<u>A075483</u>	<u>003</u> Aug 22, 2000
<u>AB</u>			<u>20MG</u>	<u>A075483</u>	<u>004</u> Aug 22, 2000
<u>VASOTEC</u>					
<u>AB</u>	+	BAUSCH	<u>2.5MG</u>	<u>N018998</u>	<u>005</u> Jul 26, 1988
<u>AB</u>	+		<u>5MG</u>	<u>N018998</u>	<u>001</u> Dec 24, 1985
<u>AB</u>	+		<u>10MG</u>	<u>N018998</u>	<u>002</u> Dec 24, 1985
<u>AB</u>	+	!	<u>20MG</u>	<u>N018998</u>	<u>003</u> Dec 24, 1985

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE

<u>AB</u>		COSETTE	<u>5MG;12.5MG</u>	<u>A075727</u>	<u>001</u> Sep 18, 2001
<u>AB</u>			<u>10MG;25MG</u>	<u>A075727</u>	<u>002</u> Sep 18, 2001
<u>AB</u>		DR REDDYS LABS LTD	<u>5MG;12.5MG</u>	<u>A075909</u>	<u>001</u> Oct 15, 2001
<u>AB</u>			<u>10MG;25MG</u>	<u>A075909</u>	<u>002</u> Oct 15, 2001
<u>AB</u>		TARO PHARM INDS	<u>5MG;12.5MG</u>	<u>A075788</u>	<u>001</u> Sep 18, 2001
<u>AB</u>			<u>10MG;25MG</u>	<u>A075788</u>	<u>002</u> Sep 18, 2001

VASERETIC

<u>AB</u>	+	BAUSCH	<u>5MG;12.5MG</u>	<u>N019221</u>	<u>003</u> Jul 12, 1995
<u>AB</u>	+	!	<u>10MG;25MG</u>	<u>N019221</u>	<u>001</u> Oct 31, 1986

ENALAPRILAT

INJECTABLE; INJECTION

ENALAPRILAT

<u>AP</u>		CHARTWELL	<u>1.25MG/ML</u>	<u>A075634</u>	<u>001</u> Aug 22, 2000
		INJECTABLE			
<u>AP</u>	!	HIKMA FARMACEUTICA	<u>1.25MG/ML</u>	<u>A078687</u>	<u>001</u> Dec 23, 2008
<u>AP</u>		HOSPIRA	<u>1.25MG/ML</u>	<u>A075458</u>	<u>001</u> Aug 22, 2000

PRESCRIPTION DRUG PRODUCT LIST

3-168 (of 474)

ENASIDENIB MESYLATE

TABLET; ORAL

IDHIFA

+	BRISTOL MYERS SQUIBB	EQ 50MG BASE	N209606 001	Aug 01, 2017
+	!	EQ 100MG BASE	N209606 002	Aug 01, 2017

ENCORAFENIB

CAPSULE; ORAL

BRAFTOVI

+	!	ARRAY BIOPHARMA INC	75MG	N210496 002	Jun 27, 2018

ENFUVIRTIDE

INJECTABLE; SUBCUTANEOUS

FUZEON

+	!	ROCHE	90MG/VIAL	N021481 001	Mar 13, 2003

ENOXAPARIN SODIUM

INJECTABLE; INTRAVENOUS, SUBCUTANEOUS

ENOXAPARIN SODIUM

<u>AB</u>	AMPHASTAR PHARMS INC	<u>300MG/3ML (100MG/ML)</u>	<u>A208600 001</u>	Mar 14, 2019
<u>AB</u>	NANJING KING-FRIEND	<u>300MG/3ML (100MG/ML)</u>	<u>A214856 001</u>	Jun 14, 2022
<u>AB</u>	SANDOZ INC	<u>300MG/3ML (100MG/ML)</u>	<u>A078660 001</u>	Nov 28, 2011

LOVENOX

<u>AB</u>	+	SANOFI AVENTIS US	<u>300MG/3ML (100MG/ML)</u>	<u>N020164 009</u>	Jan 23, 2003

INJECTABLE; SUBCUTANEOUS

ENOXAPARIN SODIUM (PRESERVATIVE FREE)

<u>AP</u>	AMPHASTAR PHARM	<u>30MG/0.3ML (100MG/ML)</u>	<u>A076684 001</u>	Sep 19, 2011	
<u>AP</u>		<u>40MG/0.4ML (100MG/ML)</u>	<u>A076684 002</u>	Sep 19, 2011	
<u>AP</u>		<u>60MG/0.6ML (100MG/ML)</u>	<u>A076684 003</u>	Sep 19, 2011	
<u>AP</u>		<u>80MG/0.8ML (100MG/ML)</u>	<u>A076684 004</u>	Sep 19, 2011	
<u>AP</u>		<u>100MG/ML (100MG/ML)</u>	<u>A076684 005</u>	Sep 19, 2011	
<u>AP</u>		<u>120MG/0.8ML (150MG/ML)</u>	<u>A076684 006</u>	Sep 19, 2011	
<u>AP</u>		<u>150MG/ML (150MG/ML)</u>	<u>A076684 007</u>	Sep 19, 2011	
<u>AP</u>	APOTEX INC	<u>30MG/0.3ML (100MG/ML)</u>	<u>A078990 001</u>	Sep 28, 2018	
<u>AP</u>		<u>40MG/0.4ML (100MG/ML)</u>	<u>A078990 002</u>	Sep 28, 2018	
<u>AP</u>		<u>60MG/0.6ML (100MG/ML)</u>	<u>A078990 003</u>	Sep 28, 2018	
<u>AP</u>		<u>80MG/0.8ML (100MG/ML)</u>	<u>A078990 004</u>	Sep 28, 2018	
<u>AP</u>		<u>100MG/ML (100MG/ML)</u>	<u>A078990 005</u>	Sep 28, 2018	
<u>AP</u>		<u>120MG/0.8ML (150MG/ML)</u>	<u>A078990 006</u>	Sep 28, 2018	
<u>AP</u>		<u>150MG/ML (150MG/ML)</u>	<u>A078990 007</u>	Sep 28, 2018	
<u>AP</u>	NANJING KING-FRIEND	<u>30MG/0.3ML (100MG/ML)</u>	<u>A206834 001</u>	Nov 29, 2019	
<u>AP</u>		<u>40MG/0.4ML (100MG/ML)</u>	<u>A206834 002</u>	Nov 29, 2019	
<u>AP</u>		<u>60MG/0.6ML (100MG/ML)</u>	<u>A206834 003</u>	Nov 29, 2019	
<u>AP</u>		<u>80MG/0.8ML (100MG/ML)</u>	<u>A206834 004</u>	Nov 29, 2019	
<u>AP</u>		<u>100MG/ML (100MG/ML)</u>	<u>A206834 005</u>	Nov 29, 2019	
<u>AP</u>		<u>120MG/0.8ML (150MG/ML)</u>	<u>A206834 006</u>	Nov 29, 2019	
<u>AP</u>		<u>150MG/ML (150MG/ML)</u>	<u>A206834 007</u>	Nov 29, 2019	
<u>AP</u>	SANDOZ	<u>30MG/0.3ML (100MG/ML)</u>	<u>A077857 002</u>	Jul 23, 2010	
<u>AP</u>		<u>40MG/0.4ML (100MG/ML)</u>	<u>A077857 003</u>	Jul 23, 2010	
<u>AP</u>		<u>60MG/0.6ML (100MG/ML)</u>	<u>A077857 004</u>	Jul 23, 2010	
<u>AP</u>		<u>80MG/0.8ML (100MG/ML)</u>	<u>A077857 005</u>	Jul 23, 2010	
<u>AP</u>		<u>100MG/ML (100MG/ML)</u>	<u>A077857 001</u>	Jul 23, 2010	
<u>AP</u>		<u>120MG/0.8ML (150MG/ML)</u>	<u>A077857 006</u>	Jul 23, 2010	
<u>AP</u>		<u>150MG/ML (150MG/ML)</u>	<u>A077857 007</u>	Jul 23, 2010	
<u>AP</u>	ZYDUS PHARMS	<u>30MG/0.3ML (100MG/ML)</u>	<u>A076726 001</u>	Jun 23, 2014	
<u>AP</u>		<u>40MG/0.4ML (100MG/ML)</u>	<u>A076726 002</u>	Jun 23, 2014	
<u>AP</u>		<u>60MG/0.6ML (100MG/ML)</u>	<u>A076726 003</u>	Jun 23, 2014	
<u>AP</u>		<u>80MG/0.8ML (100MG/ML)</u>	<u>A076726 004</u>	Jun 23, 2014	
<u>AP</u>		<u>100MG/ML (100MG/ML)</u>	<u>A076726 005</u>	Jun 23, 2014	
<u>AP</u>		<u>120MG/0.8ML (150MG/ML)</u>	<u>A076726 006</u>	Jun 23, 2014	
<u>AP</u>		<u>150MG/ML (150MG/ML)</u>	<u>A076726 007</u>	Jun 23, 2014	
<u>LOVENOX (PRESERVATIVE FREE)</u>					
<u>AP</u>	+	SANOFI AVENTIS US	<u>30MG/0.3ML (100MG/ML)</u>	<u>N020164 001</u>	Mar 29, 1993
<u>AP</u>	+		<u>40MG/0.4ML (100MG/ML)</u>	<u>N020164 002</u>	Jan 30, 1998
<u>AP</u>	+		<u>60MG/0.6ML (100MG/ML)</u>	<u>N020164 003</u>	Mar 27, 1998
<u>AP</u>	+		<u>80MG/0.8ML (100MG/ML)</u>	<u>N020164 004</u>	Mar 27, 1998
<u>AP</u>	+	!	<u>100MG/ML (100MG/ML)</u>	<u>N020164 005</u>	Mar 27, 1998
<u>AP</u>	+		<u>120MG/0.8ML (150MG/ML)</u>	<u>N020164 007</u>	Jun 02, 2000
<u>AP</u>	+		<u>150MG/ML (150MG/ML)</u>	<u>N020164 008</u>	Jun 02, 2000

PRESCRIPTION DRUG PRODUCT LIST

3-169 (of 474)

ENTACAPONE

TABLET; ORAL

COMTAN

AB	+ !	ORION PHARMA	200MG	N020796	001	Oct 19, 1999

ENTACAPONE

AB		AJANTA PHARMA LTD	200MG	A205792	001	Aug 31, 2017
AB		ALEMBIC PHARMS	200MG	A212601	001	Jan 04, 2022
AB		AUROBINDO PHARMA LTD	200MG	A203437	001	Jun 19, 2015
AB		MACLEODS PHARMS LTD	200MG	A207210	001	Jun 05, 2017
AB		SUN PHARM	200MG	A090690	001	Jul 16, 2012
AB		SUNSHINE	200MG	A206669	001	Oct 03, 2018
AB		WOCKHARDT BIO AG	200MG	A078941	001	Aug 16, 2012

ENTECAVIR

SOLUTION; ORAL

BARACLUDE

+ !	BRISTOL MYERS SQUIBB	0.05MG/ML	N021798	001	Mar 29, 2005

TABLET; ORAL

BARACLUDE

AB	+	BRISTOL MYERS SQUIBB	0.5MG	N021797	001	Mar 29, 2005

AB	+ !		1MG	N021797	002	Mar 29, 2005

ENTECAVIR

AB		AMNEAL PHARMS	0.5MG	A206652	001	Nov 12, 2015
AB			1MG	A206652	002	Nov 12, 2015
AB		AUROBINDO PHARMA	0.5MG	A206217	001	Aug 26, 2015
AB			1MG	A206217	002	Aug 26, 2015
AB		BRECKENRIDGE	0.5MG	A208721	001	Mar 15, 2018
AB			1MG	A208721	002	Mar 15, 2018
AB		BRIGHTGENE	0.5MG	A212126	001	Sep 25, 2019
AB			1MG	A212126	002	Sep 25, 2019
AB		CASI PHARMS INC	0.5MG	A206672	001	May 11, 2017
AB			1MG	A206672	002	May 11, 2017
AB		CIPLA	0.5MG	A206872	001	Dec 06, 2016
AB			1MG	A206872	002	Dec 06, 2016
AB		HETERO LABS LTD V	0.5MG	A205740	001	Aug 21, 2015
AB			1MG	A205740	002	Aug 21, 2015
AB		PHARMADAX INC	0.5MG	A212106	001	Aug 10, 2020
AB			1MG	A212106	002	Aug 10, 2020
AB		PRINSTON INC	0.5MG	A208782	001	Oct 10, 2017
AB			1MG	A208782	002	Oct 10, 2017
AB		ZYDUS PHARMS	0.5MG	A206745	001	Jun 23, 2017
AB			1MG	A206745	002	Jun 23, 2017

ENTRECTINIB

CAPSULE; ORAL

ROZLYTREK

+	GENENTECH INC	100MG	N212725	001	Aug 15, 2019
+ !		200MG	N212725	002	Aug 15, 2019

ENZALUTAMIDE

CAPSULE; ORAL

XTANDI

+ !	ASTELLAS	40MG	N203415	001	Aug 31, 2012

TABLET; ORAL

XTANDI

+	ASTELLAS	40MG	N213674	001	Aug 04, 2020
+ !		80MG	N213674	002	Aug 04, 2020

EPHEDRINE HYDROCHLORIDE

SOLUTION; INTRAVENOUS

REZIPRES

+ !	DR REDDYS LABS SA	23.5MG/5ML (4.7MG/ML)	N213536	001	Jun 14, 2021

EPHEDRINE SULFATE

SOLUTION; INTRAVENOUS

AKOVAZ

AP	+ !	EXELA PHARMA	50MG/ML (50MG/ML)	N208289	001	Apr 29, 2016

CORPHEDRA

AP		PAR STERILE PRODUCTS	50MG/ML (50MG/ML)	N208943	001	Jan 27, 2017

EPHEDRINE SULFATE

AP		AKORN	50MG/ML (50MG/ML)	N208609	001	Mar 01, 2017
AP		AMNEAL	50MG/ML (50MG/ML)	A212932	001	Oct 23, 2019

PRESCRIPTION DRUG PRODUCT LIST

3-170 (of 474)

EPHEDRINE SULFATE

SOLUTION; INTRAVENOUS

EPHEDRINE SULFATE

AP	DR REDDYS	<u>50MG/ML (50MG/ML)</u>	<u>A212649</u>	<u>001</u>	Oct 03, 2020
AP	EUGIA PHARMA	<u>50MG/ML (50MG/ML)</u>	<u>A214579</u>	<u>001</u>	Jun 14, 2021
AP	FRESENIUS KABI USA	<u>50MG/ML (50MG/ML)</u>	<u>A209646</u>	<u>001</u>	Aug 04, 2020
AP	GLAND PHARMA LTD	<u>50MG/ML (50MG/ML)</u>	<u>A216146</u>	<u>001</u>	Feb 25, 2022
AP	HIKMA	<u>50MG/ML (50MG/ML)</u>	<u>A214334</u>	<u>001</u>	Dec 15, 2020
AP	MANKIND PHARMA	<u>50MG/ML (50MG/ML)</u>	<u>A216129</u>	<u>001</u>	Apr 14, 2022
AP	SANDOZ INC	<u>50MG/ML (50MG/ML)</u>	<u>A209784</u>	<u>001</u>	Aug 23, 2017
AP	XIROMED	<u>50MG/ML (50MG/ML)</u>	<u>A215825</u>	<u>001</u>	Apr 21, 2022
AKOVAZ					
	+! EXELA PHARMA	25MG/5ML (5MG/ML)	N208289	002	Aug 02, 2021
EMERPHED					
	+! NEXUS PHARMS	50MG/10ML (5MG/ML)	N213407	001	Apr 17, 2020
EPHEDRINE SULFATE					
	+! ENDO VENTURES	25MG/5ML (5MG/ML)	N213994	002	Apr 22, 2022
	+!	50MG/10ML (5MG/ML)	N213994	001	Oct 16, 2020

EPINASTINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

EPINASTINE HYDROCHLORIDE

AT	APOTEX	<u>0.05%</u>	<u>A090919</u>	<u>001</u>	Oct 31, 2011
AT	BRECKENRIDGE	<u>0.05%</u>	<u>A090870</u>	<u>001</u>	Mar 14, 2011
AT	! SOMERSET THERAPS LLC	<u>0.05%</u>	<u>A090951</u>	<u>001</u>	Oct 31, 2011

EPINEPHRINE

INJECTABLE; INTRAMUSCULAR, SUBCUTANEOUS

EPINEPHRINE (AUTOINJECTOR)

AB	TEVA PHARMS USA	<u>0.15MG/DELIVERY</u>	<u>A090589</u>	<u>002</u>	Aug 16, 2018
AB		<u>0.3MG/DELIVERY</u>	<u>A090589</u>	<u>001</u>	Aug 16, 2018
<u>EPIPEN</u>					
AB	+! MYLAN SPECIALITY LP	<u>0.3MG/DELIVERY</u>	<u>N019430</u>	<u>001</u>	Dec 22, 1987
<u>EPIPEN JR.</u>					
AB	+! MYLAN SPECIALITY LP	<u>0.15MG/DELIVERY</u>	<u>N019430</u>	<u>002</u>	Dec 22, 1987
ADRENALCLICK					
BX	+! IMPAX	EQ 0.15MG/DELIVERY	N020800	003	Nov 25, 2009
BX	+!	EQ 0.3MG/DELIVERY	N020800	004	Nov 25, 2009

SOLUTION; INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS

ADRENALIN

AP	+! PAR STERILE PRODUCTS	<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>N204200</u>	<u>001</u>	Dec 07, 2012
AP	+!	<u>EQ 30MG BASE/30ML (EQ 1MG BASE/ML)</u>	<u>N204640</u>	<u>001</u>	Dec 18, 2013
<u>EPINEPHRINE</u>					
AP	AM REGENT	<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A207568</u>	<u>001</u>	Jul 06, 2018
AP	INTL MEDICATION SYS	<u>EQ 30MG BASE/30ML (EQ 1MG BASE/ML)</u>	<u>A211880</u>	<u>001</u>	Apr 24, 2020
	+! BPI LABS	10MG/10ML (1MG/ML)	N205029	002	Feb 04, 2022

SOLUTION; INTRAMUSCULAR, SUBCUTANEOUS

AUVI-Q

BX	+! KALEO INC	EQ 0.15MG/DELIVERY	N201739	002	Aug 10, 2012
BX	+	EQ 0.3MG/DELIVERY	N201739	001	Aug 10, 2012
	+	EQ 0.1MG/DELIVERY	N201739	003	Nov 17, 2017
SYMJEPI					
	+! ADAMIS PHARMS CORP	0.15MG/0.3ML (0.15MG/0.3ML)	N207534	002	Sep 27, 2018
	+!	0.3MG/0.3ML (0.3MG/0.3ML)	N207534	001	Jun 15, 2017

SOLUTION; INTRAVENOUS

EPINEPHRINE

	+! HOSPIRA	1MG/10ML (0.1MG/ML)	N209359	001	Nov 05, 2019
	+! INTL MEDICATION SYS	1MG/10ML (0.1MG/ML)	N211363	001	Aug 15, 2022
SOLUTION; INTRAVENOUS, INTRAOCULAR, INTRAMUSCULAR, SUBCUTANEOUS					
<u>EPINEPHRINE</u>					
	+! BPI LABS	1MG/ML (1MG/ML)	N205029	001	Jul 29, 2014

EPINEPHRINE BITARTRATE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIGNOSPAN FORTE

	+! DEPROCO	EQ 0.02MG BASE/ML; 2%	A088389	001	Jan 22, 1985
<u>LIGNOSPAN STANDARD</u>					
	+! DEPROCO	EQ 0.01MG BASE/ML; 2%	A088390	001	Jan 22, 1985

PRESCRIPTION DRUG PRODUCT LIST

3-171 (of 474)

EPINEPHRINE BITARTRATE; PRILOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

CITANEST FORTE DENTAL

AP	+!	DENTSPLY PHARM	<u>0.005MG/ML;4%</u>	<u>N021383</u>	<u>001</u>	

PRILOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE

AP		SEPTODONT INC	<u>0.005MG/ML;4%</u>	<u>A078959</u>	<u>001</u>	Aug 30, 2011

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE

AP		B BRAUN MEDICAL INC	<u>0.005MG/ML;1.5%</u>	<u>A208475</u>	<u>001</u>	Sep 08, 2021

AP		HOSPIRA	<u>0.005MG/ML;0.5%</u>	<u>A089635</u>	<u>001</u>	Jun 21, 1988

AP			<u>0.005MG/ML;1.5%</u>	<u>A088571</u>	<u>001</u>	Sep 13, 1985

AP			<u>0.005MG/ML;1.5%</u>	<u>A089645</u>	<u>001</u>	Jun 21, 1988

AP			<u>0.005MG/ML;2%</u>	<u>A089651</u>	<u>001</u>	Jun 21, 1988

AP			<u>0.01MG/ML;1%</u>	<u>A089644</u>	<u>001</u>	Jun 21, 1988

AP	!		<u>0.01MG/ML;2%</u>	<u>A089646</u>	<u>001</u>	Jun 21, 1988

XYLOCAINE W/ EPINEPHRINE

AP	+!	FRESENIUS KABI USA	<u>0.005MG/ML;0.5%</u>	<u>N006488</u>	<u>012</u>	

AP	+!		<u>0.005MG/ML;1.5%</u>	<u>N006488</u>	<u>017</u>	

AP	+!		<u>0.005MG/ML;2%</u>	<u>N006488</u>	<u>019</u>	Nov 13, 1986

AP	+!		<u>0.01MG/ML;1%</u>	<u>N006488</u>	<u>004</u>	

AP	+!		<u>0.02MG/ML;2%</u>	<u>N006488</u>	<u>005</u>	

	+!		<u>0.005MG/ML;1%</u>	<u>N006488</u>	<u>018</u>	Nov 13, 1986

EPIRUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

ELLECE

AP	+!	PFIZER INC	<u>200MG/100ML (2MG/ML)</u>	<u>N050778</u>	<u>001</u>	Sep 15, 1999

AP	+		<u>50MG/25ML (2MG/ML)</u>	<u>N050778</u>	<u>002</u>	Sep 15, 1999

EPIRUBICIN HYDROCHLORIDE

AP		AKORN	<u>50MG/25ML (2MG/ML)</u>	<u>A090163</u>	<u>001</u>	Jun 24, 2009

AP		CIPLA LTD	<u>50MG/25ML (2MG/ML)</u>	<u>A065361</u>	<u>001</u>	Oct 22, 2007

AP			<u>200MG/100ML (2MG/ML)</u>	<u>A065361</u>	<u>002</u>	Oct 22, 2007

AP		HIKMA	<u>50MG/25ML (2MG/ML)</u>	<u>A065289</u>	<u>001</u>	Jun 27, 2007

AP			<u>200MG/100ML (2MG/ML)</u>	<u>A065289</u>	<u>002</u>	Jun 27, 2007

AP		HISUN PHARM	<u>50MG/25ML (2MG/ML)</u>	<u>A090075</u>	<u>001</u>	Mar 25, 2010

		HANGZHOU				

AP			<u>200MG/100ML (2MG/ML)</u>	<u>A090075</u>	<u>002</u>	Mar 25, 2010

AP		IMPAX LABS INC	<u>50MG/25ML (2MG/ML)</u>	<u>A065331</u>	<u>001</u>	Aug 09, 2007

AP			<u>200MG/100ML (2MG/ML)</u>	<u>A065331</u>	<u>002</u>	Aug 09, 2007

EPLERENONE

TABLET; ORAL

EPLERENONE

AB		ACCORD HLTHCARE	<u>25MG</u>	<u>A206922</u>	<u>001</u>	Jul 13, 2017

AB			<u>50MG</u>	<u>A206922</u>	<u>002</u>	Jul 13, 2017

AB		BRECKENRIDGE	<u>25MG</u>	<u>A208283</u>	<u>001</u>	Sep 14, 2018

AB			<u>50MG</u>	<u>A208283</u>	<u>002</u>	Sep 14, 2018

AB		CHARTWELL RX	<u>25MG</u>	<u>A078482</u>	<u>001</u>	Jul 30, 2008

AB			<u>50MG</u>	<u>A078482</u>	<u>002</u>	Jul 30, 2008

AB		KARTHA	<u>25MG</u>	<u>A214663</u>	<u>001</u>	Mar 23, 2022

AB			<u>50MG</u>	<u>A214663</u>	<u>002</u>	Mar 23, 2022

AB		PIRAMAL HLTHCARE UK	<u>25MG</u>	<u>A212765</u>	<u>001</u>	Aug 10, 2020

AB			<u>50MG</u>	<u>A212765</u>	<u>002</u>	Aug 10, 2020

AB		PRASCO	<u>25MG</u>	<u>A203896</u>	<u>001</u>	Feb 02, 2017

AB			<u>50MG</u>	<u>A203896</u>	<u>002</u>	Feb 02, 2017

AB		SANDOZ	<u>25MG</u>	<u>A078510</u>	<u>001</u>	Aug 01, 2008

AB			<u>50MG</u>	<u>A078510</u>	<u>002</u>	Aug 01, 2008

AB		WESTMINSTER PHARMS	<u>25MG</u>	<u>A207842</u>	<u>001</u>	Oct 25, 2021

AB			<u>50MG</u>	<u>A207842</u>	<u>002</u>	Oct 25, 2021

INSPIRA

AB	+	UPJOHN	<u>25MG</u>	<u>N021437</u>	<u>001</u>	Sep 27, 2002

AB	+!		<u>50MG</u>	<u>N021437</u>	<u>002</u>	Sep 27, 2002

EPOPROSTENOL SODIUM

INJECTABLE; INJECTION

EPOPROSTENOL SODIUM

AP1		TEVA PHARMS USA	<u>EQ 0.5MG BASE/VIAL</u>	<u>A078396</u>	<u>001</u>	Apr 23, 2008

AP1			<u>EQ 1.5MG BASE/VIAL</u>	<u>A078396</u>	<u>002</u>	Apr 23, 2008

FLOLAN

AP1	+!	GLAXOSMITHKLINE LLC	<u>EQ 0.5MG BASE/VIAL</u>	<u>N020444</u>	<u>001</u>	Sep 20, 1995

AP1	+!		<u>EQ 1.5MG BASE/VIAL</u>	<u>N020444</u>	<u>002</u>	Sep 20, 1995

PRESCRIPTION DRUG PRODUCT LIST

3-172 (of 474)

EPOPROSTENOL SODIUM

INJECTABLE; INJECTION

EPOPROSTENOL SODIUMAP2 SUN PHARMEQ 0.5MG BASE/VIALA210473 001 Jan 15, 2021AP2EQ 1.5MG BASE/VIALA210473 002 Jan 15, 2021VELETRIAP2 +! ACTELIONEQ 0.5MG BASE/VIALN022260 002 Jun 28, 2012AP2 +!EQ 1.5MG BASE/VIALN022260 001 Jun 27, 2008EPTIFIBATIDE

INJECTABLE; INJECTION

EPTIFIBATIDEAP ACCORD HLTHCARE2MG/MLA205557 001 Nov 06, 2017AP75MG/100MLA205557 002 Nov 06, 2017AP BAXTER HLTHCARE75MG/100MLA208554 002 Nov 23, 2018

CORP

AP EUGIA PHARMA2MG/MLA206127 001 Dec 08, 2015AP75MG/100MLA206127 002 Dec 08, 2015AP HAINAN POLY PHARM2MG/MLA209864 001 Jan 25, 2019AP75MG/100MLA209864 002 Jan 25, 2019AP ! MYLAN LABS LTD2MG/MLA203258 001 Jul 20, 2018AP !75MG/100MLA203258 002 Jul 20, 2018AP SAGENT PHARMS INC2MG/MLA204693 001 Mar 07, 2018AP75MG/100MLA204693 002 Mar 07, 2018AP SHUANGCHENG2MG/MLA213081 001 Sep 07, 2021AP75MG/100MLA213081 002 Apr 20, 2022AP TEVA PHARMS USA2MG/MLA090854 001 Jun 12, 2015ERAVACYCLINE DIHYDROCHLORIDE

POWDER; INTRAVENOUS

XERAVA

+! TETRAPHASE PHARMS

EQ 50MG BASE/VIAL

N211109 001 Aug 27, 2018

+!

EQ 100MG BASE/VIAL

N211109 002 Jun 03, 2020

ERDAFITINIB

TABLET; ORAL

BALVERSA

+ JANSSEN BIOTECH

3MG

N212018 001 Apr 12, 2019

+

4MG

N212018 002 Apr 12, 2019

+!

5MG

N212018 003 Apr 12, 2019

ERGOCALCIFEROL

CAPSULE; ORAL

DRISDOLAA +! VALIDUS PHARMS50,000 IUN003444 001ERGOCALCIFEROLAA ALEMBIC LABS50,000 IUA040833 001 May 20, 2009AA PURACAP PHARM LLC50,000 IUA204276 001 Dec 07, 2018AA STRIDES PHARMA50,000 IUA090455 001 Aug 03, 2010AA SUN PHARM INDS INC50,000 IUA040865 001 Dec 29, 2009VITAMIN DAA BIONPHARMA INC50,000 IUA080704 001ERGOLOID MESYLATES

TABLET; ORAL

ERGOLOID MESYLATES

! SUN PHARM

1MG

A081113 001 Oct 31, 1991

INDUSTRIES

ERGOTAMINE TARTRATE

TABLET; SUBLINGUAL

ERGOMAR

! TERSERA

2MG

A087693 001 Feb 24, 1983

ERIBULIN MESYLATE

SOLUTION; INTRAVENOUS

HALAVEN

+! EISAI INC

1MG/2ML (0.5MG/ML)

N201532 001 Nov 15, 2010

ERLOTINIB HYDROCHLORIDE

TABLET; ORAL

ERLOTINIB HYDROCHLORIDEAB ALEMBIC PHARMSEQ 25MG BASEA214719 001 Jul 08, 2021ABEQ 100MG BASEA214719 002 Jul 08, 2021ABEQ 150MG BASEA214719 003 Jul 08, 2021AB APOTEXEQ 25MG BASEA208396 001 Nov 05, 2019ABEQ 100MG BASEA208396 002 Nov 05, 2019

PRESCRIPTION DRUG PRODUCT LIST

3-173 (of 474)

ERLOTINIB HYDROCHLORIDE

TABLET; ORAL

ERLOTINIB HYDROCHLORIDE

<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A208396</u>	<u>003</u>	Nov 05, 2019
<u>AB</u>	MSN	<u>EQ 25MG BASE</u>	<u>A214366</u>	<u>001</u>	May 10, 2021
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A214366</u>	<u>002</u>	May 10, 2021
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A214366</u>	<u>003</u>	May 10, 2021
<u>AB</u>	NATCO PHARMA LTD	<u>EQ 25MG BASE</u>	<u>A208488</u>	<u>001</u>	Nov 05, 2019
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A208488</u>	<u>002</u>	Nov 05, 2019
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A208488</u>	<u>003</u>	Nov 05, 2019
<u>AB</u>	RISING	<u>EQ 25MG BASE</u>	<u>A091002</u>	<u>001</u>	Jun 11, 2014
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A091002</u>	<u>002</u>	Jun 11, 2014
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A091002</u>	<u>003</u>	Jun 11, 2014
<u>AB</u>	SHILPA	<u>EQ 25MG BASE</u>	<u>A211960</u>	<u>001</u>	Nov 05, 2019
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A211960</u>	<u>002</u>	Nov 05, 2019
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A211960</u>	<u>003</u>	Nov 05, 2019
<u>AB</u>	SUN PHARM	<u>EQ 25MG BASE</u>	<u>A210300</u>	<u>001</u>	Nov 05, 2019
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A210300</u>	<u>002</u>	Nov 05, 2019
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A210300</u>	<u>003</u>	Nov 05, 2019
<u>AB</u>	TEVA PHARMS USA INC	<u>EQ 25MG BASE</u>	<u>A091059</u>	<u>001</u>	Nov 09, 2020
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A091059</u>	<u>002</u>	Aug 28, 2015
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A091059</u>	<u>003</u>	Aug 28, 2015
<u>AB</u>	ZYDUS PHARMS	<u>EQ 25MG BASE</u>	<u>A213065</u>	<u>001</u>	Apr 16, 2020
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A213065</u>	<u>002</u>	Apr 16, 2020
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A213065</u>	<u>003</u>	Apr 16, 2020
<u>TARCEVA</u>					
<u>AB</u>	+	<u>OSI PHARMS</u>	<u>EQ 25MG BASE</u>	<u>N021743</u>	<u>001</u> Nov 18, 2004
<u>AB</u>	+		<u>EQ 100MG BASE</u>	<u>N021743</u>	<u>002</u> Nov 18, 2004
<u>AB</u>	+	!	<u>EQ 150MG BASE</u>	<u>N021743</u>	<u>003</u> Nov 18, 2004

ERTAPENEM SODIUM

INJECTABLE; INTRAMUSCULAR, INTRAVENOUS

ERTAPENEM SODIUM

<u>AP</u>	ACS DOBFAR SPA	<u>EQ 1GM BASE/VIAL</u>	<u>A208790</u>	<u>001</u>	Apr 16, 2018
<u>AP</u>	EUGIA PHARMA	<u>EQ 1GM BASE/VIAL</u>	<u>A209133</u>	<u>001</u>	Jun 25, 2018
<u>AP</u>	GLAND PHARMA LTD	<u>EQ 1GM BASE/VIAL</u>	<u>A212040</u>	<u>001</u>	Mar 26, 2021
<u>AP</u>	SAVIOR LIFETEC CORP	<u>EQ 1GM BASE/VIAL</u>	<u>A207647</u>	<u>001</u>	Mar 19, 2019
<u>INVANZ</u>					
<u>AP</u>	+	!	<u>MSD SUB MERCK</u>	<u>EQ 1GM BASE/VIAL</u>	<u>N021337</u> <u>001</u> Nov 21, 2001

ERTUGLIFLOZIN

TABLET; ORAL

STEGLATRO

+	MSD SUB MERCK	5MG	N209803	001	Dec 19, 2017
+	!	15MG	N209803	002	Dec 19, 2017

ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE

TABLET; ORAL

SEGLUROMET

+	MSD SUB MERCK	2.5MG; 500MG	N209806	001	Dec 19, 2017
+		2.5MG; 1GM	N209806	002	Dec 19, 2017
+		7.5MG; 500MG	N209806	003	Dec 19, 2017
+	!	7.5MG; 1GM	N209806	004	Dec 19, 2017

ERTUGLIFLOZIN; SITAGLIPTIN PHOSPHATE

TABLET; ORAL

STEGLUJAN

+	MSD SUB MERCK	5MG; EQ 100MG BASE	N209805	001	Dec 19, 2017
+	!	15MG; EQ 100MG BASE	N209805	002	Dec 19, 2017

ERYTHROMYCIN

CAPSULE, DELAYED REL PELLETS; ORAL

ERYC

<u>AB</u>	+	MAYNE PHARMA	<u>250MG</u>	<u>N050536</u>	<u>001</u>
<u>ERYTHROMYCIN</u>					
<u>AB</u>		ARBOR PHARMS LLC	<u>250MG</u>	<u>A062746</u>	<u>001</u> Dec 22, 1986
<u>GEL; TOPICAL</u>					
<u>ERYGEL</u>					
<u>AT</u>	+	!	MYLAN	<u>2%</u>	<u>N050617</u> <u>001</u> Oct 21, 1987
<u>ERYTHROMYCIN</u>					
<u>AT</u>		FOUGERA PHARMS	<u>2%</u>	<u>A064184</u>	<u>001</u> Sep 30, 1997
<u>AT</u>		PADAGIS US	<u>2%</u>	<u>A063211</u>	<u>001</u> Jan 29, 1993
<u>AT</u>		PAI HOLDINGS PHARM	<u>2%</u>	<u>A208154</u>	<u>001</u> Jul 19, 2017

PRESCRIPTION DRUG PRODUCT LIST

3-174 (of 474)

ERYTHROMYCIN

OINTMENT;OPHTHALMIC

ERYTHROMYCIN

AT	AKORN	<u>0.5%</u>	<u>A064030</u>	<u>001</u>	Jul 18, 1996
AT	BAUSCH AND LOMB	<u>0.5%</u>	<u>A064067</u>	<u>001</u>	Jul 29, 1994
AT	! PADAGIS US	<u>0.5%</u>	<u>A062447</u>	<u>001</u>	Sep 26, 1983

SOLUTION;TOPICAL

ERYTHRA-DERM

AT	MICRO LABS	<u>2%</u>	<u>A062687</u>	<u>001</u>	Feb 05, 1988

ERYTHROMYCIN

AT	! PADAGIS US	<u>2%</u>	<u>A063038</u>	<u>001</u>	Jan 11, 1991
AT	PAI HOLDINGS PHARM	<u>2%</u>	<u>A208100</u>	<u>001</u>	Nov 20, 2017
AT	XTTRIUM LABS INC	<u>2%</u>	<u>A062825</u>	<u>001</u>	Oct 23, 1987

SWAB;TOPICAL

ERYTHROMYCIN

AT	AKORN	<u>2%</u>	<u>A090215</u>	<u>001</u>	May 12, 2010
AT	! PADAGIS US	<u>2%</u>	<u>A064126</u>	<u>001</u>	Jul 03, 1996

TABLET;ORAL

ERYTHROMYCIN

AB	ALKEM LABS LTD	<u>250MG</u>	<u>A216066</u>	<u>001</u>	Jul 13, 2022
AB		<u>500MG</u>	<u>A216066</u>	<u>002</u>	Jul 13, 2022
AB	AMNEAL PHARMS CO	<u>250MG</u>	<u>A209720</u>	<u>001</u>	Mar 09, 2018
AB		<u>500MG</u>	<u>A209720</u>	<u>002</u>	Mar 09, 2018
AB	ARBOR PHARMS LLC	<u>250MG</u>	<u>A061621</u>	<u>001</u>	
AB	!	<u>500MG</u>	<u>A061621</u>	<u>002</u>	
AB	CADILA PHARMS LTD	<u>250MG</u>	<u>A213628</u>	<u>001</u>	Jun 28, 2021
AB		<u>500MG</u>	<u>A213628</u>	<u>002</u>	Jun 28, 2021
AB	TEVA PHARMS USA INC	<u>250MG</u>	<u>A214549</u>	<u>001</u>	Feb 11, 2021
AB		<u>500MG</u>	<u>A214549</u>	<u>002</u>	Feb 11, 2021
AB	TORRENT	<u>250MG</u>	<u>A212015</u>	<u>001</u>	Jul 06, 2020
AB		<u>500MG</u>	<u>A212015</u>	<u>002</u>	Jul 06, 2020

TABLET, DELAYED RELEASE;ORAL

ERY-TAB

AB	ARBOR PHARMS LLC	<u>250MG</u>	<u>A062298</u>	<u>001</u>	
AB		<u>333MG</u>	<u>A062298</u>	<u>003</u>	Mar 29, 1982
AB	!	<u>500MG</u>	<u>A062298</u>	<u>002</u>	

ERYTHROMYCIN

AB	AMNEAL PHARMS CO	<u>250MG</u>	<u>A210954</u>	<u>001</u>	Jul 02, 2019
AB		<u>333MG</u>	<u>A210954</u>	<u>002</u>	Jul 02, 2019
AB		<u>500MG</u>	<u>A210954</u>	<u>003</u>	Jul 02, 2019
AB	TORRENT	<u>250MG</u>	<u>A211975</u>	<u>001</u>	Jul 26, 2021
AB		<u>500MG</u>	<u>A211975</u>	<u>002</u>	Jul 26, 2021

ERYTHROMYCIN ETHYLSUCCINATE

GRANULE;ORAL

E.E.S.

AB	+	AZURITY	<u>EQ 200MG BASE/5ML</u>	<u>N050207</u>	<u>001</u>

ERYPED

AB	+	AZURITY	<u>EQ 200MG BASE/5ML</u>	<u>N050207</u>	<u>003</u>	Mar 30, 1987
AB	+	!	<u>EQ 400MG BASE/5ML</u>	<u>N050207</u>	<u>002</u>	

ERYTHROMYCIN ETHYLSUCCINATE

AB	AMNEAL PHARMS	<u>EQ 200MG BASE/5ML</u>	<u>A211204</u>	<u>001</u>	Nov 01, 2019
AB		<u>EQ 400MG BASE/5ML</u>	<u>A211204</u>	<u>002</u>	Nov 01, 2019
AB	ANI PHARMS	<u>EQ 200MG BASE/5ML</u>	<u>A062055</u>	<u>001</u>	
AB		<u>EQ 200MG BASE/5ML</u>	<u>A062055</u>	<u>003</u>	Nov 02, 2018
AB		<u>EQ 400MG BASE/5ML</u>	<u>A062055</u>	<u>002</u>	Nov 02, 2018
AB	CADILA PHARMS LTD	<u>EQ 200MG BASE/5ML</u>	<u>A216212</u>	<u>001</u>	Nov 21, 2022
AB		<u>EQ 400MG BASE/5ML</u>	<u>A216212</u>	<u>002</u>	Nov 21, 2022

TABLET;ORAL

E.E.S. 400

BX	!	ARBOR PHARMS LLC	<u>EQ 400MG BASE</u>	<u>A061905</u>	<u>002</u>	Aug 12, 1982

ERYTHROMYCIN ETHYLSUCCINATE

BX	!	ARBOR PHARMS LLC	<u>EQ 400MG BASE</u>	<u>A061904</u>	<u>001</u>	

ERYTHROMYCIN LACTOBIONATE

INJECTABLE;INJECTION

ERYTHROCIN

AP	HOSPIRA	<u>EQ 500MG BASE/VIAL</u>	<u>A062638</u>	<u>001</u>	Oct 31, 1986	
AP	+	!	<u>EQ 500MG BASE/VIAL</u>	<u>N050609</u>	<u>001</u>	Sep 24, 1986

ERYTHROMYCIN LACTOBIONATE

AP	EXELA PHARMA	<u>EQ 500MG BASE/VIAL</u>	<u>A211086</u>	<u>001</u>	Sep 17, 2020
AP	NEXUS PHARMS	<u>EQ 500MG BASE/VIAL</u>	<u>A215290</u>	<u>001</u>	Feb 14, 2022

PRESCRIPTION DRUG PRODUCT LIST

3-175 (of 474)

ERYTHROMYCIN STEARATE

TABLET;ORAL

ERYTHROCIN STEARATE

! ARBOR PHARMS LLC

EQ 250MG BASE

A060359 001

ESCITALOPRAM OXALATE

SOLUTION;ORAL

ESCITALOPRAM OXALATE

<u>AA</u>	AMNEAL PHARMS	<u>EQ 5MG BASE/5ML</u>	<u>A202227</u>	<u>001</u>	Mar 14, 2012
<u>AA</u>	AUROBINDO PHARMA LTD	<u>EQ 5MG BASE/5ML</u>	<u>A079062</u>	<u>001</u>	Apr 02, 2012
<u>AA</u>	! HETERO LABS LTD III	<u>EQ 5MG BASE/5ML</u>	<u>A202221</u>	<u>001</u>	Jun 12, 2012
<u>AA</u>	LANNETT CO INC	<u>EQ 5MG BASE/5ML</u>	<u>A090477</u>	<u>001</u>	Jun 12, 2013
<u>AA</u>	MACLEODS PHARMS LTD	<u>EQ 5MG BASE/5ML</u>	<u>A202754</u>	<u>001</u>	Mar 31, 2016
<u>AA</u>	TARO	<u>EQ 5MG BASE/5ML</u>	<u>A079121</u>	<u>001</u>	May 03, 2012

TABLET;ORAL

ESCITALOPRAM OXALATE

<u>AB</u>	ACCORD HLTHCARE	<u>EQ 5MG BASE</u>	<u>A202389</u>	<u>001</u>	Sep 11, 2012
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A202389</u>	<u>002</u>	Sep 11, 2012
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A202389</u>	<u>003</u>	Sep 11, 2012
<u>AB</u>	AMNEAL PHARMS	<u>EQ 5MG BASE</u>	<u>A205619</u>	<u>001</u>	May 17, 2017
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A205619</u>	<u>002</u>	May 17, 2017
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A205619</u>	<u>003</u>	May 17, 2017
<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 5MG BASE</u>	<u>A090432</u>	<u>001</u>	Sep 11, 2012
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A090432</u>	<u>002</u>	Sep 11, 2012
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A090432</u>	<u>003</u>	Sep 11, 2012
<u>AB</u>	CADILA	<u>EQ 5MG BASE</u>	<u>A077734</u>	<u>001</u>	Sep 11, 2012
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077734</u>	<u>002</u>	Sep 11, 2012
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A077734</u>	<u>003</u>	Sep 11, 2012
<u>AB</u>	GRAVITI PHARMS	<u>EQ 5MG BASE</u>	<u>A078777</u>	<u>001</u>	Sep 11, 2012
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078777</u>	<u>002</u>	Sep 11, 2012
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A078777</u>	<u>003</u>	Sep 11, 2012
<u>AB</u>	INVAGEN PHARMS	<u>EQ 5MG BASE</u>	<u>A078604</u>	<u>001</u>	Sep 11, 2012
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078604</u>	<u>002</u>	Sep 11, 2012
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A078604</u>	<u>003</u>	Sep 11, 2012
<u>AB</u>	JUBILANT GENERICS	<u>EQ 5MG BASE</u>	<u>A202280</u>	<u>001</u>	Sep 12, 2012
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A202280</u>	<u>002</u>	Sep 12, 2012
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A202280</u>	<u>003</u>	Sep 12, 2012
<u>AB</u>	LUPIN LTD	<u>EQ 5MG BASE</u>	<u>A078169</u>	<u>001</u>	Sep 11, 2012
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078169</u>	<u>002</u>	Sep 11, 2012
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A078169</u>	<u>003</u>	Sep 11, 2012
<u>AB</u>	PHARM ASSOC	<u>EQ 5MG BASE</u>	<u>A077512</u>	<u>001</u>	Sep 12, 2012
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077512</u>	<u>002</u>	Sep 12, 2012
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A077512</u>	<u>003</u>	Sep 12, 2012
<u>AB</u>	PRINSTON INC	<u>EQ 5MG BASE</u>	<u>A078032</u>	<u>001</u>	Aug 28, 2015
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078032</u>	<u>002</u>	Aug 28, 2015
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A078032</u>	<u>003</u>	Aug 28, 2015
<u>AB</u>	TORRENT PHARMS LTD	<u>EQ 5MG BASE</u>	<u>A090939</u>	<u>001</u>	Sep 11, 2012
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A090939</u>	<u>002</u>	Sep 11, 2012
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A090939</u>	<u>003</u>	Sep 11, 2012
<u>LEXAPRO</u>					
<u>AB</u>	+ ALLERGAN	<u>EQ 5MG BASE</u>	<u>N021323</u>	<u>001</u>	Aug 14, 2002
<u>AB</u>	+	<u>EQ 10MG BASE</u>	<u>N021323</u>	<u>002</u>	Aug 14, 2002
<u>AB</u>	+!	<u>EQ 20MG BASE</u>	<u>N021323</u>	<u>003</u>	Aug 14, 2002

ESKETAMINE HYDROCHLORIDE

SPRAY;NASAL

SPRAVATO

+! JANSSEN PHARMS

EQ 28MG BASE

N211243 001 Mar 05, 2019

ESLICARBAZEPINE ACETATE

TABLET;ORAL

APTOM

<u>AB</u>	+ SUNOVION PHARMS INC	<u>200MG</u>	<u>N022416</u>	<u>001</u>	Nov 08, 2013
<u>AB</u>	+	<u>400MG</u>	<u>N022416</u>	<u>002</u>	Nov 08, 2013
<u>AB</u>	+	<u>600MG</u>	<u>N022416</u>	<u>003</u>	Nov 08, 2013
<u>AB</u>	+!	<u>800MG</u>	<u>N022416</u>	<u>004</u>	Nov 08, 2013

ESLICARBAZEPINE ACETATE

<u>AB</u>	DR REDDYS	<u>200MG</u>	<u>A211238</u>	<u>001</u>	Jun 29, 2021
<u>AB</u>		<u>400MG</u>	<u>A211238</u>	<u>002</u>	Jun 29, 2021
<u>AB</u>		<u>600MG</u>	<u>A211238</u>	<u>003</u>	Jun 29, 2021
<u>AB</u>		<u>800MG</u>	<u>A211238</u>	<u>004</u>	Jun 29, 2021

PRESCRIPTION DRUG PRODUCT LIST

3-176 (of 474)

ESMOLOL HYDROCHLORIDE

INJECTABLE; INJECTION

BREVIBLOC

<u>AP</u>	<u>+!</u>	<u>BAXTER HLTHCARE</u>	<u>10MG/ML</u>	<u>N019386</u>	<u>006</u>	Feb 25, 2003
<u>ESMOLOL HYDROCHLORIDE</u>						
<u>AP</u>		<u>AMNEAL</u>	<u>10MG/ML</u>	<u>A216603</u>	<u>001</u>	Dec 13, 2022
<u>AP</u>			<u>20MG/ML</u>	<u>A216603</u>	<u>002</u>	Dec 13, 2022
<u>AP</u>		<u>EUGIA PHARMA</u>	<u>10MG/ML</u>	<u>A205520</u>	<u>001</u>	Jul 23, 2015
<u>AP</u>			<u>10MG/ML</u>	<u>A216244</u>	<u>001</u>	Mar 21, 2022
<u>AP</u>			<u>20MG/ML</u>	<u>A216244</u>	<u>002</u>	Mar 21, 2022
<u>AP</u>		<u>FRESENIUS KABI USA</u>	<u>10MG/ML</u>	<u>A076573</u>	<u>001</u>	May 02, 2005
<u>AP</u>		<u>GLAND PHARMA LTD</u>	<u>10MG/ML</u>	<u>A208538</u>	<u>001</u>	Aug 14, 2019
<u>AP</u>		<u>HIKMA</u>	<u>10MG/ML</u>	<u>A076323</u>	<u>001</u>	Aug 10, 2004
<u>AP</u>		<u>HQ SPCLT PHARMA</u>	<u>10MG/ML</u>	<u>A214172</u>	<u>001</u>	Dec 02, 2022
<u>AP</u>			<u>20MG/ML</u>	<u>A214172</u>	<u>002</u>	Dec 02, 2022
<u>AP</u>		<u>MYLAN INSTITUTIONAL</u>	<u>10MG/ML</u>	<u>A076474</u>	<u>001</u>	May 02, 2005
<u>AP</u>		<u>MYLAN LABS LTD</u>	<u>10MG/ML</u>	<u>A206608</u>	<u>001</u>	Jun 08, 2018
<u>AP</u>			<u>20MG/ML</u>	<u>A206608</u>	<u>002</u>	Jun 08, 2018
<u>AP</u>		<u>SAGENT PHARMS INC</u>	<u>10MG/ML</u>	<u>A207107</u>	<u>001</u>	Jun 08, 2018
<u>AP</u>			<u>20MG/ML</u>	<u>A207107</u>	<u>002</u>	Jun 08, 2018
BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER						
	<u>+!</u>	<u>BAXTER HLTHCARE</u>	<u>2GM/100ML</u>	<u>N019386</u>	<u>005</u>	Jan 27, 2003
BREVIBLOC IN PLASTIC CONTAINER						
	<u>+!</u>	<u>BAXTER HLTHCARE</u>	<u>1GM/100ML</u>	<u>N019386</u>	<u>004</u>	Feb 16, 2001
SOLUTION; INTRAVENOUS						
ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER						
	<u>+!</u>	<u>HQ SPCLT PHARMA</u>	<u>2GM/100ML (20MG/ML)</u>	<u>N205703</u>	<u>002</u>	Apr 07, 2016
ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER						
	<u>+!</u>	<u>HQ SPCLT PHARMA</u>	<u>2.5GM/250ML (10MG/ML)</u>	<u>N205703</u>	<u>001</u>	Apr 07, 2016

ESOMEFRAZOLE MAGNESIUM

CAPSULE, DELAYED REL PELLETS; ORAL

ESOMEFRAZOLE MAGNESIUM

<u>AB</u>		<u>ALKEM LABS LTD</u>	<u>EQ 20MG BASE</u>	<u>A208333</u>	<u>001</u>	Oct 20, 2017
<u>AB</u>			<u>EQ 40MG BASE</u>	<u>A208333</u>	<u>002</u>	Oct 20, 2017
<u>AB</u>		<u>AUROBINDO PHARMA LTD</u>	<u>EQ 20MG BASE</u>	<u>A205606</u>	<u>001</u>	Apr 21, 2016
<u>AB</u>			<u>EQ 40MG BASE</u>	<u>A205606</u>	<u>002</u>	Apr 21, 2016
<u>AB</u>		<u>CISEN</u>	<u>EQ 20MG BASE</u>	<u>A213158</u>	<u>001</u>	Sep 22, 2020
<u>AB</u>			<u>EQ 40MG BASE</u>	<u>A213158</u>	<u>002</u>	Sep 22, 2020
<u>AB</u>		<u>CSPC OUYI</u>	<u>EQ 20MG BASE</u>	<u>A212949</u>	<u>001</u>	Oct 02, 2020
<u>AB</u>			<u>EQ 40MG BASE</u>	<u>A212949</u>	<u>002</u>	Oct 02, 2020
<u>AB</u>		<u>DR REDDYS</u>	<u>EQ 20MG BASE</u>	<u>A078279</u>	<u>001</u>	Sep 25, 2015
<u>AB</u>			<u>EQ 40MG BASE</u>	<u>A078279</u>	<u>002</u>	Sep 25, 2015
<u>AB</u>		<u>ETHYPHARM</u>	<u>EQ 20MG BASE</u>	<u>A090841</u>	<u>001</u>	Mar 31, 2021
<u>AB</u>			<u>EQ 40MG BASE</u>	<u>A090841</u>	<u>002</u>	Mar 31, 2021
<u>AB</u>		<u>GLENMARK PHARMS</u>	<u>EQ 20MG BASE</u>	<u>A209495</u>	<u>001</u>	May 10, 2019
<u>AB</u>			<u>EQ 40MG BASE</u>	<u>A209495</u>	<u>002</u>	May 10, 2019
<u>AB</u>		<u>GRAVITI PHARMS</u>	<u>EQ 20MG BASE</u>	<u>A213486</u>	<u>001</u>	Mar 19, 2021
<u>AB</u>			<u>EQ 40MG BASE</u>	<u>A213486</u>	<u>002</u>	Mar 19, 2021
<u>AB</u>		<u>HETERO LABS LTD III</u>	<u>EQ 20MG BASE</u>	<u>A202784</u>	<u>001</u>	Sep 21, 2015
<u>AB</u>			<u>EQ 20MG BASE</u>	<u>A211977</u>	<u>001</u>	Jun 02, 2020
<u>AB</u>			<u>EQ 40MG BASE</u>	<u>A202784</u>	<u>002</u>	Sep 21, 2015
<u>AB</u>			<u>EQ 40MG BASE</u>	<u>A211977</u>	<u>002</u>	Jun 02, 2020
<u>AB</u>		<u>INDCHEMIE HEALTH</u>	<u>EQ 20MG BASE</u>	<u>A210559</u>	<u>001</u>	Feb 26, 2021
<u>AB</u>			<u>EQ 40MG BASE</u>	<u>A210559</u>	<u>002</u>	Feb 26, 2021
<u>AB</u>		<u>IVAX SUB TEVA PHARMS</u>	<u>EQ 20MG BASE</u>	<u>A078003</u>	<u>001</u>	Jan 26, 2015
<u>AB</u>			<u>EQ 40MG BASE</u>	<u>A078003</u>	<u>002</u>	Jan 26, 2015
<u>AB</u>		<u>LANNETT CO INC</u>	<u>EQ 20MG BASE</u>	<u>A205563</u>	<u>001</u>	Sep 01, 2017
<u>AB</u>			<u>EQ 40MG BASE</u>	<u>A205563</u>	<u>002</u>	Sep 01, 2017
<u>AB</u>		<u>MYLAN</u>	<u>EQ 20MG BASE</u>	<u>A078936</u>	<u>001</u>	Aug 02, 2015
<u>AB</u>			<u>EQ 40MG BASE</u>	<u>A078936</u>	<u>002</u>	Aug 03, 2015
<u>AB</u>		<u>SUN PHARM</u>	<u>EQ 20MG BASE</u>	<u>A209735</u>	<u>001</u>	Apr 30, 2018
<u>AB</u>			<u>EQ 40MG BASE</u>	<u>A209735</u>	<u>002</u>	Apr 30, 2018
<u>AB</u>		<u>TORRENT</u>	<u>EQ 20MG BASE</u>	<u>A203636</u>	<u>001</u>	Oct 19, 2015
<u>AB</u>			<u>EQ 40MG BASE</u>	<u>A203636</u>	<u>002</u>	Oct 19, 2015
<u>AB</u>		<u>ZYDUS PHARMS</u>	<u>EQ 20MG BASE</u>	<u>A206296</u>	<u>001</u>	May 22, 2019
<u>AB</u>			<u>EQ 40MG BASE</u>	<u>A206296</u>	<u>002</u>	May 22, 2019
<u>NEXIUM</u>						
<u>AB</u>	<u>+</u>	<u>ASTRAZENECA</u>	<u>EQ 20MG BASE</u>	<u>N021153</u>	<u>001</u>	Feb 20, 2001
<u>AB</u>	<u>+!</u>		<u>EQ 40MG BASE</u>	<u>N021153</u>	<u>002</u>	Feb 20, 2001

PRESCRIPTION DRUG PRODUCT LIST

3-177 (of 474)

ESOMEPRAZOLE MAGNESIUM

FOR SUSPENSION, DELAYED RELEASE; ORAL

ESOMEPRAZOLE MAGNESIUM

<u>AB</u>	CIPLA	<u>EQ 10MG BASE/PACKET</u>	<u>A211752</u>	<u>001</u>	Mar 23, 2020
<u>AB</u>		<u>EQ 20MG BASE/PACKET</u>	<u>A211751</u>	<u>001</u>	Mar 23, 2020
<u>AB</u>		<u>EQ 40MG BASE/PACKET</u>	<u>A211751</u>	<u>002</u>	Mar 23, 2020

NEXIUM

<u>AB</u>	+	ASTRAZENECA	<u>EQ 10MG BASE/PACKET</u>	<u>N022101</u>	<u>001</u>	Feb 27, 2008
<u>AB</u>	+		<u>EQ 20MG BASE/PACKET</u>	<u>N021957</u>	<u>001</u>	Oct 20, 2006
<u>AB</u>	+	!	<u>EQ 40MG BASE/PACKET</u>	<u>N021957</u>	<u>002</u>	Oct 20, 2006
	+		EQ 2.5MG BASE/PACKET	N021957	003	Dec 15, 2011
	+		EQ 5MG BASE/PACKET	N021957	004	Dec 15, 2011

ESOMEPRAZOLE MAGNESIUM; NAPROXEN

TABLET, DELAYED RELEASE; ORAL

NAPROXEN AND ESOMEPRAZOLE MAGNESIUM

<u>AB</u>		ACTAVIS LABS FL INC	<u>EQ 20MG BASE:375MG</u>	<u>A204470</u>	<u>001</u>	Aug 24, 2022
<u>AB</u>			<u>EQ 20MG BASE:500MG</u>	<u>A204470</u>	<u>002</u>	Aug 24, 2022
<u>AB</u>		AJANTA PHARMA LTD	<u>EQ 20MG BASE:375MG</u>	<u>A213699</u>	<u>001</u>	Oct 06, 2022
<u>AB</u>			<u>EQ 20MG BASE:500MG</u>	<u>A213699</u>	<u>002</u>	Oct 06, 2022
<u>AB</u>		DR REDDYS	<u>EQ 20MG BASE:375MG</u>	<u>A204206</u>	<u>001</u>	Feb 18, 2020
<u>AB</u>			<u>EQ 20MG BASE:500MG</u>	<u>A204206</u>	<u>002</u>	Feb 18, 2020
<u>AB</u>		MYLAN	<u>EQ 20MG BASE:375MG</u>	<u>A204920</u>	<u>001</u>	Jul 20, 2021
<u>AB</u>			<u>EQ 20MG BASE:500MG</u>	<u>A204920</u>	<u>002</u>	Jul 20, 2021

VIMOVO

<u>AB</u>	+	HORIZON	<u>EQ 20MG BASE:375MG</u>	<u>N022511</u>	<u>002</u>	Apr 30, 2010
<u>AB</u>	+	!	<u>EQ 20MG BASE:500MG</u>	<u>N022511</u>	<u>001</u>	Apr 30, 2010

ESOMEPRAZOLE SODIUM

INJECTABLE; INTRAVENOUS

ESOMEPRAZOLE SODIUM

<u>AP</u>		ACCORD HLTHCARE	<u>EQ 40MG BASE/VIAL</u>	<u>A205379</u>	<u>001</u>	Sep 25, 2015
<u>AP</u>		DEVA HOLDING AS	<u>EQ 40MG BASE/VIAL</u>	<u>A207181</u>	<u>001</u>	Mar 06, 2017
<u>AP</u>	!	EUGIA PHARMA	<u>EQ 40MG BASE/VIAL</u>	<u>A204657</u>	<u>002</u>	Aug 10, 2016
<u>AP</u>		GLAND PHARMA LTD	<u>EQ 20MG BASE/VIAL</u>	<u>A203349</u>	<u>001</u>	Apr 01, 2020
<u>AP</u>			<u>EQ 40MG BASE/VIAL</u>	<u>A203349</u>	<u>002</u>	Apr 01, 2020
<u>AP</u>		HAINAN POLY	<u>EQ 40MG BASE/VIAL</u>	<u>A215732</u>	<u>001</u>	Feb 10, 2022
<u>AP</u>		SUN PHARM	<u>EQ 40MG BASE/VIAL</u>	<u>A200882</u>	<u>002</u>	Mar 18, 2013

NEXIUM IV

<u>AP</u>	+	!	ASTRAZENECA	<u>EQ 40MG BASE/VIAL</u>	<u>N021689</u>	<u>002</u>	Mar 31, 2005

ESTAZOLAM

TABLET; ORAL

ESTAZOLAM

<u>AB</u>		MAYNE PHARMA	<u>1MG</u>	<u>A074921</u>	<u>001</u>	Jul 10, 1997
<u>AB</u>	!		<u>2MG</u>	<u>A074921</u>	<u>002</u>	Jul 10, 1997
<u>AB</u>		NOVITIUM PHARMA	<u>1MG</u>	<u>A074826</u>	<u>001</u>	Jul 03, 1997
<u>AB</u>			<u>2MG</u>	<u>A074826</u>	<u>002</u>	Jul 03, 1997
<u>AB</u>		WATSON LABS	<u>1MG</u>	<u>A074818</u>	<u>001</u>	Aug 19, 1997
<u>AB</u>			<u>2MG</u>	<u>A074818</u>	<u>002</u>	Aug 19, 1997

ESTRADIOL

CREAM; VAGINAL

ESTRACE

<u>AB</u>	+	!	ALLERGAN	<u>0.01%</u>	<u>A086069</u>	<u>001</u>	Jan 31, 1984

ESTRADIOL

<u>AB</u>		ALVOGEN	<u>0.01%</u>	<u>A209767</u>	<u>001</u>	Mar 05, 2018
<u>AB</u>		MYLAN	<u>0.01%</u>	<u>A208788</u>	<u>001</u>	Dec 29, 2017
<u>AB</u>		PADAGIS ISRAEL	<u>0.01%</u>	<u>A210194</u>	<u>001</u>	Jan 22, 2018
<u>AB</u>		PRASCO LABS LLC	<u>0.01%</u>	<u>A212313</u>	<u>001</u>	Jul 15, 2021
<u>AB</u>		TEVA PHARMS USA	<u>0.01%</u>	<u>A210488</u>	<u>001</u>	Mar 30, 2018

FILM, EXTENDED RELEASE; TRANSDERMAL

CLIMARA

<u>AB</u>	+		BAYER HLTHCARE	<u>0.06MG/24HR</u>	<u>N020375</u>	<u>006</u>	May 27, 2003

ESTRADIOL

<u>AB</u>			MYLAN TECHNOLOGIES	<u>0.06MG/24HR</u>	<u>A075182</u>	<u>005</u>	Jul 20, 2006

CLIMARA

<u>AB2</u>	+		BAYER HLTHCARE	<u>0.025MG/24HR</u>	<u>N020375</u>	<u>004</u>	Mar 05, 1999
<u>AB2</u>	+			<u>0.0375MG/24HR</u>	<u>N020375</u>	<u>005</u>	May 27, 2003
<u>AB2</u>	+			<u>0.05MG/24HR</u>	<u>N020375</u>	<u>001</u>	Dec 22, 1994
<u>AB2</u>	+			<u>0.075MG/24HR</u>	<u>N020375</u>	<u>003</u>	Mar 23, 1998
<u>AB2</u>	+	!		<u>0.1MG/24HR</u>	<u>N020375</u>	<u>002</u>	Dec 22, 1994

ESTRADIOL

<u>AB2</u>			MYLAN TECHNOLOGIES	<u>0.025MG/24HR</u>	<u>A075182</u>	<u>003</u>	Jan 26, 2005

PRESCRIPTION DRUG PRODUCT LIST

3-178 (of 474)

ESTRADIOL

FILM, EXTENDED RELEASE;TRANSDERMAL

ESTRADIOL

<u>AB2</u>		<u>0.0375MG/24HR</u>	<u>A075182</u>	<u>004</u>	Jul 20, 2006
<u>AB2</u>		<u>0.05MG/24HR</u>	<u>A075182</u>	<u>006</u>	Feb 24, 2000
<u>AB2</u>		<u>0.075MG/24HR</u>	<u>A075182</u>	<u>002</u>	Jan 26, 2005
<u>AB2</u>		<u>0.1MG/24HR</u>	<u>A075182</u>	<u>001</u>	Feb 24, 2000
<u>AB3</u>	AMNEAL	<u>0.025MG/24HR</u>	<u>A211396</u>	<u>001</u>	Sep 28, 2020
<u>AB3</u>		<u>0.0375MG/24HR</u>	<u>A211396</u>	<u>002</u>	Sep 28, 2020
<u>AB3</u>		<u>0.05MG/24HR</u>	<u>A211396</u>	<u>003</u>	Sep 28, 2020
<u>AB3</u>		<u>0.075MG/24HR</u>	<u>A211396</u>	<u>004</u>	Sep 28, 2020
<u>AB3</u>		<u>0.1MG/24HR</u>	<u>A211396</u>	<u>005</u>	Sep 28, 2020
<u>AB3</u>	MYLAN TECHNOLOGIES	<u>0.025MG/24HR</u>	<u>A206685</u>	<u>001</u>	Aug 15, 2018
<u>AB3</u>		<u>0.0375MG/24HR</u>	<u>A206685</u>	<u>002</u>	Aug 15, 2018
<u>AB3</u>		<u>0.05MG/24HR</u>	<u>A206685</u>	<u>003</u>	Aug 15, 2018
<u>AB3</u>		<u>0.075MG/24HR</u>	<u>A206685</u>	<u>004</u>	Aug 15, 2018
<u>AB3</u>		<u>0.1MG/24HR</u>	<u>A206685</u>	<u>005</u>	Aug 15, 2018

MINIVELLE

<u>AB3</u>	+	NOVEN	<u>0.025MG/24HR</u>	<u>N203752</u>	<u>005</u>	Sep 23, 2014
<u>AB3</u>	+		<u>0.0375MG/24HR</u>	<u>N203752</u>	<u>001</u>	Oct 29, 2012
<u>AB3</u>	+		<u>0.05MG/24HR</u>	<u>N203752</u>	<u>003</u>	Oct 29, 2012
<u>AB3</u>	+		<u>0.075MG/24HR</u>	<u>N203752</u>	<u>002</u>	Oct 29, 2012
<u>AB3</u>	+	!	<u>0.1MG/24HR</u>	<u>N203752</u>	<u>004</u>	Oct 29, 2012

GEL;TRANSDERMAL

DIVIGEL

<u>AB</u>	+	!	VERTICAL PHARMS LLC	<u>0.1%</u>	<u>N022038</u>	<u>001</u>	Jun 04, 2007

ESTRADIOL

<u>AB</u>		CHEMO RESEARCH SL	<u>0.1%</u>	<u>A211783</u>	<u>001</u>	Aug 10, 2022

GEL, METERED;TRANSDERMAL

ELESTRIN

+	!	MYLAN SPECIALITY LP	0.06% (0.87GM/ACTIVATION)	N021813	001	Dec 15, 2006

ESTROGEL

+	!	ASCEND THERAPS US	0.06% (1.25GM/ACTIVATION)	N021166	002	Feb 09, 2004

INSERT;VAGINAL

IMVEXXY

+		THERAPEUTICSMD INC	0.004MG	N208564	001	May 29, 2018

+	!		0.01MG	N208564	002	May 29, 2018

INSERT, EXTENDED RELEASE;VAGINAL

ESTRING

+	!	PFIZER	0.0075MG/24HR	N020472	001	Apr 26, 1996

SPRAY;TRANSDERMAL

EVAMIST

+	!	PADAGIS US	1.53MG/SPRAY	N022014	001	Jul 27, 2007

SYSTEM;TRANSDERMAL

ESTRADIOL

<u>AB1</u>		AMNEAL	<u>0.025MG/24HR</u>	<u>A211293</u>	<u>001</u>	Feb 04, 2019
<u>AB1</u>			<u>0.0375MG/24HR</u>	<u>A211293</u>	<u>002</u>	Feb 04, 2019
<u>AB1</u>			<u>0.05MG/24HR</u>	<u>A211293</u>	<u>003</u>	Feb 04, 2019
<u>AB1</u>			<u>0.075MG/24HR</u>	<u>A211293</u>	<u>004</u>	Feb 04, 2019
<u>AB1</u>			<u>0.1MG/24HR</u>	<u>A211293</u>	<u>005</u>	Feb 04, 2019
<u>AB1</u>		MYLAN TECHNOLOGIES	<u>0.025MG/24HR</u>	<u>A201675</u>	<u>001</u>	Dec 19, 2014
<u>AB1</u>			<u>0.0375MG/24HR</u>	<u>A201675</u>	<u>002</u>	Dec 19, 2014
<u>AB1</u>			<u>0.05MG/24HR</u>	<u>A201675</u>	<u>003</u>	Dec 19, 2014
<u>AB1</u>			<u>0.075MG/24HR</u>	<u>A201675</u>	<u>004</u>	Dec 19, 2014
<u>AB1</u>			<u>0.1MG/24HR</u>	<u>A201675</u>	<u>005</u>	Dec 19, 2014
<u>AB1</u>		ZYDUS NOVELTECH INC	<u>0.025MG/24HR</u>	<u>A206241</u>	<u>001</u>	Dec 01, 2022
<u>AB1</u>			<u>0.0375MG/24HR</u>	<u>A206241</u>	<u>002</u>	Dec 01, 2022
<u>AB1</u>			<u>0.05MG/24HR</u>	<u>A206241</u>	<u>003</u>	Dec 01, 2022
<u>AB1</u>			<u>0.075MG/24HR</u>	<u>A206241</u>	<u>004</u>	Dec 01, 2022
<u>AB1</u>			<u>0.1MG/24HR</u>	<u>A206241</u>	<u>005</u>	Dec 01, 2022

VIVELLE-DOT

<u>AB1</u>	+	NOVARTIS	<u>0.025MG/24HR</u>	<u>N020538</u>	<u>009</u>	May 03, 2002
<u>AB1</u>	+		<u>0.0375MG/24HR</u>	<u>N020538</u>	<u>005</u>	Jan 08, 1999
<u>AB1</u>	+		<u>0.05MG/24HR</u>	<u>N020538</u>	<u>006</u>	Jan 08, 1999
<u>AB1</u>	+		<u>0.075MG/24HR</u>	<u>N020538</u>	<u>007</u>	Jan 08, 1999
<u>AB1</u>	+	!	<u>0.1MG/24HR</u>	<u>N020538</u>	<u>008</u>	Jan 08, 1999

MENOSTAR

+	!	BAYER HLTHCARE	0.014MG/24HR	N021674	001	Jun 08, 2004

TABLET;ORAL

ESTRADIOL

<u>AB</u>		BARR LABS INC	<u>0.5MG</u>	<u>A040197</u>	<u>001</u>	Oct 22, 1997
<u>AB</u>			<u>1MG</u>	<u>A040197</u>	<u>002</u>	Oct 22, 1997

PRESCRIPTION DRUG PRODUCT LIST

3-179 (of 474)

ESTRADIOL

TABLET; ORAL

ESTRADIOL

AB	!		<u>2MG</u>	<u>A040197</u>	<u>003</u>	Oct 22, 1997
AB		EPIC PHARMA	<u>0.5MG</u>	<u>A040275</u>	<u>001</u>	Dec 29, 1998
AB			<u>1MG</u>	<u>A040275</u>	<u>002</u>	Dec 29, 1998
AB			<u>2MG</u>	<u>A040275</u>	<u>003</u>	Dec 29, 1998

TABLET; VAGINAL

ESTRADIOL

AB		AMNEAL PHARMS	<u>10MCG</u>	<u>A205256</u>	<u>001</u>	May 29, 2015
AB		GLENMARK PHARMS LTD	<u>10MCG</u>	<u>A210264</u>	<u>001</u>	Sep 14, 2018
AB		TEVA PHARMS USA	<u>10MCG</u>	<u>A206388</u>	<u>001</u>	Jul 21, 2017

VAGIFEM

AB	+	NOVO NORDISK INC	<u>10MCG</u>	<u>N020908</u>	<u>002</u>	Nov 25, 2009

ESTRADIOL ACETATE

INSERT, EXTENDED RELEASE; VAGINAL

FEMRING

+	MILLICENT	EQ 0.05MG BASE/24HR	N021367	001	Mar 20, 2003
+	!	EQ 0.1MG BASE/24HR	N021367	002	Mar 20, 2003

ESTRADIOL CYPIONATE

INJECTABLE; INJECTION

DEPO-ESTRADIOL

!	PFIZER	5MG/ML	A085470	003	

ESTRADIOL VALERATE

INJECTABLE; INJECTION

DELESTROGEN

AO	+	PAR STERILE PRODUCTS	<u>10MG/ML</u>	<u>N009402</u>	<u>002</u>	
AO	+		<u>20MG/ML</u>	<u>N009402</u>	<u>004</u>	
AO	+		<u>40MG/ML</u>	<u>N009402</u>	<u>003</u>	

ESTRADIOL VALERATE

AO		AM REGENT	<u>20MG/ML</u>	<u>A090920</u>	<u>001</u>	Jan 19, 2010
AO			<u>40MG/ML</u>	<u>A090920</u>	<u>002</u>	Jan 19, 2010
AO		HIKMA	<u>10MG/ML</u>	<u>A203723</u>	<u>001</u>	Apr 21, 2020
AO			<u>20MG/ML</u>	<u>A203723</u>	<u>002</u>	Apr 21, 2020
AO			<u>40MG/ML</u>	<u>A203723</u>	<u>003</u>	Apr 21, 2020

ESTRADIOL; LEVONORGESTREL

FILM, EXTENDED RELEASE; TRANSDERMAL

CLIMARA PRO

+	!	BAYER HLTHCARE	0.045MG/24HR; 0.015MG/24HR	N021258	001	Nov 21, 2003

ESTRADIOL; NORETHINDRONE ACETATE

FILM, EXTENDED RELEASE; TRANSDERMAL

COMBIPATCH

+		NOVEN PHARMS INC	0.05MG/24HR; 0.14MG/24HR	N020870	001	Aug 07, 1998
+	!		0.05MG/24HR; 0.25MG/24HR	N020870	002	Aug 07, 1998

TABLET; ORAL

ACTIVELLA

AB	+	AMNEAL	<u>1MG; 0.5MG</u>	<u>N020907</u>	<u>001</u>	Nov 18, 1998

ESTRADIOL AND NORETHINDRONE ACETATE

AB		BARR	<u>1MG; 0.5MG</u>	<u>A079193</u>	<u>001</u>	May 11, 2010
AB		BRECKENRIDGE PHARM	<u>0.5MG; 0.1MG</u>	<u>A078324</u>	<u>002</u>	Jun 09, 2011
AB			<u>1MG; 0.5MG</u>	<u>A078324</u>	<u>001</u>	Apr 17, 2008
AB		MYLAN LABS LTD	<u>0.5MG; 0.1MG</u>	<u>A207261</u>	<u>001</u>	Feb 10, 2017
AB			<u>1MG; 0.5MG</u>	<u>A207261</u>	<u>002</u>	Feb 10, 2017
AB		NOVAST LABS	<u>0.5MG; 0.1MG</u>	<u>A210612</u>	<u>001</u>	Apr 03, 2019
AB			<u>1MG; 0.5MG</u>	<u>A210612</u>	<u>002</u>	Apr 03, 2019
		AMABELZ				
BX		LUPIN LTD	0.5MG; 0.1MG	A203339	001	Jun 20, 2016
BX			1MG; 0.5MG	A203339	002	Jun 20, 2016

ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX

TABLET; ORAL

MYFEMBREE

+	!	MYOVANT SCIENCES	1MG; 0.5MG; 40MG	N214846	001	May 26, 2021

PRESCRIPTION DRUG PRODUCT LIST

3-180 (of 474)

ESTRADIOL; NORGESTIMATE

TABLET; ORAL

ESTRADIOL AND NORGESTIMATE

! BARR

1MG, 1MG; N/A, 0.09MG

A076812 001 Apr 29, 2005

ESTRADIOL; PROGESTERONE

CAPSULE; ORAL

BIJUVA

+! MAYNE PHARMA

1MG; 100MG

N210132 001 Oct 28, 2018

ESTRAMUSTINE PHOSPHATE SODIUM

CAPSULE; ORAL

EMCYT

+! PHARMACIA AND
UPJOHN

EQ 140MG PHOSPHATE

N018045 001

ESTROGENS, CONJUGATED

CREAM; TOPICAL, VAGINAL

PREMARIN

+! WYETH PHARMS

0.625MG/GM

N020216 001

INJECTABLE; INJECTION

PREMARIN

+! WYETH PHARMS

25MG/VIAL

N010402 001

TABLET; ORAL

PREMARIN

+ WYETH PHARMS

0.3MG

N004782 003

+

0.45MG

N004782 006 Jul 16, 2003

+!

0.625MG

N004782 004

+!

0.9MG

N004782 005 Jan 26, 1984

+!

1.25MG

N004782 001

ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE

TABLET; ORAL-28

PREMPHASE 14/14

+! WYETH PHARMS

0.625MG, 0.625MG; N/A, 5MG

N020527 002 Nov 17, 1995

PREMPRO

+! WYETH PHARMS

0.3MG; 1.5MG

N020527 005 Jun 04, 2003

+!

0.45MG; 1.5MG

N020527 004 Mar 12, 2003

+!

0.625MG; 2.5MG

N020527 001 Nov 17, 1995

+!

0.625MG; 5MG

N020527 003 Jan 09, 1998

ESTROGENS, ESTERIFIED

TABLET; ORAL

MENEST

MONARCH PHARMS

0.3MG

A084951 001

0.625MG

A084948 001

1.25MG

A084950 001

!

2.5MG

A084949 001

ESTROPIPATE

TABLET; ORAL

OGEN 5

+ PFIZER

6MG

A083220 004

ESZOPICLONE

TABLET; ORAL

ESZOPICLONE

<u>AB</u>	AUROBINDO PHARMA	<u>1MG</u>	<u>A208451</u>	<u>001</u>	Sep 15, 2016
<u>AB</u>		<u>2MG</u>	<u>A208451</u>	<u>002</u>	Sep 15, 2016
<u>AB</u>		<u>3MG</u>	<u>A208451</u>	<u>003</u>	Sep 15, 2016
<u>AB</u>	DR REDDYS	<u>1MG</u>	<u>A091024</u>	<u>001</u>	Apr 15, 2014
<u>AB</u>		<u>2MG</u>	<u>A091024</u>	<u>002</u>	Apr 15, 2014
<u>AB</u>		<u>3MG</u>	<u>A091024</u>	<u>003</u>	Apr 15, 2014
<u>AB</u>	GLENMARK GENERICS	<u>1MG</u>	<u>A091166</u>	<u>001</u>	Apr 15, 2014
<u>AB</u>		<u>2MG</u>	<u>A091166</u>	<u>002</u>	Apr 15, 2014
<u>AB</u>		<u>3MG</u>	<u>A091166</u>	<u>003</u>	Apr 15, 2014
<u>AB</u>	LUPIN LTD	<u>1MG</u>	<u>A091124</u>	<u>001</u>	Sep 13, 2011
<u>AB</u>		<u>2MG</u>	<u>A091124</u>	<u>002</u>	Sep 13, 2011
<u>AB</u>		<u>3MG</u>	<u>A091124</u>	<u>003</u>	Sep 13, 2011
<u>AB</u>	MACLEODS PHARMS LTD	<u>1MG</u>	<u>A202929</u>	<u>001</u>	Jan 30, 2015
<u>AB</u>		<u>2MG</u>	<u>A202929</u>	<u>002</u>	Jan 30, 2015
<u>AB</u>		<u>3MG</u>	<u>A202929</u>	<u>003</u>	Jan 30, 2015
<u>AB</u>	MYLAN PHARMS INC	<u>1MG</u>	<u>A091151</u>	<u>001</u>	Mar 26, 2013
<u>AB</u>		<u>2MG</u>	<u>A091151</u>	<u>002</u>	Mar 26, 2013
<u>AB</u>		<u>3MG</u>	<u>A091151</u>	<u>003</u>	Mar 26, 2013
<u>AB</u>	ORBION PHARMS	<u>1MG</u>	<u>A091113</u>	<u>001</u>	Jun 10, 2014

PRESCRIPTION DRUG PRODUCT LIST

3-181 (of 474)

ESZOPICLONE

TABLET; ORAL

ESZOPICLONE

<u>AB</u>		<u>2MG</u>	<u>A091113</u>	<u>002</u>	Jun 10, 2014
<u>AB</u>		<u>3MG</u>	<u>A091113</u>	<u>003</u>	Jun 10, 2014
<u>AB</u>	SUN PHARM	<u>1MG</u>	<u>A091103</u>	<u>001</u>	Apr 03, 2013
<u>AB</u>		<u>2MG</u>	<u>A091103</u>	<u>002</u>	Apr 03, 2013
<u>AB</u>		<u>3MG</u>	<u>A091103</u>	<u>003</u>	Apr 03, 2013
<u>AB</u>	TEVA	<u>1MG</u>	<u>A091169</u>	<u>001</u>	May 23, 2011
<u>AB</u>		<u>2MG</u>	<u>A091169</u>	<u>002</u>	May 23, 2011
<u>AB</u>		<u>3MG</u>	<u>A091169</u>	<u>003</u>	May 23, 2011

LUNESTA

<u>AB</u>	+	WOODWARD	<u>1MG</u>	<u>N021476</u>	<u>001</u>	Dec 15, 2004
<u>AB</u>	+		<u>2MG</u>	<u>N021476</u>	<u>002</u>	Dec 15, 2004
<u>AB</u>	+	!	<u>3MG</u>	<u>N021476</u>	<u>003</u>	Dec 15, 2004

ETELCALCETIDE

SOLUTION; INTRAVENOUS

PARSABIV

+	!	KAI PHARMS INC	2.5MG/0.5ML (2.5MG/0.5ML)	N208325	001	Feb 07, 2017
+	!		5MG/ML (5MG/ML)	N208325	002	Feb 07, 2017
+	!		10MG/2ML (5MG/ML)	N208325	003	Feb 07, 2017

ETEPLIRSEN

SOLUTION; INTRAVENOUS

EXONDYS 51

+	!	SAREPTA THERAPS INC	100MG/2ML (50MG/ML)	N206488	001	Sep 19, 2016
+	!		500MG/10ML (50MG/ML)	N206488	002	Sep 19, 2016

ETHACRYNATE SODIUM

INJECTABLE; INJECTION

EDECRI

AP	+!	BAUSCH	EQ 50MG BASE/VIAL	N016093	001	
ETHACRYNATE SODIUM						
AP		MYLAN INSTITUTIONAL	EQ 50MG BASE/VIAL	A204634	001	Aug 23, 2016
AP		PAR STERILE PRODUCTS	EQ 50MG BASE/VIAL	A205473	001	Jul 29, 2015
AP		VPI PHARMS INC	EQ 50MG BASE/VIAL	A208663	001	Jun 09, 2020
AP		ZYDUS PHARMS	EQ 50MG BASE/VIAL	A207758	001	Nov 17, 2017

ETHACRYNIC ACID

TABLET; ORAL

EDECRI

<u>AB</u>	<u>+</u> !	BAUSCH	<u>25MG</u>	<u>N016092</u>	<u>001</u>	
<u>ETHACRYNIC ACID</u>						
<u>AB</u>		AGNITIO	<u>25MG</u>	<u>A211809</u>	<u>001</u>	Jul 12, 2019
<u>AB</u>		AMNEAL PHARMS CO	<u>25MG</u>	<u>A208805</u>	<u>001</u>	May 08, 2018
<u>AB</u>		EDENBRIDGE PHARMS	<u>25MG</u>	<u>A205609</u>	<u>001</u>	Jun 30, 2016
<u>AB</u>		HIKMA	<u>25MG</u>	<u>A207262</u>	<u>001</u>	Feb 23, 2017
<u>AB</u>		LUPIN LTD	<u>25MG</u>	<u>A211719</u>	<u>001</u>	Sep 06, 2019
<u>AB</u>		PAR PHARM INC	<u>25MG</u>	<u>A208501</u>	<u>001</u>	Jul 21, 2017
<u>AB</u>		SCIEGEN PHARMS INC	<u>25MG</u>	<u>A211232</u>	<u>001</u>	Aug 27, 2019
<u>AB</u>		STRIDES PHARMA	<u>25MG</u>	<u>A213240</u>	<u>001</u>	Oct 19, 2020
<u>AB</u>		UPSHER SMITH LABS	<u>25MG</u>	<u>A212417</u>	<u>001</u>	Feb 19, 2020

ETHAMBUTOL HYDROCHLORIDE

TABLET; ORAL

ETHAMBUTOL HYDROCHLORIDE

<u>AB</u>		AKORN	<u>100MG</u>	<u>A075095</u>	<u>001</u>	Nov 30, 1999
<u>AB</u>			<u>400MG</u>	<u>A075095</u>	<u>002</u>	Nov 30, 1999
<u>AB</u>		LUPIN	<u>100MG</u>	<u>A078939</u>	<u>001</u>	Jun 17, 2009
<u>AB</u>			<u>400MG</u>	<u>A078939</u>	<u>002</u>	Jun 17, 2009
<u>MYAMBUTOL</u>						
<u>AB</u>	+	STI PHARMA LLC	<u>100MG</u>	<u>N016320</u>	<u>001</u>	
<u>AB</u>	+	!	<u>400MG</u>	<u>N016320</u>	<u>003</u>	

ETHANOLAMINE OLEATE

INJECTABLE; INJECTION

ETHAMOLIN

+	!	QOL MEDCL	50MG/ML	N019357	001	Dec 22, 1988

PRESCRIPTION DRUG PRODUCT LIST

3-182 (of 474)

ETHINYL ESTRADIOL; ETHYNODIOL DIACETATE

TABLET; ORAL-28

ETHYNODIOL DIACETATE AND ETHINYL ESTRADIOL

AB	MYLAN LABS LTD	<u>0.035MG;1MG</u>	<u>A204703</u>	<u>001</u>	Jul 28, 2016
AB		<u>0.05MG;1MG</u>	<u>A204704</u>	<u>001</u>	Feb 09, 2016
	<u>KELNOR</u>				
AB	BARR	<u>0.035MG;1MG</u>	<u>A076785</u>	<u>001</u>	May 23, 2005
	<u>LO-MALMOREDE</u>				
AB	NOVAST LABS	<u>0.035MG;1MG</u>	<u>A209548</u>	<u>001</u>	Feb 11, 2019
	<u>MALMOREDE</u>				
AB	NOVAST LABS	<u>0.05MG;1MG</u>	<u>A209547</u>	<u>001</u>	Jul 25, 2018
	<u>ZOVIA 1/50E-28</u>				
AB	! WATSON LABS	<u>0.05MG;1MG</u>	<u>A072723</u>	<u>001</u>	Dec 30, 1991

ETHINYL ESTRADIOL; ETONOGESTREL

RING; VAGINAL

ELURYNG

AB	AMNEAL	<u>0.015MG/24HR;0.12MG/24HR</u>	<u>A210830</u>	<u>001</u>	Dec 11, 2019
	<u>ETHINYL ESTRADIOL; ETONOGESTREL</u>				
AB	TEVA PHARMS USA INC	<u>0.015MG/24HR;0.12MG/24HR</u>	<u>A204305</u>	<u>001</u>	Jan 13, 2021
	<u>HALOETTE</u>				
AB	MAYNE PHARMA	<u>0.015MG/24HR;0.12MG/24HR</u>	<u>A211328</u>	<u>001</u>	Aug 05, 2022
	<u>NUVARING</u>				
AB	+! ORGANON USA ORGANON	<u>0.015MG/24HR;0.12MG/24HR</u>	<u>N021187</u>	<u>001</u>	Oct 03, 2001

ETHINYL ESTRADIOL; LEVONORGESTREL

SYSTEM; TRANSDERMAL

TWIRLA

+! AGILE

0.03MG/24HR;0.12MG/24HR

N204017 001 Feb 14, 2020

TABLET; ORAL

ASHLYNA

AB	GLENMARK GENERICS	<u>0.03MG,0.01MG;0.15MG,N/A</u>	<u>A203163</u>	<u>001</u>	Feb 23, 2015
	<u>DAYSEE</u>				
AB	LUPIN LTD	<u>0.03MG,0.01MG;0.15MG,N/A</u>	<u>A091467</u>	<u>001</u>	Apr 10, 2013
	<u>DOLISHALE</u>				
AB	NOVAST LABS	<u>0.02MG;0.09MG</u>	<u>A091692</u>	<u>001</u>	Oct 22, 2020
	<u>ICLEVIA</u>				
AB	AUROBINDO PHARMA LTD	<u>0.03MG;0.15MG</u>	<u>A206850</u>	<u>001</u>	Jun 29, 2018
	<u>INTROVALE</u>				
AB	XIROMED	<u>0.03MG;0.15MG</u>	<u>A079064</u>	<u>001</u>	Sep 27, 2010
	<u>JAIMIESS</u>				
AB	XIROMED	<u>0.03MG,0.01MG;0.15MG,N/A</u>	<u>A203770</u>	<u>001</u>	Dec 27, 2017
	<u>LEVONORGESTREL AND ETHINYL ESTRADIOL</u>				
AB	AMNEAL PHARMS	<u>0.03MG;0.15MG</u>	<u>A203871</u>	<u>001</u>	Nov 13, 2015
AB		<u>0.03MG,0.01MG;0.15MG,N/A</u>	<u>A203872</u>	<u>001</u>	Dec 22, 2015
AB	GLENMARK GENERICS	<u>0.02MG;0.09MG</u>	<u>A202791</u>	<u>001</u>	Apr 09, 2015
AB	GLENMARK PHARMS LTD	<u>0.03MG;0.15MG</u>	<u>A203164</u>	<u>001</u>	Jun 12, 2015
AB	LUPIN LTD	<u>0.03MG;0.15MG</u>	<u>A091440</u>	<u>001</u>	Oct 23, 2012
AB	MYLAN LABS LTD	<u>0.03MG;0.15MG</u>	<u>A200490</u>	<u>001</u>	Apr 21, 2015
AB	! WATSON LABS	<u>0.02MG;0.09MG</u>	<u>A079218</u>	<u>001</u>	Jun 06, 2011
	<u>LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL</u>				
AB	LUPIN LTD	<u>0.02MG,0.1MG;0.01MG,N/A</u>	<u>A091674</u>	<u>001</u>	Oct 26, 2011
AB	MAYNE PHARMA	<u>0.03MG,0.01MG;0.15MG,N/A</u>	<u>A078834</u>	<u>001</u>	May 31, 2011
AB	MYLAN LABS LTD	<u>0.02MG,0.15MG;0.025MG,0.15MG;0.03MG,0.15MG;0.01MG,N/A</u>	<u>A206053</u>	<u>001</u>	Oct 02, 2017
AB		<u>0.02MG,0.1MG;0.01MG,N/A</u>	<u>A200493</u>	<u>001</u>	Jun 17, 2015
AB		<u>0.03MG,0.01MG;0.15MG,N/A</u>	<u>A200492</u>	<u>001</u>	May 27, 2015
AB	XIROMED	<u>0.02MG,0.1MG;0.01MG,N/A</u>	<u>A205131</u>	<u>001</u>	Dec 14, 2017
	<u>LO SIMPESS</u>				
AB	AUROBINDO PHARMA	<u>0.02MG,0.1MG;0.01MG,N/A</u>	<u>A206852</u>	<u>001</u>	Apr 28, 2017
	<u>LOSEASONIQUE</u>				
AB	TEVA BRANDED PHARM	<u>0.02MG,0.1MG;0.01MG,N/A</u>	<u>N022262</u>	<u>001</u>	Oct 24, 2008
	<u>QUARTETTE</u>				
AB	+! TEVA BRANDED PHARM	<u>0.02MG,0.15MG;0.025MG,0.15MG;0.03MG,0.15MG;0.01MG,N/A</u>	<u>N204061</u>	<u>001</u>	Mar 28, 2013
	<u>OUASENSE</u>				
AB	WATSON LABS	<u>0.03MG;0.15MG</u>	<u>A077101</u>	<u>001</u>	Sep 06, 2006
	<u>SEASONALE</u>				
AB	+! TEVA BRANDED PHARM	<u>0.03MG;0.15MG</u>	<u>N021544</u>	<u>001</u>	Sep 05, 2003
	<u>SEASONIQUE</u>				
AB	+! TEVA BRANDED PHARM	<u>0.03MG,0.01MG;0.15MG,N/A</u>	<u>N021840</u>	<u>001</u>	May 25, 2006

PRESCRIPTION DRUG PRODUCT LIST

3-183(of 474)

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL

SETLAKIN

AB	NOVAST LABS	<u>0.03MG;0.15MG</u>	<u>A090716</u>	<u>001</u>	Sep 15, 2014

SIMPESSE

AB	AUROBINDO PHARMA	<u>0.03MG,0.01MG;0.15MG,N/A</u>	<u>A206851</u>	<u>001</u>	Apr 07, 2017

BALCOLTRA

+	AVION PHARMS	0.02MG;0.1MG	N208612	001	Jan 09, 2018

TYBLUME

+	EXELTIS USA INC	0.02MG;0.1MG	N209405	001	Mar 30, 2020

TABLET; ORAL-28

ALTAVERA

AB	XIROMED	<u>0.03MG;0.15MG</u>	<u>A079102</u>	<u>001</u>	Aug 03, 2010

AYUNA

AB	AUROBINDO PHARMA	<u>0.03MG;0.15MG</u>	<u>A206866</u>	<u>001</u>	Sep 23, 2016

ENPRESSE-28

AB	DURAMED PHARMS BARR	<u>0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG</u>	<u>A075809</u>	<u>002</u>	Jul 16, 2001

KURVELO

AB	LUPIN LTD	<u>0.03MG;0.15MG</u>	<u>A091408</u>	<u>001</u>	Oct 17, 2012

LEVONEST

AB	NOVAST LABS LTD	<u>0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG</u>	<u>A090719</u>	<u>001</u>	Dec 29, 2010

LEVONORGESTREL AND ETHINYL ESTRADIOL

AB	AMNEAL PHARMS	<u>0.03MG;0.15MG</u>	<u>A201095</u>	<u>001</u>	Dec 08, 2014

AB	MYLAN LABS LTD	<u>0.03MG;0.15MG</u>	<u>A091663</u>	<u>001</u>	Dec 21, 2012

AB	NAARI PTE LTD	<u>0.03MG;0.15MG</u>	<u>A207033</u>	<u>001</u>	Oct 09, 2020

LEVORA 0.15/30-28

AB	!	MAYNE PHARMA	<u>0.03MG;0.15MG</u>	<u>A073594</u>	<u>001</u>	Dec 13, 1993

MARLISSA

AB	GLENMARK GENERICS	<u>0.03MG;0.15MG</u>	<u>A091452</u>	<u>001</u>	Feb 29, 2012

MYZILRA

AB	VINTAGE PHARMS LLC	<u>0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG</u>	<u>A077502</u>	<u>001</u>	Nov 23, 2011

PORTIA-28

AB	BARR	<u>0.03MG;0.15MG</u>	<u>A075866</u>	<u>002</u>	May 23, 2002

TRIVORA-28

AB	!	MAYNE PHARMA	<u>0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG</u>	<u>A074538</u>	<u>002</u>	Dec 18, 1997

AFIRMELLE

AB1	AUROBINDO PHARMA	<u>0.02MG;0.1MG</u>	<u>A206886</u>	<u>001</u>	Nov 14, 2016

AVIANE-28

AB1	DURAMED PHARMS BARR	<u>0.02MG;0.1MG</u>	<u>A075796</u>	<u>001</u>	Apr 30, 2001

FALMINA

AB1	NOVAST LABS LTD	<u>0.02MG;0.1MG</u>	<u>A090721</u>	<u>001</u>	Mar 28, 2012

LEVONORGESTREL AND ETHINYL ESTRADIOL

AB1	AMNEAL PHARMS	<u>0.02MG;0.1MG</u>	<u>A201108</u>	<u>001</u>	Feb 05, 2014

AB1	LUPIN LTD	<u>0.02MG;0.1MG</u>	<u>A091425</u>	<u>001</u>	Jan 18, 2013

AB1	!	MAYNE PHARMA	<u>0.02MG;0.1MG</u>	<u>A076625</u>	<u>001</u>	Nov 18, 2004

AB1	MYLAN LABS LTD	<u>0.02MG;0.1MG</u>	<u>A200245</u>	<u>001</u>	Oct 09, 2013

AB1	NAARI PTE LTD	<u>0.02MG;0.1MG</u>	<u>A207065</u>	<u>001</u>	Aug 17, 2020

VIENVA

AB1	XIROMED	<u>0.02MG;0.1MG</u>	<u>A201088</u>	<u>001</u>	May 21, 2015

LESSINA-28

AB2	BARR	<u>0.02MG;0.1MG</u>	<u>A075803</u>	<u>002</u>	Mar 20, 2002

LEVONORGESTREL AND ETHINYL ESTRADIOL

AB2	!	MAYNE PHARMA	<u>0.02MG;0.1MG</u>	<u>A077681</u>	<u>001</u>	May 31, 2006

BX	LUPIN LTD	0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG	A200248	001	Nov 19, 2015

ETHINYL ESTRADIOL; NORELGESTROMIN

FILM, EXTENDED RELEASE; TRANSDERMAL

ETHINYL ESTRADIOL AND NORELGESTROMIN

AB	AMNEAL	<u>0.035MG/24HR;0.15MG/24HR</u>	<u>A213950</u>	<u>001</u>	Feb 25, 2021

ONSURA

AB	TEVA PHARMS USA	<u>0.035MG/24HR;0.15MG/24HR</u>	<u>A213977</u>	<u>001</u>	Aug 25, 2021

XULANE

AB	!	MYLAN TECHNOLOGIES	<u>0.035MG/24HR;0.15MG/24HR</u>	<u>A200910</u>	<u>001</u>	Apr 16, 2014

PRESCRIPTION DRUG PRODUCT LIST

3-184 (of 474)

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL

NEXESTA FE

AB	AUROBINDO PHARMA	<u>0.035MG;0.4MG</u>	<u>A207535</u>	<u>001</u>	Feb 02, 2017

NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

AB	AMNEAL PHARMS	<u>0.035MG;0.4MG</u>	<u>A078892</u>	<u>001</u>	Sep 26, 2011
AB	BARR	<u>0.035MG;0.4MG</u>	<u>A078965</u>	<u>001</u>	Aug 05, 2010
AB	LUPIN LTD	<u>0.035MG;0.4MG</u>	<u>A091332</u>	<u>001</u>	Mar 23, 2016
AB	! MYLAN LABS LTD	<u>0.035MG;0.4MG</u>	<u>A202086</u>	<u>001</u>	Apr 01, 2015
AB	NAARI PTE LTD	<u>0.035MG;0.4MG</u>	<u>A207066</u>	<u>001</u>	Mar 29, 2017

TABLET; ORAL-21

NORTREL 1/35-21

AB	BARR	<u>0.035MG;1MG</u>	<u>A072693</u>	<u>001</u>	Feb 28, 1992
	NORTREL 7/7/7				
	BARR	0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG	A075478	001	Aug 30, 2002

TABLET; ORAL-28

ALYACEN 1/35

AB	GLENMARK GENERICS	<u>0.035MG;1MG</u>	<u>A091634</u>	<u>001</u>	Jan 19, 2012

ALYACEN 7/7/7

AB	GLENMARK GENERICS	<u>0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG</u>	<u>A091636</u>	<u>001</u>	Jan 19, 2012

ARANELLE

AB	BARR	<u>0.035MG,0.035MG,0.035MG;0.5MG,1MG,0.5MG</u>	<u>A076783</u>	<u>001</u>	Sep 29, 2004

BALZIVA-28

AB	! BARR	<u>0.035MG;0.4MG</u>	<u>A076238</u>	<u>001</u>	Apr 22, 2004

BRIELLYN

AB	GLENMARK GENERICS	<u>0.035MG;0.4MG</u>	<u>A090538</u>	<u>001</u>	Mar 22, 2011

CYONANZ

AB	AUROBINDO PHARMA	<u>0.035MG;0.5MG</u>	<u>A207055</u>	<u>001</u>	Oct 21, 2016

DASETTA 1/35

AB	NOVAST LABS LTD	<u>0.035MG;1MG</u>	<u>A090948</u>	<u>001</u>	Dec 22, 2011

DASETTA 7/7/7

AB	! NOVAST LABS LTD	<u>0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG</u>	<u>A090946</u>	<u>001</u>	Dec 22, 2011

GILDAGIA

AB	VINTAGE PHARMS	<u>0.035MG;0.4MG</u>	<u>A078376</u>	<u>001</u>	Nov 06, 2012

NORETHINDRONE AND ETHINYL ESTRADIOL

AB	NAARI PTE LTD	<u>0.035MG;1MG</u>	<u>A206864</u>	<u>001</u>	Apr 28, 2017
AB	WATSON LABS	<u>0.035MG;0.4MG</u>	<u>A078323</u>	<u>001</u>	Feb 04, 2010
AB	WATSON LABS TEVA	<u>0.035MG;1MG</u>	<u>A070687</u>	<u>001</u>	Jan 29, 1987

NORTREL 0.5/35-28

AB	BARR	<u>0.035MG;0.5MG</u>	<u>A072695</u>	<u>001</u>	Feb 28, 1992

NORTREL 1/35-28

AB	! BARR	<u>0.035MG;1MG</u>	<u>A072696</u>	<u>001</u>	Feb 28, 1992

NORTREL 7/7/7

AB	BARR	<u>0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG</u>	<u>A075478</u>	<u>002</u>	Aug 30, 2002

NYLIA 1/35

AB	AUROBINDO PHARMA	<u>0.035MG;1MG</u>	<u>A207056</u>	<u>001</u>	Oct 21, 2016

NYLIA 7/7/7

AB	AUROBINDO PHARMA	<u>0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG</u>	<u>A207054</u>	<u>001</u>	Oct 21, 2016

PHILITH

AB	NOVAST LABS LTD	<u>0.035MG;0.4MG</u>	<u>A090947</u>	<u>001</u>	Dec 22, 2011

RHUZDAH

AB	AUROBINDO PHARMA	<u>0.035MG;0.4MG</u>	<u>A207585</u>	<u>001</u>	Oct 11, 2022

TRI-NORINYL 28-DAY

AB	+! MAYNE PHARMA	<u>0.035MG,0.035MG,0.035MG;0.5MG,1MG,0.5MG</u>	<u>N018977</u>	<u>002</u>	Apr 13, 1984

VYFEMLA

AB	LUPIN LTD	<u>0.035MG;0.4MG</u>	<u>A201886</u>	<u>001</u>	Sep 26, 2013

WERA

AB	! NOVAST LABS LTD	<u>0.035MG;0.5MG</u>	<u>A091204</u>	<u>001</u>	Mar 27, 2012

BX	PIRMELLA 1/35	0.035MG;1MG	A201512	001	Apr 24, 2013
	LUPIN LTD				
	PIRMELLA 7/7/7				

BX	LUPIN LTD	0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG	A201510	001	Apr 24, 2013
		G			

NORETHINDRONE AND ETHINYL ESTRADIOL (10/11)

	WATSON LABS TEVA	0.035MG,0.035MG;0.5MG,1MG	A071044	001	Apr 01, 1988

TABLET, CHEWABLE; ORAL

KAITLIB FE

AB	LUPIN LTD	<u>0.025MG;0.8MG</u>	<u>A203448</u>	<u>001</u>	Dec 17, 2015

PRESCRIPTION DRUG PRODUCT LIST

3-185 (of 474)

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET, CHEWABLE; ORAL

NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

AB	+	APIL	<u>0.025MG;0.8MG</u>	<u>N022573</u>	<u>001</u>	Dec 22, 2010
AB		MYLAN LABS LTD	<u>0.025MG;0.8MG</u>	<u>A203371</u>	<u>001</u>	Apr 23, 2014

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

CAPSULE; ORAL

GEMMILY

AB		XIROMED	<u>0.02MG;1MG</u>	<u>A213317</u>	<u>001</u>	Nov 09, 2020

MERZEE

AB		SLAYBACK PHARMA LLC	<u>0.02MG;1MG</u>	<u>A212706</u>	<u>001</u>	Dec 18, 2020

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

AB		AMNEAL PHARMS	<u>0.02MG;1MG</u>	<u>A214292</u>	<u>001</u>	Jul 20, 2021
AB		GLENMARK PHARMS LTD	<u>0.02MG;1MG</u>	<u>A213418</u>	<u>001</u>	Jul 27, 2022

TAYTULLA

AB	+	APIL	<u>0.02MG;1MG</u>	<u>N204426</u>	<u>001</u>	Apr 19, 2013

TABLET; ORAL

AUROVELA 24 FE

AB		AUROBINDO PHARMA	<u>0.02MG;1MG</u>	<u>A207504</u>	<u>001</u>	Jun 15, 2017

BLISOVI 24 FE

AB		LUPIN LTD	<u>0.02MG;1MG</u>	<u>A091398</u>	<u>001</u>	Oct 28, 2015

FINZALA

AB		TEVA PHARMS USA INC	<u>0.02MG;1MG</u>	<u>A210087</u>	<u>001</u>	Apr 07, 2020

FYAVOLV

AB		LUPIN LTD	<u>0.005MG;1MG</u>	<u>A204213</u>	<u>002</u>	Dec 10, 2015

AB			<u>0.0025MG;0.5MG</u>	<u>A204213</u>	<u>001</u>	Dec 10, 2015

GILDESS 24 FE

AB		VINTAGE PHARMS	<u>0.02MG;1MG</u>	<u>A090293</u>	<u>001</u>	Dec 01, 2014

LARIN 24 FE

AB		NOVAST LABS	<u>0.02MG;1MG</u>	<u>A202994</u>	<u>001</u>	Feb 18, 2015

LERIBANE

AB		NOVAST LABS	<u>0.0025MG;0.5MG</u>	<u>A203435</u>	<u>002</u>	Jun 03, 2016

AB			<u>0.005MG;1MG</u>	<u>A203435</u>	<u>001</u>	Jun 03, 2016

MIBELAS 24 FE

AB		LUPIN	<u>0.02MG;1MG</u>	<u>A206287</u>	<u>001</u>	May 24, 2016

MINASTRIN 24 FE

AB	+	APIL	<u>0.02MG;1MG</u>	<u>N203667</u>	<u>001</u>	May 08, 2013

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL

AB	!	BARR LABS INC	<u>0.005MG;1MG</u>	<u>A076221</u>	<u>001</u>	Nov 06, 2009

AB		GLENMARK GENERICS	<u>0.0025MG;0.5MG</u>	<u>A203038</u>	<u>001</u>	Apr 02, 2015

AB			<u>0.005MG;1MG</u>	<u>A203038</u>	<u>002</u>	Apr 02, 2015

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

AB		BARR LABS INC	<u>0.02MG;1MG</u>	<u>A090938</u>	<u>001</u>	Dec 01, 2014

AB	!	GLENMARK PHARMS LTD	<u>0.02MG;1MG</u>	<u>A204847</u>	<u>001</u>	Nov 17, 2017

AB			<u>0.02MG;1MG</u>	<u>A210369</u>	<u>001</u>	Dec 26, 2017

AB		XIROMED	<u>0.02MG;1MG</u>	<u>A209609</u>	<u>001</u>	Jul 16, 2018

LO LOESTRIN FE

	+	APIL	0.01MG, 0.01MG; 1MG, N/A	N022501	001	Oct 21, 2010

TABLET; ORAL-21

AUROVELA 1.5/30

AB		AUROBINDO PHARMA	<u>0.03MG;1.5MG</u>	<u>A207581</u>	<u>001</u>	Jun 26, 2017

AUROVELA 1/20

AB		AUROBINDO PHARMA	<u>0.02MG;1MG</u>	<u>A207506</u>	<u>001</u>	Jun 16, 2017

HAILEY 1.5/30

AB		GLENMARK PHARMS	<u>0.03MG;1.5MG</u>	<u>A209297</u>	<u>001</u>	Jun 05, 2018

JUNEL 1.5/30

AB		BARR	<u>0.03MG;1.5MG</u>	<u>A076381</u>	<u>001</u>	May 30, 2003

JUNEL 1/20

AB		BARR	<u>0.02MG;1MG</u>	<u>A076380</u>	<u>001</u>	May 30, 2003

LARIN 1.5/30

AB		NOVAST LABS	<u>0.03MG;1.5MG</u>	<u>A202996</u>	<u>001</u>	Mar 20, 2014

LARIN 1/20

AB		NOVAST LABS	<u>0.02MG;1MG</u>	<u>A202995</u>	<u>001</u>	Dec 04, 2013

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL

AB		GLENMARK PHARMS LTD	<u>0.02MG;1MG</u>	<u>A206969</u>	<u>001</u>	Jan 20, 2016

AB		MYLAN LABS LTD	<u>0.02MG;1MG</u>	<u>A202771</u>	<u>001</u>	Nov 06, 2013

AB			<u>0.03MG;1.5MG</u>	<u>A202770</u>	<u>001</u>	Feb 19, 2015

TRI-LEGEST 21

		BARR	0.02MG, 0.03MG, 0.035MG; 1MG, 1MG, 1MG	A076405	001	Oct 26, 2007

PRESCRIPTION DRUG PRODUCT LIST

3-186 (of 474)

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL-28

<u>AUROVELA FE 1.5/30</u>					
AB	AUROBINDO PHARMA	0.03MG;1.5MG	A207580	001	Jun 15, 2017
<u>AUROVELA FE 1/20</u>					
AB	AUROBINDO PHARMA	0.02MG;1MG	A207505	001	Jun 16, 2017
<u>BLISOVI FE 1/20</u>					
AB	LUPIN LTD	0.02MG;1MG	A201584	001	Nov 18, 2015
<u>CHABELINA FE</u>					
AB	! NOVAST LABS	0.02MG,0.03MG,0.035MG;1MG,1MG,1MG	A202962	001	Apr 15, 2020
<u>HAILEY FE 1.5/30</u>					
AB	GLENMARK PHARMS	0.03MG;1.5MG	A209031	001	Jun 05, 2018
<u>HAILEY FE 1/20</u>					
AB	GLENMARK PHARMS LTD	0.02MG;1MG	A206597	001	Nov 21, 2017
<u>JUNEL FE 1.5/30</u>					
AB	! BARR	0.03MG;1.5MG	A076064	001	Sep 18, 2003
<u>JUNEL FE 1/20</u>					
AB	BARR	0.02MG;1MG	A076081	001	Sep 18, 2003
<u>LARIN FE 1.5/30</u>					
AB	NOVAST LABS	0.03MG;1.5MG	A091453	001	Aug 23, 2013
<u>LARIN FE 1/20</u>					
AB	NOVAST LABS	0.02MG;1MG	A091454	001	Aug 26, 2013
<u>NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL</u>					
AB	MYLAN	0.02MG,0.03MG,0.035MG;1MG,1MG,1MG	A205069	001	Jun 22, 2018
AB	MYLAN LABS LTD	0.02MG;1MG	A202772	001	Nov 14, 2013
AB		0.03MG;1.5MG	A202741	001	Feb 20, 2015
<u>TRI-LEGEST FE</u>					
AB	BARR	0.02MG,0.03MG,0.035MG;1MG,1MG,1MG	A076105	001	Oct 26, 2007
	BLISOVI FE 1.5/30				
BX	LUPIN LTD	0.03MG;1.5MG	A201585	001	Nov 18, 2015

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET; ORAL-28

<u>ESTARYLLA</u>					
AB	XIROMED	0.035MG;0.25MG	A090794	001	Jan 30, 2013
<u>MILI</u>					
AB	AUROBINDO PHARMA LTD	0.035MG;0.25MG	A205449	001	Jul 07, 2016
<u>MONO-LINYAH</u>					
AB	NOVAST LABS LTD	0.035MG;0.25MG	A090523	001	May 23, 2012
<u>NORGESTIMATE AND ETHINYL ESTRADIOL</u>					
AB	AMNEAL PHARMS	0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG	A203870	001	Nov 12, 2015
AB		0.035MG;0.25MG	A203865	001	Oct 27, 2015
AB		0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG	A203873	001	May 12, 2016
AB	! GLENMARK GENERICS	0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG	A200494	001	Jun 17, 2011
AB		0.035MG;0.25MG	A200538	001	Apr 05, 2012
AB	! GLENMARK PHARMS	0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG	A204057	001	Feb 23, 2016
AB	LUPIN LTD	0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG	A205588	001	Apr 26, 2016
AB		0.035MG;0.25MG	A205630	001	Oct 27, 2016
AB	LUPIN PHARMS	0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG	A200541	001	Jun 25, 2012
AB	NAARI PTE LTD	0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG	A200383	001	Apr 07, 2015
AB		0.035MG;0.25MG	A200384	001	Apr 07, 2015
<u>PREVIFEM</u>					
AB	VINTAGE PHARMS LLC	0.035MG;0.25MG	A076334	001	Jan 09, 2004
<u>SPRINTEC</u>					
AB	! BARR	0.035MG;0.25MG	A075804	001	Sep 25, 2002
<u>TRI LO SPRINTEC</u>					
AB	BARR LABS INC	0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG	A076784	001	Jun 29, 2009
<u>TRI-ESTARYLLA</u>					
AB	XIROMED	0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG	A090793	001	Jan 30, 2013
<u>TRI-LINYAH</u>					
AB	NOVAST LABS LTD	0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG	A090524	001	May 30, 2012
<u>TRI-LO-ESTARYLLA</u>					
AB	XIROMED	0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG	A091232	001	Jun 29, 2015

PRESCRIPTION DRUG PRODUCT LIST

3-187 (of 474)

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET; ORAL-28

TRI-LO-LINYAH

AB	NOVAST LABS	<u>0.025MG, 0.025MG, 0.025MG; 0.18MG, 0.215MG, 0.25MG</u>	<u>A090541</u>	<u>001</u>	Sep 02, 2022

TRI-LO-MILI

AB	AUROBINDO PHARMA	<u>0.025MG, 0.025MG, 0.025MG; 0.18MG, 0.215MG, 0.25MG</u>	<u>A205762</u>	<u>001</u>	Nov 04, 2016

TRI-MILI

AB	AUROBINDO PHARMA LTD	<u>0.035MG, 0.035MG, 0.035MG; 0.18MG, 0.215MG, 0.25MG</u>	<u>A205441</u>	<u>001</u>	Jul 06, 2016

TRI-SPRINTEC

AB	BARR	<u>0.035MG, 0.035MG, 0.035MG; 0.18MG, 0.215MG, 0.25MG</u>	<u>A075808</u>	<u>001</u>	Dec 29, 2003

ETHINYL ESTRADIOL; NORGESTREL

TABLET; ORAL-21

CRYSSELLE

AB	DURAMED PHARMS BARR	<u>0.03MG; 0.3MG</u>	<u>A075840</u>	<u>001</u>	Nov 30, 2001

TABLET; ORAL-28

CRYSSELLE

AB	! DURAMED PHARMS BARR	<u>0.03MG; 0.3MG</u>	<u>A075840</u>	<u>002</u>	Nov 30, 2001

ELINEST

AB	NOVAST LABS LTD	<u>0.03MG; 0.3MG</u>	<u>A091105</u>	<u>001</u>	Mar 28, 2012

LOW-OGESTREL-28

AB	MAYNE PHARMA	<u>0.03MG; 0.3MG</u>	<u>A075288</u>	<u>002</u>	Jul 28, 1999

ETHINYL ESTRADIOL; SEGESTERONE ACETATE

RING; VAGINAL

ANNOVERA

+	!	THERAPEUTICSMD INC	0.013MG/24HR; 0.15MG/24HR	<u>N209627</u>	<u>001</u>	Aug 10, 2018

ETHIODIZED OIL

OIL; INTRALYMPHATIC, INTRAUTERINE

LIPIODOL

+	!	GUERBET	EQ 4.8GM IODINE/10ML (EQ 480MG IODINE/ML)	<u>N009190</u>	<u>001</u>	

ETHIONAMIDE

TABLET; ORAL

TRECATOR

+	!	WYETH PHARMS	250MG	<u>N013026</u>	<u>002</u>	

ETHOSUXIMIDE

CAPSULE; ORAL

ETHOSUXIMIDE

AB	AKORN	<u>250MG</u>	<u>A040686</u>	<u>001</u>	May 28, 2008

AB	BIONPHARMA INC	<u>250MG</u>	<u>A040430</u>	<u>001</u>	Oct 28, 2002

AB	HERITAGE PHARMS INC	<u>250MG</u>	<u>A200892</u>	<u>001</u>	Sep 25, 2012

AB	PURACAP PHARM LLC	<u>250MG</u>	<u>A210654</u>	<u>001</u>	Mar 16, 2020

AB	STRIDES PHARMA	<u>250MG</u>	<u>A211928</u>	<u>001</u>	Feb 19, 2019

ZARONTIN

AB	+	!	PARKE DAVIS	<u>250MG</u>	<u>N012380</u>	<u>001</u>

SYRUP; ORAL

ETHOSUXIMIDE

AA	MIKART	<u>250MG/5ML</u>	<u>A040506</u>	<u>001</u>	Dec 22, 2003

AA	PHARM ASSOC	<u>250MG/5ML</u>	<u>A040253</u>	<u>001</u>	Nov 22, 2000

ZARONTIN

AA	+	!	PARKE-DAVIS	<u>250MG/5ML</u>	<u>A080258</u>	<u>001</u>

ETODOLAC

CAPSULE; ORAL

ETODOLAC

AB	ANI PHARMS	<u>200MG</u>	<u>A075126</u>	<u>001</u>	Sep 16, 1999

AB		<u>300MG</u>	<u>A075126</u>	<u>002</u>	Sep 16, 1999

AB	APOTEX	<u>200MG</u>	<u>A075419</u>	<u>001</u>	Jul 28, 2000

AB		<u>300MG</u>	<u>A075419</u>	<u>002</u>	Jul 28, 2000

AB	TARO	<u>200MG</u>	<u>A075078</u>	<u>001</u>	Apr 30, 1998

AB	!	<u>300MG</u>	<u>A075078</u>	<u>002</u>	Apr 30, 1998

TABLET; ORAL

ETODOLAC

AB	AMNEAL PHARMS CO	<u>400MG</u>	<u>A208834</u>	<u>001</u>	Jun 07, 2018

AB		<u>500MG</u>	<u>A208834</u>	<u>002</u>	Jun 07, 2018

AB	APOTEX INC	<u>400MG</u>	<u>A076004</u>	<u>001</u>	Dec 03, 2002

AB		<u>500MG</u>	<u>A076004</u>	<u>002</u>	Dec 03, 2002

AB	BAYSHORE PHARMS LLC	<u>400MG</u>	<u>A210704</u>	<u>001</u>	Dec 16, 2020

PRESCRIPTION DRUG PRODUCT LIST

3-188 (of 474)

ETODOLAC

TABLET; ORAL

ETODOLAC

<u>AB</u>		<u>500MG</u>	<u>A210704</u>	<u>002</u>	Dec 16, 2020
<u>AB</u>	EDENBRIDGE PHARMS	<u>400MG</u>	<u>A209888</u>	<u>001</u>	Nov 30, 2018
<u>AB</u>		<u>500MG</u>	<u>A209888</u>	<u>002</u>	Nov 30, 2018
<u>AB</u>	SANDOZ	<u>400MG</u>	<u>A074903</u>	<u>001</u>	Apr 11, 1997
<u>AB</u>		<u>500MG</u>	<u>A074903</u>	<u>002</u>	Apr 19, 1999
<u>AB</u>	TARO PHARM INDS	<u>400MG</u>	<u>A075074</u>	<u>001</u>	Mar 11, 1998
<u>AB</u>	!	<u>500MG</u>	<u>A075074</u>	<u>002</u>	Apr 25, 2000

TABLET, EXTENDED RELEASE; ORAL

ETODOLAC

<u>AB</u>	BAYSHORE PHARMS LLC	<u>400MG</u>	<u>A212263</u>	<u>001</u>	Nov 24, 2020
<u>AB</u>		<u>500MG</u>	<u>A212263</u>	<u>002</u>	Nov 24, 2020
<u>AB</u>		<u>600MG</u>	<u>A212263</u>	<u>003</u>	Nov 24, 2020
<u>AB</u>	TARO	<u>400MG</u>	<u>A076174</u>	<u>001</u>	Mar 13, 2003
<u>AB</u>		<u>500MG</u>	<u>A076174</u>	<u>002</u>	Mar 13, 2003
<u>AB</u>		<u>600MG</u>	<u>A076174</u>	<u>003</u>	Mar 13, 2003
<u>AB</u>	TEVA	<u>400MG</u>	<u>A075665</u>	<u>003</u>	Feb 05, 2001
<u>AB</u>		<u>500MG</u>	<u>A075665</u>	<u>002</u>	Jul 31, 2000
<u>AB</u>	!	<u>600MG</u>	<u>A075665</u>	<u>001</u>	Jul 31, 2000
<u>AB</u>	ZYDUS PHARMS	<u>400MG</u>	<u>A091134</u>	<u>001</u>	Jan 23, 2014
<u>AB</u>		<u>500MG</u>	<u>A091134</u>	<u>002</u>	Jan 23, 2014
<u>AB</u>		<u>600MG</u>	<u>A091134</u>	<u>003</u>	Jan 23, 2014

ETOMIDATE

INJECTABLE; INJECTION

AMIDATE

<u>AP</u>	+!	HOSPIRA	<u>2MG/ML</u>	<u>N018227</u>	<u>001</u>	Sep 07, 1982

ETOMIDATE

<u>AP</u>		CAPLIN	<u>2MG/ML</u>	<u>A215028</u>	<u>001</u>	Dec 18, 2020
<u>AP</u>		EMCURE PHARMS LTD	<u>2MG/ML</u>	<u>A204618</u>	<u>001</u>	Aug 13, 2014
<u>AP</u>		EUGIA PHARMA	<u>2MG/ML</u>	<u>A206126</u>	<u>001</u>	Feb 24, 2017
<u>AP</u>		GLAND PHARMA LTD	<u>2MG/ML</u>	<u>A209058</u>	<u>001</u>	Apr 18, 2017
<u>AP</u>		HIKMA	<u>2MG/ML</u>	<u>A074593</u>	<u>001</u>	Nov 04, 1996
<u>AP</u>			<u>2MG/ML</u>	<u>A202354</u>	<u>001</u>	Feb 25, 2016
<u>AP</u>		MYLAN LABS LTD	<u>2MG/ML</u>	<u>A201044</u>	<u>001</u>	Feb 07, 2017
<u>AP</u>		ZYDUS PHARMS	<u>2MG/ML</u>	<u>A202360</u>	<u>001</u>	Jul 18, 2014

ETONOGESTREL

IMPLANT; IMPLANTATION

NEXPLANON

+!	ORGANON	68MG/IMPLANT	<u>N021529</u>	<u>002</u>	May 31, 2011

ETOPOSIDE

CAPSULE; ORAL

ETOPOSIDE

!	MYLAN	50MG	<u>A075635</u>	<u>001</u>	Sep 19, 2001

INJECTABLE; INJECTION

ETOPOSIDE

<u>AP</u>		ACCORD HLTHCARE	<u>20MG/ML</u>	<u>A074513</u>	<u>001</u>	Mar 14, 1996
<u>AP</u>	!	FRESENIUS KABI USA	<u>20MG/ML</u>	<u>A074983</u>	<u>001</u>	Sep 30, 1998
<u>AP</u>		HIKMA	<u>20MG/ML</u>	<u>A074290</u>	<u>001</u>	Jul 17, 1995
<u>AP</u>		TEVA PHARMS USA	<u>20MG/ML</u>	<u>A074529</u>	<u>001</u>	Jul 24, 1996

ETOPOSIDE PHOSPHATE

INJECTABLE; INJECTION

ETOPOPHOS PRESERVATIVE FREE

+!	CHEPLAPHARM	EQ 100MG BASE/VIAL	<u>N020457</u>	<u>001</u>	May 17, 1996

ETRAVIRINE

TABLET; ORAL

ETRAVIRINE

<u>AB</u>		AMNEAL	<u>100MG</u>	<u>A214196</u>	<u>002</u>	Jun 14, 2021
<u>AB</u>			<u>200MG</u>	<u>A214196</u>	<u>003</u>	Jun 14, 2021
<u>AB</u>		CARNEGIE	<u>100MG</u>	<u>A215402</u>	<u>001</u>	Apr 13, 2022
<u>AB</u>			<u>200MG</u>	<u>A215402</u>	<u>002</u>	Apr 13, 2022

INTELENCE

<u>AB</u>	+	JANSSSEN R AND D	<u>100MG</u>	<u>N022187</u>	<u>001</u>	Jan 18, 2008
<u>AB</u>	+!		<u>200MG</u>	<u>N022187</u>	<u>002</u>	Dec 22, 2010
	+		25MG	<u>N022187</u>	<u>003</u>	Mar 26, 2012

PRESCRIPTION DRUG PRODUCT LIST

3-189 (of 474)

EVEROLIMUS

TABLET; ORAL

AFINITOR

<u>AB</u>	+	NOVARTIS	<u>2.5MG</u>	<u>N022334</u>	<u>003</u>	Jul 09, 2010
<u>AB</u>	+	!	<u>5MG</u>	<u>N022334</u>	<u>001</u>	Mar 30, 2009
<u>AB</u>	+		<u>7.5MG</u>	<u>N022334</u>	<u>004</u>	Mar 30, 2012
<u>AB</u>	+		<u>10MG</u>	<u>N022334</u>	<u>002</u>	Mar 30, 2009

EVEROLIMUS

<u>AB</u>		ALKEM LABS LTD	<u>0.25MG</u>	<u>A214138</u>	<u>001</u>	Nov 26, 2021
<u>AB</u>			<u>0.5MG</u>	<u>A214138</u>	<u>002</u>	Nov 26, 2021
<u>AB</u>			<u>0.75MG</u>	<u>A214138</u>	<u>003</u>	Nov 26, 2021
<u>AB</u>			<u>1MG</u>	<u>A214138</u>	<u>004</u>	Nov 26, 2021
<u>AB</u>		BIOCON PHARMA	<u>2.5MG</u>	<u>A214182</u>	<u>001</u>	Feb 11, 2021
<u>AB</u>			<u>5MG</u>	<u>A214182</u>	<u>002</u>	Feb 11, 2021
<u>AB</u>			<u>7.5MG</u>	<u>A214182</u>	<u>003</u>	Feb 11, 2021
<u>AB</u>			<u>10MG</u>	<u>A214182</u>	<u>004</u>	Feb 11, 2021
<u>AB</u>		BRECKENRIDGE	<u>0.25MG</u>	<u>A205432</u>	<u>001</u>	May 20, 2021
<u>AB</u>			<u>0.5MG</u>	<u>A205432</u>	<u>002</u>	May 20, 2021
<u>AB</u>			<u>0.75MG</u>	<u>A205432</u>	<u>003</u>	May 20, 2021
<u>AB</u>			<u>2.5MG</u>	<u>A205426</u>	<u>001</u>	Mar 05, 2021
<u>AB</u>			<u>5MG</u>	<u>A205426</u>	<u>002</u>	Mar 05, 2021
<u>AB</u>			<u>7.5MG</u>	<u>A205426</u>	<u>003</u>	Mar 05, 2021
<u>AB</u>			<u>10MG</u>	<u>A205426</u>	<u>004</u>	Mar 05, 2021
<u>AB</u>		HIKMA	<u>0.25MG</u>	<u>A206133</u>	<u>001</u>	Apr 12, 2018
<u>AB</u>			<u>0.5MG</u>	<u>A206133</u>	<u>002</u>	Apr 12, 2018
<u>AB</u>			<u>0.75MG</u>	<u>A206133</u>	<u>003</u>	Apr 12, 2018
<u>AB</u>			<u>1MG</u>	<u>A206133</u>	<u>004</u>	Nov 18, 2021
<u>AB</u>			<u>2.5MG</u>	<u>A207486</u>	<u>001</u>	Jun 08, 2020
<u>AB</u>			<u>5MG</u>	<u>A207486</u>	<u>002</u>	Jun 08, 2020
<u>AB</u>			<u>7.5MG</u>	<u>A207486</u>	<u>003</u>	Jun 08, 2020
<u>AB</u>			<u>10MG</u>	<u>A207486</u>	<u>004</u>	Nov 23, 2021
<u>AB</u>		MYLAN	<u>2.5MG</u>	<u>A212936</u>	<u>001</u>	Jun 08, 2020
<u>AB</u>			<u>5MG</u>	<u>A212936</u>	<u>002</u>	Jun 08, 2020
<u>AB</u>			<u>7.5MG</u>	<u>A212936</u>	<u>003</u>	Jun 08, 2020
<u>AB</u>			<u>10MG</u>	<u>A212936</u>	<u>004</u>	Jun 08, 2020
<u>AB</u>		PAR PHARM	<u>0.25MG</u>	<u>A205775</u>	<u>001</u>	Oct 18, 2021
<u>AB</u>			<u>0.5MG</u>	<u>A205775</u>	<u>002</u>	Oct 18, 2021
<u>AB</u>			<u>0.75MG</u>	<u>A205775</u>	<u>003</u>	Oct 18, 2021
<u>AB</u>			<u>1MG</u>	<u>A205775</u>	<u>004</u>	Oct 18, 2021
<u>AB</u>			<u>2.5MG</u>	<u>A207934</u>	<u>001</u>	Dec 09, 2019
<u>AB</u>			<u>5MG</u>	<u>A207934</u>	<u>002</u>	Dec 09, 2019
<u>AB</u>			<u>7.5MG</u>	<u>A207934</u>	<u>003</u>	Dec 09, 2019
<u>AB</u>			<u>10MG</u>	<u>A207934</u>	<u>004</u>	Dec 09, 2020
<u>AB</u>		TEVA PHARMS USA	<u>2.5MG</u>	<u>A210050</u>	<u>001</u>	Dec 09, 2019
<u>AB</u>			<u>5MG</u>	<u>A210050</u>	<u>002</u>	Dec 09, 2019
<u>AB</u>			<u>7.5MG</u>	<u>A210050</u>	<u>003</u>	Dec 09, 2019

ZORTRESS

<u>AB</u>	+	NOVARTIS	<u>0.25MG</u>	<u>N021560</u>	<u>001</u>	Apr 20, 2010
<u>AB</u>	+		<u>0.5MG</u>	<u>N021560</u>	<u>002</u>	Apr 20, 2010
<u>AB</u>	+		<u>0.75MG</u>	<u>N021560</u>	<u>003</u>	Apr 20, 2010
<u>AB</u>	+	!	<u>1MG</u>	<u>N021560</u>	<u>004</u>	Aug 10, 2018

TABLET, FOR SUSPENSION; ORAL

AFINITOR DISPERZ

<u>AB</u>	+	NOVARTIS PHARM	<u>2MG</u>	<u>N203985</u>	<u>001</u>	Aug 29, 2012
<u>AB</u>	+		<u>3MG</u>	<u>N203985</u>	<u>002</u>	Aug 29, 2012
<u>AB</u>	+	!	<u>5MG</u>	<u>N203985</u>	<u>003</u>	Aug 29, 2012

EVEROLIMUS

<u>AB</u>		MYLAN	<u>2MG</u>	<u>A210130</u>	<u>001</u>	Apr 19, 2019
<u>AB</u>			<u>3MG</u>	<u>A210130</u>	<u>002</u>	Apr 19, 2019
<u>AB</u>			<u>5MG</u>	<u>A210130</u>	<u>003</u>	Apr 19, 2019

EXEMESTANE

TABLET; ORAL

AROMASIN

<u>AB</u>	+	!	PFIZER	<u>25MG</u>	<u>N020753</u>	<u>001</u>	Oct 21, 1999

EXEMESTANE

<u>AB</u>		ALVOGEN	<u>25MG</u>	<u>A200898</u>	<u>001</u>	Jul 28, 2014
<u>AB</u>		BRECKENRIDGE	<u>25MG</u>	<u>A211031</u>	<u>001</u>	Feb 21, 2019
<u>AB</u>		CIPLA	<u>25MG</u>	<u>A210323</u>	<u>001</u>	Apr 27, 2018
<u>AB</u>		EUGIA PHARMA	<u>25MG</u>	<u>A216454</u>	<u>001</u>	May 20, 2022
<u>AB</u>		HIKMA	<u>25MG</u>	<u>A077431</u>	<u>001</u>	Apr 01, 2011
<u>AB</u>		QILU	<u>25MG</u>	<u>A213547</u>	<u>001</u>	Apr 13, 2020
<u>AB</u>		RISING	<u>25MG</u>	<u>A203315</u>	<u>001</u>	Mar 10, 2017

PRESCRIPTION DRUG PRODUCT LIST

3-190 (of 474)

EXEMESTANE

TABLET; ORAL

EXEMESTANE

AB	UPSHER SMITH LABS	25MG	<u>A209208</u>	<u>001</u>	Jul 26, 2017
AB	ZYDUS PHARMS	25MG	<u>A202602</u>	<u>001</u>	Oct 03, 2018

EXENATIDE SYNTHETIC

INJECTABLE; SUBCUTANEOUS

BYETTA

+	!	ASTRAZENECA AB	300MCG/1.2ML (250MCG/ML)	N021773	001	Apr 28, 2005
+	!		600MCG/2.4ML (250MCG/ML)	N021773	002	Apr 28, 2005

SUSPENSION, EXTENDED RELEASE; SUBCUTANEOUS

BYDUREON BCISE

+	!	ASTRAZENECA AB	2MG/0.85ML (2MG/0.85ML)	N209210	001	Oct 20, 2017

EZETIMIBE

TABLET; ORAL

EZETIMIBE

AB	ACCORD HLTHCARE	10MG	<u>A211550</u>	<u>001</u>	Oct 26, 2018
AB	ALKEM LABS LTD	10MG	<u>A209234</u>	<u>001</u>	Dec 21, 2017
AB	AMNEAL PHARMS CO	10MG	<u>A208803</u>	<u>001</u>	Jun 12, 2017
AB	AUROBINDO PHARMA	10MG	<u>A209838</u>	<u>001</u>	Aug 25, 2017
AB	GLENMARK PHARMS LTD	10MG	<u>A078560</u>	<u>001</u>	Jun 26, 2015
AB	HETERO LABS LTD III	10MG	<u>A210859</u>	<u>001</u>	Jul 26, 2022
AB	OHM LABS INC	10MG	<u>A207311</u>	<u>001</u>	Jun 12, 2017
AB	ORIENT PHARMA	10MG	<u>A215693</u>	<u>001</u>	Sep 13, 2022
AB	SANDOZ INC	10MG	<u>A203931</u>	<u>001</u>	Jun 12, 2017
AB	SCIEGEN PHARMS INC	10MG	<u>A210673</u>	<u>001</u>	Oct 23, 2020
AB	WATSON LABS INC	10MG	<u>A200831</u>	<u>001</u>	Jun 12, 2017
AB	ZYDUS PHARMS	10MG	<u>A204331</u>	<u>001</u>	Jun 12, 2017

ZETIA

AB	+	!	ORGANON	10MG	<u>N021445</u>	<u>001</u>	Oct 25, 2002

EZETIMIBE; SIMVASTATIN

TABLET; ORAL

EZETIMIBE AND SIMVASTATIN

AB	ALKEM LABS LTD	10MG; 10MG	<u>A209222</u>	<u>001</u>	Dec 22, 2017
AB		10MG; 20MG	<u>A209222</u>	<u>002</u>	Dec 22, 2017
AB		10MG; 40MG	<u>A209222</u>	<u>003</u>	Dec 22, 2017
AB		10MG; 80MG	<u>A209222</u>	<u>004</u>	Dec 22, 2017
AB	AMNEAL PHARMS CO	10MG; 10MG	<u>A208831</u>	<u>001</u>	Nov 21, 2017
AB		10MG; 20MG	<u>A208831</u>	<u>002</u>	Nov 21, 2017
AB		10MG; 40MG	<u>A208831</u>	<u>003</u>	Nov 21, 2017
AB		10MG; 80MG	<u>A208831</u>	<u>004</u>	Nov 21, 2017
AB	DR REDDYS LABS SA	10MG; 10MG	<u>A200909</u>	<u>001</u>	Apr 26, 2017
AB		10MG; 20MG	<u>A200909</u>	<u>002</u>	Apr 26, 2017
AB		10MG; 40MG	<u>A200909</u>	<u>003</u>	Apr 26, 2017
AB		10MG; 80MG	<u>A200909</u>	<u>004</u>	Apr 26, 2017
AB	GLENMARK PHARMS LTD	10MG; 10MG	<u>A208699</u>	<u>001</u>	Jun 27, 2019
AB		10MG; 20MG	<u>A208699</u>	<u>002</u>	Jun 27, 2019
AB		10MG; 40MG	<u>A208699</u>	<u>003</u>	Jun 27, 2019
AB		10MG; 80MG	<u>A208699</u>	<u>004</u>	Jun 27, 2019
AB	WATSON LABS INC	10MG; 10MG	<u>A202968</u>	<u>001</u>	Apr 26, 2017
AB		10MG; 20MG	<u>A202968</u>	<u>002</u>	Apr 26, 2017
AB		10MG; 40MG	<u>A202968</u>	<u>003</u>	Apr 26, 2017
AB		10MG; 80MG	<u>A202968</u>	<u>004</u>	Apr 26, 2017

VYTORIN

AB	+	ORGANON	10MG; 10MG	<u>N021687</u>	<u>001</u>	Jul 23, 2004
AB	+		10MG; 20MG	<u>N021687</u>	<u>002</u>	Jul 23, 2004
AB	+		10MG; 40MG	<u>N021687</u>	<u>003</u>	Jul 23, 2004
AB	+	!	10MG; 80MG	<u>N021687</u>	<u>004</u>	Jul 23, 2004

FAMCICLOVIR

TABLET; ORAL

FAMCICLOVIR

AB	APOTEX	125MG	<u>A091480</u>	<u>001</u>	Jul 22, 2011
AB		250MG	<u>A091480</u>	<u>002</u>	Jul 22, 2011
AB		500MG	<u>A091480</u>	<u>003</u>	Jul 22, 2011
AB	AUROBINDO PHARMA LTD	125MG	<u>A091114</u>	<u>001</u>	Mar 21, 2011
AB		250MG	<u>A091114</u>	<u>002</u>	Mar 21, 2011
AB		500MG	<u>A091114</u>	<u>003</u>	Mar 21, 2011
AB	HETERO LABS LTD V	125MG	<u>A202438</u>	<u>001</u>	Sep 10, 2014
AB		250MG	<u>A202438</u>	<u>002</u>	Sep 10, 2014
AB		500MG	<u>A202438</u>	<u>003</u>	Sep 10, 2014

PRESCRIPTION DRUG PRODUCT LIST

3-191 (of 474)

FAMCICLOVIR

TABLET; ORAL

FAMCICLOVIR

<u>AB</u>	MACLEODS PHARMS LTD	<u>125MG</u>	<u>A201022</u>	<u>001</u>	Jan 12, 2012
<u>AB</u>		<u>250MG</u>	<u>A201022</u>	<u>002</u>	Jan 12, 2012
<u>AB</u>		<u>500MG</u>	<u>A201022</u>	<u>003</u>	Jan 12, 2012
<u>AB</u>	TEVA PHARMS	<u>125MG</u>	<u>A077487</u>	<u>001</u>	Aug 24, 2007
<u>AB</u>		<u>250MG</u>	<u>A077487</u>	<u>002</u>	Aug 24, 2007
<u>AB</u>	!	<u>500MG</u>	<u>A077487</u>	<u>003</u>	Aug 24, 2007

FAMOTIDINE

FOR SUSPENSION; ORAL

FAMOTIDINE

<u>AB</u>	AKORN	<u>40MG/5ML</u>	<u>A201995</u>	<u>001</u>	May 30, 2014
<u>AB</u>	AMNEALS PHARMS	<u>40MG/5ML</u>	<u>A216427</u>	<u>001</u>	Aug 04, 2022
<u>AB</u>	! LUPIN LTD	<u>40MG/5ML</u>	<u>A090440</u>	<u>001</u>	Jun 29, 2010
<u>AB</u>	NAVINTA LLC	<u>40MG/5ML</u>	<u>A091020</u>	<u>001</u>	May 27, 2010
<u>AB</u>	NOVEL LABS INC	<u>40MG/5ML</u>	<u>A201695</u>	<u>001</u>	Dec 17, 2012
<u>AB</u>	NOVITIUM PHARMA	<u>40MG/5ML</u>	<u>A215043</u>	<u>001</u>	Apr 20, 2021

INJECTABLE; INJECTION

FAMOTIDINE

<u>AP</u>	ATHENEX INC	<u>10MG/ML</u>	<u>A075651</u>	<u>001</u>	Apr 16, 2001
<u>AP</u>		<u>10MG/ML</u>	<u>A075684</u>	<u>001</u>	Apr 16, 2001
<u>AP</u>	FRESENIUS KABI USA	<u>10MG/ML</u>	<u>A075709</u>	<u>001</u>	Apr 16, 2001
<u>AP</u>	! HIKMA	<u>10MG/ML</u>	<u>A075488</u>	<u>001</u>	Apr 16, 2001
<u>AP</u>	MYLAN LABS LTD	<u>10MG/ML</u>	<u>A078641</u>	<u>001</u>	Jun 25, 2008
<u>AP</u>	ZYDUS PHARMS	<u>10MG/ML</u>	<u>A215828</u>	<u>001</u>	Nov 22, 2022

FAMOTIDINE PRESERVATIVE FREE

<u>AP</u>	ATHENEX INC	<u>10MG/ML</u>	<u>A075622</u>	<u>001</u>	Apr 16, 2001
<u>AP</u>		<u>10MG/ML</u>	<u>A075825</u>	<u>001</u>	Apr 17, 2001
<u>AP</u>	FRESENIUS KABI USA	<u>10MG/ML</u>	<u>A075813</u>	<u>001</u>	Apr 16, 2001
<u>AP</u>	! HIKMA	<u>10MG/ML</u>	<u>A075486</u>	<u>001</u>	Apr 16, 2001
<u>AP</u>	MYLAN LABS LTD	<u>10MG/ML</u>	<u>A078642</u>	<u>001</u>	Jun 25, 2008

FAMOTIDINE PRESERVATIVE FREE IN PLASTIC CONTAINER

!	BAXTER HLTHCARE	0.4MG/ML	A075591	001	May 10, 2001

TABLET; ORAL

FAMOTIDINE

<u>AB</u>	ALEMBIC PHARMS LTD	<u>20MG</u>	<u>A078916</u>	<u>001</u>	May 22, 2009
<u>AB</u>		<u>40MG</u>	<u>A078916</u>	<u>002</u>	May 22, 2009
<u>AB</u>	ALKEM LABS LTD	<u>20MG</u>	<u>A215630</u>	<u>001</u>	Jan 07, 2022
<u>AB</u>		<u>40MG</u>	<u>A215630</u>	<u>002</u>	Jan 07, 2022
<u>AB</u>	ANNORA PHARMA	<u>20MG</u>	<u>A215767</u>	<u>001</u>	Nov 04, 2021
<u>AB</u>		<u>40MG</u>	<u>A215767</u>	<u>002</u>	Nov 04, 2021
<u>AB</u>	APOTEX	<u>20MG</u>	<u>A075611</u>	<u>001</u>	Jul 23, 2001
<u>AB</u>		<u>40MG</u>	<u>A075611</u>	<u>002</u>	Jul 23, 2001
<u>AB</u>	ASCENT PHARMS INC	<u>20MG</u>	<u>A215689</u>	<u>001</u>	Oct 15, 2021
<u>AB</u>		<u>40MG</u>	<u>A215689</u>	<u>002</u>	Oct 15, 2021
<u>AB</u>	AUROBINDO PHARMA LTD	<u>20MG</u>	<u>A206530</u>	<u>001</u>	Dec 22, 2015
<u>AB</u>	!	<u>40MG</u>	<u>A206530</u>	<u>002</u>	Dec 22, 2015
<u>AB</u>	CARLSBAD	<u>20MG</u>	<u>A075805</u>	<u>001</u>	Apr 16, 2001
<u>AB</u>		<u>40MG</u>	<u>A075805</u>	<u>002</u>	Apr 16, 2001
<u>AB</u>	CELLTRION	<u>20MG</u>	<u>A075786</u>	<u>001</u>	Apr 16, 2001
<u>AB</u>		<u>40MG</u>	<u>A075786</u>	<u>002</u>	Apr 16, 2001
<u>AB</u>	DR REDDYS LABS LTD	<u>20MG</u>	<u>A075718</u>	<u>001</u>	Apr 16, 2001
<u>AB</u>		<u>40MG</u>	<u>A075718</u>	<u>002</u>	Apr 16, 2001
<u>AB</u>	IVAX SUB TEVA PHARMS	<u>20MG</u>	<u>A075511</u>	<u>001</u>	Apr 16, 2001
<u>AB</u>		<u>40MG</u>	<u>A075511</u>	<u>002</u>	Apr 16, 2001
<u>AB</u>	ZYDUS PHARMS	<u>20MG</u>	<u>A216441</u>	<u>001</u>	Jun 03, 2022
<u>AB</u>		<u>40MG</u>	<u>A216441</u>	<u>002</u>	Jun 03, 2022

FAMOTIDINE; IBUPROFEN

TABLET; ORAL

DUEXIS

<u>AB</u>	+! HORIZON	<u>26.6MG;800MG</u>	<u>N022519</u>	<u>001</u>	Apr 23, 2011

IBUPROFEN AND FAMOTIDINE

<u>AB</u>	ALKEM LABS LTD	<u>26.6MG;800MG</u>	<u>A211890</u>	<u>001</u>	Aug 03, 2021
<u>AB</u>	TEVA PHARMS USA	<u>26.6MG;800MG</u>	<u>A211278</u>	<u>001</u>	Oct 29, 2021

PRESCRIPTION DRUG PRODUCT LIST

3-192 (of 474)

FEBUXOSTAT

TABLET; ORAL

FEBUXOSTAT

<u>AB</u>	ALEMBIC PHARMS	<u>40MG</u>	<u>A205421</u>	<u>001</u>	Jul 01, 2019
<u>AB</u>		<u>80MG</u>	<u>A205421</u>	<u>002</u>	Jul 01, 2019
<u>AB</u>	ALKEM LABS LTD	<u>40MG</u>	<u>A212924</u>	<u>001</u>	Dec 07, 2021
<u>AB</u>		<u>80MG</u>	<u>A212924</u>	<u>002</u>	Dec 07, 2021
<u>AB</u>	DR REDDYS	<u>40MG</u>	<u>A205374</u>	<u>001</u>	Oct 22, 2020
<u>AB</u>		<u>80MG</u>	<u>A205374</u>	<u>002</u>	Oct 22, 2020
<u>AB</u>	HIKMA	<u>40MG</u>	<u>A205414</u>	<u>001</u>	Oct 15, 2019
<u>AB</u>		<u>80MG</u>	<u>A205414</u>	<u>002</u>	Oct 15, 2019
<u>AB</u>	INDOCO	<u>40MG</u>	<u>A210292</u>	<u>001</u>	Dec 30, 2019
<u>AB</u>		<u>80MG</u>	<u>A210292</u>	<u>002</u>	Dec 30, 2019
<u>AB</u>	MSN	<u>40MG</u>	<u>A210461</u>	<u>001</u>	Dec 30, 2019
<u>AB</u>		<u>80MG</u>	<u>A210461</u>	<u>002</u>	Dec 30, 2019
<u>AB</u>	MYLAN	<u>40MG</u>	<u>A205385</u>	<u>001</u>	Jul 01, 2019
<u>AB</u>		<u>80MG</u>	<u>A205385</u>	<u>002</u>	Jul 01, 2019
<u>AB</u>	PRINSTON INC	<u>40MG</u>	<u>A206266</u>	<u>001</u>	Mar 28, 2022
<u>AB</u>		<u>80MG</u>	<u>A206266</u>	<u>002</u>	Mar 28, 2022
<u>AB</u>	SUN PHARM	<u>40MG</u>	<u>A205467</u>	<u>001</u>	Jul 01, 2019
<u>AB</u>		<u>80MG</u>	<u>A205467</u>	<u>002</u>	Jul 01, 2019
<u>AB</u>	SUNSHINE	<u>40MG</u>	<u>A213069</u>	<u>001</u>	Jun 02, 2020
<u>AB</u>		<u>80MG</u>	<u>A213069</u>	<u>002</u>	Jun 02, 2020
<u>AB</u>	ZYDUS PHARMS	<u>40MG</u>	<u>A205443</u>	<u>001</u>	Jan 09, 2023
<u>AB</u>		<u>80MG</u>	<u>A205443</u>	<u>002</u>	Jan 09, 2023

ULORIC

<u>AB</u>	+	TAKEDA PHARMS USA	<u>40MG</u>	<u>N021856</u>	<u>001</u>	Feb 13, 2009
<u>AB</u>	+	!	<u>80MG</u>	<u>N021856</u>	<u>002</u>	Feb 13, 2009

FEDRATINIB HYDROCHLORIDE

CAPSULE; ORAL

INREBIC

+! IMPACT

EQ 100MG BASE

N212327 001 Aug 16, 2019

FELBAMATE

SUSPENSION; ORAL

FELBAMATE

<u>AB</u>	AMNEAL PHARMS	<u>600MG/5ML</u>	<u>A202385</u>	<u>001</u>	Dec 16, 2011
<u>AB</u>	NOVITIUM PHARMA	<u>600MG/5ML</u>	<u>A211333</u>	<u>001</u>	May 31, 2019
<u>AB</u>	TARO	<u>600MG/5ML</u>	<u>A206314</u>	<u>001</u>	Jun 16, 2017

FELBATOL

<u>AB</u>	+	!	MYLAN SPECIALITY LP	<u>600MG/5ML</u>	<u>N020189</u>	<u>003</u>	Jul 29, 1993

TABLET; ORAL

FELBAMATE

<u>AB</u>	ALVOGEN	<u>400MG</u>	<u>A204595</u>	<u>001</u>	Jan 11, 2016
<u>AB</u>		<u>600MG</u>	<u>A204595</u>	<u>002</u>	Jan 11, 2016
<u>AB</u>	AMNEAL PHARMS	<u>400MG</u>	<u>A201680</u>	<u>001</u>	Sep 13, 2011
<u>AB</u>		<u>600MG</u>	<u>A201680</u>	<u>002</u>	Sep 13, 2011
<u>AB</u>	ANI PHARMS	<u>400MG</u>	<u>A202284</u>	<u>001</u>	Nov 04, 2015
<u>AB</u>		<u>600MG</u>	<u>A202284</u>	<u>002</u>	Nov 04, 2015
<u>AB</u>	CADILA	<u>400MG</u>	<u>A208970</u>	<u>001</u>	May 30, 2017
<u>AB</u>		<u>600MG</u>	<u>A208970</u>	<u>002</u>	May 30, 2017
<u>AB</u>	TARO	<u>400MG</u>	<u>A207093</u>	<u>001</u>	Apr 20, 2017
<u>AB</u>		<u>600MG</u>	<u>A207093</u>	<u>002</u>	Apr 20, 2017

FELBATOL

<u>AB</u>	+	MYLAN SPECIALITY LP	<u>400MG</u>	<u>N020189</u>	<u>001</u>	Jul 29, 1993
<u>AB</u>	+	!	<u>600MG</u>	<u>N020189</u>	<u>002</u>	Jul 29, 1993

FELODIPINE

TABLET, EXTENDED RELEASE; ORAL

FELODIPINE

<u>AB</u>	AUROBINDO PHARMA LTD	<u>2.5MG</u>	<u>A203417</u>	<u>001</u>	Jan 17, 2013
<u>AB</u>		<u>5MG</u>	<u>A203417</u>	<u>002</u>	Jan 17, 2013
<u>AB</u>		<u>10MG</u>	<u>A203417</u>	<u>003</u>	Jan 17, 2013
<u>AB</u>	GLENMARK GENERICS	<u>2.5MG</u>	<u>A090365</u>	<u>001</u>	Dec 17, 2010
<u>AB</u>		<u>5MG</u>	<u>A090365</u>	<u>002</u>	Dec 17, 2010
<u>AB</u>		<u>10MG</u>	<u>A090365</u>	<u>003</u>	Dec 17, 2010
<u>AB</u>	HERITAGE PHARMS	<u>2.5MG</u>	<u>A201964</u>	<u>001</u>	Nov 08, 2013
<u>AB</u>		<u>5MG</u>	<u>A201964</u>	<u>002</u>	Nov 08, 2013
<u>AB</u>		<u>10MG</u>	<u>A201964</u>	<u>003</u>	Nov 08, 2013
<u>AB</u>	ORBION PHARMS	<u>2.5MG</u>	<u>A203032</u>	<u>001</u>	May 21, 2015
<u>AB</u>		<u>5MG</u>	<u>A203032</u>	<u>002</u>	May 21, 2015
<u>AB</u>		<u>10MG</u>	<u>A203032</u>	<u>003</u>	May 21, 2015

PRESCRIPTION DRUG PRODUCT LIST

3-193 (of 474)

FELODIPINE

TABLET, EXTENDED RELEASE;ORAL

FELODIPINE

<u>AB</u>	SUN PHARM INDS LTD	<u>2.5MG</u>	<u>A091200</u>	<u>001</u>	Dec 13, 2013
<u>AB</u>		<u>5MG</u>	<u>A091200</u>	<u>002</u>	Dec 13, 2013
<u>AB</u>		<u>10MG</u>	<u>A091200</u>	<u>003</u>	Dec 13, 2013
<u>AB</u>	SUN PHARM INDUSTRIES	<u>2.5MG</u>	<u>A075896</u>	<u>001</u>	Nov 02, 2004
<u>AB</u>		<u>5MG</u>	<u>A075896</u>	<u>002</u>	Nov 02, 2004
<u>AB</u>		<u>10MG</u>	<u>A075896</u>	<u>003</u>	Nov 02, 2004
<u>AB</u>	TORRENT PHARMS LTD	<u>2.5MG</u>	<u>A202170</u>	<u>001</u>	Nov 28, 2011
<u>AB</u>		<u>5MG</u>	<u>A202170</u>	<u>002</u>	Nov 28, 2011
<u>AB</u>	!	<u>10MG</u>	<u>A202170</u>	<u>003</u>	Nov 28, 2011
<u>AB</u>	VINTAGE PHARMS LLC	<u>2.5MG</u>	<u>A200815</u>	<u>001</u>	Oct 28, 2011
<u>AB</u>		<u>5MG</u>	<u>A200815</u>	<u>002</u>	Oct 28, 2011
<u>AB</u>		<u>10MG</u>	<u>A200815</u>	<u>003</u>	Oct 28, 2011
<u>AB</u>	YILING	<u>2.5MG</u>	<u>A210847</u>	<u>001</u>	Oct 26, 2018
<u>AB</u>		<u>5MG</u>	<u>A210847</u>	<u>002</u>	Oct 26, 2018
<u>AB</u>		<u>10MG</u>	<u>A210847</u>	<u>003</u>	Oct 26, 2018
<u>AB</u>	YUNG SHIN PHARM	<u>2.5MG</u>	<u>A204800</u>	<u>001</u>	Apr 29, 2019
<u>AB</u>		<u>5MG</u>	<u>A204800</u>	<u>002</u>	Apr 29, 2019
<u>AB</u>		<u>10MG</u>	<u>A204800</u>	<u>003</u>	Apr 29, 2019

FENFLURAMINE HYDROCHLORIDE

SOLUTION;ORAL

FINTEPLA

+! ZOGENIX INC

EQ 2.2MG BASE/ML

N212102 001 Jun 25, 2020

FENOFIBRATE

CAPSULE;ORAL

ANTARA (MICRONIZED)

<u>AB</u>	+	LUPIN	<u>43MG</u>	<u>N021695</u>	<u>001</u>	Nov 30, 2004
<u>AB</u>	+	!	<u>130MG</u>	<u>N021695</u>	<u>003</u>	Nov 30, 2004

FENOFIBRATE

<u>AB</u>	SUN PHARM INDS LTD	<u>43MG</u>	<u>A201748</u>	<u>001</u>	Oct 31, 2014
<u>AB</u>		<u>130MG</u>	<u>A201748</u>	<u>002</u>	Oct 31, 2014

FENOFIBRATE (MICRONIZED)

<u>AB</u>	AJANTA PHARMA LTD	<u>67MG</u>	<u>A210705</u>	<u>001</u>	Sep 10, 2018
<u>AB</u>		<u>134MG</u>	<u>A210705</u>	<u>002</u>	Sep 10, 2018
<u>AB</u>	!	<u>200MG</u>	<u>A210705</u>	<u>003</u>	Sep 10, 2018
<u>AB</u>	ALEMBIC PHARMS	<u>67MG</u>	<u>A213842</u>	<u>001</u>	Oct 19, 2020
<u>AB</u>		<u>134MG</u>	<u>A213842</u>	<u>002</u>	Oct 19, 2020
<u>AB</u>		<u>200MG</u>	<u>A213842</u>	<u>003</u>	Oct 19, 2020
<u>AB</u>	ANI PHARMS	<u>67MG</u>	<u>A209504</u>	<u>001</u>	Apr 30, 2018
<u>AB</u>		<u>134MG</u>	<u>A209504</u>	<u>002</u>	Apr 30, 2018
<u>AB</u>		<u>200MG</u>	<u>A209504</u>	<u>003</u>	Apr 30, 2018
<u>AB</u>	APOTEX	<u>43MG</u>	<u>A202252</u>	<u>001</u>	Jul 26, 2013
<u>AB</u>		<u>130MG</u>	<u>A202252</u>	<u>002</u>	Jul 26, 2013
<u>AB</u>	AUROBINDO PHARMA LTD	<u>67MG</u>	<u>A212232</u>	<u>001</u>	Sep 20, 2021
<u>AB</u>		<u>134MG</u>	<u>A212232</u>	<u>002</u>	Sep 20, 2021
<u>AB</u>		<u>200MG</u>	<u>A212232</u>	<u>003</u>	Sep 20, 2021
<u>AB</u>	DR REDDYS LABS SA	<u>43MG</u>	<u>A090859</u>	<u>001</u>	Mar 01, 2012
<u>AB</u>		<u>130MG</u>	<u>A090859</u>	<u>002</u>	Mar 01, 2012
<u>AB</u>	GLENMARK PHARMS LTD	<u>67MG</u>	<u>A205566</u>	<u>001</u>	Apr 07, 2017
<u>AB</u>		<u>134MG</u>	<u>A205566</u>	<u>002</u>	Apr 07, 2017
<u>AB</u>		<u>200MG</u>	<u>A205566</u>	<u>003</u>	Apr 07, 2017
<u>AB</u>	INVAGEN PHARMS	<u>67MG</u>	<u>A207378</u>	<u>001</u>	Mar 28, 2017
<u>AB</u>		<u>134MG</u>	<u>A207378</u>	<u>002</u>	Mar 28, 2017
<u>AB</u>		<u>200MG</u>	<u>A207378</u>	<u>003</u>	Mar 28, 2017
<u>AB</u>	REYOUNG	<u>67MG</u>	<u>A207805</u>	<u>001</u>	Nov 16, 2017
<u>AB</u>		<u>134MG</u>	<u>A207805</u>	<u>002</u>	Nov 16, 2017
<u>AB</u>		<u>200MG</u>	<u>A207805</u>	<u>003</u>	Nov 16, 2017
<u>AB</u>	RHODES PHARMS	<u>67MG</u>	<u>A075753</u>	<u>001</u>	Sep 03, 2002
<u>AB</u>		<u>134MG</u>	<u>A075753</u>	<u>002</u>	Apr 09, 2002
<u>AB</u>		<u>200MG</u>	<u>A075753</u>	<u>003</u>	Apr 09, 2002
<u>AB</u>	TORRENT	<u>67MG</u>	<u>A210782</u>	<u>001</u>	Jun 26, 2018
<u>AB</u>		<u>134MG</u>	<u>A210782</u>	<u>002</u>	Jun 26, 2018
<u>AB</u>		<u>200MG</u>	<u>A210782</u>	<u>003</u>	Jun 26, 2018

ANTARA (MICRONIZED)

+! LUPIN

90MG

N021695 005 Oct 18, 2013

LIPOFEN

+ CIPHER PHARMS INC

50MG

N021612 001 Jan 11, 2006

+!

150MG

N021612 003 Jan 11, 2006

PRESCRIPTION DRUG PRODUCT LIST

3-194 (of 474)

FENOFIBRATE

TABLET; ORAL

FENOFIBRATE

<u>AB</u>	AJANTA PHARMA LTD	<u>54MG</u>	<u>A210138</u>	<u>001</u>	Jul 23, 2018
<u>AB</u>		<u>160MG</u>	<u>A210138</u>	<u>002</u>	Jul 23, 2018
<u>AB</u>	ALEMBIC LABS	<u>54MG</u>	<u>A209660</u>	<u>001</u>	Feb 11, 2019
<u>AB</u>		<u>160MG</u>	<u>A209660</u>	<u>002</u>	Feb 11, 2019
<u>AB</u>	ALEMBIC PHARMS	<u>48MG</u>	<u>A210476</u>	<u>001</u>	Aug 09, 2019
<u>AB</u>		<u>145MG</u>	<u>A210476</u>	<u>002</u>	Aug 09, 2019
<u>AB</u>	AMNEAL	<u>48MG</u>	<u>A209951</u>	<u>001</u>	Feb 09, 2018
<u>AB</u>		<u>54MG</u>	<u>A209950</u>	<u>001</u>	Mar 19, 2018
<u>AB</u>		<u>145MG</u>	<u>A209951</u>	<u>002</u>	Feb 09, 2018
<u>AB</u>		<u>160MG</u>	<u>A209950</u>	<u>002</u>	Mar 19, 2018
<u>AB</u>	AUROBINDO PHARMA	<u>48MG</u>	<u>A205118</u>	<u>001</u>	May 05, 2016
<u>AB</u>		<u>54MG</u>	<u>A216798</u>	<u>001</u>	Sep 27, 2022
<u>AB</u>		<u>145MG</u>	<u>A205118</u>	<u>002</u>	May 05, 2016
<u>AB</u>		<u>160MG</u>	<u>A216798</u>	<u>002</u>	Sep 27, 2022
<u>AB</u>	AUSTARPHARMA	<u>48MG</u>	<u>A208476</u>	<u>001</u>	Feb 10, 2021
<u>AB</u>		<u>54MG</u>	<u>A207803</u>	<u>001</u>	Dec 19, 2017
<u>AB</u>		<u>145MG</u>	<u>A208476</u>	<u>002</u>	Feb 10, 2021
<u>AB</u>		<u>160MG</u>	<u>A207803</u>	<u>002</u>	Dec 19, 2017
<u>AB</u>	CIPLA	<u>48MG</u>	<u>A208709</u>	<u>001</u>	Dec 15, 2016
<u>AB</u>		<u>145MG</u>	<u>A208709</u>	<u>002</u>	Dec 15, 2016
<u>AB</u>	DR REDDYS	<u>54MG</u>	<u>A210670</u>	<u>001</u>	Sep 06, 2019
<u>AB</u>		<u>160MG</u>	<u>A210670</u>	<u>002</u>	Sep 06, 2019
<u>AB</u>	GRAVITI PHARMS	<u>48MG</u>	<u>A211122</u>	<u>001</u>	Mar 18, 2020
<u>AB</u>		<u>54MG</u>	<u>A210606</u>	<u>001</u>	Aug 17, 2018
<u>AB</u>		<u>145MG</u>	<u>A211122</u>	<u>002</u>	Mar 18, 2020
<u>AB</u>		<u>160MG</u>	<u>A210606</u>	<u>002</u>	Aug 17, 2018
<u>AB</u>	HETERO LABS LTD III	<u>48MG</u>	<u>A204598</u>	<u>001</u>	Jul 12, 2016
<u>AB</u>		<u>145MG</u>	<u>A204598</u>	<u>002</u>	Jul 12, 2016
<u>AB</u>	IMPAX LABS	<u>54MG</u>	<u>A076509</u>	<u>001</u>	Mar 26, 2008
<u>AB</u>	!	<u>160MG</u>	<u>A076509</u>	<u>002</u>	Mar 26, 2008
<u>AB</u>	LUPIN LTD	<u>48MG</u>	<u>A090856</u>	<u>001</u>	Dec 23, 2011
<u>AB</u>		<u>54MG</u>	<u>A204019</u>	<u>001</u>	Aug 17, 2015
<u>AB</u>		<u>145MG</u>	<u>A090856</u>	<u>002</u>	Dec 23, 2011
<u>AB</u>		<u>160MG</u>	<u>A204019</u>	<u>002</u>	Aug 17, 2015
<u>AB</u>	MANKIND PHARMA	<u>54MG</u>	<u>A213864</u>	<u>001</u>	Jun 12, 2020
<u>AB</u>		<u>160MG</u>	<u>A213864</u>	<u>002</u>	Jun 12, 2020
<u>AB</u>	MYLAN	<u>54MG</u>	<u>A076520</u>	<u>001</u>	Oct 25, 2007
<u>AB</u>		<u>160MG</u>	<u>A076520</u>	<u>003</u>	Oct 25, 2007
<u>AB</u>	MYLAN PHARMS INC	<u>40MG</u>	<u>A204475</u>	<u>001</u>	Jun 23, 2016
<u>AB</u>		<u>48MG</u>	<u>A202856</u>	<u>001</u>	Dec 07, 2012
<u>AB</u>		<u>120MG</u>	<u>A204475</u>	<u>002</u>	Jun 23, 2016
<u>AB</u>		<u>145MG</u>	<u>A202856</u>	<u>002</u>	Dec 07, 2012
<u>AB</u>	PRINSTON INC	<u>48MG</u>	<u>A211080</u>	<u>001</u>	Aug 28, 2018
<u>AB</u>		<u>145MG</u>	<u>A211080</u>	<u>002</u>	Aug 28, 2018
<u>AB</u>	RHODES PHARMS	<u>54MG</u>	<u>A076433</u>	<u>001</u>	May 13, 2005
<u>AB</u>		<u>160MG</u>	<u>A076433</u>	<u>002</u>	May 13, 2005
<u>AB</u>	SUN PHARM	<u>48MG</u>	<u>A200884</u>	<u>001</u>	Sep 07, 2017
<u>AB</u>		<u>145MG</u>	<u>A200884</u>	<u>002</u>	Sep 07, 2017
<u>AB</u>	SUN PHARM INDS LTD	<u>54MG</u>	<u>A076635</u>	<u>001</u>	Oct 31, 2005
<u>AB</u>		<u>160MG</u>	<u>A076635</u>	<u>003</u>	Oct 31, 2005
<u>AB</u>	VALEANT PHARMS NORTH	<u>48MG</u>	<u>A090715</u>	<u>001</u>	Apr 05, 2012
<u>AB</u>		<u>145MG</u>	<u>A090715</u>	<u>002</u>	Apr 05, 2012
<u>FENOGLIDE</u>					
<u>AB</u>	+ SALIX	<u>40MG</u>	<u>N022118</u>	<u>001</u>	Aug 10, 2007
<u>AB</u>	+!	<u>120MG</u>	<u>N022118</u>	<u>002</u>	Aug 10, 2007
<u>TRICOR</u>					
<u>AB</u>	+ ABBVIE	<u>48MG</u>	<u>N021656</u>	<u>001</u>	Nov 05, 2004
<u>AB</u>	+!	<u>145MG</u>	<u>N021656</u>	<u>002</u>	Nov 05, 2004
TRIGLIDE					
BX	+ SKYEPHARMA AG	160MG	N021350	002	May 07, 2005
FENOFIBRATE					
	SUN PHARM INDS LTD	107MG	A076635	002	Oct 31, 2005

PRESCRIPTION DRUG PRODUCT LIST

3-195 (of 474)

FENOLDOPAM MESYLATE

INJECTABLE; INJECTION

CORLOPAM

AP	+!	HOSPIRA	<u>EQ 10MG BASE/ML</u>	<u>N019922</u>	<u>001</u>	Sep 23, 1997

FENOLDOPAM MESYLATE

AP		HIKMA	<u>EQ 10MG BASE/ML</u>	<u>A076582</u>	<u>001</u>	Oct 12, 2004

AP		SANDOZ INC	<u>EQ 10MG BASE/ML</u>	<u>A077155</u>	<u>001</u>	Feb 15, 2005

FENOPROFEN CALCIUM

CAPSULE; ORAL

FENOPROFEN CALCIUM

AB		RISING	<u>EQ 400MG BASE</u>	<u>A214475</u>	<u>001</u>	Jul 18, 2022

NALFON

AB	+!	XSPIRE PHARMA	<u>EQ 400MG BASE</u>	<u>N017604</u>	<u>004</u>	Jul 21, 2009
	+		<u>EQ 200MG BASE</u>	<u>N017604</u>	<u>003</u>	

TABLET; ORAL

FENOPROFEN CALCIUM

!	XSPIRE PHARMA	<u>EQ 600MG BASE</u>	<u>A072267</u>	<u>001</u>	Aug 17, 1988

FENTANYL

FILM, EXTENDED RELEASE; TRANSDERMAL

FENTANYL-100

AB		KINDEVA	<u>100MCG/HR</u>	<u>A202097</u>	<u>005</u>	Nov 04, 2016

AB		MYLAN TECHNOLOGIES	<u>100MCG/HR</u>	<u>A076258</u>	<u>004</u>	Jan 28, 2005

AB		SPECGX LLC	<u>100MCG/HR</u>	<u>A077154</u>	<u>004</u>	Feb 09, 2011

FENTANYL-12

AB		KINDEVA	<u>12.5MCG/HR</u>	<u>A202097</u>	<u>001</u>	Nov 04, 2016

AB		MYLAN TECHNOLOGIES	<u>12.5MCG/HR</u>	<u>A076258</u>	<u>005</u>	Jan 23, 2007

AB		SPECGX LLC	<u>12.5MCG/HR</u>	<u>A077154</u>	<u>005</u>	Jun 11, 2015

FENTANYL-25

AB		KINDEVA	<u>25MCG/HR</u>	<u>A202097</u>	<u>002</u>	Nov 04, 2016

AB		MYLAN TECHNOLOGIES	<u>25MCG/HR</u>	<u>A076258</u>	<u>001</u>	Jan 28, 2005

AB	!	SPECGX LLC	<u>25MCG/HR</u>	<u>A077154</u>	<u>001</u>	Feb 09, 2011

FENTANYL-37

AB		MYLAN TECHNOLOGIES	<u>37.5MCG/HR</u>	<u>A076258</u>	<u>006</u>	Dec 29, 2014

AB		SPECGX LLC	<u>37.5MCG/HR</u>	<u>A077154</u>	<u>006</u>	Jan 14, 2020

FENTANYL-50

AB		KINDEVA	<u>50MCG/HR</u>	<u>A202097</u>	<u>003</u>	Nov 04, 2016

AB		MYLAN TECHNOLOGIES	<u>50MCG/HR</u>	<u>A076258</u>	<u>002</u>	Jan 28, 2005

AB		SPECGX LLC	<u>50MCG/HR</u>	<u>A077154</u>	<u>002</u>	Feb 09, 2011

FENTANYL-62

AB		MYLAN TECHNOLOGIES	<u>62.5MCG/HR</u>	<u>A076258</u>	<u>007</u>	Dec 29, 2014

AB		SPECGX LLC	<u>62.5MCG/HR</u>	<u>A077154</u>	<u>007</u>	Jan 14, 2020

FENTANYL-75

AB		KINDEVA	<u>75MCG/HR</u>	<u>A202097</u>	<u>004</u>	Nov 04, 2016

AB		MYLAN TECHNOLOGIES	<u>75MCG/HR</u>	<u>A076258</u>	<u>003</u>	Jan 28, 2005

AB		SPECGX LLC	<u>75MCG/HR</u>	<u>A077154</u>	<u>003</u>	Feb 09, 2011

FENTANYL-87

	MYLAN TECHNOLOGIES	<u>87.5MCG/HR</u>	<u>A076258</u>	<u>008</u>	Dec 29, 2014

FENTANYL CITRATE

INJECTABLE; INJECTION

FENTANYL CITRATE

AP		FRESENIUS KABI USA	<u>EQ 0.05MG BASE/ML</u>	<u>A212086</u>	<u>001</u>	Sep 01, 2020

AP		HOSPIRA	<u>EQ 0.05MG BASE/ML</u>	<u>N019115</u>	<u>001</u>	Jan 12, 1985

FENTANYL CITRATE PRESERVATIVE FREE

AP		FRESENIUS KABI USA	<u>EQ 0.05MG BASE/ML</u>	<u>A210762</u>	<u>001</u>	May 03, 2019

AP	+!	HIKMA	<u>EQ 0.05MG BASE/ML</u>	<u>N019101</u>	<u>001</u>	Jul 11, 1984

AP		HOSPIRA	<u>EQ 0.05MG BASE/ML</u>	<u>A072786</u>	<u>001</u>	Sep 24, 1991

SUBLIMAZE PRESERVATIVE FREE

AP	+!	AKORN	<u>EQ 0.05MG BASE/ML</u>	<u>N016619</u>	<u>001</u>	

TABLET; BUCCAL, SUBLINGUAL

FENTORA

+	CEPHALON	<u>EQ 0.1MG BASE</u>	<u>N021947</u>	<u>001</u>	Sep 25, 2006

+		<u>EQ 0.2MG BASE</u>	<u>N021947</u>	<u>002</u>	Sep 25, 2006

+!		<u>EQ 0.4MG BASE</u>	<u>N021947</u>	<u>003</u>	Sep 25, 2006

+		<u>EQ 0.6MG BASE</u>	<u>N021947</u>	<u>004</u>	Sep 25, 2006

+		<u>EQ 0.8MG BASE</u>	<u>N021947</u>	<u>005</u>	Sep 25, 2006

TROCHE/LOZENGE; TRANSMUCOSAL

ACTIQ

AB	+	CEPHALON	<u>EQ 0.2MG BASE</u>	<u>N020747</u>	<u>001</u>	Nov 04, 1998

AB	+!		<u>EQ 0.4MG BASE</u>	<u>N020747</u>	<u>002</u>	Nov 04, 1998

AB	+		<u>EQ 0.6MG BASE</u>	<u>N020747</u>	<u>003</u>	Nov 04, 1998

AB	+		<u>EQ 0.8MG BASE</u>	<u>N020747</u>	<u>004</u>	Nov 04, 1998

PRESCRIPTION DRUG PRODUCT LIST

3-196 (of 474)

FENTANYL CITRATE

TROCHE/LOZENGE; TRANSMUCOSAL

ACTIQ

AB	+	<u>EQ 1.2MG BASE</u>	<u>N020747</u>	<u>005</u>	Nov 04, 1998
AB	+	<u>EQ 1.6MG BASE</u>	<u>N020747</u>	<u>006</u>	Nov 04, 1998

FENTANYL CITRATE

AB	SPECGX LLC	<u>EQ 0.2MG BASE</u>	<u>A078907</u>	<u>001</u>	Oct 30, 2009
AB		<u>EQ 0.4MG BASE</u>	<u>A078907</u>	<u>002</u>	Oct 30, 2009
AB		<u>EQ 0.6MG BASE</u>	<u>A078907</u>	<u>003</u>	Oct 30, 2009
AB		<u>EQ 0.8MG BASE</u>	<u>A078907</u>	<u>004</u>	Oct 30, 2009
AB		<u>EQ 1.2MG BASE</u>	<u>A078907</u>	<u>005</u>	Oct 30, 2009
AB		<u>EQ 1.6MG BASE</u>	<u>A078907</u>	<u>006</u>	Oct 30, 2009

FERRIC CARBOXYMALTOS

SOLUTION; INTRAVENOUS

INJECTAFER

+	AM REGENT	750MG IRON/15ML (50MG IRON/ML)	N203565	001	Jul 25, 2013
+		100MG IRON/2ML (50MG IRON/ML)	N203565	004	Feb 04, 2022
+		500MG IRON/10ML (50MG IRON/ML)	N203565	002	Oct 08, 2020
+		1GM IRON/20ML (50MG IRON/ML)	N203565	003	Apr 28, 2021

FERRIC CITRATE

TABLET; ORAL

AURYXIA

+	KERYX BIOPHARMS	EQ 210MG IRON	N205874	001	Sep 05, 2014

FERRIC DERISOMALTOSE

SOLUTION; INTRAVENOUS

MONOFERRIC

+	PHARMACOSMOS AS	1GM/10ML (100MG/ML)	N208171	003	Jan 16, 2020

FERRIC HEXACYANOFERRATE (II)

CAPSULE; ORAL

RADIOGARDASE (PRUSSIAN BLUE)

+	HEYL CHEMISCH	500MG	N021626	001	Oct 02, 2003

FERRIC MALTOI

CAPSULE; ORAL

ACCRUFER

+	SHIELD TX	30MG IRON	N212320	001	Jul 25, 2019

FERRIC OXYHYDROXIDE

INJECTABLE; INJECTION

FERRLECIT

AB	+	SANOFI AVENTIS US	<u>EQ 62.5MG IRON/5ML (EQ 12.5MG IRON/ML)</u>	<u>N020955</u>	<u>001</u>	Feb 18, 1999

SODIUM FERRIC GLUCONATE COMPLEX IN SUCROSE

AB		WEST-WARD PHARMS	<u>EQ 62.5MG IRON/5ML (EQ 12.5MG IRON/ML)</u>	<u>A078215</u>	<u>001</u>	Mar 31, 2011

INT

INFED

BP	+	ALLERGAN	EQ 100MG IRON/2ML (EQ 50MG IRON/ML)	N017441	001	

INJECTABLE; INTRAVENOUS

VENOFER

+	AM REGENT	EQ 50MG IRON/2.5ML (EQ 20MG IRON/ML)	N021135	002	Mar 20, 2005

+		EQ 100MG IRON/5ML (EQ 20MG IRON/ML)	N021135	001	Nov 06, 2000

+		EQ 200MG IRON/10ML (EQ 20MG IRON/ML)	N021135	004	Feb 09, 2007

TABLET, CHEWABLE; ORAL

VELPHORO

+	VIFOR FRESENIUS	EQ 500MG IRON	N205109	001	Nov 27, 2013

FERUMOXYTOL

SOLUTION; INTRAVENOUS

FERAHEME

AB	+	COVIS	<u>EQ 510MG IRON/17ML (EQ 30MG IRON/ML)</u>	<u>N022180</u>	<u>001</u>	Jun 30, 2009

FERUMOXYTOL

AB		SANDOZ INC	<u>EQ 510MG IRON/17ML (EQ 30MG IRON/ML)</u>	<u>A206604</u>	<u>001</u>	Jan 15, 2021

FESOTERODINE FUMARATE

TABLET, EXTENDED RELEASE; ORAL

FESOTERODINE FUMARATE

AB		ACCORD HLTHCARE	<u>4MG</u>	<u>A205012</u>	<u>001</u>	Jan 04, 2023

AB			<u>8MG</u>	<u>A205012</u>	<u>002</u>	Jan 04, 2023

AB		ACTAVIS LABS FL INC	<u>4MG</u>	<u>A204868</u>	<u>001</u>	Jan 04, 2023

AB			<u>8MG</u>	<u>A204868</u>	<u>002</u>	Jan 04, 2023

AB		ALEMBIC PHARMS	<u>4MG</u>	<u>A204973</u>	<u>001</u>	Jan 04, 2023

AB			<u>8MG</u>	<u>A204973</u>	<u>002</u>	Jan 04, 2023

AB		ALKEM LABS LTD	<u>4MG</u>	<u>A204827</u>	<u>001</u>	Dec 10, 2015

AB			<u>8MG</u>	<u>A204827</u>	<u>002</u>	Dec 10, 2015

PRESCRIPTION DRUG PRODUCT LIST

3-197 (of 474)

FESOTERODINE FUMARATE

TABLET, EXTENDED RELEASE;ORAL

FESOTERODINE FUMARATE

<u>AB</u>	AMNEAL PHARMS NY	<u>4MG</u>	<u>A205002</u>	<u>001</u>	Jan 04, 2023
<u>AB</u>		<u>8MG</u>	<u>A205002</u>	<u>002</u>	Jan 04, 2023
<u>AB</u>	ANI PHARMS	<u>4MG</u>	<u>A204504</u>	<u>001</u>	Jan 04, 2023
<u>AB</u>		<u>8MG</u>	<u>A204504</u>	<u>002</u>	Jan 04, 2023
<u>AB</u>	AUROBINDO PHARMA	<u>4MG</u>	<u>A205007</u>	<u>001</u>	Feb 17, 2017
<u>AB</u>		<u>8MG</u>	<u>A205007</u>	<u>002</u>	Feb 17, 2017
<u>AB</u>	DR REDDYS	<u>4MG</u>	<u>A204975</u>	<u>001</u>	Aug 13, 2019
<u>AB</u>		<u>8MG</u>	<u>A204975</u>	<u>002</u>	Aug 13, 2019
<u>AB</u>	LUPIN LTD	<u>4MG</u>	<u>A204983</u>	<u>001</u>	Jan 05, 2023
<u>AB</u>		<u>8MG</u>	<u>A204983</u>	<u>002</u>	Jan 05, 2023
<u>AB</u>	ZYDUS PHARMS	<u>4MG</u>	<u>A204946</u>	<u>001</u>	Oct 03, 2017
<u>AB</u>		<u>8MG</u>	<u>A204946</u>	<u>002</u>	Oct 03, 2017

TOVIAZ

<u>AB</u>	+	PFIZER	<u>4MG</u>	<u>N022030</u>	<u>001</u>	Oct 31, 2008
<u>AB</u>	+	!	<u>8MG</u>	<u>N022030</u>	<u>002</u>	Oct 31, 2008

FEXINIDAZOLE

TABLET;ORAL

FEXINIDAZOLE

+	SANOFI	600MG	N214429	001	Jul 16, 2021

FEXOFENADINE HYDROCHLORIDE

TABLET;ORAL

FEXOFENADINE HYDROCHLORIDE

<u>AB</u>	DR REDDYS LABS LTD	<u>30MG</u>	<u>A076502</u>	<u>001</u>	Apr 11, 2006
<u>AB</u>		<u>60MG</u>	<u>A076502</u>	<u>002</u>	Apr 11, 2006
<u>AB</u>		<u>180MG</u>	<u>A076502</u>	<u>003</u>	Apr 11, 2006
<u>AB</u>	RISING	<u>60MG</u>	<u>A077081</u>	<u>003</u>	Apr 11, 2008
<u>AB</u>		<u>180MG</u>	<u>A077081</u>	<u>001</u>	Apr 16, 2007
<u>AB</u>	TEVA	<u>30MG</u>	<u>A076447</u>	<u>001</u>	Sep 01, 2005
<u>AB</u>		<u>60MG</u>	<u>A076447</u>	<u>002</u>	Sep 01, 2005
<u>AB</u>		<u>180MG</u>	<u>A076447</u>	<u>003</u>	Sep 01, 2005

FIDAXOMICIN

FOR SUSPENSION;ORAL

DIFICID

+	CUBIST PHARMS LLC	40MG/ML	N213138	001	Jan 24, 2020

TABLET;ORAL

DIFICID

+	CUBIST PHARMS LLC	200MG	N201699	001	May 27, 2011

FINASTERIDE

TABLET;ORAL

FINASTERIDE

<u>AB</u>	ACCORD HLTHCARE	<u>1MG</u>	<u>A091643</u>	<u>001</u>	Nov 05, 2013
<u>AB</u>		<u>5MG</u>	<u>A090121</u>	<u>001</u>	Feb 23, 2010
<u>AB</u>	ALKEM LABS LTD	<u>1MG</u>	<u>A207750</u>	<u>001</u>	Jan 06, 2017
<u>AB</u>		<u>5MG</u>	<u>A204304</u>	<u>001</u>	Jan 05, 2017
<u>AB</u>	AUROBINDO PHARMA	<u>5MG</u>	<u>A078341</u>	<u>001</u>	Oct 30, 2007
<u>AB</u>	AUROBINDO PHARMA LTD	<u>1MG</u>	<u>A203687</u>	<u>001</u>	Nov 05, 2013
<u>AB</u>	CIPLA	<u>1MG</u>	<u>A077335</u>	<u>001</u>	Nov 20, 2014
<u>AB</u>	DR REDDYS LABS INC	<u>1MG</u>	<u>A076436</u>	<u>001</u>	Jul 28, 2006
<u>AB</u>	DR REDDYS LABS LTD	<u>5MG</u>	<u>A076437</u>	<u>001</u>	Feb 28, 2007
<u>AB</u>	HETERO LABS LTD III	<u>1MG</u>	<u>A090060</u>	<u>001</u>	Jul 01, 2013
<u>AB</u>		<u>5MG</u>	<u>A090061</u>	<u>001</u>	Jun 07, 2010
<u>AB</u>	SUN PHARM	<u>1MG</u>	<u>A090508</u>	<u>001</u>	Jul 01, 2013
<u>AB</u>		<u>5MG</u>	<u>A090507</u>	<u>001</u>	Aug 16, 2011
<u>AB</u>	TEVA	<u>5MG</u>	<u>A076511</u>	<u>001</u>	Dec 15, 2006
<u>AB</u>	ZYDUS PHARMS USA INC	<u>5MG</u>	<u>A078900</u>	<u>001</u>	Dec 28, 2009

PROPECIA

<u>AB</u>	+	ORGANON	<u>1MG</u>	<u>N020788</u>	<u>001</u>	Dec 19, 1997

PROSCAR

<u>AB</u>	+	ORGANON	<u>5MG</u>	<u>N020180</u>	<u>001</u>	Jun 19, 1992

PRESCRIPTION DRUG PRODUCT LIST

3-198 (of 474)

FINASTERIDE; TADALAFIL

CAPSULE; ORAL

ENTADFI

+! VERU

5MG; 5MG

N215423 001 Dec 09, 2021

FINERENONE

TABLET; ORAL

KERENDIA

+ BAYER HLTHCARE

10MG

N215341 001 Jul 09, 2021

+!

20MG

N215341 002 Jul 09, 2021

FINGOLIMOD HYDROCHLORIDE

CAPSULE; ORAL

FINGOLIMOD HYDROCHLORIDE**AB** ACCORD HLTHCARE**EQ 0.5MG BASE****A207991 001** Oct 28, 2020**AB** ALKEM LABS LTD**EQ 0.5MG BASE****A208004 001** Dec 30, 2020**AB** APOTEX**EQ 0.5MG BASE****A207993 001** Dec 18, 2020**AB** DR REDDYS**EQ 0.5MG BASE****A208000 001** Mar 05, 2021**AB** GLENMARK PHARMS LTD**EQ 0.5MG BASE****A207985 001** Jun 18, 2020**AB** HEC PHARM CO LTD**EQ 0.5MG BASE****A207939 001** Nov 10, 2021**AB** HETERO LABS LTD V**EQ 0.5MG BASE****A207933 001** May 18, 2020**AB** MYLAN**EQ 0.5MG BASE****A208005 001** Jan 19, 2021**AB** PRINSTON INC**EQ 0.5MG BASE****A208003 001** Sep 07, 2022**AB** SUN PHARM**EQ 0.5MG BASE****A208014 001** Dec 04, 2019**AB** ZYDUS PHARMS**EQ 0.5MG BASE****A207994 001** Oct 14, 2020GILENYA**AB** +! NOVARTIS**EQ 0.5MG BASE****N022527 001** Sep 21, 2010

+

EQ 0.25MG BASE

N022527 002 May 11, 2018

FINGOLIMOD LAURYL SULFATE

TABLET, ORALLY DISINTEGRATING; ORAL

TASCENSO ODT

+ HANDA

EQ 0.25MG BASE

N214962 001 Dec 23, 2021

+!

EQ 0.5MG BASE

N214962 002 Dec 09, 2022

FISH OIL TRIGLYCERIDES

EMULSION; INTRAVENOUS

OMEGAVEN

+! FRESENIUS KABI USA

5GM/50ML (0.1GM/ML)

N210589 001 Jul 27, 2018

+!

10GM/100ML (0.1GM/ML)

N210589 002 Jul 27, 2018

FISH OIL; MEDIUM CHAIN TRIGLYCERIDES; OLIVE OIL; SOYBEAN OIL

EMULSION; INTRAVENOUS

SMOFLIPID 20%

+! FRESENIUS KABI USA

3GM/100ML; 6GM/100ML; 5GM/100ML; 6GM/100ML (100ML)

N207648 001 Jul 13, 2016

+!

3GM/100ML; 6GM/100ML; 5GM/100ML; 6GM/100ML (250ML)

N207648 002 Jul 13, 2016

+!

3GM/100ML; 6GM/100ML; 5GM/100ML; 6GM/100ML (500ML)

N207648 003 Jul 13, 2016

+!

3GM/100ML; 6GM/100ML; 5GM/100ML; 6GM/100ML (1000ML)

N207648 004 Aug 10, 2018

FLAVOXATE HYDROCHLORIDE

TABLET; ORAL

FLAVOXATE HYDROCHLORIDE**AB** EPIC PHARMA**100MG****A076835 001** Nov 30, 2005**AB** ! PADAGIS US**100MG****A076831 001** Dec 16, 2004FLECAINIDE ACETATE

TABLET; ORAL

FLECAINIDE ACETATE**AB** AMNEAL PHARM**50MG****A075442 001** Jul 31, 2001**AB****100MG****A075442 002** Jul 31, 2001**AB****150MG****A075442 003** Jul 31, 2001**AB** ANI PHARMS**50MG****A075882 001** Oct 28, 2002**AB****100MG****A075882 002** Oct 28, 2002**AB****150MG****A075882 003** Oct 28, 2002**AB** AUROBINDO PHARMA**50MG****A202821 001** Nov 03, 2017

LTD

AB**100MG****A202821 002** Nov 03, 2017**AB****150MG****A202821 003** Nov 03, 2017**AB** BEXIMCO PHARMS USA**50MG****A210683 001** Sep 16, 2020**AB****100MG****A210683 002** Sep 16, 2020**AB****150MG****A210683 003** Sep 16, 2020**AB** HIKMA**50MG****A076278 001** Jan 14, 2003**AB****100MG****A076278 002** Jan 14, 2003

PRESCRIPTION DRUG PRODUCT LIST

3-199 (of 474)

FLECAINIDE ACETATE

TABLET; ORAL

FLECAINIDE ACETATE

AB	!		150MG	A076278	003	Jan 14, 2003
AB		SUN PHARM INDS LTD	50MG	A076421	001	Mar 28, 2003
AB			100MG	A076421	002	Mar 28, 2003
AB			150MG	A076421	003	Mar 28, 2003
AB		YICHANG HUMANWELL	50MG	A215599	001	Sep 08, 2022
AB			100MG	A215599	002	Sep 08, 2022
AB			150MG	A215599	003	Sep 08, 2022

FLIBANSERIN

TABLET; ORAL

ADDYI

+	!	SPROUT PHARMS	100MG	N022526	001	Aug 18, 2015

FLORBETABEN F-18

SOLUTION; INTRAVENOUS

NEURACEQ

+	!	LIFE MOLECULAR	1.4-135mCi/ML	N204677	001	Mar 19, 2014

FLORBETAPIR F-18

SOLUTION; INTRAVENOUS

AMYVID

+	!	AVID RADIOPHARMS	10-30ML (13.5-51mCi/ML)	N202008	002	Apr 06, 2012

INC

+	!		10-50ML (13.5-51mCi/ML)	N202008	003	Apr 06, 2012

FLORTAUCIPIR F-18

SOLUTION; INTRAVENOUS

TAUVID

+	!	AVID RADIOPHARMS	30ML (8.1-51mCi/ML)	N212123	001	May 28, 2020

INC

+	!		50ML (8.1-51mCi/ML)	N212123	002	May 28, 2020

+	!		50ML (8.1-100mCi/ML)	N212123	003	Jul 01, 2022

+	!		100ML (8.1-100mCi/ML)	N212123	004	Jul 01, 2022

FLOXURIDINE

INJECTABLE; INJECTION

FLOXURIDINE

AP		FRESENIUS KABI USA	500MG/VIAL	A075837	001	Feb 22, 2001
AP	!	HIKMA	500MG/VIAL	A075387	001	Apr 16, 2000

FLUCICLOVINE F-18

SOLUTION; INTRAVENOUS

AXUMIN

+	!	BLUE EARTH	9-221mCi/ML	N208054	001	May 27, 2016

FLUCONAZOLE

FOR SUSPENSION; ORAL

DIFLUCAN

AB	+	PFIZER	50MG/5ML	N020090	001	Dec 23, 1993
AB	+	!	200MG/5ML	N020090	002	Dec 23, 1993

FLUCONAZOLE

AB		AUROBINDO PHARMA	50MG/5ML	A079150	001	Sep 18, 2009
AB			200MG/5ML	A079150	002	Sep 18, 2009

INJECTABLE; INJECTION

FLUCONAZOLE IN SODIUM CHLORIDE 0.9%

AP		BAXTER HLTHCARE	200MG/100ML (2MG/ML)	A077947	001	May 26, 2010

CORP

AP			400MG/200ML (2MG/ML)	A077947	002	May 26, 2010

AP		FRESENIUS KABI USA	200MG/100ML (2MG/ML)	A076145	001	Jul 29, 2004

AP			400MG/200ML (2MG/ML)	A076145	002	Jul 29, 2004

AP		HIKMA	200MG/100ML (2MG/ML)	A076087	001	Jul 29, 2004

AP			400MG/200ML (2MG/ML)	A076087	003	Jul 29, 2004

AP		HIKMA FARMACEUTICA	200MG/100ML (2MG/ML)	A076736	001	Aug 23, 2005

FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	200MG/100ML (2MG/ML)	A076766	001	Jul 29, 2004

AP			400MG/200ML (2MG/ML)	A076766	002	Jul 29, 2004

AP		HIKMA FARMACEUTICA	200MG/100ML (2MG/ML)	A078698	001	Jan 30, 2012

AP			400MG/200ML (2MG/ML)	A078698	002	Jan 30, 2012

AP		HOSPIRA	200MG/100ML (2MG/ML)	A076303	001	Jul 29, 2004

AP			400MG/200ML (2MG/ML)	A076303	002	Jul 29, 2004

AP	!	INFORLIFE	200MG/100ML (2MG/ML)	A079104	001	Jul 30, 2009

AP	!		400MG/200ML (2MG/ML)	A079104	002	Jul 30, 2009

AP		WEST-WARD PHARMS	200MG/100ML (2MG/ML)	A078107	001	Jul 30, 2008

INT

PRESCRIPTION DRUG PRODUCT LIST

3-200 (of 474)

FLUCONAZOLE

INJECTABLE; INJECTION

FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

<u>AP</u>		<u>400MG/200ML (2MG/ML)</u>	<u>A078107</u>	<u>002</u>	Jul 30, 2008
<u>AP</u>	WOODWARD	<u>200MG/100ML (2MG/ML)</u>	<u>A077909</u>	<u>001</u>	May 26, 2010
<u>AP</u>		<u>400MG/200ML (2MG/ML)</u>	<u>A077909</u>	<u>002</u>	May 26, 2010
	FLUCONAZOLE IN SODIUM CHLORIDE 0.9%				
	HIKMA	100MG/50ML (2MG/ML)	A076087	002	Sep 26, 2008
	FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
	WOODWARD	100MG/50ML (2MG/ML)	A077909	003	Apr 20, 2015

TABLET; ORAL

DIFLUCAN

<u>AB</u>	+	PFIZER	<u>50MG</u>	<u>N019949</u>	<u>001</u>	Jan 29, 1990
<u>AB</u>	+		<u>100MG</u>	<u>N019949</u>	<u>002</u>	Jan 29, 1990
<u>AB</u>	+		<u>150MG</u>	<u>N019949</u>	<u>004</u>	Jun 30, 1994
<u>AB</u>	+	!	<u>200MG</u>	<u>N019949</u>	<u>003</u>	Jan 29, 1990

FLUCONAZOLE

<u>AB</u>		ANI PHARMS	<u>50MG</u>	<u>A078423</u>	<u>001</u>	Mar 07, 2011
<u>AB</u>			<u>100MG</u>	<u>A078423</u>	<u>002</u>	Mar 07, 2011
<u>AB</u>			<u>150MG</u>	<u>A078423</u>	<u>003</u>	Mar 07, 2011
<u>AB</u>			<u>200MG</u>	<u>A078423</u>	<u>004</u>	Mar 07, 2011
<u>AB</u>		AUROBINDO PHARMA	<u>50MG</u>	<u>A077731</u>	<u>001</u>	Oct 07, 2008
<u>AB</u>			<u>100MG</u>	<u>A077731</u>	<u>002</u>	Oct 07, 2008
<u>AB</u>			<u>150MG</u>	<u>A077731</u>	<u>003</u>	Oct 07, 2008
<u>AB</u>			<u>200MG</u>	<u>A077731</u>	<u>004</u>	Oct 07, 2008
<u>AB</u>		CHARTWELL	<u>50MG</u>	<u>A076665</u>	<u>001</u>	Jul 29, 2004
<u>AB</u>			<u>100MG</u>	<u>A076665</u>	<u>002</u>	Jul 29, 2004
<u>AB</u>			<u>150MG</u>	<u>A076665</u>	<u>003</u>	Jul 29, 2004
<u>AB</u>			<u>200MG</u>	<u>A076665</u>	<u>004</u>	Jul 29, 2004
<u>AB</u>		DR REDDYS LABS INC	<u>50MG</u>	<u>A076658</u>	<u>001</u>	Jul 29, 2004
<u>AB</u>			<u>100MG</u>	<u>A076658</u>	<u>002</u>	Jul 29, 2004
<u>AB</u>			<u>150MG</u>	<u>A076658</u>	<u>003</u>	Jul 29, 2004
<u>AB</u>			<u>200MG</u>	<u>A076658</u>	<u>004</u>	Jul 29, 2004
<u>AB</u>		GLENMARK GENERICS	<u>50MG</u>	<u>A077253</u>	<u>001</u>	Jan 25, 2006
<u>AB</u>			<u>100MG</u>	<u>A077253</u>	<u>002</u>	Jan 25, 2006
<u>AB</u>			<u>150MG</u>	<u>A077253</u>	<u>003</u>	Jan 25, 2006
<u>AB</u>			<u>200MG</u>	<u>A077253</u>	<u>004</u>	Jan 25, 2006
<u>AB</u>		TARO	<u>50MG</u>	<u>A076507</u>	<u>001</u>	Jul 29, 2004
<u>AB</u>			<u>100MG</u>	<u>A076507</u>	<u>002</u>	Jul 29, 2004
<u>AB</u>			<u>150MG</u>	<u>A076507</u>	<u>003</u>	Jul 29, 2004
<u>AB</u>			<u>200MG</u>	<u>A076507</u>	<u>004</u>	Jul 29, 2004
<u>AB</u>		THINQ PHARM-CRO PVT	<u>50MG</u>	<u>A076957</u>	<u>001</u>	Sep 28, 2005
<u>AB</u>			<u>100MG</u>	<u>A076957</u>	<u>002</u>	Sep 28, 2005
<u>AB</u>			<u>150MG</u>	<u>A076957</u>	<u>004</u>	Feb 27, 2017
<u>AB</u>			<u>200MG</u>	<u>A076957</u>	<u>003</u>	Sep 28, 2005
<u>AB</u>		ZYDUS PHARMS	<u>50MG</u>	<u>A208963</u>	<u>001</u>	Feb 16, 2017
<u>AB</u>			<u>100MG</u>	<u>A208963</u>	<u>002</u>	Feb 16, 2017
<u>AB</u>			<u>150MG</u>	<u>A208963</u>	<u>003</u>	Feb 16, 2017
<u>AB</u>			<u>200MG</u>	<u>A208963</u>	<u>004</u>	Feb 16, 2017

FLUCYTOSINE

CAPSULE; ORAL

ANCOBON

<u>AB</u>	+	BAUSCH	<u>250MG</u>	<u>N017001</u>	<u>001</u>	
<u>AB</u>	+	!	<u>500MG</u>	<u>N017001</u>	<u>002</u>	

FLUCYTOSINE

<u>AB</u>		AUROBINDO PHARMA LTD	<u>250MG</u>	<u>A213665</u>	<u>001</u>	May 01, 2020
<u>AB</u>			<u>500MG</u>	<u>A213665</u>	<u>002</u>	May 01, 2020
<u>AB</u>		HIKMA	<u>250MG</u>	<u>A206550</u>	<u>001</u>	Oct 17, 2017
<u>AB</u>			<u>500MG</u>	<u>A206550</u>	<u>002</u>	Oct 17, 2017
<u>AB</u>		NOVEL LABS INC	<u>250MG</u>	<u>A204652</u>	<u>001</u>	Jul 07, 2017
<u>AB</u>			<u>500MG</u>	<u>A204652</u>	<u>002</u>	Jul 07, 2017
<u>AB</u>		SIGMAPHARM LABS LLC	<u>250MG</u>	<u>A201566</u>	<u>001</u>	Jun 28, 2011
<u>AB</u>			<u>500MG</u>	<u>A201566</u>	<u>002</u>	Jun 28, 2011
<u>AB</u>		STRIDES PHARMA	<u>250MG</u>	<u>A212632</u>	<u>001</u>	Apr 17, 2020
<u>AB</u>			<u>500MG</u>	<u>A212632</u>	<u>002</u>	Apr 17, 2020

PRESCRIPTION DRUG PRODUCT LIST

3-201 (of 474)

FLUDARABINE PHOSPHATE

INJECTABLE; INJECTION

FLUDARABINE PHOSPHATE

<u>AP</u>	ACTAVIS LLC	<u>50MG/2ML (25MG/ML)</u>	<u>A203738</u>	<u>001</u>	Feb 28, 2017
<u>AP</u>	! ACTAVIS TOTOWA	<u>50MG/VIAL</u>	<u>A078610</u>	<u>001</u>	Feb 11, 2009
<u>AP</u>	AREVA PHARMS	<u>50MG/2ML (25MG/ML)</u>	<u>A090724</u>	<u>001</u>	Sep 27, 2010
<u>AP</u>	! FRESENIUS KABI USA	<u>50MG/2ML (25MG/ML)</u>	<u>A078393</u>	<u>001</u>	Oct 15, 2007
<u>AP</u>		<u>50MG/VIAL</u>	<u>A078544</u>	<u>001</u>	Oct 15, 2007
<u>AP</u>	HIKMA	<u>50MG/VIAL</u>	<u>A076349</u>	<u>001</u>	Aug 28, 2003
<u>AP</u>	SAGENT PHARMS INC	<u>50MG/2ML (25MG/ML)</u>	<u>A076661</u>	<u>001</u>	Apr 28, 2004
<u>AP</u>	+! SANDOZ	<u>50MG/2ML (25MG/ML)</u>	<u>N022137</u>	<u>001</u>	Sep 21, 2007

FLUDEOXYGLUCOSE F-18

INJECTABLE; INTRAVENOUS

FLUDEOXYGLUCOSE F18

<u>AP</u>	3D IMAGING DRUG	<u>20-300mCi/ML</u>	<u>A203778</u>	<u>001</u>	Oct 30, 2015
<u>AP</u>	BIOMEDCL RES FDN	<u>20-300mCi/ML</u>	<u>A203710</u>	<u>001</u>	May 01, 2015
<u>AP</u>		<u>20-300mCi/ML</u>	<u>A203837</u>	<u>001</u>	May 01, 2015
<u>AP</u>	BRIGHAM WOMENS	<u>20-300mCi/ML</u>	<u>A203816</u>	<u>001</u>	Oct 30, 2014
<u>AP</u>	CARDINAL HEALTH 414	<u>20-300mCi/ML</u>	<u>A203603</u>	<u>001</u>	Nov 13, 2015
<u>AP</u>		<u>20-500mCi/ML</u>	<u>A203603</u>	<u>002</u>	Sep 27, 2018
<u>AP</u>	CHILDRENS HOSP MI	<u>20-300mCi/ML</u>	<u>A204385</u>	<u>001</u>	Oct 29, 2014
<u>AP</u>	DECATUR	<u>20-300mCi/ML</u>	<u>A204463</u>	<u>001</u>	Oct 21, 2014
<u>AP</u>	ESSENTIAL ISOTOPES	<u>20-300mCi/ML</u>	<u>A203946</u>	<u>001</u>	Feb 05, 2014
<u>AP</u>	+! FEINSTEIN	<u>20-400mCi/ML</u>	<u>N021870</u>	<u>002</u>	Nov 21, 2008
<u>AP</u>	ISOLOGIC INNOVATIVE	<u>20-300mCi/ML</u>	<u>A204525</u>	<u>001</u>	Oct 29, 2014
<u>AP</u>	JUBILANT DRAXIMAGE	<u>20-300mCi/ML</u>	<u>A203920</u>	<u>001</u>	Jun 23, 2015
<u>AP</u>	KETTERING MEDCTR	<u>4-40mCi/ML</u>	<u>A204759</u>	<u>001</u>	Oct 27, 2015
<u>AP</u>	KREITCHMAN PET CTR	<u>10-100mCi/ML</u>	<u>A203942</u>	<u>001</u>	Apr 11, 2016
<u>AP</u>	MA GENERAL HOSP	<u>20-300mCi/ML</u>	<u>A204333</u>	<u>001</u>	Sep 25, 2014
<u>AP</u>	MCPRF	<u>20-240mCi/ML</u>	<u>A203612</u>	<u>001</u>	Aug 05, 2013
<u>AP</u>	MEM SLOAN-KETTERING	<u>20-300mCi/ML</u>	<u>A208679</u>	<u>001</u>	Dec 08, 2016
<u>AP</u>	METHODIST HOSP RES	<u>20-300mCi/ML</u>	<u>A203904</u>	<u>001</u>	Apr 23, 2015
<u>AP</u>	MIPS CRF	<u>20-300mCi/ML</u>	<u>A204472</u>	<u>001</u>	Sep 11, 2015
<u>AP</u>	NCM USA BRONX LLC	<u>20-300mCi/ML</u>	<u>A204512</u>	<u>001</u>	Jan 07, 2015
<u>AP</u>	! PETNET	<u>20-200mCi/ML</u>	<u>A079086</u>	<u>001</u>	Feb 25, 2011
<u>AP</u>	PHARMALOGIC HLDGS	<u>20-200mCi/ML</u>	<u>A203664</u>	<u>001</u>	Feb 04, 2014
<u>AP</u>	PRECISION NUCLEAR	<u>20-500mCi/ML</u>	<u>A204546</u>	<u>001</u>	Apr 07, 2015
<u>AP</u>	! QUEEN HAMAMATSU PET	<u>10-100mCi/ML</u>	<u>A203771</u>	<u>001</u>	Aug 31, 2015
<u>AP</u>	SHERTECH LABS LLC	<u>20-300mCi/ML</u>	<u>A204264</u>	<u>001</u>	Dec 18, 2014
<u>AP</u>	SOFIE	<u>20-300mCi/ML</u>	<u>A203591</u>	<u>001</u>	Aug 31, 2015
<u>AP</u>	!	<u>20-500mCi/ML</u>	<u>A203665</u>	<u>001</u>	Feb 14, 2013
<u>AP</u>	TRUSTEES UNIV PA	<u>20-200mCi/ML</u>	<u>A203801</u>	<u>001</u>	Oct 29, 2014
<u>AP</u>	! UCLA BIOMEDICAL	<u>4-40mCi/ML</u>	<u>A203811</u>	<u>001</u>	Jun 27, 2013
<u>AP</u>	UCSF RADIOPHARM	<u>20-300mCi/ML</u>	<u>A203902</u>	<u>001</u>	May 09, 2014
<u>AP</u>	UIHC PET IMAGING	<u>20-300mCi/ML</u>	<u>A203990</u>	<u>001</u>	Aug 06, 2014
<u>AP</u>	UNIV MICHIGAN	<u>20-300mCi/ML</u>	<u>A204531</u>	<u>001</u>	Jul 17, 2015
<u>AP</u>	UNIV SOUTHERN CA	<u>20-300mCi/ML</u>	<u>A209341</u>	<u>001</u>	Dec 16, 2020
<u>AP</u>	UNIV TX MD ANDERSON	<u>20-300mCi/ML</u>	<u>A203246</u>	<u>002</u>	Jan 13, 2014
<u>AP</u>	UNIV UTAH CYCLOTRON	<u>20-300mCi/ML</u>	<u>A204498</u>	<u>001</u>	Jun 23, 2015
<u>AP</u>	WISCONSIN	<u>20-500mCi/ML</u>	<u>A203709</u>	<u>001</u>	Oct 23, 2013
<u>AP</u>	WUSM CYCLOTRON	<u>20-300mCi/ML</u>	<u>A203935</u>	<u>001</u>	Feb 05, 2014
	NORTHLAND	4-500mCi/ML	A203994	001	Feb 04, 2015
	NUKEMED	4-500mCi/ML	A203911	001	Apr 22, 2015
	UNIV TX MD ANDERSON	20-150mCi/ML	A203246	001	Jan 13, 2014

FLUDROCORTISONE ACETATE

TABLET; ORAL

FLUDROCORTISONE ACETATE

<u>AB</u>	BARR	<u>0.1MG</u>	<u>A040425</u>	<u>001</u>	Jan 21, 2003
<u>AB</u>	HIKMA	<u>0.1MG</u>	<u>A216013</u>	<u>001</u>	Oct 27, 2022
<u>AB</u>	! IMPAX LABS	<u>0.1MG</u>	<u>A040431</u>	<u>001</u>	Mar 18, 2002
<u>AB</u>	NOVITIUM PHARMA	<u>0.1MG</u>	<u>A215279</u>	<u>001</u>	May 31, 2022

FLUMAZENIL

INJECTABLE; INJECTION

FLUMAZENIL

<u>AP</u>	BAXTER HLTHCARE CORP	<u>0.5MG/5ML (0.1MG/ML)</u>	<u>A076755</u>	<u>002</u>	Oct 12, 2004
<u>AP</u>		<u>1MG/10ML (0.1MG/ML)</u>	<u>A076755</u>	<u>001</u>	Oct 12, 2004
<u>AP</u>	FRESENIUS KABI USA	<u>0.5MG/5ML (0.1MG/ML)</u>	<u>A076955</u>	<u>002</u>	Oct 12, 2004
<u>AP</u>		<u>1MG/10ML (0.1MG/ML)</u>	<u>A076955</u>	<u>001</u>	Oct 12, 2004
<u>AP</u>	HIKMA	<u>0.5MG/5ML (0.1MG/ML)</u>	<u>A076256</u>	<u>002</u>	Oct 12, 2004
<u>AP</u>		<u>0.5MG/5ML (0.1MG/ML)</u>	<u>A076787</u>	<u>002</u>	Oct 12, 2004

PRESCRIPTION DRUG PRODUCT LIST

3-202 (of 474)

FLUMAZENIL

INJECTABLE; INJECTION

FLUMAZENIL

<u>AP</u>		<u>1MG/10ML (0.1MG/ML)</u>	<u>A076256</u>	<u>001</u>	Oct 12, 2004
<u>AP</u>		<u>1MG/10ML (0.1MG/ML)</u>	<u>A076787</u>	<u>001</u>	Oct 12, 2004
<u>AP</u>	HIKMA FARMACEUTICA	<u>0.5MG/5ML (0.1MG/ML)</u>	<u>A078527</u>	<u>001</u>	Mar 23, 2009
<u>AP</u>	!	<u>1MG/10ML (0.1MG/ML)</u>	<u>A078527</u>	<u>002</u>	Mar 23, 2009
<u>AP</u>	RISING	<u>0.5MG/5ML (0.1MG/ML)</u>	<u>A078595</u>	<u>001</u>	May 13, 2008
<u>AP</u>	SAGENT PHARMS	<u>0.5MG/5ML (0.1MG/ML)</u>	<u>A090584</u>	<u>001</u>	Aug 28, 2012
<u>AP</u>		<u>1MG/10ML (0.1MG/ML)</u>	<u>A090584</u>	<u>002</u>	Aug 28, 2012
<u>AP</u>	SANDOZ INC	<u>0.5MG/5ML (0.1MG/ML)</u>	<u>A077071</u>	<u>001</u>	May 03, 2005
<u>AP</u>		<u>1MG/10ML (0.1MG/ML)</u>	<u>A077071</u>	<u>002</u>	May 03, 2005

FLUNISOLIDE

SPRAY, METERED; NASAL

FLUNISOLIDE

<u>AB</u>	!	BAUSCH	<u>0.025MG/SPRAY</u>	<u>A074805</u>	<u>001</u>	Feb 20, 2002
<u>AB</u>		RICONPHARMA LLC	<u>0.025MG/SPRAY</u>	<u>A207802</u>	<u>001</u>	Jun 16, 2022
<u>AB</u>		RISING	<u>0.025MG/SPRAY</u>	<u>A077704</u>	<u>001</u>	Aug 03, 2006

FLUOCINOLONE ACETONIDE

CREAM; TOPICAL

FLUOCINOLONE ACETONIDE

<u>AT</u>		COSETTE	<u>0.01%</u>	<u>A089526</u>	<u>001</u>	Jul 26, 1988
<u>AT</u>			<u>0.025%</u>	<u>A210747</u>	<u>001</u>	Nov 05, 2018
<u>AT</u>		FOUGERA PHARMS INC	<u>0.01%</u>	<u>A088170</u>	<u>001</u>	Dec 16, 1982
<u>AT</u>			<u>0.025%</u>	<u>A088169</u>	<u>001</u>	Dec 16, 1982
<u>AT</u>		TARO	<u>0.025%</u>	<u>A087104</u>	<u>001</u>	Apr 27, 1982
<u>SYNALAR</u>						
<u>AT</u>	+	MEDIMETRIKS PHARMS	<u>0.01%</u>	<u>N012787</u>	<u>004</u>	
<u>AT</u>	+		<u>0.025%</u>	<u>N012787</u>	<u>002</u>	
<u>AT</u>	+		<u>0.025%</u>	<u>N012787</u>	<u>005</u>	

IMPLANT; INTRAVITREAL

ILUVIEN

+	!	ALIMERA SCIENCES INC	0.19MG	N201923	001	Sep 26, 2014

RETISERT

+	!	BAUSCH AND LOMB	0.59MG	N021737	001	Apr 08, 2005

YUTIQ

+	!	EYEPOINT PHARMS	0.18MG	N210331	001	Oct 12, 2018

OIL; TOPICAL

DERMA-SMOOTHE/FS

<u>AT</u>	+	HILL DERMAC	<u>0.01%</u>	<u>N019452</u>	<u>001</u>	Feb 03, 1988
<u>AT</u>	+		<u>0.01%</u>	<u>N019452</u>	<u>002</u>	Nov 09, 2005

FLUCINOLONE ACETONIDE

<u>AT</u>		GLENMARK PHARMS LTD	<u>0.01%</u>	<u>A210556</u>	<u>001</u>	Oct 25, 2018

FLUOCINOLONE ACETONIDE

<u>AT</u>		LYNE	<u>0.01%</u>	<u>A090982</u>	<u>001</u>	Apr 25, 2016
<u>AT</u>			<u>0.01%</u>	<u>A203377</u>	<u>001</u>	Apr 25, 2016
<u>AT</u>		PADAGIS ISRAEL	<u>0.01%</u>	<u>A202847</u>	<u>001</u>	Aug 09, 2013
<u>AT</u>			<u>0.01%</u>	<u>A202848</u>	<u>001</u>	Aug 09, 2013
<u>AT</u>		QUAGEN	<u>0.01%</u>	<u>A212760</u>	<u>001</u>	Apr 02, 2021
<u>AT</u>			<u>0.01%</u>	<u>A212761</u>	<u>001</u>	Apr 02, 2021
<u>AT</u>		TARO	<u>0.01%</u>	<u>A202368</u>	<u>001</u>	May 19, 2016
<u>AT</u>			<u>0.01%</u>	<u>A209336</u>	<u>001</u>	May 19, 2016

FLUOCINONIDE ACETONIDE

<u>AT</u>		GLENMARK PHARMS LTD	<u>0.01%</u>	<u>A210539</u>	<u>001</u>	Oct 26, 2018

OIL/DROPS; OTIC

DERMOTIC

<u>AT</u>	+	HILL DERMAC	<u>0.01%</u>	<u>N019452</u>	<u>003</u>	Nov 09, 2005

FLAC

<u>AT</u>		ANDA REPOSITORY	<u>0.01%</u>	<u>A210736</u>	<u>001</u>	Apr 11, 2018

FLUOCINOLONE ACETONIDE

<u>AT</u>		LYNE	<u>0.01%</u>	<u>A203378</u>	<u>001</u>	Apr 25, 2016
<u>AT</u>		PADAGIS ISRAEL	<u>0.01%</u>	<u>A202849</u>	<u>001</u>	Jul 17, 2017
<u>AT</u>		QUAGEN	<u>0.01%</u>	<u>A212762</u>	<u>001</u>	Apr 02, 2021
<u>AT</u>		TASMAN PHARMA	<u>0.01%</u>	<u>A213264</u>	<u>001</u>	Feb 05, 2021

FLUOCINONIDE ACETONIDE

<u>AT</u>		GLENMARK PHARMS LTD	<u>0.01%</u>	<u>A211815</u>	<u>001</u>	Dec 14, 2018

OINTMENT; TOPICAL

FLUOCINOLONE ACETONIDE

<u>AT</u>		COSETTE	<u>0.025%</u>	<u>A089524</u>	<u>001</u>	Jul 26, 1988
<u>AT</u>		FOUGERA PHARMS INC	<u>0.025%</u>	<u>A088168</u>	<u>001</u>	Dec 16, 1982
<u>AT</u>		TARO	<u>0.025%</u>	<u>A040041</u>	<u>001</u>	Sep 15, 1994

PRESCRIPTION DRUG PRODUCT LIST

3-203 (of 474)

FLUOCINOLONE ACETONIDE

OINTMENT; TOPICAL

SYNALAR**AT** +! MEDIMETRIKS PHARMS **0.025%** **N013960 001**

SHAMPOO; TOPICAL

CAPEX

+! GALDERMA LABS LP 0.01%

N020001 001 Aug 27, 1990

SOLUTION; TOPICAL

FLUOCINOLONE ACETONIDE**AT** ENCUBE ETHICALS **0.01%** **A209913 001** Feb 13, 2019**AT** FOUGERA PHARMS INC **0.01%** **A088167 001** Dec 16, 1982**AT** GLASSHOUSE PHARMS **0.01%** **A209596 001** Dec 26, 2017**AT** LUPIN **0.01%** **A206422 001** Sep 02, 2015**AT** TARO **0.01%** **A089124 001** Sep 11, 1985SYNALAR**AT** +! MEDIMETRIKS PHARMS **0.01%** **N015296 001**FLUOCINOLONE ACETONIDE; HYDROQUINONE; TRETINOIN

CREAM; TOPICAL

TRI-LUMA

+! GALDERMA LABS LP 0.01%; 4%; 0.05%

N021112 001 Jan 18, 2002

FLUOCINOLONE ACETONIDE; NEOMYCIN SULFATE

CREAM; TOPICAL

NEO-SYNALAR

! MEDIMETRIKS PHARMS 0.025%; EQ 3.5MG BASE/GM

A060700 001

FLUOCINONIDE

CREAM; TOPICAL

FLUOCINONIDE**AB** AMNEAL **0.1%** **A211111 001** Jun 04, 2018**AB** CADILA **0.1%** **A208989 001** Feb 10, 2020**AB** FOUGERA PHARMS INC **0.1%** **A200735 001** Jul 14, 2014**AB** GLENMARK GENERICS **0.1%** **A091282 001** Jul 14, 2014**AB** PADAGIS ISRAEL **0.1%** **A090256 001** Jan 14, 2014**AB** PAI HOLDINGS PHARM **0.1%** **A211758 001** Apr 03, 2019**AB** TARO **0.1%** **A200734 001** Jul 14, 2014VANOS**AB** +! BAUSCH **0.1%** **N021758 001** Feb 11, 2005FLUOCINONIDE**AB1** AMNEAL **0.05%** **A210554 001** Aug 21, 2018**AB1** COSETTE **0.05%** **A073085 001** Feb 14, 1992**AB1** FOUGERA PHARMS INC **0.05%** **A073030 001** Oct 17, 1994**AB1** TARO **0.05%** **A071500 001** Jun 10, 1987**AB1** +! **0.05%** **N019117 001** Jun 26, 1984**AB1** TEVA **0.05%** **A072488 001** Feb 06, 1989FLUOCINONIDE EMULSIFIED BASE**AB2** COSETTE **0.05%** **A074204 001** Jun 13, 1995**AB2** FOUGERA PHARMS **0.05%** **A076586 001** Jun 23, 2004**AB2** ! TARO PHARM INDS LTD **0.05%** **A072494 001** Jan 19, 1989**AB2** TEVA **0.05%** **A072490 001** Feb 07, 1989

GEL; TOPICAL

FLUOCINONIDE**AB** + ALVOGEN **0.05%** **N017373 001****AB** COSETTE **0.05%** **A072537 001** Feb 07, 1989**AB** FOUGERA PHARMS INC **0.05%** **A072933 001** Dec 30, 1994**AB** PAI HOLDINGS PHARM **0.05%** **A209030 001** Jun 19, 2018**AB** ! TARO **0.05%** **A074935 001** Jul 29, 1997

OINTMENT; TOPICAL

FLUOCINONIDE**AB** FOUGERA PHARMS **0.05%** **A074905 001** Aug 26, 1997**AB** NOVEL LABS INC **0.05%** **A207538 001** Jul 31, 2017**AB** PAI HOLDINGS PHARM **0.05%** **A207680 001** Sep 28, 2018**AB** ! TARO **0.05%** **A075008 001** Jun 30, 1999**AB** TEVA **0.05%** **A073481 001** Dec 27, 1991**AB** XIROMED **0.05%** **A212976 001** Nov 26, 2019LIDEX**AB** + ALVOGEN **0.05%** **N016909 002**

SOLUTION; TOPICAL

FLUOCINONIDE**AT** COSETTE **0.05%** **A071535 001** Dec 02, 1988**AT** ENCUBE ETHICALS **0.05%** **A209699 001** Nov 29, 2018**AT** FOUGERA PHARMS INC **0.05%** **A072934 001** Feb 27, 1995**AT** GLASSHOUSE PHARMS **0.05%** **A209118 001** Apr 23, 2018

PRESCRIPTION DRUG PRODUCT LIST

3-204 (of 474)

FLUOCINONIDE

SOLUTION; TOPICAL

FLUOCINONIDE

<u>AT</u>	MACLEODS PHARMS LTD	<u>0.05%</u>	<u>A209283</u>	<u>001</u>	Apr 23, 2018
<u>AT</u>	NOVEL LABS INC	<u>0.05%</u>	<u>A206003</u>	<u>001</u>	Jul 21, 2017
<u>AT</u>	PAI HOLDINGS PHARM	<u>0.05%</u>	<u>A207554</u>	<u>001</u>	Mar 18, 2019
<u>AT</u>	! TARO	<u>0.05%</u>	<u>A074799</u>	<u>001</u>	Dec 31, 1996
<u>AT</u>	ZYDUS PHARMS	<u>0.05%</u>	<u>A208948</u>	<u>001</u>	Jul 17, 2018

LIDEX

<u>AT</u>	+ ALVOGEN	<u>0.05%</u>	<u>N018849</u>	<u>001</u>	Apr 06, 1984

FLUORESCHEIN SODIUM

INJECTABLE; INTRAVENOUS

AK-FLUOR 10%

<u>AP</u>	+ AKORN	<u>EQ 500MG BASE/5ML (EQ 100MG BASE/ML)</u>	<u>N022186</u>	<u>001</u>	Aug 08, 2008

FLUORESCITE

<u>AP</u>	+! ALCON LABS INC	<u>EQ 500MG BASE/5ML (EQ 100MG BASE/ML)</u>	<u>N021980</u>	<u>001</u>	Mar 28, 2006
	AK-FLUOR 25%				
	+! AKORN	<u>EQ 500MG BASE/2ML (EQ 250MG BASE/ML)</u>	<u>N022186</u>	<u>002</u>	Aug 08, 2008

FLUORODOPA F-18

SOLUTION; INTRAVENOUS

FLUORODOPA F18

+! FEINSTEIN	0.42-8.33mCi/ML	<u>N200655</u>	<u>001</u>	Oct 10, 2019

FLUOROESTRADIOL F-18

SOLUTION; INTRAVENOUS

CERIANNA

+! ZIONEXA	50ML (4-100mCi/ML)	<u>N212155</u>	<u>001</u>	May 20, 2020

FLUOROMETHOLONE

SUSPENSION/DROPS; OPHTHALMIC

FML

+! ALLERGAN	0.1%	<u>N016851</u>	<u>002</u>	Jul 28, 1982

FML FORTE

+! ALLERGAN	0.25%	<u>N019216</u>	<u>001</u>	Apr 23, 1986

FLUOROMETHOLONE ACETATE

SUSPENSION/DROPS; OPHTHALMIC

FLAREX

+! EYEVANCE	0.1%	<u>N019079</u>	<u>001</u>	Feb 11, 1986

FLUOROURACIL

CREAM; TOPICAL

EFUDEX

<u>AB</u>	+! BAUSCH	<u>5%</u>	<u>N016831</u>	<u>003</u>	

FLUOROURACIL

<u>AB</u>	ACCORD HLTHCARE	<u>5%</u>	<u>A214845</u>	<u>001</u>	Oct 07, 2021
<u>AB</u>	MAYNE PHARMA	<u>5%</u>	<u>A077524</u>	<u>001</u>	Apr 11, 2008
<u>AB</u>	TARO	<u>5%</u>	<u>A090368</u>	<u>001</u>	Mar 05, 2010

CARAC

+! VALEANT PHARMS NORTH	0.5%	<u>N020985</u>	<u>001</u>	Oct 27, 2000

TOLAK

+! HILL DERMACEUTICALS	4%	<u>N022259</u>	<u>001</u>	Sep 18, 2015

INJECTABLE; INJECTION

FLUOROURACIL

<u>AP</u>	! ACCORD HLTHCARE	<u>500MG/10ML (50MG/ML)</u>	<u>A040743</u>	<u>002</u>	Apr 26, 2007
<u>AP</u>	!	<u>1GM/20ML (50MG/ML)</u>	<u>A040743</u>	<u>001</u>	Apr 26, 2007
<u>AP</u>	!	<u>2.5GM/50ML (50MG/ML)</u>	<u>A040798</u>	<u>002</u>	Apr 26, 2007
<u>AP</u>	!	<u>5GM/100ML (50MG/ML)</u>	<u>A040798</u>	<u>001</u>	Apr 26, 2007
<u>AP</u>	FRESENIUS KABI USA	<u>500MG/10ML (50MG/ML)</u>	<u>A040279</u>	<u>002</u>	Sep 30, 1998
<u>AP</u>		<u>1GM/20ML (50MG/ML)</u>	<u>A040279</u>	<u>001</u>	Sep 30, 1998
<u>AP</u>		<u>2.5GM/50ML (50MG/ML)</u>	<u>A040278</u>	<u>001</u>	Sep 30, 1998
<u>AP</u>		<u>5GM/100ML (50MG/ML)</u>	<u>A040278</u>	<u>002</u>	Sep 30, 1998
<u>AP</u>	GLAND PHARMA LTD	<u>500MG/10ML (50MG/ML)</u>	<u>A210123</u>	<u>001</u>	Oct 27, 2017
<u>AP</u>		<u>1GM/20ML (50MG/ML)</u>	<u>A210123</u>	<u>002</u>	Oct 27, 2017
<u>AP</u>		<u>2.5GM/50ML (50MG/ML)</u>	<u>A210124</u>	<u>001</u>	Dec 26, 2017
<u>AP</u>		<u>5GM/100ML (50MG/ML)</u>	<u>A210124</u>	<u>002</u>	Dec 26, 2017
<u>AP</u>	SAGENT PHARMS INC	<u>500MG/10ML (50MG/ML)</u>	<u>A203608</u>	<u>001</u>	May 11, 2017
<u>AP</u>		<u>1GM/20ML (50MG/ML)</u>	<u>A203608</u>	<u>002</u>	May 11, 2017
<u>AP</u>		<u>2.5GM/50ML (50MG/ML)</u>	<u>A203609</u>	<u>001</u>	Feb 17, 2016
<u>AP</u>		<u>5GM/100ML (50MG/ML)</u>	<u>A203609</u>	<u>002</u>	Feb 17, 2016

PRESCRIPTION DRUG PRODUCT LIST

3-205 (of 474)

FLUOROURACIL

SOLUTION; TOPICAL

EFUDEX

AT	+!	BAUSCH	2%	N016831	001	
<u>FLUOROURACIL</u>						
AT		TARO	2%	A076526	001	Nov 05, 2003
	!		5%	A076526	002	Nov 05, 2003

FLUOXETINE HYDROCHLORIDE

CAPSULE; ORAL

FLUOXETINE HYDROCHLORIDE

AB		ALEMBIC PHARMS LTD	EQ 40MG BASE	A090223	003	Mar 19, 2009
AB		APNAR PHARMA LP	EQ 40MG BASE	A075049	003	Jan 29, 2002
AB		AUROBINDO PHARMA	EQ 40MG BASE	A078619	003	Jan 31, 2008
AB		CADILA PHARMS LTD	EQ 40MG BASE	A206993	003	May 23, 2019
AB		HERITAGE PHARMS	EQ 40MG BASE	A201336	003	Oct 01, 2012
AB		IVAX SUB TEVA PHARMS	EQ 40MG BASE	A075245	003	Sep 28, 2004
AB		MARKSANS PHARMA	EQ 40MG BASE	A075465	003	Aug 02, 2001
AB		MICRO LABS	EQ 40MG BASE	A216232	003	Mar 29, 2022
AB		SCIEGEN PHARMS INC	EQ 40MG BASE	A204597	003	Mar 16, 2015
AB		SUN PHARM INDS LTD	EQ 40MG BASE	A076990	001	Dec 13, 2004
AB		TEVA	EQ 40MG BASE	A075452	003	Jan 29, 2002

PROZAC

AB	+!	ELI LILLY AND CO	EQ 40MG BASE	N018936	003	Jun 15, 1999

FLUOXETINE HYDROCHLORIDE

AB1		ALEMBIC PHARMS LTD	EQ 10MG BASE	A090223	001	Mar 19, 2009
AB1			EQ 20MG BASE	A090223	002	Mar 19, 2009
AB1		APNAR PHARMA LP	EQ 10MG BASE	A075049	001	Aug 02, 2001
AB1			EQ 20MG BASE	A075049	002	Jan 29, 2002
AB1		AUROBINDO PHARMA	EQ 10MG BASE	A078619	001	Jan 31, 2008
AB1			EQ 20MG BASE	A078619	002	Jan 31, 2008
AB1		CADILA PHARMS LTD	EQ 10MG BASE	A206993	001	May 23, 2019
AB1			EQ 20MG BASE	A206993	002	May 23, 2019
AB1		HERITAGE PHARMS	EQ 10MG BASE	A201336	001	Oct 01, 2012
AB1			EQ 20MG BASE	A201336	002	Oct 01, 2012
AB1		IVAX SUB TEVA PHARMS	EQ 10MG BASE	A075245	002	Jan 31, 2002
AB1			EQ 20MG BASE	A075245	001	Jan 31, 2002
AB1		LANDELA PHARM	EQ 10MG BASE	A075464	001	Jan 30, 2002
AB1			EQ 20MG BASE	A075464	002	Jan 30, 2002
AB1		MARKSANS PHARMA	EQ 10MG BASE	A075465	001	Jan 29, 2002
AB1			EQ 20MG BASE	A075465	002	Jan 29, 2002
AB1		MICRO LABS	EQ 10MG BASE	A216232	001	Mar 29, 2022
AB1			EQ 20MG BASE	A216232	002	Mar 29, 2022
AB1		SCIEGEN PHARMS INC	EQ 10MG BASE	A204597	001	Mar 16, 2015
AB1			EQ 20MG BASE	A204597	002	Mar 16, 2015
AB1		TEVA	EQ 10MG BASE	A075452	001	Jan 29, 2002
AB1			EQ 20MG BASE	A075452	002	Jan 29, 2002
AB1		TEVA PHARMS USA	EQ 10MG BASE	A076001	001	Jan 29, 2002
AB1			EQ 20MG BASE	A076001	002	Jan 29, 2002

PROZAC

AB1	+	ELI LILLY AND CO	EQ 10MG BASE	N018936	006	Dec 23, 1992
AB1	+		EQ 20MG BASE	N018936	001	Dec 29, 1987

CAPSULE, DELAYED REL PELLETS; ORAL

FLUOXETINE HYDROCHLORIDE**!** DR REDDYS LABS LTD **EQ 90MG BASE****A078572** **001** Mar 22, 2010

SOLUTION; ORAL

FLUOXETINE HYDROCHLORIDE

AA		APTAPHARMA INC	EQ 20MG BASE/5ML	A216953	001	Nov 15, 2022
AA		AUROBINDO PHARMA	EQ 20MG BASE/5ML	A079209	001	Mar 20, 2009
AA		LANNETT CO INC	EQ 20MG BASE/5ML	A077849	001	Feb 09, 2007
AA		NOVITIUM PHARMA	EQ 20MG BASE/5ML	A216448	001	Nov 09, 2022
AA	!	PHARM ASSOC	EQ 20MG BASE/5ML	A076015	001	Jan 30, 2002
AA		TEVA	EQ 20MG BASE/5ML	A075506	001	Aug 02, 2001
AA		WOCKHARDT BIO AG	EQ 20MG BASE/5ML	A075514	001	Aug 29, 2002

TABLET; ORAL

FLUOXETINE HYDROCHLORIDE

AB		ALEMBIC PHARMS	EQ 10MG BASE	A208698	001	Apr 05, 2017
AB			EQ 20MG BASE	A208698	002	Apr 05, 2017
AB	+!	ALMATICA	EQ 60MG BASE	N202133	001	Oct 06, 2011
AB		AUROBINDO PHARMA LTD	EQ 10MG BASE	A213286	001	Apr 08, 2020

PRESCRIPTION DRUG PRODUCT LIST

3-206 (of 474)

FLUOXETINE HYDROCHLORIDE

TABLET; ORAL

FLUOXETINE HYDROCHLORIDE

<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A213286</u>	<u>002</u>	Apr 08, 2020
<u>AB</u>		<u>EQ 60MG BASE</u>	<u>A213265</u>	<u>001</u>	Jun 10, 2020
<u>AB</u>	DR REDDYS	<u>EQ 10MG BASE</u>	<u>A076006</u>	<u>001</u>	Jan 30, 2002
<u>AB</u>	!	<u>EQ 20MG BASE</u>	<u>A076006</u>	<u>002</u>	Apr 23, 2018
<u>AB</u>		<u>EQ 60MG BASE</u>	<u>A211721</u>	<u>001</u>	Jan 25, 2019
<u>AB</u>	INVENTIA HLTHCARE	<u>EQ 60MG BASE</u>	<u>A209695</u>	<u>001</u>	Nov 20, 2017
<u>AB</u>	LUPIN LTD	<u>EQ 10MG BASE</u>	<u>A211653</u>	<u>001</u>	Apr 15, 2019
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A211653</u>	<u>002</u>	Apr 15, 2019
<u>AB</u>		<u>EQ 60MG BASE</u>	<u>A211632</u>	<u>001</u>	Feb 08, 2019
<u>AB</u>	PAR FORM	<u>EQ 10MG BASE</u>	<u>A203836</u>	<u>001</u>	Aug 19, 2016
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A203836</u>	<u>002</u>	Aug 19, 2016
<u>AB</u>	PAR PHARM INC	<u>EQ 60MG BASE</u>	<u>A209419</u>	<u>001</u>	Nov 16, 2017
<u>AB</u>	PIRAMAL HLTHCARE UK	<u>EQ 10MG BASE</u>	<u>A211444</u>	<u>001</u>	Sep 13, 2022
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A211444</u>	<u>002</u>	Sep 13, 2022
<u>AB</u>	SCIEGEN PHARMS INC	<u>EQ 10MG BASE</u>	<u>A210935</u>	<u>001</u>	Mar 20, 2019
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A210935</u>	<u>002</u>	Mar 20, 2019
<u>AB</u>		<u>EQ 60MG BASE</u>	<u>A211282</u>	<u>001</u>	Jan 10, 2019
<u>AB</u>	TARO	<u>EQ 60MG BASE</u>	<u>A211477</u>	<u>001</u>	Nov 21, 2018
<u>AB</u>	TEVA	<u>EQ 10MG BASE</u>	<u>A075872</u>	<u>001</u>	Jan 29, 2002
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A075872</u>	<u>002</u>	Jan 04, 2019
<u>AB</u>	TEVA PHARMS USA	<u>EQ 60MG BASE</u>	<u>A211051</u>	<u>001</u>	Dec 03, 2018
<u>AB</u>	UPSHER SMITH LABS	<u>EQ 10MG BASE</u>	<u>A211696</u>	<u>001</u>	Jan 30, 2019
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A211696</u>	<u>002</u>	Jan 30, 2019
	TORRENT	EQ 10MG BASE	A206937	001	Oct 21, 2016
	!	EQ 20MG BASE	A206937	002	Oct 21, 2016

FLUOXETINE HYDROCHLORIDE; OLANZAPINE

CAPSULE; ORAL

OLANZAPINE AND FLUOXETINE HYDROCHLORIDE

<u>AB</u>	EPIC PHARMA	<u>EQ 25MG BASE;EQ 3MG BASE</u>	<u>A078901</u>	<u>005</u>	Nov 16, 2012
<u>AB</u>		<u>EQ 25MG BASE;EQ 6MG BASE</u>	<u>A078901</u>	<u>001</u>	Nov 16, 2012
<u>AB</u>		<u>EQ 25MG BASE;EQ 12MG BASE</u>	<u>A078901</u>	<u>003</u>	Nov 16, 2012
<u>AB</u>		<u>EQ 50MG BASE;EQ 6MG BASE</u>	<u>A078901</u>	<u>002</u>	Nov 16, 2012
<u>AB</u>		<u>EQ 50MG BASE;EQ 12MG BASE</u>	<u>A078901</u>	<u>004</u>	Nov 16, 2012
<u>AB</u>	PAR PHARM	<u>EQ 25MG BASE;EQ 3MG BASE</u>	<u>A077742</u>	<u>001</u>	Nov 02, 2012
<u>AB</u>		<u>EQ 25MG BASE;EQ 6MG BASE</u>	<u>A077742</u>	<u>002</u>	Nov 02, 2012
<u>AB</u>		<u>EQ 25MG BASE;EQ 12MG BASE</u>	<u>A077742</u>	<u>003</u>	Nov 02, 2012
<u>AB</u>		<u>EQ 50MG BASE;EQ 6MG BASE</u>	<u>A077742</u>	<u>004</u>	Nov 02, 2012
<u>AB</u>		<u>EQ 50MG BASE;EQ 12MG BASE</u>	<u>A077742</u>	<u>005</u>	Nov 02, 2012
<u>AB</u>	TEVA PHARMS	<u>EQ 25MG BASE;EQ 3MG BASE</u>	<u>A202074</u>	<u>001</u>	Mar 25, 2013
<u>AB</u>		<u>EQ 25MG BASE;EQ 6MG BASE</u>	<u>A077528</u>	<u>001</u>	Jun 19, 2012
<u>AB</u>		<u>EQ 25MG BASE;EQ 12MG BASE</u>	<u>A077528</u>	<u>002</u>	Jun 19, 2012
<u>AB</u>		<u>EQ 50MG BASE;EQ 6MG BASE</u>	<u>A077528</u>	<u>003</u>	Jun 19, 2012
<u>AB</u>		<u>EQ 50MG BASE;EQ 12MG BASE</u>	<u>A077528</u>	<u>004</u>	Jun 19, 2012
<u>SYMBYAX</u>					
<u>AB</u>	+	<u>EQ 25MG BASE;EQ 3MG BASE</u>	<u>N021520</u>	<u>001</u>	Apr 09, 2007
<u>AB</u>	+	<u>EQ 25MG BASE;EQ 6MG BASE</u>	<u>N021520</u>	<u>002</u>	Dec 24, 2003
<u>AB</u>	+	<u>EQ 25MG BASE;EQ 12MG BASE</u>	<u>N021520</u>	<u>004</u>	Dec 24, 2003
<u>AB</u>	+	<u>EQ 50MG BASE;EQ 6MG BASE</u>	<u>N021520</u>	<u>003</u>	Dec 24, 2003
<u>AB</u>	+	<u>EQ 50MG BASE;EQ 12MG BASE</u>	<u>N021520</u>	<u>005</u>	Dec 24, 2003

FLUPHENAZINE DECANOATE

INJECTABLE; INJECTION

FLUPHENAZINE DECANOATE

<u>AO</u>	EUGIA PHARMA	<u>25MG/ML</u>	<u>A207739</u>	<u>001</u>	Oct 17, 2017
<u>AO</u>	!	<u>25MG/ML</u>	<u>A071413</u>	<u>001</u>	Jul 14, 1987
<u>AO</u>	HIKMA	<u>25MG/ML</u>	<u>A074531</u>	<u>001</u>	Aug 30, 1996
<u>AO</u>	MYLAN LABS LTD	<u>25MG/ML</u>	<u>A075918</u>	<u>001</u>	Aug 17, 2001
<u>AO</u>	PAR STERILE PRODUCTS	<u>25MG/ML</u>	<u>A203732</u>	<u>001</u>	Jul 03, 2014

FLUPHENAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

FLUPHENAZINE HYDROCHLORIDE

!	PHARM ASSOC	5MG/ML	A074725	001	Sep 16, 1996
ELIXIR; ORAL					
	<u>FLUPHENAZINE HYDROCHLORIDE</u>				
!	PHARM ASSOC	2.5MG/5ML	A040146	001	Aug 21, 1996
INJECTABLE; INJECTION					
	<u>FLUPHENAZINE HYDROCHLORIDE</u>				
!	FRESENIUS KABI USA	2.5MG/ML	A089556	001	Apr 16, 1987

PRESCRIPTION DRUG PRODUCT LIST

3-207 (of 474)

FLUPHENAZINE HYDROCHLORIDE

TABLET; ORAL

FLUPHENAZINE HYDROCHLORIDE

<u>AB</u>	AJANTA PHARMA LTD	<u>1MG</u>	<u>A217410</u>	<u>001</u>	Jan 05, 2023
<u>AB</u>		<u>2.5MG</u>	<u>A217410</u>	<u>002</u>	Jan 05, 2023
<u>AB</u>		<u>5MG</u>	<u>A217410</u>	<u>003</u>	Jan 05, 2023
<u>AB</u>		<u>10MG</u>	<u>A217410</u>	<u>004</u>	Jan 05, 2023
<u>AB</u>	AMNEAL	<u>1MG</u>	<u>A213647</u>	<u>001</u>	Jul 09, 2020
<u>AB</u>		<u>2.5MG</u>	<u>A213647</u>	<u>002</u>	Jul 09, 2020
<u>AB</u>		<u>5MG</u>	<u>A213647</u>	<u>003</u>	Jul 09, 2020
<u>AB</u>		<u>10MG</u>	<u>A213647</u>	<u>004</u>	Jul 09, 2020
<u>AB</u>	APOTEX	<u>1MG</u>	<u>A216649</u>	<u>001</u>	Jul 15, 2022
<u>AB</u>		<u>2.5MG</u>	<u>A216649</u>	<u>002</u>	Jul 15, 2022
<u>AB</u>		<u>5MG</u>	<u>A216649</u>	<u>003</u>	Jul 15, 2022
<u>AB</u>		<u>10MG</u>	<u>A216649</u>	<u>004</u>	Jul 15, 2022
<u>AB</u>	CEROVENE INC	<u>1MG</u>	<u>A214534</u>	<u>001</u>	Jan 07, 2021
<u>AB</u>		<u>2.5MG</u>	<u>A214534</u>	<u>002</u>	Jan 07, 2021
<u>AB</u>		<u>5MG</u>	<u>A214534</u>	<u>003</u>	Jan 07, 2021
<u>AB</u>		<u>10MG</u>	<u>A214534</u>	<u>004</u>	Jan 07, 2021
<u>AB</u>	LANNETT CO INC	<u>1MG</u>	<u>A089743</u>	<u>002</u>	Aug 25, 1988
<u>AB</u>		<u>2.5MG</u>	<u>A089743</u>	<u>003</u>	Aug 25, 1988
<u>AB</u>	!	<u>5MG</u>	<u>A089743</u>	<u>004</u>	Aug 25, 1988
<u>AB</u>		<u>10MG</u>	<u>A089743</u>	<u>001</u>	Aug 25, 1988
<u>AB</u>	NOVITIUM PHARMA	<u>1MG</u>	<u>A214674</u>	<u>001</u>	Mar 01, 2021
<u>AB</u>		<u>2.5MG</u>	<u>A214674</u>	<u>002</u>	Mar 01, 2021
<u>AB</u>		<u>5MG</u>	<u>A214674</u>	<u>003</u>	Mar 01, 2021
<u>AB</u>		<u>10MG</u>	<u>A214674</u>	<u>004</u>	Mar 01, 2021
<u>AB</u>	PRASCO	<u>1MG</u>	<u>A089804</u>	<u>002</u>	Aug 12, 1988
<u>AB</u>		<u>2.5MG</u>	<u>A089804</u>	<u>003</u>	Aug 12, 1988
<u>AB</u>		<u>5MG</u>	<u>A089804</u>	<u>004</u>	Aug 12, 1988
<u>AB</u>		<u>10MG</u>	<u>A089804</u>	<u>001</u>	Aug 12, 1988
<u>AB</u>	SANDOZ INC	<u>1MG</u>	<u>A216891</u>	<u>001</u>	Nov 15, 2022
<u>AB</u>		<u>2.5MG</u>	<u>A216891</u>	<u>002</u>	Nov 15, 2022
<u>AB</u>		<u>5MG</u>	<u>A216891</u>	<u>003</u>	Nov 15, 2022
<u>AB</u>		<u>10MG</u>	<u>A216891</u>	<u>004</u>	Nov 15, 2022
<u>AB</u>	TARO PHARM INDS LTD	<u>1MG</u>	<u>A215674</u>	<u>001</u>	Apr 14, 2022
<u>AB</u>		<u>2.5MG</u>	<u>A215674</u>	<u>002</u>	Apr 14, 2022
<u>AB</u>		<u>5MG</u>	<u>A215674</u>	<u>003</u>	Apr 14, 2022
<u>AB</u>		<u>10MG</u>	<u>A215674</u>	<u>004</u>	Apr 14, 2022
<u>AB</u>	TWI PHARMS	<u>1MG</u>	<u>A215848</u>	<u>004</u>	Dec 14, 2022
<u>AB</u>		<u>2.5MG</u>	<u>A215848</u>	<u>001</u>	Apr 01, 2022
<u>AB</u>		<u>5MG</u>	<u>A215848</u>	<u>002</u>	Apr 01, 2022
<u>AB</u>		<u>10MG</u>	<u>A215848</u>	<u>003</u>	Apr 01, 2022
<u>AB</u>	UPSHER SMITH LABS	<u>1MG</u>	<u>A213784</u>	<u>001</u>	Oct 24, 2022
<u>AB</u>		<u>2.5MG</u>	<u>A213784</u>	<u>002</u>	Oct 24, 2022
<u>AB</u>		<u>5MG</u>	<u>A213784</u>	<u>003</u>	Oct 24, 2022
<u>AB</u>		<u>10MG</u>	<u>A213784</u>	<u>004</u>	Oct 24, 2022
<u>AB</u>	ZAMEER PHARMS	<u>1MG</u>	<u>A215141</u>	<u>001</u>	Oct 20, 2021
<u>AB</u>		<u>2.5MG</u>	<u>A215141</u>	<u>002</u>	Oct 20, 2021
<u>AB</u>		<u>5MG</u>	<u>A215141</u>	<u>003</u>	Oct 20, 2021
<u>AB</u>		<u>10MG</u>	<u>A215141</u>	<u>004</u>	Oct 20, 2021
<u>AB</u>	ZYDUS	<u>1MG</u>	<u>A214552</u>	<u>001</u>	May 27, 2021
<u>AB</u>		<u>2.5MG</u>	<u>A214552</u>	<u>002</u>	May 27, 2021
<u>AB</u>		<u>5MG</u>	<u>A214552</u>	<u>003</u>	May 27, 2021
<u>AB</u>		<u>10MG</u>	<u>A214552</u>	<u>004</u>	May 27, 2021

FLURANDRENOLIDE

LOTION; TOPICAL

CORDRAN

<u>AT</u>	+! ALMIRALL	<u>0.05%</u>	<u>N013790</u>	<u>001</u>	
<u>AT</u>	<u>FLURANDRENOLIDE</u>				
<u>AT</u>	PADAGIS ISRAEL	<u>0.05%</u>	<u>A207133</u>	<u>001</u>	Aug 30, 2016

OINTMENT; TOPICAL

CORDRAN

<u>AT</u>	+! ALMIRALL	<u>0.05%</u>	<u>N012806</u>	<u>001</u>	
<u>AT</u>	<u>FLURANDRENOLIDE</u>				
<u>AT</u>	TELGENT	<u>0.05%</u>	<u>A207851</u>	<u>001</u>	Dec 30, 2016

TAPE; TOPICAL

CORDRAN

	+! ALMIRALL	0.004MG/SQ CM	N016455	001	

PRESCRIPTION DRUG PRODUCT LIST

3-208 (of 474)

FLURAZEPAM HYDROCHLORIDE

CAPSULE; ORAL

FLURAZEPAM HYDROCHLORIDE

RISING

15MG

A070345 002 Nov 27, 1985

!

30MG

A070345 001 Nov 27, 1985

FLURBIPROFEN

TABLET; ORAL

FLURBIPROFEN

! TEVA

100MG

A074431 001 May 31, 1995

FLURBIPROFEN SODIUM

SOLUTION/DROPS; OPHTHALMIC

FLURBIPROFEN SODIUM

! BAUSCH AND LOMB

0.03%

A074447 001 Jan 04, 1995

FLUTAMIDE

CAPSULE; ORAL

FLUTAMIDE

! WAYLIS THERAP

125MG

A075298 001 Sep 18, 2001

FLUTEMETAMOL F-18

INJECTABLE; INTRAVENOUS

VIZAMYL

+! GE HEALTHCARE

121.5mCi/30ML (4.05mCi/ML)

N203137 002 Oct 25, 2013

FLUTICASONE FUROATE

POWDER; INHALATION

ARNUITY ELLIPTA

+! GLAXOSMITHKLINE

0.05MG/INH

N205625 003 May 17, 2018

+!

0.1MG/INH

N205625 001 Aug 20, 2014

+!

0.2MG/INH

N205625 002 Aug 20, 2014

FLUTICASONE FUROATE; UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE

POWDER; INHALATION

TRELEGY ELLIPTA

+! GLAXOSMITHKLINE

0.1MG/INH; EQ 0.0625MG BASE/INH; EQ

N209482 001 Sep 18, 2017

0.025MG BASE/INH

+!

0.2MG/INH; EQ 0.0625MG BASE/INH; EQ

N209482 002 Sep 09, 2020

0.025MG BASE/INH

FLUTICASONE FUROATE; VILANTEROL TRIFENATATE

POWDER; INHALATION

BREO ELLIPTA

+! GLAXO GRP LTD

0.1MG/INH; EQ 0.025MG BASE/INH

N204275 001 May 10, 2013

+!

0.2MG/INH; EQ 0.025MG BASE/INH

N204275 002 Apr 30, 2015

FLUTICASONE PROPIONATE

AEROSOL, METERED; INHALATION

FLOVENT HFA

+! GLAXO GRP LTD

0.044MG/INH

N021433 003 May 14, 2004

+!

0.11MG/INH

N021433 002 May 14, 2004

+!

0.22MG/INH

N021433 001 May 14, 2004

CREAM; TOPICAL

FLUTICASONE PROPIONATEAB COSETTE0.05%A077055 001 Jun 30, 2006AB FOUGERA PHARMS0.05%A076451 001 May 14, 2004AB ! PADAGIS ISRAEL0.05%A076793 001 May 14, 2004

LOTION; TOPICAL

FLUTICASONE PROPIONATEAB ! GLENMARK GENERICS0.05%A090759 001 May 02, 2011AB PADAGIS ISRAEL0.05%A091553 001 Jul 30, 2013

OINTMENT; TOPICAL

FLUTICASONE PROPIONATEAB COSETTE0.005%A077168 001 Mar 03, 2006AB ! PADAGIS ISRAEL0.005%A076668 001 May 14, 2004

POWDER; INHALATION

ARMONAIR DIGIHALER

+ TEVA PHARM

0.055MG/INH

N208798 004 Feb 20, 2020

+

0.113MG/INH

N208798 005 Feb 20, 2020

+!

0.232MG/INH

N208798 006 Feb 20, 2020

FLOVENT DISKUS 100

+! GLAXO GRP LTD

0.1MG/INH

N020833 002 Sep 29, 2000

FLOVENT DISKUS 250

+! GLAXO GRP LTD

0.25MG/INH

N020833 003 Sep 29, 2000

PRESCRIPTION DRUG PRODUCT LIST

3-209 (of 474)

FLUTICASONE PROPIONATE

POWDER; INHALATION

FLOVENT DISKUS 50

+! GLAXO GRP LTD

0.05MG/INH

N020833 001 Sep 29, 2000

SPRAY, METERED; NASAL

FLUTICASONE PROPIONATEAB AKORN0.05MG/SPRAYA077570 001 Jan 16, 2008AB APOTEX INC0.05MG/SPRAYA077538 001 Sep 12, 2007AB ! HIKMA0.05MG/SPRAYA076504 001 Feb 22, 2006AB WOCKHARDT BIO AG0.05MG/SPRAYA078492 001 Jan 09, 2012

XHANCE

+! OPTINOSE US INC

0.093MG

N209022 001 Sep 18, 2017

FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE

AEROSOL, METERED; INHALATION

ADVAIR HFA

+! GLAXO GRP LTD

0.045MG/INH; EQ 0.021MG BASE/INH

N021254 001 Jun 08, 2006

+!

0.115MG/INH; EQ 0.021MG BASE/INH

N021254 002 Jun 08, 2006

+!

0.23MG/INH; EQ 0.021MG BASE/INH

N021254 003 Jun 08, 2006

POWDER; INHALATION

ADVAIR DISKUS 100/50AB +! GLAXO GRP LTD0.1MG/INH; EQ 0.05MG BASE/INHN021077 001 Aug 24, 2000ADVAIR DISKUS 250/50AB +! GLAXO GRP LTD0.25MG/INH; EQ 0.05MG BASE/INHN021077 002 Aug 24, 2000ADVAIR DISKUS 500/50AB +! GLAXO GRP LTD0.5MG/INH; EQ 0.05MG BASE/INHN021077 003 Aug 24, 2000FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATEAB HIKMA0.1MG/INH; EQ 0.05MG BASE/INHA203433 001 Dec 17, 2020AB0.25MG/INH; EQ 0.05MG BASE/INHA203433 002 Dec 17, 2020AB TEVA PHARMS USA0.1MG/INH; EQ 0.05MG BASE/INHA213948 001 Dec 13, 2021AB0.25MG/INH; EQ 0.05MG BASE/INHA213948 002 Dec 13, 2021AB0.5MG/INH; EQ 0.05MG BASE/INHA213948 003 Dec 13, 2021Wixela InhubAB MYLAN0.1MG/INH; EQ 0.05MG BASE/INHA208891 001 Jan 30, 2019AB0.25MG/INH; EQ 0.05MG BASE/INHA208891 002 Jan 30, 2019AB0.5MG/INH; EQ 0.05MG BASE/INHA208891 003 Jan 30, 2019

AIRDUO DIGIHALER

+ TEVA PHARM

0.055MG/INH; EQ 0.014MG BASE/INH

N208799 004 Jul 12, 2019

+

0.113MG/INH; EQ 0.014MG BASE/INH

N208799 005 Jul 12, 2019

+

0.232MG/INH; EQ 0.014MG BASE/INH

N208799 006 Jul 12, 2019

AIRDUO RESPICLICK

+ TEVA PHARM

0.055MG/INH; EQ 0.014MG BASE/INH

N208799 001 Jan 27, 2017

+

0.113MG/INH; EQ 0.014MG BASE/INH

N208799 002 Jan 27, 2017

+!

0.232MG/INH; EQ 0.014MG BASE/INH

N208799 003 Jan 27, 2017

FLUVASTATIN SODIUM

CAPSULE; ORAL

FLUVASTATIN SODIUMAB MYLAN PHARMS INCEQ 20MG BASEA090595 001 Apr 11, 2012AB !EQ 40MG BASEA090595 002 Apr 11, 2012AB TEVA PHARMSEQ 20MG BASEA078407 001 Jun 12, 2012ABEQ 40MG BASEA078407 002 Jun 12, 2012

TABLET, EXTENDED RELEASE; ORAL

FLUVASTATIN SODIUMAB BEIJINGEQ 80MG BASEA209397 001 Apr 26, 2021AB TEVA PHARMS USAEQ 80MG BASEA079011 001 Jan 27, 2016IESCOL XLAB +! NOVARTISEQ 80MG BASEN021192 001 Oct 06, 2000FLUVOXAMINE MALEATE

CAPSULE, EXTENDED RELEASE; ORAL

FLUVOXAMINE MALEATEAB ACTAVIS ELIZABETH100MGA091482 001 Apr 23, 2013AB !150MGA091482 002 Nov 18, 2013AB ANCHEN PHARMS100MGA091476 001 Mar 13, 2013AB150MGA091476 002 Mar 13, 2013AB BIONPHARMA INC100MGA212182 002 Sep 16, 2020AB150MGA212182 001 May 11, 2020

TABLET; ORAL

FLUVOXAMINE MALEATEAB APOTEX25MGA075902 001 May 07, 2001AB50MGA075902 002 May 07, 2001AB100MGA075902 003 May 07, 2001AB UPSHER SMITH LABS25MGA075888 001 Nov 29, 2000

PRESCRIPTION DRUG PRODUCT LIST

3-210 (of 474)

FLUVOXAMINE MALEATE

TABLET; ORAL

FLUVOXAMINE MALEATE

<u>AB</u>		<u>50MG</u>	<u>A075888</u>	<u>002</u>	Nov 29, 2000
<u>AB</u>	!	<u>100MG</u>	<u>A075888</u>	<u>003</u>	Nov 29, 2000
<u>LUVOX</u>					
<u>AB</u>	ANI PHARMS	<u>25MG</u>	<u>N021519</u>	<u>001</u>	Dec 20, 2007
<u>AB</u>		<u>50MG</u>	<u>N021519</u>	<u>002</u>	Dec 20, 2007
<u>AB</u>		<u>100MG</u>	<u>N021519</u>	<u>003</u>	Dec 20, 2007

FOLIC ACID

INJECTABLE; INJECTION

FOLIC ACID

<u>AP</u>	!	FRESENIUS KABI USA	<u>5MG/ML</u>	<u>A089202</u>	<u>001</u>	Feb 18, 1986
<u>AP</u>		XGEN PHARMS	<u>5MG/ML</u>	<u>A202522</u>	<u>001</u>	Nov 06, 2019

TABLET; ORAL

FOLIC ACID

<u>AA</u>	!	AMNEAL PHARM	<u>1MG</u>	<u>A040625</u>	<u>001</u>	Jul 21, 2005
<u>AA</u>		ATHEM	<u>1MG</u>	<u>A211064</u>	<u>001</u>	Mar 08, 2019
<u>AA</u>		CADILA PHARMS LTD	<u>1MG</u>	<u>A202437</u>	<u>001</u>	Jan 27, 2014
<u>AA</u>		CHARTWELL MOLECULAR	<u>1MG</u>	<u>A090035</u>	<u>001</u>	Jun 09, 2009
<u>AA</u>		LEADING	<u>1MG</u>	<u>A040796</u>	<u>001</u>	Jan 12, 2009
<u>AA</u>		NUVO PHARMS INC	<u>1MG</u>	<u>A204418</u>	<u>001</u>	Jul 28, 2015
<u>AA</u>		QINGDAO BAHEAL	<u>1MG</u>	<u>A091145</u>	<u>001</u>	Jul 12, 2013
		PHARM				
<u>AA</u>	+	WATSON LABS	<u>1MG</u>	<u>A080680</u>	<u>001</u>	

FOMEPIZOLE

INJECTABLE; INJECTION

FOMEPIZOLE

<u>AP</u>		AM REGENT	<u>1.5GM/1.5ML (1GM/ML)</u>	<u>A078368</u>	<u>001</u>	Dec 14, 2007
<u>AP</u>	!	MYLAN INSTITUTIONAL	<u>1.5GM/1.5ML (1GM/ML)</u>	<u>A078639</u>	<u>001</u>	Mar 03, 2008
<u>AP</u>		NAVINTA LLC	<u>1.5GM/1.5ML (1GM/ML)</u>	<u>A078537</u>	<u>001</u>	Mar 06, 2008

FONDAPARINUX SODIUM

INJECTABLE; SUBCUTANEOUS

ARIIXTRA

<u>AP</u>	+	MYLAN IRELAND LTD	<u>2.5MG/0.5ML</u>	<u>N021345</u>	<u>001</u>	Dec 07, 2001
<u>AP</u>	+		<u>5MG/0.4ML</u>	<u>N021345</u>	<u>002</u>	May 28, 2004
<u>AP</u>	+		<u>7.5MG/0.6ML</u>	<u>N021345</u>	<u>003</u>	May 28, 2004
<u>AP</u>	+		<u>10MG/0.8ML</u>	<u>N021345</u>	<u>004</u>	May 28, 2004

FONDAPARINUX SODIUM

<u>AP</u>		DR REDDYS LABS LTD	<u>2.5MG/0.5ML</u>	<u>A091316</u>	<u>001</u>	Jul 11, 2011
<u>AP</u>			<u>5MG/0.4ML</u>	<u>A091316</u>	<u>002</u>	Jul 11, 2011
<u>AP</u>			<u>7.5MG/0.6ML</u>	<u>A091316</u>	<u>003</u>	Jul 11, 2011
<u>AP</u>			<u>10MG/0.8ML</u>	<u>A091316</u>	<u>004</u>	Jul 11, 2011
<u>AP</u>		EUGIA PHARMA	<u>2.5MG/0.5ML</u>	<u>A206918</u>	<u>001</u>	Dec 26, 2017
<u>AP</u>			<u>5MG/0.4ML</u>	<u>A206918</u>	<u>002</u>	Dec 26, 2017
<u>AP</u>			<u>7.5MG/0.6ML</u>	<u>A206918</u>	<u>003</u>	Dec 26, 2017
<u>AP</u>			<u>10MG/0.8ML</u>	<u>A206918</u>	<u>004</u>	Dec 26, 2017
<u>AP</u>		HENGRUI PHARMA	<u>2.5MG/0.5ML</u>	<u>A206812</u>	<u>001</u>	May 15, 2018
<u>AP</u>			<u>5MG/0.4ML</u>	<u>A206812</u>	<u>002</u>	May 15, 2018
<u>AP</u>			<u>7.5MG/0.6ML</u>	<u>A206812</u>	<u>003</u>	May 15, 2018
<u>AP</u>			<u>10MG/0.8ML</u>	<u>A206812</u>	<u>004</u>	May 15, 2018
<u>AP</u>		SCINOPHARM TAIWAN	<u>2.5MG/0.5ML</u>	<u>A208615</u>	<u>001</u>	Nov 14, 2018
<u>AP</u>			<u>5MG/0.4ML</u>	<u>A208615</u>	<u>002</u>	Nov 14, 2018
<u>AP</u>			<u>7.5MG/0.6ML</u>	<u>A208615</u>	<u>003</u>	Nov 14, 2018
<u>AP</u>			<u>10MG/0.8ML</u>	<u>A208615</u>	<u>004</u>	Nov 14, 2018

FORMOTEROL FUMARATE

SOLUTION; INHALATION

FORMOTEROL FUMARATE

<u>AN</u>		ALEMBIC PHARMS	<u>0.02MG/2ML</u>	<u>A215078</u>	<u>001</u>	Nov 22, 2021
<u>AN</u>		AUCTA	<u>0.02MG/2ML</u>	<u>A216486</u>	<u>001</u>	Nov 25, 2022
<u>AN</u>		LUPIN	<u>0.02MG/2ML</u>	<u>A215053</u>	<u>001</u>	Aug 22, 2022
<u>AN</u>		SLAYBACK PHARMA LLC	<u>0.02MG/2ML</u>	<u>A215621</u>	<u>001</u>	Dec 13, 2022
<u>AN</u>		TEVA PHARMS USA INC	<u>0.02MG/2ML</u>	<u>A091141</u>	<u>001</u>	Jun 22, 2021

PERFOROMIST

<u>AN</u>	+	MYLAN SPECLT	<u>0.02MG/2ML</u>	<u>N022007</u>	<u>001</u>	May 11, 2007

PRESCRIPTION DRUG PRODUCT LIST

3-211 (of 474)

FORMOTEROL FUMARATE; GLYCOPYRROLATE

AEROSOL, METERED; INHALATION

BEVESPI AEROSPHERE

+! ASTRAZENECA 0.0048MG/INH; 0.0090MG/INH

N208294 001 Apr 25, 2016

FORMOTEROL FUMARATE; MOMETASONE FUROATE

AEROSOL, METERED; INHALATION

DULERA

+ ORGANON LLC 0.005MG/INH; 0.05MG/INH

N022518 003 Aug 12, 2019

+! 0.005MG/INH; 0.1MG/INH

N022518 001 Jun 22, 2010

+! 0.005MG/INH; 0.2MG/INH

N022518 002 Jun 22, 2010

FOSAMPRENAVIR CALCIUM

SUSPENSION; ORAL

LEXIVA

+! VIIV HLTHCARE EQ 50MG BASE/ML

N022116 001 Jun 14, 2007

TABLET; ORAL

FOSAMPRENAVIR CALCIUM**AB** MYLAN**EQ 700MG BASE****A204060 001** Apr 15, 2016**AB** SUN PHARM**EQ 700MG BASE****A204024 001** Nov 20, 2019LEXIVA**AB** +! VIIV HLTHCARE**EQ 700MG BASE****N021548 001** Oct 20, 2003FOSAPREPITANT DIMEGLUMINE

POWDER; INTRAVENOUS

EMEND**AP** +! MERCK AND CO INC**EQ 150MG BASE/VIAL****N022023 002** Nov 12, 2010FOSAPREPITANT DIMEGLUMINE**AP** ACCORD HLTHCARE**EQ 150MG BASE/VIAL****A204025 001** Aug 26, 2020**AP** ASPIRO**EQ 150MG BASE/VIAL****A214616 001** Jul 29, 2021**AP** BAXTER HLTHCARE**EQ 150MG BASE/VIAL****A211860 001** Sep 05, 2019

CORP

AP BE PHARMS**EQ 150MG BASE/VIAL****A212309 001** Sep 05, 2019**AP** CHIA TAI TIANQING**EQ 150MG BASE/VIAL****A212143 001** Mar 03, 2021**AP** DR REDDYS**EQ 150MG BASE/VIAL****A211160 001** Dec 09, 2020**AP** EUGIA PHARMA**EQ 150MG BASE/VIAL****A210625 001** Jan 12, 2021**AP** FRESenius KABI USA**EQ 150MG BASE/VIAL****A206197 001** Jun 09, 2016**AP** LUPIN LTD**EQ 150MG BASE/VIAL****A210689 001** Sep 05, 2019**AP** MSN**EQ 150MG BASE/VIAL****A209965 001** Sep 05, 2019**AP** MYLAN LABS LTD**EQ 150MG BASE/VIAL****A204015 002** Sep 05, 2019**AP** NAVINTA LLC**EQ 150MG BASE/VIAL****A212957 002** Aug 20, 2020**AP** QILU PHARM HAINAN**EQ 150MG BASE/VIAL****A213106 001** Sep 08, 2020

TEVA PHARMS USA EQ 150MG BASE/VIAL

N210064 001 Sep 05, 2019

FOSCARNET SODIUM

INJECTABLE; INJECTION

FOSCARNET SODIUM**AP** FRESenius KABI USA**2.4GM/100ML****A212483 001** Jan 29, 2021**AP** GLAND PHARMA LTD**2.4GM/100ML****A213001 001** Apr 21, 2021FOSCAVIR**AP** +! CLINIGEN HLTHCARE**2.4GM/100ML****N020068 001** Sep 27, 1991FOSDENOPTERIN HYDROBROMIDE

POWDER; INTRAVENOUS

NULIBRY

+! SENTYNL THERAPS INC EQ 9.5MG BASE/VIAL

N214018 001 Feb 26, 2021

FOSFOMYCIN TROMETHAMINE

FOR SOLUTION; ORAL

FOSFOMYCIN TROMETHAMINE**AA** ALKEM LABS LTD**EQ 3GM BASE/PACKET****A214554 001** Oct 21, 2021**AA** CIPLA**EQ 3GM BASE/PACKET****A211881 001** Jan 26, 2022**AA** XIROMED**EQ 3GM BASE/PACKET****A212548 001** Oct 06, 2020MONUROL**AA** +! ZAMBON SPA**EQ 3GM BASE/PACKET****N050717 001** Dec 19, 1996FOSINOPRIL SODIUM

TABLET; ORAL

FOSINOPRIL SODIUM**AB** APOTEX INC**10MG****A076906 001** May 17, 2005**AB****20MG****A076906 002** May 17, 2005**AB****40MG****A076906 003** May 17, 2005**AB** AUROBINDO PHARMA**10MG****A091163 001** Mar 30, 2011

LTD

AB**20MG****A091163 002** Mar 30, 2011**AB****40MG****A091163 003** Mar 30, 2011

PRESCRIPTION DRUG PRODUCT LIST

3-212 (of 474)

FOSINOPRIL SODIUM

TABLET; ORAL

FOSINOPRIL SODIUM

<u>AB</u>	CHARTWELL RX	<u>10MG</u>	<u>A076483</u>	<u>001</u>	Apr 23, 2004
<u>AB</u>		<u>20MG</u>	<u>A076483</u>	<u>002</u>	Apr 23, 2004
<u>AB</u>		<u>40MG</u>	<u>A076483</u>	<u>003</u>	Apr 23, 2004
<u>AB</u>	INVAGEN PHARMS	<u>10MG</u>	<u>A077222</u>	<u>001</u>	Apr 20, 2005
<u>AB</u>		<u>20MG</u>	<u>A077222</u>	<u>002</u>	Apr 20, 2005
<u>AB</u>		<u>40MG</u>	<u>A077222</u>	<u>003</u>	Apr 20, 2005
<u>AB</u>	PRINSTON INC	<u>10MG</u>	<u>A205670</u>	<u>001</u>	Aug 29, 2016
<u>AB</u>		<u>20MG</u>	<u>A205670</u>	<u>002</u>	Aug 29, 2016
<u>AB</u>		<u>40MG</u>	<u>A205670</u>	<u>003</u>	Aug 29, 2016
<u>AB</u>	TEVA	<u>10MG</u>	<u>A076139</u>	<u>001</u>	Nov 25, 2003
<u>AB</u>		<u>20MG</u>	<u>A076139</u>	<u>002</u>	Nov 25, 2003
<u>AB</u>	!	<u>40MG</u>	<u>A076139</u>	<u>003</u>	Nov 25, 2003

FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE

TABLET; ORAL

FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

<u>AB</u>	AUROBINDO PHARMA	<u>10MG;12.5MG</u>	<u>A079245</u>	<u>001</u>	Jul 09, 2009
<u>AB</u>	!	<u>20MG;12.5MG</u>	<u>A079245</u>	<u>002</u>	Jul 09, 2009
<u>AB</u>	INVAGEN PHARMS	<u>10MG;12.5MG</u>	<u>A090228</u>	<u>001</u>	Jul 09, 2009
<u>AB</u>		<u>20MG;12.5MG</u>	<u>A090228</u>	<u>002</u>	Jul 09, 2009
<u>AB</u>	SANDOZ	<u>10MG;12.5MG</u>	<u>A076961</u>	<u>001</u>	Sep 28, 2005
<u>AB</u>		<u>20MG;12.5MG</u>	<u>A076961</u>	<u>002</u>	Sep 28, 2005

FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE

POWDER; INTRAVENOUS

AKYNZEO

+	!	HEL SINN HLTHCARE	EQ 235MG BASE/VIAL;EQ 0.25MG BASE/VIAL	N210493	001	Apr 19, 2018
SOLUTION; INTRAVENOUS						
AKYNZEO						
+	!	HEL SINN HLTHCARE	EQ 235MG BASE/20ML (EQ 11.75MG BASE/ML);EQ 0.25MG BASE/20ML (EQ 0.0125MG BASE/ML)	N210493	002	May 27, 2020

FOSPHENYTOIN SODIUM

INJECTABLE; INJECTION

CEREBYX

<u>AP</u>	+	!	PARKE DAVIS	<u>EQ 50MG PHENYTOIN NA/ML</u>	<u>N020450</u>	<u>001</u>	Aug 05, 1996

FOSPHENYTOIN SODIUM

<u>AP</u>		FRESENIUS KABI USA	<u>EQ 50MG PHENYTOIN NA/ML</u>	<u>A078052</u>	<u>001</u>	Aug 06, 2007
<u>AP</u>		HIKMA	<u>EQ 50MG PHENYTOIN NA/ML</u>	<u>A077481</u>	<u>001</u>	Aug 06, 2007
<u>AP</u>			<u>EQ 50MG PHENYTOIN NA/ML</u>	<u>A077989</u>	<u>001</u>	Aug 06, 2007
<u>AP</u>		HIKMA FARMACEUTICA	<u>EQ 50MG PHENYTOIN NA/ML</u>	<u>A078765</u>	<u>001</u>	Dec 02, 2009
<u>AP</u>		MYLAN LABS LTD	<u>EQ 50MG PHENYTOIN NA/ML</u>	<u>A078736</u>	<u>001</u>	Jun 08, 2010
<u>AP</u>		SUN PHARM	<u>EQ 50MG PHENYTOIN NA/ML</u>	<u>A078417</u>	<u>001</u>	Mar 18, 2008
<u>AP</u>		WOCKHARDT	<u>EQ 50MG PHENYTOIN NA/ML</u>	<u>A078137</u>	<u>001</u>	Aug 06, 2007

FOSTAMATINIB DISODIUM

TABLET; ORAL

TAVALISSE

+		RIGEL PHARMS INC	EQ 100MG BASE	N209299	001	Apr 17, 2018
+	!		EQ 150MG BASE	N209299	002	Apr 17, 2018

FOSTEMSAVIR TROMETHAMINE

TABLET, EXTENDED RELEASE; ORAL

RUKOBIA

+	!	VIIV HLTHCARE	EQ 600MG BASE	N212950	001	Jul 02, 2020

FROVATRIPTAN SUCCINATE

TABLET; ORAL

FROVA

<u>AB</u>	+	!	ENDO PHARMS	<u>EQ 2.5MG BASE</u>	<u>N021006</u>	<u>001</u>	Nov 08, 2001

FROVATRIPTAN SUCCINATE

<u>AB</u>		AMNEAL PHARMS CO	<u>EQ 2.5MG BASE</u>	<u>A211292</u>	<u>001</u>	Nov 06, 2018
<u>AB</u>		GLENMARK PHARMS LTD	<u>EQ 2.5MG BASE</u>	<u>A204730</u>	<u>001</u>	Mar 11, 2016
<u>AB</u>		MYLAN	<u>EQ 2.5MG BASE</u>	<u>A202931</u>	<u>001</u>	Aug 28, 2014
<u>AB</u>		RENATA	<u>EQ 2.5MG BASE</u>	<u>A213891</u>	<u>001</u>	Apr 06, 2022

PRESCRIPTION DRUG PRODUCT LIST

3-213 (of 474)

FULVESTRANT

SOLUTION; INTRAMUSCULAR

FASLODEX

<u>AO</u>	<u>+!</u>	ASTRAZENECA	<u>250MG/5ML (50MG/ML)</u>	<u>N021344</u>	<u>001</u>	Apr 25, 2002

FULVESTRANT

<u>AO</u>		ACCORD HLTHCARE	<u>250MG/5ML (50MG/ML)</u>	<u>A211689</u>	<u>001</u>	Nov 17, 2020
<u>AO</u>		ALEMBIC PHARMS	<u>250MG/5ML (50MG/ML)</u>	<u>A215077</u>	<u>001</u>	Dec 22, 2022
<u>AO</u>		AMNEAL	<u>250MG/5ML (50MG/ML)</u>	<u>A210044</u>	<u>001</u>	Mar 04, 2019
<u>AO</u>		CHIA TAI TIANQING	<u>250MG/5ML (50MG/ML)</u>	<u>A211422</u>	<u>001</u>	Feb 07, 2020
<u>AO</u>		DR REDDYS	<u>250MG/5ML (50MG/ML)</u>	<u>A209246</u>	<u>001</u>	Aug 07, 2020
<u>AO</u>		EUGIA PHARMA	<u>250MG/5ML (50MG/ML)</u>	<u>A208811</u>	<u>001</u>	Jul 23, 2019
<u>AO</u>		GLENMARK PHARMS INC	<u>250MG/5ML (50MG/ML)</u>	<u>A207754</u>	<u>001</u>	Aug 22, 2019
<u>AO</u>		HBT LABS INC	<u>250MG/5ML (50MG/ML)</u>	<u>A209714</u>	<u>001</u>	Nov 21, 2019
<u>AO</u>		JIANGSU HANSON PHARM	<u>250MG/5ML (50MG/ML)</u>	<u>A214682</u>	<u>001</u>	Feb 10, 2022
<u>AO</u>		SAGENT PHARMS INC	<u>250MG/5ML (50MG/ML)</u>	<u>A205871</u>	<u>001</u>	Aug 22, 2019
<u>AO</u>		SANDOZ INC	<u>250MG/5ML (50MG/ML)</u>	<u>A205935</u>	<u>001</u>	May 14, 2019
<u>AO</u>		XIROMED	<u>250MG/5ML (50MG/ML)</u>	<u>A213553</u>	<u>001</u>	Aug 13, 2021
<u>AO</u>		ZYDUS PHARMS	<u>250MG/5ML (50MG/ML)</u>	<u>A215234</u>	<u>001</u>	Jul 29, 2021
		FRESENIUS KABI USA	250MG/5ML (50MG/ML)	N210326	001	May 20, 2019
		TEVA PHARMS USA INC	250MG/5ML (50MG/ML)	N210063	001	Aug 19, 2019

FUROSEMIDE

INJECTABLE; INJECTION

FUROSEMIDE

<u>AP</u>		ACCORD HLTHCARE	<u>10MG/ML</u>	<u>A070017</u>	<u>001</u>	Dec 15, 1986
<u>AP</u>		AREVA PHARMS	<u>10MG/ML</u>	<u>A208435</u>	<u>001</u>	Dec 18, 2020
<u>AP</u>		ATHENEX INC	<u>10MG/ML</u>	<u>A214766</u>	<u>001</u>	Jan 27, 2021
<u>AP</u>	<u>!</u>	BAXTER HLTHCARE CORP	<u>10MG/ML</u>	<u>A202747</u>	<u>001</u>	Jan 27, 2014
<u>AP</u>		EMCURE PHARMS LTD	<u>10MG/ML</u>	<u>A203428</u>	<u>001</u>	Aug 26, 2014
<u>AP</u>		EUGIA PHARMA	<u>10MG/ML</u>	<u>A212174</u>	<u>001</u>	May 03, 2019
<u>AP</u>		FRESENIUS KABI USA	<u>10MG/ML</u>	<u>N018902</u>	<u>001</u>	May 22, 1984
<u>AP</u>		GLAND PHARMA LTD	<u>10MG/ML</u>	<u>A213902</u>	<u>001</u>	Jul 01, 2020
<u>AP</u>		HOSPIRA	<u>10MG/ML</u>	<u>A075241</u>	<u>001</u>	May 28, 1999
<u>AP</u>			<u>10MG/ML</u>	<u>N018667</u>	<u>001</u>	May 28, 1982
<u>AP</u>		MANKIND PHARMA	<u>10MG/ML</u>	<u>A216860</u>	<u>001</u>	Dec 16, 2022
<u>AP</u>		MEITHEAL	<u>10MG/ML</u>	<u>A212803</u>	<u>001</u>	Jan 27, 2022
<u>AP</u>		WOCKHARDT	<u>10MG/ML</u>	<u>A077941</u>	<u>001</u>	Mar 22, 2007

SOLUTION; ORAL

FUROSEMIDE!

HIKMA

10MG/ML	A070434	001	Apr 22, 1987
40MG/5ML	A070433	001	Apr 22, 1987

SOLUTION; SUBCUTANEOUS

FUROSCIX+!

SCPHARMACEUTICALS

80MG/10ML (8MG/ML)

N209988 001 Oct 07, 2022

TABLET; ORAL

FUROSEMIDE

<u>AB</u>		EPIC PHARMA LLC	<u>20MG</u>	<u>N018569</u>	<u>002</u>	
<u>AB</u>			<u>40MG</u>	<u>N018569</u>	<u>001</u>	
<u>AB</u>			<u>80MG</u>	<u>N018569</u>	<u>005</u>	Aug 14, 1984
<u>AB</u>		GRAVITI PHARMS	<u>20MG</u>	<u>A216629</u>	<u>001</u>	Oct 17, 2022
<u>AB</u>			<u>40MG</u>	<u>A216629</u>	<u>002</u>	Oct 17, 2022
<u>AB</u>			<u>80MG</u>	<u>A216629</u>	<u>003</u>	Oct 17, 2022
<u>AB</u>		HIKMA	<u>20MG</u>	<u>N018823</u>	<u>001</u>	Nov 10, 1983
<u>AB</u>			<u>40MG</u>	<u>N018823</u>	<u>002</u>	Nov 10, 1983
<u>AB</u>			<u>80MG</u>	<u>A070086</u>	<u>001</u>	Jan 24, 1986
<u>AB</u>		IPCA LABS LTD	<u>20MG</u>	<u>A078010</u>	<u>001</u>	Sep 18, 2006
<u>AB</u>			<u>40MG</u>	<u>A078010</u>	<u>002</u>	Sep 18, 2006
<u>AB</u>			<u>80MG</u>	<u>A078010</u>	<u>003</u>	Sep 18, 2006
<u>AB</u>		LEADING	<u>20MG</u>	<u>A077293</u>	<u>001</u>	Nov 09, 2005
<u>AB</u>			<u>40MG</u>	<u>A077293</u>	<u>002</u>	Nov 09, 2005
<u>AB</u>			<u>80MG</u>	<u>A077293</u>	<u>003</u>	Nov 09, 2005
<u>AB</u>		MYLAN	<u>20MG</u>	<u>N018487</u>	<u>001</u>	
<u>AB</u>			<u>40MG</u>	<u>N018487</u>	<u>002</u>	
<u>AB</u>			<u>80MG</u>	<u>A070082</u>	<u>001</u>	Oct 29, 1986
<u>AB</u>		PRINSTON INC	<u>20MG</u>	<u>A076796</u>	<u>001</u>	Mar 26, 2004
<u>AB</u>			<u>40MG</u>	<u>A076796</u>	<u>002</u>	Mar 26, 2004
<u>AB</u>			<u>80MG</u>	<u>A076796</u>	<u>003</u>	Mar 26, 2004

LASIX

<u>AB</u>	<u>+</u>	VALIDUS PHARMS	<u>20MG</u>	<u>N016273</u>	<u>002</u>	
<u>AB</u>	<u>+</u>		<u>40MG</u>	<u>N016273</u>	<u>001</u>	
<u>AB</u>	<u>+!</u>		<u>80MG</u>	<u>N016273</u>	<u>003</u>	

PRESCRIPTION DRUG PRODUCT LIST

3-214 (of 474)

FUTIBATINIB

TABLET; ORAL

LYTGOBI

+! TAIHO ONCOLOGY

4MG

N214801 001 Sep 30, 2022

GABAPENTIN

CAPSULE; ORAL

GABAPENTIN

<u>AB</u>	ACI	<u>100MG</u>	<u>A206943</u>	<u>001</u>	May 14, 2018
<u>AB</u>		<u>300MG</u>	<u>A206943</u>	<u>002</u>	May 14, 2018
<u>AB</u>		<u>400MG</u>	<u>A206943</u>	<u>003</u>	May 14, 2018
<u>AB</u>	ACTAVIS ELIZABETH	<u>100MG</u>	<u>A075350</u>	<u>001</u>	Sep 12, 2003
<u>AB</u>		<u>300MG</u>	<u>A075350</u>	<u>002</u>	Sep 12, 2003
<u>AB</u>		<u>400MG</u>	<u>A075350</u>	<u>003</u>	Sep 12, 2003
<u>AB</u>	ALKEM	<u>100MG</u>	<u>A090858</u>	<u>001</u>	Dec 17, 2010
<u>AB</u>		<u>300MG</u>	<u>A090858</u>	<u>002</u>	Dec 17, 2010
<u>AB</u>		<u>400MG</u>	<u>A090858</u>	<u>003</u>	Dec 17, 2010
<u>AB</u>	AMNEAL PHARMS NY	<u>100MG</u>	<u>A078428</u>	<u>001</u>	Jul 25, 2007
<u>AB</u>		<u>300MG</u>	<u>A078428</u>	<u>002</u>	Jul 25, 2007
<u>AB</u>		<u>400MG</u>	<u>A078428</u>	<u>003</u>	Jul 25, 2007
<u>AB</u>	ASCENT PHARMS INC	<u>100MG</u>	<u>A214956</u>	<u>001</u>	May 10, 2021
<u>AB</u>		<u>300MG</u>	<u>A214956</u>	<u>002</u>	May 10, 2021
<u>AB</u>		<u>400MG</u>	<u>A214956</u>	<u>003</u>	May 10, 2021
<u>AB</u>	AUROBINDO PHARMA	<u>100MG</u>	<u>A078787</u>	<u>001</u>	Jan 31, 2008
<u>AB</u>		<u>300MG</u>	<u>A078787</u>	<u>002</u>	Jan 31, 2008
<u>AB</u>		<u>400MG</u>	<u>A078787</u>	<u>003</u>	Jan 31, 2008
<u>AB</u>	CSPC OUYI	<u>100MG</u>	<u>A075477</u>	<u>001</u>	Mar 23, 2005
<u>AB</u>		<u>300MG</u>	<u>A075477</u>	<u>002</u>	Mar 23, 2005
<u>AB</u>		<u>400MG</u>	<u>A075477</u>	<u>003</u>	Mar 23, 2005
<u>AB</u>	GRANULES	<u>100MG</u>	<u>A075360</u>	<u>001</u>	Apr 06, 2005
<u>AB</u>		<u>300MG</u>	<u>A075360</u>	<u>002</u>	Apr 06, 2005
<u>AB</u>		<u>400MG</u>	<u>A075360</u>	<u>003</u>	Apr 06, 2005
<u>AB</u>	GRAVITI PHARMS	<u>100MG</u>	<u>A207099</u>	<u>001</u>	Mar 24, 2017
<u>AB</u>		<u>300MG</u>	<u>A207099</u>	<u>002</u>	Mar 24, 2017
<u>AB</u>		<u>400MG</u>	<u>A207099</u>	<u>003</u>	Mar 24, 2017
<u>AB</u>	INVAGEN PHARMS	<u>100MG</u>	<u>A090705</u>	<u>001</u>	Dec 30, 2009
<u>AB</u>		<u>300MG</u>	<u>A090705</u>	<u>002</u>	Dec 30, 2009
<u>AB</u>		<u>400MG</u>	<u>A090705</u>	<u>003</u>	Dec 30, 2009
<u>AB</u>	MARKSANS PHARMA	<u>100MG</u>	<u>A090007</u>	<u>001</u>	Jul 21, 2011
<u>AB</u>		<u>300MG</u>	<u>A090007</u>	<u>002</u>	Jul 21, 2011
<u>AB</u>		<u>400MG</u>	<u>A090007</u>	<u>003</u>	Jul 21, 2011
<u>AB</u>	SCIEGEN PHARMS INC	<u>100MG</u>	<u>A204989</u>	<u>001</u>	Feb 18, 2016
<u>AB</u>		<u>300MG</u>	<u>A204989</u>	<u>002</u>	Feb 18, 2016
<u>AB</u>		<u>400MG</u>	<u>A204989</u>	<u>003</u>	Feb 18, 2016
<u>AB</u>	STRIDES PHARMA	<u>100MG</u>	<u>A211314</u>	<u>001</u>	Oct 16, 2018
<u>AB</u>		<u>300MG</u>	<u>A211314</u>	<u>002</u>	Oct 16, 2018
<u>AB</u>		<u>400MG</u>	<u>A211314</u>	<u>003</u>	Oct 16, 2018
<u>AB</u>	SUN PHARM INDS LTD	<u>100MG</u>	<u>A077242</u>	<u>001</u>	Aug 24, 2006
<u>AB</u>		<u>300MG</u>	<u>A077242</u>	<u>002</u>	Aug 24, 2006
<u>AB</u>		<u>400MG</u>	<u>A077242</u>	<u>003</u>	Aug 24, 2006
<u>AB</u>	TARO	<u>100MG</u>	<u>A077261</u>	<u>001</u>	Aug 02, 2013
<u>AB</u>		<u>300MG</u>	<u>A077261</u>	<u>002</u>	Aug 02, 2013
<u>AB</u>		<u>400MG</u>	<u>A077261</u>	<u>003</u>	Aug 02, 2013
<u>AB</u>	ZHEJIANG YONGTAI	<u>100MG</u>	<u>A213603</u>	<u>001</u>	Aug 17, 2020
<u>AB</u>		<u>300MG</u>	<u>A213603</u>	<u>002</u>	Aug 17, 2020
<u>AB</u>		<u>400MG</u>	<u>A213603</u>	<u>003</u>	Aug 17, 2020

NEURONTIN

<u>AB</u>	+ VIATRIS	<u>100MG</u>	<u>N020235</u>	<u>001</u>	Dec 30, 1993
<u>AB</u>	+	<u>300MG</u>	<u>N020235</u>	<u>002</u>	Dec 30, 1993
<u>AB</u>	+!	<u>400MG</u>	<u>N020235</u>	<u>003</u>	Dec 30, 1993

SOLUTION; ORAL

GABAPENTIN

<u>AA</u>	ACELLA PHARMS LLC	<u>250MG/5ML</u>	<u>A076403</u>	<u>001</u>	May 01, 2012
<u>AA</u>	AKORN	<u>250MG/5ML</u>	<u>A078974</u>	<u>001</u>	Feb 18, 2011
<u>AA</u>	AMNEAL PHARMS	<u>250MG/5ML</u>	<u>A202024</u>	<u>001</u>	Mar 23, 2012
<u>AA</u>	BELCHER	<u>250MG/5ML</u>	<u>A091286</u>	<u>001</u>	Mar 14, 2016
<u>AA</u>	TARO	<u>250MG/5ML</u>	<u>A076672</u>	<u>001</u>	Jul 03, 2013

NEURONTIN

<u>AA</u>	+! VIATRIS	<u>250MG/5ML</u>	<u>N021129</u>	<u>001</u>	Mar 02, 2000

TABLET; ORAL

GABAPENTIN

<u>AB</u>	ACI	<u>600MG</u>	<u>A203244</u>	<u>002</u>	Jul 12, 2013
<u>AB</u>		<u>800MG</u>	<u>A203244</u>	<u>001</u>	Jul 12, 2013

PRESCRIPTION DRUG PRODUCT LIST

3-215 (of 474)

GABAPENTIN

TABLET; ORAL

GABAPENTIN

AB	ACTAVIS ELIZABETH	600MG	A075694 001	Oct 21, 2004
AB		800MG	A075694 002	Oct 21, 2004
AB	ALKEM LABS LTD	600MG	A206402 001	Dec 23, 2015
AB		800MG	A206402 002	Dec 23, 2015
AB	APOTEX INC	100MG	A077894 001	Oct 10, 2006
AB		300MG	A077894 002	Oct 10, 2006
AB		400MG	A077894 003	Oct 10, 2006
AB	ASCENT PHARMS INC	600MG	A214957 001	Oct 01, 2021
AB		800MG	A214957 002	Oct 01, 2021
AB	AUROBINDO PHARMA LTD	600MG	A200651 001	Oct 06, 2011
AB		800MG	A200651 002	Oct 06, 2011
AB	CSPC OUYI	600MG	A207057 001	Oct 26, 2017
AB		800MG	A207057 002	Oct 26, 2017
AB	GLENMARK PHARMS LTD	600MG	A077662 001	Aug 18, 2006
AB		800MG	A077662 002	Aug 18, 2006
AB	INVAGEN PHARMS	600MG	A202764 001	Oct 16, 2012
AB		800MG	A202764 002	Oct 16, 2012
AB	IVAX SUB TEVA PHARMS	100MG	A076017 001	Apr 28, 2004
AB		300MG	A076017 002	Apr 28, 2004
AB		400MG	A076017 003	Apr 28, 2004
AB	RUBICON	600MG	A077661 004	Sep 13, 2006
AB		800MG	A077661 005	Sep 13, 2006
AB	SCIEGEN PHARMS INC	600MG	A205101 001	Feb 04, 2016
AB		800MG	A205101 002	Feb 04, 2016
AB	SUN PHARM INDS LTD	600MG	A077525 001	Aug 24, 2006
AB		800MG	A077525 002	Aug 24, 2006
AB	ZYDUS PHARMS USA INC	600MG	A078926 001	Feb 11, 2011
AB		800MG	A078926 002	Feb 11, 2011

NEURONTIN

AB	+	VIATRIS	600MG	N020882 001	Oct 09, 1998
AB	+	!	800MG	N020882 002	Oct 09, 1998
		GRALISE			
BX	+	!	ALMATICA	300MG	N022544 001 Jan 28, 2011
BX	+	!		600MG	N022544 002 Jan 28, 2011

GABAPENTIN ENACARBIL

TABLET, EXTENDED RELEASE; ORAL

HORIZANT

+	AZURITY	300MG	N022399 002	Dec 13, 2011
+	!	600MG	N022399 001	Apr 06, 2011

GADOBENATE DIMEGLUMINE

INJECTABLE; INTRAVENOUS

MULTIHANCE

+	!	BRACCO	2.645GM/5ML (529MG/ML)	N021357 001	Nov 23, 2004
+	!		5.29GM/10ML (529MG/ML)	N021357 002	Nov 23, 2004
+	!		7.935GM/15ML (529MG/ML)	N021357 003	Nov 23, 2004
+	!		10.58GM/20ML (529MG/ML)	N021357 004	Nov 23, 2004

MULTIHANCE MULTIPACK

+	!	BRACCO	26.45GM/50ML (529MG/ML)	N021358 001	Nov 23, 2004
+	!		52.9GM/100ML (529MG/ML)	N021358 002	Nov 23, 2004

GADOBUTROL

SOLUTION; INTRAVENOUS

GADAVIST

AP	+	!	BAYER HLTHCARE	1.20944GM/2ML (604.72MG/ML)	N201277 006	Dec 18, 2013
AP	+	!		4.5354GM/7.5ML (604.72MG/ML)	N201277 001	Mar 14, 2011
AP	+	!		6.0472GM/10ML (604.72MG/ML)	N201277 002	Mar 14, 2011
AP	+	!		9.0708GM/15ML (604.72MG/ML)	N201277 003	Mar 14, 2011

GADOBUTROL

AP		HENGRI PHARMA	1.20944GM/2ML (604.72MG/ML)	A215061 001	Nov 17, 2022
AP			4.5354GM/7.5ML (604.72MG/ML)	A215061 002	Nov 17, 2022
AP			6.0472GM/10ML (604.72MG/ML)	A215061 003	Nov 17, 2022
AP			9.0708GM/15ML (604.72MG/ML)	A215061 004	Nov 17, 2022

GADAVIST

+	!	BAYER HLTHCARE	18.1416GM/30ML (604.72MG/ML)	N201277 004	Mar 14, 2011
+	!		39.3068GM/65ML (604.72MG/ML)	N201277 005	Mar 14, 2011

PRESCRIPTION DRUG PRODUCT LIST

3-216 (of 474)

GADODIAMIDE

INJECTABLE; INJECTION

OMNISCAN

+! GE HEALTHCARE

287MG/ML

N020123 001 Jan 08, 1993

+!

28.7GM/100ML (287MG/ML)

N022066 002 Sep 05, 2007

GADOPICLENOL

SOLUTION; INTRAVENOUS

ELUCIREM

+! GUERBET

1.4553GM/3ML (485.1MG/ML)

N216986 001 Sep 21, 2022

+!

3.63825GM/7.5ML (485.1MG/ML)

N216986 002 Sep 21, 2022

+!

4.851GM/10ML (485.1MG/ML)

N216986 003 Sep 21, 2022

+!

7.2765GM/15ML (485.1MG/ML)

N216986 004 Sep 21, 2022

+!

14.553GM/30ML (485.1MG/ML)

N216986 005 Sep 21, 2022

+!

24.255GM/50ML (485.1MG/ML)

N216986 006 Sep 21, 2022

+!

48.51GM/100ML (485.1MG/ML)

N216986 007 Sep 21, 2022

GADOTERATE MEGLUMINE

SOLUTION; INTRAVENOUS

CLARISCANAP GE HEALTHCARE7.538GM/20ML (376.9MG/ML)A210016 003 Nov 01, 2019AP1.8845GM/5ML (376.9MG/ML)A210016 005 Nov 24, 2020AP3.769GM/10ML (376.9MG/ML)A210016 001 Nov 01, 2019AP5.6535GM/15ML (376.9MG/ML)A210016 002 Nov 01, 2019AP37.69GM/100ML (376.9MG/ML)A210016 004 Aug 04, 2020DOTAREMAP +! GUERBET37.69GM/100ML (376.9MG/ML)N204781 001 Mar 20, 2013AP +!1.8845GM/5ML (376.9MG/ML)N204781 005 Mar 31, 2017AP +!3.769GM/10ML (376.9MG/ML)N204781 002 Mar 20, 2013AP +!5.6535GM/15ML (376.9MG/ML)N204781 003 Mar 20, 2013AP +!7.538GM/20ML (376.9MG/ML)N204781 004 Mar 20, 2013GADOTERATE MEGLUMINEAP HENG RUI PHARMA1.8845GM/5ML (376.9MG/ML)A215304 001 Apr 11, 2022AP3.769GM/10ML (376.9MG/ML)A215304 002 Apr 11, 2022AP5.6535GM/15ML (376.9MG/ML)A215304 003 Apr 11, 2022AP7.538GM/20ML (376.9MG/ML)A215304 004 Apr 11, 2022AP37.69GM/100ML (376.9MG/ML)A215982 001 Apr 15, 2022GADOTERIDOL

INJECTABLE; INJECTION

PROHANCE

+! BRACCO

279.3MG/ML

N020131 001 Nov 16, 1992

PROHANCE MULTIPACK

+! BRACCO

279.3MG/ML

N021489 001 Oct 09, 2003

GADOXETATE DISODIUM

SOLUTION; INTRAVENOUS

EOVIST

+! BAYER HLTHCARE

1.8143GM/10ML (181.43MG/ML)

N022090 001 Jul 03, 2008

+

2.72145GM/15ML (181.43MG/ML)

N022090 002 Feb 04, 2013

GALANTAMINE HYDROBROMIDE

CAPSULE, EXTENDED RELEASE; ORAL

GALANTAMINE HYDROBROMIDEAB AUROBINDO PHARMAEQ 8MG BASEA204895 001 Aug 05, 2016ABEQ 16MG BASEA204895 002 Aug 05, 2016ABEQ 24MG BASEA204895 003 Aug 05, 2016AB BARREQ 8MG BASEA078189 001 Sep 15, 2008ABEQ 16MG BASEA078189 002 Sep 15, 2008ABEQ 24MG BASEA078189 003 Sep 15, 2008AB SUN PHARMEQ 8MG BASEA090178 001 Feb 02, 2011ABEQ 16MG BASEA090178 002 Feb 02, 2011ABEQ 24MG BASEA090178 003 Feb 02, 2011AB WATSON LABSEQ 8MG BASEA079028 001 Dec 15, 2008ABEQ 16MG BASEA079028 002 Dec 15, 2008ABEQ 24MG BASEA079028 003 Dec 15, 2008RAZADYNE ERAB +! JANSSEN PHARMSEQ 8MG BASEN021615 001 Apr 01, 2005AB +EQ 16MG BASEN021615 002 Apr 01, 2005AB +EQ 24MG BASEN021615 003 Apr 01, 2005

SOLUTION; ORAL

GALANTAMINE HYDROBROMIDE

! HIKMA

4MG/ML

A078185 001 Jan 30, 2009

PRESCRIPTION DRUG PRODUCT LIST

3-217 (of 474)

GALANTAMINE HYDROBROMIDE

TABLET; ORAL

GALANTAMINE HYDROBROMIDE

AB	AUROBINDO PHARMA LTD	EQ 4MG BASE	A090957 001	Mar 29, 2011
AB		EQ 8MG BASE	A090957 002	Mar 29, 2011
AB		EQ 12MG BASE	A090957 003	Mar 29, 2011
AB	BARR	EQ 4MG BASE	A077605 001	Aug 28, 2008
AB		EQ 8MG BASE	A077605 002	Aug 28, 2008
AB		EQ 12MG BASE	A077605 003	Aug 28, 2008
AB	DR REDDYS LABS LTD	EQ 4MG BASE	A077593 001	Sep 11, 2008
AB		EQ 8MG BASE	A077593 002	Sep 11, 2008
AB		EQ 12MG BASE	A077593 003	Sep 11, 2008
AB	SANDOZ	EQ 4MG BASE	A077589 001	Jun 22, 2009
AB		EQ 8MG BASE	A077589 002	Jun 22, 2009
AB		EQ 12MG BASE	A077589 003	Jun 22, 2009
AB	! YABAO PHARM	EQ 4MG BASE	A077604 001	Feb 06, 2009
AB		EQ 8MG BASE	A077604 002	Feb 06, 2009
AB		EQ 12MG BASE	A077604 003	Feb 06, 2009
AB	ZYDUS PHARMS USA INC	EQ 4MG BASE	A078898 001	Feb 17, 2011
AB		EQ 8MG BASE	A078898 002	Feb 17, 2011
AB		EQ 12MG BASE	A078898 003	Feb 17, 2011

GALLIUM CITRATE GA-67

INJECTABLE; INJECTION

GALLIUM CITRATE GA 67

BS	CURIUM	2mCi/ML	N018058 001	
BS	LANTHEUS MEDCL	2mCi/ML	N017478 001	

GALLIUM DOTATATE GA-68

POWDER; INTRAVENOUS

NETSPOT

+	! AAA USA INC	2.1-5.5mCi/ML	N208547 001	Jun 01, 2016

GALLIUM GA-68 DOTATOC

SOLUTION; INTRAVENOUS

GALLIUM GA 68 DOTATOC

+	! UIHC PET IMAGING	0.5-4mCi/ML	N210828 001	Aug 21, 2019

GALLIUM GA-68 GOZETOTIDE

POWDER; INTRAVENOUS

ILLUCCIX

+	! TELIX	N/A	N214032 001	Dec 17, 2021

LOCAMETZ

+	! AAA USA NOVARTIS	N/A	N215841 001	Mar 23, 2022

SOLUTION; INTRAVENOUS

GALLIUM GA 68 GOZETOTIDE

+	! UNIV CA LOS ANGELES	0.5-5mCi/mL	N212642 001	Dec 01, 2020

+	! UNIV OF CA SAN FRAN	0.5-5mCi/mL	N212643 001	Dec 01, 2020

GANAXOLONE

SUSPENSION; ORAL

ZTALMY

+	! MARINUS	50MG/ML	N215904 001	Jun 01, 2022

GANCICLOVIR

GEL; OPHTHALMIC

ZIRGAN

+	! BAUSCH AND LOMB	0.15%	N022211 001	Sep 15, 2009

SOLUTION; INTRAVENOUS

GANZYK-RTU

+	! EXELA PHARMA	500MG/250ML (2MG/ML)	N209347 001	Feb 17, 2017

GANCICLOVIR SODIUM

INJECTABLE; INJECTION

GANCICLOVIR SODIUM

AP	FRESENIUS KABI USA	EQ 500MG BASE/VIAL	A090658 001	Jun 21, 2010
AP	HAINAN POLY PHARM	EQ 500MG BASE/VIAL	A204204 001	Nov 08, 2018
AP	HIKMA	EQ 500MG BASE/VIAL	A076222 001	Jul 16, 2003
AP	PAR STERILE PRODUCTS	EQ 500MG BASE/VIAL	A204950 001	Dec 06, 2016
AP	! PHARMASCIENCE INC	EQ 500MG BASE/VIAL	A207645 001	Dec 08, 2017

PRESCRIPTION DRUG PRODUCT LIST

3-218 (of 474)

GANIRELIX ACETATE

INJECTABLE; INJECTION

FYREMADEL

<u>AP</u>	SUN PHARM	<u>250MCG/0.5ML</u>	<u>A204246</u>	<u>001</u>	Nov 30, 2018

GANIRELIX ACETATE

<u>AP</u>	AMPHASTAR PHARMS	<u>250MCG/0.5ML</u>	<u>A212613</u>	<u>001</u>	Apr 07, 2022

<u>AP</u>	MEITHEAL	<u>250MCG/0.5ML</u>	<u>A214996</u>	<u>001</u>	Jun 06, 2022

<u>AP</u>	+!	ORGANON USA INC	<u>250MCG/0.5ML</u>	<u>N021057</u>	<u>001</u>	Jul 29, 1999

GATIFLOXACIN

SOLUTION/DROPS; OPHTHALMIC

GATIFLOXACIN

<u>AT</u>	AKORN	<u>0.5%</u>	<u>A203189</u>	<u>001</u>	Sep 03, 2014

<u>AT</u>	LUPIN LTD	<u>0.5%</u>	<u>A202653</u>	<u>001</u>	Aug 28, 2013

<u>AT</u>	SANDOZ INC	<u>0.5%</u>	<u>A204227</u>	<u>001</u>	Jul 11, 2016

ZYMAXID

<u>AT</u>	+!	ALLERGAN	<u>0.5%</u>	<u>N022548</u>	<u>001</u>	May 18, 2010

ZYMAR

	+!	ALLERGAN	0.3%	N021493	001	Mar 28, 2003

GEFITINIB

TABLET; ORAL

GEFITINIB

<u>AB</u>	APOTEX	<u>250MG</u>	<u>A209532</u>	<u>001</u>	Sep 23, 2022

IRESSA

<u>AB</u>	+!	ASTRAZENECA	<u>250MG</u>	<u>N206995</u>	<u>001</u>	Jul 13, 2015

GEMCITABINE HYDROCHLORIDE

INJECTABLE; INJECTION

GEMCITABINE HYDROCHLORIDE

<u>AP</u>	ACCORD HLTHCARE	<u>EQ 200MG BASE/VIAL</u>	<u>A091594</u>	<u>001</u>	Jul 25, 2011

<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A091594</u>	<u>002</u>	Jul 25, 2011

<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A091594</u>	<u>003</u>	Jul 25, 2011

<u>AP</u>	DR REDDYS LABS LTD	<u>EQ 200MG BASE/VIAL</u>	<u>A091365</u>	<u>001</u>	Jul 25, 2011

<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A091365</u>	<u>002</u>	Jul 25, 2011

<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A202997</u>	<u>001</u>	May 07, 2013

<u>AP</u>	FRESENIUS KABI USA	<u>EQ 200MG BASE/VIAL</u>	<u>A090799</u>	<u>001</u>	Jul 25, 2011

<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A090799</u>	<u>002</u>	Jul 25, 2011

<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A090242</u>	<u>003</u>	May 16, 2011

<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A090799</u>	<u>003</u>	May 16, 2011

<u>AP</u>	GLAND PHARMA LTD	<u>EQ 200MG BASE/VIAL</u>	<u>A204520</u>	<u>001</u>	Jan 05, 2016

<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A204520</u>	<u>002</u>	Jan 05, 2016

<u>AP</u>	HIKMA INTL PHARMS	<u>EQ 200MG BASE/VIAL</u>	<u>A206617</u>	<u>001</u>	Jun 25, 2021

<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A206617</u>	<u>002</u>	Jun 25, 2021

<u>AP</u>	HOSPIRA	<u>EQ 200MG BASE/VIAL</u>	<u>A078339</u>	<u>001</u>	Jul 25, 2011

<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A078339</u>	<u>002</u>	Jul 25, 2011

<u>AP</u>	+!	HOSPIRA INC	<u>200MG/5.26ML (38MG/ML)</u>	<u>N200795</u>	<u>001</u>	Aug 04, 2011

<u>AP</u>	+!		<u>1GM/26.3ML (38MG/ML)</u>	<u>N200795</u>	<u>002</u>	Aug 04, 2011

<u>AP</u>	!		<u>EQ 2GM BASE/VIAL</u>	<u>A079183</u>	<u>001</u>	Nov 15, 2010

<u>AP</u>	+!		<u>2GM/52.6ML (38MG/ML)</u>	<u>N200795</u>	<u>003</u>	Aug 04, 2011

<u>AP</u>	!	JIANGSU HANSON PHARM	<u>EQ 200MG BASE/VIAL</u>	<u>A202485</u>	<u>001</u>	May 07, 2013

<u>AP</u>	!		<u>EQ 1GM BASE/VIAL</u>	<u>A202485</u>	<u>002</u>	May 07, 2013

<u>AP</u>		MEITHEAL	<u>200MG/5.26ML (38MG/ML)</u>	<u>A212129</u>	<u>001</u>	Dec 11, 2020

<u>AP</u>			<u>1GM/26.3ML (38MG/ML)</u>	<u>A212129</u>	<u>002</u>	Dec 11, 2020

<u>AP</u>			<u>2GM/52.6ML (38MG/ML)</u>	<u>A212129</u>	<u>003</u>	Dec 11, 2020

<u>AP</u>	MYLAN LABS LTD	<u>200MG/5.26ML (38MG/ML)</u>	<u>A205242</u>	<u>001</u>	Dec 06, 2017

<u>AP</u>			<u>1GM/26.3ML (38MG/ML)</u>	<u>A205242</u>	<u>002</u>	Dec 06, 2017

<u>AP</u>			<u>2GM/52.6ML (38MG/ML)</u>	<u>A205242</u>	<u>003</u>	Dec 06, 2017

<u>AP</u>	SAGENT PHARMS INC	<u>200MG/5.26ML (38MG/ML)</u>	<u>A209077</u>	<u>001</u>	Jul 20, 2018

<u>AP</u>			<u>1GM/26.3ML (38MG/ML)</u>	<u>A209077</u>	<u>002</u>	Jul 20, 2018

<u>AP</u>			<u>2GM/52.6ML (38MG/ML)</u>	<u>A209077</u>	<u>003</u>	Jul 20, 2018

<u>AP</u>	SHILPA	<u>EQ 200MG BASE/VIAL</u>	<u>A207575</u>	<u>001</u>	Feb 22, 2019

<u>AP</u>			<u>200MG/5.26ML (38MG/ML)</u>	<u>A210991</u>	<u>001</u>	Oct 04, 2019

<u>AP</u>			<u>EQ 1GM BASE/VIAL</u>	<u>A207575</u>	<u>002</u>	Feb 22, 2019

<u>AP</u>			<u>1GM/26.3ML (38MG/ML)</u>	<u>A210991</u>	<u>002</u>	Oct 04, 2019

<u>AP</u>			<u>2GM/52.6ML (38MG/ML)</u>	<u>A210991</u>	<u>003</u>	Oct 04, 2019

<u>AP</u>	SUN PHARM	<u>EQ 200MG BASE/VIAL</u>	<u>A078433</u>	<u>001</u>	Jul 25, 2011

<u>AP</u>			<u>EQ 1GM BASE/VIAL</u>	<u>A078433</u>	<u>002</u>	Jul 25, 2011

<u>AP</u>	TEYRO LABS	<u>EQ 200MG BASE/VIAL</u>	<u>A078759</u>	<u>001</u>	Jul 25, 2011

<u>AP</u>			<u>EQ 1GM BASE/VIAL</u>	<u>A078759</u>	<u>002</u>	Jul 25, 2011

PRESCRIPTION DRUG PRODUCT LIST

3-219 (of 474)

GEMCITABINE HYDROCHLORIDE

SOLUTION; INTRAVENOUS

GEMCITABINE HYDROCHLORIDE

+	!	ACCORD HLTHCARE	1GM/10ML (100MG/ML)	N209604	002	Aug 03, 2017
+	!		1.5GM/15ML (100MG/ML)	N209604	003	Aug 03, 2017
+	!		2GM/20ML (100MG/ML)	N209604	004	Aug 03, 2017
+	!		200MG/2ML (100MG/ML)	N209604	001	Aug 03, 2017

INFUGEM

+	!	SUN PHARM	EQ 1200MG BASE/120ML (EQ 10MG BASE/ML)	N208313	001	Jul 16, 2018
+	!		EQ 1300MG BASE/130ML (EQ 10MG BASE/ML)	N208313	002	Jul 16, 2018
+	!		EQ 1400MG BASE/140ML (EQ 10MG BASE/ML)	N208313	003	Jul 16, 2018
+	!		EQ 1500MG BASE/150ML (EQ 10MG BASE/ML)	N208313	004	Jul 16, 2018
+	!		EQ 1600MG BASE/160ML (EQ 10MG BASE/ML)	N208313	005	Jul 16, 2018
+	!		EQ 1700MG BASE/170ML (EQ 10MG BASE/ML)	N208313	006	Jul 16, 2018
+	!		EQ 1800MG BASE/180ML (EQ 10MG BASE/ML)	N208313	007	Jul 16, 2018
+	!		EQ 1900MG BASE/190ML (EQ 10MG BASE/ML)	N208313	008	Jul 16, 2018
+	!		EQ 2000MG BASE/200ML (EQ 10MG BASE/ML)	N208313	009	Jul 16, 2018
+	!		EQ 2200MG BASE/220ML (EQ 10MG BASE/ML)	N208313	010	Jul 16, 2018

GEMFIBROZIL

TABLET; ORAL

GEMFIBROZIL

AB		APOTEX	600MG	A075034	001	Jul 20, 1998
AB		ASCENT PHARMS INC	600MG	A214603	001	Jan 13, 2021
AB		AUROBINDO PHARMA LTD	600MG	A202726	001	Sep 16, 2015
AB		CADILA PHARMS LTD	600MG	A203266	001	Jun 17, 2016
AB		CARIBE HOLDINGS	600MG	A078012	001	Mar 26, 2007
AB		CHARTWELL MOLECULES	600MG	A074270	001	Sep 27, 1993
AB		IMPAX PHARMS	600MG	A078207	001	Jun 01, 2007
AB		INVAGEN PHARMS	600MG	A077836	001	Jul 27, 2006
AB		NORTHSTAR HLTHCARE	600MG	A079072	001	Sep 13, 2010

LOPID

AB	+	!	PFIZER PHARMS	600MG	N018422	003	Nov 20, 1986

GENTAMICIN SULFATE

CREAM; TOPICAL

GENTAMICIN SULFATE

AT		COSETTE	EQ 0.1% BASE	A064056	001	Apr 29, 1994
AT	!	PADAGIS US	EQ 0.1% BASE	A062307	001	

INJECTABLE; INJECTION

GENTAMICIN SULFATE

AP	!	FRESENIUS KABI USA	EQ 10MG BASE/ML	A062366	002	Feb 06, 1986
AP	!		EQ 40MG BASE/ML	A062366	001	Aug 04, 1983
AP		HOSPIRA	EQ 10MG BASE/ML	A062420	001	Aug 15, 1983
AP			EQ 40MG BASE/ML	A062420	002	Aug 15, 1983

GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	EQ 1.2MG BASE/ML	A062373	007	Sep 07, 1982
AP			EQ 1.6MG BASE/ML	A062373	008	Sep 07, 1982
AP			EQ 80MG BASE/100ML	A062373	002	Sep 07, 1982
AP			EQ 100MG BASE/100ML	A062373	005	Sep 07, 1982
AP		HOSPIRA	EQ 1.2MG BASE/ML	A062414	001	Aug 15, 1983
AP			EQ 1.6MG BASE/ML	A062414	003	Aug 15, 1983
AP			EQ 80MG BASE/100ML	A062414	008	Aug 15, 1983
AP			EQ 100MG BASE/100ML	A062414	010	Aug 15, 1983
	!	BAXTER HLTHCARE	EQ 2MG BASE/ML	A062373	009	Sep 07, 1982
	!		EQ 120MG BASE/100ML	A062373	006	Sep 07, 1982

OINTMENT; OPHTHALMIC

GENTAMICIN SULFATE

AT	!	AKORN	EQ 0.3% BASE	A064093	001	Aug 31, 1995
AT		FERA PHARMS LLC	EQ 0.3% BASE	A065024	001	Jul 30, 2004

OINTMENT; TOPICAL

GENTAMICIN SULFATE

AT		COSETTE	EQ 0.1% BASE	A064054	001	Apr 29, 1994
AT		FOUGERA PHARMS INC	EQ 0.1% BASE	A062533	001	Oct 05, 1984
AT	!	PADAGIS US	EQ 0.1% BASE	A062351	001	Feb 18, 1982
AT		PAI HOLDINGS PHARM	EQ 0.1% BASE	A209233	001	Dec 31, 2018
AT		TARO	EQ 0.1% BASE	A062477	001	Dec 23, 1983

SOLUTION/DROPS; OPHTHALMIC

GENOPTIC

AT	!	ALLERGAN	EQ 0.3% BASE	A062452	001	Oct 10, 1984

GENTAK

AT		AKORN	EQ 0.3% BASE	A064163	001	Oct 12, 2001

PRESCRIPTION DRUG PRODUCT LIST

3-220 (of 474)

GENTAMICIN SULFATE

SOLUTION/DROPS;OPHTHALMIC

GENTAMICIN SULFATE

AT	BAUSCH AND LOMB	<u>EQ 0.3% BASE</u>	<u>A064048</u>	<u>001</u>	May 11, 1994
AT	PADAGIS US	<u>EQ 0.3% BASE</u>	<u>A065121</u>	<u>001</u>	Jan 30, 2004
AT	SANDOZ INC	<u>EQ 0.3% BASE</u>	<u>A062196</u>	<u>001</u>	

GENTAMICIN SULFATE; PREDNISOLONE ACETATE

OINTMENT;OPHTHALMIC

PRED-G

+	ALLERGAN	EQ 0.3% BASE;0.6%	N050612	001	Dec 01, 1989

GILTERITINIB FUMARATE

TABLET;ORAL

XOSPATA

+	ASTELLAS	EQ 40MG BASE	N211349	001	Nov 28, 2018

GIVOSIRAN SODIUM

SOLUTION;SUBCUTANEOUS

GIVLAARI

+	ALNYLAM PHARMS INC	EQ 189MG BASE/ML (EQ 189MG BASE/ML)	N212194	001	Nov 20, 2019

GLASDEGIB MALEATE

TABLET;ORAL

DAURISMO

+	PFIZER	EQ 25MG BASE	N210656	001	Nov 21, 2018
+		EQ 100MG BASE	N210656	002	Nov 21, 2018

GLATIRAMER ACETATE

INJECTABLE;SUBCUTANEOUS

COPAXONE

AP	+	TEVA PHARMS USA	<u>20MG/ML</u>	<u>N020622</u>	<u>002</u>	Feb 12, 2002
AP	+		<u>40MG/ML</u>	<u>N020622</u>	<u>003</u>	Jan 28, 2014

GLATIRAMER ACETATE

AP	MYLAN	<u>20MG/ML</u>	<u>A091646</u>	<u>001</u>	Oct 03, 2017
AP		<u>40MG/ML</u>	<u>A206936</u>	<u>001</u>	Oct 03, 2017

GLATOPIA

AP	SANDOZ INC	<u>20MG/ML</u>	<u>A090218</u>	<u>001</u>	Apr 16, 2015
AP		<u>40MG/ML</u>	<u>A206921</u>	<u>001</u>	Feb 12, 2018

GLECAPREVIR; PIBRENTASVIR

PELLETS;ORAL

MAVYRET

+	ABBVIE INC	50MG;20MG/PACKET	N215110	001	Jun 10, 2021

TABLET;ORAL

MAVYRET

+	ABBVIE INC	100MG;40MG	N209394	001	Aug 03, 2017

GLIMEPIRIDE

TABLET;ORAL

AMARYL

AB	+	SANOFI AVENTIS US	<u>1MG</u>	<u>N020496</u>	<u>001</u>	Nov 30, 1995
AB	+		<u>2MG</u>	<u>N020496</u>	<u>002</u>	Nov 30, 1995
AB	+		<u>4MG</u>	<u>N020496</u>	<u>003</u>	Nov 30, 1995

GLIMEPIRIDE

AB	ACCORD HLTHCARE	<u>1MG</u>	<u>A078181</u>	<u>001</u>	Aug 23, 2007
AB		<u>2MG</u>	<u>A078181</u>	<u>002</u>	Aug 23, 2007
AB		<u>4MG</u>	<u>A078181</u>	<u>003</u>	Aug 23, 2007
AB	AUROBINDO PHARMA LTD	<u>1MG</u>	<u>A202759</u>	<u>001</u>	Jun 29, 2012
AB		<u>2MG</u>	<u>A202759</u>	<u>002</u>	Jun 29, 2012
AB		<u>4MG</u>	<u>A202759</u>	<u>003</u>	Jun 29, 2012
AB	CARLSBAD	<u>1MG</u>	<u>A077911</u>	<u>001</u>	Sep 22, 2009
AB		<u>2MG</u>	<u>A077911</u>	<u>002</u>	Sep 22, 2009
AB		<u>4MG</u>	<u>A077911</u>	<u>003</u>	Sep 22, 2009
AB	CHARTWELL MOLECULAR	<u>1MG</u>	<u>A077295</u>	<u>001</u>	Oct 06, 2005
AB		<u>2MG</u>	<u>A077295</u>	<u>002</u>	Oct 06, 2005
AB		<u>4MG</u>	<u>A077295</u>	<u>003</u>	Oct 06, 2005
AB	DR REDDYS LABS LTD	<u>1MG</u>	<u>A077091</u>	<u>001</u>	Oct 06, 2005
AB		<u>2MG</u>	<u>A077091</u>	<u>002</u>	Oct 06, 2005
AB		<u>4MG</u>	<u>A077091</u>	<u>003</u>	Oct 06, 2005
AB	INDOCO REMEDIES	<u>1MG</u>	<u>A202112</u>	<u>001</u>	Apr 17, 2013
AB		<u>2MG</u>	<u>A202112</u>	<u>002</u>	Apr 17, 2013
AB		<u>4MG</u>	<u>A202112</u>	<u>003</u>	Apr 17, 2013
AB	MICRO LABS	<u>1MG</u>	<u>A091220</u>	<u>001</u>	Jun 29, 2012
AB		<u>2MG</u>	<u>A091220</u>	<u>002</u>	Jun 29, 2012

PRESCRIPTION DRUG PRODUCT LIST

3-221 (of 474)

GLIMEPIRIDE

TABLET; ORAL

GLIMEPIRIDE

<u>AB</u>		<u>4MG</u>	<u>A091220</u>	<u>004</u>	Jun 29, 2012
<u>AB</u>		<u>8MG</u>	<u>A091220</u>	<u>006</u>	Jun 29, 2012
<u>AB</u>	PRINSTON INC	<u>1MG</u>	<u>A077370</u>	<u>001</u>	Dec 23, 2005
<u>AB</u>		<u>2MG</u>	<u>A077370</u>	<u>002</u>	Dec 23, 2005
<u>AB</u>		<u>4MG</u>	<u>A077370</u>	<u>003</u>	Dec 23, 2005
<u>AB</u>		<u>8MG</u>	<u>A077370</u>	<u>004</u>	Dec 23, 2005
	MICRO LABS	3MG	A091220	003	Jun 29, 2012
		6MG	A091220	005	Jun 29, 2012

GLIMEPIRIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

DUETACT

<u>AB</u>	+!	TAKEDA PHARMS USA	<u>2MG;30MG</u>	<u>N021925</u>	<u>001</u>	Jul 28, 2006
<u>AB</u>	+		<u>4MG;30MG</u>	<u>N021925</u>	<u>002</u>	Jul 28, 2006
<u>PIOGLITAZONE HYDROCHLORIDE AND GLIMEPIRIDE</u>						
<u>AB</u>		SANDOZ	<u>2MG;30MG</u>	<u>A201049</u>	<u>001</u>	Jan 04, 2013
<u>AB</u>			<u>4MG;30MG</u>	<u>A201049</u>	<u>002</u>	Jan 04, 2013

GLIPIZIDE

TABLET; ORAL

GLIPIZIDE

<u>AB</u>		ACCORD HLTHCARE	<u>5MG</u>	<u>A074550</u>	<u>001</u>	Sep 11, 1997
<u>AB</u>			<u>10MG</u>	<u>A074550</u>	<u>002</u>	Sep 11, 1997
<u>AB</u>		ANI PHARMS	<u>5MG</u>	<u>A074497</u>	<u>001</u>	Aug 31, 1995
<u>AB</u>			<u>10MG</u>	<u>A074497</u>	<u>002</u>	Aug 31, 1995
<u>AB</u>		APOTEX	<u>5MG</u>	<u>A075795</u>	<u>001</u>	Jun 13, 2001
<u>AB</u>	!		<u>10MG</u>	<u>A075795</u>	<u>002</u>	Jun 13, 2001
<u>AB</u>		AUROBINDO PHARMA USA	<u>5MG</u>	<u>A074226</u>	<u>001</u>	May 10, 1994
<u>AB</u>			<u>10MG</u>	<u>A074226</u>	<u>002</u>	May 10, 1994
<u>AB</u>		SANDOZ	<u>5MG</u>	<u>A074305</u>	<u>001</u>	Apr 07, 1995
<u>AB</u>			<u>10MG</u>	<u>A074305</u>	<u>002</u>	Apr 07, 1995
<u>AB</u>		SUN PHARM INDS INC	<u>5MG</u>	<u>A077820</u>	<u>001</u>	Jul 11, 2006
<u>AB</u>			<u>10MG</u>	<u>A077820</u>	<u>002</u>	Jul 11, 2006
<u>AB</u>		WATSON LABS TEVA	<u>5MG</u>	<u>A074223</u>	<u>001</u>	Feb 27, 1995
<u>AB</u>			<u>10MG</u>	<u>A074223</u>	<u>002</u>	Feb 27, 1995

TABLET, EXTENDED RELEASE; ORAL

GLIPIZIDE

<u>AB</u>		AUROBINDO PHARMA	<u>2.5MG</u>	<u>A206928</u>	<u>001</u>	May 12, 2017
<u>AB</u>			<u>5MG</u>	<u>A206928</u>	<u>002</u>	May 12, 2017
<u>AB</u>			<u>10MG</u>	<u>A206928</u>	<u>003</u>	May 12, 2017
<u>AB</u>		UNIQUE	<u>2.5MG</u>	<u>A204720</u>	<u>001</u>	Dec 29, 2016
<u>AB</u>			<u>5MG</u>	<u>A204720</u>	<u>002</u>	Dec 29, 2016
<u>AB</u>			<u>10MG</u>	<u>A204720</u>	<u>003</u>	Dec 29, 2016
<u>AB</u>		WATSON LABS	<u>2.5MG</u>	<u>A076467</u>	<u>003</u>	Mar 27, 2006
<u>AB</u>			<u>5MG</u>	<u>A076467</u>	<u>001</u>	Sep 08, 2003
<u>AB</u>			<u>10MG</u>	<u>A076467</u>	<u>002</u>	Nov 07, 2003
<u>AB</u>		ZYDUS PHARMS	<u>2.5MG</u>	<u>A203499</u>	<u>001</u>	Jul 16, 2018
<u>AB</u>			<u>5MG</u>	<u>A203499</u>	<u>002</u>	Jul 16, 2018
<u>AB</u>			<u>10MG</u>	<u>A203499</u>	<u>003</u>	Jul 16, 2018

GLUCOTROL XL

<u>AB</u>	+	PFIZER	<u>2.5MG</u>	<u>N020329</u>	<u>003</u>	Aug 10, 1999
<u>AB</u>	+		<u>5MG</u>	<u>N020329</u>	<u>001</u>	Apr 26, 1994
<u>AB</u>	+		<u>10MG</u>	<u>N020329</u>	<u>002</u>	Apr 26, 1994

GLIPIZIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL

GLIPIZIDE AND METFORMIN HYDROCHLORIDE

<u>AB</u>		EPIC PHARMA LLC	<u>2.5MG;250MG</u>	<u>A077507</u>	<u>001</u>	Oct 27, 2005
<u>AB</u>			<u>2.5MG;500MG</u>	<u>A077507</u>	<u>002</u>	Oct 27, 2005
<u>AB</u>			<u>5MG;500MG</u>	<u>A077507</u>	<u>003</u>	Oct 27, 2005
<u>AB</u>		HERITAGE PHARMS	<u>2.5MG;250MG</u>	<u>A078728</u>	<u>001</u>	Jun 23, 2010
<u>AB</u>			<u>2.5MG;500MG</u>	<u>A078728</u>	<u>002</u>	Jun 23, 2010
<u>AB</u>			<u>5MG;500MG</u>	<u>A078728</u>	<u>003</u>	Jun 23, 2010
<u>AB</u>		TEVA PHARMS	<u>2.5MG;250MG</u>	<u>A077270</u>	<u>001</u>	Oct 28, 2005
<u>AB</u>			<u>2.5MG;500MG</u>	<u>A077270</u>	<u>002</u>	Oct 28, 2005
<u>AB</u>	!		<u>5MG;500MG</u>	<u>A077270</u>	<u>003</u>	Oct 28, 2005
<u>AB</u>		ZYDUS PHARMS USA INC	<u>2.5MG;250MG</u>	<u>A078905</u>	<u>001</u>	Jan 31, 2011
<u>AB</u>			<u>2.5MG;500MG</u>	<u>A078905</u>	<u>002</u>	Jan 31, 2011
<u>AB</u>			<u>5MG;500MG</u>	<u>A078905</u>	<u>003</u>	Jan 31, 2011

PRESCRIPTION DRUG PRODUCT LIST

3-222 (of 474)

GLUCAGON

INJECTABLE; INJECTION

GLUCAGON

AP	AMPHASTAR PHARMS INC	1MG/VIAL	A208086 001	Dec 28, 2020
AP	+ LILLY	1MG/VIAL	N020928 001	Sep 11, 1998
	POWDER; NASAL			
	BAQSIMI			
	+ ELI LILLY AND CO	3MG	N210134 001	Jul 24, 2019
	SOLUTION; SUBCUTANEOUS			
	GVOKE HYPOPEN			
	+ XERIS	0.5MG/0.1ML (0.5MG/0.1ML)	N212097 003	Sep 10, 2019
	+	1MG/0.2ML (1MG/0.2ML)	N212097 004	Sep 10, 2019
	GVOKE PFS			
	+ XERIS	0.5MG/0.1ML (0.5MG/0.1ML)	N212097 001	Sep 10, 2019
	+	1MG/0.2ML (1MG/0.2ML)	N212097 002	Sep 10, 2019

GLUCAGON HYDROCHLORIDE

INJECTABLE; INJECTION

GLUCAGON

	+ NOVO NORDISK	EQ 1MG BASE/VIAL	N020918 001	Jun 22, 1998
	POWDER; INTRAMUSCULAR, INTRAVENOUS			
	GLUCAGON			
	+ FRESENIUS KABI USA	EQ 1MG BASE/VIAL	N201849 001	May 08, 2015

GLYBURIDE

TABLET; ORAL

GLYBURIDE (MICRONIZED)

AB	HIKMA	1.5MG	A075890 001	Jul 31, 2003
AB		3MG	A075890 002	Jul 31, 2003
AB		6MG	A075890 003	Jul 31, 2003
AB	TEVA	1.5MG	A074686 001	Apr 20, 1999
AB		3MG	A074686 002	Apr 20, 1999
AB		6MG	A074686 004	Apr 20, 1999

GLYNASE

AB	+ PFIZER	1.5MG	N020051 001	Mar 04, 1992
AB	+	3MG	N020051 002	Mar 04, 1992
AB	+	6MG	N020051 004	Sep 24, 1993

GLYBURIDE

AB1	CADILA PHARMS LTD	1.25MG	A203379 001	Jan 04, 2019
AB1		2.5MG	A203379 002	Jan 04, 2019
AB1		5MG	A203379 003	Jan 04, 2019
AB1	EPIC PHARMA LLC	1.25MG	A076257 001	Jun 27, 2002
AB1		2.5MG	A076257 002	Jun 27, 2002
AB1		5MG	A076257 003	Jun 27, 2002
AB1	HERITAGE PHARMS	1.25MG	A090937 001	Feb 28, 2011
AB1		2.5MG	A090937 002	Feb 28, 2011
AB1		5MG	A090937 003	Feb 28, 2011
AB1	ORIENT PHARMA CO LTD	1.25MG	A206483 001	Feb 22, 2019
AB1		2.5MG	A206483 002	Feb 22, 2019
AB1		5MG	A206483 003	Feb 22, 2019
AB1	TEVA	1.25MG	A074388 001	Aug 29, 1995
AB1		2.5MG	A074388 002	Aug 29, 1995
AB1	!	5MG	A074388 003	Aug 29, 1995
AB1	ZYDUS PHARMS	1.25mg	A206749 001	May 10, 2016
AB1		2.5mg	A206749 002	May 10, 2016
AB1		5MG	A206749 003	May 10, 2016

DIABETA

AB2	+ SANOFI AVENTIS US	1.25MG	N017532 001	May 01, 1984
AB2	+	2.5MG	N017532 002	May 01, 1984
AB2	+	5MG	N017532 003	May 01, 1984

GLYBURIDE

AB2	IMPAX LABS INC	1.25MG	A206079 001	Sep 30, 2015
AB2		2.5MG	A206079 002	Sep 30, 2015
AB2		5MG	A206079 003	Sep 30, 2015
	GLYBURIDE (MICRONIZED)			
	TEVA	4.5MG	A074686 003	Apr 20, 1999

PRESCRIPTION DRUG PRODUCT LIST

3-223 (of 474)

GLYBURIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL

GLYBURIDE AND METFORMIN HYDROCHLORIDE

AB	ACTAVIS ELIZABETH	<u>1.25MG;250MG</u>	<u>A076716</u>	<u>001</u>	Jun 28, 2005
AB		<u>2.5MG;500MG</u>	<u>A076716</u>	<u>002</u>	Jun 28, 2005
AB		<u>5MG;500MG</u>	<u>A076716</u>	<u>003</u>	Jun 28, 2005
AB	AUROBINDO PHARMA	<u>1.25MG;250MG</u>	<u>A077870</u>	<u>001</u>	Nov 14, 2007
AB	!	<u>2.5MG;500MG</u>	<u>A077870</u>	<u>002</u>	Nov 14, 2007
AB		<u>5MG;500MG</u>	<u>A077870</u>	<u>003</u>	Nov 14, 2007
AB	IMPAX LABS INC	<u>1.25MG;250MG</u>	<u>A076345</u>	<u>001</u>	Feb 18, 2004
AB		<u>2.5MG;500MG</u>	<u>A076345</u>	<u>002</u>	Feb 18, 2004
AB		<u>5MG;500MG</u>	<u>A076345</u>	<u>003</u>	Feb 18, 2004
AB	ZYDUS PHARMS	<u>1.25MG;250MG</u>	<u>A206748</u>	<u>001</u>	Feb 29, 2016
AB		<u>2.5MG;500MG</u>	<u>A206748</u>	<u>002</u>	Feb 29, 2016
AB		<u>5MG;500MG</u>	<u>A206748</u>	<u>003</u>	Feb 29, 2016

GLYCEROL PHENYLBUTYRATE

LIQUID; ORAL

RAVICTI

+	!	HORIZON THERAP	1.1GM/ML	N203284	001	Feb 01, 2013

GLYCINE

SOLUTION; IRRIGATION

AMINOACETIC ACID 1.5% IN PLASTIC CONTAINER

AT	+	!	BAXTER HLTHCARE	<u>1.5GM/100ML</u>	<u>N017865</u>	<u>001</u>

GLYCINE 1.5% IN PLASTIC CONTAINER

AT			B BRAUN	<u>1.5GM/100ML</u>	<u>N016784</u>	<u>001</u>
AT			ICU MEDICAL INC	<u>1.5GM/100ML</u>	<u>N018315</u>	<u>001</u>

GLYCOPYRROLATE

INJECTABLE; INJECTION

GLYCOPYRROLATE

AP			ACCORD HLTHCARE	<u>0.2MG/ML</u>	<u>A213238</u>	<u>001</u>	Jul 08, 2020
AP			ALEMBIC PHARMS	<u>0.2MG/ML</u>	<u>A214635</u>	<u>001</u>	Oct 26, 2022
AP			AM REGENT	<u>0.2MG/ML</u>	<u>A089335</u>	<u>001</u>	Jul 23, 1986
AP			AMNEAL	<u>0.2MG/ML</u>	<u>A208973</u>	<u>001</u>	Jun 15, 2017
AP				<u>0.2MG/ML</u>	<u>A215333</u>	<u>001</u>	Oct 21, 2022
AP			APOTEX	<u>0.2MG/ML</u>	<u>A210246</u>	<u>001</u>	Oct 29, 2019
AP			ASPEN	<u>0.2MG/ML</u>	<u>A212871</u>	<u>001</u>	Nov 29, 2022
AP			ATHENEX INC	<u>0.2MG/ML</u>	<u>A210083</u>	<u>001</u>	Feb 21, 2020
AP			CAPLIN	<u>0.2MG/ML</u>	<u>A211705</u>	<u>001</u>	Mar 20, 2019
AP			FRESENIUS KABI USA	<u>0.2MG/ML</u>	<u>A209024</u>	<u>001</u>	Oct 31, 2018
AP				<u>0.2MG/ML</u>	<u>A209328</u>	<u>001</u>	Oct 27, 2017
AP			GLAND PHARMA LTD	<u>0.2MG/ML</u>	<u>A212612</u>	<u>001</u>	Sep 30, 2019
AP	!		HIKMA FARMACEUTICA	<u>0.2MG/ML</u>	<u>A090963</u>	<u>001</u>	Sep 21, 2011
AP			MEITHEAL	<u>0.2MG/ML</u>	<u>A212802</u>	<u>001</u>	Jul 06, 2021
AP			NIVAGEN PHARMS INC	<u>0.2MG/ML</u>	<u>A212591</u>	<u>001</u>	Oct 13, 2021
AP			PIRAMAL CRITICAL	<u>0.2MG/ML</u>	<u>A210842</u>	<u>001</u>	Oct 25, 2018
AP			PRINSTON INC	<u>0.2MG/ML</u>	<u>A210927</u>	<u>001</u>	Oct 31, 2018
AP			SANDOZ INC	<u>0.2MG/ML</u>	<u>A211334</u>	<u>001</u>	May 14, 2019
AP			SOMERSET THERAPS	<u>0.2MG/ML</u>	<u>A207639</u>	<u>001</u>	Jun 23, 2017
AP			LLC				
AP			XIROMED	<u>0.2MG/ML</u>	<u>A212227</u>	<u>001</u>	Mar 04, 2021

SOLUTION; INHALATION

LONHALA MAGNAIR KIT

+	!	SUNOVION RESP	25MCG/ML	N208437	001	Dec 05, 2017

SOLUTION; INTRAMUSCULAR, INTRAVENOUS

GLYCOPYRROLATE

+	!	FRESENIUS KABI USA	0.6MG/3ML (0.2MG/ML)	N214919	001	Apr 21, 2022

GLYRX-PF

+	!	EXELA PHARMA	0.2MG/ML (0.2MG/ML)	N210997	001	Jul 11, 2018
+	!		0.4MG/2ML (0.2MG/ML)	N210997	002	Jul 11, 2018
+	!		0.6MG/3ML (0.2MG/ML)	N210997	004	Dec 14, 2020
+	!		1MG/5ML (0.2MG/ML)	N210997	003	Apr 09, 2020

SOLUTION; ORAL

CUVPOSA

AA	+	!	MERZ PHARMS	<u>1MG/5ML</u>	<u>N022571</u>	<u>001</u>	Jul 28, 2010

GLYCOPYRROLATE

AA			ANNORA PHARMA	<u>1MG/5ML</u>	<u>A213698</u>	<u>001</u>	Jul 05, 2022
AA			PAR PHARM INC	<u>1MG/5ML</u>	<u>A204438</u>	<u>001</u>	Aug 09, 2021
AA			SUVEN PHARMS	<u>1MG/5ML</u>	<u>A212467</u>	<u>001</u>	Jul 05, 2022

TABLET; ORAL

GLYCOPYRROLATE

AA			ALEMBIC LABS	<u>1MG</u>	<u>A203657</u>	<u>001</u>	Nov 30, 2018

PRESCRIPTION DRUG PRODUCT LIST

3-224 (of 474)

GLYCOPYRROLATE

TABLET; ORAL

GLYCOPYRROLATE

<u>AA</u>		<u>2MG</u>	<u>A203657</u>	<u>002</u>	Nov 30, 2018
<u>AA</u>	AUROLIFE PHARMA LLC	<u>1MG</u>	<u>A202675</u>	<u>001</u>	Apr 15, 2013
<u>AA</u>		<u>2MG</u>	<u>A202675</u>	<u>002</u>	Oct 30, 2018
<u>AA</u>	DR REDDYS LABS LTD	<u>1MG</u>	<u>A040847</u>	<u>001</u>	Mar 21, 2008
<u>AA</u>		<u>2MG</u>	<u>A040847</u>	<u>002</u>	Mar 21, 2008
<u>AA</u>	HERITAGE PHARMS INC	<u>1MG</u>	<u>A207201</u>	<u>001</u>	Jan 03, 2017
<u>AA</u>		<u>2MG</u>	<u>A207201</u>	<u>002</u>	Jan 03, 2017
<u>AA</u>	KENTON	<u>1MG</u>	<u>A091182</u>	<u>001</u>	Feb 03, 2014
<u>AA</u>		<u>2MG</u>	<u>A091182</u>	<u>002</u>	Feb 03, 2014
<u>AA</u>	LEADING	<u>1MG</u>	<u>A090195</u>	<u>001</u>	Sep 21, 2012
<u>AA</u>		<u>2MG</u>	<u>A090195</u>	<u>002</u>	Sep 21, 2012
<u>AA</u>	NATCO	<u>1MG</u>	<u>A091413</u>	<u>001</u>	Jun 20, 2016
<u>AA</u>		<u>2MG</u>	<u>A091413</u>	<u>002</u>	Jun 20, 2016
<u>AA</u>	OXFORD PHARMS	<u>1MG</u>	<u>A090020</u>	<u>001</u>	Oct 19, 2011
<u>AA</u>		<u>2MG</u>	<u>A090020</u>	<u>002</u>	Oct 19, 2011
<u>AA</u>	! PAR PHARM	<u>1MG</u>	<u>A040653</u>	<u>001</u>	Aug 31, 2006
<u>AA</u>	!	<u>2MG</u>	<u>A040653</u>	<u>002</u>	Aug 31, 2006
<u>AA</u>	RISING	<u>1MG</u>	<u>A040821</u>	<u>001</u>	Dec 29, 2008
<u>AA</u>		<u>2MG</u>	<u>A040821</u>	<u>002</u>	Dec 29, 2008
<u>AA</u>	SUN PHARM INDS LTD	<u>1MG</u>	<u>A040844</u>	<u>001</u>	Aug 18, 2009
<u>AA</u>		<u>2MG</u>	<u>A040844</u>	<u>002</u>	Aug 18, 2009

ROBINUL

<u>AA</u>	+ CASPER PHARMA LLC	<u>1MG</u>	<u>N012827</u>	<u>001</u>	
<u>AA</u>	+ CASPER PHARMA LLC	<u>2MG</u>	<u>N012827</u>	<u>002</u>	
	GLYCOPYRROLATE				
	LGM PHARMA	1.5MG	A091522	001	Mar 12, 2012
	TABLET, ORALLY DISINTEGRATING; ORAL				
	DARTISLA ODT				
	+! EDENBRIDGE PHARMS	1.7MG	N215019	001	Dec 16, 2021

GLYCOPYRROLATE TOSYLATE

CLOTH; TOPICAL

QBREXZA

+!	JOURNEY	EQ 2.4% BASE	N210361	001	Jun 28, 2018

GOLODIRSEN

SOLUTION; INTRAVENOUS

VYONDYS 53

+!	SAREPTA THERAPS INC	100MG/2ML (50MG/ML)	N211970	001	Dec 12, 2019

GOSERELIN ACETATE

IMPLANT; IMPLANTATION

ZOLADEX

+!	TERSERA	EQ 3.6MG BASE	N019726	001	Dec 29, 1989
+!		EQ 10.8MG BASE	N020578	001	Jan 11, 1996

GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN

<u>AT</u>	AMRING PHARMS	<u>0.025MG/ML; EQ 1.75MG BASE/ML; 10,000 UNITS/ML</u>	<u>A065187</u>	<u>001</u>	Oct 28, 2005
<u>AT</u>	! BAUSCH AND LOMB	<u>0.025MG/ML; EQ 1.75MG BASE/ML; 10,000 UNITS/ML</u>	<u>A064047</u>	<u>001</u>	Jan 31, 1996
	<u>NEOSPORIN</u>				
<u>AT</u>	! MONARCH PHARMS	<u>0.025MG/ML; EQ 1.75MG BASE/ML; 10,000 UNITS/ML</u>	<u>A060582</u>	<u>001</u>	

GRANISETRON

FILM, EXTENDED RELEASE; TRANSDERMAL

SANCUSO

+!	KYOWA KIRIN	3.1MG/24HR	N022198	001	Sep 12, 2008

INJECTION, EXTENDED RELEASE; SUBCUTANEOUS

SUSTOL

+!	HERON THERAPS INC	10MG/0.4ML (10MG/0.4ML)	N022445	001	Aug 09, 2016

GRANISETRON HYDROCHLORIDE

INJECTABLE; INJECTION

GRANISETRON HYDROCHLORIDE

<u>AP</u>	AKORN	<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A079078</u>	<u>001</u>	Sep 14, 2009
<u>AP</u>		<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A079078</u>	<u>002</u>	Sep 14, 2009
<u>AP</u>	AMNEAL	<u>EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)</u>	<u>A078262</u>	<u>001</u>	Dec 31, 2007
<u>AP</u>		<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A078258</u>	<u>001</u>	Jun 30, 2008

PRESCRIPTION DRUG PRODUCT LIST

3-225 (of 474)

GRANISETRON HYDROCHLORIDE

INJECTABLE; INJECTION

GRANISETRON HYDROCHLORIDE

AP		<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A078258</u>	<u>002</u>	Jun 30, 2008
AP	BIONPHARMA INC	<u>EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)</u>	<u>A078863</u>	<u>001</u>	Jun 30, 2008
AP		<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A078880</u>	<u>001</u>	Jun 30, 2008
AP	!	<u>EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)</u>	<u>A078392</u>	<u>001</u>	Dec 31, 2007
AP	!	<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A077297</u>	<u>001</u>	Jun 30, 2008
AP	FRESENIUS KABI USA	<u>EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)</u>	<u>A078522</u>	<u>001</u>	Dec 31, 2007
AP		<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A078090</u>	<u>001</u>	Jun 30, 2008
AP	HIKMA	<u>EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)</u>	<u>A077913</u>	<u>001</u>	Jun 26, 2008
AP		<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A077186</u>	<u>001</u>	Jun 30, 2008
AP		<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A077187</u>	<u>001</u>	Jun 30, 2008
AP		<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A077177</u>	<u>001</u>	Dec 31, 2007
AP	HIKMA FARMACEUTICA	<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A078629</u>	<u>001</u>	Dec 23, 2009
AP		<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A078629</u>	<u>002</u>	Dec 23, 2009
AP	MYLAN ASI	<u>EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)</u>	<u>A091136</u>	<u>001</u>	Apr 09, 2010
AP		<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A091136</u>	<u>002</u>	Apr 09, 2010
AP		<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A091137</u>	<u>002</u>	Apr 09, 2010
AP	SANDOZ INC	<u>EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)</u>	<u>A078534</u>	<u>001</u>	Apr 30, 2009
AP		<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A078531</u>	<u>001</u>	Apr 30, 2009
AP		<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A078835</u>	<u>001</u>	Jun 30, 2008
AP		<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A078531</u>	<u>002</u>	Apr 30, 2009
AP		<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A078835</u>	<u>002</u>	Jun 30, 2008

GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE

AP	BIONPHARMA INC	<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A078863</u>	<u>002</u>	Jun 30, 2008
AP	!	<u>EQ 1MG BASE/ML (EQ 1MG BASE/ML)</u>	<u>A078096</u>	<u>001</u>	Jun 30, 2008

TABLET; ORAL

GRANISETRON HYDROCHLORIDE

AB	APOTEX INC	<u>EQ 1MG BASE</u>	<u>A078843</u>	<u>001</u>	Feb 27, 2008
AB	CHARTWELL MOLECULAR	<u>EQ 1MG BASE</u>	<u>A078037</u>	<u>001</u>	Feb 27, 2008
AB	DR REDDYS LABS LTD	<u>EQ 1MG BASE</u>	<u>A078846</u>	<u>001</u>	Feb 27, 2009
AB	!	<u>EQ 1MG BASE</u>	<u>A077842</u>	<u>001</u>	Dec 31, 2007
AB	NATCO PHARMA	<u>EQ 1MG BASE</u>	<u>A078969</u>	<u>001</u>	Jun 22, 2009
AB	ORBION PHARMS	<u>EQ 1MG BASE</u>	<u>A078678</u>	<u>001</u>	Feb 13, 2008
AB	TARO	<u>EQ 1MG BASE</u>	<u>A090817</u>	<u>001</u>	May 28, 2010

GRISEOFULVIN, MICROCRYSTALLINE

TABLET; ORAL

FULVICIN-U/F

CHARTWELL RX	250MG	A060569	002
	500MG	A060569	001

GRISEOFULVIN, MICROSIZE

SUSPENSION; ORAL

GRISEOFULVIN

AB	!	ACTAVIS MID ATLANTIC	<u>125MG/5ML</u>	<u>A065394</u>	<u>001</u>	Jul 06, 2007
AB		CHARTWELL RX	<u>125MG/5ML</u>	<u>A065200</u>	<u>001</u>	Mar 02, 2005
AB		CIPLA	<u>125MG/5ML</u>	<u>A065354</u>	<u>001</u>	Sep 10, 2007
AB		COSETTE	<u>125MG/5ML</u>	<u>A065438</u>	<u>001</u>	Oct 08, 2010

TABLET; ORAL

GRISEOFULVIN

AB	!	SANDOZ INC	<u>500MG</u>	<u>A091592</u>	<u>002</u>	Aug 07, 2013
AB		SIGMAPHARM LABS LLC	<u>500MG</u>	<u>A202482</u>	<u>001</u>	Oct 22, 2012
		SANDOZ INC	250MG	A091592	001	Aug 07, 2013

GRISEOFULVIN, ULTRAMICROCRYSTALLINE

TABLET; ORAL

FULVICIN P/G

CHARTWELL RX	125MG	A061996	001
	250MG	A061996	002

FULVICIN P/G 165

CHARTWELL RX	165MG	A061996	003	Apr 06, 1982

FULVICIN P/G 330

CHARTWELL RX	330MG	A061996	004	Apr 06, 1982

GRISEOFULVIN, ULTRAMICROSIZE

TABLET; ORAL

GRIS-PEG

AB	+	BAUSCH	<u>125MG</u>	<u>N050475</u>	<u>001</u>
AB	+		<u>250MG</u>	<u>N050475</u>	<u>002</u>

GRISEOFULVIN, ULTRAMICROSIZE

AB		MOUNTAIN	<u>125MG</u>	<u>A204371</u>	<u>001</u>	Jan 09, 2014
AB	!		<u>250MG</u>	<u>A204371</u>	<u>002</u>	Jan 09, 2014

PRESCRIPTION DRUG PRODUCT LIST

3-226 (of 474)

GRISEOFULVIN, ULTRAMICROSIZE

TABLET;ORAL

GRISEOFULVIN, ULTRAMICROSIZE

<u>AB</u>	SANDOZ INC	<u>125MG</u>	<u>A202805</u>	<u>001</u>	Dec 26, 2018
<u>AB</u>		<u>250MG</u>	<u>A202805</u>	<u>002</u>	Dec 26, 2018

GRISEOFULVIN, ULTRAMICROSIZE

<u>AB</u>	SIGMAPHARM LABS LLC	<u>125MG</u>	<u>A202545</u>	<u>001</u>	Oct 22, 2012
<u>AB</u>		<u>250MG</u>	<u>A202545</u>	<u>002</u>	Oct 22, 2012

GUANFACINE HYDROCHLORIDE

TABLET;ORAL

GUANFACINE HYDROCHLORIDE

<u>AB</u>	AMNEAL PHARM	<u>EQ 1MG BASE</u>	<u>A075109</u>	<u>001</u>	Nov 25, 1998
<u>AB</u>	!	<u>EQ 2MG BASE</u>	<u>A075109</u>	<u>002</u>	Nov 25, 1998
<u>AB</u>	EPIC PHARMA LLC	<u>EQ 1MG BASE</u>	<u>A074673</u>	<u>001</u>	Feb 28, 1997
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A074673</u>	<u>002</u>	Feb 28, 1997
<u>AB</u>	TWI PHARMS	<u>EQ 1MG BASE</u>	<u>A216399</u>	<u>001</u>	Jun 08, 2022
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A216399</u>	<u>002</u>	Jun 08, 2022
<u>AB</u>	UNICHEM	<u>EQ 1MG BASE</u>	<u>A214689</u>	<u>001</u>	Mar 03, 2021
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A214689</u>	<u>002</u>	Mar 03, 2021
<u>AB</u>	WATSON LABS	<u>EQ 1MG BASE</u>	<u>A074145</u>	<u>001</u>	Oct 17, 1995
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A074145</u>	<u>002</u>	Oct 17, 1995

TABLET, EXTENDED RELEASE;ORAL

GUANFACINE HYDROCHLORIDE

<u>AB</u>	ACTAVIS ELIZABETH	<u>EQ 1MG BASE</u>	<u>A200881</u>	<u>001</u>	Oct 05, 2012
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A200881</u>	<u>002</u>	Oct 05, 2012
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A200881</u>	<u>003</u>	Oct 05, 2012
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A200881</u>	<u>004</u>	Oct 05, 2012
<u>AB</u>	APOTEX	<u>EQ 1MG BASE</u>	<u>A205430</u>	<u>001</u>	Jul 25, 2018
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A205430</u>	<u>002</u>	Jul 25, 2018
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A205430</u>	<u>003</u>	Jul 25, 2018
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A205430</u>	<u>004</u>	Jul 25, 2018
<u>AB</u>	SANDOZ INC	<u>EQ 1MG BASE</u>	<u>A202568</u>	<u>001</u>	Jun 03, 2015
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A202568</u>	<u>002</u>	Jun 03, 2015
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A202568</u>	<u>003</u>	Jun 03, 2015
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A202568</u>	<u>004</u>	Jun 03, 2015
<u>AB</u>	SUN PHARM	<u>EQ 1MG BASE</u>	<u>A205689</u>	<u>001</u>	Nov 16, 2017
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A205689</u>	<u>002</u>	Nov 16, 2017
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A205689</u>	<u>003</u>	Nov 16, 2017
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A205689</u>	<u>004</u>	Nov 16, 2017
<u>AB</u>	TEVA PHARMS USA	<u>EQ 1MG BASE</u>	<u>A201382</u>	<u>001</u>	Jun 02, 2015
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A201382</u>	<u>002</u>	Jun 02, 2015
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A201382</u>	<u>003</u>	Jun 02, 2015
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A201382</u>	<u>004</u>	Jun 02, 2015
<u>AB</u>	TWI PHARMS	<u>EQ 1MG BASE</u>	<u>A201408</u>	<u>001</u>	Jun 02, 2015
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A201408</u>	<u>002</u>	Jun 02, 2015
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A201408</u>	<u>003</u>	Jun 02, 2015
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A201408</u>	<u>004</u>	Jun 02, 2015
<u>AB</u>	YICHANG HUMANWELL	<u>EQ 1MG BASE</u>	<u>A213428</u>	<u>001</u>	Nov 25, 2020
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A213428</u>	<u>002</u>	Nov 25, 2020
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A213428</u>	<u>003</u>	Nov 25, 2020
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A213428</u>	<u>004</u>	Nov 25, 2020

INTUNIV

<u>AB</u>	+	TAKEDA PHARMS USA	<u>EQ 1MG BASE</u>	<u>N022037</u>	<u>001</u>	Sep 02, 2009
<u>AB</u>	+		<u>EQ 2MG BASE</u>	<u>N022037</u>	<u>002</u>	Sep 02, 2009
<u>AB</u>	+		<u>EQ 3MG BASE</u>	<u>N022037</u>	<u>003</u>	Sep 02, 2009
<u>AB</u>	+	!	<u>EQ 4MG BASE</u>	<u>N022037</u>	<u>004</u>	Sep 02, 2009

HALCINONIDE

CREAM;TOPICAL

HALCINONIDE

<u>AB</u>	GLASSHOUSE PHARMS	<u>0.1%</u>	<u>A214723</u>	<u>001</u>	Sep 08, 2021
<u>AB</u>	MYLAN	<u>0.1%</u>	<u>A211027</u>	<u>001</u>	Aug 12, 2019

HALOG

<u>AB</u>	+	SUN PHARM INDS INC	<u>0.1%</u>	<u>N017556</u>	<u>001</u>

OINTMENT;TOPICAL

HALOG

+	!	SUN PHARM INDS INC	0.1%	N017824	001

SOLUTION;TOPICAL

HALOG

+	!	SUN PHARM INDS INC	0.1%	N017823	001

PRESCRIPTION DRUG PRODUCT LIST

3-227 (of 474)

HALOBETASOL PROPIONATE

AEROSOL, FOAM; TOPICAL

LEXETTE

+! MAYNE PHARMA

0.05%

N210566 001 May 24, 2018

CREAM; TOPICAL

HALOBETASOL PROPIONATEAB ! COSETTE0.05%A078162 001 Apr 24, 2007AB FOUGERA PHARMS0.05%A077001 001 Dec 16, 2004AB PADAGIS ISRAEL0.05%A077123 001 Dec 16, 2004AB TARO0.05%A077227 001 Aug 04, 2005

LOTION; TOPICAL

BRYHALI

+! BAUSCH

0.01%

N209355 001 Nov 06, 2018

ULTRAVATE

+! SUN PHARM

0.05%

N208183 001 Nov 06, 2015

INDUSTRIES

OINTMENT; TOPICAL

HALOBETASOL PROPIONATEAB COSETTE0.05%A077109 001 Jun 14, 2005AB ! PADAGIS ISRAEL0.05%A076872 001 Dec 16, 2004AB PAI HOLDINGS PHARM0.05%A209978 001 Mar 20, 2018AB QUAGEN0.05%A213560 001 Oct 06, 2020AB TARO0.05%A076994 001 Dec 16, 2004HALOBETASOL PROPIONATE; TAZAROTENE

LOTION; TOPICAL

DUOBRII

+! BAUSCH

0.01%; 0.045%

N209354 001 Apr 25, 2019

HALOPERIDOL

TABLET; ORAL

HALOPERIDOLAB ACTAVIS GROUP0.5MGA200854 001 Jul 01, 2022AB1MGA200854 002 Jul 01, 2022AB2MGA200854 003 Jul 01, 2022AB5MGA200854 004 Jul 01, 2022AB10MGA200854 005 Jul 01, 2022AB20MGA200854 006 Jul 01, 2022AB CYCLE2MGA071130 001 Feb 17, 1987AB5MGA071131 001 Feb 17, 1987AB10MGA071132 001 May 12, 1987AB INNOGENIX0.5MGA071173 002 Jan 02, 1987AB1MGA071173 003 Jan 02, 1987AB2MGA071173 004 Jan 02, 1987AB5MGA071173 005 Jan 07, 1988AB10MGA071173 001 Jan 07, 1988AB20MGA071173 006 Jan 07, 1988AB MSN0.5MGA216004 001 Nov 18, 2022AB1MGA216004 002 Nov 18, 2022AB2MGA216004 003 Nov 18, 2022AB5MGA216004 004 Nov 18, 2022AB10MGA216004 005 Nov 18, 2022AB20MGA216004 006 Nov 18, 2022AB MYLAN0.5MGA070278 006 Jun 10, 1986AB1MGA070278 004 Jun 10, 1986AB !2MGA070278 001 Jun 10, 1986AB5MGA070278 005 Jun 10, 1986AB10MGA070278 002 Jul 16, 2009AB20MGA070278 003 Jul 16, 2009AB SANDOZ0.5MGA071209 002 Nov 17, 1986AB1MGA071209 003 Nov 17, 1986AB5MGA071209 001 Nov 17, 1986AB10MGA071210 001 Mar 11, 1988AB20MGA071211 001 Mar 11, 1988AB UPSHER SMITH LABS0.5MGA211061 001 Jan 08, 2020AB1MGA211061 002 Jan 08, 2020AB2MGA211061 003 Jan 08, 2020AB5MGA211061 004 Jan 08, 2020AB10MGA211061 005 Jan 08, 2020AB20MGA211061 006 Jan 08, 2020AB ZYDUS PHARMS USA5MGA077580 003 Nov 29, 2007AB10MGA077580 004 Nov 29, 2007AB20MGA077580 005 Nov 29, 2007

PRESCRIPTION DRUG PRODUCT LIST

3-228 (of 474)

HALOPERIDOL DECANOATE

INJECTABLE; INJECTION

HALDOL

<u>AO</u>	<u>+!</u>	JANSSEN PHARMS	<u>EQ 50MG BASE/ML</u>	<u>N018701</u>	<u>001</u>	Jan 14, 1986
<u>AO</u>	<u>+!</u>		<u>EQ 100MG BASE/ML</u>	<u>N018701</u>	<u>002</u>	Jan 31, 1997

HALOPERIDOL DECANOATE

<u>AO</u>		FRESENIUS KABI USA	<u>EQ 50MG BASE/ML</u>	<u>A074893</u>	<u>001</u>	Dec 19, 1997
<u>AO</u>			<u>EQ 100MG BASE/ML</u>	<u>A074893</u>	<u>002</u>	Dec 19, 1997
<u>AO</u>		GLAND PHARMA LTD	<u>EQ 50MG BASE/ML</u>	<u>A205241</u>	<u>001</u>	May 12, 2017
<u>AO</u>			<u>EQ 100MG BASE/ML</u>	<u>A205241</u>	<u>002</u>	May 12, 2017
<u>AO</u>		HIKMA	<u>EQ 50MG BASE/ML</u>	<u>A074811</u>	<u>001</u>	Jan 30, 1998
<u>AO</u>			<u>EQ 100MG BASE/ML</u>	<u>A075305</u>	<u>001</u>	Sep 28, 1998
<u>AO</u>		MEITHEAL	<u>EQ 50MG BASE/ML</u>	<u>A214507</u>	<u>001</u>	Jul 26, 2021
<u>AO</u>			<u>EQ 100MG BASE/ML</u>	<u>A214507</u>	<u>002</u>	Jul 26, 2021
<u>AO</u>		MYLAN LABS LTD	<u>EQ 50MG BASE/ML</u>	<u>A075440</u>	<u>001</u>	Feb 28, 2000
<u>AO</u>			<u>EQ 100MG BASE/ML</u>	<u>A075440</u>	<u>002</u>	Feb 28, 2000
<u>AO</u>		SOMERSET THERAPS LLC	<u>EQ 50MG BASE/ML</u>	<u>A209101</u>	<u>001</u>	Jul 03, 2018
<u>AO</u>			<u>EQ 100MG BASE/ML</u>	<u>A209101</u>	<u>002</u>	Jul 03, 2018
<u>AO</u>		TEVA PHARMS USA	<u>EQ 50MG BASE/ML</u>	<u>A075393</u>	<u>001</u>	May 11, 1999
<u>AO</u>			<u>EQ 100MG BASE/ML</u>	<u>A075393</u>	<u>002</u>	May 11, 1999
<u>AO</u>		ZYDUS PHARMS	<u>EQ 50MG BASE/ML</u>	<u>A211180</u>	<u>001</u>	Oct 22, 2019
<u>AO</u>			<u>EQ 100MG BASE/ML</u>	<u>A211180</u>	<u>002</u>	Oct 22, 2019

HALOPERIDOL LACTATE

CONCENTRATE; ORAL

HALOPERIDOL

<u>AA</u>		LANNETT CO INC	<u>EQ 2MG BASE/ML</u>	<u>A073364</u>	<u>001</u>	Sep 28, 1993
<u>AA</u>	<u>!</u>	PHARM ASSOC	<u>EQ 2MG BASE/ML</u>	<u>A073037</u>	<u>001</u>	Feb 26, 1993

INJECTABLE; INJECTION

HALOPERIDOL

<u>AP</u>		FRESENIUS KABI USA	<u>EQ 5MG BASE/ML</u>	<u>A075689</u>	<u>001</u>	Mar 09, 2001
<u>AP</u>			<u>EQ 5MG BASE/ML</u>	<u>A210356</u>	<u>001</u>	Jul 01, 2019
<u>AP</u>		GLAND PHARMA LTD	<u>EQ 5MG BASE/ML</u>	<u>A076774</u>	<u>001</u>	Aug 25, 2004
<u>AP</u>		HIKMA	<u>EQ 5MG BASE/ML</u>	<u>A075858</u>	<u>001</u>	Jun 18, 2001
<u>AP</u>	<u>!</u>	MYLAN LABS LTD	<u>EQ 5MG BASE/ML</u>	<u>A078347</u>	<u>001</u>	Sep 14, 2009
<u>AP</u>		SAGENT PHARMS	<u>EQ 5MG BASE/ML</u>	<u>A091637</u>	<u>001</u>	Sep 02, 2011
<u>AP</u>			<u>EQ 5MG BASE/ML</u>	<u>A200742</u>	<u>001</u>	Sep 02, 2011

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM

<u>AP</u>		BE PHARMS	<u>1,000 UNITS/ML</u>	<u>A214804</u>	<u>001</u>	Dec 29, 2020
<u>AP</u>			<u>10,000 UNITS/ML</u>	<u>A214839</u>	<u>001</u>	Dec 29, 2020
<u>AP</u>	<u>+!</u>	FRESENIUS KABI USA	<u>1,000 UNITS/ML</u>	<u>N017029</u>	<u>001</u>	
<u>AP</u>			<u>5,000 UNITS/ML</u>	<u>A206552</u>	<u>001</u>	Jun 10, 2016
<u>AP</u>	<u>+!</u>		<u>5,000 UNITS/ML</u>	<u>N017651</u>	<u>006</u>	
<u>AP</u>	<u>+!</u>		<u>10,000 UNITS/ML</u>	<u>N017029</u>	<u>003</u>	
<u>AP</u>	<u>+!</u>		<u>20,000 UNITS/ML</u>	<u>N017029</u>	<u>004</u>	
<u>AP</u>		GLAND	<u>1,000 UNITS/ML</u>	<u>A205323</u>	<u>002</u>	Nov 18, 2019
<u>AP</u>			<u>5,000 UNITS/ML</u>	<u>A205323</u>	<u>001</u>	Feb 06, 2017
<u>AP</u>	<u>+!</u>	HIKMA	<u>1,000 UNITS/ML</u>	<u>N017037</u>	<u>001</u>	
<u>AP</u>	<u>+!</u>		<u>5,000 UNITS/ML</u>	<u>N017037</u>	<u>002</u>	
<u>AP</u>	<u>+!</u>		<u>10,000 UNITS/ML</u>	<u>N017037</u>	<u>003</u>	
<u>AP</u>		HOSPIRA INC	<u>1,000 UNITS/ML</u>	<u>A090571</u>	<u>001</u>	Aug 31, 2009
<u>AP</u>			<u>5,000 UNITS/ML</u>	<u>A090571</u>	<u>002</u>	Aug 31, 2009
<u>AP</u>			<u>10,000 UNITS/ML</u>	<u>A090571</u>	<u>003</u>	Aug 31, 2009
<u>AP</u>		MYLAN LABS LTD	<u>1,000 UNITS/ML</u>	<u>A203851</u>	<u>001</u>	Nov 30, 2017
<u>AP</u>			<u>5,000 UNITS/ML</u>	<u>A203851</u>	<u>002</u>	Nov 30, 2017
<u>AP</u>			<u>10,000 UNITS/ML</u>	<u>A203851</u>	<u>003</u>	Nov 30, 2017
<u>AP</u>			<u>20,000 UNITS/ML</u>	<u>A203852</u>	<u>001</u>	Nov 30, 2017
<u>AP</u>		NANJING KING-FRIEND	<u>1,000 UNITS/ML</u>	<u>A211005</u>	<u>001</u>	Dec 14, 2018
<u>AP</u>			<u>1,000 UNITS/ML</u>	<u>A211007</u>	<u>001</u>	May 28, 2019
<u>AP</u>			<u>5,000 UNITS/ML</u>	<u>A211007</u>	<u>002</u>	May 28, 2019
<u>AP</u>			<u>10,000 UNITS/ML</u>	<u>A211007</u>	<u>003</u>	May 28, 2019
<u>AP</u>			<u>20,000 UNITS/ML</u>	<u>A211004</u>	<u>001</u>	Feb 24, 2020
<u>AP</u>		SAGENT PHARMS	<u>1,000 UNITS/ML</u>	<u>A090808</u>	<u>001</u>	Jun 30, 2010
<u>AP</u>			<u>5,000 UNITS/ML</u>	<u>A090808</u>	<u>002</u>	Jun 30, 2010
<u>AP</u>			<u>10,000 UNITS/ML</u>	<u>A090808</u>	<u>003</u>	Jun 30, 2010
<u>AP</u>			<u>20,000 UNITS/ML</u>	<u>A090809</u>	<u>001</u>	Jun 30, 2010
<u>AP</u>		SANDOZ	<u>1,000 UNITS/ML</u>	<u>A091682</u>	<u>001</u>	Jun 08, 2011
<u>AP</u>			<u>5,000 UNITS/ML</u>	<u>A091682</u>	<u>002</u>	Jun 08, 2011
<u>AP</u>			<u>10,000 UNITS/ML</u>	<u>A201002</u>	<u>001</u>	Jun 08, 2011
<u>AP</u>		SHENZHEN TECHDOW	<u>1,000 UNITS/ML</u>	<u>A202957</u>	<u>001</u>	Jun 12, 2014

PRESCRIPTION DRUG PRODUCT LIST

3-229 (of 474)

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM

AP		5,000 UNITS/ML	A202733	001	Jun 12, 2014
AP		5,000 UNITS/ML	A202957	002	Jun 12, 2014
AP		10,000 UNITS/ML	A203198	001	Jun 12, 2014
AP		20,000 UNITS/ML	A203198	002	Jun 12, 2014
<u>HEPARIN SODIUM 1,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>					
AP	BAXTER HLTHCARE	200 UNITS/100ML	N018609	001	Apr 28, 1982
<u>HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>					
AP	+! B BRAUN	200 UNITS/100ML	N019953	001	Jul 20, 1992
AP	FRESENIUS KABI USA	200 UNITS/100ML	A212441	001	Jul 24, 2020
AP	+! HOSPIRA	200 UNITS/100ML	N018916	010	Jun 23, 1989
<u>HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER</u>					
AP	HOSPIRA	10,000 UNITS/100ML	N019339	003	Mar 27, 1985
<u>HEPARIN SODIUM 2,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>					
AP	BAXTER HLTHCARE	200 UNITS/100ML	N018609	002	Apr 28, 1982
<u>HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>					
AP	FRESENIUS KABI USA	200 UNITS/100ML	A212441	002	Jul 24, 2020
AP	+! HOSPIRA	200 UNITS/100ML	N018916	011	Jun 23, 1989
<u>HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER</u>					
AP	+! B BRAUN	5,000 UNITS/100ML	N019952	004	Jul 20, 1992
AP	+!	10,000 UNITS/100ML	N019952	005	Jul 20, 1992
AP	HOSPIRA	5,000 UNITS/100ML	N019339	004	Mar 27, 1985
AP		10,000 UNITS/100ML	N019339	002	Mar 27, 1985
<u>HEPARIN SODIUM IN PLASTIC CONTAINER</u>					
AP	+! FRESENIUS KABI USA	1,000 UNITS/ML	N017029	013	Dec 05, 1985
AP	+!	5,000 UNITS/ML	N017029	014	Dec 05, 1985
AP	+!	10,000 UNITS/ML	N017029	015	Dec 05, 1985
AP	+!	20,000 UNITS/ML	N017029	016	Dec 05, 1985
<u>HEPARIN SODIUM PRESERVATIVE FREE</u>					
AP	+! FRESENIUS KABI USA	1,000 UNITS/ML	N017029	010	Apr 28, 1986
AP	+!	10,000 UNITS/ML	N017029	019	Nov 22, 2010
AP	HOSPIRA	10,000 UNITS/ML	A089522	001	May 04, 1987
AP	SAGENT PHARMS	1,000 UNITS/ML	A090810	001	Jun 30, 2010
AP	SHENZHEN TECHDOW	1,000 UNITS/ML	A202732	001	Jun 12, 2014
<u>HEPARIN SODIUM</u>					
	B BRAUN MEDICAL INC	5,000 UNITS/0.5ML	A208827	001	Nov 19, 2018
	+! FRESENIUS KABI USA	10,000 UNITS/ML	N017029	020	Mar 31, 2011
	! HOSPIRA	5,000 UNITS/ML	A088100	001	Apr 28, 1983
	+! PFIZER	1,000 UNITS/ML	N201370	001	Jul 21, 2011
	+!	5,000 UNITS/ML	N201370	002	Jul 21, 2011
<u>HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER</u>					
	HOSPIRA	5,000 UNITS/100ML	N019339	001	Mar 27, 1985
<u>HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER</u>					
	HOSPIRA	5,000 UNITS/100ML	N018916	006	Jan 31, 1984
<u>HEPARIN SODIUM 2,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER</u>					
	BAXTER HLTHCARE	2,000 UNITS/1000ML	N018609	004	Apr 23, 2020
<u>HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER</u>					
	+! B BRAUN	4,000 UNITS/100ML	N019952	001	Jul 20, 1992
<u>HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER</u>					
	HOSPIRA	5,000 UNITS/100ML	N018916	007	Jan 31, 1984
		10,000 UNITS/100ML	N018916	008	Jan 31, 1984
<u>HEPARIN SODIUM PRESERVATIVE FREE</u>					
	+! PFIZER	1,000 UNITS/ML	N201370	004	Jul 21, 2011

HEXACHLOROPHENE

SPONGE; TOPICAL

PRE-OP

AT	+! DAVIS AND GECK	480MG	N017433	001	
<u>PRE-OP II</u>					
AT	+ DAVIS AND GECK	480MG	N017433	002	

HEXAMINOLEVULINATE HYDROCHLORIDE

FOR SOLUTION; INTRAVESICAL

CYSVIEW KIT

	+! PHOTOCURE ASA	100MG/VIAL	N022555	001	May 28, 2010

PRESCRIPTION DRUG PRODUCT LIST

3-230 (of 474)

HISTRELIN ACETATE

IMPLANT; SUBCUTANEOUS

SUPPRELIN LA

+! ENDO PHARM

50MG

N022058 001 May 03, 2007

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

SYRUP; ORAL

HYCODANAA + GENUS1.5MG/5ML; 5MG/5MLN005213 002 Jul 26, 1988HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDEAA ABHAI LLC1.5MG/5ML; 5MG/5MLA207487 001 Feb 21, 2017AA ACTAVIS MID1.5MG/5ML; 5MG/5MLA088017 001 Jul 05, 1983

ATLANTIC

AA ! AKORN1.5MG/5ML; 5MG/5MLA040613 001 Feb 08, 2008AA NOVEL LABS INC1.5MG/5ML; 5MG/5MLA203535 001 Feb 13, 2017AA PADAGIS US1.5MG/5ML; 5MG/5MLA205731 001 Feb 15, 2017AA WOCKHARDT BIO AG1.5MG/5ML; 5MG/5MLA088008 001 Mar 03, 1983

TABLET; ORAL

HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATEAA ! AVANTHI INC1.5MG; 5MGA207176 001 Aug 07, 2017HYCODANAA + GENUS1.5MG; 5MGN005213 001 Jul 26, 1988HYDRALAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDRALAZINE HYDROCHLORIDEAP ! AKORN20MG/MLA040730 001 Apr 21, 2009AP AM REGENT20MG/MLA040136 001 Jun 30, 1997AP BEOWULF ASSET20MG/MLA203110 001 Jun 29, 2015AP FRESENIUS KABI USA20MG/MLA040388 001 Mar 13, 2001AP HIKMA20MG/MLA213667 001 Dec 18, 2020AP MYLAN INSTITUTIONAL20MG/MLA204680 001 Apr 28, 2016AP NAVINTA LLC20MG/MLA202938 001 Mar 28, 2013

TABLET; ORAL

HYDRALAZINE HYDROCHLORIDEAA ALKEM LABS LTD10MGA200737 001 Dec 07, 2012AA25MGA200737 002 Dec 07, 2012AA50MGA200737 003 Dec 07, 2012AA100MGA200737 004 Dec 07, 2012AA CADILA PHARMS LTD25MGA203845 001 Sep 18, 2014AA50MGA203845 002 Sep 18, 2014AA100MGA203845 003 Sep 18, 2014AA GLENMARK PHARMS LTD10MGA090527 001 May 27, 2009AA25MGA090527 002 May 27, 2009AA50MGA090527 003 May 27, 2009AA100MGA090527 004 May 27, 2009AA HERITAGE PHARMS10MGA086242 001 Feb 04, 2010AA25MGA086242 003AA50MGA086242 002AA100MGA086242 004 Feb 04, 2010AA HETERO LABS LTD III10MGA040901 001 Sep 12, 2008AA25MGA040901 002 Sep 12, 2008AA50MGA040901 003 Sep 12, 2008AA100MGA040901 004 Sep 12, 2008AA INVAGEN PHARMS10MGA090255 001 Dec 15, 2008AA25MGA090255 002 Dec 15, 2008AA50MGA090255 003 Dec 15, 2008AA100MGA090255 004 Dec 15, 2008AA ! PLIVA10MGA089097 001 Dec 18, 1985AA +!25MGA088467 001 May 01, 1984AA +!50MGA088468 001 May 01, 1984AA !100MGA089098 001 Dec 18, 1985AA SCIEGEN PHARMS INC10MGA205236 001 May 26, 2017AA25MGA205236 002 May 26, 2017AA50MGA205236 003 May 26, 2017AA100MGA205236 004 May 26, 2017AA STRIDES PHARMA10MGA087836 001 Oct 05, 1982AA25MGA086961 002AA25MGA200770 001 May 03, 2013AA50MGA086962 001AA50MGA200770 002 May 03, 2013AA100MGA088391 001 Sep 27, 1983AA100MGA200770 003 May 03, 2013

PRESCRIPTION DRUG PRODUCT LIST

3-231 (of 474)

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

HYDRA-ZIDE

STRIDES PHARMA	25MG; 25MG	A088957	001	Oct 21, 1985
!	50MG; 50MG	A088946	001	Oct 21, 1985

HYDRALAZINE HYDROCHLORIDE; ISOSORBIDE DINITRATE

TABLET; ORAL

BIDIL

AB	+! AZURITY	37.5MG; 20MG	N020727	001	Jun 23, 2005
ISOSORBIDE DINITRATE AND HYDRALAZINE HYDROCHLORIDE					
AB	RICONPHARMA LLC	37.5MG; 20MG	A215586	001	Apr 06, 2022

HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

HYDROCHLOROTHIAZIDE

AB	AUROBINDO PHARMA	12.5MG	A078164	001	Sep 18, 2007
AB	IPCA LABS LTD	12.5MG	A079237	001	Apr 02, 2009
AB	JUBILANT CADISTA	12.5MG	A078391	001	Feb 11, 2008
AB	PRINSTON INC	12.5MG	A075907	001	Sep 17, 2002
AB	SCIEGEN PHARMS INC	12.5MG	A203561	001	Jan 14, 2019
AB	SUN PHARM INDS INC	12.5MG	A090651	001	Apr 07, 2014
AB	UNICHEM	12.5MG	A090510	001	Jan 19, 2010

MICROZIDE

AB	+! TEVA BRANDED PHARM	12.5MG	N020504	001	Dec 27, 1996

TABLET; ORAL

HYDROCHLOROTHIAZIDE

AB	! ACCORD HLTHCARE	12.5MG	A202556	001	Sep 24, 2012
AB		25MG	A202556	002	Sep 24, 2012
AB		50MG	A202556	003	Sep 24, 2012
AB	ACTAVIS ELIZABETH	12.5MG	A040707	001	Feb 27, 2007
AB	AUROBINDO PHARMA	25MG	A040780	001	Jul 20, 2007
AB		50MG	A040780	002	Jul 20, 2007
AB	HERITAGE PHARMS	25MG	A085182	002	
AB		50MG	A085182	001	
AB	IPCA LABS LTD	12.5MG	A040807	001	Jul 20, 2007
AB		25MG	A040807	002	Jul 20, 2007
AB		50MG	A040807	003	Jul 20, 2007
AB	+ IVAX SUB TEVA PHARMS	25MG	A083177	001	
AB	+!	50MG	A083177	002	
AB	LEADING	12.5MG	A040702	003	May 10, 2017
AB		25MG	A040702	001	Mar 16, 2007
AB		50MG	A040702	002	Mar 16, 2007
AB	OXFORD PHARMS	25MG	A087059	001	
AB		50MG	A087068	001	
AB	PRINSTON INC	25MG	A040412	001	Mar 29, 2002
AB		50MG	A040412	002	Mar 29, 2002
AB	SCIEGEN PHARMS INC	25MG	A203018	001	Jul 23, 2014
AB		50MG	A203018	002	Jul 23, 2014
AB	UNICHEM	25MG	A040907	001	Aug 15, 2008
AB		50MG	A040907	002	Aug 15, 2008

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET; ORAL

AVALIDE

AB	+! SANOFI AVENTIS US	12.5MG; 150MG	N020758	002	Sep 30, 1997
AB	+!	12.5MG; 300MG	N020758	003	Aug 31, 1998

IRBESARTAN AND HYDROCHLOROTHIAZIDE

AB	ALEMBIC PHARMS	12.5MG; 150MG	A091370	001	Oct 15, 2012
AB		12.5MG; 300MG	A091370	002	Oct 15, 2012
AB		25MG; 300MG	A091370	003	Oct 12, 2016
AB	AUROBINDO PHARMA LTD	12.5MG; 150MG	A203630	001	Feb 22, 2013
AB		12.5MG; 300MG	A203630	002	Feb 22, 2013
AB		25MG; 300MG	A203630	003	Mar 31, 2016
AB	DR REDDYS LABS LTD	12.5MG; 150MG	A203500	001	Sep 27, 2012
AB		12.5MG; 300MG	A203500	002	Sep 27, 2012
AB	HIKMA	12.5MG; 150MG	A090351	001	Oct 15, 2012
AB		12.5MG; 300MG	A090351	002	Oct 15, 2012
AB		25MG; 300MG	A090351	003	Jun 08, 2017
AB	HISUN PHARM	12.5MG; 150MG	A207896	001	Oct 14, 2016
AB	HANGZHOU	12.5MG; 300MG	A207896	002	Oct 14, 2016

PRESCRIPTION DRUG PRODUCT LIST

3-232 (of 474)

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET; ORAL

IRBESARTAN AND HYDROCHLOROTHIAZIDE

<u>AB</u>	LUPIN LTD	<u>12.5MG;150MG</u>	<u>A201524</u>	<u>001</u>	Feb 27, 2013
<u>AB</u>		<u>12.5MG;300MG</u>	<u>A201524</u>	<u>002</u>	Feb 27, 2013
<u>AB</u>	MACLEODS PHARMS LTD	<u>12.5MG;150MG</u>	<u>A202414</u>	<u>001</u>	Sep 27, 2012
<u>AB</u>		<u>12.5MG;300MG</u>	<u>A202414</u>	<u>002</u>	Sep 27, 2012
<u>AB</u>	PRINSTON INC	<u>12.5MG;150MG</u>	<u>A203072</u>	<u>001</u>	May 09, 2014
<u>AB</u>		<u>12.5MG;300MG</u>	<u>A203072</u>	<u>002</u>	May 09, 2014
<u>AB</u>	SANDOZ	<u>12.5MG;150MG</u>	<u>A077446</u>	<u>001</u>	Sep 27, 2012
<u>AB</u>		<u>12.5MG;300MG</u>	<u>A077446</u>	<u>002</u>	Sep 27, 2012
<u>AB</u>	TEVA	<u>12.5MG;150MG</u>	<u>A077369</u>	<u>001</u>	Mar 30, 2012
<u>AB</u>		<u>12.5MG;300MG</u>	<u>A077369</u>	<u>002</u>	Mar 30, 2012

HYDROCHLOROTHIAZIDE; LISINOPRIL

TABLET; ORAL

LISINOPRIL AND HYDROCHLOROTHIAZIDE

<u>AB</u>	AUROBINDO	<u>12.5MG;10MG</u>	<u>A077606</u>	<u>001</u>	Mar 14, 2006
<u>AB</u>		<u>12.5MG;20MG</u>	<u>A077606</u>	<u>002</u>	Mar 14, 2006
<u>AB</u>		<u>25MG;20MG</u>	<u>A077606</u>	<u>003</u>	Mar 14, 2006
<u>AB</u>	INVAGEN PHARMS	<u>12.5MG;10MG</u>	<u>A204058</u>	<u>001</u>	May 23, 2017
<u>AB</u>		<u>12.5MG;20MG</u>	<u>A204058</u>	<u>002</u>	May 23, 2017
<u>AB</u>		<u>25MG;20MG</u>	<u>A204058</u>	<u>003</u>	May 23, 2017
<u>AB</u>	LUPIN	<u>12.5MG;10MG</u>	<u>A077912</u>	<u>001</u>	Sep 27, 2006
<u>AB</u>		<u>12.5MG;20MG</u>	<u>A077912</u>	<u>002</u>	Sep 27, 2006
<u>AB</u>		<u>25MG;20MG</u>	<u>A077912</u>	<u>003</u>	Sep 27, 2006
<u>AB</u>	PRINSTON INC	<u>12.5MG;10MG</u>	<u>A076230</u>	<u>001</u>	Jul 01, 2002
<u>AB</u>		<u>12.5MG;20MG</u>	<u>A076230</u>	<u>002</u>	Jul 01, 2002
<u>AB</u>		<u>25MG;20MG</u>	<u>A076230</u>	<u>003</u>	Jul 01, 2002
<u>AB</u>	SANDOZ	<u>12.5MG;10MG</u>	<u>A076262</u>	<u>001</u>	Jul 01, 2002
<u>AB</u>		<u>12.5MG;20MG</u>	<u>A076262</u>	<u>002</u>	Jul 01, 2002
<u>AB</u>		<u>25MG;20MG</u>	<u>A076262</u>	<u>003</u>	Jul 01, 2002
<u>AB</u>	SUN PHARM INDS LTD	<u>12.5MG;10MG</u>	<u>A076007</u>	<u>001</u>	Jul 01, 2002
<u>AB</u>		<u>12.5MG;20MG</u>	<u>A076007</u>	<u>002</u>	Jul 01, 2002
<u>AB</u>		<u>25MG;20MG</u>	<u>A076007</u>	<u>003</u>	Jul 01, 2002
<u>AB</u>	WATSON LABS	<u>12.5MG;10MG</u>	<u>A076194</u>	<u>003</u>	Jul 01, 2002
<u>AB</u>		<u>12.5MG;20MG</u>	<u>A076194</u>	<u>001</u>	Jul 01, 2002
<u>AB</u>		<u>25MG;20MG</u>	<u>A076194</u>	<u>002</u>	Jul 01, 2002
<u>ZESTORETIC</u>					
<u>AB</u>	+ ALMATICA	<u>12.5MG;10MG</u>	<u>N019888</u>	<u>003</u>	Nov 18, 1993
<u>AB</u>	+!	<u>12.5MG;20MG</u>	<u>N019888</u>	<u>001</u>	Sep 20, 1990
<u>AB</u>	+!	<u>25MG;20MG</u>	<u>N019888</u>	<u>002</u>	Jul 20, 1989

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET; ORAL

HYZAAR

<u>AB</u>	+ ORGANON	<u>12.5MG;50MG</u>	<u>N020387</u>	<u>001</u>	Apr 28, 1995
<u>AB</u>	+	<u>12.5MG;100MG</u>	<u>N020387</u>	<u>003</u>	Oct 20, 2005
<u>AB</u>	+	<u>25MG;100MG</u>	<u>N020387</u>	<u>002</u>	Nov 10, 1998

LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE

<u>AB</u>	ALEMBIC PHARMS LTD	<u>12.5MG;50MG</u>	<u>A091617</u>	<u>001</u>	Feb 17, 2012
<u>AB</u>		<u>12.5MG;100MG</u>	<u>A091617</u>	<u>002</u>	Feb 17, 2012
<u>AB</u>		<u>25MG;100MG</u>	<u>A091617</u>	<u>003</u>	Feb 17, 2012
<u>AB</u>	AUROBINDO PHARMA	<u>12.5MG;50MG</u>	<u>A091629</u>	<u>001</u>	Oct 06, 2010
<u>AB</u>		<u>12.5MG;100MG</u>	<u>A091629</u>	<u>002</u>	Oct 06, 2010
<u>AB</u>	!	<u>25MG;100MG</u>	<u>A091629</u>	<u>003</u>	Jan 06, 2010
<u>AB</u>	IPCA LABS LTD	<u>12.5MG;50MG</u>	<u>A201682</u>	<u>001</u>	Mar 01, 2013
<u>AB</u>		<u>12.5MG;100MG</u>	<u>A201682</u>	<u>002</u>	Mar 01, 2013
<u>AB</u>		<u>25MG;100MG</u>	<u>A201682</u>	<u>003</u>	Mar 01, 2013
<u>AB</u>	JUBILANT CADISTA	<u>12.5MG;50MG</u>	<u>A201845</u>	<u>001</u>	Sep 18, 2012
<u>AB</u>		<u>12.5MG;100MG</u>	<u>A201845</u>	<u>002</u>	Sep 18, 2012
<u>AB</u>		<u>25MG;100MG</u>	<u>A201845</u>	<u>003</u>	Sep 18, 2012
<u>AB</u>	LUPIN LTD	<u>12.5MG;50MG</u>	<u>A078245</u>	<u>001</u>	Oct 06, 2010
<u>AB</u>		<u>12.5MG;100MG</u>	<u>A078245</u>	<u>002</u>	May 21, 2010
<u>AB</u>		<u>25MG;100MG</u>	<u>A078245</u>	<u>003</u>	Oct 06, 2010
<u>AB</u>	MACLEODS PHARMS LTD	<u>12.5MG;50MG</u>	<u>A202289</u>	<u>001</u>	Aug 09, 2012
<u>AB</u>		<u>12.5MG;100MG</u>	<u>A202289</u>	<u>002</u>	Aug 09, 2012
<u>AB</u>		<u>25MG;100MG</u>	<u>A202289</u>	<u>003</u>	Aug 09, 2012
<u>AB</u>	PRINSTON INC	<u>12.5MG;50MG</u>	<u>A204901</u>	<u>001</u>	Nov 06, 2017
<u>AB</u>		<u>12.5MG;100MG</u>	<u>A204901</u>	<u>002</u>	Nov 06, 2017
<u>AB</u>		<u>25MG;100MG</u>	<u>A204901</u>	<u>003</u>	Nov 06, 2017
<u>AB</u>	SANDOZ	<u>12.5MG;50MG</u>	<u>A077948</u>	<u>001</u>	Oct 06, 2010
<u>AB</u>		<u>12.5MG;100MG</u>	<u>A077948</u>	<u>003</u>	Aug 19, 2010

PRESCRIPTION DRUG PRODUCT LIST

3-233 (of 474)

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET; ORAL

LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE

<u>AB</u>		<u>25MG;100MG</u>	<u>A077948</u>	<u>002</u>	Oct 06, 2010
<u>AB</u>	TEVA PHARMS	<u>12.5MG;50MG</u>	<u>A077157</u>	<u>001</u>	Apr 06, 2010
<u>AB</u>		<u>12.5MG;100MG</u>	<u>A077157</u>	<u>002</u>	Apr 06, 2010
<u>AB</u>		<u>25MG;100MG</u>	<u>A077157</u>	<u>003</u>	Apr 06, 2010
<u>AB</u>	UNICHEM	<u>12.5MG;50MG</u>	<u>A204832</u>	<u>001</u>	Jul 21, 2017
<u>AB</u>		<u>12.5MG;100MG</u>	<u>A204832</u>	<u>002</u>	Jul 21, 2017
<u>AB</u>		<u>25MG;100MG</u>	<u>A204832</u>	<u>003</u>	Jul 21, 2017
<u>AB</u>	ZYDUS PHARMS USA INC	<u>12.5MG;50MG</u>	<u>A078385</u>	<u>001</u>	Oct 06, 2010
<u>AB</u>		<u>25MG;100MG</u>	<u>A078385</u>	<u>002</u>	Oct 06, 2010

HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE

TABLET; ORAL

LOPRESSOR HCT

<u>AB</u>	+	VALIDUS PHARMS	<u>25MG;50MG</u>	<u>N018303</u>	<u>001</u>	Dec 31, 1984
<u>METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE</u>						
<u>AB</u>		ALEMBIC PHARMS	<u>25MG;50MG</u>	<u>A202870</u>	<u>001</u>	Nov 06, 2013
<u>AB</u>	!		<u>25MG;100MG</u>	<u>A202870</u>	<u>002</u>	Nov 06, 2013
<u>AB</u>			<u>50MG;100MG</u>	<u>A202870</u>	<u>003</u>	Nov 06, 2013
<u>AB</u>		MYLAN	<u>25MG;50MG</u>	<u>A076792</u>	<u>001</u>	Aug 20, 2004
<u>AB</u>			<u>25MG;100MG</u>	<u>A076792</u>	<u>002</u>	Aug 20, 2004
<u>AB</u>			<u>50MG;100MG</u>	<u>A076792</u>	<u>003</u>	Aug 20, 2004
<u>AB</u>		SUN PHARM INDS	<u>25MG;50MG</u>	<u>A090654</u>	<u>001</u>	Jan 19, 2012
<u>AB</u>			<u>25MG;100MG</u>	<u>A090654</u>	<u>002</u>	Jan 19, 2012
<u>AB</u>			<u>50MG;100MG</u>	<u>A090654</u>	<u>003</u>	Jan 19, 2012

HYDROCHLOROTHIAZIDE; MOEXIPRIL HYDROCHLORIDE

TABLET; ORAL

MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

<u>AB</u>		GLENMARK PHARMS	<u>12.5MG;7.5MG</u>	<u>A090718</u>	<u>001</u>	Mar 17, 2010
<u>AB</u>			<u>12.5MG;15MG</u>	<u>A090718</u>	<u>002</u>	Mar 17, 2010
<u>AB</u>			<u>25MG;15MG</u>	<u>A090718</u>	<u>003</u>	Mar 17, 2010
<u>AB</u>		TEVA	<u>12.5MG;7.5MG</u>	<u>A076980</u>	<u>001</u>	Mar 07, 2007
<u>AB</u>			<u>12.5MG;15MG</u>	<u>A076980</u>	<u>003</u>	Mar 07, 2007
<u>AB</u>	!		<u>25MG;15MG</u>	<u>A076980</u>	<u>002</u>	Mar 07, 2007

HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

TABLET; ORAL

BENICAR HCT

<u>AB</u>	+	COSETTE	<u>12.5MG;20MG</u>	<u>N021532</u>	<u>002</u>	Jun 05, 2003
<u>AB</u>	+		<u>12.5MG;40MG</u>	<u>N021532</u>	<u>003</u>	Jun 05, 2003
<u>AB</u>	+	!	<u>25MG;40MG</u>	<u>N021532</u>	<u>005</u>	Jun 05, 2003

OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE

<u>AB</u>		ACCORD HLTHCARE	<u>12.5MG;20MG</u>	<u>A209281</u>	<u>001</u>	Feb 07, 2019
<u>AB</u>			<u>12.5MG;40MG</u>	<u>A209281</u>	<u>002</u>	Feb 07, 2019
<u>AB</u>			<u>25MG;40MG</u>	<u>A209281</u>	<u>003</u>	Feb 07, 2019
<u>AB</u>		ALEMBIC PHARMS	<u>12.5MG;20MG</u>	<u>A204233</u>	<u>001</u>	Apr 24, 2017
<u>AB</u>			<u>12.5MG;40MG</u>	<u>A204233</u>	<u>002</u>	Apr 24, 2017
<u>AB</u>			<u>25MG;40MG</u>	<u>A204233</u>	<u>003</u>	Apr 24, 2017
<u>AB</u>		AUROBINDO PHARMA	<u>12.5MG;20MG</u>	<u>A205391</u>	<u>001</u>	Apr 24, 2017
<u>AB</u>			<u>12.5MG;40MG</u>	<u>A205391</u>	<u>002</u>	Apr 24, 2017
<u>AB</u>			<u>25MG;40MG</u>	<u>A205391</u>	<u>003</u>	Apr 24, 2017
<u>AB</u>		PRINSTON INC	<u>12.5MG;20MG</u>	<u>A207804</u>	<u>001</u>	Apr 24, 2017
<u>AB</u>			<u>12.5MG;40MG</u>	<u>A207804</u>	<u>002</u>	Apr 24, 2017
<u>AB</u>			<u>25MG;40MG</u>	<u>A207804</u>	<u>003</u>	Apr 24, 2017
<u>AB</u>		TEVA PHARMS USA	<u>12.5MG;40MG</u>	<u>A200532</u>	<u>002</u>	Apr 24, 2017
<u>AB</u>		TORRENT	<u>12.5MG;20MG</u>	<u>A206515</u>	<u>001</u>	May 03, 2017
<u>AB</u>			<u>12.5MG;40MG</u>	<u>A206515</u>	<u>002</u>	May 03, 2017
<u>AB</u>			<u>25MG;40MG</u>	<u>A206515</u>	<u>003</u>	May 03, 2017
<u>AB</u>		UMEDICA LABS PVT LTD	<u>12.5MG;20MG</u>	<u>A208847</u>	<u>001</u>	Sep 17, 2019
<u>AB</u>			<u>12.5MG;40MG</u>	<u>A208847</u>	<u>003</u>	Sep 17, 2019
<u>AB</u>			<u>25MG;40MG</u>	<u>A208847</u>	<u>002</u>	Sep 17, 2019

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

<u>AB</u>		APOTEX CORP	<u>12.5MG;EQ 10MG BASE</u>	<u>A091524</u>	<u>001</u>	Mar 12, 2013
<u>AB</u>			<u>12.5MG;EQ 20MG BASE</u>	<u>A091524</u>	<u>002</u>	Mar 12, 2013
<u>AB</u>			<u>25MG;EQ 20MG BASE</u>	<u>A091524</u>	<u>003</u>	Mar 12, 2013
<u>AB</u>		AUROBINDO PHARMA	<u>12.5MG;EQ 10MG BASE</u>	<u>A078450</u>	<u>001</u>	Aug 24, 2007
<u>AB</u>			<u>12.5MG;EQ 20MG BASE</u>	<u>A078450</u>	<u>002</u>	Aug 24, 2007

PRESCRIPTION DRUG PRODUCT LIST

3-234 (of 474)

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

AB	!	<u>25MG;EQ 20MG BASE</u>	<u>A078450</u>	<u>003</u>	Aug 24, 2007
AB	INVAGEN PHARMS	<u>12.5MG;EQ 10MG BASE</u>	<u>A201356</u>	<u>001</u>	Apr 20, 2011
AB		<u>12.5MG;EQ 20MG BASE</u>	<u>A201356</u>	<u>002</u>	Apr 20, 2011
AB		<u>25MG;EQ 20MG BASE</u>	<u>A201356</u>	<u>003</u>	Apr 20, 2011

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

TABLET; ORAL

ALDACTAZIDE

AB	+	PFIZER	<u>25MG;25MG</u>	<u>N012616</u>	<u>004</u>	Dec 30, 1982
<u>SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE</u>						
AB		MYLAN	<u>25MG;25MG</u>	<u>A086513</u>	<u>001</u>	
AB		SUN PHARM INDUSTRIES	<u>25MG;25MG</u>	<u>A089534</u>	<u>001</u>	Jul 02, 1987
<u>ALDACTAZIDE</u>						
	+	PFIZER	<u>50MG;50MG</u>	<u>N012616</u>	<u>005</u>	Dec 30, 1982

HYDROCHLOROTHIAZIDE; TELMISARTAN

TABLET; ORAL

MICARDIS HCT

AB	+	BOEHRINGER INGELHEIM	<u>12.5MG;40MG</u>	<u>N021162</u>	<u>001</u>	Nov 17, 2000
AB	+		<u>12.5MG;80MG</u>	<u>N021162</u>	<u>002</u>	Nov 17, 2000
AB	+		<u>25MG;80MG</u>	<u>N021162</u>	<u>003</u>	Apr 19, 2004

TELMISARTAN AND HYDROCHLOROTHIAZIDE

AB		ALEMBIC PHARMS	<u>12.5MG;40MG</u>	<u>A203010</u>	<u>001</u>	Feb 25, 2014
AB			<u>12.5MG;80MG</u>	<u>A203010</u>	<u>002</u>	Feb 25, 2014
AB			<u>25MG;80MG</u>	<u>A203010</u>	<u>003</u>	Feb 25, 2014
AB		AUROBINDO PHARMA	<u>12.5MG;40MG</u>	<u>A208727</u>	<u>001</u>	Dec 15, 2016
AB			<u>12.5MG;80MG</u>	<u>A208727</u>	<u>002</u>	Dec 15, 2016
AB			<u>25MG;80MG</u>	<u>A208727</u>	<u>003</u>	Dec 15, 2016
AB		GLENMARK PHARMS LTD	<u>12.5MG;40MG</u>	<u>A202544</u>	<u>001</u>	Mar 04, 2019
AB			<u>12.5MG;80MG</u>	<u>A202544</u>	<u>002</u>	Mar 04, 2019
AB			<u>25MG;80MG</u>	<u>A202544</u>	<u>003</u>	Mar 04, 2019
AB		LUPIN LTD	<u>12.5MG;40MG</u>	<u>A091351</u>	<u>001</u>	Aug 07, 2014
AB			<u>12.5MG;80MG</u>	<u>A091351</u>	<u>002</u>	Aug 07, 2014
AB			<u>25MG;80MG</u>	<u>A091351</u>	<u>003</u>	Aug 07, 2014
AB		PRINSTON INC	<u>12.5MG;40MG</u>	<u>A209028</u>	<u>001</u>	Nov 06, 2017
AB			<u>12.5MG;80MG</u>	<u>A209028</u>	<u>002</u>	Nov 06, 2017
AB			<u>25MG;80MG</u>	<u>A209028</u>	<u>003</u>	Nov 06, 2017
AB		ZYDUS PHARMS	<u>12.5MG;40MG</u>	<u>A204221</u>	<u>001</u>	Aug 15, 2017
AB			<u>12.5MG;80MG</u>	<u>A204221</u>	<u>002</u>	Aug 15, 2017
AB			<u>25MG;80MG</u>	<u>A204221</u>	<u>003</u>	Aug 15, 2017

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE; ORAL

TRIAMTERENE AND HYDROCHLOROTHIAZIDE

AB		CADILA	<u>25MG;37.5MG</u>	<u>A208358</u>	<u>001</u>	Feb 11, 2019
AB		LANNETT CO INC	<u>25MG;37.5MG</u>	<u>A201407</u>	<u>001</u>	Dec 09, 2011
AB	!	SANDOZ	<u>25MG;37.5MG</u>	<u>A074821</u>	<u>001</u>	Jun 05, 1997

TABLET; ORAL

MAXZIDE

AB	+	AUROBINDO PHARMA USA	<u>50MG;75MG</u>	<u>N019129</u>	<u>001</u>	Oct 22, 1984

MAXZIDE-25

AB	+	AUROBINDO PHARMA USA	<u>25MG;37.5MG</u>	<u>N019129</u>	<u>003</u>	May 13, 1988

TRIAMTERENE AND HYDROCHLOROTHIAZIDE

AB		APOTEX INC	<u>25MG;37.5MG</u>	<u>A071251</u>	<u>002</u>	May 05, 1998
AB			<u>50MG;75MG</u>	<u>A071251</u>	<u>001</u>	Apr 17, 1988
AB		RUBICON	<u>25MG;37.5MG</u>	<u>A216211</u>	<u>001</u>	Feb 23, 2022
AB			<u>50MG;75MG</u>	<u>A216211</u>	<u>002</u>	Feb 23, 2022
AB		SANDOZ	<u>25MG;37.5MG</u>	<u>A073281</u>	<u>001</u>	Apr 30, 1992
AB			<u>50MG;75MG</u>	<u>A072011</u>	<u>001</u>	Jun 17, 1988
AB		WATSON LABS	<u>25MG;37.5MG</u>	<u>A073449</u>	<u>001</u>	Sep 23, 1993
AB			<u>50MG;75MG</u>	<u>A071851</u>	<u>001</u>	Nov 30, 1988
AB		ZYDUS PHARMS	<u>25MG;37.5MG</u>	<u>A208360</u>	<u>001</u>	Jun 29, 2018
AB			<u>50MG;75MG</u>	<u>A208360</u>	<u>002</u>	Jun 29, 2018

PRESCRIPTION DRUG PRODUCT LIST

3-235 (of 474)

HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET; ORAL

DIOVAN HCT

<u>AB</u>	+	NOVARTIS	<u>12.5MG;80MG</u>	<u>N020818</u>	<u>001</u>	Mar 06, 1998
<u>AB</u>	+		<u>12.5MG;160MG</u>	<u>N020818</u>	<u>002</u>	Mar 06, 1998
<u>AB</u>	+		<u>12.5MG;320MG</u>	<u>N020818</u>	<u>004</u>	Apr 28, 2006
<u>AB</u>	+		<u>25MG;160MG</u>	<u>N020818</u>	<u>003</u>	Jan 17, 2002
<u>AB</u>	+	!	<u>25MG;320MG</u>	<u>N020818</u>	<u>005</u>	Apr 28, 2006

VALSARTAN AND HYDROCHLOROTHIAZIDE

<u>AB</u>		ALEMBIC PHARMS	<u>12.5MG;80MG</u>	<u>A201662</u>	<u>001</u>	Mar 21, 2013
<u>AB</u>			<u>12.5MG;160MG</u>	<u>A201662</u>	<u>002</u>	Mar 21, 2013
<u>AB</u>			<u>12.5MG;320MG</u>	<u>A201662</u>	<u>003</u>	Mar 21, 2013
<u>AB</u>			<u>25MG;160MG</u>	<u>A201662</u>	<u>004</u>	Mar 21, 2013
<u>AB</u>			<u>25MG;320MG</u>	<u>A201662</u>	<u>005</u>	Mar 21, 2013
<u>AB</u>		AUROBINDO PHARMA LTD	<u>12.5MG;80MG</u>	<u>A202519</u>	<u>001</u>	Mar 21, 2013
<u>AB</u>			<u>12.5MG;160MG</u>	<u>A202519</u>	<u>002</u>	Mar 21, 2013
<u>AB</u>			<u>12.5MG;320MG</u>	<u>A202519</u>	<u>003</u>	Mar 21, 2013
<u>AB</u>			<u>25MG;160MG</u>	<u>A202519</u>	<u>004</u>	Mar 21, 2013
<u>AB</u>			<u>25MG;320MG</u>	<u>A202519</u>	<u>005</u>	Mar 21, 2013
<u>AB</u>		LUPIN LTD	<u>12.5MG;80MG</u>	<u>A078946</u>	<u>003</u>	Mar 21, 2013
<u>AB</u>			<u>12.5MG;160MG</u>	<u>A078946</u>	<u>004</u>	Mar 21, 2013
<u>AB</u>			<u>12.5MG;320MG</u>	<u>A078946</u>	<u>001</u>	Mar 21, 2013
<u>AB</u>			<u>25MG;160MG</u>	<u>A078946</u>	<u>005</u>	Mar 21, 2013
<u>AB</u>			<u>25MG;320MG</u>	<u>A078946</u>	<u>002</u>	Mar 21, 2013
<u>AB</u>		MACLEODS PHARMS LTD	<u>12.5MG;80MG</u>	<u>A203145</u>	<u>001</u>	Apr 19, 2013
<u>AB</u>			<u>12.5MG;160MG</u>	<u>A203145</u>	<u>002</u>	Apr 19, 2013
<u>AB</u>			<u>12.5MG;320MG</u>	<u>A203145</u>	<u>003</u>	Apr 19, 2013
<u>AB</u>			<u>25MG;160MG</u>	<u>A203145</u>	<u>004</u>	Apr 19, 2013
<u>AB</u>			<u>25MG;320MG</u>	<u>A203145</u>	<u>005</u>	Apr 19, 2013
<u>AB</u>		MYLAN PHARMS INC	<u>12.5MG;80MG</u>	<u>A078020</u>	<u>001</u>	Sep 21, 2012
<u>AB</u>			<u>12.5MG;160MG</u>	<u>A078020</u>	<u>002</u>	Sep 21, 2012
<u>AB</u>			<u>12.5MG;320MG</u>	<u>A078020</u>	<u>004</u>	Sep 21, 2012
<u>AB</u>			<u>25MG;160MG</u>	<u>A078020</u>	<u>003</u>	Sep 21, 2012
<u>AB</u>			<u>25MG;320MG</u>	<u>A078020</u>	<u>005</u>	Sep 21, 2012
<u>AB</u>		PRINSTON INC	<u>12.5MG;80MG</u>	<u>A206083</u>	<u>001</u>	Feb 08, 2016
<u>AB</u>			<u>12.5MG;160MG</u>	<u>A206083</u>	<u>002</u>	Feb 08, 2016
<u>AB</u>			<u>12.5MG;320MG</u>	<u>A206083</u>	<u>003</u>	Feb 08, 2016
<u>AB</u>			<u>25MG;160MG</u>	<u>A206083</u>	<u>004</u>	Feb 08, 2016
<u>AB</u>			<u>25MG;320MG</u>	<u>A206083</u>	<u>005</u>	Feb 08, 2016

HYDROCODONE BITARTRATE

CAPSULE, EXTENDED RELEASE; ORAL

HYDROCODONE BITARTRATE

!	ALVOGEN	10MG	A206986	001	Jan 21, 2020
		15MG	A206986	002	Jan 21, 2020
		20MG	A206986	003	Jan 21, 2020
		30MG	A206986	004	Jan 21, 2020
		40MG	A206986	005	Jan 21, 2020
		50MG	A206986	006	Jan 21, 2020

TABLET, EXTENDED RELEASE; ORAL

HYDROCODONE BITARTRATE

<u>AB</u>		ALVOGEN	<u>20MG</u>	<u>A208269</u>	<u>001</u>	Mar 01, 2021
<u>AB</u>			<u>30MG</u>	<u>A208269</u>	<u>002</u>	Mar 01, 2021
<u>AB</u>			<u>40MG</u>	<u>A208269</u>	<u>003</u>	Mar 01, 2021
<u>AB</u>			<u>60MG</u>	<u>A208269</u>	<u>004</u>	Mar 01, 2021
<u>AB</u>			<u>80MG</u>	<u>A208269</u>	<u>005</u>	Mar 01, 2021
<u>AB</u>			<u>100MG</u>	<u>A208269</u>	<u>006</u>	Mar 01, 2021
<u>AB</u>			<u>120MG</u>	<u>A208269</u>	<u>007</u>	Mar 01, 2021

HYSINGLA ER

<u>AB</u>	+	!	PURDUE PHARMA LP	<u>20MG</u>	<u>N206627</u>	<u>001</u>	Nov 20, 2014
<u>AB</u>	+			<u>30MG</u>	<u>N206627</u>	<u>002</u>	Nov 20, 2014
<u>AB</u>	+			<u>40MG</u>	<u>N206627</u>	<u>003</u>	Nov 20, 2014
<u>AB</u>	+			<u>60MG</u>	<u>N206627</u>	<u>004</u>	Nov 20, 2014
<u>AB</u>	+			<u>80MG</u>	<u>N206627</u>	<u>005</u>	Nov 20, 2014
<u>AB</u>	+			<u>100MG</u>	<u>N206627</u>	<u>006</u>	Nov 20, 2014
<u>AB</u>	+			<u>120MG</u>	<u>N206627</u>	<u>007</u>	Nov 20, 2014

PRESCRIPTION DRUG PRODUCT LIST

3-236 (of 474)

HYDROCODONE BITARTRATE; IBUPROFEN

TABLET; ORAL

HYDROCODONE

AB	NOSTRUM LABS INC	5MG; 200MG	A077723 003	Nov 06, 2006

HYDROCODONE BITARTRATE AND IBUPROFEN

AB	ACTAVIS LABS FL INC	7.5MG; 200MG	A076604 001	Dec 31, 2003
AB	AMNEAL PHARMS NY	5MG; 200MG	A076642 002	Mar 18, 2004
AB	!	7.5MG; 200MG	A076642 001	Oct 12, 2004
AB	AUROLIFE PHARMA LLC	7.5MG; 200MG	A204575 001	Jun 02, 2016
AB	NOSTRUM LABS INC	7.5MG; 200MG	A077723 001	Nov 06, 2006
		10MG; 200MG	A077723 002	Nov 06, 2006

HYDROCORTISONE

CREAM; TOPICAL

ALA-CORT

AT	CROWN LABS	2.5%	A080706 007	Jan 05, 2016
AT		1%	A080706 006	

ANUSOL HC

AT	SALIX PHARMS	2.5%	A088250 001	Jun 06, 1984

HYDROCORTISONE

AT	ACTAVIS MID ATLANTIC	1%	A087795 001	May 03, 1983
AT		2.5%	A089682 001	Mar 10, 1988
AT	+! FOUGERA PHARMS INC	1%	A080693 003	
AT	!	2.5%	A089414 001	Dec 16, 1986
AT	PADAGIS US	2.5%	A085025 001	
AT	RISING	2.5%	A040879 001	Aug 20, 2010
AT	TARO PHARM INDS LTD	2.5%	A088799 001	Nov 09, 1984

ENEMA; RECTAL

COLOCORT

AB	CHARTWELL	100MG/60ML	A075172 001	Dec 03, 1999

CORTENEMA

AB	+! ANI PHARMS	100MG/60ML	N016199 001	

GRANULE; ORAL

	ALKINDI SPRINKLE			
	+ ETON	0.5MG	N213876 001	Sep 29, 2020
	+	1MG	N213876 002	Sep 29, 2020
	+	2MG	N213876 003	Sep 29, 2020
	+!	5MG	N213876 004	Sep 29, 2020

LOTION; TOPICAL

HYDROCORTISONE

AT	TARO	2.5%	A040247 001	Jul 23, 1999

STIE-CORT

AT	! PADAGIS US	2.5%	A089074 001	Nov 26, 1985

ALA-SCALP

	DERM RX	2%	A083231 001	

OINTMENT; TOPICAL

HYDROCORTISONE

AT	+! FOUGERA PHARMS	1%	A080692 001	
AT	! FOUGERA PHARMS INC	2.5%	A081203 001	May 28, 1993
AT	PADAGIS US	2.5%	A085027 001	
AT	TARO	1%	A086257 001	

HYDROCORTISONE IN ABSORBASE

AT	CMP PHARMA INC	1%	A088138 001	Sep 06, 1985

SOLUTION; TOPICAL

TEXACORT

!	MISSION PHARMA	2.5%	A081271 001	Apr 17, 1992

TABLET; ORAL

CORTEF

AB	+ PHARMACIA AND UPJOHN	5MG	N008697 003	
AB	+	10MG	N008697 001	
AB	+!	20MG	N008697 002	

HYDROCORTISONE

AB	IMPAX LABS INC	5MG	A040646 001	Mar 30, 2007
AB		10MG	A040646 002	Mar 30, 2007
AB		20MG	A040646 003	Mar 30, 2007
AB	STRIDES PHARMA	5MG	A207029 001	Apr 27, 2017
AB		10MG	A207029 002	Apr 27, 2017
AB		20MG	A207029 003	Apr 27, 2017

PRESCRIPTION DRUG PRODUCT LIST

3-237 (of 474)

HYDROCORTISONE ACETATEAEROSOL, METERED;RECTAL
CORTIFOAM

+! MYLAN SPECIALITY LP 10%

N017351 001 Feb 10, 1982

CREAM;TOPICAL

MICORT-HC

SEBELA IRELAND LTD 2.5%

A040396 001 Feb 27, 2001

HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDEAEROSOL, METERED;TOPICAL
EPIFOAM

BX MYLAN SPECIALITY LP 1%;1%

A086457 001

PROCTOFOAM HC

BX +! MYLAN SPECIALITY LP 1%;1%

A086195 001

CREAM;TOPICAL

PRAMOSONE

SEBELA IRELAND LTD 0.5%;1%
1%;1%

A083778 001

A085368 001

LOTION;TOPICAL

PRAMOSONE

SEBELA IRELAND LTD 1%;1%
2.5%;1%

A085980 001

A085979 001

HYDROCORTISONE BUTYRATE

CREAM;TOPICAL

HYDROCORTISONE BUTYRATE**AB1** TARO PHARM INDS **0.1%****A076654 001** Aug 03, 2005LOCOID**AB1** +! BAUSCH **0.1%****N018514 001** Mar 31, 1982HYDROCORTISONE BUTYRATE**AB2** ACTAVIS MID **0.1%****A205134 001** Dec 08, 2017

ATLANTIC

AB2 GLENMARK GENERICS **0.1%****A202145 001** Sep 27, 2013LOCOID LIPOCREAM**AB2** +! PRECISION DERMAT **0.1%****N020769 001** Sep 08, 1997

LOTION;TOPICAL

HYDROCORTISONE BUTYRATE**AB** LUPIN LTD **0.1%****A210209 001** Aug 17, 2018**AB** THE J MOLNER **0.1%****A209556 001** Nov 21, 2017LOCOID**AB** +! BAUSCH **0.1%****N022076 001** May 18, 2007

OINTMENT;TOPICAL

HYDROCORTISONE BUTYRATE**AB** TARO **0.1%****A076842 001** Dec 27, 2004LOCOID**AB** +! PRECISION DERMAT **0.1%****N018652 001** Oct 29, 1982

SOLUTION;TOPICAL

HYDROCORTISONE BUTYRATE**AT** TARO PHARM INDS **0.1%****A076364 001** Jan 14, 2004LOCOID**AT** +! BAUSCH **0.1%****N019116 001** Feb 25, 1987HYDROCORTISONE PROBUTATE

CREAM;TOPICAL

PANDEL

+! ANI PHARMS 0.1%

N020453 001 Feb 28, 1997

HYDROCORTISONE SODIUM SUCCINATE

INJECTABLE;INJECTION

SOLU-CORTEF

+! PHARMACIA AND EQ 100MG BASE/VIAL
UPJOHN

N009866 001

+! EQ 250MG BASE/VIAL

N009866 002

+! EQ 500MG BASE/VIAL

N009866 003

+! EQ 1GM BASE/VIAL

N009866 004

HYDROCORTISONE VALERATE

CREAM;TOPICAL

HYDROCORTISONE VALERATE**AB** COSETTE **0.2%****A213724 001** Feb 11, 2021**AB** ENCUBE ETHICALS **0.2%****A211047 001** Nov 04, 2021**AB** GLENMARK PHARMS LTD **0.2%****A211129 001** Oct 12, 2018**AB** LUPIN LTD **0.2%****A210307 001** Aug 15, 2019**AB** PADAGIS ISRAEL **0.2%****A075666 001** May 24, 2000**AB** ! TARO **0.2%****A075042 001** Aug 25, 1998

PRESCRIPTION DRUG PRODUCT LIST

3-238 (of 474)

HYDROCORTISONE VALERATE

OINTMENT; TOPICAL

HYDROCORTISONE VALERATE

<u>AB</u>	COSETTE	<u>0.2%</u>	<u>A211764</u>	<u>001</u>	Mar 04, 2020
<u>AB</u>	GLENMARK PHARMS LTD	<u>0.2%</u>	<u>A211750</u>	<u>001</u>	Dec 14, 2018
<u>AB</u>	! TARO	<u>0.2%</u>	<u>A075043</u>	<u>001</u>	Aug 25, 1998

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OTIC

NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE

<u>AT</u>	! BAUSCH AND LOMB	<u>1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML</u>	<u>A064053</u>	<u>001</u>	Dec 29, 1995
<u>AT</u>	SANDOZ INC	<u>1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML</u>	<u>A062423</u>	<u>001</u>	Aug 25, 1983

SUSPENSION/DROPS; OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE

!	SANDOZ INC	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062874	001	May 11, 1988

SUSPENSION/DROPS; OTIC

CASPORYN HC

<u>AT</u>	+! CASPER PHARMA LLC	<u>1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML</u>	<u>N060613</u>	<u>001</u>	

NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE

<u>AT</u>	AMRING PHARMS	<u>1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML</u>	<u>A065219</u>	<u>001</u>	May 01, 2006
<u>AT</u>	SANDOZ INC	<u>1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML</u>	<u>A062488</u>	<u>001</u>	Nov 06, 1985

OTICAIR

<u>AT</u>	BAUSCH AND LOMB	<u>1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML</u>	<u>A064065</u>	<u>001</u>	Aug 28, 1996

HYDROMORPHONE HYDROCHLORIDE

INJECTABLE; INJECTION

DILAUDID

<u>AP</u>	+! FRESENIUS KABI USA	<u>1MG/ML</u>	<u>N019034</u>	<u>003</u>	Apr 30, 2009
<u>AP</u>	+!	<u>2MG/ML</u>	<u>N019034</u>	<u>004</u>	Apr 30, 2009

HYDROMORPHONE HYDROCHLORIDE

<u>AP</u>	AKORN	<u>10MG/ML</u>	<u>A078228</u>	<u>001</u>	Apr 14, 2010
<u>AP</u>		<u>10MG/ML</u>	<u>A078261</u>	<u>001</u>	Apr 14, 2010
<u>AP</u>	EUROHLTH INTL SARL	<u>2MG/ML</u>	<u>A202159</u>	<u>001</u>	Apr 27, 2018
<u>AP</u>	HOSPIRA INC	<u>1MG/ML</u>	<u>N200403</u>	<u>001</u>	Dec 01, 2011
<u>AP</u>		<u>2MG/ML</u>	<u>N200403</u>	<u>002</u>	Dec 01, 2011
<u>AP</u>		<u>4MG/ML</u>	<u>N200403</u>	<u>003</u>	Dec 01, 2011
<u>AP</u>		<u>10MG/ML</u>	<u>A078591</u>	<u>001</u>	Jun 17, 2008

DILAUDID

+!	FRESENIUS KABI USA	0.2MG/ML	N019034	006	Jan 16, 2020

HYDROMORPHONE HYDROCHLORIDE

HOSPIRA INC	0.5MG/0.5ML	N200403	004	Jun 13, 2022

SOLUTION; ORAL

DILAUDID

<u>AA</u>	+! RHODES PHARMS	<u>5MG/5ML</u>	<u>N019891</u>	<u>001</u>	Dec 07, 1992

HYDROMORPHONE HYDROCHLORIDE

<u>AA</u>	ASCENT PHARMS INC	<u>5MG/5ML</u>	<u>A210176</u>	<u>001</u>	Oct 27, 2017
<u>AA</u>	HIKMA	<u>5MG/5ML</u>	<u>A074653</u>	<u>001</u>	Jul 29, 1998

TABLET; ORAL

DILAUDID

<u>AB</u>	+ RHODES PHARMS	<u>2MG</u>	<u>N019892</u>	<u>003</u>	Nov 09, 2007
<u>AB</u>	+	<u>4MG</u>	<u>N019892</u>	<u>002</u>	Nov 09, 2007
<u>AB</u>	+!	<u>8MG</u>	<u>N019892</u>	<u>001</u>	Dec 07, 1992

HYDROMORPHONE HYDROCHLORIDE

<u>AB</u>	ASCENT PHARMS INC	<u>2MG</u>	<u>A210506</u>	<u>001</u>	Jan 17, 2018
<u>AB</u>		<u>4MG</u>	<u>A210506</u>	<u>002</u>	Jan 17, 2018
<u>AB</u>		<u>8MG</u>	<u>A210506</u>	<u>003</u>	Jan 17, 2018
<u>AB</u>	AUROLIFE PHARMA LLC	<u>2MG</u>	<u>A205814</u>	<u>001</u>	May 13, 2016
<u>AB</u>		<u>4MG</u>	<u>A205814</u>	<u>002</u>	May 13, 2016
<u>AB</u>		<u>8MG</u>	<u>A205814</u>	<u>003</u>	May 13, 2016
<u>AB</u>	SPECGX LLC	<u>2MG</u>	<u>A076855</u>	<u>002</u>	Sep 19, 2007
<u>AB</u>		<u>4MG</u>	<u>A076855</u>	<u>003</u>	Sep 19, 2007
<u>AB</u>		<u>8MG</u>	<u>A076855</u>	<u>001</u>	Dec 23, 2004

TABLET, EXTENDED RELEASE; ORAL

HYDROMORPHONE HYDROCHLORIDE

<u>AB</u>	ASCENT PHARMS INC	<u>8MG</u>	<u>A212133</u>	<u>001</u>	Sep 23, 2020
<u>AB</u>		<u>12MG</u>	<u>A212133</u>	<u>002</u>	Sep 23, 2020
<u>AB</u>		<u>16MG</u>	<u>A212133</u>	<u>003</u>	Sep 23, 2020
<u>AB</u>		<u>32MG</u>	<u>A212133</u>	<u>004</u>	Sep 23, 2020
<u>AB</u>	OSMOTICA PHARM US	<u>8MG</u>	<u>A205629</u>	<u>001</u>	Jul 07, 2016
<u>AB</u>		<u>12MG</u>	<u>A205629</u>	<u>002</u>	Jul 07, 2016
<u>AB</u>		<u>16MG</u>	<u>A205629</u>	<u>003</u>	Jul 07, 2016
<u>AB</u>	!	<u>32MG</u>	<u>A205629</u>	<u>004</u>	Jul 07, 2016
<u>AB</u>	PADAGIS US	<u>8MG</u>	<u>A204278</u>	<u>001</u>	Apr 06, 2015

PRESCRIPTION DRUG PRODUCT LIST

3-239 (of 474)

HYDROMORPHONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

HYDROMORPHONE HYDROCHLORIDE

AB		12MG	A204278 002	Apr 06, 2015
AB		16MG	A204278 003	Apr 06, 2015
AB		32MG	A204278 004	Sep 20, 2017

HYDROXOCOBALAMIN

INJECTABLE; INJECTION

CYANOKIT

+	BTG INTL	5GM/VIAL (5GM/KIT)	N022041 001	Apr 08, 2011

HYDROXOCOBALAMIN

!	ACTAVIS LLC	1MG/ML	A085998 001	

HYDROXYAMPHETAMINE HYDROBROMIDE; TROPICAMIDE

SOLUTION/DROPS; OPHTHALMIC

PAREMYD

+	AKORN	1%; 0.25%	N019261 001	Jan 30, 1992

HYDROXYCHLOROQUINE SULFATE

TABLET; ORAL

HYDROXYCHLOROQUINE SULFATE

AB	ACCORD HLTHCARE	100MG	A213342 002	Aug 18, 2021
AB		200MG	A213342 001	Apr 07, 2020
AB		300MG	A213342 003	Aug 18, 2021
AB	!	400MG	A213342 004	Aug 18, 2021
AB	ALKALOIDA ZRT	200MG	A201691 001	May 08, 2018
AB	AMNEAL PHARMS CO	200MG	A210577 001	May 15, 2018
AB	APPCO	100MG	A210441 002	Sep 19, 2022
AB		200MG	A210441 001	May 01, 2018
AB		300MG	A210441 003	Sep 19, 2022
AB		400MG	A210441 004	Sep 19, 2022
AB	AUROBINDO PHARMA USA	200MG	A040274 001	May 29, 1998
AB	IPCA LABS LTD	200MG	A040766 001	Jun 14, 2007
AB	LAURUS	200MG	A210959 001	Jan 15, 2019
AB	LUPIN LTD	200MG	A210543 001	Jul 06, 2018
AB	RISE PHARMA	200MG	A212902 001	May 14, 2020
AB	SANDOZ	200MG	A040104 001	Nov 30, 1995
AB	TEVA PHARMS	200MG	A040081 001	Sep 30, 1994
AB	ZYDUS PHARMS USA INC	200MG	A040657 001	Sep 21, 2007

PLAQUENIL

AB	+	CONCORDIA	200MG	N009768 001

HYDROXYCHLOROQUINE SULFATE

	+	NOVITIUM PHARMA	200MG	N214581 001 Jan 14, 2022
	+		300MG	N214581 002 Jan 14, 2022

HYDROXYPROGESTERONE CAPROATE

SOLUTION; INTRAMUSCULAR

HYDROXYPROGESTERONE CAPROATE

AP	AM REGENT	250MG/ML (250MG/ML)	A210723 001	Jun 21, 2018
AP	ASPEN	250MG/ML (250MG/ML)	A211777 001	Aug 08, 2019
AP	EUGIA PHARMA	250MG/ML (250MG/ML)	A211071 001	Apr 16, 2019
AP	SLAYBACK PHARMA LLC	250MG/ML (250MG/ML)	A210877 001	Mar 22, 2019

MAKENA PRESERVATIVE FREE

AP	+	COVIS	250MG/ML (250MG/ML)	N021945 002 Feb 19, 2016

HYDROXYPROGESTERONE CAPROATE

AP1	EUGIA PHARMA	1250MG/5ML (250MG/ML)	A211070 001	Apr 16, 2019
AP1	SLAYBACK PHARMA LLC	1250MG/5ML (250MG/ML)	A210618 001	Dec 28, 2018
AP1	SUN PHARM	1250MG/5ML (250MG/ML)	A208381 001	Apr 09, 2019

MAKENA

AP1	+	COVIS	1250MG/5ML (250MG/ML)	N021945 001 Feb 03, 2011

HYDROXYPROGESTERONE CAPROATE

!	ASPEN GLOBAL INC	1250MG/5ML (250MG/ML)	A200271 001	Aug 24, 2015

SOLUTION; SUBCUTANEOUS

MAKENA (AUTOINJECTOR)

+	COVIS	275MG/1.1ML (250MG/ML)	N021945 004	Feb 14, 2018

PRESCRIPTION DRUG PRODUCT LIST

3-240 (of 474)

HYDROXYPROPYL CELLULOSE

INSERT;OPHTHALMIC

LACRISERT

+! VALEANT PHARMS INTL 5MG

N018771 001

HYDROXYUREA

CAPSULE;ORAL

HYDREA**AB** +! CHEPLAPHARM**500MG****N016295 001**HYDROXYUREA**AB** BARR**500MG****A075143 001** Oct 16, 1998**AB** LEADING**500MG****A213438 001** Apr 08, 2020**AB** PAR PHARM**500MG****A075340 001** Feb 24, 1999

DROXIA

+ CHEPLAPHARM

200MG

N016295 002 Feb 25, 1998

+

300MG

N016295 003 Feb 25, 1998

+

400MG

N016295 004 Feb 25, 1998

TABLET;ORAL

SIKLOS

+ ADDMEDICA SAS

100MG

N208843 001 Dec 21, 2017

+!

1GM

N208843 002 Dec 21, 2017

HYDROXYZINE HYDROCHLORIDE

INJECTABLE;INJECTION

HYDROXYZINE HYDROCHLORIDE

! AM REGENT

25MG/ML

A087408 001

!

50MG/ML

A087408 002

SYRUP;ORAL

HYDROXYZINE HYDROCHLORIDE**AA** LANNETT CO INC**10MG/5ML****A201674 001** Aug 21, 2013**AA** +! WOCKHARDT BIO AG**10MG/5ML****A087294 001** Apr 12, 1982

TABLET;ORAL

HYDROXYZINE HYDROCHLORIDE**AB** AIPING LIFE SCI**10MG****A040804 001** Jun 30, 2008**AB****25MG****A040804 002** Jun 30, 2008**AB****50MG****A040804 003** Jun 30, 2008**AB** AMNEAL PHARM**10MG****A040808 001** Sep 24, 2008**AB****25MG****A040808 002** Sep 24, 2008**AB****50MG****A040808 003** Sep 24, 2008**AB** AUROBINDO PHARMA**10MG****A087871 002** Dec 20, 1982

LTD

AB**25MG****A087871 003** Dec 20, 1982**AB****50MG****A087871 001** Dec 20, 1982**AB** EPIC PHARMA LLC**10MG****A040604 002** Dec 28, 2004**AB****25MG****A040604 003** Dec 28, 2004**AB****50MG****A040604 001** Dec 28, 2004**AB** HERITAGE PHARMA**10MG****A204279 001** Aug 20, 2014**AB****25MG****A204279 002** Aug 20, 2014**AB****50MG****A204279 003** Aug 20, 2014**AB** HETERO LABS LTD III**10MG****A040805 001** May 29, 2008**AB****25MG****A040805 002** May 29, 2008**AB****50MG****A040805 003** May 29, 2008**AB** INVAGEN PHARMS**10MG****A040812 001** Mar 12, 2008**AB****25MG****A040812 002** Mar 12, 2008**AB****50MG****A040812 003** Mar 12, 2008**AB** KVK TECH**10MG****A040786 001** Mar 20, 2007**AB****25MG****A040786 002** Mar 20, 2007**AB****50MG****A040786 003** Mar 20, 2007**AB** NORTHSTAR HLTHCARE**10MG****A040840 002** Mar 31, 2008**AB****25MG****A040840 003** Mar 31, 2008**AB****50MG****A040840 001** Mar 31, 2008**AB** NUVO PHARMS INC**10MG****A207121 002** Mar 29, 2017**AB****25MG****A207121 001** Mar 29, 2017**AB****50MG****A207121 003** Mar 29, 2017**AB** +! PLIVA**10MG****A088617 001** Jan 10, 1986**AB** +!**25MG****A088618 001** Jan 10, 1986**AB** +!**50MG****A088619 001** Jan 10, 1986**AB** PRINSTON INC**10MG****A040580 003** May 27, 2005**AB****25MG****A040580 002** May 27, 2005**AB****50MG****A040580 001** May 27, 2005

PRESCRIPTION DRUG PRODUCT LIST

3-241 (of 474)

HYDROXYZINE PAMOATE

CAPSULE; ORAL

HYDROXYZINE PAMOATE

<u>AB</u>	BARR	<u>EQ 25MG HYDROCHLORIDE</u>	<u>A088496 001</u>	Jun 15, 1984
<u>AB</u>		<u>EQ 50MG HYDROCHLORIDE</u>	<u>A088487 001</u>	Jun 15, 1984
<u>AB</u>	IMPAX LABS INC	<u>EQ 25MG HYDROCHLORIDE</u>	<u>A040156 001</u>	Jul 15, 1996
<u>AB</u>		<u>EQ 50MG HYDROCHLORIDE</u>	<u>A040156 002</u>	Jul 15, 1996
<u>AB</u>	SANDOZ	<u>EQ 25MG HYDROCHLORIDE</u>	<u>A087479 001</u>	
<u>AB</u>	!	<u>EQ 50MG HYDROCHLORIDE</u>	<u>A086183 001</u>	
<u>VISTARIL</u>				
<u>AB</u>	+	<u>EQ 25MG HYDROCHLORIDE</u>	<u>N011459 002</u>	
<u>AB</u>	+	<u>EQ 50MG HYDROCHLORIDE</u>	<u>N011459 004</u>	
HYDROXYZINE PAMOATE				
BX	HERITAGE PHARMA	EQ 25MG HYDROCHLORIDE	A201507 001	Jun 03, 2013
BX		EQ 50MG HYDROCHLORIDE	A201507 002	Jun 03, 2013
	BARR	EQ 100MG HYDROCHLORIDE	A088488 001	Jun 15, 1984

IBANDRONATE SODIUM

INJECTABLE; INTRAVENOUS

IBANDRONATE SODIUM

<u>AP</u>	ACCORD HLTHCARE	<u>EQ 3MG BASE/3ML</u>	<u>A206058 001</u>	Feb 05, 2016
<u>AP</u>	!	<u>EQ 3MG BASE/3ML</u>	<u>A204222 001</u>	Oct 16, 2015
<u>AP</u>	EUGIA PHARMA	<u>EQ 3MG BASE/3ML</u>	<u>A205332 001</u>	Aug 19, 2015
<u>AP</u>	MYLAN LABS LTD	<u>EQ 3MG BASE/3ML</u>	<u>A202671 001</u>	Sep 02, 2014
<u>AP</u>	SAGENT PHARMS INC	<u>EQ 3MG BASE/3ML</u>	<u>A202235 001</u>	Sep 02, 2014
<u>AP</u>	SUN PHARM	<u>EQ 3MG BASE/3ML</u>	<u>A090853 001</u>	Feb 14, 2014

TABLET; ORAL

IBANDRONATE SODIUM

<u>AB</u>	APOTEX INC	<u>EQ 150MG BASE</u>	<u>A078948 001</u>	Mar 19, 2012
<u>AB</u>	AUROBINDO PHARMA	<u>EQ 150MG BASE</u>	<u>A204502 001</u>	Mar 11, 2016
<u>AB</u>	!	<u>EQ 150MG BASE</u>	<u>A078997 001</u>	Apr 30, 2012
<u>AB</u>	MACLEODS PHARMS LTD	<u>EQ 150MG BASE</u>	<u>A206887 001</u>	Oct 31, 2017
<u>AB</u>	ORBION PHARMS	<u>EQ 150MG BASE</u>	<u>A078998 001</u>	Mar 19, 2012
<u>AB</u>	WATSON LABS TEVA	<u>EQ 150MG BASE</u>	<u>A079003 001</u>	Mar 20, 2012

IBREXAFUNGERP CITRATE

TABLET; ORAL

BREXAFEMME

+	!	SCYNEXIS	EQ 150MG BASE	N214900 001	Jun 01, 2021

IBRUTINIB

CAPSULE; ORAL

IMBRUVICA

+		PHARMACYCLICS INC	70MG	N205552 002	Dec 20, 2017
+	!		140MG	N205552 001	Nov 13, 2013

SUSPENSION; ORAL

IMBRUVICA

+	!	PHARMACYCLICS INC	70MG/ML	N217003 001	Aug 24, 2022

TABLET; ORAL

IMBRUVICA

+		PHARMACYCLICS INC	140MG	N210563 001	Feb 16, 2018
+			280MG	N210563 002	Feb 16, 2018
+			420MG	N210563 003	Feb 16, 2018
+	!		560MG	N210563 004	Feb 16, 2018

IBUPROFEN

SOLUTION; INTRAVENOUS

CALDOLOR

+	!	CUMBERLAND PHARMS	800MG/8ML (100MG/ML)	N022348 002	Jun 11, 2009
+	!		800MG/200ML (4MG/ML)	N022348 003	Jan 25, 2019

SUSPENSION; ORAL

IBUPROFEN

<u>AB</u>	!	ACTAVIS MID ATLANTIC	<u>100MG/5ML</u>	<u>A074978 001</u>	Mar 25, 1998
<u>AB</u>		AUROBINDO PHARMA LTD	<u>100MG/5ML</u>	<u>A209178 001</u>	Feb 16, 2018
<u>AB</u>		PADAGIS US	<u>100MG/5ML</u>	<u>A076925 001</u>	Sep 23, 2004
<u>AB</u>		TARO	<u>100MG/5ML</u>	<u>A209204 001</u>	Jun 23, 2017

TABLET; ORAL

IBUPROFEN

<u>AB</u>		ALKEM LABS LTD	<u>400MG</u>	<u>A214699 001</u>	Sep 13, 2021
<u>AB</u>			<u>600MG</u>	<u>A214699 002</u>	Sep 13, 2021
<u>AB</u>			<u>800MG</u>	<u>A214699 003</u>	Sep 13, 2021
<u>AB</u>		AMNEAL PHARMS NY	<u>400MG</u>	<u>A071334 001</u>	Nov 25, 1986
<u>AB</u>			<u>400MG</u>	<u>A078558 001</u>	Jun 18, 2007

PRESCRIPTION DRUG PRODUCT LIST

3-242 (of 474)

IBUPROFEN

TABLET; ORAL

IBUPROFEN

<u>AB</u>		<u>600MG</u>	<u>A071335</u>	<u>001</u>	Nov 25, 1986
<u>AB</u>		<u>600MG</u>	<u>A078558</u>	<u>002</u>	Jun 18, 2007
<u>AB</u>		<u>800MG</u>	<u>A071935</u>	<u>001</u>	Oct 13, 1987
<u>AB</u>		<u>800MG</u>	<u>A078558</u>	<u>003</u>	Jun 18, 2007
<u>AB</u>	AUROBINDO PHARMA LTD	<u>400MG</u>	<u>A213794</u>	<u>001</u>	May 08, 2020
<u>AB</u>		<u>600MG</u>	<u>A213794</u>	<u>002</u>	May 08, 2020
<u>AB</u>		<u>800MG</u>	<u>A213794</u>	<u>003</u>	May 08, 2020
<u>AB</u>	CONTRACT PHARMACAL	<u>400MG</u>	<u>A071268</u>	<u>002</u>	Oct 15, 1986
<u>AB</u>		<u>600MG</u>	<u>A071268</u>	<u>001</u>	Oct 15, 1986
<u>AB</u>		<u>800MG</u>	<u>A071268</u>	<u>003</u>	Jul 01, 1988
<u>AB</u>	DR REDDYS LA	<u>400MG</u>	<u>A075682</u>	<u>001</u>	Nov 14, 2001
<u>AB</u>		<u>600MG</u>	<u>A075682</u>	<u>002</u>	Nov 14, 2001
<u>AB</u>	!	<u>800MG</u>	<u>A075682</u>	<u>003</u>	Nov 14, 2001
<u>AB</u>	DR REDDYS LABS INC	<u>400MG</u>	<u>A076112</u>	<u>001</u>	Oct 31, 2001
<u>AB</u>		<u>600MG</u>	<u>A076112</u>	<u>002</u>	Oct 31, 2001
<u>AB</u>		<u>800MG</u>	<u>A076112</u>	<u>003</u>	Oct 31, 2001
<u>AB</u>	GRANULES	<u>400MG</u>	<u>A091625</u>	<u>001</u>	Sep 15, 2015
<u>AB</u>		<u>600MG</u>	<u>A091625</u>	<u>002</u>	Sep 15, 2015
<u>AB</u>		<u>800MG</u>	<u>A091625</u>	<u>003</u>	Sep 15, 2015
<u>AB</u>	MARKSANS PHARMA	<u>400MG</u>	<u>A090796</u>	<u>001</u>	Dec 21, 2010
<u>AB</u>		<u>600MG</u>	<u>A090796</u>	<u>002</u>	Dec 21, 2010
<u>AB</u>		<u>800MG</u>	<u>A090796</u>	<u>003</u>	Dec 21, 2010
<u>AB</u>	SHANDONG XINHUA	<u>400MG</u>	<u>A202413</u>	<u>001</u>	Nov 23, 2016
<u>AB</u>		<u>600MG</u>	<u>A202413</u>	<u>002</u>	Nov 23, 2016
<u>AB</u>		<u>800MG</u>	<u>A202413</u>	<u>003</u>	Nov 23, 2016
<u>AB</u>	STRIDES PHARMA	<u>400MG</u>	<u>A078329</u>	<u>001</u>	Feb 05, 2009
<u>AB</u>		<u>600MG</u>	<u>A078329</u>	<u>002</u>	Feb 05, 2009
<u>AB</u>		<u>800MG</u>	<u>A078329</u>	<u>003</u>	Feb 05, 2009
<u>AB</u>	YICHANG HUMANWELL	<u>400MG</u>	<u>A215318</u>	<u>001</u>	Mar 30, 2022
<u>AB</u>		<u>600MG</u>	<u>A215318</u>	<u>002</u>	Mar 30, 2022
<u>AB</u>		<u>800MG</u>	<u>A215318</u>	<u>003</u>	Mar 30, 2022

IBUPROFEN LYSINE

INJECTABLE; INTRAVENOUS

IBUPROFEN LYSINE

<u>AP</u>	XGEN PHARMS	<u>EQ 20MG BASE/2ML (EQ 10MG BASE/ML)</u>	<u>A202402</u>	<u>001</u>	Mar 30, 2016
<u>AP</u>	NEOPROFEN				
<u>AP</u>	+! RECORDATI RARE	<u>EQ 20MG BASE/2ML (EQ 10MG BASE/ML)</u>	<u>N021903</u>	<u>001</u>	Apr 13, 2006

IBUTILIDE FUMARATE

INJECTABLE; INJECTION

CORVERT

<u>AP</u>	+! PFIZER	<u>0.1MG/ML</u>	<u>N020491</u>	<u>001</u>	Dec 28, 1995
<u>AP</u>	IBUTILIDE FUMARATE				
<u>AP</u>	MYLAN INSTITUTIONAL	<u>0.1MG/ML</u>	<u>A090643</u>	<u>001</u>	Jan 11, 2010

ICATIBANT ACETATE

INJECTABLE; SUBCUTANEOUS

FIRAZYR

<u>AP</u>	+! TAKEDA PHARMS USA	<u>EQ 30MG BASE/3ML (EQ 10MG BASE/ML)</u>	<u>N022150</u>	<u>001</u>	Aug 25, 2011
<u>AP</u>	ICATIBANT ACETATE				
<u>AP</u>	CIPLA	<u>EQ 30MG BASE/3ML (EQ 10MG BASE/ML)</u>	<u>A212446</u>	<u>001</u>	Jul 13, 2020
<u>AP</u>	FRESENIUS KABI USA	<u>EQ 30MG BASE/3ML (EQ 10MG BASE/ML)</u>	<u>A208317</u>	<u>001</u>	Jun 18, 2020
<u>AP</u>	JIANGSU HANSO PHARM	<u>EQ 30MG BASE/3ML (EQ 10MG BASE/ML)</u>	<u>A211021</u>	<u>001</u>	Mar 09, 2020
<u>AP</u>	NANG KUANG PHARM CO	<u>EQ 30MG BASE/3ML (EQ 10MG BASE/ML)</u>	<u>A212081</u>	<u>001</u>	Dec 16, 2020
<u>AP</u>	SLAYBACK PHARMA LLC	<u>EQ 30MG BASE/3ML (EQ 10MG BASE/ML)</u>	<u>A211501</u>	<u>001</u>	Sep 01, 2020
<u>AP</u>	TEVA PHARMS USA	<u>EQ 30MG BASE/3ML (EQ 10MG BASE/ML)</u>	<u>A210118</u>	<u>001</u>	Jul 15, 2019

ICODEXTRIN

SOLUTION; INTRAPERITONEAL

EXTRANEAL

+!	BAXTER HLTHCARE	7.5GM/100ML	N021321	001	Dec 20, 2002

ICOSAPENT ETHYL

CAPSULE; ORAL

ICOSAPENT ETHYL

<u>AB</u>	APOTEX	<u>1GM</u>	<u>A209437</u>	<u>001</u>	Jun 30, 2021
<u>AB</u>	DR REDDYS	<u>1GM</u>	<u>A209499</u>	<u>001</u>	Aug 07, 2020
<u>AB</u>	HIKMA	<u>1GM</u>	<u>A209457</u>	<u>001</u>	May 21, 2020
<u>AB</u>	TEVA PHARMS USA	<u>500MG</u>	<u>A209525</u>	<u>001</u>	Sep 11, 2020

PRESCRIPTION DRUG PRODUCT LIST

3-243 (of 474)

ICOSAPENT ETHYL

CAPSULE; ORAL

ICOSAPENT ETHYL

AB		<u>1GM</u>	<u>A209525</u>	<u>002</u>	Sep 11, 2020

VASCEPA

AB	+	AMARIN PHARMS	<u>500MG</u>	<u>N202057</u>	<u>002</u>	Feb 16, 2017

AB	+	!	<u>1GM</u>	<u>N202057</u>	<u>001</u>	Jul 26, 2012

IDARUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

IDAMYCIN PFS

AP	+	!	PFIZER	<u>1MG/ML</u>	<u>N050734</u>	<u>001</u>	Feb 17, 1997

IDARUBICIN HYDROCHLORIDE

AP			HIKMA	<u>1MG/ML</u>	<u>A065275</u>	<u>001</u>	Dec 14, 2006

AP				<u>1MG/ML</u>	<u>A065288</u>	<u>001</u>	May 15, 2007

IDARUBICIN HYDROCHLORIDE PFS

AP			TEVA PHARMS USA	<u>1MG/ML</u>	<u>A065036</u>	<u>001</u>	May 01, 2002

IDELALISIB

TABLET; ORAL

ZYDELIG

	+		GILEAD SCIENCES INC	100MG	N205858	001	Jul 23, 2014

	+	!		150MG	N205858	002	Jul 23, 2014

IFOSFAMIDE

INJECTABLE; INJECTION

IFEX

AP	+		BAXTER HLTHCARE	<u>1GM/VIAL</u>	<u>N019763</u>	<u>001</u>	Dec 30, 1988

AP	+			<u>3GM/VIAL</u>	<u>N019763</u>	<u>002</u>	Dec 30, 1988

IFOSFAMIDE

AP	!		FRESENIUS KABI USA	<u>1GM/VIAL</u>	<u>A076078</u>	<u>001</u>	May 28, 2002

AP	!			<u>3GM/VIAL</u>	<u>A076078</u>	<u>002</u>	May 28, 2002

AP			HIKMA	<u>1GM/20ML (50MG/ML)</u>	<u>A076619</u>	<u>001</u>	Jun 29, 2011

AP				<u>3GM/60ML (50MG/ML)</u>	<u>A076619</u>	<u>002</u>	Jun 29, 2011

AP	!		TEVA PHARMS USA	<u>1GM/20ML (50MG/ML)</u>	<u>A076657</u>	<u>001</u>	Apr 04, 2007

AP	!			<u>3GM/60ML (50MG/ML)</u>	<u>A076657</u>	<u>002</u>	Apr 04, 2007

ILOPERIDONE

TABLET; ORAL

FANAPT

	+	!	VANDA PHARMS INC	1MG	N022192	001	May 06, 2009

	+			2MG	N022192	002	May 06, 2009

	+			4MG	N022192	003	May 06, 2009

	+			6MG	N022192	004	May 06, 2009

	+			8MG	N022192	005	May 06, 2009

	+			10MG	N022192	006	May 06, 2009

	+			12MG	N022192	007	May 06, 2009

ILOPROST

SOLUTION; INHALATION

VENTAVIS

	+	!	ACTELION	10MCG/ML (10MCG/ML)	N021779	002	Dec 08, 2005

	+	!		20MCG/ML (20MCG/ML)	N021779	003	Aug 07, 2009

IMATINIB MESYLATE

TABLET; ORAL

GLEEVEC

AB	+		NOVARTIS	<u>EQ 100MG BASE</u>	<u>N021588</u>	<u>001</u>	Apr 18, 2003

AB	+	!		<u>EQ 400MG BASE</u>	<u>N021588</u>	<u>002</u>	Apr 18, 2003

IMATINIB MESYLATE

AB			APOTEX	<u>EQ 100MG BASE</u>	<u>A079179</u>	<u>001</u>	Aug 05, 2016

AB				<u>EQ 400MG BASE</u>	<u>A079179</u>	<u>002</u>	Aug 05, 2016

AB			BRECKENRIDGE	<u>EQ 100MG BASE</u>	<u>A205990</u>	<u>001</u>	Feb 08, 2019

AB				<u>EQ 400MG BASE</u>	<u>A205990</u>	<u>002</u>	Feb 08, 2019

AB			DR REDDYS	<u>EQ 100MG BASE</u>	<u>A206547</u>	<u>001</u>	Aug 13, 2018

AB				<u>EQ 400MG BASE</u>	<u>A206547</u>	<u>002</u>	Aug 13, 2018

AB			EUGIA PHARMA	<u>EQ 100MG BASE</u>	<u>A212773</u>	<u>001</u>	Jul 23, 2020

AB				<u>EQ 400MG BASE</u>	<u>A212773</u>	<u>002</u>	Jul 23, 2020

AB			HIKMA	<u>EQ 100MG BASE</u>	<u>A207586</u>	<u>001</u>	Jul 13, 2018

AB				<u>EQ 400MG BASE</u>	<u>A207586</u>	<u>002</u>	Jul 13, 2018

AB			MYLAN	<u>EQ 100MG BASE</u>	<u>A204644</u>	<u>001</u>	Jun 21, 2017

AB				<u>EQ 400MG BASE</u>	<u>A204644</u>	<u>002</u>	Jun 21, 2017

AB			NATCO PHARMA LTD	<u>EQ 100MG BASE</u>	<u>A207818</u>	<u>001</u>	Mar 01, 2019

AB				<u>EQ 400MG BASE</u>	<u>A207818</u>	<u>002</u>	Mar 01, 2019

AB			QILU PHARM HAINAN	<u>EQ 100MG BASE</u>	<u>A212135</u>	<u>001</u>	Jun 21, 2022

PRESCRIPTION DRUG PRODUCT LIST

3-244 (of 474)

IMATINIB MESYLATE

TABLET; ORAL

IMATINIB MESYLATE

<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A212135</u>	<u>002</u>	Jun 21, 2022
<u>AB</u>	SHILPA	<u>EQ 100MG BASE</u>	<u>A208302</u>	<u>001</u>	Jan 17, 2019
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A208302</u>	<u>002</u>	Jan 17, 2019
<u>AB</u>	SUN PHARM	<u>EQ 100MG BASE</u>	<u>A078340</u>	<u>001</u>	Dec 03, 2015
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A078340</u>	<u>002</u>	Dec 03, 2015
<u>AB</u>	TEVA PHARMS USA	<u>EQ 100MG BASE</u>	<u>A204285</u>	<u>001</u>	Aug 04, 2016
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A204285</u>	<u>002</u>	Aug 04, 2016
<u>AB</u>	WOCKHARDT BIO AG	<u>EQ 100MG BASE</u>	<u>A208429</u>	<u>001</u>	Jan 17, 2019
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A208429</u>	<u>002</u>	Jan 17, 2019
<u>AB</u>	ZYDUS PHARMS	<u>EQ 100MG BASE</u>	<u>A210658</u>	<u>001</u>	Apr 08, 2020
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A210658</u>	<u>002</u>	Apr 08, 2020

IMIPRAMINE HYDROCHLORIDE

TABLET; ORAL

IMIPRAMINE HYDROCHLORIDE

<u>AB</u>	LEADING	<u>10MG</u>	<u>A040903</u>	<u>001</u>	Oct 24, 2012
<u>AB</u>		<u>25MG</u>	<u>A040903</u>	<u>002</u>	Oct 24, 2012
<u>AB</u>		<u>50MG</u>	<u>A040903</u>	<u>003</u>	Oct 24, 2012
<u>AB</u>	OXFORD PHARMS	<u>10MG</u>	<u>A040751</u>	<u>003</u>	Feb 28, 2008
<u>AB</u>		<u>25MG</u>	<u>A040751</u>	<u>002</u>	Feb 28, 2008
<u>AB</u>		<u>50MG</u>	<u>A040751</u>	<u>001</u>	Feb 28, 2008
<u>AB</u>	SANDOZ	<u>10MG</u>	<u>A084936</u>	<u>002</u>	
<u>AB</u>		<u>25MG</u>	<u>A083745</u>	<u>001</u>	
<u>AB</u>		<u>50MG</u>	<u>A084937</u>	<u>001</u>	
<u>AB</u>	+ SPECGX LLC	<u>10MG</u>	<u>A087846</u>	<u>002</u>	May 22, 1984
<u>AB</u>	+	<u>25MG</u>	<u>A087846</u>	<u>003</u>	May 22, 1984
<u>AB</u>	STRIDES PHARMA	<u>10MG</u>	<u>A088292</u>	<u>001</u>	Oct 21, 1983
<u>AB</u>		<u>25MG</u>	<u>A088262</u>	<u>001</u>	Oct 21, 1983
<u>AB</u>		<u>50MG</u>	<u>A088276</u>	<u>001</u>	Oct 21, 1983
<u>AB</u>	SUN PHARM INDUSTRIES	<u>10MG</u>	<u>A081048</u>	<u>001</u>	Jun 05, 1990
<u>AB</u>		<u>25MG</u>	<u>A081049</u>	<u>001</u>	Jun 05, 1990
<u>AB</u>		<u>50MG</u>	<u>A081050</u>	<u>001</u>	Jun 05, 1990
	<u>TOFRANIL</u>				
<u>AB</u>	+! SPECGX LLC	<u>50MG</u>	<u>A087846</u>	<u>001</u>	May 22, 1984

IMIPRAMINE PAMOATE

CAPSULE; ORAL

IMIPRAMINE PAMOATE

<u>AB</u>	! HIKMA	<u>EQ 75MG HYDROCHLORIDE</u>	<u>A091099</u>	<u>001</u>	Apr 16, 2010
<u>AB</u>		<u>EQ 100MG HYDROCHLORIDE</u>	<u>A091099</u>	<u>002</u>	Apr 16, 2010
<u>AB</u>		<u>EQ 125MG HYDROCHLORIDE</u>	<u>A091099</u>	<u>003</u>	Apr 16, 2010
<u>AB</u>		<u>EQ 150MG HYDROCHLORIDE</u>	<u>A091099</u>	<u>004</u>	Apr 16, 2010
<u>AB</u>	LUPIN LTD	<u>EQ 75MG HYDROCHLORIDE</u>	<u>A090444</u>	<u>001</u>	Apr 16, 2010
<u>AB</u>		<u>EQ 100MG HYDROCHLORIDE</u>	<u>A090444</u>	<u>002</u>	Apr 16, 2010
<u>AB</u>		<u>EQ 125MG HYDROCHLORIDE</u>	<u>A090444</u>	<u>003</u>	Apr 16, 2010
<u>AB</u>		<u>EQ 150MG HYDROCHLORIDE</u>	<u>A090444</u>	<u>004</u>	Apr 16, 2010

IMIQUIMOD

CREAM; TOPICAL

ALDARA

<u>AB</u>	+! BAUSCH	<u>5%</u>	<u>N020723</u>	<u>001</u>	Feb 27, 1997

IMIQUIMOD

<u>AB</u>	APOTEX INC	<u>5%</u>	<u>A091308</u>	<u>001</u>	Apr 06, 2012
<u>AB</u>	FOUGERA PHARMS	<u>5%</u>	<u>A078548</u>	<u>001</u>	Feb 25, 2010
<u>AB</u>	GLENMARK GENERICS	<u>5%</u>	<u>A201994</u>	<u>001</u>	Mar 06, 2012
<u>AB</u>	PADAGIS ISRAEL	<u>5%</u>	<u>A078837</u>	<u>001</u>	Sep 07, 2010
<u>AB</u>	TARO	<u>3.75%</u>	<u>A205971</u>	<u>001</u>	Jan 26, 2021
<u>AB</u>		<u>5%</u>	<u>A200173</u>	<u>001</u>	Apr 15, 2011

ZYCLARA

<u>AB</u>	+! BAUSCH	<u>3.75%</u>	<u>N022483</u>	<u>001</u>	Mar 25, 2010
	+!	2.5%	N022483	002	Jul 15, 2011

INAMRINONE LACTATE

INJECTABLE; INJECTION

AMRINONE LACTATE

!	HIKMA	EQ 5MG BASE/ML	A075513	001	May 09, 2000

PRESCRIPTION DRUG PRODUCT LIST

3-245 (of 474)

INCLISIRAN SODIUM

SOLUTION; SUBCUTANEOUS

LEQVIO

+! NOVARTIS

EQ 284MG BASE/1.5ML (EQ 189MG BASE/ML)

N214012 001 Dec 22, 2021

INDAPAMIDE

TABLET; ORAL

INDAPAMIDEAB ACTAVIS ELIZABETH1.25MGA074722 001 Jun 17, 1996AB2.5MGA074722 002 Jun 17, 1996AB ANI PHARMS1.25MGA074299 002 Apr 29, 1996AB !2.5MGA074299 001 Jul 27, 1995INDIGOTINDISULFONATE SODIUM

SOLUTION; INTRAVENOUS

BLUDIGO

+! PROVEPHARM SAS

40MG/5ML (8MG/ML)

N216264 001 Jul 08, 2022

INDIUM IN-111 CHLORIDE

INJECTABLE; INJECTION

INDIUM IN 111 CHLORIDE

+! CURIUM

5mCi/0.5ML

N019841 001 Sep 27, 1994

INDIUM IN-111 OXYQUINOLINE

INJECTABLE; INJECTION

INDIUM IN 111 OXYQUINOLINEAP BWXT ITG1mCi/MLA202586 001 Jul 25, 2018AP +! GE HEALTHCARE1mCi/MLN019044 001 Dec 24, 1985INDIUM IN-111 PENTETATE DISODIUM

INJECTABLE; INTRATHECAL

MPI INDIUM DTPA IN 111

+! GE HEALTHCARE

1mCi/ML

N017707 001 Feb 18, 1982

INDIUM IN-111 PENTETREOTIDE KIT

INJECTABLE; INJECTION

OCTREOSCAN

+! CURIUM

3mCi/ML

N020314 001 Jun 02, 1994

INDOCYANINE GREEN

INJECTABLE; INJECTION

IC-GREENAP +! AKORN25MG/VIALN011525 001INDOCYANINE GREENAP RENEW PHARMS25MG/VIALA040811 001 Nov 21, 2007

POWDER; INTRAVENOUS, INTERSTITIAL

SPY AGENT GREEN KIT

+! NOVADAQ TECH

25MG/VIAL

N211580 001 Nov 21, 2018

INDOMETHACIN

CAPSULE; ORAL

INDOMETHACINAB CADILA25MGA090403 001 Nov 15, 2010AB50MGA090403 002 Nov 15, 2010AB CHARTWELL MOLECULES50MGA070651 001 Mar 05, 1986AB GLENMARK GENERICS25MGA091276 001 Dec 22, 2010AB !50MGA091276 002 Dec 22, 2010AB HETERO LABS LTD III25MGA091240 001 Apr 12, 2011AB50MGA091240 002 Apr 12, 2011AB SANDOZ25MGA070673 001 Apr 29, 1987AB50MGA070674 001 Apr 29, 1987

CAPSULE, EXTENDED RELEASE; ORAL

INDOMETHACINAB AMNEAL PHARMS75MGA091549 001 Dec 01, 2010AB AVANTHI INC75MGA079175 001 Mar 06, 2009AB CHARTWELL RX75MGA200529 001 Nov 30, 2010AB GLENMARK PHARMS LTD75MGA203501 001 Jun 22, 2017AB HETERO LABS LTD III75MGA201807 001 Sep 28, 2012AB NOVAST LABS75MGA204853 001 May 08, 2017AB ! SANDOZ75MGA074464 001 May 28, 1998AB ZYDUS PHARMS75MGA202711 001 Sep 25, 2017

INJECTABLE; INJECTION

INDOMETHACIN

+! FRESENIUS KABI USA

EQ 1MG BASE/VIAL

N022536 001 Mar 17, 2010

PRESCRIPTION DRUG PRODUCT LIST

3-246 (of 474)

INDOMETHACIN

SUPPOSITORY; RECTAL

INDOMETHACIN

! COSETTE

50MG

A073314 001 Aug 31, 1992

SUSPENSION; ORAL

INDOCIN

+! EGALET

25MG/5ML

N018332 001 Oct 10, 1985

INDOMETHACIN SODIUM

INJECTABLE; INJECTION

INDOMETHACIN SODIUMAP HOSPIRAEQ 1MG BASE/VIALA204118 001 Apr 19, 2016AP ! NAVINTA LLCEQ 1MG BASE/VIALA206561 001 Jul 19, 2017AP WEST-WARD PHARMS
INTEQ 1MG BASE/VIALA078713 001 Jul 16, 2008INFIGRATINIB PHOSPHATE

CAPSULE; ORAL

TRUSELTIQ

+ HELSINN HLTHCARE

25MG

N214622 001 May 28, 2021

+!

100MG

N214622 002 May 28, 2021

INOTERSEN SODIUM

SOLUTION; SUBCUTANEOUS

TEGSEDI

+! AKCEA THERAPS

EQ 284MG BASE/1.5ML (EQ 189.3MG
BASE/ML)

N211172 001 Oct 05, 2018

IOBENGUANE I-131

SOLUTION; INTRAVENOUS

AZEDRA

+! PROGENICS PHARMS
INC

15mCi/ML

N209607 001 Jul 30, 2018

IOBENGUANE SULFATE I-123

SOLUTION; INTRAVENOUS

ADREVIEW

+! GE HEALTHCARE

10mCi/5ML (2mCi/ML)

N022290 001 Sep 19, 2008

IODIXANOL

INJECTABLE; INJECTION

IODIXANOLAP HENGRUI PHARMA55%A214271 001 May 19, 2022AP65.2%A214271 002 May 19, 2022VISIPAQUE 270AP +! GE HEALTHCARE55%N020351 001 Mar 22, 1996VISIPAQUE 320AP +! GE HEALTHCARE65.2%N020351 002 Mar 22, 1996

65.2%

N020808 002 Aug 29, 1997

IOFLUPANE I-123

SOLUTION; INTRAVENOUS

DATSCANAP +! GE HLTHCARE INC5mCi/2.5ML (2mCi/ML)N022454 001 Jan 14, 2011IOFLUPANE I-123AP CURIUM5mCi/2.5ML (2mCi/ML)A213792 001 Mar 30, 2022IOHEXOL

INJECTABLE; INJECTION

OMNIPAQUE 140

+! GE HEALTHCARE

30.2%

N018956 005 Nov 30, 1988

SOLUTION; INJECTION, ORAL

OMNIPAQUE 350

+! GE HEALTHCARE

75.5%

N018956 004 Dec 26, 1985

75.5%

N020608 003 Oct 24, 1995

SOLUTION; INJECTION, ORAL, RECTAL

OMNIPAQUE 180

+! GE HEALTHCARE

38.8%

N018956 001 Dec 26, 1985

OMNIPAQUE 240

+! GE HEALTHCARE

51.8%

N018956 002 Dec 26, 1985

OMNIPAQUE 300

+! GE HEALTHCARE

64.7%

N018956 003 Dec 26, 1985

64.7%

N020608 002 Oct 24, 1995

SOLUTION; ORAL

OMNIPAQUE 12

+! GE HEALTHCARE

2.6%

N018956 009 Apr 17, 2018

PRESCRIPTION DRUG PRODUCT LIST

3-247 (of 474)

IOHEXOL

SOLUTION; ORAL

OMNIPAQUE 9

+! GE HEALTHCARE

1.9%

N018956 008 Apr 17, 2018

IOPAMIDOL

INJECTABLE; INJECTION

ISOVUE-200

+! BRACCO

41%

N018735 006 Jul 07, 1987

ISOVUE-250

+! BRACCO

51%

N018735 007 Jul 06, 1992

+!

51%

N020327 002 Oct 12, 1994

ISOVUE-300

+! BRACCO

61%

N018735 002 Dec 31, 1985

+!

61%

N020327 003 Oct 12, 1994

ISOVUE-370

+! BRACCO

76%

N018735 003 Dec 31, 1985

+!

76%

N020327 004 Oct 12, 1994

ISOVUE-M 200

+! BRACCO

41%

N018735 001 Dec 31, 1985

ISOVUE-M 300

+! BRACCO

61%

N018735 004 Dec 31, 1985

IOPROMIDE

INJECTABLE; INJECTION

ULTRAVIST (PHARMACY BULK)

+! BAYER HLTHCARE

62.3%

N021425 001 Sep 20, 2002

+!

76.9%

N021425 002 Sep 20, 2002

ULTRAVIST 300

+! BAYER HLTHCARE

62.3%

N020220 002 May 10, 1995

ULTRAVIST 370

+! BAYER HLTHCARE

76.9%

N020220 001 May 10, 1995

IOTHALAMATE MEGLUMINE

INJECTABLE; INJECTION

CONRAY

+! LIEBEL-FLARSHEIM

60%

N013295 001

SOLUTION; INTRAVESICAL

CYSTO-CONRAY II

LIEBEL-FLARSHEIM

17.2%

N017057 002

IOTHALAMATE SODIUM I-125

INJECTABLE; INJECTION

GLOFIL-125

ISOTEX

250-300uCi/ML

N017279 001

IOVERSOL

INJECTABLE; INJECTION

OPTIRAY 300

+! LIEBEL-FLARSHEIM

64%

N019710 004 Jan 22, 1992

+!

64%

N020923 004 May 13, 1999

OPTIRAY 320

+! LIEBEL-FLARSHEIM

68%

N019710 001 Dec 30, 1988

+!

68%

N020923 002 May 29, 1998

OPTIRAY 350

+! LIEBEL-FLARSHEIM

74%

N019710 005 Jan 22, 1992

+!

74%

N020923 003 May 28, 1998

IPRATROPIUM BROMIDE

AEROSOL, METERED; INHALATION

ATROVENT HFA

+! BOEHRINGER

0.021MG/INH

N021527 001 Nov 27, 2004

INGELHEIM

SOLUTION; INHALATION

IPRATROPIUM BROMIDE**AN** LUOXIN AUROVITAS**0.02%****A206543 001** Oct 27, 2016**AN** NEPHRON**0.02%****A075562 001** Sep 27, 2001**AN** ! RITEDOSE CORP**0.02%****A075693 001** Jan 26, 2001**AN** SUN PHARM**0.02%****A207903 001** Jan 03, 2017

SPRAY, METERED; NASAL

IPRATROPIUM BROMIDE**AB** AMNEAL**0.021MG/SPRAY****A215104 001** Aug 16, 2022**AB****0.042MG/SPRAY****A215105 001** Aug 16, 2022**AB** APOTEX INC**0.021MG/SPRAY****A076156 001** Apr 18, 2003**AB****0.042MG/SPRAY****A076155 001** Apr 18, 2003**AB** BAUSCH**0.021MG/SPRAY****A076025 001** Mar 31, 2003

PRESCRIPTION DRUG PRODUCT LIST

3-248 (of 474)

IPRATROPIUM BROMIDE

SPRAY, METERED;NASAL

IPRATROPIUM BROMIDE

<u>AB</u>			<u>0.042MG/SPRAY</u>	<u>A076103</u>	<u>001</u>	Mar 31, 2003
<u>AB</u>	!	HIKMA	<u>0.021MG/SPRAY</u>	<u>A076664</u>	<u>001</u>	Nov 05, 2003
<u>AB</u>	!		<u>0.042MG/SPRAY</u>	<u>A076598</u>	<u>001</u>	Nov 05, 2003

IRBESARTAN

TABLET;ORAL

AVAPRO

<u>AB</u>	+	SANOFI AVENTIS US	<u>75MG</u>	<u>N020757</u>	<u>001</u>	Sep 30, 1997
<u>AB</u>	+		<u>150MG</u>	<u>N020757</u>	<u>002</u>	Sep 30, 1997
<u>AB</u>	+	!	<u>300MG</u>	<u>N020757</u>	<u>003</u>	Sep 30, 1997

IRBESARTAN

<u>AB</u>		ALEMBIC PHARMS LTD	<u>75MG</u>	<u>A091236</u>	<u>001</u>	Oct 15, 2012
<u>AB</u>			<u>150MG</u>	<u>A091236</u>	<u>002</u>	Oct 15, 2012
<u>AB</u>			<u>300MG</u>	<u>A091236</u>	<u>003</u>	Oct 15, 2012
<u>AB</u>		AMNEAL PHARMS	<u>75MG</u>	<u>A204740</u>	<u>001</u>	Apr 17, 2018
<u>AB</u>			<u>150MG</u>	<u>A204740</u>	<u>002</u>	Apr 17, 2018
<u>AB</u>			<u>300MG</u>	<u>A204740</u>	<u>003</u>	Apr 17, 2018
<u>AB</u>		AUROBINDO PHARMA LTD	<u>75MG</u>	<u>A203081</u>	<u>001</u>	Sep 27, 2012
<u>AB</u>			<u>150MG</u>	<u>A203081</u>	<u>002</u>	Sep 27, 2012
<u>AB</u>			<u>300MG</u>	<u>A203081</u>	<u>003</u>	Sep 27, 2012
<u>AB</u>		CHARTWELL MOLECULAR	<u>75MG</u>	<u>A077205</u>	<u>001</u>	Nov 14, 2012
<u>AB</u>			<u>150MG</u>	<u>A077205</u>	<u>002</u>	Nov 14, 2012
<u>AB</u>			<u>300MG</u>	<u>A077205</u>	<u>003</u>	Nov 14, 2012
<u>AB</u>		HETERO LABS LTD V	<u>75MG</u>	<u>A202910</u>	<u>001</u>	Sep 27, 2012
<u>AB</u>			<u>150MG</u>	<u>A202910</u>	<u>002</u>	Sep 27, 2012
<u>AB</u>			<u>300MG</u>	<u>A202910</u>	<u>003</u>	Sep 27, 2012
<u>AB</u>		HISUN PHARM HANGZHOU	<u>75MG</u>	<u>A206194</u>	<u>001</u>	Jun 14, 2016
<u>AB</u>			<u>150MG</u>	<u>A206194</u>	<u>002</u>	Jun 14, 2016
<u>AB</u>			<u>300MG</u>	<u>A206194</u>	<u>003</u>	Jun 14, 2016
<u>AB</u>		JUBILANT GENERICS	<u>75MG</u>	<u>A203534</u>	<u>001</u>	Feb 23, 2015
<u>AB</u>			<u>150MG</u>	<u>A203534</u>	<u>002</u>	Feb 23, 2015
<u>AB</u>			<u>300MG</u>	<u>A203534</u>	<u>003</u>	Feb 23, 2015
<u>AB</u>		LUPIN LTD	<u>75MG</u>	<u>A201531</u>	<u>001</u>	Oct 15, 2012
<u>AB</u>			<u>150MG</u>	<u>A201531</u>	<u>002</u>	Oct 15, 2012
<u>AB</u>			<u>300MG</u>	<u>A201531</u>	<u>003</u>	Oct 15, 2012
<u>AB</u>		MACLEODS PHARMS LTD	<u>75MG</u>	<u>A202254</u>	<u>001</u>	Oct 03, 2012
<u>AB</u>			<u>150MG</u>	<u>A202254</u>	<u>002</u>	Oct 03, 2012
<u>AB</u>			<u>300MG</u>	<u>A202254</u>	<u>003</u>	Oct 03, 2012
<u>AB</u>		PRINSTON INC	<u>75MG</u>	<u>A203071</u>	<u>001</u>	Sep 27, 2012
<u>AB</u>			<u>150MG</u>	<u>A203071</u>	<u>002</u>	Sep 27, 2012
<u>AB</u>			<u>300MG</u>	<u>A203071</u>	<u>003</u>	Sep 27, 2012
<u>AB</u>		SANDOZ	<u>75MG</u>	<u>A077466</u>	<u>001</u>	Sep 27, 2012
<u>AB</u>			<u>150MG</u>	<u>A077466</u>	<u>002</u>	Sep 27, 2012
<u>AB</u>			<u>300MG</u>	<u>A077466</u>	<u>003</u>	Sep 27, 2012
<u>AB</u>		SCIEGEN PHARMS INC	<u>75MG</u>	<u>A204774</u>	<u>001</u>	Dec 07, 2015
<u>AB</u>			<u>150MG</u>	<u>A204774</u>	<u>002</u>	Dec 07, 2015
<u>AB</u>			<u>300MG</u>	<u>A204774</u>	<u>003</u>	Dec 07, 2015
<u>AB</u>		TEVA PHARMS	<u>75MG</u>	<u>A077159</u>	<u>001</u>	Mar 30, 2012
<u>AB</u>			<u>150MG</u>	<u>A077159</u>	<u>002</u>	Mar 30, 2012
<u>AB</u>			<u>300MG</u>	<u>A077159</u>	<u>003</u>	Mar 30, 2012
<u>AB</u>		ZYDUS PHARMS USA INC	<u>75MG</u>	<u>A079213</u>	<u>001</u>	Sep 27, 2012
<u>AB</u>			<u>150MG</u>	<u>A079213</u>	<u>002</u>	Sep 27, 2012
<u>AB</u>			<u>300MG</u>	<u>A079213</u>	<u>003</u>	Sep 27, 2012

IRINOTECAN HYDROCHLORIDE

INJECTABLE;INJECTION

CAMPTOSAR

<u>AP</u>	+	!	PFIZER INC	<u>40MG/2ML (20MG/ML)</u>	<u>N020571</u>	<u>001</u>	Jun 14, 1996
<u>AP</u>	+	!		<u>100MG/5ML (20MG/ML)</u>	<u>N020571</u>	<u>002</u>	Jun 14, 1996
<u>AP</u>	+	!		<u>300MG/15ML (20MG/ML)</u>	<u>N020571</u>	<u>003</u>	Aug 05, 2010

IRINOTECAN HYDROCHLORIDE

<u>AP</u>			ACCORD HLTHCARE	<u>40MG/2ML (20MG/ML)</u>	<u>A079068</u>	<u>001</u>	Nov 21, 2008
<u>AP</u>				<u>100MG/5ML (20MG/ML)</u>	<u>A079068</u>	<u>002</u>	Nov 21, 2008
<u>AP</u>			ACTAVIS TOTOWA	<u>40MG/2ML (20MG/ML)</u>	<u>A078589</u>	<u>001</u>	Feb 27, 2008
<u>AP</u>				<u>100MG/5ML (20MG/ML)</u>	<u>A078589</u>	<u>002</u>	Feb 27, 2008
<u>AP</u>				<u>500MG/25ML (20MG/ML)</u>	<u>A078589</u>	<u>003</u>	Nov 18, 2015
<u>AP</u>			AKORN	<u>40MG/2ML (20MG/ML)</u>	<u>A090726</u>	<u>001</u>	Sep 16, 2009
<u>AP</u>				<u>100MG/5ML (20MG/ML)</u>	<u>A090726</u>	<u>002</u>	Sep 16, 2009

PRESCRIPTION DRUG PRODUCT LIST

3-249 (of 474)

IRINOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION

IRINOTECAN HYDROCHLORIDE

<u>AP</u>	EUGIA PHARMA	<u>40MG/2ML (20MG/ML)</u>	<u>A213278</u>	<u>001</u>	Nov 02, 2020
<u>AP</u>		<u>100MG/5ML (20MG/ML)</u>	<u>A213278</u>	<u>002</u>	Nov 02, 2020
<u>AP</u>		<u>300MG/15ML (20MG/ML)</u>	<u>A213278</u>	<u>003</u>	Nov 02, 2020
<u>AP</u>		<u>500MG/25ML (20MG/ML)</u>	<u>A213278</u>	<u>004</u>	Apr 11, 2022
<u>AP</u>	FRESENIUS KABI USA	<u>40MG/2ML (20MG/ML)</u>	<u>A077776</u>	<u>001</u>	Feb 27, 2008
<u>AP</u>		<u>100MG/5ML (20MG/ML)</u>	<u>A077776</u>	<u>002</u>	Feb 27, 2008
<u>AP</u>	GLAND PHARMA LTD	<u>40MG/2ML (20MG/ML)</u>	<u>A212993</u>	<u>001</u>	Nov 18, 2019
<u>AP</u>		<u>100MG/5ML (20MG/ML)</u>	<u>A212993</u>	<u>002</u>	Nov 18, 2019
<u>AP</u>	HENGRUI PHARMA	<u>40MG/2ML (20MG/ML)</u>	<u>A090675</u>	<u>002</u>	Dec 16, 2011
<u>AP</u>		<u>100MG/5ML (20MG/ML)</u>	<u>A090675</u>	<u>001</u>	Dec 16, 2011
<u>AP</u>	HIKMA FARMACEUTICA	<u>40MG/2ML (20MG/ML)</u>	<u>A091032</u>	<u>001</u>	Dec 20, 2010
<u>AP</u>		<u>100MG/5ML (20MG/ML)</u>	<u>A091032</u>	<u>002</u>	Dec 20, 2010
<u>AP</u>	HISUN PHARM HANGZHOU	<u>40MG/2ML (20MG/ML)</u>	<u>A090016</u>	<u>001</u>	Jan 28, 2009
<u>AP</u>		<u>100MG/5ML (20MG/ML)</u>	<u>A090016</u>	<u>002</u>	Jan 28, 2009
<u>AP</u>	HOSPIRA	<u>40MG/2ML (20MG/ML)</u>	<u>A077915</u>	<u>001</u>	Feb 27, 2008
<u>AP</u>		<u>100MG/5ML (20MG/ML)</u>	<u>A077915</u>	<u>002</u>	Feb 27, 2008
<u>AP</u>	!	<u>500MG/25ML (20MG/ML)</u>	<u>A078796</u>	<u>001</u>	Feb 27, 2008
<u>AP</u>	INTAS PHARMS USA	<u>40MG/2ML (20MG/ML)</u>	<u>A203054</u>	<u>001</u>	Aug 31, 2017
<u>AP</u>		<u>100MG/5ML (20MG/ML)</u>	<u>A203054</u>	<u>002</u>	Aug 31, 2017
<u>AP</u>	NOVAST LABS	<u>40MG/2ML (20MG/ML)</u>	<u>A206935</u>	<u>001</u>	May 26, 2017
<u>AP</u>		<u>100MG/5ML (20MG/ML)</u>	<u>A206935</u>	<u>002</u>	May 26, 2017
<u>AP</u>	QILU PHARM HAINAN	<u>40MG/2ML (20MG/ML)</u>	<u>A203380</u>	<u>001</u>	May 03, 2016
<u>AP</u>		<u>100MG/5ML (20MG/ML)</u>	<u>A203380</u>	<u>002</u>	May 03, 2016
<u>AP</u>		<u>300MG/15ML (20MG/ML)</u>	<u>A203380</u>	<u>003</u>	May 03, 2016
<u>AP</u>	SHILPA	<u>40MG/2ML (20MG/ML)</u>	<u>A208718</u>	<u>001</u>	Dec 28, 2018
<u>AP</u>		<u>100MG/5ML (20MG/ML)</u>	<u>A208718</u>	<u>002</u>	Dec 28, 2018
<u>AP</u>		<u>300MG/15ML (20MG/ML)</u>	<u>A208718</u>	<u>003</u>	Aug 16, 2019
<u>AP</u>	TEVA PHARMS USA	<u>500MG/25ML (20MG/ML)</u>	<u>A090101</u>	<u>001</u>	Nov 26, 2008
<u>AP</u>	WEST-WARD PHARMS INT	<u>40MG/2ML (20MG/ML)</u>	<u>A078753</u>	<u>001</u>	Dec 24, 2008
<u>AP</u>		<u>100MG/5ML (20MG/ML)</u>	<u>A078753</u>	<u>002</u>	Dec 24, 2008
<u>AP</u>	ZENNOVA	<u>40MG/2ML (20MG/ML)</u>	<u>A090393</u>	<u>002</u>	May 13, 2011
<u>AP</u>		<u>100MG/5ML (20MG/ML)</u>	<u>A090393</u>	<u>003</u>	May 13, 2011

INJECTABLE, LIPOSOMAL; INTRAVENOUS

ONIVYDE

+! IPSSEN INC

EQ 43MG BASE/10ML (EQ 4.3MG BASE/ML)

N207793 001 Oct 22, 2015

ISAVUCONAZONIUM SULFATE

CAPSULE; ORAL

CRESEMBA

+ ASTELLAS

74.5MG

N207500 002 Nov 22, 2022

+!

186MG

N207500 001 Mar 06, 2015

POWDER; INTRAVENOUS

CRESEMBA

+! ASTELLAS

372MG

N207501 001 Mar 06, 2015

ISOCARBOXAZID

TABLET; ORAL

MARPLAN

+! VALIDUS PHARMS INC

10MG

N011961 001

ISOFLURANE

LIQUID; INHALATION

FORANEAN +! BAXTER HLTHCARE99.9%N017624 001ISOFLURANEAN HALOCARBON PRODS99.9%A075225 001 Oct 20, 1999AN PIRAMAL CRITICAL99.9%A074416 001 Sep 30, 1994AN PIRAMAL PHARMA99.9%A074502 001 Jun 27, 1995ISONIAZID

INJECTABLE; INJECTION

ISONIAZID

! SANDOZ INC

100MG/ML

A040648 001 Jul 05, 2005

SYRUP; ORAL

ISONIAZID

+! CMP PHARMA INC

50MG/5ML

A088235 001 Nov 10, 1983

TABLET; ORAL

ISONIAZIDAA ! BARR100MGA080936 001AA !300MGA080937 002

PRESCRIPTION DRUG PRODUCT LIST

3-250 (of 474)

ISONIAZID

TABLET; ORAL

ISONIAZID

<u>AA</u>	MIKART	<u>100MG</u>	<u>A040090</u>	<u>001</u>	Jun 26, 1997
<u>AA</u>		<u>300MG</u>	<u>A040090</u>	<u>002</u>	Jun 26, 1997
<u>AA</u>	THEPHARMANETWORK LLC	<u>100MG</u>	<u>A202610</u>	<u>001</u>	Oct 29, 2014
<u>AA</u>		<u>300MG</u>	<u>A202610</u>	<u>002</u>	Oct 29, 2014

ISOPROTERENOL HYDROCHLORIDE

INJECTABLE; INJECTION

ISOPROTERENOL HYDROCHLORIDE

<u>AP</u>	AM REGENT	<u>0.2MG/ML</u>	<u>A214775</u>	<u>001</u>	Oct 19, 2022
<u>AP</u>	AMNEAL	<u>0.2MG/ML</u>	<u>A210576</u>	<u>001</u>	Oct 17, 2018
<u>AP</u>	AMPHASTAR PHARMS INC	<u>0.2MG/ML</u>	<u>A210106</u>	<u>001</u>	Jun 18, 2018
<u>AP</u>	AMRING PHARMS	<u>0.2MG/ML</u>	<u>A211237</u>	<u>001</u>	May 19, 2021
<u>AP</u>	AVET LIFESCIENCES	<u>0.2MG/ML</u>	<u>A212189</u>	<u>001</u>	Nov 19, 2021
<u>AP</u>	CIPLA	<u>0.2MG/ML</u>	<u>A210322</u>	<u>001</u>	Jun 12, 2018
<u>AP</u>	EUGIA PHARMA	<u>0.2MG/ML</u>	<u>A211864</u>	<u>001</u>	Feb 09, 2021
<u>AP</u>	MICRO LABS	<u>0.2MG/ML</u>	<u>A210845</u>	<u>001</u>	Feb 16, 2021
<u>AP</u>	MYLAN LABS LTD	<u>0.2MG/ML</u>	<u>A212573</u>	<u>001</u>	Sep 06, 2022
<u>AP</u>	NEXUS PHARMS	<u>0.2MG/ML</u>	<u>A206961</u>	<u>001</u>	Aug 02, 2017
<u>AP</u>	STI PHARMA LLC	<u>0.2MG/ML</u>	<u>A215542</u>	<u>001</u>	Sep 20, 2022

ISUPREL

<u>AP</u>	+!	BAUSCH	<u>0.2MG/ML</u>	<u>N010515</u>	<u>001</u>

ISOSORBIDE DINITRATE

TABLET; ORAL

ISORDIL

<u>AB</u>	+	BAUSCH	<u>5MG</u>	<u>N012093</u>	<u>007</u>	Jul 29, 1988
<u>AB</u>	+	!	<u>40MG</u>	<u>N012093</u>	<u>001</u>	Jul 29, 1988

ISOSORBIDE DINITRATE

<u>AB</u>		HIKMA INTL PHARMS	<u>5MG</u>	<u>A086067</u>	<u>001</u>	Oct 29, 1987
<u>AB</u>			<u>10MG</u>	<u>A086066</u>	<u>001</u>	Oct 29, 1987
<u>AB</u>			<u>20MG</u>	<u>A088088</u>	<u>001</u>	Nov 02, 1987
<u>AB</u>		PAR PHARM	<u>5MG</u>	<u>A086923</u>	<u>001</u>	Mar 12, 1987
<u>AB</u>			<u>10MG</u>	<u>A086925</u>	<u>001</u>	Mar 12, 1987
<u>AB</u>			<u>20MG</u>	<u>A087537</u>	<u>001</u>	Oct 02, 1987
<u>AB</u>	!		<u>30MG</u>	<u>A087946</u>	<u>001</u>	Jan 12, 1988
<u>AB</u>		PAR PHARM INC	<u>40MG</u>	<u>A211290</u>	<u>001</u>	Nov 23, 2021
<u>AB</u>		RUBICON	<u>5MG</u>	<u>A215723</u>	<u>001</u>	Jul 08, 2022
<u>AB</u>			<u>10MG</u>	<u>A215723</u>	<u>002</u>	Jul 08, 2022
<u>AB</u>			<u>20MG</u>	<u>A215723</u>	<u>003</u>	Jul 08, 2022
<u>AB</u>			<u>30MG</u>	<u>A215723</u>	<u>004</u>	Jul 08, 2022
<u>AB</u>			<u>40MG</u>	<u>A215723</u>	<u>005</u>	Jul 08, 2022
<u>AB</u>		SANDOZ	<u>5MG</u>	<u>A086221</u>	<u>001</u>	Jan 07, 1988
<u>AB</u>			<u>10MG</u>	<u>A086223</u>	<u>001</u>	Jan 07, 1988
<u>AB</u>			<u>20MG</u>	<u>A089367</u>	<u>001</u>	Apr 07, 1988
<u>AB</u>		ZYDUS	<u>5MG</u>	<u>A213057</u>	<u>001</u>	Nov 20, 2019
<u>AB</u>			<u>10MG</u>	<u>A213057</u>	<u>002</u>	Nov 20, 2019
<u>AB</u>			<u>20MG</u>	<u>A213057</u>	<u>003</u>	Nov 20, 2019
<u>AB</u>			<u>30MG</u>	<u>A213057</u>	<u>004</u>	Nov 20, 2019
<u>AB</u>			<u>40MG</u>	<u>A213057</u>	<u>005</u>	Nov 20, 2019

TABLET, EXTENDED RELEASE; ORAL

ISOSORBIDE DINITRATE

!	SUN PHARM INDS INC	40MG	<u>A040009</u>	<u>001</u>	Dec 30, 1998

ISOSORBIDE MONONITRATE

TABLET; ORAL

ISOSORBIDE MONONITRATE

<u>AB</u>		ACTAVIS ELIZABETH	<u>10MG</u>	<u>A075037</u>	<u>002</u>	Oct 30, 1998
<u>AB</u>			<u>20MG</u>	<u>A075037</u>	<u>001</u>	Oct 30, 1998

MONOKET

<u>AB</u>	+	ECI PHARMS LLC	<u>10MG</u>	<u>N020215</u>	<u>002</u>	Jun 30, 1993
<u>AB</u>	+	!	<u>20MG</u>	<u>N020215</u>	<u>001</u>	Jun 30, 1993

TABLET, EXTENDED RELEASE; ORAL

ISOSORBIDE MONONITRATE

<u>AB</u>		AUROBINDO PHARMA	<u>30MG</u>	<u>A216557</u>	<u>001</u>	Nov 07, 2022
<u>AB</u>			<u>60MG</u>	<u>A216557</u>	<u>002</u>	Nov 07, 2022
<u>AB</u>			<u>120MG</u>	<u>A216557</u>	<u>003</u>	Nov 07, 2022
<u>AB</u>		CHARTWELL MOLECULAR	<u>30MG</u>	<u>A075155</u>	<u>002</u>	Jan 13, 2000
<u>AB</u>			<u>60MG</u>	<u>A075155</u>	<u>001</u>	Oct 30, 1998
<u>AB</u>	!		<u>120MG</u>	<u>A075155</u>	<u>003</u>	Aug 04, 2000

PRESCRIPTION DRUG PRODUCT LIST

3-251 (of 474)

ISOSORBIDE MONONITRATE

TABLET, EXTENDED RELEASE;ORAL

ISOSORBIDE MONONITRATE

<u>AB</u>	DEXCEL LTD	<u>30MG</u>	<u>A075522</u>	<u>002</u>	Sep 20, 2016
<u>AB</u>		<u>60MG</u>	<u>A075522</u>	<u>001</u>	Apr 17, 2000
<u>AB</u>		<u>120MG</u>	<u>A210822</u>	<u>001</u>	Aug 29, 2018
<u>AB</u>	RICONPHARMA LLC	<u>30MG</u>	<u>A210918</u>	<u>001</u>	Nov 05, 2018
<u>AB</u>		<u>60MG</u>	<u>A210918</u>	<u>002</u>	Nov 05, 2018
<u>AB</u>		<u>120MG</u>	<u>A210918</u>	<u>003</u>	Nov 05, 2018
<u>AB</u>	SHANDONG	<u>120MG</u>	<u>A214115</u>	<u>001</u>	Apr 29, 2022
<u>AB</u>	TORRENT PHARMS	<u>30MG</u>	<u>A200270</u>	<u>001</u>	Jun 03, 2011
<u>AB</u>		<u>60MG</u>	<u>A200495</u>	<u>001</u>	Jun 03, 2011
<u>AB</u>		<u>120MG</u>	<u>A200495</u>	<u>002</u>	Jun 03, 2011
<u>AB</u>	ZYDUS HLTHCARE	<u>30MG</u>	<u>A075395</u>	<u>001</u>	Mar 16, 2000
<u>AB</u>		<u>60MG</u>	<u>A075395</u>	<u>002</u>	Mar 16, 2000
<u>AB</u>		<u>120MG</u>	<u>A075395</u>	<u>003</u>	Mar 16, 2000

ISOSULFAN BLUE

INJECTABLE;INJECTION

ISOSULFAN BLUE

<u>AP</u>	MEITHEAL	<u>1%</u>	<u>A213130</u>	<u>001</u>	Nov 03, 2021
<u>AP</u>	MSN	<u>1%</u>	<u>A216090</u>	<u>001</u>	Sep 16, 2022
<u>AP</u>	! MYLAN INSTITUTIONAL	<u>1%</u>	<u>A090874</u>	<u>001</u>	Jul 20, 2010

ISOTRETINOIN

CAPSULE;ORAL

AMNESTEEM

<u>AB1</u>	MYLAN PHARMS INC	<u>10MG</u>	<u>A075945</u>	<u>001</u>	Nov 08, 2002
<u>AB1</u>		<u>20MG</u>	<u>A075945</u>	<u>002</u>	Nov 08, 2002
<u>AB1</u>		<u>40MG</u>	<u>A075945</u>	<u>003</u>	Nov 08, 2002

CLARAVIS

<u>AB1</u>	TEVA PHARMS USA	<u>10MG</u>	<u>A076356</u>	<u>001</u>	Apr 11, 2003
<u>AB1</u>		<u>20MG</u>	<u>A076135</u>	<u>002</u>	Apr 11, 2003
<u>AB1</u>		<u>30MG</u>	<u>A076135</u>	<u>003</u>	May 11, 2006
<u>AB1</u>	!	<u>40MG</u>	<u>A076135</u>	<u>001</u>	Apr 11, 2003

ISOTRETINOIN

<u>AB1</u>	AMNEAL PHARMS NY	<u>10MG</u>	<u>A207792</u>	<u>001</u>	Sep 29, 2017
<u>AB1</u>		<u>20MG</u>	<u>A207792</u>	<u>002</u>	Sep 29, 2017
<u>AB1</u>		<u>30MG</u>	<u>A207792</u>	<u>003</u>	Sep 29, 2017
<u>AB1</u>		<u>40MG</u>	<u>A207792</u>	<u>004</u>	Sep 29, 2017

MYORISAN

<u>AB1</u>	DOUGLAS PHARMS	<u>10MG</u>	<u>A076485</u>	<u>001</u>	Jan 19, 2012
<u>AB1</u>		<u>20MG</u>	<u>A076485</u>	<u>002</u>	Jan 19, 2012
<u>AB1</u>		<u>30MG</u>	<u>A076485</u>	<u>004</u>	Aug 25, 2015
<u>AB1</u>		<u>40MG</u>	<u>A076485</u>	<u>003</u>	Jan 19, 2012

ZENATANE

<u>AB1</u>	DR REDDYS LABS LTD	<u>10MG</u>	<u>A202099</u>	<u>001</u>	Mar 25, 2013
<u>AB1</u>		<u>20MG</u>	<u>A202099</u>	<u>002</u>	Mar 25, 2013
<u>AB1</u>		<u>30MG</u>	<u>A202099</u>	<u>004</u>	Feb 23, 2015
<u>AB1</u>		<u>40MG</u>	<u>A202099</u>	<u>003</u>	Mar 25, 2013

ABSORICA

<u>AB2</u>	+	SUN PHARM INDS INC	<u>10MG</u>	<u>N021951</u>	<u>001</u>	May 25, 2012
<u>AB2</u>	+		<u>20MG</u>	<u>N021951</u>	<u>002</u>	May 25, 2012
<u>AB2</u>	+		<u>25MG</u>	<u>N021951</u>	<u>005</u>	Aug 15, 2014
<u>AB2</u>	+		<u>30MG</u>	<u>N021951</u>	<u>003</u>	May 25, 2012
<u>AB2</u>	+		<u>35MG</u>	<u>N021951</u>	<u>006</u>	Aug 15, 2014
<u>AB2</u>	+	!	<u>40MG</u>	<u>N021951</u>	<u>004</u>	May 25, 2012

ISOTRETINOIN

<u>AB2</u>	ACTAVIS LABS FL	<u>10MG</u>	<u>A205063</u>	<u>001</u>	Mar 31, 2021
<u>AB2</u>		<u>20MG</u>	<u>A205063</u>	<u>002</u>	Mar 31, 2021
<u>AB2</u>		<u>25MG</u>	<u>A205063</u>	<u>003</u>	Mar 31, 2021
<u>AB2</u>		<u>30MG</u>	<u>A205063</u>	<u>004</u>	Mar 31, 2021
<u>AB2</u>		<u>35MG</u>	<u>A205063</u>	<u>005</u>	Mar 31, 2021
<u>AB2</u>		<u>40MG</u>	<u>A205063</u>	<u>006</u>	Mar 31, 2021
<u>AB2</u>	UPSHER SMITH LABS	<u>10MG</u>	<u>A212333</u>	<u>001</u>	Sep 21, 2021
<u>AB2</u>		<u>20MG</u>	<u>A212333</u>	<u>002</u>	Sep 21, 2021
<u>AB2</u>		<u>30MG</u>	<u>A212333</u>	<u>003</u>	Sep 21, 2021
<u>AB2</u>		<u>40MG</u>	<u>A213571</u>	<u>001</u>	Apr 12, 2021

ABSORICA LD

+	SUN PHARM	8MG	N211913	001	Nov 05, 2019
+		16MG	N211913	002	Nov 05, 2019
+		24MG	N211913	004	Nov 05, 2019
+	!	32MG	N211913	006	Nov 05, 2019

PRESCRIPTION DRUG PRODUCT LIST

3-252 (of 474)

ISRADIPINE

CAPSULE; ORAL

ISRADIPINE

AB	ELITE LABS INC	2.5MG	A077169	001	Apr 24, 2006
AB		5MG	A077169	002	Apr 24, 2006
AB	WATSON LABS TEVA	2.5MG	A077317	001	Jan 05, 2006
AB	!	5MG	A077317	002	Jan 05, 2006

ISTRADefylline

TABLET; ORAL

NOURIANZ

+	KYOWA KIRIN	20MG	N022075	001	Aug 27, 2019
+	!	40MG	N022075	002	Aug 27, 2019

ITRACONAZOLE

CAPSULE; ORAL

ITRACONAZOLE

AB	ACCORD HLTHCARE	100MG	A205991	001	May 26, 2016
AB	ALEMBIC PHARMS	100MG	A206741	001	Dec 13, 2016
AB	ALKEM LABS LTD	100MG	A208591	001	Jun 12, 2017
AB	AMNEAL PHARMS	100MG	A205080	001	Sep 26, 2016
AB	PAR PHARM INC	100MG	A205724	001	Dec 13, 2016
AB	SANDOZ	100MG	A076104	001	May 28, 2004
AB	TORRENT	100MG	A209460	001	Aug 24, 2018
AB	ZYDUS PHARMS	100MG	A204672	001	Sep 19, 2017

SPORANOX

AB	+	JANSSEN PHARMS	100MG	N020083	001	Sep 11, 1992
		TOLSURA				
	+	MAYNE PHARMA	65MG	N208901	001	Dec 11, 2018

SOLUTION; ORAL

ITRACONAZOLE

AA	AMNEAL PHARMS	10MG/ML	A205573	001	Oct 30, 2015
AA	ANNORA PHARMA	10MG/ML	A212239	001	Sep 01, 2020

SPORANOX

AA	+	JANSSEN PHARMS	10MG/ML	N020657	001	Feb 21, 1997

IVABRADINE

SOLUTION; ORAL

CORLANOR

+	AMGEN INC	5MG/5ML (1MG/ML)	N209964	001	Apr 22, 2019

IVABRADINE HYDROCHLORIDE

TABLET; ORAL

CORLANOR

AB	+	AMGEN INC	EQ 5MG BASE	N206143	001	Apr 15, 2015
AB	+		EQ 7.5MG BASE	N206143	002	Apr 15, 2015

IVABRADINE HYDROCHLORIDE

AB	ANNORA PHARMA	EQ 5MG BASE	A213366	001	Oct 05, 2022
AB		EQ 7.5MG BASE	A213366	002	Oct 05, 2022

IVACAFTOR

GRANULE; ORAL

KALYDECO

+	VERTEX PHARMS INC	25MG/PACKET	N207925	003	Apr 29, 2019
+		50MG/PACKET	N207925	001	Mar 17, 2015
+	!	75MG/PACKET	N207925	002	Mar 17, 2015

TABLET; ORAL

KALYDECO

+	VERTEX PHARMS	150MG	N203188	001	Jan 31, 2012

IVACAFTOR; IVACAFTOR, TEZACAFTOR

TABLET; ORAL

SYMDEKO (COPACKAGED)

+	VERTEX PHARMS INC	75MG; 75MG, 50MG	N210491	002	Jun 21, 2019
+	!	150MG; 150MG, 100MG	N210491	001	Feb 12, 2018

IVACAFTOR; LUMACAFTOR

GRANULE; ORAL

ORKAMBI

+	VERTEX PHARMS INC	94MG/PACKET; 75MG/PACKET	N211358	003	Sep 02, 2022
+		125MG/PACKET; 100MG/PACKET	N211358	001	Aug 07, 2018
+	!	188MG/PACKET; 150MG/PACKET	N211358	002	Aug 07, 2018

TABLET; ORAL

ORKAMBI

+	VERTEX PHARMS INC	125MG; 100MG	N206038	002	Sep 28, 2016
+	!	125MG; 200MG	N206038	001	Jul 02, 2015

PRESCRIPTION DRUG PRODUCT LIST

3-253 (of 474)

IVERMECTIN

CREAM; TOPICAL

IVERMECTIN

AB	TEVA PHARMS USA	1%	A210019 001	Sep 13, 2019
AB	ZYDUS	1%	A215210 001	Aug 02, 2022

SOOLANTRA

AB	+! GALDERMA LABS LP	1%	N206255 001	Dec 19, 2014

TABLET; ORAL

IVERMECTIN

AB	EDENBRIDGE PHARMS	3MG	A204154 001	Oct 24, 2014

STROMEKTOL

AB	+! MERCK SHARP DOHME	3MG	N050742 002	Oct 08, 1998

IVOSIDENIB

TABLET; ORAL

TIBSOVO

+!	SERVIER	250MG	N211192 001	Jul 20, 2018

IXABEPILONE

INJECTABLE; INTRAVENOUS

IXEMPRA KIT

+!	R-PHARM US LLC	15MG/VIAL	N022065 001	Oct 16, 2007
+!		45MG/VIAL	N022065 002	Oct 16, 2007

IXAZOMIB CITRATE

CAPSULE; ORAL

NINLARO

+	TAKEDA PHARMS USA	EQ 2.3MG BASE	N208462 001	Nov 20, 2015
+		EQ 3MG BASE	N208462 002	Nov 20, 2015
+!		EQ 4MG BASE	N208462 003	Nov 20, 2015

KETAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

KETALAR

AP	+! PAR STERILE PRODUCTS	EQ 10MG BASE/ML	N016812 001	
AP	+!	EQ 50MG BASE/ML	N016812 002	
AP	+!	EQ 100MG BASE/ML	N016812 003	

KETAMINE HYDROCHLORIDE

AP	EUGIA PHARMA	EQ 10MG BASE/ML	A076092 001	Sep 30, 2008
AP		EQ 50MG BASE/ML	A076092 002	Dec 28, 2001
AP		EQ 100MG BASE/ML	A076092 003	Oct 25, 2002
AP	HIKMA	EQ 50MG BASE/ML	A074524 001	Mar 22, 1996
AP		EQ 100MG BASE/ML	A074524 002	Mar 22, 1996
AP	HOSPIRA	EQ 50MG BASE/ML	A074549 001	Jun 27, 1996
AP		EQ 100MG BASE/ML	A074549 002	Jun 27, 1996

KETOCONAZOLE

AEROSOL, FOAM; TOPICAL

EXTINA

AB	+! MYLAN	2%	N021738 001	Jun 12, 2007

KETOCONAZOLE

AB	PADAGIS ISRAEL	2%	A091550 001	Aug 25, 2011
AB	XIROMED	2%	A213601 001	May 21, 2021

CREAM; TOPICAL

KETOCONAZOLE

AB	ENCUBE	2%	A212443 001	May 20, 2021
AB	FOUGERA PHARMS	2%	A076294 001	Apr 28, 2004
AB	TASMAN PHARMA	2%	A215185 001	Nov 17, 2021
AB	! TEVA	2%	A075581 001	Apr 25, 2000

KETOZOLE

AB	TARO	2%	A075638 001	Dec 18, 2002

SHAMPOO; TOPICAL

KETOCONAZOLE

AB	! PADAGIS ISRAEL	2%	A076419 001	Jan 07, 2004
AB	TOLMAR	2%	A076942 001	Apr 11, 2005

TABLET; ORAL

KETOCONAZOLE

AB	SENORES PHARMS	200MG	A075912 001	Jan 10, 2002
AB	STRIDES PHARMA	200MG	A210457 001	Jun 18, 2018
AB	! TARO	200MG	A075319 001	Jun 15, 1999

PRESCRIPTION DRUG PRODUCT LIST

3-254 (of 474)

KETOPROFEN

CAPSULE; ORAL

KETOPROFEN

<u>AB</u>	MISEMER	<u>50MG</u>	<u>A074014</u>	<u>002</u>	Jan 29, 1993
<u>AB</u>	TEVA	<u>50MG</u>	<u>A073516</u>	<u>001</u>	Dec 22, 1992
	MISEMER	25MG	A074014	001	Jan 29, 1993
!		75MG	A074014	003	Jan 29, 1993

CAPSULE, EXTENDED RELEASE; ORAL

KETOPROFEN

!	MYLAN	200MG	A075679	001	Feb 20, 2002

KETOROLAC TROMETHAMINE

INJECTABLE; INJECTION

KETOROLAC TROMETHAMINE

<u>AP</u>	ALEMBIC PHARMS	<u>15MG/ML</u>	<u>A214456</u>	<u>001</u>	Nov 02, 2022
<u>AP</u>		<u>30MG/ML</u>	<u>A214456</u>	<u>002</u>	Nov 02, 2022
<u>AP</u>	BAXTER HLTHCARE CORP	<u>15MG/ML</u>	<u>A209900</u>	<u>002</u>	Jul 25, 2018
<u>AP</u>		<u>30MG/ML</u>	<u>A209900</u>	<u>001</u>	Sep 15, 2017
<u>AP</u>	FRESENIUS KABI USA	<u>15MG/ML</u>	<u>A075784</u>	<u>001</u>	Jan 11, 2002
<u>AP</u>		<u>15MG/ML</u>	<u>A203242</u>	<u>001</u>	Oct 07, 2015
<u>AP</u>		<u>30MG/ML</u>	<u>A075784</u>	<u>002</u>	Jan 11, 2002
<u>AP</u>		<u>30MG/ML</u>	<u>A203242</u>	<u>002</u>	Oct 07, 2015
<u>AP</u>	GLAND	<u>15MG/ML</u>	<u>A204216</u>	<u>001</u>	Nov 01, 2016
<u>AP</u>		<u>30MG/ML</u>	<u>A204216</u>	<u>002</u>	Nov 01, 2016
<u>AP</u>	HIKMA	<u>15MG/ML</u>	<u>A075772</u>	<u>001</u>	Jul 21, 2004
<u>AP</u>		<u>30MG/ML</u>	<u>A075772</u>	<u>002</u>	Jul 21, 2004
<u>AP</u>	! HOSPIRA	<u>15MG/ML</u>	<u>A074802</u>	<u>001</u>	Jun 05, 1997
<u>AP</u>	!	<u>30MG/ML</u>	<u>A074802</u>	<u>002</u>	Jun 05, 1997
<u>AP</u>		<u>30MG/ML</u>	<u>A074993</u>	<u>002</u>	Jan 27, 1999
<u>AP</u>	NEPHRON	<u>30MG/ML</u>	<u>A211445</u>	<u>001</u>	Aug 20, 2020
<u>AP</u>	SAGENT PHARMS INC	<u>15MG/ML</u>	<u>A091065</u>	<u>001</u>	Nov 27, 2013
<u>AP</u>		<u>30MG/ML</u>	<u>A091065</u>	<u>002</u>	Nov 27, 2013
<u>AP</u>	SANDOZ INC	<u>30MG/ML</u>	<u>A076271</u>	<u>002</u>	Oct 06, 2004
<u>AP</u>	SUN PHARM	<u>15MG/ML</u>	<u>A078737</u>	<u>001</u>	Oct 06, 2008
<u>AP</u>		<u>30MG/ML</u>	<u>A078737</u>	<u>002</u>	Oct 06, 2008
<u>AP</u>	WOCKHARDT	<u>15MG/ML</u>	<u>A077942</u>	<u>001</u>	Mar 27, 2007
<u>AP</u>		<u>30MG/ML</u>	<u>A077942</u>	<u>002</u>	Mar 27, 2007

SOLUTION/DROPS; OPHTHALMIC

ACULAR

<u>AT</u>	+! ALLERGAN	<u>0.5%</u>	<u>N019700</u>	<u>001</u>	Nov 09, 1992

ACULAR LS

<u>AT</u>	+! ALLERGAN	<u>0.4%</u>	<u>N021528</u>	<u>001</u>	May 30, 2003

KETOROLAC TROMETHAMINE

<u>AT</u>	AKORN	<u>0.5%</u>	<u>A078434</u>	<u>001</u>	Nov 05, 2009
<u>AT</u>	APOTEX INC	<u>0.4%</u>	<u>A077308</u>	<u>001</u>	Nov 05, 2009
<u>AT</u>		<u>0.5%</u>	<u>A076109</u>	<u>001</u>	Nov 05, 2009
<u>AT</u>	MICRO LABS LTD INDIA	<u>0.5%</u>	<u>A203410</u>	<u>001</u>	Apr 05, 2019
<u>AT</u>	SANDOZ INC	<u>0.5%</u>	<u>A076583</u>	<u>001</u>	Nov 05, 2009
<u>AT</u>	SUN PHARM	<u>0.5%</u>	<u>A090017</u>	<u>001</u>	Nov 05, 2009

ACUVAIL

+!	ALLERGAN	0.45%	N022427	001	Jul 22, 2009

SPRAY, METERED; NASAL

SPRIX

+!	ZYLA	15.75MG/SPRAY	N022382	001	May 14, 2010

TABLET; ORAL

KETOROLAC TROMETHAMINE

<u>AB</u>	ATNAHS PHARMA US	<u>10MG</u>	<u>A216407</u>	<u>001</u>	Oct 21, 2022
<u>AB</u>	CYCLE	<u>10MG</u>	<u>A210616</u>	<u>001</u>	Aug 16, 2018
<u>AB</u>	HETERO LABS LTD III	<u>10MG</u>	<u>A216651</u>	<u>001</u>	Aug 25, 2022
<u>AB</u>	MYLAN	<u>10MG</u>	<u>A074761</u>	<u>001</u>	May 16, 1997
<u>AB</u>	SENORES PHARMS	<u>10MG</u>	<u>A215788</u>	<u>001</u>	Mar 23, 2022
<u>AB</u>	! TEVA	<u>10MG</u>	<u>A074754</u>	<u>001</u>	May 16, 1997
<u>AB</u>	ZYDUS	<u>10MG</u>	<u>A217038</u>	<u>001</u>	Oct 21, 2022

KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE

SOLUTION; IRRIGATION

KETOROLAC TROMETHAMINE AND PHENYLEPHRINE HYDROCHLORIDE

<u>AT</u>	LUPIN LTD	<u>EQ 0.3% BASE; EQ 1% BASE</u>	<u>A210183</u>	<u>001</u>	Jul 01, 2019

OMIDRIA

<u>AT</u>	+! RAYNER SURGICAL	<u>EQ 0.3% BASE; EQ 1% BASE</u>	<u>N205388</u>	<u>001</u>	May 30, 2014

PRESCRIPTION DRUG PRODUCT LIST

3-255 (of 474)

KETOTIFEN FUMARATE

DRUG-ELUTING CONTACT LENS;OPHTHALMIC

ACUVUE THERAVISION WITH KETOTIFEN

+! JOHNSON JOHNSON EQ 19MCG BASE
VISN

N022388 001 Feb 25, 2022

L-GLUTAMINE

FOR SOLUTION;ORAL

ENDARI

+ EMMAUS MEDCL 5GM/PACKET

N208587 001 Jul 07, 2017

LABETALOL HYDROCHLORIDE

INJECTABLE;INJECTION

LABETALOL HYDROCHLORIDE

AP	AKORN	<u>5MG/ML</u>	<u>A075431</u>	<u>001</u>	Nov 29, 1999
AP	BAXTER HLTHCARE	<u>5MG/ML</u>	<u>A076051</u>	<u>001</u>	Jul 05, 2002
	CORP				
AP	CAPLIN	<u>5MG/ML</u>	<u>A214533</u>	<u>001</u>	Sep 07, 2021
AP	GLAND PHARMA LTD	<u>5MG/ML</u>	<u>A090699</u>	<u>001</u>	Apr 03, 2012
AP	HIKMA	<u>5MG/ML</u>	<u>A075303</u>	<u>001</u>	May 28, 1999
AP	! HOSPIRA	<u>5MG/ML</u>	<u>A075239</u>	<u>001</u>	Nov 29, 1999
AP	!	<u>5MG/ML</u>	<u>A075240</u>	<u>001</u>	Nov 29, 1999

SOLUTION;INTRAVENOUS

LABETALOL HYDROCHLORIDE

+! HIKMA 10MG/2ML (5MG/ML)

N213330 005 Mar 18, 2022

LABETALOL HYDROCHLORIDE IN DEXTROSE

+! HIKMA 200MG/200ML (1MG/ML)

N213330 001 Nov 09, 2020

LABETALOL HYDROCHLORIDE IN SODIUM CHLORIDE

+! HIKMA 100MG/100ML (1MG/ML)

N213330 002 Nov 09, 2020

+! 200MG/200ML (1MG/ML)

N213330 003 Nov 09, 2020

+! 300MG/300ML (1MG/ML)

N213330 004 Nov 09, 2020

TABLET;ORAL

LABETALOL HYDROCHLORIDE

AB	APPCO	<u>100MG</u>	<u>A209603</u>	<u>001</u>	Jun 20, 2018
AB		<u>200MG</u>	<u>A209603</u>	<u>002</u>	Jun 20, 2018
AB		<u>300MG</u>	<u>A209603</u>	<u>003</u>	Jun 20, 2018
AB	CADILA PHARMS LTD	<u>100MG</u>	<u>A211325</u>	<u>001</u>	May 13, 2019
AB		<u>200MG</u>	<u>A211325</u>	<u>002</u>	May 13, 2019
AB		<u>300MG</u>	<u>A211325</u>	<u>003</u>	May 13, 2019
AB	EPIC PHARMA LLC	<u>100MG</u>	<u>A212990</u>	<u>001</u>	Sep 30, 2020
AB		<u>200MG</u>	<u>A212990</u>	<u>002</u>	Sep 30, 2020
AB		<u>300MG</u>	<u>A212990</u>	<u>003</u>	Sep 30, 2020
AB	EYWA	<u>100MG</u>	<u>A207863</u>	<u>001</u>	Feb 04, 2019
AB		<u>200MG</u>	<u>A207863</u>	<u>002</u>	Feb 04, 2019
AB		<u>300MG</u>	<u>A207863</u>	<u>003</u>	Feb 04, 2019
AB	HERITAGE PHARMA	<u>100MG</u>	<u>A074787</u>	<u>001</u>	Aug 03, 1998
AB		<u>200MG</u>	<u>A074787</u>	<u>002</u>	Aug 03, 1998
AB		<u>300MG</u>	<u>A074787</u>	<u>003</u>	Aug 03, 1998
AB	INNOGENIX	<u>100MG</u>	<u>A075215</u>	<u>001</u>	Jul 29, 1999
AB		<u>200MG</u>	<u>A075215</u>	<u>002</u>	Jul 29, 1999
AB		<u>300MG</u>	<u>A075215</u>	<u>003</u>	Jul 29, 1999
AB	PAR FORM	<u>100MG</u>	<u>A200908</u>	<u>001</u>	Jul 10, 2012
AB	!	<u>200MG</u>	<u>A200908</u>	<u>002</u>	Jul 10, 2012
AB		<u>300MG</u>	<u>A200908</u>	<u>003</u>	Jul 10, 2012
AB	RUBICON	<u>100MG</u>	<u>A211953</u>	<u>001</u>	Aug 18, 2021
AB		<u>200MG</u>	<u>A211953</u>	<u>002</u>	Aug 18, 2021
AB		<u>300MG</u>	<u>A211953</u>	<u>003</u>	Aug 18, 2021
AB	SANDOZ	<u>100MG</u>	<u>A075113</u>	<u>001</u>	Aug 04, 1998
AB	!	<u>200MG</u>	<u>A075113</u>	<u>002</u>	Aug 04, 1998
AB		<u>300MG</u>	<u>A075113</u>	<u>003</u>	Aug 04, 1998
AB	WATSON LABS	<u>100MG</u>	<u>A075133</u>	<u>001</u>	Aug 03, 1998
AB		<u>200MG</u>	<u>A075133</u>	<u>002</u>	Aug 03, 1998
AB		<u>300MG</u>	<u>A075133</u>	<u>003</u>	Aug 03, 1998
AB	ZYDUS PHARMS	<u>100MG</u>	<u>A207743</u>	<u>001</u>	Sep 19, 2017
AB		<u>200MG</u>	<u>A207743</u>	<u>002</u>	Sep 19, 2017
AB		<u>300MG</u>	<u>A207743</u>	<u>003</u>	Sep 19, 2017
<u>TRANDATE</u>					
AB	+ ALVOGEN	<u>200MG</u>	<u>N018716</u>	<u>002</u>	Aug 01, 1984
AB	+	<u>300MG</u>	<u>N018716</u>	<u>003</u>	Aug 01, 1984

PRESCRIPTION DRUG PRODUCT LIST

3-256 (of 474)

LACOSAMIDE

SOLUTION; INTRAVENOUS

LACOSAMIDE

<u>AP</u>	ASPIRO	<u>200MG/20ML (10MG/ML)</u>	<u>A216335</u>	<u>001</u>	Sep 14, 2022
<u>AP</u>	FRESENIUS KABI USA	<u>200MG/20ML (10MG/ML)</u>	<u>A214677</u>	<u>001</u>	May 03, 2022
<u>AP</u>	GLAND PHARMA LTD	<u>200MG/20ML (10MG/ML)</u>	<u>A215628</u>	<u>001</u>	Sep 19, 2022
<u>AP</u>	INDOCO	<u>200MG/20ML (10MG/ML)</u>	<u>A214301</u>	<u>001</u>	Apr 07, 2022
<u>AP</u>	ZYDUS PHARMS	<u>200MG/20ML (10MG/ML)</u>	<u>A209465</u>	<u>001</u>	Jun 29, 2022

VIMPAT

<u>AP</u>	+! UCB INC	<u>200MG/20ML (10MG/ML)</u>	<u>N022254</u>	<u>001</u>	Oct 28, 2008

SOLUTION; ORAL

LACOSAMIDE

<u>AA</u>	ALKEM LABS LTD	<u>10MG/ML</u>	<u>A214672</u>	<u>001</u>	May 19, 2022
<u>AA</u>	APOTEX	<u>10MG/ML</u>	<u>A206355</u>	<u>001</u>	Sep 26, 2022
<u>AA</u>	HETERO LABS LTD III	<u>10MG/ML</u>	<u>A209301</u>	<u>001</u>	May 31, 2022
<u>AA</u>	NOVITIUM PHARMA	<u>10MG/ML</u>	<u>A216151</u>	<u>001</u>	Aug 26, 2022

VIMPAT

<u>AA</u>	+! UCB INC	<u>10MG/ML</u>	<u>N022255</u>	<u>001</u>	Apr 20, 2010

TABLET; ORAL

LACOSAMIDE

<u>AB</u>	ACCORD HLTHCARE	<u>50MG</u>	<u>A205011</u>	<u>001</u>	Jul 12, 2022
<u>AB</u>		<u>100MG</u>	<u>A205011</u>	<u>002</u>	Jul 12, 2022
<u>AB</u>		<u>150MG</u>	<u>A205011</u>	<u>003</u>	Jul 12, 2022
<u>AB</u>		<u>200MG</u>	<u>A205011</u>	<u>004</u>	Jul 12, 2022
<u>AB</u>	ACTAVIS LABS FL INC	<u>50MG</u>	<u>A204855</u>	<u>001</u>	Jan 05, 2023
<u>AB</u>		<u>100MG</u>	<u>A204855</u>	<u>002</u>	Jan 05, 2023
<u>AB</u>		<u>150MG</u>	<u>A204855</u>	<u>003</u>	Jan 05, 2023
<u>AB</u>		<u>200MG</u>	<u>A204855</u>	<u>004</u>	Jan 05, 2023
<u>AB</u>	ALEMBIC PHARMS	<u>50MG</u>	<u>A204974</u>	<u>001</u>	Mar 17, 2022
<u>AB</u>		<u>100MG</u>	<u>A204974</u>	<u>002</u>	Mar 17, 2022
<u>AB</u>		<u>150MG</u>	<u>A204974</u>	<u>003</u>	Mar 17, 2022
<u>AB</u>		<u>200MG</u>	<u>A204974</u>	<u>004</u>	Mar 17, 2022
<u>AB</u>	ALKEM LABS LTD	<u>50MG</u>	<u>A214695</u>	<u>001</u>	Mar 31, 2022
<u>AB</u>		<u>100MG</u>	<u>A214695</u>	<u>002</u>	Mar 31, 2022
<u>AB</u>		<u>150MG</u>	<u>A214695</u>	<u>003</u>	Mar 31, 2022
<u>AB</u>		<u>200MG</u>	<u>A214695</u>	<u>004</u>	Mar 31, 2022
<u>AB</u>	AMNEAL PHARMS	<u>50MG</u>	<u>A204857</u>	<u>001</u>	Mar 17, 2022
<u>AB</u>		<u>100MG</u>	<u>A204857</u>	<u>002</u>	Mar 17, 2022
<u>AB</u>		<u>150MG</u>	<u>A204857</u>	<u>003</u>	Mar 17, 2022
<u>AB</u>		<u>200MG</u>	<u>A204857</u>	<u>004</u>	Mar 17, 2022
<u>AB</u>	APOTEX	<u>50MG</u>	<u>A214567</u>	<u>001</u>	Sep 23, 2022
<u>AB</u>		<u>100MG</u>	<u>A214567</u>	<u>002</u>	Sep 23, 2022
<u>AB</u>		<u>150MG</u>	<u>A214567</u>	<u>003</u>	Sep 23, 2022
<u>AB</u>		<u>200MG</u>	<u>A214567</u>	<u>004</u>	Sep 23, 2022
<u>AB</u>	AUROBINDO PHARMA LTD	<u>50MG</u>	<u>A204994</u>	<u>001</u>	Jan 05, 2023
<u>AB</u>		<u>100MG</u>	<u>A204994</u>	<u>002</u>	Jan 05, 2023
<u>AB</u>		<u>150MG</u>	<u>A204994</u>	<u>003</u>	Jan 05, 2023
<u>AB</u>		<u>200MG</u>	<u>A204994</u>	<u>004</u>	Jan 05, 2023
<u>AB</u>	GLENMARK PHARMS LTD	<u>50MG</u>	<u>A205006</u>	<u>001</u>	Mar 17, 2022
<u>AB</u>		<u>100MG</u>	<u>A205006</u>	<u>002</u>	Mar 17, 2022
<u>AB</u>		<u>150MG</u>	<u>A205006</u>	<u>003</u>	Mar 17, 2022
<u>AB</u>		<u>200MG</u>	<u>A205006</u>	<u>004</u>	Mar 17, 2022
<u>AB</u>	HETERO LABS LTD V	<u>50MG</u>	<u>A204787</u>	<u>001</u>	Mar 17, 2022
<u>AB</u>		<u>100MG</u>	<u>A204787</u>	<u>002</u>	Mar 17, 2022
<u>AB</u>		<u>150MG</u>	<u>A204787</u>	<u>003</u>	Mar 17, 2022
<u>AB</u>		<u>200MG</u>	<u>A204787</u>	<u>004</u>	Mar 17, 2022
<u>AB</u>	INDOCO	<u>50MG</u>	<u>A208308</u>	<u>001</u>	Mar 17, 2022
<u>AB</u>		<u>100MG</u>	<u>A208308</u>	<u>002</u>	Mar 17, 2022
<u>AB</u>		<u>150MG</u>	<u>A208308</u>	<u>003</u>	Mar 17, 2022
<u>AB</u>		<u>200MG</u>	<u>A208308</u>	<u>004</u>	Mar 17, 2022
<u>AB</u>	MSN LABS PVT LTD	<u>50MG</u>	<u>A204921</u>	<u>001</u>	Mar 17, 2022
<u>AB</u>		<u>100MG</u>	<u>A204921</u>	<u>002</u>	Mar 17, 2022
<u>AB</u>		<u>150MG</u>	<u>A204921</u>	<u>003</u>	Mar 17, 2022
<u>AB</u>		<u>200MG</u>	<u>A204921</u>	<u>004</u>	Mar 17, 2022
<u>AB</u>	SCIEGEN PHARMS INC	<u>50MG</u>	<u>A205237</u>	<u>001</u>	Mar 17, 2022
<u>AB</u>		<u>100MG</u>	<u>A205237</u>	<u>002</u>	Mar 17, 2022
<u>AB</u>		<u>150MG</u>	<u>A205237</u>	<u>003</u>	Mar 17, 2022
<u>AB</u>		<u>200MG</u>	<u>A205237</u>	<u>004</u>	Mar 17, 2022
<u>AB</u>	SUN PHARM	<u>50MG</u>	<u>A205031</u>	<u>001</u>	Mar 17, 2022
<u>AB</u>		<u>100MG</u>	<u>A205031</u>	<u>002</u>	Mar 17, 2022
<u>AB</u>		<u>150MG</u>	<u>A205031</u>	<u>003</u>	Mar 17, 2022
<u>AB</u>		<u>200MG</u>	<u>A205031</u>	<u>004</u>	Mar 17, 2022

PRESCRIPTION DRUG PRODUCT LIST

3-257 (of 474)

LACOSAMIDE

TABLET; ORAL

VIMPAT

<u>AB</u>	+	UCB INC	<u>50MG</u>	<u>N022253</u>	<u>001</u>	Oct 28, 2008
<u>AB</u>	+		<u>100MG</u>	<u>N022253</u>	<u>002</u>	Oct 28, 2008
<u>AB</u>	+		<u>150MG</u>	<u>N022253</u>	<u>003</u>	Oct 28, 2008
<u>AB</u>	+	!	<u>200MG</u>	<u>N022253</u>	<u>004</u>	Oct 28, 2008

LACTULOSE

FOR SOLUTION; ORAL

LACTULOSE

!	CUMBERLAND PHARMS	10GM/PACKET	A074712	001	Dec 10, 1997
!		20GM/PACKET	A074712	002	Dec 10, 1997

SOLUTION; ORAL

LACTULOSE

<u>AA</u>	!	AKORN	<u>10GM/15ML</u>	<u>A074076</u>	<u>001</u>	Jul 03, 1995
<u>AA</u>		CHARTWELL RX	<u>10GM/15ML</u>	<u>A209517</u>	<u>001</u>	Nov 23, 2018
<u>AA</u>		FRESENIUS KABI	<u>10GM/15ML</u>	<u>A090503</u>	<u>001</u>	Jan 25, 2012
<u>AA</u>		LANNETT CO INC	<u>10GM/15ML</u>	<u>A075993</u>	<u>001</u>	Jul 26, 2001
<u>AA</u>		PHARM ASSOC	<u>10GM/15ML</u>	<u>A074623</u>	<u>001</u>	Jul 30, 1996
<u>AA</u>		VISTAPHARM	<u>10GM/15ML</u>	<u>A074138</u>	<u>001</u>	Sep 30, 1992
<u>AA</u>		WOCKHARDT BIO AG	<u>10GM/15ML</u>	<u>A074602</u>	<u>001</u>	Nov 14, 1996

SOLUTION; ORAL, RECTAL

GENERLAC

<u>AA</u>		WOCKHARDT BIO AG	<u>10GM/15ML</u>	<u>A074603</u>	<u>001</u>	Oct 31, 1996

LACTULOSE

<u>AA</u>		AKORN	<u>10GM/15ML</u>	<u>A074077</u>	<u>001</u>	Jul 03, 1995
<u>AA</u>	!	FRESENIUS KABI	<u>10GM/15ML</u>	<u>A090502</u>	<u>001</u>	Jan 25, 2012

LAMIVUDINE

SOLUTION; ORAL

EPIVIR

<u>AA</u>	+	!	VIIV HLTHCARE	<u>10MG/ML</u>	<u>N020596</u>	<u>001</u>	Nov 17, 1995

LAMIVUDINE

<u>AA</u>		AUROBINDO PHARMA	<u>10MG/ML</u>	<u>A077695</u>	<u>001</u>	Nov 21, 2016
<u>AA</u>		LANNETT CO INC	<u>10MG/ML</u>	<u>A203564</u>	<u>001</u>	Oct 31, 2014

EPIVIR-HBV

+	!	GLAXOSMITHKLINE	5MG/ML	N021004	001	Dec 08, 1998

TABLET; ORAL

EPIVIR

<u>AB</u>	+	VIIV HLTHCARE	<u>150MG</u>	<u>N020564</u>	<u>001</u>	Nov 17, 1995
<u>AB</u>	+	!	<u>300MG</u>	<u>N020564</u>	<u>003</u>	Jun 24, 2002

EPIVIR-HBV

<u>AB</u>	+	!	GLAXOSMITHKLINE	<u>100MG</u>	<u>N021003</u>	<u>001</u>	Dec 08, 1998

LAMIVUDINE

<u>AB</u>		ANNORA	<u>100MG</u>	<u>A211306</u>	<u>001</u>	Mar 21, 2019
<u>AB</u>		APOTEX	<u>100MG</u>	<u>A202941</u>	<u>001</u>	Jan 02, 2014
<u>AB</u>			<u>150MG</u>	<u>A091606</u>	<u>001</u>	Dec 02, 2011
<u>AB</u>			<u>300MG</u>	<u>A091606</u>	<u>002</u>	Dec 02, 2011
<u>AB</u>		AUROBINDO PHARMA	<u>150MG</u>	<u>A077464</u>	<u>001</u>	Nov 21, 2016
<u>AB</u>			<u>300MG</u>	<u>A077464</u>	<u>002</u>	Nov 21, 2016
<u>AB</u>		BRECKENRIDGE	<u>150MG</u>	<u>A203586</u>	<u>001</u>	Nov 21, 2016
<u>AB</u>		CIPLA	<u>150MG</u>	<u>A077221</u>	<u>001</u>	Mar 03, 2017
<u>AB</u>			<u>300MG</u>	<u>A077221</u>	<u>002</u>	Mar 03, 2017
<u>AB</u>		HETERO LABS LTD V	<u>100MG</u>	<u>A203260</u>	<u>001</u>	Jan 02, 2014
<u>AB</u>			<u>150MG</u>	<u>A203277</u>	<u>001</u>	Jan 06, 2014
<u>AB</u>			<u>300MG</u>	<u>A203277</u>	<u>002</u>	Jan 06, 2014
<u>AB</u>		LUPIN LTD	<u>150MG</u>	<u>A205217</u>	<u>001</u>	Dec 18, 2014
<u>AB</u>			<u>300MG</u>	<u>A205217</u>	<u>002</u>	Dec 18, 2014
<u>AB</u>		MACLEODS PHARMS LTD	<u>150MG</u>	<u>A090198</u>	<u>001</u>	May 01, 2019
<u>AB</u>			<u>300MG</u>	<u>A090198</u>	<u>002</u>	May 01, 2019
<u>AB</u>		MYLAN LABS LTD	<u>150MG</u>	<u>A078545</u>	<u>001</u>	Mar 05, 2019
<u>AB</u>			<u>300MG</u>	<u>A078545</u>	<u>002</u>	Mar 05, 2019
<u>AB</u>		STRIDES PHARMA	<u>150MG</u>	<u>A090457</u>	<u>001</u>	Apr 19, 2018
<u>AB</u>			<u>300MG</u>	<u>A090457</u>	<u>002</u>	Apr 19, 2018
<u>AB</u>		UPSHER SMITH LABS	<u>150MG</u>	<u>A206974</u>	<u>001</u>	Nov 21, 2016
<u>AB</u>			<u>300MG</u>	<u>A206974</u>	<u>002</u>	Nov 21, 2016

PRESCRIPTION DRUG PRODUCT LIST

3-258 (of 474)

LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL

CIMDUO

+! MYLAN LABS LTD 300MG; 300MG

N022141 001 Feb 28, 2018

LAMIVUDINE; ZIDOVUDINE

TABLET; ORAL

COMBIVIRAB +! VIIV HLTHCARE 150MG; 300MGN020857 001 Sep 26, 1997LAMIVUDINE AND ZIDOVUDINEAB ANDA REPOSITORY 150MG; 300MGA206375 001 Apr 10, 2018AB AUROBINDO PHARMA 150MG; 300MGA077558 001 May 05, 2017AB AUROBINDO PHARMA LTD 150MG; 300MGA202418 001 May 15, 2012AB CIPLA 150MG; 300MGA077411 001 Sep 07, 2018AB HETERO LABS LTD III 150MG; 300MGA079124 001 Sep 17, 2015AB HETERO LABS LTD V 150MG; 300MGA203259 001 Feb 03, 2014AB LUPIN LTD 150MG; 300MGA090246 001 May 15, 2012AB MACLEODS PHARMS LTD 150MG; 300MGA090679 001 Aug 29, 2018AB STRIDES PHARMA 150MG; 300MGA079128 001 May 13, 2015LAMOTRIGINE

TABLET; ORAL

LAMICTALAB +! GLAXOSMITHKLINE LLC 25MGN020241 005 Dec 27, 1994AB + 100MGN020241 001 Dec 27, 1994AB + 150MGN020241 002 Dec 27, 1994AB + 200MGN020241 003 Dec 27, 1994LAMOTRIGINEAB ALEMBIC PHARMS LTD 25MGA090607 001 Jan 13, 2011AB 100MGA090607 002 Jan 13, 2011AB 150MGA090607 003 Jan 13, 2011AB 200MGA090607 004 Jan 13, 2011AB ALKEM LABS LTD 25MGA200694 001 Jun 14, 2013AB 100MGA200694 002 Jun 14, 2013AB 150MGA200694 003 Jun 14, 2013AB 200MGA200694 004 Jun 14, 2013AB AUROBINDO PHARMA 25MGA078956 001 Jan 27, 2009AB 100MGA078956 002 Jan 27, 2009AB 150MGA078956 003 Jan 27, 2009AB 200MGA078956 004 Jan 27, 2009AB DR REDDYS LABS LTD 25MGA076708 001 Jan 27, 2009AB 100MGA076708 002 Jan 27, 2009AB 150MGA076708 003 Jan 27, 2009AB 200MGA076708 004 Jan 27, 2009AB GLENMARK GENERICS 25MGA090169 001 May 12, 2012AB 100MGA090169 002 May 12, 2012AB 150MGA090169 003 May 12, 2012AB 200MGA090169 004 May 12, 2012AB JUBILANT CADISTA 25MGA079132 001 Jan 27, 2009AB 100MGA079132 002 Jan 27, 2009AB 150MGA079132 003 Jan 27, 2009AB 200MGA079132 004 Jan 27, 2009AB LUPIN LTD 25MGA078691 001 Jun 01, 2010AB 100MGA078691 002 Jun 01, 2010AB 150MGA078691 003 Jun 01, 2010AB 200MGA078691 004 Jun 01, 2010AB RUBICON 25MGA078625 001 Jan 27, 2009AB 100MGA078625 002 Jan 27, 2009AB 150MGA078625 003 Jan 27, 2009AB 200MGA078625 004 Jan 27, 2009AB TARO PHARM INDS 25MGA078525 001 Jan 27, 2009AB 100MGA078525 002 Jan 27, 2009AB 150MGA078525 003 Jan 27, 2009AB 200MGA078525 004 Jan 27, 2009AB TORRENT PHARMS 25MGA078947 001 Jan 27, 2009AB 100MGA078947 002 Jan 27, 2009AB 150MGA078947 003 Jan 27, 2009AB 200MGA078947 004 Jan 27, 2009AB UNICHEM LABS LTD 25MGA090170 001 Oct 06, 2011AB 100MGA090170 002 Oct 06, 2011AB 150MGA090170 003 Oct 06, 2011AB 200MGA090170 004 Oct 06, 2011AB ZYDUS PHARMS USA 25MGA077633 001 Jan 27, 2009

PRESCRIPTION DRUG PRODUCT LIST

3-259 (of 474)

LAMOTRIGINE

TABLET; ORAL

LAMOTRIGINE

<u>AB</u>		<u>100MG</u>	<u>A077633</u>	<u>003</u>	Jan 27, 2009
<u>AB</u>		<u>150MG</u>	<u>A077633</u>	<u>004</u>	Jan 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A077633</u>	<u>005</u>	Jan 27, 2009
		50MG	A077633	002	Jan 27, 2009
		250MG	A077633	006	Jan 27, 2009

TABLET, EXTENDED RELEASE; ORAL

LAMICTAL XR

<u>AB</u>	+	GLAXOSMITHKLINE LLC	<u>25MG</u>	<u>N022115</u>	<u>001</u>	May 29, 2009
<u>AB</u>	+	!	<u>50MG</u>	<u>N022115</u>	<u>002</u>	May 29, 2009
<u>AB</u>	+		<u>100MG</u>	<u>N022115</u>	<u>003</u>	May 29, 2009
<u>AB</u>	+	!	<u>200MG</u>	<u>N022115</u>	<u>004</u>	May 29, 2009
<u>AB</u>	+		<u>250MG</u>	<u>N022115</u>	<u>006</u>	Jun 21, 2011
<u>AB</u>	+		<u>300MG</u>	<u>N022115</u>	<u>005</u>	Apr 14, 2010

LAMOTRIGINE

<u>AB</u>		ACTAVIS ELIZABETH	<u>100MG</u>	<u>A200672</u>	<u>003</u>	Oct 17, 2013
<u>AB</u>			<u>200MG</u>	<u>A200672</u>	<u>004</u>	Oct 17, 2013
<u>AB</u>			<u>25MG</u>	<u>A200672</u>	<u>001</u>	Oct 17, 2013
<u>AB</u>			<u>50MG</u>	<u>A200672</u>	<u>002</u>	Oct 17, 2013
<u>AB</u>			<u>250MG</u>	<u>A200672</u>	<u>006</u>	Nov 13, 2013
<u>AB</u>			<u>300MG</u>	<u>A200672</u>	<u>005</u>	Oct 17, 2013
<u>AB</u>		AMNEAL PHARMS	<u>25MG</u>	<u>A207497</u>	<u>001</u>	Nov 30, 2018
<u>AB</u>			<u>50MG</u>	<u>A207497</u>	<u>002</u>	Nov 30, 2018
<u>AB</u>			<u>100MG</u>	<u>A207497</u>	<u>003</u>	Nov 30, 2018
<u>AB</u>			<u>200MG</u>	<u>A207497</u>	<u>004</u>	Nov 30, 2018
<u>AB</u>			<u>250MG</u>	<u>A207497</u>	<u>005</u>	Nov 30, 2018
<u>AB</u>			<u>300MG</u>	<u>A207497</u>	<u>006</u>	Nov 30, 2018
<u>AB</u>		ANCHEN PHARMS	<u>25MG</u>	<u>A201374</u>	<u>001</u>	Dec 26, 2012
<u>AB</u>			<u>50MG</u>	<u>A201374</u>	<u>002</u>	Dec 26, 2012
<u>AB</u>			<u>100MG</u>	<u>A201374</u>	<u>003</u>	Dec 26, 2012
<u>AB</u>			<u>200MG</u>	<u>A201374</u>	<u>004</u>	Dec 26, 2012
<u>AB</u>			<u>250MG</u>	<u>A201374</u>	<u>005</u>	Dec 26, 2012
<u>AB</u>			<u>300MG</u>	<u>A201374</u>	<u>006</u>	Dec 26, 2012
<u>AB</u>		DR REDDYS LABS LTD	<u>25MG</u>	<u>A202383</u>	<u>001</u>	Jun 19, 2013
<u>AB</u>			<u>50MG</u>	<u>A202383</u>	<u>002</u>	Jun 19, 2013
<u>AB</u>			<u>100MG</u>	<u>A202383</u>	<u>003</u>	Jun 19, 2013
<u>AB</u>			<u>200MG</u>	<u>A202383</u>	<u>004</u>	Jun 19, 2013
<u>AB</u>			<u>250MG</u>	<u>A202383</u>	<u>006</u>	Sep 06, 2018
<u>AB</u>			<u>300MG</u>	<u>A202383</u>	<u>005</u>	Jun 19, 2013
<u>AB</u>		PAR PHARM	<u>25MG</u>	<u>A201791</u>	<u>001</u>	Jan 18, 2013
<u>AB</u>			<u>50MG</u>	<u>A201791</u>	<u>002</u>	Jan 18, 2013
<u>AB</u>			<u>100MG</u>	<u>A201791</u>	<u>003</u>	Jan 18, 2013
<u>AB</u>			<u>200MG</u>	<u>A201791</u>	<u>004</u>	Jan 18, 2013
<u>AB</u>			<u>250MG</u>	<u>A201791</u>	<u>005</u>	Jan 18, 2013
<u>AB</u>			<u>300MG</u>	<u>A201791</u>	<u>006</u>	Jan 18, 2013
<u>AB</u>		RUBICON	<u>100MG</u>	<u>A202887</u>	<u>003</u>	Jun 17, 2013
<u>AB</u>			<u>200MG</u>	<u>A202887</u>	<u>004</u>	Jun 17, 2013
<u>AB</u>		TORRENT	<u>25MG</u>	<u>A203370</u>	<u>001</u>	Dec 23, 2013
<u>AB</u>			<u>50MG</u>	<u>A203370</u>	<u>002</u>	Dec 23, 2013
<u>AB</u>			<u>100MG</u>	<u>A203370</u>	<u>003</u>	Dec 23, 2013
<u>AB</u>		WOCKHARDT BIO AG	<u>25MG</u>	<u>A202498</u>	<u>001</u>	Jan 04, 2013
<u>AB</u>			<u>50MG</u>	<u>A202498</u>	<u>002</u>	Jan 04, 2013
<u>AB</u>			<u>100MG</u>	<u>A202498</u>	<u>003</u>	Jan 04, 2013
<u>AB</u>			<u>200MG</u>	<u>A202498</u>	<u>004</u>	Jan 04, 2013
<u>AB</u>			<u>300MG</u>	<u>A202498</u>	<u>005</u>	Jan 04, 2013
<u>AB</u>		YILING	<u>25MG</u>	<u>A213949</u>	<u>001</u>	Dec 08, 2021
<u>AB</u>			<u>50MG</u>	<u>A213949</u>	<u>002</u>	Dec 08, 2021
<u>AB</u>			<u>100MG</u>	<u>A213949</u>	<u>003</u>	Dec 08, 2021
<u>AB</u>			<u>200MG</u>	<u>A213949</u>	<u>004</u>	Dec 08, 2021
<u>AB</u>			<u>250MG</u>	<u>A213949</u>	<u>005</u>	Dec 08, 2021
<u>AB</u>			<u>300MG</u>	<u>A213949</u>	<u>006</u>	Dec 08, 2021
<u>AB</u>		ZYDUS PHARMS	<u>25MG</u>	<u>A207763</u>	<u>001</u>	Apr 01, 2020
<u>AB</u>			<u>50MG</u>	<u>A207763</u>	<u>002</u>	Apr 01, 2020
<u>AB</u>			<u>100MG</u>	<u>A207763</u>	<u>003</u>	Apr 01, 2020
<u>AB</u>			<u>200MG</u>	<u>A207763</u>	<u>004</u>	Apr 01, 2020
<u>AB</u>			<u>250MG</u>	<u>A207763</u>	<u>005</u>	Apr 01, 2020
<u>AB</u>			<u>300MG</u>	<u>A207763</u>	<u>006</u>	Apr 01, 2020

TABLET, FOR SUSPENSION; ORAL

LAMICTAL CD

<u>AB</u>	+	GLAXOSMITHKLINE LLC	<u>2MG</u>	<u>N020764</u>	<u>004</u>	Sep 08, 2000

PRESCRIPTION DRUG PRODUCT LIST

3-260 (of 474)

LAMOTRIGINE

TABLET, FOR SUSPENSION;ORAL

LAMICTAL CD

<u>AB</u>	+	<u>5MG</u>	<u>N020764</u>	<u>001</u>	Aug 24, 1998
<u>AB</u>	+	<u>25MG</u>	<u>N020764</u>	<u>002</u>	Aug 24, 1998

LAMOTRIGINE

<u>AB</u>	ALEMBIC PHARMS	<u>5MG</u>	<u>A201168</u>	<u>001</u>	Jun 12, 2014
<u>AB</u>		<u>25MG</u>	<u>A201168</u>	<u>002</u>	Jun 12, 2014
<u>AB</u>	AUROBINDO PHARMA	<u>5MG</u>	<u>A090401</u>	<u>002</u>	Nov 04, 2009
<u>AB</u>		<u>25MG</u>	<u>A090401</u>	<u>003</u>	Nov 04, 2009
<u>AB</u>	DR REDDYS LABS LTD	<u>5MG</u>	<u>A076701</u>	<u>001</u>	Jan 22, 2009
<u>AB</u>		<u>25MG</u>	<u>A076701</u>	<u>002</u>	Jan 22, 2009
<u>AB</u>	GLENMARK PHARMS LTD	<u>5MG</u>	<u>A079099</u>	<u>001</u>	Feb 19, 2009
<u>AB</u>		<u>25MG</u>	<u>A079099</u>	<u>002</u>	Feb 19, 2009
<u>AB</u>	TARO	<u>5MG</u>	<u>A079204</u>	<u>001</u>	Feb 04, 2009
<u>AB</u>		<u>25MG</u>	<u>A079204</u>	<u>002</u>	Feb 04, 2009
<u>AB</u>	WATSON LABS	<u>2MG</u>	<u>A076928</u>	<u>001</u>	Jan 22, 2009
<u>AB</u>		<u>5MG</u>	<u>A076928</u>	<u>002</u>	Jan 22, 2009
<u>AB</u>		<u>25MG</u>	<u>A076928</u>	<u>003</u>	Jan 22, 2009
<u>AB</u>	ZYDUS PHARMS USA INC	<u>5MG</u>	<u>A078009</u>	<u>002</u>	Jan 22, 2009
<u>AB</u>		<u>25MG</u>	<u>A078009</u>	<u>003</u>	Jan 22, 2009

TABLET, ORALLY DISINTEGRATING;ORAL

LAMICTAL ODT

<u>AB</u>	+	GLAXOSMITHKLINE LLC	<u>25MG</u>	<u>N022251</u>	<u>001</u>	May 08, 2009
<u>AB</u>	+		<u>50MG</u>	<u>N022251</u>	<u>002</u>	May 08, 2009
<u>AB</u>	+		<u>100MG</u>	<u>N022251</u>	<u>003</u>	May 08, 2009
<u>AB</u>	+		<u>200MG</u>	<u>N022251</u>	<u>004</u>	May 08, 2009

LAMOTRIGINE

<u>AB</u>	AJANTA PHARMA LTD	<u>25MG</u>	<u>A213271</u>	<u>001</u>	Jan 19, 2021
<u>AB</u>		<u>50MG</u>	<u>A213271</u>	<u>002</u>	Jan 19, 2021
<u>AB</u>		<u>100MG</u>	<u>A213271</u>	<u>003</u>	Jan 19, 2021
<u>AB</u>		<u>200MG</u>	<u>A213271</u>	<u>004</u>	Jan 19, 2021
<u>AB</u>	AMRING PHARMS	<u>25MG</u>	<u>A214124</u>	<u>001</u>	Feb 03, 2022
<u>AB</u>		<u>50MG</u>	<u>A214124</u>	<u>002</u>	Feb 03, 2022
<u>AB</u>		<u>100MG</u>	<u>A214124</u>	<u>003</u>	Feb 03, 2022
<u>AB</u>		<u>200MG</u>	<u>A214124</u>	<u>004</u>	Feb 03, 2022
<u>AB</u>	PAR PHARM	<u>25MG</u>	<u>A204158</u>	<u>001</u>	Oct 27, 2015
<u>AB</u>		<u>50MG</u>	<u>A204158</u>	<u>002</u>	Oct 27, 2015
<u>AB</u>		<u>100MG</u>	<u>A204158</u>	<u>003</u>	Oct 27, 2015
<u>AB</u>		<u>200MG</u>	<u>A204158</u>	<u>004</u>	Oct 27, 2015
<u>AB</u>	SCIEGEN PHARMS INC	<u>25MG</u>	<u>A206382</u>	<u>001</u>	Jun 17, 2016
<u>AB</u>		<u>50MG</u>	<u>A206382</u>	<u>002</u>	Jun 17, 2016
<u>AB</u>		<u>100MG</u>	<u>A206382</u>	<u>003</u>	Jun 17, 2016
<u>AB</u>		<u>200MG</u>	<u>A206382</u>	<u>004</u>	Jun 17, 2016

LANREOTIDE ACETATE

SOLUTION;SUBCUTANEOUS

LANREOTIDE ACETATE

+	INVAGEN PHARMS	EQ 60MG BASE/0.2ML (EQ 60MG BASE/0.2ML)	N215395	001	Dec 17, 2021
+		EQ 90MG BASE/0.3ML (EQ 90MG BASE/0.3ML)	N215395	002	Dec 17, 2021
+		EQ 120MG BASE/0.5ML (EQ 120MG BASE/0.5ML)	N215395	003	Dec 17, 2021

SOMATULINE DEPOT

+	IPSEN PHARMA	EQ 60MG BASE/0.2ML (EQ 60MG BASE/0.2ML)	N022074	001	Aug 30, 2007
+		EQ 90MG BASE/0.3ML (EQ 90MG BASE/0.3ML)	N022074	002	Aug 30, 2007
+		EQ 120MG BASE/0.5ML (EQ 120MG BASE/0.5ML)	N022074	003	Aug 30, 2007

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL

LANSOPRAZOLE

<u>AB</u>	ALKEM LABS LTD	<u>15MG</u>	<u>A207394</u>	<u>001</u>	Jan 18, 2019
<u>AB</u>		<u>30MG</u>	<u>A207394</u>	<u>002</u>	Jan 18, 2019
<u>AB</u>	CHARTWELL MOLECULAR	<u>15MG</u>	<u>A207156</u>	<u>001</u>	Sep 28, 2017
<u>AB</u>		<u>30MG</u>	<u>A207156</u>	<u>002</u>	Sep 28, 2017
<u>AB</u>	DR REDDYS LABS LTD	<u>15MG</u>	<u>A091269</u>	<u>001</u>	Oct 15, 2010
<u>AB</u>		<u>30MG</u>	<u>A091269</u>	<u>002</u>	Oct 15, 2010
<u>AB</u>	HETERO LABS LTD III	<u>15MG</u>	<u>A203083</u>	<u>001</u>	May 18, 2020
<u>AB</u>		<u>30MG</u>	<u>A203083</u>	<u>002</u>	May 18, 2020
<u>AB</u>	INVENTIA	<u>15MG</u>	<u>A205868</u>	<u>001</u>	Aug 30, 2017
<u>AB</u>		<u>30MG</u>	<u>A205868</u>	<u>002</u>	Aug 30, 2017
<u>AB</u>	MYLAN PHARMS INC	<u>15MG</u>	<u>A090763</u>	<u>001</u>	Nov 10, 2009
<u>AB</u>		<u>30MG</u>	<u>A090763</u>	<u>002</u>	Nov 10, 2009

PRESCRIPTION DRUG PRODUCT LIST

3-261 (of 474)

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL

LANSOPRAZOLE

<u>AB</u>	NATCO PHARMA LTD	<u>15MG</u>	<u>A201921</u>	<u>001</u>	Dec 18, 2012
<u>AB</u>		<u>30MG</u>	<u>A201921</u>	<u>002</u>	Dec 18, 2012
<u>AB</u>	SANDOZ	<u>15MG</u>	<u>A090331</u>	<u>001</u>	Apr 23, 2010
<u>AB</u>		<u>30MG</u>	<u>A090331</u>	<u>002</u>	Apr 23, 2010
<u>AB</u>	SUN PHARM	<u>15MG</u>	<u>A202637</u>	<u>001</u>	Sep 13, 2013
<u>AB</u>		<u>30MG</u>	<u>A091509</u>	<u>001</u>	Sep 13, 2013
<u>AB</u>	TEVA PHARMS	<u>15MG</u>	<u>A077255</u>	<u>001</u>	Nov 10, 2009
<u>AB</u>		<u>30MG</u>	<u>A077255</u>	<u>002</u>	Nov 10, 2009
<u>AB</u>	WOCKHARDT	<u>15MG</u>	<u>A202176</u>	<u>001</u>	Sep 14, 2012
<u>AB</u>		<u>30MG</u>	<u>A202176</u>	<u>002</u>	Sep 14, 2012
<u>AB</u>	XIROMED	<u>15MG</u>	<u>A203203</u>	<u>001</u>	Jul 25, 2016
<u>AB</u>		<u>30MG</u>	<u>A203203</u>	<u>002</u>	Jul 25, 2016
<u>AB</u>	ZYDUS HLTHCARE	<u>15MG</u>	<u>A202366</u>	<u>001</u>	Aug 19, 2013
<u>AB</u>		<u>30MG</u>	<u>A202366</u>	<u>002</u>	Aug 19, 2013

PREVACID

<u>AB</u>	<u>+</u> TAKEDA PHARMS USA	<u>30MG</u>	<u>N020406</u>	<u>002</u>	May 10, 1995

TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL

LANSOPRAZOLE

<u>AB</u>	DR REDDYS	<u>15MG</u>	<u>A210465</u>	<u>001</u>	Feb 01, 2021
<u>AB</u>		<u>30MG</u>	<u>A210465</u>	<u>002</u>	Feb 01, 2021
<u>AB</u>	MYLAN	<u>15MG</u>	<u>A202396</u>	<u>001</u>	Nov 28, 2018
<u>AB</u>		<u>30MG</u>	<u>A202396</u>	<u>002</u>	Nov 28, 2018
<u>AB</u>	TEVA PHARMS USA	<u>15MG</u>	<u>A208784</u>	<u>001</u>	Sep 21, 2017
<u>AB</u>		<u>30MG</u>	<u>A208784</u>	<u>002</u>	Sep 21, 2017
<u>AB</u>	ZYDUS PHARMS	<u>15MG</u>	<u>A200816</u>	<u>001</u>	Nov 27, 2018
<u>AB</u>		<u>30MG</u>	<u>A200816</u>	<u>002</u>	Nov 27, 2018

PREVACID

<u>AB</u>	<u>+</u> TAKEDA PHARMS USA	<u>15MG</u>	<u>N021428</u>	<u>001</u>	Aug 30, 2002
<u>AB</u>	<u>+</u> !	<u>30MG</u>	<u>N021428</u>	<u>002</u>	Aug 30, 2002

LANTHANUM CARBONATE

POWDER;ORAL

FOSRENOL

<u>+</u>	TAKEDA PHARMS USA	EQ 750MG BASE	N204734	001	Sep 24, 2014
<u>+</u> !		EQ 1GM BASE	N204734	002	Sep 24, 2014

TABLET, CHEWABLE;ORAL

FOSRENOL

<u>AB</u>	<u>+</u> TAKEDA PHARMS USA	<u>EQ 500MG BASE</u>	<u>N021468</u>	<u>002</u>	Oct 26, 2004
<u>AB</u>	<u>+</u>	<u>EQ 750MG BASE</u>	<u>N021468</u>	<u>003</u>	Nov 23, 2005
<u>AB</u>	<u>+</u> !	<u>EQ 1GM BASE</u>	<u>N021468</u>	<u>004</u>	Nov 23, 2005

LANTHANUM CARBONATE

<u>AB</u>	BARR	<u>EQ 500MG BASE</u>	<u>A090977</u>	<u>001</u>	Jan 27, 2022
<u>AB</u>		<u>EQ 750MG BASE</u>	<u>A090977</u>	<u>002</u>	Jan 27, 2022
<u>AB</u>		<u>EQ 1GM BASE</u>	<u>A090977</u>	<u>003</u>	Jan 27, 2022
<u>AB</u>	INVAGEN PHARMS	<u>EQ 500MG BASE</u>	<u>A206868</u>	<u>001</u>	Jan 24, 2022
<u>AB</u>		<u>EQ 750MG BASE</u>	<u>A206868</u>	<u>002</u>	Jan 24, 2022
<u>AB</u>		<u>EQ 1GM BASE</u>	<u>A206868</u>	<u>003</u>	Jan 24, 2022
<u>AB</u>	NATCO PHARMA LTD	<u>EQ 500MG BASE</u>	<u>A090978</u>	<u>001</u>	Aug 11, 2017
<u>AB</u>		<u>EQ 750MG BASE</u>	<u>A090978</u>	<u>002</u>	Aug 11, 2017
<u>AB</u>		<u>EQ 1GM BASE</u>	<u>A090978</u>	<u>003</u>	Aug 11, 2017

LAPATINIB DITOSYLATE

TABLET;ORAL

LAPATINIB DITOSYLATE

<u>AB</u>	NATCO PHARMA LTD	<u>EQ 250MG BASE</u>	<u>A203007</u>	<u>001</u>	Sep 29, 2020
<u>AB</u>	<u>TYKERB</u>				
<u>AB</u>	<u>+</u> ! NOVARTIS	<u>EQ 250MG BASE</u>	<u>N022059</u>	<u>001</u>	Mar 13, 2007

LAROTRECTINIB SULFATE

CAPSULE;ORAL

VITRAKVI

<u>+</u>	BAYER HLTHCARE	EQ 25MG BASE	N210861	001	Nov 26, 2018
<u>+</u> !		EQ 100MG BASE	N210861	002	Nov 26, 2018

SOLUTION;ORAL

VITRAKVI

<u>+</u> !	BAYER HEALTHCARE	EQ 20MG BASE/ML	N211710	001	Nov 26, 2018

PRESCRIPTION DRUG PRODUCT LIST

3-262 (of 474)

LASMIDITAN SUCCINATE

TABLET; ORAL

REYVOW

+ ELI LILLY AND CO

EQ 50MG BASE

N211280 001 Jan 31, 2020

+!

EQ 100MG BASE

N211280 002 Jan 31, 2020

LATANOPROST

EMULSION; OPHTHALMIC

XELPROS

+! SUN PHARM

0.005%

N206185 001 Sep 12, 2018

SOLUTION/DROPS; OPHTHALMIC

LATANOPROST**AT** AKORN0.005%A090887 001 Jul 19, 2011**AT** AMRING PHARMS0.005%A200925 001 Mar 22, 2011**AT** BAUSCH AND LOMB0.005%A201006 001 Mar 22, 2011**AT** DR REDDYS LABS LTD0.005%A202077 001 Feb 11, 2013**AT** FDC LTD0.005%A202442 001 Apr 22, 2016**AT** SANDOZ INC0.005%A091449 001 Mar 22, 2011**AT** SOMERSET0.005%A201786 001 Mar 22, 2011XALATAN**AT** +! UPJOHN0.005%N020597 001 Jun 05, 1996

IYUZEH

+! THEA PHARMA

0.005%

N216472 001 Dec 13, 2022

LATANOPROST; NETARSUDIL DIMESYLATE

SOLUTION/DROPS; OPHTHALMIC

ROCKLATAN

+! AERIE PHARMS INC

0.005%; EQ 0.02% BASE

N208259 001 Mar 12, 2019

LATANOPROSTENE BUNOD

SOLUTION/DROPS; OPHTHALMIC

VYZULTA

+! BAUSCH AND LOMB

0.024%

N207795 001 Nov 02, 2017

LEDIPASVIR; SOFOSBUVIR

PELLETS; ORAL

HARVONI

+ GILEAD SCIENCES INC

33.75MG; 150MG/PACKET

N212477 001 Aug 28, 2019

+!

45MG; 200MG/PACKET

N212477 002 Aug 28, 2019

TABLET; ORAL

HARVONI

+ GILEAD SCIENCES INC

45MG; 200MG

N205834 002 Aug 28, 2019

+!

90MG; 400MG

N205834 001 Oct 10, 2014

LEFAMULIN ACETATE

SOLUTION; INTRAVENOUS

XENLETA

+! NABRIVA

EQ 150MG BASE/15ML (EQ 10MG BASE/ML)

N211673 001 Aug 19, 2019

TABLET; ORAL

XENLETA

+! NABRIVA

EQ 600MG BASE

N211672 001 Aug 19, 2019

LEFLUNOMIDE

TABLET; ORAL

ARAVA**AB** + SANOFI AVENTIS US10MGN020905 001 Sep 10, 1998**AB** +!20MGN020905 002 Sep 10, 1998LEFLUNOMIDE**AB** ABHAI LLC10MGA212453 001 Jun 03, 2019**AB**20MGA212453 002 Jun 03, 2019**AB** AET PHARMA10MGA213497 001 May 10, 2021**AB**20MGA213497 002 May 10, 2021**AB** ALEMBIC PHARMS LTD10MGA091369 001 Nov 21, 2011**AB**20MGA091369 002 Nov 21, 2011**AB** APOTEX INC10MGA077090 001 Sep 13, 2005**AB**20MGA077090 002 Sep 13, 2005**AB** AUROBINDO PHARMA10MGA213652 001 Mar 29, 2021**AB**20MGA213652 002 Mar 29, 2021**AB** HERITAGE PHARMS10MGA077086 001 Sep 13, 2005**AB**20MGA077086 002 Sep 13, 2005**AB** LUPIN LTD10MGA211863 001 Feb 04, 2020**AB**20MGA211863 002 Feb 04, 2020**AB** WANBANG BIOPHARMS10MGA077087 001 Sep 13, 2005**AB**20MGA077087 002 Sep 13, 2005**AB** ZYDUS10MGA212308 001 Apr 24, 2019

PRESCRIPTION DRUG PRODUCT LIST

3-263 (of 474)

LEFLUNOMIDE

TABLET; ORAL

LEFLUNOMIDE

AB		20MG	A212308 002	Apr 24, 2019
	ARAVA			
	+! SANOFI AVENTIS US	100MG	N020905 003	Sep 10, 1998

LEMBOREXANT

TABLET; ORAL

DAYVIGO

+	EISAI INC	5MG	N212028 001	Apr 07, 2020
+	!	10MG	N212028 002	Apr 07, 2020

LENACAPAVIR SODIUM

SOLUTION; SUBCUTANEOUS

SUNLENCA

+	GILEAD SCIENCES INC	EQ 463.5MG BASE/1.5ML (EQ 309MG BASE/ML)	N215973 001	Dec 22, 2022

TABLET; ORAL

SUNLENCA

+	GILEAD SCIENCES INC	EQ 300MG BASE	N215974 001	Dec 22, 2022

LENALIDOMIDE

CAPSULE; ORAL

LENALIDOMIDE

AB	APOTEX	5MG	A211022 001	Aug 30, 2022
AB		10MG	A211022 002	Aug 30, 2022
AB		15MG	A211022 003	Aug 30, 2022
AB		25MG	A211022 004	Aug 30, 2022
AB	ARROW INTL	5MG	A201452 001	May 21, 2021
AB		10MG	A201452 002	May 21, 2021
AB		15MG	A201452 003	May 21, 2021
AB		25MG	A201452 004	May 21, 2021
AB	CIPLA	5MG	A210435 001	Sep 06, 2022
AB		10MG	A210435 002	Sep 06, 2022
AB		15MG	A210435 003	Sep 06, 2022
AB		25MG	A210435 004	Sep 06, 2022
AB	DR REDDYS	2.5MG	A209348 001	Oct 14, 2021
AB		5MG	A209348 003	Aug 30, 2022
AB		10MG	A209348 004	Aug 30, 2022
AB		15MG	A209348 005	Aug 30, 2022
AB		20MG	A209348 002	Oct 14, 2021
AB		25MG	A209348 006	Aug 30, 2022
AB	LOTUS PHARM CO LTD	5MG	A210480 001	Aug 31, 2022
AB		10MG	A210480 002	Aug 31, 2022
AB		15MG	A210480 003	Aug 31, 2022
AB		25MG	A210480 004	Aug 31, 2022
AB	MYLAN	5MG	A213912 001	Aug 30, 2022
AB		10MG	A213912 002	Aug 30, 2022
AB		15MG	A213912 003	Aug 30, 2022
AB		25MG	A213912 004	Aug 30, 2022
AB	ZYDUS PHARMS	5MG	A210154 001	Sep 12, 2022
AB		10MG	A210154 002	Sep 12, 2022
AB		15MG	A210154 003	Sep 12, 2022
AB		25MG	A210154 004	Sep 12, 2022

REVLIMID

AB	+	CELGENE	2.5MG	N021880 005	Dec 21, 2011
AB	+		5MG	N021880 001	Dec 27, 2005
AB	+		10MG	N021880 002	Dec 27, 2005
AB	+		15MG	N021880 003	Jun 29, 2006
AB	+		20MG	N021880 006	Jun 05, 2013
AB	+	!	25MG	N021880 004	Jun 29, 2006

LENVATINIB MESYLATE

CAPSULE; ORAL

LENVIMA

+	EISAI INC	EQ 4MG BASE	N206947 001	Feb 13, 2015
+	!	EQ 10MG BASE	N206947 002	Feb 13, 2015

PRESCRIPTION DRUG PRODUCT LIST

3-264 (of 474)

LETERMOVIR

SOLUTION; INTRAVENOUS

PREVMIS

+	!	MERCK SHARP DOHME	240MG/12ML (20MG/ML)	N209940	001	Nov 08, 2017
+	!		480MG/24ML (20MG/ML)	N209940	002	Nov 08, 2017

TABLET; ORAL

PREVMIS

+		MERCK SHARP DOHME	240MG	N209939	001	Nov 08, 2017
+	!		480MG	N209939	002	Nov 08, 2017

LETROZOLE

TABLET; ORAL

FEMARA

<u>AB</u>	+	!	NOVARTIS PHARMS	<u>2.5MG</u>	<u>N020726</u>	<u>001</u>	Jul 25, 1997

LETROZOLE

<u>AB</u>			ACCORD HLTHCARE	<u>2.5MG</u>	<u>A090934</u>	<u>001</u>	Jun 03, 2011
<u>AB</u>			BEIJING YILING	<u>2.5MG</u>	<u>A205869</u>	<u>001</u>	Nov 14, 2018
<u>AB</u>			DR REDDYS LABS LTD	<u>2.5MG</u>	<u>A091191</u>	<u>001</u>	Jun 03, 2011
<u>AB</u>			EUGIA PHARMA	<u>2.5MG</u>	<u>A211717</u>	<u>001</u>	Jan 11, 2019
<u>AB</u>			NATCO PHARMA LTD	<u>2.5MG</u>	<u>A200161</u>	<u>001</u>	Jun 03, 2011
<u>AB</u>			TEVA PHARMS	<u>2.5MG</u>	<u>A090289</u>	<u>001</u>	Jun 03, 2011

LETROZOLE; RIBOCICLIB SUCCINATE

TABLET; ORAL

KISQALI FEMARA CO-PACK (COPACKAGED)

+	!	NOVARTIS	2.5MG; EQ 200MG BASE	N209935	001	May 04, 2017

LEUCOVORIN CALCIUM

INJECTABLE; INJECTION

LEUCOVORIN CALCIUM

<u>AP</u>			FRESENIUS KABI USA	<u>EQ 10MG BASE/ML</u>	<u>A207226</u>	<u>001</u>	Jul 27, 2018
<u>AP</u>	!		HIKMA	<u>EQ 50MG BASE/VIAL</u>	<u>A089384</u>	<u>001</u>	Sep 14, 1987
<u>AP</u>	!			<u>EQ 100MG BASE/VIAL</u>	<u>A089717</u>	<u>001</u>	Mar 28, 1988
<u>AP</u>			TEVA PHARMS USA	<u>EQ 100MG BASE/VIAL</u>	<u>A081277</u>	<u>001</u>	Sep 28, 1993
<u>AP</u>				<u>EQ 350MG BASE/VIAL</u>	<u>A040174</u>	<u>001</u>	Jun 12, 1997

LEUCOVORIN CALCIUM PRESERVATIVE FREE

<u>AP</u>			FRESENIUS KABI USA	<u>EQ 200MG BASE/VIAL</u>	<u>A040258</u>	<u>001</u>	Feb 26, 1999
<u>AP</u>	!			<u>EQ 500MG BASE/VIAL</u>	<u>A040286</u>	<u>001</u>	Feb 26, 1999
<u>AP</u>	!		HIKMA	<u>EQ 10MG BASE/ML</u>	<u>A040347</u>	<u>001</u>	Apr 25, 2000
<u>AP</u>	!			<u>EQ 200MG BASE/VIAL</u>	<u>A040056</u>	<u>001</u>	May 23, 1995
<u>AP</u>	!			<u>EQ 350MG BASE/VIAL</u>	<u>A040335</u>	<u>001</u>	Apr 20, 2000
<u>AP</u>			MYLAN LABS LTD	<u>EQ 100MG BASE/VIAL</u>	<u>A203800</u>	<u>001</u>	May 19, 2017
<u>AP</u>				<u>EQ 200MG BASE/VIAL</u>	<u>A203800</u>	<u>002</u>	May 19, 2017
<u>AP</u>				<u>EQ 350MG BASE/VIAL</u>	<u>A203800</u>	<u>003</u>	May 19, 2017
<u>AP</u>			SAGENT PHARMS	<u>EQ 50MG BASE/VIAL</u>	<u>A200753</u>	<u>001</u>	Sep 06, 2012
<u>AP</u>				<u>EQ 100MG BASE/VIAL</u>	<u>A200753</u>	<u>002</u>	Sep 06, 2012
<u>AP</u>				<u>EQ 200MG BASE/VIAL</u>	<u>A200753</u>	<u>003</u>	Sep 06, 2012
<u>AP</u>				<u>EQ 350MG BASE/VIAL</u>	<u>A200855</u>	<u>001</u>	Sep 06, 2012
<u>AP</u>			SAGENT PHARMS INC	<u>EQ 500MG BASE/VIAL</u>	<u>A209110</u>	<u>001</u>	Oct 26, 2017

LEUCOVORIN CALCIUM

FRESENIUS KABI USA EQ 10MG BASE/ML

A207241 001 Mar 14, 2018

TABLET; ORAL

LEUCOVORIN CALCIUM

<u>AB</u>			BARR	<u>EQ 5MG BASE</u>	<u>A071198</u>	<u>001</u>	Sep 24, 1987
<u>AB</u>				<u>EQ 25MG BASE</u>	<u>A071199</u>	<u>001</u>	Sep 24, 1987
<u>AB</u>			EPIC PHARMA LLC	<u>EQ 5MG BASE</u>	<u>A074544</u>	<u>001</u>	Aug 28, 1997
<u>AB</u>				<u>EQ 10MG BASE</u>	<u>A074544</u>	<u>003</u>	May 19, 2021
<u>AB</u>				<u>EQ 15MG BASE</u>	<u>A074544</u>	<u>004</u>	May 19, 2021
<u>AB</u>				<u>EQ 25MG BASE</u>	<u>A074544</u>	<u>002</u>	Aug 28, 1997
<u>AB</u>			HIKMA	<u>EQ 5MG BASE</u>	<u>A072733</u>	<u>001</u>	Feb 22, 1993
<u>AB</u>				<u>EQ 10MG BASE</u>	<u>A072734</u>	<u>001</u>	Feb 22, 1993
<u>AB</u>				<u>EQ 15MG BASE</u>	<u>A072735</u>	<u>001</u>	Feb 22, 1993
<u>AB</u>	!			<u>EQ 25MG BASE</u>	<u>A072736</u>	<u>001</u>	Feb 22, 1993
<u>AB</u>			LEADING	<u>EQ 5MG BASE</u>	<u>A213929</u>	<u>001</u>	Oct 22, 2020
<u>AB</u>				<u>EQ 10MG BASE</u>	<u>A213929</u>	<u>002</u>	Oct 22, 2020
<u>AB</u>				<u>EQ 15MG BASE</u>	<u>A213929</u>	<u>003</u>	Oct 22, 2020
<u>AB</u>				<u>EQ 25MG BASE</u>	<u>A213929</u>	<u>004</u>	Oct 22, 2020
<u>AB</u>			NOVAST LABS	<u>EQ 5MG BASE</u>	<u>A211132</u>	<u>001</u>	Jul 30, 2020
<u>AB</u>				<u>EQ 10MG BASE</u>	<u>A211132</u>	<u>002</u>	Jul 30, 2020
<u>AB</u>				<u>EQ 15MG BASE</u>	<u>A211132</u>	<u>003</u>	Jul 30, 2020
<u>AB</u>				<u>EQ 25MG BASE</u>	<u>A211132</u>	<u>004</u>	Jul 30, 2020

PRESCRIPTION DRUG PRODUCT LIST

3-265 (of 474)

LEUPROLIDE ACETATE

FOR SUSPENSION; INTRAMUSCULAR

LUTRATE DEPOT KIT

+! INVAGEN PHARMS 22.5MG/VIAL

N205054 001 Aug 28, 2018

INJECTABLE; INJECTION

LEUPROLIDE ACETATEAP AMNEAL 1MG/0.2MLA215336 001 Oct 28, 2022AP EUGIA PHARMA 1MG/0.2MLA212963 001 Jun 06, 2022AP ! SANDOZ 1MG/0.2MLA074728 001 Aug 04, 1998AP SUN PHARM 1MG/0.2MLA078885 001 Mar 09, 2009AP TEVA PHARMS USA 1MG/0.2MLA075471 001 Oct 25, 2000AP VGYAAN 1MG/0.2MLA213829 001 Aug 13, 2021

LUPRON DEPOT

+! ABBVIE ENDOCRINE 3.75MG

N020011 002 Oct 26, 1995

INC

+! 7.5MG/VIAL

N019732 001 Jan 26, 1989

+! 11.25MG/VIAL

N020708 001 Mar 07, 1997

+ 22.5MG/VIAL

N020517 001 Dec 22, 1995

+! 30MG/VIAL

N020517 002 May 30, 1997

+! 45MG/VIAL

N020517 003 Jun 17, 2011

POWDER; INTRAMUSCULAR

LUPRON DEPOT-PED KIT

+! ABBVIE ENDOCRINE 7.5MG

N020263 002 Apr 16, 1993

INC

+! 11.25MG

N020263 005 Jan 21, 1994

+! 11.25MG

N020263 007 Aug 15, 2011

+! 15MG

N020263 006 Jan 21, 1994

+! 30MG

N020263 008 Aug 15, 2011

POWDER; SUBCUTANEOUS

ELIGARD KIT

+! TOLMAR THERAP 7.5MG

N021343 001 Jan 23, 2002

+! 22.5MG

N021379 001 Jul 24, 2002

+! 30MG

N021488 001 Feb 13, 2003

+! 45MG

N021731 001 Dec 14, 2004

FENSOLVI KIT

+! TOLMAR 45MG

N213150 001 May 01, 2020

LEUPROLIDE MESYLATE

EMULSION; SUBCUTANEOUS

CAMCEVI KIT

+! ACCORD EQ 42MG BASE

N211488 001 May 25, 2021

LEVALBUTEROL HYDROCHLORIDE

SOLUTION; INHALATION

LEVALBUTEROL HYDROCHLORIDEAN CIPLA EQ 0.021% BASEA078171 002 Dec 13, 2013AN EQ 0.042% BASEA078171 003 Dec 13, 2013AN EQ 0.0103% BASEA078171 001 Dec 13, 2013AN IMPAX LABS INC EQ 0.0103% BASEA077756 003 Apr 09, 2008AN EQ 0.021% BASEA077756 001 Apr 09, 2008AN EQ 0.042% BASEA077756 002 Apr 09, 2008AN LUOXIN AUROVITAS EQ 0.25% BASEA207628 001 Jan 31, 2017AN EQ 0.0103% BASEA207625 001 Dec 30, 2016AN EQ 0.021% BASEA207625 002 Dec 30, 2016AN EQ 0.042% BASEA207625 003 Dec 30, 2016AN MYLAN SPECIALITY LP EQ 0.25% BASEA078309 001 Mar 20, 2009AN RITEDOSE CORP EQ 0.0103% BASEA203653 001 Mar 22, 2016AN EQ 0.021% BASEA203653 002 Mar 22, 2016AN EQ 0.042% BASEA203653 003 Mar 22, 2016AN SUN PHARM EQ 0.0103% BASEA207820 001 Nov 05, 2018AN EQ 0.021% BASEA207820 002 Nov 05, 2018AN EQ 0.042% BASEA207820 003 Nov 05, 2018AN TEVA PARENTERAL EQ 0.25% BASEA200875 001 Sep 11, 2014AN TEVA PHARMS USA EQ 0.0103% BASEA090297 001 Apr 26, 2013AN EQ 0.021% BASEA090297 002 Apr 26, 2013AN EQ 0.042% BASEA090297 003 Apr 26, 2013XOPENEXAN +! AKORN EQ 0.0103% BASEN020837 003 Jan 30, 2002AN +! EQ 0.021% BASEN020837 001 Mar 25, 1999AN +! EQ 0.042% BASEN020837 002 Mar 25, 1999AN +! EQ 0.25% BASEN020837 004 Jul 18, 2003

PRESCRIPTION DRUG PRODUCT LIST

3-266 (of 474)

LEVALBUTEROL TARTRATE

AEROSOL, METERED; INHALATION

XOPENEX HFA

+! LUPIN

EQ 0.045MG BASE/INH

N021730 001 Mar 11, 2005

LEVAMLODIPINE MALEATE

TABLET; ORAL

CONJUPRI

+ CSPEC OUYI

EQ 2.5MG BASE

N212895 002 Dec 19, 2019

+!

EQ 5MG BASE

N212895 003 Dec 19, 2019

LEVETIRACETAM

INJECTABLE; INTRAVENOUS

KEPPRAAP +! UCB INC500MG/5ML (100MG/ML)N021872 001 Jul 31, 2006LEVETIRACETAMAP BEOWULF ASSET500MG/5ML (100MG/ML)A091485 001 Aug 05, 2011AP EUGIA PHARMA500MG/5ML (100MG/ML)A204312 001 Feb 01, 2016AP FRESenius KABI USA500MG/5ML (100MG/ML)A090876 001 Aug 13, 2015AP HAINAN POLY PHARM500MG/5ML (100MG/ML)A209781 001 Mar 20, 2018AP HIKMA FARMACEUTICA500MG/5ML (100MG/ML)A090981 001 Oct 13, 2011AP HOSPIRA INC500MG/5ML (100MG/ML)A202869 001 Apr 06, 2012AP MICRO LABS500MG/5ML (100MG/ML)A211954 001 Aug 09, 2019AP MSN500MG/5ML (100MG/ML)A215980 001 Nov 15, 2022AP MYLAN LABS LTD500MG/5ML (100MG/ML)A203308 001 Sep 16, 2016AP PRINSTON INC500MG/5ML (100MG/ML)A209474 001 Mar 28, 2022AP SAGENT PHARMS500MG/5ML (100MG/ML)A091627 001 Jun 26, 2013AP SUN PHARM INDS LTD500MG/5ML (100MG/ML)A090754 001 Jun 16, 2010LEVETIRACETAM IN SODIUM CHLORIDEAP EUGIA PHARMA500MG/100ML (5MG/ML)A207160 001 Jan 04, 2017AP1GM/100ML (10MG/ML)A207160 002 Jan 04, 2017AP1.5GM/100ML (15MG/ML)A207160 003 Jan 04, 2017AP GLAND PHARMA LTD500MG/100ML (5MG/ML)A206880 001 Oct 25, 2017AP1GM/100ML (10MG/ML)A206880 002 Oct 25, 2017AP1.5GM/100ML (15MG/ML)A206880 003 Oct 25, 2017AP +! HQ SPECIALITY
PHARMA500MG/100ML (5MG/ML)N202543 001 Nov 09, 2011AP +!1GM/100ML (10MG/ML)N202543 002 Nov 09, 2011AP +!1.5GM/100ML (15MG/ML)N202543 003 Nov 09, 2011AP NEXUS PHARMS500MG/100ML (5MG/ML)A213532 001 Jul 06, 2020AP1GM/100ML (10MG/ML)A213532 002 Jul 06, 2020AP1.5GM/100ML (15MG/ML)A213532 003 Jul 06, 2020AP +! HQ SPECIALITY
PHARMA250MG/50ML (5MG/ML)N202543 004 Dec 14, 2020

SOLUTION; ORAL

KEPPRAAA +! UCB INC100MG/MLN021505 001 Jul 15, 2003LEVETIRACETAMAA ACI100MG/MLA078582 001 Jan 15, 2009AA ACTAVIS MID100MG/MLA078976 001 Jan 15, 2009AA ATLANTICAA AIPING PHARM INC100MG/MLA090079 001 Apr 11, 2012AA AKORN100MG/MLA090601 001 Feb 28, 2012AA ALEMBIC LABS100MG/MLA203067 001 May 09, 2013AA AMNEAL PHARMS100MG/MLA090992 001 Oct 27, 2009AA AUROBINDO PHARMA100MG/MLA079063 001 Jan 15, 2009AA BELCHER100MG/MLA090461 001 Sep 30, 2010AA BRECKENRIDGE100MG/MLA079120 001 Jan 16, 2009AA CHARTWELL MOLECULAR100MG/MLA090263 001 Apr 03, 2009AA HETERO LABS LTD III100MG/MLA203052 001 Feb 28, 2013AA LUPIN LTD100MG/MLA090893 001 Oct 17, 2011AA MSN100MG/MLA214757 001 Jul 15, 2022AA PHARM ASSOC100MG/MLA201157 001 Jun 04, 2015AA TARO100MG/MLA078774 001 Feb 10, 2009

TABLET; ORAL

KEPPRAAB + UCB INC250MGN021035 001 Nov 30, 1999AB +500MGN021035 002 Nov 30, 1999AB +750MGN021035 003 Nov 30, 1999AB +!1GMN021035 004 Jan 06, 2006LEVETIRACETAMAB ACCORD HLTHCARE250MGA090843 001 Feb 14, 2011AB500MGA090843 002 Feb 14, 2011AB750MGA090843 003 Feb 14, 2011

PRESCRIPTION DRUG PRODUCT LIST

3-267 (of 474)

LEVETIRACETAM

TABLET; ORAL

LEVETIRACETAM

<u>AB</u>		<u>1GM</u>	<u>A090843</u>	<u>004</u>	Feb 14, 2011
<u>AB</u>	ACI	<u>250MG</u>	<u>A078042</u>	<u>001</u>	Jan 15, 2009
<u>AB</u>		<u>500MG</u>	<u>A078042</u>	<u>002</u>	Jan 15, 2009
<u>AB</u>		<u>750MG</u>	<u>A078042</u>	<u>003</u>	Jan 15, 2009
<u>AB</u>		<u>1GM</u>	<u>A078042</u>	<u>004</u>	Jan 15, 2009
<u>AB</u>	ALKEM LABS LTD	<u>250MG</u>	<u>A216375</u>	<u>001</u>	May 27, 2022
<u>AB</u>		<u>500MG</u>	<u>A216375</u>	<u>002</u>	May 27, 2022
<u>AB</u>		<u>750MG</u>	<u>A216375</u>	<u>003</u>	May 27, 2022
<u>AB</u>		<u>1GM</u>	<u>A216375</u>	<u>004</u>	May 27, 2022
<u>AB</u>	AUROBINDO PHARMA	<u>250MG</u>	<u>A078993</u>	<u>001</u>	Jan 15, 2009
<u>AB</u>		<u>500MG</u>	<u>A078993</u>	<u>002</u>	Jan 15, 2009
<u>AB</u>		<u>750MG</u>	<u>A078993</u>	<u>003</u>	Jan 15, 2009
<u>AB</u>		<u>1GM</u>	<u>A078993</u>	<u>004</u>	Jan 15, 2009
<u>AB</u>	CHARTWELL RX	<u>250MG</u>	<u>A201293</u>	<u>001</u>	Jun 14, 2011
<u>AB</u>		<u>500MG</u>	<u>A201293</u>	<u>002</u>	Jun 14, 2011
<u>AB</u>		<u>750MG</u>	<u>A201293</u>	<u>003</u>	Jun 14, 2011
<u>AB</u>		<u>1GM</u>	<u>A201293</u>	<u>004</u>	Jun 14, 2011
<u>AB</u>	DR REDDYS LABS LTD	<u>250MG</u>	<u>A076920</u>	<u>001</u>	Jan 15, 2009
<u>AB</u>		<u>500MG</u>	<u>A076920</u>	<u>002</u>	Jan 15, 2009
<u>AB</u>		<u>750MG</u>	<u>A076920</u>	<u>003</u>	Jan 15, 2009
<u>AB</u>		<u>1GM</u>	<u>A078904</u>	<u>001</u>	Jan 15, 2009
<u>AB</u>	HETERO LABS LTD III	<u>250MG</u>	<u>A090515</u>	<u>001</u>	Oct 08, 2010
<u>AB</u>		<u>500MG</u>	<u>A090515</u>	<u>002</u>	Oct 08, 2010
<u>AB</u>		<u>750MG</u>	<u>A090515</u>	<u>003</u>	Oct 08, 2010
<u>AB</u>		<u>1GM</u>	<u>A090515</u>	<u>004</u>	Oct 08, 2010
<u>AB</u>	INVAGEN PHARMS	<u>250MG</u>	<u>A078234</u>	<u>001</u>	Jan 15, 2009
<u>AB</u>		<u>500MG</u>	<u>A078234</u>	<u>002</u>	Jan 15, 2009
<u>AB</u>		<u>750MG</u>	<u>A078234</u>	<u>003</u>	Jan 15, 2009
<u>AB</u>	LUPIN	<u>250MG</u>	<u>A078154</u>	<u>001</u>	Jan 15, 2009
<u>AB</u>		<u>500MG</u>	<u>A078154</u>	<u>002</u>	Jan 15, 2009
<u>AB</u>		<u>750MG</u>	<u>A078154</u>	<u>003</u>	Jan 15, 2009
<u>AB</u>		<u>1GM</u>	<u>A090025</u>	<u>001</u>	Jan 15, 2009
<u>AB</u>	MSN	<u>250MG</u>	<u>A214815</u>	<u>001</u>	Oct 07, 2022
<u>AB</u>		<u>500MG</u>	<u>A214815</u>	<u>002</u>	Oct 07, 2022
<u>AB</u>		<u>750MG</u>	<u>A214815</u>	<u>003</u>	Oct 07, 2022
<u>AB</u>		<u>1GM</u>	<u>A214815</u>	<u>004</u>	Oct 07, 2022
<u>AB</u>	MYLAN	<u>250MG</u>	<u>A076919</u>	<u>001</u>	Nov 04, 2008
<u>AB</u>		<u>500MG</u>	<u>A076919</u>	<u>002</u>	Nov 04, 2008
<u>AB</u>		<u>750MG</u>	<u>A076919</u>	<u>003</u>	Nov 04, 2008
<u>AB</u>		<u>1GM</u>	<u>A090261</u>	<u>001</u>	Dec 08, 2009
<u>AB</u>	ORBION PHARMS	<u>250MG</u>	<u>A078526</u>	<u>001</u>	Jan 15, 2009
<u>AB</u>		<u>500MG</u>	<u>A078526</u>	<u>002</u>	Jan 15, 2009
<u>AB</u>		<u>750MG</u>	<u>A078526</u>	<u>003</u>	Jan 15, 2009
<u>AB</u>		<u>1GM</u>	<u>A090484</u>	<u>001</u>	Aug 05, 2010
<u>AB</u>	OXFORD PHARMS	<u>250MG</u>	<u>A077319</u>	<u>001</u>	Mar 20, 2009
<u>AB</u>		<u>500MG</u>	<u>A077319</u>	<u>002</u>	Mar 20, 2009
<u>AB</u>		<u>750MG</u>	<u>A077319</u>	<u>003</u>	Mar 20, 2009
<u>AB</u>	PRINSTON INC	<u>250MG</u>	<u>A078106</u>	<u>001</u>	Feb 10, 2009
<u>AB</u>		<u>500MG</u>	<u>A078106</u>	<u>002</u>	Feb 10, 2009
<u>AB</u>		<u>750MG</u>	<u>A078106</u>	<u>003</u>	Feb 10, 2009
<u>AB</u>		<u>1GM</u>	<u>A078106</u>	<u>004</u>	Feb 10, 2009
<u>AB</u>	SCIEGEN PHARMS INC	<u>250MG</u>	<u>A215069</u>	<u>003</u>	May 27, 2022
<u>AB</u>		<u>500MG</u>	<u>A215069</u>	<u>004</u>	May 27, 2022
<u>AB</u>		<u>750MG</u>	<u>A215069</u>	<u>001</u>	Jun 11, 2021
<u>AB</u>		<u>1GM</u>	<u>A215069</u>	<u>002</u>	Jun 11, 2021
<u>AB</u>	STALLION LABS	<u>250MG</u>	<u>A079042</u>	<u>001</u>	Jan 15, 2009
<u>AB</u>		<u>500MG</u>	<u>A079042</u>	<u>002</u>	Jan 15, 2009
<u>AB</u>		<u>750MG</u>	<u>A079042</u>	<u>003</u>	Jan 15, 2009
<u>AB</u>		<u>1GM</u>	<u>A079042</u>	<u>004</u>	Jan 15, 2009
<u>AB</u>	TARO	<u>250MG</u>	<u>A078960</u>	<u>004</u>	Feb 01, 2010
<u>AB</u>		<u>500MG</u>	<u>A078960</u>	<u>003</u>	Feb 01, 2010
<u>AB</u>		<u>750MG</u>	<u>A078960</u>	<u>002</u>	Feb 01, 2010
<u>AB</u>		<u>1GM</u>	<u>A078960</u>	<u>001</u>	Feb 01, 2010
<u>AB</u>	TORRENT PHARMS	<u>250MG</u>	<u>A078858</u>	<u>001</u>	Jan 15, 2009
<u>AB</u>		<u>500MG</u>	<u>A078858</u>	<u>002</u>	Jan 15, 2009
<u>AB</u>		<u>750MG</u>	<u>A078858</u>	<u>003</u>	Jan 15, 2009
<u>AB</u>		<u>1GM</u>	<u>A078858</u>	<u>004</u>	Jan 15, 2009
<u>AB</u>	VIWIT PHARM	<u>250MG</u>	<u>A078869</u>	<u>001</u>	Mar 13, 2009
<u>AB</u>		<u>500MG</u>	<u>A078869</u>	<u>002</u>	Mar 13, 2009

PRESCRIPTION DRUG PRODUCT LIST

3-268 (of 474)

LEVETIRACETAM

TABLET; ORAL

LEVETIRACETAM

<u>AB</u>		<u>750MG</u>	<u>A078869</u>	<u>003</u>	Mar 13, 2009
<u>AB</u>		<u>1GM</u>	<u>A078869</u>	<u>004</u>	Mar 13, 2009
<u>AB</u>	VKT PHARMA	<u>250MG</u>	<u>A090767</u>	<u>001</u>	Jul 28, 2010
<u>AB</u>		<u>500MG</u>	<u>A090767</u>	<u>002</u>	Jul 28, 2010
<u>AB</u>		<u>750MG</u>	<u>A090767</u>	<u>003</u>	Jul 28, 2010
<u>AB</u>		<u>1GM</u>	<u>A090767</u>	<u>004</u>	Jul 28, 2010
<u>AB</u>	ZHEJIANG JINGXIN	<u>250MG</u>	<u>A091491</u>	<u>001</u>	Dec 14, 2010
<u>AB</u>		<u>500MG</u>	<u>A091491</u>	<u>002</u>	Dec 14, 2010
<u>AB</u>		<u>750MG</u>	<u>A091491</u>	<u>003</u>	Dec 14, 2010
<u>AB</u>		<u>1GM</u>	<u>A091491</u>	<u>004</u>	Dec 14, 2010
<u>AB</u>	ZYDUS PHARMS USA INC	<u>250MG</u>	<u>A078918</u>	<u>001</u>	Apr 29, 2009
<u>AB</u>		<u>1GM</u>	<u>A078918</u>	<u>002</u>	Apr 29, 2009

TABLET, EXTENDED RELEASE; ORAL

KEPPRA XR

<u>AB</u>	+	UCB INC	<u>500MG</u>	<u>N022285</u>	<u>001</u>	Sep 12, 2008
<u>AB</u>	+	!	<u>750MG</u>	<u>N022285</u>	<u>002</u>	Feb 12, 2009

LEVETIRACETAM

<u>AB</u>	ACTAVIS LABS FL INC	<u>500MG</u>	<u>A091093</u>	<u>001</u>	Sep 12, 2011
<u>AB</u>		<u>750MG</u>	<u>A091093</u>	<u>002</u>	Sep 12, 2011
<u>AB</u>	AIPING PHARM INC	<u>500MG</u>	<u>A204754</u>	<u>001</u>	Aug 26, 2016
<u>AB</u>		<u>750MG</u>	<u>A204754</u>	<u>002</u>	Aug 26, 2016
<u>AB</u>	ANCHEN PHARMS	<u>500MG</u>	<u>A091360</u>	<u>001</u>	Oct 04, 2011
<u>AB</u>		<u>750MG</u>	<u>A091360</u>	<u>002</u>	Oct 04, 2011
<u>AB</u>	ANDA REPOSITORY	<u>500MG</u>	<u>A204511</u>	<u>001</u>	Feb 23, 2016
<u>AB</u>		<u>750MG</u>	<u>A204511</u>	<u>002</u>	Feb 23, 2016
<u>AB</u>	APOTEX INC	<u>500MG</u>	<u>A091261</u>	<u>001</u>	Sep 12, 2011
<u>AB</u>		<u>750MG</u>	<u>A091261</u>	<u>002</u>	Sep 12, 2011
<u>AB</u>	HISUN PHARM HANGZHOU	<u>500MG</u>	<u>A207175</u>	<u>001</u>	Sep 28, 2017
<u>AB</u>		<u>750MG</u>	<u>A207175</u>	<u>002</u>	Sep 28, 2017
<u>AB</u>	LUPIN LTD	<u>500MG</u>	<u>A091399</u>	<u>001</u>	Sep 12, 2011
<u>AB</u>		<u>750MG</u>	<u>A091399</u>	<u>002</u>	Sep 12, 2011
<u>AB</u>	OVERSEAS	<u>750MG</u>	<u>A212688</u>	<u>001</u>	Jun 11, 2020
<u>AB</u>	PHARMADAX INC	<u>500MG</u>	<u>A201464</u>	<u>001</u>	May 25, 2012
<u>AB</u>		<u>750MG</u>	<u>A201464</u>	<u>002</u>	May 25, 2012
<u>AB</u>	PRINSTON INC	<u>500MG</u>	<u>A202533</u>	<u>001</u>	Jul 20, 2012
<u>AB</u>		<u>500MG</u>	<u>A203468</u>	<u>001</u>	May 21, 2015
<u>AB</u>		<u>750MG</u>	<u>A202533</u>	<u>002</u>	Jul 20, 2012
<u>AB</u>		<u>750MG</u>	<u>A203468</u>	<u>002</u>	May 21, 2015
<u>AB</u>	SCIEGEN PHARMS INC	<u>500MG</u>	<u>A205130</u>	<u>001</u>	Nov 27, 2020
<u>AB</u>		<u>750MG</u>	<u>A205130</u>	<u>002</u>	Nov 27, 2020
<u>AB</u>	SUN PHARM	<u>500MG</u>	<u>A203059</u>	<u>001</u>	Sep 09, 2013
<u>AB</u>		<u>750MG</u>	<u>A203059</u>	<u>002</u>	Sep 09, 2013

ELEPSIA XR

+ TRIPOINT

+!

LEVETIRACETAM

APOTEX

TABLET, FOR SUSPENSION; ORAL

SPRITAM

+ APRECIA PHARMS

+

+

+!

LEVOBUNOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

BETAGAN

<u>AT</u>	+	ALLERGAN	<u>0.5%</u>	<u>N019219</u>	<u>002</u>	Dec 19, 1985

LEVOBUNOLOL HYDROCHLORIDE

<u>AT</u>		BAUSCH AND LOMB	<u>0.5%</u>	<u>A074326</u>	<u>001</u>	Mar 04, 1994

LEVOCARNITINE

INJECTABLE; INJECTION

CARNITOR

<u>AP</u>	+	!	LEADIANT BIOSCI INC	<u>200MG/ML</u>	<u>N020182</u>	<u>001</u>	Dec 16, 1992

LEVOCARNITINE

<u>AP</u>		AM REGENT	<u>200MG/ML</u>	<u>A075861</u>	<u>001</u>	Jun 22, 2001
<u>AP</u>		HIKMA	<u>200MG/ML</u>	<u>A075567</u>	<u>001</u>	Mar 29, 2001

PRESCRIPTION DRUG PRODUCT LIST

3-269 (of 474)

LEVOCARNITINE

SOLUTION; ORAL

CARNITOR

<u>AA</u>	<u>+!</u>	LEADIANT BIOSCI INC	<u>1GM/10ML</u>	<u>N019257</u>	<u>001</u>	Apr 10, 1986

CARNITOR SF

<u>AA</u>	<u>+</u>	LEADIANT BIOSCI INC	<u>1GM/10ML</u>	<u>N019257</u>	<u>002</u>	Mar 28, 2007

LEVOCARNITINE

<u>AA</u>		AKORN	<u>1GM/10ML</u>	<u>A077399</u>	<u>001</u>	Oct 25, 2007

<u>AA</u>		LYNE	<u>1GM/10ML</u>	<u>A076851</u>	<u>001</u>	Aug 10, 2004

<u>AA</u>		NOVITIUM PHARMA	<u>1GM/10ML</u>	<u>A211676</u>	<u>001</u>	Aug 14, 2019

<u>AA</u>		SAPTALIS PHARMS	<u>1GM/10ML</u>	<u>A212533</u>	<u>001</u>	Nov 10, 2021

LEVOCARNITINE SF

<u>AA</u>		NOVITIUM PHARMA	<u>1GM/10ML</u>	<u>A211676</u>	<u>002</u>	Aug 14, 2019

TABLET; ORAL

CARNITOR

<u>AB</u>	<u>+!</u>	LEADIANT BIOSCI INC	<u>330MG</u>	<u>N018948</u>	<u>001</u>	Dec 27, 1985

LEVOCARNITINE

<u>AB</u>		NOVITIUM PHARMA	<u>330MG</u>	<u>A216384</u>	<u>001</u>	Dec 09, 2022

<u>AB</u>		RISING	<u>330MG</u>	<u>A076858</u>	<u>001</u>	Sep 20, 2004

LEVOCETIRIZINE DIHYDROCHLORIDE

SOLUTION; ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

<u>AA</u>		CHARTWELL MOLECULAR	<u>2.5MG/5ML</u>	<u>A204599</u>	<u>001</u>	May 15, 2017

<u>AA</u>	<u>!</u>	PADAGIS US	<u>2.5MG/5ML</u>	<u>A091263</u>	<u>001</u>	Nov 07, 2011

<u>AA</u>		TARO PHARM INDS LTD	<u>2.5MG/5ML</u>	<u>A202673</u>	<u>001</u>	Jul 26, 2013

LEVOCETIRIZINE HYDROCHLORIDE

<u>AA</u>		HETERO LABS LTD III	<u>2.5MG/5ML</u>	<u>A210914</u>	<u>001</u>	Apr 01, 2019

TABLET; ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

<u>AB</u>		DR REDDYS LABS LTD	<u>5MG</u>	<u>A090392</u>	<u>001</u>	Feb 24, 2011

<u>AB</u>	<u>!</u>	GLENMARK GENERICS	<u>5MG</u>	<u>A090385</u>	<u>001</u>	Feb 24, 2011

<u>AB</u>		HETERO LABS LTD III	<u>5MG</u>	<u>A091264</u>	<u>001</u>	Jun 29, 2012

<u>AB</u>		MACLEODS PHARMS LTD	<u>5MG</u>	<u>A205564</u>	<u>001</u>	Jan 11, 2016

<u>AB</u>		MICRO LABS LTD	<u>5MG</u>	<u>A202046</u>	<u>001</u>	Sep 17, 2013

INDIA

<u>AB</u>		SCIEGEN PHARMS INC	<u>5MG</u>	<u>A203646</u>	<u>001</u>	Sep 09, 2014

<u>AB</u>		SUN PHARM	<u>5MG</u>	<u>A090362</u>	<u>001</u>	Jan 31, 2013

<u>AB</u>		SYNTHON PHARMS	<u>5MG</u>	<u>A090229</u>	<u>001</u>	Nov 26, 2010

<u>AB</u>		TEVA PHARMS	<u>5MG</u>	<u>A090199</u>	<u>001</u>	Aug 22, 2011

LEVODOPA

POWDER; INHALATION

INBRIJA

<u>+!</u>	ACORDA	42MG	<u>N209184</u>	<u>001</u>	Dec 21, 2018

LEVOFLOXACIN

INJECTABLE; INJECTION

LEVOFLOXACIN

<u>AP</u>	<u>!</u>	AKORN	<u>EQ 500MG/20ML (EQ 25MG/ML)</u>	<u>A091644</u>	<u>001</u>	Jun 20, 2011

<u>AP</u>	<u>!</u>		<u>EQ 750MG/30ML (EQ 25MG/ML)</u>	<u>A091644</u>	<u>002</u>	Jun 20, 2011

<u>AP</u>		BAXTER HLTHCARE	<u>EQ 500MG/20ML (EQ 25MG/ML)</u>	<u>A091436</u>	<u>001</u>	Jun 05, 2013

CORP

<u>AP</u>		GLAND PHARMA LTD	<u>EQ 500MG/20ML (EQ 25MG/ML)</u>	<u>A205540</u>	<u>001</u>	Apr 22, 2020

<u>AP</u>			<u>EQ 750MG/30ML (EQ 25MG/ML)</u>	<u>A205540</u>	<u>002</u>	Apr 22, 2020

LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>		BAXTER HLTHCARE	<u>EQ 250MG/50ML (EQ 5MG/ML)</u>	<u>A091397</u>	<u>001</u>	Aug 08, 2013

CORP

<u>AP</u>			<u>EQ 500MG/100ML (EQ 5MG/ML)</u>	<u>A091397</u>	<u>002</u>	Aug 08, 2013

<u>AP</u>			<u>EQ 750MG/150ML (EQ 5MG/ML)</u>	<u>A091397</u>	<u>003</u>	Aug 08, 2013

<u>AP</u>		FRESENIUS KABI USA	<u>EQ 250MG/50ML (EQ 5MG/ML)</u>	<u>A200674</u>	<u>001</u>	Jun 19, 2013

<u>AP</u>			<u>EQ 500MG/100ML (EQ 5MG/ML)</u>	<u>A200674</u>	<u>002</u>	Jun 19, 2013

<u>AP</u>			<u>EQ 750MG/150ML (EQ 5MG/ML)</u>	<u>A200674</u>	<u>003</u>	Jun 19, 2013

<u>AP</u>		GLAND PHARMA LTD	<u>EQ 250MG/50ML (EQ 5MG/ML)</u>	<u>A206908</u>	<u>001</u>	Dec 30, 2020

<u>AP</u>			<u>EQ 500MG/100ML (EQ 5MG/ML)</u>	<u>A206908</u>	<u>002</u>	Dec 30, 2020

<u>AP</u>			<u>EQ 750MG/150ML (EQ 5MG/ML)</u>	<u>A206908</u>	<u>003</u>	Dec 30, 2020

<u>AP</u>		HIKMA FARMACEUTICA	<u>EQ 250MG/50ML (EQ 5MG/ML)</u>	<u>A091375</u>	<u>001</u>	Sep 16, 2011

<u>AP</u>			<u>EQ 500MG/100ML (EQ 5MG/ML)</u>	<u>A091375</u>	<u>002</u>	Sep 16, 2011

<u>AP</u>			<u>EQ 750MG/150ML (EQ 5MG/ML)</u>	<u>A091375</u>	<u>003</u>	Sep 16, 2011

<u>AP</u>		HOSPIRA	<u>EQ 250MG/50ML (EQ 5MG/ML)</u>	<u>A078579</u>	<u>001</u>	Sep 03, 2015

<u>AP</u>			<u>EQ 500MG/100ML (EQ 5MG/ML)</u>	<u>A078579</u>	<u>002</u>	Sep 03, 2015

<u>AP</u>			<u>EQ 750MG/150ML (EQ 5MG/ML)</u>	<u>A078579</u>	<u>003</u>	Sep 03, 2015

<u>AP</u>	<u>!</u>	INFORLIFE	<u>EQ 250MG/50ML (EQ 5MG/ML)</u>	<u>A090343</u>	<u>001</u>	Jul 07, 2011

<u>AP</u>	<u>!</u>		<u>EQ 500MG/100ML (EQ 5MG/ML)</u>	<u>A090343</u>	<u>002</u>	Jul 07, 2011

PRESCRIPTION DRUG PRODUCT LIST

3-270 (of 474)

LEVOFLOXACIN

INJECTABLE; INJECTION

LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>	!	<u>EQ 750MG/150ML (EQ 5MG/ML)</u>	<u>A090343</u>	<u>003</u>	Jul 07, 2011

SOLUTION; ORAL

LEVOFLOXACIN

<u>AA</u>	!	AKORN	<u>250MG/10ML</u>	<u>A091678</u>	<u>001</u>	Jun 20, 2011

<u>AA</u>		LANNETT CO INC	<u>250MG/10ML</u>	<u>A205222</u>	<u>001</u>	May 25, 2018

SOLUTION/DROPS; OPHTHALMIC

LEVOFLOXACIN

<u>AT</u>		AKORN	<u>0.5%</u>	<u>A090268</u>	<u>001</u>	Dec 20, 2010

<u>AT</u>	!	RISING	<u>0.5%</u>	<u>A077700</u>	<u>001</u>	Dec 20, 2010

		MICRO LABS LTD	1.5%	A205600	001	Feb 27, 2019

INDIA

TABLET; ORAL

LEVOFLOXACIN

<u>AB</u>		APOTEX INC	<u>250MG</u>	<u>A090787</u>	<u>001</u>	Sep 29, 2011

<u>AB</u>			<u>500MG</u>	<u>A090787</u>	<u>002</u>	Sep 29, 2011

<u>AB</u>			<u>750MG</u>	<u>A090787</u>	<u>003</u>	Sep 29, 2011

<u>AB</u>		AUROBINDO PHARMA LTD	<u>250MG</u>	<u>A201043</u>	<u>001</u>	Jun 20, 2011

<u>AB</u>			<u>500MG</u>	<u>A201043</u>	<u>002</u>	Jun 20, 2011

<u>AB</u>	!		<u>750MG</u>	<u>A201043</u>	<u>003</u>	Jun 20, 2011

<u>AB</u>		CADILA	<u>250MG</u>	<u>A077652</u>	<u>001</u>	Sep 07, 2012

<u>AB</u>			<u>500MG</u>	<u>A077652</u>	<u>002</u>	Sep 07, 2012

<u>AB</u>			<u>750MG</u>	<u>A077652</u>	<u>003</u>	Sep 07, 2012

<u>AB</u>		CELLTRION	<u>250MG</u>	<u>A090367</u>	<u>001</u>	Jun 20, 2011

<u>AB</u>			<u>500MG</u>	<u>A090367</u>	<u>002</u>	Jun 20, 2011

<u>AB</u>			<u>750MG</u>	<u>A090367</u>	<u>003</u>	Jun 20, 2011

<u>AB</u>		CHARTWELL MOLECULAR	<u>250MG</u>	<u>A076890</u>	<u>001</u>	Mar 30, 2012

<u>AB</u>			<u>500MG</u>	<u>A076890</u>	<u>002</u>	Mar 30, 2012

<u>AB</u>			<u>750MG</u>	<u>A076890</u>	<u>003</u>	Mar 30, 2012

<u>AB</u>		DR REDDYS LABS INC	<u>250MG</u>	<u>A076710</u>	<u>001</u>	Jun 20, 2011

<u>AB</u>			<u>500MG</u>	<u>A076710</u>	<u>002</u>	Jun 20, 2011

<u>AB</u>			<u>750MG</u>	<u>A076710</u>	<u>003</u>	Jun 20, 2011

<u>AB</u>		GLENMARK GENERICS	<u>250MG</u>	<u>A200250</u>	<u>001</u>	Jun 20, 2011

<u>AB</u>			<u>500MG</u>	<u>A200250</u>	<u>002</u>	Jun 20, 2011

<u>AB</u>			<u>750MG</u>	<u>A200250</u>	<u>003</u>	Jun 20, 2011

<u>AB</u>		HEC PHARM	<u>250MG</u>	<u>A204968</u>	<u>001</u>	Feb 05, 2019

<u>AB</u>			<u>500MG</u>	<u>A204968</u>	<u>002</u>	Feb 05, 2019

<u>AB</u>			<u>750MG</u>	<u>A204968</u>	<u>003</u>	Feb 05, 2019

<u>AB</u>		HETERO LABS LTD V	<u>250MG</u>	<u>A202801</u>	<u>001</u>	Jan 08, 2015

<u>AB</u>			<u>500MG</u>	<u>A202801</u>	<u>002</u>	Jan 08, 2015

<u>AB</u>			<u>750MG</u>	<u>A202801</u>	<u>003</u>	Jan 08, 2015

<u>AB</u>		LUPIN	<u>250MG</u>	<u>A078424</u>	<u>001</u>	Jun 20, 2011

<u>AB</u>			<u>500MG</u>	<u>A078424</u>	<u>002</u>	Jun 20, 2011

<u>AB</u>			<u>750MG</u>	<u>A078424</u>	<u>003</u>	Jun 20, 2011

<u>AB</u>		MACLEODS PHARMS LTD	<u>250MG</u>	<u>A200839</u>	<u>001</u>	Mar 22, 2012

<u>AB</u>			<u>500MG</u>	<u>A200839</u>	<u>002</u>	Mar 22, 2012

<u>AB</u>			<u>750MG</u>	<u>A200839</u>	<u>003</u>	Mar 22, 2012

<u>AB</u>		ORBION PHARMS	<u>250MG</u>	<u>A202200</u>	<u>001</u>	Jan 30, 2012

<u>AB</u>			<u>500MG</u>	<u>A202200</u>	<u>002</u>	Jan 30, 2012

<u>AB</u>			<u>750MG</u>	<u>A202200</u>	<u>003</u>	Jan 30, 2012

<u>AB</u>		SANDOZ	<u>250MG</u>	<u>A077438</u>	<u>001</u>	Jun 20, 2011

<u>AB</u>			<u>500MG</u>	<u>A077438</u>	<u>002</u>	Jun 20, 2011

<u>AB</u>			<u>750MG</u>	<u>A077438</u>	<u>003</u>	Jun 20, 2011

<u>AB</u>		TEVA	<u>250MG</u>	<u>A076361</u>	<u>001</u>	Jun 20, 2011

<u>AB</u>			<u>500MG</u>	<u>A076361</u>	<u>002</u>	Jun 20, 2011

<u>AB</u>			<u>750MG</u>	<u>A076361</u>	<u>003</u>	Jun 20, 2011

LEVOKETOCONAZOLE

TABLET; ORAL

RECORLEV

+	!	STRONGBRIDGE	150MG	N214133	001	Dec 30, 2021

LEVOLEUCOVORIN

POWDER; INTRAVENOUS

KHAPZORY

+	!	ACROTECH BIOPHARMA	175MG/VIAL	N211226	001	Oct 19, 2018

+	!		300MG/VIAL	N211226	002	Oct 19, 2018

PRESCRIPTION DRUG PRODUCT LIST

3-271 (of 474)

LEVOLEUCOVORIN CALCIUM

POWDER; INTRAVENOUS

FUSILEV

AP	+!	ACROTECH BIOPHARMA	<u>EQ 50MG BASE/VIAL</u>	<u>N020140</u>	<u>001</u>	Mar 07, 2008

LEVOLEUCOVORIN CALCIUM

AP		MEITHEAL	<u>EQ 50MG BASE/VIAL</u>	<u>A211003</u>	<u>001</u>	Aug 22, 2019

SOLUTION; INTRAVENOUS

LEVOLEUCOVORIN CALCIUM

AP		AMNEAL	<u>EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)</u>	<u>A207548</u>	<u>001</u>	Sep 08, 2017

AP		GLAND PHARMA LTD	<u>EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)</u>	<u>A210892</u>	<u>001</u>	Sep 14, 2018

AP	!	MEITHEAL	<u>EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)</u>	<u>A211002</u>	<u>001</u>	Aug 16, 2019

AP		SANDOZ INC	<u>EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)</u>	<u>A203563</u>	<u>001</u>	Mar 09, 2015

!		GLAND PHARMA LTD	<u>EQ 250MG BASE/25ML (EQ 10MG BASE/ML)</u>	<u>A210892</u>	<u>002</u>	Sep 14, 2018

LEVOMILNACIPRAN HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

FETZIMA

AB	+	ALLERGAN	<u>EQ 20MG BASE</u>	<u>N204168</u>	<u>001</u>	Jul 25, 2013

AB	+		<u>EQ 40MG BASE</u>	<u>N204168</u>	<u>002</u>	Jul 25, 2013

AB	+		<u>EQ 80MG BASE</u>	<u>N204168</u>	<u>003</u>	Jul 25, 2013

AB	+!		<u>EQ 120MG BASE</u>	<u>N204168</u>	<u>004</u>	Jul 25, 2013

LEVOMILNACIPRAN HYDROCHLORIDE

AB		AUROBINDO PHARMA LTD	<u>EQ 20MG BASE</u>	<u>A210826</u>	<u>001</u>	Jan 06, 2023

AB			<u>EQ 40MG BASE</u>	<u>A210826</u>	<u>002</u>	Jan 06, 2023

AB			<u>EQ 80MG BASE</u>	<u>A210826</u>	<u>003</u>	Jan 06, 2023

AB			<u>EQ 120MG BASE</u>	<u>A210826</u>	<u>004</u>	Jan 06, 2023

LEVONORDEFIN; MEPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

SCANDONEST L

!	DEPROCO	0.05MG/ML; 2%	<u>A088388</u>	<u>001</u>	Oct 10, 1984

LEVONORGESTREL

INTRAUTERINE DEVICE; INTRAUTERINE

KYLEENA

+!	BAYER HLTHCARE	19.5MG	<u>N208224</u>	<u>001</u>	Sep 16, 2016

LILETTA

+!	MEDICINES360	52MG	<u>N206229</u>	<u>001</u>	Feb 26, 2015

MIRENA

+!	BAYER HLTHCARE	52MG	<u>N021225</u>	<u>001</u>	Dec 06, 2000

SKYLA

+!	BAYER HLTHCARE	13.5MG	<u>N203159</u>	<u>001</u>	Jan 09, 2013

LEVORPHANOL TARTRATE

TABLET; ORAL

LEVORPHANOL TARTRATE

AB		NOVITIUM PHARMA	<u>2MG</u>	<u>A213479</u>	<u>001</u>	Jul 01, 2020

AB		SPECGX LLC	<u>2MG</u>	<u>A212024</u>	<u>001</u>	Dec 13, 2019

AB		SUN PHARM INDS INC	<u>2MG</u>	<u>A213906</u>	<u>001</u>	Jun 17, 2021

AB		VIRTUS PHARMS	<u>2MG</u>	<u>A211484</u>	<u>001</u>	Dec 13, 2018

		NOVITIUM PHARMA	1MG	<u>A213479</u>	<u>003</u>	Jul 20, 2021

!			3MG	<u>A213479</u>	<u>002</u>	Jan 12, 2021

LEVOTHYROXINE SODIUM

CAPSULE; ORAL

LEVOTHYROXINE SODIUM

AB		TEVA PHARMS USA INC	<u>0.2MG</u>	<u>A211369</u>	<u>004</u>	Nov 09, 2022

TIROSINT

AB	+!	INSTITUT BIOCHIMIQUE	<u>0.2MG</u>	<u>N021924</u>	<u>012</u>	Apr 25, 2017

+			0.013MG	<u>N021924</u>	<u>013</u>	Aug 01, 2007

+			0.025MG	<u>N021924</u>	<u>002</u>	Oct 13, 2006

+			0.0375MG	<u>N021924</u>	<u>014</u>	Jun 22, 2022

+			0.044MG	<u>N021924</u>	<u>015</u>	Jun 22, 2022

+			0.05MG	<u>N021924</u>	<u>003</u>	Oct 13, 2006

+			0.0625MG	<u>N021924</u>	<u>016</u>	Jun 22, 2022

+			0.075MG	<u>N021924</u>	<u>004</u>	Oct 13, 2006

+			0.088MG	<u>N021924</u>	<u>010</u>	Oct 02, 2009

+			0.1MG	<u>N021924</u>	<u>005</u>	Oct 13, 2006

+			0.112MG	<u>N021924</u>	<u>008</u>	Oct 02, 2009

+			0.125MG	<u>N021924</u>	<u>006</u>	Oct 13, 2006

+			0.137MG	<u>N021924</u>	<u>009</u>	Oct 02, 2009

+			0.15MG	<u>N021924</u>	<u>007</u>	Oct 13, 2006

+			0.175MG	<u>N021924</u>	<u>011</u>	Apr 25, 2017

PRESCRIPTION DRUG PRODUCT LIST

3-272 (of 474)

LEVOTHYROXINE SODIUM

POWDER; INTRAVENOUS

LEVOTHYROXINE SODIUM

<u>AP</u>	+	FRESENIUS KABI USA	<u>100MCG/VIAL</u>	<u>N202231</u>	<u>001</u>	Jun 24, 2011
<u>AP</u>	+		<u>200MCG/VIAL</u>	<u>N202231</u>	<u>002</u>	Jun 24, 2011
<u>AP</u>	+		<u>500MCG/VIAL</u>	<u>N202231</u>	<u>003</u>	Jun 24, 2011
<u>AP</u>		MAIA PHARMS INC	<u>100MCG/VIAL</u>	<u>A208749</u>	<u>001</u>	Dec 21, 2018
<u>AP</u>			<u>200MCG/VIAL</u>	<u>A208749</u>	<u>002</u>	Dec 21, 2018
<u>AP</u>			<u>500MCG/VIAL</u>	<u>A208749</u>	<u>003</u>	Dec 21, 2018
<u>AP</u>		PIRAMAL CRITICAL	<u>100MCG/VIAL</u>	<u>A206163</u>	<u>001</u>	Jun 29, 2016
<u>AP</u>			<u>500MCG/VIAL</u>	<u>A206163</u>	<u>002</u>	Jun 29, 2016

SOLUTION; INTRAVENOUS

LEVOTHYROXINE SODIUM

+	FRESENIUS KABI USA	100MCG/5ML (20MCG/ML)	N210632	001	Apr 11, 2019
+		200MCG/5ML (40MCG/ML)	N210632	002	Apr 11, 2019
+		500MCG/5ML (100MCG/ML)	N210632	003	Apr 11, 2019
+	HIKMA	100MCG/ML	N214253	001	May 17, 2021

SOLUTION; ORAL

ERMEZA

+	MYLAN	150MCG/5ML	N215809	001	Apr 29, 2022

THYQUIDITY

+	AZURITY	100MCG/5ML	N214047	001	Nov 30, 2020

TIROSINT-SOL

+	INSTITUT BIOCHIMIQUE	13MCG/ML	N206977	001	Dec 15, 2016
+		25MCG/ML	N206977	002	Dec 15, 2016
+		37.5MCG/ML	N206977	013	Jan 13, 2021
+		44MCG/ML	N206977	014	Jan 13, 2021
+		50MCG/ML	N206977	003	Dec 15, 2016
+		62.5MCG/ML	N206977	015	Jan 13, 2021
+		75MCG/ML	N206977	004	Dec 15, 2016
+		88MCG/ML	N206977	005	Dec 15, 2016
+		100MCG/ML	N206977	006	Dec 15, 2016
+		112MCG/ML	N206977	007	Dec 15, 2016
+		125MCG/ML	N206977	008	Dec 15, 2016
+		137MCG/ML	N206977	009	Dec 15, 2016
+		150MCG/ML	N206977	010	Dec 15, 2016
+		175MCG/ML	N206977	011	Dec 15, 2016
+		200MCG/ML	N206977	012	Dec 15, 2016

LEVOTHYROXINE SODIUM **

**See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium

TABLET; ORAL

LEVOTHYROXINE SODIUM

-->	MACLEODS PHARMS LTD	--> <u>AB1,AB2</u>	<u>0.025MG</u>	A211417	001	Dec 21, 2022
-->		--> <u>AB1,AB2</u>	<u>0.05MG</u>	A211417	002	Dec 21, 2022
-->		--> <u>AB1,AB2</u>	<u>0.075MG</u>	A211417	003	Dec 21, 2022
-->		--> <u>AB1,AB2</u>	<u>0.088MG</u>	A211417	004	Dec 21, 2022
-->		--> <u>AB1,AB2</u>	<u>0.1MG</u>	A211417	005	Dec 21, 2022
-->		--> <u>AB1,AB2</u>	<u>0.112MG</u>	A211417	006	Dec 21, 2022
-->		--> <u>AB1,AB2</u>	<u>0.125MG</u>	A211417	007	Dec 21, 2022
-->		--> <u>AB1,AB2</u>	<u>0.137MG</u>	A211417	008	Dec 21, 2022
-->		--> <u>AB1,AB2</u>	<u>0.15MG</u>	A211417	009	Dec 21, 2022
-->		--> <u>AB1,AB2</u>	<u>0.175MG</u>	A211417	010	Dec 21, 2022
-->		--> <u>AB1,AB2</u>	<u>0.2MG</u>	A211417	011	Dec 21, 2022
-->		--> <u>AB1,AB2</u>	<u>0.3MG</u>	A211417	012	Dec 21, 2022

SYNTHROID

-->	+	ABBVIE	--> <u>AB1,AB2</u>	<u>0.025MG</u>	N021402	001	Jul 24, 2002
-->	+		--> <u>AB1,AB2</u>	<u>0.05MG</u>	N021402	002	Jul 24, 2002
-->	+		--> <u>AB1,AB2</u>	<u>0.075MG</u>	N021402	003	Jul 24, 2002
-->	+		--> <u>AB1,AB2</u>	<u>0.088MG</u>	N021402	004	Jul 24, 2002
-->	+		--> <u>AB1,AB2</u>	<u>0.1MG</u>	N021402	005	Jul 24, 2002
-->	+		--> <u>AB1,AB2</u>	<u>0.112MG</u>	N021402	006	Jul 24, 2002
-->	+		--> <u>AB1,AB2</u>	<u>0.125MG</u>	N021402	007	Jul 24, 2002
-->	+		--> <u>AB1,AB2</u>	<u>0.137MG</u>	N021402	008	Jul 24, 2002
-->	+		--> <u>AB1,AB2</u>	<u>0.15MG</u>	N021402	009	Jul 24, 2002
-->	+		--> <u>AB1,AB2</u>	<u>0.175MG</u>	N021402	010	Jul 24, 2002
-->	+		--> <u>AB1,AB2</u>	<u>0.2MG</u>	N021402	012	Jul 24, 2002
-->	+		--> <u>AB1,AB2</u>	<u>0.3MG</u>	N021402	011	Jul 24, 2002

LEVO-T

-->	CEDIPROF INC	--> <u>AB1,AB2,AB3</u>	<u>0.025MG</u>	N021342	001	Mar 01, 2002
-->		--> <u>AB1,AB2,</u>	<u>0.05MG</u>	N021342	002	Mar 01, 2002

PRESCRIPTION DRUG PRODUCT LIST

3-273 (of 474)

LEVOTHYROXINE SODIUM **

**See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium

TABLET; ORAL

LEVO-T

	<u>AB3</u>	<u>0.05MG</u>	
-->	--> <u>AB1,AB2,AB3</u>	<u>0.075MG</u>	N021342 003 Mar 01, 2002
-->	--> <u>AB1,AB2,AB3</u>	<u>0.088MG</u>	N021342 004 Mar 01, 2002
-->	--> <u>AB1,AB2,AB3</u>	<u>0.1MG</u>	N021342 005 Mar 01, 2002
-->	--> <u>AB1,AB2,AB3</u>	<u>0.112MG</u>	N021342 006 Mar 01, 2002
-->	--> <u>AB1,AB2,AB3</u>	<u>0.125MG</u>	N021342 007 Mar 01, 2002
-->	--> <u>AB1,AB2,AB3</u>	<u>0.137MG</u>	N021342 012 Dec 08, 2003
-->	--> <u>AB1,AB2,AB3</u>	<u>0.15MG</u>	N021342 008 Mar 01, 2002
-->	--> <u>AB1,AB2,AB3</u>	<u>0.175MG</u>	N021342 009 Mar 01, 2002
-->	--> <u>AB1,AB2,AB3</u>	<u>0.2MG</u>	N021342 010 Mar 01, 2002
-->	--> <u>AB1,AB2,AB3</u>	<u>0.3MG</u>	N021342 011 Mar 01, 2002

LEVOTHYROXINE SODIUM

-->	LUPIN	--> <u>AB1,AB2,AB3</u>	<u>0.025MG</u>	A209713 001 Jan 18, 2019
-->		--> <u>AB1,AB2,AB3</u>	<u>0.05MG</u>	A209713 002 Jan 18, 2019
-->		--> <u>AB1,AB2,AB3</u>	<u>0.075MG</u>	A209713 003 Jan 18, 2019
-->		--> <u>AB1,AB2,AB3</u>	<u>0.088MG</u>	A209713 004 Jan 18, 2019
-->		--> <u>AB1,AB2,AB3</u>	<u>0.1MG</u>	A209713 005 Jan 18, 2019
-->		--> <u>AB1,AB2,AB3</u>	<u>0.112MG</u>	A209713 006 Jan 18, 2019
-->		--> <u>AB1,AB2,AB3</u>	<u>0.125MG</u>	A209713 007 Jan 18, 2019
-->		--> <u>AB1,AB2,AB3</u>	<u>0.137MG</u>	A209713 008 Jan 18, 2019
-->		--> <u>AB1,AB2,AB3</u>	<u>0.15MG</u>	A209713 009 Jan 18, 2019
-->		--> <u>AB1,AB2,AB3</u>	<u>0.175MG</u>	A209713 010 Jan 18, 2019
-->		--> <u>AB1,AB2,AB3</u>	<u>0.2MG</u>	A209713 011 Jan 18, 2019
-->		--> <u>AB1,AB2,AB3</u>	<u>0.3MG</u>	A209713 012 Jan 18, 2019

UNITHROID

-->	+ STEVENS J	--> <u>AB1,AB2,AB3</u>	<u>0.025MG</u>	N021210 001 Aug 21, 2000
-->	+	--> <u>AB1,AB2,AB3</u>	<u>0.05MG</u>	N021210 002 Aug 21, 2000
-->	+	--> <u>AB1,AB2,AB3</u>	<u>0.075MG</u>	N021210 003 Aug 21, 2000
-->	+	--> <u>AB1,AB2,AB3</u>	<u>0.088MG</u>	N021210 004 Aug 21, 2000
-->	+	--> <u>AB1,AB2,AB3</u>	<u>0.1MG</u>	N021210 005 Aug 21, 2000
-->	+	--> <u>AB1,AB2,AB3</u>	<u>0.112MG</u>	N021210 006 Aug 21, 2000
-->	+	--> <u>AB1,AB2,AB3</u>	<u>0.125MG</u>	N021210 007 Aug 21, 2000
-->	+	--> <u>AB1,AB2,AB3</u>	<u>0.137MG</u>	N021210 012 Feb 08, 2008
-->	+	--> <u>AB1,AB2,AB3</u>	<u>0.15MG</u>	N021210 008 Aug 21, 2000
-->	+	--> <u>AB1,AB2,AB3</u>	<u>0.175MG</u>	N021210 009 Aug 21, 2000
-->	+	--> <u>AB1,AB2,AB3</u>	<u>0.2MG</u>	N021210 010 Aug 21, 2000
-->	+	--> <u>AB1,AB2,AB3</u>	<u>0.3MG</u>	N021210 011 Aug 21, 2000

LEVOLET

-->	GENUS LIFESCIENCES	-->	<u>0.025MG</u>	N021137 001 Jun 06, 2003
-->		<u>AB1,AB2,AB3,AB4</u>		
-->		--> <u>AB1,AB2,</u>	<u>0.05MG</u>	N021137 002 Jun 06, 2003

PRESCRIPTION DRUG PRODUCT LIST

3-274 (of 474)

LEVOTHYROXINE SODIUM **

**See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium

TABLET;ORAL

LEVOLET

	<u>AB3,AB4</u>	<u>0.05MG</u>	
-->	-->	<u>0.075MG</u>	N021137 003 Jun 06, 2003
	<u>AB1,AB2,AB3,AB4</u>		
-->	-->	<u>0.088MG</u>	N021137 004 Jun 06, 2003
	<u>AB1,AB2,AB3,AB4</u>		
-->	-->	<u>0.1MG</u>	N021137 005 Jun 06, 2003
	<u>AB1,AB2,AB3,AB4</u>		
-->	-->	<u>0.112MG</u>	N021137 006 Jun 06, 2003
	<u>AB1,AB2,AB3,AB4</u>		
-->	-->	<u>0.125MG</u>	N021137 007 Jun 06, 2003
	<u>AB1,AB2,AB3,AB4</u>		
-->	-->	<u>0.137MG</u>	N021137 008 Jun 06, 2003
	<u>AB1,AB2,AB3,AB4</u>		
-->	-->	<u>0.15MG</u>	N021137 009 Jun 06, 2003
	<u>AB1,AB2,AB3,AB4</u>		
-->	-->	<u>0.175MG</u>	N021137 010 Jun 06, 2003
	<u>AB1,AB2,AB3,AB4</u>		
-->	-->	<u>0.2MG</u>	N021137 011 Jun 06, 2003
	<u>AB1,AB2,AB3,AB4</u>		
-->	-->	<u>0.3MG</u>	N021137 012 Jun 06, 2003
	<u>AB1,AB2,AB3,AB4</u>		

LEVOTHYROXINE SODIUM

-->	ACCORD HLTHCARE	-->	<u>0.025MG</u>	A212399 001 Oct 19, 2020
		-->	<u>AB1,AB2,AB3,AB4</u>	
-->		-->	<u>0.05MG</u>	A212399 002 Oct 19, 2020
		-->	<u>AB1,AB2,AB3,AB4</u>	
-->		-->	<u>0.075MG</u>	A212399 003 Oct 19, 2020
		-->	<u>AB1,AB2,AB3,AB4</u>	
-->		-->	<u>0.088MG</u>	A212399 004 Oct 19, 2020
		-->	<u>AB1,AB2,AB3,AB4</u>	
-->		-->	<u>0.1MG</u>	A212399 005 Oct 19, 2020
		-->	<u>AB1,AB2,AB3,AB4</u>	
-->		-->	<u>0.112MG</u>	A212399 006 Oct 19, 2020
		-->	<u>AB1,AB2,AB3,AB4</u>	
-->		-->	<u>0.125MG</u>	A212399 007 Oct 19, 2020
		-->	<u>AB1,AB2,AB3,AB4</u>	
-->		-->	<u>0.137MG</u>	A212399 008 Oct 19, 2020
		-->	<u>AB1,AB2,AB3,AB4</u>	
-->		-->	<u>0.15MG</u>	A212399 009 Oct 19, 2020
		-->	<u>AB1,AB2,AB3,AB4</u>	
-->		-->	<u>0.175MG</u>	A212399 010 Oct 19, 2020
		-->	<u>AB1,AB2,AB3,AB4</u>	
-->		-->	<u>0.2MG</u>	A212399 011 Oct 19, 2020
		-->	<u>AB1,AB2,AB3,AB4</u>	
-->		-->	<u>0.3MG</u>	A212399 012 Oct 19, 2020
		-->	<u>AB1,AB2,AB3,AB4</u>	
-->	MYLAN	-->	<u>0.025MG</u>	A076187 001 Jun 05, 2002
		-->	<u>AB1,AB2,AB3,AB4</u>	
-->		-->	<u>0.05MG</u>	A076187 002 Jun 05, 2002
		-->	<u>AB1,AB2,AB3,AB4</u>	
-->		-->	<u>0.075MG</u>	A076187 003 Jun 05, 2002
		-->	<u>AB1,AB2,AB3,AB4</u>	
-->		-->	<u>0.088MG</u>	A076187 004 Jun 05, 2002
		-->	<u>AB1,AB2,AB3,AB4</u>	
-->		-->	<u>0.1MG</u>	A076187 005 Jun 05, 2002
		-->	<u>AB1,AB2,AB3,AB4</u>	
-->		-->	<u>0.112MG</u>	A076187 006 Jun 05, 2002
		-->	<u>AB1,AB2,AB3,AB4</u>	
-->		-->	<u>0.125MG</u>	A076187 007 Jun 05, 2002
		-->	<u>AB1,AB2,AB3,AB4</u>	
-->		-->	<u>0.137MG</u>	A076187 012 Dec 13, 2006
		-->	<u>AB1,AB2,AB3,AB4</u>	
-->		-->	<u>0.15MG</u>	A076187 008 Jun 05, 2002
		-->	<u>AB1,AB2,AB3,AB4</u>	
-->		-->	<u>0.175MG</u>	A076187 009 Jun 05, 2002
		-->	<u>AB1,AB2,AB3,AB4</u>	
-->		-->	<u>0.2MG</u>	A076187 010 Jun 05, 2002
		-->	<u>AB1,AB2,AB3,AB4</u>	
-->	!	-->	<u>0.3MG</u>	A076187 011 Jun 05, 2002
		-->	<u>AB1,AB2,AB3,AB4</u>	

THYRO-TABS

-->	+	ALVOGEN	-->	<u>0.025MG</u>	N021116 001 Oct 24, 2002
			-->	<u>AB1,AB2,AB3,AB4</u>	
-->	+		-->	<u>0.05MG</u>	N021116 002 Oct 24, 2002
			-->	<u>AB1,AB2,AB3,AB4</u>	
-->	+		-->	<u>AB1,AB2,</u>	<u>0.075MG</u>
					N021116 003 Oct 24, 2002

PRESCRIPTION DRUG PRODUCT LIST

3-275 (of 474)

LEVOTHYROXINE SODIUM **

**See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium

TABLET; ORAL

THYRO-TABS

		<u>AB3, AB4</u>	<u>0.075MG</u>				
-->	+	-->	<u>0.088MG</u>	N021116	010	Oct 24, 2002	
		<u>AB1, AB2, AB3, AB4</u>					
-->	+	-->	<u>0.1MG</u>	N021116	004	Oct 24, 2002	
		<u>AB1, AB2, AB3, AB4</u>					
-->	+	-->	<u>0.112MG</u>	N021116	011	Oct 24, 2002	
		<u>AB1, AB2, AB3, AB4</u>					
-->	+	-->	<u>0.125MG</u>	N021116	005	Oct 24, 2002	
		<u>AB1, AB2, AB3, AB4</u>					
-->	+	-->	<u>0.137MG</u>	N021116	012	Dec 07, 2004	
		<u>AB1, AB2, AB3, AB4</u>					
-->	+	-->	<u>0.15MG</u>	N021116	006	Oct 24, 2002	
		<u>AB1, AB2, AB3, AB4</u>					
-->	+	-->	<u>0.175MG</u>	N021116	007	Oct 24, 2002	
		<u>AB1, AB2, AB3, AB4</u>					
-->	+	-->	<u>0.2MG</u>	N021116	008	Oct 24, 2002	
		<u>AB1, AB2, AB3, AB4</u>					
-->	+	-->	<u>0.3MG</u>	N021116	009	Oct 24, 2002	
		<u>AB1, AB2, AB3, AB4</u>					

LEVOXYL

-->	+	KING PHARMS	--> <u>AB1, AB3</u>	<u>0.025MG</u>	N021301	001	May 25, 2001
-->	+		--> <u>AB1, AB3</u>	<u>0.05MG</u>	N021301	002	May 25, 2001
-->	+		--> <u>AB1, AB3</u>	<u>0.075MG</u>	N021301	003	May 25, 2001
-->	+		--> <u>AB1, AB3</u>	<u>0.088MG</u>	N021301	004	May 25, 2001
-->	+		--> <u>AB1, AB3</u>	<u>0.1MG</u>	N021301	005	May 25, 2001
-->	+		--> <u>AB1, AB3</u>	<u>0.112MG</u>	N021301	006	May 25, 2001
-->	+		--> <u>AB1, AB3</u>	<u>0.125MG</u>	N021301	007	May 25, 2001
-->	+		--> <u>AB1, AB3</u>	<u>0.137MG</u>	N021301	008	May 25, 2001
-->	+		--> <u>AB1, AB3</u>	<u>0.15MG</u>	N021301	009	May 25, 2001
-->	+		--> <u>AB1, AB3</u>	<u>0.175MG</u>	N021301	010	May 25, 2001
-->	+		--> <u>AB1, AB3</u>	<u>0.2MG</u>	N021301	011	May 25, 2001

EUTHYROX

<u>AB2</u>	PROVELL	<u>0.025MG</u>	<u>N021292 001</u>	May 31, 2002		
<u>AB2</u>		<u>0.05MG</u>	<u>N021292 002</u>	May 31, 2002		
<u>AB2</u>		<u>0.075MG</u>	<u>N021292 003</u>	May 31, 2002		
<u>AB2</u>		<u>0.088MG</u>	<u>N021292 004</u>	May 31, 2002		
<u>AB2</u>		<u>0.1MG</u>	<u>N021292 005</u>	May 31, 2002		
<u>AB2</u>		<u>0.112MG</u>	<u>N021292 006</u>	May 31, 2002		
<u>AB2</u>		<u>0.125MG</u>	<u>N021292 007</u>	May 31, 2002		
<u>AB2</u>		<u>0.137MG</u>	<u>N021292 008</u>	May 31, 2002		
<u>AB2</u>		<u>0.15MG</u>	<u>N021292 009</u>	May 31, 2002		
<u>AB2</u>		<u>0.175MG</u>	<u>N021292 010</u>	May 31, 2002		
<u>AB2</u>		<u>0.2MG</u>	<u>N021292 011</u>	May 31, 2002		

LEVOTHYROXINE SODIUM

<u>AB2</u>	WATSON LABS TEVA	<u>0.025MG</u>	<u>A207588 001</u>	May 10, 2022		
<u>AB2</u>		<u>0.05MG</u>	<u>A207588 002</u>	May 10, 2022		
<u>AB2</u>		<u>0.075MG</u>	<u>A207588 003</u>	May 10, 2022		
<u>AB2</u>		<u>0.088MG</u>	<u>A207588 004</u>	May 10, 2022		
<u>AB2</u>		<u>0.1MG</u>	<u>A207588 005</u>	May 10, 2022		
<u>AB2</u>		<u>0.112MG</u>	<u>A207588 006</u>	May 10, 2022		
<u>AB2</u>		<u>0.125MG</u>	<u>A207588 007</u>	May 10, 2022		
<u>AB2</u>		<u>0.137MG</u>	<u>A207588 008</u>	May 10, 2022		
<u>AB2</u>		<u>0.15MG</u>	<u>A207588 009</u>	May 10, 2022		
<u>AB2</u>		<u>0.175MG</u>	<u>A207588 010</u>	May 10, 2022		
<u>AB2</u>		<u>0.2MG</u>	<u>A207588 011</u>	May 10, 2022		
<u>AB2</u>		<u>0.3MG</u>	<u>A207588 012</u>	May 10, 2022		

LIDOCAINE

OINTMENT; TOPICAL

LIDOCAINE

<u>AT</u>	ALEOR	<u>5%</u>	<u>A211469 001</u>	Nov 23, 2018		
	DERMACEUTICALS					
<u>AT</u>	ALKEM LABS LTD	<u>5%</u>	<u>A207810 001</u>	Mar 10, 2017		
<u>AT</u>	AMNEAL PHARMS	<u>5%</u>	<u>A206297 001</u>	Aug 07, 2015		
<u>AT</u>	COSETTE	<u>5%</u>	<u>A211019 001</u>	Dec 12, 2018		
<u>AT</u>	DR REDDYS	<u>5%</u>	<u>A208660 001</u>	Jan 05, 2021		
<u>AT</u>	+! FOUGERA PHARMS INC	<u>5%</u>	<u>A080198 001</u>			
<u>AT</u>	GLENMARK PHARMS LTD	<u>5%</u>	<u>A206498 001</u>	Sep 09, 2016		
<u>AT</u>	MACLEODS PHARMS LTD	<u>5%</u>	<u>A211697 001</u>	Mar 16, 2020		
<u>AT</u>	PAI HOLDINGS PHARM	<u>5%</u>	<u>A205318 001</u>	Feb 01, 2016		
<u>AT</u>	QUAGEN	<u>5%</u>	<u>A212695 001</u>	Apr 20, 2021		

PRESCRIPTION DRUG PRODUCT LIST

3-276 (of 474)

LIDOCAINE

OINTMENT; TOPICAL

LIDOCAINE

<u>AT</u>	SEPTODONT INC	<u>5%</u>	<u>A040911</u>	<u>001</u>	May 23, 2011
<u>AT</u>	STRIDES PHARMA	<u>5%</u>	<u>A210958</u>	<u>001</u>	Dec 11, 2018
<u>AT</u>	TARO	<u>5%</u>	<u>A086724</u>	<u>001</u>	
<u>AT</u>	VITRUVIAS THERAP	<u>5%</u>	<u>A208822</u>	<u>001</u>	Sep 25, 2017

PATCH; TOPICAL

LIDOCAINE

<u>AB</u>	ACTAVIS LABS UT INC	<u>5%</u>	<u>A200675</u>	<u>001</u>	Aug 23, 2012
<u>AB</u>	AMNEAL	<u>5%</u>	<u>A206463</u>	<u>001</u>	Aug 24, 2020
<u>AB</u>	MYLAN TECHNOLOGIES	<u>5%</u>	<u>A202346</u>	<u>001</u>	Aug 07, 2015
<u>AB</u>	NAL PHARM	<u>5%</u>	<u>A205882</u>	<u>001</u>	Apr 29, 2021
<u>AB</u>	RHODES PHARMS	<u>5%</u>	<u>A209190</u>	<u>001</u>	Apr 30, 2020

LIDODERM

<u>AB</u>	<u>+</u> !	TEIKOKU PHARMA USA	<u>5%</u>	<u>N020612</u>	<u>001</u>	Mar 19, 1999
	ZTLIDO					
	<u>+</u> !	SCILEX PHARMS	1.8%	N207962	001	Feb 28, 2018

LIDOCAINE HYDROCHLORIDE

GEL; OPHTHALMIC

AKTEN

<u>+</u> !	THEA PHARMA	3.5%	N022221	001	Oct 07, 2008

INJECTABLE; INJECTION

LIDOCAINE HYDROCHLORIDE

<u>AP</u>	AFAXYS	<u>1%</u>	<u>A215132</u>	<u>001</u>	Jun 09, 2022
<u>AP</u>	ASPIRO	<u>1%</u>	<u>A214336</u>	<u>001</u>	Nov 08, 2021
<u>AP</u>		<u>1%</u>	<u>A214339</u>	<u>001</u>	Nov 08, 2021
<u>AP</u>		<u>2%</u>	<u>A214339</u>	<u>002</u>	Nov 08, 2021
<u>AP</u>	B BRAUN MEDICAL INC	<u>1%</u>	<u>A208474</u>	<u>001</u>	Aug 03, 2018
<u>AP</u>	EUGIA PHARMA	<u>1%</u>	<u>A207182</u>	<u>001</u>	Oct 30, 2017
<u>AP</u>		<u>2%</u>	<u>A207182</u>	<u>002</u>	Oct 30, 2017
<u>AP</u>	FRESENIUS KABI USA	<u>1%</u>	<u>A080404</u>	<u>002</u>	
<u>AP</u>		<u>2%</u>	<u>A080404</u>	<u>003</u>	
<u>AP</u>	HOSPIRA	<u>0.5%</u>	<u>A088328</u>	<u>001</u>	May 17, 1984
<u>AP</u>	!	<u>1%</u>	<u>A083158</u>	<u>001</u>	
<u>AP</u>		<u>1%</u>	<u>A088329</u>	<u>001</u>	May 17, 1984
<u>AP</u>		<u>2%</u>	<u>A040078</u>	<u>001</u>	Jun 23, 1995
<u>AP</u>	!	<u>2%</u>	<u>A083158</u>	<u>002</u>	
<u>AP</u>		<u>2%</u>	<u>A088294</u>	<u>001</u>	May 17, 1984
<u>AP</u>	HUONS	<u>1%</u>	<u>A212821</u>	<u>001</u>	May 07, 2020
<u>AP</u>	INTL MEDICATION	<u>1%</u>	<u>A083173</u>	<u>001</u>	
<u>AP</u>		<u>2%</u>	<u>A083173</u>	<u>002</u>	
<u>AP</u>	SINTETICA US	<u>1%</u>	<u>A214267</u>	<u>001</u>	Sep 19, 2022
<u>AP</u>		<u>2%</u>	<u>A214267</u>	<u>002</u>	Sep 19, 2022
<u>AP</u>		<u>4%</u>	<u>A214269</u>	<u>001</u>	May 05, 2022
<u>AP</u>	SPECTRA MDCL	<u>1%</u>	<u>A208017</u>	<u>001</u>	Apr 18, 2018
	DEVICES				
<u>AP</u>	WEST-WARD PHARMS	<u>1%</u>	<u>A080407</u>	<u>001</u>	
	INT				
<u>AP</u>		<u>2%</u>	<u>A080407</u>	<u>002</u>	

LIDOCAINE HYDROCHLORIDE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>	B BRAUN	<u>200MG/100ML</u>	<u>N019830</u>	<u>002</u>	Apr 08, 1992
<u>AP</u>	BAXTER HLTHCARE	<u>200MG/100ML</u>	<u>N018461</u>	<u>002</u>	

LIDOCAINE HYDROCHLORIDE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>	B BRAUN	<u>400MG/100ML</u>	<u>N019830</u>	<u>003</u>	Apr 08, 1992
<u>AP</u>	BAXTER HLTHCARE	<u>400MG/100ML</u>	<u>N018461</u>	<u>003</u>	

LIDOCAINE HYDROCHLORIDE 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER

<u>AP</u>	B BRAUN	<u>800MG/100ML</u>	<u>N019830</u>	<u>004</u>	Apr 08, 1992
<u>AP</u>	BAXTER HLTHCARE	<u>800MG/100ML</u>	<u>N018461</u>	<u>004</u>	Feb 22, 1982

LIDOCAINE HYDROCHLORIDE IN PLASTIC CONTAINER

<u>AP</u>	FRESENIUS KABI USA	<u>1%</u>	<u>A088586</u>	<u>001</u>	Jul 24, 1985
<u>AP</u>	HOSPIRA	<u>0.5%</u>	<u>A088325</u>	<u>001</u>	Jul 31, 1984
<u>AP</u>		<u>1%</u>	<u>A088299</u>	<u>001</u>	Jul 31, 1984
<u>AP</u>		<u>2%</u>	<u>A088327</u>	<u>001</u>	Jul 31, 1984

LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE

<u>AP</u>	EUGIA PHARMA	<u>1%</u>	<u>A203040</u>	<u>001</u>	Mar 14, 2013
<u>AP</u>		<u>1%</u>	<u>A203082</u>	<u>001</u>	Mar 14, 2013
<u>AP</u>		<u>2%</u>	<u>A203040</u>	<u>002</u>	Mar 14, 2013
<u>AP</u>		<u>2%</u>	<u>A203082</u>	<u>002</u>	Mar 14, 2013
<u>AP</u>	FRESENIUS KABI USA	<u>2%</u>	<u>N017584</u>	<u>001</u>	
<u>AP</u>		<u>4%</u>	<u>N017584</u>	<u>002</u>	
<u>AP</u>	HOSPIRA	<u>1%</u>	<u>A080408</u>	<u>001</u>	

PRESCRIPTION DRUG PRODUCT LIST

3-277 (of 474)

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE

<u>AP</u>		<u>1.5%</u>	<u>A080408</u>	<u>002</u>	
<u>AP</u>	!	<u>4%</u>	<u>A088295</u>	<u>001</u>	May 17, 1984
<u>AP</u>	WEST-WARD PHARMS	<u>1%</u>	<u>A084625</u>	<u>001</u>	
	INT				

<u>AP</u>		<u>2%</u>	<u>A084625</u>	<u>002</u>	

LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE IN PLASTIC CONTAINER

<u>AP</u>	HOSPIRA	<u>1%</u>	<u>A040302</u>	<u>001</u>	Sep 28, 1998
<u>AP</u>		<u>2%</u>	<u>A040302</u>	<u>002</u>	Sep 28, 1998

XYLOCAINE

<u>AP</u>	+!	FRESENIUS KABI USA	<u>0.5%</u>	<u>N006488</u>	<u>008</u>
<u>AP</u>	+!		<u>1%</u>	<u>N006488</u>	<u>007</u>
<u>AP</u>	+!		<u>1.5%</u>	<u>N006488</u>	<u>010</u>
<u>AP</u>	+!		<u>2%</u>	<u>N006488</u>	<u>002</u>

INJECTABLE; SPINAL

LIDOCAINE HYDROCHLORIDE 5% AND DEXTROSE 7.5%

+!	HOSPIRA	5%	A083914	001	

JELLY; TOPICAL

GLYDO

<u>AT</u>	SAGENT PHARMS INC	<u>2%</u>	<u>A201094</u>	<u>001</u>	Apr 28, 2014

LIDOCAINE HYDROCHLORIDE

<u>AT</u>	!	AKORN	<u>2%</u>	<u>A040433</u>	<u>001</u>	Feb 12, 2003
<u>AT</u>		INTL MEDICATION	<u>2%</u>	<u>A086283</u>	<u>001</u>	

SOLUTION; ORAL

LIDOCAINE HYDROCHLORIDE

<u>AT</u>	!	AKORN	<u>2%</u>	<u>A040014</u>	<u>001</u>	Jul 10, 1995
<u>AT</u>		WOCKHARDT BIO AG	<u>2%</u>	<u>A087872</u>	<u>001</u>	Nov 18, 1982

LIDOCAINE HYDROCHLORIDE VISCOUS

<u>AT</u>		LANNETT CO INC	<u>2%</u>	<u>A040708</u>	<u>001</u>	Feb 27, 2007

LIDOCAINE VISCOUS

<u>AT</u>		HIKMA	<u>2%</u>	<u>A088802</u>	<u>001</u>	Apr 26, 1985

SOLUTION; TOPICAL

LARYNG-O-JET KIT

<u>AT</u>		INTL MEDICATION	<u>4%</u>	<u>A086364</u>	<u>001</u>	

LIDOCAINE HYDROCHLORIDE

<u>AT</u>	!	HIKMA	<u>4%</u>	<u>A088803</u>	<u>001</u>	Apr 03, 1985
<u>AT</u>		LANNETT CO INC	<u>4%</u>	<u>A040710</u>	<u>001</u>	Feb 27, 2007
<u>AT</u>		NOVITIUM PHARMA	<u>4%</u>	<u>A216250</u>	<u>001</u>	Mar 23, 2022
<u>AT</u>		PAI HOLDINGS PHARM	<u>4%</u>	<u>A204494</u>	<u>001</u>	Mar 12, 2014
<u>AT</u>		WOCKHARDT BIO AG	<u>4%</u>	<u>A087881</u>	<u>001</u>	Nov 18, 1982

SYSTEM; INTRADERMAL

ZINGO

POWDER PHARMS	0.5MG	N022114	001	Aug 16, 2007	

LIDOCAINE; PRILOCAINE

CREAM; TOPICAL

LIDOCAINE AND PRILOCAINE

<u>AB</u>	!	AKORN	<u>2.5%; 2.5%</u>	<u>A076290</u>	<u>001</u>	Sep 25, 2003
<u>AB</u>		ALEOR	<u>2.5%; 2.5%</u>	<u>A213923</u>	<u>001</u>	Apr 08, 2022
		DERMACEUTICALS				
<u>AB</u>		ENCUBE	<u>2.5%; 2.5%</u>	<u>A076320</u>	<u>001</u>	Aug 27, 2003
<u>AB</u>		FOUGERA PHARMS	<u>2.5%; 2.5%</u>	<u>A076453</u>	<u>001</u>	Aug 18, 2003
<u>AB</u>		PADAGIS US	<u>2.5%; 2.5%</u>	<u>A212482</u>	<u>001</u>	Jul 27, 2021
<u>AB</u>		PAI HOLDINGS PHARM	<u>2.5%; 2.5%</u>	<u>A205887</u>	<u>001</u>	Jun 29, 2018

GEL; PERIODONTAL

ORAQIX

+!	DENTSPLY PHARM	2.5%; 2.5%	N021451	001	Dec 19, 2003

LIDOCAINE; TETRACAINE

CREAM; TOPICAL

PLIAGLIS

+!	TARO PHARMS	7%; 7%	N021717	001	Jun 29, 2006

LIFITEGRAST

SOLUTION/DROPS; OPHTHALMIC

XIIDRA

+!	NOVARTIS	5%	N208073	001	Jul 11, 2016

PRESCRIPTION DRUG PRODUCT LIST

3-278 (of 474)

LINACLOTIDE

CAPSULE; ORAL

LINZESS

+! ALLERGAN

72MCG

N202811 003 Jan 25, 2017

+!

145MCG

N202811 001 Aug 30, 2012

+

290MCG

N202811 002 Aug 30, 2012

LINAGLIPTIN

TABLET; ORAL

LINAGLIPTINAB SUNSHINE5MGA208335 001 Aug 31, 2021TRADJENTAAB +! BOEHRINGER
INGELHEIM5MGN201280 001 May 02, 2011LINAGLIPTIN; METFORMIN HYDROCHLORIDE

TABLET; ORAL

JENTADUETOAB + BOEHRINGER
INGELHEIM2.5MG; 500MGN201281 001 Jan 30, 2012AB +2.5MG; 850MGN201281 002 Jan 30, 2012AB +!2.5MG; 1GMN201281 003 Jan 30, 2012LINAGLIPTIN AND METFORMIN HYDROCHLORIDEAB SUNSHINE2.5MG; 500MGA208336 001 Aug 30, 2021AB2.5MG; 850MGA208336 002 Aug 30, 2021AB2.5MG; 1GMA208336 003 Aug 30, 2021

TABLET, EXTENDED RELEASE; ORAL

JENTADUETO XR

+ BOEHRINGER
INGELHEIM

2.5MG; 1GM

N208026 001 May 27, 2016

+!

5MG; 1GM

N208026 002 May 27, 2016

LINCOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION

LINCOCINAP +! PFIZEREQ 300MG BASE/MLN050317 001LINCOMYCIN HYDROCHLORIDEAP GLAND PHARMA LTDEQ 300MG BASE/MLA215657 001 Sep 26, 2022AP HAINAN POLYEQ 300MG BASE/MLA216662 001 Dec 21, 2022AP MICRO LABSEQ 300MG BASE/MLA215082 001 Nov 08, 2021AP XGEN PHARMSEQ 300MG BASE/MLA201746 001 Jun 04, 2015LINEZOLID

FOR SUSPENSION; ORAL

LINEZOLIDAB HETERO LABS100MG/5MLA211813 001 Oct 31, 2022AB HIKMA100MG/5MLA200068 001 Jun 03, 2015ZYVOXAB +! PFIZER100MG/5MLN021132 001 Apr 18, 2000

SOLUTION; INTRAVENOUS

LINEZOLIDAP EUGIA PHARMA600MG/300ML (2MG/ML)A206917 001 Aug 04, 2016AP FRESENIUS KABI USA600MG/300ML (2MG/ML)A204764 001 Mar 15, 2016AP HIKMA600MG/300ML (2MG/ML)A206454 001 Aug 22, 2022AP HQ SPCLT PHARMA200MG/100ML (2MG/ML)A207001 001 Jul 07, 2017AP600MG/300ML (2MG/ML)A207001 002 Jul 07, 2017AP MYLAN LABS LTD200MG/100ML (2MG/ML)A205154 001 Dec 06, 2017AP600MG/300ML (2MG/ML)A205154 002 Dec 06, 2017AP NANG KUANG PHARM CO200MG/100ML (2MG/ML)A207354 001 Dec 20, 2016AP600MG/300ML (2MG/ML)A207354 002 Dec 20, 2016AP SAGENT PHARMS INC200MG/100ML (2MG/ML)A204696 001 Mar 02, 2017AP600MG/300ML (2MG/ML)A204696 002 Mar 02, 2017AP SANDOZ INC200MG/100ML (2MG/ML)A200904 001 Jul 16, 2015AP600MG/300ML (2MG/ML)A200904 002 Jul 16, 2015ZYVOXAP + PFIZER200MG/100ML (2MG/ML)N021131 001 Apr 18, 2000AP +!600MG/300ML (2MG/ML)N021131 003 Apr 18, 2000

LINEZOLID IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

+! HOSPIRA

600MG/300ML (2MG/ML)

N206473 001 Jun 18, 2015

TABLET; ORAL

LINEZOLIDAB ALEMBIC PHARMS600MGA205233 001 Dec 21, 2015AB ALKEM LABS LTD600MGA205517 001 Dec 21, 2015AB CELLTRION600MGA210702 001 Apr 25, 2019AB GLENMARK PHARMS600MGA078987 001 Dec 21, 2015

PRESCRIPTION DRUG PRODUCT LIST

3-279 (of 474)

LINEZOLID

TABLET; ORAL

LINEZOLID

<u>AB</u>	HETERO LABS LTD V	<u>600MG</u>	<u>A204239</u>	<u>001</u>	Dec 21, 2015
<u>AB</u>	NOVEL LABS INC	<u>600MG</u>	<u>A207526</u>	<u>001</u>	Aug 22, 2016
<u>AB</u>	ZYDUS PHARMS	<u>600MG</u>	<u>A206097</u>	<u>001</u>	Feb 22, 2017

ZYVOX

<u>AB</u>	+! PFIZER	<u>600MG</u>	<u>N021130</u>	<u>002</u>	Apr 18, 2000

LIOTHYRONINE SODIUM

INJECTABLE; INJECTION

LIOTHYRONINE SODIUM

<u>AP</u>	XGEN PHARMS	<u>EQ 0.01MG BASE/ML</u>	<u>A076923</u>	<u>001</u>	Aug 17, 2005

TRIOSTAT

<u>AP</u>	+! PAR STERILE PRODUCTS	<u>EQ 0.01MG BASE/ML</u>	<u>N020105</u>	<u>001</u>	Dec 31, 1991

TABLET; ORAL

CYTOMEL

<u>AB</u>	+	KING PHARMS	<u>EQ 0.005MG BASE</u>	<u>N010379</u>	<u>001</u>
<u>AB</u>	+		<u>EQ 0.025MG BASE</u>	<u>N010379</u>	<u>002</u>
<u>AB</u>	+		<u>EQ 0.05MG BASE</u>	<u>N010379</u>	<u>003</u>

LIOTHYRONINE SODIUM

<u>AB</u>		MAYNE PHARMA INC	<u>EQ 0.005MG BASE</u>	<u>A090097</u>	<u>001</u>	Mar 20, 2009
<u>AB</u>			<u>EQ 0.025MG BASE</u>	<u>A090097</u>	<u>002</u>	Mar 20, 2009
<u>AB</u>			<u>EQ 0.05MG BASE</u>	<u>A090097</u>	<u>003</u>	Mar 20, 2009
<u>AB</u>		SIGMAPHARM LABS LLC	<u>EQ 0.005MG BASE</u>	<u>A200295</u>	<u>001</u>	Nov 29, 2012
<u>AB</u>			<u>EQ 0.025MG BASE</u>	<u>A200295</u>	<u>002</u>	Nov 29, 2012
<u>AB</u>	!		<u>EQ 0.05MG BASE</u>	<u>A200295</u>	<u>003</u>	Nov 29, 2012
<u>AB</u>		SUN PHARM	<u>EQ 0.005MG BASE</u>	<u>A091382</u>	<u>001</u>	Apr 20, 2016
<u>AB</u>			<u>EQ 0.025MG BASE</u>	<u>A091382</u>	<u>002</u>	Apr 20, 2016
<u>AB</u>			<u>EQ 0.05MG BASE</u>	<u>A091382</u>	<u>003</u>	Apr 20, 2016
<u>AB</u>		TEVA PHARMS USA	<u>EQ 0.005MG BASE</u>	<u>A211510</u>	<u>001</u>	Oct 26, 2018
<u>AB</u>			<u>EQ 0.025MG BASE</u>	<u>A211510</u>	<u>002</u>	Oct 26, 2018
<u>AB</u>			<u>EQ 0.05MG BASE</u>	<u>A211510</u>	<u>003</u>	Oct 26, 2018
<u>AB</u>		ZYDUS	<u>EQ 0.005MG BASE</u>	<u>A214803</u>	<u>001</u>	Jan 22, 2021
<u>AB</u>			<u>EQ 0.025MG BASE</u>	<u>A214803</u>	<u>002</u>	Jan 22, 2021
<u>AB</u>			<u>EQ 0.05MG BASE</u>	<u>A214803</u>	<u>003</u>	Jan 22, 2021

LIRAGLUTIDE RECOMBINANT

SOLUTION; SUBCUTANEOUS

SAXENDA

	+! NOVO	18MG/3ML (6MG/ML)	N206321	001	Dec 23, 2014

VICTOZA

	+! NOVO NORDISK INC	18MG/3ML (6MG/ML)	N022341	001	Jan 25, 2010

LISDEXAMFETAMINE DIMESYLATE

CAPSULE; ORAL

VYVANSE

+	TAKEDA PHARMS USA	10MG	N021977	007	Oct 30, 2014
+		20MG	N021977	004	Dec 10, 2007
+		30MG	N021977	001	Feb 23, 2007
+		40MG	N021977	005	Dec 10, 2007
+		50MG	N021977	002	Feb 23, 2007
+		60MG	N021977	006	Dec 10, 2007
+		70MG	N021977	003	Feb 23, 2007

TABLET, CHEWABLE; ORAL

VYVANSE

+	TAKEDA PHARMS USA	10MG	N208510	001	Jan 28, 2017
+		20MG	N208510	002	Jan 28, 2017
+		30MG	N208510	003	Jan 28, 2017
+		40MG	N208510	004	Jan 28, 2017
+		50MG	N208510	005	Jan 28, 2017
+		60MG	N208510	006	Jan 28, 2017

LISINOPRIL

SOLUTION; ORAL

QBRELIS

	+! AZURITY	1MG/ML	N208401	001	Jul 29, 2016

TABLET; ORAL

LISINOPRIL

<u>AB</u>		ACCORD HLTHCARE	<u>2.5MG</u>	<u>A202554</u>	<u>001</u>	Jul 30, 2013
<u>AB</u>			<u>5MG</u>	<u>A202554</u>	<u>002</u>	Jul 30, 2013
<u>AB</u>			<u>10MG</u>	<u>A202554</u>	<u>003</u>	Jul 30, 2013
<u>AB</u>			<u>20MG</u>	<u>A202554</u>	<u>004</u>	Jul 30, 2013
<u>AB</u>			<u>30MG</u>	<u>A202554</u>	<u>005</u>	Jul 30, 2013

PRESCRIPTION DRUG PRODUCT LIST

3-280 (of 474)

LISINOPRIL

TABLET; ORAL

LISINOPRIL

<u>AB</u>		<u>40MG</u>	<u>A202554</u>	<u>006</u>	Jul 30, 2013
<u>AB</u>	ASCENT PHARMS INC	<u>2.5MG</u>	<u>A075903</u>	<u>001</u>	Jul 01, 2002
<u>AB</u>		<u>5MG</u>	<u>A075903</u>	<u>002</u>	Jul 01, 2002
<u>AB</u>		<u>10MG</u>	<u>A075903</u>	<u>003</u>	Jul 01, 2002
<u>AB</u>		<u>20MG</u>	<u>A075903</u>	<u>004</u>	Jul 01, 2002
<u>AB</u>		<u>30MG</u>	<u>A075903</u>	<u>005</u>	Jul 01, 2002
<u>AB</u>		<u>40MG</u>	<u>A075903</u>	<u>006</u>	Jul 01, 2002
<u>AB</u>	AUROBINDO	<u>2.5MG</u>	<u>A077622</u>	<u>001</u>	Feb 22, 2006
<u>AB</u>		<u>5MG</u>	<u>A077622</u>	<u>002</u>	Feb 22, 2006
<u>AB</u>		<u>10MG</u>	<u>A077622</u>	<u>003</u>	Feb 22, 2006
<u>AB</u>		<u>20MG</u>	<u>A077622</u>	<u>004</u>	Feb 22, 2006
<u>AB</u>		<u>30MG</u>	<u>A077622</u>	<u>005</u>	Feb 22, 2006
<u>AB</u>		<u>40MG</u>	<u>A077622</u>	<u>006</u>	Feb 22, 2006
<u>AB</u>	CHARTWELL RX	<u>2.5MG</u>	<u>A075994</u>	<u>001</u>	Jul 01, 2002
<u>AB</u>		<u>5MG</u>	<u>A075994</u>	<u>002</u>	Jul 01, 2002
<u>AB</u>		<u>10MG</u>	<u>A075994</u>	<u>003</u>	Jul 01, 2002
<u>AB</u>		<u>20MG</u>	<u>A075994</u>	<u>004</u>	Jul 01, 2002
<u>AB</u>		<u>30MG</u>	<u>A075994</u>	<u>005</u>	Jul 01, 2002
<u>AB</u>		<u>40MG</u>	<u>A075994</u>	<u>006</u>	Jul 01, 2002
<u>AB</u>	COREPHARMA	<u>2.5MG</u>	<u>A076102</u>	<u>001</u>	Sep 30, 2002
<u>AB</u>		<u>5MG</u>	<u>A076102</u>	<u>002</u>	Sep 30, 2002
<u>AB</u>		<u>10MG</u>	<u>A076102</u>	<u>003</u>	Sep 30, 2002
<u>AB</u>		<u>20MG</u>	<u>A076102</u>	<u>004</u>	Sep 30, 2002
<u>AB</u>		<u>30MG</u>	<u>A076102</u>	<u>005</u>	Sep 30, 2002
<u>AB</u>		<u>40MG</u>	<u>A076102</u>	<u>006</u>	Sep 30, 2002
<u>AB</u>	INVAGEN PHARMS	<u>2.5MG</u>	<u>A203508</u>	<u>001</u>	Oct 29, 2013
<u>AB</u>		<u>5MG</u>	<u>A203508</u>	<u>002</u>	Oct 29, 2013
<u>AB</u>		<u>10MG</u>	<u>A203508</u>	<u>003</u>	Oct 29, 2013
<u>AB</u>		<u>20MG</u>	<u>A203508</u>	<u>004</u>	Oct 29, 2013
<u>AB</u>		<u>30MG</u>	<u>A203508</u>	<u>005</u>	Oct 29, 2013
<u>AB</u>		<u>40MG</u>	<u>A203508</u>	<u>006</u>	Oct 29, 2013
<u>AB</u>	LUPIN	<u>2.5MG</u>	<u>A077321</u>	<u>001</u>	Sep 09, 2005
<u>AB</u>		<u>5MG</u>	<u>A077321</u>	<u>002</u>	Sep 09, 2005
<u>AB</u>		<u>10MG</u>	<u>A077321</u>	<u>003</u>	Sep 09, 2005
<u>AB</u>		<u>20MG</u>	<u>A077321</u>	<u>004</u>	Sep 09, 2005
<u>AB</u>		<u>30MG</u>	<u>A077321</u>	<u>005</u>	Sep 09, 2005
<u>AB</u>		<u>40MG</u>	<u>A077321</u>	<u>006</u>	Sep 09, 2005
<u>AB</u>	PRINSTON INC	<u>2.5MG</u>	<u>A075743</u>	<u>001</u>	Jul 01, 2002
<u>AB</u>		<u>2.5MG</u>	<u>A076164</u>	<u>004</u>	Jul 01, 2002
<u>AB</u>		<u>5MG</u>	<u>A075743</u>	<u>002</u>	Jul 01, 2002
<u>AB</u>		<u>5MG</u>	<u>A076164</u>	<u>005</u>	Jul 01, 2002
<u>AB</u>		<u>10MG</u>	<u>A075743</u>	<u>003</u>	Jul 01, 2002
<u>AB</u>		<u>10MG</u>	<u>A076164</u>	<u>006</u>	Jul 01, 2002
<u>AB</u>		<u>20MG</u>	<u>A075743</u>	<u>004</u>	Jul 01, 2002
<u>AB</u>		<u>20MG</u>	<u>A076164</u>	<u>001</u>	Jul 01, 2002
<u>AB</u>		<u>30MG</u>	<u>A075743</u>	<u>005</u>	Jul 01, 2002
<u>AB</u>		<u>30MG</u>	<u>A076164</u>	<u>002</u>	Jul 01, 2002
<u>AB</u>		<u>40MG</u>	<u>A075743</u>	<u>006</u>	Jul 01, 2002
<u>AB</u>		<u>40MG</u>	<u>A076164</u>	<u>003</u>	Jul 01, 2002
<u>AB</u>	SUN PHARM INDS LTD	<u>2.5MG</u>	<u>A075944</u>	<u>001</u>	Jul 01, 2002
<u>AB</u>		<u>5MG</u>	<u>A075944</u>	<u>002</u>	Jul 01, 2002
<u>AB</u>		<u>10MG</u>	<u>A075944</u>	<u>003</u>	Jul 01, 2002
<u>AB</u>		<u>20MG</u>	<u>A075944</u>	<u>004</u>	Jul 01, 2002
<u>AB</u>		<u>30MG</u>	<u>A075944</u>	<u>006</u>	Feb 11, 2003
<u>AB</u>		<u>40MG</u>	<u>A075944</u>	<u>005</u>	Jul 01, 2002
<u>AB</u>	WATSON LABS	<u>2.5MG</u>	<u>A076059</u>	<u>001</u>	Jul 01, 2002
<u>AB</u>		<u>5MG</u>	<u>A076059</u>	<u>002</u>	Jul 01, 2002
<u>AB</u>		<u>10MG</u>	<u>A076059</u>	<u>003</u>	Jul 01, 2002
<u>AB</u>		<u>20MG</u>	<u>A076059</u>	<u>004</u>	Jul 01, 2002
<u>AB</u>		<u>30MG</u>	<u>A076059</u>	<u>005</u>	Jul 01, 2002
<u>AB</u>		<u>40MG</u>	<u>A076059</u>	<u>006</u>	Jul 01, 2002
<u>AB</u>	WOCKHARDT BIO AG	<u>2.5MG</u>	<u>A078402</u>	<u>001</u>	Apr 19, 2007
<u>AB</u>		<u>5MG</u>	<u>A078402</u>	<u>002</u>	Apr 19, 2007
<u>AB</u>		<u>10MG</u>	<u>A078402</u>	<u>003</u>	Apr 19, 2007
<u>AB</u>		<u>20MG</u>	<u>A078402</u>	<u>004</u>	Apr 19, 2007
<u>AB</u>		<u>30MG</u>	<u>A078402</u>	<u>005</u>	Apr 19, 2007
<u>AB</u>		<u>40MG</u>	<u>A078402</u>	<u>006</u>	Apr 19, 2007
<u>AB</u>	YILING	<u>2.5MG</u>	<u>A212041</u>	<u>001</u>	Sep 15, 2020
<u>AB</u>		<u>5MG</u>	<u>A212041</u>	<u>002</u>	Sep 15, 2020

PRESCRIPTION DRUG PRODUCT LIST

3-281 (of 474)

LISINOPRIL

TABLET; ORAL

LISINOPRIL

<u>AB</u>		<u>10MG</u>	<u>A212041</u>	<u>003</u>	Sep 15, 2020
<u>AB</u>		<u>20MG</u>	<u>A208920</u>	<u>001</u>	Mar 04, 2021
<u>AB</u>		<u>30MG</u>	<u>A208920</u>	<u>002</u>	Mar 04, 2021
<u>AB</u>		<u>40MG</u>	<u>A208920</u>	<u>003</u>	Mar 04, 2021

ZESTRIL

<u>AB</u>	+	ALMATICA	<u>2.5MG</u>	<u>N019777</u>	<u>005</u>	Apr 29, 1993
<u>AB</u>	+		<u>5MG</u>	<u>N019777</u>	<u>001</u>	May 19, 1988
<u>AB</u>	+		<u>10MG</u>	<u>N019777</u>	<u>002</u>	May 19, 1988
<u>AB</u>	+		<u>20MG</u>	<u>N019777</u>	<u>003</u>	May 19, 1988
<u>AB</u>	+		<u>30MG</u>	<u>N019777</u>	<u>006</u>	Jan 20, 1999
<u>AB</u>	+		<u>40MG</u>	<u>N019777</u>	<u>004</u>	May 19, 1988

LITHIUM CARBONATE

CAPSULE; ORAL

LITHIUM CARBONATE

<u>AB</u>		ALEMBIC LTD	<u>150MG</u>	<u>A079159</u>	<u>001</u>	Jan 12, 2009
<u>AB</u>			<u>300MG</u>	<u>A079159</u>	<u>002</u>	Jan 12, 2009
<u>AB</u>			<u>600MG</u>	<u>A079159</u>	<u>003</u>	Jan 12, 2009
<u>AB</u>		GLENMARK GENERICS	<u>150MG</u>	<u>A079139</u>	<u>001</u>	Feb 03, 2009
<u>AB</u>			<u>300MG</u>	<u>A079139</u>	<u>002</u>	Feb 03, 2009
<u>AB</u>			<u>600MG</u>	<u>A079139</u>	<u>003</u>	Feb 03, 2009
<u>AB</u>		HETERO LABS LTD III	<u>150MG</u>	<u>A090702</u>	<u>001</u>	Sep 25, 2009
<u>AB</u>			<u>300MG</u>	<u>A090702</u>	<u>002</u>	Sep 25, 2009
<u>AB</u>			<u>600MG</u>	<u>A090702</u>	<u>003</u>	Sep 25, 2009
<u>AB</u>	+	HIKMA	<u>150MG</u>	<u>N017812</u>	<u>002</u>	Jan 28, 1987
<u>AB</u>	+		<u>300MG</u>	<u>N017812</u>	<u>001</u>	
<u>AB</u>	+		<u>600MG</u>	<u>N017812</u>	<u>003</u>	Jan 28, 1987

TABLET; ORAL

LITHIUM CARBONATE

<u>AB</u>	+	HIKMA	<u>300MG</u>	<u>N018558</u>	<u>001</u>	Jan 29, 1982
<u>AB</u>		SUN PHARM INDS INC	<u>300MG</u>	<u>A091027</u>	<u>001</u>	Jun 24, 2010

TABLET, EXTENDED RELEASE; ORAL

LITHIUM CARBONATE

<u>AB</u>		GLENMARK GENERICS	<u>450MG</u>	<u>A091616</u>	<u>001</u>	Feb 14, 2011
<u>AB</u>		GLENMARK PHARMS INC	<u>300MG</u>	<u>A091544</u>	<u>001</u>	Dec 27, 2010
<u>AB</u>		HERITAGE PHARMA	<u>300MG</u>	<u>A205532</u>	<u>001</u>	Sep 29, 2016
<u>AB</u>		HIKMA	<u>300MG</u>	<u>A076832</u>	<u>001</u>	Oct 28, 2004
<u>AB</u>	!		<u>450MG</u>	<u>A076691</u>	<u>001</u>	Jan 05, 2004
<u>AB</u>		MYLAN PHARMS INC	<u>300MG</u>	<u>A202288</u>	<u>001</u>	Jun 29, 2012
<u>AB</u>			<u>450MG</u>	<u>A202219</u>	<u>001</u>	Aug 08, 2012
<u>AB</u>		UNIQUE	<u>300MG</u>	<u>A204779</u>	<u>001</u>	Jul 27, 2015
<u>AB</u>			<u>450MG</u>	<u>A205663</u>	<u>001</u>	Jun 05, 2017

LITHOBID

<u>AB</u>	+	ANI PHARMS	<u>300MG</u>	<u>N018027</u>	<u>001</u>	

LITHIUM CITRATE

SYRUP; ORAL

LITHIUM CITRATE

!	PAI HOLDINGS PHARM	EQ 300MG CARBONATE/5ML	<u>A070755</u>	<u>001</u>	May 21, 1986

LODOXAMIDE TROMETHAMINE

SOLUTION/DROPS; OPHTHALMIC

ALOMIDE

+	NOVARTIS	EQ 0.1% BASE	<u>N020191</u>	<u>001</u>	Sep 23, 1993

LOFEXIDINE HYDROCHLORIDE

TABLET; ORAL

LUCEMYRA

+	USWM	EQ 0.18MG BASE	<u>N209229</u>	<u>001</u>	May 16, 2018

LOMITAPIDE MESYLATE

CAPSULE; ORAL

JUXTAPID

+	AMRYT	EQ 5MG BASE	<u>N203858</u>	<u>001</u>	Dec 21, 2012
+		EQ 10MG BASE	<u>N203858</u>	<u>002</u>	Dec 21, 2012
+		EQ 20MG BASE	<u>N203858</u>	<u>003</u>	Dec 21, 2012
+		EQ 30MG BASE	<u>N203858</u>	<u>004</u>	Apr 23, 2015

PRESCRIPTION DRUG PRODUCT LIST

3-282 (of 474)

LOMUSTINE

CAPSULE; ORAL

GLEOSTINE

+	CORDEN PHARMA	10MG	N017588	001	
+		40MG	N017588	002	
+	!	100MG	N017588	003	

LONAFARNIB

CAPSULE; ORAL

ZOKINVY

+	EIGER BIOPHARMS	50MG	N213969	001	Nov 20, 2020
+	!	75MG	N213969	002	Nov 20, 2020

LOPERAMIDE HYDROCHLORIDE

CAPSULE; ORAL

LOPERAMIDE HYDROCHLORIDE

<u>AB</u>		BIONPHARMA INC	<u>2MG</u>	<u>A215579</u>	<u>001</u>	Oct 22, 2021
<u>AB</u>		EDENBRIDGE PHARMS	<u>2MG</u>	<u>A215001</u>	<u>001</u>	Oct 06, 2021
<u>AB</u>	!	MYLAN	<u>2MG</u>	<u>A072741</u>	<u>001</u>	Sep 18, 1991
<u>AB</u>		TEVA	<u>2MG</u>	<u>A073192</u>	<u>001</u>	Apr 30, 1992

LOPINAVIR; RITONAVIR

SOLUTION; ORAL

KALETRA

<u>AA</u>	+	ABBVIE	<u>80MG/ML; 20MG/ML</u>	<u>N021251</u>	<u>001</u>	Sep 15, 2000

LOPINAVIR AND RITONAVIR

<u>AA</u>		LANNETT CO INC	<u>80MG/ML; 20MG/ML</u>	<u>A207407</u>	<u>001</u>	Dec 27, 2016

TABLET; ORAL

KALETRA

<u>AB</u>	+	ABBVIE	<u>100MG; 25MG</u>	<u>N021906</u>	<u>002</u>	Nov 09, 2007
<u>AB</u>	+	!	<u>200MG; 50MG</u>	<u>N021906</u>	<u>001</u>	Oct 28, 2005

LOPINAVIR AND RITONAVIR

<u>AB</u>		HETERO LABS LTD III	<u>100MG; 25MG</u>	<u>A091677</u>	<u>001</u>	Jun 04, 2021
<u>AB</u>			<u>200MG; 50MG</u>	<u>A091677</u>	<u>002</u>	Jun 04, 2021
<u>AB</u>		LAURUS	<u>100MG; 25MG</u>	<u>A213857</u>	<u>001</u>	Mar 21, 2022
<u>AB</u>			<u>200MG; 50MG</u>	<u>A213857</u>	<u>002</u>	Mar 21, 2022

LORAZEPAM

CAPSULE, EXTENDED RELEASE; ORAL

LOREEV XR

+	ALMATICA	1MG	N214826	001	Aug 27, 2021
+		1.5MG	N214826	004	Feb 16, 2022
+		2MG	N214826	002	Aug 27, 2021
+	!	3MG	N214826	003	Aug 27, 2021

CONCENTRATE; ORAL

LORAZEPAM

<u>AA</u>		AKORN	<u>2MG/ML</u>	<u>A200169</u>	<u>001</u>	Jan 30, 2012
<u>AA</u>		AMNEAL PHARMS	<u>2MG/ML</u>	<u>A091383</u>	<u>001</u>	Dec 23, 2009
<u>AA</u>		LUPIN LTD	<u>2MG/ML</u>	<u>A091407</u>	<u>001</u>	Feb 19, 2013
<u>AA</u>		PHARM ASSOC	<u>2MG/ML</u>	<u>A090260</u>	<u>001</u>	Jun 15, 2010

LORAZEPAM INTENSOL

<u>AA</u>	!	HIKMA	<u>2MG/ML</u>	<u>A072755</u>	<u>001</u>	Jun 28, 1991

INJECTABLE; INJECTION

ATIVAN

<u>AP</u>	+	HIKMA	<u>2MG/ML</u>	<u>N018140</u>	<u>001</u>	
<u>AP</u>	+	!	<u>4MG/ML</u>	<u>N018140</u>	<u>002</u>	

LORAZEPAM

<u>AP</u>		AKORN	<u>2MG/ML</u>	<u>A075025</u>	<u>001</u>	Jul 23, 1998
<u>AP</u>		HOSPIRA	<u>2MG/ML</u>	<u>A074243</u>	<u>001</u>	Apr 12, 1994
<u>AP</u>			<u>2MG/ML</u>	<u>A074282</u>	<u>001</u>	May 27, 1994
<u>AP</u>			<u>4MG/ML</u>	<u>A074243</u>	<u>002</u>	Apr 12, 1994
<u>AP</u>			<u>4MG/ML</u>	<u>A074282</u>	<u>002</u>	May 27, 1994
<u>AP</u>		INTL MEDICATION SYS	<u>2MG/ML</u>	<u>A076150</u>	<u>001</u>	Nov 15, 2004

TABLET; ORAL

ATIVAN

<u>AB</u>	+	BAUSCH	<u>0.5MG</u>	<u>N017794</u>	<u>001</u>	
<u>AB</u>	+		<u>1MG</u>	<u>N017794</u>	<u>002</u>	
<u>AB</u>	+	!	<u>2MG</u>	<u>N017794</u>	<u>003</u>	

LORAZEPAM

<u>AB</u>		AMNEAL PHARMS	<u>0.5MG</u>	<u>A078826</u>	<u>001</u>	Jun 23, 2010
<u>AB</u>			<u>1MG</u>	<u>A078826</u>	<u>002</u>	Jun 23, 2010
<u>AB</u>			<u>2MG</u>	<u>A078826</u>	<u>003</u>	Jun 23, 2010
<u>AB</u>		AUROLIFE PHARMA LLC	<u>0.5MG</u>	<u>A203572</u>	<u>001</u>	Dec 22, 2017
<u>AB</u>			<u>1MG</u>	<u>A203572</u>	<u>002</u>	Dec 22, 2017

PRESCRIPTION DRUG PRODUCT LIST

3-283 (of 474)

LORAZEPAM

TABLET; ORAL

LORAZEPAM

<u>AB</u>		<u>2MG</u>	<u>A203572</u>	<u>003</u>	Dec 22, 2017
<u>AB</u>	LEADING	<u>0.5MG</u>	<u>A078203</u>	<u>001</u>	Jul 30, 2007
<u>AB</u>		<u>1MG</u>	<u>A078203</u>	<u>002</u>	Jul 30, 2007
<u>AB</u>		<u>2MG</u>	<u>A078203</u>	<u>003</u>	Jul 30, 2007
<u>AB</u>	OXFORD PHARMS	<u>0.5MG</u>	<u>A077754</u>	<u>001</u>	May 10, 2006
<u>AB</u>		<u>1MG</u>	<u>A077754</u>	<u>002</u>	May 10, 2006
<u>AB</u>		<u>2MG</u>	<u>A077754</u>	<u>003</u>	May 10, 2006
<u>AB</u>	SANDOZ	<u>0.5MG</u>	<u>A071141</u>	<u>002</u>	Apr 21, 1987
<u>AB</u>		<u>1MG</u>	<u>A071141</u>	<u>003</u>	Apr 21, 1987
<u>AB</u>		<u>2MG</u>	<u>A071141</u>	<u>001</u>	Apr 21, 1987
<u>AB</u>	WATSON LABS	<u>0.5MG</u>	<u>A072926</u>	<u>001</u>	Oct 31, 1991
<u>AB</u>		<u>1MG</u>	<u>A072927</u>	<u>001</u>	Oct 31, 1991
<u>AB</u>		<u>2MG</u>	<u>A072928</u>	<u>001</u>	Oct 31, 1991

LORLATINIB

TABLET; ORAL

LORBRENA

+ PFIZER

25MG

N210868 001 Nov 02, 2018

+!

100MG

N210868 002 Nov 02, 2018

LOSARTAN POTASSIUM

TABLET; ORAL

COZAAR

<u>AB</u>	+	ORGANON	<u>25MG</u>	<u>N020386</u>	<u>001</u>	Apr 14, 1995
<u>AB</u>	+		<u>50MG</u>	<u>N020386</u>	<u>002</u>	Apr 14, 1995
<u>AB</u>	+	!	<u>100MG</u>	<u>N020386</u>	<u>003</u>	Oct 13, 1998

LOSARTAN POTASSIUM

<u>AB</u>		ALEMBIC PHARMS LTD	<u>25MG</u>	<u>A090428</u>	<u>001</u>	Oct 06, 2010
<u>AB</u>			<u>50MG</u>	<u>A090428</u>	<u>002</u>	Oct 06, 2010
<u>AB</u>			<u>100MG</u>	<u>A090428</u>	<u>003</u>	Oct 06, 2010
<u>AB</u>		AUROBINDO PHARMA	<u>25MG</u>	<u>A090083</u>	<u>001</u>	Oct 06, 2010
<u>AB</u>			<u>50MG</u>	<u>A090083</u>	<u>002</u>	Oct 06, 2010
<u>AB</u>			<u>100MG</u>	<u>A090083</u>	<u>003</u>	Oct 06, 2010
<u>AB</u>		HETERO LABS LTD V	<u>25MG</u>	<u>A203835</u>	<u>001</u>	Aug 12, 2015
<u>AB</u>			<u>50MG</u>	<u>A203835</u>	<u>002</u>	Aug 12, 2015
<u>AB</u>			<u>100MG</u>	<u>A203835</u>	<u>003</u>	Aug 12, 2015
<u>AB</u>		IPCA LABS LTD	<u>25MG</u>	<u>A200290</u>	<u>001</u>	Aug 30, 2013
<u>AB</u>			<u>50MG</u>	<u>A200290</u>	<u>002</u>	Aug 30, 2013
<u>AB</u>			<u>100MG</u>	<u>A200290</u>	<u>003</u>	Aug 30, 2013
<u>AB</u>		JUBILANT CADISTA	<u>25MG</u>	<u>A201170</u>	<u>001</u>	Sep 18, 2012
<u>AB</u>			<u>50MG</u>	<u>A201170</u>	<u>002</u>	Sep 18, 2012
<u>AB</u>			<u>100MG</u>	<u>A201170</u>	<u>003</u>	Sep 18, 2012
<u>AB</u>		LUPIN LTD	<u>25MG</u>	<u>A078232</u>	<u>001</u>	Oct 06, 2010
<u>AB</u>			<u>50MG</u>	<u>A078232</u>	<u>002</u>	Oct 06, 2010
<u>AB</u>			<u>100MG</u>	<u>A078232</u>	<u>003</u>	Oct 06, 2010
<u>AB</u>		MACLEODS PHARMS LTD	<u>25MG</u>	<u>A202230</u>	<u>001</u>	May 30, 2012
<u>AB</u>			<u>50MG</u>	<u>A202230</u>	<u>002</u>	May 30, 2012
<u>AB</u>			<u>100MG</u>	<u>A202230</u>	<u>003</u>	May 30, 2012
<u>AB</u>		MICRO LABS	<u>25MG</u>	<u>A091541</u>	<u>001</u>	Sep 24, 2012
<u>AB</u>			<u>50MG</u>	<u>A091541</u>	<u>002</u>	Sep 24, 2012
<u>AB</u>			<u>100MG</u>	<u>A091541</u>	<u>003</u>	Sep 24, 2012
<u>AB</u>		PRINSTON INC	<u>25MG</u>	<u>A091497</u>	<u>001</u>	Jun 06, 2011
<u>AB</u>			<u>50MG</u>	<u>A091497</u>	<u>002</u>	Jun 06, 2011
<u>AB</u>			<u>100MG</u>	<u>A091497</u>	<u>003</u>	Jun 06, 2011
<u>AB</u>		SANDOZ	<u>25MG</u>	<u>A077424</u>	<u>001</u>	Oct 06, 2010
<u>AB</u>			<u>50MG</u>	<u>A077424</u>	<u>002</u>	Oct 06, 2010
<u>AB</u>			<u>100MG</u>	<u>A077424</u>	<u>003</u>	Oct 06, 2010
<u>AB</u>		STRIDES PHARMA	<u>25MG</u>	<u>A090382</u>	<u>001</u>	Oct 06, 2010
<u>AB</u>			<u>50MG</u>	<u>A090382</u>	<u>002</u>	Oct 06, 2010
<u>AB</u>			<u>100MG</u>	<u>A090382</u>	<u>003</u>	Oct 06, 2010
<u>AB</u>		UNICHEM	<u>25MG</u>	<u>A203030</u>	<u>001</u>	Oct 14, 2015
<u>AB</u>			<u>50MG</u>	<u>A203030</u>	<u>002</u>	Oct 14, 2015
<u>AB</u>			<u>100MG</u>	<u>A203030</u>	<u>003</u>	Oct 14, 2015
<u>AB</u>		WATSON LABS	<u>25MG</u>	<u>A091129</u>	<u>001</u>	Oct 06, 2010
<u>AB</u>			<u>50MG</u>	<u>A091129</u>	<u>002</u>	Oct 06, 2010
<u>AB</u>			<u>100MG</u>	<u>A091129</u>	<u>003</u>	Oct 06, 2010
<u>AB</u>		ZYDUS PHARMS USA INC	<u>25MG</u>	<u>A078243</u>	<u>001</u>	Oct 06, 2010
<u>AB</u>			<u>50MG</u>	<u>A078243</u>	<u>002</u>	Oct 06, 2010
<u>AB</u>			<u>100MG</u>	<u>A078243</u>	<u>003</u>	Oct 06, 2010

PRESCRIPTION DRUG PRODUCT LIST

3-284 (of 474)

LOTEPREDNOL ETABONATE

GEL;OPHTHALMIC

LOTEMAX

AB	+!	BAUSCH AND LOMB INC	0.5%	<u>N202872</u>	<u>001</u>	Sep 28, 2012

LOTEPREDNOL ETABONATE

AB		AKORN	0.5%	<u>A212080</u>	<u>001</u>	Feb 10, 2021

LOTEMAX SM

	+!	BAUSCH AND LOMB INC	0.38%	N208219	001	Feb 22, 2019

OINTMENT;OPHTHALMIC

LOTEMAX

	+!	BAUSCH AND LOMB	0.5%	N200738	001	Apr 15, 2011

SUSPENSION/DROPS;OPHTHALMIC

LOTEMAX

AB	+!	BAUSCH AND LOMB	0.5%	<u>N2020583</u>	<u>001</u>	Mar 09, 1998

LOTEPREDNOL ETABONATE

AB		AKORN	0.5%	<u>A207609</u>	<u>001</u>	Apr 17, 2019

AB		SUN PHARM	0.5%	<u>A212450</u>	<u>001</u>	Feb 26, 2021

ALREX

	+!	BAUSCH AND LOMB	0.2%	N020803	001	Mar 09, 1998

EYSUVIS

	+!	ALCON LABS INC	0.25%	N210933	001	Oct 26, 2020

INVELTYS

	+!	ALCON LABS INC	1%	N210565	001	Aug 22, 2018

LOTEPREDNOL ETABONATE; TOBRAMYCIN

SUSPENSION/DROPS;OPHTHALMIC

ZYLET

	+!	BAUSCH AND LOMB	0.5%;0.3%	N050804	001	Dec 14, 2004

LOVASTATIN

TABLET;ORAL

LOVASTATIN

AB		ACTAVIS ELIZABETH	10MG	<u>A075828</u>	<u>001</u>	Dec 17, 2001

AB			20MG	<u>A075828</u>	<u>002</u>	Dec 17, 2001

AB			40MG	<u>A075828</u>	<u>003</u>	Dec 17, 2001

AB		CARLSBAD	10MG	<u>A075991</u>	<u>001</u>	Jun 05, 2002

AB			20MG	<u>A075991</u>	<u>002</u>	Jun 05, 2002

AB	!		40MG	<u>A075991</u>	<u>003</u>	Jun 05, 2002

AB		CHARTWELL RX	10MG	<u>A075300</u>	<u>001</u>	Dec 17, 2001

AB			20MG	<u>A075300</u>	<u>002</u>	Dec 17, 2001

AB			40MG	<u>A075300</u>	<u>003</u>	Dec 17, 2001

AB		COREPHARMA	10MG	<u>A077748</u>	<u>001</u>	Feb 28, 2007

AB			20MG	<u>A077748</u>	<u>002</u>	Feb 28, 2007

AB			40MG	<u>A077748</u>	<u>003</u>	Feb 28, 2007

AB		EPIC PHARMA	10MG	<u>A075636</u>	<u>001</u>	Dec 17, 2001

AB			20MG	<u>A075636</u>	<u>002</u>	Dec 17, 2001

AB			40MG	<u>A075636</u>	<u>003</u>	Dec 17, 2001

AB		LUPIN	10MG	<u>A078296</u>	<u>001</u>	Mar 14, 2008

AB			20MG	<u>A078296</u>	<u>002</u>	Nov 01, 2007

AB			40MG	<u>A078296</u>	<u>003</u>	Nov 01, 2007

AB		TEVA	10MG	<u>A075551</u>	<u>003</u>	Dec 17, 2001

AB			20MG	<u>A075551</u>	<u>002</u>	Dec 17, 2001

AB			40MG	<u>A075551</u>	<u>001</u>	Dec 17, 2001

TABLET, EXTENDED RELEASE;ORAL

ALTOPREV

	+	COVIS	20MG	N021316	002	Jun 26, 2002

	+		40MG	N021316	003	Jun 26, 2002

	+!		60MG	N021316	004	Jun 26, 2002

LOXAPINE

POWDER; INHALATION

ADASUVE

	+!	ALEXZA PHARMS	10MG	N022549	001	Dec 21, 2012

LOXAPINE SUCCINATE

CAPSULE;ORAL

LOXAPINE SUCCINATE

AB		ELITE LABS INC	EQ 5MG BASE	<u>A076868</u>	<u>001</u>	Aug 04, 2005

AB			EQ 10MG BASE	<u>A076868</u>	<u>002</u>	Aug 04, 2005

AB			EQ 25MG BASE	<u>A076868</u>	<u>003</u>	Aug 04, 2005

AB			EQ 50MG BASE	<u>A076868</u>	<u>004</u>	Aug 04, 2005

AB		LANNETT CO INC	EQ 5MG BASE	<u>A090695</u>	<u>001</u>	Sep 26, 2011

AB			EQ 10MG BASE	<u>A090695</u>	<u>002</u>	Sep 26, 2011

AB			EQ 25MG BASE	<u>A090695</u>	<u>003</u>	Sep 26, 2011

PRESCRIPTION DRUG PRODUCT LIST

3-285 (of 474)

LOXAPINE SUCCINATE

CAPSULE; ORAL

LOXAPINE SUCCINATE

<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A090695</u>	<u>004</u>	Sep 26, 2011
<u>AB</u>	WATSON LABS	<u>EQ 5MG BASE</u>	<u>A072204</u>	<u>001</u>	Jun 15, 1988
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A072205</u>	<u>001</u>	Jun 15, 1988
<u>AB</u>	!	<u>EQ 25MG BASE</u>	<u>A072206</u>	<u>001</u>	Jun 15, 1988
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A072062</u>	<u>001</u>	Jun 15, 1988

LUBIPROSTONE

CAPSULE; ORAL

AMITIZA

<u>AB</u>	+	SUCAMPO PHARMA LLC	<u>8MCG</u>	<u>N021908</u>	<u>002</u>	Apr 29, 2008
<u>AB</u>	+	!	<u>24MCG</u>	<u>N021908</u>	<u>001</u>	Jan 31, 2006

LUBIPROSTONE

<u>AB</u>		DR REDDYS	<u>8MCG</u>	<u>A206994</u>	<u>001</u>	Feb 08, 2022
<u>AB</u>			<u>24MCG</u>	<u>A206994</u>	<u>002</u>	Feb 08, 2022
<u>AB</u>		TEVA PHARMS USA INC	<u>8MCG</u>	<u>A209920</u>	<u>001</u>	Jan 18, 2022
<u>AB</u>			<u>24MCG</u>	<u>A209920</u>	<u>002</u>	Jan 18, 2022

LULICONAZOLE

CREAM; TOPICAL

LUZU

+	BAUSCH	1%	N204153	001	Nov 14, 2013

LUMASIRAN SODIUM

SOLUTION; SUBCUTANEOUS

OXLUMO

+	ALNYLAM PHARMS INC	EQ 94.5MG/0.5ML BASE (EQ 94.5MG/0.5ML BASE)	N214103	001	Nov 23, 2020

LUMATEPERONE TOSYLATE

CAPSULE; ORAL

CAPLYTA

+	INTRA-CELLULAR	EQ 10.5MG BASE	N209500	002	Apr 22, 2022
+		EQ 21MG BASE	N209500	003	Apr 22, 2022
+	!	EQ 42MG BASE	N209500	001	Dec 20, 2019

LURASIDONE HYDROCHLORIDE

TABLET; ORAL

LATUDA

<u>AB</u>	+	SUNOVION PHARMS INC	<u>20MG</u>	<u>N200603</u>	<u>003</u>	Dec 07, 2011
<u>AB</u>	+	!	<u>40MG</u>	<u>N200603</u>	<u>001</u>	Oct 28, 2010
<u>AB</u>	+		<u>60MG</u>	<u>N200603</u>	<u>005</u>	Jul 12, 2013
<u>AB</u>	+		<u>80MG</u>	<u>N200603</u>	<u>002</u>	Oct 28, 2010
<u>AB</u>	+		<u>120MG</u>	<u>N200603</u>	<u>004</u>	Apr 26, 2012

LURASIDONE HYDROCHLORIDE

<u>AB</u>		ACCORD HLTHCARE	<u>20MG</u>	<u>A208049</u>	<u>001</u>	Jan 03, 2019
<u>AB</u>			<u>40MG</u>	<u>A208049</u>	<u>002</u>	Jan 03, 2019
<u>AB</u>			<u>60MG</u>	<u>A208049</u>	<u>003</u>	Jan 03, 2019
<u>AB</u>			<u>80MG</u>	<u>A208049</u>	<u>004</u>	Jan 03, 2019
<u>AB</u>			<u>120MG</u>	<u>A208049</u>	<u>005</u>	Jan 03, 2019
<u>AB</u>		ALEMBIC PHARMS	<u>20MG</u>	<u>A213248</u>	<u>001</u>	May 13, 2021
<u>AB</u>			<u>40MG</u>	<u>A213248</u>	<u>002</u>	May 13, 2021
<u>AB</u>			<u>60MG</u>	<u>A213248</u>	<u>003</u>	May 13, 2021
<u>AB</u>			<u>80MG</u>	<u>A213248</u>	<u>004</u>	May 13, 2021
<u>AB</u>			<u>120MG</u>	<u>A213248</u>	<u>005</u>	May 13, 2021
<u>AB</u>		ALKEM LABS LTD	<u>20MG</u>	<u>A212244</u>	<u>001</u>	Dec 13, 2022
<u>AB</u>			<u>40MG</u>	<u>A212244</u>	<u>002</u>	Dec 13, 2022
<u>AB</u>			<u>60MG</u>	<u>A212244</u>	<u>003</u>	Dec 13, 2022
<u>AB</u>			<u>80MG</u>	<u>A212244</u>	<u>004</u>	Dec 13, 2022
<u>AB</u>			<u>120MG</u>	<u>A212244</u>	<u>005</u>	Dec 13, 2022
<u>AB</u>		DR REDDYS	<u>20MG</u>	<u>A208047</u>	<u>001</u>	Aug 24, 2021
<u>AB</u>			<u>40MG</u>	<u>A208047</u>	<u>002</u>	Aug 24, 2021
<u>AB</u>			<u>60MG</u>	<u>A208047</u>	<u>003</u>	Aug 24, 2021
<u>AB</u>			<u>80MG</u>	<u>A208047</u>	<u>004</u>	Aug 24, 2021
<u>AB</u>		INVAGEN PHARMS	<u>20MG</u>	<u>A208028</u>	<u>001</u>	Jan 03, 2019
<u>AB</u>			<u>40MG</u>	<u>A208028</u>	<u>002</u>	Jan 03, 2019
<u>AB</u>			<u>60MG</u>	<u>A208028</u>	<u>003</u>	Jan 03, 2019
<u>AB</u>			<u>80MG</u>	<u>A208028</u>	<u>004</u>	Jan 03, 2019
<u>AB</u>			<u>120MG</u>	<u>A208028</u>	<u>005</u>	Jan 03, 2019
<u>AB</u>		MSN	<u>20MG</u>	<u>A208037</u>	<u>001</u>	Sep 09, 2022
<u>AB</u>			<u>40MG</u>	<u>A208037</u>	<u>002</u>	Sep 09, 2022
<u>AB</u>			<u>60MG</u>	<u>A208037</u>	<u>003</u>	Sep 09, 2022
<u>AB</u>			<u>80MG</u>	<u>A208037</u>	<u>004</u>	Sep 09, 2022

PRESCRIPTION DRUG PRODUCT LIST

3-286 (of 474)

LURASIDONE HYDROCHLORIDE

TABLET; ORAL

LURASIDONE HYDROCHLORIDE

<u>AB</u>		<u>120MG</u>	<u>A208037</u>	<u>005</u>	Sep 09, 2022
<u>AB</u>	SUN PHARM	<u>20MG</u>	<u>A208066</u>	<u>001</u>	Jan 04, 2019
<u>AB</u>		<u>40MG</u>	<u>A208066</u>	<u>002</u>	Jan 04, 2019
<u>AB</u>		<u>60MG</u>	<u>A208066</u>	<u>003</u>	Jan 04, 2019
<u>AB</u>		<u>80MG</u>	<u>A208066</u>	<u>004</u>	Jan 04, 2019
<u>AB</u>		<u>120MG</u>	<u>A208066</u>	<u>005</u>	Jan 04, 2019
<u>AB</u>	ZYDUS PHARMS	<u>20MG</u>	<u>A208052</u>	<u>001</u>	Mar 19, 2019
<u>AB</u>		<u>40MG</u>	<u>A208052</u>	<u>002</u>	Mar 19, 2019
<u>AB</u>		<u>60MG</u>	<u>A208052</u>	<u>003</u>	Mar 19, 2019
<u>AB</u>		<u>80MG</u>	<u>A208052</u>	<u>004</u>	Mar 19, 2019
<u>AB</u>		<u>120MG</u>	<u>A208052</u>	<u>005</u>	Mar 19, 2019

LURBINECTEDIN

POWDER; INTRAVENOUS

ZEPZELCA

+	!	JAZZ	4MG/VIAL	N213702	001	Jun 15, 2020

LUSUTROMBOPAG

TABLET; ORAL

MULPLETA

+	!	SHIONOGI INC	3MG	N210923	001	Jul 31, 2018

LUTETIUM LU 177 DOTATATE

SOLUTION; INTRAVENOUS

LUTATHERA

+	!	AAA USA INC	10mCi/ML	N208700	001	Jan 26, 2018

LUTETIUM LU-177 VIPIVOTIDE TETRAJETAN

SOLUTION; INTRAVENOUS

PLUVICTO

+	!	AAA USA NOVARTIS	27mCi/ML	N215833	001	Mar 23, 2022

MACIMORELIN ACETATE

FOR SOLUTION; ORAL

MACILEN

+	!	NOVO	EQ 60MG BASE/POUCH	N205598	001	Dec 20, 2017

MACITENTAN

TABLET; ORAL

OPSUMIT

+	!	ACTELION	10MG	N204410	001	Oct 18, 2013

MAFENIDE ACETATE

CREAM; TOPICAL

SULFAMYLOX

+	!	RISING	EQ 85MG BASE/GM	N016763	001	

FOR SOLUTION; TOPICAL

MAFENIDE ACETATE

!		NOVAST LABS	5%	A206716	001	Jul 31, 2017

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE; INJECTION

ISOLYTE S PH 7.4 IN PLASTIC CONTAINER

+	!	B BRAUN	30MG/100ML; 37MG/100ML; 0.82MG/100ML; 370MG/100ML; 530MG/100ML; 500MG/100ML; 12MG/100ML	N019696	001	Sep 29, 1989

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE; INJECTION

ISOLYTE S IN PLASTIC CONTAINER

B BRAUN	30MG/100ML; 37MG/100ML; 370MG/100ML; 530MG/100ML; 500MG/100ML	N019711	001	Sep 29, 1989

NORMOSOL-R IN PLASTIC CONTAINER

ICU MEDICAL INC	30MG/100ML; 37MG/100ML; 222MG/100ML; 526MG/100ML; 502MG/100ML	N017586	001	

PLASMA-LYTE 148 IN WATER IN PLASTIC CONTAINER

+	!	BAXTER HLTHCARE	30MG/100ML; 37MG/100ML; 368MG/100ML; 526MG/100ML; 502MG/100ML	N017378	001	

PLASMA-LYTE A IN PLASTIC CONTAINER

+	!	BAXTER HLTHCARE	30MG/100ML; 37MG/100ML; 368MG/100ML; 526MG/100ML; 502MG/100ML	N017378	002	Nov 22, 1982

SOLUTION; IRRIGATION

PHYSIOLYTE IN PLASTIC CONTAINER

B BRAUN	30MG/100ML; 37MG/100ML; 370MG/100ML;	N019024	001	Jun 08, 1984

PRESCRIPTION DRUG PRODUCT LIST

3-287 (of 474)

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

SOLUTION; IRRIGATION

PHYSIOLYTE IN PLASTIC CONTAINER

530MG/100ML; 500MG/100ML

PHYSIOSOL IN PLASTIC CONTAINER

ICU MEDICAL INC 30MG/100ML; 37MG/100ML; 222MG/100ML; 526MG
/100ML; 502MG/100ML

N017637 002 Jul 08, 1982

MAGNESIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

SOLUTION; INJECTION

NORMOCARB HF 25

+! DIALYSIS SUPS 0.21GM/100ML; 2.8GM/100ML; 9.07GM/100ML

N021910 001 Jul 26, 2006

NORMOCARB HF 35

+! DIALYSIS SUPS 0.21GM/100ML; 3.97GM/100ML; 8.3GM/100ML

N021910 002 Jul 26, 2006

MAGNESIUM SULFATE

INJECTABLE; INJECTION

MAGNESIUM SULFATEAP B BRAUN MEDICAL INC 2GM/50ML (40MG/ML) A207967 001 Apr 26, 2021AP 4GM/100ML (40MG/ML) A207967 002 Apr 26, 2021AP 4GM/50ML (80MG/ML) A207967 003 Apr 26, 2021MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINERAP B BRAUN MEDICAL INC 1GM/100ML A207966 001 Oct 27, 2020AP BAXTER HLTHCARE 1GM/100ML A211965 001 Aug 11, 2020AP FRESenius KABI USA 1GM/100ML A206486 001 Mar 07, 2016AP +! HOSPIRA 1GM/100ML N020488 001 Jul 11, 1995AP HQ SPCLT PHARMA 1GM/100ML A207349 001 Mar 02, 2016AP MYLAN LABS LTD 1GM/100ML A209932 001 Sep 10, 2018MAGNESIUM SULFATE IN PLASTIC CONTAINERAP BAXTER HLTHCARE 2GM/50ML (40MG/ML) A211966 001 Jun 01, 2020AP 4GM/50ML (80MG/ML) A211966 002 Jun 01, 2020AP 4GM/100ML (40MG/ML) A211966 003 Jun 01, 2020AP FRESenius KABI USA 4GM/100ML (40MG/ML) A206485 001 Mar 15, 2016AP 4GM/50ML (80MG/ML) A206485 002 Mar 15, 2016AP 2GM/50ML (40MG/ML) A206485 003 Mar 15, 2016AP 20GM/500ML (40MG/ML) A206485 004 Mar 15, 2016AP 40GM/1000ML (40MG/ML) A206485 005 Mar 15, 2016AP GLAND PHARMA LTD 2GM/50ML (40MG/ML) A213917 001 Jul 10, 2020AP 4GM/100ML (40MG/ML) A213917 002 Jul 10, 2020AP + HOSPIRA 2GM/50ML (40MG/ML) N020309 003 Jan 26, 2007AP +! 4GM/100ML (40MG/ML) N020309 001 Jun 24, 1994AP +! 4GM/50ML (80MG/ML) N020309 002 Jun 24, 1994AP + 20GM/500ML (40MG/ML) N020309 004 Jan 18, 1995AP + 40GM/1000ML (40MG/ML) N020309 005 Jan 18, 1995AP HQ SPCLT PHARMA 2GM/50ML (40MG/ML) A207350 001 Dec 06, 2017AP 4GM/100ML (40MG/ML) A207350 002 Dec 06, 2017AP 4GM/50ML (80MG/ML) A207350 003 Dec 06, 2017AP 20GM/500ML (40MG/ML) A207350 004 Dec 06, 2017AP 40GM/1000ML (40MG/ML) A207350 005 Dec 06, 2017AP MILLA PHARMS 2GM/50ML (40MG/ML) A209642 001 Nov 08, 2021AP 4GM/100ML (40MG/ML) A209642 002 Nov 08, 2021AP 4GM/50ML (80MG/ML) A209642 003 Nov 08, 2021AP MYLAN LABS LTD 2GM/50ML (40MG/ML) A209911 001 Sep 14, 2018AP 4GM/100ML (40MG/ML) A209911 002 Sep 14, 2018MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER

+! HOSPIRA 2GM/100ML N020488 002 Jul 11, 1995

SOLUTION; INTRAMUSCULAR, INTRAVENOUS

MAGNESIUM SULFATEAP EXELA PHARMA 5GM/10ML (500MG/ML) A206039 001 Dec 18, 2014AP +! FRESenius KABI USA 5GM/10ML (500MG/ML) N019316 001 Sep 08, 1986AP +! 10GM/20ML (500MG/ML) N019316 003 Jan 29, 2016AP ! HOSPIRA 5GM/10ML (500MG/ML) A075151 001 Apr 25, 2000AP 10GM/20ML (500MG/ML) A202411 001 May 14, 2015

+! FRESenius KABI USA 1GM/2ML (500MG/ML) N019316 002 Sep 08, 1986

+! 25GM/50ML (500MG/ML) N019316 004 Jan 29, 2016

PRESCRIPTION DRUG PRODUCT LIST

3-288 (of 474)

MAGNESIUM SULFATE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM PHOSPHATE

SOLUTION;IRRIGATION

TIS-U-SOL

AT	BAXTER HLTHCARE	20MG/100ML;40MG/100ML;6.25MG/100ML;800MG/100ML;8.75MG/100ML	N018508 001	Feb 19, 1982

TIS-U-SOL IN PLASTIC CONTAINER

AT	BAXTER HLTHCARE	20MG/100ML;40MG/100ML;6.25MG/100ML;800MG/100ML;8.75MG/100ML	N018336 001	

MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM SULFATE

TABLET;ORAL

SUTAB

+	BRAINTREE LABS	0.225GM;0.188GM;1.479GM	N213135 001	Nov 10, 2020

MAGNESIUM SULFATE; POTASSIUM SULFATE; SODIUM SULFATE

SOLUTION;ORAL

SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE

AA	NOVEL LABS INC	1.6GM/BOT;3.13GM/BOT;17.5GM/BOT	A202511 001	Feb 23, 2017

SUPREP BOWEL PREP KIT

AA	+	BRAINTREE LABS	1.6GM/BOT;3.13GM/BOT;17.5GM/BOT	N022372 001	Aug 05, 2010

MALATHION

LOTION;TOPICAL

MALATHION

!	SUVEN PHARMS	0.5%	A091559 001	May 23, 2012

MANGANESE CHLORIDE

INJECTABLE;INJECTION

MANGANESE CHLORIDE IN PLASTIC CONTAINER

+	HOSPIRA	EQ 0.1MG MANGANESE/ML	N018962 001	Jun 26, 1986

MANNITOL

INJECTABLE;INJECTION

MANNITOL 10% IN PLASTIC CONTAINER

AP	B BRAUN	10GM/100ML	N020006 002	Jul 26, 1993

MANNITOL 15% IN PLASTIC CONTAINER

AP	B BRAUN	15GM/100ML	N020006 003	Jul 26, 1993

MANNITOL 20% IN PLASTIC CONTAINER

AP	B BRAUN	20GM/100ML	N020006 004	Jul 26, 1993

AP	ICU MEDICAL INC	20GM/100ML	N019603 004	Jan 08, 1990

MANNITOL 25%

AP	FRESENIUS KABI USA	12.5GM/50ML	A080677 001	

AP	HOSPIRA	12.5GM/50ML	N016269 006	Aug 25, 1994

MANNITOL 5% IN PLASTIC CONTAINER

AP	B BRAUN	5GM/100ML	N020006 001	Jul 26, 1993

OSMITROL 10% IN WATER

AP	BAXTER HLTHCARE	10GM/100ML	N013684 002	

OSMITROL 10% IN WATER IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	10GM/100ML	N013684 006	

OSMITROL 15% IN WATER

AP	BAXTER HLTHCARE	15GM/100ML	N013684 004	

OSMITROL 15% IN WATER IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	15GM/100ML	N013684 008	

OSMITROL 20% IN WATER

AP	BAXTER HLTHCARE	20GM/100ML	N013684 003	

OSMITROL 20% IN WATER IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	20GM/100ML	N013684 007	

OSMITROL 5% IN WATER

AP	BAXTER HLTHCARE	5GM/100ML	N013684 001	

OSMITROL 5% IN WATER IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE	5GM/100ML	N013684 005	

POWDER;INHALATION

ARIDOL KIT

+	PHARMAXIS LTD	N/A, 5MG, 10MG, 20MG, 40MG	N022368 001	Oct 05, 2010

BRONCHITOL

+	CHIESI	40MG	N202049 001	Oct 30, 2020

MANNITOL; SORBITOL

SOLUTION;IRRIGATION

SORBITOL-MANNITOL IN PLASTIC CONTAINER

+	ICU MEDICAL INC	540MG/100ML;2.7GM/100ML	N018316 001	

PRESCRIPTION DRUG PRODUCT LIST

3-289 (of 474)

MARALIXIBAT CHLORIDE

SOLUTION; ORAL

LIVMARLI

+! MIRUM

EQ 9.5MG BASE/ML

N214662 001 Sep 29, 2021

MARAVIROC

SOLUTION; ORAL

SELZENTRY

+! VIIV HLTHCARE

20MG/ML

N208984 001 Nov 04, 2016

TABLET; ORAL

MARAVIROC**AB** HETERO LABS LTD III**150MG****A203347 001** Feb 07, 2022**AB** **300MG****A203347 002** Feb 07, 2022SELZENTRY**AB** + VIIV HLTHCARE**150MG****N022128 001** Aug 06, 2007**AB** +! **300MG****N022128 002** Aug 06, 2007

+ 25MG

N022128 003 Nov 04, 2016

+ 75MG

N022128 004 Nov 04, 2016

MARIBAVIR

TABLET; ORAL

LIVTENCITY

+! TAKEDA PHARMS USA

200MG

N215596 001 Nov 23, 2021

MAVACAMTEN

CAPSULE; ORAL

CAMZYOS

+ BRISTOL

2.5MG

N214998 001 Apr 28, 2022

+ 5MG

N214998 002 Apr 28, 2022

+ 10MG

N214998 003 Apr 28, 2022

+! 15MG

N214998 004 Apr 28, 2022

MEBENDAZOLE

TABLET, CHEWABLE; ORAL

EMVERM

! IMPAX LABS INC

100MG

A073580 001 Jan 04, 1995

MECAMYLAMINE HYDROCHLORIDE

TABLET; ORAL

MECAMYLAMINE HYDROCHLORIDE

! LGM PHARMA

2.5MG

A204054 001 Mar 19, 2013

MECHLORETHAMINE HYDROCHLORIDE

GEL; TOPICAL

VALCHLOR

+! HELSINN

EQ 0.016% BASE

N202317 001 Aug 23, 2013

MECLIZINE HYDROCHLORIDE

TABLET; ORAL

ANTIVERT**AA** + CASPER PHARMA LLC**12.5MG****N010721 006****AA** + **25MG****N010721 004****AA** + **50MG****N010721 001** Jan 20, 1982MECLIZINE HYDROCHLORIDE**AA** ! AMNEAL PHARMS **12.5MG****A201451 001** Feb 23, 2011**AA** ! **25MG****A201451 002** Feb 23, 2011**AA** ANI PHARMS **12.5MG****A084657 002****AA** **25MG****A084657 001****AA** APNAR PHARMA LP **12.5MG****A087128 002****AA** **25MG****A087128 001****AA** EPIC PHARMA LLC **12.5MG****A200294 001** Apr 13, 2012**AA** **25MG****A200294 002** Apr 13, 2012**AA** INDICUS PHARMA **12.5MG****A205136 001** Feb 22, 2019**AA** **25MG****A205136 002** Feb 22, 2019**AA** **50MG****A205136 003** Feb 22, 2019**AA** INVAGEN PHARMS **12.5MG****A200432 001** Feb 17, 2022**AA** **25MG****A200432 002** Feb 17, 2022**AA** **50MG****A200432 003** Feb 17, 2022**AA** INVATECH **25MG****A084092 003** May 22, 1989**AA** JUBILANT CADISTA **12.5MG****A040659 001** Jun 04, 2010**AA** **25MG****A040659 002** Jun 04, 2010**AA** LUPIN LTD **12.5MG****A203003 001** Aug 11, 2022**AA** **25MG****A203003 002** Aug 11, 2022**AA** **50MG****A203003 003** Aug 11, 2022**AA** SANDOZ **12.5MG****A084843 002** May 22, 1989**AA** ZYDUS **12.5MG****A213957 001** Jun 23, 2020

PRESCRIPTION DRUG PRODUCT LIST

3-290 (of 474)

MECLIZINE HYDROCHLORIDE

TABLET; ORAL

MECLIZINE HYDROCHLORIDE

AA		25MG	A213957	002	Jun 23, 2020

TABLET, CHEWABLE; ORAL

ANTIVERT

AA	+	CASPER PHARMA LLC	25MG	N010721	005

MECLIZINE HYDROCHLORIDE

AA		INVAGEN PHARMS	25MG	A200791	001	Feb 17, 2022

MECLOFENAMATE SODIUM

CAPSULE; ORAL

MECLOFENAMATE SODIUM

MYLAN

EQ 50MG BASE

A071081 002 Sep 03, 1986

!

EQ 100MG BASE

A071081 001 Sep 03, 1986

MEDROXYPROGESTERONE ACETATE

INJECTABLE; INJECTION

DEPO-PROVERA

AB	+	PFIZER	150MG/ML	N020246	001	Oct 29, 1992

MEDROXYPROGESTERONE ACETATE

AB		AMPHASTAR PHARMS INC	150MG/ML	A077235	001	Nov 28, 2017

AB			150MG/ML	A077334	001	Nov 28, 2017

AB		EUGIA PHARMA	150MG/ML	A212824	001	Aug 22, 2022

AB			150MG/ML	A212844	001	Aug 31, 2022

AB		HIKMA	150MG/ML	A214309	001	Jan 05, 2023

AB		MYLAN LABS LTD	150MG/ML	A210227	001	Oct 12, 2018

AB		TEVA PHARMS USA	150MG/ML	A076553	001	Jul 28, 2004

INJECTABLE; SUBCUTANEOUS

DEPO-SUBQ PROVERA 104

+! PFIZER

104MG/0.65ML

N021583 001 Dec 17, 2004

TABLET; ORAL

MEDROXYPROGESTERONE ACETATE

AB		BARR	2.5MG	A040159	001	Aug 09, 1996

AB			5MG	A040159	002	Aug 09, 1996

AB			10MG	A040159	003	Aug 09, 1996

PROVERA

AB	+	PFIZER	2.5MG	N011839	001

AB	+		5MG	N011839	003

AB	+	!	10MG	N011839	004

MEFENAMIC ACID

CAPSULE; ORAL

MEFENAMIC ACID

AB		BELCHER	250MG	A091608	001	Jun 02, 2014

AB		LUPIN LTD	250MG	A091322	001	Jul 22, 2011

AB		MICRO LABS	250MG	A090562	001	Nov 19, 2010

PONSTEL

AB	+	!	AVION PHARMS	250MG	N015034	003

MEFLOQUINE HYDROCHLORIDE

TABLET; ORAL

MEFLOQUINE HYDROCHLORIDE

AB	!	BARR	250MG	A076392	001	Dec 29, 2003

AB		HIKMA	250MG	A076523	001	Oct 01, 2004

MEGESTROL ACETATE

SUSPENSION; ORAL

MEGACE ES

AB	+	!	ENDO PHARMS INC	125MG/ML	N021778	001	Jul 05, 2005

MEGESTROL ACETATE

AB		AKORN	40MG/ML	A203960	001	Jun 09, 2017

AB		BRECKENRIDGE	125MG/ML	A204688	001	Dec 01, 2017

AB	!	STRIDES PHARMA	40MG/ML	A075671	001	Jul 25, 2001

AB		TWI PHARMS	125MG/ML	A203139	001	Aug 27, 2014

AB		WOCKHARDT BIO AG	40MG/ML	A076721	001	Nov 01, 2004

TABLET; ORAL

MEGESTROL ACETATE

AB		BARR	20MG	A074621	002	Aug 16, 1996

AB			40MG	A074621	001	Nov 30, 1995

AB		STRIDES PHARMA	20MG	A072422	001	Aug 08, 1988

AB	!		40MG	A072423	001	Aug 08, 1988

PRESCRIPTION DRUG PRODUCT LIST

3-291 (of 474)

MELOXICAM

CAPSULE; ORAL

MELOXICAM

<u>AB</u>	LUPIN LTD	<u>5MG</u>	<u>A209487</u>	<u>001</u>	Jun 01, 2020
<u>AB</u>	!	<u>10MG</u>	<u>A209487</u>	<u>002</u>	Jun 01, 2020
<u>AB</u>	NOVITIUM PHARMA	<u>5MG</u>	<u>A211398</u>	<u>001</u>	Mar 09, 2021
<u>AB</u>		<u>10MG</u>	<u>A211398</u>	<u>002</u>	Mar 09, 2021

SUSPENSION; ORAL

MELOXICAM

+	AVONDALE PHARMS	7.5MG/5ML	N021530	001	Jun 01, 2004

TABLET; ORAL

MELOXICAM

<u>AB</u>	APOTEX INC	<u>7.5MG</u>	<u>A077882</u>	<u>001</u>	Jul 20, 2006
<u>AB</u>		<u>15MG</u>	<u>A077882</u>	<u>002</u>	Jul 20, 2006
<u>AB</u>	AUROBINDO PHARMA	<u>7.5MG</u>	<u>A078008</u>	<u>001</u>	Oct 02, 2006
<u>AB</u>		<u>15MG</u>	<u>A078008</u>	<u>002</u>	Oct 02, 2006
<u>AB</u>	CIPLA	<u>7.5MG</u>	<u>A077929</u>	<u>001</u>	Jul 19, 2006
<u>AB</u>		<u>15MG</u>	<u>A077929</u>	<u>002</u>	Jul 19, 2006
<u>AB</u>	DR REDDYS LABS INC	<u>7.5MG</u>	<u>A077931</u>	<u>001</u>	Jul 25, 2006
<u>AB</u>		<u>15MG</u>	<u>A077931</u>	<u>002</u>	Jul 25, 2006
<u>AB</u>	GLENMARK GENERICS	<u>7.5MG</u>	<u>A077932</u>	<u>001</u>	Jul 19, 2006
<u>AB</u>		<u>15MG</u>	<u>A077932</u>	<u>002</u>	Jul 19, 2006
<u>AB</u>	LUPIN PHARMS	<u>7.5MG</u>	<u>A077944</u>	<u>001</u>	Jul 19, 2006
<u>AB</u>		<u>15MG</u>	<u>A077944</u>	<u>002</u>	Jul 19, 2006
<u>AB</u>	PURACAP PHARM	<u>7.5MG</u>	<u>A077938</u>	<u>001</u>	Jul 19, 2006
<u>AB</u>		<u>15MG</u>	<u>A077938</u>	<u>002</u>	Jul 19, 2006
<u>AB</u>	STRIDES PHARMA	<u>7.5MG</u>	<u>A077928</u>	<u>001</u>	May 13, 2009
<u>AB</u>		<u>15MG</u>	<u>A077928</u>	<u>002</u>	May 13, 2009
<u>AB</u>	TARO	<u>7.5MG</u>	<u>A078102</u>	<u>001</u>	Nov 07, 2006
<u>AB</u>		<u>15MG</u>	<u>A078102</u>	<u>002</u>	Nov 07, 2006
<u>AB</u>	UNICHEM	<u>7.5MG</u>	<u>A077927</u>	<u>001</u>	Dec 20, 2006
<u>AB</u>		<u>15MG</u>	<u>A077927</u>	<u>002</u>	Dec 20, 2006
<u>AB</u>	YUNG SHIN PHARM	<u>7.5MG</u>	<u>A077918</u>	<u>001</u>	Dec 07, 2006
<u>AB</u>		<u>15MG</u>	<u>A077918</u>	<u>002</u>	Dec 07, 2006
<u>AB</u>	ZYDUS PHARMS USA	<u>7.5MG</u>	<u>A077921</u>	<u>001</u>	Jul 19, 2006
<u>AB</u>		<u>15MG</u>	<u>A077921</u>	<u>002</u>	Jul 19, 2006

MOBIC

<u>AB</u>	+	BOEHRINGER	<u>7.5MG</u>	<u>N020938</u>	<u>001</u>	Apr 13, 2000
		INGELHEIM				
<u>AB</u>	+	!	<u>15MG</u>	<u>N020938</u>	<u>002</u>	Aug 23, 2000

MELPHALAN

TABLET; ORAL

MELPHALAN

!	ALVOGEN	2MG	A207809	001	Mar 22, 2017

MELPHALAN HYDROCHLORIDE

INJECTABLE; INJECTION

MELPHALAN HYDROCHLORIDE

<u>AP</u>	ACTAVIS LLC	<u>EQ 50MG BASE/VIAL</u>	<u>A206018</u>	<u>001</u>	Dec 19, 2016	
<u>AP</u>	ALMAJECT	<u>EQ 50MG BASE/VIAL</u>	<u>A204817</u>	<u>001</u>	May 17, 2019	
<u>AP</u>	ARTHUR GRP	<u>EQ 50MG BASE/VIAL</u>	<u>A211463</u>	<u>001</u>	Sep 13, 2019	
<u>AP</u>	BPI LABS	<u>EQ 50MG BASE/VIAL</u>	<u>A209197</u>	<u>001</u>	May 08, 2020	
<u>AP</u>	DR REDDYS	<u>EQ 50MG BASE/VIAL</u>	<u>A203655</u>	<u>001</u>	Dec 08, 2017	
<u>AP</u>	FRESENIUS KABI USA	<u>EQ 50MG BASE/VIAL</u>	<u>A203393</u>	<u>001</u>	Dec 22, 2017	
<u>AP</u>	GLAND PHARMA LTD	<u>EQ 50MG BASE/VIAL</u>	<u>A209826</u>	<u>001</u>	May 28, 2019	
<u>AP</u>	HIKMA	<u>EQ 50MG BASE/VIAL</u>	<u>A090303</u>	<u>001</u>	Oct 28, 2010	
<u>AP</u>	INGENUS PHARMS LLC	<u>EQ 50MG BASE/VIAL</u>	<u>A210947</u>	<u>001</u>	Feb 18, 2020	
<u>AP</u>	MEITHEAL	<u>EQ 50MG BASE/VIAL</u>	<u>A212960</u>	<u>001</u>	May 28, 2021	
<u>AP</u>	!	MYLAN INSTITUTIONAL	<u>EQ 50MG BASE/VIAL</u>	<u>A090270</u>	<u>001</u>	Jun 09, 2009
<u>AP</u>	SAGENT PHARMS INC	<u>EQ 50MG BASE/VIAL</u>	<u>A201379</u>	<u>001</u>	Feb 28, 2017	

POWDER; INTRAVENOUS

EVOMELA

+	ACROTECH BIOPHARMA	EQ 50MG BASE/VIAL	N207155	001	Mar 10, 2016

MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

MEMANTINE HYDROCHLORIDE

<u>AB</u>	AMNEAL PHARMS	<u>7MG</u>	<u>A205825</u>	<u>001</u>	Oct 12, 2016
<u>AB</u>		<u>14MG</u>	<u>A205825</u>	<u>002</u>	Oct 12, 2016
<u>AB</u>		<u>21MG</u>	<u>A205825</u>	<u>003</u>	Oct 12, 2016
<u>AB</u>		<u>28MG</u>	<u>A205825</u>	<u>004</u>	Oct 12, 2016
<u>AB</u>	ANI PHARMS	<u>28MG</u>	<u>A205365</u>	<u>004</u>	Feb 28, 2020
<u>AB</u>	APOTEX	<u>7MG</u>	<u>A206135</u>	<u>001</u>	Nov 22, 2016

PRESCRIPTION DRUG PRODUCT LIST

3-292 (of 474)

MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

MEMANTINE HYDROCHLORIDE

<u>AB</u>		<u>14MG</u>	<u>A206135</u>	<u>002</u>	Nov 22, 2016
<u>AB</u>		<u>21MG</u>	<u>A206135</u>	<u>003</u>	Nov 22, 2016
<u>AB</u>		<u>28MG</u>	<u>A206135</u>	<u>004</u>	Nov 22, 2016
<u>AB</u>	AUROBINDO PHARMA LTD	<u>7MG</u>	<u>A214651</u>	<u>001</u>	Aug 09, 2021
<u>AB</u>		<u>14MG</u>	<u>A214651</u>	<u>002</u>	Aug 09, 2021
<u>AB</u>		<u>21MG</u>	<u>A214651</u>	<u>003</u>	Aug 09, 2021
<u>AB</u>		<u>28MG</u>	<u>A214651</u>	<u>004</u>	Aug 09, 2021
<u>AB</u>	LUPIN LTD	<u>7MG</u>	<u>A206028</u>	<u>001</u>	Sep 28, 2016
<u>AB</u>		<u>14MG</u>	<u>A206028</u>	<u>002</u>	Sep 28, 2016
<u>AB</u>		<u>21MG</u>	<u>A206028</u>	<u>003</u>	Sep 28, 2016
<u>AB</u>		<u>28MG</u>	<u>A206028</u>	<u>004</u>	Sep 28, 2016
<u>AB</u>	XIAMEN LP PHARM CO	<u>7MG</u>	<u>A213985</u>	<u>001</u>	Oct 11, 2022
<u>AB</u>		<u>14MG</u>	<u>A213985</u>	<u>002</u>	Oct 11, 2022
<u>AB</u>		<u>28MG</u>	<u>A213985</u>	<u>003</u>	Oct 11, 2022
<u>AB</u>	YICHANG HUMANWELL	<u>7MG</u>	<u>A211100</u>	<u>001</u>	Apr 02, 2021
<u>AB</u>		<u>14MG</u>	<u>A211100</u>	<u>002</u>	Apr 02, 2021
<u>AB</u>		<u>21MG</u>	<u>A211100</u>	<u>003</u>	Apr 02, 2021
<u>AB</u>		<u>28MG</u>	<u>A211100</u>	<u>004</u>	Apr 02, 2021
<u>AB</u>	ZYDUS PHARMS	<u>7MG</u>	<u>A203293</u>	<u>001</u>	Aug 03, 2017
<u>AB</u>		<u>14MG</u>	<u>A203293</u>	<u>002</u>	Aug 03, 2017
<u>AB</u>		<u>21MG</u>	<u>A203293</u>	<u>003</u>	Aug 03, 2017
<u>AB</u>		<u>28MG</u>	<u>A203293</u>	<u>004</u>	Aug 03, 2017
<u>NAMENDA XR</u>					
<u>AB</u>	+	ALLERGAN	<u>7MG</u>	<u>N022525</u>	<u>001</u> Jun 21, 2010
<u>AB</u>	+		<u>14MG</u>	<u>N022525</u>	<u>002</u> Jun 21, 2010
<u>AB</u>	+		<u>21MG</u>	<u>N022525</u>	<u>003</u> Jun 21, 2010
<u>AB</u>	+	!	<u>28MG</u>	<u>N022525</u>	<u>004</u> Jun 21, 2010

SOLUTION; ORAL

MEMANTINE HYDROCHLORIDE

<u>AA</u>	APOTEX	<u>2MG/ML</u>	<u>A209955</u>	<u>001</u>	Feb 09, 2018
<u>AA</u>	! CHARTWELL MOLECULAR	<u>2MG/ML</u>	<u>A204033</u>	<u>001</u>	Oct 13, 2015
<u>AA</u>	MACLEODS PHARMS LTD	<u>2MG/ML</u>	<u>A202790</u>	<u>001</u>	Oct 13, 2015
<u>AA</u>	SETON PHARMS	<u>2MG/ML</u>	<u>A210319</u>	<u>001</u>	Aug 31, 2020

TABLET; ORAL

MEMANTINE HYDROCHLORIDE

<u>AB</u>	AJANTA PHARMA LTD	<u>5MG</u>	<u>A206528</u>	<u>001</u>	Nov 30, 2015
<u>AB</u>		<u>10MG</u>	<u>A206528</u>	<u>002</u>	Nov 30, 2015
<u>AB</u>	ALEMBIC PHARMS	<u>5MG</u>	<u>A200891</u>	<u>001</u>	Oct 13, 2015
<u>AB</u>		<u>10MG</u>	<u>A200891</u>	<u>002</u>	Oct 13, 2015
<u>AB</u>	AMNEAL PHARMS	<u>5MG</u>	<u>A090041</u>	<u>001</u>	Apr 10, 2015
<u>AB</u>		<u>10MG</u>	<u>A090041</u>	<u>002</u>	Apr 10, 2015
<u>AB</u>	AUROBINDO PHARMA LTD	<u>5MG</u>	<u>A203175</u>	<u>001</u>	Oct 13, 2015
<u>AB</u>		<u>10MG</u>	<u>A203175</u>	<u>002</u>	Oct 13, 2015
<u>AB</u>	CADILA	<u>5MG</u>	<u>A090961</u>	<u>001</u>	Jul 10, 2017
<u>AB</u>		<u>10MG</u>	<u>A090961</u>	<u>002</u>	Jul 10, 2017
<u>AB</u>	CELLTRION	<u>5MG</u>	<u>A090073</u>	<u>001</u>	Sep 04, 2015
<u>AB</u>		<u>10MG</u>	<u>A090073</u>	<u>002</u>	Sep 04, 2015
<u>AB</u>	DR REDDYS LABS LTD	<u>5MG</u>	<u>A090048</u>	<u>001</u>	Apr 14, 2010
<u>AB</u>		<u>10MG</u>	<u>A090048</u>	<u>002</u>	Apr 14, 2010
<u>AB</u>	HETERO LABS LTD V	<u>5MG</u>	<u>A204389</u>	<u>001</u>	Sep 26, 2022
<u>AB</u>		<u>10MG</u>	<u>A204389</u>	<u>002</u>	Sep 26, 2022
<u>AB</u>	HIKMA	<u>5MG</u>	<u>A208173</u>	<u>001</u>	Feb 28, 2020
<u>AB</u>		<u>10MG</u>	<u>A208173</u>	<u>002</u>	Feb 28, 2020
<u>AB</u>	LUPIN LTD	<u>5MG</u>	<u>A090051</u>	<u>001</u>	Apr 10, 2015
<u>AB</u>		<u>10MG</u>	<u>A090051</u>	<u>002</u>	Apr 10, 2015
<u>AB</u>	MACLEODS PHARMS LTD	<u>5MG</u>	<u>A202840</u>	<u>001</u>	Oct 13, 2015
<u>AB</u>		<u>10MG</u>	<u>A202840</u>	<u>002</u>	Oct 13, 2015
<u>AB</u>	POLYGEN PHARMS	<u>5MG</u>	<u>A210587</u>	<u>001</u>	Dec 11, 2020
<u>AB</u>		<u>10MG</u>	<u>A210587</u>	<u>002</u>	Dec 11, 2020
<u>AB</u>	PURACAP PHARM LLC	<u>5MG</u>	<u>A206855</u>	<u>001</u>	Nov 17, 2015
<u>AB</u>		<u>10MG</u>	<u>A206855</u>	<u>002</u>	Nov 17, 2015
<u>AB</u>	RENATA	<u>5MG</u>	<u>A209527</u>	<u>001</u>	May 07, 2018
<u>AB</u>		<u>10MG</u>	<u>A209527</u>	<u>002</u>	May 07, 2018
<u>AB</u>	STRIDES PHARMA	<u>5MG</u>	<u>A202350</u>	<u>001</u>	May 23, 2017
<u>AB</u>		<u>10MG</u>	<u>A202350</u>	<u>002</u>	May 23, 2017
<u>AB</u>	SUN PHARM	<u>5MG</u>	<u>A090058</u>	<u>001</u>	May 05, 2010
<u>AB</u>		<u>10MG</u>	<u>A090058</u>	<u>002</u>	May 05, 2010
<u>AB</u>	UNICHEM	<u>5MG</u>	<u>A200022</u>	<u>001</u>	Oct 13, 2015

PRESCRIPTION DRUG PRODUCT LIST

3-293 (of 474)

MEMANTINE HYDROCHLORIDE

TABLET; ORAL

MEMANTINE HYDROCHLORIDE

<u>AB</u>		<u>10MG</u>	<u>A200022</u>	<u>002</u>	Oct 13, 2015
<u>AB</u>	UPSHER SMITH LABS	<u>5MG</u>	<u>A090043</u>	<u>001</u>	Jul 31, 2015
<u>AB</u>		<u>10MG</u>	<u>A090043</u>	<u>002</u>	Jul 31, 2015

NAMENDA

<u>AB</u>	+	ALLERGAN	<u>5MG</u>	<u>N021487</u>	<u>001</u>	Oct 16, 2003
<u>AB</u>	+	!	<u>10MG</u>	<u>N021487</u>	<u>002</u>	Oct 16, 2003

MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

DEMEROL

<u>AP</u>	+	HOSPIRA	<u>25MG/ML</u>	<u>N021171</u>	<u>001</u>	
<u>AP</u>	+	!	<u>50MG/ML</u>	<u>N021171</u>	<u>002</u>	
<u>AP</u>	+	!	<u>75MG/ML</u>	<u>N021171</u>	<u>003</u>	
<u>AP</u>	+	!	<u>100MG/ML</u>	<u>N021171</u>	<u>004</u>	

MEPERIDINE HYDROCHLORIDE

<u>AP</u>		WEST-WARD PHARMS	<u>25MG/ML</u>	<u>A080445</u>	<u>001</u>	
		INT				
<u>AP</u>			<u>25MG/ML</u>	<u>A080455</u>	<u>007</u>	
<u>AP</u>			<u>50MG/ML</u>	<u>A080445</u>	<u>002</u>	
<u>AP</u>			<u>50MG/ML</u>	<u>A080455</u>	<u>008</u>	
<u>AP</u>			<u>75MG/ML</u>	<u>A080445</u>	<u>003</u>	
<u>AP</u>			<u>75MG/ML</u>	<u>A080455</u>	<u>009</u>	
<u>AP</u>			<u>100MG/ML</u>	<u>A080445</u>	<u>004</u>	
<u>AP</u>			<u>100MG/ML</u>	<u>A080455</u>	<u>010</u>	

MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE

!	WEST-WARD PHARMS	10MG/ML		A081002	001	Jul 30, 1993
	INT					

SYRUP; ORAL

MEPERIDINE HYDROCHLORIDE

!	HIKMA	50MG/5ML		A088744	001	Jan 30, 1985

TABLET; ORAL

MEPERIDINE HYDROCHLORIDE

	EPIC PHARMA	50MG		A040331	001	May 28, 1999
		100MG		A040331	002	May 28, 1999

MEPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

CARBOCAINE

<u>AP</u>	+	HOSPIRA	<u>1%</u>	<u>N012250</u>	<u>001</u>	
<u>AP</u>	+	!	<u>1.5%</u>	<u>N012250</u>	<u>005</u>	
<u>AP</u>	+	!	<u>2%</u>	<u>N012250</u>	<u>002</u>	

POLOCAINE

<u>AP</u>		FRESENIUS KABI USA	<u>1%</u>	<u>A089407</u>	<u>001</u>	Dec 01, 1986
<u>AP</u>			<u>2%</u>	<u>A089410</u>	<u>001</u>	Dec 01, 1986

POLOCAINE-MPF

<u>AP</u>		FRESENIUS KABI USA	<u>1%</u>	<u>A089406</u>	<u>001</u>	Dec 01, 1986
<u>AP</u>			<u>1.5%</u>	<u>A089408</u>	<u>001</u>	Dec 01, 1986
<u>AP</u>			<u>2%</u>	<u>A089409</u>	<u>001</u>	Dec 01, 1986

SCANDONEST PLAIN

<u>AP</u>	!	DEPROCO	<u>3%</u>	<u>A088387</u>	<u>001</u>	Oct 10, 1984

MEPROBAMATE

TABLET; ORAL

MEPROBAMATE

<u>AA</u>	!	ALEMBIC PHARMS LTD	<u>200MG</u>	<u>A090122</u>	<u>001</u>	Feb 18, 2009
<u>AA</u>	!		<u>400MG</u>	<u>A090122</u>	<u>002</u>	Feb 18, 2009
<u>AA</u>		INVAGEN PHARMS	<u>200MG</u>	<u>A040797</u>	<u>001</u>	Feb 27, 2008
<u>AA</u>			<u>400MG</u>	<u>A040797</u>	<u>002</u>	Feb 27, 2008

MERCAPTOPURINE

SUSPENSION; ORAL

PURIXAN

+	NOVA LABS LTD	20MG/ML		N205919	001	Apr 28, 2014

TABLET; ORAL

MERCAPTOPURINE

<u>AB</u>		DR REDDYS LABS SA	<u>50MG</u>	<u>A040461</u>	<u>001</u>	Feb 11, 2004
<u>AB</u>	!	HIKMA	<u>50MG</u>	<u>A040528</u>	<u>001</u>	Feb 13, 2004
<u>AB</u>		MYLAN	<u>50MG</u>	<u>A040594</u>	<u>001</u>	Jul 01, 2005

PURINETHOL

<u>AB</u>	+	STASON PHARMS	<u>50MG</u>	<u>N009053</u>	<u>002</u>	

PRESCRIPTION DRUG PRODUCT LIST

3-294 (of 474)

MEROPENEM

INJECTABLE; INJECTION

MEROPENEM

<u>AP</u>	ACS DOBFAR	<u>500MG/VIAL</u>	<u>A091404</u>	<u>001</u>	Oct 26, 2011
<u>AP</u>		<u>1GM/VIAL</u>	<u>A091404</u>	<u>002</u>	Oct 26, 2011
<u>AP</u>	ACS DOBFAR SPA	<u>500MG/VIAL</u>	<u>A204139</u>	<u>001</u>	Jun 09, 2016
<u>AP</u>		<u>1GM/VIAL</u>	<u>A204139</u>	<u>002</u>	Jun 09, 2016
<u>AP</u>	AMNEAL PHARMS	<u>500MG/VIAL</u>	<u>A205883</u>	<u>001</u>	Apr 12, 2016
<u>AP</u>		<u>1GM/VIAL</u>	<u>A205883</u>	<u>002</u>	Apr 12, 2016
<u>AP</u>	BROOKS STERISCIENCE	<u>500MG/VIAL</u>	<u>A216154</u>	<u>001</u>	Aug 18, 2022
<u>AP</u>		<u>1GM/VIAL</u>	<u>A216154</u>	<u>002</u>	Aug 18, 2022
<u>AP</u>	DAEWOONG PHARM CO	<u>500MG/VIAL</u>	<u>A204854</u>	<u>001</u>	Dec 18, 2015
<u>AP</u>		<u>1GM/VIAL</u>	<u>A204854</u>	<u>002</u>	Dec 18, 2015
<u>AP</u>	EUGIA PHARMA	<u>500MG/VIAL</u>	<u>A205835</u>	<u>001</u>	Mar 27, 2017
<u>AP</u>		<u>1GM/VIAL</u>	<u>A205835</u>	<u>002</u>	Mar 27, 2017
<u>AP</u>	GLAND	<u>500MG/VIAL</u>	<u>A206141</u>	<u>001</u>	Jun 08, 2016
<u>AP</u>		<u>1GM/VIAL</u>	<u>A206141</u>	<u>002</u>	Jun 08, 2016
<u>AP</u>	HQ SPCLT PHARMA	<u>500MG/VIAL</u>	<u>A210773</u>	<u>001</u>	Aug 16, 2019
<u>AP</u>		<u>1GM/VIAL</u>	<u>A210773</u>	<u>002</u>	Aug 16, 2019
<u>AP</u>	SAVIOR LIFETEC CORP	<u>500MG/VIAL</u>	<u>A206086</u>	<u>001</u>	Apr 19, 2016
<u>AP</u>		<u>1GM/VIAL</u>	<u>A206086</u>	<u>002</u>	Apr 19, 2016

MERREM

<u>AP</u>	<u>+</u> ! PFIZER	<u>500MG/VIAL</u>	<u>N050706</u>	<u>003</u>	Jun 21, 1996
<u>AP</u>	<u>+</u> !	<u>1GM/VIAL</u>	<u>N050706</u>	<u>001</u>	Jun 21, 1996

POWDER; INTRAVENOUS

MEROPENEM AND SODIUM CHLORIDE IN DUPLEX CONTAINER

B BRAUN MEDICAL INC	500MG/VIAL	N202106	001	Apr 30, 2015
	1GM/VIAL	N202106	002	Apr 30, 2015

MEROPENEM; VABORBACTAM

POWDER; INTRAVENOUS

VABOMERE

<u>+</u> ! REMPEX	1GM/VIAL; 1GM/VIAL	N209776	001	Aug 29, 2017

MESALAMINE

CAPSULE, DELAYED RELEASE; ORAL

DELZICOL

<u>AB</u>	<u>+</u> ! APIL	<u>400MG</u>	<u>N204412</u>	<u>001</u>	Feb 01, 2013

MESALAMINE

<u>AB</u>	TEVA PHARMS USA	<u>400MG</u>	<u>A207873</u>	<u>001</u>	May 09, 2019

CAPSULE, EXTENDED RELEASE; ORAL

APRISO

<u>AB</u>	<u>+</u> ! VALEANT PHARMS INTL	<u>375MG</u>	<u>N022301</u>	<u>001</u>	Oct 31, 2008

MESALAMINE

<u>AB</u>	ALEMBIC PHARMS	<u>375MG</u>	<u>A216967</u>	<u>001</u>	Oct 28, 2022
<u>AB</u>	ALKEM LABS LTD	<u>375MG</u>	<u>A214242</u>	<u>001</u>	Jul 15, 2021
<u>AB</u>	MYLAN	<u>375MG</u>	<u>A207271</u>	<u>001</u>	Nov 20, 2019
<u>AB</u>	SUN PHARM	<u>500MG</u>	<u>A214585</u>	<u>001</u>	May 11, 2022
<u>AB</u>	ZYDUS PHARMS	<u>375MG</u>	<u>A208954</u>	<u>001</u>	Aug 12, 2021

PENTASA

<u>AB</u>	<u>+</u> ! TAKEDA PHARMS USA	<u>500MG</u>	<u>N020049</u>	<u>002</u>	Jul 08, 2004
<u>+</u>		250MG	N020049	001	May 10, 1993

ENEMA; RECTAL

MESALAMINE

<u>AB</u>	PADAGIS ISRAEL	<u>4GM/60ML</u>	<u>A076751</u>	<u>001</u>	Sep 17, 2004

ROWASA

<u>AB</u>	<u>+</u> ! MYLAN SPECIALITY LP	<u>4GM/60ML</u>	<u>N019618</u>	<u>001</u>	Dec 24, 1987

SFROWASA

<u>AB</u>	<u>+</u> MYLAN SPECIALITY LP	<u>4GM/60ML</u>	<u>N019618</u>	<u>002</u>	Jun 20, 2008

SUPPOSITORY; RECTAL

CANASA

<u>AB</u>	<u>+</u> ! ALLERGAN	<u>1GM</u>	<u>N021252</u>	<u>002</u>	Nov 05, 2004

MESALAMINE

<u>AB</u>	ACTAVIS MID ATLANTIC	<u>1GM</u>	<u>A205654</u>	<u>001</u>	Aug 14, 2020
<u>AB</u>	AMRING PHARMS	<u>1GM</u>	<u>A208362</u>	<u>001</u>	Jun 21, 2019
<u>AB</u>	ANNORA PHARMA	<u>1GM</u>	<u>A213377</u>	<u>001</u>	Mar 19, 2020
<u>AB</u>	MYLAN	<u>1GM</u>	<u>A204354</u>	<u>001</u>	Nov 24, 2015
<u>AB</u>	PHARM SOURCING	<u>1GM</u>	<u>A207448</u>	<u>001</u>	Apr 19, 2019
<u>AB</u>	SANDOZ INC	<u>1GM</u>	<u>A202065</u>	<u>001</u>	Jun 12, 2019
<u>AB</u>	ZYDUS PHARMS	<u>1GM</u>	<u>A208953</u>	<u>001</u>	Feb 12, 2020

PRESCRIPTION DRUG PRODUCT LIST

3-295 (of 474)

MESALAMINE

TABLET, DELAYED RELEASE; ORAL

LIALDA

AB	+!	TAKEDA PHARMS USA	1.2GM	N022000	001	Jan 16, 2007

MESALAMINE

AB		ACTAVIS LABS FL	1.2GM	A203817	001	Mar 23, 2018

AB		SUN PHARM	1.2GM	A211858	001	Jan 25, 2019

AB		ZYDUS PHARMS	1.2GM	A091640	001	Jun 05, 2017

	!		800MG	A203286	001	Jul 21, 2017

MESNA

INJECTABLE; INTRAVENOUS

MESNA

AP		FRESENIUS KABI USA	100MG/ML	A075811	001	Apr 26, 2001

AP		GLAND	100MG/ML	A206992	001	Dec 18, 2017

AP		HIKMA	100MG/ML	A075739	001	Jan 09, 2004

AP		SAGENT PHARMS INC	100MG/ML	A090913	001	Apr 13, 2010

MESNEX

AP	+!	BAXTER HLTHCARE	100MG/ML	N019884	001	Dec 30, 1988

TABLET; ORAL

MESNEX

	+!	BAXTER HLTHCARE	400MG	N020855	001	Mar 21, 2002

METAPROTERENOL SULFATE

SYRUP; ORAL

METAPROTERENOL SULFATE

	!	ANDA REPOSITORY	10MG/5ML	A073632	001	Jul 22, 1992

METARAMINOL BITARTRATE

INJECTABLE; INJECTION

METARAMINOL BITARTRATE

		SLAYBACK PHARMA LLC	EQ 10MG BASE/ML	A211304	001	Aug 24, 2021

METAXALONE

TABLET; ORAL

METAXALONE

AB		ACTAVIS LABS FL INC	800MG	A203695	001	Jun 15, 2017

AB		AMNEAL PHARMS	800MG	A203399	001	Jun 21, 2013

AB		LANNETT CO INC	800MG	A204770	001	Nov 22, 2016

AB		MOUNTAIN	400MG	A040486	001	Feb 27, 2015

AB		SANDOZ	800MG	A040445	001	Mar 31, 2010

AB		SCIEGEN PHARMS INC	400MG	A207466	002	Mar 13, 2020

AB			800MG	A207466	001	Aug 31, 2017

SKELAXIN

AB	+!	KING PHARMS	800MG	N013217	003	Aug 30, 2002

METAXALONE

BX		APPCO	800MG	A208774	001	Sep 24, 2018

METFORMIN HYDROCHLORIDE

SOLUTION; ORAL

METFORMIN HYDROCHLORIDE

AB	!	SAPTALIS PHARMS	500MG/5ML	A211309	001	Mar 03, 2020

AB		VISTAPHARM	500MG/5ML	A212677	001	Aug 19, 2022

TABLET; ORAL

METFORMIN HYDROCHLORIDE

AB		ALKEM	500MG	A091184	001	Nov 01, 2010

AB			850MG	A091184	002	Nov 01, 2010

AB			1GM	A091184	003	Nov 01, 2010

AB		AMNEAL PHARMS NY	500MG	A077880	001	Jun 05, 2006

AB			850MG	A077880	002	Jun 05, 2006

AB			1GM	A077880	003	Jun 05, 2006

AB		APOTEX	500MG	A075984	001	Apr 23, 2002

AB			500MG	A090666	001	Dec 07, 2011

AB			850MG	A075984	002	Apr 23, 2002

AB			850MG	A090666	002	Dec 07, 2011

AB			1GM	A075984	003	Apr 23, 2002

AB			1GM	A090666	003	Dec 07, 2011

AB		ATLAS PHARMS LLC	500MG	A076033	001	Jan 24, 2002

AB			850MG	A076033	002	Jan 24, 2002

AB			1GM	A076033	003	Jan 24, 2002

AB		AUROBINDO	500MG	A077095	001	Jan 14, 2005

AB			850MG	A077095	002	Jan 14, 2005

AB			1GM	A077095	003	Jan 14, 2005

AB		CHARTWELL	500MG	A075972	001	Jan 24, 2002

AB			850MG	A075972	002	Jan 24, 2002

PRESCRIPTION DRUG PRODUCT LIST

3-296 (of 474)

METFORMIN HYDROCHLORIDE

TABLET; ORAL

METFORMIN HYDROCHLORIDE

<u>AB</u>		<u>1GM</u>	<u>A075972</u>	<u>003</u>	Jan 24, 2002
<u>AB</u>	CSPC OUYI	<u>500MG</u>	<u>A205096</u>	<u>001</u>	Jul 11, 2016
<u>AB</u>		<u>850MG</u>	<u>A205096</u>	<u>002</u>	Jul 11, 2016
<u>AB</u>		<u>1GM</u>	<u>A205096</u>	<u>003</u>	Jul 11, 2016
<u>AB</u>	DR REDDYS LABS INC	<u>500MG</u>	<u>A077787</u>	<u>001</u>	Aug 23, 2006
<u>AB</u>		<u>850MG</u>	<u>A077787</u>	<u>002</u>	Aug 23, 2006
<u>AB</u>		<u>1GM</u>	<u>A077787</u>	<u>003</u>	Aug 23, 2006
<u>AB</u>	EPIC PHARMA	<u>500MG</u>	<u>A075965</u>	<u>001</u>	Jan 25, 2002
<u>AB</u>		<u>850MG</u>	<u>A075965</u>	<u>002</u>	Jan 25, 2002
<u>AB</u>		<u>1GM</u>	<u>A075965</u>	<u>003</u>	Jan 25, 2002
<u>AB</u>	GLENMARK GENERICS	<u>500MG</u>	<u>A078170</u>	<u>001</u>	May 23, 2008
<u>AB</u>		<u>850MG</u>	<u>A078170</u>	<u>002</u>	May 23, 2008
<u>AB</u>		<u>1GM</u>	<u>A078170</u>	<u>003</u>	May 23, 2008
<u>AB</u>	GRANULES INDIA	<u>500MG</u>	<u>A090564</u>	<u>001</u>	Apr 22, 2010
<u>AB</u>		<u>850MG</u>	<u>A090564</u>	<u>002</u>	Apr 22, 2010
<u>AB</u>	!	<u>1GM</u>	<u>A090564</u>	<u>003</u>	Apr 22, 2010
<u>AB</u>	HARMAN FINOCHEM	<u>500MG</u>	<u>A213320</u>	<u>001</u>	Dec 03, 2021
<u>AB</u>		<u>850MG</u>	<u>A213320</u>	<u>002</u>	Dec 03, 2021
<u>AB</u>		<u>1GM</u>	<u>A213320</u>	<u>003</u>	Dec 03, 2021
<u>AB</u>	LAURUS	<u>500MG</u>	<u>A209882</u>	<u>001</u>	Aug 27, 2018
<u>AB</u>		<u>850MG</u>	<u>A209882</u>	<u>002</u>	Aug 27, 2018
<u>AB</u>		<u>1GM</u>	<u>A209882</u>	<u>003</u>	Aug 27, 2018
<u>AB</u>	MARKSANS PHARMA	<u>500MG</u>	<u>A090888</u>	<u>001</u>	Mar 12, 2012
<u>AB</u>		<u>850MG</u>	<u>A090888</u>	<u>002</u>	Mar 12, 2012
<u>AB</u>		<u>1GM</u>	<u>A090888</u>	<u>003</u>	Mar 12, 2012
<u>AB</u>	MYLAN	<u>500MG</u>	<u>A075973</u>	<u>001</u>	Jan 25, 2002
<u>AB</u>		<u>850MG</u>	<u>A075973</u>	<u>002</u>	Jan 25, 2002
<u>AB</u>		<u>1GM</u>	<u>A075973</u>	<u>003</u>	Jan 25, 2002
<u>AB</u>	SCIEGEN PHARMS INC	<u>500MG</u>	<u>A203769</u>	<u>001</u>	Sep 11, 2013
<u>AB</u>		<u>850MG</u>	<u>A203769</u>	<u>002</u>	Sep 11, 2013
<u>AB</u>		<u>1GM</u>	<u>A203769</u>	<u>003</u>	Sep 11, 2013
<u>AB</u>	SUN PHARM INDS INC	<u>500MG</u>	<u>A075967</u>	<u>001</u>	Jan 29, 2002
<u>AB</u>		<u>850MG</u>	<u>A075967</u>	<u>002</u>	Jan 29, 2002
<u>AB</u>		<u>1GM</u>	<u>A075967</u>	<u>003</u>	Jan 29, 2002
<u>AB</u>	ZYDUS HLTHCARE	<u>500MG</u>	<u>A203686</u>	<u>001</u>	Aug 28, 2014
<u>AB</u>		<u>850MG</u>	<u>A203686</u>	<u>002</u>	Aug 28, 2014
<u>AB</u>		<u>1GM</u>	<u>A203686</u>	<u>003</u>	Aug 28, 2014
<u>AB</u>	ZYDUS PHARMS USA	<u>500MG</u>	<u>A077064</u>	<u>001</u>	Apr 18, 2005
<u>AB</u>		<u>850MG</u>	<u>A077064</u>	<u>002</u>	Apr 18, 2005
<u>AB</u>		<u>1GM</u>	<u>A077064</u>	<u>003</u>	Apr 18, 2005
	CHARTWELL	625MG	A075972	005	Jan 24, 2002
		750MG	A075972	004	Jan 24, 2002

TABLET, EXTENDED RELEASE; ORAL

METFORMIN HYDROCHLORIDE

<u>AB</u>	ACTAVIS LABS FL INC	<u>750MG</u>	<u>A076869</u>	<u>001</u>	Apr 12, 2005
<u>AB</u>	!	<u>750MG</u>	<u>A206145</u>	<u>002</u>	Oct 22, 2018
<u>AB</u>	AMNEAL PHARMS NY	<u>750MG</u>	<u>A078596</u>	<u>002</u>	Jan 03, 2008
<u>AB</u>	AUROBINDO PHARMA LTD	<u>750MG</u>	<u>A079118</u>	<u>002</u>	Jul 20, 2012
<u>AB</u>	BEXIMCO PHARMS USA	<u>750MG</u>	<u>A207427</u>	<u>002</u>	Dec 13, 2016
<u>AB</u>	CADILA	<u>750MG</u>	<u>A077078</u>	<u>001</u>	Apr 21, 2005
<u>AB</u>	CSPC OUYI	<u>750MG</u>	<u>A078321</u>	<u>002</u>	Apr 17, 2008
<u>AB</u>	GRANULES	<u>750MG</u>	<u>A209313</u>	<u>002</u>	Mar 16, 2018
<u>AB</u>	INTELLIPHARMACEUTIC S	<u>750MG</u>	<u>A202306</u>	<u>002</u>	Feb 23, 2017
<u>AB</u>	MACLEODS PHARMS LTD	<u>750MG</u>	<u>A206955</u>	<u>002</u>	Dec 07, 2016
<u>AB</u>	MARKSANS PHARMA	<u>750MG</u>	<u>A090295</u>	<u>002</u>	Apr 29, 2016
<u>AB</u>	NOSTRUM PHARMS LLC	<u>750MG</u>	<u>A076756</u>	<u>002</u>	Dec 12, 2011
<u>AB</u>	PRINSTON INC	<u>750MG</u>	<u>A208880</u>	<u>002</u>	Sep 10, 2018
<u>AB</u>	SUN PHARM INDS (IN)	<u>750MG</u>	<u>A077336</u>	<u>002</u>	Feb 09, 2006
<u>AB</u>	TEVA	<u>750MG</u>	<u>A076864</u>	<u>001</u>	Apr 12, 2005
<u>AB</u>	UNICHEM	<u>750MG</u>	<u>A213359</u>	<u>002</u>	Aug 11, 2021
<u>AB</u>	YICHANG HUMANWELL	<u>750MG</u>	<u>A211052</u>	<u>002</u>	Sep 24, 2018
<u>AB1</u>	ALIGNSCIENCE PHARMA	<u>500MG</u>	<u>A209303</u>	<u>001</u>	Mar 19, 2018
<u>AB1</u>	ALKEM LABS LTD	<u>500MG</u>	<u>A206145</u>	<u>001</u>	Oct 22, 2018
<u>AB1</u>	AMNEAL PHARMS NY	<u>500MG</u>	<u>A078596</u>	<u>001</u>	Jan 03, 2008
<u>AB1</u>	AUROBINDO PHARMA LTD	<u>500MG</u>	<u>A079118</u>	<u>001</u>	Jul 20, 2012
<u>AB1</u>	BEXIMCO PHARMS USA	<u>500MG</u>	<u>A207427</u>	<u>001</u>	Dec 13, 2016
<u>AB1</u>	CADILA	<u>500MG</u>	<u>A077060</u>	<u>001</u>	Apr 20, 2005

PRESCRIPTION DRUG PRODUCT LIST

3-297 (of 474)

METFORMIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

METFORMIN HYDROCHLORIDE

<u>AB1</u>	CSPC OUYI	<u>500MG</u>	<u>A078321</u>	<u>001</u>	Apr 17, 2008
<u>AB1</u>	GRANULES	<u>500MG</u>	<u>A209313</u>	<u>001</u>	Mar 16, 2018
<u>AB1</u>	INTELLIPHARMACEUTIC S	<u>500MG</u>	<u>A202306</u>	<u>001</u>	Feb 23, 2017
<u>AB1</u>	INVENTIA	<u>500MG</u>	<u>A201991</u>	<u>001</u>	Jan 18, 2012
<u>AB1</u>	MACLEODS PHARMS LTD	<u>500MG</u>	<u>A206955</u>	<u>001</u>	Dec 07, 2016
<u>AB1</u>	MARKSANS PHARMA	<u>500MG</u>	<u>A090295</u>	<u>001</u>	Apr 29, 2016
<u>AB1</u>	NOSTRUM PHARMS LLC	<u>500MG</u>	<u>A076756</u>	<u>001</u>	Jul 26, 2006
<u>AB1</u>	PRINSTON INC	<u>500MG</u>	<u>A208880</u>	<u>001</u>	Sep 10, 2018
<u>AB1</u>	SANDOZ	<u>500MG</u>	<u>A076873</u>	<u>001</u>	Dec 14, 2004
<u>AB1</u>	SUN PHARM INDS (IN)	<u>500MG</u>	<u>A077336</u>	<u>001</u>	Feb 09, 2006
<u>AB1</u>	TEVA	<u>500MG</u>	<u>A076269</u>	<u>001</u>	Jun 18, 2004
<u>AB1</u>	UNICHEM	<u>500MG</u>	<u>A213359</u>	<u>001</u>	Aug 11, 2021
<u>AB1</u>	YICHANG HUMANWELL	<u>500MG</u>	<u>A211052</u>	<u>001</u>	Sep 24, 2018

FORTAMET

<u>AB2</u>	+ ANDRX LABS LLC	<u>1GM</u>	<u>N021574</u>	<u>002</u>	Apr 27, 2004

METFORMIN HYDROCHLORIDE

<u>AB2</u>	AJANTA PHARMA LTD	<u>500MG</u>	<u>A213651</u>	<u>001</u>	Apr 09, 2020
<u>AB2</u>		<u>1GM</u>	<u>A213651</u>	<u>002</u>	Apr 09, 2020
<u>AB2</u>	LUPIN LTD	<u>500MG</u>	<u>A090692</u>	<u>001</u>	Jun 29, 2011
<u>AB2</u>	!	<u>1GM</u>	<u>A090692</u>	<u>002</u>	Jun 29, 2011
<u>AB2</u>	MYLAN PHARMS INC	<u>500MG</u>	<u>A200690</u>	<u>001</u>	Aug 01, 2012
<u>AB2</u>		<u>1GM</u>	<u>A200690</u>	<u>002</u>	Aug 01, 2012
<u>AB2</u>	NOSTRUM LABS INC	<u>500MG</u>	<u>A203832</u>	<u>001</u>	Dec 26, 2017
<u>AB2</u>		<u>1GM</u>	<u>A203832</u>	<u>002</u>	Dec 26, 2017
<u>AB2</u>	NOVAST LABS	<u>500MG</u>	<u>A209674</u>	<u>001</u>	Nov 02, 2018
<u>AB2</u>		<u>1GM</u>	<u>A209674</u>	<u>002</u>	Nov 02, 2018
<u>AB2</u>	QINGDAO BAHEAL PHARM	<u>500MG</u>	<u>A209993</u>	<u>001</u>	Dec 27, 2018
<u>AB2</u>		<u>1GM</u>	<u>A209993</u>	<u>002</u>	Dec 27, 2018
<u>AB2</u>	SCIEGEN PHARMS INC	<u>500MG</u>	<u>A214629</u>	<u>001</u>	Feb 22, 2022
<u>AB2</u>		<u>1GM</u>	<u>A214629</u>	<u>002</u>	Feb 22, 2022
<u>AB2</u>	TWI PHARMS	<u>500MG</u>	<u>A213247</u>	<u>001</u>	Sep 29, 2021
<u>AB2</u>		<u>1GM</u>	<u>A213247</u>	<u>002</u>	Sep 29, 2021

GLUMETZA

<u>AB3</u>	+ SANTARUS INC	<u>500MG</u>	<u>N021748</u>	<u>001</u>	Jun 03, 2005
<u>AB3</u>	+!	<u>1GM</u>	<u>N021748</u>	<u>002</u>	Jun 03, 2005

METFORMIN HYDROCHLORIDE

<u>AB3</u>	ACTAVIS LABS FL INC	<u>500MG</u>	<u>A203755</u>	<u>001</u>	Aug 01, 2016
<u>AB3</u>		<u>1GM</u>	<u>A203755</u>	<u>002</u>	Aug 01, 2016
<u>AB3</u>	AJANTA PHARMA LTD	<u>500MG</u>	<u>A213962</u>	<u>001</u>	Mar 09, 2021
<u>AB3</u>		<u>1GM</u>	<u>A213962</u>	<u>002</u>	Mar 09, 2021
<u>AB3</u>	APOTEX	<u>500MG</u>	<u>A213356</u>	<u>001</u>	Dec 13, 2021
<u>AB3</u>		<u>1GM</u>	<u>A213356</u>	<u>002</u>	Dec 13, 2021
<u>AB3</u>	GLENMARK PHARMS LTD	<u>500MG</u>	<u>A212969</u>	<u>001</u>	Nov 25, 2019
<u>AB3</u>		<u>1GM</u>	<u>A212969</u>	<u>002</u>	Nov 25, 2019
<u>AB3</u>	GRANULES	<u>500MG</u>	<u>A213344</u>	<u>001</u>	Jan 12, 2021
<u>AB3</u>		<u>1GM</u>	<u>A213344</u>	<u>002</u>	Jan 12, 2021
<u>AB3</u>	LUPIN LTD	<u>500MG</u>	<u>A091664</u>	<u>001</u>	Jul 19, 2013
<u>AB3</u>		<u>1GM</u>	<u>A091664</u>	<u>002</u>	Jul 19, 2013
<u>AB3</u>	MICRO LABS	<u>500MG</u>	<u>A212448</u>	<u>001</u>	Jan 10, 2023
<u>AB3</u>		<u>1GM</u>	<u>A212448</u>	<u>002</u>	Jan 10, 2023
<u>AB3</u>	PRINSTON INC	<u>500MG</u>	<u>A212681</u>	<u>001</u>	Jun 09, 2022
<u>AB3</u>		<u>1GM</u>	<u>A212681</u>	<u>002</u>	Jun 09, 2022
<u>AB3</u>	SCIEGEN PHARMS INC	<u>500MG</u>	<u>A213334</u>	<u>001</u>	Apr 16, 2021
<u>AB3</u>		<u>1GM</u>	<u>A213334</u>	<u>002</u>	Apr 16, 2021
<u>AB3</u>	SUN PHARM	<u>500MG</u>	<u>A202917</u>	<u>001</u>	Aug 01, 2016
<u>AB3</u>		<u>1GM</u>	<u>A202917</u>	<u>002</u>	Aug 01, 2016

METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET;ORAL

ACTOPLUS MET

<u>AB</u>	+! TAKEDA PHARMS USA	<u>850MG;EQ 15MG BASE</u>	<u>N021842</u>	<u>002</u>	Aug 29, 2005

PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE

<u>AB</u>	AUROBINDO PHARMA LTD	<u>500MG;EQ 15MG BASE</u>	<u>A200823</u>	<u>001</u>	Feb 13, 2013
<u>AB</u>		<u>850MG;EQ 15MG BASE</u>	<u>A200823</u>	<u>002</u>	Feb 13, 2013
<u>AB</u>	MACLEODS PHARMS LTD	<u>500MG;EQ 15MG BASE</u>	<u>A204802</u>	<u>001</u>	Nov 05, 2015
<u>AB</u>		<u>850MG;EQ 15MG BASE</u>	<u>A204802</u>	<u>002</u>	Nov 05, 2015
<u>AB</u>	TEVA PHARMS USA	<u>500MG;EQ 15MG BASE</u>	<u>A091155</u>	<u>001</u>	Mar 10, 2014

PRESCRIPTION DRUG PRODUCT LIST

3-298 (of 474)

METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE

<u>AB</u>	<u>850MG;EQ 15MG BASE</u>	<u>A091155</u>	<u>002</u>	Mar 10, 2014

METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

KOMBIGLYZE XR

+	ASTRAZENECA AB	500MG;EQ 5MG BASE	N200678	001	Nov 05, 2010
+		1GM;EQ 2.5MG BASE	N200678	003	Nov 05, 2010
+	!	1GM;EQ 5MG BASE	N200678	002	Nov 05, 2010

METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE

TABLET; ORAL

JANUMET

+	MERCK SHARP DOHME	500MG;EQ 50MG BASE	N022044	001	Mar 30, 2007
+	!	1GM;EQ 50MG BASE	N022044	002	Mar 30, 2007

TABLET, EXTENDED RELEASE; ORAL

JANUMET XR

+	MERCK SHARP DOHME	500MG;EQ 50MG BASE	N202270	001	Feb 02, 2012
+		1GM;EQ 50MG BASE	N202270	002	Feb 02, 2012
+	!	1GM;EQ 100MG BASE	N202270	003	Feb 02, 2012

METHACHOLINE CHLORIDE

FOR SOLUTION; INHALATION

PROVOCHOLINE

+	!	METHAPHARM	100MG/VIAL	N019193	001	Oct 31, 1986

METHADONE HYDROCHLORIDE

CONCENTRATE; ORAL

METHADONE HYDROCHLORIDE

<u>AA</u>	HIKMA	<u>10MG/ML</u>	<u>A040180</u>	<u>001</u>	Apr 30, 1998
<u>AA</u>	LANNETT CO INC	<u>10MG/ML</u>	<u>A212093</u>	<u>001</u>	Nov 02, 2020
<u>AA</u>	SPECGX LLC	<u>10MG/ML</u>	<u>A207368</u>	<u>001</u>	Aug 22, 2019
<u>AA</u>	VISTAPHARM	<u>10MG/ML</u>	<u>A040088</u>	<u>001</u>	Nov 30, 1994

METHADONE HYDROCHLORIDE INTENSOL

<u>AA</u>	HIKMA	<u>10MG/ML</u>	<u>A089897</u>	<u>001</u>	Sep 06, 1988

METHADOSE

<u>AA</u>	+	!	SPECGX LLC	<u>10MG/ML</u>	<u>N017116</u>	<u>002</u>

INJECTABLE; INJECTION

METHADONE HYDROCHLORIDE

<u>AP</u>	AKORN	<u>10MG/ML</u>	<u>A208306</u>	<u>001</u>	Oct 27, 2017	
<u>AP</u>	+	!	MYLAN INSTITUTIONAL	<u>10MG/ML</u>	<u>N021624</u>	<u>001</u>

SOLUTION; ORAL

METHADONE HYDROCHLORIDE

<u>AA</u>	+	!	HIKMA	<u>5MG/5ML</u>	<u>A087393</u>	<u>001</u>
<u>AA</u>	+	!		<u>10MG/5ML</u>	<u>A087997</u>	<u>001</u>
					Aug 30, 1982	
<u>AA</u>			SPECGX LLC	<u>5MG/5ML</u>	<u>A207537</u>	<u>001</u>
				<u>10MG/5ML</u>	<u>A207537</u>	<u>002</u>
					Oct 02, 2019	
<u>AA</u>				<u>10MG/5ML</u>	<u>A207537</u>	<u>002</u>
					Oct 01, 2019	
<u>AA</u>			VISTAPHARM	<u>5MG/5ML</u>	<u>A090707</u>	<u>001</u>
				<u>10MG/5ML</u>	<u>A090707</u>	<u>002</u>
					Jun 30, 2010	
<u>AA</u>				<u>10MG/5ML</u>	<u>A090707</u>	<u>002</u>
					Jun 30, 2010	

TABLET; ORAL

METHADONE HYDROCHLORIDE

<u>AA</u>	ASCENT PHARMS INC	<u>5MG</u>	<u>A211228</u>	<u>001</u>	Jan 03, 2019
<u>AA</u>		<u>10MG</u>	<u>A211228</u>	<u>002</u>	Jan 03, 2019
<u>AA</u>	AUROLIFE PHARMA LLC	<u>5MG</u>	<u>A203502</u>	<u>001</u>	Aug 31, 2015
<u>AA</u>		<u>10MG</u>	<u>A203502</u>	<u>002</u>	Aug 31, 2015
<u>AA</u>	EPIC PHARMA LLC	<u>5MG</u>	<u>A090065</u>	<u>001</u>	Aug 18, 2015
<u>AA</u>		<u>10MG</u>	<u>A090065</u>	<u>002</u>	Aug 18, 2015
<u>AA</u>	ROXANE	<u>5MG</u>	<u>A088108</u>	<u>001</u>	Mar 08, 1983
<u>AA</u>		<u>10MG</u>	<u>A088109</u>	<u>001</u>	Mar 08, 1983
<u>AA</u>	!	SPECGX LLC	<u>5MG</u>	<u>A040517</u>	<u>001</u>
	!		<u>10MG</u>	<u>A040517</u>	<u>002</u>
					Apr 27, 2004
<u>AA</u>	SUN PHARM INDUSTRIES	<u>5MG</u>	<u>A208305</u>	<u>001</u>	Mar 30, 2018
<u>AA</u>		<u>10MG</u>	<u>A208305</u>	<u>002</u>	Mar 30, 2018
<u>AA</u>	THEPHARMANETWORK LLC	<u>5MG</u>	<u>A090635</u>	<u>002</u>	Sep 22, 2020
<u>AA</u>		<u>10MG</u>	<u>A090635</u>	<u>001</u>	Nov 25, 2009
<u>AA</u>	VISTAPHARM	<u>10MG</u>	<u>A040241</u>	<u>002</u>	May 29, 1998
<u>AA</u>		<u>10MG</u>	<u>A204166</u>	<u>001</u>	Mar 16, 2020

TABLET, FOR SUSPENSION; ORAL

METHADONE HYDROCHLORIDE

<u>AA</u>	+	!	HIKMA	<u>40MG</u>	<u>N017058</u>	<u>001</u>
<u>AA</u>			SPECGX LLC	<u>40MG</u>	<u>A077142</u>	<u>001</u>
					Jul 12, 2005	

PRESCRIPTION DRUG PRODUCT LIST

3-299 (of 474)

METHADONE HYDROCHLORIDE

TABLET, FOR SUSPENSION;ORAL

METHADONE HYDROCHLORIDE

AA	VISTAPHARM	40MG	A075082	001	Mar 25, 1998

METHADOSE

AA	SPECGX LLC	40MG	A074184	001	Apr 29, 1993

METHAMPHETAMINE HYDROCHLORIDE

TABLET;ORAL

DESOXYN

AA	+ KEY THERAP	5MG	N005378	002	

METHAMPHETAMINE HYDROCHLORIDE

AA	HIKMA	5MG	A203846	001	Nov 17, 2015

AA	MAYNE PHARMA INC	5MG	A091189	001	Apr 21, 2010

METHAZOLAMIDE

TABLET;ORAL

METHAZOLAMIDE

AB	ANI PHARMS	25MG	A040001	001	Jun 30, 1993

AB		50MG	A040001	002	Jun 30, 1993

AB	BAUSCH AND LOMB INC	25MG	A207438	001	Oct 05, 2018

AB		50MG	A207438	002	Oct 05, 2018

AB	MIKART	25MG	A040062	001	Jan 27, 1994

AB	!	50MG	A040062	002	Jan 27, 1994

AB	SANDOZ	25MG	A040036	001	Jun 30, 1993

AB		50MG	A040036	002	Jun 30, 1993

AB	TAGI	25MG	A215615	001	Oct 18, 2022

AB		50MG	A215615	002	Oct 18, 2022

METHENAMINE HIPPURATE

TABLET;ORAL

HIPREX

AB	+ VALIDUS PHARMS	1GM	N017681	001	

METHENAMINE HIPPURATE

AB	! AUROBINDO PHARMA LTD	1GM	A205661	001	Jul 05, 2016

AB	MICRO LABS	1GM	A212172	001	Aug 01, 2019

AB	NOVAST LABS	1GM	A210068	001	Nov 27, 2020

UREX

AB	ALVOGEN	1GM	N016151	001	

METHIMAZOLE

TABLET;ORAL

METHIMAZOLE

AB	AIPING LIFE SCI	5MG	A040547	001	Feb 18, 2005

AB		10MG	A040547	002	Feb 18, 2005

AB	CHARTWELL RX	5MG	A040411	001	Mar 27, 2001

AB		10MG	A040411	002	Mar 27, 2001

AB	HERITAGE PHARMA	5MG	A040734	001	Dec 14, 2007

AB		10MG	A040734	002	Dec 14, 2007

AB	MYLAN	5MG	A040350	001	Mar 29, 2000

AB	!	10MG	A040350	002	Mar 29, 2000

AB	RISING	5MG	A202068	001	Mar 07, 2012

AB		10MG	A202068	002	Mar 07, 2012

METHOCARBAMOL

SOLUTION;IM-IV

METHOCARBAMOL

AP	AM REGENT	1GM/10ML (100MG/ML)	A207496	001	Jun 22, 2017

AP	BAXTER HLTHCARE CORP	1GM/10ML (100MG/ML)	A215065	001	Jul 14, 2022

AP	EUGIA PHARMA	1GM/10ML (100MG/ML)	A206128	001	May 27, 2016

AP	FRESENIUS KABI USA	1GM/10ML (100MG/ML)	A209331	001	Apr 17, 2018

AP	GLAND PHARMA LTD	1GM/10ML (100MG/ML)	A211504	001	Oct 26, 2018

AP	HAINAN POLY	1GM/10ML (100MG/ML)	A208116	001	Jan 19, 2017

AP	MONTEREY PHARMS LLC	1GM/10ML (100MG/ML)	A205354	001	Oct 27, 2016

AP	NAVINTA LLC	1GM/10ML (100MG/ML)	A206071	001	Nov 24, 2017

AP	SAGENT PHARMS INC	1GM/10ML (100MG/ML)	A205404	001	Jul 18, 2017

AP	SOMERSET THERAPS LLC	1GM/10ML (100MG/ML)	A207522	001	Jul 31, 2017

ROBAXIN

AP	+ HIKMA	1GM/10ML (100MG/ML)	N011790	001	

TABLET;ORAL

METHOCARBAMOL

AA	ACME LABS	500MG	A203550	001	Feb 08, 2017

PRESCRIPTION DRUG PRODUCT LIST

3-300 (of 474)

METHOCARBAMOL

TABLET; ORAL

METHOCARBAMOL

<u>AA</u>		<u>750MG</u>	<u>A203550</u>	<u>002</u>	Feb 08, 2017
<u>AA</u>	AUSTARPHARMA LLC	<u>500MG</u>	<u>A200958</u>	<u>001</u>	Oct 21, 2011
<u>AA</u>		<u>750MG</u>	<u>A200958</u>	<u>002</u>	Oct 21, 2011
<u>AA</u>	BEXIMCO PHARMS USA	<u>500MG</u>	<u>A208507</u>	<u>001</u>	Jul 21, 2017
<u>AA</u>		<u>750MG</u>	<u>A208507</u>	<u>002</u>	Jul 21, 2017
<u>AA</u>	!	<u>500MG</u>	<u>A209312</u>	<u>001</u>	May 07, 2018
<u>AA</u>	!	<u>750MG</u>	<u>A209312</u>	<u>002</u>	May 07, 2018
<u>AA</u>	HETERO LABS LTD III	<u>500MG</u>	<u>A090200</u>	<u>001</u>	Nov 06, 2009
<u>AA</u>		<u>750MG</u>	<u>A090200</u>	<u>002</u>	Nov 06, 2009
<u>AA</u>	MLV	<u>500MG</u>	<u>A212623</u>	<u>001</u>	Apr 30, 2021
<u>AA</u>		<u>750MG</u>	<u>A212623</u>	<u>002</u>	Apr 30, 2021
<u>AA</u>	OXFORD PHARMS	<u>500MG</u>	<u>A040489</u>	<u>001</u>	Jan 29, 2003
<u>AA</u>		<u>750MG</u>	<u>A040489</u>	<u>002</u>	Jan 29, 2003
<u>AA</u>	PRINSTON INC	<u>500MG</u>	<u>A086988</u>	<u>002</u>	
<u>AA</u>		<u>750MG</u>	<u>A086988</u>	<u>001</u>	
	!	AUSTARPHARMA LLC	A200958	003	Dec 06, 2021

METHOHEXITAL SODIUM

INJECTABLE; INJECTION

BREVITAL SODIUM

+! PAR STERILE
PRODUCTS

N011559 001

METHOTREXATE

SOLUTION; ORAL

JYLAMVO

+! THERAKIND

N212479 001 Nov 29, 2022

SOLUTION; SUBCUTANEOUS

OTREXUP

+!	OTTER PHARMS	10MG/0.4ML (10MG/0.4ML)	N204824	001	Oct 11, 2013
+!		12.5MG/0.4ML (12.5MG/0.4ML)	N204824	006	Mar 24, 2016
+!		15MG/0.4ML (15MG/0.4ML)	N204824	002	Oct 11, 2013
+!		17.5MG/0.4ML (17.5MG/0.4ML)	N204824	007	Mar 24, 2016
+!		20MG/0.4ML (20MG/0.4ML)	N204824	003	Oct 11, 2013
+!		22.5MG/0.4ML (22.5MG/0.4ML)	N204824	008	Mar 24, 2016
+!		25MG/0.4ML (25MG/0.4ML)	N204824	004	Oct 11, 2013

RASUVO

+!	MEDEXUS	7.5MG/0.15ML (7.5MG/0.15ML)	N205776	001	Jul 10, 2014
+!		10MG/0.20ML (10MG/0.20ML)	N205776	002	Jul 10, 2014
+!		12.5MG/0.25ML (12.5MG/0.25ML)	N205776	003	Jul 10, 2014
+!		15MG/0.30ML (15MG/0.30ML)	N205776	004	Jul 10, 2014
+!		17.5MG/0.35ML (17.5MG/0.35ML)	N205776	005	Jul 10, 2014
+!		20MG/0.4ML (20MG/0.4ML)	N205776	006	Jul 10, 2014
+!		22.5MG/0.45ML (22.5MG/0.45ML)	N205776	007	Jul 10, 2014
+!		25MG/0.5ML (25MG/0.5ML)	N205776	008	Jul 10, 2014
+!		30MG/0.6ML (30MG/0.6ML)	N205776	010	Jul 10, 2014

REDITREX

+!	NORDIC GRP	15MG/0.6ML (15MG/0.6ML)	N210737	004	Nov 27, 2019
+!		20MG/0.8ML (20MG/0.8ML)	N210737	006	Nov 27, 2019
+!		25MG/1ML (25MG/1ML)	N210737	008	Nov 27, 2019

METHOTREXATE SODIUM

INJECTABLE; INJECTION

METHOTREXATE PRESERVATIVE FREE

<u>AP</u>	FRESENIUS KABI USA	<u>EQ 1GM BASE/VIAL</u>	<u>A040266</u>	<u>001</u>	Feb 26, 1999

METHOTREXATE SODIUM

<u>AP</u>	!	FRESENIUS KABI USA	<u>EQ 50MG BASE/2ML (EQ 25MG BASE/ML)</u>	<u>A040263</u>	<u>001</u>	Feb 26, 1999
<u>AP</u>	!	HIKMA	<u>EQ 100MG BASE/4ML (EQ 25MG BASE/ML)</u>	<u>A089341</u>	<u>001</u>	Sep 16, 1986
<u>AP</u>	+!	HOSPIRA	<u>EQ 50MG BASE/2ML (EQ 25MG BASE/ML)</u>	<u>N011719</u>	<u>010</u>	Dec 15, 2004

METHOTREXATE SODIUM PRESERVATIVE FREE

<u>AP</u>	!	ACCORD HLTHCARE	<u>EQ 50MG BASE/2ML (EQ 25MG BASE/ML)</u>	<u>A040767</u>	<u>001</u>	Apr 30, 2007
<u>AP</u>	!		<u>EQ 250MG BASE/10ML (EQ 25MG BASE/ML)</u>	<u>A040768</u>	<u>001</u>	Apr 30, 2007
<u>AP</u>	!		<u>EQ 1GM BASE/40ML (EQ 25MG BASE/ML)</u>	<u>A040716</u>	<u>001</u>	Apr 30, 2007
<u>AP</u>	!	HIKMA	<u>EQ 50MG BASE/2ML (EQ 25MG BASE/ML)</u>	<u>A089340</u>	<u>001</u>	Sep 16, 1986
<u>AP</u>			<u>EQ 250MG BASE/10ML (EQ 25MG BASE/ML)</u>	<u>A089343</u>	<u>001</u>	Sep 16, 1986
<u>AP</u>	+!	HOSPIRA	<u>EQ 1GM BASE/40ML (EQ 25MG BASE/ML)</u>	<u>N011719</u>	<u>012</u>	Apr 13, 2005
<u>AP</u>		PHARMACHEMIE BV	<u>EQ 50MG BASE/2ML (EQ 25MG BASE/ML)</u>	<u>A040843</u>	<u>002</u>	Jan 11, 2010
<u>AP</u>			<u>EQ 250MG BASE/10ML (EQ 25MG BASE/ML)</u>	<u>A040843</u>	<u>004</u>	Jan 11, 2010
<u>AP</u>			<u>EQ 1GM BASE/40ML (EQ 25MG BASE/ML)</u>	<u>A040843</u>	<u>001</u>	Jan 11, 2010
<u>AP</u>		SAGENT PHARMS INC	<u>EQ 50MG BASE/2ML (EQ 25MG BASE/ML)</u>	<u>A203407</u>	<u>001</u>	Aug 09, 2018
<u>AP</u>			<u>EQ 250MG BASE/10ML (EQ 25MG BASE/ML)</u>	<u>A203407</u>	<u>002</u>	Aug 09, 2018

PRESCRIPTION DRUG PRODUCT LIST

3-301 (of 474)

METHOTREXATE SODIUM

INJECTABLE; INJECTION

METHOTREXATE SODIUM PRESERVATIVE FREE

AP		<u>EQ 1GM BASE/40ML (EQ 25MG BASE/ML)</u>	<u>A203407</u>	<u>003</u>	Aug 09, 2018
AP	SANDOZ INC	<u>EQ 50MG BASE/2ML (EQ 25MG BASE/ML)</u>	<u>A090039</u>	<u>001</u>	Mar 31, 2009
AP		<u>EQ 250MG BASE/10ML (EQ 25MG BASE/ML)</u>	<u>A090039</u>	<u>002</u>	Mar 31, 2009
AP		<u>EQ 1GM BASE/40ML (EQ 25MG BASE/ML)</u>	<u>A090029</u>	<u>001</u>	Mar 31, 2009

METHOTREXATE SODIUM

! HIKMA

EQ 200MG BASE/8ML (EQ 25MG BASE/ML)

A089342 001 Sep 16, 1986

METHOTREXATE SODIUM PRESERVATIVE FREE

! HIKMA

EQ 1GM BASE/VIAL

A040632 001 Aug 12, 2005

PHARMACHEMIE BV

EQ 100MG BASE/4ML (EQ 25MG BASE/ML)

A040843 003 Feb 27, 2012

SOLUTION; ORAL

XATMEP

+! AZURITY

EQ 2.5MG BASE/ML

N208400 001 Apr 25, 2017

TABLET; ORAL

METHOTREXATE SODIUM

AB	ACCORD HLTHCARE	<u>EQ 2.5MG BASE</u>	<u>A213343</u>	<u>001</u>	Jan 24, 2020
AB	AMNEAL PHARMS	<u>EQ 2.5MG BASE</u>	<u>A210040</u>	<u>001</u>	Dec 22, 2017
AB	BARR	<u>EQ 2.5MG BASE</u>	<u>A081099</u>	<u>001</u>	Oct 15, 1990
AB	EUGIA PHARMA	<u>EQ 2.5MG BASE</u>	<u>A210454</u>	<u>001</u>	Jan 30, 2020
AB	! HIKMA	<u>EQ 2.5MG BASE</u>	<u>A040054</u>	<u>001</u>	Aug 01, 1994
AB	LOTUS PHARM CO LTD	<u>EQ 2.5MG BASE</u>	<u>A209787</u>	<u>001</u>	Apr 23, 2021
AB	MYLAN	<u>EQ 2.5MG BASE</u>	<u>A081235</u>	<u>001</u>	May 15, 1992
AB	SUN PHARM	<u>EQ 2.5MG BASE</u>	<u>A201749</u>	<u>001</u>	May 21, 2015
AB	ZYDUS PHARMS	<u>EQ 2.5MG BASE</u>	<u>A207812</u>	<u>001</u>	Jan 13, 2017

TREXALL

BARR

EQ 5MG BASE

A040385 001 Mar 21, 2001

EQ 7.5MG BASE

A040385 002 Mar 21, 2001

EQ 10MG BASE

A040385 003 Mar 21, 2001

!

EQ 15MG BASE

A040385 004 Mar 21, 2001

METHOXSALLEN

CAPSULE; ORAL

METHOXSALLEN

AB	STRIDES PHARMA	<u>10MG</u>	<u>A202687</u>	<u>001</u>	Jun 05, 2014

OXSORALEN-ULTRA

AB	+! BAUSCH	<u>10MG</u>	<u>N019600</u>	<u>001</u>	Oct 30, 1986

INJECTABLE; INJECTION

UVADEX

+! MALLINCKRODT HOSP

0.02MG/ML

N020969 001 Feb 25, 1999

METHSCOPOLAMINE BROMIDE

TABLET; ORAL

METHSCOPOLAMINE BROMIDE

AA	BAYSHORE PHARMS LLC	<u>2.5MG</u>	<u>A200602</u>	<u>001</u>	Sep 24, 2012
AA	!	<u>5MG</u>	<u>A200602</u>	<u>002</u>	Sep 24, 2012
AA	BRECKENRIDGE PHARM	<u>2.5MG</u>	<u>A040642</u>	<u>001</u>	Dec 06, 2011
AA		<u>5MG</u>	<u>A040642</u>	<u>002</u>	Dec 06, 2011

METHSUXIMIDE

CAPSULE; ORAL

CELONTIN

+! PARKE DAVIS

300MG

N010596 008

METHYLENE BLUE

SOLUTION; INTRAVENOUS

PROVAYBLUE

+! PROVEPHARM SAS

10MG/2ML (5MG/ML)

N204630 002 Jul 18, 2019

+!

50MG/10ML (5MG/ML)

N204630 001 Apr 08, 2016

METHYLERGONOVINE MALEATE

INJECTABLE; INJECTION

METHERGINE

AP	+! EDISON THERAPS LLC	<u>0.2MG/ML</u>	<u>N006035</u>	<u>004</u>	

METHYLERGONOVINE MALEATE

AP	AM REGENT	<u>0.2MG/ML</u>	<u>A090193</u>	<u>001</u>	Nov 24, 2008

AP	BRECKENRIDGE	<u>0.2MG/ML</u>	<u>A040889</u>	<u>001</u>	Sep 13, 2010

TABLET; ORAL

METHYLERGONOVINE MALEATE

AB	AMNEAL PHARMS	<u>0.2MG</u>	<u>A211483</u>	<u>001</u>	Sep 10, 2018
AB	GRANULES	<u>0.2MG</u>	<u>A210424</u>	<u>001</u>	May 15, 2018
AB	! NOVEL LABS INC	<u>0.2MG</u>	<u>A091577</u>	<u>001</u>	May 02, 2011
AB	RISING	<u>0.2MG</u>	<u>A211919</u>	<u>001</u>	Jan 15, 2021
AB	TEVA PHARMS USA	<u>0.2MG</u>	<u>A211455</u>	<u>001</u>	Mar 20, 2019

PRESCRIPTION DRUG PRODUCT LIST

3-302 (of 474)

METHYLERGONOVINE MALEATE

TABLET; ORAL

METHYLERGONOVINE MALEATE

AB	TULEX PHARMS INC	0.2MG	<u>A212233</u>	<u>001</u>	May 01, 2020

METHYLNALTREXONE BROMIDE

SOLUTION; SUBCUTANEOUS

RELISTOR

+	SALIX PHARMS	8MG/0.4ML (8MG/0.4ML)	N021964	002	Sep 27, 2010
+		12MG/0.6ML (12MG/0.6ML)	N021964	001	Apr 24, 2008
+		12MG/0.6ML (12MG/0.6ML)	N021964	003	Sep 27, 2010

TABLET; ORAL

RELISTOR

+	SALIX	150MG	N208271	001	Jul 19, 2016

METHYLPHENIDATE

FILM, EXTENDED RELEASE; TRANSDERMAL

DAYTRANA

AB	+	NOVEN PHARMS INC	10MG/9HR (1.1MG/HR)	<u>N021514</u>	<u>001</u>	Apr 06, 2006
AB	+		15MG/9HR (1.6MG/HR)	<u>N021514</u>	<u>002</u>	Apr 06, 2006
AB	+		20MG/9HR (2.2MG/HR)	<u>N021514</u>	<u>003</u>	Apr 06, 2006
AB	+		30MG/9HR (3.3MG/HR)	<u>N021514</u>	<u>004</u>	Apr 06, 2006

METHYLPHENIDATE

AB	MYLAN TECH VIATRIS	10MG/9HR (1.1MG/HR)	<u>A206497</u>	<u>001</u>	Mar 14, 2022
AB		15MG/9HR (1.6MG/HR)	<u>A206497</u>	<u>002</u>	Mar 14, 2022
AB		20MG/9HR (2.2MG/HR)	<u>A206497</u>	<u>003</u>	Mar 14, 2022
AB		30MG/9HR (3.3MG/HR)	<u>A206497</u>	<u>004</u>	Mar 14, 2022

TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE; ORAL

COTEMPLA XR-ODT

+	NEOS THERAPS INC	8.6MG	N205489	001	Jun 19, 2017
+		17.3MG	N205489	002	Jun 19, 2017
+		25.9MG	N205489	003	Jun 19, 2017

METHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

METHYLPHENIDATE HYDROCHLORIDE

AB1	GRANULES	10MG	<u>A211796</u>	<u>001</u>	May 23, 2019
AB1		20MG	<u>A211796</u>	<u>002</u>	May 23, 2019
AB1		30MG	<u>A211796</u>	<u>003</u>	May 23, 2019
AB1		40MG	<u>A211796</u>	<u>004</u>	May 23, 2019
AB1		60MG	<u>A211796</u>	<u>005</u>	May 23, 2019
AB1	MAYNE PHARMA	10MG	<u>A200886</u>	<u>001</u>	Feb 26, 2018
AB1		20MG	<u>A078458</u>	<u>001</u>	Dec 01, 2011
AB1		30MG	<u>A078458</u>	<u>002</u>	Dec 01, 2011
AB1		40MG	<u>A078458</u>	<u>003</u>	Dec 01, 2011
AB1	!	60MG	<u>A078458</u>	<u>004</u>	Jun 23, 2016

RITALIN LA

AB1	+	NOVARTIS	10MG	<u>N021284</u>	<u>004</u>	Apr 10, 2004
AB1	+		20MG	<u>N021284</u>	<u>001</u>	Jun 05, 2002
AB1	+		30MG	<u>N021284</u>	<u>002</u>	Jun 05, 2002
AB1	+		40MG	<u>N021284</u>	<u>003</u>	Jun 05, 2002

METADATE CD

AB2	+	AYTU BIOPHARMA	10MG	<u>N021259</u>	<u>003</u>	May 27, 2003
AB2	+		20MG	<u>N021259</u>	<u>001</u>	Apr 03, 2001
AB2	+		30MG	<u>N021259</u>	<u>002</u>	Jun 19, 2003
AB2	+		40MG	<u>N021259</u>	<u>004</u>	Feb 19, 2006
AB2	+		50MG	<u>N021259</u>	<u>005</u>	Feb 19, 2006
AB2	+		60MG	<u>N021259</u>	<u>006</u>	Feb 19, 2006

METHYLPHENIDATE HYDROCHLORIDE

AB2	IMPAX LABS INC	10MG	<u>A205105</u>	<u>001</u>	Jul 28, 2016
AB2		20MG	<u>A205105</u>	<u>002</u>	Jul 28, 2016
AB2		30MG	<u>A205105</u>	<u>003</u>	Jul 28, 2016
AB2		40MG	<u>A205105</u>	<u>004</u>	Jul 28, 2016
AB2		50MG	<u>A205105</u>	<u>005</u>	Jul 28, 2016
AB2		60MG	<u>A205105</u>	<u>006</u>	Jul 28, 2016
AB2	SPECGX LLC	10MG	<u>A203583</u>	<u>001</u>	Sep 29, 2015
AB2		20MG	<u>A203583</u>	<u>002</u>	Sep 29, 2015
AB2		30MG	<u>A203583</u>	<u>003</u>	Sep 29, 2015
AB2		40MG	<u>A203583</u>	<u>004</u>	Sep 29, 2015
AB2		50MG	<u>A203583</u>	<u>005</u>	Sep 29, 2015
AB2		60MG	<u>A203583</u>	<u>006</u>	Sep 29, 2015
AB2	TEVA PHARMS	10MG	<u>A077707</u>	<u>001</u>	Jul 19, 2012
AB2		20MG	<u>A077707</u>	<u>002</u>	Jul 19, 2012
AB2		30MG	<u>A077707</u>	<u>003</u>	Jul 19, 2012

PRESCRIPTION DRUG PRODUCT LIST

3-303 (of 474)

METHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

METHYLPHENIDATE HYDROCHLORIDE

<u>AB2</u>	<u>40MG</u>	<u>A078873</u>	<u>001</u>	Jul 19, 2012
<u>AB2</u>	<u>50MG</u>	<u>A078873</u>	<u>002</u>	Jul 19, 2012
<u>AB2</u>	<u>60MG</u>	<u>A078873</u>	<u>003</u>	Jul 19, 2012

APTENSIO XR

<u>AB3</u>	+	RHODES PHARMS	<u>10MG</u>	<u>N205831</u>	<u>001</u>	Apr 17, 2015
<u>AB3</u>	+		<u>15MG</u>	<u>N205831</u>	<u>002</u>	Apr 17, 2015
<u>AB3</u>	+		<u>20MG</u>	<u>N205831</u>	<u>003</u>	Apr 17, 2015
<u>AB3</u>	+		<u>30MG</u>	<u>N205831</u>	<u>004</u>	Apr 17, 2015
<u>AB3</u>	+		<u>40MG</u>	<u>N205831</u>	<u>005</u>	Apr 17, 2015
<u>AB3</u>	+		<u>50MG</u>	<u>N205831</u>	<u>006</u>	Apr 17, 2015
<u>AB3</u>	+		<u>60MG</u>	<u>N205831</u>	<u>007</u>	Apr 17, 2015

METHYLPHENIDATE HYDROCHLORIDE

<u>AB3</u>		ACTAVIS ELIZABETH	<u>10MG</u>	<u>A208861</u>	<u>001</u>	Dec 13, 2018
<u>AB3</u>			<u>15MG</u>	<u>A208861</u>	<u>002</u>	Dec 13, 2018
<u>AB3</u>			<u>20MG</u>	<u>A208861</u>	<u>003</u>	Dec 13, 2018
<u>AB3</u>			<u>30MG</u>	<u>A208861</u>	<u>004</u>	Dec 13, 2018
<u>AB3</u>			<u>40MG</u>	<u>A208861</u>	<u>005</u>	Dec 13, 2018
<u>AB3</u>			<u>50MG</u>	<u>A208861</u>	<u>006</u>	Dec 13, 2018
<u>AB3</u>			<u>60MG</u>	<u>A208861</u>	<u>007</u>	Dec 13, 2018

JORNAY PM

+	IRONSHORE PHARMS	20MG	N209311	001	Aug 08, 2018
+		40MG	N209311	002	Aug 08, 2018
+		60MG	N209311	003	Aug 08, 2018
+		80MG	N209311	004	Aug 08, 2018
+		100MG	N209311	005	Aug 08, 2018

FOR SUSPENSION, EXTENDED RELEASE;ORAL

METHYLPHENIDATE HYDROCHLORIDE

<u>AB</u>		ACTAVIS LABS FL INC	<u>5MG/ML</u>	<u>A206049</u>	<u>001</u>	May 17, 2018

QUILLIVANT XR

<u>AB</u>	+	NEXTWAVE	<u>5MG/ML</u>	<u>N202100</u>	<u>001</u>	Sep 27, 2012

SOLUTION;ORAL

METHYLIN

<u>AA</u>	+	SPECGX LLC	<u>5MG/5ML</u>	<u>N021419</u>	<u>001</u>	Dec 19, 2002
<u>AA</u>	+		<u>10MG/5ML</u>	<u>N021419</u>	<u>002</u>	Dec 19, 2002

METHYLPHENIDATE HYDROCHLORIDE

<u>AA</u>		ABHAI LLC	<u>5MG/5ML</u>	<u>A207485</u>	<u>001</u>	Nov 18, 2016
<u>AA</u>			<u>10MG/5ML</u>	<u>A207485</u>	<u>002</u>	Nov 18, 2016
<u>AA</u>		ALKEM LABS LTD	<u>5MG/5ML</u>	<u>A211647</u>	<u>001</u>	Mar 30, 2020
<u>AA</u>			<u>10MG/5ML</u>	<u>A211647</u>	<u>002</u>	Mar 30, 2020
<u>AA</u>		ANDA REPOSITORY	<u>5MG/5ML</u>	<u>A210764</u>	<u>001</u>	Apr 10, 2020
<u>AA</u>			<u>10MG/5ML</u>	<u>A210764</u>	<u>002</u>	Apr 10, 2020
<u>AA</u>		ASCENT PHARMS INC	<u>5MG/5ML</u>	<u>A207417</u>	<u>001</u>	Jan 29, 2021
<u>AA</u>			<u>10MG/5ML</u>	<u>A207417</u>	<u>002</u>	Jan 29, 2021
<u>AA</u>		BRECKENRIDGE	<u>5MG/5ML</u>	<u>A201466</u>	<u>001</u>	Nov 12, 2013
<u>AA</u>			<u>10MG/5ML</u>	<u>A201466</u>	<u>002</u>	Nov 12, 2013
<u>AA</u>		EYWA	<u>5MG/5ML</u>	<u>A210139</u>	<u>001</u>	Oct 03, 2018
<u>AA</u>			<u>10MG/5ML</u>	<u>A210139</u>	<u>002</u>	Oct 03, 2018
<u>AA</u>		NOVEL LABS INC	<u>5MG/5ML</u>	<u>A204602</u>	<u>001</u>	Aug 14, 2015
<u>AA</u>			<u>10MG/5ML</u>	<u>A204602</u>	<u>002</u>	Aug 14, 2015
<u>AA</u>		QUAGEN	<u>5MG/5ML</u>	<u>A213567</u>	<u>001</u>	Jun 04, 2020
<u>AA</u>			<u>10MG/5ML</u>	<u>A213567</u>	<u>002</u>	Jun 04, 2020
<u>AA</u>		TRIS PHARMA INC	<u>5MG/5ML</u>	<u>A091601</u>	<u>001</u>	Jul 23, 2010
<u>AA</u>			<u>10MG/5ML</u>	<u>A091601</u>	<u>002</u>	Jul 23, 2010

TABLET;ORAL

METHYLPHENIDATE HYDROCHLORIDE

<u>AB</u>		ABHAI INC	<u>5MG</u>	<u>A206932</u>	<u>001</u>	May 11, 2017
<u>AB</u>			<u>10MG</u>	<u>A206932</u>	<u>002</u>	May 11, 2017
<u>AB</u>			<u>20MG</u>	<u>A206932</u>	<u>003</u>	May 11, 2017
<u>AB</u>		ACCORD HLTHCARE	<u>5MG</u>	<u>A213936</u>	<u>001</u>	Oct 28, 2020
<u>AB</u>			<u>10MG</u>	<u>A213936</u>	<u>002</u>	Oct 28, 2020
<u>AB</u>			<u>20MG</u>	<u>A213936</u>	<u>003</u>	Oct 28, 2020
<u>AB</u>		ALKEM LABS LTD	<u>5MG</u>	<u>A211779</u>	<u>001</u>	Oct 04, 2019
<u>AB</u>			<u>10MG</u>	<u>A211779</u>	<u>002</u>	Oct 04, 2019
<u>AB</u>			<u>20MG</u>	<u>A211779</u>	<u>003</u>	Oct 04, 2019
<u>AB</u>		ASCENT PHARMS INC	<u>5MG</u>	<u>A207416</u>	<u>001</u>	Sep 22, 2015
<u>AB</u>			<u>10MG</u>	<u>A207416</u>	<u>002</u>	Sep 22, 2015
<u>AB</u>			<u>20MG</u>	<u>A207416</u>	<u>003</u>	Sep 22, 2015
<u>AB</u>		BIONPHARMA INC	<u>5MG</u>	<u>A209753</u>	<u>001</u>	Mar 02, 2018
<u>AB</u>			<u>10MG</u>	<u>A209753</u>	<u>002</u>	Mar 02, 2018

PRESCRIPTION DRUG PRODUCT LIST

3-304 (of 474)

METHYLPHENIDATE HYDROCHLORIDE

TABLET; ORAL

METHYLPHENIDATE HYDROCHLORIDE

<u>AB</u>		<u>20MG</u>	<u>A209753</u>	<u>003</u>	Mar 02, 2018
<u>AB</u>	MOUNTAIN	<u>5MG</u>	<u>A091159</u>	<u>001</u>	Mar 12, 2014
<u>AB</u>		<u>10MG</u>	<u>A091159</u>	<u>002</u>	Mar 12, 2014
<u>AB</u>		<u>20MG</u>	<u>A091159</u>	<u>003</u>	Mar 12, 2014
<u>AB</u>	NOVEL LABS INC	<u>5MG</u>	<u>A207884</u>	<u>001</u>	Nov 13, 2015
<u>AB</u>		<u>10MG</u>	<u>A207884</u>	<u>002</u>	Nov 13, 2015
<u>AB</u>		<u>20MG</u>	<u>A207884</u>	<u>003</u>	Nov 13, 2015
<u>AB</u>	OXFORD PHARMS	<u>5MG</u>	<u>A202892</u>	<u>001</u>	Sep 23, 2014
<u>AB</u>		<u>10MG</u>	<u>A202892</u>	<u>002</u>	Sep 23, 2014
<u>AB</u>		<u>20MG</u>	<u>A202892</u>	<u>003</u>	Sep 23, 2014
<u>AB</u>	PRINSTON INC	<u>5MG</u>	<u>A212697</u>	<u>001</u>	Jul 23, 2020
<u>AB</u>		<u>10MG</u>	<u>A212697</u>	<u>002</u>	Jul 23, 2020
<u>AB</u>		<u>20MG</u>	<u>A212697</u>	<u>003</u>	Jul 23, 2020
<u>AB</u>	SPECGX LLC	<u>5MG</u>	<u>A040300</u>	<u>001</u>	Nov 27, 1998
<u>AB</u>		<u>10MG</u>	<u>A040300</u>	<u>002</u>	Nov 27, 1998
<u>AB</u>		<u>20MG</u>	<u>A040300</u>	<u>003</u>	Nov 27, 1998
<u>AB</u>	SUN PHARM INDS INC	<u>5MG</u>	<u>A090710</u>	<u>001</u>	Mar 15, 2012
<u>AB</u>		<u>10MG</u>	<u>A090710</u>	<u>002</u>	Mar 15, 2012
<u>AB</u>		<u>20MG</u>	<u>A090710</u>	<u>003</u>	Mar 15, 2012

RITALIN

<u>AB</u>	+	NOVARTIS	<u>5MG</u>	<u>N010187</u>	<u>003</u>
<u>AB</u>	+		<u>10MG</u>	<u>N010187</u>	<u>006</u>
<u>AB</u>	+	!	<u>20MG</u>	<u>N010187</u>	<u>010</u>

TABLET, CHEWABLE; ORAL

METHYLPHENIDATE HYDROCHLORIDE

<u>AB</u>	ASCENT PHARMS INC	<u>2.5MG</u>	<u>A210354</u>	<u>001</u>	Dec 29, 2017
<u>AB</u>		<u>5MG</u>	<u>A210354</u>	<u>002</u>	Dec 29, 2017
<u>AB</u>	!	<u>10MG</u>	<u>A210354</u>	<u>003</u>	Dec 29, 2017
<u>AB</u>	RISING	<u>2.5MG</u>	<u>A205756</u>	<u>001</u>	Nov 07, 2016
<u>AB</u>		<u>5MG</u>	<u>A205756</u>	<u>002</u>	Nov 07, 2016
<u>AB</u>		<u>10MG</u>	<u>A205756</u>	<u>003</u>	Nov 07, 2016

TABLET, EXTENDED RELEASE; ORAL

CONCERTA

<u>AB</u>	+	JANSSEN PHARMS	<u>18MG</u>	<u>N021121</u>	<u>001</u>	Aug 01, 2000
<u>AB</u>	+		<u>27MG</u>	<u>N021121</u>	<u>004</u>	Apr 01, 2002
<u>AB</u>	+		<u>36MG</u>	<u>N021121</u>	<u>002</u>	Aug 01, 2000
<u>AB</u>	+	!	<u>54MG</u>	<u>N021121</u>	<u>003</u>	Dec 08, 2000

METHYLIN ER

<u>AB</u>	SPECGX LLC	<u>10MG</u>	<u>A075629</u>	<u>001</u>	May 09, 2000
<u>AB</u>		<u>20MG</u>	<u>A075629</u>	<u>002</u>	May 09, 2000

METHYLPHENIDATE HYDROCHLORIDE

<u>AB</u>	ABHAI LLC	<u>10MG</u>	<u>A207488</u>	<u>001</u>	Jun 09, 2015
<u>AB</u>	!	<u>20MG</u>	<u>A207488</u>	<u>002</u>	Jun 09, 2015
<u>AB</u>	ACTAVIS LABS FL	<u>18MG</u>	<u>A076772</u>	<u>001</u>	Mar 22, 2018
<u>AB</u>		<u>27MG</u>	<u>A076772</u>	<u>002</u>	Mar 22, 2018
<u>AB</u>		<u>36MG</u>	<u>A076772</u>	<u>003</u>	Mar 22, 2018
<u>AB</u>		<u>54MG</u>	<u>A076655</u>	<u>001</u>	Mar 21, 2018
<u>AB</u>		<u>72MG</u>	<u>A076655</u>	<u>002</u>	Feb 28, 2022
<u>AB</u>	ALKEM LABS LTD	<u>20MG</u>	<u>A212288</u>	<u>001</u>	Oct 06, 2020
<u>AB</u>	ANDOR PHARMS	<u>18MG</u>	<u>A211918</u>	<u>001</u>	Apr 24, 2019
<u>AB</u>		<u>27MG</u>	<u>A211918</u>	<u>002</u>	Apr 24, 2019
<u>AB</u>		<u>36MG</u>	<u>A211918</u>	<u>003</u>	Apr 24, 2019
<u>AB</u>		<u>54MG</u>	<u>A211918</u>	<u>004</u>	Apr 24, 2019
<u>AB</u>	ASCENT PHARMS INC	<u>18MG</u>	<u>A211009</u>	<u>001</u>	Sep 03, 2019
<u>AB</u>		<u>27MG</u>	<u>A211009</u>	<u>002</u>	Sep 03, 2019
<u>AB</u>		<u>36MG</u>	<u>A211009</u>	<u>003</u>	Sep 03, 2019
<u>AB</u>		<u>54MG</u>	<u>A211009</u>	<u>004</u>	Sep 03, 2019
<u>AB</u>	AUROLIFE PHARMA LLC	<u>18MG</u>	<u>A206726</u>	<u>001</u>	Oct 21, 2016
<u>AB</u>		<u>27MG</u>	<u>A206726</u>	<u>002</u>	Oct 21, 2016
<u>AB</u>		<u>36MG</u>	<u>A206726</u>	<u>003</u>	Oct 21, 2016
<u>AB</u>		<u>54MG</u>	<u>A206726</u>	<u>004</u>	Oct 21, 2016
<u>AB</u>	DR REDDYS	<u>18MG</u>	<u>A213473</u>	<u>001</u>	Jul 29, 2020
<u>AB</u>		<u>27MG</u>	<u>A213473</u>	<u>002</u>	Jul 29, 2020
<u>AB</u>		<u>36MG</u>	<u>A213473</u>	<u>003</u>	Jul 29, 2020
<u>AB</u>		<u>54MG</u>	<u>A213473</u>	<u>004</u>	Jul 29, 2020
<u>AB</u>	GRANULES	<u>10MG</u>	<u>A210992</u>	<u>001</u>	Nov 21, 2018
<u>AB</u>		<u>20MG</u>	<u>A210992</u>	<u>002</u>	Nov 21, 2018
<u>AB</u>	OSMOTICA	<u>18MG</u>	<u>A205327</u>	<u>001</u>	Jul 28, 2017
<u>AB</u>		<u>27MG</u>	<u>A205327</u>	<u>002</u>	Jul 28, 2017

PRESCRIPTION DRUG PRODUCT LIST

3-305 (of 474)

METHYLPHENIDATE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

METHYLPHENIDATE HYDROCHLORIDE

<u>AB</u>		<u>36MG</u>	<u>A205327</u>	<u>003</u>	Jul 28, 2017
<u>AB</u>		<u>54MG</u>	<u>A205327</u>	<u>004</u>	Jul 28, 2017
<u>AB</u>	!	<u>72MG</u>	<u>A205327</u>	<u>005</u>	Jul 28, 2017
<u>AB</u>	SUN PHARM INDS INC	<u>18MG</u>	<u>A205135</u>	<u>001</u>	Aug 19, 2020
<u>AB</u>		<u>27MG</u>	<u>A205135</u>	<u>002</u>	Aug 19, 2020
<u>AB</u>		<u>36MG</u>	<u>A205135</u>	<u>003</u>	Aug 19, 2020
<u>AB</u>		<u>54MG</u>	<u>A205135</u>	<u>004</u>	Aug 19, 2020
BX	AMNEAL PHARMS	18MG	A207515	001	Feb 01, 2018
BX		27MG	A207515	002	Feb 01, 2018
BX		36MG	A207515	003	Feb 01, 2018
BX		54MG	A207515	004	Feb 01, 2018
BX	LANNETT CO INC	18MG	A091695	001	Jul 09, 2013
BX		27MG	A091695	002	Jul 09, 2013
BX		36MG	A091695	003	Sep 23, 2013
BX		54MG	A091695	004	Sep 23, 2013
BX	SPECGX LLC	27MG	A202608	001	Dec 28, 2012
BX		36MG	A202608	002	Dec 28, 2012
BX		54MG	A202608	003	Dec 28, 2012
RELEXXII					
+	OSMOTICA PHARM US	18MG	N216117	001	Jun 23, 2022
+		27MG	N216117	002	Jun 23, 2022
+		36MG	N216117	003	Jun 23, 2022
+		45MG	N216117	004	Jun 23, 2022
+		54MG	N216117	005	Jun 23, 2022
+		63MG	N216117	006	Jun 23, 2022
+	!	72MG	N216117	007	Jun 23, 2022
TABLET, EXTENDED RELEASE, CHEWABLE;ORAL					
QUILLICHEW ER					
+	NEXTWAVE PHARMS	20MG	N207960	001	Dec 04, 2015
+		30MG	N207960	002	Dec 04, 2015
+	!	40MG	N207960	003	Dec 04, 2015

METHYLPREDNISOLONE

TABLET;ORAL

MEDROL

<u>AB</u>	+	PFIZER	<u>2MG</u>	<u>N011153</u>	<u>002</u>
<u>AB</u>	+		<u>4MG</u>	<u>N011153</u>	<u>001</u>
<u>AB</u>	+		<u>8MG</u>	<u>N011153</u>	<u>004</u>
<u>AB</u>	+		<u>16MG</u>	<u>N011153</u>	<u>003</u>
<u>AB</u>	+	!	<u>32MG</u>	<u>N011153</u>	<u>006</u>

METHYLPREDNISOLONE

<u>AB</u>	JUBILANT CADISTA	<u>4MG</u>	<u>A040189</u>	<u>001</u>	Oct 31, 1997
<u>AB</u>		<u>8MG</u>	<u>A040189</u>	<u>002</u>	Oct 31, 1997
<u>AB</u>		<u>16MG</u>	<u>A040189</u>	<u>003</u>	Jul 20, 2007
<u>AB</u>		<u>32MG</u>	<u>A040189</u>	<u>004</u>	Jul 20, 2007
<u>AB</u>	PRAXGEN	<u>4MG</u>	<u>A212262</u>	<u>001</u>	Jun 27, 2019
<u>AB</u>	SANDOZ	<u>4MG</u>	<u>A040194</u>	<u>001</u>	Oct 31, 1997
<u>AB</u>	TIANJIN TIANYAO	<u>4MG</u>	<u>A204072</u>	<u>001</u>	May 14, 2018
<u>AB</u>	VINTAGE PHARMS	<u>4MG</u>	<u>A040183</u>	<u>001</u>	Dec 22, 1998
<u>AB</u>	WATSON LABS	<u>4MG</u>	<u>A040232</u>	<u>001</u>	Oct 16, 1997
<u>AB</u>	ZYDUS PHARMS	<u>4MG</u>	<u>A206751</u>	<u>001</u>	Apr 23, 2018
<u>AB</u>		<u>8MG</u>	<u>A206751</u>	<u>002</u>	Apr 23, 2018
<u>AB</u>		<u>16MG</u>	<u>A206751</u>	<u>003</u>	Apr 23, 2018
<u>AB</u>		<u>32MG</u>	<u>A206751</u>	<u>004</u>	Apr 23, 2018

METHYLPREDNISOLONE ACETATE

INJECTABLE; INJECTION

DEPO-MEDROL

<u>AB</u>	+	PFIZER	<u>40MG/ML</u>	<u>N011757</u>	<u>001</u>
<u>AB</u>	+		<u>80MG/ML</u>	<u>N011757</u>	<u>004</u>

METHYLPREDNISOLONE ACETATE

<u>AB</u>	!	AMNEAL	<u>40MG/ML</u>	<u>A210043</u>	<u>001</u>	May 20, 2019
<u>AB</u>	!		<u>80MG/ML</u>	<u>A210043</u>	<u>002</u>	May 20, 2019
<u>AB</u>		PAR STERILE PRODUCTS	<u>80MG/ML</u>	<u>A214297</u>	<u>002</u>	Jan 21, 2022
<u>AB</u>	!	SAGENT PHARMS INC	<u>40MG/ML</u>	<u>A201835</u>	<u>002</u>	Jun 27, 2018
<u>AB</u>	!		<u>80MG/ML</u>	<u>A201835</u>	<u>003</u>	Jun 27, 2018
<u>AB</u>		SANDOZ INC	<u>40MG/ML</u>	<u>A040719</u>	<u>001</u>	Jan 29, 2009
<u>AB</u>			<u>40MG/ML</u>	<u>A040794</u>	<u>001</u>	Mar 05, 2009
<u>AB</u>			<u>80MG/ML</u>	<u>A040719</u>	<u>002</u>	Jan 29, 2009
<u>AB</u>			<u>80MG/ML</u>	<u>A040794</u>	<u>002</u>	Mar 05, 2009

PRESCRIPTION DRUG PRODUCT LIST

3-306 (of 474)

METHYLPREDNISOLONE ACETATE

INJECTABLE; INJECTION

METHYLPREDNISOLONE ACETATE

<u>AB</u>	SLAYBACK PHARMA LLC	<u>80MG/ML</u>	<u>A214870</u>	<u>001</u>	Jan 03, 2023
<u>AB</u>	TEVA PHARMS USA	<u>40MG/ML</u>	<u>A040557</u>	<u>001</u>	Feb 23, 2005
<u>AB</u>		<u>40MG/ML</u>	<u>A040620</u>	<u>001</u>	Oct 27, 2006
<u>AB</u>		<u>80MG/ML</u>	<u>A040557</u>	<u>002</u>	Feb 23, 2005
<u>AB</u>		<u>80MG/ML</u>	<u>A040620</u>	<u>002</u>	Oct 27, 2006
	DEPO-MEDROL				
	+! PFIZER	20MG/ML	N011757	002	

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE; INJECTION

METHYLPREDNISOLONE SODIUM SUCCINATE

<u>AP</u>	AMNEAL	<u>EQ 40MG BASE/VIAL</u>	<u>A207549</u>	<u>001</u>	Nov 09, 2016
<u>AP</u>		<u>EQ 125MG BASE/VIAL</u>	<u>A207549</u>	<u>002</u>	Nov 09, 2016
<u>AP</u>	FRESENIUS KABI USA	<u>EQ 40MG BASE/VIAL</u>	<u>A040583</u>	<u>001</u>	Jul 30, 2004
<u>AP</u>		<u>EQ 125MG BASE/VIAL</u>	<u>A040583</u>	<u>002</u>	Jul 30, 2004
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A040612</u>	<u>001</u>	Aug 12, 2004
<u>AP</u>	HIKMA	<u>EQ 40MG BASE/VIAL</u>	<u>A203125</u>	<u>001</u>	Sep 26, 2022
<u>AP</u>		<u>EQ 125MG BASE/VIAL</u>	<u>A203125</u>	<u>002</u>	Sep 26, 2022
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A202691</u>	<u>001</u>	Feb 16, 2016
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A202691</u>	<u>002</u>	Feb 16, 2016
<u>AP</u>	SAGENT PHARMS INC	<u>EQ 40MG BASE/VIAL</u>	<u>A040888</u>	<u>001</u>	Jul 18, 2011
<u>AP</u>		<u>EQ 125MG BASE/VIAL</u>	<u>A040888</u>	<u>002</u>	Jul 18, 2011
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A040888</u>	<u>003</u>	Jul 18, 2011
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A040888</u>	<u>004</u>	Jul 18, 2011
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A040888</u>	<u>005</u>	Jul 18, 2011
<u>AP</u>	TIANJIN KINGYORK	<u>EQ 40MG BASE/VIAL</u>	<u>A212396</u>	<u>001</u>	Apr 20, 2021
<u>AP</u>		<u>EQ 125MG BASE/VIAL</u>	<u>A212396</u>	<u>002</u>	Apr 20, 2021
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A212396</u>	<u>003</u>	Apr 20, 2021
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A212396</u>	<u>004</u>	Apr 20, 2021
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A212396</u>	<u>005</u>	Apr 20, 2021

SOLU-MEDROL

<u>AP</u>	+! PHARMACIA AND UPJOHN	<u>EQ 40MG BASE/VIAL</u>	<u>N011856</u>	<u>003</u>	
<u>AP</u>	+!	<u>EQ 125MG BASE/VIAL</u>	<u>N011856</u>	<u>004</u>	
<u>AP</u>	+!	<u>EQ 500MG BASE/VIAL</u>	<u>N011856</u>	<u>005</u>	
<u>AP</u>	+!	<u>EQ 1GM BASE/VIAL</u>	<u>N011856</u>	<u>006</u>	
<u>AP</u>	+!	<u>EQ 2GM BASE/VIAL</u>	<u>N011856</u>	<u>007</u>	Feb 27, 1985

METHYLTESTOSTERONE

CAPSULE; ORAL

METHYLTESTOSTERONE

<u>AB</u>	! IMPAX LABS INC	<u>10MG</u>	<u>A204851</u>	<u>001</u>	Sep 21, 2015
<u>AB</u>	NOVITIUM PHARMA	<u>10MG</u>	<u>A215270</u>	<u>001</u>	Feb 18, 2022
	TABLET; ORAL				
	ANDROID 25				
BP	VALEANT PHARM INTL	25MG	A087147	001	
	METHYLTESTOSTERONE				
BP	IMPAX LABS	10MG	A080767	002	

METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

METOCLOPRAMIDE

<u>AP</u>	EMCURE PHARMS LTD	<u>EQ 5MG BASE/ML</u>	<u>A204756</u>	<u>001</u>	Dec 20, 2013
	<u>METOCLOPRAMIDE HYDROCHLORIDE</u>				
<u>AP</u>	FRESENIUS KABI USA	<u>EQ 5MG BASE/ML</u>	<u>A091392</u>	<u>001</u>	Apr 19, 2013
<u>AP</u>	! HOSPIRA	<u>EQ 5MG BASE/ML</u>	<u>A073118</u>	<u>001</u>	Jan 17, 1991
<u>AP</u>	TEVA PHARMS USA	<u>EQ 5MG BASE/ML</u>	<u>A073135</u>	<u>001</u>	Nov 27, 1991

SOLUTION; ORAL

METOCLOPRAMIDE HYDROCHLORIDE

<u>AA</u>	ANI PHARMS	<u>EQ 5MG BASE/5ML</u>	<u>A071402</u>	<u>001</u>	Jun 25, 1993
<u>AA</u>	PHARM ASSOC	<u>EQ 5MG BASE/5ML</u>	<u>A072744</u>	<u>001</u>	May 28, 1991
<u>AA</u>	VISTAPHARM	<u>EQ 5MG BASE/5ML</u>	<u>A075051</u>	<u>001</u>	Jan 26, 2001
<u>AA</u>	! WOCKHARDT BIO AG	<u>EQ 5MG BASE/5ML</u>	<u>A074703</u>	<u>001</u>	Oct 31, 1997
	SPRAY, METERED; NASAL				
	GIMOTI				
	+! EVOKE PHARMA INC	EQ 15MG BASE/SPRAY	N209388	001	Jun 19, 2020
	TABLET; ORAL				

METOCLOPRAMIDE HYDROCHLORIDE

<u>AB</u>	IMPAX LABS INC	<u>EQ 5MG BASE</u>	<u>A071250</u>	<u>002</u>	Dec 28, 1995
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A071250</u>	<u>001</u>	Feb 03, 1988
<u>AB</u>	IPCA LABS LTD	<u>EQ 5MG BASE</u>	<u>A078807</u>	<u>001</u>	Jun 12, 2008

PRESCRIPTION DRUG PRODUCT LIST

3-307 (of 474)

METOCLOPRAMIDE HYDROCHLORIDE

TABLET; ORAL

METOCLOPRAMIDE HYDROCHLORIDE

<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078807</u>	<u>002</u>	Jun 12, 2008
<u>AB</u>	STRIDES PHARMA	<u>EQ 5MG BASE</u>	<u>A077878</u>	<u>001</u>	Aug 28, 2006
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A070581</u>	<u>001</u>	Oct 17, 1985
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077878</u>	<u>002</u>	Aug 28, 2006
<u>AB</u>	TEVA	<u>EQ 5MG BASE</u>	<u>A072801</u>	<u>001</u>	Jun 15, 1993
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A070184</u>	<u>001</u>	Jul 29, 1985

REGLAN

<u>AB</u>	+	ANI PHARMS	<u>EQ 5MG BASE</u>	<u>N017854</u>	<u>002</u>	May 05, 1987
<u>AB</u>	+	!	<u>EQ 10MG BASE</u>	<u>N017854</u>	<u>001</u>	

TABLET, ORALLY DISINTEGRATING; ORAL

METOCLOPRAMIDE HYDROCHLORIDE

	NOVEL LABS INC	EQ 5MG BASE	A202191	001	Aug 15, 2014
!		EQ 10MG BASE	A202191	002	Aug 15, 2014

METOLAZONE

TABLET; ORAL

METOLAZONE

<u>AB</u>	AACE PHARMS	<u>2.5MG</u>	<u>A216216</u>	<u>001</u>	Oct 25, 2022
<u>AB</u>		<u>5MG</u>	<u>A216216</u>	<u>002</u>	Oct 25, 2022
<u>AB</u>		<u>10MG</u>	<u>A216216</u>	<u>003</u>	Oct 25, 2022
<u>AB</u>	ALEMBIC PHARMS	<u>2.5MG</u>	<u>A213251</u>	<u>001</u>	Dec 02, 2020
<u>AB</u>		<u>5MG</u>	<u>A213251</u>	<u>002</u>	Dec 02, 2020
<u>AB</u>		<u>10MG</u>	<u>A213251</u>	<u>003</u>	Dec 02, 2020
<u>AB</u>	BAYSHORE PHARMS LLC	<u>2.5MG</u>	<u>A214799</u>	<u>001</u>	Mar 30, 2021
<u>AB</u>		<u>5MG</u>	<u>A214799</u>	<u>002</u>	Mar 30, 2021
<u>AB</u>		<u>10MG</u>	<u>A214799</u>	<u>003</u>	Mar 30, 2021
<u>AB</u>	INNOGENIX	<u>2.5MG</u>	<u>A213827</u>	<u>001</u>	Mar 30, 2021
<u>AB</u>		<u>5MG</u>	<u>A213827</u>	<u>002</u>	Mar 30, 2021
<u>AB</u>		<u>10MG</u>	<u>A213827</u>	<u>003</u>	Mar 30, 2021
<u>AB</u>	MYLAN	<u>2.5MG</u>	<u>A076698</u>	<u>001</u>	Dec 23, 2003
<u>AB</u>		<u>5MG</u>	<u>A076698</u>	<u>002</u>	Oct 19, 2004
<u>AB</u>		<u>10MG</u>	<u>A076698</u>	<u>003</u>	Oct 19, 2004
<u>AB</u>	RENATA	<u>2.5MG</u>	<u>A215616</u>	<u>001</u>	Oct 24, 2022
<u>AB</u>		<u>5MG</u>	<u>A215616</u>	<u>002</u>	Oct 24, 2022
<u>AB</u>		<u>10MG</u>	<u>A215616</u>	<u>003</u>	Oct 24, 2022
<u>AB</u>	RUBICON	<u>2.5MG</u>	<u>A215184</u>	<u>001</u>	Aug 20, 2021
<u>AB</u>		<u>5MG</u>	<u>A215184</u>	<u>002</u>	Aug 20, 2021
<u>AB</u>		<u>10MG</u>	<u>A215184</u>	<u>003</u>	Aug 20, 2021
<u>AB</u>	SANDOZ	<u>2.5MG</u>	<u>A076732</u>	<u>001</u>	Dec 19, 2003
<u>AB</u>	!	<u>5MG</u>	<u>A076466</u>	<u>001</u>	Dec 19, 2003
<u>AB</u>	!	<u>10MG</u>	<u>A076466</u>	<u>002</u>	Dec 19, 2003

METOPROLOL SUCCINATE

CAPSULE, EXTENDED RELEASE; ORAL

KAPSPARGO SPRINKLE

+	SPIL	EQ 25MG TARTRATE	N210428	001	Jan 26, 2018
+		EQ 50MG TARTRATE	N210428	002	Jan 26, 2018
+		EQ 100MG TARTRATE	N210428	003	Jan 26, 2018
+	!	EQ 200MG TARTRATE	N210428	004	Jan 26, 2018

TABLET, EXTENDED RELEASE; ORAL

METOPROLOL SUCCINATE

<u>AB</u>	ACCORD HLTHCARE	<u>EQ 25MG TARTRATE</u>	<u>A215637</u>	<u>001</u>	Oct 18, 2022
<u>AB</u>		<u>EQ 50MG TARTRATE</u>	<u>A215637</u>	<u>002</u>	Oct 18, 2022
<u>AB</u>		<u>EQ 100MG TARTRATE</u>	<u>A215637</u>	<u>003</u>	Oct 18, 2022
<u>AB</u>		<u>EQ 200MG TARTRATE</u>	<u>A215637</u>	<u>004</u>	Oct 18, 2022
<u>AB</u>	ACTAVIS ELIZABETH	<u>EQ 25MG TARTRATE</u>	<u>A204161</u>	<u>001</u>	Nov 25, 2016
<u>AB</u>		<u>EQ 50MG TARTRATE</u>	<u>A204161</u>	<u>002</u>	Nov 25, 2016
<u>AB</u>		<u>EQ 100MG TARTRATE</u>	<u>A204161</u>	<u>003</u>	Nov 25, 2016
<u>AB</u>		<u>EQ 200MG TARTRATE</u>	<u>A204161</u>	<u>004</u>	Nov 25, 2016
<u>AB</u>	ACTAVIS LABS FL INC	<u>EQ 50MG TARTRATE</u>	<u>A076862</u>	<u>001</u>	Aug 03, 2009
<u>AB</u>	ALKEM LABS LTD	<u>EQ 25MG TARTRATE</u>	<u>A211143</u>	<u>001</u>	Nov 25, 2020
<u>AB</u>		<u>EQ 50MG TARTRATE</u>	<u>A211143</u>	<u>002</u>	Nov 25, 2020
<u>AB</u>		<u>EQ 100MG TARTRATE</u>	<u>A211143</u>	<u>003</u>	Nov 25, 2020
<u>AB</u>		<u>EQ 200MG TARTRATE</u>	<u>A211143</u>	<u>004</u>	Nov 25, 2020
<u>AB</u>	CIPLA	<u>EQ 50MG TARTRATE</u>	<u>A207465</u>	<u>001</u>	Oct 26, 2018
<u>AB</u>		<u>EQ 100MG TARTRATE</u>	<u>A207465</u>	<u>002</u>	Oct 26, 2018
<u>AB</u>		<u>EQ 200MG TARTRATE</u>	<u>A207465</u>	<u>003</u>	Oct 26, 2018
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 25MG TARTRATE</u>	<u>A090617</u>	<u>001</u>	Aug 01, 2012
<u>AB</u>		<u>EQ 50MG TARTRATE</u>	<u>A090617</u>	<u>002</u>	Aug 01, 2012
<u>AB</u>	HETERO LABS LTD III	<u>EQ 25MG TARTRATE</u>	<u>A205541</u>	<u>001</u>	Nov 06, 2020

PRESCRIPTION DRUG PRODUCT LIST

3-308 (of 474)

METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE; ORAL

METOPROLOL SUCCINATE

AB		<u>EQ 50MG TARTRATE</u>	<u>A205541</u>	<u>002</u>	Nov 06, 2020
AB		<u>EQ 100MG TARTRATE</u>	<u>A205541</u>	<u>003</u>	Nov 06, 2020
AB		<u>EQ 200MG TARTRATE</u>	<u>A205541</u>	<u>004</u>	Nov 06, 2020
AB	MYLAN PHARMS INC	<u>EQ 25MG TARTRATE</u>	<u>A202033</u>	<u>001</u>	Dec 15, 2011
AB		<u>EQ 50MG TARTRATE</u>	<u>A202033</u>	<u>002</u>	Dec 15, 2011
AB		<u>EQ 100MG TARTRATE</u>	<u>A202033</u>	<u>003</u>	Dec 15, 2011
AB		<u>EQ 200MG TARTRATE</u>	<u>A202033</u>	<u>004</u>	Dec 15, 2011
AB	NOVAST LABS	<u>EQ 25MG TARTRATE</u>	<u>A204106</u>	<u>001</u>	Feb 06, 2018
AB		<u>EQ 50MG TARTRATE</u>	<u>A204106</u>	<u>002</u>	Feb 06, 2018
AB		<u>EQ 100MG TARTRATE</u>	<u>A204106</u>	<u>003</u>	Feb 06, 2018
AB		<u>EQ 200MG TARTRATE</u>	<u>A204106</u>	<u>004</u>	Feb 06, 2018
AB	PHARMADAX INC	<u>EQ 25MG TARTRATE</u>	<u>A203028</u>	<u>001</u>	Mar 31, 2020
AB		<u>EQ 50MG TARTRATE</u>	<u>A203028</u>	<u>002</u>	Mar 31, 2020
AB		<u>EQ 100MG TARTRATE</u>	<u>A203699</u>	<u>001</u>	Mar 30, 2020
AB		<u>EQ 200MG TARTRATE</u>	<u>A203699</u>	<u>002</u>	Mar 30, 2020
AB	REDDYS	<u>EQ 100MG TARTRATE</u>	<u>A078889</u>	<u>001</u>	Aug 15, 2012
AB		<u>EQ 200MG TARTRATE</u>	<u>A078889</u>	<u>002</u>	Aug 15, 2012
AB	SUNSHINE	<u>EQ 50MG TARTRATE</u>	<u>A214004</u>	<u>001</u>	Sep 26, 2022
AB		<u>EQ 100MG TARTRATE</u>	<u>A214004</u>	<u>002</u>	Sep 26, 2022
AB		<u>EQ 200MG TARTRATE</u>	<u>A214004</u>	<u>003</u>	Sep 26, 2022
AB	VISUM PHARM	<u>EQ 25MG TARTRATE</u>	<u>A207206</u>	<u>001</u>	Dec 19, 2018
AB		<u>EQ 50MG TARTRATE</u>	<u>A207206</u>	<u>002</u>	Dec 19, 2018
AB		<u>EQ 100MG TARTRATE</u>	<u>A207206</u>	<u>003</u>	Dec 19, 2018
AB		<u>EQ 200MG TARTRATE</u>	<u>A207206</u>	<u>004</u>	Dec 19, 2018
AB	WOCKHARDT	<u>EQ 25MG TARTRATE</u>	<u>A090615</u>	<u>001</u>	Jul 22, 2010
AB		<u>EQ 50MG TARTRATE</u>	<u>A090615</u>	<u>002</u>	Jul 22, 2010
AB		<u>EQ 100MG TARTRATE</u>	<u>A090615</u>	<u>003</u>	Jul 22, 2010
AB		<u>EQ 200MG TARTRATE</u>	<u>A090615</u>	<u>004</u>	Jul 22, 2010
AB	YICHANG HUMANWELL	<u>EQ 25MG TARTRATE</u>	<u>A213854</u>	<u>004</u>	Aug 01, 2022
AB		<u>EQ 50MG TARTRATE</u>	<u>A213854</u>	<u>003</u>	Nov 08, 2021
AB		<u>EQ 100MG TARTRATE</u>	<u>A213854</u>	<u>001</u>	Feb 12, 2021
AB		<u>EQ 200MG TARTRATE</u>	<u>A213854</u>	<u>002</u>	Feb 12, 2021
AB	ZYDUS PHARMS	<u>EQ 25MG TARTRATE</u>	<u>A203894</u>	<u>001</u>	Mar 23, 2018
AB		<u>EQ 50MG TARTRATE</u>	<u>A203894</u>	<u>002</u>	Mar 23, 2018
AB		<u>EQ 100MG TARTRATE</u>	<u>A203894</u>	<u>003</u>	Mar 23, 2018
AB		<u>EQ 200MG TARTRATE</u>	<u>A203894</u>	<u>004</u>	Mar 23, 2018
<u>TOPROL-XL</u>					
AB	+	<u>EQ 25MG TARTRATE</u>	<u>N019962</u>	<u>004</u>	Feb 05, 2001
AB	+	<u>EQ 50MG TARTRATE</u>	<u>N019962</u>	<u>001</u>	Jan 10, 1992
AB	+	<u>EQ 100MG TARTRATE</u>	<u>N019962</u>	<u>002</u>	Jan 10, 1992
AB	+	<u>EQ 200MG TARTRATE</u>	<u>N019962</u>	<u>003</u>	Jan 10, 1992

METOPROLOL TARTRATE

INJECTABLE; INJECTION

METOPROLOL TARTRATE

AP	BAXTER HLTHCARE CORP	<u>1MG/ML</u>	<u>A078950</u>	<u>001</u>	Apr 29, 2013
AP	FRESENIUS KABI USA	<u>1MG/ML</u>	<u>A091045</u>	<u>001</u>	Oct 25, 2010
AP	GLAND PHARMA LTD	<u>1MG/ML</u>	<u>A204205</u>	<u>001</u>	Aug 27, 2014
AP	HIKMA	<u>1MG/ML</u>	<u>A076495</u>	<u>001</u>	Jul 07, 2003
AP	HIKMA FARMACEUTICA	<u>1MG/ML</u>	<u>A077761</u>	<u>001</u>	May 30, 2007
AP	HOSPIRA	<u>1MG/ML</u>	<u>A074133</u>	<u>001</u>	Dec 21, 1993
AP		<u>1MG/ML</u>	<u>A075160</u>	<u>001</u>	Jul 06, 1998
AP	!	<u>1MG/ML</u>	<u>A078085</u>	<u>001</u>	Apr 29, 2008
AP	SANDOZ INC	<u>1MG/ML</u>	<u>A077360</u>	<u>001</u>	Oct 02, 2007

TABLET; ORAL

LOPRESSOR

AB	+	<u>50MG</u>	<u>N017963</u>	<u>001</u>	
AB	+	<u>100MG</u>	<u>N017963</u>	<u>002</u>	

METOPROLOL TARTRATE

AB	ALEMBIC PHARMS LTD	<u>25MG</u>	<u>A202871</u>	<u>001</u>	May 28, 2013
AB		<u>50MG</u>	<u>A202871</u>	<u>002</u>	May 28, 2013
AB		<u>100MG</u>	<u>A202871</u>	<u>003</u>	May 28, 2013
AB	AUROBINDO PHARMA	<u>25MG</u>	<u>A077739</u>	<u>001</u>	Sep 11, 2007
AB		<u>50MG</u>	<u>A077739</u>	<u>002</u>	Sep 11, 2007
AB		<u>100MG</u>	<u>A077739</u>	<u>003</u>	Sep 11, 2007
AB	IPCA LABS LTD	<u>25MG</u>	<u>A078459</u>	<u>001</u>	Jun 17, 2008
AB		<u>50MG</u>	<u>A078459</u>	<u>002</u>	Jun 17, 2008
AB		<u>100MG</u>	<u>A078459</u>	<u>003</u>	Jun 17, 2008
AB	MYLAN	<u>25MG</u>	<u>A076704</u>	<u>001</u>	Jan 16, 2004

PRESCRIPTION DRUG PRODUCT LIST

3-309 (of 474)

METOPROLOL TARTRATE

TABLET; ORAL

METOPROLOL TARTRATE

<u>AB</u>		<u>37.5MG</u>	<u>A076704</u>	<u>004</u>	Mar 18, 2015
<u>AB</u>		<u>50MG</u>	<u>A076704</u>	<u>002</u>	Jan 16, 2004
<u>AB</u>		<u>75MG</u>	<u>A076704</u>	<u>005</u>	Mar 18, 2015
<u>AB</u>	!	<u>100MG</u>	<u>A076704</u>	<u>003</u>	Jan 16, 2004
<u>AB</u>	RUBICON	<u>25MG</u>	<u>A200981</u>	<u>001</u>	Oct 28, 2014
<u>AB</u>		<u>37.5MG</u>	<u>A200981</u>	<u>004</u>	Aug 21, 2019
<u>AB</u>		<u>50MG</u>	<u>A200981</u>	<u>002</u>	Oct 28, 2014
<u>AB</u>		<u>75MG</u>	<u>A200981</u>	<u>005</u>	Aug 21, 2019
<u>AB</u>		<u>100MG</u>	<u>A200981</u>	<u>003</u>	Oct 28, 2014
<u>AB</u>	SUN PHARM INDS INC	<u>25MG</u>	<u>A076670</u>	<u>001</u>	Jan 15, 2004
<u>AB</u>		<u>50MG</u>	<u>A074644</u>	<u>001</u>	Dec 10, 1996
<u>AB</u>		<u>100MG</u>	<u>A074644</u>	<u>002</u>	Dec 10, 1996
<u>AB</u>	YOUNGTECH PHARMS INC	<u>25MG</u>	<u>A208955</u>	<u>001</u>	Feb 05, 2020
<u>AB</u>		<u>50MG</u>	<u>A208955</u>	<u>002</u>	Feb 05, 2020
<u>AB</u>		<u>100MG</u>	<u>A208955</u>	<u>003</u>	Feb 05, 2020

METRONIDAZOLE

CAPSULE; ORAL

FLAGYL

<u>AB</u>	+	PFIZER	<u>375MG</u>	<u>N020334</u>	<u>001</u>	May 03, 1995

METRONIDAZOLE

<u>AB</u>		ALEMBIC PHARMS	<u>375MG</u>	<u>A079065</u>	<u>001</u>	Jun 23, 2009
<u>AB</u>		STRIDES PHARMA	<u>375MG</u>	<u>A076522</u>	<u>001</u>	Jan 29, 2004

CREAM; TOPICAL

METROCREAM

<u>AB</u>	+	GALDERMA LABS LP	<u>0.75%</u>	<u>N020531</u>	<u>001</u>	Sep 20, 1995

METRONIDAZOLE

<u>AB</u>		COSETTE	<u>0.75%</u>	<u>A077549</u>	<u>001</u>	Dec 19, 2007
<u>AB</u>		FOUGERA PHARMS	<u>0.75%</u>	<u>A076408</u>	<u>001</u>	May 28, 2004

NORITATE

+	BAUSCH	1%	N020743	001	Sep 26, 1997

GEL; TOPICAL

METROGEL

<u>AB</u>	+	GALDERMA LABS LP	<u>0.75%</u>	<u>N019737</u>	<u>001</u>	Nov 22, 1988
<u>AB</u>	+		<u>1%</u>	<u>N021789</u>	<u>001</u>	Jun 30, 2005

METRONIDAZOLE

<u>AB</u>		ALEOR	<u>1%</u>	<u>A212646</u>	<u>001</u>	Sep 03, 2021
<u>AB</u>		DERMACEUTICALS				
<u>AB</u>		COSETTE	<u>0.75%</u>	<u>A078178</u>	<u>001</u>	Jan 19, 2011
<u>AB</u>		ENCUBE	<u>0.75%</u>	<u>A077547</u>	<u>001</u>	Jul 13, 2006
<u>AB</u>		FOUGERA PHARMS	<u>0.75%</u>	<u>A077018</u>	<u>001</u>	Jun 06, 2006
<u>AB</u>		TARO	<u>0.75%</u>	<u>A077819</u>	<u>001</u>	Jul 18, 2006
<u>AB</u>			<u>1%</u>	<u>A204651</u>	<u>001</u>	Mar 14, 2017
<u>AB</u>		TOLMAR	<u>1%</u>	<u>A090903</u>	<u>001</u>	Jul 22, 2011

GEL; VAGINAL

METROGEL-VAGINAL

<u>AB</u>	+	BAUSCH	<u>0.75%</u>	<u>N020208</u>	<u>001</u>	Aug 17, 1992

METRONIDAZOLE

<u>AB</u>		GLENMARK PHARMS LTD	<u>0.75%</u>	<u>A215794</u>	<u>001</u>	Jan 27, 2022
<u>AB</u>		PADAGIS ISRAEL	<u>0.75%</u>	<u>A211786</u>	<u>001</u>	Jul 02, 2019
<u>AB</u>		SOLARIS PHARMA CORP	<u>0.75%</u>	<u>A213648</u>	<u>001</u>	Oct 14, 2021

VANDAZOLE

BX	!	TEVA PHARMS	0.75%	N021806	001	May 20, 2005

NUVESSA

+	CHEMO RESEARCH SL	1.3%	N205223	001	Mar 24, 2014

INJECTABLE; INJECTION

FLAGYL I.V. RTU IN PLASTIC CONTAINER

<u>AP</u>	+	BAXTER HLTHCARE	<u>500MG/100ML</u>	<u>N018657</u>	<u>001</u>	

METRO I.V. IN PLASTIC CONTAINER

<u>AP</u>	+	B BRAUN	<u>500MG/100ML</u>	<u>N018900</u>	<u>001</u>	Sep 29, 1983

METRONIDAZOLE IN PLASTIC CONTAINER

<u>AP</u>		BAXTER HLTHCARE CORP	<u>500MG/100ML</u>	<u>A078084</u>	<u>001</u>	Mar 31, 2008
<u>AP</u>		GLAND PHARMA LTD	<u>500MG/100ML</u>	<u>A212435</u>	<u>001</u>	Aug 03, 2020
<u>AP</u>	+	HOSPIRA	<u>500MG/100ML</u>	<u>N018890</u>	<u>002</u>	Nov 18, 1983
<u>AP</u>		INFORLIFE	<u>500MG/100ML</u>	<u>A206191</u>	<u>001</u>	Feb 25, 2019

LOTION; TOPICAL

METROLOTION

<u>AB</u>	+	GALDERMA LABS LP	<u>0.75%</u>	<u>N020901</u>	<u>001</u>	Nov 24, 1998

PRESCRIPTION DRUG PRODUCT LIST

3-310 (of 474)

METRONIDAZOLE

LOTION; TOPICAL

METRONIDAZOLE

AB	FOUGERA PHARMS	0.75%	<u>A077197</u>	<u>001</u>	May 24, 2006

TABLET; ORAL

FLAGYL

AB	+	PFIZER	250MG	<u>N012623</u>	<u>001</u>

AB	+	!	500MG	<u>N012623</u>	<u>003</u>

METRONIDAZOLE

AB	ALEMBIC LABS	250MG	<u>A208681</u>	<u>001</u>	Jun 20, 2017

AB		500MG	<u>A208681</u>	<u>002</u>	Jun 20, 2017

AB	ALEMBIC PHARMS LTD	250MG	<u>A079067</u>	<u>001</u>	Mar 13, 2009

AB		500MG	<u>A079067</u>	<u>002</u>	Mar 13, 2009

AB	AMICI	250MG	<u>A070772</u>	<u>001</u>	Jul 16, 1986

AB		500MG	<u>A070772</u>	<u>002</u>	Jul 16, 1986

AB	AUROBINDO PHARMA LTD	250MG	<u>A203974</u>	<u>001</u>	May 29, 2015

AB		500MG	<u>A203974</u>	<u>002</u>	May 29, 2015

AB	CADILA	250MG	<u>A206560</u>	<u>001</u>	Nov 16, 2016

AB		500MG	<u>A206560</u>	<u>002</u>	Nov 16, 2016

AB	CADILA PHARMS LTD	250MG	<u>A209794</u>	<u>001</u>	Dec 12, 2017

AB		500MG	<u>A209794</u>	<u>002</u>	Dec 12, 2017

AB	FLAMINGO PHARMS	250MG	<u>A207309</u>	<u>001</u>	May 16, 2016

AB		500MG	<u>A207309</u>	<u>002</u>	May 16, 2016

AB	HERITAGE PHARMS INC	250MG	<u>A205245</u>	<u>001</u>	Sep 23, 2015

AB		500MG	<u>A205245</u>	<u>002</u>	Sep 23, 2015

AB	LUPIN LTD	250MG	<u>A209096</u>	<u>001</u>	Sep 12, 2017

AB		500MG	<u>A209096</u>	<u>002</u>	Sep 12, 2017

AB	PLIVA	500MG	<u>A070033</u>	<u>001</u>	Dec 06, 1984

AB	STRIDES PHARMA	250MG	<u>A070040</u>	<u>001</u>	Jan 29, 1985

AB		250MG	<u>A208162</u>	<u>001</u>	May 25, 2016

AB		500MG	<u>A070039</u>	<u>001</u>	Jan 29, 1985

AB		500MG	<u>A208162</u>	<u>002</u>	May 25, 2016

AB	TEVA PHARMS USA	250MG	<u>A070027</u>	<u>001</u>	Nov 06, 1984

AB	UNICHEM	250MG	<u>A203458</u>	<u>001</u>	Jan 22, 2014

AB		500MG	<u>A203458</u>	<u>002</u>	Jan 22, 2014

AB	WATSON LABS	250MG	<u>A070035</u>	<u>001</u>	Dec 20, 1984

AB	WATSON LABS INC	500MG	<u>A070044</u>	<u>001</u>	Feb 08, 1985

METRAPONE

CAPSULE; ORAL

METOPIRON

+	!	HRA PHARMA	250MG	<u>N012911</u>	<u>002</u>	Aug 09, 1996

METTYROSINE

CAPSULE; ORAL

DEMSE

AB	+	!	BAUSCH	250MG	<u>N017871</u>	<u>001</u>

METTYROSINE

AB	AMNEAL	250MG	<u>A213734</u>	<u>001</u>	Jul 24, 2020

MEXILETINE HYDROCHLORIDE

CAPSULE; ORAL

MEXILETINE HYDROCHLORIDE

AB	ANI PHARMS	150MG	<u>A074450</u>	<u>001</u>	May 16, 1996

AB		200MG	<u>A074450</u>	<u>002</u>	May 16, 1996

AB		250MG	<u>A074450</u>	<u>003</u>	May 16, 1996

AB	ANNORA PHARMA	150MG	<u>A216463</u>	<u>001</u>	Nov 09, 2022

AB		200MG	<u>A216463</u>	<u>002</u>	Nov 09, 2022

AB		250MG	<u>A216463</u>	<u>003</u>	Nov 09, 2022

AB	AUCTA	150MG	<u>A215315</u>	<u>001</u>	Aug 26, 2022

AB		200MG	<u>A215315</u>	<u>002</u>	Aug 26, 2022

AB		250MG	<u>A215315</u>	<u>003</u>	Aug 26, 2022

AB	CROSSMEDIKA SA	150MG	<u>A213500</u>	<u>001</u>	Jul 22, 2020

AB		200MG	<u>A213500</u>	<u>002</u>	Jul 22, 2020

AB		250MG	<u>A213500</u>	<u>003</u>	Jul 22, 2020

AB	NOVAST LABS	150MG	<u>A214352</u>	<u>001</u>	Jan 25, 2021

AB		200MG	<u>A214352</u>	<u>002</u>	Jan 25, 2021

AB		250MG	<u>A214352</u>	<u>003</u>	Jan 25, 2021

AB	SENORES PHARMS	150MG	<u>A214089</u>	<u>001</u>	Oct 01, 2021

AB		200MG	<u>A214089</u>	<u>002</u>	Oct 01, 2021

AB		250MG	<u>A214089</u>	<u>003</u>	Oct 01, 2021

AB	TEVA	150MG	<u>A074377</u>	<u>001</u>	May 16, 1995

AB		200MG	<u>A074377</u>	<u>002</u>	May 16, 1995

PRESCRIPTION DRUG PRODUCT LIST

3-311 (of 474)

MEXILETINE HYDROCHLORIDE

CAPSULE; ORAL

MEXILETINE HYDROCHLORIDE

AB	!	250MG	A074377	003	May 16, 1995

MICAFUNGIN SODIUM

INJECTABLE; INTRAVENOUS

MICAFUNGIN SODIUM

AP	APOTEX	EQ 50MG BASE/VIAL	A208366	001	Nov 05, 2020
AP		EQ 100MG BASE/VIAL	A208366	002	Nov 05, 2020
AP	FRESENIUS KABI USA	EQ 50MG BASE/VIAL	A207344	001	May 17, 2019
AP		EQ 100MG BASE/VIAL	A207344	002	May 17, 2019
AP	HIKMA	EQ 50MG BASE/VIAL	A213261	001	Jul 09, 2021
AP		EQ 100MG BASE/VIAL	A213261	002	Jul 09, 2021
AP	JIANGSU HANSON PHARM	EQ 50MG BASE/VIAL	A213363	001	Jul 09, 2021
AP		EQ 100MG BASE/VIAL	A213363	002	Jul 09, 2021
AP	MEITHEAL	EQ 50MG BASE/VIAL	A215381	001	Sep 28, 2022
AP		EQ 100MG BASE/VIAL	A215381	002	Sep 28, 2022
AP	XELLIA PHARMS APS	EQ 50MG BASE/VIAL	A211713	001	Jun 02, 2021
AP		EQ 100MG BASE/VIAL	A211713	002	Jun 02, 2021
AP	ZYDUS PHARMS	EQ 50MG BASE/VIAL	A215241	001	Oct 24, 2022
AP		EQ 100MG BASE/VIAL	A215241	002	Oct 24, 2022

MYCAMINE

AP	+	ASTELLAS	EQ 50MG BASE/VIAL	N021506	002	Mar 16, 2005
AP	+		EQ 100MG BASE/VIAL	N021506	003	Jun 27, 2006

POWDER; INTRAVENOUS

MICAFUNGIN

+	!	PAR STERILE PRODUCTS	EQ 50MG BASE/VIAL	N212156	001	Jun 16, 2021
+	!		EQ 100MG BASE/VIAL	N212156	002	Jun 16, 2021

MICONAZOLE

TABLET; BUCCAL

ORAVIG

+	!	GALT PHARMS	50MG	N022404	001	Apr 16, 2010

MICONAZOLE NITRATE

SUPPOSITORY; VAGINAL

MICONAZOLE NITRATE

AB		ACTAVIS PHARMA	200MG	A073508	001	Nov 19, 1993
AB	+	MONISTAT 3				
AB	+	MEDTECH PRODUCTS	200MG	N018888	001	Aug 15, 1984

MICONAZOLE NITRATE; WHITE PETROLATUM; ZINC OXIDE

OINTMENT; TOPICAL

VUSION

+	!	MYLAN	0.25%; 81.35%; 15%	N021026	001	Feb 16, 2006

MIDAZOLAM

SOLUTION; INTRAVENOUS

MIDAZOLAM IN 0.8% SODIUM CHLORIDE

+	!	EXELA PHARMA	50MG/50ML (1MG/ML)	N215868	001	Jul 20, 2022
+	!		100MG/100ML (1MG/ML)	N215868	002	Jul 20, 2022

MIDAZOLAM IN 0.9% SODIUM CHLORIDE

+	!	INFORLIFE	50MG/50ML (1MG/ML)	N211844	001	Mar 22, 2021
+	!		100MG/100ML (1MG/ML)	N211844	002	Mar 22, 2021

SPRAY; NASAL

NAYZILAM

+	!	UCB INC	5MG/SPRAY	N211321	001	May 17, 2019

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION

MIDAZOLAM HYDROCHLORIDE

AP	AKORN	EQ 1MG BASE/ML	A075494	001	Jun 30, 2000
AP		EQ 5MG BASE/ML	A075494	002	Jun 30, 2000
AP	FRESENIUS KABI USA	EQ 1MG BASE/ML	A075154	002	Jun 20, 2000
AP		EQ 5MG BASE/ML	A075154	001	Jun 20, 2000
AP	GLAND PHARMA LTD	EQ 1MG BASE/ML	A090696	001	Feb 29, 2012
AP		EQ 5MG BASE/ML	A090850	001	Jan 25, 2012
AP	HIKMA	EQ 1MG BASE/ML	A075243	001	Jun 20, 2000
AP		EQ 1MG BASE/ML	A075247	002	Jun 23, 2000
AP		EQ 1MG BASE/ML	A075324	001	Jun 20, 2000
AP		EQ 1MG BASE/ML	A075421	002	Jun 20, 2000
AP		EQ 1MG BASE/ML	A212847	001	Dec 11, 2020
AP		EQ 5MG BASE/ML	A075243	002	Jun 20, 2000

PRESCRIPTION DRUG PRODUCT LIST

3-312 (of 474)

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION

MIDAZOLAM HYDROCHLORIDE

<u>AP</u>		<u>EQ 5MG BASE/ML</u>	<u>A075247</u>	<u>001</u>	Jun 23, 2000
<u>AP</u>		<u>EQ 5MG BASE/ML</u>	<u>A075324</u>	<u>002</u>	Jun 20, 2000
<u>AP</u>		<u>EQ 5MG BASE/ML</u>	<u>A075421</u>	<u>001</u>	Jun 20, 2000
<u>AP</u>		<u>EQ 5MG BASE/ML</u>	<u>A212847</u>	<u>002</u>	Dec 11, 2020
<u>AP</u>	!	<u>EQ 1MG BASE/ML</u>	<u>A075293</u>	<u>001</u>	Jun 20, 2000
<u>AP</u>	!	<u>EQ 5MG BASE/ML</u>	<u>A075293</u>	<u>002</u>	Jun 20, 2000

MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE

<u>AP</u>	FRESENIUS KABI USA	<u>EQ 1MG BASE/ML</u>	<u>A203460</u>	<u>001</u>	Aug 22, 2014
<u>AP</u>		<u>EQ 5MG BASE/ML</u>	<u>A203460</u>	<u>002</u>	Aug 22, 2014
<u>AP</u>	!	<u>EQ 1MG BASE/ML</u>	<u>A075857</u>	<u>001</u>	Jul 22, 2002
<u>AP</u>	!	<u>EQ 5MG BASE/ML</u>	<u>A075857</u>	<u>002</u>	Jul 22, 2002

MIDAZOLAM HYDROCHLORIDE

FRESENIUS KABI USA

EQ 5MG BASE/ML

A208878 001 Mar 28, 2017

SOLUTION; INTRAMUSCULAR

SEIZALAM

+! MMT

EQ 50MG BASE/10ML (EQ 5MG BASE/ML)

N209566 001 Sep 14, 2018

SYRUP; ORAL

MIDAZOLAM HYDROCHLORIDE

<u>AA</u>	!	<u>EQ 2MG BASE/ML</u>	<u>A075873</u>	<u>001</u>	Apr 30, 2002
<u>AA</u>	PADAGIS US	<u>EQ 2MG BASE/ML</u>	<u>A076379</u>	<u>001</u>	May 02, 2005

MIDODRINE HYDROCHLORIDE

TABLET; ORAL

MIDODRINE HYDROCHLORIDE

<u>AB</u>	ALEMBIC PHARMS	<u>2.5MG</u>	<u>A214734</u>	<u>001</u>	Jan 21, 2021
<u>AB</u>		<u>5MG</u>	<u>A214734</u>	<u>002</u>	Jan 21, 2021
<u>AB</u>		<u>10MG</u>	<u>A214734</u>	<u>003</u>	Jan 21, 2021
<u>AB</u>	APOTEX	<u>2.5MG</u>	<u>A077746</u>	<u>001</u>	Sep 12, 2006
<u>AB</u>		<u>5MG</u>	<u>A077746</u>	<u>002</u>	Sep 12, 2006
<u>AB</u>		<u>10MG</u>	<u>A077746</u>	<u>003</u>	Sep 12, 2006
<u>AB</u>	AUROBINDO PHARMA LTD	<u>2.5MG</u>	<u>A212774</u>	<u>001</u>	Aug 10, 2020
<u>AB</u>		<u>5MG</u>	<u>A212774</u>	<u>002</u>	Aug 10, 2020
<u>AB</u>		<u>10MG</u>	<u>A212774</u>	<u>003</u>	Aug 10, 2020
<u>AB</u>	IMPAX PHARMS	<u>2.5MG</u>	<u>A076449</u>	<u>001</u>	May 27, 2004
<u>AB</u>		<u>5MG</u>	<u>A076449</u>	<u>002</u>	May 27, 2004
<u>AB</u>		<u>10MG</u>	<u>A076449</u>	<u>003</u>	Dec 16, 2005
<u>AB</u>	MYLAN PHARMS INC	<u>2.5MG</u>	<u>A076577</u>	<u>001</u>	Sep 10, 2003
<u>AB</u>		<u>5MG</u>	<u>A076577</u>	<u>002</u>	Sep 10, 2003
<u>AB</u>		<u>10MG</u>	<u>A076577</u>	<u>003</u>	Sep 10, 2003
<u>AB</u>	PAR PHARM INC	<u>2.5MG</u>	<u>A207169</u>	<u>001</u>	Oct 29, 2018
<u>AB</u>		<u>5MG</u>	<u>A207169</u>	<u>002</u>	Oct 29, 2018
<u>AB</u>		<u>10MG</u>	<u>A207169</u>	<u>003</u>	Oct 29, 2018
<u>AB</u>	RUBICON	<u>2.5MG</u>	<u>A212543</u>	<u>001</u>	Aug 19, 2019
<u>AB</u>		<u>5MG</u>	<u>A212543</u>	<u>002</u>	Aug 19, 2019
<u>AB</u>		<u>10MG</u>	<u>A212543</u>	<u>003</u>	Aug 19, 2019
<u>AB</u>	UNIQUE	<u>2.5MG</u>	<u>A207613</u>	<u>001</u>	Nov 02, 2018
<u>AB</u>		<u>5MG</u>	<u>A207613</u>	<u>002</u>	Nov 02, 2018
<u>AB</u>		<u>10MG</u>	<u>A207613</u>	<u>003</u>	Nov 02, 2018
<u>AB</u>	XIROMED	<u>2.5MG</u>	<u>A207849</u>	<u>001</u>	Oct 01, 2020
<u>AB</u>		<u>5MG</u>	<u>A207849</u>	<u>002</u>	Oct 01, 2020
<u>AB</u>		<u>10MG</u>	<u>A207849</u>	<u>003</u>	Oct 01, 2020
<u>AB</u>	ZYDUS	<u>2.5MG</u>	<u>A213055</u>	<u>001</u>	Sep 01, 2020
<u>AB</u>		<u>5MG</u>	<u>A213055</u>	<u>002</u>	Sep 01, 2020
<u>AB</u>		<u>10MG</u>	<u>A213055</u>	<u>003</u>	Sep 01, 2020

ORVATEN

<u>AB</u>	UPSHER SMITH LABS	<u>2.5MG</u>	<u>A076725</u>	<u>001</u>	Nov 03, 2004
<u>AB</u>	!	<u>5MG</u>	<u>A076725</u>	<u>002</u>	Nov 03, 2004
<u>AB</u>		<u>10MG</u>	<u>A076725</u>	<u>003</u>	Nov 03, 2004

MIDOSTAURIN

CAPSULE; ORAL

RYDAPT

+! NOVARTIS

25MG

N207997 001 Apr 28, 2017

PRESCRIPTION DRUG PRODUCT LIST

3-313 (of 474)

MIFEPRISTONE

TABLET; ORAL

KORLYM

AB	+	!	CORCEPT THERAP	300MG	N202107	001	Feb 17, 2012

MIFEPREX

AB	+	!	DANCO LABS LLC	200MG	N020687	001	Sep 28, 2000

MIFEPRISTONE

AB			GENBIOPRO	200MG	A091178	001	Apr 11, 2019

AB			TEVA PHARMS USA INC	300MG	A211436	001	Aug 03, 2020

MIGALASTAT HYDROCHLORIDE

CAPSULE; ORAL

GALAFOLD

+	!		AMICUS THERAP US	EQ 123MG BASE	N208623	001	Aug 10, 2018

MIGLITOL

TABLET; ORAL

GLYSET

AB	+	!	PFIZER	25MG	N020682	001	Dec 18, 1996

AB	+			50MG	N020682	002	Dec 18, 1996

AB	+			100MG	N020682	003	Dec 18, 1996

MIGLITOL

AB			WESTMINSTER PHARMS	25MG	A203965	001	Feb 24, 2015

AB				50MG	A203965	002	Feb 24, 2015

AB				100MG	A203965	003	Feb 24, 2015

MIGLUSTAT

CAPSULE; ORAL

MIGLUSTAT

AB			ANI PHARMS	100MG	A208342	001	Apr 17, 2018

AB			BRECKENRIDGE	100MG	A209325	001	Feb 03, 2022

AB			EDENBRIDGE PHARMS	100MG	A209821	001	Aug 06, 2020

ZAVESCA

AB	+	!	ACTELION	100MG	N021348	001	Jul 31, 2003

MILNACIPRAN HYDROCHLORIDE

TABLET; ORAL

SAVELLA

+			ALLERGAN	12.5MG	N022256	001	Jan 14, 2009

+				25MG	N022256	002	Jan 14, 2009

+	!			50MG	N022256	003	Jan 14, 2009

+				100MG	N022256	004	Jan 14, 2009

MILRINONE LACTATE

INJECTABLE; INJECTION

MILRINONE LACTATE

AP			CAPLIN	EQ 1MG BASE/ML	A214380	001	Apr 16, 2021

AP			FRESENIUS KABI USA	EQ 1MG BASE/ML	A075936	001	May 28, 2002

AP			HIKMA	EQ 1MG BASE/ML	A075530	001	May 28, 2002

AP				EQ 1MG BASE/ML	A075660	001	May 28, 2002

AP	!		HIKMA FARMACEUTICA	EQ 1MG BASE/ML	A077966	001	Dec 03, 2010

AP			HOSPIRA	EQ 1MG BASE/ML	A203280	001	Sep 03, 2014

AP			MEITHEAL	EQ 1MG BASE/ML	A211671	001	Mar 24, 2020

MILRINONE LACTATE IN DEXTROSE 5%

AP			EUGIA PHARMA	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A209666	001	Sep 03, 2020

AP				EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)	A209666	002	Sep 03, 2020

AP			WOODWARD	EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)	A077151	002	Jul 20, 2005

MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	!		BAXTER HLTHCARE	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A075834	001	May 28, 2002

AP	!			EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)	A075834	002	May 28, 2002

AP			GLAND PHARMA LTD	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A213585	001	Jul 16, 2020

AP				EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)	A213585	002	Jul 16, 2020

AP			HOSPIRA	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A075885	001	May 28, 2002

AP				EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)	A075885	002	May 28, 2002

AP			WEST-WARD PHARMS	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A078113	001	May 21, 2008

AP			INT	EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)	A078113	002	May 21, 2008

MILRINONE LACTATE IN PLASTIC CONTAINER

AP			HIKMA FARMACEUTICA	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A090038	001	Jan 21, 2010

AP				EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)	A090038	002	Jan 21, 2010

PRESCRIPTION DRUG PRODUCT LIST

3-314 (of 474)

MILTEFOSINE

CAPSULE; ORAL

IMPAVIDO

+! KNIGHT THERAPS

50MG

N204684 001 Mar 19, 2014

MINOCYCLINE HYDROCHLORIDE

AEROSOL, FOAM; TOPICAL

AMZEEQ

+! JOURNEY

EQ 4% BASE

N212379 001 Oct 18, 2019

ZILXI

+! JOURNEY

EQ 1.5% BASE

N213690 001 May 28, 2020

CAPSULE; ORAL

DYNACIN**AB** ALVOGENEQ 50MG BASEA063067 003 Aug 14, 1990**AB**EQ 75MG BASEA063067 002 Sep 15, 1999**AB**EQ 100MG BASEA063067 001 Jul 31, 1990MINOCIN**AB** + BAUSCHEQ 50MG BASEN050649 001 May 31, 1990**AB** +EQ 100MG BASEN050649 002 May 31, 1990MINOCYCLINE HYDROCHLORIDE**AB** AUROBINDO PHARMAEQ 50MG BASEA065470 001 Mar 11, 2008**AB**EQ 75MG BASEA065470 002 Mar 11, 2008**AB**EQ 100MG BASEA065470 003 Mar 11, 2008**AB** IMPAX LABSEQ 50MG BASEA065005 001 Mar 23, 1999**AB**EQ 75MG BASEA065005 003 Apr 18, 2001**AB**EQ 100MG BASEA065005 002 Mar 23, 1999**AB** SUN PHARM INDS INCEQ 50MG BASEA090867 001 May 13, 2013**AB**EQ 75MG BASEA090867 002 May 13, 2013**AB**EQ 100MG BASEA090867 003 May 13, 2013**AB** TORRENTEQ 50MG BASEA065062 001 Nov 30, 2000**AB**EQ 75MG BASEA065062 002 Nov 30, 2000**AB**EQ 100MG BASEA065062 003 Nov 30, 2000**AB** WATSON LABSEQ 75MG BASEA063065 002 Jun 10, 1999**AB**EQ 100MG BASEA063065 001 Dec 30, 1991**AB** WATSON LABS TEVAEQ 50MG BASEA063181 001 Dec 30, 1991**AB** ZYDUSEQ 50MG BASEA063011 001 Mar 02, 1992**AB**EQ 75MG BASEA063009 002 Aug 12, 2003**AB** !EQ 100MG BASEA063009 001 Mar 02, 1992

CAPSULE, EXTENDED RELEASE; ORAL

XIMINO

JOURNEY

EQ 45MG BASE

N201922 001 Jul 11, 2012

EQ 90MG BASE

N201922 003 Jul 11, 2012

EQ 135MG BASE

N201922 005 Jul 11, 2012

INJECTABLE; INJECTION

MINOCIN**AP** +! REMPEXEQ 100MG BASE/VIALN050444 001MINOCYCLINE HYDROCHLORIDE**AP** NEXUS PHARMSEQ 100MG BASE/VIALA214934 001 Jul 22, 2022

POWDER, EXTENDED RELEASE; DENTAL

ARESTIN

+! ORAPHARMA

EQ 1MG BASE

N050781 001 Feb 16, 2001

TABLET; ORAL

MINOCYCLINE HYDROCHLORIDE**AB** AUROBINDO PHARMAEQ 50MG BASEA213662 001 May 01, 2020**AB** LTDEQ 75MG BASEA213662 002 May 01, 2020**AB**EQ 100MG BASEA213662 003 May 01, 2020**AB** BEXIMCO PHARMS USAEQ 50MG BASEA215466 001 May 27, 2022**AB**EQ 75MG BASEA215466 002 May 27, 2022**AB**EQ 100MG BASEA215466 003 May 27, 2022**AB** DR REDDYS LABS LTDEQ 50MG BASEA065436 001 Dec 26, 2007**AB**EQ 75MG BASEA065436 002 Dec 26, 2007**AB**EQ 100MG BASEA065436 003 Dec 26, 2007**AB** STRIDES PHARMAEQ 50MG BASEA065131 001 Apr 16, 2003**AB**EQ 75MG BASEA065131 002 Apr 16, 2003**AB** !EQ 100MG BASEA065131 003 Apr 16, 2003**AB** SUN PHARMEQ 50MG BASEA090217 001 Jan 29, 2016**AB** INDUSTRIESEQ 75MG BASEA090217 002 Jan 29, 2016**AB**EQ 100MG BASEA090217 003 Jan 29, 2016**AB**EQ 50MG BASEA065156 001 Jan 06, 2004**AB**EQ 75MG BASEA065156 002 Jan 06, 2004**AB**EQ 100MG BASEA065156 003 Jan 06, 2004

PRESCRIPTION DRUG PRODUCT LIST

3-315 (of 474)

MINOCYCLINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

MINOCYCLINE HYDROCHLORIDE

<u>AB</u>	ALKEM LABS LTD	<u>EQ 45MG BASE</u>	<u>A204453 001</u>	Sep 28, 2016
<u>AB</u>		<u>EQ 55MG BASE</u>	<u>A204453 008</u>	Dec 19, 2019
<u>AB</u>		<u>EQ 65MG BASE</u>	<u>A204453 006</u>	Mar 16, 2018
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A204453 002</u>	Sep 28, 2016
<u>AB</u>		<u>EQ 90MG BASE</u>	<u>A204453 003</u>	Sep 28, 2016
<u>AB</u>		<u>EQ 105MG BASE</u>	<u>A204453 004</u>	Sep 28, 2016
<u>AB</u>		<u>EQ 115MG BASE</u>	<u>A204453 007</u>	Mar 16, 2018
<u>AB</u>		<u>EQ 135MG BASE</u>	<u>A204453 005</u>	Sep 28, 2016
<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 45MG BASE</u>	<u>A202261 001</u>	Nov 19, 2012
<u>AB</u>		<u>EQ 55MG BASE</u>	<u>A202261 008</u>	Aug 21, 2019
<u>AB</u>		<u>EQ 65MG BASE</u>	<u>A202261 002</u>	Sep 28, 2018
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A202261 006</u>	Jun 13, 2016
<u>AB</u>		<u>EQ 90MG BASE</u>	<u>A202261 003</u>	Nov 19, 2012
<u>AB</u>		<u>EQ 105MG BASE</u>	<u>A202261 007</u>	Jun 13, 2016
<u>AB</u>		<u>EQ 115MG BASE</u>	<u>A202261 004</u>	Sep 28, 2018
<u>AB</u>		<u>EQ 135MG BASE</u>	<u>A202261 005</u>	Nov 19, 2012
<u>AB</u>	LUPIN LTD	<u>EQ 45MG BASE</u>	<u>A091424 001</u>	Nov 30, 2011
<u>AB</u>		<u>EQ 55MG BASE</u>	<u>A091424 002</u>	Nov 30, 2011
<u>AB</u>		<u>EQ 90MG BASE</u>	<u>A091424 003</u>	Nov 30, 2011
<u>AB</u>		<u>EQ 135MG BASE</u>	<u>A091424 004</u>	Nov 30, 2011
<u>AB</u>	SANDOZ	<u>EQ 45MG BASE</u>	<u>A090422 001</u>	Aug 13, 2009
<u>AB</u>		<u>EQ 90MG BASE</u>	<u>A090422 002</u>	Aug 13, 2009
<u>AB</u>	!	<u>EQ 135MG BASE</u>	<u>A090422 003</u>	Aug 13, 2009
<u>AB</u>	SIDMAK LABS INDIA	<u>EQ 45MG BASE</u>	<u>A204394 001</u>	Dec 30, 2015
<u>AB</u>		<u>EQ 55MG BASE</u>	<u>A204394 002</u>	Oct 07, 2022
<u>AB</u>		<u>EQ 65MG BASE</u>	<u>A204394 003</u>	Oct 07, 2022
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A204394 004</u>	Dec 30, 2015
<u>AB</u>		<u>EQ 105MG BASE</u>	<u>A204394 005</u>	Dec 30, 2015
<u>AB</u>		<u>EQ 115MG BASE</u>	<u>A204394 006</u>	Oct 07, 2022
<u>AB</u>		<u>EQ 135MG BASE</u>	<u>A204394 007</u>	Dec 30, 2015
<u>AB</u>	SUN PHARM INDS LTD	<u>EQ 45MG BASE</u>	<u>A091118 001</u>	Sep 25, 2014
<u>AB</u>		<u>EQ 65MG BASE</u>	<u>A091118 003</u>	Dec 03, 2019
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A091118 004</u>	Sep 25, 2014
<u>AB</u>		<u>EQ 90MG BASE</u>	<u>A091118 005</u>	Sep 25, 2014
<u>AB</u>		<u>EQ 105MG BASE</u>	<u>A091118 006</u>	Sep 25, 2014
<u>AB</u>		<u>EQ 115MG BASE</u>	<u>A091118 007</u>	Dec 03, 2019
<u>AB</u>		<u>EQ 135MG BASE</u>	<u>A091118 008</u>	Sep 25, 2014
<u>AB</u>	ZYDUS PHARMS	<u>EQ 45MG BASE</u>	<u>A203553 001</u>	Nov 16, 2017
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A203553 004</u>	Nov 16, 2017
<u>AB</u>		<u>EQ 90MG BASE</u>	<u>A203553 005</u>	Nov 16, 2017
<u>AB</u>		<u>EQ 105MG BASE</u>	<u>A203553 006</u>	Nov 16, 2017
<u>AB</u>		<u>EQ 135MG BASE</u>	<u>A203553 008</u>	Nov 16, 2017
<u>SOLODYN</u>				
<u>AB</u>	+ BAUSCH	<u>EQ 55MG BASE</u>	<u>N050808 008</u>	Aug 27, 2010
<u>AB</u>	+	<u>EQ 65MG BASE</u>	<u>N050808 004</u>	Jul 23, 2009
<u>AB</u>	+	<u>EQ 80MG BASE</u>	<u>N050808 007</u>	Aug 27, 2010
<u>AB</u>	+	<u>EQ 105MG BASE</u>	<u>N050808 006</u>	Aug 27, 2010
<u>AB</u>	+	<u>EQ 115MG BASE</u>	<u>N050808 005</u>	Jul 23, 2009
<u>MINOLIRA</u>				
	EPI HLTH	EQ 105MG BASE	N209269 001	May 08, 2017
	!	EQ 135MG BASE	N209269 002	May 08, 2017
<u>MINOXIDIL</u>				
TABLET;ORAL				
<u>MINOXIDIL</u>				
<u>AB</u>	PAR PHARM	<u>2.5MG</u>	<u>A071826 001</u>	Nov 14, 1988
<u>AB</u>		<u>10MG</u>	<u>A071839 001</u>	Nov 14, 1988
<u>AB</u>	SUN PHARM INDUSTRIES	<u>2.5MG</u>	<u>A072709 002</u>	Dec 14, 1995
<u>AB</u>		<u>10MG</u>	<u>A072709 001</u>	Dec 14, 1995
<u>AB</u>	WATSON LABS	<u>2.5MG</u>	<u>A071344 001</u>	Mar 03, 1987
<u>AB</u>	!	<u>10MG</u>	<u>A071345 001</u>	Mar 03, 1987
<u>MIRABEGRON</u>				
FOR SUSPENSION, EXTENDED RELEASE;ORAL				
MYRBETRIQ GRANULES				
	+! APGDI	8MG/ML	N213801 001	Mar 25, 2021

PRESCRIPTION DRUG PRODUCT LIST

3-316 (of 474)

MIRABEGRON

TABLET, EXTENDED RELEASE;ORAL

MIRABEGRON

<u>AB</u>	LUPIN LTD	<u>25MG</u>	<u>A209485</u>	<u>001</u>	Sep 28, 2022
<u>AB</u>		<u>50MG</u>	<u>A209485</u>	<u>002</u>	Sep 28, 2022
<u>AB</u>	ZYDUS PHARMS	<u>25MG</u>	<u>A209488</u>	<u>001</u>	Sep 29, 2022
<u>AB</u>		<u>50MG</u>	<u>A209488</u>	<u>002</u>	Sep 29, 2022

MYRBETRIO

<u>AB</u>	+! APGDI	<u>25MG</u>	<u>N202611</u>	<u>001</u>	Jun 28, 2012
<u>AB</u>	+!	<u>50MG</u>	<u>N202611</u>	<u>002</u>	Jun 28, 2012

MIRTAZAPINE

TABLET;ORAL

MIRTAZAPINE

<u>AB</u>	APOTEX INC	<u>15MG</u>	<u>A077666</u>	<u>001</u>	Aug 22, 2007
<u>AB</u>		<u>30MG</u>	<u>A077666</u>	<u>002</u>	Aug 22, 2007
<u>AB</u>		<u>45MG</u>	<u>A077666</u>	<u>003</u>	Aug 22, 2007
<u>AB</u>	AUROBINDO	<u>7.5MG</u>	<u>A076921</u>	<u>001</u>	Oct 22, 2004
<u>AB</u>		<u>15MG</u>	<u>A076921</u>	<u>002</u>	Oct 22, 2004
<u>AB</u>		<u>30MG</u>	<u>A076921</u>	<u>003</u>	Oct 22, 2004
<u>AB</u>		<u>45MG</u>	<u>A076921</u>	<u>004</u>	Oct 22, 2004
<u>AB</u>	MYLAN	<u>15MG</u>	<u>A076122</u>	<u>001</u>	Jun 19, 2003
<u>AB</u>		<u>30MG</u>	<u>A076122</u>	<u>002</u>	Jun 19, 2003
<u>AB</u>		<u>45MG</u>	<u>A076122</u>	<u>003</u>	Jun 19, 2003
<u>AB</u>	SUN PHARM INDS INC	<u>7.5MG</u>	<u>A076541</u>	<u>004</u>	Apr 22, 2004
<u>AB</u>		<u>15MG</u>	<u>A076541</u>	<u>001</u>	Apr 22, 2004
<u>AB</u>		<u>30MG</u>	<u>A076541</u>	<u>002</u>	Apr 22, 2004
<u>AB</u>		<u>45MG</u>	<u>A076541</u>	<u>003</u>	Apr 22, 2004
<u>AB</u>	TEVA	<u>15MG</u>	<u>A076119</u>	<u>001</u>	Jan 24, 2003
<u>AB</u>		<u>30MG</u>	<u>A076119</u>	<u>002</u>	Jan 24, 2003
<u>AB</u>		<u>45MG</u>	<u>A076119</u>	<u>003</u>	Jun 19, 2003
<u>AB</u>	UPSHER SMITH LABS	<u>15MG</u>	<u>A076219</u>	<u>001</u>	Jun 19, 2003
<u>AB</u>		<u>30MG</u>	<u>A076219</u>	<u>002</u>	Jun 19, 2003
<u>AB</u>		<u>45MG</u>	<u>A076219</u>	<u>003</u>	Jun 19, 2003

REMERON

<u>AB</u>	+! ORGANON USA INC	<u>15MG</u>	<u>N020415</u>	<u>001</u>	Jun 14, 1996
<u>AB</u>	+	<u>30MG</u>	<u>N020415</u>	<u>002</u>	Jun 14, 1996

TABLET, ORALLY DISINTEGRATING;ORAL

MIRTAZAPINE

<u>AB</u>	AUROBINDO PHARMA	<u>15MG</u>	<u>A077376</u>	<u>002</u>	Dec 08, 2005
<u>AB</u>		<u>30MG</u>	<u>A077376</u>	<u>003</u>	Dec 08, 2005
<u>AB</u>		<u>45MG</u>	<u>A077376</u>	<u>004</u>	Feb 28, 2006
<u>AB</u>	SQUARE PHARMS	<u>15MG</u>	<u>A205798</u>	<u>001</u>	Jun 01, 2017
<u>AB</u>		<u>30MG</u>	<u>A205798</u>	<u>002</u>	Jun 01, 2017
<u>AB</u>		<u>45MG</u>	<u>A205798</u>	<u>003</u>	Jun 01, 2017

REMERON SOLTAB

<u>AB</u>	+! ORGANON USA INC	<u>15MG</u>	<u>N021208</u>	<u>001</u>	Jan 12, 2001
<u>AB</u>	+	<u>30MG</u>	<u>N021208</u>	<u>002</u>	Jan 12, 2001
<u>AB</u>	+	<u>45MG</u>	<u>N021208</u>	<u>003</u>	Jan 12, 2001

MISOPROSTOL

TABLET;ORAL

CYTOTEC

<u>AB</u>	+ PFIZER	<u>0.1MG</u>	<u>N019268</u>	<u>003</u>	Sep 21, 1990
<u>AB</u>	+!	<u>0.2MG</u>	<u>N019268</u>	<u>001</u>	Dec 27, 1988

MISOPROSTOL

<u>AB</u>	ANI PHARMS	<u>0.1MG</u>	<u>A076095</u>	<u>001</u>	Jul 10, 2002
<u>AB</u>		<u>0.2MG</u>	<u>A076095</u>	<u>002</u>	Jul 10, 2002
<u>AB</u>	MICRO LABS	<u>0.1MG</u>	<u>A216872</u>	<u>001</u>	Oct 17, 2022
<u>AB</u>		<u>0.2MG</u>	<u>A216872</u>	<u>002</u>	Oct 17, 2022
BX	NOVEL LABS INC	0.1MG	A091667	001	Jul 25, 2012
BX		0.2MG	A091667	002	Jul 25, 2012

MITAPIVAT SULFATE

TABLET;ORAL

PYRUKYND

+	AGIOS PHARMS INC	EQ 5MG BASE	N216196	001	Feb 17, 2022
+		EQ 20MG BASE	N216196	002	Feb 17, 2022
+		EQ 50MG BASE	N216196	003	Feb 17, 2022

PRESCRIPTION DRUG PRODUCT LIST

3-317 (of 474)

MITOMYCIN

FOR SOLUTION; TOPICAL

MITOSOL

+! MOBIUS THERAP

0.2MG/VIAL

N022572 001 Feb 07, 2012

INJECTABLE; INJECTION

MITOMYCINAP ! ACCORD HLTHCARE5MG/VIALA064144 001 Apr 30, 1998AP !20MG/VIALA064144 002 Apr 30, 1998AP !40MG/VIALA064144 003 Aug 11, 2009AP GLAND PHARMA LTD5MG/VIALA215687 001 Oct 20, 2021AP20MG/VIALA215687 002 Oct 20, 2021AP40MG/VIALA216648 001 Nov 22, 2022AP HIKMA5MG/VIALA064180 001 Dec 23, 1999AP20MG/VIALA064117 002 Apr 19, 1995AP20MG/VIALA064180 002 Dec 23, 1999AP40MG/VIALA064117 003 Jun 02, 1999AP MEITHEAL5MG/VIALA214505 001 Sep 08, 2022AP20MG/VIALA214505 002 Sep 08, 2022AP40MG/VIALA214504 001 Sep 06, 2022AP RK PHARMA5MG/VIALA202670 001 Oct 13, 2017AP20MG/VIALA202670 002 Oct 13, 2017AP40MG/VIALA203386 001 Oct 13, 2017

POWDER; PYELOALYCEAL

JELMYTO

+! UROGEN PHARMA

40MG/VIAL

N211728 001 Apr 15, 2020

MITOTANE

TABLET; ORAL

LYSODREN

+! HRA PHARMA

500MG

N016885 001

MITOXANTRONE HYDROCHLORIDE

INJECTABLE; INJECTION

MITOXANTRONE HYDROCHLORIDEAP FRESENIUS KABI USAEQ 20MG BASE/10ML (EQ 2MG BASE/ML)A077496 001 Apr 11, 2006APEQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)A077496 002 Apr 11, 2006APEQ 30MG BASE/15ML (EQ 2MG BASE/ML)A077496 003 Apr 11, 2006AP HIKMAEQ 20MG BASE/10ML (EQ 2MG BASE/ML)A076611 001 Apr 11, 2006APEQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)A076611 002 Apr 11, 2006APEQ 30MG BASE/15ML (EQ 2MG BASE/ML)A076611 003 Apr 11, 2006AP ! HOSPIRAEQ 20MG BASE/10ML (EQ 2MG BASE/ML)A076871 001 Apr 11, 2006AP !EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)A076871 002 Apr 11, 2006AP !EQ 30MG BASE/15ML (EQ 2MG BASE/ML)A076871 003 Apr 11, 2006AP TEVA PHARMS USAEQ 20MG BASE/10ML (EQ 2MG BASE/ML)A077356 001 Apr 11, 2006APEQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)A077356 002 Apr 11, 2006APEQ 30MG BASE/15ML (EQ 2MG BASE/ML)A077356 003 Apr 11, 2006MIVACURIUM CHLORIDE

SOLUTION; INTRAVENOUS

MIVACURIUM CHLORIDE

WOODWARD

EQ 10MG BASE/5ML (EQ 2MG BASE/ML)

A209708 001 Oct 12, 2021

EQ 20MG BASE/10ML (EQ 2MG BASE/ML)

A209708 002 Oct 12, 2021

MOBOCERTINIB SUCCINATE

CAPSULE; ORAL

EXKIVITY

+! TAKEDA PHARMS USA

EQ 40MG BASE

N215310 001 Sep 15, 2021

MODAFINIL

TABLET; ORAL

MODAFINILAB ALEMBIC PHARMS100MGA202700 001 Oct 18, 2012AB200MGA202700 002 Oct 18, 2012AB APOTEX INC100MGA077667 001 Feb 03, 2014AB200MGA077667 002 Feb 03, 2014AB APPCO100MGA207196 001 Aug 16, 2017AB200MGA207196 002 Aug 16, 2017AB AUROBINDO PHARMA100MGA202566 001 Sep 27, 2012

LTD

AB200MGA202566 002 Sep 27, 2012AB CADILA100MGA209966 001 Sep 14, 2017AB200MGA209966 002 Sep 14, 2017AB ORBION PHARMS100MGA078963 001 Sep 26, 2012AB200MGA078963 002 Sep 26, 2012AB WATSON LABS INC100MGA076715 001 Nov 01, 2012

PRESCRIPTION DRUG PRODUCT LIST

3-318 (of 474)

MODAFINIL

TABLET; ORAL

MODAFINIL

AB		200MG	A076715 002	Nov 01, 2012
<u>PROVIGIL</u>				
AB	+	CEPHALON	N020717 001	Dec 24, 1998
AB	+	!	N020717 002	Dec 24, 1998

MOEXIPRIL HYDROCHLORIDE

TABLET; ORAL

MOEXIPRIL HYDROCHLORIDE

AB		APOTEX INC	7.5MG	A078454 001	Jun 02, 2008
AB			15MG	A078454 002	Jun 02, 2008
AB		CHARTWELL RX	7.5MG	A077536 001	Nov 30, 2006
AB			15MG	A077536 002	Nov 30, 2006
AB		GLENMARK GENERICS	7.5MG	A090416 001	Mar 30, 2010
AB			15MG	A090416 002	Mar 30, 2010
AB		TEVA	7.5MG	A076204 001	May 08, 2003
AB	!		15MG	A076204 002	May 08, 2003

MOLINDONE HYDROCHLORIDE

TABLET; ORAL

MOLINDONE HYDROCHLORIDE

EPIC PHARMA LLC

5MG

A090453 001 Mar 20, 2015

10MG

A090453 002 Mar 20, 2015

!

25MG

A090453 003 Mar 20, 2015

MOMETASONE FUROATE

AEROSOL, METERED; INHALATION

ASMANEX HFA

+ ORGANON LLC

0.05MG/INH

N205641 003 Aug 12, 2019

+

0.10MG/INH

N205641 001 Apr 25, 2014

+!

0.20MG/INH

N205641 002 Apr 25, 2014

CREAM; TOPICAL

MOMETASONE FUROATE

AB		COSETTE	0.1%	A077447 001	May 22, 2006
AB	!	GLENMARK GENERICS	0.1%	A078541 001	May 28, 2008
AB		TARO	0.1%	A076679 001	Dec 21, 2004

IMPLANT; IMPLANTATION

SINUVA

+ INTERSECT ENT INC

1.35MG

N209310 001 Dec 08, 2017

LOTION; TOPICAL

ELOCON

AB	+	!	ORGANON	0.1%	N019796 001	Mar 30, 1989

MOMETASONE FUROATE

AB		COSETTE	0.1%	A077678 001	Nov 21, 2007
AB		FOUGERA PHARMS	0.1%	A075919 001	Nov 29, 2007
AB		GLENMARK GENERICS	0.1%	A090506 001	Aug 09, 2010
AB		PADAGIS ISRAEL	0.1%	A077180 001	Apr 06, 2005
AB		TARO	0.1%	A076788 001	Mar 15, 2006

OINTMENT; TOPICAL

MOMETASONE FUROATE

AB		COSETTE	0.1%	A077401 001	Jun 20, 2006
AB		FOUGERA PHARMS	0.1%	A077061 001	Mar 28, 2005
AB	!	GLENMARK GENERICS	0.1%	A078571 001	May 28, 2008
AB		PADAGIS US	0.1%	A076067 001	Mar 18, 2002

POWDER; INHALATION

ASMANEX TWISTHALER

+ ORGANON LLC

0.11MG/INH

N021067 002 Feb 01, 2008

+!

0.22MG/INH

N021067 001 Mar 30, 2005

SPRAY, METERED; NASAL

MOMETASONE FUROATE

AB		AMNEAL PHARMS	0.05MG/SPRAY	A207989 001	Apr 03, 2017
AB	!	APOTEX INC	0.05MG/SPRAY	A091161 001	Mar 22, 2016

MOMETASONE FUROATE; OLOPATADINE HYDROCHLORIDE

SPRAY, METERED; NASAL

RYALTRIS

+! GLENMARK SPECIALTY

0.025MG/SPRAY; 0.665MG/SPRAY

N211746 001 Jan 13, 2022

PRESCRIPTION DRUG PRODUCT LIST

3-319 (of 474)

MONOMETHYL FUMARATE

CAPSULE, DELAYED RELEASE;ORAL

BAFIERTAM

+! BANNER LIFE SCIENCES 95MG

N210296 001 Apr 28, 2020

MONTELUKAST SODIUM

GRANULE;ORAL

MONTELUKAST SODIUM

<u>AB</u>	AJANTA PHARMA LTD	<u>EQ 4MG BASE/PACKET</u>	<u>A203438 001</u>	Jul 31, 2015
<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 4MG BASE/PACKET</u>	<u>A213471 001</u>	Feb 18, 2020
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 4MG BASE/PACKET</u>	<u>A202906 001</u>	Sep 17, 2012
<u>AB</u>	TEVA PHARMS	<u>EQ 4MG BASE/PACKET</u>	<u>A090955 001</u>	Aug 03, 2012
<u>AB</u>	TORRENT	<u>EQ 4MG BASE/PACKET</u>	<u>A210431 001</u>	Jul 31, 2018

SINGULAIR

<u>AB</u>	+! ORGANON	<u>EQ 4MG BASE/PACKET</u>	<u>N021409 001</u>	Jul 26, 2002

TABLET;ORAL

MONTELUKAST SODIUM

<u>AB</u>	ACCORD HLTHCARE	<u>EQ 10MG BASE</u>	<u>A202717 001</u>	Sep 21, 2012
<u>AB</u>	AMNEAL PHARMS	<u>EQ 10MG BASE</u>	<u>A204604 001</u>	Sep 04, 2015
<u>AB</u>	ANBISON LAB	<u>EQ 10MG BASE</u>	<u>A205683 001</u>	Jan 12, 2016
<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 10MG BASE</u>	<u>A202468 001</u>	Aug 03, 2012
<u>AB</u>	CHARTWELL MOLECULAR	<u>EQ 10MG BASE</u>	<u>A201522 001</u>	Aug 03, 2012
<u>AB</u>	CIPLA	<u>EQ 10MG BASE</u>	<u>A207463 001</u>	Oct 28, 2016
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 10MG BASE</u>	<u>A201582 001</u>	Aug 06, 2012
<u>AB</u>	GLENMARK GENERICS	<u>EQ 10MG BASE</u>	<u>A090926 001</u>	Aug 03, 2012
<u>AB</u>	GRAVITI PHARMS	<u>EQ 10MG BASE</u>	<u>A209012 001</u>	Apr 24, 2017
<u>AB</u>	HETERO LABS LTD V	<u>EQ 10MG BASE</u>	<u>A202843 001</u>	Sep 10, 2014
<u>AB</u>	MACLEODS PHARMS LTD	<u>EQ 10MG BASE</u>	<u>A203366 001</u>	Sep 11, 2014
<u>AB</u>	SANDOZ INC	<u>EQ 10MG BASE</u>	<u>A200889 001</u>	Aug 03, 2012
<u>AB</u>	TEVA PHARMS	<u>EQ 10MG BASE</u>	<u>A078605 001</u>	Aug 03, 2012
<u>AB</u>	TORRENT PHARMS LTD	<u>EQ 10MG BASE</u>	<u>A201515 001</u>	Aug 03, 2012
<u>AB</u>	UNICHEM	<u>EQ 10MG BASE</u>	<u>A204290 001</u>	Oct 08, 2015
<u>AB</u>	UNIMARK REMEDIES LTD	<u>EQ 10MG BASE</u>	<u>A202859 001</u>	Oct 30, 2014

SINGULAIR

<u>AB</u>	+! ORGANON	<u>EQ 10MG BASE</u>	<u>N020829 002</u>	Feb 20, 1998

TABLET, CHEWABLE;ORAL

MONTELUKAST SODIUM

<u>AB</u>	AMNEAL PHARMS	<u>EQ 4MG BASE</u>	<u>A205107 001</u>	Sep 04, 2020
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A205107 002</u>	Sep 04, 2020
<u>AB</u>	ANBISON LAB	<u>EQ 4MG BASE</u>	<u>A205695 001</u>	Nov 05, 2015
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A205695 002</u>	Nov 05, 2015
<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 4MG BASE</u>	<u>A202096 001</u>	Aug 03, 2012
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A202096 002</u>	Aug 03, 2012
<u>AB</u>	CIPLA	<u>EQ 4MG BASE</u>	<u>A207464 001</u>	Dec 06, 2018
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A207464 002</u>	Dec 06, 2018
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 4MG BASE</u>	<u>A201581 001</u>	Aug 06, 2012
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A201581 002</u>	Aug 06, 2012
<u>AB</u>	GRAVITI PHARMS	<u>EQ 4MG BASE</u>	<u>A209011 001</u>	Apr 18, 2017
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A209011 002</u>	Apr 18, 2017
<u>AB</u>	HETERO LABS LTD V	<u>EQ 4MG BASE</u>	<u>A204093 001</u>	May 22, 2015
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A204093 002</u>	May 22, 2015
<u>AB</u>	LANNETT CO INC	<u>EQ 4MG BASE</u>	<u>A200405 001</u>	Aug 03, 2012
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A200405 002</u>	Aug 03, 2012
<u>AB</u>	MACLEODS PHARMS LTD	<u>EQ 4MG BASE</u>	<u>A203582 001</u>	Mar 12, 2015
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A203582 002</u>	Mar 12, 2015
<u>AB</u>	SANDOZ INC	<u>EQ 4MG BASE</u>	<u>A091414 001</u>	Aug 03, 2012
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A091414 002</u>	Aug 03, 2012
<u>AB</u>	TEVA PHARMS	<u>EQ 4MG BASE</u>	<u>A078723 001</u>	Aug 03, 2012
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078723 002</u>	Aug 03, 2012
<u>AB</u>	TORRENT PHARMS LTD	<u>EQ 4MG BASE</u>	<u>A090984 001</u>	Aug 03, 2012
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A090984 002</u>	Aug 03, 2012
<u>AB</u>	UNICHEM	<u>EQ 4MG BASE</u>	<u>A208621 001</u>	Jul 02, 2018
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A208621 002</u>	Jul 02, 2018
<u>AB</u>	UNIMARK REMEDIES LTD	<u>EQ 4MG BASE</u>	<u>A203037 001</u>	Oct 30, 2014
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A203037 002</u>	Oct 30, 2014

SINGULAIR

<u>AB</u>	+ ORGANON	<u>EQ 4MG BASE</u>	<u>N020830 002</u>	Mar 03, 2000

<u>AB</u>	+!	<u>EQ 5MG BASE</u>	<u>N020830 001</u>	Feb 20, 1998

PRESCRIPTION DRUG PRODUCT LIST

3-320 (of 474)

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

MORPHINE SULFATE

ACTAVIS ELIZABETH	30MG	A079040	001	Jan 16, 2013
	45MG	A079040	002	Jan 16, 2013
	60MG	A079040	003	Jan 16, 2013
	75MG	A079040	004	Jan 16, 2013
	90MG	A079040	005	Jan 16, 2013
!	120MG	A079040	006	Jan 16, 2013
! UPSHER SMITH LABS	10MG	A202104	001	Jun 03, 2013
	20MG	A202104	002	Jun 03, 2013
	30MG	A202104	003	Jun 03, 2013
	50MG	A202104	004	Jun 03, 2013
	60MG	A202104	005	Jun 03, 2013
	80MG	A202104	006	Jun 03, 2013
!	100MG	A202104	007	Jun 03, 2013

INJECTABLE; INJECTION

DURAMORPH PF

AP	+	!	HIKMA	<u>0.5MG/ML</u>	<u>N018565</u>	<u>001</u>	Sep 18, 1984
AP	+	!		<u>1MG/ML</u>	<u>N018565</u>	<u>002</u>	Sep 18, 1984

INFUMORPH

AP	+	!	HIKMA	<u>10MG/ML</u>	<u>N018565</u>	<u>003</u>	Jul 19, 1991
AP	+	!		<u>25MG/ML</u>	<u>N018565</u>	<u>004</u>	Jul 19, 1991

MITIGO

AP			PIRAMAL CRITICAL	<u>10MG/ML</u>	<u>A204393</u>	<u>001</u>	Jul 16, 2018
AP				<u>25MG/ML</u>	<u>A204393</u>	<u>002</u>	Jul 16, 2018

MORPHINE SULFATE

AP	!		HIKMA	<u>4MG/ML</u>	<u>A205758</u>	<u>001</u>	May 21, 2015
AP	!			<u>8MG/ML</u>	<u>A205758</u>	<u>002</u>	May 21, 2015
AP				<u>10MG/ML</u>	<u>A205758</u>	<u>003</u>	May 21, 2015
AP			HOSPIRA	<u>0.5MG/ML</u>	<u>A071849</u>	<u>001</u>	May 11, 1988
AP				<u>0.5MG/ML</u>	<u>A073509</u>	<u>001</u>	Sep 30, 1992
AP				<u>1MG/ML</u>	<u>A073510</u>	<u>001</u>	Sep 30, 1992
AP	+		HOSPIRA INC	<u>4MG/ML</u>	<u>N202515</u>	<u>002</u>	Nov 14, 2011
AP	+			<u>8MG/ML</u>	<u>N202515</u>	<u>003</u>	Nov 14, 2011
AP	+			<u>10MG/ML</u>	<u>N202515</u>	<u>004</u>	Nov 14, 2011
	+	!		2MG/ML	N202515	001	Nov 14, 2011
	+	!		50MG/ML	N202515	006	Apr 29, 2021
			INTL MEDICATION SYS	1MG/ML	A202861	001	Apr 29, 2021

SOLUTION; INTRAMUSCULAR, INTRAVENOUS

MORPHINE SULFATE

+	!		FRESENIUS KABI USA	2MG/ML (2MG/ML)	N204223	001	Oct 30, 2013
+	!			4MG/ML (4MG/ML)	N204223	002	Oct 30, 2013
+	!			5MG/ML (5MG/ML)	N204223	003	Oct 30, 2013
+	!			8MG/ML (8MG/ML)	N204223	004	Oct 30, 2013
+	!			10MG/ML (10MG/ML)	N204223	005	Oct 30, 2013

SOLUTION; ORAL

MORPHINE SULFATE

AA			AKORN	<u>100MG/5ML</u>	<u>A208809</u>	<u>001</u>	Jul 06, 2017
AA	+		HIKMA	<u>10MG/5ML</u>	<u>N022195</u>	<u>001</u>	Mar 17, 2008
AA	+			<u>20MG/5ML</u>	<u>N022195</u>	<u>002</u>	Mar 17, 2008
AA	+	!		<u>100MG/5ML</u>	<u>N022195</u>	<u>003</u>	Jan 25, 2010
AA			PADAGIS US	<u>100MG/5ML</u>	<u>A201574</u>	<u>001</u>	Aug 06, 2012
AA			PHARM ASSOC	<u>100MG/5ML</u>	<u>A206573</u>	<u>001</u>	Nov 14, 2016
AA			RHODES PHARMS	<u>10MG/5ML</u>	<u>A206308</u>	<u>001</u>	Jun 22, 2017
AA				<u>20MG/5ML</u>	<u>A206420</u>	<u>001</u>	Jul 12, 2016
AA				<u>100MG/5ML</u>	<u>A206308</u>	<u>002</u>	Jun 22, 2017
AA			SPECGX LLC	<u>100MG/5ML</u>	<u>A202348</u>	<u>001</u>	Jul 15, 2011
AA			TRIS PHARMA INC	<u>10MG/5ML</u>	<u>A203518</u>	<u>001</u>	May 12, 2015
AA				<u>100MG/5ML</u>	<u>A203518</u>	<u>002</u>	May 12, 2015

TABLET; ORAL

MORPHINE SULFATE

AB			ALKEM LABS LTD	<u>15MG</u>	<u>A212451</u>	<u>001</u>	Dec 03, 2020
AB				<u>30MG</u>	<u>A212451</u>	<u>002</u>	Dec 03, 2020
AB	+		HIKMA	<u>15MG</u>	<u>N022207</u>	<u>001</u>	Mar 17, 2008
AB	+	!		<u>30MG</u>	<u>N022207</u>	<u>002</u>	Mar 17, 2008
AB			MAYNE PHARMA INC	<u>15MG</u>	<u>A207270</u>	<u>001</u>	Jan 12, 2022
AB				<u>30MG</u>	<u>A207270</u>	<u>002</u>	Jan 12, 2022
AB			UPSHER SMITH LABS	<u>15MG</u>	<u>A210610</u>	<u>001</u>	Jul 22, 2019
AB				<u>30MG</u>	<u>A210610</u>	<u>002</u>	Jul 22, 2019

PRESCRIPTION DRUG PRODUCT LIST

3-321 (of 474)

MORPHINE SULFATE

TABLET, EXTENDED RELEASE;ORAL

MORPHINE SULFATE

<u>AB</u>	ACTAVIS ELIZABETH	<u>15MG</u>	<u>A203849</u>	<u>001</u>	Apr 06, 2015
<u>AB</u>		<u>30MG</u>	<u>A203849</u>	<u>002</u>	Apr 06, 2015
<u>AB</u>		<u>60MG</u>	<u>A203849</u>	<u>003</u>	Apr 06, 2015
<u>AB</u>		<u>100MG</u>	<u>A203849</u>	<u>004</u>	Apr 06, 2015
<u>AB</u>		<u>200MG</u>	<u>A203849</u>	<u>005</u>	Apr 06, 2015
<u>AB</u>	DAVA PHARMS INC	<u>15MG</u>	<u>A075407</u>	<u>001</u>	Jan 28, 2000
<u>AB</u>	MAYNE PHARMA INC	<u>15MG</u>	<u>A205386</u>	<u>001</u>	Oct 28, 2016
<u>AB</u>		<u>30MG</u>	<u>A205386</u>	<u>002</u>	Oct 28, 2016
<u>AB</u>		<u>60MG</u>	<u>A205386</u>	<u>003</u>	Oct 28, 2016
<u>AB</u>		<u>100MG</u>	<u>A205386</u>	<u>004</u>	Oct 28, 2016
<u>AB</u>	NOVEL LABS INC	<u>15MG</u>	<u>A203602</u>	<u>001</u>	Dec 16, 2015
<u>AB</u>		<u>30MG</u>	<u>A203602</u>	<u>002</u>	Dec 16, 2015
<u>AB</u>		<u>60MG</u>	<u>A203602</u>	<u>003</u>	Dec 16, 2015
<u>AB</u>		<u>100MG</u>	<u>A203602</u>	<u>004</u>	Dec 16, 2015
<u>AB</u>		<u>200MG</u>	<u>A203602</u>	<u>005</u>	Dec 16, 2015
<u>AB</u>	RHODES PHARMS	<u>15MG</u>	<u>A074862</u>	<u>001</u>	Jul 07, 1998
<u>AB</u>		<u>30MG</u>	<u>A074862</u>	<u>002</u>	Jul 07, 1998
<u>AB</u>		<u>60MG</u>	<u>A074862</u>	<u>003</u>	Jul 07, 1998
<u>AB</u>		<u>100MG</u>	<u>A074769</u>	<u>001</u>	Jul 02, 1998
<u>AB</u>		<u>200MG</u>	<u>A074769</u>	<u>002</u>	Jul 02, 1998
<u>AB</u>	SPECGX LLC	<u>15MG</u>	<u>A076412</u>	<u>001</u>	Jul 31, 2003
<u>AB</u>		<u>30MG</u>	<u>A076412</u>	<u>002</u>	Jul 31, 2003
<u>AB</u>		<u>60MG</u>	<u>A076412</u>	<u>003</u>	Jul 31, 2003
<u>AB</u>		<u>100MG</u>	<u>A076438</u>	<u>001</u>	Jul 03, 2003
<u>AB</u>		<u>200MG</u>	<u>A076438</u>	<u>002</u>	Jul 03, 2003
<u>AB</u>	STRIDES PHARMA	<u>15MG</u>	<u>A075295</u>	<u>001</u>	Oct 28, 1998
<u>AB</u>		<u>30MG</u>	<u>A075295</u>	<u>002</u>	Oct 28, 1998
<u>AB</u>		<u>60MG</u>	<u>A075295</u>	<u>003</u>	Oct 28, 1998
<u>AB</u>		<u>100MG</u>	<u>A075295</u>	<u>004</u>	Sep 15, 2000
<u>AB</u>		<u>200MG</u>	<u>A075295</u>	<u>005</u>	Sep 15, 2000
<u>AB</u>	SUN PHARM INDS LTD	<u>15MG</u>	<u>A078761</u>	<u>001</u>	May 11, 2012
<u>AB</u>		<u>30MG</u>	<u>A078761</u>	<u>002</u>	May 11, 2012
<u>AB</u>		<u>60MG</u>	<u>A078761</u>	<u>003</u>	May 11, 2012
<u>AB</u>		<u>100MG</u>	<u>A078761</u>	<u>004</u>	May 11, 2012
<u>AB</u>		<u>200MG</u>	<u>A078761</u>	<u>005</u>	May 11, 2012
<u>MS CONTIN</u>					
<u>AB</u>	+	PURDUE PHARMA LP	<u>15MG</u>	<u>N019516</u>	<u>003</u> Sep 12, 1989
<u>AB</u>	+		<u>30MG</u>	<u>N019516</u>	<u>001</u> May 29, 1987
<u>AB</u>	+		<u>60MG</u>	<u>N019516</u>	<u>002</u> Apr 08, 1988
<u>AB</u>	+		<u>100MG</u>	<u>N019516</u>	<u>004</u> Jan 16, 1990
<u>AB</u>	+		<u>200MG</u>	<u>N019516</u>	<u>005</u> Nov 08, 1993

MOXIDECTIN

TABLET;ORAL

MOXIDECTIN

+	!	MDGH	2MG	N210867	001	Jun 13, 2018

MOXIFLOXACIN HYDROCHLORIDE

SOLUTION;INTRAVENOUS

MOXIFLOXACIN HYDROCHLORIDE

+	!	FRESENIUS KABI USA	EQ 400MG BASE/250ML (EQ 1.6MG BASE/ML)	N205572	001	Apr 03, 2015

MOXIFLOXACIN HYDROCHLORIDE IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER

!		MYLAN LABS LTD	400MG/250ML (1.6MG/ML)	A205833	001	May 05, 2017

SOLUTION/DROPS;OPHTHALMIC

MOXIFLOXACIN HYDROCHLORIDE

<u>AT1</u>	AKORN	<u>EQ 0.5% BASE</u>	<u>A202916</u>	<u>001</u>	Nov 09, 2017
<u>AT1</u>	ALEMBIC PHARMS	<u>EQ 0.5% BASE</u>	<u>A209469</u>	<u>001</u>	Feb 13, 2019
<u>AT1</u>	APOTEX	<u>EQ 0.5% BASE</u>	<u>A090080</u>	<u>001</u>	Jun 30, 2017
<u>AT1</u>	EUGIA PHARMA	<u>EQ 0.5% BASE</u>	<u>A206242</u>	<u>001</u>	Oct 04, 2017
<u>AT1</u>	GLAND PHARMA LTD	<u>EQ 0.5% BASE</u>	<u>A208778</u>	<u>001</u>	Mar 30, 2020
<u>AT1</u>	INDOCO	<u>EQ 0.5% BASE</u>	<u>A202525</u>	<u>001</u>	Mar 06, 2015
<u>AT1</u>	LUPIN LTD	<u>EQ 0.5% BASE</u>	<u>A202867</u>	<u>001</u>	Sep 04, 2014
<u>AT1</u>	MYLAN	<u>EQ 0.5% BASE</u>	<u>A206447</u>	<u>001</u>	Mar 30, 2020
<u>AT1</u>	UPSHER SMITH LABS	<u>EQ 0.5% BASE</u>	<u>A212616</u>	<u>001</u>	Feb 10, 2021
<u>VIGAMOX</u>					
<u>AT1</u>	+	!	NOVARTIS	<u>EQ 0.5% BASE</u>	<u>N021598</u> <u>001</u> Apr 15, 2003
<u>MOXEZA</u>					
<u>AT2</u>	+	!	IMPRIMIS PHARMS USA	<u>EQ 0.5% BASE</u>	<u>N022428</u> <u>001</u> Nov 19, 2010
<u>MOXIFLOXACIN HYDROCHLORIDE</u>					
<u>AT2</u>	LUPIN LTD	<u>EQ 0.5% BASE</u>	<u>A204079</u>	<u>001</u>	May 28, 2015

PRESCRIPTION DRUG PRODUCT LIST

3-322 (of 474)

MOXIFLOXACIN HYDROCHLORIDE

TABLET; ORAL

MOXIFLOXACIN HYDROCHLORIDE

AB	AUROBINDO PHARMA LTD	EQ 400MG BASE	A202632 001	Mar 04, 2014
AB	CROSSMEDIKA SA	EQ 400MG BASE	A205348 001	Jan 14, 2016
AB	! DR REDDYS	EQ 400MG BASE	A076938 001	Mar 04, 2014
AB	MSN	EQ 400MG BASE	A208682 001	Sep 22, 2017
AB	NOVEL LABS INC	EQ 400MG BASE	A207285 001	Feb 13, 2017
AB	TEVA PHARMS USA	EQ 400MG BASE	A077437 001	Feb 18, 2014
AB	TORRENT	EQ 400MG BASE	A200160 001	Apr 03, 2014

MUPIROICIN

OINTMENT; TOPICAL

MUPIROICIN

AB	FOUGERA PHARMS	2%	A065192 001	Nov 30, 2005
AB	GLENMARK PHARMS	2%	A090480 001	Jun 08, 2011
AB	! PADAGIS ISRAEL	2%	A065123 001	Nov 07, 2003
AB	TARO	2%	A065170 001	Sep 23, 2005
AB	TEVA	2%	A065085 001	Nov 07, 2003
CENTANY				
BX	PADAGIS US	2%	N050788 001	Dec 04, 2002

MUPIROICIN CALCIUM

CREAM; TOPICAL

MUPIROICIN

AB	ALEOR	EQ 2% BASE	A213053 001	Nov 16, 2021
DERMACEUTICALS				
AB	AMNEAL	EQ 2% BASE	A214811 001	Nov 15, 2022
AB	ENCUBE	EQ 2% BASE	A213076 001	Aug 31, 2021
AB	! GLENMARK PHARMS INC	EQ 2% BASE	A201587 001	Jan 24, 2013
AB	PADAGIS ISRAEL	EQ 2% BASE	A212465 001	Aug 03, 2022
AB	TARO	EQ 2% BASE	A207116 001	Apr 27, 2020

MYCOPHENOLATE MOFETIL

CAPSULE; ORAL

CELLCEPT

AB	+! ROCHE PALO	250MG	N050722 001	May 03, 1995

MYCOPHENOLATE MOFETIL

AB	ACCORD HLTHCARE	250MG	A090253 001	May 04, 2009
AB	ALKEM LABS LTD	250MG	A200197 001	Jun 13, 2013
AB	CONCORD BIOTECH LTD	250MG	A210181 001	Jan 08, 2019
AB	HIKMA	250MG	A065410 001	Jul 29, 2008
AB	MYLAN	250MG	A065520 001	May 04, 2009
AB	SANDOZ	250MG	A065379 001	Oct 15, 2008
AB	STRIDES PHARMA	250MG	A090055 001	Jun 10, 2010
AB	TEVA PHARMS	250MG	A065491 001	May 06, 2009
AB	ZHEJIANG HISUN PHARM	250MG	A204077 001	Nov 13, 2017

FOR SUSPENSION; ORAL

CELLCEPT

AB	+! ROCHE PALO	200MG/ML	N050759 001	Oct 01, 1998

MYCOPHENOLATE MOFETIL

AB	ALKEM LABS LTD	200MG/ML	A203005 001	Nov 14, 2014
AB	AMNEAL	200MG/ML	A214871 001	Nov 02, 2021
AB	LANNETT CO INC	200MG/ML	A214525 001	Jul 29, 2021
AB	TEVA PHARMS USA	200MG/ML	A211272 001	Jan 25, 2022
AB	VISTAPHARM	200MG/ML	A210370 001	Feb 12, 2019

TABLET; ORAL

CELLCEPT

AB	+! ROCHE PALO	500MG	N050723 001	Jun 19, 1997

MYCOPHENOLATE MOFETIL

AB	ACCORD HLTHCARE	500MG	A065416 001	May 04, 2009
AB	ALKEM LABS LTD	500MG	A091249 001	Nov 04, 2011
AB	AMNEAL	500MG	A090606 001	Jul 16, 2010
AB	CONCORD BIOTECH LTD	500MG	A212087 001	Jul 31, 2020
AB	HIKMA	500MG	A065413 001	Jul 29, 2008
AB	MYLAN	500MG	A065521 001	May 04, 2009
AB	SANDOZ	500MG	A065451 001	Oct 15, 2008
AB	STRIDES PHARMA	500MG	A090456 001	Jun 10, 2010
AB	ZHEJIANG HISUN PHARM	500MG	A204076 001	Nov 16, 2017

PRESCRIPTION DRUG PRODUCT LIST

3-323 (of 474)

MYCOPHENOLATE MOFETIL HYDROCHLORIDE

INJECTABLE; INJECTION

CELLCEPT

<u>AP</u>	<u>+</u> !	ROCHE PALO	<u>500MG/VIAL</u>	<u>N050758</u>	<u>001</u>	Aug 12, 1998
<u>MYCOPHENOLATE MOFETIL HYDROCHLORIDE</u>						
<u>AP</u>		AKORN	<u>500MG/VIAL</u>	<u>A204043</u>	<u>001</u>	Feb 28, 2017
<u>AP</u>		MEITHEAL	<u>500MG/VIAL</u>	<u>A212130</u>	<u>001</u>	Jan 15, 2021
<u>AP</u>		MYLAN LABS LTD	<u>500MG/VIAL</u>	<u>A203859</u>	<u>001</u>	Mar 31, 2017
<u>AP</u>		PAR STERILE PRODUCTS	<u>500MG/VIAL</u>	<u>A203575</u>	<u>001</u>	Oct 28, 2016
<u>AP</u>		STERISCIENCE	<u>500MG/VIAL</u>	<u>A216390</u>	<u>001</u>	Dec 23, 2022
<u>AP</u>		ZYDUS PHARMS	<u>500MG/VIAL</u>	<u>A204473</u>	<u>001</u>	Aug 31, 2017

MYCOPHENOLIC SODIUM

TABLET, DELAYED RELEASE; ORAL

MYCOPHENOLIC SODIUM

<u>AB</u>		ACCORD HLTHCARE	<u>EQ 180MG BASE</u>	<u>A202555</u>	<u>001</u>	Aug 23, 2017
<u>AB</u>			<u>EQ 360MG BASE</u>	<u>A202555</u>	<u>002</u>	Aug 23, 2017
<u>AB</u>		ALKEM LABS LTD	<u>EQ 180MG BASE</u>	<u>A208315</u>	<u>001</u>	Sep 23, 2021
<u>AB</u>			<u>EQ 360MG BASE</u>	<u>A208315</u>	<u>002</u>	Sep 23, 2021
<u>AB</u>		AMTA	<u>EQ 180MG BASE</u>	<u>A214376</u>	<u>001</u>	Feb 10, 2021
<u>AB</u>			<u>EQ 360MG BASE</u>	<u>A214376</u>	<u>002</u>	Feb 10, 2021
<u>AB</u>		APOTEX INC	<u>EQ 180MG BASE</u>	<u>A091558</u>	<u>001</u>	Aug 21, 2012
<u>AB</u>			<u>EQ 360MG BASE</u>	<u>A091558</u>	<u>002</u>	Aug 19, 2014
<u>AB</u>		BIOCON PHARMA	<u>EQ 180MG BASE</u>	<u>A214630</u>	<u>001</u>	Nov 29, 2021
<u>AB</u>			<u>EQ 360MG BASE</u>	<u>A214630</u>	<u>002</u>	Nov 29, 2021
<u>AB</u>		CONCORD BIOTECH LTD	<u>EQ 180MG BASE</u>	<u>A211173</u>	<u>001</u>	Dec 13, 2019
<u>AB</u>			<u>EQ 360MG BASE</u>	<u>A211173</u>	<u>002</u>	Dec 13, 2019
<u>AB</u>		RK PHARMA	<u>EQ 180MG BASE</u>	<u>A091248</u>	<u>002</u>	Jan 08, 2014
<u>AB</u>			<u>EQ 360MG BASE</u>	<u>A091248</u>	<u>001</u>	Jan 08, 2014
<u>AB</u>		TWI PHARMS	<u>EQ 180MG BASE</u>	<u>A214289</u>	<u>001</u>	Nov 03, 2021
<u>AB</u>			<u>EQ 360MG BASE</u>	<u>A214289</u>	<u>002</u>	Nov 03, 2021

MYFORTIC

<u>AB</u>	<u>+</u>	NOVARTIS	<u>EQ 180MG BASE</u>	<u>N050791</u>	<u>001</u>	Feb 27, 2004
<u>AB</u>	<u>+</u> !		<u>EQ 360MG BASE</u>	<u>N050791</u>	<u>002</u>	Feb 27, 2004

NABILONE

CAPSULE; ORAL

CESAMET

<u>+</u> !	BAUSCH	1MG	<u>N018677</u>	<u>001</u>	Dec 26, 1985

NABUMETONE

TABLET; ORAL

NABUMETONE

<u>AB</u>		ANNORA PHARMA	<u>500MG</u>	<u>A090445</u>	<u>001</u>	Jan 12, 2011
<u>AB</u>			<u>750MG</u>	<u>A090445</u>	<u>002</u>	Jan 12, 2011
<u>AB</u>		CHARTWELL MOLECULES	<u>500MG</u>	<u>A076009</u>	<u>001</u>	Jan 24, 2003
<u>AB</u>			<u>750MG</u>	<u>A076009</u>	<u>002</u>	Jan 24, 2003
<u>AB</u>		CHARTWELL RX	<u>500MG</u>	<u>A075280</u>	<u>001</u>	Feb 25, 2002
<u>AB</u>			<u>750MG</u>	<u>A075280</u>	<u>002</u>	Feb 25, 2002
<u>AB</u>		INVAGEN PHARMS	<u>500MG</u>	<u>A078671</u>	<u>001</u>	Mar 07, 2008
<u>AB</u>	<u>!</u>		<u>750MG</u>	<u>A078671</u>	<u>002</u>	Mar 07, 2008
<u>AB</u>		LGM PHARMA	<u>500MG</u>	<u>A203166</u>	<u>001</u>	Aug 30, 2019
<u>AB</u>			<u>750MG</u>	<u>A203166</u>	<u>002</u>	Aug 30, 2019
<u>AB</u>		SCIEGEN PHARMS INC	<u>500MG</u>	<u>A078420</u>	<u>001</u>	Sep 24, 2008
<u>AB</u>			<u>750MG</u>	<u>A078420</u>	<u>002</u>	Sep 24, 2008
<u>AB</u>		WATSON LABS	<u>500MG</u>	<u>A091083</u>	<u>001</u>	Jun 13, 2011
<u>AB</u>			<u>750MG</u>	<u>A091083</u>	<u>002</u>	Jun 13, 2011
		LGM PHARMA	1GM	A203166	003	Aug 30, 2019

NADOLOL

TABLET; ORAL

CORGARD

<u>AB</u>	<u>+</u>	USWM	<u>20MG</u>	<u>N018063</u>	<u>005</u>	Oct 28, 1986
<u>AB</u>	<u>+</u>		<u>40MG</u>	<u>N018063</u>	<u>001</u>	
<u>AB</u>	<u>+</u> !		<u>80MG</u>	<u>N018063</u>	<u>002</u>	

NADOLOL

<u>AB</u>		AMNEAL PHARMS CO	<u>20MG</u>	<u>A208832</u>	<u>001</u>	Jun 02, 2017
<u>AB</u>			<u>40MG</u>	<u>A208832</u>	<u>002</u>	Jun 02, 2017
<u>AB</u>			<u>80MG</u>	<u>A208832</u>	<u>003</u>	Jun 02, 2017
<u>AB</u>		AUROBINDO PHARMA	<u>20MG</u>	<u>A201893</u>	<u>003</u>	Jun 07, 2022
<u>AB</u>			<u>40MG</u>	<u>A201893</u>	<u>001</u>	Sep 16, 2015
<u>AB</u>			<u>80MG</u>	<u>A201893</u>	<u>002</u>	Sep 16, 2015
<u>AB</u>		BEXIMCO PHARMS USA	<u>20MG</u>	<u>A210955</u>	<u>001</u>	Jul 23, 2018
<u>AB</u>			<u>40MG</u>	<u>A210955</u>	<u>002</u>	Jul 23, 2018

PRESCRIPTION DRUG PRODUCT LIST

3-324 (of 474)

NADOLOL

TABLET; ORAL

NADOLOL

<u>AB</u>		<u>80MG</u>	<u>A210955</u>	<u>003</u>	Jul 23, 2018
<u>AB</u>	CHARTWELL RX	<u>20MG</u>	<u>A209309</u>	<u>001</u>	Oct 05, 2017
<u>AB</u>		<u>40MG</u>	<u>A209309</u>	<u>002</u>	Oct 05, 2017
<u>AB</u>		<u>80MG</u>	<u>A209309</u>	<u>003</u>	Oct 05, 2017
<u>AB</u>	HERITAGE PHARMA	<u>20MG</u>	<u>A074229</u>	<u>001</u>	Aug 30, 1996
<u>AB</u>		<u>40MG</u>	<u>A074229</u>	<u>002</u>	Aug 30, 1996
<u>AB</u>		<u>80MG</u>	<u>A074255</u>	<u>001</u>	Jan 24, 1996
<u>AB</u>	INVAGEN PHARMS	<u>20MG</u>	<u>A203455</u>	<u>001</u>	Dec 18, 2015
<u>AB</u>		<u>40MG</u>	<u>A203455</u>	<u>002</u>	Dec 18, 2015
<u>AB</u>		<u>80MG</u>	<u>A203455</u>	<u>003</u>	Dec 18, 2015
<u>AB</u>	RISING	<u>20MG</u>	<u>A074172</u>	<u>001</u>	Oct 31, 1993
<u>AB</u>		<u>40MG</u>	<u>A074172</u>	<u>002</u>	Oct 31, 1993
<u>AB</u>		<u>80MG</u>	<u>A074172</u>	<u>003</u>	Oct 31, 1993
<u>AB</u>	SANDOZ	<u>20MG</u>	<u>A074501</u>	<u>001</u>	Nov 09, 1995
<u>AB</u>		<u>40MG</u>	<u>A074501</u>	<u>002</u>	Nov 09, 1995
<u>AB</u>		<u>80MG</u>	<u>A074501</u>	<u>003</u>	Nov 09, 1995
<u>AB</u>	VGYAAN	<u>20MG</u>	<u>A212856</u>	<u>001</u>	Sep 13, 2019
<u>AB</u>		<u>40MG</u>	<u>A212856</u>	<u>002</u>	Sep 13, 2019
<u>AB</u>		<u>80MG</u>	<u>A212856</u>	<u>003</u>	Sep 13, 2019
<u>AB</u>	ZYDUS PHARMS	<u>20MG</u>	<u>A207761</u>	<u>001</u>	Jul 28, 2017
<u>AB</u>		<u>40MG</u>	<u>A207761</u>	<u>002</u>	Jul 28, 2017
<u>AB</u>		<u>80MG</u>	<u>A207761</u>	<u>003</u>	Jul 28, 2017

NAFARELIN ACETATE

SPRAY, METERED; NASAL

SYNAREL

+! PFIZER

EQ 0.2MG BASE/SPRAY

N019886 001 Feb 13, 1990

NAFCILLIN SODIUM

INJECTABLE; INJECTION

NAFCILLIN SODIUM

<u>AP</u>	ANTIBIOTICE	<u>EQ 1GM BASE/VIAL</u>	<u>A090560</u>	<u>001</u>	Oct 03, 2011
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A090560</u>	<u>002</u>	Oct 03, 2011
<u>AP</u>	EUGIA PHARMA	<u>EQ 1GM BASE/VIAL</u>	<u>A091613</u>	<u>001</u>	Dec 26, 2012
	SPECLTS				
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A091613</u>	<u>002</u>	Dec 26, 2012
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A091614</u>	<u>001</u>	Dec 26, 2012
<u>AP</u>	FRESENIUS	<u>EQ 10GM BASE/VIAL</u>	<u>A206761</u>	<u>001</u>	Jun 02, 2020
<u>AP</u>	ISTITUTO BIO ITA	<u>EQ 1GM BASE/VIAL</u>	<u>A090002</u>	<u>001</u>	Jun 30, 2011
	SPA				
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A090002</u>	<u>002</u>	Jun 30, 2011
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A090005</u>	<u>001</u>	Apr 20, 2011
<u>AP</u>	SAGENT PHARMS	<u>EQ 1GM BASE/VIAL</u>	<u>A090582</u>	<u>001</u>	Aug 24, 2012
<u>AP</u>		<u>EQ 2GM BASE/VIAL</u>	<u>A090582</u>	<u>002</u>	Aug 24, 2012
<u>AP</u>		<u>EQ 10GM BASE/VIAL</u>	<u>A090580</u>	<u>001</u>	Aug 24, 2012
<u>AP</u>	! SANDOZ	<u>EQ 1GM BASE/VIAL</u>	<u>A062527</u>	<u>002</u>	Aug 02, 1984
<u>AP</u>	!	<u>EQ 1GM BASE/VIAL</u>	<u>A062732</u>	<u>001</u>	Dec 23, 1986
<u>AP</u>	!	<u>EQ 2GM BASE/VIAL</u>	<u>A062527</u>	<u>003</u>	Aug 02, 1984
<u>AP</u>	!	<u>EQ 2GM BASE/VIAL</u>	<u>A062732</u>	<u>002</u>	Dec 23, 1986
<u>AP</u>	!	<u>EQ 10GM BASE/VIAL</u>	<u>A062527</u>	<u>004</u>	Aug 02, 1984
	NALLPEN IN PLASTIC CONTAINER				
	+! BAXTER HLTHCARE	EQ 20MG BASE/ML	N050655	001	Oct 31, 1989
	+!	EQ 2GM BASE/100ML	N050655	002	Oct 31, 1989

NAFTIFINE HYDROCHLORIDE

CREAM; TOPICAL

NAFTIFINE HYDROCHLORIDE

<u>AB</u>	TARO PHARMS	<u>2%</u>	<u>A206901</u>	<u>001</u>	Jan 06, 2016
<u>AB</u>	TOLMAR	<u>2%</u>	<u>A206960</u>	<u>001</u>	Apr 10, 2017
<u>AB</u>	XIROMED	<u>2%</u>	<u>A210038</u>	<u>001</u>	Sep 22, 2020
	<u>NAFTIN</u>				
<u>AB</u>	+! SEBELA IRELAND LTD	<u>2%</u>	<u>N019599</u>	<u>002</u>	Jan 13, 2012
	NAFTIFINE HYDROCHLORIDE				
	! TARO PHARMS	1%	A205975	001	Sep 08, 2016
	GEL; TOPICAL				
	<u>NAFTIFINE HYDROCHLORIDE</u>				
<u>AB</u>	TOLMAR	<u>1%</u>	<u>A206165</u>	<u>001</u>	Mar 20, 2019
	<u>NAFTIN</u>				
<u>AB</u>	+! SEBELA IRELAND LTD	<u>1%</u>	<u>N019356</u>	<u>001</u>	Jun 18, 1990
<u>AB</u>	+!	<u>2%</u>	<u>N204286</u>	<u>001</u>	Jun 27, 2013

PRESCRIPTION DRUG PRODUCT LIST

3-325 (of 474)

NALBUPHINE HYDROCHLORIDE

INJECTABLE; INJECTION

NALBUPHINE HYDROCHLORIDE

AP	!	HOSPIRA	<u>10MG/ML</u>	<u>A070914</u>	<u>001</u>	Feb 03, 1989
AP	!		<u>10MG/ML</u>	<u>A070915</u>	<u>001</u>	Feb 03, 1989
AP	!		<u>20MG/ML</u>	<u>A070916</u>	<u>001</u>	Feb 03, 1989
AP	!		<u>20MG/ML</u>	<u>A070918</u>	<u>001</u>	Feb 03, 1989

NALDEMEDINE TOSYLATE

TABLET; ORAL

SYMPROIC

+! BDSI

EQ 0.2MG BASE

N208854 001 Mar 23, 2017

NALMEFENE HYDROCHLORIDE

SOLUTION; INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS

NALMEFENE HYDROCHLORIDE

! PURDUE PHARMA LP

EQ 2MG BASE/2ML (EQ 1MG BASE/ML)

A212955 001 Feb 08, 2022

NALOXEGOL OXALATE

TABLET; ORAL

MOVANTIK

+ REDHILL

EQ 12.5MG BASE

N204760 001 Sep 16, 2014

+!

EQ 25MG BASE

N204760 002 Sep 16, 2014

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION

NALOXONE

AP		HIKMA	<u>0.4MG/ML</u>	<u>A070299</u>	<u>001</u>	Sep 24, 1986

NALOXONE HYDROCHLORIDE

AP		ACCORD HLTHCARE	<u>0.4MG/ML</u>	<u>A216624</u>	<u>001</u>	Oct 26, 2022
AP			<u>1MG/ML</u>	<u>A216624</u>	<u>002</u>	Oct 26, 2022
AP		AKORN	<u>0.4MG/ML</u>	<u>A208871</u>	<u>001</u>	Feb 28, 2017
AP			<u>0.4MG/ML</u>	<u>A208872</u>	<u>001</u>	Mar 14, 2017
AP		BAXTER HLTHCARE CORP	<u>0.4MG/ML</u>	<u>A214785</u>	<u>001</u>	Jan 29, 2021
AP			<u>0.4MG/ML</u>	<u>A214792</u>	<u>001</u>	Nov 07, 2022
AP		DR REDDYS	<u>1MG/ML</u>	<u>A213209</u>	<u>001</u>	Mar 16, 2020
AP		EUGIA PHARMA	<u>0.4MG/ML</u>	<u>A212455</u>	<u>001</u>	Oct 15, 2019
AP			<u>1MG/ML</u>	<u>A213279</u>	<u>001</u>	Jan 14, 2021
AP			<u>0.4MG/ML</u>	<u>A212456</u>	<u>001</u>	Nov 04, 2019
AP		HIKMA	<u>1MG/ML</u>	<u>A212300</u>	<u>001</u>	Jun 10, 2022
AP	!	HOSPIRA	<u>0.4MG/ML</u>	<u>A070172</u>	<u>001</u>	Sep 24, 1986
AP	!		<u>0.4MG/ML</u>	<u>A070256</u>	<u>001</u>	Jan 07, 1987
AP	!		<u>0.4MG/ML</u>	<u>A070257</u>	<u>001</u>	Jan 07, 1987
AP	!	INTL MEDICATION	<u>1MG/ML</u>	<u>A072076</u>	<u>001</u>	Mar 24, 1988
AP		MYLAN INSTITUTIONAL	<u>0.4MG/ML</u>	<u>A204997</u>	<u>001</u>	Mar 06, 2014
AP			<u>0.4MG/ML</u>	<u>A205014</u>	<u>001</u>	Jun 29, 2016
AP		MYLAN LABS LTD	<u>1MG/ML</u>	<u>A213843</u>	<u>001</u>	Jun 09, 2022
AP		PAR STERILE PRODUCTS	<u>1MG/ML</u>	<u>A215964</u>	<u>001</u>	Jul 29, 2022
AP		SOMERSET THERAPS LLC	<u>0.4MG/ML</u>	<u>A207633</u>	<u>001</u>	Aug 08, 2017
AP			<u>0.4MG/ML</u>	<u>A207634</u>	<u>001</u>	Jul 26, 2017

SOLUTION; INTRAMUSCULAR, SUBCUTANEOUS

ZIMHI

+! ADAMIS PHARMS CORP

5MG/0.5ML (5MG/0.5ML)

N212854 001 Oct 15, 2021

SPRAY; NASAL

KLOXXADO

+! HIKMA

8MG/SPRAY

N212045 001 Apr 29, 2021

SPRAY, METERED; NASAL

NALOXONE HYDROCHLORIDE

AB		PADAGIS ISRAEL	<u>4MG/SPRAY</u>	<u>A211951</u>	<u>001</u>	Jun 21, 2022
AB		TEVA PHARMS USA	<u>4MG/SPRAY</u>	<u>A209522</u>	<u>001</u>	Apr 19, 2019

NARCAN

AB	+	EMERGENT	<u>4MG/SPRAY</u>	<u>N208411</u>	<u>001</u>	Nov 18, 2015

NALOXONE HYDROCHLORIDE; PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL

NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE

AB		LUPIN	<u>EQ 0.5MG BASE; EQ 50MG BASE</u>	<u>A075735</u>	<u>001</u>	Jul 11, 2001
AB		SUN PHARM INDS LTD	<u>EQ 0.5MG BASE; EQ 50MG BASE</u>	<u>A075523</u>	<u>001</u>	Mar 17, 2000
AB	!	WATSON LABS	<u>EQ 0.5MG BASE; EQ 50MG BASE</u>	<u>A074736</u>	<u>001</u>	Jan 21, 1997

PRESCRIPTION DRUG PRODUCT LIST

3-326 (of 474)

NALTREXONE

FOR SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR

VIVITROL

+! ALKERMES

380MG/VIAL

N021897 001 Apr 13, 2006

NALTREXONE HYDROCHLORIDE

TABLET; ORAL

NALTREXONE HYDROCHLORIDEAB ACCORD HLTHCARE 50MGA091205 001 Aug 17, 2011AB BARR 50MGA074918 001 May 08, 1998AB CHARTWELL 50MGA207905 001 Jul 21, 2017AB ELITE LABS 50MGA075274 001 May 26, 1999AB ! SPECGX LLC 50MGA076264 002 Mar 22, 2002AB SUN PHARM 50MGA090356 001 Feb 24, 2012

SPECGX LLC 25MG

A076264 001 Mar 22, 2002

100MG

A076264 003 Mar 22, 2002

NAPROXEN

SUSPENSION; ORAL

NAPROSYNAB + ATNAHS PHARMA US 25MG/MLN018965 001 Mar 23, 1987NAPROXENAB AMNEAL 25MG/MLA212705 001 Jul 31, 2020AB HETERO LABS LTD III 25MG/MLA215776 001 Jun 07, 2022AB ! HIKMA 25MG/MLA074190 001 Mar 30, 1994AB NOVITIUM PHARMA 25MG/MLA211910 001 Mar 10, 2021

TABLET; ORAL

NAPROSYNAB +! ATNAHS PHARMA US 500MGN017581 004 Apr 15, 1982NAPROXENAB AMNEAL PHARMS NY 250MGA075927 001 Dec 18, 2001AB 375MGA075927 002 Dec 18, 2001AB 500MGA075927 003 Dec 18, 2001AB AUROBINDO PHARMA 250MGA200429 001 Nov 08, 2011AB 375MGA200429 002 Nov 08, 2011AB 500MGA200429 003 Nov 08, 2011AB GLENMARK GENERICS 250MGA078250 001 Mar 28, 2007AB 375MGA078250 002 Mar 28, 2007AB 500MGA078250 003 Mar 28, 2007AB GRANULES 250MGA074140 001 Dec 21, 1993AB 375MGA074140 002 Dec 21, 1993AB 500MGA074140 003 Dec 21, 1993AB INVAGEN PHARMS 250MGA091305 001 Aug 24, 2011AB 375MGA091305 002 Aug 24, 2011AB 500MGA091305 003 Aug 24, 2011AB MARKSANS PHARMA 250MGA091416 001 Feb 14, 2011AB 375MGA091416 002 Feb 14, 2011AB 500MGA091416 003 Feb 14, 2011AB SCIEGEN PHARMS INC 250MGA212517 001 Feb 21, 2020AB 375MGA212517 002 Feb 21, 2020AB 500MGA212517 003 Feb 21, 2020AB TEVA 250MGA074201 001 Dec 21, 1993AB 375MGA074201 002 Dec 21, 1993AB 500MGA074201 003 Dec 21, 1993AB ZYDUS PHARMS USA 250MGA078620 001 Jun 07, 2007AB 375MGA078620 002 Jun 07, 2007AB 500MGA078620 003 Jun 07, 2007

TABLET, DELAYED RELEASE; ORAL

EC-NAPROSYNAB +! ATNAHS PHARMA US 375MGN020067 002 Oct 14, 1994AB +! 500MGN020067 003 Oct 14, 1994NAPROXENAB NUVO PHARMS INC 375MGA091432 001 Sep 19, 2011AB 500MGA091432 002 Sep 19, 2011AB TEVA 375MGA075227 001 Jun 30, 1998AB 500MGA075227 002 Jun 30, 1998NAPROXEN SODIUM

TABLET; ORAL

ANAPROX DSAB +! ATNAHS PHARMA US EQ 500MG BASEN018164 003 Sep 30, 1987NAPROXEN SODIUMAB AMNEAL PHARMS NY EQ 250MG BASEA078432 001 Apr 25, 2007AB EQ 500MG BASEA078432 002 Apr 25, 2007

PRESCRIPTION DRUG PRODUCT LIST

3-327 (of 474)

NAPROXEN SODIUM

TABLET; ORAL

NAPROXEN SODIUM

<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 250MG BASE</u>	<u>A200629 001</u>	Oct 31, 2011
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A200629 002</u>	Oct 31, 2011
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 250MG BASE</u>	<u>A078486 001</u>	Jul 26, 2007
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A078486 002</u>	Jul 26, 2007
<u>AB</u>	GLENMARK PHARMS LTD	<u>EQ 250MG BASE</u>	<u>A078314 001</u>	Apr 27, 2007
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A078314 002</u>	Apr 27, 2007
<u>AB</u>	SCIEGEN PHARMS INC	<u>EQ 250MG BASE</u>	<u>A212199 001</u>	Oct 30, 2019
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A212199 002</u>	Oct 30, 2019

TABLET, EXTENDED RELEASE; ORAL

NAPRELAN

<u>AB</u>	+	ALMATICA	<u>EQ 375MG BASE</u>	<u>N020353 001</u>	Jan 05, 1996
<u>AB</u>	+		<u>EQ 500MG BASE</u>	<u>N020353 002</u>	Jan 05, 1996
<u>AB</u>	+	!	<u>EQ 750MG BASE</u>	<u>N020353 003</u>	Jan 05, 1996

NAPROXEN SODIUM

<u>AB</u>	ACTAVIS LABS FL INC	<u>EQ 375MG BASE</u>	<u>A075416 002</u>	Apr 23, 2003
<u>AB</u>		<u>EQ 500MG BASE</u>	<u>A075416 001</u>	Aug 27, 2002
<u>AB</u>		<u>EQ 750MG BASE</u>	<u>A075416 003</u>	Aug 11, 2016

NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE

TABLET; ORAL

SUMATRIPTAN AND NAPROXEN SODIUM

<u>AB</u>	AUROBINDO PHARMA LTD	<u>500MG;EQ 85MG BASE</u>	<u>A207457 001</u>	Feb 15, 2018
<u>AB</u>	RISING	<u>500MG;EQ 85MG BASE</u>	<u>A090872 001</u>	Sep 04, 2018
<u>AB</u>	SUN PHARM	<u>500MG;EQ 85MG BASE</u>	<u>A202803 001</u>	Jul 20, 2018
<u>TREXIMET</u>				
<u>AB</u>	+! CURRAX	<u>500MG;EQ 85MG BASE</u>	<u>N021926 001</u>	Apr 15, 2008

NARATRIPTAN HYDROCHLORIDE

TABLET; ORAL

AMERGE

<u>AB</u>	+	GLAXOSMITHKLINE LLC	<u>EQ 1MG BASE</u>	<u>N020763 002</u>	Feb 10, 1998
<u>AB</u>	+	!	<u>EQ 2.5MG BASE</u>	<u>N020763 001</u>	Feb 10, 1998

NARATRIPTAN

<u>AB</u>	HERITAGE PHARMS	<u>EQ 1MG BASE</u>	<u>A200502 001</u>	Feb 28, 2011
<u>AB</u>		<u>EQ 2.5MG BASE</u>	<u>A200502 002</u>	Feb 28, 2011
<u>AB</u>	HIKMA	<u>EQ 1MG BASE</u>	<u>A090381 001</u>	Jul 07, 2010
<u>AB</u>		<u>EQ 2.5MG BASE</u>	<u>A090381 002</u>	Jul 07, 2010
<u>AB</u>	ORBION PHARMS	<u>EQ 1MG BASE</u>	<u>A091441 001</u>	Apr 30, 2012
<u>AB</u>		<u>EQ 2.5MG BASE</u>	<u>A091441 002</u>	Apr 30, 2012
<u>AB</u>	PADAGIS US	<u>EQ 1MG BASE</u>	<u>A091326 001</u>	Jul 08, 2010
<u>AB</u>		<u>EQ 2.5MG BASE</u>	<u>A091326 002</u>	Jul 08, 2010
<u>AB</u>	SUN PHARM INDS LTD	<u>EQ 2.5MG BASE</u>	<u>A091552 001</u>	Feb 14, 2011

NATAMYCIN

SUSPENSION; OPHTHALMIC

NATACYN

+	!	EYEVANCE	5%	N050514 001

NATEGLINIDE

TABLET; ORAL

NATEGLINIDE

<u>AB</u>	CADILA PHARMS LTD	<u>60MG</u>	<u>A206432 001</u>	Apr 19, 2019
<u>AB</u>		<u>120MG</u>	<u>A206432 002</u>	Apr 19, 2019
<u>AB</u>	DR REDDYS LABS LTD	<u>60MG</u>	<u>A077461 001</u>	Sep 09, 2009
<u>AB</u>		<u>120MG</u>	<u>A077461 002</u>	Sep 09, 2009
<u>AB</u>	RISING	<u>60MG</u>	<u>A205544 001</u>	Jun 18, 2018
<u>AB</u>		<u>120MG</u>	<u>A205544 002</u>	Jun 18, 2018
<u>AB</u>	STRIDES PHARMA	<u>60MG</u>	<u>A077463 001</u>	Sep 09, 2009
<u>AB</u>		<u>120MG</u>	<u>A077463 002</u>	Sep 09, 2009
<u>AB</u>	WATSON LABS	<u>60MG</u>	<u>A077462 001</u>	Mar 30, 2011
<u>AB</u>		<u>120MG</u>	<u>A077462 002</u>	Mar 30, 2011
<u>AB</u>	ZYDUS PHARMS	<u>60MG</u>	<u>A205248 001</u>	Jul 06, 2016
<u>AB</u>	!	<u>120MG</u>	<u>A205248 002</u>	Jul 06, 2016

PRESCRIPTION DRUG PRODUCT LIST

3-328 (of 474)

NEBIVOLOL HYDROCHLORIDE

TABLET; ORAL

BYSTOLIC

<u>AB</u>	+	ALLERGAN	<u>EQ 2.5MG BASE</u>	<u>N021742</u>	<u>002</u>	Dec 17, 2007
<u>AB</u>	+		<u>EQ 5MG BASE</u>	<u>N021742</u>	<u>003</u>	Dec 17, 2007
<u>AB</u>	+		<u>EQ 10MG BASE</u>	<u>N021742</u>	<u>004</u>	Dec 17, 2007
<u>AB</u>	+	!	<u>EQ 20MG BASE</u>	<u>N021742</u>	<u>005</u>	Oct 08, 2008

NEBIVOLOL HYDROCHLORIDE

<u>AB</u>		ANI PHARMS	<u>EQ 2.5MG BASE</u>	<u>A203659</u>	<u>001</u>	Apr 16, 2015
<u>AB</u>			<u>EQ 5MG BASE</u>	<u>A203659</u>	<u>002</u>	Apr 16, 2015
<u>AB</u>			<u>EQ 10MG BASE</u>	<u>A203659</u>	<u>003</u>	Apr 16, 2015
<u>AB</u>			<u>EQ 20MG BASE</u>	<u>A203659</u>	<u>004</u>	Apr 16, 2015
<u>AB</u>		AUROBINDO PHARMA LTD	<u>EQ 2.5MG BASE</u>	<u>A211053</u>	<u>001</u>	Dec 17, 2021
<u>AB</u>			<u>EQ 5MG BASE</u>	<u>A211053</u>	<u>002</u>	Dec 17, 2021
<u>AB</u>			<u>EQ 10MG BASE</u>	<u>A211053</u>	<u>003</u>	Dec 17, 2021
<u>AB</u>			<u>EQ 20MG BASE</u>	<u>A211053</u>	<u>004</u>	Dec 17, 2021
<u>AB</u>		CADILA PHARMS LTD	<u>EQ 2.5MG BASE</u>	<u>A208717</u>	<u>001</u>	Dec 17, 2021
<u>AB</u>			<u>EQ 5MG BASE</u>	<u>A208717</u>	<u>002</u>	Dec 17, 2021
<u>AB</u>			<u>EQ 10MG BASE</u>	<u>A208717</u>	<u>003</u>	Dec 17, 2021
<u>AB</u>			<u>EQ 20MG BASE</u>	<u>A208717</u>	<u>004</u>	Dec 17, 2021
<u>AB</u>		HETERO LABS LTD III	<u>EQ 2.5MG BASE</u>	<u>A203825</u>	<u>001</u>	Nov 03, 2020
<u>AB</u>			<u>EQ 5MG BASE</u>	<u>A203825</u>	<u>002</u>	Nov 03, 2020
<u>AB</u>			<u>EQ 10MG BASE</u>	<u>A203825</u>	<u>003</u>	Nov 03, 2020
<u>AB</u>			<u>EQ 20MG BASE</u>	<u>A203825</u>	<u>004</u>	Nov 03, 2020
<u>AB</u>		INDCHEMIE HEALTH	<u>EQ 2.5MG BASE</u>	<u>A203828</u>	<u>001</u>	Jul 29, 2015
<u>AB</u>			<u>EQ 5MG BASE</u>	<u>A203828</u>	<u>002</u>	Jul 29, 2015
<u>AB</u>			<u>EQ 10MG BASE</u>	<u>A203828</u>	<u>003</u>	Jul 29, 2015
<u>AB</u>			<u>EQ 20MG BASE</u>	<u>A203828</u>	<u>004</u>	Jul 29, 2015
<u>AB</u>		MANKIND PHARMA	<u>EQ 2.5MG BASE</u>	<u>A216172</u>	<u>001</u>	Nov 14, 2022
<u>AB</u>			<u>EQ 5MG BASE</u>	<u>A216172</u>	<u>002</u>	Nov 14, 2022
<u>AB</u>			<u>EQ 10MG BASE</u>	<u>A216172</u>	<u>003</u>	Nov 14, 2022
<u>AB</u>			<u>EQ 20MG BASE</u>	<u>A216172</u>	<u>004</u>	Nov 14, 2022
<u>AB</u>		PRINSTON INC	<u>EQ 2.5MG BASE</u>	<u>A212682</u>	<u>001</u>	Apr 07, 2022
<u>AB</u>			<u>EQ 5MG BASE</u>	<u>A212682</u>	<u>002</u>	Apr 07, 2022
<u>AB</u>			<u>EQ 10MG BASE</u>	<u>A212682</u>	<u>003</u>	Apr 07, 2022
<u>AB</u>			<u>EQ 20MG BASE</u>	<u>A212682</u>	<u>004</u>	Apr 07, 2022
<u>AB</u>		REYOUNG	<u>EQ 2.5MG BASE</u>	<u>A212917</u>	<u>001</u>	Dec 17, 2021
<u>AB</u>			<u>EQ 5MG BASE</u>	<u>A212917</u>	<u>002</u>	Dec 17, 2021
<u>AB</u>			<u>EQ 10MG BASE</u>	<u>A212917</u>	<u>003</u>	Dec 17, 2021
<u>AB</u>			<u>EQ 20MG BASE</u>	<u>A212917</u>	<u>004</u>	Dec 17, 2021
<u>AB</u>		TORRENT	<u>EQ 2.5MG BASE</u>	<u>A203966</u>	<u>001</u>	Mar 02, 2018
<u>AB</u>			<u>EQ 5MG BASE</u>	<u>A203966</u>	<u>002</u>	Mar 02, 2018
<u>AB</u>			<u>EQ 10MG BASE</u>	<u>A203966</u>	<u>003</u>	Mar 02, 2018
<u>AB</u>			<u>EQ 20MG BASE</u>	<u>A203966</u>	<u>004</u>	Mar 02, 2018

NEBIVOLOL HYDROCHLORIDE; VALSARTAN

TABLET; ORAL

VYDUO

PRINSTON INC	EQ 5MG BASE; 80MG	A210596	001	Sep 19, 2022

NEFAZODONE HYDROCHLORIDE

TABLET; ORAL

NEFAZODONE HYDROCHLORIDE

TEVA	50MG	A076037	001	Sep 16, 2003
	100MG	A076037	002	Sep 16, 2003
	150MG	A076037	003	Sep 16, 2003
	200MG	A076037	004	Sep 16, 2003
!	250MG	A076037	005	Sep 16, 2003

NELARABINE

INJECTABLE; INTRAVENOUS

ARRANON

<u>AP</u>	+	NOVARTIS	<u>250MG/50ML (5MG/ML)</u>	<u>N021877</u>	<u>001</u>	Oct 28, 2005

NELARABINE

<u>AP</u>		DR REDDYS	<u>250MG/50ML (5MG/ML)</u>	<u>A216934</u>	<u>001</u>	Dec 23, 2022
<u>AP</u>		KINDOS	<u>250MG/50ML (5MG/ML)</u>	<u>A216038</u>	<u>001</u>	Jan 10, 2023
<u>AP</u>		ZYDUS PHARMS	<u>250MG/50ML (5MG/ML)</u>	<u>A215037</u>	<u>001</u>	Nov 17, 2021

PRESCRIPTION DRUG PRODUCT LIST

3-329 (of 474)

NELFINAVIR MESYLATE

TABLET; ORAL

VIRACEPT

+	!	AGOURON PHARMS	EQ 250MG BASE
+	!		EQ 625MG BASE

N020779	001	Mar 14, 1997
N021503	001	Apr 30, 2003

NEOMYCIN SULFATE

TABLET; ORAL

NEOMYCIN SULFATE

AA	!	TEVA	500MG
AA		XGEN PHARMS	500MG

A060304	001	
A065220	001	Jul 28, 2006

NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION; IRRIGATION

NEOMYCIN AND POLYMYXIN B SULFATE

AT		WATSON LABS	EQ 40MG BASE/ML; 200,000 UNITS/ML
AT		XGEN PHARMS	EQ 40MG BASE/ML; 200,000 UNITS/ML
AT			EQ 40MG BASE/ML; 200,000 UNITS/ML

A062664	001	Apr 08, 1986
A065106	001	Jan 31, 2006
A065108	001	Jan 31, 2006

NEOSPORIN G.U. IRRIGANT

AT	!	MONARCH PHARMS	EQ 40MG BASE/ML; 200,000 UNITS/ML

A060707	001	

NEOSTIGMINE METHYLSULFATE

SOLUTION; INTRAVENOUS

BLOXIVERZ

AP	+	!	EXELA PHARMA	5MG/10ML (0.5MG/ML)
AP	+	!		10MG/10ML (1MG/ML)

N204078	001	May 31, 2013
N204078	002	May 31, 2013

NEOSTIGMINE METHYLSULFATE

AP		AMNEAL	5MG/10ML (0.5MG/ML)	
AP			10MG/10ML (1MG/ML)	
AP		AMPHASTAR PHARMS INC	5MG/10ML (0.5MG/ML)	
AP			10MG/10ML (1MG/ML)	
AP		AMRING PHARMS	5MG/10ML (0.5MG/ML)	
AP			10MG/10ML (1MG/ML)	
AP		BE PHARMS	5MG/10ML (0.5MG/ML)	
AP			10MG/10ML (1MG/ML)	
AP		CAPLIN	5MG/10ML (0.5MG/ML)	
AP			10MG/10ML (1MG/ML)	
AP		DR REDDYS	3MG/3ML (1MG/ML)	
AP			5MG/10ML (0.5MG/ML)	
AP			10MG/10ML (1MG/ML)	
AP		EUROHLTH INTL SARL	5MG/10ML (0.5MG/ML)	
AP			10MG/10ML (1MG/ML)	
AP	+	!	FRESENIUS KABI USA	3MG/3ML (1MG/ML)
AP		GLAND PHARMA LTD	5MG/10ML (0.5MG/ML)	
AP			10MG/10ML (1MG/ML)	
AP		HIKMA	3MG/3ML (1MG/ML)	
AP		INDOCO	5MG/10ML (0.5MG/ML)	
AP			10MG/10ML (1MG/ML)	
AP		MEITHEAL	5MG/10ML (0.5MG/ML)	
AP			10MG/10ML (1MG/ML)	
AP		NIVAGEN PHARMS INC	5MG/10ML (0.5MG/ML)	
AP			10MG/10ML (1MG/ML)	
AP		PAR STERILE PRODUCTS	5MG/10ML (0.5MG/ML)	
AP			10MG/10ML (1MG/ML)	

A210051	001	Jun 15, 2018
A210051	002	Jun 15, 2018
A209933	001	Sep 25, 2017
A209933	002	Sep 25, 2017
A210989	001	Aug 22, 2018
A210989	002	Aug 22, 2018
A212512	001	May 13, 2019
A212512	002	May 13, 2019
A213074	001	Apr 20, 2021
A213074	002	Apr 20, 2021
A216291	001	Jul 06, 2022
A209135	001	Jul 10, 2018
A209135	002	Jul 10, 2018
A207042	001	Dec 28, 2015
A207042	002	Dec 28, 2015
N203629	003	Sep 18, 2018
A212968	001	Oct 16, 2019
A212968	002	Oct 16, 2019
A216206	001	Jul 13, 2022
A210652	001	Oct 01, 2021
A210652	002	Oct 01, 2021
A212804	001	Apr 05, 2021
A212804	002	Apr 05, 2021
A212627	001	Nov 03, 2022
A212627	002	Nov 03, 2022
A208405	001	Apr 26, 2017
A208405	002	Apr 26, 2017

NEOSTIGMINE METHYSULFATE

AP		AVET LIFESCIENCES	5MG/10ML (0.5MG/ML)
AP			10MG/10ML (1MG/ML)

A208230	001	Nov 25, 2022
A208230	002	Nov 25, 2022

NEOSTIGMINE METHYLSULFATE

+	!	FRESENIUS KABI USA	5MG/10ML (0.5MG/ML)
+	!		10MG/10ML (1MG/ML)

N203629	001	Jan 08, 2015
N203629	002	Jan 08, 2015

NEPAFENAC

SUSPENSION/DROPS; OPHTHALMIC

ILEVRO

+	!	NOVARTIS	0.3%

N203491	001	Oct 16, 2012

NEVANAC

+	!	NOVARTIS	0.1%

N021862	001	Aug 19, 2005

PRESCRIPTION DRUG PRODUCT LIST

3-330 (of 474)

NERATINIB MALEATE

TABLET; ORAL

NERLYNX

+! PUMA BIOTECH

EQ 40MG BASE

N208051 001 Jul 17, 2017

NETARSUDIL MESYLATE

SOLUTION/DROPS; OPHTHALMIC

RHOPRESSA

+! AERIE PHARMS INC

EQ 0.02% BASE

N208254 001 Dec 18, 2017

NETUPITANT; PALONOSETRON HYDROCHLORIDE

CAPSULE; ORAL

AKYNZEO

+! HELSINN HLTHCARE

300MG; EQ 0.5MG BASE

N205718 001 Oct 10, 2014

NEVIRAPINE

SUSPENSION; ORAL

NEVIRAPINEAA AUROBINDO50MG/5MLA077702 001 May 22, 2012AA CIPLA50MG/5MLA207684 001 Aug 03, 2017VIRAMUNEAA +! BOEHRINGER
INGELHEIM50MG/5MLN020933 001 Sep 11, 1998

TABLET; ORAL

NEVIRAPINEAB AUROBINDO200MGA077521 001 May 22, 2012AB CIPLA200MGA077956 001 May 22, 2012AB HETERO LABS LTD III200MGA078584 001 May 22, 2012AB ! MACLEODS PHARMS LTD200MGA090688 001 Jan 14, 2019AB MICRO LABS LTD200MGA203080 001 May 22, 2012AB MYLAN PHARMS INC200MGA202523 001 May 22, 2012AB STRIDES PHARMA200MGA078195 001 May 22, 2012

TABLET, EXTENDED RELEASE; ORAL

NEVIRAPINEAB AUROBINDO PHARMA100MGA208616 001 Nov 23, 2016AB400MGA207698 001 Feb 28, 2017AB MACLEODS PHARMS LTD400MGA206879 001 Oct 06, 2017AB MYLAN400MGA205651 001 Oct 27, 2014AB SANDOZ INC400MGA203411 001 Apr 03, 2014VIRAMUNE XRAB + BOEHRINGER
INGELHEIM100MGN201152 002 Nov 08, 2012AB +!400MGN201152 001 Mar 25, 2011NIACIN

TABLET; ORAL

NIACOR

! AVONDALE PHARMS

500MG

A040378 001 May 03, 2000

TABLET, EXTENDED RELEASE; ORAL

NIACINAB AMNEAL PHARMS500MGA203578 001 Jul 24, 2015AB750MGA204178 001 Dec 11, 2015AB1GMA203578 002 Jul 24, 2015AB AUROBINDO PHARMA
LTD500MGA209236 001 Feb 01, 2018AB750MGA209236 002 Feb 01, 2018AB1GMA209236 003 Feb 01, 2018AB BARR500MGA076378 001 Apr 26, 2005AB750MGA076378 002 Apr 26, 2005AB1GMA076250 001 Apr 14, 2005AB LANNETT CO INC500MGA203899 001 Jun 16, 2017AB1GMA203899 002 Jun 16, 2017AB LUPIN LTD500MGA090860 001 Mar 20, 2014AB750MGA090892 001 Mar 20, 2014AB1GMA090446 001 Mar 20, 2014AB MACLEODS PHARMS LTD500MGA204934 001 Mar 03, 2022AB1GMA204934 002 Mar 03, 2022AB SUN PHARM500MGA200484 001 Apr 23, 2014AB !750MGA201273 001 Apr 23, 2014AB !1GMA200484 002 Apr 23, 2014

PRESCRIPTION DRUG PRODUCT LIST

3-331 (of 474)

NICARDIPINE HYDROCHLORIDE

CAPSULE; ORAL

NICARDIPINE HYDROCHLORIDE

AB	ANI PHARMS	<u>20MG</u>	<u>A074670</u>	<u>001</u>	Oct 28, 1996
AB		<u>30MG</u>	<u>A074670</u>	<u>002</u>	Oct 28, 1996
AB	EPIC PHARMA	<u>20MG</u>	<u>A074928</u>	<u>001</u>	Mar 19, 1998
AB	!	<u>30MG</u>	<u>A074928</u>	<u>002</u>	Mar 19, 1998
AB	GLENMARK PHARMS LTD	<u>20MG</u>	<u>A216357</u>	<u>001</u>	Dec 16, 2022
AB		<u>30MG</u>	<u>A216357</u>	<u>002</u>	Dec 16, 2022

INJECTABLE; INJECTION

NICARDIPINE HYDROCHLORIDE

AP	!	AM REGENT	<u>25MG/10ML (2.5MG/ML)</u>	<u>A090534</u>	<u>001</u>	Nov 17, 2009
AP		EUGIA PHARMA	<u>25MG/10ML (2.5MG/ML)</u>	<u>A211121</u>	<u>001</u>	Apr 08, 2021
AP		SUN PHARM	<u>25MG/10ML (2.5MG/ML)</u>	<u>N078405</u>	<u>001</u>	Nov 17, 2009
	+	!	HIKMA INTL PHARMS	25MG/10ML (2.5MG/ML)	N022276	001 Jul 24, 2008

INJECTABLE; INTRAVENOUS

CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER

+	!	CHIESI	40MG/200ML (0.2MG/ML)	N019734	004	Nov 07, 2008

CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER

+	!	CHIESI	20MG/200ML (0.1MG/ML)	N019734	003	Jul 31, 2008

CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER

+	!	CHIESI	20MG/200ML (0.1MG/ML)	N019734	002	Jul 31, 2008

NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE

+	!	HIKMA INTL PHARMS	20MG/200ML (0.1MG/ML)	N022276	002	Apr 07, 2016

+	!		40MG/200ML (0.2MG/ML)	N022276	003	Apr 07, 2016

NICOTINE

INHALANT; ORAL

NICOTROL

+	!	PFIZER	4MG/CARTRIDGE	N020714	001	May 02, 1997

SPRAY, METERED; NASAL

NICOTROL

+	!	PFIZER INC	0.5MG/SPRAY	N020385	001	Mar 22, 1996

NIFEDIPINE

CAPSULE; ORAL

NIFEDIPINE

AB	ACELLA	<u>10MG</u>	<u>A072781</u>	<u>001</u>	Jul 30, 1993
AB	ACTAVIS ELIZABETH	<u>10MG</u>	<u>A072579</u>	<u>001</u>	Jan 08, 1991
AB		<u>20MG</u>	<u>A072556</u>	<u>001</u>	Sep 20, 1990
AB	HERITAGE PHARMA	<u>10MG</u>	<u>A202644</u>	<u>001</u>	Apr 25, 2013
AB		<u>20MG</u>	<u>A202644</u>	<u>002</u>	Apr 25, 2013
AB	LEADING	<u>10MG</u>	<u>A073250</u>	<u>001</u>	Oct 08, 1991
AB		<u>20MG</u>	<u>A074045</u>	<u>001</u>	Apr 30, 1992

PROCARDIA

AB	+	!	PFIZER	<u>10MG</u>	<u>N018482</u>	<u>001</u>

TABLET, EXTENDED RELEASE; ORAL

NIFEDIPINE

AB1	AUROBINDO PHARMA	<u>30MG</u>	<u>A213361</u>	<u>001</u>	Jul 19, 2021
AB1		<u>60MG</u>	<u>A213361</u>	<u>002</u>	Jul 19, 2021
AB1		<u>90MG</u>	<u>A213361</u>	<u>003</u>	Jul 19, 2021
AB1	NOVAST LABS	<u>30MG</u>	<u>A202987</u>	<u>001</u>	Aug 25, 2016
AB1	!	<u>60MG</u>	<u>A202987</u>	<u>002</u>	Aug 25, 2016
AB1	!	<u>90MG</u>	<u>A202987</u>	<u>003</u>	Aug 25, 2016
AB1	VALEANT PHARMS NORTH	<u>30MG</u>	<u>A075269</u>	<u>001</u>	Dec 04, 2000
AB1		<u>60MG</u>	<u>A075269</u>	<u>002</u>	Dec 04, 2000
AB1		<u>90MG</u>	<u>A076070</u>	<u>001</u>	Aug 16, 2002
AB1	ZYDUS PHARMS	<u>30MG</u>	<u>A210184</u>	<u>001</u>	Jun 29, 2018
AB1		<u>60MG</u>	<u>A210184</u>	<u>002</u>	Jun 29, 2018
AB1		<u>90MG</u>	<u>A210184</u>	<u>003</u>	Jun 29, 2018
AB2	ALEMBIC PHARMS	<u>30MG</u>	<u>A216896</u>	<u>001</u>	Nov 18, 2022
AB2		<u>60MG</u>	<u>A216896</u>	<u>002</u>	Nov 18, 2022
AB2		<u>90MG</u>	<u>A216896</u>	<u>003</u>	Nov 18, 2022
AB2	ALKEM LABS LTD	<u>30MG</u>	<u>A216067</u>	<u>001</u>	Mar 29, 2022
AB2		<u>60MG</u>	<u>A216067</u>	<u>002</u>	Mar 29, 2022
AB2		<u>90MG</u>	<u>A216067</u>	<u>003</u>	Mar 29, 2022
AB2	ELITE PHARM SOLUTION	<u>90MG</u>	<u>A212016</u>	<u>001</u>	Nov 18, 2020
AB2	NOVAST LABS	<u>30MG</u>	<u>A210614</u>	<u>001</u>	Mar 12, 2019
AB2		<u>60MG</u>	<u>A210614</u>	<u>002</u>	Mar 12, 2019
AB2		<u>90MG</u>	<u>A210614</u>	<u>003</u>	Mar 12, 2019
AB2	OSMOTICA PHARM US	<u>30MG</u>	<u>A077127</u>	<u>001</u>	Nov 21, 2005
AB2		<u>60MG</u>	<u>A077127</u>	<u>002</u>	Nov 21, 2005

PRESCRIPTION DRUG PRODUCT LIST

3-332 (of 474)

NIFEDIPINE

TABLET, EXTENDED RELEASE;ORAL

NIFEDIPINE

<u>AB2</u>		<u>90MG</u>	<u>A077127</u>	<u>003</u>	Oct 03, 2007
<u>AB2</u>	PHARMADAX INC	<u>30MG</u>	<u>A216019</u>	<u>001</u>	Nov 18, 2022
<u>AB2</u>		<u>60MG</u>	<u>A216019</u>	<u>002</u>	Nov 18, 2022
<u>AB2</u>	SPIL	<u>30MG</u>	<u>A210838</u>	<u>001</u>	Apr 16, 2019
<u>AB2</u>		<u>60MG</u>	<u>A210838</u>	<u>002</u>	Apr 16, 2019
<u>AB2</u>		<u>90MG</u>	<u>A210838</u>	<u>003</u>	Apr 16, 2019
<u>AB2</u>	TWI PHARMS	<u>30MG</u>	<u>A203126</u>	<u>001</u>	Apr 03, 2014
<u>AB2</u>		<u>60MG</u>	<u>A203126</u>	<u>002</u>	Apr 03, 2014
<u>AB2</u>		<u>90MG</u>	<u>A203126</u>	<u>003</u>	Apr 03, 2014
<u>AB2</u>	VALEANT PHARMS NORTH	<u>30MG</u>	<u>A075289</u>	<u>002</u>	Feb 06, 2001
<u>AB2</u>		<u>60MG</u>	<u>A075289</u>	<u>001</u>	Sep 27, 2000
<u>AB2</u>	ZYDUS PHARMS	<u>30MG</u>	<u>A210012</u>	<u>001</u>	Dec 19, 2017
<u>AB2</u>		<u>60MG</u>	<u>A210012</u>	<u>002</u>	Dec 19, 2017
<u>AB2</u>		<u>90MG</u>	<u>A210012</u>	<u>003</u>	Dec 19, 2017

PROCARDIA XL

<u>AB2</u>	+	PFIZER	<u>30MG</u>	<u>N019684</u>	<u>001</u>	Sep 06, 1989
<u>AB2</u>	+		<u>60MG</u>	<u>N019684</u>	<u>002</u>	Sep 06, 1989
<u>AB2</u>	+	!	<u>90MG</u>	<u>N019684</u>	<u>003</u>	Sep 06, 1989

NIFURTIMOX

TABLET;ORAL

LAMPIT

+	BAYER HEALTHCARE	30MG	N213464	001	Aug 06, 2020
+	!	120MG	N213464	002	Aug 06, 2020

NILOTINIB HYDROCHLORIDE

CAPSULE;ORAL

TASIGNA

+	NOVARTIS	EQ 50MG BASE	N022068	003	Mar 22, 2018
+		EQ 150MG BASE	N022068	002	Jun 17, 2010
+	!	EQ 200MG BASE	N022068	001	Oct 29, 2007

NILUTAMIDE

TABLET;ORAL

NILANDRON

<u>AB</u>	+	CONCORDIA	<u>150MG</u>	<u>N020169</u>	<u>002</u>	Apr 30, 1999

NILUTAMIDE

<u>AB</u>		ANI PHARMS	<u>150MG</u>	<u>A207631</u>	<u>001</u>	Jul 15, 2016

NIMODIPINE

CAPSULE;ORAL

NIMODIPINE

<u>AB</u>	!	BIONPHARMA INC	<u>30MG</u>	<u>A076740</u>	<u>001</u>	Jan 17, 2008
<u>AB</u>		HERITAGE PHARMS	<u>30MG</u>	<u>A077811</u>	<u>001</u>	May 02, 2007
<u>AB</u>		THEPHARMANETWORK LLC	<u>30MG</u>	<u>A090103</u>	<u>001</u>	Apr 07, 2014

SOLUTION;ORAL

NYMALIZE

+	AZURITY	6MG/ML	N203340	002	Apr 08, 2020

NINTEDANIB ESYLATE

CAPSULE;ORAL

OFEV

+	BOEHRINGER INGELHEIM	EQ 100MG BASE	N205832	001	Oct 15, 2014
+	!	EQ 150MG BASE	N205832	002	Oct 15, 2014

NIRAPARIB TOSYLATE

CAPSULE;ORAL

ZEJULA

+	GLAXOSMITHKLINE	EQ 100MG BASE	N208447	001	Mar 27, 2017

NISOLDIPINE

TABLET, EXTENDED RELEASE;ORAL

NISOLDIPINE

<u>AB</u>		MYLAN	<u>8.5MG</u>	<u>A091001</u>	<u>001</u>	Jan 26, 2011
<u>AB</u>			<u>17MG</u>	<u>A091001</u>	<u>002</u>	Jan 26, 2011
<u>AB</u>			<u>34MG</u>	<u>A091001</u>	<u>004</u>	Jan 26, 2011

SULAR

<u>AB</u>	+	COVIS	<u>8.5MG</u>	<u>N020356</u>	<u>008</u>	Jan 02, 2008
<u>AB</u>	+	!	<u>17MG</u>	<u>N020356</u>	<u>007</u>	Jan 02, 2008
<u>AB</u>	+	!	<u>34MG</u>	<u>N020356</u>	<u>005</u>	Jan 02, 2008

PRESCRIPTION DRUG PRODUCT LIST

3-333 (of 474)

NISOLDIPINE

TABLET, EXTENDED RELEASE; ORAL

NISOLDIPINE

! MYLAN

20MG

A079051 001 Jul 25, 2008

25.5MG

A091001 003 Jan 26, 2011

30MG

A079051 002 Jul 25, 2008

!

40MG

A079051 003 Jul 25, 2008

NITAZOXANIDE

FOR SUSPENSION; ORAL

ALINIA

+! ROMARK

100MG/5ML

N021498 001 Nov 22, 2002

TABLET; ORAL

ALINIAAB +! ROMARK500MGN021497 001 Jul 21, 2004NITAZOXANIDEAB RISING500MGA213820 001 Nov 27, 2020NITISINONE

CAPSULE; ORAL

NITISINONEAB MEDUNIK2MGA212390 001 May 26, 2022AB5MGA212390 002 May 26, 2022AB10MGA212390 003 May 26, 2022AB NOVITIUM PHARMA2MGA211041 001 Aug 26, 2019AB5MGA211041 002 Aug 26, 2019AB10MGA211041 003 Aug 26, 2019AB TORRENT2MGA215908 001 Jan 09, 2023AB5MGA215908 002 Jan 09, 2023AB10MGA215908 003 Jan 09, 2023AB20MGA215908 004 Jan 09, 2023ORFADINAB + SWEDISH ORPHAN2MGN021232 001 Jan 18, 2002AB +5MGN021232 002 Jan 18, 2002AB +10MGN021232 003 Jan 18, 2002AB +!20MGN021232 004 Jun 13, 2016

SUSPENSION; ORAL

ORFADIN

+! SWEDISH ORPHAN

4MG/ML

N206356 001 Apr 22, 2016

TABLET; ORAL

NITYR

+ CYCLE

2MG

N209449 001 Jul 26, 2017

+

5MG

N209449 002 Jul 26, 2017

+!

10MG

N209449 003 Jul 26, 2017

NITRIC OXIDE

GAS; INHALATION

INOMAXAA +! MALLINCKRODT HOSP800PPMN020845 003 Dec 23, 1999NOXIVENTAA LINDE GAS EQUIP800PPMA207141 002 Oct 02, 2018

GENOSYL

+! VERO BIOTECH

800PPM

N202860 001 Dec 20, 2019

NOXIVENT

LINDE GAS EQUIP

100PPM

A207141 001 Oct 02, 2018

NITROFURANTOIN

SUSPENSION; ORAL

FURADANTINAB +! CASPER PHARMA LLC25MG/5MLN009175 001NITROFURANTOINAB ACTAVIS MID25MG/5MLA205180 001 May 03, 2016

ATLANTIC

AB NOSTRUM LABS INC25MG/5MLA201355 001 Aug 14, 2013AB NOVEL LABS INC25MG/5MLA201693 001 Sep 08, 2014NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL

MACRODANTINAB + ALMATICA25MGN016620 003AB +50MGN016620 001AB +!100MGN016620 002NITROFURANTOINAB ACTAVIS LABS FL INC25MGA091095 001 Jun 18, 2015AB50MGA091095 002 Jun 18, 2015

PRESCRIPTION DRUG PRODUCT LIST

3-334 (of 474)

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL

NITROFURANTOIN

<u>AB</u>		<u>100MG</u>	<u>A091095</u>	<u>003</u>	Jun 18, 2015
<u>AB</u>	ALEMBIC PHARMS	<u>25MG</u>	<u>A211935</u>	<u>001</u>	Jun 25, 2021
<u>AB</u>		<u>50MG</u>	<u>A211935</u>	<u>002</u>	Jun 25, 2021
<u>AB</u>		<u>100MG</u>	<u>A211935</u>	<u>003</u>	Jun 25, 2021
<u>AB</u>	IMPAX LABS INC	<u>50MG</u>	<u>A073671</u>	<u>001</u>	Jan 28, 1993
<u>AB</u>		<u>100MG</u>	<u>A073652</u>	<u>001</u>	Jan 28, 1993
<u>AB</u>	NOVEL LABS INC	<u>50MG</u>	<u>A203233</u>	<u>001</u>	Jul 09, 2018
<u>AB</u>		<u>100MG</u>	<u>A203233</u>	<u>002</u>	Jul 09, 2018
<u>AB</u>	SUN PHARM INDUSTRIES	<u>25MG</u>	<u>A201722</u>	<u>001</u>	Feb 16, 2016
<u>AB</u>		<u>50MG</u>	<u>A201722</u>	<u>002</u>	Feb 16, 2016
<u>AB</u>		<u>100MG</u>	<u>A201722</u>	<u>003</u>	Feb 16, 2016
<u>AB</u>	ZYDUS PHARMS	<u>50MG</u>	<u>A205005</u>	<u>001</u>	Dec 12, 2017
<u>AB</u>		<u>100MG</u>	<u>A205005</u>	<u>002</u>	Dec 12, 2017

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL

MACROBID

<u>AB</u>	<u>+</u> !	ALMATICA	<u>75MG; 25MG</u>	<u>N020064</u>	<u>001</u>	Dec 24, 1991

NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)

<u>AB</u>		ALVOGEN	<u>75MG; 25MG</u>	<u>A215002</u>	<u>001</u>	Jul 20, 2022
<u>AB</u>		AMNEAL PHARMS	<u>75MG; 25MG</u>	<u>A207372</u>	<u>001</u>	May 15, 2017
<u>AB</u>		INVENTIA	<u>75MG; 25MG</u>	<u>A211013</u>	<u>001</u>	Feb 18, 2022
<u>AB</u>		SANDOZ	<u>75MG; 25MG</u>	<u>A077066</u>	<u>001</u>	Apr 05, 2005
<u>AB</u>		SUNNY	<u>75MG; 25MG</u>	<u>A208516</u>	<u>001</u>	May 24, 2018
<u>AB</u>		WATSON LABS INC	<u>75MG; 25MG</u>	<u>A202250</u>	<u>001</u>	Jul 08, 2015

NITROGLYCERIN

AEROSOL, METERED; SUBLINGUAL

NITROMIST+! EVUS 0.4MG/SPRAY

N021780 001 Nov 02, 2006

FILM, EXTENDED RELEASE; TRANSDERMAL

NITROGLYCERIN

<u>AB2</u>	<u>!</u>	MYLAN TECHNOLOGIES	<u>0.1MG/HR</u>	<u>A074559</u>	<u>004</u>	Feb 06, 1998
<u>AB2</u>	<u>!</u>		<u>0.2MG/HR</u>	<u>A074559</u>	<u>003</u>	Aug 30, 1996
<u>AB2</u>	<u>!</u>		<u>0.4MG/HR</u>	<u>A074559</u>	<u>002</u>	Aug 30, 1996
<u>AB2</u>	<u>!</u>		<u>0.6MG/HR</u>	<u>A074559</u>	<u>001</u>	Aug 30, 1996
<u>AB2</u>		ZYDUS PHARMS	<u>0.1MG/HR</u>	<u>A089885</u>	<u>002</u>	Oct 30, 2017
<u>AB2</u>			<u>0.2MG/HR</u>	<u>A089884</u>	<u>001</u>	Oct 30, 1998
<u>AB2</u>			<u>0.4MG/HR</u>	<u>A089885</u>	<u>001</u>	Oct 30, 1998
<u>AB2</u>			<u>0.6MG/HR</u>	<u>A089886</u>	<u>001</u>	Oct 30, 1998

NITRO-DUR

+! USPHARMA 0.1MG/HR
+! 0.2MG/HR
+! 0.3MG/HR
+! 0.4MG/HR
+! 0.6MG/HR
+! 0.8MG/HR

N020145 001 Apr 04, 1995
N020145 002 Apr 04, 1995
N020145 003 Apr 04, 1995
N020145 004 Apr 04, 1995
N020145 005 Apr 04, 1995
N020145 006 Apr 04, 1995

INJECTABLE; INJECTION

NITROGLYCERIN IN DEXTROSE 5%

<u>AP</u>	<u>+</u> !	BAXTER HLTHCARE	<u>10MG/100ML</u>	<u>N019970</u>	<u>001</u>	Dec 29, 1989
<u>AP</u>	<u>+</u> !		<u>20MG/100ML</u>	<u>N019970</u>	<u>002</u>	Dec 29, 1989
<u>AP</u>	<u>+</u> !		<u>40MG/100ML</u>	<u>N019970</u>	<u>003</u>	Dec 29, 1989

NITROGLYCERIN! AM REGENT 5MG/ML

A072034 001 May 24, 1988

OINTMENT; INTRA-ANAL

RECTIV+! ALLERGAN 0.4%

N021359 001 Jun 21, 2011

OINTMENT; TRANSDERMAL

NITROGLYCERIN! FOUGERA PHARMS INC 2%

A087355 001 Jul 08, 1988

SPRAY, METERED; SUBLINGUAL

NITROGLYCERIN

<u>AB</u>		PADAGIS ISRAEL	<u>0.4MG/SPRAY</u>	<u>A091496</u>	<u>001</u>	Sep 20, 2013

NITROLINGUAL PUMPSPRAY

<u>AB</u>	<u>+</u> !	POHL BOSKAMP	<u>0.4MG/SPRAY</u>	<u>N018705</u>	<u>002</u>	Jan 10, 1997

TABLET; SUBLINGUAL

NITROGLYCERIN

<u>AB</u>		DR REDDYS	<u>0.3MG</u>	<u>A208191</u>	<u>001</u>	Aug 26, 2016
<u>AB</u>			<u>0.4MG</u>	<u>A208191</u>	<u>002</u>	Aug 26, 2016
<u>AB</u>			<u>0.6MG</u>	<u>A208191</u>	<u>003</u>	Aug 26, 2016

PRESCRIPTION DRUG PRODUCT LIST

3-335 (of 474)

NITROGLYCERIN

TABLET;SUBLINGUAL

NITROGLYCERIN

<u>AB</u>	GLENMARK PHARMS SA	<u>0.3MG</u>	<u>A206391</u>	<u>001</u>	Sep 19, 2017
<u>AB</u>		<u>0.4MG</u>	<u>A206391</u>	<u>002</u>	Sep 19, 2017
<u>AB</u>		<u>0.6MG</u>	<u>A206391</u>	<u>003</u>	Sep 19, 2017
<u>AB</u>	NATCO	<u>0.3MG</u>	<u>A211604</u>	<u>001</u>	Apr 30, 2019
<u>AB</u>		<u>0.4MG</u>	<u>A211604</u>	<u>002</u>	Apr 30, 2019
<u>AB</u>		<u>0.6MG</u>	<u>A211604</u>	<u>003</u>	Apr 30, 2019
<u>AB</u>	RUBICON	<u>0.3MG</u>	<u>A209779</u>	<u>001</u>	May 03, 2021
<u>AB</u>		<u>0.4MG</u>	<u>A209779</u>	<u>002</u>	May 03, 2021
<u>AB</u>		<u>0.6MG</u>	<u>A209779</u>	<u>003</u>	May 03, 2021
<u>NITROSTAT</u>					
<u>AB</u>	+ VIATRIS	<u>0.3MG</u>	<u>N021134</u>	<u>001</u>	May 01, 2000
<u>AB</u>	+	<u>0.4MG</u>	<u>N021134</u>	<u>002</u>	May 01, 2000
<u>AB</u>	+!	<u>0.6MG</u>	<u>N021134</u>	<u>003</u>	May 01, 2000

NIZATIDINE

CAPSULE;ORAL

NIZATIDINE

<u>AB</u>	DR REDDYS LABS LTD	<u>150MG</u>	<u>A077314</u>	<u>001</u>	Sep 15, 2005
<u>AB</u>		<u>300MG</u>	<u>A077314</u>	<u>002</u>	Sep 15, 2005
<u>AB</u>	EPIC PHARMA	<u>150MG</u>	<u>A076178</u>	<u>001</u>	Jul 05, 2002
<u>AB</u>		<u>300MG</u>	<u>A076178</u>	<u>002</u>	Jul 05, 2002
<u>AB</u>	GLENMARK GENERICS	<u>150MG</u>	<u>A090618</u>	<u>001</u>	Jul 15, 2011
<u>AB</u>		<u>300MG</u>	<u>A090618</u>	<u>002</u>	Jul 15, 2011
<u>AB</u>	WATSON LABS	<u>150MG</u>	<u>A075616</u>	<u>001</u>	Jul 09, 2002
<u>AB</u>	!	<u>300MG</u>	<u>A075616</u>	<u>002</u>	Jul 09, 2002

NOREPINEPHRINE BITARTRATE

INJECTABLE;INJECTION

LEVOPHED

<u>AP</u>	+! HOSPIRA	<u>EQ 1MG BASE/ML</u>	<u>N007513</u>	<u>001</u>	

NOREPINEPHRINE BITARTRATE

<u>AP</u>	AMNEAL	<u>EQ 1MG BASE/ML</u>	<u>A210839</u>	<u>001</u>	Dec 17, 2018
<u>AP</u>	BAXTER HLTHCARE	<u>EQ 1MG BASE/ML</u>	<u>A040859</u>	<u>001</u>	Mar 27, 2012
	CORP				
<u>AP</u>	BRECKENRIDGE	<u>EQ 1MG BASE/ML</u>	<u>A214455</u>	<u>001</u>	Jan 22, 2021
<u>AP</u>	FRESENIUS KABI USA	<u>EQ 1MG BASE/ML</u>	<u>A211382</u>	<u>001</u>	Nov 03, 2020
<u>AP</u>	GLAND PHARMA LTD	<u>EQ 1MG BASE/ML</u>	<u>A214323</u>	<u>001</u>	May 06, 2021
<u>AP</u>	HIKMA	<u>EQ 1MG BASE/ML</u>	<u>A040462</u>	<u>001</u>	Oct 31, 2003
<u>AP</u>		<u>EQ 1MG BASE/ML</u>	<u>A203662</u>	<u>001</u>	Nov 07, 2018
<u>AP</u>	MYLAN LABS LTD	<u>EQ 1MG BASE/ML</u>	<u>A211242</u>	<u>001</u>	Oct 04, 2018
<u>AP</u>	SANDOZ INC	<u>EQ 1MG BASE/ML</u>	<u>A211359</u>	<u>001</u>	Oct 18, 2018
<u>AP</u>	SUN PHARM	<u>EQ 1MG BASE/ML</u>	<u>A211980</u>	<u>001</u>	Jan 29, 2021
<u>AP</u>	TEVA PHARMS USA	<u>EQ 1MG BASE/ML</u>	<u>A040455</u>	<u>001</u>	Mar 03, 2003

SOLUTION;INTRAVENOUS

NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE

+!	INFORLIFE	EQ 4MG BASE/250ML (EQ 16MCG BASE/ML)	N215700	001	Sep 15, 2022
+!		EQ 8MG BASE/250ML (EQ 32MCG BASE/ML)	N215700	002	Sep 15, 2022
+!		EQ 16MG BASE/250ML (EQ 64MCG BASE/ML)	N215700	003	Sep 15, 2022
+!	NEVAKAR INJECTABLES	EQ 4MG BASE/250 ML (EQ 16MCG BASE/ML)	N214628	001	Oct 06, 2022
+!		EQ 8MG BASE/250ML (EQ 32MCG BASE/ML)	N214628	002	Oct 06, 2022
+!		EQ 16MG BASE/250ML (EQ 64MCG BASE/ML)	N214628	003	Oct 06, 2022

NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE

+!	BAXTER HLTHCARE	EQ 4MG BASE/250ML (EQ 16MCG BASE/ML)	N214313	001	Jan 15, 2021
	CORP				
+!		EQ 8MG BASE/250ML (EQ 32MCG BASE/ML)	N214313	002	Jan 15, 2021

NORETHINDRONE

TABLET;ORAL-28

CAMILA

<u>AB1</u>	MAYNE PHARMA	<u>0.35MG</u>	<u>A076177</u>	<u>001</u>	Oct 21, 2002

HEATHER

<u>AB1</u>	GLENMARK GENERICS	<u>0.35MG</u>	<u>A090454</u>	<u>001</u>	Apr 23, 2010

INCASSIA

<u>AB1</u>	AUROBINDO PHARMA	<u>0.35MG</u>	<u>A207304</u>	<u>001</u>	Sep 23, 2016

NOR-QD

<u>AB1</u>	+! TEVA BRANDED PHARM	<u>0.35MG</u>	<u>N017060</u>	<u>001</u>	

NORETHINDRONE

<u>AB1</u>	LUPIN LTD	<u>0.35MG</u>	<u>A091325</u>	<u>001</u>	Sep 19, 2011
<u>AB1</u>	MYLAN LABS LTD	<u>0.35MG</u>	<u>A201483</u>	<u>001</u>	Jun 24, 2013
<u>AB1</u>	NAARI PTE LTD	<u>0.35MG</u>	<u>A206807</u>	<u>001</u>	Dec 13, 2016
<u>AB1</u>	NOVAST LABS	<u>0.35MG</u>	<u>A202014</u>	<u>001</u>	Sep 13, 2013

PRESCRIPTION DRUG PRODUCT LIST

3-336 (of 474)

NORETHINDRONE

TABLET; ORAL-28

EMZAHH

AB2	AUROBINDO PHARMA	0.35MG	A216796	001	Jan 06, 2023

ERRIN

AB2	MAYNE PHARMA	0.35MG	A076225	001	Oct 21, 2002

JENCYCLA

AB2	LUPIN LTD	0.35MG	A091323	001	Mar 28, 2013

NORETHINDRONE

AB2	GLENMARK GENERICS	0.35MG	A091209	001	Jul 22, 2010

AB2	!	MYLAN LABS LTD	0.35MG	A200980	001	Jun 12, 2013

AB2		NOVAST LABS	0.35MG	A200961	001	Sep 13, 2013

NORETHINDRONE ACETATE

TABLET; ORAL

NORETHINDRONE ACETATE

AB	AMNEAL PHARMS	5MG	A200275	001	Jul 30, 2012

AB	!	BARR	5MG	A075951	001	May 25, 2001

AB		GLENMARK GENERICS	5MG	A091090	001	Jul 21, 2010

AB		MYLAN LABS LTD	5MG	A205278	001	Nov 10, 2016

AB		NOVAST LABS	5MG	A206490	001	Nov 05, 2018

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE; ORAL

NORTRIPTYLINE HYDROCHLORIDE

AB		MAYNE PHARMA	EQ 10MG BASE	A073556	002	Mar 30, 1992

AB			EQ 25MG BASE	A073556	003	Mar 30, 1992

AB			EQ 50MG BASE	A073556	004	Mar 30, 1992

AB			EQ 75MG BASE	A073556	001	Mar 30, 1992

AB		TARO	EQ 10MG BASE	A075520	004	May 08, 2000

AB			EQ 25MG BASE	A075520	003	May 08, 2000

AB			EQ 50MG BASE	A075520	001	May 08, 2000

AB			EQ 75MG BASE	A075520	002	May 08, 2000

AB		TEVA	EQ 10MG BASE	A074132	001	Mar 27, 1995

AB			EQ 25MG BASE	A074132	002	Mar 27, 1995

AB			EQ 50MG BASE	A074132	003	Mar 27, 1995

AB			EQ 75MG BASE	A074132	004	Mar 27, 1995

PAMELOR

AB	+	SPECGX LLC	EQ 10MG BASE	N018013	001	

AB	+		EQ 25MG BASE	N018013	002	

AB	+		EQ 50MG BASE	N018013	004	

AB	+	!	EQ 75MG BASE	N018013	003	

SOLUTION; ORAL

NORTRIPTYLINE HYDROCHLORIDE

!	PHARM ASSOC	EQ 10MG BASE/5ML	A075606	001	Aug 23, 2000

NUSINERSEN SODIUM

SOLUTION; INTRATHECAL

SPINRAZA

+	!	BIOGEN IDEC	EQ 12MG BASE/5ML (EQ 2.4MG BASE/ML)	N209531	001	Dec 23, 2016

NYSTATIN

CREAM; TOPICAL

NYSTATIN

AT		ACTAVIS MID ATLANTIC	100,000 UNITS/GM	A062949	001	Jun 13, 1988

AT		COSETTE	100,000 UNITS/GM	A061966	001	

AT		CROWN LABS INC	100,000 UNITS/GM	A207733	001	Sep 26, 2017

AT		FOUGERA PHARMS	100,000 UNITS/GM	A062129	001	

AT		MACLEODS PHARMS LTD	100,000 UNITS/GM	A213566	001	Aug 10, 2021

AT		PADAGIS US	100,000 UNITS/GM	A062225	001	

AT	!	TARO	100,000 UNITS/GM	A064022	001	Jan 29, 1993

AT		TORRENT	100,000 UNITS/GM	A212557	001	Jul 24, 2019

OINTMENT; TOPICAL

NYSTATIN

AT		ACTAVIS MID ATLANTIC	100,000 UNITS/GM	A062840	001	Nov 13, 1987

AT		CADILA	100,000 UNITS/GM	A207767	001	May 25, 2018

AT		COSETTE	100,000 UNITS/GM	A209114	001	Oct 06, 2017

AT	!	FOUGERA PHARMS	100,000 UNITS/GM	A062124	002	Sep 23, 1982

AT		LYNE	100,000 UNITS/GM	A209082	001	May 21, 2018

AT		MACLEODS PHARMS LTD	100,000 UNITS/GM	A213826	001	Jan 14, 2021

AT		PADAGIS US	100,000 UNITS/GM	A062472	001	Feb 13, 1984

AT		TORRENT	100,000 UNITS/GM	A211838	001	Jan 28, 2019

PRESCRIPTION DRUG PRODUCT LIST

3-337 (of 474)

NYSTATIN

POWDER; TOPICAL

NYSTATIN

AT	EPIC PHARMA LLC	<u>100,000 UNITS/GM</u>	<u>A210532</u>	<u>001</u>	Apr 30, 2018
AT	LUPIN	<u>100,000 UNITS/GM</u>	<u>A065138</u>	<u>001</u>	Jul 23, 2004
AT	LYNE	<u>100,000 UNITS/GM</u>	<u>A208838</u>	<u>001</u>	May 30, 2017
AT	! MAYNE PHARMA INC	<u>100,000 UNITS/GM</u>	<u>A065203</u>	<u>001</u>	Jul 15, 2004
AT	UPSHER SMITH LABS	<u>100,000 UNITS/GM</u>	<u>A065183</u>	<u>001</u>	May 03, 2005
AT	XGEN PHARMS	<u>100,000 UNITS/GM</u>	<u>A065175</u>	<u>001</u>	Dec 17, 2004
AT	ZYDUS PHARMS	<u>100,000 UNITS/GM</u>	<u>A208581</u>	<u>001</u>	Jun 08, 2017

NYSTOP

AT	PADAGIS US	<u>100,000 UNITS/GM</u>	<u>A064118</u>	<u>001</u>	Aug 16, 1996

SUSPENSION; ORAL

NYSTATIN

AA	DASTECH GENERICS	<u>100,000 UNITS/ML</u>	<u>A062832</u>	<u>001</u>	Dec 27, 1991
AA	FOUGERA PHARMS INC	<u>100,000 UNITS/ML</u>	<u>A062517</u>	<u>001</u>	Jun 07, 1984
AA	GENUS	<u>100,000 UNITS/ML</u>	<u>A065148</u>	<u>001</u>	Jun 28, 2005
AA	LEADING	<u>100,000 UNITS/ML</u>	<u>A214346</u>	<u>001</u>	Mar 10, 2022
AA	PHARM ASSOC	<u>100,000 UNITS/ML</u>	<u>A203621</u>	<u>001</u>	Jan 07, 2016
AA	TARO	<u>100,000 UNITS/ML</u>	<u>A062876</u>	<u>001</u>	Feb 29, 1988
AA	VISTAPHARM	<u>100,000 UNITS/ML</u>	<u>A064142</u>	<u>001</u>	Jun 25, 1998
AA		<u>100,000 UNITS/ML</u>	<u>A064142</u>	<u>002</u>	Mar 07, 2011
AA	! WOCKHARDT BIO AG	<u>100,000 UNITS/ML</u>	<u>A062512</u>	<u>001</u>	Oct 29, 1984

TABLET; ORAL

NYSTATIN

AA	HERITAGE PHARMS	<u>500,000 UNITS</u>	<u>A062474</u>	<u>001</u>	Dec 22, 1983
AA	SUN PHARM	<u>500,000 UNITS</u>	<u>A062838</u>	<u>001</u>	Dec 22, 1988
AA	INDUSTRIES				
AA	! TEVA	<u>500,000 UNITS</u>	<u>A062506</u>	<u>001</u>	Jan 16, 1984

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

MYKACET

AT	COSETTE	<u>100,000 UNITS/GM; 0.1%</u>	<u>A062367</u>	<u>001</u>	May 28, 1985

NYSTATIN AND TRIAMCINOLONE ACETONIDE

AT	ALEOR	<u>100,000 UNITS/GM; 0.1%</u>	<u>A214090</u>	<u>001</u>	Mar 31, 2021
	DERMACEUTICALS				
AT	AMNEAL	<u>100,000 UNITS/GM; 0.1%</u>	<u>A209990</u>	<u>001</u>	Feb 15, 2018
AT	CROWN LABS INC	<u>100,000 UNITS/GM; 0.1%</u>	<u>A207730</u>	<u>001</u>	Dec 26, 2017
AT	DR REDDYS	<u>100,000 UNITS/GM; 0.1%</u>	<u>A208326</u>	<u>001</u>	Oct 26, 2016
AT	FOUGERA PHARMS INC	<u>100,000 UNITS/GM; 0.1%</u>	<u>A062599</u>	<u>001</u>	Oct 08, 1985
AT	GLENMARK PHARMS LTD	<u>100,000 UNITS/GM; 0.1%</u>	<u>A208136</u>	<u>001</u>	Oct 24, 2016
AT	LUPIN LTD	<u>100,000 UNITS/GM; 0.1%</u>	<u>A208205</u>	<u>001</u>	May 31, 2018
AT	MACLEODS PHARMS LTD	<u>100,000 UNITS/GM; 0.1%</u>	<u>A214181</u>	<u>001</u>	Jul 13, 2022
AT	PADAGIS ISRAEL	<u>100,000 UNITS/GM; 0.1%</u>	<u>A208479</u>	<u>001</u>	Aug 14, 2017
AT	! TARO	<u>100,000 UNITS/GM; 0.1%</u>	<u>A062364</u>	<u>001</u>	Dec 22, 1987
AT	TORRENT	<u>100,000 UNITS/GM; 0.1%</u>	<u>A213142</u>	<u>001</u>	Jul 14, 2020

OINTMENT; TOPICAL

MYKACET

AT	COSETTE	<u>100,000 UNITS/GM; 0.1%</u>	<u>A062733</u>	<u>001</u>	Mar 06, 1987

NYSTATIN AND TRIAMCINOLONE ACETONIDE

AT	AKORN	<u>100,000 UNITS/GM; 0.1%</u>	<u>A207217</u>	<u>001</u>	Aug 04, 2017
AT	ALEOR	<u>100,000 UNITS/GM; 0.1%</u>	<u>A214186</u>	<u>001</u>	Mar 04, 2022
	DERMACEUTICALS				
AT	CADILA	<u>100,000 UNITS/GM; 0.1%</u>	<u>A207764</u>	<u>001</u>	Nov 08, 2018
AT	DR REDDYS	<u>100,000 UNITS/GM; 0.1%</u>	<u>A207741</u>	<u>001</u>	Jan 31, 2017
AT	FOUGERA PHARMS INC	<u>100,000 UNITS/GM; 0.1%</u>	<u>A062602</u>	<u>001</u>	Oct 09, 1985
AT	GLENMARK PHARMS LTD	<u>100,000 UNITS/GM; 0.1%</u>	<u>A208300</u>	<u>001</u>	Jun 23, 2016
AT	MACLEODS PHARMS LTD	<u>100,000 UNITS/GM; 0.1%</u>	<u>A214751</u>	<u>001</u>	Aug 17, 2021
AT	PADAGIS ISRAEL	<u>100,000 UNITS/GM; 0.1%</u>	<u>A207380</u>	<u>001</u>	Dec 20, 2016
AT	PAI HOLDINGS PHARM	<u>100,000 UNITS/GM; 0.1%</u>	<u>A208287</u>	<u>001</u>	Dec 30, 2016
AT	RISING	<u>100,000 UNITS/GM; 0.1%</u>	<u>A206785</u>	<u>001</u>	Dec 29, 2016
AT	STRIDES PHARMA	<u>100,000 UNITS/GM; 0.1%</u>	<u>A210077</u>	<u>001</u>	Jan 29, 2018
AT	! TARO	<u>100,000 UNITS/GM; 0.1%</u>	<u>A063305</u>	<u>001</u>	Mar 29, 1993

OBETICHLIC ACID

TABLET; ORAL

OCALIVA

+	INTERCEPT PHARMS	5MG	N207999	001	May 27, 2016
	INC				
+	!	10MG	N207999	002	May 27, 2016

PRESCRIPTION DRUG PRODUCT LIST

3-338 (of 474)

OCTREOTIDE ACETATE

CAPSULE, DELAYED RELEASE;ORAL

MYCAPSSA

+! AMRYT

EQ 20MG BASE

N208232 001 Jun 26, 2020

INJECTABLE;INJECTION

OCTREOTIDE ACETATE

<u>AP</u>	FRESENIUS KABI USA	<u>EQ 0.2MG BASE/ML</u>	<u>A077450 001</u>	Feb 10, 2006
<u>AP</u>		<u>EQ 1MG BASE/ML</u>	<u>A077450 002</u>	Feb 10, 2006
<u>AP</u>	HERITAGE PHARMS	<u>EQ 0.05MG BASE/ML</u>	<u>A204669 001</u>	Dec 27, 2018
<u>AP</u>		<u>EQ 0.1MG BASE/ML</u>	<u>A204669 002</u>	Dec 27, 2018
<u>AP</u>		<u>EQ 0.2MG BASE/ML</u>	<u>A203765 001</u>	Sep 07, 2018
<u>AP</u>		<u>EQ 0.5MG BASE/ML</u>	<u>A204669 003</u>	Dec 27, 2018
<u>AP</u>		<u>EQ 1MG BASE/ML</u>	<u>A203765 002</u>	Sep 07, 2018
<u>AP</u>	SAGENT PHARMS INC	<u>EQ 0.2MG BASE/ML</u>	<u>A091041 001</u>	Nov 12, 2013
<u>AP</u>		<u>EQ 1MG BASE/ML</u>	<u>A091041 002</u>	Nov 12, 2013
<u>AP</u>	TEVA PHARMS USA	<u>EQ 0.05MG BASE/ML</u>	<u>A075957 001</u>	Oct 03, 2005
<u>AP</u>		<u>EQ 0.1MG BASE/ML</u>	<u>A075957 002</u>	Oct 03, 2005
<u>AP</u>		<u>EQ 0.2MG BASE/ML</u>	<u>A075959 001</u>	Nov 21, 2005
<u>AP</u>		<u>EQ 0.5MG BASE/ML</u>	<u>A075957 003</u>	Oct 03, 2005
<u>AP</u>		<u>EQ 1MG BASE/ML</u>	<u>A075959 002</u>	Nov 21, 2005
<u>AP</u>	! WEST-WARD PHARMS	<u>EQ 0.2MG BASE/ML</u>	<u>A076330 001</u>	Apr 08, 2005
	INT			
<u>AP</u>	!	<u>EQ 1MG BASE/ML</u>	<u>A076330 002</u>	Apr 08, 2005

OCTREOTIDE ACETATE (PRESERVATIVE FREE)

<u>AP</u>	FRESENIUS KABI USA	<u>EQ 0.05MG BASE/ML</u>	<u>A077457 001</u>	Feb 10, 2006
<u>AP</u>		<u>EQ 0.1MG BASE/ML</u>	<u>A077457 002</u>	Feb 10, 2006
<u>AP</u>		<u>EQ 0.5MG BASE/ML</u>	<u>A077457 003</u>	Feb 10, 2006
<u>AP</u>	MYLAN INSTITUTIONAL	<u>EQ 0.05MG BASE/ML</u>	<u>A079198 001</u>	Feb 10, 2011
<u>AP</u>		<u>EQ 0.1MG BASE/ML</u>	<u>A079198 002</u>	Feb 10, 2011
<u>AP</u>		<u>EQ 0.5MG BASE/ML</u>	<u>A079198 003</u>	Feb 10, 2011
<u>AP</u>	SAGENT PHARMS INC	<u>EQ 0.05MG BASE/ML</u>	<u>A090834 001</u>	Nov 12, 2013
<u>AP</u>		<u>EQ 0.1MG BASE/ML</u>	<u>A090834 002</u>	Nov 12, 2013
<u>AP</u>		<u>EQ 0.5MG BASE/ML</u>	<u>A090834 003</u>	Nov 12, 2013
<u>AP</u>	! WEST-WARD PHARMS	<u>EQ 0.05MG BASE/ML</u>	<u>A076313 001</u>	Mar 28, 2005
	INT			
<u>AP</u>	!	<u>EQ 0.1MG BASE/ML</u>	<u>A076313 003</u>	Mar 28, 2005
<u>AP</u>	!	<u>EQ 0.5MG BASE/ML</u>	<u>A076313 002</u>	Mar 28, 2005

SANDOSTATIN

<u>AP</u>	+! NOVARTIS	<u>EQ 0.05MG BASE/ML</u>	<u>N019667 001</u>	Oct 21, 1988
<u>AP</u>	+!	<u>EQ 0.1MG BASE/ML</u>	<u>N019667 002</u>	Oct 21, 1988
<u>AP</u>	+!	<u>EQ 0.5MG BASE/ML</u>	<u>N019667 003</u>	Oct 21, 1988
	SANDOSTATIN LAR			
	+ NOVARTIS	EQ 10MG BASE/VIAL	N021008 001	Nov 25, 1998
	+	EQ 20MG BASE/VIAL	N021008 002	Nov 25, 1998
	+!	EQ 30MG BASE/VIAL	N021008 003	Nov 25, 1998

ODEVIXIBAT

CAPSULE;ORAL

BYLVAY

+ ALBIREO

0.4MG

N215498 002 Jul 20, 2021

+!

1.2MG

N215498 004 Jul 20, 2021

CAPSULE, PELLETS;ORAL

BYLVAY

+ ALBIREO

0.2MG

N215498 001 Jul 20, 2021

+!

0.6MG

N215498 003 Jul 20, 2021

OFLOXACIN

SOLUTION/DROPS;OPHTHALMIC

OCUFLOX

<u>AT</u>	+! ALLERGAN	<u>0.3%</u>	<u>N019921 001</u>	Jul 30, 1993
	<u>OFLOXACIN</u>			
<u>AT</u>	AKORN	<u>0.3%</u>	<u>A076407 001</u>	Apr 15, 2008
<u>AT</u>	ALTAIRE PHARMS INC	<u>0.3%</u>	<u>A202692 001</u>	Apr 29, 2013
<u>AT</u>	APOTEX INC	<u>0.3%</u>	<u>A076513 001</u>	May 14, 2004
<u>AT</u>	BAUSCH AND LOMB	<u>0.3%</u>	<u>A076622 001</u>	May 14, 2004
<u>AT</u>	FDC LTD	<u>0.3%</u>	<u>A078559 001</u>	Feb 25, 2009
<u>AT</u>	MANKIND PHARMA	<u>0.3%</u>	<u>A215886 001</u>	Nov 23, 2022

SOLUTION/DROPS;OTIC

OFLOXACIN

<u>AT</u>	AKORN	<u>0.3%</u>	<u>A076616 001</u>	Mar 17, 2008
<u>AT</u>	AMNEAL	<u>0.3%</u>	<u>A211525 001</u>	Aug 30, 2019
<u>AT</u>	APOTEX INC	<u>0.3%</u>	<u>A076527 001</u>	Sep 28, 2007
<u>AT</u>	! BAUSCH AND LOMB	<u>0.3%</u>	<u>A076128 001</u>	Mar 17, 2008
<u>AT</u>	MANKIND PHARMA	<u>0.3%</u>	<u>A216130 001</u>	Jul 14, 2022

PRESCRIPTION DRUG PRODUCT LIST

3-339 (of 474)

OFLOXACIN

TABLET; ORAL

OFLOXACIN

<u>AB</u>	CADILA PHARMS LTD	<u>200MG</u>	<u>A091656</u>	<u>001</u>	Sep 18, 2014
<u>AB</u>		<u>300MG</u>	<u>A091656</u>	<u>002</u>	Sep 18, 2014
<u>AB</u>		<u>400MG</u>	<u>A091656</u>	<u>003</u>	Sep 18, 2014
<u>AB</u>	DR REDDYS LABS LTD	<u>200MG</u>	<u>A077098</u>	<u>001</u>	Feb 10, 2006
<u>AB</u>		<u>300MG</u>	<u>A077098</u>	<u>002</u>	Feb 10, 2006
<u>AB</u>		<u>400MG</u>	<u>A077098</u>	<u>003</u>	Feb 10, 2006
<u>AB</u>	LARKEN LABS	<u>400MG</u>	<u>A076093</u>	<u>003</u>	Sep 02, 2003
<u>AB</u>	TEVA	<u>200MG</u>	<u>A076182</u>	<u>001</u>	Sep 02, 2003
<u>AB</u>		<u>300MG</u>	<u>A076182</u>	<u>002</u>	Sep 02, 2003
<u>AB</u>	!	<u>400MG</u>	<u>A076182</u>	<u>003</u>	Sep 02, 2003

OLANZAPINE

INJECTABLE; INTRAMUSCULAR

OLANZAPINE

<u>AP</u>	AM REGENT	<u>10MG/VIAL</u>	<u>A201741</u>	<u>001</u>	Mar 20, 2012
<u>AP</u>	EUGIA PHARMA	<u>10MG/VIAL</u>	<u>A210968</u>	<u>001</u>	Oct 22, 2020
<u>AP</u>	SANDOZ INC	<u>10MG/VIAL</u>	<u>A201588</u>	<u>001</u>	Oct 24, 2011

ZYPREXA

<u>AP</u>	+! LILLY	<u>10MG/VIAL</u>	<u>N021253</u>	<u>001</u>	Mar 29, 2004

TABLET; ORAL

OLANZAPINE

<u>AB</u>	ALKEM LABS LTD	<u>2.5MG</u>	<u>A202295</u>	<u>001</u>	Oct 20, 2015
<u>AB</u>		<u>5MG</u>	<u>A202295</u>	<u>002</u>	Oct 20, 2015
<u>AB</u>		<u>7.5MG</u>	<u>A202295</u>	<u>003</u>	Oct 20, 2015
<u>AB</u>		<u>10MG</u>	<u>A202295</u>	<u>004</u>	Oct 20, 2015
<u>AB</u>		<u>15MG</u>	<u>A202295</u>	<u>005</u>	Oct 20, 2015
<u>AB</u>		<u>20MG</u>	<u>A202295</u>	<u>006</u>	Oct 20, 2015
<u>AB</u>	APOTEX INC	<u>2.5MG</u>	<u>A090798</u>	<u>001</u>	Apr 23, 2012
<u>AB</u>		<u>5MG</u>	<u>A090798</u>	<u>002</u>	Apr 23, 2012
<u>AB</u>		<u>7.5MG</u>	<u>A090798</u>	<u>003</u>	Apr 23, 2012
<u>AB</u>		<u>10MG</u>	<u>A090798</u>	<u>004</u>	Apr 23, 2012
<u>AB</u>		<u>15MG</u>	<u>A090798</u>	<u>005</u>	Apr 23, 2012
<u>AB</u>		<u>20MG</u>	<u>A090798</u>	<u>006</u>	Apr 23, 2012
<u>AB</u>	AUROBINDO PHARMA LTD	<u>2.5MG</u>	<u>A202050</u>	<u>001</u>	Apr 23, 2012
<u>AB</u>		<u>5MG</u>	<u>A202050</u>	<u>002</u>	Apr 23, 2012
<u>AB</u>		<u>7.5MG</u>	<u>A202050</u>	<u>003</u>	Apr 23, 2012
<u>AB</u>		<u>10MG</u>	<u>A202050</u>	<u>004</u>	Apr 23, 2012
<u>AB</u>		<u>15MG</u>	<u>A202050</u>	<u>005</u>	Apr 23, 2012
<u>AB</u>		<u>20MG</u>	<u>A202050</u>	<u>006</u>	Apr 23, 2012
<u>AB</u>	CHARTWELL MOLECULAR	<u>2.5MG</u>	<u>A203333</u>	<u>001</u>	Mar 15, 2016
<u>AB</u>		<u>5MG</u>	<u>A203333</u>	<u>002</u>	Mar 15, 2016
<u>AB</u>		<u>7.5MG</u>	<u>A203333</u>	<u>003</u>	Mar 15, 2016
<u>AB</u>		<u>10MG</u>	<u>A203333</u>	<u>004</u>	Mar 15, 2016
<u>AB</u>		<u>15MG</u>	<u>A203333</u>	<u>005</u>	Mar 15, 2016
<u>AB</u>		<u>20MG</u>	<u>A203333</u>	<u>006</u>	Mar 15, 2016
<u>AB</u>	DR REDDYS LABS LTD	<u>2.5MG</u>	<u>A076255</u>	<u>001</u>	Apr 23, 2012
<u>AB</u>		<u>5MG</u>	<u>A076255</u>	<u>002</u>	Apr 23, 2012
<u>AB</u>		<u>7.5MG</u>	<u>A076255</u>	<u>003</u>	Apr 23, 2012
<u>AB</u>		<u>10MG</u>	<u>A076255</u>	<u>004</u>	Apr 23, 2012
<u>AB</u>		<u>15MG</u>	<u>A076133</u>	<u>001</u>	Apr 23, 2012
<u>AB</u>		<u>20MG</u>	<u>A076133</u>	<u>002</u>	Oct 24, 2011
<u>AB</u>	INDOCO	<u>2.5MG</u>	<u>A206155</u>	<u>001</u>	Jul 31, 2020
<u>AB</u>		<u>5MG</u>	<u>A206155</u>	<u>002</u>	Jul 31, 2020
<u>AB</u>		<u>7.5MG</u>	<u>A206155</u>	<u>003</u>	Jul 31, 2020
<u>AB</u>		<u>10MG</u>	<u>A206155</u>	<u>004</u>	Jul 31, 2020
<u>AB</u>		<u>15MG</u>	<u>A206155</u>	<u>005</u>	Jul 31, 2020
<u>AB</u>		<u>20MG</u>	<u>A206155</u>	<u>006</u>	Jul 31, 2020
<u>AB</u>	MACLEODS PHARMS LTD	<u>2.5MG</u>	<u>A202862</u>	<u>001</u>	Aug 15, 2014
<u>AB</u>		<u>5MG</u>	<u>A202862</u>	<u>002</u>	Aug 15, 2014
<u>AB</u>		<u>7.5MG</u>	<u>A202862</u>	<u>003</u>	Aug 15, 2014
<u>AB</u>		<u>10MG</u>	<u>A202862</u>	<u>004</u>	Aug 15, 2014
<u>AB</u>		<u>15MG</u>	<u>A202862</u>	<u>005</u>	Aug 15, 2014
<u>AB</u>		<u>20MG</u>	<u>A202862</u>	<u>006</u>	Aug 15, 2014
<u>AB</u>	ORBION PHARMS	<u>2.5MG</u>	<u>A202287</u>	<u>001</u>	Apr 23, 2012
<u>AB</u>		<u>5MG</u>	<u>A202287</u>	<u>002</u>	Apr 23, 2012
<u>AB</u>		<u>7.5MG</u>	<u>A202287</u>	<u>003</u>	Apr 23, 2012
<u>AB</u>		<u>10MG</u>	<u>A202287</u>	<u>004</u>	Apr 23, 2012
<u>AB</u>		<u>15MG</u>	<u>A202287</u>	<u>005</u>	Apr 23, 2012
<u>AB</u>		<u>20MG</u>	<u>A202287</u>	<u>006</u>	Apr 23, 2012

PRESCRIPTION DRUG PRODUCT LIST

3-340 (of 474)

OLANZAPINE

TABLET; ORAL

OLANZAPINE

<u>AB</u>	QILU	<u>2.5MG</u>	<u>A204319</u>	<u>001</u>	Jan 27, 2016
<u>AB</u>		<u>5MG</u>	<u>A204319</u>	<u>002</u>	Jan 27, 2016
<u>AB</u>		<u>7.5MG</u>	<u>A204319</u>	<u>003</u>	Jan 27, 2016
<u>AB</u>		<u>10MG</u>	<u>A204319</u>	<u>004</u>	Jan 27, 2016
<u>AB</u>		<u>15MG</u>	<u>A204319</u>	<u>005</u>	Jan 27, 2016
<u>AB</u>		<u>20MG</u>	<u>A204319</u>	<u>006</u>	Jan 27, 2016
<u>AB</u>	SUN PHARM INDS	<u>2.5MG</u>	<u>A091038</u>	<u>001</u>	Apr 23, 2012
<u>AB</u>		<u>5MG</u>	<u>A091038</u>	<u>002</u>	Apr 23, 2012
<u>AB</u>		<u>7.5MG</u>	<u>A091038</u>	<u>003</u>	Apr 23, 2012
<u>AB</u>		<u>10MG</u>	<u>A091038</u>	<u>004</u>	Apr 23, 2012
<u>AB</u>		<u>15MG</u>	<u>A091038</u>	<u>005</u>	Apr 23, 2012
<u>AB</u>		<u>20MG</u>	<u>A091038</u>	<u>006</u>	Apr 23, 2012
<u>AB</u>	ZYDUS PHARMS	<u>2.5MG</u>	<u>A090459</u>	<u>001</u>	Jul 16, 2018
<u>AB</u>		<u>5MG</u>	<u>A090459</u>	<u>002</u>	Jul 16, 2018
<u>AB</u>		<u>7.5MG</u>	<u>A090459</u>	<u>003</u>	Jul 16, 2018
<u>AB</u>		<u>10MG</u>	<u>A090459</u>	<u>004</u>	Jul 16, 2018
<u>AB</u>		<u>15MG</u>	<u>A090459</u>	<u>005</u>	Jul 16, 2018
<u>AB</u>		<u>20MG</u>	<u>A090459</u>	<u>006</u>	Jul 16, 2018

ZYPREXA

<u>AB</u>	+	LILLY	<u>2.5MG</u>	<u>N020592</u>	<u>001</u>	Sep 30, 1996
<u>AB</u>	+	!	<u>5MG</u>	<u>N020592</u>	<u>002</u>	Sep 30, 1996
<u>AB</u>	+		<u>7.5MG</u>	<u>N020592</u>	<u>003</u>	Sep 30, 1996
<u>AB</u>	+		<u>10MG</u>	<u>N020592</u>	<u>004</u>	Sep 30, 1996
<u>AB</u>	+		<u>15MG</u>	<u>N020592</u>	<u>005</u>	Sep 09, 1997
<u>AB</u>	+		<u>20MG</u>	<u>N020592</u>	<u>006</u>	Sep 09, 1997

TABLET, ORALLY DISINTEGRATING; ORAL

OLANZAPINE

<u>AB</u>	APOTEX INC	<u>5MG</u>	<u>A091265</u>	<u>001</u>	Oct 24, 2011
<u>AB</u>		<u>10MG</u>	<u>A091265</u>	<u>002</u>	Oct 24, 2011
<u>AB</u>		<u>15MG</u>	<u>A091265</u>	<u>003</u>	Oct 24, 2011
<u>AB</u>		<u>20MG</u>	<u>A091265</u>	<u>004</u>	Oct 24, 2011
<u>AB</u>	AUROBINDO PHARMA LTD	<u>5MG</u>	<u>A203708</u>	<u>001</u>	May 15, 2014
<u>AB</u>		<u>10MG</u>	<u>A203708</u>	<u>002</u>	May 15, 2014
<u>AB</u>		<u>15MG</u>	<u>A203708</u>	<u>003</u>	May 15, 2014
<u>AB</u>		<u>20MG</u>	<u>A203708</u>	<u>004</u>	May 15, 2014
<u>AB</u>	BARR LABS INC	<u>5MG</u>	<u>A077243</u>	<u>001</u>	Jan 30, 2012
<u>AB</u>		<u>10MG</u>	<u>A077243</u>	<u>002</u>	Jan 30, 2012
<u>AB</u>		<u>15MG</u>	<u>A077243</u>	<u>003</u>	Jan 30, 2012
<u>AB</u>		<u>20MG</u>	<u>A077243</u>	<u>004</u>	Jan 30, 2012
<u>AB</u>	CHARTWELL MOLECULAR	<u>5MG</u>	<u>A203456</u>	<u>001</u>	Mar 16, 2016
<u>AB</u>		<u>10MG</u>	<u>A203456</u>	<u>002</u>	Mar 16, 2016
<u>AB</u>		<u>15MG</u>	<u>A203456</u>	<u>003</u>	Mar 16, 2016
<u>AB</u>		<u>20MG</u>	<u>A203456</u>	<u>004</u>	Mar 16, 2016
<u>AB</u>	DR REDDYS LABS LTD	<u>5MG</u>	<u>A076534</u>	<u>001</u>	Oct 24, 2011
<u>AB</u>		<u>10MG</u>	<u>A076534</u>	<u>002</u>	Oct 24, 2011
<u>AB</u>		<u>15MG</u>	<u>A076534</u>	<u>003</u>	Oct 24, 2011
<u>AB</u>		<u>20MG</u>	<u>A076534</u>	<u>004</u>	Oct 24, 2011
<u>AB</u>	HEC PHARM	<u>5MG</u>	<u>A208146</u>	<u>001</u>	Jul 02, 2018
<u>AB</u>		<u>10MG</u>	<u>A208146</u>	<u>002</u>	Jul 02, 2018
<u>AB</u>		<u>15MG</u>	<u>A208146</u>	<u>003</u>	Jul 02, 2018
<u>AB</u>		<u>20MG</u>	<u>A208146</u>	<u>004</u>	Jul 02, 2018
<u>AB</u>	JUBILANT GENERICS	<u>5MG</u>	<u>A200221</u>	<u>001</u>	Sep 12, 2012
<u>AB</u>		<u>10MG</u>	<u>A200221</u>	<u>002</u>	Sep 12, 2012
<u>AB</u>		<u>15MG</u>	<u>A200221</u>	<u>003</u>	Sep 12, 2012
<u>AB</u>		<u>20MG</u>	<u>A200221</u>	<u>004</u>	Sep 12, 2012
<u>AB</u>	MACLEODS PHARMS LTD	<u>5MG</u>	<u>A203044</u>	<u>001</u>	Feb 20, 2015
<u>AB</u>		<u>10MG</u>	<u>A203044</u>	<u>002</u>	Feb 20, 2015
<u>AB</u>		<u>15MG</u>	<u>A203044</u>	<u>003</u>	Feb 20, 2015
<u>AB</u>		<u>20MG</u>	<u>A203044</u>	<u>004</u>	Feb 20, 2015
<u>AB</u>	MYLAN	<u>5MG</u>	<u>A202285</u>	<u>001</u>	May 12, 2014
<u>AB</u>		<u>10MG</u>	<u>A202285</u>	<u>002</u>	May 12, 2014
<u>AB</u>		<u>15MG</u>	<u>A202285</u>	<u>003</u>	May 12, 2014
<u>AB</u>		<u>20MG</u>	<u>A202285</u>	<u>004</u>	May 12, 2014
<u>AB</u>	ORBION PHARMS	<u>5MG</u>	<u>A202937</u>	<u>001</u>	Mar 02, 2015
<u>AB</u>		<u>10MG</u>	<u>A202937</u>	<u>002</u>	Mar 02, 2015
<u>AB</u>		<u>15MG</u>	<u>A202937</u>	<u>003</u>	Mar 02, 2015
<u>AB</u>		<u>20MG</u>	<u>A202937</u>	<u>004</u>	Mar 02, 2015
<u>AB</u>	STRIDES PHARMA	<u>5MG</u>	<u>A078109</u>	<u>001</u>	Oct 24, 2011
<u>AB</u>		<u>10MG</u>	<u>A078109</u>	<u>002</u>	Oct 24, 2011

PRESCRIPTION DRUG PRODUCT LIST

3-341 (of 474)

OLANZAPINE

TABLET, ORALLY DISINTEGRATING; ORAL

OLANZAPINE

AB		15MG	A078109 003	Oct 24, 2011
AB		20MG	A078109 004	Oct 24, 2011
AB	SUN PHARM INDS	5MG	A090881 001	Feb 28, 2012
AB		10MG	A090881 002	Feb 28, 2012
AB		15MG	A090881 003	Feb 28, 2012
AB		20MG	A090881 004	Feb 28, 2012
AB	TORRENT	5MG	A091415 001	Oct 25, 2011
AB		10MG	A091415 002	Oct 25, 2011
AB		15MG	A091415 003	Oct 25, 2011
AB		20MG	A091415 004	Oct 25, 2011

ZYPREXA ZYDIS

AB	+! LILLY	5MG	N021086 001	Apr 06, 2000
AB	+	10MG	N021086 002	Apr 06, 2000
AB	+	15MG	N021086 003	Apr 06, 2000
AB	+	20MG	N021086 004	Apr 06, 2000

OLANZAPINE PAMOATE

SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR

ZYPREXA RELPREVV

+	ELI LILLY CO	EQ 210MG BASE/VIAL	N022173 001	Dec 11, 2009
+		EQ 300MG BASE/VIAL	N022173 002	Dec 11, 2009
+!		EQ 405MG BASE/VIAL	N022173 003	Dec 11, 2009

OLANZAPINE; SAMIDORPHAN L-MALATE

TABLET; ORAL

LYBALVI

+	ALKERMES INC	5MG; EQ 10MG BASE	N213378 001	May 28, 2021
+		10MG; EQ 10MG BASE	N213378 002	May 28, 2021
+		15MG; EQ 10MG BASE	N213378 003	May 28, 2021
+		20MG; EQ 10MG BASE	N213378 004	May 28, 2021

OLAPARIB

TABLET; ORAL

LYNPARZA

+	ASTRAZENECA	100MG	N208558 001	Aug 17, 2017
+!		150MG	N208558 002	Aug 17, 2017

OLICERIDINE

SOLUTION; INTRAVENOUS

OLINVYK

+	TREVENA	1MG/ML (1MG/ML)	N210730 001	Oct 30, 2020
+		2MG/2ML (1MG/ML)	N210730 002	Oct 30, 2020
+		30MG/30ML (1MG/ML)	N210730 003	Oct 30, 2020

OLIVE OIL; SOYBEAN OIL

EMULSION; INTRAVENOUS

CLINOLIPID 20%

+	BAXTER HLTHCARE CORP	16% (160GM/1000ML); 4% (40GM/1000ML)	N204508 001	Oct 03, 2013

OLMESARTAN MEDOXOMIL

TABLET; ORAL

BENICAR

AB	+	COSETTE	5MG	N021286 001	Apr 25, 2002
AB	+		20MG	N021286 003	Apr 25, 2002
AB	+!		40MG	N021286 004	Apr 25, 2002

OLMESARTAN MEDOXOMIL

AB	ACCORD HLTHCARE	5MG	A207662 001	Apr 24, 2017
AB		20MG	A207662 002	Apr 24, 2017
AB		40MG	A207662 003	Apr 24, 2017
AB	ALEMBIC PHARMS	5MG	A203012 001	Apr 24, 2017
AB		20MG	A203012 002	Apr 24, 2017
AB		40MG	A203012 003	Apr 24, 2017
AB	ALKEM LABS LTD	5MG	A206763 001	Apr 24, 2017
AB		20MG	A206763 002	Apr 24, 2017
AB		40MG	A206763 003	Apr 24, 2017
AB	AUROBINDO PHARMA	5MG	A204798 001	Apr 24, 2017
AB		20MG	A204798 002	Apr 24, 2017
AB		40MG	A204798 003	Apr 24, 2017
AB	GLENMARK PHARMS LTD	5MG	A203281 001	May 25, 2017
AB		20MG	A203281 002	May 25, 2017
AB		40MG	A203281 003	May 25, 2017
AB	MACLEODS PHARMS LTD	5MG	A204814 001	Apr 24, 2017

PRESCRIPTION DRUG PRODUCT LIST

3-342 (of 474)

OLMESARTAN MEDOXOMIL

TABLET; ORAL

OLMESARTAN MEDOXOMIL

AB		20MG	A204814	002	Apr 24, 2017
AB		40MG	A204814	003	Apr 24, 2017
AB	MICRO LABS	5MG	A206372	001	Sep 17, 2019
AB		20MG	A206372	002	Sep 17, 2019
AB		40MG	A206372	003	Sep 17, 2019
AB	PRINSTON INC	5MG	A206720	001	Dec 02, 2022
AB		20MG	A206720	002	Dec 02, 2022
AB		40MG	A206720	003	Dec 02, 2022
AB	QILU	5MG	A210552	001	Jan 10, 2019
AB		20MG	A210552	002	Jan 10, 2019
AB		40MG	A210552	003	Jan 10, 2019
AB	SCIEGEN PHARMS INC	5MG	A208130	001	Jun 29, 2018
AB		20MG	A208130	002	Jun 29, 2018
AB		40MG	A208130	003	Jun 29, 2018
AB	SUNSHINE	5MG	A211049	001	Feb 22, 2019
AB		20MG	A211049	002	Feb 22, 2019
AB		40MG	A211049	003	Feb 22, 2019
AB	TORRENT	5MG	A202375	001	Apr 24, 2017
AB		20MG	A202375	002	Apr 24, 2017
AB		40MG	A202375	003	Apr 24, 2017
AB	UMEDICA LABS PVT LTD	5MG	A207135	001	Jul 18, 2019
AB		20MG	A207135	002	Jul 18, 2019
AB		40MG	A207135	003	Jul 18, 2019
AB	ZYDUS PHARMS	5MG	A205192	001	Apr 24, 2017
AB		20MG	A205192	002	Apr 24, 2017
AB		40MG	A205192	003	Apr 24, 2017

OLODATEROL HYDROCHLORIDE

SPRAY, METERED; INHALATION

STRIVERDI RESPIMAT

+! BOEHRINGER EQ 0.0025MG BASE/INH
INGELHEIM

N203108 001 Jul 31, 2014

OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE

SPRAY, METERED; INHALATION

STIOLTO RESPIMAT

+! BOEHRINGER EQ 0.0025MG BASE/INH; EQ 0.0025MG
INGELHEIM BASE/INH

N206756 001 May 21, 2015

OLOPATADINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

OLOPATADINE HYDROCHLORIDE

SOMERSET THERAPS EQ 0.1% BASE
LLC

A206306 001 Dec 07, 2015

SPRAY, METERED; NASAL

OLOPATADINE HYDROCHLORIDE

AB	AKORN	0.665MG/SPRAY	A213757	001	Aug 19, 2020
AB	AMNEAL	0.665MG/SPRAY	A210901	001	Jan 28, 2020
AB	APOTEX INC	0.665MG/SPRAY	A091572	001	Oct 08, 2014
AB	PADAGIS ISRAEL	0.665MG/SPRAY	A202853	001	Jan 31, 2017
PATANASE					
AB	+! NOVARTIS	0.665MG/SPRAY	N021861	001	Apr 15, 2008

OLSALAZINE SODIUM

CAPSULE; ORAL

DIPENTUM

+! MYLAN SPCLT VIATRIS 250MG

N019715 001 Jul 31, 1990

OLUTASIDENIB

CAPSULE; ORAL

REZLIDHIA

+! RIGEL PHARMS INC 150MG

N215814 001 Dec 01, 2022

OMACETAXINE MEPESUCCINATE

POWDER; SUBCUTANEOUS

SYNRIBO

+! TEVA PHARMS INTL 3.5MG/VIAL

N203585 001 Oct 26, 2012

PRESCRIPTION DRUG PRODUCT LIST

3-343 (of 474)

OMADACYCLINE TOSYLATE

POWDER; INTRAVENOUS

NUZYRA

+! PARATEK PHARMS INC EQ 100MG BASE/VIAL

N209817 001 Oct 02, 2018

TABLET; ORAL

NUZYRA

+! PARATEK PHARMS INC EQ 150MG BASE

N209816 001 Oct 02, 2018

OMEGA-3-ACID ETHYL ESTERS

CAPSULE; ORAL

LOVAZAAB +! WOODWARD1GM CONTAINS AT LEAST 900MG OF THE
ETHYL ESTERS OF OMEGA-3 FATTY ACIDSN021654 001 Nov 10, 2004OMEGA-3-ACID ETHYL ESTERSAB AMNEAL PHARMS1GM CONTAINS AT LEAST 900MG OF THE
ETHYL ESTERS OF OMEGA-3 FATTY ACIDSA204940 001 Nov 27, 2015AB APOTEX1GM CONTAINS AT LEAST 900MG OF THE
ETHYL ESTERS OF OMEGA-3 FATTY ACIDSA090973 001 Sep 30, 2014AB ASCENT PHARMS INC1GM CONTAINS AT LEAST 900MG OF THE
ETHYL ESTERS OF OMEGA-3 FATTY ACIDSA207420 001 Feb 25, 2019AB BIONPHARMA INC1GM CONTAINS AT LEAST 900MG OF THE
ETHYL ESTERS OF OMEGA-3 FATTY ACIDSA206455 001 Aug 07, 2019AB CSPEC-NBP PHARM1GM CONTAINS AT LEAST 900MG OF THE
ETHYL ESTERS OF OMEGA-3 FATTY ACIDSA211979 001 May 12, 2020AB GLW1GM CONTAINS AT LEAST 900MG OF THE
ETHYL ESTERS OF OMEGA-3 FATTY ACIDSA091028 001 Apr 07, 2014AB MANKIND PHARMA1GM CONTAINS AT LEAST 900MG OF THE
ETHYL ESTERS OF OMEGA-3 FATTY ACIDSA212504 001 Aug 19, 2020AB PURACAP PHARM LLC1GM CONTAINS AT LEAST 900MG OF THE
ETHYL ESTERS OF OMEGA-3 FATTY ACIDSA210093 001 Jun 15, 2020AB SOFGEN PHARMS1GM CONTAINS AT LEAST 900MG OF THE
ETHYL ESTERS OF OMEGA-3 FATTY ACIDSA211355 001 Jul 10, 2019AB STRIDES PHARMA1GM CONTAINS AT LEAST 900MG OF THE
ETHYL ESTERS OF OMEGA-3 FATTY ACIDSA203893 001 Sep 19, 2017AB SUN PHARM1GM CONTAINS AT LEAST 900MG OF THE
ETHYL ESTERS OF OMEGA-3 FATTY ACIDSA210834 001 Jan 09, 2020OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL

OMEPRAZOLEAB ACTAVIS LABS FL INC 10MGA075347 001 May 30, 2008AB 20MGA075347 002 May 30, 2008AB 40MGA075347 003 May 30, 2008AB APOTEX 10MGA076048 001 Oct 22, 2007AB 20MGA076048 002 Oct 22, 2007AB 40MGA076048 003 Jan 21, 2009AB AUROBINDO PHARMA 10MGA203270 001 Aug 19, 2015AB 20MGA203270 002 Aug 19, 2015AB 40MGA203270 003 Aug 19, 2015AB BRECKENRIDGE 10MGA203481 001 Jul 03, 2017AB 20MGA203481 002 Jul 03, 2017AB 40MGA203481 003 Jul 03, 2017AB DR REDDYS LABS LTD 10MGA075576 003 Oct 22, 2007AB 10MGA078490 002 Mar 16, 2009AB 20MGA075576 002 Oct 22, 2007AB 20MGA078490 003 Mar 16, 2009AB 40MGA075576 001 Jan 21, 2009AB 40MGA078490 001 Apr 17, 2009AB GLENMARK GENERICS 10MGA091672 001 Oct 31, 2014AB 20MGA091672 002 Oct 31, 2014AB 40MGA091672 003 Oct 31, 2014AB HETERO LABS LTD III 10MGA204012 001 Sep 26, 2019AB 20MGA204012 002 Sep 26, 2019AB IMPAX LABS 10MGA075785 001 Oct 22, 2007AB 20MGA075785 002 Oct 22, 2007AB 40MGA075785 003 Jan 21, 2009AB LANNETT CO INC 10MGA075410 001 Nov 01, 2002AB 20MGA075410 002 Nov 01, 2002AB 40MGA075410 003 Jan 23, 2009AB SANDOZ 10MGA075757 001 Jan 28, 2003AB ! 20MGA075757 002 Jan 28, 2003AB ! 40MGA076515 001 Jan 21, 2009AB TEVA PHARMS USA 20MGA204661 001 Jun 13, 2017AB XIROMED 10MGA212977 001 Dec 10, 2020

PRESCRIPTION DRUG PRODUCT LIST

3-344 (of 474)

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL

OMEPRAZOLE

<u>AB</u>		<u>20MG</u>	<u>A212977</u>	<u>002</u>	Dec 10, 2020
<u>AB</u>	ZYDUS PHARMS USA	<u>10MG</u>	<u>A091352</u>	<u>001</u>	Nov 19, 2012
	INC				
<u>AB</u>		<u>20MG</u>	<u>A091352</u>	<u>002</u>	Nov 19, 2012
<u>AB</u>		<u>40MG</u>	<u>A091352</u>	<u>003</u>	Nov 19, 2012

OMEPRAZOLE MAGNESIUM

FOR SUSPENSION, DELAYED RELEASE;ORAL

PRIOLOSEC

+	COVIS	EQ 2.5MG BASE/PACKET	N022056	001	Mar 20, 2008
+	!	EQ 10MG BASE/PACKET	N022056	002	Mar 20, 2008

OMEPRAZOLE; SODIUM BICARBONATE

CAPSULE;ORAL

OMEPRAZOLE AND SODIUM BICARBONATE

<u>AB</u>	AJANTA PHARMA LTD	<u>20MG;1.1GM</u>	<u>A204228</u>	<u>001</u>	Jul 15, 2016
<u>AB</u>		<u>40MG;1.1GM</u>	<u>A204228</u>	<u>002</u>	Jul 15, 2016
<u>AB</u>	AUROLIFE PHARMA LLC	<u>20MG;1.1GM</u>	<u>A204922</u>	<u>001</u>	Aug 19, 2016
<u>AB</u>		<u>40MG;1.1GM</u>	<u>A204922</u>	<u>002</u>	Aug 19, 2016
<u>AB</u>	DR REDDYS	<u>20MG;1.1GM</u>	<u>A204068</u>	<u>001</u>	Jul 15, 2016
<u>AB</u>		<u>40MG;1.1GM</u>	<u>A204068</u>	<u>002</u>	Jul 15, 2016
<u>AB</u>	GUARDIAN DRUG	<u>20MG;1.1GM</u>	<u>A212587</u>	<u>001</u>	Apr 30, 2020
<u>AB</u>		<u>40MG;1.1GM</u>	<u>A212587</u>	<u>002</u>	Apr 30, 2020
<u>AB</u>	SCIEGEN PHARMS INC	<u>20MG;1.1GM</u>	<u>A207476</u>	<u>001</u>	Dec 06, 2016
<u>AB</u>		<u>40MG;1.1GM</u>	<u>A207476</u>	<u>002</u>	Dec 06, 2016
<u>AB</u>	ZYDUS PHARMS	<u>20MG;1.1GM</u>	<u>A203290</u>	<u>001</u>	May 25, 2018
<u>AB</u>		<u>40MG;1.1GM</u>	<u>A203290</u>	<u>002</u>	May 25, 2018

ZEGERID

<u>AB</u>	+	SALIX	<u>20MG;1.1GM</u>	<u>N021849</u>	<u>001</u>	Feb 27, 2006
<u>AB</u>	+	!	<u>40MG;1.1GM</u>	<u>N021849</u>	<u>002</u>	Feb 27, 2006

FOR SUSPENSION;ORAL

OMEPRAZOLE AND SODIUM BICARBONATE

<u>AB</u>	AJANTA PHARMA LTD	<u>20MG/PACKET;1.68GM/PACKET</u>	<u>A205545</u>	<u>001</u>	Jul 27, 2016
<u>AB</u>		<u>40MG/PACKET;1.68GM/PACKET</u>	<u>A205545</u>	<u>002</u>	Jul 27, 2016
<u>AB</u>	STRIDES PHARMA	<u>20MG/PACKET;1.68GM/PACKET</u>	<u>A079182</u>	<u>001</u>	Apr 19, 2013
<u>AB</u>		<u>40MG/PACKET;1.68GM/PACKET</u>	<u>A079182</u>	<u>002</u>	Apr 19, 2013

ZEGERID

<u>AB</u>	+	SALIX	<u>20MG/PACKET;1.68GM/PACKET</u>	<u>N021636</u>	<u>001</u>	Jun 15, 2004	
<u>AB</u>	+	!	<u>40MG/PACKET;1.68GM/PACKET</u>	<u>N021636</u>	<u>002</u>	Dec 21, 2004	
KONVOMEF							
	+	!	AZURITY	2MG/ML;84MG/ML	N213593	001	Aug 30, 2022

OMIDENEPAG ISOPROPYL

SOLUTION;OPHTHALMIC

OMLONTI

+	SANTEN	0.002%	N215092	001	Sep 22, 2022

ONDANSETRON

TABLET, ORALLY DISINTEGRATING;ORAL

ONDANSETRON

<u>AB</u>	AUROBINDO PHARMA	<u>4MG</u>	<u>A090469</u>	<u>001</u>	Apr 12, 2010
<u>AB</u>	!	<u>8MG</u>	<u>A090469</u>	<u>002</u>	Apr 12, 2010
<u>AB</u>	CHARTWELL MOLECULES	<u>4MG</u>	<u>A077406</u>	<u>003</u>	Dec 26, 2006
<u>AB</u>		<u>8MG</u>	<u>A077406</u>	<u>004</u>	Dec 26, 2006
<u>AB</u>	GLENMARK GENERICS	<u>4MG</u>	<u>A078152</u>	<u>001</u>	Jun 27, 2007
<u>AB</u>		<u>8MG</u>	<u>A078152</u>	<u>002</u>	Jun 27, 2007
<u>AB</u>	MYLAN	<u>4MG</u>	<u>A078139</u>	<u>001</u>	Jun 25, 2007
<u>AB</u>		<u>8MG</u>	<u>A078139</u>	<u>002</u>	Jun 25, 2007
<u>AB</u>	SANDOZ	<u>4MG</u>	<u>A078050</u>	<u>001</u>	Aug 13, 2007
<u>AB</u>		<u>8MG</u>	<u>A078050</u>	<u>002</u>	Aug 13, 2007
<u>AB</u>	SUN PHARM INDS	<u>4MG</u>	<u>A077557</u>	<u>001</u>	Aug 02, 2007
<u>AB</u>		<u>8MG</u>	<u>A077557</u>	<u>002</u>	Aug 02, 2007
<u>AB</u>	SUN PHARM INDS LTD	<u>4MG</u>	<u>A078602</u>	<u>001</u>	Feb 24, 2011
<u>AB</u>		<u>8MG</u>	<u>A078602</u>	<u>002</u>	Feb 24, 2011
	CHARTWELL MOLECULES	16MG	A077406	001	Dec 26, 2006
		24MG	A077406	002	Dec 26, 2006

PRESCRIPTION DRUG PRODUCT LIST

3-345 (of 474)

ONDANSETRON HYDROCHLORIDE

INJECTABLE; INJECTION

ONDANSETRON HYDROCHLORIDE

<u>AP</u>	ACCORD HLTHCARE	<u>EQ 2MG BASE/ML</u>	<u>A206846</u>	<u>001</u>	Jul 13, 2015
<u>AP</u>	FRESENIUS KABI USA	<u>EQ 2MG BASE/ML</u>	<u>A076974</u>	<u>001</u>	Dec 26, 2006
<u>AP</u>	GLAND PHARMA LTD	<u>EQ 2MG BASE/ML</u>	<u>A079224</u>	<u>001</u>	Sep 25, 2009
<u>AP</u>	!	<u>EQ 2MG BASE/ML</u>	<u>A090648</u>	<u>001</u>	Jun 15, 2012
<u>AP</u>	HIKMA	<u>EQ 2MG BASE/ML</u>	<u>A076967</u>	<u>001</u>	Dec 26, 2006
<u>AP</u>		<u>EQ 2MG BASE/ML</u>	<u>A077365</u>	<u>001</u>	Dec 26, 2006
<u>AP</u>	HIKMA FARMACEUTICA	<u>EQ 2MG BASE/ML</u>	<u>A076781</u>	<u>001</u>	Dec 26, 2006
<u>AP</u>	HOSPIRA	<u>EQ 2MG BASE/ML</u>	<u>A077473</u>	<u>001</u>	Dec 26, 2006
<u>AP</u>	!	<u>EQ 2MG BASE/ML</u>	<u>A203711</u>	<u>001</u>	Sep 08, 2014
<u>AP</u>	SANDOZ INC	<u>EQ 2MG BASE/ML</u>	<u>A077430</u>	<u>001</u>	Jun 27, 2007
<u>AP</u>	WOCKHARDT	<u>EQ 2MG BASE/ML</u>	<u>A077577</u>	<u>001</u>	Dec 26, 2006

ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE

<u>AP</u>	ACCORD HLTHCARE	<u>EQ 2MG BASE/ML</u>	<u>A206845</u>	<u>001</u>	Mar 10, 2016
<u>AP</u>	!	<u>EQ 2MG BASE/ML</u>	<u>A078287</u>	<u>001</u>	Feb 22, 2013
<u>AP</u>	FRESENIUS KABI USA	<u>EQ 2MG BASE/ML</u>	<u>A076972</u>	<u>001</u>	Dec 26, 2006
<u>AP</u>		<u>EQ 2MG BASE/ML</u>	<u>A202253</u>	<u>001</u>	Jul 19, 2013
<u>AP</u>	HIKMA	<u>EQ 2MG BASE/ML</u>	<u>A077011</u>	<u>001</u>	Dec 26, 2006
<u>AP</u>		<u>EQ 2MG BASE/ML</u>	<u>A077541</u>	<u>001</u>	Dec 26, 2006
<u>AP</u>	HOSPIRA	<u>EQ 2MG BASE/ML</u>	<u>A077548</u>	<u>001</u>	Dec 26, 2006
<u>AP</u>	SANDOZ INC	<u>EQ 2MG BASE/ML</u>	<u>A077551</u>	<u>001</u>	Jun 27, 2007
<u>AP</u>	WOCKHARDT	<u>EQ 2MG BASE/ML</u>	<u>A077716</u>	<u>001</u>	Dec 26, 2006

SOLUTION; ORAL

ONDANSETRON HYDROCHLORIDE

<u>AA</u>	AMNEAL PHARMS	<u>EQ 4MG BASE/5ML</u>	<u>A091483</u>	<u>001</u>	Jan 31, 2011
<u>AA</u>	AUROBINDO PHARMA	<u>EQ 4MG BASE/5ML</u>	<u>A078776</u>	<u>001</u>	Nov 28, 2007
<u>AA</u>	!	<u>EQ 4MG BASE/5ML</u>	<u>A076960</u>	<u>001</u>	Dec 26, 2006
<u>AA</u>	LANNETT CO INC	<u>EQ 4MG BASE/5ML</u>	<u>A091342</u>	<u>001</u>	Jan 27, 2011
<u>AA</u>	PHARM ASSOC	<u>EQ 4MG BASE/5ML</u>	<u>A078127</u>	<u>001</u>	Jun 25, 2007
<u>AA</u>	TARO	<u>EQ 4MG BASE/5ML</u>	<u>A077009</u>	<u>001</u>	Nov 30, 2007

TABLET; ORAL

ONDANSETRON HYDROCHLORIDE

<u>AB</u>	APOTEX	<u>EQ 4MG BASE</u>	<u>A077306</u>	<u>001</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A077306</u>	<u>002</u>	Jun 25, 2007
<u>AB</u>	AUROBINDO PHARMA	<u>EQ 4MG BASE</u>	<u>A078539</u>	<u>001</u>	Jul 31, 2007
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A078539</u>	<u>002</u>	Jul 31, 2007
<u>AB</u>	CASI PHARMS INC	<u>EQ 4MG BASE</u>	<u>A077517</u>	<u>001</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A077517</u>	<u>002</u>	Jun 25, 2007
<u>AB</u>	CHARTWELL MOLECULES	<u>EQ 4MG BASE</u>	<u>A077303</u>	<u>001</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A077303</u>	<u>002</u>	Jun 25, 2007
<u>AB</u>	!	<u>EQ 24MG BASE</u>	<u>A077303</u>	<u>004</u>	Jun 25, 2007
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 4MG BASE</u>	<u>A076183</u>	<u>003</u>	Dec 26, 2006
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A076183</u>	<u>002</u>	Dec 26, 2006
<u>AB</u>	GLENMARK GENERICS	<u>EQ 4MG BASE</u>	<u>A077535</u>	<u>001</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A077535</u>	<u>002</u>	Jun 25, 2007
<u>AB</u>	IPCA LABS LTD	<u>EQ 4MG BASE</u>	<u>A203761</u>	<u>001</u>	Jan 23, 2014
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A203761</u>	<u>002</u>	Jan 23, 2014
<u>AB</u>	NATCO PHARMA LTD	<u>EQ 4MG BASE</u>	<u>A077851</u>	<u>001</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A077851</u>	<u>002</u>	Jun 25, 2007
<u>AB</u>	SUN PHARM INDS (IN)	<u>EQ 4MG BASE</u>	<u>A077050</u>	<u>001</u>	Jun 25, 2007
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A077050</u>	<u>002</u>	Jun 25, 2007

OPICAPONE

CAPSULE; ORAL

ONGENTYS

+	NEUROCRINE	25MG	N212489	001	Apr 24, 2020
+	!	50MG	N212489	002	Apr 24, 2020

ORITAVANCIN DIPHOSPHATE

POWDER; INTRAVENOUS

KIMYRSA

+	MELINTA THERAP	EQ 1.2GM BASE/VIAL	N214155	001	Mar 12, 2021

ORBACTIV

+	MELINTA THERAP	EQ 400MG BASE/VIAL	N206334	001	Aug 06, 2014

PRESCRIPTION DRUG PRODUCT LIST

3-346 (of 474)

ORLISTAT

CAPSULE; ORAL

XENICAL

+! CHEPLAPHARM

120MG

N020766 001 Apr 23, 1999

ORPHENADRINE CITRATE

INJECTABLE; INJECTION

ORPHENADRINE CITRATEAP ! AKORN30MG/MLA040484 001 May 24, 2006AP HIKMA30MG/MLA040463 001 Mar 04, 2003AP SAGENT PHARMS30MG/MLA090585 001 Aug 30, 2011AP WATSON LABS30MG/MLA084779 001 Mar 15, 1982

TABLET, EXTENDED RELEASE; ORAL

ORPHENADRINE CITRATEAB ANDA REPOSITORY100MGA040249 001 Jan 29, 1999AB BAYSHORE PHARMS LLC100MGA091158 001 Jul 27, 2012AB LUPIN100MGA040284 001 Jun 19, 1998AB ! SANDOZ100MGA040327 001 Feb 15, 2000OSELTAMIVIR PHOSPHATE

CAPSULE; ORAL

OSELTAMIVIR PHOSPHATEAB ACCORD HLTHCAREEQ 30MG BASEA214726 001 Jul 25, 2022ABEQ 45MG BASEA214726 002 Jul 25, 2022ABEQ 75MG BASEA214726 003 Jul 25, 2022AB ALEMBIC PHARMSEQ 30MG BASEA211823 001 Jun 24, 2019ABEQ 45MG BASEA211823 002 Jun 24, 2019ABEQ 75MG BASEA211823 003 Jun 24, 2019AB AMNEAL PHARMSEQ 30MG BASEA209093 001 May 17, 2017ABEQ 45MG BASEA209093 002 May 17, 2017ABEQ 75MG BASEA209093 003 May 17, 2017AB EPIC PHARMA LLCEQ 30MG BASEA215208 001 Oct 01, 2021ABEQ 45MG BASEA215208 002 Oct 01, 2021ABEQ 75MG BASEA215208 003 Oct 01, 2021AB HETERO LABS LTD IIIEQ 30MG BASEA209438 001 Feb 23, 2018ABEQ 45MG BASEA209438 002 Feb 23, 2018ABEQ 75MG BASEA209438 003 Feb 23, 2018AB LUPINEQ 30MG BASEA208348 001 Jan 09, 2018ABEQ 45MG BASEA208348 002 Jan 09, 2018ABEQ 75MG BASEA208348 003 Jan 09, 2018AB MACLEODS PHARMS LTDEQ 30MG BASEA207211 001 Sep 14, 2017ABEQ 45MG BASEA207211 002 Sep 14, 2017ABEQ 75MG BASEA207211 003 Sep 14, 2017AB MSNEQ 30MG BASEA212544 001 May 20, 2020ABEQ 45MG BASEA212544 002 May 20, 2020ABEQ 75MG BASEA212544 003 May 20, 2020AB NATCOEQ 30MG BASEA202595 001 Aug 03, 2016ABEQ 45MG BASEA202595 002 Aug 03, 2016ABEQ 75MG BASEA202595 003 Aug 03, 2016AB STRIDES PHARMAEQ 30MG BASEA209421 001 Jun 08, 2018ABEQ 45MG BASEA209421 002 Jun 08, 2018ABEQ 75MG BASEA209421 003 Jun 08, 2018AB ZYDUS PHARMSEQ 30MG BASEA208578 001 Feb 24, 2017ABEQ 45MG BASEA208578 002 Feb 24, 2017ABEQ 75MG BASEA208578 003 Feb 24, 2017TAMIFLUAB + ROCHEEQ 30MG BASEN021087 003 Jul 02, 2007AB +EQ 45MG BASEN021087 002 Jul 02, 2007AB +!EQ 75MG BASEN021087 001 Oct 27, 1999

FOR SUSPENSION; ORAL

OSELTAMIVIR PHOSPHATEAB AJANTA PHARMA LTDEQ 6MG BASE/MLA212784 001 May 27, 2020AB ALVOGENEQ 6MG BASE/MLA208823 001 Oct 31, 2017AB AMNEAL PHARMS NYEQ 6MG BASE/MLA210186 001 Feb 27, 2018AB APTAPHARMA INCEQ 6MG BASE/MLA212858 001 Aug 30, 2021AB HETERO LABS LTD VEQ 6MG BASE/MLA209590 001 Mar 28, 2022AB LUPINEQ 6MG BASE/MLA208347 001 Feb 20, 2018AB MSNEQ 6MG BASE/MLA215313 001 May 02, 2022AB STRIDES PHARMAEQ 6MG BASE/MLA211894 001 Jan 13, 2022AB SUNSHINEEQ 6MG BASE/MLA213594 001 Jan 05, 2022AB TEVA PHARMS USAEQ 6MG BASE/MLA211125 001 Feb 27, 2019AB ZYDUS PHARMSEQ 6MG BASE/MLA209113 001 Sep 14, 2017

PRESCRIPTION DRUG PRODUCT LIST

3-347 (of 474)

OSELTAMIVIR PHOSPHATE

FOR SUSPENSION; ORAL

TAMIFLU

AB	+!	ROCHE	<u>EQ 6MG BASE/ML</u>	<u>N021246</u>	<u>002</u>	Mar 21, 2011

OSILODROSTAT PHOSPHATE

TABLET; ORAL

ISTURISA

+	RECORDATI RARE	EQ 1MG BASE	N212801	001	Mar 06, 2020
+		EQ 5MG BASE	N212801	002	Mar 06, 2020
+	!	EQ 10MG BASE	N212801	003	Mar 06, 2020

OSIMERTINIB MESYLATE

TABLET; ORAL

TAGRISSO

+	ASTRAZENECA	EQ 40MG BASE	N208065	001	Nov 13, 2015
+	!	EQ 80MG BASE	N208065	002	Nov 13, 2015

OSPEMIFENE

TABLET; ORAL

OSPHENA

+	!	DUCHESNAY	60MG	N203505	001	Feb 26, 2013

OTECSECONAZOLE

CAPSULE; ORAL

VIVJOA

+	!	MYCOVIA PHARMS	150MG	N215888	001	Apr 26, 2022

OXACILLIN SODIUM

INJECTABLE; INJECTION

OXACILLIN SODIUM

AP		EUGIA PHARMA SPECLTS	<u>EQ 1GM BASE/VIAL</u>	<u>A201539</u>	<u>001</u>	Jan 18, 2013	
AP			<u>EQ 2GM BASE/VIAL</u>	<u>A201539</u>	<u>002</u>	Jan 18, 2013	
AP			<u>EQ 10GM BASE/VIAL</u>	<u>A201538</u>	<u>001</u>	Jan 18, 2013	
AP		FRESENIUS KABI USA	<u>EQ 1GM BASE/VIAL</u>	<u>A206198</u>	<u>001</u>	Jul 20, 2020	
AP			<u>EQ 2GM BASE/VIAL</u>	<u>A206198</u>	<u>002</u>	Jul 20, 2020	
AP			<u>EQ 10GM BASE/VIAL</u>	<u>A206199</u>	<u>001</u>	Jul 27, 2020	
AP		PIRAMAL CRITICAL	<u>EQ 10GM BASE/VIAL</u>	<u>A206760</u>	<u>001</u>	Oct 26, 2017	
AP	!	SAGENT PHARMS	<u>EQ 1GM BASE/VIAL</u>	<u>A091246</u>	<u>001</u>	Mar 30, 2012	
AP	!		<u>EQ 2GM BASE/VIAL</u>	<u>A091246</u>	<u>002</u>	Mar 30, 2012	
AP	!		<u>EQ 10GM BASE/VIAL</u>	<u>A091245</u>	<u>001</u>	Mar 30, 2012	
AP		STERISCIENCE	<u>EQ 2GM BASE/VIAL</u>	<u>A091486</u>	<u>002</u>	Aug 25, 2014	
AP		WOCKHARDT BIO AG	<u>EQ 1GM BASE/VIAL</u>	<u>A207147</u>	<u>001</u>	Jul 31, 2017	
AP			<u>EQ 2GM BASE/VIAL</u>	<u>A207147</u>	<u>002</u>	Jul 31, 2017	
AP			<u>EQ 10GM BASE/VIAL</u>	<u>A207148</u>	<u>001</u>	Nov 24, 2017	
		BACTOCILL IN PLASTIC CONTAINER					
	+	!	BAXTER HLTHCARE	EQ 20MG BASE/ML	N050640	001	Oct 26, 1989
	+	!		EQ 40MG BASE/ML	N050640	002	Oct 26, 1989

OXALIPLATIN

INJECTABLE; INTRAVENOUS

ELOXATIN

AP	+!	SANOFI AVENTIS US	<u>50MG/10ML (5MG/ML)</u>	<u>N021759</u>	<u>001</u>	Jan 31, 2005
AP	+!		<u>100MG/20ML (5MG/ML)</u>	<u>N021759</u>	<u>002</u>	Jan 31, 2005

OXALIPLATIN

AP		ACCORD HLTHCARE	<u>50MG/10ML (5MG/ML)</u>	<u>A207474</u>	<u>001</u>	Mar 21, 2017
AP			<u>100MG/20ML (5MG/ML)</u>	<u>A207474</u>	<u>002</u>	Mar 21, 2017
AP		ACTAVIS LLC	<u>50MG/10ML (5MG/ML)</u>	<u>A204880</u>	<u>001</u>	Mar 05, 2018
AP			<u>100MG/20ML (5MG/ML)</u>	<u>A204880</u>	<u>002</u>	Mar 05, 2018
AP	!	ACTAVIS TOTOWA	<u>50MG/VIAL</u>	<u>A078803</u>	<u>001</u>	Aug 08, 2012
AP	!		<u>100MG/VIAL</u>	<u>A078803</u>	<u>002</u>	Aug 08, 2012
AP		EUGIA PHARMA	<u>50MG/10ML (5MG/ML)</u>	<u>A205529</u>	<u>001</u>	Sep 06, 2017
AP			<u>100MG/20ML (5MG/ML)</u>	<u>A205529</u>	<u>002</u>	Sep 06, 2017
AP		FRESENIUS KABI USA	<u>50MG/10ML (5MG/ML)</u>	<u>A078811</u>	<u>001</u>	Jun 10, 2010
AP			<u>100MG/20ML (5MG/ML)</u>	<u>A078811</u>	<u>002</u>	Jun 10, 2010
AP			<u>50MG/VIAL</u>	<u>A078819</u>	<u>001</u>	Jun 02, 2010
AP			<u>50MG/10ML (5MG/ML)</u>	<u>A090030</u>	<u>001</u>	Jan 31, 2017
AP			<u>100MG/VIAL</u>	<u>A078819</u>	<u>002</u>	Jun 02, 2010
AP			<u>100MG/20ML (5MG/ML)</u>	<u>A090030</u>	<u>002</u>	Jan 31, 2017
AP		GLAND	<u>50MG/10ML (5MG/ML)</u>	<u>A207325</u>	<u>001</u>	Feb 10, 2017
AP			<u>100MG/20ML (5MG/ML)</u>	<u>A207325</u>	<u>002</u>	Feb 10, 2017
AP		GLAND PHARMA LTD	<u>50MG/VIAL</u>	<u>A207385</u>	<u>001</u>	May 23, 2017
AP			<u>100MG/VIAL</u>	<u>A207385</u>	<u>002</u>	May 23, 2017
AP		HENGRUI PHARMA	<u>50MG/10ML (5MG/ML)</u>	<u>A203869</u>	<u>001</u>	Jun 18, 2014
AP			<u>100MG/20ML (5MG/ML)</u>	<u>A203869</u>	<u>002</u>	Jun 18, 2014

PRESCRIPTION DRUG PRODUCT LIST

3-348 (of 474)

OXALIPLATIN

INJECTABLE; INTRAVENOUS

OXALIPLATIN

<u>AP</u>	HOSPIRA WORLDWIDE	<u>50MG/10ML (5MG/ML)</u>	<u>A078813</u>	<u>001</u>	Aug 07, 2009
<u>AP</u>		<u>100MG/20ML (5MG/ML)</u>	<u>A078813</u>	<u>002</u>	Aug 07, 2009
<u>AP</u>	MYLAN LABS LTD	<u>50MG/10ML (5MG/ML)</u>	<u>A091358</u>	<u>001</u>	Aug 07, 2012
<u>AP</u>		<u>100MG/20ML (5MG/ML)</u>	<u>A091358</u>	<u>002</u>	Aug 07, 2012
<u>AP</u>	NOVAST LABS	<u>50MG/10ML (5MG/ML)</u>	<u>A207562</u>	<u>001</u>	Oct 16, 2018
<u>AP</u>		<u>100MG/20ML (5MG/ML)</u>	<u>A207562</u>	<u>002</u>	Oct 16, 2018
<u>AP</u>	QILU PHARM HAINAN	<u>50MG/10ML (5MG/ML)</u>	<u>A204368</u>	<u>001</u>	Jun 07, 2016
<u>AP</u>		<u>50MG/VIAL</u>	<u>A204616</u>	<u>001</u>	May 11, 2016
<u>AP</u>		<u>100MG/20ML (5MG/ML)</u>	<u>A204368</u>	<u>002</u>	Jun 07, 2016
<u>AP</u>		<u>100MG/VIAL</u>	<u>A204616</u>	<u>002</u>	May 11, 2016
<u>AP</u>	SANDOZ	<u>50MG/10ML (5MG/ML)</u>	<u>A078817</u>	<u>001</u>	Jan 24, 2011
<u>AP</u>		<u>100MG/20ML (5MG/ML)</u>	<u>A078817</u>	<u>002</u>	Jan 24, 2011
<u>AP</u>	+! TEVA PHARMS	<u>50MG/10ML (5MG/ML)</u>	<u>N022160</u>	<u>001</u>	Aug 07, 2009
<u>AP</u>	+!	<u>100MG/20ML (5MG/ML)</u>	<u>N022160</u>	<u>002</u>	Aug 07, 2009
	! QILU PHARM HAINAN	200MG/40ML (5MG/ML)	A204368	003	Jun 07, 2016

OXANDROLONE

TABLET; ORAL

OXANDROLONE

<u>AB</u>	PAR PHARM	<u>2.5MG</u>	<u>A077827</u>	<u>001</u>	Jun 22, 2007
<u>AB</u>	!	<u>10MG</u>	<u>A077827</u>	<u>002</u>	Jun 22, 2007
<u>AB</u>	UPSHER SMITH LABS	<u>2.5MG</u>	<u>A076761</u>	<u>001</u>	Dec 01, 2006
<u>AB</u>		<u>10MG</u>	<u>A078033</u>	<u>001</u>	Mar 22, 2007

OXAPROZIN

TABLET; ORAL

DAYPRO

<u>AB</u>	+! PFIZER	<u>600MG</u>	<u>N018841</u>	<u>004</u>	Oct 29, 1992

OXAPROZIN

<u>AB</u>	AMNEAL PHARMS CO	<u>600MG</u>	<u>A208633</u>	<u>001</u>	May 04, 2017
<u>AB</u>	CHARTWELL	<u>600MG</u>	<u>A075987</u>	<u>001</u>	Sep 02, 2004
<u>AB</u>	DR REDDYS LABS LTD	<u>600MG</u>	<u>A075855</u>	<u>001</u>	Jan 31, 2001
<u>AB</u>	SANDOZ	<u>600MG</u>	<u>A075845</u>	<u>001</u>	Jan 31, 2001
<u>AB</u>	TEVA	<u>600MG</u>	<u>A075849</u>	<u>001</u>	Jul 03, 2002

OXAZEPAM

CAPSULE; ORAL

OXAZEPAM

<u>AB</u>	ACTAVIS ELIZABETH	<u>10MG</u>	<u>A072253</u>	<u>002</u>	Apr 14, 1988
<u>AB</u>		<u>15MG</u>	<u>A072253</u>	<u>003</u>	Apr 14, 1988
<u>AB</u>	!	<u>30MG</u>	<u>A072253</u>	<u>001</u>	Apr 14, 1988
<u>AB</u>	EPIC PHARMA	<u>10MG</u>	<u>A071813</u>	<u>001</u>	Apr 19, 1988
<u>AB</u>		<u>15MG</u>	<u>A071756</u>	<u>001</u>	Apr 19, 1988
<u>AB</u>		<u>30MG</u>	<u>A071814</u>	<u>001</u>	Apr 19, 1988
<u>AB</u>	UNITED RES LABS	<u>10MG</u>	<u>A071026</u>	<u>002</u>	Aug 10, 1987
<u>AB</u>		<u>15MG</u>	<u>A071026</u>	<u>003</u>	Aug 10, 1987
<u>AB</u>		<u>30MG</u>	<u>A071026</u>	<u>001</u>	Aug 10, 1987

OXCARBAZEPINE

SUSPENSION; ORAL

OXCARBAZEPINE

<u>AB</u>	AKORN	<u>300MG/5ML</u>	<u>A211420</u>	<u>001</u>	Jul 09, 2021
<u>AB</u>	AMNEAL PHARMS	<u>300MG/5ML</u>	<u>A202961</u>	<u>001</u>	Sep 17, 2012
<u>AB</u>	AUCTA	<u>300MG/5ML</u>	<u>A215332</u>	<u>001</u>	Nov 30, 2022
<u>AB</u>	BIONPHARMA INC	<u>300MG/5ML</u>	<u>A209652</u>	<u>001</u>	Nov 04, 2022
<u>AB</u>	GLASSHOUSE PHARMS	<u>300MG/5ML</u>	<u>A212428</u>	<u>001</u>	Jun 21, 2021
<u>AB</u>	HIKMA	<u>300MG/5ML</u>	<u>A201193</u>	<u>001</u>	Oct 03, 2012
<u>AB</u>	RUBICON	<u>300MG/5ML</u>	<u>A215726</u>	<u>001</u>	Aug 30, 2022
<u>AB</u>	SUN PHARM INDS LTD	<u>300MG/5ML</u>	<u>A078734</u>	<u>001</u>	Jun 26, 2009
<u>TRILEPTAL</u>					
<u>AB</u>	+! NOVARTIS	<u>300MG/5ML</u>	<u>N021285</u>	<u>001</u>	May 25, 2001

TABLET; ORAL

OXCARBAZEPINE

<u>AB</u>	ANNORA PHARMA	<u>150MG</u>	<u>A215939</u>	<u>001</u>	Jan 11, 2022
<u>AB</u>		<u>300MG</u>	<u>A215939</u>	<u>002</u>	Jan 11, 2022
<u>AB</u>		<u>600MG</u>	<u>A215939</u>	<u>003</u>	Jan 11, 2022
<u>AB</u>	BRECKENRIDGE PHARM	<u>150MG</u>	<u>A078069</u>	<u>001</u>	Jan 11, 2008
<u>AB</u>		<u>300MG</u>	<u>A078069</u>	<u>002</u>	Jan 11, 2008
<u>AB</u>		<u>600MG</u>	<u>A078069</u>	<u>003</u>	Jan 11, 2008
<u>AB</u>	GLENMARK PHARMS LTD	<u>150MG</u>	<u>A077802</u>	<u>001</u>	Oct 09, 2007
<u>AB</u>		<u>300MG</u>	<u>A077802</u>	<u>002</u>	Oct 09, 2007

PRESCRIPTION DRUG PRODUCT LIST

3-349 (of 474)

OXCARBAZEPINE

TABLET; ORAL

OXCARBAZEPINE

<u>AB</u>		<u>600MG</u>	<u>A077802</u>	<u>003</u>	Oct 09, 2007
<u>AB</u>	RUBICON	<u>150MG</u>	<u>A077747</u>	<u>001</u>	Apr 09, 2008
<u>AB</u>		<u>300MG</u>	<u>A077747</u>	<u>002</u>	Apr 09, 2008
<u>AB</u>		<u>600MG</u>	<u>A077747</u>	<u>003</u>	Apr 09, 2008
<u>AB</u>	SUN PHARM INDS	<u>150MG</u>	<u>A077794</u>	<u>001</u>	Oct 09, 2007
<u>AB</u>		<u>300MG</u>	<u>A077794</u>	<u>002</u>	Oct 09, 2007
<u>AB</u>		<u>600MG</u>	<u>A077794</u>	<u>003</u>	Oct 09, 2007
<u>AB</u>	TARO	<u>150MG</u>	<u>A077801</u>	<u>001</u>	Nov 15, 2007
<u>AB</u>		<u>300MG</u>	<u>A077801</u>	<u>002</u>	Nov 15, 2007
<u>AB</u>		<u>600MG</u>	<u>A077801</u>	<u>003</u>	Nov 15, 2007
<u>TRILEPTAL</u>					
<u>AB</u>	+	<u>150MG</u>	<u>N021014</u>	<u>001</u>	Jan 14, 2000
<u>AB</u>	+	<u>300MG</u>	<u>N021014</u>	<u>002</u>	Jan 14, 2000
<u>AB</u>	+	<u>600MG</u>	<u>N021014</u>	<u>003</u>	Jan 14, 2000

TABLET, EXTENDED RELEASE; ORAL

OXTELLAR XR

+	SUPERNUS PHARMS	150MG	N202810	001	Oct 19, 2012
+		300MG	N202810	002	Oct 19, 2012
+		600MG	N202810	003	Oct 19, 2012

OXICONAZOLE NITRATE

CREAM; TOPICAL

OXICONAZOLE NITRATE

<u>AB</u>	TARO PHARMS	<u>EQ 1% BASE</u>	<u>A205076</u>	<u>001</u>	Mar 07, 2016
<u>OXISTAT</u>					
<u>AB</u>	+! FOUGERA PHARMS	<u>EQ 1% BASE</u>	<u>N019828</u>	<u>001</u>	Dec 30, 1988
LOTION;TOPICAL					
OXISTAT					
	+! ANI PHARMS	EQ 1% BASE	N020209	001	Sep 30, 1992

OXYBUTYNIN

FILM, EXTENDED RELEASE; TRANSDERMAL

OXYTROL

+	ALLERGAN	3.9MG/24HR	N021351	002	Feb 26, 2003

OXYBUTYNIN CHLORIDE

GEL; TRANSDERMAL

GELNIQUE

+	ALLERGAN	10% (100MG/PACKET)	N022204	001	Jan 27, 2009

SYRUP; ORAL

OXYBUTYNIN CHLORIDE

<u>AA</u>	!	LANNETT CO INC	<u>5MG/5ML</u>	<u>A074520</u>	<u>001</u>	Mar 29, 1996
<u>AA</u>		PHARM ASSOC	<u>5MG/5ML</u>	<u>A075137</u>	<u>001</u>	Dec 18, 1998

TABLET; ORAL

OXYBUTYNIN CHLORIDE

<u>AB</u>	ABHAI LLC	<u>5MG</u>	<u>A209335</u>	<u>001</u>	Dec 22, 2017
<u>AB</u>	APPCO	<u>5MG</u>	<u>A209025</u>	<u>001</u>	Dec 21, 2017
<u>AB</u>	BEXIMCO PHARMS USA	<u>5MG</u>	<u>A213550</u>	<u>001</u>	Jul 14, 2022
<u>AB</u>	LEADING	<u>5MG</u>	<u>A212798</u>	<u>001</u>	Apr 06, 2020
<u>AB</u>	NOVAST LABS	<u>5MG</u>	<u>A210611</u>	<u>001</u>	Oct 30, 2019
<u>AB</u>	NOVITIUM PHARMA	<u>5MG</u>	<u>A209823</u>	<u>001</u>	Oct 23, 2017
<u>AB</u>	!	STRIDES PHARMA	<u>A075079</u>	<u>001</u>	Oct 31, 1997
<u>AB</u>		<u>5MG</u>	<u>A208165</u>	<u>001</u>	Dec 17, 2020
<u>AB</u>	TEVA PHARMS USA	<u>5MG</u>	<u>A071655</u>	<u>001</u>	Nov 14, 1988
<u>AB</u>	TULEX PHARMS INC	<u>5MG</u>	<u>A210125</u>	<u>001</u>	Sep 06, 2018
<u>AB</u>	UPSHER SMITH LABS	<u>5MG</u>	<u>A074625</u>	<u>001</u>	Jul 31, 1996
BX	EMCURE PHARMS LTD	5MG	A211682	001	May 10, 2019
BX	EYWA	5MG	A211062	001	Feb 06, 2019

TABLET, EXTENDED RELEASE; ORAL

DITROPAN XL

<u>AB</u>	+	JANSSEN PHARMS	<u>5MG</u>	<u>N020897</u>	<u>001</u>	Dec 16, 1998
<u>AB</u>	+		<u>10MG</u>	<u>N020897</u>	<u>002</u>	Dec 16, 1998

OXYBUTYNIN CHLORIDE

<u>AB</u>	ACCORD HLTHCARE	<u>5MG</u>	<u>A207138</u>	<u>001</u>	Feb 29, 2016
<u>AB</u>		<u>10MG</u>	<u>A207138</u>	<u>002</u>	Feb 29, 2016
<u>AB</u>	!	<u>15MG</u>	<u>A207138</u>	<u>003</u>	Feb 29, 2016
<u>AB</u>	AJANTA PHARMA LTD	<u>5MG</u>	<u>A211655</u>	<u>001</u>	Feb 28, 2019
<u>AB</u>		<u>10MG</u>	<u>A211655</u>	<u>002</u>	Feb 28, 2019
<u>AB</u>		<u>15MG</u>	<u>A211655</u>	<u>003</u>	Feb 28, 2019
<u>AB</u>	AMNEAL PHARMS	<u>5MG</u>	<u>A204010</u>	<u>001</u>	Nov 23, 2015
<u>AB</u>		<u>10MG</u>	<u>A204010</u>	<u>002</u>	Nov 23, 2015

PRESCRIPTION DRUG PRODUCT LIST

3-350 (of 474)

OXYBUTYNIN CHLORIDE

TABLET, EXTENDED RELEASE;ORAL

OXYBUTYNIN CHLORIDE

<u>AB</u>		<u>15MG</u>	<u>A204010</u>	<u>003</u>	Nov 23, 2015
<u>AB</u>	BIONPHARMA INC	<u>5MG</u>	<u>A210717</u>	<u>001</u>	Dec 17, 2019
<u>AB</u>		<u>10MG</u>	<u>A210717</u>	<u>002</u>	Dec 17, 2019
<u>AB</u>		<u>15MG</u>	<u>A210717</u>	<u>003</u>	Dec 17, 2019
<u>AB</u>	OSMOTICA PHARM US	<u>5MG</u>	<u>A078503</u>	<u>001</u>	Feb 04, 2009
<u>AB</u>		<u>10MG</u>	<u>A078503</u>	<u>002</u>	Feb 04, 2009
<u>AB</u>		<u>15MG</u>	<u>A078503</u>	<u>003</u>	Feb 04, 2009
<u>AB</u>	RUBICON	<u>5MG</u>	<u>A214415</u>	<u>001</u>	Oct 27, 2020
<u>AB</u>		<u>10MG</u>	<u>A214415</u>	<u>002</u>	Oct 27, 2020
<u>AB</u>		<u>15MG</u>	<u>A214415</u>	<u>003</u>	Oct 27, 2020
<u>AB</u>	UNIQUE	<u>5MG</u>	<u>A206121</u>	<u>001</u>	May 27, 2016
<u>AB</u>		<u>10MG</u>	<u>A206121</u>	<u>002</u>	May 27, 2016
<u>AB</u>		<u>15MG</u>	<u>A206121</u>	<u>003</u>	May 27, 2016
<u>AB</u>	ZYDUS PHARMS	<u>5MG</u>	<u>A202332</u>	<u>001</u>	Jun 26, 2017
<u>AB</u>		<u>10MG</u>	<u>A202332</u>	<u>002</u>	Jun 26, 2017
<u>AB</u>		<u>15MG</u>	<u>A202332</u>	<u>003</u>	Jun 26, 2017

OXYCODONE

CAPSULE, EXTENDED RELEASE;ORAL

XTAMPZA ER

+	COLLEGIUM PHARM INC	9MG	N208090	001	Apr 26, 2016
+		13.5MG	N208090	002	Apr 26, 2016
+		18MG	N208090	003	Apr 26, 2016
+		27MG	N208090	004	Apr 26, 2016
+	!	36MG	N208090	005	Apr 26, 2016

OXYCODONE HYDROCHLORIDE

CAPSULE;ORAL

OXYCODONE HYDROCHLORIDE

<u>AB</u>	ANI PHARMS	<u>5MG</u>	<u>A205177</u>	<u>001</u>	Mar 31, 2016
<u>AB</u>	AVANTHI INC	<u>5MG</u>	<u>A202773</u>	<u>001</u>	Aug 17, 2015
<u>AB</u>	+!	GENUS LIFESCIENCES	<u>N200534</u>	<u>001</u>	Oct 20, 2010
<u>AB</u>	MAYNE PHARMA INC	<u>5MG</u>	<u>A203107</u>	<u>001</u>	Jul 26, 2012
<u>AB</u>	NOVEL LABS INC	<u>5MG</u>	<u>A204752</u>	<u>001</u>	Aug 24, 2015

SOLUTION;ORAL

OXYCODONE HYDROCHLORIDE

<u>AA</u>	ABHAI LLC	<u>5MG/5ML</u>	<u>A208593</u>	<u>001</u>	Jul 21, 2017
<u>AA</u>		<u>100MG/5ML</u>	<u>A208593</u>	<u>002</u>	Jul 21, 2017
<u>AA</u>	AKORN	<u>5MG/5ML</u>	<u>A208817</u>	<u>001</u>	Aug 10, 2017
<u>AA</u>		<u>100MG/5ML</u>	<u>A208795</u>	<u>001</u>	Aug 07, 2017
<u>AA</u>	ALKEM LABS LTD	<u>5MG/5ML</u>	<u>A211748</u>	<u>001</u>	Feb 07, 2019
<u>AA</u>		<u>100MG/5ML</u>	<u>A211749</u>	<u>001</u>	Feb 04, 2019
<u>AA</u>	ANI PHARMS	<u>5MG/5ML</u>	<u>A204979</u>	<u>001</u>	Jun 01, 2015
<u>AA</u>	ASCENT PHARMS INC	<u>5MG/5ML</u>	<u>A209021</u>	<u>001</u>	Nov 09, 2017
<u>AA</u>		<u>100MG/5ML</u>	<u>A209021</u>	<u>002</u>	Nov 09, 2017
<u>AA</u>	EYWA	<u>5MG/5ML</u>	<u>A207511</u>	<u>001</u>	Nov 23, 2016
<u>AA</u>		<u>100MG/5ML</u>	<u>A209897</u>	<u>001</u>	Sep 06, 2017
<u>AA</u>	+	GENUS LIFESCIENCES	<u>N200535</u>	<u>002</u>	Aug 22, 2013
<u>AA</u>	+!		<u>N200535</u>	<u>001</u>	Oct 20, 2010
<u>AA</u>	HIKMA	<u>5MG/5ML</u>	<u>A204037</u>	<u>001</u>	Jul 15, 2013
<u>AA</u>	MAYNE PHARMA INC	<u>100MG/5ML</u>	<u>A204092</u>	<u>001</u>	Jun 05, 2014
<u>AA</u>	PHARM ASSOC	<u>5MG/5ML</u>	<u>A206914</u>	<u>001</u>	Feb 01, 2019
<u>AA</u>		<u>100MG/5ML</u>	<u>A206822</u>	<u>001</u>	Aug 15, 2017
<u>AA</u>	QUAGEN	<u>5MG/5ML</u>	<u>A213761</u>	<u>001</u>	Jun 02, 2021
<u>AA</u>		<u>100MG/5ML</u>	<u>A213761</u>	<u>002</u>	Jun 02, 2021
<u>AA</u>	SPECGX LLC	<u>5MG/5ML</u>	<u>A210758</u>	<u>001</u>	Apr 30, 2018
<u>AA</u>		<u>100MG/5ML</u>	<u>A210758</u>	<u>002</u>	Apr 30, 2018
<u>AA</u>	+!	VISTAPHARM	<u>N201194</u>	<u>001</u>	Jan 12, 2012
<u>AA</u>		<u>100MG/5ML</u>	<u>A202537</u>	<u>001</u>	Jul 30, 2012

TABLET;ORAL

OXYCODONE HYDROCHLORIDE

<u>AB</u>	ALVOGEN	<u>5MG</u>	<u>A202116</u>	<u>001</u>	Dec 30, 2011
<u>AB</u>		<u>15MG</u>	<u>A202116</u>	<u>002</u>	Dec 30, 2011
<u>AB</u>		<u>30MG</u>	<u>A202116</u>	<u>003</u>	Dec 30, 2011
<u>AB</u>	AMNEAL PHARMS	<u>5MG</u>	<u>A203638</u>	<u>001</u>	Jun 03, 2014
<u>AB</u>		<u>10MG</u>	<u>A203638</u>	<u>002</u>	Jun 03, 2014
<u>AB</u>		<u>15MG</u>	<u>A203638</u>	<u>003</u>	Jun 03, 2014
<u>AB</u>		<u>20MG</u>	<u>A203638</u>	<u>004</u>	Jun 03, 2014
<u>AB</u>		<u>30MG</u>	<u>A203638</u>	<u>005</u>	Jun 03, 2014
<u>AB</u>	ASCENT PHARMS INC	<u>15MG</u>	<u>A207418</u>	<u>001</u>	Aug 07, 2017

PRESCRIPTION DRUG PRODUCT LIST

3-351 (of 474)

OXYCODONE HYDROCHLORIDE

TABLET; ORAL

OXYCODONE HYDROCHLORIDE

<u>AB</u>		<u>30MG</u>	<u>A207418</u>	<u>002</u>	Aug 07, 2017
<u>AB</u>	AUROLIFE PHARMA LLC	<u>5MG</u>	<u>A202160</u>	<u>001</u>	Nov 19, 2012
<u>AB</u>		<u>15MG</u>	<u>A202160</u>	<u>002</u>	Nov 19, 2012
<u>AB</u>		<u>30MG</u>	<u>A202160</u>	<u>003</u>	Nov 19, 2012
<u>AB</u>	AVANTHI INC	<u>5MG</u>	<u>A091393</u>	<u>001</u>	Aug 31, 2009
<u>AB</u>	!	<u>10MG</u>	<u>A091393</u>	<u>002</u>	Aug 31, 2009
<u>AB</u>		<u>15MG</u>	<u>A091393</u>	<u>003</u>	Aug 31, 2009
<u>AB</u>		<u>20MG</u>	<u>A091393</u>	<u>004</u>	Aug 31, 2009
<u>AB</u>		<u>30MG</u>	<u>A091393</u>	<u>005</u>	Aug 31, 2009
<u>AB</u>	EPIC PHARMA LLC	<u>5MG</u>	<u>A090895</u>	<u>001</u>	Aug 24, 2009
<u>AB</u>		<u>5MG</u>	<u>A202662</u>	<u>001</u>	Sep 22, 2015
<u>AB</u>		<u>10MG</u>	<u>A202662</u>	<u>002</u>	Sep 22, 2015
<u>AB</u>		<u>15MG</u>	<u>A090895</u>	<u>002</u>	Aug 24, 2009
<u>AB</u>		<u>15MG</u>	<u>A202662</u>	<u>003</u>	Sep 22, 2015
<u>AB</u>		<u>20MG</u>	<u>A202662</u>	<u>005</u>	Apr 27, 2017
<u>AB</u>		<u>30MG</u>	<u>A090895</u>	<u>003</u>	Aug 24, 2009
<u>AB</u>		<u>30MG</u>	<u>A202662</u>	<u>004</u>	Sep 22, 2015
<u>AB</u>	NOVEL LABS INC	<u>5MG</u>	<u>A204021</u>	<u>001</u>	Jun 12, 2017
<u>AB</u>		<u>10MG</u>	<u>A204021</u>	<u>002</u>	Jun 12, 2017
<u>AB</u>		<u>15MG</u>	<u>A204021</u>	<u>003</u>	Jun 12, 2017
<u>AB</u>		<u>20MG</u>	<u>A204021</u>	<u>004</u>	Jun 12, 2017
<u>AB</u>		<u>30MG</u>	<u>A204021</u>	<u>005</u>	Jun 12, 2017
<u>AB</u>	NUVO PHARM	<u>5MG</u>	<u>A207119</u>	<u>001</u>	Apr 12, 2016
<u>AB</u>		<u>10MG</u>	<u>A207119</u>	<u>002</u>	Apr 12, 2016
<u>AB</u>		<u>15MG</u>	<u>A207119</u>	<u>003</u>	Apr 12, 2016
<u>AB</u>		<u>20MG</u>	<u>A207119</u>	<u>004</u>	Apr 12, 2016
<u>AB</u>		<u>30MG</u>	<u>A207119</u>	<u>005</u>	Apr 12, 2016
<u>AB</u>	RHODES PHARMS	<u>5MG</u>	<u>A091490</u>	<u>001</u>	Mar 09, 2011
<u>AB</u>		<u>10MG</u>	<u>A091490</u>	<u>002</u>	Mar 09, 2011
<u>AB</u>		<u>15MG</u>	<u>A091490</u>	<u>003</u>	Mar 09, 2011
<u>AB</u>		<u>20MG</u>	<u>A091490</u>	<u>004</u>	Mar 09, 2011
<u>AB</u>		<u>30MG</u>	<u>A091490</u>	<u>005</u>	Mar 09, 2011
<u>AB</u>	SPECGX LLC	<u>5MG</u>	<u>A076758</u>	<u>003</u>	Mar 19, 2007
<u>AB</u>		<u>10MG</u>	<u>A076758</u>	<u>004</u>	Oct 12, 2021
<u>AB</u>		<u>15MG</u>	<u>A076758</u>	<u>001</u>	Jun 30, 2004
<u>AB</u>		<u>20MG</u>	<u>A076758</u>	<u>005</u>	Oct 12, 2021
<u>AB</u>		<u>30MG</u>	<u>A076758</u>	<u>002</u>	Jun 30, 2004
<u>AB</u>	SUN PHARM INDS INC	<u>5MG</u>	<u>A090659</u>	<u>001</u>	Apr 10, 2009
<u>AB</u>		<u>10MG</u>	<u>A090659</u>	<u>005</u>	Nov 06, 2012
<u>AB</u>		<u>15MG</u>	<u>A090659</u>	<u>002</u>	Apr 10, 2009
<u>AB</u>		<u>20MG</u>	<u>A090659</u>	<u>004</u>	Nov 06, 2012
<u>AB</u>		<u>30MG</u>	<u>A090659</u>	<u>003</u>	Apr 10, 2009

ROXICODONE

<u>AB</u>	+	SPECGX LLC	<u>5MG</u>	<u>N021011</u>	<u>003</u>	May 15, 2009
<u>AB</u>	+	!	<u>15MG</u>	<u>N021011</u>	<u>001</u>	Aug 31, 2000
<u>AB</u>	+		<u>30MG</u>	<u>N021011</u>	<u>002</u>	Aug 31, 2000

OXAYDO

+	ZYLA	5MG	N202080	001	Jun 17, 2011
+		7.5MG	N202080	002	Jun 17, 2011

ROXYBOND

PROTEGA PHARMS	5MG	N209777	001	Apr 20, 2017
	15MG	N209777	002	Apr 20, 2017
	30MG	N209777	003	Apr 20, 2017

TABLET, EXTENDED RELEASE; ORAL

OXYCONTIN

+	PURDUE PHARMA LP	10MG	N022272	001	Apr 05, 2010
+		15MG	N022272	002	Apr 05, 2010
+		20MG	N022272	003	Apr 05, 2010
+		30MG	N022272	004	Apr 05, 2010
+	!	40MG	N022272	005	Apr 05, 2010
+		60MG	N022272	006	Apr 05, 2010
+		80MG	N022272	007	Apr 05, 2010

OXYMETAZOLINE HYDROCHLORIDE

CREAM; TOPICAL

RHOFADE

+	!	EPI HLTH	1%	N208552	001	Jan 18, 2017

PRESCRIPTION DRUG PRODUCT LIST

3-352 (of 474)

OXYMETAZOLINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

UPNEEQ

+! RVL PHARMS

0.1%

N212520 001 Jul 08, 2020

OXYMETAZOLINE HYDROCHLORIDE; TETRACAINE HYDROCHLORIDE

SPRAY, METERED;NASAL

KOVANAZE

+! ST RENATUS

0.1MG/SPRAY;6MG/SPRAY

N208032 001 Jun 29, 2016

OXYMORPHONE HYDROCHLORIDE

TABLET;ORAL

OXYMORPHONE HYDROCHLORIDEAB ASCENT PHARMS INC5MGA210175 001 Feb 02, 2018AB10MGA210175 002 Feb 02, 2018AB AUROLIFE PHARMA LLC5MGA204459 001 Apr 26, 2016AB10MGA204459 002 Apr 26, 2016AB AVANTHI INC5MGA203601 001 Jan 30, 2013AB !10MGA203601 002 Jan 30, 2013AB EPIC PHARMA LLC5MGA201187 001 Dec 15, 2014AB10MGA201187 002 Dec 15, 2014AB HIKMA5MGA090964 001 Sep 27, 2010AB10MGA090964 002 Sep 27, 2010AB SPECGX LLC5MGA202321 001 Apr 25, 2013AB10MGA202321 002 Apr 25, 2013AB TEVA5MGA091443 002 Feb 15, 2011AB10MGA091443 001 Feb 15, 2011

TABLET, EXTENDED RELEASE;ORAL

OXYMORPHONE HYDROCHLORIDE

IMPAX LABS

5MG

A079087 001 Jun 14, 2010

7.5MG

A079087 002 Dec 21, 2010

10MG

A079087 003 Jun 14, 2010

15MG

A079087 004 Dec 21, 2010

20MG

A079087 005 Jun 14, 2010

30MG

A079087 006 Jul 22, 2010

!

40MG

A079087 007 Jun 14, 2010

OXYTOCIN

INJECTABLE;INJECTION

OXYTOCINAP +! FRESenius KABI USA10USP UNITS/ML (10USP UNITS/ML)N018248 001AP +!100USP UNITS/10ML (10USP UNITS/ML)N018248 002AP +! HIKMA10USP UNITS/ML (10USP UNITS/ML)N018243 001AP +!100USP UNITS/10ML (10USP UNITS/ML)N018243 002

Jan 10, 2007

AP HIKMA FARMACEUTICA10USP UNITS/ML (10USP UNITS/ML)A200219 001

Feb 13, 2013

AP SAGENT PHARMS INC10USP UNITS/ML (10USP UNITS/ML)A091676 001

Jul 13, 2018

AP100USP UNITS/10ML (10USP UNITS/ML)A091676 002

Jul 13, 2018

PITOCINAP +! PAR STERILE10USP UNITS/ML (10USP UNITS/ML)N018261 001

PRODUCTS

AP

+

100USP UNITS/10ML (10USP UNITS/ML)N018261 002

Jul 27, 2007

OXYTOCIN

+! FRESenius KABI USA

300USP UNITS/30ML (10USP UNITS/ML)

N018248 003

Jul 27, 2007

PITOCIN

+ PAR STERILE

500USP UNITS/50ML (10USP UNITS/ML)

N018261 003

Sep 05, 2012

PRODUCTS

OZANIMOD HYDROCHLORIDE

CAPSULE;ORAL

ZEPOSIA

+ CELGENE INTL

EQ 0.23MG BASE

N209899 001 Mar 25, 2020

+

EQ 0.46MG BASE

N209899 002 Mar 25, 2020

+!

EQ 0.92MG BASE

N209899 003 Mar 25, 2020

OZENOXACIN

CREAM;TOPICAL

XEPI

+! FERRER

1%

N208945 001 Dec 11, 2017

INTERNACIONAL

PRESCRIPTION DRUG PRODUCT LIST

3-353 (of 474)

PACLITAXEL

INJECTABLE; INJECTION

PACLITAXEL

<u>AP</u>	ACCORD HLTHCARE	<u>6MG/ML</u>	<u>A205720</u>	<u>001</u>	Aug 17, 2018
<u>AP</u>	ACTAVIS TOTOWA	<u>6MG/ML</u>	<u>A090130</u>	<u>001</u>	Dec 09, 2009
<u>AP</u>	ALEMBIC PHARMS	<u>6MG/ML</u>	<u>A216874</u>	<u>001</u>	Oct 20, 2022
<u>AP</u>	FRESENIUS KABI USA	<u>6MG/ML</u>	<u>A077574</u>	<u>001</u>	Nov 27, 2006
<u>AP</u>	GLAND PHARMA LTD	<u>6MG/ML</u>	<u>A207326</u>	<u>001</u>	Aug 23, 2016
<u>AP</u>	HIKMA	<u>6MG/ML</u>	<u>A075190</u>	<u>001</u>	Jan 28, 2002
<u>AP</u>	! HOSPIRA	<u>6MG/ML</u>	<u>A076131</u>	<u>001</u>	May 08, 2002
<u>AP</u>	MSN	<u>6MG/ML</u>	<u>A213434</u>	<u>001</u>	Aug 24, 2020
<u>AP</u>	TEVA PHARMS	<u>6MG/ML</u>	<u>A075184</u>	<u>001</u>	Jan 25, 2002
POWDER; INTRAVENOUS					
ABRAXANE					
	+! BRISTOL-MYERS	100MG/VIAL	N021660	001	Jan 07, 2005
PACLITAXEL					
	+! HBT LABS INC	100MG/VIAL	N211875	001	Jul 27, 2022

PACRITINIB CITRATE

CAPSULE; ORAL

VONJO

+!	CTI BIOPHARMA CORP	EQ 100MG BASE	N208712	001	Feb 28, 2022

PAFOLACIANINE SODIUM

SOLUTION; INTRAVENOUS

CYTALUX

+!	ON TARGET LABS	EQ 3.2MG BASE/1.6ML (EQ 2MG BASE/ML)	N214907	001	Nov 29, 2021

PALBOCICLIB

CAPSULE; ORAL

IBRANCE

+	PFIZER	75MG	N207103	001	Feb 03, 2015
+		100MG	N207103	002	Feb 03, 2015
+!		125MG	N207103	003	Feb 03, 2015

TABLET; ORAL

IBRANCE

+	PFIZER	75MG	N212436	001	Nov 01, 2019
+		100MG	N212436	002	Nov 01, 2019
+!		125MG	N212436	003	Nov 01, 2019

PALIPERIDONE

TABLET, EXTENDED RELEASE; ORAL

INVEGA

<u>AB</u>	+	JANSSEN PHARMS	<u>1.5MG</u>	<u>N021999</u>	<u>006</u>	Aug 26, 2008
<u>AB</u>	+		<u>3MG</u>	<u>N021999</u>	<u>001</u>	Dec 19, 2006
<u>AB</u>	+!		<u>6MG</u>	<u>N021999</u>	<u>002</u>	Dec 19, 2006
<u>AB</u>	+		<u>9MG</u>	<u>N021999</u>	<u>003</u>	Dec 19, 2006

PALIPERIDONE

<u>AB</u>		ACTAVIS LABS FL INC	<u>1.5MG</u>	<u>A202645</u>	<u>001</u>	Aug 03, 2015
<u>AB</u>			<u>3MG</u>	<u>A202645</u>	<u>002</u>	Aug 03, 2015
<u>AB</u>			<u>6MG</u>	<u>A202645</u>	<u>003</u>	Aug 03, 2015
<u>AB</u>			<u>9MG</u>	<u>A202645</u>	<u>004</u>	Aug 03, 2015
<u>AB</u>		AMNEAL PHARMS	<u>1.5MG</u>	<u>A204707</u>	<u>001</u>	Sep 23, 2019
<u>AB</u>			<u>3MG</u>	<u>A204707</u>	<u>002</u>	Sep 23, 2019
<u>AB</u>			<u>6MG</u>	<u>A204707</u>	<u>003</u>	Sep 23, 2019
<u>AB</u>			<u>9MG</u>	<u>A204707</u>	<u>004</u>	Sep 23, 2019
<u>AB</u>		CSPC OUYI	<u>1.5MG</u>	<u>A212807</u>	<u>001</u>	Oct 29, 2020
<u>AB</u>			<u>3MG</u>	<u>A212807</u>	<u>002</u>	Oct 29, 2020
<u>AB</u>			<u>6MG</u>	<u>A212807</u>	<u>003</u>	Oct 29, 2020
<u>AB</u>			<u>9MG</u>	<u>A212807</u>	<u>004</u>	Oct 29, 2020
<u>AB</u>		INVENTIA	<u>1.5MG</u>	<u>A204452</u>	<u>001</u>	Jun 12, 2019
<u>AB</u>			<u>3MG</u>	<u>A204452</u>	<u>002</u>	Jun 12, 2019
<u>AB</u>			<u>6MG</u>	<u>A204452</u>	<u>003</u>	Jun 12, 2019
<u>AB</u>			<u>9MG</u>	<u>A204452</u>	<u>004</u>	Jun 12, 2019
<u>AB</u>		LUPIN LTD	<u>1.5MG</u>	<u>A208643</u>	<u>001</u>	Jun 29, 2022
<u>AB</u>			<u>3MG</u>	<u>A208643</u>	<u>002</u>	Jun 29, 2022
<u>AB</u>			<u>6MG</u>	<u>A208643</u>	<u>003</u>	Jun 29, 2022
<u>AB</u>			<u>9MG</u>	<u>A208643</u>	<u>004</u>	Jun 29, 2022
<u>AB</u>		RK PHARMA	<u>1.5MG</u>	<u>A203802</u>	<u>001</u>	Sep 24, 2015
<u>AB</u>			<u>3MG</u>	<u>A203802</u>	<u>002</u>	Sep 24, 2015
<u>AB</u>			<u>6MG</u>	<u>A203802</u>	<u>003</u>	Sep 24, 2015
<u>AB</u>			<u>9MG</u>	<u>A203802</u>	<u>004</u>	Sep 24, 2015
<u>AB</u>		SUN PHARM	<u>1.5mg</u>	<u>A205618</u>	<u>001</u>	Apr 06, 2018
<u>AB</u>			<u>3MG</u>	<u>A205618</u>	<u>002</u>	Apr 06, 2018

PRESCRIPTION DRUG PRODUCT LIST

3-354 (of 474)

PALIPERIDONE

TABLET, EXTENDED RELEASE;ORAL

PALIPERIDONE

<u>AB</u>		<u>6MG</u>	<u>A205618</u>	<u>003</u>	Apr 06, 2018
<u>AB</u>		<u>9MG</u>	<u>A205618</u>	<u>004</u>	Apr 06, 2018

PALIPERIDONE PALMITATE

SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

INVEGA HAFYERA

+	JANSSEN PHARMS	1.092GM/3.5ML (312MG/ML)	N207946	005	Aug 30, 2021
+		1.560GM/5ML (312MG/ML)	N207946	006	Aug 30, 2021

INVEGA SUSTENNA

+	JANSSEN PHARMS	39MG/0.25ML (39MG/0.25ML)	N022264	001	Jul 31, 2009
+		78MG/0.5ML (78MG/0.5ML)	N022264	002	Jul 31, 2009
+		117MG/0.75ML (117MG/0.75ML)	N022264	003	Jul 31, 2009
+	!	156MG/ML (156MG/ML)	N022264	004	Jul 31, 2009
+		234MG/1.5ML (156MG/ML)	N022264	005	Jul 31, 2009

INVEGA TRINZA

+	JANSSEN PHARMS	273MG/0.875ML (273MG/0.875ML)	N207946	001	May 18, 2015
+		410MG/1.315ML (311.79MG/ML)	N207946	002	May 18, 2015
+		546MG/1.75ML (312MG/ML)	N207946	003	May 18, 2015
+	!	819MG/2.625ML (312MG/ML)	N207946	004	May 18, 2015

PALONOSETRON HYDROCHLORIDE

INJECTABLE; INTRAVENOUS

PALONOSETRON HYDROCHLORIDE

<u>AP</u>	BAXTER HLTHCARE CORP	<u>EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)</u>	<u>A206916</u>	<u>001</u>	Nov 12, 2021
<u>AP</u>	CIPLA	<u>EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)</u>	<u>A206396</u>	<u>001</u>	Sep 19, 2018
<u>AP</u>	!	<u>EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)</u>	<u>A201533</u>	<u>002</u>	Apr 21, 2016
<u>AP</u>	EMCURE PHARMS LTD	<u>EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)</u>	<u>A202951</u>	<u>002</u>	Jun 29, 2021
<u>AP</u>	EUGIA PHARMA	<u>EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)</u>	<u>A204702</u>	<u>001</u>	Nov 06, 2018
<u>AP</u>	FRESENIUS KABI USA	<u>EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)</u>	<u>A206801</u>	<u>001</u>	Sep 19, 2018
<u>AP</u>		<u>EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)</u>	<u>A206802</u>	<u>001</u>	Sep 19, 2018
<u>AP</u>	HOSPIRA	<u>EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)</u>	<u>A207005</u>	<u>001</u>	Sep 19, 2018
<u>AP</u>	INGENUS PHARMS LLC	<u>EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)</u>	<u>A208789</u>	<u>001</u>	May 22, 2020
<u>AP</u>	MYLAN INSTITUTIONAL	<u>EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)</u>	<u>A206416</u>	<u>001</u>	Sep 19, 2018
<u>AP</u>	QILU PHARM HAINAN	<u>EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)</u>	<u>A205648</u>	<u>001</u>	Sep 19, 2018
<u>AP</u>	SAGENT PHARMS INC	<u>EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)</u>	<u>A204289</u>	<u>001</u>	Sep 19, 2018
<u>AP</u>		<u>EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)</u>	<u>A205870</u>	<u>001</u>	Sep 19, 2018
<u>AP</u>	SANDOZ INC	<u>EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)</u>	<u>A202521</u>	<u>001</u>	Oct 13, 2015
<u>AP</u>	TEVA PHARMS USA	<u>EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)</u>	<u>A090713</u>	<u>001</u>	Mar 23, 2018
<u>AP</u>	VIRTUS PHARM	<u>EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)</u>	<u>A209287</u>	<u>001</u>	Sep 19, 2018
	!	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	A202951	001	Jun 29, 2021

SOLUTION; INTRAVENOUS

PALONOSETRON HYDROCHLORIDE

HIKMA

EQ 0.25MG BASE/2ML (EQ 0.125MG BASE/ML) N207963 001 Aug 22, 2016

PAMIDRONATE DISODIUM

INJECTABLE; INJECTION

PAMIDRONATE DISODIUM

<u>AP</u>	AREVA PHARMS	<u>30MG/VIAL</u>	<u>A077433</u>	<u>001</u>	Nov 26, 2008
<u>AP</u>		<u>90MG/VIAL</u>	<u>A077433</u>	<u>003</u>	Nov 26, 2008
<u>AP</u>	DR REDDYS	<u>30MG/10ML (3MG/ML)</u>	<u>A078156</u>	<u>001</u>	Aug 19, 2008
<u>AP</u>		<u>60MG/10ML (6MG/ML)</u>	<u>A078156</u>	<u>002</u>	Aug 19, 2008
<u>AP</u>		<u>90MG/10ML (9MG/ML)</u>	<u>A078156</u>	<u>003</u>	Aug 19, 2008
<u>AP</u>	HIKMA	<u>30MG/VIAL</u>	<u>A075290</u>	<u>001</u>	Apr 30, 2001
<u>AP</u>	+	<u>30MG/10ML (3MG/ML)</u>	<u>N021113</u>	<u>001</u>	Mar 04, 2002
<u>AP</u>		<u>90MG/VIAL</u>	<u>A075290</u>	<u>003</u>	Apr 30, 2001
<u>AP</u>	+	<u>90MG/10ML (9MG/ML)</u>	<u>N021113</u>	<u>002</u>	Mar 04, 2002
<u>AP</u>	!	<u>30MG/10ML (3MG/ML)</u>	<u>A075841</u>	<u>001</u>	Jun 27, 2002
<u>AP</u>	!	<u>60MG/10ML (6MG/ML)</u>	<u>A075841</u>	<u>002</u>	Jun 27, 2002
<u>AP</u>	!	<u>90MG/10ML (9MG/ML)</u>	<u>A075841</u>	<u>003</u>	Jun 27, 2002
<u>AP</u>	MYLAN LABS LTD	<u>30MG/10ML (3MG/ML)</u>	<u>A078520</u>	<u>001</u>	Oct 31, 2008
<u>AP</u>		<u>90MG/10ML (9MG/ML)</u>	<u>A078520</u>	<u>002</u>	Oct 31, 2008
<u>AP</u>	SAGENT PHARMS INC	<u>30MG/10ML (3MG/ML)</u>	<u>A078373</u>	<u>001</u>	Dec 23, 2008
<u>AP</u>		<u>90MG/10ML (9MG/ML)</u>	<u>A078373</u>	<u>002</u>	Dec 23, 2008
	AREVA PHARMS	60MG/VIAL	A077433	002	Nov 26, 2008

PRESCRIPTION DRUG PRODUCT LIST

3-355 (of 474)

PANCURONIUM BROMIDE

INJECTABLE; INJECTION

PANCURONIUM BROMIDE

<u>AP</u>	!	DR REDDYS	<u>1MG/ML</u>	<u>A072759</u>	<u>001</u>	Jul 31, 1990
<u>AP</u>		HOSPIRA	<u>1MG/ML</u>	<u>A072320</u>	<u>001</u>	Jan 19, 1989
	!	DR REDDYS	2MG/ML	A072760	001	Jul 31, 1990

PANTOPRAZOLE SODIUM

FOR SUSPENSION, DELAYED RELEASE; ORAL

PANTOPRAZOLE SODIUM

<u>AB</u>		SUN PHARM	<u>EQ 40MG BASE</u>	<u>A213725</u>	<u>001</u>	Jun 30, 2020

PROTONIX

<u>AB</u>	+	WYETH PHARMS	<u>EQ 40MG BASE</u>	<u>N022020</u>	<u>001</u>	Nov 14, 2007

INJECTABLE; INTRAVENOUS

PANTOPRAZOLE SODIUM

<u>AP</u>		ACIC PHARMS	<u>EQ 40MG BASE/VIAL</u>	<u>A209524</u>	<u>001</u>	Aug 30, 2021
<u>AP</u>		AKORN	<u>EQ 40MG BASE/VIAL</u>	<u>A079197</u>	<u>001</u>	Nov 08, 2012
<u>AP</u>		ASPIRO	<u>EQ 40MG BASE/VIAL</u>	<u>A213778</u>	<u>001</u>	May 18, 2022
<u>AP</u>		BE PHARMS	<u>EQ 40MG BASE/VIAL</u>	<u>A216171</u>	<u>001</u>	May 18, 2022
<u>AP</u>		EUGIA PHARMA	<u>EQ 40MG BASE/VIAL</u>	<u>A205675</u>	<u>001</u>	Mar 30, 2016
<u>AP</u>		GLAND PHARMA LTD	<u>EQ 40MG BASE/VIAL</u>	<u>A204400</u>	<u>001</u>	May 18, 2022
<u>AP</u>		MEITHEAL	<u>EQ 40MG BASE/VIAL</u>	<u>A215860</u>	<u>001</u>	Aug 29, 2022
<u>AP</u>		SANDOZ INC	<u>EQ 40MG BASE/VIAL</u>	<u>A090296</u>	<u>001</u>	Jul 14, 2015
<u>AP</u>		SUN PHARM	<u>EQ 40MG BASE/VIAL</u>	<u>A077674</u>	<u>001</u>	Aug 19, 2019

PROTONIX IV

<u>AP</u>	+	WYETH PHARMS	<u>EQ 40MG BASE/VIAL</u>	<u>N020988</u>	<u>001</u>	Mar 22, 2001

POWDER; INTRAVENOUS

PANTOPRAZOLE SODIUM

+! HIKMA

EQ 40MG BASE/VIAL

N209463 001 Jun 30, 2017

TABLET, DELAYED RELEASE; ORAL

PANTOPRAZOLE SODIUM

<u>AB</u>		ACTAVIS TOTOWA	<u>EQ 20MG BASE</u>	<u>A090797</u>	<u>001</u>	Feb 07, 2011
<u>AB</u>			<u>EQ 40MG BASE</u>	<u>A090797</u>	<u>002</u>	Feb 07, 2011
<u>AB</u>		AMNEAL PHARMS	<u>EQ 20MG BASE</u>	<u>A205119</u>	<u>001</u>	Jan 26, 2016
<u>AB</u>			<u>EQ 40MG BASE</u>	<u>A205119</u>	<u>002</u>	Jan 26, 2016
<u>AB</u>		AUROBINDO PHARMA LTD	<u>EQ 20MG BASE</u>	<u>A202038</u>	<u>001</u>	Sep 28, 2012
<u>AB</u>			<u>EQ 40MG BASE</u>	<u>A202038</u>	<u>002</u>	Sep 28, 2012
<u>AB</u>		DR REDDYS LABS LTD	<u>EQ 20MG BASE</u>	<u>A077619</u>	<u>001</u>	Jan 19, 2011
<u>AB</u>			<u>EQ 40MG BASE</u>	<u>A077619</u>	<u>002</u>	Jan 19, 2011
<u>AB</u>		HETERO LABS LTD V	<u>EQ 20MG BASE</u>	<u>A202882</u>	<u>001</u>	Sep 10, 2014
<u>AB</u>			<u>EQ 40MG BASE</u>	<u>A202882</u>	<u>002</u>	Sep 10, 2014
<u>AB</u>		INGENUS PHARMS LLC	<u>EQ 40MG BASE</u>	<u>A211368</u>	<u>001</u>	Mar 01, 2019
<u>AB</u>		LANNETT CO INC	<u>EQ 20MG BASE</u>	<u>A078281</u>	<u>001</u>	Jan 20, 2011
<u>AB</u>			<u>EQ 40MG BASE</u>	<u>A078281</u>	<u>002</u>	Jan 20, 2011
<u>AB</u>		MANKIND PHARMA	<u>EQ 40MG BASE</u>	<u>A215880</u>	<u>001</u>	Jul 26, 2022
<u>AB</u>		MYLAN PHARMS INC	<u>EQ 20MG BASE</u>	<u>A090970</u>	<u>001</u>	Jan 19, 2011
<u>AB</u>			<u>EQ 40MG BASE</u>	<u>A090970</u>	<u>002</u>	Jan 19, 2011
<u>AB</u>		ORBION PHARMS	<u>EQ 20MG BASE</u>	<u>A202052</u>	<u>001</u>	Dec 02, 2014
<u>AB</u>			<u>EQ 40MG BASE</u>	<u>A202052</u>	<u>002</u>	Dec 02, 2014
<u>AB</u>		RUBICON	<u>EQ 20MG BASE</u>	<u>A090807</u>	<u>001</u>	May 02, 2012
<u>AB</u>			<u>EQ 40MG BASE</u>	<u>A090807</u>	<u>002</u>	May 02, 2012
<u>AB</u>		TORRENT PHARMS	<u>EQ 20MG BASE</u>	<u>A090074</u>	<u>001</u>	Jan 19, 2011
<u>AB</u>			<u>EQ 40MG BASE</u>	<u>A090074</u>	<u>002</u>	Jan 19, 2011
<u>AB</u>		WOCKHARDT BIO AG	<u>EQ 20MG BASE</u>	<u>A091231</u>	<u>001</u>	Jan 19, 2011
<u>AB</u>			<u>EQ 40MG BASE</u>	<u>A091231</u>	<u>002</u>	Jan 19, 2011

PROTONIX

<u>AB</u>	+	WYETH PHARMS	<u>EQ 20MG BASE</u>	<u>N020987</u>	<u>002</u>	Jun 12, 2001

<u>AB</u>	+	!	<u>EQ 40MG BASE</u>	<u>N020987</u>	<u>001</u>	Feb 02, 2000

PARICALCITOL

CAPSULE; ORAL

PARICALCITOL

<u>AB</u>		AMNEAL PHARMS	<u>1MCG</u>	<u>A204327</u>	<u>001</u>	Jan 13, 2016
<u>AB</u>			<u>2MCG</u>	<u>A204327</u>	<u>002</u>	Jan 13, 2016
<u>AB</u>			<u>4MCG</u>	<u>A204327</u>	<u>003</u>	Jan 13, 2016
<u>AB</u>		AUROBINDO PHARMA LTD	<u>1MCG</u>	<u>A207672</u>	<u>001</u>	Jan 14, 2016
<u>AB</u>			<u>2MCG</u>	<u>A207672</u>	<u>002</u>	Jan 14, 2016
<u>AB</u>			<u>4MCG</u>	<u>A207672</u>	<u>003</u>	Jan 14, 2016
<u>AB</u>		BIONPHARMA INC	<u>1MCG</u>	<u>A202539</u>	<u>001</u>	Mar 27, 2014
<u>AB</u>			<u>2MCG</u>	<u>A202539</u>	<u>002</u>	Mar 27, 2014
<u>AB</u>			<u>4MCG</u>	<u>A202539</u>	<u>003</u>	Mar 27, 2014
<u>AB</u>		DR REDDYS	<u>1MCG</u>	<u>A091412</u>	<u>001</u>	Jun 24, 2014

PRESCRIPTION DRUG PRODUCT LIST

3-356 (of 474)

PARICALCITOL

CAPSULE; ORAL

PARICALCITOL

<u>AB</u>		<u>2MCG</u>	<u>A091412</u>	<u>002</u>	Jun 24, 2014
<u>AB</u>		<u>4MCG</u>	<u>A091412</u>	<u>003</u>	Jun 24, 2014
<u>AB</u>	MARKSANS PHARMA	<u>1MCG</u>	<u>A204948</u>	<u>001</u>	Oct 07, 2016
<u>AB</u>		<u>2MCG</u>	<u>A204948</u>	<u>002</u>	Oct 07, 2016
<u>AB</u>		<u>4MCG</u>	<u>A204948</u>	<u>003</u>	Oct 07, 2016
<u>AB</u>	RISING	<u>1MCG</u>	<u>A202124</u>	<u>001</u>	Jun 24, 2014
<u>AB</u>		<u>2MCG</u>	<u>A202124</u>	<u>002</u>	Jun 24, 2014
<u>AB</u>		<u>4MCG</u>	<u>A202124</u>	<u>003</u>	Jun 24, 2014
<u>AB</u>	TEVA PHARMS USA	<u>1MCG</u>	<u>A090829</u>	<u>001</u>	Sep 27, 2013
<u>AB</u>		<u>2MCG</u>	<u>A090829</u>	<u>002</u>	Sep 27, 2013
<u>AB</u>	!	<u>4MCG</u>	<u>A090829</u>	<u>003</u>	Sep 27, 2013
<u>ZEMPLAR</u>					
<u>AB</u>	+ ABBVIE	<u>1MCG</u>	<u>N021606</u>	<u>001</u>	May 26, 2005
<u>AB</u>	+	<u>2MCG</u>	<u>N021606</u>	<u>002</u>	May 26, 2005

SOLUTION; INTRAVENOUS

PARICALCITOL

<u>AP</u>	ACCORD HLTHCARE	<u>0.002MG/ML (0.002MG/ML)</u>	<u>N207174</u>	<u>001</u>	Feb 04, 2016
<u>AP</u>		<u>0.005MG/ML (0.005MG/ML)</u>	<u>N207174</u>	<u>002</u>	Feb 04, 2016
<u>AP</u>		<u>0.01MG/2ML (0.005MG/ML)</u>	<u>N207174</u>	<u>003</u>	Feb 04, 2016
<u>AP</u>	AMNEAL PHARMS CO	<u>0.002MG/ML (0.002MG/ML)</u>	<u>A206699</u>	<u>001</u>	Mar 09, 2017
<u>AP</u>		<u>0.005MG/ML (0.005MG/ML)</u>	<u>A206699</u>	<u>002</u>	Mar 09, 2017
<u>AP</u>		<u>0.01MG/2ML (0.005MG/ML)</u>	<u>A206699</u>	<u>003</u>	Mar 09, 2017
<u>AP</u>	DR REDDYS	<u>0.002MG/ML (0.002MG/ML)</u>	<u>A204910</u>	<u>001</u>	Aug 17, 2016
<u>AP</u>		<u>0.005MG/ML (0.005MG/ML)</u>	<u>A204910</u>	<u>002</u>	Aug 17, 2016
<u>AP</u>		<u>0.01MG/2ML (0.005MG/ML)</u>	<u>A204910</u>	<u>003</u>	Aug 17, 2016
<u>AP</u>	EUGIA PHARMA	<u>0.002MG/ML (0.002MG/ML)</u>	<u>A205982</u>	<u>001</u>	Oct 09, 2018
<u>AP</u>		<u>0.005MG/ML (0.005MG/ML)</u>	<u>A205982</u>	<u>002</u>	Oct 09, 2018
<u>AP</u>		<u>0.01MG/2ML (0.005MG/ML)</u>	<u>A205982</u>	<u>003</u>	Oct 09, 2018
<u>AP</u>	HIKMA PHARMS	<u>0.002MG/ML (0.002MG/ML)</u>	<u>N205917</u>	<u>001</u>	Nov 18, 2014
<u>AP</u>		<u>0.005MG/ML (0.005MG/ML)</u>	<u>N205917</u>	<u>002</u>	Nov 18, 2014
<u>AP</u>		<u>0.01MG/2ML (0.005MG/ML)</u>	<u>N205917</u>	<u>003</u>	Nov 18, 2014
<u>AP</u>	HOSPIRA	<u>0.002MG/ML (0.002MG/ML)</u>	<u>N201657</u>	<u>001</u>	Oct 21, 2014
<u>AP</u>		<u>0.005MG/ML (0.005MG/ML)</u>	<u>N201657</u>	<u>002</u>	Oct 21, 2014
<u>AP</u>		<u>0.01MG/2ML (0.005MG/ML)</u>	<u>N201657</u>	<u>003</u>	Oct 21, 2014
<u>AP</u>	RISING	<u>0.005MG/ML (0.005MG/ML)</u>	<u>A203897</u>	<u>002</u>	Nov 02, 2017
<u>AP</u>		<u>0.01MG/2ML (0.005MG/ML)</u>	<u>A203897</u>	<u>003</u>	Nov 02, 2017
<u>AP</u>	SANDOZ INC	<u>0.002MG/ML (0.002MG/ML)</u>	<u>A091108</u>	<u>001</u>	Jul 27, 2011
<u>AP</u>		<u>0.005MG/ML (0.005MG/ML)</u>	<u>A091108</u>	<u>002</u>	Jul 27, 2011
<u>AP</u>		<u>0.01MG/2ML (0.005MG/ML)</u>	<u>A091108</u>	<u>003</u>	Jul 27, 2011
<u>ZEMPLAR</u>					
<u>AP</u>	+! ABBVIE	<u>0.002MG/ML (0.002MG/ML)</u>	<u>N020819</u>	<u>002</u>	Feb 01, 2000
<u>AP</u>	+!	<u>0.005MG/ML (0.005MG/ML)</u>	<u>N020819</u>	<u>001</u>	Apr 17, 1998
<u>AP</u>	+!	<u>0.01MG/2ML (0.005MG/ML)</u>	<u>N020819</u>	<u>003</u>	Feb 01, 2000

PAROMOMYCIN SULFATE

CAPSULE; ORAL

PAROMOMYCIN SULFATE

<u>AA</u>	HERITAGE PHARMS	<u>EQ 250MG BASE</u>	<u>A065173</u>	<u>001</u>	Dec 14, 2007
<u>AA</u>	! SUN PHARM INDS INC	<u>EQ 250MG BASE</u>	<u>A064171</u>	<u>001</u>	Jun 30, 1997

PAROXETINE HYDROCHLORIDE

SUSPENSION; ORAL

PAROXETINE HYDROCHLORIDE

<u>AB</u>	NOVITIUM PHARMA	<u>EQ 10MG BASE/5ML</u>	<u>A215003</u>	<u>001</u>	Sep 03, 2021
<u>PAXIL</u>					
<u>AB</u>	+! APOTEX	<u>EQ 10MG BASE/5ML</u>	<u>N020710</u>	<u>001</u>	Jun 25, 1997

TABLET; ORAL

PAROXETINE

<u>AB</u>	PRINSTON INC	<u>EQ 10MG BASE</u>	<u>A203854</u>	<u>001</u>	Oct 31, 2014
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A203854</u>	<u>002</u>	Oct 31, 2014
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A203854</u>	<u>003</u>	Oct 31, 2014
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A203854</u>	<u>004</u>	Oct 31, 2014

PAROXETINE HYDROCHLORIDE

<u>AB</u>	APOTEX	<u>EQ 10MG BASE</u>	<u>A075356</u>	<u>001</u>	Jul 30, 2003
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A075356</u>	<u>002</u>	Jul 30, 2003
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A075356</u>	<u>003</u>	Jul 30, 2003
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A075356</u>	<u>004</u>	Jul 30, 2003
<u>AB</u>	AUROBINDO PHARMA	<u>EQ 10MG BASE</u>	<u>A078406</u>	<u>001</u>	Jul 25, 2007
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A078406</u>	<u>002</u>	Jul 25, 2007
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A078406</u>	<u>003</u>	Jul 25, 2007

PRESCRIPTION DRUG PRODUCT LIST

3-357 (of 474)

PAROXETINE HYDROCHLORIDE

TABLET; ORAL

PAROXETINE HYDROCHLORIDE

<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A078406 004</u>	Jul 25, 2007
<u>AB</u>	CHARTWELL RX	<u>EQ 10MG BASE</u>	<u>A076618 001</u>	Aug 15, 2005
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A076618 002</u>	Aug 15, 2005
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A076618 003</u>	Aug 15, 2005
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A076618 004</u>	Aug 15, 2005
<u>AB</u>	MYLAN	<u>EQ 10MG BASE</u>	<u>A078902 001</u>	Mar 13, 2008
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A078902 002</u>	Mar 13, 2008
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A078902 003</u>	Mar 13, 2008
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A078902 004</u>	Mar 13, 2008
<u>AB</u>	OXFORD PHARMS	<u>EQ 10MG BASE</u>	<u>A076968 001</u>	Jun 21, 2010
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A076968 002</u>	Jun 21, 2010
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A076968 003</u>	Jun 21, 2010
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A076968 004</u>	Jun 21, 2010
<u>AB</u>	YILING	<u>EQ 10MG BASE</u>	<u>A211248 001</u>	Nov 02, 2021
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A211248 002</u>	Nov 02, 2021
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A211248 003</u>	Nov 02, 2021
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A211248 004</u>	Nov 02, 2021
<u>AB</u>	ZYDUS PHARMS USA	<u>EQ 10MG BASE</u>	<u>A077584 001</u>	Mar 07, 2007
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A077584 002</u>	Mar 07, 2007
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A077584 003</u>	Mar 07, 2007
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077584 004</u>	Mar 07, 2007
<u>PAXIL</u>				
<u>AB</u>	+	<u>EQ 10MG BASE</u>	<u>N020031 001</u>	Dec 29, 1992
<u>AB</u>	+	<u>EQ 20MG BASE</u>	<u>N020031 002</u>	Dec 29, 1992
<u>AB</u>	+	<u>EQ 30MG BASE</u>	<u>N020031 003</u>	Dec 29, 1992
<u>AB</u>	+	<u>EQ 40MG BASE</u>	<u>N020031 005</u>	Dec 29, 1992

TABLET, EXTENDED RELEASE; ORAL

PAROXETINE HYDROCHLORIDE

<u>AB</u>	AUROBINDO PHARMA USA	<u>EQ 12.5MG BASE</u>	<u>A077873 001</u>	Jun 29, 2007
<u>AB</u>		<u>EQ 25MG BASE</u>	<u>A077873 002</u>	Jun 29, 2007
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A091427 001</u>	Apr 14, 2011
<u>AB</u>	CADILA PHARMS LTD	<u>EQ 12.5MG BASE</u>	<u>A212645 001</u>	Aug 27, 2021
<u>AB</u>		<u>EQ 25MG BASE</u>	<u>A212645 002</u>	Aug 27, 2021
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A212645 003</u>	Aug 27, 2021
<u>AB</u>	CSPC OUYI	<u>EQ 12.5MG BASE</u>	<u>A213485 001</u>	Feb 16, 2021
<u>AB</u>		<u>EQ 25MG BASE</u>	<u>A213485 002</u>	Feb 16, 2021
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A213485 003</u>	Feb 16, 2021
<u>AB</u>	LANNETT CO INC	<u>EQ 12.5MG BASE</u>	<u>A204744 001</u>	Jun 10, 2016
<u>AB</u>		<u>EQ 25MG BASE</u>	<u>A204744 002</u>	Jun 10, 2016
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A204744 003</u>	Jun 10, 2016
<u>AB</u>	LUPIN LTD	<u>EQ 12.5MG BASE</u>	<u>A204134 001</u>	Jan 20, 2017
<u>AB</u>		<u>EQ 25MG BASE</u>	<u>A204134 002</u>	Jan 20, 2017
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A204134 003</u>	Jan 20, 2017
<u>AB</u>	SCIECURE PHARMA INC	<u>EQ 12.5MG BASE</u>	<u>A209293 001</u>	Jun 12, 2018
<u>AB</u>		<u>EQ 25MG BASE</u>	<u>A209293 002</u>	Jun 12, 2018
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A209293 003</u>	Jun 12, 2018
<u>PAXIL CR</u>				
<u>AB</u>	+	<u>EQ 12.5MG BASE</u>	<u>N020936 001</u>	Feb 16, 1999
<u>AB</u>	+	<u>EQ 25MG BASE</u>	<u>N020936 002</u>	Feb 16, 1999
<u>AB</u>	+	<u>EQ 37.5MG BASE</u>	<u>N020936 003</u>	Dec 06, 2000

PAROXETINE MESYLATE

CAPSULE; ORAL

BRISDELLE

<u>AB</u>	+	<u>EQ 7.5MG BASE</u>	<u>N204516 001</u>	Jun 28, 2013
<u>PAROXETINE MESYLATE</u>				
<u>AB</u>	ACTAVIS LABS FL INC	<u>EQ 7.5MG BASE</u>	<u>A207139 001</u>	Jun 20, 2017
<u>AB</u>	PRINSTON INC	<u>EQ 7.5MG BASE</u>	<u>A207188 001</u>	Aug 18, 2017

TABLET; ORAL

PEXEVA

+	SEBELA IRELAND LTD	EQ 10MG BASE	N021299 001	Jul 03, 2003
+		EQ 20MG BASE	N021299 002	Jul 03, 2003
+		EQ 30MG BASE	N021299 003	Jul 03, 2003

PRESCRIPTION DRUG PRODUCT LIST

3-358 (of 474)

PASIREOTIDE DIASPARTATE

SOLUTION; SUBCUTANEOUS

SIGNIFOR

+	RECORDATI RARE	EQ 0.3MG BASE/ML (EQ 0.3MG BASE/ML)	N200677	001	Dec 14, 2012
+		EQ 0.6MG BASE/ML (EQ 0.6MG BASE/ML)	N200677	002	Dec 14, 2012
+	!	EQ 0.9MG BASE/ML (EQ 0.9MG BASE/ML)	N200677	003	Dec 14, 2012

PASIREOTIDE PAMOATE

FOR SUSPENSION; INTRAMUSCULAR

SIGNIFOR LAR KIT

+	RECORDATI RARE	EQ 10MG BASE/VIAL	N203255	004	Jun 29, 2018
+		EQ 20MG BASE/VIAL	N203255	001	Dec 15, 2014
+		EQ 30MG BASE/VIAL	N203255	005	Jun 29, 2018
+		EQ 40MG BASE/VIAL	N203255	002	Dec 15, 2014
+	!	EQ 60MG BASE/VIAL	N203255	003	Dec 15, 2014

PATROMER SORBITE X CALCIUM

POWDER; ORAL

VELTASSA

+	VIFOR PHARMA	EQ 8.4GM BASE/PACKET	N205739	001	Oct 21, 2015
+		EQ 16.8GM BASE/PACKET	N205739	002	Oct 21, 2015
+	!	EQ 25.2GM BASE/PACKET	N205739	003	Oct 21, 2015

PATISIRAN SODIUM

SOLUTION; INTRAVENOUS

ONPATRO

+	ALNYLAM PHARMS INC	EQ 10MG BASE/5ML (EQ 2MG BASE/ML)	N210922	001	Aug 10, 2018

PAZOPANIB HYDROCHLORIDE

TABLET; ORAL

VOTRIENT

+	NOVARTIS	EQ 200MG BASE	N022465	001	Oct 19, 2009

PEGCETACOPLAN

SOLUTION; SUBCUTANEOUS

EMPAVELI

+	APELLIS PHARMS	1080MG/20ML (54MG/ML)	N215014	001	May 14, 2021

PEMETREXED

SOLUTION; INTRAVENOUS

PEMETREXED

+	ACTAVIS LLC	100MG/4ML (25MG/ML)	N208419	001	Aug 21, 2020
+		500MG/20ML (25MG/ML)	N208419	002	Aug 21, 2020
+		1GM/40ML (25MG/ML)	N208419	003	Aug 21, 2020

PEMFEXY

+	EAGLE PHARMS	500MG/20ML (25MG/ML)	N209472	001	Feb 08, 2020

PEMETREXED DISODIUM

POWDER; INTRAVENOUS

ALIMTA

AP	+	LILLY	<u>EQ 100MG BASE/VIAL</u>	<u>N021462</u>	<u>002</u>	Sep 07, 2007
AP	+		<u>EQ 500MG BASE/VIAL</u>	<u>N021462</u>	<u>001</u>	Feb 04, 2004

PEMETREXED DISODIUM

AP		ACCORD HLTHCARE	<u>EQ 100MG BASE/VIAL</u>	<u>A203485</u>	<u>001</u>	May 25, 2022
AP			<u>EQ 500MG BASE/VIAL</u>	<u>A203485</u>	<u>002</u>	May 25, 2022
AP			<u>EQ 1GM BASE/VIAL</u>	<u>A203485</u>	<u>003</u>	May 25, 2022
AP		AMNEAL	<u>EQ 500MG BASE/VIAL</u>	<u>A210047</u>	<u>001</u>	Aug 04, 2022
AP		APOTEX	<u>EQ 100MG BASE/VIAL</u>	<u>A203774</u>	<u>001</u>	May 25, 2022
AP			<u>EQ 500MG BASE/VIAL</u>	<u>A203774</u>	<u>002</u>	May 25, 2022
AP			<u>EQ 750MG BASE/VIAL</u>	<u>A209851</u>	<u>001</u>	May 25, 2022
AP			<u>EQ 1GM BASE/VIAL</u>	<u>A209085</u>	<u>001</u>	May 25, 2022
AP		BAXTER HLTHCARE CORP	<u>EQ 100MG BASE/VIAL</u>	<u>A214436</u>	<u>001</u>	Aug 18, 2022
AP			<u>EQ 500MG BASE/VIAL</u>	<u>A214436</u>	<u>002</u>	Aug 18, 2022
AP		DR REDDYS	<u>EQ 100MG BASE/VIAL</u>	<u>A202596</u>	<u>001</u>	May 25, 2022
AP			<u>EQ 500MG BASE/VIAL</u>	<u>A202596</u>	<u>002</u>	May 25, 2022
AP			<u>EQ 1GM BASE/VIAL</u>	<u>A202596</u>	<u>003</u>	May 25, 2022
AP		EUGIA PHARMA	<u>EQ 100MG BASE/VIAL</u>	<u>A214632</u>	<u>001</u>	May 25, 2022
AP			<u>EQ 500MG BASE/VIAL</u>	<u>A214632</u>	<u>002</u>	May 25, 2022
AP			<u>EQ 1GM BASE/VIAL</u>	<u>A214632</u>	<u>003</u>	May 25, 2022
AP		FRESENIUS KABI USA	<u>EQ 100MG BASE/VIAL</u>	<u>A090384</u>	<u>001</u>	May 25, 2022
AP			<u>EQ 500MG BASE/VIAL</u>	<u>A090384</u>	<u>002</u>	May 25, 2022
AP	!		<u>EQ 750MG BASE/VIAL</u>	<u>A090384</u>	<u>003</u>	May 25, 2022
AP	!		<u>EQ 1GM BASE/VIAL</u>	<u>A090384</u>	<u>004</u>	May 25, 2022
AP		HONG KONG	<u>EQ 100MG BASE/VIAL</u>	<u>A215479</u>	<u>001</u>	Dec 13, 2022
AP			<u>EQ 500MG BASE/VIAL</u>	<u>A215479</u>	<u>002</u>	Dec 13, 2022

PEMETREXED DISODIUM

POWDER; INTRAVENOUS

PEMETREXED DISODIUM

<u>AP</u>		<u>EQ 750MG BASE/VIAL</u>	<u>A215479</u>	<u>003</u>	Dec 13, 2022
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A215479</u>	<u>004</u>	Dec 13, 2022
<u>AP</u>	JIANGSU HANSOH PHARM	<u>EQ 100MG BASE/VIAL</u>	<u>A208696</u>	<u>001</u>	May 25, 2022
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A208696</u>	<u>002</u>	May 25, 2022
<u>AP</u>	NANG KUANG PHARM CO	<u>EQ 100MG BASE/VIAL</u>	<u>A207352</u>	<u>001</u>	May 25, 2022
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A207352</u>	<u>002</u>	May 25, 2022
<u>AP</u>	QILU PHARM HAINAN	<u>EQ 100MG BASE/VIAL</u>	<u>A204890</u>	<u>001</u>	May 25, 2022
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A204890</u>	<u>002</u>	May 25, 2022
<u>AP</u>	WAVERLEY PHARMA INC	<u>EQ 100MG BASE/VIAL</u>	<u>A211899</u>	<u>001</u>	May 25, 2022
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A211899</u>	<u>002</u>	May 25, 2022
<u>AP</u>	ZYDUS PHARMS	<u>EQ 100MG BASE/VIAL</u>	<u>A214073</u>	<u>001</u>	May 25, 2022
<u>AP</u>		<u>EQ 500MG BASE/VIAL</u>	<u>A214073</u>	<u>002</u>	May 25, 2022
<u>AP</u>		<u>EQ 1GM BASE/VIAL</u>	<u>A214073</u>	<u>003</u>	May 25, 2022

SOLUTION; INTRAVENOUS

PEMETREXED DISODIUM

+	ACCORD HLTHCARE	EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	N214408 001	Jul 19, 2022
+		EQ 500MG BASE/20ML (EQ 25MG BASE/ML)	N214408 002	Jul 19, 2022
+		EQ 850MG BASE/34ML (EQ 25MG BASE/ML)	N214408 003	Jul 19, 2022
+		EQ 1GM BASE/40ML (EQ 25MG BASE/ML)	N214408 004	Jul 19, 2022
+	HOSPIRA	EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	N214218 001	Jun 22, 2022
+		EQ 500MG BASE/20ML (EQ 25MG BASE/ML)	N214218 002	Jun 22, 2022
+		EQ 1GM BASE/40ML (EQ 25MG BASE/ML)	N214218 003	Jun 22, 2022
+	SANDOZ INC	EQ 100MG BASE/4ML (EQ 25MG BASE/MG)	N214657 001	May 26, 2022
+		EQ 500MG BASE/20ML (EQ 25MG BASE/ML)	N214657 002	May 26, 2022
+		EQ 1GM BASE/40ML (EQ 25MG BASE/ML)	N214657 003	May 26, 2022

PEMETREXED DITROMETHAMINE

POWDER; INTRAVENOUS

PEMETREXED DITROMETHAMINE

+	HOSPIRA	EQ 100MG BASE/VIAL	N208746 001	Jun 10, 2022
+		EQ 500MG BASE/VIAL	N208746 002	Jun 10, 2022

PEMIGATINIB

TABLET; ORAL

PEMAZYRE

+	INCYTE CORP	4.5MG	N213736 001	Apr 17, 2020
+		9MG	N213736 002	Apr 17, 2020
+		13.5MG	N213736 003	Apr 17, 2020

PENCICLOVIR

CREAM; TOPICAL

DENAVIR

AB +! MYLAN 1% N020629 001 Sep 24, 1996

PENCICLOVIR

AB TEVA PHARMS USA **1%** **A212710 001** Nov 09, 2022

PENICILLAMINE

CAPSULE; ORAL

CUPRIMINE

<u>AB</u>	<u>+</u>	<u>VALEANT PHARMS INTL</u>	<u>250MG</u>	<u>N019853 001</u>

PENICILLAMINE

<u>AB</u>	ANI PHARMS	<u>250MG</u>	<u>A209921</u>	<u>001</u>	May 07, 2019
<u>AB</u>	APOTEX	<u>250MG</u>	<u>A213310</u>	<u>001</u>	Apr 28, 2020
<u>AB</u>	BRECKENRIDGE	<u>250MG</u>	<u>A215409</u>	<u>001</u>	Aug 23, 2021
<u>AB</u>	DR REDDYS	<u>250MG</u>	<u>A211867</u>	<u>001</u>	Aug 04, 2020
<u>AB</u>	GRANULES	<u>250MG</u>	<u>A211735</u>	<u>001</u>	Dec 02, 2020
<u>AB</u>	INVAGEN PHARMS	<u>250MG</u>	<u>A213293</u>	<u>001</u>	Aug 19, 2021
<u>AB</u>	NAVINTA LLC	<u>250MG</u>	<u>A214363</u>	<u>001</u>	Oct 08, 2021
<u>AB</u>	PAR PHARM INC	<u>250MG</u>	<u>A211231</u>	<u>001</u>	Dec 23, 2019
<u>AB</u>	WATSON LABS INC	<u>250MG</u>	<u>A210976</u>	<u>001</u>	Jun 24, 2019

TABLET; ORAL

DEPEN

<u>AB</u>	<u>+</u>	MYLAN SPECIALITY LP	<u>250MG</u>	<u>N019854</u>	<u>001</u>

PENICILLAMINE

<u>AB</u>	LUPIN LTD	250MG	<u>A212933</u>	<u>001</u>	Nov 30, 2020
<u>AB</u>	PAR PHARM INC	250MG	<u>A211196</u>	<u>001</u>	Dec 23, 2019

PRESCRIPTION DRUG PRODUCT LIST

3-360 (of 474)

PENICILLIN G BENZATHINE

INJECTABLE; INJECTION

BICILLIN L-A

BC +! KING PHARMS LLC 600,000 UNITS/ML N050141 001

PENICILLIN G BENZATHINE; PENICILLIN G PROCAINE

INJECTABLE; INJECTION

BICILLIN C-R

+! KING PHARMS LLC 300,000 UNITS/ML; 300,000 UNITS/ML N050138 001

BICILLIN C-R 900/300

+! KING PHARMS LLC 900,000 UNITS/2ML; 300,000 UNITS/2ML N050138 003

PENICILLIN G POTASSIUM

INJECTABLE; INJECTION

PENICILLIN G POTASSIUM

AP ACS DOBFAR SPA 20,000,000 UNITS/VIAL A205043 002 Oct 26, 2018

AP 5,000,000 UNITS/VIAL A205043 001 Oct 26, 2018

AP HQ SPECLT PHARMA 5,000,000 UNITS/VIAL A065149 002 Jul 23, 2009

AP 20,000,000 UNITS/VIAL A065149 003 Jul 23, 2009

AP ISTITUTO BIO ITA SPA 5,000,000 UNITS/VIAL A065448 001 Aug 18, 2009

AP 20,000,000 UNITS/VIAL A065448 002 Aug 18, 2009

AP SANDOZ 5,000,000 UNITS/VIAL A065079 002 Aug 30, 2002

AP 20,000,000 UNITS/VIAL A065079 003 Aug 30, 2002

PFIZERPEN

AP ! PFIZER 5,000,000 UNITS/VIAL A060657 002

AP ! 20,000,000 UNITS/VIAL A060657 003

PENICILLIN G POTASSIUM

HQ SPECLT PHARMA 1,000,000 UNITS/VIAL A065149 001 Jul 23, 2009

PENICILLIN G POTASSIUM IN PLASTIC CONTAINER

+! BAXTER HLTHCARE 20,000 UNITS/ML N050638 001 Jun 25, 1990

+! 40,000 UNITS/ML N050638 002 Jun 25, 1990

+! 60,000 UNITS/ML N050638 003 Jun 25, 1990

PENICILLIN G PROCAINE

INJECTABLE; INJECTION

PENICILLIN G PROCAINE

! KING PHARMS LLC 300,000 UNITS/ML A060101 002

! 600,000 UNITS/ML A060101 001

PENICILLIN G SODIUM

INJECTABLE; INTRAMUSCULAR, INTRAVENOUS

PENICILLIN G SODIUM

! SANDOZ 5,000,000 UNITS/VIAL A065068 001 Feb 26, 2001

PENICILLIN V POTASSIUM

FOR SOLUTION; ORAL

PENICILLIN-VK

TEVA EQ 125MG BASE/5ML A060456 001

! EQ 250MG BASE/5ML A060456 002

TABLET; ORAL

PENICILLIN V POTASSIUM

AB AUROBINDO PHARMA EQ 250MG BASE A065435 001 Apr 29, 2008

AB EQ 500MG BASE A065435 002 Apr 29, 2008

AB HIKMA PHARMS EQ 250MG BASE A090549 001 Oct 11, 2013

AB EQ 500MG BASE A090549 002 Oct 11, 2013

AB SANDOZ EQ 250MG BASE A064071 001 Nov 30, 1995

AB ! EQ 500MG BASE A064071 002 Nov 30, 1995

AB STRIDES PHARMA EQ 250MG BASE A062936 001 Nov 25, 1988

AB EQ 500MG BASE A062935 001 Nov 23, 1988

PENICILLIN-VK

AB TEVA EQ 250MG BASE A060711 002

AB EQ 500MG BASE A060711 003

PENTAMIDINE ISETHIONATE

FOR SOLUTION; INHALATION

NEBUPENT

AN +! FRESENIUS KABI USA 300MG/VIAL N019887 001 Jun 15, 1989

PENTAMIDINE ISETHIONATE

AN SETON PHARMS 300MG/VIAL A206667 001 Apr 24, 2019

INJECTABLE; INJECTION

PENTAM

AP +! FRESENIUS KABI USA 300MG/VIAL N019264 001 Oct 16, 1984

PENTAMIDINE ISETHIONATE

AP EMCURE PHARMS LTD 300MG/VIAL A213806 001 Jan 07, 2021

AP SETON PHARMS 300MG/VIAL A206666 001 Sep 28, 2017

PRESCRIPTION DRUG PRODUCT LIST

3-361 (of 474)

PENTAMIDINE ISETHIONATE

INJECTABLE; INJECTION

PENTAMIDINE ISETHIONATE

AP	XGEN PHARMS	300MG/VIAL	A206982	001	Mar 17, 2022

PENTOBARBITAL SODIUM

INJECTABLE; INJECTION

NEMBUTAL SODIUM

AP	+! AKORN	50MG/ML	A083246	001	

PENTOBARBITAL SODIUM

AP	ATHENEX	50MG/ML	A206677	001	Nov 27, 2017

AP	HIKMA	50MG/ML	A203619	001	Nov 13, 2017

AP	SAGENT PHARMS INC	50MG/ML	A206404	001	May 23, 2016

PENTOSAN POLYSULFATE SODIUM

CAPSULE; ORAL

ELMIRON

+!	JANSSEN PHARMS	100MG	N020193	001	Sep 26, 1996

PENTOSTATIN

INJECTABLE; INJECTION

NIPENT

AP	+! HOSPIRA INC	10MG/VIAL	N020122	001	Oct 11, 1991

PENTOSTATIN

AP	WEST-WARD PHARMS	10MG/VIAL	A077841	001	Aug 07, 2007

INT

PENTOXIFYLLINE

TABLET, EXTENDED RELEASE; ORAL

PENTOXIFYLLINE

AB	! APOTEX	400MG	A075191	001	Jun 09, 1999

AB	VALEANT PHARMS	400MG	A075028	001	Jul 20, 1998

PERAMIVIR

SOLUTION; INTRAVENOUS

RAPIVAB

+!	BIOCRIST	200MG/20ML (10MG/ML)	N206426	001	Dec 19, 2014

PERAMPANEL

SUSPENSION; ORAL

FYCOMPA

+!	EISAI INC	0.5MG/ML	N208277	001	Apr 29, 2016

TABLET; ORAL

FYCOMPA

+	EISAI INC	2MG	N202834	001	Oct 22, 2012

+		4MG	N202834	002	Oct 22, 2012

+		6MG	N202834	003	Oct 22, 2012

+		8MG	N202834	004	Oct 22, 2012

+		10MG	N202834	005	Oct 22, 2012

+!		12MG	N202834	006	Oct 22, 2012

PERFLUTREN

INJECTABLE; INTRAVENOUS

DEFINITY

+!	LANTHEUS MEDCL	6.52MG/ML	N021064	001	Jul 31, 2001

DEFINITY RT

+!	LANTHEUS MEDCL	6.52MG/ML	N021064	002	Nov 17, 2020

PERINDOPRIL ERBUMINE

TABLET; ORAL

PERINDOPRIL ERBUMINE

AUROBINDO PHARMA

2MG	A079070	001	Nov 10, 2009

4MG	A079070	002	Nov 10, 2009

!	A079070	003	Nov 10, 2009

PERMETHRIN

CREAM; TOPICAL

PERMETHRIN

AB	ACTAVIS LABS	5%	A074806	001	Jan 23, 1998

AB	ENCUBE ETHICALS	5%	A211303	001	Apr 03, 2019

AB	! PADAGIS ISRAEL	5%	A076369	001	Apr 21, 2003

PRESCRIPTION DRUG PRODUCT LIST

3-362 (of 474)

PERPHENAZINE

TABLET; ORAL

PERPHENAZINE

AB	APPCO	2MG	A210163 001	May 18, 2022
AB		4MG	A210163 002	May 18, 2022
AB		8MG	A210163 003	May 18, 2022
AB		16MG	A210163 004	May 18, 2022
AB	RISING	2MG	A205056 001	Mar 01, 2019
AB		4MG	A205056 002	Mar 01, 2019
AB		8MG	A205056 003	Mar 01, 2019
AB		16MG	A205056 004	Mar 01, 2019
AB	SANDOZ	2MG	A089685 002	Dec 08, 1988
AB		4MG	A089685 003	Dec 08, 1988
AB		8MG	A089685 001	Dec 08, 1988
AB	!	16MG	A089685 004	Dec 08, 1988
AB	VINTAGE PHARMS	2MG	A040226 001	Dec 31, 1998
AB		4MG	A040226 002	Dec 31, 1998
AB		8MG	A040226 003	Dec 31, 1998
AB		16MG	A040226 004	Dec 31, 1998
AB	WATSON LABS INC	2MG	A207582 001	Oct 17, 2016
AB		4MG	A207582 002	Oct 17, 2016
AB		8MG	A207582 003	Oct 17, 2016
AB		16MG	A207582 004	Oct 17, 2016
AB	WILSHIRE PHARMS INC	2MG	A205973 001	Dec 17, 2015
AB		4MG	A205973 002	Dec 17, 2015
AB		8MG	A205973 003	Dec 17, 2015
AB		16MG	A205973 004	Dec 17, 2015
AB	ZYDUS PHARMS	2MG	A205232 001	Apr 06, 2020
AB		4MG	A205232 002	Apr 06, 2020
AB		8MG	A205232 003	Apr 06, 2020
AB		16MG	A205232 004	Apr 06, 2020

PEXIDARTINIB HYDROCHLORIDE

CAPSULE; ORAL

TURALIO

+	DAIICHI SANKYO INC	EQ 125MG BASE	N211810 002	Oct 14, 2022
+	!	EQ 200MG BASE	N211810 001	Aug 02, 2019

PHENDIMETRAZINE TARTRATE

CAPSULE, EXTENDED RELEASE; ORAL

PHENDIMETRAZINE TARTRATE

+	!	VIRTUS PHARMS	105MG	N018074 001

TABLET; ORAL

BONTRIL PDM

AA	+	!	VALEANT	35MG	A085272 001	
PHENDIMETRAZINE TARTRATE						
AA			CHARTWELL	35MG	A089452 001	Oct 30, 1991
AA			ELITE LABS INC	35MG	A040762 001	Jan 28, 2008
AA			KVK TECH	35MG	A091042 001	Aug 31, 2010
AA			VIRTUS PHARMS	35MG	A085588 001	

PHENELZINE SULFATE

TABLET; ORAL

NARDIL

AB	+	!	PARKE DAVIS	EQ 15MG BASE	N011909 002	
PHENELZINE SULFATE						
AB			NOVEL LABS INC	EQ 15MG BASE	A200181 001	Dec 08, 2010

PHENOBARBITAL SODIUM

POWDER; INTRAVENOUS

SEZABY

+	!	SUN PHARM INDS INC	100MG/VIAL	N215910 001	Nov 17, 2022

PHENOXYBENZAMINE HYDROCHLORIDE

CAPSULE; ORAL

DIBENZYLINE

AB	+		CONCORDIA	10MG	N008708 001	
PHENOXYBENZAMINE HYDROCHLORIDE						
AB			AMNEAL	10MG	A212568 001	Oct 27, 2020
AB			HIKMA	10MG	A201050 001	Jul 16, 2012
AB			NOVITIUM PHARMA	10MG	A215042 001	Jul 19, 2022
AB	!		PAR PHARM INC	10MG	A204522 001	Jan 24, 2017

PRESCRIPTION DRUG PRODUCT LIST

3-363 (of 474)

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL

ADIPEX-P

AA	+	TEVA	37.5MG	A088023	001	Aug 02, 1983
<u>PHENTERMINE HYDROCHLORIDE</u>						
AA		AUROLIFE PHARMA LLC	15MG	A204318	001	Nov 09, 2016
AA			30MG	A204318	002	Nov 09, 2016
AA		ELITE LABS	15MG	A202248	001	Sep 28, 2012
AA			30MG	A202248	002	Sep 28, 2012
AA		ELITE LABS INC	37.5MG	A040228	001	Jun 19, 1997
AA		INVAGEN PHARMS	15MG	A202858	001	Feb 14, 2014
AA			30MG	A202858	002	Feb 14, 2014
AA			30MG	A204414	001	May 05, 2014
AA			37.5MG	A202846	001	Feb 05, 2014
AA		KVK TECH	15MG	A040886	002	Mar 31, 2008
AA			30MG	A040875	001	Mar 21, 2008
AA			30MG	A040886	001	Mar 31, 2008
AA			37.5MG	A040887	001	Apr 24, 2008
AA		LANNETT	15MG	A087022	002	Jan 20, 2012
AA			30MG	A087022	001	Feb 03, 1983
AA		NUVO PHARM	15MG	A205019	001	Dec 05, 2014
AA			30MG	A205019	002	Dec 05, 2014
AA			37.5MG	A205017	001	Sep 25, 2014
AA	+	SANDOZ	15MG	A087190	002	
AA	+		30MG	A086945	001	Jul 20, 1983
AA	+		30MG	A087190	001	
AA		SUN PHARM INDUSTRIES	30MG	A040525	001	Oct 23, 2003

TABLET; ORAL

ADIPEX-P

AA	+	TEVA	37.5MG	A085128	001	
<u>LOMAIRA</u>						
AA	!	AVANTHI INC	8MG	A203495	001	Sep 12, 2016
<u>PHENTERMINE HYDROCHLORIDE</u>						
AA		AUROLIFE PHARMA LLC	37.5MG	A203068	001	Aug 06, 2014
AA		ELITE LABS	37.5MG	A200272	001	Jan 31, 2011
AA		ELITE LABS INC	37.5MG	A040190	001	May 30, 1997
AA		INVAGEN PHARMS	37.5MG	A202942	001	Feb 05, 2014
AA		KVK TECH	37.5MG	A040876	001	Mar 31, 2008
AA		KVK TECH INC	8MG	A203436	001	Mar 17, 2017
AA		MERRO PHARM USA	37.5MG	A206342	001	Nov 18, 2016
AA		NUVO PHARM	37.5MG	A205008	001	Sep 25, 2014
AA		PRINSTON INC	37.5MG	A040377	001	Jan 04, 2002
AA		SUN PHARM INDUSTRIES	37.5MG	A040526	001	Oct 23, 2003

TABLET, ORALLY DISINTEGRATING; ORAL

PHENTERMINE HYDROCHLORIDE

ZYDUS PHARMS	15MG	A204663	001	Jun 28, 2017
	30MG	A204663	002	Jun 28, 2017
	37.5MG	A204663	003	Jun 28, 2017

PHENTERMINE HYDROCHLORIDE; TOPIRAMATE

CAPSULE, EXTENDED RELEASE; ORAL

QSYMIA

+	VIVUS	EQ 3.75MG BASE; 23MG	N022580	001	Jul 17, 2012
+		EQ 7.5MG BASE; 46MG	N022580	002	Jul 17, 2012
+		EQ 11.25MG BASE; 69MG	N022580	003	Jul 17, 2012
+		EQ 15MG BASE; 92MG	N022580	004	Jul 17, 2012

PHENTOLAMINE MESYLATE

INJECTABLE; INJECTION

PHENTOLAMINE MESYLATE

AP	!	HIKMA	5MG/VIAL	A040235	001	Mar 11, 1998
AP		PRECISION DOSE INC	5MG/VIAL	A207686	001	Jul 14, 2017
ORAVVERSE						
+	SEPTODONT HOLDING	0.4MG/1.7ML	N022159	001	May 09, 2008	

PHENYLEPHRINE HYDROCHLORIDE

SOLUTION; INTRAVENOUS

PHENYLEPHRINE HYDROCHLORIDE

AP1		ACCORD HLTHCARE	10MG/ML (10MG/ML)	A213237	001	Jul 01, 2020
AP1			50MG/5ML (10MG/ML)	A213237	002	Jul 01, 2020
AP1			100MG/10ML (10MG/ML)	A213237	003	Jul 01, 2020
AP1		AMNEAL	10MG/ML (10MG/ML)	A211079	001	Jul 05, 2018

PRESCRIPTION DRUG PRODUCT LIST

3-364 (of 474)

PHENYLEPHRINE HYDROCHLORIDE

SOLUTION; INTRAVENOUS

PHENYLEPHRINE HYDROCHLORIDE

<u>AP1</u>		<u>50MG/5ML (10MG/ML)</u>	<u>A211078 001</u>	Jul 19, 2018
<u>AP1</u>		<u>100MG/10ML (10MG/ML)</u>	<u>A211078 002</u>	Jul 19, 2018
<u>AP1</u>	CAPLIN	<u>10MG/ML (10MG/ML)</u>	<u>A213318 001</u>	Jun 11, 2020
<u>AP1</u>		<u>50MG/5ML (10MG/ML)</u>	<u>A213318 002</u>	Jun 11, 2020
<u>AP1</u>		<u>100MG/10ML (10MG/ML)</u>	<u>A213318 003</u>	Jun 11, 2020
<u>AP1</u>	EUGIA PHARMA	<u>50MG/5ML (10MG/ML)</u>	<u>A210697 001</u>	Nov 13, 2020
<u>AP1</u>		<u>100MG/10ML (10MG/ML)</u>	<u>A210697 002</u>	Nov 13, 2020
<u>AP1</u>	FRESENIUS KABI USA	<u>50MG/5ML (10MG/ML)</u>	<u>A210666 001</u>	Jan 30, 2019
<u>AP1</u>		<u>100MG/10ML (10MG/ML)</u>	<u>A210666 002</u>	Jan 30, 2019
<u>AP1</u>	GLAND PHARMA LTD	<u>10MG/ML (10MG/ML)</u>	<u>A211920 003</u>	Apr 08, 2021
<u>AP1</u>		<u>50MG/5ML (10MG/ML)</u>	<u>A211920 001</u>	Jun 05, 2020
<u>AP1</u>		<u>100MG/10ML (10MG/ML)</u>	<u>A211920 002</u>	Jun 05, 2020
<u>AP1</u>	MANKIND PHARMA	<u>10MG/ML (10MG/ML)</u>	<u>A217069 001</u>	Aug 30, 2022
<u>AP1</u>		<u>50MG/5ML (10MG/ML)</u>	<u>A217069 002</u>	Aug 30, 2022
<u>AP1</u>		<u>100MG/10ML (10MG/ML)</u>	<u>A217069 003</u>	Aug 30, 2022
<u>AP1</u>	MEITHEAL	<u>50MG/5ML (10MG/ML)</u>	<u>A210333 001</u>	Apr 27, 2018
<u>AP1</u>		<u>100MG/10ML (10MG/ML)</u>	<u>A210333 002</u>	Apr 27, 2018
<u>AP1</u>	PAR STERILE PRODUCTS	<u>50MG/5ML (10MG/ML)</u>	<u>A210025 002</u>	Dec 21, 2018
<u>AP1</u>		<u>100MG/10ML (10MG/ML)</u>	<u>A210025 003</u>	Dec 21, 2018
<u>AP1</u>	PROVEPHARM SAS	<u>10MG/ML (10MG/ML)</u>	<u>A211081 001</u>	Jul 17, 2020
<u>AP1</u>		<u>50MG/5ML (10MG/ML)</u>	<u>A211081 002</u>	Jul 17, 2020
<u>AP1</u>		<u>100MG/10ML (10MG/ML)</u>	<u>A211081 003</u>	Jul 17, 2020
<u>AP1</u>	SAGENT PHARMS INC	<u>10MG/ML (10MG/ML)</u>	<u>A209967 001</u>	Jan 16, 2020
<u>AP1</u>		<u>50MG/5ML (10MG/ML)</u>	<u>A209967 002</u>	Jan 16, 2020
<u>AP1</u>		<u>100MG/10ML (10MG/ML)</u>	<u>A209967 003</u>	Jan 16, 2020
<u>AP1</u>	SANDOZ INC	<u>10MG/ML (10MG/ML)</u>	<u>A208905 001</u>	Jan 31, 2019
<u>AP1</u>		<u>50MG/5ML (10MG/ML)</u>	<u>A208905 002</u>	Jan 31, 2019
<u>AP1</u>		<u>100MG/10ML (10MG/ML)</u>	<u>A208905 003</u>	Jan 31, 2019

VAZCULEP

<u>AP1</u>	+	EXELA PHARMA	<u>10MG/ML (10MG/ML)</u>	<u>N204300 001</u>	Jun 27, 2014
<u>AP1</u>	+		<u>50MG/5ML (10MG/ML)</u>	<u>N204300 002</u>	Jun 27, 2014
<u>AP1</u>	+		<u>100MG/10ML (10MG/ML)</u>	<u>N204300 003</u>	Jun 27, 2014

PHENYLEPHRINE HYDROCHLORIDE

<u>AP2</u>		EUGIA PHARMA	<u>10MG/ML (10MG/ML)</u>	<u>A210696 001</u>	Jan 07, 2021
<u>AP2</u>		FRESENIUS KABI USA	<u>10MG/ML (10MG/ML)</u>	<u>A210665 001</u>	Jan 29, 2019
<u>AP2</u>	+	HIKMA	<u>10MG/ML (10MG/ML)</u>	<u>N203826 001</u>	Dec 20, 2012
<u>AP2</u>	+		<u>50MG/5ML (10MG/ML)</u>	<u>N203826 002</u>	Jun 19, 2019
<u>AP2</u>	+		<u>100MG/10ML (10MG/ML)</u>	<u>N203826 003</u>	Jun 19, 2019
<u>AP2</u>		MEITHEAL	<u>10MG/ML (10MG/ML)</u>	<u>A210334 001</u>	Apr 27, 2018

BIORPHEN

+	DR REDDYS LABS SA	0.5MG/5ML (0.1MG/ML)	N212909 001	Oct 21, 2019

SOLUTION/DROPS; OPHTHALMIC

PHENYLEPHRINE HYDROCHLORIDE

<u>AT</u>	+	AKORN	<u>2.5%</u>	<u>N207926 001</u>	Jan 15, 2015
<u>AT</u>	+		<u>10%</u>	<u>N207926 002</u>	Jan 15, 2015
<u>AT</u>		MANKIND PHARMA	<u>2.5%</u>	<u>A216859 001</u>	Sep 29, 2022
<u>AT</u>			<u>10%</u>	<u>A216496 001</u>	Jan 11, 2023
<u>AT</u>	+	PARAGON BIOTECK	<u>2.5%</u>	<u>N203510 001</u>	Mar 21, 2013
<u>AT</u>	+		<u>10%</u>	<u>N203510 002</u>	Mar 21, 2013

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE

<u>AA</u>		AKORN	<u>5MG/5ML; 6.25MG/5ML</u>	<u>A040675 001</u>	Dec 23, 2014
<u>AA</u>	!	PHARM ASSOC	<u>5MG/5ML; 6.25MG/5ML</u>	<u>A040654 001</u>	Dec 07, 2006

PROMETHAZINE HYDROCHLORIDE AND PHENYLEPHRINE HYDROCHLORIDE

<u>AA</u>		AMNEAL PHARMS	<u>5MG/5ML; 6.25MG/5ML</u>	<u>A040902 001</u>	Aug 25, 2009

PHENYTOIN

SUSPENSION; ORAL

DILANTIN-125

<u>AB</u>	+	VIATRIS	<u>125MG/5ML</u>	<u>N008762 001</u>	

PHENYTOIN

<u>AB</u>		PAI HOLDINGS PHARM	<u>125MG/5ML</u>	<u>A040420 001</u>	Apr 19, 2002
<u>AB</u>		TARO	<u>125MG/5ML</u>	<u>A040521 001</u>	Mar 08, 2004
<u>AB</u>		VISTAPHARM	<u>125MG/5ML</u>	<u>A040342 001</u>	Jan 31, 2001
<u>AB</u>			<u>125MG/5ML</u>	<u>A040342 002</u>	Aug 18, 2005

PRESCRIPTION DRUG PRODUCT LIST

3-365 (of 474)

PHENYTOIN

TABLET, CHEWABLE; ORAL

DILANTIN

AB	+!	PHARMACIA	50MG	A084427	001	

PHENYTOIN

AB		EPIC PHARMA LLC	50MG	A040884	001	Nov 28, 2014
AB		RISING	50MG	A200691	001	Dec 26, 2012
AB		TARO	50MG	A200565	001	Apr 17, 2014

PHENYTOIN SODIUM

CAPSULE; ORAL

DILANTIN

AB	+!	VIATRIS	100MG EXTENDED	A084349	002	

EXTENDED PHENYTOIN SODIUM

AB		AMNEAL PHARMS NY	100MG EXTENDED	A040765	001	Nov 12, 2008
AB		MYLAN	100MG EXTENDED	A040298	001	Dec 28, 1998
AB		SUN PHARM INDS	200MG EXTENDED	A040731	001	Jun 30, 2008
AB			300MG EXTENDED	A040731	002	Jun 30, 2008
AB		TARO	100MG EXTENDED	A040684	001	Sep 05, 2006
AB		UNICHEM	100MG EXTENDED	A213834	001	Oct 13, 2022

PHENYTEK

AB		MYLAN	200MG EXTENDED	A040298	002	Dec 06, 2001
AB	!		300MG EXTENDED	A040298	003	Dec 06, 2001

PHENYTOIN SODIUM

AB		AUROBINDO PHARMA	100MG EXTENDED	A204309	001	Jun 10, 2015

DILANTIN

+! VIATRIS

30MG EXTENDED

A084349 001

INJECTABLE; INJECTION

PHENYTOIN SODIUM

AP		ACELLA	50MG/ML	A040573	001	Sep 13, 2006

AP	+!	WEST-WARD PHARMS	50MG/ML	A084307	001	

INT

PHYTONADIONE

INJECTABLE; INJECTION

PHYTONADIONE

AB1		DR REDDYS	10MG/ML	A207719	001	May 22, 2019

VITAMIN K1

AB1	+!	HOSPIRA	10MG/ML	A087955	001	Jul 25, 1983

PHYTONADIONE

BP	+!	INTL MEDICATION	1MG/0.5ML	A083722	001	

VITAMIN K1

BP	+!	HOSPIRA	1MG/0.5ML	A087954	001	Jul 25, 1983

PHYTONADIONE

! CIPLA

1MG/0.5ML

A214596 001 Apr 22, 2022

!

10MG/ML

A214596 002 Apr 22, 2022

TABLET; ORAL

MEPHYTON

AB	+!	BAUSCH	5MG	N010104	003	

PHYTONADIONE

AB		AMNEAL PHARMS CO	5MG	A209373	001	May 11, 2018

AB		ZYDUS	5MG	A210189	001	Feb 20, 2019

PIFLUFOLASTAT F-18

SOLUTION; INTRAVENOUS

PYLARIFY

+! PROGENICS PHARMS

50ML (1-80mCi/ML)

N214793 001 May 26, 2021

INC

PILOCARPINE HYDROCHLORIDE

SOLUTION; OPHTHALMIC

ISOPTO CARPINE

AT	+!	NOVARTIS	1%	N200890	001	Jun 22, 2010

AT	+!		2%	N200890	002	Jun 22, 2010

AT	+!		4%	N200890	003	Jun 22, 2010

PILOCARPINE HYDROCHLORIDE

AT		AKORN	1%	A204398	001	Sep 27, 2017

AT			2%	A204398	002	Sep 27, 2017

AT			4%	A204398	003	Sep 27, 2017

AT		AMNEAL	1%	A214193	001	Sep 21, 2020

AT			2%	A214193	002	Sep 21, 2020

AT			4%	A214193	003	Sep 21, 2020

AT		SOMERSET THERAPS	1%	A210384	001	Nov 25, 2019

LLC

AT			2%	A210384	002	Nov 25, 2019

PRESCRIPTION DRUG PRODUCT LIST

3-366 (of 474)

PILOCARPINE HYDROCHLORIDE

SOLUTION;OPHTHALMIC

PILOCARPINE HYDROCHLORIDE

AT		4%	A210384	003	Nov 25, 2019

VUITY

+! ABBVIE INC

1.25%

N214028 001 Oct 28, 2021

TABLET;ORAL

PILOCARPINE HYDROCHLORIDE

AB	AMICI	5MG	A076963	001	Dec 22, 2004

AB		7.5MG	A076963	002	Feb 27, 2007

AB	AUROBINDO PHARMA LTD	5MG	A212377	001	Aug 13, 2019

AB		7.5MG	A212377	002	Aug 13, 2019

AB	IMPAX LABS	5MG	A077248	001	Mar 31, 2006

AB		7.5MG	A077248	002	Mar 31, 2006

AB	LANNETT CO INC	5MG	A077220	001	Oct 14, 2005

AB		7.5MG	A077220	002	May 06, 2009

AB	PADAGIS US	5MG	A076746	001	Nov 16, 2004

SALAGEN

AB	+ CONCORDIA	5MG	N020237	001	Mar 22, 1994

AB	+!	7.5MG	N020237	002	Apr 18, 2003

PIMAVANSERIN TARTRATE

CAPSULE;ORAL

NUPLAZID

+! ACADIA PHARMS INC

EQ 34MG BASE

N210793 001 Jun 28, 2018

TABLET;ORAL

NUPLAZID

+! ACADIA PHARMS INC

EQ 10MG BASE

N207318 002 Jun 28, 2018

PIMECROLIMUS

CREAM;TOPICAL

ELIDEL

AB	+! BAUSCH	1%	N021302	001	Dec 13, 2001

PIMECROLIMUS

AB	ACTAVIS LABS UT INC	1%	A209345	001	Dec 27, 2018

AB	GLENMARK PHARMS LTD	1%	A211769	001	Aug 29, 2019

PIMOZIDE

TABLET;ORAL

PIMOZIDE

PAR PHARM

1MG

A204521 001 Sep 28, 2015

!

2MG

A204521 002 Sep 28, 2015

PINDOLOL

TABLET;ORAL

PINDOLOL

AB	ANI PHARMS	5MG	A073609	002	Mar 29, 1993

AB		10MG	A073609	001	Mar 29, 1993

AB	AUROBINDO PHARMA USA	5MG	A074019	001	Sep 03, 1992

AB	!	10MG	A074019	002	Sep 03, 1992

AB	BAYSHORE PHARMS LLC	5MG	A211712	001	Aug 01, 2019

AB		10MG	A211712	002	Aug 01, 2019

AB	NOSTRUM LABS INC	5MG	A205415	001	Jan 13, 2016

AB		10MG	A205415	002	Jan 13, 2016

AB	SUN PHARM INDUSTRIES	5MG	A074063	001	Jan 27, 1994

AB		10MG	A074063	002	Jan 27, 1994

PIOGLITAZONE HYDROCHLORIDE

TABLET;ORAL

ACTOS

AB	+ TAKEDA PHARMS USA	EQ 15MG BASE	N021073	001	Jul 15, 1999

AB	+	EQ 30MG BASE	N021073	002	Jul 15, 1999

AB	+!	EQ 45MG BASE	N021073	003	Jul 15, 1999

PIOGLITAZONE HYDROCHLORIDE

AB	ACCORD HLTHCARE	EQ 15MG BASE	A200044	001	Feb 13, 2013

AB		EQ 30MG BASE	A200044	002	Feb 13, 2013

AB		EQ 45MG BASE	A200044	003	Feb 13, 2013

AB	ANNORA PHARMA	EQ 15MG BASE	A204133	001	Apr 07, 2014

AB		EQ 30MG BASE	A204133	002	Apr 07, 2014

AB		EQ 45MG BASE	A204133	003	Apr 07, 2014

AB	AUROBINDO PHARMA LTD	EQ 15MG BASE	A200268	001	Feb 13, 2013

AB		EQ 30MG BASE	A200268	002	Feb 13, 2013

PRESCRIPTION DRUG PRODUCT LIST

3-367 (of 474)

PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

PIOGLITAZONE HYDROCHLORIDE

<u>AB</u>		<u>EQ 45MG BASE</u>	<u>A200268</u>	<u>003</u>	Feb 13, 2013
<u>AB</u>	CELLTRION	<u>EQ 15MG BASE</u>	<u>A076798</u>	<u>001</u>	Oct 26, 2012
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A076798</u>	<u>002</u>	Oct 26, 2012
<u>AB</u>		<u>EQ 45MG BASE</u>	<u>A076798</u>	<u>003</u>	Oct 26, 2012
<u>AB</u>	MACLEODS PHARMS LTD	<u>EQ 15MG BASE</u>	<u>A202467</u>	<u>001</u>	Feb 06, 2013
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A202467</u>	<u>002</u>	Feb 06, 2013
<u>AB</u>		<u>EQ 45MG BASE</u>	<u>A202467</u>	<u>003</u>	Feb 06, 2013
<u>AB</u>	PRINSTON INC	<u>EQ 15MG BASE</u>	<u>A207806</u>	<u>001</u>	Apr 17, 2018
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A207806</u>	<u>002</u>	Apr 17, 2018
<u>AB</u>		<u>EQ 45MG BASE</u>	<u>A207806</u>	<u>003</u>	Apr 17, 2018
<u>AB</u>	PURACAP PHARM LLC	<u>EQ 15MG BASE</u>	<u>A206738</u>	<u>001</u>	Oct 06, 2017
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A206738</u>	<u>002</u>	Oct 06, 2017
<u>AB</u>		<u>EQ 45MG BASE</u>	<u>A206738</u>	<u>003</u>	Oct 06, 2017
<u>AB</u>	SANDOZ	<u>EQ 15MG BASE</u>	<u>A078670</u>	<u>001</u>	Feb 13, 2013
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A078670</u>	<u>002</u>	Feb 13, 2013
<u>AB</u>		<u>EQ 45MG BASE</u>	<u>A078670</u>	<u>003</u>	Feb 13, 2013
<u>AB</u>	SHUANGCHENG	<u>EQ 15MG BASE</u>	<u>A210165</u>	<u>001</u>	Jan 22, 2021
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A210165</u>	<u>002</u>	Jan 22, 2021
<u>AB</u>		<u>EQ 45MG BASE</u>	<u>A210165</u>	<u>003</u>	Jan 22, 2021
<u>AB</u>	TEVA PHARMS USA	<u>EQ 15MG BASE</u>	<u>A077210</u>	<u>001</u>	Jan 10, 2014
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A077210</u>	<u>002</u>	Jan 10, 2014
<u>AB</u>		<u>EQ 45MG BASE</u>	<u>A077210</u>	<u>003</u>	Jan 10, 2014
<u>AB</u>	ZYDUS PHARMS USA INC	<u>EQ 15MG BASE</u>	<u>A202456</u>	<u>001</u>	Feb 13, 2013
<u>AB</u>		<u>EQ 30MG BASE</u>	<u>A202456</u>	<u>002</u>	Feb 13, 2013
<u>AB</u>		<u>EQ 45MG BASE</u>	<u>A202456</u>	<u>003</u>	Feb 13, 2013

PIPERACILLIN SODIUM

INJECTABLE; INJECTION

PIPERACILLIN

!	ISTITUTO BIO ITA SPA	EQ 2GM BASE/VIAL	A065114	001	Nov 14, 2003
!		EQ 3GM BASE/VIAL	A065114	002	Nov 14, 2003
!		EQ 4GM BASE/VIAL	A065114	003	Nov 14, 2003
!		EQ 40GM BASE/VIAL	A065157	001	Jul 12, 2004

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE; INJECTION

PIPERACILLIN AND TAZOBACTAM

<u>AP</u>	ASTRAL	<u>EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL</u>	<u>A212287</u>	<u>001</u>	Jul 29, 2019
<u>AP</u>		<u>EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL</u>	<u>A212287</u>	<u>002</u>	Jul 29, 2019
<u>AP</u>		<u>EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A212287</u>	<u>003</u>	Jul 29, 2019
<u>AP</u>	EUGIA PHARMA SPECLTS	<u>EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL</u>	<u>A065498</u>	<u>001</u>	May 23, 2011
<u>AP</u>		<u>EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL</u>	<u>A065498</u>	<u>002</u>	May 23, 2011
<u>AP</u>		<u>EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A065498</u>	<u>003</u>	May 23, 2011
<u>AP</u>	FRESENIUS KABI	<u>EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL</u>	<u>A203719</u>	<u>001</u>	May 18, 2018
<u>AP</u>		<u>EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL</u>	<u>A203719</u>	<u>002</u>	May 18, 2018
<u>AP</u>		<u>EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A203719</u>	<u>003</u>	May 18, 2018
<u>AP</u>		<u>EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL</u>	<u>A203720</u>	<u>001</u>	May 11, 2018
<u>AP</u>	FRESENIUS KABI USA	<u>EQ 12GM BASE/VIAL;EQ 1.5GM BASE/VIAL</u>	<u>A206204</u>	<u>001</u>	May 11, 2018
<u>AP</u>	ISTITUTO BIO ITA SPA	<u>EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL</u>	<u>A065523</u>	<u>001</u>	May 31, 2011
<u>AP</u>		<u>EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL</u>	<u>A065523</u>	<u>002</u>	May 31, 2011
<u>AP</u>		<u>EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A065523</u>	<u>003</u>	May 31, 2011
<u>AP</u>		<u>EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL</u>	<u>A090498</u>	<u>001</u>	May 31, 2011
<u>AP</u>	PROVEPHARM SAS	<u>EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL</u>	<u>A207847</u>	<u>001</u>	Jan 13, 2017
<u>AP</u>		<u>EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL</u>	<u>A207847</u>	<u>002</u>	Jan 13, 2017
<u>AP</u>		<u>EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL</u>	<u>A207848</u>	<u>002</u>	Jan 13, 2017
<u>AP</u>		<u>EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A207847</u>	<u>003</u>	Jan 13, 2017
<u>AP</u>		<u>EQ 12GM BASE/VIAL;EQ 1.5GM BASE/VIAL</u>	<u>A207848</u>	<u>001</u>	May 11, 2018
<u>AP</u>	QILU	<u>EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL</u>	<u>A204959</u>	<u>001</u>	Aug 10, 2018
<u>AP</u>		<u>EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL</u>	<u>A204959</u>	<u>002</u>	Aug 10, 2018
<u>AP</u>		<u>EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A204959</u>	<u>003</u>	Aug 10, 2018
<u>AP</u>	SAGENT PHARMS INC	<u>EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL</u>	<u>A208674</u>	<u>001</u>	Feb 16, 2021
<u>AP</u>		<u>EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL</u>	<u>A208674</u>	<u>002</u>	Feb 16, 2021
<u>AP</u>		<u>EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A208674</u>	<u>003</u>	Feb 16, 2021
<u>AP</u>		<u>EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL</u>	<u>A208675</u>	<u>001</u>	Feb 16, 2021
<u>AP</u>	SANDOZ	<u>EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL</u>	<u>A065362</u>	<u>001</u>	Oct 21, 2010
<u>AP</u>		<u>EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL</u>	<u>A065362</u>	<u>001</u>	Oct 21, 2010
<u>AP</u>		<u>EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL</u>	<u>A065362</u>	<u>002</u>	Oct 21, 2010

PRESCRIPTION DRUG PRODUCT LIST

3-368 (of 474)

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE; INJECTION

PIPERACILLIN AND TAZOBACTAM

<u>AP</u>		<u>EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL</u>	<u>A065363</u>	<u>002</u>	Oct 21, 2010
<u>AP</u>		<u>EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A065362</u>	<u>003</u>	Oct 21, 2010
<u>AP</u>		<u>EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A065363</u>	<u>003</u>	Oct 21, 2010
<u>AP</u>	SANDOZ INC	<u>EQ 12GM BASE/VIAL;EQ 1.5GM BASE/VIAL</u>	<u>A203557</u>	<u>001</u>	Oct 29, 2014
<u>AP</u>		<u>EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL</u>	<u>A203557</u>	<u>002</u>	Jul 08, 2021
<u>AP</u>	STERISCIENCE	<u>EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL</u>	<u>A065458</u>	<u>001</u>	Aug 15, 2014
<u>AP</u>		<u>EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL</u>	<u>A065458</u>	<u>002</u>	Aug 15, 2014
<u>AP</u>		<u>EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A065458</u>	<u>003</u>	Aug 15, 2014
<u>AP</u>	! WOCKHARDT BIO AG	<u>EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL</u>	<u>A206996</u>	<u>001</u>	Mar 22, 2017
<u>AP</u>	!	<u>EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL</u>	<u>A206996</u>	<u>002</u>	Mar 22, 2017
<u>AP</u>	!	<u>EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL</u>	<u>A206996</u>	<u>003</u>	Mar 22, 2017
<u>AP</u>	!	<u>EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL</u>	<u>A207146</u>	<u>001</u>	Mar 17, 2017
	ZOSYN IN PLASTIC CONTAINER				
	+! WYETH PHARMS	EQ 40MG BASE/ML;EQ 5MG BASE/ML	N050750	001	Feb 24, 1998
	+!	EQ 60MG BASE/ML;EQ 7.5MG BASE/ML	N050750	002	Feb 24, 1998
	+!	EQ 4GM BASE/100ML;EQ 500MG BASE/100ML	N050750	003	Feb 24, 1998

PIRFENIDONE

CAPSULE; ORAL

ESBRIET

<u>AB</u>	+! GENENTECH INC	<u>267MG</u>	<u>N022535</u>	<u>001</u>	Oct 15, 2014

PIRFENIDONE

<u>AB</u>	ACCORD HLTHCARE	<u>267MG</u>	<u>A212731</u>	<u>001</u>	Jan 20, 2022
<u>AB</u>	AMNEAL	<u>267MG</u>	<u>A212569</u>	<u>001</u>	Jan 03, 2022
<u>AB</u>	LAURUS	<u>267MG</u>	<u>A212724</u>	<u>001</u>	Jul 19, 2022
<u>AB</u>	SANDOZ INC	<u>267MG</u>	<u>A212600</u>	<u>001</u>	Jun 13, 2022
<u>AB</u>	SCIEGEN PHARMS INC	<u>267MG</u>	<u>A212077</u>	<u>001</u>	Aug 01, 2022

TABLET; ORAL

ESBRIET

<u>AB</u>	+ GENENTECH INC	<u>267MG</u>	<u>N208780</u>	<u>001</u>	Jan 11, 2017
<u>AB</u>	+!	<u>801MG</u>	<u>N208780</u>	<u>003</u>	Jan 11, 2017

PIRFENIDONE

<u>AB</u>	ACCORD HLTHCARE	<u>267MG</u>	<u>A212730</u>	<u>001</u>	Jan 25, 2022
<u>AB</u>		<u>801MG</u>	<u>A212730</u>	<u>002</u>	Jan 25, 2022
<u>AB</u>	AIZANT	<u>267MG</u>	<u>A212747</u>	<u>001</u>	Jul 21, 2022
<u>AB</u>		<u>534MG</u>	<u>A212747</u>	<u>002</u>	Jul 21, 2022
<u>AB</u>		<u>801MG</u>	<u>A212747</u>	<u>003</u>	Jul 21, 2022
<u>AB</u>	ALEMBIC PHARMS	<u>267MG</u>	<u>A212708</u>	<u>001</u>	May 20, 2022
<u>AB</u>		<u>801MG</u>	<u>A212708</u>	<u>002</u>	May 20, 2022
<u>AB</u>	AMNEAL	<u>267MG</u>	<u>A212570</u>	<u>001</u>	Mar 25, 2022
<u>AB</u>		<u>801MG</u>	<u>A212570</u>	<u>002</u>	Mar 25, 2022
<u>AB</u>	HETERO LABS LTD V	<u>267MG</u>	<u>A212674</u>	<u>001</u>	Sep 21, 2022
<u>AB</u>		<u>801MG</u>	<u>A212674</u>	<u>002</u>	Sep 21, 2022
<u>AB</u>	LAURUS	<u>267MG</u>	<u>A212722</u>	<u>001</u>	Jul 19, 2022
<u>AB</u>		<u>534MG</u>	<u>A212722</u>	<u>002</u>	Jul 19, 2022
<u>AB</u>		<u>801MG</u>	<u>A212722</u>	<u>003</u>	Jul 19, 2022
<u>AB</u>	MICRO LABS	<u>267MG</u>	<u>A212680</u>	<u>001</u>	May 18, 2022
<u>AB</u>		<u>801MG</u>	<u>A212680</u>	<u>002</u>	May 18, 2022
<u>AB</u>	MSN	<u>267MG</u>	<u>A212772</u>	<u>001</u>	May 24, 2022
<u>AB</u>		<u>801MG</u>	<u>A212772</u>	<u>002</u>	May 24, 2022
<u>AB</u>	SANDOZ INC	<u>267MG</u>	<u>A212560</u>	<u>001</u>	Apr 28, 2022
<u>AB</u>		<u>801MG</u>	<u>A212560</u>	<u>002</u>	Apr 28, 2022
<u>AB</u>	SCIEGEN PHARMS INC	<u>267MG</u>	<u>A212078</u>	<u>001</u>	Aug 01, 2022
<u>AB</u>		<u>801MG</u>	<u>A212078</u>	<u>002</u>	Aug 01, 2022
<u>AB</u>	TEVA PHARMS USA	<u>267MG</u>	<u>A212759</u>	<u>001</u>	Jan 25, 2022
<u>AB</u>		<u>801MG</u>	<u>A212759</u>	<u>002</u>	Jan 25, 2022

PIROXICAM

CAPSULE; ORAL

FELDENE

<u>AB</u>	+ PFIZER	<u>10MG</u>	<u>N018147</u>	<u>002</u>	Apr 06, 1982
<u>AB</u>	+!	<u>20MG</u>	<u>N018147</u>	<u>003</u>	Apr 06, 1982

PIROXICAM

<u>AB</u>	CADILA	<u>10MG</u>	<u>A205585</u>	<u>001</u>	Jul 17, 2018
<u>AB</u>		<u>20MG</u>	<u>A205585</u>	<u>002</u>	Jul 17, 2018
<u>AB</u>	FLAMINGO PHARMS	<u>10MG</u>	<u>A207938</u>	<u>001</u>	Sep 09, 2016
<u>AB</u>		<u>20MG</u>	<u>A207938</u>	<u>002</u>	Sep 09, 2016
<u>AB</u>	HIKMA	<u>10MG</u>	<u>A209256</u>	<u>001</u>	Aug 11, 2017
<u>AB</u>		<u>20MG</u>	<u>A209256</u>	<u>002</u>	Aug 11, 2017
<u>AB</u>	MICRO LABS	<u>10MG</u>	<u>A206152</u>	<u>001</u>	Dec 29, 2017

PRESCRIPTION DRUG PRODUCT LIST

3-369 (of 474)

PIROXICAM

CAPSULE; ORAL

PIROXICAM

AB		20MG	A206152 002	Dec 29, 2017
AB	NOSTRUM LABS INC	10MG	A074118 002	Jun 15, 1993
AB		20MG	A074118 001	Jun 15, 1993
AB	STRIDES PHARMA	10MG	A206136 001	Jun 20, 2017
AB		10MG	A210347 001	Jan 26, 2018
AB		20MG	A206136 002	Jun 20, 2017
AB		20MG	A210347 002	Jan 26, 2018
AB	TEVA	10MG	A074131 001	Dec 11, 1992
AB		20MG	A074131 002	Dec 11, 1992
BX	UNICHEM	10MG	A208340 001	Apr 13, 2017
BX		20MG	A208340 002	Apr 13, 2017

PITAVASTATIN CALCIUM

TABLET; ORAL

LIVALO

AB	+	KOWA CO	EQ 1MG BASE	N022363 001	Aug 03, 2009
AB	+		EQ 2MG BASE	N022363 002	Aug 03, 2009
AB	+	!	EQ 4MG BASE	N022363 003	Aug 03, 2009

PITAVASTATIN CALCIUM

AB		AUROBINDO PHARMA	EQ 1MG BASE	A206015 001	Dec 20, 2016
AB			EQ 2MG BASE	A206015 002	Dec 20, 2016
AB			EQ 4MG BASE	A206015 003	Dec 20, 2016
AB		ORIENT PHARMA CO LTD	EQ 1MG BASE	A205932 001	Feb 03, 2017
AB			EQ 2MG BASE	A205932 002	Feb 03, 2017
AB			EQ 4MG BASE	A205932 003	Feb 03, 2017
AB		SAWAI USA	EQ 1MG BASE	A205955 001	Feb 03, 2017
AB			EQ 2MG BASE	A205955 002	Feb 03, 2017
AB			EQ 4MG BASE	A205955 003	Feb 03, 2017

PITAVASTATIN MAGNESIUM

TABLET; ORAL

ZYPITAMAG

	+	MEDICURE	EQ 2MG BASE	N208379 002	Jul 14, 2017
	+	!	EQ 4MG BASE	N208379 003	Jul 14, 2017

PITOLISANT HYDROCHLORIDE

TABLET; ORAL

WAKIX

	+	HARMONY	EQ 4.45MG BASE	N211150 001	Aug 14, 2019
	+	!	EQ 17.8MG BASE	N211150 002	Aug 14, 2019

PLAZOMICIN SULFATE

SOLUTION; INTRAVENOUS

ZEMDRI

	+	CIPLA USA	EQ 500MG BASE/10ML (EQ 50MG BASE/ML)	N210303 001	Jun 25, 2018

PLECANATIDE

TABLET; ORAL

TRULANCE

	+	SALIX	3MG	N208745 001	Jan 19, 2017

PLERIXAFOR

SOLUTION; SUBCUTANEOUS

MOZOBIL

	+	GENZYME	24MG/1.2ML (20MG/ML)	N022311 001	Dec 15, 2008

PODOFILOX

GEL; TOPICAL

CONDYLOX

	+	ALLERGAN	0.5%	N020529 001	Mar 13, 1997

SOLUTION; TOPICAL

CONDYLOX

AT	+	TEVA BRANDED PHARM	0.5%	N019795 001	Dec 13, 1990

PODOFILOX

AT		PADAGIS US	0.5%	A075600 001	Jan 29, 2002

POLIDOCANOL

SOLUTION; INTRAVENOUS

ASCLERA

	+	CHEMISCH FBRK	10MG/2ML (5MG/ML)	N021201 001	Mar 30, 2010

KRSSLR

	+	!	20MG/2ML (10MG/ML)	N021201 002	Mar 30, 2010

PRESCRIPTION DRUG PRODUCT LIST

3-370 (of 474)

POLIDOCANOL

SOLUTION; INTRAVENOUS

VARITHENA

+! PROVENISIS

180MG/18ML (10MG/ML)

N205098 001 Nov 25, 2013

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

FOR SOLUTION; ORAL

NULYTELY**AA** +! BRAINTREE420GM/BOT; 1.48GM/BOT; 5.72GM/BOT; 11.2GM/BOT**N019797 001** Apr 22, 1991NULYTELY-FLAVORED**AA** +! BRAINTREE420GM/BOT; 1.48GM/BOT; 5.72GM/BOT; 11.2GM/BOT**N019797 002** Nov 18, 1994PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE**AA** STRIDES PHARMA420GM/BOT; 1.48GM/BOT; 5.72GM/BOT; 11.2GM/BOT**A204559 001** Apr 13, 2015POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUS

FOR SOLUTION; ORAL

COLYTE WITH FLAVOR PACKS**AA** MYLAN SPECIALITY LP240GM/BOT; 2.98GM/BOT; 6.72GM/BOT; 5.84GM/BOT; 22.72GM/BOT**N018983 012** Oct 08, 1998GOLYTELY**AA** +! BRAINTREE236GM/BOT; 2.97GM/BOT; 6.74GM/BOT; 5.86GM/BOT; 22.74GM/BOT**N019011 001** Jul 13, 1984PEG 3350 AND ELECTROLYTES**AA** NOVEL LABS INC236GM/BOT; 2.97GM/BOT; 6.74GM/BOT; 5.86GM/BOT; 22.74GM/BOT**A090231 001** Jun 01, 2009**AA**240GM/BOT; 2.98GM/BOT; 6.72GM/BOT; 5.84GM/BOT; 22.72GM/BOT**A090186 001** Jun 01, 2009POLYETHYLENE GLYCOL 3350 AND ELECTROLYTES**AA** STRIDES PHARMA236GM/BOT; 2.97GM/BOT; 6.74GM/BOT; 5.86GM/BOT; 22.74GM/BOT**A204558 001** Dec 21, 2018POLYMYXIN B SULFATE

INJECTABLE; INJECTION

POLYMYXIN B SULFATE**AP** EUGIA PHARMAEQ 500,000 UNITS BASE/VIAL**A206589 001** Apr 04, 2016**AP** FRESenius KABI USAEQ 500,000 UNITS BASE/VIAL**A065372 001** Jan 10, 2008**AP** GLANDEQ 500,000 UNITS BASE/VIAL**A207322 001** Apr 14, 2016**AP** ! XELLIA PHARMS APSEQ 500,000 UNITS BASE/VIAL**A202766 001** Jan 15, 2014**AP** XGEN PHARMSEQ 500,000 UNITS BASE/VIAL**A063000 001** Sep 30, 1994POLYMYXIN B SULFATE; TRIMETHOPRIM SULFATE

SOLUTION/DROPS; OPHTHALMIC

POLYTRIM**AT** +! ALLERGAN10,000 UNITS/ML; EQ 1MG BASE/ML**N050567 001** Oct 20, 1988TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE**AT** AKORN10,000 UNITS/ML; EQ 1MG BASE/ML**A065006 001** Dec 17, 1998**AT** BAUSCH AND LOMB10,000 UNITS/ML; EQ 1MG BASE/ML**A064120 001** Feb 14, 1997**AT** SANDOZ INC10,000 UNITS/ML; EQ 1MG BASE/ML**A064211 001** Apr 13, 1998POMALIDOMIDE

CAPSULE; ORAL

POMALYST

+ CELGENE

1MG

N204026 001 Feb 08, 2013

+

2MG

N204026 002 Feb 08, 2013

+

3MG

N204026 003 Feb 08, 2013

+!

4MG

N204026 004 Feb 08, 2013

PONATINIB HYDROCHLORIDE

TABLET; ORAL

ICLUSIG

+ TAKEDA PHARMS USA

EQ 10MG BASE

N203469 004 Dec 18, 2020

+

EQ 15MG BASE

N203469 001 Dec 14, 2012

+

EQ 30MG BASE

N203469 003 Apr 23, 2015

+!

EQ 45MG BASE

N203469 002 Dec 14, 2012

PONESIMOD

TABLET; ORAL

PONVORY

+! JANSSEN PHARMS

2MG

N213498 001 Mar 18, 2021

+

3MG

N213498 002 Mar 18, 2021

+

4MG

N213498 003 Mar 18, 2021

+

5MG

N213498 004 Mar 18, 2021

+

6MG

N213498 005 Mar 18, 2021

+

7MG

N213498 006 Mar 18, 2021

PRESCRIPTION DRUG PRODUCT LIST

3-371 (of 474)

PONESIMOD

TABLET; ORAL

PONVORY

+	8MG	N213498	007	Mar 18, 2021
+	9MG	N213498	008	Mar 18, 2021
+	10MG	N213498	009	Mar 18, 2021
+	20MG	N213498	010	Mar 18, 2021

PORTIMER SODIUM

INJECTABLE; INJECTION

PHOTOFRIN

PINNACLE BIOLGS	75MG/VIAL	N020451	001	Dec 27, 1995

POSACONAZOLE

FOR SUSPENSION, DELAYED RELEASE; ORAL

NOXAFIL POWDERMIX KIT

+! MSD MERCK CO	300MG	N214770	001	May 31, 2021

SOLUTION; INTRAVENOUS

NOXAFIL

AP +! MERCK SHARP DOHME	<u>300MG/16.7ML (18MG/ML)</u>	<u>N205596</u>	<u>001</u>	Mar 13, 2014

POSACONAZOLE

AP PAR STERILE PRODUCTS	<u>300MG/16.7ML (18MG/ML)</u>	<u>A208768</u>	<u>001</u>	May 25, 2022

SUSPENSION; ORAL

NOXAFIL

AB +! SCHERING	<u>40MG/ML</u>	<u>N022003</u>	<u>001</u>	Sep 15, 2006

POSACONAZOLE

AB HIKMA	<u>40MG/ML</u>	<u>A208773</u>	<u>001</u>	May 15, 2020

TABLET, DELAYED RELEASE; ORAL

NOXAFIL

AB +! MERCK SHARP DOHME	<u>100MG</u>	<u>N205053</u>	<u>001</u>	Nov 25, 2013

POSACONAZOLE

AB ACTAVIS LABS FL INC	<u>100MG</u>	<u>A207355</u>	<u>001</u>	Nov 30, 2022

AB AET PHARMA	<u>100MG</u>	<u>A213454</u>	<u>001</u>	Feb 01, 2021

AB AMNEAL	<u>100MG</u>	<u>A216626</u>	<u>001</u>	Dec 22, 2022

AB BIOCON PHARMA	<u>100MG</u>	<u>A214476</u>	<u>001</u>	Feb 04, 2022

AB DR REDDYS	<u>100MG</u>	<u>A212500</u>	<u>001</u>	Apr 07, 2022

AB HETERO LABS LTD III	<u>100MG</u>	<u>A214321</u>	<u>001</u>	Dec 08, 2022

AB SINOTHERAPEUTICS INC	<u>100MG</u>	<u>A212411</u>	<u>001</u>	Aug 21, 2019

AB SPECGX LLC	<u>100MG</u>	<u>A212226</u>	<u>001</u>	May 10, 2022

POTASSIUM ACETATE

INJECTABLE; INJECTION

POTASSIUM ACETATE

AP EXELA PHARMA	<u>2MEQ/ML</u>	<u>A206203</u>	<u>001</u>	Dec 29, 2015

AP +! HOSPIRA	<u>2MEQ/ML</u>	<u>N018896</u>	<u>001</u>	Jul 20, 1984

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

KLOR-CON

AB UPSHER SMITH LABS	<u>8MEQ</u>	<u>A203106</u>	<u>001</u>	Jul 10, 2015

AB	<u>10MEQ</u>	<u>A203106</u>	<u>002</u>	Jul 10, 2015

POTASSIUM CHLORIDE

AB ACTAVIS LABS FL INC	<u>8MEQ</u>	<u>A077419</u>	<u>001</u>	Jun 02, 2008

AB !	<u>10MEQ</u>	<u>A077419</u>	<u>002</u>	Jun 02, 2008

AB ADARE PHARMS INC	<u>8MEQ</u>	<u>A208864</u>	<u>001</u>	Mar 17, 2017

AB	<u>10MEQ</u>	<u>A208864</u>	<u>002</u>	Mar 17, 2017

AB AMNEAL PHARMS	<u>10MEQ</u>	<u>A202128</u>	<u>001</u>	Feb 22, 2013

AB ANCHEN PHARMS	<u>8MEQ</u>	<u>A202886</u>	<u>001</u>	Dec 26, 2013

AB	<u>10MEQ</u>	<u>A202886</u>	<u>002</u>	Dec 26, 2013

AB GLENMARK PHARMS LTD	<u>10MEQ</u>	<u>A202868</u>	<u>001</u>	Jan 19, 2016

AB GRANULES	<u>8MEQ</u>	<u>A214686</u>	<u>001</u>	Feb 16, 2021

AB	<u>10MEQ</u>	<u>A214686</u>	<u>002</u>	Feb 16, 2021

AB LUPIN LTD	<u>8MEQ</u>	<u>A203002</u>	<u>001</u>	Dec 18, 2015

AB	<u>10MEQ</u>	<u>A203002</u>	<u>002</u>	Dec 18, 2015

AB NOVEL LABS INC	<u>8MEQ</u>	<u>A204828</u>	<u>001</u>	Aug 16, 2016

AB	<u>10MEQ</u>	<u>A204828</u>	<u>002</u>	Aug 16, 2016

AB PADAGIS US	<u>8MEQ</u>	<u>A200185</u>	<u>001</u>	May 18, 2011

AB	<u>10MEQ</u>	<u>A200185</u>	<u>002</u>	May 18, 2011

AB PRINSTON INC	<u>8MEQ</u>	<u>A209026</u>	<u>001</u>	Jun 11, 2019

AB	<u>10MEQ</u>	<u>A209026</u>	<u>002</u>	Jun 11, 2019

AB STRIDES PHARMA	<u>8MEQ</u>	<u>A205549</u>	<u>001</u>	Dec 08, 2015

AB	<u>10MEQ</u>	<u>A205549</u>	<u>002</u>	Dec 08, 2015

AB ZYDUS PHARMS	<u>8MEQ</u>	<u>A208445</u>	<u>001</u>	Mar 11, 2019

PRESCRIPTION DRUG PRODUCT LIST

3-372 (of 474)

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

POTASSIUM CHLORIDE

AB		10MEQ	A208445	002	Mar 11, 2019
	FOR SOLUTION; ORAL				

KLOR-CON

AA	UPSHER SMITH LABS	20MEQ	A209662	001	Oct 23, 2017

POTASSIUM CHLORIDE

AA	AMNEAL	20MEQ	A210902	001	May 23, 2019
AA	BELCHER	20MEQ	A212183	001	May 06, 2019
AA	EPIC PHARMA LLC	20MEQ	A210200	001	Nov 23, 2018
AA	NOVEL LABS INC	20MEQ	A210241	001	Nov 21, 2018
AA	+! PHARMA RES SOFTWARE	20MEQ	N208019	001	Aug 19, 2015
AA	RUBICON	20MEQ	A214108	001	Mar 24, 2022
AA	STRIDES PHARMA	20MEQ	A211667	001	Mar 11, 2021

INJECTABLE; INJECTION

POTASSIUM CHLORIDE

AP	B BRAUN	2MEQ/ML	A085870	001	
AP	+! HOSPIRA	2MEQ/ML	A080205	001	

POTASSIUM CHLORIDE 10MEQ

AP	FRESENIUS KABI USA	14.9MG/ML	A211087	001	Sep 09, 2020
AP		746MG/100ML	A211087	002	Sep 09, 2020
AP	NEXUS PHARMS	14.9MG/ML	A214727	001	Mar 18, 2021
AP		745MG/100ML	A214727	002	Mar 18, 2021

POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER

AP	+! BAXTER HLTHCARE	14.9MG/ML	N019904	001	Dec 26, 1989
AP	+!	746MG/100ML	N019904	005	Dec 17, 1990
AP	+! ICU MEDICAL INC	14.9MG/ML	N020161	005	Nov 30, 1992
AP	+!	745MG/100ML	N020161	001	Nov 30, 1992

POTASSIUM CHLORIDE 20MEQ

AP	FRESENIUS KABI USA	29.8MG/ML	A211087	003	Sep 09, 2020
AP		1.49GM/100ML	A211087	005	May 07, 2021
AP	NEXUS PHARMS	29.8MG/ML	A214727	003	Mar 18, 2021
AP		1.49GM/100ML	A214727	004	Mar 18, 2021

POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER

AP	+! BAXTER HLTHCARE	29.8MG/ML	N019904	002	Dec 26, 1989
AP	+!	1.49GM/100ML	N019904	006	Dec 17, 1990
AP	+! ICU MEDICAL INC	29.8MG/ML	N020161	006	Aug 11, 1998
AP	+!	1.49GM/100ML	N020161	002	Nov 30, 1992

POTASSIUM CHLORIDE 40MEQ

AP	FRESENIUS KABI USA	2.98GM/100ML	A211087	004	Sep 09, 2020
AP	NEXUS PHARMS	2.98GM/100ML	A214727	005	Mar 18, 2021

POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER

AP	+! BAXTER HLTHCARE	2.98GM/100ML	N019904	004	Dec 26, 1989
AP	+! ICU MEDICAL INC	2.98GM/100ML	N020161	004	Aug 11, 1998

POTASSIUM CHLORIDE IN PLASTIC CONTAINER

AP	FRESENIUS KABI USA	2MEQ/ML	A088901	001	Jan 25, 1985
AP		2MEQ/ML	A088908	001	Jan 25, 1985

POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER

+!	BAXTER HLTHCARE	2.24GM/100ML	N019904	003	Dec 26, 1989

SOLUTION; ORAL

POTASSIUM CHLORIDE

AA	AMNEAL	20MEQ/15ML	A210041	001	Jul 19, 2018
AA		40MEQ/15ML	A210041	002	Jul 19, 2018
AA	APOTEX	20MEQ/15ML	A211067	001	Aug 08, 2018
AA		40MEQ/15ML	A211067	002	Aug 08, 2018
AA	+ GENUS LIFESCIENCES	20MEQ/15ML	N206814	001	Dec 22, 2014
AA	+!	40MEQ/15ML	N206814	002	Dec 22, 2014
AA	GRANULES	20MEQ/15ML	A213392	001	Jan 29, 2021
AA		40MEQ/15ML	A213392	002	Jan 29, 2021
AA	GUARDIAN DRUG	20MEQ/15ML	A214892	001	Dec 30, 2022
AA		40MEQ/15ML	A214892	002	Dec 30, 2022
AA	NOVEL LABS INC	20MEQ/15ML	A209786	001	Aug 29, 2018
AA		40MEQ/15ML	A209786	002	Aug 29, 2018
AA	PHARM ASSOC	20MEQ/15ML	A210766	001	Mar 29, 2019
AA		40MEQ/15ML	A210766	002	Mar 29, 2019
AA	RUBICON	20MEQ/15ML	A214656	001	Jan 13, 2022
AA		40MEQ/15ML	A214656	002	Jan 13, 2022
AA	SAPTALIS PHARMS	20MEQ/15ML	A211648	001	May 21, 2021
AA		40MEQ/15ML	A211648	002	May 21, 2021
AA	STRIDES PHARMA	40MEQ/15ML	A211665	001	Nov 17, 2022
AA	WES PHARMA INC	20MEQ/15ML	A213062	001	Jun 06, 2022

PRESCRIPTION DRUG PRODUCT LIST

3-373 (of 474)

POTASSIUM CHLORIDE

SOLUTION; ORAL

POTASSIUM CHLORIDEAA 40MEO/15MLA213062 002 Jun 06, 2022

TABLET, EXTENDED RELEASE; ORAL

KLOR-CON M10AB1 UPSHER SMITH LABS 10MEOA074726 002 Aug 09, 2000KLOR-CON M15AB1 UPSHER SMITH LABS 15MEOA074726 003 Jun 06, 2003KLOR-CON M20AB1 ! UPSHER SMITH LABS 20MEOA074726 001 Nov 20, 1998POTASSIUM CHLORIDEAB1 ACTAVIS LABS FL INC 10MEOA075604 001 Apr 10, 2002AB1 20MEOA075604 002 Apr 10, 2002AB1 ADARE PHARMS INC 10MEOA076368 002 Jun 05, 2019AB1 20MEOA076368 001 Aug 18, 2004AB1 AMNEAL 10MEOA212861 001 May 08, 2020AB1 20MEOA212861 003 May 08, 2020AB1 ASCENT PHARMS INC 10MEOA214422 001 Dec 29, 2020AB1 15MEOA214422 002 Dec 29, 2020AB1 20MEOA214422 003 Dec 29, 2020AB1 GLENMARK PHARMS LTD 10MEOA203562 001 Jul 26, 2016AB1 20MEOA203562 002 Jul 26, 2016AB1 GRANULES 10MEOA214452 001 Oct 21, 2020AB1 20MEOA214452 002 Oct 21, 2020AB1 GUANGZHOU NOVAKEN 10MEOA214395 001 Jan 28, 2021AB1 20MEOA214395 002 Jan 28, 2021AB1 NOVEL LABS INC 10MEOA206347 001 Jan 21, 2016AB1 20MEOA206347 002 Jan 21, 2016AB1 PRINSTON INC 10MEOA209922 001 Apr 30, 2019AB1 15MEOA209922 002 Apr 30, 2019AB1 20MEOA209922 003 Apr 30, 2019AB1 ZYDUS PHARMS 10MEOA210395 001 Sep 17, 2020AB1 20MEOA210395 002 Sep 17, 2020KLOR-CONAB2 + UPSHER SMITH LABS 8MEON019123 001 Apr 17, 1986AB2 +! 10MEON019123 002 Apr 17, 1986POTASSIUM CHLORIDEAB2 AUROBINDO PHARMA 8MEOA210921 001 Dec 19, 2018AB2 10MEOA210921 002 Dec 19, 2018AB2 GRANULES 8MEOA211797 001 Mar 04, 2020AB2 10MEOA211797 002 Mar 04, 2020AB2 MYLAN 8MEOA204662 001 Aug 21, 2014AB2 10MEOA204662 002 Aug 21, 2014AB2 NOVEL LABS INC 8MEOA206759 001 Aug 09, 2016AB2 10MEOA206759 002 Aug 09, 2016AB2 PADAGIS US 8MEOA205993 001 Nov 05, 2015AB2 10MEOA205993 002 Nov 05, 2015AB2 STRIDES PHARMA 8MEOA210733 001 Aug 31, 2018AB2 10MEOA210733 002 Aug 31, 2018AB2 YICHANG HUMANWELL 8MEOA209314 001 Jun 22, 2018AB2 10MEOA209314 002 Jun 22, 2018K-TABAB3 + ABBVIE 10MEON018279 001AB3 +! 20MEON018279 003 Nov 25, 2013POTASSIUM CHLORIDEAB3 RUBICON 10MEOA215725 001 Jul 25, 2022AB3 20MEOA215725 002 Jul 25, 2022AB3 VITRUVIAS THERAP 10MEOA209688 001 Jan 12, 2018AB3 20MEOA209688 002 Jan 12, 2018AB3 YICHANG HUMANWELL 10MEOA212561 001 Sep 30, 2019AB3 20MEOA212561 002 Sep 30, 2019POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 0.149% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINERAP ICU MEDICAL INC 149MG/100ML; 450MG/100MLA078446 001 Sep 10, 2008POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.45%AP +! BAXTER HLTHCARE 150MG/100ML; 450MG/100MLN017648 005 Nov 26, 2002AP FRESENIUS KABI USA 150MG/100ML; 450MG/100MLA212347 001 Sep 17, 2020POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.9%AP +! BAXTER HLTHCARE 150MG/100ML; 900MG/100MLN017648 001AP FRESENIUS KABI USA 150MG/100ML; 900MG/100MLA212347 003 Jun 02, 2021

PRESCRIPTION DRUG PRODUCT LIST

3-374 (of 474)

POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	B BRAUN	150MG/100ML; 900MG/100ML	N019708 004	Sep 29, 1989

POTASSIUM CHLORIDE 0.3% AND SODIUM CHLORIDE 0.9%

AP	+!	BAXTER HLTHCARE	300MG/100ML; 900MG/100ML	N017648 002	

AP		FRESENIUS KABI USA	300MG/100ML; 900MG/100ML	A212347 002	Sep 17, 2020

POTASSIUM CHLORIDE 20MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP		ICU MEDICAL INC	149MG/100ML; 900MG/100ML	N019686 001	Oct 17, 1988

POTASSIUM CHLORIDE 40MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP		ICU MEDICAL INC	298MG/100ML; 900MG/100ML	N019686 002	Oct 17, 1988

POTASSIUM CITRATE

TABLET, EXTENDED RELEASE; ORAL

POTASSIUM CITRATE

AB		ANI PHARMS	10MEQ	A212779 001	Jan 14, 2020

AB			15MEQ	A212779 002	Jan 14, 2020

AB		ASCENT PHARMS INC	5MEQ	A214420 001	Feb 05, 2021

AB			10MEQ	A214420 002	Feb 05, 2021

AB			15MEQ	A214420 003	Feb 05, 2021

AB		BIONPHARMA INC	10MEQ	A212799 001	Jun 29, 2020

AB			15MEQ	A212799 002	Jun 29, 2020

AB		EYWA	5MEQ	A214426 001	Feb 19, 2021

AB			10MEQ	A214426 002	Feb 19, 2021

AB			15MEQ	A214426 003	Feb 19, 2021

AB		RISING	5MEQ	A077440 001	Jun 09, 2006

AB			10MEQ	A077440 002	Jun 09, 2006

AB		STRIDES PHARMA	5MEQ	A206813 001	Sep 11, 2017

AB			10MEQ	A206813 002	Sep 11, 2017

AB			15MEQ	A206813 003	Sep 11, 2017

AB		TEVA PHARMS USA INC	5MEQ	A209758 001	Mar 05, 2018

AB			10MEQ	A209758 002	Mar 05, 2018

AB			15MEQ	A209758 003	Mar 05, 2018

AB		ZYDUS PHARMS	5MEQ	A203546 001	Aug 06, 2014

AB			10MEQ	A203546 002	Aug 06, 2014

AB			15MEQ	A203546 003	Aug 06, 2014

UROCIT-K

AB	+	MISSION PHARMA	5MEQ	N019071 001	Aug 30, 1985

AB	+		10MEQ	N019071 002	Aug 31, 1992

AB	+!		15MEQ	N019071 003	Dec 30, 2009

POTASSIUM PHOSPHATE, DIBASIC; POTASSIUM PHOSPHATE, MONOBASIC

SOLUTION; INTRAVENOUS

POTASSIUM PHOSPHATES

+	!	CMP DEV LLC	4.5GM/15ML (300MG/ML); 2.65GM/15ML (175MG/ML)	N212121 001	Sep 19, 2019

+	!	FRESENIUS KABI USA	1.18GM/5ML (236MG/ML); 1.12GM/5ML (224MG/ML)	N212832 001	Nov 26, 2019

+	!		3.54GM/15ML (236MG/ML); 3.36GM/15ML (224MG/ML)	N212832 002	Nov 26, 2019

+	!		11.8GM/50ML (236MG/ML); 11.2GM/50ML (224MG/ML)	N212832 003	Nov 26, 2019

POVIDONE-IODINE

SOLUTION/DROPS; OPHTHALMIC

BETADINE

+	!	ALCON PHARMS LTD	5%	N018634 001	Dec 17, 1986

PRALATREXATE

SOLUTION; INTRAVENOUS

FOLOTYN

+		ACROTECH BIOPHARMA	20MG/ML (20MG/ML)	N022468 001	Sep 24, 2009

+	!		40MG/2ML (20MG/ML)	N022468 002	Sep 24, 2009

PRALIDOXIME CHLORIDE

INJECTABLE; INJECTION

PROTOPAM CHLORIDE

+	!	BAXTER HLTHCARE CORP	1GM/VIAL	N014134 001	

PRESCRIPTION DRUG PRODUCT LIST

3-375 (of 474)

PRALSETINIB

CAPSULE; ORAL

GAVRETO

+! GENENTECH INC

100MG

N213721 001 Sep 04, 2020

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET; ORAL

PRAMIPEXOLE DIHYDROCHLORIDE

<u>AB</u>	AUROBINDO PHARMA LTD	<u>0.125MG</u>	<u>A202633 001</u>	Oct 26, 2012
<u>AB</u>		<u>0.25MG</u>	<u>A202633 002</u>	Oct 26, 2012
<u>AB</u>		<u>0.5MG</u>	<u>A202633 003</u>	Oct 26, 2012
<u>AB</u>		<u>0.75MG</u>	<u>A202633 004</u>	Oct 26, 2012
<u>AB</u>		<u>1MG</u>	<u>A202633 005</u>	Oct 26, 2012
<u>AB</u>		<u>1.5MG</u>	<u>A202633 006</u>	Oct 26, 2012
<u>AB</u>	GLENMARK GENERICS	<u>0.125MG</u>	<u>A090781 001</u>	Oct 08, 2010
<u>AB</u>	!	<u>0.25MG</u>	<u>A090781 002</u>	Oct 08, 2010
<u>AB</u>		<u>0.5MG</u>	<u>A090781 003</u>	Oct 08, 2010
<u>AB</u>		<u>0.75MG</u>	<u>A090781 006</u>	Sep 11, 2015
<u>AB</u>		<u>1MG</u>	<u>A090781 004</u>	Oct 08, 2010
<u>AB</u>		<u>1.5MG</u>	<u>A090781 005</u>	Oct 08, 2010
<u>AB</u>	RISING	<u>0.25MG</u>	<u>A211088 001</u>	Oct 03, 2018
<u>AB</u>		<u>0.5MG</u>	<u>A211088 002</u>	Oct 03, 2018
<u>AB</u>		<u>0.75MG</u>	<u>A211088 003</u>	Oct 03, 2018
<u>AB</u>		<u>1MG</u>	<u>A211088 004</u>	Oct 03, 2018
<u>AB</u>		<u>1.5MG</u>	<u>A211088 005</u>	Oct 03, 2018
<u>AB</u>	SCIEGEN PHARMS INC	<u>0.125MG</u>	<u>A203855 001</u>	Oct 28, 2014
<u>AB</u>		<u>0.25MG</u>	<u>A203855 002</u>	Oct 28, 2014
<u>AB</u>		<u>0.5MG</u>	<u>A203855 003</u>	Oct 28, 2014
<u>AB</u>		<u>0.75MG</u>	<u>A203855 004</u>	Oct 28, 2014
<u>AB</u>		<u>1MG</u>	<u>A203855 005</u>	Oct 28, 2014
<u>AB</u>		<u>1.5MG</u>	<u>A203855 006</u>	Oct 28, 2014
<u>AB</u>	STRIDES PHARMA	<u>0.125MG</u>	<u>A202702 001</u>	Jun 03, 2014
<u>AB</u>		<u>0.25MG</u>	<u>A202702 002</u>	Jun 03, 2014
<u>AB</u>		<u>0.5MG</u>	<u>A202702 003</u>	Jun 03, 2014
<u>AB</u>		<u>0.75MG</u>	<u>A202702 004</u>	Jun 03, 2014
<u>AB</u>		<u>1MG</u>	<u>A202702 005</u>	Jun 03, 2014
<u>AB</u>		<u>1.5MG</u>	<u>A202702 006</u>	Jun 03, 2014
<u>AB</u>	TORRENT PHARMS	<u>0.125MG</u>	<u>A090865 001</u>	Oct 08, 2010
<u>AB</u>		<u>0.25MG</u>	<u>A090865 002</u>	Oct 08, 2010
<u>AB</u>		<u>0.5MG</u>	<u>A090865 003</u>	Oct 08, 2010
<u>AB</u>		<u>0.75MG</u>	<u>A090865 004</u>	Oct 08, 2010
<u>AB</u>		<u>1MG</u>	<u>A090865 005</u>	Oct 08, 2010
<u>AB</u>		<u>1.5MG</u>	<u>A090865 006</u>	Oct 08, 2010
<u>AB</u>	ZENNOVA	<u>0.125MG</u>	<u>A090151 001</u>	Apr 30, 2012
<u>AB</u>		<u>0.25MG</u>	<u>A090151 002</u>	Apr 30, 2012
<u>AB</u>		<u>0.5MG</u>	<u>A090151 003</u>	Apr 30, 2012
<u>AB</u>		<u>0.75MG</u>	<u>A090151 006</u>	Apr 30, 2012
<u>AB</u>		<u>1MG</u>	<u>A090151 004</u>	Apr 30, 2012
<u>AB</u>		<u>1.5MG</u>	<u>A090151 005</u>	Apr 30, 2012
<u>AB</u>	ZYDUS PHARMS USA INC	<u>0.125MG</u>	<u>A078920 001</u>	Jul 06, 2010
<u>AB</u>		<u>0.25MG</u>	<u>A078920 002</u>	Jul 06, 2010
<u>AB</u>		<u>0.5MG</u>	<u>A078920 003</u>	Jul 06, 2010
<u>AB</u>		<u>0.75MG</u>	<u>A078920 006</u>	Nov 23, 2022
<u>AB</u>		<u>1MG</u>	<u>A078920 004</u>	Jul 06, 2010
<u>AB</u>		<u>1.5MG</u>	<u>A078920 005</u>	Jul 06, 2010

TABLET, EXTENDED RELEASE; ORAL

MIRAPEX ER

<u>AB</u>	+! BOEHRINGER INGELHEIM	<u>0.375MG</u>	<u>N022421 001</u>	Feb 19, 2010
<u>AB</u>	+	<u>0.75MG</u>	<u>N022421 002</u>	Feb 19, 2010
<u>AB</u>	+	<u>1.5MG</u>	<u>N022421 003</u>	Feb 19, 2010
<u>AB</u>	+	<u>2.25MG</u>	<u>N022421 006</u>	Jun 17, 2011
<u>AB</u>	+	<u>3MG</u>	<u>N022421 004</u>	Feb 19, 2010
<u>AB</u>	+	<u>3.75MG</u>	<u>N022421 007</u>	Jun 17, 2011
<u>AB</u>	+	<u>4.5MG</u>	<u>N022421 005</u>	Feb 19, 2010

PRAMIPEXOLE DIHYDROCHLORIDE

<u>AB</u>	ACTAVIS ELIZABETH	<u>0.375MG</u>	<u>A201963 001</u>	Apr 21, 2016
<u>AB</u>		<u>0.75MG</u>	<u>A201963 002</u>	Apr 21, 2016
<u>AB</u>		<u>1.5MG</u>	<u>A201963 003</u>	Apr 21, 2016
<u>AB</u>		<u>2.25MG</u>	<u>A203615 001</u>	Oct 14, 2016
<u>AB</u>		<u>3MG</u>	<u>A201963 004</u>	Apr 21, 2016

PRESCRIPTION DRUG PRODUCT LIST

3-376 (of 474)

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

PRAMIPEXOLE DIHYDROCHLORIDE

<u>AB</u>		<u>3.75MG</u>	<u>A203615</u>	<u>002</u>	Jan 03, 2017
<u>AB</u>		<u>4.5MG</u>	<u>A201963</u>	<u>005</u>	Apr 21, 2016
<u>AB</u>	ALEMBIC PHARMS	<u>0.375MG</u>	<u>A204518</u>	<u>001</u>	Jan 02, 2019
<u>AB</u>		<u>0.75MG</u>	<u>A204518</u>	<u>002</u>	Jan 02, 2019
<u>AB</u>		<u>1.5MG</u>	<u>A204518</u>	<u>003</u>	Jan 02, 2019
<u>AB</u>		<u>2.25MG</u>	<u>A204518</u>	<u>004</u>	Jan 02, 2019
<u>AB</u>		<u>3MG</u>	<u>A204518</u>	<u>005</u>	Jan 02, 2019
<u>AB</u>		<u>3.75MG</u>	<u>A204518</u>	<u>006</u>	Jan 02, 2019
<u>AB</u>		<u>4.5MG</u>	<u>A204518</u>	<u>007</u>	Jan 02, 2019
<u>AB</u>	DR REDDYS	<u>0.375MG</u>	<u>A203354</u>	<u>001</u>	Aug 07, 2015
<u>AB</u>		<u>0.75MG</u>	<u>A203354</u>	<u>002</u>	Aug 07, 2015
<u>AB</u>		<u>1.5MG</u>	<u>A203354</u>	<u>003</u>	Aug 07, 2015
<u>AB</u>		<u>3MG</u>	<u>A203354</u>	<u>004</u>	Aug 07, 2015
<u>AB</u>		<u>4.5MG</u>	<u>A203354</u>	<u>005</u>	Aug 07, 2015
<u>AB</u>	MACLEODS PHARMS LTD	<u>0.375MG</u>	<u>A206156</u>	<u>001</u>	Jun 24, 2016
<u>AB</u>		<u>0.75MG</u>	<u>A206156</u>	<u>002</u>	Jun 24, 2016
<u>AB</u>		<u>1.5MG</u>	<u>A206156</u>	<u>003</u>	Jun 24, 2016
<u>AB</u>		<u>2.25MG</u>	<u>A206156</u>	<u>004</u>	Jun 24, 2016
<u>AB</u>		<u>3MG</u>	<u>A206156</u>	<u>005</u>	Jun 24, 2016
<u>AB</u>		<u>3.75MG</u>	<u>A206156</u>	<u>007</u>	Jan 23, 2017
<u>AB</u>		<u>4.5MG</u>	<u>A206156</u>	<u>006</u>	Jun 24, 2016
<u>AB</u>	NOVAST LABS	<u>0.375MG</u>	<u>A213444</u>	<u>001</u>	Feb 03, 2022
<u>AB</u>		<u>0.75MG</u>	<u>A213444</u>	<u>002</u>	Feb 03, 2022
<u>AB</u>		<u>1.5MG</u>	<u>A213444</u>	<u>003</u>	Feb 03, 2022
<u>AB</u>		<u>2.25MG</u>	<u>A213444</u>	<u>004</u>	Feb 03, 2022
<u>AB</u>		<u>3MG</u>	<u>A213444</u>	<u>005</u>	Feb 03, 2022
<u>AB</u>		<u>3.75MG</u>	<u>A213444</u>	<u>006</u>	Feb 03, 2022
<u>AB</u>		<u>4.5MG</u>	<u>A213444</u>	<u>007</u>	Feb 03, 2022
<u>AB</u>	SANDOZ INC	<u>0.375MG</u>	<u>A202353</u>	<u>001</u>	Dec 04, 2014
<u>AB</u>		<u>0.75MG</u>	<u>A202353</u>	<u>002</u>	Dec 04, 2014
<u>AB</u>		<u>1.5MG</u>	<u>A202353</u>	<u>003</u>	Dec 04, 2014
<u>AB</u>		<u>3MG</u>	<u>A202353</u>	<u>004</u>	Dec 04, 2014
<u>AB</u>		<u>4.5MG</u>	<u>A202353</u>	<u>005</u>	Dec 04, 2014
<u>AB</u>	XIAMEN LP PHARM CO	<u>0.375MG</u>	<u>A212797</u>	<u>001</u>	Jun 11, 2021
<u>AB</u>		<u>0.75MG</u>	<u>A212797</u>	<u>002</u>	Jun 11, 2021
<u>AB</u>	ZYDUS PHARMS	<u>0.375MG</u>	<u>A202891</u>	<u>001</u>	Dec 12, 2017
<u>AB</u>		<u>0.75MG</u>	<u>A202891</u>	<u>002</u>	Dec 12, 2017
<u>AB</u>		<u>1.5MG</u>	<u>A202891</u>	<u>003</u>	Dec 12, 2017
<u>AB</u>		<u>2.25MG</u>	<u>A202891</u>	<u>004</u>	Dec 12, 2017
<u>AB</u>		<u>3MG</u>	<u>A202891</u>	<u>005</u>	Dec 12, 2017
<u>AB</u>		<u>3.75MG</u>	<u>A202891</u>	<u>006</u>	Dec 12, 2017
<u>AB</u>		<u>4.5MG</u>	<u>A202891</u>	<u>007</u>	Dec 12, 2017

PRAMLINTIDE ACETATE

INJECTABLE; SUBCUTANEOUS

SYMLIN

+ ASTRAZENECA AB

EQ 1.5MG BASE/1.5ML (EQ 1MG BASE/ML)

N021332 002 Sep 25, 2007

+!

EQ 2.7MG BASE/2.7ML (EQ 1MG BASE/ML)

N021332 003 Sep 25, 2007

PRASTERONE

INSERT; VAGINAL

INTRAROSA

+! MILLICENT

6.5MG

N208470 001 Nov 16, 2016

PRASUGREL

TABLET; ORAL

PRASUGREL HYDROCHLORIDE

<u>AB</u>	LUPIN LTD	<u>EQ 5MG BASE</u>	<u>A205930</u>	<u>001</u>	Jan 09, 2023
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A205930</u>	<u>002</u>	Jan 09, 2023

PRASUGREL HYDROCHLORIDE

TABLET; ORAL

EFFIENT

<u>AB</u>	+	COSETTE	<u>EQ 5MG BASE</u>	<u>N022307</u>	<u>001</u>	Jul 10, 2009
<u>AB</u>	+	!	<u>EQ 10MG BASE</u>	<u>N022307</u>	<u>002</u>	Jul 10, 2009

PRASUGREL

<u>AB</u>	ACCORD HLTHCARE	<u>EQ 5MG BASE</u>	<u>A205987</u>	<u>001</u>	Feb 02, 2018
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A205987</u>	<u>002</u>	Feb 02, 2018
<u>AB</u>	AUROBINDO PHARMA	<u>EQ 5MG BASE</u>	<u>A205888</u>	<u>001</u>	Oct 16, 2017
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A205888</u>	<u>002</u>	Oct 16, 2017
<u>AB</u>	HEC PHARM	<u>EQ 5MG BASE</u>	<u>A206021</u>	<u>001</u>	Jan 16, 2019

PRESCRIPTION DRUG PRODUCT LIST

3-377 (of 474)

PRASUGREL HYDROCHLORIDE

TABLET; ORAL

PRASUGREL

<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A206021</u>	<u>002</u>	Jan 16, 2019
<u>AB</u>	MYLAN	<u>EQ 5MG BASE</u>	<u>A205927</u>	<u>001</u>	Jul 12, 2017
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A205927</u>	<u>002</u>	Jul 12, 2017
<u>AB</u>	PANACEA	<u>EQ 5MG BASE</u>	<u>A205897</u>	<u>001</u>	Oct 16, 2017
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A205897</u>	<u>002</u>	Oct 16, 2017
BX	AMNEAL PHARMS	EQ 5MG BASE	A205913	001	Jun 19, 2018
BX		EQ 10MG BASE	A205913	002	Jun 19, 2018

PRAVASTATIN SODIUM

TABLET; ORAL

PRAVASTATIN SODIUM

<u>AB</u>	ACCORD HLTHCARE	<u>10MG</u>	<u>A207068</u>	<u>001</u>	Nov 17, 2016
<u>AB</u>		<u>20MG</u>	<u>A207068</u>	<u>002</u>	Nov 17, 2016
<u>AB</u>		<u>40MG</u>	<u>A207068</u>	<u>003</u>	Nov 17, 2016
<u>AB</u>		<u>80MG</u>	<u>A207068</u>	<u>004</u>	Nov 17, 2016
<u>AB</u>	APNAR PHARMA LP	<u>10MG</u>	<u>A077491</u>	<u>002</u>	Oct 23, 2006
<u>AB</u>		<u>20MG</u>	<u>A077491</u>	<u>003</u>	Oct 23, 2006
<u>AB</u>		<u>40MG</u>	<u>A077491</u>	<u>004</u>	Oct 23, 2006
<u>AB</u>		<u>80MG</u>	<u>A077491</u>	<u>001</u>	Feb 11, 2008
<u>AB</u>	APOTEX	<u>10MG</u>	<u>A076341</u>	<u>001</u>	Oct 23, 2006
<u>AB</u>		<u>20MG</u>	<u>A076341</u>	<u>002</u>	Oct 23, 2006
<u>AB</u>		<u>40MG</u>	<u>A076341</u>	<u>003</u>	Oct 23, 2006
<u>AB</u>		<u>80MG</u>	<u>A076341</u>	<u>004</u>	Dec 28, 2007
<u>AB</u>	AUROBINDO PHARMA	<u>10MG</u>	<u>A203367</u>	<u>001</u>	Feb 02, 2017
<u>AB</u>		<u>20MG</u>	<u>A203367</u>	<u>002</u>	Feb 02, 2017
<u>AB</u>		<u>40MG</u>	<u>A203367</u>	<u>003</u>	Feb 02, 2017
<u>AB</u>		<u>80MG</u>	<u>A203367</u>	<u>004</u>	Feb 02, 2017
<u>AB</u>	BIOCON PHARMA	<u>10MG</u>	<u>A209869</u>	<u>001</u>	Apr 13, 2018
<u>AB</u>		<u>20MG</u>	<u>A209869</u>	<u>002</u>	Apr 13, 2018
<u>AB</u>		<u>40MG</u>	<u>A209869</u>	<u>003</u>	Apr 13, 2018
<u>AB</u>		<u>80MG</u>	<u>A209869</u>	<u>004</u>	Apr 13, 2018
<u>AB</u>	CIPLA	<u>10MG</u>	<u>A077904</u>	<u>001</u>	Oct 23, 2006
<u>AB</u>		<u>20MG</u>	<u>A077904</u>	<u>002</u>	Oct 23, 2006
<u>AB</u>		<u>40MG</u>	<u>A077904</u>	<u>003</u>	Oct 23, 2006
<u>AB</u>		<u>80MG</u>	<u>A077904</u>	<u>004</u>	Mar 22, 2016
<u>AB</u>	DR REDDYS LABS INC	<u>10MG</u>	<u>A076714</u>	<u>001</u>	Oct 23, 2006
<u>AB</u>		<u>20MG</u>	<u>A076714</u>	<u>002</u>	Oct 23, 2006
<u>AB</u>		<u>40MG</u>	<u>A076714</u>	<u>003</u>	Oct 23, 2006
<u>AB</u>		<u>80MG</u>	<u>A076714</u>	<u>004</u>	Dec 28, 2007
<u>AB</u>	GLENMARK GENERICS	<u>10MG</u>	<u>A077987</u>	<u>001</u>	May 11, 2007
<u>AB</u>		<u>20MG</u>	<u>A077987</u>	<u>002</u>	May 11, 2007
<u>AB</u>		<u>40MG</u>	<u>A077987</u>	<u>003</u>	May 11, 2007
<u>AB</u>		<u>80MG</u>	<u>A077987</u>	<u>004</u>	Dec 28, 2007
<u>AB</u>	LUPIN PHARMS	<u>10MG</u>	<u>A077917</u>	<u>001</u>	Jan 08, 2008
<u>AB</u>		<u>20MG</u>	<u>A077917</u>	<u>002</u>	Jan 08, 2008
<u>AB</u>		<u>40MG</u>	<u>A077917</u>	<u>003</u>	Jan 08, 2008
<u>AB</u>		<u>80MG</u>	<u>A077917</u>	<u>004</u>	Jan 08, 2008
<u>AB</u>	TEVA	<u>10MG</u>	<u>A076056</u>	<u>001</u>	Apr 24, 2006
<u>AB</u>		<u>20MG</u>	<u>A076056</u>	<u>002</u>	Apr 24, 2006
<u>AB</u>		<u>40MG</u>	<u>A076056</u>	<u>003</u>	Apr 24, 2006
<u>AB</u>	! TEVA PHARMS	<u>80MG</u>	<u>A077793</u>	<u>001</u>	Jan 15, 2008
<u>AB</u>	WATSON LABS	<u>10MG</u>	<u>A076939</u>	<u>004</u>	Oct 23, 2006
<u>AB</u>		<u>20MG</u>	<u>A076939</u>	<u>003</u>	Oct 23, 2006
<u>AB</u>		<u>40MG</u>	<u>A076939</u>	<u>002</u>	Oct 23, 2006
<u>AB</u>		<u>80MG</u>	<u>A076939</u>	<u>001</u>	Dec 28, 2007
<u>AB</u>	ZYDUS PHARMS USA	<u>20MG</u>	<u>A077751</u>	<u>002</u>	Apr 30, 2008
<u>AB</u>		<u>40MG</u>	<u>A077751</u>	<u>003</u>	Apr 30, 2008
<u>AB</u>		<u>80MG</u>	<u>A077751</u>	<u>004</u>	Apr 30, 2008

PRAZICUANTEL

TABLET; ORAL

BILTRICIDE

<u>AB</u>	+! BAYER HLTHCARE	<u>600MG</u>	<u>N018714</u>	<u>001</u>	Dec 29, 1982
<u>AB</u>	<u>PRAZICUANTEL</u>				
<u>AB</u>	PAR PHARM INC	<u>600MG</u>	<u>A208820</u>	<u>001</u>	Nov 27, 2017

PRESCRIPTION DRUG PRODUCT LIST

3-378 (of 474)

PRAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

MINIPRESS

<u>AB</u>	+	PFIZER	<u>EQ 1MG BASE</u>	<u>N017442</u>	<u>002</u>	
<u>AB</u>	+	!	<u>EQ 2MG BASE</u>	<u>N017442</u>	<u>003</u>	
<u>AB</u>	+		<u>EQ 5MG BASE</u>	<u>N017442</u>	<u>001</u>	

PRAZOSIN HYDROCHLORIDE

<u>AB</u>		APPCO	<u>EQ 1MG BASE</u>	<u>A213406</u>	<u>001</u>	Oct 21, 2022
<u>AB</u>			<u>EQ 2MG BASE</u>	<u>A213406</u>	<u>002</u>	Oct 21, 2022
<u>AB</u>			<u>EQ 5MG BASE</u>	<u>A213406</u>	<u>003</u>	Oct 21, 2022
<u>AB</u>		GRANULES	<u>EQ 1MG BASE</u>	<u>A214608</u>	<u>001</u>	Dec 23, 2021
<u>AB</u>			<u>EQ 2MG BASE</u>	<u>A214608</u>	<u>002</u>	Dec 23, 2021
<u>AB</u>			<u>EQ 5MG BASE</u>	<u>A214608</u>	<u>003</u>	Dec 23, 2021
<u>AB</u>		MANKIND PHARMA	<u>EQ 1MG BASE</u>	<u>A215697</u>	<u>001</u>	Dec 30, 2022
<u>AB</u>			<u>EQ 2MG BASE</u>	<u>A215697</u>	<u>002</u>	Dec 30, 2022
<u>AB</u>			<u>EQ 5MG BASE</u>	<u>A215697</u>	<u>003</u>	Dec 30, 2022
<u>AB</u>		MYLAN	<u>EQ 1MG BASE</u>	<u>A072575</u>	<u>003</u>	May 16, 1989
<u>AB</u>			<u>EQ 2MG BASE</u>	<u>A072575</u>	<u>002</u>	May 16, 1989
<u>AB</u>			<u>EQ 5MG BASE</u>	<u>A072575</u>	<u>001</u>	May 16, 1989
<u>AB</u>		NOVITIUM PHARMA	<u>EQ 1MG BASE</u>	<u>A210971</u>	<u>001</u>	Oct 03, 2018
<u>AB</u>			<u>EQ 2MG BASE</u>	<u>A210971</u>	<u>002</u>	Oct 03, 2018
<u>AB</u>			<u>EQ 5MG BASE</u>	<u>A210971</u>	<u>003</u>	Oct 03, 2018
<u>AB</u>		TEVA PHARMS	<u>EQ 1MG BASE</u>	<u>A071745</u>	<u>002</u>	Sep 12, 1988
<u>AB</u>			<u>EQ 2MG BASE</u>	<u>A071745</u>	<u>003</u>	Sep 12, 1988
<u>AB</u>			<u>EQ 5MG BASE</u>	<u>A071745</u>	<u>001</u>	Sep 12, 1988

PREDNICARBATE

OINTMENT; TOPICAL

PREDNICARBATE

! FOUGERA PHARMS

0.1%

A077236 001 Mar 09, 2007

PREDNISOLONE

SYRUP; ORAL

PREDNISOLONE

<u>AA</u>	!	AKORN	<u>15MG/5ML</u>	<u>A040401</u>	<u>001</u>	Feb 27, 2003
<u>AA</u>		CHARTWELL RX	<u>15MG/5ML</u>	<u>A040323</u>	<u>001</u>	May 13, 1999
<u>AA</u>		LANNETT CO INC	<u>15MG/5ML</u>	<u>A040775</u>	<u>001</u>	Sep 21, 2007
<u>AA</u>		PHARM ASSOC	<u>15MG/5ML</u>	<u>A040399</u>	<u>001</u>	Mar 05, 2003
<u>AA</u>		WOCKHARDT BIO AG	<u>15MG/5ML</u>	<u>A040313</u>	<u>001</u>	Sep 10, 2003

PRELONE

<u>AA</u>		TEVA	<u>15MG/5ML</u>	<u>A089081</u>	<u>001</u>	Feb 04, 1986

TABLET; ORAL

PREDNISOLONE

+! WATSON LABS

5MG

A080354 001

PREDNISOLONE ACETATE

SUSPENSION/DROPS; OPHTHALMIC

OMNIPRED

<u>AB</u>	+	!	NOVARTIS	<u>1%</u>	<u>N017469</u>	<u>001</u>

PRED FORTE

<u>AB</u>	+	!	ALLERGAN	<u>1%</u>	<u>N017011</u>	<u>001</u>

PRED MILD

+! ALLERGAN

0.12%

N017100 001

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION; ORAL

PEDIAPRED

<u>AA</u>	+	!	SETON PHARM	<u>EQ 5MG BASE/5ML</u>	<u>N019157</u>	<u>001</u>	May 28, 1986

PREDNISOLONE SODIUM PHOSPHATE

<u>AA</u>		AKORN	<u>EQ 5MG BASE/5ML</u>	<u>A075183</u>	<u>001</u>	Mar 26, 2003
<u>AA</u>		AMNEAL	<u>EQ 15MG BASE/5ML</u>	<u>A216715</u>	<u>001</u>	Oct 25, 2022
<u>AA</u>		CHARTWELL RX	<u>EQ 5MG BASE/5ML</u>	<u>A075988</u>	<u>001</u>	May 25, 2004
<u>AA</u>		EDENBRIDGE PHARMS	<u>EQ 10MG BASE/5ML</u>	<u>A203559</u>	<u>001</u>	Dec 20, 2016
<u>AA</u>			<u>EQ 20MG BASE/5ML</u>	<u>A203559</u>	<u>002</u>	Dec 20, 2016
<u>AA</u>	!	PHARM ASSOC	<u>EQ 10MG BASE/5ML</u>	<u>A078465</u>	<u>001</u>	Mar 07, 2008
<u>AA</u>			<u>EQ 15MG BASE/5ML</u>	<u>A076913</u>	<u>001</u>	Apr 25, 2005
<u>AA</u>	!		<u>EQ 20MG BASE/5ML</u>	<u>A078988</u>	<u>001</u>	Jun 09, 2008
<u>AA</u>		WOCKHARDT BIO AG	<u>EQ 5MG BASE/5ML</u>	<u>A075099</u>	<u>001</u>	Jun 28, 2002
<u>AA</u>	!		<u>EQ 15MG BASE/5ML</u>	<u>A076895</u>	<u>001</u>	Oct 04, 2004
	!	MISSION PHARMA	<u>EQ 25MG BASE/5ML</u>	A091396	001	Sep 13, 2010
		PHARM ASSOC	<u>EQ 30MG BASE/5ML</u>	A204962	001	Mar 11, 2020

SOLUTION/DROPS; OPHTHALMIC

PREDNISOLONE SODIUM PHOSPHATE

! BAUSCH AND LOMB

EQ 0.9% PHOSPHATE

A040070 001 Jul 29, 1994

PRESCRIPTION DRUG PRODUCT LIST

3-379 (of 474)

PREDNISOLONE SODIUM PHOSPHATE

TABLET, ORALLY DISINTEGRATING;ORAL

ORAPRED ODT

+	CONCORDIA PHARMS	EQ 10MG BASE	N021959	001	Jun 01, 2006
	INC				
+		EQ 15MG BASE	N021959	002	Jun 01, 2006
+		EQ 30MG BASE	N021959	003	Jun 01, 2006

PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM

SOLUTION/DROPS;OPHTHALMIC

SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE

!	BAUSCH AND LOMB	EQ 0.23% PHOSPHATE;10%	A074449	001	Dec 29, 1995

PREDNISON

SOLUTION;ORAL

PREDNISON

+	HIKMA	5MG/5ML	A088703	001	Nov 08, 1984

PREDNISON INTENSOL

!	HIKMA	5MG/ML	A088810	001	Feb 20, 1985

TABLET;ORAL

PREDNISON

<u>AB</u>	AMNEAL	<u>1MG</u>	<u>A213385</u>	<u>001</u>	Jun 16, 2020
<u>AB</u>		<u>5MG</u>	<u>A213385</u>	<u>002</u>	Jun 16, 2020
<u>AB</u>		<u>10MG</u>	<u>A213386</u>	<u>001</u>	Jun 24, 2020
<u>AB</u>		<u>20MG</u>	<u>A213386</u>	<u>002</u>	Jun 24, 2020
<u>AB</u>	AUROBINDO PHARMA LTD	<u>1MG</u>	<u>A215671</u>	<u>001</u>	Nov 16, 2021
<u>AB</u>		<u>2.5MG</u>	<u>A215672</u>	<u>001</u>	Mar 28, 2022
<u>AB</u>		<u>5MG</u>	<u>A215672</u>	<u>002</u>	Mar 28, 2022
<u>AB</u>		<u>10MG</u>	<u>A215672</u>	<u>003</u>	Mar 28, 2022
<u>AB</u>		<u>20MG</u>	<u>A215672</u>	<u>004</u>	Mar 28, 2022
<u>AB</u>		<u>50MG</u>	<u>A215672</u>	<u>005</u>	Mar 28, 2022
<u>AB</u>	GENEYORK PHARMS	<u>1MG</u>	<u>A211496</u>	<u>001</u>	Dec 28, 2018
<u>AB</u>		<u>2.5MG</u>	<u>A211495</u>	<u>001</u>	Dec 07, 2018
<u>AB</u>		<u>5MG</u>	<u>A211495</u>	<u>002</u>	Dec 07, 2018
<u>AB</u>		<u>10MG</u>	<u>A210525</u>	<u>001</u>	Dec 04, 2018
<u>AB</u>		<u>20MG</u>	<u>A210525</u>	<u>002</u>	Dec 04, 2018
<u>AB</u>		<u>50MG</u>	<u>A210525</u>	<u>003</u>	Dec 04, 2018
<u>AB</u>	+	<u>1MG</u>	<u>A087800</u>	<u>001</u>	Apr 22, 1982
<u>AB</u>	!	<u>2.5MG</u>	<u>A087801</u>	<u>001</u>	Apr 22, 1982
<u>AB</u>	!	<u>5MG</u>	<u>A080352</u>	<u>001</u>	
<u>AB</u>	+	<u>10MG</u>	<u>A084122</u>	<u>001</u>	
<u>AB</u>	+	<u>20MG</u>	<u>A087342</u>	<u>001</u>	
<u>AB</u>	!	<u>50MG</u>	<u>A084283</u>	<u>001</u>	
<u>AB</u>	JUBILANT CADISTA	<u>1MG</u>	<u>A040611</u>	<u>001</u>	Jun 06, 2005
<u>AB</u>		<u>5MG</u>	<u>A040362</u>	<u>002</u>	Aug 29, 2001
<u>AB</u>		<u>10MG</u>	<u>A040362</u>	<u>001</u>	Aug 29, 2001
<u>AB</u>		<u>20MG</u>	<u>A040362</u>	<u>003</u>	Jun 29, 2005
<u>AB</u>	MYLAN	<u>5MG</u>	<u>A080292</u>	<u>001</u>	
<u>AB</u>		<u>10MG</u>	<u>A088832</u>	<u>001</u>	Dec 04, 1985
<u>AB</u>		<u>20MG</u>	<u>A083677</u>	<u>001</u>	
<u>AB</u>	NOVITIUM PHARMA	<u>1MG</u>	<u>A215246</u>	<u>001</u>	Jul 06, 2021
<u>AB</u>		<u>2.5MG</u>	<u>A211575</u>	<u>001</u>	Nov 15, 2019
<u>AB</u>		<u>5MG</u>	<u>A211575</u>	<u>002</u>	Nov 15, 2019
<u>AB</u>		<u>10MG</u>	<u>A211575</u>	<u>003</u>	Nov 15, 2019
<u>AB</u>		<u>20MG</u>	<u>A211575</u>	<u>004</u>	Nov 15, 2019
<u>AB</u>		<u>50MG</u>	<u>A211575</u>	<u>005</u>	Nov 15, 2019
<u>AB</u>	STRIDES PHARMA	<u>1MG</u>	<u>A210785</u>	<u>001</u>	Sep 02, 2020
<u>AB</u>		<u>2.5MG</u>	<u>A209727</u>	<u>001</u>	Nov 20, 2020
<u>AB</u>		<u>5MG</u>	<u>A209727</u>	<u>002</u>	Nov 20, 2020
<u>AB</u>		<u>10MG</u>	<u>A208412</u>	<u>001</u>	Feb 11, 2021
<u>AB</u>		<u>20MG</u>	<u>A208412</u>	<u>002</u>	Feb 11, 2021
<u>AB</u>		<u>50MG</u>	<u>A208412</u>	<u>003</u>	Jan 11, 2022
<u>AB</u>	SUN PHARM INDUSTRIES	<u>5MG</u>	<u>A089247</u>	<u>002</u>	Dec 04, 1985
<u>AB</u>		<u>10MG</u>	<u>A089247</u>	<u>003</u>	Dec 04, 1985
<u>AB</u>		<u>20MG</u>	<u>A089247</u>	<u>001</u>	Dec 04, 1985
<u>AB</u>	VINTAGE PHARMS	<u>1MG</u>	<u>A040584</u>	<u>001</u>	Dec 21, 2004
<u>AB</u>		<u>2.5MG</u>	<u>A040581</u>	<u>001</u>	Dec 21, 2004
<u>AB</u>		<u>5MG</u>	<u>A040256</u>	<u>001</u>	Jul 12, 2002
<u>AB</u>		<u>10MG</u>	<u>A040256</u>	<u>002</u>	Jul 12, 2002
<u>AB</u>		<u>20MG</u>	<u>A040392</u>	<u>001</u>	Feb 12, 2003
<u>AB</u>	WATSON LABS	<u>5MG</u>	<u>A080356</u>	<u>001</u>	
<u>AB</u>		<u>10MG</u>	<u>A085162</u>	<u>001</u>	

PRESCRIPTION DRUG PRODUCT LIST

3-380 (of 474)

PREDNISONE

TABLET; ORAL

PREDNISONEAB 20MGA085161 001

TABLET, DELAYED RELEASE; ORAL

PREDNISONEAB ACTAVIS LABS FL INC 1MGA204867 001 Apr 25, 2017AB 2MGA204867 002 Apr 25, 2017AB 5MGA204867 003 Apr 25, 2017RAYOSAB + HORIZON 1MGN202020 001 Jul 26, 2012AB + 2MGN202020 002 Jul 26, 2012AB +! 5MGN202020 003 Jul 26, 2012PREGABALIN

CAPSULE; ORAL

LYRICAAB + UPJOHN 25MGN021446 001 Dec 30, 2004AB + 50MGN021446 002 Dec 30, 2004AB + 75MGN021446 003 Dec 30, 2004AB + 100MGN021446 004 Dec 30, 2004AB + 150MGN021446 005 Dec 30, 2004AB + 200MGN021446 006 Dec 30, 2004AB + 225MGN021446 007 Dec 30, 2004AB +! 300MGN021446 008 Dec 30, 2004PREGABALINAB ACTAVIS ELIZABETH 25MGA091025 001 Jul 09, 2020AB 50MGA091025 002 Jul 09, 2020AB 75MGA091025 003 Jul 09, 2020AB 100MGA091025 004 Jul 09, 2020AB 150MGA091025 005 Jul 09, 2020AB 200MGA091025 006 Jul 09, 2020AB 225MGA091025 007 Jul 09, 2020AB 300MGA091025 008 Jul 09, 2020AB ALEMBIC PHARMS 25MGA203459 001 Jul 19, 2019AB 50MGA203459 002 Jul 19, 2019AB 75MGA203459 003 Jul 19, 2019AB 100MGA203459 004 Jul 19, 2019AB 150MGA203459 005 Jul 19, 2019AB 200MGA203459 006 Jul 19, 2019AB 225MGA203459 007 Jul 19, 2019AB 300MGA203459 008 Jul 19, 2019AB ALKEM LABS LTD 25MGA207799 007 Sep 30, 2019AB 50MGA207799 008 Sep 30, 2019AB 75MGA207799 001 Jul 19, 2019AB 100MGA207799 002 Jul 19, 2019AB 150MGA207799 003 Jul 19, 2019AB 200MGA207799 004 Jul 19, 2019AB 225MGA207799 005 Jul 19, 2019AB 300MGA207799 006 Jul 19, 2019AB AMNEAL PHARMS CO 25MGA209743 001 Jul 19, 2019AB 50MGA209743 002 Jul 19, 2019AB 75MGA209743 003 Jul 19, 2019AB 100MGA209743 004 Jul 19, 2019AB 150MGA209743 005 Jul 19, 2019AB 200MGA209743 006 Jul 19, 2019AB 225MGA209743 007 Jul 19, 2019AB 300MGA209743 008 Jul 19, 2019AB APOTEX 25MGA211685 001 Jul 07, 2021AB 50MGA211685 002 Jul 07, 2021AB 75MGA211685 003 Jul 07, 2021AB 100MGA211685 004 Jul 07, 2021AB 150MGA211685 005 Jul 07, 2021AB 200MGA211685 006 Jul 07, 2021AB 225MGA211685 007 Jul 07, 2021AB 300MGA211685 008 Jul 07, 2021AB CELLTRION 50MGA212865 001 Mar 20, 2020AB 75MGA212865 002 Mar 20, 2020AB 100MGA212865 003 Mar 20, 2020AB 150MGA212865 004 Mar 20, 2020AB CHANGZHOU PHARM 50MGA214322 001 Jul 15, 2021AB 75MGA214322 002 Jul 15, 2021AB 100MGA214322 003 Jul 15, 2021

PRESCRIPTION DRUG PRODUCT LIST

3-381 (of 474)

PREGABALIN

CAPSULE; ORAL

PREGABALIN

<u>AB</u>		<u>150MG</u>	<u>A214322</u>	<u>004</u>	Jul 15, 2021
<u>AB</u>		<u>200MG</u>	<u>A214322</u>	<u>005</u>	Jul 15, 2021
<u>AB</u>		<u>225MG</u>	<u>A214322</u>	<u>006</u>	Jul 15, 2021
<u>AB</u>		<u>300MG</u>	<u>A214322</u>	<u>007</u>	Jul 15, 2021
<u>AB</u>	CIPLA	<u>25MG</u>	<u>A212280</u>	<u>001</u>	Jan 10, 2020
<u>AB</u>		<u>50MG</u>	<u>A212280</u>	<u>002</u>	Jan 10, 2020
<u>AB</u>		<u>75MG</u>	<u>A212280</u>	<u>003</u>	Jan 10, 2020
<u>AB</u>		<u>100MG</u>	<u>A212280</u>	<u>004</u>	Jan 10, 2020
<u>AB</u>		<u>150MG</u>	<u>A212280</u>	<u>005</u>	Jan 10, 2020
<u>AB</u>		<u>200MG</u>	<u>A212280</u>	<u>006</u>	Jan 10, 2020
<u>AB</u>		<u>225MG</u>	<u>A212280</u>	<u>007</u>	Jan 10, 2020
<u>AB</u>		<u>300MG</u>	<u>A212280</u>	<u>008</u>	Jan 10, 2020
<u>AB</u>	DR REDDYS	<u>25MG</u>	<u>A209664</u>	<u>001</u>	Jul 19, 2019
<u>AB</u>		<u>50MG</u>	<u>A209664</u>	<u>002</u>	Jul 19, 2019
<u>AB</u>		<u>75MG</u>	<u>A209664</u>	<u>003</u>	Jul 19, 2019
<u>AB</u>		<u>100MG</u>	<u>A209664</u>	<u>004</u>	Jul 19, 2019
<u>AB</u>		<u>150MG</u>	<u>A209664</u>	<u>005</u>	Jul 19, 2019
<u>AB</u>		<u>200MG</u>	<u>A209664</u>	<u>006</u>	Jul 19, 2019
<u>AB</u>		<u>225MG</u>	<u>A209664</u>	<u>007</u>	Jul 19, 2019
<u>AB</u>		<u>300MG</u>	<u>A209664</u>	<u>008</u>	Jul 19, 2019
<u>AB</u>	ESKAYEF	<u>25MG</u>	<u>A212988</u>	<u>001</u>	Mar 08, 2022
<u>AB</u>		<u>50MG</u>	<u>A212988</u>	<u>002</u>	Mar 08, 2022
<u>AB</u>		<u>75MG</u>	<u>A212988</u>	<u>003</u>	Mar 08, 2022
<u>AB</u>		<u>100MG</u>	<u>A212988</u>	<u>004</u>	Mar 08, 2022
<u>AB</u>		<u>150MG</u>	<u>A212988</u>	<u>005</u>	Mar 08, 2022
<u>AB</u>		<u>200MG</u>	<u>A212988</u>	<u>006</u>	Mar 08, 2022
<u>AB</u>		<u>225MG</u>	<u>A212988</u>	<u>007</u>	Mar 08, 2022
<u>AB</u>		<u>300MG</u>	<u>A212988</u>	<u>008</u>	Mar 08, 2022
<u>AB</u>	HETERO LABS LTD III	<u>25MG</u>	<u>A206912</u>	<u>001</u>	Oct 08, 2019
<u>AB</u>		<u>50MG</u>	<u>A206912</u>	<u>002</u>	Oct 08, 2019
<u>AB</u>		<u>75MG</u>	<u>A206912</u>	<u>003</u>	Oct 08, 2019
<u>AB</u>		<u>100MG</u>	<u>A206912</u>	<u>004</u>	Oct 08, 2019
<u>AB</u>		<u>150MG</u>	<u>A206912</u>	<u>005</u>	Oct 08, 2019
<u>AB</u>		<u>200MG</u>	<u>A206912</u>	<u>006</u>	Oct 08, 2019
<u>AB</u>		<u>225MG</u>	<u>A206912</u>	<u>007</u>	Oct 08, 2019
<u>AB</u>		<u>300MG</u>	<u>A206912</u>	<u>008</u>	Oct 08, 2019
<u>AB</u>	HIKAL	<u>25MG</u>	<u>A213423</u>	<u>001</u>	Mar 23, 2020
<u>AB</u>		<u>50MG</u>	<u>A213423</u>	<u>002</u>	Mar 23, 2020
<u>AB</u>		<u>75MG</u>	<u>A213423</u>	<u>003</u>	Mar 23, 2020
<u>AB</u>		<u>100MG</u>	<u>A213423</u>	<u>004</u>	Mar 23, 2020
<u>AB</u>		<u>150MG</u>	<u>A213423</u>	<u>005</u>	Mar 23, 2020
<u>AB</u>		<u>200MG</u>	<u>A213423</u>	<u>006</u>	Mar 23, 2020
<u>AB</u>		<u>225MG</u>	<u>A213423</u>	<u>007</u>	Mar 23, 2020
<u>AB</u>		<u>300MG</u>	<u>A213423</u>	<u>008</u>	Mar 23, 2020
<u>AB</u>	INVAGEN PHARMS	<u>25MG</u>	<u>A211384</u>	<u>001</u>	Jul 19, 2019
<u>AB</u>		<u>50MG</u>	<u>A211384</u>	<u>002</u>	Jul 19, 2019
<u>AB</u>		<u>75MG</u>	<u>A211384</u>	<u>003</u>	Jul 19, 2019
<u>AB</u>		<u>100MG</u>	<u>A211384</u>	<u>004</u>	Jul 19, 2019
<u>AB</u>		<u>150MG</u>	<u>A211384</u>	<u>005</u>	Jul 19, 2019
<u>AB</u>		<u>200MG</u>	<u>A211384</u>	<u>006</u>	Jul 19, 2019
<u>AB</u>		<u>225MG</u>	<u>A211384</u>	<u>007</u>	Jul 19, 2019
<u>AB</u>		<u>300MG</u>	<u>A211384</u>	<u>008</u>	Jul 19, 2019
<u>AB</u>	MARKSANS PHARMA	<u>25MG</u>	<u>A216197</u>	<u>001</u>	Jul 18, 2022
<u>AB</u>		<u>50MG</u>	<u>A216197</u>	<u>002</u>	Jul 18, 2022
<u>AB</u>		<u>75MG</u>	<u>A216197</u>	<u>003</u>	Jul 18, 2022
<u>AB</u>		<u>100MG</u>	<u>A216197</u>	<u>004</u>	Jul 18, 2022
<u>AB</u>		<u>150MG</u>	<u>A216197</u>	<u>005</u>	Jul 18, 2022
<u>AB</u>		<u>200MG</u>	<u>A216197</u>	<u>006</u>	Jul 18, 2022
<u>AB</u>		<u>225MG</u>	<u>A216197</u>	<u>007</u>	Jul 18, 2022
<u>AB</u>		<u>300MG</u>	<u>A216197</u>	<u>008</u>	Jul 18, 2022
<u>AB</u>	MSN	<u>25MG</u>	<u>A209357</u>	<u>001</u>	Jul 19, 2019
<u>AB</u>		<u>50MG</u>	<u>A209357</u>	<u>002</u>	Jul 19, 2019
<u>AB</u>		<u>75MG</u>	<u>A209357</u>	<u>003</u>	Jul 19, 2019
<u>AB</u>		<u>100MG</u>	<u>A209357</u>	<u>004</u>	Jul 19, 2019
<u>AB</u>		<u>150MG</u>	<u>A209357</u>	<u>005</u>	Jul 19, 2019
<u>AB</u>		<u>200MG</u>	<u>A209357</u>	<u>006</u>	Jul 19, 2019
<u>AB</u>		<u>225MG</u>	<u>A209357</u>	<u>007</u>	Jul 19, 2019
<u>AB</u>		<u>300MG</u>	<u>A209357</u>	<u>008</u>	Jul 19, 2019
<u>AB</u>	PRINSTON INC	<u>25MG</u>	<u>A207883</u>	<u>001</u>	Sep 01, 2022

PRESCRIPTION DRUG PRODUCT LIST

3-382 (of 474)

PREGABALIN

CAPSULE; ORAL

PREGABALIN

<u>AB</u>		<u>50MG</u>	<u>A207883</u>	<u>002</u>	Sep 01, 2022
<u>AB</u>		<u>75MG</u>	<u>A207883</u>	<u>003</u>	Sep 01, 2022
<u>AB</u>		<u>100MG</u>	<u>A207883</u>	<u>004</u>	Sep 01, 2022
<u>AB</u>		<u>150MG</u>	<u>A207883</u>	<u>005</u>	Sep 01, 2022
<u>AB</u>		<u>200MG</u>	<u>A207883</u>	<u>006</u>	Sep 01, 2022
<u>AB</u>		<u>225MG</u>	<u>A207883</u>	<u>007</u>	Sep 01, 2022
<u>AB</u>		<u>300MG</u>	<u>A207883</u>	<u>008</u>	Sep 01, 2022
<u>AB</u>	RENATA	<u>50MG</u>	<u>A210585</u>	<u>001</u>	Dec 26, 2019
<u>AB</u>		<u>75MG</u>	<u>A210585</u>	<u>002</u>	Dec 26, 2019
<u>AB</u>		<u>100MG</u>	<u>A210585</u>	<u>003</u>	Dec 26, 2019
<u>AB</u>		<u>150MG</u>	<u>A210585</u>	<u>004</u>	Dec 26, 2019
<u>AB</u>		<u>200MG</u>	<u>A210585</u>	<u>005</u>	Dec 26, 2019
<u>AB</u>		<u>300MG</u>	<u>A210585</u>	<u>006</u>	Dec 26, 2019
<u>AB</u>	RISING	<u>25MG</u>	<u>A210432</u>	<u>001</u>	Jul 19, 2019
<u>AB</u>		<u>50MG</u>	<u>A210432</u>	<u>002</u>	Jul 19, 2019
<u>AB</u>		<u>75MG</u>	<u>A210432</u>	<u>003</u>	Jul 19, 2019
<u>AB</u>		<u>100MG</u>	<u>A210432</u>	<u>004</u>	Jul 19, 2019
<u>AB</u>		<u>150MG</u>	<u>A210432</u>	<u>005</u>	Jul 19, 2019
<u>AB</u>		<u>200MG</u>	<u>A210432</u>	<u>006</u>	Jul 19, 2019
<u>AB</u>		<u>225MG</u>	<u>A210432</u>	<u>007</u>	Jul 19, 2019
<u>AB</u>		<u>300MG</u>	<u>A210432</u>	<u>008</u>	Jul 19, 2019
<u>AB</u>	SCIEGEN PHARMS INC	<u>25MG</u>	<u>A208677</u>	<u>001</u>	Jul 19, 2019
<u>AB</u>		<u>50MG</u>	<u>A208677</u>	<u>002</u>	Jul 19, 2019
<u>AB</u>		<u>75MG</u>	<u>A208677</u>	<u>003</u>	Jul 19, 2019
<u>AB</u>		<u>100MG</u>	<u>A208677</u>	<u>004</u>	Jul 19, 2019
<u>AB</u>		<u>150MG</u>	<u>A208677</u>	<u>005</u>	Jul 19, 2019
<u>AB</u>		<u>200MG</u>	<u>A208677</u>	<u>006</u>	Jul 19, 2019
<u>AB</u>		<u>225MG</u>	<u>A208677</u>	<u>007</u>	Jul 19, 2019
<u>AB</u>		<u>300MG</u>	<u>A208677</u>	<u>008</u>	Jul 19, 2019
<u>AB</u>	SHUANGCHENG	<u>75MG</u>	<u>A210891</u>	<u>001</u>	Sep 30, 2019
<u>AB</u>		<u>300MG</u>	<u>A210891</u>	<u>002</u>	Sep 30, 2019
<u>AB</u>	SUN PHARM	<u>25MG</u>	<u>A091157</u>	<u>001</u>	Nov 29, 2019
<u>AB</u>		<u>50MG</u>	<u>A091157</u>	<u>002</u>	Nov 29, 2019
<u>AB</u>		<u>75MG</u>	<u>A091157</u>	<u>003</u>	Nov 29, 2019
<u>AB</u>		<u>100MG</u>	<u>A091157</u>	<u>004</u>	Nov 29, 2019
<u>AB</u>		<u>150MG</u>	<u>A091157</u>	<u>005</u>	Nov 29, 2019
<u>AB</u>		<u>200MG</u>	<u>A091157</u>	<u>006</u>	Nov 29, 2019
<u>AB</u>		<u>225MG</u>	<u>A091157</u>	<u>007</u>	Nov 29, 2019
<u>AB</u>		<u>300MG</u>	<u>A091157</u>	<u>008</u>	Nov 29, 2019
<u>AB</u>	TEVA PHARMS	<u>25MG</u>	<u>A091219</u>	<u>001</u>	Jul 19, 2019
<u>AB</u>		<u>50MG</u>	<u>A091219</u>	<u>002</u>	Jul 19, 2019
<u>AB</u>		<u>75MG</u>	<u>A091224</u>	<u>001</u>	Jul 19, 2019
<u>AB</u>		<u>100MG</u>	<u>A091224</u>	<u>002</u>	Jul 19, 2019
<u>AB</u>		<u>150MG</u>	<u>A091224</u>	<u>003</u>	Jul 19, 2019
<u>AB</u>		<u>200MG</u>	<u>A091224</u>	<u>004</u>	Jul 19, 2019
<u>AB</u>		<u>225MG</u>	<u>A091224</u>	<u>005</u>	Jul 19, 2019
<u>AB</u>		<u>300MG</u>	<u>A091224</u>	<u>006</u>	Jul 19, 2019
<u>AB</u>	ZYDUS PHARMS	<u>25MG</u>	<u>A206752</u>	<u>001</u>	Dec 09, 2022
<u>AB</u>		<u>50MG</u>	<u>A206752</u>	<u>002</u>	Dec 09, 2022
<u>AB</u>		<u>75MG</u>	<u>A206752</u>	<u>003</u>	Dec 09, 2022
<u>AB</u>		<u>100MG</u>	<u>A206752</u>	<u>004</u>	Dec 09, 2022
<u>AB</u>		<u>150MG</u>	<u>A206752</u>	<u>005</u>	Dec 09, 2022
<u>AB</u>		<u>200MG</u>	<u>A206752</u>	<u>006</u>	Dec 09, 2022
<u>AB</u>		<u>225MG</u>	<u>A206752</u>	<u>007</u>	Dec 09, 2022
<u>AB</u>		<u>300MG</u>	<u>A206752</u>	<u>008</u>	Dec 09, 2022

SOLUTION; ORAL

LYRICA

<u>AA</u>	<u>+</u> UPJOHN	<u>20MG/ML</u>	<u>N022488</u>	<u>001</u>	Jan 04, 2010

PREGABALIN

<u>AA</u>	ALKEM LABS LTD	<u>20MG/ML</u>	<u>A207623</u>	<u>001</u>	Jul 19, 2019
<u>AA</u>	INVATECH	<u>20MG/ML</u>	<u>A212604</u>	<u>001</u>	Feb 18, 2022

TABLET, EXTENDED RELEASE; ORAL

LYRICA CR

<u>AB</u>	<u>+</u> UPJOHN	<u>82.5MG</u>	<u>N209501</u>	<u>001</u>	Oct 11, 2017
<u>AB</u>	<u>+</u>	<u>165MG</u>	<u>N209501</u>	<u>002</u>	Oct 11, 2017
<u>AB</u>	<u>+</u>	<u>330MG</u>	<u>N209501</u>	<u>003</u>	Oct 11, 2017

PREGABALIN

<u>AB</u>	ALVOGEN	<u>82.5MG</u>	<u>A211593</u>	<u>001</u>	Apr 13, 2021
<u>AB</u>		<u>165MG</u>	<u>A211593</u>	<u>002</u>	Apr 13, 2021

PRESCRIPTION DRUG PRODUCT LIST

3-383 (of 474)

PREGABALIN

TABLET, EXTENDED RELEASE;ORAL

PREGABALIN

<u>AB</u>		<u>330MG</u>	<u>A211593</u>	<u>003</u>	Apr 13, 2021
<u>AB</u>	APOTEX	<u>165MG</u>	<u>A213313</u>	<u>001</u>	Apr 13, 2021
<u>AB</u>		<u>330MG</u>	<u>A213313</u>	<u>002</u>	Apr 13, 2021
<u>AB</u>	MSN	<u>82.5MG</u>	<u>A213226</u>	<u>001</u>	Apr 13, 2021
<u>AB</u>		<u>165MG</u>	<u>A213226</u>	<u>002</u>	Apr 13, 2021
<u>AB</u>		<u>330MG</u>	<u>A213226</u>	<u>003</u>	Apr 13, 2021
<u>AB</u>	RUBICON	<u>82.5MG</u>	<u>A215249</u>	<u>001</u>	Mar 22, 2022
<u>AB</u>		<u>165MG</u>	<u>A215249</u>	<u>002</u>	Mar 22, 2022
<u>AB</u>		<u>330MG</u>	<u>A215249</u>	<u>003</u>	Mar 22, 2022
<u>AB</u>	SCIEGEN PHARMS INC	<u>82.5MG</u>	<u>A215675</u>	<u>001</u>	Sep 14, 2022
<u>AB</u>		<u>165MG</u>	<u>A215675</u>	<u>002</u>	Sep 14, 2022
<u>AB</u>		<u>330MG</u>	<u>A215675</u>	<u>003</u>	Sep 14, 2022
<u>AB</u>	SUN PHARM	<u>82.5MG</u>	<u>A211889</u>	<u>001</u>	Apr 13, 2021
<u>AB</u>		<u>165MG</u>	<u>A211889</u>	<u>002</u>	Apr 13, 2021
<u>AB</u>		<u>330MG</u>	<u>A211889</u>	<u>003</u>	Apr 13, 2021
<u>AB</u>	ZYDUS PHARMS	<u>82.5MG</u>	<u>A215577</u>	<u>001</u>	Aug 26, 2022
<u>AB</u>		<u>165MG</u>	<u>A215577</u>	<u>002</u>	Aug 26, 2022
<u>AB</u>		<u>330MG</u>	<u>A215577</u>	<u>003</u>	Aug 26, 2022

PRETOMANID

TABLET;ORAL

PRETOMANID

+	MYLAN IRELAND LTD	200MG	N212862	001	Aug 14, 2019

PRILOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION

PRILOCAINE HYDROCHLORIDE

!	SEPTODONT INC	4%	A079235	001	Sep 29, 2010

PRIMAQUINE PHOSPHATE

TABLET;ORAL

PRIMAQUINE

<u>AB</u>	+	SANOFI AVENTIS US	<u>EQ 15MG BASE</u>	<u>N008316</u>	<u>001</u>
<u>PRIMAQUINE PHOSPHATE</u>					
<u>AB</u>		BAYSHORE PHARMS LLC	<u>EQ 15MG BASE</u>	<u>A204476</u>	<u>001</u> Feb 25, 2014
<u>AB</u>		NOVAST LABS	<u>EQ 15MG BASE</u>	<u>A206043</u>	<u>001</u> Jun 23, 2016

PRIMIDONE

TABLET;ORAL

MYSOLINE

<u>AB</u>	+	VALEANT	<u>50MG</u>	<u>N009170</u>	<u>003</u>
<u>AB</u>	+		<u>250MG</u>	<u>N009170</u>	<u>002</u>

PRIMIDONE

<u>AB</u>		AMNEAL PHARM	<u>50MG</u>	<u>A040866</u>	<u>001</u> Apr 23, 2008
<u>AB</u>			<u>250MG</u>	<u>A040866</u>	<u>002</u> Apr 23, 2008
<u>AB</u>		ANDA REPOSITORY	<u>50MG</u>	<u>A040626</u>	<u>001</u> Sep 29, 2005
<u>AB</u>			<u>250MG</u>	<u>A040626</u>	<u>002</u> Sep 29, 2005
<u>AB</u>		LANNETT	<u>50MG</u>	<u>A084903</u>	<u>002</u> May 24, 2001
<u>AB</u>			<u>250MG</u>	<u>A084903</u>	<u>001</u>
<u>AB</u>		OXFORD PHARMS	<u>50MG</u>	<u>A040586</u>	<u>001</u> Feb 24, 2005
<u>AB</u>			<u>250MG</u>	<u>A040586</u>	<u>002</u> Feb 24, 2005
<u>AB</u>		RUBICON	<u>50MG</u>	<u>A214896</u>	<u>001</u> Jun 28, 2022
<u>AB</u>			<u>125MG</u>	<u>A214896</u>	<u>003</u> Dec 28, 2022
<u>AB</u>			<u>250MG</u>	<u>A214896</u>	<u>002</u> Jun 28, 2022
<u>AB</u>		WATSON LABS	<u>250MG</u>	<u>A083551</u>	<u>001</u>

PROBENECID

TABLET;ORAL

PROBALAN

<u>AB</u>		LANNETT	<u>500MG</u>	<u>A080966</u>	<u>001</u>
<u>PROBENECID</u>					
<u>AB</u>	!	WATSON LABS TEVA	<u>500MG</u>	<u>A084442</u>	<u>004</u> Mar 29, 1983

PROCAINAMIDE HYDROCHLORIDE

INJECTABLE;INJECTION

PROCAINAMIDE HYDROCHLORIDE

<u>AP</u>	!	HOSPIRA	<u>100MG/ML</u>	<u>A089069</u>	<u>001</u> Feb 12, 1986
<u>AP</u>		INTL MEDICATION	<u>100MG/ML</u>	<u>A088636</u>	<u>001</u> Jul 31, 1984
<u>AP</u>		NEXUS PHARMS	<u>100MG/ML</u>	<u>A206332</u>	<u>001</u> Oct 13, 2017
<u>AP</u>			<u>500MG/ML</u>	<u>A206332</u>	<u>002</u> Oct 13, 2017
	!	HOSPIRA	500MG/ML	A089070	001 Feb 12, 1986

PRESCRIPTION DRUG PRODUCT LIST

3-384 (of 474)

PROCARBAZINE HYDROCHLORIDE

CAPSULE; ORAL

MATULANE

+! LEADIANT BIOSCI INC EQ 50MG BASE

N016785 001

PROCHLORPERAZINE

SUPPOSITORY; RECTAL

COMPROAB PADAGIS US25MGA040246 001 Jun 28, 2000PROCHLORPERAZINEAB ! COSETTE25MGA040058 001 Nov 24, 1993PROCHLORPERAZINE EDISYLATE

INJECTABLE; INJECTION

PROCHLORPERAZINE EDISYLATEAP AMNEALEQ 5MG BASE/MLA214192 001 Nov 28, 2022AP ATHENEX INCEQ 5MG BASE/MLA040540 001 May 28, 2004AP CAPLINEQ 5MG BASE/MLA214379 001 Apr 22, 2021AP ! EMCURE PHARMS LTDEQ 5MG BASE/MLA204147 001 Oct 15, 2013AP EUGIA PHARMAEQ 5MG BASE/MLA213873 001 Jul 14, 2022AP GLAND PHARMA LTDEQ 5MG BASE/MLA214107 001 Sep 22, 2021AP HIKMAEQ 5MG BASE/MLA089903 001 Aug 29, 1989APEQ 5MG BASE/MLA213630 001 Nov 22, 2022AP MYLAN LABS LTDEQ 5MG BASE/MLA210710 001 Oct 25, 2018AP NEXUS PHARMSEQ 5MG BASE/MLA204860 001 Feb 15, 2019AP VIWIT PHARMEQ 5MG BASE/MLA213626 001 Sep 28, 2021PROCHLORPERAZINE MALEATE

TABLET; ORAL

PROCHLORPERAZINE MALEATEAB NOVITIUM PHARMAEQ 5MG BASEA216202 001 Jun 13, 2022ABEQ 10MG BASEA216202 002 Jun 13, 2022AB ZYDUSEQ 5MG BASEA216495 001 Aug 08, 2022ABEQ 10MG BASEA216495 002 Aug 08, 2022PROCOMPAB JUBILANT CADISTAEQ 5MG BASEA040268 001 Feb 27, 1998AB !EQ 10MG BASEA040268 002 Feb 27, 1998PROGESTERONE

CAPSULE; ORAL

PROGESTERONEAB AMNEAL PHARMS NY100MGA207724 001 Sep 07, 2017AB200MGA207724 002 Sep 07, 2017AB BIONPHARMA INC100MGA200900 001 Aug 16, 2013AB200MGA200900 002 Aug 16, 2013AB DR REDDYS100MGA208801 001 Feb 28, 2017AB200MGA208801 002 Feb 28, 2017AB EUGIA PHARMA100MGA211285 001 Oct 26, 2018AB200MGA211285 002 Oct 26, 2018AB XIROMED100MGA205229 001 Oct 20, 2017AB200MGA205229 002 Oct 20, 2017PROMETRIUMAB + VIRTUS PHARMS100MGN019781 001 May 14, 1998AB +!200MGN019781 002 Oct 15, 1999

PROGESTERONE

BX SOFGEN PHARMS

100MG

A200456 001 Sep 28, 2012

BX

200MG

A200456 002 Sep 28, 2012

GEL; VAGINAL

CRINONE

+! ALLERGAN

4%

N020701 001 Jul 31, 1997

+!

8%

N020701 002 Jul 31, 1997

INJECTABLE; INJECTION

PROGESTERONEAO ! EUGIA PHARMA50MG/MLA210965 001 Dec 06, 2018AO FRESenius KABI USA50MG/MLA075906 001 Apr 25, 2001AO HIKMA FARMACEUTICA50MG/MLA091033 001 Oct 28, 2010AO XIROMED50MG/MLA215634 001 Jan 05, 2022

INSERT; VAGINAL

ENDOMETRIN

+! FERRING

100MG

N022057 001 Jun 21, 2007

PRESCRIPTION DRUG PRODUCT LIST

3-385 (of 474)

PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

PROMETHAZINE HYDROCHLORIDE

<u>AP</u>	<u>+!</u>	<u>WEST-WARD PHARMS</u>	<u>25MG/ML</u>	<u>A083312</u>	<u>001</u>	
		<u>INT</u>				
<u>AP</u>	<u>+!</u>		<u>50MG/ML</u>	<u>A083312</u>	<u>002</u>	
<u>AP</u>		<u>XGEN PHARMS</u>	<u>25MG/ML</u>	<u>A040737</u>	<u>001</u>	Apr 24, 2008
<u>AP</u>			<u>50MG/ML</u>	<u>A040737</u>	<u>002</u>	Apr 24, 2008

SUPPOSITORY; RECTAL

PROMETHAZINE HYDROCHLORIDE

<u>AB</u>		<u>ANNORA PHARMA</u>	<u>12.5MG</u>	<u>A216446</u>	<u>001</u>	Nov 02, 2022
<u>AB</u>			<u>25MG</u>	<u>A216446</u>	<u>002</u>	Nov 02, 2022
<u>AB</u>		<u>COSETTE</u>	<u>12.5MG</u>	<u>A040428</u>	<u>002</u>	Mar 31, 2003
<u>AB</u>	<u>!</u>		<u>25MG</u>	<u>A040428</u>	<u>001</u>	Feb 05, 2002
<u>AB</u>		<u>PADAGIS ISRAEL</u>	<u>12.5MG</u>	<u>A040500</u>	<u>001</u>	Jun 30, 2003
<u>AB</u>			<u>25MG</u>	<u>A040500</u>	<u>002</u>	Jun 30, 2003
<u>AB</u>		<u>TARO</u>	<u>12.5MG</u>	<u>A040603</u>	<u>001</u>	Oct 26, 2006
<u>AB</u>			<u>25MG</u>	<u>A040603</u>	<u>002</u>	Oct 26, 2006
		<u>PROMETHEGAN</u>				
	<u>!</u>	<u>COSETTE</u>	<u>50MG</u>	<u>A087165</u>	<u>001</u>	Aug 14, 1987

SYRUP; ORAL

PROMETHAZINE HYDROCHLORIDE

<u>AA</u>		<u>AKORN</u>	<u>6.25MG/5ML</u>	<u>A040026</u>	<u>001</u>	Sep 25, 1998
<u>AA</u>		<u>AMNEAL PHARMS</u>	<u>6.25MG/5ML</u>	<u>A040882</u>	<u>001</u>	Dec 30, 2009
<u>AA</u>		<u>NOSTRUM LABS INC</u>	<u>6.25MG/5ML</u>	<u>A040891</u>	<u>001</u>	Mar 13, 2009
<u>AA</u>		<u>PHARM ASSOC</u>	<u>6.25MG/5ML</u>	<u>A040643</u>	<u>001</u>	Apr 26, 2006
<u>AA</u>		<u>QUAGEN</u>	<u>6.25MG/5ML</u>	<u>A213890</u>	<u>001</u>	Jul 12, 2021
<u>AA</u>		<u>TARO</u>	<u>6.25MG/5ML</u>	<u>A040718</u>	<u>001</u>	Apr 04, 2007
<u>AA</u>		<u>TRIS PHARMA INC</u>	<u>6.25MG/5ML</u>	<u>A091675</u>	<u>001</u>	Jun 28, 2012

PROMETHAZINE PLAIN

<u>AA</u>	<u>+!</u>	<u>WOCKHARDT BIO AG</u>	<u>6.25MG/5ML</u>	<u>A087953</u>	<u>001</u>	Nov 15, 1982

TABLET; ORAL

PROMETHAZINE HYDROCHLORIDE

<u>AB</u>		<u>AMNEAL PHARMS NY</u>	<u>12.5MG</u>	<u>A091179</u>	<u>001</u>	Dec 13, 2010
<u>AB</u>			<u>25MG</u>	<u>A091179</u>	<u>002</u>	Dec 13, 2010
<u>AB</u>			<u>50MG</u>	<u>A091179</u>	<u>003</u>	Dec 13, 2010
<u>AB</u>		<u>KVK TECH</u>	<u>12.5MG</u>	<u>A040712</u>	<u>002</u>	May 04, 2007
<u>AB</u>			<u>25MG</u>	<u>A040712</u>	<u>001</u>	Jul 31, 2006
<u>AB</u>			<u>50MG</u>	<u>A040712</u>	<u>003</u>	Jul 31, 2006
<u>AB</u>		<u>PRINSTON INC</u>	<u>12.5MG</u>	<u>A040622</u>	<u>001</u>	Jul 18, 2006
<u>AB</u>			<u>25MG</u>	<u>A040622</u>	<u>002</u>	Jul 18, 2006
<u>AB</u>			<u>50MG</u>	<u>A040622</u>	<u>003</u>	Jul 18, 2006
<u>AB</u>		<u>QUAGEN</u>	<u>12.5MG</u>	<u>A040673</u>	<u>001</u>	Mar 05, 2008
<u>AB</u>			<u>25MG</u>	<u>A040673</u>	<u>002</u>	Mar 05, 2008
<u>AB</u>			<u>50MG</u>	<u>A040673</u>	<u>003</u>	Mar 05, 2008
<u>AB</u>	<u>+</u>	<u>SANDOZ</u>	<u>25MG</u>	<u>A084176</u>	<u>003</u>	
<u>AB</u>	<u>+!</u>		<u>50MG</u>	<u>A084176</u>	<u>001</u>	
<u>AB</u>		<u>STRIDES PHARMA</u>	<u>12.5MG</u>	<u>A209177</u>	<u>001</u>	Jun 30, 2017
<u>AB</u>			<u>25MG</u>	<u>A209177</u>	<u>002</u>	Jun 30, 2017
<u>AB</u>			<u>50MG</u>	<u>A209177</u>	<u>003</u>	Jun 30, 2017
<u>AB</u>		<u>SUN PHARM INDS INC</u>	<u>12.5MG</u>	<u>A040863</u>	<u>001</u>	Dec 30, 2008
<u>AB</u>			<u>25MG</u>	<u>A040863</u>	<u>002</u>	Dec 30, 2008
<u>AB</u>			<u>50MG</u>	<u>A040863</u>	<u>003</u>	Dec 30, 2008
<u>AB</u>		<u>WATSON LABS</u>	<u>25MG</u>	<u>A083426</u>	<u>001</u>	
<u>AB</u>			<u>50MG</u>	<u>A083711</u>	<u>001</u>	
<u>AB</u>		<u>ZYDUS PHARMS USA</u>	<u>12.5MG</u>	<u>A040596</u>	<u>001</u>	Nov 18, 2005
<u>AB</u>			<u>25MG</u>	<u>A040596</u>	<u>002</u>	Nov 18, 2005
<u>AB</u>			<u>50MG</u>	<u>A040596</u>	<u>003</u>	Nov 18, 2005

PROPAFENONE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

PROPAFENONE HYDROCHLORIDE

<u>AB</u>		<u>GLENMARK PHARMS LTD</u>	<u>225MG</u>	<u>A205268</u>	<u>001</u>	Sep 08, 2017
<u>AB</u>			<u>325MG</u>	<u>A205268</u>	<u>002</u>	Sep 08, 2017
<u>AB</u>			<u>425MG</u>	<u>A205268</u>	<u>003</u>	Sep 08, 2017
<u>AB</u>		<u>RISING</u>	<u>225MG</u>	<u>A205956</u>	<u>001</u>	Jul 02, 2018
<u>AB</u>			<u>325MG</u>	<u>A205956</u>	<u>002</u>	Jul 02, 2018
<u>AB</u>			<u>425MG</u>	<u>A205956</u>	<u>003</u>	Jul 02, 2018
<u>AB</u>		<u>STRIDES PHARMA</u>	<u>225MG</u>	<u>A078540</u>	<u>001</u>	Oct 18, 2010
<u>AB</u>			<u>325MG</u>	<u>A078540</u>	<u>002</u>	Oct 18, 2010
<u>AB</u>			<u>425MG</u>	<u>A078540</u>	<u>003</u>	Oct 18, 2010
<u>AB</u>		<u>TWI PHARMS</u>	<u>225MG</u>	<u>A212928</u>	<u>001</u>	Jun 18, 2020
<u>AB</u>			<u>325MG</u>	<u>A212928</u>	<u>002</u>	Jun 18, 2020

PRESCRIPTION DRUG PRODUCT LIST

3-386 (of 474)

PROPAFENONE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

PROPAFENONE HYDROCHLORIDE

<u>AB</u>		<u>425MG</u>	<u>A212928</u>	<u>003</u>	Jun 18, 2020
<u>AB</u>	UPSHER SMITH LABS	<u>225MG</u>	<u>A212744</u>	<u>001</u>	Jun 25, 2020
<u>AB</u>		<u>325MG</u>	<u>A212744</u>	<u>002</u>	Jun 25, 2020
<u>AB</u>		<u>425MG</u>	<u>A212744</u>	<u>003</u>	Jun 25, 2020
<u>AB</u>	WATSON LABS INC	<u>225MG</u>	<u>A202688</u>	<u>001</u>	Aug 24, 2015
<u>AB</u>		<u>325MG</u>	<u>A202688</u>	<u>002</u>	Aug 24, 2015
<u>AB</u>		<u>425MG</u>	<u>A202688</u>	<u>003</u>	Aug 24, 2015
<u>AB</u>	ZYDUS	<u>225MG</u>	<u>A214184</u>	<u>001</u>	Apr 21, 2021
<u>AB</u>		<u>325MG</u>	<u>A214184</u>	<u>002</u>	Apr 21, 2021
<u>AB</u>		<u>425MG</u>	<u>A214184</u>	<u>003</u>	Apr 21, 2021

RYTHMOL SR

<u>AB</u>	+	GLAXOSMITHKLINE LLC	<u>225MG</u>	<u>N021416</u>	<u>001</u>	Sep 04, 2003
<u>AB</u>	+		<u>325MG</u>	<u>N021416</u>	<u>002</u>	Sep 04, 2003
<u>AB</u>	+	!	<u>425MG</u>	<u>N021416</u>	<u>003</u>	Sep 04, 2003

PROPAFENONE HYDROCHLORIDE

BX	SINOTHERAPEUTICS INC	225MG	A210339	001	Jan 04, 2019
BX		325MG	A210339	002	Jan 04, 2019
BX		425MG	A210339	003	Jan 04, 2019

TABLET; ORAL

PROPAFENONE HYDROCHLORIDE

<u>AB</u>		ANI PHARMS	<u>150MG</u>	<u>A076550</u>	<u>001</u>	Apr 23, 2004
<u>AB</u>			<u>225MG</u>	<u>A076550</u>	<u>002</u>	Apr 23, 2004
<u>AB</u>			<u>300MG</u>	<u>A076550</u>	<u>003</u>	Apr 23, 2004
<u>AB</u>		AUROBINDO PHARMA	<u>150MG</u>	<u>A202445</u>	<u>001</u>	May 11, 2016
<u>AB</u>			<u>225MG</u>	<u>A202445</u>	<u>002</u>	May 11, 2016
<u>AB</u>			<u>300MG</u>	<u>A202445</u>	<u>003</u>	May 11, 2016
<u>AB</u>		STRIDES PHARMA	<u>150MG</u>	<u>A075938</u>	<u>001</u>	Oct 17, 2002
<u>AB</u>			<u>225MG</u>	<u>A075938</u>	<u>002</u>	Oct 17, 2002
<u>AB</u>	!		<u>300MG</u>	<u>A075938</u>	<u>003</u>	Oct 17, 2002
<u>AB</u>		SUN PHARM INDUSTRIES	<u>150MG</u>	<u>A075998</u>	<u>001</u>	Nov 29, 2001
<u>AB</u>			<u>225MG</u>	<u>A075998</u>	<u>002</u>	Nov 29, 2001
<u>AB</u>			<u>300MG</u>	<u>A075998</u>	<u>003</u>	Nov 29, 2001
<u>AB</u>		WATSON LABS	<u>150MG</u>	<u>A075203</u>	<u>001</u>	Oct 24, 2000
<u>AB</u>			<u>225MG</u>	<u>A075203</u>	<u>002</u>	Oct 24, 2000

PROPARACAINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

ALCAINE

<u>AT</u>		ALCON LABS INC	<u>0.5%</u>	<u>A080027</u>	<u>001</u>	

PROPARACAINE HYDROCHLORIDE

<u>AT</u>	!	AKORN	<u>0.5%</u>	<u>A040277</u>	<u>001</u>	Mar 16, 2000
<u>AT</u>		BAUSCH AND LOMB	<u>0.5%</u>	<u>A040074</u>	<u>001</u>	Sep 29, 1995

PROPOFOL

INJECTABLE; INJECTION

DIPRIVAN

<u>AB</u>	+	FRESENIUS KABI USA	<u>10MG/ML</u>	<u>N019627</u>	<u>002</u>	Jun 11, 1996

PROPOFOL

<u>AB</u>		DR REDDYS	<u>10MG/ML</u>	<u>A205067</u>	<u>001</u>	Nov 15, 2018
<u>AB</u>		EMCURE PHARMS LTD	<u>10MG/ML</u>	<u>A206408</u>	<u>001</u>	Oct 12, 2021
<u>AB</u>		HIKMA	<u>10MG/ML</u>	<u>A074848</u>	<u>001</u>	Apr 19, 2005
<u>AB</u>		HOSPIRA	<u>10MG/ML</u>	<u>A077908</u>	<u>001</u>	Mar 17, 2006
<u>AB</u>		INNOPHARMA	<u>10MG/ML</u>	<u>A205576</u>	<u>001</u>	Sep 16, 2020
<u>AB</u>		SAGENT PHARMS INC	<u>10MG/ML</u>	<u>A075102</u>	<u>001</u>	Jan 04, 1999
<u>AB</u>		WATSON LABS INC	<u>10MG/ML</u>	<u>A205307</u>	<u>001</u>	Dec 22, 2015

PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

INDERAL LA

<u>AB</u>	+	ANI PHARMS	<u>60MG</u>	<u>N018553</u>	<u>004</u>	Mar 18, 1987
<u>AB</u>	+		<u>80MG</u>	<u>N018553</u>	<u>002</u>	Apr 19, 1983
<u>AB</u>	+		<u>120MG</u>	<u>N018553</u>	<u>003</u>	Apr 19, 1983
<u>AB</u>	+	!	<u>160MG</u>	<u>N018553</u>	<u>001</u>	Apr 19, 1983

PROPRANOLOL HYDROCHLORIDE

<u>AB</u>		ACTAVIS ELIZABETH	<u>60MG</u>	<u>A078494</u>	<u>001</u>	Aug 10, 2007
<u>AB</u>			<u>80MG</u>	<u>A078494</u>	<u>002</u>	Aug 10, 2007
<u>AB</u>			<u>120MG</u>	<u>A078494</u>	<u>003</u>	Aug 10, 2007
<u>AB</u>			<u>160MG</u>	<u>A078494</u>	<u>004</u>	Aug 10, 2007
<u>AB</u>		ADARE PHARMS INC	<u>60MG</u>	<u>A078703</u>	<u>001</u>	Jul 15, 2011

PRESCRIPTION DRUG PRODUCT LIST

3-387 (of 474)

PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

PROPRANOLOL HYDROCHLORIDE

<u>AB</u>		<u>80MG</u>	<u>A078703</u>	<u>002</u>	Jul 15, 2011
<u>AB</u>		<u>120MG</u>	<u>A078703</u>	<u>003</u>	Jul 15, 2011
<u>AB</u>		<u>160MG</u>	<u>A078703</u>	<u>004</u>	Jul 15, 2011
<u>AB</u>	AMTA	<u>60MG</u>	<u>A212026</u>	<u>001</u>	Jan 06, 2020
<u>AB</u>		<u>80MG</u>	<u>A212026</u>	<u>002</u>	Jan 06, 2020
<u>AB</u>		<u>120MG</u>	<u>A212026</u>	<u>003</u>	Jan 06, 2020
<u>AB</u>		<u>160MG</u>	<u>A212026</u>	<u>004</u>	Jan 06, 2020
<u>AB</u>	NORTEC DEV ASSOC	<u>60MG</u>	<u>A078065</u>	<u>001</u>	Jan 26, 2007
<u>AB</u>		<u>80MG</u>	<u>A078065</u>	<u>002</u>	Jan 26, 2007
<u>AB</u>		<u>120MG</u>	<u>A078065</u>	<u>003</u>	Jan 26, 2007
<u>AB</u>		<u>160MG</u>	<u>A078065</u>	<u>004</u>	Jan 26, 2007
<u>AB</u>	ZYDUS PHARMS USA INC	<u>60MG</u>	<u>A090321</u>	<u>001</u>	Mar 25, 2011
<u>AB</u>		<u>80MG</u>	<u>A090321</u>	<u>002</u>	Mar 25, 2011
<u>AB</u>		<u>120MG</u>	<u>A090321</u>	<u>003</u>	Mar 25, 2011
<u>AB</u>		<u>160MG</u>	<u>A090321</u>	<u>004</u>	Mar 25, 2011
	INNOPRAN XL				
BX	+ ANI PHARMS	80MG	N021438	001	Mar 12, 2003
BX	+!	120MG	N021438	002	Mar 12, 2003

INJECTABLE; INJECTION

PROPRANOLOL HYDROCHLORIDE

<u>AP</u>	FRESENIUS KABI USA	<u>1MG/ML</u>	<u>A075826</u>	<u>001</u>	Aug 31, 2001
<u>AP</u>	! HIKMA FARMACEUTICA	<u>1MG/ML</u>	<u>A077760</u>	<u>001</u>	Jan 31, 2008
	SOLUTION; ORAL				
	HEMANGEOL				
	+! PIERRE FABRE DERMA	4.28MG/ML	N205410	001	Mar 14, 2014
	PROPRANOLOL HYDROCHLORIDE				
	! HIKMA	20MG/5ML	A070979	001	May 15, 1987
	!	40MG/5ML	A070690	001	May 15, 1987

TABLET; ORAL

PROPRANOLOL HYDROCHLORIDE

<u>AB</u>	IMPAX LABS INC	<u>10MG</u>	<u>A071972</u>	<u>001</u>	Apr 06, 1988
<u>AB</u>		<u>20MG</u>	<u>A071972</u>	<u>002</u>	Apr 06, 1988
<u>AB</u>		<u>40MG</u>	<u>A071972</u>	<u>003</u>	Apr 06, 1988
<u>AB</u>		<u>60MG</u>	<u>A071976</u>	<u>002</u>	May 13, 1986
<u>AB</u>		<u>80MG</u>	<u>A071976</u>	<u>001</u>	Apr 06, 1988
<u>AB</u>	INNOGENIX	<u>10MG</u>	<u>A070322</u>	<u>002</u>	Oct 22, 1985
<u>AB</u>		<u>20MG</u>	<u>A070322</u>	<u>003</u>	Oct 22, 1985
<u>AB</u>		<u>40MG</u>	<u>A070322</u>	<u>004</u>	Oct 22, 1985
<u>AB</u>		<u>60MG</u>	<u>A070322</u>	<u>005</u>	Sep 24, 1986
<u>AB</u>		<u>80MG</u>	<u>A070322</u>	<u>001</u>	Aug 04, 1986
<u>AB</u>	IPCA LABS LTD	<u>10MG</u>	<u>A078955</u>	<u>001</u>	Jun 02, 2008
<u>AB</u>		<u>20MG</u>	<u>A078955</u>	<u>002</u>	Jun 02, 2008
<u>AB</u>		<u>40MG</u>	<u>A078955</u>	<u>003</u>	Jun 02, 2008
<u>AB</u>		<u>60MG</u>	<u>A078955</u>	<u>004</u>	Jun 02, 2008
<u>AB</u>		<u>80MG</u>	<u>A078955</u>	<u>005</u>	Jun 02, 2008
<u>AB</u>	MYLAN	<u>10MG</u>	<u>A070213</u>	<u>002</u>	Nov 19, 1985
<u>AB</u>		<u>20MG</u>	<u>A070213</u>	<u>003</u>	Nov 19, 1985
<u>AB</u>		<u>40MG</u>	<u>A070213</u>	<u>001</u>	Nov 19, 1985
<u>AB</u>		<u>60MG</u>	<u>A070213</u>	<u>005</u>	Apr 08, 2011
<u>AB</u>		<u>80MG</u>	<u>A070213</u>	<u>004</u>	Nov 19, 1985
<u>AB</u>	NORTHSTAR HLTHCARE	<u>10MG</u>	<u>A078213</u>	<u>001</u>	Jan 10, 2008
<u>AB</u>		<u>20MG</u>	<u>A078213</u>	<u>002</u>	Jan 10, 2008
<u>AB</u>		<u>40MG</u>	<u>A078213</u>	<u>003</u>	Jan 10, 2008
<u>AB</u>		<u>60MG</u>	<u>A078213</u>	<u>004</u>	Jan 10, 2008
<u>AB</u>		<u>80MG</u>	<u>A078213</u>	<u>005</u>	Jan 10, 2008
<u>AB</u>	VINTAGE PHARMS	<u>10MG</u>	<u>A070221</u>	<u>002</u>	Aug 01, 1986
<u>AB</u>		<u>20MG</u>	<u>A070221</u>	<u>003</u>	Aug 01, 1986
<u>AB</u>		<u>40MG</u>	<u>A070221</u>	<u>004</u>	Aug 01, 1986
<u>AB</u>		<u>60MG</u>	<u>A070221</u>	<u>005</u>	Sep 24, 1986
<u>AB</u>		<u>80MG</u>	<u>A070221</u>	<u>001</u>	Apr 14, 1986
<u>AB</u>	WATSON LABS	<u>10MG</u>	<u>A070175</u>	<u>001</u>	May 13, 1986
<u>AB</u>		<u>20MG</u>	<u>A070176</u>	<u>001</u>	May 13, 1986
<u>AB</u>		<u>40MG</u>	<u>A070177</u>	<u>001</u>	May 13, 1986
<u>AB</u>	!	<u>80MG</u>	<u>A070178</u>	<u>001</u>	May 13, 1986

PRESCRIPTION DRUG PRODUCT LIST

3-388 (of 474)

PROPYLTHIOURACIL

TABLET; ORAL

PROPYLTHIOURACIL

BD	ACTAVIS ELIZABETH	50MG	A080172	001	
BD	+! DAVA PHARMS INC	50MG	N006188	001	
BD	QUAGEN	50MG	A080154	001	

PROTAMINE SULFATE

INJECTABLE; INJECTION

PROTAMINE SULFATE

!	FRESENIUS KABI USA	10MG/ML	A089454	001	Apr 07, 1987

PROTRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

PROTRIPTYLINE HYDROCHLORIDE

AB	EPIC PHARMA LLC	5MG	A202220	001	Nov 19, 2012
AB		10MG	A202220	002	Nov 19, 2012
AB	HIKMA	5MG	A078913	001	Sep 16, 2008
AB	!	10MG	A078913	002	Sep 16, 2008
AB	SIGMAPHARM LABS LLC	5MG	A090462	001	May 03, 2010
AB		10MG	A090462	002	May 03, 2010

PRUCALOPRIDE SUCCINATE

TABLET; ORAL

MOTEGRITY

+	TAKEDA PHARMS USA	EQ 1MG BASE	N210166	001	Dec 14, 2018
+!		EQ 2MG BASE	N210166	002	Dec 14, 2018

PYRAZINAMIDE

TABLET; ORAL

PYRAZINAMIDE

AB	!	AKORN	500MG	A081319	001	Jun 30, 1992
AB		MACLEODS PHARMS LTD	500MG	A212541	001	Jul 27, 2020
AB	+	NOVITIUM PHARMA	500MG	A080157	001	

PYRIDOSTIGMINE BROMIDE

INJECTABLE; INJECTION

MESTINON

AP	+!	BAUSCH	5MG/ML	N009830	001	

REGONOL

AP		SANDOZ INC	5MG/ML	N017398	001	

SYRUP; ORAL

MESTINON

AA	+!	BAUSCH	60MG/5ML	N015193	001	

PYRIDOSTIGMINE BROMIDE

AA		AMNEAL	60MG/5ML	A212702	001	Jan 10, 2020
AA		ELYSIUM	60MG/5ML	A208797	001	Jan 09, 2020
AA		MILLA PHARMS	60MG/5ML	A212405	001	Apr 19, 2022
AA		NOVITIUM PHARMA	60MG/5ML	A211694	001	Mar 08, 2019

TABLET; ORAL

MESTINON

AB	+!	BAUSCH	60MG	N009829	002	

PYRIDOSTIGMINE BROMIDE

AB		EYWA	30MG	A211181	002	May 14, 2019
AB			60MG	A211181	001	Jul 20, 2018
AB		IMPAX LABS	30MG	A040502	002	Jun 28, 2022
AB			60MG	A040502	001	Apr 24, 2003
AB		ZYDUS PHARMS	60MG	A205650	001	Jun 22, 2015

TABLET, EXTENDED RELEASE; ORAL

MESTINON

AB	+!	BAUSCH	180MG	N011665	001	

PYRIDOSTIGMINE BROMIDE

AB		ALVOGEN	180MG	A204737	001	Jun 26, 2015
AB		IMPAX LABS INC	180MG	A203184	001	Sep 15, 2015
AB		RISING	180MG	A205464	001	Aug 15, 2017

PYRIDOXINE HYDROCHLORIDE

INJECTABLE; INJECTION

PYRIDOXINE HYDROCHLORIDE

+	FRESENIUS KABI USA	100MG/ML	A080618	001	

PRESCRIPTION DRUG PRODUCT LIST

3-389 (of 474)

PYRIMETHAMINE

TABLET; ORAL

DARAPRIM

AB	+ !	VYERA PHARMS LLC	25MG	N008578	001	
<u>PYRIMETHAMINE</u>						
AB		ALVOGEN	25MG	A211271	001	Jul 27, 2021
AB		AUROBINDO PHARMA LTD	25MG	A216983	001	Oct 25, 2022
AB		CEROVENE INC	25MG	A207127	001	Feb 28, 2020
AB		TEVA PHARMS	25MG	A215506	001	Aug 13, 2021

QUAZEPAM

TABLET; ORAL

DORAL

+ !	GALT PHARMS	15MG	N018708	001	Dec 27, 1985

QUETIAPINE FUMARATE

TABLET; ORAL

QUETIAPINE FUMARATE

AB		ACCORD HLTHCARE	EQ 25MG BASE	A202152	001	Mar 27, 2012
AB			EQ 50MG BASE	A202152	002	Mar 27, 2012
AB			EQ 100MG BASE	A202152	003	Mar 27, 2012
AB			EQ 200MG BASE	A202152	004	Mar 27, 2012
AB			EQ 300MG BASE	A202152	005	Mar 27, 2012
AB			EQ 400MG BASE	A202152	006	Mar 27, 2012
AB		ALKEM LABS LTD	EQ 25MG BASE	A201504	001	Feb 12, 2013
AB			EQ 50MG BASE	A201504	002	Feb 12, 2013
AB			EQ 100MG BASE	A201504	003	Feb 12, 2013
AB			EQ 150MG BASE	A201504	004	Feb 12, 2013
AB			EQ 200MG BASE	A201504	005	Feb 12, 2013
AB			EQ 300MG BASE	A201504	006	Feb 12, 2013
AB			EQ 400MG BASE	A201504	007	Feb 12, 2013
AB		AUROBINDO PHARMA LTD	EQ 25MG BASE	A091388	001	Mar 27, 2012
AB			EQ 50MG BASE	A091388	002	Mar 27, 2012
AB			EQ 100MG BASE	A091388	003	Mar 27, 2012
AB			EQ 150MG BASE	A091388	004	Mar 27, 2012
AB			EQ 200MG BASE	A091388	005	Mar 27, 2012
AB			EQ 300MG BASE	A091388	006	Mar 27, 2012
AB			EQ 400MG BASE	A091388	007	Mar 27, 2012
AB		DR REDDYS LABS LTD	EQ 25MG BASE	A077380	001	Mar 27, 2012
AB			EQ 50MG BASE	A077380	002	Mar 27, 2012
AB			EQ 100MG BASE	A077380	003	Mar 27, 2012
AB			EQ 150MG BASE	A077380	004	Mar 27, 2012
AB			EQ 200MG BASE	A077380	005	Mar 27, 2012
AB			EQ 300MG BASE	A077380	006	Mar 27, 2012
AB			EQ 400MG BASE	A077380	007	Mar 27, 2012
AB		HETERO LABS LTD V	EQ 25MG BASE	A204316	001	Jun 16, 2022
AB			EQ 50MG BASE	A204316	002	Jun 16, 2022
AB			EQ 100MG BASE	A204316	003	Jun 16, 2022
AB			EQ 200MG BASE	A204316	004	Jun 16, 2022
AB			EQ 300MG BASE	A204316	005	Jun 16, 2022
AB			EQ 400MG BASE	A204316	006	Jun 16, 2022
AB		HIKMA	EQ 25MG BASE	A090120	001	Mar 27, 2012
AB			EQ 50MG BASE	A090749	001	Mar 27, 2012
AB			EQ 100MG BASE	A090749	002	Mar 27, 2012
AB			EQ 200MG BASE	A090749	003	Mar 27, 2012
AB			EQ 300MG BASE	A090749	004	Mar 27, 2012
AB			EQ 400MG BASE	A090749	005	Mar 27, 2012
AB		LUPIN LTD	EQ 25MG BASE	A201109	001	Mar 27, 2012
AB			EQ 50MG BASE	A201109	002	Mar 27, 2012
AB			EQ 100MG BASE	A201109	003	Mar 27, 2012
AB			EQ 200MG BASE	A201109	004	Mar 27, 2012
AB			EQ 300MG BASE	A201109	005	Mar 27, 2012
AB			EQ 400MG BASE	A201109	006	Mar 27, 2012
AB		MACLEODS PHARMS LTD	EQ 25MG BASE	A203359	001	May 17, 2016
AB			EQ 50MG BASE	A203359	002	May 17, 2016
AB			EQ 100MG BASE	A203359	003	May 17, 2016
AB			EQ 200MG BASE	A203359	004	May 17, 2016
AB			EQ 300MG BASE	A203359	005	May 17, 2016
AB			EQ 400MG BASE	A203359	006	May 17, 2016
AB		PRINSTON INC	EQ 25MG BASE	A206954	001	Aug 24, 2022
AB			EQ 50MG BASE	A206954	002	Aug 24, 2022
AB			EQ 100MG BASE	A206954	003	Aug 24, 2022

PRESCRIPTION DRUG PRODUCT LIST

3-390 (of 474)

QUETIAPINE FUMARATE

TABLET; ORAL

QUETIAPINE FUMARATE

AB		<u>EQ 200MG BASE</u>	<u>A206954</u>	<u>004</u>	Aug 24, 2022
AB		<u>EQ 300MG BASE</u>	<u>A206954</u>	<u>005</u>	Aug 24, 2022
AB		<u>EQ 400MG BASE</u>	<u>A206954</u>	<u>006</u>	Aug 24, 2022
AB	SANDOZ	<u>EQ 25MG BASE</u>	<u>A078679</u>	<u>001</u>	Dec 14, 2012
AB		<u>EQ 50MG BASE</u>	<u>A078679</u>	<u>002</u>	Dec 14, 2012
AB		<u>EQ 100MG BASE</u>	<u>A078679</u>	<u>003</u>	Dec 14, 2012
AB		<u>EQ 150MG BASE</u>	<u>A078679</u>	<u>004</u>	Dec 14, 2012
AB		<u>EQ 200MG BASE</u>	<u>A078679</u>	<u>005</u>	Dec 14, 2012
AB		<u>EQ 300MG BASE</u>	<u>A078679</u>	<u>006</u>	Dec 14, 2012
AB		<u>EQ 400MG BASE</u>	<u>A078679</u>	<u>007</u>	Dec 14, 2012
AB	SUN PHARM	<u>EQ 25MG BASE</u>	<u>A201190</u>	<u>001</u>	Mar 27, 2012
AB		<u>EQ 50MG BASE</u>	<u>A201190</u>	<u>002</u>	Mar 27, 2012
AB		<u>EQ 100MG BASE</u>	<u>A201190</u>	<u>003</u>	Mar 27, 2012
AB		<u>EQ 200MG BASE</u>	<u>A201190</u>	<u>004</u>	Mar 27, 2012
AB		<u>EQ 300MG BASE</u>	<u>A201190</u>	<u>005</u>	Mar 27, 2012
AB		<u>EQ 400MG BASE</u>	<u>A201190</u>	<u>006</u>	Mar 27, 2012
AB	TEVA PHARMS	<u>EQ 25MG BASE</u>	<u>A077745</u>	<u>001</u>	Mar 27, 2012
AB		<u>EQ 50MG BASE</u>	<u>A077745</u>	<u>002</u>	Mar 27, 2012
AB		<u>EQ 100MG BASE</u>	<u>A077745</u>	<u>003</u>	Mar 27, 2012
AB		<u>EQ 150MG BASE</u>	<u>A077745</u>	<u>004</u>	Mar 27, 2012
AB		<u>EQ 200MG BASE</u>	<u>A077745</u>	<u>005</u>	Mar 27, 2012
AB		<u>EQ 300MG BASE</u>	<u>A077745</u>	<u>006</u>	Mar 27, 2012
AB		<u>EQ 400MG BASE</u>	<u>A077745</u>	<u>007</u>	Mar 27, 2012
AB	UNICHEM	<u>EQ 25MG BASE</u>	<u>A202674</u>	<u>001</u>	Mar 08, 2016
AB		<u>EQ 50MG BASE</u>	<u>A202674</u>	<u>002</u>	Mar 08, 2016
AB		<u>EQ 100MG BASE</u>	<u>A202674</u>	<u>003</u>	Mar 08, 2016
AB		<u>EQ 200MG BASE</u>	<u>A202674</u>	<u>004</u>	Mar 08, 2016
AB		<u>EQ 300MG BASE</u>	<u>A202674</u>	<u>005</u>	Mar 08, 2016
AB		<u>EQ 400MG BASE</u>	<u>A202674</u>	<u>006</u>	Mar 08, 2016
AB	ZENNOVA	<u>EQ 25MG BASE</u>	<u>A090960</u>	<u>001</u>	Mar 27, 2012
AB		<u>EQ 50MG BASE</u>	<u>A090960</u>	<u>002</u>	Mar 27, 2012
AB		<u>EQ 100MG BASE</u>	<u>A090960</u>	<u>003</u>	Mar 27, 2012
AB		<u>EQ 200MG BASE</u>	<u>A090960</u>	<u>004</u>	Mar 27, 2012
AB		<u>EQ 300MG BASE</u>	<u>A090960</u>	<u>005</u>	Mar 27, 2012
AB		<u>EQ 400MG BASE</u>	<u>A090960</u>	<u>006</u>	Mar 27, 2012
<u>SEROQUEL</u>					
AB	+! ASTRAZENECA	<u>EQ 25MG BASE</u>	<u>N020639</u>	<u>001</u>	Sep 26, 1997
AB	+	<u>EQ 50MG BASE</u>	<u>N020639</u>	<u>007</u>	Oct 04, 2005
AB	+	<u>EQ 100MG BASE</u>	<u>N020639</u>	<u>002</u>	Sep 26, 1997
AB	+	<u>EQ 200MG BASE</u>	<u>N020639</u>	<u>003</u>	Sep 26, 1997
AB	+!	<u>EQ 300MG BASE</u>	<u>N020639</u>	<u>005</u>	Jul 26, 2000
AB	+	<u>EQ 400MG BASE</u>	<u>N020639</u>	<u>006</u>	Oct 04, 2005

TABLET, EXTENDED RELEASE; ORAL

QUETIAPINE FUMARATE

AB	ACCORD HLTHCARE	<u>EQ 50MG BASE</u>	<u>A206252</u>	<u>001</u>	Nov 29, 2017
AB		<u>EQ 150MG BASE</u>	<u>A090681</u>	<u>001</u>	May 09, 2017
AB		<u>EQ 200MG BASE</u>	<u>A090681</u>	<u>002</u>	May 09, 2017
AB		<u>EQ 300MG BASE</u>	<u>A090681</u>	<u>003</u>	May 09, 2017
AB		<u>EQ 400MG BASE</u>	<u>A090681</u>	<u>004</u>	Nov 01, 2016
AB	ALIGNSCIENCE PHARMA	<u>EQ 150MG BASE</u>	<u>A209497</u>	<u>001</u>	Sep 28, 2018
AB		<u>EQ 200MG BASE</u>	<u>A209497</u>	<u>002</u>	Sep 28, 2018
AB	AUROBINDO PHARMA	<u>EQ 50MG BASE</u>	<u>A207655</u>	<u>001</u>	Nov 29, 2017
AB		<u>EQ 150MG BASE</u>	<u>A207655</u>	<u>002</u>	Nov 29, 2017
AB		<u>EQ 200MG BASE</u>	<u>A207655</u>	<u>003</u>	Nov 29, 2017
AB		<u>EQ 300MG BASE</u>	<u>A207655</u>	<u>004</u>	Nov 29, 2017
AB		<u>EQ 400MG BASE</u>	<u>A207655</u>	<u>005</u>	Nov 29, 2017
AB	INTELLIPHARMACEUTICS	<u>EQ 50MG BASE</u>	<u>A202939</u>	<u>001</u>	May 09, 2017
AB		<u>EQ 150MG BASE</u>	<u>A202939</u>	<u>002</u>	May 09, 2017
AB		<u>EQ 200MG BASE</u>	<u>A202939</u>	<u>003</u>	May 09, 2017
AB		<u>EQ 300MG BASE</u>	<u>A202939</u>	<u>004</u>	May 09, 2017
AB		<u>EQ 400MG BASE</u>	<u>A202939</u>	<u>005</u>	May 09, 2017
AB	LUPIN LTD	<u>EQ 50MG BASE</u>	<u>A204203</u>	<u>001</u>	May 17, 2017
AB		<u>EQ 150MG BASE</u>	<u>A204203</u>	<u>002</u>	May 17, 2017
AB		<u>EQ 200MG BASE</u>	<u>A204203</u>	<u>003</u>	May 17, 2017
AB		<u>EQ 300MG BASE</u>	<u>A204203</u>	<u>004</u>	May 17, 2017
AB		<u>EQ 400MG BASE</u>	<u>A204203</u>	<u>005</u>	May 17, 2017
AB	MACLEODS PHARMS LTD	<u>EQ 150MG BASE</u>	<u>A204253</u>	<u>001</u>	Nov 29, 2017
AB		<u>EQ 200MG BASE</u>	<u>A204253</u>	<u>002</u>	Nov 29, 2017
AB		<u>EQ 300MG BASE</u>	<u>A204253</u>	<u>003</u>	Nov 29, 2017

PRESCRIPTION DRUG PRODUCT LIST

3-391 (of 474)

QUETIAPINE FUMARATE

TABLET, EXTENDED RELEASE;ORAL

QUETIAPINE FUMARATE

<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A204253</u>	<u>004</u>	Nov 29, 2017
<u>AB</u>	NOVAST LABS	<u>EQ 50MG BASE</u>	<u>A208947</u>	<u>001</u>	Nov 29, 2017
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A208947</u>	<u>002</u>	Nov 29, 2017
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A208947</u>	<u>003</u>	Nov 29, 2017
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A208947</u>	<u>004</u>	Nov 29, 2017
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A208947</u>	<u>005</u>	Nov 29, 2017
<u>AB</u>	PAR PHARM	<u>EQ 50MG BASE</u>	<u>A090482</u>	<u>001</u>	May 09, 2017
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A090482</u>	<u>002</u>	May 09, 2017
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A090482</u>	<u>003</u>	May 09, 2017
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A090482</u>	<u>004</u>	May 09, 2017
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A090482</u>	<u>005</u>	May 09, 2017
<u>AB</u>	PHARMADAX INC	<u>EQ 50MG BASE</u>	<u>A206260</u>	<u>001</u>	May 09, 2017
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A206260</u>	<u>002</u>	May 09, 2017
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A206260</u>	<u>003</u>	May 09, 2017
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A206260</u>	<u>004</u>	May 09, 2017
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A206260</u>	<u>005</u>	May 09, 2017
<u>AB</u>	PRINSTON INC	<u>EQ 50MG BASE</u>	<u>A208781</u>	<u>001</u>	Apr 26, 2022
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A208781</u>	<u>002</u>	Apr 26, 2022
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A208781</u>	<u>003</u>	Apr 26, 2022
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A208781</u>	<u>004</u>	Apr 26, 2022
<u>AB</u>	SCIEGEN PHARMS INC	<u>EQ 50MG BASE</u>	<u>A209635</u>	<u>005</u>	Nov 16, 2018
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A209635</u>	<u>001</u>	Nov 29, 2017
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A209635</u>	<u>002</u>	Nov 29, 2017
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A209635</u>	<u>003</u>	Nov 29, 2017
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A209635</u>	<u>004</u>	Nov 29, 2017
<u>AB</u>	UNICHEM	<u>EQ 50MG BASE</u>	<u>A215478</u>	<u>001</u>	Aug 15, 2022
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A215478</u>	<u>002</u>	Aug 15, 2022
<u>AB</u>		<u>EQ 200MG BASE</u>	<u>A215478</u>	<u>003</u>	Aug 15, 2022
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A215478</u>	<u>004</u>	Aug 15, 2022
<u>AB</u>		<u>EQ 400MG BASE</u>	<u>A215478</u>	<u>005</u>	Aug 15, 2022
<u>SEROQUEL XR</u>					
<u>AB</u>	+	<u>EQ 50MG BASE</u>	<u>N022047</u>	<u>001</u>	May 17, 2007
<u>AB</u>	+	<u>EQ 150MG BASE</u>	<u>N022047</u>	<u>005</u>	Aug 11, 2008
<u>AB</u>	+	<u>EQ 200MG BASE</u>	<u>N022047</u>	<u>002</u>	May 17, 2007
<u>AB</u>	+	<u>EQ 300MG BASE</u>	<u>N022047</u>	<u>003</u>	May 17, 2007
<u>AB</u>	+	<u>EQ 400MG BASE</u>	<u>N022047</u>	<u>004</u>	May 17, 2007

QUINAPRIL HYDROCHLORIDE

TABLET;ORAL

QUINAPRIL HYDROCHLORIDE

<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 5MG BASE</u>	<u>A202725</u>	<u>001</u>	Apr 29, 2013
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A202725</u>	<u>002</u>	Apr 29, 2013
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A202725</u>	<u>003</u>	Apr 29, 2013
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A202725</u>	<u>004</u>	Apr 29, 2013
<u>AB</u>	INVAGEN PHARMS	<u>EQ 5MG BASE</u>	<u>A078457</u>	<u>001</u>	Aug 24, 2007
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A078457</u>	<u>002</u>	Aug 24, 2007
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A078457</u>	<u>003</u>	Aug 24, 2007
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A078457</u>	<u>004</u>	Aug 24, 2007
<u>AB</u>	LUPIN	<u>EQ 5MG BASE</u>	<u>A077690</u>	<u>001</u>	Jun 20, 2006
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077690</u>	<u>002</u>	Jun 20, 2006
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A077690</u>	<u>003</u>	Jun 20, 2006
<u>AB</u>	!	<u>EQ 40MG BASE</u>	<u>A077690</u>	<u>004</u>	Jun 20, 2006
<u>AB</u>	PRINSTON INC	<u>EQ 5MG BASE</u>	<u>A205823</u>	<u>001</u>	Sep 15, 2016
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A205823</u>	<u>002</u>	Sep 15, 2016
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A205823</u>	<u>003</u>	Sep 15, 2016
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A205823</u>	<u>004</u>	Sep 15, 2016

QUINIDINE GLUCONATE

TABLET, EXTENDED RELEASE;ORAL

QUINIDINE GLUCONATE

<u>AB</u>	EYWA	<u>324MG</u>	<u>A212589</u>	<u>001</u>	Sep 17, 2021
<u>AB</u>	!	<u>324MG</u>	<u>A089338</u>	<u>001</u>	Feb 11, 1987

PRESCRIPTION DRUG PRODUCT LIST

3-392 (of 474)

QUINIDINE SULFATE

TABLET; ORAL

QUINIDINE SULFATE

! EPIC PHARMA

200MG

A088072 002

!

300MG

A088072 001 Sep 26, 1983

QUININE SULFATE

CAPSULE; ORAL

QUALAQUIN**AB** +! SUN PHARM INDUSTRIES **324MG****N021799 001** Aug 12, 2005QUININE SULFATE**AB** AMNEAL PHARMS **324MG****A203729 001** Jul 15, 2015**AB** LUPIN LTD **324MG****A203112 001** Apr 24, 2015**AB** NOVAST LABS **324MG****A204372 001** Jul 22, 2015**AB** TEVA PHARMS **324MG****A091661 001** Sep 28, 2012RABEPRAZOLE SODIUM

TABLET, DELAYED RELEASE; ORAL

ACIPHEX**AB** +! WOODWARD **20MG****N020973 002** Aug 19, 1999RABEPRAZOLE SODIUM**AB** ALKEM LABS LTD **20MG****A208644 001** Apr 24, 2018**AB** AMNEAL PHARMS **20MG****A204179 001** Jul 31, 2015**AB** AUROBINDO PHARMA **20MG****A205761 001** Feb 17, 2017**AB** DR REDDYS **20MG****A076824 001** Nov 08, 2013**AB** LANNETT CO INC **20MG****A090678 001** Nov 08, 2013**AB** LUPIN LTD **20MG****A078964 001** Nov 08, 2013**AB** RUBICON **20MG****A204237 001** Nov 18, 2015**AB** TORRENT **20MG****A202376 001** Nov 08, 2013RADIUM RA-223 DICHLORIDE

SOLUTION; INTRAVENOUS

XOFIGO

+! BAYER HLTHCARE

162mCi/6ML (27mCi/ML)

N203971 001 May 15, 2013

RALOXIFENE HYDROCHLORIDE

TABLET; ORAL

EVISTA**AB** +! LILLY **60MG****N020815 001** Dec 09, 1997RALOXIFENE HYDROCHLORIDE**AB** AMNEAL PHARMS **60MG****A208206 001** Apr 08, 2016**AB** AUROBINDO PHARMA **60MG****A204310 001** Aug 28, 2015**AB** CADILA PHARMS LTD **60MG****A211324 001** Aug 18, 2020**AB** GLENMARK PHARMS LTD **60MG****A204491 001** Mar 22, 2016**AB** INVAGEN PHARMS **60MG****A090842 001** Sep 24, 2014**AB** SCIEGEN PHARMS INC **60MG****A206384 001** Oct 12, 2016**AB** TEVA PHARMS USA **60MG****A078193 001** Mar 04, 2014**AB** WATSON LABS INC **60MG****A200825 001** Jan 21, 2015RALTEGRAVIR POTASSIUM

POWDER; ORAL

ISENTRESS

+! MSD SUB MERCK

EQ 100MG BASE/PACKET

N205786 001 Dec 20, 2013

TABLET; ORAL

ISENTRESS

+! MSD SUB MERCK

EQ 400MG BASE

N022145 001 Oct 12, 2007

ISENTRESS HD

+! MSD SUB MERCK

EQ 600MG BASE

N022145 002 May 26, 2017

TABLET, CHEWABLE; ORAL

ISENTRESS

+ MSD SUB MERCK

EQ 25MG BASE

N203045 001 Dec 21, 2011

+!

EQ 100MG BASE

N203045 002 Dec 21, 2011

RAMELTEON

TABLET; ORAL

RAMELTEON**AB** ACTAVIS LABS FL INC **8MG****A091610 001** Aug 19, 2015**AB** DR REDDYS LABS SA **8MG****A091693 001** Jul 26, 2013**AB** ENALTEC **8MG****A215435 001** Aug 24, 2022**AB** GRANULES **8MG****A213186 001** Aug 21, 2020**AB** I3 PHARMS **8MG****A212650 001** Apr 10, 2020**AB** UPSHER SMITH LABS **8MG****A213815 001** Oct 26, 2020**AB** XIROMED **8MG****A216209 001** Nov 25, 2022**AB** ZYDUS PHARMS **8MG****A211567 001** Jul 22, 2019

PRESCRIPTION DRUG PRODUCT LIST

3-393 (of 474)

RAMELTEON

TABLET; ORAL

ROZEREM

<u>AB</u>	<u>+</u> !	TAKEDA PHARMS USA	<u>8MG</u>	<u>N021782</u>	<u>001</u>	Jul 22, 2005

RAMIPRIL

CAPSULE; ORAL

ALTACE

<u>AB</u>	<u>+</u>	KING PHARMS LLC	<u>1.25MG</u>	<u>N019901</u>	<u>001</u>	Jan 28, 1991
<u>AB</u>	<u>+</u>		<u>2.5MG</u>	<u>N019901</u>	<u>002</u>	Jan 28, 1991
<u>AB</u>	<u>+</u>		<u>5MG</u>	<u>N019901</u>	<u>003</u>	Jan 28, 1991
<u>AB</u>	<u>+</u> !		<u>10MG</u>	<u>N019901</u>	<u>004</u>	Jan 28, 1991

RAMIPRIL

<u>AB</u>		ACCORD HLTHCARE	<u>1.25MG</u>	<u>A202392</u>	<u>001</u>	Apr 15, 2014
<u>AB</u>			<u>2.5MG</u>	<u>A202392</u>	<u>002</u>	Apr 15, 2014
<u>AB</u>			<u>5MG</u>	<u>A202392</u>	<u>003</u>	Apr 15, 2014
<u>AB</u>			<u>10MG</u>	<u>A202392</u>	<u>004</u>	Apr 15, 2014
<u>AB</u>		APOTEX	<u>1.25MG</u>	<u>A079116</u>	<u>001</u>	Jun 20, 2008
<u>AB</u>			<u>2.5MG</u>	<u>A079116</u>	<u>002</u>	Jun 20, 2008
<u>AB</u>			<u>5MG</u>	<u>A079116</u>	<u>003</u>	Jun 20, 2008
<u>AB</u>			<u>10MG</u>	<u>A079116</u>	<u>004</u>	Jun 20, 2008
<u>AB</u>		AUROBINDO PHARMA LTD	<u>1.25MG</u>	<u>A091604</u>	<u>001</u>	Jun 08, 2011
<u>AB</u>			<u>2.5MG</u>	<u>A091604</u>	<u>002</u>	Jun 08, 2011
<u>AB</u>			<u>5MG</u>	<u>A091604</u>	<u>003</u>	Jun 08, 2011
<u>AB</u>			<u>10MG</u>	<u>A091604</u>	<u>004</u>	Jun 08, 2011
<u>AB</u>		CHARTWELL MOLECULAR	<u>1.25MG</u>	<u>A078745</u>	<u>001</u>	Jun 18, 2008
<u>AB</u>			<u>2.5MG</u>	<u>A078745</u>	<u>002</u>	Jun 18, 2008
<u>AB</u>			<u>5MG</u>	<u>A078745</u>	<u>003</u>	Jun 18, 2008
<u>AB</u>			<u>10MG</u>	<u>A078745</u>	<u>004</u>	Jun 18, 2008
<u>AB</u>		DR REDDYS LABS LTD	<u>1.25MG</u>	<u>A078191</u>	<u>001</u>	Jun 18, 2008
<u>AB</u>			<u>2.5MG</u>	<u>A078191</u>	<u>002</u>	Jun 18, 2008
<u>AB</u>			<u>5MG</u>	<u>A078191</u>	<u>003</u>	Jun 18, 2008
<u>AB</u>			<u>10MG</u>	<u>A078191</u>	<u>004</u>	Jun 18, 2008
<u>AB</u>		HIKMA	<u>1.25MG</u>	<u>A077900</u>	<u>001</u>	Jun 18, 2008
<u>AB</u>			<u>2.5MG</u>	<u>A077900</u>	<u>002</u>	Jun 18, 2008
<u>AB</u>			<u>5MG</u>	<u>A077900</u>	<u>003</u>	Jun 18, 2008
<u>AB</u>			<u>10MG</u>	<u>A077900</u>	<u>004</u>	Jun 18, 2008
<u>AB</u>		LUPIN	<u>1.25MG</u>	<u>A077626</u>	<u>001</u>	Jun 09, 2008
<u>AB</u>			<u>2.5MG</u>	<u>A077626</u>	<u>002</u>	Jun 09, 2008
<u>AB</u>			<u>5MG</u>	<u>A077626</u>	<u>003</u>	Jun 09, 2008
<u>AB</u>			<u>10MG</u>	<u>A077626</u>	<u>004</u>	Jun 09, 2008
<u>AB</u>		WATSON LABS	<u>1.25MG</u>	<u>A076549</u>	<u>001</u>	Oct 24, 2005
<u>AB</u>			<u>2.5MG</u>	<u>A076549</u>	<u>002</u>	Oct 24, 2005
<u>AB</u>			<u>10MG</u>	<u>A076549</u>	<u>004</u>	Oct 24, 2005
<u>AB</u>		ZYDUS PHARMS USA	<u>1.25MG</u>	<u>A078832</u>	<u>001</u>	Sep 02, 2008
<u>AB</u>			<u>2.5MG</u>	<u>A078832</u>	<u>002</u>	Sep 02, 2008
<u>AB</u>			<u>5MG</u>	<u>A078832</u>	<u>003</u>	Sep 02, 2008
<u>AB</u>			<u>10MG</u>	<u>A078832</u>	<u>004</u>	Sep 02, 2008

RANITIDINE HYDROCHLORIDE

CAPSULE; ORAL

RANITIDINE HYDROCHLORIDE

<u>AB</u>		DR REDDYS LABS LTD	<u>EQ 150MG BASE</u>	<u>A075742</u>	<u>001</u>	Nov 29, 2000
<u>AB</u>			<u>EQ 300MG BASE</u>	<u>A075742</u>	<u>002</u>	Nov 29, 2000
<u>AB</u>		SANDOZ	<u>EQ 150MG BASE</u>	<u>A074655</u>	<u>001</u>	Oct 22, 1997
<u>AB</u>	<u>!</u>		<u>EQ 300MG BASE</u>	<u>A074655</u>	<u>002</u>	Oct 22, 1997

INJECTABLE; INJECTION

RANITIDINE HYDROCHLORIDE

<u>AP</u>		HIKMA	<u>EQ 25MG BASE/ML</u>	<u>A074777</u>	<u>001</u>	Mar 02, 2005
<u>AP</u>			<u>EQ 25MG BASE/ML</u>	<u>A077458</u>	<u>001</u>	Feb 16, 2006
<u>AP</u>		ZYDUS PHARMS USA INC	<u>EQ 25MG BASE/ML</u>	<u>A091534</u>	<u>001</u>	Feb 22, 2013

ZANTAC

<u>AP</u>	<u>+</u> !	PAI HOLDINGS PHARM	<u>EQ 25MG BASE/ML</u>	<u>N019090</u>	<u>001</u>	Oct 19, 1984

SYRUP; ORAL

RANITIDINE HYDROCHLORIDE

<u>AA</u>		LANNETT CO INC	<u>EQ 15MG BASE/ML</u>	<u>A091288</u>	<u>001</u>	Dec 09, 2010
<u>AA</u>	<u>!</u>	PHARM ASSOC	<u>EQ 15MG BASE/ML</u>	<u>A077405</u>	<u>001</u>	Sep 21, 2007

TABLET; ORAL

RANITIDINE HYDROCHLORIDE

<u>AB</u>		APOTEX	<u>EQ 150MG BASE</u>	<u>A074680</u>	<u>001</u>	Sep 12, 1997
<u>AB</u>			<u>EQ 300MG BASE</u>	<u>A074680</u>	<u>002</u>	Sep 12, 1997
<u>AB</u>		DR REDDYS LABS INC	<u>EQ 150MG BASE</u>	<u>A076705</u>	<u>001</u>	Jul 27, 2005

PRESCRIPTION DRUG PRODUCT LIST

3-394 (of 474)

RANITIDINE HYDROCHLORIDE

TABLET; ORAL

RANITIDINE HYDROCHLORIDE

<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A076705</u>	<u>002</u>	Jul 27, 2005
<u>AB</u>	GLENMARK PHARMS INC	<u>EQ 150MG BASE</u>	<u>A078542</u>	<u>001</u>	Nov 19, 2008
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A078542</u>	<u>002</u>	Nov 19, 2008
<u>AB</u>	PAR PHARM	<u>EQ 150MG BASE</u>	<u>A075180</u>	<u>001</u>	Jan 28, 1999
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A075180</u>	<u>002</u>	Jan 28, 1999
<u>AB</u>	SANDOZ	<u>EQ 150MG BASE</u>	<u>A074467</u>	<u>001</u>	Aug 29, 1997
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A074467</u>	<u>002</u>	Aug 29, 1997
<u>AB</u>	VKT PHARMA	<u>EQ 150MG BASE</u>	<u>A211289</u>	<u>001</u>	Jan 31, 2019
<u>AB</u>		<u>EQ 300MG BASE</u>	<u>A211289</u>	<u>002</u>	Jan 31, 2019

RANOLAZINE

GRANULES, EXTENDED RELEASE; ORAL

ASPRUZYO SPRINKLE

+	SPIL	500MG	N216018	001	Feb 28, 2022
+	!	1GM	N216018	002	Feb 28, 2022

TABLET, EXTENDED RELEASE; ORAL

RANEXA

<u>AB</u>	+	GILEAD	<u>500MG</u>	<u>N021526</u>	<u>002</u>	Jan 27, 2006
<u>AB</u>	+	!	<u>1GM</u>	<u>N021526</u>	<u>001</u>	Feb 12, 2007

RANOLAZINE

<u>AB</u>	ACTAVIS ELIZABETH	<u>500MG</u>	<u>A208862</u>	<u>001</u>	May 28, 2019
<u>AB</u>		<u>1GM</u>	<u>A208862</u>	<u>002</u>	May 28, 2019
<u>AB</u>	AJANTA PHARMA LTD	<u>500MG</u>	<u>A210054</u>	<u>001</u>	May 28, 2019
<u>AB</u>		<u>1GM</u>	<u>A210054</u>	<u>002</u>	May 28, 2019
<u>AB</u>	ALKEM LABS LTD	<u>500MG</u>	<u>A209953</u>	<u>001</u>	Nov 30, 2020
<u>AB</u>		<u>1GM</u>	<u>A209953</u>	<u>002</u>	Nov 30, 2020
<u>AB</u>	AUROBINDO PHARMA	<u>500MG</u>	<u>A209081</u>	<u>001</u>	Dec 23, 2022
<u>AB</u>		<u>1GM</u>	<u>A209081</u>	<u>002</u>	Dec 23, 2022
<u>AB</u>	CADILA	<u>500MG</u>	<u>A210188</u>	<u>001</u>	Aug 19, 2019
<u>AB</u>		<u>1GM</u>	<u>A210188</u>	<u>002</u>	Aug 19, 2019
<u>AB</u>	GLENMARK PHARMS LTD	<u>500MG</u>	<u>A211082</u>	<u>001</u>	Jul 05, 2019
<u>AB</u>		<u>1GM</u>	<u>A211082</u>	<u>002</u>	Jul 05, 2019
<u>AB</u>	GRAVITI PHARMS	<u>500MG</u>	<u>A212889</u>	<u>001</u>	Jan 28, 2021
<u>AB</u>		<u>1GM</u>	<u>A212889</u>	<u>002</u>	Jan 28, 2021
<u>AB</u>	HETERO LABS LTD III	<u>500MG</u>	<u>A212788</u>	<u>001</u>	May 05, 2022
<u>AB</u>		<u>1GM</u>	<u>A212788</u>	<u>002</u>	May 05, 2022
<u>AB</u>	I3 PHARMS	<u>500MG</u>	<u>A213517</u>	<u>001</u>	Apr 27, 2022
<u>AB</u>		<u>1GM</u>	<u>A213517</u>	<u>002</u>	Apr 27, 2022
<u>AB</u>	LUPIN LTD	<u>500MG</u>	<u>A201046</u>	<u>001</u>	Jul 29, 2013
<u>AB</u>		<u>1GM</u>	<u>A201046</u>	<u>002</u>	Jul 29, 2013
<u>AB</u>	MANKIND PHARMA	<u>500MG</u>	<u>A212284</u>	<u>001</u>	Feb 12, 2020
<u>AB</u>		<u>1GM</u>	<u>A212284</u>	<u>002</u>	Feb 12, 2020
<u>AB</u>	MICRO LABS	<u>500MG</u>	<u>A211745</u>	<u>001</u>	Feb 27, 2020
<u>AB</u>		<u>1GM</u>	<u>A211745</u>	<u>002</u>	Feb 27, 2020
<u>AB</u>	PRAXGEN	<u>500MG</u>	<u>A212781</u>	<u>001</u>	Mar 23, 2020
<u>AB</u>		<u>1GM</u>	<u>A212781</u>	<u>002</u>	Mar 23, 2020
<u>AB</u>	SCIEGEN PHARMS INC	<u>500MG</u>	<u>A211829</u>	<u>001</u>	Jun 04, 2019
<u>AB</u>		<u>1GM</u>	<u>A211829</u>	<u>002</u>	Jun 04, 2019
<u>AB</u>	SUN PHARM	<u>500MG</u>	<u>A211707</u>	<u>001</u>	May 28, 2019
<u>AB</u>		<u>1GM</u>	<u>A211707</u>	<u>002</u>	May 28, 2019
<u>AB</u>	SUNSHINE	<u>500MG</u>	<u>A211865</u>	<u>001</u>	Mar 23, 2020
<u>AB</u>		<u>1GM</u>	<u>A211865</u>	<u>002</u>	Mar 23, 2020
<u>AB</u>	VKT PHARMA	<u>500MG</u>	<u>A214035</u>	<u>001</u>	Jan 19, 2022
<u>AB</u>		<u>1GM</u>	<u>A214035</u>	<u>002</u>	Jan 19, 2022

RASAGILINE MESYLATE

TABLET; ORAL

AZILECT

<u>AB</u>	+	TEVA	<u>EQ 0.5MG BASE</u>	<u>N021641</u>	<u>001</u>	May 16, 2006
<u>AB</u>	+	!	<u>EQ 1MG BASE</u>	<u>N021641</u>	<u>002</u>	May 16, 2006

RASAGILINE MESYLATE

<u>AB</u>	ALKEM LABS LTD	<u>EQ 0.5MG BASE</u>	<u>A201889</u>	<u>001</u>	Oct 30, 2017
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A201889</u>	<u>002</u>	Oct 30, 2017
<u>AB</u>	AUROBINDO PHARMA USA	<u>EQ 0.5MG BASE</u>	<u>A201971</u>	<u>001</u>	May 15, 2017
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A201971</u>	<u>002</u>	May 15, 2017
<u>AB</u>	CHARTWELL RX	<u>EQ 0.5MG BASE</u>	<u>A201892</u>	<u>001</u>	Jul 27, 2018
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A201892</u>	<u>002</u>	Jul 27, 2018
<u>AB</u>	INDOCO	<u>EQ 0.5MG BASE</u>	<u>A206153</u>	<u>001</u>	Oct 04, 2019
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A206153</u>	<u>002</u>	Oct 04, 2019
<u>AB</u>	MICRO LABS	<u>EQ 0.5MG BASE</u>	<u>A207004</u>	<u>001</u>	Mar 29, 2019

PRESCRIPTION DRUG PRODUCT LIST

3-395 (of 474)

RASAGILINE MESYLATE

TABLET; ORAL

RASAGILINE MESYLATE

AB		<u>EQ 1MG BASE</u>	<u>A207004</u>	<u>002</u>	Mar 29, 2019
AB	ORBION PHARMS	<u>EQ 0.5MG BASE</u>	<u>A201970</u>	<u>001</u>	Mar 15, 2016
AB		<u>EQ 1MG BASE</u>	<u>A201970</u>	<u>002</u>	Mar 15, 2016

REGADENOSON

SOLUTION; INTRAVENOUS

LEXISCAN

AP	+ !	ASTELLAS	<u>0.4MG/5ML (0.08MG/ML)</u>	<u>N022161</u>	<u>001</u>	Apr 10, 2008

REGADENOSON

AP		ACCORD HLTHCARE	<u>0.4MG/5ML (0.08MG/ML)</u>	<u>A213236</u>	<u>001</u>	Apr 11, 2022
AP		APOTEX	<u>0.4MG/5ML (0.08MG/ML)</u>	<u>A207604</u>	<u>001</u>	Apr 11, 2022
AP		DR REDDYS	<u>0.4MG/5ML (0.08MG/ML)</u>	<u>A213210</u>	<u>001</u>	Apr 11, 2022
AP		EUGIA PHARMA	<u>0.4MG/5ML (0.08MG/ML)</u>	<u>A216437</u>	<u>001</u>	Oct 26, 2022
AP		GLAND PHARMA LTD	<u>0.4MG/5ML (0.08MG/ML)</u>	<u>A207320</u>	<u>001</u>	Jul 12, 2022
AP		HOSPIRA	<u>0.4MG/5ML (0.08MG/ML)</u>	<u>A214349</u>	<u>001</u>	Aug 31, 2022
AP		MEITHEAL	<u>0.4MG/5ML (0.08MG/ML)</u>	<u>A212806</u>	<u>001</u>	Apr 11, 2022

REGORAFENIB

TABLET; ORAL

STIVARGA

+ !	BAYER HLTHCARE	40MG	<u>N203085</u>	<u>001</u>	Sep 27, 2012

RELUGOLIX

TABLET; ORAL

ORGOVYX

+ !	MYOVANT SCIENCES	120MG	<u>N214621</u>	<u>001</u>	Dec 18, 2020

REMDESIVIR

POWDER; INTRAVENOUS

VEKLURY

+ !	GILEAD SCIENCES INC	100MG/VIAL	<u>N214787</u>	<u>001</u>	Oct 22, 2020

SOLUTION; INTRAVENOUS

VEKLURY

+ !	GILEAD SCIENCES INC	100MG/20ML (5MG/ML)	<u>N214787</u>	<u>002</u>	Oct 22, 2020

REMIFENTANIL HYDROCHLORIDE

INJECTABLE; INJECTION

REMIFENTANIL HYDROCHLORIDE

AP		FRESENIUS KABI USA	<u>EQ 1MG BASE/VIAL</u>	<u>A206223</u>	<u>001</u>	Jan 16, 2018
AP			<u>EQ 2MG BASE/VIAL</u>	<u>A206223</u>	<u>002</u>	Jan 16, 2018
AP			<u>EQ 5MG BASE/VIAL</u>	<u>A206223</u>	<u>003</u>	Jan 16, 2018
AP		HIKMA	<u>EQ 1MG BASE/VIAL</u>	<u>A210594</u>	<u>001</u>	Oct 13, 2020
AP			<u>EQ 2MG BASE/VIAL</u>	<u>A210594</u>	<u>002</u>	Oct 13, 2020
AP			<u>EQ 5MG BASE/VIAL</u>	<u>A210594</u>	<u>003</u>	Oct 13, 2020

ULTIVA

AP	+	MYLAN INSTITUTIONAL	<u>EQ 1MG BASE/VIAL</u>	<u>N020630</u>	<u>001</u>	Jul 12, 1996
AP	+		<u>EQ 2MG BASE/VIAL</u>	<u>N020630</u>	<u>002</u>	Jul 12, 1996
AP	+ !		<u>EQ 5MG BASE/VIAL</u>	<u>N020630</u>	<u>003</u>	Jul 12, 1996

REMIMAZOLAM BESYLATE

POWDER; INTRAVENOUS

BYFAVO

+ !	ACACIA	EQ 20MG BASE/VIAL	<u>N212295</u>	<u>001</u>	Oct 06, 2020

REPAGLINIDE

TABLET; ORAL

REPAGLINIDE

AB		AUROBINDO PHARMA LTD	<u>0.5MG</u>	<u>A203820</u>	<u>001</u>	Jan 22, 2014
AB			<u>1MG</u>	<u>A203820</u>	<u>002</u>	Jan 22, 2014
AB	!		<u>2MG</u>	<u>A203820</u>	<u>003</u>	Jan 22, 2014
AB		CHARTWELL RX	<u>0.5MG</u>	<u>A078555</u>	<u>001</u>	Nov 22, 2013
AB			<u>1MG</u>	<u>A078555</u>	<u>002</u>	Jan 22, 2014
AB			<u>2MG</u>	<u>A078555</u>	<u>003</u>	Jan 22, 2014
AB		PADAGIS US	<u>0.5MG</u>	<u>A201189</u>	<u>001</u>	Jul 17, 2013
AB			<u>1MG</u>	<u>A201189</u>	<u>002</u>	Jan 22, 2014
AB			<u>2MG</u>	<u>A201189</u>	<u>003</u>	Jan 22, 2014
AB		SUN PHARM INDS INC	<u>1MG</u>	<u>A077571</u>	<u>002</u>	Jul 11, 2013
AB			<u>2MG</u>	<u>A077571</u>	<u>003</u>	Jul 11, 2013

PRESCRIPTION DRUG PRODUCT LIST

3-396 (of 474)

RETAPAMULIN

OINTMENT; TOPICAL

ALTABAX

+! ALMIRALL

1%

N022055 001 Apr 12, 2007

REVEFENACIN

SOLUTION; INHALATION

YUPELRI

+! MYLAN IRELAND LTD

175MCG/3ML

N210598 001 Nov 09, 2018

RIBAVIRIN

CAPSULE; ORAL

RIBAVIRINAB ! AUROBINDO PHARMA200MGA079117 001 Sep 17, 2009AB ZYDUS PHARMS USA200MGA077224 001 Oct 28, 2005

FOR SOLUTION; INHALATION

RIBAVIRINAN NAVINTA LLC6GM/VIALA207366 001 Oct 06, 2016VIRAZOLEAN +! BAUSCH6GM/VIALN018859 001 Dec 31, 1985

TABLET; ORAL

RIBAVIRINAB AUROBINDO PHARMA200MGA079111 001 Sep 17, 2009AB SANDOZ200MGA077743 001 Oct 03, 2006AB ZYDUS PHARMS USA200MGA077094 001 Dec 05, 2005RIBOCICLIB SUCCINATE

TABLET; ORAL

KISQALI

+! NOVARTIS

EQ 200MG BASE

N209092 001 Mar 13, 2017

RIBOFLAVIN 5'-PHOSPHATE SODIUM

SOLUTION/DROPS; OPHTHALMIC

PHOTREXA

+! GLAUKOS

0.146%

N203324 001 Apr 15, 2016

PHOTREXA VISCOUS IN DEXTRAN 20%

+! GLAUKOS

0.146%

N203324 002 Apr 15, 2016

RIFABUTIN

CAPSULE; ORAL

MYCOBUTINAB +! PFIZER150MGN050689 001 Dec 23, 1992RIFABUTINAB LUPIN LTD150MGA090033 001 Feb 24, 2014AB NOVITIUM PHARMA150MGA215041 001 Dec 17, 2021RIFAMPIN

CAPSULE; ORAL

RIFAMPINAB AKORN150MGA065028 001 Mar 14, 2001AB300MGA065028 002 Mar 14, 2001AB CHARTWELL MOLECULAR150MGA065390 001 Mar 28, 2008AB300MGA065390 002 Mar 28, 2008AB EPIC PHARMA150MGA064150 002 Jan 02, 1998AB300MGA064150 001 May 28, 1997AB LUPIN PHARMS150MGA090034 001 Aug 21, 2013AB !300MGA090034 002 Aug 21, 2013RIMACTANEAB OXFORD PHARMS300MGN050429 001

INJECTABLE; INJECTION

RIFADINAP +! SANOFI AVENTIS US600MG/VIALN050627 001 May 25, 1989RIFAMPINAP AKORN600MG/VIALA065502 001 Sep 21, 2010AP FRESENIUS KABI USA600MG/VIALA091181 001 Aug 21, 2014AP HIKMA600MG/VIALA064217 001 Oct 29, 1999AP HIKMA PHARMS600MG/VIALA205039 001 Mar 03, 2016AP MYLAN LABS LTD600MG/VIALA065421 001 May 22, 2008RIFAMYCIN SODIUM

TABLET, DELAYED RELEASE; ORAL

AEMCOLO

+! REDHILL

EQ 194MG BASE

N210910 001 Nov 16, 2018

PRESCRIPTION DRUG PRODUCT LIST

3-397 (of 474)

RIFAPENTINE

TABLET; ORAL

PRIFTIN

+	!	SANOFI AVENTIS US	150MG	N021024	001	Jun 22, 1998

RIFAXIMIN

TABLET; ORAL

XIFAXAN

+	!	SALIX PHARMS	200MG	N021361	001	May 25, 2004

+	!		550MG	N021361	002	Mar 24, 2010

RILPIVIRINE HYDROCHLORIDE

TABLET; ORAL

EDURANT

+	!	JANSSEN PRODS	EQ 25MG BASE	N202022	001	May 20, 2011

RILUZOLE

FILM; ORAL

EXSERVAN

+	!	AQUESTIVE	50MG	N212640	001	Nov 22, 2019

SUSPENSION; ORAL

TIGLUTIK KIT

+	!	ITALFARMACO SA	50MG/10ML	N209080	001	Sep 05, 2018

TABLET; ORAL

RILUTEK

AB	+	!	COVIS	50MG	N020599	001	Dec 12, 1995

RILUZOLE

AB			ALKEM LABS LTD	50MG	A204048	001	Mar 30, 2016

AB			GLENMARK PHARMS LTD	50MG	A091394	001	Jun 18, 2013

AB			IMPAX LABS	50MG	A076173	001	Jan 29, 2003

AB			KENTON	50MG	A206045	001	Dec 09, 2019

AB			MYLAN PHARMS INC	50MG	A203042	001	Jul 01, 2013

AB			SUN PHARM INDS LTD	50MG	A091417	001	Jun 18, 2013

RIMANTADINE HYDROCHLORIDE

TABLET; ORAL

FLUMADINE

AB	+	!	SUN PHARM INDS INC	100MG	N019649	001	Sep 17, 1993

RIMANTADINE HYDROCHLORIDE

AB			IMPAX LABS	100MG	A076132	001	Aug 30, 2002

RIMEGEPANT SULFATE

TABLET, ORALLY DISINTEGRATING; ORAL

NURTEC ODT

+	!	BIOHAVEN IRELAND	EQ 75MG BASE	N212728	001	Feb 27, 2020

RIOCIGUAT

TABLET; ORAL

ADEMPAS

AB	+		BAYER HLTHCARE	0.5MG	N204819	001	Oct 08, 2013

AB	+			1MG	N204819	002	Oct 08, 2013

AB	+			1.5MG	N204819	003	Oct 08, 2013

AB	+			2MG	N204819	004	Oct 08, 2013

AB	+	!		2.5MG	N204819	005	Oct 08, 2013

RIOCIGUAT

AB			MSN	0.5MG	A211135	001	Sep 01, 2022

AB				1MG	A211135	002	Sep 01, 2022

AB				1.5MG	A211135	003	Sep 01, 2022

AB				2MG	A211135	004	Sep 01, 2022

AB				2.5MG	A211135	005	Sep 01, 2022

RIPRETINIB

TABLET; ORAL

QINLOCK

+	!	DECIPHERA PHARMS	50MG	N213973	001	May 15, 2020

RISDIPLAM

FOR SOLUTION; ORAL

EVRYSDI

+	!	GENENTECH INC	0.75MG/ML	N213535	001	Aug 07, 2020

PRESCRIPTION DRUG PRODUCT LIST

3-398 (of 474)

RISEDRONATE SODIUM

TABLET; ORAL

ACTONEL

<u>AB</u>	<u>+</u> !	APIL	<u>35MG</u>	<u>N020835</u>	<u>003</u>	May 25, 2002
<u>AB</u>	<u>+</u> !		<u>150MG</u>	<u>N020835</u>	<u>005</u>	Apr 22, 2008

RISEDRONATE SODIUM

<u>AB</u>		APOTEX INC	<u>35MG</u>	<u>A090877</u>	<u>001</u>	Nov 30, 2015
<u>AB</u>			<u>75MG</u>	<u>A090877</u>	<u>002</u>	Jun 10, 2014
<u>AB</u>			<u>150MG</u>	<u>A090877</u>	<u>003</u>	Jun 10, 2014
<u>AB</u>		AUROBINDO PHARMA	<u>150MG</u>	<u>A206768</u>	<u>001</u>	Oct 21, 2016
<u>AB</u>		AUROBINDO PHARMA LTD	<u>5MG</u>	<u>A200296</u>	<u>001</u>	Nov 30, 2015
<u>AB</u>			<u>30MG</u>	<u>A200296</u>	<u>002</u>	Nov 30, 2015
<u>AB</u>			<u>35MG</u>	<u>A200296</u>	<u>003</u>	Nov 30, 2015
<u>AB</u>		MACLEODS PHARMS LTD	<u>5MG</u>	<u>A203533</u>	<u>001</u>	Dec 09, 2015
<u>AB</u>			<u>30MG</u>	<u>A203533</u>	<u>002</u>	Dec 09, 2015
<u>AB</u>			<u>35MG</u>	<u>A203533</u>	<u>003</u>	Nov 29, 2016
<u>AB</u>		ORBION PHARMS	<u>30MG</u>	<u>A205280</u>	<u>001</u>	May 13, 2019
<u>AB</u>			<u>35MG</u>	<u>A205280</u>	<u>002</u>	May 13, 2019
<u>AB</u>		SUN PHARM	<u>5MG</u>	<u>A090886</u>	<u>001</u>	Nov 30, 2015
<u>AB</u>			<u>30MG</u>	<u>A090886</u>	<u>002</u>	Nov 30, 2015
<u>AB</u>			<u>35MG</u>	<u>A090886</u>	<u>003</u>	Nov 30, 2015
<u>AB</u>			<u>75MG</u>	<u>A090886</u>	<u>004</u>	Jun 10, 2014
<u>AB</u>			<u>150MG</u>	<u>A090886</u>	<u>005</u>	Jun 10, 2014
<u>AB</u>		TEVA PHARMS USA	<u>5MG</u>	<u>A077132</u>	<u>001</u>	Oct 05, 2007
<u>AB</u>			<u>30MG</u>	<u>A077132</u>	<u>002</u>	Oct 05, 2007
<u>AB</u>			<u>35MG</u>	<u>A077132</u>	<u>003</u>	Oct 05, 2007
<u>AB</u>			<u>150MG</u>	<u>A079215</u>	<u>001</u>	Jun 13, 2014

TABLET, DELAYED RELEASE; ORAL

ATELVIA

<u>AB</u>	<u>+</u> !	APIL	<u>35MG</u>	<u>N022560</u>	<u>001</u>	Oct 08, 2010

RISEDRONATE SODIUM

<u>AB</u>		SUN PHARM	<u>35MG</u>	<u>A203925</u>	<u>001</u>	Jul 09, 2019
<u>AB</u>		TEVA PHARMS USA	<u>35MG</u>	<u>A203217</u>	<u>001</u>	May 18, 2015

RISPERIDONE

FOR SUSPENSION, EXTENDED RELEASE; SUBCUTANEOUS

PERSERIS KIT

<u>+</u>	INDIVIOR INC	90MG	N210655	001	Jul 27, 2018
<u>+</u> !		120MG	N210655	002	Jul 27, 2018

INJECTABLE; INTRAMUSCULAR

RISPERDAL CONSTA

<u>+</u>	JANSSEN PHARMS	12.5MG/VIAL	N021346	004	Apr 12, 2007
<u>+</u> !		25MG/VIAL	N021346	001	Oct 29, 2003
<u>+</u>		37.5MG/VIAL	N021346	002	Oct 29, 2003
<u>+</u>		50MG/VIAL	N021346	003	Oct 29, 2003

SOLUTION; ORAL

RISPERDAL

<u>AA</u>	<u>+</u> !	JANSSEN PHARMS	<u>1MG/ML</u>	<u>N020588</u>	<u>001</u>	Jun 10, 1996

RISPERIDONE

<u>AA</u>		AMNEAL PHARMS	<u>1MG/ML</u>	<u>A091384</u>	<u>001</u>	May 25, 2011
<u>AA</u>		AUROBINDO PHARMA LTD	<u>1MG/ML</u>	<u>A078452</u>	<u>001</u>	Sep 04, 2009
<u>AA</u>		CHARTWELL MOLECULAR	<u>1MG/ML</u>	<u>A202386</u>	<u>001</u>	Jan 12, 2015
<u>AA</u>		HIKMA	<u>1MG/ML</u>	<u>A076904</u>	<u>001</u>	Jul 29, 2009
<u>AA</u>		LANNETT CO INC	<u>1MG/ML</u>	<u>A079158</u>	<u>001</u>	Dec 03, 2010
<u>AA</u>		PHARM ASSOC	<u>1MG/ML</u>	<u>A077719</u>	<u>001</u>	Jul 29, 2009
<u>AA</u>		TARO	<u>1MG/ML</u>	<u>A090347</u>	<u>001</u>	Feb 07, 2011
<u>AA</u>		TRIS PHARMA INC	<u>1MG/ML</u>	<u>A079059</u>	<u>001</u>	Dec 12, 2012

TABLET; ORAL

RISPERDAL

<u>AB</u>	<u>+</u>	JANSSEN PHARMS	<u>0.25MG</u>	<u>N020272</u>	<u>008</u>	May 10, 1999
<u>AB</u>	<u>+</u>		<u>0.5MG</u>	<u>N020272</u>	<u>007</u>	Jan 27, 1999
<u>AB</u>	<u>+</u> !		<u>1MG</u>	<u>N020272</u>	<u>001</u>	Dec 29, 1993
<u>AB</u>	<u>+</u>		<u>2MG</u>	<u>N020272</u>	<u>002</u>	Dec 29, 1993
<u>AB</u>	<u>+</u>		<u>3MG</u>	<u>N020272</u>	<u>003</u>	Dec 29, 1993
<u>AB</u>	<u>+</u>		<u>4MG</u>	<u>N020272</u>	<u>004</u>	Dec 29, 1993

RISPERIDONE

<u>AB</u>		AJANTA PHARMA LTD	<u>0.25MG</u>	<u>A201003</u>	<u>001</u>	Aug 24, 2011
<u>AB</u>			<u>0.5MG</u>	<u>A201003</u>	<u>002</u>	Aug 24, 2011
<u>AB</u>			<u>1MG</u>	<u>A201003</u>	<u>003</u>	Aug 24, 2011
<u>AB</u>			<u>2MG</u>	<u>A201003</u>	<u>004</u>	Aug 24, 2011
<u>AB</u>			<u>3MG</u>	<u>A201003</u>	<u>005</u>	Aug 24, 2011

PRESCRIPTION DRUG PRODUCT LIST

3-399 (of 474)

RISPERIDONE

TABLET; ORAL

RISPERIDONE

<u>AB</u>		<u>4MG</u>	<u>A201003</u>	<u>006</u>	Aug 24, 2011
<u>AB</u>	AMNEAL	<u>0.25MG</u>	<u>A078071</u>	<u>001</u>	Jun 17, 2009
<u>AB</u>		<u>0.5MG</u>	<u>A078071</u>	<u>002</u>	Jun 17, 2009
<u>AB</u>		<u>1MG</u>	<u>A078071</u>	<u>003</u>	Jun 17, 2009
<u>AB</u>		<u>2MG</u>	<u>A078071</u>	<u>004</u>	Jun 17, 2009
<u>AB</u>		<u>3MG</u>	<u>A078071</u>	<u>005</u>	Jun 17, 2009
<u>AB</u>		<u>4MG</u>	<u>A078071</u>	<u>006</u>	Jun 17, 2009
<u>AB</u>	APOTEX INC	<u>0.25MG</u>	<u>A077953</u>	<u>001</u>	Sep 15, 2008
<u>AB</u>		<u>0.5MG</u>	<u>A077953</u>	<u>002</u>	Sep 15, 2008
<u>AB</u>		<u>1MG</u>	<u>A077953</u>	<u>003</u>	Sep 15, 2008
<u>AB</u>		<u>2MG</u>	<u>A077953</u>	<u>004</u>	Sep 15, 2008
<u>AB</u>		<u>3MG</u>	<u>A077953</u>	<u>005</u>	Sep 15, 2008
<u>AB</u>		<u>4MG</u>	<u>A077953</u>	<u>006</u>	Sep 15, 2008
<u>AB</u>	CELLTRION	<u>0.25MG</u>	<u>A078871</u>	<u>001</u>	Oct 09, 2008
<u>AB</u>		<u>0.5MG</u>	<u>A078871</u>	<u>002</u>	Oct 09, 2008
<u>AB</u>		<u>1MG</u>	<u>A078871</u>	<u>003</u>	Oct 09, 2008
<u>AB</u>		<u>2MG</u>	<u>A078871</u>	<u>004</u>	Oct 09, 2008
<u>AB</u>		<u>3MG</u>	<u>A078871</u>	<u>005</u>	Oct 09, 2008
<u>AB</u>		<u>4MG</u>	<u>A078871</u>	<u>006</u>	Oct 09, 2008
<u>AB</u>	CHARTWELL MOLECULAR	<u>0.25MG</u>	<u>A077543</u>	<u>001</u>	May 18, 2011
<u>AB</u>		<u>0.5MG</u>	<u>A077543</u>	<u>002</u>	May 18, 2011
<u>AB</u>		<u>1MG</u>	<u>A077543</u>	<u>003</u>	May 18, 2011
<u>AB</u>		<u>2MG</u>	<u>A077543</u>	<u>004</u>	May 18, 2011
<u>AB</u>		<u>3MG</u>	<u>A077543</u>	<u>005</u>	May 18, 2011
<u>AB</u>		<u>4MG</u>	<u>A077543</u>	<u>006</u>	May 18, 2011
<u>AB</u>	DR REDDYS LABS LTD	<u>0.25MG</u>	<u>A076879</u>	<u>001</u>	Oct 24, 2008
<u>AB</u>		<u>0.5MG</u>	<u>A076879</u>	<u>002</u>	Oct 24, 2008
<u>AB</u>		<u>1MG</u>	<u>A076879</u>	<u>003</u>	Oct 24, 2008
<u>AB</u>		<u>2MG</u>	<u>A076879</u>	<u>004</u>	Oct 24, 2008
<u>AB</u>		<u>3MG</u>	<u>A076879</u>	<u>005</u>	Oct 24, 2008
<u>AB</u>		<u>4MG</u>	<u>A076879</u>	<u>006</u>	Oct 24, 2008
<u>AB</u>	PRINSTON INC	<u>0.25MG</u>	<u>A077493</u>	<u>001</u>	Nov 29, 2011
<u>AB</u>		<u>0.5MG</u>	<u>A077493</u>	<u>002</u>	Nov 29, 2011
<u>AB</u>		<u>1MG</u>	<u>A077493</u>	<u>003</u>	Nov 29, 2011
<u>AB</u>		<u>2MG</u>	<u>A077493</u>	<u>004</u>	Nov 29, 2011
<u>AB</u>		<u>3MG</u>	<u>A077493</u>	<u>005</u>	Nov 29, 2011
<u>AB</u>		<u>4MG</u>	<u>A077493</u>	<u>006</u>	Nov 29, 2011
<u>AB</u>	RENATA	<u>0.25MG</u>	<u>A078707</u>	<u>001</u>	Dec 29, 2008
<u>AB</u>		<u>0.5MG</u>	<u>A078707</u>	<u>002</u>	Dec 29, 2008
<u>AB</u>		<u>1MG</u>	<u>A078707</u>	<u>003</u>	Dec 29, 2008
<u>AB</u>		<u>2MG</u>	<u>A078707</u>	<u>004</u>	Dec 29, 2008
<u>AB</u>		<u>3MG</u>	<u>A078707</u>	<u>005</u>	Dec 29, 2008
<u>AB</u>		<u>4MG</u>	<u>A078707</u>	<u>006</u>	Dec 29, 2008
<u>AB</u>	RISING	<u>0.25MG</u>	<u>A078269</u>	<u>001</u>	Oct 08, 2008
<u>AB</u>		<u>0.5MG</u>	<u>A078269</u>	<u>002</u>	Oct 08, 2008
<u>AB</u>		<u>1MG</u>	<u>A078269</u>	<u>003</u>	Oct 08, 2008
<u>AB</u>		<u>2MG</u>	<u>A078269</u>	<u>004</u>	Oct 08, 2008
<u>AB</u>		<u>3MG</u>	<u>A078269</u>	<u>005</u>	Oct 08, 2008
<u>AB</u>		<u>4MG</u>	<u>A078269</u>	<u>006</u>	Oct 08, 2008
<u>AB</u>	SANDOZ	<u>0.25MG</u>	<u>A078528</u>	<u>001</u>	Oct 16, 2009
<u>AB</u>		<u>0.5MG</u>	<u>A078528</u>	<u>002</u>	Oct 16, 2009
<u>AB</u>		<u>1MG</u>	<u>A078528</u>	<u>003</u>	Oct 16, 2009
<u>AB</u>		<u>2MG</u>	<u>A078528</u>	<u>004</u>	Oct 16, 2009
<u>AB</u>		<u>3MG</u>	<u>A078528</u>	<u>005</u>	Oct 16, 2009
<u>AB</u>		<u>4MG</u>	<u>A078528</u>	<u>006</u>	Oct 16, 2009
<u>AB</u>	TORRENT PHARMS	<u>0.25MG</u>	<u>A079088</u>	<u>001</u>	Oct 30, 2008
<u>AB</u>		<u>0.5MG</u>	<u>A079088</u>	<u>002</u>	Oct 30, 2008
<u>AB</u>		<u>1MG</u>	<u>A079088</u>	<u>003</u>	Oct 30, 2008
<u>AB</u>		<u>2MG</u>	<u>A079088</u>	<u>004</u>	Oct 30, 2008
<u>AB</u>		<u>3MG</u>	<u>A079088</u>	<u>005</u>	Oct 30, 2008
<u>AB</u>		<u>4MG</u>	<u>A079088</u>	<u>006</u>	Oct 30, 2008
<u>AB</u>	ZYDUS PHARMS USA INC	<u>0.25MG</u>	<u>A078040</u>	<u>001</u>	Oct 16, 2008
<u>AB</u>		<u>0.5MG</u>	<u>A078040</u>	<u>002</u>	Oct 16, 2008
<u>AB</u>		<u>1MG</u>	<u>A078040</u>	<u>003</u>	Oct 16, 2008
<u>AB</u>		<u>2MG</u>	<u>A078040</u>	<u>004</u>	Oct 16, 2008
<u>AB</u>		<u>3MG</u>	<u>A078040</u>	<u>005</u>	Oct 16, 2008
<u>AB</u>		<u>4MG</u>	<u>A078040</u>	<u>006</u>	Oct 16, 2008

PRESCRIPTION DRUG PRODUCT LIST

3-400 (of 474)

RISPERIDONE

TABLET, ORALLY DISINTEGRATING;ORAL

RISPERIDONE

<u>AB</u>	DR REDDYS LABS LTD	<u>0.5MG</u>	<u>A077328</u>	<u>001</u>	Feb 24, 2009
<u>AB</u>		<u>1MG</u>	<u>A077328</u>	<u>002</u>	Oct 05, 2009
<u>AB</u>		<u>2MG</u>	<u>A077328</u>	<u>003</u>	Feb 24, 2009
<u>AB</u>		<u>3MG</u>	<u>A077328</u>	<u>004</u>	Nov 30, 2009
<u>AB</u>		<u>4MG</u>	<u>A077328</u>	<u>005</u>	Nov 30, 2009
<u>AB</u>	JUBILANT GENERICS	<u>0.5MG</u>	<u>A090839</u>	<u>001</u>	Nov 04, 2011
<u>AB</u>	!	<u>1MG</u>	<u>A090839</u>	<u>002</u>	Nov 04, 2011
<u>AB</u>		<u>2MG</u>	<u>A090839</u>	<u>003</u>	Nov 04, 2011
<u>AB</u>		<u>3MG</u>	<u>A090839</u>	<u>004</u>	Nov 04, 2011
<u>AB</u>		<u>4MG</u>	<u>A090839</u>	<u>005</u>	Nov 04, 2011
<u>AB</u>	PAR PHARM	<u>0.5MG</u>	<u>A077494</u>	<u>002</u>	Apr 30, 2009
<u>AB</u>		<u>1MG</u>	<u>A077494</u>	<u>003</u>	Oct 26, 2009
<u>AB</u>		<u>2MG</u>	<u>A077494</u>	<u>004</u>	Apr 30, 2009
<u>AB</u>		<u>3MG</u>	<u>A077494</u>	<u>005</u>	Apr 30, 2009
<u>AB</u>		<u>4MG</u>	<u>A077494</u>	<u>006</u>	Apr 30, 2009
<u>AB</u>	SANDOZ	<u>0.5MG</u>	<u>A078116</u>	<u>001</u>	Dec 22, 2009
<u>AB</u>		<u>1MG</u>	<u>A078116</u>	<u>002</u>	Dec 22, 2009
<u>AB</u>		<u>2MG</u>	<u>A078116</u>	<u>003</u>	Dec 22, 2009
<u>AB</u>		<u>3MG</u>	<u>A078116</u>	<u>004</u>	Dec 22, 2009
<u>AB</u>		<u>4MG</u>	<u>A078116</u>	<u>005</u>	Dec 22, 2009
<u>AB</u>	SUN PHARM INDS LTD	<u>0.5MG</u>	<u>A077542</u>	<u>001</u>	Aug 06, 2010
<u>AB</u>		<u>0.5MG</u>	<u>A078464</u>	<u>001</u>	Apr 08, 2013
<u>AB</u>		<u>1MG</u>	<u>A077542</u>	<u>002</u>	Aug 06, 2010
<u>AB</u>		<u>1MG</u>	<u>A078464</u>	<u>002</u>	Apr 08, 2013
<u>AB</u>		<u>2MG</u>	<u>A077542</u>	<u>003</u>	Aug 06, 2010
<u>AB</u>		<u>2MG</u>	<u>A078464</u>	<u>003</u>	Apr 08, 2013
<u>AB</u>		<u>3MG</u>	<u>A078464</u>	<u>004</u>	Apr 08, 2013
<u>AB</u>		<u>3MG</u>	<u>A078474</u>	<u>001</u>	Aug 06, 2010
<u>AB</u>		<u>4MG</u>	<u>A078464</u>	<u>005</u>	Apr 08, 2013
<u>AB</u>		<u>4MG</u>	<u>A078474</u>	<u>002</u>	Aug 06, 2010
<u>AB</u>	ZYDUS PHARMS USA	<u>0.5MG</u>	<u>A078516</u>	<u>001</u>	May 01, 2009
<u>AB</u>		<u>2MG</u>	<u>A078516</u>	<u>003</u>	May 01, 2009
	PAR PHARM	0.25MG	A077494	001	Apr 30, 2009

RITONAVIR

POWDER;ORAL

NORVIR

+! ABBVIE INC

100MG/PACKET

N209512 001 Jun 07, 2017

SOLUTION;ORAL

NORVIR

+! ABBVIE

80MG/ML

N020659 001 Mar 01, 1996

TABLET;ORAL

NORVIR

<u>AB</u>	+! ABBVIE	<u>100MG</u>	<u>N022417</u>	<u>001</u>	Feb 10, 2010

RITONAVIR

<u>AB</u>	AMNEAL	<u>100MG</u>	<u>A208890</u>	<u>001</u>	Sep 17, 2018
<u>AB</u>	AUROBINDO PHARMA LTD	<u>100MG</u>	<u>A206614</u>	<u>001</u>	Sep 17, 2018
<u>AB</u>	CIPLA	<u>100MG</u>	<u>A202573</u>	<u>001</u>	Jan 15, 2015
<u>AB</u>		<u>100MG</u>	<u>A203759</u>	<u>001</u>	May 10, 2022
<u>AB</u>	HETERO LABS LTD III	<u>100MG</u>	<u>A204587</u>	<u>001</u>	Sep 17, 2018

RIVAROXABAN

FOR SUSPENSION;ORAL

XARELTO

+! JANSSEN PHARMS

1MG/ML

N215859 001 Dec 20, 2021

TABLET;ORAL

XARELTO

+ JANSSEN PHARMS

2.5MG

N022406 004 Oct 11, 2018

+

10MG

N022406 001 Jul 01, 2011

+

15MG

N022406 002 Nov 04, 2011

+!

20MG

N022406 003 Nov 04, 2011

RIVASTIGMINE

FILM, EXTENDED RELEASE;TRANSDERMAL

EXELON

<u>AB</u>	+	NOVARTIS	<u>4.6MG/24HR</u>	<u>N022083</u>	<u>001</u>	Jul 06, 2007
<u>AB</u>	+!		<u>9.5MG/24HR</u>	<u>N022083</u>	<u>002</u>	Jul 06, 2007
<u>AB</u>	+		<u>13.3MG/24HR</u>	<u>N022083</u>	<u>005</u>	Aug 31, 2012

RIVASTIGMINE

<u>AB</u>	ALVOGEN	<u>4.6MG/24HR</u>	<u>A204403</u>	<u>001</u>	Sep 03, 2015

PRESCRIPTION DRUG PRODUCT LIST

3-401 (of 474)

RIVASTIGMINE

FILM, EXTENDED RELEASE; TRANSDERMAL

RIVASTIGMINE

<u>AB</u>		<u>9.5MG/24HR</u>	<u>A204403</u>	<u>002</u>	Sep 03, 2015
<u>AB</u>		<u>13.3MG/24HR</u>	<u>A204403</u>	<u>003</u>	Aug 31, 2015
<u>AB</u>	AMNEAL PHARMS	<u>4.6MG/24HR</u>	<u>A207308</u>	<u>001</u>	Jan 08, 2019
<u>AB</u>		<u>9.5MG/24HR</u>	<u>A207308</u>	<u>002</u>	Jan 08, 2019
<u>AB</u>		<u>13.3MG/24HR</u>	<u>A207308</u>	<u>003</u>	Jan 08, 2019
<u>AB</u>	BRECKENRIDGE	<u>4.6MG/24HR</u>	<u>A209063</u>	<u>001</u>	Nov 26, 2019
<u>AB</u>		<u>9.5MG/24HR</u>	<u>A209063</u>	<u>002</u>	Nov 26, 2019
<u>AB</u>		<u>13.3MG/24HR</u>	<u>A209063</u>	<u>003</u>	Nov 26, 2019
<u>AB</u>	MYLAN TECHNOLOGIES	<u>4.6MG/24HR</u>	<u>A205622</u>	<u>001</u>	Jun 20, 2018
<u>AB</u>		<u>9.5MG/24HR</u>	<u>A205622</u>	<u>002</u>	Jun 20, 2018
<u>AB</u>		<u>13.3MG/24HR</u>	<u>A205622</u>	<u>003</u>	Jun 20, 2018
<u>AB</u>	ZYDUS PHARMS	<u>4.6MG/24HR</u>	<u>A206318</u>	<u>001</u>	Mar 04, 2019
<u>AB</u>		<u>9.5MG/24HR</u>	<u>A206318</u>	<u>002</u>	Mar 04, 2019
<u>AB</u>		<u>13.3MG/24HR</u>	<u>A206318</u>	<u>003</u>	Mar 04, 2019

RIVASTIGMINE TARTRATE

CAPSULE; ORAL

RIVASTIGMINE TARTRATE

<u>AB</u>	ALEMBIC PHARMS LTD	<u>EQ 1.5MG BASE</u>	<u>A091689</u>	<u>001</u>	Jun 12, 2012
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A091689</u>	<u>002</u>	Jun 12, 2012
<u>AB</u>		<u>EQ 4.5MG BASE</u>	<u>A091689</u>	<u>003</u>	Jun 12, 2012
<u>AB</u>		<u>EQ 6MG BASE</u>	<u>A091689</u>	<u>004</u>	Jun 12, 2012
<u>AB</u>	AUROBINDO PHARMA	<u>EQ 1.5MG BASE</u>	<u>A204572</u>	<u>001</u>	Mar 25, 2016
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A204572</u>	<u>002</u>	Mar 25, 2016
<u>AB</u>		<u>EQ 4.5MG BASE</u>	<u>A204572</u>	<u>003</u>	Mar 25, 2016
<u>AB</u>		<u>EQ 6MG BASE</u>	<u>A204572</u>	<u>004</u>	Mar 25, 2016
<u>AB</u>	CADILA PHARMS LTD	<u>EQ 1.5MG BASE</u>	<u>A203844</u>	<u>001</u>	Feb 13, 2017
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A203844</u>	<u>002</u>	Feb 13, 2017
<u>AB</u>		<u>EQ 4.5MG BASE</u>	<u>A203844</u>	<u>003</u>	Feb 13, 2017
<u>AB</u>		<u>EQ 6MG BASE</u>	<u>A203844</u>	<u>004</u>	Feb 13, 2017
<u>AB</u>	CHARTWELL RX	<u>EQ 1.5MG BASE</u>	<u>A207797</u>	<u>001</u>	Sep 28, 2017
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A207797</u>	<u>002</u>	Sep 28, 2017
<u>AB</u>		<u>EQ 4.5MG BASE</u>	<u>A207797</u>	<u>003</u>	Sep 28, 2017
<u>AB</u>		<u>EQ 6MG BASE</u>	<u>A207797</u>	<u>004</u>	Sep 28, 2017
<u>AB</u>	! DR REDDYS LABS INC	<u>EQ 1.5MG BASE</u>	<u>A077130</u>	<u>001</u>	Oct 31, 2007
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A077130</u>	<u>002</u>	Oct 31, 2007
<u>AB</u>		<u>EQ 4.5MG BASE</u>	<u>A077130</u>	<u>003</u>	Oct 31, 2007
<u>AB</u>	!	<u>EQ 6MG BASE</u>	<u>A077130</u>	<u>004</u>	Oct 31, 2007
<u>AB</u>	MACLEODS PHARMS LTD	<u>EQ 1.5MG BASE</u>	<u>A203148</u>	<u>001</u>	Aug 22, 2014
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A203148</u>	<u>002</u>	Aug 22, 2014
<u>AB</u>		<u>EQ 4.5MG BASE</u>	<u>A203148</u>	<u>003</u>	Aug 22, 2014
<u>AB</u>		<u>EQ 6MG BASE</u>	<u>A203148</u>	<u>004</u>	Aug 22, 2014
<u>AB</u>	ORBION PHARMS	<u>EQ 1.5MG BASE</u>	<u>A090879</u>	<u>001</u>	Jun 10, 2015
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A090879</u>	<u>002</u>	Jun 10, 2015
<u>AB</u>		<u>EQ 4.5MG BASE</u>	<u>A090879</u>	<u>003</u>	Jun 10, 2015
<u>AB</u>		<u>EQ 6MG BASE</u>	<u>A090879</u>	<u>004</u>	Jun 10, 2015
<u>AB</u>	SUN PHARM	<u>EQ 1.5MG BASE</u>	<u>A077131</u>	<u>001</u>	Oct 22, 2007
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A077131</u>	<u>002</u>	Oct 22, 2007
<u>AB</u>		<u>EQ 4.5MG BASE</u>	<u>A077131</u>	<u>003</u>	Oct 22, 2007
<u>AB</u>		<u>EQ 6MG BASE</u>	<u>A077131</u>	<u>004</u>	Oct 22, 2007
<u>AB</u>	WATSON LABS	<u>EQ 1.5MG BASE</u>	<u>A077129</u>	<u>001</u>	Jan 08, 2008
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A077129</u>	<u>002</u>	Jan 08, 2008
<u>AB</u>		<u>EQ 4.5MG BASE</u>	<u>A077129</u>	<u>003</u>	Jan 08, 2008
<u>AB</u>		<u>EQ 6MG BASE</u>	<u>A077129</u>	<u>004</u>	Jan 08, 2008

RIZATRIPTAN BENZOATE

TABLET; ORAL

MAXALT

<u>AB</u>	+! ORGANON LLC	<u>EQ 10MG BASE</u>	<u>N020864</u>	<u>002</u>	Jun 29, 1998

RIZATRIPTAN BENZOATE

<u>AB</u>	ALKEM LABS LTD	<u>EQ 5MG BASE</u>	<u>A203269</u>	<u>001</u>	Feb 18, 2016
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A203269</u>	<u>002</u>	Feb 18, 2016
<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 5MG BASE</u>	<u>A202490</u>	<u>001</u>	Dec 31, 2012
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A202490</u>	<u>002</u>	Dec 31, 2012
<u>AB</u>	CELLTRION	<u>EQ 5MG BASE</u>	<u>A077526</u>	<u>001</u>	Mar 26, 2013
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077526</u>	<u>002</u>	Mar 26, 2013
<u>AB</u>	GLENMARK GENERICS	<u>EQ 5MG BASE</u>	<u>A201967</u>	<u>001</u>	Dec 31, 2012
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A201967</u>	<u>002</u>	Dec 31, 2012
<u>AB</u>	INVAGEN PHARMS	<u>EQ 5MG BASE</u>	<u>A204339</u>	<u>001</u>	Jul 01, 2013
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A204339</u>	<u>002</u>	Jul 01, 2013

PRESCRIPTION DRUG PRODUCT LIST

3-402 (of 474)

RIZATRIPTAN BENZOATE

TABLET; ORAL

RIZATRIPTAN BENZOATE

<u>AB</u>	MACLEODS PHARMS LTD	<u>EQ 5MG BASE</u>	<u>A203147</u>	<u>001</u>	Feb 11, 2014
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A203147</u>	<u>002</u>	Feb 11, 2014
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 5MG BASE</u>	<u>A201993</u>	<u>001</u>	Dec 31, 2012
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A201993</u>	<u>002</u>	Dec 31, 2012
<u>AB</u>	NATCO PHARMA LTD	<u>EQ 5MG BASE</u>	<u>A200482</u>	<u>001</u>	Dec 31, 2012
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A200482</u>	<u>002</u>	Dec 31, 2012
<u>AB</u>	PHARMGEN	<u>EQ 5MG BASE</u>	<u>A202047</u>	<u>001</u>	Dec 31, 2012
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A202047</u>	<u>002</u>	Dec 31, 2012
<u>AB</u>	TEVA PHARMS	<u>EQ 5MG BASE</u>	<u>A077263</u>	<u>001</u>	Dec 31, 2012
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A077263</u>	<u>002</u>	Dec 31, 2012

TABLET, ORALLY DISINTEGRATING; ORAL

MAXALT-MLT

<u>AB</u>	+! ORGANON	<u>EQ 10MG BASE</u>	<u>N020865</u>	<u>002</u>	Jun 29, 1998

RIZATRIPTAN BENZOATE

<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 5MG BASE</u>	<u>A203062</u>	<u>001</u>	Jul 01, 2013
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A203062</u>	<u>002</u>	Jul 01, 2013
<u>AB</u>	GLENMARK PHARMS LTD	<u>EQ 5MG BASE</u>	<u>A201914</u>	<u>001</u>	Jul 01, 2013
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A201914</u>	<u>002</u>	Jul 01, 2013
<u>AB</u>	MACLEODS PHARMS LTD	<u>EQ 5MG BASE</u>	<u>A203146</u>	<u>001</u>	Sep 19, 2014
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A203146</u>	<u>002</u>	Sep 19, 2014
<u>AB</u>	NATCO PHARMA LTD	<u>EQ 5MG BASE</u>	<u>A203478</u>	<u>001</u>	Jul 01, 2013
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A203478</u>	<u>002</u>	Jul 01, 2013
<u>AB</u>	PANACEA	<u>EQ 5MG BASE</u>	<u>A204722</u>	<u>001</u>	Jan 11, 2017
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A204722</u>	<u>002</u>	Jan 11, 2017
<u>AB</u>	UNICHEM	<u>EQ 5MG BASE</u>	<u>A207835</u>	<u>001</u>	Mar 07, 2017
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A207835</u>	<u>002</u>	Mar 07, 2017

ROCURONIUM BROMIDE

INJECTABLE; INJECTION

ROCURONIUM BROMIDE

<u>AP</u>	EUGIA PHARMA	<u>50MG/5ML (10MG/ML)</u>	<u>A206206</u>	<u>001</u>	Apr 12, 2017
<u>AP</u>		<u>100MG/10ML (10MG/ML)</u>	<u>A206206</u>	<u>002</u>	Apr 12, 2017
<u>AP</u>	FRESENIUS KABI USA	<u>50MG/5ML (10MG/ML)</u>	<u>A078651</u>	<u>001</u>	Dec 29, 2008
<u>AP</u>		<u>100MG/10ML (10MG/ML)</u>	<u>A078651</u>	<u>002</u>	Dec 29, 2008
<u>AP</u>	GLAND PHARMA LTD	<u>50MG/5ML (10MG/ML)</u>	<u>A205656</u>	<u>001</u>	Apr 04, 2018
<u>AP</u>		<u>100MG/10ML (10MG/ML)</u>	<u>A205656</u>	<u>002</u>	Apr 04, 2018
<u>AP</u>	HOSPIRA	<u>50MG/5ML (10MG/ML)</u>	<u>A078519</u>	<u>001</u>	Nov 26, 2008
<u>AP</u>		<u>100MG/10ML (10MG/ML)</u>	<u>A078519</u>	<u>002</u>	Nov 26, 2008
<u>AP</u>	MYLAN INSTITUTIONAL	<u>50MG/5ML (10MG/ML)</u>	<u>A079199</u>	<u>001</u>	Nov 26, 2008
<u>AP</u>		<u>100MG/10ML (10MG/ML)</u>	<u>A079199</u>	<u>002</u>	Nov 26, 2008
<u>AP</u>	PIRAMAL CRITICAL	<u>50MG/5ML (10MG/ML)</u>	<u>A210437</u>	<u>001</u>	Aug 13, 2019
<u>AP</u>		<u>100MG/10ML (10MG/ML)</u>	<u>A210437</u>	<u>002</u>	Aug 13, 2019
<u>AP</u>	PRINSTON INC	<u>50MG/5ML (10MG/ML)</u>	<u>A212668</u>	<u>001</u>	May 26, 2022
<u>AP</u>		<u>100MG/10ML (10MG/ML)</u>	<u>A212668</u>	<u>002</u>	May 26, 2022
<u>AP</u>	SAGENT PHARMS INC	<u>50MG/5ML (10MG/ML)</u>	<u>A091458</u>	<u>001</u>	Jul 28, 2010
<u>AP</u>		<u>100MG/10ML (10MG/ML)</u>	<u>A091458</u>	<u>002</u>	Jul 28, 2010
<u>AP</u>	! SANDOZ INC	<u>50MG/5ML (10MG/ML)</u>	<u>A079195</u>	<u>001</u>	Dec 05, 2008
<u>AP</u>	!	<u>100MG/10ML (10MG/ML)</u>	<u>A079195</u>	<u>002</u>	Dec 05, 2008
<u>AP</u>	TAMARANG	<u>50MG/5ML (10MG/ML)</u>	<u>A091115</u>	<u>001</u>	Aug 27, 2012
<u>AP</u>		<u>100MG/10ML (10MG/ML)</u>	<u>A091115</u>	<u>002</u>	Aug 27, 2012
<u>AP</u>	WEST WARD PHARM CORP	<u>50MG/5ML (10MG/ML)</u>	<u>A204679</u>	<u>001</u>	Feb 28, 2017
<u>AP</u>		<u>100MG/10ML (10MG/ML)</u>	<u>A204679</u>	<u>002</u>	Feb 28, 2017

ROFLUMILAST

CREAM; TOPICAL

ZORYVE

+! ARCUTIS

0.3%

N215985 001 Jul 29, 2022

TABLET; ORAL

DALIRESP

<u>AB</u>	+ ASTRAZENECA	<u>250MCG</u>	<u>N022522</u>	<u>002</u>	Jan 23, 2018
<u>AB</u>	+!	<u>500MCG</u>	<u>N022522</u>	<u>001</u>	Feb 28, 2011

ROFLUMILAST

<u>AB</u>	HETERO LABS LTD III	<u>500MCG</u>	<u>A208213</u>	<u>001</u>	Nov 23, 2018
<u>AB</u>	MICRO LABS	<u>500MCG</u>	<u>A208180</u>	<u>001</u>	Mar 22, 2019
<u>AB</u>	MSN	<u>250MCG</u>	<u>A208256</u>	<u>001</u>	Sep 07, 2022
<u>AB</u>		<u>500MCG</u>	<u>A208256</u>	<u>002</u>	Sep 07, 2022
<u>AB</u>	MYLAN	<u>500MCG</u>	<u>A208257</u>	<u>001</u>	Jul 13, 2018
<u>AB</u>	PRINSTON INC	<u>500MCG</u>	<u>A208299</u>	<u>001</u>	May 10, 2022
<u>AB</u>	STRIDES PHARMA	<u>500MCG</u>	<u>A208247</u>	<u>001</u>	Mar 30, 2020

PRESCRIPTION DRUG PRODUCT LIST

3-403 (of 474)

ROFLUMILAST

TABLET; ORAL

ROFLUMILAST

<u>AB</u>	TORRENT	<u>500MCG</u>	<u>A208272</u>	<u>001</u>	Aug 06, 2018
<u>AB</u>	ZYDUS PHARMS	<u>500MCG</u>	<u>A208303</u>	<u>001</u>	Feb 10, 2022

ROLAPITANT HYDROCHLORIDE

TABLET; ORAL

VARUBI

+! TERSERA

EQ 90MG BASE

N206500 001 Sep 01, 2015

ROMIDEPSIN

POWDER; INTRAVENOUS

ISTODAX

<u>AP</u>	+! CELGENE	<u>10MG/VIAL</u>	<u>N022393</u>	<u>001</u>	Nov 05, 2009

ROMIDEPSIN

<u>AP</u>	FRESENIUS KABI USA	<u>10MG/VIAL</u>	<u>A206254</u>	<u>001</u>	Oct 12, 2021

ROPINIROLE HYDROCHLORIDE

TABLET; ORAL

ROPINIROLE HYDROCHLORIDE

<u>AB</u>	ACCORD HLTHCARE	<u>EQ 0.25MG BASE</u>	<u>A204022</u>	<u>001</u>	Feb 28, 2017
<u>AB</u>		<u>EQ 0.5MG BASE</u>	<u>A204022</u>	<u>002</u>	Feb 28, 2017
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A204022</u>	<u>003</u>	Feb 28, 2017
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A204022</u>	<u>004</u>	Feb 28, 2017
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A204022</u>	<u>005</u>	Feb 28, 2017
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A204022</u>	<u>006</u>	Feb 28, 2017
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A204022</u>	<u>007</u>	Feb 28, 2017
<u>AB</u>	ALEMBIC LTD	<u>EQ 0.25MG BASE</u>	<u>A090429</u>	<u>001</u>	Mar 24, 2010
<u>AB</u>		<u>EQ 0.5MG BASE</u>	<u>A090429</u>	<u>002</u>	Mar 24, 2010
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A090429</u>	<u>003</u>	Mar 24, 2010
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A090429</u>	<u>004</u>	Mar 24, 2010
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A090429</u>	<u>005</u>	Mar 24, 2010
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A090429</u>	<u>006</u>	Mar 24, 2010
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A090429</u>	<u>007</u>	Mar 24, 2010
<u>AB</u>	CADILA	<u>EQ 0.25MG BASE</u>	<u>A090411</u>	<u>001</u>	Jun 01, 2009
<u>AB</u>		<u>EQ 0.5MG BASE</u>	<u>A090411</u>	<u>002</u>	Jun 01, 2009
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A090411</u>	<u>003</u>	Jun 01, 2009
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A090411</u>	<u>004</u>	Jun 01, 2009
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A090411</u>	<u>005</u>	Jun 01, 2009
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A090411</u>	<u>006</u>	Jun 01, 2009
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A090411</u>	<u>007</u>	Jun 01, 2009
<u>AB</u>	CELLTRION	<u>EQ 0.25MG BASE</u>	<u>A079050</u>	<u>001</u>	May 29, 2008
<u>AB</u>		<u>EQ 0.5MG BASE</u>	<u>A079050</u>	<u>002</u>	May 29, 2008
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A079050</u>	<u>003</u>	May 29, 2008
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A079050</u>	<u>004</u>	May 29, 2008
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A079050</u>	<u>005</u>	May 29, 2008
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A079050</u>	<u>006</u>	May 29, 2008
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A079050</u>	<u>007</u>	May 29, 2008
<u>AB</u>	GLENMARK GENERICS	<u>EQ 0.25MG BASE</u>	<u>A090135</u>	<u>001</u>	Feb 25, 2010
<u>AB</u>		<u>EQ 0.5MG BASE</u>	<u>A090135</u>	<u>002</u>	Feb 25, 2010
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A090135</u>	<u>003</u>	Feb 25, 2010
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A090135</u>	<u>004</u>	Feb 25, 2010
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A090135</u>	<u>005</u>	Feb 25, 2010
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A090135</u>	<u>006</u>	Feb 25, 2010
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A090135</u>	<u>007</u>	Feb 25, 2010
<u>AB</u>	MLV	<u>EQ 0.25MG BASE</u>	<u>A079165</u>	<u>001</u>	Feb 07, 2012
<u>AB</u>		<u>EQ 0.5MG BASE</u>	<u>A079165</u>	<u>002</u>	Feb 07, 2012
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A079165</u>	<u>003</u>	Feb 07, 2012
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A079165</u>	<u>004</u>	Feb 07, 2012
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A079165</u>	<u>005</u>	Feb 07, 2012
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A079165</u>	<u>006</u>	Feb 07, 2012
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A079165</u>	<u>007</u>	Feb 07, 2012
<u>AB</u>	MYLAN	<u>EQ 0.25MG BASE</u>	<u>A078881</u>	<u>001</u>	May 05, 2008
<u>AB</u>		<u>EQ 0.5MG BASE</u>	<u>A078881</u>	<u>002</u>	May 05, 2008
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A078881</u>	<u>003</u>	May 05, 2008
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A078881</u>	<u>004</u>	May 05, 2008
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A078881</u>	<u>005</u>	May 05, 2008
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A078881</u>	<u>006</u>	May 05, 2008
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078881</u>	<u>007</u>	May 19, 2008
<u>AB</u>	ORBION PHARMS	<u>EQ 0.25MG BASE</u>	<u>A079229</u>	<u>001</u>	Nov 28, 2012
<u>AB</u>		<u>EQ 0.5MG BASE</u>	<u>A079229</u>	<u>002</u>	Nov 28, 2012
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A079229</u>	<u>003</u>	Nov 28, 2012
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A079229</u>	<u>004</u>	Nov 28, 2012

PRESCRIPTION DRUG PRODUCT LIST

3-404 (of 474)

ROPINIROLE HYDROCHLORIDE

TABLET; ORAL

ROPINIROLE HYDROCHLORIDE

<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A079229</u>	<u>005</u>	Nov 28, 2012
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A079229</u>	<u>006</u>	Nov 28, 2012
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A079229</u>	<u>007</u>	Nov 28, 2012
<u>AB</u>	!	<u>EQ 0.25MG BASE</u>	<u>A078110</u>	<u>001</u>	May 05, 2008
<u>AB</u>		<u>EQ 0.5MG BASE</u>	<u>A078110</u>	<u>002</u>	May 05, 2008
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A078110</u>	<u>003</u>	May 05, 2008
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A078110</u>	<u>004</u>	May 05, 2008
<u>AB</u>		<u>EQ 3MG BASE</u>	<u>A078110</u>	<u>005</u>	May 05, 2008
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A078110</u>	<u>006</u>	May 05, 2008
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A078110</u>	<u>007</u>	Jul 11, 2008

TABLET, EXTENDED RELEASE; ORAL

ROPINIROLE HYDROCHLORIDE

<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A090869</u>	<u>001</u>	May 17, 2012
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A090869</u>	<u>002</u>	May 17, 2012
<u>AB</u>		<u>EQ 6MG BASE</u>	<u>A090869</u>	<u>003</u>	May 17, 2012
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A090869</u>	<u>004</u>	May 17, 2012
<u>AB</u>		<u>EQ 12MG BASE</u>	<u>A090869</u>	<u>005</u>	May 17, 2012
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A202786</u>	<u>001</u>	Apr 22, 2013
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A202786</u>	<u>002</u>	Apr 22, 2013
<u>AB</u>		<u>EQ 6MG BASE</u>	<u>A202786</u>	<u>003</u>	Apr 22, 2013
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A202786</u>	<u>004</u>	Apr 22, 2013
<u>AB</u>		<u>EQ 12MG BASE</u>	<u>A202786</u>	<u>005</u>	Apr 22, 2013
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A091395</u>	<u>001</u>	Aug 27, 2012
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A091395</u>	<u>002</u>	Aug 27, 2012
<u>AB</u>		<u>EQ 6MG BASE</u>	<u>A091395</u>	<u>003</u>	Aug 27, 2012
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A091395</u>	<u>004</u>	Aug 27, 2012
<u>AB</u>		<u>EQ 12MG BASE</u>	<u>A091395</u>	<u>005</u>	Aug 27, 2012
<u>AB</u>	!	<u>EQ 2MG BASE</u>	<u>A201576</u>	<u>001</u>	Jun 06, 2012
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A201576</u>	<u>002</u>	Jun 06, 2012
<u>AB</u>		<u>EQ 6MG BASE</u>	<u>A201576</u>	<u>003</u>	Jun 06, 2012
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A201576</u>	<u>004</u>	Jun 06, 2012
<u>AB</u>		<u>EQ 12MG BASE</u>	<u>A201576</u>	<u>005</u>	Jun 06, 2012
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A204413</u>	<u>001</u>	May 11, 2022
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A204413</u>	<u>002</u>	May 11, 2022
<u>AB</u>		<u>EQ 6MG BASE</u>	<u>A204413</u>	<u>003</u>	May 11, 2022
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A204413</u>	<u>004</u>	May 11, 2022
<u>AB</u>		<u>EQ 12MG BASE</u>	<u>A204413</u>	<u>005</u>	May 11, 2022
<u>AB</u>		<u>EQ 2MG BASE</u>	<u>A201047</u>	<u>001</u>	Jun 06, 2012
<u>AB</u>		<u>EQ 4MG BASE</u>	<u>A201047</u>	<u>003</u>	Jun 06, 2012
<u>AB</u>		<u>EQ 6MG BASE</u>	<u>A201047</u>	<u>004</u>	Jun 06, 2012
<u>AB</u>		<u>EQ 8MG BASE</u>	<u>A201047</u>	<u>005</u>	Jun 06, 2012
<u>AB</u>		<u>EQ 12MG BASE</u>	<u>A201047</u>	<u>006</u>	Jun 06, 2012

ROPIVACAINE HYDROCHLORIDE

SOLUTION; INJECTION

NAROPIN

<u>AP</u>	+	<u>20MG/10ML (2MG/ML)</u>	<u>N020533</u>	<u>001</u>	May 01, 1998
<u>AP</u>	+	<u>40MG/20ML (2MG/ML)</u>	<u>N020533</u>	<u>002</u>	Sep 24, 1996
<u>AP</u>	+	<u>100MG/20ML (5MG/ML)</u>	<u>N020533</u>	<u>003</u>	May 01, 1998
<u>AP</u>	+	<u>100MG/10ML (10MG/ML)</u>	<u>N020533</u>	<u>005</u>	Sep 24, 1996
<u>AP</u>	+	<u>150MG/20ML (7.5MG/ML)</u>	<u>N020533</u>	<u>004</u>	Sep 24, 1996
<u>AP</u>	+	<u>150MG/30ML (5MG/ML)</u>	<u>N020533</u>	<u>008</u>	Sep 24, 1996
<u>AP</u>	+	<u>200MG/100ML (2MG/ML)</u>	<u>N020533</u>	<u>006</u>	Sep 24, 1996
<u>AP</u>	+	<u>200MG/20ML (10MG/ML)</u>	<u>N020533</u>	<u>011</u>	Sep 24, 1996
<u>AP</u>	+	<u>400MG/200ML (2MG/ML)</u>	<u>N020533</u>	<u>007</u>	Sep 24, 1996
<u>AP</u>	+	<u>500MG/100ML (5MG/ML)</u>	<u>N020533</u>	<u>009</u>	Jan 04, 2011
<u>AP</u>	+	<u>1GM/200ML (5MG/ML)</u>	<u>N020533</u>	<u>010</u>	Jan 04, 2011

ROPIVACAINE HYDROCHLORIDE

<u>AP</u>		<u>200MG/100ML (2MG/ML)</u>	<u>A204636</u>	<u>001</u>	Mar 16, 2018
<u>AP</u>		<u>400MG/200ML (2MG/ML)</u>	<u>A204636</u>	<u>002</u>	Mar 16, 2018
<u>AP</u>		<u>150MG/30ML (5MG/ML)</u>	<u>A203955</u>	<u>001</u>	Apr 11, 2016
<u>AP</u>		<u>40MG/20ML (2MG/ML)</u>	<u>A212808</u>	<u>001</u>	Apr 09, 2020
<u>AP</u>		<u>100MG/20ML (5MG/ML)</u>	<u>A212808</u>	<u>002</u>	Apr 09, 2020
<u>AP</u>		<u>150MG/30ML (5MG/ML)</u>	<u>A212808</u>	<u>003</u>	Apr 09, 2020
<u>AP</u>		<u>200MG/20ML (10MG/ML)</u>	<u>A212808</u>	<u>004</u>	Apr 09, 2020
<u>AP</u>		<u>40MG/20ML (2MG/ML)</u>	<u>A205612</u>	<u>001</u>	Jul 13, 2016
<u>AP</u>		<u>100MG/20ML (5MG/ML)</u>	<u>A205612</u>	<u>003</u>	Jul 13, 2016
<u>AP</u>		<u>100MG/10ML (10MG/ML)</u>	<u>A205612</u>	<u>006</u>	Jul 13, 2016
<u>AP</u>		<u>150MG/30ML (5MG/ML)</u>	<u>A205612</u>	<u>004</u>	Jul 13, 2016
<u>AP</u>		<u>150MG/20ML (7.5MG/ML)</u>	<u>A205612</u>	<u>005</u>	Jul 13, 2016

PRESCRIPTION DRUG PRODUCT LIST

3-405 (of 474)

ROPIVACAINE HYDROCHLORIDE

SOLUTION; INJECTION

ROPIVACAINE HYDROCHLORIDE

<u>AP</u>		<u>200MG/100ML (2MG/ML)</u>	<u>A205612</u>	<u>002</u>	Jul 13, 2016
<u>AP</u>		<u>200MG/20ML (10MG/ML)</u>	<u>A205612</u>	<u>007</u>	Jul 13, 2016
<u>AP</u>	GLAND PHARMA LTD	<u>200MG/100ML (2MG/ML)</u>	<u>A210102</u>	<u>001</u>	Aug 18, 2022
<u>AP</u>		<u>400MG/200ML (2MG/ML)</u>	<u>A210102</u>	<u>002</u>	Aug 18, 2022
<u>AP</u>	HIKMA	<u>40MG/20ML (2MG/ML)</u>	<u>A214074</u>	<u>001</u>	Jul 20, 2020
<u>AP</u>		<u>150MG/30ML (5MG/ML)</u>	<u>A214074</u>	<u>002</u>	Jul 20, 2020
<u>AP</u>		<u>150MG/20ML (7.5MG/ML)</u>	<u>A214074</u>	<u>003</u>	Jul 20, 2020
<u>AP</u>		<u>200MG/20ML (10MG/ML)</u>	<u>A214074</u>	<u>004</u>	Jul 20, 2020
<u>AP</u>	HOSPIRA	<u>20MG/10ML (2MG/ML)</u>	<u>A090194</u>	<u>001</u>	Sep 23, 2014
<u>AP</u>		<u>40MG/20ML (2MG/ML)</u>	<u>A090194</u>	<u>005</u>	Sep 23, 2014
<u>AP</u>		<u>100MG/10ML (10MG/ML)</u>	<u>A090194</u>	<u>004</u>	Sep 23, 2014
<u>AP</u>		<u>150MG/30ML (5MG/ML)</u>	<u>A090194</u>	<u>002</u>	Sep 23, 2014
<u>AP</u>		<u>150MG/20ML (7.5MG/ML)</u>	<u>A090194</u>	<u>003</u>	Sep 23, 2014
<u>AP</u>		<u>200MG/20ML (10MG/ML)</u>	<u>A090194</u>	<u>006</u>	Sep 23, 2014
<u>AP</u>	INFORLIFE	<u>200MG/100ML (2MG/ML)</u>	<u>A206166</u>	<u>001</u>	Jun 11, 2018
<u>AP</u>		<u>400MG/200ML (2MG/ML)</u>	<u>A206166</u>	<u>002</u>	Jun 11, 2018
<u>AP</u>		<u>500MG/100ML (5MG/ML)</u>	<u>A206166</u>	<u>003</u>	Jun 11, 2018
<u>AP</u>		<u>1GM/200ML (5MG/ML)</u>	<u>A206166</u>	<u>004</u>	Jun 11, 2018
<u>AP</u>	NAVINTA LLC	<u>150MG/30ML (5MG/ML)</u>	<u>A078601</u>	<u>002</u>	Jul 17, 2014
<u>AP</u>		<u>200MG/20ML (10MG/ML)</u>	<u>A078601</u>	<u>003</u>	Jul 17, 2014
<u>AP</u>	SOMERSET THERAPY LLC	<u>20MG/10ML (2MG/ML)</u>	<u>A207636</u>	<u>001</u>	Jun 15, 2018
<u>AP</u>		<u>40MG/20ML (2MG/ML)</u>	<u>A207636</u>	<u>002</u>	Jun 15, 2018
<u>AP</u>		<u>100MG/20ML (5MG/ML)</u>	<u>A207636</u>	<u>003</u>	Jun 15, 2018
<u>AP</u>		<u>100MG/10ML (10MG/ML)</u>	<u>A207636</u>	<u>006</u>	Jun 15, 2018
<u>AP</u>		<u>150MG/30ML (5MG/ML)</u>	<u>A207636</u>	<u>004</u>	Jun 15, 2018
<u>AP</u>		<u>150MG/20ML (7.5MG/ML)</u>	<u>A207636</u>	<u>005</u>	Jun 15, 2018
<u>AP</u>		<u>200MG/20ML (10MG/ML)</u>	<u>A207636</u>	<u>007</u>	Jun 15, 2018

ROSIGLITAZONE MALEATE

TABLET; ORAL

AVANDIA

+ WOODWARD

EQ 2MG BASE

N021071 002 May 25, 1999

+

EQ 4MG BASE

N021071 003 May 25, 1999

ROSUVASTATIN CALCIUM

CAPSULE; ORAL

EZALLOR SPRINKLE

+ SUN PHARM

EQ 5MG BASE

N208647 001 Dec 18, 2018

+

EQ 10MG BASE

N208647 002 Dec 18, 2018

+

EQ 20MG BASE

N208647 003 Dec 18, 2018

+!

EQ 40MG BASE

N208647 004 Dec 18, 2018

TABLET; ORAL

CRESTOR

<u>AB</u>	+	IPR	<u>EQ 5MG BASE</u>	<u>N021366</u>	<u>002</u>	Aug 12, 2003
<u>AB</u>	+		<u>EQ 10MG BASE</u>	<u>N021366</u>	<u>003</u>	Aug 12, 2003
<u>AB</u>	+		<u>EQ 20MG BASE</u>	<u>N021366</u>	<u>004</u>	Aug 12, 2003
<u>AB</u>	+	!	<u>EQ 40MG BASE</u>	<u>N021366</u>	<u>005</u>	Aug 12, 2003

ROSUVASTATIN CALCIUM

<u>AB</u>	ACCORD HLTHCARE	<u>EQ 5MG BASE</u>	<u>A206434</u>	<u>001</u>	Oct 31, 2016
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A206434</u>	<u>002</u>	Oct 31, 2016
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A206434</u>	<u>003</u>	Oct 31, 2016
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A206434</u>	<u>004</u>	Oct 31, 2016
<u>AB</u>	ALKEM LABS LTD	<u>EQ 5MG BASE</u>	<u>A206465</u>	<u>001</u>	Mar 21, 2017
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A206465</u>	<u>002</u>	Mar 21, 2017
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A206465</u>	<u>003</u>	Mar 21, 2017
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A206465</u>	<u>004</u>	Mar 21, 2017
<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 5MG BASE</u>	<u>A079170</u>	<u>001</u>	Jul 19, 2016
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A079170</u>	<u>002</u>	Jul 19, 2016
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A079170</u>	<u>003</u>	Jul 19, 2016
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A079170</u>	<u>004</u>	Jul 19, 2016
<u>AB</u>	BIOCON PHARMA	<u>EQ 5MG BASE</u>	<u>A207752</u>	<u>001</u>	Oct 31, 2016
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A207752</u>	<u>002</u>	Oct 31, 2016
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A207752</u>	<u>003</u>	Oct 31, 2016
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A207752</u>	<u>004</u>	Oct 31, 2016
<u>AB</u>	CADILA PHARMS LTD	<u>EQ 5MG BASE</u>	<u>A207453</u>	<u>001</u>	Nov 23, 2016
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A207453</u>	<u>002</u>	Nov 23, 2016
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A207453</u>	<u>003</u>	Nov 23, 2016
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A207453</u>	<u>004</u>	Nov 23, 2016
<u>AB</u>	CHANGZHOU PHARM	<u>EQ 5MG BASE</u>	<u>A207408</u>	<u>001</u>	Oct 31, 2016

PRESCRIPTION DRUG PRODUCT LIST

3-406 (of 474)

ROSUVASTATIN CALCIUM

TABLET; ORAL

ROSUVASTATIN CALCIUM

<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A207408 002</u>	Oct 31, 2016
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A207408 003</u>	Oct 31, 2016
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A207408 004</u>	Oct 31, 2016
<u>AB</u>	CHARTWELL RX	<u>EQ 5MG BASE</u>	<u>A079168 001</u>	Jul 19, 2016
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A079168 002</u>	Jul 19, 2016
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A079168 003</u>	Jul 19, 2016
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A079168 004</u>	Jul 19, 2016
<u>AB</u>	GLENMARK PHARMS	<u>EQ 5MG BASE</u>	<u>A079172 001</u>	Jul 19, 2016
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A079172 002</u>	Jul 19, 2016
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A079172 003</u>	Jul 19, 2016
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A079172 004</u>	Jul 19, 2016
<u>AB</u>	HETERO LABS LTD V	<u>EQ 5MG BASE</u>	<u>A207616 001</u>	Oct 31, 2016
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A207616 002</u>	Oct 31, 2016
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A207616 003</u>	Oct 31, 2016
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A207616 004</u>	Oct 31, 2016
<u>AB</u>	LUPIN	<u>EQ 5MG BASE</u>	<u>A205587 001</u>	Jul 31, 2017
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A205587 002</u>	Jul 31, 2017
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A205587 003</u>	Jul 31, 2017
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A205587 004</u>	Jul 31, 2017
<u>AB</u>	MSN	<u>EQ 5MG BASE</u>	<u>A208898 001</u>	Nov 22, 2017
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A208898 002</u>	Nov 22, 2017
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A208898 003</u>	Nov 22, 2017
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A208898 004</u>	Nov 22, 2017
<u>AB</u>	RENATA	<u>EQ 5MG BASE</u>	<u>A207062 001</u>	Oct 31, 2016
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A207062 002</u>	Oct 31, 2016
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A207062 003</u>	Oct 31, 2016
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A207062 004</u>	Oct 31, 2016
<u>AB</u>	SANDOZ INC	<u>EQ 5MG BASE</u>	<u>A079171 001</u>	Jul 19, 2016
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A079171 002</u>	Jul 19, 2016
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A079171 003</u>	Jul 19, 2016
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A079171 004</u>	Jul 19, 2016
<u>AB</u>	SCIEGEN PHARMS INC	<u>EQ 5MG BASE</u>	<u>A206381 001</u>	Apr 24, 2019
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A206381 002</u>	Apr 24, 2019
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A206381 003</u>	Apr 24, 2019
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A206381 004</u>	Apr 24, 2019
<u>AB</u>	SHANDONG	<u>EQ 5MG BASE</u>	<u>A207375 001</u>	May 07, 2019
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A207375 002</u>	May 07, 2019
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A207375 003</u>	May 07, 2019
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A207375 004</u>	May 07, 2019
<u>AB</u>	SUN PHARM	<u>EQ 5MG BASE</u>	<u>A079169 001</u>	Jul 19, 2016
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A079169 002</u>	Jul 19, 2016
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A079169 003</u>	Jul 19, 2016
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A079169 004</u>	Jul 19, 2016
<u>AB</u>	TORRENT	<u>EQ 5MG BASE</u>	<u>A201619 001</u>	Oct 31, 2016
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A201619 002</u>	Oct 31, 2016
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A201619 003</u>	Oct 31, 2016
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A201619 004</u>	Oct 31, 2016
<u>AB</u>	WATSON LABS INC	<u>EQ 5MG BASE</u>	<u>A079167 001</u>	Apr 29, 2016
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A079167 002</u>	Apr 29, 2016
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A079167 003</u>	Apr 29, 2016
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A079167 004</u>	Apr 29, 2016
<u>AB</u>	ZHEJIANG YONGTAI	<u>EQ 5MG BASE</u>	<u>A212059 001</u>	Nov 04, 2019
<u>AB</u>		<u>EQ 10MG BASE</u>	<u>A212059 002</u>	Nov 04, 2019
<u>AB</u>		<u>EQ 20MG BASE</u>	<u>A212059 003</u>	Nov 04, 2019
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A212059 004</u>	Nov 04, 2019

ROTIGOTINE

FILM, EXTENDED RELEASE; TRANSDERMAL

NEUPRO

+	UCB INC	1MG/24HR	N021829 004	Apr 02, 2012
+	!	2MG/24HR	N021829 001	May 09, 2007
+		3MG/24HR	N021829 005	Apr 02, 2012
+		4MG/24HR	N021829 002	May 09, 2007
+		6MG/24HR	N021829 003	May 09, 2007
+		8MG/24HR	N021829 006	Apr 02, 2012

PRESCRIPTION DRUG PRODUCT LIST

3-407 (of 474)

RUBIDIUM CHLORIDE RB-82

INJECTABLE; INJECTION

CARDIOGEN-82

BRACCO

N/A

N019414 001 Dec 29, 1989

SOLUTION; INTRAVENOUS

RUBY-FILL

JUBILANT

N/A

N202153 001 Sep 30, 2016

RUCAPARIB CAMSYLATE

TABLET; ORAL

RUBRACA

+ CLOVIS ONCOLOGY INC

EQ 200MG BASE

N209115 001 Dec 19, 2016

+

EQ 250MG BASE

N209115 003 May 01, 2017

+!

EQ 300MG BASE

N209115 002 Dec 19, 2016

RUFINAMIDE

SUSPENSION; ORAL

BANZEL**AB** +! EISAI INC40MG/MLN201367 001 Mar 03, 2011RUFINAMIDE**AB** ALKEM LABS LTD40MG/MLA213410 001 Feb 23, 2021**AB** AUROBINDO PHARMA40MG/MLA216549 001 Oct 26, 2022**AB** BIONPHARMA INC40MG/MLA211388 001 Apr 23, 2019**AB** GLASSHOUSE PHARMS40MG/MLA214009 001 Nov 07, 2022**AB** HIKMA40MG/MLA207363 001 Apr 23, 2019**AB** LUPIN LTD40MG/MLA213457 001 Dec 18, 2020

TABLET; ORAL

BANZEL**AB** + EISAI INC200MGN021911 002 Nov 14, 2008**AB** +!400MGN021911 003 Nov 14, 2008RUFINAMIDE**AB** GLENMARK PHARMS LTD200MGA205075 001 May 16, 2016**AB**400MGA205075 002 May 16, 2016**AB** HETERO LABS LTD III200MGA204993 001 May 11, 2021**AB**400MGA204993 002 May 11, 2021**AB** HIKMA200MGA204988 001 May 16, 2016**AB**400MGA204988 002 May 16, 2016**AB** LUPIN LTD200MGA204964 002 Aug 17, 2022**AB**400MGA204964 003 Aug 17, 2022**AB** MYLAN200MGA205095 001 May 16, 2016**AB**400MGA205095 002 May 16, 2016

LUPIN LTD

100MG

A204964 001 Aug 17, 2022

RUXOLITINIB PHOSPHATE

CREAM; TOPICAL

OPZELURA

+! INCYTE CORP

EQ 1.5% BASE

N215309 001 Sep 21, 2021

TABLET; ORAL

JAKAFI

+ INCYTE CORP

EQ 5MG BASE

N202192 001 Nov 16, 2011

+

EQ 10MG BASE

N202192 002 Nov 16, 2011

+

EQ 15MG BASE

N202192 003 Nov 16, 2011

+

EQ 20MG BASE

N202192 004 Nov 16, 2011

+!

EQ 25MG BASE

N202192 005 Nov 16, 2011

SACUBITRIL; VALSARTAN

TABLET; ORAL

ENTRESTO

+ NOVARTIS PHARMS

24MG; 26MG

N207620 001 Jul 07, 2015

CORP

+

49MG; 51MG

N207620 002 Jul 07, 2015

+!

97MG; 103MG

N207620 003 Jul 07, 2015

SAFINAMIDE MESYLATE

TABLET; ORAL

XADAGO

+ MDD US

EQ 50MG BASE

N207145 001 Mar 21, 2017

+!

EQ 100MG BASE

N207145 002 Mar 21, 2017

SALMETEROL XINAFOATE

POWDER; INHALATION

SEREVENT

+! GLAXOSMITHKLINE

EQ 0.05MG BASE/INH

N020692 001 Sep 19, 1997

PRESCRIPTION DRUG PRODUCT LIST

3-408 (of 474)

SAPROPTERIN DIHYDROCHLORIDE

POWDER; ORAL

KUVAN

AB	+!	BIOMARIN PHARM	100MG/PACKET	N205065 001	Dec 19, 2013
AB	+		500MG/PACKET	N205065 002	Oct 27, 2015

SAPROPTERIN DIHYDROCHLORIDE

AB		ANNORA PHARMA	100MG/PACKET	A215420 001	Aug 18, 2022
AB			500MG/PACKET	A215420 002	Aug 18, 2022
AB		DR REDDYS	100MG/PACKET	A209452 001	Mar 30, 2021
AB			500MG/PACKET	A215798 001	May 13, 2022
AB		PAR PHARM INC	100MG/PACKET	A207207 001	Aug 20, 2019
AB			500MG/PACKET	A210027 001	Aug 20, 2019

TABLET; ORAL

KUVAN

AB	+!	BIOMARIN PHARM	100MG	N022181 001	Dec 13, 2007

SAPROPTERIN DIHYDROCHLORIDE

AB		ANNORA PHARMA	100MG	A215534 001	Aug 23, 2022
AB		DR REDDYS	100MG	A207685 001	Jun 15, 2021
AB		PAR PHARM INC	100MG	A207200 001	May 10, 2019

SARECYCLINE HYDROCHLORIDE

TABLET; ORAL

SEYSARA

+	ALMIRALL	EQ 60MG BASE	N209521 001	Oct 01, 2018
+		EQ 100MG BASE	N209521 002	Oct 01, 2018
+!		EQ 150MG BASE	N209521 003	Oct 01, 2018

SAXAGLIPTIN HYDROCHLORIDE

TABLET; ORAL

ONGLYZA

+	ASTRAZENECA AB	EQ 2.5MG BASE	N022350 001	Jul 31, 2009
+!		EQ 5MG BASE	N022350 002	Jul 31, 2009

SCOPOLAMINE

SYSTEM; TRANSDERMAL

SCOPOLAMINE

AB		ACTAVIS LABS UT INC	1MG/72HR	A208769 001	Jan 10, 2022
AB		MYLAN TECHNOLOGIES	1MG/72HR	A203753 001	Jun 19, 2019
AB		PADAGIS US	1MG/72HR	A078830 001	Jan 30, 2015
AB		RICONPHARMA LLC	1MG/72HR	A212342 001	Nov 24, 2020

TRANSDERM SCOP

AB	+!	BAXTER HLTHCARE CORP	1MG/72HR	N017874 001	

SECNIDAZOLE

GRANULE; ORAL

SOLOSEC

+!	LUPIN	2GM/PACKET	N209363 001	Sep 15, 2017

SECRETIN SYNTHETIC HUMAN

FOR SOLUTION; INTRAVENOUS

CHIRHOSTIM

+!	CHIRHOCLIN	16MCG/VIAL	N021256 001	Apr 09, 2004
+		40MCG/VIAL	N021256 002	Jun 21, 2007

SELEGILINE

FILM, EXTENDED RELEASE; TRANSDERMAL

EMSAM

+!	SOMERSET	6MG/24HR	N021336 001	Feb 27, 2006
+		9MG/24HR	N021336 002	Feb 27, 2006
+		12MG/24HR	N021336 003	Feb 27, 2006

SELEGILINE HYDROCHLORIDE

CAPSULE; ORAL

SELEGILINE HYDROCHLORIDE

AB	!	APOTEX	5MG	A075321 001	Dec 04, 1998
AB		NOVITIUM PHARMA	5MG	A075352 001	Nov 30, 1998
AB		RISING	5MG	A206803 001	Apr 02, 2019

TABLET; ORAL

SELEGILINE HYDROCHLORIDE

AB	!	APOTEX INC	5MG	A074871 001	Jun 06, 1997
AB		I3 PHARMS	5MG	A074672 001	Apr 01, 1997

TABLET, ORALLY DISINTEGRATING; ORAL

ZELAPAR

+!	BAUSCH	1.25MG	N021479 001	Jun 14, 2006

PRESCRIPTION DRUG PRODUCT LIST

3-409 (of 474)

SELENIOS ACID

SOLUTION; INTRAVENOUS

SELENIOS ACID

+!	AM REGENT	EQ 12MCG SELENIUM/2ML (EQ 6MCG SELENIUM/ML)	N209379	003	Aug 30, 2021
+!		EQ 60MCG SELENIUM/ML (EQ 60MCG SELENIUM/ML)	N209379	002	Jan 25, 2021
+!		EQ 600MCG SELENIUM/10ML (EQ 60MCG SELENIUM/ML)	N209379	001	Apr 30, 2019

SELENIUM SULFIDE

LOTION/SHAMPOO; TOPICAL

SELENIUM SULFIDE

!	PADAGIS US	2.5%	A089996	001	Jan 10, 1991

SELEXIPAG

POWDER; INTRAVENOUS

UPTRAVI

+!	ACTELION	1.8MG/VIAL	N214275	001	Jul 29, 2021

TABLET; ORAL

SELEXIPAG

<u>AB</u>	ZYDUS	<u>0.2MG</u>	<u>A214302</u>	<u>001</u>	Dec 21, 2022
<u>AB</u>		<u>0.4MG</u>	<u>A214302</u>	<u>002</u>	Dec 21, 2022
<u>AB</u>		<u>0.6MG</u>	<u>A214302</u>	<u>003</u>	Dec 21, 2022
<u>AB</u>		<u>0.8MG</u>	<u>A214302</u>	<u>004</u>	Dec 21, 2022
<u>AB</u>		<u>1MG</u>	<u>A214302</u>	<u>005</u>	Dec 21, 2022
<u>AB</u>		<u>1.2MG</u>	<u>A214302</u>	<u>006</u>	Dec 21, 2022
<u>AB</u>		<u>1.4MG</u>	<u>A214302</u>	<u>007</u>	Dec 21, 2022
<u>AB</u>		<u>1.6MG</u>	<u>A214302</u>	<u>008</u>	Dec 21, 2022

UPTRAVI

<u>AB</u>	+	ACTELION	<u>0.2MG</u>	<u>N207947</u>	<u>001</u>	Dec 21, 2015
<u>AB</u>	+	!	<u>0.4MG</u>	<u>N207947</u>	<u>002</u>	Dec 21, 2015
<u>AB</u>	+		<u>0.6MG</u>	<u>N207947</u>	<u>003</u>	Dec 21, 2015
<u>AB</u>	+		<u>0.8MG</u>	<u>N207947</u>	<u>004</u>	Dec 21, 2015
<u>AB</u>	+		<u>1MG</u>	<u>N207947</u>	<u>005</u>	Dec 21, 2015
<u>AB</u>	+		<u>1.2MG</u>	<u>N207947</u>	<u>006</u>	Dec 21, 2015
<u>AB</u>	+		<u>1.4MG</u>	<u>N207947</u>	<u>007</u>	Dec 21, 2015
<u>AB</u>	+		<u>1.6MG</u>	<u>N207947</u>	<u>008</u>	Dec 21, 2015

SELINEXOR

TABLET; ORAL

XPOVIO

+	KARYOPHARM THERAPS	20MG	N212306	001	Jul 03, 2019
+		40MG	N212306	002	Apr 15, 2021
+		50MG	N212306	003	Apr 15, 2021
+	!	60MG	N212306	004	Apr 15, 2021

SELPERCATINIB

CAPSULE; ORAL

RETEVMO

+	LOXO ONCOL ELI LILLY	40MG	N213246	001	May 08, 2020
+	!	80MG	N213246	002	May 08, 2020

SELUMETINIB SULFATE

CAPSULE; ORAL

KOSELUGO

+	ASTRAZENECA	EQ 10MG BASE	N213756	001	Apr 10, 2020
+	!	EQ 25MG BASE	N213756	002	Apr 10, 2020

SEMAGLUTIDE

SOLUTION; SUBCUTANEOUS

OZEMPIC

+	NOVO	2MG/1.5ML (1.34MG/ML)	N209637	001	Dec 05, 2017
+		2MG/3ML (0.68MG/ML)	N209637	004	Oct 06, 2022
+		4MG/3ML (1.34MG/ML)	N209637	002	Apr 09, 2019
+		8MG/3ML (2.68MG/ML)	N209637	003	Mar 28, 2022

WEGOVY

+	NOVO	0.25MG/0.5ML (0.25MG/0.5ML)	N215256	001	Jun 04, 2021
+		0.5MG/0.5ML (0.5MG/0.5ML)	N215256	002	Jun 04, 2021
+		1MG/0.5ML (1MG/0.5ML)	N215256	003	Jun 04, 2021
+		1.7MG/0.75ML (1.7MG/0.75ML)	N215256	004	Jun 04, 2021
+		2.4MG/0.75ML (2.4MG/0.75ML)	N215256	005	Jun 04, 2021

TABLET; ORAL

RYBELSUS

+	NOVO	3MG	N213051	001	Sep 20, 2019

PRESCRIPTION DRUG PRODUCT LIST

3-410 (of 474)

SEMAGLUTIDE

TABLET; ORAL

RYBELSUS

+

7MG

N213051 002 Sep 20, 2019

+!

14MG

N213051 003 Sep 20, 2019

SERTACONAZOLE NITRATE

CREAM; TOPICAL

ERTACZO

+!

BAUSCH

2%

N021385 001 Dec 10, 2003

SERTRALINE HYDROCHLORIDE

CAPSULE; ORAL

SERTRALINE HYDROCHLORIDE

+ ALMATICA

EQ 150MG BASE

N215133 001 Oct 04, 2021

+!

EQ 200MG BASE

N215133 002 Oct 04, 2021

CONCENTRATE; ORAL

SERTRALINE HYDROCHLORIDE**AA** ACI**EQ 20MG BASE/ML****A076934 001** Jun 30, 2006**AA** AUROBINDO PHARMA**EQ 20MG BASE/ML****A078861 001** Oct 31, 2008ZOLOFT**AA** +! VIATRIS**EQ 20MG BASE/ML****N020990 001** Dec 07, 1999

TABLET; ORAL

SERTRALINE HYDROCHLORIDE**AB** ACCORD HLTHCARE**EQ 25MG BASE****A202825 001** Nov 07, 2014**AB****EQ 50MG BASE****A202825 002** Nov 07, 2014**AB****EQ 100MG BASE****A202825 003** Nov 07, 2014**AB**

ACI

EQ 25MG BASE**A076881 001** Feb 06, 2007**AB****EQ 50MG BASE****A076881 002** Feb 06, 2007**AB****EQ 100MG BASE****A076881 003** Feb 06, 2007**AB**

ASCENT PHARMS INC

EQ 25MG BASE**A214790 001** May 03, 2021**AB****EQ 50MG BASE****A214790 002** May 03, 2021**AB****EQ 100MG BASE****A214790 003** May 03, 2021**AB**

AUROBINDO PHARMA

EQ 25MG BASE**A077206 001** Feb 06, 2007**AB****EQ 50MG BASE****A077206 002** Feb 06, 2007**AB****EQ 100MG BASE****A077206 003** Feb 06, 2007**AB**

GRANULES

EQ 25MG BASE**A078403 001** Jan 08, 2008**AB****EQ 50MG BASE****A078403 002** Jan 08, 2008**AB****EQ 100MG BASE****A078403 003** Jan 08, 2008**AB**

INVAGEN PHARMS

EQ 25MG BASE**A077397 001** Feb 06, 2007**AB****EQ 50MG BASE****A077397 002** Feb 06, 2007**AB****EQ 100MG BASE****A077397 003** Feb 06, 2007**AB**

LUPIN

EQ 25MG BASE**A077670 001** Feb 06, 2007**AB****EQ 50MG BASE****A077670 002** Feb 06, 2007**AB****EQ 100MG BASE****A077670 003** Feb 06, 2007**AB**

OXFORD PHARMS

EQ 25MG BASE**A078175 001** Jul 21, 2010**AB****EQ 50MG BASE****A078175 002** Jul 21, 2010**AB****EQ 100MG BASE****A078175 003** Jul 21, 2010**AB**

REYOUNG

EQ 25MG BASE**A078677 001** Mar 04, 2009**AB****EQ 50MG BASE****A078677 002** Mar 04, 2009**AB****EQ 100MG BASE****A078677 003** Mar 04, 2009**AB**

SCIEGEN PHARMS INC

EQ 25MG BASE**A076442 001** Apr 30, 2007**AB****EQ 50MG BASE****A076442 002** Apr 30, 2007**AB****EQ 100MG BASE****A076442 003** Apr 30, 2007**AB**

VIWIT PHARM

EQ 25MG BASE**A076882 001** Feb 06, 2007**AB****EQ 50MG BASE****A076882 002** Feb 06, 2007**AB****EQ 100MG BASE****A076882 003** Feb 06, 2007ZOLOFT**AB** + VIATRIS**EQ 25MG BASE****N019839 005** Mar 06, 1996**AB** +**EQ 50MG BASE****N019839 001** Dec 30, 1991**AB** +!**EQ 100MG BASE****N019839 002** Dec 30, 1991SETMELANOTIDE ACETATE

SOLUTION; SUBCUTANEOUS

IMCIVREE

+!

RHYTHM

EQ 10MG/ML BASE (EQ 10MG/ML BASE)

N213793 001 Nov 25, 2020

SEVELAMER CARBONATE

FOR SUSPENSION; ORAL

RENEVELA**AB** + GENZYME**800MG/PACKET****N022318 001** Aug 12, 2009**AB** +!**2.4GM/PACKET****N022318 002** Feb 18, 2009SEVELAMER CARBONATE**AB** AUROBINDO PHARMA**800MG/PACKET****A207624 001** Jun 13, 2017

PRESCRIPTION DRUG PRODUCT LIST

3-411 (of 474)

SEVELAMER CARBONATE

FOR SUSPENSION;ORAL

SEVELAMER CARBONATE

<u>AB</u>		<u>2.4GM/PACKET</u>	<u>A207624</u>	<u>002</u>	Jun 13, 2017
<u>AB</u>	BIONPHARMA INC	<u>800MG/PACKET</u>	<u>A209374</u>	<u>001</u>	May 17, 2021
<u>AB</u>	DR REDDYS	<u>800MG/PACKET</u>	<u>A210464</u>	<u>001</u>	Oct 25, 2018
<u>AB</u>		<u>2.4GM/PACKET</u>	<u>A210464</u>	<u>002</u>	Oct 25, 2018
<u>AB</u>	IMPAX	<u>800MG/PACKET</u>	<u>A211316</u>	<u>001</u>	Nov 20, 2020
<u>AB</u>		<u>2.4GM/PACKET</u>	<u>A211316</u>	<u>002</u>	Nov 20, 2020

TABLET;ORAL

RENVELA

<u>AB</u>	<u>+</u> !	SANOFI	<u>800MG</u>	<u>N022127</u>	<u>001</u>	Oct 19, 2007

SEVELAMER CARBONATE

<u>AB</u>		AMNEAL PHARMS CO	<u>800MG</u>	<u>A207288</u>	<u>001</u>	Nov 28, 2017
<u>AB</u>		ANXIN	<u>800MG</u>	<u>A212970</u>	<u>001</u>	Apr 09, 2020
<u>AB</u>		ARTHUR GRP	<u>800MG</u>	<u>A200959</u>	<u>001</u>	Mar 20, 2018
<u>AB</u>		AUROBINDO PHARMA	<u>800MG</u>	<u>A207179</u>	<u>001</u>	Jul 17, 2017
<u>AB</u>		DR REDDYS	<u>800MG</u>	<u>A206094</u>	<u>001</u>	Sep 29, 2017
<u>AB</u>		INVAGEN PHARMS	<u>800MG</u>	<u>A203860</u>	<u>001</u>	Oct 26, 2017
<u>AB</u>		MICRO LABS	<u>800MG</u>	<u>A215537</u>	<u>001</u>	Feb 07, 2022
<u>AB</u>		RISING	<u>800MG</u>	<u>A204451</u>	<u>001</u>	Nov 29, 2018
<u>AB</u>		ZYDUS PHARMS	<u>800MG</u>	<u>A207759</u>	<u>001</u>	Aug 11, 2020

SEVELAMER HYDROCHLORIDE

TABLET;ORAL

RENAGEL

<u>AB</u>	<u>+</u>	GENZYME	<u>400MG</u>	<u>N021179</u>	<u>001</u>	Jul 12, 2000
<u>AB</u>	<u>+</u> !		<u>800MG</u>	<u>N021179</u>	<u>002</u>	Jul 12, 2000

SEVELAMER HYDROCHLORIDE

<u>AB</u>		GLENMARK PHARMS LTD	<u>400MG</u>	<u>A204724</u>	<u>001</u>	Feb 08, 2019
<u>AB</u>			<u>800MG</u>	<u>A204724</u>	<u>002</u>	Feb 08, 2019
<u>AB</u>		LUPIN LTD	<u>400MG</u>	<u>A213145</u>	<u>001</u>	Jun 16, 2021
<u>AB</u>			<u>800MG</u>	<u>A213145</u>	<u>002</u>	Jun 16, 2021

SEVOFLURANE

LIQUID;INHALATION

SEVOFLURANE

<u>AN</u>		BAXTER HLTHCARE	<u>100%</u>	<u>A075895</u>	<u>001</u>	Jul 02, 2002
<u>AN</u>		HALOCARBON PRODS	<u>100%</u>	<u>A078650</u>	<u>001</u>	Nov 19, 2007
<u>AN</u>		SHANGHAI HENGRUI	<u>100%</u>	<u>A203793</u>	<u>001</u>	Nov 03, 2015

SOJOURN

<u>AN</u>		PIRAMAL CRITICAL	<u>100%</u>	<u>A077867</u>	<u>001</u>	May 02, 2007

ULTANE

<u>AN</u>	<u>+</u> !	ABBVIE	<u>100%</u>	<u>N020478</u>	<u>001</u>	Jun 07, 1995

SILDENAFIL CITRATE

FOR SUSPENSION;ORAL

REVATIO

<u>AB</u>	<u>+</u> !	VIATRIS	<u>EQ 10MG BASE/ML</u>	<u>N203109</u>	<u>001</u>	Aug 30, 2012

SILDENAFIL CITRATE

<u>AB</u>		AJANTA PHARMA LTD	<u>EQ 10MG BASE/ML</u>	<u>A212883</u>	<u>001</u>	Nov 27, 2019
<u>AB</u>		ALKEM LABS LTD	<u>EQ 10MG BASE/ML</u>	<u>A212440</u>	<u>001</u>	Nov 27, 2019
<u>AB</u>		AMNEAL PHARMS	<u>EQ 10MG BASE/ML</u>	<u>A211092</u>	<u>001</u>	Nov 27, 2019
<u>AB</u>		APPCO	<u>EQ 10MG BASE/ML</u>	<u>A213814</u>	<u>001</u>	Apr 29, 2021
<u>AB</u>		APTAPHARMA INC	<u>EQ 10MG BASE/ML</u>	<u>A213041</u>	<u>001</u>	Aug 06, 2020
<u>AB</u>		AUROBINDO PHARMA LTD	<u>EQ 10MG BASE/ML</u>	<u>A214773</u>	<u>001</u>	Dec 23, 2022
<u>AB</u>		HETERO LABS LTD V	<u>EQ 10MG BASE/ML</u>	<u>A213014</u>	<u>001</u>	May 11, 2021
<u>AB</u>		LUPIN LTD	<u>EQ 10MG BASE/ML</u>	<u>A211638</u>	<u>001</u>	Mar 23, 2022
<u>AB</u>		MSN	<u>EQ 10MG BASE/ML</u>	<u>A214641</u>	<u>001</u>	Feb 08, 2022
<u>AB</u>		NOVITIUM PHARMA	<u>EQ 10MG BASE/ML</u>	<u>A212260</u>	<u>001</u>	May 31, 2019
<u>AB</u>		TARO PHARM INDS LTD	<u>EQ 10MG BASE/ML</u>	<u>A215522</u>	<u>001</u>	Nov 16, 2021
<u>AB</u>		TEVA PHARMS USA	<u>EQ 10MG BASE/ML</u>	<u>A211534</u>	<u>001</u>	May 29, 2020
<u>AB</u>		ZYDUS	<u>EQ 10MG BASE/ML</u>	<u>A215708</u>	<u>001</u>	Sep 29, 2022

SOLUTION;INTRAVENOUS

REVATIO

<u>AP</u>	<u>+</u> !	VIATRIS	<u>EQ 10MG BASE/12.5ML (EQ 0.8MG BASE/ML)</u>	<u>N022473</u>	<u>001</u>	Nov 18, 2009

SILDENAFIL CITRATE

<u>AP</u>		EUGIA PHARMA	<u>EQ 10MG BASE/12.5ML (EQ 0.8MG BASE/ML)</u>	<u>A203988</u>	<u>001</u>	Apr 01, 2015

TABLET;ORAL

REVATIO

<u>AB</u>	<u>+</u> !	VIATRIS	<u>EQ 20MG BASE</u>	<u>N021845</u>	<u>001</u>	Jun 03, 2005

SILDENAFIL CITRATE

<u>AB</u>		AJANTA PHARMA LTD	<u>EQ 20MG BASE</u>	<u>A210394</u>	<u>001</u>	May 04, 2018

PRESCRIPTION DRUG PRODUCT LIST

3-412 (of 474)

SILDENAFIL CITRATE

TABLET; ORAL

SILDENAFIL CITRATE

<u>AB</u>		<u>EQ 25MG BASE</u>	<u>A206401 001</u>	Oct 12, 2018
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A206401 002</u>	Oct 12, 2018
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A206401 003</u>	Oct 12, 2018
<u>AB</u>	AMNEAL PHARMS	<u>EQ 20MG BASE</u>	<u>A202025 001</u>	Feb 28, 2013
<u>AB</u>	AMNEAL PHARMS NY	<u>EQ 25MG BASE</u>	<u>A202023 001</u>	Jun 27, 2018
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A202023 002</u>	Jun 27, 2018
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A202023 003</u>	Jun 27, 2018
<u>AB</u>	APPCO	<u>EQ 25MG BASE</u>	<u>A207178 001</u>	Mar 02, 2020
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A207178 002</u>	Mar 02, 2020
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A207178 003</u>	Mar 02, 2020
<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 20MG BASE</u>	<u>A203963 001</u>	Nov 18, 2015
<u>AB</u>		<u>EQ 25MG BASE</u>	<u>A203962 001</u>	Jun 11, 2018
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A203962 002</u>	Jun 11, 2018
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A203962 003</u>	Jun 11, 2018
<u>AB</u>	CHARTWELL RX	<u>EQ 20MG BASE</u>	<u>A202598 001</u>	Nov 06, 2012
<u>AB</u>	HETERO LABS LTD V	<u>EQ 20MG BASE</u>	<u>A203623 001</u>	Nov 26, 2014
<u>AB</u>		<u>EQ 25MG BASE</u>	<u>A202659 001</u>	Jun 11, 2018
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A202659 002</u>	Jun 11, 2018
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A202659 003</u>	Jun 11, 2018
<u>AB</u>	LUPIN LTD	<u>EQ 25MG BASE</u>	<u>A212051 001</u>	Mar 22, 2019
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A212051 002</u>	Mar 22, 2019
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A212051 003</u>	Mar 22, 2019
<u>AB</u>	MACLEODS PHARMS LTD	<u>EQ 20MG BASE</u>	<u>A203814 001</u>	Dec 17, 2013
<u>AB</u>	MYLAN	<u>EQ 25MG BASE</u>	<u>A201171 001</u>	Mar 25, 2019
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A201171 002</u>	Mar 25, 2019
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A201171 003</u>	Mar 25, 2019
<u>AB</u>	MYLAN PHARMS INC	<u>EQ 20MG BASE</u>	<u>A201150 001</u>	Nov 09, 2012
<u>AB</u>	REYOUNG	<u>EQ 25MG BASE</u>	<u>A208494 001</u>	Jun 12, 2020
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A208494 002</u>	Jun 12, 2020
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A208494 003</u>	Jun 12, 2020
<u>AB</u>	RUBICON	<u>EQ 20MG BASE</u>	<u>A204883 001</u>	Jun 20, 2016
<u>AB</u>		<u>EQ 25MG BASE</u>	<u>A204882 001</u>	Jun 11, 2018
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A204882 002</u>	Jun 11, 2018
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A204882 003</u>	Jun 11, 2018
<u>AB</u>	SUNSHINE	<u>EQ 25MG BASE</u>	<u>A213032 001</u>	Jun 11, 2020
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A213032 002</u>	Jun 11, 2020
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A213032 003</u>	Jun 11, 2020
<u>AB</u>	TEVA	<u>EQ 25MG BASE</u>	<u>A077342 001</u>	Mar 09, 2016
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A077342 002</u>	Mar 09, 2016
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A077342 003</u>	Mar 09, 2016
<u>AB</u>	TEVA PHARMS	<u>EQ 20MG BASE</u>	<u>A078380 001</u>	Jan 07, 2013
<u>AB</u>	TORRENT	<u>EQ 25MG BASE</u>	<u>A091448 001</u>	Jun 11, 2018
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A091448 002</u>	Jun 11, 2018
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A091448 003</u>	Jun 11, 2018
<u>AB</u>	TORRENT PHARMS LTD	<u>EQ 20MG BASE</u>	<u>A091479 001</u>	Nov 06, 2012
<u>AB</u>	UMEDICA LABS PVT LTD	<u>EQ 25MG BASE</u>	<u>A209302 003</u>	Jun 15, 2021
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A209302 001</u>	Aug 25, 2020
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A209302 002</u>	Aug 25, 2020
<u>AB</u>	WATSON LABS INC	<u>EQ 20MG BASE</u>	<u>A202503 001</u>	Nov 06, 2012
<u>VIAGRA</u>				
<u>AB</u>	+	<u>EQ 25MG BASE</u>	<u>N020895 001</u>	Mar 27, 1998
<u>AB</u>	+	<u>EQ 50MG BASE</u>	<u>N020895 002</u>	Mar 27, 1998
<u>AB</u>	+	<u>EQ 100MG BASE</u>	<u>N020895 003</u>	Mar 27, 1998

SILODOSIN

CAPSULE; ORAL

RAPAFLO

<u>AB</u>	+	ALLERGAN	<u>4MG</u>	<u>N022206 001</u>	Oct 08, 2008
<u>AB</u>	+		<u>8MG</u>	<u>N022206 002</u>	Oct 08, 2008
<u>SILODOSIN</u>					
<u>AB</u>		AJANTA PHARMA LTD	<u>4MG</u>	<u>A211060 001</u>	Dec 03, 2018
<u>AB</u>			<u>8MG</u>	<u>A211060 002</u>	Dec 03, 2018
<u>AB</u>		AMNEAL PHARMS CO	<u>4MG</u>	<u>A209745 001</u>	Dec 03, 2018
<u>AB</u>			<u>8MG</u>	<u>A209745 002</u>	Dec 03, 2018
<u>AB</u>		AUROBINDO PHARMA LTD	<u>4MG</u>	<u>A210626 001</u>	Dec 10, 2018
<u>AB</u>			<u>8MG</u>	<u>A210626 002</u>	Dec 10, 2018
<u>AB</u>		HETERO LABS LTD V	<u>4MG</u>	<u>A204793 001</u>	Feb 14, 2020

PRESCRIPTION DRUG PRODUCT LIST

3-413 (of 474)

SILODOSIN

CAPSULE;ORAL

SILODOSIN

<u>AB</u>		<u>8MG</u>	<u>A204793</u>	<u>002</u>	Feb 14, 2020
<u>AB</u>	LUPIN LTD	<u>4MG</u>	<u>A206541</u>	<u>001</u>	Dec 03, 2018
<u>AB</u>		<u>8MG</u>	<u>A206541</u>	<u>002</u>	Dec 03, 2018
<u>AB</u>	MACLEODS PHARMS LTD	<u>4MG</u>	<u>A211166</u>	<u>001</u>	Dec 03, 2018
<u>AB</u>		<u>8MG</u>	<u>A211166</u>	<u>002</u>	Dec 03, 2018
<u>AB</u>	MSN	<u>4MG</u>	<u>A210687</u>	<u>001</u>	Dec 03, 2018
<u>AB</u>		<u>8MG</u>	<u>A210687</u>	<u>002</u>	Dec 03, 2018
<u>AB</u>	PRINSTON INC	<u>4MG</u>	<u>A209029</u>	<u>001</u>	Jan 04, 2022
<u>AB</u>		<u>8MG</u>	<u>A209029</u>	<u>002</u>	Jan 04, 2022
<u>AB</u>	SANDOZ INC	<u>4MG</u>	<u>A204726</u>	<u>001</u>	Mar 31, 2017
<u>AB</u>		<u>8MG</u>	<u>A204726</u>	<u>002</u>	Mar 31, 2017
<u>AB</u>	ZYDUS PHARMS	<u>4MG</u>	<u>A204816</u>	<u>001</u>	Dec 08, 2022
<u>AB</u>		<u>8MG</u>	<u>A204816</u>	<u>002</u>	Dec 08, 2022

SILVER SULFADIAZINE

CREAM;TOPICAL

SILVADENE

<u>AB</u>	+! KING PHARMS LLC	<u>1%</u>	<u>N017381</u>	<u>001</u>	
<u>AB</u>					
<u>AB</u>	DR REDDYS LA	<u>1%</u>	<u>N018578</u>	<u>001</u>	Feb 25, 1982
<u>AB</u>					
<u>AB</u>	THEPHARMANETWORK LLC	<u>1%</u>	<u>N018810</u>	<u>001</u>	Dec 23, 1985

SIMVASTATIN

SUSPENSION;ORAL

FLOLIPID

+	TCG FLUENT PHARMA	20MG/5ML	N206679	001	Apr 21, 2016
+	!	40MG/5ML	N206679	002	Apr 21, 2016

TABLET;ORAL

SIMVASTATIN

<u>AB</u>	ACCORD HLTHCARE	<u>5MG</u>	<u>A078155</u>	<u>005</u>	Apr 05, 2013
<u>AB</u>		<u>10MG</u>	<u>A078155</u>	<u>002</u>	Feb 26, 2008
<u>AB</u>		<u>20MG</u>	<u>A078155</u>	<u>003</u>	Feb 26, 2008
<u>AB</u>		<u>40MG</u>	<u>A078155</u>	<u>004</u>	Feb 26, 2008
<u>AB</u>		<u>80MG</u>	<u>A078155</u>	<u>001</u>	Feb 26, 2008
<u>AB</u>	AUROBINDO PHARMA	<u>5MG</u>	<u>A077691</u>	<u>001</u>	Dec 20, 2006
<u>AB</u>		<u>10MG</u>	<u>A077691</u>	<u>002</u>	Dec 20, 2006
<u>AB</u>		<u>20MG</u>	<u>A077691</u>	<u>003</u>	Dec 20, 2006
<u>AB</u>		<u>40MG</u>	<u>A077691</u>	<u>004</u>	Dec 20, 2006
<u>AB</u>		<u>80MG</u>	<u>A077691</u>	<u>005</u>	Dec 20, 2006
<u>AB</u>	BIOCON PHARMA	<u>5MG</u>	<u>A078034</u>	<u>001</u>	Dec 20, 2006
<u>AB</u>		<u>10MG</u>	<u>A078034</u>	<u>002</u>	Dec 20, 2006
<u>AB</u>		<u>20MG</u>	<u>A078034</u>	<u>003</u>	Dec 20, 2006
<u>AB</u>		<u>40MG</u>	<u>A078034</u>	<u>004</u>	Dec 20, 2006
<u>AB</u>		<u>80MG</u>	<u>A078034</u>	<u>005</u>	Dec 20, 2006
<u>AB</u>	DR REDDYS LABS INC	<u>5MG</u>	<u>A077752</u>	<u>005</u>	Jan 23, 2008
<u>AB</u>		<u>10MG</u>	<u>A077752</u>	<u>001</u>	Dec 20, 2006
<u>AB</u>		<u>20MG</u>	<u>A077752</u>	<u>002</u>	Dec 20, 2006
<u>AB</u>		<u>40MG</u>	<u>A077752</u>	<u>003</u>	Dec 20, 2006
<u>AB</u>		<u>80MG</u>	<u>A077752</u>	<u>004</u>	Dec 20, 2006
<u>AB</u>	HETERO LABS LTD III	<u>5MG</u>	<u>A200895</u>	<u>001</u>	Nov 25, 2014
<u>AB</u>		<u>10MG</u>	<u>A200895</u>	<u>002</u>	Nov 25, 2014
<u>AB</u>		<u>20MG</u>	<u>A200895</u>	<u>003</u>	Nov 25, 2014
<u>AB</u>		<u>40MG</u>	<u>A200895</u>	<u>004</u>	Nov 25, 2014
<u>AB</u>		<u>80MG</u>	<u>A200895</u>	<u>005</u>	Nov 25, 2014
<u>AB</u>	HISUN PHARM HANGZHOU	<u>10MG</u>	<u>A206557</u>	<u>001</u>	Nov 13, 2017
<u>AB</u>		<u>20MG</u>	<u>A206557</u>	<u>002</u>	Nov 13, 2017
<u>AB</u>		<u>40MG</u>	<u>A206557</u>	<u>003</u>	Nov 13, 2017
<u>AB</u>		<u>80MG</u>	<u>A206557</u>	<u>004</u>	Nov 13, 2017
<u>AB</u>	LUPIN	<u>5MG</u>	<u>A078103</u>	<u>005</u>	Apr 14, 2009
<u>AB</u>		<u>10MG</u>	<u>A078103</u>	<u>001</u>	May 11, 2007
<u>AB</u>		<u>20MG</u>	<u>A078103</u>	<u>002</u>	May 11, 2007
<u>AB</u>		<u>40MG</u>	<u>A078103</u>	<u>003</u>	May 11, 2007
<u>AB</u>	!	<u>80MG</u>	<u>A078103</u>	<u>004</u>	May 11, 2007
<u>AB</u>	MICRO LABS	<u>5MG</u>	<u>A090383</u>	<u>001</u>	Sep 16, 2011
<u>AB</u>		<u>10MG</u>	<u>A090383</u>	<u>002</u>	Sep 16, 2011
<u>AB</u>		<u>20MG</u>	<u>A090383</u>	<u>003</u>	Sep 16, 2011
<u>AB</u>		<u>40MG</u>	<u>A090383</u>	<u>004</u>	Sep 16, 2011
<u>AB</u>		<u>80MG</u>	<u>A090383</u>	<u>005</u>	Sep 16, 2011

PRESCRIPTION DRUG PRODUCT LIST

3-414 (of 474)

SIMVASTATIN

TABLET; ORAL

SIMVASTATIN

<u>AB</u>	OXFORD PHARMS	<u>5MG</u>	<u>A078735</u>	<u>001</u>	Aug 30, 2010
<u>AB</u>		<u>10MG</u>	<u>A078735</u>	<u>002</u>	Aug 30, 2010
<u>AB</u>		<u>20MG</u>	<u>A078735</u>	<u>003</u>	Aug 30, 2010
<u>AB</u>		<u>40MG</u>	<u>A078735</u>	<u>004</u>	Aug 30, 2010
<u>AB</u>		<u>80MG</u>	<u>A078735</u>	<u>005</u>	Aug 30, 2010
<u>AB</u>	WATSON LABS TEVA	<u>5MG</u>	<u>A076685</u>	<u>001</u>	Dec 20, 2006
<u>AB</u>		<u>10MG</u>	<u>A076685</u>	<u>002</u>	Dec 20, 2006
<u>AB</u>		<u>20MG</u>	<u>A076685</u>	<u>003</u>	Dec 20, 2006
<u>AB</u>		<u>40MG</u>	<u>A076685</u>	<u>004</u>	Dec 20, 2006
<u>AB</u>		<u>80MG</u>	<u>A076685</u>	<u>005</u>	Dec 20, 2006
<u>AB</u>	ZYDUS PHARMS USA	<u>5MG</u>	<u>A077837</u>	<u>001</u>	Dec 20, 2006
<u>AB</u>		<u>10MG</u>	<u>A077837</u>	<u>002</u>	Dec 20, 2006
<u>AB</u>		<u>20MG</u>	<u>A077837</u>	<u>003</u>	Dec 20, 2006
<u>AB</u>		<u>40MG</u>	<u>A077837</u>	<u>004</u>	Dec 20, 2006
<u>AB</u>		<u>80MG</u>	<u>A077837</u>	<u>005</u>	Dec 20, 2006
<u>ZOCOR</u>					
<u>AB</u>	+	ORGANON	<u>5MG</u>	<u>N019766</u>	<u>001</u> Dec 23, 1991
<u>AB</u>	+		<u>10MG</u>	<u>N019766</u>	<u>002</u> Dec 23, 1991
<u>AB</u>	+		<u>20MG</u>	<u>N019766</u>	<u>003</u> Dec 23, 1991
<u>AB</u>	+		<u>40MG</u>	<u>N019766</u>	<u>004</u> Dec 23, 1991

SINCALIDE

INJECTABLE; INJECTION

KINEVAC

+! BRACCO

0.005MG/VIAL

N017697 001

POWDER; INTRAVENOUS

SINCALIDE

+! MAIA PHARMS INC

0.005MG/VIAL

N210850 001 Nov 22, 2022

SINECATECHINS

OINTMENT; TOPICAL

VEREGEN

+! ANI PHARMS

15%

N021902 001 Oct 31, 2006

SIPONIMOD FUMARIC ACID

TABLET; ORAL

MAYZENT

+ NOVARTIS

EQ 0.25MG BASE

N209884 001 Mar 26, 2019

+

EQ 1MG BASE

N209884 003 Aug 24, 2021

+!

EQ 2MG BASE

N209884 002 Mar 26, 2019

SIROLIMUS

GEL; TOPICAL

HYFTOR

+! NOBELPHARMA

0.2%

N213478 001 Mar 22, 2022

POWDER; INTRAVENOUS

FYARRO

+! AADI

100MG/VIAL

N213312 001 Nov 22, 2021

SOLUTION; ORAL

RAPAMUNE

<u>AA</u>	+	PF PRISM CV	<u>1MG/ML</u>	<u>N021083</u>	<u>001</u> Sep 15, 1999
<u>SIROLIMUS</u>					
<u>AA</u>		AMNEAL	<u>1MG/ML</u>	<u>A211212</u>	<u>001</u> Oct 18, 2019
<u>AA</u>		APOTEX	<u>1MG/ML</u>	<u>A211406</u>	<u>001</u> Oct 22, 2019
<u>AA</u>		NOVITIUM PHARMA	<u>1MG/ML</u>	<u>A211040</u>	<u>001</u> Jan 28, 2019

TABLET; ORAL

RAPAMUNE

<u>AB</u>	+	PF PRISM CV	<u>0.5MG</u>	<u>N021110</u>	<u>004</u> Jan 25, 2010
<u>AB</u>	+		<u>1MG</u>	<u>N021110</u>	<u>001</u> Aug 25, 2000
<u>AB</u>	+	!	<u>2MG</u>	<u>N021110</u>	<u>002</u> Aug 22, 2002

SIROLIMUS

<u>AB</u>		ALKEM LABS LTD	<u>0.5MG</u>	<u>A214753</u>	<u>001</u> Mar 12, 2021
<u>AB</u>			<u>1MG</u>	<u>A214753</u>	<u>002</u> Mar 12, 2021
<u>AB</u>			<u>2MG</u>	<u>A214753</u>	<u>003</u> Mar 12, 2021
<u>AB</u>		DR REDDYS	<u>1MG</u>	<u>A201578</u>	<u>001</u> Oct 27, 2014
<u>AB</u>			<u>2MG</u>	<u>A201578</u>	<u>002</u> Oct 27, 2014
<u>AB</u>		GLENMARK PHARMS LTD	<u>0.5MG</u>	<u>A208691</u>	<u>001</u> Oct 16, 2020
<u>AB</u>			<u>1MG</u>	<u>A208691</u>	<u>002</u> Oct 16, 2020
<u>AB</u>			<u>2MG</u>	<u>A208691</u>	<u>003</u> Oct 16, 2020
<u>AB</u>		ZYDUS PHARMS	<u>0.5MG</u>	<u>A201676</u>	<u>003</u> Jan 08, 2014

PRESCRIPTION DRUG PRODUCT LIST

3-415 (of 474)

SITAGLIPTIN PHOSPHATE

TABLET; ORAL

JANUVIA

+	MERCK SHARP DOHME	EQ 25MG BASE	N021995	001	Oct 16, 2006
+		EQ 50MG BASE	N021995	002	Oct 16, 2006
+		EQ 100MG BASE	N021995	003	Oct 16, 2006

SODIUM ACETATE

INJECTABLE; INJECTION

SODIUM ACETATE

AP	+	HOSPIRA	2MEQ/ML	N018893	001	May 04, 1983
AP		MILLA PHARMS	2MEQ/ML	A214805	001	May 04, 2021
		FRESENIUS KABI USA	4MEQ/ML	A206687	001	Oct 30, 2017

SODIUM BENZOATE; SODIUM PHENYLACETATE

SOLUTION; INTRAVENOUS

AMMONUL

AP	+	BAUSCH	10%;10% (5GM/50ML;5GM/50ML)	N020645	001	Feb 17, 2005

SODIUM PHENYLACETATE AND SODIUM BENZOATE

AP		AILEX PHARMS LLC	10%;10% (5GM/50ML;5GM/50ML)	A207096	001	Feb 24, 2016
AP		MAIA PHARMS INC	10%;10% (5GM/50ML;5GM/50ML)	A208521	001	May 08, 2017
AP		NAVINTA LLC	10%;10% (5GM/50ML;5GM/50ML)	A205880	001	Aug 04, 2016
	+	MAIA PHARMS INC	10%;10% (2GM/20ML;2GM/20ML)	N215025	001	Jun 10, 2021

SODIUM BICARBONATE

INJECTABLE; INJECTION

SODIUM BICARBONATE

AP	!	EXELA PHARMA	0.5MEQ/ML	A211091	001	Jun 20, 2019
AP	!		0.9MEQ/ML	A211091	002	Jun 20, 2019
AP	!		1MEQ/ML	A211091	003	Jun 20, 2019
AP		HOSPIRA	0.5MEQ/ML	A202679	001	Mar 07, 2017
AP	!		0.5MEQ/ML	A202981	001	Mar 04, 2016
AP			0.9MEQ/ML	A202494	001	Mar 06, 2017
AP			1MEQ/ML	A202432	001	Sep 26, 2017
AP			1MEQ/ML	A202494	002	Mar 06, 2017
AP		INTL MEDICATION SYS	1MEQ/ML	A203449	001	Sep 19, 2017
		HOSPIRA	1MEQ/ML	A202495	001	Mar 06, 2017

SODIUM CHLORIDE

INJECTABLE; INJECTION

BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP		FRESENIUS KABI USA	9MG/ML	A088911	001	Feb 07, 1985
AP	+	HOSPIRA	9MG/ML	N018800	001	Oct 29, 1982

SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	+	B BRAUN	450MG/100ML	N019635	001	Mar 09, 1988
AP	+	BAXTER HLTHCARE	450MG/100ML	N018016	001	
AP		FRESENIUS KABI USA	450MG/100ML	A208122	001	Jul 23, 2018
AP		HOSPIRA	450MG/100ML	N019759	001	Jun 08, 1988
AP	+	ICU MEDICAL INC	450MG/100ML	N018090	001	

SODIUM CHLORIDE 0.9%

AP		HIKMA	9MG/ML	A201850	001	Jan 20, 2012
AP		SPECTRA MDCL DEVICES	9MG/ML	A206171	001	Jul 21, 2017

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	+	B BRAUN	900MG/100ML	N017464	001	
AP	+		900MG/100ML	N019635	002	Mar 09, 1988
AP	+	BAXTER HLTHCARE	9MG/ML	N016677	004	Oct 30, 1985
AP	+		9MG/ML	N020178	002	Dec 07, 1992
AP	+		900MG/100ML	N016677	001	
AP	+		900MG/100ML	N020178	001	Dec 07, 1992
AP	!	FRESENIUS KABI USA	9MG/ML	A088912	001	Jan 10, 1985
AP			900MG/100ML	A207310	001	Sep 19, 2017
AP		FRESENIUS MEDCL	900MG/100ML	A078177	001	Apr 12, 2007
AP		HAEMONETICS	900MG/100ML	A076316	001	Oct 27, 2004
AP	+	HOSPIRA	9MG/ML	N018803	001	Oct 29, 1982
AP	+		9MG/ML	N019465	002	Jul 15, 1985
AP	+		900MG/100ML	N019465	001	Jul 15, 1985
AP	+		900MG/100ML	N019480	001	Sep 17, 1985
AP	+	ICU MEDICAL INC	900MG/100ML	N016366	001	
AP		LABORATORIOS GRIFOLS	900MG/100ML	A207956	001	May 25, 2017
AP		NEPHRON	9MG/ML	A211968	001	Apr 23, 2020
AP	!	TARO	9MG/ML	A077407	001	Aug 11, 2006

PRESCRIPTION DRUG PRODUCT LIST

3-416 (of 474)

SODIUM CHLORIDE

INJECTABLE; INJECTION

SODIUM CHLORIDE 3% IN PLASTIC CONTAINER

<u>AP</u>	B BRAUN	<u>3GM/100ML</u>	<u>N019635</u>	<u>003</u>	Mar 09, 1988
<u>AP</u>	+! BAXTER HLTHCARE	<u>3GM/100ML</u>	<u>N019022</u>	<u>001</u>	Nov 01, 1983
<u>AP</u>	FRESENIUS KABI USA	<u>3GM/100ML</u>	<u>A209476</u>	<u>001</u>	Mar 13, 2019

SODIUM CHLORIDE 5% IN PLASTIC CONTAINER

<u>AP</u>	B BRAUN	<u>5GM/100ML</u>	<u>N019635</u>	<u>004</u>	Mar 09, 1988
<u>AP</u>	+ BAXTER HLTHCARE	<u>5GM/100ML</u>	<u>N019022</u>	<u>002</u>	Nov 01, 1983
	SODIUM CHLORIDE 0.9%				
	+ B BRAUN	9MG/10ML	N019635	005	Aug 08, 2016
	HIKMA	9MG/ML	A201833	001	Sep 24, 2013
	+! MEDEFIL INC	90MG/10ML (9MG/ML)	N202832	006	Jan 06, 2012
	SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
	+ LIEBEL-FLARSHEIM	1012.5MG/125ML (9MG/ML)	N021569	002	Jul 27, 2006
	SODIUM CHLORIDE 23.4%				
	FRESENIUS KABI USA	234MG/ML	A212248	001	Apr 28, 2021

SOLUTION; INTRAVENOUS

SODIUM CHLORIDE 14.6%

<u>AP</u>	FRESENIUS KABI USA	<u>100MEQ/40ML (2.5MEQ/ML)</u>	<u>A212070</u>	<u>002</u>	Apr 28, 2021
<u>AP</u>	+! HOSPIRA	<u>100MEQ/40ML (2.5MEQ/ML)</u>	<u>N018897</u>	<u>002</u>	Jul 20, 1984

SODIUM CHLORIDE 23.4%

<u>AP</u>	FRESENIUS KABI USA	<u>400MEQ/100ML (4MEQ/ML)</u>	<u>A212070</u>	<u>003</u>	Feb 14, 2022
<u>AP</u>	+! HOSPIRA	<u>400MEQ/100ML (4MEQ/ML)</u>	<u>N018897</u>	<u>003</u>	Jun 18, 2020
	SODIUM CHLORIDE 14.6%				
	FRESENIUS KABI USA	50MEQ/20ML (2.5MEQ/ML)	A212070	001	Apr 28, 2021

SOLUTION; IRRIGATION

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

<u>AT</u>	+! B BRAUN	<u>900MG/100ML</u>	<u>N016733</u>	<u>001</u>	
<u>AT</u>	BAXTER HLTHCARE	<u>900MG/100ML</u>	<u>N017427</u>	<u>001</u>	
<u>AT</u>		<u>900MG/100ML</u>	<u>N017867</u>	<u>001</u>	
<u>AT</u>	+ ICU MEDICAL INC	<u>900MG/100ML</u>	<u>N017514</u>	<u>001</u>	
<u>AT</u>		<u>900MG/100ML</u>	<u>N018314</u>	<u>001</u>	

SOLUTION FOR SLUSH; IRRIGATION

SODIUM CHLORIDE 0.9% IN STERILE PLASTIC CONTAINER

	+! BAXTER HLTHCARE	900MG/100ML	N019319	002	May 17, 1985

SODIUM FLUORIDE F-18

INJECTABLE; INTRAVENOUS

SODIUM FLUORIDE F-18

<u>AP</u>	3D IMAGING DRUG	<u>10-200mCi/ML</u>	<u>A203777</u>	<u>001</u>	Oct 19, 2015
<u>AP</u>	BAMF	<u>10-200mCi/ML</u>	<u>A216126</u>	<u>001</u>	Dec 06, 2022
<u>AP</u>	BIOMEDCL RES FDN	<u>10-200mCi/ML</u>	<u>A204351</u>	<u>001</u>	Jan 09, 2015
<u>AP</u>	CARDINAL HEALTH 414	<u>10-200mCi/ML</u>	<u>A203780</u>	<u>001</u>	Jul 30, 2015
<u>AP</u>	ESSENTIAL ISOTOPE	<u>10-200mCi/ML</u>	<u>A204541</u>	<u>001</u>	Oct 29, 2014
<u>AP</u>	HOT SHOTS NM LLC	<u>10-200mCi/ML</u>	<u>A204530</u>	<u>001</u>	Jul 29, 2015
<u>AP</u>	JUBILANT DRAXIMAGE	<u>10-200mCi/ML</u>	<u>A203968</u>	<u>001</u>	Oct 23, 2015
<u>AP</u>	KREITCHMAN PET CTR	<u>10-200mCi/ML</u>	<u>A203936</u>	<u>001</u>	May 19, 2016
<u>AP</u>	MIDWEST MEDCL	<u>10-200mCi/ML</u>	<u>A204440</u>	<u>001</u>	Nov 17, 2015
<u>AP</u>	MIPS CRF	<u>10-200mCi/ML</u>	<u>A204517</u>	<u>001</u>	Jul 21, 2015
<u>AP</u>	NCM USA BRONX LLC	<u>10-200mCi/ML</u>	<u>A204513</u>	<u>001</u>	Nov 28, 2014
<u>AP</u>	NUKEMED	<u>10-200mCi/ML</u>	<u>A203912</u>	<u>001</u>	Apr 22, 2015
<u>AP</u>	PETNET	<u>10-200mCi/ML</u>	<u>A203890</u>	<u>001</u>	Sep 28, 2015
<u>AP</u>	PRECISION NUCLEAR	<u>10-200mCi/ML</u>	<u>A204542</u>	<u>001</u>	Feb 27, 2015
<u>AP</u>	SHERTECH LABS LLC	<u>10-200mCi/ML</u>	<u>A204315</u>	<u>001</u>	Sep 22, 2014
<u>AP</u>	SOFIE	<u>10-200mCi/ML</u>	<u>A203592</u>	<u>001</u>	Aug 18, 2015
<u>AP</u>	!	<u>10-200mCi/ML</u>	<u>A203544</u>	<u>001</u>	Dec 26, 2012
<u>AP</u>	UNIV UTAH CYCLOTRON	<u>10-200mCi/ML</u>	<u>A204497</u>	<u>001</u>	Apr 20, 2015
	! MCPRF	10-91.5mCi/ML	A203605	001	Jun 28, 2013
	THE FEINSTEIN INST	20-600mCi/ML	A204328	001	Nov 19, 2014

SODIUM IODIDE I-123

CAPSULE; ORAL

SODIUM IODIDE I 123

<u>AA</u>	+! CARDINAL HEALTH 418	<u>100uCi</u>	<u>N018671</u>	<u>001</u>	May 27, 1982
<u>AA</u>	+!	<u>200uCi</u>	<u>N018671</u>	<u>002</u>	May 27, 1982
<u>AA</u>	CURIUM	<u>100uCi</u>	<u>A071909</u>	<u>001</u>	Feb 28, 1989
<u>AA</u>		<u>200uCi</u>	<u>A071910</u>	<u>001</u>	Feb 28, 1989

PRESCRIPTION DRUG PRODUCT LIST

3-417 (of 474)

SODIUM IODIDE I-131

CAPSULE; ORAL

SODIUM IODIDE I 131

+ JUBILANT

0.009-0.1mCi

N021305 006 May 19, 2005

SOLUTION; ORAL

HICON**AA** +! JUBILANT**250-1000mCi****N021305 007** Dec 05, 2011SODIUM IODIDE I 131**AA** INTL ISOTOPES**250-1000mCi****A209166 001** Feb 05, 2020SODIUM NITRITE

SOLUTION; INTRAVENOUS

SODIUM NITRITE

+! HOPE PHARMS

300MG/10ML (30MG/ML)

N203922 001 Feb 14, 2012

SODIUM NITRITE; SODIUM THIOSULFATE

SOLUTION, SOLUTION; INTRAVENOUS, INTRAVENOUS

NITHIODE

+! HOPE PHARMS

300MG/10ML (30MG/ML), N/A; N/A, 12.5GM/50ML
(250MG/ML)

N201444 001 Jan 14, 2011

SODIUM NITROPRUSSIDE

INJECTABLE; INJECTION

SODIUM NITROPRUSSIDE**AP** AMNEAL**25MG/ML****A209493 001** Nov 07, 2017**AP** BE PHARMS**25MG/ML****A214971 001** Jul 12, 2021**AP** CAPLIN**25MG/ML****A211016 001** Nov 29, 2019**AP** DR REDDYS**25MG/ML****A210114 001** Apr 10, 2019**AP** HAINAN POLY PHARM**25MG/ML****A214199 001** Aug 25, 2020**AP** MEDICURE**25MG/ML****A209584 001** Aug 10, 2018**AP** ! MICRO LABS**25MG/ML****A209352 001** Dec 08, 2017**AP** MYLAN LABS LTD**25MG/ML****A210763 001** Apr 17, 2018**AP** NEXUS PHARMS**25MG/ML****A207499 001** May 25, 2017**AP** SAGENT PHARMS INC**25MG/ML****A207426 001** Dec 08, 2016**AP** SOMERSET THERAPS**25MG/ML****A210882 001** Aug 17, 2018

LLC

AP XIROMED**25MG/ML****A211277 001** Oct 29, 2020

SOLUTION; INTRAVENOUS

NIPRIDE RTU IN SODIUM CHLORIDE 0.9%**AP** +! EXELA PHARMA**20MG/100ML (0.2MG/ML)****N209387 003** Jul 13, 2018**AP** +!**50MG/100ML (0.5MG/ML)****N209387 001** Mar 08, 2017SODIUM NITROPRUSSIDE**AP** HAINAN POLY**20MG/100ML (0.2MG/ML)****A215846 002** Aug 26, 2022**AP****50MG/100ML (0.5MG/ML)****A215846 003** Aug 26, 2022

10MG/50ML (0.2MG/ML)

A215846 001 Aug 26, 2022

SODIUM OXYBATE

SOLUTION; ORAL

XYREM

+! JAZZ PHARMS

0.5GM/ML

N021196 001 Jul 17, 2002

SODIUM PHENYLBUTYRATE

FOR SUSPENSION; ORAL

OLPRUVA

+ ACER

2GM/PACKET

N214860 001 Dec 22, 2022

+

3GM/PACKET

N214860 002 Dec 22, 2022

+

4GM/PACKET

N214860 003 Dec 22, 2022

+

5GM/PACKET

N214860 004 Dec 22, 2022

+

6GM/PACKET

N214860 005 Dec 22, 2022

+!

6.67GM/PACKET

N214860 006 Dec 22, 2022

PELLETS; ORAL

PHEBURANE

+! MEDUNIK

84GM/BOT

N216513 001 Jun 17, 2022

POWDER; ORAL

BUPHENYL**AB** +! HORIZON THERAP**3GM/TEASPOONFUL****N020573 001** Apr 30, 1996SODIUM PHENYLBUTYRATE**AB** PAR PHARM**3GM/TEASPOONFUL****A203918 001** Jun 15, 2016**AB** SIGMAPHARM LABS LLC**3GM/TEASPOONFUL****A202819 001** Mar 22, 2013

TABLET; ORAL

BUPHENYL**AB** +! HORIZON THERAP**500MG****N020572 001** May 13, 1996SODIUM PHENYLBUTYRATE**AB** GLENMARK PHARMS LTD**500MG****A216462 001** Nov 01, 2022**AB** PAR PHARM**500MG****A204395 001** Apr 15, 2016

PRESCRIPTION DRUG PRODUCT LIST

3-418 (of 474)

SODIUM PHENYLBUTYRATE; TAURURSODIOL

FOR SUSPENSION; ORAL

RELYVRIO

+! AMYLYX

3GM/PACKET; 1GM/PACKET

N216660 001 Sep 29, 2022

SODIUM PHOSPHATE, DIBASIC, ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE

TABLET; ORAL

MONOBASIC SODIUM PHOSPHATE AND DIBASIC SODIUM PHOSPHATE**AB** NOVEL LABS INC0.398GM;1.102GM**A079247 001** Dec 30, 2011OSMOPREP**AB** +! SALIX PHARMS0.398GM;1.102GM**N021892 001** Mar 16, 2006SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS

INJECTABLE; INJECTION

SODIUM PHOSPHATES**AP** FRESENIUS KABI USA142MG/ML;276MG/ML**A209997 001** Mar 30, 2022SODIUM PHOSPHATES IN PLASTIC CONTAINER**AP** +! HOSPIRA142MG/ML;276MG/ML**N018892 001** May 10, 1983SODIUM POLYSTYRENE SULFONATE

POWDER; ORAL, RECTAL

KALEXATE**AA** ! KVK TECH454GM/BOT**A040905 001** Mar 30, 2009KIONEX**AA** ANI PHARMS454GM/BOT**A040029 001** Feb 06, 1998SODIUM POLYSTYRENE SULFONATE**AA** AIPING LIFE SCI453.6GM/BOT**A090313 001** Dec 21, 2011**AA** BELCHER454GM/BOT**A205727 001** Feb 23, 2016**AA** CHARTWELL RX454GM/BOT**A206815 001** Feb 18, 2016**AA** CMP PHARMA INC454GM/BOT**A089910 001** Jan 19, 1989**AA** EPIC PHARMA LLC453.6GM/BOT**A202333 001** Mar 19, 2014**AA** NUVO PHARMS INC454GM/BOT**A204071 001** Nov 28, 2014

KALEXATE

KVK TECH

15GM/BOT

A040905 002 Apr 03, 2015

SODIUM POLYSTYRENE SULFONATE

NUVO PHARMS INC

15GM/BOT

A204071 002 Nov 28, 2014

SUSPENSION; ORAL, RECTAL

KIONEX**AA** ANI PHARMS15GM/60ML**A040028 001** Sep 17, 2007SPS**AA** +! CMP PHARMA INC15GM/60ML**A087859 001** Dec 08, 1982SODIUM TETRADECYL SULFATE

INJECTABLE; INJECTION

SODIUM TETRADECYL SULFATE**AP** HIKMA60MG/2ML (30MG/ML)**A209937 001** Dec 09, 2019SOTRADECOL**AP** ! MYLAN INSTITUTIONAL60MG/2ML (30MG/ML)**A040541 002** Nov 12, 2004

!

20MG/2ML (10MG/ML)

A040541 001 Nov 12, 2004

SODIUM THIOSULFATE

SOLUTION; INTRAVENOUS

PEDMARK

+! FENNEC PHARMS INC

12.5GM/100ML (125MG/ML)

N212937 001 Sep 20, 2022

SODIUM THIOSULFATE

+! HOPE PHARMS

12.5GM/50ML (250MG/ML)

N203923 001 Feb 14, 2012

SODIUM ZIRCONIUM CYCLOSILICATE

FOR SUSPENSION; ORAL

LOKELMA

+ ASTRAZENECA

5GM/PACKET

N207078 001 May 18, 2018

+!

10GM/PACKET

N207078 002 May 18, 2018

SOFOSBUVIR

PELLETS; ORAL

SOVALDI

+ GILEAD SCIENCES INC

150MG/PACKET

N212480 001 Aug 28, 2019

+!

200MG/PACKET

N212480 002 Aug 28, 2019

TABLET; ORAL

SOVALDI

+ GILEAD SCIENCES INC

200MG

N204671 002 Aug 28, 2019

+!

400MG

N204671 001 Dec 06, 2013

PRESCRIPTION DRUG PRODUCT LIST

3-419 (of 474)

SOFOSBUVIR; VELPATASVIR

PELLETS; ORAL

EPCLUSA

+ GILEAD SCIENCES INC 150MG; 37.5MG/PACKET
 +! 200MG; 50MG/PACKET

N214187 001 Jun 10, 2021
 N214187 002 Jun 10, 2021

TABLET; ORAL

EPCLUSA

+ GILEAD SCIENCES INC 200MG; 50MG
 +! 400MG; 100MG

N208341 002 Mar 19, 2020
 N208341 001 Jun 28, 2016

SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR

TABLET; ORAL

VOSEVI

+! GILEAD SCIENCES INC 400MG; 100MG; 100MG

N209195 001 Jul 18, 2017

SOLIFENACIN SUCCINATE

SUSPENSION; ORAL

VESICARE LS

+! ASTELLAS 1MG/ML

N209529 001 May 26, 2020

TABLET; ORAL

SOLIFENACIN SUCCINATE

AB	ALEMBIC PHARMS	5MG	A205575 001	May 20, 2019
AB		10MG	A205575 002	May 20, 2019
AB	ALKEM LABS LTD	5MG	A210224 001	May 20, 2019
AB		10MG	A210224 002	May 20, 2019
AB	ANNORA PHARMA	5MG	A215761 001	Jun 15, 2022
AB		10MG	A215761 002	Jun 15, 2022
AB	AUROBINDO PHARMA	5MG	A206817 001	Dec 27, 2022
AB		10MG	A206817 002	Dec 27, 2022
AB	AUSTARPHARMA	5MG	A210281 001	May 20, 2019
AB		10MG	A210281 002	May 20, 2019
AB	CELLTRION	5MG	A210582 001	May 20, 2019
AB		10MG	A210582 002	May 20, 2019
AB	CIPLA	5MG	A209839 001	May 20, 2019
AB		10MG	A209839 002	May 20, 2019
AB	GLENMARK PHARMS INC	5MG	A209239 001	May 20, 2019
AB		10MG	A209239 002	May 20, 2019
AB	GRAVITI PHARMS	5MG	A211423 001	Dec 11, 2019
AB		10MG	A211423 002	Dec 11, 2019
AB	MSN	5MG	A210688 001	May 20, 2019
AB		10MG	A210688 002	May 20, 2019
AB	QILU	5MG	A209333 001	May 20, 2019
AB		10MG	A209333 002	May 20, 2019
AB	SCIEGEN PHARMS INC	5MG	A211657 001	May 20, 2019
AB		10MG	A211657 002	May 20, 2019
AB	STRIDES PHARMA	5MG	A212214 001	Sep 26, 2019
AB		10MG	A212214 002	Sep 26, 2019
AB	TEVA PHARMS USA	5MG	A091464 001	Apr 02, 2014
AB		10MG	A091464 002	Apr 02, 2014
AB	UNICHEM	5MG	A211701 001	Aug 27, 2019
AB		10MG	A211701 002	Aug 27, 2019
AB	WATSON LABS INC	5MG	A202551 001	May 20, 2019
AB		10MG	A202551 002	May 20, 2019
<u>VESICARE</u>				
AB	+ ASTELLAS	5MG	N021518 001	Nov 19, 2004
AB	+!	10MG	N021518 002	Nov 19, 2004

SOLRIAMFETOL HYDROCHLORIDE

TABLET; ORAL

SUNOSI

+ AXSOME MALTA EQ 75MG BASE
 +! EQ 150MG BASE

N211230 001 Jun 17, 2019
 N211230 002 Jun 17, 2019

SONIDEGIB PHOSPHATE

CAPSULE; ORAL

ODOMZO

+! SUN PHARM EQ 200MG BASE

N205266 001 Jul 24, 2015

SORAFENIB TOSYLATE

TABLET; ORAL

NEXAVAR

AB	+! BAYER HLTHCARE	EQ 200MG BASE	N021923 001	Dec 20, 2005
<u>SORAFENIB TOSYLATE</u>				
AB	DR REDDYS	EQ 200MG BASE	A216073 001	Jun 07, 2022
AB	MYLAN	EQ 200MG BASE	A207012 001	Sep 10, 2020

PRESCRIPTION DRUG PRODUCT LIST

3-420 (of 474)

SORAFENIB TOSYLATE

TABLET; ORAL

SORAFENIB TOSYLATE

AB	TEVA PHARMS USA INC	EQ 200MG BASE	A209567 001	Nov 12, 2020
AB	YABAO PHARM	EQ 200MG BASE	A209050 001	Nov 09, 2022

SORBITOL

SOLUTION; IRRIGATION

SORBITOL 3% IN PLASTIC CONTAINER

BAXTER HLTHCARE 3GM/100ML

N017863 001

SORBITOL 3.3% IN PLASTIC CONTAINER

B BRAUN 3.3GM/100ML

N016741 001

SOTALOL HYDROCHLORIDE

SOLUTION; INTRAVENOUS

SOTALOL HYDROCHLORIDE

+! ALTATHERA PHARMS LLC 150MG/10ML (15MG/ML)

N022306 001 Jul 02, 2009

SOLUTION; ORAL

SOTYLIZE

+! AZURITY 5MG/ML (5MG/ML)

N205108 001 Oct 22, 2014

TABLET; ORAL

BETAPACE

AB	+	LEGACY PHARMA	80MG	N019865 001	Oct 30, 1992
AB	+		120MG	N019865 005	Apr 20, 1994
AB	+	!	160MG	N019865 002	Oct 30, 1992
AB	+		240MG	N019865 003	Oct 30, 1992

BETAPACE AF

AB	+	LEGACY PHARMA	80MG	N021151 001	Feb 22, 2000
AB	+		120MG	N021151 002	Feb 22, 2000
AB	+	!	160MG	N021151 003	Feb 22, 2000

SORINE

AB	UPSHER SMITH LABS	80MG	A075500 001	Apr 27, 2001
AB		120MG	A075500 004	Apr 27, 2001
AB		160MG	A075500 002	Apr 27, 2001
AB		240MG	A075500 003	Apr 27, 2001

SOTALOL HYDROCHLORIDE

AB	APOTEX	80MG	A076140 001	Sep 26, 2002
AB		80MG	A076214 001	Aug 27, 2003
AB		120MG	A076140 002	Sep 26, 2002
AB		120MG	A076214 002	Aug 27, 2003
AB		160MG	A076140 003	Sep 26, 2002
AB		160MG	A076214 003	Aug 27, 2003
AB		240MG	A076140 004	Sep 26, 2002
AB	BEXIMCO PHARMS USA	80MG	A207428 001	Oct 21, 2016
AB		80MG	A207429 001	Nov 02, 2018
AB		120MG	A207428 002	Oct 21, 2016
AB		120MG	A207429 002	Nov 02, 2018
AB		160MG	A207428 003	Oct 21, 2016
AB		160MG	A207429 003	Nov 02, 2018
AB	EPIC PHARMA INC	80MG	A077070 001	Nov 04, 2005
AB		120MG	A077070 002	Nov 04, 2005
AB		160MG	A077070 003	Nov 04, 2005
AB	OXFORD PHARMS	80MG	A075563 001	Nov 07, 2003
AB		120MG	A075563 002	Nov 07, 2003
AB		160MG	A075563 003	Nov 07, 2003
AB		240MG	A075563 004	Nov 07, 2003
AB	TEVA	80MG	A075429 001	May 01, 2000
AB		120MG	A075429 002	May 01, 2000
AB		160MG	A075429 003	May 01, 2000
AB		240MG	A075429 004	May 01, 2000

SOTORASIB

TABLET; ORAL

LUMAKRAS

+! AMGEN INC 120MG

N214665 001 May 28, 2021

SOYBEAN OIL

INJECTABLE; INJECTION

INTRALIPID 10%

AP	+	FRESENIUS	10%	N017643 001

INTRALIPID 20%

AP	+	FRESENIUS	20%	N018449 001	
AP	+		20%	N020248 001	Aug 07, 1996

PRESCRIPTION DRUG PRODUCT LIST

3-421 (of 474)

SOYBEAN OIL

INJECTABLE; INJECTION

NUTRILIPID 10%

AP	+	B BRAUN	10%	N019531	001	May 28, 1993

NUTRILIPID 20%

AP	+	B BRAUN	20%	N019531	002	May 28, 1993

INTRALIPID 30%

	+	FRESENIUS	30%	N019942	001	Dec 30, 1993

SPINOSAD

SUSPENSION; TOPICAL

NATROBA

	+	PARAPRO LLC	0.9%	N022408	001	Jan 18, 2011

SPIRONOLACTONE

SUSPENSION; ORAL

CAROSPIR

	+	CMP DEV LLC	25MG/5ML	N209478	001	Aug 04, 2017

TABLET; ORAL

ALDACTONE

AB	+	PFIZER	25MG	N012151	009	Dec 30, 1983

AB	+		50MG	N012151	008	Dec 30, 1982

AB	+		100MG	N012151	010	Dec 30, 1983

SPIRONOLACTONE

AB		ACCORD HLTHCARE	25MG	A203512	001	Sep 19, 2016

AB			50MG	A203512	002	Sep 19, 2016

AB			100MG	A203512	003	Sep 19, 2016

AB		AMNEAL PHARMS	25MG	A091426	001	Jul 02, 2010

AB			50MG	A091426	002	Jul 02, 2010

AB			100MG	A091426	003	Jul 02, 2010

AB		AUROBINDO PHARMA	25MG	A202187	001	Mar 06, 2014

AB			50MG	A202187	002	Mar 06, 2014

AB			100MG	A202187	003	Mar 06, 2014

AB		JUBILANT GENERICS	25MG	A203253	001	Apr 23, 2014

AB			50MG	A203253	002	Apr 23, 2014

AB			100MG	A203253	003	Apr 23, 2014

AB		MYLAN	25MG	A040424	001	Aug 20, 2001

AB			50MG	A040424	002	Aug 20, 2001

AB			100MG	A040424	003	Aug 20, 2001

AB		OXFORD PHARMS	25MG	A040750	001	Aug 29, 2006

AB			50MG	A040750	002	Aug 29, 2006

AB			100MG	A040750	003	Aug 29, 2006

AB		SUN PHARM	25MG	A089424	001	Jul 23, 1986

		INDUSTRIES				

AB			50MG	A089424	002	Aug 11, 1999

AB			100MG	A089424	003	Aug 11, 1999

AB		ZYDUS PHARMS	25MG	A205936	001	Jul 18, 2018

AB			50MG	A205936	002	Jul 18, 2018

AB			100MG	A205936	003	Jul 18, 2018

STERILE WATER FOR INJECTION

LIQUID; N/A

BACTERIOSTATIC WATER FOR INJECTION IN PLASTIC CONTAINER

AP	+	HOSPIRA	100%	N018802	001	Oct 27, 1982

STERILE WATER FOR INJECTION

AP		FRESENIUS KABI USA	100%	A209689	001	Nov 24, 2017

AP		HIKMA	100% (10ML)	A206369	001	Sep 02, 2015

AP	+	HOSPIRA	100% (10ML)	N018801	002	Oct 27, 1982

AP	!	MEDEFIL INC	100% (5ML)	A211188	004	Dec 02, 2019

AP			100% (10ML)	A211188	005	Dec 02, 2019

AP		NEPHRON	100% (5ML)	A211222	001	Feb 10, 2021

STERILE WATER FOR INJECTION IN PLASTIC CONTAINER

AP	+	B BRAUN	100%	N019633	001	Feb 29, 1988

AP	+	BAXTER HLTHCARE	100%	N018632	001	Jun 30, 1982

AP	+		100%	N018632	002	Apr 19, 1988

AP		FRESENIUS KABI USA	100%	A088400	001	Jan 16, 1984

AP	+	ICU MEDICAL INC	100%	N018233	001	

AP	+		100%	N019869	001	Dec 26, 1989

AP		TARO	100%	A077393	001	Aug 11, 2006

STERILE WATER FOR INJECTION

+	HOSPIRA	100% (20ML)	N018801	003	Oct 27, 1982

+		100% (50ML)	N018801	004	Oct 27, 1982

+		100% (100ML)	N018801	005	Oct 27, 1982

	MEDEFIL INC	100% (1ML)	A211188	001	Dec 02, 2019

PRESCRIPTION DRUG PRODUCT LIST

3-422 (of 474)

STERILE WATER FOR INJECTION

LIQUID;N/A

STERILE WATER FOR INJECTION

! 100% (2.5ML)
! 100% (3ML)

A211188 002 Dec 02, 2019
A211188 003 Dec 02, 2019

STERILE WATER FOR IRRIGATION

LIQUID;IRRIGATION

STERILE WATER**AT** + BAXTER HLTHCARE **100%****N017428 001**STERILE WATER IN PLASTIC CONTAINER**AT** + B BRAUN **100%****N016734 001****AT** BAXTER HLTHCARE **100%****N017866 001****AT** ICU MEDICAL INC **100%****N017513 001****AT** **100%****N018313 001**STIRIPENTOL

CAPSULE;ORAL

DIACOMIT

+ BIOCODEX SA 250MG
+! 500MG

N206709 001 Aug 20, 2018
N206709 002 Aug 20, 2018

FOR SUSPENSION;ORAL

DIACOMIT

+ BIOCODEX SA 250MG/PACKET
+! 500MG/PACKET

N207223 001 Aug 20, 2018
N207223 002 Aug 20, 2018

STREPTOMYCIN SULFATE

INJECTABLE;INJECTION

STREPTOMYCIN SULFATE

! XGEN PHARMS EQ 1GM BASE/VIAL

A064210 001 Jun 30, 1998

STREPTOZOCIN

INJECTABLE;INJECTION

ZANOSAR

+! TEVA PHARMS USA 1GM/VIAL

N050577 001 May 07, 1982

STRONTIUM CHLORIDE SR-89

INJECTABLE;INJECTION

METASTRON**AP** +! Q BIOMED **1mCi/ML****N020134 001** Jun 18, 1993STRONTIUM CHLORIDE SR-89**AP** Q BIOMED **1mCi/ML****A075941 001** Jan 06, 2003SUCCIMER

CAPSULE;ORAL

CHEMET

+! RECORDATI RARE 100MG

N019998 002 Jan 30, 1991

SUCCINYLCHOLINE CHLORIDE

INJECTABLE;INJECTION

ANECTINE**AP** +! SANDOZ INC **20MG/ML****N008453 002**QUELICIN**AP** +! HOSPIRA **20MG/ML****N008845 006**SUCCINYLCHOLINE CHLORIDE**AP** ACCORD HLTHCARE **20MG/ML****A213705 001** May 20, 2020**AP** AMNEAL **20MG/ML****A211432 001** Nov 16, 2018**AP** AMRING PHARMS **20MG/ML****A210231 001** Jun 04, 2018**AP** ASPIRO **20MG/ML****A213810 001** May 04, 2020**AP** BRECKENRIDGE **20MG/ML****A212638 001** Oct 09, 2019**AP** DEVA HOLDING AS **20MG/ML****A214491 001** Dec 21, 2020**AP** DR REDDYS **20MG/ML****A210698 001** Aug 02, 2019**AP** FRESENIUS KABI USA **20MG/ML****A211346 001** Nov 20, 2020**AP** GLAND PHARMA LTD **20MG/ML****A214246 001** Jun 16, 2020**AP** HIKMA **20MG/ML****A213229 001** Jun 12, 2020**AP** INDOCO **20MG/ML****A214308 001** May 22, 2020**AP** MEITHEAL **20MG/ML****A214514 001** Oct 19, 2021**AP** MICRO LABS **20MG/ML****A214879 001** Nov 24, 2020**AP** NEXUS PHARMS **20MG/ML****A213552 001** Oct 27, 2020**AP** NIVAGEN PHARMS INC **20MG/ML****A211625 001** May 19, 2020**AP** SAGENT PHARMS INC **20MG/ML****A215022 001** Mar 29, 2021**AP** SOMERSET THERAPS **20MG/ML****A211589 001** Jan 15, 2020**AP** ! ZYDUS PHARMS **20MG/ML****A209467 001** May 04, 2018

PRESCRIPTION DRUG PRODUCT LIST

3-423 (of 474)

SUCCINYLCHOLINE CHLORIDE

SOLUTION;INTRAMUSCULAR, INTRAVENOUS

SUCCINYLCHOLINE CHLORIDE

+! HIKMA 100MG/5ML (20MG/ML)

N215143 001 Aug 20, 2021

SUCRALFATE

SUSPENSION;ORAL

CARAFATE**AB** +! ALLERGAN1GM/10ML**N019183 001** Dec 16, 1993SUCRALFATE**AB** AMNEAL1GM/10ML**A209356 001** Dec 02, 2019**AB** MYLAN1GM/10ML**A212913 001** Sep 12, 2022**AB** VISTAPHARM1GM/10ML**A211884 001** Mar 15, 2022

TABLET;ORAL

CARAFATE**AB** +! ALLERGAN1GM**N018333 001**SUCRALFATE**AB** AMNEAL PHARMS1GM**A215576 001** Apr 15, 2022**AB** NOSTRUM LABS INC1GM**A074415 001** Jun 08, 1998**AB** TEVA1GM**A070848 001** Mar 29, 1996SUFENTANIL CITRATE

INJECTABLE;INJECTION

SUFENTA PRESERVATIVE FREE**AP** +! AKORNEQ 0.05MG BASE/ML**N019050 001** May 04, 1984SUFENTANIL CITRATE**AP** HIKMAEQ 0.05MG BASE/ML**A074413 001** Dec 15, 1995**AP** HOSPIRAEQ 0.05MG BASE/ML**A074534 001** Dec 11, 1996

TABLET;SUBLINGUAL

DSUVIA

+! ACELRX PHARMS EQ 0.03MG BASE

N209128 001 Nov 02, 2018

SUGAMMADEX SODIUM

SOLUTION;INTRAVENOUS

BRIDION

+ ORGANON SUB MERCK EQ 200MG BASE/2ML (EQ 100MG BASE/ML)

N022225 002 Dec 15, 2015

+! EQ 500MG BASE/5ML (EQ 100MG BASE/ML)

N022225 001 Dec 15, 2015

SULCONAZOLE NITRATE

CREAM;TOPICAL

EXELDERM

+! JOURNEY 1%

N018737 001 Feb 28, 1989

SOLUTION;TOPICAL

EXELDERM

+! JOURNEY 1%

N018738 001 Aug 30, 1985

SULFACETAMIDE SODIUM

LOTION;TOPICAL

KLARON**AB** +! BAUSCH10%**N019931 001** Dec 23, 1996SULFACETAMIDE SODIUM**AB** FOUGERA PHARMS10%**A077015 001** Nov 17, 2006**AB** PADAGIS US10%**A078649 001** Mar 23, 2009**AB** TARO10%**A078668 001** May 20, 2009

OINTMENT;OPHTHALMIC

SULFACETAMIDE SODIUM

! PADAGIS US 10%

A080029 001

SOLUTION/DROPS;OPHTHALMIC

BLEPH-10**AT** +! ALLERGAN10%**A080028 001**SULFACETAMIDE SODIUM**AT** AKORN10%**A040215 001** May 25, 1999**AT** BAUSCH AND LOMB10%**A040066 001** Dec 28, 1994**AT** SANDOZ INC10%**A089560 001** Oct 18, 1988SULFADIAZINE

TABLET;ORAL

SULFADIAZINE

! EPIC PHARMA 500MG

A040091 001 Jul 29, 1994

PRESCRIPTION DRUG PRODUCT LIST

3-424 (of 474)

SULFAMETHOXAZOLE; TRIMETHOPRIM

INJECTABLE; INJECTION

SULFAMETHOXAZOLE AND TRIMETHOPRIM

AP	!	MYLAN LABS LTD	80MG/ML; 16MG/ML	<u>A206607</u>	<u>001</u>	Aug 30, 2017
AP		SOMERSET	80MG/ML; 16MG/ML	<u>A212231</u>	<u>001</u>	Jun 26, 2019
AP		TEVA PHARMS USA	80MG/ML; 16MG/ML	<u>A073303</u>	<u>001</u>	Oct 31, 1991

SUSPENSION; ORAL

SULFAMETHOXAZOLE AND TRIMETHOPRIM

AB	!	AKORN	200MG/5ML; 40MG/5ML	<u>A074650</u>	<u>001</u>	Dec 29, 1997
AB		AUROBINDO PHARMA	200MG/5ML; 40MG/5ML	<u>A091348</u>	<u>001</u>	Jun 08, 2010
AB		LANNETT CO INC	200MG/5ML; 40MG/5ML	<u>A077785</u>	<u>001</u>	Jan 24, 2007
AB		NOVITIUM PHARMA	200MG/5ML; 40MG/5ML	<u>A214330</u>	<u>001</u>	Feb 08, 2022
AB		PRASCO	200MG/5ML; 40MG/5ML	<u>A077612</u>	<u>001</u>	Nov 13, 2006

SULFATRIM PEDIATRIC

AB		PHARM ASSOC	200MG/5ML; 40MG/5ML	<u>N018615</u>	<u>001</u>	Jan 07, 1983

TABLET; ORAL

BACTRIM

AB	+	SUN PHARM INDUSTRIES	400MG; 80MG	<u>N017377</u>	<u>001</u>	

BACTRIM DS

AB	+	SUN PHARM INDUSTRIES	800MG; 160MG	<u>N017377</u>	<u>002</u>	

SEPTRA

AB		MONARCH PHARMS	400MG; 80MG	<u>N017376</u>	<u>001</u>	

SEPTRA DS

AB		MONARCH PHARMS	800MG; 160MG	<u>N017376</u>	<u>002</u>	

SULFAMETHOXAZOLE AND TRIMETHOPRIM

AB		AMNEAL PHARMS NY	400MG; 80MG	<u>A076899</u>	<u>001</u>	Jan 27, 2005
AB			800MG; 160MG	<u>A076899</u>	<u>002</u>	Jan 27, 2005
AB		AUROBINDO PHARMA	400MG; 80MG	<u>A090624</u>	<u>001</u>	Feb 16, 2010
AB			800MG; 160MG	<u>A090624</u>	<u>002</u>	Feb 16, 2010
AB		CHARTWELL MOLECULES	400MG; 80MG	<u>A078060</u>	<u>002</u>	Jan 25, 2007
AB			800MG; 160MG	<u>A078060</u>	<u>001</u>	Jan 25, 2007
AB		GLENMARK GENERICS	400MG; 80MG	<u>A090828</u>	<u>002</u>	Dec 22, 2010
AB			800MG; 160MG	<u>A090828</u>	<u>001</u>	Dec 22, 2010
AB		SUN PHARM INDUSTRIES	400MG; 80MG	<u>A071017</u>	<u>002</u>	Aug 25, 1986
AB			800MG; 160MG	<u>A071017</u>	<u>001</u>	Aug 25, 1986
AB		VISTA PHARMS	400MG; 80MG	<u>A076817</u>	<u>001</u>	Oct 07, 2005
AB			800MG; 160MG	<u>A076817</u>	<u>002</u>	Oct 07, 2005

SULFASALAZINE

TABLET; ORAL

AZULFIDINE

AB	+	PFIZER	500MG	<u>N007073</u>	<u>001</u>	

SULFASALAZINE

AB		CHARTWELL	500MG	<u>A080197</u>	<u>001</u>	
AB		NUVO PHARMS INC	500MG	<u>A040349</u>	<u>001</u>	Jan 11, 2002
AB		WATSON LABS	500MG	<u>A085828</u>	<u>001</u>	

TABLET, DELAYED RELEASE; ORAL

AZULFIDINE EN-TABS

AB	+	PFIZER	500MG	<u>N007073</u>	<u>002</u>	Apr 06, 1983

SULFASALAZINE

AB		NUVO PHARMS INC	500MG	<u>A075339</u>	<u>001</u>	Jan 11, 2002

SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSPHERES

FOR SUSPENSION; INTRAVENOUS

LUMASON

+	!	BRACCO	60.7MG/25MG	<u>N203684</u>	<u>001</u>	Oct 15, 2014

SULINDAC

TABLET; ORAL

SULINDAC

AB		EPIC PHARMA	150MG	<u>A072710</u>	<u>001</u>	Mar 25, 1991
AB			200MG	<u>A072711</u>	<u>001</u>	Mar 25, 1991
AB		SUN PHARM INDUSTRIES	150MG	<u>A072050</u>	<u>001</u>	Apr 17, 1991
AB			200MG	<u>A072051</u>	<u>001</u>	Apr 17, 1991
AB		WATSON LABS	150MG	<u>A071891</u>	<u>001</u>	Apr 03, 1990
AB	!		200MG	<u>A071795</u>	<u>001</u>	Apr 03, 1990

PRESCRIPTION DRUG PRODUCT LIST

3-425 (of 474)

SUMATRIPTAN

SPRAY;NASAL

IMITREX

<u>AB</u>	<u>+</u> !	GLAXOSMITHKLINE	<u>5MG/SPRAY</u>	<u>N020626</u>	<u>001</u>	Aug 26, 1997
<u>AB</u>	<u>+</u> !		<u>20MG/SPRAY</u>	<u>N020626</u>	<u>003</u>	Aug 26, 1997

SUMATRIPTAN

<u>AB</u>		CIPLA	<u>20MG/SPRAY</u>	<u>A214209</u>	<u>001</u>	Feb 22, 2021
<u>AB</u>		FLORIDA	<u>20MG/SPRAY</u>	<u>A208967</u>	<u>001</u>	Feb 17, 2021
<u>AB</u>		LANNETT CO INC	<u>5MG/SPRAY</u>	<u>A204841</u>	<u>001</u>	Feb 19, 2016
<u>AB</u>			<u>20MG/SPRAY</u>	<u>A204841</u>	<u>002</u>	Feb 19, 2016
<u>AB</u>		PADAGIS ISRAEL	<u>5MG/SPRAY</u>	<u>A213465</u>	<u>002</u>	Sep 21, 2020
<u>AB</u>			<u>20MG/SPRAY</u>	<u>A213465</u>	<u>001</u>	Sep 21, 2020
TOSYMRA						
	<u>+</u> !	UPSHER SMITH LABS	10MG/SPRAY	N210884	001	Jan 25, 2019

SUMATRIPTAN SUCCINATE

INJECTABLE;SUBCUTANEOUS

IMITREX STATDOSE

<u>AB</u>	<u>+</u> !	GLAXOSMITHKLINE	<u>EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)</u>	<u>N020080</u>	<u>002</u>	Feb 01, 2006
<u>AB</u>	<u>+</u> !		<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>N020080</u>	<u>003</u>	Dec 23, 1996

SUMATRIPTAN SUCCINATE

<u>AB</u>		ANTARES PHARMA INC	<u>EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)</u>	<u>A078319</u>	<u>001</u>	Dec 10, 2015
<u>AB</u>			<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>A078319</u>	<u>002</u>	Dec 10, 2015
<u>AB</u>		DR REDDYS	<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>A090495</u>	<u>001</u>	Jan 29, 2014
<u>AB</u>		SUN PHARM	<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>A090358</u>	<u>001</u>	Jun 21, 2011

IMITREX

<u>AP</u>	<u>+</u> !	GLAXOSMITHKLINE	<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>N020080</u>	<u>001</u>	Dec 28, 1992

SUMATRIPTAN SUCCINATE

<u>AP</u>		CAPLIN	<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>A213998</u>	<u>001</u>	Jul 13, 2021
<u>AP</u>		EUGIA PHARMA	<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>A202758</u>	<u>001</u>	Apr 23, 2013
<u>AP</u>		FRESENIUS KABI USA	<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>A079242</u>	<u>001</u>	Mar 02, 2009
<u>AP</u>		HIKMA	<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>A200183</u>	<u>001</u>	Sep 16, 2013
<u>AP</u>		PAR PHARM	<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>A077332</u>	<u>001</u>	Oct 09, 2009
<u>AP</u>		WEST-WARD PHARMS	<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>A079123</u>	<u>001</u>	Feb 06, 2009
<u>AP</u>		INT				
<u>AP</u>		WOCKHARDT	<u>EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)</u>	<u>A078593</u>	<u>001</u>	Feb 06, 2009

POWDER;NASAL

ONZETRA XSAIL

+! CURRAX

EQ 11MG BASE

N206099 001 Jan 27, 2016

SOLUTION;SUBCUTANEOUS

ZEMBRACE SYMTOUCH

+ UPSHER SMITH LABS

EQ 3MG BASE/0.5ML (EQ 3MG BASE/0.5ML)

N208223 001 Jan 28, 2016

TABLET;ORAL

IMITREX

<u>AB</u>	<u>+</u>	GLAXOSMITHKLINE	<u>EQ 25MG BASE</u>	<u>N020132</u>	<u>002</u>	Jun 01, 1995
<u>AB</u>	<u>+</u>		<u>EQ 50MG BASE</u>	<u>N020132</u>	<u>003</u>	Jun 01, 1995
<u>AB</u>	<u>+</u> !		<u>EQ 100MG BASE</u>	<u>N020132</u>	<u>001</u>	Jun 01, 1995

SUMATRIPTAN SUCCINATE

<u>AB</u>		AUROBINDO PHARMA	<u>EQ 25MG BASE</u>	<u>A078327</u>	<u>001</u>	Aug 10, 2009
<u>AB</u>			<u>EQ 50MG BASE</u>	<u>A078327</u>	<u>002</u>	Aug 10, 2009
<u>AB</u>			<u>EQ 100MG BASE</u>	<u>A078327</u>	<u>003</u>	Aug 10, 2009
<u>AB</u>		COREPHARMA	<u>EQ 25MG BASE</u>	<u>A200263</u>	<u>001</u>	Jun 19, 2012
<u>AB</u>			<u>EQ 50MG BASE</u>	<u>A200263</u>	<u>002</u>	Jun 19, 2012
<u>AB</u>			<u>EQ 100MG BASE</u>	<u>A200263</u>	<u>003</u>	Jun 19, 2012
<u>AB</u>		DR REDDYS LABS INC	<u>EQ 25MG BASE</u>	<u>A076847</u>	<u>001</u>	Aug 10, 2009
<u>AB</u>			<u>EQ 50MG BASE</u>	<u>A076847</u>	<u>002</u>	Aug 10, 2009
<u>AB</u>			<u>EQ 100MG BASE</u>	<u>A076847</u>	<u>003</u>	Aug 10, 2009
<u>AB</u>		MYLAN	<u>EQ 25MG BASE</u>	<u>A077744</u>	<u>001</u>	Aug 10, 2009
<u>AB</u>			<u>EQ 50MG BASE</u>	<u>A077744</u>	<u>002</u>	Aug 10, 2009
<u>AB</u>			<u>EQ 100MG BASE</u>	<u>A077744</u>	<u>003</u>	Aug 10, 2009
<u>AB</u>		ORBION PHARMS	<u>EQ 25MG BASE</u>	<u>A078284</u>	<u>001</u>	Aug 10, 2009
<u>AB</u>			<u>EQ 50MG BASE</u>	<u>A078284</u>	<u>002</u>	Aug 10, 2009
<u>AB</u>			<u>EQ 100MG BASE</u>	<u>A078284</u>	<u>003</u>	Aug 10, 2009
<u>AB</u>		SUN PHARM INDS	<u>EQ 25MG BASE</u>	<u>A078295</u>	<u>001</u>	Aug 10, 2009
<u>AB</u>			<u>EQ 50MG BASE</u>	<u>A078295</u>	<u>002</u>	Aug 10, 2009
<u>AB</u>			<u>EQ 100MG BASE</u>	<u>A078295</u>	<u>003</u>	Aug 10, 2009
<u>AB</u>		SUN PHARM INDS LTD	<u>EQ 25MG BASE</u>	<u>A076554</u>	<u>001</u>	Aug 10, 2009
<u>AB</u>			<u>EQ 50MG BASE</u>	<u>A076554</u>	<u>002</u>	Aug 10, 2009
<u>AB</u>			<u>EQ 100MG BASE</u>	<u>A076572</u>	<u>001</u>	Feb 09, 2009
<u>AB</u>		WATSON LABS	<u>EQ 25MG BASE</u>	<u>A076933</u>	<u>001</u>	Aug 10, 2009
<u>AB</u>			<u>EQ 50MG BASE</u>	<u>A076933</u>	<u>002</u>	Aug 10, 2009
<u>AB</u>			<u>EQ 100MG BASE</u>	<u>A076933</u>	<u>003</u>	Aug 10, 2009

PRESCRIPTION DRUG PRODUCT LIST

3-426 (of 474)

SUNITINIB MALATE

CAPSULE;ORAL

SUNITINIB MALATE

<u>AB</u>	DR REDDYS	<u>EQ 12.5MG BASE</u>	<u>A215843 001</u>	Apr 11, 2022
<u>AB</u>		<u>EQ 25MG BASE</u>	<u>A215843 002</u>	Apr 11, 2022
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A215843 003</u>	Apr 11, 2022
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A215843 004</u>	Apr 11, 2022
<u>AB</u>	MYLAN	<u>EQ 12.5MG BASE</u>	<u>A201275 001</u>	Dec 06, 2021
<u>AB</u>		<u>EQ 25MG BASE</u>	<u>A201275 002</u>	Dec 06, 2021
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A201275 003</u>	Dec 06, 2021
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A201275 004</u>	Dec 06, 2021
<u>AB</u>	SUN PHARM	<u>EQ 12.5MG BASE</u>	<u>A213914 001</u>	Aug 16, 2021
<u>AB</u>		<u>EQ 25MG BASE</u>	<u>A213914 002</u>	Aug 16, 2021
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A213914 003</u>	Aug 16, 2021
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A213914 004</u>	Aug 16, 2021
<u>AB</u>	TEVA PHARMS USA	<u>EQ 12.5MG BASE</u>	<u>A213803 001</u>	Nov 30, 2021
<u>AB</u>		<u>EQ 25MG BASE</u>	<u>A213803 002</u>	Nov 30, 2021
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A213803 003</u>	Nov 30, 2021
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A213803 004</u>	Nov 30, 2021

SUTENT

<u>AB</u>	+	CPPI CV	<u>EQ 12.5MG BASE</u>	<u>N021938 001</u>	Jan 26, 2006
<u>AB</u>	+		<u>EQ 25MG BASE</u>	<u>N021938 002</u>	Jan 26, 2006
<u>AB</u>	+		<u>EQ 37.5MG BASE</u>	<u>N021938 004</u>	Mar 31, 2009
<u>AB</u>	+	!	<u>EQ 50MG BASE</u>	<u>N021938 003</u>	Jan 26, 2006

SUVOREXANT

TABLET;ORAL

BELSOMRA

+	MERCK SHARP DOHME	5MG	N204569 001	Aug 13, 2014
+		10MG	N204569 002	Aug 13, 2014
+		15MG	N204569 003	Aug 13, 2014
+	!	20MG	N204569 004	Aug 13, 2014

TACROLIMUS

CAPSULE;ORAL

PROGRAF

<u>AB</u>	+	ASTELLAS	<u>EQ 0.5MG BASE</u>	<u>N050708 003</u>	Aug 24, 1998
<u>AB</u>	+		<u>EQ 1MG BASE</u>	<u>N050708 001</u>	Apr 08, 1994
<u>AB</u>	+	!	<u>EQ 5MG BASE</u>	<u>N050708 002</u>	Apr 08, 1994

TACROLIMUS

<u>AB</u>	ACCORD HLTHCARE	<u>EQ 0.5MG BASE</u>	<u>A091195 001</u>	Aug 31, 2011
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A091195 002</u>	Aug 31, 2011
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A091195 003</u>	Aug 31, 2011
<u>AB</u>	ALKEM LABS LTD	<u>EQ 0.5MG BASE</u>	<u>A203740 001</u>	Nov 12, 2020
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A203740 002</u>	Nov 12, 2020
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A203740 003</u>	Nov 12, 2020
<u>AB</u>	BELCHER	<u>EQ 0.5MG BASE</u>	<u>A206651 001</u>	Nov 30, 2017
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A206651 002</u>	Nov 30, 2017
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A206651 003</u>	Nov 30, 2017
<u>AB</u>	BIOCON PHARMA	<u>EQ 0.5MG BASE</u>	<u>A212297 001</u>	Nov 10, 2020
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A212297 002</u>	Nov 10, 2020
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A212297 003</u>	Nov 10, 2020
<u>AB</u>	CONCORD BIOTECH LTD	<u>EQ 1MG BASE</u>	<u>A213112 002</u>	Nov 10, 2020
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A213112 003</u>	Nov 10, 2020
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 0.5MG BASE</u>	<u>A090509 001</u>	May 12, 2010
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A090509 002</u>	May 12, 2010
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A090509 003</u>	May 12, 2010
<u>AB</u>	GLENMARK PHARMS LTD	<u>EQ 0.5MG BASE</u>	<u>A206662 001</u>	Nov 10, 2020
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A206662 002</u>	Nov 10, 2020
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A206662 003</u>	Nov 10, 2020
<u>AB</u>	MYLAN	<u>EQ 0.5MG BASE</u>	<u>A090596 001</u>	Sep 17, 2010
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A090596 002</u>	Sep 17, 2010
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A090596 003</u>	Sep 17, 2010
<u>AB</u>	PANACEA	<u>EQ 0.5MG BASE</u>	<u>A090802 001</u>	Sep 28, 2012
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A090802 002</u>	Sep 28, 2012
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A090802 003</u>	Sep 28, 2012
<u>AB</u>	SANDOZ	<u>EQ 0.5MG BASE</u>	<u>A065461 001</u>	Aug 10, 2009
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A065461 002</u>	Aug 10, 2009
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A065461 003</u>	Aug 10, 2009
<u>AB</u>	STRIDES PHARMA	<u>EQ 0.5MG BASE</u>	<u>A090687 001</u>	Jul 22, 2014
<u>AB</u>		<u>EQ 1MG BASE</u>	<u>A090687 002</u>	Jul 22, 2014
<u>AB</u>		<u>EQ 5MG BASE</u>	<u>A090687 003</u>	Jul 22, 2014

PRESCRIPTION DRUG PRODUCT LIST

3-427 (of 474)

TACROLIMUS

CAPSULE, EXTENDED RELEASE;ORAL

ASTAGRAF XL

+	ASTELLAS	EQ 0.5MG BASE	N204096	001	Jul 19, 2013
+		EQ 1MG BASE	N204096	002	Jul 19, 2013
+		EQ 5MG BASE	N204096	003	Jul 19, 2013

FOR SUSPENSION;ORAL

PROGRAF

+	ASTELLAS	EQ 0.2MG BASE/PACKET	N210115	001	May 24, 2018
+		EQ 1MG BASE/PACKET	N210115	002	May 24, 2018

INJECTABLE;INJECTION

PROGRAF

+	ASTELLAS	EQ 5MG BASE/ML	N050709	001	Apr 08, 1994

OINTMENT;TOPICAL

PROTOPIC

<u>AB</u>	+	LEO PHARMA AS	<u>0.03%</u>	<u>N050777</u>	<u>001</u>	Dec 08, 2000
<u>AB</u>	+		<u>0.1%</u>	<u>N050777</u>	<u>002</u>	Dec 08, 2000

TACROLIMUS

<u>AB</u>		ACCORD HLTHCARE	<u>0.03%</u>	<u>A211688</u>	<u>001</u>	Jan 31, 2019
<u>AB</u>			<u>0.1%</u>	<u>A211688</u>	<u>002</u>	Jan 31, 2019
<u>AB</u>		FOUGERA PHARMS INC	<u>0.03%</u>	<u>A200744</u>	<u>001</u>	Sep 09, 2014
<u>AB</u>			<u>0.1%</u>	<u>A200744</u>	<u>002</u>	Sep 09, 2014
<u>AB</u>		GLENMARK PHARMS LTD	<u>0.1%</u>	<u>A210393</u>	<u>001</u>	Apr 16, 2018

TABLET, EXTENDED RELEASE;ORAL

ENVARUS XR

+	VELOXIS PHARMS INC	EQ 0.75MG BASE	N206406	001	Jul 10, 2015
+		EQ 1MG BASE	N206406	002	Jul 10, 2015
+		EQ 4MG BASE	N206406	003	Jul 10, 2015

TADALAFIL

SUSPENSION;ORAL

TADLIQ

+	CMP DEV LLC	20MG/5ML	N214522	001	Jun 17, 2022

TABLET;ORAL

CIALIS

<u>AB1</u>	+	LILLY	<u>2.5MG</u>	<u>N021368</u>	<u>004</u>	Jan 07, 2008
<u>AB1</u>	+		<u>5MG</u>	<u>N021368</u>	<u>001</u>	Nov 21, 2003
<u>AB1</u>	+		<u>10MG</u>	<u>N021368</u>	<u>002</u>	Nov 21, 2003
<u>AB1</u>	+		<u>20MG</u>	<u>N021368</u>	<u>003</u>	Nov 21, 2003

TADALAFIL

<u>AB1</u>		ACCORD HLTHCARE	<u>2.5MG</u>	<u>A209167</u>	<u>001</u>	Mar 26, 2019
<u>AB1</u>			<u>5MG</u>	<u>A209167</u>	<u>002</u>	Mar 26, 2019
<u>AB1</u>			<u>10MG</u>	<u>A209167</u>	<u>003</u>	Oct 23, 2019
<u>AB1</u>			<u>20MG</u>	<u>A209167</u>	<u>004</u>	Mar 26, 2019
<u>AB1</u>		AJANTA PHARMA LTD	<u>2.5MG</u>	<u>A209654</u>	<u>001</u>	Mar 26, 2019
<u>AB1</u>			<u>5MG</u>	<u>A209654</u>	<u>002</u>	Mar 26, 2019
<u>AB1</u>			<u>10MG</u>	<u>A209654</u>	<u>003</u>	Mar 26, 2019
<u>AB1</u>			<u>20MG</u>	<u>A209654</u>	<u>004</u>	Mar 26, 2019
<u>AB1</u>		ALEMBIC PHARMS	<u>2.5MG</u>	<u>A204809</u>	<u>001</u>	Mar 26, 2019
<u>AB1</u>			<u>5MG</u>	<u>A204809</u>	<u>002</u>	Mar 26, 2019
<u>AB1</u>			<u>10MG</u>	<u>A204809</u>	<u>003</u>	Mar 26, 2019
<u>AB1</u>			<u>20MG</u>	<u>A204809</u>	<u>004</u>	Mar 26, 2019
<u>AB1</u>		AMNEAL PHARMS CO	<u>2.5MG</u>	<u>A209744</u>	<u>001</u>	Mar 26, 2019
<u>AB1</u>			<u>5MG</u>	<u>A209744</u>	<u>002</u>	Mar 26, 2019
<u>AB1</u>			<u>10MG</u>	<u>A209744</u>	<u>003</u>	Mar 26, 2019
<u>AB1</u>			<u>20MG</u>	<u>A209744</u>	<u>004</u>	Mar 26, 2019
<u>AB1</u>		AUROBINDO PHARMA LTD	<u>2.5MG</u>	<u>A206285</u>	<u>001</u>	Mar 26, 2019
<u>AB1</u>			<u>5MG</u>	<u>A206285</u>	<u>002</u>	Mar 26, 2019
<u>AB1</u>			<u>10MG</u>	<u>A206285</u>	<u>003</u>	Mar 26, 2019
<u>AB1</u>			<u>20MG</u>	<u>A206285</u>	<u>004</u>	Mar 26, 2019
<u>AB1</u>		AUSTARPHARMA	<u>2.5MG</u>	<u>A208824</u>	<u>001</u>	Oct 27, 2020
<u>AB1</u>			<u>5MG</u>	<u>A208824</u>	<u>002</u>	Oct 27, 2020
<u>AB1</u>			<u>10MG</u>	<u>A208824</u>	<u>003</u>	Oct 27, 2020
<u>AB1</u>			<u>20MG</u>	<u>A208824</u>	<u>004</u>	Oct 27, 2020
<u>AB1</u>		CIPLA	<u>2.5MG</u>	<u>A209539</u>	<u>001</u>	Mar 26, 2019
<u>AB1</u>			<u>5MG</u>	<u>A209539</u>	<u>002</u>	Mar 26, 2019
<u>AB1</u>			<u>10MG</u>	<u>A209539</u>	<u>003</u>	Mar 26, 2019
<u>AB1</u>			<u>20MG</u>	<u>A209539</u>	<u>004</u>	Mar 26, 2019
<u>AB1</u>		DR REDDYS	<u>2.5MG</u>	<u>A210069</u>	<u>001</u>	Mar 26, 2019
<u>AB1</u>			<u>5MG</u>	<u>A210069</u>	<u>002</u>	Mar 26, 2019
<u>AB1</u>			<u>10MG</u>	<u>A210069</u>	<u>003</u>	Mar 26, 2019
<u>AB1</u>			<u>20MG</u>	<u>A210069</u>	<u>004</u>	Mar 26, 2019

PRESCRIPTION DRUG PRODUCT LIST

3-428 (of 474)

TADALAFIL

TABLET; ORAL

TADALAFIL

<u>AB1</u>	HETERO LABS LTD III	<u>2.5MG</u>	<u>A209908</u>	<u>001</u>	Mar 26, 2019
<u>AB1</u>		<u>5MG</u>	<u>A209908</u>	<u>002</u>	Mar 26, 2019
<u>AB1</u>		<u>10MG</u>	<u>A209908</u>	<u>003</u>	Mar 26, 2019
<u>AB1</u>		<u>20MG</u>	<u>A209908</u>	<u>004</u>	Mar 26, 2019
<u>AB1</u>	LUPIN LTD	<u>2.5MG</u>	<u>A210567</u>	<u>001</u>	Mar 26, 2019
<u>AB1</u>		<u>5MG</u>	<u>A210567</u>	<u>002</u>	Mar 26, 2019
<u>AB1</u>		<u>10MG</u>	<u>A210567</u>	<u>003</u>	Mar 26, 2019
<u>AB1</u>		<u>20MG</u>	<u>A210567</u>	<u>004</u>	Mar 26, 2019
<u>AB1</u>	MACLEODS PHARMS LTD	<u>2.5MG</u>	<u>A207244</u>	<u>001</u>	Oct 07, 2019
<u>AB1</u>		<u>5MG</u>	<u>A207244</u>	<u>002</u>	Oct 07, 2019
<u>AB1</u>		<u>10MG</u>	<u>A207244</u>	<u>003</u>	Oct 07, 2019
<u>AB1</u>		<u>20MG</u>	<u>A207244</u>	<u>004</u>	Oct 07, 2019
<u>AB1</u>	PRINSTON INC	<u>2.5MG</u>	<u>A210609</u>	<u>001</u>	Aug 11, 2022
<u>AB1</u>		<u>5MG</u>	<u>A210609</u>	<u>002</u>	Aug 11, 2022
<u>AB1</u>		<u>10MG</u>	<u>A210609</u>	<u>003</u>	Aug 11, 2022
<u>AB1</u>		<u>20MG</u>	<u>A210609</u>	<u>004</u>	Aug 11, 2022
<u>AB1</u>	QILU PHARM HAINAN	<u>2.5MG</u>	<u>A210420</u>	<u>001</u>	Mar 26, 2019
<u>AB1</u>		<u>5MG</u>	<u>A210420</u>	<u>002</u>	Mar 26, 2019
<u>AB1</u>		<u>10MG</u>	<u>A210420</u>	<u>003</u>	Mar 26, 2019
<u>AB1</u>		<u>20MG</u>	<u>A210420</u>	<u>004</u>	Mar 26, 2019
<u>AB1</u>	SUN PHARM	<u>2.5MG</u>	<u>A208934</u>	<u>001</u>	Mar 26, 2019
<u>AB1</u>		<u>5MG</u>	<u>A208934</u>	<u>002</u>	Mar 26, 2019
<u>AB1</u>		<u>10MG</u>	<u>A208934</u>	<u>003</u>	Mar 26, 2019
<u>AB1</u>		<u>20MG</u>	<u>A208934</u>	<u>004</u>	Mar 26, 2019
<u>AB1</u>	SUNSHINE	<u>2.5MG</u>	<u>A211335</u>	<u>001</u>	Mar 26, 2019
<u>AB1</u>		<u>5MG</u>	<u>A211335</u>	<u>002</u>	Mar 26, 2019
<u>AB1</u>		<u>10MG</u>	<u>A211335</u>	<u>003</u>	Mar 26, 2019
<u>AB1</u>		<u>20MG</u>	<u>A211335</u>	<u>004</u>	Mar 26, 2019
<u>AB1</u>	TEVA PHARMS USA	<u>2.5MG</u>	<u>A090141</u>	<u>001</u>	May 22, 2018
<u>AB1</u>		<u>5MG</u>	<u>A090141</u>	<u>002</u>	May 22, 2018
<u>AB1</u>		<u>10MG</u>	<u>A090141</u>	<u>003</u>	May 22, 2018
<u>AB1</u>		<u>20MG</u>	<u>A090141</u>	<u>004</u>	May 22, 2018
<u>AB1</u>	TORRENT	<u>2.5MG</u>	<u>A211839</u>	<u>001</u>	Mar 26, 2019
<u>AB1</u>		<u>5MG</u>	<u>A211839</u>	<u>002</u>	Mar 26, 2019
<u>AB1</u>		<u>10MG</u>	<u>A211839</u>	<u>003</u>	Mar 26, 2019
<u>AB1</u>		<u>20MG</u>	<u>A211839</u>	<u>004</u>	Mar 26, 2019
<u>AB1</u>	UMEDICA LABS PVT LTD	<u>2.5MG</u>	<u>A211298</u>	<u>001</u>	Oct 23, 2020
<u>AB1</u>		<u>5MG</u>	<u>A211298</u>	<u>002</u>	Oct 23, 2020
<u>AB1</u>		<u>10MG</u>	<u>A211298</u>	<u>003</u>	Oct 23, 2020
<u>AB1</u>		<u>20MG</u>	<u>A211298</u>	<u>004</u>	Oct 23, 2020
<u>AB1</u>	VKT PHARMA	<u>2.5MG</u>	<u>A215556</u>	<u>001</u>	Nov 04, 2021
<u>AB1</u>		<u>5MG</u>	<u>A215556</u>	<u>002</u>	Nov 04, 2021
<u>AB1</u>		<u>10MG</u>	<u>A215556</u>	<u>003</u>	Nov 04, 2021
<u>AB1</u>		<u>20MG</u>	<u>A215556</u>	<u>004</u>	Nov 04, 2021
<u>AB1</u>	ZYDUS PHARMS	<u>2.5MG</u>	<u>A206693</u>	<u>001</u>	Mar 26, 2019
<u>AB1</u>		<u>5MG</u>	<u>A206693</u>	<u>002</u>	Mar 26, 2019
<u>AB1</u>		<u>10MG</u>	<u>A206693</u>	<u>003</u>	Mar 26, 2019
<u>AB1</u>		<u>20MG</u>	<u>A206693</u>	<u>004</u>	Mar 26, 2019
<u>ADCIRCA</u>					
<u>AB2</u>	<u>+</u> ELI LILLY CO	<u>20MG</u>	<u>N022332</u>	<u>001</u>	May 22, 2009
<u>ALYQ</u>					
<u>AB2</u>	TEVA PHARMS INC	<u>20MG</u>	<u>A216932</u>	<u>001</u>	Oct 12, 2022
<u>AB2</u>	TEVA PHARMS USA	<u>20MG</u>	<u>A209942</u>	<u>001</u>	Feb 05, 2019
<u>TADALAFIL</u>					
<u>AB2</u>	AJANTA PHARMA LTD	<u>20MG</u>	<u>A210392</u>	<u>001</u>	Feb 05, 2019
<u>AB2</u>	AUROBINDO PHARMA LTD	<u>20MG</u>	<u>A206286</u>	<u>001</u>	Feb 05, 2019
<u>AB2</u>	CIPLA	<u>20MG</u>	<u>A210255</u>	<u>001</u>	Feb 05, 2019
<u>AB2</u>	DR REDDYS	<u>20MG</u>	<u>A210145</u>	<u>001</u>	Feb 05, 2019
<u>AB2</u>	HETERO LABS LTD III	<u>20MG</u>	<u>A209907</u>	<u>001</u>	Feb 05, 2019
<u>AB2</u>	LUPIN LTD	<u>20MG</u>	<u>A210572</u>	<u>001</u>	Feb 05, 2019
<u>AB2</u>	MACLEODS PHARMS LTD	<u>20MG</u>	<u>A207290</u>	<u>001</u>	Oct 16, 2019
<u>AB2</u>	PRINSTON INC	<u>20MG</u>	<u>A210608</u>	<u>001</u>	Aug 11, 2022
<u>AB2</u>	SUNSHINE	<u>20MG</u>	<u>A213496</u>	<u>001</u>	Nov 23, 2020
<u>AB2</u>	TORRENT	<u>20MG</u>	<u>A212062</u>	<u>001</u>	Mar 26, 2019
BX	UNICHEM	2.5MG	A209250	001	Mar 26, 2019
BX		5MG	A209250	002	Mar 26, 2019
BX		10MG	A209250	003	Mar 26, 2019
BX		20MG	A209250	004	Mar 26, 2019

PRESCRIPTION DRUG PRODUCT LIST

3-429 (of 474)

TAFAMIDIS

CAPSULE; ORAL

VYNDAMAX

+! FOLDRX PHARMS

61MG

N212161 001 May 03, 2019

TAFAMIDIS MEGGLUMINE

CAPSULE; ORAL

VYNDAQEL

+! FOLDRX PHARMS

20MG

N211996 001 May 03, 2019

TAFENOQUINE SUCCINATE

TABLET; ORAL

ARAKODA

+! 60 DEGREES PHARMS

EQ 100MG BASE

N210607 001 Aug 08, 2018

KRINTAFEL

+! GLAXOSMITHKLINE

EQ 150MG BASE

N210795 001 Jul 20, 2018

TAFLUPROST

SOLUTION/DROPS; OPHTHALMIC

TAFLUPROST**AT** MICRO LABS**0.0015%****A209051 001** Aug 19, 2019**AT** SANDOZ INC**0.0015%****A209040 001** Jan 28, 2022ZIOPTAN**AT** +! THEA PHARMA**0.0015%****N202514 001** Feb 10, 2012TALAZOPARIB TOSYLATE

CAPSULE; ORAL

TALZENNA

+ PFIZER

EQ 0.25MG BASE

N211651 001 Oct 16, 2018

+

EQ 0.5MG BASE

N211651 003 Sep 20, 2021

+

EQ 0.75MG BASE

N211651 004 Sep 20, 2021

+!

EQ 1MG BASE

N211651 002 Oct 16, 2018

TALC

AEROSOL; INTRAPLEURAL

SCLEROSOL

+! SCIARRA LABS

4GM/SPRAY

N020587 001 Dec 24, 1997

POWDER; INTRAPLEURAL

STERITALC

+ NOVATECH SA

2GM/VIAL

N205555 001 May 01, 2017

+

3GM/VIAL

N205555 002 May 01, 2017

+!

4GM/VIAL

N205555 003 May 01, 2017

TALC

+! SCIARRA LABS

5GM/BOT

N021388 001 Dec 15, 2003

TAMOXIFEN CITRATE

SOLUTION; ORAL

SOLTAMOX

+! MAYNE PHARMA INC

EQ 20MG BASE/10ML

N021807 001 Oct 29, 2005

TABLET; ORAL

TAMOXIFEN CITRATE**AB** ACTAVIS LABS FL INC**EQ 10MG BASE****A070929 001** Feb 20, 2003**AB****EQ 20MG BASE****A070929 002** Feb 20, 2003**AB**

APOTEX

EQ 10MG BASE**A090878 001** Sep 23, 2011**AB****EQ 20MG BASE****A090878 002** Sep 23, 2011**AB**

EUGIA PHARMA

EQ 10MG BASE**A213358 001** Aug 14, 2020**AB****EQ 20MG BASE****A213358 002** Aug 14, 2020**AB**

MAYNE PHARMA

EQ 10MG BASE**A075797 001** Feb 20, 2003**AB**

!

EQ 20MG BASE**A075797 002** Feb 20, 2003**AB**

MYLAN

EQ 10MG BASE**A074732 002** Feb 20, 2003**AB****EQ 20MG BASE****A074732 001** Feb 20, 2003**AB**

ZYDUS PHARMS

EQ 10MG BASE**A206694 001** Oct 27, 2017**AB****EQ 20MG BASE****A206694 002** Oct 27, 2017TAMSULOSIN HYDROCHLORIDE

CAPSULE; ORAL

FLOMAX**AB** +! SANOFI**0.4MG****N020579 001** Apr 15, 1997TAMSULOSIN HYDROCHLORIDE**AB** ALKEM LABS LTD**0.4MG****A207405 001** Aug 11, 2017**AB**

ANBISON LAB

0.4MG**A211885 001** Oct 17, 2019**AB**

AUROBINDO PHARMA

0.4MG**A202433 001** Apr 30, 2013

LTD

AB

IMPAX LABS

0.4MG**A090377 001** Mar 02, 2010**AB**

MACLEODS PHARMS LTD

0.4MG**A204645 001** Jan 20, 2017**AB**

SANDOZ

0.4MG**A078015 001** Apr 27, 2010

PRESCRIPTION DRUG PRODUCT LIST

3-430 (of 474)

TAMSULOSIN HYDROCHLORIDE

CAPSULE; ORAL

TAMSULOSIN HYDROCHLORIDE

AB	SUN PHARM INDS LTD	0.4MG	A090931	001	Jul 15, 2010
AB	SYNTHON PHARMS	0.4MG	A078801	001	Apr 27, 2010
AB	TEVA PHARMS	0.4MG	A077630	001	Apr 27, 2010
AB	WOCKHARDT	0.4MG	A078938	001	Apr 27, 2010
AB	ZYDUS PHARMS USA INC	0.4MG	A078225	001	Apr 27, 2010

TAPENTADOL HYDROCHLORIDE

TABLET; ORAL

NUCYNTA

+	COLLEGIUM PHARM INC	EQ 50MG BASE	N022304	001	Nov 20, 2008
+		EQ 75MG BASE	N022304	002	Nov 20, 2008
+	!	EQ 100MG BASE	N022304	003	Nov 20, 2008

TABLET, EXTENDED RELEASE; ORAL

NUCYNTA ER

+	COLLEGIUM PHARM INC	EQ 50MG BASE	N200533	001	Aug 25, 2011
+		EQ 100MG BASE	N200533	002	Aug 25, 2011
+		EQ 150MG BASE	N200533	003	Aug 25, 2011
+		EQ 200MG BASE	N200533	004	Aug 25, 2011
+	!	EQ 250MG BASE	N200533	005	Aug 25, 2011

TAPINAROF

CREAM; TOPICAL

VTAMA

+	!	DERMAVANT SCI	1%	N215272	001	May 23, 2022

TASIMELTEON

CAPSULE; ORAL

HETLIOZ

AB	+	VANDA PHARMS INC	20MG	N205677	001	Jan 31, 2014

TASIMELTEON

AB		APOTEX CORP	20MG	A211607	001	Dec 20, 2022
AB		TEVA PHARMS USA INC	20MG	A211601	001	Dec 12, 2022

SUSPENSION; ORAL

HETLIOZ LQ

+	!	VANDA PHARMS INC	4MG/ML	N214517	001	Dec 01, 2020

TAVABOROLE

SOLUTION; TOPICAL

KERYDIN

AB	+	ANACOR PHARMS INC	5%	N204427	001	Jul 07, 2014

TAVABOROLE

AB		ALEOR DERMACEUTICALS	5%	A212188	001	Oct 21, 2020
AB		AMNEAL	5%	A212256	001	Nov 25, 2020
AB		CHARTWELL RX	5%	A211963	001	Feb 03, 2021
AB		CIPLA	5%	A212224	001	Feb 09, 2021
AB		ENCUBE	5%	A211297	001	Oct 13, 2020
AB		LUPIN LTD	5%	A212168	001	Feb 08, 2021
AB		PADAGIS US	5%	A211848	001	Oct 13, 2020
AB		TARO PHARMS	5%	A212215	001	May 07, 2021

TAZAROTENE

AEROSOL, FOAM; TOPICAL

FABIOR

+	!	MAYNE PHARMA	0.1%	N202428	001	May 11, 2012

CREAM; TOPICAL

AVAGE

AB	+	ALLERGAN	0.1%	N021184	003	Sep 30, 2002

TAZAROTENE

AB		COSETTE	0.1%	A208662	001	Dec 22, 2017
AB		TARO PHARMS	0.1%	A208258	001	Apr 03, 2017

TAZORAC

AB	+	ALLERGAN	0.1%	N021184	002	Sep 29, 2000
	+		0.05%	N021184	001	Sep 29, 2000

GEL; TOPICAL

TAZAROTENE

AB		COSETTE	0.05%	A215433	001	Sep 13, 2022
AB			0.1%	A214136	001	Sep 13, 2022

TAZORAC

AB	+	ALLERGAN	0.05%	N020600	001	Jun 13, 1997
AB	+		0.1%	N020600	002	Jun 13, 1997

PRESCRIPTION DRUG PRODUCT LIST

3-431 (of 474)

TAZAROTENE

LOTION; TOPICAL

ARAZLO

+! BAUSCH 0.045%

N211882 001 Dec 18, 2019

TAZEMETOSTAT HYDROBROMIDE

TABLET; ORAL

TAZVERIK

+! EPIZYME INC EQ 200MG BASE

N211723 001 Jan 23, 2020

TECHNETIUM TC-99M BICISATE KIT

INJECTABLE; INJECTION

NEUROLITE

+! LANTHEUS MEDCL N/A

N020256 001 Nov 23, 1994

TECHNETIUM TC-99M EXAMETAZIME KIT

INJECTABLE; INJECTION

CERETEC

+! GE HEALTHCARE N/A

N019829 001 Dec 30, 1988

POWDER; INTRAVENOUS

DRAX EXAMETAZIME

JUBILANT N/A

N208870 001 Aug 17, 2017

TECHNETIUM TC-99M MEBROFENIN KIT

INJECTABLE; INJECTION

CHOLETEC**AP +! BRACCO N/A****N018963 001** Jan 21, 1987**TECHNETIUM TC-99M MEBROFENIN****AP SUN PHARM INDS INC N/A****A078242 001** Jan 29, 2008TECHNETIUM TC-99M MEDRONATE

INJECTABLE; INJECTION

DRAXIMAGE MDP-25

+! JUBILANT N/A

N018035 002 Feb 27, 2004

TECHNETIUM TC-99M MEDRONATE KIT

INJECTABLE; INJECTION

CIS-MDP**AP SUN PHARM INDS INC N/A****N018124 001****TECHNETIUM TC-99M MEDRONATE KIT****AP CARDINAL HEALTH 414 N/A****N018107 001**TECHNETIUM TC-99M MERTIATIDE KIT

INJECTABLE; INJECTION

TECHNESCAN MAG3**AP +! CURIUM N/A****N019882 001** Jun 15, 1990**TECHNETIUM TC99M MERTIATIDE KIT****AP MEDI-RADIOPHARMA N/A****A206489 001** Feb 06, 2020**AP SUN PHARM INDS INC N/A****A208994 001** Jul 12, 2019TECHNETIUM TC-99M OXIDRONATE KIT

INJECTABLE; INJECTION

TECHNESCAN

+! CURIUM N/A

N018321 001

TECHNETIUM TC-99M PENTETATE KIT

INJECTABLE; INJECTION

DRAXIMAGE DTPA

+! JUBILANT N/A

N018511 001 Dec 29, 1989

TECHNETIUM TC-99M PYROPHOSPHATE KIT

INJECTABLE; INJECTION

CIS-PYRO**AP SUN PHARM INDS INC N/A****N019039 001** Jun 30, 1987**TECHNESCAN PYP KIT****AP CURIUM N/A****N017538 001**TECHNETIUM TC-99M RED BLOOD CELL KIT

INJECTABLE; INJECTION

ULTRATAG

+! CURIUM N/A

N019981 001 Jun 10, 1991

PRESCRIPTION DRUG PRODUCT LIST

3-432 (of 474)

TECHNETIUM TC-99M SESTAMIBI KIT

INJECTABLE; INJECTION

CARDIOLITE

AP	+	LANTHEUS MEDCL	N/A	N019785	001	Dec 21, 1990

TECHNETIUM TC 99M SESTAMIBI

AP		CARDINAL HEALTH 414	N/A	A078809	001	Apr 28, 2009

AP		CURIUM	N/A	A078098	001	Sep 22, 2008

AP		JUBILANT DRAXIMAGE	N/A	A078806	001	Apr 29, 2009

AP		SUN PHARM INDS INC	10-30mCi	A079157	001	Jul 10, 2009

TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR

SOLUTION; INTRAVENOUS

TECHNELITE

+	LANTHEUS MEDCL	1-20 CI/GENERATOR	N017771	002	Feb 12, 2014

ULTRA-TECHNEKOW FM

+	CURIUM	1-19 CI/GENERATOR	N017243	003	Feb 18, 2014

SOLUTION; INTRAVENOUS, INTRAVESICULAR, OPHTHALMIC
RADIOGENIX SYSTEM

+	NORTHSTAR MEDICAL	30-1153mCi/GENERATOR	N202158	001	Feb 08, 2018

TECHNETIUM TC-99M SUCCIMER

POWDER; INTRAVENOUS

NEPHROSCAN

+	THERAGNOSTICS	N/A	N214993	001	Feb 18, 2022

TECHNETIUM TC-99M SULFUR COLLOID KIT

SOLUTION; INJECTION, ORAL

AN-SULFUR COLLOID

+	SUN PHARM INDS INC	N/A	N017858	001	

TECHNETIUM TC-99M TETROFOSMIN KIT

INJECTABLE; INJECTION

MYOVUE

+	GE HEALTHCARE	N/A	N020372	001	Feb 09, 1996

MYOVUE 30ML

+	GE HEALTHCARE	N/A	N020372	002	Jul 07, 2005

TECHNETIUM TC-99M TILMANOCEPT

INJECTABLE; INJECTION

LYMPHOSEEK KIT

+	CARDINAL HEALTH 414	N/A	N202207	001	Mar 13, 2013

TECOVIRIMAT

CAPSULE; ORAL

TPOXX

+	SIGA TECHNOLOGIES	200MG	N208627	001	Jul 13, 2018

SOLUTION; INTRAVENOUS

TPOXX

+	SIGA TECHNOLOGIES	200MG/20ML (10MG/ML)	N214518	001	May 18, 2022

TEDIZOLID PHOSPHATE

POWDER; INTRAVENOUS

SIVEXTRO

+	CUBIST PHARMS LLC	200MG/VIAL	N205436	001	Jun 20, 2014

TABLET; ORAL

SIVEXTRO

+	CUBIST PHARMS LLC	200MG	N205435	001	Jun 20, 2014

TEDUGLUTIDE RECOMBINANT

POWDER; SUBCUTANEOUS

GATTEX KIT

+	TAKEDA PHARMS USA	5MG/VIAL	N203441	001	Dec 21, 2012

TELAVANCIN HYDROCHLORIDE

POWDER; INTRAVENOUS

VIBATIV

+	CUMBERLAND PHARMS	EQ 750MG BASE/VIAL	N022110	002	Sep 11, 2009

TELMISARTAN

TABLET; ORAL

MICARDIS

AB	+	BOEHRINGER INGELHEIM	20MG	N020850	003	Apr 04, 2000

AB	+		40MG	N020850	001	Nov 10, 1998

AB	+		80MG	N020850	002	Nov 10, 1998

TELMISARTAN

AB		ALEMBIC PHARMS	20MG	A202130	001	Jul 07, 2014

AB			40MG	A202130	002	Jul 07, 2014

PRESCRIPTION DRUG PRODUCT LIST

3-433 (of 474)

TELMISARTAN

TABLET; ORAL

TELMISARTAN

<u>AB</u>		<u>80MG</u>	<u>A202130</u>	<u>003</u>	Jul 07, 2014
<u>AB</u>	AMNEAL PHARMS	<u>20MG</u>	<u>A204415</u>	<u>001</u>	Sep 08, 2015
<u>AB</u>		<u>40MG</u>	<u>A204415</u>	<u>002</u>	Sep 08, 2015
<u>AB</u>		<u>80MG</u>	<u>A204415</u>	<u>003</u>	Sep 08, 2015
<u>AB</u>	AUROBINDO PHARMA	<u>20MG</u>	<u>A206511</u>	<u>001</u>	Sep 03, 2015
<u>AB</u>		<u>40MG</u>	<u>A206511</u>	<u>002</u>	Sep 03, 2015
<u>AB</u>		<u>80MG</u>	<u>A206511</u>	<u>003</u>	Sep 03, 2015
<u>AB</u>	CADILA PHARMS LTD	<u>20MG</u>	<u>A208605</u>	<u>001</u>	Jul 25, 2017
<u>AB</u>		<u>40MG</u>	<u>A208605</u>	<u>002</u>	Jul 25, 2017
<u>AB</u>		<u>80MG</u>	<u>A208605</u>	<u>003</u>	Jul 25, 2017
<u>AB</u>	CELLTRION	<u>20MG</u>	<u>A078710</u>	<u>001</u>	Jan 08, 2014
<u>AB</u>		<u>40MG</u>	<u>A078710</u>	<u>002</u>	Jan 08, 2014
<u>AB</u>		<u>80MG</u>	<u>A078710</u>	<u>003</u>	Jan 08, 2014
<u>AB</u>	GLENMARK PHARMS LTD	<u>20MG</u>	<u>A090032</u>	<u>001</u>	Jul 07, 2014
<u>AB</u>		<u>40MG</u>	<u>A090032</u>	<u>002</u>	Jul 07, 2014
<u>AB</u>		<u>80MG</u>	<u>A090032</u>	<u>003</u>	Jul 07, 2014
<u>AB</u>	HETERO LABS LTD V	<u>20MG</u>	<u>A205901</u>	<u>001</u>	Apr 22, 2016
<u>AB</u>		<u>40MG</u>	<u>A205901</u>	<u>002</u>	Apr 22, 2016
<u>AB</u>		<u>80MG</u>	<u>A205901</u>	<u>003</u>	Apr 22, 2016
<u>AB</u>	INVENTIA	<u>20MG</u>	<u>A205150</u>	<u>001</u>	Oct 30, 2015
<u>AB</u>		<u>40MG</u>	<u>A205150</u>	<u>002</u>	Oct 30, 2015
<u>AB</u>		<u>80MG</u>	<u>A205150</u>	<u>003</u>	Oct 30, 2015
<u>AB</u>	MICRO LABS	<u>20MG</u>	<u>A207016</u>	<u>001</u>	Oct 03, 2017
<u>AB</u>		<u>40MG</u>	<u>A207016</u>	<u>002</u>	Oct 03, 2017
<u>AB</u>		<u>80MG</u>	<u>A207016</u>	<u>003</u>	Oct 03, 2017
<u>AB</u>	MYLAN	<u>20MG</u>	<u>A202397</u>	<u>001</u>	Jul 07, 2014
<u>AB</u>		<u>40MG</u>	<u>A202397</u>	<u>002</u>	Jul 07, 2014
<u>AB</u>		<u>80MG</u>	<u>A202397</u>	<u>003</u>	Jul 07, 2014
<u>AB</u>	PRINSTON INC	<u>20MG</u>	<u>A207882</u>	<u>001</u>	May 03, 2017
<u>AB</u>		<u>40MG</u>	<u>A207882</u>	<u>002</u>	May 03, 2017
<u>AB</u>		<u>80MG</u>	<u>A207882</u>	<u>003</u>	May 03, 2017
<u>AB</u>	SANDOZ INC	<u>20MG</u>	<u>A203867</u>	<u>001</u>	Nov 03, 2014
<u>AB</u>		<u>40MG</u>	<u>A203867</u>	<u>002</u>	Nov 03, 2014
<u>AB</u>		<u>80MG</u>	<u>A203867</u>	<u>003</u>	Nov 03, 2014
<u>AB</u>	ZYDUS PHARMS	<u>20MG</u>	<u>A203325</u>	<u>001</u>	Aug 26, 2014
<u>AB</u>		<u>40MG</u>	<u>A203325</u>	<u>002</u>	Aug 26, 2014
<u>AB</u>		<u>80MG</u>	<u>A203325</u>	<u>003</u>	Aug 26, 2014

TELOTTRISTAT ETIPRATE

TABLET; ORAL

XERMELO

+! TERSERA

EQ 250MG BASE

N208794 001 Feb 28, 2017

TEMAZEPAM

CAPSULE; ORAL

RESTORIL

<u>AB</u>	+	SPECGX LLC	<u>7.5MG</u>	<u>N018163</u>	<u>003</u>	Oct 25, 1991
<u>AB</u>	+		<u>15MG</u>	<u>N018163</u>	<u>001</u>	
<u>AB</u>	+		<u>22.5MG</u>	<u>N018163</u>	<u>004</u>	Nov 02, 2004
<u>AB</u>	+!		<u>30MG</u>	<u>N018163</u>	<u>002</u>	

TEMAZEPAM

<u>AB</u>	ACTAVIS ELIZABETH	<u>15MG</u>	<u>A071620</u>	<u>002</u>	Aug 07, 1987
<u>AB</u>		<u>30MG</u>	<u>A071620</u>	<u>001</u>	Aug 07, 1987
<u>AB</u>	ALEMBIC PHARMS	<u>7.5MG</u>	<u>A211542</u>	<u>001</u>	Nov 23, 2018
<u>AB</u>		<u>15MG</u>	<u>A211542</u>	<u>002</u>	Nov 23, 2018
<u>AB</u>		<u>22.5MG</u>	<u>A211542</u>	<u>003</u>	Nov 23, 2018
<u>AB</u>		<u>30MG</u>	<u>A211542</u>	<u>004</u>	Nov 23, 2018
<u>AB</u>	AMNEAL PHARMS	<u>7.5MG</u>	<u>A203482</u>	<u>001</u>	May 23, 2016
<u>AB</u>		<u>15MG</u>	<u>A203482</u>	<u>002</u>	May 23, 2016
<u>AB</u>		<u>22.5MG</u>	<u>A203482</u>	<u>003</u>	May 23, 2016
<u>AB</u>		<u>30MG</u>	<u>A203482</u>	<u>004</u>	May 23, 2016
<u>AB</u>	NOVEL LABS INC	<u>7.5MG</u>	<u>A071457</u>	<u>002</u>	Jun 22, 2012
<u>AB</u>		<u>15MG</u>	<u>A071456</u>	<u>001</u>	Apr 21, 1987
<u>AB</u>		<u>22.5MG</u>	<u>A071457</u>	<u>003</u>	Jun 22, 2012
<u>AB</u>		<u>30MG</u>	<u>A071457</u>	<u>001</u>	Apr 21, 1987
<u>AB</u>	PRINSTON INC	<u>7.5MG</u>	<u>A201781</u>	<u>001</u>	Jun 04, 2015
<u>AB</u>		<u>15MG</u>	<u>A201781</u>	<u>002</u>	Jun 04, 2015
<u>AB</u>		<u>22.5MG</u>	<u>A201781</u>	<u>003</u>	Jun 04, 2015
<u>AB</u>		<u>30MG</u>	<u>A201781</u>	<u>004</u>	Jun 04, 2015
<u>AB</u>	SANDOZ	<u>15MG</u>	<u>A071427</u>	<u>001</u>	Jan 12, 1988

PRESCRIPTION DRUG PRODUCT LIST

3-434 (of 474)

TEMAZEPAM

CAPSULE; ORAL

TEMAZEPAM

<u>AB</u>		<u>30MG</u>	<u>A071428</u>	<u>001</u>	Jan 12, 1988
<u>AB</u>	SUN PHARM	<u>7.5MG</u>	<u>A078581</u>	<u>001</u>	Sep 08, 2009
	INDUSTRIES				
<u>AB</u>		<u>22.5MG</u>	<u>A071175</u>	<u>002</u>	Sep 14, 2009

TEMOZOLOMIDE

CAPSULE; ORAL

TEMOZOLOMIDE

<u>AB</u>	ACCORD HLTHCARE	<u>5MG</u>	<u>A201528</u>	<u>001</u>	Feb 27, 2017
<u>AB</u>		<u>20MG</u>	<u>A201528</u>	<u>002</u>	Feb 27, 2017
<u>AB</u>		<u>100MG</u>	<u>A201528</u>	<u>003</u>	Feb 27, 2017
<u>AB</u>		<u>140MG</u>	<u>A201528</u>	<u>004</u>	Feb 27, 2017
<u>AB</u>		<u>180MG</u>	<u>A201528</u>	<u>005</u>	Feb 27, 2017
<u>AB</u>	!	<u>250MG</u>	<u>A201528</u>	<u>006</u>	Feb 27, 2017
<u>AB</u>	AMNEAL PHARMS	<u>5MG</u>	<u>A203691</u>	<u>001</u>	May 08, 2015
<u>AB</u>		<u>20MG</u>	<u>A203691</u>	<u>002</u>	May 08, 2015
<u>AB</u>		<u>100MG</u>	<u>A203691</u>	<u>003</u>	May 08, 2015
<u>AB</u>		<u>140MG</u>	<u>A203691</u>	<u>004</u>	May 08, 2015
<u>AB</u>		<u>180MG</u>	<u>A203691</u>	<u>005</u>	May 08, 2015
<u>AB</u>		<u>250MG</u>	<u>A203691</u>	<u>006</u>	May 08, 2015
<u>AB</u>	CHARTWELL	<u>5MG</u>	<u>A206413</u>	<u>001</u>	Apr 12, 2016
<u>AB</u>		<u>20MG</u>	<u>A206413</u>	<u>002</u>	Apr 12, 2016
<u>AB</u>		<u>100MG</u>	<u>A206413</u>	<u>003</u>	Apr 12, 2016
<u>AB</u>		<u>140MG</u>	<u>A206413</u>	<u>004</u>	Apr 12, 2016
<u>AB</u>		<u>180MG</u>	<u>A206413</u>	<u>005</u>	Apr 12, 2016
<u>AB</u>		<u>250MG</u>	<u>A206413</u>	<u>006</u>	Apr 12, 2016
<u>AB</u>	CHEMI SPA	<u>5MG</u>	<u>A204639</u>	<u>001</u>	Nov 23, 2016
<u>AB</u>		<u>20MG</u>	<u>A204639</u>	<u>002</u>	Nov 23, 2016
<u>AB</u>		<u>100MG</u>	<u>A204639</u>	<u>003</u>	Nov 23, 2016
<u>AB</u>		<u>140MG</u>	<u>A204639</u>	<u>004</u>	Nov 23, 2016
<u>AB</u>		<u>180MG</u>	<u>A204639</u>	<u>005</u>	Nov 23, 2016
<u>AB</u>		<u>250MG</u>	<u>A204639</u>	<u>006</u>	Nov 23, 2016
<u>AB</u>	DEVA HOLDING AS	<u>5MG</u>	<u>A207658</u>	<u>001</u>	Apr 26, 2017
<u>AB</u>		<u>20MG</u>	<u>A207658</u>	<u>002</u>	Apr 26, 2017
<u>AB</u>		<u>100MG</u>	<u>A207658</u>	<u>003</u>	Apr 26, 2017
<u>AB</u>		<u>140MG</u>	<u>A207658</u>	<u>004</u>	Apr 26, 2017
<u>AB</u>		<u>180MG</u>	<u>A207658</u>	<u>005</u>	Apr 26, 2017
<u>AB</u>		<u>250MG</u>	<u>A207658</u>	<u>006</u>	Apr 26, 2017
<u>AB</u>	HERITAGE	<u>5MG</u>	<u>A078879</u>	<u>001</u>	Mar 01, 2010
<u>AB</u>		<u>20MG</u>	<u>A078879</u>	<u>002</u>	Mar 01, 2010
<u>AB</u>		<u>100MG</u>	<u>A078879</u>	<u>003</u>	Mar 01, 2010
<u>AB</u>		<u>140MG</u>	<u>A078879</u>	<u>005</u>	Mar 01, 2010
<u>AB</u>		<u>180MG</u>	<u>A078879</u>	<u>006</u>	Mar 01, 2010
<u>AB</u>		<u>250MG</u>	<u>A078879</u>	<u>004</u>	Mar 01, 2010
<u>AB</u>	NIVAGEN PHARMS INC	<u>5MG</u>	<u>A213328</u>	<u>001</u>	Nov 23, 2021
<u>AB</u>		<u>20MG</u>	<u>A213328</u>	<u>002</u>	Nov 23, 2021
<u>AB</u>		<u>100MG</u>	<u>A213328</u>	<u>003</u>	Nov 23, 2021
<u>AB</u>		<u>140MG</u>	<u>A213328</u>	<u>004</u>	Nov 23, 2021
<u>AB</u>		<u>180MG</u>	<u>A213328</u>	<u>005</u>	Nov 23, 2021
<u>AB</u>		<u>250MG</u>	<u>A213328</u>	<u>006</u>	Nov 23, 2021
<u>AB</u>	RISING	<u>5MG</u>	<u>A206309</u>	<u>001</u>	Apr 27, 2016
<u>AB</u>		<u>20MG</u>	<u>A206309</u>	<u>002</u>	Apr 27, 2016
<u>AB</u>		<u>100MG</u>	<u>A206309</u>	<u>003</u>	Apr 27, 2016
<u>AB</u>		<u>140MG</u>	<u>A206309</u>	<u>004</u>	Apr 27, 2016
<u>AB</u>		<u>180MG</u>	<u>A206309</u>	<u>005</u>	Apr 27, 2016
<u>AB</u>		<u>250MG</u>	<u>A206309</u>	<u>006</u>	Apr 27, 2016
<u>AB</u>	SUN PHARM	<u>5MG</u>	<u>A201742</u>	<u>001</u>	Feb 12, 2014
<u>AB</u>		<u>20MG</u>	<u>A201742</u>	<u>002</u>	Feb 12, 2014
<u>AB</u>		<u>100MG</u>	<u>A201742</u>	<u>003</u>	Feb 12, 2014
<u>AB</u>		<u>140MG</u>	<u>A201742</u>	<u>004</u>	Feb 12, 2014
<u>AB</u>		<u>180MG</u>	<u>A201742</u>	<u>005</u>	Feb 12, 2014
<u>AB</u>		<u>250MG</u>	<u>A201742</u>	<u>006</u>	Feb 12, 2014
<u>AB</u>	ZYDUS PHARMS	<u>5MG</u>	<u>A206750</u>	<u>001</u>	Jul 31, 2017
<u>AB</u>		<u>20MG</u>	<u>A206750</u>	<u>002</u>	Jul 31, 2017
<u>AB</u>		<u>100MG</u>	<u>A206750</u>	<u>003</u>	Jul 31, 2017
<u>AB</u>		<u>140MG</u>	<u>A206750</u>	<u>004</u>	Jul 31, 2017
<u>AB</u>		<u>180MG</u>	<u>A206750</u>	<u>005</u>	Jul 31, 2017
<u>AB</u>		<u>250MG</u>	<u>A206750</u>	<u>006</u>	Jul 31, 2017

PRESCRIPTION DRUG PRODUCT LIST

3-435 (of 474)

TEMOZOLOMIDE

POWDER; INTRAVENOUS

TEMODAR

+! MERCK SHARP DOHME 100MG/VIAL

N022277 001 Feb 27, 2009

TEMSIROLIMUS

SOLUTION; INTRAVENOUS

TEMSIROLIMUSAP ACCORD HLTHCARE 25MG/ML (25MG/ML)A203153 001 Jul 30, 2018AP GLAND PHARMA LTD 25MG/ML (25MG/ML)A207383 001 Aug 16, 2019TORISELAP +! PF PRISM CV 25MG/ML (25MG/ML)N022088 001 May 30, 2007TENAPANOR HYDROCHLORIDE

TABLET; ORAL

IBSRELA

+! ARDELYX INC EQ 50MG BASE

N211801 001 Sep 12, 2019

TENOFOVIR ALAFENAMIDE FUMARATE

TABLET; ORAL

VEMLIDY

+! GILEAD SCIENCES INC EQ 25MG BASE

N208464 001 Nov 10, 2016

TENOFOVIR DISOPROXIL FUMARATE

POWDER; ORAL

VIREAD

+! GILEAD SCIENCES INC 40MG/SCOOPFUL

N022577 001 Jan 18, 2012

TABLET; ORAL

TENOFOVIR DISOPROXIL FUMARATEAB AUROBINDO PHARMA 150MGA090647 001 Jan 26, 2018AB 200MGA090647 002 Jan 26, 2018AB 250MGA090647 003 Jan 26, 2018AB 300MGA090647 004 Jan 26, 2018AB CASI PHARMS INC 300MGA209550 001 Feb 26, 2018AB CHARTWELL 300MGA206481 001 Jul 26, 2018AB CIPLA 300MGA078800 001 Jan 26, 2018AB HETERO LABS LTD III 300MGA090636 001 Jan 26, 2018AB MACLEODS PHARMS LTD 300MGA203232 001 Jan 26, 2018AB QILU 200MGA209498 001 Mar 02, 2018AB 250MGA209498 002 Mar 02, 2018AB 300MGA209498 003 Mar 02, 2018AB STRIDES PHARMA 300MGA090742 001 Jan 26, 2018AB TEVA PHARMS USA 150MGA091612 002 Jan 26, 2018AB 200MGA091612 003 Jan 26, 2018AB 250MGA091612 004 Jan 26, 2018AB 300MGA091612 001 Mar 18, 2015VIREADAB + GILEAD SCIENCES INC 150MGN021356 002 Jan 18, 2012AB + 200MGN021356 003 Jan 18, 2012AB + 250MGN021356 004 Jan 18, 2012AB +! 300MGN021356 001 Oct 26, 2001TEPOTINIB HYDROCHLORIDE

TABLET; ORAL

TEPMETKO

+! EMD SERONO INC EQ 225MG BASE

N214096 001 Feb 03, 2021

TERAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

TERAZOSIN HYDROCHLORIDEAB APNAR PHARMA LP EQ 1MG BASEA074823 001 Mar 30, 1998AB EQ 2MG BASEA074823 002 Mar 30, 1998AB EQ 5MG BASEA074823 003 Mar 30, 1998AB EQ 10MG BASEA074823 004 Mar 30, 1998AB HERITAGE PHARMA EQ 1MG BASEA075614 002 Jan 30, 2001AB AVET EQ 2MG BASEA075614 001 Jan 30, 2001AB EQ 5MG BASEA075614 003 Jan 30, 2001AB EQ 10MG BASEA075614 004 Jan 30, 2001AB ! JUBILANT CADISTA EQ 1MG BASEA075317 001 Dec 20, 2004AB EQ 2MG BASEA075317 002 Dec 20, 2004AB EQ 5MG BASEA075317 003 Dec 20, 2004AB EQ 10MG BASEA075317 004 Dec 20, 2004

PRESCRIPTION DRUG PRODUCT LIST

3-436 (of 474)

TERBINAFINE HYDROCHLORIDE

TABLET; ORAL

TERBINAFINE HYDROCHLORIDE

<u>AB</u>	!	AUROBINDO PHARMA	<u>EQ 250MG BASE</u>	<u>A078297</u>	<u>001</u>	Jul 02, 2007
<u>AB</u>		BRECKENRIDGE PHARM	<u>EQ 250MG BASE</u>	<u>A077714</u>	<u>001</u>	Jun 04, 2010
<u>AB</u>		CHARTWELL	<u>EQ 250MG BASE</u>	<u>A078199</u>	<u>001</u>	Jul 02, 2007
<u>AB</u>		CIPLA	<u>EQ 250MG BASE</u>	<u>A077137</u>	<u>001</u>	Jul 02, 2007
<u>AB</u>		DR REDDYS LABS INC	<u>EQ 250MG BASE</u>	<u>A076390</u>	<u>001</u>	Jul 02, 2007
<u>AB</u>		EMED MEDCL	<u>EQ 250MG BASE</u>	<u>A077919</u>	<u>001</u>	Jul 02, 2007
<u>AB</u>		GLENMARK GENERICS	<u>EQ 250MG BASE</u>	<u>A078157</u>	<u>001</u>	Jul 02, 2007
<u>AB</u>		INVAGEN PHARMS	<u>EQ 250MG BASE</u>	<u>A077533</u>	<u>001</u>	Jul 02, 2007
<u>AB</u>		ORBION PHARMS	<u>EQ 250MG BASE</u>	<u>A078163</u>	<u>001</u>	Jul 02, 2007

TERBUTALINE SULFATE

INJECTABLE; INJECTION

TERBUTALINE SULFATE

<u>AP</u>	!	CHARTWELL INJECTABLE	<u>1MG/ML</u>	<u>A076770</u>	<u>001</u>	Apr 23, 2004
<u>AP</u>		FRESENIUS KABI USA	<u>1MG/ML</u>	<u>A076887</u>	<u>001</u>	May 26, 2004
<u>AP</u>		HIKMA FARMACEUTICA	<u>1MG/ML</u>	<u>A078630</u>	<u>001</u>	May 20, 2009
<u>AP</u>		UNITED BIOMEDCL	<u>1MG/ML</u>	<u>A200122</u>	<u>001</u>	Nov 08, 2013

TABLET; ORAL

BRETHINE

<u>AB</u>	+	ANI PHARMS	<u>2.5MG</u>	<u>N017849</u>	<u>001</u>	
<u>AB</u>	+		<u>5MG</u>	<u>N017849</u>	<u>002</u>	

TERBUTALINE SULFATE

<u>AB</u>		IMPAX LABS	<u>2.5MG</u>	<u>A075877</u>	<u>001</u>	Jun 26, 2001
<u>AB</u>			<u>5MG</u>	<u>A075877</u>	<u>002</u>	Jun 26, 2001
<u>AB</u>		LANNETT CO INC	<u>2.5MG</u>	<u>A077152</u>	<u>001</u>	Mar 25, 2005
<u>AB</u>	!		<u>5MG</u>	<u>A077152</u>	<u>002</u>	Mar 25, 2005
<u>AB</u>		TWI PHARMS	<u>2.5MG</u>	<u>A211832</u>	<u>001</u>	Jun 19, 2020
<u>AB</u>			<u>5MG</u>	<u>A211832</u>	<u>002</u>	Jun 19, 2020

TERCONAZOLE

CREAM; VAGINAL

TERCONAZOLE

<u>AB</u>		FOUGERA PHARMS	<u>0.4%</u>	<u>A076712</u>	<u>001</u>	Feb 18, 2005
<u>AB</u>	!	TARO	<u>0.4%</u>	<u>A076043</u>	<u>001</u>	Jan 19, 2005
BX	+	FOUGERA PHARMS INC	0.8%	N021735	001	Oct 01, 2004
BX	!	TARO	0.8%	A075953	001	Apr 06, 2004

SUPPOSITORY; VAGINAL

TERCONAZOLE

<u>AB</u>	!	PADAGIS ISRAEL	<u>80MG</u>	<u>A077149</u>	<u>001</u>	Mar 17, 2006
<u>AB</u>		TARO	<u>80MG</u>	<u>A077553</u>	<u>001</u>	Mar 09, 2007

TERIFLUNOMIDE

TABLET; ORAL

AUBAGIO

<u>AB</u>	+	SANOFI AVENTIS US	<u>7MG</u>	<u>N202992</u>	<u>001</u>	Sep 12, 2012
<u>AB</u>	+	!	<u>14MG</u>	<u>N202992</u>	<u>002</u>	Sep 12, 2012

TERIFLUNOMIDE

<u>AB</u>		ACCORD HLTHCARE	<u>7MG</u>	<u>A209690</u>	<u>001</u>	Jan 07, 2019
<u>AB</u>			<u>14MG</u>	<u>A209690</u>	<u>002</u>	Jan 07, 2019
<u>AB</u>		ALEMBIC PHARMS	<u>7MG</u>	<u>A209572</u>	<u>001</u>	Apr 19, 2019
<u>AB</u>			<u>14MG</u>	<u>A209572</u>	<u>002</u>	Apr 19, 2019
<u>AB</u>		GLENMARK PHARMS	<u>7MG</u>	<u>A209663</u>	<u>001</u>	Nov 15, 2018
<u>AB</u>			<u>14MG</u>	<u>A209663</u>	<u>002</u>	Nov 15, 2018
<u>AB</u>		SANDOZ INC	<u>7MG</u>	<u>A209710</u>	<u>001</u>	Jan 03, 2019
<u>AB</u>			<u>14MG</u>	<u>A209710</u>	<u>002</u>	Jan 03, 2019

TERIPARATIDE

SOLUTION; SUBCUTANEOUS

BONSITY

	ALVOGEN	0.62MG/2.48ML (0.25MG/ML)	N211939	001	Oct 04, 2019
FORTEO					
+	LILLY	0.6MG/2.4ML (0.25MG/ML)	N021318	002	Jun 25, 2008

TERLIPRESSIN ACETATE

POWDER; INTRAVENOUS

TERLIVAZ

	+	!	MALLINCKRODT IRELAND	EQ 0.85MG BASE/VIAL	N022231	001	Sep 14, 2022

PRESCRIPTION DRUG PRODUCT LIST

3-437 (of 474)

TESTOSTERONE

FILM, EXTENDED RELEASE;TRANSDERMAL

ANDRODERM

+! ALLERGAN

2MG/24HR

N020489 003 Oct 20, 2011

+!

4MG/24HR

N020489 004 Oct 20, 2011

GEL;TRANSDERMAL

TESTOSTERONEAB1 ACTAVIS LABS UT INC25MG/2.5GM PACKETA076737 001 Jan 27, 2006AB1 !50MG/5GM PACKETA076737 002 Jan 27, 2006AB1 ENCUBE50MG/5GM PACKETA212984 001 Nov 09, 2021AB1 STRIDES PHARMA25MG/2.5GM PACKETA076744 001 May 23, 2007AB150MG/5GM PACKETA076744 002 May 23, 2007TESTIMAB2 +! AUXILIUM PHARMS LLC50MG/5GM PACKETN021454 001 Oct 31, 2002TESTOSTERONEAB2 ACTAVIS LABS UT INC1.62% (20.25MG/1.25GM PACKET)A204570 002 Jul 17, 2020AB21.62% (40.5MG/2.5GM PACKET)A204570 003 Jul 17, 2020AB250MG/5GM PACKETA091073 001 Sep 18, 2017AB2 PADAGIS ISRAEL1.62% (20.25MG/1.25GM PACKET)A205781 001 Jul 12, 2017AB2 !1.62% (40.5MG/2.5GM PACKET)A205781 002 Jul 12, 2017VOGELXOAB2 UPSHER SMITH LABS50MG/5GM PACKETN204399 002 Jun 04, 2014

GEL, METERED;NASAL

NATESTO

ACERUS

5.5MG/0.122GM ACTUATION

N205488 001 May 28, 2014

GEL, METERED;TRANSDERMAL

ANDROGELAB +! ABBVIE1.62% (20.25MG/1.25GM ACTUATION)N022309 001 Apr 29, 2011FORTESTAAB +! ENDO PHARMS10MG/0.5GM ACTUATIONN021463 001 Dec 29, 2010TESTOSTERONEAB ACTAVIS LABS UT INC1.62% (20.25MG/1.25GM ACTUATION)A204570 001 Apr 10, 2019AB10MG/0.5GM ACTUATIONA204571 001 Aug 05, 2015AB AMNEAL1.62% (20.25MG/1.25GM ACTUATION)A207373 001 Apr 10, 2019AB DR REDDYS1.62% (20.25MG/1.25GM ACTUATION)A208620 001 Apr 10, 2019AB1.62% (20.25MG/1.25GM ACTUATION)A208560 001 Apr 10, 2019AB PADAGIS ISRAEL1.62% (20.25MG/1.25GM ACTUATION)A204268 001 Aug 04, 2015AB1.62% (20.25MG/1.25GM ACTUATION)A209390 001 Sep 23, 2019AB TWI PHARMS1.62% (20.25MG/1.25GM ACTUATION)A210835 001 Apr 16, 2020AB XIROMED1.62% (20.25MG/1.25GM ACTUATION)A076737 003 Mar 09, 2015

BX ! ACTAVIS LABS UT INC

12.5MG/1.25GM ACTUATION

A076737 003 Mar 09, 2015

VOGELXO

BX UPSHER SMITH LABS

12.5MG/1.25GM ACTUATION

N204399 003 Jun 04, 2014

PELLET;IMPLANTATION

TESTOPEL

! AUXILIUM PHARMS INC 75MG

A080911 001

SOLUTION, METERED;TRANSDERMAL

TESTOSTERONEAT ACTAVIS LABS UT INC30MG/1.5ML ACTUATIONA205328 001 Aug 07, 2017AT30MG/1.5ML ACTUATIONA209533 001 Jan 29, 2018AT DASH PHARMS30MG/1.5ML ACTUATIONA212301 001 Jan 11, 2021AT LUPIN LTD30MG/1.5ML ACTUATIONA208061 001 Oct 23, 2017AT ! PADAGIS ISRAEL30MG/1.5ML ACTUATIONA204255 001 Feb 28, 2017AT30MG/1.5ML ACTUATIONA209836 001 Sep 03, 2021TESTOSTERONE CYPIONATE

INJECTABLE;INJECTION

DEPO-TESTOSTERONEAO +! PFIZER100MG/MLA085635 002AO200MG/MLA085635 003TESTOSTERONE CYPIONATEAO AM REGENT200MG/MLA207742 001 Jun 16, 2017AO100MG/MLA210362 001 Jun 19, 2018AO200MG/MLA210362 002 Jun 19, 2018AO100MG/MLA090387 001 Jul 15, 2010AO200MG/MLA090387 002 Jul 15, 2010AO HIKMA FARMACEUTICA200MG/MLA091244 001 May 01, 2012AO200MG/MLA040530 001 Jan 31, 2005AO PADAGIS US100MG/MLA040615 001 Aug 10, 2006AO200MG/MLA040615 002 Aug 10, 2006AO SUN PHARM INDS LTD100MG/MLA201720 001 Jun 03, 2013AO200MG/MLA201720 002 Jun 03, 2013AO WATSON PHARMS INC200MG/MLA086030 001AO200MG/MLA206368 001 Apr 24, 2019

PRESCRIPTION DRUG PRODUCT LIST

3-438 (of 474)

TESTOSTERONE ENANTHATE

INJECTABLE; INJECTION

TESTOSTERONE ENANTHATE

<u>AO</u>	HIKMA FARMACEUTICA	<u>200MG/ML</u>	<u>A091120</u>	<u>001</u>	Sep 18, 2012
<u>AO</u>	NEXUS PHARMS	<u>200MG/ML</u>	<u>A040575</u>	<u>001</u>	Jun 14, 2006
<u>AO</u>	! WATSON PHARMS INC	<u>200MG/ML</u>	<u>A085598</u>	<u>001</u>	
	SOLUTION; SUBCUTANEOUS				
	XYOSTED (AUTOINJECTOR)				
	+! ANTARES PHARMA INC	50MG/0.5ML (50MG/0.5ML)	N209863	001	Sep 28, 2018
	+!	75MG/0.5ML (75MG/0.5ML)	N209863	002	Sep 28, 2018
	+!	100MG/0.5ML (100MG/0.5ML)	N209863	003	Sep 28, 2018

TESTOSTERONE UNDECANOATE

CAPSULE; ORAL

JATENZO

+	TOLMAR	158MG	N206089	001	Mar 27, 2019
+		198MG	N206089	002	Mar 27, 2019
+!		237MG	N206089	003	Mar 27, 2019

KYZATREX

+	MARIUS PHARMS LLC	100MG	N213953	001	Jul 27, 2022
+		150MG	N213953	002	Jul 27, 2022
+!		200MG	N213953	003	Jul 27, 2022

TLANDO

+!	ANTARES PHARMA INC	112.5MG	N208088	001	Mar 28, 2022

INJECTABLE; INTRAMUSCULAR

AVEED

+!	ENDO PHARMS INC	750MG/3ML (250MG/ML)	N022219	001	Mar 05, 2014

TETRABENAZINE

TABLET; ORAL

TETRABENAZINE

<u>AB</u>	ACTAVIS LABS FL INC	<u>25MG</u>	<u>A206686</u>	<u>001</u>	Jul 07, 2017
<u>AB</u>	APOTEX	<u>12.5MG</u>	<u>A206093</u>	<u>001</u>	Mar 17, 2020
<u>AB</u>		<u>25MG</u>	<u>A206093</u>	<u>002</u>	Mar 17, 2020
<u>AB</u>	BIONPHARMA INC	<u>12.5MG</u>	<u>A208826</u>	<u>001</u>	Dec 18, 2017
<u>AB</u>		<u>25MG</u>	<u>A208826</u>	<u>002</u>	Dec 18, 2017
<u>AB</u>	DR REDDYS	<u>12.5MG</u>	<u>A209284</u>	<u>001</u>	Jan 08, 2018
<u>AB</u>		<u>25MG</u>	<u>A209284</u>	<u>002</u>	Jan 08, 2018
<u>AB</u>	HETERO LABS LTD V	<u>12.5MG</u>	<u>A204574</u>	<u>001</u>	Feb 03, 2016
<u>AB</u>		<u>25MG</u>	<u>A204574</u>	<u>002</u>	Feb 03, 2016
<u>AB</u>	LUPIN LTD	<u>12.5MG</u>	<u>A210544</u>	<u>001</u>	Apr 20, 2018
<u>AB</u>		<u>25MG</u>	<u>A210544</u>	<u>002</u>	Apr 20, 2018
<u>AB</u>	MYLAN	<u>12.5MG</u>	<u>A207682</u>	<u>001</u>	Jan 31, 2017
<u>AB</u>		<u>25MG</u>	<u>A207682</u>	<u>002</u>	Jan 31, 2017
<u>AB</u>	PIRAMAL HLTHCARE UK	<u>12.5MG</u>	<u>A213316</u>	<u>001</u>	Jan 22, 2020
<u>AB</u>		<u>25MG</u>	<u>A213316</u>	<u>002</u>	Jan 22, 2020
<u>AB</u>	SUN PHARM	<u>12.5MG</u>	<u>A206129</u>	<u>001</u>	Aug 17, 2015
<u>AB</u>		<u>25MG</u>	<u>A206129</u>	<u>002</u>	Aug 17, 2015

XENAZINE

<u>AB</u>	+ BAUSCH	<u>12.5MG</u>	<u>N021894</u>	<u>001</u>	Aug 15, 2008
<u>AB</u>	+!	<u>25MG</u>	<u>N021894</u>	<u>002</u>	Aug 15, 2008

TETRACAINE HYDROCHLORIDE

SOLUTION; OPHTHALMIC

TETRACAINE HYDROCHLORIDE

+!	ALCON LABS	0.5%	N208135	001	Feb 29, 2016
+!	BAUSCH LOMB IRELAND	0.5%	N210821	001	Mar 12, 2019

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL

ACHROMYCIN V

<u>AB</u>	+ AVET	<u>250MG</u>	<u>N050278</u>	<u>003</u>	
<u>AB</u>	+!	<u>500MG</u>	<u>N050278</u>	<u>001</u>	

TETRACYCLINE HYDROCHLORIDE

<u>AB</u>	AMNEAL PHARMS NY	<u>250MG</u>	<u>A210674</u>	<u>001</u>	Sep 18, 2018
<u>AB</u>		<u>500MG</u>	<u>A210674</u>	<u>002</u>	Sep 18, 2018
<u>AB</u>	BRECKENRIDGE	<u>250MG</u>	<u>A210662</u>	<u>001</u>	Nov 07, 2018
<u>AB</u>		<u>500MG</u>	<u>A210662</u>	<u>002</u>	Nov 07, 2018
<u>AB</u>	CHARTWELL TETRA	<u>250MG</u>	<u>A062752</u>	<u>001</u>	Aug 12, 1988
<u>AB</u>		<u>500MG</u>	<u>A062752</u>	<u>002</u>	Aug 12, 1988
<u>AB</u>	STRIDES PHARMA	<u>250MG</u>	<u>A212635</u>	<u>001</u>	Mar 03, 2020
<u>AB</u>		<u>500MG</u>	<u>A212635</u>	<u>002</u>	Mar 03, 2020
<u>AB</u>	WATSON LABS	<u>250MG</u>	<u>A061837</u>	<u>001</u>	
<u>AB</u>		<u>500MG</u>	<u>A061837</u>	<u>002</u>	

PRESCRIPTION DRUG PRODUCT LIST

3-439 (of 474)

TETRAHYDROZOLINE HYDROCHLORIDE

SOLUTION; NASAL

TYZINE

!	FOUGERA PHARMS	0.05%	A086576 002
		0.1%	A086576 001

SPRAY; NASAL

TYZINE

!	FOUGERA PHARMS	0.1%	A086576 003

THALIDOMIDE

CAPSULE; ORAL

THALOMID

+	CELGENE	50MG	N020785 001	Jul 16, 1998
+		100MG	N020785 002	Jan 17, 2003
+		150MG	N020785 004	Jan 10, 2007
+	!	200MG	N020785 003	Jan 17, 2003

THALLOUS CHLORIDE TL-201

INJECTABLE; INJECTION

THALLOUS CHLORIDE TL 201

AP	+ !	CURIUM	<u>1mCi/ML</u>	<u>N018150 001</u>
AP	+ !	LANTHEUS MEDCL	<u>1mCi/ML</u>	<u>N017806 001</u>

THEOPHYLLINE

CAPSULE, EXTENDED RELEASE; ORAL

THEO-24

	ACTIENT PHARMS	100MG	A087942 001	Aug 22, 1983
!	AUXILIUM PHARMS INC	400MG	A081034 001	Feb 28, 1992
+	AUXILIUM PHARMS LLC	200MG	A087943 001	Aug 22, 1983
		300MG	A087944 001	Aug 22, 1983

INJECTABLE; INJECTION

THEOPHYLLINE 0.04% AND DEXTROSE 5% IN PLASTIC CONTAINER

+	!	B BRAUN	40MG/100ML	N019826 001	Aug 14, 1992

THEOPHYLLINE 0.08% AND DEXTROSE 5% IN PLASTIC CONTAINER

+	!	B BRAUN	80MG/100ML	N019826 002	Aug 14, 1992

THEOPHYLLINE 0.16% AND DEXTROSE 5% IN PLASTIC CONTAINER

+	!	B BRAUN	160MG/100ML	N019826 003	Aug 14, 1992

THEOPHYLLINE 0.32% AND DEXTROSE 5% IN PLASTIC CONTAINER

+	!	B BRAUN	320MG/100ML	N019826 006	Aug 14, 1992

SOLUTION; ORAL

THEOPHYLLINE

AA	!	CHARTWELL MOLECULAR	<u>80MG/15ML</u>	<u>A091156 001</u>	Apr 13, 2011
AA		TRIS PHARMA INC	<u>80MG/15ML</u>	<u>A091586 001</u>	Jun 15, 2012

SOLUTION, ELIXIR; ORAL

ELIXOPHYLLIN

AA	+ !	NOSTRUM LABS INC	<u>80MG/15ML</u>	<u>A085186 001</u>

THEOPHYLLINE

AA		PHARM ASSOC	<u>80MG/15ML</u>	<u>A206344 001</u>	Dec 16, 2016

TABLET, EXTENDED RELEASE; ORAL

THEOPHYLLINE

AB		ALEMBIC PHARMS	<u>300MG</u>	<u>A090430 001</u>	Oct 27, 2010
AB	!		<u>450MG</u>	<u>A090430 002</u>	Oct 27, 2010
AB		GLENMARK GENERICS	<u>400MG</u>	<u>A090355 001</u>	Jul 13, 2010
AB			<u>600MG</u>	<u>A090355 002</u>	Jul 13, 2010
AB		GLENMARK PHARMS LTD	<u>300MG</u>	<u>A212184 001</u>	Jun 03, 2021
AB			<u>450MG</u>	<u>A212184 002</u>	Jun 03, 2021
AB		HERITAGE PHARMA	<u>300MG</u>	<u>A089763 001</u>	Apr 30, 1990
AB		AVET	<u>450MG</u>	<u>A081236 001</u>	Nov 09, 1992
AB		NOSTRUM LABS INC	<u>400MG</u>	<u>A040560 003</u>	Apr 21, 2006
AB	!		<u>600MG</u>	<u>A040560 002</u>	Apr 21, 2006
AB	+	RHODES PHARMS	<u>400MG</u>	<u>A040086 002</u>	Sep 01, 1982
AB			<u>600MG</u>	<u>A040086 001</u>	Apr 15, 1996
AB		TEVA PHARMS INC	<u>300MG</u>	<u>A216961 001</u>	Oct 12, 2022
AB			<u>450MG</u>	<u>A216961 002</u>	Oct 12, 2022

THIAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

THIAMINE HYDROCHLORIDE

AP		EUGIA PHARMA	<u>100MG/ML</u>	<u>A208703 001</u>	Apr 20, 2022
AP	+ !	FRESENIUS KABI USA	<u>100MG/ML</u>	<u>A080556 001</u>	
AP		MYLAN INSTITUTIONAL	<u>100MG/ML</u>	<u>A091623 001</u>	Jun 25, 2012
AP		SAGENT PHARMS INC	<u>100MG/ML</u>	<u>A206106 001</u>	Dec 01, 2017
AP		WEST-WARD PHARMS	<u>100MG/ML</u>	<u>A080575 001</u>	
		INT			

PRESCRIPTION DRUG PRODUCT LIST

3-440 (of 474)

THIOGUANINE

TABLET; ORAL

THIOGUANINE

+! WOODWARD SPECL 40MG

N012429 001

THIORIDAZINE HYDROCHLORIDE

TABLET; ORAL

THIORIDAZINE HYDROCHLORIDE

MYLAN

10MG

A088004 002 Mar 15, 1983

25MG

A088004 003 Mar 15, 1983

50MG

A088004 004 Mar 15, 1983

!

100MG

A088004 001 Nov 18, 1983

THIOTEPA

INJECTABLE; INJECTION

THIOTEPA

AP BELOTECA INC

15MG/VIALA211831 001 Dec 08, 2021

AP DR REDDYS

15MG/VIALA210337 001 May 04, 2018

AP HENGRUI PHARMA

15MG/VIALA209150 001 May 04, 2018

AP STI PHARMA LLC

15MG/VIALA208242 001 Jan 10, 2020

AP ! WEST-WARD PHARMS

15MG/VIALA075547 001 Apr 02, 2001

INT

POWDER; INTRACAVITARY, INTRAVENOUS, INTRAVESICAL

TEPADINA

AP +! ADIENNE SA

15MG/VIALN208264 001 Jan 26, 2017

AP +!

100MG/VIALN208264 002 Jan 26, 2017THIOTEPA

AP GLAND PHARMA LTD

15MG/VIALA214222 001 Mar 08, 2021

AP

100MG/VIALA214222 002 Jan 03, 2022

AP MSN

15MG/VIALA213049 001 Mar 04, 2020

AP

100MG/VIALA213049 002 Mar 04, 2020THIOTHIXENE

CAPSULE; ORAL

THIOTHIXENE

AB AMNEAL

1MGA215456 001 Feb 28, 2022

AB

2MGA215456 002 Feb 28, 2022

AB

5MGA215456 003 Feb 28, 2022

AB

10MGA215456 004 Feb 28, 2022

AB MYLAN

1MGA071093 002 Jun 23, 1987

AB

2MGA071093 003 Jun 23, 1987

AB

5MGA071093 004 Jun 23, 1987

AB

10MGA071093 001 Jun 23, 1987

AB NOVITIUM PHARMA

1MGA211642 001 Apr 05, 2019

AB

2MGA211642 002 Apr 05, 2019

AB !

5MGA211642 003 Apr 05, 2019

AB

10MGA211642 004 Apr 05, 2019TIAGABINE HYDROCHLORIDE

TABLET; ORAL

GABITRIL

AB + CEPHALON

2MGN020646 005 Apr 16, 1999

AB +!

4MGN020646 001 Sep 30, 1997

AB +

12MGN020646 002 Sep 30, 1997

AB +

16MGN020646 003 Sep 30, 1997TIAGABINE HYDROCHLORIDE

AB MSN

2MGA214816 001 Nov 16, 2021

AB

4MGA214816 002 Nov 16, 2021

AB

12MGA214816 003 Nov 16, 2021

AB

16MGA214816 004 Nov 16, 2021

AB SUN PHARM INDS

2MGA077555 001 Nov 04, 2011

AB

4MGA077555 002 Nov 04, 2011TICAGRELOR

TABLET; ORAL

BRILINTA

AB +! ASTRAZENECA

90MGN022433 001 Jul 20, 2011TICAGRELOR

AB HISUN PHARM

90MGA208575 001 Jan 23, 2019

HANGZHOU

BRILINTA

+ ASTRAZENECA

60MG

N022433 002 Sep 03, 2015

PRESCRIPTION DRUG PRODUCT LIST

3-441 (of 474)

TICLOPIDINE HYDROCHLORIDE

TABLET; ORAL

TICLOPIDINE HYDROCHLORIDE

<u>AB</u>	APOTEX	<u>250MG</u>	<u>A075089</u>	<u>001</u>	Jul 01, 1999
<u>AB</u>	! TEVA	<u>250MG</u>	<u>A075149</u>	<u>001</u>	Aug 20, 1999

TIGECYCLINE

POWDER; INTRAVENOUS

TIGECYCLINE

<u>AP</u>	AMNEAL	<u>50MG/VIAL</u>	<u>N211158</u>	<u>001</u>	Aug 02, 2018
<u>AP</u>	APOTEX	<u>50MG/VIAL</u>	<u>A204439</u>	<u>001</u>	Dec 21, 2018
<u>AP</u>	EUGIA PHARMA	<u>50MG/VIAL</u>	<u>A206335</u>	<u>001</u>	Jun 11, 2019
<u>AP</u>	+! FRESenius KABI USA	<u>50MG/VIAL</u>	<u>N205645</u>	<u>001</u>	Dec 01, 2016
<u>AP</u>	MEITHEAL	<u>50MG/VIAL</u>	<u>A214020</u>	<u>001</u>	May 13, 2021
<u>AP</u>	SANDOZ INC	<u>50MG/VIAL</u>	<u>A091620</u>	<u>001</u>	May 27, 2015

TYGACIL

<u>AP</u>	+! PF PRISM CV	<u>50MG/VIAL</u>	<u>N021821</u>	<u>001</u>	Jun 15, 2005
TIGECYCLINE					
	ACCORD HLTHCARE INC	50MG/VIAL	N208744	001	Jan 18, 2018

TIMOLOL

SOLUTION/DROPS; OPHTHALMIC

BETIMOL

<u>AT</u>	+! THEA PHARMA	<u>EQ 0.25% BASE</u>	<u>N020439</u>	<u>001</u>	Mar 31, 1995
<u>AT</u>	+!	<u>EQ 0.5% BASE</u>	<u>N020439</u>	<u>002</u>	Mar 31, 1995

TIMOLOL

<u>AT</u>	AKORN	<u>EQ 0.25% BASE</u>	<u>A205309</u>	<u>001</u>	Sep 30, 2016
<u>AT</u>		<u>EQ 0.5% BASE</u>	<u>A205309</u>	<u>002</u>	Sep 30, 2016

TIMOLOL MALEATE

SOLUTION, GEL FORMING/DROPS; OPHTHALMIC

TIMOLOL MALEATE

<u>AB</u>	! ALEMBIC PHARMS	<u>EQ 0.25% BASE</u>	<u>A212942</u>	<u>001</u>	Oct 22, 2020
<u>AB</u>	!	<u>EQ 0.5% BASE</u>	<u>A212942</u>	<u>002</u>	Oct 22, 2020
<u>AB</u>	DR REDDYS	<u>EQ 0.25% BASE</u>	<u>A215733</u>	<u>001</u>	Sep 22, 2022
<u>AB</u>		<u>EQ 0.5% BASE</u>	<u>A215733</u>	<u>002</u>	Sep 22, 2022
<u>AB</u>	GLAND PHARMA LTD	<u>EQ 0.25% BASE</u>	<u>A214645</u>	<u>001</u>	Jun 24, 2022
<u>AB</u>	+! SANDOZ INC	<u>EQ 0.25% BASE</u>	<u>N020963</u>	<u>001</u>	Oct 21, 1998
<u>AB</u>	+!	<u>EQ 0.5% BASE</u>	<u>N020963</u>	<u>002</u>	Oct 21, 1998

TIMOPTIC-XE

<u>AB</u>	+ BAUSCH AND LOMB INC	<u>EQ 0.25% BASE</u>	<u>N020330</u>	<u>001</u>	Nov 04, 1993
<u>AB</u>	+	<u>EQ 0.5% BASE</u>	<u>N020330</u>	<u>002</u>	Nov 04, 1993

SOLUTION/DROPS; OPHTHALMIC

TIMOLOL MALEATE

<u>AT1</u>	AKORN	<u>EQ 0.5% BASE</u>	<u>A074466</u>	<u>001</u>	Mar 25, 1997
<u>AT1</u>	BAUSCH AND LOMB	<u>EQ 0.25% BASE</u>	<u>A074778</u>	<u>001</u>	Mar 25, 1997
<u>AT1</u>		<u>EQ 0.5% BASE</u>	<u>A074776</u>	<u>001</u>	Mar 25, 1997
<u>AT1</u>	FDC LTD	<u>EQ 0.25% BASE</u>	<u>A077259</u>	<u>001</u>	Apr 30, 2008
<u>AT1</u>		<u>EQ 0.5% BASE</u>	<u>A077259</u>	<u>002</u>	Apr 30, 2008
<u>AT1</u>	MANKIND PHARMA	<u>EQ 0.25% BASE</u>	<u>A078771</u>	<u>001</u>	Sep 28, 2009
<u>AT1</u>		<u>EQ 0.5% BASE</u>	<u>A078771</u>	<u>002</u>	Sep 28, 2009
<u>AT1</u>	PACIFIC PHARMA	<u>EQ 0.25% BASE</u>	<u>A074746</u>	<u>001</u>	Mar 25, 1997
<u>AT1</u>		<u>EQ 0.5% BASE</u>	<u>A074747</u>	<u>001</u>	Mar 25, 1997
<u>AT1</u>	! SANDOZ INC	<u>EQ 0.25% BASE</u>	<u>A074261</u>	<u>001</u>	Apr 28, 1995
<u>AT1</u>	!	<u>EQ 0.5% BASE</u>	<u>A074262</u>	<u>001</u>	Apr 28, 1995

TIMOPTIC

<u>AT1</u>	+ BAUSCH AND LOMB INC	<u>EQ 0.25% BASE</u>	<u>N018086</u>	<u>001</u>	
<u>AT1</u>	+	<u>EQ 0.5% BASE</u>	<u>N018086</u>	<u>002</u>	

ISTALOL

<u>AT2</u>	+! BAUSCH AND LOMB	<u>EQ 0.5% BASE</u>	<u>N021516</u>	<u>001</u>	Jun 04, 2004

TIMOLOL MALEATE

<u>AT2</u>	APOTEX	<u>EQ 0.5% BASE</u>	<u>A204936</u>	<u>001</u>	Apr 17, 2015
<u>AT3</u>	AKORN	<u>EQ 0.5% BASE</u>	<u>A212291</u>	<u>001</u>	Sep 11, 2020
<u>AT3</u>	AMRING PHARMS	<u>EQ 0.25% BASE</u>	<u>A212592</u>	<u>001</u>	Dec 13, 2021
<u>AT3</u>		<u>EQ 0.5% BASE</u>	<u>A212592</u>	<u>002</u>	Dec 13, 2021
<u>AT3</u>	INGENUS PHARMS LLC	<u>EQ 0.25% BASE</u>	<u>A216533</u>	<u>001</u>	Sep 13, 2022
<u>AT3</u>		<u>EQ 0.5% BASE</u>	<u>A216533</u>	<u>002</u>	Sep 13, 2022
<u>AT3</u>	MICRO LABS	<u>EQ 0.5% BASE</u>	<u>A216596</u>	<u>001</u>	Sep 07, 2022

TIMOPTIC IN OCULOSE

<u>AT3</u>	+! BAUSCH AND LOMB INC	<u>EQ 0.25% BASE</u>	<u>N019463</u>	<u>001</u>	Nov 05, 1986
<u>AT3</u>	+!	<u>EQ 0.5% BASE</u>	<u>N019463</u>	<u>002</u>	Nov 05, 1986

PRESCRIPTION DRUG PRODUCT LIST

3-442 (of 474)

TIMOLOL MALEATE

TABLET; ORAL

TIMOLOL MALEATE

<u>AB</u>	ELYSIUM	<u>5MG</u>	<u>A207556</u>	<u>001</u>	May 02, 2019
<u>AB</u>		<u>10MG</u>	<u>A207556</u>	<u>002</u>	May 02, 2019
<u>AB</u>		<u>20MG</u>	<u>A207556</u>	<u>003</u>	May 02, 2019
<u>AB</u>	MYLAN	<u>5MG</u>	<u>A072668</u>	<u>002</u>	Jun 08, 1990
<u>AB</u>		<u>10MG</u>	<u>A072668</u>	<u>003</u>	Jun 08, 1990
<u>AB</u>	!	<u>20MG</u>	<u>A072668</u>	<u>001</u>	Jun 08, 1990

TINIDAZOLE

TABLET; ORAL

TINDAMAX

<u>AB</u>	+	MISSION PHARMA	<u>250MG</u>	<u>N021618</u>	<u>001</u>	May 17, 2004
<u>AB</u>	+	!	<u>500MG</u>	<u>N021618</u>	<u>002</u>	May 17, 2004

TINIDAZOLE

<u>AB</u>		EDENBRIDGE PHARMS	<u>250MG</u>	<u>A203808</u>	<u>001</u>	Aug 04, 2015
<u>AB</u>			<u>500MG</u>	<u>A203808</u>	<u>002</u>	Aug 04, 2015
<u>AB</u>		NOVEL LABS INC	<u>250MG</u>	<u>A202044</u>	<u>001</u>	Apr 30, 2012
<u>AB</u>			<u>500MG</u>	<u>A202044</u>	<u>002</u>	Apr 30, 2012
<u>AB</u>		UNIQUE	<u>250MG</u>	<u>A202489</u>	<u>001</u>	Oct 09, 2013
<u>AB</u>			<u>500MG</u>	<u>A202489</u>	<u>002</u>	Oct 09, 2013

TIOPRONIN

TABLET; ORAL

THIOLA

<u>AB</u>	+	!	MISSION PHARMA	<u>100MG</u>	<u>N019569</u>	<u>001</u>	Aug 11, 1988

TIOPRONIN

<u>AB</u>		PAR PHARM INC	<u>100MG</u>	<u>A216198</u>	<u>001</u>	Jun 02, 2022
<u>AB</u>		TEVA PHARMS USA INC	<u>100MG</u>	<u>A214326</u>	<u>001</u>	Apr 26, 2021

TABLET, DELAYED RELEASE; ORAL

THIOLA EC

	+	MISSION PHARMACAL	100MG	N211843	001	Jun 28, 2019
		CO				
	+	!	300MG	N211843	002	Jun 28, 2019

TIOTROPIUM BROMIDE

POWDER; INHALATION

SPIRIVA

	+	!	BOEHRINGER	EQ 0.018MG BASE/INH	N021395	001	Jan 30, 2004
			INGELHEIM				

SPRAY, METERED; INHALATION

SPIRIVA RESPIMAT

	+	!	BOEHRINGER	EQ 0.00125MG BASE/INH	N021936	002	Sep 15, 2015
			INGELHEIM				
	+	!		EQ 0.0025MG BASE/INH	N021936	001	Sep 24, 2014

TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE

TABLET; ORAL

LONSURF

	+	TAIHO ONCOLOGY	EQ 6.14MG BASE; 15MG	N207981	001	Sep 22, 2015
	+	!	EQ 8.19MG BASE; 20MG	N207981	002	Sep 22, 2015

TIPIRANAVIR

CAPSULE; ORAL

APTIVUS

	+	!	BOEHRINGER	250MG	N021814	001	Jun 22, 2005
			INGELHEIM				

TIRBANIBULIN

OINTMENT; TOPICAL

KLISYRI

	+	!	ALMIRALL	1%	N213189	001	Dec 14, 2020

TIROFIBAN HYDROCHLORIDE

SOLUTION; INJECTION

AGGRASTAT

	+	!	MEDICURE	EQ 3.75MG BASE/15ML (EQ 0.25MG BASE/ML)	N020912	002	Aug 31, 2016

SOLUTION; INTRAVENOUS

AGGRASTAT

<u>AP</u>	+	!	MEDICURE	<u>EQ 12.5MG BASE/250ML (EQ 0.05MG BASE/ML)</u>	<u>N020913</u>	<u>003</u>	Apr 20, 2000

TIROFIBAN HYDROCHLORIDE

<u>AP</u>		GLAND PHARMA LTD	<u>EQ 12.5MG BASE/250ML (EQ 0.05MG BASE/ML)</u>	<u>A206888</u>	<u>001</u>	Apr 08, 2021

AGGRASTAT

	+	MEDICURE	EQ 5MG BASE/100ML (EQ 0.05MG BASE/ML)	N020913	002	May 17, 2002

PRESCRIPTION DRUG PRODUCT LIST

3-443 (of 474)

TIRZEPATIDE

SOLUTION;SUBCUTANEOUS

MOUNJARO

+	!	ELI LILLY AND CO	2.5MG/0.5ML (2.5MG/0.5ML)	N215866	001	May 13, 2022
+	!		5MG/0.5ML (5MG/0.5ML)	N215866	002	May 13, 2022
+	!		7.5MG/0.5ML (7.5MG/0.5ML)	N215866	003	May 13, 2022
+	!		10MG/0.5ML (10MG/0.5ML)	N215866	004	May 13, 2022
+	!		12.5MG/0.5ML (12.5MG/0.5ML)	N215866	005	May 13, 2022
+	!		15MG/0.5ML (15MG/0.5ML)	N215866	006	May 13, 2022

TIVOZANIB HYDROCHLORIDE

CAPSULE;ORAL

FOTIVDA

+		AVEO PHARMS	EQ 0.89MG BASE	N212904	001	Mar 10, 2021
+	!		EQ 1.34MG BASE	N212904	002	Mar 10, 2021

TIZANIDINE HYDROCHLORIDE

CAPSULE;ORAL

TIZANIDINE HYDROCHLORIDE

<u>AB</u>		ALEMBIC PHARMS	<u>EQ 2MG BASE</u>	<u>A213223</u>	<u>001</u>	Jan 13, 2020
<u>AB</u>			<u>EQ 4MG BASE</u>	<u>A213223</u>	<u>002</u>	Jan 13, 2020
<u>AB</u>			<u>EQ 6MG BASE</u>	<u>A213223</u>	<u>003</u>	Jan 13, 2020
<u>AB</u>		ALKEM LABS LTD	<u>EQ 2MG BASE</u>	<u>A212196</u>	<u>001</u>	Mar 27, 2019
<u>AB</u>			<u>EQ 4MG BASE</u>	<u>A212196</u>	<u>002</u>	Mar 27, 2019
<u>AB</u>			<u>EQ 6MG BASE</u>	<u>A212196</u>	<u>003</u>	Mar 27, 2019
<u>AB</u>		APOTEX INC	<u>EQ 2MG BASE</u>	<u>A078868</u>	<u>001</u>	Feb 03, 2012
<u>AB</u>			<u>EQ 4MG BASE</u>	<u>A078868</u>	<u>002</u>	Feb 03, 2012
<u>AB</u>			<u>EQ 6MG BASE</u>	<u>A078868</u>	<u>003</u>	Feb 03, 2012
<u>AB</u>		AUROBINDO PHARMA LTD	<u>EQ 2MG BASE</u>	<u>A213544</u>	<u>001</u>	Mar 24, 2020
<u>AB</u>			<u>EQ 4MG BASE</u>	<u>A213544</u>	<u>002</u>	Mar 24, 2020
<u>AB</u>			<u>EQ 6MG BASE</u>	<u>A213544</u>	<u>003</u>	Mar 24, 2020
<u>AB</u>		CADILA PHARMS LTD	<u>EQ 2MG BASE</u>	<u>A210021</u>	<u>001</u>	Mar 26, 2019
<u>AB</u>			<u>EQ 4MG BASE</u>	<u>A210021</u>	<u>002</u>	Mar 26, 2019
<u>AB</u>			<u>EQ 6MG BASE</u>	<u>A210021</u>	<u>003</u>	Mar 26, 2019
<u>AB</u>		JUBILANT GENERICS	<u>EQ 2MG BASE</u>	<u>A209605</u>	<u>001</u>	Aug 04, 2017
<u>AB</u>			<u>EQ 4MG BASE</u>	<u>A209605</u>	<u>002</u>	Aug 04, 2017
<u>AB</u>			<u>EQ 6MG BASE</u>	<u>A209605</u>	<u>003</u>	Aug 04, 2017
<u>AB</u>		NOVAST LABS	<u>EQ 2MG BASE</u>	<u>A210267</u>	<u>001</u>	Mar 12, 2019
<u>AB</u>			<u>EQ 4MG BASE</u>	<u>A210267</u>	<u>002</u>	Mar 12, 2019
<u>AB</u>			<u>EQ 6MG BASE</u>	<u>A210267</u>	<u>003</u>	Mar 12, 2019
<u>AB</u>		RUBICON	<u>EQ 2MG BASE</u>	<u>A213798</u>	<u>001</u>	May 27, 2020
<u>AB</u>			<u>EQ 4MG BASE</u>	<u>A213798</u>	<u>002</u>	May 27, 2020
<u>AB</u>			<u>EQ 6MG BASE</u>	<u>A213798</u>	<u>003</u>	May 27, 2020
<u>AB</u>		ZYDUS PHARMS	<u>EQ 2MG BASE</u>	<u>A208622</u>	<u>001</u>	Mar 03, 2017
<u>AB</u>			<u>EQ 4MG BASE</u>	<u>A208622</u>	<u>002</u>	Mar 03, 2017
<u>AB</u>			<u>EQ 6MG BASE</u>	<u>A208622</u>	<u>003</u>	Mar 03, 2017
<u>ZANAFLEX</u>						
<u>AB</u>	+	LEGACY PHARMA	<u>EQ 2MG BASE</u>	<u>N021447</u>	<u>001</u>	Aug 29, 2002
<u>AB</u>	+		<u>EQ 4MG BASE</u>	<u>N021447</u>	<u>002</u>	Aug 29, 2002
<u>AB</u>	+	!	<u>EQ 6MG BASE</u>	<u>N021447</u>	<u>003</u>	Aug 29, 2002

TABLET;ORAL

TIZANIDINE HYDROCHLORIDE

<u>AB</u>		ALKEM LABS LTD	<u>EQ 2MG BASE</u>	<u>A211798</u>	<u>001</u>	Jan 25, 2019
<u>AB</u>			<u>EQ 4MG BASE</u>	<u>A211798</u>	<u>002</u>	Jan 25, 2019
<u>AB</u>		APOTEX	<u>EQ 2MG BASE</u>	<u>A076533</u>	<u>001</u>	Jan 16, 2004
<u>AB</u>			<u>EQ 4MG BASE</u>	<u>A076533</u>	<u>002</u>	Jan 16, 2004
<u>AB</u>		CADILA	<u>EQ 2MG BASE</u>	<u>A208187</u>	<u>001</u>	Mar 09, 2018
<u>AB</u>			<u>EQ 4MG BASE</u>	<u>A208187</u>	<u>002</u>	Mar 09, 2018
<u>AB</u>		CASI PHARMS INC	<u>EQ 2MG BASE</u>	<u>A076280</u>	<u>001</u>	Nov 26, 2002
<u>AB</u>			<u>EQ 4MG BASE</u>	<u>A076280</u>	<u>002</u>	Jun 27, 2002
<u>AB</u>		DR REDDYS LABS INC	<u>EQ 2MG BASE</u>	<u>A076286</u>	<u>001</u>	Jul 03, 2002
<u>AB</u>			<u>EQ 4MG BASE</u>	<u>A076286</u>	<u>002</u>	Jul 03, 2002
<u>AB</u>		EPIC PHARMA LLC	<u>EQ 2MG BASE</u>	<u>A076347</u>	<u>001</u>	Oct 11, 2002
<u>AB</u>			<u>EQ 4MG BASE</u>	<u>A076347</u>	<u>002</u>	Oct 11, 2002
<u>AB</u>		OXFORD PHARMS	<u>EQ 2MG BASE</u>	<u>A076281</u>	<u>001</u>	Oct 20, 2003
<u>AB</u>			<u>EQ 4MG BASE</u>	<u>A076281</u>	<u>002</u>	Oct 20, 2003
<u>AB</u>		SUN PHARM INDS INC	<u>EQ 2MG BASE</u>	<u>A076416</u>	<u>001</u>	Sep 29, 2003
<u>AB</u>			<u>EQ 4MG BASE</u>	<u>A076416</u>	<u>002</u>	Sep 29, 2003
<u>AB</u>		UNICHEM LABS LTD	<u>EQ 2MG BASE</u>	<u>A091283</u>	<u>001</u>	Nov 28, 2012
<u>AB</u>			<u>EQ 4MG BASE</u>	<u>A091283</u>	<u>002</u>	Nov 28, 2012

ZANAFLEX

<u>AB</u>	+	!	LEGACY PHARMA	<u>EQ 4MG BASE</u>	<u>N020397</u>	<u>001</u>	Nov 27, 1996

PRESCRIPTION DRUG PRODUCT LIST

3-444 (of 474)

TOBRAMYCIN

OINTMENT;OPHTHALMIC

TOBREX

+! NOVARTIS 0.3%

N050555 001

POWDER;INHALATION

TOBI PODHALER

+! MYLAN SPECIALITY LP 28MG

N201688 001 Mar 22, 2013

SOLUTION;INHALATION

BETHKISAN +! CHIESI300MG/4MLN201820 001 Oct 12, 2012KITABIS PAKAN PULMOFLOW INC300MG/5MLN205433 001 Dec 02, 2014TOBIAN +! MYLAN SPECIALITY LP300MG/5MLN050753 001 Dec 22, 1997TOBRAMYCINAN AKORN300MG/5MLA201422 001 May 28, 2014AN ALKEM LABS LTD300MG/5MLA212848 001 Apr 01, 2021AN AMNEAL PHARMS300MG/5MLA205501 001 Jul 13, 2015AN DR REDDYS LABS SA300MG/5MLA207080 001 Jul 09, 2018AN LUPIN300MG/5MLA208964 001 Mar 22, 2017AN MANKIND PHARMA300MG/4MLA216725 001 Sep 22, 2022AN SUN PHARM300MG/5MLA207136 001 Dec 26, 2019AN TEVA PHARMS USA300MG/5MLA091589 001 Oct 10, 2013AN300MG/4MLA210915 001 Jun 26, 2019

SOLUTION/DROPS;OPHTHALMIC

AKTOBAT AKORN0.3%A064096 001 Jan 31, 1996TOBRAMYCINAT ALEMBIC PHARMS0.3%A211847 001 Apr 19, 2019AT BAUSCH AND LOMB0.3%A064052 001 Nov 29, 1993AT FERA PHARMS0.3%A065026 001 Sep 11, 2001AT GLAND PHARMA LTD0.3%A212628 001 Mar 09, 2021AT SOMERSET THERAPS
LLC0.3%A207444 001 Jun 28, 2017TOBREXAT +! NOVARTIS0.3%N050541 001AT SANDOZ INC0.3%A062535 001 Dec 13, 1984TOBRAMYCIN SULFATE

INJECTABLE;INJECTION

TOBRAMYCIN SULFATEAP BAXTER HLTHCARE
CORPEQ 40MG BASE/MLA206965 001 Jul 01, 2016AP FRESENIUS KABI USAEQ 10MG BASE/MLA065122 001 Nov 29, 2002AP !EQ 40MG BASE/MLA065122 002 Nov 29, 2002APEQ 1.2GM BASE/VIALN050789 001 Jul 13, 2004AP GLAND PHARMA LTDEQ 10MG BASE/MLA209621 001 Feb 11, 2021APEQ 40MG BASE/MLA209621 002 Feb 11, 2021APEQ 1.2GM BASE/VIALA211189 001 May 18, 2021AP HIKMAEQ 40MG BASE/MLA063117 001 Apr 26, 1991AP ! HOSPIRAEQ 10MG BASE/MLA063112 001 Apr 30, 1991APEQ 40MG BASE/MLA063111 001 Apr 30, 1991AP MYLAN LABS LTDEQ 40MG BASE/MLA065407 001 Mar 11, 2008AP XELLIA PHARMS APSEQ 1.2GM BASE/VIALA205685 001 Sep 16, 2014AP ! XGEN PHARMSEQ 1.2GM BASE/VIALA065013 001 Aug 17, 2001TOBRAMYCIN SULFATE (PHARMACY BULK)AP ! FRESENIUS KABI USAEQ 40MG BASE/MLA065120 001 Nov 29, 2002AP GLAND PHARMA LTDEQ 40MG BASE/MLA209346 001 Feb 09, 2021

TOBRAMYCIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

! HOSPIRA

EQ 1.2MG BASE/ML

A063081 003 Jul 31, 1990

!

EQ 1.6MG BASE/ML

A063081 006 Jun 02, 1993

!

EQ 80MG BASE/100ML

A063081 001 Jul 31, 1990

TOFACITINIB CITRATE

SOLUTION;ORAL

XELJANZ

+! PFIZER

EQ 1MG/ML BASE

N213082 001 Sep 25, 2020

TABLET;ORAL

XELJANZ

+ PF PRISM CV

EQ 5MG BASE

N203214 001 Nov 06, 2012

+!

EQ 10MG BASE

N203214 002 May 30, 2018

PRESCRIPTION DRUG PRODUCT LIST

3-445 (of 474)

TOFACITINIB CITRATE

TABLET, EXTENDED RELEASE;ORAL

XELJANZ XR

+ PFIZER

EQ 11MG BASE

N208246 001 Feb 23, 2016

+!

EQ 22MG BASE

N208246 002 Dec 12, 2019

TOLCAPONE

TABLET;ORAL

TASMAR**AB** +! BAUSCH**100MG****N020697 001** Jan 29, 1998TOLCAPONE**AB** NOVAST LABS**100MG****A208937 001** Aug 07, 2018**AB** PAR PHARM INC**100MG****A204584 001** Mar 26, 2015TOLTERODINE TARTRATE

CAPSULE, EXTENDED RELEASE;ORAL

DETROL LA**AB** + UPJOHN**2MG****N021228 001** Dec 22, 2000**AB** +!**4MG****N021228 002** Dec 22, 2000TOLTERODINE TARTRATE**AB** AJANTA PHARMA LTD**2MG****A213397 001** May 19, 2020**AB** **4MG****A213397 002** May 19, 2020**AB** AMTA**2MG****A213858 001** Feb 02, 2021**AB** **4MG****A213858 002** Feb 02, 2021**AB** HETERO LABS LTD III**2MG****A206419 001** Dec 12, 2017**AB** **4MG****A206419 002** Dec 12, 2017**AB** INVENTIA HLTHCARE**2MG****A204562 001** Aug 19, 2019**AB** **4MG****A204562 002** Aug 19, 2019**AB** TEVA PHARMS USA**2MG****A079141 001** Nov 22, 2016**AB** **4MG****A079141 002** Nov 22, 2016**AB** TORRENT**2MG****A203016 001** Aug 11, 2015**AB** **4MG****A203016 002** Aug 11, 2015

TABLET;ORAL

DETROL**AB** + UPJOHN**1MG****N020771 001** Mar 25, 1998**AB** +!**2MG****N020771 002** Mar 25, 1998TOLTERODINE TARTRATE**AB** ATHEM**1MG****A210775 001** Dec 30, 2019**AB** **2MG****A210775 002** Dec 30, 2019**AB** HETERO LABS LTD V**1MG****A204397 001** Aug 02, 2021**AB** **2MG****A204397 002** Aug 02, 2021**AB** IVAX SUB TEVA
PHARMS**1MG****A077006 001** Feb 23, 2015**AB** **2MG****A077006 002** Feb 23, 2015**AB** MACLEODS PHARMS LTD**1MG****A203409 001** Aug 31, 2015**AB** **2MG****A203409 002** Aug 31, 2015**AB** UNICHEM**1MG****A205399 001** Aug 05, 2020**AB** **2MG****A205399 002** Aug 05, 2020**AB** UNIQUE**1MG****A204721 001** Jan 24, 2020**AB** **2MG****A204721 002** Jan 24, 2020TOLVAPTAN

TABLET;ORAL

SAMSCA**AB** + OTSUKA**15MG****N022275 001** May 19, 2009**AB** +!**30MG****N022275 002** May 19, 2009TOLVAPTAN**AB** ALKEM LABS LTD**15MG****A211891 003** Sep 06, 2022**AB** **30MG****A211891 001** May 19, 2020**AB** APOTEX**15MG****A207605 002** Sep 06, 2022**AB** **30MG****A207605 001** May 19, 2020**AB** HETERO LABS LTD V**15MG****A205646 002** Sep 06, 2022**AB** **30MG****A205646 001** Jul 16, 2021**AB** PAR PHARM INC**15MG****A206119 001** Feb 15, 2022**AB** **30MG****A206119 002** Feb 15, 2022

JYNARQUE

+ OTSUKA

15MG

N204441 001 Apr 23, 2018

+

30MG

N204441 002 Apr 23, 2018

+!

45MG

N204441 003 Apr 23, 2018

+

60MG

N204441 004 Apr 23, 2018

+

90MG

N204441 005 Apr 23, 2018

TOLVAPTAN

ALKEM LABS LTD

60MG

A211891 002 May 19, 2020

PRESCRIPTION DRUG PRODUCT LIST

3-446 (of 474)

TOPIRAMATE

CAPSULE; ORAL

TOPAMAX

<u>AB</u>	+	JANSSEN PHARMS	<u>15MG</u>	<u>N020844</u>	<u>001</u>	Oct 26, 1998
<u>AB</u>	+	!	<u>25MG</u>	<u>N020844</u>	<u>002</u>	Oct 26, 1998

TOPIRAMATE

<u>AB</u>		TEVA	<u>15MG</u>	<u>A076575</u>	<u>001</u>	Apr 17, 2009
<u>AB</u>			<u>25MG</u>	<u>A076575</u>	<u>002</u>	Apr 17, 2009
<u>AB</u>		WATSON LABS	<u>15MG</u>	<u>A077868</u>	<u>001</u>	Apr 15, 2009
<u>AB</u>			<u>25MG</u>	<u>A077868</u>	<u>002</u>	Apr 15, 2009
<u>AB</u>		ZYDUS PHARMS USA INC	<u>15MG</u>	<u>A078877</u>	<u>001</u>	Oct 14, 2009
<u>AB</u>			<u>25MG</u>	<u>A078877</u>	<u>002</u>	Oct 14, 2009

CAPSULE, EXTENDED RELEASE; ORAL

TOPIRAMATE

<u>AB1</u>		ZYDUS PHARMS	<u>25MG</u>	<u>A207382</u>	<u>001</u>	Nov 24, 2017
<u>AB1</u>			<u>50MG</u>	<u>A207382</u>	<u>002</u>	Nov 24, 2017
<u>AB1</u>			<u>100MG</u>	<u>A207382</u>	<u>003</u>	Nov 24, 2017

TROKENDI XR

<u>AB1</u>	+	SUPERNUS PHARMS	<u>25MG</u>	<u>N201635</u>	<u>001</u>	Aug 16, 2013
<u>AB1</u>	+		<u>50MG</u>	<u>N201635</u>	<u>002</u>	Aug 16, 2013
<u>AB1</u>	+		<u>100MG</u>	<u>N201635</u>	<u>003</u>	Aug 16, 2013

OUDEXY XR

<u>AB2</u>	+	UPSHER SMITH LABS	<u>25MG</u>	<u>N205122</u>	<u>001</u>	Mar 11, 2014
<u>AB2</u>	+		<u>50MG</u>	<u>N205122</u>	<u>002</u>	Mar 11, 2014
<u>AB2</u>	+		<u>100MG</u>	<u>N205122</u>	<u>003</u>	Mar 11, 2014
<u>AB2</u>	+		<u>150MG</u>	<u>N205122</u>	<u>004</u>	Mar 11, 2014
<u>AB2</u>	+	!	<u>200MG</u>	<u>N205122</u>	<u>005</u>	Mar 11, 2014

TOPIRAMATE

<u>AB2</u>		GLENMARK PHARMS LTD	<u>25MG</u>	<u>A210278</u>	<u>001</u>	Feb 01, 2021
<u>AB2</u>			<u>50MG</u>	<u>A210278</u>	<u>002</u>	Feb 01, 2021
<u>AB2</u>			<u>100MG</u>	<u>A210278</u>	<u>003</u>	Feb 01, 2021
<u>AB2</u>			<u>150MG</u>	<u>A210278</u>	<u>004</u>	Feb 01, 2021
<u>AB2</u>			<u>200MG</u>	<u>A210278</u>	<u>005</u>	Feb 01, 2021
<u>AB2</u>		ZYDUS PHARMS	<u>25MG</u>	<u>A208949</u>	<u>001</u>	Nov 29, 2022
<u>AB2</u>			<u>50MG</u>	<u>A208949</u>	<u>002</u>	Nov 29, 2022
<u>AB2</u>			<u>100MG</u>	<u>A208949</u>	<u>003</u>	Nov 29, 2022
<u>AB2</u>			<u>150MG</u>	<u>A208949</u>	<u>004</u>	Nov 29, 2022
<u>AB2</u>			<u>200MG</u>	<u>A208949</u>	<u>005</u>	Nov 29, 2022

TROKENDI XR

BC	+	!	SUPERNUS PHARMS	200MG	N201635	004	Aug 16, 2013

SOLUTION; ORAL

EPRONTIA

	+	!	AZURITY	25MG/ML	N214679	001	Nov 05, 2021

TABLET; ORAL

TOPAMAX

<u>AB</u>	+	JANSSEN PHARMS	<u>25MG</u>	<u>N020505</u>	<u>004</u>	Dec 24, 1996
<u>AB</u>	+		<u>50MG</u>	<u>N020505</u>	<u>005</u>	Dec 24, 1996
<u>AB</u>	+	!	<u>100MG</u>	<u>N020505</u>	<u>001</u>	Dec 24, 1996
<u>AB</u>	+		<u>200MG</u>	<u>N020505</u>	<u>002</u>	Dec 24, 1996

TOPIRAMATE

<u>AB</u>		ACCORD HLTHCARE	<u>25MG</u>	<u>A076311</u>	<u>001</u>	Mar 27, 2009
<u>AB</u>			<u>50MG</u>	<u>A076311</u>	<u>002</u>	Mar 27, 2009
<u>AB</u>			<u>100MG</u>	<u>A076311</u>	<u>003</u>	Mar 27, 2009
<u>AB</u>			<u>200MG</u>	<u>A076311</u>	<u>004</u>	Mar 27, 2009
<u>AB</u>		ASCENT PHARMS INC	<u>25MG</u>	<u>A215414</u>	<u>001</u>	Aug 26, 2021
<u>AB</u>			<u>50MG</u>	<u>A215414</u>	<u>002</u>	Aug 26, 2021
<u>AB</u>			<u>100MG</u>	<u>A215414</u>	<u>003</u>	Aug 26, 2021
<u>AB</u>			<u>200MG</u>	<u>A215414</u>	<u>004</u>	Aug 26, 2021
<u>AB</u>		AUROBINDO PHARMA	<u>25MG</u>	<u>A078462</u>	<u>001</u>	Mar 27, 2009
<u>AB</u>			<u>50MG</u>	<u>A078462</u>	<u>002</u>	Mar 27, 2009
<u>AB</u>			<u>100MG</u>	<u>A078462</u>	<u>003</u>	Mar 27, 2009
<u>AB</u>			<u>200MG</u>	<u>A078462</u>	<u>004</u>	Mar 27, 2009
<u>AB</u>		CIPLA LTD	<u>25MG</u>	<u>A076343</u>	<u>001</u>	Mar 27, 2009
<u>AB</u>			<u>50MG</u>	<u>A076343</u>	<u>002</u>	Mar 27, 2009
<u>AB</u>			<u>100MG</u>	<u>A076343</u>	<u>003</u>	Mar 27, 2009
<u>AB</u>			<u>200MG</u>	<u>A076343</u>	<u>004</u>	Mar 27, 2009
<u>AB</u>		GLENMARK GENERICS	<u>25MG</u>	<u>A077627</u>	<u>001</u>	Mar 27, 2009
<u>AB</u>			<u>50MG</u>	<u>A077627</u>	<u>002</u>	Mar 27, 2009
<u>AB</u>			<u>100MG</u>	<u>A077627</u>	<u>003</u>	Mar 27, 2009
<u>AB</u>			<u>200MG</u>	<u>A077627</u>	<u>004</u>	Mar 27, 2009
<u>AB</u>		INVAGEN PHARMS	<u>25MG</u>	<u>A079162</u>	<u>001</u>	Mar 27, 2009
<u>AB</u>			<u>50MG</u>	<u>A079162</u>	<u>002</u>	Mar 27, 2009

PRESCRIPTION DRUG PRODUCT LIST

3-447 (of 474)

TOPIRAMATE

TABLET; ORAL

TOPIRAMATE

<u>AB</u>		<u>100MG</u>	<u>A079162</u>	<u>003</u>	Mar 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A079162</u>	<u>004</u>	Mar 27, 2009
<u>AB</u>	SUN PHARM	<u>25MG</u>	<u>A090278</u>	<u>001</u>	Mar 27, 2009
<u>AB</u>		<u>50MG</u>	<u>A090278</u>	<u>002</u>	Mar 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A090278</u>	<u>003</u>	Mar 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A090278</u>	<u>004</u>	Mar 27, 2009
<u>AB</u>	SUN PHARM INDS LTD	<u>25MG</u>	<u>A076327</u>	<u>001</u>	Mar 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A076327</u>	<u>002</u>	Mar 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A076327</u>	<u>003</u>	Mar 27, 2009
<u>AB</u>	TEVA	<u>25MG</u>	<u>A076317</u>	<u>001</u>	Mar 27, 2009
<u>AB</u>		<u>50MG</u>	<u>A076317</u>	<u>002</u>	Mar 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A076317</u>	<u>003</u>	Mar 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A076317</u>	<u>004</u>	Mar 27, 2009
<u>AB</u>	UNICHEM LABS LTD	<u>25MG</u>	<u>A090162</u>	<u>001</u>	Mar 27, 2009
<u>AB</u>		<u>50MG</u>	<u>A090162</u>	<u>002</u>	Mar 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A090162</u>	<u>003</u>	Mar 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A090162</u>	<u>004</u>	Feb 19, 2013
<u>AB</u>	VIWIT PHARM	<u>25MG</u>	<u>A077733</u>	<u>001</u>	Mar 27, 2009
<u>AB</u>		<u>50MG</u>	<u>A077733</u>	<u>002</u>	Mar 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A077733</u>	<u>003</u>	Mar 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A077733</u>	<u>004</u>	Mar 27, 2009
<u>AB</u>	ZYDUS PHARMS USA INC	<u>25MG</u>	<u>A078235</u>	<u>001</u>	Mar 27, 2009
<u>AB</u>		<u>50MG</u>	<u>A078235</u>	<u>002</u>	Mar 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A078235</u>	<u>003</u>	Mar 27, 2009
<u>AB</u>		<u>200MG</u>	<u>A078235</u>	<u>004</u>	Mar 27, 2009

TOPOTECAN HYDROCHLORIDE

CAPSULE; ORAL

HYCANTIN

+ NOVARTIS

EQ 0.25MG BASE

N020981 001 Oct 11, 2007

+!

EQ 1MG BASE

N020981 002 Oct 11, 2007

INJECTABLE; INJECTION

HYCANTINAP +! NOVARTISEQ 4MG BASE/VIALN020671 001 May 28, 1996TOPOTECAN HYDROCHLORIDE

<u>AP</u>	ACCORD HLTHCARE	<u>EQ 4MG BASE/VIAL</u>	<u>A202351</u>	<u>001</u>	Jun 26, 2013
<u>AP</u>	ACTAVIS TOTOWA	<u>EQ 4MG BASE/VIAL</u>	<u>A090620</u>	<u>001</u>	Dec 02, 2010
<u>AP</u>	DR REDDYS LABS LTD	<u>EQ 4MG BASE/VIAL</u>	<u>A201191</u>	<u>001</u>	Mar 09, 2011
<u>AP</u>	FRESENIUS KABI USA	<u>EQ 4MG BASE/VIAL</u>	<u>A091089</u>	<u>001</u>	Nov 29, 2010
<u>AP</u>	NOVAST LABS	<u>EQ 4MG BASE/VIAL</u>	<u>A206962</u>	<u>001</u>	Nov 30, 2016
<u>AP</u>	SAGENT PHARMS	<u>EQ 4MG BASE/VIAL</u>	<u>A091284</u>	<u>001</u>	Jan 26, 2011
<u>AP</u>	TEYRO LABS	<u>EQ 4MG BASE/VIAL</u>	<u>A091199</u>	<u>001</u>	Dec 01, 2010

SOLUTION; INTRAVENOUS

TOPOTECAN HYDROCHLORIDE

<u>AP</u>	ACCORD HLTHCARE	<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>A204406</u>	<u>002</u>	Jul 06, 2017
<u>AP</u>	+! HOSPIRA INC	<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>N200582</u>	<u>001</u>	Feb 02, 2011
<u>AP</u>	TEVA PHARMS USA	<u>EQ 4MG BASE/4ML (EQ 1MG BASE/ML)</u>	<u>N022453</u>	<u>001</u>	Dec 20, 2012
	ACCORD HLTHCARE	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A204406	001	Jul 06, 2017

TOREMIFENE CITRATE

TABLET; ORAL

FARESTONAB +! KYOWA KIRINEQ 60MG BASEN020497 001 May 29, 1997TOREMIFENE CITRATE

<u>AB</u>	MSN	<u>EQ 60MG BASE</u>	<u>A212818</u>	<u>001</u>	Aug 18, 2020
<u>AB</u>	RISING	<u>EQ 60MG BASE</u>	<u>A208813</u>	<u>001</u>	Dec 04, 2018

TORSEMIDE

TABLET; ORAL

TORSEMIDE

<u>AB</u>	AUROBINDO PHARMA	<u>5MG</u>	<u>A078249</u>	<u>001</u>	Oct 17, 2007
<u>AB</u>		<u>10MG</u>	<u>A078249</u>	<u>002</u>	Oct 17, 2007
<u>AB</u>		<u>20MG</u>	<u>A078249</u>	<u>003</u>	Oct 17, 2007
<u>AB</u>		<u>100MG</u>	<u>A078249</u>	<u>004</u>	Oct 17, 2007
<u>AB</u>	COREPHARMA	<u>5MG</u>	<u>A076894</u>	<u>001</u>	May 31, 2005
<u>AB</u>		<u>10MG</u>	<u>A076894</u>	<u>002</u>	May 31, 2005
<u>AB</u>		<u>20MG</u>	<u>A076894</u>	<u>003</u>	May 31, 2005
<u>AB</u>		<u>100MG</u>	<u>A076894</u>	<u>004</u>	May 31, 2005
<u>AB</u>	HETERO LABS LTD III	<u>5MG</u>	<u>A079234</u>	<u>001</u>	Jan 27, 2009
<u>AB</u>		<u>10MG</u>	<u>A079234</u>	<u>002</u>	Jan 27, 2009

PRESCRIPTION DRUG PRODUCT LIST

3-448 (of 474)

TORSEMIDE

TABLET; ORAL

TORSEMIDE

<u>AB</u>		<u>20MG</u>	<u>A079234</u>	<u>003</u>	Jan 27, 2009
<u>AB</u>		<u>100MG</u>	<u>A079234</u>	<u>004</u>	Jan 27, 2009
<u>AB</u>	HIKMA	<u>5MG</u>	<u>A076943</u>	<u>001</u>	Mar 01, 2005
<u>AB</u>		<u>10MG</u>	<u>A076943</u>	<u>002</u>	Mar 01, 2005
<u>AB</u>		<u>20MG</u>	<u>A076943</u>	<u>003</u>	Mar 01, 2005
<u>AB</u>	PLIVA PHARM IND	<u>5MG</u>	<u>A076346</u>	<u>001</u>	May 30, 2003
<u>AB</u>		<u>10MG</u>	<u>A076346</u>	<u>002</u>	May 30, 2003
<u>AB</u>	!	<u>20MG</u>	<u>A076346</u>	<u>003</u>	May 30, 2003
<u>AB</u>		<u>100MG</u>	<u>A076346</u>	<u>004</u>	Oct 19, 2004
<u>AB</u>	STRIDES PHARMA	<u>5MG</u>	<u>A076226</u>	<u>001</u>	May 27, 2003
<u>AB</u>		<u>5MG</u>	<u>A090613</u>	<u>001</u>	Mar 22, 2011
<u>AB</u>		<u>10MG</u>	<u>A076226</u>	<u>002</u>	May 27, 2003
<u>AB</u>		<u>10MG</u>	<u>A090613</u>	<u>002</u>	Mar 22, 2011
<u>AB</u>		<u>20MG</u>	<u>A076226</u>	<u>003</u>	May 27, 2003
<u>AB</u>		<u>20MG</u>	<u>A090613</u>	<u>003</u>	Mar 22, 2011
<u>AB</u>		<u>100MG</u>	<u>A076226</u>	<u>004</u>	May 27, 2003
<u>AB</u>		<u>100MG</u>	<u>A090613</u>	<u>004</u>	Mar 22, 2011
<u>AB</u>	TEVA	<u>5MG</u>	<u>A076110</u>	<u>001</u>	May 14, 2002
<u>AB</u>		<u>10MG</u>	<u>A076110</u>	<u>002</u>	May 14, 2002
<u>AB</u>		<u>20MG</u>	<u>A076110</u>	<u>003</u>	May 14, 2002
<u>AB</u>		<u>100MG</u>	<u>A076110</u>	<u>004</u>	May 14, 2002
	SOAANZ				
	+!	SARFE PHARMS	20MG	N213218	001 Jun 14, 2021
	+		40MG	N213218	003 Nov 17, 2021
	+		60MG	N213218	002 Jun 14, 2021

TRABECTEDIN

POWDER; INTRAVENOUS

YONDELIS

+!	JANSSEN PRODS	1MG/VIAL	N207953	001	Oct 23, 2015

TRAMADOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

CONZIP

+!	CIPHER PHARMS INC	100MG	N022370	001	May 07, 2010
+		200MG	N022370	002	May 07, 2010
+		300MG	N022370	003	May 07, 2010

SOLUTION; ORAL

QDOLO

+!	ATHENA	5MG/ML	N214044	001	Sep 01, 2020

TABLET; ORAL

TRAMADOL HYDROCHLORIDE

<u>AB</u>	ACI	<u>50MG</u>	<u>A202075</u>	<u>001</u>	Nov 28, 2011
<u>AB</u>	AMNEAL PHARMS	<u>50MG</u>	<u>A076003</u>	<u>001</u>	Jun 20, 2002
<u>AB</u>	APOTEX	<u>50MG</u>	<u>A075981</u>	<u>001</u>	Jul 10, 2002
<u>AB</u>	AUROBINDO PHARMA LTD	<u>50MG</u>	<u>A203494</u>	<u>001</u>	Mar 31, 2014
<u>AB</u>	CSPC OUYI PHARM CO	<u>50MG</u>	<u>A091498</u>	<u>001</u>	Mar 29, 2013
<u>AB</u>	IPCA LABS LTD	<u>50MG</u>	<u>A201973</u>	<u>001</u>	Nov 16, 2012
<u>AB</u>	MERRO PHARM USA	<u>50MG</u>	<u>A206706</u>	<u>001</u>	Jul 02, 2019
<u>AB</u>	PLIVA	<u>50MG</u>	<u>A075982</u>	<u>001</u>	Jul 01, 2002
<u>AB</u>	RUBICON	<u>50MG</u>	<u>A208708</u>	<u>001</u>	Jun 28, 2019
<u>AB</u>	! SUN PHARM INDS INC	<u>50MG</u>	<u>A075964</u>	<u>001</u>	Jun 19, 2002
<u>AB</u>	TEVA	<u>50MG</u>	<u>A075977</u>	<u>001</u>	Jun 19, 2002
<u>AB</u>	UNICHEM	<u>50MG</u>	<u>A211825</u>	<u>001</u>	Aug 09, 2019
<u>AB</u>	ZYDUS PHARMS USA INC	<u>50MG</u>	<u>A090404</u>	<u>001</u>	Jan 31, 2011
	RUBICON	100MG	A208708	002	Jun 28, 2019

TABLET, EXTENDED RELEASE; ORAL

TRAMADOL HYDROCHLORIDE

<u>AB1</u>	!	LUPIN LTD	<u>100MG</u>	<u>A200503</u>	<u>001</u>	Aug 29, 2011
<u>AB1</u>			<u>200MG</u>	<u>A200503</u>	<u>002</u>	Aug 29, 2011
<u>AB1</u>			<u>300MG</u>	<u>A200503</u>	<u>003</u>	Aug 29, 2011
<u>AB1</u>		SUN PHARM	<u>100MG</u>	<u>A201384</u>	<u>001</u>	Dec 07, 2011
<u>AB1</u>			<u>200MG</u>	<u>A201384</u>	<u>002</u>	Dec 07, 2011
<u>AB1</u>			<u>300MG</u>	<u>A201384</u>	<u>003</u>	Dec 07, 2011
<u>AB2</u>		ACTAVIS ELIZABETH	<u>100MG</u>	<u>A091609</u>	<u>001</u>	Jun 27, 2012
<u>AB2</u>			<u>200MG</u>	<u>A091609</u>	<u>002</u>	Jun 27, 2012
<u>AB2</u>			<u>300MG</u>	<u>A091609</u>	<u>003</u>	Jun 27, 2012
<u>AB2</u>	!	SUN PHARM	<u>100MG</u>	<u>A091607</u>	<u>001</u>	Dec 30, 2011
<u>AB2</u>			<u>200MG</u>	<u>A091607</u>	<u>002</u>	Dec 30, 2011

PRESCRIPTION DRUG PRODUCT LIST

3-449 (of 474)

TRAMADOL HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

TRAMADOL HYDROCHLORIDE

AB2		300MG	A091607	003	Dec 30, 2011

TRAMETINIB DIMETHYL SULFOXIDE

TABLET; ORAL

MEKINIST

+ NOVARTIS

EQ 0.5MG

N204114 001 May 29, 2013

+!

EQ 2MG

N204114 003 May 29, 2013

TRANOLAPRIL

TABLET; ORAL

TRANOLAPRIL

AB	AUROBINDO PHARMA	1MG	A078438	001	Jun 12, 2007
AB		2MG	A078438	002	Jun 12, 2007
AB		4MG	A078438	003	Jun 12, 2007
AB	EPIC PHARMA	1MG	A078508	003	Jun 18, 2008
AB		2MG	A078508	001	Jun 18, 2008
AB		4MG	A078508	002	Jun 18, 2008
AB	LUPIN	1MG	A077522	001	Jun 12, 2007
AB		2MG	A077522	002	Jun 12, 2007
AB	!	4MG	A077522	003	Jun 12, 2007
AB	TEVA PHARMS	1MG	A077489	001	Dec 12, 2006
AB		2MG	A077489	002	Dec 12, 2006
AB		4MG	A077489	003	Dec 12, 2006

TRANOLAPRIL; VERAPAMIL HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

TRANOLAPRIL AND VERAPAMIL HYDROCHLORIDE

GLENMARK GENERICS

1MG; 240MG

A079135 004 Aug 30, 2010

2MG; 180MG

A079135 001 May 26, 2010

2MG; 240MG

A079135 002 May 26, 2010

!

4MG; 240MG

A079135 003 May 05, 2010

TRANEXAMIC ACID

INJECTABLE; INJECTION

CYKLOKAPRON

AP	+! PFIZER	100MG/ML	N019281	001	Dec 30, 1986

TRANEXAMIC ACID

AP	ACIC PHARMS	100MG/ML	A202436	001	Feb 11, 2014
AP	AKORN	100MG/ML	A202373	001	Nov 17, 2011
AP	AM REGENT	100MG/ML	A201885	001	Aug 10, 2011
AP	AMNEAL PHARMS CO	100MG/ML	A208840	001	Feb 28, 2017
AP	APOTEX	100MG/ML	A209860	001	Jan 14, 2020
AP	CAPLIN	100MG/ML	A212360	001	Jul 17, 2019
AP	EMCURE PHARMS LTD	100MG/ML	A203521	001	Aug 12, 2014
AP	EUGIA PHARMA	100MG/ML	A205035	001	Jan 14, 2016
AP	FRESENIUS KABI USA	100MG/ML	A091596	001	Mar 02, 2012
AP	GLAND	100MG/ML	A207239	001	Feb 13, 2017
AP	MICRO LABS	100MG/ML	A206713	001	Jun 27, 2017
AP	MYLAN INSTITUTIONAL	100MG/ML	A091657	001	Nov 03, 2011
AP	PROVEPHARM SAS	100MG/ML	A212676	001	Jul 17, 2019
AP	XGEN PHARMS	100MG/ML	A201580	001	Jun 14, 2013

SOLUTION; INTRAVENOUS

TRANEXAMIC ACID

+! EXELA PHARMA

1GM/100ML (10MG/ML)

N212020 001 Apr 15, 2019

TABLET; ORAL

LYSTEDA

AB	+! AMRING PHARMS	650MG	N022430	001	Nov 13, 2009

TRANEXAMIC ACID

AB	ACTAVIS LABS FL INC	650MG	A202093	001	Dec 27, 2012
AB	ANI PHARMS	650MG	A203256	001	Jul 25, 2016

TRANLYCYPROMINE SULFATE

TABLET; ORAL

PARNATE

AB	+! CONCORDIA	EQ 10MG BASE	N012342	003	Aug 16, 1985

TRANLYCYPROMINE SULFATE

AB	CROSSMEDIKA SA	EQ 10MG BASE	A213503	001	Jun 27, 2022
AB	NOVITIUM PHARMA	EQ 10MG BASE	A206856	001	Apr 17, 2018
AB	STRIDES PHARMA	EQ 10MG BASE	A040640	001	Jun 29, 2006

PRESCRIPTION DRUG PRODUCT LIST

3-450 (of 474)

TRAVOPROST

SOLUTION/DROPS;OPHTHALMIC

TRAVATAN Z

<u>AT</u>	<u>+</u> !	NOVARTIS	<u>0.004%</u>	<u>N021994</u>	<u>001</u>	Sep 21, 2006

TRAVOPROST

<u>AT</u>		APOTEX	<u>0.004%</u>	<u>A203431</u>	<u>001</u>	Jul 10, 2015
<u>AT</u>		MICRO LABS	<u>0.004%</u>	<u>A203767</u>	<u>001</u>	Mar 19, 2021
<u>AT</u>		MYLAN	<u>0.004%</u>	<u>A205050</u>	<u>001</u>	Jul 07, 2017
<u>AT1</u>		ALEMBIC PHARMS	<u>0.004%</u>	<u>A210458</u>	<u>001</u>	Dec 20, 2019
<u>AT1</u>	<u>!</u>	STRIDES PHARMA	<u>0.004%</u>	<u>A091340</u>	<u>001</u>	Mar 01, 2013

TRAZODONE HYDROCHLORIDE

TABLET;ORAL

TRAZODONE HYDROCHLORIDE

<u>AB</u>		ACCORD HLTHCARE	<u>50MG</u>	<u>A206923</u>	<u>001</u>	Sep 08, 2017
<u>AB</u>			<u>100MG</u>	<u>A206923</u>	<u>002</u>	Sep 08, 2017
<u>AB</u>			<u>150MG</u>	<u>A206923</u>	<u>003</u>	Sep 08, 2017
<u>AB</u>			<u>300MG</u>	<u>A206923</u>	<u>004</u>	Sep 08, 2017
<u>AB</u>		APOTEX	<u>50MG</u>	<u>A071258</u>	<u>001</u>	Mar 25, 1987
<u>AB</u>	<u>!</u>	APOTEX INC	<u>100MG</u>	<u>A071196</u>	<u>001</u>	Mar 25, 1987
<u>AB</u>			<u>150MG</u>	<u>A071196</u>	<u>002</u>	Apr 26, 1999
<u>AB</u>			<u>300MG</u>	<u>A071196</u>	<u>003</u>	Apr 26, 1999
<u>AB</u>		AUROLIFE PHARMA LLC	<u>50MG</u>	<u>A204852</u>	<u>001</u>	Feb 05, 2020
<u>AB</u>			<u>100MG</u>	<u>A204852</u>	<u>002</u>	Feb 05, 2020
<u>AB</u>			<u>150MG</u>	<u>A204852</u>	<u>003</u>	Feb 05, 2020
<u>AB</u>			<u>300MG</u>	<u>A204852</u>	<u>004</u>	Feb 05, 2020
<u>AB</u>		OXFORD PHARMS	<u>50MG</u>	<u>A072192</u>	<u>001</u>	Feb 02, 1989
<u>AB</u>			<u>100MG</u>	<u>A072193</u>	<u>001</u>	Feb 02, 1989
<u>AB</u>		PLIVA	<u>150MG</u>	<u>A071525</u>	<u>001</u>	Mar 09, 1988
<u>AB</u>		SUN PHARM	<u>50MG</u>	<u>A073137</u>	<u>002</u>	Mar 24, 1993
		INDUSTRIES				
<u>AB</u>			<u>100MG</u>	<u>A073137</u>	<u>001</u>	Mar 24, 1993
<u>AB</u>			<u>150MG</u>	<u>A073137</u>	<u>003</u>	Dec 22, 1995
<u>AB</u>		TEVA PHARMS USA	<u>50MG</u>	<u>A071523</u>	<u>001</u>	Dec 11, 1987
<u>AB</u>			<u>100MG</u>	<u>A071524</u>	<u>001</u>	Dec 11, 1987
<u>AB</u>		TORRENT	<u>50MG</u>	<u>A202180</u>	<u>001</u>	Nov 27, 2013
<u>AB</u>			<u>100MG</u>	<u>A202180</u>	<u>002</u>	Nov 27, 2013
<u>AB</u>			<u>150MG</u>	<u>A202180</u>	<u>003</u>	Nov 27, 2013
<u>AB</u>			<u>300MG</u>	<u>A202180</u>	<u>004</u>	Nov 27, 2013
<u>AB</u>		ZYDUS PHARMS	<u>50MG</u>	<u>A205253</u>	<u>001</u>	Oct 10, 2017
<u>AB</u>			<u>100MG</u>	<u>A205253</u>	<u>002</u>	Oct 10, 2017
<u>AB</u>			<u>150MG</u>	<u>A205253</u>	<u>003</u>	Oct 10, 2017
<u>AB</u>			<u>300MG</u>	<u>A205253</u>	<u>004</u>	Oct 10, 2017

TREPROSTINIL

INJECTABLE;IV (INFUSION), SUBCUTANEOUS

REMODULIN

<u>AP</u>	<u>+</u> !	UNITED THERAP	<u>1MG/ML</u>	<u>N021272</u>	<u>001</u>	May 21, 2002
<u>AP</u>	<u>+</u> !		<u>2.5MG/ML</u>	<u>N021272</u>	<u>002</u>	May 21, 2002
<u>AP</u>	<u>+</u> !		<u>5MG/ML</u>	<u>N021272</u>	<u>003</u>	May 21, 2002
<u>AP</u>	<u>+</u> !		<u>10MG/ML</u>	<u>N021272</u>	<u>004</u>	May 21, 2002

TREPROSTINIL

<u>AP</u>		ALEMBIC GLOBAL	<u>1MG/ML</u>	<u>A211574</u>	<u>001</u>	Feb 11, 2021
<u>AP</u>			<u>2.5MG/ML</u>	<u>A211574</u>	<u>002</u>	Feb 11, 2021
<u>AP</u>			<u>5MG/ML</u>	<u>A211574</u>	<u>003</u>	Feb 11, 2021
<u>AP</u>			<u>10MG/ML</u>	<u>A211574</u>	<u>004</u>	Feb 11, 2021
<u>AP</u>		PAR STERILE	<u>1MG/ML</u>	<u>A209382</u>	<u>001</u>	Sep 24, 2019
		PRODUCTS				
<u>AP</u>			<u>2.5MG/ML</u>	<u>A209382</u>	<u>002</u>	Sep 24, 2019
<u>AP</u>			<u>5MG/ML</u>	<u>A209382</u>	<u>003</u>	Sep 24, 2019
<u>AP</u>			<u>10MG/ML</u>	<u>A209382</u>	<u>004</u>	Sep 24, 2019
<u>AP</u>		SANDOZ INC	<u>1MG/ML</u>	<u>A203649</u>	<u>001</u>	Nov 30, 2017
<u>AP</u>			<u>2.5MG/ML</u>	<u>A203649</u>	<u>002</u>	Nov 30, 2017
<u>AP</u>			<u>5MG/ML</u>	<u>A203649</u>	<u>003</u>	Nov 30, 2017
<u>AP</u>			<u>10MG/ML</u>	<u>A203649</u>	<u>004</u>	Nov 30, 2017
<u>AP</u>		TEVA PHARMS USA	<u>1MG/ML</u>	<u>A206648</u>	<u>001</u>	Sep 26, 2019
<u>AP</u>			<u>2.5MG/ML</u>	<u>A206648</u>	<u>002</u>	Sep 26, 2019
<u>AP</u>			<u>5MG/ML</u>	<u>A206648</u>	<u>003</u>	Sep 26, 2019
<u>AP</u>			<u>10MG/ML</u>	<u>A206648</u>	<u>004</u>	Sep 26, 2019

REMODULIN

<u>+</u> !	UNITED THERAP	20MG/ML	N021272	005	Jul 30, 2021

PRESCRIPTION DRUG PRODUCT LIST

3-451 (of 474)

TREPROSTINIL

POWDER; INHALATION

TYVASO DPI

+	UNITED THERAP	0.016MG/INH	N214324	001	May 23, 2022
+		0.032MG/INH	N214324	002	May 23, 2022
+		0.048MG/INH	N214324	003	May 23, 2022
+	!	0.064MG/INH	N214324	004	May 23, 2022

SOLUTION; INHALATION

TYVASO

+	!	UNITED THERAP	0.6MG/ML	N022387	001	Jul 30, 2009

TREPROSTINIL DIOLAMINE

TABLET, EXTENDED RELEASE; ORAL

ORENITRAM

+	UNITED THERAP	EQ 0.125MG BASE	N203496	001	Dec 20, 2013
+		EQ 0.25MG BASE	N203496	002	Dec 20, 2013
+	!	EQ 1MG BASE	N203496	003	Dec 20, 2013
+		EQ 2.5MG BASE	N203496	004	Dec 20, 2013
+		EQ 5MG BASE	N203496	005	Oct 07, 2016

TRETINOIN

CAPSULE; ORAL

TRETINOIN

<u>AB</u>		ANCHEN PHARMS	<u>10MG</u>	<u>A201687</u>	<u>001</u>	Oct 24, 2012
<u>AB</u>	!	BARR LABS INC	<u>10MG</u>	<u>A077684</u>	<u>001</u>	Jun 22, 2007
<u>AB</u>		GLENMARK PHARMS LTD	<u>10MG</u>	<u>A208279</u>	<u>001</u>	Dec 23, 2016

CREAM; TOPICAL

AVITA

<u>AB</u>		MYLAN PHARMS INC	<u>0.025%</u>	<u>N020404</u>	<u>003</u>	Jan 14, 1997

RETIN-A

<u>AB</u>	+	!	VALEANT BERMUDA	<u>0.025%</u>	<u>N019049</u>	<u>001</u>	Sep 16, 1988
<u>AB</u>	+	!	VALEANT PHARMS NORTH	<u>0.1%</u>	<u>N017340</u>	<u>001</u>	

TRETINOIN

<u>AB</u>		PADAGIS US	<u>0.025%</u>	<u>A075264</u>	<u>001</u>	Dec 24, 1998
<u>AB</u>			<u>0.1%</u>	<u>A075213</u>	<u>001</u>	Dec 24, 1998
<u>AB</u>		TARO PHARMS	<u>0.025%</u>	<u>A215713</u>	<u>001</u>	Jan 05, 2023
<u>AB</u>			<u>0.1%</u>	<u>A211645</u>	<u>001</u>	Jan 22, 2019

RETIN-A

<u>AB1</u>	+	!	VALEANT BERMUDA	<u>0.05%</u>	<u>N017522</u>	<u>001</u>	

TRETINOIN

<u>AB1</u>		PADAGIS US	<u>0.05%</u>	<u>A075265</u>	<u>001</u>	Dec 24, 1998
<u>AB1</u>		TARO PHARMS	<u>0.05%</u>	<u>A211644</u>	<u>001</u>	Jan 25, 2019

RENOVA

+	!	VALEANT PHARMS NORTH	0.02%	N021108	001	Aug 31, 2000

GEL; TOPICAL

ATRALIN

<u>AB</u>	+	!	DOW PHARM	<u>0.05%</u>	<u>N022070</u>	<u>001</u>	Jul 26, 2007

RETIN-A

<u>AB</u>	+	!	VALEANT INTL	<u>0.01%</u>	<u>N017955</u>	<u>001</u>	
<u>AB</u>	+	!		<u>0.025%</u>	<u>N017579</u>	<u>002</u>	

TRETINOIN

<u>AB</u>		MYLAN	<u>0.05%</u>	<u>A207955</u>	<u>001</u>	Aug 13, 2015
<u>AB</u>		PADAGIS US	<u>0.01%</u>	<u>A075589</u>	<u>001</u>	Jun 11, 2002
<u>AB</u>			<u>0.025%</u>	<u>A075529</u>	<u>001</u>	Feb 22, 2000

AVITA

BT		MYLAN	0.025%	N020400	001	Jan 29, 1998

RETIN-A MICRO

+	!	VALEANT INTL	0.04%	N020475	002	May 10, 2002
+	!		0.1%	N020475	001	Feb 07, 1997

RETIN-A-MICRO

+	!	VALEANT INTL	0.06%	N020475	004	Oct 23, 2017
+	!		0.08%	N020475	003	Jan 28, 2014

LOTION; TOPICAL

ALTRENO

+	!	DOW PHARM	0.05%	N209353	001	Aug 23, 2018

PRESCRIPTION DRUG PRODUCT LIST

3-452 (of 474)

TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

TRIAMCINOLONE ACETONIDE

<u>AT</u>	ALKEM LABS LTD	<u>0.025%</u>	<u>A207651</u>	<u>001</u>	Dec 26, 2017
<u>AT</u>		<u>0.1%</u>	<u>A207651</u>	<u>002</u>	Dec 26, 2017
<u>AT</u>		<u>0.5%</u>	<u>A207651</u>	<u>003</u>	Dec 26, 2017
<u>AT</u>	COSETTE	<u>0.025%</u>	<u>A089797</u>	<u>001</u>	May 31, 1991
<u>AT</u>		<u>0.1%</u>	<u>A089798</u>	<u>001</u>	May 31, 1991
<u>AT</u>	ENCUBE	<u>0.1%</u>	<u>A208848</u>	<u>001</u>	Sep 18, 2017
<u>AT</u>	+! FOUGERA PHARMS	<u>0.025%</u>	<u>A085692</u>	<u>001</u>	
<u>AT</u>	+!	<u>0.1%</u>	<u>A085692</u>	<u>003</u>	
<u>AT</u>	+!	<u>0.5%</u>	<u>A085692</u>	<u>002</u>	
<u>AT</u>	GLENMARK PHARMS LTD	<u>0.1%</u>	<u>A207117</u>	<u>001</u>	Aug 05, 2016
<u>AT</u>	LUPIN	<u>0.025%</u>	<u>A208763</u>	<u>001</u>	Feb 01, 2017
<u>AT</u>		<u>0.1%</u>	<u>A208763</u>	<u>002</u>	Feb 01, 2017
<u>AT</u>		<u>0.5%</u>	<u>A208763</u>	<u>003</u>	Feb 01, 2017
<u>AT</u>	MACLEODS PHARMS LTD	<u>0.025%</u>	<u>A209535</u>	<u>001</u>	May 18, 2018
<u>AT</u>		<u>0.1%</u>	<u>A209535</u>	<u>002</u>	May 18, 2018
<u>AT</u>		<u>0.5%</u>	<u>A209535</u>	<u>003</u>	May 18, 2018
<u>AT</u>	MICRO LABS	<u>0.025%</u>	<u>A040671</u>	<u>001</u>	Jun 09, 2006
<u>AT</u>		<u>0.1%</u>	<u>A040671</u>	<u>002</u>	Jun 09, 2006
<u>AT</u>	PADAGIS US	<u>0.025%</u>	<u>A086413</u>	<u>002</u>	
<u>AT</u>		<u>0.1%</u>	<u>A086413</u>	<u>003</u>	
<u>AT</u>		<u>0.5%</u>	<u>A086413</u>	<u>001</u>	
<u>AT</u>	STRIDES PHARMA	<u>0.025%</u>	<u>A210346</u>	<u>001</u>	Feb 11, 2019
<u>AT</u>		<u>0.1%</u>	<u>A210346</u>	<u>002</u>	Feb 11, 2019
<u>AT</u>		<u>0.5%</u>	<u>A210346</u>	<u>003</u>	Feb 11, 2019
<u>AT</u>	TARO PHARM INDS LTD	<u>0.1%</u>	<u>A040039</u>	<u>001</u>	Nov 26, 1997

TRIDERM

<u>AT</u>	CROWN LABS	<u>0.025%</u>	<u>A088042</u>	<u>002</u>	Mar 25, 2015
<u>AT</u>		<u>0.1%</u>	<u>A088042</u>	<u>001</u>	Mar 19, 1984
<u>AT</u>		<u>0.5%</u>	<u>A088042</u>	<u>003</u>	Mar 25, 2015

FOR SUSPENSION, EXTENDED RELEASE; INTRA-ARTICULAR

ZILRETTA

+! PACIRA PHARMS INC 32MG/VIAL

N208845 001 Oct 06, 2017

INJECTABLE; INJECTION

KENALOG-40

<u>AB</u>	+! APOTHECON	<u>40MG/ML</u>	<u>N014901</u>	<u>001</u>	

TRIAMCINOLONE ACETONIDE

<u>AB</u>	AMNEAL	<u>40MG/ML</u>	<u>A207550</u>	<u>001</u>	Dec 11, 2017
<u>AB</u>	EUGIA PHARMA	<u>40MG/ML</u>	<u>A212400</u>	<u>001</u>	Jul 05, 2022
<u>AB</u>	LONG GROVE PHARMS	<u>40MG/ML</u>	<u>A213543</u>	<u>001</u>	Jan 19, 2022
<u>AB</u>	MYLAN LABS LTD	<u>40MG/ML</u>	<u>A212567</u>	<u>001</u>	Nov 02, 2022
<u>AB</u>	TEVA PHARMS USA	<u>40MG/ML</u>	<u>A209852</u>	<u>001</u>	Oct 05, 2018

KENALOG-10

+ APOTHECON 10MG/ML

N012041 001

KENALOG-80

+! APOTHECON 80MG/ML

N014901 002 Apr 12, 2019

INJECTABLE; INTRAVITREAL

TRIESENCE

+! NOVARTIS 40MG/ML (40MG/ML)

N022048 001 Nov 29, 2007

LOTION; TOPICAL

TRIAMCINOLONE ACETONIDE

<u>AT</u>	AKORN	<u>0.025%</u>	<u>A202374</u>	<u>001</u>	May 08, 2013
<u>AT</u>		<u>0.1%</u>	<u>A202374</u>	<u>002</u>	May 08, 2013
<u>AT</u>	COSETTE	<u>0.1%</u>	<u>A089129</u>	<u>001</u>	Aug 14, 1986
<u>AT</u>	FOUGERA PHARMS	<u>0.025%</u>	<u>A040467</u>	<u>001</u>	Apr 21, 2003
<u>AT</u>		<u>0.1%</u>	<u>A040467</u>	<u>002</u>	Apr 21, 2003
<u>AT</u>	MICRO LABS	<u>0.1%</u>	<u>A040672</u>	<u>002</u>	Dec 13, 2006
<u>AT</u>	PAI HOLDINGS PHARM	<u>0.025%</u>	<u>A204608</u>	<u>001</u>	Jul 07, 2016
<u>AT</u>		<u>0.1%</u>	<u>A204606</u>	<u>001</u>	Jul 07, 2016
<u>AT</u>	QUAGEN	<u>0.025%</u>	<u>A213559</u>	<u>001</u>	Jul 01, 2020
<u>AT</u>		<u>0.1%</u>	<u>A213559</u>	<u>002</u>	Jul 01, 2020
<u>AT</u>	! WOCKHARDT BIO AG	<u>0.025%</u>	<u>A088450</u>	<u>001</u>	Apr 01, 1985
<u>AT</u>	!	<u>0.1%</u>	<u>A088451</u>	<u>001</u>	Apr 03, 1985

OINTMENT; TOPICAL

TRIAMCINOLONE ACETONIDE

<u>AT</u>	CINTEX SVCS	<u>0.05%</u>	<u>A213619</u>	<u>001</u>	Nov 10, 2020
<u>AT</u>	COSETTE	<u>0.025%</u>	<u>A089795</u>	<u>001</u>	Dec 23, 1988
<u>AT</u>		<u>0.1%</u>	<u>A089796</u>	<u>001</u>	Dec 23, 1988
<u>AT</u>		<u>0.5%</u>	<u>A208925</u>	<u>001</u>	Oct 06, 2017
<u>AT</u>	ENCUBE	<u>0.05%</u>	<u>A212384</u>	<u>001</u>	Nov 29, 2019

PRESCRIPTION DRUG PRODUCT LIST

3-453 (of 474)

TRIAMCINOLONE ACETONIDE

OINTMENT; TOPICAL

TRIAMCINOLONE ACETONIDE

<u>AT</u>		<u>0.1%</u>	<u>A205373</u>	<u>001</u>	May 13, 2016
<u>AT</u>	FOUGERA PHARMS	<u>0.025%</u>	<u>A085691</u>	<u>001</u>	
<u>AT</u>		<u>0.1%</u>	<u>A085691</u>	<u>003</u>	
<u>AT</u>		<u>0.5%</u>	<u>A085691</u>	<u>002</u>	
<u>AT</u>	GLENMARK PHARMS	<u>0.1%</u>	<u>A208320</u>	<u>001</u>	Aug 22, 2017
<u>AT</u>	GLENMARK PHARMS LTD	<u>0.5%</u>	<u>A206379</u>	<u>001</u>	Jul 22, 2016
<u>AT</u>	MACLEODS PHARMS LTD	<u>0.025%</u>	<u>A209828</u>	<u>001</u>	Nov 23, 2018
<u>AT</u>		<u>0.1%</u>	<u>A209828</u>	<u>002</u>	Nov 23, 2018
<u>AT</u>		<u>0.5%</u>	<u>A209828</u>	<u>003</u>	Nov 23, 2018
<u>AT</u>	NOVEL LABS INC	<u>0.1%</u>	<u>A207365</u>	<u>001</u>	Oct 12, 2018
<u>AT</u>	PADAGIS ISRAEL	<u>0.05%</u>	<u>A212460</u>	<u>001</u>	Feb 05, 2021
<u>AT</u>	+! PADAGIS US	<u>0.025%</u>	<u>A087385</u>	<u>002</u>	
<u>AT</u>	+!	<u>0.1%</u>	<u>A087385</u>	<u>003</u>	
<u>AT</u>	+!	<u>0.5%</u>	<u>A087385</u>	<u>001</u>	
<u>AT</u>	PAI HOLDINGS PHARM	<u>0.5%</u>	<u>A208590</u>	<u>001</u>	Mar 03, 2017
<u>AT</u>	STRIDES PHARMA	<u>0.05%</u>	<u>A212356</u>	<u>001</u>	Jun 01, 2020
<u>AT</u>	TARO PHARM INDS LTD	<u>0.1%</u>	<u>A040037</u>	<u>001</u>	Sep 30, 1994

TRIANEX

<u>AT</u>	! CMP PHARMA INC	<u>0.05%</u>	<u>A089595</u>	<u>001</u>	Mar 23, 1995

PASTE; DENTAL

TRIAMCINOLONE ACETONIDE

<u>AT</u>	AKORN	<u>0.1%</u>	<u>A206312</u>	<u>001</u>	Aug 11, 2016
<u>AT</u>	COSETTE	<u>0.1%</u>	<u>A205592</u>	<u>001</u>	Jan 12, 2017
<u>AT</u>	LYNE	<u>0.1%</u>	<u>A040771</u>	<u>001</u>	Jul 01, 2010
<u>AT</u>	QUAGEN	<u>0.1%</u>	<u>A214582</u>	<u>001</u>	Dec 09, 2022
<u>AT</u>	! TARO	<u>0.1%</u>	<u>A070730</u>	<u>001</u>	Oct 01, 1986

SPRAY; TOPICAL

KENALOG

<u>AT</u>	+! SUN PHARM INDS INC	<u>0.147MG/GM</u>	<u>N012104</u>	<u>001</u>	

TRIAMCINOLONE ACETONIDE

<u>AT</u>	AKORN	<u>0.147MG/GM</u>	<u>A207094</u>	<u>001</u>	Dec 07, 2016
<u>AT</u>	PADAGIS ISRAEL	<u>0.147MG/GM</u>	<u>A205782</u>	<u>001</u>	Apr 13, 2015
<u>AT</u>	RISING	<u>0.147MG/GM</u>	<u>A206786</u>	<u>001</u>	Sep 08, 2017

SUSPENSION; INJECTION

XIPERE

+!	BAUSCH AND LOMB INC	40MG/ML	N211950	001	Oct 22, 2021

TRIAMTERENE

CAPSULE; ORAL

DYRENIUM

<u>AB</u>	+ CONCORDIA	<u>50MG</u>	<u>N013174</u>	<u>001</u>	
<u>AB</u>	+!	<u>100MG</u>	<u>N013174</u>	<u>002</u>	

TRIAMTERENE

<u>AB</u>	AGNITIO	<u>50MG</u>	<u>A211581</u>	<u>001</u>	Aug 19, 2019
<u>AB</u>		<u>100MG</u>	<u>A211581</u>	<u>002</u>	Aug 19, 2019
<u>AB</u>	EYWA	<u>50MG</u>	<u>A214768</u>	<u>001</u>	Jul 06, 2022
<u>AB</u>		<u>100MG</u>	<u>A214768</u>	<u>002</u>	Jul 06, 2022

TRIAZOLAM

TABLET; ORAL

HALCION

<u>AB</u>	+ PFIZER	<u>0.125MG</u>	<u>N017892</u>	<u>003</u>	Apr 26, 1985
<u>AB</u>	+!	<u>0.25MG</u>	<u>N017892</u>	<u>001</u>	Nov 15, 1982

TRIAZOLAM

<u>AB</u>	HIKMA	<u>0.125MG</u>	<u>A074224</u>	<u>001</u>	Jun 01, 1994
<u>AB</u>		<u>0.25MG</u>	<u>A074224</u>	<u>002</u>	Jun 01, 1994
<u>AB</u>	NOVAST LABS	<u>0.125MG</u>	<u>A214219</u>	<u>001</u>	Oct 20, 2020
<u>AB</u>		<u>0.25MG</u>	<u>A214219</u>	<u>002</u>	Oct 20, 2020
<u>AB</u>	SANDOZ INC	<u>0.125MG</u>	<u>A216890</u>	<u>001</u>	Nov 08, 2022
<u>AB</u>		<u>0.25MG</u>	<u>A216890</u>	<u>002</u>	Nov 08, 2022
<u>AB</u>	ZYDUS PHARMS	<u>0.125MG</u>	<u>A213003</u>	<u>001</u>	Dec 28, 2022
<u>AB</u>		<u>0.25MG</u>	<u>A213003</u>	<u>002</u>	Dec 28, 2022

TRICLABENDAZOLE

TABLET; ORAL

EGATEN

+!	NOVARTIS	250MG	N208711	001	Feb 13, 2019

PRESCRIPTION DRUG PRODUCT LIST

3-454 (of 474)

TRIENTINE HYDROCHLORIDE

CAPSULE; ORAL

SYPRINE

AB	+ !	BAUSCH	250MG	N019194	001	Nov 08, 1985
<u>TRIENTINE HYDROCHLORIDE</u>						
AB		DR REDDYS	250MG	A211076	001	Jul 03, 2019
AB		ECI PHARMS LLC	250MG	A209945	001	Aug 13, 2021
AB		HETERO LABS LTD III	250MG	A216356	001	Jun 23, 2022
AB		NAVINTA LLC	250MG	A211251	001	Jan 16, 2019
AB		PAR PHARM INC	250MG	A210096	001	Sep 25, 2019
AB		RISING	250MG	A212238	001	Feb 20, 2020
AB		WATSON LABS TEVA	250MG	A207567	001	Feb 07, 2018
AB		ZYDUS PHARMS	250MG	A211554	001	Apr 26, 2019
BX		MSN	250MG	A211134	001	May 22, 2019

TRIENTINE TETRAHYDROCHLORIDE

TABLET; ORAL

CUVRIOR

+ !	ORPHALAN	300MG	N215760	001	Apr 28, 2022

TRIFAROTENE

CREAM; TOPICAL

AKLIEF

+ !	GALDERMA LABS LP	0.005%	N211527	001	Oct 04, 2019

TRIFLUOPERAZINE HYDROCHLORIDE

TABLET; ORAL

TRIFLUOPERAZINE HYDROCHLORIDE

AB		MYLAN	EQ 1MG BASE	A040209	001	Jul 07, 1997
AB			EQ 2MG BASE	A040209	002	Jul 07, 1997
AB			EQ 5MG BASE	A040209	003	Jul 07, 1997
AB	!		EQ 10MG BASE	A040209	004	Jul 07, 1997
AB		SANDOZ	EQ 1MG BASE	A085785	001	
AB			EQ 2MG BASE	A085786	001	
AB			EQ 5MG BASE	A085789	001	
AB			EQ 10MG BASE	A085788	001	

TRIFLURIDINE

SOLUTION/DROPS; OPHTHALMIC

TRIFLURIDINE

AT		SANDOZ INC	1%	A074311	001	Oct 06, 1995
<u>VIROPTIC</u>						
AT	+ !	MONARCH PHARMS	1%	N018299	001	

TRIEPTANOLIN

LIQUID; ORAL

DOJOLVI

+ !	ULTRAGENYX PHARM INC	100% w/w	N213687	001	Jun 30, 2020

TRIHENXYPHENIDYL HYDROCHLORIDE

ELIXIR; ORAL

TRIHENXYPHENIDYL HYDROCHLORIDE

AA		MIKART	2MG/5ML	A040251	001	Sep 27, 1999
AA	!	PHARM ASSOC	2MG/5ML	A040177	001	Apr 17, 1997

TABLET; ORAL

TRIHENXYPHENIDYL HYDROCHLORIDE

AA		NATCO PHARMA LTD	2MG	A091630	001	Nov 17, 2010
AA			5MG	A091630	002	Nov 17, 2010
AA		NOVITIUM PHARMA	2MG	A040254	001	Dec 24, 1998
AA			5MG	A040254	002	Dec 24, 1998
AA	!	WATSON LABS	2MG	A084363	001	
AA	!		5MG	A084364	001	

TRILACICLIB DIHYDROCHLORIDE

POWDER; INTRAVENOUS

COSELA

+ !	G1 THERAP	EQ 300MG BASE/VIAL	N214200	001	Feb 12, 2021

TRIMETHOENZAMIDE HYDROCHLORIDE

CAPSULE; ORAL

TRIMETHOENZAMIDE HYDROCHLORIDE

AB		LUPIN	300MG	A076546	001	Aug 20, 2003
AB	!	SUN PHARM INDUSTRIES	300MG	A076570	001	Aug 28, 2003

PRESCRIPTION DRUG PRODUCT LIST

3-455 (of 474)

TRIMETHOBENZAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

TIGAN

+! PAR STERILE 100MG/ML
PRODUCTS

N017530 001

TRIMETHOPRIM

TABLET; ORAL

TRIMETHOPRIM

<u>AB</u>	+!	MAYNE PHARMA	<u>100MG</u>	<u>N018679</u>	<u>001</u>	Jul 30, 1982
<u>AB</u>		NOVEL LABS INC	<u>100MG</u>	<u>A091437</u>	<u>001</u>	Jun 15, 2011
<u>AB</u>		NOVITIUM PHARMA	<u>100MG</u>	<u>A216393</u>	<u>001</u>	Oct 28, 2022
<u>AB</u>		WATSON LABS	<u>100MG</u>	<u>A070049</u>	<u>001</u>	Jun 06, 1985

TRIMIPRAMINE MALEATE

CAPSULE; ORAL

TRIMIPRAMINE MALEATE

<u>AB</u>		CROSSMEDIKA SA	<u>EQ 25MG BASE</u>	<u>A208127</u>	<u>001</u>	Apr 15, 2016
<u>AB</u>	!		<u>EQ 50MG BASE</u>	<u>A208127</u>	<u>002</u>	Apr 15, 2016
<u>AB</u>			<u>EQ 100MG BASE</u>	<u>A208127</u>	<u>003</u>	Apr 15, 2016
<u>AB</u>		ELITE LABS INC	<u>EQ 25MG BASE</u>	<u>A077361</u>	<u>001</u>	Aug 02, 2006
<u>AB</u>			<u>EQ 50MG BASE</u>	<u>A077361</u>	<u>002</u>	Aug 02, 2006
<u>AB</u>			<u>EQ 100MG BASE</u>	<u>A077361</u>	<u>003</u>	Aug 02, 2006

TRIPTORELIN PAMOATE

FOR SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR

TRIPTODUR KIT

+! AZURITY EQ 22.5MG BASE/VIAL

N208956 001 Jun 29, 2017

INJECTABLE; INTRAMUSCULAR

TRELSTAR

+!	VERITY	EQ 3.75MG BASE/VIAL	N020715	001	Jun 15, 2000
+!		EQ 11.25MG BASE/VIAL	N021288	001	Jun 29, 2001
+!		EQ 22.5MG BASE/VIAL	N022437	001	Mar 10, 2010

TROMETHAMINE

SOLUTION; INJECTION

THAM

+! HOSPIRA 18GM/500ML (3.6GM/100ML)

N013025 002

TROPICAMIDE

SOLUTION/DROPS; OPHTHALMIC

MYDRIACYL

<u>AT</u>	+!	ALCON LABS INC	<u>1%</u>	<u>A084306</u>	<u>001</u>	
<u>AT</u>	+!	SANDOZ INC	<u>0.5%</u>	<u>A084305</u>	<u>001</u>	

TROPICACYL

<u>AT</u>		AKORN	<u>0.5%</u>	<u>A040314</u>	<u>001</u>	Sep 29, 2000
<u>AT</u>			<u>1%</u>	<u>A040315</u>	<u>001</u>	Sep 29, 2000

TROPICAMIDE

<u>AT</u>		BAUSCH AND LOMB	<u>0.5%</u>	<u>A040067</u>	<u>001</u>	Jul 27, 1994
<u>AT</u>			<u>1%</u>	<u>A040064</u>	<u>001</u>	Jul 27, 1994
<u>AT</u>		SOMERSET THERAPS LLC	<u>1%</u>	<u>A207524</u>	<u>001</u>	Dec 12, 2019

TROSPIMUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

TROSPIMUM CHLORIDE

<u>AB</u>	!	ACTAVIS LABS FL INC	<u>60MG</u>	<u>A091289</u>	<u>001</u>	Oct 12, 2012
<u>AB</u>		AMTA	<u>60MG</u>	<u>A214760</u>	<u>001</u>	Apr 30, 2021
<u>AB</u>		GRANULES	<u>60MG</u>	<u>A213185</u>	<u>001</u>	Apr 23, 2020
<u>AB</u>		PADAGIS US	<u>60MG</u>	<u>A201291</u>	<u>001</u>	May 24, 2013

TABLET; ORAL

TROSPIMUM CHLORIDE

<u>AB</u>		APOTEX	<u>20MG</u>	<u>A091513</u>	<u>001</u>	Dec 06, 2011
<u>AB</u>	!	GLENMARK GENERICS	<u>20MG</u>	<u>A091575</u>	<u>001</u>	Aug 13, 2010
<u>AB</u>		HERITAGE PHARMS INC	<u>20MG</u>	<u>A204945</u>	<u>001</u>	Aug 30, 2016
<u>AB</u>		INVAGEN PHARMS	<u>20MG</u>	<u>A091688</u>	<u>001</u>	Aug 23, 2016
<u>AB</u>		PADAGIS US	<u>20MG</u>	<u>A091573</u>	<u>001</u>	Nov 17, 2010
<u>AB</u>		ZAMEER PHARMS	<u>20MG</u>	<u>A215781</u>	<u>001</u>	Feb 16, 2022

TRYPAN BLUE

SOLUTION; OPHTHALMIC

VISIONBLUE

+! DORC 0.06%

N021670 001 Dec 16, 2004

PRESCRIPTION DRUG PRODUCT LIST

3-456 (of 474)

TUCATINIB

TABLET; ORAL

TUKYSA

+ SEAGEN

50MG

N213411 001 Apr 17, 2020

+!

150MG

N213411 002 Apr 17, 2020

UBROGEPANT

TABLET; ORAL

UBRELVI

+ ALLERGAN

50MG

N211765 001 Dec 23, 2019

+!

100MG

N211765 002 Dec 23, 2019

ULIPRISTAL ACETATE

TABLET; ORAL

ELLA**AB** +! LAB HRA PHARMA**30MG****N022474 001** Aug 13, 2010LOGILIA**AB** TEVA PHARMS USA**30MG****A207952 001** Feb 13, 2017UMECLIDINIUM BROMIDE

POWDER; INHALATION

INCRUSE ELLIPTA

+! GLAXO GRP ENGLAND

EQ 62.5MCG BASE/INH

N205382 001 Apr 30, 2014

UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE

POWDER; INHALATION

ANORO ELLIPTA

+! GLAXOSMITHKLINE

EQ 0.0625MG BASE/INH; EQ 0.025MG
BASE/INH

N203975 001 Dec 18, 2013

UPADACITINIB

TABLET, EXTENDED RELEASE; ORAL

RINVOQ

+ ABBVIE INC

15MG

N211675 001 Aug 16, 2019

+

30MG

N211675 002 Jan 14, 2022

+!

45MG

N211675 003 Mar 16, 2022

UREA, C-14

CAPSULE; ORAL

PYTEST

+! AVENT

1uCi

N020617 001 May 09, 1997

PYTEST KIT

+! AVENT

1uCi

N020617 002 May 09, 1997

URIDINE TRIACETATE

GRANULE; ORAL

VISTOGARD

+! WELLSTAT THERAP

10GM/PACKET

N208159 001 Dec 11, 2015

XURIDEN

+! WELLSTAT THERAP

2GM/PACKET

N208169 001 Sep 04, 2015

URSODIOL

CAPSULE; ORAL

ACTIGALL**AB** +! TEVA BRANDED PHARM**300MG****N019594 002** Dec 31, 1987URSODIOL**AB** ABHAI LLC**300MG****A210707 001** May 17, 2018**AB** AMNEAL PHARMS CO**300MG****A211301 001** Oct 16, 2018**AB** AUROBINDO PHARMA**300MG****A214849 001** Nov 28, 2022

LTD

AB CHARTWELL RX**300MG****A213555 001** Aug 17, 2020**AB** EPIC PHARMA**300MG****A075517 001** Mar 14, 2000**AB** EYWA PHARMA**300MG****A212452 001** Oct 30, 2019**AB** LANNETT CO INC**300MG****A079082 001** Dec 15, 2008**AB** MYLAN**300MG****A090530 001** Feb 17, 2010**AB** RISING**300MG****A213200 001** Feb 12, 2020**AB** STRIDES PHARMA**300MG****A210344 001** Jan 22, 2021**AB** TEVA PHARMS**300MG****A075592 001** May 25, 2000**AB** ZYDUS**300MG****A214295 001** Oct 16, 2020

LGM PHARMA

200MG

A205789 001 May 08, 2020

!

400MG

A205789 002 May 08, 2020

TABLET; ORAL

URSO 250**AB** + ALLERGAN**250MG****N020675 001** Dec 10, 1997URSO FORTE**AB** +! ALLERGAN**500MG****N020675 002** Jul 21, 2004

TABLET; ORAL

URSODIOL

<u>AB</u>	GLENMARK GENERICS	<u>250MG</u>	<u>A090801</u>	<u>001</u>	Jul 12, 2011
<u>AB</u>		<u>500MG</u>	<u>A090801</u>	<u>002</u>	Jul 12, 2011
<u>AB</u>	PAR PHARM	<u>250MG</u>	<u>A202540</u>	<u>001</u>	Feb 14, 2013
<u>AB</u>		<u>500MG</u>	<u>A202540</u>	<u>002</u>	Feb 14, 2013
<u>AB</u>	STRIDES PHARMA	<u>250MG</u>	<u>A213504</u>	<u>001</u>	Aug 20, 2020
<u>AB</u>		<u>500MG</u>	<u>A213504</u>	<u>002</u>	Aug 20, 2020
<u>AB</u>	ZYDUS	<u>250MG</u>	<u>A211145</u>	<u>001</u>	Oct 30, 2018
<u>AB</u>		<u>500MG</u>	<u>A211145</u>	<u>002</u>	Oct 30, 2018

VALACYCLOVIR HYDROCHLORIDE

TABLET: ORAL.

VALACYCLOVIR HYDROCHLORIDE

AB	APOTEX	<u>EQ 500MG BASE</u>	<u>A090500</u>	<u>001</u>	Apr 04, 2014
AB		<u>EQ 1GM BASE</u>	<u>A090500</u>	<u>002</u>	Apr 04, 2014
AB	AUROBINDO PHARMA	<u>EQ 500MG BASE</u>	<u>A090682</u>	<u>001</u>	May 24, 2010
AB		<u>EQ 1GM BASE</u>	<u>A090682</u>	<u>002</u>	May 24, 2010
AB	CADILA	<u>EQ 500MG BASE</u>	<u>A079137</u>	<u>001</u>	Dec 29, 2017
AB		<u>EQ 1GM BASE</u>	<u>A079137</u>	<u>002</u>	Dec 29, 2017
AB	CIPLA	<u>EQ 500MG BASE</u>	<u>A077135</u>	<u>001</u>	May 24, 2010
AB		<u>EQ 1GM BASE</u>	<u>A077135</u>	<u>002</u>	May 24, 2010
AB	HETERO LABS LTD V	<u>EQ 500MG BASE</u>	<u>A203047</u>	<u>001</u>	Apr 08, 2015
AB		<u>EQ 1GM BASE</u>	<u>A203047</u>	<u>002</u>	Apr 08, 2015
AB	JUBILANT GENERICS	<u>EQ 500MG BASE</u>	<u>A201506</u>	<u>001</u>	Apr 03, 2012
AB		<u>EQ 1GM BASE</u>	<u>A201506</u>	<u>002</u>	Apr 03, 2012
AB	MYLAN PHARMS INC	<u>EQ 500MG BASE</u>	<u>A078518</u>	<u>001</u>	May 24, 2010
AB		<u>EQ 1GM BASE</u>	<u>A078518</u>	<u>002</u>	May 24, 2010
AB	SANDOZ	<u>EQ 500MG BASE</u>	<u>A077478</u>	<u>001</u>	May 24, 2010
AB		<u>EQ 1GM BASE</u>	<u>A077478</u>	<u>002</u>	May 24, 2010
AB	SUN PHARM INDS LTD	<u>EQ 500MG BASE</u>	<u>A076588</u>	<u>001</u>	Jan 31, 2007
AB		<u>EQ 1GM BASE</u>	<u>A076588</u>	<u>002</u>	Jan 31, 2007
AB	TIME-CAP LABS INC	<u>EQ 500MG BASE</u>	<u>A079012</u>	<u>001</u>	May 24, 2010
AB		<u>EQ 1GM BASE</u>	<u>A079012</u>	<u>002</u>	May 24, 2010
AB	WOCKHARDT BIO AG	<u>EQ 1GM BASE</u>	<u>A090216</u>	<u>002</u>	May 24, 2010
AB		<u>EQ 500MG BASE</u>	<u>A090216</u>	<u>001</u>	May 24, 2010
AB	YILING	<u>EQ 500MG BASE</u>	<u>A209553</u>	<u>001</u>	Mar 18, 2020
AB		<u>EQ 1GM BASE</u>	<u>A209553</u>	<u>002</u>	Mar 18, 2020

VALTREX

AB	+	GLAXOSMITHKLINE	<u>EQ 500MG BASE</u>	<u>N020487 001</u>	Jun 23, 1995
AB	+		<u>EQ 1GM BASE</u>	<u>N020487 002</u>	Jun 23, 1995

VALBENAZINE TOSYLATE

CAPSULE: ORAL.

INGREZZA

+	NEUROCRINE	EQ 40MG BASE	N209241 001	Apr 11, 2017
+		EQ 60MG BASE	N209241 003	Apr 23, 2021
+	!	EQ 80MG BASE	N209241 002	Oct 04, 2017

VALGANCICLOVIR HYDROCHLORIDE

FOR SOLUTION; ORAL

VALCYTE

AB +! HOFFMANN LA ROCHE 50MG/ML N022257 001 Aug 28, 2009

VALGANCICLOVIR HYDROCHLORIDE

<u>AB</u>	ACTAVIS LABS FL INC	<u>50MG/ML</u>	<u>A205220</u>	<u>001</u>	Jul 18, 2016
<u>AB</u>	AJANTA PHARMA LTD	<u>50MG/ML</u>	<u>A212890</u>	<u>001</u>	Jan 13, 2020
<u>AB</u>	AUROBINDO PHARMA	<u>50MG/ML</u>	<u>A215124</u>	<u>001</u>	Nov 17, 2022
<u>AB</u>	GRANULES	<u>50MG/ML</u>	<u>A213306</u>	<u>001</u>	Jan 31, 2020
<u>AB</u>	HETERO LABS LTD V	<u>50MG/ML</u>	<u>A211475</u>	<u>001</u>	Oct 04, 2022
<u>AB</u>	MSN	<u>50MG/ML</u>	<u>A210169</u>	<u>001</u>	Feb 17, 2022

TABLET; ORAL

VALCYTE

AB +! HOFFMANN LA ROCHE EQ 450MG BASE N021304 001 Mar 29, 2001

VALGANCICLOVIR HYDROCHLORIDE

<u>AB</u>	AJANTA PHARMA LTD	<u>EQ 450MG BASE</u>	<u>A212234</u>	<u>001</u>	Dec 26, 2019
<u>AB</u>	AUROBINDO PHARMA LTD	<u>EQ 450MG BASE</u>	<u>A204750</u>	<u>001</u>	Mar 31, 2016
<u>AB</u>	CIPLA	<u>EQ 450MG BASE</u>	<u>A209672</u>	<u>001</u>	Nov 09, 2018
<u>AB</u>	DR REDDYS	<u>EQ 450MG BASE</u>	<u>A203511</u>	<u>001</u>	Nov 04, 2014
<u>AB</u>		<u>EQ 450MG BASE</u>	<u>A206876</u>	<u>001</u>	Dec 12, 2017
<u>AB</u>	HETERO LABS LTD V	<u>EQ 450MG BASE</u>	<u>A205166</u>	<u>001</u>	Mar 18, 2016
<u>AB</u>	STRIDES PHARMA	<u>EQ 450MG BASE</u>	<u>A200790</u>	<u>001</u>	Nov 04, 2014

PRESCRIPTION DRUG PRODUCT LIST

3-458 (of 474)

VALPROATE SODIUM

INJECTABLE; INJECTION

VALPROATE SODIUM

<u>AP</u>	ATHENEX INC	<u>EQ 100MG BASE/ML</u>	<u>A076295</u>	<u>001</u>	Nov 14, 2002
<u>AP</u>	FRESENIUS KABI USA	<u>EQ 100MG BASE/ML</u>	<u>A076539</u>	<u>001</u>	Jun 26, 2003
<u>AP</u>	! HIKMA FARMACEUTICA	<u>EQ 100MG BASE/ML</u>	<u>A078523</u>	<u>001</u>	Feb 17, 2010

VALPROIC ACID

CAPSULE; ORAL

VALPROIC ACID

<u>AB</u>	! BIONPHARMA INC	<u>250MG</u>	<u>A073484</u>	<u>001</u>	Jun 29, 1993
<u>AB</u>	CATALENT	<u>250MG</u>	<u>A073229</u>	<u>001</u>	Oct 29, 1991
<u>AB</u>	SUN PHARM INDS LTD	<u>250MG</u>	<u>A091037</u>	<u>001</u>	Feb 22, 2013
<u>BX</u>	EYWA	250MG	A207611	001	Aug 05, 2019

SYRUP; ORAL

VALPROIC ACID

<u>AA</u>	CHARTWELL RX	<u>250MG/5ML</u>	<u>A075782</u>	<u>001</u>	Dec 22, 2000
<u>AA</u>	ECI PHARMS LLC	<u>250MG/5ML</u>	<u>A090517</u>	<u>001</u>	May 28, 2010
<u>AA</u>	HIGH TECH PHARMA	<u>250MG/5ML</u>	<u>A074060</u>	<u>001</u>	Jan 13, 1995
<u>AA</u>	! PHARM ASSOC	<u>250MG/5ML</u>	<u>A075379</u>	<u>001</u>	Dec 15, 2000

VALRUBICIN

SOLUTION; INTRAVESICAL

VALRUBICIN

<u>AO</u>	HIKMA	<u>40MG/ML</u>	<u>A206430</u>	<u>001</u>	Apr 19, 2019
<u>AO</u>	+! VALSTAR PRESERVATIVE FREE ENDO PHARM	<u>40MG/ML</u>	<u>N020892</u>	<u>001</u>	Sep 25, 1998

VALSARTAN

SOLUTION; ORAL

VALSARTAN

NOVITIUM PHARMA

20MG/5ML

A214102 001 Nov 02, 2021

TABLET; ORAL

DIOVAN

<u>AB</u>	+ NOVARTIS	<u>40MG</u>	<u>N021283</u>	<u>004</u>	Aug 14, 2002
<u>AB</u>	+	<u>80MG</u>	<u>N021283</u>	<u>001</u>	Jul 18, 2001
<u>AB</u>	+	<u>160MG</u>	<u>N021283</u>	<u>002</u>	Jul 18, 2001
<u>AB</u>	+!	<u>320MG</u>	<u>N021283</u>	<u>003</u>	Jul 18, 2001

VALSARTAN

<u>AB</u>	ALEMIC PHARMS	<u>40MG</u>	<u>A091367</u>	<u>001</u>	Jan 05, 2015
<u>AB</u>		<u>80MG</u>	<u>A091367</u>	<u>002</u>	Jan 05, 2015
<u>AB</u>		<u>160MG</u>	<u>A091367</u>	<u>003</u>	Jan 05, 2015
<u>AB</u>		<u>320MG</u>	<u>A091367</u>	<u>004</u>	Jan 05, 2015
<u>AB</u>	ALKEM LABS LTD	<u>40MG</u>	<u>A205536</u>	<u>001</u>	Mar 12, 2019
<u>AB</u>		<u>80MG</u>	<u>A205536</u>	<u>002</u>	Mar 12, 2019
<u>AB</u>		<u>160MG</u>	<u>A205536</u>	<u>003</u>	Mar 12, 2019
<u>AB</u>		<u>320MG</u>	<u>A205536</u>	<u>004</u>	Mar 12, 2019
<u>AB</u>	AMNEAL PHARMS	<u>40MG</u>	<u>A204011</u>	<u>001</u>	Jan 11, 2016
<u>AB</u>		<u>80MG</u>	<u>A204011</u>	<u>002</u>	Jan 11, 2016
<u>AB</u>		<u>160MG</u>	<u>A204011</u>	<u>003</u>	Jan 11, 2016
<u>AB</u>		<u>320MG</u>	<u>A204011</u>	<u>004</u>	Jan 11, 2016
<u>AB</u>	AUROBINDO PHARMA LTD	<u>40MG</u>	<u>A202223</u>	<u>001</u>	Jan 05, 2015
<u>AB</u>		<u>80MG</u>	<u>A202223</u>	<u>002</u>	Jan 05, 2015
<u>AB</u>		<u>160MG</u>	<u>A202223</u>	<u>003</u>	Jan 05, 2015
<u>AB</u>		<u>320MG</u>	<u>A202223</u>	<u>004</u>	Jan 05, 2015
<u>AB</u>	DR REDDYS	<u>40MG</u>	<u>A201618</u>	<u>001</u>	Oct 05, 2021
<u>AB</u>		<u>80MG</u>	<u>A201618</u>	<u>002</u>	Oct 05, 2021
<u>AB</u>		<u>160MG</u>	<u>A201618</u>	<u>003</u>	Oct 05, 2021
<u>AB</u>		<u>320MG</u>	<u>A201618</u>	<u>004</u>	Oct 05, 2021
<u>AB</u>	HETERO LABS LTD V	<u>40MG</u>	<u>A203311</u>	<u>001</u>	Jan 05, 2015
<u>AB</u>		<u>80MG</u>	<u>A203311</u>	<u>002</u>	Jan 05, 2015
<u>AB</u>		<u>160MG</u>	<u>A203311</u>	<u>003</u>	Jan 05, 2015
<u>AB</u>		<u>320MG</u>	<u>A203311</u>	<u>004</u>	Jan 05, 2015
<u>AB</u>	IVAX PHARMS	<u>40MG</u>	<u>A077530</u>	<u>001</u>	Jan 04, 2016
<u>AB</u>		<u>80MG</u>	<u>A077530</u>	<u>002</u>	Jan 04, 2016
<u>AB</u>		<u>160MG</u>	<u>A077530</u>	<u>003</u>	Jan 04, 2016
<u>AB</u>		<u>320MG</u>	<u>A077530</u>	<u>004</u>	Jan 04, 2016
<u>AB</u>	JUBILANT GENERICS	<u>40MG</u>	<u>A203536</u>	<u>001</u>	Jan 05, 2015
<u>AB</u>		<u>80MG</u>	<u>A203536</u>	<u>002</u>	Jan 05, 2015
<u>AB</u>		<u>160MG</u>	<u>A203536</u>	<u>003</u>	Jan 05, 2015
<u>AB</u>		<u>320MG</u>	<u>A203536</u>	<u>004</u>	Jan 05, 2015
<u>AB</u>	LUPIN LTD	<u>40MG</u>	<u>A201677</u>	<u>001</u>	Jan 05, 2015
<u>AB</u>		<u>80MG</u>	<u>A201677</u>	<u>002</u>	Jan 05, 2015

PRESCRIPTION DRUG PRODUCT LIST

3-459 (of 474)

VALSARTAN

TABLET; ORAL

VALSARTAN

<u>AB</u>		<u>160MG</u>	<u>A201677</u>	<u>003</u>	Jan 05, 2015
<u>AB</u>		<u>320MG</u>	<u>A201677</u>	<u>004</u>	Jan 05, 2015
<u>AB</u>	MACLEODS PHARMS LTD	<u>40MG</u>	<u>A202696</u>	<u>001</u>	Sep 16, 2016
<u>AB</u>		<u>80MG</u>	<u>A202696</u>	<u>002</u>	Sep 16, 2016
<u>AB</u>		<u>160MG</u>	<u>A202696</u>	<u>003</u>	Sep 16, 2016
<u>AB</u>		<u>320MG</u>	<u>A202696</u>	<u>004</u>	Sep 16, 2016
<u>AB</u>	MYLAN	<u>40MG</u>	<u>A090866</u>	<u>001</u>	Jan 05, 2015
<u>AB</u>		<u>80MG</u>	<u>A090866</u>	<u>002</u>	Jan 05, 2015
<u>AB</u>		<u>160MG</u>	<u>A090866</u>	<u>003</u>	Jan 05, 2015
<u>AB</u>		<u>320MG</u>	<u>A090866</u>	<u>004</u>	Jan 05, 2015
<u>AB</u>	OHM LABS INC	<u>40MG</u>	<u>A077492</u>	<u>001</u>	Jun 26, 2014
<u>AB</u>		<u>80MG</u>	<u>A077492</u>	<u>002</u>	Jun 26, 2014
<u>AB</u>		<u>160MG</u>	<u>A077492</u>	<u>003</u>	Jun 26, 2014
<u>AB</u>		<u>320MG</u>	<u>A077492</u>	<u>004</u>	Jun 26, 2014
<u>AB</u>	PRINSTON INC	<u>40MG</u>	<u>A204821</u>	<u>001</u>	Jun 09, 2015
<u>AB</u>		<u>80MG</u>	<u>A204821</u>	<u>002</u>	Jun 09, 2015
<u>AB</u>		<u>160MG</u>	<u>A204821</u>	<u>003</u>	Jun 09, 2015
<u>AB</u>		<u>320MG</u>	<u>A204821</u>	<u>004</u>	Jun 09, 2015
<u>AB</u>	SCIEGEN PHARMS INC	<u>40MG</u>	<u>A204038</u>	<u>001</u>	Oct 27, 2021
<u>AB</u>		<u>80MG</u>	<u>A204038</u>	<u>002</u>	Oct 27, 2021
<u>AB</u>		<u>160MG</u>	<u>A204038</u>	<u>003</u>	Oct 27, 2021
<u>AB</u>		<u>320MG</u>	<u>A204038</u>	<u>004</u>	Oct 27, 2021
<u>AB</u>	SQUARE PHARMS	<u>40MG</u>	<u>A205347</u>	<u>001</u>	Apr 09, 2018
<u>AB</u>		<u>80MG</u>	<u>A205347</u>	<u>002</u>	Apr 09, 2018
<u>AB</u>		<u>160MG</u>	<u>A205347</u>	<u>003</u>	Apr 09, 2018
<u>AB</u>		<u>320MG</u>	<u>A205347</u>	<u>004</u>	Apr 09, 2018

VANCOMYCIN

SOLUTION; INTRAVENOUS, ORAL

VANCOMYCIN

+! XELLIA PHARMS APS 5GM/100ML (50MG/ML) N213895 001 Aug 26, 2021

VANCOMYCIN HYDROCHLORIDE

CAPSULE; ORAL

VANCOCIN HYDROCHLORIDE

<u>AB</u>	+	ANI PHARMS	<u>EQ 125MG BASE</u>	<u>N050606</u>	<u>001</u>	Apr 15, 1986
<u>AB</u>	+	!	<u>EQ 250MG BASE</u>	<u>N050606</u>	<u>002</u>	Apr 15, 1986
<u>VANCOMYCIN HYDROCHLORIDE</u>						
<u>AB</u>		AKORN	<u>EQ 125MG BASE</u>	<u>A065478</u>	<u>001</u>	Apr 09, 2012
<u>AB</u>			<u>EQ 250MG BASE</u>	<u>A065478</u>	<u>002</u>	Apr 09, 2012
<u>AB</u>		LUPIN LTD	<u>EQ 125MG BASE</u>	<u>A090439</u>	<u>001</u>	Jan 28, 2015
<u>AB</u>			<u>EQ 250MG BASE</u>	<u>A090439</u>	<u>002</u>	Jan 28, 2015
<u>AB</u>		ORIENT PHARMA CO LTD	<u>EQ 125MG BASE</u>	<u>A210729</u>	<u>001</u>	Apr 29, 2019
<u>AB</u>			<u>EQ 250MG BASE</u>	<u>A210729</u>	<u>002</u>	Apr 29, 2019
<u>AB</u>		STRIDES PHARMA	<u>EQ 125MG BASE</u>	<u>A065490</u>	<u>001</u>	Apr 09, 2012
<u>AB</u>			<u>EQ 250MG BASE</u>	<u>A065490</u>	<u>002</u>	Apr 09, 2012
<u>AB</u>		WATSON LABS	<u>EQ 125MG BASE</u>	<u>A065510</u>	<u>001</u>	Apr 09, 2012
<u>AB</u>			<u>EQ 250MG BASE</u>	<u>A065510</u>	<u>002</u>	Apr 09, 2012

FOR SOLUTION; ORAL

FIRVANO KIT

<u>AB</u>	+	!	AZURITY	<u>EQ 25MG BASE/ML</u>	<u>N208910</u>	<u>001</u>	Jan 26, 2018
<u>AB</u>	+	!		<u>EQ 50MG BASE/ML</u>	<u>N208910</u>	<u>002</u>	Jan 26, 2018

VANCOMYCIN HYDROCHLORIDE

<u>AB</u>		ALKEM LABS LTD	<u>EQ 25MG BASE/ML</u>	<u>A214913</u>	<u>001</u>	Nov 14, 2022
<u>AB</u>			<u>EQ 50MG BASE/ML</u>	<u>A214913</u>	<u>002</u>	Nov 14, 2022

VANCOCIN HYDROCHLORIDE

! ANI PHARMS EQ 250MG BASE/5ML A061667 002 Jul 13, 1983

INJECTABLE; INJECTION

VANCOMYCIN HYDROCHLORIDE

<u>AP</u>		ASPIRO	<u>EQ 500MG BASE/VIAL</u>	<u>A216591</u>	<u>001</u>	Jul 06, 2022
<u>AP</u>			<u>EQ 1GM BASE/VIAL</u>	<u>A216591</u>	<u>002</u>	Jul 06, 2022
<u>AP</u>		EUGIA PHARMA	<u>EQ 500MG BASE/VIAL</u>	<u>A205780</u>	<u>001</u>	Mar 31, 2016
<u>AP</u>			<u>EQ 1GM BASE/VIAL</u>	<u>A205780</u>	<u>002</u>	Mar 31, 2016
<u>AP</u>			<u>EQ 5GM BASE/VIAL</u>	<u>A205779</u>	<u>001</u>	Mar 29, 2016
<u>AP</u>			<u>EQ 10GM BASE/VIAL</u>	<u>A205779</u>	<u>002</u>	Mar 29, 2016
<u>AP</u>	!	FRESENIUS KABI USA	<u>EQ 500MG BASE/VIAL</u>	<u>A062663</u>	<u>001</u>	Mar 17, 1987
<u>AP</u>			<u>EQ 750MG BASE/VIAL</u>	<u>A062663</u>	<u>005</u>	Aug 17, 2016
<u>AP</u>	!		<u>EQ 1GM BASE/VIAL</u>	<u>A062663</u>	<u>002</u>	Jul 31, 1987
<u>AP</u>	!		<u>EQ 5GM BASE/VIAL</u>	<u>A062663</u>	<u>003</u>	Jun 03, 1988
<u>AP</u>	!		<u>EQ 10GM BASE/VIAL</u>	<u>A062663</u>	<u>004</u>	Nov 28, 1997

PRESCRIPTION DRUG PRODUCT LIST

3-460 (of 474)

VANCOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION

VANCOMYCIN HYDROCHLORIDE

AP	GLAND PHARMA LTD	<u>EQ 500MG BASE/VIAL</u>	<u>A205694</u>	<u>001</u>	Jan 21, 2016
AP		<u>EQ 1GM BASE/VIAL</u>	<u>A205694</u>	<u>002</u>	Jan 21, 2016
AP	HAINAN POLY	<u>EQ 5GM BASE/VIAL</u>	<u>A215821</u>	<u>001</u>	Nov 18, 2021
AP		<u>EQ 10GM BASE/VIAL</u>	<u>A215821</u>	<u>002</u>	Nov 18, 2021
AP	HAINAN POLY PHARM	<u>EQ 500MG BASE/VIAL</u>	<u>A212332</u>	<u>001</u>	Jun 12, 2019
AP		<u>EQ 1GM BASE/VIAL</u>	<u>A212332</u>	<u>002</u>	Jun 12, 2019
AP	HIKMA	<u>EQ 5GM BASE/VIAL</u>	<u>A204360</u>	<u>001</u>	Oct 15, 2018
AP		<u>EQ 10GM BASE/VIAL</u>	<u>A204360</u>	<u>002</u>	Oct 15, 2018
AP	HIKMA PHARMS	<u>EQ 750MG BASE/VIAL</u>	<u>A206616</u>	<u>001</u>	Oct 03, 2018
AP	! HOSPIRA	<u>EQ 500MG BASE/VIAL</u>	<u>A062911</u>	<u>001</u>	Aug 04, 1988
AP	!	<u>EQ 500MG BASE/VIAL</u>	<u>A062931</u>	<u>001</u>	Oct 29, 1992
AP		<u>EQ 750MG BASE/VIAL</u>	<u>A062912</u>	<u>002</u>	Jan 07, 2009
AP		<u>EQ 750MG BASE/VIAL</u>	<u>A062933</u>	<u>002</u>	May 27, 2009
AP	!	<u>EQ 1GM BASE/VIAL</u>	<u>A062912</u>	<u>001</u>	Aug 04, 1988
AP	!	<u>EQ 1GM BASE/VIAL</u>	<u>A062933</u>	<u>001</u>	Oct 29, 1992
AP	!	<u>EQ 5GM BASE/VIAL</u>	<u>A063076</u>	<u>001</u>	Dec 21, 1990
AP		<u>EQ 10GM BASE/VIAL</u>	<u>A063076</u>	<u>002</u>	Sep 14, 2020
AP	HOSPIRA INC	<u>EQ 10GM BASE/VIAL</u>	<u>A065455</u>	<u>001</u>	Apr 29, 2009
AP	MEITHEAL	<u>EQ 500MG BASE/VIAL</u>	<u>A215197</u>	<u>001</u>	Jul 28, 2022
AP		<u>EQ 750MG BASE/VIAL</u>	<u>A215195</u>	<u>001</u>	Sep 15, 2022
AP		<u>EQ 1GM BASE/VIAL</u>	<u>A215197</u>	<u>002</u>	Jul 28, 2022
AP		<u>EQ 5GM BASE/VIAL</u>	<u>A215196</u>	<u>001</u>	Jul 27, 2022
AP		<u>EQ 10GM BASE/VIAL</u>	<u>A215196</u>	<u>002</u>	Jul 27, 2022
AP	MYLAN LABS LTD	<u>EQ 500MG BASE/VIAL</u>	<u>A065397</u>	<u>001</u>	Dec 30, 2008
AP		<u>EQ 1GM BASE/VIAL</u>	<u>A065397</u>	<u>002</u>	Dec 30, 2008
AP		<u>EQ 5GM BASE/VIAL</u>	<u>A065432</u>	<u>001</u>	Dec 30, 2008
AP	!	<u>EQ 10GM BASE/VIAL</u>	<u>A091554</u>	<u>001</u>	Sep 19, 2011
AP	PHARM ASSOC	<u>EQ 500MG BASE/VIAL</u>	<u>A065401</u>	<u>001</u>	Jun 30, 2008
AP		<u>EQ 1GM BASE/VIAL</u>	<u>A065401</u>	<u>002</u>	Jun 30, 2008
AP	SAGENT PHARMS	<u>EQ 5GM BASE/VIAL</u>	<u>A200837</u>	<u>001</u>	Aug 10, 2012
AP		<u>EQ 10GM BASE/VIAL</u>	<u>A200837</u>	<u>002</u>	Sep 02, 2014
AP	SANDOZ INC	<u>EQ 5GM BASE/VIAL</u>	<u>A201048</u>	<u>001</u>	Aug 10, 2012
AP		<u>EQ 10GM BASE/VIAL</u>	<u>A201048</u>	<u>002</u>	Aug 10, 2012
AP	XELLIA PHARMS APS	<u>EQ 5GM BASE/VIAL</u>	<u>A204125</u>	<u>001</u>	Dec 28, 2015
AP		<u>EQ 10GM BASE/VIAL</u>	<u>A204125</u>	<u>002</u>	Dec 28, 2015
AP		<u>EQ 500MG BASE/VIAL</u>	<u>A204107</u>	<u>001</u>	Dec 28, 2015
AP		<u>EQ 1GM BASE/VIAL</u>	<u>A204107</u>	<u>002</u>	Dec 28, 2015
VANCOCIN HYDROCHLORIDE IN PLASTIC CONTAINER					
+	! BAXTER HLTHCARE	EQ 500MG BASE/100ML	N050671	001	Apr 29, 1993
+	!	EQ 750MG BASE/150ML	N050671	002	Dec 20, 2010
+	!	EQ 1GM BASE/200ML	N050671	003	Mar 01, 1999
VANCOMYCIN HYDROCHLORIDE					
!	HOSPIRA	EQ 1.5GM BASE/VIAL	A062912	003	Jul 10, 2020
POWDER; INTRAVENOUS					
VANCOMYCIN HYDROCHLORIDE					
+	! MYLAN LABS LTD	EQ 750MG BASE/VIAL	N209481	002	Jul 10, 2018
+	!	EQ 1.25GM BASE/VIAL	N209481	003	Jul 10, 2018
+	!	EQ 1.5GM BASE/VIAL	N209481	004	Jul 10, 2018
VANCOMYCIN HYDROCHLORIDE IN PLASTIC CONTAINER					
	SAMSON MEDCL	EQ 100GM BASE	A091532	001	Jan 06, 2016
SOLUTION; INTRAVENOUS					
VANCOMYCIN HYDROCHLORIDE					
+	! XELLIA PHARMS APS	EQ 500MG BASE/100ML (EQ 5MG BASE/ML)	N211962	001	Feb 15, 2019
+	!	EQ 750MG BASE/150ML (EQ 5MG BASE/ML)	N211962	005	May 13, 2020
+	!	EQ 1GM BASE/200ML (EQ 5MG BASE/ML)	N211962	002	Feb 15, 2019
+	!	EQ 1.25GM BASE/250ML (EQ 5MG BASE/ML)	N211962	006	May 13, 2020
+	!	EQ 1.5GM BASE/300ML (EQ 5MG BASE/ML)	N211962	003	Feb 15, 2019
+	!	EQ 1.75GM BASE/350ML (EQ 5MG BASE/ML)	N211962	007	May 13, 2020
+	!	EQ 2GM BASE/400ML (EQ 5MG BASE/ML)	N211962	004	Feb 15, 2019
<u>VANDETANIB</u>					
TABLET; ORAL					
CAPRELSA					
+	GENZYME CORP	100MG	N022405	001	Apr 06, 2011
+	!	300MG	N022405	002	Apr 06, 2011

PRESCRIPTION DRUG PRODUCT LIST

3-461 (of 474)

VARDENAFIL HYDROCHLORIDE

TABLET; ORAL

VARDENAFIL HYDROCHLORIDE

AB	ALEMBIC PHARMS	<u>EQ 2.5MG BASE</u>	<u>A214031</u>	<u>001</u>	Aug 04, 2020
AB		<u>EQ 5MG BASE</u>	<u>A214031</u>	<u>002</u>	Aug 04, 2020
AB		<u>EQ 10MG BASE</u>	<u>A214031</u>	<u>003</u>	Aug 04, 2020
AB		<u>EQ 20MG BASE</u>	<u>A214031</u>	<u>004</u>	Aug 04, 2020
AB	CROSSMEDIKA SA	<u>EQ 2.5MG BASE</u>	<u>A209057</u>	<u>001</u>	Oct 31, 2018
AB		<u>EQ 5MG BASE</u>	<u>A209057</u>	<u>002</u>	Oct 31, 2018
AB		<u>EQ 10MG BASE</u>	<u>A209057</u>	<u>003</u>	Oct 31, 2018
AB		<u>EQ 20MG BASE</u>	<u>A209057</u>	<u>004</u>	Oct 31, 2018
AB	MACLEODS PHARMS LTD	<u>EQ 2.5MG BASE</u>	<u>A204632</u>	<u>001</u>	Oct 22, 2019
AB		<u>EQ 5MG BASE</u>	<u>A204632</u>	<u>002</u>	Oct 22, 2019
AB		<u>EQ 10MG BASE</u>	<u>A204632</u>	<u>003</u>	Oct 22, 2019
AB		<u>EQ 20MG BASE</u>	<u>A204632</u>	<u>004</u>	Oct 22, 2019
AB	TEVA PHARMS	<u>EQ 2.5MG BASE</u>	<u>A091347</u>	<u>001</u>	May 03, 2012
AB		<u>EQ 5MG BASE</u>	<u>A091347</u>	<u>002</u>	May 03, 2012
AB		<u>EQ 10MG BASE</u>	<u>A091347</u>	<u>003</u>	May 03, 2012
AB		<u>EQ 20MG BASE</u>	<u>A091347</u>	<u>004</u>	May 03, 2012
AB	ZYDUS PHARMS	<u>EQ 2.5MG BASE</u>	<u>A208960</u>	<u>001</u>	Oct 31, 2018
AB		<u>EQ 5MG BASE</u>	<u>A208960</u>	<u>002</u>	Oct 31, 2018
AB		<u>EQ 10MG BASE</u>	<u>A208960</u>	<u>003</u>	Oct 31, 2018
AB	!	<u>EQ 20MG BASE</u>	<u>A208960</u>	<u>004</u>	Oct 31, 2018

TABLET, ORALLY DISINTEGRATING; ORAL

VARDENAFIL HYDROCHLORIDE

AB	!	ALEMBIC PHARMS	<u>10MG</u>	<u>A208324</u>	<u>001</u>	Nov 16, 2018
AB		MACLEODS PHARMS LTD	<u>10MG</u>	<u>A205988</u>	<u>001</u>	Mar 10, 2020

VARENICLINE TARTRATE

SPRAY; NASAL

TYRVAYA

+! OYSTER POINT PHARMA EQ 0.03MG BASE/SPRAY

N213978 001 Oct 15, 2021

TABLET; ORAL

VARENICLINE TARTRATE

PAR PHARM INC EQ 0.5MG BASE

A201785 001 Aug 11, 2021

! EQ 1MG BASE

A201785 002 Aug 11, 2021

VASOPRESSIN

SOLUTION; INTRAVENOUS

VASOPRESSIN

AP	AMNEAL	<u>20UNITS/ML (20UNITS/ML)</u>	<u>A212944</u>	<u>001</u>	Aug 05, 2022
AP	AMPHASTAR PHARMS	<u>20UNITS/ML (20UNITS/ML)</u>	<u>A211857</u>	<u>001</u>	Jul 18, 2022
	INC				
AP	EAGLE PHARMS	<u>20UNITS/ML (20UNITS/ML)</u>	<u>A211538</u>	<u>001</u>	Dec 15, 2021
AP	EUGIA PHARMA	<u>20UNITS/ML (20UNITS/ML)</u>	<u>A214314</u>	<u>001</u>	Aug 15, 2022
VASOSTRICT					
AP	+! PAR STERILE PRODUCTS	<u>20UNITS/ML (20UNITS/ML)</u>	<u>N204485</u>	<u>001</u>	Apr 17, 2014
VASOPRESSIN					
	+! AM REGENT	20UNITS/ML (20UNITS/ML)	N212593	001	Aug 03, 2020
VASOSTRICT					
	+! PAR STERILE PRODUCTS	20UNITS/100ML (0.2UNITS/ML)	N204485	005	Apr 21, 2021
	+!	40UNITS/100ML (0.4UNITS/ML)	N204485	003	Apr 15, 2020
	+!	60UNITS/100ML (0.6UNITS/ML)	N204485	004	Apr 15, 2020
	+!	200UNITS/10ML (20UNITS/ML)	N204485	002	Dec 17, 2016

VECURONIUM BROMIDE

INJECTABLE; INJECTION

VECURONIUM BROMIDE

AP	EUGIA PHARMA	<u>10MG/VIAL</u>	<u>A206670</u>	<u>001</u>	Dec 20, 2018
AP		<u>20MG/VIAL</u>	<u>A206670</u>	<u>002</u>	Dec 20, 2018
AP	GLAND	<u>10MG/VIAL</u>	<u>A205390</u>	<u>001</u>	May 26, 2016
AP		<u>20MG/VIAL</u>	<u>A205390</u>	<u>002</u>	May 26, 2016
AP	HIKMA	<u>10MG/VIAL</u>	<u>A075549</u>	<u>001</u>	Jun 13, 2000
AP		<u>10MG/VIAL</u>	<u>A203725</u>	<u>001</u>	Jul 30, 2019
AP		<u>20MG/VIAL</u>	<u>A075549</u>	<u>002</u>	Jun 13, 2000
AP		<u>20MG/VIAL</u>	<u>A203725</u>	<u>002</u>	Jul 30, 2019
AP	HOSPIRA	<u>10MG/VIAL</u>	<u>A075164</u>	<u>001</u>	Oct 21, 1999
AP		<u>20MG/VIAL</u>	<u>A075164</u>	<u>002</u>	Oct 21, 1999
AP	MYLAN LABS LTD	<u>10MG/VIAL</u>	<u>A090243</u>	<u>001</u>	May 11, 2010
AP		<u>20MG/VIAL</u>	<u>A090243</u>	<u>002</u>	May 11, 2010
AP	SAGENT PHARMS INC	<u>10MG/VIAL</u>	<u>A078274</u>	<u>001</u>	Dec 29, 2008
AP		<u>20MG/VIAL</u>	<u>A078274</u>	<u>002</u>	Dec 29, 2008

PRESCRIPTION DRUG PRODUCT LIST

3-462 (of 474)

VECURONIUM BROMIDE

INJECTABLE; INJECTION

VECURONIUM BROMIDE

<u>AP</u>	!	SUN PHARM	<u>10MG/VIAL</u>	<u>A079001</u>	<u>001</u>	Jun 17, 2009
<u>AP</u>	!		<u>20MG/VIAL</u>	<u>A079001</u>	<u>002</u>	Jun 17, 2009
<u>AP</u>		TEVA PHARMS USA	<u>10MG/VIAL</u>	<u>A074688</u>	<u>001</u>	Aug 25, 1999
<u>AP</u>			<u>20MG/VIAL</u>	<u>A074688</u>	<u>002</u>	Aug 25, 1999

VEMURAFENIB

TABLET; ORAL

ZELBORAF

+	!	HOFFMANN LA ROCHE	240MG	N202429	001	Aug 17, 2011

VENETOCLAX

TABLET; ORAL

VENCLEXTA

+		ABBVIE INC	10MG	N208573	001	Apr 11, 2016
+			50MG	N208573	002	Apr 11, 2016
+	!		100MG	N208573	003	Apr 11, 2016

VENLAFAXINE BESYLATE

TABLET, EXTENDED RELEASE; ORAL

VENLAFAXINE BESYLATE

+	!	ALMATICA	EQ 112.5MG BASE	N215429	001	Jun 29, 2022

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

EFFEXOR XR

<u>AB</u>	+	UPJOHN	<u>EQ 37.5MG BASE</u>	<u>N020699</u>	<u>001</u>	Oct 20, 1997
<u>AB</u>	+		<u>EQ 75MG BASE</u>	<u>N020699</u>	<u>002</u>	Oct 20, 1997
<u>AB</u>	+	!	<u>EQ 150MG BASE</u>	<u>N020699</u>	<u>004</u>	Oct 20, 1997

VENLAFAXINE HYDROCHLORIDE

<u>AB</u>		ANNORA PHARMA	<u>EQ 37.5MG BASE</u>	<u>A212277</u>	<u>001</u>	Jul 08, 2019
<u>AB</u>			<u>EQ 75MG BASE</u>	<u>A212277</u>	<u>002</u>	Jul 08, 2019
<u>AB</u>			<u>EQ 150MG BASE</u>	<u>A212277</u>	<u>003</u>	Jul 08, 2019
<u>AB</u>		AUROBINDO PHARMA LTD	<u>EQ 37.5MG BASE</u>	<u>A200834</u>	<u>001</u>	Apr 14, 2011
<u>AB</u>			<u>EQ 75MG BASE</u>	<u>A200834</u>	<u>002</u>	Apr 14, 2011
<u>AB</u>			<u>EQ 150MG BASE</u>	<u>A200834</u>	<u>003</u>	Apr 14, 2011
<u>AB</u>		DR REDDYS LABS LTD	<u>EQ 37.5MG BASE</u>	<u>A078421</u>	<u>001</u>	May 06, 2011
<u>AB</u>			<u>EQ 75MG BASE</u>	<u>A078421</u>	<u>002</u>	May 06, 2011
<u>AB</u>			<u>EQ 150MG BASE</u>	<u>A078421</u>	<u>003</u>	May 06, 2011
<u>AB</u>		INTELLIPHARMACEUTICS	<u>EQ 37.5MG BASE</u>	<u>A201272</u>	<u>001</u>	Nov 23, 2018
<u>AB</u>			<u>EQ 75MG BASE</u>	<u>A201272</u>	<u>002</u>	Nov 23, 2018
<u>AB</u>			<u>EQ 150MG BASE</u>	<u>A201272</u>	<u>003</u>	Nov 23, 2018
<u>AB</u>		INVENTIA HLTHCARE	<u>EQ 37.5MG BASE</u>	<u>A203332</u>	<u>001</u>	Mar 12, 2020
<u>AB</u>			<u>EQ 75MG BASE</u>	<u>A203332</u>	<u>002</u>	Mar 12, 2020
<u>AB</u>			<u>EQ 150MG BASE</u>	<u>A203332</u>	<u>003</u>	Mar 12, 2020
<u>AB</u>		MACLEODS PHARMS LTD	<u>EQ 37.5MG BASE</u>	<u>A204889</u>	<u>001</u>	Oct 05, 2017
<u>AB</u>			<u>EQ 75MG BASE</u>	<u>A204889</u>	<u>002</u>	Oct 05, 2017
<u>AB</u>			<u>EQ 150MG BASE</u>	<u>A204889</u>	<u>003</u>	Oct 05, 2017
<u>AB</u>		ORBION PHARMS	<u>EQ 37.5MG BASE</u>	<u>A091123</u>	<u>001</u>	Jul 11, 2011
<u>AB</u>			<u>EQ 75MG BASE</u>	<u>A091123</u>	<u>002</u>	Jul 11, 2011
<u>AB</u>			<u>EQ 150MG BASE</u>	<u>A091123</u>	<u>003</u>	Jul 11, 2011
<u>AB</u>		TEVA	<u>EQ 37.5MG BASE</u>	<u>A076565</u>	<u>001</u>	Jun 28, 2010
<u>AB</u>			<u>EQ 75MG BASE</u>	<u>A076565</u>	<u>002</u>	Jun 28, 2010
<u>AB</u>			<u>EQ 150MG BASE</u>	<u>A076565</u>	<u>003</u>	Jun 28, 2010
<u>AB</u>		TORRENT	<u>EQ 37.5MG BASE</u>	<u>A090899</u>	<u>001</u>	Jun 01, 2011
<u>AB</u>			<u>EQ 75MG BASE</u>	<u>A090899</u>	<u>002</u>	Jun 01, 2011
<u>AB</u>			<u>EQ 150MG BASE</u>	<u>A090899</u>	<u>003</u>	Jun 01, 2011
<u>AB</u>		VALEANT PHARMS NORTH	<u>EQ 37.5MG BASE</u>	<u>A090071</u>	<u>001</u>	Apr 15, 2011
<u>AB</u>			<u>EQ 75MG BASE</u>	<u>A090071</u>	<u>002</u>	Apr 15, 2011
<u>AB</u>			<u>EQ 150MG BASE</u>	<u>A090071</u>	<u>003</u>	Apr 15, 2011
<u>AB</u>		WOCKHARDT BIO AG	<u>EQ 37.5MG BASE</u>	<u>A078865</u>	<u>001</u>	Apr 14, 2011
<u>AB</u>			<u>EQ 75MG BASE</u>	<u>A078865</u>	<u>002</u>	Apr 14, 2011
<u>AB</u>			<u>EQ 150MG BASE</u>	<u>A078865</u>	<u>003</u>	Apr 14, 2011
<u>AB</u>		YICHANG HUMANWELL	<u>EQ 37.5MG BASE</u>	<u>A214654</u>	<u>001</u>	Aug 06, 2021
<u>AB</u>			<u>EQ 75MG BASE</u>	<u>A214654</u>	<u>002</u>	Aug 06, 2021
<u>AB</u>			<u>EQ 150MG BASE</u>	<u>A214654</u>	<u>003</u>	Aug 06, 2021
<u>AB</u>		ZYDUS PHARMS USA INC	<u>EQ 37.5MG BASE</u>	<u>A090174</u>	<u>001</u>	Apr 14, 2011
<u>AB</u>			<u>EQ 75MG BASE</u>	<u>A090174</u>	<u>002</u>	Apr 14, 2011
<u>AB</u>			<u>EQ 150MG BASE</u>	<u>A090174</u>	<u>003</u>	Apr 14, 2011

PRESCRIPTION DRUG PRODUCT LIST

3-463 (of 474)

VENLAFAXINE HYDROCHLORIDE

TABLET; ORAL

VENLAFAXINE HYDROCHLORIDE

<u>AB</u>	ALEMBIC PHARMS LTD	<u>EQ 25MG BASE</u>	<u>A078932</u>	<u>001</u>	Dec 14, 2010
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A078932</u>	<u>002</u>	Dec 14, 2010
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A078932</u>	<u>003</u>	Dec 14, 2010
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A078932</u>	<u>004</u>	Dec 14, 2010
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A078932</u>	<u>005</u>	Dec 14, 2010
<u>AB</u>	AMNEAL PHARMS	<u>EQ 25MG BASE</u>	<u>A079098</u>	<u>001</u>	May 11, 2010
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A079098</u>	<u>002</u>	May 11, 2010
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A079098</u>	<u>003</u>	May 11, 2010
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A079098</u>	<u>004</u>	May 11, 2010
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A079098</u>	<u>005</u>	May 11, 2010
<u>AB</u>	AUROBINDO PHARMA	<u>EQ 25MG BASE</u>	<u>A090555</u>	<u>001</u>	Apr 07, 2010
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A090555</u>	<u>002</u>	Apr 07, 2010
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A090555</u>	<u>003</u>	Apr 07, 2010
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A090555</u>	<u>004</u>	Apr 07, 2010
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A090555</u>	<u>005</u>	Apr 07, 2010
<u>AB</u>	CADILA PHARMS LTD	<u>EQ 25MG BASE</u>	<u>A206250</u>	<u>001</u>	Nov 21, 2018
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A206250</u>	<u>002</u>	Nov 21, 2018
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A206250</u>	<u>003</u>	Nov 21, 2018
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A206250</u>	<u>004</u>	Nov 21, 2018
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A206250</u>	<u>005</u>	Nov 21, 2018
<u>AB</u>	DR REDDYS LABS LTD	<u>EQ 25MG BASE</u>	<u>A078301</u>	<u>001</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A078301</u>	<u>002</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A078301</u>	<u>003</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A078301</u>	<u>004</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A078301</u>	<u>005</u>	Jun 13, 2008
<u>AB</u>	HERITAGE PHARMS	<u>EQ 25MG BASE</u>	<u>A078554</u>	<u>001</u>	Jan 09, 2009
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A078554</u>	<u>002</u>	Jan 09, 2009
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A078554</u>	<u>003</u>	Jan 09, 2009
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A078554</u>	<u>004</u>	Jan 09, 2009
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A078554</u>	<u>005</u>	Jan 09, 2009
<u>AB</u>	SUN PHARM INDS INC	<u>EQ 25MG BASE</u>	<u>A078627</u>	<u>001</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A078627</u>	<u>002</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A078627</u>	<u>003</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A078627</u>	<u>004</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A078627</u>	<u>005</u>	Jun 13, 2008
<u>AB</u>	TEVA	<u>EQ 25MG BASE</u>	<u>A076690</u>	<u>001</u>	Aug 03, 2006
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A076690</u>	<u>002</u>	Aug 03, 2006
<u>AB</u>	!	<u>EQ 50MG BASE</u>	<u>A076690</u>	<u>003</u>	Aug 03, 2006
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A076690</u>	<u>004</u>	Aug 03, 2006
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A076690</u>	<u>005</u>	Aug 03, 2006
<u>AB</u>	YAOPHARMA CO LTD	<u>EQ 25MG BASE</u>	<u>A202036</u>	<u>001</u>	May 28, 2015
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A202036</u>	<u>002</u>	May 28, 2015
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A202036</u>	<u>003</u>	May 28, 2015
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A202036</u>	<u>004</u>	May 28, 2015
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A202036</u>	<u>005</u>	May 28, 2015
<u>AB</u>	ZYDUS PHARMS USA	<u>EQ 25MG BASE</u>	<u>A077653</u>	<u>001</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A077653</u>	<u>002</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 50MG BASE</u>	<u>A077653</u>	<u>003</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A077653</u>	<u>004</u>	Jun 13, 2008
<u>AB</u>		<u>EQ 100MG BASE</u>	<u>A077653</u>	<u>005</u>	Jun 13, 2008

TABLET, EXTENDED RELEASE; ORAL

VENLAFAXINE HYDROCHLORIDE

<u>AB</u>	ALKEM LABS LTD	<u>EQ 37.5MG BASE</u>	<u>A214127</u>	<u>001</u>	Jun 10, 2021
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A214127</u>	<u>002</u>	Jun 10, 2021
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A214127</u>	<u>003</u>	Jun 10, 2021
<u>AB</u>		<u>EQ 225MG BASE</u>	<u>A214127</u>	<u>004</u>	Jun 10, 2021
<u>AB</u>	APPCO	<u>EQ 150MG BASE</u>	<u>A214609</u>	<u>001</u>	Jun 30, 2021
<u>AB</u>		<u>EQ 225MG BASE</u>	<u>A214609</u>	<u>002</u>	Jun 30, 2021
<u>AB</u>	ASCENT PHARMS INC	<u>EQ 37.5MG BASE</u>	<u>A214419</u>	<u>001</u>	Oct 21, 2020
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A214419</u>	<u>002</u>	Oct 21, 2020
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A214419</u>	<u>003</u>	Oct 21, 2020
<u>AB</u>		<u>EQ 225MG BASE</u>	<u>A214419</u>	<u>004</u>	Oct 21, 2020
<u>AB</u>	CADILA PHARMS LTD	<u>EQ 75MG BASE</u>	<u>A211323</u>	<u>001</u>	Aug 29, 2019
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A211323</u>	<u>002</u>	Aug 29, 2019
<u>AB</u>		<u>EQ 225MG BASE</u>	<u>A211323</u>	<u>003</u>	Aug 29, 2019
<u>AB</u>	DEXCEL	<u>EQ 75MG BASE</u>	<u>A213927</u>	<u>001</u>	Jan 21, 2021
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A209193</u>	<u>001</u>	Oct 31, 2019
<u>AB</u>		<u>EQ 225MG BASE</u>	<u>A209193</u>	<u>002</u>	Oct 31, 2019
<u>AB</u>	NOSTRUM LABS INC	<u>EQ 150MG BASE</u>	<u>A205468</u>	<u>002</u>	Mar 24, 2017

PRESCRIPTION DRUG PRODUCT LIST

3-464 (of 474)

VENLAFAXINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

VENLAFAXINE HYDROCHLORIDE

<u>AB</u>		<u>EQ 225MG BASE</u>	<u>A205468</u>	<u>003</u>	Mar 24, 2017
<u>AB</u>	+	<u>EQ 37.5MG BASE</u>	<u>N022104</u>	<u>001</u>	May 20, 2008
<u>AB</u>	+	<u>EQ 75MG BASE</u>	<u>N022104</u>	<u>002</u>	May 20, 2008
<u>AB</u>	+	<u>EQ 150MG BASE</u>	<u>N022104</u>	<u>003</u>	May 20, 2008
<u>AB</u>	+	<u>EQ 225MG BASE</u>	<u>N022104</u>	<u>004</u>	May 20, 2008
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A091272</u>	<u>001</u>	Aug 18, 2010
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A091272</u>	<u>002</u>	Aug 18, 2010
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A091272</u>	<u>003</u>	Aug 18, 2010
<u>AB</u>		<u>EQ 225MG BASE</u>	<u>A091272</u>	<u>004</u>	Jan 08, 2019
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A216044</u>	<u>001</u>	Nov 28, 2022
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A216044</u>	<u>002</u>	Nov 28, 2022
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A216044</u>	<u>003</u>	Nov 28, 2022
<u>AB</u>		<u>EQ 225MG BASE</u>	<u>A216044</u>	<u>004</u>	Nov 28, 2022
<u>AB</u>		<u>EQ 37.5MG BASE</u>	<u>A215622</u>	<u>001</u>	Aug 30, 2022
<u>AB</u>		<u>EQ 75MG BASE</u>	<u>A215622</u>	<u>002</u>	Aug 30, 2022
<u>AB</u>		<u>EQ 150MG BASE</u>	<u>A215622</u>	<u>003</u>	Aug 30, 2022
<u>AB</u>		<u>EQ 225MG BASE</u>	<u>A215622</u>	<u>004</u>	Aug 30, 2022

VERAPAMIL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

VERAPAMIL HYDROCHLORIDE

<u>AB</u>		<u>120MG</u>	<u>A075138</u>	<u>001</u>	Apr 20, 1999
<u>AB</u>		<u>180MG</u>	<u>A075138</u>	<u>002</u>	Apr 20, 1999
<u>AB</u>		<u>240MG</u>	<u>A075138</u>	<u>003</u>	Apr 20, 1999

VERELAN

<u>AB</u>	+	<u>120MG</u>	<u>N019614</u>	<u>001</u>	May 29, 1990
<u>AB</u>	+	<u>180MG</u>	<u>N019614</u>	<u>003</u>	Jan 09, 1992
<u>AB</u>	+	<u>240MG</u>	<u>N019614</u>	<u>002</u>	May 29, 1990
	+	360MG	N019614	004	May 10, 1996
	VERELAN PM				
	+	100MG	N020943	001	Nov 25, 1998
	+	200MG	N020943	002	Nov 25, 1998
	+	300MG	N020943	003	Nov 25, 1998

INJECTABLE; INJECTION

VERAPAMIL HYDROCHLORIDE

<u>AP</u>		<u>2.5MG/ML</u>	<u>A215829</u>	<u>001</u>	Mar 17, 2022
<u>AP</u>	!	<u>2.5MG/ML</u>	<u>A212965</u>	<u>001</u>	Jul 06, 2020
<u>AP</u>		<u>2.5MG/ML</u>	<u>A214361</u>	<u>001</u>	Oct 15, 2020
<u>AP</u>		<u>2.5MG/ML</u>	<u>A214653</u>	<u>001</u>	Jun 15, 2022
<u>AP</u>		<u>2.5MG/ML</u>	<u>A214215</u>	<u>001</u>	Oct 15, 2020

SOLUTION; INTRAVENOUS

VERAPAMIL HYDROCHLORIDE

<u>AP</u>		<u>5MG/2ML (2.5MG/ML)</u>	<u>A210994</u>	<u>001</u>	Jul 13, 2018
<u>AP</u>		<u>10MG/4ML (2.5MG/ML)</u>	<u>A210994</u>	<u>002</u>	Jul 13, 2018
<u>AP</u>		<u>5MG/2ML (2.5MG/ML)</u>	<u>A213352</u>	<u>002</u>	Sep 16, 2020
<u>AP</u>		<u>10MG/4ML (2.5MG/ML)</u>	<u>A213352</u>	<u>001</u>	Mar 17, 2020
<u>AP</u>		<u>5MG/2ML (2.5MG/ML)</u>	<u>A213232</u>	<u>001</u>	Mar 25, 2020
<u>AP</u>		<u>10MG/4ML (2.5MG/ML)</u>	<u>A213232</u>	<u>002</u>	Mar 25, 2020
<u>AP</u>		<u>5MG/2ML (2.5MG/ML)</u>	<u>N018925</u>	<u>001</u>	Mar 30, 1984
<u>AP</u>	!	<u>5MG/2ML (2.5MG/ML)</u>	<u>A070738</u>	<u>001</u>	May 06, 1987
<u>AP</u>	!	<u>5MG/2ML (2.5MG/ML)</u>	<u>A075136</u>	<u>001</u>	Oct 20, 1998
<u>AP</u>	!	<u>5MG/2ML (2.5MG/ML)</u>	<u>A070737</u>	<u>001</u>	May 06, 1987
<u>AP</u>	!	<u>10MG/4ML (2.5MG/ML)</u>	<u>A070737</u>	<u>002</u>	May 06, 1987
<u>AP</u>		<u>5MG/2ML (2.5MG/ML)</u>	<u>A211370</u>	<u>001</u>	Dec 28, 2018
<u>AP</u>		<u>10MG/4ML (2.5MG/ML)</u>	<u>A211370</u>	<u>002</u>	Dec 28, 2018
<u>AP</u>		<u>5MG/2ML (2.5MG/ML)</u>	<u>A211035</u>	<u>001</u>	Jun 18, 2018
<u>AP</u>		<u>10MG/4ML (2.5MG/ML)</u>	<u>A211035</u>	<u>002</u>	Jun 18, 2018
<u>AP</u>		<u>5MG/2ML (2.5MG/ML)</u>	<u>A211015</u>	<u>001</u>	Jun 18, 2018
<u>AP</u>		<u>10MG/4ML (2.5MG/ML)</u>	<u>A211015</u>	<u>002</u>	Jun 18, 2018

TABLET; ORAL

VERAPAMIL HYDROCHLORIDE

<u>AB</u>		<u>40MG</u>	<u>A071881</u>	<u>002</u>	Oct 14, 2015
<u>AB</u>		<u>80MG</u>	<u>A071881</u>	<u>003</u>	Apr 05, 1988
<u>AB</u>	!	<u>120MG</u>	<u>A071881</u>	<u>001</u>	Apr 05, 1988
<u>AB</u>		<u>40MG</u>	<u>A072924</u>	<u>001</u>	Jun 29, 1993
<u>AB</u>		<u>80MG</u>	<u>A070995</u>	<u>001</u>	Oct 01, 1986
<u>AB</u>		<u>120MG</u>	<u>A070994</u>	<u>001</u>	Oct 01, 1986

PRESCRIPTION DRUG PRODUCT LIST

3-465 (of 474)

VERAPAMIL HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

CALAN SR

<u>AB</u>	<u>+</u> !	PFIZER	<u>120MG</u>	<u>N019152</u>	<u>003</u>	Mar 06, 1991
<u>AB</u>	<u>+</u> !		<u>240MG</u>	<u>N019152</u>	<u>001</u>	Dec 16, 1986

VERAPAMIL HYDROCHLORIDE

<u>AB</u>		CADILA PHARMS LTD	<u>180MG</u>	<u>A206173</u>	<u>001</u>	May 05, 2017
<u>AB</u>			<u>240MG</u>	<u>A206173</u>	<u>002</u>	May 05, 2017
<u>AB</u>		GLENMARK GENERICS	<u>120MG</u>	<u>A090700</u>	<u>001</u>	Aug 03, 2011
<u>AB</u>	<u>!</u>		<u>180MG</u>	<u>A090700</u>	<u>002</u>	Aug 03, 2011
<u>AB</u>			<u>240MG</u>	<u>A078906</u>	<u>001</u>	Sep 17, 2009
<u>AB</u>		IVAX SUB TEVA PHARMS	<u>120MG</u>	<u>A073568</u>	<u>002</u>	Oct 10, 1997
<u>AB</u>			<u>180MG</u>	<u>A074330</u>	<u>001</u>	Jan 31, 1994
<u>AB</u>			<u>240MG</u>	<u>A073568</u>	<u>001</u>	Jul 31, 1992
<u>AB</u>		STRIDES PHARMA	<u>120MG</u>	<u>A075072</u>	<u>001</u>	May 25, 1999
<u>AB</u>			<u>240MG</u>	<u>A075072</u>	<u>003</u>	May 25, 1999
<u>AB</u>		SUN PHARM INDS INC	<u>120MG</u>	<u>A090529</u>	<u>001</u>	Dec 30, 2011
<u>AB</u>			<u>180MG</u>	<u>A090529</u>	<u>002</u>	Dec 30, 2011
<u>AB</u>			<u>240MG</u>	<u>A090529</u>	<u>003</u>	Dec 30, 2011

VERICIGUAT

TABLET;ORAL

VERQUVO

<u>+</u>	MERCK SHARP DOHME	2.5MG	N214377	001	Jan 19, 2021
<u>+</u>		5MG	N214377	002	Jan 19, 2021
<u>+</u> !		10MG	N214377	003	Jan 19, 2021

VERTEPORFIN

INJECTABLE;INJECTION

VISUDYNE

<u>+</u> !	VALEANT LUXEMBOURG	15MG/VIAL	N021119	001	Apr 12, 2000

VIBEGRON

TABLET;ORAL

GEMTESA

<u>+</u> !	UROVANT	75MG	N213006	001	Dec 23, 2020

VIGABATRIN

FOR SOLUTION;ORAL

SABRIL

<u>AA</u>	<u>+</u> !	LUNDBECK PHARMS LLC	<u>500MG/PACKET</u>	<u>N022006</u>	<u>001</u>	Aug 21, 2009

VIGABATRIN

<u>AA</u>		ACCORD HLTHCARE	<u>500MG/PACKET</u>	<u>A214425</u>	<u>001</u>	Nov 13, 2020
<u>AA</u>		ALKEM LABS LTD	<u>500MG/PACKET</u>	<u>A213375</u>	<u>001</u>	Dec 02, 2020
<u>AA</u>		AMNEAL PHARMS	<u>500MG/PACKET</u>	<u>A210155</u>	<u>001</u>	Mar 13, 2018
<u>AA</u>		ANNORA PHARMA	<u>500MG/PACKET</u>	<u>A213519</u>	<u>001</u>	Jan 26, 2021
<u>AA</u>		AUROBINDO PHARMA LTD	<u>500MG/PACKET</u>	<u>A213899</u>	<u>001</u>	Sep 29, 2021
<u>AA</u>		DEXCEL	<u>500MG/PACKET</u>	<u>A214992</u>	<u>001</u>	May 13, 2021
<u>AA</u>		DR REDDYS	<u>500MG/PACKET</u>	<u>A211481</u>	<u>001</u>	Nov 20, 2018
<u>AA</u>		INVAGEN PHARMS	<u>500MG/PACKET</u>	<u>A211592</u>	<u>001</u>	Dec 03, 2019
<u>AA</u>		MSN	<u>500MG/PACKET</u>	<u>A215363</u>	<u>001</u>	Sep 07, 2022
<u>AA</u>		PAR PHARM INC	<u>500MG/PACKET</u>	<u>A208218</u>	<u>001</u>	Apr 27, 2017
<u>AA</u>		PROPEL PHARMA	<u>500MG/PACKET</u>	<u>A213390</u>	<u>001</u>	Jul 29, 2021
<u>AA</u>		PYROS PHARMS	<u>500MG/PACKET</u>	<u>A214961</u>	<u>001</u>	Jun 24, 2022
<u>AA</u>		TEVA PHARMS USA	<u>500MG/PACKET</u>	<u>A209824</u>	<u>001</u>	Apr 23, 2018

VIGADRONE

<u>AA</u>		AUCTA	<u>500MG/PACKET</u>	<u>A210196</u>	<u>001</u>	Jun 21, 2018

TABLET;ORAL

SABRIL

<u>AB</u>	<u>+</u> !	LUNDBECK PHARMS LLC	<u>500MG</u>	<u>N020427</u>	<u>001</u>	Aug 21, 2009

VIGABATRIN

<u>AB</u>		AMNEAL PHARMS	<u>500MG</u>	<u>A210042</u>	<u>001</u>	Jun 22, 2022
<u>AB</u>		AUROBINDO PHARMA LTD	<u>500MG</u>	<u>A215601</u>	<u>001</u>	May 10, 2022
<u>AB</u>		DEXCEL	<u>500MG</u>	<u>A215109</u>	<u>001</u>	Sep 23, 2021
<u>AB</u>		DR REDDYS	<u>500MG</u>	<u>A211539</u>	<u>001</u>	Jan 29, 2021
<u>AB</u>		HIKMA	<u>500MG</u>	<u>A213104</u>	<u>001</u>	Aug 29, 2022
<u>AB</u>		TEVA PHARMS USA	<u>500MG</u>	<u>A209822</u>	<u>001</u>	Jan 14, 2019
<u>AB</u>		ZYDUS	<u>500MG</u>	<u>A215707</u>	<u>001</u>	Jan 19, 2022

PRESCRIPTION DRUG PRODUCT LIST

3-466 (of 474)

VILAZODONE HYDROCHLORIDE

TABLET; ORAL

VIIBRYD

AB	+	ALLERGAN	10MG	<u>N022567</u>	<u>001</u>	Jan 21, 2011
AB	+		20MG	<u>N022567</u>	<u>002</u>	Jan 21, 2011
AB	+		40MG	<u>N022567</u>	<u>003</u>	Jan 21, 2011

VILAZODONE HYDROCHLORIDE

AB		ACCORD HLTHCARE	10MG	<u>A208209</u>	<u>001</u>	Apr 27, 2021
AB			20MG	<u>A208209</u>	<u>002</u>	Apr 27, 2021
AB			40MG	<u>A208209</u>	<u>003</u>	Apr 27, 2021
AB		ALEMBIC PHARMS	10MG	<u>A208202</u>	<u>001</u>	Jan 10, 2020
AB			20MG	<u>A208202</u>	<u>002</u>	Jan 10, 2020
AB			40MG	<u>A208202</u>	<u>003</u>	Jan 10, 2020
AB		INVAGEN PHARMS	10MG	<u>A208200</u>	<u>001</u>	Apr 07, 2021
AB			20MG	<u>A208200</u>	<u>003</u>	Dec 06, 2022
AB			40MG	<u>A208200</u>	<u>002</u>	Apr 07, 2021
AB		TEVA PHARMS USA	10MG	<u>A208212</u>	<u>001</u>	Sep 30, 2019
AB			20MG	<u>A208212</u>	<u>002</u>	Sep 30, 2019
AB			40MG	<u>A208212</u>	<u>003</u>	Sep 30, 2019

VILOXAZINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

QELBREE

+	SUPERNUS PHARMS	EQ 100MG BASE	N211964	001	Apr 02, 2021
+		EQ 150MG BASE	N211964	002	Apr 02, 2021
+		EQ 200MG BASE	N211964	003	Apr 02, 2021

VILTOLARSEN

SOLUTION; INTRAVENOUS

VILTEPSO

+	NIPPON SHINYAKU	250MG/5ML (50MG/ML)	N212154	001	Aug 12, 2020

VINBLASTINE SULFATE

INJECTABLE; INJECTION

VINBLASTINE SULFATE

!	FRESENIUS KABI USA	1MG/ML	A089515	001	Apr 29, 1987
!	HIKMA	10MG/VIAL	A089395	001	Apr 09, 1987

VINCRISTINE SULFATE

INJECTABLE; INJECTION

VINCRISTINE SULFATE PFS

AP	!	HOSPIRA	1MG/ML	<u>A071484</u>	<u>001</u>	Apr 19, 1988
AP		TEVA PHARMS USA	1MG/ML	<u>A075493</u>	<u>001</u>	Sep 01, 1999

VINORELBINE TARTRATE

INJECTABLE; INJECTION

VINORELBINE TARTRATE

AP		ACTAVIS TOTOWA	EQ 10MG BASE/ML	<u>A078011</u>	<u>001</u>	Jul 22, 2009
AP		DR REDDYS	EQ 10MG BASE/ML	<u>A202017</u>	<u>001</u>	Sep 12, 2013
AP		HIKMA	EQ 10MG BASE/ML	<u>A075992</u>	<u>001</u>	Jun 10, 2003
AP			EQ 10MG BASE/ML	<u>A076461</u>	<u>001</u>	Dec 11, 2003
AP	!	JIANGSU HANSO PHARM	EQ 10MG BASE/ML	<u>A091106</u>	<u>001</u>	Sep 26, 2012

VISMODEGIB

CAPSULE; ORAL

ERIVEDGE

+	GENENTECH	150MG	N203388	001	Jan 30, 2012

VITAMIN A PALMITATE

INJECTABLE; INJECTION

AQUASOL A

+	CASPER PHARMA LLC	EQ 50,000 UNITS BASE/ML	N006823	001	

VOCLOSPORIN

CAPSULE; ORAL

LUPKYNIS

+	AURINIA	7.9MG	N213716	001	Jan 22, 2021

VORAPAXAR SULFATE

TABLET; ORAL

ZONTIVITY

+	XSPIRE PHARMA	EQ 2.08MG BASE	N204886	001	May 08, 2014

PRESCRIPTION DRUG PRODUCT LIST

3-467 (of 474)

VORICONAZOLE

FOR SUSPENSION; ORAL

VFEND

AB	+	PF PRISM CV	200MG/5ML	N021630	001	Dec 19, 2003

VORICONAZOLE

AB		AMNEAL PHARMS	200MG/5ML	A205034	001	Apr 13, 2016

AB		NOVEL LABS INC	200MG/5ML	A206799	001	May 31, 2016

INJECTABLE; INTRAVENOUS

VFEND

AP	+	PF PRISM CV	200MG/VIAL	N021267	001	May 24, 2002

VORICONAZOLE

AP		ALMAJECT	200MG/VIAL	A206398	001	Mar 23, 2016

AP		GLAND PHARMA LTD	200MG/VIAL	A211099	001	Mar 31, 2020

AP		HAINAN POLY PHARM	200MG/VIAL	A211661	001	Nov 30, 2018

AP		MEITHEAL	200MG/VIAL	A214516	001	May 09, 2022

AP		SANDOZ INC	200MG/VIAL	A090862	001	May 30, 2012

AP		ZYDUS PHARMS	200MG/VIAL	A208983	001	Jul 16, 2018

POWDER; INTRAVENOUS

VORICONAZOLE

AP		XELLIA PHARMS APS	200MG/VIAL	N208562	001	Mar 09, 2017

TABLET; ORAL

VFEND

AB	+	PF PRISM CV	50MG	N021266	001	May 24, 2002

AB	+		200MG	N021266	002	May 24, 2002

VORICONAZOLE

AB		AJANTA PHARMA LTD	50MG	A206181	001	May 24, 2016

AB			200MG	A206181	002	May 24, 2016

AB		AKORN	50MG	A207049	001	Sep 07, 2016

AB			200MG	A207049	002	Sep 07, 2016

AB		AUROBINDO PHARMA LTD	50MG	A206837	001	Jan 22, 2016

AB			200MG	A206837	002	Jan 22, 2016

AB		CADILA	50MG	A206747	001	May 24, 2016

AB			200MG	A206747	002	May 24, 2016

AB		GLENMARK PHARMS LTD	50MG	A203503	001	Sep 02, 2015

AB			200MG	A203503	002	Sep 02, 2015

AB		MYLAN PHARMS INC	50MG	A090547	001	Apr 22, 2010

AB			200MG	A090547	002	Apr 22, 2010

AB		NOVEL LABS INC	50MG	A207371	001	May 24, 2016

AB			200MG	A207371	002	May 24, 2016

AB		PRINSTON INC	50MG	A206654	001	Aug 08, 2016

AB			200MG	A206654	002	Aug 08, 2016

AB		RISING	50MG	A206762	001	May 24, 2016

AB			200MG	A206762	002	May 24, 2016

AB		SANDOZ INC	50MG	A200265	001	Dec 12, 2011

AB			200MG	A200265	002	Dec 12, 2011

VORINOSTAT

CAPSULE; ORAL

ZOLINZA

+	MSD SUB MERCK	100MG	N021991	001	Oct 06, 2006

VORTIOXETINE HYDROBROMIDE

TABLET; ORAL

TRINTELLIX

+	TAKEDA PHARMS USA	EQ 5MG BASE	N204447	001	Sep 30, 2013

+		EQ 10MG BASE	N204447	002	Sep 30, 2013

+		EQ 20MG BASE	N204447	004	Sep 30, 2013

VOSORITIDE

POWDER; SUBCUTANEOUS

VOXZOGO

+	BIOMARIN PHARM	0.4MG/VIAL	N214938	001	Nov 19, 2021

+		0.56MG/VIAL	N214938	002	Nov 19, 2021

+		1.2MG/VIAL	N214938	003	Nov 19, 2021

VOXELOTOR

TABLET; ORAL

OXBRYTA

+	GLOBAL BLOOD THERAPS	300MG	N213137	002	Oct 14, 2022

+		500MG	N213137	001	Nov 25, 2019

PRESCRIPTION DRUG PRODUCT LIST

3-468 (of 474)

VOXELOTOR

TABLET, FOR SUSPENSION;ORAL

OXBRYTA

+! GLOBAL BLOOD
THERAPS

300MG

N216157 001 Dec 17, 2021

VUTRISIRAN

SOLUTION;SUBCUTANEOUS

AMVUTTRA

+! ALNYLAM PHARMS INC

25MG/0.5ML (25MG/0.5ML)

N215515 001 Jun 13, 2022

WARFARIN SODIUM

TABLET;ORAL

JANTOVENAB UPSHER SMITH LABS1MGA040416 001 Oct 02, 2003AB 2MGA040416 002 Oct 02, 2003AB 2.5MGA040416 003 Oct 02, 2003AB 3MGA040416 004 Oct 02, 2003AB 4MGA040416 005 Oct 02, 2003AB 5MGA040416 006 Oct 02, 2003AB 6MGA040416 007 Oct 02, 2003AB 7.5MGA040416 008 Oct 02, 2003AB 10MGA040416 009 Oct 02, 2003WARFARIN SODIUMAB AMNEAL PHARMS1MGA202202 001 Mar 04, 2013AB 2MGA202202 002 Mar 04, 2013AB 2.5MGA202202 003 Mar 04, 2013AB 3MGA202202 004 Mar 04, 2013AB 4MGA202202 005 Mar 04, 2013AB 5MGA202202 006 Mar 04, 2013AB 6MGA202202 007 Mar 04, 2013AB 7.5MGA202202 008 Mar 04, 2013AB 10MGA202202 009 Mar 04, 2013AB BARR1MGA040145 001 Mar 26, 1997AB 2MGA040145 002 Mar 26, 1997AB 2.5MGA040145 003 Mar 26, 1997AB 3MGA040145 008 Nov 05, 1998AB 4MGA040145 004 Mar 26, 1997AB 5MGA040145 005 Mar 26, 1997AB 6MGA040145 009 Nov 05, 1998AB 7.5MGA040145 006 Mar 26, 1997AB 10MGA040145 007 Mar 26, 1997AB INVAGEN PHARMS1MGA090935 001 May 25, 2011AB 2MGA090935 002 May 25, 2011AB 2.5MGA090935 003 May 25, 2011AB 3MGA090935 004 May 25, 2011AB 4MGA090935 005 May 25, 2011AB 5MGA090935 006 May 25, 2011AB 6MGA090935 007 May 25, 2011AB 7.5MGA090935 008 May 25, 2011AB 10MGA090935 009 May 25, 2011AB IPCA LABS LTD1MGA200104 001 Jun 27, 2013AB 2MGA200104 002 Jun 27, 2013AB 2.5MGA200104 003 Jun 27, 2013AB 3MGA200104 004 Jun 27, 2013AB 4MGA200104 005 Jun 27, 2013AB 5MGA200104 006 Jun 27, 2013AB 6MGA200104 007 Jun 27, 2013AB 7.5MGA200104 008 Jun 27, 2013AB 10MGA200104 009 Jun 27, 2013AB PLIVA1MGA040616 009 Jul 05, 2006AB 2MGA040616 001 Jul 05, 2006AB 2.5MGA040616 002 Jul 05, 2006AB 3MGA040616 003 Jul 05, 2006AB 4MGA040616 004 Jul 05, 2006AB 5MGA040616 005 Jul 05, 2006AB 6MGA040616 006 Jul 05, 2006AB 7.5MGA040616 007 Jul 05, 2006AB 10MGA040616 008 Jul 05, 2006AB ! TARO1MGA040301 002 Jul 15, 1999AB 2MGA040301 003 Jul 15, 1999AB 2.5MGA040301 004 Jul 15, 1999AB 3MGA040301 005 Jul 15, 1999AB 4MGA040301 006 Jul 15, 1999

PRESCRIPTION DRUG PRODUCT LIST

3-469 (of 474)

WARFARIN SODIUM

TABLET; ORAL

WARFARIN SODIUM

<u>AB</u>		<u>5MG</u>	<u>A040301</u>	<u>007</u>	Jul 15, 1999
<u>AB</u>		<u>6MG</u>	<u>A040301</u>	<u>008</u>	Jul 15, 1999
<u>AB</u>		<u>7.5MG</u>	<u>A040301</u>	<u>009</u>	Jul 15, 1999
<u>AB</u>		<u>10MG</u>	<u>A040301</u>	<u>001</u>	Jul 15, 1999
<u>AB</u>	ZYDUS PHARMS USA	<u>1MG</u>	<u>A040663</u>	<u>001</u>	May 30, 2006
<u>AB</u>		<u>2MG</u>	<u>A040663</u>	<u>002</u>	May 30, 2006
<u>AB</u>		<u>2.5MG</u>	<u>A040663</u>	<u>003</u>	May 30, 2006
<u>AB</u>		<u>3MG</u>	<u>A040663</u>	<u>004</u>	May 30, 2006
<u>AB</u>		<u>4MG</u>	<u>A040663</u>	<u>005</u>	May 30, 2006
<u>AB</u>		<u>5MG</u>	<u>A040663</u>	<u>006</u>	May 30, 2006
<u>AB</u>		<u>6MG</u>	<u>A040663</u>	<u>007</u>	May 30, 2006
<u>AB</u>		<u>7.5MG</u>	<u>A040663</u>	<u>008</u>	May 30, 2006
<u>AB</u>		<u>10MG</u>	<u>A040663</u>	<u>009</u>	May 30, 2006

XENON XE-133

GAS; INHALATION

XENON XE 133

CURIUM

10mCi/VIAL

N018327 001 Mar 09, 1982

20mCi/VIAL

N018327 002 Mar 09, 1982

LANTHEUS MEDCL

10mCi/VIAL

N017284 001

20mCi/VIAL

N017284 002

ZAFIRLUKAST

TABLET; ORAL

ACCOLATE

<u>AB</u>	+	STRIDES PHARMA	<u>10MG</u>	<u>N020547</u>	<u>003</u>	Sep 17, 1999
<u>AB</u>	+	!	<u>20MG</u>	<u>N020547</u>	<u>001</u>	Sep 26, 1996

ZAFIRLUKAST

<u>AB</u>		ANNORA PHARMA	<u>10MG</u>	<u>A212475</u>	<u>001</u>	Sep 10, 2020
<u>AB</u>			<u>20MG</u>	<u>A212475</u>	<u>002</u>	Sep 10, 2020
<u>AB</u>		DR REDDYS LABS LTD	<u>10MG</u>	<u>A090372</u>	<u>001</u>	Nov 18, 2010
<u>AB</u>			<u>20MG</u>	<u>A090372</u>	<u>002</u>	Nov 18, 2010
<u>AB</u>		RISING PHARMS	<u>10MG</u>	<u>A204928</u>	<u>001</u>	Aug 25, 2022
<u>AB</u>			<u>20MG</u>	<u>A204928</u>	<u>002</u>	Aug 25, 2022

ZALEPLON

CAPSULE; ORAL

SONATA

<u>AB</u>	+	PFIZER	<u>5MG</u>	<u>N020859</u>	<u>001</u>	Aug 13, 1999
<u>AB</u>	+	!	<u>10MG</u>	<u>N020859</u>	<u>002</u>	Aug 13, 1999

ZALEPLON

<u>AB</u>		AUROBINDO PHARMA	<u>5MG</u>	<u>A078829</u>	<u>001</u>	Jun 06, 2008
<u>AB</u>			<u>10MG</u>	<u>A078829</u>	<u>002</u>	Jun 06, 2008
<u>AB</u>		CHARTWELL MOLECULAR	<u>5MG</u>	<u>A077505</u>	<u>001</u>	Jun 20, 2008
<u>AB</u>			<u>10MG</u>	<u>A077505</u>	<u>002</u>	Jun 20, 2008
<u>AB</u>		HIKMA	<u>5MG</u>	<u>A077237</u>	<u>001</u>	Jun 06, 2008
<u>AB</u>			<u>10MG</u>	<u>A077237</u>	<u>002</u>	Jun 06, 2008
<u>AB</u>		ORBION PHARMS	<u>5MG</u>	<u>A090374</u>	<u>001</u>	Sep 17, 2009
<u>AB</u>			<u>10MG</u>	<u>A090374</u>	<u>002</u>	Sep 17, 2009
<u>AB</u>		UNICHEM	<u>5MG</u>	<u>A078989</u>	<u>001</u>	Jun 06, 2008
<u>AB</u>			<u>10MG</u>	<u>A078989</u>	<u>002</u>	Jun 06, 2008

ZANAMIVIR

POWDER; INHALATION

RELENZA

+! GLAXOSMITHKLINE

5MG

N021036 001 Jul 26, 1999

ZANUBRUTINIB

CAPSULE; ORAL

BRUKINSA

+! BEIGENE

80MG

N213217 001 Nov 14, 2019

ZICONOTIDE ACETATE

INJECTABLE; INTRATHECAL

PRIALT

+! TERSERA

100MCG/1ML (100MCG/ML)

N021060 002 Dec 28, 2004

+!

500MCG/20ML (25MCG/ML)

N021060 001 Dec 28, 2004

+!

500MCG/5ML (100MCG/ML)

N021060 004 Dec 28, 2004

PRESCRIPTION DRUG PRODUCT LIST

3-470 (of 474)

ZIDOVUDINE

CAPSULE; ORAL

RETROVIR

AB	+!	VIIV HLTHCARE	100MG	N019655	001	Mar 19, 1987

ZIDOVUDINE

AB		AUROBINDO PHARMA LTD	100MG	A078128	001	Mar 27, 2006

AB		CIPLA LTD	100MG	A078349	001	May 23, 2007

INJECTABLE; INJECTION

RETROVIR

+!	VIIV HLTHCARE	10MG/ML	N019951	001	Feb 02, 1990

SOLUTION; ORAL

RETROVIR

AA	+!	VIIV HLTHCARE	50MG/5ML	N019910	001	Sep 28, 1989

ZIDOVUDINE

AA		AUROBINDO	50MG/5ML	A077268	001	Sep 19, 2005

AA		CIPLA LTD	50MG/5ML	A077981	001	Jun 26, 2008

TABLET; ORAL

ZIDOVUDINE

AB		AUROBINDO	300MG	A077267	001	Sep 19, 2005

AB		CIPLA	300MG	A090561	001	Oct 27, 2010

AB	!	HETERO LABS LTD III	300MG	A090092	001	Apr 25, 2008

AB		MYLAN PHARMS INC	300MG	A078922	001	Feb 14, 2008

ZILEUTON

TABLET; ORAL

ZYFLO

+!	CHIESI	600MG	N020471	003	Dec 09, 1996

TABLET, EXTENDED RELEASE; ORAL

ZILEUTON

AB		ANNORA PHARMA	600MG	A215742	001	Oct 11, 2022

AB		DASH PHARMS	600MG	A211390	001	Oct 23, 2020

AB		RISING	600MG	A204929	001	Mar 17, 2017

AB		STRIDES PHARMA	600MG	A212670	001	Dec 16, 2019

ZYFLO CR

AB	+!	CHIESI	600MG	N022052	001	May 30, 2007

ZILEUTON

BX		LUPIN LTD	600MG	A211972	001	Nov 05, 2019

ZINC ACETATE

CAPSULE; ORAL

GALZIN

+	TEVA	EQ 25MG ZINC	N020458	001	Jan 28, 1997

+!		EQ 50MG ZINC	N020458	002	Jan 28, 1997

ZINC CHLORIDE

INJECTABLE; INJECTION

ZINC CHLORIDE

AP		EXELA PHARMA	EQ 1MG ZINC/ML	A212007	001	May 21, 2021

ZINC CHLORIDE IN PLASTIC CONTAINER

AP	+!	HOSPIRA	EQ 1MG ZINC/ML	N018959	001	Jun 26, 1986

ZINC SULFATE

SOLUTION; INTRAVENOUS

ZINC SULFATE

AP	+!	AM REGENT	EQ 10MG BASE/10ML (EQ 1MG BASE/ML)	N209377	003	Apr 15, 2020

AP	+!		EQ 25MG BASE/5ML (EQ 5MG BASE/ML)	N209377	002	Jul 18, 2019

AP	+!		EQ 30MG BASE/10ML (EQ 3MG BASE/ML)	N209377	001	Jul 18, 2019

AP		GLAND PHARMA LTD	EQ 25MG BASE/5ML (EQ 5MG BASE/ML)	A216249	001	May 03, 2022

AP			EQ 30MG BASE/10ML (EQ 3MG BASE/ML)	A216249	002	May 03, 2022

ZINC SULFATE MONOHYDRATE

SOLUTION; INTRAVENOUS

ZINC SULFATE

AP		FRESENIUS KABI USA	EQ 10MG BASE/10ML (EQ 1MG BASE/ML)	A216145	001	Dec 27, 2022

AP			EQ 25MG BASE/5ML (EQ 5MG BASE/ML)	A216145	002	Dec 27, 2022

AP			EQ 30MG BASE/10ML (EQ 3MG BASE/ML)	A216145	003	Dec 27, 2022

ZIPRASIDONE HYDROCHLORIDE

CAPSULE; ORAL

GEODON

AB	+!	VIATRIS	EQ 20MG BASE	N020825	001	Feb 05, 2001

AB	+		EQ 40MG BASE	N020825	002	Feb 05, 2001

AB	+		EQ 60MG BASE	N020825	003	Feb 05, 2001

AB	+		EQ 80MG BASE	N020825	004	Feb 05, 2001

PRESCRIPTION DRUG PRODUCT LIST

3-471 (of 474)

ZIPRASIDONE HYDROCHLORIDE

CAPSULE; ORAL

ZIPRASIDONE HYDROCHLORIDE

<u>AB</u>	APOTEX	<u>EQ 20MG BASE</u>	<u>A077561 001</u>	Mar 02, 2012
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077561 002</u>	Mar 02, 2012
<u>AB</u>		<u>EQ 60MG BASE</u>	<u>A077561 003</u>	Mar 02, 2012
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A077561 004</u>	Mar 02, 2012
<u>AB</u>	AUROBINDO PHARMA	<u>EQ 20MG BASE</u>	<u>A204117 001</u>	Dec 27, 2016
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A204117 002</u>	Dec 27, 2016
<u>AB</u>		<u>EQ 60MG BASE</u>	<u>A204117 003</u>	Dec 27, 2016
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A204117 004</u>	Dec 27, 2016
<u>AB</u>	CADILA	<u>EQ 20MG BASE</u>	<u>A208988 001</u>	Aug 22, 2017
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A208988 002</u>	Aug 22, 2017
<u>AB</u>		<u>EQ 60MG BASE</u>	<u>A208988 003</u>	Aug 22, 2017
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A208988 004</u>	Aug 22, 2017
<u>AB</u>	CHARTWELL RX	<u>EQ 20MG BASE</u>	<u>A090348 001</u>	Sep 05, 2012
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A090348 002</u>	Sep 05, 2012
<u>AB</u>		<u>EQ 60MG BASE</u>	<u>A090348 003</u>	Sep 05, 2012
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A090348 004</u>	Sep 05, 2012
<u>AB</u>	DR REDDYS LABS INC	<u>EQ 20MG BASE</u>	<u>A077565 001</u>	Mar 02, 2012
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077565 002</u>	Mar 02, 2012
<u>AB</u>		<u>EQ 60MG BASE</u>	<u>A077565 003</u>	Mar 02, 2012
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A077565 004</u>	Mar 02, 2012
<u>AB</u>	LUPIN PHARMS	<u>EQ 20MG BASE</u>	<u>A077560 001</u>	Mar 02, 2012
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077560 002</u>	Mar 02, 2012
<u>AB</u>		<u>EQ 60MG BASE</u>	<u>A077560 003</u>	Mar 02, 2012
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A077560 004</u>	Mar 02, 2012
<u>AB</u>	MACLEODS PHARMS LTD	<u>EQ 20MG BASE</u>	<u>A204375 001</u>	Feb 17, 2017
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A204375 002</u>	Feb 17, 2017
<u>AB</u>		<u>EQ 60MG BASE</u>	<u>A204375 003</u>	Feb 17, 2017
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A204375 004</u>	Feb 17, 2017
<u>AB</u>	SANDOZ INC	<u>EQ 20MG BASE</u>	<u>A077562 001</u>	Jun 01, 2012
<u>AB</u>		<u>EQ 40MG BASE</u>	<u>A077562 002</u>	Jun 01, 2012
<u>AB</u>		<u>EQ 60MG BASE</u>	<u>A077562 003</u>	Jun 01, 2012
<u>AB</u>		<u>EQ 80MG BASE</u>	<u>A077562 004</u>	Jun 01, 2012

ZIPRASIDONE MESYLATE

POWDER; INTRAMUSCULAR

GEODON

<u>AP</u>	+! VIATRIS	<u>EQ 20MG BASE/VIAL</u>	<u>N020919 001</u>	Jun 21, 2002

ZIPRASIDONE MESYLATE

<u>AP</u>	GLAND PHARMA LTD	<u>EQ 20MG BASE/VIAL</u>	<u>A211908 001</u>	Dec 26, 2019
<u>AP</u>	MSN	<u>EQ 20MG BASE/VIAL</u>	<u>A216091 001</u>	Sep 15, 2022

ZOLEDRONIC ACID

INJECTABLE; INTRAVENOUS

RECLAST

<u>AP</u>	+! NOVARTIS	<u>EQ 5MG BASE/100ML</u>	<u>N021817 001</u>	Apr 16, 2007

ZOLEDRONIC

<u>AP</u>	GLAND PHARMA LTD	<u>EQ 4MG BASE/100ML</u>	<u>A205749 001</u>	Jun 29, 2018

ZOLEDRONIC ACID

<u>AP</u>	ACCORD HLTHCARE	<u>EQ 4MG BASE/5ML</u>	<u>A205279 001</u>	Nov 28, 2016
<u>AP</u>	AKORN	<u>EQ 4MG BASE/5ML</u>	<u>A202548 001</u>	May 22, 2014
<u>AP</u>		<u>EQ 5MG BASE/100ML</u>	<u>A200918 001</u>	Aug 21, 2014
<u>AP</u>	AMNEAL	<u>EQ 4MG BASE/100ML</u>	<u>A210174 001</u>	Oct 27, 2017
<u>AP</u>	APOTEX	<u>EQ 5MG BASE/100ML</u>	<u>A204367 001</u>	Dec 24, 2015
<u>AP</u>	BPI LABS	<u>EQ 4MG BASE/5ML</u>	<u>A207341 001</u>	Dec 29, 2017
<u>AP</u>	BRECKENRIDGE	<u>EQ 4MG BASE/5ML</u>	<u>A091170 001</u>	Mar 04, 2013
<u>AP</u>		<u>EQ 4MG BASE/5ML</u>	<u>A202571 001</u>	May 07, 2013
<u>AP</u>		<u>EQ 5MG BASE/100ML</u>	<u>A202163 001</u>	Aug 05, 2013
<u>AP</u>	DR REDDYS LABS LTD	<u>EQ 4MG BASE/5ML</u>	<u>A091186 001</u>	Mar 04, 2013
<u>AP</u>		<u>EQ 5MG BASE/100ML</u>	<u>A091363 001</u>	Mar 29, 2013
<u>AP</u>	FRESENIUS KABI USA	<u>EQ 4MG BASE/5ML</u>	<u>A091516 001</u>	Apr 23, 2015
<u>AP</u>	GLAND	<u>EQ 5MG BASE/100ML</u>	<u>A204217 001</u>	Aug 18, 2016
<u>AP</u>	GLAND PHARMA LTD	<u>EQ 4MG BASE/5ML</u>	<u>A202930 001</u>	Aug 05, 2013
<u>AP</u>		<u>EQ 5MG BASE/100ML</u>	<u>A209578 001</u>	Aug 08, 2019
<u>AP</u>	HIKMA FARMACEUTICA	<u>EQ 4MG BASE/5ML</u>	<u>A202182 001</u>	Jun 03, 2013
<u>AP</u>	HOSPIRA	<u>EQ 4MG BASE/5ML</u>	<u>A090621 001</u>	Mar 19, 2015
<u>AP</u>	HOSPIRA INC	<u>EQ 5MG BASE/100ML</u>	<u>A202837 001</u>	Apr 05, 2013
<u>AP</u>	INFORLIFE	<u>EQ 4MG BASE/100ML</u>	<u>N203231 001</u>	Aug 02, 2013
<u>AP</u>		<u>EQ 5MG BASE/100ML</u>	<u>A202828 001</u>	Sep 23, 2013
<u>AP</u>	INGENUS PHARMS LLC	<u>EQ 4MG BASE/5ML</u>	<u>A208968 001</u>	Feb 19, 2020
<u>AP</u>	MYLAN LABS LTD	<u>EQ 4MG BASE/5ML</u>	<u>A202650 001</u>	Mar 04, 2013

PRESCRIPTION DRUG PRODUCT LIST

3-472 (of 474)

ZOLEDRONIC ACID

INJECTABLE; INTRAVENOUS

ZOLEDRONIC ACID

<u>AP</u>		<u>EQ 5MG BASE/100ML</u>	<u>A203841</u>	<u>001</u>	Feb 14, 2017
<u>AP</u>		<u>EQ 5MG BASE/100ML</u>	<u>A205254</u>	<u>001</u>	Oct 27, 2017
<u>AP</u>	SAGENT PHARMS INC	<u>EQ 4MG BASE/5ML</u>	<u>A091493</u>	<u>001</u>	Nov 24, 2014
<u>AP</u>	USV	<u>EQ 4MG BASE/5ML</u>	<u>A202923</u>	<u>001</u>	Sep 04, 2014
<u>ZOMETA</u>					
<u>AP</u>	+!	<u>EQ 4MG BASE/5ML</u>	<u>N021223</u>	<u>002</u>	Mar 07, 2003
<u>AP</u>	+!	<u>EQ 4MG BASE/100ML</u>	<u>N021223</u>	<u>003</u>	Jun 17, 2011
SOLUTION; INTRAVENOUS					
ZOLEDRONIC ACID					
	HOSPIRA	EQ 4MG BASE/100ML (EQ 0.04MG BASE/ML)	N204016	001	Dec 28, 2015

ZOLMITRIPTAN

SPRAY; NASAL

ZOLMITRIPTAN

<u>AB</u>	PADAGIS ISRAEL	<u>2.5MG/SPRAY</u>	<u>A212469</u>	<u>001</u>	Sep 30, 2021
<u>AB</u>		<u>5MG/SPRAY</u>	<u>A212469</u>	<u>002</u>	Sep 30, 2021
<u>ZOMIG</u>					
<u>AB</u>	+	<u>ASTRAZENECA</u>	<u>2.5MG/SPRAY</u>	<u>N021450</u>	<u>003</u> Sep 16, 2013
<u>AB</u>	+!	<u>5MG/SPRAY</u>	<u>N021450</u>	<u>004</u>	Sep 30, 2003

TABLET; ORAL

ZOLMITRIPTAN

<u>AB</u>	AJANTA PHARMA LTD	<u>2.5MG</u>	<u>A204041</u>	<u>001</u>	May 20, 2016
<u>AB</u>		<u>5MG</u>	<u>A204041</u>	<u>002</u>	May 20, 2016
<u>AB</u>	ALEMBIC PHARMS	<u>2.5MG</u>	<u>A204232</u>	<u>001</u>	Sep 30, 2015
<u>AB</u>		<u>5MG</u>	<u>A204232</u>	<u>002</u>	Sep 30, 2015
<u>AB</u>	APPCO	<u>2.5MG</u>	<u>A206973</u>	<u>001</u>	Jun 30, 2017
<u>AB</u>		<u>5MG</u>	<u>A206973</u>	<u>002</u>	Jun 30, 2017
<u>AB</u>	AUROBINDO PHARMA	<u>2.5MG</u>	<u>A207021</u>	<u>001</u>	May 11, 2016
<u>AB</u>		<u>5MG</u>	<u>A207021</u>	<u>002</u>	May 11, 2016
<u>AB</u>	GLENMARK GENERICS	<u>2.5MG</u>	<u>A201779</u>	<u>001</u>	May 14, 2013
<u>AB</u>		<u>5MG</u>	<u>A201779</u>	<u>002</u>	May 14, 2013
<u>AB</u>	INVAGEN PHARMS	<u>2.5MG</u>	<u>A204284</u>	<u>001</u>	Apr 09, 2014
<u>AB</u>		<u>5MG</u>	<u>A204284</u>	<u>002</u>	Apr 09, 2014
<u>AB</u>	JUBILANT GENERICS	<u>2.5MG</u>	<u>A202279</u>	<u>001</u>	Nov 20, 2014
<u>AB</u>		<u>5MG</u>	<u>A202279</u>	<u>002</u>	Nov 20, 2014
<u>AB</u>	ORBION PHARMS	<u>2.5MG</u>	<u>A203726</u>	<u>001</u>	Oct 21, 2019
<u>AB</u>		<u>5MG</u>	<u>A203726</u>	<u>002</u>	Oct 21, 2019
<u>AB</u>	PLD ACQUISITIONS LLC	<u>2.5MG</u>	<u>A207867</u>	<u>001</u>	Feb 27, 2017
<u>AB</u>		<u>5MG</u>	<u>A207867</u>	<u>002</u>	Feb 27, 2017
<u>AB</u>	ZYDUS PHARMS	<u>2.5MG</u>	<u>A203019</u>	<u>001</u>	Jul 11, 2018
<u>AB</u>		<u>5MG</u>	<u>A203019</u>	<u>002</u>	Jul 11, 2018
<u>ZOMIG</u>					
<u>AB</u>	+	<u>IPR</u>	<u>N020768</u>	<u>001</u>	Nov 25, 1997
<u>AB</u>	+	<u>!</u>	<u>N020768</u>	<u>002</u>	Nov 25, 1997

TABLET, ORALLY DISINTEGRATING; ORAL

ZOLMITRIPTAN

<u>AB</u>	ALEMBIC PHARMS	<u>2.5MG</u>	<u>A205074</u>	<u>001</u>	Dec 01, 2016
<u>AB</u>		<u>5MG</u>	<u>A205074</u>	<u>002</u>	Dec 01, 2016
<u>AB</u>	GLENMARK GENERICS	<u>2.5MG</u>	<u>A202560</u>	<u>001</u>	May 14, 2013
<u>AB</u>		<u>5MG</u>	<u>A202560</u>	<u>002</u>	May 14, 2013
<u>AB</u>	JUBILANT GENERICS	<u>2.5MG</u>	<u>A202956</u>	<u>001</u>	Sep 17, 2015
<u>AB</u>		<u>5MG</u>	<u>A202956</u>	<u>002</u>	Sep 17, 2015
<u>AB</u>	ZYDUS PHARMS USA INC	<u>2.5MG</u>	<u>A202890</u>	<u>001</u>	May 15, 2013
<u>AB</u>		<u>5MG</u>	<u>A202890</u>	<u>002</u>	May 15, 2013

ZOMIG-ZMT

<u>AB</u>	+	ASTRAZENECA	<u>2.5MG</u>	<u>N021231</u>	<u>001</u>	Feb 13, 2001
<u>AB</u>	+!		<u>5MG</u>	<u>N021231</u>	<u>002</u>	Sep 17, 2001

ZOLPIDEM TARTRATE

TABLET; ORAL

AMBIEN

<u>AB</u>	+	SANOFI AVENTIS US	<u>5MG</u>	<u>N019908</u>	<u>001</u>	Dec 16, 1992
<u>AB</u>	+	!	<u>10MG</u>	<u>N019908</u>	<u>002</u>	Dec 16, 1992

ZOLPIDEM TARTRATE

<u>AB</u>	ACME LABS	<u>5MG</u>	<u>A077214</u>	<u>001</u>	Apr 23, 2007
<u>AB</u>		<u>10MG</u>	<u>A077214</u>	<u>002</u>	Apr 23, 2007
<u>AB</u>	APOTEX INC	<u>5MG</u>	<u>A077884</u>	<u>001</u>	Apr 23, 2007
<u>AB</u>		<u>10MG</u>	<u>A077884</u>	<u>002</u>	Apr 23, 2007
<u>AB</u>	AUROBINDO PHARMA	<u>5MG</u>	<u>A078413</u>	<u>001</u>	May 04, 2007

PRESCRIPTION DRUG PRODUCT LIST

3-473 (of 474)

ZOLPIDEM TARTRATE

TABLET; ORAL

ZOLPIDEM TARTRATE

<u>AB</u>		<u>10MG</u>	<u>A078413</u>	<u>002</u>	May 04, 2007
<u>AB</u>	CHARTWELL MOLECULAR	<u>5MG</u>	<u>A077388</u>	<u>001</u>	Jul 30, 2012
<u>AB</u>		<u>10MG</u>	<u>A077388</u>	<u>002</u>	Jul 30, 2012
<u>AB</u>	INVAGEN PHARMS	<u>5MG</u>	<u>A078184</u>	<u>001</u>	Sep 07, 2007
<u>AB</u>		<u>10MG</u>	<u>A078184</u>	<u>002</u>	Sep 07, 2007
<u>AB</u>	SANDOZ INC	<u>5MG</u>	<u>A077322</u>	<u>001</u>	Apr 23, 2007
<u>AB</u>		<u>10MG</u>	<u>A077322</u>	<u>002</u>	Apr 23, 2007
<u>AB</u>	TEVA	<u>5MG</u>	<u>A076410</u>	<u>001</u>	Apr 23, 2007
<u>AB</u>		<u>10MG</u>	<u>A076410</u>	<u>002</u>	Apr 23, 2007
<u>AB</u>	TORRENT PHARMS	<u>5MG</u>	<u>A077903</u>	<u>001</u>	Aug 17, 2007
<u>AB</u>		<u>10MG</u>	<u>A077903</u>	<u>002</u>	Aug 17, 2007

TABLET; SUBLINGUAL

EDLUAR

<u>AB</u>	+	MYLAN SPECIALITY LP	<u>5MG</u>	<u>N021997</u>	<u>001</u>	Mar 13, 2009
<u>AB</u>	+	!	<u>10MG</u>	<u>N021997</u>	<u>002</u>	Mar 13, 2009

ZOLPIDEM TARTRATE

<u>AB</u>		DR REDDYS	<u>1.75MG</u>	<u>A204503</u>	<u>001</u>	Nov 18, 2016
<u>AB</u>			<u>3.5MG</u>	<u>A204503</u>	<u>002</u>	Nov 18, 2016
<u>AB</u>		NOVEL LABS INC	<u>1.75MG</u>	<u>A204299</u>	<u>001</u>	Jun 03, 2015
<u>AB</u>	!		<u>3.5MG</u>	<u>A204299</u>	<u>002</u>	Jun 03, 2015
<u>AB</u>		PAR FORM	<u>5MG</u>	<u>A201509</u>	<u>001</u>	Aug 01, 2016
<u>AB</u>			<u>10MG</u>	<u>A201509</u>	<u>002</u>	Aug 01, 2016
<u>AB</u>		PAR PHARM INC	<u>1.75MG</u>	<u>A204229</u>	<u>001</u>	Sep 11, 2017
<u>AB</u>			<u>3.5MG</u>	<u>A204229</u>	<u>002</u>	Sep 11, 2017

TABLET, EXTENDED RELEASE; ORAL

AMBIEN CR

<u>AB</u>	+	SANOFI AVENTIS US	<u>6.25MG</u>	<u>N021774</u>	<u>002</u>	Sep 02, 2005
<u>AB</u>	+	!	<u>12.5MG</u>	<u>N021774</u>	<u>001</u>	Sep 02, 2005

ZOLPIDEM TARTRATE

<u>AB</u>		ACTAVIS LABS FL INC	<u>6.25MG</u>	<u>A090153</u>	<u>001</u>	Mar 25, 2013
<u>AB</u>			<u>12.5MG</u>	<u>A090153</u>	<u>002</u>	Mar 25, 2013
<u>AB</u>		ANCHEN PHARMS	<u>6.25MG</u>	<u>A078148</u>	<u>002</u>	Apr 14, 2011
<u>AB</u>			<u>12.5MG</u>	<u>A078148</u>	<u>001</u>	Dec 03, 2010
<u>AB</u>		APOTEX INC	<u>6.25MG</u>	<u>A200266</u>	<u>001</u>	Sep 10, 2013
<u>AB</u>			<u>12.5MG</u>	<u>A200266</u>	<u>002</u>	Sep 10, 2013
<u>AB</u>		BRECKENRIDGE	<u>6.25MG</u>	<u>A213592</u>	<u>001</u>	Jun 04, 2020
<u>AB</u>			<u>12.5MG</u>	<u>A213592</u>	<u>002</u>	Jun 04, 2020
<u>AB</u>		LUPIN LTD	<u>6.25MG</u>	<u>A078970</u>	<u>001</u>	Sep 11, 2013
<u>AB</u>			<u>12.5MG</u>	<u>A078970</u>	<u>002</u>	Sep 11, 2013
<u>AB</u>		SANDOZ	<u>6.25MG</u>	<u>A090107</u>	<u>001</u>	Jul 01, 2011
<u>AB</u>			<u>12.5MG</u>	<u>A090107</u>	<u>002</u>	Jul 01, 2011
<u>AB</u>		SUN PHARM	<u>6.25MG</u>	<u>A204170</u>	<u>001</u>	Jan 24, 2017
<u>AB</u>			<u>12.5MG</u>	<u>A204170</u>	<u>002</u>	Jan 24, 2017

ZONISAMIDE

CAPSULE; ORAL

ZONEGRAN

<u>AB</u>	+	CONCORDIA	<u>25MG</u>	<u>N020789</u>	<u>003</u>	Aug 22, 2003
<u>AB</u>	+	!	<u>100MG</u>	<u>N020789</u>	<u>001</u>	Mar 27, 2000

ZONISAMIDE

<u>AB</u>		APOTEX INC	<u>25MG</u>	<u>A077642</u>	<u>001</u>	Dec 22, 2005
<u>AB</u>			<u>50MG</u>	<u>A077642</u>	<u>002</u>	Dec 22, 2005
<u>AB</u>			<u>100MG</u>	<u>A077642</u>	<u>003</u>	Dec 22, 2005
<u>AB</u>		AUROBINDO PHARMA LTD	<u>25MG</u>	<u>A077645</u>	<u>002</u>	Sep 29, 2006
<u>AB</u>			<u>50MG</u>	<u>A077645</u>	<u>003</u>	Sep 29, 2006
<u>AB</u>			<u>100MG</u>	<u>A077645</u>	<u>001</u>	Dec 22, 2005
<u>AB</u>		BIONPHARMA INC	<u>25MG</u>	<u>A077813</u>	<u>001</u>	Aug 16, 2006
<u>AB</u>			<u>50MG</u>	<u>A077813</u>	<u>002</u>	Aug 16, 2006
<u>AB</u>			<u>100MG</u>	<u>A077813</u>	<u>003</u>	Aug 16, 2006
<u>AB</u>		CADILA	<u>25MG</u>	<u>A077625</u>	<u>001</u>	Oct 16, 2006
<u>AB</u>			<u>50MG</u>	<u>A077625</u>	<u>002</u>	Oct 16, 2006
<u>AB</u>			<u>100MG</u>	<u>A077625</u>	<u>003</u>	Oct 16, 2006
<u>AB</u>		GLENMARK GENERICS	<u>25MG</u>	<u>A077651</u>	<u>001</u>	Jan 30, 2006
<u>AB</u>			<u>50MG</u>	<u>A077651</u>	<u>002</u>	Jan 30, 2006
<u>AB</u>			<u>100MG</u>	<u>A077651</u>	<u>003</u>	Jan 30, 2006
<u>AB</u>		GRANULES	<u>25MG</u>	<u>A077636</u>	<u>003</u>	Jul 27, 2006
<u>AB</u>			<u>50MG</u>	<u>A077636</u>	<u>002</u>	Jul 27, 2006
<u>AB</u>			<u>100MG</u>	<u>A077636</u>	<u>001</u>	Dec 22, 2005
<u>AB</u>		INVAGEN PHARMS	<u>25MG</u>	<u>A077869</u>	<u>001</u>	May 31, 2006

PRESCRIPTION DRUG PRODUCT LIST

3-474 (of 474)

ZONISAMIDE

CAPSULE; ORAL

ZONISAMIDE

<u>AB</u>		<u>50MG</u>	<u>A077869</u>	<u>002</u>	May 31, 2006
<u>AB</u>		<u>100MG</u>	<u>A077869</u>	<u>003</u>	May 31, 2006
<u>AB</u>	SUN PHARM INDS (IN)	<u>25MG</u>	<u>A077634</u>	<u>001</u>	Mar 17, 2006
<u>AB</u>		<u>50MG</u>	<u>A077634</u>	<u>002</u>	Mar 17, 2006
<u>AB</u>		<u>100MG</u>	<u>A077634</u>	<u>003</u>	Mar 17, 2006
<u>AB</u>	UNICHEM	<u>25MG</u>	<u>A214492</u>	<u>001</u>	Jan 26, 2021
<u>AB</u>		<u>50MG</u>	<u>A214492</u>	<u>002</u>	Jan 26, 2021
<u>AB</u>		<u>100MG</u>	<u>A214492</u>	<u>003</u>	Jan 26, 2021
SUSPENSION; ORAL					
ZONISADE					
+	!	AZURITY	100MG/5ML	N214273	001 Jul 15, 2022

OTC DRUG PRODUCT LIST

4-1 (of 20)

ACETAMINOPHEN

SUPPOSITORY; RECTAL

ACEPHEN

COSETTE	120MG	N018060	001	
	325MG	A072344	001	Mar 27, 1992
	650MG	A072237	001	Mar 27, 1992

ACETAMINOPHEN

PERRIGO NEW YORK	120MG	A070607	001	Apr 06, 1987
	650MG	A070608	001	Dec 01, 1986
+ TARO PHARM INDS LTD	120MG	N018337	003	Sep 12, 1983
+	325MG	N018337	002	
+!	650MG	N018337	001	

INFANTS' FEVERALL

+ TARO PHARM INDS LTD	80MG	N018337	004	Aug 26, 1992

TABLET, EXTENDED RELEASE; ORAL

ACETAMINOPHEN

AUROBINDO PHARMA	650MG	A207229	001	Nov 09, 2016
GRANULES	650MG	A211544	001	Apr 16, 2019
HERITAGE PHARMA	650MG	A207035	001	May 31, 2018
MARKSANS PHARMA	650MG	A215486	001	Aug 25, 2021
OHM LABS	650MG	A076200	001	Mar 19, 2002
PERRIGO	650MG	A075077	001	Feb 25, 2000
SUN PHARM INDS LTD	650MG	A078569	001	Dec 14, 2011

TYLENOL

+! J AND J CONSUMER	650MG	N019872	001	Jun 08, 1994
INC				
+!	650MG	N019872	002	Jan 11, 2001

ACETAMINOPHEN; ASPIRIN; CAFFEINE

TABLET; ORAL

ACETAMINOPHEN, ASPIRIN AND CAFFEINE

AUROBINDO PHARMA	250MG; 250MG; 65MG	A211695	001	Feb 02, 2022
LTD				
GRANULES	250MG; 250MG; 65MG	A214039	001	Feb 23, 2021
PERRIGO	250MG; 250MG; 65MG	A075794	001	Nov 26, 2001

EXCEDRIN (MIGRAINE)

+! GLAXOSMITHKLINE	250MG; 250MG; 65MG	N020802	001	Jan 14, 1998
CONS				

ACETAMINOPHEN; IBUPROFEN

TABLET; ORAL

ADVIL DUAL ACTION WITH ACETAMINOPHEN

+! GLAXOSMITHKLINE	250MG; 125MG	N211733	001	Feb 28, 2020

ADAPALENE

GEL; TOPICAL

ADAPALENE

GLENMARK GENERICS	0.1%	A091314	001	Jul 01, 2010
P AND L	0.1%	A090962	001	Jun 02, 2010
TARO PHARMS	0.1%	A215940	001	Jan 14, 2022

DIFFERIN

+! GALDERMA LABS LP	0.1%	N020380	002	Jul 08, 2016

ALCAFTADINE

SOLUTION/DROPS; OPHTHALMIC

LASTACFT

+! ALLERGAN	0.25%	N022134	001	Jul 28, 2010

ALCOHOL; CHLORHEXIDINE GLUCONATE

SOLUTION; TOPICAL

AVAGARD

+! 3M	61%; 1%	N021074	001	Jun 07, 2001

ASPIRIN

CAPSULE; ORAL

VAZALORE

+ PLX PHARMA	81MG	N203697	002	Feb 26, 2021
+!	325MG	N203697	001	Jan 14, 2013

AVOBENZONE; ECAMSULE; OCTOCRYLENE

CREAM; TOPICAL

ANTHELIOS SX

+! LOREAL USA	2%; 2%; 10%	N021502	001	Jul 21, 2006

CAPITAL SOLEIL 15

+! LOREAL USA	2%; 3%; 10%	N021501	001	Oct 02, 2006

OTC DRUG PRODUCT LIST

AVOBENZONE; ECAMSULE; OCTOCRYLENE; TITANIUM DIOXIDE

CREAM; TOPICAL

ANTHELIOS 20

+! LOREAL USA 2%;2%;10%;2%

N021471 001 Oct 05, 2006

ANTHELIOS 40

+! LOREAL USA 2%;3%;10%;5%

N022009 001 Mar 31, 2008

+! 2%;3%;10%;5%

N022009 002 Oct 29, 2009

AZELASTINE HYDROCHLORIDE

SPRAY, METERED; NASAL

ASTEPRO ALLERGY

+! BAYER HLTHCARE 0.2055MG/SPRAY

N213872 001 Jun 17, 2021

CHILDREN'S ASTEPRO ALLERGY

+! BAYER HLTHCARE 0.2055MG/SPRAY

N213872 002 Jun 17, 2021

BENTOQUATAM

LOTION; TOPICAL

IVY BLOCK

+! STAND HOMEOPATH 5%

N020532 001 Aug 26, 1996

BRIMONIDINE TARTRATE

SOLUTION/DROPS; OPHTHALMIC

LUMIFY

+! BAUSCH AND LOMB INC 0.025%

N208144 001 Dec 22, 2017

BUDESONIDE

SPRAY, METERED; NASAL

BUDESONIDE

APOTEX INC 0.032MG/SPRAY

A078949 002 Nov 20, 2015

RHINOCORT ALLERGY

+! J AND J CONSUMER INC 0.032MG/SPRAY

N020746 003 Mar 23, 2015

BUTENAFINE HYDROCHLORIDE

CREAM; TOPICAL

BUTENAFINE HYDROCHLORIDE

TARO PHARMS 1%

A205181 001 Nov 16, 2017

LOTRIMIN ULTRA

+! BAYER HEALTHCARE LLC 1%

N021307 001 Dec 07, 2001

CALCIUM CARBONATE; FAMOTIDINE; MAGNESIUM HYDROXIDE

TABLET, CHEWABLE; ORAL

FAMOTIDINE, CALCIUM CARBONATE, AND MAGNESIUM HYDROXIDE

PERRIGO R AND D 800MG;10MG;165MG

A077355 001 Feb 06, 2008

800MG;10MG;165MG

A204782 001 Aug 29, 2016

PEPCID COMPLETE

+! J AND J CONSUMER INC 800MG;10MG;165MG

N020958 001 Oct 16, 2000

CETIRIZINE HYDROCHLORIDE

CAPSULE; ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

APOTEX 10MG

A207235 001 Aug 12, 2016

AUROBINDO PHARMA 10MG

A209107 001 Jul 20, 2018

LTD

+ BIONPHARMA INC 5MG

N022429 001 Jul 23, 2009

+! 10MG

N022429 004 Jul 23, 2009

CATALENT 10MG

A213105 001 Sep 21, 2020

STRIDES PHARMA 10MG

A205291 001 Jul 21, 2017

CETIRIZINE HYDROCHLORIDE HIVES RELIEF

AUROBINDO PHARMA 10MG

A209107 002 Jul 20, 2018

LTD

+ BIONPHARMA INC 5MG

N022429 003 Jul 23, 2009

+! 10MG

N022429 002 Jul 23, 2009

SYRUP; ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

AMNEAL PHARMS 5MG/5ML

A090765 002 Oct 07, 2009

AUROBINDO PHARMA 5MG/5ML

A090750 002 Feb 02, 2010

BAJAJ 5MG/5ML

A091327 001 Oct 17, 2011

CHARTWELL MOLECULAR 5MG/5ML

A091130 001 Apr 22, 2011

HETERO LABS LTD III 5MG/5ML

A210622 001 Mar 13, 2019

PERRIGO R AND D 5MG/5ML

A204226 001 Sep 09, 2013

5MG/5ML

A090254 002 Apr 09, 2008

QUAGEN 5MG/5ML

A212266 001 May 16, 2019

TARO 5MG/5ML

A090182 002 Apr 22, 2008

5MG/5ML

A201546 001 May 20, 2011

OTC DRUG PRODUCT LIST

4-3 (of 20)

CETIRIZINE HYDROCHLORIDE

SYRUP; ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF

AMNEAL PHARMS	5MG/5ML	A090765	001	Oct 07, 2009
AUROBINDO PHARMA	5MG/5ML	A090750	001	Feb 02, 2010
BAJAJ	5MG/5ML	A091327	002	Oct 17, 2011
CHARTWELL MOLECULAR	5MG/5ML	A091130	002	Apr 22, 2011
PERRIGO R AND D	5MG/5ML	A090254	001	Apr 09, 2008
TARO	5MG/5ML	A090182	001	Apr 22, 2008
	5MG/5ML	A201546	002	May 20, 2011

CHILDREN'S ZYRTEC ALLERGY

+! J AND J CONSUMER	5MG/5ML	N022155	002	Nov 16, 2007

INC

CHILDREN'S ZYRTEC HIVES RELIEF

+! J AND J CONSUMER	5MG/5ML	N022155	001	Nov 16, 2007

INC

TABLET; ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

AMNEAL PHARMS NY	5MG	A078780	001	Jan 21, 2010
	10MG	A078780	004	Jan 21, 2010
APOTEX INC	5MG	A078317	001	Dec 27, 2007
	10MG	A078317	002	Dec 27, 2007
AUROBINDO PHARMA	5MG	A090760	001	Aug 05, 2015
LTD				
	10MG	A090760	003	Aug 05, 2015
CONTRACT PHARMACAL	5MG	A076047	001	Dec 27, 2007
	10MG	A076047	002	Dec 27, 2007
DR REDDYS LABS LTD	5MG	A078343	004	Jan 15, 2008
	10MG	A078343	003	Jan 15, 2008
GLENMARK PHARMS INC	5MG	A078427	003	Dec 28, 2007
	10MG	A078427	004	Dec 28, 2007
GRANULES	10MG	A209274	001	Dec 22, 2017
IPCA LABS LTD	5MG	A202277	002	Mar 11, 2014
	10MG	A202277	004	Mar 11, 2014
MARKSANS PHARMA	5MG	A078933	001	Jun 15, 2010
	10MG	A078933	002	Jun 15, 2010
MYLAN	5MG	A076677	001	Dec 27, 2007
	10MG	A076677	002	Dec 27, 2007
ORBION PHARMS	5MG	A078862	001	Feb 19, 2009
	10MG	A078862	002	Feb 19, 2009
PERRIGO R AND D	5MG	A078336	001	Dec 27, 2007
	10MG	A078336	002	Dec 27, 2007
PLD ACQUISITIONS	5MG	A077946	001	Dec 27, 2007
	10MG	A077946	002	Dec 27, 2007
SUN PHARM INDS LTD	5MG	A077498	001	Dec 27, 2007
	10MG	A077498	002	Dec 27, 2007
TARO	5MG	A078072	001	Jul 22, 2009
	5MG	A078072	003	Jul 22, 2009
UNIQUE	5MG	A077829	001	Aug 26, 2009
	10MG	A077829	004	Aug 26, 2009

CETIRIZINE HYDROCHLORIDE HIVES

DR REDDYS LABS LTD	5MG	A078343	001	Jan 15, 2008
	10MG	A078343	002	Jan 15, 2008
IPCA LABS LTD	5MG	A202277	001	Mar 11, 2014
	10MG	A202277	003	Mar 11, 2014
MARKSANS PHARMA	5MG	A078933	003	Jun 15, 2010
	10MG	A078933	004	Jun 15, 2010
MYLAN	5MG	A076677	004	Dec 27, 2007
	10MG	A076677	003	Dec 27, 2007
ORBION PHARMS	5MG	A078862	003	Feb 19, 2009
	10MG	A078862	004	Feb 19, 2009
PERRIGO R AND D	5MG	A078336	003	Dec 27, 2007
	10MG	A078336	004	Dec 27, 2007
SUN PHARM INDS LTD	5MG	A077498	003	Dec 27, 2007
	10MG	A077498	004	Dec 27, 2007
UNIQUE	5MG	A077829	003	Aug 26, 2009
!	10MG	A077829	002	Aug 26, 2009

CETIRIZINE HYDROCHLORIDE HIVES RELIEF

AMNEAL PHARMS NY	5MG	A078780	003	Jan 21, 2010
	10MG	A078780	002	Jan 21, 2010
AUROBINDO PHARMA	5MG	A090760	002	Aug 05, 2015
LTD				
	10MG	A090760	004	Aug 05, 2015

OTC DRUG PRODUCT LIST

4-4 (of 20)

CETIRIZINE HYDROCHLORIDE

TABLET;ORAL

CETIRIZINE HYDROCHLORIDE HIVES RELIEF

TARO 10MG
10MGA078072 002 Jul 22, 2009
A078072 004 Jul 22, 2009

Zyrtec Allergy

+! J AND J CONSUMER 10MG
INC

N019835 004 Nov 16, 2007

TABLET, CHEWABLE;ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

JUBILANT GENERICS 5MG
10MGA091116 001 Feb 19, 2015
A091116 002 Feb 19, 2015NOVEL LABS INC 5MG
10MGA206793 001 Mar 08, 2016
A206793 002 Mar 08, 2016SANDOZ 5MG
10MGA078692 001 Feb 14, 2008
A078692 002 Feb 14, 2008! SUN PHARM 5MG
10MGA090142 001 Aug 30, 2011
A090142 002 Aug 30, 2011

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF

JUBILANT GENERICS 5MG
10MGA091116 003 Feb 19, 2015
A091116 004 Feb 19, 2015SUN PHARM 5MG
10MGA090142 003 Aug 30, 2011
A090142 004 Aug 30, 2011

CHILDREN'S Zyrtec Allergy

+ J AND J CONSUMER 2.5MG
INC

N021621 007 Nov 30, 2020

+ 10MG

N021621 004 Nov 16, 2007

TABLET, ORALLY DISINTEGRATING;ORAL

CETIRIZINE HYDROCHLORIDE

AUROBINDO PHARMA 10MG
LTD

A213557 001 Sep 11, 2020

CETIRIZINE HYDROCHLORIDE ALLERGY

PERRIGO R AND D 10MG

A205490 001 Sep 02, 2015

Zyrtec Allergy

+! J AND J CONSUMER 10MG
INC

N022578 001 Sep 03, 2010

CETIRIZINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

IVAX SUB TEVA 5MG;120MG
PHARMS

A077170 001 Feb 25, 2008

PERRIGO R AND D 5MG;120MG

A210719 001 Nov 16, 2018

PLD ACQUISITIONS 5MG;120MG

A077991 001 Mar 05, 2008

SUN PHARM INDS LTD 5MG;120MG

A090922 001 Sep 28, 2012

Zyrtec-D 12 HOUR

+! J AND J CONSUMER 5MG;120MG
INC

N021150 002 Nov 09, 2007

CHLORHEXIDINE GLUCONATE

AEROSOL, METERED;TOPICAL

EXIDINE

+! XTTRIUM 4%

N019127 001 Dec 24, 1984

CLOTH;TOPICAL

CHLORHEXIDINE GLUCONATE

+! SAGE PRODS 2%

N021669 001 Apr 25, 2005

READYPREP CHG

MEDLINE INDUSTRIES 2%

N207964 001 Nov 20, 2018

SOLUTION;TOPICAL

CHG SCRUB

ECOLAB 4%

N019258 002 Jul 22, 1986

CHLORHEXIDINE GLUCONATE

BAJAJ 0.75%

N020111 001 Sep 11, 1997

CIDA-STAT

ECOLAB 2%

N019258 001 Jul 22, 1986

EXIDINE

+! XTTRIUM 2%
4%N019422 001 Dec 17, 1985
N019125 001 Dec 24, 1984

HIBICLENS

+! MOLNLYCKE HLTH 4%

N017768 001

HIBISTAT

+! MOLNLYCKE HLTH 0.5%

N018300 001

OTC DRUG PRODUCT LIST

4-5 (of 20)

CHLORHEXIDINE GLUCONATE

SPONGE; TOPICAL

BIOSCRUB

GRIFFEN

4%

N019822 001 Mar 31, 1989

CHLORHEXIDINE GLUCONATE

!

BECTON DICKINSON

4%

A072525 001 Oct 24, 1989

CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL

SOLUTION; TOPICAL

SOLUPREP

+! 3M HEALTH CARE

2%; 70%

N208288 001 Aug 08, 2018

SPONGE; TOPICAL

CHLORAPREP ONE-STEP

+! BECTON DICKINSON CO

2%; 70% (3ML)

N020832 001 Jul 14, 2000

+!

2%; 70% (10.5ML)

N020832 004 Aug 20, 2003

+!

2%; 70% (26ML)

N020832 006 Nov 21, 2006

+!

2%; 70% (1ML)

N020832 008 Oct 23, 2008

CHLORAPREP ONE-STEP FREPP

+! BECTON DICKINSON CO

2%; 70% (1.5ML)

N020832 003 Apr 26, 2002

CHLORAPREP WITH TINT

+! BECTON DICKINSON CO

2%; 70% (26ML)

N020832 002 May 03, 2005

+!

2%; 70% (10.5ML)

N020832 005 Apr 03, 2006

+!

2%; 70% (3ML)

N020832 007 Oct 10, 2006

SWAB; TOPICAL

CHLORAPREP ONE-STEP SEPP

+! BECTON DICKINSON CO

2%; 70% (0.67ML)

N021555 001 Oct 07, 2002

CHLORAPREP SINGLE SWABSTICK

+! BECTON DICKINSON CO

2%; 70% (1.75ML)

N021555 002 May 10, 2005

CHLORAPREP TRIPLE SWABSTICK

+! BECTON DICKINSON CO

2%; 70% (5.25ML)

N021555 003 Jun 10, 2009

PREVANTICS MAXI SWABSTICK

+! PROF DSPLS

3.15%; 70% (5.1ML)

N021524 003 Jun 03, 2005

PREVANTICS SWAB

+! PROF DSPLS

3.15%; 70% (1ML)

N021524 001 Jun 03, 2005

PREVANTICS SWABSTICK

+! PROF DSPLS

3.15%; 70% (1.6ML)

N021524 002 Jun 03, 2005

CHLORPHENIRAMINE MALEATE

TABLET, EXTENDED RELEASE; ORAL

CHLORPHENIRAMINE MALEATE

!

AVANTHI INC

12MG

A040829 001 May 13, 2009

CHLORPHENIRAMINE MALEATE; IBUPROFEN; PHENYLEPHRINE HYDROCHLORIDE

TABLET; ORAL

ADVIL ALLERGY AND CONGESTION RELIEF

+! GLAXOSMITHKLINE

4MG; 200MG; 10MG

N022113 001 Dec 21, 2011

ADVIL MULTI-SYMPTOM COLD & FLU

+! GLAXOSMITHKLINE

4MG; 200MG; 10MG

N022113 002 Apr 28, 2017

CHLORPHENIRAMINE MALEATE; IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

SUSPENSION; ORAL

CHILDREN'S ADVIL ALLERGY SINUS

+! GLAXOSMITHKLINE

1MG/5ML; 100MG/5ML; 15MG/5ML

N021587 001 Feb 24, 2004

TABLET; ORAL

ADVIL ALLERGY SINUS

+! GLAXOSMITHKLINE

2MG; 200MG; 30MG

N021441 001 Dec 19, 2002

CIMETIDINE

TABLET; ORAL

CIMETIDINE

APOTEX

100MG

A074948 001 Jun 19, 1998

200MG

A074948 002 Jul 26, 2002

IVAX SUB TEVA

200MG

A075345 001 Jun 16, 1999

PHARMS

L PERRIGO CO

200MG

A075285 001 Oct 29, 1998

TAGAMET HB

+! MEDTECH PRODUCTS

200MG

N020238 002 Aug 21, 1996

CLOTRIMAZOLE

CREAM; VAGINAL

CLOTRIMAZOLE

!

P AND L

1%

A074165 001 Jul 16, 1993

TARO

1%

A072641 001 Dec 04, 1995

TRIVAGIZOLE 3

TARO

2%

N021143 001 Apr 12, 2000

OTC DRUG PRODUCT LIST

CROMOLYN SODIUM

SPRAY, METERED;NASAL

CROMOLYN SODIUM

! BAUSCH AND LOMB 5.2MG/SPRAY

A075702 001 Jul 03, 2001

DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN

TABLET, EXTENDED RELEASE;ORAL

GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE

ACTAVIS LABS FL 30MG;600MG

A091070 001 Aug 31, 2015

60MG;1.2GM

A091070 002 Aug 31, 2015

AMNEAL PHARMS 30MG;600MG

A209692 001 Nov 01, 2018

60MG;1.2GM

A209692 002 Nov 01, 2018

AUROBINDO PHARMA 30MG;600MG

A206941 001 Mar 17, 2017

60MG;1.2GM

A206941 002 Mar 17, 2017

PERRIGO R AND D 30MG;600MG

A207602 002 Mar 05, 2018

60MG;1.2GM

A207602 001 Mar 05, 2018

SUN PHARM 30MG;600MG

A214781 001 Jul 01, 2021

60MG;1.2GM

A214781 002 Jul 01, 2021

MUCINEX DM

+ RB HLTH 30MG;600MG

N021620 002 Apr 29, 2004

+! 60MG;1.2GM

N021620 001 Apr 29, 2004

DEXTROMETHORPHAN POLISTIREX

SUSPENSION, EXTENDED RELEASE;ORAL

DELSYM

+! RB HLTH EQ 30MG HYDROBROMIDE/5ML

N018658 001 Oct 08, 1982

DEXTROMETHORPHAN POLISTIREX

AMNEAL EQ 30MG HYDROBROMIDE/5ML

A203133 001 Jul 28, 2017

TRIS PHARMA INC EQ 30MG HYDROBROMIDE/5ML

A091135 001 May 25, 2012

DICLOFENAC SODIUM

GEL;TOPICAL

DICLOFENAC SODIUM

AKORN 1%

A209484 001 Nov 21, 2018

AMNEAL PHARMS 1%

A208077 001 Mar 18, 2016

AUROLIFE PHARMA LLC 1%

A204306 001 May 06, 2019

ENCUBE 1%

A210986 001 Jan 27, 2020

PERRIGO PHARMA INTL 1%

A211253 001 May 16, 2019

VOLTAREN ARTHRITIS PAIN

+! GLAXOSMITHKLINE 1%

N022122 001 Oct 17, 2007

CONS

DIPHENHYDRAMINE CITRATE; IBUPROFEN

TABLET;ORAL

ADVIL PM

+! GLAXOSMITHKLINE 38MG;200MG

N021394 001 Dec 21, 2005

IBUPROFEN AND DIPHENHYDRAMINE CITRATE

AUROBINDO PHARMA 38MG;200MG

A216204 001 May 31, 2022

DR REDDYS LABS LTD 38MG;200MG

A090619 001 Jul 08, 2009

PERRIGO R AND D 38MG;200MG

A079113 001 Dec 22, 2008

DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN

CAPSULE;ORAL

ADVIL PM

+! GLAXOSMITHKLINE 25MG;EQ 200MG FREE ACID AND POTASSIUM SALT

N021393 001 Dec 21, 2005

IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE

AUROBINDO PHARMA 25MG;EQ 200MG FREE ACID AND POTASSIUM

A210676 001 Feb 14, 2019

LTD SALT

BIONPHARMA INC 25MG;EQ 200MG FREE ACID AND POTASSIUM

A090397 001 Nov 22, 2010

SALT

STRIDES PHARMA 25MG;EQ 200MG FREE ACID AND POTASSIUM

A200888 001 Mar 05, 2012

SALT

DIPHENHYDRAMINE HYDROCHLORIDE; NAPROXEN SODIUM

TABLET;ORAL

ALEVE PM

+! BAYER HLTHCARE 25MG;220MG

N205352 001 Jan 17, 2014

NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE

AMNEAL PHARMS CO 25MG;220MG

A209726 001 Oct 23, 2018

APOTEX 25MG;220MG

A211830 001 Aug 22, 2019

GRANULES 25MG;220MG

A213663 001 Sep 24, 2020

PERRIGO R AND D 25MG;220MG

A208499 001 May 10, 2019

OTC DRUG PRODUCT LIST

4-7 (of 20)

DOCOSANOL

CREAM; TOPICAL

ABREVA

+! GLAXOSMITHKLINE 10%

N020941 001 Jul 25, 2000

DOCOSANOL

ALEOR 10%

A215839 001 May 03, 2022

DERMACEUTICALS

ENCUBE 10%

A212385 001 Oct 07, 2022

P AND L 10%

A208754 001 Nov 19, 2018

DOXYLAMINE SUCCINATE

TABLET; ORAL

DOXYLAMINE SUCCINATE

LNK 25MG

A040564 001 Aug 27, 2004

PERRIGO 25MG

A040167 001 Sep 18, 1996

UNISOM

+! CHATTEM 25MG

N018066 001

EPINEPHRINE

AEROSOL, METERED; INHALATION

PRIMATENE MIST

+! ARMSTRONG PHARMS 0.125MG/INH

N205920 001 Nov 07, 2018

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED RELEASE; ORAL

ESOMEPRAZOLE MAGNESIUM

AMNEAL PHARMS NY EQ 20MG BASE

A209716 001 Jun 05, 2019

AUROBINDO PHARMA EQ 20MG BASE

A209339 001 Oct 16, 2017

DR REDDYS EQ 20MG BASE

A207673 001 May 15, 2018

GRAVITI PHARMS EQ 20MG BASE

A216349 001 Jun 24, 2022

HETERO LABS LTD III EQ 20MG BASE

A208939 001 May 28, 2020

EQ 20MG BASE

A212507 001 Jun 02, 2020

PERRIGO R AND D EQ 20MG BASE

A207193 001 Aug 18, 2017

SUN PHARM EQ 20MG BASE

A212866 001 May 04, 2020

NEXIUM 24HR

+! ASTRAZENECA LP EQ 20MG BASE

N204655 001 Mar 28, 2014

TABLET, DELAYED RELEASE; ORAL

ESOMEPRAZOLE MAGNESIUM

DR REDDYS EQ 20MG BASE

A211571 001 May 14, 2020

MYLAN EQ 20MG BASE

A212088 001 Jun 25, 2020

NEXIUM 24HR

+! ASTRAZENECA LP EQ 20MG BASE

N207920 001 Nov 23, 2015

FAMOTIDINE

TABLET; ORAL

FAMOTIDINE

ANNORA PHARMA 10MG

A215766 001 Nov 08, 2021

20MG

A215766 002 Nov 08, 2021

ASCENT PHARMS INC 10MG

A216030 001 Nov 03, 2021

20MG

A216030 002 Nov 03, 2021

AUROBINDO PHARMA 10MG

A206531 001 Apr 26, 2016

20MG

A206531 002 Apr 26, 2016

DR REDDYS LABS LTD 10MG

A077367 002 Aug 17, 2001

20MG

A077367 001 Sep 25, 2006

GLENMARK PHARMS INC 10MG

A077146 001 Mar 07, 2005

20MG

A090837 001 Aug 04, 2010

P AND L 10MG

A075512 001 Jul 26, 2001

PERRIGO 10MG

A075400 001 Mar 18, 2005

PERRIGO R AND D 20MG

A077351 001 Sep 25, 2006

SUN PHARM INDS LTD 10MG

A090283 001 Nov 17, 2009

20MG

A090283 002 Nov 17, 2009

VKT PHARMA 10MG

A215822 001 Jan 28, 2022

20MG

A215822 002 Jan 28, 2022

PEPCID AC

+ J AND J CONSUMER 10MG

N020325 001 Apr 28, 1995

INC 10MG

N020902 001 Aug 05, 1999

+! 20MG

N020325 002 Sep 23, 2003

TABLET, CHEWABLE; ORAL

PEPCID AC

+! J AND J CONSUMER 20MG

N020801 002 Dec 17, 2007

INC

OTC DRUG PRODUCT LIST

4-8 (of 20)

FEXOFENADINE HYDROCHLORIDE

SUSPENSION; ORAL

CHILDREN'S ALLEGRA ALLERGY

+!	CHATTEM SANOFI	30MG/5ML	N201373	001	Jan 24, 2011

CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY

P AND L	30MG/5ML	A203330	001	Nov 18, 2014

TARO	30MG/5ML	A208123	001	Nov 09, 2017

CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES

!	P AND L	30MG/5ML	A203330	002	Nov 18, 2014

TARO	30MG/5ML	A208123	002	Nov 09, 2017

TABLET; ORAL

ALLEGRA ALLERGY

+	CHATTEM SANOFI	60MG	N020872	007	Jan 24, 2011

+!		180MG	N020872	010	Jan 24, 2011

ALLEGRA HIVES

+!	CHATTEM SANOFI	180MG	N020872	009	Jan 24, 2011

CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY

AUROLIFE PHARMA LLC	30MG	A202039	001	Nov 19, 2014

DR REDDYS LABS LTD	30MG	A076502	004	Apr 12, 2011

HETERO LABS LTD V	30MG	A204097	001	Aug 19, 2016

TEVA	30MG	A076447	004	Apr 13, 2011

WOCKHARDT	30MG	A079112	002	Feb 08, 2012

CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES

DR REDDYS LABS LTD	30MG	A076502	005	Apr 12, 2011

TEVA	30MG	A076447	005	Apr 13, 2011

WOCKHARDT	30MG	A079112	001	Feb 08, 2012

FEXOFENADINE HYDROCHLORIDE

L PERRIGO CO	60MG	A212971	001	Feb 24, 2020

	180MG	A212971	002	Feb 24, 2020

FEXOFENADINE HYDROCHLORIDE ALLERGY

AUROLIFE PHARMA LLC	60MG	A202039	002	Nov 19, 2014

	180MG	A202039	003	Nov 19, 2014

DR REDDYS LABS LTD	60MG	A076502	006	Apr 12, 2011

	180MG	A076502	008	Apr 12, 2011

GRANULES	60MG	A211075	001	Oct 18, 2019

	180MG	A211075	002	Oct 18, 2019

HETERO LABS LTD V	60MG	A204097	002	Aug 19, 2016

	180MG	A204097	003	Aug 19, 2016

RISING	60MG	A077081	006	Jul 21, 2011

	180MG	A077081	008	Jul 21, 2011

SCIEGEN PHARMS INC	60MG	A204507	002	Sep 16, 2015

	180MG	A204507	003	Sep 16, 2015

SUN PHARM INDS	180MG	A091567	006	Feb 06, 2012

TEVA	60MG	A076447	006	Apr 13, 2011

	180MG	A076447	008	Apr 13, 2011

UNIQUE	180MG	A210137	001	Aug 13, 2018

WOCKHARDT	60MG	A079112	004	Feb 08, 2012

	180MG	A079112	006	Feb 08, 2012

FEXOFENADINE HYDROCHLORIDE HIVES

DR REDDYS LABS LTD	60MG	A076502	007	Apr 12, 2011

	180MG	A076502	009	Apr 12, 2011

RISING	60MG	A077081	007	Jul 21, 2011

	180MG	A077081	009	Jul 21, 2011

SCIEGEN PHARMS INC	60MG	A204507	004	Sep 16, 2015

	180MG	A204507	005	Sep 16, 2015

SUN PHARM INDS	180MG	A091567	005	Feb 06, 2012

TEVA	60MG	A076447	007	Apr 13, 2011

WOCKHARDT	60MG	A079112	003	Feb 08, 2012

	180MG	A079112	005	Feb 08, 2012

FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION

+!	CHATTEM SANOFI	60MG;120MG	N020786	002	Jan 24, 2011

ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION

+!	CHATTEM SANOFI	180MG;240MG	N021704	002	Jan 24, 2011

FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

AUROBINDO PHARMA	60MG;120MG	A209116	001	Oct 30, 2017

DR REDDYS	60MG;120MG	A076667	001	Nov 18, 2014

	60MG;120MG	A215434	001	May 31, 2022

DR REDDYS LABS LTD	180MG;240MG	A079043	002	Jun 22, 2011

SUN PHARM	60MG;120MG	A090818	001	Jan 29, 2015

OTC DRUG PRODUCT LIST

4-9 (of 20)

FLUTICASONE FUROATE

SPRAY, METERED;NASAL

FLONASE SENSIMIST ALLERGY RELIEF

+! GLAXOSMITHKLINE 0.0275MG/SPRAY
CONS

N022051 002 Aug 02, 2016

FLUTICASONE PROPIONATE

SPRAY, METERED;NASAL

FLONASE ALLERGY RELIEF

+ GLAXOSMITHKLINE 0.05MG/SPRAY
CONS

N205434 001 Jul 23, 2014

FLUTICASONE PROPIONATE

AKORN 0.05MG/SPRAY

A208024 001 Apr 17, 2019

APOTEX 0.05MG/SPRAY

A208150 001 Feb 29, 2016

! HIKMA 0.05MG/SPRAY

A207957 001 May 26, 2016

GUAIFENESIN

TABLET, EXTENDED RELEASE;ORAL

GUAIFENESIN

ACTAVIS LABS FL 1.2GM

A091009 002 Sep 03, 2015

AMNEAL PHARMS 600MG

A207342 001 Jul 11, 2018

1.2GM

A207342 002 Jul 11, 2018

AUROBINDO PHARMA 600MG

A210453 001 Oct 21, 2019

1.2GM

A210453 002 Oct 21, 2019

DR REDDYS 600MG

A215932 001 Mar 15, 2022

1.2GM

A215932 002 Mar 15, 2022

GRANULES 600MG

A213420 001 May 08, 2020

1.2GM

A213420 002 May 08, 2020

GUARDIAN DRUG 600MG

A209215 001 Sep 06, 2017

1.2GM

A209215 002 Sep 06, 2017

OHM LABS INC 600MG

A209254 001 Jul 16, 2018

1.2GM

A209254 002 Jul 16, 2018

PERRIGO R AND D 600MG

A078912 001 Nov 23, 2011

1.2GM

A078912 002 Nov 05, 2020

MUCINEX

+ RB HLTH 600MG

N021282 001 Jul 12, 2002

+! 1.2GM

N021282 002 Dec 18, 2002

GUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE

ACTAVIS LABS FL 600MG;60MG

A091071 001 May 27, 2015

1.2GM;120MG

A091071 002 May 27, 2015

AUROBINDO PHARMA 600MG;60MG

A213203 001 Mar 25, 2020

LTD

1.2GM;120MG

A213203 002 Mar 25, 2020

DR REDDYS 600MG;60MG

A208369 001 Dec 29, 2017

1.2GM;120MG

A208369 002 Dec 29, 2017

GRANULES 600MG;60MG

A216082 001 Aug 22, 2022

1.2GM;120MG

A216082 002 Aug 22, 2022

L PERRIGO CO 600MG;60MG

A214407 001 Feb 01, 2022

1.2GM;120MG

A214407 002 Feb 01, 2022

SUN PHARM INDS INC 600MG;60MG

A212542 001 Apr 28, 2020

1.2GM;120MG

A212542 002 Apr 28, 2020

MUCINEX D

+ RB HLTH 600MG;60MG

N021585 001 Jun 22, 2004

+! 1.2GM;120MG

N021585 002 Jun 22, 2004

IBUPROFEN

CAPSULE;ORAL

ADVIL LIQUI-GELS

+! GLAXOSMITHKLINE EQ 200MG FREE ACID AND POTASSIUM SALT

N020402 001 Apr 20, 1995

ADVIL MIGRAINE LIQUI-GELS

+! GLAXOSMITHKLINE EQ 200MG FREE ACID AND POTASSIUM SALT

N020402 002 Mar 16, 2000

IBUPROFEN

AMNEAL PHARMS EQ 200MG FREE ACID AND POTASSIUM SALT

A202300 001 Dec 23, 2011

ASCENT PHARMS INC EQ 200MG FREE ACID AND POTASSIUM SALT

A206999 001 Dec 21, 2017

AUROBINDO PHARMA EQ 200MG FREE ACID AND POTASSIUM SALT

A207753 001 Jun 29, 2018

LTD

BIONPHARMA INC EQ 200MG FREE ACID AND POTASSIUM SALT

A078682 001 Mar 24, 2009

HUMANWELL PURACAP EQ 200MG FREE ACID AND POTASSIUM SALT

A206568 001 Jun 21, 2016

MARKSANS PHARMA EQ 200MG FREE ACID AND POTASSIUM SALT

A079205 001 Jun 26, 2009

P AND L DEV LLC EQ 200MG FREE ACID AND POTASSIUM SALT

A077338 001 Jul 10, 2009

SOFGEN PHARMS EQ 200MG FREE ACID AND POTASSIUM SALT

A203599 001 Sep 07, 2016

STRIDES PHARMA EQ 200MG FREE ACID AND POTASSIUM SALT

A204469 001 Mar 28, 2018

OTC DRUG PRODUCT LIST

4-10 (of 20)

IBUPROFEN

CAPSULE;ORAL

MIDOL LIQUID GELS

+! BIONPHARMA INC 200MG N021472 001 Oct 18, 2002

SUSPENSION;ORAL

CHILDREN'S ADVIL

GLAXOSMITHKLINE 100MG/5ML N020589 001 Jun 27, 1996

CHILDREN'S ADVIL-FLAVORED

GLAXOSMITHKLINE 100MG/5ML N020589 002 Nov 07, 1997

CHILDREN'S IBUPROFEN

PERRIGO 100MG/5ML A074937 001 Dec 22, 1998

CHILDREN'S MOTRIN

+! J AND J CONSUMER INC 100MG/5ML N020516 001 Jun 16, 1995

IBUPROFEN

APTAPHARMA INC 100MG/5ML A210602 001 Nov 23, 2018

ARISE 100MG/5ML A200457 001 Aug 18, 2011

AUROBINDO PHARMA LTD 100MG/5ML A209179 001 Apr 17, 2018

GUARDIAN DRUG 100MG/5ML A210149 001 Aug 17, 2018

P AND L 100MG/5ML A074916 001 Apr 30, 1999

TARO 100MG/5ML A209207 001 Jun 27, 2017

SUSPENSION/DROPS;ORAL

CHILDREN'S MOTRIN

+! J AND J CONSUMER INC 40MG/ML N020603 001 Jun 10, 1996

IBUPROFEN

GUARDIAN DRUG 40MG/ML A210755 001 Sep 26, 2018

L PERRIGO CO 40MG/ML A075217 001 Dec 16, 1998

TRIS PHARMA INC 40MG/ML A079058 001 Aug 31, 2009

INFANT'S ADVIL

+! GLAXOSMITHKLINE 50MG/1.25ML N020812 002 Jan 12, 2000

TABLET;ORAL

ADVIL

+! GLAXOSMITHKLINE 200MG N018989 001 May 18, 1984

IBUPROFEN

AMNEAL PHARMS 200MG A079233 001 Mar 18, 2014

AMNEAL PHARMS NY 200MG A071333 001 Feb 17, 1987

200MG A072199 001 May 23, 1988

AUROBINDO PHARMA 200MG A208865 001 Nov 08, 2017

AVEMA PHARMA 200MG A076460 001 Nov 26, 2003

CONTRACT PHARMACAL 200MG A072299 001 Jul 01, 1988

DR REDDYS LA 200MG A075661 001 Dec 12, 2001

DR REDDYS LABS INC 200MG A076117 001 Nov 20, 2001

GRANULES 200MG A202312 001 Oct 07, 2016

GRANULES INDIA 200MG A079174 001 Dec 10, 2010

LNK 200MG A075010 001 Mar 01, 1999

200MG A075139 001 Mar 01, 1999

MARKSANS PHARMA 200MG A091237 001 Feb 08, 2011

200MG A091239 001 Feb 01, 2011

MCNEIL 200MG A073019 001 Mar 30, 1994

OHM 200MG A071163 001 Jul 15, 1986

PERRIGO 200MG A072096 001 Dec 08, 1987

! PERRIGO R AND D 200MG A077349 001 Jun 21, 2005

SHANDONG XINHUA 200MG A207095 001 May 05, 2017

200MG A207095 002 Aug 21, 2018

STRIDES PHARMA 200MG A070481 001 Sep 24, 1986

200MG A079129 001 Mar 28, 2011

200MG A091355 001 Apr 04, 2011

200MG A206989 001 Jun 29, 2018

200MG A207052 001 May 30, 2017

200MG A071229 001 Apr 01, 1987

JUNIOR STRENGTH ADVIL

GLAXOSMITHKLINE 100MG N020267 002 Dec 13, 1996

JUNIOR STRENGTH MOTRIN

J AND J CONSUMER INC 100MG N020602 001 Jun 10, 1996

MOTRIN IB

+ J AND J CONSUMER INC 200MG N019012 003 Dec 17, 1990

TABLET, CHEWABLE;ORAL

CHILDREN'S ADVIL

GLAXOSMITHKLINE 50MG N020944 001 Dec 18, 1998

OTC DRUG PRODUCT LIST

4-11 (of 20)

IBUPROFEN

TABLET, CHEWABLE; ORAL

IBUPROFEN

! PERRIGO

100MG

A076359 002 Jan 16, 2004

JUNIOR STRENGTH ADVIL

GLAXOSMITHKLINE

100MG

N020944 002 Dec 18, 1998

IBUPROFEN SODIUM

TABLET; ORAL

ADVIL

+! GLAXOSMITHKLINE

EQ 200MG BASE

N201803 001 Jun 12, 2012

IBUPROFEN; PHENYLEPHRINE HYDROCHLORIDE

TABLET; ORAL

ADVIL CONGESTION RELIEF

+! GLAXOSMITHKLINE

200MG; 10MG

N022565 001 May 27, 2010

IBUPROFEN AND PHENYLEPHRINE HYDROCHLORIDE

PERRIGO R AND D

200MG; 10MG

A203200 001 Jul 03, 2014

IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE; ORAL

ADVIL COLD AND SINUS

+! GLAXOSMITHKLINE

EQ 200MG FREE ACID AND POTASSIUM
SALT; 30MG

N021374 001 May 30, 2002

IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE

AUROBINDO PHARMA

EQ 200MG FREE ACID AND POTASSIUM
SALT; 30MG

A209235 001 Dec 01, 2017

SUSPENSION; ORAL

CHILDREN'S ADVIL COLD

GLAXOSMITHKLINE

100MG/5ML; 15MG/5ML

N021373 001 Apr 18, 2002

CHILDREN'S MOTRIN COLD

+! J AND J CONSUMER

100MG/5ML; 15MG/5ML

N021128 001 Aug 01, 2000

INC

TABLET; ORAL

ADVIL COLD AND SINUS

+! GLAXOSMITHKLINE

200MG; 30MG

N019771 001 Sep 19, 1989

IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE

DR REDDYS LABS LTD

200MG; 30MG

A077628 001 Aug 14, 2006

IBUPROHM COLD AND SINUS

OHM LABS

200MG; 30MG

A074567 001 Apr 17, 2001

SINE-AID IB

J AND J CONSUMER

200MG; 30MG

N019899 001 Dec 31, 1992

INC

IODINE POVACRYLEX; ISOPROPYL ALCOHOL

SPONGE; TOPICAL

DURAPREP

+! 3M

EQ 0.7% IODINE; 74% (6ML)

N021586 001 Sep 29, 2006

+!

EQ 0.7% IODINE; 74% (26ML)

N021586 002 Sep 29, 2006

ISOPROPYL ALCOHOL

SOLUTION; TOPICAL

ZURAGARD

+! ZUREX PHARMA

70%

N210872 001 Apr 26, 2019

IVERMECTIN

LOTION; TOPICAL

IVERMECTIN

TARO

0.5%

A210720 001 May 06, 2020

SKLICE

+! ARBOR PHARMS LLC

0.5%

N202736 001 Feb 07, 2012

KETOCONAZOLE

SHAMPOO; TOPICAL

NIZORAL ANTI-DANDRUFF

+! KRAMER

1%

N020310 001 Oct 10, 1997

KETOTIFEN FUMARATE

SOLUTION/DROPS; OPHTHALMIC

ALAWAY

+! BAUSCH AND LOMB

EQ 0.025% BASE

N021996 001 Dec 01, 2006

BAUSCH AND LOMB INC

EQ 0.025% BASE

A208158 001 Sep 24, 2020

CHILDREN'S ALAWAY

+ BAUSCH AND LOMB

EQ 0.025% BASE

N021996 002 Feb 11, 2015

KETOTIFEN FUMARATE

AKORN

EQ 0.025% BASE

A077958 001 Jul 26, 2007

APOTEX INC

EQ 0.025% BASE

A077354 001 May 09, 2006

OTC DRUG PRODUCT LIST

4-12 (of 20)

KETOTIFEN FUMARATE

SOLUTION/DROPS;OPHTHALMIC

KETOTIFEN FUMARATE

BAYSHORE PHARMS LLC EQ 0.025% BASE

A204059 001 Jun 01, 2020

ZADITOR

! ALCON PHARMS LTD EQ 0.025% BASE

A077200 001 Sep 02, 2008

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL

LANSOPRAZOLE

DR REDDYS LABS LTD 15MG

A202194 001 May 18, 2012

GLENMARK PHARMS INC 15MG

A202727 001 May 18, 2012

MYLAN 15MG

A203187 001 Jun 01, 2016

NATCO 15MG

A203306 001 Jan 13, 2016

PERRIGO R AND D 15MG

A202319 001 May 18, 2012

PREVACID 24 HR

+! PERRIGO PHARMA INTL 15MG

N022327 001 May 18, 2009

TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL

LANSOPRAZOLE

DEXCEL 15MG

N208025 001 Jun 07, 2016

LEVOCETIRIZINE DIHYDROCHLORIDE

SOLUTION;ORAL

XYZAL ALLERGY 24HR

+! CHATTEM SANOFI 2.5MG/5ML

N209090 001 Jan 31, 2017

TABLET;ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

APOTEX 5MG

A211443 001 Apr 21, 2021

DR REDDYS 5MG

A210375 001 Jan 19, 2018

HETERO LABS LTD III 5MG

A213513 001 Apr 29, 2020

MICRO LABS 5MG

A211551 001 Nov 20, 2018

PERRIGO R AND D 5MG

A211983 001 Mar 28, 2019

XYZAL ALLERGY 24HR

+! CHATTEM SANOFI 5MG

N209089 001 Jan 31, 2017

LEVONORGESTREL

TABLET;ORAL

ATHENTIA NEXT

AUROBINDO PHARMA 1.5MG

A206867 001 Dec 08, 2015

FALLBACK SOLO

LUPIN LTD 1.5MG

A201446 001 Jun 19, 2014

HER STYLE

NOVAST LABS 1.5MG

A207976 001 Mar 11, 2016

LEVONORGESTREL

GLENMARK PHARMS LTD 1.5MG

A207044 001 Mar 25, 2016

LABORATOIRE HRA 1.5MG

A204044 001 Jul 03, 2018

MYLAN LABS LTD 1.5MG

A202739 001 Oct 31, 2014

NAARI PTE LTD 1.5MG

A202380 001 May 29, 2015

NOVEL LABS INC 1.5MG

A202508 001 Feb 22, 2013

PERRIGO R AND D 1.5MG

A202334 001 Aug 20, 2014

XIROMED 1.5MG

A205329 001 Sep 18, 2018

OPCICON ONE-STEP

SUN PHARM 1.5MG

A202635 001 Sep 11, 2014

PLAN B ONE-STEP

+! FDN CONSUMER 1.5MG

N021998 001 Jul 10, 2009

LOPERAMIDE HYDROCHLORIDE

CAPSULE;ORAL

LOPERAMIDE HYDROCHLORIDE

+ BIONPHARMA INC 1MG

N021855 001 Aug 04, 2005

+! 2MG

N021855 002 Aug 04, 2005

STRIDES PHARMA 2MG

A213070 001 Aug 11, 2021

SOLUTION;ORAL

IMODIUM A-D

+! J AND J CONSUMER 1MG/5ML

N019487 001 Mar 01, 1988

INC

LOPERAMIDE HYDROCHLORIDE

WOCKHARDT BIO AG 1MG/5ML

A074730 001 Aug 28, 1997

SUSPENSION;ORAL

IMODIUM A-D

+! J AND J CONSUMER 1MG/7.5ML

N019487 002 Jul 08, 2004

INC

LOPERAMIDE HYDROCHLORIDE

PERRIGO R AND D 1MG/7.5ML

A091292 001 May 20, 2011

OTC DRUG PRODUCT LIST

4-13 (of 20)

LOPERAMIDE HYDROCHLORIDE

TABLET; ORAL

IMODIUM A-D

+	!	J AND J CONSUMER	2MG						
		INC							

N019860 001 Nov 22, 1989

LOPERAMIDE HYDROCHLORIDE

		AUROBINDO PHARMA	2MG						

A206548 001 Dec 15, 2015

		L PERRIGO CO	2MG						

A075232 001 Jan 06, 2000

		LNK	2MG						

A076497 001 Jun 10, 2003

		OHM LABS	2MG						

A074091 001 Dec 10, 1992

LOPERAMIDE HYDROCHLORIDE; SIMETHICONE

TABLET; ORAL

IMODIUM MULTI-SYMPTOM RELIEF

+	!	J AND J CONSUMER	2MG;125MG						
		INC							

N021140 001 Nov 30, 2000

LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE

		AUROBINDO PHARMA	2MG;125MG						

A211059 001 Dec 14, 2020

LTD

		BIONPHARMA INC	2MG;125MG						

A213484 001 Sep 10, 2021

		GRANULES	2MG;125MG						

A215981 001 Aug 29, 2022

		GUARDIAN DRUG	2MG;125MG						

A214541 001 May 27, 2021

		HETERO LABS LTD V	2MG;125MG						

A211438 001 Jun 17, 2021

		PERRIGO R AND D	2MG;125MG						

A209837 001 Sep 05, 2018

		SUN PHARM INDS LTD	2MG;125MG						

A077500 001 Sep 06, 2006

LORATADINE

CAPSULE; ORAL

CLARITIN

+	!	BAYER HEALTHCARE	10MG						
		LLC							

N021952 001 Jun 16, 2008

LORATADINE

		BIONPHARMA INC	10MG						

A202538 001 Dec 21, 2018

		MARKSANS PHARMA	10MG						

A206214 001 Sep 23, 2016

SUSPENSION; ORAL

LORATADINE

+	!	TARO	1MG/ML						

N021734 001 Oct 04, 2005

SYRUP; ORAL

CLARITIN

+	!	BAYER HEALTHCARE	1MG/ML						
		LLC							

N020641 002 Nov 27, 2002

LORATADINE

		AUROBINDO PHARMA	1MG/ML						

A208931 001 Jun 29, 2018

LTD

		HETERO LABS LTD III	1MG/ML						

A210409 001 May 07, 2021

		LANNETT CO INC	1MG/ML						

A077421 001 Jun 29, 2006

		PERRIGO	1MG/ML						

A075728 001 Aug 20, 2004

		TARO	1MG/ML						

A076805 001 Aug 20, 2004

			1MG/ML						

A201865 001 Jul 31, 2015

		WOCKHARDT BIO AG	1MG/ML						

A075815 001 Aug 20, 2004

TABLET; ORAL

CLARITIN

+	!	BAYER HEALTHCARE	10MG						
		LLC							

N019658 002 Nov 27, 2002

CLARITIN HIVES RELIEF

+	!	BAYER HEALTHCARE	10MG						
		LLC							

N019658 003 Nov 19, 2003

LORATADINE

		APOTEX INC	10MG						

A076471 001 Feb 14, 2006

		APPCO	10MG						

A207569 001 Mar 12, 2019

		AUROBINDO PHARMA	10MG						

A208314 001 Apr 16, 2018

LTD

		GRANULES	10MG						

A210722 001 Dec 23, 2019

		MYLAN	10MG						

A076154 001 Aug 20, 2003

		PERRIGO	10MG						

A076301 001 Jun 25, 2004

		PLD ACQUISITIONS	10MG						

A075209 001 Jan 21, 2003

LLC

		SUN PHARM INDS LTD	10MG						

A076134 001 Aug 18, 2003

		UNIQUE PHARM	10MG						

A214684 001 Jan 07, 2021

TABLET, CHEWABLE; ORAL

CHILDREN'S CLARITIN

+		BAYER HEALTHCARE	5MG						
		LLC							

N021891 001 Aug 23, 2006

CLARITIN

+	!	BAYER HEALTHCARE	10MG						
		LLC							

N021891 002 Nov 21, 2018

OTC DRUG PRODUCT LIST

4-14 (of 20)

LORATADINE

TABLET, CHEWABLE;ORAL

LORATADINE

PERRIGO PHARMA INTL 5MG

A210033 001 Jun 12, 2019

SUN PHARM 5MG

A210088 001 Apr 16, 2018

TABLET, ORALLY DISINTEGRATING;ORAL

ALAVERT

FDN CONSUMER 10MG

N021375 001 Dec 19, 2002

CLARITIN HIVES RELIEF REDITAB

+! BAYER HEALTHCARE 10MG
LLC

N020704 003 Nov 19, 2003

CLARITIN REDITABS

+! BAYER HEALTHCARE 5MG
LLC

N021993 001 Dec 12, 2006

+! 10MG

N020704 002 Nov 27, 2002

LORATADINE

AUROBINDO PHARMA 10MG
LTD

A208477 001 Apr 11, 2018

PERRIGO PHARMA INTL 10MG

A076011 001 Sep 29, 2003

RUBICON 10MG

A214280 001 Sep 10, 2020

TENSHI 5MG

A212795 001 Sep 18, 2020

10MG

A213294 001 Oct 30, 2020

LORATADINE REDIDOSE

SUN PHARM INDS LTD 10MG

A077153 001 Apr 11, 2007

LORATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE;ORAL

CLARITIN-D

+! BAYER HEALTHCARE 5MG;120MG
LLC

N019670 002 Nov 27, 2002

CLARITIN-D 24 HOUR

+! BAYER HEALTHCARE 10MG;240MG
LLC

N020470 002 Nov 27, 2002

LORATADINE AND PSEUDOEPHEDRINE SULFATE

P AND L 10MG;240MG

A075706 001 Feb 21, 2003

PERRIGO PHARMA INTL 5MG;120MG

A076050 001 Jan 30, 2003

10MG;240MG

A075989 001 Mar 04, 2004

SUN PHARM INDS LTD 10MG;240MG

A076557 001 Sep 22, 2004

MENTHOL; METHYL SALICYLATE

PATCH;TOPICAL

SALONPAS

+! HISAMITSU PHARM CO 3%;10%

N022029 001 Feb 20, 2008

+ 3%;10%

N022029 002 Nov 05, 2012

MICONAZOLE NITRATE

CREAM;TOPICAL, VAGINAL

MICONAZOLE 3 COMBINATION PACK

PERRIGO 2%,4%

A076357 001 Mar 30, 2004

MONISTAT 3 COMBINATION PACK

+ MEDTECH PRODUCTS 2%,4%

N021261 003 Jun 17, 2003

MONISTAT 3 COMBINATION PACK (PREFILLED)

+! MEDTECH PRODUCTS 2%,4%

N021261 001 Feb 02, 2001

CREAM;VAGINAL

MICONAZOLE 3

TARO 4%

A076773 001 Mar 02, 2005

MICONAZOLE 7

P AND L 2%

A074164 001 Mar 29, 1996

MICONAZOLE NITRATE

COSETTE 2%

A074366 001 Feb 22, 1996

PERRIGO 2%

A074760 001 May 15, 1997

PERRIGO R AND D 4%

A091366 001 Jan 15, 2010

TARO PHARMS 2%

A074444 001 Jan 13, 1997

MONISTAT 3

+! MEDTECH PRODUCTS 4%

N020827 001 Mar 30, 1998

MONISTAT 7

+! MEDTECH PRODUCTS 2%

N017450 002 Feb 15, 1991

CREAM, INSERT;TOPICAL, VAGINAL

MICONAZOLE NITRATE

PERRIGO R AND D 2%,1.2GM

A079114 001 Jun 02, 2010

MONISTAT 1 COMBINATION PACK

+! MEDTECH PRODUCTS 2%,1.2GM

N021308 001 Jun 29, 2001

OTC DRUG PRODUCT LIST

4-15 (of 20)

MICONAZOLE NITRATE

CREAM, SUPPOSITORY;TOPICAL, VAGINAL

M-ZOLE 3 COMBINATION PACK

P AND L 2%,200MG

A074926 001 Apr 16, 1999

MICONAZOLE NITRATE COMBINATION PACK

L PERRIGO CO 2%,200MG

A075329 001 Apr 20, 1999

MONISTAT 3 COMBINATION PACK

+! MEDTECH PRODUCTS 2%,200MG

N020670 002 Apr 16, 1996

MONISTAT 7 COMBINATION PACK

+! MEDTECH PRODUCTS 2%,100MG

N020288 002 Apr 26, 1993

SUPPOSITORY;VAGINAL

MICONAZOLE NITRATE

COSETTE 100MG

A074414 001 Apr 30, 1997

P AND L 100MG

A073507 001 Nov 19, 1993

MONISTAT 7

+! MEDTECH PRODUCTS 100MG

N018520 002 Feb 15, 1991

MINOXIDIL

AEROSOL, FOAM;TOPICAL

MEN'S ROGAINE

+! JOHNSON AND JOHNSON 5%

N021812 001 Jan 20, 2006

MINOXIDIL

PERRIGO PHARMA INTL 5%

A091344 001 Apr 28, 2011

MINOXIDIL (FOR MEN)

P AND L 5%

A208092 001 Feb 17, 2017

TARO 5%

A209074 001 Dec 31, 2018

MINOXIDIL (FOR WOMEN)

P AND L 5%

A208092 002 Jul 27, 2017

TARO 5%

A209074 002 Apr 22, 2019

WOMEN'S ROGAINE

+! JOHNSON AND JOHNSON 5%

N021812 002 Feb 28, 2014

SOLUTION;TOPICAL

MINOXIDIL (FOR MEN)

L PERRIGO CO 2%

A075357 001 Jul 30, 1999

P AND L 2%

A074588 001 Apr 05, 1996

WOCKHARDT BIO AG 2%

A074767 001 Feb 28, 1997

MINOXIDIL (FOR WOMEN)

L PERRIGO CO 2%

A075357 002 Jul 30, 1999

MINOXIDIL EXTRA STRENGTH (FOR MEN)

P AND L 5%

A075518 001 Nov 17, 2000

PERRIGO 5%

A075598 001 Jun 13, 2001

WOCKHARDT BIO AG 5%

A075438 001 Feb 27, 2003

ROGAINE (FOR MEN)

+! JOHNSON AND JOHNSON 2%

N019501 002 Feb 09, 1996

ROGAINE (FOR WOMEN)

+! JOHNSON AND JOHNSON 2%

N019501 003 Feb 09, 1996

ROGAINE EXTRA STRENGTH (FOR MEN)

+! JOHNSON AND JOHNSON 5%

N020834 001 Nov 14, 1997

THEROXIDIL

PURE SOURCE 2%

A078176 001 Nov 09, 2007

5%

A076239 001 Aug 24, 2004

MOMETASONE FUROATE

SPRAY, METERED;NASAL

NASONEX 24HR ALLERGY

+! PERRIGO PHARMA INTL 0.05MG/SPRAY

N215712 001 Mar 17, 2022

NAPHAZOLINE HYDROCHLORIDE; PHENIRAMINE MALEATE

SOLUTION/DROPS;OPHTHALMIC

NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE

AKORN 0.025%;0.3%

A202795 001 Jan 24, 2013

ALTAIRE PHARMS INC 0.02675%;0.315%

A078208 001 Sep 27, 2010

NAPHCN-A

+! ALCON 0.025%;0.3%

N020226 001 Jun 08, 1994

OPCON-A

+! BAUSCH AND LOMB 0.02675%;0.315%

N020065 001 Jun 08, 1994

VISINE

+! JOHNSON AND JOHNSON 0.025%;0.3%

N020485 001 Jan 31, 1996

OTC DRUG PRODUCT LIST

4-16 (of 20)

NAPROXEN SODIUM

CAPSULE; ORAL

NAPROXEN SODIUM

+!	BIONPHARMA INC	EQ 200MG BASE	N021920	001	Feb 17, 2006
	CATALENT	EQ 200MG BASE	A202807	001	Jan 04, 2019
	PATHEON SOFTGELS	EQ 200MG BASE	A214463	001	Jan 10, 2023
	PURACAP PHARM LLC	EQ 200MG BASE	A208363	001	Mar 15, 2018
	STRIDES PHARMA	EQ 200MG BASE	A215472	001	Aug 17, 2022

TABLET; ORAL

ALEVE

+!	BAYER	220MG	N020204	002	Jan 11, 1994

NAPROXEN SODIUM

	AMNEAL PHARMS NY	220MG	A079096	001	Dec 16, 2008
	AUROBINDO PHARMA LTD	220MG	A205497	001	Mar 18, 2016
	CONTRACT PHARMACAL	220MG	A074635	001	Jan 13, 1997
	DR REDDYS LABS INC	220MG	A075168	001	Jul 28, 1998
	GRANULES INDIA	220MG	A091353	001	Sep 20, 2011
	HETERO LABS LTD V	220MG	A211065	001	Oct 28, 2022
	LNK INTL INC	220MG	A204872	001	Jan 23, 2017
	MARKSANS PHARMA	220MG	A090545	001	Mar 16, 2011
	NOVELGENIX THERAPS	220MG	A207612	001	Nov 16, 2018
	PERRIGO	220MG	A074661	001	Jan 13, 1997
	SUN PHARM INDS LTD	220MG	A091183	001	May 20, 2011
	YICHANG HUMANWELL	220MG	A212033	001	Aug 30, 2019

NAPROXEN SODIUM; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE

	DR REDDYS LABS INC	220MG; 120MG	A077381	001	Sep 27, 2006
!	PERRIGO	220MG; 120MG	A076518	001	Mar 17, 2004

NICOTINE

FILM, EXTENDED RELEASE; TRANSDERMAL

HABITROL

+	DR REDDYS LABS SA	7MG/24HR	N020076	004	Nov 12, 1999
+		14MG/24HR	N020076	005	Nov 12, 1999
+!		21MG/24HR	N020076	006	Nov 12, 1999

NICODERM CQ

+	CHATTEM SANOFI	7MG/24HR	N020165	006	Aug 02, 1996
+		14MG/24HR	N020165	005	Aug 02, 1996
+!		21MG/24HR	N020165	004	Aug 02, 1996

NICOTINE

	AVEVA	7MG/24HR	A074612	002	Jul 28, 2003
		14MG/24HR	A074612	003	Oct 20, 1997
		21MG/24HR	A074612	001	Oct 20, 1997

NICOTINE POLACRILEX

GUM, CHEWING; BUCCAL

NICORETTE

+	GLAXOSMITHKLINE	EQ 2MG BASE	N018612	002	Feb 09, 1996
+		EQ 2MG BASE	N018612	004	Sep 25, 2000
+!		EQ 4MG BASE	N020066	002	Feb 09, 1996
+		EQ 4MG BASE	N020066	004	Sep 25, 2000

NICORETTE (MINT)

+	GLAXOSMITHKLINE	EQ 2MG BASE	N018612	003	Dec 23, 1998
+		EQ 4MG BASE	N020066	003	Dec 23, 1998

NICOTINE POLACRILEX

	FERTIN PHARMA	EQ 4MG BASE	A214354	001	Dec 21, 2022
	L PERRIGO CO	EQ 2MG BASE	A076775	001	Sep 16, 2004
		EQ 2MG BASE	A076777	001	Sep 16, 2004
		EQ 4MG BASE	A076779	001	Sep 16, 2004
		EQ 4MG BASE	A076789	001	Sep 16, 2004
	P AND L	EQ 2MG BASE	A074507	001	Mar 15, 1999
		EQ 2MG BASE	A076569	001	Jul 29, 2004
		EQ 2MG BASE	A078699	001	Dec 29, 2008
		EQ 2MG BASE	A079044	001	Jul 08, 2009
		EQ 2MG BASE	A079216	001	Jul 08, 2009
		EQ 2MG BASE	A204794	001	May 10, 2016
		EQ 4MG BASE	A074707	001	Mar 19, 1999
		EQ 4MG BASE	A076568	002	Jul 29, 2004
		EQ 4MG BASE	A078697	001	Dec 29, 2008
		EQ 4MG BASE	A079038	001	Jul 08, 2009
		EQ 4MG BASE	A079219	001	Jul 08, 2009

OTC DRUG PRODUCT LIST

4-17 (of 20)

NICOTINE POLACRILEX

GUM, CHEWING;BUCCAL

NICOTINE POLACRILEX

		EQ 4MG BASE	A204833	001	Feb 26, 2016
	PERRIGO R AND D	EQ 2MG BASE	A078325	001	Oct 30, 2006
		EQ 2MG BASE	A078547	001	May 24, 2007
		EQ 2MG BASE	A091349	001	Jul 20, 2011
		EQ 2MG BASE	A206394	001	Dec 15, 2016
		EQ 4MG BASE	A078326	001	Oct 30, 2006
		EQ 4MG BASE	A078546	001	May 24, 2007
		EQ 4MG BASE	A091354	001	Jul 20, 2011
		EQ 4MG BASE	A206393	001	Dec 15, 2016
TROCHE/LOZENGE;ORAL					
NICORETTE					
+	GLAXOSMITHKLINE	EQ 2MG BASE	N022360	001	May 18, 2009
+	!	EQ 4MG BASE	N022360	002	May 18, 2009
+	GLAXOSMITHKLINE	EQ 2MG BASE	N021330	001	Oct 31, 2002
	CONS				
+	!	EQ 4MG BASE	N021330	002	Oct 31, 2002
NICOTINE POLACRILEX					
	AUROBINDO PHARMA	EQ 2MG BASE	A213266	001	Aug 03, 2021
		EQ 4MG BASE	A213266	002	Aug 03, 2021
	AUROBINDO PHARMA	EQ 2MG BASE	A215357	001	May 13, 2022
	LTD				
		EQ 4MG BASE	A215357	002	May 13, 2022
	DR REDDYS LABS SA	EQ 2MG BASE	A212796	001	Jan 08, 2020
		EQ 2MG BASE	A212983	001	Feb 21, 2020
		EQ 2MG BASE	A213233	001	Aug 04, 2020
		EQ 4MG BASE	A212796	002	Jan 08, 2020
		EQ 4MG BASE	A212983	002	Feb 21, 2020
		EQ 4MG BASE	A213233	002	Aug 04, 2020
	P AND L	EQ 2MG BASE	A208875	001	Oct 31, 2019
		EQ 2MG BASE	A209206	001	Jun 26, 2018
		EQ 2MG BASE	A209519	001	Jul 02, 2018
		EQ 2MG BASE	A209520	001	Oct 31, 2019
		EQ 2MG BASE	A210711	001	Oct 31, 2019
		EQ 2MG BASE	A210712	001	Sep 06, 2019
		EQ 2MG BASE	A212056	001	Jul 26, 2019
		EQ 2MG BASE	A212057	001	May 14, 2020
		EQ 4MG BASE	A208875	002	Oct 31, 2019
		EQ 4MG BASE	A209206	002	Jun 26, 2018
		EQ 4MG BASE	A209519	002	Jul 02, 2018
		EQ 4MG BASE	A209520	002	Oct 31, 2019
		EQ 4MG BASE	A210711	002	Oct 31, 2019
		EQ 4MG BASE	A210712	002	Sep 06, 2019
		EQ 4MG BASE	A212056	002	Jul 26, 2019
		EQ 4MG BASE	A212057	002	May 14, 2020
	PERRIGO R AND D	EQ 2MG BASE	A077007	001	Jan 31, 2006
		EQ 2MG BASE	A090711	001	Jul 10, 2009
		EQ 2MG BASE	A090821	001	Jul 10, 2009
		EQ 2MG BASE	A203690	001	Oct 09, 2012
		EQ 4MG BASE	A077007	002	Jan 31, 2006
		EQ 4MG BASE	A090711	002	Jul 10, 2009
		EQ 4MG BASE	A090821	002	Jul 10, 2009
		EQ 4MG BASE	A203690	002	Oct 09, 2012
	PLD ACQUISITIONS	EQ 2MG BASE	A207868	001	Feb 07, 2019
		EQ 4MG BASE	A207868	002	Feb 07, 2019

NIZATIDINE

TABLET;ORAL

AXID AR

+! GLAXOSMITHKLINE 75MG

N020555 001 May 09, 1996

OLOPATADINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

OLOPATADINE HYDROCHLORIDE

AKORN

EQ 0.1% BASE

A204532 001 Jan 10, 2017

EQ 0.2% BASE

A204723 001 Dec 05, 2017

ALEMBIC PHARMS

EQ 0.1% BASE

A209919 001 Dec 07, 2018

EQ 0.2% BASE

A209420 001 Apr 29, 2019

APOTEX

EQ 0.1% BASE

A078350 001 Dec 07, 2015

APOTEX INC

EQ 0.2% BASE

A090918 001 Dec 05, 2017

BARR LABS INC

EQ 0.2% BASE

A090848 001 Jul 13, 2015

EUGIA PHARMA

EQ 0.1% BASE

A204812 001 Dec 18, 2015

OTC DRUG PRODUCT LIST

4-18 (of 20)

OLOPATADINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

OLOPATADINE HYDROCHLORIDE

		EQ 0.2% BASE	A209995	001	Apr 04, 2019
	GLAND PHARMA LTD	EQ 0.1% BASE	A209619	001	Aug 02, 2019
		EQ 0.2% BASE	A209752	001	May 20, 2020
	USV	EQ 0.1% BASE	A203152	001	Dec 07, 2015
	PATADAY ONCE DAILY RELIEF				
+	ALCON LABS INC	EQ 0.2% BASE	N021545	001	Dec 22, 2004
+		EQ 0.7% BASE	N206276	001	Jan 30, 2015
	PATADAY TWICE DAILY RELIEF				
+	ALCON LABS INC	EQ 0.1% BASE	N020688	001	Dec 18, 1996

OMEPRAZOLE

TABLET, DELAYED RELEASE;ORAL

OMEPRAZOLE

	APOTEX	20MG	A210070	001	Feb 11, 2019
+	DEXCEL PHARMA	20MG	N022032	001	Dec 04, 2007
	DR REDDYS	20MG	A207740	001	Nov 05, 2018
	SUN PHARM	20MG	A207891	001	Oct 12, 2018

TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL

OMEPRAZOLE

+	DEXCEL	20MG	N209400	001	Jul 05, 2017

OMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED RELEASE;ORAL

OMEPRAZOLE MAGNESIUM

!	DR REDDYS LABS LTD	EQ 20MG BASE	A078878	001	Jun 05, 2009
	L PERRIGO CO	EQ 20MG BASE	A216096	001	May 24, 2022
	SPIL	EQ 20MG BASE	A210593	001	Jul 20, 2018

TABLET, DELAYED RELEASE;ORAL

OMEPRAZOLE MAGNESIUM

	AUROBINDO PHARMA	EQ 20MG BASE	A206877	001	Jun 06, 2018
	HETERO LABS LTD III	EQ 20MG BASE	A211732	001	Mar 25, 2020
	P AND L	EQ 20MG BASE	A206582	001	Jun 01, 2020
	PRILOSEC OTC				
+	ASTRAZENECA	EQ 20MG BASE	N021229	001	Jun 20, 2003

OMEPRAZOLE; SODIUM BICARBONATE

CAPSULE;ORAL

OMEPRAZOLE AND SODIUM BICARBONATE

	AUROLIFE PHARMA LLC	20MG;1.1GM	A204923	001	Nov 07, 2016
	PERRIGO R AND D	20MG;1.1GM	A201361	001	Jul 15, 2016
	ZYDUS PHARMS	20MG;1.1GM	A203345	001	Mar 16, 2018
	ZEGERID OTC				
+	RILEY CONSUMER	20MG;1.1GM	N022281	001	Dec 01, 2009

FOR SUSPENSION;ORAL

ZEGERID OTC

+	RILEY CONSUMER	20MG/PACKET;1.68GM/PACKET	N022283	001	Jun 17, 2013

ORLISTAT

CAPSULE;ORAL

ALLI

+	GLAXOSMITHKLINE CONS	60MG	N021887	001	Feb 07, 2007

OXYBUTYNIN

FILM, EXTENDED RELEASE;TRANSDERMAL

OXYTROL FOR WOMEN

+	ALLERGAN	3.9MG/24HR	N202211	001	Jan 25, 2013

OXYMETAZOLINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

VISINE L.R.

+	JOHNSON AND JOHNSON	0.025%	N019407	001	Mar 31, 1989

PERMETHRIN

LOTION;TOPICAL

NIX

+	MEDTECH PRODUCTS	1%	N019918	001	May 02, 1990

PERMETHRIN

	ACTAVIS MID	1%	A075014	001	Mar 28, 2000
	ATLANTIC				
	PERRIGO NEW YORK	1%	A076090	001	Dec 20, 2001

OTC DRUG PRODUCT LIST

4-19 (of 20)

POLYETHYLENE GLYCOL 3350

FOR SOLUTION;ORAL

MIRALAX

+	!	BAYER HEALTHCARE LLC	17GM/SCOOPFUL	N022015	001	Oct 06, 2006

POLYETHYLENE GLYCOL 3350

		ANI PHARMS	17GM/SCOOPFUL	A202850	001	Dec 15, 2015
		ANNORA PHARMA	17GM/SCOOPFUL	A214990	001	Apr 14, 2021
		AUROBINDO PHARMA LTD	17GM/SCOOPFUL	A209017	001	Apr 09, 2018
		LGM PHARMA	17GM/SCOOPFUL	A090812	001	Oct 07, 2009
		MYLAN	17GM/PACKET	A078915	001	Oct 06, 2009
			17GM/SCOOPFUL	A078915	002	Oct 06, 2009
		NOVEL LABS INC	17GM/SCOOPFUL	A091077	001	Oct 06, 2009
		NOVELGENIX THERAPS	17GM/SCOOPFUL	A202071	001	Dec 28, 2012
		NUVO PHARMS INC	17GM/SCOOPFUL	A206105	001	Oct 28, 2016
		PERRIGO R AND D	17GM/PACKET	A090685	001	Oct 06, 2009
			17GM/SCOOPFUL	A090685	002	Oct 06, 2009
		STRIDES PHARMA	17GM/SCOOPFUL	A079214	001	Jan 31, 2013
			17GM/SCOOPFUL	A203928	001	Aug 24, 2016
			17GM/PACKET	A203928	002	Aug 24, 2016

POTASSIUM IODIDE

SOLUTION;ORAL

POTASSIUM IODIDE

!		MISSION PHARMACAL CO	65MG/ML	A206211	001	Mar 24, 2016

TABLET;ORAL

IOSAT

+		ANBEX	65MG	N018664	002	May 12, 2011
+	!		130MG	N018664	001	Oct 14, 1982

THYROSAFE

!		BTG INTL	65MG	A076350	001	Sep 10, 2002

POVIDONE-IODINE

SOLUTION;TOPICAL

POVIDONE IODINE

+	!	ALLEGIANCE HLTHCARE	1%	N019522	001	Mar 31, 1989

SPONGE;TOPICAL

E-Z SCRUB 201

+	!	BECTON DICKINSON	20%	N019240	001	Nov 29, 1985

E-Z SCRUB 241

+	!	BECTON DICKINSON	10%	N019476	001	Jan 07, 1987

PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

PSEUDOEPHEDRINE HYDROCHLORIDE

		AUROBINDO PHARMA	120MG	A209008	001	Jun 09, 2017
!		L PERRIGO CO	120MG	A075153	001	Feb 26, 1999
		SUN PHARM INDS LTD	120MG	A077442	001	Sep 28, 2005

SUDAFED 24 HOUR

+	!	J AND J CONSUMER INC	240MG	N020021	002	Dec 15, 1992

PURIFIED WATER

SOLUTION;OPHTHALMIC

PUR-WASH

+	!	NIAGARA PHARMS	98.3%	N022305	001	Sep 01, 2011

RANITIDINE HYDROCHLORIDE

TABLET;ORAL

RANITIDINE HYDROCHLORIDE

		DR REDDYS LABS LTD	EQ 75MG BASE	A075294	001	Mar 28, 2000
			EQ 150MG BASE	A078192	001	Aug 31, 2007
		THINQ PHARM-CRO PVT	EQ 75MG BASE	A210250	001	Aug 30, 2019
			EQ 150MG BASE	A210228	001	Aug 30, 2019

TERBINAFINE

GEL;TOPICAL

LAMISIL AT

+	!	GLAXOSMITHKLINE CONS	1%	N021958	001	Jul 24, 2006

OTC DRUG PRODUCT LIST

4-20 (of 20)

TERBINAFINE HYDROCHLORIDE

CREAM; TOPICAL

LAMISIL

+! GLAXOSMITHKLINE 1%

N020980 001 Mar 09, 1999

TERBINAFINE HYDROCHLORIDE

TARO 1%

A077511 001 Jul 02, 2007

SOLUTION; TOPICAL

LAMISIL AT

+! GLAXOSMITHKLINE 1%

N021124 001 Mar 17, 2000

CONS

SPRAY; TOPICAL

LAMISIL AT

+! GLAXOSMITHKLINE 1%

N021124 002 Mar 17, 2000

CONS

TIOCONAZOLE

OINTMENT; VAGINAL

TIOCONAZOLE

PERRIGO 6.5%

A075915 001 Nov 21, 2001

VAGISTAT-1

+! COMBE 6.5%

N020676 001 Feb 11, 1997

TRIAMCINOLONE ACETONIDE

SPRAY, METERED; NASAL

NASACORT ALLERGY 24 HOUR

+! CHATTEM SANOFI 0.055MG/SPRAY

N020468 002 Oct 11, 2013

TRIAMCINOLONE ACETONIDE

PERRIGO PHARMA INTL 0.055MG/SPRAY

A078104 002 Nov 14, 2014

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

0.9% SODIUM CHLORIDE INJECTION USP SOLUTION

INJECTABLE; INJECTION

NONE

FRESENIUS KABI AG

N125695

Sep 05, 2019

ANTICOAGULANT 4% SODIUM CITRATE SOLUTION USP

INJECTABLE; INJECTION

NONE

HAEMONETICS
MANUFACTURING INC

N760305

Jun 30, 1978

NONE

CSL PLASMA INC

A125750

Apr 25, 2022

ANTICOAGULANT CITRATE DEXTROSE SOLUTION (ACD)

INJECTABLE; INJECTION

NONE

CITRA LABS LLC

N020037

Aug 26, 2003

ACD-A SOLUTION

TERUMO BCT INC

A010228

Feb 25, 2002

ADSOL WITH ACD-A

FENWAL INC

N000922

Aug 29, 2002

ANTICOAGULANT CITRATE DEXTROSE SOLUTION FORMULA A

HAEMONETICS CORP

A980728

Feb 06, 2002

AS3 SOLUTION/ACD-A

TERUMO BCT INC

N001214

May 29, 2002

ANTICOAGULANT CITRATE DEXTROSE SOLUTION A

TERUMO BCT INC

A110057

May 11, 2012

ANTICOAGULANT CITRATE DEXTROSE SOLUTION USP

INJECTABLE; INJECTION

NONE

FENWAL INC

N160918

Mar 17, 1978

ANTICOAGULANT CITRATE PHOSPHATE 2X DEXTROSE SOLUTION (CP2D)

INJECTABLE; INJECTION

CITRATE PHOSPHATE DOUBLE DEXTROSE/ADDITIVE SOLUTION 3

HAEMONETICS CORP

N000127

Jan 18, 2002

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE SOLUTION

INJECTABLE; INJECTION

NONE

TERUMO MEDICAL CORP

N820528

Nov 03, 1982

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE SOLUTION (CPDA)

INJECTABLE; INJECTION

CPDA-1 BLOOD-PACK UNIT (PL 146 PLASTIC) 250, 450, 500 ML BLOOD PACK UNITS

FENWAL INC

N770420

May 12, 1978

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE SOLUTION USP

INJECTABLE; INJECTION

BLOOD PACK UNIT CPDA-1 IN PLASTIC CONTAINER

FENWAL INC

N940404

Jul 28, 1994

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE-1 SOLUTION

INJECTABLE; INJECTION

NONE

HAEMONETICS

MANUFACTURING INC

N800077

Nov 06, 1980

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION

INJECTABLE; INJECTION

ADSOL IN PLASTIC CONTAINER

FENWAL INC

N900223

Dec 27, 1991

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION (CPD)

INJECTABLE; INJECTION

CPD ANTICOAGULANT IN PL 2209 PLASTIC CONTAINER

FENWAL INC

N900224

Dec 27, 1991

MACOPRODUCTIONS SAS CPD/AS-1: MACOPHARMA LEUCOFLEX MTL1 LEUKOREDUCTION SYSTEM FOR BLOOD
COMPONENTS KNOWN AS MTL1-WB

MACOPHARMA

N040083

Nov 21, 2005

NONE

TERUMO BCT INC

A070025

Jan 06, 2009

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION USP

INJECTABLE; INJECTION

NONE

FENWAL INC

N170401

Dec 06, 1977

N811012

Jun 28, 1983

PALL CORP

N800222

Aug 23, 1982

TERUMO MEDICAL CORP

N781211

Jun 10, 1981

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION USP WITH: AS-1:
DEXTROSE USP; SODIUM CHLORIDE USP; MANNITOL USP; ADENINE

INJECTABLE; INJECTION

ADSOL RED BLOOD CELL PRESERVATIVE SOLUTION

FENWAL INC

N811104

May 16, 1983

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION USP WITH: AS-5:
DEXTROSE USP; SODIUM CHLORIDE USP; MANNITOL USP; ADENINE

INJECTABLE; INJECTION

OPTISOL RED BLOOD CELL PRESERVATIVE SOLUTION

TERUMO MEDICAL CORP

N880217

Oct 07, 1988

ANTICOAGULANT CITRATE PHOSPHATE DOUBLE DEXTROSE SOLUTION WITH:
AS-3: CITRIC ACID USP; MONOBASIC SODIUM PHOSPHATE USP; SODIUM CHLORIDE USP; ADENINE;
DEXTROSE USP; SODIUM CITRATE USP

INJECTABLE; INJECTION

AS-3 NUTRICEL ADDITIVE SYSTEM

HAEMONETICS

MANUFACTURING INC

0.042GM/100ML;0.276GM/100ML;
0.410GM/100ML;0.30GM/100ML;
1.10GM/100ML;0.588GM/100ML

N820915

Oct 19, 1984

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

ANTICOAGULANT CITRATE PHOSPHATE DOUBLE DEXTROSE SOLUTION WITH:

AS-2: CITRIC ACID USP; DIBASIC SODIUM PHOSPHATE USP; SODIUM CHLORIDE USP; ADENINE;
DEXTROSE USP; SODIUM CITRATE USP

INJECTABLE; INJECTION

AS-2 NUTRICEL ADDITIVE SYSTEM

MEDSEP CORP

0.042GM/100ML;0.285GM/100ML;
0.718GM/100ML;0.017GM/100ML;
0.396GM/100ML;0.588GM/100ML

N820915

Sep 22, 1983

ANTICOAGULANT SODIUM CITRATE 4% SOLUTION

INJECTABLE; INJECTION

NONE

HAEMONETICS CORPORATION

N980123

Mar 03, 2000

LABORATORIES
GRIFOIS, S.A.

A125697

Oct 25, 2019

TERUMO BCT

A125608

Jun 26, 2018

ANTICOAGULANT SODIUM CITRATE SOLUTION

INJECTABLE; INJECTION

TRICITRASOL

CITRA LABS, LLC

N010409

Jul 10, 2003

ANTICOAGULANT SODIUM CITRATE SOLUTION USP

INJECTABLE; INJECTION

NONE

FENWAL INC

N770923

Jan 20, 1978

TERUMO MEDICAL CORP

N781214

Feb 08, 1980

CORD BLOOD STERILE COLLECTION BAG, ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION (CPD)

STERILE CORD BLOOD COLLECTION UNIT

NONE

MACOPHARMA

N125552

Dec 21, 2016

DEXTRAN 1 IN SODIUM CHLORIDE 0.6%

INJECTABLE; INJECTION

PROMIT

MEDA AB

N830715

Oct 30, 1984

DEXTRAN 40, 10% IN DEXTROSE 5%

INJECTABLE; INJECTION

LMD IN GLASS BOTTLE

HOSPIRA INC

10GM/100ML;5GM/100ML

A720563

Oct 30, 1992

DEXTRAN 40, 10% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION

LMD IN PLASTIC CONTAINER

HOSPIRA INC

10GM/100ML;0.9GM/100ML

A720562

Oct 30, 1992

HETASTARCH 6% IN LACTATED ELECTROLYTE INJECTION

INJECTABLE; INJECTION

HEXTEND

BIOTIME INC

6GM/100ML

N200952

Mar 31, 1999

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

HETASTARCH 6% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION

6% HETASTARCH IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

HOSPIRA INC 6GM/100ML;0.9GM/100ML

A740193

Jan 30, 1995

HESPAN IN PLASTIC CONTAINER

B BRAUN MEDICAL INC 6GM/100ML;0.9GM/100ML

N890105

Apr 04, 1991

NONE

TEVA PHARMACEUTICALS 6GM/100ML;0.9GM/100ML

A740592

Nov 12, 1998

USA INC

ISOPLATE SOLUTION IN THE 500 ML EXCEL CONTAINER

STORAGE/PROCESSING SOLUTION ONLY; SHOULD NEVER BE
INFUSED DIRECTLY TO THE PATIENT.

ISOPLATE SOLUTION

TERUMO BCT

N90067

Mar 05, 2013

LEUKOCYTE REDUCTION FILTRATION SYSTEM FOR WHOLE BLOOD WITH CPD ANTICOAGULANT AND
SOLX ADDITIVE

INJECTABLE; INJECTION

LEUKOSEP HWB-600-XL

HEMERUS MEDICAL, LLC

N110059

Apr 25, 2013

RED BLOOD CELL PROCESSING SOLUTION

STORAGE/PROCESSING SOLUTION ONLY; SHOULD NEVER BE
INFUSED DIRECTLY TO THE PATIENT.

REJUVESOL

CITRA LABS LLC

N950522

Feb 26, 1997

SODIUM CHLORIDE; SODIUM ACETATE; SODIUM CITRATE DIHYDRATE; SODIUM PHOSPHATE,
DIABASIC ANHYDROUS; SODIUM PHOSPHATE MONOBASIC, MONOHYDRATE

STORAGE/PROCESSING SOLUTION ONLY; SHOULD NEVER BE
INFUSED DIRECTLY TO THE PATIENT.

INTERSOL SOLUTION

FRESENIUS KABI USA, LLC 2.26GM/500ML;2.21GM/500ML;1.59GM/
500ML;1.53GM/500ML;0.465GM/500ML

N080041

Dec 09, 2009

DISCONTINUED DRUG PRODUCT LIST

6-1(of 478)

** See List Footnote

ABACAVIR SULFATE

TABLET; ORAL

ABACAVIR SULFATE

APOTEX INC

EQ 300MG BASE

A201570 001 Dec 17, 2012

ABACAVIR SULFATE; LAMIVUDINE

TABLET; ORAL

ABACAVIR SULFATE AND LAMIVUDINE

AUROBINDO PHARMA

EQ 600MG BASE; 300MG

A206151 001 Mar 28, 2017

TEVA PHARMS USA

EQ 600MG BASE; 300MG

A079246 001 Sep 29, 2016

ZYDUS PHARMS

EQ 600MG BASE; 300MG

A208990 001 Nov 15, 2018

ABAMETAPIR

LOTION; TOPICAL

KEGLYZE

+ HATCHTECH

0.74%

N206966 001 Jul 24, 2020

ABARELIX

INJECTABLE; INTRAMUSCULAR

PLENAXIS

SPECIALITY EUROPEAN

100MG/VIAL

N021320 001 Nov 25, 2003

ABIRATERONE ACETATE

TABLET; ORAL

ABIRATERONE ACETATE

TEVA PHARMS USA

125MG

A212206 001 Jun 24, 2022

ACAMPROSATE CALCIUM

TABLET, DELAYED RELEASE; ORAL

ACAMPROSATE CALCIUM

BARR LABS DIV TEVA

333MG

A200143 001 Nov 18, 2013

CAMPRAL

+ FOREST LABS

333MG **

N021431 001 Jul 29, 2004

ACARBOSE

TABLET; ORAL

ACARBOSE

HANGZHOU ZHONGMEI

25MG

A213821 001 Aug 18, 2020

50MG

A213821 002 Aug 18, 2020

100MG

A213821 003 Aug 18, 2020

MYLAN

25MG

A091053 001 Jan 06, 2011

50MG

A091053 002 Jan 06, 2011

100MG

A091053 003 Jan 06, 2011

PRECOSE

+ BAYER HLTHCARE

25MG **

N020482 004 May 29, 1997

+

50MG **

N020482 001 Sep 06, 1995

+

100MG **

N020482 002 Sep 06, 1995

ACEBUTOLOL HYDROCHLORIDE

CAPSULE; ORAL

ACEBUTOLOL HYDROCHLORIDE

MYLAN

EQ 200MG BASE

A074288 001 Apr 24, 1995

EQ 400MG BASE

A074288 002 Apr 24, 1995

SECTRAL

+ PROMIUS PHARMA

EQ 200MG BASE **

N018917 001 Dec 28, 1984

+

EQ 400MG BASE **

N018917 003 Dec 28, 1984

ACETAMINOPHEN

INJECTABLE; INJECTION

INJECTAPAP

ORTHO MCNEIL PHARM

100MG/ML

N017785 001 Mar 07, 1986

POWDER; INTRAVENOUS

ACETAMINOPHEN

+ RISING

1GM/VIAL

N206610 001 Jan 15, 2021

SOLUTION; INTRAVENOUS

OFIRMEV

+ MALLINCKRODT HOSP

1GM/100ML (10MG/ML)

N022450 001 Nov 02, 2010

SUPPOSITORY; RECTAL

ACEPHEN

COSETTE

120MG

A072218 001 Mar 27, 1992

325MG

N018060 003 Dec 18, 1986

650MG

N018060 002

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-2(of 478)

** See List Footnote

ACETAMINOPHEN

SUPPOSITORY;RECTAL

ACETAMINOPHEN

ABLE	120MG	A073106	001	Feb 27, 1995
	325MG	A073107	001	Feb 27, 1995
	650MG	A073108	001	Feb 27, 1995
ACINO PRODS	120MG	A071010	001	May 12, 1987
	650MG	A071011	001	May 12, 1987
NEOPAP				
POLYMEDICA	120MG	N016401	001	
TYLENOL				
J AND J CONSUMER INC	120MG	N017756	002	
	650MG	N017756	001	

TABLET, EXTENDED RELEASE;ORAL

ACETAMINOPHEN

SUN PHARM INDS LTD	650MG	A090205	001	Nov 18, 2009

ACETAMINOPHEN; ASPIRIN; CODEINE PHOSPHATE

CAPSULE;ORAL

ACETAMINOPHEN, ASPIRIN, AND CODEINE PHOSPHATE

MIKART	150MG;180MG;15MG	A081095	001	Oct 26, 1990
	150MG;180MG;30MG	A081096	001	Oct 26, 1990
	150MG;180MG;60MG	A081097	001	Oct 26, 1990

CODEINE, ASPIRIN, APAP FORMULA NO. 2

+ SCHERER LABS	150MG;180MG;15MG	A085640	001	

CODEINE, ASPIRIN, APAP FORMULA NO. 3

+ SCHERER LABS	150MG;180MG;30MG	A085639	001	

CODEINE, ASPIRIN, APAP FORMULA NO. 4

SCHERER LABS	150MG;180MG;60MG	A085638	001	

ACETAMINOPHEN; BUTALBITAL

CAPSULE;ORAL

BANCAP

FOREST PHARMS	325MG;50MG	A088889	001	Jan 16, 1986

BUCET

MALLINCKRODT	650MG;50MG	A088991	001	Jun 28, 1985

PHRENILIN FORTE

VALEANT	650MG;50MG	A088831	001	Jun 19, 1985

TENCON

MALLINCKRODT	650MG;50MG	A089405	001	May 15, 1990

TRIAPRIN

DUNHALL	325MG;50MG	A089268	001	Jul 02, 1987

TABLET;ORAL

BUTALBITAL AND ACETAMINOPHEN

ALVOGEN	325MG;50MG	A205120	001	Oct 30, 2015

HALSEY	325MG;50MG	A089568	001	Oct 05, 1988

+ WATSON LABS	325MG;50MG	A087550	001	Oct 19, 1984

BUTAPAP

MIKART	650MG;50MG	A089988	001	Oct 26, 1992

PHRENILIN

+ VALEANT	325MG;50MG **	A087811	001	Jun 19, 1985

SEDAPAP

MAYRAND	650MG;50MG	A088944	001	Oct 17, 1985

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE;ORAL

ANOQUAN

SHIRE	325MG;50MG;40MG	A087628	001	Oct 01, 1986

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

+ GILBERT LABS	325MG;50MG;40MG **	A088825	001	Dec 05, 1984

GRAHAM DM	325MG;50MG;40MG	A088743	001	Jul 18, 1985

	325MG;50MG;40MG	A088765	001	Mar 27, 1985

	325MG;50MG;40MG	A089067	001	Apr 19, 1985

HIKMA	300MG;50MG;40MG	A215135	001	Mar 25, 2022

	325MG;50MG;40MG	A215135	002	Mar 25, 2022

	500MG;50MG;40MG	A040261	001	Oct 28, 1998

MALLINCKRODT	325MG;50MG;40MG	A088758	001	Mar 27, 1985

ESGIC-PLUS

MIKART	500MG;50MG;40MG	A040085	001	Mar 28, 1996

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-3(of 478)

** See List Footnote

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL

FEMCET

MALLINCKRODT 325MG; 50MG; 40MG A089102 001 Jun 19, 1985

MEDIGESIC PLUS

US CHEM 325MG; 50MG; 40MG A089115 001 Jan 14, 1986

TRIAD

MALLINCKRODT 325MG; 50MG; 40MG A089023 001 Jun 19, 1985

TABLET; ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

ABLE 325MG; 50MG; 40MG A040390 001 Jul 23, 2001

500MG; 50MG; 40MG A040394 001 Jul 23, 2001

ALVOGEN 325MG; 50MG; 40MG A204984 001 Jan 10, 2017

GILBERT LABS 325MG; 50MG; 40MG A087629 001 Nov 13, 1984

HIKMA 500MG; 50MG; 40MG A040336 001 Aug 18, 1999

HIKMA PHARMS 325MG; 50MG; 40MG A089718 001 Jun 12, 1995

MIKART 750MG; 50MG; 40MG A040496 001 Dec 23, 2003

MIRROR PHARMS LLC 500MG; 50MG; 40MG A040883 001 Dec 23, 2008

NESHER PHARMS 325MG; 50MG; 40MG A211543 001 Jul 17, 2020

SPECGX LLC 325MG; 50MG; 40MG A087804 001 Jan 24, 1985

SUN PHARM INDUSTRIES 325MG; 50MG; 40MG A040601 001 Jul 29, 2005

VINTAGE PHARMS 500MG; 50MG; 40MG A040513 001 Aug 25, 2003

WATSON LABS 325MG; 50MG; 40MG A089536 001 Feb 16, 1988

500MG; 50MG; 40MG A040267 001 Jul 30, 1998

ESGIC

FOREST PHARMS 325MG; 50MG; 40MG A089660 001 Dec 23, 1988

ESGIC-PLUS

MIKART 500MG; 50MG; 40MG A089451 001 May 23, 1988

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE

ABLE 325MG; 50MG; 40MG; 30MG A076528 001 Aug 21, 2003

HIKMA INTL PHARMS 325MG; 50MG; 40MG; 30MG A075618 001 Mar 23, 2001

PHRENILIN WITH CAFFEINE AND CODEINE

VALEANT 325MG; 50MG; 40MG; 30MG A074911 001 Aug 22, 2001

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE; ORAL

ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE

MIKART 356.4MG; 30MG; 16MG A040109 001 Aug 26, 1997

WRASER PHARMS LLC 356.4MG; 30MG; 16MG A040688 001 Apr 03, 2007

DHC PLUS

PHARM RES ASSOC 356.4MG; 30MG; 16MG A088584 001 Mar 04, 1986

SYNALGOS-DC-A

LEITNER PHARMS 356.4MG; 30MG; 16MG A089166 001 May 14, 1986

TABLET; ORAL

ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE

BOCA PHARMA LLC 712.8MG; 60MG; 32MG A040701 001 Apr 03, 2007

MIKART 712.8MG; 60MG; 32MG A040316 001 Apr 28, 1999

WEST-WARD PHARM CORP 712.8MG; 60MG; 32MG A040637 001 Sep 22, 2006

ACETAMINOPHEN; CLEMASTINE FUMARATE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET; ORAL

TAVIST ALLERGY/SINUS/HEADACHE

NOVARTIS 500MG; EQ 0.25MG BASE; 30MG N021082 001 Mar 01, 2001

ACETAMINOPHEN; CODEINE PHOSPHATE

CAPSULE; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

TEVA 300MG; 15MG A088537 001 Jun 04, 1984

300MG; 30MG A088324 001 Dec 29, 1983

300MG; 60MG A088599 001 Jun 01, 1984

PHENAPHEN W/ CODEINE NO. 2

ROBINS AH 325MG; 15MG A084444 001

PHENAPHEN W/ CODEINE NO. 3

+ ROBINS AH 325MG; 30MG A084445 001

PHENAPHEN W/ CODEINE NO. 4

+ ROBINS AH 325MG; 60MG A084446 001

PROVAL #3

SOLVAY 325MG; 30MG A085685 001

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-4(of 478)

** See List Footnote

ACETAMINOPHEN; CODEINE PHOSPHATE

CAPSULE;ORAL

TYLENOL W/ CODEINE NO. 3

ORTHO MCNEIL PHARM 300MG;30MG

A087422 001

TYLENOL W/ CODEINE NO. 4

ORTHO MCNEIL PHARM 300MG;60MG

A087421 001

SOLUTION;ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

ACI 120MG/5ML;12MG/5ML

A086366 001

+ ACTAVIS MID ATLANTIC 120MG/5ML;12MG/5ML

A085861 001

CHARTWELL MOLECULAR 120MG/5ML;12MG/5ML

A091238 001 Nov 10, 2011

DAVA PHARMS INC 120MG/5ML;12MG/5ML

A040098 001 Sep 20, 1996

WOCKHARDT BIO AG 120MG/5ML;12MG/5ML

A087006 001

TYLENOL W/ CODEINE

+ ORTHO MCNEIL PHARM 120MG/5ML;12MG/5ML

A085057 001

SUSPENSION;ORAL

CAPITAL AND CODEINE

ACTAVIS MID ATLANTIC 120MG/5ML;12MG/5ML

A085883 001

VALEANT PHARMS LLC 120MG/5ML;12MG/5ML

A086024 001

TABLET;ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

ABLE 300MG;30MG

A040452 001 Aug 01, 2002

300MG;60MG

A040459 001 Aug 01, 2002

AM THERAP 300MG;15MG

A089478 001 Mar 03, 1987

300MG;15MG

A089481 001 Mar 03, 1987

300MG;30MG

A089479 001 Mar 03, 1987

300MG;30MG

A089482 001 Mar 03, 1987

300MG;60MG

A089480 001 Mar 03, 1987

300MG;60MG

A089483 001 Mar 03, 1987

CHARTWELL 300MG;15MG

A089997 001 Dec 28, 1994

300MG;30MG

A089998 001 Dec 28, 1994

300MG;60MG

A089999 001 Dec 28, 1994

DURAMED PHARMS BARR 300MG;15MG

A040223 001 Nov 18, 1997

300MG;15MG

A088353 001 Feb 06, 1984

300MG;30MG

A040223 002 Nov 18, 1997

300MG;30MG

A088354 001 Feb 06, 1984

300MG;60MG

A040223 003 Nov 18, 1997

300MG;60MG

A088355 001 Feb 06, 1984

EVERYLIFE 325MG;30MG

A085217 001

FOSUN PHARMA 300MG;30MG

A081250 001 Jul 16, 1992

300MG;60MG

A081249 001 Jul 16, 1992

HALSEY 300MG;15MG

A083871 001

300MG;30MG

A083872 001

300MG;60MG

A086549 001

KV PHARM 300MG;30MG

A085288 001

300MG;60MG

A085365 001

325MG;15MG

A085364 001

325MG;45MG **

A085363 001

LEDERLE 300MG;30MG

A087141 001

MIKART 300MG;30MG

A089238 001 Feb 25, 1986

300MG;60MG

A089244 001 Feb 25, 1986

650MG;30MG

A089231 001 Mar 03, 1986

650MG;60MG

A089363 001 Sep 09, 1991

MUTUAL PHARM 300MG;15MG

A085795 001

300MG;30MG

A085794 001

300MG;60MG

A087653 001 Apr 13, 1982

PURACAP PHARM 300MG;30MG

A087762 001 Dec 10, 1982

+ PUREPAC PHARM 300MG;30MG

A086681 001

300MG;30MG

A089080 001 Jul 17, 1986

300MG;60MG

A086683 001

RHODES PHARMS 300MG;15MG

A089673 002 Feb 10, 1988

300MG;30MG

A089673 003 Feb 10, 1988

300MG;60MG

A089673 001 Feb 10, 1988

ROXANE 300MG;15MG

A084659 001

300MG;30MG

A084656 001

300MG;60MG

A084667 001

500MG;15MG

A089511 001 Apr 25, 1989

500MG;30MG

A089512 001 Apr 25, 1989

500MG;60MG

A089513 001 Apr 25, 1989

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-5(of 478)

** See List Footnote

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

+	SANDOZ	300MG;15MG	A087433	001	
		300MG;30MG	A085291	002	
+		300MG;30MG	A085917	001	
		300MG;60MG	A085964	001	
		300MG;60MG	A087423	001	
	STRIDES PHARMA	300MG;15MG	A089990	001	Sep 30, 1988
		300MG;30MG	A089805	001	Sep 30, 1988
		300MG;60MG	A089828	001	Sep 30, 1988
	SUPERPHARM	300MG;15MG	A089183	001	Oct 18, 1985
		300MG;30MG	A089184	001	Oct 18, 1985
		300MG;30MG	A089253	001	May 19, 1986
		300MG;60MG	A089185	001	Oct 18, 1985
		300MG;60MG	A089254	001	May 19, 1986
	USL PHARMA	300MG;30MG	A087919	001	Jun 22, 1982
		300MG;60MG	A087920	001	Jun 22, 1982
	VALEANT PHARM INTL	300MG;30MG	A085896	001	
	VITARINE	300MG;30MG	A085676	001	
	WARNER CHILCOTT	300MG;15MG	A085992	001	
		300MG;30MG	A085218	002	
		300MG;60MG	A087306	001	
	WATSON LABS	300MG;15MG	A087277	001	May 26, 1982
		300MG;30MG	A087276	001	May 26, 1982
		300MG;60MG	A087275	001	May 26, 1982
	WATSON LABS FLORIDA	300MG;15MG	A040443	001	Jan 22, 2003
		300MG;30MG	A040443	002	Jan 22, 2003
		300MG;60MG	A040443	003	Jan 22, 2003
	WHITEWORTH TOWN PLSN	300MG;30MG	A084360	001	
		300MG;60MG	A085607	001	
	CAPITAL AND CODEINE				
	CARNRICK	325MG;30MG	A083643	001	
	CODRIX				
	WATSON LABS FLORIDA	500MG;15MG	A040447	001	Feb 26, 2003
		500MG;30MG	A040441	001	Mar 27, 2003
		500MG;60MG	A040488	001	Mar 28, 2003
	EMPRACET W/ CODEINE PHOSPHATE #3				
	GLAXOSMITHKLINE	300MG;30MG	A083951	001	
	EMPRACET W/ CODEINE PHOSPHATE #4				
	GLAXOSMITHKLINE	300MG;60MG	A083951	002	
	PAPA-DEINE #3				
	VANGARD	300MG;30MG	A088037	001	Mar 20, 1984
	PAPA-DEINE #4				
	VANGARD	300MG;60MG	A088715	001	Mar 20, 1984
	PHENAPHEN-650 W/ CODEINE				
	ROBINS AH	650MG;30MG	A085856	001	
	TYLENOL W/ CODEINE				
	ORTHO MCNEIL PHARM	325MG;7.5MG **	A085056	001	
		325MG;15MG **	A085056	002	
		325MG;30MG **	A085056	003	
		325MG;60MG **	A085056	004	
	TYLENOL W/ CODEINE NO. 1				
	JANSSEN PHARMS	300MG;7.5MG	A085055	001	
	TYLENOL W/ CODEINE NO. 2				
	+ JANSSEN PHARMS	300MG;15MG	A085055	002	
	TYLENOL W/ CODEINE NO. 3				
	+ JANSSEN PHARMS	300MG;30MG	A085055	003	
	TYLENOL W/ CODEINE NO. 4				
	+ JANSSEN PHARMS	300MG;60MG	A085055	004	

ACETAMINOPHEN; DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

DRIXORAL PLUS

	SCHERING PLOUGH	500MG;3MG;60MG	N019453	001	May 22, 1987

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-6(of 478)

** See List Footnote

ACETAMINOPHEN; HYDROCODONE BITARTRATE

CAPSULE; ORAL

ACETAMINOPHEN AND HYDROCODONE BITARTRATE

CENT PHARMS	500MG; 5MG	A088898	001	Mar 27, 1985
ALLAY				
IVAX PHARMS	500MG; 5MG	A089907	001	Jan 13, 1989
BANCAP HC				
FOREST PHARMS	500MG; 5MG	A087961	001	Mar 17, 1983
CO-GESIC				
CENT PHARMS	500MG; 5MG	A089360	001	Mar 02, 1988
HYDROCODONE BITARTRATE AND ACETAMINOPHEN				
MALLINCKRODT	500MG; 5MG	A088956	001	Jul 19, 1985
	500MG; 5MG	A089006	001	Aug 09, 1985
MIKART	500MG; 5MG	A081067	001	Nov 30, 1989
	500MG; 5MG	A081068	001	Nov 30, 1989
	500MG; 5MG	A081069	001	Nov 30, 1989
	500MG; 5MG	A081070	001	Nov 30, 1989
	500MG; 5MG	A089008	001	Feb 21, 1986
LORCET-HD				
MALLINCKRODT	500MG; 5MG	A087336	001	Jul 08, 1982

SOLUTION; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

MALLINCKRODT	500MG/15ML; 7.5MG/15ML	A040418	001	Jun 27, 2001
MALLINCKRODT INC	500MG/15ML; 10MG/15ML	A040508	001	Aug 29, 2003
MIKART	500MG/15ML; 5MG/15ML	A081226	001	Oct 27, 1992
	500MG/15ML; 5MG/15ML	A089557	001	Apr 29, 1992
	500MG/15ML; 7.5MG/15ML	A081051	001	Aug 28, 1992
NESHER PHARMS	500MG/15ML; 7.5MG/15ML	A040366	001	Jan 23, 2002
PHARM ASSOC	500MG/15ML; 7.5MG/15ML	A040182	001	Mar 13, 1998
TRIS PHARMA INC	300MG/15ML; 10MG/15ML	A201295	002	Dec 30, 2021
	325MG/15ML; 7.5MG/15ML	A201295	001	Dec 30, 2021
VINTAGE PHARMS	500MG/15ML; 7.5MG/15ML	A040520	001	Oct 30, 2003
ZYFREL				
CYPRESS PHARM INC	325MG/15ML; 7.5MG/15ML	A090468	001	Apr 14, 2016

TABLET; ORAL

ANEXSIA

MALLINCKRODT	500MG; 5MG	A089160	001	Apr 23, 1987
	750MG; 10MG	A040468	001	Oct 31, 2002
ANEXSIA 7.5/650				
MALLINCKRODT	650MG; 7.5MG	A089725	001	Sep 30, 1987
CO-GESIC				
UCB INC	500MG; 5MG	A087757	001	May 03, 1982
DURADYNE DHC				
FOREST PHARMS	500MG; 5MG	A087809	001	Mar 17, 1983
HY-PHEN				
ASCHER	500MG; 5MG	A087677	001	May 03, 1982
HYDROCODONE BITARTRATE AND ACETAMINOPHEN				
ABLE	325MG; 5MG	A040478	001	Nov 08, 2002
	325MG; 7.5MG	A040464	001	Oct 23, 2002
	325MG; 10MG	A040464	002	Oct 23, 2002
	500MG; 5MG	A040477	001	Nov 06, 2002
	500MG; 7.5MG	A040490	001	May 21, 2003
	500MG; 10MG	A040473	001	Nov 06, 2002
	650MG; 7.5MG	A040474	001	Jan 02, 2003
	650MG; 10MG	A040476	001	Oct 23, 2002
	750MG; 7.5MG	A040469	001	Oct 25, 2002
ACTAVIS LABS FL INC	300MG; 5MG	A206470	001	Jun 02, 2016
	300MG; 7.5MG	A206470	002	Jun 02, 2016
	300MG; 10MG	A206470	003	Jun 02, 2016
ALVOGEN	300MG; 5MG	A208540	001	Nov 08, 2018
	300MG; 7.5MG	A208540	002	Nov 08, 2018
	300MG; 10MG	A208540	003	Nov 08, 2018
	325MG; 2.5MG	A209958	001	Oct 24, 2018
	325MG; 5MG	A209958	002	Oct 24, 2018
	325MG; 7.5MG	A209958	003	Oct 24, 2018
	325MG; 10MG	A209958	004	Oct 24, 2018
AMNEAL PHARMS NY	500MG; 5MG	A040729	001	Aug 25, 2006
	500MG; 7.5MG	A040748	001	Aug 25, 2006
	500MG; 10MG	A040813	001	Feb 23, 2007

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-7(of 478)

** See List Footnote

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET;ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

	650MG;7.5MG	A040754	001	Aug 25, 2006
	650MG;10MG	A040757	001	Aug 25, 2006
	750MG;7.5MG	A040769	001	Aug 28, 2006
APIL	500MG;10MG	A040148	002	Feb 14, 1997
BARR	500MG;2.5MG	A040307	001	Jul 26, 2000
	500MG;5MG	A040308	001	Jul 26, 2000
	500MG;5MG	A088577	001	Dec 21, 1984
	500MG;7.5MG	A040307	002	Jul 26, 2000
	500MG;10MG	A040309	001	Jul 26, 2000
	650MG;7.5MG	A040307	003	Jul 26, 2000
	650MG;10MG	A040307	004	Jul 26, 2000
	750MG;7.5MG	A040308	002	Jul 26, 2000
CARACO	500MG;5MG	A090265	001	Dec 23, 2008
	500MG;7.5MG	A090265	002	Dec 23, 2008
	500MG;10MG	A090265	003	Dec 23, 2008
	650MG;7.5MG	A090380	001	Dec 23, 2008
	650MG;10MG	A090380	002	Dec 23, 2008
	660MG;10MG	A090380	003	Dec 23, 2008
	750MG;7.5MG	A090380	004	Dec 23, 2008
CEROVENE INC	325MG;5MG	A211690	001	Feb 07, 2020
	325MG;7.5MG	A211690	002	Feb 07, 2020
	325MG;10MG	A211690	003	Feb 07, 2020
CHARTWELL	325MG;7.5MG	A040248	001	Apr 28, 2000
	325MG;10MG	A040248	002	Apr 28, 2000
GRANULES	325MG;5MG	A211729	001	Jan 03, 2020
	325MG;7.5MG	A211729	002	Jan 03, 2020
	325MG;10MG	A211729	003	Jan 03, 2020
HALSEY	500MG;5MG	A089554	001	Jun 12, 1987
IVAX PHARMS	500MG;5MG	A089696	001	Apr 21, 1988
LANNETT CO INC	300MG;5MG	A207171	001	Jun 20, 2017
	300MG;7.5MG	A207171	002	Jun 20, 2017
	300MG;10MG	A207171	003	Jun 20, 2017
	325MG;5MG	A207172	001	Jun 22, 2017
	325MG;7.5MG	A207172	002	Jun 22, 2017
	325MG;10MG	A207172	003	Jun 22, 2017
MALLINCKRODT	500MG;5MG	A040084	002	Jun 01, 1995
	500MG;7.5MG	A040201	001	Feb 27, 1998
	500MG;10MG	A040201	002	Feb 27, 1998
	650MG;10MG	A040084	004	Oct 16, 1996
	660MG;10MG	A040084	003	Jul 29, 1996
	750MG;7.5MG	A040084	001	Jun 01, 1995
MIKART	325MG;2.5MG	A040846	001	Jun 09, 2010
	500MG;2.5MG	A089698	001	Aug 25, 1989
	500MG;5MG	A089271	001	Jul 16, 1986
	500MG;5MG	A089697	001	Jan 28, 1992
	500MG;7.5MG	A089699	001	Aug 25, 1989
	650MG;5MG	A040849	001	Jun 09, 2010
	650MG;7.5MG	A089689	001	Jun 29, 1988
	650MG;10MG	A081223	001	May 29, 1992
MUTUAL PHARM	500MG;5MG	A040236	001	Sep 25, 1997
	650MG;7.5MG	A040240	002	Nov 26, 1997
	650MG;10MG	A040240	001	Nov 26, 1997
	750MG;7.5MG	A040236	002	Sep 25, 1997
NOSTRUM LABS INC	325MG;2.5MG	A209924	001	Nov 16, 2018
	325MG;5MG	A209924	002	Nov 16, 2018
	325MG;7.5MG	A209924	003	Nov 16, 2018
	325MG;10MG	A209924	004	Nov 16, 2018
RANBAXY	500MG;5MG	A040825	001	Aug 16, 2007
	500MG;10MG	A040824	001	Aug 16, 2007
RANBAXY LABS LTD	750MG;7.5MG	A040822	001	Aug 16, 2007
SANDOZ	500MG;5MG	A040149	001	Jan 27, 1997
	750MG;7.5MG	A040149	002	Jan 27, 1997
STRIDES PHARMA	300MG;5MG	A205001	001	Jul 05, 2016
	300MG;7.5MG	A205001	002	Jul 05, 2016
	300MG;10MG	A205001	003	Jul 05, 2016
SUN PHARM INDS LTD	325MG;10MG	A040826	001	Aug 16, 2007

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-8(of 478)

** See List Footnote

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

UCB INC	500MG;10MG	A040210	001	Aug 13, 1997
	650MG;7.5MG	A040134	001	Nov 21, 1996
UPSHER SMITH LABS	325MG;5MG	A206484	001	Mar 24, 2017
	325MG;7.5MG	A206484	002	Mar 24, 2017
USL PHARMA	325MG;10MG	A206484	003	Mar 24, 2017
	500MG;5MG	A089290	001	May 29, 1987
VINTAGE PHARMS	500MG;5MG	A089291	001	May 29, 1987
	300MG;5MG	A090415	001	Jan 24, 2011
	300MG;7.5MG	A090415	002	Jan 24, 2011
	300MG;10MG	A090415	003	Jan 24, 2011
	500MG;2.5MG	A040144	002	Apr 25, 1997
	500MG;5MG	A089831	001	Sep 07, 1988
	500MG;5MG	A089971	001	Dec 02, 1988
	500MG;7.5MG	A040144	001	Feb 22, 1996
	500MG;10MG	A040356	001	May 31, 2000
	650MG;7.5MG	A040155	001	Apr 14, 1997
	650MG;10MG	A040143	001	Feb 22, 1996
	660MG;10MG	A040358	001	May 31, 2000
	750MG;7.5MG	A040157	001	Apr 12, 1996
	500MG;5MG	A040281	001	Sep 30, 1998
VINTAGE PHARMS LLC	500MG;7.5MG	A040280	001	Sep 30, 1998
	650MG;7.5MG	A040280	002	Sep 30, 1998
	650MG;10MG	A040280	003	Sep 30, 1998
	750MG;7.5MG	A040281	002	Sep 30, 1998
WATSON LABS	500MG;2.5MG	A040123	003	Mar 04, 1996
	500MG;2.5MG	A081079	001	Aug 30, 1991
	500MG;5MG	A040122	001	Mar 04, 1996
	500MG;5MG	A089883	001	Dec 01, 1988
	500MG;7.5MG	A040123	004	Mar 04, 1996
	500MG;7.5MG	A081080	001	Aug 30, 1991
	650MG;7.5MG	A040094	001	Sep 29, 1995
	650MG;7.5MG	A040123	001	Mar 04, 1996
	650MG;10MG	A040094	002	Sep 29, 1995
	650MG;10MG	A040123	002	Mar 04, 1996
	660MG;10MG	A040094	003	Aug 08, 2000
	750MG;7.5MG	A040122	002	Mar 04, 1996
	750MG;7.5MG	A081083	001	Aug 30, 1991
	750MG;10MG	A040094	004	Mar 22, 1999
WATSON LABS FLORIDA	500MG;5MG	A040493	001	May 28, 2003
	660MG;10MG	A040495	001	May 28, 2003
	750MG;7.5MG	A040494	001	May 28, 2003
LORTAB				
UCB INC	500MG;5MG	A087722	001	Jul 09, 1982
	500MG;10MG	A040100	001	Jan 26, 1996
NORCET				
ABANA	500MG;5MG	A088871	001	May 15, 1986
NORCO				
APIL	325MG;2.5MG	A040148	004	Jul 07, 2014
	325MG;5MG	A040099	001	Jun 25, 1997
	325MG;5MG	A040148	005	Jul 07, 2014
	325MG;7.5MG	A040148	003	Sep 12, 2000
	325MG;10MG	A040148	001	Feb 14, 1997
TYCOLET				
ORTHO MCNEIL PHARM	500MG;5MG	A089385	001	Aug 27, 1986
VICODIN				
ABBOTT	500MG;5MG	A085667	001	
ABBVIE	500MG;5MG	A088058	001	Jan 07, 1983
VICODIN ES				
ABBVIE	750MG;7.5MG	A089736	001	Dec 09, 1988
VICODIN HP				
ABBVIE	660MG;10MG	A040117	001	Sep 23, 1996
ZYDONE				
VINTAGE PHARMS LLC	400MG;5MG	A040288	001	Nov 27, 1998
	400MG;7.5MG	A040288	002	Nov 27, 1998
	400MG;10MG	A040288	003	Nov 27, 1998

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-9(of 478)

** See List Footnote

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

CAPSULE; ORAL

OXYCODONE AND ACETAMINOPHEN

ACTAVIS ELIZABETH	500MG; 5MG	A040199	001	Dec 30, 1998
BARR	500MG; 5MG	A040304	001	Oct 02, 2000
DURAMED PHARMS BARR	500MG; 5MG	A040289	001	Mar 16, 1999
HALSEY	500MG; 5MG	A089994	001	May 04, 1989
MALLINCKRODT	500MG; 5MG	A040257	001	Aug 04, 1998
MUTUAL PHARM	500MG; 5MG	A040219	001	Jan 22, 1998
VINTAGE PHARMS	500MG; 5MG	A040106	001	Jul 30, 1996
VINTAGE PHARMS LLC	500MG; 5MG	A040303	001	Dec 30, 1999
WATSON LABS	500MG; 5MG	A040234	001	Oct 30, 1997

ROXILOX

ROXANE	500MG; 5MG	A040061	001	Jul 03, 1995

TYLOX

JANSSEN PHARMS	500MG; 5MG	A088790	001	Dec 12, 1984

TYLOX-325

ORTHO MCNEIL PHARM	325MG; 5MG	A088246	001	Nov 08, 1984

SOLUTION; ORAL

OXYCODONE AND ACETAMINOPHEN

SPECGX LLC	325MG/5ML; 5MG/5ML	A040680	001	Sep 29, 2006

OXYCODONE HYDROCHLORIDE AND ACETAMINOPHEN

VINTAGE PHARMS	325MG/5ML; 5MG/5ML	A203573	001	Dec 18, 2014

ROXICET

HIKMA	325MG/5ML; 5MG/5ML	A089351	001	Dec 03, 1986

TABLET; ORAL

OXYCODONE 2.5/APAP 500

BRISTOL MYERS SQUIBB	500MG; 2.5MG	A085910	001	

OXYCODONE 5/APAP 500

BRISTOL MYERS SQUIBB	500MG; 5MG	A085911	001	

OXYCODONE AND ACETAMINOPHEN

ACTAVIS ELIZABETH	325MG; 5MG	A040203	001	Mar 15, 1999
	325MG; 7.5MG	A040800	001	Apr 03, 2012
	325MG; 10MG	A040800	002	Apr 03, 2012
AMNEAL PHARMS NY	500MG; 7.5MG	A040789	001	Nov 27, 2007
	650MG; 10MG	A040789	002	Nov 27, 2007
BARR	325MG; 5MG	A087406	001	
CEROVENE INC	325MG; 5MG	A207574	001	Dec 13, 2016
DURAMED PHARMS BARR	325MG; 5MG	A040272	001	Jun 30, 1998
GRANULES	325MG; 2.5MG	A211708	001	Oct 31, 2019
	325MG; 5MG	A211708	002	Oct 31, 2019
	325MG; 7.5MG	A211708	003	Oct 31, 2019
	325MG; 10MG	A211708	004	Oct 31, 2019
LANNETT CO INC	325MG; 5MG	A207333	001	Sep 25, 2017
	325MG; 10MG	A207333	002	Sep 25, 2017
MALLINCKRODT	500MG; 7.5MG	A040550	001	Jun 30, 2004
	650MG; 10MG	A040550	002	Jun 30, 2004
MAYNE PHARMA INC	500MG; 7.5MG	A090177	005	Oct 20, 2008
	650MG; 10MG	A090177	006	Oct 20, 2008
MIKART	400MG; 2.5MG	A040679	001	May 16, 2006
	400MG; 5MG	A040687	001	Apr 27, 2006
	400MG; 7.5MG	A040698	001	Apr 27, 2006
	400MG; 10MG	A040692	001	Apr 27, 2006
	500MG; 10MG	A040676	001	Apr 19, 2006
NESHER PHARMS	325MG; 2.5MG	A210079	001	Dec 28, 2017
	325MG; 5MG	A210079	002	Dec 28, 2017
	325MG; 7.5MG	A210079	003	Dec 28, 2017
	325MG; 10MG	A210079	004	Dec 28, 2017
NOSTRUM LABS INC	325MG; 5MG	A209385	001	Jul 02, 2018
	325MG; 7.5MG	A209385	002	Jul 02, 2018
	325MG; 10MG	A209385	003	Jul 02, 2018
VINTAGE PHARMS	325MG; 2.5MG	A090733	001	Jul 11, 2013
	325MG; 5MG	A040105	001	Jul 30, 1996
	325MG; 7.5MG	A090734	001	Jul 11, 2013
	325MG; 10MG	A090734	002	Jul 11, 2013
WATSON LABS	325MG; 5MG	A040171	001	Oct 30, 1997
	325MG; 7.5MG	A040535	001	Sep 05, 2003
	325MG; 10MG	A040535	002	Sep 05, 2003
	500MG; 7.5MG	A040371	001	Dec 29, 2000

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-10(of 478)

** See List Footnote

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

TABLET;ORAL

OXYCODONE AND ACETAMINOPHEN

650MG;10MG

A040371 002 Dec 29, 2000

PERCOCET

+ VINTAGE PHARMS LLC

325MG;5MG

A085106 002

500MG;7.5MG

A040341 001 Jul 26, 1999

650MG;10MG

A040341 002 Jul 26, 1999

ROXICET

+ HIKMA

325MG;5MG

A087003 001

ROXICET 5/500

ROXANE

500MG;5MG

A089775 001 Jan 12, 1989

TABLET, EXTENDED RELEASE;ORAL

XARTEMIS XR

+ MALLINCKRODT INC

325MG;7.5MG

N204031 001 Mar 11, 2014

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE

CAPSULE;ORAL

TYLOX

ORTHO MCNEIL PHARM

500MG;4.5MG;0.38MG

A085375 001

ACETAMINOPHEN; PENTAZOCINE HYDROCHLORIDE

TABLET;ORAL

ACETAMINOPHEN AND PENTAZOCINE HYDROCHLORIDE

GAVIS PHARMS

650MG;EQ 25MG BASE

A076202 001 Aug 02, 2002

WATSON LABS

650MG;EQ 25MG BASE

A074699 001 Mar 24, 2000

TALACEN

SANOFI AVENTIS US

650MG;EQ 25MG BASE

N018458 001 Sep 23, 1982

ACETAMINOPHEN; PROPOXYPHENE HYDROCHLORIDE

TABLET;ORAL

DARVOCET

AAIPHARMA LLC

325MG;32.5MG

N016844 001

DOLENE AP-65

LEDERLE

650MG;65MG

A085100 001

PROPOXYPHENE HYDROCHLORIDE AND ACETAMINOPHEN

MYLAN

325MG;32MG

A083689 001

650MG;65MG

A083978 001

SANDOZ

650MG;65MG

A089959 001 Jul 18, 1989

VINTAGE PHARMS

650MG;65MG

A040507 001 Jul 30, 2003

WATSON LABS

650MG;65MG

A040139 001 Dec 16, 1996

WYGESIC

CARACO

650MG;65MG

A084999 001

ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE

TABLET;ORAL

DARVOCET A500

XANODYNE PHARM

500MG;100MG

A076429 001 Sep 10, 2003

DARVOCET-N 100

XANODYNE PHARM

650MG;100MG

N017122 002

DARVOCET-N 50

XANODYNE PHARM

325MG;50MG

N017122 001

PROPACET 100

TEVA

650MG;100MG

A070107 001 Jun 12, 1985

PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN

ABLE

650MG;100MG

A075838 001 Jul 11, 2001

ACTAVIS ELIZABETH

650MG;100MG

A070910 001 Jan 02, 1987

CORNERSTONE

325MG;100MG

A076743 001 May 07, 2004

500MG;100MG

A076750 001 Jun 28, 2004

HALSEY

325MG;50MG

A072105 001 May 13, 1988

650MG;100MG

A072106 001 May 13, 1988

IVAX SUB TEVA PHARMS

650MG;100MG

A070146 001 Aug 02, 1985

MALLINCKRODT

650MG;100MG

A075738 001 Feb 02, 2001

MIRROR PHARMS

650MG;100MG

A077821 001 Feb 11, 2008

MUTUAL PHARM

325MG;50MG

A070115 001 Jun 12, 1985

650MG;100MG

A070116 001 Jun 12, 1985

650MG;100MG

A070615 001 Mar 21, 1986

650MG;100MG

A070771 001 Mar 21, 1986

650MG;100MG

A070775 001 Mar 21, 1986

MYLAN

650MG;100MG

A072195 001 Feb 16, 1988

MYLAN PHARMS INC

650MG;100MG

A070145 001 Jun 12, 1985

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-11(of 478)

** See List Footnote

ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE

TABLET;ORAL

PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN

SANDOZ	650MG;100MG	A070443	001	Jan 23, 1986
SUPERPHARM	650MG;100MG	A071319	001	Jan 06, 1987
TEVA	650MG;100MG	A070732	001	Jan 03, 1986
	650MG;100MG	A074119	001	Dec 19, 1994
VINTAGE PHARMS	325MG;50MG	A074843	002	Feb 15, 2001
	650MG;100MG	A074843	001	Feb 12, 1997
WATSON LABS	325MG;50MG	A070398	001	Dec 18, 1986
	650MG;100MG	A070399	001	Dec 18, 1986
WATSON LABS FLORIDA	500MG;100MG	A077196	001	Jun 28, 2005
	650MG;100MG	A076609	001	Nov 16, 2004
WOCKHARDT LTD	325MG;50MG	A077677	001	Mar 16, 2007
	650MG;100MG	A077677	002	Mar 16, 2007

ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE

TABLET;ORAL

TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN

GRAVITI PHARMS	325MG;37.5MG	A076914	001	Jul 26, 2006
MACLEODS PHARMS LTD	325MG;37.5MG	A206885	001	May 02, 2017
NOSTRUM LABS INC	325MG;37.5MG	A078778	001	Apr 07, 2014
STRIDES PHARMA	325MG;37.5MG	A076475	001	Apr 21, 2005

ACETAZOLAMIDE

CAPSULE, EXTENDED RELEASE;ORAL

ACETAZOLAMIDE

INDICUS PHARMA	500MG	A090779	001	Jul 14, 2011
RISING	500MG	A203917	001	Jun 18, 2019

DIAMOX

+ TEVA BRANDED PHARM	500MG **	N012945	001	

TABLET;ORAL

ACETAZOLAMIDE

ALRA	250MG	A083320	001	
ASCOT	250MG	A087686	001	Oct 20, 1982
HERITAGE PHARMA	250MG	A088882	001	Oct 22, 1985
SUN PHARM INDUSTRIES	125MG	A089753	002	Jun 22, 1988
	250MG	A089753	001	Jun 22, 1988
VANGARD	250MG	A087654	001	Feb 05, 1982
WATSON LABS	250MG	A084498	002	

DIAMOX

+ TEVA BRANDED PHARM	125MG **	N008943	001	
+	250MG **	N008943	002	

ACETAZOLAMIDE SODIUM

INJECTABLE;INJECTION

ACETAZOLAMIDE SODIUM

HOSPIRA	EQ 500MG BASE/VIAL	A040108	001	Oct 30, 1995
PAR STERILE PRODUCTS	EQ 500MG BASE/VIAL	A205358	001	Jun 20, 2017

DIAMOX

+ TEVA WOMENS	EQ 500MG BASE/VIAL **	N009388	001	

ACETIC ACID, GLACIAL

SOLUTION/DROPS;OTIC

ACETASOL

ACTAVIS MID ATLANTIC	2%	A087146	001	

ACETIC ACID

KV PHARM	2%	A085493	001	
WOCKHARDT BIO AG	2%	A040166	001	Jul 26, 1996

ORLEX

WARNER CHILCOTT	2%	A086845	001	

ACETIC ACID, GLACIAL; ALUMINUM ACETATE

SOLUTION/DROPS;OTIC

ACETIC ACID 2% IN AQUEOUS ALUMINUM ACETATE

BAUSCH AND LOMB	2%;0.79%	A040063	001	Feb 25, 1994

BOROFAIR

PHARMAFAIR	2%;0.79%	A088606	001	Aug 21, 1985

DOMBORO

+ BAYER PHARMS	2%;0.79%	A084476	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-12(of 478)

** See List Footnote

ACETIC ACID, GLACIAL; DESONIDE

SOLUTION/DROPS;OTIC

TRIDESILON

BAYER PHARMS

2%;0.05%

N017914 001

ACETIC ACID, GLACIAL; HYDROCORTISONE

SOLUTION/DROPS;OTIC

ACETASOL HC

ACTAVIS MID ATLANTIC 2%;1%

A087143 001 Jan 13, 1982

ACETIC ACID W/ HYDROCORTISONE

KV PHARM 2%;1%

A085492 001

HYDROCORTISONE AND ACETIC ACID

BAUSCH AND LOMB 2%;1%

A040097 001 Oct 31, 1994

WOCKHARDT 2%;1%

A040168 001 Aug 30, 1996

ORLEX HC

WARNER CHILCOTT 2%;1%

A086844 001

ACETIC ACID, GLACIAL; HYDROCORTISONE; NEOMYCIN SULFATE

SUSPENSION/DROPS;OTIC

NEO-CORT-DOME

BAYER PHARMS 2%;1%;EQ 0.35% BASE

N050238 001

ACETOHEXAMIDE

TABLET;ORAL

ACETOHEXAMIDE

ANI PHARMS 250MG

A070870 002 Feb 09, 1987

500MG

A070870 001 Feb 09, 1987

USL PHARMA 250MG

A070753 001 Nov 03, 1986

500MG

A070754 001 Nov 03, 1986

WATSON LABS TEVA 250MG

A071893 001 Nov 25, 1987

500MG

A071894 001 Nov 25, 1987

DYMELOR

LILLY 250MG

N013378 002

500MG

N013378 001

ACETOPHENAZINE MALEATE

TABLET;ORAL

TINDAL

SCHERING 20MG

N012254 002

ACETRIZOATE SODIUM

SOLUTION;INTRAUTERINE

SALPIX

ORTHO MCNEIL PHARM 53%

N009008 001

ACETYLCOLINE CHLORIDE

FOR SOLUTION;OPHTHALMIC

MIOCHOL

+ NOVARTIS 20MG/VIAL **

N016211 001

ACETYLCYSTEINE

INJECTABLE;INTRAVENOUS

ACETYLCYSTEINE

EXELA PHARMA 6GM/30ML (200MG/ML)

A204797 001 Apr 15, 2021

RISING 6GM/30ML (200MG/ML)

A203624 001 Jun 19, 2015

SOLUTION;INHALATION, ORAL

ACETYLCYSTEINE

HOSPIRA 10%

A071364 001 May 01, 1989

20%

A071365 001 May 01, 1989

ROXANE 10%

A072323 001 Apr 30, 1992

10%

A072621 001 Sep 30, 1992

20%

A072324 001 Apr 30, 1992

20%

A072622 001 Sep 30, 1992

MUCOMYST

+ APOTHECON 10% **

N013601 002

+ 20% **

N013601 001

MUCOSIL-10

DEY 10%

A070575 001 Oct 14, 1986

MUCOSIL-20

DEY 20%

A070576 001 Oct 14, 1986

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-13(of 478)

** See List Footnote

ACETYLCYSTEINE

TABLET, EFFERVESCENT;ORAL

CETYLEV

+ ARBOR PHARMS LLC

500MG

N207916 001 Jan 29, 2016

+ 2.5GM

N207916 002 Jan 29, 2016

ACETYLCYSTEINE; ISOPROTERENOL HYDROCHLORIDE

SOLUTION;INHALATION

MUCOMYST W/ ISOPROTERENOL

MEAD JOHNSON

10%;0.05%

N017366 001

ACETYLDIGITOXIN

TABLET;ORAL

ACYLANID

NOVARTIS

0.1MG

N009436 001

ACITRETIN

CAPSULE;ORAL

ACITRETIN

MYLAN

17.5MG

A203707 001 Sep 10, 2015

22.5MG

A203707 002 Sep 10, 2015

SORIATANE

+ STIEFEL LABS INC

10MG

N019821 001 Oct 28, 1996

+ 17.5MG

17.5MG

N019821 003 Aug 06, 2009

+ 22.5MG

22.5MG

N019821 004 Aug 06, 2009

+ 25MG

25MG

N019821 002 Oct 28, 1996

ACRISORCIN

CREAM;TOPICAL

AKRINOL

SCHERING

2MG/GM

N012470 001

ACRIVASTINE; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE;ORAL

SEMPREX-D

+ AUXILIUM PHARMS LLC

8MG;60MG

N019806 001 Mar 25, 1994

ACYCLOVIR

CAPSULE;ORAL

ACYCLOVIR

ACTAVIS ELIZABETH

200MG

A074906 001 Aug 26, 1997

CHARTWELL MOLECULES

200MG

A074872 001 Apr 22, 1997

IVAX SUB TEVA PHARMS

200MG

A074674 001 Apr 22, 1997

LEK PHARM

200MG

A074750 001 Apr 22, 1997

MYLAN

200MG

A074727 001 Apr 22, 1997

200MG

200MG

A074977 001 Apr 13, 1998

RANBAXY

200MG

A074975 001 Sep 30, 1998

ROXANE

200MG

A074570 002 Apr 22, 1997

STRIDES PHARMA

200MG

A074833 001 Apr 22, 1997

TEVA

200MG

A074828 001 Apr 22, 1997

TEVA PHARMS

200MG

A074914 001 Nov 26, 1997

WATSON LABS

200MG

A075101 001 Apr 15, 1998

ZOVIRAX

+ MYLAN

200MG **

N018828 001 Jan 25, 1985

OINTMENT;OPHTHALMIC

AVACLYR

+ FERA PHARMS LLC

3% **

N202408 001 Mar 29, 2019

OINTMENT;TOPICAL

ACYCLOVIR

ANDA REPOSITORY

5%

A206437 001 Jul 31, 2017

PADAGIS ISRAEL

5%

A205659 001 Feb 20, 2019

PRINSTON INC

5%

A212202 001 Nov 15, 2021

SUSPENSION;ORAL

ACYCLOVIR

AUROBINDO PHARMA

200MG/5ML

A216331 001 Mar 31, 2022

TABLET;ORAL

ACYCLOVIR

ACTAVIS ELIZABETH

400MG

A074870 001 Jun 05, 1997

800MG

800MG

A074870 002 Jun 05, 1997

CHARTWELL MOLECULES

400MG

A074834 001 Apr 24, 1997

800MG

A074834 002 Apr 24, 1997

IVAX SUB TEVA PHARMS

400MG

A074836 001 Apr 22, 1997

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-14(of 478)

** See List Footnote

ACYCLOVIR

TABLET; ORAL

ACYCLOVIR

	800MG	A074836 002	Apr 22, 1997
LEK PHARM	400MG	A074658 001	Apr 22, 1997
	800MG	A074658 002	Apr 22, 1997
MYLAN	400MG	A074976 001	Apr 13, 1998
	400MG	A075211 001	Sep 28, 1998
	800MG	A074976 002	Apr 13, 1998
	800MG	A075211 002	Sep 28, 1998
SUN PHARM INDS LTD	400MG	A074980 001	Sep 30, 1998
	800MG	A074980 002	Sep 30, 1998
TEVA	200MG **	A074556 001	Apr 22, 1997
TEVA PHARMS	400MG	A075021 001	Mar 18, 1998
	800MG	A075021 002	Mar 18, 1998
ZOVIRAX			
+ MYLAN	400MG **	N020089 001	Apr 30, 1991
+	800MG **	N020089 002	Apr 30, 1991

ACYCLOVIR SODIUM

INJECTABLE; INJECTION

ACYCLOVIR

ABBVIE	EQ 50MG BASE/ML	A075114 001	Jul 26, 1999
ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE			
EUROHLTH INTL SARL	EQ 500MG BASE/VIAL	A074885 001	Dec 19, 1997
	EQ 1GM BASE/VIAL	A074885 002	Dec 19, 1997
ACYCLOVIR SODIUM			
APOTHECON	EQ 500MG BASE/VIAL	A074897 001	Feb 27, 1998
	EQ 1GM BASE/VIAL	A074897 002	Feb 27, 1998
CHARTWELL INJECTABLE	EQ 500MG BASE/VIAL	A074596 002	Apr 22, 1997
	EQ 1GM BASE/VIAL	A074596 001	Apr 22, 1997
DR REDDYS	EQ 50MG BASE/ML	A207919 001	Jun 17, 2020
EUROHLTH INTL SARL	EQ 500MG BASE/VIAL	A074913 001	Oct 15, 1997
	EQ 1GM BASE/VIAL	A074913 002	Oct 15, 1997
FRESENIUS KABI USA	EQ 500MG BASE/VIAL	A075015 001	Apr 30, 1998
HIKMA	EQ 500MG BASE/VIAL	A205771 001	Feb 29, 2016
	EQ 1GM BASE/VIAL	A205771 002	Feb 29, 2016
HOSPIRA	EQ 25MG BASE/ML	A074720 001	Apr 22, 1997
	EQ 50MG BASE/ML	A075065 001	Feb 25, 1999
	EQ 500MG BASE/VIAL	A074663 001	Apr 22, 1997
	EQ 500MG BASE/VIAL	A074758 001	Apr 22, 1997
	EQ 1GM BASE/VIAL	A074663 002	Apr 22, 1997
	EQ 1GM BASE/VIAL	A074758 002	Apr 22, 1997
MYLAN LABS LTD	EQ 500MG BASE/VIAL	A203927 001	Mar 29, 2017
	EQ 1GM BASE/VIAL	A203927 002	Mar 29, 2017
TEVA PARENTERAL	EQ 50MG BASE/ML	A075627 001	Mar 28, 2001
	EQ 500MG BASE/VIAL	A074969 001	Aug 26, 1997
	EQ 1GM BASE/VIAL	A074969 002	Aug 26, 1997
ZYDUS PHARMS	EQ 500MG BASE/VIAL	A206606 001	Jun 13, 2017
	EQ 1GM BASE/VIAL	A206606 002	Jun 13, 2017
ZOVIRAX			
+ GLAXOSMITHKLINE	EQ 1GM BASE/VIAL **	N018603 002	Jun 29, 1989
+	EQ 250MG BASE/VIAL **	N018603 003	Aug 30, 1983
+	EQ 500MG BASE/VIAL **	N018603 001	Oct 22, 1982

ADAPALENE

GEL; TOPICAL

ADAPALENE

ENCUBE ETHICALS	0.3%	A200298 001	Jun 14, 2012
SOLUTION; TOPICAL			
DIFFERIN			
+ GALDERMA LABS LP	0.1% **	N020338 001	May 31, 1996

ADAPALENE; BENZOYL PEROXIDE

GEL; TOPICAL

ADAPALENE AND BENZOYL PEROXIDE

ACTAVIS MID ATLANTIC	0.1%; 2.5%	A203790 001	Sep 30, 2015
ENCUBE	0.1%; 2.5%	A206164 001	May 23, 2018

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-15(of 478)

** See List Footnote

ADENOSINE

INJECTABLE; INJECTION

ADENOCARD

+ ASTELLAS 3MG/ML **

N019937 002 Oct 30, 1989

ADENOSINE

AM REGENT 3MG/ML

A090010 001 Apr 28, 2009

HIKMA 3MG/ML

A076501 001 Jun 16, 2004

MYLAN LABS LTD 3MG/ML

A078640 001 Mar 21, 2014

TEVA PHARMS USA 3MG/ML

A076564 001 Jun 16, 2004

3MG/ML

A078676 001 Jul 31, 2008

WOCKHARDT 3MG/ML

A090220 001 Jul 20, 2009

SOLUTION; INTRAVENOUS

ADENOSCAN

+ ASTELLAS 60MG/20ML (3MG/ML) **

N020059 001 May 18, 1995

+ 90MG/30ML (3MG/ML) **

N020059 002 May 18, 1995

ALATROFLOXACIN MESYLATE

INJECTABLE; INJECTION

TROVAN PRESERVATIVE FREE

PFIZER EQ 200MG BASE/VIAL

N020760 001 Dec 18, 1997

EQ 300MG BASE/VIAL

N020760 002 Dec 18, 1997

ALBENDAZOLE

TABLET; ORAL

ALBENDAZOLE

LUPIN LTD 200MG

A211636 001 Jun 10, 2020

ALBENZA

+ IMPAX LABS INC 200MG

N020666 001 Jun 11, 1996

ALBUTEROL

AEROSOL, METERED; INHALATION

ALBUTEROL

ARMSTRONG PHARMS 0.09MG/INH

A072273 001 Aug 14, 1996

GENPHARM 0.09MG/INH

A073045 001 Aug 19, 1997

IVAX SUB TEVA PHARMS 0.09MG/INH

A073272 001 Dec 28, 1995

PLIVA 0.09MG/INH

A074072 001 Aug 01, 1996

PROVENTIL

SCHERING 0.09MG/INH

N017559 001

VENTOLIN

GLAXOSMITHKLINE 0.09MG/INH

N018473 001

ALBUTEROL SULFATE

AEROSOL, METERED; INHALATION

ALBUTEROL SULFATE

PADAGIS US EQ 0.09MG BASE/INH

A203760 001 Feb 24, 2020

CAPSULE; INHALATION

VENTOLIN ROTACAPS

GLAXOSMITHKLINE EQ 0.2MG BASE

N019489 001 May 04, 1988

SOLUTION; INHALATION

ACCUNEB

+ MYLAN SPECIALITY LP EQ 0.042% BASE

N020949 001 Apr 30, 2001

ALBUTEROL SULFATE

ACTAVIS MID ATLANTIC EQ 0.083% BASE

A073533 001 Sep 26, 1995

AKORN EQ 0.083% BASE

A075063 001 Feb 09, 1999

APOTEX INC EQ 0.021% BASE

A078623 001 Apr 05, 2010

EQ 0.042% BASE

A078623 002 Apr 05, 2010

EQ 0.083% BASE

A075717 001 Feb 02, 2007

EQ 0.5% BASE

A076391 001 Apr 01, 2003

BAUSCH EQ 0.083% BASE

A075358 001 Mar 29, 2000

EQ 0.5% BASE

A075050 001 Jun 18, 1998

COPLEY PHARM EQ 0.083% BASE

A073495 001 May 28, 1993

EQ 0.5% BASE

A073307 001 Nov 27, 1991

LANDELA PHARM EQ 0.083% BASE

A077569 001 Apr 04, 2006

LUOXIN AUROVITAS EQ 0.021% BASE

A211888 001 Apr 20, 2020

EQ 0.042% BASE

A211888 002 Apr 20, 2020

MYLAN SPECALT EQ 0.083% BASE **

A072652 001 Feb 21, 1992

ROXANE EQ 0.083% BASE

A075129 001 Feb 13, 2001

TEVA PHARMS EQ 0.083% BASE

A075343 001 Nov 09, 1999

WATSON LABS INC EQ 0.083% BASE

A076370 001 Nov 24, 2003

WOCKHARDT EU OPERATN EQ 0.083% BASE

A075394 001 Nov 22, 1999

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-16(of 478)

** See List Footnote

ALBUTEROL SULFATE

SOLUTION; INHALATION

PROVENTIL

+ SCHERING	EQ 0.083% BASE **	N019243 002	Jan 14, 1987
+	EQ 0.5% BASE **	N019243 001	Jan 14, 1987

VENTOLIN

+ GLAXOSMITHKLINE	EQ 0.083% BASE **	N019773 001	Apr 23, 1992
	EQ 0.5% BASE **	N019269 002	Jan 16, 1987

SYRUP; ORAL

ALBUTEROL SULFATE

ACTAVIS MID ATLANTIC	EQ 2MG BASE/5ML	A075262 001	Mar 30, 1999
MOVA	EQ 2MG BASE/5ML	A074302 001	Sep 30, 1994
WATSON LABS	EQ 2MG BASE/5ML	A073165 001	Apr 29, 1993

PROVENTIL

+ SCHERING	EQ 2MG BASE/5ML **	N018062 001	Jan 19, 1983

VENTOLIN

GLAXOSMITHKLINE	EQ 2MG BASE/5ML **	N019621 001	Jun 10, 1987

TABLET; ORAL

ALBUTEROL SULFATE

AM THERAP	EQ 2MG BASE	A072449 001	Dec 05, 1989
	EQ 4MG BASE	A072450 001	Dec 05, 1989
AUROBINDO PHARMA LTD	EQ 2MG BASE	A213657 001	May 14, 2020
	EQ 4MG BASE	A213657 002	May 14, 2020
CHARTWELL RX	EQ 2MG BASE	A072151 001	Dec 05, 1989
	EQ 4MG BASE	A072151 002	Dec 05, 1989
COPLEY PHARM	EQ 2MG BASE	A072966 001	Nov 22, 1991
	EQ 4MG BASE	A072967 001	Nov 22, 1991
EYWA	EQ 2MG BASE	A213524 001	Oct 08, 2020
	EQ 4MG BASE	A213524 002	Oct 08, 2020
PLIVA	EQ 2MG BASE	A072316 001	Dec 05, 1989
	EQ 4MG BASE	A072317 001	Dec 05, 1989
STRIDES PHARMA	EQ 2MG BASE	A072860 002	Dec 20, 1989
	EQ 4MG BASE	A072860 001	Dec 20, 1989
TEVA	EQ 2MG BASE	A072619 001	Dec 05, 1989
	EQ 2MG BASE	A072779 001	Jun 25, 1993
	EQ 2MG BASE	A072938 001	Mar 30, 1990
	EQ 4MG BASE	A072620 001	Dec 05, 1989
	EQ 4MG BASE	A072780 001	Jun 25, 1993
	EQ 4MG BASE	A072939 001	Mar 30, 1990
UCB INC	EQ 2MG BASE	A073120 001	Sep 29, 1992
	EQ 4MG BASE	A073121 001	Sep 29, 1992
WARNER CHILCOTT	EQ 2MG BASE	A072817 001	Jan 09, 1990
	EQ 4MG BASE	A072818 001	Jan 09, 1990
WATSON LABS	EQ 2MG BASE	A072629 001	Jan 31, 1991
	EQ 2MG BASE	A072764 001	Aug 28, 1991
	EQ 4MG BASE	A072630 001	Jan 31, 1991
	EQ 4MG BASE	A072765 001	Aug 28, 1991

PROVENTIL

+ SCHERING	EQ 2MG BASE **	N017853 001	May 07, 1982
+	EQ 4MG BASE **	N017853 002	May 07, 1982

VENTOLIN

GLAXOSMITHKLINE	EQ 2MG BASE	N019112 001	Jul 10, 1986
	EQ 4MG BASE	N019112 002	Jul 10, 1986

TABLET, EXTENDED RELEASE; ORAL

ALBUTEROL SULFATE

RISING	EQ 4MG BASE	A078092 002	Jan 29, 2007
	EQ 8MG BASE	A078092 001	Jan 29, 2007

PROVENTIL

SCHERING	EQ 4MG BASE	N019383 001	Jul 13, 1987

VOLMAX

+ MURO	EQ 4MG BASE	N019604 002	Dec 23, 1992
+	EQ 8MG BASE	N019604 001	Dec 23, 1992

VOSPIRE ER

STRIDES PHARMA	EQ 4MG BASE	A076130 002	Sep 26, 2002
	EQ 8MG BASE	A076130 003	Sep 26, 2002

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-17(of 478)

** See List Footnote

ALBUTEROL SULFATE; IPRATROPIUM BROMIDE

AEROSOL, METERED; INHALATION

COMBIVENT

BOEHRINGER INGELHEIM EQ 0.09MG BASE/INH; 0.018MG/INH

N020291 001 Oct 24, 1996

SOLUTION; INHALATION

ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE

APOTEX INC EQ 0.083% BASE; 0.017%

A077117 001 Dec 31, 2007

FOSUN PHARMA EQ 0.083% BASE; 0.017%

A076867 001 Dec 21, 2006

LUOXIN AUROVITAS EQ 0.083% BASE; 0.017%

A206532 001 Jul 08, 2020

TEVA PHARMS EQ 0.083% BASE; 0.017%

A076724 001 Dec 31, 2007

WATSON LABS TEVA EQ 0.083% BASE; 0.017%

A077063 001 Dec 31, 2007

DUONEB

+ MYLAN SPECIALITY LP EQ 0.083% BASE; 0.017% **

N020950 001 Mar 21, 2001

ALCLOMETASONE DIPROPIONATE

CREAM; TOPICAL

ACLOVATE

+ FOUGERA PHARMS 0.05% **

N018707 001 Dec 14, 1982

OINTMENT; TOPICAL

ACLOVATE

+ FOUGERA PHARMS 0.05% **

N018702 001 Dec 14, 1982

ALENDRONATE SODIUM

SOLUTION; ORAL

FOSAMAX

+ MERCK EQ 70MG BASE/75ML **

N021575 001 Sep 17, 2003

TABLET; ORAL

ALENDRONATE SODIUM

CHARTWELL RX

EQ 5MG BASE

A075871 001 Apr 22, 2009

EQ 10MG BASE

A075871 002 Apr 22, 2009

EQ 35MG BASE

A075871 004 Apr 22, 2009

EQ 40MG BASE

A075871 003 Apr 22, 2009

EQ 70MG BASE

A075871 005 Apr 22, 2009

IMPAX LABS INC

EQ 5MG BASE

A075710 001 Feb 06, 2008

EQ 10MG BASE

A075710 002 Feb 06, 2008

EQ 35MG BASE

A075710 003 Feb 06, 2008

EQ 40MG BASE

A075710 004 Feb 06, 2008

EQ 70MG BASE

A075710 005 Feb 06, 2008

JUBILANT CADISTA

EQ 5MG BASE

A090557 001 Feb 18, 2010

EQ 10MG BASE

A090557 002 Feb 18, 2010

EQ 35MG BASE

A090557 003 Feb 18, 2010

EQ 70MG BASE

A090557 004 Feb 18, 2010

MYLAN

EQ 35MG BASE

A078638 001 Aug 04, 2008

EQ 70MG BASE

A078638 002 Aug 04, 2008

PICKET PHARMS

EQ 5MG BASE

A079049 003 Aug 04, 2008

EQ 10MG BASE

A079049 004 Aug 04, 2008

EQ 35MG BASE

A079049 001 Aug 04, 2008

EQ 70MG BASE

A079049 002 Aug 04, 2008

RISING

EQ 5MG BASE

A076584 001 Aug 04, 2008

EQ 10MG BASE

A076584 002 Aug 04, 2008

EQ 35MG BASE

A076584 003 Aug 04, 2008

EQ 70MG BASE

A076584 004 Aug 04, 2008

TEVA PHARMS

EQ 35MG BASE

A076184 002 Aug 04, 2008

EQ 70MG BASE

A076184 001 Feb 06, 2008

FOSAMAX

+ ORGANON EQ 5MG BASE **

N020560 003 Apr 25, 1997

+ EQ 10MG BASE **

N020560 001 Sep 29, 1995

+ EQ 35MG BASE **

N020560 004 Oct 20, 2000

+ EQ 40MG BASE **

N020560 002 Sep 29, 1995

ALFUZOSIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

ALFUZOSIN HYDROCHLORIDE

HERITAGE PHARMA 10MG

A079056 001 Jul 18, 2011

MYLAN 10MG

A079014 001 Jul 18, 2011

TORRENT PHARMS 10MG

A079054 001 Jul 18, 2011

WOCKHARDT 10MG

A090221 001 Aug 10, 2012

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-18(of 478)

** See List Footnote

ALISKIREN HEMIFUMARATE

CAPSULE, PELLET; ORAL

TEKTURNA

+ NODEN PHARMA EQ 37.5MG BASE

N210709 001 Nov 14, 2017

ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE

TABLET; ORAL

TEKAMLO

NOVARTIS

EQ 150MG BASE; EQ 5MG BASE

N022545 001 Aug 26, 2010

EQ 150MG BASE; EQ 10MG BASE

N022545 002 Aug 26, 2010

EQ 300MG BASE; EQ 5MG BASE

N022545 003 Aug 26, 2010

EQ 300MG BASE; EQ 10MG BASE

N022545 004 Aug 26, 2010

ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

AMTURNIDE

NOVARTIS

EQ 150MG BASE; EQ 5MG BASE; 12.5MG

N200045 001 Dec 21, 2010

EQ 300MG BASE; EQ 5MG BASE; 12.5MG

N200045 002 Dec 21, 2010

EQ 300MG BASE; EQ 5MG BASE; 25MG

N200045 003 Dec 21, 2010

EQ 300MG BASE; EQ 10MG BASE; 12.5MG

N200045 004 Dec 21, 2010

EQ 300MG BASE; EQ 10MG BASE; 25MG

N200045 005 Dec 21, 2010

ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

TEKTURNA HCT

+ NODEN PHARMA

EQ 150MG BASE; 12.5MG

N022107 001 Jan 18, 2008

+

EQ 150MG BASE; 25MG

N022107 002 Jan 18, 2008

+

EQ 300MG BASE; 12.5MG

N022107 003 Jan 18, 2008

+

EQ 300MG BASE; 25MG

N022107 004 Jan 18, 2008

ALISKIREN HEMIFUMARATE; VALSARTAN

TABLET; ORAL

VALTURNA

NOVARTIS

EQ 150MG BASE; 160MG

N022217 001 Sep 16, 2009

EQ 300MG BASE; 320MG

N022217 002 Sep 16, 2009

ALKAVERVIR

TABLET; ORAL

VERILOID

3M

2MG

N007336 002

3MG

N007336 003

ALLOPURINOL

TABLET; ORAL

ALLOPURINOL

FOSUN PHARMA

100MG

A070268 001 Dec 31, 1985

MUTUAL PHARM

100MG

A070466 001 Dec 24, 1985

300MG

A070467 001 Dec 24, 1985

PURACAP PHARM

100MG

A070150 001 Dec 10, 1985

300MG

A070147 001 Dec 10, 1985

PUREPAC PHARM

100MG

A070579 001 Apr 14, 1986

300MG

A070580 001 Apr 14, 1986

SANDOZ

300MG

A070269 001 Dec 31, 1985

SUN PHARM INDS INC

100MG

A078390 001 Aug 30, 2007

300MG

A078390 002 Aug 30, 2007

SUPERPHARM

100MG

A070950 001 Nov 30, 1988

300MG

A070951 001 Nov 30, 1988

WATSON LABS

100MG

N018241 001 Nov 16, 1984

100MG

N018785 001 Sep 28, 1984

300MG

N018241 002 Nov 16, 1984

300MG

N018785 002 Sep 28, 1984

LOPURIN

ABBOTT

100MG

N018297 001

300MG

N018297 002

ALLOPURINOL; LESINURAD

TABLET; ORAL

DUZALLO

+ IRONWOOD PHARMS INC

200MG; 200MG

N209203 001 Aug 18, 2017

+

300MG; 200MG

N209203 002 Aug 18, 2017

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-19(of 478)

** See List Footnote

ALMOTRIPTAN MALATE

TABLET;ORAL

AXERT

+	JANSSEN PHARMS	EQ 6.25MG BASE **	N021001	001	May 07, 2001
+		EQ 12.5MG BASE **	N021001	002	May 07, 2001

ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE

TABLET;ORAL

OSEN

+	TAKEDA PHARMS USA	EQ 12.5MG BASE;EQ 15MG BASE	N022426	004	Jan 25, 2013
+		EQ 12.5MG BASE;EQ 45MG BASE	N022426	006	Jan 25, 2013

ALOSETRON HYDROCHLORIDE

TABLET;ORAL

ALOSETRON HYDROCHLORIDE

EYWA PHARMA	EQ 0.5MG BASE	A211621	001	Sep 16, 2019
	EQ 1MG BASE	A211621	002	Sep 16, 2019
PAR PHARM INC	EQ 0.5MG BASE	A206113	001	Feb 23, 2018
	EQ 1MG BASE	A206113	002	Feb 23, 2018

ALPRAZOLAM

SOLUTION;ORAL

ALPRAZOLAM

ROXANE	0.5MG/5ML	A074314	001	Oct 31, 1993

TABLET;ORAL

ALPRAZOLAM

ANI PHARMS	0.25MG	A074085	001	Feb 16, 1994
	0.5MG	A074085	002	Feb 16, 1994
	1MG	A074085	003	Feb 16, 1994
	2MG	A074085	004	Feb 26, 1996
IVAX SUB TEVA PHARMS	0.25MG	A074294	001	Jul 29, 1994
	0.5MG	A074294	002	Jul 29, 1994
	1MG	A074294	003	Jul 29, 1994
	2MG	A074294	004	Jul 29, 1994
MYLAN	0.25MG	A074215	001	Jan 27, 1994
	0.5MG	A074215	002	Jan 27, 1994
	1MG	A074215	003	Jan 27, 1994
	2MG	A074215	004	Jan 27, 1994
MYLAN PHARMS INC	0.25MG	A074046	001	Oct 19, 1993
	0.5MG	A074046	002	Oct 19, 1993
	1MG	A074046	003	Oct 19, 1993
	2MG	A074046	004	May 07, 1997
OXFORD PHARMS	0.25MG	A078491	001	Sep 25, 2008
	0.5MG	A078491	002	Sep 25, 2008
	1MG	A078491	003	Sep 25, 2008
	2MG	A078491	004	Dec 12, 2008
ROXANE	0.25MG	A074199	001	Oct 19, 1993
	0.5MG	A074199	002	Oct 19, 1993
	1MG	A074199	003	Oct 19, 1993
WATSON LABS	0.25MG	A074456	001	Aug 31, 1995
	0.25MG	A074479	001	Jan 21, 1997
	0.5MG	A074456	002	Aug 31, 1995
	0.5MG	A074479	002	Jan 21, 1997
	1MG	A074456	003	Aug 31, 1995
	1MG	A074479	003	Jan 21, 1997

TABLET, EXTENDED RELEASE;ORAL

ALPRAZOLAM

ACTAVIS LABS FL INC	0.5MG	A077198	001	May 13, 2010
	1MG	A077198	002	May 13, 2010
	2MG	A077198	003	May 13, 2010
	3MG	A077198	004	May 13, 2010
ANI PHARMS	0.5MG	A077725	001	Jul 31, 2006
	0.5MG	A077979	001	Feb 28, 2007
	1MG	A077725	002	Jul 31, 2006
	1MG	A077979	002	Feb 28, 2007
	2MG	A077725	004	Jul 31, 2006
	2MG	A077979	003	Feb 28, 2007
	3MG	A077725	003	Jul 31, 2006
	3MG	A077979	004	Feb 28, 2007
HERITAGE PHARMS INC	0.5MG	A078489	001	Oct 17, 2008
	1MG	A078489	002	Oct 17, 2008

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-20(of 478)

** See List Footnote

ALPRAZOLAMTABLET, EXTENDED RELEASE;ORAL
ALPRAZOLAM

	2MG	A078489 003	Oct 17, 2008
	3MG	A078489 004	Oct 17, 2008
IMPAX LABS	0.5MG	A077968 004	May 24, 2007
	1MG	A077968 003	May 24, 2007
	2MG	A077968 002	May 24, 2007
	3MG	A077968 001	May 24, 2007
IMPAX LABS INC	0.5MG	A077996 001	Jan 31, 2007
	1MG	A077996 002	Jan 31, 2007
	2MG	A077996 003	Jan 31, 2007
	3MG	A077996 004	Jan 31, 2007
MYLAN	0.5MG	A077391 002	Jan 26, 2006
	1MG	A077391 003	Jan 26, 2006
	2MG	A077391 004	Jan 26, 2006
	3MG	A077391 001	Jan 26, 2006
SANDOZ INC	0.5MG	A077777 001	Jun 30, 2006
	1MG	A077777 002	Jun 30, 2006
	2MG	A077777 003	Jun 30, 2006
	3MG	A077777 004	Jun 30, 2006
VINTAGE PHARMS	0.5MG	A078442 001	Oct 15, 2007
	1MG	A078442 002	Oct 15, 2007
	2MG	A078442 003	Oct 15, 2007
	3MG	A078442 004	Oct 15, 2007

TABLET, ORALLY DISINTEGRATING;ORAL
NIRAVAM

+	UCB INC	0.25MG **	N021726 001	Jan 19, 2005
+		0.5MG **	N021726 002	Jan 19, 2005
+		1MG **	N021726 003	Jan 19, 2005
+		2MG **	N021726 004	Jan 19, 2005

ALPROSTADILINJECTABLE;INJECTION
CAVERJECT

+	PFIZER	0.005MG/VIAL	N020379 003	Jun 27, 1996
		0.005MG/ML	N020755 001	Oct 31, 1997
		0.01MG/ML	N020755 002	Oct 01, 1997
		0.02MG/ML	N020755 003	Oct 01, 1997

EDEX

AUXILIUM PHARMS LLC 0.005MG/VIAL N020649 001 Jun 12, 1997

SUPPOSITORY;URETHRAL

MUSE

+ MYLAN SPECIALITY LP 0.125MG N020700 001 Nov 19, 1996

ALSEROXYLON

TABLET;ORAL

RAUTENSIN

NOVARTIS 2MG N009215 001

RAUWILOID

3M 2MG N008867 001

ALTRETAMINE

CAPSULE;ORAL

HEXALEN

+ EISAI INC 50MG N019926 001 Dec 26, 1990

ALUMINUM HYDROXIDE; MAGNESIUM TRISILICATE

TABLET, CHEWABLE;ORAL

ALUMINUM HYDROXIDE AND MAGNESIUM TRISILICATE

PENNEX 80MG;20MG A089449 001 Nov 27, 1987

FOAMCOAT

GUARDIAN DRUG 80MG;20MG A071793 001 Sep 04, 1987

FOAMICON

NOVARTIS 80MG;20MG A072687 001 Jun 28, 1989

GAVISCON

+ CHATTEM SANOFI 80MG;20MG N018685 001 Dec 09, 1983

+ 160MG;40MG N018685 002 Dec 09, 1983

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-21(of 478)

** See List Footnote

AMANTADINE HYDROCHLORIDE

CAPSULE; ORAL

AMANTADINE HYDROCHLORIDE

ACTAVIS ELIZABETH	100MG	A077659	001	Feb 23, 2006
CHARTWELL MOLECULAR	100MG	A209221	001	Jun 15, 2017
INVAGEN PHARMS	100MG	A207570	001	Sep 30, 2016
WATSON LABS	100MG	A071382	001	Jan 21, 1987
WATSON LABS INC	100MG	A208107	001	Dec 06, 2016

SYMADINE

SOLVAY	100MG	A071000	001	Sep 04, 1986

SYMMETREL

+ ENDO PHARMS	100MG **	N016020	001	

SYRUP; ORAL

AMANTADINE HYDROCHLORIDE

ANDA REPOSITORY	50MG/5ML	A076352	001	Sep 10, 2004
G AND W LABS INC	50MG/5ML	A072655	001	Oct 30, 1990
TEVA PHARMS	50MG/5ML	A073115	001	Aug 23, 1991
VINTAGE	50MG/5ML	A077992	001	Dec 12, 2006
XTTRIUM LABS INC	50MG/5ML	A075060	001	Dec 24, 1998

SYMMETREL

+ ENDO PHARMS	50MG/5ML **	N016023	002	

TABLET; ORAL

AMANTADINE HYDROCHLORIDE

EDENBRIDGE PHARMS	100MG	A212407	001	May 27, 2022
INVAGEN PHARMS	100MG	A207571	001	Jan 31, 2017
JUBILANT GENERICS	100MG	A210403	001	Feb 07, 2018

SYMMETREL

+ ENDO PHARMS	100MG **	N018101	001	

TABLET, EXTENDED RELEASE; ORAL

OSMOLEX ER

+ ADAMAS OPERATIONS	EQ 161MG BASE	N209410	004	Apr 22, 2020
+	EQ 258MG BASE	N209410	003	Feb 16, 2018

AMBENONIUM CHLORIDE

TABLET; ORAL

MYTELASE

SANOFI AVENTIS US	10MG	N010155	002	

AMCINONIDE

CREAM; TOPICAL

CYCLOCORT

+ ASTELLAS	0.025% **	N018116	001	
+	0.1% **	N018116	002	

LOTION; TOPICAL

CYCLOCORT

+ ASTELLAS	0.1%	N019729	001	Jun 13, 1988

OINTMENT; TOPICAL

CYCLOCORT

+ ASTELLAS	0.1% **	N018498	001	

AMINOCILLIN

INJECTABLE; INJECTION

COACTIN

ROCHE	250MG/VIAL	N050565	001	Dec 21, 1984
	500MG/VIAL	N050565	002	Dec 21, 1984
	1GM/VIAL	N050565	003	Dec 21, 1984

AMIFOSTINE

INJECTABLE; INJECTION

AMIFOSTINE

EUGIA PHARMA SPECLTS	500MG/VIAL	A204363	001	Jul 17, 2017

ETHYOL

CLINIGEN	375MG/VIAL	N020221	002	Sep 10, 1999

AMIKACIN SULFATE

INJECTABLE; INJECTION

AMIKACIN SULFATE

ABBOTT	EQ 250MG BASE/ML	A063265	001	Nov 30, 1994
	EQ 250MG BASE/ML	A063266	001	Oct 31, 1994
HIKMA	EQ 50MG BASE/ML	A063274	001	May 18, 1992
	EQ 250MG BASE/ML	A063275	001	May 18, 1992
HOSPIRA	EQ 50MG BASE/ML	A063263	001	Nov 30, 1994

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-22(of 478)

** See List Footnote

AMIKACIN SULFATE

INJECTABLE; INJECTION

AMIKACIN SULFATE

	EQ 50MG BASE/ML	A063350	001	Jul 30, 1993
	EQ 62.5MG BASE/ML	A063283	001	Oct 31, 1994
	EQ 250MG BASE/ML	A063264	001	Nov 30, 1994
	EQ 250MG BASE/ML	A063350	002	Jul 30, 1993
	EQ 250MG BASE/ML	A064098	001	Jun 26, 1995
	EQ 250MG BASE/ML	A064099	001	Jun 20, 1995
IGI LABS INC	EQ 50MG BASE/ML	A063167	001	Dec 14, 1995
	EQ 250MG BASE/ML	A063169	001	Dec 14, 1995
TEVA PHARMS USA	EQ 50MG BASE/ML	A064045	001	Sep 28, 1993
AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
HOSPIRA	EQ 500MG BASE/100ML	A064146	001	Apr 02, 1997
AMIKIN				
APOTHECON	EQ 50MG BASE/ML	A062311	001	
	EQ 50MG BASE/ML	A062562	001	Sep 20, 1984
+	EQ 50MG BASE/ML **	N050495	001	
	EQ 250MG BASE/ML	A062311	002	
	EQ 250MG BASE/ML	A062562	002	Sep 20, 1984
+	EQ 250MG BASE/ML **	N050495	002	
AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
APOTHECON	EQ 5MG BASE/ML	N050618	002	Nov 30, 1987
	EQ 10MG BASE/ML	N050618	001	Nov 30, 1987

AMILORIDE HYDROCHLORIDE

TABLET; ORAL

AMILORIDE HYDROCHLORIDE

CHARTWELL RX

5MG

A204180 001 Aug 07, 2015

AMILORIDE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

CHARTWELL RX

EQ 5MG ANHYDROUS; 50MG

A073357 001 Nov 27, 1991

TEVA

EQ 5MG ANHYDROUS; 50MG

A070795 001 Apr 17, 1988

WATSON LABS

EQ 5MG ANHYDROUS; 50MG

A073334 001 Jul 19, 1991

HYDRO-RIDE

PAR PHARM

EQ 5MG ANHYDROUS; 50MG

A070347 001 Dec 25, 1990

MODURETIC 5-50

+ MERCK

EQ 5MG ANHYDROUS; 50MG **

N018201 001

AMINO ACIDS

INJECTABLE; INJECTION

AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE

HOSPIRA

5.2% (5.2GM/100ML)

N018901 001 Apr 06, 1984

AMINOSYN 10%

ICU MEDICAL INC

10% (10GM/100ML)

N017673 003

AMINOSYN 10% (PH6)

ICU MEDICAL INC

10% (10GM/100ML)

N017673 008 Nov 18, 1985

AMINOSYN 3.5%

ICU MEDICAL INC

3.5% (3.5GM/100ML)

N017789 004

AMINOSYN 3.5% IN PLASTIC CONTAINER

ABBOTT

3.5% (3.5GM/100ML)

N018804 001 May 15, 1984

3.5% (3.5GM/100ML)

N018875 001 Aug 08, 1984

AMINOSYN 5%

ICU MEDICAL INC

5% (5GM/100ML)

N017673 001

AMINOSYN 7%

ICU MEDICAL INC

7% (7GM/100ML)

N017673 002

AMINOSYN 7% (PH6)

ICU MEDICAL INC

7% (7GM/100ML)

N017673 006 Nov 18, 1985

AMINOSYN 8.5%

ICU MEDICAL INC

8.5% (8.5GM/100ML)

N017673 004

AMINOSYN 8.5% (PH6)

ICU MEDICAL INC

8.5% (8.5GM/100ML)

N017673 007 Nov 18, 1985

AMINOSYN II 10%

ICU MEDICAL INC

10% (10GM/100ML)

N019438 005 Apr 03, 1986

AMINOSYN II 3.5%

ICU MEDICAL INC

3.5% (3.5GM/100ML)

N019438 001 Apr 03, 1986

AMINOSYN II 3.5% IN PLASTIC CONTAINER

ABBOTT

3.5% (3.5GM/100ML)

N019491 001 Oct 10, 1986

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-23(of 478)

** See List Footnote

AMINO ACIDS

INJECTABLE; INJECTION

AMINOSYN II 5%				
ICU MEDICAL INC	5% (5GM/100ML)	N019438	002	Apr 03, 1986
AMINOSYN II 7%				
ICU MEDICAL INC	7% (7GM/100ML)	N019438	003	Apr 03, 1986
AMINOSYN II 8.5%				
ICU MEDICAL INC	8.5% (8.5GM/100ML)	N019438	004	Apr 03, 1986
AMINOSYN-HBC 7%				
ICU MEDICAL INC	7% (7GM/100ML)	N019374	001	Jul 12, 1985
AMINOSYN-HBC 7% IN PLASTIC CONTAINER				
ABBOTT	7% (7GM/100ML)	N019400	001	Jul 23, 1986
AMINOSYN-HF 8%				
ICU MEDICAL INC	8% (8GM/100ML)	A020345	001	Apr 04, 1996
AMINOSYN-RF 5.2%				
ICU MEDICAL INC	5.2% (5.2GM/100ML)	N018429	001	
BRANCHAMIN 4%				
BAXTER HLTHCARE	4% (4GM/100ML)	N018678	001	Sep 28, 1984
BRANCHAMIN 4% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	4% (4GM/100ML)	N018684	001	Sep 28, 1984
FREAMINE 8.5%				
B BRAUN	8.5% (8.5GM/100ML)	N016822	001	
FREAMINE II 8.5%				
B BRAUN	8.5% (8.5GM/100ML)	N016822	002	
HEPATASOL 8%				
BAXTER HLTHCARE	8% (8GM/100ML)	A020360	001	Apr 04, 1996
NEOPHAM 6.4%				
HOSPIRA	6.4% (6.4GM/100ML)	N018792	001	Jan 17, 1984
NEPHRAMINE 5.4%				
B BRAUN	5.4% (5.4GM/100ML)	N017766	001	
NOVAMINE 11.4%				
HOSPIRA INC	11.4% (11.4GM/100ML)	N017957	003	Aug 09, 1982
NOVAMINE 15%				
HOSPIRA INC	15% (75GM/500ML)	N017957	004	Nov 28, 1986
NOVAMINE 15% SULFITE FREE IN PLASTIC CONTAINER				
BAXTER HLTHCARE	15% (15GM/100ML) **	N020107	001	Feb 05, 1993
NOVAMINE 8.5%				
HOSPIRA INC	8.5% (8.5GM/100ML)	N017957	002	Aug 09, 1982
RENAMIN W/O ELECTROLYTES				
BAXTER HLTHCARE	6.5% (6.5GM/100ML)	N017493	007	Oct 15, 1982
TRAVASOL 10% W/O ELECTROLYTES				
BAXTER HLTHCARE	10% (10GM/100ML)	N017493	006	
TRAVASOL 5.5% W/O ELECTROLYTES				
BAXTER HLTHCARE	5.5% (5.5GM/100ML)	N017493	004	
TRAVASOL 8.5% W/O ELECTROLYTES				
BAXTER HLTHCARE	8.5% (8.5GM/100ML)	N017493	005	

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN II 3.5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER				
ABBOTT	3.5%; 36.8MG/100ML; 25GM/100ML; 51MG/100ML ; 22.4MG/100ML; 261MG/100ML; 205MG/100ML	N019714	001	Sep 12, 1988
HOSPIRA INC	3.5%; 36.8MG/100ML; 25GM/100ML; 51MG/100ML ; 22.4MG/100ML; 261MG/100ML; 205MG/100ML	N019683	001	Nov 07, 1988
AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER				
ABBOTT	4.25%; 36.8MG/100ML; 20GM/100ML; 51MG/100ML L; 22.4MG/100ML; 261MG/100ML; 205MG/100ML	N019714	002	Sep 12, 1988
HOSPIRA INC	4.25%; 36.8MG/100ML; 20GM/100ML; 51MG/100ML L; 22.4MG/100ML; 261MG/100ML; 205MG/100ML	N019683	002	Nov 07, 1988
AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER				
ABBOTT	4.25%; 36.8MG/100ML; 25GM/100ML; 51MG/100ML L; 22.4MG/100ML; 261MG/100ML; 205MG/100ML	N019714	004	Sep 12, 1988
HOSPIRA INC	4.25%; 36.8MG/100ML; 25GM/100ML; 51MG/100ML L; 22.4MG/100ML; 261MG/100ML; 205MG/100ML	N019683	003	Nov 07, 1988

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-24(of 478)

** See List Footnote

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN II 5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER

ABBOTT	5%;36.8MG/100ML;25GM/100ML;51MG/100ML;2	N019714	003	Sep 12, 1988
	2.4MG/100ML;261MG/100ML;205MG/100ML			
HOSPIRA INC	5%;36.8MG/100ML;25GM/100ML;51MG/100ML;2	N019683	004	Nov 07, 1988
	2.4MG/100ML;261MG/100ML;205MG/100ML			

AMINO ACIDS; DEXTROSE

INJECTABLE; INJECTION

AMINOSYN 3.5% W/ DEXTROSE 25% IN PLASTIC CONTAINER

ABBOTT	3.5%;25GM/100ML	N019118	001	Oct 11, 1984

AMINOSYN 3.5% W/ DEXTROSE 5% IN PLASTIC CONTAINER

ABBOTT	3.5%;5GM/100ML	N019120	001	Oct 11, 1984

AMINOSYN 4.25% W/ DEXTROSE 25% IN PLASTIC CONTAINER

ABBOTT	4.25%;25GM/100ML	N019119	001	Oct 11, 1984

AMINOSYN II 3.5% IN DEXTROSE 25% IN PLASTIC CONTAINER

ABBOTT	3.5%;25GM/100ML	N019505	002	Nov 07, 1986

	3.5%;25GM/100ML	N019713	006	Sep 09, 1988

HOSPIRA	3.5%;25GM/100ML	N019681	001	Nov 01, 1988

AMINOSYN II 3.5% IN DEXTROSE 5% IN PLASTIC CONTAINER

ABBOTT	3.5%;5GM/100ML	N019506	001	Nov 07, 1986

	3.5%;5GM/100ML	N019713	002	Sep 09, 1988

HOSPIRA	3.5%;5GM/100ML	N019681	002	Nov 01, 1988

AMINOSYN II 4.25% IN DEXTROSE 10% IN PLASTIC CONTAINER

ABBOTT	4.25%;10GM/100ML	N019713	001	Sep 09, 1988

HOSPIRA	4.25%;10GM/100ML	N019681	004	Nov 01, 1988

AMINOSYN II 4.25% IN DEXTROSE 20% IN PLASTIC CONTAINER

ABBOTT	4.25%;20GM/100ML	N019713	004	Sep 09, 1988

HOSPIRA	4.25%;20GM/100ML	N019681	005	Nov 01, 1988

AMINOSYN II 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER

ABBOTT	4.25%;25GM/100ML	N019504	002	Nov 07, 1986

	4.25%;25GM/100ML	N019713	005	Sep 09, 1988

HOSPIRA	4.25%;25GM/100ML	N019681	003	Nov 01, 1988

AMINOSYN II 5% IN DEXTROSE 25% IN PLASTIC CONTAINER

ABBOTT	5%;25GM/100ML	N019565	001	Dec 17, 1986

	5%;25GM/100ML	N019713	003	Sep 09, 1988

HOSPIRA	5%;25GM/100ML	N019681	006	Nov 01, 1988

TRAVASOL 2.75% IN DEXTROSE 10% IN PLASTIC CONTAINER

BAXTER HLTHCARE	2.75%;10GM/100ML	N019520	002	Sep 23, 1988

TRAVASOL 2.75% IN DEXTROSE 15% IN PLASTIC CONTAINER

BAXTER HLTHCARE	2.75%;15GM/100ML	N019520	003	Sep 23, 1988

TRAVASOL 2.75% IN DEXTROSE 20% IN PLASTIC CONTAINER

BAXTER HLTHCARE	2.75%;20GM/100ML	N019520	004	Sep 23, 1988

TRAVASOL 2.75% IN DEXTROSE 25% IN PLASTIC CONTAINER

BAXTER HLTHCARE	2.75%;25GM/100ML	N019520	005	Sep 23, 1988

TRAVASOL 2.75% IN DEXTROSE 5% IN PLASTIC CONTAINER

BAXTER HLTHCARE	2.75%;5GM/100ML	N019520	001	Sep 23, 1988

TRAVASOL 4.25% IN DEXTROSE 10% IN PLASTIC CONTAINER

BAXTER HLTHCARE	4.25%;10GM/100ML	N019520	007	Sep 23, 1988

TRAVASOL 4.25% IN DEXTROSE 15% IN PLASTIC CONTAINER

BAXTER HLTHCARE	4.25%;15GM/100ML	N019520	008	Sep 23, 1988

TRAVASOL 4.25% IN DEXTROSE 20% IN PLASTIC CONTAINER

BAXTER HLTHCARE	4.25%;20GM/100ML	N019520	009	Sep 23, 1988

TRAVASOL 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER

BAXTER HLTHCARE	4.25%;25GM/100ML	N019520	010	Sep 23, 1988

TRAVASOL 4.25% IN DEXTROSE 5% IN PLASTIC CONTAINER

BAXTER HLTHCARE	4.25%;5GM/100ML	N019520	006	Sep 23, 1988

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM ACETATE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN II 4.25% W/ ELECT AND ADJUSTED PHOSPHATE IN DEXTROSE 10% IN PLASTIC CONTAINER

ABBOTT	4.25%;10GM/100ML;51MG/100ML;176.5MG/100	N019712	002	Sep 08, 1988
	ML;22.4MG/100ML;104.5MG/100ML;205MG/100			
	ML			

HOSPIRA INC	4.25%;10GM/100ML;51MG/100ML;176.5MG/100	N019682	003	Nov 01, 1988
	ML;22.4MG/100ML;104.5MG/100ML;205MG/100			
	ML			

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-25(of 478)

** See List Footnote

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN II 3.5% W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER

ABBOTT	3.5%; 25GM/100ML; 51MG/100ML; 22.4MG/100ML	N019564 002	Dec 16, 1986
	; 261MG/100ML; 205MG/100ML		

AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER

ABBOTT	4.25%; 25GM/100ML; 51MG/100ML; 22.4MG/100ML	N019564 004	Dec 16, 1986
	; 261MG/100ML; 205MG/100ML		

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE; INJECTION

AMINOSYN II 3.5% M IN DEXTROSE 5% IN PLASTIC CONTAINER

ABBOTT	3.5%; 5GM/100ML; 30MG/100ML; 97MG/100ML; 12	N019564 001	Dec 16, 1986
	0MG/100ML; 49.3MG/100ML		

	3.5%; 5GM/100ML; 30MG/100ML; 97MG/100ML; 12	N019712 001	Sep 08, 1988
	0MG/100ML; 49.3MG/100ML		

HOSPIRA INC	3.5%; 5GM/100ML; 30MG/100ML; 97MG/100ML; 12	N019682 001	Nov 01, 1988
	0MG/100ML; 49.3MG/100ML		

AMINOSYN II 4.25% M IN DEXTROSE 10% IN PLASTIC CONTAINER

ABBOTT	4.25%; 10GM/100ML; 30MG/100ML; 97MG/100ML;	N019564 003	Dec 16, 1986
	120MG/100ML; 49.3MG/100ML		

HOSPIRA INC	4.25%; 5GM/100ML; 30MG/100ML; 97MG/100ML; 1	N019682 002	Nov 01, 1988
	20MG/100ML; 49.3MG/100ML		

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 10% IN PLASTIC CONTAINER

BAXTER HLTHCARE	2.75%; 10GM/100ML; 51MG/100ML; 261MG/100ML	N020147 002	Oct 23, 1995
	; 216MG/100ML; 112MG/100ML		

TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 15% IN PLASTIC CONTAINER

BAXTER HLTHCARE	2.75%; 15GM/100ML; 51MG/100ML; 261MG/100ML	N020147 003	Oct 23, 1995
	; 216MG/100ML; 112MG/100ML		

TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 20% IN PLASTIC CONTAINER

BAXTER HLTHCARE	2.75%; 20GM/100ML; 51MG/100ML; 261MG/100ML	N020147 004	Oct 23, 1995
	; 216MG/100ML; 112MG/100ML		

TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER

BAXTER HLTHCARE	2.75%; 25GM/100ML; 51MG/100ML; 261MG/100ML	N020147 005	Oct 23, 1995
	; 216MG/100ML; 112MG/100ML		

TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 5% IN PLASTIC CONTAINER

BAXTER HLTHCARE	2.75%; 5GM/100ML; 51MG/100ML; 261MG/100ML;	N020147 001	Oct 23, 1995
	216MG/100ML; 112MG/100ML		

TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 10% IN PLASTIC CONTAINER

BAXTER HLTHCARE	4.25%; 10GM/100ML; 51MG/100ML; 261MG/100ML	N020147 007	Oct 23, 1995
	; 297MG/100ML; 77MG/100ML		

TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 15% IN PLASTIC CONTAINER

BAXTER HLTHCARE	4.25%; 15GM/100ML; 51MG/100ML; 261MG/100ML	N020147 008	Oct 23, 1995
	; 297MG/100ML; 77MG/100ML		

TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 20% IN PLASTIC CONTAINER

BAXTER HLTHCARE	4.25%; 20GM/100ML; 51MG/100ML; 261MG/100ML	N020147 009	Oct 23, 1995
	; 297MG/100ML; 77MG/100ML		

TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER

BAXTER HLTHCARE	4.25%; 25GM/100ML; 51MG/100ML; 261MG/100ML	N020147 010	Oct 23, 1995
	; 297MG/100ML; 77MG/100ML		

TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 5% IN PLASTIC CONTAINER

BAXTER HLTHCARE	4.25%; 5GM/100ML; 51MG/100ML; 261MG/100ML;	N020147 006	Oct 23, 1995
	297MG/100ML; 77MG/100ML		

AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN 3.5% M

ICU MEDICAL INC	3.5%; 21MG/100ML; 40MG/100ML; 128MG/100ML;	N017789 003	
	234MG/100ML		

AMINOSYN 3.5% M IN PLASTIC CONTAINER

ABBOTT	3.5%; 21MG/100ML; 40MG/100ML; 128MG/100ML;	N018804 002	May 15, 1984
	234MG/100ML		

	3.5%; 21MG/100ML; 40MG/100ML; 128MG/100ML;	N018875 002	Aug 08, 1984
	234MG/100ML		

DISCONTINUED DRUG PRODUCT LIST

6-26(of 478)

** See List Footnote

AMINO ACIDS; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN 3.5% M

ICU MEDICAL INC 3.5%; 21MG/100ML; 128MG/100ML; 234MG/100ML N017789 005

AMINO ACIDS; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE; INJECTION

AMINOSYN II 3.5% M IN PLASTIC CONTAINER

ABBOTT 3.5%; 32MG/100ML; 128MG/100ML; 222MG/100ML N019493 001 Oct 16, 1986
; 49MG/100MLAMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM ACETATE; POTASSIUM CHLORIDE; SODIUM ACETATE

INJECTABLE; INJECTION

VEINAMINE 8%

HOSPIRA INC 8%; 61MG/100ML; 211MG/100ML; 56MG/100ML; 38 N017957 001
8MG/100MLAMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN II 10% W/ ELECTROLYTES

ICU MEDICAL INC 10%; 102MG/100ML; 45MG/100ML; 522MG/100ML; N019437 004 Apr 03, 1986
410MG/100ML

AMINOSYN II 7% W/ ELECTROLYTES

ICU MEDICAL INC 7%; 102MG/100ML; 45MG/100ML; 522MG/100ML; 4 N019437 006 Apr 03, 1986
10MG/100ML

AMINOSYN II 8.5% W/ ELECTROLYTES

ICU MEDICAL INC 8.5%; 102MG/100ML; 45MG/100ML; 522MG/100ML N019437 005 Apr 03, 1986
; 410MG/100MLAMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC

INJECTABLE; INJECTION

AMINOSYN 8.5% W/ELECTROLYTES

ICU MEDICAL INC 8.5%; 102MG/100ML; 487MG/100ML; 28MG/100ML N017673 009 Oct 25, 2002
; 425MG/100ML

AMINOSYN II 8.5% W/ELECTROLYTES

ICU MEDICAL INC 8.5%; 102MG/100ML; 492MG/100ML; 60MG/100ML N019437 008 Oct 25, 2002
; 425MG/100MLAMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE; INJECTION

AMINOSYN II 3.5% M

ICU MEDICAL INC 3.5%; 30MG/100ML; 97MG/100ML; 120MG/100ML; N019437 007 Apr 03, 1986
49MG/100MLAMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

TRAVASOL 3.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER

BAXTER HLTHCARE 3.5%; 51MG/100ML; 131MG/100ML; 218MG/100ML N020177 001 Oct 23, 1995
; 35MG/100ML

TRAVASOL 3.5% W/ ELECTROLYTES

BAXTER HLTHCARE 3.5%; 51MG/100ML; 131MG/100ML; 218MG/100ML N017493 003
; 35MG/100ML

TRAVASOL 5.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER

BAXTER HLTHCARE 5.5%; 102MG/100ML; 522MG/100ML; 431MG/100M N020173 001 Oct 27, 1995
L; 224MG/100ML

TRAVASOL 5.5% W/ ELECTROLYTES

BAXTER HLTHCARE 5.5%; 102MG/100ML; 522MG/100ML; 431MG/100M N017493 001
L; 224MG/100ML

TRAVASOL 8.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER

BAXTER HLTHCARE 8.5%; 102MG/100ML; 522MG/100ML; 594MG/100M N020173 002 Oct 27, 1995
L; 154MG/100ML

TRAVASOL 8.5% W/ ELECTROLYTES

BAXTER HLTHCARE 8.5%; 102MG/100ML; 522MG/100ML; 594MG/100M N017493 002
L; 154MG/100MLAMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION

AMINOSYN 7% W/ ELECTROLYTES

ICU MEDICAL INC 7%; 102MG/100ML; 522MG/100ML; 410MG/100ML N017789 002

AMINOSYN 8.5% W/ ELECTROLYTES

ICU MEDICAL INC 8.5%; 102MG/100ML; 522MG/100ML; 410MG/100M N017673 005
L

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-27(of 478)

** See List Footnote

AMINOCAPROIC ACID

INJECTABLE; INJECTION

AMICAR

+ AKORN

250MG/ML **

N015229 002

AMINOCAPROIC ACID

ABRAXIS PHARM

250MG/ML

A070522 001 Jun 17, 1986

BAXTER HLTHCARE

250MG/ML

N018590 001 Oct 29, 1982

HOSPIRA

250MG/ML

A070888 001 Jun 16, 1988

SOLUTION; ORAL

AMINOCAPROIC ACID

AKORN

0.25GM/ML

A074759 001 Sep 02, 1998

TABLET; ORAL

AMINOCAPROIC

AKORN

500MG

A075602 001 May 24, 2001

AMINOCAPROIC ACID

EDENBRIDGE PHARMS

500MG

A212110 001 Jun 14, 2021

AMINOGLUTETHIMIDE

TABLET; ORAL

CYTADREN

NOVARTIS

250MG

N018202 001

AMINOHIPPURATE SODIUM

INJECTABLE; INJECTION

AMINOHIPPURATE SODIUM

MERCK

20%

N005619 001

AMINOPHYLLINE

ENEMA; RECTAL

SOMOPHYLLIN

FISONS

300MG/5ML

N018232 001 Apr 02, 1982

INJECTABLE; INJECTION

AMINOPHYLLIN

+ GD SEARLE LLC

25MG/ML

A087243 001 May 24, 1982

+

25MG/ML

A087621 001 May 24, 1982

AMINOPHYLLINE

ABRAXIS PHARM

25MG/ML

A084568 001

25MG/ML

A087200 001

25MG/ML

A087250 001 Jan 06, 1982

25MG/ML

A087886 001 Aug 30, 1983

25MG/ML

A088407 001 Jan 25, 1984

AM REGENT

25MG/ML

A087600 001

ELKINS SINN

25MG/ML

A087239 001

HOSPIRA

25MG/ML

A087601 001 Jul 23, 1982

INTL MEDICATION

25MG/ML

A087209 001 Feb 01, 1982

25MG/ML

A087867 001 Nov 10, 1983

25MG/ML

A087868 001 Nov 10, 1983

KING PHARMS

25MG/ML

A086606 001

LUITPOLD

25MG/ML

A087240 001

LYPHOMED

25MG/ML

A087431 001

PHARMA SERVE NY

25MG/ML

A087387 001 Jun 03, 1983

25MG/ML

A087392 001 Dec 15, 1983

SMITH AND NEPHEW

25MG/ML

A088429 001 May 30, 1985

25MG/ML

A088749 001 May 30, 1985

TEVA PARENTERAL

25MG/ML

A081142 001 Sep 25, 1991

AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%

HOSPIRA

100MG/100ML

A088147 002 May 03, 1983

200MG/100ML

A088147 003 May 03, 1983

AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

HOSPIRA

100MG/100ML

N018924 001 Dec 12, 1984

200MG/100ML

N018924 002 Dec 12, 1984

400MG/100ML

N018924 003 Dec 12, 1984

500MG/100ML

N018924 004 Dec 12, 1984

SOLUTION; ORAL

AMINOPHYLLINE

MORTON GROVE

105MG/5ML

A088156 001 Dec 05, 1983

ROXANE

105MG/5ML

A088126 001 Aug 19, 1983

AMINOPHYLLINE DYE FREE

ACTAVIS MID ATLANTIC

105MG/5ML

A087727 001 Apr 16, 1982

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-28(of 478)

** See List Footnote

AMINOPHYLLINE

SOLUTION; ORAL

SOMOPHYLLIN

FISONS

105MG/5ML

A086466 001

SOMOPHYLLIN-DF

FISONS

105MG/5ML

A087045 001

SUPPOSITORY; RECTAL

TRUPHYLLINE

COSETTE

250MG

A085498 001 Mar 23, 1983

500MG

A085498 002 Jan 03, 1983

TABLET; ORAL

AMINOPHYLLIN

GD SEARLE LLC

100MG

N002386 002

200MG

N002386 003

AMINOPHYLLINE

ANI PHARMS

100MG

A085261 004

200MG

A085261 002

ASCOT

100MG

A087522 001 Feb 12, 1982

200MG

A087523 001 Feb 12, 1982

BARR

100MG

A088297 001 Aug 19, 1983

200MG

A088298 001 Aug 19, 1983

DURAMED PHARMS BARR

100MG

A088182 001 Mar 31, 1983

200MG

A088183 001 Mar 31, 1983

HALSEY

100MG

A084674 001

HIKMA INTL PHARMS

100MG

A084540 001

200MG

A085003 001

IMPAX LABS

100MG

A084574 001

200MG

A084576 001

KV PHARM

100MG

A085284 001

200MG

A085289 001

LANNETT

100MG

A084588 001

200MG

A084588 002

PAL PAK

100MG

A084533 001

PANRAY

100MG

A084552 001

200MG

A084552 002

PUREPAC PHARM

100MG

A084699 001

200MG

A085333 001

ROXANE

100MG

A087500 001 Feb 09, 1982

200MG

A087501 001 Feb 09, 1982

VALEANT PHARM INTL

200MG

A084563 001

VANGARD

100MG

A088314 001 Oct 03, 1983

200MG

A088319 001 Oct 03, 1983

VINTAGE PHARMS

100MG

A085409 001

200MG

A085410 001

WATSON LABS

100MG

A085567 001

200MG

A085564 001

TABLET, DELAYED RELEASE; ORAL

AMINOPHYLLINE

IMPAX LABS

100MG

A084577 001

200MG

A084575 001

TABLICAPS

100MG

A084632 002

VALE

100MG

A084531 001

200MG

A084530 001

TABLET, EXTENDED RELEASE; ORAL

PHYLLOCONTIN

PHARM RES ASSOC

225MG

A086760 001

AMINOSALICYLATE SODIUM

POWDER; ORAL

P.A.S. SODIUM

CENTURY PHARMS

4GM/PACKET

A080947 001

SODIUM AMINOSALICYLATE

HEXCEL

100%

A080097 001

TABLET; ORAL

PARASAL SODIUM

PANRAY

500MG

N006811 006

1GM

N006811 011

SODIUM P.A.S.

LANNETT

500MG

A080138 002

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-29(of 478)

** See List Footnote

AMINOSALICYLATE SODIUM

TABLET; ORAL

TEEBACIN

CONSOLIDATED MIDLAND 500MG

N007320 002

AMINOSALICYLATE SODIUM; AMINOSALICYLIC ACID

TABLET; ORAL

NEOPASALATE

MEDPOINTE PHARM HLC 846MG;112MG

A080059 002

AMINOSALICYLIC ACID

TABLET; ORAL

PARASAL

PANRAY

500MG

N006811 001

1GM

N006811 002

AMINOSALICYLIC ACID RESIN COMPLEX

POWDER; ORAL

REZIPAS

BRISTOL MYERS SQUIBB EQ 500MG BASE/GM

N009052 001

AMIODARONE HYDROCHLORIDE

INJECTABLE; INJECTION

AMIODARONE HYDROCHLORIDE

AKORN 50MG/ML

A076232 001 Jul 05, 2006

BEDFORD 50MG/ML

A076018 001 Oct 15, 2002

BEDFORD LABS 50MG/ML

A076299 001 Oct 24, 2002

BEN VENUE 50MG/ML

A076088 001 Oct 15, 2002

DR REDDYS 50MG/ML

A076163 001 Sep 05, 2003

EUGIA PHARMA 50MG/ML

A204550 001 Oct 25, 2017

HOSPIRA 50MG/ML

A075955 001 Oct 18, 2002

50MG/ML

A076108 001 Oct 15, 2002

50MG/ML

A203885 001 Nov 25, 2013

INTL MEDICATION SYS 50MG/ML

N021594 001 Feb 04, 2004

PAR STERILE PRODUCTS 50MG/ML

A076394 001 Apr 25, 2003

CORDARONE

+ WYETH PHARMS INC 50MG/ML **

N020377 001 Aug 03, 1995

NEXTERONE

+ BAXTER HLTHCARE 50MG/ML **

N022325 001 Dec 24, 2008

TABLET; ORAL

AMIODARONE HYDROCHLORIDE

MYLAN 200MG

A075188 001 Feb 24, 1999

TEVA 200MG

A074895 001 Apr 16, 1999

UPSHER SMITH LABS 200MG

A075315 001 Dec 23, 1998

400MG

A075315 002 Jun 30, 2000

CORDARONE

+ WYETH PHARMS 200MG **

N018972 001 Dec 24, 1985

AMITRIPTYLINE HYDROCHLORIDE

CONCENTRATE; ORAL

ENDEP

+ ROCHE 40MG/ML **

A085749 001

INJECTABLE; INJECTION

AMITRIPTYLINE HYDROCHLORIDE

WATSON LABS 10MG/ML

A085594 001

ELAVIL

ASTRAZENECA 10MG/ML

N012704 001

TABLET; ORAL

AMITID

BRISTOL MYERS SQUIBB 10MG

A086454 001

25MG

A086454 002

50MG

A086454 003

75MG

A086454 004

100MG

A086454 005

AMITRIL

WARNER CHILCOTT 10MG

A083939 001

25MG

A083937 001

50MG

A083938 002

75MG

A084957 001

100MG

A085093 001

150MG

A086295 001

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-30(of 478)

** See List Footnote

AMITRIPTYLINE HYDROCHLORIDE

TABLET;ORAL

AMITRIPTYLINE HYDROCHLORIDE

AIPING PHARM INC	10MG	A212654 002	Sep 29, 2021
	25MG	A212654 001	Apr 07, 2020
	50MG	A212654 003	Sep 29, 2021
	75MG	A212654 004	Sep 29, 2021
	100MG	A212654 005	Sep 29, 2021
	150MG	A212654 006	Sep 29, 2021
AM THERAP	25MG	A088672 001	Nov 20, 1984
	50MG	A088673 001	Nov 20, 1984
	75MG	A088674 001	Nov 20, 1984
	100MG	A088675 001	Nov 20, 1984
ANI PHARMS	10MG	A085031 002	
	25MG	A085031 001	
	50MG	A085031 003	
	75MG	A085031 004	
AUROBINDO PHARMA USA	10MG	A086009 002	
	25MG	A086009 003	
	50MG	A086009 001	
	75MG	A086009 004	
	100MG	A086009 005	
	150MG	A086009 006	
COPLEY PHARM	10MG	A088421 001	Apr 30, 1984
	25MG	A088422 001	Apr 30, 1984
	50MG	A088423 001	Apr 30, 1984
	75MG	A088424 001	Apr 30, 1984
	100MG	A088425 001	Apr 30, 1984
	150MG	A088426 001	Apr 30, 1984
HALSEY	10MG	A085923 001	
	25MG	A085922 001	
	50MG	A085925 001	
	50MG	A087557 001	Mar 05, 1982
	75MG	A085926 001	May 20, 1983
	100MG	A085927 001	May 20, 1983
LEDERLE	10MG	A086744 001	
	10MG	A087366 001	Jan 04, 1982
	25MG	A086746 001	
	25MG	A087367 001	May 03, 1982
	50MG	A086743 001	
	50MG	A087181 001	Jan 04, 1982
	75MG	A086745 001	
	75MG	A087369 001	Jan 04, 1982
	100MG	A086747 001	
	100MG	A087368 001	May 03, 1982
	150MG	A087370 001	Jan 04, 1982
MUTUAL PHARM	10MG	A085744 001	
	25MG	A085627 001	
	50MG	A085745 001	
	75MG	A085743 001	
	100MG	A085742 002	May 11, 1982
	150MG	A089423 001	Feb 17, 1987
PAR PHARM	10MG	A088697 001	Sep 25, 1984
	25MG	A088698 001	Sep 25, 1984
	50MG	A088699 001	Sep 25, 1984
	75MG	A088700 001	Sep 25, 1984
	100MG	A088701 001	Sep 25, 1984
	150MG	A088702 001	Sep 25, 1984
PLIVA	10MG	A088883 001	Sep 26, 1984
	25MG	A088884 001	Sep 26, 1984
	50MG	A088885 001	Sep 26, 1984
	75MG	A088886 001	Sep 26, 1984
	100MG	A088887 001	Sep 26, 1984
	150MG	A088888 001	Sep 26, 1984
PUREPAC PHARM	10MG	A088075 001	Sep 16, 1983
	10MG	A088084 001	Jul 18, 1983
	25MG	A088076 001	May 20, 1983
	25MG	A088085 001	Jul 18, 1983
	50MG	A088077 001	Sep 16, 1983

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-31(of 478)

** See List Footnote

AMITRIPTYLINE HYDROCHLORIDE

TABLET;ORAL

AMITRIPTYLINE HYDROCHLORIDE

	50MG	A088105	001	Jul 18, 1983
	75MG	A088078	001	Sep 16, 1983
	75MG	A088106	001	Jul 18, 1983
	100MG	A088079	001	Sep 16, 1983
	100MG	A088107	001	Jul 18, 1983
ROXANE	10MG	A086002	001	
	10MG	A086144	001	
	25MG	A085944	001	
	25MG	A086145	001	
	50MG	A085945	001	
	50MG	A086143	001	
	75MG	A086004	001	
	75MG	A086147	001	
	100MG	A086003	001	
	100MG	A086146	001	
	150MG	A086090	001	
	150MG	A086148	001	
SUN PHARM INDS INC	10MG	A040816	002	Jun 27, 2008
	25MG	A040816	001	Jun 27, 2008
	50MG	A040816	003	Jun 27, 2008
	75MG	A040816	004	Jun 27, 2008
	100MG	A040816	005	Jun 27, 2008
	150MG	A040816	006	Jun 27, 2008
SUPERPHARM	10MG	A088853	001	Nov 13, 1984
	25MG	A088854	001	Nov 13, 1984
	50MG	A088855	001	Nov 13, 1984
	75MG	A088856	001	Nov 13, 1984
	100MG	A088857	001	Nov 13, 1984
TEVA	10MG	A086610	001	
	25MG	A086859	001	
	50MG	A086857	001	
	75MG	A086860	001	
	100MG	A085836	001	
	100MG	A086854	001	
	150MG	A086853	001	
UCB INC	10MG	A085864	001	
	25MG	A085935	001	
	50MG	A085936	001	
	75MG	A086337	001	
	100MG	A086336	001	
	150MG	A086335	001	
USL PHARMA	25MG	A087775	001	Feb 10, 1982
VANGARD	10MG	A087632	001	Feb 01, 1982
	50MG	A087616	001	Feb 08, 1982
	75MG	A087617	001	Feb 05, 1982
	100MG	A087639	001	Feb 08, 1982
VINTAGE PHARMS	10MG	A040218	001	Sep 11, 1997
	25MG	A040218	002	Sep 11, 1997
	50MG	A040218	003	Sep 11, 1997
	75MG	A040218	004	Sep 11, 1997
	100MG	A040218	005	Sep 11, 1997
	150MG	A040218	006	Sep 11, 1997
WATSON LABS	10MG	A085816	001	
	10MG	A088620	001	Mar 02, 1984
	25MG	A085817	001	
	25MG	A088621	001	Mar 02, 1984
	50MG	A085815	001	
	50MG	A088622	001	Mar 02, 1984
	75MG	A085819	001	
	75MG	A088633	001	Mar 02, 1984
	100MG	A085820	001	
	100MG	A088634	001	Mar 02, 1984
	150MG	A085821	001	
	150MG	A088635	001	Mar 02, 1984
WEST WARD	10MG	A087647	001	Mar 05, 1982
	25MG	A087278	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-32(of 478)

** See List Footnote

AMITRIPTYLINE HYDROCHLORIDE

TABLET;ORAL

ELAVIL

+	ASTRAZENECA	10MG **	N012703 001
+		25MG **	N012703 003
+		50MG **	N012703 004
+		75MG **	N012703 005
+		100MG **	N012703 006
+		150MG **	N012703 007

ENDEP

ROCHE	10MG	A083639 001
	25MG	A083639 002
	50MG	A083639 003
	75MG	A083639 004
	100MG	A083639 005
	150MG	A085303 001

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET;ORAL

CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE

HERITAGE PHARMA	EQ 12.5MG BASE;5MG	A072052 001	Dec 16, 1988
	EQ 25MG BASE;10MG	A072053 001	Dec 16, 1988
STRIDES PHARMA	EQ 12.5MG BASE;5MG	A072277 001	May 09, 1988
	EQ 25MG BASE;10MG	A072278 001	May 09, 1988
UNITED RES LABS	EQ 12.5MG BASE;5MG	A070765 001	Dec 10, 1986
	EQ 25MG BASE;10MG	A070766 001	Dec 10, 1986
USL PHARMA	EQ 12.5MG BASE;5MG	A070477 001	Jan 12, 1988
	EQ 25MG BASE;10MG	A070478 001	Jan 12, 1988

LIMBITROL

+	HERITAGE PHARMS INC	EQ 12.5MG BASE;5MG **	N016949 001

LIMBITROL DS

+	HERITAGE PHARMS INC	EQ 25MG BASE;10MG **	N016949 002

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET;ORAL

ETRAFON 2-10

SCHERING	10MG;2MG **	N014713 007

ETRAFON 2-25

SCHERING	25MG;2MG **	N014713 004

ETRAFON-A

SCHERING	10MG;4MG **	N014713 002

ETRAFON-FORTE

SCHERING	25MG;4MG **	N014713 006

PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE

FOSUN PHARMA	10MG;2MG	A071062 001	Nov 27, 1987
	10MG;4MG	A071862 001	Dec 21, 1987
	25MG;2MG	A071063 001	Nov 27, 1987
	25MG;4MG	A071064 001	Nov 27, 1987
	50MG;4MG	A071863 001	Dec 21, 1987
HERITAGE PHARMA	10MG;2MG	A073007 001	Oct 17, 1991
	10MG;4MG	A073009 001	Oct 17, 1991
	25MG;2MG	A073008 001	Oct 17, 1991
	25MG;4MG	A073010 001	Oct 17, 1991
IVAX SUB TEVA PHARMS	10MG;2MG	A070935 001	Sep 11, 1986
	10MG;4MG	A070937 001	Sep 11, 1986
	25MG;2MG	A070936 001	Sep 11, 1986
	25MG;4MG	A070938 001	Sep 11, 1986
	50MG;4MG	A070939 001	Sep 12, 1986
PAR PHARM	10MG;2MG	A070565 001	Sep 11, 1986
	10MG;4MG	A070620 001	Sep 11, 1986
	25MG;2MG	A070621 001	Sep 11, 1986
	25MG;4MG	A070595 001	Sep 11, 1986
	50MG;4MG	A070574 001	Sep 11, 1986
SUN PHARM INDUSTRIES	10MG;2MG	A071077 001	Nov 12, 1986
	10MG;4MG	A071078 001	Nov 12, 1986
	25MG;2MG	A070297 001	Nov 12, 1986
	25MG;4MG	A071079 001	Nov 12, 1986
WATSON LABS	10MG;2MG	A070373 001	Aug 25, 1986
	10MG;2MG	A072539 001	Feb 15, 1989
	10MG;4MG	A070375 001	Aug 25, 1986

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-33(of 478)

** See List Footnote

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET;ORAL

PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE

	10MG;4MG	A072540 001	Feb 15, 1989
	25MG;2MG	A070374 001	Aug 25, 1986
	25MG;2MG	A072541 001	Feb 15, 1989
	25MG;4MG	A070376 001	Aug 25, 1986
	25MG;4MG	A072134 001	Feb 15, 1989
	50MG;4MG	A070377 001	Nov 04, 1986
	50MG;4MG	A071558 001	Mar 02, 1987
	50MG;4MG	A072135 001	Feb 15, 1989
TRIAVIL 2-10			
NEW RIVER	10MG;2MG **	N014715 004	
TRIAVIL 2-25			
NEW RIVER	25MG;2MG **	N014715 002	
TRIAVIL 4-10			
NEW RIVER	10MG;4MG **	N014715 003	
TRIAVIL 4-25			
NEW RIVER	25MG;4MG **	N014715 005	
TRIAVIL 4-50			
NEW RIVER	50MG;4MG **	N014715 006	

AMLEXANOX

PASTE;DENTAL

APHTHASOL

ULURU

5%

N020511 001 Dec 17, 1996

PATCH;TOPICAL

AMLEXANOX

ULURU

2MG

N021727 001 Sep 29, 2004

AMLODIPINE BESYLATE

TABLET;ORAL

AMLODIPINE BESYLATE

AMNEAL PHARMS NY

EQ 2.5MG BASE

A078477 001 Jan 16, 2008

EQ 5MG BASE

A078477 002 Jan 16, 2008

EQ 10MG BASE

A078477 003 Jan 16, 2008

CHARTWELL RX

EQ 2.5MG BASE

A076859 001 Sep 10, 2007

EQ 5MG BASE

A076859 002 Sep 10, 2007

EQ 10MG BASE

A076859 003 Sep 10, 2007

GEDEON RICHTER USA

EQ 2.5MG BASE

A077333 001 Jul 17, 2007

EQ 5MG BASE

A077333 002 Jul 17, 2007

EQ 10MG BASE

A077333 003 Jul 17, 2007

GENPHARM

EQ 2.5MG BASE

A077362 001 Jul 09, 2007

EQ 5MG BASE

A077362 002 Jul 09, 2007

EQ 10MG BASE

A077362 003 Jul 09, 2007

HIKMA

EQ 2.5MG BASE

A077262 001 Jul 09, 2007

EQ 5MG BASE

A077262 002 Jul 09, 2007

EQ 10MG BASE

A077262 003 Jul 09, 2007

HIKMA PHARMS

EQ 2.5MG BASE

A077771 001 Apr 12, 2011

EQ 5MG BASE

A077771 002 Apr 12, 2011

EQ 10MG BASE

A077771 003 Apr 12, 2011

MACLEODS PHARMS LTD

EQ 5MG BASE

A201380 001 Apr 13, 2012

EQ 10MG BASE

A201380 002 Apr 13, 2012

MYLAN

EQ 2.5MG BASE

A076418 001 Oct 03, 2005

EQ 2.5MG BASE

A078224 001 Feb 27, 2008

EQ 5MG BASE

A076418 002 Oct 03, 2005

EQ 5MG BASE

A078224 002 Feb 27, 2008

EQ 10MG BASE

A076418 003 Oct 03, 2005

EQ 10MG BASE

A078224 003 Feb 27, 2008

PURACAP PHARM

EQ 2.5MG BASE

A078131 001 Sep 04, 2007

EQ 5MG BASE

A078131 002 Sep 04, 2007

EQ 10MG BASE

A078131 003 Sep 04, 2007

SOVEREIGN PHARMS

EQ 2.5MG BASE

A204900 001 Jul 23, 2015

EQ 5MG BASE

A204900 002 Jul 23, 2015

EQ 10MG BASE

A204900 003 Jul 23, 2015

SUN PHARM INDS INC

EQ 2.5MG BASE

A078231 001 Nov 30, 2007

EQ 5MG BASE

A078231 002 Nov 30, 2007

EQ 10MG BASE

A078231 003 Nov 30, 2007

SUN PHARM INDUSTRIES

EQ 2.5MG BASE

A078081 001 Jan 31, 2008

EQ 5MG BASE

A078081 002 Jan 31, 2008

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-34(of 478)

** See List Footnote

AMLODIPINE BESYLATE

TABLET;ORAL

AMLODIPINE BESYLATE

	EQ 10MG BASE	A078081 003	Jan 31, 2008
SUNSHINE	EQ 2.5MG BASE	A206524 001	May 04, 2018
	EQ 5MG BASE	A206524 002	May 04, 2018
	EQ 10MG BASE	A206524 003	May 04, 2018
SYNTHON PHARMS	EQ 2.5MG BASE	A077080 001	Jun 27, 2007
	EQ 5MG BASE	A077080 002	Jun 27, 2007
	EQ 10MG BASE	A077080 003	Jun 27, 2007
TORRENT PHARMS	EQ 2.5MG BASE	A078573 001	Sep 22, 2008
	EQ 5MG BASE	A078573 002	Sep 22, 2008
	EQ 10MG BASE	A078573 003	Sep 22, 2008
UPSHER SMITH LABS	EQ 2.5MG BASE	A077759 001	Jul 09, 2007
	EQ 5MG BASE	A077759 002	Jul 09, 2007
	EQ 10MG BASE	A077759 003	Jul 09, 2007
WATSON LABS	EQ 2.5MG BASE	A077671 001	Jul 19, 2007
	EQ 5MG BASE	A077671 002	Jul 19, 2007
	EQ 10MG BASE	A077671 003	Jul 19, 2007
WOCKHARDT	EQ 2.5MG BASE	A078500 001	Sep 06, 2007
	EQ 5MG BASE	A078500 002	Sep 06, 2007
	EQ 10MG BASE	A078500 003	Sep 06, 2007

TABLET, ORALLY DISINTEGRATING;ORAL

AMLODIPINE BESYLATE

+	SYNTHON PHARMS	EQ 2.5MG BASE	N022026 001	Sep 27, 2007
+		EQ 5MG BASE	N022026 002	Sep 27, 2007
+		EQ 10MG BASE	N022026 003	Sep 27, 2007

AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM

TABLET;ORAL

AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM

MYLAN	EQ 2.5MG BASE;EQ 10MG BASE	A200465 001	Nov 29, 2013
	EQ 2.5MG BASE;EQ 20MG BASE	A200465 002	Nov 29, 2013
	EQ 2.5MG BASE;EQ 40MG BASE	A200465 003	Nov 29, 2013

AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

CAPSULE;ORAL

AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE

CIPLA	EQ 2.5MG BASE;10MG	A077215 001	Dec 07, 2018
	EQ 5MG BASE;10MG	A077215 002	Dec 07, 2018
	EQ 5MG BASE;20MG	A077215 003	Dec 07, 2018
	EQ 10MG BASE;20MG	A077215 004	Dec 07, 2018
MYLAN	EQ 2.5MG BASE;10MG	A077375 001	May 21, 2010
	EQ 5MG BASE;10MG	A077375 002	May 21, 2010
	EQ 5MG BASE;20MG	A077375 003	May 21, 2010
	EQ 5MG BASE;40MG	A079047 001	Jul 05, 2011
	EQ 10MG BASE;20MG	A077375 004	May 21, 2010
	EQ 10MG BASE;40MG	A079047 002	Jul 05, 2011
STRIDES PHARMA	EQ 2.5MG BASE;10MG	A078381 001	Jul 29, 2010
	EQ 5MG BASE;10MG	A078381 002	Jul 29, 2010
	EQ 5MG BASE;20MG	A078381 003	Jul 29, 2010
	EQ 5MG BASE;40MG	A078381 005	Jul 29, 2010
	EQ 10MG BASE;20MG	A078381 004	Jul 29, 2010
	EQ 10MG BASE;40MG	A078381 006	Jul 29, 2010
TEVA PHARMS	EQ 2.5MG BASE;10MG	A077179 001	May 18, 2007
	EQ 5MG BASE;10MG	A077179 002	May 18, 2007
	EQ 5MG BASE;20MG	A077179 003	May 18, 2007
	EQ 5MG BASE;40MG	A077179 005	Jul 05, 2011
	EQ 10MG BASE;20MG	A077179 004	May 18, 2007
	EQ 10MG BASE;40MG	A077179 006	Jul 05, 2011

AMLODIPINE BESYLATE; CELECOXIB

TABLET;ORAL

CONSENSI

+	PURPLE BIOTECH	EQ 2.5MG BASE;200MG	N210045 001	May 31, 2018
+		EQ 5MG BASE;200MG	N210045 002	May 31, 2018
+		EQ 10MG BASE;200MG	N210045 003	May 31, 2018

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-35(of 478)

** See List Footnote

AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET;ORAL

AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE

TEVA PHARMS	EQ 5MG BASE;12.5MG;160MG	A200435 001	Sep 25, 2012
	EQ 5MG BASE;25MG;160MG	A200435 002	Sep 25, 2012
	EQ 10MG BASE;12.5MG;160MG	A200435 005	Sep 25, 2012
	EQ 10MG BASE;25MG;160MG	A200435 003	Sep 25, 2012
	EQ 10MG BASE;25MG;320MG	A200435 004	Sep 25, 2012
TORRENT	EQ 5MG BASE;12.5MG;160MG	A201593 001	Jun 03, 2015
	EQ 5MG BASE;25MG;160MG	A201593 002	Jun 03, 2015
	EQ 10MG BASE;12.5MG;160MG	A201593 003	Jun 03, 2015
	EQ 10MG BASE;25MG;160MG	A201593 004	Jun 03, 2015
	EQ 10MG BASE;25MG;320MG	A201593 005	Jun 03, 2015

AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL

TABLET;ORAL

AMLODIPINE AND OLMESARTAN MEDOXOMIL

ACCORD HLTHCARE INC	EQ 5MG BASE;20MG	A209600 001	Aug 30, 2018
	EQ 5MG BASE;40MG	A209600 003	Aug 30, 2018
	EQ 10MG BASE;20MG	A209600 002	Aug 30, 2018
	EQ 10MG BASE;40MG	A209600 004	Aug 30, 2018
JUBILANT GENERICS	EQ 5MG BASE;20MG	A207450 001	May 15, 2017
	EQ 5MG BASE;40MG	A207450 002	May 15, 2017
	EQ 10MG BASE;20MG	A207450 003	May 15, 2017
	EQ 10MG BASE;40MG	A207450 004	May 15, 2017
SCIEGEN PHARMS INC	EQ 5MG BASE;20MG	A209010 001	Dec 03, 2018
	EQ 5MG BASE;40MG	A209010 002	Dec 03, 2018
	EQ 10MG BASE;20MG	A209010 003	Dec 03, 2018
	EQ 10MG BASE;40MG	A209010 004	Dec 03, 2018
TEVA PHARMS USA	EQ 5MG BASE;20MG	A091154 001	Oct 26, 2016
	EQ 5MG BASE;40MG	A091154 002	Oct 26, 2016
	EQ 10MG BASE;20MG	A091154 003	Oct 26, 2016
	EQ 10MG BASE;40MG	A091154 004	Oct 26, 2016
TORRENT	EQ 5MG BASE;20MG	A202933 001	Nov 25, 2016
	EQ 5MG BASE;40MG	A202933 002	Nov 25, 2016
	EQ 10MG BASE;20MG	A202933 003	Nov 25, 2016
	EQ 10MG BASE;40MG	A202933 004	Nov 25, 2016

AMLODIPINE BESYLATE; TELMISARTAN

TABLET;ORAL

TELMISARTAN AND AMLODIPINE

ALEMBIC PHARMS	EQ 5MG BASE;40MG	A205234 001	Nov 17, 2016
	EQ 5MG BASE;80MG	A205234 003	Nov 17, 2016
	EQ 10MG BASE;40MG	A205234 002	Nov 17, 2016
	EQ 10MG BASE;80MG	A205234 004	Nov 17, 2016
TORRENT	EQ 5MG BASE;40MG	A202517 001	Jan 08, 2014
	EQ 5MG BASE;80MG	A202517 003	Jan 08, 2014
	EQ 10MG BASE;40MG	A202517 002	Jan 08, 2014
	EQ 10MG BASE;80MG	A202517 004	Jan 08, 2014
TA			
BOEHRINGER INGELHEIM	EQ 5MG BASE;40MG	N022401 001	Oct 16, 2009
	EQ 5MG BASE;80MG	N022401 003	Oct 16, 2009
	EQ 10MG BASE;40MG	N022401 002	Oct 16, 2009
	EQ 10MG BASE;80MG	N022401 004	Oct 16, 2009

AMLODIPINE BESYLATE; VALSARTAN

TABLET;ORAL

AMLODIPINE BESYLATE AND VALSARTAN

TEVA PHARMS USA	EQ 5MG BASE;160MG	A091235 001	Mar 30, 2015
	EQ 5MG BASE;320MG	A091235 003	Mar 30, 2015
	EQ 10MG BASE;160MG	A091235 002	Mar 30, 2015
	EQ 10MG BASE;320MG	A091235 004	Mar 30, 2015
TORRENT	EQ 5MG BASE;160MG	A202377 001	Mar 30, 2015
	EQ 5MG BASE;320MG	A202377 002	Mar 30, 2015
	EQ 10MG BASE;160MG	A202377 003	Mar 30, 2015
	EQ 10MG BASE;320MG	A202377 004	Mar 30, 2015

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-36(of 478)

** See List Footnote

AMLODIPINE MALEATE

TABLET; ORAL

AMVAZ

DR REDDYS LABS INC	2.5MG	N021435 001	Oct 31, 2003
	5MG	N021435 002	Oct 31, 2003
	10MG	N021435 003	Oct 31, 2003

AMMONIA N-13

INJECTABLE; INTRAVENOUS

AMMONIA N 13

CENTRAL RADIOPHARM	3.75-260mCi/ML	A204539 001	Jun 23, 2015
UNIV TX MD ANDERSON	30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A203933 001	Jun 27, 2014

AMMONIUM CHLORIDE

INJECTABLE; INJECTION

AMMONIUM CHLORIDE

ABBOTT	5MEQ/ML	A083130 001	
GD SEARLE LLC	3MEQ/ML	A086205 001	
AMMONIUM CHLORIDE 0.9% IN NORMAL SALINE			
MCGAW	900MG/100ML	N006580 001	
AMMONIUM CHLORIDE 2.14%			
B BRAUN	40MEQ/100ML	A085734 001	

AMMONIUM LACTATE

CREAM; TOPICAL

AMMONIUM LACTATE

WATSON LABS INC	EQ 12% BASE	A076829 001	Feb 07, 2006
LAC-HYDRIN			
+ SUN PHARM INDS INC	EQ 12% BASE **	N020508 001	Aug 29, 1996

LOTION; TOPICAL

AMMONIUM LACTATE

WATSON LABS INC	EQ 12% BASE	A075575 001	Jun 11, 2002
LAC-HYDRIN			
+ SUN PHARM INDS INC	EQ 12% BASE **	N019155 001	Apr 24, 1985

AMODIAQUINE HYDROCHLORIDE

TABLET; ORAL

CAMOQUIN HYDROCHLORIDE

PARKE DAVIS	EQ 200MG BASE	N006441 001	

AMOXAPINE

TABLET; ORAL

AMOXAPINE

CHARTWELL RX	25MG	A072943 001	Jun 28, 1991
	50MG	A072944 001	Jun 28, 1991
	100MG	A072878 001	Jun 28, 1991
	150MG	A072879 001	Jun 28, 1991
WATSON PHARMS TEVA	25MG	A072418 001	Aug 01, 1989
	50MG	A072419 001	Aug 01, 1989
	100MG	A072420 001	May 11, 1989
	150MG	A072421 001	May 11, 1989
ASENDIN			
LEDERLE	25MG	N018021 001	
	50MG	N018021 002	
	100MG	N018021 003	
	150MG	N018021 004	

AMOXICILLIN

CAPSULE; ORAL

AMOXICILLIN

LABS ATRAL	250MG	A062528 001	Aug 07, 1985
	500MG	A062528 002	Aug 07, 1985
MYLAN	250MG	A062067 001	
	500MG	A062067 002	
STRIDES PHARMA	250MG	A062884 001	Feb 25, 1988
	500MG	A062881 001	Feb 25, 1988
SUN PHARM INDS LTD	250MG	A065016 001	Apr 08, 1999
	500MG	A065016 002	Apr 08, 1999
TEVA	250MG	A062853 001	Dec 22, 1987
	250MG	A063030 001	Feb 28, 1989
	500MG	A062854 001	Dec 22, 1987
	500MG	A063031 001	Feb 28, 1989

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-37(of 478)

** See List Footnote

AMOXICILLIN

CAPSULE;ORAL

AMOXIL

+ GLAXOSMITHKLINE 250MG **

+ 500MG **

N050459 001

N050459 002

TRIMOX

APOTHECON

250MG

250MG

250MG

250MG

500MG

500MG

500MG

500MG

A061885 001

A062098 001

A062152 001

A063099 001 Mar 20, 1992

A061885 002

A062098 002

A062152 002

A063099 002 Mar 20, 1992

UTIMOX

PARKE DAVIS

250MG

500MG

A062107 001

A062107 002

WYMOX

WYETH AYERST

250MG

500MG

A062120 001

A062120 002

FOR SUSPENSION;ORAL

AMOXICILLIN

BELCHER PHARMS

125MG/5ML

250MG/5ML

A062059 001

A062059 002

MYLAN

125MG/5ML

250MG/5ML

A062090 001

A062090 002

SUN PHARM INDS LTD

200MG/5ML

400MG/5ML

A065113 001 Nov 29, 2002

A065113 002 Nov 29, 2002

TEVA

125MG/5ML

125MG/5ML

250MG/5ML

A061931 001

A062946 001 Nov 01, 1988

A063001 001 Jan 06, 1989

AMOXIL

+ GLAXOSMITHKLINE 50MG/ML **

+ 125MG/5ML **

+ 250MG/5ML **

+ US ANTIBIOTICS 200MG/5ML **

+ 400MG/5ML **

N050460 005

N050460 001

N050460 002

N050760 001 Apr 15, 1999

N050760 002 Apr 15, 1999

LAROTID

+ GLAXOSMITHKLINE

50MG/ML **

N050460 006

POLYMOX

APOTHECON

125MG/5ML

125MG/5ML

250MG/5ML

250MG/5ML

A061851 001

A062323 001

A061851 002

A062323 002

TRIMOX

APOTHECON

50MG/ML

125MG/5ML

125MG/5ML

125MG/5ML

125MG/5ML

250MG/5ML

250MG/5ML

250MG/5ML

250MG/5ML

A061886 001

A061886 002

A062099 001

A062154 001

A062885 001 Mar 08, 1988

A061886 003

A062099 002

A062154 002

A062885 002 Mar 08, 1988

UTIMOX

PARKE DAVIS

125MG/5ML

250MG/5ML

A062127 001

A062127 002

WYMOX

WYETH AYERST

125MG/5ML

250MG/5ML

A062131 001

A062131 002

TABLET;ORAL

AMOXICILLIN

STRIDES PHARMA

875MG

A065344 001 Jan 15, 2009

SUN PHARM INDS LTD

500MG

A065059 001 Nov 24, 2000

875MG

A065059 002 Nov 24, 2000

AMOXIL

+ US ANTIBIOTICS 500MG **

+ 875MG **

N050754 002 Jul 10, 1998

N050754 001 Jul 10, 1998

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-38(of 478)

** See List Footnote

AMOXICILLIN

TABLET, CHEWABLE;ORAL

AMOXICILLIN

APOTHECON	125MG	A064131 001	May 06, 1996
	250MG	A064131 002	May 06, 1996
HIKMA	125MG	A205274 001	Jun 25, 2020
	250MG	A205274 002	Jun 25, 2020
STRIDES PHARMA	125MG	A064139 001	Jan 29, 1996
	250MG	A064139 002	Jan 29, 1996
SUN PHARM INDS LTD	125MG	A065021 001	Dec 23, 1999
	200MG	A065060 001	Nov 29, 2000
	250MG	A065021 002	Dec 23, 1999
	400MG	A065060 002	Nov 29, 2000
TEVA	125MG	A064031 001	Dec 19, 1996
	250MG	A064031 002	Dec 19, 1996

AMOXIL

+ US ANTIBIOTICS	125MG **	N050542 002	
	200MG	N050761 001	Apr 15, 1999
+	250MG **	N050542 001	
	400MG	N050761 002	Apr 15, 1999

TABLET, EXTENDED RELEASE;ORAL

MOXATAG

+ PRAGMA	775MG	N050813 001	Jan 23, 2008

TABLET, FOR SUSPENSION;ORAL

AMOXICILLIN

AUROBINDO PHARMA LTD	200MG	A065324 001	Jan 17, 2007
	400MG	A065324 002	Jan 17, 2007
DISPERMOX			
RANBAXY LABS LTD	200MG	A065080 002	Aug 11, 2003
	400MG	A065080 001	Aug 11, 2003
	600MG	A065159 001	Dec 04, 2003

AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE

CAPSULE, TABLET, CAPSULE, DELAYED REL PELLETS;ORAL

LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN (COPACKAGED)

ANI PHARMS	500MG;500MG;30MG	A200218 001	Aug 30, 2013

PREVPAC (COPACKAGED)

+ TAKEDA PHARMS USA	500MG;500MG;30MG **	N050757 001	Dec 02, 1997

AMOXICILLIN; CLARITHROMYCIN; OMEPRAZOLE

CAPSULE, TABLET, CAPSULE, DELAYED RELEASE;ORAL

OMEPRAZOLE AND CLARITHROMYCIN AND AMOXICILLIN

+ CUMBERLAND PHARMS	500MG,N/A,N/A;N/A,500MG,N/A;N/A,N/A,20MG	N050824 001	Feb 08, 2011

AMOXICILLIN; CLARITHROMYCIN; VONOPRAZAN FUMARATE

CAPSULE, TABLET, TABLET;ORAL

VOQUEZNA TRIPLE PAK

+ PHATHOM	500MG;500MG;EQ 20MG BASE	N215152 001	May 03, 2022

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

SUN PHARM INDS LTD	200MG/5ML;EQ 28.5MG BASE/5ML	A065132 001	Mar 19, 2003
	400MG/5ML;EQ 57MG BASE/5ML	A065132 002	Mar 19, 2003
	600MG/5ML;EQ 42.9MG BASE/5ML	A065207 002	Jan 30, 2007

AUGMENTIN '200'

+ US ANTIBIOTICS	200MG/5ML;EQ 28.5MG BASE/5ML	N050725 001	May 31, 1996

AUGMENTIN '400'

+ US ANTIBIOTICS	400MG/5ML;EQ 57MG BASE/5ML	N050725 002	May 31, 1996

TABLET;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

APOTEX INC	250MG;EQ 125MG BASE	A065333 001	Feb 24, 2009
	500MG;EQ 125MG BASE	A065333 002	Feb 24, 2009
	875MG;EQ 125MG BASE	A065317 003	Oct 20, 2008
SUN PHARM INDS LTD	500MG;EQ 125MG BASE	A065109 001	Nov 04, 2002
	875MG;EQ 125MG BASE	A065102 001	Sep 17, 2002

AUGMENTIN '250'

+ US ANTIBIOTICS	250MG;EQ 125MG BASE **	N050564 001	Aug 06, 1984

AUGMENTIN '500'

+ US ANTIBIOTICS	500MG;EQ 125MG BASE **	N050564 002	Aug 06, 1984

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-39(of 478)

** See List Footnote

AMOXICILLIN; CLAVULANATE POTASSIUM

TABLET, CHEWABLE;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

SANDOZ	200MG;EQ 28.5MG BASE	A065065 001	Apr 18, 2002
	400MG;EQ 57MG BASE	A065065 002	Apr 18, 2002
SUN PHARM INDS LTD	200MG;EQ 28.5MG BASE	A065161 001	Dec 03, 2003
	400MG;EQ 57MG BASE	A065161 002	Dec 03, 2003

AUGMENTIN '125'

+ US ANTIBIOTICS	125MG;EQ 31.25MG BASE **	N050597 001	Jul 22, 1985

AUGMENTIN '200'

+ US ANTIBIOTICS	200MG;EQ 28.5MG BASE	N050726 001	May 31, 1996

AUGMENTIN '250'

+ US ANTIBIOTICS	250MG;EQ 62.5MG BASE **	N050597 002	Jul 22, 1985

AUGMENTIN '400'

+ US ANTIBIOTICS	400MG;EQ 57MG BASE	N050726 002	May 31, 1996

TABLET, EXTENDED RELEASE;ORAL

AUGMENTIN XR

+ US ANTIBIOTICS	1GM;EQ 62.5MG BASE	N050785 001	Sep 25, 2002

AMOXICILLIN; VONOPRAZAN FUMARATE

CAPSULE, TABLET;ORAL

VOQUEZNA DUAL PAK

+ PHATHOM	500MG;EQ 20MG BASE	N215153 001	May 03, 2022

AMPHETAMINE

SUSPENSION, EXTENDED RELEASE;ORAL

ADZENYS ER

+ NEOS THERAPS INC	EQ 1.25MG BASE/ML	N204325 001	Sep 15, 2017

AMPHETAMINE ADIPATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE ADIPATE; DEXTROAMPHETAMINE SULFATE

CAPSULE;ORAL

DELCOBESE

TEVA	1.25MG;1.25MG;1.25MG;1.25MG **	A083564 001
	2.5MG;2.5MG;2.5MG;2.5MG **	A083564 002
	3.75MG;3.75MG;3.75MG;3.75MG **	A083564 003
	5MG;5MG;5MG;5MG **	A083564 004

TABLET;ORAL

DELCOBESE

TEVA	1.25MG;1.25MG;1.25MG;1.25MG	A083563 004
	2.5MG;2.5MG;2.5MG;2.5MG	A083563 003
	3.75MG;3.75MG;3.75MG;3.75MG	A083563 002
	5MG;5MG;5MG;5MG	A083563 001

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL

DETROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

LANNETT CO INC	1.25MG;1.25MG;1.25MG;1.25MG	A214403 001	Nov 26, 2021
	2.5MG;2.5MG;2.5MG;2.5MG	A214403 002	Nov 26, 2021
	3.75MG;3.75MG;3.75MG;3.75MG	A214403 003	Nov 26, 2021
	5MG;5MG;5MG;5MG	A214403 004	Nov 26, 2021
	6.25MG;6.25MG;6.25MG;6.25MG	A214403 005	Nov 26, 2021
	7.5MG;7.5MG;7.5MG;7.5MG	A214403 006	Nov 26, 2021

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

ANI PHARMS	2.5MG;2.5MG;2.5MG;2.5MG	A205401 002	Jan 22, 2019
AUROLIFE PHARMA LLC	1.25MG;1.25MG;1.25MG;1.25MG	A211876 001	Jun 24, 2020
	2.5MG;2.5MG;2.5MG;2.5MG	A211876 002	Jun 24, 2020
	3.75MG;3.75MG;3.75MG;3.75MG	A211876 003	Jun 24, 2020
	5MG;5MG;5MG;5MG	A211876 004	Jun 24, 2020
	6.25MG;6.25MG;6.25MG;6.25MG	A211876 005	Jun 24, 2020
	7.5MG;7.5MG;7.5MG;7.5MG	A211876 006	Jun 24, 2020
NESHER PHARMS	1.25MG;1.25MG;1.25MG;1.25MG	A210080 001	Jul 17, 2019
	2.5MG;2.5MG;2.5MG;2.5MG	A210080 002	Jul 17, 2019
	3.75MG;3.75MG;3.75MG;3.75MG	A210080 003	Jul 17, 2019
	5MG;5MG;5MG;5MG	A210080 004	Jul 17, 2019
	6.25MG;6.25MG;6.25MG;6.25MG	A210080 005	Jul 17, 2019
	7.5MG;7.5MG;7.5MG;7.5MG	A210080 006	Jul 17, 2019
PAR PHARM INC	1.25MG;1.25MG;1.25MG;1.25MG	A206159 001	May 31, 2019
	2.5MG;2.5MG;2.5MG;2.5MG	A206159 002	May 31, 2019
	3.75MG;3.75MG;3.75MG;3.75MG	A206159 003	May 31, 2019
	5MG;5MG;5MG;5MG	A206159 004	May 31, 2019

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-40(of 478)

** See List Footnote

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

	6.25MG;6.25MG;6.25MG;6.25MG	A206159	005	May	31,	2019
	7.5MG;7.5MG;7.5MG;7.5MG	A206159	006	May	31,	2019
TEVA	1.25MG;1.25MG;1.25MG;1.25MG	A077488	001	Apr	29,	2013
	2.5MG;2.5MG;2.5MG;2.5MG	A077488	002	Apr	29,	2013
	3.75MG;3.75MG;3.75MG;3.75MG	A077488	003	Apr	29,	2013
	5MG;5MG;5MG;5MG	A077488	004	Apr	29,	2013
	6.25MG;6.25MG;6.25MG;6.25MG	A077488	005	Apr	29,	2013
	7.5MG;7.5MG;7.5MG;7.5MG	A077488	006	Apr	29,	2013
TEVA PHARMS USA	3.125MG;3.125MG;3.125MG;3.125MG	A210876	001	Jan	31,	2022
	6.25MG;6.25MG;6.25MG;6.25MG	A210876	002	Jan	31,	2022
	9.375MG;9.375MG;9.375MG;9.375MG	A210876	003	Jan	31,	2022
	12.5MG;12.5MG;12.5MG;12.5MG	A210876	004	Jan	31,	2022
DEXTROAMP SACCHARATE,AMP ASPARTATE,DEXTROAMP SULFATE AND AMP SULFATE						
BARR LABS INC	1.25MG;1.25MG;1.25MG;1.25MG	A076536	001	Feb	12,	2013
	2.5MG;2.5MG;2.5MG;2.5MG	A076536	002	Feb	12,	2013
	3.75MG;3.75MG;3.75MG;3.75MG	A076536	003	Feb	12,	2013
	5MG;5MG;5MG;5MG	A076536	004	Feb	12,	2013
	6.25MG;6.25MG;6.25MG;6.25MG	A076536	005	Feb	12,	2013
	7.5MG;7.5MG;7.5MG;7.5MG	A076536	006	Feb	12,	2013

TABLET;ORAL

ADDERALL 10

+ TEVA WOMENS	2.5MG;2.5MG;2.5MG;2.5MG **	N011522	007	Feb	13,	1996
ADDERALL 12.5						
+ TEVA WOMENS	3.125MG;3.125MG;3.125MG;3.125MG **	N011522	012	Aug	31,	2000
ADDERALL 15						
+ TEVA WOMENS	3.75MG;3.75MG;3.75MG;3.75MG **	N011522	013	Aug	31,	2000
ADDERALL 20						
+ TEVA WOMENS	5MG;5MG;5MG;5MG **	N011522	008	Feb	13,	1996
ADDERALL 30						
+ TEVA WOMENS	7.5MG;7.5MG;7.5MG;7.5MG **	N011522	010	May	12,	1997
ADDERALL 5						
+ TEVA WOMENS	1.25MG;1.25MG;1.25MG;1.25MG **	N011522	009	May	12,	1997
ADDERALL 7.5						
+ TEVA WOMENS	1.875MG;1.875MG;1.875MG;1.875MG **	N011522	011	Aug	31,	2000

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

ACCORD HLTHCARE

	1.25MG;1.25MG;1.25MG;1.25MG	A214347	001	Nov	22,	2021
	1.875MG;1.875MG;1.875MG;1.875MG	A214347	002	Nov	22,	2021
	2.5MG;2.5MG;2.5MG;2.5MG	A214347	003	Nov	22,	2021
	3.125MG;3.125MG;3.125MG;3.125MG	A214347	004	Nov	22,	2021
	3.75MG;3.75MG;3.75MG;3.75MG	A214347	005	Nov	22,	2021
	5MG;5MG;5MG;5MG	A214347	006	Nov	22,	2021
	7.5MG;7.5MG;7.5MG;7.5MG	A214347	007	Nov	22,	2021
ACTAVIS ELIZABETH	1.25MG;1.25MG;1.25MG;1.25MG	A040456	001	May	06,	2003
	2.5MG;2.5MG;2.5MG;2.5MG	A040456	002	May	06,	2003
	5MG;5MG;5MG;5MG	A040456	003	May	06,	2003
	7.5MG;7.5MG;7.5MG;7.5MG	A040456	004	May	06,	2003
CEDIPROF INC	1.25MG;1.25MG;1.25MG;1.25MG	A210754	001	Jul	05,	2022
	2.5MG;2.5MG;2.5MG;2.5MG	A210754	002	Jul	05,	2022
	3.75MG;3.75MG;3.75MG;3.75MG	A210754	003	Jul	05,	2022
	5MG;5MG;5MG;5MG	A210754	004	Jul	05,	2022
	7.5MG;7.5MG;7.5MG;7.5MG	A210754	005	Jul	05,	2022
LANNETT CO INC	1.25MG;1.25MG;1.25MG;1.25MG	A215565	001	Jul	08,	2022
	1.875MG;1.875MG;1.875MG;1.875MG	A215565	002	Jul	08,	2022
	2.5MG;2.5MG;2.5MG;2.5MG	A215565	003	Jul	08,	2022
	3.125MG;3.125MG;3.125MG;3.125MG	A215565	004	Jul	08,	2022
	3.75MG;3.75MG;3.75MG;3.75MG	A215565	005	Jul	08,	2022
	5MG;5MG;5MG;5MG	A215565	006	Jul	08,	2022
	7.5MG;7.5MG;7.5MG;7.5MG	A215565	007	Jul	08,	2022
MYLAN	1.25MG;1.25MG;1.25MG;1.25MG	A206721	001	Nov	10,	2015
	1.875MG;1.875MG;1.875MG;1.875MG	A206721	002	Nov	10,	2015
	2.5MG;2.5MG;2.5MG;2.5MG	A206721	003	Nov	10,	2015
	3.125MG;3.125MG;3.125MG;3.125MG	A206721	004	Nov	10,	2015
	3.75MG;3.75MG;3.75MG;3.75MG	A206721	005	Nov	10,	2015
	5MG;5MG;5MG;5MG	A206721	006	Nov	10,	2015
	7.5MG;7.5MG;7.5MG;7.5MG	A206721	007	Nov	10,	2015

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-41(of 478)

** See List Footnote

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

TABLET;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

TEVA PHARMS	1.25MG;1.25MG;1.25MG;1.25MG	A040472	001	Sep 30, 2003
	2.5MG;2.5MG;2.5MG;2.5MG	A040472	002	Sep 30, 2003
	5MG;5MG;5MG;5MG	A040472	003	Sep 30, 2003
	7.5MG;7.5MG;7.5MG;7.5MG	A040472	004	Sep 30, 2003

AMPHETAMINE RESIN COMPLEX; DEXTROAMPHETAMINE RESIN COMPLEX

CAPSULE, EXTENDED RELEASE;ORAL

BIPHETAMINE 12.5

UCB INC	EQ 6.25MG BASE;EQ 6.25MG BASE	N010093	007	

BIPHETAMINE 20

UCB INC	EQ 10MG BASE;EQ 10MG BASE	N010093	003	

BIPHETAMINE 7.5

UCB INC	EQ 3.75MG BASE;EQ 3.75MG BASE	N010093	009	

AMPHETAMINE SULFATE

TABLET;ORAL

AMPHETAMINE SULFATE

GLENMARK PHARMS LTD	5MG	A212186	001	Jan 27, 2021
	10MG	A212186	002	Jan 27, 2021
+ LANNETT	5MG	A083901	001	Aug 31, 1984
+	10MG	A083901	002	Aug 31, 1984
MAYNE PHARMA	5MG	A213898	001	Jul 14, 2020
	10MG	A213898	002	Jul 14, 2020
NOVAST LABS	5MG	A213763	001	Aug 24, 2020
	10MG	A213763	002	Aug 24, 2020

TABLET, ORALLY DISINTEGRATING;ORAL

EVEKEO ODT

+ AZURITY	2.5MG	N209905	005	Apr 16, 2021

AMPHOTERICIN B

CREAM;TOPICAL

FUNGIZONE

APOTHECON	3%	N050314	001	

INJECTABLE;INJECTION

AMPHOTERICIN B

ABBOTT	50MG/VIAL	A064141	001	Dec 23, 1996
ABRAXIS PHARM	50MG/VIAL	A062728	001	Apr 13, 1987
TEVA PARENTERAL	50MG/VIAL	A064062	001	Mar 31, 1995

FUNGIZONE

APOTHECON	50MG/VIAL	A060517	001	

INJECTABLE, LIPID COMPLEX;INJECTION

AMPHOTEC

ALKOPHARMA USA	50MG/VIAL	N050729	001	Nov 22, 1996
	100MG/VIAL	N050729	002	Nov 22, 1996

LOTION;TOPICAL

FUNGIZONE

APOTHECON	3%	A060570	001	

OINTMENT;TOPICAL

FUNGIZONE

APOTHECON	3%	N050313	001	

SUSPENSION;ORAL

FUNGIZONE

BRISTOL MYERS SQUIBB	100MG/ML	N050341	003	

AMPICILLIN SODIUM

INJECTABLE;INJECTION

AMPICILLIN SODIUM

ACS DOBFAR SPA	EQ 500MG BASE/VIAL	A090884	001	Apr 03, 2013
	EQ 1GM BASE/VIAL	A090884	002	Apr 03, 2013
	EQ 2GM BASE/VIAL	A090884	003	Apr 03, 2013
APOTHECON	EQ 125MG BASE/VIAL	A062860	001	Feb 05, 1988
	EQ 250MG BASE/VIAL	A062860	002	Feb 05, 1988
	EQ 500MG BASE/VIAL	A062860	003	Feb 05, 1988
	EQ 1GM BASE/VIAL	A062860	004	Feb 05, 1988
	EQ 2GM BASE/VIAL	A062860	005	Feb 05, 1988
CONSOLIDATED PHARM	EQ 125MG BASE/VIAL	A061936	005	
	EQ 250MG BASE/VIAL	A061936	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-42(of 478)

** See List Footnote

AMPICILLIN SODIUM

INJECTABLE; INJECTION

AMPICILLIN SODIUM

	EQ 500MG BASE/VIAL	A061936 002	
	EQ 1GM BASE/VIAL	A061936 003	
	EQ 2GM BASE/VIAL	A061936 004	
EUGIA PHARMA SPECLTS	EQ 125MG BASE/VIAL	A065499 001	Aug 17, 2010
HIKMA	EQ 125MG BASE/VIAL	A062692 001	Jun 24, 1986
	EQ 250MG BASE/VIAL	A062692 002	Jun 24, 1986
	EQ 500MG BASE/VIAL	A062692 003	Jun 24, 1986
	EQ 1GM BASE/VIAL	A062692 004	Jun 24, 1986
	EQ 2GM BASE/VIAL	A062692 005	Jun 24, 1986
	EQ 10GM BASE/VIAL	A062692 006	Jun 24, 1986
HOSPIRA	EQ 250MG BASE/VIAL	A202864 001	Sep 04, 2015
	EQ 500MG BASE/VIAL	A202864 002	Sep 04, 2015
	EQ 1GM BASE/VIAL	A202864 003	Sep 04, 2015
	EQ 2GM BASE/VIAL	A202864 004	Sep 04, 2015
	EQ 10GM BASE/VIAL	A202865 001	Sep 04, 2015
HQ SPECLT PHARMA	EQ 125MG BASE/VIAL	A062772 005	Apr 15, 1993
	EQ 500MG BASE/VIAL	A062772 008	Apr 15, 1993
	EQ 1GM BASE/VIAL	A062772 002	Apr 15, 1993
	EQ 2GM BASE/VIAL	A062772 004	Apr 15, 1993
INTL MEDICATION	EQ 1GM BASE/VIAL	A062634 002	Jan 09, 1987
	EQ 2GM BASE/VIAL	A062634 003	Jan 09, 1987
ISTITUTO BIO ITA SPA	EQ 125MG BASE/VIAL	A062797 001	Jul 12, 1993
LILLY	EQ 500MG BASE/VIAL	A062565 001	Apr 04, 1985
	EQ 1GM BASE/VIAL	A062565 002	Apr 04, 1985
	EQ 2GM BASE/VIAL	A062565 003	Jun 24, 1986
MYLAN LABS LTD	EQ 250MG BASE/VIAL	A201025 001	Apr 09, 2014
	EQ 500MG BASE/VIAL	A201025 002	Apr 09, 2014
WATSON LABS INC	EQ 125MG BASE/VIAL	A062816 001	Oct 24, 1988
	EQ 250MG BASE/VIAL	A062816 002	Oct 24, 1988
	EQ 500MG BASE/VIAL	A062816 003	Oct 24, 1988
	EQ 1GM BASE/VIAL	A062816 004	Oct 24, 1988
	EQ 2GM BASE/VIAL	A062816 005	Oct 24, 1988
	EQ 10GM BASE/VIAL	A062994 001	Sep 15, 1988
OMNIPEN-N			
WYETH AYERST	EQ 125MG BASE/VIAL	A060626 001	
	EQ 125MG BASE/VIAL	A062718 001	Dec 16, 1986
	EQ 250MG BASE/VIAL	A060626 002	
	EQ 250MG BASE/VIAL	A062718 002	Dec 16, 1986
	EQ 500MG BASE/VIAL	A060626 003	
	EQ 500MG BASE/VIAL	A062718 003	Dec 16, 1986
	EQ 1GM BASE/VIAL	A060626 004	
	EQ 1GM BASE/VIAL	A062718 004	Dec 16, 1986
	EQ 2GM BASE/VIAL	A060626 005	
	EQ 2GM BASE/VIAL	A062718 005	Dec 16, 1986
PENBRITIN-S			
+ WYETH AYERST	EQ 125MG BASE/VIAL **	N050072 001	
+	EQ 250MG BASE/VIAL **	N050072 002	
+	EQ 500MG BASE/VIAL **	N050072 003	
+	EQ 1GM BASE/VIAL **	N050072 004	
+	EQ 2GM BASE/VIAL **	N050072 005	
+	EQ 4GM BASE/VIAL **	N050072 006	
POLYCILLIN-N			
BRISTOL	EQ 125MG BASE/VIAL **	N050309 001	
	EQ 250MG BASE/VIAL **	N050309 002	
	EQ 500MG BASE/VIAL **	N050309 003	
	EQ 1GM BASE/VIAL **	N050309 004	
	EQ 2GM BASE/VIAL **	N050309 005	
TOTACILLIN-N			
GLAXOSMITHKLINE	EQ 125MG BASE/VIAL	A060677 001	
	EQ 250MG BASE/VIAL	A060677 002	
	EQ 500MG BASE/VIAL	A060677 003	
	EQ 1GM BASE/VIAL	A060677 004	
	EQ 1GM BASE/VIAL	A062727 001	Dec 19, 1986
	EQ 2GM BASE/VIAL	A060677 005	
	EQ 2GM BASE/VIAL	A062727 002	Dec 19, 1986
	EQ 10GM BASE/VIAL	A060677 006	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-43(of 478)

** See List Footnote

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE; INJECTION

AMPICILLIN AND SULBACTAM

EUGIA PHARMA SPECLTS	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A090340 001	Sep 20, 2010
	EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A090340 002	Sep 20, 2010
HOSPIRA INC	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A090375 001	Dec 21, 2011
	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A090653 001	Dec 21, 2011
	EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A090375 002	Dec 21, 2011
	EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A090653 002	Dec 21, 2011
PHARM ASSOC	EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL	A090646 001	Dec 21, 2011
	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A065316 001	Jun 29, 2007
	EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A065316 002	Jun 29, 2007
UNASYN			
Pfizer	EQ 500MG BASE/VIAL;EQ 250MG BASE/VIAL	N050608 003	Dec 31, 1986

AMPICILLIN/AMPICILLIN TRIHYDRATE

CAPSULE; ORAL

AMCILL

PARKE DAVIS	EQ 250MG BASE	A062041 001	
	EQ 500MG BASE	A062041 002	
AMPICILLIN TRIHYDRATE			
BELCHER PHARMS	EQ 250MG BASE	A061602 001	
	EQ 500MG BASE	A061602 002	
HERITAGE PHARMA	EQ 250MG BASE	A061502 001	
	EQ 500MG BASE	A061502 002	
IVAX SUB TEVA PHARMS	EQ 250MG BASE	A060765 001	
	EQ 500MG BASE	A060765 002	
LEDERLE	EQ 250MG BASE	A062208 001	
	EQ 500MG BASE	A062208 002	
MYLAN	EQ 250MG BASE	A061755 001	
	EQ 500MG BASE	A061755 002	
PUREPAC PHARM	EQ 250MG BASE	A061853 001	
	EQ 500MG BASE	A061853 002	
SANDOZ	EQ 250MG BASE	A064082 001	Aug 29, 1995
STRIDES PHARMA	EQ 250MG BASE	A062883 001	Feb 25, 1988
	EQ 500MG BASE	A062882 001	Feb 25, 1988
VITARINE	EQ 250MG BASE	A061387 001	
	EQ 500MG BASE	A061387 003	
OMNIPEN (AMPICILLIN)			
WYETH AYERST	250MG	A060624 001	
	500MG	A060624 002	
PENBRITIN			
WYETH AYERST	EQ 250MG BASE	A060908 001	
	EQ 500MG BASE	A060908 002	
PFIZERPEN-A			
Pfizer	EQ 250MG BASE	A062050 001	
	EQ 500MG BASE	A062050 002	
POLYCILLIN			
BRISTOL	EQ 250MG BASE	N050310 001	
	EQ 500MG BASE	N050310 002	
PRINCIPEN			
APOTHECON	EQ 250MG BASE	A062888 001	Mar 04, 1988
	EQ 500MG BASE	A062888 002	Mar 04, 1988
BRISTOL MYERS SQUIBB	EQ 250MG BASE	A061392 001	
	EQ 500MG BASE	A061392 002	
PRINCIPEN '250'			
APOTHECON	EQ 250MG BASE	A062157 002	
	EQ 250MG BASE	N050056 001	
PRINCIPEN '500'			
APOTHECON	EQ 500MG BASE	A062157 001	
	EQ 500MG BASE	N050056 002	
TOTACILLIN			
GLAXOSMITHKLINE	EQ 250MG BASE	A060060 001	
	EQ 250MG BASE	A062212 001	
	EQ 500MG BASE	A060060 002	
	EQ 500MG BASE	A062212 002	
FOR SUSPENSION; ORAL			
AMCILL			
PARKE DAVIS	EQ 125MG BASE/5ML	A062030 001	
	EQ 250MG BASE/5ML	A062030 002	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-44(of 478)

** See List Footnote

AMPICILLIN/AMPICILLIN TRIHYDRATE

FOR SUSPENSION;ORAL

AMPICILLIN TRIHYDRATE

BELCHER PHARMS	EQ 125MG BASE/5ML	A061601	001	
	EQ 250MG BASE/5ML	A061601	002	
DAVA PHARMS INC	EQ 125MG BASE/5ML	A062982	001	Feb 10, 1989
	EQ 250MG BASE/5ML	A062982	002	Feb 10, 1989
MYLAN	EQ 125MG BASE/5ML	A061829	002	
	EQ 250MG BASE/5ML	A061829	001	
PUREPAC PHARM	EQ 125MG BASE/5ML	A061980	001	
	EQ 250MG BASE/5ML	A061980	002	
TEVA	EQ 125MG BASE/5ML	A061370	001	
	EQ 250MG BASE/5ML	A061370	002	
OMNIPEN (AMPICILLIN)				
WYETH AYERST	100MG/ML	A060625	001	
	125MG/5ML	A060625	002	
	250MG/5ML	A060625	003	
	500MG/5ML	A060625	004	
PENBRITIN				
WYETH AYERST	EQ 100MG BASE/ML	N050019	001	
	EQ 125MG BASE/5ML	N050019	002	
	EQ 250MG BASE/5ML	N050019	003	
PFIZERPEN-A				
PFIZER	EQ 125MG BASE/5ML	A062049	001	
	EQ 250MG BASE/5ML	A062049	002	
POLYCILLIN				
APOTHECON	EQ 125MG BASE/5ML	A062297	001	
	EQ 250MG BASE/5ML	A062297	002	
BRISTOL	EQ 100MG BASE/ML	N050308	004	
	EQ 125MG BASE/5ML	N050308	001	
	EQ 250MG BASE/5ML	N050308	002	
	EQ 500MG BASE/5ML	N050308	003	
PRINCIPEN				
APOTHECON	EQ 100MG BASE/ML	A061394	001	
	EQ 125MG BASE/5ML	A061394	002	
	EQ 250MG BASE/5ML	A061394	003	
PRINCIPEN '125'				
APOTHECON	EQ 125MG BASE/5ML	A060127	002	
	EQ 125MG BASE/5ML	A062151	001	
PRINCIPEN '250'				
APOTHECON	EQ 250MG BASE/5ML	A060127	001	
	EQ 250MG BASE/5ML	A062151	002	
TOTACILLIN				
GLAXOSMITHKLINE	EQ 125MG BASE/5ML	A060666	001	
	EQ 125MG BASE/5ML	A062223	001	
	EQ 250MG BASE/5ML	A060666	002	
	EQ 250MG BASE/5ML	A062223	002	
TABLET, CHEWABLE;ORAL				
POLYCILLIN				
BRISTOL	EQ 125MG BASE	N050093	001	

AMPICILLIN/AMPICILLIN TRIHYDRATE; PROBENECID

CAPSULE;ORAL

PRINCIPEN W/ PROBENECID

APOTHECON	EQ 389MG BASE;111MG	A062150	001	
	EQ 389MG BASE;111MG	N050488	001	

FOR SUSPENSION;ORAL

POLYCILLIN-PRB

APOTHECON	EQ 3.5GM BASE/BOT;1GM/BOT	A061898	001	
BRISTOL	EQ 3.5GM BASE/BOT;1GM/BOT	N050457	001	
PROBAMPACIN				
COSETTE	EQ 3.5GM BASE/BOT;1GM/BOT	A061741	001	

AMPRENAVIR

CAPSULE;ORAL

AGENERASE

GLAXOSMITHKLINE	50MG	N021007	001	Apr 15, 1999
	150MG	N021007	002	Apr 15, 1999

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-45(of 478)

** See List Footnote

AMPRENAVIR

SOLUTION; ORAL

AGENERASE

+ GLAXOSMITHKLINE 15MG/ML **

N021039 001 Apr 15, 1999

ANAGRELIDE HYDROCHLORIDE

CAPSULE; ORAL

AGRYLIN

+ TAKEDA PHARMS USA EQ 1MG BASE **

N020333 002 Mar 14, 1997

ANAGRELIDE HYDROCHLORIDE

BARR EQ 0.5MG BASE

A076530 001 Apr 18, 2005

EQ 1MG BASE

A076530 002 Apr 18, 2005

CHARTWELL RX EQ 0.5MG BASE

A076683 001 Apr 18, 2005

EQ 1MG BASE

A076683 002 Apr 18, 2005

MYLAN EQ 0.5MG BASE

A076811 001 Apr 18, 2005

EQ 1MG BASE

A076811 002 Apr 18, 2005

RISING EQ 0.5MG BASE

A077613 001 Jun 27, 2006

EQ 1MG BASE

A077613 002 Jun 27, 2006

ROXANE EQ 0.5MG BASE

A076489 001 Apr 18, 2005

EQ 1MG BASE

A076489 002 Apr 18, 2005

WATSON LABS EQ 0.5MG BASE

A076417 001 Apr 18, 2005

EQ 1MG BASE

A076417 002 Apr 18, 2005

ANASTROZOLE

TABLET; ORAL

ANASTROZOLE

APOTEX INC 1MG

A200654 001 May 11, 2012

CHARTWELL MOLECULAR 1MG

A091331 001 Jan 05, 2011

FRESENIUS KABI USA 1MG

A090088 001 Jun 28, 2010

HIKMA 1MG

A078485 001 Jun 28, 2010

IMPAX LABS INC 1MG

A091242 001 May 31, 2012

MYLAN 1MG

A091051 001 Jun 28, 2010

PICKET PHARMS 1MG

A090732 001 Jun 28, 2010

SANDOZ 1MG

A079007 001 Jun 28, 2010

SUN PHARM INDS LTD 1MG

A091177 001 Jul 15, 2011

SYNTHON PHARMS 1MG

A078322 001 Jun 28, 2010

WATSON LABS TEVA 1MG

A078984 001 Jun 28, 2010

ANGIOTENSIN II ACETATE

SOLUTION; INTRAVENOUS

GIAPREZA

+ LA JOLLA PHARMA EQ 5MG BASE/2ML (EQ 2.5MG BASE/ML)

N209360 002 Dec 21, 2017

ANILERIDINE HYDROCHLORIDE

TABLET; ORAL

LERITINE

MERCK EQ 25MG BASE

N010585 002

ANILERIDINE PHOSPHATE

INJECTABLE; INJECTION

LERITINE

MERCK 25MG/ML

N010520 003

ANISINDIONE

TABLET; ORAL

MIRADON

SCHERING 50MG

N010909 003

ANISOTROPINE METHYLBROMIDE

TABLET; ORAL

ANISOTROPINE METHYLBROMIDE

WATSON LABS 50MG

A086046 001

VALPIN 50

ENDO PHARMS 50MG

N013428 001

ANTAZOLINE PHOSPHATE; NAPHAZOLINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

VASOCON-A

NOVARTIS 0.5%; 0.05%

N018746 002 Jul 11, 1994

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-46(of 478)

** See List Footnote

APIXABAN

TABLET; ORAL

APIXABAN

BIONPHARMA INC	2.5MG	A210152 001	Apr 08, 2020
	5MG	A210152 002	Apr 08, 2020
BRECKENRIDGE	2.5MG	A209845 001	Jul 26, 2021
	5MG	A209845 002	Jul 26, 2021
MICRO LABS	2.5MG	A210013 001	Dec 23, 2019
	5MG	A210013 002	Dec 23, 2019
MYLAN	2.5MG	A210128 001	Dec 23, 2019
	5MG	A210128 002	Dec 23, 2019

APOMORPHINE HYDROCHLORIDE

INJECTABLE; SUBCUTANEOUS

APOKYN

MDD US	20MG/2ML (10MG/ML)	N021264 001	Apr 20, 2004

APREMILAST

TABLET; ORAL

APREMILAST

AMNEAL	10MG	A211782 001	Jun 30, 2021
	20MG	A211782 002	Jun 30, 2021
	30MG	A211782 003	Jun 30, 2021
UNICHEM	10MG	A211819 001	Feb 17, 2021
	20MG	A211819 002	Feb 17, 2021
	30MG	A211819 003	Feb 17, 2021

APREPITANT

CAPSULE; ORAL

EMEND

+ MERCK	40MG **	N021549 003	Jun 30, 2006

ARBUTAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

GENESA

GENSIA AUTOMEDICS	0.05MG/ML	N020420 001	Sep 12, 1997

ARDEPARIN SODIUM

INJECTABLE; INJECTION

NORMIFLO

+ PHARMACIA AND UPJOHN	5,000 UNITS/0.5ML **	N020227 002	May 23, 1997
+	10,000 UNITS/0.5ML **	N020227 001	May 23, 1997

ARFORMOTEROL TARTRATE

SOLUTION; INHALATION

ARFORMOTEROL TARTRATE

GLENMARK PHARMS LTD	EQ 0.015MG BASE/2ML	A213132 001	Jun 22, 2021
RITEDOSE CORP	EQ 0.015MG BASE/2ML	A214736 001	Mar 02, 2022

ARGATROBAN

INJECTABLE; INTRAVENOUS

ARGATROBAN IN 0.9% SODIUM CHLORIDE

TEVA PHARMS USA	250MG/250ML (1MG/ML)	N206769 001	Dec 15, 2014

ARGATROBAN IN SODIUM CHLORIDE

+ CIPLA	50MG/50ML (1MG/ML)	N022434 001	Jun 29, 2011

SOLUTION; INTRAVENOUS

ARGATROBAN IN DEXTROSE

SANDOZ	125MG/125ML (1MG/ML)	N201743 001	May 09, 2011

ARIPIRAZOLE

INJECTABLE; INTRAMUSCULAR

ABILIFY

OTSUKA	9.75MG/1.3ML (7.5MG/ML)	N021866 001	Sep 20, 2006

SOLUTION; ORAL

ABILIFY

+ OTSUKA	1MG/ML **	N021713 001	Dec 10, 2004

TABLET; ORAL

ARIPIRAZOLE

MYLAN	2MG	A206240 001	Sep 19, 2018
	5MG	A206240 002	Sep 19, 2018
	10MG	A206240 003	Sep 19, 2018
	15MG	A206240 004	Sep 19, 2018
	20MG	A206240 005	Sep 19, 2018

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-47(of 478)

** See List Footnote

ARIPRAZOLE

TABLET;ORAL

ARIPRAZOLE

	30MG	A206240 006 Sep 19, 2018
TEVA PHARMS USA	2MG	A078607 001 Apr 28, 2015
	5MG	A078607 002 Apr 28, 2015
	10MG	A078608 001 Apr 28, 2015
	15MG	A078708 001 Apr 28, 2015
	20MG	A078708 002 Apr 28, 2015
	30MG	A078708 003 Apr 28, 2015
ZYDUS PHARMS	2MG	A090472 001 Jan 07, 2019
	5MG	A090472 002 Jan 07, 2019
	10MG	A090472 003 Jan 07, 2019
	15MG	A090472 004 Jan 07, 2019
	20MG	A090472 005 Jan 07, 2019
	30MG	A090472 006 Jan 07, 2019

TABLET, ORALLY DISINTEGRATING;ORAL

ABILIFY

+	OTSUKA	10MG **	N021729 002 Jun 07, 2006
+		15MG **	N021729 003 Jun 07, 2006
+		20MG **	N021729 004 Jun 07, 2006
+		30MG **	N021729 005 Jun 07, 2006

ARMODAFINIL

TABLET;ORAL

ARMODAFINIL

APOTEX INC	50MG	A201514 001 Mar 25, 2019	
	150MG	A201514 002 Mar 25, 2019	
	250MG	A201514 003 Mar 25, 2019	
WATSON LABS INC	100MG	A200156 002 Aug 29, 2012	
	200MG	A200156 004 Aug 29, 2012	
NUVIGIL			
+	CEPHALON	100MG **	N021875 002 Mar 26, 2009

ARSENIC TRIOXIDE

INJECTABLE;INJECTION

ARSENIC TRIOXIDE

INGENUS PHARMS LLC	2MG/ML	A209315 002 Jan 14, 2021	
TRISENOX			
+	CEPHALON	1MG/ML **	N021248 001 Sep 25, 2000

ARTICAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE

INJECTABLE;INJECTION

ARTICAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE

HOSPIRA	4%;EQ 0.017MG BASE/1.7ML (4%;EQ 0.01MG BASE/ML)	A079138 001 Jun 18, 2010
ULTACAN		
HANSAMED INC	4%;EQ 0.0085MG BASE/1.7ML (4%; EQ 0.005MG BASE/ML)	A201751 001 Jul 11, 2017
ULTACAN FORTE		
HANSAMED INC	4%;EQ 0.017MG BASE/1.7ML (4%; EQ 0.01MG BASE/ML)	A201750 001 Jul 11, 2017

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PHYTONADIONE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

FOR SOLUTION;INTRAVENOUS

M.V.I. PEDIATRIC

+	HOSPIRA	80MG/VIAL;0.02MG/VIAL;0.001MG/VIAL;5MG/VIAL;0.01MG/VIAL;0.14MG/VIAL;17MG/VIAL;0.2MG/VIAL;1MG/VIAL;1.4MG/VIAL;EQ 1.2MG BASE/VIAL;0.7MG/VIAL;7MG/VIAL	N018920 001 Sep 21, 2000

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE; VITAMIN E

INJECTABLE;INJECTION

BEROCCA PN

ROCHE	50MG/ML;0.03MG/ML;0.0025MG/ML;7.5MG/ML;100 IU/ML;0.2MG/ML;20MG/ML;2MG/ML;1.8MG/ML;	N006071 003 Oct 10, 1985

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-48(of 478)

** See List Footnote

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

INJECTABLE; INJECTION

M.V.C. 9+3

ABRAXIS PHARM

10MG/ML; 0.006MG/ML; 0.5MCG/ML; 1.5MG/ML; 2
0

N018440 002 Aug 08, 1985

M.V.I.-12 ADULT

HOSPIRA

10MG/ML; 0.006MG/ML; 0.5MCG/ML; 1.5MG/ML; 2
0

N008809 004 Aug 08, 1985

+

IU/ML; 0.04MG/ML; 4MG/ML; 0.4MG/ML; 0.36MG/
20MG/ML; 0.006MG/ML; 0.05MCG/ML; 1.5MG/ML;
0.0005MG/ML; 0.06MG/ML; 4MG/ML; 0.6MG/ML; 0
.36MG/ML; 0.6MG/ML; 0.1MG/ML; 1MG/ML

N008809 006 Sep 09, 2004

MVC PLUS

WATSON LABS

10MG/ML; 0.006MG/ML; 0.5MCG/ML; 1.5MG/ML; 2
0

N018439 002 Aug 08, 1985

IU/ML; 0.04MG/ML; 4MG/ML; 0.4MG/ML; 0.36MG/

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E; VITAMIN K

INJECTABLE; INTRAVENOUS

M.V.I. ADULT

+

HOSPIRA

200MG/VIAL; 0.06MG/VIAL; 0.005MG/VIAL; 15M
G/VIAL; 0.005MG/VIAL; 0.6MG/VIAL; 40MG/VIA
L; 6MG/VIAL; 3.6MG/VIAL; 6MG/VIAL; 1MG/VIAL
; 10MG/VIAL; 0.15MG/VIAL

N021625 001 Jan 30, 2004

M.V.I. ADULT (PHARMACY BULK PACKAGE)

+

HOSPIRA

200MG/5ML; 0.06MG/5ML; 0.005MG/5ML; 15MG/5
ML; 0.005MG/5ML; 0.6MG/5ML; 40MG/5ML; 6MG/5
ML; 3.6MG/5ML; 6MG/5ML; 1MG/5ML; 10MG/5ML; 0
.15MG/5ML

N021643 001 Feb 18, 2004

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

INJECTABLE; INJECTION

M.V.I.-12 ADULT

HOSPIRA

20MG/ML; 0.006MG/ML; 0.5MCG/ML; 1.5MG/ML; 2
0

N008809 005 Apr 22, 2004

IU/ML; 0.6MG/ML; 4MG/ML; 0.4MG/ML; 0.36MG/M

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE; VITAMIN A; VITAMIN E

INJECTABLE; INJECTION

M.V.I.-12 LYOPHILIZED

TELIGENT

100MG/VIAL; 0.06MG/VIAL; 0.005MG/VIAL; 15M
G/VIAL; 5MCG/VIAL; 0.4MG/VIAL; 40MG/VIAL; 4
MG/VIAL; 3.6MG/VIAL; 3MG/VIAL; 1MG/VIAL; 10
MG/VIAL

N018933 002 Aug 08, 1985

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PANTOTHENIC ACID; PHYTONADIONE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A PALMITATE; VITAMIN E

INJECTABLE; INJECTION

VITAPED

HOSPIRA

N/A, 80MG/VIAL; N/A, 0.02MG/VIAL; N/A, 0.001
MG/VIAL; 400
IU/10ML, N/A; N/A, 0.14MG/VIAL; N/A, 17MG/VI
AL; N/A, 5MG/VIAL; 0.2MG/10ML, N/A; N/A, 1MG/
VIAL; N/A, 1.4MG/VIAL; N/A, 1.2MG/VIAL; EQ
2, 300 UNITS BASE/10ML, N/A; 7 IU/10ML, N/A

N020176 001 Dec 29, 1993

ASPIRIN

TABLET; ORAL

BAYER EXTRA STRENGTH ASPIRIN FOR MIGRAINE PAIN

BAYER

500MG

N021317 001 Oct 18, 2001

TABLET, EXTENDED RELEASE; ORAL

8-HOUR BAYER

BAYER

650MG

N016030 001

MEASURIN

BAYER

650MG

N016030 002

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-49(of 478)

** See List Footnote

ASPIRIN; BUTALBITAL

TABLET; ORAL

AXOTAL

SAVAGE LABS

650MG; 50MG

A088305 001 Oct 13, 1983

ASPIRIN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL

BUTALBITAL, ASPIRIN AND CAFFEINE

LGM PHARMA

500MG; 50MG; 40MG

A205230 001 Oct 18, 2021

WATSON LABS

325MG; 50MG; 40MG

A086231 002 Feb 12, 1985

FIORINAL

+ ALLERGAN

325MG; 50MG; 40MG

N017534 005 Apr 16, 1986

TABLET; ORAL

BUTALBITAL, ASPIRIN AND CAFFEINE

ACTAVIS ELIZABETH

325MG; 50MG; 40MG

A086710 002 Aug 23, 1983

FOSUN PHARMA

325MG; 50MG; 40MG

A086398 002 Apr 06, 1984

HALSEY

325MG; 50MG; 40MG

A089448 001 Dec 01, 1986

+ HIKMA INTL PHARMS

325MG; 50MG; 40MG

A086162 002 Feb 16, 1984

IVAX PHARMS

325MG; 50MG; 40MG

A085441 002 Oct 31, 1984

PURACAP PHARM

325MG; 50MG; 40MG

A087048 002 Dec 09, 1983

QUANTUM PHARMICS

325MG; 50MG; 40MG

A088972 001 Jun 18, 1985

WATSON LABS

325MG; 50MG; 40MG

A086237 002 Mar 23, 1984

FIORINAL

+ ALLERGAN

325MG; 50MG; 40MG **

N017534 003 Apr 16, 1986

LANORINAL

LANNETT

325MG; 50MG; 40MG

A086986 002 Oct 18, 1985

ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE

MAYNE PHARMA INC

325MG; 50MG; 40MG; 30MG

A203335 001 Oct 30, 2015

STRIDES PHARMA

325MG; 50MG; 40MG; 30MG

A075351 001 Mar 05, 1999

WATSON LABS

325MG; 50MG; 40MG; 30MG

A074359 001 Aug 31, 1995

FIORINAL W/CODEINE

+ ALLERGAN

325MG; 50MG; 40MG; 30MG

N019429 003 Oct 26, 1990

ASPIRIN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE; ORAL

SYNALGOS-DC

+ SUN PHARM INDUSTRIES

356.4MG; 30MG; 16MG

N011483 004 Sep 06, 1983

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET; ORAL

INVAGESIC

SANDOZ

385MG; 30MG; 25MG

A074817 001 Nov 27, 1996

INVAGESIC FORTE

SANDOZ

770MG; 60MG; 50MG

A074817 002 Nov 27, 1996

NORGESIC

+ BAUSCH

385MG; 30MG; 25MG **

N013416 003 Oct 27, 1982

NORGESIC FORTE

+ BAUSCH

770MG; 60MG; 50MG **

N013416 004 Oct 27, 1982

ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE

SANDOZ

385MG; 30MG; 25MG

A074654 001 Dec 31, 1996

770MG; 60MG; 50MG

A074654 002 Dec 31, 1996

STEVENS J

385MG; 30MG; 25MG

A074988 001 Apr 30, 1999

770MG; 60MG; 50MG

A074988 002 Apr 30, 1999

ASPIRIN; CAFFEINE; PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL

COMPOUND 65

ALRA

389MG; 32.4MG; 65MG

A084553 002 Aug 17, 1983

DARVON COMPOUND

XANODYNE PHARM

389MG; 32.4MG; 32MG

N010996 006 Mar 08, 1983

DARVON COMPOUND-65

XANODYNE PHARM

389MG; 32.4MG; 65MG

N010996 007 Mar 08, 1983

PROPOXYPHENE COMPOUND 65

IVAX SUB TEVA PHARMS

389MG; 32.4MG; 65MG

A083077 002 Dec 07, 1984

+ SANDOZ

389MG; 32.4MG; 65MG

A080044 002 Sep 16, 1983

TEVA

389MG; 32.4MG; 65MG

A089025 001 Mar 29, 1985

PROPOXYPHENE COMPOUND-65

SANDOZ

389MG; 32.4MG; 65MG

A083101 002 Jun 24, 1985

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-50(of 478)

** See List Footnote

ASPIRIN; CAFFEINE; PROPOXYPHENE HYDROCHLORIDE

CAPSULE;ORAL

PROPOXYPHENE HYDROCHLORIDE W/ ASPIRIN AND CAFFEINE

WATSON LABS

389MG;32.4MG;65MG

A085732 002 Sep 03, 1984

ASPIRIN; CARISOPRODOL

TABLET;ORAL

CARISOPRODOL AND ASPIRIN

HERITAGE PHARMS

325MG;200MG

A089594 001 Mar 31, 1989

NOVAST LABS

325MG;200MG

A040832 001 Jan 07, 2010

OXFORD PHARMS

325MG;200MG

A040252 001 Dec 10, 1997

SANDOZ

325MG;200MG

A040116 001 Apr 25, 1996

CARISOPRODOL COMPOUND

WATSON LABS

325MG;200MG

A088809 001 Oct 03, 1985

SOMA COMPOUND

MEDA PHARMS

325MG;200MG **

N012365 005 Jul 11, 1983

ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE

TABLET;ORAL

CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE

INGENUS PHARMS NJ

325MG;200MG;16MG

A040860 001 Jan 07, 2010

OXFORD PHARMS

325MG;200MG;16MG

A040283 001 Dec 29, 1998

SANDOZ

325MG;200MG;16MG

A040118 001 Apr 16, 1996

SOMA COMPOUND W/ CODEINE

MEDA PHARMS

325MG;200MG;16MG **

N012366 002 Jul 11, 1983

ASPIRIN; DIPYRIDAMOLE

CAPSULE, EXTENDED RELEASE;ORAL

AGGRENOLX

+

BOEHRINGER INGELHEIM 25MG;200MG

N020884 001 Nov 22, 1999

ASPIRIN AND DIPYRIDAMOLE

ANI PHARMS

25MG;200MG

A206964 001 Jan 18, 2017

CHARTWELL MOLECULAR

25MG;200MG

A204552 001 Mar 20, 2019

SUN PHARM

25MG;200MG

A208572 001 Aug 21, 2018

ASPIRIN; HYDROCODONE BITARTRATE

TABLET;ORAL

AZDONE

SCHWARZ PHARMA

500MG;5MG **

A089420 001 Jan 25, 1988

VICOPRIN

ABBOTT

500MG;5MG

A086333 001 Sep 14, 1983

ASPIRIN; MEPROBAMATE

TABLET;ORAL

EQUAGESIC

SUN PHARM INDUSTRIES

325MG;200MG

N011702 003 Dec 29, 1983

MEPRO-ASPIRIN

SANDOZ

325MG;200MG

A089127 001 Mar 02, 1987

MEPROBAMATE AND ASPIRIN

PAR PHARM

325MG;200MG

A089126 001 Aug 19, 1986

MICRAININ

MEDPOINTE PHARM HLC

325MG;200MG

A084978 001

Q-GESIC

QUANTUM PHARMICS

325MG;200MG

A088740 001 Jun 01, 1984

ASPIRIN; METHOCARBAMOL

TABLET;ORAL

METHOCARBAMOL AND ASPIRIN

IVAX SUB TEVA PHARMS

325MG;400MG

A087211 001 Dec 22, 1982

MCNEIL

325MG;400MG

A089193 001 Feb 12, 1986

PAR PHARM

325MG;400MG

A089657 001 Nov 04, 1988

STEVENS J

325MG;400MG

A081145 001 Jan 31, 1995

ROBAXISAL

ROBINS AH

325MG;400MG

N012281 001

ASPIRIN; OMEPRAZOLE

TABLET, DELAYED RELEASE;ORAL

YOSPRALA

+

GENUS LIFESCIENCES

81MG;40MG

N205103 001 Sep 14, 2016

+

325MG;40MG

N205103 002 Sep 14, 2016

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-51(of 478)

** See List Footnote

ASPIRIN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL

OXYCODONE AND ASPIRIN

ACTAVIS LABS FL INC 325MG; 4.8355MG

A090084 001 Mar 22, 2011

MAYNE PHARMA INC 325MG; 4.8355MG

A091670 001 Mar 16, 2011

ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE

TABLET; ORAL

CODOXY

HALSEY 325MG; 4.5MG; 0.38MG

A087464 001 Jul 01, 1982

OXYCODONE AND ASPIRIN

ANI PHARMS 325MG; 4.5MG; 0.38MG

A040255 001 Feb 27, 1998

SUN PHARM INDUSTRIES 325MG; 4.5MG; 0.38MG

A040260 001 Jul 17, 1998

325MG; 4.5MG; 0.38MG

A087794 001 May 26, 1982

OXYCODONE AND ASPIRIN (HALF-STRENGTH)

ROXANE 325MG; 2.25MG; 0.19MG

A087742 001 Jun 04, 1982

PERCODAN

ENDO PHARMS 325MG; 4.5MG; 0.38MG **

N007337 006

PERCODAN-DEMI

ENDO PHARMS 325MG; 2.25MG; 0.19MG **

N007337 005

ROXIPIRIN

ROXANE 325MG; 4.5MG; 0.38MG

A087743 001 Jun 04, 1982

ASPIRIN; PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL

TALWIN COMPOUND

+ SANOFI AVENTIS US 325MG; EQ 12.5MG BASE **

N016891 001

ASPIRIN; PRAVASTATIN SODIUM

TABLET; ORAL

PRAVIGARD PAC (COPACKAGED)

BRISTOL MYERS SQUIBB 81MG; 20MG

N021387 001 Jun 24, 2003

81MG; 40MG

N021387 002 Jun 24, 2003

81MG; 80MG

N021387 003 Jun 24, 2003

325MG; 20MG

N021387 004 Jun 24, 2003

325MG; 40MG

N021387 005 Jun 24, 2003

325MG; 80MG

N021387 006 Jun 24, 2003

ASPIRIN; PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL

DARVON W/ ASA

XANODYNE PHARM 325MG; 65MG

N010996 005

ASPIRIN; PROPOXYPHENE NAPSYLATE

CAPSULE; ORAL

DARVON-N W/ ASA

AAIPHARMA LLC 325MG; 100MG

N016829 001

TABLET; ORAL

DARVON-N W/ ASA

AAIPHARMA LLC 325MG; 100MG

N016863 001

ATAZANAVIR SULFATE

CAPSULE; ORAL

ATAZANAVIR SULFATE

AMNEAL EQ 100MG BASE

A209717 001 Jun 01, 2020

MYLAN EQ 150MG BASE

A208177 001 Sep 24, 2018

EQ 200MG BASE

A208177 002 Sep 24, 2018

EQ 300MG BASE

A208177 003 Sep 24, 2018

ZYDUS PHARMS EQ 150MG BASE

A210575 001 Jun 04, 2020

EQ 200MG BASE

A210575 002 Jun 04, 2020

EQ 300MG BASE

A210575 003 Jun 04, 2020

REYATAZ

+ BRISTOL MYERS SQUIBB EQ 100MG BASE **

N021567 001 Jun 20, 2003

+ EQ 150MG BASE

N021567 002 Jun 20, 2003

ATENOLOL

INJECTABLE; INJECTION

TENORMIN

+ ASTRAZENECA 0.5MG/ML **

N019058 001 Sep 13, 1989

TABLET; ORAL

ATENOLOL

ABLE 25MG

A076907 001 Jul 30, 2004

50MG

A076907 002 Jul 30, 2004

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-52(of 478)

** See List Footnote

ATENOLOL

TABLET; ORAL

ATENOLOL

	100MG	A076907 003	Jul 30, 2004
APOTHECON	50MG	A073317 001	Mar 20, 1992
	100MG	A073318 001	Mar 20, 1992
CHARTWELL RX	25MG	A074265 001	Feb 28, 1994
	50MG	A074265 002	Feb 28, 1994
	100MG	A074265 003	Feb 28, 1994
MYLAN	25MG	A074126 003	Aug 26, 1998
	50MG	A074126 001	Mar 23, 1994
	100MG	A074126 002	Mar 23, 1994
NORTHSTAR HLTHCARE	25MG	A078254 001	Sep 25, 2009
	50MG	A078254 002	Sep 25, 2009
	100MG	A078254 003	Sep 25, 2009
NOSTRUM LABS	50MG	A074127 001	Feb 21, 1995
	100MG	A074127 002	Feb 21, 1995
PLIVA	25MG	A074101 001	Jul 17, 1997
	50MG	A074101 002	Jul 17, 1997
	100MG	A074101 003	Jul 17, 1997
SCS	50MG	A073676 001	Oct 30, 1992
	100MG	A073676 002	Oct 30, 1992
STRIDES PHARMA	25MG	A074099 001	Apr 28, 1992
	50MG	A073542 001	Dec 19, 1991
	100MG	A073543 001	Dec 19, 1991
SUN PHARM INDS INC	25MG	A078210 001	Jul 10, 2007
	50MG	A078210 002	Jul 10, 2007
	100MG	A078210 003	Jul 10, 2007
SUN PHARM INDUSTRIES	25MG	A074499 001	Jul 30, 1997
	50MG	A073475 001	Mar 30, 1993
	100MG	A073476 001	Mar 30, 1993
TEVA	50MG	A073315 001	May 28, 1993
	100MG	A073316 001	May 28, 1993
TEVA PHARMS	50MG	A074120 001	Feb 24, 1995
	100MG	A074120 002	Feb 24, 1995
WATSON LABS	50MG	A073352 001	Dec 27, 1991
WATSON LABS TEVA	100MG	A073353 001	Dec 27, 1991

ATENOLOL; CHLORTHALIDONE

TABLET; ORAL

ATENOLOL AND CHLORTHALIDONE

MYLAN	50MG; 25MG	A074203 001	Oct 31, 1993
	100MG; 25MG	A074203 002	Oct 31, 1993
NOSTRUM LABS	50MG; 25MG	A074404 001	May 14, 1998
	100MG; 25MG	A074404 002	May 14, 1998
PLIVA	50MG; 25MG	A074107 001	Sep 24, 1997
	100MG; 25MG	A074107 002	Sep 24, 1997
SUN PHARM INDUSTRIES	50MG; 25MG	A073582 002	Apr 29, 1993
	100MG; 25MG	A073582 001	Apr 29, 1993

ATOMOXETINE HYDROCHLORIDE

CAPSULE; ORAL

ATOMOXETINE HYDROCHLORIDE

STRIDES PHARMA	10MG	A079021 001	Feb 18, 2021
	18MG	A079021 002	Feb 18, 2021
	25MG	A079021 003	Feb 18, 2021
	40MG	A079021 004	Feb 18, 2021
	60MG	A079021 005	Feb 18, 2021
	80MG	A079021 006	Feb 18, 2021
	100MG	A079021 007	Feb 18, 2021
STRATTERA			
LILLY	5MG	N021411 001	Nov 26, 2002

ATORVASTATIN CALCIUM

TABLET; ORAL

ATORVASTATIN CALCIUM

PERRIGO R AND D	EQ 10MG BASE	A208478 001	Jun 23, 2020
	EQ 20MG BASE	A208478 002	Jun 23, 2020
TEVA PHARMS	EQ 10MG BASE	A078773 001	May 29, 2012
	EQ 20MG BASE	A078773 002	May 29, 2012
	EQ 40MG BASE	A078773 003	May 29, 2012

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-53(of 478)

** See List Footnote

ATORVASTATIN CALCIUM

TABLET; ORAL

ATORVASTATIN CALCIUM

EQ 80MG BASE

A078773 004 May 29, 2012

ATORVASTATIN CALCIUM; EZETIMIBE

TABLET; ORAL

LIPTRUZET

+ ORGANON

EQ 10MG BASE; 10MG **

N200153 001 May 03, 2013

+

EQ 20MG BASE; 10MG **

N200153 002 May 03, 2013

+

EQ 40MG BASE; 10MG **

N200153 003 May 03, 2013

+

EQ 80MG BASE; 10MG **

N200153 004 May 03, 2013

ATOVAQUONE

TABLET; ORAL

MEPRON

+ GLAXOSMITHKLINE LLC

250MG **

N020259 001 Nov 25, 1992

ATRACURIUM BESYLATE

INJECTABLE; INJECTION

ATRACURIUM BESYLATE

BAXTER HLTHCARE

10MG/ML

A074824 001 Sep 30, 1997

BAXTER HLTHCARE CORP

10MG/ML

A074753 001 Jan 23, 1997

HOSPIRA

10MG/ML

A074632 001 Dec 23, 1996

10MG/ML

A074740 001 Mar 28, 1997

MYLAN LABS LTD

10MG/ML

A206096 001 Jun 22, 2017

TEVA PARENTERAL

10MG/ML

A074784 001 Jun 11, 1997

WATSON PHARMS TEVA

10MG/ML

A074945 001 Jul 28, 1998

ATRACURIUM BESYLATE PRESERVATIVE FREE

BAXTER HLTHCARE

10MG/ML

A074825 001 Sep 30, 1997

BAXTER HLTHCARE CORP

10MG/ML

A074768 001 Jan 23, 1997

HOSPIRA

10MG/ML

A074633 001 Dec 23, 1996

10MG/ML

A074639 001 Mar 25, 1997

10MG/ML

A074741 001 Mar 28, 1997

MYLAN LABS LTD

10MG/ML

A206001 001 Apr 07, 2017

WATSON LABS INC

10MG/ML

A074944 001 Jul 28, 1998

TRACRIUM

+ HOSPIRA

10MG/ML **

N018831 002 Jun 20, 1985

TRACRIUM PRESERVATIVE FREE

+ HOSPIRA

10MG/ML **

N018831 001 Nov 23, 1983

ATROPINE

SOLUTION; INTRAMUSCULAR

ATROPINE

ABBVIE

EQ 2MG SULFATE/0.7ML

A071295 001 Jan 30, 1987

ATROPINE (AUTOINJECTOR)

RAFA LABS LTD

EQ 2MG SULFATE/0.7ML (EQ 2MG
SULFATE/0.7ML)

N212319 001 Jul 09, 2018

ATROPINE SULFATE

AEROSOL, METERED; INHALATION

ATROPINE SULFATE

US ARMY

EQ 0.36MG BASE/INH

N020056 001 Sep 19, 1990

ATROPINE SULFATE; DIFENOXIN HYDROCHLORIDE

TABLET; ORAL

MOTOFEN HALF-STRENGTH

SEBELA IRELAND LTD

0.025MG; 0.5MG

N017744 001

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

CAPSULE; ORAL

DIPHENOXYLATE HYDROCHLORIDE W/ ATROPINE SULFATE

SCHERER RP

0.025MG; 2.5MG

A086440 001

SOLUTION; ORAL

COLONAL

MEDPOINTE PHARM HLC

0.025MG/5ML; 2.5MG/5ML

A085735 001

LOMANATE

ALPHARMA US PHARMS

0.025MG/5ML; 2.5MG/5ML

A085746 001

LOMOTIL

GD SEARLE LLC

0.025MG/5ML; 2.5MG/5ML

N012699 001

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-54(of 478)

** See List Footnote

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET; ORAL

COLONAIID

MEDPOINTE PHARM HLC 0.025MG;2.5MG A085737 001

DI-ATRO

MD PHARM 0.025MG;2.5MG A085266 001

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

ABLE 0.025MG;2.5MG A040395 001 Nov 27, 2000

ASCOT 0.025MG;2.5MG A087934 001 Jul 19, 1983

FOSUN PHARMA 0.025MG;2.5MG A086173 001

HEATHER 0.025MG;2.5MG A086798 001

HIKMA 0.025MG;2.5MG A087765 001 Mar 15, 1982

INWOOD LABS 0.025MG;2.5MG A085509 001

KV PHARM 0.025MG;2.5MG A085659 001

LEDERLE 0.025MG;2.5MG A086950 001

MAYNE PHARMA INC 0.025MG;2.5MG A210789 001 Jun 03, 2020

PARKE DAVIS 0.025MG;2.5MG A087131 001

PVT FORM 0.025MG;2.5MG A085766 001

R AND S PHARMA 0.025MG;2.5MG A085035 001

ROXANE 0.025MG;2.5MG A086057 001

STRIDES PHARMA 0.025MG;2.5MG A040357 001 May 02, 2000

SUN PHARM INDUSTRIES 0.025MG;2.5MG A085506 001

USL PHARMA 0.025MG;2.5MG A087842 001 Mar 29, 1982

VALEANT PHARM INTL 0.025MG;2.5MG A087195 001 Feb 16, 1982

WATSON LABS 0.025MG;2.5MG A085876 001

LO-TROL

VANGARD 0.025MG;2.5MG A088009 001 Mar 25, 1983

LOGEN

SUPERPHARM 0.025MG;2.5MG A088962 001 May 10, 1985

LONOX

FOSUN PHARMA 0.025MG;2.5MG A085311 002

LOW-QUEL

HALSEY 0.025MG;2.5MG A085211 001

ATROPINE SULFATE; EDROPHONIUM CHLORIDE

INJECTABLE; INJECTION

ENLON-PLUS

+ MYLAN 0.14MG/ML;10MG/ML N019678 001 Nov 06, 1991

MYLAN INSTITUTIONAL 0.14MG/ML;10MG/ML N019677 001 Nov 06, 1991

ATROPINE SULFATE; MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

ATROPINE AND DEMEROL

ABBVIE 0.4MG/ML;50MG/ML A087853 001 Nov 26, 1982

0.4MG/ML;75MG/ML A087847 001 Nov 26, 1982

0.4MG/ML;100MG/ML A087848 001 Nov 26, 1982

MEPERIDINE AND ATROPINE SULFATE

WYETH AYERST 0.4MG/ML;50MG/ML A085121 001

0.4MG/ML;75MG/ML A085121 002

0.4MG/ML;100MG/ML A085121 003

ATROPINE; PRALIDOXIME CHLORIDE

INJECTABLE; INTRAMUSCULAR

ATNAA

US ARMY 2.1MG/0.7ML;600MG/2ML N021175 001 Jan 17, 2002

AVOBENZONE; OCTINOXATE; OXYBENZONE

LOTION; TOPICAL

SHADE UVAGUARD

+ BAYER HEALTHCARE LLC 3%;7.5%;3% N020045 001 Dec 07, 1992

AZACITIDINE

POWDER; INTRAVENOUS, SUBCUTANEOUS

AZACITIDINE

LUPIN LTD 100MG/VIAL A210748 001 Feb 27, 2019

MYLAN INSTITUTIONAL 100MG/VIAL A204949 001 Apr 28, 2016

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-55(of 478)

** See List Footnote

AZATADINE MALEATE

TABLET;ORAL

OPTIMINE

SCHERING

1MG

N017601 001

AZATADINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE;ORAL

TRINALIN

SCHERING

1MG;120MG

N018506 001 Mar 23, 1982

AZATHIOPRINE

TABLET;ORAL

IMURAN

+

SEBELA IRELAND LTD

25MG **

N016324 002

AZATHIOPRINE SODIUM

INJECTABLE;INJECTION

IMURAN

+

CASPER PHARMA LLC

EQ 100MG BASE/VIAL **

N017391 001

AZELAIC ACID

AEROSOL, FOAM;TOPICAL

AZELAIC ACID

TEVA PHARMS USA

15%

A210928 001 Oct 07, 2020

AZELASTINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

AZELASTINE HYDROCHLORIDE

AKORN

0.05%

A203660 001 Nov 08, 2016

OPTIVAR

+

MYLAN SPECIALITY LP

0.05% **

N021127 001 May 22, 2000

SPRAY, METERED;NASAL

ASTELIN

+

MYLAN SPCLT VIATRIS

0.137MG/SPRAY

N020114 001 Nov 01, 1996

ASTEPRO

+

MYLAN SPECIALITY LP

0.137MG/SPRAY

N022203 001 Oct 15, 2008

0.2055MG/SPRAY

N022203 002 Aug 31, 2009

AZELASTINE HYDROCHLORIDE

AKORN

0.2055MG/SPRAY

A210032 001 Aug 23, 2019

AMNEAL

0.2055MG/SPRAY

A208199 001 Dec 15, 2017

APOTEX INC

0.2055MG/SPRAY

A201846 001 Aug 31, 2012

AUROBINDO PHARMA LTD

0.2055MG/SPRAY

A212775 001 Nov 12, 2020

HIKMA

0.2055MG/SPRAY

A207243 001 Sep 22, 2017

AZILSARTAN KAMEDOXOMIL

TABLET;ORAL

AZILSARTAN MEDOXOMIL

LUPIN LTD

EQ 40MG MEDOXOMIL

A214489 001 Jul 20, 2022

EQ 80MG MEDOXOMIL

A214489 002 Jul 20, 2022

AZITHROMYCIN

CAPSULE;ORAL

ZITHROMAX

+

PFIZER

EQ 250MG BASE **

N050670 001 Nov 01, 1991

FOR SUSPENSION;ORAL

AZITHROMYCIN

CHARTWELL RX

EQ 100MG BASE/5ML

A065488 001 May 15, 2015

EQ 200MG BASE/5ML

A065488 002 May 15, 2015

SANDOZ

EQ 100MG BASE/5ML

A065297 001 Sep 18, 2006

EQ 200MG BASE/5ML

A065297 002 Sep 18, 2006

TARO

EQ 200MG BASE/5ML

A211521 001 Dec 11, 2019

TEVA PHARMS

EQ 100MG BASE/5ML

A065419 001 Jun 24, 2008

EQ 200MG BASE/5ML

A065419 002 Jun 24, 2008

FOR SUSPENSION, EXTENDED RELEASE;ORAL

ZMAX

+

PF PRISM CV

EQ 2GM BASE/BOT

N050797 001 Jun 10, 2005

INJECTABLE;INJECTION

AZITHROMYCIN

HIKMA

EQ 500MG BASE/VIAL

A065265 001 Jan 18, 2007

MYLAN ASI

EQ 500MG BASE/VIAL

A065506 001 Mar 24, 2009

RISING

EQ 500MG BASE/VIAL

A204732 001 Jan 26, 2017

TEVA PARENTERAL

EQ 500MG BASE/VIAL

N050809 001 Dec 19, 2006

EQ 2.5GM BASE/VIAL

N050809 002 Dec 19, 2006

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-56(of 478)

** See List Footnote

AZITHROMYCIN

TABLET; ORAL

AZITHROMYCIN

APOTEX CORP

EQ 250MG BASE

A065507 001 Jul 13, 2011

EQ 500MG BASE

A065509 001 Jul 13, 2011

EQ 600MG BASE

A065508 001 Jul 13, 2011

MYLAN

EQ 250MG BASE

A065365 001 May 30, 2007

EQ 500MG BASE

A065366 001 May 30, 2007

EQ 600MG BASE

A065360 001 Jan 08, 2007

TEVA

EQ 250MG BASE

A065153 001 Nov 14, 2005

EQ 600MG BASE

A065150 001 Nov 14, 2005

YUNG SHIN PHARM

EQ 500MG BASE

A211318 001 Mar 17, 2021

ZITHROMAX

+ PFIZER

EQ 600MG BASE **

N050730 001 Jun 12, 1996

AZITHROMYCIN DIHYDRATE; TROVAFLOXACIN MESYLATE

FOR SUSPENSION, TABLET; ORAL

TROVAN/ZITHROMAX COMPLIANCE PAK

PFIZER

EQ 1GM BASE, N/A; N/A, EQ 100MG BASE

N050762 001 Dec 18, 1998

AZLOCILLIN SODIUM

INJECTABLE; INJECTION

AZLIN

BAYER PHARMS

EQ 2GM BASE/VIAL

A062388 001 Sep 08, 1982

EQ 2GM BASE/VIAL

A062417 001 Oct 12, 1982

EQ 2GM BASE/VIAL

N050562 001 Sep 03, 1982

EQ 3GM BASE/VIAL

A062388 002 Sep 08, 1982

EQ 3GM BASE/VIAL

A062417 002 Oct 12, 1982

EQ 3GM BASE/VIAL

N050562 002 Sep 03, 1982

EQ 4GM BASE/VIAL

A062388 003 Sep 08, 1982

EQ 4GM BASE/VIAL

A062417 003 Oct 12, 1982

EQ 4GM BASE/VIAL

N050562 003 Sep 03, 1982

AZTREONAM

INJECTABLE; INJECTION

AZACTAM

BRISTOL MYERS SQUIBB 500MG/VIAL

N050580 001 Dec 31, 1986

AZACTAM IN PLASTIC CONTAINER

BRISTOL MYERS SQUIBB 10MG/ML

N050632 003 May 24, 1989

+

20MG/ML

N050632 002 May 24, 1989

+

40MG/ML

N050632 001 May 24, 1989

AZTREONAM

HIKMA

1GM/VIAL

A065286 001 Mar 23, 2011

2GM/VIAL

A065286 002 Mar 23, 2011

BACAMPICILLIN HYDROCHLORIDE

FOR SUSPENSION; ORAL

SPECTROBID

PFIZER

125MG/5ML

N050556 001 Mar 23, 1982

TABLET; ORAL

SPECTROBID

PFIZER

400MG

N050520 001

800MG

N050520 002 Sep 12, 1983

BACITRACIN

OINTMENT; OPHTHALMIC

BACIGUENT

PHARMACIA AND UPJOHN 500 UNITS/GM

A060734 001

BACITRACIN

LILLY

500 UNITS/GM

A060687 001

PHARMADERM

500 UNITS/GM

A062158 001

PHARMAFAIR

500 UNITS/GM

A062453 001 Mar 28, 1984

OINTMENT; TOPICAL

BACITRACIN

COMBE

500 UNITS/GM

A062799 001 May 14, 1987

NASKA

500 UNITS/GM

A062857 001 Nov 13, 1987

POWDER; FOR RX COMPOUNDING

BACI-RX

X GEN PHARMS

5,000,000 UNITS/BOT

A061580 001

BACITRACIN

APOTHEKERNES

5,000,000 UNITS/BOT

A061699 001

PADDOCK LLC

5,000,000 UNITS/BOT

A062456 001 Jul 27, 1983

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-57(of 478)

** See List Footnote

BACITRACIN ZINC

POWDER;FOR RX COMPOUNDING

ZIBA-RX

X GEN PHARMS

500,000 UNITS/BOT

A061737 001

BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

CORTISPORIN

+

CASPER PHARMA LLC

400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM **

N050416 002

ZINC BACITRACIN,NEOMYCIN SULFATE,POLYMYXIN B SULFATE & HYDROCORTISONE

PHARMAFAIR

400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM

A062389 001 Jul 02, 1982

OINTMENT;TOPICAL

CORTISPORIN

+

MONARCH PHARMS

400 UNITS/GM;1%;EQ 3.5MG BASE/GM;5,000 UNITS/GM

N050168 002 May 04, 1984

NEOMYCIN & POLYMYXIN B SULFATES & BACITRACIN ZINC & HYDROCORTISONE

PHARMAFAIR

400 UNITS/GM;1%;EQ 3.5MG BASE/GM;5,000 UNITS/GM

A062381 001 Sep 06, 1985

BACITRACIN ZINC; LIDOCAINE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;TOPICAL

LANABIOTIC

COMBE

400 UNITS/GM;40MG/GM;EQ 5MG BASE/GM;5,000 UNITS/GM

A062499 001 Jun 03, 1985

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE

PHARMAFAIR

400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM

A062386 001 Sep 09, 1982

BACITRACIN-NEOMYCIN-POLYMYXIN

PHARMADERM

400 UNITS/GM;EQ 3.5MG BASE/GM;5,000 UNITS/GM

A062167 001

NEO-POLYCIN

DOW PHARM

500 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM

A060647 001

OINTMENT;TOPICAL

BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE

NASKA

400 UNITS/GM;EQ 3.5MG BASE/GM;5,000 UNITS/GM

A062833 001 Nov 09, 1987

BACITRACIN ZINC; POLYMYXIN B SULFATE

AEROSOL;TOPICAL

POLYSPORIN

GLAXOSMITHKLINE

10,000 UNITS/GM;2,000,000 UNITS/GM

N050167 002 Mar 01, 1985

OINTMENT;OPHTHALMIC

OCUMYCIN

PHARMAFAIR

500 UNITS/GM;10,000 UNITS/GM

A062430 001 Apr 08, 1983

POLYSPORIN

MONARCH PHARMS

500 UNITS/GM;10,000 UNITS/GM **

A061229 001

OINTMENT;TOPICAL

BACITRACIN ZINC-POLYMYXIN B SULFATE

NASKA

500 UNITS/GM;10,000 UNITS/GM

A062849 001 Nov 13, 1987

BACITRACIN; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE

ALTANA

400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM

A060731 002

BACITRACIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

MYCITRACIN

PHARMACIA AND UPJOHN

500 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM

A061048 001

BACITRACIN; POLYMYXIN B SULFATE

DISC;TOPICAL

LANABIOTIC

COMBE

500 UNITS/GM;5,000 UNITS/GM

N050598 001 Sep 22, 1986

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-58(of 478)

** See List Footnote

BACLOFEN

TABLET;ORAL

BACLOFEN

APPCO	10MG	A090334 001	Feb 18, 2010
	20MG	A090334 002	Feb 18, 2010
MYLAN	10MG	A077181 001	Jul 29, 2005
	20MG	A077121 002	Jul 29, 2005
SUN PHARM INDS INC	10MG	A077862 001	Aug 14, 2006
	20MG	A077862 002	Aug 14, 2006
TEVA	10MG	A073043 001	Feb 27, 1992
	20MG	A073044 001	Feb 27, 1992
USL PHARMA	10MG	A071260 001	May 06, 1988
	20MG	A071261 001	May 06, 1988
WATSON LABS	10MG	A072824 001	Sep 18, 1991
	10MG	A073092 001	Jan 28, 1994
	10MG	A074698 001	Aug 20, 1996
	20MG	A072825 001	Sep 18, 1991
	20MG	A073093 001	Jan 28, 1994
	20MG	A074698 002	Aug 20, 1996

LIORESAL

+ NOVARTIS 10MG **

N017851 001

+ 20MG **

N017851 003 Jan 20, 1982

TABLET, ORALLY DISINTEGRATING;ORAL

KEMSTRO

+ UCB INC 10MG N021589 001 Oct 30, 2003

+ 20MG N021589 002 Oct 30, 2003

BALSALAZIDE DISODIUM

CAPSULE;ORAL

BALSALAZIDE DISODIUM

MYLAN 750MG A077807 001 Dec 28, 2007

TABLET;ORAL

BALSALAZIDE DISODIUM

STRIDES PHARMA 1.1GM A206336 001 Sep 08, 2015

GIAZO

+ VALEANT PHARMS INTL 1.1GM ** N022205 001 Feb 03, 2012

BARIUM SULFATE

FOR SUSPENSION;ORAL

E-Z-CAT DRY

+ BRACCO 40% (9GM/POUCH) N208036 003 Jan 03, 2017

BECLOMETHASONE DIPROPIONATE

AEROSOL, METERED;INHALATION

BECLOVENT

GLAXOSMITHKLINE 0.042MG/INH N018153 001

QVAR 40

+ TEVA BRANDED PHARM 0.04MG/INH ** N020911 002 Sep 15, 2000

QVAR 80

+ TEVA BRANDED PHARM 0.08MG/INH ** N020911 001 Sep 15, 2000

VANCERIL

SCHERING 0.042MG/INH N017573 001

VANCERIL DOUBLE STRENGTH

SCHERING 0.084MG/INH N020486 001 Dec 24, 1996

AEROSOL, METERED;NASAL

BECONASE

GLAXOSMITHKLINE 0.042MG/INH N018584 001

VANCENASE

SCHERING 0.042MG/INH N018521 001

BECLOMETHASONE DIPROPIONATE MONOHYDRATE

SPRAY, METERED;NASAL

VANCENASE AQ

SCHERING EQ 0.042MG DIPROP/SPRAY N019589 001 Dec 23, 1987

EQ 0.084MG DIPROP/SPRAY N020469 001 Jun 26, 1996

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-59(of 478)

** See List Footnote

BENAZEPRIL HYDROCHLORIDE

TABLET; ORAL

BENAZEPRIL HYDROCHLORIDE

ANI PHARMS

5MG

A076333 001 Feb 11, 2004

10MG

A076333 002 Feb 11, 2004

20MG

A076333 003 Feb 11, 2004

40MG

A076333 004 Feb 11, 2004

GENPHARM

5MG

A076476 001 Feb 11, 2004

10MG

A076476 002 Feb 11, 2004

20MG

A076476 003 Feb 11, 2004

40MG

A076476 004 Feb 11, 2004

RISING

5MG

A076430 001 Feb 11, 2004

10MG

A076430 002 Feb 11, 2004

20MG

A076430 003 Feb 11, 2004

40MG

A076430 004 Feb 11, 2004

LOTENSIN

+ VALIDUS PHARMS

5MG

N019851 001 Jun 25, 1991

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

ANI PHARMS

5MG; 6.25MG

A076348 001 Feb 11, 2004

10MG; 12.5MG

A076348 002 Feb 11, 2004

20MG; 12.5MG

A076348 003 Feb 11, 2004

20MG; 25MG

A076348 004 Feb 11, 2004

APOTEX

5MG; 6.25MG

A078794 001 Aug 21, 2014

10MG; 12.5MG

A078794 002 Aug 21, 2014

20MG; 12.5MG

A078794 003 Aug 21, 2014

20MG; 25MG

A078794 004 Aug 21, 2014

AUROBINDO PHARMA USA

5MG; 6.25MG

A076688 001 Feb 11, 2004

10MG; 12.5MG

A076688 002 Feb 11, 2004

20MG; 12.5MG

A076688 003 Feb 11, 2004

20MG; 25MG

A076688 004 Feb 11, 2004

MYLAN PHARMS INC

5MG; 6.25MG

A076612 001 Feb 11, 2004

10MG; 12.5MG

A076612 002 Feb 11, 2004

20MG; 12.5MG

A076612 003 Feb 11, 2004

20MG; 25MG

A076612 004 Feb 11, 2004

SUN PHARM INDS LTD

5MG; 6.25MG

A077483 001 Sep 08, 2005

10MG; 12.5MG

A077483 002 Sep 08, 2005

20MG; 12.5MG

A077483 003 Sep 08, 2005

20MG; 25MG

A077483 004 Sep 08, 2005

LOTENSIN HCT

+ VALIDUS PHARMS

5MG; 6.25MG **

N020033 001 May 19, 1992

BENDAMUSTINE HYDROCHLORIDE

SOLUTION; IV (INFUSION)

TREANDA

+ CEPHALON

45MG/0.5ML (90MG/ML)

N022249 003 Sep 13, 2013

+

180MG/2ML (90MG/ML)

N022249 004 Sep 13, 2013

BENDROFLUMETHIAZIDE

TABLET; ORAL

NATURETIN-10

APOTHECON

10MG

N012164 003

NATURETIN-2.5

APOTHECON

2.5MG

N012164 001

NATURETIN-5

APOTHECON

5MG

N012164 002

BENDROFLUMETHIAZIDE; NADOLOL

TABLET; ORAL

CORZIDE

+ KING PHARMS LLC

5MG; 40MG

N018647 001 May 25, 1983

+

5MG; 80MG

N018647 002 May 25, 1983

NADOLOL AND BENDROFLUMETHIAZIDE

IMPAX LABS

5MG; 40MG

A077833 001 Mar 30, 2007

5MG; 80MG

A077833 002 Mar 30, 2007

MYLAN

5MG; 40MG

A078688 001 Feb 15, 2008

5MG; 80MG

A078688 002 Feb 15, 2008

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-60(of 478)

** See List Footnote

BENOXINATE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

BENOXINATE HYDROCHLORIDE

SOLA BARNES HIND 0.4%

A084149 001

BENTIROMIDE

SOLUTION;ORAL

CHYMEX

SAVAGE LABS 500MG/7.5ML

N018366 001 Dec 29, 1983

BENZONATATE

CAPSULE;ORAL

BENZONATATE

MIKART 100MG

A040851 001 Nov 09, 2009

150MG

A040851 002 Nov 09, 2009

200MG

A040851 003 Nov 09, 2009

NESHER PHARMS 100MG

A040795 001 Oct 31, 2007

200MG

A040795 002 Oct 31, 2007

SUN PHARM INDS INC 100MG

A040587 001 Mar 19, 2008

200MG

A040587 002 Mar 19, 2008

TESSALON

+ PFIZER 200MG **

N011210 003 Jun 25, 1999

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

GEL;TOPICAL

BENZACLIN

BAUSCH 5%;EQ 1% BASE

N050756 002 Apr 20, 2007

CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE

ENCUBE 2.5%;EQ 1.2% BASE

A207194 001 Aug 19, 2019

5%;EQ 1% BASE

A204087 001 Jun 27, 2017

TARO 3.75%;EQ 1.2% BASE

A208683 001 Jun 05, 2018

TOLMAR 5%;1.2%

A203688 001 Aug 25, 2016

BENZOYL PEROXIDE; ERYTHROMYCIN

GEL;TOPICAL

AKTIPAK

+ BIOFRONTERA 5%;3%

N050769 001 Nov 27, 2000

ERYTHROMYCIN AND BENZOYL PEROXIDE

ENCUBE 5%;3%

A065112 001 Mar 29, 2004

BENZPHETAMINE HYDROCHLORIDE

TABLET;ORAL

BENZPHETAMINE HYDROCHLORIDE

EMCURE PHARMS LTD 50MG

A202061 001 Jan 27, 2012

EPIC PHARMA LLC 50MG

A040714 001 Oct 29, 2007

IMPAX LABS 50MG

A040845 001 Nov 18, 2008

SCINOPHARM TAIWAN 50MG

A040578 001 Apr 17, 2006

SPECGX LLC 50MG

A040773 001 Apr 25, 2007

TEDOR PHARM 25MG

A040747 002 Nov 20, 2015

50MG

A040747 001 Mar 30, 2007

DIDREX

+ PFIZER 25MG **

N012427 003

+ 50MG **

N012427 002

BENZQUINAMIDE HYDROCHLORIDE

INJECTABLE;INJECTION

EMETE-CON

PFIZER EQ 50MG BASE/VIAL

N016820 001

SUPPOSITORY;RECTAL

EMETE-CON

ROERIG EQ 100MG BASE

N016818 006

BENZTHIAZIDE

TABLET;ORAL

AQUATAG

SOLVAY 25MG

N016001 001

50MG

N016001 002

BENZTHIAZIDE

PVT FORM 50MG

A083206 001

EXNA

AH ROBINS INC 50MG

N012489 001

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-61(of 478)

** See List Footnote

BENZTHIAZIDE

TABLET;ORAL

FOVANE

PFIZER

50MG

N012128 002

URESE

PFIZER

25MG

N012128 003

BENZTROPINE MESYLATE

INJECTABLE;INJECTION

BENZTROPINE MESYLATE

LUITPOLD

1MG/ML

A091152 001 Mar 29, 2010

COGENTIN

+ AKORN

1MG/ML

N012015 001

TABLET;ORAL

BENZTROPINE MESYLATE

AIPING PHARM INC

0.5MG

A040103 001 Dec 12, 1996

1MG

A040103 002 Dec 12, 1996

2MG

A040103 003 Dec 12, 1996

LANNETT CO INC

0.5MG **

A088877 001 Apr 11, 1985

1MG **

A088894 001 Apr 11, 1985

2MG **

A088895 001 Apr 11, 1985

OXFORD PHARMS

0.5MG

A040706 002 Feb 14, 2008

1MG

A040706 003 Feb 14, 2008

2MG

A040706 001 Feb 14, 2008

QUANTUM PHARMICS

0.5MG

A088514 001 Jan 31, 1984

1MG

A088510 001 Jan 31, 1984

2MG

A088511 001 Jan 31, 1984

USL PHARMA

0.5MG

A089211 001 Jun 14, 1988

1MG

A089212 001 Jun 14, 1988

2MG

A089213 001 Jun 14, 1988

COGENTIN

+ MERCK

0.5MG **

N009193 004

+

1MG **

N009193 003

+

2MG **

N009193 002

BENZYL ALCOHOL

LOTION;TOPICAL

ULESFIA

+ SHIONOGI INC

5% **

N022129 001 Apr 09, 2009

BENZYL BENZOATE

EMULSION;TOPICAL

BENZYL BENZOATE

LANNETT

50%

A084535 001

BEPRIDIL HYDROCHLORIDE

TABLET;ORAL

BEPADIN

MEDPOINTE PHARM HLC

200MG

N019001 001 Dec 28, 1990

300MG

N019001 002 Dec 28, 1990

400MG

N019001 003 Dec 28, 1990

VASCOR

JOHNSON AND JOHNSON

200MG

N019002 001 Dec 28, 1990

300MG

N019002 002 Dec 28, 1990

400MG

N019002 003 Dec 28, 1990

BETA CAROTENE

CAPSULE;ORAL

SOLATENE

ROCHE

30MG

N017589 001

BETAMETHASONE

CREAM;TOPICAL

CELESTONE

SCHERING

0.2%

N014762 001

SYRUP;ORAL

CELESTONE

MERCK SHARP DOHME

0.6MG/5ML

N014215 002

TABLET;ORAL

CELESTONE

SCHERING

0.6MG

N012657 003

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-62(of 478)

** See List Footnote

BETAMETHASONE BENZOATE

CREAM;TOPICAL

UTICORT

PARKE DAVIS

0.025%

N016998 002

GEL;TOPICAL

UTICORT

PARKE DAVIS

0.025%

N017244 001

LOTION;TOPICAL

UTICORT

PARKE DAVIS

0.025%

N017528 001

OINTMENT;TOPICAL

UTICORT

PARKE DAVIS

0.025%

N018089 001

BETAMETHASONE DIPROPIONATE

CREAM;TOPICAL

ALPHATREX

SAVAGE LABS

EQ 0.05% BASE

N019138 001 Jun 26, 1984

BETAMETHASONE DIPROPIONATE

PERRIGO NEW YORK

EQ 0.05% BASE

A072536 001 Jan 31, 1990

EQ 0.05% BASE

A074579 001 Nov 26, 1997

PHARMADERM

EQ 0.05% BASE

N019136 001 Jun 26, 1984

TARO

EQ 0.05% BASE

A071143 001 Jun 17, 1987

TEVA

EQ 0.05% BASE

A071476 001 Aug 10, 1987

DIPROSONE

SCHERING

EQ 0.05% BASE

N017536 001

CREAM, AUGMENTED;TOPICAL

BETAMETHASONE DIPROPIONATE

ANDA REPOSITORY

EQ 0.05% BASE

A076603 001 Jan 23, 2004

DIPROLENE

SCHERING

EQ 0.05% BASE

N019408 001 Jan 31, 1986

DIPROLENE AF

+ ORGANON

EQ 0.05% BASE **

N019555 001 Apr 27, 1987

DISC;TOPICAL

DIPROSONE

SCHERING

EQ 0.1% BASE

N017829 001

GEL, AUGMENTED;TOPICAL

DIPROLENE

SCHERING

EQ 0.05% BASE

N019408 002 Nov 22, 1991

LOTION;TOPICAL

ALPHATREX

SAVAGE LABS

EQ 0.05% BASE

A070273 001 Aug 12, 1985

BETAMETHASONE DIPROPIONATE

ACTAVIS MID ATLANTIC

EQ 0.05% BASE

A070281 001 Jul 31, 1985

AKORN

EQ 0.05% BASE

A209896 001 Feb 06, 2018

ALPHARMA US PHARMS

EQ 0.05% BASE

A071085 001 Feb 03, 1987

COSETTE

EQ 0.05% BASE

A071882 001 Jun 06, 1988

PHARMGEN

EQ 0.05% BASE

A070274 001 Aug 12, 1985

TARO

EQ 0.05% BASE

A072276 001 Aug 24, 1988

EQ 0.05% BASE

A074272 001 Sep 30, 1994

DIPROSONE

+ SCHERING

EQ 0.05% BASE **

N017781 001

LOTION, AUGMENTED;TOPICAL

DIPROLENE

+ ORGANON

EQ 0.05% BASE **

N019716 001 Aug 01, 1988

OINTMENT;TOPICAL

ALPHATREX

SAVAGE LABS

EQ 0.05% BASE

N019143 001 Sep 04, 1984

BETAMETHASONE DIPROPIONATE

PERRIGO NEW YORK

EQ 0.05% BASE

A072526 001 Jan 31, 1990

PHARMADERM

EQ 0.05% BASE

N019140 001 Sep 04, 1984

TEVA

EQ 0.05% BASE

A071477 001 Aug 10, 1987

DIPROSONE

SCHERING

EQ 0.05% BASE

N017691 001

SPRAY;TOPICAL

BETAMETHASONE DIPROPIONATE

TARO PHARMS

EQ 0.05% BASE/SPRAY

A211722 001 Jun 17, 2020

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-63(of 478)

** See List Footnote

BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE

LOTION; TOPICAL

LOTIRISONE

+ MERCK SHARP DOHME EQ 0.05% BASE; 1% **

N020010 001 Dec 08, 2000

BETAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

BETAMETHASONE SODIUM PHOSPHATE

WATSON LABS

EQ 3MG BASE/ML

A085738 001

CELESTONE

+ SCHERING

EQ 3MG BASE/ML **

N017561 001

BETAMETHASONE VALERATE

AEROSOL, FOAM; TOPICAL

BETAMETHASONE VALERATE

NOVAST LABS

0.12%

A207144 001 May 24, 2017

CREAM; TOPICAL

BETADERM

ROACO

EQ 0.1% BASE

N018839 001 Jun 30, 1983

BETAMETHASONE VALERATE

PERRIGO NEW YORK

EQ 0.1% BASE

A070053 001 Jun 10, 1986

PHARMADERM

EQ 0.1% BASE

N018860 002 Aug 31, 1983

PHARMAFAIR

EQ 0.1% BASE

A070485 001 May 29, 1987

TARO

EQ 0.1% BASE

A070062 001 May 14, 1985

BETATREX

SAVAGE LABS

EQ 0.1% BASE

N018862 001 Aug 31, 1983

VALISONE

SCHERING

EQ 0.01% BASE

N016322 002

EQ 0.1% BASE

N016322 001

LOTION; TOPICAL

BETA-VAL

COSETTE

EQ 0.1% BASE

A070072 001 Jun 27, 1985

BETAMETHASONE VALERATE

PHARMADERM

EQ 0.1% BASE

N018870 001 Aug 31, 1983

PHARMAFAIR

EQ 0.1% BASE

A070484 001 May 29, 1987

TEVA PHARMS

EQ 0.1% BASE

A071883 001 Apr 22, 1988

BETATREX

SAVAGE LABS

EQ 0.1% BASE

N018867 001 Aug 31, 1983

VALISONE

SCHERING

EQ 0.1% BASE

N016932 001

OINTMENT; TOPICAL

BETAMETHASONE VALERATE

PERRIGO NEW YORK

EQ 0.1% BASE

A071478 001 Dec 23, 1987

PHARMADERM

EQ 0.1% BASE

N018864 001 Aug 31, 1983

PHARMAFAIR

EQ 0.1% BASE

A070486 001 May 29, 1987

BETATREX

SAVAGE LABS

EQ 0.1% BASE

N018863 001 Aug 31, 1983

VALISONE

SCHERING

EQ 0.1% BASE

N016740 001

BETAXOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

BETAXOLOL HYDROCHLORIDE

APOTEX INC

EQ 0.5% BASE

A075446 001 Sep 28, 2000

TABLET; ORAL

KERLONE

SANOFI AVENTIS US

10MG **

N019507 001 Oct 27, 1989

20MG **

N019507 002 Oct 27, 1989

BETAXOLOL HYDROCHLORIDE; CHLORTHALIDONE

TABLET; ORAL

KERLEDEX

SANOFI AVENTIS US

5MG; 12.5MG

N019807 001 Oct 30, 1992

10MG; 12.5MG

N019807 002 Oct 30, 1992

BETAXOLOL HYDROCHLORIDE; PILOCARPINE HYDROCHLORIDE

SUSPENSION/DROPS; OPHTHALMIC

BETOPTIC PILO

ALCON

EQ 0.25% BASE; 1.75%

N020619 001 Apr 17, 1997

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-64(of 478)

** See List Footnote

BETAZOLE HYDROCHLORIDE

INJECTABLE; INJECTION

HISTALOG

LILLY

50MG/ML

N009344 001

BETHANECHOL CHLORIDE

INJECTABLE; INJECTION

URECHOLINE

+ ODYSSEY PHARMS

5MG/ML **

N006536 001

TABLET; ORAL

BETHANECHOL CHLORIDE

ABLE

5MG

A040492 001 Jul 27, 2004

10MG

A040483 001 Jul 27, 2004

25MG

A040485 001 Jul 27, 2004

50MG

A040509 001 Jul 27, 2004

ACTAVIS ELIZABETH

5MG

A040552 001 Oct 28, 2004

10MG

A040553 001 Oct 28, 2004

25MG

A040554 001 Oct 28, 2004

50MG

A040551 001 Oct 28, 2004

ASCOT

10MG

A088288 001 Jun 08, 1983

25MG

A088289 001 Jun 08, 1983

HERITAGE PHARMA

5MG

A091256 001 May 04, 2010

10MG

A091256 002 May 04, 2010

25MG

A091256 003 May 04, 2010

50MG

A091256 004 May 04, 2010

IMPAX LABS

5MG

A040721 001 Nov 01, 2006

10MG

A040721 002 Nov 01, 2006

25MG

A040721 003 Nov 01, 2006

50MG

A040721 004 Nov 01, 2006

IVAX SUB TEVA PHARMS

25MG

A084689 001

LANNETT

5MG

A084702 001

10MG

A084712 001

25MG

A084074 001

LANNETT CO INC

5MG

A040677 002 Mar 27, 2008

10MG

A040677 003 Mar 27, 2008

25MG

A040677 004 Mar 27, 2008

50MG

A040677 001 Mar 27, 2008

SANDOZ

5MG

A084353 001

10MG

A084378 001

10MG

A084379 001

25MG

A084383 001

25MG

A084384 001

SUN PHARM INDS INC

5MG

A040897 001 Apr 22, 2009

10MG

A040897 002 Apr 22, 2009

25MG

A040897 003 Apr 22, 2009

50MG

A040897 004 Apr 22, 2009

WATSON LABS

5MG

A084402 001

5MG

A085230 002

5MG

A085841 001

10MG

A084408 001

10MG

A085228 001

10MG

A085842 001

25MG

A084441 001

25MG

A085229 001

25MG

A085839 001

50MG

A087397 001

50MG

A087444 001

WOCKHARDT

5MG

A040532 001 Sep 29, 2003

10MG

A040533 001 Sep 29, 2003

25MG

A040534 001 Sep 29, 2003

50MG

A040518 001 Sep 29, 2003

MYOTONACHOL

GLENWOOD

5MG

A084188 001

10MG

A084188 003

25MG

A084188 004

URECHOLINE

ODYSSEY PHARMS

5MG

A089095 001 Dec 19, 1985

+

5MG **

N006536 003

+

10MG

A088440 001 May 29, 1984

+

10MG **

N006536 002

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-65(of 478)

** See List Footnote

BETHANECHOL CHLORIDETABLET; ORAL
URECHOLINE

+	25MG	A088441 001	May 29, 1984
+	25MG **	N006536 004	
	50MG	A089096 001	Dec 19, 1985
+	50MG **	N006536 005	

BETHANIDINE SULFATETABLET; ORAL
TENATHAN

ROBINS AH	10MG	N017675 001	
	25MG	N017675 002	

BETRIXABANCAPSULE; ORAL
BEVYXXA

+	PORTOLA PHARMS INC	40MG	N208383 001	Jun 23, 2017
+		80MG	N208383 002	Jun 23, 2017

BICALUTAMIDETABLET; ORAL
BICALUTAMIDE

FRESENIUS KABI USA	50MG	A079045 001	May 13, 2010
KUDCO IRELAND	50MG	A077995 001	Jul 06, 2009
MYLAN	50MG	A079185 001	Jul 06, 2009
ROXANE	50MG	A078285 001	Mar 24, 2011
SYNTHON PHARMS	50MG	A077973 001	Jul 06, 2009
TEVA	50MG	A076932 001	Jul 06, 2009

BIMATOPROSTSOLUTION/DROPS; OPHTHALMIC
BIMATOPROST

AKORN	0.03%	A203299 001	Nov 08, 2018	
LUMIGAN				
+	ALLERGAN	0.03% **	N021275 001	Mar 16, 2001

BIPERIDEN HYDROCHLORIDETABLET; ORAL
AKINETON

ABBVIE	2MG	N012003 001	

BIPERIDEN LACTATEINJECTABLE; INJECTION
AKINETON

ABBVIE	5MG/ML	N012418 002	

BISACODYL; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

FOR SOLUTION, TABLET, DELAYED RELEASE; ORAL

HALFLYTELY

+	BRAINTREE	5MG, N/A; N/A, 210GM; N/A, 0.74GM; N/A, 2.86GM	N021551 003	Jul 16, 2010
		; N/A, 5.6GM **		

PEG-3350, SODIUM CHLORIDE, SODIUM BICARBONATE, POTASSIUM CHLORIDE AND BISACODYL

NOVEL LABS INC	5MG, N/A; N/A, 210GM; N/A, 0.74GM; N/A, 2.86GM	A202217 001	Aug 20, 2014
	; N/A, 5.6GM		

BISMUTH SUBSALICYLATE; METRONIDAZOLE; TETRACYCLINE HYDROCHLORIDE

TABLET, CHEWABLE, TABLET, CAPSULE; ORAL

HELIDAC

+	CASPER PHARMA LLC	262.4MG, N/A, N/A; N/A, 250MG, N/A; N/A, N/A, 500MG **	N050719 001	Aug 15, 1996

BISOPROLOL FUMARATE

TABLET; ORAL

BISOPROLOL FUMARATE

MYLAN	5MG	A075831 001	Dec 14, 2005
	10MG	A075831 002	Dec 14, 2005
TEVA PHARMS	5MG	A075644 001	Jun 26, 2001
	10MG	A075644 002	Jun 26, 2001

ZEBETA

+	TEVA WOMENS	5MG **	N019982 002	Jul 31, 1992
+		10MG **	N019982 001	Jul 31, 1992

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-66(of 478)

** See List Footnote

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE

ACTAVIS ELIZABETH	2.5MG; 6.25MG	A075672 001	Sep 25, 2000
	5MG; 6.25MG	A075672 002	Sep 25, 2000
	10MG; 6.25MG	A075672 003	Sep 25, 2000
APOTHECON	2.5MG; 6.25MG	A075642 002	Dec 27, 2000
	5MG; 6.25MG	A075642 001	Dec 27, 2000
	10MG; 6.25MG	A075642 003	Dec 27, 2000
CHARTWELL RX	2.5MG; 6.25MG	A075527 001	Sep 25, 2000
	5MG; 6.25MG	A075527 003	Sep 25, 2000
	10MG; 6.25MG	A075527 002	Sep 25, 2000
IVAX SUB TEVA PHARMS	2.5MG; 6.25MG	A075632 001	Sep 27, 2000
	5MG; 6.25MG	A075632 002	Sep 27, 2000
	10MG; 6.25MG	A075632 003	Sep 27, 2000
TEVA	2.5MG; 6.25MG	A075686 001	Jan 19, 2001
	5MG; 6.25MG	A075686 002	Jan 19, 2001
	10MG; 6.25MG	A075686 003	Jan 19, 2001
WATSON LABS TEVA	2.5MG; 6.25MG	A075469 001	Sep 25, 2000
	5MG; 6.25MG	A075469 002	Sep 25, 2000
	10MG; 6.25MG	A075469 003	Sep 25, 2000

BITOLTEROL MESYLATE

AEROSOL, METERED; INHALATION

TORNALATE

SANOFI AVENTIS US	0.37MG/INH	N018770 001	Dec 28, 1984

SOLUTION; INHALATION

TORNALATE

SANOFI AVENTIS US	0.2%	N019548 001	Feb 19, 1992

BIVALIRUDIN

INJECTABLE; INTRAVENOUS

BIVALIRUDIN

APOTEX	250MG/VIAL	A204876 001	Jul 06, 2017

SOLUTION; INTRAVENOUS

BIVALIRUDIN IN 0.9% SODIUM CHLORIDE

+ BAXTER HLTHCARE CORP	250MG/50ML (5MG/ML)	N208374 001	Dec 21, 2017

+ 500MG/100ML (5MG/ML)	N208374 002	Dec 21, 2017

BLEOMYCIN SULFATE

INJECTABLE; INJECTION

BLENOXANE

+ BRISTOL MYERS SQUIBB	EQ 15 UNITS BASE/VIAL **	N050443 001	

+ EQ 30 UNITS BASE/VIAL **	N050443 002	Sep 07, 1995

BLEOMYCIN SULFATE

CIPLA	EQ 15 UNITS BASE/VIAL	A209439 001	Mar 11, 2019

PHARMACHEMIE BV	EQ 15 UNITS BASE/VIAL	A065201 001	Dec 13, 2007

TEVA PARENTERAL	EQ 15 UNITS BASE/VIAL	A064084 001	Jun 01, 1996

	EQ 30 UNITS BASE/VIAL	A064084 002	Jun 01, 1996

BOCEPREVIR

CAPSULE; ORAL

VICTRELIS

MERCK SHARP DOHME	200MG	N202258 001	May 13, 2011

BORTEZOMIB

INJECTABLE; INTRAVENOUS, SUBCUTANEOUS

BORTEZOMIB

MYLAN LABS LTD	3.5MG/VIAL	A205160 001	Oct 31, 2022

TEVA PHARMS USA	3.5MG/VIAL	A205857 001	May 02, 2022

SOLUTION; INTRAVENOUS

BORTEZOMIB

+ MAIA PHARMS INC	3.5MG/3.5ML (1MG/ML)	N215331 001	Jul 27, 2022

BOSENTAN

TABLET; ORAL

BOSENTAN

ALEMBIC PHARMS	62.5MG	A211461 001	Jan 23, 2020

	125MG	A211461 002	Jan 23, 2020

ALVOGEN PINE BROOK	62.5MG	A206002 001	Apr 26, 2019

	125MG	A206002 002	Apr 26, 2019

AMNEAL PHARMS CO	62.5MG	A209742 001	Apr 26, 2019

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-67(of 478)

** See List Footnote

BOSENTAN

TABLET; ORAL

BOSENTAN

	125MG	A209742	002	Apr 26, 2019
CHARTWELL MOLECULAR	62.5MG	A210342	001	Jan 03, 2020
	125MG	A210342	002	Jan 03, 2020
MYLAN	62.5MG	A205173	001	Jan 15, 2020
	125MG	A205173	002	Jan 15, 2020
NATCO PHARMA LTD	62.5MG	A206987	001	Apr 26, 2019
	125MG	A206987	002	Apr 26, 2019

BRETYLIUM TOSYLATE

INJECTABLE; INJECTION

BRETYLIUM TOSYLATE

ABRAXIS PHARM	50MG/ML	A070134	001	Apr 29, 1986
	100MG/ML	A071298	001	Feb 13, 1987
ASTRAZENECA	50MG/ML	A071151	001	Aug 10, 1987
	50MG/ML	A071152	001	Aug 10, 1987
	50MG/ML	A071153	001	Aug 10, 1987
HIKMA	50MG/ML	A070545	001	May 14, 1986
	50MG/ML	A070546	001	May 14, 1986
+ HOSPIRA	50MG/ML **	N019030	001	Apr 29, 1986
	50MG/ML	N019033	001	Apr 29, 1986
INTL MEDICATION	50MG/ML	A070119	001	Apr 29, 1986
LUITPOLD	50MG/ML	A070891	001	Jul 26, 1988
BRETYLIUM TOSYLATE IN DEXTROSE 5%				
ABBOTT	200MG/100ML	N019005	002	Apr 29, 1986
	400MG/100ML	N019005	003	Apr 29, 1986
	800MG/100ML	N019005	001	Apr 29, 1986
BRETYLIUM TOSYLATE IN DEXTROSE 5% IN PLASTIC CONTAINER				
B BRAUN	100MG/100ML	N019121	001	Apr 29, 1986
	200MG/100ML	N019121	002	Apr 29, 1986
	400MG/100ML	N019121	003	Apr 29, 1986
BAXTER HLTHCARE	200MG/100ML	N019837	002	Apr 12, 1989
	400MG/100ML	N019837	001	Apr 12, 1989
HOSPIRA INC	200MG/100ML	N019008	002	Apr 29, 1986
	400MG/100ML	N019008	003	Apr 29, 1986
	800MG/100ML	N019008	001	Apr 29, 1986
BRETYLOL				
HOSPIRA	50MG/ML	N017954	001	

BREXPIRAZOLE

TABLET; ORAL

BREXPIRAZOLE

SANDOZ INC	0.25MG	A213570	001	Sep 26, 2022
	0.5MG	A213570	002	Sep 26, 2022
	1MG	A213570	003	Sep 26, 2022
	2MG	A213570	004	Sep 26, 2022
	3MG	A213570	005	Sep 26, 2022
	4MG	A213570	006	Sep 26, 2022

BRIMONIDINE TARTRATE

SOLUTION/DROPS; OPHTHALMIC

ALPHAGAN

+ ALLERGAN	0.2% **	N020613	001	Sep 06, 1996
	0.5%	N020490	001	Mar 13, 1997
BRIMONIDINE TARTRATE				
TEVA PARENTERAL	0.2%	A076372	001	Sep 10, 2004

BRIVARACETAM

TABLET; ORAL

BRIVARACETAM

SUNSHINE	10MG	A214748	001	Jun 09, 2022
	25MG	A214748	002	Jun 09, 2022
	50MG	A214748	003	Jun 09, 2022
	75MG	A214748	004	Jun 09, 2022
	100MG	A214748	005	Jun 09, 2022
ZYDUS PHARMS	10MG	A214501	001	Oct 03, 2022
	25MG	A214501	002	Oct 03, 2022
	50MG	A214501	003	Oct 03, 2022
	75MG	A214501	004	Oct 03, 2022

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-68(of 478)

** See List Footnote

BRIVARACETAM

TABLET; ORAL

BRIVARACETAM

100MG

A214501 005 Oct 03, 2022

BROMFENAC SODIUM

SOLUTION/DROPS; OPHTHALMIC

BROMDAY

+ BAUSCH AND LOMB INC EQ 0.09% ACID **

N021664 002 Oct 16, 2010

BROMFENAC SODIUM

AMRING PHARMS

EQ 0.09% ACID

A202030 001 Jan 09, 2013

APOTEX

EQ 0.09% ACID

A202435 001 Jun 19, 2014

EQ 0.09% ACID

A202620 001 Jun 23, 2014

CHARTWELL RX

EQ 0.09% ACID

A201941 001 Feb 10, 2015

COASTAL PHARMS

EQ 0.09% ACID

A201211 001 May 11, 2011

RISING

EQ 0.09% ACID

A203368 001 Jun 03, 2019

XIBROM

+ BAUSCH AND LOMB INC EQ 0.09% ACID **

N021664 001 Mar 24, 2005

BROMOCRIPTINE MESYLATE

CAPSULE; ORAL

BROMOCRIPTINE MESYLATE

LEK PHARM

EQ 5MG BASE

A075100 001 Dec 10, 1998

TABLET; ORAL

BROMOCRIPTINE MESYLATE

MYLAN

EQ 2.5MG BASE

A076962 001 Sep 24, 2004

BROMODIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE; ORAL

AMBODRYL

PARKE DAVIS

25MG

N007984 001

BROMODIPHENHYDRAMINE HYDROCHLORIDE; CODEINE PHOSPHATE

SYRUP; ORAL

AMBENYL

FOREST LABS

12.5MG/5ML; 10MG/5ML

N009319 006 Jan 10, 1984

BROMANYL

ALPHARMA US PHARMS

12.5MG/5ML; 10MG/5ML

A088343 001 Aug 15, 1984

BROMODIPHENHYDRAMINE HYDROCHLORIDE AND CODEINE PHOSPHATE

WOCKHARDT

12.5MG/5ML; 10MG/5ML

A088626 001 Oct 12, 1984

BROMPHENIRAMINE MALEATE

ELIXIR; ORAL

BROMPHENIRAMINE MALEATE

ALPHARMA US PHARMS

2MG/5ML

A086936 001

KV PHARM

2MG/5ML

A085466 001

PHARM ASSOC

2MG/5ML

A087517 001

USL PHARMA

2MG/5ML

A087964 001 Jan 25, 1983

INJECTABLE; INJECTION

BROMPHENIRAMINE MALEATE

WATSON LABS

10MG/ML

A083821 001

100MG/ML

A083820 001

DIMETANE-TEN

WYETH AYERST

10MG/ML

N011418 002

TABLET; ORAL

BROMPHENIRAMINE MALEATE

BARR

4MG

A084468 001

IVAX SUB TEVA PHARMS

4MG

A084351 001

NEWTRON PHARMS

4MG

A086987 001

NEXGEN PHARMA INC

4MG

A086187 001

PAR PHARM

4MG

A087009 001

PIONEER PHARMS

4MG

A088604 001 Jul 13, 1984

UPSHER SMITH LABS

4MG

A083215 001

VITARINE

4MG

A085850 001

WATSON LABS

4MG

A083123 001

4MG

A085769 001

DIMETANE

WYETH CONS

4MG

N010799 003

TABLET, EXTENDED RELEASE; ORAL

DIMETANE

WYETH CONS

8MG

N010799 010 Jun 10, 1983

12MG

N010799 011 Jun 10, 1983

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-69(of 478)

** See List Footnote

BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SYRUP; ORAL

BROMANATE DM

ALPHARMA US PHARMS 2MG/5ML; 10MG/5ML; 30MG/5ML

A088722 001 Mar 07, 1985

BROMFED-DM

WOCKHARDT 2MG/5ML; 10MG/5ML; 30MG/5ML

A089681 001 Dec 22, 1988

BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE

RHODES PHARMS 2MG/5ML; 10MG/5ML; 30MG/5ML

A202955 001 Nov 05, 2020

DIMETANE-DX

+ ROBINS AH 2MG/5ML; 10MG/5ML; 30MG/5ML **

N019279 001 Aug 24, 1984

BROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

EFIDAC 24 PSEUDOEPHEDRINE HYDROCHLORIDE/BROMPHENIRAMINE MALEATE

ALZA 16MG; 240MG

N019672 001 Mar 29, 1996

BUCLIZINE HYDROCHLORIDE

TABLET; ORAL

BUCLADIN-S

STUART PHARMS 50MG

N010911 006

BUDESONIDE

AEROSOL, METERED; NASAL

RHINOCORT

ASTRAZENECA 0.032MG/INH

N020233 001 Feb 14, 1994

CAPSULE, DELAYED RELEASE; ORAL

BUDESONIDE

BARR LABS DIV TEVA 3MG

A090379 001 Apr 02, 2014

NATCO 3MG

A206724 001 Nov 23, 2016

SCIECURE PHARMA INC 3MG

A209041 001 Sep 28, 2017

POWDER, METERED; INHALATION

PULMICORT

ASTRAZENECA 0.16MG/INH

N020441 002 Jun 24, 1997

0.32MG/INH

N020441 003 Jun 24, 1997

BUMETANIDE

INJECTABLE; INJECTION

BUMETANIDE

HOSPIRA 0.25MG/ML

A074160 001 Oct 30, 1997

TEVA PARENTERAL 0.25MG/ML

A074613 001 Nov 18, 1997

BUMEX

+ VALIDUS PHARMS 0.25MG/ML **

N018226 001 Feb 28, 1983

BUPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

BUPIVACAINE HYDROCHLORIDE

CIVICA 0.5%

A211096 001 Feb 19, 2019

HOSPIRA 0.25%

A070586 001 Mar 03, 1987

0.25%

N018053 002

0.5%

N018053 001

0.75%

A070587 001 Mar 03, 1987

0.75%

N018053 003

STERISCIENCE 0.25%

A091503 001 Oct 18, 2011

0.5%

A091503 002 Oct 18, 2011

BUPIVACAINE HYDROCHLORIDE KIT

HOSPIRA 0.075%

N019978 001 Sep 03, 1992

0.114%

N019978 002 Sep 03, 1992

0.23%

N019978 003 Sep 03, 1992

BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE

INTL MEDICATED 0.25%

A076012 001 Jan 09, 2002

0.5%

A076012 002 Jan 09, 2002

0.75%

A076012 003 Jan 09, 2002

STERISCIENCE 0.25%

A091487 002 Oct 18, 2011

0.5%

A091487 001 Oct 18, 2011

0.75%

A091487 003 Oct 18, 2011

INJECTABLE; SPINAL

SENSORCAINE

FRESENIUS KABI USA 0.75%

A071202 001 Apr 15, 1987

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-70(of 478)

** See List Footnote

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE

INJECTABLE; INJECTION

BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE

HOSPIRA

0.25%; 0.005MG/ML

A071166 001 Jun 16, 1988

0.5%; 0.005MG/ML

A071169 001 Jun 16, 1988

0.75%; 0.005MG/ML

A071171 001 Jun 16, 1988

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE

+ HOSPIRA

0.5%; 0.0091MG/ML

N022046 001 Jul 13, 1983

BUPIVACAINE HYDROCHLORIDE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

DUOCAINE

AMPHASTAR PHARMS INC EQ 0.375% (37.5MG/10ML); EQ 1% (100MG/10ML)

N021496 001 May 23, 2003

BUPIVACAINE; MELOXICAM

SOLUTION, EXTENDED RELEASE; PERIARTICULAR

ZYNRELEF KIT

+ HERON THERAPS INC

60MG/2.3ML (29.25MG/ML); 1.8MG/2.3ML (0.88MG/ML)

N211988 001 May 12, 2021

+

300MG/10.5ML (29.25MG/ML); 9MG/10.5ML (0.88MG/ML)

N211988 003 May 12, 2021

BUPRENORPHINE

FILM, EXTENDED RELEASE; TRANSDERMAL

BUPRENORPHINE

MYLAN TECH VIATRIS

5MCG/HR

A210162 001 May 03, 2021

7.5MCG/HR

A210162 002 May 03, 2021

10MCG/HR

A210162 003 May 03, 2021

15MCG/HR

A210162 004 May 03, 2021

20MCG/HR

A210162 005 May 03, 2021

BUPRENORPHINE HYDROCHLORIDE

FILM; BUCCAL

BUPRENORPHINE HYDROCHLORIDE

ALVOGEN

EQ 0.075MG BASE

A211594 001 Aug 03, 2021

EQ 0.15MG BASE

A211594 002 Aug 03, 2021

EQ 0.3MG BASE

A211594 003 Aug 03, 2021

EQ 0.45MG BASE

A211594 004 Aug 03, 2021

EQ 0.6MG BASE

A211594 005 Aug 03, 2021

EQ 0.75MG BASE

A211594 006 Aug 03, 2021

EQ 0.9MG BASE

A211594 007 Aug 03, 2021

IMPLANT; IMPLANTATION

PROBUPHINE

+ TITAN PHARMS

EQ 80MG BASE/IMPLANT

N204442 001 May 26, 2016

TABLET; SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE

BARR

EQ 2MG BASE

A090360 001 May 07, 2010

EQ 8MG BASE

A090360 002 May 07, 2010

MYLAN

EQ 2MG BASE

A201066 001 Mar 06, 2015

EQ 8MG BASE

A201066 002 Mar 06, 2015

SUBUTEX

+ INDIVIOR INC

EQ 2MG BASE **

N020732 002 Oct 08, 2002

+

EQ 8MG BASE **

N020732 003 Oct 08, 2002

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

FILM; BUCCAL

BUNAVAIL

+ BDSI

EQ 2.1MG BASE; EQ 0.3MG BASE

N205637 001 Jun 06, 2014

+

EQ 4.2MG BASE; EQ 0.7MG BASE

N205637 002 Jun 06, 2014

+

EQ 6.3MG BASE; EQ 1MG BASE

N205637 003 Jun 06, 2014

FILM; SUBLINGUAL

CASSIPA

+ TEVA PHARMS USA

EQ 16MG BASE; EQ 4MG BASE

N208042 001 Sep 07, 2018

TABLET; SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE

MAYNE PHARMA INC

EQ 2MG BASE; EQ 0.5MG BASE

A206953 001 Jul 17, 2020

EQ 8MG BASE; EQ 2MG BASE

A206953 002 Jul 17, 2020

TEVA PHARMS USA

EQ 2MG BASE; EQ 0.5MG BASE

A091149 001 Sep 08, 2014

EQ 8MG BASE; EQ 2MG BASE

A091149 002 Sep 08, 2014

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-71(of 478)

** See List Footnote

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

TABLET;SUBLINGUAL

SUBOXONE

+	INDIVIOR INC	EQ 2MG BASE;EQ 0.5MG BASE **	N020733	001	Oct 08, 2002
+		EQ 8MG BASE;EQ 2MG BASE **	N020733	002	Oct 08, 2002

BUPROPION HYDROCHLORIDE

TABLET;ORAL

BUPROPION HYDROCHLORIDE

AUROBINDO PHARMA USA	75MG	A075491	001	Apr 17, 2000
	100MG	A075491	002	Apr 17, 2000
HERITAGE PHARMA	75MG	A075310	001	Nov 29, 1999
	100MG	A075310	002	Nov 29, 1999
INVATECH	75MG	A075613	002	Oct 10, 2000
	100MG	A075613	001	Oct 10, 2000

WELLBUTRIN

+	GLAXOSMITHKLINE	50MG **	N018644	001	Dec 30, 1985
+		75MG **	N018644	002	Dec 30, 1985
+		100MG **	N018644	003	Dec 30, 1985

TABLET, EXTENDED RELEASE;ORAL

BUPROPION HYDROCHLORIDE

ACTAVIS LABS FL INC	300MG	A077715	002	Jun 13, 2007
AUROBINDO PHARMA USA	100MG	A090325	001	Apr 08, 2010
	150MG	A090325	002	Apr 08, 2010
	150MG	A090942	001	Jul 14, 2010
	200MG	A090325	003	Apr 08, 2010
	300MG	A090942	002	Jul 14, 2010
IMPAX LABS	150MG	A077415	001	Nov 26, 2008
	200MG	A076711	001	Dec 03, 2004
	300MG	A077415	002	Dec 15, 2006
JUBILANT GENERICS	100MG	A202774	001	Oct 11, 2013
	150MG	A202774	002	Oct 11, 2013
	150MG	A202775	001	Oct 11, 2013
	150MG	A207459	001	Jun 30, 2017
	200MG	A202774	003	Oct 11, 2013
	300MG	A207459	002	Jun 30, 2017
MYLAN	150MG	A090941	001	May 03, 2010
SANDOZ	100MG	A076845	001	Jul 14, 2005
	150MG	A076834	001	Jul 14, 2005
	150MG	A076845	002	Jul 14, 2005
SUN PHARM	150MG	A200695	001	Dec 18, 2014
TORRENT	100MG	A203969	001	Oct 31, 2014
	150MG	A203969	002	Oct 31, 2014
	200MG	A203969	003	Oct 31, 2014
WATSON LABS INC	100MG	A077455	001	Jul 19, 2010
	150MG	A077455	002	Mar 12, 2008
	200MG	A077455	003	Jul 19, 2010
WOCKHARDT LTD	100MG	A201331	001	Aug 30, 2012
	150MG	A201331	002	Aug 30, 2012
	200MG	A201331	003	Aug 30, 2012

WELLBUTRIN SR

GLAXOSMITHKLINE	50MG	N020358	001	Oct 04, 1996

ZYBAN

GLAXOSMITHKLINE	100MG	N020711	002	May 14, 1997
+	150MG **	N020711	003	May 14, 1997

BUSPIRONE HYDROCHLORIDE

CAPSULE;ORAL

BUSPAR

+	BRISTOL MYERS SQUIBB	5MG	N021190	001	Dec 20, 2000
+		7.5MG	N021190	002	Dec 20, 2000
+		10MG	N021190	003	Dec 20, 2000
+		15MG	N021190	004	Dec 20, 2000

TABLET;ORAL

BUSPAR

+	BRISTOL MYERS SQUIBB	5MG **	N018731	001	Sep 29, 1986
+		10MG **	N018731	002	Sep 29, 1986
+		15MG **	N018731	003	Apr 22, 1996
+		30MG **	N018731	004	Apr 22, 1996

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-72(of 478)

** See List Footnote

BUSPIRONE HYDROCHLORIDE

TABLET;ORAL

BUSPIRONE HYDROCHLORIDE

EGIS	5MG	A075119 001	Mar 14, 2002
	10MG	A075119 002	Mar 14, 2002
	15MG	A075119 003	Jan 23, 2003
FOSUN PHARMA	5MG	A075413 001	Mar 19, 2002
	10MG	A075413 002	Mar 19, 2002
	15MG	A075413 003	Mar 19, 2002
IVAX SUB TEVA PHARMS	5MG **	A075385 001	Mar 01, 2002
	10MG **	A075385 002	Mar 01, 2002
	15MG **	A075385 003	Mar 01, 2002
MYLAN	5MG	A075467 001	Feb 28, 2002
	7.5MG	A075467 002	Mar 28, 2001
	10MG	A075467 003	Feb 28, 2002
	15MG	A075467 004	Feb 28, 2002
NESHER PHARMS	5MG	A075572 001	Feb 27, 2002
	10MG	A075572 002	Feb 27, 2002
	15MG	A075572 003	Feb 27, 2002

BUSULFAN

INJECTABLE;INJECTION

BUSULFAN

ACTAVIS LLC	6MG/ML	A205139 001	Dec 08, 2017
MYLAN LABS LTD	6MG/ML	A205184 001	Jul 13, 2018

BUTABARBITAL SODIUM

CAPSULE;ORAL

BUTICAPS

MEDPOINTE PHARM HLC	15MG	A085381 001	
	30MG	A085381 002	
	50MG	A085381 003	
	100MG	A085381 004	

ELIXIR;ORAL

BUTABARB

ALPHARMA US PHARMS	30MG/5ML	A085873 001	
BUTABARBITAL SODIUM			
WOCKHARDT	30MG/5ML	A085383 001	
BUTALAN			
LANNETT	33.3MG/5ML	A085880 001	
BUTISOL SODIUM			
MEDA PHARMS	30MG/5ML	A085380 001	
SARISOL			
HALSEY	30MG/5ML	A084723 001	

TABLET;ORAL

BUTABARBITAL

BUNDY	30MG	A085550 001	

BUTABARBITAL SODIUM

SANDOZ	15MG	A084292 003	Feb 09, 1982
+	15MG	A085938 001	
	30MG	A084272 002	
	30MG	A085934 001	
SOLVAY	16.2MG	A083606 001	
	32.4MG	A083898 001	
	48.6MG	A083897 001	
	97.2MG	A083896 001	
TEVA	15MG	A088632 001	May 18, 1985
	30MG	A088631 001	May 01, 1985
WATSON LABS	15MG	A085764 001	
	30MG	A085772 001	
WHITEWORTH TOWN PLSN	15MG	A083325 002	
	30MG	A083337 001	
BUTISOL SODIUM			
MYLAN SPECIALITY LP	15MG **	N000793 002	
+	30MG	N000793 004	
	50MG **	N000793 003	
	100MG **	N000793 005	
SARISOL NO. 1			
HALSEY	15MG	A084719 001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-73(of 478)

** See List Footnote

BUTABARBITAL SODIUM

TABLET; ORAL

SARISOL NO. 2

HALSEY	30MG	A084719	002

SODIUM BUTABARBITAL

HIKMA	15MG	A085418	001

	30MG	A085432	001

IVAX SUB TEVA PHARMS	15MG	A083484	001

	30MG	A084040	001

LANNETT	15MG	A085849	001

	30MG	A085866	001

	100MG	A085881	001

MARSHALL PHARMA	16.2MG	A083524	001

	32.4MG	A083858	001

BUTENAFINE HYDROCHLORIDE

CREAM; TOPICAL

MENTAX-TC

MYLAN	1%	N021408	001	Oct 17, 2002

BUTOCONAZOLE NITRATE

CREAM; VAGINAL

BUTOCONAZOLE NITRATE

PADAGIS US	2%	N019881	001	Feb 07, 1997

FEMSTAT

ROCHE PALO	2%	N019215	001	Nov 25, 1985

FEMSTAT 3

+ BAYER	2%	N020421	001	Dec 21, 1995

SUPPOSITORY; VAGINAL

FEMSTAT

ROCHE PALO	100MG	N019359	001	Nov 25, 1985

BUTORPHANOL TARTRATE

INJECTABLE; INJECTION

BUTORPHANOL TARTRATE

BAXTER HLTHCARE CORP	2MG/ML	A075697	001	Oct 23, 2001

HIKMA FARMACEUTICA	2MG/ML	A078247	001	Apr 29, 2009

HOSPIRA	1MG/ML	A075342	001	Nov 04, 1999

	1MG/ML	A075559	001	Mar 20, 2000

	2MG/ML	A075342	002	Nov 04, 1999

	2MG/ML	A075559	002	Mar 20, 2000

BUTORPHANOL TARTRATE PRESERVATIVE FREE

BAXTER HLTHCARE CORP	1MG/ML	A075695	001	Oct 23, 2001

	2MG/ML	A075695	002	Oct 23, 2001

HOSPIRA	1MG/ML	A074620	001	Jan 22, 1997

	1MG/ML	A075170	001	Sep 28, 1998

	2MG/ML	A074620	002	Jan 22, 1997

	2MG/ML	A075170	002	Sep 28, 1998

STADOL

+ APOTHECON	2MG/ML **	N017857	004

STADOL PRESERVATIVE FREE

+ APOTHECON	1MG/ML **	N017857	001

+	2MG/ML **	N017857	002

SPRAY, METERED; NASAL

STADOL

BRISTOL MYERS SQUIBB	1MG/SPRAY **	N019890	001	Dec 12, 1991

CABAZITAXEL

SOLUTION; INTRAVENOUS

CABAZITAXEL

+ ACCORD HLTHCARE	60MG/3ML (20MG/ML)	N207949	001	Dec 29, 2021

BRECKENRIDGE	60MG/1.5ML (40MG/ML)	A207619	001	Jun 23, 2022

CABERGOLINE

TABLET; ORAL

CABERGOLINE

ACTAVIS LABS FL INC	0.5MG	A078035	001	Apr 21, 2008

APOTEX CORP	0.5MG	A201503	001	Mar 08, 2013

IMPAX LABS INC	0.5MG	A077843	001	Jul 03, 2007

MYLAN	0.5MG	A202947	001	Dec 02, 2013

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-74(of 478)

** See List Footnote

CABERGOLINE

TABLET; ORAL

DOSTINEX

+ PFIZER

0.5MG **

N020664 001 Dec 23, 1996

CAFFEINE CITRATE

SOLUTION; INTRAVENOUS

CAFFEINE CITRATE

SUN PHARM

EQ 30MG BASE/3ML (EQ 10MG BASE/ML)

A090077 001 Sep 30, 2009

SOLUTION; ORAL

CAFCIT

+ HIKMA

EQ 30MG BASE/3ML (EQ 10MG BASE/ML)

N020793 002 Apr 12, 2000

CAFFEINE CITRATE

AM REGENT

EQ 30MG BASE/3ML (EQ 10MG BASE/ML)

A090064 001 Nov 20, 2009

CAFFEINE; ERGOTAMINE TARTRATE

SUPPOSITORY; RECTAL

CAFERGOT

+ NOVARTIS

100MG; 2MG **

N009000 002

TABLET; ORAL

CAFERGOT

NOVARTIS

100MG; 1MG

N006620 001

+ SANDOZ

100MG; 1MG

A084294 001

ERGOTAMINE TARTRATE AND CAFFEINE

HIKMA INTL PHARMS

100MG; 1MG

A040510 001 Sep 17, 2004

WIGRAINE

ORGANON USA INC

100MG; 1MG

A086562 001

CALCIFEDIOL

CAPSULE; ORAL

CALDEROL

ORGANON USA INC

0.02MG

N018312 001

0.05MG

N018312 002

CALCIPOTRIENE

SOLUTION; TOPICAL

DOVONEX

+ LEO PHARM

0.005% **

N020611 001 Mar 03, 1997

CALCITONIN HUMAN

INJECTABLE; INJECTION

CIBACALCIN

NOVARTIS

0.5MG/VIAL

N018470 001 Oct 31, 1986

CALCITONIN SALMON

INJECTABLE; INJECTION

CALCIMAR

+ SANOFI AVENTIS US

200 IU/ML **

N017769 001

400 IU/VIAL

N017497 001

CALCITONIN-SALMON

IGI LABS INC

200 IU/ML

A073690 001 Apr 14, 1995

MIACALCIN

+ MYLAN IRELAND LTD

100 IU/ML

N017808 001 Jul 03, 1986

SPRAY, METERED; NASAL

CALCITONIN-SALMON

PAR PHARM

200 IU/SPRAY

A076979 001 Jun 08, 2009

MIACALCIN

+ MYLAN IRELAND LTD

200 IU/SPRAY **

N020313 002 Aug 17, 1995

CALCITONIN SALMON RECOMBINANT

SPRAY, METERED; NASAL

FORTICAL

UPSHER SMITH LABS

200 IU/SPRAY **

N021406 001 Aug 12, 2005

CALCITRIOL

INJECTABLE; INJECTION

CALCIJEX

+ ABBVIE

0.001MG/ML **

N018874 001 Sep 25, 1986

+

0.002MG/ML **

N018874 002 Sep 25, 1986

CALCITRIOL

AKORN

0.002MG/ML

A078066 002 Jan 29, 2008

AM REGENT

0.001MG/ML

A075746 001 Sep 26, 2003

0.002MG/ML

A075746 002 Sep 26, 2003

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-75(of 478)

** See List Footnote

CALCITRIOL

INJECTABLE; INJECTION

CALCITRIOL

FRESENIUS KABI USA	0.001MG/ML	A075836 001	Dec 31, 2002
	0.002MG/ML	A075836 002	Dec 31, 2002
FRESENIUS MEDCL	0.001MG/ML	A075766 001	Feb 20, 2003
	0.002MG/ML	A075766 002	Feb 20, 2003
HOSPIRA	0.001MG/ML	A075816 001	Jan 16, 2004
	0.002MG/ML	A075816 002	Jan 16, 2004
ROCKWELL MEDCL	0.001MG/ML	A076206 001	Sep 17, 2003
SAGENT PHARMS	0.001MG/ML	A077102 001	Feb 08, 2006
TEVA PARENTERAL	0.001MG/ML	A075823 001	Mar 31, 2003
	0.002MG/ML	A075823 002	Mar 31, 2003

CALCIUM ACETATE

CAPSULE; ORAL

CALCIUM ACETATE

AMNEAL PHARMS	667MG	A201658 001	Oct 06, 2014
LOTUS PHARM CO LTD	667MG	A203298 001	Jul 26, 2016
PHOSLO			
FRESENIUS MEDCL	333.5MG	N021160 001	Apr 02, 2001
	667MG	N021160 002	Apr 02, 2001

TABLET; ORAL

CALCIUM ACETATE

HIKMA	667MG	A077693 001	Jan 30, 2008
ELIPHOS			
CYPRESS PHARM	667MG	A078502 001	Nov 25, 2008
PHOSLO			
+ FRESENIUS MEDCL	667MG **	N019976 001	Dec 10, 1990

CALCIUM CARBONATE; RISEDRONATE SODIUM

TABLET; ORAL

ACTONEL WITH CALCIUM (COPACKAGED)

+ WARNER CHILCOTT	EQ 500MG BASE; 35MG **	N021823 001	Aug 12, 2005

CALCIUM CHLORIDE; DEXTROSE; GLUTATHIONE DISULFIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

SOLUTION; IRRIGATION

METHOTREXATE SODIUM

AKORN	0.154MG/ML; 0.92MG/ML; 0.184MG/ML; 0.2MG/ML; 0.38MG/ML; 2.1MG/ML; 7.14MG/ML; 0.42MG/ML	N020079 001	Feb 26, 1999

CALCIUM CHLORIDE; DEXTROSE; LACTIC ACID; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

PRISMASOL B22GK 2/0 IN PLASTIC CONTAINER

+ BAXTER HLTHCARE CORP	N/A/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.157GM/1000ML; 2.21GM/1000ML; 7.07GM/1000ML (5000ML)	N021703 010	Oct 10, 2008

PRISMASOL B22GK 2/2.5 IN PLASTIC CONTAINER

BAXTER HLTHCARE CORP	3.68GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.157GM/1000ML; 2.21GM/1000ML; 7.07GM/1000ML (5000ML)	N021703 012	Oct 10, 2008

PRISMASOL B22GK 4/2.5 IN PLASTIC CONTAINER

+ BAXTER HLTHCARE CORP	3.68GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 2.21GM/1000ML; 7.07GM/1000ML (5000ML)	N021703 013	Oct 10, 2008

PRISMASOL BGK 4/0 IN PLASTIC CONTAINER

BAXTER HLTHCARE CORP	N/A/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703 005	Oct 25, 2006

PRISMASOL BGK 4/3.5 IN PLASTIC CONTAINER

BAXTER HLTHCARE CORP	5.15GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 2.03GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703 008	Oct 25, 2006

PRISMASOL BK 0/0 IN PLASTIC CONTAINER

BAXTER HLTHCARE CORP	N/A/1000ML; N/A/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; N/A/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703 007	Oct 25, 2006

PRISMASOL BK 0/3.5 IN PLASTIC CONTAINER

+ BAXTER HLTHCARE CORP	5.15GM/1000ML; N/A/1000ML; 5.4GM/1000ML; 2.03GM/1000ML; N/A/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703 001	Oct 25, 2006

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-76(of 478)

** See List Footnote

CALCIUM CHLORIDE; DEXTROSE; LACTIC ACID; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

PRISMASOL BK 4/2.5 IN PLASTIC CONTAINER

BAXTER HLTHCARE CORP	3.68GM/1000ML; N/A/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703 009	Oct 25, 2006

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; OXIGLUTATONE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

SOLUTION; IRRIGATION

NAVSTEL

ALCON PHARMS LTD	0.154MG/ML; 0.92MG/ML; 0.2MG/ML; 0.184MG/ML; 0.38MG/ML; 2.1MG/ML; 7.14MG/ML; 0.42MG/ML	N022193 001	Jul 24, 2008

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

ISOLYTE R IN DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	37MG/100ML; 5GM/100ML; 31MG/100ML; 120MG/100ML; 330MG/100ML; 88MG/100ML	N019864 001	Jun 10, 1993

ISOLYTE R W/ DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	37MG/100ML; 5GM/100ML; 31MG/100ML; 120MG/100ML; 330MG/100ML; 88MG/100ML	N018271 001	

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

INJECTABLE; INJECTION

ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	35MG/100ML; 5GM/100ML; 30MG/100ML; 74MG/100ML; 640MG/100ML; 500MG/100ML; 74MG/100ML	N019867 001	Dec 20, 1993

ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN	35MG/100ML; 5GM/100ML; 30MG/100ML; 74MG/100ML; 640MG/100ML; 500MG/100ML; 74MG/100ML	N018269 002	Jan 17, 1983

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

PLASMA-LYTE M AND DEXTROSE 5% IN PLASTIC CONTAINER

+ BAXTER HLTHCARE	37MG/100ML; 5GM/100ML; 30MG/100ML; 119MG/100ML; 161MG/100ML; 94MG/100ML; 138MG/100ML	N017390 001	

**

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

SOLUTION; INTRAPERITONEAL

DIALYTE CONCENTRATE W/ DEXTROSE 30% IN PLASTIC CONTAINER

B BRAUN	510MG/100ML; 30GM/100ML; 200MG/100ML; 9.2GM/100ML; 9.6GM/100ML	N018807 001	Aug 26, 1983

	510MG/100ML; 30GM/100ML; 200MG/100ML; 9.4GM/100ML; 11GM/100ML	N018807 003	Aug 26, 1983

DIALYTE CONCENTRATE W/ DEXTROSE 50% IN PLASTIC CONTAINER

B BRAUN	510MG/100ML; 50GM/100ML; 200MG/100ML; 9.2GM/100ML; 9.6GM/100ML	N018807 002	Aug 26, 1983

	510MG/100ML; 50GM/100ML; 200MG/100ML; 9.4GM/100ML; 11GM/100ML	N018807 004	Aug 26, 1983

DIALYTE LM/ DEXTROSE 2.5% IN PLASTIC CONTAINER

B BRAUN	29MG/100ML; 2.5GM/100ML; 15MG/100ML; 610MG/100ML; 560MG/100ML	N018460 006	Jan 29, 1986

DIALYTE W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

B BRAUN	29MG/100ML; 1.5GM/100ML; 15MG/100ML; 610MG/100ML; 560MG/100ML	N018460 001	

DIALYTE W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

B BRAUN	29MG/100ML; 4.25GM/100ML; 15MG/100ML; 610MG/100ML; 560MG/100ML	N018460 003	

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL

DELFLEX W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

FRESENIUS MEDCL	25.7MG/100ML; 1.5GM/100ML; 15.2MG/100ML; 567MG/100ML; 392MG/100ML	N018379 002	

DELFLEX W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

FRESENIUS MEDCL	25.7MG/100ML; 2.5GM/100ML; 15.2MG/100ML; 567MG/100ML; 392MG/100ML	N018379 003	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-77(of 478)

** See List Footnote

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL

DELFLEX W/ DEXTROSE 3.5% IN PLASTIC CONTAINER				
FRESENIUS MEDCL	25.7MG/100ML; 3.5GM/100ML; 15.2MG/100ML; 567MG/100ML; 392MG/100ML	N018379	007	Jun 24, 1988
DELFLEX W/ DEXTROSE 4.25% IN PLASTIC CONTAINER				
FRESENIUS MEDCL	25.7MG/100ML; 4.25GM/100ML; 15.2MG/100ML; 567MG/100ML; 392MG/100ML	N018379	001	
DELFLEX-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER				
FRESENIUS MEDCL	25.7MG/100ML; 1.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N018379	004	Jul 07, 1982
DELFLEX-LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER				
FRESENIUS MEDCL	25.7MG/100ML; 2.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N018379	005	Jul 07, 1982
DELFLEX-LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER				
FRESENIUS MEDCL	25.7MG/100ML; 3.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N018379	008	Jun 24, 1988
DELFLEX-LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER				
FRESENIUS MEDCL	25.7MG/100ML; 4.25GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N018379	006	Jul 07, 1982
DIALYTE LM/ DEXTROSE 1.5% IN PLASTIC CONTAINER				
B BRAUN	26MG/100ML; 1.5GM/100ML; 5MG/100ML; 530MG/100ML; 450MG/100ML	N018460	007	Jan 29, 1986
	26MG/100ML; 1.5GM/100ML; 15MG/100ML; 560MG/100ML; 390MG/100ML	N018460	002	
DIALYTE LM/ DEXTROSE 2.5% IN PLASTIC CONTAINER				
B BRAUN	26MG/100ML; 2.5GM/100ML; 5MG/100ML; 530MG/100ML; 450MG/100ML	N018460	005	Nov 02, 1983
	26MG/100ML; 5GM/100ML; 5MG/100ML; 530MG/100ML; 450MG/100ML	N018460	008	Jan 29, 1986
DIALYTE LM/ DEXTROSE 4.25% IN PLASTIC CONTAINER				
B BRAUN	26MG/100ML; 4.25GM/100ML; 5MG/100ML; 530MG/100ML; 450MG/100ML	N018460	009	Jan 29, 1986
	26MG/100ML; 4.25GM/100ML; 15MG/100ML; 560MG/100ML; 390MG/100ML	N018460	004	
DIANEAL 137 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	25.7MG/100ML; 1.5GM/100ML; 15.2MG/100ML; 567MG/100ML; 392MG/100ML	N017512	001	
DIANEAL 137 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	25.7MG/100ML; 2.5GM/100ML; 15.2MG/100ML; 567MG/100ML; 392MG/100ML	N017512	003	
DIANEAL 137 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	25.7MG/100ML; 4.25GM/100ML; 15.2MG/100ML; 567MG/100ML; 392MG/100ML	N017512	002	
DIANEAL LOW CALCIUM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER				
+ BAXTER HLTHCARE	18.3MG/100ML; 3.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N020183	003	Dec 04, 1992
DIANEAL PD-1 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	25.7MG/100ML; 1.5GM/100ML; 15.2MG/100ML; 567MG/100ML; 392MG/100ML	N017512	007	Jul 09, 1984
DIANEAL PD-1 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	25.7MG/100ML; 2.5GM/100ML; 15.2MG/100ML; 567MG/100ML; 392MG/100ML	N017512	008	Jul 09, 1984
DIANEAL PD-1 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	25.7MG/100ML; 3.5GM/100ML; 15.2MG/100ML; 567MG/100ML; 392MG/100ML	N017512	010	Nov 18, 1985
DIANEAL PD-1 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	25.7MG/100ML; 4.25GM/100ML; 15.2MG/100ML; 567MG/100ML; 392MG/100ML	N017512	009	Jul 09, 1984
DIANEAL PD-2 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER				
+ BAXTER HLTHCARE	25.7MG/100ML; 3.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N017512	011	Nov 18, 1985
INPERSOL-LC/LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER				
FRESENIUS	18.4MG/100ML; 1.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	A020374	001	Jun 13, 1994
INPERSOL-LC/LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER				
FRESENIUS	18.4MG/100ML; 2.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	A020374	002	Jun 13, 1994
INPERSOL-LC/LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER				
FRESENIUS	18.4MG/100ML; 3.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	A020374	003	Jun 13, 1994
INPERSOL-LC/LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER				
FRESENIUS	18.4MG/100ML; 4.25GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	A020374	004	Jun 13, 1994

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-78(of 478)

** See List Footnote

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5% IN ACETATED RINGER'S IN PLASTIC CONTAINER

B BRAUN	20MG/100ML; 5GM/100ML; 30MG/100ML; 380MG/100ML; 600MG/100ML	N018258 001

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5% AND RINGER'S IN PLASTIC CONTAINER

HOSPIRA	33MG/100ML; 5GM/100ML; 30MG/100ML; 860MG/100ML	N018254 001

DEXTROSE 5% IN RINGER'S IN PLASTIC CONTAINER

B BRAUN	33MG/100ML; 5GM/100ML; 30MG/100ML; 860MG/100ML	N018256 001

	33MG/100ML; 5GM/100ML; 30MG/100ML; 860MG/100ML	N020000 001	Apr 17, 1992

BAXTER HLTHCARE	33MG/100ML; 5GM/100ML; 30MG/100ML; 860MG/100ML	N016695 001

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

DEXTROSE 4% IN MODIFIED LACTATED RINGER'S IN PLASTIC CONTAINER

B BRAUN	4MG/100ML; 4GM/100ML; 6MG/100ML; 120MG/100ML; 62MG/100ML	N019634 002	Feb 24, 1988

DEXTROSE 5% AND LACTATED RINGER'S

FRESENIUS KABI USA	20MG/100ML; 5GM/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML	A210332 001	Mar 28, 2022

DEXTROSE 5% IN LACTATED RINGER'S IN PLASTIC CONTAINER

B BRAUN	20MG/100ML; 5GM/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML	N017510 001

MILES	20MG/100ML; 5GM/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML	N018499 001

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

+ ICU MEDICAL INC	20MG/100ML; 5GM/100ML; 104MG/100ML; 600MG/100ML; 310MG/100ML	N019685 005	Oct 17, 1988

+ ICU MEDICAL INC	20MG/100ML; 5GM/100ML; 179MG/100ML; 600MG/100ML; 310MG/100ML	N019685 006	Oct 17, 1988

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

+ ICU MEDICAL INC	20MG/100ML; 5GM/100ML; 254MG/100ML; 600MG/100ML; 310MG/100ML	N019685 007	Oct 17, 1988

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

FRESENIUS KABI USA	20MG/100ML; 5GM/100ML; 179MG/100ML; 600MG/100ML; 310MG/100ML	A211428 001	Nov 09, 2021

+ ICU MEDICAL INC	20MG/100ML; 5GM/100ML; 328MG/100ML; 600MG/100ML; 310MG/100ML	N019685 008	Oct 17, 1988

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

+ ICU MEDICAL INC	20MG/100ML; 5GM/100ML; 254MG/100ML; 600MG/100ML; 310MG/100ML	N019685 003	Oct 17, 1988

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

+ ICU MEDICAL INC	20MG/100ML; 5GM/100ML; 328MG/100ML; 600MG/100ML; 310MG/100ML	N019685 004	Oct 17, 1988

POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

+ ICU MEDICAL INC	20MG/100ML; 5GM/100ML; 104MG/100ML; 600MG/100ML; 310MG/100ML	N019685 001	Oct 17, 1988

CALCIUM CHLORIDE; DEXTROSE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL

INPERSOL-ZM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

FRESENIUS MEDCL	25.7MG/100ML; 1.5GM/100ML; 538MG/100ML; 448MG/100ML	N019395 001	Mar 26, 1986

INPERSOL-ZM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

FRESENIUS MEDCL	25.7MG/100ML; 2.5GM/100ML; 538MG/100ML; 448MG/100ML	N019395 002	Mar 26, 1986

INPERSOL-ZM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

FRESENIUS MEDCL	25.7MG/100ML; 4.25GM/100ML; 538MG/100ML; 448MG/100ML	N019395 003	Mar 26, 1986

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

TPN ELECTROLYTES IN PLASTIC CONTAINER

ABBOTT	16.5MG/ML; 25.4MG/ML; 74.6MG/ML; 121MG/ML; 16.1MG/ML	N019399 001	Jun 16, 1986

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-79(of 478)

** See List Footnote

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

INJECTABLE; INJECTION

ISOLYTE E IN PLASTIC CONTAINER

B BRAUN

35MG/100ML; 30MG/100ML; 74MG/100ML; 640MG/
100ML; 500MG/100ML; 74MG/100ML

N018899 001 Oct 31, 1983

35MG/100ML; 30MG/100ML; 74MG/100ML; 640MG/
100ML; 500MG/100ML; 74MG/100ML

N019718 001 Sep 29, 1989

SOLUTION; IRRIGATION

BALANCED SALT

AKORN

0.48MG/ML; 0.3MG/ML; 0.75MG/ML; 3.9MG/ML; 6
.4MG/ML; 1.7MG/ML

A075503 001 Sep 27, 2006

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

PLASMA-LYTE R IN PLASTIC CONTAINER

BAXTER HLTHCARE

36.8MG/100ML; 30.5MG/100ML; 74.6MG/100ML;
640MG/100ML; 496MG/100ML; 89.6MG/100ML

N017438 001

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

ACETATED RINGER'S IN PLASTIC CONTAINER

B BRAUN

20MG/100ML; 30MG/100ML; 380MG/100ML; 600MG
/100ML

N018725 001 Nov 29, 1982

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

RINGER'S IN PLASTIC CONTAINER

B BRAUN

33MG/100ML; 30MG/100ML; 860MG/100ML

N018721 001 Nov 09, 1982

SOLUTION; IRRIGATION

RINGER'S IN PLASTIC CONTAINER

ABBOTT

33MG/100ML; 30MG/100ML; 860MG/100ML

N018462 001

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

LACTATED RINGER'S IN PLASTIC CONTAINER

ABBOTT

20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG
/100ML

N019485 001 Oct 24, 1985

B BRAUN

20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG
/100ML

N018023 001

MILES

20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG
/100ML

N018417 001

SOLUTION; IRRIGATION

LACTATED RINGER'S IN PLASTIC CONTAINER

BAXTER HLTHCARE

20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG
/100ML

N019933 001 Aug 29, 1989

CALCIUM GLUCEPTATE

INJECTABLE; INJECTION

CALCIUM GLUCEPTATE

+

ABBOTT

EQ 90MG CALCIUM/5ML

A080001 001

EQ 90MG CALCIUM/5ML

A083159 001

ABRAXIS PHARM

EQ 90MG CALCIUM/5ML

A089373 001 Apr 30, 1987

LILLY

EQ 90MG CALCIUM/5ML

N006470 001

CALCIUM METRIZOATE; MEGLUMINE METRIZOATE; METRIZOATE MAGNESIUM; METRIZOATE SODIUM

INJECTABLE; INJECTION

ISOPAQUE 440

GE HEALTHCARE

0.78MG/ML; 75.9MG/ML; 0.15MG/ML; 16.6MG/ML

N016847 001

CALCIUM; MEGLUMINE; METRIZOIC ACID

INJECTABLE; INJECTION

ISOPAQUE 280

GE HEALTHCARE

0.35MG/ML; 140.1MG/ML; 461.8MG/ML

N017506 001

CANDESARTAN CILEXETIL

TABLET; ORAL

CANDESARTAN CILEXETIL

APOTEX INC

4MG

A202079 001 Jan 10, 2014

8MG

A202079 002 Jan 10, 2014

16MG

A202079 003 Jan 10, 2014

32MG

A202079 004 Jan 10, 2014

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-80(of 478)

** See List Footnote

CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE

TABLET;ORAL

CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE

APOTEX INC

16MG;12.5MG

A202884 001 Dec 04, 2012

32MG;12.5MG

A202884 002 Dec 04, 2012

32MG;25MG

A202884 003 Jun 03, 2013

CANDICIDIN

OINTMENT;VAGINAL

VANOBI

SANOFI AVENTIS US

0.6MG/GM

A061596 001

TABLET;VAGINAL

VANOBI

SANOFI AVENTIS US

3MG

A061613 001

CAPECITABINE

TABLET;ORAL

CAPECITABINE

AMNEAL PHARMS

150MG

A204741 001 Feb 28, 2017

500MG

A204741 002 Feb 28, 2017

CAPREOMYCIN SULFATE

INJECTABLE;INJECTION

CAPASTAT SULFATE

+ AKORN

EQ 1GM BASE/VIAL

N050095 001

CAPREOMYCIN SULFATE

HISUN PHARM HANGZHOU

EQ 1GM BASE/VIAL

A204796 001 Oct 18, 2018

MYLAN LABS LTD

EQ 1GM BASE/VIAL

A202634 001 Nov 27, 2017

CAPTOPRIL

TABLET;ORAL

CAPOTEN

+ STRIDES PHARMA

12.5MG **

N018343 005 Jan 17, 1985

+

25MG **

N018343 002

+

37.5MG **

N018343 006 Sep 17, 1986

+

50MG **

N018343 001

+

75MG **

N018343 007 Jun 13, 1995

+

100MG **

N018343 003

+

150MG **

N018343 004 Jun 13, 1995

CAPTOPRIL

APOTHECON

12.5MG

A074472 001 Mar 31, 1995

25MG

A074472 002 Mar 31, 1995

50MG

A074472 003 Mar 31, 1995

100MG

A074472 004 Mar 31, 1995

CHARTWELL RX

12.5MG

A074363 001 Nov 09, 1995

12.5MG

A074519 001 Feb 13, 1996

25MG

A074363 002 Nov 09, 1995

25MG

A074519 002 Feb 13, 1996

50MG

A074363 003 Nov 09, 1995

50MG

A074519 003 Feb 13, 1996

100MG

A074363 004 Nov 09, 1995

100MG

A074519 004 Feb 13, 1996

COSETTE

12.5MG

A074433 001 Feb 13, 1996

12.5MG

A074462 001 Feb 13, 1996

12.5MG

A074483 001 Feb 13, 1996

25MG

A074433 002 Feb 13, 1996

25MG

A074462 002 Feb 13, 1996

25MG

A074483 002 Feb 13, 1996

50MG

A074433 003 Feb 13, 1996

50MG

A074462 003 Feb 13, 1996

50MG

A074483 003 Feb 13, 1996

100MG

A074433 004 Feb 13, 1996

100MG

A074462 004 Feb 13, 1996

100MG

A074483 004 Feb 13, 1996

DAVA PHARMS INC

12.5MG

A074423 001 Feb 13, 1996

25MG

A074423 002 Feb 13, 1996

50MG

A074423 003 Feb 13, 1996

100MG

A074423 004 Feb 13, 1996

EGIS PHARMS

12.5MG

A074748 004 May 29, 1997

25MG

A074748 002 May 29, 1997

50MG

A074748 001 May 29, 1997

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-81(of 478)

** See List Footnote

CAPTOPRIL

TABLET;ORAL

CAPTOPRIL

	100MG	A074748 003	May 29, 1997
G AND W LABS INC	12.5MG	A074590 004	Aug 30, 1996
	25MG	A074590 002	Aug 30, 1996
	50MG	A074590 001	Aug 30, 1996
	100MG	A074590 003	Aug 30, 1996
MYLAN	12.5MG	A074434 001	Feb 13, 1996
	25MG	A074434 002	Feb 13, 1996
	50MG	A074434 003	Feb 13, 1996
	100MG	A074434 004	Feb 13, 1996
OXFORD PHARMS	12.5MG	A074418 001	Feb 13, 1996
	25MG	A074418 002	Feb 13, 1996
	50MG	A074418 003	Feb 13, 1996
	100MG	A074418 004	Feb 13, 1996
PUREPAC PHARM	12.5MG	A074640 001	Mar 31, 1997
	25MG	A074640 002	Mar 31, 1997
	50MG	A074640 003	Mar 31, 1997
	100MG	A074640 004	Mar 31, 1997
SANDOZ	12.5MG	A074481 001	Feb 13, 1996
	25MG	A074481 002	Feb 13, 1996
	50MG	A074481 003	Feb 13, 1996
	100MG	A074481 004	Feb 13, 1996
SETON PHARMS	12.5MG	A212223 001	Oct 30, 2019
	25MG	A212223 002	Oct 30, 2019
	50MG	A212223 003	Oct 30, 2019
	100MG	A212223 004	Oct 30, 2019
STRIDES PHARMA	12.5MG	A074493 001	Feb 13, 1996
	25MG	A074493 002	Feb 13, 1996
	50MG	A074493 003	Feb 13, 1996
	100MG	A074493 004	Feb 13, 1996
TEVA	12.5MG	A074322 001	Feb 13, 1996
	25MG	A074322 002	Feb 13, 1996
	50MG	A074322 003	Feb 13, 1996
	100MG	A074322 004	Feb 13, 1996
WATSON LABS	12.5MG	A074386 001	May 23, 1996
	12.5MG	A074451 001	Feb 13, 1996
	12.5MG	A074576 001	Apr 23, 1996
	25MG	A074386 002	May 23, 1996
	25MG	A074451 002	Feb 13, 1996
	25MG	A074576 002	Apr 23, 1996
	50MG	A074386 003	May 23, 1996
	50MG	A074451 003	Feb 13, 1996
	50MG	A074576 003	Apr 23, 1996
	100MG	A074386 004	May 23, 1996
	100MG	A074451 004	Feb 13, 1996
	100MG	A074576 004	Apr 23, 1996

CAPTOPRIL; HYDROCHLOROTHIAZIDE

TABLET;ORAL

CAPOZIDE 25/15			
+ APOTHECON	25MG;15MG **	N018709 001	Oct 12, 1984
CAPOZIDE 25/25			
+ APOTHECON	25MG;25MG **	N018709 002	Oct 12, 1984
CAPOZIDE 50/15			
+ APOTHECON	50MG;15MG **	N018709 004	Oct 12, 1984
CAPOZIDE 50/25			
+ APOTHECON	50MG;25MG **	N018709 003	Oct 12, 1984
CAPTOPRIL AND HYDROCHLOROTHIAZIDE			
COSETTE	25MG;15MG	A074827 001	Dec 29, 1997
	25MG;25MG	A074827 002	Dec 29, 1997
	50MG;15MG	A074827 004	Dec 29, 1997
	50MG;25MG	A074827 003	Dec 29, 1997
IVAX SUB TEVA PHARMS	25MG;15MG	A075055 001	Jun 18, 1998
	25MG;25MG	A075055 002	Jun 18, 1998
	50MG;15MG	A075055 004	Jun 18, 1998
	50MG;25MG	A075055 003	Jun 18, 1998
RISING	25MG;15MG	A074896 001	Dec 29, 1997
	25MG;25MG	A074896 002	Dec 29, 1997

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-82(of 478)

** See List Footnote

CAPTOPRIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL

CAPTOPRIL AND HYDROCHLOROTHIAZIDE

	50MG; 15MG	A074896 004	Dec 29, 1997
	50MG; 25MG	A074896 003	Dec 29, 1997
STRIDES PHARMA	25MG; 15MG	A074788 001	Dec 29, 1997
	25MG; 25MG	A074788 002	Dec 29, 1997
	50MG; 15MG	A074788 004	Dec 29, 1997
	50MG; 25MG	A074788 003	Dec 29, 1997
WATSON LABS	50MG; 25MG	A074832 001	Dec 29, 1997

CARBACHOL

SOLUTION; INTRAOCULAR

CARBACHOL

PHARMAFAIR	0.01%	A070292 001	May 21, 1986
CARBASTAT			
NOVARTIS	0.01%	A073677 001	Apr 28, 1995

CARBAMAZEPINE

SOLUTION; INTRAVENOUS

CARNEXIV

+ LUNDBECK PHARMS LLC	200MG/20ML (10MG/ML)	N206030 001	Oct 07, 2016

SUSPENSION; ORAL

CARBAMAZEPINE

TARO	100MG/5ML	A075875 001	Dec 21, 2000

TABLET; ORAL

CARBAMAZEPINE

ACTAVIS ELIZABETH	200MG	A071696 001	Nov 09, 1987
INWOOD LABS	200MG	A070231 001	Aug 14, 1986
PLIVA	200MG	A071479 001	Jul 24, 1987
USL PHARMA	200MG	A070300 001	May 15, 1986
VGYAAN	200MG	A214328 001	Aug 16, 2021
WARNER CHILCOTT	200MG	A070429 001	Jan 02, 1987

TERIL

TARO	200MG	A076525 001	Sep 26, 2003

TABLET, CHEWABLE; ORAL

CARBAMAZEPINE

JUBILANT CADISTA	100MG	A071940 001	Feb 01, 1988

TEGRETOL

+ NOVARTIS	100MG **	N018281 001	

TABLET, EXTENDED RELEASE; ORAL

CARBAMAZEPINE

RICONPHARMA LLC	100MG	A216404 001	Dec 02, 2022
	200MG	A216404 002	Dec 02, 2022
	400MG	A216404 003	Dec 02, 2022

CARBENICILLIN DISODIUM

INJECTABLE; INJECTION

GEOPEN

ROERIG	EQ 1GM BASE/VIAL	N050306 001	
	EQ 2GM BASE/VIAL	N050306 004	
	EQ 5GM BASE/VIAL	N050306 002	
	EQ 10GM BASE/VIAL	N050306 006	
	EQ 30GM BASE/VIAL	N050306 007	

PYOPEN

GLAXOSMITHKLINE	EQ 1GM BASE/VIAL	N050298 001	
	EQ 2GM BASE/VIAL	N050298 002	
	EQ 5GM BASE/VIAL	N050298 003	
	EQ 10GM BASE/VIAL	N050298 006	
	EQ 20GM BASE/VIAL	N050298 007	

CARBENICILLIN INDANYL SODIUM

TABLET; ORAL

GEOCILLIN

PFIZER	EQ 382MG BASE	N050435 001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-83(of 478)

** See List Footnote

CARBIDOPA

TABLET; ORAL

CARBIDOPA

ANI PHARMS

25MG

A203261 001 Mar 10, 2014

CARBIDOPA; ENTACAPONE; LEVODOPA

TABLET; ORAL

CARBIDOPA, LEVODOPA AND ENTACAPONE

MYLAN

12.5MG; 200MG; 50MG

A203424 001 Aug 13, 2020

18.75MG; 200MG; 75MG

A203424 002 Aug 13, 2020

25MG; 200MG; 100MG

A203424 003 Aug 13, 2020

31.25MG; 200MG; 125MG

A203424 004 Aug 13, 2020

37.5MG; 200MG; 150MG

A203424 005 Aug 13, 2020

50MG; 200MG; 200MG

A203424 006 Aug 13, 2020

WOCKHARDT LTD

12.5MG; 200MG; 50MG

A090786 001 Nov 20, 2012

18.75MG; 200MG; 75MG

A090833 001 Nov 20, 2012

25MG; 200MG; 100MG

A090833 002 Nov 20, 2012

31.25MG; 200MG; 125MG

A090833 003 Nov 20, 2012

37.5MG; 200MG; 150MG

A090833 004 Nov 20, 2012

50MG; 200MG; 200MG

A090833 005 Nov 20, 2012

CARBIDOPA; LEVODOPA

TABLET; ORAL

CARBIDOPA AND LEVODOPA

ANI PHARMS

10MG; 100MG

A073587 002 Jun 29, 1995

25MG; 100MG

A073587 001 Jun 29, 1995

25MG; 250MG

A073587 003 Jun 29, 1995

SCS

10MG; 100MG

A074080 001 Mar 25, 1994

25MG; 100MG

A074080 002 Mar 25, 1994

25MG; 250MG

A074080 003 Mar 25, 1994

WATSON LABS

10MG; 100MG

A073381 001 Sep 28, 1993

25MG; 100MG

A073382 001 Sep 28, 1993

25MG; 250MG

A073383 001 Sep 28, 1993

TABLET, EXTENDED RELEASE; ORAL

CARBIDOPA AND LEVODOPA

KV PHARM

50MG; 200MG

A076663 001 Jun 24, 2004

SINEMET CR

+ ORGANON LLC

25MG; 100MG **

N019856 002 Dec 24, 1992

+

50MG; 200MG **

N019856 001 May 30, 1991

TABLET, FOR SUSPENSION; ORAL

CARBILEV

RANBAXY

10MG; 100MG

A076643 001 Jun 10, 2005

25MG; 100MG

A076643 002 Jun 10, 2005

25MG; 250MG

A076643 003 Jun 10, 2005

TABLET, ORALLY DISINTEGRATING; ORAL

CARBIDOPA AND LEVODOPA

IMPAX LABS

10MG; 100MG

A090631 001 Jun 08, 2010

25MG; 100MG

A090631 002 Jun 08, 2010

25MG; 250MG

A090631 003 Jun 08, 2010

RISING

10MG; 100MG

A078893 001 Sep 18, 2008

25MG; 100MG

A078893 002 Sep 18, 2008

25MG; 250MG

A078893 003 Sep 18, 2008

PARCOPA

UCB INC

10MG; 100MG **

A076699 001 Aug 27, 2004

25MG; 100MG **

A076699 002 Aug 27, 2004

25MG; 250MG **

A076699 003 Aug 27, 2004

CARBINOXAMINE MALEATE

ELIXIR; ORAL

CLISTIN

+ MCNEIL

4MG/5ML **

N008955 001

SOLUTION; ORAL

CARBINOXAMINE MALEATE

CYPRESS PHARM

4MG/5ML

A090418 001 May 04, 2010

VINTAGE PHARMS

4MG/5ML

A040814 001 Feb 26, 2008

TABLET; ORAL

CARBINOXAMINE MALEATE

CYPRESS PHARM

4MG

A090417 001 Aug 23, 2010

STRIDES PHARMA

4MG

A040639 002 May 30, 2008

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-84(of 478)

** See List Footnote

CARBINOXAMINE MALEATE

TABLET; ORAL

CLISTIN

+ ORTHO MCNEIL PHARM

4MG **

N008915 001

CARBOPLATIN

INJECTABLE; INJECTION

CARBOPLATIN

CIPLA LTD

50MG/VIAL

A077383 001 Jan 27, 2006

150MG/VIAL

A077383 002 Jan 27, 2006

450MG/VIAL

A077383 003 Jan 27, 2006

FRESENIUS KABI USA

50MG/VIAL

A076235 001 Oct 14, 2004

150MG/VIAL

A076235 002 Oct 14, 2004

450MG/VIAL

A076235 003 Oct 14, 2004

HIKMA

50MG/VIAL

A076099 001 Oct 14, 2004

150MG/VIAL

A076099 002 Oct 14, 2004

450MG/VIAL

A076099 003 Oct 14, 2004

HOSPIRA

50MG/VIAL

A076473 001 Oct 27, 2004

150MG/VIAL

A076473 002 Oct 27, 2004

450MG/VIAL

A076473 003 Oct 27, 2004

MYLAN LABS LTD

50MG/VIAL

A091510 001 May 29, 2012

150MG/VIAL

A091510 002 May 29, 2012

450MG/VIAL

A091510 003 May 29, 2012

PLIVA

50MG/VIAL

A076602 001 Nov 16, 2004

150MG/VIAL

A076602 002 Nov 16, 2004

450MG/VIAL

A076602 003 Nov 16, 2004

SANDOZ

50MG/VIAL

A076959 001 Mar 18, 2005

150MG/VIAL

A076959 002 Mar 18, 2005

450MG/VIAL

A076959 003 Mar 18, 2005

WATSON LABS TEVA

50MG/VIAL

A076162 001 Oct 14, 2004

150MG/VIAL

A076162 002 Oct 14, 2004

450MG/VIAL

A076162 003 Oct 14, 2004

PARAPLATIN

+ CORDEN PHARMA

50MG/VIAL **

N019880 001 Mar 03, 1989

+

150MG/VIAL **

N019880 002 Mar 03, 1989

+

450MG/VIAL **

N019880 003 Mar 03, 1989

INJECTABLE; INTRAVENOUS

CARBOPLATIN

ACTAVIS TOTOWA

50MG/5ML (10MG/ML)

A078732 001 Feb 06, 2012

150MG/15ML (10MG/ML)

A078732 002 Feb 06, 2012

450MG/45ML (10MG/ML)

A078732 003 Feb 06, 2012

600MG/60ML (10MG/ML)

A078732 004 Feb 06, 2012

FRESENIUS KABI USA

50MG/5ML (10MG/ML)

A077432 001 Sep 29, 2006

150MG/15ML (10MG/ML)

A077432 002 Sep 29, 2006

450MG/45ML (10MG/ML)

A077432 003 Sep 29, 2006

50MG/5ML (10MG/ML)

A077247 001 Oct 21, 2004

50MG/5ML (10MG/ML)

A077266 001 Feb 15, 2006

150MG/15ML (10MG/ML)

A077247 002 Oct 21, 2004

150MG/15ML (10MG/ML)

A077266 002 Feb 15, 2006

MEITHEAL

50MG/5ML (10MG/ML)

A077096 001 Jun 14, 2005

150MG/15ML (10MG/ML)

A077096 002 Jun 14, 2005

450MG/45ML (10MG/ML)

A077096 003 Jun 14, 2005

600MG/60ML (10MG/ML)

A077096 004 Jun 03, 2013

MYLAN INSTITUTIONAL

50MG/5ML (10MG/ML)

A077998 001 Apr 24, 2007

150MG/15ML (10MG/ML)

A077998 002 Apr 24, 2007

450MG/45ML (10MG/ML)

A077998 003 Apr 24, 2007

MYLAN LABS LTD

50MG/5ML (10MG/ML)

A091063 001 Nov 09, 2011

150MG/15ML (10MG/ML)

A091063 002 Nov 09, 2011

450MG/45ML (10MG/ML)

A091063 003 Nov 09, 2011

600MG/60ML (10MG/ML)

A091063 004 Nov 09, 2011

1GM/100ML (10MG/ML)

A091478 001 Nov 23, 2011

NOVAST LABS

450MG/45ML (10MG/ML)

A208487 003 Apr 26, 2017

600MG/60ML (10MG/ML)

A208487 004 Apr 26, 2017

PHARMACHEMIE BV

50MG/5ML (10MG/ML)

A077679 001 Feb 25, 2009

150MG/15ML (10MG/ML)

A077679 002 Feb 25, 2009

450MG/45ML (10MG/ML)

A077679 003 Feb 25, 2009

PLIVA LACHEMA

50MG/5ML (10MG/ML)

A078631 001 Dec 02, 2008

150MG/15ML (10MG/ML)

A078631 002 Dec 02, 2008

450MG/45ML (10MG/ML)

A078631 003 Dec 02, 2008

600MG/60ML (10MG/ML)

A078631 004 Dec 02, 2008

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-85(of 478)

** See List Footnote

CARBOPLATIN

INJECTABLE; INTRAVENOUS

CARBOPLATIN

TEVA PARENTERAL	50MG/5ML (10MG/ML)	A077389	001	Mar 30, 2007
	150MG/15ML (10MG/ML)	A077389	002	Mar 30, 2007
	450MG/45ML (10MG/ML)	A077389	003	Mar 30, 2007
TEVA PHARMS USA	50MG/5ML (10MG/ML)	A077139	001	Sep 21, 2005
	150MG/15ML (10MG/ML)	A077139	002	Sep 21, 2005
	450MG/45ML (10MG/ML)	A077139	003	Sep 21, 2005
	600MG/60ML (10MG/ML)	A077139	004	Sep 21, 2005
PARAPLATIN				
+ CORDENPHARMA	50MG/5ML (10MG/ML) **	N020452	001	Jul 14, 2003
	150MG/15ML (10MG/ML) **	N020452	002	Jul 14, 2003
	450MG/45ML (10MG/ML) **	N020452	003	Jul 14, 2003
	600MG/60ML (10MG/ML) **	N020452	004	Jan 15, 2004

CARFILZOMIB

POWDER; INTRAVENOUS

CARFILZOMIB

APOTEX	30MG/VIAL	A211185	001	Mar 20, 2020
	60MG/VIAL	A209425	001	Mar 16, 2020
BRECKENRIDGE	10MG/VIAL	A209330	001	Jun 11, 2021
	60MG/VIAL	A209330	002	Jun 11, 2021

CARIPRAZINE HYDROCHLORIDE

CAPSULE; ORAL

CARIPRAZINE HYDROCHLORIDE

SUN PHARM	EQ 1.5MG BASE	A213932	001	Sep 30, 2022
	EQ 3MG BASE	A213932	002	Sep 30, 2022
	EQ 4.5MG BASE	A213932	003	Sep 30, 2022
	EQ 6MG BASE	A213932	004	Sep 30, 2022
ZYDUS PHARMS	EQ 1.5MG BASE	A213984	001	Sep 09, 2022
	EQ 3MG BASE	A213984	002	Sep 09, 2022
	EQ 4.5MG BASE	A213984	003	Sep 09, 2022
	EQ 6MG BASE	A213984	004	Sep 09, 2022

CARISOPRODOL

CAPSULE; ORAL

SOMA

+ MYLAN SPECIALITY LP	250MG	N011792	003	

TABLET; ORAL

CARISOPRODOL

ABLE	350MG	A040421	001	Jun 21, 2001
EPIC PHARMA LLC	350MG	A040397	001	Sep 21, 2000
HIKMA INTL PHARMS	350MG	A040124	001	Jan 24, 1996
PIONEER PHARMS	350MG	A089390	001	Oct 13, 1988
SANDOZ	350MG	A089566	001	Aug 30, 1988
STRIDES PHARMA	250MG	A205513	001	Nov 12, 2015
	350MG	A205513	002	Nov 12, 2015
SUN PHARM INDS LTD	350MG	A040755	001	Feb 27, 2007
SUN PHARM INDUSTRIES	350MG	A089346	001	Oct 17, 1991
WATSON LABS	350MG	A040152	001	Dec 03, 1996
	350MG	A085433	001	
WATSON LABS TEVA	350MG	A086179	001	
RELA				
SCHERING	350MG	N012155	001	

CARPENAZINE MALEATE

CONCENTRATE; ORAL

PROKETAZINE

WYETH AYERST	50MG/ML	N014173	001	

TABLET; ORAL

PROKETAZINE

WYETH AYERST	12.5MG	N012768	001	
	25MG	N012768	002	
	50MG	N012768	004	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-86(of 478)

** See List Footnote

CARPROFEN

TABLET;ORAL

RIMADYL

ROCHE

100MG

N018550 002 Dec 31, 1987

150MG

N018550 003 Dec 31, 1987

CARTEOLOL HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

CARTEOLOL HYDROCHLORIDE

APOTEX INC

1%

A076097 001 Feb 06, 2002

BAUSCH AND LOMB

1%

A075546 001 Jan 20, 2000

OCUPRESS

+ NOVARTIS

1% **

N019972 001 May 23, 1990

TABLET;ORAL

CARTROL

ABBVIE

2.5MG

N019204 001 Dec 28, 1988

5MG

N019204 002 Dec 28, 1988

10MG

N019204 003 Dec 28, 1988

CARVEDILOL

TABLET;ORAL

CARVEDILOL

ACI

3.125MG

A078786 001 Dec 22, 2009

6.25MG

A078786 002 Dec 22, 2009

12.5MG

A078786 003 Dec 22, 2009

25MG

A078786 004 Dec 22, 2009

HIKMA

3.125MG

A077887 001 Sep 07, 2007

6.25MG

A077887 002 Sep 07, 2007

12.5MG

A077887 003 Sep 07, 2007

25MG

A077887 004 Sep 07, 2007

PLIVA HRVATSKA DOO

3.125MG

A078240 001 Oct 30, 2007

6.25MG

A078240 002 Oct 30, 2007

12.5MG

A078240 003 Oct 30, 2007

25MG

A078240 004 Oct 30, 2007

SUN PHARM INDS INC

3.125MG

A077346 004 Sep 05, 2007

6.25MG

A077346 001 Sep 05, 2007

12.5MG

A077346 002 Sep 05, 2007

25MG

A077346 003 Sep 05, 2007

CASPOFUNGIN ACETATE

POWDER;INTRAVENOUS

CASPOFUNGIN ACETATE

CIPLA

50MG/VIAL

A209489 001 Jul 12, 2018

70MG/VIAL

A209489 002 Jul 12, 2018

MYLAN LABS LTD

50MG/VIAL

A207650 001 Sep 29, 2017

70MG/VIAL

A207650 002 Sep 29, 2017

XELLIA PHARMS APS

50MG/VIAL

A205923 001 Jul 02, 2018

70MG/VIAL

A205923 002 Jul 02, 2018

CEFACLOL

CAPSULE;ORAL

CECLOR

+ LILLY

EQ 250MG BASE **

N050521 001

+

EQ 500MG BASE **

N050521 002

CEFACLOL

CEPH INTL

EQ 250MG BASE

A062205 001

EQ 500MG BASE

A062205 002

DAVA PHARMS INC

EQ 250MG BASE

A064107 001 Apr 27, 1995

EQ 500MG BASE

A064107 002 Apr 27, 1995

HERITAGE PHARMA

EQ 250MG BASE

A064148 001 May 23, 1996

EQ 500MG BASE

A064148 002 May 23, 1996

IVAX SUB TEVA PHARMS

EQ 250MG BASE

A064061 001 Apr 27, 1995

EQ 500MG BASE

A064061 002 Apr 27, 1995

RANBAXY

EQ 250MG BASE

A064156 001 Aug 28, 1997

EQ 500MG BASE

A064156 002 Aug 28, 1997

TEVA

EQ 250MG BASE

A064081 001 Sep 16, 1996

EQ 250MG BASE

A064145 001 Jun 24, 1996

EQ 500MG BASE

A064081 002 Sep 16, 1996

EQ 500MG BASE

A064145 002 Jun 24, 1996

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-87(of 478)

** See List Footnote

CEFACLOR

FOR SUSPENSION;ORAL

CECLOR

+ LILLY

EQ 125MG BASE/5ML **

N050522 001

+

EQ 250MG BASE/5ML **

N050522 002

CEFACLOR

DAVA PHARMS INC

EQ 125MG BASE/5ML

A064114 001 Apr 28, 1995

EQ 187MG BASE/5ML

A064115 001 Apr 28, 1995

EQ 250MG BASE/5ML

A064116 001 Apr 28, 1995

EQ 375MG BASE/5ML

A064110 001 Apr 28, 1995

FACTA FARMA

EQ 125MG BASE/5ML

A062206 001

EQ 187MG BASE/5ML

A062206 003 Apr 20, 1988

EQ 250MG BASE/5ML

A062206 002

EQ 375MG BASE/5ML

A062206 004 Apr 20, 1988

IVAX SUB TEVA PHARMS

EQ 125MG BASE/5ML

A064087 001 Apr 28, 1995

EQ 187MG BASE/5ML

A064086 001 Apr 28, 1995

EQ 250MG BASE/5ML

A064085 001 Apr 28, 1995

EQ 375MG BASE/5ML

A064070 001 Apr 28, 1995

RANBAXY

EQ 125MG BASE/5ML

A064166 001 Oct 02, 1997

EQ 187MG BASE/5ML

A064165 001 Oct 02, 1997

EQ 250MG BASE/5ML

A064164 001 Oct 02, 1997

EQ 375MG BASE/5ML

A064155 001 Oct 02, 1997

WATSON LABS INC

EQ 125MG BASE/5ML

A064204 001 Feb 18, 1998

EQ 187MG BASE/5ML

A064205 001 Feb 18, 1998

EQ 250MG BASE/5ML

A064206 001 Feb 18, 1998

EQ 375MG BASE/5ML

A064207 001 Feb 18, 1998

TABLET, CHEWABLE;ORAL

RANICLOR

RANBAXY LABS LTD

EQ 125MG BASE

A065092 001 Dec 22, 2003

EQ 187MG BASE

A065092 002 Dec 22, 2003

EQ 250MG BASE

A065092 003 Dec 22, 2003

EQ 375MG BASE

A065092 004 Dec 22, 2003

TABLET, EXTENDED RELEASE;ORAL

CECLOR CD

LILLY

EQ 375MG BASE **

N050673 001 Jun 28, 1996

EQ 500MG BASE **

N050673 002 Jun 28, 1996

CEFACLOR

WORLD GEN

EQ 500MG BASE

A065057 001 Jan 05, 2001

CEFADROXIL/CEFADROXIL HEMIHYDRATE

CAPSULE;ORAL

CEFADROXIL

CHARTWELL RX

EQ 500MG BASE

A065309 001 Sep 18, 2006

CSPC OUYI

EQ 500MG BASE

A205072 001 Jul 28, 2017

IVAX SUB TEVA PHARMS

EQ 500MG BASE

A062766 001 Mar 03, 1987

PUREPAC PHARM

EQ 500MG BASE

A063017 001 Jan 05, 1989

RANBAXY LABS LTD

EQ 500MG BASE

A065015 001 Jun 22, 1999

SANDOZ

EQ 500MG BASE

A062291 001

TEVA

EQ 500MG BASE

A062695 001 Feb 10, 1989

DURICEF

WARNER CHILCOTT

EQ 250MG BASE

N050512 002

+

EQ 500MG BASE **

N050512 001

ULTRACEF

BRISTOL

EQ 500MG BASE

A062378 001 Mar 16, 1982

FOR SUSPENSION;ORAL

CEFADROXIL

ANI PHARMS

EQ 125MG BASE/5ML

A062698 001 Mar 01, 1989

EQ 250MG BASE/5ML

A062698 002 Mar 01, 1989

EQ 250MG BASE/5ML

A065278 001 Jan 20, 2006

EQ 500MG BASE/5ML

A062698 003 Mar 01, 1989

EQ 500MG BASE/5ML

A065278 002 Jan 20, 2006

APOTHECON

EQ 125MG BASE/5ML

A062334 001

EQ 250MG BASE/5ML

A062334 002

EQ 500MG BASE/5ML

A062334 003

CHARTWELL RX

EQ 250MG BASE/5ML

A065307 002 Oct 16, 2006

EQ 500MG BASE/5ML

A065307 003 Oct 16, 2006

SUN PHARM INDS LTD

EQ 125MG BASE/5ML

A065115 001 Mar 26, 2003

EQ 250MG BASE/5ML

A065115 002 Mar 26, 2003

EQ 500MG BASE/5ML

A065115 003 Mar 26, 2003

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-88(of 478)

** See List Footnote

CEFADROXIL/CEFADROXIL HEMIHYDRATE

FOR SUSPENSION; ORAL

DURICEF

+	WARNER CHILCOTT	EQ 125MG BASE/5ML **	N050527	002
+		EQ 250MG BASE/5ML **	N050527	003
+		EQ 500MG BASE/5ML **	N050527	001

ULTRACEF

BRISTOL	EQ 125MG BASE/5ML	A062376	001	Mar 16, 1982
	EQ 250MG BASE/5ML	A062376	002	Mar 16, 1982
	EQ 500MG BASE/5ML	A062376	003	Mar 16, 1982

TABLET; ORAL

CEFADROXIL

CHARTWELL RX	EQ 1GM BASE	A065301	001	Sep 18, 2006
RANBAXY	EQ 1GM BASE	A065018	001	Apr 23, 1999

DURICEF

+	WARNER CHILCOTT	EQ 1GM BASE **	N050528	001

ULTRACEF

APOTHECON	EQ 1GM BASE	A062390	001	Jun 10, 1982
BRISTOL	EQ 1GM BASE	A062408	001	Aug 31, 1982

CEFAMANDOLE NAFATE

INJECTABLE; INJECTION

MANDOL

LILLY	EQ 500MG BASE/VIAL	N050504	001	
	EQ 1GM BASE/VIAL	A062560	001	Sep 10, 1985
	EQ 1GM BASE/VIAL	N050504	002	
	EQ 2GM BASE/VIAL	A062560	002	Sep 10, 1985
	EQ 2GM BASE/VIAL	N050504	003	
	EQ 10GM BASE/VIAL	N050504	004	

CEFAZOLIN SODIUM

INJECTABLE; INJECTION

ANCEF

+	GLAXOSMITHKLINE	EQ 250MG BASE/VIAL **	N050461	001
+		EQ 500MG BASE/VIAL	N050461	002
+		EQ 1GM BASE/VIAL **	N050461	003
+		EQ 5GM BASE/VIAL **	N050461	004
+		EQ 10GM BASE/VIAL **	N050461	005

ANCEF IN DEXTROSE 5% IN PLASTIC CONTAINER

+	BAXTER HLTHCARE	EQ 10MG BASE/ML	N050566	003	Jun 08, 1983
+		EQ 20MG BASE/ML	N050566	004	Jun 08, 1983

ANCEF IN PLASTIC CONTAINER

BAXTER HLTHCARE	EQ 10MG BASE/ML	A063002	001	Mar 28, 1991

ANCEF IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

+	BAXTER HLTHCARE	EQ 10MG BASE/ML	N050566	001	Jun 08, 1983
+		EQ 20MG BASE/ML	N050566	002	Jun 08, 1983

CEFAZOLIN AND DEXTROSE

B BRAUN	EQ 500MG BASE/VIAL	N050779	001	Jul 27, 2000

CEFAZOLIN SODIUM

ABRAXIS PHARM	EQ 500MG BASE/VIAL	A062688	002	Nov 17, 1986
	EQ 1GM BASE/VIAL	A062688	003	Nov 17, 1986
	EQ 10GM BASE/VIAL	A062688	004	Nov 17, 1986
	EQ 20GM BASE/VIAL	A062688	005	Aug 03, 1987
AUROBINDO PHARMA	EQ 500MG BASE/VIAL	A065395	001	Aug 08, 2008
	EQ 1GM BASE/VIAL	A065395	002	Aug 08, 2008
BEDFORD	EQ 250MG BASE/VIAL	A062894	001	Jul 21, 1988
	EQ 500MG BASE/VIAL	A062894	002	Jul 21, 1988
	EQ 1GM BASE/VIAL	A062894	003	Jul 21, 1988
	EQ 5GM BASE/VIAL	A062894	004	Jul 21, 1988
	EQ 10GM BASE/VIAL	A062894	005	Jul 21, 1988
CEPHAZONE PHARMA	EQ 500MG BASE/VIAL	A065280	001	Mar 18, 2009
	EQ 1GM BASE/VIAL	A065280	002	Mar 18, 2009
	EQ 10GM BASE/VIAL	A065295	001	Mar 18, 2009
	EQ 20GM BASE/VIAL	A065296	001	Mar 18, 2009
DR REDDYS	EQ 250MG BASE/VIAL	A062988	001	Dec 29, 1989
	EQ 500MG BASE/VIAL	A062988	002	Dec 29, 1989
	EQ 1GM BASE/VIAL	A062988	003	Dec 29, 1989
	EQ 5GM BASE/VIAL	A062989	001	Dec 29, 1989
	EQ 10GM BASE/VIAL	A062989	002	Dec 29, 1989
	EQ 20GM BASE/VIAL	A062989	003	Dec 29, 1989

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-89(of 478)

** See List Footnote

CEFAZOLIN SODIUM

INJECTABLE; INJECTION

CEFAZOLIN SODIUM

FACTA FARMA	EQ 500MG BASE/VIAL	A063214 001	Dec 27, 1991
	EQ 1GM BASE/VIAL	A063207 001	Dec 27, 1991
	EQ 10GM BASE/VIAL	A063209 001	Dec 27, 1991
	EQ 20GM BASE/VIAL	A063209 002	Apr 30, 1999
FRESENIUS KABI USA	EQ 500MG BASE/VIAL **	A064169 001	Aug 14, 1998
	EQ 1GM BASE/VIAL **	A064169 002	Aug 14, 1998
	EQ 10GM BASE/VIAL	A064170 001	Mar 18, 1998
	EQ 20GM BASE/VIAL	A064170 002	Mar 18, 1998
GLAXOSMITHKLINE	EQ 1GM BASE/VIAL	A064033 001	Oct 31, 1993
HIKMA	EQ 250MG BASE/VIAL	A062807 001	Jan 12, 1988
	EQ 500MG BASE/VIAL	A062807 002	Jan 12, 1988
	EQ 1GM BASE/VIAL	A062807 003	Jan 12, 1988
	EQ 5GM BASE/VIAL	A062807 004	Jan 12, 1988
	EQ 10GM BASE/VIAL	A062807 005	Jan 12, 1988
	EQ 20GM BASE/VIAL	A062807 006	Jan 12, 1988
HOSPIRA	EQ 1GM BASE/VIAL	A201654 001	Feb 03, 2016
HOSPIRA INC	EQ 500MG BASE/VIAL	A065226 001	Apr 21, 2005
	EQ 1GM BASE/VIAL	A065226 002	Apr 21, 2005
	EQ 1GM BASE/VIAL	A065244 001	Aug 12, 2005
	EQ 10GM BASE/VIAL	A065247 001	Aug 12, 2005
STERI PHARMA	EQ 500MG BASE/VIAL	A063216 001	Dec 27, 1991
	EQ 1GM BASE/VIAL	A063208 001	Dec 27, 1991
TEVA PHARMS	EQ 250MG BASE/VIAL	A063016 001	Mar 14, 1989
	EQ 500MG BASE/VIAL	A063016 002	Mar 14, 1989
	EQ 1GM BASE/VIAL	A063016 003	Mar 14, 1989
	EQ 5GM BASE/VIAL	A063018 001	Mar 05, 1990
	EQ 10GM BASE/VIAL	A063018 002	Mar 05, 1990
KEFZOL			
ACS DOBFAR	EQ 250MG BASE/VIAL	A061773 001	
	EQ 500MG BASE/VIAL	A061773 002	
	EQ 1GM BASE/VIAL	A061773 003	
	EQ 10GM BASE/VIAL	A061773 004	
	EQ 20GM BASE/VIAL	A061773 005	Sep 08, 1987
LILLY	EQ 500MG BASE/VIAL	A062557 001	Sep 10, 1985
	EQ 1GM BASE/VIAL	A062557 002	Sep 10, 1985

CEFDINIR

CAPSULE; ORAL

OMNICEF

+ ABBVIE	300MG **	N050739 001	Dec 04, 1997
FOR SUSPENSION; ORAL			
OMNICEF			
+ ABBVIE	125MG/5ML **	N050749 001	Dec 04, 1997
+	250MG/5ML **	N050749 002	Jul 29, 2004

CEFDITOREN PIVOXIL

TABLET; ORAL

SPECTRACEF

VANSEN PHARMA	200MG	N021222 001	Aug 29, 2001
	400MG	N021222 002	Jul 21, 2008

CEFEPIME HYDROCHLORIDE

INJECTABLE; INJECTION

CEFEPIME HYDROCHLORIDE

FOSUN PHARMA	EQ 500MG BASE/VIAL	A090291 001	Dec 21, 2010
	EQ 1GM BASE/VIAL	A090291 002	Dec 21, 2010
	EQ 2GM BASE/VIAL	A090291 003	Dec 21, 2010
HOSPIRA INC	EQ 500MG BASE/VIAL	A065369 001	Jun 18, 2007
	EQ 1GM BASE/VIAL	A065369 002	Jun 18, 2007
	EQ 1GM BASE/VIAL	A202268 001	Jul 30, 2012
	EQ 2GM BASE/VIAL	A065369 003	Jun 18, 2007
	EQ 2GM BASE/VIAL	A202268 002	Jul 30, 2012

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-90(of 478)

** See List Footnote

CEFIXIME

FOR SUSPENSION; ORAL

CEFIXIME

SANDOZ INC

100MG/5ML

A206144 001 Nov 17, 2017

200MG/5ML

A206144 002 Nov 17, 2017

SUPRAX

+ LEDERLE

100MG/5ML **

N050622 001 Apr 28, 1989

LUPIN PHARMS

100MG/5ML

A065129 001 Feb 23, 2004

TABLET; ORAL

SUPRAX

+ LEDERLE

200MG **

N050621 001 Apr 28, 1989

+

400MG **

N050621 002 Apr 28, 1989

LUPIN PHARMS

400MG

A065130 001 Feb 12, 2004

CEFMENOXIME HYDROCHLORIDE

INJECTABLE; INJECTION

CEFMAX

TAP PHARM

EQ 500MG BASE/VIAL

N050571 001 Dec 30, 1987

EQ 1GM BASE/VIAL

N050571 002 Dec 30, 1987

EQ 2GM BASE/VIAL

N050571 003 Dec 30, 1987

CEFMETAZOLE SODIUM

INJECTABLE; INJECTION

ZEFAZONE

+ PHARMACIA AND UPJOHN

EQ 1GM BASE/VIAL **

N050637 001 Dec 11, 1989

+

EQ 2GM BASE/VIAL **

N050637 002 Dec 11, 1989

ZEFAZONE IN PLASTIC CONTAINER

+ PHARMACIA AND UPJOHN

EQ 20MG BASE/ML **

N050683 001 Dec 29, 1992

+

EQ 40MG BASE/ML **

N050683 002 Dec 29, 1992

CEFONICID SODIUM

INJECTABLE; INJECTION

MONOCID

GLAXOSMITHKLINE

EQ 500MG BASE/VIAL

N050579 001 May 23, 1984

EQ 1GM BASE/VIAL

A063295 001 Jul 26, 1993

EQ 1GM BASE/VIAL

N050579 002 May 23, 1984

EQ 2GM BASE/VIAL

N050579 003 May 23, 1984

EQ 10GM BASE/VIAL

N050579 004 May 23, 1984

CEFOPERAZONE SODIUM

INJECTABLE; INJECTION

CEFOBID

PFIZER

EQ 1GM BASE/VIAL

A063333 001 Mar 31, 1995

EQ 1GM BASE/VIAL

N050551 001 Nov 18, 1982

EQ 2GM BASE/VIAL

A063333 002 Mar 31, 1995

EQ 2GM BASE/VIAL

N050551 002 Nov 18, 1982

EQ 10GM BASE/VIAL

N050551 003 Mar 05, 1990

CEFOBID IN PLASTIC CONTAINER

PFIZER

EQ 20MG BASE/ML

N050613 002 Jul 31, 1987

EQ 40MG BASE/ML

N050613 001 Jul 23, 1986

CEFORANIDE

INJECTABLE; INJECTION

PRECEF

APOTHECON

500MG/VIAL

A062579 001 Nov 26, 1984

1GM/VIAL

A062579 002 Nov 26, 1984

2GM/VIAL

A062579 003 Nov 26, 1984

10GM/VIAL

A062579 004 Nov 26, 1984

20GM/VIAL

A062579 005 Nov 26, 1984

BRISTOL

500MG/VIAL

N050554 001 May 24, 1984

1GM/VIAL

N050554 002 May 24, 1984

2GM/VIAL

N050554 003 May 24, 1984

10GM/VIAL

N050554 004 May 24, 1984

20GM/VIAL

N050554 005 May 24, 1984

CEFOTAXIME SODIUM

INJECTABLE; INJECTION

CEFOTAXIME

FRESENIUS KABI USA

EQ 500MG BASE/VIAL

A064200 001 Mar 24, 2000

EQ 1GM BASE/VIAL

A064200 002 Mar 24, 2000

EQ 2GM BASE/VIAL

A064200 003 Mar 24, 2000

EQ 10GM BASE/VIAL

A064201 001 Mar 24, 2000

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-91(of 478)

** See List Footnote

CEFOTAXIME SODIUM

INJECTABLE; INJECTION

CEFOTAXIME

	EQ 20GM BASE/VIAL	A064201	002	Mar 24, 2000
WOCKHARDT	EQ 1GM BASE/VIAL	A065197	001	Aug 29, 2006
CEFOTAXIME AND DEXTROSE 2.4% IN PLASTIC CONTAINER				
B BRAUN	EQ 2GM BASE	N050792	001	Jul 29, 2004
CEFOTAXIME AND DEXTROSE 3.9% IN PLASTIC CONTAINER				
B BRAUN	EQ 1GM BASE	N050792	002	Jul 29, 2004
CEFOTAXIME SODIUM				
AUROBINDO PHARMA	EQ 500MG BASE/VIAL	A065517	001	Nov 06, 2009
	EQ 1GM BASE/VIAL	A065517	002	Nov 06, 2009
	EQ 2GM BASE/VIAL	A065517	003	Nov 06, 2009
AUROBINDO PHARMA LTD	EQ 10GM BASE/VIAL	A065516	001	Nov 06, 2009
CEPHAZONE PHARMA	EQ 10GM BASE/VIAL	A065348	001	Jan 25, 2010
HOSPIRA	EQ 1GM BASE/VIAL	A203132	001	Feb 19, 2016
	EQ 2GM BASE/VIAL	A203132	002	Feb 19, 2016
HOSPIRA INC	EQ 500MG BASE/VIAL	A065290	001	Aug 11, 2006
	EQ 1GM BASE/VIAL	A065290	002	Aug 11, 2006
	EQ 1GM BASE/VIAL	A065293	001	Aug 10, 2006
	EQ 2GM BASE/VIAL	A065290	003	Aug 11, 2006
	EQ 2GM BASE/VIAL	A065293	002	Aug 10, 2006
	EQ 10GM BASE/VIAL	A065292	001	Aug 10, 2006
LUPIN	EQ 500MG BASE/VIAL	A065124	001	Sep 24, 2003
	EQ 1GM BASE/VIAL	A065124	002	Sep 24, 2003
	EQ 2GM BASE/VIAL	A065124	003	Sep 24, 2003
WOCKHARDT	EQ 500MG BASE/VIAL	A065197	002	Jun 20, 2008
	EQ 2GM BASE/VIAL	A065197	003	Jun 20, 2008
CLAFORAN				
SANOFI AVENTIS US	EQ 1GM BASE/VIAL	A062659	001	Jan 13, 1987
	EQ 2GM BASE/VIAL	A062659	002	Jan 13, 1987
+ VALIDUS PHARMS	EQ 500MG BASE/VIAL **	N050547	001	
+	EQ 1GM BASE/VIAL **	N050547	002	
+	EQ 2GM BASE/VIAL **	N050547	003	
+	EQ 10GM BASE/VIAL **	N050547	004	Dec 29, 1983
CLAFORAN IN DEXTROSE 5% IN PLASTIC CONTAINER				
VALIDUS PHARMS	EQ 20MG BASE/ML	N050596	002	May 20, 1985
	EQ 40MG BASE/ML	N050596	004	May 20, 1985
CLAFORAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
VALIDUS PHARMS	EQ 20MG BASE/ML	N050596	001	May 20, 1985
	EQ 40MG BASE/ML	N050596	003	May 20, 1985

CEFOTETAN DISODIUM

INJECTABLE; INJECTION

CEFOTAN

PAI HOLDINGS PHARM	EQ 10GM BASE/VIAL	N050588	003	Apr 25, 1988
TELIGENT	EQ 1GM BASE/VIAL	A063293	001	Apr 29, 1993
	EQ 2GM BASE/VIAL	A063293	002	Apr 29, 1993
CEFOTAN IN PLASTIC CONTAINER				
PAI HOLDINGS PHARM	EQ 20MG BASE/ML	N050694	002	Jul 30, 1993
	EQ 40MG BASE/ML	N050694	001	Jul 30, 1993
CEFOTETAN				
FRESENIUS KABI USA	EQ 10GM BASE/VIAL	A065375	001	Aug 09, 2007
HIKMA	EQ 1GM BASE/VIAL	A091031	001	Oct 26, 2011
	EQ 2GM BASE/VIAL	A091031	002	Oct 26, 2011
WEST-WARD PHARM CORP	EQ 10GM BASE/VIAL	A091030	001	Oct 26, 2011
CEFOTETAN AND DEXTROSE IN DUPLEX CONTAINER				
+ B BRAUN	EQ 1GM BASE/VIAL	N065430	001	Aug 09, 2007
+	EQ 2GM BASE/VIAL	N065430	002	Aug 09, 2007

CEFOTIAM HYDROCHLORIDE

INJECTABLE; INJECTION

CERADON

TAKEDA	EQ 1GM BASE/VIAL	N050601	001	Dec 30, 1988

DISCONTINUED DRUG PRODUCT LIST

6-92(of 478)

** See List Footnote

CEFOXITIN SODIUM

INJECTABLE; INJECTION

CEFOXITIN

ACS DOBFAR SPA	EQ 1GM BASE/VIAL	A065467	001	Aug 31, 2011
	EQ 2GM BASE/VIAL	A065467	002	Aug 31, 2011
	EQ 10GM BASE/VIAL	A065464	001	Aug 31, 2011
FRESENIUS KABI USA	EQ 1GM BASE/VIAL **	A065012	001	Jul 03, 2000
	EQ 2GM BASE/VIAL **	A065012	002	Jul 03, 2000
	EQ 10GM BASE/VIAL	A065011	001	Jul 03, 2000
HOSPIRA INC	EQ 1GM BASE/VIAL	A065313	001	Jan 23, 2006
	EQ 2GM BASE/VIAL	A065313	002	Jan 23, 2006
	EQ 10GM BASE/VIAL	A065312	001	Feb 13, 2006
MEFOXIN				
MYLAN INSTITUTIONAL	EQ 1GM BASE/VIAL	A062757	001	Jan 08, 1987
+	EQ 1GM BASE/VIAL **	N050517	001	
	EQ 2GM BASE/VIAL	A062757	002	Jan 08, 1987
+	EQ 2GM BASE/VIAL **	N050517	002	
	EQ 10GM BASE/VIAL **	N050517	003	
MEFOXIN IN DEXTROSE 5% IN PLASTIC CONTAINER				
+	MERCK	EQ 20MG BASE/ML **	N050581	003 Sep 20, 1984
+		EQ 40MG BASE/ML **	N050581	004 Sep 20, 1984
MEFOXIN IN PLASTIC CONTAINER				
MYLAN INSTITUTIONAL	EQ 20MG BASE/ML	A063182	001	Jan 25, 1993
	EQ 40MG BASE/ML	A063182	002	Jan 25, 1993
MEFOXIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
+	MERCK	EQ 20MG BASE/ML **	N050581	002 Sep 20, 1984
+		EQ 40MG BASE/ML **	N050581	001 Sep 20, 1984

CEFPIRAMIDE SODIUM

INJECTABLE; INJECTION

CEFPIRAMIDE SODIUM

WYETH AYERST	EQ 1GM BASE/VIAL	N050633	002	Jan 31, 1989
	EQ 2GM BASE/VIAL	N050633	003	Jan 31, 1989
	EQ 10GM BASE/VIAL	N050633	005	Jan 31, 1989

CEFPODOXIME PROXETIL

FOR SUSPENSION; ORAL

BANAN

SANKYO	EQ 50MG BASE/5ML	N050688	002	Aug 07, 1992
	EQ 100MG BASE/5ML	N050688	001	Aug 07, 1992
CEFPODOXIME PROXETIL				
SANDOZ	EQ 50MG BASE/5ML	A090031	001	Jan 14, 2009
	EQ 100MG BASE/5ML	A090031	002	Jan 14, 2009
SUN PHARM INDS LTD	EQ 50MG BASE/5ML	A065082	001	May 31, 2002
	EQ 100MG BASE/5ML	A065082	002	May 31, 2002
VANTIN				
+	PHARMACIA AND UPJOHN	EQ 50MG BASE/5ML **	N050675	001 Aug 07, 1992
+		EQ 100MG BASE/5ML **	N050675	002 Aug 07, 1992
TABLET; ORAL				
BANAN				
SANKYO	EQ 100MG BASE	N050687	001	Aug 07, 1992
	EQ 200MG BASE	N050687	002	Aug 07, 1992
CEFPODOXIME PROXETIL				
SUN PHARM INDS LTD	EQ 100MG BASE	A065083	001	Aug 20, 2003
	EQ 200MG BASE	A065083	002	Aug 20, 2003
VANTIN				
+	PHARMACIA AND UPJOHN	EQ 100MG BASE **	N050674	001 Aug 07, 1992
+		EQ 200MG BASE **	N050674	002 Aug 07, 1992

CEFPROZIL

FOR SUSPENSION; ORAL

CEFPROZIL

CHARTWELL RX	125MG/5ML	A065236	001	Dec 08, 2005
	250MG/5ML	A065236	002	Dec 08, 2005
ORCHID HLTHCARE	125MG/5ML	A065284	002	Dec 30, 2005
	250MG/5ML	A065284	001	Dec 30, 2005
RANBAXY LABS LTD	125MG/5ML	A065202	001	Jun 30, 2006
	250MG/5ML	A065202	002	Jun 30, 2006
SANDOZ	125MG/5ML	A065257	001	Dec 08, 2005
	250MG/5ML	A065257	002	Dec 08, 2005

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-93(of 478)

** See List Footnote

CEFPROZIL

FOR SUSPENSION; ORAL

CEFZIL

+	CORDEN PHARMA	125MG/5ML **	N050665 001	Dec 23, 1991
+		250MG/5ML **	N050665 002	Dec 23, 1991

TABLET; ORAL

CEFPROZIL

ORCHID HLTHCARE	250MG	A065267 001	Dec 19, 2005
	500MG	A065267 002	Dec 19, 2005
RANBAXY LABS LTD	250MG	A065198 001	Dec 13, 2006
	500MG	A065198 002	Dec 13, 2006
WOCKHARDT	250MG	A065428 001	Jun 14, 2007
	500MG	A065428 002	Jun 14, 2007

CEFZIL

+	CORDEN PHARMA	250MG **	N050664 001	Dec 23, 1991
+		500MG **	N050664 002	Dec 23, 1991

CEFTAROLINE FOSAMIL

POWDER; INTRAVENOUS

CEFTAROLINE FOSAMIL

APOTEX	400MG/VIAL	A208075 001	Sep 21, 2021
	600MG/VIAL	A208075 002	Sep 21, 2021

CEFTAZIDIME

INJECTABLE; INJECTION

CEFTAZIDIME

ACS DOBFAR	500MG/VIAL	A062640 001	Nov 20, 1985
AUROBINDO PHARMA LTD	500MG/VIAL	A065481 001	May 28, 2010
	1GM/VIAL	A065481 002	May 28, 2010
	2GM/VIAL	A065481 003	May 28, 2010
	6GM/VIAL	A065482 001	May 28, 2010
WOCKHARDT	1GM/VIAL	A065196 001	Oct 15, 2008

CEFTAZIDIME IN DEXTROSE CONTAINER

+	B BRAUN	EQ 1GM BASE	N050823 001	Jun 13, 2011
+		EQ 2GM BASE	N050823 002	Jun 13, 2011

CEPTAZ

GLAXOSMITHKLINE	500MG/VIAL	N050646 001	Sep 27, 1990
	1GM/VIAL	N050646 002	Sep 27, 1990
	2GM/VIAL	N050646 003	Sep 27, 1990
	10GM/VIAL	N050646 004	Sep 27, 1990

PENTACEF

GLAXOSMITHKLINE	1GM/VIAL	A063322 001	Nov 07, 1995
	1GM/VIAL	A064006 001	Mar 31, 1992
	2GM/VIAL	A063322 002	Nov 07, 1995
	2GM/VIAL	A064006 002	Mar 31, 1992
	6GM/VIAL	A064008 001	Mar 31, 1992
	10GM/VIAL	A064008 002	Mar 31, 1992

TAZIDIME

LILLY	1GM/VIAL	A062655 001	Nov 20, 1985
	2GM/VIAL	A062655 002	Nov 20, 1985

TAZIDIME IN PLASTIC CONTAINER

LILLY	1GM/VIAL	A062739 001	Jul 10, 1986
	2GM/VIAL	A062739 002	Jul 10, 1986

CEFTAZIDIME SODIUM

INJECTABLE; INJECTION

CEFTAZIDIME SODIUM IN PLASTIC CONTAINER

BAXTER HLTHCARE	EQ 10MG BASE/ML	A063221 001	Apr 29, 1993
	EQ 20MG BASE/ML	A063221 002	Apr 29, 1993
	EQ 40MG BASE/ML	A063221 003	Apr 29, 1993

FORTAZ IN PLASTIC CONTAINER

PAI HOLDINGS PHARM	EQ 10MG BASE/ML	N050634 001	Apr 28, 1989
+	EQ 20MG BASE/ML	N050634 002	Apr 28, 1989
+	EQ 40MG BASE/ML	N050634 003	Apr 28, 1989

DISCONTINUED DRUG PRODUCT LIST

6-94(of 478)

** See List Footnote

CEFTIBUTEN DIHYDRATE

CAPSULE; ORAL

CEDAX

SI PHARMS
FOR SUSPENSION; ORAL
CEDAX

EQ 400MG BASE

N050685 002 Dec 20, 1995

+ SI PHARMS
+EQ 90MG BASE/5ML **
EQ 180MG BASE/5ML **N050686 001 Dec 20, 1995
N050686 002 Dec 20, 1995CEFTIZOXIME SODIUM

INJECTABLE; INJECTION

CEFIZOX

ASTELLAS

EQ 500MG BASE/VIAL
EQ 1GM BASE/VIAL
EQ 1GM BASE/VIAL
EQ 2GM BASE/VIAL
EQ 2GM BASE/VIAL
EQ 10GM BASE/VIALN050560 001 Sep 15, 1983
A063294 002 Mar 31, 1994
N050560 002 Sep 15, 1983
A063294 003 Mar 31, 1994
N050560 003 Sep 15, 1983
N050560 005 Mar 19, 1993

CEFIZOX IN DEXTROSE 5% IN PLASTIC CONTAINER

ASTELLAS

EQ 20MG BASE/ML
EQ 40MG BASE/MLN050589 001 Oct 03, 1984
N050589 002 Oct 03, 1984

CEFIZOX IN PLASTIC CONTAINER

ASTELLAS

EQ 20MG BASE/ML
EQ 40MG BASE/MLN050589 003 Apr 13, 1995
N050589 004 Apr 13, 1995CEFTRIAXONE SODIUM

INJECTABLE; INJECTION

CEFTRIAXONE

AGILA SPECLTS

EQ 10GM BASE/VIAL

A091068 001 Jan 07, 2013

AUROBINDO PHARMA LTD

EQ 10GM BASE/VIAL

A065504 001 Jul 31, 2008

BEDFORD

EQ 10GM BASE/VIAL

A065475 001 Aug 18, 2008

FACTA FARMA

EQ 10GM BASE/VIAL

A065269 001 Feb 28, 2007

FRESENIUS KABI USA

EQ 10GM BASE/VIAL

A065252 001 Feb 15, 2006

HOSPIRA INC

EQ 1GM BASE/VIAL

A065231 001 Aug 02, 2005

EQ 1GM BASE/VIAL

A202563 001 Aug 20, 2012

EQ 2GM BASE/VIAL

A065231 002 Aug 02, 2005

EQ 2GM BASE/VIAL

A202563 002 Aug 20, 2012

EQ 10GM BASE/VIAL

A065232 001 Aug 02, 2005

LUPIN

EQ 10GM BASE/VIAL

A065263 001 Sep 12, 2006

TEVA

EQ 10GM BASE/VIAL

A065274 001 May 01, 2006

ROCEPHIN

HOFFMANN LA ROCHE

EQ 250MG BASE/VIAL

A063239 001 Aug 13, 1993

EQ 500MG BASE/VIAL

A062654 001 Apr 30, 1987

EQ 500MG BASE/VIAL

A063239 002 Aug 13, 1993

EQ 1GM BASE/VIAL

A062654 002 Apr 30, 1987

EQ 1GM BASE/VIAL

A063239 003 Aug 13, 1993

EQ 2GM BASE/VIAL

A062654 003 Apr 30, 1987

+ EQ 10GM BASE/VIAL **

N050585 005 Dec 21, 1984

ROCHE

EQ 250MG BASE/VIAL

A062510 001 Mar 12, 1985

EQ 500MG BASE/VIAL

A062510 002 Mar 12, 1985

EQ 1GM BASE/VIAL

A062510 003 Mar 12, 1985

ROCEPHIN W/ DEXTROSE IN PLASTIC CONTAINER

+ HOFFMANN LA ROCHE

EQ 10MG BASE/ML **

N050624 001 Feb 11, 1987

+ EQ 20MG BASE/ML **

N050624 002 Feb 11, 1987

+ EQ 40MG BASE/ML **

N050624 003 Feb 11, 1987

INJECTABLE; INTRAMUSCULAR, INTRAVENOUS

CEFTRIAXONE

AUROBINDO PHARMA LTD

EQ 250MG BASE/VIAL

A065505 001 Jul 31, 2008

EQ 500MG BASE/VIAL

A065505 002 Jul 31, 2008

EQ 1GM BASE/VIAL

A065505 003 Jul 31, 2008

EQ 2GM BASE/VIAL

A065505 004 Jul 31, 2008

BEDFORD

EQ 250MG BASE/VIAL

A065465 001 Aug 18, 2008

EQ 500MG BASE/VIAL

A065465 002 Aug 18, 2008

EQ 1GM BASE/VIAL

A065465 003 Aug 18, 2008

EQ 2GM BASE/VIAL

A065465 004 Aug 18, 2008

CEPHAZONE PHARMA

EQ 250MG BASE/VIAL

A065294 001 Mar 26, 2007

EQ 500MG BASE/VIAL

A065294 002 Mar 26, 2007

EQ 1GM BASE/VIAL

A065294 003 Mar 26, 2007

EQ 2GM BASE/VIAL

A065294 004 Mar 26, 2007

FACTA FARMA

EQ 1GM BASE/VIAL

A065268 001 Feb 28, 2007

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-95(of 478)

** See List Footnote

CEFTRIAXONE SODIUM

INJECTABLE;INTRAMUSCULAR, INTRAVENOUS

CEFTRIAXONE

	EQ 2GM BASE/VIAL	A065268	002	Feb 28, 2007
FRESENIUS KABI USA	EQ 250MG BASE/VIAL	A065245	001	Feb 15, 2006
	EQ 500MG BASE/VIAL	A065245	002	Feb 15, 2006
	EQ 1GM BASE/VIAL	A065245	003	Feb 15, 2006
	EQ 2GM BASE/VIAL	A065245	004	Feb 15, 2006
HOSPIRA INC	EQ 250MG BASE/VIAL	A065230	001	Aug 02, 2005
	EQ 500MG BASE/VIAL	A065230	002	Aug 02, 2005
	EQ 1GM BASE/VIAL	A065230	003	Aug 02, 2005
	EQ 2GM BASE/VIAL	A065230	004	Aug 02, 2005
LUPIN	EQ 250MG BASE/VIAL	A065125	001	Sep 30, 2003
	EQ 500MG BASE/VIAL	A065125	002	Sep 30, 2003
	EQ 1GM BASE/VIAL	A065125	003	Sep 30, 2003
	EQ 2GM BASE/VIAL	A065125	004	Sep 30, 2003
TEVA	EQ 1GM BASE/VIAL	A065262	001	Jun 29, 2006
	EQ 2GM BASE/VIAL	A065262	002	Jun 29, 2006
TEVA PHARMS USA	EQ 250MG BASE/VIAL	A065227	001	Mar 15, 2007
	EQ 500MG BASE/VIAL	A065227	002	Mar 15, 2007
	EQ 1GM BASE/VIAL	A065227	003	Mar 15, 2007
	EQ 2GM BASE/VIAL	A065227	004	Mar 15, 2007
ROCEPHIN				
+ HOFFMANN LA ROCHE	EQ 250MG BASE/VIAL **	N050585	001	Dec 21, 1984
+	EQ 500MG BASE/VIAL **	N050585	002	Dec 21, 1984
+	EQ 1GM BASE/VIAL **	N050585	003	Dec 21, 1984
+	EQ 2GM BASE/VIAL **	N050585	004	Dec 21, 1984

CEFTRIAXONE SODIUM; LIDOCAINE

INJECTABLE;INJECTION

ROCEPHIN KIT

HOFFMANN LA ROCHE	EQ 500MG BASE/VIAL,N/A;N/A,1%	N050585	007	May 08, 1996
	EQ 1GM BASE/VIAL,N/A;N/A,1%	N050585	006	May 08, 1996

CEFUROXIME AXETIL

FOR SUSPENSION;ORAL

CEFTIN

+ GLAXOSMITHKLINE	EQ 125MG BASE/5ML	N050672	001	Jun 30, 1994
+	EQ 250MG BASE/5ML	N050672	002	Apr 29, 1997

CEFUROXIME AXETIL

SUN PHARM INDS LTD	EQ 125MG BASE/5ML	A065323	001	Feb 05, 2008
	EQ 250MG BASE/5ML	A065323	002	Feb 05, 2008

TABLET;ORAL

CEFTIN

+ GLAXOSMITHKLINE	EQ 125MG BASE **	N050605	001	Dec 28, 1987
+	EQ 250MG BASE **	N050605	002	Dec 28, 1987
+	EQ 500MG BASE **	N050605	003	Dec 28, 1987

CEFUROXIME AXETIL

ANI PHARMS	EQ 250MG BASE	A065190	001	Oct 18, 2004
	EQ 500MG BASE	A065190	002	Oct 18, 2004
FOSUN PHARMA	EQ 250MG BASE	A065126	001	Oct 28, 2003
	EQ 500MG BASE	A065126	002	Oct 28, 2003
RANBAXY LABS LTD	EQ 125MG BASE	A065043	003	Feb 15, 2002
	EQ 250MG BASE	A065043	002	Feb 15, 2002
	EQ 500MG BASE	A065043	001	Feb 15, 2002
SUN PHARM INDS LTD	EQ 125MG BASE	A065118	001	Apr 25, 2003
	EQ 250MG BASE	A065118	002	Apr 25, 2003
	EQ 500MG BASE	A065118	003	Apr 25, 2003

CEFUROXIME SODIUM

INJECTABLE;INJECTION

CEFUROXIME SODIUM

FRESENIUS KABI USA	EQ 1.5GM BASE/VIAL	A065001	002	May 30, 2001
	EQ 7.5GM BASE/VIAL	A065002	001	Sep 28, 1998
HOSPIRA INC	EQ 1.5GM BASE/VIAL	A065483	002	Oct 15, 2008
	EQ 1.5GM BASE/VIAL	A065503	001	Oct 15, 2008
	EQ 7.5GM BASE/VIAL	A065484	001	Oct 15, 2008
TEVA PHARMS	EQ 7.5GM BASE/VIAL	A064191	001	Apr 16, 1998
WATSON LABS INC	EQ 1.5GM BASE/VIAL	A064035	002	Feb 26, 1993
	EQ 7.5GM BASE/VIAL	A064036	001	Feb 26, 1993

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-96(of 478)

** See List Footnote

CEFUROXIME SODIUM

INJECTABLE;INJECTION

CEFUROXIME SODIUM IN PLASTIC CONTAINER

SAMSON MEDCL	EQ 75GM BASE/VIAL	A065251	001	Dec 30, 2009
	EQ 225GM BASE/VIAL	A065251	002	Dec 30, 2009

KEFUROX

ACS DOBFAR	EQ 1.5GM BASE/VIAL	A062591	002	Jan 10, 1986
	EQ 7.5GM BASE/VIAL	A062591	003	Dec 17, 1987
LILLY	EQ 1.5GM BASE/VIAL	A062592	002	Jan 10, 1986

KEFUROX IN PLASTIC CONTAINER

LILLY	EQ 1.5GM BASE/VIAL	A062590	002	Jan 10, 1986

ZINACEF IN PLASTIC CONTAINER

PAI HOLDINGS PHARM	EQ 15MG BASE/ML	N050643	001	Apr 28, 1989
+	EQ 30MG BASE/ML	N050643	002	Apr 28, 1989

INJECTABLE;INTRAMUSCULAR, INTRAVENOUS

CEFUROXIME SODIUM

FRESENIUS KABI USA	EQ 750MG BASE/VIAL	A065001	001	May 30, 2001
HOSPIRA INC	EQ 750MG BASE/VIAL	A065483	001	Oct 15, 2008
TEVA PHARMS	EQ 750MG BASE/VIAL	A064192	002	Apr 16, 1998
	EQ 1.5GM BASE/VIAL	A064192	001	Apr 16, 1998
WATSON LABS INC	EQ 750MG BASE/VIAL	A064035	001	Feb 26, 1993

KEFUROX

ACS DOBFAR	EQ 750MG BASE/VIAL	A062591	001	Jan 10, 1986

INJECTABLE;INTRAVENOUS

KEFUROX

LILLY	EQ 750MG BASE/VIAL	A062592	001	Jan 10, 1986

KEFUROX IN PLASTIC CONTAINER

LILLY	EQ 750MG BASE/VIAL	A062590	001	Jan 10, 1986

CELECOXIB

CAPSULE;ORAL

CELECOXIB

ACIC PHARMS	200MG	A212925	001	Dec 09, 2020
	400MG	A212925	002	Dec 09, 2020
JUBILANT GENERICS	50MG	A207061	001	Apr 04, 2017
	100MG	A207061	002	Apr 04, 2017
	200MG	A207061	003	Apr 04, 2017
	400MG	A207061	004	Apr 04, 2017
UNICHEM	50MG	A213301	001	Jan 12, 2021
	100MG	A213301	002	Jan 12, 2021
	200MG	A213301	003	Jan 12, 2021
	400MG	A213301	004	Jan 12, 2021

SOLUTION;ORAL

ELYXYB

+	BDSI	25MG/ML	N212157	001	May 05, 2020

CELLULOSE SODIUM PHOSPHATE

POWDER;ORAL

CALCIBIND

MISSION PHARMA	2.5GM/PACKET	N018757	002	Dec 28, 1982
	300GM/BOT	N018757	003	Oct 16, 1984

CEPHALEXIN

CAPSULE;ORAL

CEPHALEXIN

APOTHECON	EQ 250MG BASE	A062973	001	Nov 08, 1988
	EQ 250MG BASE	A063063	001	Sep 29, 1989
	EQ 250MG BASE	A063186	001	Dec 30, 1994
	EQ 500MG BASE	A062974	001	Nov 23, 1988
	EQ 500MG BASE	A063063	002	Sep 29, 1989
	EQ 500MG BASE	A063186	002	Dec 30, 1994
BARR	EQ 250MG BASE	A062773	001	Jun 26, 1987
	EQ 500MG BASE	A062775	001	Apr 22, 1987
FACTA FARMA	EQ 250MG BASE	A062118	001	
	EQ 500MG BASE	A062118	002	
IVAX SUB TEVA PHARMS	EQ 250MG BASE	A061969	001	
	EQ 500MG BASE	A061969	002	
PUREPAC PHARM	EQ 250MG BASE	A062809	001	Apr 22, 1987
	EQ 500MG BASE	A062809	002	Apr 22, 1987
STEVENS J	EQ 250MG BASE	A062870	001	Mar 17, 1988
	EQ 500MG BASE	A062869	001	Mar 17, 1988

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-97(of 478)

** See List Footnote

CEPHALEXIN

CAPSULE;ORAL

CEPHALEXIN

SUN PHARM INDS (IN)	EQ 250MG BASE	A062791 001	Jun 11, 1987
	EQ 500MG BASE	A062791 002	Jun 11, 1987
SUN PHARM INDS LTD	EQ 250MG BASE	A065007 001	Sep 16, 1999
	EQ 500MG BASE	A065007 002	Sep 16, 1999
TEVA	EQ 250MG BASE	A062760 001	Apr 24, 1987
	EQ 250MG BASE	A062821 001	Feb 05, 1988
	EQ 500MG BASE	A062761 001	Apr 24, 1987
	EQ 500MG BASE	A062823 001	Feb 05, 1988
YOSHITOMI	EQ 250MG BASE	A062872 001	Jun 20, 1988
	EQ 500MG BASE	A062871 001	Jul 05, 1988

KEFLEX

+ PRAGMA	EQ 250MG BASE **	N050405 002	
+	EQ 333MG BASE **	N050405 004	May 12, 2006
+	EQ 500MG BASE **	N050405 003	
+	EQ 750MG BASE **	N050405 005	May 12, 2006

FOR SUSPENSION;ORAL

CEPHALEXIN

APOTHECON	EQ 125MG BASE/5ML	A062986 001	Apr 18, 1991
	EQ 250MG BASE/5ML	A062987 001	Jul 25, 1989
BARR	EQ 125MG BASE/5ML	A062778 001	Aug 06, 1987
	EQ 250MG BASE/5ML	A062777 001	Aug 06, 1987
CHARTWELL RX	EQ 125MG BASE/5ML	A065326 001	Jul 10, 2006
	EQ 250MG BASE/5ML	A065326 002	Jul 10, 2006
FACTA FARMA	EQ 100MG BASE/ML **	A062117 001	
	EQ 125MG BASE/5ML **	A062117 002	
	EQ 250MG BASE/5ML **	A062117 003	
HIKMA PHARMS	EQ 125MG BASE/5ML	A065444 001	Aug 28, 2009
	EQ 250MG BASE/5ML	A065444 002	Aug 28, 2009
SUN PHARM INDS LTD	EQ 125MG BASE/5ML	A065081 001	Jul 27, 2001
	EQ 250MG BASE/5ML	A065081 002	Jul 27, 2001
TEVA	EQ 125MG BASE/5ML	A062767 001	Jun 16, 1987
	EQ 125MG BASE/5ML	A062873 001	May 23, 1988
	EQ 250MG BASE/5ML	A062768 001	Jun 16, 1987
	EQ 250MG BASE/5ML	A062867 001	Apr 15, 1988
VITARINE	EQ 125MG BASE/5ML	A062779 001	Dec 22, 1987
	EQ 250MG BASE/5ML	A062781 001	Dec 22, 1987

KEFLEX

+ PRAGMA	EQ 100MG BASE/ML **	N050406 003	
+	EQ 125MG BASE/5ML **	N050406 001	
+	EQ 250MG BASE/5ML **	N050406 002	

TABLET;ORAL

CEPHALEXIN

BARR	EQ 250MG BASE	A062826 001	Aug 17, 1987
	EQ 500MG BASE	A062827 001	Aug 17, 1987
VITARINE	EQ 250MG BASE	A062863 001	Aug 11, 1988
	EQ 500MG BASE	A062863 002	Aug 11, 1988
	EQ 1GM BASE	A062863 003	Aug 11, 1988

KEFLET

LILLY	EQ 250MG BASE	A062745 001	Dec 01, 1986
	EQ 250MG BASE	N050440 003	Feb 26, 1987
	EQ 500MG BASE	A062745 002	Dec 01, 1986
	EQ 500MG BASE	N050440 001	
	EQ 1GM BASE	N050440 002	

TABLET, FOR SUSPENSION;ORAL

PANIXINE DISPERDOSE

RANBAXY LABS LTD	EQ 125MG BASE	A065100 002	Sep 11, 2003
	EQ 250MG BASE	A065100 001	Sep 11, 2003

CEPHALEXIN HYDROCHLORIDE

TABLET;ORAL

KEFTAB

LILLY	EQ 250MG BASE	N050614 001	Oct 29, 1987
	EQ 333MG BASE	N050614 003	May 16, 1988
	EQ 500MG BASE	N050614 002	Oct 29, 1987

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-98(of 478)

** See List Footnote

CEPHALOGLYCIN

CAPSULE; ORAL

KAFOCIN

LILLY

250MG

N050219 001

CEPHALOTHIN SODIUM

INJECTABLE; INJECTION

CEPHALOTHIN

INTL MEDICATION

EQ 500MG BASE/VIAL

A062426 001 May 03, 1985

EQ 1GM BASE/VIAL

A062426 002 May 03, 1985

EQ 2GM BASE/VIAL

A062426 003 May 03, 1985

EQ 4GM BASE/VIAL

A062426 004 May 03, 1985

CEPHALOTHIN SODIUM

ABBOTT

EQ 1GM BASE/VIAL

A062547 001 Sep 11, 1985

EQ 1GM BASE/VIAL

A062548 001 Sep 11, 1985

EQ 2GM BASE/VIAL

A062547 002 Sep 11, 1985

EQ 2GM BASE/VIAL

A062548 002 Sep 11, 1985

ABRAXIS PHARM

EQ 1GM BASE/VIAL

A062666 002 Jun 10, 1987

EQ 2GM BASE/VIAL

A062666 001 Jun 10, 1987

BRISTOL

EQ 1GM BASE/VIAL

A062464 001 May 07, 1984

EQ 2GM BASE/VIAL

A062464 002 May 07, 1984

EQ 4GM BASE/VIAL

A062464 003 May 07, 1984

CEPHALOTHIN SODIUM W/ DEXTROSE IN PLASTIC CONTAINER

BAXTER HLTHCARE

EQ 20MG BASE/ML

A062422 003 Jan 31, 1984

EQ 20MG BASE/ML

A062422 005 Jul 16, 1991

EQ 20MG BASE/ML

A062730 001 Mar 05, 1987

EQ 40MG BASE/ML

A062422 004 Jan 31, 1984

EQ 40MG BASE/ML

A062422 006 Jul 16, 1991

EQ 40MG BASE/ML

A062730 002 Mar 05, 1987

CEPHALOTHIN SODIUM W/ SODIUM CHLORIDE IN PLASTIC CONTAINER

BAXTER HLTHCARE

EQ 20MG BASE/ML

A062422 001 Jan 31, 1984

EQ 40MG BASE/ML

A062422 002 Jan 31, 1984

KEFLIN

LILLY

EQ 1GM BASE/VIAL

N050482 001

EQ 2GM BASE/VIAL

N050482 002

EQ 4GM BASE/VIAL

N050482 003

EQ 20GM BASE/VIAL

N050482 007

KEFLIN IN PLASTIC CONTAINER

LILLY

EQ 1GM BASE/VIAL

A062549 001 Sep 10, 1985

EQ 2GM BASE/VIAL

A062549 002 Sep 10, 1985

SEFFIN

GLAXOSMITHKLINE

EQ 1GM BASE/VIAL

A062435 001 Nov 15, 1983

EQ 2GM BASE/VIAL

A062435 002 Nov 15, 1983

EQ 10GM BASE/VIAL

A062435 003 Nov 15, 1983

CEPHAPIRIN SODIUM

INJECTABLE; INJECTION

CEFADYL

APOTHECON

EQ 500MG BASE/VIAL

A062961 001 Sep 20, 1988

EQ 500MG BASE/VIAL

N050446 005

EQ 1GM BASE/VIAL

A061769 001

EQ 1GM BASE/VIAL

A062724 001 Dec 23, 1986

EQ 1GM BASE/VIAL

A062961 002 Sep 20, 1988

EQ 1GM BASE/VIAL

N050446 001

EQ 2GM BASE/VIAL

A061769 002

EQ 2GM BASE/VIAL

A062724 002 Dec 23, 1986

EQ 2GM BASE/VIAL

A062961 003 Sep 20, 1988

EQ 2GM BASE/VIAL

N050446 002

EQ 4GM BASE/VIAL

A061769 003

EQ 4GM BASE/VIAL

A062961 004 Sep 20, 1988

EQ 4GM BASE/VIAL

N050446 003

EQ 20GM BASE/VIAL

N050446 004

CEPHAPIRIN SODIUM

ABRAXIS PHARM

EQ 500MG BASE/VIAL

A062723 001 Nov 17, 1986

EQ 1GM BASE/VIAL

A062723 002 Nov 17, 1986

EQ 2GM BASE/VIAL

A062723 003 Nov 17, 1986

EQ 4GM BASE/VIAL

A062723 004 Nov 17, 1986

EQ 20GM BASE/VIAL

A062723 005 Nov 17, 1986

HIKMA

EQ 500MG BASE/VIAL

A062720 001 Jul 02, 1987

EQ 1GM BASE/VIAL

A062720 002 Jul 02, 1987

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-99(of 478)

** See List Footnote

CEPHAPIRIN SODIUM

INJECTABLE; INJECTION

CEPHAPIRIN SODIUM

EQ 2GM BASE/VIAL

A062720 003 Jul 02, 1987

EQ 20GM BASE/VIAL

A062720 004 Jul 02, 1987

CEPHRADINE

CAPSULE; ORAL

ANSPOR

GLAXOSMITHKLINE

250MG

A061859 001

500MG

A061859 002

CEPHRADINE

BARR

250MG

A062850 001 Apr 22, 1988

500MG

A062851 001 Apr 22, 1988

IVAX SUB TEVA PHARMS

250MG

A062762 001 Mar 06, 1987

500MG

A062762 002 Mar 06, 1987

TEVA

250MG

A062683 001 Jan 09, 1987

500MG

A062683 002 Jan 09, 1987

VITARINE

250MG

A062813 001 Feb 25, 1988

500MG

A062813 002 Feb 25, 1988

VELOSEF

APOTHECON

250MG

A061764 001

500MG

A061764 002

VELOSEF '250'

ERSANA

250MG

N050548 001

VELOSEF '500'

ERSANA

500MG

N050548 002

FOR SUSPENSION; ORAL

ANSPOR

GLAXOSMITHKLINE

125MG/5ML

A061866 001

250MG/5ML

A061866 002

CEPHRADINE

BARR

125MG/5ML

A062858 001 May 19, 1988

250MG/5ML

A062859 001 May 19, 1988

TEVA

125MG/5ML

A062693 001 Jan 09, 1987

250MG/5ML

A062693 002 Jan 09, 1987

VELOSEF '125'

APOTHECON

125MG/5ML

A061763 001

VELOSEF '250'

APOTHECON

250MG/5ML

A061763 002

INJECTABLE; INJECTION

VELOSEF

APOTHECON

250MG/VIAL

A061976 001

500MG/VIAL

A061976 002

1GM/VIAL

A061976 004

2GM/VIAL

A061976 003

4GM/VIAL

A061976 005

TABLET; ORAL

VELOSEF

BRISTOL MYERS SQUIBB 1GM

N050530 001

CERITINIB

CAPSULE; ORAL

ZYKADIA

+

NOVARTIS

150MG

N205755 001 Apr 29, 2014

CERIVASTATIN SODIUM

TABLET; ORAL

BAYCOL

BAYER PHARMS

0.05MG

N020740 001 Jun 26, 1997

0.1MG

N020740 002 Jun 26, 1997

0.2MG

N020740 003 Jun 26, 1997

0.3MG

N020740 004 Jun 26, 1997

0.4MG

N020740 005 May 24, 1999

0.8MG

N020740 006 Jul 24, 2000

DISCONTINUED DRUG PRODUCT LIST

6-100(of 478)

** See List Footnote

CERULETIDE DIETHYLAMINE

INJECTABLE;INJECTION

TYMTRAN

PHARMACIA AND UPJOHN 0.02MG/ML

N018296 001

CETIRIZINE HYDROCHLORIDE

SYRUP;ORAL

CETIRIZINE HYDROCHLORIDE

ACTAVIS MID ATLANTIC 5MG/5ML

A078617 001 Feb 02, 2010

AUROBINDO PHARMA LTD 5MG/5ML

A090751 001 Dec 16, 2009

LANNETT CO INC 5MG/5ML

A078496 001 Sep 25, 2009

PHARM ASSOC 5MG/5ML

A078412 001 Jun 18, 2008

RANBAXY LABS LTD 5MG/5ML

A077472 001 Jun 18, 2008

TORRENT 5MG/5ML

A078870 001 Apr 27, 2009

WOCKHARDT 5MG/5ML

A078757 001 Aug 28, 2009

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

CHARTWELL RX 5MG/5ML

A090378 002 May 09, 2008

CYPRESS PHARM 5MG/5ML

A090300 001 Oct 10, 2008

PHARM ASSOC 5MG/5ML

A090188 002 Apr 22, 2008

RANBAXY LABS LTD 5MG/5ML

A090183 002 Apr 24, 2008

TORRENT 5MG/5ML

A090474 002 Mar 30, 2009

TRIS PHARMA INC 5MG/5ML

A090572 001 Nov 16, 2012

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF

CHARTWELL RX 5MG/5ML

A090378 001 May 09, 2008

CYPRESS PHARM 5MG/5ML

A090300 002 Oct 10, 2008

PHARM ASSOC 5MG/5ML

A090188 001 Apr 22, 2008

RANBAXY LABS LTD 5MG/5ML

A090183 001 Apr 24, 2008

TORRENT 5MG/5ML

A090474 001 Mar 30, 2009

TRIS PHARMA INC 5MG/5ML

A090572 002 Nov 16, 2012

ZYRTEC

J AND J CONSUMER INC 5MG/5ML **

N020346 001 Sep 27, 1996

TABLET;ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

CIPLA LTD 5MG

A077318 001 Jul 25, 2013

10MG

A077318 002 Jul 25, 2013

HERITAGE PHARMA 5MG

A078615 003 Dec 28, 2007

10MG

A078615 004 Dec 28, 2007

SUN PHARM INDS INC 5MG

A077499 001 Dec 27, 2007

10MG

A077499 002 Dec 27, 2007

TORRENT PHARMS LLC 5MG

A079191 001 Apr 15, 2010

10MG

A079191 004 Apr 15, 2010

UNICHEM 5MG

A078680 003 Jun 26, 2009

10MG

A078680 004 Jun 26, 2009

CETIRIZINE HYDROCHLORIDE HIVES

SUN PHARM INDS INC 5MG

A077499 003 Dec 27, 2007

10MG

A077499 004 Dec 27, 2007

UNICHEM 5MG

A078680 001 Jun 26, 2009

10MG

A078680 002 Jun 26, 2009

CETIRIZINE HYDROCHLORIDE HIVES RELIEF

TORRENT PHARMS LLC 5MG

A079191 003 Apr 15, 2010

10MG

A079191 002 Apr 15, 2010

ZYRTEC ALLERGY

+ J AND J CONSUMER INC 5MG

N019835 003 Nov 16, 2007

ZYRTEC HIVES RELIEF

+ J AND J CONSUMER INC 5MG

N019835 005 Nov 16, 2007

+ 10MG

N019835 006 Nov 16, 2007

TABLET, CHEWABLE;ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

SUN PHARM INDS INC 5MG

A077631 004 Jan 11, 2008

10MG

A077631 003 Jan 11, 2008

CETIRIZINE HYDROCHLORIDE HIVES RELIEF

SUN PHARM INDS INC 5MG

A077631 001 Jan 11, 2008

10MG

A077631 002 Jan 11, 2008

CHILDREN'S ZYRTEC ALLERGY

+ J AND J CONSUMER INC 5MG **

N021621 003 Nov 16, 2007

CHILDREN'S ZYRTEC HIVES RELIEF

+ J AND J CONSUMER INC 5MG **

N021621 005 Nov 16, 2007

+ 10MG **

N021621 006 Nov 16, 2007

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-101(of 478)

** See List Footnote

CETRORELIX ACETATE

POWDER;SUBCUTANEOUS

CETROTIDE

+ EMD SERONO INC EQ 3MG BASE/VIAL

N021197 002 Aug 11, 2000

CETYL ALCOHOL; COLFOSCERIL PALMITATE; TYLOXAPOL

FOR SUSPENSION;INTRATRACHEAL

EXOSURF NEONATAL

GLAXOSMITHKLINE 12MG/VIAL;108MG/VIAL;8MG/VIAL

N020044 001 Aug 02, 1990

CEVIMELINE HYDROCHLORIDE

CAPSULE;ORAL

CEVIMELINE HYDROCHLORIDE

APOTEX INC 30MG

A091260 001 Aug 25, 2011

CHENODIOL

TABLET;ORAL

CHENIX

+ LEADIANT BIOSCI INC 250MG **

N018513 002 Jul 28, 1983

CHLOPHEDIANOL HYDROCHLORIDE

SYRUP;ORAL

ULO

3M 25MG/5ML

N012126 001

CHLORAMPHENICOL

CREAM;TOPICAL

CHLOROMYCETIN

PARKE DAVIS 1%

N050183 001

FOR SOLUTION;OPHTHALMIC

CHLOROMYCETIN

PARKEDALE 25MG/VIAL

N050143 001

INJECTABLE;INJECTION

CHLOROMYCETIN

PARKE DAVIS 250MG/ML

N050153 001

OINTMENT;OPHTHALMIC

CHLORAMPHENICOL

ALTANA 1%

A060133 001

CHLOROFAIR

PHARMAFAIR 1%

A062439 001 Apr 21, 1983

CHLOROMYCETIN

PARKEDALE 1%

N050156 001

CHLOROPTIC S.O.P.

ALLERGAN 1%

A061187 001

ECONOCHLOR

ALCON 1%

A061648 001

SOLUTION/DROPS;OPHTHALMIC

CHLORAMPHENICOL

AKORN 0.5%

A062042 001

ALCON 0.5%

A062628 001 Sep 25, 1985

CHLOROFAIR

PHARMAFAIR 0.5%

A062437 001 Apr 14, 1983

CHLOROPTIC

ALLERGAN 0.5%

N050091 001

ECONOCHLOR

ALCON 0.5%

A061645 001

OPHTHOCHLOR

PARKEDALE 0.5%

A061220 001

OPTOMYCIN

OPTOPICS 0.5%

A062171 001 Mar 31, 1982

SOLUTION/DROPS;OTIC

CHLOROMYCETIN

PARKEDALE 0.5%

N050205 001

CHLORAMPHENICOL SODIUM SUCCINATE

INJECTABLE;INJECTION

CHLORAMPHENICOL

ELKINS SINN EQ 1GM BASE/VIAL

A062406 001 Nov 09, 1982

CHLORAMPHENICOL SODIUM SUCCINATE

GRUPPO LEPETIT EQ 1GM BASE/VIAL

A062278 001

CHLOROMYCETIN

+ PARKEDALE EQ 1GM BASE/VIAL

N050155 001

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-102(of 478)

** See List Footnote

CHLORAMPHENICOL SODIUM SUCCINATE

INJECTABLE; INJECTION

MYCHEL-S

ANGUS

EQ 1GM BASE/VIAL

A060132 001

CHLORAMPHENICOL; HYDROCORTISONE ACETATE

FOR SUSPENSION; OPHTHALMIC

CHLOROMYCETIN HYDROCORTISONE

PARKEDALE

12.5MG/VIAL; 25MG/VIAL

N050202 001

CHLORAMPHENICOL; HYDROCORTISONE ACETATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

OPHTHOCORT

PARKEDALE

10MG/GM; 5MG/GM; 10,000 UNITS/GM

N050201 002

CHLORAMPHENICOL; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

CHLOROMYCIN

PARKE DAVIS

1%; 10,000 UNITS/GM

N050203 002

CHLORAMPHENICOL; PREDNISOLONE

OINTMENT; OPHTHALMIC

CHLOROPTIC-P S.O.P.

ALLERGAN

1%; 0.5%

A061188 001

CHLORDIAZEPOXIDE

CAPSULE, EXTENDED RELEASE; ORAL

LIBRELEASE

VALEANT PHARM INTL

30MG

N017813 001 Sep 12, 1983

TABLET; ORAL

LIBRITABS

VALEANT PHARM INTL

5MG

A085482 001

10MG

A085481 001

25MG

A085488 001

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE; ORAL

A-POXIDE

ABBOTT

5MG

A085447 001

5MG

A085517 001

10MG

A085447 002

10MG

A085518 001

25MG

A085447 003

25MG

A085513 001

CHLORDIAZACHEL

RACHELLE

5MG

A085086 001

10MG

A084639 001

25MG

A085087 001

CHLORDIAZEPOXIDE HYDROCHLORIDE

ASCOT

5MG

A087525 001 Jan 07, 1982

10MG

A087524 001 Jan 07, 1982

25MG

A087512 001 Jan 07, 1982

FERRANTE

5MG

A085118 001

10MG

A085119 001

25MG

A085120 001

HALSEY

5MG

A085340 001

10MG

A085339 001

25MG

A084685 001

IMPAX LABS

5MG

A086213 001

10MG

A085113 001

25MG

A086212 001

IVAX SUB TEVA PHARMS

5MG

A083741 001

10MG

A083742 001

25MG

A083570 001

LEDERLE

5MG

A086892 001

5MG

A087234 001

10MG

A086876 001

10MG

A087037 001

25MG

A086893 001

25MG

A087231 001

MAST MM

10MG

A086217 001

MYLAN

5MG

A084886 001

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-103(of 478)

** See List Footnote

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE; ORAL

CHLORDIAZEPOXIDE HYDROCHLORIDE

	10MG	A084601	001	
	25MG	A084887	001	
PARKE DAVIS	5MG	A085163	001	
	10MG	A084598	001	
	25MG	A085164	001	
PIONEER PHARMS	10MG	A089533	001	Jul 15, 1988
	25MG	A089558	001	Jul 15, 1988
PUREPAC PHARM	5MG	A085155	001	
	10MG	A084939	002	
	25MG	A085144	001	
ROXANE	5MG	A084706	001	
	10MG	A084700	001	
	25MG	A084705	001	
SUPERPHARM	5MG	A088987	001	Apr 25, 1985
	10MG	A088986	001	Apr 25, 1985
	25MG	A088988	001	Apr 25, 1985
TEVA	5MG	A088705	001	Jan 18, 1985
	10MG	A088706	001	Jan 18, 1985
	25MG	A086494	001	
	25MG	A088707	001	Jan 18, 1985
UPSHER SMITH LABS	5MG	A084919	001	
+	10MG	A084920	001	
	25MG	A084823	001	
USL PHARMA	5MG	A084644	001	
	10MG	A084623	001	
	25MG	A084645	001	
VANGARD	5MG	A088129	001	Mar 28, 1983
	10MG	A088010	001	Mar 28, 1983
	25MG	A088130	001	Mar 28, 1983
WATSON LABS	5MG	A086383	001	
	10MG	A086294	001	
	25MG	A086382	001	
WEST WARD	5MG	A085014	001	
	10MG	A085000	001	
	25MG	A085294	001	
LIBRIUM				
+	VALEANT PHARM INTL	5MG **	N012249	002
+		10MG **	N012249	001
+		25MG **	N012249	003
LYGEN				
ALRA	5MG	A085107	001	
	10MG	A085009	001	
	25MG	A085108	001	

INJECTABLE; INJECTION

LIBRIUM

BAUSCH	100MG/AMP	N012301	001	

CHLORDIAZEPOXIDE HYDROCHLORIDE; CLIDINIUM BROMIDE

CAPSULE; ORAL

CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDE

TEVA PHARMS USA	5MG; 2.5MG	A211476	001	Nov 02, 2021

CHLORDIAZEPOXIDE; ESTROGENS, ESTERIFIED

TABLET; ORAL

MENRIUM 10-4

ROCHE	10MG; 0.4MG	N014740	006	

MENRIUM 5-2

ROCHE	5MG; 0.2MG	N014740	002	

MENRIUM 5-4

ROCHE	5MG; 0.4MG	N014740	004	

CHLORHEXIDINE GLUCONATE

SOLUTION; DENTAL

CHLORHEXIDINE GLUCONATE

AKORN	0.12%	A074356	001	May 07, 1996

PAROEX

SUNSTAR AMERICAS	0.12%	A076434	001	Nov 29, 2005

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-104(of 478)

** See List Footnote

CHLORHEXIDINE GLUCONATE

SOLUTION;DENTAL

PERIOGARD

COLGATE PALMOLIVE CO 0.12%

A073695 001 Jan 14, 1994

SOLUTION;TOPICAL

BRIAN CARE

SOAPCO 4%

A071419 001 Dec 17, 1987

EXIDINE

XTTRIUM 2.5%

N019421 001 Dec 17, 1985

MICRODERM

J AND J 4%

A072255 001 Apr 15, 1991

PREVACARE R

J AND J 0.5%

A072292 001 Jan 28, 1992

STERI-STAT

MATRIX MEDCL 4%

A070104 001 Jul 24, 1986

SPONGE;TOPICAL

CHLORHEXIDINE GLUCONATE

KENDALL IL 4%

N019490 001 Mar 27, 1987

E-Z SCRUB

BECTON DICKINSON 4%

A073416 001 Mar 14, 2000

HIBICLENS

+ MOLNLYCKE HLTH 4% **

N018423 001

MICRODERM

J AND J 4%

A072295 001 Feb 28, 1991

PHARMASEAL SCRUB CARE

CAREFUSION 2200 4%

N019793 001 Dec 02, 1988

TABLET;DENTAL

PERIOCHIP

+ DEXCEL PHARMA 2.5MG

N020774 001 May 15, 1998

CHLORMERODRIN HG-197

INJECTABLE;INJECTION

CHLORMERODRIN HG 197

BRACCO 0.6-1.4mCi/ML

N017269 001

CHLORMEZANONE

TABLET;ORAL

TRANCOPAL

SANOFI AVENTIS US 100MG

N011467 003

200MG

N011467 005

CHLOROPROCAINE HYDROCHLORIDE

INJECTABLE;INJECTION

CHLOROPROCAINE HYDROCHLORIDE

HOSPIRA 2%

A087447 001 Apr 16, 1982

3%

A087446 001 Apr 16, 1982

NESACAINE-MPF

FRESENIUS KABI USA 2%

N009435 003

3%

N009435 004

CHLOROQUINE HYDROCHLORIDE

INJECTABLE;INJECTION

ARALEN HYDROCHLORIDE

SANOFI AVENTIS US EQ 40MG BASE/ML

N006002 002

CHLOROQUINE PHOSPHATE

TABLET;ORAL

ARALEN

+ SANOFI AVENTIS US 500MG **

N006002 001

CHLOROQUINE PHOSPHATE

HIKMA PHARMS 250MG **

A083082 001

500MG **

A083082 002 Sep 17, 1999

MD PHARM 250MG

A087228 001

PUREPAC PHARM 250MG

A080886 001

TEVA 250MG

A087504 001 Jan 13, 1982

WATSON LABS 250MG

A087979 001 Dec 21, 1982

500MG

A088030 001 Dec 21, 1982

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-105(of 478)

** See List Footnote

CHLOROQUINE PHOSPHATE; PRIMAQUINE PHOSPHATE

TABLET;ORAL

ARALEN PHOSPHATE W/ PRIMAQUINE PHOSPHATE

SANOFI AVENTIS US EQ 300MG BASE;EQ 45MG BASE

N014860 002

CHLOROTHIAZIDE

TABLET;ORAL

CHLOROTHIAZIDE

ABC HOLDING 250MG

A085569 001

HIKMA INTL PHARMS 250MG

A086028 001 Jul 14, 1982

500MG

A087736 001 Jul 14, 1982

LEDERLE 250MG

A086940 001

500MG

A086938 001

MYLAN 250MG

A084217 002

500MG

A084217 001

SANDOZ 250MG

A085485 001

WATSON LABS 250MG

A085165 001

250MG

A085173 001

250MG

A086795 001 Aug 15, 1983

500MG

A084026 001 Sep 01, 1982

500MG

A086796 001 Aug 15, 1983

DIURIL

+ AKORN 250MG **

N011145 004

+ 500MG **

N011145 002

CHLOROTHIAZIDE; METHYLDOPA

TABLET;ORAL

ALDOCLOR-150

MERCK 150MG;250MG

N016016 001

ALDOCLOR-250

MERCK 250MG;250MG

N016016 002

METHYLDOPA AND CHLOROTHIAZIDE

PAR PHARM 150MG;250MG

A070783 001 Nov 06, 1987

250MG;250MG

A070654 001 Nov 06, 1987

CHLOROTHIAZIDE; RESERPINE

TABLET;ORAL

CHLOROTHIAZIDE AND RESERPINE

HIKMA 250MG;0.125MG

A088557 001 Dec 22, 1983

500MG;0.125MG

A088365 001 Dec 22, 1983

CHLOROTHIAZIDE W/ RESERPINE

WATSON LABS 250MG;0.125MG

A084853 001

500MG;0.125MG

A088151 001 Jun 09, 1983

CHLOROTHIAZIDE-RESERPINE

MYLAN 250MG;0.125MG

A087744 001 May 06, 1982

500MG;0.125MG

A087745 001 May 06, 1982

DIUPRES-250

MERCK 250MG;0.125MG

N011635 003 Aug 26, 1987

DIUPRES-500

MERCK 500MG;0.125MG

N011635 006 Aug 26, 1987

CHLOROTRIANISENE

CAPSULE;ORAL

CHLOROTRIANISENE

BANNER PHARMACAPS 12MG

A084652 001

TACE

SANOFI AVENTIS US 12MG

N008102 004

25MG

N011444 001

72MG

N016235 001

CHLOROXINE

SHAMPOO;TOPICAL

CAPITROL

WESTWOOD SQUIBB 2%

N017594 001

CHLORPHENESIN CARBAMATE

TABLET;ORAL

MAOLATE

PAMLAB LLC 400MG

N014217 002

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-106(of 478)

** See List Footnote

CHLORPHENIRAMINE MALEATE

CAPSULE, EXTENDED RELEASE;ORAL

CHLORPHENIRAMINE MALEATE

AUROLIFE PHARMA LLC 12MG

A070797 001 Aug 12, 1988

TELDRIN

GLAXOSMITHKLINE 8MG

N017369 001

12MG

N017369 002

INJECTABLE;INJECTION

CHLOR-TRIMETON

SCHERING PLOUGH 10MG/ML
100MG/ML

N008826 001

N008794 001

CHLORPHENIRAMINE MALEATE

BEL MAR 10MG/ML
ELKINS SINN 10MG/ML
WATSON LABS 10MG/ML
10MG/ML
100MG/ML

A080821 001

A080797 001

A083593 001

A086096 001

A086095 001

PYRIDAMAL 100

BEL MAR 100MG/ML

A083733 001

SYRUP;ORAL

CHLOR-TRIMETON

SCHERING 2MG/5ML

N006921 006

CHLORPHENIRAMINE MALEATE

PHARM ASSOC 2MG/5ML

A087520 001 Feb 10, 1982

TABLET;ORAL

ANTAGONATE

BAYER PHARMS 4MG

A083381 001

CHLOR-TRIMETON

SCHERING 4MG

N006921 002

CHLORPHENIRAMINE MALEATE

ANABOLIC 4MG

A083078 001

AUROLIFE PHARMA LLC 4MG

A080961 001

BELL PHARMA 4MG

A083062 001

ELKINS SINN 4MG

A080938 001

IMPAX LABS 4MG

A080809 001

IVAX SUB TEVA PHARMS 4MG

A080779 001

KV PHARM 4MG

A087164 001

LEDERLE 4MG

A086941 001

NEWTRON PHARMS 4MG

A086519 001

PANRAY 4MG

A083243 001

PHARMAVITE 4MG

A085104 001

PHARMERAL 4MG

A083753 001

PIONEER PHARMS 4MG

A088556 001 Jul 13, 1984

PUREPAC PHARM 4MG

A086306 001

PVT FORM 4MG

A080786 001

ROXANE 4MG

A080626 001

SUN PHARM INDUSTRIES 4MG

A080700 001

VITARINE 4MG

A085837 001

WATSON LABS 4MG

A080696 001

4MG

A080791 001

4MG

A085139 001

WEST WARD 4MG

A083787 001

KLOROMIN

HALSEY 4MG

A083629 001

PHENETRON

LANNETT 4MG

A080846 001

TABLET, EXTENDED RELEASE;ORAL

CHLOR-TRIMETON

+ BAYER HEALTHCARE LLC 8MG **

N007638 001

+ 12MG **

N007638 002

EFIDAC 24 CHLORPHENIRAMINE MALEATE

ALZA 16MG

N019746 002 Nov 18, 1994

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE

SOLUTION;ORAL

HYDROCODONE BITARTRATE AND CHLORPHENIRAMINE MALEATE

ACELLA 4MG/5ML;5MG/5ML

A206891 001 Jun 09, 2017

TRIS PHARMA INC 4MG/5ML;5MG/5ML

A206438 001 Jan 27, 2015

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-107(of 478)

** See List Footnote

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE

SOLUTION; ORAL

VITUZ

+ PERSION

4MG/5ML; 5MG/5ML

N204307 001 Feb 20, 2013

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION; ORAL

HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE

MAYNE PHARMA INC

4MG/5ML; 5MG/5ML; 60MG/5ML

A205657 001 Aug 03, 2015

TORRENT

4MG/5ML; 5MG/5ML; 60MG/5ML

A206660 001 May 15, 2017

TRIS PHARMA INC

4MG/5ML; 5MG/5ML; 60MG/5ML

A203838 001 Nov 26, 2014

ZUTRIPRO

+ PERSION

4MG/5ML; 5MG/5ML; 60MG/5ML **

N022439 001 Jun 08, 2011

CHLORPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

COLD CAPSULE IV

GRAHAM DM

12MG; 75MG

N018793 001 Apr 25, 1985

COLD CAPSULE V

GRAHAM DM

8MG; 75MG

N018794 001 Apr 23, 1985

TABLET, EXTENDED RELEASE; ORAL

TRIAMINIC-12

NOVARTIS

12MG; 75MG

N018115 001

CHLORPHENIRAMINE MALEATE; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

CODIMAL-L.A. 12

SCHWARZ PHARMA

12MG; 120MG

N018935 001 Apr 15, 1985

ISOCLOL

FISONS

8MG; 120MG

N018747 001 Mar 06, 1986

PSEUDOEPHEDRINE HYDROCHLORIDE AND CHLORPHENIRAMINE MALEATE

CENT PHARMS

8MG; 120MG

N019428 001 Aug 02, 1988

GRAHAM DM

8MG; 120MG

N018844 001 Mar 20, 1985

12MG; 120MG

N018843 001 Mar 18, 1985

KV PHARM

12MG; 120MG

A071455 001 Mar 01, 1989

CHLORPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

CHLOR-TRIMETON

+ BAYER HEALTHCARE LLC

8MG; 120MG

N018397 001

CHLORPHENIRAMINE POLISTIREX; CODEINE POLISTIREX

SUSPENSION, EXTENDED RELEASE; ORAL

CODEPREX

LANNETT CO INC

EQ 4MG MALEATE/5ML; EQ 20MG BASE/5ML

N021369 001 Jun 21, 2004

PENNTUSS

FISONS

EQ 4MG MALEATE/5ML; EQ 10MG BASE/5ML

N018928 001 Aug 14, 1985

TUZISTRA XR

+ TRIS PHARMA INC

EQ 2.8MG BASE/5ML; EQ 14.7MG BASE/5ML

N207768 001 Apr 30, 2015

CHLORPHENIRAMINE POLISTIREX; HYDROCODONE POLISTIREX

CAPSULE, EXTENDED RELEASE; ORAL

TUSSICAPS

ECR PHARMA

EQ 4MG MALEATE; EQ 5MG BITARTRATE

A077273 002 Sep 24, 2007

EQ 8MG MALEATE; EQ 10MG BITARTRATE

A077273 001 Sep 24, 2007

SUSPENSION, EXTENDED RELEASE; ORAL

HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX

NEOS THERAPS INC

EQ 8MG MALEATE/5ML; EQ 10MG

A091671 001 Jun 29, 2012

BITARTRATE/5ML

TUSSIONEX PENNKINETIC

+ UCB INC

EQ 8MG MALEATE/5ML; EQ 10MG

N019111 001 Dec 31, 1987

BITARTRATE/5ML **

CHLORPHENTERMINE HYDROCHLORIDE

TABLET; ORAL

PRE-SATE

PARKE DAVIS

EQ 65MG BASE

N014696 001

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-108(of 478)

** See List Footnote

CHLORPROMAZINE

SUPPOSITORY;RECTAL

THORAZINE

+	GLAXOSMITHKLINE	25MG **	N009149	024
+		100MG **	N009149	033

CHLORPROMAZINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

THORAZINE

GLAXOSMITHKLINE	30MG	N011120	016
	75MG	N011120	017
	150MG	N011120	018
	200MG	N011120	019
	300MG	N011120	020

CONCENTRATE;ORAL

CHLORPROMAZINE HYDROCHLORIDE

ACTAVIS MID ATLANTIC	100MG/ML	A086863	001	
PHARM ASSOC	30MG/ML	A040231	001	Dec 30, 1999
	100MG/ML	A040224	001	Jan 26, 1999
WOCKHARDT	30MG/ML	A087032	001	Jul 08, 1982
	100MG/ML	A087053	001	

CHLORPROMAZINE HYDROCHLORIDE INTENSOL

HIKMA	30MG/ML	A088157	001	Apr 27, 1983
	100MG/ML	A088158	001	Apr 27, 1983

SONAZINE

FOSUN PHARMA	30MG/ML	A080983	004
	100MG/ML	A080983	005

THORAZINE

+	GLAXOSMITHKLINE	30MG/ML **	N009149	032
+		100MG/ML **	N009149	043

INJECTABLE;INJECTION

CHLORPROMAZINE HYDROCHLORIDE

ABRAXIS PHARM	25MG/ML	A084911	001	
DR REDDYS	25MG/ML	A080365	001	
MARSAM PHARMS LLC	25MG/ML	A089563	001	Apr 15, 1988
WATSON LABS	25MG/ML	A085591	001	
WYETH AYERST	25MG/ML	A080370	001	

THORAZINE

+	GLAXOSMITHKLINE	25MG/ML **	N009149	011

SYRUP;ORAL

CHLORPROMAZINE HYDROCHLORIDE

ALPHARMA US PHARMS	10MG/5ML	A086712	001

SONAZINE

FOSUN PHARMA	10MG/5ML	A083040	001

THORAZINE

+	GLAXOSMITHKLINE	10MG/5ML **	N009149	022

TABLET;ORAL

CHLORPROMAZINE HYDROCHLORIDE

ABBOTT	10MG	A084414	001	
	25MG	A084415	001	
	50MG	A084411	001	
	100MG	A084412	001	
	200MG	A084413	001	
APPCO	10MG	A213590	001	Aug 31, 2020
	25MG	A213590	002	Aug 31, 2020
	50MG	A213590	003	Aug 31, 2020
	100MG	A213590	004	Aug 31, 2020
	200MG	A213590	005	Aug 31, 2020
CYCLE	10MG	A085331	001	
	25MG	A085331	002	
	50MG	A085331	003	
	100MG	A085331	004	
	200MG	A085331	005	
IVAX SUB TEVA PHARMS	10MG	A083549	001	
	25MG	A083549	002	
	50MG	A083549	003	
	100MG	A083574	001	
	200MG	A083575	001	
KV PHARM	10MG	A085750	002	Jan 04, 1982
	25MG	A085751	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-109(of 478)

** See List Footnote

CHLORPROMAZINE HYDROCHLORIDE

TABLET;ORAL

CHLORPROMAZINE HYDROCHLORIDE

	50MG	A085484	001	
	100MG	A085752	001	
	200MG	A085748	002	Jan 04, 1982
LEDERLE	10MG	A084803	001	
	25MG	A084801	001	
	50MG	A084800	001	
	100MG	A084789	001	
	200MG	A084802	001	
PUREPAC PHARM	10MG	A080403	004	
	25MG	A080403	001	
	50MG	A080403	002	
	100MG	A080403	003	
	200MG	A080403	005	
PVT FORM	25MG	A080340	001	
	50MG	A080340	002	
	200MG	A080340	003	
SANDOZ	10MG **	A080439	001	
	25MG **	A080439	002	
	50MG **	A080439	003	
	100MG **	A080439	004	
	200MG **	A080439	005	
VANGARD	10MG	A088038	001	Aug 16, 1982
	25MG	A087645	001	
	50MG	A087646	001	
WATSON LABS	10MG	A085959	001	
	25MG	A085956	001	
	50MG	A085960	001	
	100MG	A085957	001	
	200MG	A085958	001	
WEST WARD	10MG	A087783	001	Sep 16, 1982
	25MG	A087865	001	Sep 16, 1982
	50MG	A087878	001	Sep 15, 1982
	100MG	A087884	001	Sep 15, 1982
	200MG	A087880	001	Sep 16, 1982
PROMAPAR				
PARKE DAVIS	10MG	A086886	001	
	25MG	A084423	001	
	50MG	A086887	001	
	100MG	A086888	001	
	200MG	A086885	001	
THORAZINE				
GLAXOSMITHKLINE	10MG **	N009149	002	
	25MG **	N009149	007	
	50MG **	N009149	013	
	100MG **	N009149	018	
	200MG **	N009149	020	

CHLORPROPAMIDE

TABLET;ORAL

CHLORPROPAMIDE

ANI PHARMS	100MG	A088768	001	Oct 11, 1984
	100MG	A088812	001	Oct 19, 1984
	100MG	A088840	001	Oct 25, 1984
	100MG	A088918	001	Oct 16, 1984
	100MG	A088921	001	Apr 12, 1985
	100MG	A089446	001	Nov 17, 1986
	250MG	A087353	001	
	250MG	A088813	001	Oct 19, 1984
	250MG	A088826	001	Sep 26, 1984
	250MG	A088919	001	Oct 16, 1984
	250MG	A088922	001	Apr 12, 1985
	250MG	A089447	001	Nov 17, 1986
DAVA PHARMS INC	100MG	A089561	001	Sep 04, 1987
	250MG	A089562	001	Sep 04, 1987
HALSEY	100MG	A089321	001	Jan 16, 1986
	250MG	A088662	001	Jan 09, 1986
MYLAN	100MG	A088549	002	Jun 01, 1984

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-110(of 478)

** See List Footnote

CHLORPROPAMIDE

TABLET; ORAL

CHLORPROPAMIDE

	250MG	A088549 001	Jun 01, 1984
PAR PHARM	100MG	A088175 001	Feb 27, 1984
	250MG	A088176 001	Feb 27, 1984
RISING	100MG	A088725 001	Aug 31, 1984
	250MG	A088726 001	Aug 31, 1984
SANDOZ	250MG	A084669 001	
SUPERPHARM	100MG	A088694 001	Sep 17, 1984
	250MG	A088695 001	Sep 17, 1984
USL PHARMA	100MG	A088708 001	Aug 30, 1984
	250MG	A088709 001	Aug 30, 1984
WATSON LABS	100MG	A086865 001	Sep 24, 1984
	100MG	A088608 001	Apr 12, 1984
	250MG	A086866 001	
	250MG	A088568 001	Apr 12, 1984
WATSON LABS TEVA	100MG	A088852 001	Sep 26, 1984
DIABINESE			
+ PFIZER	100MG	N011641 003	
+	250MG	N011641 006	
GLUCAMIDE			
ANI PHARMS	250MG	A088641 001	Oct 11, 1984

CHLORPROTHIXENE

CONCENTRATE; ORAL

TARACTAN

ROCHE	100MG/5ML	N016149 002

INJECTABLE; INJECTION

TARACTAN

ROCHE

12.5MG/ML

N012487 001

TABLET; ORAL

TARACTAN

ROCHE

10MG

N012486 005

25MG

N012486 004

50MG

N012486 003

100MG

N012486 001

CHLORTETRACYCLINE HYDROCHLORIDE

OINTMENT; OPHTHALMIC

AUREOMYCIN

LEDERLE

1%

N050404 001

CHLORTHALIDONE

TABLET; ORAL

CHLORTHALIDONE

ABBOTT

25MG

A087364 001

50MG

A087384 001

ANI PHARMS

25MG

A087296 001

25MG

A087706 001

25MG

A088164 001 Jan 09, 1984

50MG

A087689 001

ASCOT

25MG

A087698 001 Oct 20, 1982

50MG

A087699 001 Oct 20, 1982

BARR LABS INC

25MG

A088902 001 Sep 19, 1985

50MG

A088903 001 Sep 19, 1985

COSETTE

50MG

A088651 001 May 30, 1985

DAVA PHARMS INC

25MG

A087451 001

50MG

A087450 001

IVAX PHARMS

25MG

A087555 001

50MG

A087176 001

50MG

A087947 001 Feb 27, 1984

KV PHARM

25MG

A087311 001

50MG

A087312 001

MUTUAL PHARM

25MG

A087292 001

25MG

A089738 001 Sep 19, 1988

50MG

A087293 001

50MG

A089739 001 Sep 19, 1988

PIONEER PHARMS

50MG

A089591 001 Jul 21, 1988

PUREPAC PHARM

25MG

A088139 001 Jul 16, 1986

50MG

A088140 001 Aug 11, 1983

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-111(of 478)

** See List Footnote

CHLORTHALIDONE

TABLET; ORAL

CHLORTHALIDONE

SANDOZ	25MG	A087380	001	
	50MG	A087118	001	
	50MG	A087381	001	
SUNNY	25MG	A209068	001	Jan 25, 2022
	50MG	A209068	002	Jan 25, 2022
SUPERPHARM	25MG	A087473	001	Feb 09, 1983
	50MG	A087247	001	Feb 09, 1983
USL PHARMA	25MG	A089051	001	Jun 01, 1987
	50MG	A089052	001	Jun 01, 1987
VANGARD	25MG	A088012	001	Jul 14, 1982
	50MG	A088073	001	Mar 25, 1983
WARNER CHILCOTT	25MG	A087515	001	Jan 24, 1983
	50MG	A087516	001	Feb 09, 1983
WATSON LABS	25MG	A087050	001	
	25MG	A087100	001	
	50MG	A087029	001	
	50MG	A087082	001	
	50MG	A087521	001	
HYGROTON				
+ SANOFI AVENTIS US	25MG **	N012283	004	
+	50MG **	N012283	003	
THALITONE				
MONARCH PHARMS	25MG	A088051	001	Nov 12, 1982

CHLORTHALIDONE; CLONIDINE HYDROCHLORIDE

TABLET; ORAL

CLONIDINE HYDROCHLORIDE AND CHLORTHALIDONE

PAR PHARM	15MG; 0.1MG	A071179	001	Dec 16, 1987
	15MG; 0.2MG	A071178	001	Dec 16, 1987
	15MG; 0.3MG	A071142	001	Dec 16, 1987
CLORPRES				
MYLAN	15MG; 0.1MG	A071325	003	Feb 09, 1987
	15MG; 0.2MG	A071325	002	Feb 09, 1987
	15MG; 0.3MG	A071325	001	Feb 09, 1987
COMBIPRES				
+ BOEHRINGER INGELHEIM	15MG; 0.1MG **	N017503	001	
+	15MG; 0.2MG **	N017503	002	
+	15MG; 0.3MG **	N017503	003	Apr 10, 1984

CHLORTHALIDONE; METOPROLOL TARTRATE

CAPSULE; ORAL

LOPRESSIDONE

NOVARTIS	25MG; 100MG	N019451	001	Dec 31, 1987
	25MG; 200MG	N019451	002	Dec 31, 1987

CHLORTHALIDONE; RESERPINE

TABLET; ORAL

DEMI-REGROTON

SANOFI AVENTIS US	25MG; 0.125MG	N015103	002	
REGROTON				
SANOFI AVENTIS US	50MG; 0.25MG	N015103	001	

CHLORZOXAZONE

TABLET; ORAL

CHLORZOXAZONE

ACTAVIS ELIZABETH	250MG	A088928	001	May 08, 1987
	500MG	A040113	001	Sep 29, 1995
BARR	500MG	A089895	001	May 04, 1988
GLENMARK PHARMS LTD	375MG	A212185	001	May 26, 2020
	750MG	A212185	002	May 26, 2020
OHM LABS	250MG	A081298	001	Dec 29, 1993
	500MG	A081299	001	Dec 29, 1993
PIONEER PHARMS	250MG	A089592	001	Jan 06, 1989
	500MG	A089948	001	Jan 06, 1989
RISING	250MG	A089852	001	May 04, 1988
STRIDES PHARMA	250MG	A087981	001	Sep 20, 1983
SUN PHARM INDUSTRIES	500MG	A089970	001	Sep 27, 1990
WATSON LABS	250MG	A086901	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-112(of 478)

** See List Footnote

CHLORZOXAZONE

TABLET; ORAL

CHLORZOXAZONE

250MG	A086948	001	Aug 09, 1982
500MG	A040137	001	Aug 09, 1996
500MG	A081019	001	Jul 29, 1991
500MG	A081040	001	Aug 22, 1989

PARAFLEX

+ ORTHO MCNEIL PHARM 250MG **

N011300 003

PARAFON FORTE DSC

+ JANSSEN R AND D 500MG **

N011529 002 Jun 15, 1987

STRIFON FORTE DSC

FERNDAL LABS 500MG

A081008 001 Dec 23, 1988

CHOLESTYRAMINE

BAR, CHEWABLE; ORAL

CHOLYBAR

PARKE DAVIS EQ 4GM RESIN/BAR

A071621 001 May 26, 1988

EQ 4GM RESIN/BAR

A071739 001 May 26, 1988

POWDER; ORAL

CHOLESTYRAMINE

IVAX SUB TEVA PHARMS EQ 4GM RESIN/PACKET

A074771 001 Jul 09, 1997

EQ 4GM RESIN/SCOOPFUL

A074771 002 Jul 09, 1997

TEVA

EQ 4GM RESIN/PACKET

A074347 001 May 28, 1998

EQ 4GM RESIN/SCOOPFUL

A074347 002 May 28, 1998

UPSHER SMITH LABS

EQ 4GM RESIN/PACKET

A214877 001 Jan 21, 2022

EQ 4GM RESIN/SCOOPFUL

A214877 002 Jan 21, 2022

CHOLESTYRAMINE LIGHT

TEVA

EQ 4GM RESIN/PACKET

A074348 001 May 28, 1998

EQ 4GM RESIN/SCOOPFUL

A074348 002 May 28, 1998

TEVA PHARMS

EQ 4GM RESIN/PACKET

A074555 001 Sep 30, 1998

EQ 4GM RESIN/SCOOPFUL

A074555 002 Sep 30, 1998

QUESTRAN

+ BRISTOL MYERS

EQ 4GM RESIN/PACKET **

N016640 001

+

EQ 4GM RESIN/SCOOPFUL **

N016640 003

QUESTRAN LIGHT

+ BRISTOL MYERS

EQ 4GM RESIN/PACKET **

N019669 001 Dec 05, 1988

+

EQ 4GM RESIN/SCOOPFUL **

N019669 003 Dec 05, 1988

TABLET; ORAL

QUESTRAN

APOTHECON

EQ 800MG RESIN

A073403 002 Dec 27, 1999

EQ 1GM RESIN

A073403 001 Apr 28, 1994

CHOLINE C-11

INJECTABLE; INTRAVENOUS

CHOLINE C-11

UCSF RODIOPHARM 4-33.1mCi/ML

A208444 001 Nov 20, 2017

UNIV TX MD ANDERSON 4-100mCi/ML

A205690 001 Oct 29, 2015

CHOLINE FENOFIBRATE

CAPSULE, DELAYED RELEASE; ORAL

FENOFIBRIC ACID

MYLAN PHARMS INC EQ 45MG FENOFIBRIC ACID

A200913 001 Mar 25, 2013

EQ 135MG FENOFIBRIC ACID

A200913 002 Mar 25, 2013

CHROMIC CHLORIDE

INJECTABLE; INJECTION

CHROMIC CHLORIDE

ABRAXIS PHARM EQ 0.004MG CHROMIUM/ML

N019271 001 May 05, 1987

CHROMIC PHOSPHATE P-32

INJECTABLE; INJECTION

PHOSPHOCOL P32

CURIUM 5mCi/ML

N017084 001

CICLOPIROX

GEL; TOPICAL

CICLOPIROX

+ ALVOGEN 0.77%

N020519 001 Jul 21, 1997

SOLUTION; TOPICAL

CICLOPIROX

AKORN 8%

A078975 001 Feb 17, 2010

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-113(of 478)

** See List Footnote

CICLOPIROX

SOLUTION; TOPICAL

CICLOPIROX

ENCUBE	8%	A077687	001	Sep 18, 2007
MYLAN PHARMS INC	8%	A078567	001	Sep 18, 2007
TEVA PHARMS	8%	A078079	001	Sep 18, 2007

CIDOFOVIR

INJECTABLE; INJECTION

VISTIDE

+ GILEAD SCIENCES INC	EQ 75MG BASE/ML **	N020638	001	Jun 26, 1996

CILASTATIN SODIUM; IMIPENEM

INJECTABLE; INJECTION

PRIMAXIN

MERCK	EQ 250MG BASE/VIAL; 250MG/VIAL	A062756	001	Jan 08, 1987
	EQ 500MG BASE/VIAL; 500MG/VIAL	A062756	002	Jan 08, 1987

POWDER; INTRAMUSCULAR

PRIMAXIN

MERCK	EQ 500MG BASE/VIAL; 500MG/VIAL	N050630	001	Dec 14, 1990
	EQ 750MG BASE/VIAL; 750MG/VIAL	N050630	002	Dec 14, 1990

POWDER; INTRAVENOUS

IMIPENEM AND CILASTATIN

HOSPIRA INC	EQ 250MG BASE/VIAL; 250MG/VIAL	A090825	001	Nov 16, 2011
	EQ 500MG BASE/VIAL; 500MG/VIAL	A090825	002	Nov 16, 2011
	EQ 500MG BASE/VIAL; 500MG/VIAL	A091007	001	Nov 16, 2011

PRIMAXIN

+ MERCK	EQ 250MG BASE/VIAL; 250MG/VIAL **	N050587	001	Nov 26, 1985

CILOSTAZOL

TABLET; ORAL

CILOSTAZOL

ACTAVIS ELIZABETH	100MG	A077028	002	Nov 26, 2004
EPIC PHARMA LLC	50MG	A077022	002	Mar 11, 2005
	100MG	A077022	001	Nov 23, 2004
HIKMA	50MG	A077024	001	May 17, 2005
	100MG	A077024	002	May 17, 2005
IVAX SUB TEVA PHARMS	100MG	A077020	002	Mar 01, 2005
MYLAN	50MG	A077323	002	Apr 20, 2006
	100MG	A077323	001	Apr 20, 2006
MYLAN PHARMS INC	50MG	A077019	001	Nov 23, 2004
	100MG	A077019	002	Nov 23, 2004
NOSTRUM LABS INC	50MG	A077708	001	Sep 28, 2009
	100MG	A077708	002	Sep 28, 2009
PLIVA HRVATSKA DOO	50MG	A077898	001	Oct 29, 2007
	100MG	A077898	002	Oct 29, 2007

PLETAL

+ OTSUKA	50MG **	N020863	001	Jan 15, 1999
+	100MG **	N020863	002	Jan 15, 1999

CIMETIDINE

SUSPENSION; ORAL

TAGAMET HB 200

GLAXOSMITHKLINE	200MG/20ML	N020951	001	Jul 09, 1999

TABLET; ORAL

CIMETIDINE

CHARTWELL MOLECULES	200MG	A074329	002	May 17, 1994
	300MG	A074329	003	May 17, 1994
	400MG	A074329	004	May 17, 1994
	800MG	A074329	001	May 17, 1994
CHARTWELL RX	200MG	A074100	001	Jan 31, 1995
	300MG	A074100	002	Jan 31, 1995
	400MG	A074100	003	Jan 31, 1995
	800MG	A074100	004	Jan 31, 1995
CONTRACT PHARMACAL	200MG	A074961	001	Jun 19, 1998
	200MG	A074963	001	Jun 19, 1998
CYCLE	300MG	A074361	001	Dec 23, 1994
	400MG	A074361	002	Dec 23, 1994
	800MG	A074371	001	Dec 23, 1994
HIKMA	200MG	A074890	001	Dec 18, 1998
	300MG	A074890	002	Dec 18, 1998

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-114(of 478)

** See List Footnote

CIMETIDINETABLET; ORAL
CIMETIDINE

	400MG	A074890	003	Dec 18, 1998
	800MG	A074890	004	Dec 18, 1998
IVAX SUB TEVA PHARMS	200MG	A074401	001	May 30, 1995
	200MG	A074424	001	Jul 28, 1995
	300MG	A074401	002	May 30, 1995
	300MG	A074424	002	Jul 28, 1995
	400MG	A074401	003	May 30, 1995
	400MG	A074424	003	Jul 28, 1995
	800MG	A074402	001	May 30, 1995
	800MG	A074424	004	Jul 28, 1995
NOVITIUM PHARMA	300MG	A074340	001	Jun 23, 1995
	400MG	A074340	002	Jun 23, 1995
	800MG	A074339	001	Jun 23, 1995
PERRIGO	100MG	A074972	001	Jun 19, 1998
PLIVA	200MG	A074568	001	Feb 27, 1997
	300MG	A074568	002	Feb 27, 1997
	400MG	A074568	003	Feb 27, 1997
SANDOZ INC	100MG	A075122	001	Jun 19, 1998
	200MG	A074250	001	Jun 29, 1995
	200MG	A075122	002	Jun 19, 1998
	300MG	A074250	002	Jun 29, 1995
	400MG	A074250	003	Jun 29, 1995
	800MG	A074250	004	Jun 29, 1995
TEVA	200MG	A074365	001	Feb 28, 1995
	300MG	A074365	002	Feb 28, 1995
	400MG	A074365	003	Feb 28, 1995
	800MG	A074365	004	Feb 28, 1995
UPSHER SMITH LABS	200MG	A074506	001	Jan 24, 1996
	300MG	A074506	002	Jan 24, 1996
	400MG	A074506	003	Jan 24, 1996
	800MG	A074506	004	Jan 24, 1996
WATSON LABS INC	200MG	A074349	001	Aug 30, 1996
	300MG	A074349	002	Aug 30, 1996
	400MG	A074349	003	Aug 30, 1996
	800MG	A074316	001	Feb 28, 1996
WATSON LABS TEVA	200MG	A075425	001	Jul 29, 1999
TAGAMET				
+ GLAXOSMITHKLINE	200MG **	N017920	002	
+	300MG **	N017920	003	
+	400MG **	N017920	004	Dec 14, 1983
+	800MG **	N017920	005	Apr 30, 1986
TAGAMET HB				
+ MEDTECH PRODUCTS	100MG **	N020238	001	Jun 19, 1995

CIMETIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

CIMETIDINE HYDROCHLORIDE

DAVA PHARMS INC	EQ 300MG BASE/2ML	A074428	001	Apr 25, 1996
HOSPIRA	EQ 300MG BASE/2ML	A074296	001	Mar 28, 1997
	EQ 300MG BASE/2ML	A074344	001	Jan 31, 1995
	EQ 300MG BASE/2ML	A074345	001	Jan 31, 1995
	EQ 300MG BASE/2ML	A074412	001	Mar 28, 1997
	EQ 300MG BASE/2ML	A074422	001	Jan 31, 1995
LUITPOLD	EQ 300MG BASE/2ML	A074353	001	Dec 20, 1994
TEVA PARENTERAL	EQ 300MG BASE/2ML	A074252	001	Nov 26, 1997
VINTAGE PHARMS LLC	EQ 300MG BASE/2ML	A074005	001	Aug 31, 1994
CIMETIDINE HYDROCHLORIDE IN	SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
HOSPIRA	EQ 6MG BASE/ML	A074269	001	Dec 27, 1994
	EQ 90MG BASE/100ML	A074468	005	Dec 29, 1994
	EQ 120MG BASE/100ML	A074468	006	Dec 29, 1994
	EQ 180MG BASE/100ML	A074468	003	Dec 29, 1994
	EQ 240MG BASE/100ML	A074468	004	Dec 29, 1994
	EQ 360MG BASE/100ML	A074468	001	Dec 29, 1994
	EQ 480MG BASE/100ML	A074468	002	Dec 29, 1994
TAGAMET				
GLAXOSMITHKLINE	EQ 300MG BASE/2ML **	N017939	002	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-115(of 478)

** See List Footnote

CIMETIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

TAGAMET HYDROCHLORIDE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

+ GLAXOSMITHKLINE

EQ 6MG BASE/ML **

N019434 001 Oct 31, 1985

SOLUTION; ORAL

CIMETIDINE HYDROCHLORIDE

ANI PHARMS

EQ 300MG BASE/5ML

A074610 001 Sep 26, 1996

EQ 300MG BASE/5ML

A074859 001 Jul 09, 1998

EQ 300MG BASE/5ML

A075110 001 Jun 18, 1998

CHARTWELL MOLECULAR

EQ 300MG BASE/5ML

A074251 001 Dec 22, 1994

CYCLE

EQ 300MG BASE/5ML

A074541 001 Aug 05, 1997

G AND W LABS INC

EQ 300MG BASE/5ML

A074176 001 Jun 01, 1994

PHARM ASSOC

EQ 300MG BASE/5ML

A075560 001 Mar 15, 2000

TAGAMET

GLAXOSMITHKLINE

EQ 300MG BASE/5ML **

N017924 001

CINACALCET HYDROCHLORIDE

TABLET; ORAL

CINACALCET HYDROCHLORIDE

AMNEAL PHARMS

30MG

A204364 001 Dec 02, 2021

60MG

A204364 002 Dec 02, 2021

90MG

A204364 003 Dec 02, 2021

LUPIN LTD

EQ 30MG BASE

A210548 001 Jun 28, 2019

EQ 60MG BASE

A210548 002 Jun 28, 2019

EQ 90MG BASE

A210548 003 Jun 28, 2019

MYLAN

EQ 30MG BASE

A203422 001 Oct 16, 2018

EQ 60MG BASE

A203422 002 Oct 16, 2018

EQ 90MG BASE

A203422 003 Oct 16, 2018

CINOXACIN

CAPSULE; ORAL

CINOBAC

LILLY

250MG

N018067 001

500MG

N018067 002

CINOXACIN

TEVA

250MG

A073005 001 Feb 28, 1992

500MG

A073006 001 Feb 28, 1992

CIPROFLOXACIN

FOR SUSPENSION; ORAL

CIPROFLOXACIN

CHARTWELL

250MG/5ML

A200563 001 Mar 05, 2014

500MG/5ML

A200563 002 Mar 05, 2014

INJECTABLE; INJECTION

CIPRO

+ BAYER HLTHCARE

400MG/40ML (10MG/ML) **

N019847 001 Dec 26, 1990

+

200MG/20ML (10MG/ML) **

N019847 002 Dec 26, 1990

1200MG/120ML (10MG/ML) **

N019847 003 Dec 26, 1990

CIPRO IN DEXTROSE 5% IN PLASTIC CONTAINER

+ BAYER HLTHCARE

200MG/100ML **

N019857 001 Dec 26, 1990

+

400MG/200ML **

N019857 002 Dec 26, 1990

CIPRO IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

BAYER PHARMS

200MG/100ML

N019858 001 Dec 26, 1990

CIPROFLOXACIN

BEDFORD LABS

200MG/20ML (10MG/ML)

A076992 001 Aug 28, 2006

400MG/40ML (10MG/ML)

A076992 002 Aug 28, 2006

1200MG/120ML (10MG/ML)

A076993 001 Aug 28, 2006

DR REDDYS

200MG/20ML (10MG/ML)

A077782 001 Aug 28, 2006

400MG/40ML (10MG/ML)

A077782 002 Aug 28, 2006

FRESENIUS KABI USA

200MG/20ML (10MG/ML)

A076484 001 Aug 28, 2006

400MG/40ML (10MG/ML)

A076484 002 Aug 28, 2006

HOSPIRA

200MG/20ML (10MG/ML)

A077245 001 Aug 28, 2006

400MG/40ML (10MG/ML)

A077245 002 Aug 28, 2006

CIPROFLOXACIN IN DEXTROSE 5%

HIKMA FARMACEUTICA

200MG/100ML

A076757 001 Apr 21, 2008

CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER

BAXTER HLTHCARE

200MG/100ML

A077888 001 Mar 18, 2008

400MG/200ML

A077888 002 Mar 18, 2008

BEDFORD

200MG/100ML

A078114 001 Mar 18, 2008

400MG/200ML

A078114 002 Mar 18, 2008

TEVA PHARMS

200MG/100ML

A077138 001 Mar 18, 2008

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-116(of 478)

** See List Footnote

CIPROFLOXACIN

INJECTABLE; INJECTION

CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER

400MG/200ML

A077138 002 Mar 18, 2008

CIPROFLOXACIN HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

CIPROFLOXACIN HYDROCHLORIDE

AMRING PHARMS

EQ 0.3% BASE

A078598 001 Jan 16, 2008

RUBICON

EQ 0.3% BASE

A075928 001 Jun 09, 2004

TABLET; ORAL

CIPRO

+ BAYER HLTHCARE

EQ 100MG BASE **

N019537 001 Apr 08, 1996

+

EQ 750MG BASE **

N019537 004 Oct 22, 1987

CIPROFLOXACIN HYDROCHLORIDE

AIPING PHARM INC

EQ 250MG BASE

A076593 002 Jun 09, 2004

EQ 500MG BASE

A076593 003 Jun 09, 2004

EQ 750MG BASE

A076593 004 Jun 09, 2004

AMNEAL

EQ 100MG BASE

A075939 001 Mar 03, 2005

EQ 250MG BASE

A075939 002 Jun 09, 2004

EQ 500MG BASE

A075939 003 Jun 09, 2004

EQ 750MG BASE

A075939 004 Jun 09, 2004

BARR

EQ 250MG BASE

A074124 001 Jun 09, 2004

EQ 500MG BASE

A074124 002 Jun 09, 2004

EQ 750MG BASE

A074124 003 Jun 09, 2004

MYLAN

EQ 250MG BASE

A075685 002 Jun 09, 2004

EQ 500MG BASE

A075685 003 Jun 09, 2004

EQ 750MG BASE

A075685 001 Jun 09, 2004

NOSTRUM LABS

EQ 250MG BASE

A076138 001 Jun 09, 2004

EQ 500MG BASE

A076138 002 Jun 09, 2004

EQ 750MG BASE

A076138 003 Jun 09, 2004

PLIVA

EQ 100MG BASE

A076426 001 Jun 15, 2005

EQ 250MG BASE

A076426 002 Jun 15, 2005

EQ 500MG BASE

A076426 003 Jun 15, 2005

EQ 750MG BASE

A076426 004 Jun 15, 2005

RISING

EQ 100MG BASE

A075817 001 Jun 25, 2007

EQ 250MG BASE

A075817 002 Jun 09, 2004

EQ 750MG BASE

A075817 004 Jun 09, 2004

SUN PHARM INDS LTD

EQ 250MG BASE

A075747 001 Jun 09, 2004

EQ 500MG BASE

A075747 002 Jun 09, 2004

EQ 750MG BASE

A075747 003 Jun 09, 2004

TEVA

EQ 250MG BASE

A076136 001 Jun 09, 2004

EQ 500MG BASE

A076136 002 Jun 09, 2004

EQ 750MG BASE

A076136 003 Jun 09, 2004

TABLET, EXTENDED RELEASE; ORAL

PROQUIN XR

DEPOMED INC

EQ 500MG BASE

N021744 001 May 19, 2005

CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

CIPRO XR

BAYER HLTHCARE

212.6MG; EQ 287.5MG BASE **

N021473 001 Dec 13, 2002

425.2MG; EQ 574.9MG BASE **

N021473 002 Aug 28, 2003

CIPROFLOXACIN EXTENDED RELEASE

ANI PHARMS

212.6MG; EQ 287.5MG BASE

A077809 002 Nov 30, 2010

425.2MG; EQ 574.9MG BASE

A077809 001 Nov 30, 2010

DR REDDYS LABS LTD

212.6MG; EQ 287.5MG BASE

A077701 002 Oct 31, 2007

FOSUN PHARMA

212.6MG; EQ 287.5MG BASE

A078712 001 Dec 11, 2007

MYLAN PHARMS INC

212.6MG; EQ 287.5MG BASE

A078183 001 Mar 22, 2007

425.2MG; EQ 574.9MG BASE

A078183 002 Mar 22, 2007

CISAPRIDE MONOHYDRATE

SUSPENSION; ORAL

PROPULSID

JANSSEN PHARMS

EQ 1MG BASE/ML

N020398 001 Sep 15, 1995

TABLET; ORAL

PROPULSID

JANSSEN PHARMS

EQ 10MG BASE

N020210 001 Jul 29, 1993

EQ 20MG BASE

N020210 002 Dec 23, 1993

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-117(of 478)

** See List Footnote

CISAPRIDE MONOHYDRATE

TABLET, ORALLY DISINTEGRATING;ORAL

PROPULSID QUICKSOLV

JANSSEN PHARMA

EQ 20MG BASE

N020767 001 Nov 07, 1997

CISATRACURIUM BESYLATE

INJECTABLE;INJECTION

CISATRACURIUM BESYLATE

ACCORD HLTHCARE

EQ 2MG BASE/ML

A205873 001 Jun 16, 2017

PIRAMAL HLTHCARE UK

EQ 2MG BASE/ML

A212190 001 May 04, 2020

EQ 2MG BASE/ML

A212432 001 Mar 11, 2022

EQ 10MG BASE/ML

A212432 002 Mar 11, 2022

ZYDUS PHARMS

EQ 2MG BASE/ML

A213527 001 Aug 31, 2020

CISATRACURIUM BESYLATE PRESERVATIVE FREE

ACCORD HLTHCARE

EQ 2MG BASE/ML

A205872 001 Jun 16, 2017

EQ 10MG BASE/ML

A205872 002 Jun 16, 2017

CISPLATIN

INJECTABLE;INJECTION

CISPLATIN

BEDFORD

10MG/VIAL

A074713 001 Nov 14, 2000

50MG/VIAL

A074713 002 Nov 14, 2000

MYLAN LABS LTD

1MG/ML

A091062 001 Apr 18, 2012

TEVA PHARMS USA

1MG/ML

A074814 001 May 16, 2000

PLATINOL

+ HQ SPCLT PHARMA

10MG/VIAL

N018057 001

PLATINOL-AQ

+ HQ SPCLT PHARMA

0.5MG/ML

N018057 003 Jul 18, 1984

CITALOPRAM HYDROBROMIDE

CAPSULE;ORAL

CITALOPRAM HYDROBROMIDE

MYLAN PHARMS INC

EQ 10MG BASE

A077668 001 Feb 28, 2007

EQ 20MG BASE

A077668 002 Feb 28, 2007

EQ 40MG BASE

A077668 003 Feb 28, 2007

SOLUTION;ORAL

CELEXA

+ FOREST LABS

EQ 10MG BASE/5ML **

N021046 001 Dec 22, 1999

CITALOPRAM HYDROBROMIDE

PHARM ASSOC

EQ 10MG BASE/5ML

A077601 001 Nov 15, 2005

TABLET;ORAL

CELEXA

ALLERGAN

EQ 60MG BASE

N020822 004 Jul 17, 1998

CITALOPRAM HYDROBROMIDE

EPIC PHARMA LLC

EQ 10MG BASE

A077036 001 Oct 28, 2004

EQ 20MG BASE

A077036 002 Oct 28, 2004

EQ 40MG BASE

A077036 003 Oct 28, 2004

FOSUN PHARMA

EQ 10MG BASE

A077035 001 Oct 28, 2004

EQ 10MG BASE

A077040 001 Aug 17, 2005

EQ 20MG BASE

A077035 002 Oct 28, 2004

EQ 20MG BASE

A077040 002 Aug 17, 2005

EQ 40MG BASE

A077035 003 Oct 28, 2004

EQ 40MG BASE

A077040 003 Aug 17, 2005

HERITAGE PHARMA

EQ 10MG BASE

A077033 001 Oct 28, 2004

EQ 10MG BASE

A077034 001 Jun 30, 2005

EQ 10MG BASE

A077213 001 Mar 31, 2006

EQ 10MG BASE

A077232 001 Oct 31, 2005

EQ 20MG BASE

A077033 002 Oct 28, 2004

EQ 20MG BASE

A077034 002 Jun 30, 2005

EQ 20MG BASE

A077213 002 Mar 31, 2006

EQ 20MG BASE

A077232 002 Oct 31, 2005

EQ 40MG BASE

A077033 003 Oct 28, 2004

EQ 40MG BASE

A077034 003 Jun 30, 2005

EQ 40MG BASE

A077213 003 Mar 31, 2006

EQ 40MG BASE

A077232 003 Oct 31, 2005

JUBILANT GENERICS

EQ 10MG BASE

A205407 001 Dec 23, 2015

EQ 20MG BASE

A205407 002 Dec 23, 2015

EQ 40MG BASE

A205407 003 Dec 23, 2015

MYLAN

EQ 10MG BASE

A077039 001 Feb 03, 2005

EQ 20MG BASE

A077039 002 Feb 03, 2005

EQ 40MG BASE

A077039 003 Feb 03, 2005

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-118(of 478)

** See List Footnote

CITALOPRAM HYDROBROMIDE

TABLET; ORAL

CITALOPRAM HYDROBROMIDE

MYLAN PHARMS INC	EQ 10MG BASE	A077037 001	Nov 05, 2004
	EQ 20MG BASE	A077037 002	Nov 05, 2004
	EQ 40MG BASE	A077037 003	Nov 05, 2004
NATCO PHARMA LTD	EQ 20MG BASE	A077141 002	Apr 10, 2008
	EQ 40MG BASE	A077141 001	Apr 10, 2008
ROXANE	EQ 10MG BASE	A077041 001	Nov 23, 2004
	EQ 20MG BASE	A077041 002	Nov 23, 2004
	EQ 40MG BASE	A077041 003	Nov 23, 2004
SUN PHARM INDS INC	EQ 10MG BASE	A077032 001	Nov 12, 2004
	EQ 20MG BASE	A077032 002	Nov 12, 2004
	EQ 40MG BASE	A077032 003	Nov 12, 2004
SUN PHARM INDUSTRIES	EQ 10MG BASE	A077052 001	Jul 03, 2006
	EQ 20MG BASE	A077052 002	Jul 03, 2006
	EQ 40MG BASE	A077052 003	Jul 03, 2006
TARO	EQ 10MG BASE	A077278 001	Mar 22, 2006
	EQ 20MG BASE	A077278 002	Mar 22, 2006
	EQ 40MG BASE	A077278 003	Mar 22, 2006

TABLET, ORALLY DISINTEGRATING; ORAL

CITALOPRAM HYDROBROMIDE

+	BIOVAIL LABS INTL	EQ 10MG BASE	N021763 001	Dec 20, 2005
+		EQ 20MG BASE	N021763 002	Dec 20, 2005
+		EQ 40MG BASE	N021763 003	Dec 20, 2005

CITRIC ACID; MAGNESIUM OXIDE; SODIUM CARBONATE

SOLUTION; IRRIGATION

IRRIGATING SOLUTION G IN PLASTIC CONTAINER

BAXTER HLTHCARE	3.24GM/100ML; 380MG/100ML; 430MG/100ML	N018519 001	Jun 22, 1982

UROLOGIC G IN PLASTIC CONTAINER

HOSPIRA	3.24GM/100ML; 380MG/100ML; 430MG/100ML	N018904 001	May 27, 1983

CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE

FOR SOLUTION; ORAL

PREPOPIK

+	FERRING PHARMS INC	12GM/PACKET; 3.5GM/PACKET; 10MG/PACKET **	N202535 001	Jul 16, 2012

CLADRIBINE

INJECTABLE; INJECTION

CLADRIBINE

MYLAN LABS LTD	1MG/ML	A200510 001	Oct 06, 2011

LEUSTATIN

+	JANSSEN PHARMS	1MG/ML **	N020229 001	Feb 26, 1993

CLARITHROMYCIN

FOR SUSPENSION; ORAL

BIAXIN

+	ABBVIE	125MG/5ML	N050698 001	Dec 23, 1993
		187MG/5ML	N050698 003	Sep 30, 1998
+		250MG/5ML	N050698 002	Dec 23, 1993

CLARITHROMYCIN

SUN PHARM INDS LTD	125MG/5ML	A065382 001	Aug 30, 2007
	250MG/5ML	A065382 002	Aug 30, 2007

TABLET; ORAL

BIAXIN

+	ABBVIE	250MG **	N050662 001	Oct 31, 1991
+		500MG **	N050662 002	Oct 31, 1991

CLARITHROMYCIN

AJANTA PHARMA LTD	250MG	A206714 001	Apr 25, 2019
	500MG	A206714 002	Apr 25, 2019
HIKMA	250MG	A065178 002	May 25, 2004
	500MG	A065178 001	May 25, 2004
IVAX SUB TEVA PHARMS	250MG	A065137 001	May 31, 2005
	500MG	A065137 002	May 31, 2005
MYLAN	250MG	A065195 001	Mar 11, 2005
	500MG	A065195 002	Mar 11, 2005
SUN PHARM INDS LTD	250MG	A065174 001	Sep 24, 2004
	500MG	A065174 002	Sep 24, 2004
WOCKHARDT	250MG	A065266 001	May 31, 2006
	500MG	A065266 002	May 31, 2006

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-119(of 478)

** See List Footnote

CLARITHROMYCIN

TABLET, EXTENDED RELEASE;ORAL

BIAXIN XL

+ ABBVIE 500MG **

N050775 001 Mar 03, 2000

CLARITHROMYCIN

ANI PHARMS 500MG

A065250 001 Aug 25, 2005

LUPIN LTD 500MG

A202532 001 Sep 15, 2015

NOSTRUM LABS INC 500MG

A203243 001 Feb 29, 2016

RANBAXY 1GM

A065210 001 Jan 26, 2005

CLAVULANATE POTASSIUM; TICARCILLIN DISODIUM

INJECTABLE; INJECTION

TIMENTIN

GLAXOSMITHKLINE EQ 100MG BASE/VIAL;EQ 3GM BASE/VIAL

A062691 001 Dec 19, 1986

EQ 100MG BASE/VIAL;EQ 3GM BASE/VIAL

N050590 001 Apr 01, 1985

EQ 200MG BASE/VIAL;EQ 3GM BASE/VIAL

N050590 002 Apr 01, 1985

EQ 1GM BASE/VIAL;EQ 30GM BASE/VIAL

N050590 003 Aug 18, 1987

TIMENTIN IN PLASTIC CONTAINER

GLAXOSMITHKLINE EQ 100MG BASE/100ML;EQ 3GM BASE/100ML

N050658 001 Dec 15, 1989

CLEMASTINE FUMARATE

SYRUP;ORAL

CLEMASTINE FUMARATE

ACTAVIS MID ATLANTIC EQ 0.5MG BASE/5ML

A074075 001 Oct 31, 1993

APOTEX INC EQ 0.5MG BASE/5ML

A075703 001 Nov 27, 2000

CHARTWELL MOLECULAR EQ 0.5MG BASE/5ML

A074884 001 Dec 17, 1997

TEVA PHARMS EQ 0.5MG BASE/5ML

A073095 001 Apr 21, 1992

WOCKHARDT BIO AG EQ 0.5MG BASE/5ML

A074863 001 Mar 13, 1998

TAVIST

+ NOVARTIS EQ 0.5MG BASE/5ML **

N018675 001 Jun 28, 1985

TABLET;ORAL

CLEMASTINE FUMARATE

ANI PHARMS 1.34MG

A073282 001 Jan 31, 1992

1.34MG

A073282 002 Dec 03, 1992

L PERRIGO CO 1.34MG

A074512 001 Nov 22, 1995

PLD ACQUISITIONS LLC 1.34MG

A073458 001 Oct 31, 1993

SANDOZ 2.68MG

A073459 001 Oct 31, 1993

TAVIST

+ NOVARTIS 2.68MG

N017661 001

TAVIST-1

+ GLAXOSMITHKLINE CONS 1.34MG **

N020925 001 Aug 21, 1992

NOVARTIS 1.34MG

N017661 002

1.34MG

N017661 003 Aug 21, 1992

CLEVIDIPINE

EMULSION; INTRAVENOUS

CLEVIPREX

+ CHIESI 125MG/250ML (0.5MG/ML)

N022156 003 Nov 08, 2013

CLIDINIUM BROMIDE

CAPSULE;ORAL

QUARZAN

ROCHE 2.5MG

N010355 001

5MG

N010355 002

CLINDAMYCIN HYDROCHLORIDE

CAPSULE;ORAL

CLEOCIN

PHARMACIA AND UPJOHN EQ 75MG BASE

A061809 001

EQ 150MG BASE

A061809 002

CLINDAMYCIN HYDROCHLORIDE

CHARTWELL MOLECULAR EQ 150MG BASE

A065243 003 Aug 12, 2005

EQ 300MG BASE

A065243 001 Aug 12, 2005

MYLAN PHARMS INC EQ 75MG BASE

A091225 001 May 31, 2011

EQ 150MG BASE

A091225 002 May 31, 2011

EQ 300MG BASE

A091225 003 May 31, 2011

TEVA EQ 75MG BASE

A063027 001 Sep 20, 1989

WATSON LABS EQ 75MG BASE

A063082 001 Jul 31, 1991

EQ 150MG BASE

A063083 001 Jul 31, 1991

EQ 300MG BASE

A063083 002 Mar 18, 2003

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-120(of 478)

** See List Footnote

CLINDAMYCIN PALMITATE HYDROCHLORIDE

FOR SOLUTION;ORAL

CLEOCIN

PHARMACIA AND UPJOHN EQ 75MG BASE/5ML **

A061827 001

CLINDAMYCIN PALMITATE HYDROCHLORIDE

MYLAN

EQ 75MG BASE/5ML

A203063 001 May 25, 2016

CLINDAMYCIN PHOSPHATE

CREAM;VAGINAL

CLEOCIN

PFIZER

EQ 2% BASE

N050680 001 Aug 11, 1992

INJECTABLE;INJECTION

CLEOCIN PHOSPHATE

PHARMACIA AND UPJOHN EQ 150MG BASE/ML

A061839 001

CLEOCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER

+ PFIZER

EQ 6MG BASE/ML **

N050639 001 Aug 30, 1989

+

EQ 12MG BASE/ML **

N050639 002 Aug 30, 1989

+

EQ 18MG BASE/ML **

N050639 003 Apr 10, 1991

CLINDAMYCIN PHOSPHATE

ABRAXIS PHARM

EQ 150MG BASE/ML

A062747 001 Jun 03, 1988

ALMAJECT

EQ 150MG BASE/ML

A062801 001 Jul 24, 1987

BEDFORD

EQ 150MG BASE/ML

A063163 001 Jun 30, 1994

BRISTOL MYERS SQUIBB

EQ 150MG BASE/ML

A062908 001 Feb 01, 1989

HIKMA

EQ 150MG BASE/ML

A062806 001 Oct 15, 1987

EQ 150MG BASE/ML

A062953 001 Apr 21, 1988

EQ 150MG BASE/ML

A063068 001 Aug 28, 1989

IGI LABS INC

EQ 150MG BASE/ML

A062928 001 Feb 13, 1989

LOCH

EQ 150MG BASE/ML

A062905 001 May 09, 1988

MARSAM PHARMS LLC

EQ 150MG BASE/ML

A062913 001 Oct 20, 1988

RISING

EQ 150MG BASE/ML

A204748 001 Oct 10, 2017

EQ 150MG BASE/ML

A204749 001 Oct 10, 2017

SOLOPAK

EQ 150MG BASE/ML

A062819 001 Mar 15, 1988

EQ 150MG BASE/ML

A062852 001 Mar 17, 1988

TEVA PARENTERAL

EQ 150MG BASE/ML

A063041 001 Dec 29, 1989

EQ 150MG BASE/ML

A063282 001 May 29, 1992

WATSON LABS

EQ 150MG BASE/ML

A062900 001 Jun 08, 1988

EQ 150MG BASE/ML

A063079 001 Mar 05, 1990

CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%

ABRAXIS PHARM

EQ 12MG BASE/ML

N050636 001 Dec 22, 1989

CLINDAMYCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER

ABBOTT LABS

EQ 6MG BASE/ML

A065027 001 Jun 29, 2001

EQ 12MG BASE/ML

A065027 002 Jun 29, 2001

EQ 18MG BASE/ML

A065027 003 Jun 29, 2001

BAXTER HLTHCARE

EQ 6MG BASE/ML

N050648 001 Dec 29, 1989

EQ 12MG BASE/ML

N050648 002 Dec 29, 1989

EQ 900MG BASE/100ML

N050648 003 Dec 29, 1989

SOLUTION;TOPICAL

CLEOCIN T

+ PFIZER

EQ 1% BASE

N050537 001

PHARMACIA AND UPJOHN

EQ 1% BASE

A062363 001 Feb 08, 1982

CLINDAMYCIN PHOSPHATE

BOCA PHARMA LLC

EQ 1% BASE

A062944 001 Jan 11, 1989

FOUGERA PHARMS

EQ 1% BASE

A065254 001 Feb 14, 2006

G AND W LABS INC

EQ 1% BASE

A062811 001 Sep 01, 1988

NOVAST LABS

EQ 1% BASE

A064108 001 Sep 27, 1996

VINTAGE PHARMS

EQ 1% BASE

A062930 001 Jun 28, 1989

EQ 1% BASE

A203343 001 May 29, 2015

WOCKHARDT BIO AG

EQ 1% BASE

A063304 001 Jul 15, 1997

SWAB;TOPICAL

CLEOCIN

+ PFIZER

EQ 1% BASE

N050537 002 Feb 22, 1994

CLIOQUINOL; NYSTATIN

OINTMENT;TOPICAL

NYSTAFORM

BAYER PHARMS

10MG/GM;100,000 UNITS/GM

N050235 001

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-121(of 478)

** See List Footnote

CLOBAZAM

SUSPENSION;ORAL

CLOBAZAM

HIKMA	2.5MG/ML	A209715	001	Oct 22, 2018
TEVA PHARMS USA	2.5MG/ML	A211032	001	Jan 31, 2020

TABLET;ORAL

CLOBAZAM

ACCORD HLTHCARE	10MG	A212398	001	May 23, 2019
	20MG	A212398	002	May 23, 2019
APOTEX	10MG	A209853	001	Jun 09, 2020
	20MG	A209853	002	Jun 09, 2020
BRECKENRIDGE	5MG	A209308	003	Oct 19, 2021
CELLTRION	10MG	A211959	001	Dec 09, 2020
	20MG	A211959	002	Dec 09, 2020
CHARTWELL MOLECULAR	10MG	A212092	001	Oct 30, 2019
	20MG	A212092	002	Oct 30, 2019
HIKMA	10MG	A208785	001	Oct 22, 2018
	20MG	A208785	002	Oct 22, 2018
TARO	10MG	A209440	001	Oct 22, 2018
	20MG	A209440	002	Oct 22, 2018

ONFI

+ LUNDBECK PHARMS LLC	5MG **	N202067	001	Oct 21, 2011

CLOBETASOL PROPIONATE

AEROSOL, FOAM;TOPICAL

CLOBETASOL PROPIONATE

INGENUS PHARMS LLC	0.05%	A206805	001	Jul 31, 2017

CREAM;TOPICAL

CLOBETASOL PROPIONATE

GLASSHOUSE PHARMS	0.05%	A211207	001	Mar 26, 2021
TEVA PHARMS USA	0.05%	A074087	001	Feb 16, 1994

EMBELINE E

AKORN	0.05%	A075325	001	Dec 24, 1998

TEMOVATE

+ FOUGERA PHARMS	0.05% **	N019322	001	Dec 27, 1985

TEMOVATE E

+ FOUGERA PHARMS	0.05% **	N020340	001	Jun 17, 1994

GEL;TOPICAL

TEMOVATE

+ FOUGERA PHARMS	0.05% **	N020337	001	Apr 29, 1994

LOTION;TOPICAL

CLOBETASOL PROPIONATE

AKORN	0.05%	A211348	001	Oct 26, 2018

OINTMENT;TOPICAL

CLOBETASOL PROPIONATE

ACTAVIS MID ATLANTIC	0.05%	A074128	001	Aug 03, 1994
AMNEAL	0.05%	A210551	001	Aug 21, 2018
TORRENT	0.05%	A212926	001	Oct 25, 2019

TEMOVATE

+ FOUGERA PHARMS	0.05% **	N019323	001	Dec 27, 1985

SOLUTION;TOPICAL

CLOBETASOL PROPIONATE

ENCUBE	0.05%	A076977	001	Aug 05, 2005
PRINSTON INC	0.05%	A213139	001	Feb 08, 2021
WOCKHARDT BIO AG	0.05%	A075205	001	Nov 13, 1998

TEMOVATE

+ FOUGERA PHARMS	0.05% **	N019966	001	Feb 22, 1990

SPRAY;TOPICAL

CLOBETASOL PROPIONATE

AKORN	0.05%	A207218	001	Apr 28, 2017
APOTEX	0.05%	A210446	001	Apr 17, 2018

CLOFARABINE

SOLUTION;INTRAVENOUS

CLOFARABINE

HOSPIRA	20MG/20ML (1MG/ML)	A210283	001	Dec 27, 2018
NOVAST LABS	20MG/20ML (1MG/ML)	A210270	001	Sep 14, 2018

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-122(of 478)

** See List Footnote

CLOFAZIMINE

CAPSULE;ORAL

LAMPRENE

+ NOVARTIS

50MG

N019500 002 Dec 15, 1986

100MG

N019500 001 Dec 15, 1986

CLOFIBRATE

CAPSULE;ORAL

ATROMID-S

WYETH AYERST

500MG

N016099 002

CLOFIBRATE

BANNER PHARMACAPS

500MG

A073396 001 Mar 20, 1992

SANDOZ

500MG

A072191 001 May 02, 1988

TEVA

500MG

A072600 001 Jul 25, 1991

USL PHARMA

500MG

A070531 001 Jun 16, 1986

WATSON LABS

500MG

A071603 001 Sep 18, 1987

CLOMIPHENE CITRATE

TABLET;ORAL

CLOMID

+ SANOFI AVENTIS US

50MG **

N016131 002

MILOPHENE

GRANATA BIO

50MG

A072196 001 Dec 20, 1988

SEROPHENE

EMD SERONO

50MG

N018361 001 Mar 22, 1982

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE;ORAL

CLOMIPRAMINE HYDROCHLORIDE

TEVA

25MG

A074849 001 Apr 04, 1997

25MG

A074958 001 Aug 26, 1997

50MG

A074849 002 Apr 04, 1997

50MG

A074958 002 Aug 26, 1997

75MG

A074849 003 Apr 04, 1997

75MG

A074958 003 Aug 26, 1997

WATSON LABS

25MG

A074600 001 Nov 27, 1996

25MG

A074751 001 Sep 30, 1998

50MG

A074600 002 Nov 27, 1996

50MG

A074751 002 Sep 30, 1998

75MG

A074600 003 Nov 27, 1996

75MG

A074751 003 Sep 30, 1998

CLONAZEPAM

TABLET;ORAL

CLONAZEPAM

AUROBINDO PHARMA USA

0.5MG

A075150 001 Oct 05, 1998

1MG

A075150 002 Oct 05, 1998

2MG

A075150 003 Oct 05, 1998

MYLAN PHARMS INC

0.5MG

A074940 001 Oct 30, 1997

1MG

A074940 002 Oct 30, 1997

2MG

A074940 003 Oct 30, 1997

SANDOZ

0.5MG

A074925 001 Sep 30, 1997

1MG

A074925 002 Sep 30, 1997

2MG

A074925 003 Sep 30, 1997

SUN PHARM INDS INC

0.5MG

A075423 001 Apr 27, 2001

1MG

A075423 002 Apr 27, 2001

2MG

A075423 003 Apr 27, 2001

TEVA

0.5MG

A074920 001 Aug 04, 1998

1MG

A074920 002 Aug 04, 1998

2MG

A074920 003 Aug 04, 1998

WATSON LABS

0.5MG

A074964 001 Dec 30, 1997

1MG

A074964 002 Dec 30, 1997

2MG

A074964 003 Dec 30, 1997

KLONOPIN

CHEPLAPHARM

0.125MG

N017533 005 Apr 09, 1997

0.25MG

N017533 006 Apr 09, 1997

TABLET, ORALLY DISINTEGRATING;ORAL

KLONOPIN RAPIDLY DISINTEGRATING

+ ROCHE

0.125MG **

N020813 001 Dec 23, 1997

+

0.25MG **

N020813 002 Dec 23, 1997

+

0.5MG **

N020813 003 Dec 23, 1997

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-123(of 478)

** See List Footnote

CLONAZEPAMTABLET, ORALLY DISINTEGRATING;ORAL
KLONOPIN RAPIDLY DISINTEGRATING+ 1MG **
+ 2MG **N020813 004 Dec 23, 1997
N020813 005 Dec 23, 1997CLONIDINESUSPENSION, EXTENDED RELEASE;ORAL
CLONIDINE

TRIS PHARMA INC EQ 0.09MG BASE/ML

N022499 001 Dec 03, 2009

TABLET, EXTENDED RELEASE;ORAL

NEXICLON XR

ATHENA EQ 0.26MG BASE

N022500 002 Dec 03, 2009

CLONIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

CLONIDINE HYDROCHLORIDE

AM REGENT 1MG/10ML (0.1MG/ML)
5MG/10ML (0.5MG/ML)A091104 001 Oct 08, 2009
A091104 002 Oct 08, 2009

DURACLON

+ MYLAN INSTITUTIONAL 5MG/10ML (0.5MG/ML) **

N020615 002 Apr 27, 1999

TABLET;ORAL

CATAPRES

+ BOEHRINGER INGELHEIM 0.1MG
+ 0.2MG
+ 0.3MGN017407 001
N017407 002
N017407 003

CLONIDINE HYDROCHLORIDE

AM THERAP 0.1MG
0.2MG
0.3MGA070881 001 Jul 08, 1986
A070882 001 Jul 08, 1986
A070883 001 Jul 08, 1986DURAMED PHARMS BARR 0.1MG
0.2MG
0.3MGA071103 001 Aug 14, 1986
A071102 001 Aug 14, 1986
A071101 001 Aug 14, 1986INTERPHARM 0.1MG
0.2MG
0.3MGA071252 001 Oct 01, 1986
A071253 001 Oct 01, 1986
A071254 001 Oct 01, 1986PAR PHARM 0.1MG
0.2MG
0.3MGA070461 001 Jul 08, 1986
A070460 001 Jul 08, 1986
A070459 001 Jul 08, 1986RISING 0.1MG
0.2MG
0.3MGA070317 002 Jul 09, 1987
A070317 003 Jun 09, 1987
A070317 001 Jun 09, 1987SUN PHARM INDS INC 0.1MG
0.2MG
0.3MGA090329 001 Jul 03, 2014
A090329 002 Jul 03, 2014
A090329 003 Jul 03, 2014TEVA 0.1MG
0.2MG
0.3MGA070747 001 Jul 08, 1986
A070702 001 Jul 08, 1986
A070659 001 Jul 08, 1986WARNER CHILCOTT 0.1MG
0.2MG
0.3MGA072138 001 Jun 13, 1988
A072139 001 Jun 13, 1988
A072140 001 Jun 13, 1988WATSON LABS 0.1MG
0.1MG
0.2MGA070395 001 Mar 23, 1987
A070965 001 Jul 08, 1986
A070396 001 Mar 23, 19870.2MG
0.3MG
0.3MGA070964 001 Jul 08, 1986
A070397 001 Mar 23, 1987
A070963 001 Jul 08, 1986

TABLET, EXTENDED RELEASE;ORAL

CLONIDINE HYDROCHLORIDE

ACTAVIS ELIZABETH 0.2MG
0.2MGA202792 002 May 15, 2015
A203320 002 May 15, 2015ANCHEN PHARMS 0.1MG
0.2MG
0.2MGA202983 001 Apr 02, 2014
A202983 002 Apr 02, 2014
A202984 002 Sep 30, 2013

MAYNE PHARMA INC 0.1MG

A210680 001 Apr 30, 2018

UPSHER SMITH LABS 0.1MG

A211433 001 Oct 12, 2018

JENLOGA

+ CONCORDIA PHARMS INC 0.1MG **
+ 0.2MG **N022331 001 Sep 30, 2009
N022331 002 May 25, 2010

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-124(of 478)

** See List Footnote

CLONIDINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

KAPVAY

+ CONCORDIA PHARMS INC 0.2MG **

N022331 004 Sep 28, 2010

CLOPIDOGREL BISULFATE

TABLET;ORAL

CLOPIDOGREL BISULFATE

ACTAVIS TOTOWA EQ 75MG BASE
 ANI PHARMS EQ 300MG BASE
 EQ 300MG BASE
 CADILA EQ 75MG BASE
 CELLTRION EQ 75MG BASE
 EQ 300MG BASE
 RISING EQ 75MG BASE
 EQ 300MG BASE
 SUN PHARM INDUSTRIES EQ 75MG BASE

A090307 001 May 28, 2013
 A090625 001 May 17, 2012
 A091216 001 May 17, 2012
 A201686 001 Oct 10, 2012
 A202266 001 Aug 14, 2012
 A202266 002 Nov 20, 2012
 A077665 001 May 17, 2012
 A077665 002 May 17, 2012
 A078133 001 Jun 10, 2013

CLORAZEPATE DIPOTASSIUM

CAPSULE;ORAL

CLORAZEPATE DIPOTASSIUM

ABLE 3.75MG
 7.5MG
 15MG
 AM THERAP 3.75MG
 7.5MG
 15MG
 DAVA PHARMS INC 3.75MG
 7.5MG
 15MG
 GD SEARLE LLC 3.75MG
 7.5MG
 15MG
 MYLAN 3.75MG
 7.5MG
 15MG
 PUREPAC PHARM 3.75MG
 7.5MG
 15MG
 QUANTUM PHARMICS 3.75MG
 7.5MG
 15MG
 RISING 3.75MG
 7.5MG
 15MG
 USL PHARMA 3.75MG
 7.5MG
 15MG
 WARNER CHILCOTT 3.75MG
 7.5MG
 15MG
 WATSON LABS 3.75MG
 7.5MG
 15MG

A071777 001 Jul 14, 1987
 A071778 001 Jul 14, 1987
 A071779 001 Jul 14, 1987
 A071429 001 Jun 23, 1987
 A071430 001 Jun 23, 1987
 A071431 001 Jun 23, 1987
 A071742 001 Dec 14, 1987
 A071743 001 Dec 14, 1987
 A071744 001 Dec 14, 1987
 A071727 001 Dec 18, 1987
 A071728 001 Dec 18, 1987
 A071729 001 Dec 18, 1987
 A071509 001 Oct 19, 1987
 A071510 001 Oct 19, 1987
 A071511 001 Oct 19, 1987
 A071924 001 Apr 25, 1988
 A071925 001 Apr 25, 1988
 A071926 001 Apr 25, 1988
 A071549 001 Sep 12, 1988
 A071550 001 Sep 12, 1988
 A071522 001 Sep 12, 1988
 A072112 002 Aug 26, 1988
 A072112 003 Aug 26, 1988
 A072112 001 Aug 26, 1988
 A071242 001 Jun 23, 1987
 A071243 001 Jun 23, 1987
 A071244 001 Jun 23, 1987
 A071774 001 Mar 01, 1988
 A071775 001 Mar 01, 1988
 A071776 001 Mar 01, 1988
 A071878 001 Mar 15, 1988
 A071879 001 Mar 15, 1988
 A071860 001 Mar 15, 1988

TRANXENE

+ KEY THERAP 3.75MG **
 + 7.5MG **
 + 15MG **

N017105 001
 N017105 002
 N017105 003

TABLET;ORAL

CLORAZEPATE DIPOTASSIUM

ABLE 3.75MG
 7.5MG
 15MG
 AM THERAP 3.75MG
 7.5MG
 15MG
 AUROLIFE PHARMA LLC 3.75MG
 7.5MG
 15MG
 LEDERLE 3.75MG

A071780 001 Jun 26, 1987
 A071781 001 Jun 26, 1987
 A071782 001 Jun 26, 1987
 A071747 001 Jun 23, 1987
 A071748 001 Jun 23, 1987
 A071749 001 Jun 23, 1987
 A072514 002 May 11, 1990
 A072514 003 May 11, 1990
 A072514 001 May 11, 1990
 A072013 001 Dec 15, 1987

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-125(of 478)

** See List Footnote

CLORAZEPATE DIPOTASSIUM

TABLET;ORAL

CLORAZEPATE DIPOTASSIUM

	7.5MG	A072014	001	Dec 15, 1987
	15MG	A072015	001	Dec 15, 1987
PUREPAC PHARM	3.75MG	A072330	001	Aug 08, 1988
	7.5MG	A072331	001	Aug 08, 1988
	15MG	A072332	001	Aug 08, 1988
QUANTUM PHARMICS	3.75MG	A071730	001	Oct 26, 1987
	7.5MG	A071731	001	Oct 26, 1987
	15MG	A071702	001	Oct 26, 1987
SUN PHARM INDS LTD	3.75MG	A076911	001	Sep 29, 2004
	7.5MG	A076911	002	Sep 29, 2004
	15MG	A076911	003	Sep 29, 2004
WARNER CHILCOTT	3.75MG	A071828	001	Mar 03, 1988
	7.5MG	A071829	001	Mar 03, 1988
	15MG	A071830	001	Mar 03, 1988
WATSON LABS	3.75MG	A071852	001	Feb 09, 1988
	7.5MG	A071853	001	Feb 09, 1988
	15MG	A071854	001	Feb 09, 1988
GEN-XENE				
ALRA	3.75MG	A071787	001	Apr 26, 1988
	7.5MG	A071788	001	Apr 26, 1988
	15MG	A071789	001	Apr 26, 1988
TRANXENE				
+ KEY THERAP	3.75MG **	N017105	006	
+	15MG **	N017105	008	
TRANXENE SD				
+ KEY THERAP	11.25MG **	N017105	005	
+	22.5MG **	N017105	004	

CLOTRIMAZOLE

CREAM;TOPICAL

LOTRIMIN

SCHERING PLOUGH	1% **	N017619	001	
MYCELEX				
BAYER HEALTHCARE LLC	1%	N018183	001	
CREAM;VAGINAL				
GYNE-LOTRIMIN				
+ BAYER HEALTHCARE LLC	1% **	N018052	002	Nov 30, 1990
GYNE-LOTRIMIN 3				
+ BAYER HEALTHCARE LLC	2%	N020574	001	Nov 24, 1998
MYCELEX-7				
BAYER HEALTHCARE LLC	1%	N018230	002	Dec 26, 1991
CREAM, TABLET;TOPICAL, VAGINAL				
GYNE-LOTRIMIN 3 COMBINATION PACK				
+ BAYER HEALTHCARE LLC	1%,200MG	N020526	002	Jul 29, 1996
GYNE-LOTRIMIN COMBINATION PACK				
+ BAYER HEALTHCARE LLC	1%,100MG	N020289	002	Apr 26, 1993
MYCELEX-7 COMBINATION PACK				
BAYER HEALTHCARE LLC	1%,100MG	N020389	002	Jun 23, 1994
LOTION;TOPICAL				
LOTRIMIN				
SCHERING	1%	N018813	001	Feb 17, 1984
SOLUTION;TOPICAL				
LOTRIMIN				
+ SCHERING PLOUGH	1% **	N017613	001	
MYCELEX				
+ BAYER HLTHCARE	1% **	N018181	001	
TABLET;VAGINAL				
GYNE-LOTRIMIN				
+ BAYER HEALTHCARE LLC	100MG	N017717	002	Nov 30, 1990
GYNE-LOTRIMIN 3				
+ BAYER HEALTHCARE LLC	200MG	N020525	001	Jul 29, 1996
GYNIX				
TEVA PHARMS	100MG	A073249	001	Feb 13, 1998
MYCELEX-7				
BAYER HEALTHCARE LLC	100MG	N018182	002	Dec 26, 1991

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-126(of 478)

** See List Footnote

CLOTRIMAZOLE

TABLET;VAGINAL

MYCELEX-G

BAYER PHARMS

500MG

N019069 001 Apr 19, 1985

TROCHE/LOZENGE;ORAL

MYCELEX

+ BAYER HLTHCARE

10MG **

N018713 001 Jun 17, 1983

CLOXACILLIN SODIUM

CAPSULE;ORAL

CLOXACILLIN SODIUM

APOTHECON

EQ 250MG BASE

A061452 001

EQ 500MG BASE

A061452 002

TEVA

EQ 250MG BASE

A062240 001

EQ 500MG BASE

A062240 002

CLOXAPEN

GLAXOSMITHKLINE

EQ 250MG BASE

A061806 001

EQ 250MG BASE

A062233 001

EQ 500MG BASE

A061806 002

EQ 500MG BASE

A062233 002

FOR SOLUTION;ORAL

CLOXACILLIN SODIUM

TEVA

EQ 125MG BASE/5ML

A062268 001

EQ 125MG BASE/5ML

A062978 001 Apr 06, 1989

TEGOPEN

APOTHECON

EQ 125MG BASE/5ML

A061453 001

EQ 125MG BASE/5ML

N050192 001

CLOZAPINE

TABLET;ORAL

CLOZAPINE

MYLAN

12.5MG

A075417 003 Apr 15, 2010

PAR PHARM

25MG

A075162 001 Apr 26, 2005

100MG

A075162 002 Apr 26, 2005

SANDOZ

25MG

A074546 001 Aug 30, 1996

100MG

A074546 002 Aug 30, 1996

ZYDUS PHARMS

25MG

A209480 001 Dec 06, 2017

50MG

A209480 002 Dec 06, 2017

100MG

A209480 003 Dec 06, 2017

200MG

A209480 004 Dec 06, 2017

TABLET, ORALLY DISINTEGRATING;ORAL

FAZACLO ODT

+ JAZZ

12.5MG **

N021590 004 May 30, 2007

+

25MG **

N021590 001 Feb 10, 2004

50MG **

N021590 003 Jun 03, 2005

+

100MG **

N021590 002 Feb 10, 2004

+

150MG **

N021590 005 Jul 09, 2010

+

200MG **

N021590 006 Jul 09, 2010

CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PHENERGAN VC W/ CODEINE

+ ANI PHARMS

10MG/5ML;5MG/5ML;6.25MG/5ML **

N008306 005 Apr 02, 1984

PHERAZINE VC W/ CODEINE

HALSEY

10MG/5ML;5MG/5ML;6.25MG/5ML

A088870 001 Mar 02, 1987

PROMETH VC W/ CODEINE

NOSTRUM LABS INC

10MG/5ML;5MG/5ML;6.25MG/5ML

A088764 001 Oct 31, 1984

PROMETHAZINE VC W/ CODEINE

CENCI

10MG/5ML;5MG/5ML;6.25MG/5ML

A088816 001 Nov 22, 1985

WOCKHARDT

10MG/5ML;5MG/5ML;6.25MG/5ML

A088896 001 Jan 04, 1985

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PHENERGAN W/ CODEINE

+ ANI PHARMS

10MG/5ML;6.25MG/5ML **

N008306 004 Apr 02, 1984

PHERAZINE W/ CODEINE

HALSEY

10MG/5ML;6.25MG/5ML

A088739 001 Dec 23, 1988

PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE

PHARM ASSOC

10MG/5ML;6.25MG/5ML

A089647 001 Dec 22, 1988

PROMETHAZINE W/ CODEINE

CENCI

10MG/5ML;6.25MG/5ML

A088814 001 Nov 22, 1985

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-127(of 478)

** See List Footnote

CODEINE PHOSPHATE; PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

SYRUP; ORAL

ACTIFED W/ CODEINE

GLAXOSMITHKLINE 10MG/5ML; 30MG/5ML; 1.25MG/5ML

N012575 003 Apr 04, 1984

TRIPROLIDINE AND PSEUDOEPHEDRINE HYDROCHLORIDES W/ CODEINE

CENCI 10MG/5ML; 30MG/5ML; 1.25MG/5ML

A089018 001 Jul 23, 1986

TRIPROLIDINE HYDROCHLORIDE, PSEUDOEPHEDRINE HYDROCHLORIDE AND CODEINE PHOSPHATE

WOCKHARDT 10MG/5ML; 30MG/5ML; 1.25MG/5ML

A088833 001 Nov 16, 1984

CODEINE SULFATE

SOLUTION; ORAL

CODEINE SULFATE

HIKMA 30MG/5ML

N202245 001 Jun 30, 2011

COLCHICINE

CAPSULE; ORAL

COLCHICINE

PAR PHARM INC 0.6MG

A208678 001 Nov 29, 2018

COLCHICINE; PROBENECID

TABLET; ORAL

COLBENEMID

+ MERCK 0.5MG; 500MG **

N012383 001

PROBEN-C

WATSON LABS 0.5MG; 500MG

A085552 001

PROBENECID AND COLCHICINE

ANI PHARMS 0.5MG; 500MG

A083734 001

BEECHAM 0.5MG; 500MG

A084321 001

IMPAX LABS 0.5MG; 500MG

A083720 002

SANDOZ 0.5MG; 500MG

A086130 001

PROBENECID W/ COLCHICINE

LEDERLE 0.5MG; 500MG

A086954 001

WATSON LABS 0.5MG; 500MG

A083221 001

COLESEVELAM HYDROCHLORIDE

BAR, CHEWABLE; ORAL

WELCHOL

+ COSETTE 3.75GM

N210895 001 Apr 03, 2019

CAPSULE; ORAL

WELCHOL

COSETTE 375MG

N021141 001 May 26, 2000

FOR SUSPENSION; ORAL

COLESEVELAM HYDROCHLORIDE

WATSON LABS INC 1.875GM/PACKET

A202178 001 Sep 01, 2020

3.75GM/PACKET

A202178 002 Sep 01, 2020

WELCHOL

+ COSETTE 1.875GM/PACKET **

N022362 001 Oct 02, 2009

TABLET; ORAL

COLESEVELAM HYDROCHLORIDE

INVAGEN PHARMS 625MG

A212602 001 Apr 20, 2020

LUPIN LTD 625MG

A201354 001 Dec 17, 2020

WATSON LABS INC 625MG

A200830 001 Sep 02, 2020

COLISTIN SULFATE

SUSPENSION; ORAL

COLY-MYCIN S

PARKE DAVIS EQ 25MG BASE/5ML

N050355 001

CONIVAPTAN HYDROCHLORIDE

INJECTABLE; INTRAVENOUS

VAPRISOL

CUMBERLAND PHARMS 20MG/4ML (5MG/ML)

N021697 001 Dec 29, 2005

COPPER

INTRAUTERINE DEVICE; INTRAUTERINE

CU-7

GD SEARLE LLC 89MG

N017408 001

TATUM-T

GD SEARLE LLC 120MG

N018205 001

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-128(of 478)

** See List Footnote

CORTICOTROPIN

INJECTABLE; INJECTION

ACTH

PARKEDALE	25 UNITS/VIAL	N008317 002
	40 UNITS/VIAL	N008317 004

ACTHAR

SANOFI AVENTIS US	25 UNITS/VIAL	N007504 002
	40 UNITS/VIAL	N007504 003

ACTHAR GEL

MALLINCKRODT ARD	40 UNITS/ML	N008372 006

CORTICOTROPIN

ORGANICS LAGRANGE	40 UNITS/ML	N010831 001
	80 UNITS/ML	N010831 002

WATSON LABS

PURIFIED CORTROPHIN GEL

ANI PHARMS	40 UNITS/VIAL	A088772 001	Nov 21, 1984

	40 UNITS/ML	N008975 001

CORTICOTROPIN-ZINC HYDROXIDE

INJECTABLE; INJECTION

CORTROPHIN-ZINC

ANI PHARMS	40 UNITS/ML	N009854 001

CORTISONE ACETATE

INJECTABLE; INJECTION

CORTISONE ACETATE

PHARMACIA AND UPJOHN	25MG/ML	N008126 002
WATSON LABS	25MG/ML	A083147 003
	25MG/ML	A085677 001
	50MG/ML	A083147 004
	50MG/ML	A085677 002

CORTONE

MERCK	25MG/ML	N007110 002
	50MG/ML	N007110 003

TABLET; ORAL

CORTISONE ACETATE

BARR	25MG	A083471 001
CHARTWELL MOLECULAR	25MG	A080694 001
ELKINS SINN	25MG	A080836 001
EVERYLIFE	25MG	A084246 001
HEATHER	25MG	A085736 001
IMPAX LABS	25MG	N009458 001
INWOOD LABS	25MG	A080731 001
IVAX SUB TEVA PHARMS	25MG	A080630 001
	25MG	A083536 001
PANRAY	5MG	N008284 002
	25MG	N008284 001
PHARMACIA AND UPJOHN	5MG	N008126 003
	10MG	N008126 004
	25MG	N008126 001
PUREPAC PHARM	25MG	A080493 001
VITARINE	25MG	A080333 001
WATSON LABS	25MG	A085884 001
WHITEWORTH TOWN PLSN	25MG	A080341 001

CORTONE

+ MERCK	25MG **	N007750 003

COSYNTROPIN

SOLUTION; INTRAVENOUS

COSYNTROPIN

SANDOZ INC	0.25MG/ML (0.25MG/ML)	N022028 001	Feb 21, 2008

CROMOLYN SODIUM

AEROSOL, METERED; INHALATION

INTAL

KING PHARMS LLC	0.8MG/INH	N018887 001	Dec 05, 1985

CAPSULE; INHALATION

INTAL

+ SANOFI AVENTIS US	20MG **	N016990 001

CAPSULE; ORAL

GASTROCROM

UCB INC	100MG	N019188 001	Dec 22, 1989

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-129(of 478)

** See List Footnote

CROMOLYN SODIUM

CONCENTRATE; ORAL

CROMOLYN SODIUM

GENERA PHARMS

100MG/5ML

A090954 001 Dec 18, 2009

SOLUTION; INHALATION

CROMOLYN SODIUM

ACTAVIS MID ATLANTIC

10MG/ML

A075067 001 Jul 19, 1999

BAUSCH

10MG/ML

A075585 001 Dec 21, 2000

HIKMA

10MG/ML

A075333 001 Apr 30, 2002

MYLAN SPECIALITY LP

10MG/ML

A074209 001 Apr 26, 1994

ROXANE

10MG/ML

A075175 001 Sep 30, 1999

WATSON LABS

10MG/ML

A076469 001 Jun 17, 2005

INTAL

+

KING PHARMS LLC

10MG/ML **

N018596 001 May 28, 1982

SOLUTION/DROPS; OPHTHALMIC

CROLOM

BAUSCH AND LOMB

4%

A074443 001 Jan 30, 1995

CROMOLYN SODIUM

APOTEX INC

4%

A075615 001 Jan 26, 2001

CROMOPTIC

KING PHARMS

4%

A075088 001 Apr 27, 1999

OPTICROM

+

ALLERGAN

4% **

N018155 001 Oct 03, 1984

SPRAY, METERED; NASAL

CROMOLYN SODIUM

ACTAVIS MID ATLANTIC

5.2MG/SPRAY

A074800 001 Jul 26, 2001

HH AND P

5.2MG/SPRAY

A077976 001 Sep 07, 2007

PERRIGO

5.2MG/SPRAY

A075427 001 Dec 12, 2001

NASALCROM

+

BLACKSMITH BRANDS

5.2MG/SPRAY **

N020463 001 Jan 03, 1997

CROTAMITON

CREAM; TOPICAL

EURAX

+

JOURNEY

10%

N006927 001

CRYPTENAMINE ACETATES

INJECTABLE; INJECTION

UNITENSEN

MEDPOINTE PHARM HLC

260CSR UNIT/ML

N008814 001

CRYPTENAMINE TANNATES

TABLET; ORAL

UNITENSEN

MEDPOINTE PHARM HLC

260CSR UNIT

N009217 001

CUPRIC SULFATE

INJECTABLE; INJECTION

CUPRIC SULFATE

+

ABRAXIS PHARM

EQ 0.4MG COPPER/ML **

N019350 001 May 05, 1987

CYANOCOBALAMIN

GEL, METERED; NASAL

NASCOBAL

PAR PHARM

0.5MG/INH

N019722 001 Nov 05, 1996

INJECTABLE; INJECTION

BERUBIGEN

PHARMACIA AND UPJOHN

1MG/ML

N006798 001

BETALIN 12

LILLY

0.1MG/ML

A080855 001

1MG/ML

A080855 002

COBAVITE

WATSON LABS

0.1MG/ML

A083013 001

1MG/ML

A083064 001

CYANOCOBALAMIN

ABRAXIS PHARM

0.03MG/ML

A080510 003

0.1MG/ML

A080510 001

1MG/ML

A080510 002

AKORN

1MG/ML

A087969 001 Nov 10, 1983

DELL LABS

0.03MG/ML

A080689 001

0.1MG/ML

A080689 002

1MG/ML

A080689 003

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-130(of 478)

** See List Footnote

CYANOCOBALAMIN

INJECTABLE; INJECTION

CYANOCOBALAMIN

DR REDDYS	0.1MG/ML	A080573	002	
	1MG/ML	A080573	001	
FRESENIUS KABI USA	0.1MG/ML	A080557	002	
LUITPOLD	0.03MG/ML	A080668	001	
LYPHOMED	1MG/ML	A083075	001	
MYLAN INSTITUTIONAL	1MG/ML	A040451	001	Sep 23, 2003
SANOFI AVENTIS US	1MG/ML	A080564	001	
SOLOPAK	1MG/ML	A087551	001	Feb 29, 1984
WARNER CHILCOTT	1MG/ML	N007085	002	
WATSON LABS	0.1MG/ML	A083120	001	
	1MG/ML	A083120	002	
WYETH AYERST	0.1MG/ML	A080554	001	
	1MG/ML	A080554	002	
XIROMED	1MG/ML	A215046	001	Aug 20, 2021
REDISOL				
MERCK	1MG/ML	N006668	010	
RUBIVITE				
BEL MAR	0.03MG/ML	N010791	004	
	0.05MG/ML	N010791	001	
	0.1MG/ML	N010791	002	
	0.12MG/ML	N010791	005	
	1MG/ML	N010791	003	
RUBRAMIN PC				
BRISTOL MYERS SQUIBB	0.1MG/ML	N006799	002	
+	1MG/ML **	N006799	004	
+	1MG/ML **	N006799	010	Apr 28, 1988
RUVITE				
SAVAGE LABS	1MG/ML	A080570	002	
VI-TWEL				
BAYER HLTHCARE	1MG/ML	N007012	002	
SPRAY, METERED; NASAL				
CALOMIST				
PAR PHARM	25MCG/SPRAY	N022102	001	Jul 27, 2007
CYANOCOBALAMIN				
PADAGIS ISRAEL	0.5MG/SPRAY	A212458	001	Sep 09, 2020
TABLET; ORAL				
CYANOCOBALAMIN				
WEST WARD	1MG	A084264	001	

CYANOCOBALAMIN; CYANOCOBALAMIN CO-57; CYANOCOBALAMIN CO-58

N/A; N/A

DICOPAC KIT

GE HEALTHCARE	N/A; N/A; N/A	N017406	001	

CYANOCOBALAMIN; TANNIC ACID; ZINC ACETATE

INJECTABLE; INJECTION

DEPINAR

ARMOUR PHARM	0.5MG/ML; 2.3MG/ML; 1MG/ML	N011208	001	

CYCLACILLIN

FOR SUSPENSION; ORAL

CYCLAPEN-W

WYETH AYERST	125MG/5ML	N050508	001	
	250MG/5ML	N050508	002	
	500MG/5ML	N050508	003	

TABLET; ORAL

CYCLACILLIN

TEVA	250MG	A062895	001	Aug 04, 1988
	500MG	A062895	002	Aug 04, 1988

CYCLAPEN-W

WYETH AYERST	250MG	N050509	001	
	500MG	N050509	002	

DISCONTINUED DRUG PRODUCT LIST

6-131(of 478)

** See List Footnote

CYCLIZINE LACTATE

INJECTABLE; INJECTION

MAREZINE

GLAXOSMITHKLINE 50MG/ML

N009495 001

CYCLOBENZAPRINE HYDROCHLORIDE

TABLET; ORAL

CYCLOBENZAPRINE HYDROCHLORIDE

CHARTWELL RX 5MG

A072854 002 Feb 03, 2006

10MG

A072854 001 Nov 19, 1991

PLIVA 10MG

A074421 001 Sep 29, 1995

RISING 5MG

A073144 002 Feb 03, 2006

7.5MG

A073144 003 Mar 25, 2013

10MG

A073144 001 May 30, 1991

SANDOZ 10MG

A073683 001 Feb 26, 1993

WATSON LABS 10MG

A073143 001 Nov 27, 1991

10MG

A074436 001 Nov 30, 1994

FLEXERIL

+ JANSSEN RES AND DEV 5MG **

N017821 001

+ 10MG **

N017821 002

CYCLOPENTOLATE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

AK-PENTOLATE

AKORN 1%

A085555 001

CYCLOPENTOLATE HYDROCHLORIDE

ALCON PHARMS LTD 1%

A089162 001 Jan 24, 1991

SOLA BARNES HIND 1%

A084150 001

1%

A084863 001

PENTOLAIR

PHARMAFAIR 0.5%

A088643 001 Feb 09, 1987

1%

A088150 001 Feb 25, 1983

CYCLOPHOSPHAMIDE

CAPSULE; ORAL

CYCLOPHOSPHAMIDE

ANI PHARMS 25MG

A207014 001 Mar 19, 2018

50MG

A207014 002 Mar 19, 2018

INJECTABLE; INJECTION

CYCLOPHOSPHAMIDE

BAXTER HLTHCARE 100MG/VIAL

A088371 001 Jul 03, 1986

200MG/VIAL

A088372 001 Jul 03, 1986

500MG/VIAL

A088373 001 Jul 03, 1986

1GM/VIAL

A088374 001 Sep 24, 1986

CYTOXAN

+ BAXTER HLTHCARE 100MG/VIAL **

N012142 001

+ 200MG/VIAL **

N012142 002

CYTOXAN (LYOPHILIZED)

+ BAXTER HLTHCARE 500MG/VIAL

N012142 003

+ 500MG/VIAL **

N012142 008 Jan 04, 1984

+ 1GM/VIAL

N012142 004 Aug 30, 1982

+ 1GM/VIAL **

N012142 010 Sep 24, 1985

+ 2GM/VIAL

N012142 005 Aug 30, 1982

+ 2GM/VIAL **

N012142 009 Dec 10, 1985

LYOPHILIZED CYTOXAN

+ BAXTER HLTHCARE 100MG/VIAL **

N012142 006 Dec 05, 1985

+ 200MG/VIAL **

N012142 007 Dec 10, 1985

NEOSAR

BEDFORD 100MG/VIAL

A087442 001 Feb 16, 1982

200MG/VIAL

A087442 002 Feb 16, 1982

500MG/VIAL

A087442 003 Feb 16, 1982

1GM/VIAL

A087442 004 Jul 08, 1983

2GM/VIAL

A087442 005 Mar 30, 1989

TEVA PARENTERAL 100MG/VIAL

A040015 001 Apr 29, 1993

200MG/VIAL

A040015 002 Apr 29, 1993

500MG/VIAL

A040015 003 Apr 29, 1993

1GM/VIAL

A040015 004 Apr 29, 1993

2GM/VIAL

A040015 005 Apr 29, 1993

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-132(of 478)

** See List Footnote

CYCLOPHOSPHAMIDE

TABLET;ORAL

CYCLOPHOSPHAMIDE

ROXANE

25MG

A040032 001 Aug 17, 1999

50MG

A040032 002 Aug 17, 1999

CYCLOSPORINE

CAPSULE;ORAL

GENGRAF

ABBVIE

50MG

A065003 002 May 12, 2000

NEORAL

+ NOVARTIS

50MG **

N050715 003 Jul 14, 1995

SOLUTION;ORAL

CYCLOSPORINE

MAYNE PHARMA

100MG/ML

A065054 001 Dec 18, 2001

PHARM ASSOC

100MG/ML

A065167 001 Jan 05, 2005

CYCLOTHIAZIDE

TABLET;ORAL

ANHYDRON

LILLY

2MG

N013157 002

FLUIDIL

PHARMACIA AND UPJOHN

2MG

N018173 001

CYCRIMINE HYDROCHLORIDE

TABLET;ORAL

PAGITANE

LILLY

1.25MG

N008951 001

2.5MG

N008951 002

CYPROHEPTADINE HYDROCHLORIDE

SYRUP;ORAL

CYPROHEPTADINE HYDROCHLORIDE

+ ACTAVIS MID ATLANTIC

2MG/5ML **

A086833 001

HALSEY

2MG/5ML

A089199 001 Jul 03, 1986

MORTON GROVE

2MG/5ML

A087001 001 Nov 04, 1982

NASKA

2MG/5ML

A089021 001 Dec 21, 1987

TRIS PHARMA INC

2MG/5ML

A205431 001 Dec 21, 2021

PERIACTIN

+ MERCK

2MG/5ML **

N013220 002

TABLET;ORAL

CYPROHEPTADINE HYDROCHLORIDE

AM THERAP

4MG

A088798 001 Feb 15, 1985

ASCOT

4MG

A087685 001 Oct 25, 1982

CHARTWELL RX

4MG

A088212 001 May 26, 1983

DURAMED PHARMS BARR

4MG

A088232 001 Oct 25, 1983

FOSUN PHARMA

4MG

A086808 001

HALSEY

4MG

A089057 001 Jul 03, 1986

KV PHARM

4MG

A086737 001

MD PHARM

4MG

A087566 001 Nov 10, 1982

MYLAN

4MG

A086678 001

PIONEER PHARMS

4MG

A087839 001 Feb 08, 1984

PLIVA

4MG

A088205 001 Jul 26, 1983

STRIDES PHARMA

4MG

A087129 001

SUPERPHARM

4MG

A087405 001

VITARINE

4MG

A087284 001

WATSON LABS

4MG

A085245 001

4MG

A086165 001

4MG

A086580 001

PERIACTIN

+ MERCK

4MG **

N012649 001

CYSTEINE HYDROCHLORIDE

INJECTABLE;INJECTION

CYSTEINE HYDROCHLORIDE

+ HOSPIRA

7.25% **

N019523 001 Oct 22, 1986

SOLUTION;INTRAVENOUS

CYSTEINE HYDROCHLORIDE

DR REDDYS LABS SA

500MG/10ML (50MG/ML)

A214082 001 Apr 08, 2022

NOURESS

+ BAXTER HLTHCARE CORP

500MG/10ML (50MG/ML)

N212535 001 Dec 13, 2019

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-133(of 478)

** See List Footnote

CYTARABINE

INJECTABLE; INJECTION

CYTARABINE

MEITHEAL	20MG/ML	A206189 001	Jun 26, 2020
	20MG/ML	A206190 001	Nov 09, 2017
MYLAN LABS LTD	20MG/ML	A200916 001	Dec 13, 2011
RISING	20MG/ML	A200914 001	Dec 13, 2011
+ TEVA PARENTERAL	100MG/VIAL **	N016793 001	
+	500MG/VIAL **	N016793 002	
+	1GM/VIAL **	N016793 003	Dec 21, 1987
+	2GM/VIAL **	N016793 004	Dec 21, 1987
CYTOSAR-U			
TEVA PHARMS USA	100MG/VIAL	A075206 001	Dec 30, 1998
	500MG/VIAL	A075206 002	Dec 30, 1998
	1GM/VIAL	A075206 004	Dec 30, 1998
	2GM/VIAL	A075206 003	Dec 30, 1998

INJECTABLE, LIPOSOMAL; INJECTION

DEPOCYT

+ PACIRA PHARMS INC	10MG/ML	N021041 001	Apr 01, 1999

DACARBAZINE

INJECTABLE; INJECTION

DACARBAZINE

ABRAXIS PHARM	100MG/VIAL	A070962 001	Aug 28, 1986
	200MG/VIAL	A070990 001	Aug 28, 1986
DTIC-DOME			
+ BAYER HLTHCARE	100MG/VIAL **	N017575 001	
+	200MG/VIAL **	N017575 002	

DACLATASVIR DIHYDROCHLORIDE

TABLET; ORAL

DAKLINZA

+ BRISTOL-MYERS SQUIBB	EQ 30MG BASE	N206843 001	Jul 24, 2015
+	EQ 60MG BASE	N206843 002	Jul 24, 2015
+	EQ 90MG BASE	N206843 003	Apr 13, 2016

DACTINOMYCIN

INJECTABLE; INJECTION

DACTINOMYCIN

AM REGENT	0.5MG/VIAL	A202562 001	Aug 23, 2013
HIKMA	0.5MG/VIAL	A090304 001	Mar 16, 2010

DALFAMPRIDINE

TABLET, EXTENDED RELEASE; ORAL

DALFAMPRIDINE

HIKMA	10MG	A206646 001	Oct 24, 2018
RISING	10MG	A206858 001	Jul 06, 2020

DALFOPRISTIN; QUINUPRISTIN

INJECTABLE; INTRAVENOUS

SYNERCID

KING PHARMS	420MG/VIAL; 180MG/VIAL	N050748 002	Aug 24, 2000

DALTEPARIN SODIUM

INJECTABLE; INJECTION

FRAGMIN

PFIZER	7,500 IU/0.75ML	N020287 008	Apr 04, 2002

INJECTABLE; SUBCUTANEOUS

FRAGMIN

PFIZER	10,000IU/0.4ML (25,000IU/ML)	N020287 002	May 01, 2007
	95,000IU/9.5ML (10,000IU/ML)	N020287 007	Apr 04, 2002

DANAPAROID SODIUM

INJECTABLE; INJECTION

ORGARAN

ASPEN GLOBAL INC	750 UNITS/0.6ML	N020430 001	Dec 24, 1996

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-134(of 478)

** See List Footnote

DANAZOL

CAPSULE; ORAL

DANAZOL

AM THERAP

200MG

A071569 001 Dec 30, 1987

DANOCRINE

SANOFI AVENTIS US

50MG **

N017557 003

100MG **

N017557 004

200MG **

N017557 002

DANTROLENE SODIUM

INJECTABLE; INJECTION

DANTROLENE SODIUM

EUGIA PHARMA SPECLTS 20MG/VIAL

A205239 001 Feb 18, 2016

DAPAGLIFLOZIN

TABLET; ORAL

DAPAGLIFLOZIN

ZYDUS PHARMS

5MG

A211582 001 Feb 22, 2022

10MG

A211582 002 Feb 22, 2022

DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

QTERNMET XR

+ ASTRAZENECA AB

2.5MG; 1GM; EQ 2.5MG BASE

N210874 001 May 02, 2019

+

5MG; 1GM; EQ 2.5MG BASE

N210874 002 May 02, 2019

+

5MG; 1GM; EQ 5MG BASE

N210874 003 May 02, 2019

+

10MG; 1GM; EQ 5MG BASE

N210874 004 May 02, 2019

DAPIPRAZOLE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

DAPIPRAZOLE HYDROCHLORIDE

+ FERA PHARMS

0.5% **

N019849 001 Dec 31, 1990

WOODWARD

0.5%

A204902 001 May 30, 2019

DAPSONE

TABLET; ORAL

DAPSONE

ANDA REPOSITORY

25MG

A204074 001 May 10, 2016

100MG

A204074 002 May 10, 2016

TARO

25MG

A209430 001 Mar 01, 2019

100MG

A209430 002 Mar 01, 2019

DAPTOMYCIN

POWDER; INTRAVENOUS

CUBICIN

CUBIST PHARMS LLC

250MG/VIAL

N021572 001 Sep 12, 2003

CUBICIN RF

+ CUBIST PHARMS LLC

500MG/VIAL

N021572 003 Jul 06, 2016

DAPTOMYCIN

HISUN PHARM HANGZHOU

500MG/VIAL

A212250 001 Apr 21, 2021

HOSPIRA

500MG/VIAL

A202857 001 Sep 12, 2014

DAPZURA RT

+ BAXTER HLTHCARE CORP

500MG/VIAL

N213645 001 Jan 25, 2022

DARIFENACIN HYDROBROMIDE

TABLET, EXTENDED RELEASE; ORAL

DARIFENACIN HYDROBROMIDE

ANCHEN PHARMS

EQ 7.5MG BASE

A091190 001 Mar 13, 2015

EQ 15MG BASE

A091190 002 Mar 13, 2015

JUBILANT GENERICS

EQ 7.5MG BASE

A205550 001 Oct 12, 2016

EQ 15MG BASE

A205550 002 Oct 12, 2016

XIROMED

EQ 7.5MG BASE

A209571 002 Oct 22, 2019

EQ 15MG BASE

A209571 001 Oct 22, 2019

ENABLEX

+ APIL

EQ 7.5MG BASE

N021513 001 Dec 22, 2004

+

EQ 15MG BASE

N021513 002 Dec 22, 2004

DISCONTINUED DRUG PRODUCT LIST

6-135(of 478)

** See List Footnote

DARUNAVIR

TABLET;ORAL

PREZISTA

+ JANSSEN PRODS

300MG **

N021976 001 Jun 23, 2006

+

400MG **

N021976 003 Oct 21, 2008

DASABUVIR SODIUM; OMBITASVIR, PARITAPREVIR, RITONAVIR

TABLET;ORAL

VIEKIRA PAK (COPACKAGED)

+ ABBVIE INC

EQ 250MG BASE;12.5MG, 75MG, 50MG

N206619 001 Dec 19, 2014

DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR

TABLET, EXTENDED RELEASE;ORAL

VIEKIRA XR

+ ABBVIE INC

EQ 200MG BASE;8.33MG;50MG;33.33MG **

N208624 001 Jul 22, 2016

DASATINIB

TABLET;ORAL

DASATINIB

APOTEX

80MG

A203180 001 Nov 23, 2021

140MG

A203180 002 Nov 23, 2021

APOTEX INC

20MG

A202103 001 Jun 10, 2016

50MG

A202103 002 Jun 10, 2016

70MG

A202103 003 Jun 10, 2016

100MG

A202103 004 Jun 10, 2016

DAUNORUBICIN CITRATE

INJECTABLE, LIPOSOMAL;INJECTION

DAUNOXOME

GALEN (UK)

EQ 2MG BASE/ML

N050704 002 Apr 08, 1996

DAUNORUBICIN HYDROCHLORIDE

INJECTABLE;INJECTION

CERUBIDINE

SANOFI AVENTIS US

EQ 20MG BASE/VIAL

A061876 001

WYETH AYERST

EQ 20MG BASE/VIAL **

N050484 001

DAUNORUBICIN HYDROCHLORIDE

HISUN PHARM HANGZHOU

EQ 20MG BASE/VIAL

A206195 001 Apr 25, 2019

TEVA PARENTERAL

EQ 20MG BASE/VIAL

A064212 001 Jun 23, 1998

EQ 50MG BASE/VIAL

A064212 002 May 03, 1999

DECAMETHONIUM BROMIDE

INJECTABLE;INJECTION

SYNCURINE

GLAXOSMITHKLINE

1MG/ML

N006931 002

DECITABINE

INJECTABLE;INTRAVENOUS

DACOGEN

+ OTSUKA

50MG/VIAL

N021790 001 May 02, 2006

DECITABINE

CIPLA

50MG/VIAL

A208601 001 Nov 16, 2017

DEFERASIROX

GRANULE;ORAL

DEFERASIROX

AMNEAL

90MG

A214194 003 Aug 02, 2021

180MG

A214194 001 Feb 09, 2021

360MG

A214194 002 Feb 09, 2021

TABLET;ORAL

DEFERASIROX

AMNEAL

90MG

A210727 001 Dec 27, 2019

180MG

A210727 003 Jun 15, 2020

360MG

A210727 002 Dec 27, 2019

TEVA PHARMS USA

90MG

A209223 001 Nov 25, 2019

180MG

A209223 003 Apr 24, 2020

360MG

A209223 002 Nov 25, 2019

TABLET, FOR SUSPENSION;ORAL

DEFERASIROX

ZYDUS PHARMS

125MG

A208882 001 May 05, 2020

250MG

A208882 002 May 05, 2020

500MG

A208882 003 May 05, 2020

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-136(of 478)

** See List Footnote

DEFERIPRONE

SOLUTION; ORAL

FERRIPROX

+ CHIESI

80MG/ML

N208030 002 Apr 20, 2018

DEFEROXAMINE MESYLATE

INJECTABLE; INJECTION

DEFEROXAMINE MESYLATE

DR REDDYS

500MG/VIAL

A076806 001 Mar 31, 2006

2GM/VIAL

A076806 002 Mar 31, 2006

DESFERAL

+ NOVARTIS

2GM/VIAL

N016267 002 May 25, 2000

DELAVIDINE MESYLATE

TABLET; ORAL

RESCRIPTOR

+ VIIIV HLTHCARE

100MG

N020705 001 Apr 04, 1997

+

200MG

N020705 002 Jul 14, 1999

DEMECARIUM BROMIDE

SOLUTION/DROPS; OPHTHALMIC

HUMORSOL

MERCK

0.125%

N011860 002

0.25%

N011860 001

DEMECLOCYCLINE HYDROCHLORIDE

CAPSULE; ORAL

DECLOMYCIN

LEDERLE

150MG

N050262 001

SYRUP; ORAL

DECLOMYCIN

LEDERLE

75MG/5ML

N050257 001

TABLET; ORAL

DECLOMYCIN

COREPHARMA

75MG **

N050261 001

150MG **

N050261 002

300MG **

N050261 003

DEMECLOCYCLINE HYDROCHLORIDE

BARR

150MG

A065171 001 Dec 13, 2004

300MG

A065171 002 Dec 13, 2004

IMPAX LABS

150MG

A065094 001 Mar 22, 2004

300MG

A065094 002 Mar 22, 2004

DESERPIDINE

TABLET; ORAL

HARMONYL

ABBVIE

0.1MG

N010796 001

0.25MG

N010796 002

DESERPIDINE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

ORETICYL 25

ABBVIE

0.125MG; 25MG

N012148 001

ORETICYL 50

ABBVIE

0.125MG; 50MG

N012148 003

ORETICYL FORTE

ABBVIE

0.25MG; 25MG

N012148 002

DESERPIDINE; METHYCLOTHIAZIDE

TABLET; ORAL

ENDURONYL

ABBOTT

0.25MG; 5MG

N012775 001

ENDURONYL FORTE

ABBOTT

0.5MG; 5MG

N012775 002

METHYCLOTHIAZIDE AND DESERPIDINE

WATSON LABS

0.25MG; 5MG

A088486 001 Aug 10, 1984

0.5MG; 5MG

A088452 001 Aug 10, 1984

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-137(of 478)

** See List Footnote

DESIPRAMINE HYDROCHLORIDE

CAPSULE; ORAL

PERTOFRANE

SANOFI AVENTIS US

25MG

N013621 001

50MG

N013621 002

TABLET; ORAL

DESIPRAMINE HYDROCHLORIDE

ANI PHARMS

10MG

A205153 001 Oct 28, 2016

25MG

A071803 002 Dec 08, 1987

25MG

A205153 002 Oct 28, 2016

50MG

A071803 003 Dec 08, 1987

50MG

A205153 003 Oct 28, 2016

75MG

A071803 004 Dec 08, 1987

75MG

A205153 004 Oct 28, 2016

100MG

A071803 001 May 29, 1997

100MG

A205153 005 Oct 28, 2016

150MG

A071803 005 May 29, 1997

150MG

A205153 006 Oct 28, 2016

USL PHARMA

25MG

A071864 001 Sep 09, 1987

50MG

A071865 001 Sep 09, 1987

75MG

A071866 001 Sep 09, 1987

100MG

A071867 001 Sep 09, 1987

DESLANOSIDE

INJECTABLE; INJECTION

CEDILANID-D

NOVARTIS

0.2MG/ML

N009282 002

DESLORATADINE

SOLUTION; ORAL

CLARINEX

+ MERCK SHARP DOHME

0.5MG/ML **

N021300 001 Sep 01, 2004

DESLORATADINE

TARO

0.5MG/ML

A202936 001 May 26, 2016

TARO PHARM INDS LTD

0.5MG/ML

A202592 001 Jun 30, 2015

TABLET; ORAL

DESLORATADINE

MYLAN PHARMS INC

5MG

A078351 001 Feb 10, 2012

PERRIGO

5MG

A078361 001 Dec 22, 2011

SANDOZ

5MG

A078364 001 Dec 03, 2010

SUN PHARM INDS

5MG

A078359 001 Nov 16, 2010

TABLET, ORALLY DISINTEGRATING; ORAL

CLARINEX

+ ORGANON

2.5MG **

N021312 002 Jul 14, 2005

+

5MG **

N021312 001 Jun 26, 2002

DESLORATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

CLARINEX D 24 HOUR

+ ORGANON

5MG; 240MG **

N021605 001 Mar 03, 2005

DESMOPRESSIN ACETATE

INJECTABLE; INJECTION

DDAVP

FERRING PHARMS INC

0.015MG/ML

N018938 002 Apr 25, 1995

DESMOPRESSIN ACETATE

BEDFORD

0.004MG/ML

A074575 001 Feb 18, 2000

HOSPIRA

0.004MG/ML

A075220 001 Aug 28, 2000

DESMOPRESSIN ACETATE PRESERVATIVE FREE

BEDFORD

0.004MG/ML

A074574 001 Feb 18, 2000

SOLUTION; NASAL

CONCENTRAID

FERRING

0.01%

N019776 001 Dec 26, 1990

DDAVP

+ FERRING PHARMS INC

0.01%

N017922 001

DESMOPRESSIN ACETATE

SUN PHARM INDS

0.01%

A077212 001 Apr 12, 2012

SPRAY, METERED; NASAL

DDAVP

+ FERRING PHARMS INC

0.01MG/SPRAY **

N017922 002 Feb 06, 1989

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-138(of 478)

** See List Footnote

DESMOPRESSIN ACETATE

SPRAY, METERED;NASAL

DDAVP (NEEDS NO REFRIGERATION)

+ FERRING PHARMS INC 0.01MG/SPRAY

N017922 003 Aug 07, 1996

MINIRIN

+ FERRING 0.01MG/SPRAY

N021333 001 Sep 16, 2002

NOCTIVA

+ ACERUS PHARMS 0.00083MG/SPRAY

N201656 001 Mar 03, 2017

+ 0.00166MG/SPRAY

N201656 002 Mar 03, 2017

STIMATE

FERRING PHARMS INC 0.15MG/SPRAY

N020355 001 Mar 07, 1994

STIMATE (NEEDS NO REFRIGERATION)

+ FERRING PHARMS INC 0.15MG/SPRAY

N020355 002 Oct 24, 2007

TABLET;ORAL

DESMOPRESSIN ACETATE

FERRING 0.1MG

N021795 001 May 08, 2008

0.2MG

N021795 002 May 08, 2008

IMPAX LABS INC 0.1MG

A077122 001 Jan 25, 2006

0.2MG

A077122 002 Jan 25, 2006

MYLAN 0.1MG

A200653 001 Jun 27, 2014

0.2MG

A200653 002 Jun 27, 2014

DESOGESTREL; ETHINYL ESTRADIOL

TABLET;ORAL-21

DESOGEN

ORGANON USA INC 0.15MG;0.03MG

N020071 001 Dec 10, 1992

DESOGESTREL AND ETHINYL ESTRADIOL

DURAMED PHARMS BARR 0.15MG;0.03MG

A075256 001 Aug 12, 1999

ORTHO-CEPT

+ JANSSEN PHARMS 0.15MG;0.03MG **

N020301 001 Dec 14, 1992

TABLET;ORAL-28

DESOGEN

ORGANON USA INC 0.15MG;0.03MG

N020071 002 Dec 10, 1992

DESOGESTREL AND ETHINYL ESTRADIOL

MAYNE PHARMA 0.15MG,N/A;0.02MG,0.01MG

A076916 001 Dec 29, 2008

0.1MG,0.125MG,0.15MG;0.025MG,0.025MG,0.025MG

A077182 001 Jan 24, 2006

MYLAN LABS LTD 0.15MG;0.03MG

A202085 001 May 20, 2015

NAARI PTE LTD 0.15MG;0.03MG

A207067 001 Sep 13, 2018

EMOQUETTE

VINTAGE PHARMS LLC 0.15MG;0.03MG

A076675 001 Feb 25, 2011

MIRCETTE

+ TEVA BRANDED PHARM 0.15MG,N/A;0.02MG,0.01MG **

N020713 001 Apr 22, 1998

ORTHO-CEPT

+ JANSSEN PHARMS 0.15MG;0.03MG **

N020301 002 Dec 14, 1992

DESONIDE

GEL;TOPICAL

DESONATE

+ LEO PHARMA AS 0.05% **

N021844 001 Oct 20, 2006

DESOXIMETASONE

CREAM;TOPICAL

DESOXIMETASONE

AKORN 0.05%

A203787 001 Jan 06, 2017

0.25%

A203234 001 Jun 12, 2015

TOPICORT

+ TARO PHARM INDS LTD 0.25% **

N017856 001

TOPICORT LP

+ TARO PHARM INDS LTD 0.05% **

N018309 001

GEL;TOPICAL

TOPICORT

+ TARO PHARM INDS LTD 0.05% **

N018586 001 Mar 29, 1982

OINTMENT;TOPICAL

DESOXIMETASONE

ALTANA 0.25%

A073440 001 Apr 01, 1998

TOPICORT

TARO PHARM INDS LTD 0.25%

A074286 001 Jun 07, 1996

+ 0.25% **

N018763 001 Sep 30, 1983

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-139(of 478)

** See List Footnote

DESOXYCORTICOSTERONE ACETATE

INJECTABLE; INJECTION

DOCA

ORGANON USA INC

5MG/ML

N001104 001

PELLET; IMPLANTATION

PERCORTEN

NOVARTIS

125MG

N005151 001

DESOXYCORTICOSTERONE PIVALATE

INJECTABLE; INJECTION

PERCORTEN

NOVARTIS

25MG/ML

N008822 001

DESVENLAFAXINE

TABLET, EXTENDED RELEASE; ORAL

KHEDEZLA

OSMOTICA PHARM CORP

50MG

N204683 001 Jul 10, 2013

100MG

N204683 002 Jul 10, 2013

DESVENLAFAXINE FUMARATE

TABLET, EXTENDED RELEASE; ORAL

DESVENLAFAXINE

+ SUN PHARM

EQ 50MG BASE

N205583 001 Jan 28, 2014

+

EQ 100MG BASE

N205583 002 Jan 28, 2014

TEVA PHARMS USA

EQ 50MG BASE

N205208 001 Oct 11, 2013

EQ 100MG BASE

N205208 002 Oct 11, 2013

DESVENLAFAXINE SUCCINATE

TABLET, EXTENDED RELEASE; ORAL

DESVENLAFAXINE SUCCINATE

MYLAN

EQ 50MG BASE

A204095 001 Jun 29, 2015

EQ 100MG BASE

A204095 002 Jun 29, 2015

DEXAMETHASONE

AEROSOL; TOPICAL

AEROSEB-DEX

ALLERGAN HERBERT

0.01% **

A083296 002

DECASPRAY

+ MERCK

0.04% **

N012731 002

ELIXIR; ORAL

DECADRON

MERCK

0.5MG/5ML

N012376 002

DEXAMETHASONE

ALPHARMA US PHARMS

0.5MG/5ML

A088997 001 Oct 10, 1986

+ WOCKHARDT BIO AG

0.5MG/5ML

A088254 001 Jul 27, 1983

HEXADROL

ASPEN GLOBAL INC

0.5MG/5ML

N012674 001

GEL; TOPICAL

DECADERM

MERCK

0.1%

N013538 001

SUSPENSION/DROPS; OPHTHALMIC

DEXAMETHASONE

WATSON LABS

0.1%

A089170 001 May 09, 1989

TABLET; ORAL

DECADRON

+ MERCK

0.25MG **

N011664 004

+

0.5MG **

N011664 001

+

0.75MG **

N011664 002

+

1.5MG **

N011664 003

+

4MG **

N011664 005

+

6MG **

N011664 006 Jul 30, 1982

DEXAMETHASONE

BAUSCH

1.5MG

A040700 001 Aug 15, 2008

HERITAGE PHARMA

1.5MG

A085456 001

IMPAX LABS

0.75MG

A085376 001

PHOENIX LABS NY

0.75MG

A083806 001

PRASCO

0.75MG

A080399 001

PVT FORM

0.75MG

A083420 001

ROXANE

0.25MG

A084614 001

STRIDES PHARMA

0.25MG

A088149 001 Apr 28, 1983

SUN PHARM INDUSTRIES

0.25MG

A084013 001

0.25MG

A084764 001

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-140(of 478)

** See List Footnote

DEXAMETHASONE

TABLET; ORAL

DEXAMETHASONE

	0.5MG	A084084	001
	0.5MG	A084766	001
	0.75MG	A084081	001
	0.75MG	A084765	001
	1.5MG	A084086	001
	1.5MG	A084763	001
UPSHER SMITH	0.75MG	A087534	001
	1.5MG	A087533	001
WATSON LABS	0.25MG	A085455	001
	0.5MG	A085458	001
	0.75MG	A080968	001
	0.75MG	A084457	001
	0.75MG	A085818	001
	1.5MG	A085840	001
WHITEWORTH TOWN PLSN	0.75MG	A084327	001
DEXONE 0.5			
SOLVAY	0.5MG	A084991	001
DEXONE 0.75			
SOLVAY	0.75MG	A084993	001
DEXONE 1.5			
SOLVAY	1.5MG	A084990	001
DEXONE 4			
SOLVAY	4MG	A084992	001
HEXADROL			
ASPEN GLOBAL INC	0.5MG	N012675	004
	0.75MG	N012675	007
	1.5MG	N012675	009
	4MG	N012675	010

DEXAMETHASONE ACETATE

INJECTABLE; INJECTION

DECADRON-LA

+ MERCK

EQ 8MG BASE/ML **

N016675 001

DEXAMETHASONE ACETATE

WATSON LABS

EQ 8MG BASE/ML

A084315 001

WATSON LABS TEVA

EQ 16MG BASE/ML

A087711 001

May 24, 1982

DEXAMETHASONE SODIUM PHOSPHATE

AEROSOL; NASAL

DEXACORT

UCB INC

EQ 0.1MG PHOSPHATE/INH

N014242 001

AEROSOL, METERED; INHALATION

DEXACORT

UCB INC

EQ 0.1MG PHOSPHATE/INH

N013413 001

CREAM; TOPICAL

DECADRON

MERCK

EQ 0.1% PHOSPHATE

N011983 002

INJECTABLE; INJECTION

DECADRON

+ MERCK

EQ 4MG PHOSPHATE/ML **

N012071 002

+

EQ 24MG PHOSPHATE/ML **

N012071 004

DEXACEN-4

CENT PHARMS

EQ 4MG PHOSPHATE/ML

A084342 001

DEXAMETHASONE

ABRAXIS PHARM

EQ 4MG PHOSPHATE/ML

A088448 001

Jan 25, 1984

FRESENIUS KABI USA

EQ 10MG PHOSPHATE/ML

A088469 001

Jan 25, 1984

DEXAMETHASONE SODIUM PHOSPHATE

AKORN

EQ 4MG PHOSPHATE/ML

A084493 001

BEL MAR

EQ 4MG PHOSPHATE/ML

A084752 001

DELL LABS

EQ 4MG PHOSPHATE/ML

A083161 001

DR REDDYS

EQ 4MG PHOSPHATE/ML

A089169 001

Apr 09, 1986

INTL MEDICATION

EQ 20MG PHOSPHATE/ML

A088522 001

Feb 17, 1984

+

LUITPOLD

EQ 4MG PHOSPHATE/ML

A087440 001

Jul 21, 1982

LYPHOMED

EQ 4MG PHOSPHATE/ML

A087065 001

TEVA PARENTERAL

EQ 4MG PHOSPHATE/ML

A081125 001

Aug 31, 1990

EQ 10MG PHOSPHATE/ML

A081126 001

Aug 31, 1990

WATSON LABS

EQ 4MG PHOSPHATE/ML

A083702 001

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-141(of 478)

** See List Footnote

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE;INJECTION

DEXAMETHASONE SODIUM PHOSPHATE

	EQ 4MG PHOSPHATE/ML	A084355 001	
	EQ 10MG PHOSPHATE/ML	A087668 001	Jul 01, 1982
	EQ 24MG PHOSPHATE/ML	A085606 001	
WYETH AYERST	EQ 4MG PHOSPHATE/ML	A085641 001	
HEXADROL			
+ ASPEN GLOBAL INC	EQ 4MG PHOSPHATE/ML **	N014694 002	
+	EQ 10MG PHOSPHATE/ML **	N014694 003	
	EQ 20MG PHOSPHATE/ML	N014694 004	

OINTMENT;OPHTHALMIC

DECADRON

MERCK	EQ 0.05% PHOSPHATE	N011977 001	

DEXAIR

PHARMAFAIR	EQ 0.05% PHOSPHATE	A088071 001	Dec 28, 1982

MAXIDEX

ALCON	EQ 0.05% PHOSPHATE	A083342 001	

SOLUTION/DROPS;OPHTHALMIC

DEXAIR

PHARMAFAIR	EQ 0.1% PHOSPHATE	A088433 001	Dec 15, 1983

DEXAMETHASONE SODIUM PHOSPHATE

SOLA BARNES HIND	EQ 0.1% PHOSPHATE	A084170 001	
	EQ 0.1% PHOSPHATE	A084173 001	

SOLUTION/DROPS;OPHTHALMIC, OTIC

DECADRON

+ MERCK	EQ 0.1% PHOSPHATE	N011984 001	

DEXAMETHASONE SODIUM PHOSPHATE

SANDOZ INC	EQ 0.1% PHOSPHATE	A088771 001	Jan 16, 1985

SOLUTION/DROPS;OTIC

DEXAMETHASONE SODIUM PHOSPHATE

AKORN	EQ 0.1% PHOSPHATE	A084855 001	

DEXAMETHASONE SODIUM PHOSPHATE; LIDOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION

DECADRON W/ XYLOCAINE

MERCK	EQ 4MG PHOSPHATE/ML;10MG/ML	N013334 002	

DEXAMETHASONE SODIUM PHOSPHATE; NEOMYCIN SULFATE

OINTMENT;OPHTHALMIC

NEODECADRON

MERCK	EQ 0.05% PHOSPHATE;EQ 3.5MG BASE/GM	N050324 001	

SOLUTION/DROPS;OPHTHALMIC

NEODECADRON

MERCK	EQ 0.1% PHOSPHATE;EQ 3.5MG BASE/ML	N050322 001	

NEOMYCIN SULFATE AND DEXAMETHASONE SODIUM PHOSPHATE

BAUSCH AND LOMB	EQ 0.1% PHOSPHATE;EQ 3.5MG BASE/ML	A064055 001	Oct 30, 1995

NEOMYCIN SULFATE-DEXAMETHASONE SODIUM PHOSPHATE

ALCON PHARMS LTD	EQ 0.1% PHOSPHATE;EQ 3.5MG BASE/ML	A062714 001	Jul 21, 1986
PHARMAFAIR	EQ 0.1% PHOSPHATE;EQ 3.5MG BASE/ML	A062539 001	Jan 10, 1985

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

DEXACIDIN

NOVARTIS	0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A062566 001	Feb 22, 1985

DEXASPORIN

PHARMAFAIR	0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A062411 001	May 16, 1983

SUSPENSION/DROPS;OPHTHALMIC

DEXACIDIN

NOVARTIS	0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062544 001	Oct 29, 1984

DEXASPORIN

PHARMAFAIR	0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062428 001	May 18, 1983

NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE

ALCON PHARMS LTD	0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062721 001	Nov 17, 1986

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-142(of 478)

** See List Footnote

DEXBROMPHENIRAMINE MALEATE

SYRUP;ORAL

DISOMER

SCHERING

2MG/5ML

N011814 002

TABLET;ORAL

DISOMER

SCHERING

2MG

N011814 001

DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET;ORAL

DISOPHROL

SCHERING

2MG;60MG

N012394 002

TABLET, EXTENDED RELEASE;ORAL

BROMPHERIL

COPLEY PHARM

6MG;120MG

A089116 001 Jan 22, 1987

DEXBROMPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE SULFATE

AVANTHI INC

6MG;120MG

A078648 001 Feb 27, 2013

DISOBROM

SANDOZ

6MG;120MG

A070770 001 Sep 30, 1991

DISOPHROL

SCHERING PLOUGH

6MG;120MG

N013483 004 Sep 13, 1982

DRIXORAL

+ SCHERING PLOUGH

6MG;120MG **

N013483 003 Sep 13, 1982

RESPORAL

PIONEER PHARMS

6MG;120MG

A089139 001 Jun 16, 1988

DEXCHLORPHENIRAMINE MALEATE

SYRUP;ORAL

POLARAMINE

SCHERING

2MG/5ML

A086837 001 Jul 19, 1982

TABLET;ORAL

DEXCHLORPHENIRAMINE MALEATE

ANI PHARMS

2MG

A088682 001 Jan 17, 1986

POLARAMINE

+ SCHERING

2MG

A086835 001

DEXLANSOPRAZOLE

TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL

DEXILANT SOLUTAB

+ TAKEDA PHARMS USA

30MG

N208056 001 Jan 26, 2016

DEXMEDETOMIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

DEXMEDETOMIDINE HYDROCHLORIDE

AM REGENT

EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)

A203773 001 May 12, 2017

PIRAMAL CRITICAL

EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)

A214794 001 Sep 03, 2021

SLAYBACK PHARMA LLC

EQ 80MCG BASE/20ML (EQ 4MCG BASE/ML)

A212791 003 May 08, 2020

DEXMETHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

DEXMETHYLPHENIDATE HYDROCHLORIDE

AUROLIFE PHARMA LLC

5MG

A204266 001 Aug 25, 2015

10MG

A204266 002 Aug 25, 2015

15MG

A204266 003 Aug 25, 2015

20MG

A204266 004 Dec 21, 2015

25MG

A204266 005 May 04, 2021

30MG

A202580 001 Aug 28, 2013

35MG

A204266 006 May 04, 2021

40MG

A204266 007 Aug 25, 2015

TABLET;ORAL

DEXMETHYLPHENIDATE HYDROCHLORIDE

BIONPHARMA INC

5MG

A209754 001 Mar 24, 2020

10MG

A209754 002 Mar 24, 2020

LANNETT CO INC

2.5MG

A209468 001 Sep 25, 2017

5MG

A209468 002 Sep 25, 2017

10MG

A209468 003 Sep 25, 2017

TEVA PHARMS

2.5MG

A077107 003 Jan 29, 2007

5MG

A077107 001 Jan 29, 2007

10MG

A077107 002 Jan 29, 2007

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-143(of 478)

** See List Footnote

DEXRAZOXANE HYDROCHLORIDE

INJECTABLE; INJECTION

TOTECT

+ CLINIGEN

EQ 500MG BASE/VIAL **

N022025 001 Sep 06, 2007

ZINECARD

+ PFIZER

EQ 250MG BASE/VIAL

N020212 001 May 26, 1995

+

EQ 500MG BASE/VIAL

N020212 002 May 26, 1995

DEXTROAMPHETAMINE SULFATE

CAPSULE; ORAL

DEXAMPEX

TEVA

15MG

A085355 001

CAPSULE, EXTENDED RELEASE; ORAL

DEXTROAMPHETAMINE SULFATE

ABLE

5MG

A076814 001 Aug 25, 2004

10MG

A076814 002 Aug 25, 2004

15MG

A076814 003 Aug 25, 2004

MAYNE PHARMA

5MG

A076137 001 Jan 18, 2002

10MG

A076137 002 Jan 18, 2002

15MG

A076137 003 Jan 18, 2002

MYLAN

5MG

A206735 001 Jan 27, 2016

10MG

A206735 002 Jan 27, 2016

15MG

A206735 003 Jan 27, 2016

NESHER PHARMS

5MG

A209111 001 Jun 27, 2017

10MG

A209111 002 Jun 27, 2017

15MG

A209111 003 Jun 27, 2017

STRIDES PHARMA

5MG

A205077 001 Jun 21, 2019

10MG

A205077 002 Jun 21, 2019

15MG

A205077 003 Jun 21, 2019

ELIXIR; ORAL

DEXEDRINE

GLAXOSMITHKLINE

5MG/5ML **

A083902 001

TABLET; ORAL

DEXAMPEX

TEVA

5MG

A083735 001

10MG

A083735 002

DEXEDRINE

+ GLAXOSMITHKLINE

5MG **

A084935 001

DEXTROAMPHETAMINE SULFATE

ANI PHARMS

5MG

A085370 001

EPIC PHARMA LLC

5MG

A090652 001 Mar 07, 2014

10MG

A090652 002 Mar 07, 2014

HALSEY

10MG

A083930 001

LANNETT

5MG

A083903 001

10MG

A083903 003

15MG

A085652 001

MAST MM

5MG

A086521 001

NESHER PHARMS

5MG

A040365 001 Oct 31, 2002

5MG

A206588 001 Mar 28, 2016

10MG

A040367 001 Oct 31, 2002

10MG

A206588 002 Mar 28, 2016

PUREPAC PHARM

5MG

A084125 001

SANDOZ

10MG

A085371 001

STRIDES PHARMA

5MG

A040299 001 May 13, 1999

VITARINE

5MG

A084986 001

10MG

A085892 001

WINDER LABS LLC

2.5MG

A212160 001 Jun 07, 2021

5MG

A212160 002 Jun 07, 2021

7.5MG

A212160 003 Jun 07, 2021

10MG

A212160 004 Jun 07, 2021

15MG

A212160 005 Jun 07, 2021

20MG

A212160 006 Jun 07, 2021

30MG

A212160 007 Jun 07, 2021

DEXTROSTAT

+ SHIRE

5MG **

A084051 001

+

10MG **

A084051 002

FERNDEX

FERNDALE LABS

5MG

A084001 001

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-144(of 478)

** See List Footnote

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PHERAZINE DM

HALSEY

15MG/5ML; 6.25MG/5ML

A088913 001 Mar 02, 1987

PROMETH W/ DEXTROMETHORPHAN

G AND W LABS INC

15MG/5ML; 6.25MG/5ML **

A088762 001 Oct 31, 1984

PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE

AKORN

15MG/5ML; 6.25MG/5ML

A040027 001 Jul 31, 1996

+ ANI PHARMS

15MG/5ML; 6.25MG/5ML **

N011265 002 Apr 02, 1984

DEXTROSE

INJECTABLE; INJECTION

DEXTROSE 10% IN PLASTIC CONTAINER

B BRAUN

10GM/100ML

N018046 001

MILES

10GM/100ML

N018504 001

DEXTROSE 2.5% IN PLASTIC CONTAINER

B BRAUN

2.5GM/100ML

N018358 001

2.5GM/100ML

N019626 001 Feb 02, 1988

DEXTROSE 20% IN PLASTIC CONTAINER

+ BAXTER HLTHCARE

20GM/100ML **

N017521 004

DEXTROSE 30% IN PLASTIC CONTAINER

+ BAXTER HLTHCARE

30GM/100ML **

N017521 003

DEXTROSE 38.5% IN PLASTIC CONTAINER

ABBOTT

38.5GM/100ML

N018923 001 Sep 19, 1984

DEXTROSE 40% IN PLASTIC CONTAINER

+ BAXTER HLTHCARE

40GM/100ML **

N017521 002

DEXTROSE 5% IN PLASTIC CONTAINER

DHL

5GM/100ML

N019971 001 Sep 28, 1995

+ ICU MEDICAL INC

50MG/ML

N019222 001 Jul 13, 1984

DEXTROSE 50% IN PLASTIC CONTAINER

+ BAXTER HLTHCARE

50GM/100ML **

N017521 001

ICU MEDICAL INC

50GM/100ML

N019894 001 Dec 26, 1989

DEXTROSE 60%

B BRAUN

60GM/100ML

N017995 002 Sep 22, 1982

DEXTROSE 60% IN PLASTIC CONTAINER

B BRAUN

60GM/100ML

N017995 001

+ BAXTER HLTHCARE

60GM/100ML **

N017521 005 Mar 26, 1982

60GM/100ML

N020047 002 Jul 02, 1991

HOSPIRA

60GM/100ML

N019346 001 Jan 25, 1985

DEXTROSE 7.7% IN PLASTIC CONTAINER

B BRAUN

7.7GM/100ML

N019626 003 Feb 02, 1988

DEXTROSE 70% IN PLASTIC CONTAINER

+ BAXTER HLTHCARE

70GM/100ML **

N017521 006 Mar 26, 1982

DEXTROSE; MAGNESIUM ACETATE TETRAHYDRATE; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

PLASMA-LYTE 56 AND DEXTROSE 5% IN PLASTIC CONTAINER

BAXTER HLTHCARE

5GM/100ML; 32MG/100ML; 128MG/100ML; 234MG/100ML

N017385 001

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE

INJECTABLE; INJECTION

ISOLYTE P W/ DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN

5GM/100ML; 31MG/100ML; 130MG/100ML; 26MG/100ML; 320MG/100ML

N019025 001 Dec 27, 1984

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE; SODIUM LACTATE; SODIUM PHOSPHATE, MONOBASIC ANHYDROUS

INJECTABLE; INJECTION

IONOSOL B AND DEXTROSE 5% IN PLASTIC CONTAINER

HOSPIRA

5GM/100ML; 53MG/100ML; 100MG/100ML; 100MG/100ML; 180MG/100ML; 280MG/100ML; 16MG/100ML

N019515 001 May 08, 1986

L

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN

5GM/100ML; 30MG/100ML; 97MG/100ML; 220MG/100ML; 140MG/100ML

N019844 001 Jun 10, 1993

ISOLYTE H W/ DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN

5GM/100ML; 30MG/100ML; 97MG/100ML; 220MG/100ML; 140MG/100ML

N018273 001

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-145(of 478)

** See List Footnote

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE; INJECTION

ISOLYTE S IN DEXTROSE 5% IN PLASTIC CONTAINER			
B BRAUN	5GM/100ML; 30MG/100ML; 37MG/100ML; 370MG/100ML; 530MG/100ML; 500MG/100ML	N019843 001	Aug 09, 1993
ISOLYTE S W/ DEXTROSE 5% IN PLASTIC CONTAINER			
B BRAUN	5GM/100ML; 30MG/100ML; 37MG/100ML; 370MG/100ML; 530MG/100ML; 500MG/100ML	N018274 001	
PLASMA-LYTE 148 AND DEXTROSE 5% IN PLASTIC CONTAINER			
+ BAXTER HLTHCARE	5GM/100ML; 30MG/100ML; 37MG/100ML; 368MG/100ML; 526MG/100ML; 502MG/100ML	N017451 001	

DEXTROSE; POTASSIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% IN PLASTIC CONTAINER			
B BRAUN	5GM/100ML; 37MG/100ML	N019699 001	Sep 29, 1989
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% IN PLASTIC CONTAINER			
B BRAUN	5GM/100ML; 75MG/100ML	N018744 001	Nov 09, 1982
	5GM/100ML; 75MG/100ML	N019699 002	Sep 29, 1989
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% IN PLASTIC CONTAINER			
B BRAUN	5GM/100ML; 110MG/100ML	N019699 003	Sep 29, 1989
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% IN PLASTIC CONTAINER			
B BRAUN	5GM/100ML; 150MG/100ML	N018744 002	Nov 09, 1982
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% IN PLASTIC CONTAINER			
B BRAUN	5GM/100ML; 220MG/100ML	N018744 003	Nov 09, 1982
	5GM/100ML; 220MG/100ML	N019699 005	Sep 29, 1989
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% IN PLASTIC CONTAINER			
B BRAUN	5GM/100ML; 300MG/100ML	N018744 004	Nov 09, 1982
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER			
ICU MEDICAL INC	5GM/100ML; 224MG/100ML	N018371 003	
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER			
ICU MEDICAL INC	5GM/100ML; 298MG/100ML	N018371 002	

DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM LACTATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, MONOBASIC ANHYDROUS

INJECTABLE; INJECTION

IONOSOL T AND DEXTROSE 5% IN PLASTIC CONTAINER			
HOSPIRA	5GM/100ML; 111MG/100ML; 256MG/100ML; 146MG/100ML; 207MG/100ML	N019514 001	May 08, 1986

DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

ISOLYTE M IN DEXTROSE 5% IN PLASTIC CONTAINER			
B BRAUN	5GM/100ML; 150MG/100ML; 130MG/100ML; 280MG/100ML; 91MG/100ML	N019870 001	Jun 10, 1993
ISOLYTE M W/ DEXTROSE 5% IN PLASTIC CONTAINER			
B BRAUN	5GM/100ML; 150MG/100ML; 130MG/100ML; 280MG/100ML; 91MG/100ML	N018270 001	

DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

DEXTROSE 5% AND ELECTROLYTE NO. 75 IN PLASTIC CONTAINER			
BAXTER HLTHCARE	5GM/100ML; 205MG/100ML; 100MG/100ML; 120MG/100ML; 220MG/100ML	N018840 001	Jun 29, 1983

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.075%			
B BRAUN	5GM/100ML; 75MG/100ML; 200MG/100ML	N018268 009	
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER			
B BRAUN	5GM/100ML; 150MG/100ML; 200MG/100ML	N018268 004	
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER			
B BRAUN	5GM/100ML; 220MG/100ML; 200MG/100ML	N018268 005	
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER			
B BRAUN	5GM/100ML; 300MG/100ML; 200MG/100ML	N018268 006	
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER			
B BRAUN	5GM/100ML; 75MG/100ML; 330MG/100ML	N018268 011	Jan 18, 1986
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER			
B BRAUN	5GM/100ML; 150MG/100ML; 330MG/100ML	N018268 012	Jan 18, 1986
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.22% IN PLASTIC CONTAINER			
B BRAUN	5GM/100ML; 220MG/100ML; 330MG/100ML	N018268 013	Jan 18, 1986

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-146(of 478)

** See List Footnote

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.30% IN PLASTIC CONTAINER					
B BRAUN	5GM/100ML; 300MG/100ML; 330MG/100ML	N018268	014	Jan 18,	1986
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.075%					
B BRAUN	5GM/100ML; 75MG/100ML; 450MG/100ML	N018268	010		
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER					
B BRAUN	5GM/100ML; 150MG/100ML; 450MG/100ML	N018268	001		
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.22% IN PLASTIC CONTAINER					
B BRAUN	5GM/100ML; 220MG/100ML; 450MG/100ML	N018268	002		
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER					
B BRAUN	5GM/100ML; 300MG/100ML; 450MG/100ML	N018268	003		
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 15MEQ IN PLASTIC CONTAINER					
BAXTER HLTHCARE	5GM/100ML; 224MG/100ML; 450MG/100ML	N018008	003		
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 20MEQ (K) IN PLASTIC CONTAINER					
BAXTER HLTHCARE	5GM/100ML; 300MG/100ML; 450MG/100ML	N018008	001		
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 5MEQ IN PLASTIC CONTAINER					
BAXTER HLTHCARE	5GM/100ML; 75MG/100ML; 450MG/100ML	N018008	002		
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER					
FRESENIUS KABI USA	5GM/100ML; 149MG/100ML; 225MG/100ML	A212348	001	Jul 30,	2021
+ ICU MEDICAL INC	5GM/100ML; 74.5MG/100ML; 225MG/100ML **	N018365	002	Jul 05,	1983
+ ICU MEDICAL INC	5GM/100ML; 149MG/100ML; 225MG/100ML **	N018365	006	Mar 28,	1988
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER					
ICU MEDICAL INC	5GM/100ML; 74.5MG/100ML; 300MG/100ML	N018876	001	Jan 17,	1986
	5GM/100ML; 149MG/100ML; 300MG/100ML	N018876	006	Mar 28,	1988
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45%					
FRESENIUS KABI USA	5GM/100ML; 74.5MG/100ML; 450MG/100ML	A213523	001	Mar 09,	2021
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
+ ICU MEDICAL INC	5GM/100ML; 74.5MG/100ML; 900MG/100ML	N019691	002	Mar 24,	1988
+ ICU MEDICAL INC	5GM/100ML; 149MG/100ML; 900MG/100ML	N019691	004	Mar 24,	1988
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER					
ICU MEDICAL INC	5GM/100ML; 224MG/100ML; 225MG/100ML **	N018365	008	Mar 28,	1988
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER					
ICU MEDICAL INC	5GM/100ML; 224MG/100ML; 300MG/100ML	N018876	007	Mar 28,	1988
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER					
+ ICU MEDICAL INC	5GM/100ML; 224MG/100ML; 450MG/100ML	N018362	006	Mar 28,	1988
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
+ ICU MEDICAL INC	5GM/100ML; 224MG/100ML; 900MG/100ML	N019691	006	Mar 24,	1988
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER					
FRESENIUS KABI USA	5GM/100ML; 149MG/100ML; 225MG/100ML	A212348	002	Jul 30,	2021
+ ICU MEDICAL INC	5GM/100ML; 298MG/100ML; 225MG/100ML **	N018365	009	Mar 28,	1988
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER					
ICU MEDICAL INC	5GM/100ML; 298MG/100ML; 300MG/100ML	N018876	008	Mar 28,	1988
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45%					
FRESENIUS KABI USA	5GM/100ML; 149MG/100ML; 450MG/100ML	A213523	002	Mar 09,	2021
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER					
+ ICU MEDICAL INC	5GM/100ML; 298MG/100ML; 450MG/100ML	N018362	007	Mar 28,	1988
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9%					
FRESENIUS KABI USA	5GM/100ML; 149MG/100ML; 900MG/100ML	A213445	001	Mar 09,	2021
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
+ ICU MEDICAL INC	5GM/100ML; 298MG/100ML; 900MG/100ML	N019691	008	Mar 24,	1988
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER					
ICU MEDICAL INC	5GM/100ML; 149MG/100ML; 300MG/100ML	N018876	002	Jan 17,	1986
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER					
ICU MEDICAL INC	5GM/100ML; 224MG/100ML; 225MG/100ML **	N018365	003	Jul 05,	1983
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER					
ICU MEDICAL INC	5GM/100ML; 224MG/100ML; 300MG/100ML	N018876	003	Jan 17,	1986
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45%					
FRESENIUS KABI USA	5GM/100ML; 224MG/100ML; 450MG/100ML	A213523	003	Mar 09,	2021
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
+ ICU MEDICAL INC	5GM/100ML; 224MG/100ML; 900MG/100ML	N019691	007	Mar 24,	1988
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER					
ICU MEDICAL INC	5GM/100ML; 298MG/100ML; 225MG/100ML **	N018365	004	Jul 05,	1983
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER					
ICU MEDICAL INC	5GM/100ML; 298MG/100ML; 300MG/100ML	N018876	004	Mar 28,	1988
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45%					
FRESENIUS KABI USA	5GM/100ML; 298MG/100ML; 450MG/100ML	A213523	004	Mar 09,	2021
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9%					
FRESENIUS KABI USA	5GM/100ML; 298MG/100ML; 900MG/100ML	A213445	002	Mar 09,	2021

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-147(of 478)

** See List Footnote

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER

ICU MEDICAL INC	5GM/100ML; 74.5MG/100ML; 225MG/100ML **	N018365 005	Mar 28, 1988
	5GM/100ML; 149MG/100ML; 225MG/100ML **	N018365 007	Mar 28, 1988

POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

ICU MEDICAL INC	5GM/100ML; 74.5MG/100ML; 300MG/100ML	N018876 005	Mar 28, 1988
	5GM/100ML; 149MG/100ML; 300MG/100ML	N018876 009	Mar 28, 1988

POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

+ ICU MEDICAL INC	5GM/100ML; 74.5MG/100ML; 450MG/100ML	N018362 008	Mar 28, 1988
+	5GM/100ML; 149MG/100ML; 450MG/100ML	N018362 004	Mar 28, 1988

POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

+ ICU MEDICAL INC	5GM/100ML; 74.5MG/100ML; 900MG/100ML	N019691 001	Mar 24, 1988
+	5GM/100ML; 149MG/100ML; 900MG/100ML	N019691 003	Mar 24, 1988

DEXTROSE; SODIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

B BRAUN	10GM/100ML; 200MG/100ML	N018386 001	

DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

B BRAUN	10GM/100ML; 450MG/100ML	N018229 001	

DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

B BRAUN	10GM/100ML; 900MG/100ML	N018047 001	
BAXTER HLTHCARE	10GM/100ML; 900MG/100ML	N016696 001	

DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

B BRAUN	2.5GM/100ML; 450MG/100ML	N018030 001	
HOSPIRA	2.5GM/100ML; 450MG/100ML	N018096 001	

DEXTROSE 2.5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

B BRAUN	2.5GM/100ML; 900MG/100ML	N018376 001	

DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

ABBOTT	3.3GM/100ML; 300MG/100ML	N018055 001	

DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML; 110MG/100ML	N018030 005	

DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML; 200MG/100ML	N018030 004	
MILES	5GM/100ML; 200MG/100ML	N018399 001	

DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER

ABBOTT	5GM/100ML; 225MG/100ML	N019482 001	Oct 04, 1985

DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

ABBOTT	5GM/100ML; 300MG/100ML	N019486 001	Oct 04, 1985
MILES	5GM/100ML; 300MG/100ML	N018501 001	

DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER

B BRAUN	5GM/100ML; 330MG/100ML	N018030 003	

DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

ABBOTT	5GM/100ML; 450MG/100ML	N019484 001	Oct 04, 1985
B BRAUN	5GM/100ML; 450MG/100ML	N018030 002	
MILES	5GM/100ML; 450MG/100ML	N018400 001	

DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

ABBOTT	5GM/100ML; 900MG/100ML	N019483 001	Oct 04, 1985
B BRAUN	5GM/100ML; 900MG/100ML	N018026 001	
MILES	5GM/100ML; 900MG/100ML	N018500 001	

DEXTROTHYROXINE SODIUM

TABLET; ORAL

CHOLOXIN

ABBVIE	1MG	N012302 005	
	2MG	N012302 002	
	4MG	N012302 004	
	6MG	N012302 006	

DEZOCINE

INJECTABLE; INJECTION

DALGAN

ASTRAZENECA	5MG/ML	N019082 001	Dec 29, 1989
	10MG/ML	N019082 002	Dec 29, 1989
	15MG/ML	N019082 003	Dec 29, 1989

DISCONTINUED DRUG PRODUCT LIST

6-148(of 478)

** See List Footnote

DIATRIZOATE MEGLUMINE

INJECTABLE; INJECTION

ANGIOVIST 282			
BAYER HLTHCARE	60%	A087726 001	Sep 23, 1982
CARDIOGRAFIN			
BRACCO	85%	N011620 002	
DIATRIZOATE MEGLUMINE			
BRACCO	76%	N010040 017	
HYPAAQUE			
GE HEALTHCARE	30%	N016403 002	
	60%	N016403 001	
RENO-60			
BRACCO	60%	N010040 016	
RENO-DIP			
BRACCO	30%	N010040 012	
UROVIST MEGLUMINE DIU/CT			
BAYER HLTHCARE	30%	A087739 001	Sep 23, 1982
SOLUTION; URETERAL			
RENO-30			
BRACCO	30%	N010040 021	
UROVIST CYSTO			
BAYER HLTHCARE	30%	A087729 001	Sep 23, 1982
UROVIST CYSTO PEDIATRIC			
BAYER HLTHCARE	30%	A087731 001	Sep 23, 1982
SOLUTION; URETHRAL			
HYPAAQUE-CYSTO			
GE HEALTHCARE	30%	N016403 003	

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM

INJECTABLE; INJECTION

ANGIOVIST 292			
BAYER HLTHCARE	52%; 8%	A087724 001	Sep 23, 1982
ANGIOVIST 370			
BAYER HLTHCARE	66%; 10%	A087723 001	Sep 23, 1982
DIATRIZOATE-60			
INTL MEDICATION	52%; 8%	A088166 001	Jun 17, 1983
HYPAAQUE-76			
GE HEALTHCARE	66%; 10%	A086505 001	
HYPAAQUE-M, 75%			
GE HEALTHCARE	50%; 25%	N010220 003	
HYPAAQUE-M, 90%			
GE HEALTHCARE	60%; 30%	N010220 002	
MD-60			
MALLINCKRODT	52%; 8%	A087074 001	
MD-76			
MALLINCKRODT	66%; 10%	A087073 001	
MD-76R			
+ LIEBEL-FLARSHEIM	66%; 10%	N019292 001	Sep 29, 1989
RENOCAL-76			
BRACCO	66%; 10%	A089347 001	Jun 01, 1988
RENOGRAFIN-60			
BRACCO	52%; 8%	N010040 006	
RENOGRAFIN-76			
+ BRACCO	66%; 10%	N010040 001	
RENOVIST			
BRACCO	34.3%; 35%	N010040 020	
RENOVIST II			
BRACCO	28.5%; 29.1%	N010040 019	
SOLUTION; ORAL, RECTAL			
GASTROVIST			
BAYER HLTHCARE	66%; 10%	A087728 001	Sep 23, 1982

DIATRIZOATE MEGLUMINE; IODIPAMIDE MEGLUMINE

SOLUTION; INTRAUTERINE

SINOGRAFIN			
+ BRACCO	52.7%; 26.8%	N011324 002	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-149(of 478)

** See List Footnote

DIATRIZOATE SODIUM

FOR SOLUTION;ORAL, RECTAL

HYPAQUE

GE HEALTHCARE 100%

N011386 001

INJECTABLE;INJECTION

HYPAQUE

GE HEALTHCARE 25%

N009561 003

50%

N009561 001

MD-50

MALLINCKRODT 50%

A087075 001

UROVIST SODIUM 300

BAYER HLTHCARE 50%

A087725 001 Sep 23, 1982

SOLUTION;ORAL, RECTAL

HYPAQUE

GE HEALTHCARE 40%

N011386 003

SOLUTION;URETERAL

HYPAQUE SODIUM 20%

GE HEALTHCARE 20%

N009561 002

DIAZEPAM

CAPSULE, EXTENDED RELEASE;ORAL

VALRELEASE

ROCHE 15MG

N018179 001

GEL;RECTAL

DIASTAT

+ BAUSCH 5MG/ML (5MG/ML) **

N020648 002 Jul 29, 1997

+ 10MG/2ML (5MG/ML) **

N020648 003 Jul 29, 1997

+ 15MG/3ML (5MG/ML) **

N020648 004 Jul 29, 1997

+ 20MG/4ML (5MG/ML) **

N020648 005 Jul 29, 1997

INJECTABLE;INJECTION

DIAZEPAM

ABRAXIS PHARM 5MG/ML

A070662 001 Jun 25, 1986

HIKMA 5MG/ML

A070311 001 Dec 16, 1985

5MG/ML

A070312 001 Dec 16, 1985

5MG/ML

A071308 001 Jul 17, 1987

5MG/ML

A071309 001 Jul 17, 1987

5MG/ML

A071310 001 Jul 17, 1987

HOSPIRA 5MG/ML

A071584 001 Oct 13, 1987

MARSAM PHARMS LLC 5MG/ML

A072371 001 Jan 29, 1993

PARENTA PHARMS 5MG/ML

A076815 001 Apr 15, 2004

US ARMY 5MG/ML **

N020124 001 Dec 05, 1990

WARNER CHILCOTT 5MG/ML

A071613 001 Oct 22, 1987

5MG/ML

A071614 001 Oct 22, 1987

WATSON LABS 5MG/ML

A070296 001 Feb 12, 1986

5MG/ML

A070911 001 Aug 28, 1986

5MG/ML

A070912 001 Aug 28, 1986

5MG/ML

A070930 001 Dec 01, 1986

WATSON LABS INC 5MG/ML

A072370 001 Jan 29, 1993

5MG/ML

A072397 001 Jan 29, 1993

DIZAC

PHARMACIA AND UPJOHN 5MG/ML **

N019287 001 Jun 18, 1993

VALIUM

+ ROCHE 5MG/ML **

N016087 001

TABLET;ORAL

DIAZEPAM

ACTAVIS ELIZABETH 2MG

A070781 001 Mar 19, 1986

5MG

A070706 001 Mar 19, 1986

10MG

A070707 001 Mar 19, 1986

BARR 2MG

A070152 001 Nov 01, 1985

10MG

A070154 001 Nov 01, 1985

DAVA PHARMS INC 2MG

A070228 002 Sep 26, 1985

5MG

A070228 003 Sep 26, 1985

10MG

A070228 001 Sep 26, 1985

DURAMED PHARMS BARR 2MG

A070894 001 Aug 27, 1986

5MG

A070895 001 Aug 27, 1986

10MG

A070896 001 Aug 27, 1986

FERNDAL LABS 2MG

A070903 001 Apr 01, 1987

5MG

A070904 001 Apr 01, 1987

10MG

A070905 001 Apr 01, 1987

HALSEY 2MG

A070987 001 Aug 15, 1986

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-150(of 478)

** See List Footnote

DIAZEPAM

TABLET; ORAL

DIAZEPAM

	5MG	A070996 001	Aug 15, 1986
	10MG	A070956 001	Aug 15, 1986
IVAX SUB TEVA PHARMS	2MG	A070360 001	Sep 04, 1985
	5MG	A070361 001	Sep 04, 1985
	10MG	A070362 001	Sep 04, 1985
MARTEC USA LLC	10MG	A072402 001	Apr 25, 1989
NUVO PHARM	10MG	A070464 001	Feb 25, 1986
PIONEER PHARMS	2MG	A070787 001	Aug 02, 1988
	5MG	A070788 001	Aug 02, 1988
	10MG	A070776 001	Aug 02, 1988
ROXANE	2MG	A070356 001	Jun 17, 1986
	5MG	A070357 001	Jun 17, 1986
	10MG	A070358 001	Jun 17, 1986
TEVA PHARMS	5MG	A070153 001	Nov 01, 1985
UPSHER SMITH LABS	2MG	A070302 001	Dec 20, 1985
	5MG	A070303 001	Dec 20, 1985
	10MG	A070304 001	Dec 20, 1985
VIRTUS PHARMS	2MG	A070462 001	Feb 25, 1986
	5MG	A070463 001	Feb 25, 1986
WARNER CHILCOTT	2MG	A070209 001	Sep 04, 1985
	5MG	A070210 001	Sep 04, 1985
	10MG	A070222 001	Sep 04, 1985
WATSON LABS	2MG	A070456 001	Nov 01, 1985
	5MG	A070457 001	Nov 01, 1985
	10MG	A070458 001	Nov 01, 1985
Q-PAM			
QUANTUM PHARMICS	2MG	A070423 001	Dec 12, 1985
	2MG	A072431 001	Apr 29, 1988
	5MG	A070424 001	Dec 12, 1985
	5MG	A072432 001	Apr 29, 1988
	10MG	A070425 001	Dec 12, 1985
	10MG	A072433 001	Apr 29, 1988

DIAZOXIDE

CAPSULE; ORAL

PROGLYCEM

TEVA BRANDED PHARM	50MG	N017425 001	
	100MG	N017425 002	

INJECTABLE; INJECTION

DIAZOXIDE

ABRAXIS PHARM	15MG/ML	A071519 001	Aug 26, 1987
HYPERSTAT			
SCHERING	15MG/ML	N016996 001	

DIBUCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

HEAVY SOLUTION NUPERCALINE

NOVARTIS	2.5MG/ML	N006203 001	

DICHLORPHENAMIDE

TABLET; ORAL

DARANIDE

+ XERIS	50MG **	N011366 001	

DICLOFENAC

CAPSULE; ORAL

ZORVOLEX

+ ZYLA	18MG **	N204592 001	Oct 18, 2013
+	35MG	N204592 002	Oct 18, 2013

DICLOFENAC POTASSIUM

TABLET; ORAL

CATAFLAM

+ NOVARTIS	25MG **	N020142 001	Nov 24, 1993
+	50MG **	N020142 002	Nov 24, 1993

DICLOFENAC POTASSIUM

SANDOZ	50MG	A075582 001	Feb 23, 2001
SUN PHARM INDUSTRIES	50MG	A075470 001	Feb 21, 2002
WATSON LABS TEVA	50MG	A075152 001	Nov 27, 1998

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-151(of 478)

** See List Footnote

DICLOFENAC SODIUM

GEL; TOPICAL

SOLARAZE

+ FOUGERA PHARMS

3% **

N021005 001 Oct 16, 2000

SOLUTION; INTRAVENOUS

DICLOFENAC SODIUM

RISING

37.5MG/ML (37.5MG/ML)

A208786 001 Jun 18, 2019

DYLOJECT

+ JAVELIN PHARMS INC

37.5MG/ML (37.5MG/ML) **

N022396 001 Dec 23, 2014

SOLUTION; TOPICAL

DICLOFENAC SODIUM

APOTEX INC

1.5%

A202027 001 May 27, 2014

RISING

1.5%

A206715 001 Aug 07, 2017

TWI PHARMS

1.5%

A202393 001 Nov 24, 2014

PENNSAID

+ NUVO PHARMS INC

1.5% **

N020947 001 Nov 04, 2009

SOLUTION/DROPS; OPHTHALMIC

DICLOFENAC SODIUM

AKORN

0.1%

A077845 001 Apr 17, 2008

FALCON PHARMS

0.1%

N020809 001 May 04, 1998

RUBICON

0.1%

A077600 001 Nov 13, 2008

VOLTAREN

+ NOVARTIS

0.1%

N020037 001 Mar 28, 1991

TABLET, DELAYED RELEASE; ORAL

DICLOFENAC SODIUM

AUROBINDO PHARMA USA

50MG

A075281 002 Feb 12, 2002

75MG

A075281 003 Feb 12, 2002

CHARTWELL RX

25MG

A074376 001 Sep 28, 1995

50MG

A074376 002 Sep 28, 1995

75MG

A074394 001 Nov 30, 1995

MICRO LABS

50MG

A074986 001 Feb 26, 1999

75MG

A074986 002 Feb 26, 1999

PLIVA

50MG

A074432 002 Jul 29, 1999

75MG

A074432 003 Jul 29, 1999

ROXANE

25MG

A074391 001 Jun 29, 1995

50MG

A074391 002 Jun 29, 1995

75MG

A074391 003 Jun 29, 1995

TEVA

50MG

A074723 001 Mar 30, 1999

75MG

A074390 001 Aug 15, 1996

TEVA PHARMS

25MG

A074459 001 Jun 25, 1997

50MG

A074459 002 Jun 25, 1997

75MG

A074459 003 Jun 25, 1997

VOLTAREN

+ NOVARTIS

25MG **

N019201 001 Jul 28, 1988

+

50MG **

N019201 002 Jul 28, 1988

+

75MG **

N019201 003 Jul 28, 1988

TABLET, EXTENDED RELEASE; ORAL

DICLOFENAC SODIUM

ACTAVIS ELIZABETH

100MG

A075910 001 Jan 07, 2002

MYLAN

100MG

A076152 001 Dec 13, 2001

VOLTAREN-XR

+ NOVARTIS

100MG **

N020254 001 Mar 08, 1996

DICLOFENAC SODIUM; MISOPROSTOL

TABLET, DELAYED RELEASE; ORAL

DICLOFENAC SODIUM AND MISOPROSTOL

EXELA HOLDINGS

50MG; 0.2MG

A200540 001 Mar 14, 2014

75MG; 0.2MG

A200540 002 Mar 14, 2014

DICLOXACILLIN SODIUM

CAPSULE; ORAL

DICLOXACILLIN SODIUM

SANDOZ

EQ 125MG BASE

A061454 002

EQ 250MG BASE

A061454 001

EQ 500MG BASE

A061454 003

DYCILL

GLAXOSMITHKLINE

EQ 250MG BASE

A060254 002

EQ 250MG BASE

A062238 001

EQ 500MG BASE

A060254 003

EQ 500MG BASE

A062238 002

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-152(of 478)

** See List Footnote

DICLOXACILLIN SODIUM

CAPSULE; ORAL

PATHOCIL

+ WYETH AYERST

EQ 250MG BASE **

N050011 002

+

EQ 500MG BASE **

N050011 003 Mar 28, 1983

FOR SUSPENSION; ORAL

DICLOXACILLIN SODIUM

APOTHECON

EQ 62.5MG BASE/5ML

A061455 001

DYNAPEN

APOTHECON

EQ 62.5MG BASE/5ML

N050337 002

PATHOCIL

WYETH AYERST

EQ 62.5MG BASE/5ML

N050092 001

DICUMAROL

CAPSULE; ORAL

DICUMAROL

LILLY

25MG

N005509 003

50MG

N005509 001

TABLET; ORAL

DICUMAROL

ABBVIE

25MG

N005545 003

50MG

N005545 004

100MG

N005545 005

DICYCLOMINE HYDROCHLORIDE

CAPSULE; ORAL

BENTYL

+ ALLERGAN

10MG **

N007409 003 Oct 15, 1984

DICYCLOMINE HYDROCHLORIDE

PIONEER PHARMS

10MG

A089361 001 Jan 10, 1989

SUN PHARM INDUSTRIES

10MG

A084505 001 Oct 21, 1986

WATSON LABS

10MG

A083179 001 Feb 12, 1986

INJECTABLE; INJECTION

DICYCLOMINE HYDROCHLORIDE

ATHENEX INC

10MG/ML

A212058 001 Apr 26, 2019

DR REDDYS

10MG/ML

A080614 001 Feb 11, 1986

HIKMA

10MG/ML

A210788 001 Feb 11, 2019

SYRUP; ORAL

BENTYL

+ APTALIS PHARMA US

10MG/5ML **

N007961 002 Oct 15, 1984

DICYCLOMINE HYDROCHLORIDE

ALPHARMA US PHARMS

10MG/5ML

A084479 001

TABLET; ORAL

BENTYL

+ ALLERGAN

20MG **

N007409 001 Oct 15, 1984

DICYCLOMINE HYDROCHLORIDE

AUROBINDO PHARMA USA

20MG

A040317 001 Sep 07, 1999

PIONEER PHARMS

20MG

A088585 001 Aug 20, 1986

SUN PHARM INDUSTRIES

20MG

A084600 001 Jul 29, 1985

WATSON LABS

20MG

A084361 001 Feb 06, 1986

DIDANOSINE

CAPSULE, DELAYED REL PELLETS; ORAL

DIDANOSINE

AUROBINDO PHARMA

125MG

A090094 001 Sep 24, 2008

200MG

A090094 002 Sep 24, 2008

250MG

A090094 003 Sep 24, 2008

400MG

A090094 004 Sep 24, 2008

BARR

200MG

A077167 001 Dec 03, 2004

250MG

A077167 002 Dec 03, 2004

400MG

A077167 003 Dec 03, 2004

MYLAN PHARMS INC

125MG

A090788 001 Apr 08, 2010

200MG

A090788 002 Apr 08, 2010

250MG

A090788 003 Apr 08, 2010

400MG

A090788 004 Apr 08, 2010

VIDEX EC

+ BRISTOL MYERS SQUIBB

125MG **

N021183 001 Oct 31, 2000

+

200MG **

N021183 002 Oct 31, 2000

+

250MG **

N021183 003 Oct 31, 2000

+

400MG **

N021183 004 Oct 31, 2000

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-153(of 478)

** See List Footnote

DIDANOSINE

FOR SOLUTION;ORAL

DIDANOSINE

AUROBINDO PHARMA 10MG/ML

A078112 001 Mar 08, 2007

VIDEX

+ BRISTOL 10MG/ML

N020156 001 Oct 09, 1991

BRISTOL MYERS SQUIBB 100MG/PACKET

N020155 003 Oct 09, 1991

167MG/PACKET

N020155 004 Oct 09, 1991

250MG/PACKET

N020155 005 Oct 09, 1991

375MG/PACKET

N020155 006 Oct 09, 1991

TABLET, CHEWABLE;ORAL

VIDEX

+ BRISTOL MYERS SQUIBB 25MG **

N020154 002 Oct 09, 1991

+ 50MG **

N020154 003 Oct 09, 1991

+ 100MG **

N020154 004 Oct 09, 1991

+ 150MG **

N020154 005 Oct 09, 1991

+ 200MG **

N020154 006 Oct 28, 1999

TABLET, FOR SUSPENSION;ORAL

DIDANOSINE

AUROBINDO 100MG

A077275 001 Aug 14, 2012

150MG

A077275 002 Aug 14, 2012

200MG

A077275 003 Aug 14, 2012

DIENESTROL

CREAM;VAGINAL

DIENESTROL

ORTHO MCNEIL PHARM 0.01%

N006110 005

DV

SANOFI AVENTIS US 0.01%

A083518 001

ESTRAGUARD

SOLVAY 0.01%

A084436 001

SUPPOSITORY;VAGINAL

DV

SANOFI AVENTIS US 0.7MG

A083517 001

DIETHYLCARBAMAZINE CITRATE

TABLET;ORAL

HETRAZAN

LEDERLE 50MG

N006459 001

DIETHYLPROPION HYDROCHLORIDE

TABLET;ORAL

DIETHYLPROPION HYDROCHLORIDE

CHARTWELL RX 25MG

A088267 001 Aug 25, 1983

25MG

A088268 001 Aug 25, 1983

EPIC PHARMA LLC 25MG

A040828 001 Nov 05, 2008

SANDOZ 25MG

A085916 001

TEVA 25MG

A088642 001 Sep 20, 1984

UCB INC 25MG

A085544 001

WATSON LABS 25MG

A085741 001

TENUATE

+ NOSTRUM LABS INC 25MG

N011722 002

SANOFI AVENTIS US 25MG

N017668 001

TEPANIL

3M 25MG

N011673 001

TABLET, EXTENDED RELEASE;ORAL

TENUATE

SANOFI AVENTIS US 75MG

N017669 001

TENUATE DOSPAN

+ NOSTRUM LABS INC 75MG

N012546 001

TEPANIL TEN-TAB

3M 75MG

N017956 001

DIETHYLSTILBESTROL

INJECTABLE;INJECTION

STILBESTROL

BRISTOL MYERS SQUIBB 0.2MG/ML

N004056 003

0.5MG/ML

N004056 004

1MG/ML

N004056 005

5MG/ML

N004056 006

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-154(of 478)

** See List Footnote

DIETHYLSTILBESTROL

SUPPOSITORY;VAGINAL

DIETHYLSTILBESTROL

LILLY

0.1MG

N004040 001

0.5MG

N004040 002

STILBESTROL

BRISTOL MYERS SQUIBB

0.1MG

N004056 001

0.5MG

N004056 002

TABLET;ORAL

DIETHYLSTILBESTROL

LILLY

0.1MG

N004041 002

0.5MG

N004041 003

1MG

N004041 004

5MG

N004041 005

STILBESTROL

TABLICAPS

0.5MG

A083004 001

1MG

A083002 001

5MG

A083006 001

STILBETIN

BRISTOL MYERS SQUIBB

0.1MG

N004056 007

0.25MG

N004056 017

0.5MG

N004056 008

1MG

N004056 009

5MG

N004056 010

TABLET, DELAYED RELEASE;ORAL

DIETHYLSTILBESTROL

LILLY

0.1MG

N004039 002

0.25MG

N004039 005

0.5MG

N004039 003

1MG

N004039 004

5MG

N004039 006

STILBESTROL

TABLICAPS

0.5MG

A083003 001

1MG

A083005 001

5MG

A083007 001

STILBETIN

BRISTOL MYERS SQUIBB

0.1MG

N004056 011

0.5MG

N004056 012

1MG

N004056 013

5MG

N004056 014

DIETHYLSTILBESTROL DIPHOSPHATE

INJECTABLE; INJECTION

STILPHOSTROL

BAYER PHARMS

250MG/5ML

N010010 001

TABLET;ORAL

STILPHOSTROL

BAYER PHARMS

50MG

N010010 002

DIFLORASONE DIACETATE

CREAM;TOPICAL

DIFLORASONE DIACETATE

FOUGERA PHARMS

0.05%

A075187 001 Mar 30, 1998

FLORONE

PFIZER

0.05% **

N017741 001

FLORONE E

PFIZER

0.05%

N019259 001 Aug 28, 1985

PSORCON

+ TARO PHARMS NORTH

0.05% **

N020205 001 Nov 20, 1992

OINTMENT;TOPICAL

DIFLORASONE DIACETATE

AKORN

0.05%

A206572 001 Jul 24, 2015

PSORCON

+ PFIZER

0.05%

N019260 001 Aug 28, 1985

PSORCON E

PFIZER

0.05%

N017994 001

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-155(of 478)

** See List Footnote

DIFLUNISAL

TABLET; ORAL

DIFLUNISAL

ANI PHARMS	500MG	A074604	001	Jun 10, 1996
DASTECH INTL	250MG	A073562	001	Nov 27, 1992
	500MG	A073563	001	Nov 27, 1992
PUREPAC PHARM	250MG	A074285	001	May 07, 1996
	500MG	A074285	002	May 07, 1996
TEVA	250MG	A073679	001	Jul 31, 1992
WATSON LABS	250MG	A074400	001	Jul 17, 1997
	500MG	A074400	002	Jul 17, 1997
DOLOBID				
+ MERCK	250MG **	N018445	001	Apr 19, 1982
+	500MG **	N018445	002	Apr 19, 1982

DIGITOXIN

INJECTABLE; INJECTION

CRYSTODIGIN

LILLY	0.2MG/ML	A084100	005	

DIGOXIN

CAPSULE; ORAL

LANOXICAPS

GLAXOSMITHKLINE LLC	0.05MG	N018118	002	Jul 26, 1982
	0.1MG	N018118	003	Jul 26, 1982
	0.15MG	N018118	004	Sep 24, 1984
	0.2MG	N018118	001	Jul 26, 1982

INJECTABLE; INJECTION

DIGOXIN

ABRAXIS PHARM	0.25MG/ML	A083217	001	
HOSPIRA	0.25MG/ML	A040093	001	May 16, 1996
	0.25MG/ML	A040206	001	Aug 28, 1998
WYETH AYERST	0.25MG/ML	A084386	001	
DIGOXIN PEDIATRIC				
HOSPIRA	0.1MG/ML	A040092	001	Apr 25, 1996

TABLET; ORAL

LANOXIN

+ CONCORDIA	0.1875MG	N020405	003	Sep 30, 1997
	0.375MG	N020405	005	Sep 30, 1997
	0.5MG	N020405	006	Sep 30, 1997

DIHYDROERGOTAMINE MESYLATE

INJECTABLE; INJECTION

D.H.E. 45

+ BAUSCH	1MG/ML	N005929	001	

SPRAY, METERED; NASAL

DIHYDROERGOTAMINE MESYLATE

AMNEAL	0.5MG/SPRAY	A214105	001	Jan 04, 2022

DIHYDROERGOTAMINE MESYLATE; HEPARIN SODIUM; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

EMBOLEX

NOVARTIS	0.5MG/0.5ML; 2,500 UNITS/0.5ML; 5.33MG/0.5ML	N018885	001	Nov 30, 1984
	0.5MG/0.7ML; 5,000 UNITS/0.7ML; 7.46MG/0.7ML	N018885	002	Nov 30, 1984

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

CARDIZEM SR

+ BIOVAIL	60MG **	N019471	001	Jan 23, 1989
+	90MG **	N019471	002	Jan 23, 1989
+	120MG **	N019471	003	Jan 23, 1989
+	180MG **	N019471	004	Jan 23, 1989

DILACOR XR

+ ALLERGAN	120MG **	N020092	001	May 29, 1992
+	180MG **	N020092	002	May 29, 1992
+	240MG **	N020092	003	May 29, 1992

DILT-CD

APOTEX	120MG	A076151	001	May 20, 2004
	180MG	A076151	002	May 20, 2004
	240MG	A076151	003	May 20, 2004

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-156(of 478)

** See List Footnote

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

DILT-CD

	300MG	A076151	004	May 20, 2004
DILTIAZEM HYDROCHLORIDE				
ACTAVIS LABS FL INC	120MG	A074852	001	Oct 10, 1997
	180MG	A074852	002	Oct 10, 1997
	240MG	A074852	003	Oct 10, 1997
BIOVAIL	60MG	A074845	001	Sep 15, 1999
	90MG	A074845	002	Sep 15, 1999
	120MG	A074845	003	Sep 15, 1999
	120MG	N020939	001	Jan 28, 2000
	180MG	N020939	002	Jan 28, 2000
	240MG	N020939	003	Jan 28, 2000
	300MG	N020939	004	Jan 28, 2000
	360MG	N020939	005	Sep 14, 2001
	420MG	N020939	006	Sep 14, 2001
MYLAN	120MG	A075124	002	Mar 18, 1998
	180MG	A075124	003	Mar 18, 1998
	240MG	A075124	001	Mar 18, 1998
NESHER PHARMS	120MG	A076563	002	Sep 12, 2006
	180MG	A076563	003	Sep 12, 2006
	240MG	A076563	004	Sep 12, 2006
	300MG	A076563	005	Sep 12, 2006
	360MG	A076563	006	Sep 12, 2006
	420MG	A076563	001	Sep 12, 2006
PAR PHARM	360MG	A209766	001	May 30, 2018
SUN PHARM	120MG	A090492	001	Oct 28, 2011
	180MG	A090492	002	Oct 28, 2011
	240MG	A090492	003	Oct 28, 2011
	300MG	A090492	004	Oct 28, 2011
TEVA	60MG	A074079	001	Nov 30, 1993
	90MG	A074079	002	Nov 30, 1993
	120MG	A074079	003	Nov 30, 1993
DILTIZAC				
APOTEX	120MG	A076395	001	Feb 01, 2006
	180MG	A076395	002	Feb 01, 2006
	240MG	A076395	003	Feb 01, 2006
	300MG	A076395	004	Feb 01, 2006
	360MG	A076395	005	Feb 01, 2006
INJECTABLE; INJECTION				
CARDIZEM				
BIOVAIL	100MG/VIAL **	N020792	001	Sep 05, 1997
+ BIOVAIL LABS INTL	5MG/ML **	N020027	001	Oct 24, 1991
+	25MG/VIAL **	N020027	003	Aug 18, 1995
DILTIAZEM HYDROCHLORIDE				
DR REDDYS	5MG/ML	A074894	001	Aug 26, 1997
HOSPIRA	5MG/ML	A075004	001	Feb 16, 2000
	5MG/ML	A075106	001	Apr 29, 1999
INTL MEDICATION	5MG/ML	A075749	001	Nov 21, 2001
MYLAN LABS LTD	5MG/ML	A075375	001	Sep 30, 1999
SOLUTION; INTRAVENOUS				
DILTIAZEM HYDROCHLORIDE IN DEXTROSE 5%				
+ EXELA PHARMA	125MG/125ML (1MG/ML)	N215252	001	Oct 28, 2021
+	250MG/250ML (1MG/ML)	N215252	002	Oct 28, 2021
TABLET; ORAL				
DILTIAZEM HYDROCHLORIDE				
APOTHECON	30MG	A074051	001	Mar 31, 1993
	60MG	A074051	002	Mar 31, 1993
	90MG	A074051	003	Mar 31, 1993
	120MG	A074051	004	Mar 31, 1993
CHARTWELL MOLECULES	30MG	A074093	001	Nov 05, 1992
	60MG	A074093	002	Nov 05, 1992
	90MG	A074093	003	Nov 05, 1992
	120MG	A074093	004	Nov 05, 1992
IVAX SUB TEVA PHARMS	30MG	A074168	001	Mar 03, 1995
	60MG	A074168	002	Mar 03, 1995
	90MG	A074168	003	Mar 03, 1995
	120MG	A074168	004	Mar 03, 1995

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-157(of 478)

** See List Footnote

DILTIAZEM HYDROCHLORIDE

TABLET; ORAL

DILTIAZEM HYDROCHLORIDE

RISING	30MG	A072838 004	Nov 05, 1992
	60MG	A072838 003	Nov 05, 1992
	90MG	A072838 002	Nov 05, 1992
	120MG	A072838 001	Nov 05, 1992
TEVA	30MG	A074084 001	Feb 25, 1994
	60MG	A074084 002	Feb 25, 1994
TEVA PHARMS	30MG	A074067 001	Nov 05, 1992
	60MG	A074067 002	Nov 05, 1992
	90MG	A074067 003	Nov 05, 1992
	120MG	A074067 004	Nov 05, 1992

DILTIAZEM MALATE

TABLET, EXTENDED RELEASE; ORAL

TIAMATE

MERCK	EQ 120MG HYDROCHLORIDE	N020506 001	Oct 04, 1996
	EQ 180MG HYDROCHLORIDE	N020506 002	Oct 04, 1996
	EQ 240MG HYDROCHLORIDE	N020506 003	Oct 04, 1996

DILTIAZEM MALATE; ENALAPRIL MALEATE

TABLET, EXTENDED RELEASE; ORAL

TECZEM

BIOVAIL	EQ 180MG HYDROCHLORIDE; 5MG	N020507 001	Oct 04, 1996

DIMENHYDRINATE

INJECTABLE; INJECTION

DIMENHYDRINATE

BAXTER HLTHCARE	50MG/ML	A084767 001
WATSON LABS	50MG/ML	A083531 001
+ WATSON LABS TEVA	50MG/ML	A080615 001
WYETH AYERST	50MG/ML	A084316 001

LIQUID; ORAL

DIMENHYDRINATE

ALRA	12.5MG/4ML	A080715 001

TABLET; ORAL

DIMENHYDRINATE

HEATHER	50MG	A080841 001
NEXGEN PHARMA INC	50MG	A085985 001
+ WATSON LABS	50MG	A085166 001

DIMETHYL FUMARATE

CAPSULE, DELAYED RELEASE; ORAL

DIMETHYL FUMARATE

SAWAI USA	120MG	A210285 001	Dec 21, 2021
	240MG	A210285 002	Dec 21, 2021
SOLA PHARMS	120MG	A210436 001	Mar 26, 2021
	240MG	A210436 002	Mar 26, 2021
ZYDUS PHARMS	120MG	A210538 001	Sep 24, 2020
	240MG	A210538 002	Sep 24, 2020

DIMETHYL SULFOXIDE

SOLUTION; INTRAVESICAL

DIMETHYL SULFOXIDE

MYLAN INSTITUTIONAL	50%	A076185 001	Nov 29, 2002

DIMYRISTOYL LECITHIN; PERFLEXANE

INJECTABLE; INTRAVENOUS

IMAGENT

VESSELON SPV LLC	0.92MG/VIAL; 0.092MG/VIAL	N021191 001	May 31, 2002

DINOPROST TROMETHAMINE

INJECTABLE; INJECTION

PROSTIN F2 ALPHA

PHARMACIA AND UPJOHN	EQ 5MG BASE/ML	N017434 001

DISCONTINUED DRUG PRODUCT LIST

6-158(of 478)

** See List Footnote

DINOPROSTONE

SUPPOSITORY;VAGINAL

PROSTIN E2

+ PFIZER

20MG

N017810 001

DIPHEMANIL METHYLSULFATE

TABLET;ORAL

PRANTAL

SCHERING

100MG

N008114 004

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE;ORAL

BENADRYL

MCNEIL CONS

25MG

N005845 007

50MG

N005845 001

DIPHENHYDRAMINE HYDROCHLORIDE

ALRA

25MG

A080519 004

50MG

A080519 003

ANABOLIC

50MG

A083275 001

ELKINS SINN

25MG

A085701 001

50MG

A085701 002

FOSUN PHARMA

25MG

A080832 001

25MG

A080845 002

50MG

A080832 002

50MG

A080845 001

HALSEY

50MG

A087914 001

Jun 04, 1984

HEATHER

25MG

A084524 001

50MG

A083953 001

HERITAGE PHARMA

50MG

A080727 001

50MG

A080738 001

HIKMA INTL PHARMS

50MG

A083567 001

IMPAX LABS

25MG

A080807 001

50MG

A080807 002

IVAX SUB TEVA PHARMS

25MG

A080762 001

50MG

A080762 002

LANNETT

25MG

A080868 001

50MG

A080868 002

LEDERLE

25MG

A086874 001

50MG

A086875 001

LNK

25MG

A087977 001

Jan 27, 1983

50MG

A087978 001

Jan 27, 1983

MK LABS

25MG

A083087 001

50MG

A083087 002

MUTUAL PHARM

25MG

A084506 001

NEWTRON PHARMS

25MG

A086543 001

50MG

A086544 001

NEXGEN PHARMA INC

25MG

A083634 001

PERRIGO

25MG

A083061 001

50MG

A083061 002

PIONEER PHARMS

25MG

A089101 001

Dec 20, 1985

50MG

A088880 001

Dec 20, 1985

PUREPAC PHARM

25MG

A085156 001

50MG

A085150 001

PVT FORM

25MG

A083027 001

50MG

A083027 002

ROXANE

50MG

A080635 001

SUN PHARM INDUSTRIES

25MG

A089488 001

Jan 02, 1987

50MG

A089489 001

Jan 02, 1987

SUPERPHARM

25MG

A089040 001

May 15, 1985

50MG

A089041 001

May 15, 1985

TEVA

25MG

A085874 001

50MG

A085874 002

VALEANT PHARM INTL

25MG

A080596 001

50MG

A080592 001

VANGARD

25MG

A088034 001

Oct 27, 1982

50MG

A087630 001

WATSON LABS

25MG

A080728 001

25MG

A083797 001

25MG

A085138 001

50MG

A083797 002

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-159(of 478)

** See List Footnote

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE; ORAL

DIPHENHYDRAMINE HYDROCHLORIDE

	50MG	A085083	001
WHITEWORTH TOWN PLSN	25MG	A083441	001
	50MG	A080800	001

ELIXIR; ORAL

BELIX

HALSEY	12.5MG/5ML	A086586	001 Oct 03, 1983

BENADRYL

MCNEIL CONS	12.5MG/5ML	N005845	004

DIBENIL

CENCI	12.5MG/5ML	A088304	001 Dec 16, 1983

DIPHEN

USL PHARMA	12.5MG/5ML	A084640	001

DIPHENHYDRAMINE HYDROCHLORIDE

BUNDY	12.5MG/5ML	A083674	001
CENCI	12.5MG/5ML	A087941	001 Dec 17, 1982
KV PHARM	12.5MG/5ML	A085621	001
LANNETT	12.5MG/5ML	A080939	002
LEDERLE	12.5MG/5ML	A086937	001
MK LABS	12.5MG/5ML	A083088	002
NASKA	12.5MG/5ML	A088680	001 May 31, 1985
PERRIGO	12.5MG/5ML	A083063	001
PUREPAC PHARM	12.5MG/5ML	A083237	001 Jan 25, 1982
PVT FORM	12.5MG/5ML	A085287	001
ROXANE	12.5MG/5ML	A080643	001

HYDRAMINE

ALPHARMA US PHARMS	12.5MG/5ML	A080763	002

INJECTABLE; INJECTION

BENADRYL

MCNEIL CONS	10MG/ML	N006146	001
+	50MG/ML **	N006146	002

BENADRYL PRESERVATIVE FREE

+	MCNEIL CONS	50MG/ML **	N009486	001

DIPHENHYDRAMINE HYDROCHLORIDE

BEL MAR	10MG/ML	A080822	001
DR REDDYS	10MG/ML	A080873	001
	50MG/ML	A080873	002
EUROHLTH INTL SARL	50MG/ML	A083183	001
HOSPIRA	50MG/ML	A040140	001 Nov 20, 1998
LYPHOMED	10MG/ML	A087066	001
WATSON LABS	10MG/ML	A083533	001
WYETH AYERST	50MG/ML	A080577	001

DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE

ABRAXIS PHARM	50MG/ML	A080586	002
DR REDDYS	50MG/ML	A080873	003
INTL MEDICATION	50MG/ML	A084094	001

SYRUP; ORAL

ANTITUSSIVE

PERRIGO	12.5MG/5ML	A071292	001 Apr 10, 1987

BELDIN

HALSEY	12.5MG/5ML	A089179	001 Jun 05, 1986

BENYLIN

PARKE DAVIS	12.5MG/5ML	N006514	004

DIPHEN

MORTON GROVE	12.5MG/5ML	A070118	001 Oct 01, 1985

DIPHENHYDRAMINE HYDROCHLORIDE

AKORN	12.5MG/5ML	A072416	001 Sep 28, 1990
ALPHARMA US PHARMS	12.5MG/5ML	A070497	001 Apr 25, 1989
CUMBERLAND SWAN	12.5MG/5ML	A073611	001 Aug 20, 1992

HYDRAMINE

ALPHARMA US PHARMS	12.5MG/5ML	A070205	001 Jan 28, 1986

SILPHEN

LANNETT CO INC	12.5MG/5ML	A072646	001 Feb 27, 1992

VICKS FORMULA 44

WARNER CHILCOTT	12.5MG/5ML	A070524	001 Jan 14, 1987

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-160(of 478)

** See List Footnote

DIPHENHYDRAMINE HYDROCHLORIDE; NAPROXEN SODIUM

TABLET;ORAL

NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE

P AND L

25MG;220MG

A207597 001 Jan 25, 2019

DIPHENHYDRAMINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION;ORAL

BENYLIN

PARKE DAVIS

12.5MG/5ML;30MG/5ML

N019014 001 Jun 11, 1985

DIPHENIDOL HYDROCHLORIDE

TABLET;ORAL

VONTROL

GLAXOSMITHKLINE

EQ 25MG BASE

N016033 001

DIPHENYLPYRALINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

HISPRIL

GLAXOSMITHKLINE

5MG

N011945 001

DIPIVEFRIN HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

AKPRO

AKORN

0.1%

A074382 001 Sep 29, 1995

DIPIVEFRIN HYDROCHLORIDE

BAUSCH AND LOMB

0.1%

A074188 001 May 19, 1995

FALCON PHARMS

0.1%

A073636 001 Jun 30, 1994

PROPINE

ALLERGAN

0.1%

N018239 001

DIPYRIDAMOLE

INJECTABLE;INJECTION

DIPYRIDAMOLE

DR REDDYS

5MG/ML

A074952 001 Nov 26, 1997

EUGIA PHARMA SPECLTS

5MG/ML

A075769 001 Nov 27, 2002

HOSPIRA

5MG/ML

A074601 001 Dec 19, 1997

IV PERSANTINE

+ BOEHRINGER INGELHEIM

5MG/ML **

N019817 001 Dec 13, 1990

TABLET;ORAL

DIPYRIDAMOLE

ANDA REPOSITORY

25MG

A040898 001 Apr 23, 2008

50MG

A040898 002 Apr 23, 2008

75MG

A040898 003 Apr 23, 2008

GLENMARK GENERICS

25MG

A088999 001 Feb 05, 1991

50MG

A089000 001 Feb 05, 1991

75MG

A089001 001 Feb 05, 1991

PUREPAC PHARM

25MG

A089425 001 Jul 12, 1990

50MG

A089426 001 Jul 12, 1990

75MG

A089427 001 Jul 12, 1990

WATSON LABS

50MG

A087160 001 Jun 07, 1996

DIRITHROMYCIN

TABLET, DELAYED RELEASE;ORAL

DYNABAC

LILLY RES LABS

250MG

N050678 001 Jun 19, 1995

DISOPYRAMIDE PHOSPHATE

CAPSULE;ORAL

DISOPYRAMIDE PHOSPHATE

INTERPHARM

EQ 100MG BASE

A071190 001 Jan 15, 1987

EQ 150MG BASE

A071191 001 Jan 15, 1987

IVAX SUB TEVA PHARMS

EQ 100MG BASE

A070186 001 Nov 18, 1985

EQ 150MG BASE

A070187 001 Nov 18, 1985

MYLAN

EQ 100MG BASE

A070138 001 Jun 14, 1985

EQ 150MG BASE

A070139 001 Jun 14, 1985

RISING

EQ 100MG BASE

A070470 001 Dec 10, 1985

EQ 150MG BASE

A070471 001 Dec 10, 1985

SUN PHARM INDUSTRIES

EQ 100MG BASE

A070351 001 Dec 17, 1985

EQ 150MG BASE

A070352 001 Dec 17, 1985

SUPERPHARM

EQ 100MG BASE

A070940 001 Feb 09, 1987

EQ 150MG BASE

A070941 001 Feb 09, 1987

WATSON LABS

EQ 100MG BASE

A070240 001 Feb 02, 1986

EQ 150MG BASE

A070241 001 Feb 02, 1986

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-161(of 478)

** See List Footnote

DISOPYRAMIDE PHOSPHATE

CAPSULE, EXTENDED RELEASE;ORAL

DISOPYRAMIDE PHOSPHATE

NESHER PHARMS

EQ 150MG BASE

A071200 001 Dec 15, 1987

DISULFIRAM

TABLET;ORAL

ANTABUSE

+ ODYSSEY PHARMS

250MG

A088482 001 Dec 08, 1983

+

500MG

A088483 001 Dec 08, 1983

+

TEVA WOMENS

250MG **

N007883 003

+

500MG **

N007883 002

DISULFIRAM

MYLAN

250MG

A203916 001 Mar 04, 2015

500MG

A203916 002 Mar 04, 2015

STRIDES PHARMA

250MG

A088792 001 Aug 14, 1984

500MG

A088793 001 Aug 14, 1984

WATSON LABS

250MG

A086889 001

250MG

A087973 001 Aug 05, 1983

500MG

A087974 001 Aug 05, 1983

WATSON LABS TEVA

500MG

A086890 001

DIVALPROEX SODIUM

CAPSULE, DELAYED REL PELLETS;ORAL

DIVALPROEX SODIUM

RISING

EQ 125MG VALPROIC ACID

A090407 001 Mar 28, 2011

TEVA PHARMS USA

EQ 125MG VALPROIC ACID

A211505 001 Nov 17, 2020

TABLET, DELAYED RELEASE;ORAL

DEPAKOTE CP

ABBOTT

EQ 250MG BASE

N019794 001 Jul 11, 1990

EQ 500MG BASE

N019794 002 Jul 11, 1990

DIVALPROEX SODIUM

ANCHEN PHARMS

EQ 500MG VALPROIC ACID

A078411 001 Nov 03, 2008

MYLAN

EQ 125MG VALPROIC ACID

A077254 001 Jul 29, 2008

EQ 125MG VALPROIC ACID

A090062 001 Mar 17, 2009

EQ 250MG VALPROIC ACID

A077254 002 Jul 29, 2008

EQ 250MG VALPROIC ACID

A090062 002 Mar 17, 2009

EQ 500MG VALPROIC ACID

A077254 003 Jul 29, 2008

EQ 500MG VALPROIC ACID

A090062 003 Mar 17, 2009

TEVA

EQ 125MG VALPROIC ACID

A076941 001 Jul 29, 2008

EQ 250MG VALPROIC ACID

A076941 002 Jul 29, 2008

EQ 500MG VALPROIC ACID

A076941 003 Jul 29, 2008

TABLET, EXTENDED RELEASE;ORAL

DIVALPROEX SODIUM

AMTA

EQ 250MG VALPROIC ACID

A214462 001 Mar 15, 2021

EQ 500MG VALPROIC ACID

A214462 002 Mar 15, 2021

ANCHEN PHARMS

EQ 250MG VALPROIC ACID

A078445 001 Feb 26, 2009

EQ 500MG VALPROIC ACID

A078445 002 Aug 04, 2009

COSETTE

EQ 500MG VALPROIC ACID

A078700 001 Aug 03, 2009

IMPAX LABS

EQ 250MG VALPROIC ACID

A078791 001 May 06, 2009

EQ 500MG VALPROIC ACID

A078791 002 Aug 04, 2009

DOBUTAMINE HYDROCHLORIDE

INJECTABLE;INJECTION

DOBUTAMINE HYDROCHLORIDE

BAXTER HLTHCARE

EQ 12.5MG BASE/ML

A074381 001 Sep 26, 1996

DR REDDYS

EQ 12.5MG BASE/ML

A074995 001 Mar 31, 1998

HOSPIRA

EQ 12.5MG BASE/ML

A074292 001 Feb 16, 1995

EQ 1.25GM BASE/100ML

A074634 001 Sep 27, 1996

LUITPOLD

EQ 12.5MG BASE/ML

A074545 001 Jun 25, 1998

TELIGENT

EQ 12.5MG BASE/ML

A074098 001 Feb 21, 1995

TEVA PARENTERAL

EQ 12.5MG BASE/ML

A074206 001 Oct 19, 1993

WATSON LABS

EQ 12.5MG BASE/ML

A074114 001 Nov 30, 1993

WATSON LABS INC

EQ 12.5MG BASE/ML

A074279 001 Feb 18, 1998

DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5%

HOSPIRA

EQ 50MG BASE/100ML

N020269 001 Oct 19, 1993

EQ 100MG BASE/100ML

N020269 002 Oct 19, 1993

EQ 200MG BASE/100ML

N020269 003 Oct 19, 1993

DOBUTREX

+ LILLY

EQ 12.5MG BASE/ML **

N017820 002

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-162(of 478)

** See List Footnote

DOCETAXEL

INJECTABLE; INJECTION

DOCEFREZ

+	SUN PHARM	20MG/VIAL	N022534	001	May 03, 2011
+		80MG/VIAL	N022534	002	May 03, 2011

DOCETAXEL

+	ACCORD HLTHCARE	20MG/0.5ML (40MG/ML)	N201195	001	Jun 08, 2011
+		80MG/2ML (40MG/ML)	N201195	002	Jun 08, 2011
	APOTEX INC	20MG/0.5ML (40MG/ML)	N022312	001	Jan 11, 2012
		80MG/2ML (40MG/ML)	N022312	002	Jan 11, 2012
	DFB ONCOLOGY LTD	20MG/ML (20MG/ML)	A206177	001	Jan 20, 2017
		80MG/4ML (20MG/ML)	A206177	002	Jan 20, 2017
		200MG/10ML (20MG/ML)	A206177	003	Jan 20, 2017
	HENGRUI PHARMA	40MG/ML	A203170	001	Feb 15, 2017
+	HOSPIRA INC	120MG/6ML (20MG/ML)	N022234	006	Jun 23, 2016
	INGENUS PHARMS LLC	20MG/2ML (10MG/ML)	A207563	001	Aug 31, 2017
	PFIZER LABS	20MG/2ML (10MG/ML)	N202356	001	Mar 13, 2014
		80MG/8ML (10MG/ML)	N202356	002	Mar 13, 2014
		130MG/13ML (10MG/ML)	N202356	003	Mar 13, 2014
		200MG/20ML (10MG/ML)	N202356	004	Mar 13, 2014
	TEVA PHARMS USA	20MG/ML (20MG/ML)	A203877	001	Sep 16, 2015
		80MG/4ML (20MG/ML)	A203877	002	Sep 16, 2015

TAXOTERE

+	SANOFI AVENTIS US	40MG/ML **	N020449	001	May 14, 1996

DOFETILIDE

CAPSULE; ORAL

DOFETILIDE

	NOVAST LABS	0.125MG	A212410	001	Dec 27, 2019
		0.25MG	A212410	002	Dec 27, 2019
		0.5MG	A212410	003	Dec 27, 2019
	PRINSTON INC	0.125MG	A211223	001	Dec 17, 2019
		0.25MG	A211223	002	Dec 17, 2019
		0.5MG	A211223	003	Dec 17, 2019
	TEVA PHARMS USA	0.125MG	A210018	001	Apr 15, 2022
		0.25MG	A210018	002	Apr 15, 2022
		0.5MG	A210018	003	Apr 15, 2022
	VGYAAN	0.125MG	A215323	001	Apr 14, 2022
		0.25MG	A215323	002	Apr 14, 2022
		0.5MG	A215323	003	Apr 14, 2022

DOLASETRON MESYLATE

INJECTABLE; INJECTION

ANZEMET

+	VALIDUS PHARMS	12.5MG/0.625ML (20MG/ML)	N020624	002	Sep 11, 1997
+		100MG/5ML (20MG/ML)	N020624	001	Sep 11, 1997
		500MG/25ML (20MG/ML)	N020624	003	Dec 11, 2001

TABLET; ORAL

ANZEMET

+	VALIDUS PHARMS	100MG	N020623	002	Sep 11, 1997

DONEPEZIL HYDROCHLORIDE

SOLUTION; ORAL

ARICEPT

	EISAI INC	5MG/5ML	N021719	001	Oct 18, 2004

TABLET; ORAL

DONEPEZIL HYDROCHLORIDE

	ACCORD HLTHCARE	5MG	A201335	001	Aug 29, 2011
		10MG	A201335	002	Aug 29, 2011
	ACTAVIS ELIZABETH	23MG	A202415	001	Dec 17, 2015
	APOTEX	5MG	A078841	001	Jun 02, 2011
		10MG	A078841	002	Jun 02, 2011
	HERITAGE PHARMA	5MG	A077344	001	May 31, 2011
		10MG	A077344	002	May 31, 2011
	HIKMA PHARMS	5MG	A090247	001	May 31, 2011
		10MG	A090247	002	May 31, 2011
	HISUN PHARM HANGZHOU	23MG	A202410	001	Mar 24, 2017
	INDICUS PHARMA	23MG	A203419	001	Apr 12, 2016
	MYLAN PHARMS INC	5MG	A090521	001	May 31, 2011
		10MG	A090521	002	May 31, 2011
	OSMOTICA PHARM US	23MG	A203114	001	Jan 26, 2016

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-163(of 478)

** See List Footnote

DONEPEZIL HYDROCHLORIDE

TABLET; ORAL

DONEPEZIL HYDROCHLORIDE

PAR PHARM	23MG	A202542	001	Jul 24, 2013
RISING	23MG	A202656	001	Oct 22, 2015
SANDOZ	5MG	A090290	001	May 31, 2011
	10MG	A090290	002	May 31, 2011
SUN PHARM	23MG	A204293	001	Jun 05, 2015
SUN PHARM INDS LTD	5MG	A076786	001	Nov 26, 2010
	10MG	A076786	002	Nov 26, 2010
UNICHEM	5MG	A203656	001	Jun 23, 2016
	10MG	A203656	002	Jun 23, 2016
WOCKHARDT	5MG	A091267	001	May 31, 2011
	10MG	A091267	002	May 31, 2011

TABLET, ORALLY DISINTEGRATING; ORAL

ARICEPT ODT

+	EISAI INC	5MG	N021720	001	Oct 18, 2004
+		10MG	N021720	002	Oct 18, 2004

DONEPEZIL HYDROCHLORIDE

HERITAGE PHARMA	5MG	A078388	002	Nov 26, 2010
	10MG	A078388	001	Nov 26, 2010
SUN PHARM INDUSTRIES	5MG	A077975	002	Dec 11, 2009
	10MG	A077975	001	Dec 11, 2009
UNICHEM	5MG	A204831	001	Nov 10, 2016
	10MG	A204831	002	Nov 10, 2016
ZYDUS PHARMS USA INC	5MG	A090175	001	May 10, 2011
	10MG	A090175	002	May 10, 2011

DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE

AMNEAL PHARMS	10MG; 14MG	A208328	001	Jan 27, 2017
	10MG; 28MG	A208328	002	Jan 27, 2017

DOPAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DOPAMINE HYDROCHLORIDE

ABBOTT	40MG/ML	A070656	001	Jan 24, 1989
	80MG/ML	A070657	001	Jan 24, 1989
ABRAXIS PHARM	40MG/ML	A070012	001	Jun 12, 1985
	40MG/ML	A070058	001	Mar 20, 1985
	80MG/ML	A070013	001	Jun 12, 1985
	80MG/ML	A070059	001	Mar 20, 1985
	160MG/ML	A070364	001	Dec 04, 1985
AM REGENT	40MG/ML	A070799	001	Feb 11, 1987
	80MG/ML	A070820	001	Feb 11, 1987
	160MG/ML	A070826	001	Feb 11, 1987
BAXTER HLTHCARE	40MG/ML	N018398	001	
	80MG/ML	N018398	002	Mar 22, 1982
HOSPIRA	40MG/ML	A074403	001	May 23, 1996
IGI LABS INC	40MG/ML	A070087	001	Oct 23, 1985
	80MG/ML	A070089	001	Oct 23, 1985
	80MG/ML	A070090	001	Oct 23, 1985
	80MG/ML	A070091	001	Oct 23, 1985
	160MG/ML	A070092	001	Oct 23, 1985
	160MG/ML	A070093	001	Oct 23, 1985
	160MG/ML	A070094	001	Oct 23, 1985
INTL MEDICATION	40MG/ML	N018014	001	
LYPHOMED	40MG/ML	N018549	001	Mar 11, 1983
SMITH AND NEPHEW	40MG/ML	A070011	001	Aug 29, 1985
	40MG/ML	A070046	001	Aug 29, 1985
	80MG/ML	A070047	001	Aug 29, 1985
TELIGENT	40MG/ML	N018656	001	Jun 28, 1983
TEVA PARENTERAL	40MG/ML	A072999	001	Oct 23, 1991
	80MG/ML	A073000	001	Oct 23, 1991
WARNER CHILCOTT	40MG/ML	A070558	001	Sep 20, 1985
	40MG/ML	N018138	001	
	80MG/ML	A070559	001	Sep 20, 1985
DOPAMINE HYDROCHLORIDE IN DEXTROSE 5%				
HOSPIRA	1.6MG/ML	N020542	001	Aug 30, 1995

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-164(of 478)

** See List Footnote

DOPAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

INTROPIN

HOSPIRA

40MG/ML

N017395 001

80MG/ML

N017395 002

160MG/ML

N017395 003

DORIPENEM

INJECTABLE; INTRAVENOUS

DORIBAX

+ SHIONOGI INC

250MG/VIAL **

N022106 002 Oct 05, 2010

+

500MG/VIAL **

N022106 001 Oct 12, 2007

DORZOLAMIDE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE

AM REGENT

EQ 2% BASE

A079186 001 Nov 18, 2009

RUBICON

EQ 2% BASE

A078395 001 Oct 28, 2008

TEVA PHARMS

EQ 2% BASE

A078756 001 Dec 04, 2008

ZAMBON SPA

EQ 2% BASE

A091034 001 Dec 04, 2013

TRUSOPT

+ MSD SUB MERCK

EQ 2% BASE

N020408 001 Dec 09, 1994

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE

CHARTWELL MOLECULAR

EQ 2% BASE; EQ 0.5% BASE

A201998 001 Dec 17, 2014

RUBICON

EQ 2% BASE; EQ 0.5% BASE

A078201 001 Oct 28, 2008

ZAMBON SPA

EQ 2% BASE; EQ 0.5% BASE

A091180 001 Dec 04, 2013

DOXACURIUM CHLORIDE

INJECTABLE; INJECTION

NUROMAX

ABBVIE

EQ 1MG BASE/ML

N019946 001 Mar 07, 1991

DOXAPRAM HYDROCHLORIDE

INJECTABLE; INJECTION

DOXAPRAM HYDROCHLORIDE

WATSON LABS

20MG/ML

A073529 001 Jan 30, 1992

DOXAZOSIN MESYLATE

TABLET; ORAL

DOXAZOSIN MESYLATE

ACTAVIS ELIZABETH

EQ 1MG BASE

A075574 001 Oct 18, 2000

EQ 2MG BASE

A075574 002 Oct 18, 2000

EQ 4MG BASE

A075574 003 Oct 18, 2000

EQ 8MG BASE

A075574 004 Oct 18, 2000

ANI PHARMS

EQ 1MG BASE

A075432 001 Oct 18, 2000

EQ 2MG BASE

A075432 002 Oct 18, 2000

EQ 4MG BASE

A075432 003 Oct 18, 2000

EQ 8MG BASE

A075432 004 Oct 18, 2000

AUROBINDO PHARMA USA

EQ 1MG BASE

A075509 001 Oct 19, 2000

EQ 2MG BASE

A075509 002 Oct 19, 2000

EQ 4MG BASE

A075509 003 Oct 19, 2000

EQ 8MG BASE

A075509 004 Oct 19, 2000

CHARTWELL RX

EQ 1MG BASE

A075646 001 Oct 18, 2000

EQ 2MG BASE

A075646 002 Oct 18, 2000

EQ 4MG BASE

A075646 003 Oct 18, 2000

EQ 8MG BASE

A075646 004 Oct 18, 2000

GENPHARM

EQ 1MG BASE

A075466 001 Oct 18, 2000

EQ 2MG BASE

A075466 002 Oct 18, 2000

EQ 4MG BASE

A075466 003 Oct 18, 2000

EQ 8MG BASE

A075466 004 Oct 18, 2000

IVAX SUB TEVA PHARMS

EQ 1MG BASE

A075453 001 Oct 18, 2000

EQ 2MG BASE

A075453 002 Oct 18, 2000

EQ 4MG BASE

A075453 003 Oct 18, 2000

EQ 8MG BASE

A075453 004 Oct 18, 2000

NESHER PHARMS

EQ 1MG BASE

A075609 001 Oct 18, 2000

EQ 2MG BASE

A075609 002 Oct 18, 2000

EQ 4MG BASE

A075609 003 Oct 18, 2000

EQ 8MG BASE

A075609 004 Oct 18, 2000

STRIDES PHARMA

EQ 1MG BASE

A076161 001 Jun 10, 2004

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-165(of 478)

** See List Footnote

DOXAZOSIN MESYLATE

TABLET;ORAL

DOXAZOSIN MESYLATE

	EQ 2MG BASE	A076161 002	Jun 10, 2004
	EQ 4MG BASE	A076161 003	Jun 10, 2004
	EQ 8MG BASE	A076161 004	Jun 10, 2004
TEVA	EQ 1MG BASE	A075353 001	Jan 12, 2001
	EQ 2MG BASE	A075353 002	Jan 12, 2001
	EQ 4MG BASE	A075353 003	Jan 12, 2001
	EQ 8MG BASE	A075353 004	Jan 12, 2001
WATSON LABS INC	EQ 1MG BASE	A075426 001	Oct 18, 2000
	EQ 2MG BASE	A075426 002	Oct 18, 2000
	EQ 4MG BASE	A075426 003	Oct 18, 2000
	EQ 8MG BASE	A075426 004	Oct 18, 2000

DOXEPIN HYDROCHLORIDE

CAPSULE;ORAL

DOXEPIN HYDROCHLORIDE

DAVA PHARMS INC	EQ 10MG BASE	A071685 001	Jan 05, 1988
	EQ 25MG BASE	A071686 001	Jan 05, 1988
	EQ 50MG BASE	A071673 001	Jan 05, 1988
	EQ 75MG BASE	A071674 001	Jan 05, 1988
	EQ 100MG BASE	A071675 001	Jan 05, 1988
	EQ 150MG BASE	A071676 001	Jan 05, 1988
LANNETT CO INC	EQ 10MG BASE	A212997 001	Jul 24, 2020
	EQ 25MG BASE	A212997 002	Jul 24, 2020
	EQ 50MG BASE	A212997 003	Jul 24, 2020
	EQ 75MG BASE	A212997 004	Jul 24, 2020
	EQ 100MG BASE	A212997 005	Jul 24, 2020
NEW RIVER	EQ 10MG BASE	N016987 001	
	EQ 25MG BASE	N016987 002	
	EQ 50MG BASE	N016987 003	
	EQ 75MG BASE	N016987 006	
	EQ 100MG BASE	N016987 004	
	EQ 150MG BASE	N016987 007	Apr 13, 1987
PAR PHARM	EQ 10MG BASE	A071422 002	Nov 09, 1987
	EQ 25MG BASE	A071422 003	Nov 09, 1987
	EQ 50MG BASE	A071422 004	Nov 09, 1987
	EQ 75MG BASE	A071422 005	Nov 09, 1987
	EQ 100MG BASE	A071422 001	Nov 09, 1987
PUREPAC PHARM	EQ 10MG BASE	A073054 001	Dec 28, 1990
	EQ 25MG BASE	A072109 001	Dec 28, 1990
	EQ 50MG BASE	A073055 001	Dec 28, 1990
	EQ 75MG BASE	A072386 001	Sep 08, 1988
	EQ 100MG BASE	A072110 001	Sep 08, 1988
	EQ 150MG BASE	A072387 001	Sep 08, 1988
QUANTUM PHARMICS	EQ 10MG BASE	A070972 001	Sep 29, 1987
	EQ 25MG BASE	A070973 001	Sep 29, 1987
	EQ 50MG BASE	A070931 001	Sep 29, 1987
	EQ 75MG BASE	A070932 001	Sep 29, 1987
	EQ 100MG BASE	A072375 001	Mar 15, 1989
	EQ 150MG BASE	A072376 001	Mar 15, 1989
SANDOZ	EQ 10MG BASE	A071487 001	Mar 02, 1987
	EQ 25MG BASE	A070827 001	May 15, 1986
	EQ 50MG BASE	A070828 001	May 15, 1986
	EQ 75MG BASE	A070825 001	May 15, 1986
	EQ 100MG BASE	A071562 001	Mar 02, 1987
SUN PHARM INDUSTRIES	EQ 25MG BASE	A071502 001	Feb 18, 1988
	EQ 50MG BASE	A071653 001	Feb 18, 1988
	EQ 75MG BASE	A071654 001	Feb 18, 1988
	EQ 100MG BASE	A071521 001	Feb 18, 1988
WATSON LABS	EQ 10MG BASE	A070952 001	Mar 04, 1987
	EQ 10MG BASE	A071485 001	Apr 30, 1987
	EQ 10MG BASE	A072985 001	Mar 29, 1991
	EQ 25MG BASE	A070953 001	May 15, 1986
	EQ 25MG BASE	A071486 001	Apr 30, 1987
	EQ 25MG BASE	A072986 001	Mar 29, 1991
	EQ 50MG BASE	A070954 001	May 15, 1986
	EQ 50MG BASE	A071238 001	Apr 30, 1987
	EQ 75MG BASE	A071326 001	Apr 30, 1987

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-166(of 478)

** See List Footnote

DOXEPIN HYDROCHLORIDE

CAPSULE; ORAL

DOXEPIN HYDROCHLORIDE

EQ 75MG BASE	A071763 001	Feb 09, 1988
EQ 100MG BASE	A070955 001	May 15, 1986
EQ 100MG BASE	A071239 001	Apr 30, 1987
EQ 150MG BASE	A071764 001	Feb 09, 1988
WATSON LABS TEVA EQ 50MG BASE	A072987 001	Mar 29, 1991

SINEQUAN

+ PFIZER EQ 10MG BASE **	N016798 003	
+ EQ 25MG BASE **	N016798 001	
+ EQ 50MG BASE **	N016798 002	
+ EQ 75MG BASE **	N016798 006	
+ EQ 100MG BASE **	N016798 005	
+ EQ 150MG BASE **	N016798 007	

CONCENTRATE; ORAL

DOXEPIN HYDROCHLORIDE

PHARM ASSOC

EQ 10MG BASE/ML

A075924 001 Jan 15, 2004

TEVA PHARMS

EQ 10MG BASE/ML

A071609 001 Nov 09, 1987

SINEQUAN

+ PFIZER EQ 10MG BASE/ML **	N017516 001	

DOXERCALCIFEROL

CAPSULE; ORAL

DOXERCALCIFEROL

HIKMA

0.5MCG

A091433 001 Sep 23, 2011

1MCG

A091433 002 Jan 14, 2014

2.5MCG

A091433 003 Jan 14, 2014

INJECTABLE; INJECTION

DOXERCALCIFEROL

AKORN

2MCG/ML (2MCG/ML)

A203929 002 Mar 28, 2016

4MCG/2ML (2MCG/ML)

A203929 001 May 07, 2015

AMNEAL

4MCG/2ML (2MCG/ML)

A208975 001 May 24, 2017

+ HOSPIRA

10MCG/5ML (2MCG/ML)

N208614 002 Jul 24, 2018

SUN PHARM

2MCG/ML (2MCG/ML)

A203875 001 Nov 14, 2019

4MCG/2ML (2MCG/ML)

A203875 002 Nov 14, 2019

DOXORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

ADRIAMYCIN PFS

PFIZER

2MG/ML

A063165 001 Jan 30, 1991

200MG/100ML

A063165 002 Jan 30, 1991

DOXORUBICIN HYDROCHLORIDE

ALMAJECT

2MG/ML

A065515 001 Nov 08, 2012

HISUN PHARM HANGZHOU

20MG/VIAL

A206062 001 May 13, 2019

HLTHCARE

2MG/ML

A200146 001 Jul 18, 2012

MYLAN LABS LTD

2MG/ML

A200901 001 Feb 14, 2012

10MG/VIAL

A200170 001 Oct 28, 2011

PFIZER

10MG/VIAL

N050467 001

20MG/VIAL

N050467 003 May 20, 1985

50MG/VIAL

N050467 002

150MG/VIAL

N050467 004 Jul 22, 1987

TEVA PHARMS USA

2MG/ML

A064140 001 Jul 28, 1995

200MG/100ML

A064140 002 Jul 28, 1995

RUBEX

BRISTOL MYERS SQUIBB

10MG/VIAL

A062926 001 Apr 13, 1989

50MG/VIAL

A062926 002 Apr 13, 1989

100MG/VIAL

A062926 003 Apr 13, 1989

DOXYCYCLINE

CAPSULE; ORAL

DOXYCYCLINE

IMPAX LABS INC

EQ 150MG BASE

A200065 001 Feb 17, 2011

RISING

EQ 50MG BASE

A208942 001 Jan 21, 2021

EQ 75MG BASE

A208942 002 Jan 21, 2021

EQ 100MG BASE

A208942 003 Jan 21, 2021

SANDOZ INC

EQ 50MG BASE

A065032 001 Jun 30, 2000

EQ 100MG BASE

A065032 002 Jun 30, 2000

STRIDES PHARMA

EQ 75MG BASE

A065055 004 Apr 18, 2005

EQ 150MG BASE

A202778 001 Jun 08, 2012

WATSON LABS

EQ 50MG BASE

A065041 001 Apr 28, 2000

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-167(of 478)

** See List Footnote

DOXYCYCLINE

CAPSULE;ORAL

DOXYCYCLINE

EQ 100MG BASE

A065041 002 Apr 28, 2000

FOR SUSPENSION;ORAL

DOXYCHEL

RACHELLE

EQ 25MG BASE/5ML

A061720 001

TABLET;ORAL

DOXYCYCLINE

APPCO

EQ 50MG BASE

A065377 001 Nov 07, 2006

EQ 75MG BASE

A065377 002 Nov 07, 2006

EQ 100MG BASE

A065377 003 Nov 07, 2006

EQ 150MG BASE

A065427 001 Jun 07, 2007

SANDOZ INC

EQ 50MG BASE

A065353 001 Nov 27, 2006

EQ 75MG BASE

A065353 002 Nov 27, 2006

EQ 100MG BASE

A065353 003 Nov 27, 2006

SUN PHARM INDUSTRIES

EQ 50MG BASE

A065471 001 Apr 17, 2009

EQ 75MG BASE

A065471 002 Apr 17, 2009

EQ 100MG BASE

A065471 003 Apr 17, 2009

DOXYCYCLINE HYCLATE

CAPSULE;ORAL

ACTICLATE CAP

+ ALMIRALL

EQ 75MG BASE

N208253 001 Apr 26, 2016

DOXY-LEMMON

TEVA

EQ 50MG BASE

A062497 001 Aug 23, 1984

EQ 100MG BASE

A062497 002 Jun 15, 1984

DOXYCYCLINE HYCLATE

AJANTA PHARMA LTD

EQ 50MG BASE

A211012 001 Sep 24, 2018

EQ 100MG BASE

A211012 002 Sep 24, 2018

HALSEY

EQ 50MG BASE

A062119 002 May 24, 1985

EQ 100MG BASE

A062119 001 May 24, 1985

HEATHER

EQ 50MG BASE

A062463 001 Dec 07, 1983

EQ 100MG BASE

A062463 002 Dec 07, 1983

HIKMA INTL PHARMS

EQ 20MG BASE

A065103 001 May 13, 2005

INTERPHARM

EQ 50MG BASE

A062763 001 Sep 02, 1988

EQ 100MG BASE

A062763 002 Sep 02, 1988

MUTUAL PHARM

EQ 50MG BASE

A062418 001 Jan 28, 1983

EQ 100MG BASE

A062418 002 Jan 28, 1983

NESHER PHARMS

EQ 50MG BASE

A208263 001 Nov 22, 2021

EQ 100MG BASE

A208263 002 Nov 22, 2021

NOSTRUM LABS INC

EQ 50MG BASE

A209393 001 Dec 10, 2020

EQ 100MG BASE

A209393 002 Dec 10, 2020

PAR PHARM

EQ 50MG BASE

A062434 001 Oct 19, 1984

EQ 100MG BASE

A062442 001 Dec 22, 1983

PVT FORM

EQ 50MG BASE

A062631 001 Jul 24, 1986

EQ 100MG BASE

A062631 002 Jul 24, 1986

RANBAXY

EQ 50MG BASE

A062479 001 Dec 23, 1983

EQ 100MG BASE

A062479 002 Dec 23, 1983

STRIDES PHARMA

EQ 50MG BASE

A062337 001 Mar 29, 1982

EQ 100MG BASE

A062337 002 Mar 29, 1982

SUPERPHARM

EQ 50MG BASE

A062469 001 Oct 31, 1984

EQ 100MG BASE

A062469 002 Oct 31, 1984

WARNER CHILCOTT

EQ 50MG BASE

A062594 001 Dec 05, 1985

EQ 100MG BASE

A062594 002 Dec 05, 1985

WATSON LABS

EQ 50MG BASE

A061717 001

EQ 50MG BASE

A062142 001

EQ 100MG BASE

A061717 002

EQ 100MG BASE

A062142 002

ZHEJIANG YONGTAI

EQ 50MG BASE

A212610 001 Mar 31, 2020

EQ 100MG BASE

A212610 002 Mar 31, 2020

PERIOSTAT

+ COLLAGENEX

EQ 20MG BASE **

N050744 001 Sep 30, 1998

VIBRAMYCIN

+ PFIZER

EQ 50MG BASE **

N050007 001

CAPSULE, COATED PELLETS;ORAL

DOXYCYCLINE HYCLATE

PLIVA

EQ 100MG BASE

A063187 001 Jun 30, 1992

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-168(of 478)

** See List Footnote

DOXYCYCLINE HYCLATE

CAPSULE, DELAYED RELEASE;ORAL

DORYX

+	MAYNE PHARMA	EQ 75MG BASE	N050582	002	Aug 13, 2001
+		EQ 100MG BASE	N050582	001	Jul 22, 1985
	WARNER CHILCOTT	EQ 100MG BASE	A062653	001	Oct 30, 1985

DOXYCYCLINE HYCLATE

BAUSCH	EQ 75MG BASE	A065281	001	Dec 21, 2005
	EQ 100MG BASE	A065281	002	Dec 21, 2005

INJECTABLE; INJECTION

DOXYCHEL HYCLATE

RACHELLE	EQ 100MG BASE/VIAL	A061953	001	

DOXYCYCLINE

HIKMA	EQ 100MG BASE/VIAL	A062450	001	Oct 27, 1983
	EQ 200MG BASE/VIAL	A062450	002	Oct 27, 1983
	EQ 200MG BASE/VIAL	A062569	002	Mar 09, 1988

VIBRAMYCIN

+	PFIZER	EQ 100MG BASE/VIAL **	N050442	002
+		EQ 200MG BASE/VIAL **	N050442	001

SYSTEM, EXTENDED RELEASE;PERIODONTAL

ATRIDOX

+	DEN-MAT	50MG	N050751	001	Sep 03, 1998

TABLET;ORAL

DOXY-LEMMON

TEVA	EQ 100MG BASE	A062581	001	Mar 15, 1985

DOXYCYCLINE HYCLATE

ALEMBIC PHARMS	EQ 100MG BASE	A210536	001	May 14, 2020
AMICI	EQ 100MG BASE	A213475	001	Mar 10, 2021
AMNEAL	EQ 100MG BASE	A216599	001	Oct 24, 2022
AMNEAL PHARMS CO	EQ 75MG BASE	A209372	001	Oct 06, 2017
	EQ 150MG BASE	A209372	002	Oct 06, 2017
EMCURE PHARMS LTD	EQ 100MG BASE	A209969	001	Nov 09, 2018
HEATHER	EQ 100MG BASE	A062462	001	May 11, 1983
HERITAGE PHARMA	EQ 20MG BASE	A065163	001	May 13, 2005
INTERPHARM	EQ 100MG BASE	A062764	001	Sep 02, 1988
MUTUAL PHARM	EQ 100MG BASE	A062391	001	Sep 30, 1982
MYLAN	EQ 100MG BASE	A062432	001	Feb 15, 1983
PRAXGEN	EQ 100MG BASE	A212487	001	Mar 30, 2022
RISING	EQ 75MG BASE	A209987	001	Oct 05, 2020
	EQ 150MG BASE	A209987	002	Oct 05, 2020
STRIDES PHARMA	EQ 100MG BASE	A062538	001	Apr 07, 1986
SUPERPHARM	EQ 100MG BASE	A062494	001	Feb 20, 1985
WARNER CHILCOTT	EQ 100MG BASE	A062593	001	Aug 28, 1985
WATSON LABS	EQ 50MG BASE	A062392	001	Mar 31, 1983
	EQ 100MG BASE	A062392	002	Mar 31, 1983

LYMEPAK

+	CHARTWELL PHARMA	EQ 100MG BASE	N209844	001	Jun 15, 2018

PERIOSTAT

+	GALDERMA LABS LP	EQ 20MG BASE **	N050783	001	Feb 02, 2001

VIBRA-TABS

+	PFIZER	EQ 100MG BASE **	N050533	001

TABLET, DELAYED RELEASE;ORAL

DOXYCYCLINE HYCLATE

IMPAX LABS INC	EQ 75MG BASE	A090505	001	Dec 28, 2010
	EQ 100MG BASE	A090505	002	Dec 28, 2010
MYLAN PHARMS INC	EQ 150MG BASE	A091052	001	Feb 08, 2012
RISING	EQ 50MG BASE	A090431	003	May 23, 2016
	EQ 75MG BASE	A090431	001	Dec 28, 2010
	EQ 80MG BASE	A090431	004	Apr 29, 2016
	EQ 100MG BASE	A090431	002	Dec 28, 2010
	EQ 200MG BASE	A090431	005	May 19, 2016
ZYDUS PHARMS	EQ 75MG BASE	A206772	001	Dec 21, 2018
	EQ 100MG BASE	A206772	002	Dec 21, 2018
	EQ 150MG BASE	A206772	003	Dec 21, 2018

DISCONTINUED DRUG PRODUCT LIST

6-169(of 478)

** See List Footnote

DOXYLAMINE SUCCINATE

CAPSULE; ORAL

UNISOM

PFIZER

25MG

N019440 001 Feb 05, 1986

TABLET; ORAL

DECAPRYN

SANOFI AVENTIS US

12.5MG

N006412 015

25MG

N006412 014

DOXY-SLEEP-AID

PAR PHARM

25MG

A070156 001 Jul 02, 1987

DOXYLAMINE SUCCINATE

COPLEY PHARM

25MG

A088900 002 Feb 12, 1988

QUANTUM PHARMICS

25MG

A088603 001 Aug 07, 1984

DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

BENDECTIN

SANOFI AVENTIS US

10MG; 10MG **

N010598 002

DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE

ACTAVIS LABS FL INC

20MG; 20MG

A212472 001 Mar 01, 2022

DROMOSTANOLONE PROPIONATE

INJECTABLE; INJECTION

DROLBAN

LILLY

50MG/ML

N012936 001

DRONABINOL

CAPSULE; ORAL

DRONABINOL

INSYS THERAP

2.5MG

A078501 001 Aug 19, 2011

5MG

A078501 002 Aug 19, 2011

10MG

A078501 003 Aug 19, 2011

LANNETT CO INC

2.5MG

A201463 001 May 18, 2018

5MG

A201463 002 May 18, 2018

10MG

A201463 003 May 18, 2018

DROPERIDOL

INJECTABLE; INJECTION

DROPERIDOL

ABRAXIS PHARM

2.5MG/ML

A070992 001 Nov 17, 1986

2.5MG/ML

A070993 001 Nov 17, 1986

ASTRAZENECA

2.5MG/ML

A072018 001 Oct 20, 1988

HOSPIRA

2.5MG/ML

A071645 001 Apr 07, 1988

2.5MG/ML

A072272 001 Aug 31, 1995

IGI LABS INC

2.5MG/ML

A072019 001 Oct 19, 1988

2.5MG/ML

A072020 001 Oct 19, 1988

2.5MG/ML

A072021 001 Oct 19, 1988

LUITPOLD

2.5MG/ML

A072335 001 Oct 24, 1988

SMITH AND NEPHEW

2.5MG/ML

A071750 001 Sep 06, 1988

SOLOPAK

2.5MG/ML

A071754 001 Sep 06, 1988

2.5MG/ML

A071755 001 Sep 06, 1988

WATSON LABS

2.5MG/ML

A073520 001 Nov 27, 1991

2.5MG/ML

A073521 001 Nov 27, 1991

2.5MG/ML

A073523 001 Nov 27, 1991

DROPERIDOL; FENTANYL CITRATE

INJECTABLE; INJECTION

FENTANYL CITRATE AND DROPERIDOL

ASTRAZENECA

2.5MG/ML; EQ 0.05MG BASE/ML

A072026 001 Apr 13, 1989

2.5MG/ML; EQ 0.05MG BASE/ML

A072027 001 Apr 13, 1989

2.5MG/ML; EQ 0.05MG BASE/ML

A072028 001 Apr 13, 1989

HOSPIRA

2.5MG/ML; EQ 0.05MG BASE/ML

A071982 001 May 04, 1988

INNOVAR

AKORN

2.5MG/ML; EQ 0.05MG BASE/ML

N016049 001

DROSPIRENONE; ETHINYL ESTRADIOL

TABLET; ORAL

DROSPIRENONE AND ETHINYL ESTRADIOL

JUBILANT CADISTA

3MG; 0.02MG

A209423 001 Dec 22, 2017

KYRA

SUN PHARM

3MG; 0.02MG

A202318 001 Jul 23, 2019

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-170(of 478)

** See List Footnote

DROSPIRENONE; ETHINYL ESTRADIOL

TABLET;ORAL-28

DROSPIRENONE AND ETHINYL ESTRADIOL

APOTEX	3MG;0.03MG	A205876	001	Sep 21, 2016
JUBILANT CADISTA	3MG;0.03MG	A210017	001	Sep 10, 2018
KEMEYA				
SUN PHARM	3MG;0.03MG	A202138	001	Mar 13, 2019

DROXIDOPA

CAPSULE;ORAL

DROXIDOPA

CELLTRION	100MG	A214217	001	May 05, 2022
	200MG	A214217	002	May 05, 2022
	300MG	A214217	003	May 05, 2022
TEVA PHARMS USA INC	100MG	A213162	001	Feb 18, 2021
	200MG	A213162	002	Feb 18, 2021
	300MG	A213162	003	Feb 18, 2021

DULOXETINE HYDROCHLORIDE

CAPSULE, DELAYED REL PELLETS;ORAL

DRIZALMA SPRINKLE

+ SUN PHARM	EQ 20MG BASE	N212516	001	Jul 19, 2019
DULOXETINE HYDROCHLORIDE				
TEVA PHARMS USA	EQ 20MG BASE	A090783	001	Dec 11, 2013
	EQ 30MG BASE	A090783	002	Dec 11, 2013
	EQ 60MG BASE	A090783	003	Dec 11, 2013
YAOPHARMA CO LTD	EQ 20MG BASE	A207219	001	Aug 16, 2019
	EQ 30MG BASE	A207219	002	Aug 16, 2019
	EQ 60MG BASE	A207219	003	Aug 16, 2019

DUTASTERIDE

CAPSULE;ORAL

DUTASTERIDE

ACTAVIS LABS FL INC	0.5MG	A202808	001	Nov 20, 2015
APOTEX INC	0.5MG	A204292	001	Nov 24, 2015
HERITAGE PHARMS INC	0.5MG	A207935	001	Oct 13, 2017
HIKMA	0.5MG	A202204	001	Nov 23, 2015
MYLAN	0.5MG	A203241	001	Jun 14, 2016
NOSTRUM LABS INC	0.5MG	A204705	001	Nov 20, 2015
RISING	0.5MG	A202530	001	Nov 20, 2015
STRIDES PHARMA	0.5MG	A208227	001	Jun 22, 2018

DUTASTERIDE; TAMSULOSIN HYDROCHLORIDE

CAPSULE;ORAL

DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE

ACTAVIS LABS FL INC	0.5MG;0.4MG	A202975	001	Nov 20, 2015

DYCLONINE HYDROCHLORIDE

SOLUTION;TOPICAL

DYCLONE

+ ASTRAZENECA	0.5% **	N009925	002	
+	1% **	N009925	001	

DYDROGESTERONE

TABLET;ORAL

GYNOREST

+ SOLVAY	5MG **	N017388	001	
+	10MG **	N017388	002	

DYPHYLLINE

ELIXIR;ORAL

NEOTHYLLINE

TEVA	160MG/15ML	N007794	003	

INJECTABLE; INJECTION

NEOTHYLLINE

TEVA	250MG/ML	N009088	001	

TABLET;ORAL

DILOR

SAVAGE LABS	200MG	A084514	001	

DILOR-400

SAVAGE LABS	400MG	A084751	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-171(of 478)

** See List Footnote

DYPHYLLINE

TABLET;ORAL

LUFYLLIN

MYLAN SPECIALITY LP

200MG

A084566 001

400MG

A084566 002

NEOTHYLLINE

TEVA

200MG

N007794 001

400MG

N007794 002

ECHOTHIOPHATE IODIDE

FOR SOLUTION;OPHTHALMIC

PHOSPHOLINE IODIDE

FERA PHARMS LLC

0.03%

N011963 002

0.06%

N011963 004

0.25%

N011963 003

ECONAZOLE NITRATE

CREAM;TOPICAL

ECONAZOLE NITRATE

CHARTWELL RX

1%

A076075 001 Nov 26, 2002

MYLAN

1%

A210364 001 Apr 18, 2018

SPECTAZOLE

+ ALVOGEN

1%

N018751 001 Dec 23, 1982

EDETATE CALCIUM DISODIUM

TABLET;ORAL

CALCIUM DISODIUM VERSENATE

BAUSCH

500MG

N008922 002

EDROPHONIUM CHLORIDE

INJECTABLE;INJECTION

EDROPHONIUM CHLORIDE

HOSPIRA

10MG/ML

A040131 001 Feb 24, 1998

WATSON LABS

10MG/ML

A040044 001 Mar 20, 1996

EDROPHONIUM CHLORIDE PRESERVATIVE FREE

WATSON LABS

10MG/ML

A040043 001 Mar 20, 1996

ENLON

MYLAN INSTITUTIONAL

10MG/ML

A088873 001 Aug 06, 1985

REVERSOL

ORGANON USA INC

10MG/ML

A089624 001 May 13, 1988

TENSILON

+ PAI HOLDINGS PHARM

10MG/ML **

N007959 001

TENSILON PRESERVATIVE FREE

+ PAI HOLDINGS PHARM

10MG/ML **

N007959 002

EFAVIRENZ

CAPSULE;ORAL

SUSTIVA

+ BRISTOL MYERS SQUIBB

100MG **

N020972 002 Sep 17, 1998

TABLET;ORAL

EFAVIRENZ

AUROBINDO PHARMA

600MG

A205322 001 Aug 30, 2018

MYLAN

600MG

A091471 001 Feb 17, 2016

STRIDES PHARMA

600MG

A078509 001 Jun 16, 2021

SUSTIVA

+ BRISTOL MYERS SQUIBB

300MG **

N021360 001 Feb 01, 2002

+

600MG

N021360 002 Feb 01, 2002

EFAVIRENZ; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL

EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE

+ AUROBINDO PHARMA LTD

600MG;300MG;300MG

N022343 001 Aug 15, 2018

MACLEODS PHARMS LTD

400MG;300MG;300MG

N210649 001 Mar 15, 2019

EFINAACONAZOLE

SOLUTION;TOPICAL

EFINAACONAZOLE

AUROBINDO PHARMA LTD

10%

A212066 001 Mar 29, 2021

LUPIN LTD

10%

A212169 001 Mar 02, 2022

PADAGIS US

10%

A211851 001 Dec 16, 2020

ZYDUS

10%

A212178 001 Jul 15, 2022

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-172(of 478)

** See List Footnote

EFLORNITHINE HYDROCHLORIDE

CREAM;TOPICAL

VANIQA

+ SKINMEDICA

13.9%

N021145 001 Jul 27, 2000

INJECTABLE; INJECTION

ORNIDYL

SANOFI AVENTIS US

200MG/ML

N019879 002 Nov 28, 1990

ELETRIPTAN HYDROBROMIDE

TABLET;ORAL

ELETRIPTAN HYDROBROMIDE

AMNEAL PHARMS CO

EQ 20MG BASE

A206787 001 May 25, 2018

EQ 40MG BASE

A206787 002 May 25, 2018

YUNG SHIN PHARM

EQ 20MG BASE

A209680 001 Jul 13, 2020

EQ 40MG BASE

A209680 002 Jul 13, 2020

ELIGLUSTAT TARTRATE

CAPSULE;ORAL

ELIGLUSTAT TARTRATE

DR REDDYS

EQ 84MG BASE

A212449 001 Aug 17, 2022

TEVA PHARMS USA INC

EQ 84MG BASE

A212474 001 Dec 27, 2021

ELTROMBOPAG OLAMINE

TABLET;ORAL

PROMACTA

+ NOVARTIS

EQ 100MG ACID **

N022291 005 Nov 16, 2012

ELVITEGRAVIR

TABLET;ORAL

VITEKTA

+ GILEAD SCIENCES INC

85MG

N203093 001 Sep 24, 2014

+

150MG

N203093 002 Sep 24, 2014

EMEDASTINE DIFUMARATE

SOLUTION/DROPS;OPHTHALMIC

EMADINE

+ NOVARTIS

0.05%

N020706 001 Dec 29, 1997

EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE

TABLET;ORAL

EMPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE

ZYDUS PHARMS

5MG;500MG

A212198 001 Jul 07, 2022

5MG;1GM

A212198 002 Jul 07, 2022

12.5MG;500MG

A212198 003 Jul 07, 2022

12.5MG;1GM

A212198 004 Jul 07, 2022

ENALAPRIL MALEATE

FOR SOLUTION;ORAL

EPANED KIT

+ SILVERGATE PHARMS

1MG/ML **

N204308 001 Aug 13, 2013

SOLUTION;ORAL

ENALAPRIL MALEATE

AMNEAL

1MG/ML

A212894 001 Jun 29, 2022

TABLET;ORAL

ENALAPRIL MALEATE

AIPING PHARM INC

2.5MG

A075178 002 Mar 23, 2001

5MG

A075178 001 Mar 23, 2001

10MG

A075178 003 Mar 23, 2001

20MG

A075178 004 Mar 23, 2001

APOTHECON

2.5MG

A075583 001 Aug 22, 2000

5MG

A075583 002 Aug 22, 2000

10MG

A075583 003 Aug 22, 2000

20MG

A075583 004 Aug 22, 2000

AUROBINDO PHARMA USA

2.5MG

A075480 001 Aug 22, 2000

5MG

A075480 002 Aug 22, 2000

10MG

A075480 003 Aug 22, 2000

20MG

A075480 004 Aug 22, 2000

BEXIMCO PHARMS USA

2.5MG

A075621 001 Aug 22, 2000

5MG

A075621 002 Aug 22, 2000

10MG

A075621 003 Aug 22, 2000

20MG

A075621 004 Aug 22, 2000

IVAX SUB TEVA PHARMS

2.5MG

A075482 001 Aug 22, 2000

5MG

A075482 002 Aug 22, 2000

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-173(of 478)

** See List Footnote

ENALAPRIL MALEATE

TABLET; ORAL

ENALAPRIL MALEATE

	10MG	A075482 003	Aug 22, 2000
	20MG	A075482 004	Aug 22, 2000
KRKA DD NOVO MESTO	2.5MG	A075370 001	Aug 22, 2000
	5MG	A075370 002	Aug 22, 2000
	10MG	A075369 001	Aug 22, 2000
	20MG	A075369 002	Aug 22, 2000
MYLAN	2.5MG	A075472 001	Aug 22, 2000
	5MG	A075472 002	Aug 22, 2000
	10MG	A075472 003	Aug 22, 2000
	20MG	A075472 004	Aug 22, 2000
SANDOZ	2.5MG	A075048 001	Aug 22, 2000
	5MG	A075048 002	Aug 22, 2000
	10MG	A075048 003	Aug 22, 2000
	20MG	A075048 004	Aug 22, 2000
SUN PHARM INDS LTD	2.5MG	A075556 001	Aug 22, 2000
	5MG	A075556 002	Aug 22, 2000
	10MG	A075556 003	Aug 22, 2000
	20MG	A075556 004	Aug 22, 2000
WATSON LABS	2.5MG	A075501 001	Aug 22, 2000
	5MG	A075501 002	Aug 22, 2000
	10MG	A075501 003	Aug 22, 2000
	20MG	A075501 004	Aug 22, 2000

ENALAPRIL MALEATE; FELODIPINE

TABLET, EXTENDED RELEASE; ORAL

LEXCEL

ASTRAZENECA	5MG; 2.5MG	N020668 002	Oct 28, 1998
	5MG; 5MG	N020668 001	Dec 27, 1996

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE

CHARTWELL RX	5MG; 12.5MG	A076116 001	Sep 19, 2001
	10MG; 25MG	A076116 002	Sep 19, 2001
IVAX SUB TEVA PHARMS	5MG; 12.5MG	A075736 001	Mar 25, 2003
	10MG; 25MG	A075736 002	Mar 25, 2003
NOSTRUM LABS INC	5MG; 12.5MG	A076486 001	Oct 27, 2004
	10MG; 25MG	A076486 002	Oct 27, 2004
RISING	5MG; 12.5MG	A075624 001	Sep 18, 2001
	10MG; 25MG	A075624 002	Sep 18, 2001

ENALAPRILAT

INJECTABLE; INJECTION

ENALAPRILAT

DR REDDYS	1.25MG/ML	A075578 001	Aug 22, 2000
HOSPIRA	1.25MG/ML	A075456 001	Aug 22, 2000
	1.25MG/ML	A075571 001	Aug 22, 2000
VASOTEC			
+ BIOVAIL LABS INTL	1.25MG/ML **	N019309 001	Feb 09, 1988

ENCORAFENIB

CAPSULE; ORAL

BRAFTOVI

+ ARRAY BIOPHARMA INC	50MG	N210496 001	Jun 27, 2018

ENFLURANE

LIQUID; INHALATION

ENFLURANE

ABBOTT	99.9%	A070803 001	Sep 08, 1987
PIRAMAL CRITICAL	99.9%	A074396 001	Jul 29, 1994
ETHRANE			
BAXTER HLTHCARE	99.9%	N017087 001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-174(of 478)

** See List Footnote

ENOXACIN

TABLET; ORAL

PENETREX

SANOFI AVENTIS US

200MG

N019616 004 Dec 31, 1991

400MG

N019616 005 Dec 31, 1991

ENOXAPARIN SODIUM

INJECTABLE; SUBCUTANEOUS

LOVENOX (PRESERVATIVE FREE)

+ SANOFI AVENTIS US 90MG/0.6ML (150MG/ML) **

N020164 006 Jun 02, 2000

ENTACAPONE

TABLET; ORAL

ENTACAPONE

MYLAN PHARMS INC

200MG

A202394 001 May 13, 2013

ENTECAVIR

TABLET; ORAL

ENTECAVIR

ACCORD HLTHCARE

0.5MG

A205824 001 Aug 25, 2017

1MG

A205824 002 Aug 25, 2017

RISING

0.5MG

A206226 001 Mar 26, 2019

1MG

A206226 002 Mar 26, 2019

STRIDES PHARMA

0.5MG

A206294 001 Nov 23, 2016

1MG

A206294 002 Nov 23, 2016

SUNSHINE

0.5MG

A211978 001 May 20, 2020

1MG

A211978 002 May 20, 2020

TEVA PHARMS USA

0.5MG

A202122 001 Aug 26, 2014

1MG

A202122 002 Aug 26, 2014

YAOPHARMA CO LTD

0.5MG

A212201 001 Nov 04, 2019

1MG

A212201 002 Nov 04, 2019

YUNG SHIN PHARM

0.5MG

A208195 001 Nov 10, 2021

1MG

A208195 002 Nov 10, 2021

ENZALUTAMIDE

CAPSULE; ORAL

ENZALUTAMIDE

ACTAVIS LABS FL INC

40MG

A209614 001 May 14, 2021

APOTEX

40MG

A209645 001 Apr 22, 2022

EPHEDRINE HYDROCHLORIDE

SOLUTION; INTRAVENOUS

REZIPRES

+ DR REDDYS LABS SA 47MG/ML (47MG/ML)

N213536 002 Jun 14, 2021

+ 47MG/5ML (9.4MG/ML)

N213536 003 Jun 14, 2021

EPINASTINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

ELESTAT

+ ALLERGAN

0.05%

N021565 001 Oct 16, 2003

EPINASTINE HYDROCHLORIDE

AKORN

0.05%

A204055 001 May 05, 2017

CHARTWELL RX

0.05%

A203384 001 Dec 07, 2016

SUN PHARM INDS

0.05%

A091626 001 Oct 31, 2011

EPINEPHRINE

AEROSOL, METERED; INHALATION

BRONKAID MIST

STERLING

0.25MG/INH

N016803 001

EPINEPHRINE

ARMSTRONG PHARMS

0.2MG/INH

A087907 001 May 23, 1984

PRIMATENE MIST

WYETH CONS

0.2MG/INH

N016126 001

INJECTABLE; INJECTION

SUS-PHRINE SULFITE FREE

FOREST LABS

1.5MG/AMP

N007942 003 Feb 05, 1999

5MG/ML

N007942 001

INJECTABLE; INTRAMUSCULAR

EPI E Z PEN JR

MYLAN SPECIALITY LP

0.15MG/DELIVERY

N019430 004 Aug 03, 1995

EPIPEN E Z PEN

MYLAN SPECIALITY LP

0.3MG/DELIVERY

N019430 003 Aug 03, 1995

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-175(of 478)

** See List Footnote

EPINEPHRINE

INJECTABLE; INTRAMUSCULAR, SUBCUTANEOUS

TWINJECT 0.15

IMPAX

EQ 0.15MG/DELIVERY

N020800 002 May 28, 2004

TWINJECT 0.3

IMPAX

EQ 0.3MG/DELIVERY

N020800 001 May 30, 2003

EPINEPHRINE BITARTRATE

AEROSOL, METERED; INHALATION

BRONITIN MIST

WYETH CONS

0.3MG/INH

N016126 002

MEDIHALER-EPI

3M

0.3MG/INH

N010374 003

EPINEPHRINE BITARTRATE; ETIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

DURANEST

+ ASTRAZENECA

0.005MG/ML; 1% **

N017751 006

+

0.005MG/ML; 1.5% **

N017751 007

+ DENTSPLY PHARM

0.005MG/ML; 1.5% **

N021384 001

EPINEPHRINE BITARTRATE; PRILOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

CITANEST FORTE

ASTRAZENECA

0.005MG/ML; 4%

N014763 008

EPINEPHRINE; ETIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

DURANEST

+ ASTRAZENECA

0.005MG/ML; 0.5% **

N017751 004

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

ALPHACAINE HYDROCHLORIDE W/ EPINEPHRINE

CARLISLE

0.01MG/ML; 2%

A084720 001

0.02MG/ML; 2%

A084732 001

LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE

BELMORA LLC

0.01MG/ML; 2%

A080504 004 Oct 19, 1983

0.02MG/ML; 2%

A080504 005 Oct 19, 1983

EASTMAN KODAK

0.01MG/ML; 2%

A040057 002 Feb 26, 1993

0.02MG/ML; 2%

A040057 001 Feb 26, 1993

HOSPIRA

0.005MG/ML; 1%

A089649 001 Jun 21, 1988

0.005MG/ML; 1.5%

A089650 001 Jun 21, 1988

0.01MG/ML; 2%

A078772 001 May 12, 2008

0.02MG/ML; 2%

A078772 002 May 12, 2008

WEST-WARD PHARMS INT

0.01MG/ML; 1%

A080406 001

0.01MG/ML; 2%

A080406 002

LIDOCAINE HYDROCHLORIDE W/ EPINEPHRINE

ABBOTT

0.01MG/ML; 1%

A083154 001

BEL MAR

0.01MG/ML; 1%

A080820 001

0.01MG/ML; 2%

A080757 001

DELL LABS

0.01MG/ML; 1%

A083389 001

0.01MG/ML; 2%

A083390 001

INTL MEDICATION

0.01MG/ML; 1%

A086402 001

WATSON LABS

0.01MG/ML; 1%

A080377 003

0.01MG/ML; 1%

A085463 001

0.01MG/ML; 2%

A080377 004

LIDOCATON

PHARMATON

0.01MG/ML; 2%

A084729 001 Aug 17, 1983

0.02MG/ML; 2%

A084728 001 Aug 17, 1983

OCTOCAINE

SEPTODONT

0.01MG/ML; 2%

A084048 001

0.02MG/ML; 2%

A084048 002

XYLOCAINE DENTAL WITH EPINEPHRINE

DENTSPLY PHARM

0.01MG/ML; 2% **

N021381 001

0.02MG/ML; 2% **

N021381 002

XYLOCAINE W/ EPINEPHRINE

ASTRAZENECA

0.005MG/ML; 1%

N010418 006

0.005MG/ML; 1.5%

N010418 010

0.005MG/ML; 2%

N010418 008

FRESENIUS KABI USA

0.01MG/ML; 2%

N006488 003

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-176(of 478)

** See List Footnote

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

PATCH; IONTOPHORESIS, TOPICAL

LIDOSITE TOPICAL SYSTEM KIT

VYTERIS

1.05MG/PATCH; 100MG/PATCH

N021504 001 May 06, 2004

SOLUTION; IONTOPHORESIS

IONTOCAINE

IOMED

0.01MG/ML; 2%

N020530 001 Dec 21, 1995

SOLUTION; IONTOPHORESIS, TOPICAL

LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE

EMPI

0.01MG/ML; 2%

N021486 001 Oct 26, 2004

EPINEPHRINE; PROCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

PROCAINE HYDROCHLORIDE W/ EPINEPHRINE

BEL MAR

0.02MG/ML; 1%

A080758 001

0.02MG/ML; 2%

A080759 001

EPIRUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

EPIRUBICIN HYDROCHLORIDE

ACTAVIS TOTOWA

10MG/5ML (2MG/ML)

A065445 001 Sep 18, 2008

50MG/25ML (2MG/ML)

A065445 002 Sep 18, 2008

200MG/100ML (2MG/ML)

A065445 003 Sep 18, 2008

EBEWE PHARMA

50MG/25ML (2MG/ML)

A065339 001 Dec 22, 2009

200MG/100ML (2MG/ML)

A065339 002 Dec 22, 2009

FRESENIUS KABI USA

10MG/5ML (2MG/ML)

A065408 001 Oct 15, 2007

50MG/25ML (2MG/ML)

A065408 002 Oct 15, 2007

150MG/75ML (2MG/ML)

A065408 003 Oct 15, 2007

200MG/100ML (2MG/ML)

A065408 004 Oct 15, 2007

200MG/100ML (2MG/ML)

A065411 001 Aug 20, 2007

50MG/25ML (2MG/ML)

A065411 002 Aug 20, 2007

HOSPIRA

10MG/5ML (2MG/ML)

A065343 001 Apr 19, 2007

50MG/25ML (2MG/ML)

A065343 002 Apr 19, 2007

150MG/75ML (2MG/ML)

A065343 003 Apr 19, 2007

200MG/100ML (2MG/ML)

A065343 004 Apr 19, 2007

MYLAN INSTITUTIONAL

50MG/25ML (2MG/ML)

A065371 001 Nov 28, 2007

200MG/100ML (2MG/ML)

A065371 002 Nov 28, 2007

MYLAN LABS LTD

50MG/25ML (2MG/ML)

A091599 001 Mar 12, 2012

200MG/100ML (2MG/ML)

A091599 002 Mar 12, 2012

ZENNOVA

50MG/25ML (2MG/ML)

A090266 001 Apr 15, 2011

200MG/100ML (2MG/ML)

A090266 002 Apr 15, 2011

POWDER; INTRAVENOUS

EPIRUBICIN HYDROCHLORIDE

HOSPIRA

50MG/VIAL

N050807 001 Sep 15, 2006

200MG/VIAL

N050807 002 Sep 15, 2006

EPLERENONE

TABLET; ORAL

INSPIRA

UPJOHN

100MG

N021437 003 Sep 27, 2002

EPROSARTAN MESYLATE

TABLET; ORAL

EPROSARTAN MESYLATE

MYLAN PHARMS INC

EQ 400MG BASE

A202012 001 Nov 16, 2011

EQ 600MG BASE

A202012 002 Nov 16, 2011

TEVETEN

ABBVIE

EQ 300MG BASE **

N020738 004 Dec 22, 1997

+

EQ 400MG BASE **

N020738 005 Dec 22, 1997

+

EQ 600MG BASE **

N020738 006 May 27, 1999

EPROSARTAN MESYLATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

TEVETEN HCT

ABBVIE

600MG; 12.5MG

N021268 001 Nov 01, 2001

600MG; 25MG

N021268 002 Nov 01, 2001

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-177(of 478)

** See List Footnote

EPTIFIBATIDE

INJECTABLE; INJECTION

EPTIFIBATIDE

AKORN	2MG/ML	A204589 001	Apr 18, 2017
	75MG/100ML	A204589 002	Apr 18, 2017
AMNEAL PHARMS	2MG/ML	A205581 001	Dec 08, 2016
	75MG/100ML	A205581 002	Dec 08, 2016
BAXTER HLTHCARE CORP	2MG/ML	A208554 001	Nov 23, 2018
HYBIO	2MG/ML	A207864 001	Mar 20, 2020
	75MG/100ML	A207864 002	Mar 20, 2020
TEVA PHARMS USA	75MG/100ML	A091555 001	Jun 05, 2015
USV	2MG/ML	A204361 001	Mar 14, 2019
	2MG/ML	A204362 001	Mar 11, 2019
	75MG/100ML	A204361 002	Mar 14, 2019
INTEGRILIN			
+ MSD SUB MERCK	2MG/ML **	N020718 001	May 18, 1998
+	75MG/100ML **	N020718 002	May 18, 1998

ERGOCALCIFEROL

CAPSULE; ORAL

DELTALIN

LILLY	50,000 IU	A080884 001	

ERGOCALCIFEROL

SIGMAPHARM LABS LLC	50,000 IU	A091004 001	Jul 14, 2010

VITAMIN D

CHARTWELL MOLECULAR	50,000 IU	A080825 001	
CHASE CHEM	50,000 IU	A080747 001	
EVERYLIFE	50,000 IU	A080956 001	
IMPAX LABS	50,000 IU	A080951 001	
VITARINE	50,000 IU	A084053 001	
WEST WARD	50,000 IU	A083102 001	

ERGOLOID MESYLATES

CAPSULE; ORAL

HYDERGINE LC

NOVARTIS	1MG	N018706 001	Jan 18, 1983

SOLUTION; ORAL

HYDERGINE

NOVARTIS	1MG/ML	N018418 001	

TABLET; ORAL

ERGOLOID MESYLATES

MUTUAL PHARM	1MG	A088891 001	Nov 01, 1985
WATSON LABS	1MG	A086433 001	May 27, 1982
	1MG	A087244 001	Aug 16, 1982

GERIMAL

WATSON LABS	1MG	A088207 001	Mar 22, 1984

HYDERGINE

NOVARTIS	0.5MG **	N017993 003	

+	1MG **	N017993 001	

TABLET; SUBLINGUAL

ALKERGOT

SANDOZ	0.5MG	A085153 001	
	1MG	A087417 001	

CIRCANOL

3M	0.5MG	A084868 001	
	1MG	A085809 001	

DEAPRIL-ST

BRISTOL MYERS SQUIBB	1MG	A085020 002	

ERGOLOID MESYLATES

KV PHARM	0.5MG	A085899 001	
	0.5MG	A086265 001	
	1MG	A085900 001	
	1MG	A086264 001	
LEDERLE	0.5MG	A086984 001	
	1MG	A086985 001	
SUN PHARM INDUSTRIES	0.5MG	A087407 001	
	1MG	A087552 001	
SUPERPHARM	0.5MG	A089233 001	Sep 23, 1986
	1MG	A089234 001	Sep 23, 1986
VANGARD	0.5MG	A088013 001	Sep 20, 1982

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-178(of 478)

** See List Footnote

ERGOLOID MESYLATES

TABLET;SUBLINGUAL

ERGOLOID MESYLATES

	1MG	A088014 001	Sep 20, 1982
WATSON LABS	0.5MG	A084930 001	
	0.5MG	A087233 001	
	1MG	A085177 001	
	1MG	A087183 001	
GERIMAL			
WATSON LABS	0.5MG	A086189 001	
	1MG	A086188 001	
HYDERGINE			
NOVARTIS	0.5MG	N009087 002	
	1MG	N009087 001	
HYDROGENATED ERGOT ALKALOIDS			
IVAX PHARMS	0.5MG	A087186 001	
	1MG	A087185 001	

ERGOTAMINE TARTRATE

AEROSOL, METERED;INHALATION

MEDIHALER ERGOTAMINE

3M 0.36MG/INH

N012102 001

TABLET;SUBLINGUAL

ERGOSTAT

WATSON LABS INC	2MG	A088337 001	Jun 08, 1984
WIGRETTES			
ORGANON USA INC	2MG	A086750 001	Jul 29, 1982

ERLOTINIB HYDROCHLORIDE

TABLET;ORAL

ERLOTINIB HYDROCHLORIDE

ACCORD HLTHCARE	EQ 25MG BASE	A211083 001	Jul 02, 2020
	EQ 100MG BASE	A211083 002	Jul 02, 2020
	EQ 150MG BASE	A211083 003	Jul 02, 2020
EUGIA PHARMA	EQ 25MG BASE	A216342 001	Jun 22, 2022
	EQ 100MG BASE	A216342 002	Jun 22, 2022
	EQ 150MG BASE	A216342 003	Jun 22, 2022

ERYTHROMYCIN

CAPSULE, DELAYED REL PELLETS;ORAL

ERYC

PARKE DAVIS	250MG	A062546 001	Jul 25, 1985
	250MG	A062618 001	Sep 25, 1985
WARNER CHILCOTT LLC	250MG	A062338 001	

ERYC 125

PARKE DAVIS	125MG	A062648 001	Oct 24, 1985

ERYC SPRINKLES

HOSPIRA	125MG	N050593 001	Jul 22, 1985

ERYTHROMYCIN

BARR	250MG	A063098 001	May 04, 1989

GEL;TOPICAL

E-GLADES

MYLAN	2%	A065009 001	Mar 18, 2002

EMGEL

ALTANA	2%	A063107 001	Aug 23, 1991

LOTION;TOPICAL

E-SOLVE 2

SYOSSET	2%	A062467 001	Jul 03, 1985

OINTMENT;OPHTHALMIC

ERYTHROMYCIN

PHARMADERM	5MG/GM	A062446 001	Sep 26, 1983

PHARMAFAIR	5MG/GM	A062481 001	Apr 05, 1984

ILOTYCIN

DISTA	0.5% **	N050368 001	

OINTMENT;TOPICAL

AKNE-MYCIN

+ BAUSCH	2%	N050584 001	Jan 10, 1985

POWDER;FOR RX COMPOUNDING

ERYTHROMYCIN

PADDOCK LLC	100%	N050610 001	Nov 07, 1986

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-179(of 478)

** See List Footnote

ERYTHROMYCIN

SOLUTION; TOPICAL

A/T/S

TARO	2%	A062405	001	Nov 18, 1982
C-SOLVE-2				
FOUGERA PHARMS	2%	A062468	001	Jul 03, 1985
ERYDERM				
ARBOR PHARMS INC	2%	A062290	001	
ERYMAX				
MERZ PHARMS	2%	A062508	002	Jul 11, 1985
ERYTHRO-STATIN				
AKORN	2%	A064101	001	Oct 22, 1996
ERYTHROMYCIN				
ALPHARMA US PHARMS	1.5%	A062328	001	Apr 19, 1982
	2%	A062326	001	Apr 19, 1982
	2%	A062327	001	Apr 19, 1982
	2%	A062342	001	Feb 25, 1982
	2%	A062957	001	Jul 21, 1988
BAUSCH	2%	A064039	001	Jan 27, 1994
FOUGERA PHARMS	2%	A064187	001	Sep 30, 1997
LILLY	2%	N050532	001	
PHARMAFAIR	1.5%	A062485	001	Jul 11, 1984
	2%	A062616	001	Jul 25, 1985
RENAISSANCE PHARMA	2%	A064127	001	Feb 14, 1997
SANSAC				
DOW PHARM	2%	A062522	001	Jan 24, 1985
STATICIN				
+ WESTWOOD SQUIBB	1.5% **	N050526	001	
T-STAT				
WESTWOOD SQUIBB	2% **	A062436	001	Mar 09, 1983
SWAB; TOPICAL				
C-SOLVE-2				
IVAX SUB TEVA PHARMS	2%	A062751	001	Jul 30, 1993
ERYCETTE				
+ JOHNSON AND JOHNSON	2% **	N050594	001	Feb 15, 1985
ERYTHROMYCIN				
FOUGERA PHARMS	2%	A065320	001	Jul 25, 2006
MYLAN	2%	A064128	001	Jul 03, 1996
T-STAT				
WESTWOOD SQUIBB	2%	A062748	001	Jul 23, 1987
TABLET, COATED PARTICLES; ORAL				
PCE				
+ AZURITY	333MG	N050611	001	Sep 09, 1986
+	500MG	N050611	002	Aug 22, 1990
TABLET, DELAYED RELEASE; ORAL				
E-BASE				
BARR	333MG	A063028	001	May 15, 1990
	333MG	A063086	001	May 15, 1990
	500MG	A062999	001	Nov 25, 1988
E-MYCIN				
ARBOR PHARMS INC	250MG	A060272	001	
	333MG	A060272	002	
ILOTYCIN				
DISTA	250MG	A061910	001	
R-P MYCIN				
SOLVAY	250MG	A061659	001	
ROBIMYCIN				
ROBINS AH	250MG	A061633	001	

ERYTHROMYCIN ESTOLATE

CAPSULE; ORAL

ERYTHROMYCIN ESTOLATE

BARR	EQ 125MG BASE	A062162	001	
	EQ 250MG BASE	A062162	002	
IVAX SUB TEVA PHARMS	EQ 250MG BASE	A062237	001	
WATSON LABS	EQ 250MG BASE	A062087	001	
ILOSONE				
LILLY	EQ 125MG BASE	A061897	001	
	EQ 250MG BASE	A061897	002	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-180(of 478)

** See List Footnote

ERYTHROMYCIN ESTOLATE

FOR SUSPENSION;ORAL

ILOSONE

DISTA

EQ 125MG BASE/5ML

A061893 001

SUSPENSION;ORAL

ERYTHROMYCIN ESTOLATE

ALPHARMA US PHARMS

EQ 125MG BASE/5ML

A062353 001 Nov 18, 1982

EQ 250MG BASE/5ML

A062409 001 Dec 16, 1982

COSETTE

EQ 125MG BASE/5ML

A062169 001 Oct 17, 1990

EQ 250MG BASE/5ML

A062169 002 Oct 17, 1990

LIFE LABS

EQ 250MG BASE/5ML

A062362 001 Dec 17, 1982

ILOSONE

LILLY

EQ 125MG BASE/5ML

A061894 001

EQ 125MG BASE/5ML

N050010 001

EQ 250MG BASE/5ML

A061894 002

EQ 250MG BASE/5ML

N050010 002

SUSPENSION/DROPS;ORAL

ILOSONE

LILLY

EQ 100MG BASE/ML

A061894 003

TABLET;ORAL

ILOSONE

LILLY

EQ 500MG BASE

A061896 001

TABLET, CHEWABLE;ORAL

ILOSONE

DISTA

EQ 125MG BASE

A061895 001

EQ 250MG BASE

A061895 002

ERYTHROMYCIN ESTOLATE; SULFISOXAZOLE ACETYL

SUSPENSION;ORAL

ILOSONE SULFA

LILLY

EQ 125MG BASE/5ML;EQ 600MG BASE/5ML

N050599 001 Sep 29, 1989

ERYTHROMYCIN ETHYLSUCCINATE

GRANULE;ORAL

ERYTHROMYCIN ETHYLSUCCINATE

PAR PHARM INC

EQ 200MG BASE/5ML

A211991 001 Oct 23, 2019

EQ 400MG BASE/5ML

A211991 002 Oct 23, 2019

PEDIAMYCIN

ROSS LABS

EQ 200MG BASE/5ML

A062305 001

SUSPENSION;ORAL

E-MYCIN E

PHARMACIA AND UPJOHN

EQ 200MG BASE/5ML

A062198 001

EQ 400MG BASE/5ML

A062198 002

E.E.S. 200

ARBOR PHARMS LLC

EQ 200MG BASE/5ML **

A061639 001

E.E.S. 400

ARBOR PHARMS LLC

EQ 400MG BASE/5ML **

A061639 002

ERYTHROMYCIN ETHYLSUCCINATE

ALPHARMA US PHARMS

EQ 200MG BASE/5ML

A062200 001

EQ 400MG BASE/5ML

A062200 002

DISTA

EQ 200MG BASE/5ML

A062177 001

EQ 400MG BASE/5ML

A062177 002

NASKA

EQ 400MG BASE/5ML

A062674 001 Mar 10, 1987

PARKE DAVIS

EQ 200MG BASE/5ML

A062231 001

EQ 400MG BASE/5ML

A062231 002

PHARMAFAIR

EQ 200MG BASE/5ML

A062559 001 Mar 15, 1985

EQ 400MG BASE/5ML

A062558 001 Mar 15, 1985

PEDIAMYCIN

ARBOR PHARMS LLC

EQ 200MG BASE/5ML

A062304 001

PEDIAMYCIN 400

ARBOR PHARMS LLC

EQ 400MG BASE/5ML

A062304 002

WYAMYCIN E

WYETH AYERST

EQ 200MG BASE/5ML

A062123 002

EQ 400MG BASE/5ML

A062123 001

SUSPENSION/DROPS;ORAL

PEDIAMYCIN

ROSS LABS

EQ 100MG BASE/2.5ML

A062305 002

TABLET;ORAL

E.E.S. 400

ARBOR PHARMS LLC

EQ 400MG BASE

A061905 001

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-181(of 478)

** See List Footnote

ERYTHROMYCIN ETHYLSUCCINATE

TABLET; ORAL

ERYTHROMYCIN ETHYLSUCCINATE

BARR EQ 400MG BASE A062256 001

MYLAN EQ 400MG BASE A062847 001 Sep 14, 1988

TABLET, CHEWABLE; ORAL

E.E.S.

AZURITY EQ 200MG BASE N050297 002

ERYPED

AZURITY EQ 200MG BASE N050297 003 Jul 05, 1988

PEDIAMYCIN

ROSS LABS EQ 200MG BASE A062306 001

ERYTHROMYCIN ETHYLSUCCINATE; SULFISOXAZOLE ACETYL

GRANULE; ORAL

ERYTHROMYCIN ETHYLSUCCINATE AND SULFISOXAZOLE ACETYL

BARR EQ 200MG BASE/5ML; EQ 600MG BASE/5ML A062759 001 May 20, 1988

ERYZOLE

ALRA EQ 200MG BASE/5ML; EQ 600MG BASE/5ML A062758 001 Jun 15, 1988

PEDIAZOLE

ROSS LABS EQ 200MG BASE/5ML; EQ 600MG BASE/5ML ** N050529 001

ERYTHROMYCIN GLUCEPTATE

INJECTABLE; INJECTION

ILOTYCIN GLUCEPTATE

DISTA EQ 250MG BASE/VIAL N050370 001

EQ 500MG BASE/VIAL N050370 002

EQ 1GM BASE/VIAL N050370 003

ERYTHROMYCIN LACTOBIONATE

INJECTABLE; INJECTION

ERYTHROCIN

ABBOTT EQ 500MG BASE/VIAL A062586 001 Jan 04, 1988

EQ 1GM BASE/VIAL A062586 002 Jan 04, 1988

HOSPIRA EQ 500MG BASE/VIAL N050182 002

EQ 1GM BASE/VIAL A062638 002 Oct 31, 1986

EQ 1GM BASE/VIAL N050182 003

+

EQ 1GM BASE/VIAL N050609 002 Sep 24, 1986

ERYTHROMYCIN

ELKINS SINN EQ 500MG BASE/VIAL A062563 001 Mar 28, 1985

EQ 1GM BASE/VIAL A062563 002 Mar 28, 1985

ERYTHROMYCIN LACTOBIONATE

ABRAXIS PHARM EQ 500MG BASE/VIAL A062604 001 Nov 24, 1986

EQ 1GM BASE/VIAL A062604 002 Nov 24, 1986

BAXTER HLTHCARE EQ 500MG BASE/VIAL A062993 001 May 09, 1989

EQ 1GM BASE/VIAL A062993 002 May 09, 1989

TEVA PARENTERAL EQ 500MG BASE/VIAL A063253 001 Jul 30, 1993

EQ 1GM BASE/VIAL A063253 002 Jul 30, 1993

ERYTHROMYCIN STEARATE

TABLET; ORAL

BRISTAMYCIN

BRISTOL EQ 250MG BASE A061304 001

EQ 250MG BASE A061887 001

ERYPAR

PARKE DAVIS EQ 250MG BASE A062032 001

EQ 500MG BASE A062032 002

WARNER CHILCOTT EQ 250MG BASE A062322 001

ERYTHROCIN STEARATE

ARBOR PHARMS LLC EQ 125MG BASE A060359 002

EQ 500MG BASE A060359 003

ERYTHROMYCIN STEARATE

ANI PHARMS EQ 250MG BASE A061461 001

EQ 250MG BASE A061591 001

EQ 500MG BASE A061461 002

EQ 500MG BASE A063179 001 May 15, 1990

LEDERLE EQ 250MG BASE A062089 001

EQ 500MG BASE A062089 002

MYLAN EQ 250MG BASE A061505 001

EQ 500MG BASE A061505 002

PUREPAC PHARM EQ 250MG BASE A061743 001

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-182(of 478)

** See List Footnote

ERYTHROMYCIN STEARATE

TABLET;ORAL

ERYTHROMYCIN STEARATE

WATSON LABS

EQ 250MG BASE

A062121 002

EQ 500MG BASE

A062121 001

ETHRIL 250

BRISTOL MYERS SQUIBB

EQ 250MG BASE

A061605 001

ETHRIL 500

BRISTOL MYERS SQUIBB

EQ 500MG BASE

A061605 002

PFIZER-E

PFIZER

EQ 250MG BASE

A061791 001

EQ 500MG BASE

A061791 002

WYAMYCIN S

WYETH AYERST

EQ 250MG BASE

A061675 001

EQ 500MG BASE

A061675 002

ESCITALOPRAM OXALATE

CAPSULE;ORAL

ESCITALOPRAM OXALATE

MYLAN PHARMS INC

EQ 5MG BASE

A077660 001 Jul 31, 2007

EQ 10MG BASE

A077660 002 Jul 31, 2007

EQ 20MG BASE

A077660 003 Jul 31, 2007

SOLUTION;ORAL

ESCITALOPRAM OXALATE

ANTRIM PHARMS LLC

EQ 5MG BASE/5ML

A203967 001 May 26, 2015

LEXAPRO

+ ALLERGAN

EQ 5MG BASE/5ML **

N021365 001 Nov 27, 2002

TABLET;ORAL

ESCITALOPRAM OXALATE

HIKMA PHARMS

EQ 5MG BASE

A078766 001 Sep 11, 2012

EQ 10MG BASE

A078766 002 Sep 11, 2012

EQ 20MG BASE

A078766 003 Sep 11, 2012

MACLEODS PHARMS LTD

EQ 5MG BASE

A202210 001 Sep 11, 2012

EQ 10MG BASE

A202210 002 Sep 11, 2012

EQ 20MG BASE

A202210 003 Sep 11, 2012

MYLAN

EQ 5MG BASE

A077550 001 May 14, 2015

EQ 10MG BASE

A077550 002 May 14, 2015

EQ 20MG BASE

A077550 003 May 14, 2015

TEVA PHARMS USA

EQ 5MG BASE

A076765 001 Mar 14, 2012

EQ 10MG BASE

A076765 002 Mar 14, 2012

EQ 20MG BASE

A076765 003 Mar 14, 2012

ESMOLOL HYDROCHLORIDE

INJECTABLE;INJECTION

BREVIBLOC

BAXTER HLTHCARE

10MG/ML

N019386 003 Aug 15, 1988

20MG/ML

N019386 007 May 28, 2003

ESMOLOL HYDROCHLORIDE

AM REGENT

10MG/ML

A201126 001 Feb 20, 2015

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED REL PELLETS;ORAL

ESOMEPRAZOLE MAGNESIUM

AMNEAL PHARMS NY

EQ 20MG BASE

A209647 001 Apr 10, 2019

EQ 40MG BASE

A209647 002 Apr 10, 2019

GUANGZHOU NOVAKEN

EQ 20MG BASE

A213859 001 Nov 18, 2020

EQ 40MG BASE

A213859 002 Nov 18, 2020

HEC PHARM

EQ 20MG BASE

A207265 002 May 18, 2018

EQ 40MG BASE

A207265 001 May 18, 2018

CAPSULE, DELAYED RELEASE;ORAL

ESOMEPRAZOLE MAGNESIUM

MYLAN

EQ 20MG BASE

A212376 001 Oct 16, 2019

TABLET, DELAYED RELEASE;ORAL

ESOMEPRAZOLE MAGNESIUM

P AND L

EQ 20MG BASE

A209202 001 Mar 05, 2019

TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL

ESOMEPRAZOLE MAGNESIUM

+ DEXCEL

EQ 20MG BASE

N214278 001 Oct 20, 2020

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-183(of 478)

** See List Footnote

ESOMEPRAZOLE SODIUM

INJECTABLE; INTRAVENOUS

ESOMEPRAZOLE SODIUM

EUGIA PHARMA

EQ 20MG BASE/VIAL

A204657 001 Aug 10, 2016

MYLAN

EQ 20MG BASE/VIAL

A202686 001 May 17, 2017

EQ 40MG BASE/VIAL

A202686 002 May 17, 2017

SUN PHARM

EQ 20MG BASE/VIAL

A200882 001 Mar 18, 2013

NEXIUM IV

+ ASTRAZENECA

EQ 20MG BASE/VIAL **

N021689 001 Mar 31, 2005

ESOMEPRAZOLE STRONTIUM

CAPSULE, DELAYED RELEASE; ORAL

ESOMEPRAZOLE STRONTIUM

+ BELCHER

24.65MG

N202342 001 Aug 06, 2013

+

49.3MG

N202342 002 Aug 06, 2013

ESTAZOLAM

TABLET; ORAL

PROSOM

+ ABBOTT

1MG **

N019080 001 Dec 26, 1990

+

2MG **

N019080 002 Dec 26, 1990

ESTRADIOL

FILM, EXTENDED RELEASE; TRANSDERMAL

ALORA

ALLERGAN

0.025MG/24HR

N020655 004 Apr 05, 2002

0.05MG/24HR

N020655 001 Dec 20, 1996

0.075MG/24HR

N020655 002 Dec 20, 1996

0.1MG/24HR

N020655 003 Dec 20, 1996

FEMPATCH

PARKE DAVIS

0.025MG/24HR

N020417 001 Dec 03, 1996

GEL; TOPICAL

ESTROGEL

ASCEND THERAPS US

0.06%

N021166 001 Feb 09, 2004

SYSTEM; TRANSDERMAL

ESCLIM

WOMEN FIRST HLTHCARE

0.025MG/24HR

N020847 001 Aug 04, 1998

0.0375MG/24HR

N020847 002 Aug 04, 1998

0.05MG/24HR

N020847 003 Aug 04, 1998

0.075MG/24HR

N020847 004 Aug 04, 1998

0.1MG/24HR

N020847 005 Aug 04, 1998

ESTRADERM

+ NOVARTIS

0.05MG/24HR

N019081 002 Sep 10, 1986

+

0.1MG/24HR

N019081 003 Sep 10, 1986

ESTRADIOL

ORTHO MCNEIL PHARM

0.05MG/24HR

N021048 001 Sep 20, 1999

0.075MG/24HR

N021048 002 Sep 20, 1999

0.1MG/24HR

N021048 003 Sep 20, 1999

VIVELLE

NOVARTIS

0.025MG/24HR

N020323 005 Aug 16, 2000

0.0375MG/24HR

N020323 001 Oct 28, 1994

0.05MG/24HR

N020323 002 Oct 28, 1994

0.075MG/24HR

N020323 003 Oct 28, 1994

0.1MG/24HR

N020323 004 Oct 28, 1994

TABLET; ORAL

ESTRACE

BRISTOL MYERS SQUIBB

0.5MG

A081295 001 Jun 30, 1993

+

1MG

A084499 001

+

2MG

A084500 001

ESTRADIOL

LANNETT CO INC

0.5MG

A040138 001 Jan 30, 1998

1MG

A040138 002 Jan 30, 1998

2MG

A040138 003 Jan 30, 1998

MAYNE PHARMA

0.5MG

A040114 003 Mar 14, 1996

1MG

A040114 001 Mar 14, 1996

2MG

A040114 002 Mar 14, 1996

MYLAN

0.5MG

A040326 001 Apr 21, 1999

1MG

A040326 002 Apr 21, 1999

2MG

A040326 003 Apr 21, 1999

USL PHARMA

0.5MG

A040297 001 Apr 17, 2002

1MG

A040297 002 Apr 17, 2002

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-184(of 478)

** See List Footnote

ESTRADIOL

TABLET; ORAL

ESTRADIOL

2MG

A040297 003 Apr 17, 2002

GYNODIOL

DURAMED PHARMS BARR

0.5MG

A040212 001 Dec 29, 1997

1MG

A040212 002 Dec 29, 1997

1.5MG

A040212 003 Dec 29, 1997

2MG

A040212 004 Dec 29, 1997

INNOFEM

NOVO NORDISK INC

0.5MG

A040312 001 Nov 19, 1999

1MG

A040312 002 Nov 19, 1999

2MG

A040312 003 Nov 19, 1999

TABLET; VAGINAL

VAGIFEM

+ NOVO NORDISK INC

25MCG **

N020908 001 Mar 26, 1999

ESTRADIOL ACETATE

TABLET; ORAL

FEMTRACE

+ APIL

0.45MG

N021633 001 Aug 20, 2004

+

0.9MG

N021633 002 Aug 20, 2004

+

1.8MG

N021633 003 Aug 20, 2004

ESTRADIOL CYPIONATE

INJECTABLE; INJECTION

DEPO-ESTRADIOL

PFIZER

1MG/ML

A085470 001

3MG/ML

A085470 002

ESTRADIOL CYPIONATE

DR REDDYS

5MG/ML

A085620 001

ESTRADIOL CYPIONATE; MEDROXYPROGESTERONE ACETATE

INJECTABLE; INTRAMUSCULAR

LUNELLE

PHARMACIA AND UPJOHN 5MG/0.5ML; 25MG/0.5ML

N020874 001 Oct 05, 2000

ESTRADIOL CYPIONATE; TESTOSTERONE CYPIONATE

INJECTABLE; INJECTION

DEPO-TESTADIOL

PHARMACIA AND UPJOHN

2MG/ML; 50MG/ML

N017968 001

TESTOSTERONE CYPIONATE-ESTRADIOL CYPIONATE

WATSON LABS

2MG/ML; 50MG/ML

A085603 001 Mar 13, 1986

ESTRADIOL HEMIHYDRATE

EMULSION; TOPICAL

ESTRASORB

+ EXELTIS USA INC

0.25%

N021371 001 Oct 09, 2003

ESTRADIOL VALERATE

INJECTABLE; INJECTION

ESTRADIOL VALERATE

DR REDDYS

20MG/ML

A083547 001

40MG/ML

A083714 001

FOSUN PHARMA

10MG/ML

A040628 001 Oct 04, 2007

20MG/ML

A040628 002 Oct 04, 2007

40MG/ML

A040628 003 Oct 04, 2007

WATSON LABS

10MG/ML

A083546 001

ESTRADIOL VALERATE; TESTOSTERONE ENANTHATE

INJECTABLE; INJECTION

DITATE-DS

SAVAGE LABS

8MG/ML; 180MG/ML

A086423 001

TESTOSTERONE ENANTHATE AND ESTRADIOL VALERATE

WATSON LABS

4MG/ML; 90MG/ML

A085865 001

8MG/ML; 180MG/ML

A085860 001

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-185(of 478)

** See List Footnote

ESTRADIOL; NORETHINDRONE ACETATE

TABLET;ORAL

ACTIVELLA

+ AMNEAL 0.5MG;0.1MG

N020907 002 Dec 28, 2006

ESTRADIOL AND NORETHINDRONE ACETATE

NAARI PTE LTD 1MG;0.5MG

A210233 001 Feb 28, 2018

TEVA PHARMS USA 0.5MG;0.1MG

A200747 001 Mar 08, 2012

ESTRADIOL; NORGESTIMATE

TABLET;ORAL

PREFEST

+ TEVA WOMENS 1MG,1MG;N/A,0.09MG **

N021040 001 Oct 22, 1999

ESTRADIOL; PROGESTERONE

CAPSULE;ORAL

BIJUVA

+ MAYNE PHARMA 0.5MG;100MG

N210132 002 Dec 28, 2021

ESTRADIOL AND PROGESTERONE

AMNEAL PHARMS 1MG;100MG

A214293 001 May 16, 2022

ESTROGENS, CONJUGATED

TABLET;ORAL

PREMARIN

WYETH PHARMS 2.5MG

N004782 002

ESTROGENS, CONJUGATED SYNTHETIC A

CREAM;VAGINAL

SYNTHETIC CONJUGATED ESTROGENS A

TEVA WOMENS 0.625MG/GM

N021788 001 Nov 28, 2008

TABLET;ORAL

CENESTIN

+ ASPEN 0.3MG **

N020992 001 Jun 21, 2002

+ 0.45MG **

N020992 005 Feb 05, 2004

+ 0.625MG **

N020992 002 Mar 24, 1999

+ 0.9MG **

N020992 003 Mar 24, 1999

+ 1.25MG **

N020992 004 Mar 13, 2000

ESTROGENS, CONJUGATED SYNTHETIC B

TABLET;ORAL

ENJUVA

ASPEN 0.3MG

N021443 001 Dec 20, 2004

0.45MG

N021443 002 Dec 20, 2004

0.625MG **

N021443 003 May 10, 2004

0.9MG

N021443 005 Apr 27, 2007

1.25MG **

N021443 004 May 10, 2004

ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE

TABLET;ORAL-28

PREMPHASE (PREMARIN;CYCRIN 14/14)

WYETH PHARMS INC 0.625MG,0.625MG;N/A,5MG

N020303 002 Dec 30, 1994

PREMPRO (PREMARIN;CYCRIN)

WYETH PHARMS INC 0.625MG,0.625MG;2.5MG,2.5MG

N020303 001 Dec 30, 1994

ESTROGENS, CONJUGATED; MEPROBAMATE

TABLET;ORAL

MILPREM-200

MEDPOINTE PHARM HLC 0.45MG;200MG

N011045 002

MILPREM-400

MEDPOINTE PHARM HLC 0.45MG;400MG

N011045 001

PMB 200

WYETH AYERST 0.45MG;200MG

N010971 005

PMB 400

WYETH AYERST 0.45MG;400MG

N010971 003

ESTROGENS, ESTERIFIED

TABLET;ORAL

AMNESTROGEN

BRISTOL MYERS SQUIBB 0.3MG

A083266 001

0.625MG

A083266 002

1.25MG

A083266 003

2.5MG

A083266 004

ESTERIFIED ESTROGENS

PVT FORM 0.625MG

A083414 001

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-186(of 478)

** See List Footnote

ESTROGENS, ESTERIFIED

TABLET; ORAL

ESTERIFIED ESTROGENS

	1.25MG	A083765	001
	2.5MG	A085907	001
SANDOZ	1.25MG	A085302	001
ESTRATAB			
SOLVAY	0.3MG	A086715	001
	0.625MG	A083209	001
	1.25MG	A083856	001
	2.5MG	A083857	001
EVEX			
ROCHE PALO	0.625MG	A084215	001
	1.25MG	A083376	002
FEMOGEN			
PVT FORM	0.625MG	A085076	001
	1.25MG	A085008	001
	2.5MG	A085007	001

ESTRONE

INJECTABLE; INJECTION

ESTROGENIC SUBSTANCE

WYETH AYERST	2MG/ML	A083488	001
ESTRONE			
DR REDDYS	5MG/ML	A085239	001
WATSON LABS	2MG/ML	A083397	001
NATURAL ESTROGENIC SUBSTANCE-ESTRONE			
WATSON LABS	2MG/ML	A085237	001 Nov 23, 1982
THEELIN			
PARKEDALE	1MG/ML	N003977	001
	2MG/ML	N003977	002
	5MG/ML	N003977	003

ESTROPIPATE

CREAM; VAGINAL

OGEN

PHARMACIA AND UPJOHN	1.5MG/GM	A084710	001

TABLET; ORAL

ESTROPIPATE

BARR	0.75MG	A040135	001 Nov 27, 1996
	1.5MG	A040135	002 Nov 27, 1996
	3MG	A040135	003 Nov 27, 1996
DURAMED PHARMS BARR	0.75MG	A040296	001 Nov 01, 1999
	1.5MG	A040296	002 Nov 01, 1999
	3MG	A040296	003 Nov 01, 1999
MYLAN	0.75MG	A040359	001 Aug 26, 1999
	1.5MG	A040359	002 Aug 26, 1999
	3MG	A040359	003 Aug 26, 1999
WATSON LABS	0.75MG	A081213	001 Sep 23, 1993
	1.5MG	A081214	001 Sep 23, 1993
	6MG	A081216	001 Sep 23, 1993
WATSON LABS TEVA	3MG	A081215	001 Sep 23, 1993
OGEN .625			
+ PFIZER	0.75MG	A083220	001
OGEN 1.25			
+ PFIZER	1.5MG	A083220	002
OGEN 2.5			
+ PFIZER	3MG	A083220	003
ORTHO-EST			
SUN PHARM INDS INC	0.75MG	A089567	001 Feb 27, 1991
	1.5MG	A089582	001 Jul 17, 1991

ESZOPICLONE

TABLET; ORAL

ESZOPICLONE

CHARTWELL RX	1MG	A091165	001 Jul 14, 2011
	2MG	A091165	002 Jul 14, 2011
	3MG	A091165	003 Jul 14, 2011
HIKMA	1MG	A091153	001 Apr 15, 2014
	2MG	A091153	002 Apr 15, 2014
	3MG	A091153	003 Apr 15, 2014

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-187(of 478)

** See List Footnote

ESZOPICLONE

TABLET;ORAL

ESZOPICLONE

NOSTRUM LABS INC

1MG

A203087 001 May 08, 2019

2MG

A203087 002 May 08, 2019

3MG

A203087 003 May 08, 2019

ETHACRYNIC ACID

TABLET;ORAL

EDECIN

BAUSCH

50MG

N016092 002

ETHACRYNIC ACID

ALVOGEN

25MG

A205709 001 Jul 24, 2018

ETHAMBUTOL HYDROCHLORIDE

TABLET;ORAL

ETHAMBUTOL HYDROCHLORIDE

BARR

400MG

A076057 001 Nov 26, 2001

MYAMBUTOL

STI PHARMA LLC

200MG

N016320 002

500MG

N016320 004

ETHCHLORVYNOL

CAPSULE;ORAL

ETHCHLORVYNOL

BANNER PHARMACAPS

100MG

A084463 001

200MG

A084463 002

500MG

A084463 003

750MG

A084463 004

PLACIDYL

ABBVIE

100MG

N010021 004

200MG

N010021 007

500MG

N010021 002

750MG

N010021 010

ETHINAMATE

CAPSULE;ORAL

VALMID

DISTA

500MG

N009750 001

ETHINYL ESTRADIOL

TABLET;ORAL

ESTINYL

SCHERING

0.02MG

N005292 001

0.05MG

N005292 002

0.5MG

N005292 003

FEMINONE

PHARMACIA AND UPJOHN

0.05MG

N016649 001

LYNORAL

ORGANON USA INC

0.01MG

N005490 003

0.05MG

N005490 002

ETHINYL ESTRADIOL; ETHYNODIOL DIACETATE

TABLET;ORAL-21

DEMULEN 1/35-21

GD SEARLE LLC

0.035MG;1MG **

N018168 001

DEMULEN 1/50-21

GD SEARLE LLC

0.05MG;1MG

N016927 001

ZOVIA 1/35E-21

WATSON PHARMS TEVA

0.035MG;1MG

A072720 001 Dec 30, 1991

ZOVIA 1/50E-21

WATSON LABS

0.05MG;1MG

A072722 001 Dec 30, 1991

TABLET;ORAL-28

DEMULEN 1/35-28

GD SEARLE LLC

0.035MG;1MG **

N018160 001

DEMULEN 1/50-28

GD SEARLE LLC

0.05MG;1MG **

N016936 001

ZOVIA 1/35E-28

MAYNE PHARMA

0.035MG;1MG

A072721 001 Dec 30, 1991

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-188(of 478)

** See List Footnote

ETHINYL ESTRADIOL; ETONOGESTREL

RING;VAGINAL

VERARING

DR REDDYS LABS SA 0.015MG/24HR;0.12MG/24HR

A207577 001 Dec 09, 2021

ETHINYL ESTRADIOL; FERROUS FUMARATE; NORETHINDRONE

TABLET;ORAL-28

NORQUEST FE

PFIZER 0.035MG;75MG;1MG

N018926 001 Jul 18, 1986

ETHINYL ESTRADIOL; FERROUS FUMARATE; NORETHINDRONE ACETATE

TABLET;ORAL-28

NORLESTRIN FE 1/50

PARKE DAVIS 0.05MG;75MG;1MG

N016766 001

NORLESTRIN FE 2.5/50

PARKE DAVIS 0.05MG;75MG;2.5MG

N016854 001

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET;ORAL

FAYOSIM

LUPIN LTD 0.02MG,0.15MG;0.025MG,0.15MG;0.03MG,0.15MG;0.01MG,N/A

A205943 001 Mar 29, 2016

LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL

MAYNE PHARMA 0.02MG,0.1MG;0.01MG,N/A

A200407 001 Oct 25, 2011

LYBREL

+ WYETH PHARMS INC 0.02MG;0.09MG **

N021864 001 May 22, 2007

PREVEN EMERGENCY CONTRACEPTIVE KIT

TEVA BRANDED PHARM 0.05MG;0.25MG

N020946 001 Sep 01, 1998

SYLEVIA

SUN PHARM 0.03MG;0.15MG

A202988 001 Feb 06, 2019

TABLET;ORAL-21

ALESSE

+ CADENCE HEALTH 0.02MG;0.1MG **

N020683 001 Mar 27, 1997

AVIANE-21

DURAMED PHARMS BARR 0.02MG;0.1MG

A075796 002 Apr 30, 2001

ENPRESSE-21

DURAMED PHARMS BARR 0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG

A075809 001 Jul 16, 2001

LESSINA-21

BARR 0.02MG;0.1MG

A075803 001 Mar 20, 2002

LEVLITE

+ BAYER HLTHCARE 0.02MG;0.1MG **

N020860 001 Jul 13, 1998

LEVONORGESTREL AND ETHINYL ESTRADIOL

BARR 0.02MG;0.1MG

A075862 001 Apr 29, 2003

LEVORA 0.15/30-21

WATSON LABS 0.03MG;0.15MG

A073592 001 Dec 13, 1993

NORDETTE-21

TEVA BRANDED PHARM 0.03MG;0.15MG

N018668 001 May 10, 1982

PORTIA-21

BARR 0.03MG;0.15MG

A075866 001 May 23, 2002

TRIPHASIL-21

+ WYETH PHARMS 0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG **

N019192 001 Nov 01, 1984

TRIVORA-21

MAYNE PHARMA 0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG

A074538 001 Dec 18, 1997

TABLET;ORAL-28

ALESSE

+ CADENCE HEALTH 0.02MG;0.1MG **

N020683 002 Mar 27, 1997

CERINTA

SUN PHARM 0.02MG;0.1MG

A202817 001 Jan 07, 2019

ELIFEMME

XIROMED 0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG

A202507 001 Dec 04, 2015

LEVLITE

+ BAYER HLTHCARE 0.02MG;0.1MG **

N020860 002 Jul 13, 1998

LEVONORGESTREL AND ETHINYL ESTRADIOL

BARR 0.02MG;0.1MG

A075862 002 Apr 29, 2003

MYLAN LABS LTD 0.02MG;0.1MG

A202247 001 Dec 08, 2014

0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG

A202970 001 Mar 23, 2018

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-189(of 478)

** See List Footnote

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET;ORAL-28

NORDETTE-28

+ TEVA BRANDED PHARM 0.03MG;0.15MG ** N018782 001 Jul 21, 1982

ORSYTHIA

VINTAGE PHARMS LLC 0.02MG;0.1MG A077099 001 May 11, 2011

TRIPHASIL-28

+ WYETH PHARMS INC 0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG ** N019190 001 Nov 01, 1984

ETHINYL ESTRADIOL; NORELGESTROMIN

FILM, EXTENDED RELEASE;TRANSDERMAL

ORTHO EVRA

+ JANSSEN PHARMS 0.035MG/24HR;0.15MG/24HR ** N021180 001 Nov 20, 2001

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET;ORAL

FEMCON FE

+ APIL 0.035MG;0.4MG ** N021490 001 Nov 14, 2003

TABLET;ORAL-21

BALZIVA-21

BARR 0.035MG;0.4MG A076198 001 Apr 22, 2004

BREVICON 21-DAY

ALLERGAN 0.035MG;0.5MG N017566 001

GENCEPT 10/11-21

BARR 0.035MG,0.035MG;0.5MG,1MG A072694 001 Feb 28, 1992

MODICON 21

ORTHO MCNEIL PHARM 0.035MG;0.5MG ** N017488 001

N.E.E. 1/35 21

LPI 0.035MG;1MG A071541 001 Dec 14, 1987

NORCEPT-E 1/35 21

ORTHO MCNEIL PHARM 0.035MG;1MG A071545 001 Feb 09, 1989

NORETHIN 1/35E-21

WATSON PHARMS TEVA 0.035MG;1MG A071480 001 Apr 12, 1988

NORETHINDRONE AND ETHINYL ESTRADIOL

WATSON LABS 0.035MG;0.4MG A078379 001 Feb 23, 2010

0.035MG;0.5MG A070684 001 Jan 29, 1987

WATSON PHARMS TEVA 0.035MG;1MG A070685 001 Jan 29, 1987

NORETHINDRONE AND ETHINYL ESTRADIOL (10/11)

WATSON LABS 0.035MG,0.035MG;0.5MG,1MG A071043 001 Apr 01, 1988

NORETHINDRONE AND ETHINYL ESTRADIOL (7/14)

WATSON LABS TEVA 0.035MG,0.035MG;0.5MG,1MG A071041 001 Sep 24, 1991

NORINYL 1+35 21-DAY

ALLERGAN 0.035MG;1MG N017565 001

NORTREL 0.5/35-21

BARR 0.035MG;0.5MG A072692 001 Feb 28, 1992

ORTHO-NOVUM 1/35-21

ORTHO MCNEIL PHARM 0.035MG;1MG ** N017489 002

ORTHO-NOVUM 10/11-21

+ ORTHO MCNEIL JANSSEN 0.035MG,0.035MG;0.5MG,1MG ** N018354 001 Jan 11, 1982

ORTHO-NOVUM 7/14-21

ORTHO MCNEIL PHARM 0.035MG,0.035MG;0.5MG,1MG ** N019004 001 Apr 04, 1984

ORTHO-NOVUM 7/7/7-21

JANSSEN PHARMS 0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG N018985 001 Apr 04, 1984

OVCON-35

+ WARNER CHILCOTT 0.035MG;0.4MG ** N018127 001

OVCON-50

WARNER CHILCOTT 0.05MG;1MG N018128 001

TRI-NORINYL 21-DAY

MAYNE PHARMA 0.035MG,0.035MG,0.035MG;0.5MG,1MG,0.5MG N018977 001 Apr 13, 1984

TABLET;ORAL-28

BREVICON 28-DAY

ALLERGAN 0.035MG;0.5MG N017743 001

CYCLAFEM 0.5/35

VINTAGE PHARMS 0.035MG;0.5MG A203413 001 Dec 16, 2015

CYCLAFEM 1/35

VINTAGE PHARMS LLC 0.035MG;1MG A076337 001 Nov 12, 2010

CYCLAFEM 7/7/7

VINTAGE PHARMS LLC 0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG A076338 001 Nov 16, 2010

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-190(of 478)

** See List Footnote

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-28

GENCEPT 10/11-28

BARR 0.035MG, 0.035MG; 0.5MG, 1MG A072697 001 Feb 28, 1992

MODICON 28

+ JANSSEN PHARMS 0.035MG; 0.5MG N017735 001

N.E.E. 1/35 28

LPI 0.035MG; 1MG A071542 001 Dec 14, 1987

NORCEPT-E 1/35 28

ORTHO MCNEIL PHARM 0.035MG; 1MG A071546 001 Feb 09, 1989

NORETHIN 1/35E-28

WATSON LABS 0.035MG; 1MG A071481 001 Apr 12, 1988

NORETHINDRONE AND ETHINYL ESTRADIOL

MAYNE PHARMA 0.035MG; 0.5MG A070686 001 Jan 29, 1987

MYLAN LABS LTD 0.035MG; 0.4MG A200897 001 May 11, 2015

0.035MG, 0.035MG, 0.035MG; 0.5MG, 0.75MG, 1M A200486 001 Dec 28, 2015

G 0.035MG; 0.5MG A200488 001 Oct 21, 2015

0.035MG; 1MG A200489 001 Oct 21, 2015

0.05MG; 1MG A203006 001 Aug 05, 2013

WATSON LABS 0.035MG, 0.035MG, 0.035MG; 0.5MG, 0.75MG, 1M A076393 001 Feb 04, 2010

G

NORETHINDRONE AND ETHINYL ESTRADIOL (7/14)

WATSON LABS 0.035MG, 0.035MG; 0.5MG, 1MG A071042 001 Sep 24, 1991

NORINYL 1+35 28-DAY

ALLERGAN 0.035MG; 1MG N017565 002

ORTHO-NOVUM 1/35-28

+ JANSSEN PHARMS 0.035MG; 1MG ** N017919 002

ORTHO-NOVUM 10/11-28

+ ORTHO MCNEIL JANSSEN 0.035MG, 0.035MG; 0.5MG, 1MG N018354 002 Jan 11, 1982

ORTHO-NOVUM 7/14-28

ORTHO MCNEIL PHARM 0.035MG, 0.035MG; 0.5MG, 1MG ** N019004 002 Apr 04, 1984

ORTHO-NOVUM 7/7/7-28

+ JANSSEN PHARMS 0.035MG, 0.035MG, 0.035MG; 0.5MG, 0.75MG, 1M N018985 002 Apr 04, 1984

G **

OVCON-35

+ WARNER CHILCOTT LLC 0.035MG; 0.4MG ** N017716 001

OVCON-50

WARNER CHILCOTT LLC 0.05MG; 1MG ** N017576 001

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

CAPSULE; ORAL

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

MAYNE PHARMA 0.02MG; 1MG A213901 001 Apr 28, 2022

TABLET; ORAL

FEMHRT

+ APIL 0.0025MG; 0.5MG N021065 001 Jan 14, 2005

+ 0.005MG; 1MG ** N021065 002 Oct 15, 1999

LOESTRIN 24 FE

+ TEVA BRANDED PHARM 0.02MG; 1MG ** N021871 001 Feb 17, 2006

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL

MYLAN LABS LTD 0.0025MG; 0.5MG A207260 001 Feb 02, 2017

0.005MG; 1MG A207259 001 Dec 27, 2016

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

MYLAN LABS LTD 0.01MG, 0.01MG; 1MG, N/A A205049 001 May 31, 2016

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

AMNEAL PHARMS 0.02MG; 1MG A078267 001 Sep 01, 2009

0.02MG; 1MG A207514 001 Sep 11, 2017

APOTEX 0.02MG; 1MG A208639 001 Mar 21, 2018

MYLAN LABS LTD 0.02MG; 1MG A202742 001 Oct 30, 2014

0.02MG; 1MG A206120 001 Sep 12, 2017

TABLET; ORAL-21

ESTROSTEP 21

+ APIL 0.02MG, 0.03MG, 0.035MG; 1MG, 1MG, 1MG ** N020130 001 Oct 09, 1996

GILDESS 1.5/30

VINTAGE PHARMS LLC 0.03MG; 1.5MG A077075 002 Jul 24, 2012

GILDESS 1/20

VINTAGE PHARMS LLC 0.02MG; 1MG A077077 002 Jul 24, 2012

LOESTRIN 21 1.5/30

+ TEVA BRANDED PHARM 0.03MG; 1.5MG N017875 001

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-191(of 478)

** See List Footnote

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET;ORAL-21

LOESTRIN 21 1/20

+ TEVA BRANDED PHARM 0.02MG;1MG N017876 001

LOESTRIN FE 1.5/30

+ TEVA BRANDED PHARM 0.03MG;1.5MG N017355 001

MICROGESTIN 1.5/30

MAYNE PHARMA 0.03MG;1.5MG A075548 002 Jul 30, 2003

MICROGESTIN 1/20

MAYNE PHARMA 0.02MG;1MG A075647 002 Jul 30, 2003

NORLESTRIN 21 1/50

PARKE DAVIS 0.05MG;1MG N016749 001

NORLESTRIN 21 2.5/50

PARKE DAVIS 0.05MG;2.5MG N016852 001

TABLET;ORAL-28

ESTROSTEP FE

+ APIL 0.02MG,0.03MG,0.035MG;1MG,1MG,1MG N020130 002 Oct 09, 1996

GILDESS FE 1.5/30

VINTAGE PHARMS LLC 0.03MG;1.5MG A077075 001 Apr 28, 2005

GILDESS FE 1/20

VINTAGE PHARMS LLC 0.02MG;1MG A077077 001 May 20, 2005

LOESTRIN FE 1/20

+ TEVA BRANDED PHARM 0.02MG;1MG N017354 001

MICROGESTIN FE 1.5/30

MAYNE PHARMA 0.03MG;1.5MG A075548 001 Feb 05, 2001

MICROGESTIN FE 1/20

MAYNE PHARMA 0.02MG;1MG A075647 001 Feb 05, 2001

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL

MAYNE PHARMA 0.02MG,0.03MG,0.035MG;1MG,1MG,1MG A076629 001 Mar 18, 2010

NORLESTRIN 28 1/50

PARKE DAVIS 0.05MG;1MG N016723 001

TABLET, CHEWABLE, TABLET;ORAL

LO MINASTRIN FE

+ APIL 0.01MG,0.01MG,N/A;1MG,N/A,N/A N204654 001 Jul 24, 2013

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET;ORAL-21

ORTHO CYCLEN-21

JANSSEN PHARMS 0.035MG;0.25MG ** N019653 001 Dec 29, 1989

ORTHO TRI-CYCLEN

JANSSEN PHARMS 0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG ** N019697 002 Jul 03, 1992

TABLET;ORAL-28

NORGESTIMATE AND ETHINYL ESTRADIOL

MYLAN 0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG A201897 001 Jan 27, 2016

0.035MG;0.25MG A201896 001 Jan 27, 2016

MYLAN LABS LTD 0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG A202132 001 Sep 09, 2015

WATSON LABS 0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG A090479 001 Mar 09, 2011

0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG A076626 001 Aug 17, 2006

0.035MG;0.25MG A076627 001 Aug 17, 2006

ORTHO CYCLEN-28

+ JANSSEN PHARMS 0.035MG;0.25MG ** N019653 002 Dec 29, 1989

ORTHO TRI-CYCLEN

+ JANSSEN PHARMS 0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG ** N019697 001 Jul 03, 1992

ORTHO TRI-CYCLEN LO

+ JANSSEN PHARMS 0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG ** N021241 001 Aug 22, 2002

TRI-PREVIFEM

VINTAGE PHARMS LLC 0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG A076335 001 Mar 26, 2004

DISCONTINUED DRUG PRODUCT LIST

6-192(of 478)

** See List Footnote

ETHINYL ESTRADIOL; NORGESTREL

TABLET; ORAL-21

LO/OVRAL

+ CADENCE HEALTH 0.03MG; 0.3MG N017612 001

LOW-OGESTREL-21

MAYNE PHARMA 0.03MG; 0.3MG A075288 001 Jul 28, 1999

OGESTREL 0.5/50-21

WATSON LABS 0.05MG; 0.5MG A075406 001 Dec 15, 1999

OVRAL

WYETH PHARMS 0.05MG; 0.5MG N016672 001

TABLET; ORAL-28

LO/OVRAL-28

+ WYETH PHARMS 0.03MG; 0.3MG ** N017802 001

NORGESTREL AND ETHINYL ESTRADIOL

MYLAN LABS LTD 0.03MG; 0.3MG A201828 001 Jun 21, 2016

0.05MG; 0.5MG A202875 001 May 08, 2017

OGESTREL 0.5/50-28

WATSON LABS 0.05MG; 0.5MG A075406 002 Dec 15, 1999

OVRAL-28

WYETH PHARMS 0.05MG; 0.5MG N016806 001

ETHOPROPAZINE HYDROCHLORIDE

TABLET; ORAL

PARSIDOL

PARKE DAVIS 10MG N009078 003

50MG N009078 006

100MG N009078 008

ETHOSUXIMIDE

SYRUP; ORAL

ETHOSUXIMIDE

TEVA PHARMS 250MG/5ML A081306 001 Jul 30, 1993

ETHOTOIN

TABLET; ORAL

PEGANONE

+ RECORDATI RARE 250MG N010841 001

500MG N010841 003

ETHOXZOLAMIDE

TABLET; ORAL

CARDRASE

PHARMACIA AND UPJOHN 62.5MG N011047 002

125MG N011047 001

ETHAMIDE

ALLERGAN 125MG N016144 001

ETHYLESTRENOL

ELIXIR; ORAL

MAXIBOLIN

ORGANON USA INC 2MG/5ML N014006 002

TABLET; ORAL

MAXIBOLIN

ORGANON USA INC 2MG N014005 002

ETHYNODIOL DIACETATE; MESTRANOL

TABLET; ORAL-20

OVULEN

GD SEARLE LLC 1MG; 0.1MG N016029 002

TABLET; ORAL-21

OVULEN-21

GD SEARLE LLC 1MG; 0.1MG N016029 003

TABLET; ORAL-28

OVULEN-28

GD SEARLE LLC 1MG; 0.1MG N016705 001

ETIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

DURANEST

+ ASTRAZENECA 0.5% ** N017751 003

+ 1% ** N017751 005

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-193(of 478)

** See List Footnote

ETIDRONATE DISODIUM

INJECTABLE; INJECTION

DIDRONEL

MGI PHARMA INC

50MG/ML

N019545 001 Apr 20, 1987

TABLET; ORAL

DIDRONEL

+ APIL

200MG **

N017831 001

+

400MG **

N017831 002

ETIDRONATE DISODIUM

MYLAN

200MG

A075800 001 Jan 24, 2003

400MG

A075800 002 Jan 24, 2003

ETODOLAC

CAPSULE; ORAL

ETODOLAC

ANI PHARMS

200MG

A074840 001 Aug 29, 1997

200MG

A074844 001 Dec 23, 1997

200MG

A074899 001 Jul 08, 1997

300MG

A074840 002 Aug 29, 1997

300MG

A074844 002 Dec 23, 1997

300MG

A074899 002 Jul 08, 1997

BIOPHARM

300MG

A074929 001 Jan 30, 1998

CHARTWELL MOLECULES

200MG

A074842 001 Jul 17, 1997

300MG

A074842 002 Jul 17, 1997

MYLAN

200MG

A074932 001 May 16, 1997

200MG

A075071 001 Sep 30, 1998

300MG

A074932 002 May 16, 1997

300MG

A075071 002 Sep 30, 1998

SANDOZ

200MG

A074942 001 Sep 30, 1997

300MG

A074942 002 Sep 30, 1997

LODINE

+ WYETH PHARMS INC

200MG **

N018922 002 Jan 31, 1991

+

300MG

N018922 003 Jan 31, 1991

TABLET; ORAL

ETODOLAC

BIOPHARM

400MG

A074927 001 Oct 30, 1997

CHARTWELL MOLECULES

400MG

A074841 001 Jun 27, 1997

IVAX SUB TEVA PHARMS

400MG

A074883 001 Feb 28, 1997

500MG

A074883 002 Nov 20, 1998

MYLAN

400MG

A075012 001 Sep 30, 1998

400MG

A075104 001 Feb 06, 1998

500MG

A075012 002 Sep 30, 1998

500MG

A075104 002 Nov 20, 1998

OXFORD PHARMS

400MG

A074819 001 Feb 28, 1997

500MG

A074819 002 Apr 28, 1998

PHARMGEN

400MG

A074839 001 Jul 11, 1997

400MG

A074846 001 Feb 28, 1997

RANBAXY LABS LTD

400MG

A075226 001 Nov 24, 1998

500MG

A075226 002 Nov 24, 1998

TEVA

400MG

A074847 001 Apr 23, 1999

400MG

A075009 001 Nov 26, 1997

500MG

A074847 002 Apr 23, 1999

500MG

A075009 002 Dec 28, 1999

WATSON LABS

400MG

A074892 001 Apr 16, 1997

400MG

A075069 001 Apr 16, 1998

500MG

A074892 002 Oct 29, 1998

LODINE

+ WYETH PHARMS INC

400MG **

N018922 004 Jul 29, 1993

+

500MG **

N018922 005 Jun 28, 1996

TABLET, EXTENDED RELEASE; ORAL

ETODOLAC

ACTAVIS ELIZABETH

400MG

A075696 001 Jul 31, 2000

ANI PHARMS

400MG

A075943 001 Jul 26, 2002

500MG

A075943 002 Jul 26, 2002

600MG

A075943 003 Jul 26, 2002

WATSON LABS FLORIDA

400MG

A075829 001 Nov 30, 2001

500MG

A075829 002 Nov 30, 2001

LODINE XL

WYETH PHARMS INC

400MG **

N020584 001 Oct 25, 1996

500MG **

N020584 003 Jan 20, 1998

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-194(of 478)

** See List Footnote

ETODOLAC

TABLET, EXTENDED RELEASE;ORAL

LODINE XL

+

600MG **

N020584 002 Oct 25, 1996

ETOMIDATE

INJECTABLE;INJECTION

ETOMIDATE

LUITPOLD

2MG/ML

A078867 001 Dec 22, 2009

PAR STERILE PRODUCTS

2MG/ML

A091297 001 Jun 20, 2012

RISING

2MG/ML

A078289 001 Jan 02, 2009

ETONOGESTREL

IMPLANT;IMPLANTATION

IMPLANON

ORGANON

68MG/IMPLANT

N021529 001 Jul 17, 2006

ETOPOSIDE

CAPSULE;ORAL

VEPESID

+

STRIDES PHARMA

50MG

N019557 001 Dec 30, 1986

+

100MG

N019557 002 Dec 30, 1986

INJECTABLE;INJECTION

ETOPOSIDE

HOSPIRA

20MG/ML

A074320 001 Aug 30, 1995

20MG/ML

A074351 001 Aug 30, 1995

MYLAN LABS LTD

20MG/ML

A203507 001 Nov 20, 2017

20MG/ML

A204927 001 Oct 31, 2017

PHARMACHEMIE BV

20MG/ML

A074227 001 Feb 22, 1996

PIERRE FABRE

20MG/ML

A074813 001 Jul 09, 1997

TEVA PARENTERAL

20MG/ML

A074510 001 Jun 29, 1995

TEVA PHARMS USA

20MG/ML

A074284 001 Feb 10, 1994

WATSON LABS

20MG/ML

A074228 001 Oct 15, 1996

WATSON LABS INC

20MG/ML

A074968 001 Jan 09, 1998

TOPOSAR

TEVA PARENTERAL

20MG/ML

A074166 001 Feb 27, 1995

VEPESID

+

CORDEN PHARMA

20MG/ML **

N018768 001 Nov 10, 1983

ETOPOSIDE PHOSPHATE

INJECTABLE;INJECTION

ETOPOPHOS PRESERVATIVE FREE

BRISTOL MYERS SQUIBB

EQ 500MG BASE/VIAL

N020906 001 Feb 27, 1998

EQ 1GM BASE/VIAL

N020906 002 Feb 27, 1998

ETRAVIRINE

TABLET;ORAL

ETRAVIRINE

AMNEAL

25MG

A214196 001 Jun 14, 2021

ETRETINATE

CAPSULE;ORAL

TEGISON

ROCHE

10MG

N019369 001 Sep 30, 1986

25MG

N019369 002 Sep 30, 1986

EVANS BLUE

INJECTABLE;INJECTION

EVANS BLUE

PARKE DAVIS

0.5% **

N008041 001

EVEROLIMUS

TABLET;ORAL

EVEROLIMUS

TEVA PHARMS USA

10MG

A210050 004 Dec 09, 2019

EXEMESTANE

TABLET;ORAL

EXEMESTANE

AMNEAL PHARMS

25MG

A206421 001 Dec 28, 2018

MAYNE PHARMA INC

25MG

A208764 001 Aug 08, 2019

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-195(of 478)

** See List Footnote

EXENATIDE SYNTHETIC

FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS

BYDUREON

+ ASTRAZENECA AB 2MG/VIAL

N022200 001 Jan 27, 2012

BYDUREON PEN

+ ASTRAZENECA AB 2MG

N022200 002 Feb 28, 2014

EZETIMIBE

TABLET;ORAL

EZETIMIBE

APOTEX 10MG

A208332 001 Jun 12, 2017

RISING 10MG

A201790 001 Apr 26, 2019

TEVA PHARMS USA 10MG

A078724 001 Jun 12, 2017

EZETIMIBE; ROSUVASTATIN CALCIUM

TABLET;ORAL

ROSZET

+ ALTHERA PHARMS 10MG;EQ 5MG BASE

N213072 001 Mar 23, 2021

+ 10MG;EQ 10MG BASE

N213072 002 Mar 23, 2021

+ 10MG;EQ 20MG BASE

N213072 003 Mar 23, 2021

+ 10MG;EQ 40MG BASE

N213072 004 Mar 23, 2021

EZETIMIBE; SIMVASTATIN

TABLET;ORAL

EZETIMIBE AND SIMVASTATIN

ANI PHARMS 10MG;10MG

A201890 001 Apr 26, 2017

10MG;20MG

A201890 002 Apr 26, 2017

10MG;40MG

A201890 003 Apr 26, 2017

10MG;80MG

A201890 004 Apr 26, 2017

AUROBINDO PHARMA USA 10MG;10MG

A200082 001 Dec 17, 2020

10MG;20MG

A200082 002 Dec 17, 2020

10MG;40MG

A200082 003 Dec 17, 2020

10MG;80MG

A200082 004 Dec 17, 2020

EZOGBINE

TABLET;ORAL

POTIGA

+ GLAXOSMITHKLINE 50MG

N022345 001 Jun 10, 2011

+ 200MG

N022345 002 Jun 10, 2011

+ 300MG

N022345 003 Jun 10, 2011

+ 400MG

N022345 004 Jun 10, 2011

FAMCICLOVIR

TABLET;ORAL

FAMCICLOVIR

CIPLA 125MG

A078278 001 Mar 21, 2011

250MG

A078278 002 Mar 21, 2011

500MG

A078278 003 Mar 21, 2011

HIKMA 125MG

A090128 001 Mar 21, 2011

250MG

A090128 002 Mar 21, 2011

500MG

A090128 003 Mar 21, 2011

MYLAN 125MG

A201333 001 Mar 24, 2011

250MG

A201333 002 Mar 24, 2011

500MG

A201333 003 Mar 24, 2011

FAMVIR

+ NOVARTIS 125MG **

N020363 003 Dec 11, 1995

+ 250MG **

N020363 001 Apr 26, 1996

+ 500MG **

N020363 002 Jun 29, 1994

FAMOTIDINE

FOR SUSPENSION;ORAL

PEPCID

+ SALIX PHARMS 40MG/5ML **

N019527 001 Feb 02, 1987

INJECTABLE;INJECTION

FAMOTIDINE

APOTEX INC 10MG/ML

A075942 001 Aug 02, 2002

APOTHECON 10MG/ML

A075707 001 Apr 16, 2001

HIKMA 10MG/ML

A075799 001 Apr 30, 2002

HOSPIRA 10MG/ML

A075705 001 Apr 16, 2001

10MG/ML

A075870 001 Nov 23, 2001

10MG/ML

A075905 001 Nov 23, 2001

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-196(of 478)

** See List Footnote

FAMOTIDINE

INJECTABLE; INJECTION

FAMOTIDINE PRESERVATIVE FREE

AKORN	10MG/ML	A076324	001	Nov 27, 2002
APOTHECON	10MG/ML	A075708	001	Apr 16, 2001
HIKMA	10MG/ML	A075789	001	Apr 30, 2002
HOSPIRA	10MG/ML	A075669	001	Apr 16, 2001

FAMOTIDINE PRESERVATIVE FREE (PHARMACY BULK)

AKORN	10MG/ML	A076322	001	Nov 27, 2002

FAMOTIDINE PRESERVATIVE FREE IN PLASTIC CONTAINER

ABBVIE	0.4MG/ML	A075729	001	Dec 17, 2001

PEPCID

+ MERCK	10MG/ML **	N019510	001	Nov 04, 1986

PEPCID PRESERVATIVE FREE

+ MERCK	10MG/ML **	N019510	004	Nov 04, 1986

PEPCID PRESERVATIVE FREE IN PLASTIC CONTAINER

+ MERCK SHARP DOHME	0.4MG/ML **	N020249	001	Feb 18, 1994

TABLET; ORAL

FAMOTIDINE

ACTAVIS ELIZABETH	20MG	A075650	001	Sep 14, 2001
	40MG	A075650	002	Sep 14, 2001
APOTEX	10MG	A075610	001	Mar 12, 2002
MANKIND PHARMA	20MG	A075302	001	Apr 16, 2001
	40MG	A075302	002	Apr 16, 2001
MYLAN	10MG	A075674	001	Dec 21, 2001
MYLAN PHARMS INC	20MG	A075457	001	Apr 18, 2001
	40MG	A075457	002	Apr 18, 2001
PERRIGO R AND D	20MG	A077352	002	Jul 27, 2005
	40MG	A077352	001	Jul 27, 2005
RISING	20MG	A075704	001	Apr 16, 2001
	40MG	A075704	002	Apr 16, 2001
SANDOZ	10MG	A076101	001	Oct 21, 2002
	20MG	A075607	001	May 10, 2001
	20MG	A075793	001	Apr 16, 2001
	40MG	A075607	002	May 10, 2001
	40MG	A075793	002	Apr 16, 2001
SUN PHARM INDUSTRIES	20MG	A075639	002	Dec 12, 2001
	40MG	A075639	001	Dec 12, 2001
TEVA	10MG	A075312	001	May 31, 2001
	20MG	A075311	001	Apr 16, 2001
	40MG	A075311	002	Apr 16, 2001
WATSON LABS	10MG	A075404	001	Nov 28, 2001
	20MG	A075062	002	Apr 16, 2001
	40MG	A075062	001	Apr 16, 2001

PEPCID

+ BAUSCH	20MG **	N019462	001	Oct 15, 1986
+	40MG **	N019462	002	Oct 15, 1986

TABLET, CHEWABLE; ORAL

FAMOTIDINE

PERRIGO	10MG	A075715	001	Aug 22, 2003

PEPCID AC

+ J AND J CONSUMER INC	10MG **	N020801	001	Sep 24, 1998

TABLET, ORALLY DISINTEGRATING; ORAL

FLUXID

UCB INC	20MG	N021712	001	Sep 24, 2004
	40MG	N021712	002	Sep 24, 2004

PEPCID RPD

MERCK	20MG	N020752	001	May 28, 1998
	40MG	N020752	002	May 28, 1998

FELODIPINE

TABLET, EXTENDED RELEASE; ORAL

FELODIPINE

JUBILANT GENERICS	2.5MG	A203983	001	Aug 19, 2016
	5MG	A203983	002	Aug 19, 2016
	10MG	A203983	003	Aug 19, 2016
MYLAN	2.5MG	A078855	001	Apr 17, 2008
	5MG	A078855	002	Apr 17, 2008
	10MG	A078855	003	Apr 17, 2008
WOCKHARDT	2.5MG	A091484	001	Aug 15, 2012

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-197(of 478)

** See List Footnote

FELODIPINETABLET, EXTENDED RELEASE;ORAL
FELODIPINE

	5MG	A091484 002	Aug 15, 2012
	10MG	A091484 003	Aug 15, 2012
PLENDIL			
+ ASTRAZENECA	2.5MG **	N019834 004	Sep 22, 1994
+	5MG **	N019834 001	Jul 25, 1991
+	10MG **	N019834 002	Jul 25, 1991

FENOFIBRATE

CAPSULE;ORAL

ANTARA (MICRONIZED)

+ LUPIN	30MG	N021695 004	Oct 18, 2013
	87MG	N021695 002	Nov 30, 2004

FENOFIBRATE (MICRONIZED)
IMPAX LABS

	67MG	A075868 001	Oct 27, 2003
	134MG	A075868 002	Oct 27, 2003
	200MG	A075868 003	Oct 27, 2003
MYLAN PHARMS INC	43MG	A202579 001	Jan 10, 2013
	130MG	A202579 002	Jan 10, 2013
NOVAST LABS	67MG	A207564 001	Apr 19, 2019
	134MG	A207564 002	Apr 19, 2019
	200MG	A207564 003	Apr 19, 2019
RISING	67MG	A202676 001	Oct 23, 2012
	134MG	A202676 002	Oct 23, 2012
	200MG	A202676 003	Oct 23, 2012

LIPIDIL

ABBVIE	100MG	N019304 001	Dec 31, 1993

LIPOFEN

CIPHER PHARMS INC	100MG	N021612 002	Jan 11, 2006

TRICOR (MICRONIZED)

+ ABBVIE	67MG **	N019304 002	Feb 09, 1998
+	134MG **	N019304 003	Jun 30, 1999
+	200MG **	N019304 004	Jun 30, 1999

TABLET;ORAL

FENOFIBRATE

ALEMBIC PHARMS	54MG	A213252 001	Jan 17, 2020
	160MG	A213252 002	Jan 17, 2020
MYLAN	107MG	A076520 002	Dec 29, 2005

TRICOR

+ ABBVIE INC	54MG **	N021203 001	Sep 04, 2001
+	160MG **	N021203 003	Sep 04, 2001

TRIGLIDE

SKYEPHARMA AG	50MG	N021350 001	May 07, 2005

FENOFIBRIC ACID

TABLET;ORAL

FIBRICOR

+ ATHENA	35MG	N022418 001	Aug 14, 2009
+	105MG	N022418 002	Aug 14, 2009

FENOLDOPAM MESYLATE

INJECTABLE;INJECTION

FENOLDOPAM MESYLATE

LUITPOLD	EQ 10MG BASE/ML	A076656 001	Dec 01, 2003
TEVA PARENTERAL	EQ 10MG BASE/ML	A077826 001	Mar 07, 2007

FENOPROFEN CALCIUM

CAPSULE;ORAL

FENOPROFEN CALCIUM

AM THERAP	EQ 200MG BASE	A072307 001	Aug 22, 1988
	EQ 300MG BASE	A072308 001	Aug 22, 1988
HALSEY	EQ 200MG BASE	A072355 001	Aug 17, 1988
	EQ 300MG BASE	A072356 001	Aug 17, 1988
PAR PHARM	EQ 200MG BASE	A072437 001	Aug 22, 1988
	EQ 300MG BASE	A072438 001	Aug 22, 1988
QUANTUM PHARMICS	EQ 200MG BASE	A072214 001	Aug 17, 1988
	EQ 300MG BASE	A071738 001	Aug 17, 1988
RISING	EQ 200MG BASE	A072394 001	Oct 17, 1988
	EQ 300MG BASE	A072395 001	Oct 17, 1988

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-198(of 478)

** See List Footnote

FENOPROFEN CALCIUM

CAPSULE;ORAL

FENOPROFEN CALCIUM

WARNER CHILCOTT	EQ 200MG BASE	A072946 001	Apr 30, 1991
	EQ 300MG BASE	A072472 001	Apr 30, 1991
WATSON LABS	EQ 200MG BASE	A072294 001	Aug 17, 1988
	EQ 200MG BASE	A072981 001	Aug 19, 1991
	EQ 300MG BASE	A072293 001	Aug 17, 1988
	EQ 300MG BASE	A072982 001	Aug 19, 1991

NALFON

XSPIRE PHARMA	EQ 300MG BASE	N017604 002	

TABLET;ORAL

FENOPROFEN CALCIUM

AM THERAP	EQ 600MG BASE	A072309 001	Aug 17, 1988
ANI PHARMS	EQ 600MG BASE	A072274 001	May 02, 1988
DAVA PHARMS INC	EQ 600MG BASE	A072326 001	Aug 17, 1988
HALSEY	EQ 600MG BASE	A072357 001	Aug 17, 1988
IVAX SUB TEVA PHARMS	EQ 600MG BASE	A072557 001	Aug 29, 1988
QUANTUM PHARMICS	EQ 600MG BASE	A072194 001	Aug 17, 1988
RISING	EQ 600MG BASE	A072396 001	Oct 17, 1988
STRIDES PHARMA	EQ 600MG BASE	A072429 001	Aug 17, 1988
SUN PHARM INDUSTRIES	EQ 600MG BASE	A072902 001	Dec 21, 1990
USL PHARMA	EQ 600MG BASE	A072362 001	Aug 17, 1988
WATSON LABS	EQ 600MG BASE	A072165 001	Aug 17, 1988
	EQ 600MG BASE	A072602 001	Oct 11, 1988
WATSON LABS TEVA	EQ 600MG BASE	A072407 001	Aug 17, 1988

NALFON

DISTA	EQ 600MG BASE	N017710 001	

FENTANYL

FILM, EXTENDED RELEASE;TRANSDERMAL

DURAGESIC-100

+ JANSSEN PHARMS	100MCG/HR	N019813 001	Aug 07, 1990

DURAGESIC-12

+ JANSSEN PHARMS	12.5MCG/HR	N019813 005	Feb 04, 2005

DURAGESIC-25

+ JANSSEN PHARMS	25MCG/HR	N019813 004	Aug 07, 1990

DURAGESIC-37

+ JANSSEN PHARMS	37.5MCG/HR	N019813 006	Jan 24, 2018

DURAGESIC-50

+ JANSSEN PHARMS	50MCG/HR	N019813 003	Aug 07, 1990

DURAGESIC-75

+ JANSSEN PHARMS	75MCG/HR	N019813 002	Aug 07, 1990

FENTANYL-100

ACTAVIS LABS UT INC	100MCG/HR	A076709 004	Aug 20, 2007
AVEVA	100MCG/HR	A077449 004	Oct 20, 2008
LAVIPHARM LABS	100MCG/HR	A077051 004	Aug 04, 2006
MAYNE PHARMA	100MCG/HR	A077062 004	Aug 20, 2007
NOVEN	100MCG/HR	A077775 004	Oct 16, 2009

FENTANYL-12

AVEVA	12.5MCG/HR	A077449 005	Sep 11, 2015

FENTANYL-25

ACTAVIS LABS UT INC	25MCG/HR	A076709 001	Aug 20, 2007
AVEVA	25MCG/HR	A077449 001	Oct 20, 2008
LAVIPHARM LABS	25MCG/HR	A077051 001	Aug 04, 2006
MAYNE PHARMA	25MCG/HR	A077062 001	Aug 20, 2007
NOVEN	25MCG/HR	A077775 001	Oct 16, 2009

FENTANYL-37

AVEVA	37.5MCG/HR	A077449 006	Dec 06, 2017

FENTANYL-50

ACTAVIS LABS UT INC	50MCG/HR	A076709 002	Aug 20, 2007
AVEVA	50MCG/HR	A077449 002	Oct 20, 2008
LAVIPHARM LABS	50MCG/HR	A077051 002	Aug 04, 2006
MAYNE PHARMA	50MCG/HR	A077062 002	Aug 20, 2007
NOVEN	50MCG/HR	A077775 002	Oct 16, 2009

FENTANYL-62

AVEVA	62.5MCG/HR	A077449 007	Dec 06, 2017

FENTANYL-75

ACTAVIS LABS UT INC	75MCG/HR	A076709 003	Aug 20, 2007
AVEVA	75MCG/HR	A077449 003	Oct 20, 2008

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-199(of 478)

** See List Footnote

FENTANYL

FILM, EXTENDED RELEASE;TRANSDERMAL

FENTANYL-75

LAVIPHARM LABS	75MCG/HR	A077051	003	Aug 04, 2006
MAYNE PHARMA	75MCG/HR	A077062	003	Aug 20, 2007
NOVEN	75MCG/HR	A077775	003	Oct 16, 2009

FENTANYL-87

AVEVA	87.5MCG/HR	A077449	008	Dec 06, 2017

SPRAY;SUBLINGUAL

SUBSYS

+ BTCP PHARMA	0.1MG	N202788	001	Jan 04, 2012
+	0.2MG	N202788	002	Jan 04, 2012
+	0.4MG	N202788	003	Jan 04, 2012
+	0.6MG	N202788	004	Jan 04, 2012
+	0.8MG	N202788	005	Jan 04, 2012
+	1.2MG	N202788	006	Aug 30, 2012
+	1.6MG	N202788	007	Aug 30, 2012

FENTANYL CITRATE

FILM;BUCCAL

ONSOLIS

ADALVO	EQ 0.2MG BASE	N022266	001	Jul 16, 2009
	EQ 0.4MG BASE	N022266	002	Jul 16, 2009
	EQ 0.6MG BASE	N022266	003	Jul 16, 2009
	EQ 0.8MG BASE	N022266	004	Jul 16, 2009
	EQ 1.2MG BASE	N022266	005	Jul 16, 2009

INJECTABLE;INJECTION

FENTANYL CITRATE

ABBOTT	EQ 0.05MG BASE/ML	A070636	001	Apr 30, 1990
	EQ 0.05MG BASE/ML	A070637	001	Apr 30, 1990
WATSON LABS	EQ 0.05MG BASE/ML	A073488	001	Jun 30, 1992

FENTANYL CITRATE PRESERVATIVE FREE

DR REDDYS	EQ 0.05MG BASE/ML	A074917	001	Feb 03, 1998

SPRAY, METERED;NASAL

LAZANDA

+ BTCP PHARMA	EQ 0.1MG BASE	N022569	001	Jun 30, 2011
+	EQ 0.3MG BASE	N022569	003	Dec 21, 2015
+	EQ 0.4MG BASE	N022569	002	Jun 30, 2011

TABLET;BUCCAL, SUBLINGUAL

FENTANYL CITRATE

MAYNE PHARMA	EQ 0.1MG BASE	A206329	001	Aug 22, 2022
	EQ 0.2MG BASE	A206329	002	Aug 22, 2022
	EQ 0.3MG BASE	A206329	003	Aug 22, 2022
	EQ 0.4MG BASE	A206329	004	Aug 22, 2022
	EQ 0.6MG BASE	A206329	005	Aug 22, 2022
	EQ 0.8MG BASE	A206329	006	Aug 22, 2022
WATSON LABS	EQ 0.1MG BASE	A079075	001	Jan 07, 2011
	EQ 0.2MG BASE	A079075	002	Jan 07, 2011
	EQ 0.4MG BASE	A079075	003	Jan 07, 2011
	EQ 0.6MG BASE	A079075	004	Jan 07, 2011
	EQ 0.8MG BASE	A079075	005	Jan 07, 2011

FENTORA

+ CEPHALON	EQ 0.3MG BASE **	N021947	006	Mar 02, 2007

TABLET;SUBLINGUAL

ABSTRAL

+ SENTYNL THERAPS INC	EQ 0.1MG BASE **	N022510	001	Jan 07, 2011
+	EQ 0.2MG BASE **	N022510	002	Jan 07, 2011
+	EQ 0.3MG BASE **	N022510	003	Jan 07, 2011
+	EQ 0.4MG BASE **	N022510	004	Jan 07, 2011
+	EQ 0.6MG BASE **	N022510	005	Jan 07, 2011
+	EQ 0.8MG BASE **	N022510	006	Jan 07, 2011

FENTANYL CITRATE

ACTAVIS LABS FL INC	EQ 0.1MG BASE	A207338	001	Nov 17, 2017
	EQ 0.2MG BASE	A207338	002	Nov 17, 2017
	EQ 0.3MG BASE	A207338	003	Nov 17, 2017
	EQ 0.4MG BASE	A207338	004	Nov 17, 2017
	EQ 0.6MG BASE	A207338	005	Nov 17, 2017
	EQ 0.8MG BASE	A207338	006	Nov 17, 2017

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-200(of 478)

** See List Footnote

FENTANYL CITRATE

TROCHE/LOZENGE;ORAL

FENTANYL

CEPHALON

EQ 0.1MG BASE

N020195 007 Oct 30, 1995

EQ 0.2MG BASE

N020195 001 Oct 04, 1993

EQ 0.3MG BASE

N020195 002 Oct 04, 1993

EQ 0.4MG BASE

N020195 003 Oct 04, 1993

TROCHE/LOZENGE;TRANSMUCOSAL

FENTANYL CITRATE

PAR PHARM

EQ 0.2MG BASE

A077312 001 Oct 30, 2009

EQ 0.4MG BASE

A077312 002 Oct 30, 2009

EQ 0.6MG BASE

A077312 003 Oct 30, 2009

EQ 0.8MG BASE

A077312 004 Oct 30, 2009

EQ 1.2MG BASE

A077312 005 Oct 30, 2009

EQ 1.6MG BASE

A077312 006 Oct 30, 2009

FENTANYL HYDROCHLORIDE

SYSTEM;IONTOPHORESIS, TRANSDERMAL

IONSYS

+

THE MEDICINES CO

EQ 40MCG BASE/ACTIVATION

N021338 001 May 22, 2006

FERRIC AMMONIUM CITRATE

FOR SOLUTION;ORAL

FERRISELTZ

OTSUKA

600MG/PACKET

N020292 001 Oct 14, 1997

FERRIC DERISOMALTOSE

SOLUTION;INTRAVENOUS

MONOFERRIC

+

PHARMACOSMOS AS

100MG/ML (100MG/ML)

N208171 001 Jan 16, 2020

+

500MG/5ML (100MG/ML)

N208171 002 Jan 16, 2020

FERRIC OXYHYDROXIDE

INJECTABLE;INJECTION

DEXFERRUM

AM REGENT

EQ 50MG IRON/ML

N040024 001 Feb 23, 1996

IRON DEXTRAN

SANOFI AVENTIS US

EQ 50MG IRON/ML

N010787 002

PROFERDEX

NEW RIVER

EQ 50MG IRON/ML

N017807 001

INJECTABLE;INTRAVENOUS

VENOFER

AM REGENT

EQ 65MG IRON/3.25ML (EQ 20MG IRON/ML)

N021135 005 Mar 29, 2013

EQ 75MG IRON/3.75ML (EQ 20MG IRON/ML)

N021135 003 Mar 29, 2005

FERRIC PYROPHOSPHATE CITRATE

FOR SOLUTION;INTRAVENOUS

TRIFERIC

+

ROCKWELL MEDICAL INC

272MG IRON/PACKET

N208551 001 Apr 25, 2016

SOLUTION;INTRAVENOUS

TRIFERIC

+

ROCKWELL MEDICAL INC

27.2MG IRON/5ML (5.44MG IRON/ML)

N206317 001 Jan 23, 2015

+

272MG IRON/50ML (5.44MG IRON/ML)

N206317 002 Sep 04, 2015

TRIFERIC AVNU

+

ROCKWELL MEDICAL INC

6.75MG IRON/4.5ML (1.5MG IRON/ML)

N212860 001 Mar 27, 2020

FERROUS CITRATE, FE-59

INJECTABLE;INJECTION

FERROUS CITRATE FE 59

MALLINCKRODT

25uCi/ML

N016729 001

FERROUS SULFATE; FOLIC ACID

CAPSULE;ORAL

FOLVRON

LEDERLE

182MG;0.33MG

N006012 003

FERUMOXIDES

INJECTABLE;INJECTION

FERIDEX I.V.

AMAG PHARMS INC

EQ 11.2MG IRON/ML

N020416 001 Aug 30, 1996

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-201(of 478)

** See List Footnote

FERUMOXSI

SUSPENSION;ORAL

GASTROMARK

AMAG PHARMS INC

EQ 0.175MG IRON/ML

N020410 001 Dec 06, 1996

FEXOFENADINE HYDROCHLORIDE

CAPSULE;ORAL

ALLEGRA

CHATTEM SANOFI

60MG **

N020625 001 Jul 25, 1996

FEXOFENADINE HYDROCHLORIDE

BARR

60MG

A076169 001 Jul 13, 2005

SUSPENSION;ORAL

ALLEGRA

+ CHATTEM SANOFI

30MG/5ML

N021963 001 Oct 16, 2006

CHILDREN'S ALLEGRA HIVES

+ CHATTEM SANOFI

30MG/5ML **

N201373 002 Jan 24, 2011

FEXOFENADINE HYDROCHLORIDE

P AND L

30MG/5ML

A201311 001 Jul 25, 2012

TABLET;ORAL

ALLEGRA HIVES

+ CHATTEM SANOFI

60MG

N020872 008 Jan 24, 2011

CHILDREN'S ALLEGRA ALLERGY

+ CHATTEM SANOFI

30MG **

N020872 005 Jan 24, 2011

CHILDREN'S ALLEGRA HIVES

+ CHATTEM SANOFI

30MG

N020872 006 Jan 24, 2011

CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY

RISING

30MG

A077081 004 Jul 21, 2011

SUN PHARM INDS

30MG

A091567 002 Feb 06, 2012

CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES

RISING

30MG

A077081 005 Jul 21, 2011

SUN PHARM INDS

30MG

A091567 001 Feb 06, 2012

FEXOFENADINE HYDROCHLORIDE

BARR

30MG

A076191 001 Aug 31, 2005

60MG

A076191 002 Aug 31, 2005

180MG

A076191 003 Aug 31, 2005

RISING

30MG

A077081 002 Apr 11, 2008

FEXOFENADINE HYDROCHLORIDE ALLERGY

SUN PHARM INDS

60MG

A091567 004 Feb 06, 2012

FEXOFENADINE HYDROCHLORIDE HIVES

SUN PHARM INDS

60MG

A091567 003 Feb 06, 2012

TABLET, ORALLY DISINTEGRATING;ORAL

CHILDREN'S ALLEGRA ALLERGY

+ CHATTEM SANOFI

30MG

N021909 002 Jan 24, 2011

CHILDREN'S ALLEGRA HIVES

+ CHATTEM SANOFI

30MG **

N021909 003 Jan 24, 2011

CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY

DR REDDYS LABS LTD

30MG

A202978 001 Jan 18, 2013

CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES

DR REDDYS LABS LTD

30MG

A202978 002 Jan 18, 2013

FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

BARR

60MG;120MG

A076236 001 Apr 14, 2005

IMPAX PHARMS

60MG;120MG

A076298 001 Nov 12, 2010

FINAFLOXACIN

SUSPENSION/DROPS;OTIC

XTORO

+ MERLION PHARMS GMBH 0.3%

N206307 001 Dec 17, 2014

FINASTERIDE

TABLET;ORAL

FINASTERIDE

ACTAVIS TOTOWA

1MG

A078371 001 Nov 05, 2013

ACTAVIS TOTOWA TEVA

5MG

A077914 001 Mar 28, 2007

GEDEON RICHTER USA

5MG

A077251 001 Dec 22, 2006

IVAX SUB TEVA PHARMS

5MG

A076340 001 Jun 19, 2006

MYLAN

1MG

A078161 001 Nov 05, 2013

5MG

A077578 001 Dec 18, 2006

TEVA

1MG

A076905 001 Nov 05, 2013

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-202(of 478)

** See List Footnote

FINGOLIMOD HYDROCHLORIDE

CAPSULE; ORAL

FINGOLIMOD HYDROCHLORIDE

BIOCON LTD	EQ 0.5MG BASE
STRIDES PHARMA	EQ 0.5MG BASE
TEVA PHARMS USA	EQ 0.25MG BASE
	EQ 0.5MG BASE

A207979	001	Dec 04, 2019
A207971	001	Jun 29, 2020
A212152	001	Nov 12, 2021
A208008	001	Jul 02, 2020

FLAVOXATE HYDROCHLORIDE

TABLET; ORAL

FLAVOXATE HYDROCHLORIDE

IMPAX PHARMS	100MG

A076234	001	Aug 28, 2003

URISPAS

ORTHO MCNEIL JANSSEN	100MG

N016769	001	

FLECAINIDE ACETATE

TABLET; ORAL

FLECAINIDE ACETATE

ANI PHARMS	50MG
	100MG
	150MG
CHARTWELL	50MG
	100MG
	150MG

A076030	001	Oct 28, 2002
A076030	002	Oct 28, 2002
A076030	003	Oct 28, 2002
A079164	001	Jul 09, 2009
A079164	002	Jul 09, 2009
A079164	003	Jul 09, 2009

TAMBOCOR

+	ALVOGEN	50MG **
+		100MG **
+		150MG **
		200MG

N018830	004	Aug 23, 1988
N018830	001	Oct 31, 1985
N018830	003	Jun 03, 1988
N018830	002	Oct 31, 1985

FLORBETAPIR F-18

SOLUTION; INTRAVENOUS

AMYVID

AVID RADIOPHARMS INC	10ML (13.5-51mCi/ML)

N202008	001	Apr 06, 2012

FLOXURIDINE

INJECTABLE; INJECTION

FLOXURIDINE

AM REGENT	500MG/VIAL

A203008	001	Nov 22, 2017

FUDR

+	HOSPIRA	500MG/VIAL **

N016929	001	

FLUCONAZOLE

FOR SUSPENSION; ORAL

FLUCONAZOLE

HIKMA	50MG/5ML
	200MG/5ML
IVAX SUB TEVA PHARMS	50MG/5ML
	200MG/5ML
SUN PHARM INDS LTD	50MG/5ML
	200MG/5ML
TARO PHARM INDS	50MG/5ML
	200MG/5ML

A076246	001	Jul 29, 2004
A076246	002	Jul 29, 2004
A077523	001	Sep 12, 2007
A077523	002	Sep 12, 2007
A076332	001	Jul 29, 2004
A076332	002	Jul 29, 2004
A076918	001	Dec 18, 2006
A076918	002	Dec 18, 2006

INJECTABLE; INJECTION

DIFLUCAN IN DEXTROSE 5% IN PLASTIC CONTAINER

+	PFIZER	200MG/100ML (2MG/ML)
+		400MG/200ML (2MG/ML)

N019950	003	Sep 29, 1992
N019950	005	Jul 08, 1994

DIFLUCAN IN SODIUM CHLORIDE 0.9%

+	PFIZER	200MG/100ML (2MG/ML)
+		400MG/200ML (2MG/ML)

N019950	001	Jan 29, 1990
N019950	006	Jan 29, 1990

DIFLUCAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

+	PFIZER	200MG/100ML (2MG/ML)
+		400MG/200ML (2MG/ML)

N019950	002	Jan 29, 1990
N019950	004	Jan 29, 1990

FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER

HIKMA FARMACEUTICA	200MG/100ML (2MG/ML)
	400MG/200ML (2MG/ML)

A078764	001	Jan 30, 2012
A078764	002	Jan 30, 2012

HOSPIRA	200MG/100ML (2MG/ML)
	400MG/200ML (2MG/ML)

A076304	001	Jul 29, 2004
A076304	002	Jul 29, 2004

MYLAN LABS LTD	200MG/100ML (2MG/ML)
	400MG/200ML (2MG/ML)

A076888	001	Mar 25, 2005
A076888	002	Mar 25, 2005

WOODWARD	200MG/100ML (2MG/ML)
	400MG/200ML (2MG/ML)

A077988	001	May 26, 2010
A077988	002	May 26, 2010

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-203(of 478)

** See List Footnote

FLUCONAZOLE

INJECTABLE; INJECTION

FLUCONAZOLE IN SODIUM CHLORIDE 0.9%

DR REDDYS	200MG/100ML (2MG/ML)	A076653	001	Jul 29, 2004
	400MG/200ML (2MG/ML)	A076653	002	Jul 29, 2004

FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

DR REDDYS	200MG/100ML (2MG/ML)	A076837	001	Jan 13, 2005
	400MG/200ML (2MG/ML)	A076837	002	Jan 13, 2005
HOSPIRA	200MG/100ML (2MG/ML)	A076617	001	Jul 29, 2004
	400MG/200ML (2MG/ML)	A076617	002	Jul 29, 2004
MYLAN LABS LTD	200MG/100ML (2MG/ML)	A076889	001	Mar 25, 2005
	400MG/200ML (2MG/ML)	A076889	002	Mar 25, 2005

TABLET; ORAL

FLUCONAZOLE

ANI PHARMS	50MG	A076086	001	Jul 29, 2004
	100MG	A076086	002	Jul 29, 2004
	150MG	A076086	003	Jul 29, 2004
	200MG	A076086	004	Jul 29, 2004
GEDEON RICHTER USA	50MG	A076432	001	Jul 29, 2004
	100MG	A076432	002	Jul 29, 2004
	150MG	A076432	003	Jul 29, 2004
	200MG	A076432	004	Jul 29, 2004
IVAX SUB TEVA PHARMS	50MG	A076077	001	Jul 29, 2004
	100MG	A076077	002	Jul 29, 2004
	150MG	A076077	003	Jul 29, 2004
	200MG	A076077	004	Jul 29, 2004
MYLAN	50MG	A076351	001	Jul 29, 2004
	100MG	A076351	002	Jul 29, 2004
	150MG	A076351	003	Jul 29, 2004
	200MG	A076351	004	Jul 29, 2004
MYLAN PHARMS INC	50MG	A076042	001	Jul 29, 2004
	100MG	A076042	002	Jul 29, 2004
	150MG	A076042	003	Jul 29, 2004
	200MG	A076042	004	Jul 29, 2004
PLIVA	50MG	A076424	001	Jul 29, 2004
	100MG	A076424	002	Jul 29, 2004
	150MG	A076424	003	Jul 29, 2004
	200MG	A076424	004	Jul 29, 2004
RANBAXY LABS LTD	50MG	A076386	001	Jul 29, 2004
	100MG	A076386	002	Jul 29, 2004
	150MG	A076386	003	Jul 29, 2004
	200MG	A076386	004	Jul 29, 2004
ROXANE	50MG	A076213	001	Jul 29, 2004
	100MG	A076213	002	Jul 29, 2004
	150MG	A076213	003	Jul 29, 2004
	200MG	A076213	004	Jul 29, 2004
TEVA	50MG	A074681	001	Jul 29, 2004
	100MG	A074681	002	Jul 29, 2004
	150MG	A074681	003	Jul 29, 2004
	200MG	A074681	004	Jul 29, 2004

FLUCYTOSINE

CAPSULE; ORAL

FLUCYTOSINE

STRIDES PHARMA	250MG	A207536	001	Jun 18, 2018
	500MG	A207536	002	Jun 18, 2018

FLUDARABINE PHOSPHATE

INJECTABLE; INJECTION

FLUDARA

+	GENZYME CORP	50MG/VIAL **	N020038	001	Apr 18, 1991

FLUDARABINE PHOSPHATE

HOSPIRA	50MG/VIAL	A077790	001	Apr 06, 2007
MYLAN LABS LTD	50MG/2ML (25MG/ML)	A200647	001	Dec 21, 2011
	50MG/VIAL	A200648	001	Oct 16, 2012

TABLET; ORAL

OFORTA

SANOFI AVENTIS US	10MG	N022273	001	Dec 18, 2008

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-204(of 478)

** See List Footnote

FLUDEOXYGLUCOSE F-18

INJECTABLE; INJECTION

FLUDEOXYGLUCOSE F18

+ DOWNSTATE CLINCL

4-40mCi/ML **

N020306 001 Aug 19, 1994

+

4-90mCi/ML **

N020306 002 Sep 25, 2001

INJECTABLE; INTRAVENOUS

FLUDEOXYGLUCOSE F18

+ FEINSTEIN

20-200mCi/ML **

N021870 001 Aug 19, 2005

HOT SHOTS NM LLC

4-500mCi/ML

A203937 001 Oct 30, 2014

MIDWEST MEDCL

20-200mCi/ML

A203736 001 Nov 19, 2015

UNIV TX SW MEDCTR

20-200mCi/ML

A210265 001 Feb 06, 2020

WEILL MEDCL COLL

10-100mCi/ML **

N021768 001 Aug 05, 2004

FLUDROCORTISONE ACETATE

TABLET; ORAL

FLORINEF

+ CASPER PHARMA LLC

0.1MG **

N010060 001

FLUDROCORTISONE ACETATE

HIKMA PHARMS

0.1MG

A091302 001 Jul 22, 2011

FLUMAZENIL

INJECTABLE; INJECTION

FLUMAZENIL

DR REDDYS

0.5MG/5ML (0.1MG/ML)

A076589 002 Oct 12, 2004

1MG/10ML (0.1MG/ML)

A076589 001 Oct 12, 2004

RISING

1MG/10ML (0.1MG/ML)

A078595 002 May 13, 2008

ROMAZICON

+ HOFFMANN LA ROCHE

1MG/10ML (0.1MG/ML) **

N020073 001 Dec 20, 1991

+

0.5MG/5ML (0.1MG/ML) **

N020073 002 Dec 20, 1991

FLUMETHASONE PIVALATE

CREAM; TOPICAL

LOCORTEN

NOVARTIS

0.03%

N016379 001

FLUNISOLIDE

AEROSOL, METERED; INHALATION

AEROBID

ROCHE PALO

0.25MG/INH

N018340 001 Aug 17, 1984

AEROSPAN HFA

+ MYLAN SPECIALITY LP

0.078MG/INH

N021247 001 Jan 27, 2006

SPRAY, METERED; NASAL

FLUNISOLIDE

APOTEX

0.029MG/SPRAY

A077436 001 Aug 09, 2007

NASALIDE

+ IVAX RES

0.025MG/SPRAY **

N018148 001

NASAREL

TEVA BRANDED PHARM

0.029MG/SPRAY

N020409 001 Mar 08, 1995

FLUOCINOLONE ACETONIDE

CREAM; TOPICAL

FLUOCET

ALPHARMA US PHARMS

0.025%

A088360 001 Jan 16, 1984

FLUOCINOLONE ACETONIDE

ALLIED

0.01%

A088047 001 Dec 16, 1982

ALPHARMA US PHARMS

0.01%

A088361 001 Jan 16, 1984

COSETTE

0.025%

A089525 001 Jul 26, 1988

MLV

0.025%

A088045 001 Dec 16, 1982

PERRIGO NEW YORK

0.01%

A086810 001 Mar 04, 1982

0.025%

A086811 001 Mar 04, 1982

PHARMAFAIR

0.01%

A088499 001 Aug 02, 1984

0.025%

A088506 001 Aug 02, 1984

TARO

0.01%

A040035 001 Oct 31, 1994

0.01%

A087102 001 Apr 27, 1982

0.025%

A040042 001 Oct 31, 1994

USL PHARMA

0.01%

A088757 001 Feb 11, 1985

0.025%

A088756 001 Mar 28, 1985

FLUONID

ALLERGAN HERBERT

0.025%

A087156 002 Sep 06, 1984

FLUOTREX

SAVAGE LABS

0.01%

A088174 001 May 06, 1983

0.025%

A088173 001 Mar 09, 1983

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-205(of 478)

** See List Footnote

FLUOCINOLONE ACETONIDE

CREAM;TOPICAL

SYNALAR-HP

MEDIMETRIKS PHARMS 0.2%

N016161 002

GEL;TOPICAL

FLUONID

ALLERGAN HERBERT 0.025%

A087300 001 May 27, 1982

OIL;TOPICAL

FLUOCINOLONE ACETONIDE

AKORN 0.01%

A091514 001 Jun 25, 2015

AMNEAL 0.01%

A201759 001 Oct 17, 2011

0.01%

A201764 001 Oct 17, 2011

OIL/DROPS;OTIC

FLUOCINOLONE ACETONIDE

AKORN 0.01%

A202705 001 Sep 09, 2016

AMNEAL 0.01%

A091306 001 Oct 17, 2011

OINTMENT;TOPICAL

FLUOCINOLONE ACETONIDE

PHARMADERM 0.025%

A088046 001 Dec 16, 1982

PHARMAFAIR 0.025%

A088507 001 Feb 27, 1984

USL PHARMA 0.025%

A088742 001 Feb 08, 1985

FLUONID

ALLERGAN HERBERT 0.025%

A087157 001 Sep 06, 1984

FLUOTREX

SAVAGE LABS 0.025%

A088172 001 Mar 09, 1983

SOLUTION;TOPICAL

FLUOCINOLONE ACETONIDE

ACTAVIS LABS UT INC 0.01%

A208386 001 Oct 21, 2016

ALLIED 0.01%

A088048 001 Dec 16, 1982

ALPHARMA US PHARMS 0.01%

A087159 001 Jun 16, 1982

BAUSCH AND LOMB 0.01%

A040059 001 Dec 20, 1993

COSETTE 0.01%

A207441 001 Sep 28, 2016

PAI HOLDINGS PHARM 0.01%

A088312 001 Jan 27, 1984

PHARMAFAIR 0.01%

A088449 001 Feb 08, 1984

FLUONID

ALLERGAN HERBERT 0.01%

A087158 001 Mar 17, 1983

FLUOTREX

SAVAGE LABS 0.01%

A088171 001 Mar 09, 1983

FLUOCINONIDE

CREAM;TOPICAL

FLUOCINONIDE

ENCUBE 0.05%

A211410 001 Oct 16, 2018

PERRIGO NEW YORK 0.05%

A071790 001 Jul 13, 1988

LIDEX

+ ALVOGEN 0.05%

N016908 002

LIDEX-E

+ ALVOGEN 0.05% **

N016908 003

SOLUTION;TOPICAL

FLUOCINONIDE

TARO 0.05%

A072857 001 Aug 02, 1989

TEVA 0.05%

A072511 001 Feb 07, 1989

TEVA PHARMS 0.05%

A072522 001 Sep 28, 1990

FLUORESCEIN SODIUM

INJECTABLE;INJECTION

FUNDUSCEIN-25

+ NOVARTIS 25% **

N017869 001

FLUOROMETHOLONE

CREAM;TOPICAL

OXYLONE

PHARMACIA AND UPJOHN 0.025%

N011748 001

OINTMENT;OPHTHALMIC

FML

+ ALLERGAN 0.1%

N017760 001 Sep 04, 1985

SUSPENSION/DROPS;OPHTHALMIC

FLUOR-OP

NOVARTIS 0.1%

A070185 001 Feb 27, 1986

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-206(of 478)

** See List Footnote

FLUOROMETHOLONE ACETATE; TOBRAMYCIN

SUSPENSION/DROPS;OPHTHALMIC

TOBRASONE

EYEVANCE 0.1%;0.3%

N050628 001 Jul 21, 1989

FLUOROMETHOLONE; SULFACETAMIDE SODIUM

SUSPENSION/DROPS;OPHTHALMIC

FML-S

ALLERGAN 0.1%;10%

N019525 001 Sep 29, 1989

FLUOROURACIL

CREAM;TOPICAL

FLUOROPLEX

+ CHARTWELL RX 1%

N016988 001

FLUOROURACIL

MYLAN 0.5%

A203122 001 Apr 20, 2015

INJECTABLE; INJECTION

ADRUCIL

PHARMACIA AND UPJOHN 50MG/ML

A081222 001 Jun 28, 1991

+ 50MG/ML **

N017959 001

TEVA PARENTERAL 50MG/ML

A040023 001 Oct 18, 1991

50MG/ML

A081225 001 Aug 28, 1991

FLUOROURACIL

ABIC 50MG/ML

A088929 001 Mar 04, 1986

ABRAXIS PHARM 50MG/ML

A089152 001 Mar 21, 1986

50MG/ML

A089428 001 Jan 12, 1987

50MG/ML

A089519 001 Mar 12, 1987

BEDFORD 50MG/ML

A089508 001 Jan 26, 1988

EBEWE PHARMA 500MG/10ML (50MG/ML)

A040772 001 Aug 11, 2008

EUGIA PHARMA SPECLTS 500MG/10ML (50MG/ML)

A202668 001 Jul 17, 2012

1GM/20ML (50MG/ML)

A202668 002 Jul 17, 2012

2.5GM/50ML (50MG/ML)

A202669 001 Jul 17, 2012

5GM/100ML (50MG/ML)

A202669 002 Jul 17, 2012

FRESENIUS KABI USA 50MG/ML

A040291 001 Mar 24, 1999

50MG/ML

A040379 001 Nov 15, 2000

MARCHAR 50MG/ML

A087791 001 Jan 18, 1983

NOVAST LABS 500MG/10ML (50MG/ML)

A209219 001 Dec 12, 2019

1GM/20ML (50MG/ML)

A209219 002 Dec 12, 2019

2.5GM/50ML (50MG/ML)

A209271 002 Dec 11, 2019

5GM/100ML (50MG/ML)

A209271 001 Dec 11, 2019

SANDOZ 2.5GM/50ML (50MG/ML)

A091299 001 May 02, 2011

5GM/100ML (50MG/ML)

A091299 002 May 02, 2011

SMITH AND NEPHEW 50MG/ML

A088766 001 Dec 28, 1984

50MG/ML

A088767 001 Dec 28, 1984

50MG/ML

A089434 001 Mar 26, 1987

+ SPECTRUM PHARMS 2.5GM/50ML (50MG/ML) **

N012209 002 Jul 29, 2016

50MG/ML

A087792 001 Oct 13, 1982

+ 500MG/10ML (50MG/ML) **

N012209 001

TEVA PHARMS USA 500MG/10ML (50MG/ML)

A040333 001 Jan 27, 2000

2.5GM/50ML (50MG/ML)

A040334 001 Feb 25, 2000

5GM/100ML (50MG/ML)

A040334 002 Feb 25, 2000

SOLUTION;TOPICAL

EFUDEX

+ BAUSCH 5% **

N016831 002

FLUOROPLEX

ELORAC 1%

N016765 001

FLUOXETINE HYDROCHLORIDE

CAPSULE;ORAL

FLUOXETINE

SUN PHARM INDUSTRIES EQ 10MG BASE

A075787 001 Jan 29, 2002

EQ 20MG BASE

A075787 002 Jan 29, 2002

WATSON LABS EQ 10MG BASE

A075662 001 Jan 29, 2002

EQ 20MG BASE

A075662 002 Jan 29, 2002

FLUOXETINE HYDROCHLORIDE

ACCORD HLTHCARE EQ 10MG BASE

A202729 001 Aug 27, 2020

EQ 20MG BASE

A202729 002 Aug 27, 2020

EQ 40MG BASE

A202729 003 Aug 27, 2020

ANI PHARMS EQ 10MG BASE

A076287 001 May 20, 2008

EQ 20MG BASE

A076287 002 May 20, 2008

BARR EQ 10MG BASE

A074803 002 Jan 30, 2002

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-207(of 478)

** See List Footnote

FLUOXETINE HYDROCHLORIDE

CAPSULE;ORAL

FLUOXETINE HYDROCHLORIDE

	EQ 20MG BASE	A074803 001	Aug 02, 2001
	EQ 40MG BASE	A076251 001	May 18, 2005
BEXIMCO PHARMS USA	EQ 10MG BASE	A075807 001	Jan 29, 2002
	EQ 20MG BASE	A075807 002	Jan 29, 2002
CARLSBAD	EQ 10MG BASE	A076022 001	Jan 30, 2002
	EQ 20MG BASE	A076022 002	Jan 30, 2002
CR DOUBLE CRANE	EQ 10MG BASE	A076165 001	Feb 01, 2002
	EQ 20MG BASE	A076165 002	Feb 01, 2002
GRANULES	EQ 10MG BASE	A078143 001	Jan 16, 2008
	EQ 20MG BASE	A078143 002	Jan 16, 2008
	EQ 40MG BASE	A078143 003	Jan 16, 2008
MYLAN	EQ 10MG BASE	A075207 001	Jan 30, 2002
	EQ 10MG BASE	A078045 001	Nov 17, 2008
	EQ 20MG BASE	A075207 002	Jan 30, 2002
	EQ 20MG BASE	A078045 002	Nov 17, 2008
	EQ 40MG BASE	A075207 003	May 25, 2007
MYLAN PHARMS INC	EQ 10MG BASE	A075577 001	Jan 29, 2002
	EQ 20MG BASE	A075577 002	Jan 29, 2002
SANDOZ	EQ 10MG BASE	A077469 001	Nov 17, 2008
	EQ 20MG BASE	A077469 002	Nov 17, 2008
SPECGX LLC	EQ 10MG BASE	A075658 001	Jan 29, 2002
	EQ 20MG BASE	A075658 002	Jan 29, 2002
STRIDES PHARMA	EQ 10MG BASE	A076922 001	Dec 16, 2004
	EQ 20MG BASE	A076922 002	Dec 16, 2004
	EQ 40MG BASE	A076922 003	Dec 16, 2004
PROZAC			
ELI LILLY AND CO	EQ 60MG BASE	N018936 004	Jun 15, 1999
SARAFEM			
+ ELI LILLY AND CO	EQ 10MG BASE **	N018936 007	Jul 06, 2000
+	EQ 20MG BASE **	N018936 008	Jul 06, 2000
CAPSULE, DELAYED REL PELLETS;ORAL			
FLUOXETINE HYDROCHLORIDE			
BARR	EQ 90MG BASE	A076237 001	Mar 24, 2010
PROZAC WEEKLY			
+ LILLY	EQ 90MG BASE **	N021235 001	Feb 26, 2001
SOLUTION;ORAL			
FLUOXETINE HYDROCHLORIDE			
ACTAVIS MID ATLANTIC	EQ 20MG BASE/5ML	A075690 001	Jan 31, 2002
AKORN	EQ 20MG BASE/5ML	A075525 001	Jun 27, 2002
LANNETT CO INC	EQ 20MG BASE/5ML	A076458 001	May 14, 2004
NOSTRUM LABS INC	EQ 20MG BASE/5ML	A075292 001	Feb 07, 2002
SPECGX LLC	EQ 20MG BASE/5ML	A075920 001	Jan 29, 2002
PROZAC			
+ LILLY	EQ 20MG BASE/5ML **	N020101 001	Apr 24, 1991
TABLET;ORAL			
FLUOXETINE HYDROCHLORIDE			
BARR	EQ 10MG BASE	A075810 001	Feb 01, 2002
FOSUN PHARMA	EQ 10MG BASE	A076024 001	Jan 29, 2002
G AND W LABS INC	EQ 60MG BASE	A212191 001	Jul 05, 2019
IVAX SUB TEVA PHARMS	EQ 10MG BASE	A075865 001	Feb 28, 2002
	EQ 40MG BASE	A075865 003	Aug 30, 2004
RISING	EQ 10MG BASE	A075755 001	Aug 02, 2001
	EQ 20MG BASE	A075755 002	Aug 02, 2001
PROZAC			
+ LILLY	EQ 10MG BASE **	N020974 001	Mar 09, 1999
+	EQ 20MG BASE **	N020974 002	Mar 09, 1999
SARAFEM			
+ APIL	EQ 10MG BASE **	N021860 001	May 19, 2006
+	EQ 15MG BASE **	N021860 002	May 19, 2006
+	EQ 20MG BASE **	N021860 003	May 19, 2006
SELFEMRA			
TEVA PHARMS USA	EQ 10MG BASE	A200151 001	Feb 03, 2014
	EQ 15MG BASE	A200151 002	Feb 03, 2014
	EQ 20MG BASE	A200151 003	Feb 03, 2014

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-208(of 478)

** See List Footnote

FLUOXYMESTERONE

TABLET; ORAL

ANDROID-F

VALEANT PHARM INTL 10MG

A087196 001

FLUOXYMESTERONE

UPSHER SMITH LABS 10MG

A088342 001 Oct 21, 1983

VALEANT PHARM INTL 10MG

A088221 001 May 05, 1983

WATSON LABS 2MG

A088260 001 Dec 06, 1983

5MG

A088265 001 Dec 06, 1983

10MG

A088309 001 Dec 06, 1983

HALOTESTIN

PHARMACIA AND UPJOHN 2MG

N010611 002

5MG

N010611 006

10MG

N010611 010

ORA-TESTRYL

BRISTOL MYERS SQUIBB 2MG

N011359 001

5MG

N011359 002

FLUPHENAZINE DECANOATE

INJECTABLE; INJECTION

FLUPHENAZINE DECANOATE

HOSPIRA 25MG/ML

A074966 001 Apr 16, 1998

TEVA PARENTERAL 25MG/ML

A074795 001 Sep 10, 1996

PROLIXIN DECANOATE

+ BRISTOL MYERS SQUIBB 25MG/ML **

N016727 001

FLUPHENAZINE ENANTHATE

INJECTABLE; INJECTION

PROLIXIN ENANTHATE

APOTHECON 25MG/ML **

N016110 001

FLUPHENAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

FLUPHENAZINE HYDROCHLORIDE

ANI PHARMS 5MG/ML

A073058 001 Aug 30, 1991

PERMITIL

SCHERING 5MG/ML **

N016008 001

PROLIXIN

APOTHECON 5MG/ML

A070533 001 Nov 07, 1985

ELIXIR; ORAL

FLUPHENAZINE HYDROCHLORIDE

ANI PHARMS 2.5MG/5ML

A081310 001 Apr 29, 1993

PROLIXIN

+ APOTHECON 2.5MG/5ML **

N012145 003

INJECTABLE; INJECTION

PROLIXIN

APOTHECON 2.5MG/ML **

N011751 005

TABLET; ORAL

FLUPHENAZINE HYDROCHLORIDE

SANDOZ 1MG

A089586 002 Oct 16, 1987

2.5MG

A089586 003 Oct 16, 1987

5MG

A089586 004 Oct 16, 1987

10MG

A089586 001 Oct 16, 1987

WATSON LABS 1MG

A088555 001 Dec 18, 1987

2.5MG

A088544 001 Dec 18, 1987

5MG

A088527 001 Dec 18, 1987

10MG

A088550 001 Dec 18, 1987

PERMITIL

SCHERING 0.25MG

N012034 001

2.5MG

N012034 004

5MG

N012034 005

10MG

N012034 006

PROLIXIN

+ APOTHECON 1MG **

N011751 004

+ 2.5MG **

N011751 001

+ 5MG **

N011751 003

+ 10MG **

N011751 002

TABLET, EXTENDED RELEASE; ORAL

PERMITIL

SCHERING 1MG

N012419 004

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-209(of 478)

** See List Footnote

FLUPREDNISOLONE

TABLET;ORAL

ALPHADROL

PHARMACIA AND UPJOHN 1.5MG

N012259 002

FLURANDRENOLIDE

CREAM;TOPICAL

CORDRAN SP

+ ALMIRALL 0.025% **

N012806 003

+ 0.05%

N012806 002

FLURANDRENOLIDE

CINTEX SVCS 0.05%

A205342 001 Apr 13, 2016

LOTION;TOPICAL

FLURANDRENOLIDE

ALPHARMA US PHARMS 0.05%

A087203 001 Apr 29, 1982

CINTEX SVCS 0.05%

A205343 001 Dec 22, 2016

OINTMENT;TOPICAL

CORDRAN

+ ALMIRALL 0.025% **

N012806 004

FLURANDRENOLIDE; NEOMYCIN SULFATE

CREAM;TOPICAL

CORDRAN N

LILLY 0.05%;EQ 3.5MG BASE/GM

N050346 001

OINTMENT;TOPICAL

CORDRAN N

LILLY 0.05%;EQ 3.5MG BASE/GM

N050345 001

FLURAZEPAM HYDROCHLORIDE

CAPSULE;ORAL

DALMANE

VALEANT PHARM INTL 15MG **

N016721 001

+ 30MG **

N016721 002

FLURAZEPAM HYDROCHLORIDE

HALSEY

15MG

A071808 001 Jan 07, 1988

30MG

A071809 001 Jan 07, 1988

HERITAGE PHARMA

15MG

A071205 001 Nov 25, 1986

15MG

A072368 001 Mar 30, 1989

30MG

A071068 001 Nov 25, 1986

30MG

A072369 001 Mar 30, 1989

HIKMA

30MG

A071108 001 Dec 08, 1986

HIKMA INTL PHARMS

15MG

A071107 001 Dec 08, 1986

PUREPAC PHARM

15MG

A071927 001 Sep 09, 1987

30MG

A071551 001 Sep 09, 1987

RISING

15MG

A071717 002 Jul 31, 1991

30MG

A071717 001 Jul 31, 1991

STRIDES PHARMA

15MG

A070444 001 Mar 20, 1986

30MG

A070445 001 Mar 20, 1986

SUN PHARM INDUSTRIES

15MG

A070454 001 Aug 04, 1986

30MG

A070455 001 Aug 04, 1986

SUPERPHARM

15MG

A071659 001 Aug 04, 1988

30MG

A071660 001 Aug 04, 1988

USL PHARMA

15MG

A070562 001 Jul 09, 1987

30MG

A070563 001 Jul 09, 1987

WARNER CHILCOTT

15MG

A071767 001 Dec 04, 1987

30MG

A071768 001 Dec 04, 1987

FLURBIPROFEN

TABLET;ORAL

ANSAID

PHARMACIA AND UPJOHN 50MG

N018766 002 Oct 31, 1988

100MG

N018766 003 Oct 31, 1988

FLURBIPROFEN

IVAX SUB TEVA PHARMS 50MG

A074411 001 May 31, 1995

100MG

A074411 002 May 31, 1995

MYLAN

50MG

A074358 001 Jun 20, 1994

100MG

A074358 002 Jun 20, 1994

PLIVA

50MG

A074647 001 Apr 01, 1997

100MG

A074647 002 Apr 01, 1997

RISING

50MG

A074448 001 Jul 28, 1995

100MG

A074448 002 Jul 28, 1995

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-210(of 478)

** See List Footnote

FLURBIPROFEN

TABLET; ORAL

FLURBIPROFEN

SUN PHARM INDS INC

50MG

A075058 001 Apr 27, 2001

100MG

A075058 002 Apr 27, 2001

TEVA

50MG

A074405 002 May 24, 1995

100MG

A074405 001 May 24, 1995

THERAGEN

100MG

A074560 002 May 16, 1997

FLURBIPROFEN SODIUM

SOLUTION/DROPS; OPHTHALMIC

OCUFEN

+ ALLERGAN

0.03% **

N019404 001 Dec 31, 1986

FLUTAMIDE

CAPSULE; ORAL

EULEXIN

+ SCHERING

125MG **

N018554 001 Jan 27, 1989

FLUTAMIDE

ACTAVIS LABS FL INC

125MG

A075820 001 Sep 18, 2001

CHARTWELL RX

125MG

A075818 001 Sep 18, 2001

CIPLA

125MG

A075780 001 Sep 19, 2001

MYLAN

125MG

A076224 001 May 09, 2003

FLUTEMETAMOL F-18

INJECTABLE; INTRAVENOUS

VIZAMYL

+ GE HEALTHCARE

40.5mCi/10ML (4.05mCi/ML)

N203137 001 Oct 25, 2013

FLUTICASONE PROPIONATE

AEROSOL, METERED; INHALATION

FLOVENT

GLAXOSMITHKLINE

0.044MG/INH

N020548 001 Mar 27, 1996

0.11MG/INH

N020548 002 Mar 27, 1996

0.22MG/INH

N020548 003 Mar 27, 1996

CREAM; TOPICAL

CUTIVATE

+ FOUGERA PHARMS

0.05% **

N019958 001 Dec 18, 1990

FLUTICASONE PROPIONATE

ENCUBE

0.05%

A076633 001 May 14, 2004

NESHER PHARMS

0.05%

A076865 001 Sep 10, 2004

LOTION; TOPICAL

CUTIVATE

+ FOUGERA PHARMS

0.05%

N021152 001 Mar 31, 2005

OINTMENT; TOPICAL

CUTIVATE

+ FOUGERA PHARMS

0.005% **

N019957 001 Dec 14, 1990

FLUTICASONE PROPIONATE

FOUGERA PHARMS

0.005%

A076300 001 May 14, 2004

TARO PHARM INDS

0.005%

A077145 001 Jun 14, 2005

POWDER; INHALATION

ARMONAIR DIGIHALER

+ TEVA PHARM

0.03MG/INH

N208798 008 Apr 08, 2022

ARMONAIR RESPICLICK

+ TEVA PHARM

0.03MG/INH

N208798 007 Jul 09, 2021

+

0.055MG/INH

N208798 001 Jan 27, 2017

+

0.113MG/INH

N208798 002 Jan 27, 2017

+

0.232MG/INH

N208798 003 Jan 27, 2017

FLOVENT

GLAXOSMITHKLINE

0.044MG/INH

N020549 001 Nov 07, 1997

0.088MG/INH

N020549 002 Nov 07, 1997

0.22MG/INH

N020549 003 Nov 07, 1997

SPRAY, METERED; NASAL

FLONASE

+ GLAXOSMITHKLINE

0.05MG/SPRAY **

N020121 001 Oct 19, 1994

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-211(of 478)

** See List Footnote

FLUVASTATIN SODIUM

CAPSULE;ORAL

LESCOL

+ NOVARTIS

EQ 20MG BASE **

N020261 001 Dec 31, 1993

+

EQ 40MG BASE **

N020261 002 Dec 31, 1993

TABLET, EXTENDED RELEASE;ORAL

FLUVASTATIN SODIUM

MYLAN

EQ 80MG BASE

A202458 001 Sep 11, 2015

FLUVOXAMINE MALEATE

CAPSULE, EXTENDED RELEASE;ORAL

FLUVOXAMINE MALEATE

TORRENT

100MG

A203240 001 Oct 31, 2014

150MG

A203240 002 Oct 31, 2014

LUVOX CR

+ JAZZ PHARMS

100MG **

N022033 001 Feb 28, 2008

+

150MG **

N022033 002 Feb 28, 2008

TABLET;ORAL

FLUVOXAMINE MALEATE

ACTAVIS ELIZABETH

25MG

A075901 001 Dec 28, 2000

50MG

A075901 002 Dec 28, 2000

100MG

A075901 003 Dec 28, 2000

ANI PHARMS

25MG

A075897 001 Jan 25, 2001

25MG

A075898 001 Mar 12, 2001

50MG

A075897 002 Jan 25, 2001

50MG

A075898 002 Mar 12, 2001

100MG

A075897 003 Jan 25, 2001

100MG

A075898 003 Mar 12, 2001

CHARTWELL RX

25MG

A075900 001 Feb 23, 2006

50MG

A075900 002 Feb 23, 2006

100MG

A075900 003 Feb 23, 2006

HERITAGE PHARMA

25MG

A075894 001 Apr 18, 2001

50MG

A075894 002 Apr 18, 2001

100MG

A075894 003 Apr 18, 2001

MYLAN

25MG

A075889 001 Nov 29, 2000

50MG

A075889 002 Nov 29, 2000

50MG

A075950 001 Oct 15, 2001

100MG

A075889 003 Nov 29, 2000

100MG

A075950 002 Oct 15, 2001

SUN PHARM INDUSTRIES

25MG

A076125 001 Apr 29, 2002

50MG

A076125 002 Apr 29, 2002

100MG

A076125 003 Apr 29, 2002

SYNTHON PHARMS

25MG

A075899 001 Jan 17, 2001

50MG

A075899 002 Jan 17, 2001

100MG

A075899 003 Jan 17, 2001

TEVA

25MG

A075893 001 Sep 10, 2002

50MG

A075893 002 Sep 10, 2002

100MG

A075893 003 Sep 10, 2002

UPSHER SMITH LABS

25MG

A075887 001 Jan 05, 2001

50MG

A075887 002 Jan 05, 2001

100MG

A075887 003 Jan 05, 2001

LUVOX

+ SOLVAY

25MG **

N020243 001 Dec 05, 1994

+

50MG **

N020243 002 Dec 05, 1994

+

100MG **

N020243 003 Dec 05, 1994

+

150MG **

N020243 004 Dec 05, 1994

FOLIC ACID

INJECTABLE;INJECTION

FOLIC ACID

BEN VENUE

5MG/ML

A081066 001 Dec 29, 1993

FOLVITE

+ WYETH PHARMS INC

5MG/ML **

N005897 008

TABLET;ORAL

FOLIC ACID

BARR

1MG

A089177 001 Jan 08, 1986

CONTRACT PHARMACAL

1MG

A085061 001

EVERYLIFE

1MG

A080755 001

HALSEY

1MG

A083598 001

HIKMA PHARMS

1MG

A080600 001

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-212(of 478)

** See List Footnote

FOLIC ACID

TABLET;ORAL

FOLIC ACID

IMPAX LABS	1MG	A080686	001	
IVAX SUB TEVA PHARMS	1MG	A083000	001	
JUBILANT CADISTA	1MG	A040514	001	Jun 14, 2005
LANNETT	1MG	A080816	001	
LILLY	1MG **	N006135	003	
MK LABS	1MG	A083526	001	
NEXGEN PHARMA INC	1MG	A084915	001	
PHARMERAL	1MG	A084158	001	
PIONEER PHARMS	1MG	A088949	001	Sep 13, 1985
PUREPAC PHARM	1MG	A080784	001	
SANDOZ	1MG	A084472	001	
SUN PHARM INDUSTRIES	1MG	A040582	001	Jul 18, 2005
TABLICAPS	1MG	A083133	002	
UDL	1MG	A088199	001	Mar 29, 1983
USL PHARMA	1MG	A087828	001	May 13, 1982
VALEANT PHARM INTL	1MG	A080903	001	
VANGARD	1MG	A088730	001	Mar 23, 1984
VINTAGE	1MG	A040756	001	Jun 04, 2010
VINTAGE PHARMS	1MG	A086296	001	
WATSON LABS	1MG	A083141	001	
	1MG	A085141	002	
WHITEWORTH TOWN PLSN	1MG	A080691	002	
FOLICET				
MISSION PHARMA	1MG	A087438	001	
FOLVITE				
WYETH PHARMS INC	1MG **	N005897	004	

FOMEPIZOLE

INJECTABLE;INJECTION

ANTIZOL

+ PAR PHARM INC	1.5GM/1.5ML (1GM/ML) **	N020696	001	Dec 04, 1997
FOMEPIZOLE				
MYLAN INSTITUTIONAL	1.5GM/1.5ML (1GM/ML)	A079033	001	Apr 07, 2009

FOMIVIRSEN SODIUM

INJECTABLE;INJECTION

VITRAVENE PRESERVATIVE FREE

NOVARTIS	6.6MG/ML	N020961	001	Aug 26, 1998

FORMOTEROL FUMARATE

POWDER;INHALATION

FORADIL

+ NOVARTIS	0.012MG/INH	N020831	001	Feb 16, 2001
FORADIL CERTIHALER				
NOVARTIS	0.0085MG/INH	N021592	001	Dec 15, 2006

FOSAPREPITANT DIMEGLUMINE

POWDER;INTRAVENOUS

EMEND

+ MERCK AND CO INC	EQ 115MG BASE/VIAL **	N022023	001	Jan 25, 2008
FOSAPREPITANT DIMEGLUMINE				
APOTEX	EQ 150MG BASE/VIAL	A205020	001	Sep 05, 2019
ARTHUR GRP	EQ 150MG BASE/VIAL	A211624	001	Sep 05, 2019
	EQ 150MG BASE/VIAL	A213199	001	Oct 04, 2021
MYLAN LABS LTD	EQ 115MG BASE/VIAL	A204015	001	Sep 05, 2019
SANDOZ INC	EQ 150MG BASE/VIAL	A203939	001	Dec 08, 2020

FOSCARNET SODIUM

INJECTABLE;INJECTION

FOSCARNET SODIUM

HOSPIRA	2.4GM/100ML	A077174	001	May 31, 2005

FOSINOPRIL SODIUM

TABLET;ORAL

FOSINOPRIL SODIUM

ACTAVIS LABS FL INC	10MG	A076620	001	Oct 15, 2004
	20MG	A076620	002	Oct 15, 2004
	40MG	A076620	003	Oct 15, 2004
RANBAXY LABS LTD	10MG	A076580	001	Apr 23, 2004

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-213(of 478)

** See List Footnote

FOSINOPRIL SODIUM

TABLET; ORAL

FOSINOPRIL SODIUM

	20MG	A076580 002	Apr 23, 2004
	40MG	A076580 003	Apr 23, 2004
UPSHER SMITH LABS	10MG	A076188 001	Oct 08, 2004
	20MG	A076188 002	Oct 08, 2004
	40MG	A076188 003	Oct 08, 2004
WATSON LABS	10MG	A076987 001	Dec 23, 2004
	10MG	A077531 001	Aug 31, 2006
	20MG	A076987 002	Dec 23, 2004
	20MG	A077531 002	Aug 31, 2006
	40MG	A076987 003	Dec 23, 2004
	40MG	A077531 003	Aug 31, 2006
MONOPRIL			
+	BRISTOL MYERS SQUIBB 10MG **	N019915 002	May 16, 1991
+	20MG **	N019915 003	May 16, 1991
+	40MG **	N019915 004	Mar 28, 1995

FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE

TABLET; ORAL

FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

ANI PHARMS	10MG; 12.5MG	A076608 001	Dec 03, 2004
	10MG; 12.5MG	A077144 001	Aug 16, 2005
	20MG; 12.5MG	A076608 002	Dec 03, 2004
	20MG; 12.5MG	A077144 002	Aug 16, 2005
EMCURE PHARMS LTD	10MG; 12.5MG	A079025 001	Sep 17, 2010
	20MG; 12.5MG	A079025 002	Sep 17, 2010
MYLAN	10MG; 12.5MG	A077705 001	Aug 14, 2006
	20MG; 12.5MG	A077705 002	Aug 14, 2006
SUN PHARM INDS LTD	10MG; 12.5MG	A076739 001	Dec 17, 2004
	20MG; 12.5MG	A076739 002	Dec 17, 2004
TEVA	10MG; 12.5MG	A076945 001	Jul 05, 2006
	20MG; 12.5MG	A076945 002	Jul 05, 2006
MONOPRIL-HCT			
+	BRISTOL MYERS SQUIBB 10MG; 12.5MG **	N020286 002	Nov 30, 1994
+	20MG; 12.5MG **	N020286 001	Nov 30, 1994

FOSPHENYTOIN SODIUM

INJECTABLE; INJECTION

FOSPHENYTOIN SODIUM

AM REGENT	EQ 50MG PHENYTOIN NA/ML	A078277 001	Aug 06, 2007
	EQ 50MG PHENYTOIN NA/ML	A090099 001	May 13, 2010
AMNEAL	EQ 50MG PHENYTOIN NA/ML	A078476 001	Mar 18, 2008
APOTEX INC	EQ 50MG PHENYTOIN NA/ML	A078126 001	Aug 06, 2007
DR REDDYS	EQ 50MG PHENYTOIN NA/ML	A076886 001	Aug 06, 2007
HOSPIRA	EQ 50MG PHENYTOIN NA/ML	A078158 001	Aug 06, 2007
SOLUTION; INTRAVENOUS			
SESQUIENT			
+	LUPIN EQ 100MG PHENYTOIN NA/2ML (EQ 50MG PHENYTOIN NA/ML)	N210864 001	Nov 05, 2020
+	EQ 500MG PHENYTOIN NA/10ML (EQ 50MG PHENYTOIN NA/ML)	N210864 002	Nov 05, 2020

FOSPROPOFOL DISODIUM

SOLUTION; INTRAVENOUS

LUSEDRA

EISAI INC	1050MG/30ML (35MG/ML)	N022244 001	Dec 12, 2008

FULVESTRANT

SOLUTION; INTRAMUSCULAR

FASLODEX

+	ASTRAZENECA 125MG/2.5ML (50MG/ML)	N021344 002	Apr 25, 2002
FULVESTRANT			
APOTEX	250MG/5ML (50MG/ML)	A211730 001	Jun 11, 2021

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-214(of 478)

** See List Footnote

FURAZOLIDONE

SUSPENSION; ORAL

FUROXONE

SHIRE

50MG/15ML

N011323 002

TABLET; ORAL

FUROXONE

SHIRE

100MG

N011270 002

FUROSEMIDE

INJECTABLE; INJECTION

FUROSEMIDE

ABRAXIS PHARM

10MG/ML

N018507 001 Jul 30, 1982

10MG/ML

N019036 001 Aug 13, 1984

+ AM REGENT

10MG/ML **

N018579 001 Nov 30, 1983

AMNEAL PHARMS CO

10MG/ML

A207552 001 Jul 20, 2016

ASTRAZENECA

10MG/ML

A070014 001 Sep 09, 1985

HIKMA

10MG/ML

A071439 001 Sep 14, 1990

10MG/ML

N018267 001

HOSPIRA

10MG/ML

A070578 001 Jul 08, 1987

10MG/ML

A072080 001 Aug 13, 1991

10MG/ML

A074337 001 Oct 31, 1994

IGI LABS INC

10MG/ML

A070095 001 Sep 09, 1985

10MG/ML

A070096 001 Sep 09, 1985

INTL MEDICATION

10MG/ML

N018025 001

MARSAM PHARMS LLC

10MG/ML

A074017 001 Jun 30, 1994

SMITH AND NEPHEW

10MG/ML

A070023 001 Feb 05, 1986

10MG/ML

A070078 001 Feb 05, 1986

WARNER CHILCOTT

10MG/ML

N018420 001 Feb 26, 1982

WATSON LABS

10MG/ML

A070019 001 Sep 22, 1986

10MG/ML

A070604 001 Jan 02, 1987

WYETH AYERST

10MG/ML

N018670 001 Jul 20, 1982

LASIX

+ SANOFI AVENTIS US

10MG/ML **

N016363 001

SOLUTION; ORAL

FUROSEMIDE

WOCKHARDT BIO AG

10MG/ML

A070655 001 Oct 02, 1987

LASIX

SANOFI AVENTIS US

10MG/ML

N017688 001

TABLET; ORAL

FUROSEMIDE

ANI PHARMS

20MG

A071379 001 Jan 02, 1987

40MG

A070413 001 Feb 26, 1986

80MG

A071594 001 Feb 09, 1988

AVET

20MG

N018413 001 Nov 30, 1983

40MG

N018413 002 Nov 30, 1983

EPIC PHARMA LLC

40MG

N018750 002 Jul 30, 1984

INTL MEDICATION

20MG

N018753 001 Feb 28, 1984

40MG

N018753 002 Feb 28, 1984

KALAPHARM

20MG

N018868 001 Jun 28, 1983

40MG

N018868 002 Jun 28, 1983

STRIDES PHARMA

20MG

N018415 001 Jul 27, 1982

40MG

N018415 002 Jul 27, 1982

80MG

N018415 003 Nov 26, 1984

SUN PHARM INDS INC

20MG

A091258 001 Apr 01, 2014

40MG

A091258 002 Apr 01, 2014

40MG

N018790 001 Nov 29, 1983

80MG

A091258 003 Apr 01, 2014

SUN PHARM INDUSTRIES

20MG

A070043 001 Sep 26, 1985

80MG

A070100 001 Jan 26, 1988

SUPERPHARM

20MG

N018370 002 Jun 26, 1984

40MG

N018370 001 Feb 10, 1983

WARNER CHILCOTT

20MG

N018419 001 Jan 31, 1983

40MG

N018419 002 Jan 31, 1983

80MG

N018419 003 Nov 13, 1984

WATSON LABS

20MG

A070412 001 Feb 26, 1986

20MG

N018369 001 May 14, 1982

40MG

A070450 001 Nov 22, 1985

40MG

N018369 002 May 14, 1982

WATSON LABS TEVA

20MG

A070449 001 Nov 22, 1985

80MG

A070528 001 Jan 07, 1986

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-215(of 478)

** See List Footnote

GABAPENTIN

CAPSULE; ORAL

GABAPENTIN

CHARTWELL RX	100MG	A091008 001	Oct 26, 2017
	300MG	A091008 002	Oct 26, 2017
	400MG	A091008 003	Oct 26, 2017
HIKMA	100MG	A078150 001	Sep 25, 2007
	300MG	A078150 002	Sep 25, 2007
	400MG	A078150 003	Sep 25, 2007
MYLAN	100MG	A090158 001	Feb 14, 2011
	300MG	A090158 002	Feb 14, 2011
	400MG	A090158 003	Feb 14, 2011
SANDOZ	100MG	A075428 001	Jan 24, 2006
	100MG	A075539 001	Apr 06, 2005
	300MG	A075428 002	Jan 24, 2006
	300MG	A075539 002	Apr 06, 2005
	400MG	A075428 003	Jan 24, 2006
	400MG	A075539 003	Apr 06, 2005
SUN PHARM INDS LTD	100MG	A076606 001	Oct 07, 2005
	300MG	A076606 002	Oct 07, 2005
	400MG	A076606 003	Oct 07, 2005
SUN PHARM INDUSTRIES	100MG	A076537 001	Jun 30, 2005
	300MG	A076537 002	Jun 30, 2005
	400MG	A076537 003	Jun 30, 2005
TEVA PHARMS	100MG	A075435 001	Oct 08, 2004
	300MG	A075435 002	Oct 08, 2004
	400MG	A075435 003	Oct 08, 2004
WATSON LABS	100MG	A075485 003	May 11, 2007
	300MG	A075485 002	May 11, 2007
	400MG	A075485 001	May 11, 2007

SOLUTION; ORAL

GABAPENTIN

PAI HOLDINGS PHARM	250MG/5ML	A211330 001	Dec 03, 2019

TABLET; ORAL

GABAPENTIN

HIKMA PHARMS	600MG	A078782 001	Jul 21, 2011
	800MG	A078782 002	Jul 21, 2011
INVATECH	600MG	A076877 001	Jul 06, 2006
	800MG	A076877 002	Jul 06, 2006
IVAX SUB TEVA PHARMS	600MG	A076017 004	Apr 29, 2005
	800MG	A076017 005	Apr 29, 2005
LUPIN LTD	600MG	A209306 001	Aug 24, 2018
	800MG	A209306 002	Aug 24, 2018
MYLAN PHARMS INC	600MG	A090335 001	Jun 01, 2010
	800MG	A090335 002	Jun 01, 2010
RANBAXY	600MG	A076605 001	Sep 14, 2005
	800MG	A076605 002	Sep 14, 2005
SANDOZ	600MG	A076120 001	Jan 27, 2006
	800MG	A076120 002	Jan 27, 2006
TEVA	600MG	A075827 001	Dec 15, 2004
	800MG	A075827 002	Dec 15, 2004
TEVA PHARMS USA	600MG	A205807 001	Mar 10, 2017
	800MG	A205807 002	Mar 10, 2017

GADODIAMIDE

INJECTABLE; INJECTION

OMNISCAN

GE HEALTHCARE	14.35GM/50ML (287MG/ML)	N022066 001	Sep 05, 2007

GADOFOSVESET TRISODIUM

SOLUTION; INTRAVENOUS

ABLAVAR

LANTHEUS MEDCL	2440MG/10ML (244MG/ML)	N021711 001	Dec 22, 2008
	3660MG/15ML (244MG/ML)	N021711 002	Dec 22, 2008

DISCONTINUED DRUG PRODUCT LIST

6-216(of 478)

** See List Footnote

GADOPENTETATE DIMEGLUMINE

INJECTABLE; INJECTION

MAGNEVIST

+	BAYER HLTHCARE	469.01MG/ML	N019596	001	Jun 02, 1988
+		469.01MG/ML	N021037	001	Mar 10, 2000

GADOVERSETAMIDE

INJECTABLE; INJECTION

OPTIMARK

+	LIEBEL-FLARSHEIM	1654.5MG/5ML (330.9MG/ML)	N020937	001	Dec 08, 1999
+		3309MG/10ML (330.9MG/ML)	N020937	002	Dec 08, 1999
+		4963.5MG/15ML (330.9MG/ML)	N020937	003	Dec 08, 1999
+		6618MG/20ML (330.9MG/ML)	N020937	004	Dec 08, 1999
+		16.545GM/50ML (330.9MG/ML)	N020975	001	Dec 08, 1999

OPTIMARK IN PLASTIC CONTAINER

+	LIEBEL-FLARSHEIM	3309MG/10ML (330.9MG/ML)	N020976	002	Dec 08, 1999
+		4963.5MG/15ML (330.9MG/ML)	N020976	003	Dec 08, 1999
+		6618MG/20ML (330.9MG/ML)	N020976	004	Dec 08, 1999
+		9927MG/30ML (330.9MG/ML)	N020976	001	Dec 08, 1999

GALANTAMINE HYDROBROMIDE

CAPSULE, EXTENDED RELEASE; ORAL

GALANTAMINE HYDROBROMIDE

IMPAX LABS

	EQ 8MG BASE	A078484	001	May 27, 2009
	EQ 16MG BASE	A078484	002	May 27, 2009
	EQ 24MG BASE	A078484	003	May 27, 2009
MYLAN	EQ 8MG BASE	A090900	001	Jan 24, 2011
	EQ 16MG BASE	A090900	002	Jan 24, 2011
	EQ 24MG BASE	A090900	003	Jan 24, 2011

SOLUTION; ORAL

RAZADYNE

JANSSEN PHARMS

4MG/ML **	N021224	001	Jun 22, 2001

TABLET; ORAL

GALANTAMINE HYDROBROMIDE

APOTEX INC

EQ 4MG BASE	A077781	001	Sep 27, 2011
EQ 8MG BASE	A077781	002	Sep 27, 2011
EQ 12MG BASE	A077781	003	Sep 27, 2011
HERITAGE PHARMA	A077585	001	Sep 15, 2009
EQ 4MG BASE	A077587	001	Jul 09, 2009
EQ 8MG BASE	A077585	002	Sep 15, 2009
EQ 8MG BASE	A077587	002	Jul 09, 2009
EQ 12MG BASE	A077585	003	Sep 15, 2009
EQ 12MG BASE	A077587	003	Jul 09, 2009
HIKMA	A077608	001	Feb 11, 2009
EQ 8MG BASE	A077608	002	Feb 11, 2009
EQ 12MG BASE	A077608	003	Feb 11, 2009
MYLAN	A077590	001	May 29, 2009
EQ 4MG BASE	A077603	001	Aug 28, 2008
EQ 8MG BASE	A077590	002	May 29, 2009
EQ 8MG BASE	A077603	002	Aug 28, 2008
EQ 12MG BASE	A077590	003	May 29, 2009
EQ 12MG BASE	A077603	003	Aug 28, 2008

RAZADYNE

+	JANSSEN PHARMS	EQ 4MG BASE	N021169	001	Feb 28, 2001
+		EQ 8MG BASE	N021169	002	Feb 28, 2001
+		EQ 12MG BASE	N021169	003	Feb 28, 2001

GALLAMINE TRIETHIODIDE

INJECTABLE; INJECTION

FLAXEDIL

DAVIS AND GECK

20MG/ML	N007842	001
100MG/ML	N007842	002

GALLIUM CITRATE GA-67

INJECTABLE; INJECTION

GALLIUM CITRATE GA 67

GE HEALTHCARE

1mCi/ML	N017700	001

NEOSCAN

GE HEALTHCARE

2mCi/ML	N017655	001

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-217(of 478)

** See List Footnote

GALLIUM NITRATE

INJECTABLE; INJECTION

GANITE

CHAPTER 7 TRUSTEE

25MG/ML **

N019961 002 Jan 17, 1991

GANCICLOVIR

CAPSULE; ORAL

CYTOVENE

+ ROCHE PALO

250MG **

N020460 001 Dec 22, 1994

+

500MG **

N020460 002 Dec 12, 1997

GANCICLOVIR

RANBAXY LABS LTD

250MG

A076457 001 Jun 27, 2003

500MG

A076457 002 Jun 27, 2003

IMPLANT; IMPLANTATION

VITRASERT

BAUSCH AND LOMB

4.5MG

N020569 001 Mar 04, 1996

GANCICLOVIR SODIUM

INJECTABLE; INJECTION

CYTOVENE

+ CHEPLAPHARM

EQ 500MG BASE/VIAL **

N019661 001 Jun 23, 1989

GANCICLOVIR SODIUM

AM REGENT

EQ 500MG BASE/VIAL

A202624 001 Sep 18, 2013

CUSTOPHARM INC

EQ 500MG BASE/VIAL

A212001 001 Jun 20, 2019

STERISCIENCE

EQ 500MG BASE/VIAL

A204560 001 Nov 17, 2017

GATIFLOXACIN

SOLUTION/DROPS; OPHTHALMIC

GATIFLOXACIN

APOTEX INC

0.3%

A079084 001 Aug 19, 2011

RISING

0.5%

A206446 001 Jun 08, 2018

TORRENT

0.5%

A213542 001 Nov 03, 2021

GEFITINIB

TABLET; ORAL

IRESSA

ASTRAZENECA

250MG

N021399 001 May 05, 2003

GEMCITABINE HYDROCHLORIDE

INJECTABLE; INJECTION

GEMCITABINE HYDROCHLORIDE

ACTAVIS INC

200MG/5.26ML (38MG/ML)

A204549 001 Apr 11, 2016

1GM/26.3ML (38MG/ML)

A204549 002 Apr 11, 2016

2GM/52.6ML (38MG/ML)

A204549 003 Apr 11, 2016

ACTAVIS TOTOWA

EQ 200MG BASE/VIAL

A079160 001 Jul 25, 2011

EQ 1GM BASE/VIAL

A079160 002 Jul 25, 2011

EQ 2GM BASE/VIAL

A079160 003 Jul 28, 2016

AM REGENT

EQ 200MG BASE/VIAL

A202031 001 May 07, 2013

EQ 1GM BASE/VIAL

A202031 002 May 07, 2013

APOTEX

200MG/5.26ML (38MG/ML)

A206776 001 May 23, 2017

1GM/26.3ML (38MG/ML)

A206776 002 May 23, 2017

2GM/52.6ML (38MG/ML)

A206776 003 May 23, 2017

EMCURE PHARMS LTD

EQ 200MG BASE/VIAL

A202063 001 Sep 11, 2012

EQ 1GM BASE/VIAL

A202063 002 Sep 11, 2012

HAMELN RDS GMBH

EQ 200MG BASE/VIAL

A090663 001 Sep 10, 2012

EQ 1GM BASE/VIAL

A090663 002 Sep 10, 2012

MYLAN LABS LTD

EQ 200MG BASE/VIAL

A200145 001 Jul 25, 2011

EQ 1GM BASE/VIAL

A200145 002 Jul 25, 2011

EQ 2GM BASE/VIAL

A200145 003 Jul 25, 2011

NOVAST LABS

200MG/5.26ML (38MG/ML)

A210383 001 Feb 14, 2019

1GM/26.3ML (38MG/ML)

A210383 002 Feb 14, 2019

2GM/52.6ML (38MG/ML)

A210383 003 Feb 14, 2019

SAGENT PHARMS

EQ 200MG BASE/VIAL

A091597 001 May 07, 2013

EQ 1GM BASE/VIAL

A091597 002 May 07, 2013

TEVA PHARMS

EQ 200MG BASE/VIAL

A077983 002 Jan 25, 2011

EQ 1GM BASE/VIAL

A077983 001 Jan 25, 2011

GEMZAR

+ LILLY

EQ 200MG BASE/VIAL **

N020509 001 May 15, 1996

+

EQ 1GM BASE/VIAL **

N020509 002 May 15, 1996

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-218(of 478)

** See List Footnote

GEMFIBROZIL

CAPSULE;ORAL

GEMFIBROZIL

MYLAN	300MG	A073466	001	Jan 25, 1993
PUREPAC PHARM	300MG	A072929	001	Jan 29, 1993

LOPID

PFIZER PHARMS	200MG	N018422	001	
	300MG	N018422	002	

TABLET;ORAL

GEMFIBROZIL

CADILA	600MG	A204189	001	Aug 28, 2018
CHARTWELL RX	600MG	A074615	001	Sep 29, 1995
HIKMA PHARMS	600MG	A078599	001	Aug 16, 2010
MYLAN	600MG	A074452	001	Feb 16, 1995
PUREPAC PHARM	600MG	A074360	001	Aug 31, 1994
SUN PHARM INDS INC	600MG	A079239	001	Dec 29, 2008
TEVA	600MG	A074256	001	Oct 31, 1993
WATSON LABS	600MG	A074156	001	Oct 24, 1994
	600MG	A074442	001	Apr 28, 1995

GEMIFLOXACIN MESYLATE

TABLET;ORAL

FACTIVE

+ LG CHEM LTD	EQ 320MG BASE	N021158	001	Apr 04, 2003

GEMIFLOXACIN MESYLATE

ORBION PHARMS	EQ 320MG BASE	A090466	001	Jun 15, 2015

GENTAMICIN SULFATE

CREAM;TOPICAL

GARAMYCIN

SCHERING	EQ 0.1% BASE **	A060462	001	

GENTAFAIR

PHARMAFAIR	EQ 0.1% BASE	A062458	001	Sep 01, 1983

GENTAMICIN SULFATE

ALPHARMA US PHARMS	EQ 0.1% BASE	A062471	001	Sep 27, 1983
FOUGERA PHARMS INC	EQ 0.1% BASE	A062531	001	Jul 05, 1984
PHARMADERM	EQ 1MG BASE/GM	A062530	001	Jul 05, 1984
TARO	EQ 0.1% BASE	A062427	001	May 26, 1983

INJECTABLE;INJECTION

APOGEN

KING PHARMS	EQ 10MG BASE/ML	A062289	001	
	EQ 40MG BASE/ML	A062289	002	

BRISTAGEN

BRISTOL	EQ 40MG BASE/ML	A062288	001	

GARAMYCIN

SCHERING	EQ 1MG BASE/ML **	A061716	002	
	EQ 10MG BASE/ML **	A061739	001	
	EQ 40MG BASE/ML **	A061716	001	

GENTAFAIR

PHARMAFAIR	EQ 40MG BASE/ML	A062493	001	Aug 28, 1985

GENTAMICIN

INTL MEDICATION	EQ 1MG BASE/ML	A062325	003	Jun 23, 1982
	EQ 40MG BASE/ML	A062325	001	
	EQ 100MG BASE/100ML	A062325	004	Jun 23, 1982

GENTAMICIN SULFATE

ABBOTT	EQ 1.2MG BASE/ML	A062413	001	Aug 11, 1983
	EQ 1.4MG BASE/ML	A062413	002	Aug 11, 1983
	EQ 1.6MG BASE/ML	A062413	003	Aug 11, 1983
	EQ 1.8MG BASE/ML	A062413	004	Aug 11, 1983
	EQ 2MG BASE/ML	A062413	005	Aug 11, 1983
	EQ 60MG BASE/100ML	A062413	006	Aug 11, 1983
	EQ 70MG BASE/100ML	A062413	007	Aug 11, 1983
	EQ 80MG BASE/100ML	A062413	008	Aug 11, 1983
	EQ 90MG BASE/100ML	A062413	009	Aug 11, 1983
	EQ 100MG BASE/100ML	A062413	010	Aug 11, 1983
FRESENIUS KABI USA	EQ 10MG BASE/ML	A062356	001	Mar 04, 1982
	EQ 40MG BASE/ML	A062356	002	Mar 04, 1982
HIKMA	EQ 10MG BASE/ML	A062251	002	
	EQ 40MG BASE/ML	A062251	001	
HOSPIRA	EQ 10MG BASE/ML	A062612	004	Feb 20, 1986

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-219(of 478)

** See List Footnote

GENTAMICIN SULFATE

INJECTABLE; INJECTION

GENTAMICIN SULFATE

KALAPHARM	EQ 40MG BASE/ML	A062354 001	Apr 05, 1982
PHARM SPEC	EQ 40MG BASE/ML	A062340 001	Mar 28, 1983
SOLOPAK	EQ 10MG BASE/ML	A062507 001	Jun 06, 1985
	EQ 40MG BASE/ML	A062507 002	Jun 06, 1985
TEVA PARENTERAL	EQ 10MG BASE/ML	A063149 001	Nov 21, 1991
	EQ 40MG BASE/ML	A063106 002	Nov 21, 1991
WATSON LABS	EQ 10MG BASE/ML	A062318 002	
	EQ 40MG BASE/ML	A062318 001	
WYETH AYERST	EQ 10MG BASE/ML	A062264 001	
	EQ 40MG BASE/ML	A062264 002	

GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

B BRAUN	EQ 0.8MG BASE/ML	A062814 001	Aug 28, 1987
	EQ 1.2MG BASE/ML	A062814 002	Aug 28, 1987
	EQ 1.4MG BASE/ML	A062814 003	Aug 28, 1987
	EQ 1.6MG BASE/ML	A062814 004	Aug 28, 1987
	EQ 1.8MG BASE/ML	A062814 005	Aug 28, 1987
	EQ 2MG BASE/ML	A062814 006	Aug 28, 1987
	EQ 2.4MG BASE/ML	A062814 007	Aug 28, 1987
	EQ 40MG BASE/100ML	A062814 008	Aug 28, 1987
	EQ 60MG BASE/100ML	A062814 009	Aug 28, 1987
	EQ 70MG BASE/100ML	A062814 010	Aug 28, 1987
	EQ 80MG BASE/100ML	A062814 011	Aug 28, 1987
	EQ 90MG BASE/100ML	A062814 012	Aug 28, 1987
	EQ 100MG BASE/100ML	A062814 013	Aug 28, 1987
	EQ 120MG BASE/100ML	A062814 014	Aug 28, 1987
BAXTER HLTHCARE	EQ 0.8MG BASE/ML	A062373 001	Sep 07, 1982
	EQ 2.4MG BASE/ML	A062373 010	Sep 07, 1982
	EQ 40MG BASE/100ML	A062373 003	Sep 07, 1982
	EQ 60MG BASE/100ML	A062373 004	Sep 07, 1982
HOSPIRA	EQ 1.2MG BASE/ML	A062588 001	Jan 06, 1986
	EQ 1.4MG BASE/ML	A062414 002	Aug 15, 1983
	EQ 1.4MG BASE/ML	A062588 002	Jan 06, 1986
	EQ 1.6MG BASE/ML	A062588 003	Jan 06, 1986
	EQ 1.8MG BASE/ML	A062414 004	Aug 15, 1983
	EQ 1.8MG BASE/ML	A062588 004	Jan 06, 1986
	EQ 2MG BASE/ML	A062414 005	Aug 15, 1983
	EQ 2MG BASE/ML	A062588 005	Jan 06, 1986
	EQ 60MG BASE/100ML	A062414 006	Aug 15, 1983
	EQ 60MG BASE/100ML	A062588 006	Jan 06, 1986
	EQ 70MG BASE/100ML	A062414 007	Aug 15, 1983
	EQ 70MG BASE/100ML	A062588 007	Jan 06, 1986
	EQ 80MG BASE/100ML	A062588 008	Jan 06, 1986
	EQ 90MG BASE/100ML	A062414 009	Aug 15, 1983
	EQ 90MG BASE/100ML	A062588 009	Jan 06, 1986
	EQ 100MG BASE/100ML	A062588 010	Jan 06, 1986

U-GENCIN

PHARMACIA AND UPJOHN	EQ 10MG BASE/ML	A062248 001	
	EQ 40MG BASE/ML	A062248 002	

INJECTABLE; INTRATHECAL

GARAMYCIN

+ SCHERING	EQ 2MG BASE/ML **	N050505 001	

OINTMENT; OPHTHALMIC

GARAMYCIN

SCHERING	EQ 0.3% BASE	N050425 001	

GENTACIDIN

NOVARTIS	EQ 0.3% BASE	A062501 001	Jul 26, 1984

GENTAFAIR

PHARMAFAIR	EQ 3MG BASE/GM	A062443 001	May 26, 1983

OINTMENT; TOPICAL

GARAMYCIN

SCHERING	EQ 0.1% BASE **	A060463 001	

GENTAFAIR

PHARMAFAIR	EQ 0.1% BASE	A062444 001	May 26, 1983

GENTAMICIN SULFATE

ALPHARMA US PHARMS	EQ 0.1% BASE	A062496 001	Mar 14, 1984
PHARMADERM	EQ 0.1% BASE	A062534 001	Oct 10, 1984

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-220(of 478)

** See List Footnote

GENTAMICIN SULFATE

SOLUTION/DROPS;OPHTHALMIC

GARAMYCIN

+ SCHERING

EQ 0.3% BASE **

N050039 002

GENTACIDIN

NOVARTIS

EQ 0.3% BASE

A062480 001 Mar 30, 1984

GENTAFAIR

PHARMAFAIR

EQ 0.3% BASE

A062440 001 May 03, 1983

GENTAMICIN SULFATE

AKORN

EQ 0.3% BASE

A062635 001 Jan 08, 1987

ALCON PHARMS LTD

EQ 0.3% BASE

A062523 001 Nov 25, 1985

PACO

EQ 3MG BASE/ML

A062932 001 Nov 07, 1988

GENTAMICIN SULFATE; PREDNISOLONE ACETATE

SUSPENSION/DROPS;OPHTHALMIC

PRED-G

+ ALLERGAN

EQ 0.3% BASE;1%

N050586 001 Jun 10, 1988

GENTIAN VIOLET

SUPPOSITORY;VAGINAL

GVS

SAVAGE LABS

0.4%

A083513 001

TAMPON;VAGINAL

GENAPAX

KEY PHARMS

5MG

A085017 001

GLATIRAMER ACETATE

FOR SOLUTION;SUBCUTANEOUS

COPAXONE

TEVA PHARMS USA

20MG/VIAL

N020622 001 Dec 20, 1996

GLIMEPIRIDE

TABLET;ORAL

GLIMEPIRIDE

ACTAVIS LABS FL INC

1MG

A076995 001 Apr 27, 2010

2MG

A076995 002 Apr 27, 2010

4MG

A076995 003 Apr 27, 2010

EPIC PHARMA LLC

1MG

A077274 001 Oct 06, 2005

2MG

A077274 002 Oct 06, 2005

4MG

A077274 003 Oct 06, 2005

HIKMA PHARMS

1MG

A078952 001 Aug 01, 2013

2MG

A078952 002 Aug 01, 2013

4MG

A078952 003 Aug 01, 2013

MYLAN

1MG

A077486 001 Feb 10, 2006

1MG

A077624 001 Nov 28, 2005

2MG

A077486 002 Feb 10, 2006

2MG

A077624 002 Nov 28, 2005

4MG

A077486 003 Feb 10, 2006

4MG

A077624 003 Nov 28, 2005

RANBAXY

3MG

A077366 001 Oct 06, 2005

6MG

A077366 002 Oct 06, 2005

RANBAXY LABS LTD

1MG

A076875 001 Oct 06, 2005

2MG

A076875 002 Oct 06, 2005

4MG

A076875 003 Oct 06, 2005

8MG

A076875 004 Oct 06, 2005

TEVA

1MG

A076802 001 Oct 06, 2005

2MG

A076802 002 Oct 06, 2005

4MG

A076802 003 Oct 06, 2005

WATSON LABS

1MG

A077280 001 Feb 03, 2006

2MG

A077280 002 Feb 03, 2006

4MG

A077280 003 Feb 03, 2006

GLIMEPIRIDE; ROSIGLITAZONE MALEATE

TABLET;ORAL

AVANDARYL

+ SB PHARMC0

1MG;4MG **

N021700 001 Nov 23, 2005

+

2MG;4MG **

N021700 002 Nov 23, 2005

+

2MG;8MG **

N021700 004 Mar 30, 2007

+

4MG;4MG **

N021700 003 Nov 23, 2005

+

4MG;8MG **

N021700 005 Mar 30, 2007

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-221(of 478)

** See List Footnote

GLIMEPIRIDE; ROSIGLITAZONE MALEATE

TABLET; ORAL

ROSIGLITAZONE MALEATE AND GLIMEPIRIDE

TEVA PHARMS USA	1MG; 4MG	A078709 001	Apr 01, 2016
	2MG; 4MG	A078709 002	Apr 01, 2016
	2MG; 8MG	A078709 004	Apr 01, 2016
	4MG; 4MG	A078709 003	Apr 01, 2016
	4MG; 8MG	A078709 005	Apr 01, 2016

GLIPIZIDE

TABLET; ORAL

GLIPIZIDE

ANI PHARMS	5MG	A074387 001	Mar 04, 1996
	10MG	A074387 002	Mar 04, 1996
BARR LABS INC	5MG	A074619 001	Apr 04, 1997
	10MG	A074619 002	Apr 04, 1997
CHARTWELL RX	5MG	A074542 001	Jun 20, 1995
	10MG	A074542 002	Jun 20, 1995
MYLAN	5MG	A074438 001	Jun 20, 1995
	10MG	A074438 002	Jun 20, 1995
OXFORD PHARMS	5MG	A074378 001	Nov 28, 1994
	10MG	A074378 002	Nov 28, 1994
WATSON LABS	5MG	A074370 001	Nov 22, 1994
	10MG	A074370 002	Nov 22, 1994

GLUCOTROL

+	PFIZER	2.5MG **	N017783 003	May 11, 1993
+		5MG	N017783 001	May 08, 1984
+		10MG	N017783 002	May 08, 1984

TABLET, EXTENDED RELEASE; ORAL

GLIPIZIDE

MYLAN	2.5MG	A202298 001	May 19, 2015
	5MG	A202298 002	May 19, 2015
	10MG	A202298 003	May 19, 2015
PAR PHARM	5MG	A076159 002	Sep 20, 2013
	10MG	A076159 001	Sep 20, 2013

GLIPIZIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL

GLIPIZIDE AND METFORMIN HYDROCHLORIDE

MYLAN	2.5MG; 250MG	A078083 001	Apr 12, 2007
	2.5MG; 500MG	A078083 002	Apr 12, 2007
	5MG; 500MG	A078083 003	Apr 12, 2007
SUN PHARM INDS INC	2.5MG; 250MG	A077620 001	Jan 11, 2008
	2.5MG; 500MG	A077620 002	Jan 11, 2008
	5MG; 500MG	A077620 003	Jan 11, 2008

METAGLIP

+	BRISTOL MYERS SQUIBB	2.5MG; 250MG **	N021460 001	Oct 21, 2002
+		2.5MG; 500MG **	N021460 002	Oct 21, 2002
+		5MG; 500MG **	N021460 003	Oct 21, 2002

GLUCAGON HYDROCHLORIDE

INJECTABLE; INJECTION

GLUCAGON

+	LILLY	EQ 1MG BASE/VIAL **	N012122 001
+		EQ 10MG BASE/VIAL **	N012122 002

GLUTETHIMIDE

CAPSULE; ORAL

DORIDEN

SANOFI AVENTIS US	500MG	N009519 008

TABLET; ORAL

DORIDEN

SANOFI AVENTIS US	250MG	N009519 002
	500MG	N009519 005

GLUTETHIMIDE

HALSEY	250MG	A089458 001	Oct 10, 1986
	500MG	A089459 001	Oct 10, 1986
LANNETT	250MG	A083475 001	
	500MG	A085571 001	
UCB INC	500MG	A085171 001	
UPSHER SMITH LABS	500MG	A083234 002	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-222(of 478)

** See List Footnote

GLUTETHIMIDE

TABLET;ORAL

GLUTETHIMIDE

VITARINE	500MG	A087297	001
WATSON LABS	500MG	A084362	001
	500MG	A085763	001

GLYBURIDE

TABLET;ORAL

GLYBURIDE

ACTAVIS ELIZABETH	1.5MG	A075947	001	Nov 14, 2002
	3MG	A075947	002	Nov 14, 2002
	6MG	A075947	003	Nov 14, 2002
AUROBINDO PHARMA	1.25MG	A077537	001	Oct 18, 2007
	2.5MG	A077537	002	Oct 18, 2007
	5MG	A077537	003	Oct 18, 2007
CHARTWELL RX	1.25MG	A203581	001	Apr 14, 2016
	2.5MG	A203581	002	Apr 14, 2016
	5MG	A203581	003	Apr 14, 2016

GLYBURIDE (MICRONIZED)

CHARTWELL RX	1.5MG	A075174	001	Jun 22, 1998
	3MG	A075174	002	Jun 22, 1998
MYLAN	1.5MG	A074792	001	Jun 26, 1998
	3MG	A074792	002	Jun 26, 1998
	6MG	A074792	003	Aug 17, 1999
SANOFI AVENTIS US	1.5MG	N020055	001	Apr 17, 1992
	3MG	N020055	002	Apr 17, 1992
	6MG	N020055	003	Mar 08, 2000
STRIDES PHARMA	1.5MG	A074591	001	Dec 22, 1997
	3MG	A074591	002	Dec 22, 1997
	4.5MG	A074591	003	Dec 22, 1997
	6MG	A074591	004	Dec 22, 1997

GLYNASE

+ PFIZER	4.5MG **	N020051	003	Sep 24, 1993

MICRONASE

+ PFIZER	1.25MG **	N017498	001	May 01, 1984
	2.5MG	N017498	002	May 01, 1984
	5MG **	N017498	003	May 01, 1984

GLYBURIDE; METFORMIN HYDROCHLORIDE

TABLET;ORAL

GLUCOVANCE

+ BRISTOL MYERS SQUIBB	1.25MG;250MG **	N021178	001	Jul 31, 2000
	2.5MG;500MG **	N021178	002	Jul 31, 2000
	5MG;500MG **	N021178	003	Jul 31, 2000

GLYBURIDE AND METFORMIN HYDROCHLORIDE

HERITAGE PHARMS	1.25MG;250MG	A079009	001	Jun 03, 2009
	2.5MG;500MG	A079009	002	Jun 03, 2009
	5MG;500MG	A079009	003	Jun 03, 2009
IMPAX LABS INC	1.25MG;250MG	A076731	001	Nov 19, 2004
	2.5MG;500MG	A076731	002	Nov 19, 2004
	5MG;500MG	A076731	003	Nov 19, 2004
TEVA	1.25MG;250MG	A076821	001	Jan 27, 2005
	2.5MG;500MG	A076821	002	Jan 27, 2005
	5MG;500MG	A076821	003	Jan 27, 2005

GLYCEROL PHENYLBUTYRATE

LIQUID;ORAL

GLYCEROL PHENYLBUTYRATE

PAR PHARM INC	1.1GM/ML	A205742	001	Dec 02, 2021

GLYCINE

SOLUTION;IRRIGATION

GLYCINE 1.5% IN PLASTIC CONTAINER

BAXTER HLTHCARE	1.5GM/100ML	N018522	001	Feb 19, 1982
HOSPIRA	1.5GM/100ML	N017633	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-223(of 478)

** See List Footnote

GLYCOPYRROLATE

INJECTABLE; INJECTION

GLYCOPYRROLATE

ABRAXIS PHARM	0.2MG/ML	A088475	001	Jun 12, 1984
EUGIA PHARMA	0.2MG/ML	A210244	001	Nov 28, 2018
HOSPIRA	0.2MG/ML	A089393	001	Jun 15, 1988
TEVA PARENTERAL	0.2MG/ML	A081169	001	Sep 10, 1991
WATSON LABS	0.2MG/ML	A086947	001	Jun 24, 1983
ZYDUS PHARMS	0.2MG/ML	A214213	001	Nov 09, 2021

ROBINUL

+	HIKMA	0.2MG/ML **	N017558	001
	ROBINS AH	0.2MG/ML	N014764	001

POWDER; INHALATION

SEEBRI

+	NOVARTIS	15.6MCG/INH	N207923	001 Oct 29, 2015

TABLET; ORAL

GLYCOPYRROLATE

CHARTWELL RX	1MG	A040568	001	Dec 22, 2004
	2MG	A040568	002	Dec 22, 2004
HIKMA INTL PHARMS	1MG	A040836	001	Mar 05, 2009
	2MG	A040836	002	Mar 05, 2009
WATSON LABS	1MG	A085562	001	
	1MG	A086902	001	
	2MG	A085563	001	
	2MG	A086178	001	
	2MG	A086900	001	

GLYCOPYRROLATE; INDACATEROL MALEATE

POWDER; INHALATION

UTIBRON

+	NOVARTIS	15.6MCG/INH; 27.5MCG/INH	N207930	001 Oct 29, 2015

GONADORELIN ACETATE

INJECTABLE; INJECTION

LUTREPULSE KIT

FERRING	0.8MG/VIAL	N019687	001	Oct 10, 1989
	3.2MG/VIAL	N019687	002	Oct 10, 1989

GONADORELIN HYDROCHLORIDE

INJECTABLE; INJECTION

FACTREL

HIKMA	EQ 0.1MG BASE/VIAL	N018123	001	Sep 30, 1982
	EQ 0.2MG BASE/VIAL	N018123	002	Sep 30, 1982
	EQ 0.5MG BASE/VIAL	N018123	003	Sep 30, 1982

GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OPHTHALMIC

NEO-POLYCIN

DOW PHARM	0.025MG/ML; EQ 1.75MG BASE/ML; 10,000 UNITS/ML	A060427	001	
NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN				
IPHARM	0.025MG/ML; EQ 1.75MG BASE/ML; 10,000 UNITS/ML	A062818	001	Oct 11, 1988
WATSON LABS	0.025MG/ML; EQ 1.75MG BASE/ML; 10,000 UNITS/ML	A062788	001	Jun 11, 1987
NEOMYCIN SULFATE AND POLYMYXIN B SULFATE GRAMICIDIN				
PHARMAFAIR	0.025MG/ML; EQ 1.75MG BASE/ML; 10,000 UNITS/ML	A062383	001	Aug 31, 1982

GRANISETRON HYDROCHLORIDE

INJECTABLE; INJECTION

GRANISETRON HYDROCHLORIDE

AKORN	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A079119	001	Sep 10, 2009
AM REGENT	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A091274	001	Sep 22, 2010
BAXTER HLTHCARE CORP	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078197	001	Dec 31, 2007
	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078198	001	Jun 30, 2008
	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078198	002	Jun 30, 2008
EUGIA PHARMA	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A204238	001	Jul 06, 2016
	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A204238	002	Jul 06, 2016
MYLAN LABS LTD	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A203454	001	Apr 04, 2017
	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A203454	002	Apr 04, 2017
	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A203453	001	Jan 31, 2017

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-224(of 478)

** See List Footnote

GRANISETRON HYDROCHLORIDE

INJECTABLE; INJECTION

GRANISETRON HYDROCHLORIDE

SANDOZ INC	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078808 001	Apr 29, 2008
TEVA PHARMS USA	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A077963 001	Jan 03, 2008
WOCKHARDT USA	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078566 001	Feb 29, 2008
	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078564 001	Jun 30, 2008
	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078565 001	Jun 30, 2008
YUNG SHIN PHARM	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A202647 001	Mar 06, 2020
	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A202648 001	Jun 29, 2020
	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A202648 002	Jun 29, 2020

GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE

DR REDDYS	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A077165 001	Dec 31, 2007

KYTRIL

+ ROCHE	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML) **	N020239 003	Sep 17, 2004
+	EQ 1MG BASE/ML (EQ 1MG BASE/ML) **	N020239 004	Mar 11, 1994
+	EQ 3MG BASE/ML **	N020239 001	Dec 29, 1993
+	EQ 4MG BASE/4ML (EQ 1MG BASE/ML) **	N020239 002	Mar 11, 1994

SOLUTION; ORAL

GRANISOL

INTRA SANA LABS	EQ 2MG BASE/10ML	A078334 001	Feb 28, 2008

KYTRIL

+ ROCHE	EQ 2MG BASE/10ML **	N021238 001	Jun 27, 2001

TABLET; ORAL

GRANISETRON HYDROCHLORIDE

BARR	EQ 1MG BASE	A078221 001	Dec 31, 2007
EPIC PHARMA LLC	EQ 1MG BASE	A078260 001	Dec 31, 2007
MYLAN	EQ 1MG BASE	A078725 001	Jan 30, 2008
TEVA PHARMS	EQ 1MG BASE	A078080 001	Dec 31, 2007

KYTRIL

+ ROCHE	EQ 1MG BASE **	N020305 001	Mar 16, 1995
+	EQ 2MG BASE **	N020305 002	Jun 15, 1998

GREPAFLOXACIN HYDROCHLORIDE

TABLET; ORAL

RAXAR

OTSUKA	EQ 200MG BASE	N020695 001	Nov 06, 1997
	EQ 400MG BASE	N020695 002	May 14, 1998
	EQ 600MG BASE	N020695 003	May 14, 1998

GRISOFULVIN, MICROCRYSTALLINE

CAPSULE; ORAL

GRISACTIN

WYETH AYERST	125MG	N050051 002	
	250MG	N050051 001	

SUSPENSION; ORAL

GRIFULVIN V

+ JOHNSON AND JOHNSON	125MG/5ML **	N050448 001	

TABLET; ORAL

GRIFULVIN V

J AND J	125MG	A060618 001	
	250MG	A060618 002	
	500MG	A060618 003	
VALEANT LUXEMBOURG	125MG	A062279 001	
	250MG **	A062279 002	

GRISACTIN

WYETH AYERST	500MG	A060212 001	

GRISOFULVIN, MICROSIZE

SUSPENSION; ORAL

GRIFULVIN V

VALEANT LUXEMBOURG	125MG/5ML **	A062483 001	Jan 26, 1984

TABLET; ORAL

GRIFULVIN V

VALEANT LUXEMBOURG	500MG	A062279 003	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-225(of 478)

** See List Footnote

GRISEOFULVIN, ULTRAMICROCRYSTALLINE

TABLET;ORAL

GRISACTIN ULTRA

WYETH AYERST

125MG

A062178 001

165MG

A062438 001 Nov 17, 1983

250MG

A062178 002

330MG

A062438 002 Nov 17, 1983

ULTRAGRIS-165

PLIVA

165MG

A062645 001 Jun 30, 1992

ULTRAGRIS-330

PLIVA

330MG

A062646 001 Jun 30, 1992

GUAIFENESIN; HYDROCODONE BITARTRATE

SOLUTION;ORAL

FLOWTUSS

CHARTWELL RX

200MG/5ML;2.5MG/5ML

N022424 001 May 14, 2015

OBREDON

+ SOVEREIGN PHARMS

200MG/5ML;2.5MG/5ML

N205474 001 Nov 14, 2014

TABLET;ORAL

XTRELUS

+ ECI PHARMS LLC

400MG;5MG

N208085 001 Apr 25, 2018

GUAIFENESIN; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION;ORAL

HYCOFENIX

+ CHARTWELL RX

200MG/5ML;2.5MG/5ML;30MG/5ML

N022279 001 May 14, 2015

GUANABENZ ACETATE

TABLET;ORAL

GUANABENZ ACETATE

ANI PHARMS

EQ 4MG BASE

A074149 001 Apr 07, 1995

EQ 4MG BASE

A074267 001 Jun 01, 1994

EQ 8MG BASE

A074149 002 Apr 07, 1995

EQ 8MG BASE

A074267 002 Jun 01, 1994

CHARTWELL RX

EQ 4MG BASE

A074517 001 Sep 30, 1998

EQ 8MG BASE

A074517 002 Sep 30, 1998

WATSON LABS

EQ 4MG BASE

A074025 001 Feb 28, 1994

EQ 8MG BASE

A074025 002 Feb 28, 1994

WYTENSIN

WYETH AYERST

EQ 4MG BASE

N018587 001 Sep 07, 1982

EQ 8MG BASE

N018587 002 Sep 07, 1982

EQ 16MG BASE

N018587 003 Sep 07, 1982

GUANADREL SULFATE

TABLET;ORAL

HYLOREL

PHARMACIA AND UPJOHN

10MG

N018104 001 Dec 29, 1982

25MG

N018104 002 Dec 29, 1982

GUANETHIDINE MONOSULFATE

TABLET;ORAL

GUANETHIDINE MONOSULFATE

WATSON LABS

EQ 10MG SULFATE

A086113 001 Mar 26, 1985

EQ 25MG SULFATE

A086114 001 Mar 26, 1985

ISMELIN

NOVARTIS

EQ 10MG SULFATE

N012329 001

EQ 25MG SULFATE

N012329 002

GUANETHIDINE MONOSULFATE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

ESIMIL

NOVARTIS

10MG;25MG

N013553 001

GUANFACINE HYDROCHLORIDE

TABLET;ORAL

GUANFACINE HYDROCHLORIDE

AUROBINDO PHARMA USA

EQ 1MG BASE

A074796 001 Jan 27, 1997

EQ 2MG BASE

A074796 002 Jan 27, 1997

WATSON LABS

EQ 1MG BASE

A074762 001 Jun 25, 1997

EQ 2MG BASE

A074762 002 Jun 25, 1997

TENEX

+ PROMIUS PHARMA

EQ 1MG BASE **

N019032 001 Oct 27, 1986

+

EQ 2MG BASE **

N019032 002 Nov 07, 1988

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-226(of 478)

** See List Footnote

GUANFACINE HYDROCHLORIDE

TABLET;ORAL

TENEX

EQ 3MG BASE **

N019032 003 Nov 07, 1988

TABLET, EXTENDED RELEASE;ORAL

GUANFACINE HYDROCHLORIDE

IMPAX LABS INC

EQ 1MG BASE

A202238 001 Oct 20, 2015

EQ 2MG BASE

A202238 002 Oct 20, 2015

EQ 3MG BASE

A202238 003 Oct 20, 2015

EQ 4MG BASE

A202238 004 Oct 20, 2015

MYLAN

EQ 1MG BASE

A202578 001 Jun 02, 2015

EQ 2MG BASE

A202578 002 Jun 02, 2015

EQ 3MG BASE

A202578 003 Jun 02, 2015

EQ 4MG BASE

A202578 004 Jun 02, 2015

GUANIDINE HYDROCHLORIDE

TABLET;ORAL

GUANIDINE HYDROCHLORIDE

MERCK SHARP DOHME

125MG

N001546 001

HALAZEPAM

TABLET;ORAL

PAXIPAM

SCHERING

20MG

N017736 003

40MG

N017736 004

HALCINONIDE

CREAM;TOPICAL

HALOG

WESTWOOD SQUIBB

0.025%

N017818 001

HALOG-E

SUN PHARM INDS INC

0.1%

N018234 001

OINTMENT;TOPICAL

HALOG

BRISTOL MYERS SQUIBB

0.025%

N018125 001

HALOBETASOL PROPIONATE

CREAM;TOPICAL

ULTRAVATE

+ SUN PHARM INDS INC

0.05% **

N019967 001 Dec 27, 1990

LOTION;TOPICAL

HALOBETASOL PROPIONATE

PADAGIS ISRAEL

0.05%

A211464 001 Jun 03, 2020

OINTMENT;TOPICAL

HALOBETASOL PROPIONATE

COSETTE

0.05%

A077721 001 Sep 07, 2006

FOUGERA PHARMS

0.05%

A076903 001 Dec 16, 2004

ULTRAVATE

+ SUN PHARM INDS INC

0.05% **

N019968 001 Dec 17, 1990

HALOFANTRINE HYDROCHLORIDE

TABLET;ORAL

HALFAN

GLAXOSMITHKLINE

250MG

N020250 001 Jul 24, 1992

HALOPERIDOL

TABLET;ORAL

HALDOL

+ ORTHO MCNEIL

0.5MG **

N015921 001

+

1MG **

N015921 002

+

2MG **

N015921 003

+

5MG **

N015921 004

+

10MG **

N015921 005

+

20MG **

N015921 006 Feb 02, 1982

HALDOL SOLUTAB

ORTHO MCNEIL PHARM

1MG

N017079 001

HALOPERIDOL

CYCLE

0.5MG

A071128 001 Feb 17, 1987

1MG

A071129 001 Feb 17, 1987

20MG

A071133 001 May 12, 1987

DURAMED PHARMS BARR

0.5MG

A071216 001 Dec 04, 1986

1MG

A071217 001 Dec 04, 1986

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-227(of 478)

** See List Footnote

HALOPERIDOL

TABLET; ORAL

HALOPERIDOL

	2MG	A071218	001	Dec 04, 1986
	5MG	A071219	001	Dec 04, 1986
	10MG	A071220	001	Jul 07, 1987
	20MG	A071221	001	Jul 07, 1987
LEDERLE	0.5MG	A072727	001	Sep 19, 1989
	1MG	A072728	001	Sep 19, 1989
	2MG	A072729	001	Sep 19, 1989
	5MG	A072730	001	Sep 19, 1989
	10MG	A072731	001	Sep 19, 1989
	20MG	A072732	001	Sep 19, 1989
PAR PHARM	20MG	A071328	001	Jul 20, 1987
PUREPAC PHARM	0.5MG	A071071	001	Nov 03, 1986
	1MG	A071072	001	Nov 03, 1986
	2MG	A071073	001	Nov 03, 1986
	5MG	A071074	001	Nov 03, 1986
	10MG	A071075	001	Aug 04, 1987
	20MG	A071076	001	Aug 04, 1987
QUANTUM PHARMICS	0.5MG	A071255	001	Feb 17, 1987
	1MG	A071269	001	Feb 17, 1987
	2MG	A071256	001	Feb 17, 1987
	5MG	A071257	001	Feb 17, 1987
ROYCE LABS	0.5MG	A071722	001	Dec 24, 1987
	1MG	A071723	001	Dec 24, 1987
	2MG	A071724	001	Dec 24, 1987
	5MG	A071725	001	Dec 24, 1987
	10MG	A072121	001	Dec 24, 1987
	20MG	A072122	001	Dec 24, 1987
SANDOZ	2MG	A071209	004	Nov 17, 1986
SCS	0.5MG	A070720	001	Jun 10, 1986
	1MG	A070721	001	Jun 10, 1986
	2MG	A070722	001	Jun 10, 1986
	5MG	A070723	001	Jun 10, 1986
	10MG	A070724	001	Jun 10, 1986
	20MG	A070725	001	Sep 24, 1986
STRIDES PHARMA	0.5MG	A071235	002	Nov 03, 1986
	1MG	A071235	003	Nov 03, 1986
	2MG	A071235	001	Nov 03, 1986
	5MG	A071235	004	Nov 03, 1986
	10MG	A071235	005	Jul 20, 1987
WATSON LABS	0.5MG	A070981	001	Mar 06, 1987
	0.5MG	A071571	001	Jun 03, 1988
	1MG	A070982	001	Mar 06, 1987
	1MG	A071572	001	Jun 03, 1988
	2MG	A070983	001	Mar 06, 1987
	2MG	A071573	001	Jun 03, 1988
	5MG	A070984	001	Mar 06, 1987
	5MG	A071374	001	Jun 03, 1988
	10MG	A071375	001	Jun 03, 1988
	10MG	A072113	001	Aug 27, 1991
	20MG	A071376	001	Jun 03, 1988
	20MG	A072353	001	Aug 27, 1991

HALOPERIDOL DECANOATE

INJECTABLE; INJECTION

HALOPERIDOL DECANOATE

HOSPIRA	EQ 50MG BASE/ML	A075176	001	Feb 09, 2000
	EQ 100MG BASE/ML	A075176	002	Feb 09, 2000
SANDOZ INC	EQ 50MG BASE/ML	A076463	001	Jun 24, 2005
	EQ 100MG BASE/ML	A076463	002	Jun 24, 2005

HALOPERIDOL LACTATE

CONCENTRATE; ORAL

HALDOL

+ ORTHO MCNEIL

HALOPERIDOL

ALPHARMA	EQ 2MG BASE/ML	A070318	001	Apr 11, 1986
MORTON GROVE	EQ 2MG BASE/ML	A070710	001	Mar 07, 1986

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-228(of 478)

** See List Footnote

HALOPERIDOL LACTATE

CONCENTRATE; ORAL

HALOPERIDOL

SCS	EQ 2MG BASE/ML	A070726 001	Jun 10, 1986
TEVA	EQ 2MG BASE/ML	A071015 001	Aug 25, 1987
TEVA PHARMS	EQ 2MG BASE/ML	A071617 001	Dec 01, 1988

HALOPERIDOL INTENSOL

HIKMA	EQ 2MG BASE/ML	A072045 001	Apr 12, 1988

INJECTABLE; INJECTION

HALDOL

+ JANSSEN PHARMS	EQ 5MG BASE/ML **	N015923 001	

HALOPERIDOL

ABRAXIS PHARM	EQ 5MG BASE/ML	A071187 001	Jan 20, 1987
AKORN	EQ 5MG BASE/ML	A204849 001	Sep 06, 2017
BAXTER HLTHCARE CORP	EQ 5MG BASE/ML	A076791 001	Aug 25, 2004
	EQ 5MG BASE/ML	A076828 001	Aug 25, 2004
FOSUN PHARMA	EQ 5MG BASE/ML	A076464 001	Sep 29, 2004
MARSAM PHARMS LLC	EQ 5MG BASE/ML	A072516 001	Feb 25, 1993
	EQ 5MG BASE/ML	A072517 001	Feb 25, 1993
SMITH AND NEPHEW	EQ 5MG BASE/ML	A070802 001	Dec 14, 1987
SOLOPAK	EQ 5MG BASE/ML	A070800 001	Dec 14, 1987
	EQ 5MG BASE/ML	A070801 001	Dec 14, 1987
	EQ 5MG BASE/ML	A070864 001	Dec 14, 1987
TEVA PHARMS USA	EQ 5MG BASE/ML	A076035 001	Aug 29, 2001
WATSON LABS	EQ 5MG BASE/ML	A070713 001	May 17, 1988
	EQ 5MG BASE/ML	A070714 001	May 17, 1988
	EQ 5MG BASE/ML	A070744 001	May 17, 1988

SOLUTION; ORAL

HALOPERIDOL LACTATE

ACTAVIS MID ATLANTIC	EQ 1MG BASE/ML	A074536 001	Nov 02, 1995

HALOPROGIN

CREAM; TOPICAL

HALOTEX

WESTWOOD SQUIBB	1%	N016942 001	

SOLUTION; TOPICAL

HALOTEX

WESTWOOD SQUIBB	1%	N016943 001	

HALOTHANE

LIQUID; INHALATION

FLUOTHANE

WYETH AYERST	99.99%	N011338 001	

HALOTHANE

BH	99.99%	A084977 001	
HALOCARBON	99.99%	A080810 001	
HOSPIRA	99.99%	A083254 001	

HEPARIN CALCIUM

INJECTABLE; INJECTION

CALCIPARINE

SANOFI AVENTIS US	25,000 UNITS/ML	N018237 001	

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN LOCK FLUSH

HOSPIRA	100 UNITS/ML	N005264 010	
INTL MEDICATION	10 UNITS/ML	A086357 001	
	500 UNITS/ML	A086357 002	
LUITPOLD	10 UNITS/ML	A089063 001	Oct 09, 1985
	100 UNITS/ML	A089064 001	Oct 09, 1985
PARKE DAVIS	10 UNITS/ML	N017346 006	
SMITH AND NEPHEW	10 UNITS/ML	A087904 001	Apr 20, 1983
	10 UNITS/ML	A087958 001	Apr 20, 1983
	10 UNITS/ML	A088458 001	Jul 26, 1984
	10 UNITS/ML	A088580 001	Oct 25, 1984
	100 UNITS/ML	A087906 001	Apr 20, 1983
	100 UNITS/ML	A087959 001	Apr 20, 1983
	100 UNITS/ML	A088460 001	Jul 26, 1984
	100 UNITS/ML	A088581 001	Oct 25, 1984
SOLOPAK	10 UNITS/ML	A087903 001	Apr 20, 1983

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-229(of 478)

** See List Footnote

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN LOCK FLUSH

	10 UNITS/ML	A088457	001	Oct 25, 1984
	100 UNITS/ML	A087905	001	Apr 20, 1983
	100 UNITS/ML	A088459	001	Jul 26, 1984
HEPARIN SODIUM				
ABRAXIS PHARM	1,000 UNITS/ML	N017033	001	
	1,000 UNITS/ML	N017979	001	
	5,000 UNITS/ML	N017979	003	
	10,000 UNITS/ML	N017979	002	
AKORN	1,000 UNITS/ML	N017486	001	
	5,000 UNITS/ML	N017486	002	
	10,000 UNITS/ML	N017486	003	
	20,000 UNITS/ML	N017486	004	
	40,000 UNITS/ML	N017486	005	
CASI PHARMS INC	5,000 UNITS/ML	A091659	001	Jun 08, 2011
CHAMBERLIN PARENTERL	1,000 UNITS/ML	N017130	001	
	5,000 UNITS/ML	N017130	002	
	10,000 UNITS/ML	N017130	003	
	20,000 UNITS/ML	N017130	004	
DELL LABS	1,000 UNITS/ML	N017540	001	
	5,000 UNITS/ML	N017540	002	
	10,000 UNITS/ML	N017540	003	
	20,000 UNITS/ML	N017540	004	
	40,000 UNITS/ML	N017540	005	
DR REDDYS	1,000 UNITS/ML	A040007	001	Jun 07, 1996
	1,000 UNITS/ML	N017064	002	
	2,500 UNITS/ML	N017064	015	
	3,000 UNITS/ML	N017064	016	
	4,000 UNITS/ML	N017064	017	
	5,000 UNITS/ML	N017064	003	
	6,000 UNITS/ML	N017064	018	
	7,500 UNITS/ML	N017064	019	
	10,000 UNITS/ML	N017064	004	
	20,000 UNITS/ML	N017064	005	
	40,000 UNITS/ML	N017064	006	
FRESENIUS KABI USA	1,000 UNITS/ML	N017651	005	
	5,000 UNITS/ML	N017029	002	
	10,000 UNITS/ML	N017651	003	
	20,000 UNITS/ML	N017651	008	
+	1,000 UNITS/ML **	N017007	001	
+	2,500 UNITS/ML **	N017007	007	
+	5,000 UNITS/ML **	N017007	002	
+	5,000 UNITS/0.5ML **	N017007	010	
	5,000 UNITS/0.5ML	N017037	013	Apr 07, 1986
+	7,500 UNITS/ML **	N017007	003	
+	10,000 UNITS/ML **	N017007	004	
+	15,000 UNITS/ML **	N017007	005	
+	20,000 UNITS/ML **	N017007	006	
HOSPIRA	2,500 UNITS/ML	A088099	001	Apr 28, 1983
	10,000 UNITS/ML	A040095	001	Jul 26, 1996
LILLY	1,000 UNITS/ML	N005521	001	
	10,000 UNITS/ML	N005521	002	
	20,000 UNITS/ML	N005521	004	
LUITPOLD	1,000 UNITS/ML	A087452	001	Oct 31, 1983
NANJING KING-FRIEND	5,000 UNITS/ML	A212061	001	Jul 15, 2020
ORGANON USA INC	1,000 UNITS/ML	N000552	008	
	5,000 UNITS/ML	N000552	009	
	10,000 UNITS/ML	N000552	010	
PARKE DAVIS	1,000 UNITS/ML	N017346	001	
	5,000 UNITS/ML	N017346	002	
	7,500 UNITS/ML	N017346	003	
	10,000 UNITS/ML	N017346	004	
	20,000 UNITS/ML	N017346	005	
+	10,000 UNITS/ML	N201370	003	Jul 21, 2011
PFIZER	1,000 UNITS/ML	N017780	001	
PHARM SPEC	5,000 UNITS/ML	N017780	002	
	10,000 UNITS/ML	N017780	003	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-230(of 478)

** See List Footnote

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM

	20,000 UNITS/ML	N017780	004	
	40,000 UNITS/ML	N017780	005	
PHARMACIA AND UPJOHN	1,000 UNITS/ML	N004570	001	
	5,000 UNITS/ML	N004570	002	
	10,000 UNITS/ML	N004570	003	
SMITH AND NEPHEW	1,000 UNITS/ML	A088239	001	Jul 26, 1984
SOLOPAK	1,000 UNITS/ML	A087043	001	
	5,000 UNITS/ML	A087077	001	
	5,000 UNITS/0.5ML	A087395	001	
	10,000 UNITS/ML	A087107	001	
	10,000 UNITS/0.5ML	A087363	001	
WATSON LABS INC	1,000 UNITS/ML	A040008	001	Oct 10, 1995
HEPARIN SODIUM 1,000 UNITS	IN DEXTROSE 5% IN PLASTIC CONTAINER			
MCGAW	200 UNITS/100ML	N019130	001	Dec 31, 1984
HEPARIN SODIUM 1,000 UNITS	IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
B BRAUN	200 UNITS/100ML	N019042	001	Mar 29, 1985
HEPARIN SODIUM 10,000 UNITS	AND DEXTROSE 5% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	2,000 UNITS/100ML	N018814	002	Jul 09, 1985
HEPARIN SODIUM 10,000 UNITS	IN DEXTROSE 5%			
HOSPIRA	10,000 UNITS/100ML	N018911	006	Jan 30, 1985
HEPARIN SODIUM 10,000 UNITS	IN SODIUM CHLORIDE 0.45%			
HOSPIRA	10,000 UNITS/100ML	N018911	001	Jan 30, 1985
	10,000 UNITS/100ML	N018916	005	Jan 31, 1984
HEPARIN SODIUM 10,000 UNITS	IN SODIUM CHLORIDE 0.9%			
HOSPIRA	10,000 UNITS/100ML	N018911	003	Jan 30, 1985
	10,000 UNITS/100ML	N018916	002	Jan 31, 1984
HEPARIN SODIUM 12,500 UNITS	IN DEXTROSE 5%			
HOSPIRA	5,000 UNITS/100ML	N018911	007	Jan 30, 1985
HEPARIN SODIUM 12,500 UNITS	IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER			
B BRAUN	5,000 UNITS/100ML	N019802	001	Jul 20, 1992
HEPARIN SODIUM 12,500 UNITS	IN SODIUM CHLORIDE 0.9%			
HOSPIRA	5,000 UNITS/100ML	N018911	005	Jan 30, 1985
	5,000 UNITS/100ML	N018916	003	Jan 31, 1984
HEPARIN SODIUM 2,000 UNITS	IN DEXTROSE 5% IN PLASTIC CONTAINER			
MCGAW	200 UNITS/100ML	N019130	003	Dec 31, 1984
HEPARIN SODIUM 2,000 UNITS	IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
B BRAUN	200 UNITS/100ML	N019042	002	Mar 29, 1985
HEPARIN SODIUM 20,000 UNITS	AND DEXTROSE 5% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	4,000 UNITS/100ML	N018814	001	Oct 31, 1983
HEPARIN SODIUM 20,000 UNITS	IN DEXTROSE 5% IN PLASTIC CONTAINER			
HOSPIRA	4,000 UNITS/100ML	N019805	001	Jan 25, 1989
HEPARIN SODIUM 25,000 UNITS	AND DEXTROSE 5% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	5,000 UNITS/100ML	N018814	003	Jul 09, 1985
	10,000 UNITS/100ML	N018814	004	Jul 02, 1987
HEPARIN SODIUM 25,000 UNITS	IN DEXTROSE 5%			
HOSPIRA	5,000 UNITS/100ML	N018911	009	Jan 30, 1985
	10,000 UNITS/100ML	N018911	008	Jan 30, 1985
HEPARIN SODIUM 25,000 UNITS	IN DEXTROSE 5% IN PLASTIC CONTAINER			
B BRAUN	5,000 UNITS/100ML	N019134	001	Mar 29, 1985
HOSPIRA	5,000 UNITS/100ML	N019805	002	Jan 25, 1989
HEPARIN SODIUM 25,000 UNITS	IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER			
B BRAUN	5,000 UNITS/100ML	N019802	005	Jul 20, 1992
	10,000 UNITS/100ML	N019802	002	Jul 20, 1992
HEPARIN SODIUM 25,000 UNITS	IN SODIUM CHLORIDE 0.9%			
HOSPIRA	5,000 UNITS/100ML	N018911	004	Jan 30, 1985
HEPARIN SODIUM 25,000 UNITS	IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
B BRAUN	5,000 UNITS/100ML	N019135	001	Mar 29, 1985
	5,000 UNITS/100ML	N019802	003	Jul 20, 1992
HOSPIRA	5,000 UNITS/100ML	N018916	009	Jan 31, 1984
HEPARIN SODIUM 5,000 UNITS	AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
BAXTER HLTHCARE	500 UNITS/100ML	N018609	003	Apr 28, 1982
HEPARIN SODIUM 5,000 UNITS	IN DEXTROSE 5% IN PLASTIC CONTAINER			
MCGAW	1,000 UNITS/100ML	N019130	002	Dec 31, 1984
HEPARIN SODIUM 5,000 UNITS	IN SODIUM CHLORIDE 0.45%			
HOSPIRA	100 UNITS/ML	N018911	002	Jan 30, 1985
	100 UNITS/ML	N018916	004	Jan 31, 1984

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-231(of 478)

** See List Footnote

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.9%				
HOSPIRA	1,000 UNITS/100ML	N018916	001	Jan 31, 1984
HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER				
B BRAUN	1,000 UNITS/100ML	N019042	004	Mar 29, 1985
HEPARIN SODIUM PRESERVATIVE FREE				
DR REDDYS	1,000 UNITS/ML	A089464	001	Jun 03, 1986
HOSPIRA	2,000 UNITS/ML	N005264	013	Apr 07, 1986
	2,500 UNITS/ML	N005264	014	Apr 07, 1986
NANJING KING-FRIEND	10,000 UNITS/ML	A212060	001	Apr 02, 2020
PHARMA SERVE NY	1,000 UNITS/ML	A086129	001	
LIPO-HEPIN				
3M	1,000 UNITS/0.5ML	N017027	001	
	1,000 UNITS/ML	N017027	006	
	5,000 UNITS/0.5ML	N017027	002	
	5,000 UNITS/ML	N017027	008	
	7,500 UNITS/0.5ML	N017027	010	
	10,000 UNITS/0.5ML	N017027	003	
	10,000 UNITS/ML	N017027	009	
	15,000 UNITS/0.5ML	N017027	011	
	20,000 UNITS/0.5ML	N017027	004	
	20,000 UNITS/ML	N017027	007	
	40,000 UNITS/ML	N017027	005	
LIQUAEMIN LOCK FLUSH				
ORGANON USA INC	100 UNITS/ML	N000552	007	
LIQUAEMIN SODIUM				
ORGANON USA INC	1,000 UNITS/ML	N000552	004	
	5,000 UNITS/ML	N000552	003	
	10,000 UNITS/ML	N000552	005	
	20,000 UNITS/ML	N000552	001	
	40,000 UNITS/ML	N000552	002	
LIQUAEMIN SODIUM PRESERVATIVE FREE				
ORGANON USA INC	1,000 UNITS/ML	N000552	011	Apr 11, 1986
	5,000 UNITS/ML	N000552	012	Apr 11, 1986
	10,000 UNITS/ML	N000552	013	Apr 11, 1986
PANHEPRIN				
HOSPIRA	1,000 UNITS/ML	N005264	004	
	5,000 UNITS/ML	N005264	006	
	10,000 UNITS/ML	N005264	007	
	20,000 UNITS/ML	N005264	008	
	40,000 UNITS/ML	N005264	009	
SODIUM HEPARIN				
ABRAXIS PHARM	5,000 UNITS/ML	N017033	002	
	10,000 UNITS/ML	N017033	003	
	20,000 UNITS/ML	N017033	004	
BAXTER HLTHCARE	1,000 UNITS/ML	N017036	001	Mar 04, 1988

HETACILLIN

FOR SUSPENSION; ORAL

VERSAPEN				
BRISTOL	EQ 112.5MG AMPICIL/ML	A061398	001	
	EQ 112.5MG AMPICIL/5ML	N050060	001	
	EQ 112.5MG AMPICIL/ML	N050060	003	
	EQ 225MG AMPICIL/5ML	A061398	002	

HETACILLIN POTASSIUM

CAPSULE; ORAL

VERSAPEN-K				
BRISTOL	EQ 225MG AMPICIL	A061396	001	
	EQ 450MG AMPICIL	A061396	002	

HEXACHLOROPHENE

AEROSOL; TOPICAL

SEPTISOL				
VESTAL LABS	0.23%	N017424	001	
TURGEX				
XTTRIUM	3%	N018375	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-232(of 478)

** See List Footnote

HEXACHLOROPHENE

EMULSION; TOPICAL

HEXA-GERM

HUNTINGTON LABS

3%

N017411 001

PHISOHEX

SANOFI AVENTIS US

3%

N006882 001

3%

N008402 001

SOY-DOME

BAYER PHARMS

3%

N017405 001

TURGEX

XTTRIUM

3%

N019055 001 Nov 30, 1984

SOAP; TOPICAL

GAMOPHEN

ARBROOK

2%

N006270 003

SOLUTION; TOPICAL

DIAL

DIAL

0.25%

N017421 002

GERMA-MEDICA

HUNTINGTON LABS

1%

N017412 001

GERMA-MEDICA "MG"

HUNTINGTON LABS

0.25%

N017412 002

SEPTI-SOFT

CALGON

0.25%

N017460 001

SEPTISOL

VESTAL LABS

0.25%

N017423 001

SPONGE; TOPICAL

E-Z SCRUB

BECTON DICKINSON

450MG

N017452 001

HEXASCRUB

PROF DSPLS

3%

N018363 001

PHISO-SCRUB

SANOFI AVENTIS US

3%

N017446 001

SCRUBTEAM SURGICAL SPONGEBRUSH

3M

330MG

N017413 001

HEXAFLUORENIUM BROMIDE

INJECTABLE; INJECTION

MYLAXEN

MEDPOINTE PHARM HLC

20MG/ML

N009789 003

HEXOCYCLIUM METHYLSULFATE

TABLET; ORAL

TRAL

ABBVIE

25MG

N010599 001

HEXYLCAINE HYDROCHLORIDE

SOLUTION; TOPICAL

CYCLAINE

MERCK

5%

N008472 001

HISTAMINE PHOSPHATE

INJECTABLE; INJECTION

HISTAMINE PHOSPHATE

LILLY

EQ 0.1MG BASE/ML

N000734 003

EQ 0.2MG BASE/ML

N000734 002

EQ 1MG BASE/ML

N000734 001

HISTRELIN ACETATE

IMPLANT; SUBCUTANEOUS

VANTAS

+

ENDO PHARM

50MG

N021732 001 Oct 12, 2004

INJECTABLE; INJECTION

SUPPRELIN

SHIRE

EQ 0.2MG BASE/ML

N019836 001 Dec 24, 1991

EQ 0.5MG BASE/ML

N019836 002 Dec 24, 1991

EQ 1MG BASE/ML

N019836 003 Dec 24, 1991

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-233(of 478)

** See List Footnote

HOMATROPINE METHYLBROMIDE

TABLET; ORAL

HOMAPIN-10

MISSION PHARMA 10MG

A086308 001

HOMAPIN-5

MISSION PHARMA 5MG

A086309 001

TABLET, CHEWABLE; ORAL

EQUIPIN

MISSION PHARMA 3MG

A086310 001

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

SYRUP; ORAL

HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE

IVAX SUB TEVA PHARMS 1.5MG/5ML; 5MG/5ML

A040285 001 Jul 19, 1999

NOSTRUM LABS INC 1.5MG/5ML; 5MG/5ML

A210663 001 Jun 11, 2019

TORRENT 1.5MG/5ML; 5MG/5ML

A204765 001 Mar 06, 2017

HYDROPANE

HALSEY 1.5MG/5ML; 5MG/5ML

A088066 001 Jun 28, 1985

TABLET; ORAL

HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE

ACTAVIS ELIZABETH 1.5MG; 5MG

A040295 001 Dec 01, 2000

NOVEL LABS INC 1.5MG; 5MG

A091528 001 Apr 20, 2011

TUSSIGON

KING PHARMS 1.5MG; 5MG

A088508 001 Jul 30, 1985

HYDRALAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

APRESOLINE

+ NOVARTIS 20MG/ML **

N008303 003

HYDRALAZINE HYDROCHLORIDE

ABRAXIS PHARM 20MG/ML

A089532 001 Aug 11, 1987

SMITH AND NEPHEW 20MG/ML

A088518 001 Apr 20, 1984

SOLOPAK 20MG/ML

A088517 001 Aug 22, 1985

TEVA PARENTERAL 20MG/ML

A040373 001 Feb 23, 2000

TABLET; ORAL

APRESOLINE

+ NOVARTIS 10MG **

N008303 004

+ 25MG **

N008303 001

+ 50MG **

N008303 002

+ 100MG **

N008303 005

DRALZINE

TEVA 25MG

A084301 001

HYDRALAZINE HYDROCHLORIDE

ACTAVIS ELIZABETH 25MG

A088560 001 Oct 04, 1984

50MG

A088649 001 Oct 18, 1984

ACTAVIS GRP PTC 10MG

A091679 001 Mar 04, 2013

25MG

A091679 002 Mar 04, 2013

50MG

A091679 003 Mar 04, 2013

100MG

A091679 004 Mar 04, 2013

ANDA REPOSITORY 10MG

A089359 001 Jul 25, 1986

25MG

A089258 001 May 05, 1986

50MG

A089259 001 May 05, 1986

100MG

A088729 001 Apr 11, 1985

ASCOT 25MG

A088310 001 Dec 19, 1984

50MG

A088311 001 Dec 19, 1984

CHARTWELL RX 10MG

A088846 001 Feb 26, 1985

25MG

A088847 001 Feb 26, 1985

50MG

A088848 001 Feb 26, 1985

100MG

A088849 001 Feb 26, 1985

HALSEY 10MG

A089218 001 Jan 22, 1986

25MG

A089130 001 Jan 15, 1986

50MG

A089222 001 Jan 22, 1986

100MG

A089178 001 Jan 15, 1986

HERITAGE PHARMS INC 10MG

A040858 001 Feb 26, 2010

25MG

A040858 002 Feb 26, 2010

50MG

A040858 003 Feb 26, 2010

100MG

A040858 004 Feb 26, 2010

IMPAX LABS 25MG

A084922 001

50MG

A084923 001

IVAX SUB TEVA PHARMS 10MG

A084443 001

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-234(of 478)

** See List Footnote

HYDRALAZINE HYDROCHLORIDE

TABLET; ORAL

HYDRALAZINE HYDROCHLORIDE

	25MG	A084437	001	
	50MG	A084469	002	
	100MG	A084581	001	
MUTUAL PHARM	10MG	A088728	001	Apr 11, 1985
	25MG	A084106	002	
	50MG	A084107	002	
MYLAN	10MG	A090413	001	Dec 08, 2010
	25MG	A090413	002	Dec 08, 2010
	50MG	A090413	003	Dec 08, 2010
	100MG	A090413	004	Dec 08, 2010
PUREPAC PHARM	25MG	A088177	001	Jul 29, 1983
	50MG	A088178	001	Aug 15, 1983
QUANTUM PHARMICS	10MG	A088671	001	May 01, 1984
	25MG	A088657	001	Jun 15, 1984
	50MG	A088652	001	May 08, 1984
	100MG	A088686	001	May 01, 1984
STRIDES PHARMA	10MG	A200770	004	Jun 25, 2019
SUPERPHARM	10MG	A088787	001	Aug 28, 1984
	25MG	A088788	001	Aug 28, 1984
	50MG	A088789	001	Aug 28, 1984
UPSHER SMITH LABS	10MG	A083241	001	
	10MG	A209251	001	Jul 09, 2018
	25MG	A083560	001	
	25MG	A209251	002	Jul 09, 2018
	50MG	A083561	001	
	50MG	A085088	001	
	50MG	A209251	003	Jul 09, 2018
	100MG	A209251	004	Jul 09, 2018
USL PHARMA	25MG	A087780	001	Mar 29, 1982
	50MG	A087751	001	Mar 29, 1982
VANGARD	25MG	A087712	001	
	50MG	A087908	001	May 07, 1982
VITARINE	25MG	A086088	001	
WATSON LABS	25MG	A084504	001	
	25MG	A085532	002	May 24, 1982
	50MG	A084503	001	
	50MG	A085533	002	May 25, 1982
WEST WARD	25MG	A088240	001	May 27, 1983
	50MG	A088241	001	May 27, 1983

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

APRESAZIDE

+ NOVARTIS

+

25MG; 25MG

50MG; 50MG

100MG; 50MG

A084735 001

A084810 001

A084811 001

HYDRA-ZIDE

STRIDES PHARMA

100MG; 50MG

A088961 001 Oct 21, 1985

HYDRALAZINE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

SOLVAY

25MG; 25MG

50MG; 50MG

100MG; 50MG

A087608 001 Feb 08, 1982

A087213 001 Feb 08, 1982

A087609 001 Feb 08, 1982

SUPERPHARM

25MG; 25MG

50MG; 50MG

A089200 001 Feb 09, 1987

A089201 001 Feb 09, 1987

WATSON LABS

25MG; 25MG

50MG; 50MG

100MG; 50MG

A085457 001 Mar 04, 1982

A085446 001 Mar 04, 1982

A085440 001 Mar 04, 1982

HYDRALAZINE HYDROCHLORIDE W/ HYDROCHLOROTHIAZIDE 100/50

IVAX PHARMS

100MG; 50MG

A088358 001 Apr 10, 1984

HYDRALAZINE HYDROCHLORIDE W/ HYDROCHLOROTHIAZIDE 25/25

IVAX PHARMS

25MG; 25MG

A088356 001 Apr 10, 1984

HYDRALAZINE HYDROCHLORIDE W/ HYDROCHLOROTHIAZIDE 50/50

IVAX PHARMS

50MG; 50MG

A088357 001 Apr 10, 1984

TABLET; ORAL

APRESOLINE-ESIDRIX

NOVARTIS

25MG; 15MG

N012026 002

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-235(of 478)

** See List Footnote

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

HYDRALAZINE AND HYDROCHLOROTHIAZIDE

WATSON LABS 25MG;15MG

A085827 001

HYDROCHLOROTHIAZIDE W/ HYDRALAZINE

WATSON LABS 25MG;15MG

A085373 001

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; RESERPINE

TABLET; ORAL

CAM-AP-ES

CHARTWELL RX 25MG;15MG;0.1MG

A084897 001

HYDRALAZINE HYDROCHLORIDE, HYDROCHLOROTHIAZIDE AND RESERPINE

IVAX SUB TEVA PHARMS 25MG;15MG;0.1MG

A084291 001

HYDRALAZINE HYDROCHLORIDE-HYDROCHLOROTHIAZIDE-RESERPINE

MYLAN 25MG;15MG;0.1MG

A087085 001

HYDRALAZINE, HYDROCHLOROTHIAZIDE W/ RESERPINE

WATSON LABS 25MG;15MG;0.1MG

A085771 001

HYDRAP-ES

SANDOZ 25MG;15MG;0.1MG

A084876 001

HYDROCHLOROTHIAZIDE W/ RESERPINE AND HYDRALAZINE

WATSON LABS 25MG;15MG;0.1MG

A083770 001

HYDROSERPINE PLUS (R-H-H)

IVAX SUB TEVA PHARMS 25MG;15MG;0.1MG

A083877 001

RESERPINE, HYDRALAZINE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

SOLVAY 25MG;15MG;0.1MG

A088376 001 Oct 28, 1983

SUN PHARM INDUSTRIES 25MG;15MG;0.1MG

A088570 001 Apr 10, 1984

WATSON LABS 25MG;15MG;0.1MG

A085549 001

25MG;15MG;0.1MG

A087556 001

RESERPINE, HYDROCHLOROTHIAZIDE, AND HYDRALAZINE HYDROCHLORIDE

LEDERLE 25MG;15MG;0.1MG

A087709 001 May 13, 1982

SER-A-GEN

SOLVAY 25MG;15MG;0.1MG

A087210 001

SER-AP-ES

NOVARTIS 25MG;15MG;0.1MG

N012193 005

UNIPRES

SOLVAY 25MG;15MG;0.1MG

A085893 001

25MG;15MG;0.1MG

A086298 001

HYDRALAZINE HYDROCHLORIDE; RESERPINE

TABLET; ORAL

DRALSERP

SANDOZ 25MG;0.1MG

A084617 001

SERPASIL-APRESOLINE

NOVARTIS 25MG;0.1MG

N009296 004

50MG;0.2MG

N009296 002

HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

HYDROCHLOROTHIAZIDE

ALEMBIC PHARMS LTD 12.5MG

A200645 001 Nov 30, 2010

APOTEX 12.5MG

A078389 001 May 16, 2008

CHARTWELL MOLECULAR 12.5MG

A091662 001 Jan 27, 2012

HIKMA INTL PHARMS 12.5MG

A077885 001 Nov 26, 2007

IVAX SUB TEVA PHARMS 12.5MG

A077005 001 Jul 13, 2005

MYLAN 12.5MG

A075640 001 Jan 28, 2000

SOLUTION; ORAL

HYDROCHLOROTHIAZIDE

MORTON GROVE 50MG/5ML

A089661 001 Jun 20, 1988

+ ROXANE 50MG/5ML

A088587 001 Jul 02, 1984

HYDROCHLOROTHIAZIDE INTENSOL

ROXANE 100MG/ML

A088588 001 Jul 02, 1984

TABLET; ORAL

ESIDRIX

NOVARTIS 25MG

N011793 005

50MG

N011793 008

100MG

N011793 009

HYDRO-D

HALSEY 25MG

A086504 001

50MG

A083891 002

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-236(of 478)

** See List Footnote

HYDROCHLOROTHIAZIDE

TABLET;ORAL

HYDROCHLOROTHIAZIDE

ABC HOLDING	50MG	A085672	001	
ACTAVIS ELIZABETH	25MG	A085054	002	
	50MG	A085208	001	
ALRA	25MG	A086369	001	
	50MG	A083554	001	
APOTEX	25MG	A040774	001	Oct 03, 2007
	50MG	A040774	002	Oct 03, 2007
ASCOT	25MG	A087539	001	Feb 03, 1982
	50MG	A087540	001	Feb 03, 1982
AUROLIFE PHARMA LLC	25MG	A083899	001	
	50MG	A085219	001	
BARR	50MG	A084771	001	
CHARTWELL RX	25MG	A085683	001	
	25MG	A087565	001	Mar 09, 1982
	50MG	A083965	001	
	50MG	A084912	001	
DAVA PHARMS INC	100MG	A087060	001	
ELKINS SINN	50MG	A085152	002	
HEATHER	50MG	A084135	001	
HIKMA INTL PHARMS	25MG	A084878	002	Jul 12, 2006
	50MG	A084878	001	
IMPAX LABS	25MG	A084029	001	
	50MG	A083607	002	
	100MG	A085098	001	
INWOOD LABS	25MG	A084776	001	
	25MG	A085067	001	
	50MG	A084776	002	
IVAX SUB TEVA PHARMS	50MG	A084658	001	
+	100MG	A085022	001	
JUBILANT CADISTA	25MG	A040809	001	Sep 04, 2007
	50MG	A040809	002	Sep 04, 2007
LANNETT CO INC	25MG	A084325	001	
	50MG	A084324	001	
MAST MM	25MG	A086192	001	
	50MG	A086192	002	
MYLAN	25MG	A084880	001	
	50MG	A085112	001	
MYLAN PHARMS INC	12.5MG	A040770	001	Jan 23, 2007
	25MG	A040735	002	Jan 23, 2007
	50MG	A040735	003	Jan 23, 2007
PVT FORM	50MG	A086597	001	
ROXANE	25MG	A085004	001	
	50MG	A084536	002	
	50MG	A085005	001	
SOLVAY	25MG	A085323	001	
SUN PHARM INDS INC	12.5MG	A040857	001	May 30, 2008
	25MG	A040810	001	Mar 27, 2007
	50MG	A040810	002	Mar 27, 2007
SUN PHARM INDUSTRIES	25MG	A083972	001	
	50MG	A083972	002	
	100MG	A083972	003	
SUPERPHARM	25MG	A088827	001	Dec 28, 1984
	50MG	A088828	001	Dec 28, 1984
	100MG	A088829	001	Dec 28, 1984
TEVA	25MG	A088924	001	Feb 07, 1985
	50MG	A088923	001	Feb 07, 1985
USL PHARMA	25MG	A087827	001	Apr 19, 1982
	50MG	A087752	001	Apr 19, 1982
VANGARD	25MG	A087638	001	
	50MG	A087610	001	
WARNER CHILCOTT	25MG	A087586	001	May 03, 1982
	50MG	A087587	001	May 03, 1982
WATSON LABS	25MG	A081189	001	Jan 24, 1992
	25MG	A083458	001	
	25MG	A085232	002	
	50MG	A083456	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-237(of 478)

** See List Footnote

HYDROCHLOROTHIAZIDE

TABLET; ORAL

HYDROCHLOROTHIAZIDE

	50MG	A085233	001	
	50MG	A086087	001	
	50MG	A086594	001	
	100MG	A081190	001	Jan 24, 1992
	100MG	A085099	001	
	100MG	A087002	001	
WATSON LABS TEVA	50MG	A083232	001	
WEST WARD	25MG	A084899	001	
WHITEWORTH TOWN PLSN	25MG	A083809	002	
	50MG	A083809	001	
	100MG	A085347	001	
HYDRODIURIL				
+ MERCK	25MG **	N011835	003	
+	50MG **	N011835	006	
+	100MG **	N011835	007	
ORETIC				
ABBVIE	25MG	N011971	001	
	50MG	N011971	002	
ZIDE				
SOLVAY	50MG	A083925	001	

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET; ORAL

AVALIDE

+ SANOFI AVENTIS US	12.5MG; 75MG **	N020758	001	Sep 30, 1997
+	25MG; 300MG **	N020758	004	Mar 15, 2005

IRBESARTAN AND HYDROCHLOROTHIAZIDE

APOTEX INC	12.5MG; 150MG	A201505	001	Oct 15, 2012
	12.5MG; 300MG	A201505	002	Oct 15, 2012
ATLAS PHARMS LLC	12.5MG; 150MG	A203036	001	Jan 15, 2016
	12.5MG; 300MG	A203036	002	Jan 15, 2016
	25MG; 300MG	A203036	003	Jan 15, 2016
MYLAN PHARMS INC	12.5MG; 150MG	A077969	001	Sep 27, 2012
	12.5MG; 300MG	A077969	002	Sep 27, 2012
	25MG; 300MG	A077969	003	Jul 20, 2016
TEVA	25MG; 300MG	A077369	003	Mar 30, 2012
UNICHEM	12.5MG; 150MG	A207018	001	Sep 19, 2017
	12.5MG; 300MG	A207018	002	Sep 19, 2017
WATSON LABS INC	12.5MG; 150MG	A091539	001	Oct 22, 2012
	12.5MG; 300MG	A091539	002	Oct 22, 2012

HYDROCHLOROTHIAZIDE; LABETALOL HYDROCHLORIDE

TABLET; ORAL

NORMOZIDE

SCHERING	25MG; 100MG	N019046	001	Apr 06, 1987
	25MG; 200MG	N019046	002	Apr 06, 1987
	25MG; 300MG	N019046	003	Apr 06, 1987
	25MG; 400MG	N019046	004	Apr 06, 1987
TRANDATE HCT				
GLAXOSMITHKLINE	25MG; 100MG	N019174	001	Apr 10, 1987
	25MG; 200MG	N019174	002	Apr 10, 1987
	25MG; 300MG	N019174	003	Apr 10, 1987
	25MG; 400MG	N019174	004	Apr 10, 1987

HYDROCHLOROTHIAZIDE; LISINAPRIL

TABLET; ORAL

LISINAPRIL AND HYDROCHLOROTHIAZIDE

COREPHARMA	12.5MG; 10MG	A076674	001	Oct 05, 2004
	12.5MG; 20MG	A076674	002	Oct 05, 2004
	25MG; 20MG	A076674	003	Oct 05, 2004
EPIC PHARMA	12.5MG; 10MG	A075926	001	Jul 01, 2002
	12.5MG; 20MG	A075926	002	Jul 01, 2002
	25MG; 20MG	A075926	003	Jul 01, 2002
HERITAGE PHARMA	12.5MG; 10MG	A075776	001	Jul 01, 2002
	12.5MG; 20MG	A075776	002	Jul 01, 2002
	25MG; 20MG	A075776	003	Jul 01, 2002
HIKMA INTL PHARMS	12.5MG; 10MG	A076265	001	Jul 08, 2002
	12.5MG; 20MG	A076265	002	Jul 08, 2002

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-238(of 478)

** See List Footnote

HYDROCHLOROTHIAZIDE; LISINOPRIL

TABLET; ORAL

LISINOPRIL AND HYDROCHLOROTHIAZIDE

	25MG; 20MG	A076265	003	Jul 08, 2002
MYLAN	12.5MG; 10MG	A076113	001	Jul 01, 2002
	12.5MG; 20MG	A076113	002	Jul 01, 2002
	25MG; 20MG	A076113	003	Jul 01, 2002
TEVA	12.5MG; 10MG	A075869	001	Jul 01, 2002
	12.5MG; 20MG	A075869	002	Jul 01, 2002
	25MG; 20MG	A075869	003	Jul 01, 2002
PRINZIDE				
+ MERCK	12.5MG; 10MG **	N019778	003	Nov 18, 1993
+	12.5MG; 20MG **	N019778	001	Feb 16, 1989
+	25MG; 20MG **	N019778	002	Feb 16, 1989

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET; ORAL

LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE

APOTEX	12.5MG; 50MG	A090150	001	Oct 06, 2010
	12.5MG; 100MG	A090150	002	Aug 11, 2010
	25MG; 100MG	A090150	003	Oct 06, 2010
HIKMA	12.5MG; 50MG	A077732	002	Oct 06, 2010
	12.5MG; 100MG	A077732	001	Apr 06, 2010
	25MG; 100MG	A077732	003	Oct 06, 2010
MYLAN	12.5MG; 50MG	A091652	001	Oct 06, 2010
	12.5MG; 100MG	A091652	002	Apr 06, 2010
	25MG; 100MG	A091652	003	Oct 06, 2010
TORRENT PHARMS	12.5MG; 50MG	A090528	001	Oct 06, 2010
	12.5MG; 100MG	A090528	003	Apr 06, 2010
	25MG; 100MG	A090528	002	Oct 06, 2010
WATSON LABS	12.5MG; 50MG	A200180	001	Jan 12, 2011
	12.5MG; 100MG	A200180	002	Jan 12, 2011
	25MG; 100MG	A200180	003	Jan 12, 2011

HYDROCHLOROTHIAZIDE; METHYLDOPA

TABLET; ORAL

ALDORIL 15

MERCK	15MG; 250MG	N013402	001	

ALDORIL 25

MERCK	25MG; 250MG	N013402	002	

ALDORIL D30

MERCK	30MG; 500MG	N013402	003	

ALDORIL D50

MERCK	50MG; 500MG	N013402	004	

METHYLDOPA AND HYDROCHLOROTHIAZIDE

CHARTWELL RX	15MG; 250MG	A070182	001	Jan 15, 1986
	25MG; 250MG	A070183	001	Jan 15, 1986
	30MG; 500MG	A070543	001	Jan 15, 1986
	50MG; 500MG	A070544	001	Jan 15, 1986
DAVA PHARMS INC	15MG; 250MG	A072507	001	Jun 02, 1989
	25MG; 250MG	A072508	001	Jun 02, 1989
	30MG; 500MG	A072509	001	Jun 02, 1989
	50MG; 500MG	A072510	001	Jun 02, 1989
IVAX SUB TEVA PHARMS	15MG; 250MG	A071458	001	Mar 08, 1988
	25MG; 250MG	A071459	001	Mar 08, 1988
	30MG; 500MG	A071460	001	Mar 08, 1988
	50MG; 500MG	A071461	001	Mar 08, 1988
PARKE DAVIS	15MG; 250MG	A071897	001	Nov 23, 1987
	25MG; 250MG	A071898	001	Nov 23, 1987
	30MG; 500MG	A071899	001	Nov 23, 1987
	50MG; 500MG	A071900	001	Nov 23, 1987
PUREPAC PHARM	15MG; 250MG	A070853	001	Oct 08, 1986
	25MG; 250MG	A070688	001	Apr 24, 1986
	30MG; 500MG	A070854	001	Oct 08, 1986
	50MG; 500MG	A070689	001	Apr 24, 1986
RISING	15MG; 250MG	A070265	002	Jan 23, 1986
	25MG; 250MG	A070265	001	Jan 23, 1986
SANDOZ	15MG; 250MG	A070829	001	Mar 09, 1987
	25MG; 250MG	A070830	001	Mar 09, 1987
STRIDES PHARMA	15MG; 250MG	A070616	001	Feb 02, 1987

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-239(of 478)

** See List Footnote

HYDROCHLOROTHIAZIDE; METHYLDOPA

TABLET; ORAL

METHYLDOPA AND HYDROCHLOROTHIAZIDE

	25MG; 250MG	A070612	001	Feb 02, 1987
	30MG; 500MG	A070613	001	Feb 02, 1987
	50MG; 500MG	A070614	001	Feb 02, 1987
TEVA	15MG; 250MG	A071819	001	Apr 08, 1988
	25MG; 250MG	A071820	001	Apr 08, 1988
	30MG; 500MG	A071821	001	Apr 08, 1988
	50MG; 500MG	A071822	001	Apr 08, 1988
WATSON LABS	15MG; 250MG	A070365	001	Mar 19, 1986
	15MG; 250MG	A070958	001	Feb 06, 1989
	15MG; 250MG	A071920	001	Aug 29, 1988
	25MG; 250MG	A070366	001	Apr 16, 1986
	25MG; 250MG	A070959	001	Jan 19, 1989
	25MG; 250MG	A071921	001	Aug 29, 1988
	30MG; 500MG	A070367	001	Mar 19, 1986
	30MG; 500MG	A071069	001	Jan 19, 1989
	30MG; 500MG	A071922	001	Aug 29, 1988
	50MG; 500MG	A070368	001	Apr 16, 1986
	50MG; 500MG	A070960	001	Feb 06, 1989
	50MG; 500MG	A071923	001	Aug 29, 1988

HYDROCHLOROTHIAZIDE; METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE; ORAL

DUTOPROL

+	CONCORDIA	12.5MG; EQ 25MG TARTRATE **	N021956	001	Aug 28, 2006
+		12.5MG; EQ 50MG TARTRATE **	N021956	002	Aug 28, 2006
+		12.5MG; EQ 100MG TARTRATE **	N021956	003	Aug 28, 2006

HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE

TABLET; ORAL

LOPRESSOR HCT

+	VALIDUS PHARMS	25MG; 100MG **	N018303	002	Dec 31, 1984
+		50MG; 100MG **	N018303	003	Dec 31, 1984

HYDROCHLOROTHIAZIDE; MOEXIPRIL HYDROCHLORIDE

TABLET; ORAL

MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

CHARTWELL RX	12.5MG; 7.5MG	A090096	001	Sep 25, 2008
	12.5MG; 15MG	A090096	002	Sep 25, 2008
	25MG; 15MG	A090096	003	Sep 25, 2008
HERITAGE PHARMS	12.5MG; 7.5MG	A202150	001	Mar 07, 2014
	12.5MG; 15MG	A202150	002	Mar 07, 2014
	25MG; 15MG	A202150	003	Mar 07, 2014
UNIRETIC				
UCB INC	12.5MG; 7.5MG **	N020729	001	Jun 27, 1997
	12.5MG; 15MG **	N020729	003	Feb 14, 2002
	25MG; 15MG **	N020729	002	Jun 27, 1997

HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

TABLET; ORAL

OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE

MYLAN	12.5MG; 20MG	A078827	001	Oct 26, 2016
	12.5MG; 40MG	A078827	002	Oct 26, 2016
	25MG; 40MG	A078827	003	Oct 26, 2016
TEVA PHARMS USA	12.5MG; 20MG	A200532	001	Apr 24, 2017
	25MG; 40MG	A200532	003	Apr 24, 2017

HYDROCHLOROTHIAZIDE; PINDOLOL

TABLET; ORAL

VISKAZIDE

NOVARTIS	25MG; 5MG	N018872	001	Jul 22, 1987
	25MG; 10MG	N018872	002	Jul 22, 1987

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

INDERIDE LA 120/50

WYETH AYERST	50MG; 120MG	N019059	002	Jul 03, 1985
INDERIDE LA 160/50				
WYETH AYERST	50MG; 160MG	N019059	003	Jul 03, 1985

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-240(of 478)

** See List Footnote

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

INDERIDE LA 80/50

WYETH AYERST

50MG;80MG

N019059 001 Jul 03, 1985

TABLET;ORAL

INDERIDE-40/25

+ WYETH PHARMS INC

25MG;40MG **

N018031 001

INDERIDE-80/25

+ WYETH PHARMS INC

25MG;80MG **

N018031 002

PROPRANOLOL HYDROCHLORIDE & HYDROCHLOROTHIAZIDE

DURAMED PHARMS BARR

25MG;40MG

A071126 001 Mar 02, 1987

25MG;80MG

A071127 001 Mar 02, 1987

PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

ACTAVIS ELIZABETH

25MG;40MG

A070851 001 May 15, 1986

25MG;80MG

A070852 001 May 15, 1986

ANI PHARMS

25MG;40MG

A070705 002 Oct 01, 1986

25MG;40MG

A072043 002 Mar 14, 1988

25MG;80MG

A070705 001 Oct 01, 1986

25MG;80MG

A072043 001 Mar 14, 1988

CHARTWELL RX

25MG;40MG

A071060 001 Aug 26, 1987

25MG;80MG

A071061 001 Aug 26, 1987

IVAX SUB TEVA PHARMS

25MG;40MG

A071552 001 Dec 01, 1988

25MG;80MG

A071553 001 Dec 01, 1988

RISING

25MG;40MG

A070947 002 Mar 04, 1987

25MG;80MG

A070947 001 Apr 01, 1987

WARNER CHILCOTT

25MG;40MG

A071771 001 Jan 26, 1988

25MG;80MG

A071772 001 Jan 26, 1988

WATSON LABS

25MG;40MG

A070301 001 Apr 18, 1986

25MG;40MG

A071498 001 Dec 18, 1991

25MG;80MG

A070305 001 Apr 18, 1986

25MG;80MG

A071501 001 Dec 18, 1991

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

TABLET;ORAL

ACCURETIC

+ PFIZER PHARMS

12.5MG;EQ 10MG BASE

N020125 001 Dec 28, 1999

+

12.5MG;EQ 20MG BASE

N020125 002 Dec 28, 1999

+

25MG;EQ 20MG BASE

N020125 003 Dec 28, 1999

QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

LUPIN

12.5MG;EQ 10MG BASE

A076374 001 Mar 31, 2004

12.5MG;EQ 20MG BASE

A076374 002 Mar 31, 2004

25MG;EQ 20MG BASE

A076374 003 Mar 31, 2004

MYLAN

12.5MG;EQ 10MG BASE

A077093 001 Mar 28, 2005

12.5MG;EQ 20MG BASE

A077093 002 Mar 28, 2005

25MG;EQ 20MG BASE

A077093 003 Mar 28, 2005

SUN PHARM INDS LTD

12.5MG;EQ 10MG BASE

A078211 001 Mar 04, 2009

12.5MG;EQ 20MG BASE

A078211 002 Mar 04, 2009

25MG;EQ 20MG BASE

A078211 003 Mar 04, 2009

HYDROCHLOROTHIAZIDE; RESERPINE

TABLET;ORAL

H.R.-50

WHITEWORTH TOWN PLSN

50MG;0.125MG

A085338 001

HYDRO-RESERP

ABC HOLDING

50MG;0.125MG

A084714 002 Jun 29, 1982

HYDRO-SERP "25"

SANDOZ

25MG;0.125MG

A084827 001

HYDRO-SERP "50"

SANDOZ

50MG;0.125MG

A085213 001

HYDROCHLOROTHIAZIDE W/ RESERPINE

IVAX SUB TEVA PHARMS

25MG;0.1MG

A083572 001

25MG;0.125MG

A083571 001

50MG;0.1MG

A083568 001

50MG;0.125MG

A083573 001

PHARMERAL

25MG;0.125MG

A085421 001

50MG;0.125MG

A085420 001

ROXANE

50MG;0.125MG

A084603 001

WATSON LABS

25MG;0.125MG

A084466 001

25MG;0.125MG

A085317 001

25MG;0.125MG

A086330 002

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-241(of 478)

** See List Footnote

HYDROCHLOROTHIAZIDE; RESERPINE

TABLET; ORAL

HYDROCHLOROTHIAZIDE W/ RESERPINE

50MG; 0.125MG	A083666	001	
50MG; 0.125MG	A084467	001	
50MG; 0.125MG	A086331	001	
HYDROPRES 25			
MERCK	25MG; 0.125MG	N011958	002
HYDROPRES 50			
MERCK	50MG; 0.125MG	N011958	003
RESERPINE AND HYDROCHLOROTHIAZIDE			
BARR	25MG; 0.125MG	A084580	001
	50MG; 0.125MG	A084579	001
SANDOZ	50MG; 0.125MG	A088200	001 Jan 31, 1984
RESERPINE AND HYDROCHLOROTHIAZIDE-50			
WEST WARD	50MG; 0.125MG	A088189	001 May 10, 1984
SERPASIL-ESIDRIX #1			
NOVARTIS	25MG; 0.1MG	N011878	003
SERPASIL-ESIDRIX #2			
NOVARTIS	50MG; 0.1MG	N011878	005

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

TABLET; ORAL

SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE

ASCOT	25MG; 25MG	A088025	001 Nov 23, 1984
CHARTWELL RX	25MG; 25MG	A086881	001
MUTUAL PHARM	25MG; 25MG	A087267	001
PUREPAC PHARM	25MG; 25MG	A087999	001 Nov 06, 1985
SUPERPHARM	25MG; 25MG	A089137	001 Aug 26, 1985
WATSON LABS	25MG; 25MG	A087398	001
SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE			
IVAX PHARMS	25MG; 25MG	A087004	002 May 24, 1982
LEDERLE	25MG; 25MG	A087511	001
PARKE DAVIS	25MG; 25MG	A087948	001 Feb 22, 1983
PUREPAC PHARM	25MG; 25MG	A088054	001 Aug 18, 1983
UPSHER SMITH	25MG; 25MG	A087553	001
USL PHARMA	25MG; 25MG	A087651	001
VANGARD	25MG; 25MG	A087655	001
WATSON LABS	25MG; 25MG	A085974	001
	25MG; 25MG	A086026	001

HYDROCHLOROTHIAZIDE; TELMISARTAN

TABLET; ORAL

TELMISARTAN AND HYDROCHLOROTHIAZIDE

MACLEODS PHARMS LTD	12.5MG; 40MG	A204169	001 Nov 02, 2015
	12.5MG; 80MG	A204169	002 Nov 02, 2015
	25MG; 80MG	A204169	003 Nov 02, 2015
MYLAN	12.5MG; 40MG	A091648	001 Feb 25, 2014
	12.5MG; 80MG	A091648	002 Feb 25, 2014
	25MG; 80MG	A091648	003 Feb 25, 2014
TORRENT	12.5MG; 40MG	A201192	001 Feb 25, 2014
	12.5MG; 80MG	A201192	002 Feb 25, 2014
	25MG; 80MG	A201192	003 Feb 25, 2014

HYDROCHLOROTHIAZIDE; TIMOLOL MALEATE

TABLET; ORAL

TIMOLIDE 10-25

MERCK	25MG; 10MG	N018061	001

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE; ORAL

DYAZIDE

+	GLAXOSMITHKLINE LLC	25MG; 37.5MG **	N016042	003 Mar 03, 1994
		25MG; 50MG **	N016042	002

TRIAMTERENE AND HYDROCHLOROTHIAZIDE

ANI PHARMS	25MG; 37.5MG	A074970	001 Jan 06, 1998
	25MG; 50MG	A074259	001 Mar 30, 1995
CHARTWELL RX	25MG; 50MG	A073191	001 Jul 31, 1991
DURAMED PHARMS BARR	25MG; 37.5MG	A075052	001 Jun 18, 1999
MYLAN	25MG; 37.5MG	A074701	001 Jun 07, 1996
NOVARTIS	25MG; 37.5MG	A074857	001 Sep 09, 1997

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-242(of 478)

** See List Footnote

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE;ORAL

TRIAMTERENE AND HYDROCHLOROTHIAZIDE

VITARINE 25MG;50MG

A071737 001 Feb 12, 1988

TABLET;ORAL

TRIAMTERENE AND HYDROCHLOROTHIAZIDE

AM THERAP 50MG;75MG

A072022 001 Apr 17, 1988

ANI PHARMS 50MG;75MG

A073467 001 Jan 31, 1996

PLIVA 25MG;37.5MG

A074026 001 Apr 26, 1996

QUANTUM PHARMICS 50MG;75MG

A071980 001 Apr 17, 1988

WATSON LABS 50MG;75MG

A071969 001 Apr 17, 1988

HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET;ORAL

VALSARTAN AND HYDROCHLOROTHIAZIDE

APOTEX INC 12.5MG;80MG

A203026 001 Mar 21, 2013

12.5MG;160MG

A203026 002 Mar 21, 2013

12.5MG;320MG

A203026 003 Mar 21, 2013

25MG;160MG

A203026 004 Mar 21, 2013

25MG;320MG

A203026 005 Mar 21, 2013

CADILA 12.5MG;80MG

A203000 001 Mar 15, 2019

12.5MG;160MG

A203000 002 Mar 15, 2019

12.5MG;320MG

A203000 003 Mar 15, 2019

25MG;160MG

A203000 004 Mar 15, 2019

25MG;320MG

A203000 005 Mar 15, 2019

WATSON LABS TEVA 12.5MG;80MG

A091519 001 Mar 21, 2013

12.5MG;160MG

A091519 002 Mar 21, 2013

12.5MG;320MG

A091519 003 Mar 21, 2013

25MG;160MG

A091519 004 Mar 21, 2013

25MG;320MG

A091519 005 Mar 21, 2013

HYDROCODONE BITARTRATE

CAPSULE, EXTENDED RELEASE;ORAL

ZOHYDRO ER

+ RECRO GAINESVILLE 10MG

N202880 001 Oct 25, 2013

+ 15MG

N202880 002 Oct 25, 2013

+ 20MG

N202880 003 Oct 25, 2013

+ 30MG

N202880 004 Oct 25, 2013

+ 40MG

N202880 005 Oct 25, 2013

+ 50MG

N202880 006 Oct 25, 2013

TABLET, EXTENDED RELEASE;ORAL

VANTRELA ER

+ TEVA BRANDED PHARM 15MG

N207975 001 Jan 17, 2017

+ 30MG

N207975 002 Jan 17, 2017

+ 45MG

N207975 003 Jan 17, 2017

+ 60MG

N207975 004 Jan 17, 2017

+ 90MG

N207975 005 Jan 17, 2017

HYDROCODONE BITARTRATE; IBUPROFEN

TABLET;ORAL

HYDROCODONE BITARTRATE AND IBUPROFEN

ANI PHARMS 5MG;200MG

A077454 001 Jun 23, 2010

SUN PHARM INDS INC 2.5MG;200MG

A091633 001 May 28, 2013

5MG;200MG

A091633 002 May 28, 2013

7.5MG;200MG

A091633 003 May 28, 2013

10MG;200MG

A091633 004 May 28, 2013

TEVA 7.5MG;200MG

A076023 001 Apr 11, 2003

REPREXAIN

AMNEAL PHARMS NY 2.5MG;200MG

A076642 003 Oct 19, 2007

10MG;200MG

A076642 004 Oct 19, 2007

VICOPROFEN

+ ABBVIE 7.5MG;200MG **

N020716 001 Sep 23, 1997

HYDROCODONE BITARTRATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

SYRUP;ORAL

CODAMINE

ALPHARMA US PHARMS 5MG/5ML;25MG/5ML

A075103 001 Sep 29, 2000

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-243(of 478)

** See List Footnote

HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION;ORAL

HYDROCODONE BITARTRATE AND PSEUDOEPHEDRINE HYDROCHLORIDE

MAYNE PHARMA INC	5MG/5ML; 60MG/5ML	A205658	001	Nov 17, 2015
PADAGIS US	5MG/5ML; 60MG/5ML	A204658	001	Apr 29, 2014
TORRENT	5MG/5ML; 60MG/5ML	A206661	001	Jan 23, 2019
TRIS PHARMA INC	5MG/5ML; 60MG/5ML	A203839	001	Oct 28, 2014
REZIRA				
+ PERSION	5MG/5ML; 60MG/5ML **	N022442	001	Jun 08, 2011

HYDROCORTAMATE HYDROCHLORIDE

OINTMENT;TOPICAL

MAGNACORT

PFIZER	0.5%	N010554	001	

HYDROCORTISONE

AEROSOL;TOPICAL

AEROSEB-HC

ALLERGAN HERBERT	0.5%	A085805	001	

CREAM;TOPICAL

CORT-DOME

BAYER PHARMS	0.5%	N009585	003	
	1%	N009585	001	

DERMACORT

MONARCH PHARMS	1%	A083011	002	

ELDECORT

VALEANT PHARM INTL	1%	A080459	001	
	2.5%	A084055	001	

FLEXICORT

WESTWOOD SQUIBB	0.5%	A087136	003	Apr 08, 1982
	1%	A087136	002	Apr 08, 1982
	2.5%	A087136	001	Apr 08, 1982

H-CORT

PHARM ASSOC	0.5%	A086823	001	

HC #1

BAYER PHARMS	0.5%	A080438	001	

HC #4

BAYER PHARMS	1%	A080438	002	

HC (HYDROCORTISONE)

C AND M PHARMA	0.5%	A080482	003	
	1%	A080482	004	

HI-COR

C AND M PHARMA	2.5%	A080483	001	

HYDROCORTISONE

ALPHARMA US PHARMS	2.5%	A089754	001	Feb 01, 1989
ALTANA	0.5%	A080848	002	
	1%	A080848	003	

AMBIX	1%	A086080	001	

	2.5%	A086271	001	

CHARTWELL MOLECULAR	2.5%	A040503	001	Mar 12, 2004

ENCUBE	2.5%	A203810	001	Jul 23, 2018

EVERYLIFE	0.5%	A080452	001	

	1%	A080452	002	

G AND W LABS	1%	A084059	001	

INGRAM PHARM	0.5%	A080456	002	

	1%	A080456	003	

IVAX PHARMS	1%	A085733	001	

NASKA	1%	A089706	001	Mar 10, 1988

PERRIGO NEW YORK	0.5%	A084970	002	

	1%	A085026	001	

PHARMADERM	1%	A088845	001	Feb 27, 1986

	2.5%	A089413	001	Dec 16, 1986

PHARMAFAIR	1%	A087838	001	Jul 28, 1982

STIEFEL	1%	A086170	001	

SYOSSET	0.5%	A085527	001	

TARO	0.5%	A086154	001	

TARO PHARM INDS LTD	1%	A086155	001	

TEVA	0.5%	A080400	002	

	1%	A080400	003	

	1%	A085191	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-244(of 478)

** See List Footnote

HYDROCORTISONE

CREAM;TOPICAL

HYDROCORTISONE

	2.5%	A080400	004	
TOPIDERM	1%	A089273	001	Feb 17, 1989
USL PHARMA	1%	A088027	001	Sep 27, 1983
	2.5%	A088029	001	Sep 27, 1983
WHITEWORTH TOWN PLSN	1%	A080496	002	
HYTONE				
+ VALEANT INTL	1% **	A080472	003	
+	2.5% **	A080472	004	
NOGENIC HC				
IVAX PHARMS	1%	A087427	001	Apr 04, 1988
NUTRACORT				
BAUSCH	0.5%	A080442	002	
	1%	A080442	003	
PENECORT				
ALLERGAN HERBERT	1%	A088216	001	Jun 06, 1984
PROCTOCORT				
MONARCH PHARMS	1%	A083011	001	
SYNACORT				
BAUSCH	0.5%	A087459	001	
+	1%	A087458	001	
+	2.5%	A087457	001	
ENEMA;RECTAL				
HYDROCORTISONE				
TEVA PHARMS	100MG/60ML	A074171	001	May 27, 1994
GEL;TOPICAL				
NUTRACORT				
HEALTHPOINT	1%	A084698	001	
PENECORT				
ALLERGAN HERBERT	1%	A088215	001	Jun 06, 1984
INJECTABLE;INJECTION				
CORTEF				
PHARMACIA AND UPJOHN	50MG/ML	N009864	001	
LOTION;TOPICAL				
ACTICORT				
BAKER NORTON	1%	A086535	001	
ALA-CORT				
CROWN LABS	1%	A083201	001	
BALNEOL-HC				
SOLVAY	1%	A088041	001	Dec 03, 1982
BETA-HC				
BETA DERMAC	1%	A089495	001	Jan 25, 1988
CETACORT				
BAUSCH	0.5%	A080426	002	
	1%	A080426	001	
CORT-DOME				
BAYER PHARMS	0.5%	N009895	003	
	1%	N009895	001	
DERMACORT				
SOLVAY	0.5%	A084573	002	
	1%	A086462	001	
EPICORT				
BLULINE	0.5%	A083219	002	
GLYCORT				
HERAN	1%	A087489	001	Oct 03, 1983
H-CORT				
PHARM ASSOC	0.5%	A086824	001	
HYDROCORTISONE				
ALPHARMA US PHARMS	0.5%	A087317	001	Jun 07, 1982
	1%	A087315	001	Jun 07, 1982
CHARTWELL MOLECULAR	2.5%	A040417	001	Jul 30, 2003
FOUGERA PHARMS	2.5%	A040351	001	Jul 25, 2000
MERICON	0.5%	A085282	001	
	1%	A085282	002	Feb 26, 1987
NASKA	1%	A089705	001	Apr 25, 1988
PAI HOLDINGS PHARM	2.5%	A203804	001	Jul 27, 2018
PERRIGO NEW YORK	0.5%	A085662	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-245(of 478)

** See List Footnote

HYDROCORTISONE

LOTION;TOPICAL

HYDROCORTISONE

1%

A085663 001

TARO

1%

A089024 001 Feb 12, 1986

HYTONE

+ VALEANT INTL

1% **

A080473 003

+

2.5% **

A080473 004 Nov 30, 1982

NUTRACORT

DOW PHARM

0.5%

A080443 002

1%

A080443 003

2.5%

A087644 001 Aug 24, 1982

STIE-CORT

PADAGIS US

1%

A089066 001 Nov 25, 1985

OINTMENT;TOPICAL

CORTRIL

PFIZER GLOBAL

1%

N009176 001

2.5%

N009176 002

HC (HYDROCORTISONE)

C AND M PHARMA

0.5%

A080481 001

1%

A080481 002

HYDROCORTISONE

ACTAVIS MID ATLANTIC

1%

A087796 001 Oct 13, 1982

ALTANA

0.5%

A080489 002

1%

A080489 003

AMBIX

1%

A086079 001

2.5%

A086272 001

NASKA

1%

A089704 001 Mar 10, 1988

PERRIGO NEW YORK

0.5%

A084969 003

1%

A085028 001

PHARMADERM

1%

A088842 001 Feb 09, 1987

TARO

0.5%

A086256 001

2.5%

A040310 001 Dec 29, 2000

USL PHARMA

1%

A088061 001 Sep 27, 1983

2.5%

A088039 001 Sep 27, 1983

HYTONE

+ DERMIK LABS

1% **

A080474 003

+

2.5% **

A080474 004

PENECORT

ALLERGAN HERBERT

2.5%

A088217 001 Jun 06, 1984

POWDER;FOR RX COMPOUNDING

H-CORT

TORCH

100%

A087834 001 Mar 29, 1982

HYDRO-RX

X GEN PHARMS

100%

A085982 001

HYDROCORTISONE

PADDOCK LLC

100%

A088082 001 Apr 08, 1983

SOLUTION;TOPICAL

PENECORT

+ ALLERGAN HERBERT

1%

A088214 001 Jun 06, 1984

TEXACORT

MISSION PHARMA

1%

A080425 001

TABLET;ORAL

CORTRIL

PFIZER

10MG

N009127 005

20MG

N009127 003

HYDROCORTISONE

BARR

20MG

A083999 001

CHARTWELL MOLECULAR

20MG

A085070 001

ELKINS SINN

20MG

A080624 001

FERRANTE

10MG

A080568 001

20MG

A080568 002

HIKMA INTL PHARMS

5MG

A083365 002 Feb 23, 2015

10MG

A083365 003 Feb 23, 2015

20MG

A083365 001

IMPAX LABS

20MG

A080781 001

INWOOD LABS

20MG

A080732 001

NEXGEN PHARMA INC

20MG

A083140 001

PANRAY

10MG

N009659 001

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-246(of 478)

** See List Footnote

HYDROCORTISONE

TABLET;ORAL

HYDROCORTISONE

	20MG	N009659 002	
PARKE DAVIS	20MG	A084243 001	
PUREPAC PHARM	10MG	A084247 003	Aug 31, 1982
	20MG	A080395 001	
	20MG	A084247 002	
ROXANE	10MG	A088539 001	Mar 21, 1984
SANDOZ	20MG	A080642 002	
STRIDES PHARMA	5MG	A040761 001	Jul 16, 2007
	10MG	A040761 002	Jul 16, 2007
	20MG	A040761 003	Jul 16, 2007
WATSON LABS	20MG	A080355 001	
WHITEWORTH TOWN PLSN	10MG	A080344 001	
	20MG	A080344 002	
HYDROCORTONE			
MERCK	10MG	N008506 007	
	20MG	N008506 011	

TABLET;VAGINAL

CORTRIL

PFIPHARMECS	10MG	N009796 001	

HYDROCORTISONE ACETATE

CREAM;TOPICAL

CARMOL HC

+ FOUGERA PHARMS	1%	A080505 001	

HEMSOL-HC

ABLE	1%	A081274 001	Jun 19, 1992

HYDROCORTISONE ACETATE

CENCI	1%	A080419 001	Jan 25, 1982

IMPERIUM	2.5%	A040259 001	Jul 29, 1999

PARKE DAVIS	1%	A089914 001	Jan 03, 1989

PUREPAC PHARM	0.5%	A086050 001	

+	1%	A086052 001	

MICORT-HC

SEBELA IRELAND LTD	2%	A040398 001	Mar 29, 2002

U-CORT

TARO	1%	A089472 001	Jun 13, 1988

INJECTABLE;INJECTION

CORTEF ACETATE

PHARMACIA AND UPJOHN	50MG/ML	N009378 002	

CORTRIL

PFIZER	25MG/ML	N009164 001	

HYDROCORTISONE ACETATE

AKORN	25MG/ML	N009637 001	

	50MG/ML	N009637 002	

BEL MAR	25MG/ML	A083739 001	

	50MG/ML	A083739 002	

WATSON LABS	25MG/ML	A083128 001	

	25MG/ML	A083759 001	

	50MG/ML	A083759 002	

	50MG/ML	A085214 001	

HYDROCORTONE

MERCK	25MG/ML	N008228 001	

	50MG/ML	N008228 004	

LOTION;TOPICAL

DRICORT

INGRAM PHARM	0.5%	A086207 001	

OINTMENT;OPHTHALMIC

HYDROCORTISONE ACETATE

FERA PHARMS	0.5%	A080828 001	

OINTMENT;OPHTHALMIC, OTIC

HYDROCORTONE

MERCK	1.5%	N009018 003	

OINTMENT;TOPICAL

CORTEF ACETATE

PHARMACIA AND UPJOHN	1%	N008917 002	

+	2.5% **	N008917 001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-247(of 478)

** See List Footnote

HYDROCORTISONE ACETATE

PASTE;TOPICAL

ORABASE HCA

COLGATE

0.5%

A083205 001

POWDER;FOR RX COMPOUNDING

HYDROCORTISONE ACETATE

X GEN PHARMS

100%

A085981 001

HYDROCORTISONE ACETATE; NEOMYCIN SULFATE

CREAM;TOPICAL

NEO-CORTEF

PHARMACIA AND UPJOHN 1%;EQ 3.5MG BASE/GM

A061049 001

2.5%;EQ 3.5MG BASE/GM

A061049 002

OINTMENT;OPHTHALMIC

NEO-CORTEF

PHARMACIA AND UPJOHN 0.5%;EQ 3.5MG BASE/GM

A060610 001

1.5%;EQ 3.5MG BASE/GM

A060610 002

OINTMENT;TOPICAL

NEO-CORTEF

PHARMACIA AND UPJOHN 0.5%;EQ 3.5MG BASE/GM

A060751 001

1%;EQ 3.5MG BASE/GM

A060751 002

2.5%;EQ 3.5MG BASE/GM

A060751 003

SUSPENSION/DROPS;OPHTHALMIC

COR-OTICIN

AKORN

1.5%;EQ 3.5MG BASE/ML

A060188 001

NEO-CORTEF

PHARMACIA AND UPJOHN 0.5%;EQ 3.5MG BASE/ML

A060612 002

1.5%;EQ 3.5MG BASE/ML

A060612 001

HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

CREAM;TOPICAL

CORTISPORIN

+

MONARCH PHARMS

0.5%;EQ 3.5MG BASE/GM;10,000 UNITS/GM

N050218 001 Aug 09, 1985

HYDROCORTISONE ACETATE; OXYTETRACYCLINE HYDROCHLORIDE

SUSPENSION;OPHTHALMIC

TERRA-CORTRIL

PFIZER

1.5%;EQ 5MG BASE/ML

A061016 001

HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE

AEROSOL, METERED;TOPICAL

HYDROCORTISONE ACETATE 1% AND PRAMOXINE HYDROCHLORIDE 1%

GENUS

1%;1%

A089440 001 May 17, 1988

LOTION;TOPICAL

PRAMOSONE

FERNDAL LABS

0.5%;1%

A083213 002

HYDROCORTISONE BUTYRATE

CREAM;TOPICAL

LOCOID

YAMANOUCHI

0.1%

N018795 001 Jan 07, 1983

OINTMENT;TOPICAL

LOCOID

YAMANOUCHI

0.1%

N019106 001 Jul 03, 1984

SOLUTION;TOPICAL

LOCOID

YAMANOUCHI

0.1%

N019819 001 Sep 15, 1988

HYDROCORTISONE CYPIONATE

SUSPENSION;ORAL

CORTEF

PHARMACIA AND UPJOHN EQ 10MG BASE/5ML

N009900 001

HYDROCORTISONE SODIUM PHOSPHATE

INJECTABLE;INJECTION

HYDROCORTONE

+

MERCK

EQ 50MG BASE/ML

N012052 001

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-248(of 478)

** See List Footnote

HYDROCORTISONE SODIUM SUCCINATE

INJECTABLE; INJECTION

A-HYDROCORT

ABBOTT

EQ 100MG BASE/VIAL

A085928 001

EQ 100MG BASE/VIAL

A089577 001 Apr 11, 1989

EQ 250MG BASE/VIAL

A089578 001 Apr 11, 1989

EQ 500MG BASE/VIAL

A089579 001 Apr 11, 1989

EQ 1GM BASE/VIAL

A089580 001 Apr 11, 1989

HOSPIRA

EQ 100MG BASE/VIAL

A040666 001 Apr 06, 2006

EQ 100MG BASE/VIAL

A085929 001

EQ 250MG BASE/VIAL

A085930 001

EQ 500MG BASE/VIAL

A085931 001

EQ 1GM BASE/VIAL

A085932 001

HYDROCORTISONE SODIUM SUCCINATE

ABRAXIS PHARM

EQ 100MG BASE/VIAL

A088667 001 Jun 08, 1984

EQ 100MG BASE/VIAL

A088712 001 Jun 08, 1984

EQ 250MG BASE/VIAL

A088668 001 Jun 08, 1984

EQ 500MG BASE/VIAL

A088669 001 Jun 08, 1984

EQ 1GM BASE/VIAL

A088670 001 Jun 08, 1984

BAXTER HLTHCARE

EQ 100MG BASE/VIAL

A086619 001

EQ 250MG BASE/VIAL

A087567 001

EQ 500MG BASE/VIAL

A087568 001

EQ 1GM BASE/VIAL

A087569 001

INTL MEDICATION

EQ 100MG BASE/VIAL

A087532 001 Mar 19, 1982

WATSON LABS

EQ 100MG BASE/VIAL

A084737 002

EQ 100MG BASE/VIAL

A084738 001

EQ 250MG BASE/VIAL

A084737 001

EQ 500MG BASE/VIAL

A084747 001

EQ 1GM BASE/VIAL

A084748 001

HYDROCORTISONE VALERATE

CREAM; TOPICAL

HYDROCORTISONE VALERATE

COSETTE

0.2%

A074489 001 Aug 12, 1998

WESTCORT

+ SUN PHARM INDS INC

0.2% **

N017950 001

OINTMENT; TOPICAL

HYDROCORTISONE VALERATE

FOUGERA PHARMS

0.2%

A075085 001 Jul 31, 2001

WESTCORT

+ SUN PHARM INDS INC

0.2% **

N018726 001 Aug 08, 1983

HYDROCORTISONE; NEOMYCIN SULFATE

CREAM; TOPICAL

NEO-CORT-DOME

BAYER PHARMS

0.5%;EQ 3.5MG BASE/GM

N050237 006 Jun 05, 1984

1%;EQ 3.5MG BASE/GM

N050237 005 Jun 05, 1984

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OTIC

CORTISPORIN

+ MONARCH PHARMS

1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML **

N050479 001

NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE

AMRING PHARMS

1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML

A065216 001 Oct 31, 2005

NEOMYCIN SULFATE-POLYMYXIN B SULFATE-HYDROCORTISONE

PHARMAFAIR

1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML

A062394 001 Sep 29, 1982

OTOCORT

WATSON LABS

1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML

A060730 002

SUSPENSION/DROPS; OPHTHALMIC

CORTISPORIN

MONARCH PHARMS

1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML

N050169 001

NEOMYCIN SULFATE-POLYMYXIN B SULFATE-HYDROCORTISONE

PHARMAFAIR

1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML

A062623 001 Sep 24, 1985

SUSPENSION/DROPS; OTIC

NEOMYCIN SULFATE, POLYMYXIN B SULFATE & HYDROCORTISONE

PHARMAFAIR

1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML

A062617 001 Sep 18, 1985

OTICAIR

PHARMAFAIR

1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML

A062399 001 Nov 18, 1982

OTOBIONE

SCHERING

1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML

A061816 001

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-249(of 478)

** See List Footnote

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SUSPENSION/DROPS;OTIC

OTOCORT

ACTAVIS LABS FL INC 1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML A062521 001 Jul 11, 1985

PEDIOTIC

MONARCH PHARMS 1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML A062822 001 Sep 29, 1987

HYDROCORTISONE; POLYMYXIN B SULFATE

SOLUTION/DROPS;OTIC

OTOBiotic

SCHERING 5MG/ML;EQ 10,000 UNITS BASE/ML A062302 001

PYOCIDIN

FOREST LABS 5MG/ML;EQ 10,000 UNITS BASE/ML A061606 001

HYDROCORTISONE; TETRACYCLINE HYDROCHLORIDE

OINTMENT;OPHTHALMIC

ACHROMYCIN

LEDERLE 1.5%;1% N050272 001

HYDROCORTISONE; UREA

CREAM;TOPICAL

ALPHADERM

BIOGLAN 1%;10% A086008 001

CALMURID HC

PHARMACIA AND UPJOHN 1%;10% A083947 001

HYDROFLUMETHIAZIDE

TABLET;ORAL

DIUCARDIN

WYETH AYERST 50MG A083383 001

HYDROFLUMETHIAZIDE

PAR PHARM 50MG A088850 001 May 31, 1985

WATSON LABS 50MG A088031 001 Apr 06, 1983

50MG A088528 001 Aug 15, 1984

SALURON

+ SHIRE LLC 50MG N011949 001

HYDROFLUMETHIAZIDE; RESERPINE

TABLET;ORAL

HYDROFLUMETHIAZIDE AND RESERPINE

USL PHARMA 50MG;0.125MG A088195 001 Oct 26, 1983

WATSON LABS 25MG;0.125MG A088127 001 Mar 22, 1983

50MG;0.125MG A088110 001 Mar 22, 1983

RESERPINE AND HYDROFLUMETHIAZIDE

IVAX PHARMS 50MG;0.125MG A088932 001 Jan 11, 1985

PAR PHARM 50MG;0.125MG A088907 001 Sep 20, 1985

SALUTENSIN

SHIRE 50MG;0.125MG N012359 003

SALUTENSIN-DEMI

SHIRE 25MG;0.125MG N012359 004

HYDROGEN PEROXIDE

SOLUTION;TOPICAL

ESKATA

+ ACLARIS 40% N209305 001 Dec 14, 2017

HYDROMORPHONE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

PALLADONE

PURDUE PHARMA LP 12MG N021044 001 Sep 24, 2004

16MG N021044 002 Sep 24, 2004

24MG N021044 003 Sep 24, 2004

32MG N021044 004 Sep 24, 2004

INJECTABLE;INJECTION

DILAUDID

+ FRESENIUS KABI USA 4MG/ML N019034 005 Apr 30, 2009

DILAUDID-HP

+ FRESENIUS KABI USA 10MG/ML N019034 001 Jan 11, 1984

250MG/VIAL N019034 002 Aug 04, 1994

HYDROMORPHONE HYDROCHLORIDE

BARR 10MG/ML A076444 001 Apr 25, 2003

HOSPIRA 10MG/ML A074598 001 Jun 19, 1997

WATSON LABS 10MG/ML A074317 001 Aug 23, 1995

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-250(of 478)

** See List Footnote

HYDROMORPHONE HYDROCHLORIDE

SOLUTION; ORAL

HYDROMORPHONE HYDROCHLORIDE

ANDA REPOSITORY 5MG/5ML

A207108 001 Apr 22, 2020

TABLET; ORAL

HYDROMORPHONE HYDROCHLORIDE

ANDA REPOSITORY 2MG

A077471 002 Dec 09, 2009

4MG

A077471 003 Dec 09, 2009

8MG

A077471 001 Dec 09, 2009

HIKMA 4MG

A074597 003 May 29, 2009

8MG

A074597 001 Jul 29, 1998

NESHER PHARMS 2MG

A077311 001 Nov 09, 2005

4MG

A077311 002 Nov 09, 2005

8MG

A077311 003 Nov 09, 2005

NOSTRUM LABS INC 8MG

A076723 001 Oct 18, 2005

TABLET, EXTENDED RELEASE; ORAL

EXALGO

+ SPECGX LLC 8MG **

N021217 001 Mar 01, 2010

+ 12MG **

N021217 002 Mar 01, 2010

+ 16MG **

N021217 003 Mar 01, 2010

+ 32MG **

N021217 004 Aug 24, 2012

HYDROMORPHONE HYDROCHLORIDE

ACTAVIS LABS FL INC 8MG

A202144 001 May 12, 2014

12MG

A202144 002 May 12, 2014

16MG

A202144 003 May 12, 2014

32MG

A202144 004 Jun 30, 2016

HYDROXOCOBALAMIN

INJECTABLE; INJECTION

ALPHAREDISOL

MERCK 1MG/ML

A080778 001

CYANOKIT

BTG INTL 2.5GM/VIAL (5GM/KIT)

N022041 002 Dec 15, 2006

HYDROXOCOBALAMIN

ABRAXIS PHARM 1MG/ML

A084921 001

WATSON LABS 1MG/ML

A085528 001

HYDROXOMIN

BEL MAR 1MG/ML

A084629 001

HYDROXYAMPHETAMINE HYDROBROMIDE

SOLUTION/DROPS; OPHTHALMIC

PAREDRIE

PHARMICS 1%

N000004 004

HYDROXYCHLOROQUINE SULFATE

TABLET; ORAL

HYDROXYCHLOROQUINE SULFATE

HIKMA PHARMS 200MG

A040760 001 Aug 15, 2007

INVATECH 200MG

A040150 001 Jan 27, 1996

WATSON LABS 200MG

A040133 001 Nov 30, 1995

HYDROXYPROGESTERONE CAPROATE

INJECTABLE; INJECTION

HYDROXYPROGESTERONE CAPROATE

AKORN 125MG/ML

N018004 001

ALLERGAN 125MG/ML

N017439 001

250MG/ML

N017439 002

SOLUTION; INTRAMUSCULAR

DELALUTIN

+ BRISTOL MYERS SQUIBB 125MG/ML (125MG/ML) **

N010347 004

+ 125MG/ML (125MG/ML) **

N016911 001

+ 250MG/ML (250MG/ML) **

N010347 002

+ 250MG/ML (250MG/ML) **

N016911 002

HYDROXYPROGESTERONE CAPROATE

AM REGENT 1250MG/5ML (250MG/ML)

A210724 001 Aug 09, 2019

EUGIA PHARMA 1250MG/5ML (250MG/ML)

A211142 001 May 09, 2019

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-251(of 478)

** See List Footnote

HYDROXYSTILBAMIDINE ISETHIONATE

INJECTABLE; INJECTION

HYDROXYSTILBAMIDINE ISETHIONATE

SANOFI AVENTIS US 225MG/AMP

N009166 001

HYDROXYUREA

CAPSULE; ORAL

HYDROXYUREA

BARR 250MG

A075143 002 Sep 21, 2000

BARR LABS INC 250MG

A075020 002 Jun 26, 2000

500MG

A075020 001 Jul 30, 1998

ROXANE 500MG

A074476 001 Aug 18, 1995

TABLET; ORAL

HYDROXYUREA

BARR 1GM

A075734 001 Aug 29, 2000

HYDROXYZINE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDROXYZINE

BAXTER HLTHCARE 50MG/ML

A085551 002

HYDROXYZINE HYDROCHLORIDE

ALTANA 25MG/ML

A087273 001 Apr 20, 1982

50MG/ML

A087273 002 Apr 20, 1982

BAXTER HLTHCARE 25MG/ML

A085551 001

DR REDDYS 50MG/ML

A085779 001

FRESENIUS KABI USA 25MG/ML

A087329 001

25MG/ML

A088184 001 Mar 31, 1983

50MG/ML

A087329 002

50MG/ML

A088185 001 Mar 31, 1983

HOSPIRA 25MG/ML

A087416 001

50MG/ML

A086821 001

50MG/ML

A087546 001

PHARMAFAIR 25MG/ML

A088862 001 Feb 14, 1986

25MG/ML

A089106 001 Feb 14, 1986

50MG/ML

A088881 001 Feb 14, 1986

50MG/ML

A089107 001 Feb 14, 1986

SMITH AND NEPHEW 25MG/ML

A087592 001

SOLOPAK 25MG/ML

A086822 001

25MG/ML

A087591 001

50MG/ML

A087310 001

50MG/ML

A087593 001

50MG/ML

A087595 001

50MG/ML

A087596 001

WATSON LABS 25MG/ML

A085778 001

25MG/ML

A087274 001

50MG/ML

A087274 002

WYETH AYERST 25MG/ML

A086258 001

50MG/ML

A086258 002

ORGATRA

ORGANON USA INC 25MG/ML

A087014 001

50MG/ML

A087014 002

VISTARIL

+ PFIZER 25MG/ML **

N011111 001

+ 50MG/ML **

N011111 002

SYRUP; ORAL

ATARAX

ROERIG 10MG/5ML **

N010485 001

HYDROXYZINE HYDROCHLORIDE

AKORN 10MG/5ML

A040010 001 Oct 28, 1994

ALPHARMA US PHARMS 10MG/5ML

A088785 001 Feb 03, 1988

ANIMA 10MG/5ML

A086880 001

KV PHARM 10MG/5ML

A087730 001 Jul 01, 1982

PAI HOLDINGS PHARM 10MG/5ML

A040391 001 Apr 10, 2002

TORRENT 10MG/5ML

A210634 001 Feb 26, 2019

TABLET; ORAL

ATARAX

+ PFIZER 10MG **

N010392 001

+ 25MG **

N010392 004

+ 50MG **

N010392 006

+ 100MG **

N010392 005

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-252(of 478)

** See List Footnote

HYDROXYZINE HYDROCHLORIDE

TABLET; ORAL

HYDROXYZINE HYDROCHLORIDE

ABLE	10MG	A040559	001	Jul 22, 2004
	25MG	A040562	001	Jul 22, 2004
	50MG	A040563	001	Jul 22, 2004
ACTAVIS ELIZABETH	10MG	A089071	001	Jul 22, 1986
	25MG	A089072	001	Jul 22, 1986
	50MG	A089073	001	Jul 22, 1986
HALSEY	10MG	A089366	001	May 02, 1988
	25MG	A089117	001	May 02, 1988
	50MG	A089396	001	May 02, 1988
IVAX PHARMS	10MG	A087216	001	
	25MG	A087410	001	
	50MG	A087411	001	
KV PHARM	10MG	A087819	001	Jun 23, 1982
	25MG	A087820	001	Jun 23, 1982
	50MG	A087821	001	Jun 23, 1982
	100MG	A087822	001	Jun 23, 1982
MUTUAL PHARM	10MG	A088409	001	Nov 15, 1983
	25MG	A087857	001	Apr 18, 1983
	50MG	A087860	001	Apr 18, 1983
PLIVA	100MG	A081054	001	Sep 25, 1995
PUREPAC PHARM	10MG	A088120	001	Sep 25, 1984
	25MG	A088121	001	Sep 25, 1984
	50MG	A088122	001	Sep 25, 1984
QUANTUM PHARMICS	10MG	A088540	001	Oct 22, 1985
	25MG	A088551	001	Oct 22, 1985
	50MG	A088529	001	Oct 22, 1985
RISING	10MG	A091176	001	Jun 07, 2010
	25MG	A091176	002	Jun 07, 2010
	50MG	A091176	003	Jun 07, 2010
SANDOZ	10MG	A087246	002	
	25MG	A085247	001	
	50MG	A087245	001	
STRIDES PHARMA	10MG	A087602	001	Jan 22, 1982
	25MG	A087603	001	Jan 22, 1982
	50MG	A087604	001	Jan 22, 1982
SUN PHARM INDS INC	10MG	A040899	001	Jun 10, 2008
	25MG	A040899	002	Jun 10, 2008
	50MG	A040899	003	Jun 10, 2008
SUN PHARM INDUSTRIES	10MG	A089381	001	May 19, 1986
	25MG	A089382	001	May 19, 1986
	50MG	A089383	001	May 19, 1986
	100MG	A087862	001	Apr 18, 1983
SUPERPHARM	10MG	A088794	001	Dec 05, 1984
	25MG	A088795	001	Dec 05, 1984
	50MG	A088796	001	Dec 05, 1984
USL PHARMA	10MG	A089121	001	Mar 20, 1986
	25MG	A089122	001	Mar 20, 1986
	50MG	A089123	001	Mar 20, 1986
WATSON LABS	10MG	A081149	001	Mar 18, 1994
	10MG	A086827	001	
	10MG	A088348	001	Sep 15, 1983
	25MG	A081150	001	Mar 18, 1994
	25MG	A086829	001	
	25MG	A088349	001	Sep 15, 1983
	50MG	A081151	001	Mar 18, 1994
	50MG	A086836	001	
	50MG	A088350	001	Sep 15, 1983

HYDROXYZINE PAMOATE

CAPSULE; ORAL

HY-PAM "25"

TEVA	EQ 25MG HYDROCHLORIDE	A088713	001	Mar 04, 1985
HYDROXYZINE PAMOATE				
BEXIMCO PHARMS USA	EQ 25MG HYDROCHLORIDE	A081127	001	Jun 28, 1991
DURAMED PHARMS BARR	EQ 25MG HYDROCHLORIDE	A088593	001	Feb 29, 1984
	EQ 50MG HYDROCHLORIDE	A088594	001	Feb 29, 1984
	EQ 100MG HYDROCHLORIDE	A088595	001	Feb 29, 1984

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-253(of 478)

** See List Footnote

HYDROXYZINE PAMOATE

CAPSULE;ORAL

HYDROXYZINE PAMOATE

IVAX SUB TEVA PHARMS	EQ 25MG HYDROCHLORIDE	A087761	001	Mar 05, 1982
	EQ 50MG HYDROCHLORIDE	A087760	001	Mar 05, 1982
PAR PHARM	EQ 25MG HYDROCHLORIDE	A087656	001	Jun 11, 1982
	EQ 25MG HYDROCHLORIDE	A089145	001	Mar 17, 1986
	EQ 50MG HYDROCHLORIDE	A087657	001	Jun 11, 1982
	EQ 50MG HYDROCHLORIDE	A089146	001	Mar 17, 1986
	EQ 100MG HYDROCHLORIDE	A087658	001	Jun 11, 1982
SANDOZ	EQ 50MG HYDROCHLORIDE	A081128	001	Jun 28, 1991
	EQ 100MG HYDROCHLORIDE	A081129	001	Jun 28, 1991
SUPERPHARM	EQ 25MG HYDROCHLORIDE	A089031	001	Jan 02, 1987
	EQ 50MG HYDROCHLORIDE	A089032	001	Jan 02, 1987
	EQ 100MG HYDROCHLORIDE	A089033	001	Jan 02, 1987
VANGARD	EQ 25MG HYDROCHLORIDE	A088392	001	Sep 19, 1983
	EQ 50MG HYDROCHLORIDE	A088393	001	Sep 19, 1983
WATSON LABS	EQ 25MG HYDROCHLORIDE	A081165	001	Jul 31, 1991
	EQ 25MG HYDROCHLORIDE	A086698	001	
	EQ 25MG HYDROCHLORIDE	A086840	001	Jul 01, 1982
	EQ 50MG HYDROCHLORIDE	A086695	001	
	EQ 50MG HYDROCHLORIDE	A086705	001	Jul 01, 1982
	EQ 50MG HYDROCHLORIDE	A087767	001	Aug 16, 1982
	EQ 100MG HYDROCHLORIDE	A086697	001	
	EQ 100MG HYDROCHLORIDE	A086728	001	Oct 05, 1982
	EQ 100MG HYDROCHLORIDE	A087790	001	Aug 16, 1982
VISTARIL				
PFIZER	EQ 100MG HYDROCHLORIDE **	N011459	006	
SUSPENSION;ORAL				
VISTARIL				
PFIZER	EQ 25MG HYDROCHLORIDE/5ML	N011795	001	

IBANDRONATE SODIUM

INJECTABLE;INTRAVENOUS

BONIVA

+ ROCHE	EQ 3MG BASE/3ML **	N021858	001	Jan 06, 2006
IBANDRONATE SODIUM				
EMCURE PHARMS LTD	EQ 3MG BASE/3ML	A203987	001	Sep 02, 2014
NANG KUANG PHARM CO	EQ 3MG BASE/3ML	A204329	001	Jun 16, 2021
TABLET;ORAL				
BONIVA				
+ HOFFMANN LA ROCHE	EQ 2.5MG BASE **	N021455	001	May 16, 2003
+	EQ 150MG BASE **	N021455	002	Mar 24, 2005
IBANDRONATE SODIUM				
MYLAN PHARMS INC	EQ 150MG BASE	A078995	001	Mar 19, 2012
SUN PHARM INDUSTRIES	EQ 150MG BASE	A078996	001	Aug 15, 2012

IBRUTINIB

CAPSULE;ORAL

IBRUTINIB

ZYDUS	70MG	A211344	001	Mar 31, 2021
	140MG	A211344	002	Mar 31, 2021

IBUPROFEN

CAPSULE;ORAL

IBUPROFEN

CONTRACT PHARMACAL	200MG	A074782	001	Jul 06, 1998
MIDOL				
BAYER	200MG **	A070626	001	Sep 02, 1987
	200MG **	A071002	001	Sep 02, 1987
SOLUTION;INTRAVENOUS				
CALDOLOR				
CUMBERLAND PHARMS	400MG/4ML (100MG/ML)	N022348	001	Jun 11, 2009
SUSPENSION;ORAL				
CHILDREN'S ADVIL				
GLAXOSMITHKLINE	100MG/5ML	N019833	002	Sep 19, 1989
CHILDREN'S ELIXSURE				
MOBERG PHARMA NORTH	100MG/5ML	N021604	001	Jan 07, 2004
IBU				
ABBOTT	100MG/5ML	N019784	001	Dec 18, 1989

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-254(of 478)

** See List Footnote

IBUPROFEN

SUSPENSION;ORAL

IBUPROFEN

AKORN 100MG/5ML

A205647 001 Nov 03, 2016

STRIDES PHARMA 100MG/5ML

A211666 001 Feb 22, 2021

100MG/5ML

A215311 001 May 27, 2022

MOTRIN

+ MCNEIL CONSUMER 100MG/5ML **

N019842 001 Sep 19, 1989

SUSPENSION/DROPS;ORAL

IBUPROFEN

STRIDES PHARMA 50MG/1.25ML

A214071 001 Jun 09, 2022

MOTRIN

MCNEIL 40MG/ML

N020476 001 May 25, 1995

PEDIATRIC ADVIL

+ GLAXOSMITHKLINE 100MG/2.5ML

N020812 001 Jan 30, 1998

TABLET;ORAL

ACHES-N-PAIN

LEDERLE 200MG

A071065 001 May 28, 1987

CAP-PROFEN

PERRIGO 200MG

A072097 001 Dec 08, 1987

IBU

BASF 400MG

A070083 001 Feb 22, 1985

400MG

N018197 001

600MG

A070088 001 Feb 08, 1985

600MG

A070099 001 Mar 29, 1985

800MG

A070745 001 Jul 23, 1986

IBU-TAB

ALRA 400MG

A071058 001 Aug 11, 1988

600MG

A071059 001 Aug 11, 1988

800MG

A071965 001 Aug 11, 1988

IBU-TAB 200

ALRA 200MG

A071057 001 Aug 11, 1988

IBUPRIN

PLIVA 200MG

A071773 001 Jul 16, 1987

IBUPROFEN

ABBOTT 600MG

A070556 001 Jun 14, 1985

800MG

A071264 001 Jul 25, 1986

ANI PHARMS 200MG

A071144 001 Jan 20, 1987

200MG

A072901 001 Dec 19, 1991

200MG

A072903 001 Dec 19, 1991

CONTRACT PHARMACAL 200MG

A071265 001 Oct 15, 1986

200MG

A071265 002 Sep 10, 1987

200MG

A071735 001 Sep 10, 1987

200MG

A073691 001 Feb 25, 1994

200MG

A074931 001 Jul 20, 1998

HALSEY 200MG

A071027 001 Sep 29, 1987

300MG

A071028 001 Mar 23, 1987

400MG

A071029 001 Mar 23, 1987

600MG

A071030 001 Mar 23, 1987

800MG

A072137 001 Feb 05, 1988

IVAX SUB TEVA PHARMS 200MG

A071154 001 Oct 27, 1987

200MG

A072040 001 Apr 29, 1988

400MG

A071145 001 Sep 23, 1986

600MG

A071146 001 Sep 23, 1986

800MG

A071769 001 May 08, 1987

J AND J CONSUMER INC 400MG

A070081 001 Jun 16, 1986

L PERRIGO CO 400MG

A077114 001 Jul 18, 2005

600MG

A077114 002 Jul 18, 2005

800MG

A077114 003 Jul 18, 2005

LEDERLE 400MG

A070629 001 Sep 19, 1986

600MG

A070630 001 Sep 19, 1986

LEINER 300MG

A071266 001 Oct 15, 1986

LNK 100MG

A076741 001 Jun 17, 2004

MCNEIL 600MG

A070476 001 Jun 16, 1986

MERRO PHARM 200MG

A070985 001 Oct 02, 1987

MYLAN 200MG

A071870 001 May 05, 1988

400MG

A070045 001 Sep 24, 1985

600MG

A070057 001 Sep 24, 1985

800MG

A071999 001 Dec 03, 1987

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-255(of 478)

** See List Footnote

IBUPROFEN

TABLET;ORAL

IBUPROFEN

NORTHSTAR HLTHCARE	400MG	A078132 001	Sep 10, 2007
	600MG	A078132 002	Sep 10, 2007
	800MG	A078132 003	Sep 10, 2007
OHM LABS	400MG	A070818 001	Dec 26, 1985
P AND L DEV LLC	200MG	A070733 001	Sep 19, 1986
PAR PHARM	300MG	A070328 001	Aug 06, 1985
PERRIGO	200MG	A072098 001	Dec 08, 1987
	200MG	A075995 001	Mar 14, 2002
PLIVA	400MG	A071666 001	Jun 18, 1987
	600MG	A071667 001	Jun 18, 1987
	800MG	A071668 001	Jun 18, 1987
PUREPAC PHARM	200MG	A071122 001	Oct 03, 1986
	200MG	A071664 001	Feb 03, 1987
	300MG	A071123 001	Sep 19, 1986
	400MG	A071124 001	Sep 19, 1986
	600MG	A071125 001	Sep 19, 1986
	800MG	A071964 001	Feb 01, 1988
RISING	300MG	A070736 002	Jun 12, 1986
	400MG	A070736 003	Jun 12, 1986
	600MG	A070736 001	Jun 12, 1986
	800MG	A071938 001	Jan 14, 1988
SANDOZ	200MG	A071807 001	Feb 25, 1988
	200MG	A074525 001	Dec 15, 1995
	200MG	A074533 001	Dec 15, 1995
	400MG	A072064 001	Jan 14, 1988
	600MG	A072065 001	Jan 14, 1988
	800MG	A072169 001	Dec 11, 1987
STRIDES PHARMA	200MG	A071575 001	May 08, 1987
	400MG	A070329 001	Aug 06, 1985
	600MG	A070330 001	Aug 06, 1985
	800MG	A070986 001	Jul 25, 1986
SUN PHARM INDUSTRIES	200MG	A070493 001	Dec 24, 1985
	200MG	A070908 001	Sep 26, 1986
	200MG	A071462 001	Oct 02, 1986
	400MG	A070079 001	Jul 24, 1985
	600MG	A070080 001	Jul 24, 1985
	800MG	A071448 001	Feb 18, 1987
SUNSHINE	400MG	A204062 001	Sep 10, 2018
	600MG	A204062 002	Sep 10, 2018
	800MG	A204062 003	Sep 10, 2018
SUPERPHARM	600MG	A070709 001	Apr 25, 1986
TEVA	200MG	A073141 001	May 29, 1992
	400MG	A073343 001	Jun 30, 1992
	600MG	A073344 001	Jun 30, 1992
	800MG	A073345 001	Jun 30, 1992
ULTRATAB LABS INC	200MG	A209076 001	Jan 06, 2020
VINTAGE PHARMS	200MG	A071639 001	Feb 02, 1988
	200MG	A072249 001	Jan 10, 1989
	300MG	A071230 001	Oct 22, 1986
	400MG	A071231 001	Oct 22, 1986
	400MG	A071644 001	Feb 01, 1988
	600MG	A071232 001	Oct 22, 1986
	800MG	A072004 001	Nov 18, 1987
WATSON LABS	200MG	A070435 001	Mar 05, 1986
	200MG	A071765 001	Sep 04, 1987
	200MG	A071905 001	Mar 08, 1988
	300MG	A071338 001	Dec 01, 1986
	400MG	A070038 001	Sep 06, 1985
	400MG	A070436 001	Aug 21, 1985
	600MG	A070041 001	Sep 06, 1985
	600MG	A070437 001	Aug 21, 1985
	800MG	A071547 001	Jul 02, 1987
	800MG	A071911 001	Oct 13, 1987
YICHANG HUMANWELL	200MG	A214003 001	Oct 19, 2020
IBUPROHM			
OHM LABS	200MG	A071214 001	Dec 01, 1986

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-256(of 478)

** See List Footnote

IBUPROFEN

TABLET;ORAL

IBUPROHM	400MG	A070469	001	Aug 29, 1985
JUNIOR STRENGTH IBUPROFEN				
L PERRIGO CO	100MG	A075367	001	Apr 22, 1999
MEDIPREN				
MCNEIL	200MG	A070475	001	Feb 06, 1986
	200MG	A071215	001	Jun 26, 1986
MIDOL				
BAYER	200MG	A070591	001	Sep 02, 1987
	200MG	A071001	001	Sep 02, 1987
MOTRIN				
+ MCNEIL CONSUMER	300MG **	N017463	003	
+	400MG **	N017463	002	
+	600MG **	N017463	004	
+	800MG **	N017463	005	May 22, 1985
MCNEIL PED	100MG	N020418	001	Nov 16, 1994
MOTRIN MIGRAINE PAIN				
J AND J CONSUMER INC	200MG	N019012	004	Feb 25, 2000
NUPRIN				
BRISTOL MYERS	200MG	A072035	001	Feb 16, 1988
	200MG	A072036	001	Feb 16, 1988
J AND J CONSUMER INC	200MG	N019012	001	May 18, 1984
	200MG	N019012	002	Jul 29, 1987
RUFEN				
BASF	600MG	N018197	002	Mar 05, 1984
TAB-PROFEN				
PERRIGO	200MG	A072095	001	Dec 08, 1987
TABLET, CHEWABLE;ORAL				
CHILDREN'S MOTRIN				
+ J AND J CONSUMER INC	50MG	N020601	001	Nov 15, 1996
IBUPROFEN				
PERRIGO	50MG	A076359	001	Jan 16, 2004
JUNIOR STRENGTH MOTRIN				
+ J AND J CONSUMER INC	100MG	N020601	003	Nov 15, 1996
MOTRIN				
MCNEIL PED	50MG	N020135	001	Nov 16, 1994
	100MG	N020135	002	Nov 16, 1994

IBUPROFEN SODIUM

TABLET;ORAL

IBUPROFEN SODIUM				
PERRIGO R AND D	EQ 200MG BASE	A206581	001	Aug 03, 2015

IBUPROFEN; OXYCODONE HYDROCHLORIDE

TABLET;ORAL

COMBUNOX				
+ FOREST LABS	400MG;5MG **	N021378	001	Nov 26, 2004
OXYCODONE HYDROCHLORIDE AND IBUPROFEN				
ACTAVIS ELIZABETH	400MG;5MG	A078769	001	Jan 04, 2008
BARR LABS INC	400MG;5MG	A078316	001	Nov 29, 2007
WATSON LABS	400MG;5MG	A078394	001	Nov 26, 2007

IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

SUSPENSION;ORAL

IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE				
PERRIGO	100MG/5ML;15MG/5ML	A076478	001	Nov 05, 2003

TABLET;ORAL

IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE				
CONTRACT PHARMACAL	200MG;30MG	A075588	001	Apr 08, 2002

IBUTILIDE FUMARATE

INJECTABLE;INJECTION

IBUTILIDE FUMARATE				
LUITPOLD	0.1MG/ML	A090240	001	Jan 11, 2010
MYLAN INSTITUTIONAL	0.1MG/ML	A090924	001	Jan 11, 2010

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-257(of 478)

** See List Footnote

ICATIBANT ACETATE

INJECTABLE;SUBCUTANEOUS

ICATIBANT ACETATE

DR REDDYS

EQ 30MG BASE/3ML (EQ 10MG BASE/ML)

A213054 001 Oct 05, 2020

GLENMARK PHARMS LTD

EQ 30MG BASE/3ML (EQ 10MG BASE/ML)

A213222 001 May 21, 2021

IDARUBICIN HYDROCHLORIDE

INJECTABLE;INJECTION

IDAMYCIN

PFIZER

5MG/VIAL

N050661 002 Sep 27, 1990

10MG/VIAL

N050661 001 Sep 27, 1990

20MG/VIAL

N050661 003 Apr 25, 1995

IDARUBICIN HYDROCHLORIDE

FRESENIUS KABI USA

1MG/ML

A065440 001 Aug 04, 2009

MYLAN LABS LTD

1MG/ML

A200144 001 Oct 11, 2012

SANDOZ

1MG/ML

A091293 001 Mar 29, 2011

TEVA PARENTERAL

5MG/VIAL

A065037 003 May 01, 2002

10MG/VIAL

A065037 002 May 01, 2002

20MG/VIAL

A065037 001 May 01, 2002

IDOXURIDINE

OINTMENT;OPHTHALMIC

STOXIL

GLAXOSMITHKLINE

0.5%

N015868 001

SOLUTION/DROPS;OPHTHALMIC

DENDRID

+ ALCON

0.1%

N014169 001

HERPLEX

ALLERGAN

0.1%

N013935 002

STOXIL

GLAXOSMITHKLINE

0.1%

N013934 001

IFOSFAMIDE

INJECTABLE;INJECTION

IFOSFAMIDE

FRESENIUS KABI USA

1GM/20ML (50MG/ML)

A090181 001 Sep 22, 2009

3GM/60ML (50MG/ML)

A090181 002 Sep 22, 2009

MYLAN LABS LTD

1GM/20ML (50MG/ML)

A201689 001 Nov 26, 2012

3GM/60ML (50MG/ML)

A201689 002 Nov 26, 2012

IFOSFAMIDE; MESNA

INJECTABLE;INJECTION

IFEX/MESNEX KIT

BAXTER HLTHCARE

1GM/VIAL;100MG/ML

N019763 003 Oct 10, 1992

3GM/VIAL;100MG/ML

N019763 004 Oct 10, 1992

INJECTABLE;INTRAVENOUS

IFOSFAMIDE/MESNA KIT

TEVA PHARMS USA

1GM/20ML;1GM/10ML (50MG/ML;100MG/ML)

A075874 001 Feb 26, 2002

3GM/60ML;1GM/10ML (50MG/ML;100MG/ML)

A075874 002 Feb 26, 2002

ILOPERIDONE

TABLET;ORAL

ILOPERIDONE

INVENTIA

1MG

A207231 001 Nov 28, 2016

2MG

A207231 002 Nov 28, 2016

4MG

A207231 003 Nov 28, 2016

6MG

A207231 004 Nov 28, 2016

8MG

A207231 005 Nov 28, 2016

10MG

A207231 006 Nov 28, 2016

12MG

A207231 007 Nov 28, 2016

LUPIN LTD

1MG

A206890 001 May 05, 2022

2MG

A206890 002 May 05, 2022

4MG

A206890 003 May 05, 2022

6MG

A206890 004 May 05, 2022

8MG

A206890 005 May 05, 2022

10MG

A206890 006 May 05, 2022

12MG

A206890 007 May 05, 2022

TARO PHARM INDS LTD

1MG

A207098 001 Jul 22, 2019

2MG

A207098 002 Jul 22, 2019

4MG

A207098 003 Jul 22, 2019

6MG

A207098 004 Jul 22, 2019

8MG

A207098 005 Jul 22, 2019

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-258(of 478)

** See List Footnote

ILOPERIDONE

TABLET; ORAL

ILOPERIDONE

10MG

A207098 006 Jul 22, 2019

12MG

A207098 007 Jul 22, 2019

ILOPROST

SOLUTION; INHALATION

VENTAVIS

ACTELION

20MCG/2ML (10MCG/ML)

N021779 001 Dec 29, 2004

IMATINIB MESYLATE

CAPSULE; ORAL

GLEEVEC

+ NOVARTIS

EQ 50MG BASE **

N021335 001 May 10, 2001

+

EQ 100MG BASE **

N021335 002 May 10, 2001

TABLET; ORAL

IMATINIB MESYLATE

AMNEAL PHARMS

EQ 100MG BASE

A207495 001 Feb 08, 2019

EQ 400MG BASE

A207495 002 Feb 08, 2019

IMIPRAMINE HYDROCHLORIDE

CONCENTRATE; ORAL

IMIPRAMINE HYDROCHLORIDE

NOVARTIS

25MG/ML

A086765 001

INJECTABLE; INJECTION

TOFRANIL

NOVARTIS

12.5MG/ML

N011838 002

TABLET; ORAL

IMIPRAMINE HYDROCHLORIDE

CHARTWELL

10MG

A090441 002 Mar 11, 2010

25MG

A090441 003 Mar 11, 2010

50MG

A090441 001 Mar 11, 2010

LEDERLE

10MG

A086269 001

25MG

A086267 001

50MG

A086268 001

PAR PHARM

10MG

A089422 001 Jul 14, 1987

25MG

A089497 001 Jul 14, 1987

ROXANE

10MG

A083799 001

25MG

A083799 002

50MG

A083799 003

SANDOZ

10MG

A085200 001

25MG

A084869 002

50MG

A085133 001

TEVA

10MG

A083729 001

25MG

A083729 004

50MG

A083729 003

USL PHARMA

25MG

A087776 001 Feb 10, 1982

VANGARD

10MG

A088036 001 Nov 03, 1982

25MG

A087619 001 Feb 09, 1982

50MG

A087631 001 Jan 04, 1982

WATSON LABS

10MG

A085220 001

10MG

A085875 001

25MG

A084252 002

25MG

A085878 001

50MG

A085221 001

50MG

A085877 001

WEST WARD

25MG

A088222 001 May 26, 1983

50MG

A088223 001 May 26, 1983

JANIMINE

ABBOTT

10MG

N017895 001

25MG

N017895 002

50MG

N017895 003

PRAMINE

ALRA

10MG

A083827 001

25MG

A083827 002

50MG

A083827 003

PRESAMINE

SANOFI AVENTIS US

10MG

N011836 006

25MG

N011836 003

50MG

N011836 007

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-259(of 478)

** See List Footnote

IMIPRAMINE PAMOATE

CAPSULE;ORAL

IMIPRAMINE PAMOATE

RISING

EQ 75MG HYDROCHLORIDE

A202338 001 Jun 28, 2013

EQ 100MG HYDROCHLORIDE

A202338 002 Jun 28, 2013

EQ 125MG HYDROCHLORIDE

A202338 003 Jun 28, 2013

EQ 150MG HYDROCHLORIDE

A202338 004 Jun 28, 2013

TOFRANIL-PM

+ SPECGX LLC

EQ 75MG HYDROCHLORIDE **

N017090 001

+

EQ 100MG HYDROCHLORIDE **

N017090 004

+

EQ 125MG HYDROCHLORIDE **

N017090 003

+

EQ 150MG HYDROCHLORIDE **

N017090 002

IMIQUIMOD

CREAM;TOPICAL

IMIQUIMOD

COSETTE

5%

A200481 001 Apr 18, 2011

ENCUBE

5%

A091044 001 Feb 28, 2011

STRIDES PHARMA

5%

A202002 001 Jun 24, 2014

INAMRINONE LACTATE

INJECTABLE;INJECTION

AMRINONE LACTATE

BAXTER HLTHCARE CORP

EQ 5MG BASE/ML

A075542 001 May 10, 2000

HOSPIRA

EQ 5MG BASE/ML

A074616 001 Aug 03, 1998

INOCOR

SANOFI AVENTIS US

EQ 5MG BASE/ML

N018700 001 Jul 31, 1984

INDACATEROL MALEATE

POWDER;INHALATION

ARCAPTA NEOHALER

+ NOVARTIS

EQ 75MCG BASE

N022383 001 Jul 01, 2011

INDAPAMIDE

TABLET;ORAL

INDAPAMIDE

ANI PHARMS

1.25MG

A074498 002 Feb 12, 1998

1.25MG

A075201 001 Dec 04, 1998

2.5MG

A074498 001 Oct 31, 1996

2.5MG

A075201 002 Dec 04, 1998

CHARTWELL RX

1.25MG

A074594 001 May 23, 1996

2.5MG

A074594 002 May 23, 1996

MYLAN PHARMS INC

1.25MG

A075105 001 Jul 23, 1998

2.5MG

A075105 002 Jul 23, 1998

RISING

1.25MG

A074461 002 Mar 26, 1997

2.5MG

A074461 001 Mar 27, 1996

TEVA

1.25MG

A074665 001 Apr 04, 1997

2.5MG

A074665 002 Apr 04, 1997

WATSON LABS

1.25MG

A074585 001 Sep 26, 1996

2.5MG

A074585 002 Sep 26, 1996

LOZOL

+ SANOFI AVENTIS US

1.25MG **

N018538 002 Apr 29, 1993

+

2.5MG **

N018538 001 Jul 06, 1983

INDECAINIDE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

DECABID

LILLY

EQ 50MG BASE

N019693 001 Dec 29, 1989

EQ 75MG BASE

N019693 002 Dec 29, 1989

EQ 100MG BASE

N019693 003 Dec 29, 1989

INDINAVIR SULFATE

CAPSULE;ORAL

CRIXIVAN

MERCK SHARP DOHME

EQ 100MG BASE

N020685 006 Apr 19, 2000

+

EQ 200MG BASE

N020685 003 Mar 13, 1996

EQ 333MG BASE

N020685 005 Dec 17, 1998

+

EQ 400MG BASE

N020685 001 Mar 13, 1996

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-260(of 478)

** See List Footnote

INDIUM IN-111 CHLORIDE

INJECTABLE; INJECTION

INDICLOR

+ GE HEALTHCARE

2mCi/0.2ML

N019862 001 Dec 29, 1992

INDOCYANINE GREEN

INJECTABLE; INJECTION

IC-GREEN

AKORN

10MG/VIAL **

N011525 003

40MG/VIAL **

N011525 004

50MG/VIAL **

N011525 002

INDOMETHACIN

CAPSULE; ORAL

INDO-LEMMON

TEVA

25MG

A070266 001 Nov 07, 1985

50MG

A070267 001 Nov 07, 1985

INDOCIN

+ EGALET

25MG **

N016059 001

+

50MG **

N016059 002

INDOMETHACIN

ABLE

25MG

A076666 001 Dec 17, 2003

50MG

A076666 002 Dec 17, 2003

ANI PHARMS

25MG

A071148 001 Mar 18, 1987

50MG

A071149 001 Mar 18, 1987

CHARTWELL MOLECULES

25MG

N018829 002 Aug 06, 1984

50MG

N018829 001 Aug 06, 1984

CYCLE

25MG

A070353 001 Jun 18, 1985

50MG

A070354 001 Jun 18, 1985

DURAMED PHARMS BARR

25MG

A070326 001 Oct 18, 1985

50MG

A070327 001 Oct 18, 1985

HALSEY

25MG

A070782 001 Jun 03, 1987

50MG

A070635 001 Jun 03, 1987

HERITAGE PHARMA

25MG

A070719 001 Feb 12, 1986

50MG

A070756 001 Feb 12, 1986

HERITAGE PHARMS

25MG

N018851 001 May 18, 1984

50MG

N018851 002 May 18, 1984

IVAX SUB TEVA PHARMS

25MG

N018730 001 May 04, 1984

50MG

N018730 002 May 04, 1984

JUBILANT GENERICS

25MG

A205215 001 Aug 25, 2017

50MG

A205215 002 Aug 25, 2017

MUTUAL PHARM

25MG

A070067 001 Oct 03, 1986

50MG

A070068 001 Oct 03, 1986

PARKE DAVIS

25MG

N018806 001 Nov 23, 1984

50MG

N018806 002 Nov 23, 1984

PIONEER PHARMS

25MG

A070813 001 Aug 11, 1986

50MG

A070592 001 Aug 11, 1986

RISING

25MG

N018858 001 Apr 20, 1984

50MG

A070624 001 Sep 04, 1985

50MG

N018858 002 Apr 20, 1984

SUN PHARM INDS INC

25MG

A091401 001 Mar 28, 2013

50MG

A091401 002 Mar 28, 2013

SUN PHARM INDUSTRIES

25MG

A070900 002 Feb 09, 1987

50MG

A070900 001 Feb 09, 1987

SUPERPHARM

25MG

A070487 001 Oct 10, 1986

50MG

A070488 001 Oct 10, 1986

TEVA

25MG

A071342 001 Apr 18, 1988

50MG

A071343 001 Apr 18, 1988

WATSON LABS

25MG

A070529 001 Oct 18, 1985

25MG

A070784 001 Aug 20, 1986

25MG

A072996 001 Jul 31, 1991

25MG

N018690 001 Jul 31, 1984

50MG

A070530 001 Oct 18, 1985

50MG

A070785 001 Aug 20, 1986

50MG

A071635 001 May 18, 1987

50MG

A072997 001 Jul 31, 1991

50MG

N018690 002 Jul 31, 1984

TIVORBEX

+ GENUS

20MG

N204768 001 Feb 24, 2014

+

40MG

N204768 002 Feb 24, 2014

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-261(of 478)

** See List Footnote

INDOMETHACIN

CAPSULE, EXTENDED RELEASE;ORAL

INDOCIN SR

+ EGALET 75MG ** N018185 001 Feb 23, 1982

INDOMETHACIN

ABLE 75MG A076114 001 Feb 06, 2002

AUROBINDO PHARMA 75MG A204243 001 Dec 27, 2016

INWOOD LABS 75MG A072410 001 Mar 15, 1989

JUBILANT GENERICS 75MG A202706 001 Oct 05, 2015

RISING 75MG A202139 001 Mar 20, 2014

WATSON LABS INC 75MG A202572 001 Dec 09, 2013

SUPPOSITORY;RECTAL

INDOCIN

+ EGALET 50MG ** N017814 001 Aug 13, 1984

SUSPENSION;ORAL

INDOMETHACIN

HIKMA 25MG/5ML A071412 001 Mar 18, 1987

INDOMETHACIN SODIUM

INJECTABLE;INJECTION

INDOCIN

+ RECORDATI RARE EQ 1MG BASE/VIAL ** N018878 001 Jan 30, 1985

INGENOL MEBUTATE

GEL;TOPICAL

INGENOL MEBUTATE

PADAGIS ISRAEL 0.015% A209018 001 Jan 07, 2019

0.05% A209019 001 Jan 09, 2019

PICATO

+ LEO LABS 0.015% N202833 001 Jan 23, 2012

+ 0.05% N202833 002 Jan 23, 2012

INULIN

INJECTABLE;INJECTION

INULIN AND SODIUM CHLORIDE

ISO TEX 100MG/ML N002282 001

INVERT SUGAR

INJECTABLE;INJECTION

TRAVERT 10% IN PLASTIC CONTAINER

BAXTER HLTHCARE 10GM/100ML N016717 001

IOBENGUANE SULFATE I-131

INJECTABLE;INJECTION

IOBENGUANE SULFATE I 131

PHARMALUCENCE 2.3mCi/ML N020084 001 Mar 25, 1994

IO CETAMIC ACID

TABLET;ORAL

CHOLEBRINE

MALLINCKRODT 750MG N017129 001

IODAMIDE MEGLUMINE

INJECTABLE;INJECTION

RENOVUE-65

BRACCO 65% N017902 001

RENOVUE-DIP

BRACCO 24% N017903 001

IODIPAMIDE MEGLUMINE

INJECTABLE;INJECTION

CHOLOGRAFIN MEGLUMINE

BRACCO 10.3% N009321 007

+ 52% N009321 003

IODIPAMIDE SODIUM

INJECTABLE;INJECTION

CHOLOGRAFIN SODIUM

BRACCO 20% N009321 001

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-262(of 478)

** See List Footnote

IODIXANOL

INJECTABLE; INJECTION

VISIPAQUE 270

GE HEALTHCARE

55%

N020808 001 Aug 29, 1997

IODOHIPPURATE SODIUM I-123

INJECTABLE; INJECTION

NEPHROFLOW

GE HEALTHCARE

1mCi/ML

N018289 001 Dec 28, 1984

IODOHIPPURATE SODIUM I-131

INJECTABLE; INJECTION

HIPURAN I 131

MALLINCKRODT

0.25mCi/ML

N016666 001

HIPPUTOPE

BRACCO

1-2mCi/VIAL

N015419 002

IODOHIPPURATE SODIUM I 131

PHARMALUCENCE

0.2mCi/ML

N017313 001

IODOXAMATE MEGLUMINE

INJECTABLE; INJECTION

CHOLOVUE

BRACCO

9.9%

N018077 001

40.3%

N018076 001

IOFETAMINE HYDROCHLORIDE I-123

INJECTABLE; INJECTION

SPECTAMINE

IMP

1mCi/ML

N019432 001 Dec 24, 1987

IOHEXOL

FOR SOLUTION; ORAL

ORALTAG

INTERPHARMA PRAHA AS 9.7GM/BOT

N205383 001 Mar 26, 2015

INJECTABLE; INJECTION

OMNIPAQUE 210

GE HEALTHCARE

45.3%

N018956 006 Jun 30, 1989

SOLUTION; INJECTION, ORAL, RECTAL

OMNIPAQUE 240

GE HEALTHCARE

51.8%

N020608 001 Oct 24, 1995

SOLUTION; URETHRAL

OMNIPAQUE 70

GE HEALTHCARE

15.1%

N018956 007 Jun 01, 1994

IOPAMIDOL

INJECTABLE; INJECTION

IOPAMIDOL

BAXTER HLTHCARE

41%

A074629 001 Nov 06, 1996

51%

A074629 004 Mar 31, 1998

61%

A074629 002 Nov 06, 1996

76%

A074629 003 Nov 06, 1996

HOSPIRA

61%

A074734 001 Dec 10, 1996

76%

A074734 002 Dec 10, 1996

IOPAMIDOL-200

COOK IMAGING

41%

A074881 001 Jul 28, 2000

HOSPIRA

41%

A074898 001 Dec 30, 1997

IOPAMIDOL-200 IN PLASTIC CONTAINER

HOSPIRA

41%

A074636 001 Dec 30, 1997

IOPAMIDOL-250

COOK IMAGING

51%

A074881 002 Jul 28, 2000

FRESENIUS KABI USA

51%

A074679 001 Apr 02, 1997

HOSPIRA

51%

A074898 002 Dec 30, 1997

51%

A075005 001 Feb 24, 1998

IOPAMIDOL-250 IN PLASTIC CONTAINER

HOSPIRA

51%

A074636 002 Dec 30, 1997

IOPAMIDOL-300

ABBVIE

61%

A074638 001 Apr 30, 1997

COOK IMAGING

61%

A074881 003 Jul 28, 2000

FRESENIUS KABI USA

61%

A074679 002 Apr 02, 1997

HOSPIRA

61%

A074898 003 Dec 30, 1997

61%

A075005 002 Feb 24, 1998

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-263(of 478)

** See List Footnote

IOPAMIDOL

INJECTABLE; INJECTION

IOPAMIDOL-300 IN PLASTIC CONTAINER

HOSPIRA	61%	A074636 003	Dec 30, 1997
	61%	A074637 001	Apr 03, 1997

IOPAMIDOL-370

COOK IMAGING	76%	A074881 004	Jul 28, 2000
FRESENIUS KABI USA	76%	A074679 003	Apr 02, 1997
HOSPIRA	76%	A074898 004	Dec 30, 1997
	76%	A075005 003	Feb 24, 1998

IOPAMIDOL-370 IN PLASTIC CONTAINER

HOSPIRA	76%	A074636 004	Dec 30, 1997

ISOVUE-128

BRACCO	26%	N018735 005	Oct 21, 1986

ISOVUE-200

BRACCO	41%	N020327 001	Oct 12, 1994

SCANLUX-300

SANOCHEMIA CORP USA	61%	A090394 001	Jun 18, 2010

SCANLUX-370

SANOCHEMIA CORP USA	76%	A090394 002	Jun 18, 2010

IOPANOIC ACID

TABLET; ORAL

TELEPAQUE

GE HEALTHCARE	500MG	N008032 001	

IOPHENDYLATE

INJECTABLE; INJECTION

PANTOPAQUE

ALCON	100%	N005319 001	

IOPROMIDE

INJECTABLE; INJECTION

ULTRAVIST (PHARMACY BULK)

+ BAYER HLTHCARE	49.9%	N021425 003	Mar 12, 2004

ULTRAVIST 150

+ BAYER HLTHCARE	31.2%	N020220 004	May 10, 1995

ULTRAVIST 240

+ BAYER HLTHCARE	49.9%	N020220 003	May 10, 1995

ULTRAVIST 300 IN PLASTIC CONTAINER

+ BAYER HLTHCARE	62.3%	N020220 005	Nov 18, 2008

IOTHALAMATE MEGLUMINE

INJECTABLE; INJECTION

CONRAY 30

+ LIEBEL-FLARSHEIM	30%	N016983 001	

CONRAY 43

+ LIEBEL-FLARSHEIM	43%	N013295 002	

IOTHALAMATE MEGLUMINE; IOTHALAMATE SODIUM

INJECTABLE; INJECTION

VASCORAY

MALLINCKRODT	52%; 26%	N016783 001	

IOTHALAMATE SODIUM

INJECTABLE; INJECTION

ANGIO-CONRAY

MALLINCKRODT	80%	N013319 001	

CONRAY 325

MALLINCKRODT	54.3%	N017685 001	

CONRAY 400

MALLINCKRODT	66.8%	N014295 001	

IOTROLAN

INJECTABLE; INTRATHECAL

OSMOVIST 190

BAYER HLTHCARE	40.6%	N019580 001	Dec 07, 1989

OSMOVIST 240

BAYER HLTHCARE	51.3%	N019580 002	Dec 07, 1989

DISCONTINUED DRUG PRODUCT LIST

6-264(of 478)

** See List Footnote

IOVERSOL

INJECTABLE; INJECTION

OPTIRAY 160

LIEBEL-FLARSHEIM 34%

N019710 003 Dec 30, 1988

OPTIRAY 240

+ LIEBEL-FLARSHEIM 51%
51%

N019710 002 Dec 30, 1988

N020923 001 May 28, 1998

IOXAGLATE MEGLUMINE; IOXAGLATE SODIUM

INJECTABLE; INJECTION

HEXABRIX

GUERBET 39.3%;19.6%

N018905 002 Jul 26, 1985

IOXILAN

INJECTABLE; INJECTION

OXILAN-300

GUERBET 62%

N020316 001 Dec 21, 1995

OXILAN-350

GUERBET 73%

N020316 002 Dec 21, 1995

IPODATE CALCIUM

GRANULE; ORAL

ORAGRAFIN CALCIUM

BRACCO 3GM/PACKET

N012968 001

IPODATE SODIUM

CAPSULE; ORAL

BILIVIST

BAYER HLTHCARE 500MG

A087768 001 Aug 11, 1982

ORAGRAFIN SODIUM

BRACCO 500MG

N012967 001

IPRATROPIUM BROMIDE

AEROSOL, METERED; INHALATION

ATROVENT

BOEHRINGER INGELHEIM 0.018MG/INH

N019085 001 Dec 29, 1986

SOLUTION; INHALATION

ATROVENT

+ BOEHRINGER INGELHEIM 0.02% **

N020228 001 Sep 29, 1993

IPRATROPIUM BROMIDE

ACTAVIS MID ATLANTIC 0.02%

A075111 001 Apr 22, 1999

APOTEX INC 0.02%

A075441 001 Mar 28, 2001

BAUSCH 0.02%

A075835 001 Oct 15, 2001

LANDELA PHARM 0.02%

A077072 001 Jul 19, 2005

MYLAN SPECIALITY LP 0.02%

A074755 001 Jan 10, 1997

ROXANE 0.02%

A075867 001 Jul 22, 2002

TEVA PHARMS USA 0.02%

A075313 001 Feb 07, 2000

WATSON LABS 0.02%

A076291 001 May 09, 2005

ZENNOVA 0.02%

A075507 001 Jan 19, 2001

SPRAY, METERED; NASAL

ATROVENT

+ BOEHRINGER INGELHEIM 0.021MG/SPRAY **

N020393 001 Oct 20, 1995

+ 0.042MG/SPRAY **

N020394 001 Oct 20, 1995

IPRATROPIUM BROMIDE

MYLAN SPECIALITY LP 0.021MG/SPRAY

A075552 001 Mar 31, 2003

0.042MG/SPRAY

A075553 001 Mar 31, 2003

IRBESARTAN

TABLET; ORAL

IRBESARTAN

AJANTA PHARMA LTD 75MG

A203685 001 Dec 10, 2015

150MG

A203685 002 Dec 10, 2015

300MG

A203685 003 Dec 10, 2015

APOTEX INC 75MG

A200832 001 Oct 15, 2012

150MG

A200832 002 Oct 15, 2012

300MG

A200832 003 Oct 15, 2012

APPCO 75MG

A200461 001 Sep 27, 2012

150MG

A200461 002 Sep 27, 2012

300MG

A200461 003 Sep 27, 2012

HIKMA 75MG

A090201 001 Oct 15, 2012

150MG

A090201 002 Oct 15, 2012

300MG

A090201 003 Oct 15, 2012

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-265(of 478)

** See List Footnote

IRBESARTAN

TABLET; ORAL

IRBESARTAN

PICKET PHARMS	75MG	A203161 001	Sep 27, 2012
	150MG	A203161 002	Sep 27, 2012
	300MG	A203161 003	Sep 27, 2012
UNICHEM	75MG	A203020 001	Dec 07, 2015
	150MG	A203020 002	Dec 07, 2015
	300MG	A203020 003	Dec 07, 2015
WATSON LABS INC	75MG	A090720 001	Oct 12, 2012
	150MG	A090720 002	Oct 12, 2012
	300MG	A090720 003	Oct 12, 2012

IRINOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION

IRINOTECAN HYDROCHLORIDE

CIPLA LTD	40MG/2ML (20MG/ML)	A077219 001	Feb 20, 2008
	100MG/5ML (20MG/ML)	A077219 002	Feb 20, 2008
EMCURE PHARMS LTD	40MG/2ML (20MG/ML)	A200771 001	Feb 14, 2012
	100MG/5ML (20MG/ML)	A200771 002	Feb 14, 2012
FRESENIUS KABI USA	40MG/2ML (20MG/ML)	A078188 001	Feb 27, 2008
	100MG/5ML (20MG/ML)	A078188 002	Feb 27, 2008
PICKET PHARMS	40MG/2ML (20MG/ML)	A078953 001	Apr 15, 2010
	100MG/5ML (20MG/ML)	A078953 002	Apr 15, 2010
PLIVA LACHEMA	40MG/2ML (20MG/ML)	A078122 001	Oct 31, 2008
	100MG/5ML (20MG/ML)	A078122 002	Oct 31, 2008
SANDOZ	40MG/2ML (20MG/ML)	A077994 001	Feb 27, 2008
	100MG/5ML (20MG/ML)	A077994 002	Feb 27, 2008
SANDOZ INC	40MG/2ML (20MG/ML)	A090137 001	Nov 12, 2009
	100MG/5ML (20MG/ML)	A090137 002	Nov 12, 2009
SUN PHARMA GLOBAL	40MG/2ML (20MG/ML)	A078805 001	Apr 21, 2008
	100MG/5ML (20MG/ML)	A078805 002	Apr 21, 2008
TEVA PHARMS USA	40MG/2ML (20MG/ML)	A090101 002	Feb 27, 2008
	100MG/5ML (20MG/ML)	A090101 003	Feb 27, 2008

ISOETHARINE HYDROCHLORIDE

SOLUTION; INHALATION

BETA-2

NEPHRON	1%	A086711 001	
BRONKOSOL			
SANOFI AVENTIS US	0.25%	N012339 009	
	1%	N012339 008	
ISOETHARINE HYDROCHLORIDE			
ALPHARMA US PHARMS	1%	A087101 001	
+ ASTRAZENECA	0.062%	A087937 001	Nov 15, 1982
	0.062%	A089614 001	Jun 13, 1991
+	0.125%	A087938 001	Nov 15, 1982
	0.125%	A089615 001	Jun 13, 1991
+	0.167%	A088470 001	Mar 14, 1984
	0.167%	A089616 001	Jun 13, 1991
+	0.2%	A088471 001	Mar 14, 1984
	0.2%	A089617 001	Jun 13, 1991
+	0.25%	A088472 001	Mar 14, 1984
	0.25%	A089618 001	Jun 13, 1991
BAXTER HLTHCARE	0.08%	A088144 001	Jul 29, 1983
	0.14%	A088145 001	Mar 26, 1984
	0.25%	A088146 001	Aug 01, 1983
DEY	0.08%	A088187 001	Dec 03, 1982
	0.1%	A087389 001	
	0.17%	A087390 001	
	0.25%	A088188 001	Dec 03, 1982
+	1%	A086763 001	
INTL MEDICATION	0.077%	A086651 001	
	0.08%	A086651 002	
	0.1%	A086651 003	
	0.143%	A086651 004	
	0.167%	A086651 005	
	0.2%	A086651 006	
	0.25%	A086651 007	
	1%	A086651 008	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-266(of 478)

** See List Footnote

ISOETHARINE HYDROCHLORIDE

SOLUTION; INHALATION

ISOETHARINE HYDROCHLORIDE

PARKE DAVIS	0.5%	A085997	001	
	1%	A085889	001	
ROXANE	0.1%	A087396	001	
	0.125%	A087025	001	
	0.167%	A088226	001	Sep 16, 1983
	0.2%	A087324	001	
	0.25%	A088275	001	Jun 03, 1983
	1%	A086899	001	
ISOETHARINE HYDROCHLORIDE S/F				
DEY	0.08%	A089817	001	Nov 22, 1988
	0.1%	A089818	001	Nov 22, 1988
	0.17%	A089819	001	Nov 22, 1988
	0.25%	A089820	001	Nov 22, 1988
	1%	A089252	001	Sep 15, 1986

ISOETHARINE MESYLATE

AEROSOL, METERED; INHALATION

BRONKOMETER

SANOFI AVENTIS US	0.34MG/INH	N012339	007	
ISOETHARINE MESYLATE				
ALPHARMA US PHARMS	0.34MG/INH	A087858	001	Aug 21, 1984

ISOFLURANE

LIQUID; INHALATION

ISOFLURANE

HOSPIRA	99.9%	A074097	001	Jan 25, 1993
WATSON LABS INC	99.9%	A074393	001	May 12, 1995

ISOFLUROPHATE

OINTMENT; OPHTHALMIC

FLOROPRYL

MERCK	0.025%	N010656	001	

ISONIAZID

INJECTABLE; INJECTION

NYDRAZID

SANDOZ	100MG/ML **	N008662	001	
RIMIFON				
ROCHE	25MG/ML	N008420	002	
	100MG/ML	N008420	003	

SYRUP; ORAL

ISONIAZID

CHARTWELL RX	50MG/5ML	A081118	001	Jul 21, 1997
LANIAZID				
LANNETT	50MG/5ML	A089243	001	Feb 03, 1986
RIMIFON				
ROCHE	50MG/5ML	N008420	001	

TABLET; ORAL

DOW-ISONIAZID

DOW PHARM	300MG	A080330	002	

HYZYD

MEDPOINTE PHARM HLC	100MG	A080134	003	
	300MG	A080134	004	

INH

NOVARTIS	300MG	A080935	001	

ISONIAZID

DURAMED PHARMS BARR	100MG	A088231	001	Mar 17, 1983
	300MG	A088119	001	Mar 17, 1983
+ EPIC PHARMA LLC	100MG **	N008678	002	
+	300MG **	N008678	003	
HALSEY	50MG	A083632	001	
HIKMA INTL PHARMS	100MG	A080212	001	
	300MG	A087425	001	
IMPAX LABS	100MG	A080153	001	
IVAX SUB TEVA PHARMS	100MG	A080270	001	
	300MG	A083610	001	
LILLY	100MG	N008499	002	
	300MG	N008499	003	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-267(of 478)

** See List Footnote

ISONIAZID

TABLET;ORAL

ISONIAZID

MK LABS	100MG	A080941	001	
NEXGEN PHARMA INC	100MG	A084050	001	
PANRAY	50MG	N008428	001	
	100MG	N008428	002	
	300MG	N008428	003	
PERRIGO	100MG	A083060	001	
PHARMAVITE	100MG	A085091	001	
PHOENIX LABS NY	50MG	A080368	001	
	100MG	A080368	002	
PUREPAC PHARM	50MG	A080132	003	Jul 14, 1982
	100MG	A080132	004	Jul 14, 1982
SUN PHARM INDUSTRIES	100MG	A080136	001	
	300MG	A083633	001	
WATSON LABS	50MG	A080522	001	
	100MG	A080401	001	
	100MG	A080523	001	
	100MG	A085790	001	
	300MG	A080521	001	
	300MG	A083178	001	
	300MG	A085784	001	
WHITEWORTH TOWN PLSN	100MG	A080120	002	
LANIAZID				
CHARTWELL MOLECULAR	300MG	A089776	001	Jun 13, 1988
LANNETT	50MG	A080140	001	
	100MG	A080140	002	
NYDRAZID				
BRISTOL MYERS SQUIBB	100MG	N008392	003	
STANOZIDE				
EVERYLIFE	100MG	A080126	001	
	300MG	A080126	002	

ISONIAZID; PYRAZINAMIDE; RIFAMPIN

TABLET;ORAL

RIFATER

+	SANOFI AVENTIS US	50MG;300MG;120MG	N050705	001	May 31, 1994

ISONIAZID; RIFAMPIN

CAPSULE;ORAL

RIFAMATE

SANOFI AVENTIS US	150MG;300MG	A061884	001	
RIFAMPIN AND ISONIAZID				
HIKMA INTL PHARMS	150MG;300MG	A065221	001	Jul 29, 2005

ISOPROPAMIDE IODIDE

TABLET;ORAL

DARBID

GLAXOSMITHKLINE	EQ 5MG BASE	N010744	001	

ISOPROTERENOL HYDROCHLORIDE

AEROSOL, METERED;INHALATION

ISOPROTERENOL HYDROCHLORIDE

3M	0.12MG/INH	N010375	004	
ALPHARMA US PHARMS	0.12MG/INH	A085904	001	

ISUPREL

SANOFI AVENTIS US	0.103MG/INH	N011178	001	

DISC;INHALATION

NORISODRINE AEROTROL

ABBOTT	0.25%	N016814	001	

INJECTABLE;INJECTION

ISOPROTERENOL HYDROCHLORIDE

ABRAXIS PHARM	0.2MG/ML	A083431	001	
BAXTER HLTHCARE	0.2MG/ML	A083486	001	
CIPLA	0.2MG/ML	A211738	001	Jun 28, 2019
HOSPIRA	0.02MG/ML	A083283	001	
	0.2MG/ML	A083346	001	
INTL MEDICATION	0.2MG/ML	A083724	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-268(of 478)

** See List Footnote

ISOPROTERENOL HYDROCHLORIDE

SOLUTION; INHALATION

AEROLONE

LILLY 0.25% N007245 001

ISOPROTERENOL HYDROCHLORIDE

ARMOUR PHARM 0.031% A087935 001 Nov 18, 1982

0.062% A087936 001 Nov 18, 1982

DEY 0.5% A086764 001 Jan 04, 1982

PARKE DAVIS 0.25% A085994 001

0.5% A085540 001

ISUPREL

SANOFI AVENTIS US 0.5% N006327 002

1% N006327 003

VAPO-ISO

FISONS 0.5% N016813 001

TABLET; RECTAL, SUBLINGUAL

ISUPREL

SANOFI AVENTIS US 10MG N006328 001

15MG N006328 002

ISOPROTERENOL HYDROCHLORIDE; PHENYLEPHRINE BITARTRATE

AEROSOL, METERED; INHALATION

DUO-MEDIHALER

3M 0.16MG/INH; 0.24MG/INH N013296 001

ISOPROTERENOL SULFATE

AEROSOL, METERED; INHALATION

MEDIHALER-ISO

3M 0.08MG/INH N010375 003

POWDER; INHALATION

NORISODRINE

ABBVIE 10% N006905 003

25% N006905 002

ISOSORBIDE

SOLUTION; ORAL

ISMOTIC

ALCON 100GM/220ML N017063 001

ISOSORBIDE DINITRATE

CAPSULE, EXTENDED RELEASE; ORAL

DILATRATE-SR

+ AUXILIUM PHARMS LLC 40MG N019790 001 Sep 02, 1988

ISORDIL

WYETH AYERST 40MG N012882 002 Jul 29, 1988

TABLET; ORAL

ISORDIL

+ BAUSCH 10MG ** N012093 002 Jul 29, 1988

+ 20MG ** N012093 006 Jul 29, 1988

+ 30MG ** N012093 005 Jul 29, 1988

ISOSORBIDE DINITRATE

ANI PHARMS 10MG A086032 001 Jan 07, 1988

HIKMA INTL PHARMS 30MG A040591 001 Jan 10, 2007

SUN PHARM INDUSTRIES 5MG A086166 002 Sep 19, 1986

10MG A086169 001 Sep 19, 1986

20MG A086167 001 Sep 19, 1986

30MG A087564 001 Sep 18, 1986

SUPERPHARM 5MG A089190 001 Feb 17, 1987

10MG A089191 001 Feb 17, 1987

20MG A089192 001 Feb 17, 1987

WATSON LABS 5MG A086034 001 Jan 06, 1988

SORBITRATE

ASTRAZENECA 5MG N016192 001 Apr 01, 1996

10MG N016192 002 Apr 01, 1996

20MG A086405 002 Aug 21, 1990

30MG A088124 001 Aug 21, 1990

40MG A088125 001 Aug 21, 1990

TABLET; SUBLINGUAL

ISORDIL

+ BIOVAIL 2.5MG ** N012940 004 Jul 29, 1988

+ 5MG ** N012940 003 Jul 29, 1988

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-269(of 478)

** See List Footnote

ISOSORBIDE DINITRATE

TABLET;SUBLINGUAL

ISORDIL

+

10MG **

N012940 005 Jul 29, 1988

ISOSORBIDE DINITRATE

HIKMA INTL PHARMS

2.5MG

A086054 001 Oct 29, 1987

5MG

A086055 001 Nov 02, 1987

SANDOZ

2.5MG

A086225 001 Feb 19, 1988

5MG

A086222 001 Feb 19, 1988

SUN PHARM INDUSTRIES

2.5MG

A084204 001 Sep 18, 1986

5MG

A086168 001 Sep 18, 1986

10MG

A087545 001 Sep 18, 1986

WATSON LABS

2.5MG **

A086033 001 Feb 26, 1988

WATSON LABS TEVA

5MG **

A086031 001 Sep 29, 1987

SORBITRATE

ASTRAZENECA

2.5MG

N016191 002 Apr 01, 1996

5MG

N016191 001 Apr 01, 1996

TABLET, CHEWABLE;ORAL

SORBITRATE

ASTRAZENECA

5MG

N016776 002 Apr 01, 1996

10MG

N016776 003 Apr 01, 1996

TABLET, EXTENDED RELEASE;ORAL

ISORDIL

WYETH AYERST

40MG

N012882 001 Jul 29, 1988

ISOSORBIDE DINITRATE

IMPAX LABS INC

40MG

A040723 001 Mar 17, 2008

ISOSORBIDE MONONITRATE

TABLET;ORAL

ISMO

PROMIUS PHARMA

20MG

N019091 001 Dec 30, 1991

ISOSORBIDE MONONITRATE

ANI PHARMS

20MG

A075147 001 Nov 27, 1998

HIKMA PHARMS

20MG

A075361 001 Oct 05, 2000

TABLET, EXTENDED RELEASE;ORAL

IMDUR

+

SCHERING PLOUGH

30MG **

N020225 001 Aug 12, 1993

+

60MG **

N020225 002 Aug 12, 1993

+

120MG **

N020225 003 Mar 30, 1995

ISOSORBIDE MONONITRATE

ACCORD HLTHCARE

30MG

A209684 001 Oct 24, 2017

60MG

A209684 002 Oct 24, 2017

120MG

A209684 003 Oct 24, 2017

ACTAVIS ELIZABETH

30MG

A075306 001 Dec 31, 1998

60MG

A075306 002 Dec 31, 1998

ALKERMES GAINESVILLE

60MG

A075041 001 Sep 22, 1998

HIKMA INTL PHARMS

30MG

A076813 002 Mar 30, 2006

60MG

A076813 001 Jan 07, 2005

IVAX SUB TEVA PHARMS

30MG

A075448 002 Aug 07, 2001

60MG

A075448 001 Jun 19, 2000

120MG

A075448 003 Aug 07, 2001

SKYEPHARMA AG

60MG

A075166 001 Oct 07, 1999

STRIDES PHARMA

30MG

A090598 001 Aug 11, 2010

60MG

A090598 002 Aug 11, 2010

120MG

A090598 003 Aug 11, 2010

ISOSULFAN BLUE

INJECTABLE;INJECTION

ISOSULFAN BLUE

BELOTECA INC

1%

A210714 001 Jan 16, 2019

EUGIA PHARMA

1%

A206831 001 Feb 02, 2016

FRESENIUS KABI USA

1%

A211869 001 Sep 08, 2022

SOMERSET THERAPS LLC

1%

A210558 001 Jul 12, 2019

LYMPHAZURIN

+

COVIDIEN

1% **

N018310 001

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-270(of 478)

** See List Footnote

ISOTRETINOIN

CAPSULE;ORAL

ABSORICA LD

+ SUN PHARM

20MG

N211913 003 Nov 05, 2019

+

28MG

N211913 005 Nov 05, 2019

ACUTANE

+ HOFFMANN LA ROCHE

10MG **

N018662 002 May 07, 1982

+

20MG **

N018662 004 Mar 28, 1983

+

40MG **

N018662 003 May 07, 1982

SOTRET

SUN PHARM INDS LTD

10MG

A076041 001 Dec 24, 2002

20MG

A076041 002 Dec 24, 2002

30MG

A076503 001 Jun 20, 2003

40MG

A076041 003 Dec 24, 2002

ISRADIPINE

CAPSULE;ORAL

DYNACIRC

+ SMITHKLINE BEECHAM

2.5MG **

N019546 001 Dec 20, 1990

+

5MG **

N019546 002 Dec 20, 1990

TABLET, EXTENDED RELEASE;ORAL

DYNACIRC CR

+ GLAXOSMITHKLINE LLC

5MG **

N020336 001 Jun 01, 1994

+

10MG **

N020336 002 Jun 01, 1994

ISRADIPINE

MYLAN

5MG

A201067 001 Nov 27, 2015

10MG

A201067 002 Nov 27, 2015

ITRACONAZOLE

CAPSULE;ORAL

ITRACONAZOLE

JUBILANT GENERICS

100MG

A203445 001 Feb 23, 2017

MYLAN PHARMS INC

100MG

A200463 001 Jul 20, 2012

STRIDES PHARMA

100MG

A206410 001 Jul 02, 2019

INJECTABLE;INJECTION

SPORANOX

JANSSEN PHARMS

10MG/ML

N020966 001 Mar 30, 1999

SOLUTION;ORAL

ITRACONAZOLE

APOTEX

10MG/ML

A208481 001 Aug 02, 2019

TABLET;ORAL

ONMEL

+ SEBELA IRELAND LTD

200MG

N022484 001 Apr 29, 2010

IVABRADINE HYDROCHLORIDE

TABLET;ORAL

IVABRADINE HYDROCHLORIDE

INGENUS PHARMS LLC

EQ 5MG BASE

A214051 001 Dec 30, 2021

EQ 7.5MG BASE

A214051 002 Dec 30, 2021

IVERMECTIN

CREAM;TOPICAL

IVERMECTIN

PADAGIS ISRAEL

1%

A210225 001 Apr 13, 2020

LOTION;TOPICAL

IVERMECTIN

TEVA PHARMS USA

0.5%

A212485 001 Mar 21, 2022

TABLET;ORAL

STROMEKTOL

+ MERCK SHARP DOHME

6MG **

N050742 001 Nov 22, 1996

KANAMYCIN SULFATE

CAPSULE;ORAL

KANTREX

APOTHECON

EQ 500MG BASE

A060516 001

EQ 500MG BASE

A061911 001

EQ 500MG BASE

A062726 001 Mar 06, 1987

INJECTABLE;INJECTION

KANAMYCIN

HIKMA

EQ 75MG BASE/2ML

A062324 001

EQ 500MG BASE/2ML

A062324 002

EQ 1GM BASE/3ML

A062324 003

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-271(of 478)

** See List Footnote

KANAMYCIN SULFATE

INJECTABLE; INJECTION

KANAMYCIN SULFATE

ABRAXIS PHARM	EQ 75MG BASE/2ML	A062504 001	Apr 05, 1984
	EQ 500MG BASE/2ML	A062504 002	Apr 05, 1984
	EQ 1GM BASE/3ML	A062504 003	Apr 05, 1984
FRESENIUS KABI USA	EQ 500MG BASE/2ML	A065111 001	Dec 17, 2002
	EQ 1GM BASE/3ML	A065111 002	Dec 17, 2002
INTL MEDICATION	EQ 500MG BASE/2ML	A062466 001	Sep 30, 1983
	EQ 1GM BASE/3ML	A062466 002	Sep 30, 1983
LOCH	EQ 75MG BASE/2ML	A063021 001	Jul 31, 1992
	EQ 500MG BASE/2ML	A063022 001	Jul 31, 1992
	EQ 1GM BASE/3ML	A063025 001	Jul 31, 1992
PHARMAFAIR	EQ 75MG BASE/2ML	A062668 001	May 07, 1987
	EQ 500MG BASE/2ML	A062672 001	May 07, 1987
	EQ 1GM BASE/3ML	A062669 001	May 07, 1987
SOLOPAK	EQ 75MG BASE/2ML	A062605 003	Feb 26, 1986
	EQ 500MG BASE/2ML	A062605 001	Feb 26, 1986
	EQ 1GM BASE/3ML	A062605 002	Feb 26, 1986
WARNER CHILCOTT	EQ 1GM BASE/3ML	A063092 001	Oct 11, 1989
WATSON LABS	EQ 1GM BASE/3ML	A062520 003	May 09, 1985
KANTREX			
APOTHECON	EQ 75MG BASE/2ML	A061655 003	
	EQ 75MG BASE/2ML	A061901 003	
	EQ 75MG BASE/2ML	A062564 001	Sep 21, 1984
	EQ 500MG BASE/2ML	A061655 001	
	EQ 500MG BASE/2ML	A061901 001	
	EQ 500MG BASE/2ML	A062564 002	Sep 21, 1984
	EQ 1GM BASE/3ML	A061655 002	
	EQ 1GM BASE/3ML	A061901 002	
	EQ 1GM BASE/3ML	A062564 003	Sep 21, 1984
KLEBCIL			
KING PHARMS	EQ 75MG BASE/2ML	A062170 001	
	EQ 500MG BASE/2ML	A062170 002	
	EQ 1GM BASE/3ML	A062170 003	

KETOCONAZOLE

CREAM; TOPICAL

NIZORAL

+	JANSSEN PHARMA	2% **	N019084 001	Dec 31, 1985

GEL; TOPICAL

XOLEGEL

+	ALMIRALL	2%	N021946 001	Jul 28, 2006

SHAMPOO; TOPICAL

NIZORAL

+	JANSSEN PHARMS	2% **	N019927 001	Aug 31, 1990

SUSPENSION; ORAL

NIZORAL

JANSSEN PHARMA	100MG/5ML	A070767 001	Nov 07, 1986

TABLET; ORAL

KETOCONAZOLE

AAIPHARMA LLC	200MG	A075341 001	Jul 27, 1999

HERITAGE PHARMA	200MG	A074971 001	Jun 15, 1999

	200MG	A075362 001	Jun 15, 1999

MYLAN	200MG	A075597 001	Dec 23, 1999

SUN PHARM INDUSTRIES	200MG	A075314 001	Jun 15, 1999

TEVA	200MG	A075273 001	Jun 15, 1999

NIZORAL

+	JANSSEN PHARMS	200MG **	N018533 001

KETOPROFEN

CAPSULE; ORAL

KETOPROFEN

RISING	50MG	A074024 001	Dec 29, 1995

	50MG	A074035 002	Dec 31, 1996

	75MG	A074024 002	Dec 29, 1995

	75MG	A074035 003	Dec 31, 1996

TEVA	25MG	A073515 001	Dec 22, 1992

	75MG	A073517 001	Dec 22, 1992

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-272(of 478)

** See List Footnote

KETOPROFEN

CAPSULE; ORAL

ORUDIS

+	WYETH AYERST	25MG **	N018754	001	Jul 31, 1987
+		50MG **	N018754	002	Jan 09, 1986
+		75MG **	N018754	003	Jan 09, 1986

CAPSULE, EXTENDED RELEASE; ORAL

KETOPROFEN

ACTAVIS LABS FL INC	100MG	A075270	002	Mar 24, 1999
	150MG	A075270	003	Mar 24, 1999
	200MG	A075270	001	Mar 24, 1999
ALKERMES GAINESVILLE	200MG	A074879	001	Dec 10, 1997
MYLAN	100MG	A075679	003	Feb 20, 2002
	150MG	A075679	002	Feb 20, 2002

ORUVAIL

+	WYETH PHARMS INC	100MG **	N019816	003	Feb 08, 1995
+		150MG **	N019816	002	Feb 08, 1995
+		200MG **	N019816	001	Sep 24, 1993

FILM; ORAL

NEXCEDE

NOVARTIS	12.5MG	N022470	001	Nov 25, 2009

TABLET; ORAL

ACTRON

BAYER	12.5MG	N020499	001	Oct 06, 1995

KETOPROFEN

PERRIGO	12.5MG	A075364	001	Feb 07, 2002

ORUDIS KT

+	WYETH CONS	12.5MG **	N020429	001	Oct 06, 1995

KETOROLAC TROMETHAMINE

INJECTABLE; INJECTION

KETOROLAC TROMETHAMINE

AMPHASTAR PHARM	15MG/ML	A076209	001	Jul 21, 2004	
	30MG/ML	A076209	002	Jul 21, 2004	
APOTEX INC	30MG/ML	A075626	001	Jul 24, 2001	
	30MG/ML	A077201	001	Oct 14, 2005	
APOTHECON	15MG/ML	A075348	001	Nov 28, 2000	
	30MG/ML	A075348	002	Nov 28, 2000	
BAXTER HLTHCARE CORP	15MG/ML	A075631	002	Jun 29, 2001	
	30MG/ML	A075631	001	Jun 29, 2001	
BEDFORD	15MG/ML	A075230	002	Oct 25, 1999	
	30MG/ML	A075230	001	Oct 25, 1999	
EUGIA PHARMA	15MG/ML	A212939	001	Oct 20, 2020	
	30MG/ML	A212939	002	Oct 20, 2020	
GLAND PHARMA LTD	15MG/ML	A076722	001	Jul 27, 2004	
	30MG/ML	A076722	002	Jul 27, 2004	
HIKMA	15MG/ML **	A075222	001	Apr 26, 1999	
	15MG/ML	A075299	001	Nov 03, 1999	
	30MG/ML **	A075222	002	Apr 26, 1999	
	30MG/ML **	A075228	001	Apr 26, 1999	
	30MG/ML	A075299	002	Nov 03, 1999	
HOSPIRA	15MG/ML	A074801	001	Jun 05, 1997	
	15MG/ML	A074993	001	Jan 27, 1999	
	30MG/ML	A074801	002	Jun 05, 1997	
LUITPOLD	15MG/ML	A078145	001	Jan 14, 2008	
	30MG/ML	A078145	002	Jan 14, 2008	
SANDOZ INC	15MG/ML	A076271	001	Oct 06, 2004	
STERISCENCE	15MG/ML	A078299	001	Jul 16, 2007	
	15MG/ML	A201155	001	Aug 04, 2014	
	30MG/ML	A078299	002	Jul 16, 2007	
	30MG/ML	A201155	002	Aug 04, 2014	
WOCKHARDT BIO AG	30MG/ML	A077943	001	Mar 27, 2007	
TORADOL					
+	ROCHE PALO	15MG/ML **	N019698	001	Nov 30, 1989
+		30MG/ML **	N019698	002	Nov 30, 1989
SOLUTION/DROPS; OPHTHALMIC					
ACULAR PRESERVATIVE FREE					
ALLERGAN	0.5%	N020811	001	Nov 03, 1997	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-273(of 478)

** See List Footnote

KETOROLAC TROMETHAMINE

SOLUTION/DROPS;OPHTHALMIC

KETOROLAC TROMETHAMINE

AKORN	0.4%	A078399 001	Nov 05, 2009
	0.45%	A203376 001	Feb 10, 2014
EUGIA PHARMA	0.4%	A205191 001	Nov 15, 2018
	0.5%	A205190 001	Dec 03, 2020
SANDOZ INC	0.4%	A078721 001	Nov 05, 2009

TABLET;ORAL

KETOROLAC TROMETHAMINE

CYCLE	10MG	A074790 001	Jun 26, 1997
PLIVA	10MG	A075284 001	Jun 23, 1999
WATSON LABS	10MG	A074955 001	Sep 19, 1997
TORADOL			
+ ROCHE PALO	10MG **	N019645 001	Dec 20, 1991

KETOTIFEN FUMARATE

SOLUTION/DROPS;OPHTHALMIC

ZADITOR

+ ALCON PHARMA	EQ 0.025% BASE **	N021066 002	Oct 19, 2006

KRYPTON, KR-81M

GAS;INHALATION

MPI KRYPTON 81M GENERATOR

GE HEALTHCARE	N/A	N018088 001	

L-GLUTAMINE

FOR SOLUTION;ORAL

NUTRESTORE

+ EMMAUS MEDCL	5GM/PACKET	N021667 001	Jun 10, 2004

LABETALOL HYDROCHLORIDE

INJECTABLE;INJECTION

LABETALOL HYDROCHLORIDE

AKORN	5MG/ML	A075524 001	Nov 29, 1999
APOTHECON	5MG/ML	A075355 001	Nov 29, 1999
HOSPIRA	5MG/ML	A075242 001	Sep 30, 1999
STERISCIENCE	5MG/ML	A079134 001	Feb 03, 2010

NORMODYNE

+ SCHERING	5MG/ML **	N018686 001	Aug 01, 1984

TRANDATE

+ SEBELA IRELAND LTD	5MG/ML **	N019425 001	Dec 31, 1985

TABLET;ORAL

LABETALOL HYDROCHLORIDE

APOTHECON	100MG	A075223 001	Nov 20, 1998
	200MG	A075223 002	Nov 20, 1998
	300MG	A075223 003	Nov 20, 1998
TEVA	100MG	A074989 001	Sep 30, 1998
	200MG	A074989 002	Sep 30, 1998
	300MG	A074989 003	Sep 30, 1998
UNICHEM	100MG	A212719 001	Aug 08, 2022
	200MG	A212719 002	Aug 08, 2022
	300MG	A212719 003	Aug 08, 2022

NORMODYNE

+ SCHERING	100MG **	N018687 001	Aug 31, 1987
	200MG **	N018687 002	Aug 01, 1984
	300MG **	N018687 003	Aug 01, 1984
	400MG **	N018687 004	Aug 01, 1984

TRANDATE

+ ALVOGEN	100MG	N018716 001	May 24, 1985
	400MG **	N018716 004	Aug 01, 1984

LACTITOL

FOR SOLUTION;ORAL

PIZENSY

+ BRAINTREE LABS	10GM	N211281 001	Feb 12, 2020

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-274(of 478)

** See List Footnote

LACTULOSE

SOLUTION; ORAL

CHRONULAC

+ SANOFI AVENTIS US 10GM/15ML **

N017884 001

CONSTILAC

ALRA 10GM/15ML

A071054 001 Jul 26, 1988

CONSTULOSE

ACTAVIS MID ATLANTIC 10GM/15ML

A070288 001 Aug 15, 1988

DUPHALAC

SOLVAY 10GM/15ML

A072372 001 Mar 22, 1989

EVALOSE

TEVA PHARMS 10GM/15ML

A073497 001 May 28, 1993

LACTULOSE

ANI PHARMS 10GM/15ML

A078430 001 Nov 28, 2007

HIKMA 10GM/15ML

A073591 001 May 29, 1992

MORTON GROVE 10GM/15ML

A071841 001 Sep 22, 1988

PACO 10GM/15ML

A073160 001 Aug 25, 1992

TORRENT 10GM/15ML

A207786 001 Jun 11, 2018

XTTRIUM LABS INC 10GM/15ML

A075911 001 Feb 21, 2002

LAXILOSE

NOSTRUM LABS 10GM/15ML

A073686 001 May 28, 1993

SOLUTION; ORAL, RECTAL

ACILAC

NOSTRUM LABS 10GM/15ML

A073685 001 May 28, 1993

CEPHULAC

+ SANOFI AVENTIS US 10GM/15ML **

N017657 001

CHOLAC

ALRA 10GM/15ML

A071331 001 Jul 26, 1988

ENULOSE

ACTAVIS MID ATLANTIC 10GM/15ML

A071548 001 Aug 15, 1988

GENERLAC

MORTON GROVE 10GM/15ML

A071842 001 Sep 27, 1988

HEPTALAC

TEVA PHARMS 10GM/15ML

A073504 001 May 28, 1993

LACTULOSE

ANI PHARMS 10GM/15ML

A090426 001 Nov 21, 2008

BAJAJ 10GM/15ML

A076645 001 Jul 28, 2003

PACO 10GM/15ML

A072029 001 Aug 25, 1992

ROXANE 10GM/15ML

A073590 001 May 29, 1992

SOLVAY 10GM/15ML

N017906 001

TORRENT 10GM/15ML

A203762 001 Mar 27, 2015

PORTALAC

SOLVAY 10GM/15ML

A072374 001 Mar 22, 1989

LAMIVUDINE

TABLET; ORAL

LAMIVUDINE

AUROBINDO PHARMA LTD 150MG

A202032 001 Nov 17, 2011

300MG

A202032 002 Nov 17, 2011

MYLAN 100MG

A204002 001 Dec 31, 2014

150MG

A204528 001 Mar 04, 2016

300MG

A204528 002 Mar 04, 2016

LAMIVUDINE; NEVIRAPINE; ZIDOVUDINE

TABLET; ORAL

LAMIVUDINE, NEVIRAPINE AND ZIDOVUDINE

+ MICRO LABS 150MG; 200MG; 300MG

N205626 001 Aug 13, 2018

LAMIVUDINE; RALTEGRAVIR POTASSIUM

TABLET; ORAL

DUTREBIS

MERCK SHARP DOHME 150MG; EQ 300MG BASE

N206510 001 Feb 06, 2015

LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL

LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE

+ AUROBINDO PHARMA LTD 300MG; 300MG

N022344 001 May 15, 2018

TEMIXYS

+ CELLTRION 300MG; 300MG

N211284 001 Nov 16, 2018

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-275(of 478)

** See List Footnote

LAMIVUDINE; ZIDOVUDINE

TABLET; ORAL

LAMIVUDINE AND ZIDOVUDINE

CHARTWELL RX	150MG;300MG	A079081	001	May 25, 2011
MYLAN	150MG;300MG	A204005	001	Aug 28, 2014
MYLAN LABS LTD	150MG;300MG	A079079	001	Aug 12, 2019
PHARMACARE	150MG;300MG	N022018	001	Mar 17, 2017

LAMOTRIGINE

TABLET; ORAL

LAMICTAL

+	GLAXOSMITHKLINE LLC	50MG **	N020241	006	Dec 27, 1994
+		250MG **	N020241	004	Dec 27, 1994

LAMOTRIGINE

ACTAVIS TOTOWA	25MG	A078669	001	Apr 08, 2011
	100MG	A078669	002	Apr 08, 2011
	150MG	A078669	003	Apr 08, 2011
	200MG	A078669	004	Apr 08, 2011
CIPLA	25MG	A077783	001	Nov 01, 2010
	100MG	A077783	002	Nov 01, 2010
	150MG	A077783	003	Nov 01, 2010
	200MG	A077783	004	Nov 01, 2010
GRANULES	25MG	A078982	001	Jan 27, 2009
	100MG	A078982	002	Jan 27, 2009
	150MG	A078982	003	Jan 27, 2009
	200MG	A078982	004	Jan 27, 2009
HIKMA PHARMS	25MG	A078134	001	Apr 19, 2011
	100MG	A078134	002	Apr 19, 2011
	150MG	A078134	003	Apr 19, 2011
	200MG	A078134	004	Apr 19, 2011
MYLAN	25MG	A077428	001	Jan 27, 2009
	100MG	A077428	002	Jan 27, 2009
	150MG	A077428	003	Jan 27, 2009
	200MG	A077428	004	Jan 27, 2009
MYLAN LABS LTD	25MG	A078443	001	Feb 11, 2009
	100MG	A078443	002	Feb 11, 2009
	150MG	A078443	003	Feb 11, 2009
	200MG	A078443	004	Feb 11, 2009
RISING	25MG	A077420	001	Jan 27, 2009
	100MG	A077420	002	Jan 27, 2009
	150MG	A077420	003	Jan 27, 2009
	200MG	A077420	004	Jan 27, 2009
ROXANE	25MG	A077392	001	Jan 27, 2009
	100MG	A077392	002	Jan 27, 2009
	150MG	A077392	003	Jan 27, 2009
	200MG	A077392	004	Jan 27, 2009
SANDOZ	25MG	A078645	001	Jan 27, 2009
	100MG	A078645	002	Jan 27, 2009
	150MG	A078645	003	Jan 27, 2009
	200MG	A078645	004	Jan 27, 2009
TEVA	25MG	A076388	001	Aug 30, 2006
	100MG	A076388	002	Aug 30, 2006
	150MG	A076388	003	Aug 30, 2006
	200MG	A076388	004	Aug 30, 2006
ZENNOVA	25MG	A078310	001	Feb 04, 2009
	100MG	A078310	002	Feb 04, 2009
	150MG	A078310	003	Feb 04, 2009
	200MG	A078310	004	Feb 04, 2009

TABLET, EXTENDED RELEASE; ORAL

LAMOTRIGINE

RUBICON	25MG	A202887	001	Jun 17, 2013
	50MG	A202887	002	Jun 17, 2013
TORRENT	200MG	A203370	004	Dec 23, 2013

TABLET, FOR SUSPENSION; ORAL

LAMICTAL CD

GLAXOSMITHKLINE LLC	100MG	N020764	003	Aug 24, 1998

LAMOTRIGINE

JUBILANT GENERICS	5MG	A200220	001	Feb 28, 2011
	25MG	A200220	002	Feb 28, 2011
MYLAN	5MG	A076630	001	Jan 22, 2009

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-276(of 478)

** See List Footnote

LAMOTRIGINE

TABLET, FOR SUSPENSION;ORAL

LAMOTRIGINE

	25MG	A076630	002	Jan 22, 2009
SANDOZ	5MG	A078409	002	Jan 22, 2009
	25MG	A078409	003	Jan 22, 2009
TEVA	5MG	A076420	001	Jun 21, 2006
	25MG	A076420	002	Jun 21, 2006

TABLET, ORALLY DISINTEGRATING;ORAL

LAMOTRIGINE

IMPAX LABS INC	25MG	A200828	001	Jul 15, 2013
	50MG	A200828	002	Jul 15, 2013
	100MG	A200828	003	Jul 15, 2013
	200MG	A200828	004	Jul 15, 2013

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL

LANSOPRAZOLE

AJANTA PHARMA LTD	15MG	A203957	001	Oct 14, 2016
	30MG	A203957	002	Oct 14, 2016
BRECKENRIDGE	15MG	A203964	001	Oct 17, 2018
	30MG	A203964	002	Oct 17, 2018
KRKA TOVARNA ZDRAVIL	15MG	A091212	001	Sep 16, 2013
	30MG	A091212	002	Sep 16, 2013
LANNETT CO INC	15MG	A207157	001	Sep 29, 2017

PREVACID

+ TAKEDA PHARMS USA 15MG

N020406 001 May 10, 1995

FOR SUSPENSION, DELAYED RELEASE;ORAL

PREVACID

TAKEDA PHARMS NA	15MG/PACKET	N021281	001	May 03, 2001
	30MG/PACKET	N021281	002	May 03, 2001

INJECTABLE;INTRAVENOUS

PREVACID IV

+ TAKEDA PHARMS NA 30MG/VIAL **

N021566 001 May 27, 2004

TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL

LANSOPRAZOLE

ANI PHARMS	15MG	A078730	001	Oct 15, 2010
	30MG	A078730	002	Oct 15, 2010

LANSOPRAZOLE; NAPROXEN

CAPSULE, DELAYED REL PELLETS, TABLET;ORAL

PREVACID NAPRAPAC 250 (COPACKAGED)

+ TAKEDA PHARMS NA 15MG,N/A;N/A,250MG **

N021507 002 Nov 14, 2003

PREVACID NAPRAPAC 375 (COPACKAGED)

TAKEDA PHARMS NA 15MG,N/A;N/A,375MG

N021507 003 Nov 14, 2003

PREVACID NAPRAPAC 500 (COPACKAGED)

TAKEDA PHARMS NA 15MG,N/A;N/A,500MG

N021507 004 Nov 14, 2003

LANTHANUM CARBONATE

TABLET, CHEWABLE;ORAL

FOSRENOL

TAKEDA PHARMS USA	EQ 250MG BASE	N021468	001	Oct 26, 2004

LAPYRIUM CHLORIDE; UNDECOYLUM CHLORIDE IODINE COMPLEX

SOLUTION;TOPICAL

VIRAC REX

CHESEBROUGH PONDS	0.5%;1.8%	N011914	001	

LASMIDITAN SUCCINATE

TABLET;ORAL

REYVOW

+ ELI LILLY AND CO EQ 200MG BASE

N211280 003 Dec 18, 2020

LATANOPROST

SOLUTION/DROPS;OPHTHALMIC

LATANOPROST

APOTEX INC	0.005%	A077697	001	Mar 22, 2011
EUGIA PHARMA	0.005%	A206519	001	Sep 03, 2019

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-277(of 478)

** See List Footnote

LEFLUNOMIDE

TABLET;ORAL

LEFLUNOMIDE

BARR	10MG	A077083	001	Sep 13, 2005
	20MG	A077083	002	Sep 13, 2005
SANDOZ	10MG	A077085	001	Sep 13, 2005
	20MG	A077085	002	Sep 13, 2005
TEVA PHARMS	10MG	A077084	001	Sep 13, 2005
	20MG	A077084	002	Sep 13, 2005

LESINURAD

TABLET;ORAL

ZURAMPIC

+ IRONWOOD PHARMS INC	200MG	N207988	001	Dec 22, 2015

LETROZOLE

TABLET;ORAL

LETROZOLE

ACTAVIS TOTOWA	2.5MG	A090292	001	Jul 13, 2011
APOTEX INC	2.5MG	A091303	001	Apr 19, 2012
FRESENIUS KABI USA	2.5MG	A090491	001	Jun 03, 2011
HENGRUI PHARMA	2.5MG	A202716	001	May 16, 2013
HIKMA	2.5MG	A090838	001	Jun 03, 2011
HIKMA PHARMS	2.5MG	A203796	001	Jun 03, 2016
IMPAX LABS	2.5MG	A091638	001	Jun 03, 2011
INDICUS PHARMA	2.5MG	A201804	001	Jun 03, 2011
LANNETT CO INC	2.5MG	A091098	001	Jun 03, 2011
	2.5MG	A202048	001	Oct 29, 2014
MYLAN	2.5MG	A078190	001	Dec 24, 2008
STRIDES PHARMA	2.5MG	A090789	001	Jun 03, 2011
SUN PHARM INDS LTD	2.5MG	A091466	001	Jun 03, 2011
SYNTHON PHARMS	2.5MG	A090196	001	Jun 03, 2011

LEUCOVORIN CALCIUM

FOR SOLUTION;ORAL

LEUCOVORIN CALCIUM

HOSPIRA	EQ 60MG BASE/VIAL	N008107	003	Jan 30, 1987

INJECTABLE;INJECTION

LEUCOVORIN CALCIUM

ABIC	EQ 3MG BASE/ML	A089352	001	Jun 01, 1988
	EQ 50MG BASE/VIAL	A089353	001	Jun 01, 1988
ABRAXIS PHARM	EQ 50MG BASE/VIAL	A088939	001	Dec 01, 1986
ELKINS SINN	EQ 50MG BASE/VIAL	A070480	001	Jan 02, 1987
	EQ 100MG BASE/VIAL	A081224	001	Jun 03, 1994
+ HOSPIRA	EQ 3MG BASE/ML **	N008107	001	
	EQ 50MG BASE/VIAL **	N008107	002	
	EQ 100MG BASE/VIAL **	N008107	004	May 23, 1988
	EQ 350MG BASE/VIAL **	N008107	005	Apr 05, 1989
NOVAST LABS	EQ 10MG BASE/ML	A210917	001	Nov 23, 2018
PHARMACHEMIE	EQ 350MG BASE/VIAL	A040262	001	Dec 15, 1999
PHARMACHEMIE USA	EQ 50MG BASE/VIAL	A089628	001	Apr 17, 1997
	EQ 100MG BASE/VIAL	A089915	001	Apr 17, 1997
TEVA PARENTERAL	EQ 50MG BASE/VIAL	A081278	001	Sep 28, 1993

LEUCOVORIN CALCIUM PRESERVATIVE FREE

AM REGENT	EQ 50MG BASE/VIAL	A040338	001	Jan 31, 2001
HOSPIRA	EQ 10MG BASE/ML **	A040147	001	Jun 25, 1997
TEVA PARENTERAL	EQ 10MG BASE/ML	A040332	001	Jun 28, 1999

WELLCOVORIN

GLAXOSMITHKLINE	EQ 5MG BASE/ML	A087439	001	Oct 19, 1982
	EQ 25MG BASE/VIAL	A089833	001	Jan 23, 1989
	EQ 50MG BASE/VIAL	A089465	001	Jan 23, 1989
	EQ 100MG BASE/VIAL	A089834	001	Jan 23, 1989

TABLET;ORAL

LEUCOVORIN CALCIUM

ANI PHARMS	EQ 15MG BASE	A075327	001	Mar 24, 1999
PAR PHARM	EQ 5MG BASE	A071600	001	Oct 14, 1987
	EQ 25MG BASE	A071598	001	Oct 14, 1987
PHARMACHEMIE	EQ 5MG BASE	A073099	001	Mar 28, 1997
	EQ 25MG BASE	A073101	001	Mar 28, 1997
XANODYNE PHARM	EQ 5MG BASE	N018459	001	Jan 30, 1986
	EQ 10MG BASE	A071962	001	Nov 19, 1987

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-278(of 478)

** See List Footnote

LEUCOVORIN CALCIUM

TABLET; ORAL

LEUCOVORIN CALCIUM

EQ 15MG BASE

A071104 001 Mar 04, 1987

WELLCOVORIN

+ GLAXOSMITHKLINE

EQ 5MG BASE **

N018342 001 Jul 08, 1983

+

EQ 25MG BASE **

N018342 002 Jul 08, 1983

LEUPROLIDE ACETATE

IMPLANT; IMPLANTATION

VIADUR

ORTHO MCNEIL JANSSEN EQ 65MG BASE

N021088 001 Mar 03, 2000

INJECTABLE; INJECTION

LEUPROLIDE ACETATE

GENZYME 1MG/0.2ML

A075721 001 Nov 29, 2001

LUPRON

+ ABBVIE ENDOCRINE INC 1MG/0.2ML **

N019010 001 Apr 09, 1985

LUPRON DEPOT

+ ABBVIE ENDOCRINE INC 3.75MG/VIAL **

N020011 001 Oct 22, 1990

POWDER; INTRAMUSCULAR

LUPRON DEPOT-PED KIT

+ ABBVIE ENDOCRINE INC 3.75MG, 7.5MG **

N020263 003 Apr 16, 1993

+

7.5MG, 7.5MG **

N020263 004 Apr 16, 1993

LEUPROLIDE ACETATE; NORETHINDRONE ACETATE

INJECTABLE, TABLET; INTRAMUSCULAR, ORAL

LUPANETA PACK

+ ABBVIE ENDOCRINE 3.75MG/VIAL, N/A; N/A, 5MG

N203696 001 Dec 14, 2012

+

11.25MG/VIAL, N/A; N/A, 5MG

N203696 002 Dec 14, 2012

LEVALBUTEROL HYDROCHLORIDE

SOLUTION; INHALATION

LEVALBUTEROL HYDROCHLORIDE

MYLAN SPECIALITY LP EQ 0.0103% BASE

A077800 001 Mar 15, 2013

EQ 0.021% BASE

A077800 002 Mar 15, 2013

EQ 0.042% BASE

A077800 003 Mar 15, 2013

LEVALLORPHAN TARTRATE

INJECTABLE; INJECTION

LORFAN

ROCHE 1MG/ML

N010423 001

LEVAMISOLE HYDROCHLORIDE

TABLET; ORAL

ERGAMISOL

JANSSEN PHARMA EQ 50MG BASE

N020035 001 Jun 18, 1990

LEVAMLODIPINE MALEATE

TABLET; ORAL

CONJUPRI

+ CSPC OUYI EQ 1.25MG BASE

N212895 001 Dec 19, 2019

LEVETIRACETAM

INJECTABLE; INTRAVENOUS

LEVETIRACETAM

AKORN 500MG/5ML (100MG/ML)

A209934 001 May 04, 2018

AM REGENT 500MG/5ML (100MG/ML)

A202143 001 Jan 31, 2012

FRESENIUS KABI USA 500MG/5ML (100MG/ML)

A090813 001 May 26, 2010

JUBILANT GENERICS 500MG/5ML (100MG/ML)

A206838 001 Jun 02, 2016

SOLUTION; ORAL

LEVETIRACETAM

APOTEX INC 100MG/ML

A090187 001 Aug 05, 2011

TOLMAR 100MG/ML

A079107 001 Jan 15, 2009

WOCKHARDT BIO AG 100MG/ML

A090028 001 Mar 03, 2010

TABLET; ORAL

LEVETIRACETAM

ACTAVIS LABS FL INC 250MG

A077408 001 Mar 02, 2009

500MG

A077408 002 Mar 02, 2009

750MG

A077408 003 Mar 02, 2009

FOSUN PHARMA 250MG

A077324 001 Jan 15, 2009

500MG

A077324 002 Jan 15, 2009

750MG

A077324 003 Jan 15, 2009

1GM

A077324 004 Jan 15, 2009

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-279(of 478)

** See List Footnote

LEVETIRACETAM

TABLET;ORAL

LEVETIRACETAM

LOTUS PHARM CO LTD	250MG	A090906 002	Oct 31, 2016
	500MG	A090906 001	Nov 05, 2010
	750MG	A090906 003	Oct 31, 2016
	1GM	A090906 004	Oct 31, 2016
MYLAN	250MG	A078731 001	Feb 10, 2009
	500MG	A078731 002	Feb 10, 2009
	750MG	A078731 003	Feb 10, 2009
	1GM	A078731 004	Feb 10, 2009
NOSTRUM LABS INC	250MG	A090511 001	Aug 18, 2011
	500MG	A090511 002	Aug 18, 2011
	750MG	A090511 003	Aug 18, 2011
	1GM	A090511 004	Aug 18, 2011
SECAN PHARMS	500MG	A205102 004	Dec 16, 2015
	1GM	A205102 003	Dec 16, 2015
TEVA PHARMS	250MG	A078101 001	Jan 15, 2009
	500MG	A078101 002	Jan 15, 2009
	750MG	A078101 003	Jan 15, 2009
	1GM	A078101 004	Jan 15, 2009
WATSON LABS INC	250MG	A078797 002	Jan 15, 2009
	500MG	A078797 003	Jan 15, 2009
	750MG	A078797 004	Jan 15, 2009
	1GM	A078797 001	Jan 15, 2009

TABLET, EXTENDED RELEASE;ORAL

LEVETIRACETAM

ACTAVIS ELIZABETH	500MG	A091557 001	Sep 12, 2011
	750MG	A091557 002	Sep 12, 2011
ANDA REPOSITORY	500MG	A091291 001	Sep 12, 2011
	750MG	A091291 002	Sep 12, 2011
DEXCEL	500MG	A202167 001	Sep 04, 2015
	750MG	A202167 002	Sep 04, 2015
LOTUS PHARM CO LTD	500MG	A202095 002	Jun 06, 2016
	750MG	A202095 001	Jun 06, 2016
MYLAN PHARMS INC	500MG	A200475 001	Dec 19, 2011
	750MG	A200475 002	Dec 19, 2011
	1GM	A200475 003	Dec 07, 2015
ROUSES POINT PHARMS	500MG	A202524 001	Aug 27, 2012
	750MG	A202524 002	Aug 27, 2012
SANDOZ	500MG	A091668 001	Nov 01, 2012
	750MG	A091668 002	Nov 01, 2012
SUN PHARM INDUSTRIES	500MG	A091285 001	Sep 12, 2011
	750MG	A091285 002	Sep 12, 2011
TEVA PHARMS	500MG	A091430 001	Sep 12, 2011
	750MG	A091430 002	Sep 12, 2011
TORRENT PHARMS LTD	500MG	A091338 001	May 29, 2012
	750MG	A091338 002	May 29, 2012

LEVOBETAXOLOL HYDROCHLORIDE

SUSPENSION/DROPS;OPHTHALMIC

BETAXON

ALCON PHARMS LTD	EQ 0.5% BASE	N021114 001	Feb 23, 2000

LEVOBUNOLOL HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

AKBETA

AKORN	0.25%	A074779 001	Oct 29, 1996
	0.5%	A074780 001	Oct 29, 1996

BETAGAN

+ ALLERGAN

0.25% **

N019814 001 Jun 28, 1989

LEVOBUNOLOL HYDROCHLORIDE

ALCON LABS INC	0.25%	A074851 001	Oct 28, 1996
APOTEX INC	0.25%	A075473 001	Aug 03, 2000
	0.5%	A075475 001	Aug 03, 2000
BAUSCH AND LOMB	0.25%	A074307 001	Mar 04, 1994
SANDOZ INC	0.5%	A074850 001	Oct 28, 1996

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-280(of 478)

** See List Footnote

LEVOPUPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

CHIROCAINE

PURDUE PHARMA LP

EQ 2.5MG BASE/ML

N020997 001 Aug 05, 1999

EQ 5MG BASE/ML

N020997 002 Aug 05, 1999

EQ 7.5MG BASE/ML

N020997 003 Aug 05, 1999

LEVOCABASTINE HYDROCHLORIDE

SUSPENSION/DROPS; OPHTHALMIC

LIVOSTIN

NOVARTIS

EQ 0.05% BASE

N020219 001 Nov 10, 1993

LEVOCARNITINE

INJECTABLE; INJECTION

LEVOCARNITINE

TEVA PHARMS USA

200MG/ML

A075881 001 Mar 29, 2001

SOLUTION; ORAL

CARNITOR

LEADIANT BIOSCI INC

1GM/10ML

N018948 002 Apr 27, 1988

LEVOCETIRIZINE DIHYDROCHLORIDE

SOLUTION; ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

APOTEX

2.5MG/5ML

A202915 001 Aug 21, 2014

XYZAL

+ CHATTEM SANOFI

2.5MG/5ML **

N022157 001 Jan 28, 2008

TABLET; ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

APOTEX

5MG

A203027 001 Feb 13, 2015

GRANULES

5MG

A090486 001 Mar 26, 2013

SUN PHARM INDS LTD

5MG

A201653 001 Jun 26, 2015

US ANTIBIOTICS

5MG

A204323 001 Dec 20, 2016

XYZAL

+ CHATTEM SANOFI

5MG **

N022064 001 May 25, 2007

LEVODOPA

CAPSULE; ORAL

BENDOPA

VALEANT PHARM INTL

100MG

N016948 003

250MG

N016948 001

500MG

N016948 002

DOPAR

SHIRE

100MG

N016913 003

250MG

N016913 001

500MG

N016913 002

LARODOPA

ROCHE

100MG

N016912 002

250MG

N016912 001

500MG

N016912 006

TABLET; ORAL

DOPAR

SHIRE

250MG

N016913 004

500MG

N016913 005

LARODOPA

ROCHE

100MG

N016912 005

250MG

N016912 003

500MG

N016912 004

LEVOFLOXACIN

INJECTABLE; INJECTION

LEVAQUIN

+ JANSSEN PHARMS

EQ 500MG/20ML (EQ 25MG/ML) **

N020635 001 Dec 20, 1996

+

EQ 750MG/30ML (EQ 25MG/ML) **

N020635 004 Dec 20, 1996

LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER

+ JANSSEN PHARMS

EQ 250MG/50ML (EQ 5MG/ML) **

N020635 002 Dec 20, 1996

+

EQ 500MG/100ML (EQ 5MG/ML) **

N020635 003 Dec 20, 1996

+

EQ 750MG/150ML (EQ 5MG/ML) **

N020635 005 Dec 20, 1996

LEVOFLOXACIN

EMCURE PHARMS LTD

EQ 500MG/20ML (EQ 25MG/ML)

A202590 001 Jan 24, 2013

EQ 750MG/30ML (EQ 25MG/ML)

A202590 002 Jan 24, 2013

EUGIA PHARMA

EQ 500MG/20ML (EQ 25MG/ML)

A202328 001 Jan 24, 2013

EQ 750MG/30ML (EQ 25MG/ML)

A202328 002 Jan 24, 2013

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-281(of 478)

** See List Footnote

LEVOFLOXACIN

INJECTABLE; INJECTION

LEVOFLOXACIN

HOSPIRA	EQ 500MG/20ML (EQ 25MG/ML)	A078577 001	Aug 12, 2015
	EQ 750MG/30ML (EQ 25MG/ML)	A078577 002	Aug 12, 2015
MYLAN ASI	EQ 500MG/20ML (EQ 25MG/ML)	A200560 001	Jun 20, 2011
	EQ 750MG/30ML (EQ 25MG/ML)	A200560 002	Jun 20, 2011
ZYDUS PHARMS	EQ 500MG/20ML (EQ 25MG/ML)	A205968 001	Jun 01, 2017
	EQ 750MG/30ML (EQ 25MG/ML)	A205968 002	Jun 01, 2017
LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER			
EUGIA PHARMA	EQ 250MG/50ML (EQ 5MG/ML)	A206919 001	Feb 10, 2016
	EQ 500MG/100ML (EQ 5MG/ML)	A206919 002	Feb 10, 2016
	EQ 750MG/150ML (EQ 5MG/ML)	A206919 003	Feb 10, 2016

SOLUTION; ORAL

LEVAQUIN

+ JANSSEN PHARMS	250MG/10ML	N021721 001	Oct 21, 2004

SOLUTION/DROPS; OPHTHALMIC

IQUIX

+ SANTEN	1.5% **	N021571 001	Mar 01, 2004

LEVOFLOXACIN

MYLAN LABS LTD	0.5%	A204899 001	Dec 08, 2017
RUBICON	0.5%	A078282 001	Dec 20, 2010
WATSON LABS TEVA	0.5%	A076826 001	Feb 10, 2011

QUIXIN

+ SANTEN	0.5% **	N021199 001	Aug 18, 2000

TABLET; ORAL

LEVAQUIN

+ JANSSEN PHARMS	250MG **	N020634 001	Dec 20, 1996
+	500MG **	N020634 002	Dec 20, 1996
+	750MG **	N020634 003	Sep 08, 2000

LEVOFLOXACIN

JUBILANT GENERICS	250MG	A203613 001	Jun 19, 2015
	500MG	A203613 002	Jun 19, 2015
MYLAN	250MG	A076276 001	Jun 20, 2011
	500MG	A076276 002	Jun 20, 2011
	750MG	A077097 001	Jun 20, 2011
TORRENT PHARMS	250MG	A090722 001	Jun 20, 2011
	500MG	A090722 002	Jun 20, 2011
	750MG	A090722 003	Jun 20, 2011
WATSON LABS INC	250MG	A201484 001	Nov 22, 2013
	500MG	A201484 002	Nov 22, 2013
	750MG	A201484 003	Nov 22, 2013

LEVOLEUCOVORIN CALCIUM

POWDER; INTRAVENOUS

LEVOLEUCOVORIN CALCIUM

ACTAVIS LLC	EQ 50MG BASE/VIAL	A206516 001	Feb 13, 2017
+	EQ 175MG BASE/VIAL	N208723 001	Sep 29, 2016
AMNEAL	EQ 50MG BASE/VIAL	A207547 001	Feb 13, 2017
HIKMA	EQ 50MG BASE/VIAL	A206263 001	Jun 16, 2016

SOLUTION; INTRAVENOUS

FUSILEV

+ ACROTECH BIOPHARMA	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	N020140 002	Apr 29, 2011
	**		
+	EQ 250MG BASE/25ML (EQ 10MG BASE/ML) **	N020140 003	Apr 29, 2011

LEVOLEUCOVORIN CALCIUM

MEITHEAL	EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	A211002 002	Aug 16, 2019
MYLAN TEORANTA	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	A203576 001	Oct 20, 2015
	EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	A203576 002	Oct 20, 2015
NOVAST LABS	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	A210623 001	May 03, 2018
	EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	A210623 002	May 03, 2018
PRAXGEN	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	A213797 001	Nov 02, 2021
SANDOZ INC	EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	A203563 002	Mar 09, 2015

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-282(of 478)

** See List Footnote

LEVOMEPRMAZINE

INJECTABLE; INJECTION

LEVOPROME

IMMUNEX

20MG/ML

N015865 001

LEVOMETHADYL ACETATE HYDROCHLORIDE

CONCENTRATE; ORAL

ORLAAM

+

ROXANE

10MG/ML **

N020315 001 Jul 09, 1993

LEVOMILNACIPRAN HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

LEVOMILNACIPRAN HYDROCHLORIDE

AMNEAL PHARMS CO

EQ 20MG BASE

A210790 001 Feb 04, 2019

EQ 40MG BASE

A210790 002 Feb 04, 2019

EQ 80MG BASE

A210790 003 Feb 04, 2019

EQ 120MG BASE

A210790 004 Feb 04, 2019

HIKMA

EQ 20MG BASE

A210732 001 Nov 05, 2020

EQ 40MG BASE

A210732 002 Nov 05, 2020

EQ 80MG BASE

A210732 003 Nov 05, 2020

EQ 120MG BASE

A210732 004 Nov 05, 2020

LEVONORDEFIN; MEPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

ARESTOCAINE HYDROCHLORIDE W/ LEVONORDEFIN

SOLVAY

0.05MG/ML; 2%

A085010 001

CARBOCAINE W/ NEO-COBEFRIN

EASTMAN KODAK

0.05MG/ML; 2%

N012125 002

ISOCAINE HYDROCHLORIDE W/ LEVONORDEFIN

SEPTODONT INC

0.05MG/ML; 2%

A084697 001

MEPIVACAINE HYDROCHLORIDE W/ LEVONORDEFIN

BELMORA LLC

0.05MG/ML; 2%

A084850 002 Oct 21, 1983

POLOCAINE W/ LEVONORDEFIN

DENTSPLY PHARM

0.05MG/ML; 2%

A089517 001 Apr 14, 1988

LEVONORDEFIN; PROCAINE HYDROCHLORIDE; PROPOXYCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

RAVOCAINE AND NOVOCAIN W/ NEO-COBEFRIN

EASTMAN KODAK

0.05MG/ML; 2%; 0.4%

N008592 007

LEVONORGESTREL

IMPLANT; IMPLANTATION

JADELLE

+

POPULATION COUNCIL

75MG/IMPLANT **

N020544 001 Nov 01, 1996

LEVONORGESTREL

WYETH PHARMS INC

75MG/IMPLANT

N020627 001 Aug 15, 1996

NORPLANT

POPULATION COUNCIL

36MG/IMPLANT

N019897 001 Dec 10, 1990

NORPLANT SYSTEM IN PLASTIC CONTAINER

WYETH PHARMS INC

36MG/IMPLANT

N020088 001 Dec 10, 1990

TABLET; ORAL

LEVONORGESTREL

ALVOGEN

1.5MG

A202246 001 Jun 05, 2015

FDN CONSUMER

0.75MG **

A078665 001 Aug 28, 2009

1.5MG

A200670 001 Jul 12, 2012

L PERRIGO CO

0.75MG

A090740 001 Dec 30, 2010

LOTUS PHARM CO LTD

0.75MG

A202684 001 Sep 02, 2016

LUPIN LTD

0.75MG

A091328 001 Jan 23, 2013

MYLAN LABS LTD

0.75MG

A202740 001 Sep 02, 2016

NAARI PTE LTD

1.5MG

A207660 001 May 02, 2019

WATSON LABS

0.75MG

A078666 001 Jun 24, 2009

PLAN B

+

FDN CONSUMER

0.75MG **

N021045 001 Jul 28, 1999

+

0.75MG **

N021045 002 Aug 24, 2006

LEVOPROPOXYPHENE NAPSYLATE ANHYDROUS

CAPSULE; ORAL

NOVRAD

LILLY

EQ 50MG BASE

N012928 006

EQ 100MG BASE

N012928 004

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-283(of 478)

** See List Footnote

LEVOPROPOXYPHENE NAPSYLATE ANHYDROUS

SUSPENSION; ORAL

NOVRAD

LILLY

EQ 50MG BASE/5ML

N012928 002

LEVORPHANOL TARTRATE

INJECTABLE; INJECTION

LEVO-DROMORAN

VALEANT PHARM INTL

2MG/ML

N008719 001 Dec 19, 1991

TABLET; ORAL

LEVO-DROMORAN

+ VALEANT PHARM INTL

2MG **

N008720 001 Dec 19, 1991

LEVORPHANOL TARTRATE

HIKMA

1MG

A074278 002 Jun 18, 2018

2MG

A074278 001 Mar 31, 2000

3MG

A074278 003 Jun 18, 2018

LEVOTHYROXINE SODIUM

CAPSULE; ORAL

LEVOTHYROXINE SODIUM

TEVA PHARMS USA INC

0.075MG

A211369 001 Oct 28, 2020

0.088MG

A213256 001 Jan 06, 2021

0.1MG

A213256 002 Jan 06, 2021

0.112MG

A211369 003 Apr 16, 2021

0.125MG

A213256 003 Jan 06, 2021

0.15MG

A211369 002 Oct 28, 2020

POWDER; INTRAVENOUS

LEVOTHYROXINE SODIUM

DR REDDYS

100MCG/VIAL

A208837 001 Mar 27, 2020

PAR STERILE PRODUCTS

200MCG/VIAL

A205366 001 Dec 07, 2015

TABLET; ORAL

EUTHYROX

PROVELL

0.3MG

N021292 012 May 31, 2002

LEVOTHYROXINE SODIUM

AMNEAL

0.025MG

A210831 001 Feb 19, 2019

0.05MG

A210831 002 Feb 19, 2019

0.075MG

A210831 003 Feb 19, 2019

0.088MG

A210831 004 Feb 19, 2019

0.1MG

A210831 005 Feb 19, 2019

0.112MG

A210831 006 Feb 19, 2019

0.125MG

A210831 007 Feb 19, 2019

0.137MG

A210831 008 Feb 19, 2019

0.15MG

A210831 009 Feb 19, 2019

0.175MG

A210831 010 Feb 19, 2019

0.2MG

A210831 011 Feb 19, 2019

0.3MG

A210831 012 Feb 19, 2019

MERCK KGAA

0.025MG

A076752 001 Jun 16, 2005

0.05MG

A076752 002 Jun 16, 2005

0.075MG

A076752 003 Jun 16, 2005

0.088MG

A076752 004 Jun 16, 2005

0.1MG

A076752 005 Jun 16, 2005

0.112MG

A076752 006 Jun 16, 2005

0.125MG

A076752 007 Jun 16, 2005

0.15MG

A076752 008 Jun 16, 2005

0.175MG

A076752 009 Jun 16, 2005

0.2MG

A076752 010 Jun 16, 2005

0.3MG

A076752 011 Jun 16, 2005

LEVOXYL

+ KING PHARMS

0.3MG **

N021301 012 May 25, 2001

LIDOCAINE

AEROSOL; ORAL

XYLOCAINE

ASTRAZENECA

10%

N014394 001

FILM, EXTENDED RELEASE; BUCCAL

DENTIPATCH

NOVEN

23MG/PATCH

N020575 001 May 21, 1996

OINTMENT; TOPICAL

ALPHACAINE

CARLISLE

5%

A084944 001

5%

A084946 001

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-284(of 478)

** See List Footnote

LIDOCAINE

OINTMENT; TOPICAL

ALPHACAINE

5%

A084947 001

LIDOCAINE

BELMORA LLC

5%

A080210 001

GENEYORK PHARMS

5%

A212486 001 Oct 17, 2019

RISING

5%

A208604 001 Sep 20, 2017

TEVA PHARMS USA

5%

A210256 001 Jan 16, 2018

XYLOCAINE

+ ASTRAZENECA

5% **

N008048 001

PATCH; TOPICAL

DENTIPATCH

NOVEN

46.1MG/PATCH

N020575 002 May 21, 1996

LIDOCAINE

NOVEN PHARMS INC

5%

A203265 001 Dec 01, 2020

SOLUTION; TOPICAL

XYLOCAINE

ASTRAZENECA

5%

N014127 001

SUPPOSITORY; RECTAL

XYLOCAINE

ASTRAZENECA

100MG

N013077 001

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

ALPHACAINE HYDROCHLORIDE

CARLISLE

2%

A084721 001

LIDOCAINE HYDROCHLORIDE

ABBOTT

10%

A087980 001 Feb 02, 1983

20%

A089362 001 May 25, 1988

ABRAXIS PHARM

1%

A080420 001

1%

A086761 001

1.5%

A080420 005

2%

A080420 002

2%

A080420 004

2%

A086761 002

2%

N017508 001

4%

N017508 002

20%

N017508 004

AKORN

1%

A085037 001

2%

A085037 002

AM REGENT

1%

A080850 001

1%

A091564 001 Aug 14, 2015

BEL MAR

1%

A080710 001

2%

A080760 001

BELMORA LLC

2%

A080504 001

DELL LABS

1%

A083387 001

2%

A083388 001

ELKINS SINN

0.5%

A085131 001

4%

A084626 001

GD SEARLE LLC

1%

A083135 001

2%

A083135 002

HOSPIRA

1%

A040013 001 Jun 23, 1995

1.5%

A088330 001 May 17, 1984

2%

A088331 001 May 17, 1984

20%

A083158 003

INTL MEDICATION

1%

N017701 002

2%

N017701 001

1GM/VIAL

N018543 001

2GM/VIAL

N018543 002

LUITPOLD

2%

A083198 001

LYPHOMED

1%

A080390 001

2%

A080390 002

MILES

1%

A080414 001

2%

A080414 002

RISING

0.5%

A091056 001 Dec 08, 2010

0.5%

A091058 001 Sep 30, 2010

1%

A091056 002 Dec 08, 2010

1%

A091058 002 Sep 30, 2010

2%

A202242 001 Apr 11, 2014

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-285(of 478)

** See List Footnote

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCAINE HYDROCHLORIDE

WATSON LABS

1%

A080377 001

1%

A083627 001

2%

A080377 002

2%

A083627 002

WYETH AYERST

1%

A083083 001

2%

A083083 002

LIDOCAINE HYDROCHLORIDE 0.1% AND DEXTROSE 5% IN PLASTIC CONTAINER

BAXTER HLTHCARE

100MG/100ML

N018461 001

LIDOCAINE HYDROCHLORIDE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN

200MG/100ML

N018967 001 Mar 30, 1984

LIDOCAINE HYDROCHLORIDE 0.2% IN DEXTROSE 5%

HOSPIRA

200MG/100ML

A083158 005

LIDOCAINE HYDROCHLORIDE 0.2% IN DEXTROSE 5% IN PLASTIC CONTAINER

ABBOTT

200MG/100ML

N018954 001 Jul 09, 1985

HOSPIRA

200MG/100ML

N018388 001

LIDOCAINE HYDROCHLORIDE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN

400MG/100ML

N018967 002 Mar 30, 1984

LIDOCAINE HYDROCHLORIDE 0.4% IN DEXTROSE 5%

HOSPIRA

400MG/100ML

A083158 006

LIDOCAINE HYDROCHLORIDE 0.4% IN DEXTROSE 5% IN PLASTIC CONTAINER

HOSPIRA

400MG/100ML

N018388 002

LIDOCAINE HYDROCHLORIDE 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER

B BRAUN

800MG/100ML

N018967 003 Mar 30, 1984

LIDOCAINE HYDROCHLORIDE 0.8% IN DEXTROSE 5% IN PLASTIC CONTAINER

HOSPIRA

800MG/100ML

N018388 003 Nov 05, 1982

LIDOCAINE HYDROCHLORIDE IN PLASTIC CONTAINER

HOSPIRA

1.5%

A088326 001 Jul 31, 1984

10%

A088367 001 Jul 31, 1984

20%

A088368 001 Jul 31, 1984

LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE

INTL MEDICATION

4%

N017702 002

20%

N017702 001

MYLAN LABS LTD

2%

A090665 001 Sep 27, 2010

LIDOCATON

PHARMATON

2%

A084727 001 Aug 17, 1983

LIDOPEN

MERIDIAN MEDCL TECHN

10%

N017549 001

XYLOCAINE

ASTRAZENECA

1%

N010418 005

1.5%

N010418 009

2%

N010418 007

XYLOCAINE 4% PRESERVATIVE FREE

+

FRESENIUS KABI USA

4%

N010417 001

XYLOCAINE DENTAL

DENTSPLY PHARM

2%

N021380 001

XYLOCAINE PRESERVATIVE FREE

+

FRESENIUS KABI USA

1% **

N016801 005 Jan 19, 1988

+

2% **

N016801 001

+

4% **

N016801 002

10% **

N016801 003

+

20% **

N016801 004

INJECTABLE; SPINAL

XYLOCAINE 1.5% W/ DEXTROSE 7.5%

FRESENIUS KABI USA

1.5%

N016297 001

XYLOCAINE 5% W/ GLUCOSE 7.5%

ASTRAZENECA

5%

N010496 002 Jul 07, 1982

JELLY; TOPICAL

ANESTACON

BIONPHARMA INC

2%

A080429 001

LIDOCAINE HYDROCHLORIDE

COSETTE

2%

A081318 001 Apr 29, 1993

WATSON LABS INC

2%

A040837 001 Mar 23, 2011

XYLOCAINE

+

AKORN

2% **

N008816 001

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-286(of 478)

** See List Footnote

LIDOCAINE HYDROCHLORIDE

SOLUTION;ORAL

LIDOCAINE HYDROCHLORIDE VISCOUS

ACTAVIS MID ATLANTIC 2%

A086578 001

INTL MEDICATION 2%

A086389 001 Feb 02, 1982

XYLOCAINE VISCOUS

+ FRESENIUS KABI USA 2% **

N009470 001

SOLUTION;TOPICAL

LARYNGOTRACHEAL ANESTHESIA KIT

KENDALL IL 4%

A087931 001 Jun 10, 1983

LIDOCAINE HYDROCHLORIDE

PACO 4%

A089688 001 Jun 30, 1989

LTA II KIT

HOSPIRA 4%

A080409 001

A088542 001 Jul 31, 1984

PEDIATRIC LTA KIT

ABBOTT 2%

A088572 001

A085995 001 Jul 31, 1984

HOSPIRA 2%

XYLOCAINE 4% PRESERVATIVE FREE

+ FRESENIUS KABI USA 4% **

N010417 002

LIDOCAINE HYDROCHLORIDE; OXYTETRACYCLINE

INJECTABLE;INJECTION

TERRAMYCIN

PFIZER 2%;50MG/ML
2%;125MG/ML

A060567 001

A060567 002

LIDOCAINE; PRILOCAINE

CREAM;TOPICAL

EMLA

+ TEVA BRANDED PHARM 2.5%;2.5%

N019941 001 Dec 30, 1992

LIDOCAINE AND PRILOCAINE

RHODES PHARMS 2.5%;2.5%

A213253 001 Sep 21, 2020

DISC;TOPICAL

EMLA

ASTRAZENECA 2.5%;2.5%

N020962 001 Feb 04, 1998

LIDOCAINE; TETRACAINE

PATCH;TOPICAL

SYNERA

+ GALEN SPECIALTY 70MG;70MG

N021623 001 Jun 23, 2005

LINACLOTIDE

CAPSULE;ORAL

LINACLOTIDE

MYLAN 145MCG
290MCG

A209564 001 Feb 09, 2021

A209564 002 Feb 09, 2021

LINCOMYCIN HYDROCHLORIDE

CAPSULE;ORAL

LINCOCIN

PHARMACIA AND UPJOHN EQ 250MG BASE
EQ 500MG BASE

N050316 001

N050316 002

INJECTABLE;INJECTION

LINCOMYCIN HYDROCHLORIDE

ATHENEX INC EQ 300MG BASE/ML

A212770 001 Mar 12, 2021

WATSON LABS EQ 300MG BASE/ML

A063180 001 Apr 16, 1991

LINDANE

CREAM;TOPICAL

KWELL

REED AND CARNRICK 1%
1%

A084218 001

N006309 001

LOTION;TOPICAL

GAMENE

SOLA BARNES HIND 1%

A084989 001

KWELL

REED AND CARNRICK 1%
1%

A084218 002

N006309 003

LINDANE

OLTA PHARMS 1%

A087313 001

WOCKHARDT BIO AG 1%

A088190 001 Aug 16, 1984

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-287(of 478)

** See List Footnote

LINDANE

LOTION; TOPICAL

SCABENE

STIEFEL

1%

A086769 001

SHAMPOO; TOPICAL

GAMENE

SOLA BARNES HIND

1%

A084988 001

KWELL

REED AND CARNRICK

1%

A084219 001

1%

N010718 001

LINDANE

OLTA PHARMS

1%

A087266 001

WOCKHARDT BIO AG

1%

A088191 001 Sep 18, 1984

SCABENE

STIEFEL

1%

A087940 001 Apr 08, 1983

LINEZOLID

SOLUTION; INTRAVENOUS

LINEZOLID

HOSPIRA

600MG/300ML (2MG/ML)

A205442 001 Jul 07, 2015

TEVA PHARMS

600MG/300ML (2MG/ML)

A200222 001 Jun 27, 2012

ZYVOX

+ PFIZER

400MG/200ML (2MG/ML) **

N021131 002 Apr 18, 2000

TABLET; ORAL

LINEZOLID

AMNEAL PHARMS

600MG

A204536 001 Dec 21, 2015

GATE PHARMS

600MG

A091210 001 Feb 05, 2016

RISING

600MG

A078845 001 Dec 21, 2015

TEVA PHARMS USA

600MG

A078061 001 May 18, 2015

ZYVOX

+ PFIZER

400MG **

N021130 001 Apr 18, 2000

LIOTHYRONINE SODIUM

TABLET; ORAL

LIOTHYRONINE SODIUM

MYLAN

EQ 0.005MG BASE

A090326 001 Jul 14, 2009

EQ 0.025MG BASE

A090326 002 Jul 14, 2009

EQ 0.05MG BASE

A090326 003 Jul 14, 2009

WATSON LABS

EQ 0.025MG BASE

A085755 001 Jan 25, 1982

EQ 0.05MG BASE

A085753 001 Feb 03, 1982

LIOTRIX (T4; T3)

TABLET; ORAL

EUTHROID-0.5

PARKE DAVIS

0.03MG; 0.0075MG

N016680 001

EUTHROID-1

PARKE DAVIS

0.06MG; 0.015MG

N016680 002

EUTHROID-2

PARKE DAVIS

0.12MG; 0.03MG

N016680 003

EUTHROID-3

PARKE DAVIS

0.18MG; 0.045MG

N016680 004

THYROLAR-0.25

+ ALLERGAN

0.0125MG; 0.0031MG

N016807 001

THYROLAR-0.5

+ ALLERGAN

0.025MG; 0.0063MG

N016807 005

THYROLAR-1

+ ALLERGAN

0.05MG; 0.0125MG

N016807 004

THYROLAR-2

+ ALLERGAN

0.1MG; 0.025MG

N016807 002

THYROLAR-3

+ ALLERGAN

0.15MG; 0.0375MG

N016807 003

THYROLAR-5

ALLERGAN

0.25MG; 0.0625MG

N016807 006

LISINOPRIL

TABLET; ORAL

LISINOPRIL

GRAVITI PHARMS

2.5MG

A075999 001 Jul 01, 2002

5MG

A075999 002 Jul 01, 2002

10MG

A075999 003 Jul 01, 2002

20MG

A075999 004 Jul 01, 2002

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-288(of 478)

** See List Footnote

LISINOPRIL

TABLET;ORAL

LISINOPRIL

	30MG	A075999 005	Jul 01, 2002
	40MG	A075999 006	Jul 01, 2002
HERITAGE PHARMA	2.5MG	A075752 001	Jul 01, 2002
	5MG	A075752 002	Jul 01, 2002
	10MG	A075752 003	Jul 01, 2002
	20MG	A075752 004	Jul 01, 2002
	30MG	A075752 005	Jul 01, 2002
	40MG	A075752 006	Jul 01, 2002
HIKMA INTL PHARMS	2.5MG	A076063 001	Jul 01, 2002
	5MG	A076063 002	Jul 01, 2002
	10MG	A076063 003	Jul 01, 2002
	20MG	A076063 004	Jul 01, 2002
	30MG	A076063 006	Jun 27, 2003
	40MG	A076063 005	Jul 01, 2002
STRIDES PHARMA	2.5MG	A076071 001	Jul 01, 2002
	5MG	A076071 002	Jul 01, 2002
	10MG	A076071 003	Jul 01, 2002
	20MG	A076071 004	Jul 01, 2002
	30MG	A076071 005	Jul 01, 2002
	40MG	A076071 006	Jul 01, 2002
TEVA	2.5MG	A075783 001	Jul 01, 2002
	5MG	A075783 002	Jul 01, 2002
	10MG	A075783 003	Jul 01, 2002
	20MG	A075783 004	Jul 01, 2002
	30MG	A075783 005	Jul 01, 2002
	40MG	A075783 006	Jul 01, 2002
PRINIVIL			
MERCK	2.5MG	N019558 006	Jan 28, 1994
	5MG	N019558 001	Dec 29, 1987
	10MG	N019558 002	Dec 29, 1987
	20MG	N019558 003	Dec 29, 1987
	40MG	N019558 004	Oct 25, 1988

LITHIUM CARBONATE

CAPSULE;ORAL

ESKALITH

NOVEN THERAP

LITHIUM CARBONATE

ABLE

APOTEX INC

MYLAN

USL PHARMA

WATSON LABS

LITHONATE

SOLVAY

TABLET;ORAL

ESKALITH

JDS PHARMS

LITHANE

BAYER PHARMS

LITHIUM CARBONATE

HIKMA INTL PHARMS

PFIZER

LITHOTABS

SOLVAY

TABLET, EXTENDED RELEASE;ORAL

ESKALITH CR

JDS PHARMS

LITHIUM CARBONATE

ABLE

ALEMBIC PHARMS

HERITAGE PHARMA

300MG	N016860 001		
150MG	A076823 001	Jun 29, 2004	
300MG	A076121 001	Sep 27, 2001	
300MG	A076823 002	Jun 29, 2004	
600MG	A076823 003	Jun 29, 2004	
300MG	A076795 001	Nov 22, 2004	
150MG	A076243 002	Feb 24, 2003	
300MG	A076243 001	Jun 27, 2002	
600MG	A078763 001	Apr 15, 2008	
300MG	A072542 001	Feb 01, 1989	
300MG	A070407 001	Mar 19, 1987	
300MG	N016782 001		
300MG	N017971 001		
300MG	N018833 001	Jul 18, 1985	
300MG	A078715 001	Dec 28, 2010	
300MG	N016834 001		
300MG	N016980 001		
450MG **	N018152 001	Mar 29, 1982	
300MG	A076382 001	Apr 21, 2003	
300MG	A204445 001	Jun 10, 2015	
300MG	A076170 001	Jun 10, 2002	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-289(of 478)

** See List Footnote

LITHIUM CARBONATETABLET, EXTENDED RELEASE;ORAL
LITHIUM CARBONATE

	450MG	A076366 001	Aug 21, 2003
HIKMA INTL PHARMS	450MG	A076490 001	Jun 17, 2003

LITHIUM CITRATE

SYRUP;ORAL

LITHIUM CITRATE

+ HIKMA

EQ 300MG CARBONATE/5ML

N018421 001

LITHONATE

SOLVAY

EQ 300MG CARBONATE/5ML

N017672 001

LOMEFLOXACIN HYDROCHLORIDE

TABLET;ORAL

MAXAQUIN

PHARMACIA

EQ 400MG BASE

N020013 001 Feb 21, 1992

LOMITAPIDE MESYLATE

CAPSULE;ORAL

JUXTAPID

+ AMRYT

EQ 40MG BASE

N203858 005 Apr 23, 2015

+

EQ 60MG BASE

N203858 006 Apr 23, 2015

LOMUSTINE

CAPSULE;ORAL

GLEOSTINE

+ CORDEN PHARMA

5MG

N017588 004 Dec 19, 2014

LOPERAMIDE HYDROCHLORIDE

CAPSULE;ORAL

IMODIUM

J AND J CONSUMER INC

2MG **

N017690 001

+

2MG **

N017694 001

LOPERAMIDE HYDROCHLORIDE

CHARTWELL RX

2MG

A072993 001 Aug 28, 1992

ROXANE

2MG

A073080 001 Nov 27, 1991

TEVA

2MG

A073122 001 Aug 30, 1991

SOLUTION;ORAL

IMODIUM

JANSSEN PHARMS

1MG/5ML

N019037 001 Jul 31, 1984

LOPERAMIDE HYDROCHLORIDE

AKORN

1MG/5ML

A074352 001 Nov 17, 1995

ALLIED

1MG/5ML

A073079 001 Apr 30, 1992

ALPHARMA US PHARMS

1MG/5ML

A073187 001 Sep 15, 1992

DURAMED PHARMS BARR

1MG/5ML

A074991 001 Dec 29, 1997

PERRIGO

1MG/5ML

A073243 001 Jan 21, 1992

TEVA

1MG/5ML

A073478 001 Jun 23, 1995

WATSON LABS

1MG/5ML

A073062 001 May 28, 1993

TABLET;ORAL

LOPERAMIDE HYDROCHLORIDE

ABLE

2MG

A073528 001 Nov 30, 1993

CONTRACT PHARMACAL

2MG

A073254 001 Jul 30, 1993

PERRIGO

2MG

A074194 001 Oct 30, 1992

TABLET, CHEWABLE;ORAL

IMODIUM A-D EZ CHEWS

+ J AND J CONSUMER INC 2MG

N020448 001 Jul 24, 1997

LOPERAMIDE HYDROCHLORIDE; SIMETHICONE

TABLET, CHEWABLE;ORAL

IMODIUM MULTI-SYMPTOM RELIEF

+ J AND J CONSUMER INC 2MG;125MG

N020606 001 Jun 26, 1996

LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE

PERRIGO

2MG;125MG

A076029 001 Aug 30, 2002

LOPINAVIR; RITONAVIR

CAPSULE;ORAL

KALETRA

ABBVIE

133.3MG;33.3MG

N021226 001 Sep 15, 2000

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-290(of 478)

** See List Footnote

LORACARBEF

CAPSULE; ORAL

LORABID

KING PHARMS

200MG

N050668 001 Dec 31, 1991

400MG

N050668 002 Apr 05, 1996

FOR SUSPENSION; ORAL

LORABID

KING PHARMS

100MG/5ML

N050667 001 Dec 31, 1991

200MG/5ML

N050667 002 Dec 31, 1991

LORATADINE

CAPSULE; ORAL

LORATADINE

STRIDES PHARMA

10MG

A211926 001 Jan 15, 2020

SYRUP; ORAL

CLARITIN HIVES RELIEF

+ BAYER HEALTHCARE LLC 1MG/ML **

N020641 003 Nov 19, 2003

LORATADINE

PHARM ASSOC

1MG/ML

A075565 001 Oct 05, 2004

RANBAXY LABS LTD

1MG/ML

A076529 001 Aug 20, 2004

TEVA

1MG/ML

A075505 001 Nov 07, 2003

TABLET; ORAL

LORATADINE

MYLAN

10MG

A075790 001 Nov 07, 2008

10MG

A078447 001 Aug 12, 2011

PERRIGO

10MG

N021512 001 Jun 24, 2004

TABLET, ORALLY DISINTEGRATING; ORAL

LORATADINE

ACTAVIS LABS FL INC

10MG

A075990 001 Nov 03, 2003

GLAXOSMITHKLINE

10MG

A075822 001 Feb 10, 2003

LORATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

LORATADINE AND PSEUDOEPHEDRINE SULFATE

HERITAGE PHARMA

5MG; 120MG

A076208 001 Jan 28, 2004

LORAZEPAM

CONCENTRATE; ORAL

LORAZEPAM

CHARTWELL MOLECULAR

2MG/ML

A079244 001 Apr 28, 2009

INJECTABLE; INJECTION

LORAZEPAM

AKORN

2MG/ML

A074974 001 Jul 23, 1998

BEDFORD

2MG/ML

A077076 001 Jul 13, 2005

4MG/ML

A077076 002 Jul 13, 2005

DAVA PHARMS INC

2MG/ML

A074793 001 Mar 16, 2000

4MG/ML

A074793 002 Mar 16, 2000

DR REDDYS

1MG/0.5ML

A074551 003 Sep 12, 1996

2MG/ML

A074535 001 Sep 12, 1996

2MG/ML

A074551 001 Sep 12, 1996

4MG/ML

A074535 002 Sep 12, 1996

4MG/ML

A074551 002 Sep 12, 1996

HIKMA

2MG/ML

A074496 001 Sep 28, 1998

4MG/ML

A074496 002 Sep 28, 1998

HOSPIRA

2MG/ML

A074280 001 May 27, 1994

2MG/ML

A074300 001 Apr 12, 1994

4MG/ML

A074280 002 May 27, 1994

4MG/ML

A074300 003 Mar 19, 1997

RISING

2MG/ML

A200217 001 Apr 04, 2017

2MG/ML

A200542 001 Apr 28, 2017

4MG/ML

A200217 002 Apr 04, 2017

4MG/ML

A200542 002 Apr 28, 2017

WATSON LABS

2MG/ML

A074276 001 Apr 15, 1994

4MG/ML

A074276 002 Apr 15, 1994

LORAZEPAM PRESERVATIVE FREE

BEDFORD LABS

2MG/ML

A077074 001 Jul 13, 2005

4MG/ML

A077074 002 Jul 13, 2005

SOLUTION; ORAL

LORAZEPAM

ROXANE

0.5MG/5ML

A074648 001 Mar 18, 1997

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-291(of 478)

** See List Footnote

LORAZEPAM

TABLET;ORAL

LORAZ

QUANTUM PHARMICS	0.5MG	A070200	001	Aug 09, 1985
	1MG	A070201	001	Aug 09, 1985
	2MG	A070202	001	Aug 09, 1985

LORAZEPAM

AM THERAP	0.5MG	A070727	001	Mar 07, 1986
	1MG	A070728	001	Mar 07, 1986
	2MG	A070729	001	Mar 07, 1986
ANDA REPOSITORY	0.5MG	A072555	002	Mar 29, 1991
	1MG	A072555	003	Mar 29, 1991
	2MG	A072555	001	Mar 29, 1991
ANI PHARMS	0.5MG	A077396	001	Dec 13, 2006
	1MG	A077396	002	Dec 13, 2006
	2MG	A077396	003	Dec 13, 2006
HALSEY	0.5MG	A071434	001	Sep 01, 1987
	1MG	A071435	001	Sep 01, 1987
	2MG	A071436	001	Sep 01, 1987
MUTUAL PHARM	0.5MG	A070472	001	Dec 10, 1985
	1MG	A070473	001	Dec 10, 1985
	2MG	A070474	001	Dec 10, 1985
PAR PHARM	0.5MG	A070675	001	Dec 01, 1986
	1MG	A070676	001	Dec 01, 1986
	2MG	A070677	001	Dec 01, 1986
RISING	0.5MG	A077657	001	Mar 16, 2006
	1MG	A077657	002	Mar 16, 2006
	2MG	A077657	003	Mar 16, 2006
SANDOZ	0.5MG	A071193	001	Apr 15, 1988
	1MG	A071194	001	Apr 15, 1988
	2MG	A071195	001	Apr 15, 1988
STRIDES PHARMA	0.5MG	A071591	002	Oct 13, 1987
	1MG	A071591	003	Oct 13, 1987
	2MG	A071591	001	Oct 13, 1987
SUN PHARM INDS LTD	0.5MG	A076045	001	Aug 29, 2001
	1MG	A076045	002	Aug 29, 2001
	2MG	A076045	003	Aug 29, 2001
SUPERPHARM	0.5MG	A071245	001	Feb 09, 1987
	1MG	A071246	001	Feb 09, 1987
	2MG	A071247	001	Feb 09, 1987
USL PHARMA	1MG	A070539	001	Dec 22, 1986
	2MG	A070540	001	Dec 22, 1986
WARNER CHILCOTT	1MG	A071038	001	Jan 12, 1988
	2MG	A071039	001	Jan 12, 1988
WATSON LABS	0.5MG	A071086	001	Mar 23, 1987
	0.5MG	A071117	001	Jul 24, 1986
	1MG	A071087	001	Mar 23, 1987
	1MG	A071118	001	Jul 24, 1986
	2MG	A071088	001	Mar 23, 1987
	2MG	A071110	001	Jul 24, 1986

LOSARTAN POTASSIUM

TABLET;ORAL

LOSARTAN POTASSIUM

APOTEX CORP	25MG	A090790	001	Oct 06, 2010
	50MG	A090790	002	Oct 06, 2010
	100MG	A090790	003	Oct 06, 2010
HIKMA	25MG	A077459	001	Oct 06, 2010
	50MG	A077459	002	Oct 06, 2010
	100MG	A077459	003	Oct 06, 2010
HISUN PHARM HANGZHOU	25MG	A204795	001	Apr 04, 2019
	50MG	A204795	002	Apr 04, 2019
	100MG	A204795	003	Apr 04, 2019
MYLAN	25MG	A091590	001	Oct 06, 2010
	50MG	A091590	002	Oct 06, 2010
	100MG	A091590	003	Oct 06, 2010
TEVA	25MG	A076958	001	Apr 06, 2010
	50MG	A076958	002	Apr 06, 2010
	100MG	A076958	003	Apr 06, 2010
TORRENT PHARMS	25MG	A090467	001	Oct 06, 2010

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-292(of 478)

** See List Footnote

LOSARTAN POTASSIUM

TABLET;ORAL

LOSARTAN POTASSIUM

	50MG	A090467	002	Oct 06, 2010
	100MG	A090467	003	Oct 06, 2010
UPSHER SMITH LABS	25MG	A090544	001	Oct 06, 2010
	50MG	A090544	002	Oct 06, 2010
	100MG	A090544	003	Oct 06, 2010

LOTEPREDNOL ETABONATE

SUSPENSION/DROPS;OPHTHALMIC

LOTEMAX

PHARMOS	0.5%	N020841	001	Mar 09, 1998

LOVASTATIN

TABLET;ORAL

LOVASTATIN

MYLAN	10MG	A075451	001	Dec 17, 2001
	10MG	A075935	001	Dec 17, 2001
	20MG	A075451	002	Dec 17, 2001
	20MG	A075935	002	Dec 17, 2001
	40MG	A075451	003	Dec 17, 2001
	40MG	A075935	003	Dec 17, 2001
SUN PHARM INDUSTRIES	10MG	A077520	001	Apr 14, 2006
	20MG	A077520	002	Apr 14, 2006
	40MG	A077520	003	Apr 14, 2006

MEVACOR

+	MERCK	10MG **	N019643	002	Mar 28, 1991
+		20MG **	N019643	003	Aug 31, 1987
+		40MG **	N019643	004	Dec 14, 1988

TABLET, EXTENDED RELEASE;ORAL

ALTOPREV

COVIS	10MG	N021316	001	Jun 26, 2002

LOXAPINE HYDROCHLORIDE

CONCENTRATE;ORAL

LOXITANE C

TEVA BRANDED PHARM	EQ 25MG BASE/ML	N017658	001	

INJECTABLE;INJECTION

LOXITANE IM

ACTAVIS LABS UT INC	EQ 50MG BASE/ML	N018039	001	

LOXAPINE SUCCINATE

CAPSULE;ORAL

LOXAPINE SUCCINATE

RISING	EQ 5MG BASE	A076762	001	Nov 01, 2004
	EQ 10MG BASE	A076762	002	Nov 01, 2004
	EQ 25MG BASE	A076762	003	Nov 01, 2004
	EQ 50MG BASE	A076762	004	Nov 01, 2004

LOXITANE

+	TEVA BRANDED PHARM	EQ 5MG BASE **	N017525	001
+		EQ 10MG BASE **	N017525	002
+		EQ 25MG BASE **	N017525	003
+		EQ 50MG BASE **	N017525	004

TABLET;ORAL

LOXITANE

+	TEVA BRANDED PHARM	EQ 10MG BASE **	N017525	006
+		EQ 25MG BASE **	N017525	007
+		EQ 50MG BASE **	N017525	008

LUBIPROSTONE

CAPSULE;ORAL

LUBIPROSTONE

AMNEAL	8MCG	A209450	001	Nov 30, 2021
	24MCG	A209450	002	Nov 30, 2021
ANCHEN PHARMS	8MCG	A201442	001	Jun 27, 2022
	24MCG	A201442	002	Jun 27, 2022

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-293(of 478)

** See List Footnote

LUCINACTANTSUSPENSION;INTRATRACHEAL
SURFAXIN

WINDTREE THERAP 8.5ML N021746 001 Mar 06, 2012

LURASIDONE HYDROCHLORIDE

TABLET;ORAL

LURASIDONE HYDROCHLORIDE

AMNEAL PHARMS CO	20MG	A208002 001	Jan 03, 2019
	40MG	A208002 002	Jan 03, 2019
	60MG	A208002 003	Jan 03, 2019
	80MG	A208002 004	Jan 03, 2019
	120MG	A208002 005	Jan 03, 2019
EMCURE PHARMS LTD	20MG	A208058 001	Sep 04, 2019
	40MG	A208058 002	Sep 04, 2019
	60MG	A208058 003	Sep 04, 2019
	80MG	A208058 004	Sep 04, 2019
LUPIN LTD	20MG	A208031 001	Jan 03, 2019
	40MG	A208031 002	Jan 03, 2019
	60MG	A208031 003	Jan 03, 2019
	80MG	A208031 004	Jan 03, 2019
	120MG	A208031 005	Jan 03, 2019
PIRAMAL HLTHCARE UK	20MG	A212091 001	Dec 28, 2020
	40MG	A212091 002	Dec 28, 2020
	60MG	A212091 003	Dec 28, 2020
	80MG	A212091 004	Dec 28, 2020
	120MG	A212091 005	Dec 28, 2020
TEVA PHARMS USA	20MG	A208060 001	May 17, 2019
	40MG	A208060 002	May 17, 2019
	60MG	A208060 003	May 17, 2019
	80MG	A208060 004	May 17, 2019
	120MG	A208060 005	May 17, 2019
TORRENT	20MG	A208055 001	Jan 03, 2019
	40MG	A208055 002	Jan 03, 2019
	80MG	A208055 003	Jan 03, 2019
	120MG	A208055 004	Jan 03, 2019
WATSON LABS TEVA	20MG	A208016 001	Feb 02, 2021
	40MG	A208016 002	Feb 02, 2021
	60MG	A208016 003	Feb 02, 2021
	80MG	A208016 004	Feb 02, 2021
	120MG	A208016 005	Feb 02, 2021

LYPRESSIN

SOLUTION;NASAL

DIAPID

NOVARTIS 0.185MG/ML N016755 001

MACITENTAN

TABLET;ORAL

MACITENTAN

ZYDUS 10MG A211224 001 Apr 06, 2021

MAFENIDE ACETATE

FOR SOLUTION;TOPICAL

MAFENIDE ACETATE

PAR FORM 5% A201511 001 Feb 12, 2013

SULFAMYLOX

+ MYLAN INSTITUTIONAL 5% N019832 003 Jun 05, 1998

MAGNESIUM ACETATE TETRAHYDRATE; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

PLASMA-LYTE 56 IN PLASTIC CONTAINER

BAXTER HLTHCARE 32MG/100ML;128MG/100ML;234MG/100ML N019047 001 Jun 15, 1984

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE;INJECTION

ISOLYTE S PH 7.4 IN PLASTIC CONTAINER

B BRAUN	30MG/100ML;37MG/100ML;0.82MG/100ML;370MG/100ML;530MG/100ML;500MG/100ML;12MG/100ML	N019006 001	Apr 04, 1984

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-294(of 478)

** See List Footnote

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE; INJECTION

ISOLYTE S IN PLASTIC CONTAINER

B BRAUN	30MG/100ML; 37MG/100ML; 370MG/100ML; 530MG /100ML; 500MG/100ML	N018252 001

MULTIPLE ELECTROLYTES INJECTION TYPE 1 USP PH 5.5

FRESENIUS KABI USA	30MG/100ML; 37MG/100ML; 368MG/100ML; 526MG /100ML; 502MG/100ML	A215370 001 Jun 29, 2022

MULTIPLE ELECTROLYTES INJECTION TYPE 1 USP PH 7.4

FRESENIUS KABI USA	30MG/100ML; 37MG/100ML; 368MG/100ML; 526MG /100ML; 502MG/100ML	A215371 001 Jun 08, 2022

SOLUTION; IRRIGATION

PHYSIOSOL IN PLASTIC CONTAINER

HOSPIRA INC	14MG/100ML; 37MG/100ML; 222MG/100ML; 526MG /100ML; 502MG/100ML	N018406 001

PHYSIOSOL PH 7.4 IN PLASTIC CONTAINER

HOSPIRA INC	30MG/100ML; 37MG/100ML; 222MG/100ML; 526MG /100ML; 502MG/100ML	N018406 002 Jul 08, 1982

SYNOVALYTE IN PLASTIC CONTAINER

BAXTER HLTHCARE	30MG/100ML; 37MG/100ML; 368MG/100ML; 526MG /100ML; 502MG/100ML	N019326 001 Jan 25, 1985

MAGNESIUM HYDROXIDE; OMEPRAZOLE; SODIUM BICARBONATE

TABLET; ORAL

MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE

SANTARUS	343MG; 20MG; 750MG	N022456 001 Dec 04, 2009
	343MG; 40MG; 750MG	N022456 002 Dec 04, 2009

TABLET, CHEWABLE; ORAL

ZEGERID

SANTARUS	700MG; 20MG; 600MG	N021850 001 Mar 24, 2006
	700MG; 40MG; 600MG	N021850 002 Mar 24, 2006

MAGNESIUM SULFATE; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; POTASSIUM SULFATE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE

SOLUTION; ORAL

SUCLEAR

+ BRAINTREE LABS	1.6GM/BOT, 3.13GM/BOT, 17.5GM/BOT, N/A, N/A , N/A, N/A; N/A, N/A, N/A, 210GM, 0.74GM, 2.86G M, 5.6GM **	N203595 001 Jan 18, 2013

MAGNESIUM SULFATE; POTASSIUM SULFATE; SODIUM SULFATE

POWDER; ORAL

COLPREP KIT

+ GATOR PHARMS	1.6GM/BOT; 3.13GM/BOT; 17.5GM/BOT	N204553 001 Dec 27, 2016

MALATHION

LOTION; TOPICAL

MALATHION

MYLAN PHARMS INC	0.5%	A078743 001 Mar 06, 2009

OVIDE

+ TARO PHARM INDS LTD	0.5% **	N018613 001 Aug 02, 1982

MANGAFODIPIR TRISODIUM

INJECTABLE; INJECTION

TESLASCAN

IC TARGETS	37.9MG/ML	N020652 001 Nov 26, 1997

MANGANESE CHLORIDE TETRAHYDRATE

FOR SOLUTION; ORAL

LUMENHANCE

BRACCO	3.49MG/GM	N020686 001 Dec 19, 1997

MANGANESE SULFATE

INJECTABLE; INJECTION

MANGANESE SULFATE

+ ABRAXIS PHARM	EQ 0.1MG MANGANESE/ML **	N019228 001 May 05, 1987

MANNITOL

INJECTABLE; INJECTION

MANNITOL 10%

B BRAUN	10GM/100ML	N016080 002
HOSPIRA	10GM/100ML	N016269 002
MILES	10GM/100ML	N016472 002

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-295(of 478)

** See List Footnote

MANNITOL

INJECTABLE; INJECTION

MANNITOL 10% IN PLASTIC CONTAINER

ICU MEDICAL INC	10GM/100ML	N019603	002	Jan 08, 1987

MANNITOL 10% W/ DEXTROSE 5% IN DISTILLED WATER

B BRAUN	10GM/100ML	N016080	006	

MANNITOL 15%

B BRAUN	15GM/100ML	N016080	003	

HOSPIRA	15GM/100ML	N016269	003	

MILES	15GM/100ML	N016472	005	

MANNITOL 15% IN PLASTIC CONTAINER

ICU MEDICAL INC	15GM/100ML	N019603	003	Jan 08, 1990

MANNITOL 15% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.45%

B BRAUN	15GM/100ML	N016080	005	

MANNITOL 20%

B BRAUN	20GM/100ML	N014738	001	

	20GM/100ML	N016080	004	

HOSPIRA	20GM/100ML	N016269	004	

MILES	20GM/100ML	N016472	004	

MANNITOL 25%

ABRAXIS PHARM	12.5GM/50ML	A086754	001	

HOSPIRA	12.5GM/50ML	N016269	005	

IGI LABS INC	12.5GM/50ML	A089239	001	May 06, 1987

	12.5GM/50ML	A089240	001	May 06, 1987

INTL MEDICATION	12.5GM/50ML	A083051	001	

LUITPOLD	12.5GM/50ML	A087409	001	Jan 21, 1982

MERCK	12.5GM/50ML	N005620	001	

WATSON LABS	12.5GM/50ML	A087460	001	Jun 27, 1983

MANNITOL 5%

B BRAUN	5GM/100ML	N016080	001	

HOSPIRA	5GM/100ML	N016269	001	

MANNITOL 5% IN PLASTIC CONTAINER

ICU MEDICAL INC	5GM/100ML	N019603	001	Jan 08, 1987

MANNITOL 5% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.12%

B BRAUN	5GM/100ML	N016080	007	

SOLUTION; IRRIGATION

RESECTISOL

B BRAUN	5GM/100ML	N016704	002	

RESECTISOL IN PLASTIC CONTAINER

B BRAUN	5GM/100ML	N016772	002	

MANNITOL; SORBITOL

SOLUTION; IRRIGATION

SORBITOL-MANNITOL

HOSPIRA	540MG/100ML; 2.7GM/100ML	A080224	001	

SORBITOL-MANNITOL IN PLASTIC CONTAINER

HOSPIRA	540MG/100ML; 2.7GM/100ML	N017636	001	

MAPROTILINE HYDROCHLORIDE

TABLET; ORAL

LUDIOMIL

NOVARTIS	25MG	N017543	001	

	50MG	N017543	002	

	75MG	N017543	003	Sep 30, 1982

MAPROTILINE HYDROCHLORIDE

AM THERAP	25MG	A072129	001	Jan 14, 1988

	50MG	A072130	001	Jan 14, 1988

	75MG	A072131	001	Jan 14, 1988

HERITAGE PHARMA	25MG	A072162	001	Jun 01, 1988

	50MG	A072163	001	Jun 01, 1988

RISING	25MG	A072285	002	Oct 03, 1988

	50MG	A072285	001	Oct 03, 1988

	75MG	A072285	003	Oct 03, 1988

WATSON LABS	25MG	A071943	001	Dec 30, 1987

	50MG	A071944	001	Dec 30, 1987

	75MG	A071945	001	Dec 30, 1987

	75MG	A072164	001	Jun 01, 1988

DISCONTINUED DRUG PRODUCT LIST

6-296(of 478)

** See List Footnote

MASOPROCOL

CREAM;TOPICAL

ACTINEX

UNIV AZ CANCER CTR 10%

N019940 001 Sep 04, 1992

MAZINDOL

TABLET;ORAL

MAZANOR

WYETH AYERST 1MG

N017980 002

2MG

N017980 001

SANOREX

+ NOVARTIS 1MG **

N017247 001

+ 2MG **

N017247 002

MEBENDAZOLE

TABLET, CHEWABLE;ORAL

VERMOX

+ JANSSEN PHARMS 100MG **

N017481 001

+ 500MG

N208398 001 Oct 19, 2016

MEBUTAMATE

TABLET;ORAL

DORMATE

MEDPOINTE PHARM HLC 600MG

N017374 001

MECAMYLAMINE HYDROCHLORIDE

TABLET;ORAL

INVERSINE

+ TARGACEPT 2.5MG **

N010251 001

MECHLORETHAMINE HYDROCHLORIDE

INJECTABLE;INJECTION

MUSTARGEN

+ RECORDATI RARE 10MG/VIAL

N006695 001

MECLIZINE HYDROCHLORIDE

TABLET;ORAL

MECLIZINE HYDROCHLORIDE

ABC HOLDING 12.5MG

A085253 001

25MG

A085252 001

AMNEAL PHARMS 50MG

A201451 003 Feb 23, 2011

ANABOLIC 25MG

A085891 001

ANI PHARMS 12.5MG

A085269 001

12.5MG

A088732 001 Dec 11, 1985

25MG

A085740 001

AUROBINDO PHARMA USA 12.5MG

A202640 001 Sep 17, 2012

25MG

A202640 002 Sep 17, 2012

50MG

A202640 003 Sep 17, 2012

BUNDY 12.5MG

A084382 001

25MG

A084872 001

IVAX SUB TEVA PHARMS 12.5MG

A083784 001

KV PHARM 12.5MG

A085524 001

25MG

A085523 001

PLIVA 25MG

A088734 001 Dec 11, 1985

RISING 12.5MG

A040179 001 Jan 30, 1997

25MG

A040179 002 Jan 30, 1997

STRIDES PHARMA 50MG

A089674 001 Mar 31, 1988

SUPERPHARM 12.5MG

A089113 001 Aug 20, 1985

25MG

A089114 001 Aug 20, 1985

UDL 12.5MG

A088256 001 Jun 13, 1983

25MG

A088257 001 Jun 13, 1983

VANGARD 12.5MG

A087877 001 Apr 20, 1982

25MG

A087620 001 Jan 04, 1982

WATSON LABS 12.5MG

A085195 001

TABLET, CHEWABLE;ORAL

MECLIZINE HYDROCHLORIDE

IVAX SUB TEVA PHARMS 25MG

A084976 001

NEXGEN PHARMA INC 25MG

A086392 001

PLIVA 25MG

A088733 001 Dec 11, 1985

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-297(of 478)

** See List Footnote

MECLOCYCLINE SULFOSALICYLATE

CREAM;TOPICAL

MECLAN

JOHNSON AND JOHNSON 1%

N050518 001

MECLOFENAMATE SODIUM

CAPSULE;ORAL

MECLODIUM

QUANTUM PHARMICS

EQ 50MG BASE

A071380 001 Jul 14, 1987

EQ 100MG BASE

A071381 001 Jul 14, 1987

MECLOFENAMATE SODIUM

AM THERAP

EQ 50MG BASE

A071362 001 Feb 10, 1987

EQ 100MG BASE

A071363 001 Feb 10, 1987

ANI PHARMS

EQ 50MG BASE

A071469 002 Apr 15, 1987

EQ 100MG BASE

A071469 001 Apr 15, 1987

BARR

EQ 50MG BASE

A072848 001 Mar 20, 1989

EQ 100MG BASE

A072809 001 Mar 20, 1989

FOSUN PHARMA

EQ 50MG BASE

A072262 001 Nov 29, 1988

EQ 100MG BASE

A072263 001 Nov 29, 1988

PAR PHARM

EQ 50MG BASE

A072077 001 Mar 10, 1988

EQ 100MG BASE

A072078 001 Mar 10, 1988

USL PHARMA

EQ 50MG BASE

A071007 001 Mar 25, 1988

EQ 100MG BASE

A071008 001 Mar 25, 1988

VITARINE

EQ 50MG BASE

A071710 001 Jun 15, 1988

EQ 100MG BASE

A071684 001 Jun 15, 1988

WATSON LABS

EQ 50MG BASE

A070400 001 Nov 25, 1986

EQ 50MG BASE

A071640 001 Aug 11, 1987

EQ 100MG BASE

A070401 001 Nov 25, 1986

EQ 100MG BASE

A071641 001 Aug 11, 1987

MECLOMEN

PARKE DAVIS

EQ 50MG BASE

N018006 001

EQ 100MG BASE

N018006 002

MEDROXYPROGESTERONE ACETATE

INJECTABLE; INJECTION

DEPO-PROVERA

+ PFIZER

100MG/ML **

N012541 002

+

400MG/ML

N012541 003

MEDROXYPROGESTERONE ACETATE

CIPLA

150MG/ML

A210335 001 Jan 25, 2019

SANDOZ INC

150MG/ML

A078711 001 May 20, 2009

SUN PHARM

150MG/ML

A210760 001 May 01, 2019

150MG/ML

A210761 001 Apr 24, 2019

TEVA PHARMS USA

150MG/ML

A076552 001 Oct 27, 2004

TABLET;ORAL

AMEN

AMARIN PHARMS

10MG

A083242 001

CURRETAB

SOLVAY

10MG

A085686 001

CYCRIN

ESI

2.5MG

A081239 001 Oct 30, 1992

5MG

A081240 001 Oct 30, 1992

10MG

A089386 001 Sep 09, 1987

MEDROXYPROGESTERONE ACETATE

DURAMED PHARMS BARR

2.5MG

A040311 001 Dec 01, 1999

5MG

A040311 002 Dec 01, 1999

10MG

A040311 003 Dec 01, 1999

UPSHER SMITH LABS

10MG

A088484 001 Jul 26, 1984

MEDRYSONE

SUSPENSION;OPHTHALMIC

HMS

ALLERGAN

1%

N016624 003

MEFENAMIC ACID

CAPSULE;ORAL

MEFENAMIC ACID

NOSTRUM LABS INC

250MG

A090359 001 Feb 05, 2013

STRIDES PHARMA

250MG

A209209 001 Sep 18, 2020

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-298(of 478)

** See List Footnote

MEFLOQUINE HYDROCHLORIDE

TABLET;ORAL

LARIAM

+ ROCHE 250MG **

N019591 001 May 02, 1989

MEFLOQUINE HYDROCHLORIDE

HIKMA INTL PHARMS 250MG

A077699 001 Apr 21, 2010

SANDOZ 250MG

A076175 001 Feb 20, 2002

US ARMY WALTER REED 250MG **

N019578 001 May 02, 1989

MEGESTROL ACETATE

SUSPENSION;ORAL

MEGACE

+ BRISTOL MYERS SQUIBB 40MG/ML **

N020264 001 Sep 10, 1993

MEGESTROL ACETATE

HIKMA 40MG/ML

A075997 001 Feb 15, 2002

PHARM ASSOC 40MG/ML

A077404 001 Feb 16, 2006

TEVA PHARMS 40MG/ML

A075681 001 May 05, 2003

TABLET;ORAL

MEGACE

+ BRISTOL MYERS SQUIBB 20MG **

N016979 001

+ 40MG **

N016979 002

MEGESTROL ACETATE

HIKMA 20MG

A074458 001 Sep 29, 1995

40MG

A074458 002 Sep 29, 1995

TEVA 40MG

A074745 001 Feb 27, 1998

USL PHARMA 20MG

A070646 001 Oct 02, 1987

40MG

A070647 001 Oct 02, 1987

MELOXICAM

CAPSULE;ORAL

VIVLODEX

+ ICEUTICA OPERATIONS 5MG **

N207233 001 Oct 22, 2015

+ 10MG **

N207233 002 Oct 22, 2015

SOLUTION;INTRAVENOUS

ANJESO

+ BAUDAX 30MG/ML (30MG/ML)

N210583 001 Feb 20, 2020

TABLET;ORAL

MELOXICAM

AIPING PHARM INC 7.5MG

A077920 001 Jul 19, 2006

15MG

A077920 002 Jul 19, 2006

ANDA REPOSITORY 7.5MG

A077935 001 Jul 19, 2006

15MG

A077935 002 Jul 19, 2006

CR DOUBLE CRANE 7.5MG

A078039 001 Dec 14, 2006

15MG

A078039 002 Dec 14, 2006

HERITAGE PHARMA 7.5MG

A077936 001 Jul 19, 2006

15MG

A077936 002 Jul 19, 2006

IMPAX LABS INC 7.5MG

A077930 001 Jul 19, 2006

15MG

A077930 002 Jul 19, 2006

MYLAN 7.5MG

A077923 001 Jul 19, 2006

7.5MG

A077934 001 Jul 20, 2006

15MG

A077923 002 Jul 19, 2006

15MG

A077934 002 Jul 20, 2006

ROXANE 7.5MG

A077925 001 Jul 19, 2006

15MG

A077925 002 Jul 19, 2006

SUN PHARM INDS INC 7.5MG

A077937 001 Jul 19, 2006

15MG

A077937 002 Jul 19, 2006

YABAO PHARM 7.5MG

A077933 001 Jul 19, 2006

15MG

A077933 002 Jul 19, 2006

TABLET, ORALLY DISINTEGRATING;ORAL

QMIIZ ODT

+ TERSERA 7.5MG

N211210 001 Oct 19, 2018

+ 15MG

N211210 002 Oct 19, 2018

MELPHALAN

TABLET;ORAL

ALKERAN

+ APOTEX 2MG **

N014691 002

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-299(of 478)

** See List Footnote

MELPHALAN FLUFENAMIDE HYDROCHLORIDE

POWDER; INTRAVENOUS

PEPAXTO

+	ONCOPEPTIDES AB	EQ 20MG BASE/VIAL	N214383	001	Feb 26, 2021

MELPHALAN HYDROCHLORIDE

INJECTABLE; INJECTION

ALKERAN

+	APOTEX	EQ 50MG BASE/VIAL **	N020207	001	Nov 18, 1992

MELPHALAN HYDROCHLORIDE

MYLAN INSTITUTIONAL	EQ 50MG BASE/VIAL	A090299	001	Oct 27, 2009

PAR STERILE PRODUCTS	EQ 50MG BASE/VIAL	A204773	001	Aug 22, 2016

USWM	EQ 50MG BASE/VIAL	A207032	001	May 03, 2019

POWDER; INTRAVENOUS

MELPHALAN HYDROCHLORIDE

ACTAVIS LLC	EQ 50MG BASE/VIAL	A209323	001	Mar 06, 2020

MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

MEMANTINE HYDROCHLORIDE

ANCHEN PHARMS	7MG	A205784	001	Jun 09, 2017

14MG	A205784	002	Jun 09, 2017

21MG	A205784	003	Jun 09, 2017

28MG	A205784	004	Jun 09, 2017

ANI PHARMS	7MG	A205365	001	Feb 28, 2020

14MG	A205365	002	Feb 28, 2020

21MG	A205365	003	Feb 28, 2020

RISING	7MG	A206032	001	Sep 28, 2016

14MG	A206032	002	Sep 28, 2016

21MG	A206032	003	Sep 28, 2016

28MG	A206032	004	Sep 28, 2016

SUN PHARM	7MG	A205905	001	Sep 28, 2016

14MG	A205905	002	Sep 28, 2016

21MG	A205905	003	Sep 28, 2016

28MG	A205905	004	Sep 28, 2016

SOLUTION; ORAL

MEMANTINE HYDROCHLORIDE

TORRENT	2MG/ML	A205446	001	Dec 07, 2015

NAMENDA

+	ALLERGAN	2MG/ML	N021627	001	Apr 18, 2005

TABLET; ORAL

MEMANTINE HYDROCHLORIDE

CHARTWELL	5MG	A090244	001	Jul 11, 2018

10MG	A090244	002	Jul 11, 2018

JUBILANT GENERICS	5MG	A091585	001	Oct 13, 2015

10MG	A091585	002	Oct 13, 2015

LANNETT CO INC	5MG	A207236	001	Nov 10, 2016

10MG	A207236	002	Nov 10, 2016

NINGBO	5MG	A212947	001	Apr 03, 2020

10MG	A212947	002	Apr 03, 2020

ORBION PHARMS	5MG	A090044	001	Mar 12, 2012

10MG	A090044	002	Mar 12, 2012

RISING	5MG	A079225	001	Jan 30, 2015

10MG	A079225	002	Jan 30, 2015

TEVA PHARMS	5MG	A090052	001	Oct 25, 2011

10MG	A090052	002	Oct 25, 2011

TORRENT	5MG	A200155	001	Oct 13, 2015

10MG	A200155	002	Oct 13, 2015

MENADIOL SODIUM DIPHOSPHATE

INJECTABLE; INJECTION

KAPPADIONE

LILLY	10MG/ML	N005725	001

SYNKAYVITE

ROCHE	5MG/ML	N003718	004

10MG/ML	N003718	006

37.5MG/ML	N003718	008

TABLET; ORAL

SYNKAYVITE

ROCHE	5MG	N003718	010

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-300(of 478)

** See List Footnote

MENADIONE

TABLET;ORAL

MENADIONE

LILLY

5MG

N002139 003

MEPENZOLATE BROMIDE

SOLUTION;ORAL

CANTIL

SANOFI AVENTIS US

25MG/5ML

N010679 004

TABLET;ORAL

CANTIL

+

SANOFI AVENTIS US

25MG

N010679 003

MEPERIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

DEMEROL

VALIDUS PHARMS

25MG/ML

N005010 007

50MG/ML

N005010 002

75MG/ML

N005010 009

100MG/ML

N005010 003

MEPERIDINE HYDROCHLORIDE

ABBOTT

25MG/ML

A080388 001

50MG/ML

A080385 001

50MG/ML

A080387 001

75MG/ML

A080389 001

100MG/ML

A080386 001

BAXTER HLTHCARE

25MG/ML

A088279 001 Jun 15, 1984

50MG/ML

A088280 001 Jun 15, 1984

75MG/ML

A088281 001 Jun 15, 1984

100MG/ML

A088282 001 Jun 15, 1984

IGI LABS INC

25MG/ML

A089781 001 Mar 31, 1989

50MG/ML

A089782 001 Mar 31, 1989

50MG/ML

A089783 001 Mar 31, 1989

50MG/ML

A089784 001 Mar 31, 1989

75MG/ML

A089785 001 Mar 31, 1989

100MG/ML

A089786 001 Mar 31, 1989

100MG/ML

A089787 001 Mar 31, 1989

100MG/ML

A089788 001 Mar 31, 1989

INTL MEDICATION

10MG/ML

A086332 001

PARKE DAVIS

50MG/ML

A080364 002

75MG/ML

A080364 003

100MG/ML

A080364 001

WATSON LABS

50MG/ML

A073444 001 Mar 17, 1992

100MG/ML

A073445 001 Mar 17, 1992

MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE

HOSPIRA

10MG/ML

A040305 001 Mar 10, 1999

+

ICU MEDICAL INC

10MG/ML

A088432 001 Aug 16, 1984

INTL MEDICATION

10MG/ML

A081309 001 Aug 30, 1993

SPECGX LLC

10MG/ML

A040163 001 May 12, 1997

WATSON LABS

10MG/ML

A073443 001 Mar 17, 1992

SYRUP;ORAL

DEMEROL

VALIDUS PHARMS

50MG/5ML **

N005010 005

TABLET;ORAL

DEMEROL

+

VALIDUS PHARMS

50MG

N005010 001

+

100MG

N005010 004

MEPERIDINE HYDROCHLORIDE

ANDA REPOSITORY

50MG

A040893 001 Jun 24, 2009

75MG

A040893 002 Jun 24, 2009

100MG

A040893 003 Jun 24, 2009

150MG

A040893 004 Jun 24, 2009

BARR

50MG

A088639 001 Jul 02, 1984

100MG

A088640 001 Sep 19, 1984

DURAMED PHARMS BARR

50MG

A040318 001 Oct 05, 1999

100MG

A040318 002 Oct 05, 1999

HIKMA

50MG

A040110 001 Mar 12, 1997

100MG

A040110 002 Mar 12, 1997

SPECGX LLC

50MG

A040352 001 Jun 13, 2000

100MG

A040352 002 Jun 13, 2000

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-301(of 478)

** See List Footnote

MEPERIDINE HYDROCHLORIDE

TABLET; ORAL

MEPERIDINE HYDROCHLORIDE

STRIDES PHARMA	50MG	A040191 001	Dec 17, 1998
	100MG	A040191 002	Dec 17, 1998
SUN PHARM INDS INC	50MG	A040446 001	Aug 08, 2002
	100MG	A040446 002	Aug 08, 2002
SUN PHARM INDUSTRIES	50MG	A080448 001	
	100MG	A080448 002	
WATSON LABS	50MG	A040186 001	Jun 30, 1997
	100MG	A040186 002	Jun 30, 1997
WYETH AYERST	50MG	A080454 001	

MEPERIDINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

MEPERGAN

HIKMA	25MG/ML; 25MG/ML	N011730 001	

MEPHENTERMINE SULFATE

INJECTABLE; INJECTION

WYAMINE SULFATE

BAXTER HLTHCARE CORP	EQ 15MG BASE/ML	N008248 002	
	EQ 30MG BASE/ML	N008248 001	

MEPHENYTOIN

TABLET; ORAL

MESANTOIN

+ NOVARTIS	100MG **	N006008 001	

MEPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

ARESTOCAINE HYDROCHLORIDE

SOLVAY	3%	A084777 002	Apr 18, 1982

CARBOCAINE

+ EASTMAN KODAK	3% **	N012125 003	

ISOCAINE HYDROCHLORIDE

SEPTODONT INC	3%	A080925 001	

MEPIVACAINE HYDROCHLORIDE

BELMORA LLC	3%	A083559 001	

HOSPIRA INC	3%	A040806 001	Apr 28, 2008

INTL MEDICATION SYS	1%	A087509 001	Oct 05, 1982

WATSON LABS	1%	A088769 001	Nov 20, 1984

	2%	A088770 001	Nov 20, 1984

POLOCAINE

DENTSPLY PHARM	3%	A088653 001	Aug 21, 1984

MEPREDNISONE

TABLET; ORAL

BETAPAR

SCHERING	4MG	N016053 002	

MEPROBAMATE

CAPSULE; ORAL

EQUANIL

WYETH AYERST	400MG	N012455 002	

CAPSULE, EXTENDED RELEASE; ORAL

MEPROSPAN

MEDPOINTE PHARM HLC	200MG	N011284 001	

	400MG	N011284 002	

TABLET; ORAL

AMOSENE

FERNDAL LABS	400MG	A084030 001	

BAMATE

ALRA	200MG	A080380 001	

	400MG	A080380 002	

EQUANIL

WYETH AYERST	200MG	N010028 005	

	400MG	N010028 004	

MEPRIAM

TEVA	400MG	N016069 001	

MEPROBAMATE

ACELLA	400MG	A084153 001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-302(of 478)

** See List Footnote

MEPROBAMATE

TABLET; ORAL

MEPROBAMATE

BARR	600MG		A084230	001	
CHARTWELL MOLECULAR	200MG		N014882	002	
	400MG		N014882	001	
ELKINS SINN	200MG		N015426	002	
	400MG		N015426	001	
HEATHER	400MG		N016928	003	
	600MG		A084329	001	
IMPAX LABS	200MG		N014322	002	
	400MG		N014322	001	
IVAX SUB TEVA PHARMS	200MG		N015438	001	
	400MG		N015438	002	
	600MG		A084181	001	
LEDERLE	400MG		A086299	001	
LEE KM	400MG		A089538	001	Nov 25, 1987
MALLARD	400MG		N015072	002	
MK LABS	200MG		N014368	004	
	400MG		N014368	002	
MYLAN	400MG		A083618	001	
NEXGEN PHARMA INC	200MG		A084220	001	
	400MG		A084589	001	
PARKE DAVIS	200MG		A084744	001	
	400MG		A084744	002	
PERRIGO	200MG		A084546	001	
	400MG		A084547	001	
PHARMAVITE	400MG		A084438	001	
PUREPAC PHARM	200MG		A084804	001	
	400MG		A084804	002	
PVT FORM	400MG		N014601	001	
RISING	400MG		A080655	001	
ROXANE	600MG		A084332	001	
SANDOZ	200MG		N014547	002	
	400MG		N014547	001	
SCHERER LABS	400MG		A083343	001	
SOLVAY	200MG		A084435	001	
STANLABS PHARM	200MG		N014474	002	
	400MG		N014474	004	
SUN PHARM INDUSTRIES	200MG		A080699	001	
	400MG		A080699	002	
TABLICAPS	400MG		A083494	001	
TARO	200MG		A200998	001	May 23, 2011
	400MG		A200998	002	May 23, 2011
USL PHARMA	200MG		A087825	001	Mar 18, 1982
	400MG		A087826	001	Mar 18, 1982
VALEANT PHARM INTL	200MG		N015139	006	
	400MG		N015139	005	
VANGARD	400MG		A088011	001	Jul 14, 1982
+ WATSON LABS	200MG		A083304	001	
	200MG		A085720	001	
+	400MG		A083308	001	
	400MG		A085721	001	
	600MG		A084274	001	
	600MG		A085719	001	
WEST WARD	200MG		N015417	003	
	400MG		N015417	002	
WHITEWORTH TOWN PLSN	200MG		A083830	001	
	400MG		A083442	001	
MILTOWN					
+ MEDPOINTE PHARM HLC	200MG	**	N009698	004	
+	400MG	**	N009698	002	
	600MG		A083919	001	
NEURAMATE					
HALSEY	200MG		N014359	002	
	400MG		N014359	001	
TRANMEP					
SOLVAY	400MG		A084369	001	
	400MG		N016249	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-303(of 478)

** See List Footnote

MEQUINOL; TRETINOINSOLUTION; TOPICAL
SOLAGE

ALMIRALL 2%;0.01%

N020922 001 Dec 10, 1999

MEROPENEMINJECTABLE; INJECTION
MEROPENEMHOSPIRA INC 500MG/VIAL
1GM/VIAL
SANDOZ 500MG/VIAL
1GM/VIALA090940 001 Jun 22, 2010
A090940 002 Jun 22, 2010
A091201 001 Mar 29, 2011
A091201 002 Mar 29, 2011MERSALYL SODIUM; THEOPHYLLINEINJECTABLE; INJECTION
MERSALYL-THEOPHYLLINE
WATSON LABS

100MG/ML; 50MG/ML

A084875 001

MESALAMINECAPSULE, EXTENDED RELEASE; ORAL
MESALAMINE

TEVA PHARMS USA 375MG

A209970 001 May 06, 2022

ENEMA; RECTAL
MESALAMINE

G AND W LABS INC 4GM/60ML

A076841 001 Sep 30, 2004

SUPPOSITORY; RECTAL
CANASA

ALLERGAN 500MG

N021252 001 Jan 05, 2001

MESALAMINE

AMNEAL 1GM

A210509 001 Jan 02, 2020

ROWASA

+ MEDA PHARMS 500MG **

N019919 001 Dec 18, 1990

TABLET, DELAYED RELEASE; ORAL

ASACOL

APIL 400MG

N019651 001 Jan 31, 1992

ASACOL HD

+ APIL 800MG

N021830 001 May 29, 2008

MESALAMINE

MYLAN 1.2GM

A203574 001 Nov 20, 2018

MESNAINJECTABLE; INTRAVENOUS
MESNAMYLAN INSTITUTIONAL 100MG/ML
MYLAN LABS LTD 100MG/ML
TEVA PHARMS USA 100MG/MLA076488 001 Mar 08, 2012
A203364 001 Jul 18, 2014
A075764 001 Apr 27, 2001MESORIDAZINE BESYLATECONCENTRATE; ORAL
SERENTIL

NOVARTIS EQ 25MG BASE/ML

N016997 001

INJECTABLE; INJECTION
SERENTIL

NOVARTIS EQ 25MG BASE/ML

N016775 001

TABLET; ORAL

SERENTIL

NOVARTIS EQ 10MG BASE **
EQ 25MG BASE **
EQ 50MG BASE **
EQ 100MG BASE **N016774 001
N016774 002
N016774 003
N016774 004MESTRANOL; NORETHINDRONETABLET; ORAL-20
NORINYL

ACTAVIS LABS UT INC 0.1MG; 2MG

N013625 004

TABLET; ORAL-21

NORETHIN 1/50M-21

HERITAGE PHARMA 0.05MG; 1MG

A071539 001 Apr 12, 1988

NORETHINDRONE AND MESTRANOL

WATSON LABS 0.05MG; 1MG

A070758 001 Jul 01, 1988

NORINYL 1+50 21-DAY

ACTAVIS LABS UT INC 0.05MG; 1MG

N013625 002

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-304(of 478)

** See List Footnote

MESTRANOL; NORETHINDRONE

TABLET; ORAL-21

NORINYL 1+80 21-DAY

GD SEARLE LLC

0.08MG;1MG

N016724 001

ORTHO-NOVUM 1/50 21

ORTHO MCNEIL PHARM

0.05MG;1MG

N012728 004

ORTHO-NOVUM 1/80 21

ORTHO MCNEIL PHARM

0.08MG;1MG

N016715 001

ORTHO-NOVUM 10-21

ORTHO MCNEIL PHARM

0.06MG;10MG

N012728 001

ORTHO-NOVUM 2-21

ORTHO MCNEIL PHARM

0.1MG;2MG

N012728 005

TABLET; ORAL-28

NORETHIN 1/50M-28

HERITAGE PHARMA

0.05MG;1MG

A071540 001 Apr 12, 1988

NORETHINDRONE AND MESTRANOL

WATSON LABS

0.05MG;1MG

A070759 001 Jul 01, 1988

NORINYL 1+50 28-DAY

+ ACTAVIS LABS UT INC

0.05MG;1MG

N016659 001

NORINYL 1+80 28-DAY

GD SEARLE LLC

0.08MG;1MG

N016725 001

ORTHO-NOVUM 1/50 28

ORTHO MCNEIL JANSSEN

0.05MG;1MG

N016709 001

ORTHO-NOVUM 1/80 28

ORTHO MCNEIL PHARM

0.08MG;1MG

N016715 002

MESTRANOL; NORETHYNODREL

TABLET; ORAL

ENOVID

GD SEARLE LLC

0.075MG;5MG

N010976 008

0.15MG;9.85MG

N010976 005

TABLET; ORAL-20

ENOVID

GD SEARLE LLC

0.075MG;5MG

N010976 004

ENOVID-E

GD SEARLE LLC

0.1MG;2.5MG

N010976 006

TABLET; ORAL-21

ENOVID-E 21

GD SEARLE LLC

0.1MG;2.5MG

N010976 007

METAPROTERENOL SULFATE

AEROSOL, METERED; INHALATION

ALUPENT

BOEHRINGER INGELHEIM

0.65MG/INH

N016402 001

SOLUTION; INHALATION

ALUPENT

BOEHRINGER INGELHEIM

0.4%

N018761 002 Oct 10, 1986

0.6%

N018761 001 Jun 30, 1983

5%

N017659 001

METAPROTERENOL SULFATE

APOTEX INC

0.4%

A075402 001 Feb 28, 2001

0.6%

A075403 001 Feb 28, 2001

ASTRAZENECA

0.4%

A071275 001 Jul 27, 1988

0.6%

A071018 001 Jul 27, 1988

DEY

0.33%

A071806 001 Aug 05, 1988

0.5%

A071805 001 Aug 05, 1988

5%

A070805 001 Aug 17, 1987

MYLAN SPECIALITY LP

0.4%

A071786 001 Aug 05, 1988

0.6%

A070804 001 Aug 17, 1987

NEPHRON

0.4%

A071855 001 Jul 14, 1988

0.6%

A071726 001 Jul 14, 1988

WOCKHARDT

0.4%

A075586 001 May 30, 2002

0.6%

A075586 002 May 30, 2002

5%

A072190 001 Jun 07, 1988

PROMETA

MURO

5%

A073340 001 Mar 30, 1992

SYRUP; ORAL

ALUPENT

BOEHRINGER INGELHEIM

10MG/5ML

N017571 001

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-305(of 478)

** See List Footnote

METAPROTERENOL SULFATE

SYRUP;ORAL

METAPROTERENOL SULFATE

APOTEX INC	10MG/5ML	A075235	001	Jan 27, 2000
COSETTE	10MG/5ML	A072761	001	Feb 27, 1992
G AND W LABS INC	10MG/5ML	A073034	001	Aug 30, 1991
MORTON GROVE	10MG/5ML	A071656	001	Oct 13, 1987
WOCKHARDT	10MG/5ML	A074702	001	Mar 24, 1997

PROMETA

MURO	10MG/5ML	A072023	001	Sep 15, 1988

TABLET;ORAL

ALUPENT

BOEHRINGER INGELHEIM	10MG	N015874	002	
	20MG	N015874	001	

METAPROTERENOL SULFATE

AM THERAP	10MG	A072054	001	Jun 23, 1988
	20MG	A072055	001	Jun 23, 1988
HERITAGE PHARMA	10MG	A072519	001	Mar 30, 1990
	20MG	A072520	001	Mar 30, 1990
STRIDES PHARMA	10MG	A072024	001	Jun 28, 1988
	20MG	A072025	001	Jun 28, 1988
USL PHARMA	10MG	A071013	001	Jan 25, 1988
	20MG	A071014	001	Jan 25, 1988
WATSON LABS	10MG	A073013	001	Jan 31, 1991
	20MG	A072795	001	Jan 31, 1991

METARAMINOL BITARTRATE

INJECTABLE;INJECTION

ARAMINE

+ MERCK	EQ 10MG BASE/ML **	N009509	002	Dec 22, 1987

METARAMINOL BITARTRATE

ABRAXIS PHARM	EQ 10MG BASE/ML	A080431	001	
ELKINS SINN	EQ 10MG BASE/ML	A083363	001	
FRESENIUS KABI USA	EQ 10MG BASE/ML	A080722	001	
GD SEARLE LLC	EQ 10MG BASE/ML	A086418	001	
	EQ 20MG BASE/ML	A086418	002	

METAXALONE

TABLET;ORAL

METAXALONE

INGENUS PHARMS LLC	800MG	A213836	001	Oct 21, 2020
+ PRIMUS PHARMS	640MG **	N022503	001	Jun 01, 2015
SKELAXIN				
+ KING PHARMS	400MG **	N013217	001	

METFORMIN HYDROCHLORIDE

FOR SUSPENSION, EXTENDED RELEASE;ORAL

RIOMET ER

+ SUN PHARM	500MG/5ML	N212595	001	Aug 29, 2019

SOLUTION;ORAL

RIOMET

+ RANBAXY	500MG/5ML	N021591	001	Sep 11, 2003

TABLET;ORAL

GLUCOPHAGE

+ EMD SERONO INC	500MG **	N020357	001	Mar 03, 1995
+	625MG **	N020357	003	Nov 05, 1998
+	750MG **	N020357	004	Nov 05, 1998
+	850MG **	N020357	002	Mar 03, 1995
+	1GM **	N020357	005	Nov 05, 1998

METFORMIN HYDROCHLORIDE

BARR	500MG	A075971	001	Jan 25, 2002
	850MG	A075971	002	Jan 25, 2002
	1GM	A075971	003	Jan 25, 2002
HERITAGE PHARMA	500MG	A075978	001	Jan 25, 2002
	850MG	A075978	002	Jan 25, 2002
	1GM	A075978	003	Nov 05, 2002
INDICUS PHARMA	500MG	A079148	001	Nov 25, 2008
	850MG	A079148	002	Nov 25, 2008
	1GM	A079148	003	Nov 25, 2008
IPCA LABS LTD	500MG	A078422	001	Aug 06, 2007
	850MG	A078422	002	Aug 06, 2007

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-306(of 478)

** See List Footnote

METFORMIN HYDROCHLORIDE

TABLET;ORAL

METFORMIN HYDROCHLORIDE

	1GM	A078422	003	Aug 06, 2007
IVAX SUB TEVA PHARMS	500MG	A075975	001	Jan 24, 2002
	625MG	A075975	004	Jan 24, 2002
	750MG	A075975	005	Jan 24, 2002
	850MG	A075975	002	Jan 24, 2002
	1GM	A075975	003	Jan 24, 2002
MACLEODS PHARMS LTD	500MG	A205330	001	Oct 31, 2017
	850MG	A205330	002	Oct 31, 2017
	1GM	A205330	003	Oct 31, 2017
MYLAN	500MG	A075976	001	Jan 24, 2002
	850MG	A075976	002	Jan 24, 2002
	1GM	A075976	003	Jan 24, 2002
MYLAN PHARMS INC	500MG	A075969	001	Jan 29, 2002
	850MG	A075969	002	Jan 29, 2002
	1GM	A075969	003	Jan 29, 2002
PROVIDENT PHARM	500MG	A077853	001	Jul 28, 2006
	850MG	A077853	002	Jul 28, 2006
	1GM	A077853	003	Jul 28, 2006
SANDOZ	500MG	A075985	001	Jan 25, 2002
	850MG	A075985	002	Jan 25, 2002
	1GM	A075985	003	Jan 25, 2002
SUN PHARM INDUSTRIES	500MG	A076038	001	Feb 21, 2002
	850MG	A076038	002	Feb 21, 2002
	1GM	A076038	003	Feb 21, 2002
SUNSHINE	500MG	A208999	001	Oct 12, 2018
	850MG	A208999	002	Oct 12, 2018
	1GM	A208999	003	Oct 12, 2018
TEVA	500MG	A076328	001	Dec 16, 2002
	850MG	A076328	002	Dec 16, 2002
	1GM	A076328	003	Dec 16, 2002
TORRENT PHARMS	500MG	A077711	001	Jan 24, 2007
	850MG	A077711	002	Jan 24, 2007
	1GM	A077711	003	Jan 24, 2007
WATSON LABS	500MG	A075979	001	Jan 24, 2002
	850MG	A075979	002	Jan 24, 2002
	1GM	A075979	003	Jan 24, 2002
WATSON LABS FLORIDA	500MG	A075961	001	Jan 25, 2002
	850MG	A075961	002	Jan 25, 2002
	1GM	A075961	003	Jan 25, 2002
TABLET, EXTENDED RELEASE;ORAL				
FORTAMET				
+ ANDRX LABS LLC	500MG **	N021574	001	Apr 27, 2004
GLUCOPHAGE XR				
+ EMD SERONO INC	500MG **	N021202	001	Oct 13, 2000
+	750MG **	N021202	004	Apr 11, 2003
METFORMIN HYDROCHLORIDE				
ACTAVIS ELIZABETH	500MG	A076450	001	Oct 01, 2004
	750MG	A076878	001	Apr 13, 2005
ACTAVIS LABS FL INC	500MG	A076172	001	Jun 16, 2004
AMTA	500MG	A213394	001	Aug 03, 2021
	1GM	A213394	002	Aug 03, 2021
APOTEX	500MG	A076706	001	Dec 14, 2004
	750MG	A076706	002	Dec 29, 2005
BARR	500MG	A076496	001	Nov 25, 2005
	750MG	A076863	001	Oct 14, 2004
IMPAX LABS	500MG	A076249	001	Jul 30, 2004
	750MG	A076985	001	Sep 13, 2005
IVAX SUB TEVA PHARMS	500MG	A076545	001	Dec 01, 2003
MYLAN	500MG	A076650	001	Sep 13, 2005
	750MG	A077113	001	Sep 08, 2005
RANBAXY LABS LTD	500MG	A076413	001	Jun 18, 2004
	750MG	A077211	001	Jun 29, 2005
SANDOZ	500MG	A076223	001	Dec 14, 2004
SUN PHARM INDUSTRIES	500MG	A077124	001	Dec 21, 2005
TORRENT	500MG	A090014	001	Dec 30, 2009
TORRENT PHARMS LTD	750MG	A079226	001	Feb 18, 2010

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-307(of 478)

** See List Footnote

METFORMIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

METFORMIN HYDROCHLORIDE

WATSON LABS INC

500MG

A076818 001 Dec 14, 2004

METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET;ORAL

ACTOPLUS MET

+ TAKEDA PHARMS USA

500MG;EQ 15MG BASE

N021842 001 Aug 29, 2005

PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE

MYLAN

500MG;EQ 15MG BASE

A090406 001 Feb 25, 2011

850MG;EQ 15MG BASE

A090406 002 Feb 25, 2011

SANDOZ

500MG;EQ 15MG BASE

A091273 001 Apr 16, 2013

850MG;EQ 15MG BASE

A091273 002 Apr 16, 2013

TORRENT PHARMS LTD

500MG;EQ 15MG BASE

A202001 001 Feb 13, 2013

850MG;EQ 15MG BASE

A202001 002 Feb 13, 2013

TABLET, EXTENDED RELEASE;ORAL

ACTOPLUS MET XR

+ TAKEDA PHARMS USA

1GM;EQ 15MG BASE

N022024 001 May 12, 2009

+

1GM;EQ 30MG BASE

N022024 002 May 12, 2009

METFORMIN HYDROCHLORIDE; REPAGLINIDE

TABLET;ORAL

PRANDIMET

+ NOVO NORDISK INC

500MG;1MG

N022386 001 Jun 23, 2008

+

500MG;2MG

N022386 002 Jun 23, 2008

REPAGLINIDE AND METFORMIN HYDROCHLORIDE

LUPIN LTD

500MG;1MG

A200624 001 Jul 15, 2015

500MG;2MG

A200624 002 Jul 15, 2015

METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE

TABLET;ORAL

AVANDAMET

+ SB PHARMCO

500MG;EQ 1MG BASE **

N021410 001 Oct 10, 2002

+

500MG;EQ 2MG BASE **

N021410 002 Oct 10, 2002

+

500MG;EQ 4MG BASE **

N021410 003 Oct 10, 2002

+

1GM;EQ 2MG BASE **

N021410 004 Aug 25, 2003

+

1GM;EQ 4MG BASE **

N021410 005 Aug 25, 2003

ROSIGLITAZONE MALEATE AND METFORMIN HYDROCHLORIDE

TEVA

500MG;EQ 2MG BASE

A077337 001 May 07, 2014

500MG;EQ 1MG BASE

A077337 005 May 19, 2017

500MG;EQ 4MG BASE

A077337 002 May 07, 2014

1GM;EQ 4MG BASE

A077337 004 May 07, 2014

1GM;EQ 2MG BASE

A077337 003 May 07, 2014

METHACHOLINE CHLORIDE

FOR SOLUTION;INHALATION

PROVOCHOLINE

+ METHAPHARM

1600MG/VIAL

N019193 002 Aug 29, 2016

METHACYCLINE HYDROCHLORIDE

CAPSULE;ORAL

RONDONMYCIN

MEDPOINTE PHARM HLC

EQ 140MG BASE

A060641 001

EQ 280MG BASE

A060641 002

SYRUP;ORAL

RONDONMYCIN

MEDPOINTE PHARM HLC

EQ 70MG BASE/5ML

A060641 003

METHADONE HYDROCHLORIDE

CONCENTRATE;ORAL

METHADONE HYDROCHLORIDE

LANNETT CO INC

10MG/ML

A212094 001 Mar 03, 2021

POWDER;FOR RX COMPOUNDING

METHADONE HYDROCHLORIDE

MALLINCKRODT INC

50GM/BOT

N006383 002

100GM/BOT

N006383 003

500GM/BOT

N006383 004

SYRUP;ORAL

DOLOPHINE HYDROCHLORIDE

HIKMA

10MG/30ML

N006134 004

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-308(of 478)

** See List Footnote

METHADONE HYDROCHLORIDE

TABLET;ORAL

DOLOPHINE HYDROCHLORIDE

+ HIKMA

5MG **

N006134 002

+

10MG **

N006134 010

METHADONE HYDROCHLORIDE

NOSTRUM LABS INC

5MG

A210484 001 Aug 02, 2018

10MG

A210484 002 Aug 02, 2018

ROXANE

40MG

A074081 001 Apr 28, 1995

VISTAPHARM

5MG

A040241 001 May 29, 1998

METHADOSE

SPECGX LLC

5MG

A040050 001 Apr 15, 1993

10MG

A040050 002 Apr 15, 1993

TABLET, DISPERSIBLE;ORAL

WESTADONE

SANDOZ

2.5MG

N017108 001

TABLET, EFFERVESCENT;ORAL

WESTADONE

SANDOZ

5MG

N017108 002

10MG

N017108 003

40MG

N017108 004

METHAMPHETAMINE HYDROCHLORIDE

TABLET;ORAL

METHAMPEX

TEVA

10MG

A083889 001

METHAMPHETAMINE HYDROCHLORIDE

ABLE

5MG

A040529 001 Feb 25, 2004

REXAR

5MG

A084931 001

10MG

A084931 002

TEVA

5MG

A086359 001

TABLET, EXTENDED RELEASE;ORAL

DESOXYN

KEY THERAP

5MG

N005378 004

10MG

N005378 003

15MG

N005378 005

METHANTHELINE BROMIDE

TABLET;ORAL

BANTHINE

SHIRE

50MG

N007390 001

METHARBITAL

TABLET;ORAL

GEMONIL

ABBVIE

100MG

N008322 001

METHAZOLAMIDE

TABLET;ORAL

METHAZOLAMIDE

APPLIED ANAL

25MG

A040011 001 Jul 17, 1997

50MG

A040011 002 Jul 17, 1997

ATHEM

25MG

A040102 001 Aug 28, 1996

50MG

A040102 002 Aug 28, 1996

NEPTAZANE

+ LEDERLE

25MG **

N011721 002 Nov 25, 1991

+

50MG **

N011721 001

METHDILAZINE

TABLET, CHEWABLE;ORAL

TACARYL

WESTWOOD SQUIBB

3.6MG

N011950 009

METHDILAZINE HYDROCHLORIDE

SYRUP;ORAL

METHDILAZINE HYDROCHLORIDE

ALPHARMA US PHARMS

4MG/5ML

A087122 001

TACARYL

WESTWOOD SQUIBB

4MG/5ML

N011950 007

TABLET;ORAL

TACARYL

WESTWOOD SQUIBB

8MG

N011950 006

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-309(of 478)

** See List Footnote

METHENAMINE HIPPURATE

TABLET; ORAL

METHENAMINE HIPPURATE

IMPAX LABS INC 1GM

A076411 001 Jun 20, 2003

METHICILLIN SODIUM

INJECTABLE; INJECTION

STAPHICILLIN

APOTHECON

EQ 900MG BASE/VIAL

A061449 001

EQ 900MG BASE/VIAL

N050117 001

EQ 3.6GM BASE/VIAL

A061449 002

EQ 3.6GM BASE/VIAL

N050117 002

EQ 5.4GM BASE/VIAL

A061449 003

EQ 5.4GM BASE/VIAL

N050117 003

METHIMAZOLE

TABLET; ORAL

METHIMAZOLE

AIPING LIFE SCI

20MG

A040547 004 Feb 18, 2005

DISCOVERY THERAP

15MG

A040619 003 Jul 12, 2005

MYLAN

20MG

A040350 003 Jun 07, 2001

SUN PHARM INDS INC

5MG

A040870 001 Sep 25, 2007

10MG

A040870 002 Sep 25, 2007

TAPAZOLE

+ KING PHARMS

5MG **

N007517 002

+

KING PHARMS LLC

5MG

A040320 001 Mar 31, 2000

10MG

A040320 002 Mar 31, 2000

METHIXENE HYDROCHLORIDE

TABLET; ORAL

TREST

NOVARTIS

1MG

N013420 001

METHOCARBAMOL

INJECTABLE; INJECTION

METHOCARBAMOL

DR REDDYS

100MG/ML

A086459 001

MARSAM PHARMS LLC

100MG/ML

A089849 001 Dec 27, 1991

SOLUTION; IM-IV

METHOCARBAMOL

MYLAN INSTITUTIONAL

1GM/10ML (100MG/ML)

A204404 001 Dec 05, 2014

TABLET; ORAL

DELAXIN

FERNDAL LABS

500MG

A085454 001

FORBAXIN

FOREST LABS

750MG

A085136 001

METHOCARBAMOL

ABLE

500MG

A040413 001 Mar 17, 2003

750MG

A040413 002 Mar 17, 2003

AM THERAP

500MG

A089417 001 Feb 11, 1987

750MG

A089418 001 Feb 11, 1987

ANI PHARMS

500MG

A084277 001

750MG

A084276 002

ASCOT

500MG

A087660 001 Oct 27, 1982

750MG

A087661 001 Oct 27, 1982

AUROBINDO PHARMA LTD

750MG

A213967 001 Aug 12, 2020

CHARTWELL MOLECULAR

500MG

A084756 002 Mar 31, 2003

750MG

A084756 001

CLONMEL HLTHCARE

500MG

A085961 001

750MG

A085963 001

FOSUN PHARMA

500MG

A084616 001

750MG

A084615 001

HEATHER

500MG

A084675 001

750MG

A084924 001

HIKMA INTL PHARMS

500MG

A085159 001

750MG

A085123 001

IMPAX LABS

500MG

A084927 001

750MG

A084928 001

INWOOD LABS

500MG

A085137 001

IVAX SUB TEVA PHARMS

500MG

A084648 001

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-310(of 478)

** See List Footnote

METHOCARBAMOL

TABLET; ORAL

METHOCARBAMOL

	750MG	A084649	001	
KV PHARM	500MG	A085660	001	
	750MG	A085658	001	
MYLAN	500MG	A084259	001	
	750MG	A084323	001	
NYLOS	750MG	A085033	001	
PIONEER PHARMS	500MG	A088731	001	Dec 13, 1985
	750MG	A089082	001	Dec 13, 1985
PURACAP PHARM	500MG	A084231	002	
	750MG	A084471	001	
PUREPAC PHARM	500MG	A085718	001	
	750MG	A085718	002	
ROXANE	500MG	A088646	001	Feb 29, 1984
	750MG	A088647	001	Feb 29, 1984
SANDOZ	500MG	A087283	001	
	750MG	A087282	001	
SOLVAY	500MG	A084448	001	
	750MG	A084449	001	
SUN PHARM INDUSTRIES	500MG	A084488	001	
	750MG	A084486	001	
SUPERPHARM	500MG	A087589	001	Jan 22, 1982
	750MG	A087590	001	Jan 22, 1982
TABLICAPS	500MG	A084846	001	
UPSHER SMITH	500MG	A087453	001	
	750MG	A087454	001	
WATSON LABS	500MG	A083605	001	
	500MG	A085180	001	
	750MG	A083605	002	
	750MG	A085192	001	
ROBAXIN				
+ AUXILIUM PHARMS LLC	500MG **	N011011	004	
ROBAXIN-750				
+ AUXILIUM PHARMS LLC	750MG **	N011011	006	

METHOHEXITAL SODIUM

INJECTABLE; INJECTION

BREVITAL SODIUM

PAR STERILE PRODUCTS	200MG/VIAL	N011559	004	Dec 21, 2012
+	2.5GM/VIAL	N011559	002	
	5GM/VIAL	N011559	003	

METHOTREXATE

SOLUTION; INTRAVENOUS

METHOTREXATE

+ ACCORD HLTHCARE	5GM/50ML (100MG/ML)	N214121	001	Aug 24, 2020

SOLUTION; SUBCUTANEOUS

OTREXUP

+ OTTER PHARMS	7.5MG/0.4ML (7.5MG/0.4ML)	N204824	005	Nov 07, 2014

OTREXUP PFS

+ OTTER PHARMS	10MG/0.4ML (10MG/0.4ML)	N204824	009	May 31, 2017
+	15MG/0.6ML (15MG/0.6ML)	N204824	010	May 31, 2017
+	17.5MG/0.7ML (17.5MG/0.7ML)	N204824	011	May 31, 2017
+	20MG/0.8ML (20MG/0.8ML)	N204824	012	May 31, 2017
+	22.5MG/0.9ML (22.5MG/0.9ML)	N204824	013	May 31, 2017
+	25MG/ML (25MG/ML)	N204824	014	May 31, 2017

RASUVO

+ MEDEXUS	27.5MG/0.55ML (27.5MG/0.55ML)	N205776	009	Jul 10, 2014

REDITREX

+ NORDIC GRP	7.5MG/0.3ML (7.5MG/0.3ML)	N210737	001	Nov 27, 2019
+	10MG/0.4ML (10MG/0.4ML)	N210737	002	Nov 27, 2019
+	12.5MG/0.5ML (12.5MG/0.5ML)	N210737	003	Nov 27, 2019
+	17.5MG/0.7ML (17.5MG/0.7ML)	N210737	005	Nov 27, 2019
+	22.5MG/ML (22.5MG/ML)	N210737	007	Nov 27, 2019

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-311(of 478)

** See List Footnote

METHOTREXATE SODIUM

INJECTABLE; INJECTION

ABITREXATE

ABIC

EQ 25MG BASE/ML	A089161	001	Mar 10, 1987
EQ 50MG BASE/VIAL	A089354	001	Jul 17, 1987
EQ 100MG BASE/VIAL	A089355	001	Jul 17, 1987
EQ 250MG BASE/VIAL	A089356	001	Jul 17, 1987

FOLEX

+ PHARMACIA AND UPJOHN	EQ 25MG BASE/VIAL	A087695	001	Apr 08, 1983
	EQ 50MG BASE/VIAL	A087695	002	Apr 08, 1983
+	EQ 100MG BASE/VIAL	A087695	003	Apr 08, 1983
	EQ 250MG BASE/VIAL	A088954	001	Oct 24, 1985

FOLEX PFS

PHARMACIA AND UPJOHN	EQ 25MG BASE/ML	A081242	001	Aug 23, 1991
	EQ 25MG BASE/ML	A089180	001	Jan 03, 1986

METHOTREXATE LPF

+ HOSPIRA	EQ 25MG BASE/ML	N011719	007	Mar 31, 1982

METHOTREXATE PRESERVATIVE FREE

FRESENIUS KABI USA	EQ 25MG BASE/ML	A040265	001	Feb 26, 1999
+ HOSPIRA	EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	N011719	014	Apr 13, 2005
+	EQ 500MG BASE/20ML (EQ 25MG BASE/ML) **	N011719	013	Apr 13, 2005
+	EQ 2.5GM BASE/100ML (EQ 25MG BASE/ML)	N011719	011	Apr 13, 2005

METHOTREXATE SODIUM

ABRAXIS PHARM

EQ 2.5MG BASE/ML	A089323	001	Jun 13, 1986
EQ 20MG BASE/VIAL	A088935	001	Oct 11, 1985
EQ 25MG BASE/ML	A089263	001	Jun 13, 1986
EQ 25MG BASE/ML	A089322	001	Jun 13, 1986
EQ 50MG BASE/VIAL	A088936	001	Oct 11, 1985
EQ 100MG BASE/VIAL	A088937	001	Oct 11, 1985
EQ 250MG BASE/10ML (EQ 25MG BASE/ML)	A040263	002	Feb 26, 1999

+ HOSPIRA	EQ 2.5MG BASE/ML	N011719	004	
+	EQ 20MG BASE/VIAL	N011719	001	
+	EQ 25MG BASE/ML	N011719	005	
+	EQ 50MG BASE/VIAL	N011719	003	
+	EQ 100MG BASE/VIAL	N011719	006	
NORBROOK	EQ 25MG BASE/ML	A088648	001	May 09, 1986
PHARMACHEMIE USA	EQ 25MG BASE/ML	A089158	001	Jul 08, 1988

METHOTREXATE SODIUM PRESERVATIVE FREE

EUGIA PHARMA SPECLTS	EQ 50MG BASE/2ML (EQ 25MG BASE/ML)	A201529	001	Mar 29, 2012
	EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	A201529	002	Mar 29, 2012
	EQ 200MG BASE/8ML (EQ 25MG BASE/ML)	A201529	003	Mar 29, 2012
	EQ 250MG BASE/10ML (EQ 25MG BASE/ML)	A201529	004	Mar 29, 2012
+ HOSPIRA	EQ 1GM BASE/VIAL	N011719	009	Apr 07, 1988
MYLAN	EQ 1GM BASE/40ML (EQ 25MG BASE/ML)	A201530	001	Mar 29, 2012

MEXATE

+ BRISTOL	EQ 20MG BASE/VIAL	A086358	001	
+	EQ 50MG BASE/VIAL	A086358	002	
+	EQ 100MG BASE/VIAL	A086358	003	
+	EQ 250MG BASE/VIAL	A086358	004	

MEXATE-AQ

+ BRISTOL MYERS	EQ 25MG BASE/ML	A088760	001	Feb 14, 1985

MEXATE-AQ PRESERVED

BRISTOL MYERS SQUIBB	EQ 25MG BASE/ML	A089887	001	Apr 14, 1989

TABLET; ORAL

METHOTREXATE SODIUM

DURAMED PHARMS BARR	EQ 2.5MG BASE	A040233	001	Jun 17, 1999
+ STRIDES PHARMA	EQ 2.5MG BASE **	N008085	002	

METHOXAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

VASOXYL

GLAXOSMITHKLINE	10MG/ML	N006772	002	
	20MG/ML	N006772	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-312(of 478)

** See List Footnote

METHOXSALEN

CAPSULE;ORAL

8-MOP

+ VALEANT PHARM INTL 10MG

N009048 001

METHOXSALEN

ACTAVIS INC 10MG

A202603 001 Jun 09, 2015

ANI PHARMS 10MG

A087781 001 Jun 08, 1982

LOTION;TOPICAL

OXSORALEN

+ VALEANT PHARM INTL 1%

N009048 002

METHSCOPOLAMINE BROMIDE

TABLET;ORAL

METHSCOPOLAMINE BROMIDE

PVT FORM 2.5MG

A080970 001

STRIDES PHARMA 2.5MG

A040624 001 Dec 28, 2006

5MG

A040624 002 Dec 28, 2006

PAMINE

FOUGERA PHARMS 2.5MG **

N008848 001

PAMINE FORTE

FOUGERA PHARMS 5MG **

N008848 002 Mar 25, 2003

METHSUXIMIDE

CAPSULE;ORAL

CELONTIN

+ PARKE DAVIS 150MG

N010596 007

METHYCLOTHIAZIDE

TABLET;ORAL

AQUATENSEN

MEDPOINTE PHARM HLC 5MG

N017364 001

ENDURON

+ ABBVIE 2.5MG **

N012524 001

+ 5MG **

N012524 004

METHYCLOTHIAZIDE

CHARTWELL RX 2.5MG

A089835 001 Aug 18, 1988

5MG

A089837 001 Aug 18, 1988

IVAX PHARMS 2.5MG

A087913 001 Jun 03, 1982

5MG

A087786 001 May 18, 1982

MYLAN 2.5MG

A087671 001 Aug 17, 1982

MYLAN PHARMS INC 5MG

A087672 001 Aug 17, 1982

PAR PHARM 2.5MG

A089135 001 Feb 12, 1986

5MG

A089136 001 Feb 12, 1986

USL PHARMA 5MG

A088745 001 Mar 21, 1985

WATSON LABS 2.5MG

A085487 001 Mar 11, 1982

2.5MG

A088750 001 Sep 06, 1984

5MG

A085476 001 Mar 11, 1982

5MG

A088724 001 Sep 06, 1984

METHYCLOTHIAZIDE; PARGYLINE HYDROCHLORIDE

TABLET;ORAL

EUTRON

ABBOTT 5MG;25MG

N016047 001

METHYCLOTHIAZIDE; RESERPINE

TABLET;ORAL

DIUTENSEN-R

MEDPOINTE PHARM HLC 2.5MG;0.1MG

N012708 005

METHYL AMINOLEVULINATE HYDROCHLORIDE

CREAM;TOPICAL

METVIXIA

GALDERMA LABS LP EQ 16.8% BASE

N021415 001 Jul 27, 2004

METHYLDOPA

SUSPENSION;ORAL

ALDOMET

MERCK 250MG/5ML

N018389 001

TABLET;ORAL

ALDOMET

+ MERCK 125MG **

N013400 003

+ 250MG **

N013400 001

+ 500MG **

N013400 002

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-313(of 478)

** See List Footnote

METHYLDOPA

TABLET; ORAL

METHYLDOPA

ACCORD HLTHCARE	125MG	A070070	003	Oct 15, 1985
	250MG	A070084	001	Oct 15, 1985
	500MG	A070085	001	Oct 15, 1985
CHARTWELL RX	125MG	A071700	001	Mar 02, 1988
	250MG	N018934	001	Jun 29, 1984
	500MG	N018934	002	Jun 29, 1984
DURAMED PHARMS BARR	250MG	A071006	001	Dec 16, 1986
	500MG	A071009	001	Dec 16, 1986
HALSEY	125MG	A071751	001	Mar 28, 1988
	250MG	A071752	001	Mar 28, 1988
	500MG	A071753	001	Mar 28, 1988
HERITAGE PHARMA	250MG	A070098	001	Feb 20, 1986
	500MG	A070343	001	Feb 20, 1986
PARKE DAVIS	125MG	A070331	001	Apr 15, 1986
	250MG	A070332	001	Apr 15, 1986
	500MG	A070333	001	Apr 15, 1986
PLIVA	125MG	A072126	001	Jul 07, 1988
	250MG	A072127	001	Jul 07, 1988
	500MG	A072128	001	Jul 07, 1988
PUREPAC PHARM	125MG	A070749	001	Feb 07, 1986
	250MG	A070750	001	Feb 07, 1986
	500MG	A070452	001	Feb 07, 1986
RISING	250MG	A070076	002	Apr 18, 1985
	500MG	A070076	001	Apr 18, 1985
ROXANE	125MG	A070192	001	Apr 25, 1986
	250MG	A070193	001	Apr 25, 1986
	500MG	A070194	001	Apr 25, 1986
STRIDES PHARMA	125MG	A070535	001	Jan 02, 1987
	250MG	A070536	001	Jan 02, 1987
	500MG	A070537	001	Jan 02, 1987
SUN PHARM INDUSTRIES	125MG	A070073	001	Oct 09, 1986
	250MG	A070060	001	Oct 09, 1986
	500MG	A070074	001	Oct 09, 1986
SUPERPHARM	250MG	A070669	001	Jun 23, 1989
	500MG	A070670	001	Jun 23, 1989
TEVA	125MG	A071105	001	Dec 05, 1986
	250MG	A071106	001	Dec 05, 1986
	500MG	A071067	001	Dec 05, 1986
WATSON LABS	125MG	A070245	001	Feb 25, 1986
	125MG	A070260	001	Jun 24, 1985
	250MG	A070246	001	Feb 25, 1986
	250MG	A070261	001	Jun 24, 1985
	250MG	A070703	001	Jun 06, 1986
	500MG	A070247	001	Feb 25, 1986
	500MG	A070262	001	Jun 24, 1985
	500MG	A070625	001	Jun 06, 1986

METHYLDOPATE HYDROCHLORIDE

INJECTABLE; INJECTION

ALDOMET

+ MERCK

50MG/ML **

N013401 001

METHYLDOPATE HYDROCHLORIDE

ABRAXIS PHARM	50MG/ML	A070652	001	Jun 03, 1986
AM REGENT	50MG/ML	A071279	001	Oct 02, 1987
BAXTER HLTHCARE	50MG/ML	A070291	001	Jul 01, 1986
HOSPIRA	50MG/ML	A070691	001	Jun 19, 1987
	50MG/ML	A070698	001	Jun 15, 1987
	50MG/ML	A070699	001	Jun 15, 1987
	50MG/ML	A070849	001	Jun 19, 1987
MARSAM PHARMS LLC	50MG/ML	A071812	001	Dec 22, 1987
SMITH AND NEPHEW	50MG/ML	A070841	001	Jan 02, 1987
TEVA PARENTERAL	50MG/ML	A072974	001	Nov 22, 1991

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-314(of 478)

** See List Footnote

METHYLERGONOVINE MALEATE

TABLET;ORAL

METHERGINE

+ EDISON THERAPS LLC 0.2MG **

N006035 003

METHYLPHENIDATE

TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL

METHYLPHENIDATE

ACTAVIS ELIZABETH 8.6MG
17.3MG
25.9MGA210924 001 Jun 19, 2020
A210924 002 Jun 19, 2020
A210924 003 Jun 19, 2020METHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

ADHANSIA XR

+ PURDUE PHARMA LP 25MG
+ 35MG
+ 45MG
+ 55MG
+ 70MG
+ 85MGN212038 001 Feb 27, 2019
N212038 002 Feb 27, 2019
N212038 003 Feb 27, 2019
N212038 004 Feb 27, 2019
N212038 005 Feb 27, 2019
N212038 006 Feb 27, 2019

METHYLPHENIDATE HYDROCHLORIDE

BARR LABS INC 10MG
20MG
30MG
40MGA079031 004 Oct 15, 2014
A079031 001 Jul 13, 2012
A079031 002 Jul 13, 2012
A079031 003 Jul 13, 2012

RITALIN LA

+ NOVARTIS 60MG **

N021284 005 Oct 27, 2014

SOLUTION;ORAL

METHYLPHENIDATE HYDROCHLORIDE

CHARTWELL MOLECULAR 5MG/5ML
10MG/5MLA207414 001 Dec 16, 2020
A207414 002 Dec 16, 2020

TABLET;ORAL

METHYLPHENIDATE HYDROCHLORIDE

ABLE 5MG
10MG
20MG
ACTAVIS ELIZABETH 5MG
10MG
20MG
ALVOGEN 5MG
10MG
20MG
AUROLIFE PHARMA LLC 5MG
10MG
20MG
CEDIPROF INC 5MG
10MG
20MG
LANNETT CO INC 5MG
10MG
20MG
NOSTRUM LABS INC 5MG
10MG
20MG
WATSON LABS 5MG
10MG
20MGA040404 001 Mar 29, 2001
A040404 002 Mar 29, 2001
A040404 003 Mar 29, 2001
A040321 001 Feb 05, 2002
A040321 002 Feb 05, 2002
A040321 003 Feb 05, 2002
A206840 001 Sep 15, 2016
A206840 002 Sep 15, 2016
A206840 003 Sep 15, 2016
A209276 001 Oct 25, 2018
A209276 002 Oct 25, 2018
A209276 003 Oct 25, 2018
A208737 001 Feb 01, 2019
A208737 002 Feb 01, 2019
A208737 003 Feb 01, 2019
A086429 001
A085799 001
A086428 001
A207587 001 Mar 03, 2017
A207587 002 Mar 03, 2017
A207587 003 Mar 03, 2017
A040220 001 Aug 29, 1997
A040220 002 Aug 29, 1997
A040220 003 Aug 29, 1997

TABLET, CHEWABLE;ORAL

METHYLIN

+ SPECGX LLC 2.5MG **
+ 5MG **
+ 10MG **N021475 001 Apr 15, 2003
N021475 002 Apr 15, 2003
N021475 003 Apr 15, 2003

METHYLPHENIDATE HYDROCHLORIDE

NOSTRUM LABS INC 2.5MG
5MG
10MG
NOVEL LABS INC 2.5MG
5MG
10MGA204954 001 Jan 26, 2017
A204954 002 Jan 26, 2017
A204954 003 Jan 26, 2017
A204115 001 Feb 25, 2015
A204115 002 Feb 25, 2015
A204115 003 Feb 25, 2015

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-315(of 478)

** See List Footnote

METHYLPHENIDATE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

METADATE ER

LANNETT CO INC 10MG
20MGA040306 001 Oct 20, 1999
A089601 001 Jun 01, 1988

METHYLPHENIDATE HYDROCHLORIDE

ABLE 20MG
ALVOGEN 10MGA076032 001 May 09, 2001
A204772 001 Feb 29, 201618MG
20MG
27MG
36MG
54MGA210818 001 Nov 30, 2018
A204772 002 Feb 29, 2016
A210818 002 Nov 30, 2018
A210818 003 Nov 30, 2018
A210818 004 Nov 30, 2018ANI PHARMS 18MG
27MG
36MG
54MGA208607 001 Jul 14, 2017
A208607 002 Jul 14, 2017
A208607 003 Jul 14, 2017
A208607 004 Jul 14, 2017

HERITAGE PHARMA 20MG

A075450 001 Dec 21, 2001

RHODES PHARMS 18MG
27MG
36MG
54MGA214111 001 May 31, 2022
A214111 002 May 31, 2022
A214111 003 May 31, 2022
A214111 004 May 31, 2022STRIDES PHARMA 36MG
54MGA204659 001 Jul 15, 2019
A204659 002 Jul 15, 2019

WATSON LABS 20MG

A040410 001 Feb 09, 2001

RITALIN-SR

+ NOVARTIS 20MG **

N018029 001 Mar 30, 1982

METHYLPREDNISOLONE

TABLET;ORAL

MEDROL

PFIZER 24MG

N011153 005

METHYLPREDNISOLONE

AMNEAL 4MG
8MG
16MG
32MGA207481 001 Sep 21, 2021
A207481 002 Sep 21, 2021
A207481 003 Sep 21, 2021
A207481 004 Sep 21, 2021

DURAMED PHARMS BARR 4MG

A088497 001 Feb 21, 1984

HEATHER 4MG

A085650 001

INVATECH 4MG

A087341 001

LUPIN LTD 2MG

A209097 001 Feb 22, 2019

4MG

A209097 002 Feb 22, 2019

8MG

A209097 003 Feb 22, 2019

16MG

A209097 004 Feb 22, 2019

32MG

A209097 005 Feb 22, 2019

NOVAST LABS 4MG

A210985 001 Jan 09, 2019

PAR PHARM 16MG

A089207 001 Apr 25, 1988

24MG

A089208 001 Apr 25, 1988

32MG

A089209 001 Apr 25, 1988

WATSON LABS 4MG

A086161 001 Feb 09, 1982

16MG

A086159 001 Feb 09, 1982

METHYLPREDNISOLONE ACETATE

ENEMA;RECTAL

MEDROL

PHARMACIA AND UPJOHN 40MG/BOT

N018102 001

INJECTABLE;INJECTION

M-PREDROL

BEL MAR 40MG/ML
80MG/MLA086666 001
A087135 001

METHYLPREDNISOLONE ACETATE

AKORN 40MG/ML
80MG/MLA086903 001 Oct 20, 1982
A086903 002 Oct 20, 1982

PAR STERILE PRODUCTS 40MG/ML

A214297 001 Jan 21, 2022

SAGENT PHARMS INC 20MG/ML

A201835 001 Jun 27, 2018

WATSON LABS 20MG/ML

A085597 001

20MG/ML

A087248 001

40MG/ML

A085374 001

40MG/ML

A085600 001

80MG/ML

A085595 001

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-316(of 478)

** See List Footnote

METHYLPREDNISOLONE ACETATE

INJECTABLE; INJECTION

METHYLPREDNISOLONE ACETATE

80MG/ML

A086507 001

OINTMENT; TOPICAL

MEDROL ACETATE

PHARMACIA AND UPJOHN 0.25%

N012421 001

1%

N012421 002

METHYLPREDNISOLONE ACETATE; NEOMYCIN SULFATE

CREAM; TOPICAL

NEO-MEDROL ACETATE

PHARMACIA AND UPJOHN 0.25%; EQ 3.5MG BASE/GM

A060611 002

1%; EQ 3.5MG BASE/GM

A060611 001

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE; INJECTION

A-METHAPRED

ABBOTT

EQ 40MG BASE/VIAL

A089573 001 Feb 22, 1991

EQ 125MG BASE/VIAL

A089574 001 Feb 22, 1991

EQ 500MG BASE/VIAL

A089575 001 Feb 22, 1991

EQ 1GM BASE/VIAL

A089576 001 Feb 22, 1991

HOSPIRA

EQ 40MG BASE/VIAL

A040664 001 Dec 20, 2005

EQ 40MG BASE/VIAL

A085853 001

EQ 125MG BASE/VIAL

A040665 001 Dec 20, 2005

EQ 125MG BASE/VIAL

A085855 001

EQ 500MG BASE/VIAL

A085854 001

EQ 500MG BASE/VIAL

A089173 001 Aug 18, 1987

EQ 1GM BASE/VIAL

A085852 001

EQ 1GM BASE/VIAL

A089174 001 Aug 18, 1987

HOSPIRA INC

EQ 40MG BASE/VIAL

A040793 001 Nov 25, 2008

EQ 125MG BASE/VIAL

A040827 001 Nov 25, 2008

METHYLPREDNISOLONE

ELKINS SINN

EQ 125MG BASE/VIAL

A086906 002

EQ 500MG BASE/VIAL

A086906 003

EQ 1GM BASE/VIAL

A086906 004

ORGANON USA INC

EQ 500MG BASE/VIAL

A087535 001 Jun 25, 1982

EQ 1GM BASE/VIAL

A087535 002 Jun 25, 1982

METHYLPREDNISOLONE SODIUM SUCCINATE

ABRAXIS PHARM

EQ 40MG BASE/VIAL

A088676 001 Jun 08, 1984

EQ 40MG BASE/VIAL

A089143 001 Mar 28, 1986

EQ 125MG BASE/VIAL

A088677 001 Jun 08, 1984

EQ 125MG BASE/VIAL

A089144 001 Mar 28, 1986

EQ 500MG BASE/VIAL

A088678 001 Jun 08, 1984

EQ 500MG BASE/VIAL

A089186 001 Mar 28, 1986

EQ 500MG BASE/VIAL

A089187 001 Mar 28, 1986

EQ 1GM BASE/VIAL

A088679 001 Jun 08, 1984

EQ 1GM BASE/VIAL

A089188 001 Mar 28, 1986

EQ 1GM BASE/VIAL

A089189 001 Mar 28, 1986

BEDFORD LABS

EQ 40MG BASE/VIAL

A040662 001 Feb 21, 2007

EQ 125MG BASE/VIAL

A040641 002 Feb 21, 2007

EQ 500MG BASE/VIAL

A040641 003 Feb 21, 2007

EQ 500MG BASE/VIAL

A040709 001 Feb 21, 2007

EQ 1GM BASE/VIAL

A040641 004 Feb 21, 2007

EQ 1GM BASE/VIAL

A040709 002 Feb 21, 2007

ELKINS SINN

EQ 40MG BASE/VIAL

A086906 001

EUGIA PHARMA

EQ 40MG BASE/VIAL

A207667 001 Dec 15, 2015

EQ 125MG BASE/VIAL

A207667 002 Dec 15, 2015

EQ 500MG BASE/VIAL

A207667 003 Dec 15, 2015

EQ 2GM BASE/VIAL

A207667 004 Dec 15, 2015

INTL MEDICATION

EQ 40MG BASE/VIAL

A087812 001 Feb 09, 1983

EQ 125MG BASE/VIAL

A087813 001 Feb 09, 1983

EQ 500MG BASE/VIAL

A087851 001 Feb 09, 1983

EQ 1GM BASE/VIAL

A087852 001 Feb 09, 1983

TEVA PARENTERAL

EQ 125MG BASE/VIAL

A081266 001 Nov 30, 1992

EQ 500MG BASE/VIAL

A081267 001 Nov 30, 1992

EQ 1GM BASE/VIAL

A081268 001 Nov 30, 1992

WATSON LABS

EQ 40MG BASE/VIAL

A086953 001 Jul 22, 1982

EQ 125MG BASE/VIAL

A087030 001 Jul 22, 1982

EQ 500MG BASE/VIAL

A088523 001 Jul 24, 1984

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-317(of 478)

** See List Footnote

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE; INJECTION

METHYLPREDNISOLONE SODIUM SUCCINATE

EQ 1GM BASE/VIAL

A088524 001 Jul 24, 1984

METHYLPREDNISOLONE; NEOMYCIN SULFATE

OINTMENT; OPHTHALMIC

NEO-MEDROL

PHARMACIA AND UPJOHN 0.1%; EQ 3.5MG BASE/GM

A060645 001

METHYLTESTOSTERONE

CAPSULE; ORAL

METHYLTESTOSTERONE

HEATHER

10MG

A084967 001

TESTRED

+ BAUSCH

10MG

A083976 001

VIRILON

CHARTWELL

10MG

A087750 001 Nov 24, 1982

TABLET; BUCCAL

ANDROID 5

VALEANT PHARM INTL

5MG

A087222 001

ORETON

SCHERING

10MG

A080281 001

TABLET; BUCCAL, SUBLINGUAL

METANDREN

NOVARTIS

5MG

N003240 004

10MG

N003240 001

10MG

N003240 005

25MG

N003240 003

METHYLTESTOSTERONE

IMPAX LABS

10MG

A084287 001

LILLY

10MG

A080256 001

25MG

A080256 002

PUREPAC PHARM

10MG

A080308 001

10MG

A080475 001

10MG

A080475 002

25MG

A080475 003

PVT FORM

5MG

A083836 001

TABLICAPS

10MG

A085125 001

USL PHARMA

10MG

A080271 001

TABLET; ORAL

ANDROID 10

VALEANT PHARMS NORTH

10MG

A086450 001

METHYLTESTOSTERONE

IMPAX LABS

25MG

A084310 001

INWOOD LABS

10MG

A080839 001

25MG

A080973 001

KV PHARM

10MG

A084312 001

LANNETT

10MG

A087092 001 Nov 05, 1982

25MG

A087111 001 Jan 27, 1983

PARKE DAVIS

10MG

A084244 001

25MG

A084241 001

PUREPAC PHARM

10MG

A080309 001

25MG

A080310 001

PVT FORM

5MG

A080214 001

10MG

A080214 002

25MG

A080214 003

TABLICAPS

10MG

A080313 001

25MG

A085270 001

WATSON LABS

10MG

A080933 001

25MG

A080931 001

WEST WARD

10MG

A084331 001

25MG

A084331 002

25MG

A084642 001

ORETON METHYL

SCHERING

10MG

N003158 001

25MG

N003158 002

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-318(of 478)

** See List Footnote

METHYPRYLON

CAPSULE; ORAL

NOLUDAR

ROCHE

300MG

N009660 008

ELIXIR; ORAL

NOLUDAR

ROCHE

50MG/5ML

N009660 007

TABLET; ORAL

NOLUDAR

ROCHE

50MG

N009660 002

200MG

N009660 004

METHYSERGIDE MALEATE

TABLET; ORAL

SANSERT

NOVARTIS

2MG

N012516 001

METIPRANOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

METIPRANOLOL

SANDOZ INC

0.3%

A075720 001 Aug 06, 2001

OPTIPRANOLOL

+ BAUSCH AND LOMB

0.3% **

N019907 001 Dec 29, 1989

METOCLOPRAMIDE HYDROCHLORIDE

CONCENTRATE; ORAL

METOCLOPRAMIDE INTENSOL

ROXANE

EQ 10MG BASE/ML

A072995 001 Jan 30, 1992

INJECTABLE; INJECTION

METOCLOPRAMIDE HYDROCHLORIDE

BEDFORD

EQ 5MG BASE/ML

A072155 001 Mar 30, 1992

EQ 5MG BASE/ML

A072244 001 Mar 30, 1992

EQ 5MG BASE/ML

A072247 001 May 18, 1992

HOSPIRA

EQ 5MG BASE/ML

A070505 001 Jun 23, 1989

EQ 5MG BASE/ML

A070506 001 Jun 22, 1989

EQ 5MG BASE/ML

A070847 001 Nov 07, 1988

EQ 5MG BASE/ML

A071291 001 Mar 03, 1989

EQ 5MG BASE/ML

A071990 001 Jan 18, 1989

EQ 5MG BASE/ML

A073117 001 Jan 17, 1991

EQ 5MG BASE/ML

A074147 001 Aug 02, 1996

LYPHOMED

EQ 10MG BASE/2ML

A070293 001 Jan 24, 1986

NORBROOK

EQ 10MG BASE/2ML

A070892 001 Aug 26, 1988

SMITH AND NEPHEW

EQ 5MG BASE/ML

A070623 001 Mar 02, 1987

EQ 10MG BASE/2ML

A070622 001 Mar 02, 1987

REGLAN

+ HIKMA

EQ 5MG BASE/ML **

N017862 001

EQ 10MG BASE/ML **

N017862 004 May 28, 1987

SOLUTION; ORAL

METOCLOPRAMIDE HYDROCHLORIDE

ACTAVIS MID ATLANTIC

EQ 5MG BASE/5ML

A071340 001 Aug 18, 1988

CHARTWELL MOLECULAR

EQ 5MG BASE/5ML

A073680 001 Oct 27, 1992

MORTON GROVE

EQ 5MG BASE/5ML

A070949 001 Mar 06, 1987

PACO

EQ 5MG BASE/5ML

A071665 001 Dec 05, 1988

ROXANE

EQ 5MG BASE/5ML

A072038 001 Dec 05, 1988

TEVA

EQ 5MG BASE/5ML

A070819 001 Jul 10, 1987

EQ 5MG BASE/5ML

A071315 001 Jun 30, 1993

REGLAN

+ ROBINS AH

EQ 5MG BASE/5ML **

N018821 001 Mar 25, 1983

TABLET; ORAL

CLOPRA

QUANTUM PHARMICS

EQ 5MG BASE

A072384 001 Jun 02, 1988

EQ 10MG BASE

A070294 001 Jul 29, 1985

CLOPRA-"YELLOW"

QUANTUM PHARMICS

EQ 10MG BASE

A070632 001 Oct 28, 1985

MAXOLON

KING PHARMS

EQ 10MG BASE

A070106 001 Mar 04, 1986

METOCLOPRAMIDE HYDROCHLORIDE

CHARTWELL RX

EQ 5MG BASE

A074478 001 Oct 05, 1995

EQ 10MG BASE

A072215 001 Jan 30, 1990

EQ 10MG BASE

A074478 002 Oct 05, 1995

CLONMEL

EQ 10MG BASE

A072639 001 May 09, 1991

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-319(of 478)

** See List Footnote

METOCLOPRAMIDE HYDROCHLORIDE

TABLET; ORAL

METOCLOPRAMIDE HYDROCHLORIDE

HALSEY	EQ 10MG BASE	A070906 001	Oct 28, 1986
INTERPHARM	EQ 10MG BASE	A071213 001	Sep 24, 1986
MUTUAL PHARM	EQ 10MG BASE	A070660 001	Feb 10, 1987
NORTHSTAR HLTHCARE	EQ 5MG BASE	A078374 001	Nov 30, 2007
	EQ 10MG BASE	A078374 002	Nov 30, 2007
PAR PHARM	EQ 10MG BASE	A070342 001	Mar 25, 1986
SANDOZ	EQ 5MG BASE	A072436 001	Jun 22, 1989
	EQ 10MG BASE	A070850 001	Feb 03, 1987
SCHERING	EQ 10MG BASE	A070598 001	Feb 02, 1987
SUN PHARM INDUSTRIES	EQ 5MG BASE	A071536 002	Jan 16, 1997
	EQ 10MG BASE	A071536 001	Apr 28, 1993
SUPERPHARM	EQ 10MG BASE	A070926 001	Jun 26, 1987
USL PHARMA	EQ 10MG BASE	A070339 001	Jul 29, 1985
WATSON LABS	EQ 10MG BASE	A070363 001	Mar 02, 1987
	EQ 10MG BASE	A070453 001	Jun 06, 1986
	EQ 10MG BASE	A070511 001	Jan 22, 1986
	EQ 10MG BASE	A070645 001	May 11, 1987

TABLET, ORALLY DISINTEGRATING; ORAL

METOZOLV ODT

+	SALIX PHARMS	EQ 5MG BASE **	N022246 001	Sep 04, 2009
+		EQ 10MG BASE **	N022246 002	Sep 04, 2009

REGLAN ODT

MEDA PHARMS	EQ 5MG BASE	N021793 001	Jun 10, 2005
	EQ 10MG BASE	N021793 002	Jun 10, 2005

METOCURINE IODIDE

INJECTABLE; INJECTION

METUBINE IODIDE

LILLY	2MG/ML	N006632 003

METOLAZONE

TABLET; ORAL

DIULO

GD SEARLE LLC	2.5MG	N018535 001
	5MG	N018535 002
	10MG	N018535 003

METOLAZONE

ANI PHARMS	2.5MG	A075543 001	Jan 06, 2004
	5MG	A075543 002	Mar 01, 2004
	10MG	A075543 003	Dec 24, 2003
ROXANE	10MG	A076482 002	Apr 29, 2004
WATSON LABS	10MG	A076891 001	Jul 21, 2004

MYKROX

LANNETT CO INC	0.5MG	N019532 001	Oct 30, 1987

ZAROXOLYN

+	I3 PHARMS	2.5MG **	N017386 001
+		5MG **	N017386 002
+		10MG **	N017386 003

METOPROLOL FUMARATE

TABLET, EXTENDED RELEASE; ORAL

LOPRESSOR

NOVARTIS	EQ 100MG TARTRATE	N019786 001	Dec 27, 1989
	EQ 200MG TARTRATE	N019786 002	Dec 27, 1989
	EQ 300MG TARTRATE	N019786 003	Dec 27, 1989
	EQ 400MG TARTRATE	N019786 004	Dec 27, 1989

METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE; ORAL

METOPROLOL SUCCINATE

ACTAVIS LABS FL INC	EQ 25MG TARTRATE	A076862 002	Aug 03, 2009
	EQ 100MG TARTRATE	A077298 001	Apr 15, 2010
	EQ 200MG TARTRATE	A077298 002	Apr 15, 2010
NESHER PHARMS	EQ 25MG TARTRATE	A077779 001	Mar 20, 2008
	EQ 50MG TARTRATE	A077176 001	May 14, 2008
	EQ 100MG TARTRATE	A076640 002	May 18, 2007
	EQ 200MG TARTRATE	A076640 001	May 18, 2007
PRINSTON INC	EQ 100MG TARTRATE	A210597 001	Jan 04, 2022

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-320(of 478)

** See List Footnote

METOPROLOL SUCCINATETABLET, EXTENDED RELEASE;ORAL
METOPROLOL SUCCINATE

	EQ 200MG TARTRATE	A210597 002	Jan 04, 2022
SANDOZ	EQ 25MG TARTRATE	A076969 001	Jul 31, 2006
	EQ 50MG TARTRATE	A076969 002	May 18, 2007
	EQ 100MG TARTRATE	A076969 003	Mar 20, 2008
	EQ 200MG TARTRATE	A076969 004	Mar 20, 2008

METOPROLOL TARTRATEINJECTABLE;INJECTION
LOPRESSOR

+ NOVARTIS	1MG/ML **	N018704 001	Mar 30, 1984

METOPROLOL TARTRATE

AM REGENT	1MG/ML	A090386 001	Sep 30, 2009
LUITPOLD	1MG/ML	A091307 001	Dec 29, 2010
STERISCIENCE	1MG/ML	A090317 001	Apr 19, 2010
WATSON LABS	1MG/ML	A074032 001	Dec 21, 1993

TABLET;ORAL

METOPROLOL TARTRATE

APOTHECON	50MG	A074258 001	Jan 27, 1994
	100MG	A074258 002	Jan 27, 1994
CHARTWELL RX	50MG	A073288 001	Mar 25, 1994
	100MG	A073289 001	Mar 25, 1994
HERITAGE PHARMA	50MG	A074141 001	Jan 31, 1995
	100MG	A074141 002	Jan 31, 1995
MYLAN	50MG	A073666 001	Dec 21, 1993
	100MG	A073666 002	Dec 21, 1993
PUREPAC PHARM	50MG	A074380 001	Jul 29, 1994
	100MG	A074380 002	Jul 29, 1994
RENATA	50MG	A074453 001	Apr 27, 1995
	100MG	A074453 002	Apr 27, 1995
SUN PHARM INDUSTRIES	25MG	A073654 002	Jul 15, 2009
	50MG	A073654 003	Dec 21, 1993
	100MG	A073654 001	Dec 21, 1993
TEVA	50MG	A074143 001	Sep 30, 1994
	100MG	A074143 002	Sep 30, 1994
TEVA PHARMS	50MG	A074333 001	Jan 27, 1994
	100MG	A074333 002	Jan 27, 1994
WATSON LABS	50MG	A074217 001	May 27, 1994
	100MG	A074217 002	May 27, 1994

METRIZAMIDE

INJECTABLE;INJECTION

AMIPAQUE

GE HEALTHCARE	2.5GM/VIAL	N017982 003	Sep 12, 1983
	3.75GM/VIAL	N017982 001	
	6.75GM/VIAL	N017982 002	
	13.5GM/VIAL	N017982 004	Sep 12, 1983

METRONIDAZOLE

CAPSULE;ORAL

METRONIDAZOLE

ABLE	375MG	A076505 001	Nov 13, 2003

GEL;VAGINAL

METRONIDAZOLE

TOLMAR	0.75%	A077264 001	Oct 31, 2006

INJECTABLE;INJECTION

FLAGYL I.V. RTU IN PLASTIC CONTAINER

PFIZER	500MG/100ML	N018353 002	

METRO I.V.

B BRAUN	500MG/100ML	N018674 001	Aug 31, 1982

METRONIDAZOLE

ABBOTT	500MG/100ML	N018889 001	Nov 18, 1983
ABRAXIS PHARM	500MG/100ML	A070071 001	Dec 03, 1984
HIKMA	500MG/100ML	N018907 001	Mar 30, 1984
INTL MEDICATION	500MG/100ML	A070004 001	May 08, 1985
WATSON LABS	500MG/100ML	A070042 001	Dec 20, 1984
	500MG/100ML	A070170 001	Apr 01, 1986

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-321(of 478)

** See List Footnote

METRONIDAZOLE

INJECTABLE; INJECTION

METRONIDAZOLE IN PLASTIC CONTAINER

RISING 500MG/100ML

A205531 001 May 09, 2017

TABLET; ORAL

METROMIDOL

LABS AF 250MG

A074523 001 Oct 24, 1996

500MG

A074523 002 Oct 24, 1996

METRONIDAZOLE

ABLE 250MG

A076519 001 Jun 27, 2003

500MG

A076519 002 Jun 27, 2003

CHARTWELL MOLECULES 250MG

N018845 001 Aug 18, 1983

500MG

N018930 001 Aug 18, 1983

FOSUN PHARMA 250MG

N018620 001 Mar 04, 1982

250MG

N018740 001 Oct 22, 1982

500MG

N018620 002 Jun 02, 1983

500MG

N018740 002 Oct 22, 1982

HALSEY 250MG

A070021 001 Apr 02, 1985

500MG

A070593 001 Feb 27, 1986

IVAX SUB TEVA PHARMS 250MG

N018517 001

500MG

N018517 002 May 05, 1982

LNK 250MG

N019029 001 Apr 10, 1984

MUTUAL PHARM 250MG

N018818 001 Feb 16, 1983

500MG

N018818 002 Feb 16, 1983

SUPERPHARM 250MG

A070008 001 Dec 11, 1984

500MG

A070009 001 Dec 11, 1984

WATSON LABS 250MG

N018599 001 Sep 17, 1982

250MG

N018764 001 Sep 17, 1982

500MG

N018599 002 Feb 13, 1984

500MG

N018764 002 Dec 20, 1982

PROTOSTAT

ORTHO MCNEIL PHARM 250MG

N018871 001 Mar 02, 1983

500MG

N018871 002 Mar 02, 1983

SATRIC

SAVAGE LABS 250MG

A070029 001 Mar 19, 1985

500MG

A070731 001 Jun 08, 1987

TABLET, EXTENDED RELEASE; ORAL

FLAGYL ER

+ PFIZER 750MG

N020868 001 Nov 26, 1997

METRONIDAZOLE

ABLE 750MG

A076462 001 Jun 25, 2003

ALEMBIC PHARMS 750MG

A090222 001 May 05, 2010

METRONIDAZOLE HYDROCHLORIDE

INJECTABLE; INJECTION

FLAGYL I.V.

PFIZER EQ 500MG BASE/VIAL **

N018353 001

METRONIDAZOLE HYDROCHLORIDE

ABRAXIS PHARM EQ 500MG BASE/VIAL

A070295 001 Oct 15, 1985

METYPAPONE

TABLET; ORAL

METOPIRONE

HRA PHARMA 250MG

N012911 001

MEXILETINE HYDROCHLORIDE

CAPSULE; ORAL

MEXILETINE HYDROCHLORIDE

WATSON LABS 150MG

A074711 001 Feb 26, 1997

150MG

A074865 001 Apr 13, 1998

200MG

A074711 002 Feb 26, 1997

200MG

A074865 002 Apr 13, 1998

250MG

A074711 003 Feb 26, 1997

250MG

A074865 003 Apr 13, 1998

MEXITIL

+ BOEHRINGER INGELHEIM 150MG

N018873 002 Dec 30, 1985

+ 200MG

N018873 003 Dec 30, 1985

+ 250MG

N018873 004 Dec 30, 1985

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-322(of 478)

** See List Footnote

MEZLOCILLIN SODIUM MONOHYDRATE

INJECTABLE; INJECTION

MEZLIN

BAYER PHARMS	EQ 1GM BASE/VIAL	A062333	001	
	EQ 1GM BASE/VIAL	A062372	005	Jan 13, 1983
	EQ 1GM BASE/VIAL	N050549	001	
	EQ 2GM BASE/VIAL	A062333	002	
	EQ 2GM BASE/VIAL	A062372	001	May 13, 1982
	EQ 2GM BASE/VIAL	N050549	002	
	EQ 3GM BASE/VIAL	A062333	003	
	EQ 3GM BASE/VIAL	A062372	002	May 13, 1982
	EQ 3GM BASE/VIAL	A062697	001	Jan 22, 1987
	EQ 3GM BASE/VIAL	N050549	003	
	EQ 4GM BASE/VIAL	A062333	004	
	EQ 4GM BASE/VIAL	A062372	003	May 13, 1982
	EQ 4GM BASE/VIAL	A062697	002	Jan 22, 1987
	EQ 4GM BASE/VIAL	N050549	004	
	EQ 20GM BASE/VIAL	A062372	004	Mar 02, 1988
	EQ 20GM BASE/VIAL	N050549	005	Mar 02, 1988

MICAFUNGIN SODIUM

POWDER; INTRAVENOUS

MICAFUNGIN

+ TEVA PHARMS USA INC	EQ 50MG BASE/VIAL	N212125	001	Jul 30, 2021
+	EQ 100MG BASE/VIAL	N212125	002	Jul 30, 2021

MICONAZOLE

INJECTABLE; INJECTION

MONISTAT

JANSSEN PHARMA	10MG/ML	N018040	001	

MICONAZOLE NITRATE

CREAM; TOPICAL

MONISTAT-DERM

INSIGHT PHARMS	2%	N017494	001	

CREAM; VAGINAL

MICONAZOLE NITRATE

TEVA	2%	A074136	001	Jan 04, 1995
TEVA PHARMS	2%	A074030	001	Oct 30, 1992

CREAM, SUPPOSITORY; TOPICAL, VAGINAL

M-ZOLE 7 DUAL PACK

ACTAVIS MID ATLANTIC	2%, 100MG	A074586	001	Jul 17, 1997

MICONAZOLE 7 COMBINATION PACK

COSETTE	2%, 100MG	A076585	001	Mar 26, 2004

LOTION; TOPICAL

MONISTAT-DERM

INSIGHT PHARMS	2%	N017739	001	

SUPPOSITORY; VAGINAL

MICONAZOLE NITRATE

PERRIGO	100MG	A074395	001	Mar 20, 1997

TAMPON; VAGINAL

MONISTAT 5

PERSONAL PRODS	100MG	N018592	001	Oct 27, 1989

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION

MIDAZOLAM HYDROCHLORIDE

AKORN	EQ 5MG BASE/ML	A075481	001	Jun 30, 2000
APOTHECON	EQ 1MG BASE/ML	A075620	001	Nov 01, 2000
	EQ 5MG BASE/ML	A075620	002	Nov 01, 2000
	EQ 5MG BASE/ML	A075641	001	Oct 19, 2000
BAXTER HLTHCARE CORP	EQ 1MG BASE/ML	A075637	001	Oct 31, 2000
	EQ 5MG BASE/ML	A075637	002	Oct 31, 2000
BEDFORD	EQ 5MG BASE/ML	A075249	001	Jun 23, 2000
BEN VENUE	EQ 5MG BASE/ML	A075455	001	Jun 20, 2000
HOSPIRA	EQ 1MG BASE/ML	A075396	001	Jun 20, 2000
	EQ 1MG BASE/ML	A075856	001	Jun 13, 2002
	EQ 5MG BASE/ML	A075396	002	Jun 20, 2000
	EQ 5MG BASE/ML	A075484	001	Jun 20, 2000
	EQ 5MG BASE/ML	A075856	002	Jun 13, 2002
HOSPIRA INC	EQ 1MG BASE/ML	A075409	002	Jun 20, 2000

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-323(of 478)

** See List Footnote

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION

MIDAZOLAM HYDROCHLORIDE

	EQ 5MG BASE/ML	A075409	001	Jun 20, 2000
IGI LABS INC	EQ 5MG BASE/ML	A075263	001	Jun 26, 2000
INTL MEDICATED	EQ 1MG BASE/ML	A076144	001	Jan 26, 2005
	EQ 5MG BASE/ML	A076144	002	Jan 26, 2005
INTL MEDICATION	EQ 1MG BASE/ML	A076020	001	Jul 16, 2004
	EQ 5MG BASE/ML	A076020	002	Jul 16, 2004
WOCKHARDT BIO AG	EQ 1MG BASE/ML	A078141	001	May 30, 2008
	EQ 1MG BASE/ML	A078511	001	Nov 10, 2008
	EQ 5MG BASE/ML	A078141	002	May 30, 2008
	EQ 5MG BASE/ML	A078511	002	Nov 10, 2008
MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE				
STERISCIENCE	EQ 1MG BASE/ML	A090315	001	Nov 29, 2010
	EQ 5MG BASE/ML	A090315	002	Nov 29, 2010
MIDOZALAM HYDROCHLORIDE				
STERISCIENCE	EQ 1MG BASE/ML	A090316	001	May 04, 2011
	EQ 5MG BASE/ML	A090316	002	May 04, 2011
VERSED				
+ HLR	EQ 1MG BASE/ML **	N018654	002	May 26, 1987
+	EQ 5MG BASE/ML **	N018654	001	Dec 20, 1985
SOLUTION; INTRAMUSCULAR				
MIDAZOLAM HYDROCHLORIDE (AUTOINJECTOR)				
+ RAFA LABS LTD	EQ 10MG BASE/0.7ML (EQ 10MG BASE/0.7ML)	N216359	001	Aug 08, 2022
SYRUP; ORAL				
MIDAZOLAM HYDROCHLORIDE				
AKORN	EQ 2MG BASE/ML	A075958	001	Sep 04, 2003
PHARM ASSOC	EQ 2MG BASE/ML	A077115	001	Sep 09, 2005
SUN PHARM INDS LTD	EQ 2MG BASE/ML	A076058	001	Mar 15, 2002
VERSED				
+ ROCHE	EQ 2MG BASE/ML **	N020942	001	Oct 15, 1998

MIDODRINE HYDROCHLORIDE

TABLET; ORAL

MIDODRINE HYDROCHLORIDE

CHARTWELL RX	2.5MG	A076514	001	Sep 11, 2003
	5MG	A076514	002	Sep 11, 2003
	10MG	A076514	003	Jul 02, 2004
PROAMATINE				
+ TAKEDA PHARMS USA	2.5MG **	N019815	001	Sep 06, 1996
+	5MG **	N019815	002	Sep 06, 1996
+	10MG **	N019815	003	Mar 20, 2002

MILNACIPRAN HYDROCHLORIDE

TABLET; ORAL

MILNACIPRAN HYDROCHLORIDE

AMNEAL PHARMS	12.5MG	A205081	001	Apr 22, 2016
	25MG	A205081	002	Apr 22, 2016
	50MG	A205081	003	Apr 22, 2016
	100MG	A205081	004	Apr 22, 2016
USPHARMA WINDLAS	12.5MG	A205071	001	Jan 27, 2016
	25MG	A205071	002	Jan 27, 2016
	50MG	A205071	003	Jan 27, 2016
	100MG	A205071	004	Jan 27, 2016

MILRINONE LACTATE

INJECTABLE; INJECTION

MILRINONE LACTATE

BAXTER HLTHCARE CORP	EQ 1MG BASE/ML	A076427	001	Sep 21, 2004
GLAND PHARMA LTD	EQ 1MG BASE/ML	A077190	001	Oct 31, 2006
HIKMA	EQ 1MG BASE/ML	A075852	001	May 28, 2002
HOSPIRA	EQ 1MG BASE/ML	A075830	001	May 28, 2002
	EQ 1MG BASE/ML	A075884	001	May 28, 2002
INTL MEDICATED	EQ 1MG BASE/ML	A076013	001	Aug 02, 2002
MYLAN INSTITUTIONAL	EQ 1MG BASE/ML	A076428	001	Jun 16, 2003
MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER				
B BRAUN	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A076414	001	Aug 18, 2004
BAXTER HLTHCARE	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A076259	001	Aug 08, 2002
HIKMA	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A075510	001	May 28, 2002
WOODWARD	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A077151	001	Jul 20, 2005

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-324(of 478)

** See List Footnote

MILRINONE LACTATE

INJECTABLE;INJECTION

PRIMACOR

+	SANOFI AVENTIS US	EQ 1MG BASE/ML **	N019436	001	Dec 31, 1987
PRIMACOR IN DEXTROSE 5% IN PLASTIC CONTAINER					
+	SANOFI AVENTIS US	EQ 10MG BASE/100ML **	N020343	001	Aug 09, 1994
+		EQ 15MG BASE/100ML **	N020343	002	Aug 09, 1994
+		EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	N020343	003	Aug 09, 1994
		**			
+		EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)	N020343	004	Aug 09, 1994
		**			

MINOCYCLINE HYDROCHLORIDE

CAPSULE;ORAL

MINOCIN

+	BAUSCH	EQ 75MG BASE **	N050649	003	Feb 12, 2001
	TRIAx PHARMS	EQ 50MG BASE	N050315	002	
		EQ 100MG BASE	N050315	001	

CAPSULE, EXTENDED RELEASE;ORAL

XIMINO

JOURNEY	EQ 67.5MG BASE	N201922	002	Jul 11, 2012
	EQ 112.5MG BASE	N201922	004	Jul 11, 2012

INJECTABLE;INJECTION

MINOCIN

LEDERLE	EQ 100MG BASE/VIAL	A062139	001	

SUSPENSION;ORAL

MINOCIN

BAUSCH	EQ 50MG BASE/5ML	N050445	001	

TABLET;ORAL

MINOCYCLINE HYDROCHLORIDE

+	TRIAx PHARMS	EQ 50MG BASE **	N050451	003	Aug 10, 1982
+		EQ 100MG BASE **	N050451	002	Aug 10, 1982

TABLET, EXTENDED RELEASE;ORAL

MINOCYCLINE HYDROCHLORIDE

BARR LABS INC	EQ 45MG BASE	A065485	001	Mar 17, 2009
	EQ 65MG BASE	A065485	004	May 18, 2012
	EQ 80MG BASE	A065485	007	Apr 26, 2017
	EQ 90MG BASE	A065485	002	Mar 17, 2009
	EQ 105MG BASE	A065485	008	Apr 26, 2017
	EQ 115MG BASE	A065485	005	May 18, 2012
	EQ 135MG BASE	A065485	003	Mar 17, 2009
IMPAX LABS INC	EQ 45MG BASE	A090024	001	Feb 03, 2009
	EQ 90MG BASE	A090024	002	Feb 03, 2009
	EQ 135MG BASE	A090024	003	Feb 03, 2009
MYLAN PHARMS INC	EQ 45MG BASE	A090911	001	Jul 20, 2010
	EQ 90MG BASE	A090911	002	Jul 20, 2010
	EQ 135MG BASE	A090911	003	Jul 20, 2010
RISING	EQ 55MG BASE	A203443	001	Aug 21, 2019
	EQ 65MG BASE	A201467	001	Jul 30, 2019
	EQ 80MG BASE	A203443	002	Aug 22, 2014
	EQ 105MG BASE	A203443	003	Aug 22, 2014
	EQ 115MG BASE	A201467	002	Jul 30, 2019

SOLODYN

+	BAUSCH	EQ 45MG BASE **	N050808	001	May 08, 2006
+		EQ 90MG BASE **	N050808	002	May 08, 2006
+		EQ 135MG BASE **	N050808	003	May 08, 2006

MINOXIDIL

SOLUTION;TOPICAL

MINOXIDIL (FOR MEN)

AKORN	2%	A074731	001	Dec 24, 1996
APOTEX INC	2%	A074924	001	Apr 29, 1998
BAUSCH AND LOMB	2%	A074643	001	Apr 09, 1996
COPLEY PHARM	2%	A074500	001	May 23, 1996
SIGHT PHARMS	2%	A074743	002	Oct 18, 1996
TEVA	2%	A074589	001	Apr 05, 1996

MINOXIDIL (FOR WOMEN)

AKORN	2%	A074731	002	May 11, 2005
APOTEX INC	2%	A074924	002	Apr 29, 1998
SIGHT PHARMS	2%	A074743	001	Oct 18, 1996

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-325(of 478)

** See List Footnote

MINOXIDIL

SOLUTION; TOPICAL

MINOXIDIL EXTRA STRENGTH (FOR MEN)

APOTEX INC	5%	A075839	001	Oct 01, 2001
AVACOR PRODS	5%	A075619	001	Nov 17, 2000
PERRIGO NEW YORK	5%	A075737	001	Mar 15, 2002

TABLET; ORAL

LONITEN

+	PFIZER	2.5MG **	N018154	001
+		10MG **	N018154	003

MINODYL

QUANTUM PHARMICS	2.5MG	A072153	001	Jul 13, 1988
	10MG	A071534	001	Mar 19, 1987

MINOXIDIL

ROYCE LABS	2.5MG	A071799	001	Nov 10, 1987
	10MG	A071796	001	Nov 10, 1987
USL PHARMA	2.5MG	A071537	001	Dec 16, 1988

MIPOMERSEN SODIUM

SOLUTION; SUBCUTANEOUS

KYNAMRO

+	KASTLE THERAPS LLC	200MG/ML (200MG/ML)	N203568	001	Jan 29, 2013

MIRABEGRON

TABLET, EXTENDED RELEASE; ORAL

MIRABEGRON

SAWAI USA	25MG	A209446	001	Dec 27, 2019

MIRTAZAPINE

TABLET; ORAL

MIRTAZAPINE

ACTAVIS ELIZABETH	15MG	A076241	001	Jun 25, 2003
	15MG	A076308	001	Jun 20, 2003
	30MG	A076241	002	Jun 25, 2003
	30MG	A076308	002	Jun 20, 2003
	45MG	A076241	003	Jun 25, 2003
	45MG	A076308	003	Jun 20, 2003
ACTAVIS LABS FL INC	15MG	A076336	001	Jun 20, 2003
	30MG	A076336	002	Jun 20, 2003
	45MG	A076336	003	Jun 20, 2003
IVAX SUB TEVA PHARMS	15MG	A076244	001	Dec 22, 2003
	30MG	A076244	002	Dec 22, 2003
	45MG	A076244	003	Dec 22, 2003
MYLAN PHARMS INC	15MG	A076176	001	Jun 19, 2003
	30MG	A076176	002	Jun 19, 2003
	45MG	A076176	003	Jun 19, 2003
ROXANE	15MG	A076270	001	Jun 19, 2003
	30MG	A076270	002	Jun 19, 2003
	45MG	A076270	003	Jun 19, 2003
UPSHER SMITH LABS	15MG	A076189	001	Jun 19, 2003
	30MG	A076189	002	Jun 19, 2003
	45MG	A076189	003	Jun 19, 2003
WATSON LABS	15MG	A076312	001	Jun 19, 2003
	30MG	A076312	002	Jun 19, 2003
	45MG	A076312	003	Jun 19, 2003

REMERON

+	ORGANON USA INC	45MG **	N020415	003	Mar 17, 1997

TABLET, ORALLY DISINTEGRATING; ORAL

MIRTAZAPINE

ACTAVIS ELIZABETH	15MG	A076689	001	Aug 31, 2005
	15MG	A077959	001	Feb 14, 2011
	30MG	A076689	002	Aug 31, 2005
	30MG	A077959	002	Feb 14, 2011
	45MG	A076689	003	Aug 31, 2005
	45MG	A077959	003	Feb 14, 2011
ACTAVIS LABS FL INC	15MG	A076307	001	Dec 17, 2003
	30MG	A076307	002	Dec 17, 2003
	45MG	A076307	003	Feb 28, 2006
IMPAX LABS INC	15MG	A076901	001	Jun 28, 2005
	30MG	A076901	002	Jun 28, 2005
	45MG	A076901	003	Jun 28, 2005

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-326(of 478)

** See List Footnote

MISOPROSTOL

TABLET; ORAL

MISOPROSTOL

ACQ PHARMA

0.1MG

A210201 001 Jul 02, 2019

0.2MG

A210201 002 Jul 02, 2019

MITOMYCIN

INJECTABLE; INJECTION

MITOMYCIN

HIKMA

5MG/VIAL

A064117 001 Apr 19, 1995

HOSPIRA

20MG/VIAL

A064106 001 Nov 29, 1995

MITOZYTREX

+ SUPERGEN

5MG/VIAL **

N050763 001 Nov 14, 2002

MUTAMYCIN

+ BRISTOL

5MG/VIAL **

N050450 001

+

20MG/VIAL **

N050450 002

BRISTOL MYERS

5MG/VIAL

A062336 001

20MG/VIAL

A062336 002

40MG/VIAL **

A062336 003 Mar 10, 1988

MITOXANTRONE HYDROCHLORIDE

INJECTABLE; INJECTION

MITOXANTRONE HYDROCHLORIDE

FRESENIUS KABI ONCOL

EQ 20MG BASE/10ML (EQ 2MG BASE/ML)

A078606 001 May 14, 2008

EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)

A078606 002 May 14, 2008

EQ 30MG BASE/15ML (EQ 2MG BASE/ML)

A078606 003 May 14, 2008

MYLAN LABS LTD

EQ 20MG BASE/10ML (EQ 2MG BASE/ML)

A201014 001 Dec 11, 2012

RISING

EQ 20MG BASE/10ML (EQ 2MG BASE/ML)

A078980 001 Apr 13, 2009

EQ 30MG BASE/15ML (EQ 2MG BASE/ML)

A078980 002 Apr 13, 2009

NOVANTRONE

+ EMD SERONO

EQ 20MG BASE/10ML (EQ 2MG BASE/ML) **

N019297 001 Dec 23, 1987

+

EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML) **

N019297 002 Dec 23, 1987

+

EQ 30MG BASE/15ML (EQ 2MG BASE/ML) **

N019297 003 Dec 23, 1987

MIVACURIUM CHLORIDE

INJECTABLE; INJECTION

MIVACRON IN DEXTROSE 5% IN PLASTIC CONTAINER

ABBVIE

EQ 0.5MG BASE/ML

N020098 002 Jan 22, 1992

EQ 50MG BASE/100ML

N020098 003 Jan 22, 1992

MIVACURIUM CHLORIDE

RISING

EQ 2MG BASE/ML

A078562 001 Apr 30, 2009

SOLUTION; INTRAVENOUS

MIVACRON

+ ABBVIE

EQ 2MG BASE/ML (EQ 2MG BASE/ML) **

N020098 001 Jan 22, 1992

+

EQ 10MG BASE/5ML (EQ 2MG BASE/ML)

N020098 004 Jan 22, 1992

+

EQ 20MG BASE/10ML (EQ 2MG BASE/ML)

N020098 005 Jan 22, 1992

MODAFINIL

TABLET; ORAL

MODAFINIL

HIKMA PHARMS

100MG

A090543 001 Sep 26, 2012

200MG

A090543 002 Sep 26, 2012

MYLAN PHARMS INC

100MG

A076594 001 Jul 16, 2012

200MG

A076594 002 Jul 16, 2012

MOEXIPRIL HYDROCHLORIDE

TABLET; ORAL

UNIVASC

UCB INC

7.5MG **

N020312 001 Apr 19, 1995

15MG **

N020312 002 Apr 19, 1995

MOLINDONE HYDROCHLORIDE

CAPSULE; ORAL

MOBAN

+ STRIDES PHARMA

5MG **

N017111 001

+

10MG **

N017111 002

+

25MG **

N017111 003

CONCENTRATE; ORAL

MOBAN

ENDO PHARMS

20MG/ML

N017938 001

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-327(of 478)

** See List Footnote

MOLINDONE HYDROCHLORIDE

TABLET;ORAL

MOBAN

+	STRIDES PHARMA	5MG **	N017111	004
+		10MG **	N017111	005
+		25MG **	N017111	006
+		50MG **	N017111	007
+		100MG **	N017111	008

MOMETASONE FUROATE

CREAM;TOPICAL

ELOCON

	ORGANON	0.1% **	N019625	001	May 06, 1987
+		0.1% **	N019625	002	Apr 19, 2013
	MOMETASONE FUROATE				
	ANDA REPOSITORY	0.1%	A076591	001	Apr 18, 2007
	FOUGERA PHARMS	0.1%	A076171	001	Apr 08, 2005

LOTION;TOPICAL

MOMETASONE FUROATE

ENCUBE

0.1%	A076499	001	Nov 21, 2007

OINTMENT;TOPICAL

ELOCON

+	ORGANON	0.1%	N019543	001	Apr 30, 1987
	MOMETASONE FUROATE				
	ENCUBE	0.1%	A076481	001	Nov 14, 2003
	TARO	0.1%	A076624	001	Dec 03, 2004
	TORRENT	0.1%	A207899	001	Jul 13, 2018

SPRAY, METERED;NASAL

NASONEX

+	ORGANON LLC	0.05MG/SPRAY **	N020762	001	Oct 01, 1997

MONOBENZONE

CREAM;TOPICAL

BENOQUIN

VALEANT PHARM INTL	20%	N008173	003

MONOCTANOIN

LIQUID;PERFUSION, BILIARY

MOCTANIN

ETHITEK	100%	N019368	001	Oct 29, 1985

MONTELUKAST SODIUM

GRANULE;ORAL

MONTELUKAST SODIUM

MYLAN PHARMS INC	EQ 4MG BASE/PACKET	A202776	001	Dec 18, 2012

TABLET;ORAL

MONTELUKAST SODIUM

AJANTA PHARMA LTD	EQ 10MG BASE	A203432	001	Jul 31, 2015
APOTEX CORP	EQ 10MG BASE	A201294	001	Aug 03, 2012
BRECKENRIDGE	EQ 10MG BASE	A205319	001	Oct 30, 2020
HIKMA	EQ 10MG BASE	A090655	001	Aug 03, 2012
L PERRIGO CO	EQ 10MG BASE	A206112	001	Apr 26, 2017
MYLAN PHARMS INC	EQ 10MG BASE	A079103	001	Aug 03, 2012
STRIDES PHARMA	EQ 10MG BASE	A091576	001	Aug 03, 2012

TABLET, CHEWABLE;ORAL

MONTELUKAST SODIUM

AJANTA PHARMA LTD	EQ 4MG BASE	A203328	001	Jul 31, 2015
	EQ 5MG BASE	A203328	002	Jul 31, 2015
APOTEX INC	EQ 4MG BASE	A201508	001	Aug 03, 2012
	EQ 5MG BASE	A201508	002	Aug 03, 2012
HIKMA	EQ 4MG BASE	A091128	001	Aug 03, 2012
	EQ 5MG BASE	A091128	002	Aug 03, 2012
JUBILANT GENERICS	EQ 4MG BASE	A203795	001	Feb 27, 2015
	EQ 5MG BASE	A203795	002	Feb 27, 2015
MYLAN PHARMS INC	EQ 4MG BASE	A079142	001	Aug 03, 2012
	EQ 5MG BASE	A079142	002	Aug 03, 2012
STRIDES PHARMA	EQ 4MG BASE	A091588	001	Aug 03, 2012
	EQ 5MG BASE	A091588	002	Aug 03, 2012

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-328(of 478)

** See List Footnote

MORICIZINE HYDROCHLORIDE

TABLET; ORAL

ETHMOZINE

SHIRE

200MG

N019753 001 Jun 19, 1990

250MG

N019753 002 Jun 19, 1990

300MG

N019753 003 Jun 19, 1990

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

AVINZA

KING PHARMS LLC

30MG

N021260 001 Mar 20, 2002

45MG

N021260 005 Dec 18, 2008

60MG

N021260 002 Mar 20, 2002

75MG

N021260 006 Dec 18, 2008

90MG

N021260 003 Mar 20, 2002

120MG

N021260 004 Mar 20, 2002

KADIAN

+ ALLERGAN

10MG

N020616 008 Apr 20, 2007

+

20MG

N020616 001 Jul 03, 1996

+

30MG

N020616 004 Mar 09, 2001

+

40MG

N020616 009 Jul 09, 2012

+

50MG

N020616 002 Jul 03, 1996

+

60MG

N020616 005 Mar 09, 2001

+

70MG

N020616 010 Jul 09, 2012

+

80MG

N020616 006 Oct 27, 2006

+

100MG

N020616 003 Jul 03, 1996

+

130MG

N020616 011 Jul 09, 2012

+

150MG

N020616 012 Jul 09, 2012

+

200MG

N020616 007 Feb 27, 2007

MORPHINE SULFATE

IMPAX LABS INC

20MG

A200411 001 Apr 12, 2016

30MG

A200411 002 Apr 12, 2016

40MG

A200411 007 Jul 25, 2018

50MG

A200411 003 Apr 12, 2016

60MG

A200411 004 Apr 12, 2016

80MG

A200411 005 Apr 12, 2016

100MG

A200411 006 Apr 12, 2016

NORTEC DEV ASSOC

20MG

A203158 001 Aug 04, 2021

30MG

A203158 002 Aug 04, 2021

50MG

A203158 003 Aug 04, 2021

60MG

A203158 004 Aug 04, 2021

80MG

A203158 005 Aug 04, 2021

100MG

A203158 006 Aug 04, 2021

STRIDES PHARMA

20MG

A200812 001 Nov 10, 2011

30MG

A200812 002 Nov 10, 2011

50MG

A200812 003 Nov 10, 2011

60MG

A200812 004 Nov 10, 2011

80MG

A200812 005 Nov 10, 2011

100MG

A200812 006 Nov 10, 2011

TEVA PHARMS USA

20MG

A202718 001 Dec 29, 2014

30MG

A202718 002 Dec 29, 2014

40MG

A202718 007 Jun 03, 2015

50MG

A202718 003 Dec 29, 2014

60MG

A202718 004 Dec 29, 2014

70MG

A202718 008 Jun 03, 2015

80MG

A202718 005 Dec 29, 2014

100MG

A202718 006 Dec 29, 2014

INJECTABLE; INJECTION

ASTRAMORPH PF

FRESENIUS KABI USA

0.5MG/ML

A071050 001 Oct 07, 1986

0.5MG/ML

A071051 001 Oct 07, 1986

1MG/ML

A071052 001 Oct 07, 1986

1MG/ML

A071053 001 Oct 07, 1986

MORPHINE SULFATE

HOSPIRA

1MG/ML

A071850 001 May 11, 1988

+

HOSPIRA INC

15MG/ML

N202515 005 Nov 14, 2011

ICU MEDICAL INC

0.5MG/ML

N019917 001 Oct 30, 1992

+

1MG/ML **

N019916 001 Oct 30, 1992

+

5MG/ML **

N019916 002 Oct 27, 2006

SPECGX LLC

1MG/ML

N020631 001 Jul 03, 1996

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-329(of 478)

** See List Footnote

MORPHINE SULFATE

INJECTABLE;INJECTION

MORPHINE SULFATE

	2MG/ML	N020631	002	Jul 03, 1996
WATSON LABS	0.5MG/ML	A073373	001	Sep 30, 1991
	0.5MG/ML	A073375	001	Sep 30, 1991
	1MG/ML	A073374	001	Sep 30, 1991
	1MG/ML	A073376	001	Sep 30, 1991
INJECTABLE, LIPOSOMAL;EPIDURAL				
DEPODUR				
PACIRA PHARMS INC	10MG/ML (10MG/ML)	N021671	001	May 18, 2004
	15MG/1.5ML (10MG/ML)	N021671	002	May 18, 2004
	20MG/2ML (10MG/ML)	N021671	003	May 18, 2004

SOLUTION;INTRAMUSCULAR

MORPHINE SULFATE (AUTOINJECTOR)

+ MERIDIAN MEDCL TECHN	10MG/0.7ML (10MG/0.7ML)	N019999	001	Jul 12, 1990

SOLUTION;ORAL

MORPHINE SULFATE

ANI PHARMS	10MG/5ML	A205509	001	Apr 17, 2018
	20MG/5ML	A205509	002	Apr 17, 2018
	100MG/5ML	A205509	003	Apr 17, 2018
CHARTWELL MOLECULAR	10MG/5ML	A202309	001	Nov 25, 2015
	20MG/5ML	A202310	001	Oct 30, 2015
	100MG/5ML	N201517	001	Jun 23, 2011
NOSTRUM LABS INC	10MG/5ML	A201011	001	Feb 05, 2014
	20MG/5ML	A201011	002	Feb 05, 2014
	100MG/5ML	A201011	003	Oct 06, 2016
TRIS PHARMA INC	20MG/5ML	A203519	001	May 18, 2016
VISTAPHARM	10MG/5ML	A201947	001	Jan 05, 2012
	20MG/5ML	A201947	002	Jan 05, 2012
WINDER LABS LLC	10MG/5ML	A211454	001	Feb 12, 2021
	20MG/5ML	A211454	002	Feb 12, 2021
	100MG/5ML	A211454	003	Feb 12, 2021

TABLET;ORAL

MORPHINE SULFATE

INGENUS PHARMS NJ	15MG	A215584	001	Feb 07, 2022
	30MG	A215584	002	Feb 07, 2022

TABLET, EXTENDED RELEASE;ORAL

ARYMO ER

+ ZYLA	15MG	N208603	001	Jan 09, 2017
	30MG	N208603	002	Jan 09, 2017
	60MG	N208603	003	Jan 09, 2017

MORPHABOND ER

+ DAIICHI SANKYO INC	15MG	N206544	001	Oct 02, 2015
	30MG	N206544	002	Oct 02, 2015
	60MG	N206544	003	Oct 02, 2015
	100MG	N206544	004	Oct 02, 2015

MORPHINE SULFATE

EPIC PHARMA LLC	15MG	A091357	001	Jun 23, 2016
	30MG	A091357	002	Jun 23, 2016
	60MG	A091357	003	Jun 23, 2016
	100MG	A091357	004	Jun 23, 2016
	200MG	A091357	005	Jun 23, 2016
NESHER PHARMS	15MG	A076733	001	May 19, 2004
	30MG	A076720	002	Dec 23, 2005
	60MG	A076720	001	May 19, 2004
	100MG	A077855	001	Sep 27, 2007
	200MG	A077855	002	Sep 27, 2007
RISING	15MG	A200824	001	Oct 18, 2011
	30MG	A200824	002	Oct 18, 2011
	60MG	A200824	003	Oct 18, 2011
	100MG	A200824	004	Oct 18, 2011
	200MG	A200824	005	Oct 18, 2011
SUN PHARM INDUSTRIES	15MG	A205634	001	Aug 25, 2016
	30MG	A205634	002	Aug 25, 2016
	60MG	A205634	003	Aug 25, 2016
	100MG	A205634	004	Aug 25, 2016
	200MG	A205634	005	Aug 25, 2016
WATSON LABS	100MG	A075656	001	Jan 30, 2001

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-330(of 478)

** See List Footnote

MORPHINE SULFATE

TABLET, EXTENDED RELEASE;ORAL

ORAMORPH SR

XANODYNE PHARMS INC 15MG
30MG
60MG
100MG

N019977 004 Nov 23, 1994
N019977 001 Aug 15, 1991
N019977 002 Aug 15, 1991
N019977 003 Aug 15, 1991

MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

EMBEDA

+ ALPHARMA PHARMS 20MG;0.8MG **
+ 30MG;1.2MG **
+ 50MG;2MG **
+ 60MG;2.4MG **
+ 80MG;3.2MG **
+ 100MG;4MG **

N022321 001 Aug 13, 2009
N022321 002 Aug 13, 2009
N022321 003 Aug 13, 2009
N022321 004 Aug 13, 2009
N022321 005 Aug 13, 2009
N022321 006 Aug 13, 2009

MOXALACTAM DISODIUM

INJECTABLE; INJECTION

MOXAM

LILLY EQ 250MG BASE/VIAL
EQ 500MG BASE/VIAL
EQ 1GM BASE/VIAL
EQ 2GM BASE/VIAL
EQ 10GM BASE/VIAL

N050550 001
N050550 002
N050550 003
N050550 004
N050550 008

MOXIFLOXACIN HYDROCHLORIDE

SOLUTION; INTRAVENOUS

AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER

+ BAYER HLTHCARE 400MG/250ML (1.6MG/ML) **

N021277 001 Nov 30, 2001

TABLET;ORAL

AVELOX

+ BAYER HLTHCARE EQ 400MG BASE **

N021085 001 Dec 10, 1999

MOXIFLOXACIN HYDROCHLORIDE

MYLAN EQ 400MG BASE
SUNSHINE EQ 400MG BASE

A204635 001 Aug 31, 2015
A206295 001 Sep 28, 2018

MUPIROICIN

OINTMENT; TOPICAL

BACTROBAN

+ GLAXOSMITHKLINE 2% **

N050591 001 Dec 31, 1987

MUPIROICIN CALCIUM

CREAM; TOPICAL

BACTROBAN

+ GLAXOSMITHKLINE EQ 2% BASE **

N050746 001 Dec 11, 1997

OINTMENT; NASAL

BACTROBAN

+ GLAXOSMITHKLINE EQ 2% BASE

N050703 001 Sep 18, 1995

MYCOPHENOLATE MOFETIL

CAPSULE; ORAL

MYCOPHENOLATE MOFETIL

APOTEX CORP 250MG
DR REDDYS LABS LTD 250MG
JUBILANT CADISTA 250MG
STRIDES PHARMA 250MG
ZYDUS PHARMS USA INC 250MG

A090419 001 Apr 22, 2009
A091315 001 Oct 27, 2011
A090762 001 Dec 15, 2014
A090111 001 Dec 22, 2009
A065433 001 May 04, 2009

TABLET; ORAL

MYCOPHENOLATE MOFETIL

APOTEX 500MG
DR REDDYS LABS LTD 500MG
JUBILANT CADISTA 500MG
TEVA PHARMS 500MG
ZYDUS PHARMS USA INC 500MG

A090499 001 Apr 22, 2009
A090464 001 Sep 13, 2010
A090661 001 Dec 15, 2014
A065457 001 May 04, 2009
A065477 001 May 04, 2009

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-331(of 478)

** See List Footnote

MYCOPHENOLATE MOFETIL HYDROCHLORIDE

INJECTABLE;INJECTION

MYCOPHENOLATE MOFETIL HYDROCHLORIDE

AMNEAL 500MG/VIAL

A211374 001 Mar 05, 2021

MYCOPHENOLIC SODIUM

TABLET, DELAYED RELEASE;ORAL

MYCOPHENOLIC SODIUM

TEVA PHARMS USA EQ 180MG BASE

A202720 001 Oct 30, 2014

EQ 360MG BASE

A202720 002 Oct 30, 2014

NABUMETONE

TABLET;ORAL

NABUMETONE

COPLEY PHARM 750MG

A075179 001 Jun 06, 2000

EPIC PHARMA 500MG

A075590 001 Feb 25, 2002

750MG

A075590 002 Feb 25, 2002

IMPAX LABS INC 500MG

A075189 001 May 26, 2000

750MG

A075189 002 Sep 24, 2001

MYLAN PHARMS INC 500MG

A090516 001 Jul 12, 2010

750MG

A090516 002 Jul 12, 2010

NOSTRUM LABS INC 500MG

A090427 001 Dec 30, 2011

750MG

A090427 002 Dec 30, 2011

OXFORD PHARMS 500MG

A079093 001 Feb 27, 2009

750MG

A079093 002 Feb 27, 2009

RELAFEN

+ SMITHKLINE BEECHAM 500MG **

N019583 001 Dec 24, 1991

+ 750MG **

N019583 002 Dec 24, 1991

NADOLOL

TABLET;ORAL

CORCARD

USWM 120MG

N018063 003

160MG

N018063 004

NADOLOL

HERITAGE PHARMA 120MG

A074255 002 Jan 24, 1996

160MG

A074255 003 Jan 24, 1996

NOVAST LABS 20MG

A210786 001 Jun 01, 2018

40MG

A210786 002 Jun 01, 2018

80MG

A210786 003 Jun 01, 2018

TEVA PHARMS 80MG

A074368 001 Aug 31, 1994

120MG

A074368 002 Aug 31, 1994

160MG

A074368 003 Aug 31, 1994

NAFCILLIN SODIUM

CAPSULE;ORAL

UNIPEN

WYETH AYERST EQ 250MG BASE

N050111 001

FOR SOLUTION;ORAL

UNIPEN

WYETH AYERST EQ 250MG BASE/5ML

N050199 001

INJECTABLE;INJECTION

NAFCILLIN SODIUM

APOTHECON EQ 500MG BASE/VIAL

A061984 001

EQ 1GM BASE/VIAL

A061984 002

EQ 2GM BASE/VIAL

A061984 003

EQ 4GM BASE/VIAL

A061984 005

FRESENIUS EQ 1GM BASE/VIAL

A206682 001 Dec 10, 2019

EQ 2GM BASE/VIAL

A206682 002 Dec 10, 2019

SANDOZ EQ 500MG BASE/VIAL

A062527 001 Aug 02, 1984

STERISCENCE EQ 1GM BASE/VIAL

A200002 001 Apr 07, 2014

EQ 2GM BASE/VIAL

A200002 002 Apr 07, 2014

WATSON LABS INC EQ 500MG BASE/VIAL

A062844 001 Oct 26, 1988

EQ 1GM BASE/VIAL

A062844 002 Oct 26, 1988

EQ 1.5GM BASE/VIAL

A062844 003 Oct 26, 1988

EQ 2GM BASE/VIAL

A062844 004 Oct 26, 1988

EQ 4GM BASE/VIAL

A062844 005 Oct 26, 1988

EQ 10GM BASE/VIAL

A063008 001 Sep 29, 1988

NALLPEN

GLAXOSMITHKLINE EQ 500MG BASE/VIAL

A061999 001

EQ 1GM BASE/VIAL

A061999 002

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-332(of 478)

** See List Footnote

NAFCILLIN SODIUM

INJECTABLE; INJECTION

NALLPEN

EQ 1GM BASE/VIAL	A062755	001	Dec 19, 1986
EQ 2GM BASE/VIAL	A061999	003	
EQ 2GM BASE/VIAL	A062755	002	Dec 19, 1986
EQ 10GM BASE/VIAL	A061999	004	

UNIPEN

WYETH AYERST

EQ 500MG BASE/VIAL **	A062717	001	Dec 16, 1986
EQ 500MG BASE/VIAL **	N050320	001	
EQ 1GM BASE/VIAL **	A062717	002	Dec 16, 1986
EQ 2GM BASE/VIAL **	A062717	004	Dec 16, 1986
EQ 2GM BASE/VIAL **	N050320	003	
EQ 4GM BASE/VIAL **	N050320	004	
EQ 10GM BASE/VIAL **	N050320	005	
EQ 20GM BASE/VIAL **	N050320	006	

UNIPEN IN PLASTIC CONTAINER

+ WYETH AYERST

EQ 1GM BASE/VIAL **	N050320	002	

TABLET; ORAL

UNIPEN

WYETH AYERST

EQ 500MG BASE	N050462	001	

NAFTIFINE HYDROCHLORIDE

CREAM; TOPICAL

NAFTIN

+ SEBELA IRELAND LTD

1% **	N019599	001	Feb 29, 1988

GEL; TOPICAL

NAFTIFINE HYDROCHLORIDE

TARO

2%	A208201	001	Apr 10, 2019

NALBUPHINE HYDROCHLORIDE

INJECTABLE; INJECTION

NALBUPHINE

ABRAXIS PHARM

10MG/ML	A070751	001	Jul 02, 1986
20MG/ML	A070752	001	Sep 24, 1986

NALBUPHINE HYDROCHLORIDE

ABBOTT

20MG/ML	A070917	001	Feb 03, 1989

ABBVIE

1.5MG/ML	N020200	001	Mar 12, 1993

DR REDDYS

10MG/ML	A074471	001	Mar 19, 1998

20MG/ML	A074471	002	Mar 19, 1998

IGI LABS INC

10MG/ML	A072070	001	Apr 10, 1989

10MG/ML	A072071	001	Apr 10, 1989

10MG/ML	A072072	001	Apr 10, 1989

20MG/ML	A072073	001	Apr 10, 1989

20MG/ML	A072074	001	Apr 10, 1989

20MG/ML	A072075	001	Apr 10, 1989

RISING

10MG/ML	A206506	001	Feb 06, 2019

10MG/ML	A207595	001	Jan 11, 2019

20MG/ML	A206506	002	Feb 06, 2019

20MG/ML	A207595	002	Jan 11, 2019

NUBAIN

+ PAR PHARM INC

10MG/ML **	N018024	001	

+

20MG/ML **	N018024	002	May 27, 1982

NALIDIXIC ACID

SUSPENSION; ORAL

NEGGRAM

SANOFI AVENTIS US

250MG/5ML	N017430	001	

TABLET; ORAL

NALIDIXIC ACID

SUN PHARM INDUSTRIES

250MG	A070270	001	Jun 29, 1988

500MG	A070271	001	Jun 29, 1988

1GM	A070272	001	Jun 29, 1988

WATSON LABS

250MG	A071936	001	Jun 29, 1988

500MG	A072061	001	Jun 29, 1988

1GM	A071919	001	Jun 29, 1988

NEGGRAM

SANOFI AVENTIS US

250MG	N014214	002	

500MG	N014214	004	

1GM	N014214	005	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-333(of 478)

** See List Footnote

NALMEFENE HYDROCHLORIDE

SOLUTION; INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS

REVEX

+	HIKMA	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML) **	N020459 001	Apr 17, 1995
+		EQ 2MG BASE/2ML (EQ 1MG BASE/ML) **	N020459 002	Apr 17, 1995

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION

NALOXONE

HIKMA	0.4MG/ML	A070298 001	Sep 24, 1986
	0.4MG/ML	A070496 001	Sep 24, 1986
WYETH AYERST	0.02MG/ML	A070188 001	Sep 24, 1986
	0.02MG/ML	A070189 001	Sep 24, 1986
	0.4MG/ML	A070190 001	Sep 24, 1986
	0.4MG/ML	A070191 001	Sep 24, 1986

NALOXONE HYDROCHLORIDE

ABRAXIS PHARM

0.02MG/ML	A070648 001	Nov 17, 1986
0.02MG/ML	A070661 001	Nov 17, 1986
0.4MG/ML	A070649 001	Nov 17, 1986
1MG/ML	A071604 001	Dec 16, 1988

ANDA REPOSITORY

0.4MG/ML	A207846 001	Dec 17, 2018

ASTRAZENECA

0.02MG/ML	A072081 001	Apr 11, 1989

HIKMA

0.02MG/ML	A071272 001	May 24, 1988

1MG/ML

A071273 001	May 24, 1988

1MG/ML

A071274 001	May 24, 1988

1MG/ML

A071287 001	May 24, 1988

HOSPIRA

0.02MG/ML	A070171 001	Sep 24, 1986

0.02MG/ML

A070252 001	Jan 16, 1987

0.02MG/ML

A070253 001	Jan 16, 1987

0.4MG/ML

A070254 001	Jan 07, 1987

0.4MG/ML

A070255 001	Jan 07, 1987

IGI LABS INC

0.02MG/ML	A072082 001	Apr 11, 1989

0.02MG/ML

A072083 001	Apr 11, 1989

0.02MG/ML

A072084 001	Apr 11, 1989

0.02MG/ML

A072085 001	Apr 11, 1989

0.4MG/ML

A072086 001	Apr 11, 1989

0.4MG/ML

A072087 001	Apr 11, 1989

0.4MG/ML

A072088 001	Apr 11, 1989

0.4MG/ML

A072089 001	Apr 11, 1989

0.4MG/ML

A072090 001	Apr 11, 1989

1MG/ML

A072091 001	Apr 11, 1989

1MG/ML

A072092 001	Apr 11, 1989

1MG/ML

A072093 001	Apr 11, 1989

INTL MEDICATION

0.4MG/ML	A070417 001	Sep 24, 1986

0.4MG/ML

A070639 001	Sep 24, 1986

1MG/ML

A072115 001	Apr 27, 1988

MARSAM PHARMS LLC

0.4MG/ML	A071811 001	Jul 19, 1988

PAR STERILE PRODUCTS

0.4MG/ML	A211286 001	Jan 17, 2020

SMITH AND NEPHEW

0.02MG/ML	A071671 001	Nov 17, 1987

0.4MG/ML

A071681 001	Nov 17, 1987

0.4MG/ML

A071682 001	Nov 17, 1987

SOLOPAK

0.02MG/ML	A071672 001	Nov 17, 1987

0.4MG/ML

A071683 001	Nov 17, 1987

WATSON LABS

0.4MG/ML	A071339 001	Nov 18, 1987

NARCAN

+	ADAPT	0.02MG/ML **	N016636 002	

+		0.4MG/ML **	N016636 001	

+		1MG/ML **	N016636 003	Jun 14, 1982

	BRISTOL MYERS SQUIBB	0.4MG/ML	A071083 001	Jul 28, 1988

1MG/ML

A071084 001	Jul 28, 1988

A071311 001	Jul 28, 1988

SOLUTION; INTRAMUSCULAR, SUBCUTANEOUS

EVZIO

+	KALEO INC	0.4MG/0.4ML (0.4MG/0.4ML)	N205787 001	Apr 03, 2014

EVZIO (AUTOINJECTOR)

+	KALEO INC	2MG/0.4ML (2MG/0.4ML)	N209862 001	Oct 19, 2016

NALOXONE HYDROCHLORIDE (AUTOINJECTOR)

+	KALEO INC	10MG/0.4ML (10MG/0.4ML)	N215457 001	Feb 28, 2022

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-334(of 478)

** See List Footnote

NALOXONE HYDROCHLORIDE

SPRAY, METERED;NASAL

NARCAN

+ EMERGENT 2MG/SPRAY **

N208411 002 Jan 24, 2017

NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

TARGINIQ

+ PURDUE PHARMA LP 5MG;10MG

N205777 001 Jul 23, 2014

+ 10MG;20MG

N205777 002 Jul 23, 2014

+ 20MG;40MG

N205777 003 Jul 23, 2014

NALOXONE HYDROCHLORIDE; PENTAZOCINE HYDROCHLORIDE

TABLET;ORAL

TALWIN NX

SANOFI AVENTIS US EQ 0.5MG BASE;EQ 50MG BASE **

N018733 001 Dec 16, 1982

NALTREXONE HYDROCHLORIDE

TABLET;ORAL

NALTREXONE HYDROCHLORIDE

FOSUN PHARMA 50MG

A075434 001 Mar 08, 2000

REVIA

+ TEVA WOMENS 50MG

N018932 001 Nov 20, 1984

NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

TROXYCA ER

PFIZER 1.2MG;10MG

N207621 001 Aug 19, 2016

2.4MG;20MG

N207621 002 Aug 19, 2016

3.6MG;30MG

N207621 003 Aug 19, 2016

4.8MG;40MG

N207621 004 Aug 19, 2016

7.2MG;60MG

N207621 005 Aug 19, 2016

9.6MG;80MG

N207621 006 Aug 19, 2016

NANDROLONE DECANOATE

INJECTABLE;INJECTION

DECA-DURABOLIN

WOODWARD SPECL 50MG/ML

N013132 001 Jun 12, 1986

100MG/ML

N013132 002 Jun 12, 1986

+ 200MG/ML **

N013132 003 Jun 12, 1986

NANDROLONE DECANOATE

ABRAXIS PHARM 100MG/ML

A088290 001 Oct 03, 1983

200MG/ML

A088317 001 Oct 14, 1983

AKORN 100MG/ML

A087519 001 Sep 28, 1983

AM REGENT 200MG/ML

A091252 001 Aug 30, 2010

WATSON LABS 50MG/ML

A086385 001 Jan 13, 1984

50MG/ML

A087598 001 Oct 06, 1983

50MG/ML

A088554 001 Feb 10, 1986

100MG/ML

A086598 001 Jan 13, 1984

100MG/ML

A087599 001 Oct 06, 1983

+ 200MG/ML

A088128 001 Dec 05, 1983

NANDROLONE PHENPROPIONATE

INJECTABLE;INJECTION

DURABOLIN

ORGANON USA INC 25MG/ML

N011891 001

50MG/ML

N011891 002

NANDROLONE PHENPROPIONATE

WATSON LABS 25MG/ML

A086386 001 Jun 17, 1983

50MG/ML

A087488 001 Jun 17, 1983

NAPHAZOLINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

ALBALON

ALLERGAN 0.1% **

A080248 001

NAFAZAIR

BAUSCH AND LOMB 0.1%

A040073 001 May 25, 1994

PHARMAFAIR 0.1%

A088101 001 Apr 15, 1983

NAPHAZOLINE HYDROCHLORIDE

AKORN 0.1%

A083590 001

NAPHCON FORTE

+ ALCON 0.1%

A080229 001

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-335(of 478)

** See List Footnote

NAPHAZOLINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

OPCON

BAUSCH AND LOMB 0.1%

A087506 001

VASOCON

NOVARTIS 0.1%

A080235 002 Mar 24, 1983

NAPROXEN

TABLET;ORAL

NAPROSYN

+ ATNAHS PHARMA US 250MG

N017581 002

+ 375MG

N017581 003

NAPROXEN

CHARTWELL MOLECULES 250MG

A074410 001 Apr 28, 1995

375MG

A074410 002 Apr 28, 1995

500MG

A074410 003 Apr 28, 1995

DAVA PHARMS INC 250MG

A074105 001 Dec 21, 1993

375MG

A074105 002 Dec 21, 1993

500MG

A074105 003 Dec 21, 1993

HAMILTON PHARMS 250MG

A074110 001 Oct 30, 1992

375MG

A074110 002 Oct 30, 1992

500MG

A074110 003 Oct 30, 1992

HIKMA INTL PHARMS 250MG

A076494 001 Jan 14, 2004

375MG

A076494 002 Jan 14, 2004

500MG

A076494 003 Jan 14, 2004

IVAX SUB TEVA PHARMS 250MG

A074111 001 Feb 28, 1995

375MG

A074111 002 Feb 28, 1995

500MG

A074111 003 Feb 28, 1995

L PERRIGO CO 250MG

A077339 001 Apr 27, 2005

375MG

A077339 002 Apr 27, 2005

500MG

A077339 003 Apr 27, 2005

MYLAN 250MG

A074121 001 Dec 21, 1993

375MG

A074121 002 Dec 21, 1993

500MG

A074121 003 Dec 21, 1993

PLIVA 250MG

A074182 001 Jun 27, 1996

375MG

A074182 002 Jun 27, 1996

500MG

A074182 003 Jun 27, 1996

PUREPAC PHARM 250MG

A074263 001 Dec 21, 1993

375MG

A074263 002 Dec 21, 1993

500MG

A074263 003 Dec 21, 1993

ROXANE 250MG

A074211 001 Feb 28, 1994

375MG

A074211 002 Feb 28, 1994

500MG

A074211 003 Feb 28, 1994

TEVA 250MG

A074129 001 Dec 21, 1993

250MG

A074216 001 Apr 11, 1996

375MG

A074129 002 Dec 21, 1993

375MG

A074216 002 Apr 11, 1996

500MG

A074129 003 Dec 21, 1993

500MG

A074216 003 Apr 11, 1996

TEVA PHARMS 250MG

A074207 001 Dec 21, 1993

375MG

A074207 002 Dec 21, 1993

500MG

A074207 003 Dec 21, 1993

WATSON LABS 250MG

A074457 001 May 31, 1995

375MG

A074457 002 May 31, 1995

500MG

A074457 003 May 31, 1995

WATSON LABS TEVA 250MG

A074163 001 Feb 10, 1995

375MG

A074163 002 Feb 10, 1995

500MG

A074163 003 Feb 10, 1995

TABLET, DELAYED RELEASE;ORAL

NAPROXEN

ACTAVIS ELIZABETH 375MG

A074936 001 Feb 24, 1998

500MG

A074936 002 Feb 24, 1998

FOSUN PHARMA 375MG

A075061 001 Feb 18, 1998

500MG

A075061 002 Feb 18, 1998

MYLAN PHARMS INC 375MG

A075390 001 Apr 19, 2001

500MG

A075390 002 Apr 19, 2001

PLIVA 375MG

A075337 001 May 26, 1999

500MG

A075337 002 May 26, 1999

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-336(of 478)

** See List Footnote

NAPROXEN SODIUM

TABLET;ORAL

ANAPROX

+ ATNAHS PHARMA US

EQ 250MG BASE **

N018164 001

NAPROXEN SODIUM

ABLE

EQ 250MG BASE

A076544 001 Aug 22, 2003

EQ 500MG BASE

A076544 002 Aug 22, 2003

CONTRACT PHARMACAL

220MG

A074789 001 Feb 27, 1997

HAMILTON PHARMS

EQ 250MG BASE

A074106 001 Aug 31, 1993

EQ 500MG BASE

A074106 002 Aug 31, 1993

HIKMA

EQ 250MG BASE

A074480 002 Feb 18, 1998

EQ 500MG BASE

A074480 001 May 14, 1996

IVAX SUB TEVA PHARMS

EQ 250MG BASE

A074230 001 Mar 14, 1995

EQ 500MG BASE

A074230 002 Mar 14, 1995

MYLAN

EQ 250MG BASE

A074367 001 Aug 31, 1994

EQ 500MG BASE

A074367 002 Aug 31, 1994

PLD ACQUISITIONS LLC

220MG

A074646 001 Jan 13, 1997

PLIVA

EQ 250MG BASE

A074242 001 Jun 20, 1996

EQ 500MG BASE

A074242 002 Jun 20, 1996

PUREPAC PHARM

EQ 250MG BASE

A074319 001 Mar 20, 1995

EQ 500MG BASE

A074319 002 Mar 20, 1995

ROXANE

EQ 250MG BASE

A074257 001 Dec 21, 1993

EQ 500MG BASE

A074257 002 Dec 21, 1993

SANDOZ

EQ 250MG BASE

A074162 001 Dec 21, 1993

EQ 250MG BASE

A074495 001 Dec 05, 1994

EQ 500MG BASE

A074162 002 Dec 21, 1993

EQ 500MG BASE

A074495 002 Dec 05, 1994

TEVA

EQ 250MG BASE

A074142 001 Dec 21, 1993

EQ 250MG BASE

A074198 001 Dec 21, 1993

EQ 500MG BASE

A074142 002 Dec 21, 1993

EQ 500MG BASE

A074198 002 Dec 21, 1993

TEVA PHARMS

EQ 250MG BASE

A074289 001 Jan 27, 1994

EQ 500MG BASE

A074289 002 Jan 27, 1994

WATSON LABS

EQ 250MG BASE

A074195 001 Dec 21, 1993

EQ 250MG BASE

A074455 001 May 31, 1995

EQ 500MG BASE

A074195 002 Dec 21, 1993

EQ 500MG BASE

A074455 002 May 31, 1995

NAPROXEN SODIUM; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

ALEVE-D SINUS & COLD

+ BAYER

220MG;120MG

N021076 001 Nov 29, 1999

NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE

AUROBINDO PHARMA

220MG;120MG

A211360 001 Jun 01, 2022

NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE

TABLET;ORAL

TREXIMET

+ CURRAX

60MG;EQ 10MG BASE

N021926 002 May 14, 2015

NARATRIPTAN HYDROCHLORIDE

TABLET;ORAL

NARATRIPTAN

ANI PHARMS

EQ 1MG BASE

A078751 001 Jul 07, 2010

EQ 2.5MG BASE

A078751 002 Jul 07, 2010

APOTEX CORP

EQ 1MG BASE

A091373 001 Apr 22, 2011

EQ 2.5MG BASE

A091373 002 Apr 22, 2011

CHARTWELL RX

EQ 1MG BASE

A090288 001 Jul 07, 2010

EQ 2.5MG BASE

A090288 002 Jul 07, 2010

MYLAN PHARMS INC

EQ 1MG BASE

A202431 001 May 31, 2012

EQ 2.5MG BASE

A202431 002 May 31, 2012

NATEGLINIDE

TABLET;ORAL

NATEGLINIDE

ALVOGEN

60MG

A205055 001 Dec 11, 2015

120MG

A205055 002 Dec 11, 2015

TEVA PHARMS

60MG

A077467 001 Sep 09, 2009

120MG

A077467 002 Sep 09, 2009

STARLIX

+ NOVARTIS

60MG **

N021204 001 Dec 22, 2000

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-337(of 478)

** See List Footnote

NATEGLINIDE

TABLET;ORAL

STARLIX

+

120MG **

N021204 002 Dec 22, 2000

NEBIVOLOL HYDROCHLORIDE

TABLET;ORAL

NEBIVOLOL HYDROCHLORIDE

AJANTA PHARMA LTD

EQ 2.5MG BASE

A213349 001 Mar 31, 2022

EQ 5MG BASE

A213349 002 Mar 31, 2022

EQ 10MG BASE

A213349 003 Mar 31, 2022

EQ 20MG BASE

A213349 004 Mar 31, 2022

ALKEM LABS LTD

EQ 2.5MG BASE

A203741 001 Jun 24, 2015

EQ 5MG BASE

A203741 002 Jun 24, 2015

EQ 10MG BASE

A203741 003 Jun 24, 2015

EQ 20MG BASE

A203741 004 Jun 24, 2015

GLENMARK PHARMS LTD

EQ 2.5MG BASE

A203821 001 May 25, 2017

EQ 5MG BASE

A203821 002 May 25, 2017

EQ 10MG BASE

A203821 003 May 25, 2017

EQ 20MG BASE

A203821 004 May 25, 2017

UNICHEM

EQ 2.5MG BASE

A213830 001 Mar 15, 2022

EQ 5MG BASE

A213830 002 Mar 15, 2022

EQ 10MG BASE

A213830 003 Mar 15, 2022

EQ 20MG BASE

A213830 004 Mar 15, 2022

WATSON LABS INC

EQ 2.5MG BASE

A203683 001 Nov 27, 2015

EQ 5MG BASE

A203683 002 Nov 27, 2015

EQ 10MG BASE

A203683 003 Nov 27, 2015

EQ 20MG BASE

A203683 004 Nov 27, 2015

NEBIVOLOL HYDROCHLORIDE; VALSARTAN

TABLET;ORAL

BYVALSON

+

ALLERGAN

EQ 5MG BASE;80MG

N206302 001 Jun 03, 2016

NEDOCROMIL SODIUM

AEROSOL, METERED;INHALATION

TILADE

KING PHARMS LLC

1.75MG/INH

N019660 001 Dec 30, 1992

SOLUTION;INHALATION

TILADE

SANOFI AVENTIS US

0.5%

N020750 001 Oct 01, 1997

SOLUTION/DROPS;OPHTHALMIC

ALOCRIL

+

ALLERGAN

2%

N021009 001 Dec 08, 1999

NEDOCROMIL SODIUM

AKORN

2%

A090638 001 Aug 22, 2012

NEFAZODONE HYDROCHLORIDE

TABLET;ORAL

NEFAZODONE HYDROCHLORIDE

ANI PHARMS

50MG

A076072 001 Sep 16, 2003

100MG

A076072 002 Sep 16, 2003

150MG

A076072 003 Sep 16, 2003

200MG

A076072 004 Sep 16, 2003

250MG

A076072 005 Sep 16, 2003

DR REDDYS LABS INC

50MG

A076309 001 Sep 16, 2003

100MG

A076309 002 Sep 16, 2003

150MG

A076309 003 Sep 16, 2003

200MG

A076309 004 Sep 16, 2003

250MG

A076309 005 Sep 16, 2003

FOSUN PHARMA

50MG

A076302 001 Sep 16, 2003

100MG

A076302 002 Sep 16, 2003

150MG

A076302 003 Sep 16, 2003

200MG

A076302 004 Sep 16, 2003

250MG

A076302 005 Sep 16, 2003

IVAX SUB TEVA PHARMS

50MG

A075763 001 Sep 16, 2003

100MG

A075763 002 Sep 16, 2003

150MG

A075763 003 Sep 16, 2003

200MG

A075763 004 Sep 16, 2003

250MG

A075763 005 Sep 16, 2003

MYLAN

100MG

A076129 002 Sep 16, 2003

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-338(of 478)

** See List Footnote

NEFAZODONE HYDROCHLORIDE

TABLET;ORAL

NEFAZODONE HYDROCHLORIDE

	150MG	A076129 003	Sep 16, 2003
	200MG	A076129 004	Sep 16, 2003
	250MG	A076129 005	Sep 16, 2003
ROXANE	50MG	A076196 001	Sep 16, 2003
	100MG	A076196 002	Sep 16, 2003
	150MG	A076196 003	Sep 16, 2003
	200MG	A076196 004	Sep 16, 2003
	250MG	A076196 005	Sep 16, 2003
SUN PHARM INDS LTD	50MG	A076409 001	Sep 16, 2003
	100MG	A076409 002	Sep 16, 2003
	150MG	A076409 003	Sep 16, 2003
	200MG	A076409 004	Sep 16, 2003
	250MG	A076409 005	Sep 16, 2003
WATSON LABS	100MG	A076073 002	Sep 16, 2003
	150MG	A076073 003	Sep 16, 2003
	200MG	A076073 004	Sep 16, 2003
	250MG	A076073 005	Sep 16, 2003
SERZONE			
+	BRISTOL MYERS SQUIBB 50MG **	N020152 001	Dec 22, 1994
+	100MG **	N020152 002	Dec 22, 1994
+	150MG **	N020152 003	Dec 22, 1994
+	200MG **	N020152 004	Dec 22, 1994
+	250MG **	N020152 005	Dec 22, 1994
+	300MG **	N020152 006	Dec 22, 1994

NELFINAVIR MESYLATE

POWDER;ORAL

VIRACEPT

AGOURON PHARMS	EQ 50MG BASE/SCOOPFUL	N020778 001	Mar 14, 1997

NEOMYCIN SULFATE

SOLUTION;ORAL

MYCIFRADIN

PHARMACIA AND UPJOHN	EQ 87.5MG BASE/5ML	N050285 001	
NEO-FRADIN			
X GEN PHARMS	EQ 87.5MG BASE/5ML	A065010 001	May 23, 2002

TABLET;ORAL

MYCIFRADIN

PHARMACIA AND UPJOHN	EQ 350MG BASE	A060520 001	
NEOBIOTIC			
PFIZER	EQ 350MG BASE	A060475 001	
NEOMYCIN SULFATE			
BRISTOL MYERS SQUIBB	500MG	A060365 001	
CHARTWELL MOLECULAR	500MG	A204435 001	Jun 10, 2016
LANNETT	500MG	A060607 001	
LILLY	500MG	A060385 001	
NOSTRUM LABS INC	500MG	A065468 001	Mar 29, 2010
ROXANE	500MG	A062173 001	
SANDOZ	500MG	A061586 001	

NEOMYCIN SULFATE; POLYMYXIN B SULFATE

CREAM;TOPICAL

NEOSPORIN

GLAXOSMITHKLINE	EQ 3.5MG BASE/GM;10,000 UNITS/GM	N050176 002	Jan 14, 1985

OINTMENT;OPHTHALMIC

STATROL

ALCON	EQ 3.5MG BASE/GM;10,000 UNITS/GM	N050344 002	

SOLUTION/DROPS;OPHTHALMIC

STATROL

ALCON	EQ 3.5MG BASE/ML;16,250 UNITS/ML	A062339 001	Nov 30, 1984
	EQ 3.5MG BASE/ML;16,250 UNITS/ML	N050456 001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-339(of 478)

** See List Footnote

NEOMYCIN SULFATE; POLYMYXIN B SULFATE; PREDNISOLONE ACETATE

SUSPENSION/DROPS;OPHTHALMIC

POLY-PRED

ALLERGAN

EQ 0.35% BASE;10,000 UNITS/ML;0.5%

N050081 002

NEOMYCIN SULFATE; PREDNISOLONE ACETATE

OINTMENT;OPHTHALMIC

NEO-DELTA-CORTEF

PHARMACIA AND UPJOHN

EQ 3.5MG BASE/GM;0.25%

A061039 002

EQ 3.5MG BASE/GM;0.5%

A061039 001

SUSPENSION/DROPS;OPHTHALMIC

NEO-DELTA-CORTEF

PHARMACIA AND UPJOHN

EQ 3.5MG BASE/ML;0.25%

A061037 001

NEOMYCIN SULFATE; PREDNISOLONE SODIUM PHOSPHATE

OINTMENT;OPHTHALMIC

NEO-HYDELTRASOL

MERCK

EQ 3.5MG BASE/GM;EQ 0.25% PHOSPHATE

N050378 001

NEOMYCIN SULFATE; TRIAMCINOLONE ACETONIDE

CREAM;TOPICAL

MYTRES A

SAVAGE LABS

EQ 3.5MG BASE/GM;0.1%

A062598 001 Jul 21, 1986

NEOMYCIN SULFATE-TRIAMCINOLONE ACETONIDE

FOUGERA

EQ 3.5MG BASE/GM;0.1%

A062600 001 Jul 21, 1986

PHARMADERM

EQ 3.5MG BASE/GM;0.1%

A062595 001 Jul 21, 1986

OINTMENT;TOPICAL

MYTRES A

SAVAGE LABS

EQ 3.5MG BASE/GM;0.1%

A062609 001 May 23, 1986

NEOMYCIN SULFATE-TRIAMCINOLONE ACETONIDE

FOUGERA

EQ 3.5MG BASE/GM;0.1%

A062608 001 May 23, 1986

PHARMADERM

EQ 3.5MG BASE/GM;0.1%

A062607 001 May 23, 1986

NEOSTIGMINE METHYLSULFATE

SOLUTION;INTRAVENOUS

NEOSTIGMINE METHYLSULFATE

AM REGENT

5MG/10ML (0.5MG/ML)

A209182 001 May 04, 2018

10MG/10ML (1MG/ML)

A209182 002 May 04, 2018

NESIRITIDE RECOMBINANT

FOR SOLUTION;INTRAVENOUS

NATRECOR

+

SCIOS LLC

1.5MG/VIAL **

N020920 001 Aug 10, 2001

NETILMICIN SULFATE

INJECTABLE;INJECTION

NETROMYCIN

SCHERING

EQ 10MG BASE/ML

N050544 001 Feb 28, 1983

EQ 25MG BASE/ML

N050544 002 Feb 28, 1983

EQ 100MG BASE/ML

N050544 003 Feb 28, 1983

NEVIRAPINE

TABLET;ORAL

NEVIRAPINE

APOTEX INC

200MG

A203021 001 May 22, 2012

MYLAN LABS

200MG

A078864 001 May 22, 2012

PRINSTON INC

200MG

A078644 001 May 22, 2012

TECH ORGANIZED

200MG

A203176 001 May 22, 2012

VIRAMUNE

+

BOEHRINGER INGELHEIM

200MG

N020636 001 Jun 21, 1996

TABLET, EXTENDED RELEASE;ORAL

NEVIRAPINE

ALVOGEN

100MG

A204621 002 Nov 09, 2015

400MG

A204621 001 Jul 10, 2015

APOTEX

400MG

A205258 001 Apr 03, 2014

CIPLA

400MG

A206448 001 Oct 15, 2015

MYLAN

100MG

A206271 001 Nov 09, 2015

TECH ORGANIZED

100MG

A207467 001 Jul 31, 2017

400MG

A207467 002 Jul 31, 2017

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-340(of 478)

** See List Footnote

NIACIN

CAPSULE; ORAL

WAMPOCAP

MEDPOINTE PHARM HLC

500MG

N011073 003

TABLET; ORAL

NIACIN

EVERYLIFE

500MG

A083203 001

HALSEY

500MG

A083453 001

HIKMA

500MG

A083718 001

IMPAX LABS

500MG

A083115 001

IVAX SUB TEVA PHARMS

500MG

A083180 001

MK LABS

500MG

A083525 001

PUREPAC PHARM

500MG

A083271 001

SANDOZ

500MG

A083306 001

TABLICAPS

500MG

A084237 001

WATSON LABS

500MG

A083136 001

500MG

A083305 001

500MG

A085172 001

WOCKHARDT

500MG

A081134 001 Apr 28, 1992

NICOLAR

+

SANOFI AVENTIS US

500MG

A083823 001

TABLET, EXTENDED RELEASE; ORAL

NIACIN

BEIJING

500MG

A214428 001 Nov 22, 2021

1GM

A214428 002 Nov 22, 2021

JUBILANT GENERICS

500MG

A209156 001 May 14, 2018

750MG

A209156 002 May 14, 2018

1GM

A209156 003 May 14, 2018

RISING

500MG

A203742 001 Feb 22, 2019

750MG

A203742 002 Feb 22, 2019

1GM

A203742 003 Feb 22, 2019

YICHANG HUMANWELL

500MG

A212017 001 Jun 10, 2019

750MG

A212017 002 Jun 10, 2019

1GM

A212017 003 Jun 10, 2019

NIASPAN

ABBVIE

375MG

N020381 001 Jul 28, 1997

+

500MG **

N020381 002 Jul 28, 1997

+

750MG **

N020381 003 Jul 28, 1997

+

1GM **

N020381 004 Jul 28, 1997

NIASPAN TITRATION STARTER PACK

ABBVIE

375MG; 500MG; 750MG

N020381 005 Jul 28, 1997

NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; TYROSINE

SUSPENSION; ORAL

TPN

INTL MINERALS

15MG/5ML; 3.75MG/5ML; 600MG/5ML

N008378 003

NICARDIPINE HYDROCHLORIDE

CAPSULE; ORAL

CARDENE

+

CHIESI

20MG **

N019488 001 Dec 21, 1988

+

30MG **

N019488 002 Dec 21, 1988

NICARDIPINE HYDROCHLORIDE

ANI PHARMS

20MG

A074439 001 Dec 10, 1996

20MG

A074540 001 Oct 28, 1996

30MG

A074439 002 Dec 10, 1996

30MG

A074540 002 Oct 28, 1996

MYLAN

20MG

A074642 001 Jul 18, 1996

30MG

A074642 002 Jul 18, 1996

CAPSULE, EXTENDED RELEASE; ORAL

CARDENE SR

+

CHIESI

30MG **

N020005 001 Feb 21, 1992

+

45MG **

N020005 002 Feb 21, 1992

+

60MG **

N020005 003 Feb 21, 1992

INJECTABLE; INJECTION

CARDENE

+

CHIESI

25MG/10ML (2.5MG/ML) **

N019734 001 Jan 30, 1992

NICARDIPINE HYDROCHLORIDE

NAVINTA LLC

25MG/10ML (2.5MG/ML)

A090125 001 Nov 17, 2009

RK PHARMA

25MG/10ML (2.5MG/ML)

A090664 001 Nov 17, 2009

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-341(of 478)

** See List Footnote

NICARDIPINE HYDROCHLORIDE

INJECTABLE; INJECTION

NICARDIPINE HYDROCHLORIDE

WEST-WARD PHARMS INT 25MG/10ML (2.5MG/ML)

A078714 001 Dec 28, 2009

WOCKHARDT 25MG/10ML (2.5MG/ML)

A090671 001 Nov 17, 2009

INJECTABLE; INTRAVENOUS

CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER

+ CHIESI 40MG/200ML (0.2MG/ML)

N019734 005 Nov 07, 2008

NICLOSAMIDE

TABLET, CHEWABLE; ORAL

NICLOCIDE

BAYER PHARMS 500MG

N018669 001 May 14, 1982

NICOTINE

FILM, EXTENDED RELEASE; TRANSDERMAL

NICOTROL

MCNEIL CONS 15MG/16HR

N020536 001 Jul 03, 1996

PROSTEP

AVEVA 11MG/24HR

N019983 003 Dec 23, 1998

22MG/24HR

N019983 004 Dec 23, 1998

NICOTINE POLACRILEX

GUM, CHEWING; BUCCAL

NICOTINE POLACRILEX

IVAX SUB TEVA PHARMS EQ 2MG BASE

A076880 001 Feb 18, 2009

EQ 4MG BASE

A077850 001 Feb 18, 2009

L PERRIGO CO EQ 2MG BASE

A076776 001 Sep 16, 2004

EQ 4MG BASE

A076778 001 Sep 16, 2004

PERRIGO R AND D EQ 2MG BASE

A078967 001 Apr 23, 2008

EQ 4MG BASE

A078968 001 Apr 23, 2008

THRIVE

GLAXOSMITHKLINE CONS EQ 2MG BASE

A077658 001 Jun 19, 2007

EQ 4MG BASE

A077656 001 Jun 19, 2007

NIFEDIPINE

CAPSULE; ORAL

ADALAT

BAYER PHARMS 10MG

N019478 001 Nov 27, 1985

20MG

N019478 002 Sep 17, 1986

NIFEDIPINE

CHASE LABS NJ 10MG

A072409 001 Jul 04, 1990

20MG

A073421 001 Jun 19, 1991

TEVA 10MG

A072651 001 Feb 19, 1992

PROCARDIA

+ PFIZER 20MG **

N018482 002 Jul 24, 1986

TABLET, EXTENDED RELEASE; ORAL

ADALAT CC

+ NORWICH 30MG **

N020198 001 Apr 21, 1993

+ 60MG **

N020198 002 Apr 21, 1993

+ 90MG **

N020198 003 Apr 21, 1993

AFEDITAB CR

WATSON LABS 60MG

A075659 001 Oct 26, 2001

WATSON LABS TEVA 30MG

A075128 001 Mar 10, 2000

NIFEDIPINE

AUROBINDO PHARMA USA 30MG

A090649 001 Jun 21, 2010

60MG

A090649 002 Jun 21, 2010

90MG

A090649 003 Jun 21, 2010

MARTEC USA LLC 90MG

A075414 003 Mar 23, 2004

MYLAN 30MG

A075108 001 Dec 17, 1999

PAR PHARM 30MG

A077899 001 Dec 13, 2006

60MG

A077899 002 Dec 13, 2006

90MG

A077899 003 May 25, 2012

RISING 30MG

A090602 001 Sep 13, 2010

30MG

A201071 001 Dec 03, 2010

60MG

A090602 002 Sep 13, 2010

60MG

A201071 002 Dec 03, 2010

90MG

A090602 003 Sep 13, 2010

90MG

A201071 003 Dec 03, 2010

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-342(of 478)

** See List Footnote

NILUTAMIDE

TABLET; ORAL

NILANDRON

CONCORDIA

50MG

N020169 001 Sep 19, 1996

NIMODIPINE

CAPSULE; ORAL

NIMODIPINE

SOFGEN PHARMS

30MG

A201832 001 Jul 24, 2015

SUN PHARM INDS INC

30MG

A077067 001 Apr 17, 2007

NIMOTOP

+ BAYER PHARMS

30MG **

N018869 001 Dec 28, 1988

SOLUTION; ORAL

NYMALIZE

+ AZURITY

3MG/ML **

N203340 001 May 10, 2013

NISOLDIPINE

TABLET, EXTENDED RELEASE; ORAL

SULAR

+ COVIS

10MG **

N020356 001 Feb 02, 1995

+

20MG **

N020356 002 Feb 02, 1995

+

25.5MG **

N020356 006 Jan 02, 2008

+

30MG **

N020356 003 Feb 02, 1995

+

40MG **

N020356 004 Feb 02, 1995

NITRIC OXIDE

GAS; INHALATION

INOMAX

+ MALLINCKRODT HOSP

100PPM **

N020845 002 Dec 23, 1999

NITROFURANTOIN

CAPSULE; ORAL

NITROFURANTOIN

WATSON LABS

50MG

A084326 001

100MG

A084326 002

SUSPENSION; ORAL

NITROFURANTOIN

AMNEAL PHARMS

25MG/5ML

A201679 001 May 11, 2011

TABLET; ORAL

FURADANTIN

PROCTER AND GAMBLE

50MG

N008693 001

100MG

N008693 002

FURALAN

LANNETT

50MG

A080017 001

100MG

A080017 002

NITROFURANTOIN

ELKINS SINN

50MG

A080003 001

100MG

A080003 002

IVAX SUB TEVA PHARMS

50MG

A080078 002

100MG

A080078 001

SANDOZ

50MG

A080043 001

100MG

A080043 002

WATSON LABS

50MG

A080447 001

50MG

A085797 001

100MG

A080447 002

100MG

A085796 001

WHITEWORTH TOWN PLSN

100MG

A084085 002

NITROFURANTOIN SODIUM

INJECTABLE; INJECTION

IVADANTIN

PROCTER AND GAMBLE

EQ 180MG BASE/VIAL

N012402 001

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL

NITROFURANTOIN

ATHEM

25MG

A074336 001 Jan 25, 1995

50MG

A074336 002 Jan 25, 1995

100MG

A074336 003 Jan 25, 1995

AUROBINDO PHARMA USA

50MG

A074967 001 Jul 09, 1997

100MG

A074967 002 Jul 09, 1997

100MG

A077025 001 Aug 18, 2004

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-343(of 478)

** See List Footnote

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL

NITROFURANTOIN

WATSON LABS

25MG

A073696 001 Dec 31, 1992

50MG

A073696 002 Dec 31, 1992

100MG

A073696 003 Dec 31, 1992

NITROFURANTOIN MACROCRYSTALLINE

WATSON LABS

50MG

A070248 001 Jun 24, 1988

100MG

A070249 001 Jun 24, 1988

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL

NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)

AUROBINDO PHARMA USA 75MG;25MG

A076648 001 Mar 22, 2004

RANBAXY LABS LTD 75MG;25MG

A076951 001 Mar 30, 2005

NITROFURAZONE

CREAM;TOPICAL

FURACIN

SHIRE

0.2%

A083789 001

DRESSING;TOPICAL

ACTIN-N

SHERWOOD MEDCL

0.2%

N017343 001

OINTMENT;TOPICAL

FURACIN

SHIRE

0.2%

N005795 001

NITROFURAZONE

AMBIX

0.2%

A086077 001

LANNETT

0.2%

A084393 001

PERRIGO NEW YORK

0.2%

A084968 001

TARO

0.2%

A086156 001

WENDT

0.2%

A086766 001

POWDER;TOPICAL

FURACIN

SHIRE

0.2%

A083791 001

SOLUTION;TOPICAL

NITROFURAZONE

PERRIGO NEW YORK

0.2%

A085130 001

WENDT

0.2%

A087081 001

NITROGLYCERIN

AEROSOL;SUBLINGUAL

NITROLINGUAL

POHL BOSKAMP

0.4MG/SPRAY

N018705 001 Oct 31, 1985

FILM, EXTENDED RELEASE;TRANSDERMAL

MINITRAN

BAUSCH

0.4MG/HR

A089773 001 Aug 30, 1996

VALEANT PHARMS

0.1MG/HR

A089771 001 Aug 30, 1996

0.6MG/HR

A089774 001 Aug 30, 1996

VALEANT PHARMS NORTH

0.2MG/HR

A089772 001 Aug 30, 1996

NITROGLYCERIN

LANNETT CO INC

0.2MG/HR

A075115 001 Aug 10, 2004

0.4MG/HR

A075115 002 Aug 10, 2004

MYLAN TECHNOLOGIES

0.1MG/HR

A074992 004 Nov 12, 1999

0.2MG/HR

A074992 003 Nov 12, 1999

0.4MG/HR

A074992 002 Nov 12, 1999

0.6MG/HR

A074992 001 Nov 12, 1999

TRANSDERM-NITRO

+ NOVARTIS

0.1MG/HR **

N020144 001 Feb 27, 1996

+

0.2MG/HR **

N020144 002 Feb 27, 1996

+

0.4MG/HR **

N020144 003 Feb 27, 1996

+

0.6MG/HR **

N020144 004 Feb 27, 1996

+

0.8MG/HR **

N020144 005 Feb 27, 1996

INJECTABLE;INJECTION

NITRO IV

POHL BOSKAMP

5MG/ML

N018672 002 Aug 30, 1983

NITRO-BID

SANOFI AVENTIS US

5MG/ML

N018621 001 Jan 05, 1982

10MG/ML

A071159 001 Feb 28, 1990

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-344(of 478)

** See List Footnote

NITROGLYCERIN

INJECTABLE; INJECTION

NITROGLYCERIN

ABRAXIS PHARM	5MG/ML	A070077	001	Dec 13, 1985
	5MG/ML	A071203	001	May 08, 1987
+ HOSPIRA	5MG/ML **	N018531	001	
INTL MEDICATION	5MG/ML	A070026	001	Sep 10, 1985
LUITPOLD	5MG/ML	A071492	001	May 24, 1988
SMITH AND NEPHEW	5MG/ML	A070633	001	Jun 19, 1986
	5MG/ML	A070634	001	Jun 19, 1986

NITROGLYCERIN IN DEXTROSE 5%

HOSPIRA	0.1MG/ML	A074083	001	Oct 26, 1994
	10MG/100ML	A071846	001	Aug 31, 1990
	20MG/100ML	A071847	001	Aug 31, 1990
	40MG/100ML	A071848	001	Aug 31, 1990

NITROL

RORER	0.8MG/ML	N018774	001	Jan 19, 1983

NITRONAL

POHL BOSKAMP	1MG/ML	N018672	001	Aug 30, 1983

NITROSTAT

PARKE DAVIS	0.8MG/ML	N018588	001	
	5MG/ML	A070863	001	Jan 08, 1987
	5MG/ML	N018588	002	Dec 23, 1983
	10MG/ML	A070871	001	Jan 08, 1987
	10MG/ML	A070872	001	Jan 08, 1987

TRIDIL

HOSPIRA	0.5MG/ML	N018537	002	Jun 16, 1983
	5MG/ML	N018537	001	

POWDER; SUBLINGUAL

GONITRO

+ POHL BOSKAMP	0.4MG/PACKET	N208424	001	Jun 08, 2016

TABLET; SUBLINGUAL

NITROGLYCERIN

ACTAVIS LABS FL INC	0.3MG	A203693	001	Oct 16, 2017
	0.4MG	A203693	002	Oct 16, 2017
	0.6MG	A203693	003	Oct 16, 2017
SIGMAPHARM LABS LLC	0.3MG	A207745	001	May 07, 2018
	0.4MG	A207745	002	May 07, 2018
	0.6MG	A207745	003	May 07, 2018
ZYDUS PHARMS	0.3MG	A210153	001	Mar 08, 2022
	0.4MG	A210153	002	Mar 08, 2022
	0.6MG	A210153	003	Mar 08, 2022

NIZATIDINE

CAPSULE; ORAL

AXID

SMITHKLINE BEECHAM	150MG	N019508	001	Apr 12, 1988
	300MG	N019508	002	Apr 12, 1988

NIZATIDINE

ANI PHARMS	150MG	A075461	001	Jul 08, 2002
	150MG	A075668	001	Sep 12, 2002
	300MG	A075461	002	Jul 08, 2002
	300MG	A075668	002	Sep 12, 2002
APOTEX INC	150MG	A076383	001	Jan 23, 2003
	300MG	A076383	002	Jan 23, 2003
MYLAN PHARMS INC	150MG	A075806	001	Jul 05, 2002
	150MG	A075934	001	Jul 09, 2002
	300MG	A075806	002	Jul 05, 2002
	300MG	A075934	002	Jul 09, 2002

SOLUTION; ORAL

AXID

+ BRAINTREE	15MG/ML **	N021494	001	May 25, 2004

NIZATIDINE

AMNEAL PHARMS	15MG/ML	A090576	001	Nov 18, 2009

DISCONTINUED DRUG PRODUCT LIST

6-345(of 478)

** See List Footnote

NONOXYNOL-9

AEROSOL;VAGINAL

DOLFEN

PERSONAL PRODS

12.5%

N014349 002

SPONGE;VAGINAL

TODAY

+ MAYER LABS INC

1GM

N018683 001 Apr 01, 1983

NOREPINEPHRINE BITARTRATE

INJECTABLE;INJECTION

NOREPINEPHRINE BITARTRATE

METRICS PHARM

EQ 1MG BASE/ML

A040522 001 Sep 30, 2004

ZYDUS PHARMS

EQ 1MG BASE/ML

A216341 001 Jul 19, 2022

NOREPINEPHRINE BITARTRATE; PROCAINE HYDROCHLORIDE; PROPOXYCAINE HYDROCHLORIDE

INJECTABLE;INJECTION

RAVOCAINE AND NOVOCAIN W/ LEVOPHED

EASTMAN KODAK

EQ 0.033MG BASE/ML;2%;0.4%

N008592 003

NORETHINDRONE

TABLET;ORAL

NORLUTIN

PARKE DAVIS

5MG

N010895 002

TABLET;ORAL-28

MICRONOR

+ JANSSEN PHARMS

0.35MG **

N016954 001

NORETHINDRONE

AMNEAL PHARMS

0.35MG

A202260 001 Aug 01, 2013

NORETHINDRONE ACETATE

TABLET;ORAL

AYGESTIN

+ DURAMED RES

5MG **

N018405 001 Apr 21, 1982

NORETHINDRONE ACETATE

AUROBINDO PHARMA LTD

5MG

A204236 001 Jan 08, 2016

NORLUTATE

PARKE DAVIS

5MG

N012184 002

NORFLOXACIN

SOLUTION/DROPS;OPHTHALMIC

CHIBROXIN

MERCK

0.3%

N019757 001 Jun 17, 1991

TABLET;ORAL

NOROXIN

+ MERCK

400MG **

N019384 002 Oct 31, 1986

NORGESTREL

TABLET;ORAL

OPILL

+ LABORATOIRE HRA

0.075MG

N017031 001

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE;ORAL

AVENTYL HYDROCHLORIDE

LILLY

EQ 10MG BASE

N014684 001

EQ 25MG BASE

N014684 002

NORTRIPTYLINE HYDROCHLORIDE

ANI PHARMS

EQ 10MG BASE

A074054 001 Dec 31, 1992

EQ 25MG BASE

A074054 002 Dec 31, 1992

EQ 50MG BASE

A074054 003 Dec 31, 1992

EQ 75MG BASE

A074054 004 Dec 31, 1992

AUROBINDO PHARMA LTD

EQ 10MG BASE

A074835 001 Jun 30, 1997

EQ 25MG BASE

A074835 002 Jun 30, 1997

EQ 50MG BASE

A074835 003 Jun 30, 1997

EQ 75MG BASE

A074835 004 Jun 30, 1997

MYLAN

EQ 10MG BASE

A074234 001 Jul 26, 1993

EQ 25MG BASE

A074234 002 Jul 26, 1993

EQ 50MG BASE

A074234 003 Jul 26, 1993

EQ 75MG BASE

A074234 004 Jul 26, 1993

TEVA

EQ 10MG BASE

A073667 001 Apr 11, 1996

EQ 25MG BASE

A073667 002 Apr 11, 1996

EQ 50MG BASE

A073667 003 Apr 11, 1996

EQ 75MG BASE

A073667 004 Apr 11, 1996

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-346(of 478)

** See List Footnote

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE;ORAL

NORTRIPTYLINE HYDROCHLORIDE

ZYDUS	EQ 10MG BASE	A213441 001	Feb 24, 2021
	EQ 25MG BASE	A213441 002	Feb 24, 2021
	EQ 50MG BASE	A213441 003	Feb 24, 2021
	EQ 75MG BASE	A213441 004	Feb 24, 2021

SOLUTION;ORAL

AVENTYL

+ RANBAXY	EQ 10MG BASE/5ML **	N014685 001	

NORTRIPTYLINE HYDROCHLORIDE

TARO	EQ 10MG BASE/5ML	A077965 001	Jun 20, 2006

PAMELOR

SPECGX LLC	EQ 10MG BASE/5ML	N018012 001	

NYSTATIN

CREAM;TOPICAL

CANDEX

BAYER PHARMS	100,000 UNITS/GM	A061810 001	

MYCOSTATIN

DELCOR ASSET CORP	100,000 UNITS/GM **	A060575 001	

MYKINAC

ALPHARMA US PHARMS	100,000 UNITS/GM	A062387 001	Jul 29, 1982

NILSTAT

LEDERLE	100,000 UNITS/GM	A061445 001	

NYSTATIN

STRIDES PHARMA	100,000 UNITS/GM	A065315 001	May 31, 2006

TARO	100,000 UNITS/GM	A062457 001	Jul 28, 1983

LOTION;TOPICAL

CANDEX

BAYER PHARMS	100,000 UNITS/ML	N050233 001	

OINTMENT;TOPICAL

MYCOSTATIN

DELCOR ASSET CORP	100,000 UNITS/GM **	A060571 001	

MYKINAC

ALPHARMA US PHARMS	100,000 UNITS/GM	A062731 001	Sep 22, 1986

NILSTAT

LEDERLE	100,000 UNITS/GM	A061444 001	

PASTILLE;ORAL

MYCOSTATIN

DELCOR ASSET CORP	200,000 UNITS	N050619 001	Apr 09, 1987

POWDER;ORAL

BARSTATIN 100

BARLAN	100%	A062489 001	Apr 27, 1988

NILSTAT

+ STRIDES PHARMA	100% **	N050576 001	Dec 22, 1983

NYSTATIN

PADDOCK LLC	100%	A062613 001	Nov 26, 1985

POWDER;TOPICAL

MYCOSTATIN

DELCOR ASSET CORP	100,000 UNITS/GM **	A060578 001	

NYSTATIN

NESHER PHARMS	100,000 UNITS/GM	A065321 001	Aug 18, 2006

SUPPOSITORY;VAGINAL

NYSERT

WARNER CHILCOTT	100,000 UNITS	N050478 001	

SUSPENSION;ORAL

MYCOSTATIN

DELCOR ASSET CORP	100,000 UNITS/ML	A061533 001	

NILSTAT

+ GLENMARK PHARMS LTD	100,000 UNITS/ML **	N050299 001	

NYSTATIN

AKORN	100,000 UNITS/ML	A064042 001	Feb 28, 1994

ALPHARMA US PHARMS	100,000 UNITS/ML	A062571 001	Oct 29, 1985

COSETTE	100,000 UNITS/ML	A062776 001	Dec 17, 1987

G AND W LABS INC	100,000 UNITS/ML	A062349 001	Jul 14, 1982

MORTON GROVE	100,000 UNITS/ML	A062835 001	Nov 19, 1987

PHARMADERM	100,000 UNITS/ML	A062518 001	Jul 06, 1984

PHARMAFAIR	100,000 UNITS/ML	A062541 001	Jan 16, 1985

TEVA	100,000 UNITS/ML	A062670 001	Jun 18, 1987

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-347(of 478)

** See List Footnote

NYSTATIN

SUSPENSION; ORAL

NYSTEX

SAVAGE LABS	100,000 UNITS/ML	A062519	001	Jul 06, 1984

TABLET; ORAL

MYCOSTATIN

DELCOR ASSET CORP	500,000 UNITS	A060574	001	

NILSTAT

LEDERLE	500,000 UNITS	A061151	001	

NYSTATIN

CHARTWELL RX	500,000 UNITS	A062524	001	Nov 26, 1985

QUANTUM PHARMICS	500,000 UNITS	A062525	001	Oct 29, 1984

SANDOZ	500,000 UNITS	A062065	001	

WATSON LABS	500,000 UNITS	A062402	001	Dec 16, 1982

TABLET; VAGINAL

KOROSTATIN

HOLLAND RANTOS	100,000 UNITS	A061718	001	

MYCOSTATIN

DELCOR ASSET CORP	100,000 UNITS	A060577	001	

NILSTAT

LEDERLE	100,000 UNITS	A061325	001	

NYSTATIN

FOUGERA	100,000 UNITS	A062459	001	Nov 09, 1983

ODYSSEY PHARMS	100,000 UNITS	A062615	001	Oct 17, 1985

PHARMADERM	100,000 UNITS	A062460	001	Nov 09, 1983

QUANTUM PHARMICS	100,000 UNITS	A062509	001	Apr 03, 1984

SANDOZ	100,000 UNITS	A061965	001	

TEVA	100,000 UNITS	A062502	001	Dec 23, 1983

WATSON LABS	100,000 UNITS	A062176	001	

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

MYCO-TRIACET II

TEVA	100,000 UNITS/GM; 0.1%	A061954	002	Sep 20, 1985

MYCOLOG-II

DELCOR ASSET CORP	100,000 UNITS/GM; 0.1% **	A060576	002	May 01, 1985

MYLAN	100,000 UNITS/GM; 0.1% **	A062606	001	May 15, 1985

MYTREX F

SAVAGE LABS	100,000 UNITS/GM; 0.1%	A062597	001	Oct 08, 1985

NYSTATIN AND TRIAMCINOLONE ACETONIDE

ALPHARMA US PHARMS	100,000 UNITS/GM; 0.1%	A063010	001	Dec 20, 1988

PERRIGO NEW YORK	100,000 UNITS/GM; 0.1%	A062186	002	Jun 06, 1985

PHARMAFAIR	100,000 UNITS/GM; 0.1%	A062657	001	Jul 30, 1986

TARO	100,000 UNITS/GM; 0.1%	A062347	001	Mar 30, 1987

NYSTATIN TRIAMCINOLONE ACETONIDE

PHARMADERM	100,000 UNITS/GM; 0.1%	A062596	001	Oct 08, 1985

OINTMENT; TOPICAL

MYCO-TRIACET II

TEVA	100,000 UNITS/GM; 0.1%	A062045	002	Nov 26, 1985

MYCOLOG-II

MYLAN	100,000 UNITS/GM; 0.1% **	A060572	001	Jun 28, 1985

MYTREX F

SAVAGE LABS	100,000 UNITS/GM; 0.1%	A062601	001	Oct 09, 1985

NYSTATIN AND TRIAMCINOLONE ACETONIDE

CHARTWELL RX	100,000 UNITS/GM; 0.1%	A207316	001	Nov 18, 2019

CROWN LABS INC	100,000 UNITS/GM; 0.1%	A207731	001	Dec 26, 2017

PERRIGO NEW YORK	100,000 UNITS/GM; 0.1%	A062280	002	Oct 10, 1985

PHARMAFAIR	100,000 UNITS/GM; 0.1%	A062656	001	Jul 30, 1986

NYSTATIN-TRIAMCINOLONE ACETONIDE

PHARMADERM	100,000 UNITS/GM; 0.1%	A062603	001	Oct 09, 1985

OCTREOTIDE ACETATE

INJECTABLE; INJECTION

OCTREOTIDE ACETATE

SUN PHARM INDS	EQ 0.05MG BASE/ML	A077329	001	Mar 04, 2008

	EQ 0.05MG BASE/ML	A077372	001	Aug 14, 2007

	EQ 0.1MG BASE/ML	A077329	002	Mar 04, 2008

	EQ 0.1MG BASE/ML	A077372	002	Aug 14, 2007

	EQ 0.2MG BASE/ML	A077330	001	Mar 04, 2008

	EQ 0.2MG BASE/ML	A077373	001	Aug 14, 2007

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-348(of 478)

** See List Footnote

OCTREOTIDE ACETATE

INJECTABLE; INJECTION

OCTREOTIDE ACETATE

	EQ 0.5MG BASE/ML	A077329	003	Mar 04, 2008
	EQ 0.5MG BASE/ML	A077372	003	Aug 14, 2007
	EQ 1MG BASE/ML	A077331	001	Mar 04, 2008
	EQ 1MG BASE/ML	A077373	002	Aug 14, 2007
WOCKHARDT USA	EQ 0.2MG BASE/ML	A090986	001	May 11, 2011
	EQ 1MG BASE/ML	A090986	002	May 11, 2011
OCTREOTIDE ACETATE PRESERVATIVE FREE				
WOCKHARDT USA	EQ 0.05MG BASE/ML	A090985	001	May 11, 2011
	EQ 0.1MG BASE/ML	A090985	002	May 11, 2011
	EQ 0.5MG BASE/ML	A090985	003	May 11, 2011
SANDOSTATIN				
+ NOVARTIS	EQ 0.2MG BASE/ML **	N019667	004	Jun 12, 1991
+	EQ 1MG BASE/ML **	N019667	005	Jun 12, 1991

OFLOXACIN

INJECTABLE; INJECTION

FLOXIN

ORTHO MCNEIL PHARM	20MG/ML	N020087	002	Mar 31, 1992
	40MG/ML	N020087	003	Mar 31, 1992
FLOXIN IN DEXTROSE 5%				
ORTHO MCNEIL PHARM	400MG/100ML	N020087	001	Mar 31, 1992
FLOXIN IN DEXTROSE 5% IN PLASTIC CONTAINER				
ORTHO MCNEIL PHARM	4MG/ML	N020087	004	Mar 31, 1992
	400MG/100ML	N020087	005	Mar 31, 1992
OFLOXACIN				
BEDFORD	40MG/ML	A075762	001	Jan 16, 2002
SOLUTION/DROPS; OPHTHALMIC				
OFLOXACIN				
AKORN	0.3%	A076615	001	May 14, 2004
ALVOGEN	0.3%	A076830	001	Aug 31, 2004
SANDOZ	0.3%	A076848	001	Nov 25, 2008
SANDOZ INC	0.3%	A076231	001	May 14, 2004
SOLUTION/DROPS; OTIC				
FLOXIN OTIC				
+ DAIICHI	0.3% **	N020799	001	Dec 16, 1997
OFLOXACIN				
ALVOGEN	0.3%	A090395	001	Aug 11, 2009
FDC LTD	0.3%	A215038	001	Jan 19, 2022
SANDOZ INC	0.3%	A078222	001	Mar 17, 2008
TABLET; ORAL				
FLOXIN				
+ JANSSEN PHARMS	200MG **	N019735	001	Dec 28, 1990
+	300MG **	N019735	002	Dec 28, 1990
+	400MG **	N019735	003	Dec 28, 1990
OFLOXACIN				
LARKEN LABS	200MG	A076093	001	Sep 02, 2003
	300MG	A076093	002	Sep 02, 2003
RANBAXY LABS LTD	200MG	A076220	001	Sep 02, 2003
	300MG	A076220	002	Sep 02, 2003
	400MG	A076220	003	Sep 02, 2003

OLANZAPINE

TABLET; ORAL

OLANZAPINE

AJANTA PHARMA LTD	2.5MG	A206711	001	Aug 30, 2016
	5MG	A206711	002	Aug 30, 2016
	7.5MG	A206711	003	Aug 30, 2016
	10MG	A206711	004	Aug 30, 2016
	15MG	A206711	005	Aug 30, 2016
	20MG	A206711	006	Aug 30, 2016
HIKMA	2.5MG	A204866	001	Jun 16, 2017
	5MG	A204866	002	Jun 16, 2017
	7.5MG	A204866	003	Jun 16, 2017
	10MG	A204866	004	Jun 16, 2017
	15MG	A204866	005	Jun 16, 2017
	20MG	A204866	006	Jun 16, 2017
HISUN PHARM HANGZHOU	2.5MG	A206924	001	Dec 31, 2020

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-349(of 478)

** See List Footnote

OLANZAPINETABLET; ORAL
OLANZAPINE

	5MG	A206924 002	Dec 31, 2020
	7.5MG	A206924 003	Dec 31, 2020
	10MG	A206924 004	Dec 31, 2020
	15MG	A206924 005	Dec 31, 2020
	20MG	A206924 006	Dec 31, 2020
IVAX PHARMS INC	20MG	A077301 001	Apr 29, 2015
JIANGSU HANSON PHARM	2.5MG	A209399 001	Sep 24, 2018
	5MG	A209399 002	Sep 24, 2018
	10MG	A209399 003	Sep 24, 2018
MYLAN	2.5MG	A076866 001	Apr 23, 2012
	5MG	A076866 002	Apr 23, 2012
	7.5MG	A076866 003	Apr 23, 2012
	10MG	A076866 004	Apr 23, 2012
	15MG	A076866 005	Apr 23, 2012
	20MG	A076866 006	Apr 23, 2012
SUNSHINE	2.5MG	A206238 001	Nov 19, 2018
	5MG	A206238 002	Nov 19, 2018
	7.5MG	A206238 003	Nov 19, 2018
	10MG	A206238 004	Nov 19, 2018
	15MG	A206238 005	Nov 19, 2018
	20MG	A206238 006	Nov 19, 2018
TEVA PHARMS	2.5MG	A076000 001	Oct 24, 2011
	5MG	A076000 002	Oct 24, 2011
	7.5MG	A076000 003	Oct 24, 2011
	10MG	A076000 004	Oct 24, 2011
	15MG	A076000 005	Oct 24, 2011
TORRENT PHARMS LTD	2.5MG	A091434 001	Apr 23, 2012
	5MG	A091434 002	Apr 23, 2012
	7.5MG	A091434 003	Apr 23, 2012
	10MG	A091434 004	Apr 23, 2012
	15MG	A091434 005	Apr 23, 2012
	20MG	A091434 006	Apr 23, 2012
TABLET, ORALLY DISINTEGRATING; ORAL			
OLANZAPINE			
AJANTA PHARMA LTD	5MG	A204320 001	May 30, 2017
	10MG	A204320 002	May 30, 2017
	15MG	A204320 003	May 30, 2017
	20MG	A204320 004	May 30, 2017
HISUN PHARM HANGZHOU	5MG	A206892 001	Dec 31, 2020
	10MG	A206892 002	Dec 31, 2020
	15MG	A206892 003	Dec 31, 2020
	20MG	A206892 004	Dec 31, 2020

OLAPARIBCAPSULE; ORAL
LYNPARZA

+ ASTRAZENECA 50MG N206162 001 Dec 19, 2014

OLMESARTAN MEDOXOMIL

TABLET; ORAL

OLMESARTAN MEDOXOMIL

INVENTIA	5MG	A208659 001	May 18, 2020
	20MG	A208659 002	May 18, 2020
	40MG	A208659 003	May 18, 2020
JUBILANT GENERICS	5MG	A205482 001	Apr 24, 2017
	20MG	A205482 002	Apr 24, 2017
	40MG	A205482 003	Apr 24, 2017
LUPIN LTD	5MG	A206631 001	Apr 27, 2017
	20MG	A206631 002	Apr 27, 2017
	40MG	A206631 003	Apr 27, 2017
RISING	5MG	A078276 001	Oct 26, 2016
	20MG	A078276 002	Oct 26, 2016
	40MG	A078276 003	Oct 26, 2016
SANDOZ INC	5MG	A090237 001	Apr 13, 2020
	20MG	A090237 002	Apr 13, 2020
	40MG	A090237 003	Apr 13, 2020
TEVA PHARMS USA	5MG	A091079 001	Apr 24, 2017

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-350(of 478)

** See List Footnote

OLMESARTAN MEDOXOMIL

TABLET;ORAL

OLMESARTAN MEDOXOMIL

20MG

A091079 002 Apr 24, 2017

40MG

A091079 003 Apr 24, 2017

OLOPATADINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

OLOPATADINE HYDROCHLORIDE

BAUSCH AND LOMB INC EQ 0.1% BASE

A206046 001 Jul 26, 2017

CIPLA EQ 0.2% BASE

A206087 001 Dec 05, 2017

FDC LTD EQ 0.1% BASE

A209282 001 Sep 26, 2019

GLENMARK PHARMS INC EQ 0.1% BASE

A200810 001 Jun 28, 2017

RISING EQ 0.1% BASE

A204392 001 Mar 21, 2018

EQ 0.2% BASE

A204620 001 Jun 16, 2020

WATSON LABS INC EQ 0.7% BASE

A208637 001 Feb 19, 2020

ZAMBON SPA EQ 0.1% BASE

A204706 001 Dec 07, 2015

OMBITASVIR; PARITAPREVIR; RITONAVIR

TABLET;ORAL

TECHNIVIE

+ ABBVIE INC

12.5MG;75MG;50MG **

N207931 001 Jul 24, 2015

OMEGA-3-ACID ETHYL ESTERS

CAPSULE;ORAL

OMEGA-3-ACID ETHYL ESTERS

STRIDES PHARMA 1GM CONTAINS AT LEAST 900MG OF THE

A091018 001 Jun 24, 2014

ETHYL ESTERS OF OMEGA-3 FATTY ACIDS

ZYDUS 1GM CONTAINS AT LEAST 900MG OF THE

A210107 001 Jun 14, 2019

ETHYL ESTERS OF OMEGA-3 FATTY ACIDS

OMEGA-3-ACID ETHYL ESTERS TYPE A

CAPSULE;ORAL

OMTRYG

+ OSMOTICA PHARM US

1.2GM CONTAINS AT LEAST 900MG OF THE
ETHYL ESTERS OF OMEGA-3 FATTY ACIDS

N204977 001 Apr 23, 2014

OMEGA-3-CARBOXYLIC ACIDS

CAPSULE;ORAL

EPANOVA

+ ASTRAZENECA

1GM CONTAINS AT LEAST 850MG OF
POLYUNSATURATED FATTY ACIDS

N205060 001 May 05, 2014

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL

OMEPRAZOLE

LUPIN LTD 40MG

A202384 001 Aug 25, 2015

MYLAN 10MG

A205070 001 Jun 29, 2018

20MG

A205070 002 Jun 29, 2018

40MG

A205070 003 Jun 29, 2018

STRIDES PHARMA 10MG

A075876 001 May 29, 2003

20MG

A075876 002 May 29, 2003

40MG

A075876 003 Jan 21, 2009

TEVA PHARMS USA 40MG

A204661 002 Jun 13, 2017

PRILOSEC

+ ASTRAZENECA 10MG **

N019810 003 Oct 05, 1995

+ 20MG **

N019810 001 Sep 14, 1989

+ 40MG **

N019810 002 Jan 15, 1998

OMEPRAZOLE MAGNESIUM

TABLET, DELAYED RELEASE;ORAL

OMEPRAZOLE MAGNESIUM

PERRIGO R AND D EQ 20MG BASE

A204152 001 Jul 30, 2015

OMEPRAZOLE; SODIUM BICARBONATE

CAPSULE;ORAL

OMEPRAZOLE AND SODIUM BICARBONATE

CHARTWELL RX 20MG;1.1GM

A204137 001 Jul 15, 2016

STRIDES PHARMA 20MG;1.1GM

A078966 001 May 25, 2010

20MG;1.1GM

A201946 001 Jul 15, 2016

40MG;1.1GM

A078966 002 May 25, 2010

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-351(of 478)

** See List Footnote

ONDANSETRON

FILM;ORAL

ZUPLENZ

+ AQUESTIVE

4MG

N022524 001 Jul 02, 2010

+

8MG

N022524 002 Jul 02, 2010

TABLET, ORALLY DISINTEGRATING;ORAL

ONDANSETRON

BARR

4MG

A076693 001 Jun 25, 2007

8MG

A076693 002 Jun 25, 2007

NESHER PHARMS

4MG

A077717 001 Jun 25, 2007

8MG

A077717 002 Jun 25, 2007

TEVA

4MG

A076810 001 Jun 25, 2007

8MG

A076810 002 Jun 25, 2007

ZOFTRAN ODT

+ NOVARTIS

4MG

N020781 001 Jan 27, 1999

+

8MG

N020781 002 Jan 27, 1999

ONDANSETRON HYDROCHLORIDE

INJECTABLE;INJECTION

ONDANSETRON HYDROCHLORIDE

APOTEX INC

EQ 2MG BASE/ML

A077368 001 Dec 26, 2006

BAXTER HLTHCARE CORP

EQ 2MG BASE/ML

A078288 001 Feb 22, 2013

CHARTWELL MOLECULAR

EQ 2MG BASE/ML

A090116 001 Apr 14, 2010

EMCURE PHARMS

EQ 2MG BASE/ML

A090424 001 Apr 16, 2010

EUGIA PHARMA

EQ 2MG BASE/ML

A202599 001 Dec 21, 2012

HOSPIRA

EQ 2MG BASE/ML

A076695 001 Dec 26, 2006

EQ 2MG BASE/ML

A077840 001 Jan 19, 2007

LANNETT CO INC

EQ 2MG BASE/ML

A090883 001 Aug 05, 2010

LUITPOLD

EQ 2MG BASE/ML

A077582 001 Dec 26, 2006

EQ 2MG BASE/ML

A079039 001 Nov 18, 2008

PLIVA HRVATSKA DOO

EQ 2MG BASE/ML

A077544 001 Dec 26, 2006

RISING

EQ 2MG BASE/ML

A204906 001 Jul 31, 2017

SAGENT PHARMS

EQ 2MG BASE/ML

A078180 001 Mar 26, 2007

STERISCIENCE

EQ 2MG BASE/ML

A078257 001 Apr 23, 2008

SUN PHARM INDS (IN)

EQ 2MG BASE/ML

A077172 001 Dec 26, 2006

TEVA

EQ 2MG BASE/ML

A076876 001 Nov 22, 2006

ONDANSETRON HYDROCHLORIDE AND DEXTROSE IN PLASTIC CONTAINER

HOSPIRA

EQ 0.64MG BASE/ML

A076978 001 Feb 26, 2007

ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE

AM REGENT

EQ 2MG BASE/ML

A079032 001 Nov 18, 2008

APOTEX INC

EQ 2MG BASE/ML

A077343 001 Dec 26, 2006

EMCURE PHARMS LTD

EQ 2MG BASE/ML

A078945 001 Jan 03, 2013

EUGIA PHARMA

EQ 2MG BASE/ML

A202600 001 Dec 21, 2012

HIKMA FARMACEUTICA

EQ 2MG BASE/ML

A076780 001 Dec 26, 2006

HOSPIRA

EQ 2MG BASE/ML

A076696 001 Dec 26, 2006

LUITPOLD

EQ 2MG BASE/ML

A077387 001 Dec 26, 2006

STERISCIENCE

EQ 2MG BASE/ML

A078244 001 Apr 23, 2008

SUN PHARM INDS LTD

EQ 2MG BASE/ML

A077173 001 Dec 26, 2006

TARO PHARMS IRELAND

EQ 2MG BASE/ML

A078014 001 Mar 21, 2008

TEVA

EQ 2MG BASE/ML

A076759 001 Nov 22, 2006

ZOFTRAN

+ NOVARTIS

EQ 2MG BASE/ML **

N020007 001 Jan 04, 1991

ZOFTRAN AND DEXTROSE IN PLASTIC CONTAINER

+ GLAXOSMITHKLINE

EQ 0.64MG BASE/ML **

N020403 001 Jan 31, 1995

ZOFTRAN PRESERVATIVE FREE

+ NOVARTIS

EQ 2MG BASE/ML **

N020007 003 Dec 10, 1993

SOLUTION;ORAL

ZOFTRAN

+ NOVARTIS

EQ 4MG BASE/5ML

N020605 001 Jan 24, 1997

TABLET;ORAL

ONDANSETRON HYDROCHLORIDE

AUROBINDO PHARMA

EQ 24MG BASE

A078539 003 Jul 31, 2007

CASI PHARMS INC

EQ 24MG BASE

A077517 003 Jun 25, 2007

DR REDDYS LABS LTD

EQ 16MG BASE

A076183 004 Dec 26, 2006

EQ 24MG BASE

A076183 001 Dec 26, 2006

GLENMARK GENERICS

EQ 24MG BASE

A077535 003 Jun 25, 2007

HIKMA INTL PHARMS

EQ 4MG BASE

A077545 001 Sep 06, 2007

EQ 8MG BASE

A077545 002 Sep 06, 2007

EQ 24MG BASE

A077545 003 Sep 06, 2007

PLIVA HRVATSKA DOO

EQ 4MG BASE

A077112 001 Jun 25, 2007

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-352(of 478)

** See List Footnote

ONDANSETRON HYDROCHLORIDE

TABLET; ORAL

ONDANSETRON HYDROCHLORIDE

	EQ 8MG BASE	A077112 002	Jun 25, 2007
	EQ 24MG BASE	A077112 003	Jun 25, 2007
RISING	EQ 4MG BASE	A076930 001	Jun 25, 2007
	EQ 8MG BASE	A076930 002	Jun 25, 2007
	EQ 24MG BASE	A076930 004	Jun 25, 2007
TARO	EQ 4MG BASE	A077729 001	Mar 28, 2011
	EQ 8MG BASE	A077729 002	Mar 28, 2011
	EQ 24MG BASE	A077729 003	Mar 28, 2011
TEVA	EQ 4MG BASE	A076252 001	Jun 25, 2007
	EQ 8MG BASE	A076252 002	Jun 25, 2007
	EQ 24MG BASE	A076252 003	Jun 25, 2007
ZOFTRAN			
+	NOVARTIS	EQ 4MG BASE	N020103 001 Dec 31, 1992
+		EQ 8MG BASE	N020103 002 Dec 31, 1992
+		EQ 24MG BASE	N020103 003 Aug 27, 1999

ORPHENADRINE CITRATE

INJECTABLE; INJECTION

NORFLEX

+	PAI HOLDINGS PHARM	30MG/ML **	N013055 001

ORPHENADRINE CITRATE

	WATSON LABS	30MG/ML	A087062 001

TABLET, EXTENDED RELEASE; ORAL

NORFLEX

+	BAUSCH	100MG **	N012157 001

ORPHENADRINE CITRATE

	ASCOT	100MG	A088067 001 Apr 06, 1983

	IMPAX PHARMS	100MG	A040368 001 Jun 23, 2000

	SANDOZ	100MG	A085046 001

	WATSON LABS	100MG	A084303 001

ORPHENADRINE HYDROCHLORIDE

TABLET; ORAL

DISIPAL

	3M	50MG	N010653 001

OSELTAMIVIR PHOSPHATE

CAPSULE; ORAL

OSELTAMIVIR PHOSPHATE

	RISING	EQ 30MG BASE	A210157 001 Jan 21, 2021

		EQ 45MG BASE	A210157 002 Jan 21, 2021

		EQ 75MG BASE	A210157 003 Jan 21, 2021

	SUNSHINE	EQ 30MG BASE	A212739 001 Mar 04, 2020

		EQ 45MG BASE	A212739 002 Mar 04, 2020

		EQ 75MG BASE	A212739 003 Mar 04, 2020

FOR SUSPENSION; ORAL

OSELTAMIVIR PHOSPHATE

	LEADING	EQ 6MG BASE/ML	A214949 001 Feb 28, 2022

TAMIFLU

	ROCHE	EQ 12MG BASE/ML	N021246 001 Dec 14, 2000

OXACILLIN SODIUM

CAPSULE; ORAL

BACTOCILL

	GLAXOSMITHKLINE	EQ 250MG BASE	A061336 001

		EQ 250MG BASE	A062241 001

		EQ 500MG BASE	A061336 002

		EQ 500MG BASE	A062241 002

OXACILLIN SODIUM

	ANI PHARMS	EQ 250MG BASE	A062222 001

		EQ 500MG BASE	A062222 002

	APOTHECON	EQ 250MG BASE	A061450 002

		EQ 500MG BASE	A061450 001

PROSTAPHLIN

	APOTHECON	EQ 500MG BASE	N050118 002

FOR SOLUTION; ORAL

BACTOCILL

	GLAXOSMITHKLINE	EQ 250MG BASE/5ML	A062321 001

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-353(of 478)

** See List Footnote

OXACILLIN SODIUM

FOR SOLUTION;ORAL

OXACILLIN SODIUM

APOTHECON

EQ 250MG BASE/5ML

A061457 001

TEVA

EQ 250MG BASE/5ML

A062252 001

PROSTAPHLIN

APOTHECON

EQ 250MG BASE/5ML

N050194 001

INJECTABLE;INJECTION

BACTOCILL

GLAXOSMITHKLINE

EQ 500MG BASE/VIAL **

A061334 009 Mar 26, 1982

EQ 1GM BASE/VIAL **

A061334 006 Mar 26, 1982

EQ 1GM BASE/VIAL **

A062736 001 Dec 19, 1986

EQ 2GM BASE/VIAL **

A061334 007 Mar 26, 1982

EQ 2GM BASE/VIAL **

A062736 002 Dec 19, 1986

EQ 4GM BASE/VIAL **

A061334 008 Mar 26, 1982

EQ 10GM BASE/VIAL **

A061334 010

OXACILLIN SODIUM

+ APOTHECON

EQ 250MG BASE/VIAL **

N050195 001

+

EQ 500MG BASE/VIAL **

N050195 002

+

EQ 1GM BASE/VIAL **

N050195 003

+

EQ 2GM BASE/VIAL **

N050195 004

+

EQ 4GM BASE/VIAL **

N050195 005

ELKINS SINN

EQ 250MG BASE/VIAL

A062711 001 Feb 03, 1989

EQ 500MG BASE/VIAL

A062711 002 Feb 03, 1989

EQ 1GM BASE/VIAL

A062711 003 Feb 03, 1989

EQ 2GM BASE/VIAL

A062711 004 Feb 03, 1989

EQ 4GM BASE/VIAL

A062711 005 Feb 03, 1989

EQ 10GM BASE/VIAL

A062711 006 Feb 03, 1989

HOSPIRA

EQ 1GM BASE/VIAL

A203950 001 Dec 11, 2015

EQ 2GM BASE/VIAL

A203950 002 Dec 11, 2015

ISTITUTO BIO ITA SPA

EQ 125MG BASE/VIAL

A062798 003 Dec 11, 1995

EQ 250MG BASE/VIAL

A062798 004 Dec 11, 1995

EQ 500MG BASE/VIAL

A062798 005 Dec 11, 1995

EQ 1GM BASE/VIAL

A062798 001 Dec 11, 1995

EQ 2GM BASE/VIAL

A062798 002 Dec 11, 1995

PIRAMAL CRITICAL

EQ 1GM BASE/VIAL

A206681 001 Sep 11, 2017

EQ 2GM BASE/VIAL

A206681 002 Sep 11, 2017

SANDOZ

EQ 250MG BASE/VIAL

A061490 001

EQ 500MG BASE/VIAL

A061490 002

EQ 1GM BASE/VIAL

A061490 003

EQ 2GM BASE/VIAL

A061490 004

EQ 10GM BASE/VIAL

A061490 006 May 09, 1991

STERISCIENCE

EQ 1GM BASE/VIAL

A091486 001 Aug 25, 2014

WATSON LABS INC

EQ 250MG BASE/VIAL

A062856 001 Oct 26, 1988

EQ 500MG BASE/VIAL

A062856 002 Oct 26, 1988

EQ 1GM BASE/VIAL

A062856 003 Oct 26, 1988

EQ 2GM BASE/VIAL

A062856 004 Oct 26, 1988

EQ 4GM BASE/VIAL

A062856 005 Oct 26, 1988

EQ 10GM BASE/VIAL

A062984 001 Sep 29, 1988

POWDER;INTRAVENOUS

OXACILLIN SODIUM

SANDOZ

EQ 1GM BASE/VIAL

A062737 001 Dec 23, 1986

EQ 2GM BASE/VIAL

A062737 002 Dec 23, 1986

OXALIPLATIN

INJECTABLE;INTRAVENOUS

ELOXATIN

+ SANOFI AVENTIS US

50MG/VIAL **

N021492 001 Aug 09, 2002

+

100MG/VIAL **

N021492 002 Aug 09, 2002

+

200MG/40ML (5MG/ML) **

N021759 003 Nov 17, 2006

OXALIPLATIN

ACCORD HLTHCARE

200MG/40ML (5MG/ML)

A207474 003 Mar 21, 2017

AM REGENT

50MG/10ML (5MG/ML)

A204378 001 May 12, 2017

CHARTWELL MOLECULAR

100MG/20ML (5MG/ML)

A204378 002 May 12, 2017

CHARTWELL MOLECULAR

50MG/10ML (5MG/ML)

A208523 001 Feb 10, 2017

CHARTWELL MOLECULAR

100MG/20ML (5MG/ML)

A208523 002 Feb 10, 2017

FRESENIUS KABI ONCOL

50MG/VIAL

A078810 001 Aug 07, 2009

FRESENIUS KABI ONCOL

100MG/VIAL

A078810 002 Aug 07, 2009

FRESENIUS KABI USA

200MG/40ML (5MG/ML)

A090030 003 Jan 31, 2017

GLAND

200MG/40ML (5MG/ML)

A207325 003 Oct 18, 2017

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-354(of 478)

** See List Footnote

OXALIPLATIN

INJECTABLE; INTRAVENOUS

OXALIPLATIN

HOSPIRA INC	50MG/VIAL	A078815 001	Sep 30, 2009
	100MG/VIAL	A078815 002	Sep 30, 2009
MYLAN LABS LTD	50MG/VIAL	A200979 001	Aug 08, 2012
	100MG/VIAL	A200979 002	Aug 08, 2012
	200MG/40ML (5MG/ML)	A091358 003	Nov 14, 2017
SANDOZ	50MG/VIAL	A090849 001	Apr 28, 2011
	100MG/VIAL	A090849 002	Apr 28, 2011
SANDOZ INC	50MG/10ML (5MG/ML)	A078812 001	Aug 07, 2009
	100MG/20ML (5MG/ML)	A078812 002	Aug 07, 2009
SUN PHARM	50MG/VIAL	A078818 001	Aug 07, 2009
	50MG/10ML (5MG/ML)	A202922 001	Apr 08, 2014
	100MG/VIAL	A078818 002	Aug 07, 2009
	100MG/20ML (5MG/ML)	A202922 002	Apr 08, 2014
	200MG/40ML (5MG/ML)	A202922 003	Feb 15, 2019

OXAMNIQUINE

CAPSULE; ORAL

VANSIL

PFIZER	250MG	N018069 001	

OXANDROLONE

TABLET; ORAL

OXANDRIN

+ GEMINI LABS LLC	2.5MG	N013718 001	
+	10MG	N013718 002	Nov 05, 2001

OXANDROLONE

ROXANE	2.5MG	A077249 001	Jul 10, 2007
	10MG	A077249 002	Jul 10, 2007
SANDOZ	2.5MG	A076897 001	Dec 01, 2006
	10MG	A076897 002	Dec 01, 2006

OXAPROZIN

TABLET; ORAL

OXAPROZIN

ACTAVIS ELIZABETH	600MG	A075843 001	Oct 03, 2001
BEXIMCO PHARMS USA	600MG	A075842 001	Apr 12, 2001
IVAX SUB TEVA PHARMS	600MG	A075846 001	May 13, 2002
MYLAN	600MG	A075851 001	Aug 17, 2001
MYLAN PHARMS INC	600MG	A075847 001	Feb 28, 2001
SANDOZ	600MG	A075850 001	Apr 27, 2001
SUN PHARM INDS INC	600MG	A075844 001	Jan 03, 2002
WATSON LABS	600MG	A075848 001	Feb 09, 2001

OXAPROZIN POTASSIUM

TABLET; ORAL

DAYPRO ALTA

PFIZER	600MG	N020776 001	Oct 17, 2002

OXAZEPAM

CAPSULE; ORAL

OXAZEPAM

AM THERAP	10MG	A071955 001	Mar 03, 1988
	15MG	A071956 001	Mar 03, 1988
	30MG	A071957 001	Mar 03, 1988
IVAX SUB TEVA PHARMS	10MG	A070943 001	Aug 03, 1987
	15MG	A070944 001	Aug 03, 1987
	30MG	A070945 001	Aug 03, 1987
MYLAN	10MG	A071713 001	Oct 20, 1987
	15MG	A071714 001	Oct 20, 1987
	30MG	A071715 001	Oct 20, 1987
WATSON LABS	15MG	A072953 001	Sep 28, 1990
	30MG	A072954 001	Sep 28, 1990
WATSON LABS TEVA	10MG	A072952 001	Sep 28, 1990

SERAX

+ ALPHARMA US PHARMS	10MG **	N015539 002	
+	15MG **	N015539 004	
+	30MG **	N015539 006	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-355(of 478)

** See List Footnote

OXAZEPAM

CAPSULE; ORAL

ZAXOPAM

QUANTUM PHARMICS

10MG

A070650 001 Mar 01, 1988

15MG

A070640 001 Mar 01, 1988

30MG

A070641 001 Mar 01, 1988

TABLET; ORAL

OXAZEPAM

PARKE DAVIS

15MG

A071508 001 Feb 02, 1987

SUN PHARM INDUSTRIES

15MG

A070683 001 Jan 16, 1987

WATSON LABS

15MG

A071494 001 Apr 21, 1987

SERAX

ALPHARMA US PHARMS

15MG **

N015539 008

OXCARBAZEPINE

TABLET; ORAL

OXCARBAZEPINE

ANI PHARMS

150MG

A078005 001 Dec 11, 2007

300MG

A078005 002 Dec 11, 2007

600MG

A078005 003 Dec 11, 2007

HIKMA

150MG

A077795 001 Oct 09, 2007

300MG

A077795 002 Oct 09, 2007

600MG

A077795 003 Oct 09, 2007

JUBILANT CADISTA

150MG

A090239 001 Jan 25, 2010

300MG

A090239 002 Jan 25, 2010

600MG

A090239 003 Jan 25, 2010

OXPRENOLOL HYDROCHLORIDE

CAPSULE; ORAL

TRASICOR

NOVARTIS

20MG

N018166 001 Dec 28, 1983

40MG

N018166 002 Dec 28, 1983

80MG

N018166 003 Dec 28, 1983

160MG

N018166 004 Dec 28, 1983

OXTRIPHYLLINE

SOLUTION; ORAL

CHOLEDYL

PARKE DAVIS

100MG/5ML

N009268 012 Nov 27, 1984

OXTRIPHYLLINE

MORTON GROVE

100MG/5ML

A088243 001 Dec 05, 1983

SYRUP; ORAL

CHOLEDYL

PARKE DAVIS

50MG/5ML

N009268 011

OXTRIPHYLLINE PEDIATRIC

MORTON GROVE

50MG/5ML

A088242 001 Dec 05, 1983

TABLET, DELAYED RELEASE; ORAL

CHOLEDYL

PARKE DAVIS

100MG

N009268 003

200MG

N009268 007

OXTRIPHYLLINE

WATSON LABS

100MG

A087866 001 Aug 25, 1983

200MG

A087835 001 Aug 25, 1983

TABLET, EXTENDED RELEASE; ORAL

CHOLEDYL SA

WARNER CHILCOTT LLC

400MG

A087863 001 May 24, 1983

600MG

A086742 001

OXYBUTYNIN

FILM, EXTENDED RELEASE; TRANSDERMAL

OXYBUTYNIN

BARR LABS DIV TEVA

3.9MG/24HR

A090526 001 Mar 04, 2014

GEL, METERED; TRANSDERMAL

GELNIQUE 3%

+ ALLERGAN

3%

N202513 001 Dec 07, 2011

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-356(of 478)

** See List Footnote

OXYBUTYNIN CHLORIDE

GEL;TRANSDERMAL

OXYBUTYNIN CHLORIDE

STRIDES PHARMA

10% (100MG/PACKET)

A207329 001 May 31, 2018

SYRUP;ORAL

DITROPAN

+ ORTHO MCNEIL JANSSEN

5MG/5ML **

N018211 001

OXYBUTYNIN CHLORIDE

CHARTWELL RX

5MG/5ML

A075039 001 Jan 29, 1999

LANNETT CO INC

5MG/5ML

A076682 001 Dec 28, 2004

PHARM ASSOC

5MG/5ML

A074997 001 Oct 15, 1997

WOCKHARDT BIO AG

5MG/5ML

A074868 001 Feb 12, 1997

TABLET;ORAL

DITROPAN

+ JANSSEN PHARMS

5MG **

N017577 001

OXYBUTYNIN CHLORIDE

QUANTUM PHARMICS

5MG

A072296 001 Dec 08, 1988

USL PHARMA

5MG

A070746 001 Mar 10, 1988

WATSON LABS

5MG

A072485 001 Apr 19, 1989

TABLET, EXTENDED RELEASE;ORAL

DITROPAN XL

+ JANSSEN PHARMS

15MG **

N020897 003 Jun 22, 1999

OXYBUTYNIN CHLORIDE

IMPAX PHARMS

5MG

A076745 002 May 09, 2007

10MG

A076745 003 May 09, 2007

15MG

A076745 001 Nov 09, 2006

MYLAN

5MG

A076702 001 Nov 09, 2006

MYLAN PHARMS INC

10MG

A076644 001 Nov 09, 2006

15MG

A076644 002 May 10, 2007

OXYCODONE HYDROCHLORIDE

CAPSULE;ORAL

OXYCODONE HYDROCHLORIDE

LANNETT CO INC

5MG

A203823 001 Aug 01, 2014

SOLUTION;ORAL

OXYCODONE HYDROCHLORIDE

ANI PHARMS

100MG/5ML

A203447 001 Aug 30, 2017

AUROLIFE PHARMA LLC

5MG/5ML

A212429 001 Jan 27, 2020

100MG/5ML

A212429 002 Jan 27, 2020

CHARTWELL MOLECULAR

100MG/5ML

A204085 001 Sep 09, 2014

HIKMA

100MG/5ML

A203208 001 Jul 12, 2013

NOVEL LABS INC

100MG/5ML

A204603 001 Apr 29, 2015

RHODES PHARMS

100MG/5ML

A205853 001 Apr 29, 2020

XTTRIUM LABS INC

5MG/5ML

A206456 001 Jun 16, 2015

TABLET;ORAL

OXYCODONE HYDROCHLORIDE

ACTAVIS ELIZABETH

5MG

A076636 003 Apr 07, 2015

15MG

A076636 001 Feb 06, 2004

30MG

A076636 002 Feb 06, 2004

MAYNE PHARMA INC

5MG

A091313 001 Feb 18, 2011

10MG

A091313 004 Apr 29, 2016

15MG

A091313 002 Feb 18, 2011

20MG

A091313 005 Apr 29, 2016

30MG

A091313 003 Feb 18, 2011

NESHER PHARMS

5MG

A077290 001 Dec 08, 2005

10MG

A077290 002 Dec 08, 2005

15MG

A077290 003 Dec 08, 2005

20MG

A077290 004 Dec 08, 2005

30MG

A077290 005 Dec 08, 2005

STRIDES PHARMA

5MG

A077712 003 Mar 02, 2009

10MG

A077712 004 Apr 13, 2015

15MG

A077712 001 Jan 31, 2007

20MG

A077712 005 Apr 13, 2015

30MG

A077712 002 Jan 31, 2007

TABLET, EXTENDED RELEASE;ORAL

ROXICODONE

ROXANE

10MG

N020932 001 Oct 26, 1998

30MG

N020932 002 Oct 26, 1998

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-357(of 478)

** See List Footnote

OXYMETAZOLINE HYDROCHLORIDE

CREAM;TOPICAL

OXYMETAZOLINE HYDROCHLORIDE

TARO PHARMS

1%

A213584 001 Oct 04, 2021

SOLUTION/DROPS;OPHTHALMIC

OCUCLEAR

BAYER HEALTHCARE LLC 0.025%

N018471 001 May 30, 1986

OXYMETHOLONE

TABLET;ORAL

ANADROL-50

+ MYLAN SPECIALITY LP 50MG

N016848 001

OXYMORPHONE HYDROCHLORIDE

INJECTABLE;INJECTION

OPANA

+ ENDO PHARMS

1MG/ML

N011707 002

1.5MG/ML

N011707 001

SUPPOSITORY;RECTAL

NUMORPHAN

ENDO PHARMS

5MG

N011738 004

TABLET;ORAL

OPANA

+ ENDO PHARMS

5MG

N021611 001 Jun 22, 2006

+ 10MG

N021611 002 Jun 22, 2006

TABLET, EXTENDED RELEASE;ORAL

OPANA ER

+ ENDO PHARMS

5MG **

N021610 001 Jun 22, 2006

+ 5MG

N201655 001 Dec 09, 2011

+ 7.5MG **

N021610 005 Feb 29, 2008

+ 7.5MG

N201655 002 Dec 09, 2011

+ 10MG **

N021610 002 Jun 22, 2006

+ 10MG

N201655 003 Dec 09, 2011

+ 15MG **

N021610 006 Feb 29, 2008

+ 15MG

N201655 004 Dec 09, 2011

+ 20MG **

N021610 003 Jun 22, 2006

+ 20MG

N201655 005 Dec 09, 2011

+ 30MG **

N021610 007 Feb 29, 2008

+ 30MG

N201655 006 Dec 09, 2011

+ 40MG **

N021610 004 Jun 22, 2006

+ 40MG

N201655 007 Dec 09, 2011

OXYMORPHONE HYDROCHLORIDE

ACTAVIS ELIZABETH

5MG

A079046 003 Jul 11, 2013

7.5MG

A079046 001 Dec 13, 2010

10MG

A079046 004 Jul 11, 2013

15MG

A079046 002 Dec 13, 2010

20MG

A079046 005 Jul 11, 2013

30MG

A079046 006 Jul 11, 2013

40MG

A079046 007 Jul 11, 2013

HIKMA

5MG

A200822 002 Jul 15, 2013

7.5MG

A200822 003 Jul 15, 2013

10MG

A200822 004 Jul 15, 2013

15MG

A200822 005 Jul 15, 2013

20MG

A200822 006 Jul 15, 2013

30MG

A200822 007 Jul 15, 2013

40MG

A200822 001 Jul 15, 2013

PAR PHARM

5MG

A200792 001 Oct 24, 2014

7.5MG

A200792 002 Oct 24, 2014

10MG

A200792 003 Oct 24, 2014

15MG

A200792 004 Oct 24, 2014

20MG

A200792 005 Oct 24, 2014

30MG

A200792 006 Oct 24, 2014

40MG

A200792 007 Oct 24, 2014

SPECGX LLC

5MG

A202946 001 Jun 27, 2014

7.5MG

A202946 002 Jun 27, 2014

10MG

A202946 003 Jun 27, 2014

15MG

A202946 004 Jun 27, 2014

20MG

A202946 005 Jun 27, 2014

30MG

A202946 006 Jun 27, 2014

40MG

A202946 007 Jun 27, 2014

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-358(of 478)

** See List Footnote

OXYMORPHONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

OXYMORPHONE HYDROCHLORIDE

SUN PHARM INDS LTD

5MG

A203506 001 Apr 24, 2015

7.5MG

A203506 002 Apr 24, 2015

10MG

A203506 003 Apr 24, 2015

15MG

A203506 004 Apr 24, 2015

20MG

A203506 005 Apr 24, 2015

30MG

A203506 006 Apr 24, 2015

40MG

A203506 007 Apr 24, 2015

OXYPHENBUTAZONE

TABLET;ORAL

OXYPHENBUTAZONE

WATSON LABS

100MG

A088399 001 Sep 17, 1984

TANDEARIL

NOVARTIS

100MG

N012542 004 Sep 03, 1982

OXYPHENCYCLIMINE HYDROCHLORIDE

TABLET;ORAL

DARICON

PFIZER

10MG

N011612 001

OXYPHENONIUM BROMIDE

TABLET;ORAL

ANTRENYL

NOVARTIS

5MG

N008492 002

OXYTETRACYCLINE

TABLET;ORAL

TERRAMYCIN

PFIZER

250MG

N050287 001

OXYTETRACYCLINE CALCIUM

SYRUP;ORAL

TERRAMYCIN

PFIZER

EQ 125MG BASE/5ML

A060595 001

OXYTETRACYCLINE HYDROCHLORIDE

CAPSULE;ORAL

OXY-KESSO-TETRA

FERRANTE

EQ 250MG BASE

A060179 001

OXYTETRACYCLINE HYDROCHLORIDE

HIKMA

EQ 250MG BASE

A060770 001

IMPAX LABS

EQ 250MG BASE

A060760 001

PROTER

EQ 250MG BASE

A060869 001

PUREPAC PHARM

EQ 250MG BASE

A060634 001

TERRAMYCIN

PFIZER

EQ 125MG BASE

N050286 001

EQ 250MG BASE

N050286 002

INJECTABLE;INJECTION

TERRAMYCIN

PFIZER

EQ 250MG BASE/VIAL

A060586 001

EQ 500MG BASE/VIAL

A060586 002

OXYTETRACYCLINE HYDROCHLORIDE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

TERRAMYCIN W/ POLYMYXIN B SULFATE

CASPER PHARMA LLC

EQ 5MG BASE/GM;10,000 UNITS/GM

N061015 001

OINTMENT;OTIC

TERRAMYCIN W/ POLYMYXIN

PFIZER

EQ 5MG BASE/GM;10,000 UNITS/GM

A061841 001

TABLET;VAGINAL

TERRAMYCIN-POLYMYXIN

PFIZER

EQ 100MG BASE;100,000 UNITS

A061009 001

OXYTOCIN

INJECTABLE;INJECTION

OXYTOCIN

DR REDDYS

10USP UNITS/ML (10USP UNITS/ML)

A077453 001 Jan 24, 2008

100USP UNITS/10ML (10USP UNITS/ML)

A077453 002 Jan 24, 2008

OXYTOCIN 10 USP UNITS IN DEXTROSE 5%

+ ABBOTT

1USP UNITS/100ML **

N019185 004 Mar 29, 1985

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-359(of 478)

** See List Footnote

OXYTOCIN

INJECTABLE;INJECTION

OXYTOCIN 10 USP UNITS IN DEXTROSE 5%				
+	2USP UNITS/100ML **	N019185	003	Mar 29, 1985
OXYTOCIN 20 USP UNITS IN DEXTROSE 5%				
+	ABBOTT 2USP UNITS/100ML **	N019185	002	Mar 29, 1985
OXYTOCIN 5 USP UNITS IN DEXTROSE 5%				
+	ABBOTT 1USP UNITS/100ML **	N019185	001	Mar 29, 1985
SYNTOCINON				
NOVARTIS	10USP UNITS/ML	N018245	001	
SOLUTION;NASAL				
SYNTOCINON				
RTRX	40USP UNITS/ML	N012285	001	

PACLITAXEL

INJECTABLE;INJECTION

PACLITAXEL				
ACCORD HLTHCARE	6MG/ML	A075436	001	Nov 12, 2004
HOSPIRA	6MG/ML	A076233	001	Aug 01, 2002
MYLAN	6MG/ML	A075278	001	Jan 25, 2002
MYLAN LABS LTD	6MG/ML	A091540	001	Sep 29, 2011
PLIVA LACHEMA	6MG/ML	A077413	001	Mar 12, 2008
SANDOZ INC	6MG/ML	A078167	001	Dec 26, 2007
TEVA PHARMS USA	6MG/ML	A075297	001	Jan 25, 2002
TAXOL				
+	HQ SPCLT PHARMA 6MG/ML **	N020262	001	Dec 29, 1992

PALIPERIDONE

TABLET, EXTENDED RELEASE;ORAL

INVEGA				
+	JANSSEN PHARMS 12MG **	N021999	004	Dec 19, 2006

PALIPERIDONE PALMITATE

SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

PALIPERIDONE PALMITATE				
TEVA PHARMS USA	39MG/0.25ML (39MG/0.25ML)	A211149	001	Jul 06, 2021
	78MG/0.5ML (78MG/0.5ML)	A211149	002	Jul 06, 2021
	117MG/0.75ML (117MG/0.75ML)	A211149	003	Jul 06, 2021
	156MG/ML (156MG/ML)	A211149	004	Jul 06, 2021
	234MG/1.5ML (156MG/ML)	A211149	005	Jul 06, 2021

PALONOSETRON HYDROCHLORIDE

CAPSULE;ORAL

ALOXI				
+	HELSINN HLTHCARE EQ 0.5MG BASE **	N022233	001	Aug 22, 2008

INJECTABLE;INTRAVENOUS

ALOXI				
+	HELSINN HLTHCARE EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML) **	N021372	002	Feb 29, 2008
+	EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML) **	N021372	001	Jul 25, 2003

PALONOSETRON HYDROCHLORIDE

ACCORD HLTHCARE	EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	A204615	001	Mar 15, 2021
DR REDDYS	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	A201533	001	Apr 21, 2016
HOSPIRA	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	A207005	002	Sep 19, 2018
QILU PHARM HAINAN	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	A205648	002	Sep 19, 2018
TEVA PHARMS USA	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	A090713	002	Mar 23, 2018
SOLUTION;INTRAVENOUS				
PALONOSETRON HYDROCHLORIDE				
DR REDDYS	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	N203050	001	Mar 01, 2016
	EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	N203050	002	Mar 01, 2016
+	FRESENIUS KABI USA EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	N208109	001	Nov 21, 2017

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-360(of 478)

** See List Footnote

PAMIDRONATE DISODIUM

INJECTABLE; INJECTION

AREDIA

+ NOVARTIS

30MG/VIAL **

N020036 001 Oct 31, 1991

60MG/VIAL

N020036 003 May 06, 1993

90MG/VIAL

N020036 004 May 06, 1993

PAMIDRONATE DISODIUM

AESGEN

30MG/VIAL

A075594 001 May 06, 2002

90MG/VIAL

A075594 002 May 06, 2002

AM REGENT

30MG/10ML (3MG/ML)

A078942 001 Jul 25, 2008

90MG/10ML (9MG/ML)

A078942 002 Jul 25, 2008

FRESENIUS KABI USA

30MG/VIAL

A075773 001 May 06, 2002

30MG/10ML (3MG/ML)

A076207 001 May 17, 2002

90MG/VIAL

A075773 002 May 06, 2002

90MG/10ML (9MG/ML)

A076207 002 May 17, 2002

MN PHARMS

30MG/VIAL

A078300 001 Mar 10, 2009

90MG/VIAL

A078300 002 Mar 10, 2009

SUN PHARMA GLOBAL

30MG/VIAL

A077703 001 Dec 24, 2008

90MG/VIAL

A077703 002 Dec 24, 2008

TEVA PHARMS USA

30MG/10ML (3MG/ML)

A076153 001 Mar 27, 2002

90MG/10ML (9MG/ML)

A076153 002 Mar 27, 2002

PANCURONIUM BROMIDE

INJECTABLE; INJECTION

PANCURONIUM BROMIDE

ELKINS SINN

1MG/ML

A072058 001 Mar 23, 1988

2MG/ML

A072059 001 Mar 23, 1988

2MG/ML

A072060 001 Mar 23, 1988

HOSPIRA

2MG/ML

A072321 001 Jan 19, 1989

IGI LABS INC

1MG/ML

A072210 001 Mar 31, 1988

2MG/ML

A072211 001 Mar 31, 1988

2MG/ML

A072212 001 Mar 31, 1988

2MG/ML

A072213 001 Mar 31, 1988

PAVULON

+ ORGANON USA INC

1MG/ML **

N017015 002

+

2MG/ML **

N017015 001

PANOBINOSTAT LACTATE

CAPSULE; ORAL

FARYDAK

+ SECURA

EQ 10MG BASE

N205353 001 Feb 23, 2015

+

EQ 15MG BASE

N205353 002 Feb 23, 2015

+

EQ 20MG BASE

N205353 003 Feb 23, 2015

PANTOPRAZOLE SODIUM

INJECTABLE; INTRAVENOUS

PANTOPRAZOLE SODIUM

KNACK

EQ 40MG BASE/VIAL

A214680 001 May 19, 2022

MYLAN LABS LTD

EQ 40MG BASE/VIAL

A208580 001 May 04, 2018

TABLET, DELAYED RELEASE; ORAL

PANTOPRAZOLE SODIUM

JUBILANT GENERICS

EQ 20MG BASE

A090901 001 Aug 30, 2011

EQ 40MG BASE

A090901 002 Aug 30, 2011

L PERRIGO CO

EQ 20MG BASE

A203024 001 May 07, 2014

MACLEODS PHARMS LTD

EQ 20MG BASE

A200821 001 Feb 16, 2012

EQ 40MG BASE

A200821 002 Feb 16, 2012

SUN PHARM

EQ 20MG BASE

A077058 001 Sep 10, 2007

EQ 40MG BASE

A077058 002 Sep 10, 2007

SUN PHARM INDS LTD

EQ 20MG BASE

A200794 001 May 02, 2012

EQ 40MG BASE

A200794 002 May 02, 2012

TEVA

EQ 20MG BASE

A077056 001 Aug 02, 2007

EQ 40MG BASE

A077056 002 Aug 02, 2007

PARAMETHADIONE

CAPSULE; ORAL

PARADIONE

ABBVIE

150MG

N006800 003

300MG

N006800 001

SOLUTION; ORAL

PARADIONE

ABBVIE

300MG/ML

N006800 002

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-361(of 478)

** See List Footnote

PARAMETHASONE ACETATE

TABLET; ORAL

HALDRONE

LILLY

1MG

N012772 005

2MG

N012772 006

PARGYLINE HYDROCHLORIDE

TABLET; ORAL

EUTONYL

ABBOTT

10MG

N013448 002

25MG

N013448 003

50MG

N013448 004

PARICALCITOL

CAPSULE; ORAL

PARICALCITOL

LOTUS PHARM CO LTD

1MCG

A206710 001 Feb 24, 2016

2MCG

A206710 002 Feb 24, 2016

4MCG

A206710 003 Feb 24, 2016

ZEMPLAR

+ ABBVIE

4MCG **

N021606 003 May 26, 2005

SOLUTION; INTRAVENOUS

PARICALCITOL

AKORN

0.01MG/2ML (0.005MG/ML)

A207692 001 Oct 16, 2017

RISING

0.002MG/ML (0.002MG/ML)

A203897 001 Nov 02, 2017

PAROMOMYCIN SULFATE

CAPSULE; ORAL

HUMATIN

KING PFIZER

EQ 250MG BASE

A062310 001

PARKEDALE

EQ 250MG BASE

A060521 001

SYRUP; ORAL

HUMATIN

PARKE DAVIS

EQ 125MG BASE/5ML

A060522 001

PAROXETINE HYDROCHLORIDE

CAPSULE; ORAL

PAXIL

+ APOTEX

EQ 10MG BASE **

N020885 001 Oct 09, 1998

+

EQ 20MG BASE **

N020885 002 Oct 09, 1998

+

EQ 30MG BASE **

N020885 003 Oct 09, 1998

+

EQ 40MG BASE **

N020885 004 Oct 09, 1998

SUSPENSION; ORAL

PAROXETINE HYDROCHLORIDE

APOTEX INC

EQ 10MG BASE/5ML

A077395 001 Dec 05, 2006

TABLET; ORAL

PAROXETINE HYDROCHLORIDE

JUBILANT GENERICS

EQ 10MG BASE

A205528 001 Nov 27, 2015

EQ 20MG BASE

A205528 002 Nov 27, 2015

EQ 30MG BASE

A205528 003 Nov 27, 2015

EQ 40MG BASE

A205528 004 Nov 27, 2015

MYLAN PHARMS INC

EQ 10MG BASE

A075716 001 Mar 08, 2004

EQ 20MG BASE

A075716 002 Mar 08, 2004

EQ 30MG BASE

A075716 003 Mar 08, 2004

EQ 40MG BASE

A075716 004 Mar 08, 2004

ROXANE

EQ 10MG BASE

A078026 001 Jun 29, 2007

EQ 20MG BASE

A078026 002 Jun 29, 2007

EQ 30MG BASE

A078026 003 Jun 29, 2007

EQ 40MG BASE

A078026 004 Jun 29, 2007

SUN PHARM INDS INC

EQ 10MG BASE

A078194 001 Jun 29, 2007

EQ 20MG BASE

A078194 002 Jun 29, 2007

EQ 30MG BASE

A078194 003 Jun 29, 2007

EQ 40MG BASE

A078194 004 Jun 29, 2007

TEVA PHARMS

EQ 10MG BASE

A077082 001 Jun 29, 2007

EQ 20MG BASE

A077082 002 Jun 29, 2007

EQ 30MG BASE

A077082 003 Jun 29, 2007

EQ 40MG BASE

A077082 004 Jun 29, 2007

UPSHER SMITH LABS

EQ 10MG BASE

A075566 001 Mar 08, 2004

EQ 20MG BASE

A075566 002 Mar 08, 2004

EQ 30MG BASE

A075566 003 Mar 08, 2004

EQ 40MG BASE

A075566 004 Mar 08, 2004

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-362(of 478)

** See List Footnote

PAROXETINE HYDROCHLORIDE

TABLET;ORAL

PAXIL

APOTEX

EQ 50MG BASE

N020031 004 Dec 29, 1992

TABLET, EXTENDED RELEASE;ORAL

PAROXETINE HYDROCHLORIDE

SINOTHERAPEUTICS INC

EQ 12.5MG BASE

A213612 001 Aug 11, 2021

EQ 25MG BASE

A213612 002 Aug 11, 2021

EQ 37.5MG BASE

A213612 003 May 26, 2022

PAROXETINE MESYLATE

TABLET;ORAL

PEXEVA

+

SEBELA IRELAND LTD

EQ 40MG BASE

N021299 004 Jul 03, 2003

PAZOPANIB HYDROCHLORIDE

TABLET;ORAL

VOTRIENT

+

NOVARTIS

EQ 400MG BASE **

N022465 002 Oct 19, 2009

PEGAPTANIB SODIUM

INJECTABLE;INTRAVITREAL

MACUGEN

+

BAUSCH AND LOMB INC

EQ 0.3MG ACID/0.09ML

N021756 001 Dec 17, 2004

PEGINESATIDE ACETATE

SOLUTION;INTRAVENOUS, SUBCUTANEOUS

OMONTYS

TAKEDA PHARMS USA

EQ 10MG BASE/ML (EQ 10MG BASE/ML)

N202799 007 Mar 27, 2012

EQ 20MG BASE/2ML (EQ 10MG BASE/ML)

N202799 008 Mar 27, 2012

OMONTYS PRESERVATIVE FREE

TAKEDA PHARMS USA

EQ 1MG BASE/0.5ML (EQ 1MG BASE/0.5ML)

N202799 001 Mar 27, 2012

EQ 2MG BASE/0.5ML (EQ 2MG BASE/0.5ML)

N202799 002 Mar 27, 2012

EQ 3MG BASE/0.5ML (EQ 3MG BASE/0.5ML)

N202799 003 Mar 27, 2012

EQ 4MG BASE/0.5ML (EQ 4MG BASE/0.5ML)

N202799 004 Mar 27, 2012

EQ 5MG BASE/0.5ML (EQ 5MG BASE/0.5ML)

N202799 005 Mar 27, 2012

EQ 6MG BASE/0.5ML (EQ 6MG BASE/0.5ML)

N202799 006 Mar 27, 2012

PEMETREXED DISODIUM

POWDER;INTRAVENOUS

PEMETREXED DISODIUM

BIOCON PHARMA

EQ 1GM BASE/VIAL

A211090 001 May 25, 2022

HOSPIRA

EQ 100MG BASE/VIAL

A202111 001 May 25, 2022

EQ 500MG BASE/VIAL

A202111 002 May 25, 2022

EQ 1GM BASE/VIAL

A202111 003 May 25, 2022

PEMETREXED DITROMETHAMINE

POWDER;INTRAVENOUS

PEMETREXED DITROMETHAMINE

+

HOSPIRA

EQ 1GM BASE/VIAL

N208746 003 Jun 10, 2022

PEMIROLAST POTASSIUM

SOLUTION/DROPS;OPHTHALMIC

ALAMAST

SANTEN

0.1%

N021079 001 Sep 24, 1999

PEMOLINE

TABLET;ORAL

CYLERT

ABBOTT

18.75MG

N016832 001

37.5MG

N016832 002

75MG

N016832 003

PEMOLINE

ACTAVIS ELIZABETH

18.75MG

A075595 001 Feb 28, 2000

37.5MG

A075595 002 Feb 28, 2000

75MG

A075595 003 Feb 28, 2000

FOSUN PHARMA

18.75MG

A075286 001 Dec 27, 1999

37.5MG

A075286 002 Jun 30, 1999

75MG

A075286 003 Jun 30, 1999

MALLINCKRODT

18.75MG

A075726 003 Mar 30, 2001

37.5MG

A075726 002 Mar 30, 2001

75MG

A075726 001 Mar 30, 2001

TEVA PHARMS

18.75MG

A075030 003 Feb 22, 2000

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-363(of 478)

** See List Footnote

PEMOLINE

TABLET;ORAL

PEMOLINE

37.5MG

A075030 001 Jan 29, 1999

75MG

A075030 002 Jan 29, 1999

VINTAGE PHARMS

18.75MG

A075328 001 Apr 19, 2000

37.5MG

A075328 002 Apr 19, 2000

75MG

A075328 003 Apr 19, 2000

WATSON LABS

18.75MG

A075287 001 Jun 13, 2001

37.5MG

A075287 002 Sep 18, 2000

75MG

A075287 003 Sep 18, 2000

TABLET, CHEWABLE;ORAL

CYLERT

ABBOTT

37.5MG

N017703 001

PEMOLINE

ACTAVIS ELIZABETH

37.5MG

A075678 001 Jul 26, 2000

TEVA PHARMS

37.5MG

A075555 001 Feb 18, 2000

PENBUTOLOL SULFATE

TABLET;ORAL

LEVATOL

+ AUXILIUM PHARMS LLC

10MG **

N018976 001 Dec 30, 1987

+

20MG **

N018976 004 Jan 05, 1989

PENICILLAMINE

CAPSULE;ORAL

CUPRIMINE

VALEANT PHARMS INTL

125MG

N019853 002

TABLET;ORAL

PENICILLAMINE

TEVA PHARMS USA

250MG

A211497 001 Feb 13, 2020

PENICILLIN G BENZATHINE

INJECTABLE;INJECTION

BICILLIN L-A

+ KING PHARMS LLC

300,000 UNITS/ML

N050141 003

WYETH AYERST

300,000 UNITS/ML

N050131 001

PERMAPEN

CASPER PHARMA LLC

600,000 UNITS/ML

N060014 001

SUSPENSION;ORAL

BICILLIN

WYETH AYERST

300,000 UNITS/5ML

N050126 002

TABLET;ORAL

BICILLIN

WYETH AYERST

200,000 UNITS

N050128 001

PENICILLIN G BENZATHINE; PENICILLIN G PROCAINE

INJECTABLE;INJECTION

BICILLIN C-R

+ KING PHARMS LLC

150,000 UNITS/ML;150,000 UNITS/ML

N050138 002

PENICILLIN G POTASSIUM

FOR SOLUTION;ORAL

PENICILLIN

TEVA

200,000 UNITS/5ML

A060307 002

400,000 UNITS/5ML

A060307 004

PENICILLIN G POTASSIUM

MYLAN

200,000 UNITS/5ML

A060752 003

250,000 UNITS/5ML

A060752 002

400,000 UNITS/5ML

A060752 001

PUREPAC PHARM

250,000 UNITS/5ML

A061740 001

400,000 UNITS/5ML

A061740 002

PENICILLIN-2

TEVA

250,000 UNITS/5ML

A060307 003

PENTIDS '200'

APOTHECON

200,000 UNITS/5ML

A062149 001

PENTIDS '400'

APOTHECON

400,000 UNITS/5ML

A062149 002

PFIZERPEN G

PFIZER

400,000 UNITS/5ML

A060587 001

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-364(of 478)

** See List Footnote

PENICILLIN G POTASSIUM

INJECTABLE; INJECTION

PENICILLIN G POTASSIUM

APOTHECON	1,000,000 UNITS/VIAL	A060362	001	
	5,000,000 UNITS/VIAL	A060362	003	
	10,000,000 UNITS/VIAL	A060362	004	
	20,000,000 UNITS/VIAL	A060362	002	
CONSOLIDATED PHARM	500,000 UNITS/VIAL	A060806	001	
	1,000,000 UNITS/VIAL	A060806	002	
	5,000,000 UNITS/VIAL	A060806	003	
	10,000,000 UNITS/VIAL	A060806	004	
LILLY	200,000 UNITS/VIAL	A060384	004	
	500,000 UNITS/VIAL	A060384	003	
	1,000,000 UNITS/VIAL	A060384	002	
	5,000,000 UNITS/VIAL	A060384	001	
	20,000,000 UNITS/VIAL	A060384	005	
	20,000,000 UNITS/VIAL	A060601	001	
PARKE DAVIS	1,000,000 UNITS/VIAL	A062003	001	
	5,000,000 UNITS/VIAL	A062003	002	
PFIZER	20,000,000 UNITS/VIAL	A060074	003	
SANDOZ	1,000,000 UNITS/VIAL **	A065079	001	Aug 30, 2002
WATSON LABS INC	1,000,000 UNITS/VIAL	A062991	001	Sep 13, 1988
	5,000,000 UNITS/VIAL	A062991	002	Sep 13, 1988
	10,000,000 UNITS/VIAL	A062991	003	Sep 13, 1988
	20,000,000 UNITS/VIAL	A062991	004	Sep 13, 1988

PFIZERPEN

PFIZER	1,000,000 UNITS/VIAL **	A060657	001	

TABLET; ORAL

PENICILLIN G POTASSIUM

APOTHECON	250,000 UNITS	A060392	003	
IVAX SUB TEVA PHARMS	400,000 UNITS	A060073	004	
LILLY	250,000 UNITS	A060403	001	
MYLAN	200,000 UNITS	A060781	001	
	250,000 UNITS	A060781	002	
	400,000 UNITS	A060781	003	
	500,000 UNITS	A060781	005	
	800,000 UNITS	A060781	004	
PUREPAC PHARM	200,000 UNITS	A061588	001	
	250,000 UNITS	A061588	002	
	400,000 UNITS	A061588	003	
TEVA	200,000 UNITS	A060306	001	
	250,000 UNITS	A060306	002	
	400,000 UNITS	A060306	003	
	500,000 UNITS	A060306	004	
WYETH AYERST	200,000 UNITS	A060413	001	
	250,000 UNITS	A060413	002	
	400,000 UNITS	A060413	003	

PENTIDS '200'

APOTHECON	200,000 UNITS	A062155	001	

PENTIDS '250'

APOTHECON	250,000 UNITS	A062155	002	

PENTIDS '400'

APOTHECON	400,000 UNITS	A060392	004	
	400,000 UNITS	A062155	003	

PENTIDS '800'

APOTHECON	800,000 UNITS	A060392	005	
	800,000 UNITS	A062155	004	

PFIZERPEN G

PFIZER	50,000 UNITS	A060075	001	
	100,000 UNITS	A060075	002	
	200,000 UNITS	A060075	003	
	250,000 UNITS	A060075	004	
	400,000 UNITS	A060075	005	
	800,000 UNITS	A060075	006	

DISCONTINUED DRUG PRODUCT LIST

6-365(of 478)

** See List Footnote

PENICILLIN G PROCAINE

INJECTABLE; INJECTION

DURACILLIN A.S.

LILLY

300,000 UNITS/ML

A060093 001

PENICILLIN G PROCAINE

CONSOLIDATED PHARM

300,000 UNITS/ML

A060800 001

600,000 UNITS/1.2ML

A060800 002

PARKE DAVIS

300,000 UNITS/ML

A062029 001

PFIZER

300,000 UNITS/VIAL

A060099 001

1,500,000 UNITS/VIAL

A060099 002

PFIZERPEN-AS

PFIZER

300,000 UNITS/ML

A060286 001

600,000 UNITS/ML

A060286 002

PENICILLIN G SODIUM

INJECTABLE; INJECTION

PENICILLIN G SODIUM

BRISTOL MYERS SQUIBB

5,000,000 UNITS/VIAL

A061935 001

COPANOS

5,000,000 UNITS/VIAL

A061051 001

PHARMACIA AND UPJOHN

1,000,000 UNITS/VIAL

A061046 001

INJECTABLE; INTRAMUSCULAR, INTRAVENOUS

PENICILLIN G SODIUM

WATSON LABS INC

5,000,000 UNITS/VIAL

A063014 001 Sep 13, 1988

PENICILLIN V

FOR SUSPENSION; ORAL

V-CILLIN

LILLY

125MG/0.6ML

A060002 001

PENICILLIN V POTASSIUM

FOR SOLUTION; ORAL

BEEPEN-VK

GLAXOSMITHKLINE

EQ 125MG BASE/5ML

A062270 001

EQ 250MG BASE/5ML

A062270 002

BETAPEN-VK

APOTHECON

EQ 125MG BASE/5ML

A061149 001

EQ 250MG BASE/5ML

A061149 002

LEDERCILLIN VK

LEDERLE

EQ 125MG BASE/5ML

A060136 001

EQ 250MG BASE/5ML

A060136 002

PEN-VEE K

WYETH AYERST

EQ 125MG BASE/5ML

A060007 001

EQ 250MG BASE/5ML

A060007 002

PENAPAR-VK

PARKE DAVIS

EQ 125MG BASE/5ML

A062002 001

EQ 250MG BASE/5ML

A062002 002

PENICILLIN V POTASSIUM

BELCHER PHARMS

EQ 125MG BASE/5ML

A061529 001

EQ 250MG BASE/5ML

A061529 002

MYLAN

EQ 125MG BASE/5ML

A061624 002

EQ 250MG BASE/5ML

A061624 001

PUREPAC PHARM

EQ 125MG BASE/5ML

A061758 001

EQ 250MG BASE/5ML

A061758 002

STRIDES PHARMA

EQ 125MG BASE/5ML

A062981 001 Feb 10, 1989

EQ 250MG BASE/5ML

A062981 002 Feb 10, 1989

PFIZERPEN VK

PFIZER

EQ 125MG BASE/5ML

A061815 001

EQ 250MG BASE/5ML

A061815 002

V-CILLIN K

LILLY

EQ 125MG BASE/5ML

A060004 001

EQ 250MG BASE/5ML

A060004 002

VEETIDS

APOTHECON

EQ 125MG BASE/5ML

A061410 001

EQ 250MG BASE/5ML

A061410 002

VEETIDS '125'

APOTHECON

EQ 125MG BASE/5ML

A061206 001

EQ 125MG BASE/5ML

A062153 001

VEETIDS '250'

APOTHECON

EQ 250MG BASE/5ML

A061206 002

EQ 250MG BASE/5ML

A062153 002

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-366(of 478)

** See List Footnote

PENICILLIN V POTASSIUM

TABLET; ORAL

BEEPEN-VK

GLAXOSMITHKLINE	EQ 250MG BASE	A062273 001
	EQ 500MG BASE	A062273 002

BETAPEN-VK

BRISTOL	EQ 250MG BASE	A061150 001
	EQ 500MG BASE	A061150 002

LEDERCILLIN VK

LEDERLE	EQ 250MG BASE	A060134 001
	EQ 500MG BASE	A060134 002

PEN-VEE K

WYETH AYERST	EQ 125MG BASE	A060006 001
	EQ 250MG BASE	A060006 002
	EQ 500MG BASE	A060006 003

PENAPAR-VK

PARKE DAVIS	EQ 250MG BASE	A062001 001
	EQ 500MG BASE	A062001 002

PENICILLIN V POTASSIUM

BELCHER PHARMS	EQ 250MG BASE	A061528 001
	EQ 500MG BASE	A061528 002
IVAX SUB TEVA PHARMS	EQ 125MG BASE	A060518 001
	EQ 250MG BASE	A060518 002
	EQ 500MG BASE	A060518 003
MYLAN	EQ 250MG BASE	A061530 001
	EQ 500MG BASE	A061530 002
PUREPAC PHARM	EQ 125MG BASE	A061571 001
	EQ 250MG BASE	A061571 002
	EQ 500MG BASE	A061571 003

PFIZERPEN VK

PFIZER	EQ 250MG BASE	A061836 001
	EQ 500MG BASE	A061836 002

UTICILLIN VK

PHARMACIA AND UPJOHN	EQ 250MG BASE	A061651 001
	EQ 500MG BASE	A061651 002

V-CILLIN K

LILLY	EQ 125MG BASE **	A060003 001
	EQ 250MG BASE **	A060003 002
	EQ 500MG BASE **	A060003 003

VEETIDS

APOTHECON	EQ 250MG BASE	A061411 001
	EQ 500MG BASE	A061411 002

VEETIDS '250'

APOTHECON	EQ 250MG BASE	A061164 001
	EQ 250MG BASE	A062156 002

VEETIDS '500'

APOTHECON	EQ 500MG BASE	A061164 002
	EQ 500MG BASE	A062156 001

PENTAGASTRIN

INJECTABLE; INJECTION

PEPTAVLON

+ WYETH AYERST	0.25MG/ML **	N017048 001

PENTAMIDINE ISETHIONATE

FOR SOLUTION; INHALATION

NEBUPENT

FRESENIUS KABI USA	600MG/VIAL	N019887 002	Mar 22, 1996

INJECTABLE; INJECTION

PENTACARINAT

ARMOUR PHARM	300MG/VIAL	A073447 001	Apr 28, 1994

PENTAMIDINE ISETHIONATE

BAXTER HLTHCARE	300MG/VIAL	A073617 001	Dec 18, 1995
HOSPIRA	300MG/VIAL	A073479 001	Jun 30, 1992
WATSON LABS	300MG/VIAL	A074303 001	Aug 17, 1995

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-367(of 478)

** See List Footnote

PENTAZOCINE HYDROCHLORIDE

TABLET;ORAL

TALWIN 50

SANOFI AVENTIS US

EQ 50MG BASE

N016732 001

PENTAZOCINE LACTATE

INJECTABLE;INJECTION

TALWIN

+ HOSPIRA

EQ 30MG BASE/ML

N016194 001

PENTETATE CALCIUM TRISODIUM

SOLUTION;INHALATION, INTRAVENOUS

PENTETATE CALCIUM TRISODIUM

+ HAMELN

EQ 1GM BASE/5ML (EQ 200MG BASE/ML) **

N021749 001 Aug 11, 2004

PENTETATE CALCIUM TRISODIUM YB-169

INJECTABLE;INJECTION

YTTERBIUM YB 169 DTPA

3M

2mCi/ML

N017518 001

PENTETATE ZINC TRISODIUM

SOLUTION;INHALATION, INTRAVENOUS

PENTETATE ZINC TRISODIUM

+ HAMELN PHARMA PLUS

EQ 1GM BASE/5ML (EQ 200MG BASE/ML) **

N021751 001 Aug 11, 2004

PENTOBARBITAL

ELIXIR;ORAL

NEMBUTAL

AKORN

18.2MG/5ML

A083244 001

PENTOBARBITAL SODIUM

CAPSULE;ORAL

NEMBUTAL SODIUM

AKORN

30MG

A084095 001

50MG

A084093 001

100MG

A083245 001

PENTOBARBITAL SODIUM

LANNETT

50MG

A085937 001

100MG

A085915 001

VITARINE

100MG

A083284 001

WHITEWORTH TOWN PLSN

100MG

A083338 001

SODIUM PENTOBARBITAL

ANABOLIC

100MG

A084590 001

ELKINS SINN

100MG

A083368 001

EVERYLIFE

100MG

A083259 001

HALSEY

100MG

A084677 001

IVAX SUB TEVA PHARMS

50MG

A083461 001

100MG

A083461 002

PARKE DAVIS

100MG

A084156 001

PERRIGO

100MG

A084560 001

PUREPAC PHARM

100MG

A083301 001

VALEANT PHARM INTL

100MG

A083264 001

WATSON LABS

100MG

A085791 001

WYETH AYERST

100MG

A083239 001

INJECTABLE;INJECTION

PENTOBARBITAL SODIUM

ELKINS SINN

50MG/ML

A083270 001

SODIUM PENTOBARBITAL

WYETH AYERST

50MG/ML

A083261 001

SUPPOSITORY;RECTAL

NEMBUTAL

AKORN

30MG

A083247 001 Jan 25, 1982

60MG

A083247 002 Jan 25, 1982

120MG

A083247 003 Jan 25, 1982

200MG

A083247 004 Jan 25, 1982

TABLET;ORAL

PENTOBARBITAL SODIUM

VITARINE

100MG

A083285 001

SODIUM PENTOBARBITAL

NEXGEN PHARMA INC

100MG

A084238 001

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-368(of 478)

** See List Footnote

PENTOLINIUM TARTRATE

INJECTABLE; INJECTION

ANSOLYSEN

WYETH AYERST

10MG/ML

N009372 001

PENTOSTATIN

INJECTABLE; INJECTION

PENTOSTATIN

RISING

10MG/VIAL

A203554 001 Sep 19, 2014

PENTOXIFYLLINE

TABLET, EXTENDED RELEASE; ORAL

PENTOXIFYLLINE

ANI PHARMS

400MG

A074878 001 Jul 09, 1997

400MG

A075107 001 Sep 04, 1998

400MG

A075199 001 Sep 03, 1999

HERITAGE PHARMS

400MG

A074877 001 Jul 08, 1997

IMPAX LABS

400MG

A075093 001 Aug 10, 1999

PLIVA

400MG

A074874 001 May 25, 1999

RISING

400MG

A074425 001 Jul 08, 1997

PENTOXIL

UPSHER SMITH LABS

400MG

A074962 001 Mar 31, 1999

TRENTAL

+ VALIDUS PHARMS

400MG **

N018631 001 Aug 30, 1984

PERFLUBRON

LIQUID; ORAL

IMAGENT

ALLIANCE PHARM

100%

N020091 001 Aug 13, 1993

PERFLUOROPOLYMETHYLISOPROPYL ETHER; POLYTETRAFLUOROETHYLENE

PASTE; TOPICAL

SKIN EXPOSURE REDUCTION PASTE AGAINST CHEMICAL WARFARE AGENTS

US ARMY

50%; 50%

N021084 001 Feb 17, 2000

PERGOLIDE MESYLATE

TABLET; ORAL

PERGOLIDE MESYLATE

IVAX SUB TEVA PHARMS

EQ 0.05MG BASE

A076094 001 Sep 04, 2003

EQ 0.25MG BASE

A076094 002 Sep 04, 2003

EQ 1MG BASE

A076094 003 Sep 04, 2003

STRIDES PHARMA

EQ 0.05MG BASE

A076061 001 Nov 27, 2002

EQ 0.25MG BASE

A076061 002 Nov 27, 2002

EQ 1MG BASE

A076061 003 Nov 27, 2002

PERMAX

VALEANT PHARM INTL

EQ 0.05MG BASE

N019385 001 Dec 30, 1988

EQ 0.25MG BASE

N019385 002 Dec 30, 1988

EQ 1MG BASE

N019385 003 Dec 30, 1988

PERINDOPRIL ERBUMINE

TABLET; ORAL

ACEON

+ SYMPLMED PHARMS LLC

2MG

N020184 001 Dec 30, 1993

+

4MG

N020184 002 Dec 30, 1993

+

8MG

N020184 003 Dec 30, 1993

PERINDOPRIL ERBUMINE

ANI PHARMS

2MG

A078138 001 Nov 10, 2009

4MG

A078138 002 Nov 10, 2009

8MG

A078138 003 Nov 10, 2009

APOTEX

2MG

A090463 001 Aug 30, 2010

4MG

A090463 002 Aug 30, 2010

8MG

A090463 003 Aug 30, 2010

HIKMA

2MG

A090072 001 Nov 10, 2009

4MG

A090072 002 Nov 10, 2009

8MG

A090072 003 Nov 10, 2009

LUPIN LTD

2MG

A078263 001 Jan 27, 2010

4MG

A078263 002 Jan 27, 2010

8MG

A078263 003 Jan 27, 2010

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-369(of 478)

** See List Footnote

PERMETHRIN

CREAM;TOPICAL

ELIMITE

+ AUROBINDO PHARMA USA 5%

N019855 001 Aug 25, 1989

LOTION;TOPICAL

NIX

GLAXOSMITHKLINE

1% **

N019435 001 Mar 31, 1986

PERPHENAZINE

CONCENTRATE;ORAL

PERPHENAZINE

PHARM ASSOC

16MG/5ML

A040360 001 May 25, 2001

TRILAFON

SCHERING

16MG/5ML

N011557 001

INJECTABLE;INJECTION

TRILAFON

SCHERING

5MG/ML

N011213 002

SYRUP;ORAL

TRILAFON

SCHERING

2MG/5ML

N011294 002

TABLET;ORAL

PERPHENAZINE

ANI PHARMS

2MG

A089707 001 Sep 10, 1987

4MG

A089708 001 Sep 10, 1987

8MG

A089456 001 Sep 10, 1987

16MG

A089457 001 Sep 10, 1987

MYLAN

2MG

A206691 001 Apr 14, 2017

4MG

A206691 002 Apr 14, 2017

8MG

A206691 003 Apr 14, 2017

16MG

A206691 004 Apr 14, 2017

TRILAFON

+ SCHERING

2MG **

N010775 001

+

4MG **

N010775 002

+

8MG **

N010775 003

+

16MG **

N010775 004

TABLET, EXTENDED RELEASE;ORAL

TRILAFON

SCHERING

8MG

N011361 002

PHENACEMIDE

TABLET;ORAL

PHENURONE

+ ABBVIE

500MG **

N007707 001

PHENAZOPYRIDINE HYDROCHLORIDE; SULFAMETHOXAZOLE

TABLET;ORAL

AZO GANTANOL

+ ROCHE

100MG;500MG **

N013294 001 Sep 10, 1987

PHENAZOPYRIDINE HYDROCHLORIDE; SULFAMETHOXAZOLE; TRIMETHOPRIM

TABLET;ORAL

SULFAMETHOXAZOLE AND TRIMETHOPRIM AND PHENAZOPYRIDINE HYDROCHLORIDE

ABLE

200MG,N/A,N/A;N/A,800MG,160MG

N021105 001 Jun 26, 2001

PHENAZOPYRIDINE HYDROCHLORIDE; SULFISOXAZOLE

TABLET;ORAL

AZO GANTRISIN

+ ROCHE

50MG;500MG **

N019358 001 Aug 31, 1990

PHENDIMETRAZINE TARTRATE

CAPSULE;ORAL

PHENAZINE

MAST MM

35MG

A086523 001

35MG

A086524 001

35MG

A086525 001

PHENDIMETRAZINE TARTRATE

SANDOZ

35MG

A085633 001

35MG

A085694 001

35MG

A085702 001

VIRTUS PHARMS

35MG

A085695 001

VITARINE

35MG

A085634 001

35MG

A085645 001

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-370(of 478)

** See List Footnote

PHENDIMETRAZINE TARTRATE

CAPSULE;ORAL

PHENDIMETRAZINE TARTRATE

35MG	A085670	001
35MG	A086403	001
35MG	A086408	001
35MG	A086410	001
35MG	A087424	001

SPRX-3

SOLVAY	35MG	A085897	001

STATOBEX

TEVA	35MG	A085507	001

X-TROZINE

SHIRE RICHWOOD	35MG	A087394	001	Sep 22, 1982

CAPSULE, EXTENDED RELEASE;ORAL

BONTRIL

VALEANT	105MG	A088021	001	Sep 21, 1982

MELFIAT-105

NUMARK	105MG	A087487	001	Oct 13, 1982

PHENDIMETRAZINE TARTRATE

GRAHAM DM	105MG	A087214	001	May 26, 1982
	105MG	A088020	001	Aug 16, 1982
	105MG	A088028	001	Aug 16, 1982
	105MG	A088062	001	Sep 13, 1982
	105MG	A088063	001	Sep 10, 1982
	105MG	A088111	001	Oct 18, 1982
VIRTUS PHARMS	105MG	A087378	001	

SPRX-105

NUMARK	105MG	A088024	001	Dec 22, 1982

X-TROZINE L.A.

SHIRE RICHWOOD	105MG	A087371	001	Aug 24, 1982

TABLET;ORAL

ADPHEN

FERNDAL LABS	35MG	A083655	001	

ALPHAZINE

SANDOZ	35MG	A085034	001	

CAM-METRAZINE

ABC HOLDING	35MG	A085511	001	
CAMALL	35MG	A085756	001	
CHARTWELL RX	35MG	A083922	001	
	35MG	A085318	001	
	35MG	A085320	001	
	35MG	A085321	001	

DI-METREX

PVT FORM	35MG	A085698	001	

MELFIAT

NUMARK	35MG	A083790	002	

METRA

FOREST PHARMS	35MG	A083754	001	

PHENAZINE

MAST MM	35MG	A087305	001	

PHENAZINE-35

ABC HOLDING	35MG	A085512	001	

PHENDIMETRAZINE TARTRATE

BARR	35MG	A083644	001	
	35MG	A083684	001	
	35MG	A083686	001	
	35MG	A083687	001	
	35MG	A084831	001	
	35MG	A084834	001	
	35MG	A084835	001	
CHARTWELL RX	35MG	A085761	001	
	35MG	A085941	001	Jun 27, 1983

FERNDAL LABS	35MG	A086834	001	Sep 15, 1983

INWOOD LABS	35MG	A084740	001	

	35MG	A084741	001	

	35MG	A084742	001	

	35MG	A084743	001	

IVAX PHARMS	35MG	A085611	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-371(of 478)

** See List Footnote

PHENDIMETRAZINE TARTRATE

TABLET;ORAL

PHENDIMETRAZINE TARTRATE

	35MG	A085612 001	
IVAX SUB TEVA PHARMS	35MG	A083682 001	
KV PHARM	35MG	A084138 001	
	35MG	A084141 001	
	35MG	A085525 001	
MFG CHEMISTS	35MG	A085914 001	
NEXGEN PHARMA INC	35MG	A086020 001	
NOSTRUM LABS INC	35MG	A203600 001	Dec 27, 2017
NUMARK	35MG	A083790 001	
PVT FORM	35MG	A085199 001	
	35MG	A085697 001	
SANDOZ	35MG	A085402 001	
	35MG	A085830 001	
	35MG	A086370 001	
SOLVAY	35MG	A083993 001	
UPSHER SMITH LABS	35MG	A084399 001	
USL PHARMA	35MG	A083805 001	
	35MG	A084398 001	
VIRTUS PHARMS	35MG	A085497 001	
	35MG	A086365 001	
VITARINE	35MG	A085519 001	
	35MG	A086005 001	
	35MG	A086106 001	
WATSON LABS	35MG	A085767 001	
	35MG	A085768 001	
	35MG	A085770 001	
	35MG	A085773 001	
PLEGINE			
WYETH AYERST	35MG **	N012248 001	
STATOBEX			
TEVA	35MG	A086013 001	
STATOBEX-G			
TEVA	35MG	A085095 001	
X-TROZINE			
SHIRE RICHWOOD	35MG	A086550 001	
	35MG	A086551 001	
	35MG	A086552 001	
	35MG	A086553 001	
	35MG	A086554 001	

PHENINDIONE

TABLET;ORAL

HEDULIN

SANOFI AVENTIS US	50MG	N008767 002

PHENMETRAZINE HYDROCHLORIDE

TABLET;ORAL

PRELUDIN

BOEHRINGER INGELHEIM	25MG	N010460 005

TABLET, EXTENDED RELEASE;ORAL

PRELUDIN

BOEHRINGER INGELHEIM	50MG	N011752 004
	75MG	N011752 003

PHENPROCOUMON

TABLET;ORAL

LIQUAMAR

ORGANON USA INC	3MG	N011228 001

PHENSUXIMIDE

CAPSULE;ORAL

MILONTIN

PARKE DAVIS	500MG	N008855 004

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-372(of 478)

** See List Footnote

PHENTERMINE HYDROCHLORIDE

CAPSULE;ORAL

FASTIN

GLAXOSMITHKLINE	30MG **	N017352	001	
OBESTIN-30				
FERNDAL LABS	30MG	A087144	001	
OBY-TRIM				
SHIRE RICHWOOD	30MG	A087764	001	Mar 18, 1982
ONA-MAST				
MAST MM	30MG	A086511	001	
	30MG	A086516	001	

PHENTERMINE HYDROCHLORIDE

ABC HOLDING	30MG	A085411	001	
ABLE	15MG	A040497	001	Mar 13, 2003
	30MG	A040403	001	Aug 30, 2001
	30MG	A040427	001	Aug 30, 2001
BARR	15MG	A090591	001	Mar 18, 2010
	30MG	A090591	002	Mar 18, 2010
CAMALL	15MG	A086735	001	
	30MG	A087226	001	
CHARTWELL RX	18.75MG	A088576	001	May 23, 1984
	30MG	A085417	001	
	30MG	A086732	002	
	30MG	A087215	001	
	37.5MG	A087915	001	Dec 22, 1983
	37.5MG	A087918	001	Dec 22, 1983
	37.5MG	A087930	001	Oct 14, 1983
	37.5MG	A088610	001	Jun 04, 1984
	37.5MG	A088611	001	Jun 04, 1984
	37.5MG	A088625	001	Aug 23, 1984
DURAMED PHARMS BARR	30MG	A088948	001	Apr 25, 1986
ELITE LABS INC	15MG	A040460	001	Jan 14, 2003
	30MG	A040227	001	Jun 18, 1997
	30MG	A040448	001	Jan 22, 2003
IVAX PHARMS	30MG	A086329	001	
LANNETT CO INC	30MG	A091359	001	Jul 16, 2010
	37.5MG	A201961	001	Jul 20, 2011
SANDOZ	30MG	A087208	001	
	30MG	A087223	001	
	37.5MG	A088414	001	Oct 19, 1983
SUN PHARM INDUSTRIES	37.5MG	A040527	001	Oct 23, 2003
TEVA	30MG	A086911	001	
	30MG	A087126	001	
	30MG	A087777	001	Nov 01, 1985
	30MG	A088612	001	Apr 04, 1984
	30MG	A088613	001	Apr 09, 1984
	30MG	A088614	001	Apr 09, 1984
TG UNITED INC	30MG	A040083	001	Mar 07, 1997
UPSHER SMITH LABS	30MG	A084487	001	Apr 09, 1982
	30MG	A088430	001	Mar 27, 1984
USL PHARMA	30MG	A088797	001	Dec 10, 1984
VITARINE	30MG	A087202	001	
	30MG	A087235	001	
WATSON LABS	30MG	A086740	001	Mar 21, 1985

TABLET;ORAL

ONA-MAST

MAST MM	8MG	A086260	001	

PHENTERMINE HYDROCHLORIDE

ABLE	37.5MG	A040402	001	Aug 30, 2001
ACTAVIS ELIZABETH	37.5MG	A040276	001	Nov 25, 1998
BARR	37.5MG	A090470	001	Aug 31, 2009
CHARTWELL RX	8MG	A083923	001	
	8MG	A085319	001	
	37.5MG	A087805	001	Dec 06, 1982
	37.5MG	A088596	001	Apr 04, 1984
IVAX PHARMS	8MG	A085553	001	
LANNETT	37.5MG	A040555	001	Apr 15, 2005
NOVAST LABS	37.5MG	A091451	001	Sep 21, 2012
SANDOZ	8MG	A085671	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-373(of 478)

** See List Footnote

PHENTERMINE HYDROCHLORIDE

TABLET;ORAL

PHENTERMINE HYDROCHLORIDE	8MG	A085689	001	
SANDOZ INC	30MG	A088605	001	Sep 28, 1987
SUN PHARM INDS INC	37.5MG	A040790	001	Aug 21, 2007
+ USL PHARMA	8MG	A083804	001	
	37.5MG	A088910	001	Jul 17, 1985
	37.5MG	A088917	001	Jul 17, 1985
VITARINE	8MG	A086453	001	
	8MG	A086456	001	
WATSON LABS	8MG	A085739	001	
TORA				
SOLVAY	8MG	A084035	001	
WILPO				
+ SANDOZ	8MG **	N012737	001	
TABLET, ORALLY DISINTEGRATING;ORAL				
SUPRENZA				
CITIUS PHARMS	15MG **	N202088	001	Jun 13, 2011
	30MG **	N202088	002	Jun 13, 2011
	37.5MG **	N202088	003	Mar 27, 2012

PHENTERMINE RESIN COMPLEX

CAPSULE, EXTENDED RELEASE;ORAL

IONAMIN				
UCB INC	EQ 15MG BASE **	N011613	004	
	EQ 30MG BASE **	N011613	002	
PHENTERMINE RESIN 30				
QUANTUM PHARMICS	EQ 30MG BASE	A089120	001	Feb 04, 1988
PHENTERMINE RESIN COMPLEX				
LANNETT CO INC	EQ 15MG BASE	A040872	001	Jul 28, 2011
	EQ 30MG BASE	A040872	002	Jul 28, 2011

PHENTOLAMINE MESYLATE

INJECTABLE;INJECTION

REGITINE				
+ NOVARTIS	5MG/VIAL **	N008278	003	

PHENYL AMINOSALICYLATE

POWDER;ORAL

PHENY-PAS-TEBAMIN				
PHARM RES ASSOC	50%	N011695	002	

TABLET;ORAL

PHENY-PAS-TEBAMIN				
PHARM RES ASSOC	500MG	N011695	003	

PHENYLBUTAZONE

CAPSULE;ORAL

AZOLID				
SANOFI AVENTIS US	100MG	A087260	001	
BUTAZOLIDIN				
NOVARTIS	100MG	N008319	009	
PHENYLBUTAZONE				
FOSUN PHARMA	100MG	A087774	001	Jun 16, 1982
IVAX PHARMS	100MG	A088218	001	Jun 24, 1983
SUN PHARM INDUSTRIES	100MG	A088994	001	Dec 04, 1985
WATSON LABS	100MG	A087756	001	Dec 17, 1982

TABLET;ORAL

AZOLID				
SANOFI AVENTIS US	100MG	A087091	001	
BUTAZOLIDIN				
NOVARTIS	100MG	N008319	008	
PHENYLBUTAZONE				
FOSUN PHARMA	100MG	A084339	001	
SUN PHARM INDUSTRIES	100MG	A088863	001	Dec 04, 1985
WATSON LABS	100MG	A086151	001	
	100MG	A087674	001	Apr 21, 1982

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-374(of 478)

** See List Footnote

PHENYLEPHRINE HYDROCHLORIDE

SOLUTION;INTRAVENOUS

BIORPHEN

+ DR REDDYS LABS SA 10MG/ML (10MG/ML) N212909 002 Mar 11, 2021

PHENYLEPHRINE HYDROCHLORIDE

PAR STERILE PRODUCTS 10MG/ML (10MG/ML) A210025 001 Dec 21, 2018

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PHENERGAN VC

+ ANI PHARMS 5MG/5ML;6.25MG/5ML ** N008604 003 Apr 02, 1984

PHERAZINE VC

HALSEY 5MG/5ML;6.25MG/5ML A088868 001 Mar 02, 1987

PROMETH VC PLAIN

+ G AND W LABS INC 5MG/5ML;6.25MG/5ML A088761 001 Nov 08, 1984

PROMETHAZINE VC PLAIN

CENCI 5MG/5ML;6.25MG/5ML A088815 001 Nov 22, 1985

WOCKHARDT 5MG/5ML;6.25MG/5ML A088897 001 Jan 04, 1985

PHENYLEPHRINE HYDROCHLORIDE; PYRILAMINE MALEATE

SOLUTION/DROPS;OPHTHALMIC

PREFRIN-A

ALLERGAN 0.12%;0.1% N007953 001

PHENYTOIN

SUSPENSION;ORAL

DILANTIN-30

VIATRIS 30MG/5ML N008762 002

PHENYTOIN

ACTAVIS MID ATLANTIC 125MG/5ML A089892 001 Sep 25, 1992

PHENYTOIN SODIUM

CAPSULE;ORAL

DIPHENYLAN SODIUM

LANNETT 30MG PROMPT A080857 001

100MG PROMPT A080857 002

EXTENDED PHENYTOIN SODIUM

ANI PHARMS 100MG EXTENDED A040435 001 Jun 20, 2003

100MG EXTENDED A089441 001 Dec 18, 1986

LUPIN LTD 100MG EXTENDED A211633 001 Sep 30, 2019

SUN PHARM INDS (IN) 100MG EXTENDED A040621 001 Dec 11, 2006

WOCKHARDT 30MG EXTENDED A040759 001 Dec 18, 2007

WOCKHARDT USA 100MG EXTENDED A040732 001 Jan 30, 2008

PHENYTEX

WATSON LABS 100MG EXTENDED A088711 001 Dec 21, 1984

PHENYTOIN SODIUM

PHARMERAL 100MG PROMPT A085435 001

WATSON LABS 100MG PROMPT A085894 001

PROMPT PHENYTOIN SODIUM

ANI PHARMS 100MG PROMPT A080259 001

WATSON LABS 100MG PROMPT A080905 001

INJECTABLE;INJECTION

DILANTIN

PARKE DAVIS 50MG/ML N010151 001

PHENYTOIN SODIUM

AM REGENT 50MG/ML A040781 001 Dec 04, 2007

FRESENIUS KABI USA 50MG/ML A089003 001 May 31, 1985

HOSPIRA 50MG/ML A089521 001 Mar 17, 1987

50MG/ML A089744 001 Dec 18, 1987

MARSAM PHARMS LLC 50MG/ML A089501 001 Oct 13, 1987

50MG/ML A089779 001 Nov 27, 1992

SMITH AND NEPHEW 50MG/ML A088519 001 Dec 19, 1984

50MG/ML A088521 001 Dec 18, 1984

SOLOPAK 50MG/ML A088520 001 Dec 17, 1984

WARNER CHILCOTT 50MG/ML A089900 001 Mar 30, 1990

WATSON LABS 50MG/ML A085434 001

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-375(of 478)

** See List Footnote

PHYTONADIONE

INJECTABLE; INJECTION

AQUAMEPHYTON

+	PAI HOLDINGS PHARM	1MG/0.5ML **	N012223	002
+		10MG/ML **	N012223	001

KONAKION

ROCHE	1MG/0.5ML	N011745	001
	10MG/ML	N011745	003

PHYTONADIONE

CIPLA	1MG/0.5ML	A212424	001	Apr 22, 2022
	10MG/ML	A212424	002	Apr 22, 2022
GLAXOSMITHKLINE	1MG/0.5ML	A084060	001	
	10MG/ML	A084060	002	

VITAMIN K1

HOSPIRA	10MG/ML	A087956	001	Jul 25, 1983

PILOCARPINE

INSERT, EXTENDED RELEASE; OPTHALMIC

OCUSERT PILO-20

AKORN	5MG	N017431	001

OCUSERT PILO-40

AKORN	11MG	N017548	001

PILOCARPINE HYDROCHLORIDE

GEL; OPTHALMIC

PILOPINE HS

ALCON	4%	N018796	001	Oct 01, 1984

PIMAVANSERIN TARTRATE

TABLET; ORAL

NUPLAZID

+	ACADIA PHARMS INC	EQ 17MG BASE	N207318	001	Apr 29, 2016

PIMOZIDE

TABLET; ORAL

ORAP

+	TEVA	1MG **	N017473	003	Aug 27, 1997
+		2MG **	N017473	001	Jul 31, 1984

PINACIDIL

CAPSULE, EXTENDED RELEASE; ORAL

PINDAC

LEO PHARM	12.5MG	N019456	001	Dec 28, 1989
	25MG	N019456	002	Dec 28, 1989

PINDOLOL

TABLET; ORAL

PINDOLOL

COSETTE	5MG	A073661	001	Oct 31, 1993
	5MG	A073687	001	Feb 26, 1993
	5MG	A074123	001	Apr 17, 1997
	10MG	A073661	002	Oct 31, 1993
	10MG	A073687	002	Feb 26, 1993
	10MG	A074123	002	Apr 17, 1997
MYLAN PHARMS INC	5MG	A074013	001	Sep 24, 1992
	10MG	A074018	001	Sep 24, 1992
NOSTRUM LABS	5MG	A074474	001	Oct 28, 1996
	10MG	A074474	002	Oct 28, 1996
PUREPAC PHARM	5MG	A074125	001	Apr 28, 1993
	10MG	A074125	002	Apr 28, 1993
WATSON LABS	5MG	A074437	001	Feb 27, 1995
	10MG	A074437	002	Feb 27, 1995
ZYDUS PHARMS	5MG	A209866	001	Aug 18, 2017
	10MG	A209866	002	Aug 18, 2017

VISKEN

+	NOVARTIS	5MG **	N018285	001	Sep 03, 1982
+		10MG **	N018285	002	Sep 03, 1982

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-376(of 478)

** See List Footnote

PIOGLITAZONE HYDROCHLORIDE

TABLET;ORAL

PIOGLITAZONE HYDROCHLORIDE

MYLAN PHARMS INC	EQ 15MG BASE	A076801 001	Aug 17, 2012
	EQ 30MG BASE	A076801 002	Aug 17, 2012
	EQ 45MG BASE	A076801 003	Aug 17, 2012
NOSTRUM LABS INC	EQ 15MG BASE	A078472 001	Feb 13, 2013
	EQ 30MG BASE	A078472 002	Feb 13, 2013
	EQ 45MG BASE	A078472 003	Feb 13, 2013
PICKET PHARMS	EQ 15MG BASE	A078383 001	Mar 12, 2013
	EQ 30MG BASE	A078383 002	Mar 12, 2013
	EQ 45MG BASE	A078383 003	Mar 12, 2013
TORRENT PHARMS LTD	EQ 15MG BASE	A091298 001	Feb 13, 2013
	EQ 30MG BASE	A091298 002	Feb 13, 2013
	EQ 45MG BASE	A091298 003	Feb 13, 2013

PIPECURONIUM BROMIDE

INJECTABLE;INJECTION

ARDUAN

ORGANON USA INC	10MG/VIAL	N019638 001	Jun 26, 1990

PIPERACETAZINE

TABLET;ORAL

QUIDE

DOW PHARM	10MG	N013615 001	
	25MG	N013615 002	

PIPERACILLIN SODIUM

INJECTABLE;INJECTION

PIPRACIL

WYETH PHARMS INC	EQ 2GM BASE/VIAL	A062750 001	Oct 13, 1987
+	EQ 2GM BASE/VIAL **	N050545 002	
	EQ 3GM BASE/VIAL	A062750 002	Oct 13, 1987
+	EQ 3GM BASE/VIAL **	N050545 003	
	EQ 4GM BASE/VIAL	A062750 003	Oct 13, 1987
+	EQ 4GM BASE/VIAL **	N050545 004	
+	EQ 40GM BASE/VIAL **	N050545 006	Sep 30, 1985

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE;INJECTION

PIPERACILLIN AND TAZOBACTAM

HOSPIRA INC	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	A065386 001	Sep 15, 2009
	EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	A065386 002	Sep 15, 2009
	EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	A065386 003	Sep 15, 2009
	EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL	A065446 001	Sep 15, 2009
ZOSYN			
+	WYETH PHARMS	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL **	N050684 001
+		EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL **	N050684 002
+		EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL **	N050684 003
+		EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL **	N050684 004

PIPERAZINE CITRATE

SYRUP;ORAL

ANTEPAR

GLAXOSMITHKLINE	EQ 500MG BASE/5ML	N009102 001	
BRYREL			
SANOFI AVENTIS US	EQ 500MG BASE/5ML	N017796 001	
MULTIFUGE			
BLULINE	EQ 500MG BASE/5ML	N009452 001	
PIPERAZINE CITRATE			
ALPHARMA US PHARMS	EQ 500MG BASE/5ML	A080774 001	
LANNETT	EQ 500MG BASE/5ML	A080963 001	
LUITPOLD	EQ 500MG BASE/5ML	A080671 001	
VERMIDOL			
SOLVAY	EQ 500MG BASE/5ML	A080992 001	
TABLET;ORAL			
ANTEPAR			
GLAXOSMITHKLINE	EQ 500MG BASE	N009102 003	
PIPERAZINE CITRATE			
IMPAX LABS	EQ 250MG BASE	A080874 001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-377(of 478)

** See List Footnote

PIPERONYL BUTOXIDE; PYRETHRINS

AEROSOL; TOPICAL

RID MOUSSE

BAYER HEALTHCARE LLC 4%;EQ 0.33% BASE

N021043 001 Mar 07, 2000

PIPOBROMAN

TABLET; ORAL

VERCYTE

ABBOTT

10MG

N016245 001

25MG

N016245 002

PIRBUTEROL ACETATE

AEROSOL, METERED; INHALATION

MAXAIR

BAUSCH

EQ 0.2MG BASE/INH

N019009 001 Dec 30, 1986

EQ 0.2MG BASE/INH

N020014 001 Nov 30, 1992

PIRFENIDONE

TABLET; ORAL

ESBRIET

+

GENENTECH INC

534MG **

N208780 002 Jan 11, 2017

PIROXICAM

CAPSULE; ORAL

PIROXICAM

BRECKENRIDGE

10MG

A208991 001 Feb 21, 2018

20MG

A208991 002 Feb 21, 2018

CYCLE

10MG

A073651 001 Feb 26, 1993

20MG

A073651 002 Feb 26, 1993

EGIS

10MG

A074808 001 Jul 08, 1997

20MG

A074808 002 Jul 08, 1997

IVAX SUB TEVA PHARMS

10MG

A074148 001 Jun 03, 1996

20MG

A074148 002 Jun 03, 1996

MYLAN

10MG

A074043 001 Sep 22, 1992

10MG

A074102 001 Jul 31, 1992

20MG

A074043 002 Sep 22, 1992

20MG

A074102 002 Jul 31, 1992

SCS

10MG

A074036 001 May 29, 1992

20MG

A074036 002 May 29, 1992

SUN PHARM INDUSTRIES

10MG

A073536 002 Jan 23, 2008

20MG

A073536 001 Mar 12, 1993

TEVA

10MG

A073637 001 Jan 28, 1994

20MG

A073638 001 Jan 28, 1994

TEVA PHARMS

10MG

A074103 001 Aug 28, 1992

20MG

A074103 002 Aug 28, 1992

WATSON LABS

10MG

A074287 001 May 16, 1996

10MG

A074460 001 Sep 29, 1995

20MG

A074287 002 May 16, 1996

20MG

A074460 002 Sep 29, 1995

PITAVASTATIN CALCIUM

TABLET; ORAL

PITAVASTATIN CALCIUM

MYLAN

EQ 1MG BASE

A206070 001 Apr 04, 2019

EQ 2MG BASE

A206070 002 Apr 04, 2019

EQ 4MG BASE

A206070 003 Apr 04, 2019

PITAVASTATIN MAGNESIUM

TABLET; ORAL

ZYPITAMAG

+

MEDICURE

EQ 1MG BASE

N208379 001 Jul 14, 2017

PITAVASTATIN SODIUM

TABLET; ORAL

NIKITA

+

LUPIN LTD

EQ 1MG BASE

N209875 001 Aug 04, 2017

+

EQ 2MG BASE

N209875 002 Aug 04, 2017

+

EQ 4MG BASE

N209875 003 Aug 04, 2017

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-378(of 478)

** See List Footnote

PLICAMYCIN

INJECTABLE; INJECTION

MITHRACIN

PFIZER

2.5MG/VIAL

N050109 001

PODOFILOX

SOLUTION; TOPICAL

PODOFILOX

BAUSCH AND LOMB INC 0.5%

A090184 001 Jul 21, 2010

POLIDOCANOL

SOLUTION; INTRAVENOUS

VARITHENA

+ PROVENIS

77.5MG/7.75ML (10MG/ML)

N205098 002 Dec 21, 2017

POLYESTRADIOL PHOSPHATE

INJECTABLE; INJECTION

ESTRADURIN

WYETH AYERST

40MG/AMP

N010753 001

POLYETHYLENE GLYCOL 3350

FOR SOLUTION; ORAL

GLYCOLAX

LANNETT CO INC

17GM/SCOOPFUL

A076652 001 Jul 02, 2004

17GM/PACKET

A090600 001 Oct 06, 2009

17GM/SCOOPFUL

A090600 002 Oct 06, 2009

POLYETHYLENE GLYCOL 3350

BRECKENRIDGE PHARM

17GM/SCOOPFUL

A077736 001 May 26, 2006

NEXGEN PHARMA INC

17GM/SCOOPFUL

A077706 001 Sep 27, 2006

PADDOCK LLC

17GM/SCOOPFUL

A077893 001 May 26, 2006

17GM/SCOOPFUL

A090567 001 Oct 15, 2009

TEVA PHARMS

17GM/SCOOPFUL

A077445 001 May 04, 2006

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

FOR SOLUTION; ORAL

LAX-LYTE WITH FLAVOR PACKS

L PERRIGO CO

420GM/BOT; 1.48GM/BOT; 5.72GM/BOT; 11.2GM/BOT

A079232 001 Feb 25, 2010

PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE

MYLAN

420GM/BOT; 1.48GM/BOT; 5.72GM/BOT; 11.2GM/BOT

A090409 001 Apr 02, 2010

NOSTRUM LABS INC

420GM/BOT; 1.48GM/BOT; 5.72GM/BOT; 11.2GM/BOT

A202060 001 Mar 08, 2017

NOVEL LABS INC

420GM/BOT; 1.48GM/BOT; 5.72GM/BOT; 11.2GM/BOT

A090019 001 May 27, 2009

TRILYTE

AUROBINDO PHARMA USA

420GM/BOT; 1.48GM/BOT; 5.72GM/BOT; 11.2GM/BOT

A076491 001 Feb 05, 2004

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE

FOR SOLUTION; ORAL

CLENZ-LYTE

PADDOCK LLC

236GM/BOT; 2.97GM/BOT; 6.74GM/BOT; 5.86GM/BOT; 22.74GM/BOT

A090769 001 Jun 07, 2010

SOLUTION; ORAL

OCL

HOSPIRA

6GM/100ML; 75MG/100ML; 168MG/100ML; 146MG/100ML; 1.29GM/100ML

N019284 001 Apr 30, 1986

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATEANHYDROUS

FOR SOLUTION; ORAL

COLYTE

MYLAN SPECIALITY LP

120GM/PACKET; 1.49GM/PACKET; 3.36GM/PACKET; 2.92GM/PACKET; 11.36GM/PACKET

N018983 005 Oct 26, 1984

227.1GM/PACKET; 2.82GM/PACKET; 6.36GM/PACKET; 5.53GM/PACKET; 21.5GM/PACKET

N018983 004 Oct 26, 1984

227.1GM/BOT; 2.82GM/BOT; 6.36GM/BOT; 5.53GM/BOT; 21.5GM/BOT

N018983 010 Jan 31, 1989

240GM/BOT; 2.98GM/BOT; 6.72GM/BOT; 5.84GM/BOT; 22.72GM/BOT

N018983 007 Jun 12, 1987

360GM/PACKET; 4.47GM/PACKET; 10.08GM/PACKET; 8.76GM/PACKET; 34.08GM/PACKET

N018983 006 Oct 26, 1984

COLYTE-FLAVORED

MYLAN SPECIALITY LP

227.1GM/BOT; 2.82GM/BOT; 6.36GM/BOT; 5.53

N018983 008 Nov 14, 1991

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-379(of 478)

** See List Footnote

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUS

FOR SOLUTION;ORAL

COLYTE-FLAVORED

GM/BOT;21.5GM/BOT

240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT

N018983 009 Nov 14, 1991

GOLYTELY

+ BRAINTREE

227.1GM/PACKET;2.82GM/PACKET;6.36GM/PACKET;5.53GM/PACKET;21.5GM/PACKET

N019011 002 Jun 02, 1992

PEG 3350 AND ELECTROLYTES

MYLAN

236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/BOT;22.74GM/BOT

A090928 001 Jan 28, 2010

POLYETHYLENE GLYCOL 3350 AND ELECTROLYTES

PADDOCK LLC

240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT

A090712 001 Feb 25, 2010

FOR SUSPENSION;ORAL

CO-LAV

VINTAGE PHARMS

240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT

A073428 001 Jan 28, 1992

COLOVAGE

DYNAPHARM

227.1GM/PACKET;2.82GM/PACKET;6.36GM/PACKET;5.53GM/PACKET;21.5GM/PACKET

A071320 001 Apr 20, 1988

E-Z-EM PREP LYTE

E Z EM

236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/BOT;22.74GM/BOT

A071278 001 Nov 21, 1988

GLYCOPREP

GOLDLINE

236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/BOT;22.74GM/BOT

A072319 001 Dec 23, 1988

GO-EVAC

VINTAGE PHARMS

236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/BOT;22.74GM/BOT

A073433 001 Apr 28, 1992

PEG-LYTE

SANDOZ

236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/BOT;22.74GM/BOT

A073098 001 Aug 31, 1993

POLYMYXIN B SULFATE

INJECTABLE;INJECTION

AEROSPORIN

GLAXOSMITHKLINE

EQ 500,000 UNITS BASE/VIAL

A062036 001

POLYMYXIN B SULFATE

HIKMA

EQ 500,000 UNITS BASE/VIAL

A060716 001

RISING

EQ 500,000 UNITS BASE/VIAL

A090110 001 Jun 29, 2011

POWDER;FOR RX COMPOUNDING

POLY-RX

X GEN PHARMS

100,000,000 UNITS/BOT

A061578 001

POLYMYXIN B SULFATE

PADDOCK LLC

100,000,000 UNITS/BOT

A062455 001 Jul 27, 1983

POLYTHIAZIDE

TABLET;ORAL

RENESE

PFIZER

1MG

N012845 001

2MG

N012845 002

4MG

N012845 003

POLYTHIAZIDE; PRAZOSIN HYDROCHLORIDE

CAPSULE;ORAL

MINIZIDE

PFIZER

0.5MG;EQ 1MG BASE

N017986 001

0.5MG;EQ 2MG BASE

N017986 002

0.5MG;EQ 5MG BASE

N017986 003

POLYTHIAZIDE; RESERPINE

TABLET;ORAL

RENESE-R

PFIZER

2MG;0.25MG

N013636 001

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-380(of 478)

** See List Footnote

POMALIDOMIDE

CAPSULE; ORAL

POMALIDOMIDE

BRECKENRIDGE	1MG	A210111 001	Oct 30, 2020
	2MG	A210111 002	Oct 30, 2020
	3MG	A210111 003	Oct 30, 2020
	4MG	A210111 004	Oct 30, 2020
EUGIA PHARMA	1MG	A210249 001	Oct 30, 2020
	2MG	A210249 002	Oct 30, 2020
	3MG	A210249 003	Oct 30, 2020
	4MG	A210249 004	Oct 30, 2020
MYLAN	1MG	A210275 001	Jan 26, 2022
	2MG	A210275 002	Jan 26, 2022
	3MG	A210275 003	Jan 26, 2022
	4MG	A210275 004	Jan 26, 2022
TEVA PHARMS USA	1MG	A209956 001	May 04, 2022
	2MG	A209956 002	May 04, 2022
	3MG	A209956 003	May 04, 2022
	4MG	A209956 004	May 04, 2022

POTASSIUM ACETATE

INJECTABLE; INJECTION

POTASSIUM ACETATE

EXELA PHARMA	2MEQ/ML	A212692 001	Oct 20, 2021

POTASSIUM AMINOSALICYLATE

CAPSULE; ORAL

PASKALIUM

GLENWOOD	500MG	N009395 004	

POWDER; ORAL

POTASSIUM AMINOSALICYLATE

HEXCEL	100%	A080098 001	

TABLET; ORAL

PASKALIUM

GLENWOOD	1GM	N009395 003	

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

K-LEASE

SAVAGE LABS	8MEQ	A073398 001	Jan 28, 1992
	10MEQ	A072427 001	Mar 28, 1990

MICRO-K

+ NESHER PHARMS	8MEQ **	N018238 001	

MICRO-K 10

+ NESHER PHARMS	10MEQ **	N018238 002	May 14, 1984

POTASSIUM CHLORIDE

LANNETT CO INC	8MEQ	A204210 001	Mar 28, 2016
	10MEQ	A204210 002	Mar 28, 2016
NESHER PHARMS	10MEQ	A070980 001	Feb 17, 1987
TEVA	8MEQ	A073531 001	Apr 26, 1996
	10MEQ	A073532 001	Apr 26, 1996
TRIS PHARMA INC	8MEQ	A201944 001	Mar 04, 2016
	10MEQ	A201944 002	Mar 04, 2016

FOR SOLUTION; ORAL

POTASSIUM CHLORIDE

GRANULES	20MEQ	A213467 001	Jan 27, 2022

FOR SUSPENSION, EXTENDED RELEASE; ORAL

MICRO-K LS

+ KV PHARM	20MEQ/PACKET **	N019561 003	Aug 26, 1988

INJECTABLE; INJECTION

POTASSIUM CHLORIDE

+ ABRAXIS PHARM	2MEQ/ML	A080204 001	
	2MEQ/ML	A084290 001	
	2MEQ/ML	A086713 001	
	2MEQ/ML	A086714 001	
	2MEQ/ML	A087787 001	Apr 20, 1982
	2MEQ/ML	A087885 001	Feb 03, 1983
AKORN	2MEQ/ML	A088286 001	Sep 05, 1985
BAXTER HLTHCARE	2MEQ/ML	A080203 001	
	2MEQ/ML	A085499 001	
+ FRESENIUS KABI USA	2MEQ/ML	A080225 001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-381(of 478)

** See List Footnote

POTASSIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE

	2MEQ/ML	A087817	001	Oct 20, 1982
	3MEQ/ML	A080225	003	
GD SEARLE LLC	1MEQ/ML	A086219	001	
	2MEQ/ML	A086219	002	
	2MEQ/ML	A086220	002	
	3MEQ/ML	A086219	003	
	3MEQ/ML	A086220	001	
	4MEQ/ML	A086219	004	
HOSPIRA	1MEQ/ML	A080205	003	
	1MEQ/ML	A083345	003	
	1.5MEQ/ML	A083345	001	
	2MEQ/ML	A083345	002	
	2.4MEQ/ML	A080205	004	
	3.2MEQ/ML	A080205	005	
INTL MEDICATION	2MEQ/ML	A083163	001	
LILLY	2MEQ/ML	N007865	002	
LUITPOLD	2MEQ/ML	A080221	001	
	2MEQ/ML	A080736	001	
	2MEQ/ML	A087584	001	
	2MEQ/ML	A087585	001	
MILES	1MEQ/ML	A080195	002	
	2MEQ/ML	A080195	001	
	3MEQ/ML	A080195	003	
	4MEQ/ML	A080195	004	
PHARMA SERVE NY	2MEQ/ML	A086297	001	
	2MEQ/ML	A087362	001	Mar 08, 1983
WATSON LABS	2MEQ/ML	A086208	001	
	2MEQ/ML	A089163	001	Mar 10, 1988
	2MEQ/ML	A089421	001	Jan 02, 1987
	3MEQ/ML	A086210	001	
POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER				
+ ICU MEDICAL INC	2.24GM/100ML	N020161	003	Aug 11, 1998
SOLUTION; ORAL				
POTASSIUM CHLORIDE				
TRIS PHARMA INC	20MEQ/15ML	A214076	001	Jan 26, 2022
	40MEQ/15ML	A214076	002	Jan 26, 2022
TABLET, EXTENDED RELEASE; ORAL				
K+10				
FUTURE PAK	10MEQ	A070999	001	Oct 22, 1987
K+8				
FUTURE PAK	8MEQ	A070998	001	Jan 25, 1993
K-TAB				
+ ABBVIE	8MEQ	N018279	002	Aug 01, 1988
KAON CL				
SAVAGE LABS	6.7MEQ	N017046	001	
KAON CL-10				
SAVAGE LABS	10MEQ	N017046	002	
KLOTRIX				
APOTHECON	10MEQ	N017850	001	
POTASSIUM CHLORIDE				
AMNEAL	15MEQ	A212861	002	May 08, 2020
AUROBINDO PHARMA LTD	10MEQ	A214728	001	Mar 31, 2021
	15MEQ	A214728	002	Mar 31, 2021
	20MEQ	A214728	003	Mar 31, 2021
BRECKENRIDGE	10MEQ	A213588	001	Aug 21, 2020
	20MEQ	A213588	002	Aug 21, 2020
COPLEY PHARM	8MEQ	A070618	001	Sep 09, 1987
NESHER PHARMS	20MEQ	A076044	001	Apr 05, 2002
+ SCHERING	10MEQ **	N019439	002	Jun 13, 1986
+	20MEQ **	N019439	001	Jun 13, 1986
SIGMAPHARM LABS LLC	8MEQ	A207528	001	Aug 19, 2016
	10MEQ	A207528	002	Aug 19, 2016
STRIDES PHARMA	8MEQ	A206881	001	Jan 22, 2019
	10MEQ	A206630	001	Mar 29, 2019
	10MEQ	A206881	002	Jan 22, 2019
	10MEQ	A210097	001	Jun 17, 2019

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-382(of 478)

** See List Footnote

POTASSIUM CHLORIDETABLET, EXTENDED RELEASE;ORAL
POTASSIUM CHLORIDE

	15MEQ	A206630 002	Mar 29, 2019
	20MEQ	A206630 003	Mar 29, 2019
	20MEQ	A210098 001	Apr 26, 2019
SLOW-K			
NOVARTIS	8MEQ	N017476 002	
TEN-K			
NOVARTIS	10MEQ	N019381 001	Apr 16, 1986

POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE;INJECTION

POTASSIUM CHLORIDE 0.037% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
B BRAUN	37MG/100ML;900MG/100ML	N019708 001	Sep 29, 1989
POTASSIUM CHLORIDE 0.075% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
B BRAUN	75MG/100ML;900MG/100ML	N019708 002	Sep 29, 1989
POTASSIUM CHLORIDE 0.11% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
B BRAUN	110MG/100ML;900MG/100ML	N019708 003	Sep 29, 1989
POTASSIUM CHLORIDE 0.22% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
B BRAUN	220MG/100ML;900MG/100ML	N019708 005	Sep 29, 1989
POTASSIUM CHLORIDE 0.224% IN SODIUM CHLORIDE 0.9%			
+ BAXTER HLTHCARE	224MG/100ML;900MG/100ML	N017648 003	
POTASSIUM CHLORIDE 0.3% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER			
B BRAUN	300MG/100ML;900MG/100ML	N019708 006	Sep 29, 1989
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.075%			
BAXTER HLTHCARE	75MG/100ML;900MG/100ML	N017648 004	
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER			
B BRAUN	75MG/100ML;900MG/100ML	N018722 001	Nov 09, 1982
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER			
B BRAUN	150MG/100ML;900MG/100ML	N018722 002	Nov 09, 1982
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.22% IN PLASTIC CONTAINER			
B BRAUN	220MG/100ML;900MG/100ML	N018722 003	Nov 09, 1982
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER			
B BRAUN	300MG/100ML;900MG/100ML	N018722 004	Nov 09, 1982

POTASSIUM CHLORIDE; SODIUM CHLORIDE; TROMETHAMINE

INJECTABLE;INJECTION

THAM-E			
HOSPIRA	370MG/VIAL;1.75GM/VIAL;36GM/VIAL	N013025 001	

POTASSIUM CITRATE

FOR SOLUTION;ORAL

POTASSIUM CITRATE			
+ UT SW MEDCTR	10MEQ/PACKET **	N019647 002	Oct 13, 1988
+	20MEQ/PACKET **	N019647 001	Oct 13, 1988

POTASSIUM IODIDE

SOLUTION;ORAL

POTASSIUM IODIDE			
+ ROXANE	1GM/ML **	N018551 001	Feb 19, 1982
THYROSHIELD			
ARCO PHARMS LLC	65MG/ML	A077218 001	Jan 12, 2005

TABLET;ORAL

THYRO-BLOCK			
MEDA PHARMS	130MG	N018307 001	

POTASSIUM PERCHLORATE

CAPSULE;ORAL

PERCHLORACAP			
MALLINCKRODT	200MG	N017551 001	

POVIDONE-IODINE

SOLUTION;TOPICAL

E-Z PREP			
CLINIPAD	10%	N019382 001	Jul 25, 1989

SPONGE;TOPICAL

E-Z PREP			
CLINIPAD	5%	N019382 002	Jul 25, 1989
E-Z PREP 220			
CLINIPAD	5%	N019382 003	Jul 25, 1989

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-383(of 478)

** See List Footnote

PRALIDOXIME CHLORIDE

INJECTABLE; INJECTION

PRALIDOXIME CHLORIDE

BAXTER HLTHCARE CORP 300MG/ML

N018799 001 Dec 13, 1982

SOLUTION; INTRAMUSCULAR

PRALIDOXIME CHLORIDE (AUTOINJECTOR)

+ MERIDIAN MEDCL TECHN 600MG/2ML (300MG/ML)

N018986 001 Apr 26, 1983

TABLET; ORAL

PROTOPAM CHLORIDE

WYETH AYERST 500MG

N014122 002

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET; ORAL

MIRAPEX

+ BOEHRINGER INGELHEIM 0.125MG

N020667 001 Jul 01, 1997

+ 0.25MG

N020667 002 Jul 01, 1997

+ 0.5MG

N020667 006 Feb 12, 1998

+ 0.75MG

N020667 007 Jul 30, 2007

+ 1MG

N020667 003 Jul 01, 1997

+ 1.25MG

N020667 004 Jul 01, 1997

+ 1.5MG

N020667 005 Jul 01, 1997

PRAMIPEXOLE DIHYDROCHLORIDE

ALEMBIC PHARMS 0.125MG

A078894 001 Oct 08, 2010

0.25MG

A078894 002 Oct 08, 2010

0.5MG

A078894 003 Oct 08, 2010

1MG

A078894 004 Oct 08, 2010

1.5MG

A078894 005 Oct 08, 2010

HERITAGE PHARMA AVET 0.125MG

A077724 001 Feb 19, 2008

0.125MG

A078551 001 Oct 08, 2010

0.125MG

A090241 001 Oct 08, 2010

0.125MG

A091254 001 Nov 30, 2010

0.25MG

A077724 002 Feb 19, 2008

0.25MG

A078551 002 Oct 08, 2010

0.25MG

A090241 002 Oct 08, 2010

0.25MG

A091254 002 Nov 30, 2010

0.5MG

A077724 003 Feb 19, 2008

0.5MG

A078551 003 Oct 08, 2010

0.5MG

A090241 003 Oct 08, 2010

0.5MG

A091254 003 Nov 30, 2010

0.75MG

A090241 004 Oct 08, 2010

0.75MG

A091254 004 Nov 30, 2010

1MG

A077724 004 Feb 19, 2008

1MG

A078551 004 Oct 08, 2010

1MG

A090241 005 Oct 08, 2010

1MG

A091254 005 Nov 30, 2010

1.5MG

A077724 005 Feb 19, 2008

1.5MG

A078551 005 Oct 08, 2010

1.5MG

A090241 006 Oct 08, 2010

1.5MG

A091254 006 Nov 30, 2010

MACLEODS PHARMS LTD 0.125MG

A202164 001 Sep 20, 2012

0.25MG

A202164 002 Sep 20, 2012

0.5MG

A202164 003 Sep 20, 2012

1MG

A202164 004 Sep 20, 2012

1.5MG

A202164 005 Sep 20, 2012

MYLAN 0.125MG

A077854 001 Oct 08, 2010

0.25MG

A077854 002 Oct 08, 2010

0.5MG

A077854 003 Oct 08, 2010

0.75MG

A090764 001 Apr 09, 2010

1MG

A077854 004 Oct 08, 2010

1.5MG

A077854 005 Oct 08, 2010

NOSTRUM LABS INC 0.125MG

A091450 001 Oct 08, 2010

0.25MG

A091450 002 Oct 08, 2010

0.5MG

A091450 003 Oct 08, 2010

1MG

A091450 004 Oct 08, 2010

1.5MG

A091450 005 Oct 08, 2010

SANDOZ 0.125MG

A090190 001 Jul 06, 2010

0.25MG

A090190 002 Jul 06, 2010

0.5MG

A090190 003 Jul 06, 2010

0.75MG

A090190 006 Oct 08, 2010

1MG

A090190 004 Jul 06, 2010

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-384(of 478)

** See List Footnote

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET;ORAL

PRAMIPEXOLE DIHYDROCHLORIDE

	1.5MG	A090190	005	Jul 06, 2010
SUN PHARM INDS INC	0.125MG	A091683	001	Mar 27, 2013
	0.25MG	A091683	002	Mar 27, 2013
	0.5MG	A091683	003	Mar 27, 2013
	0.75MG	A091683	004	Mar 27, 2013
	1MG	A091683	005	Mar 27, 2013
	1.5MG	A091683	006	Mar 27, 2013
UNICHEM	0.125MG	A207011	001	Dec 19, 2018
	0.25MG	A207011	002	Dec 19, 2018
	0.5MG	A207011	003	Dec 19, 2018
	0.75MG	A207011	004	Dec 19, 2018
	1MG	A207011	005	Dec 19, 2018
	1.5MG	A207011	006	Dec 19, 2018

TABLET, EXTENDED RELEASE;ORAL

PRAMIPEXOLE DIHYDROCHLORIDE

ANCHEN PHARMS	0.375MG	A202206	001	Feb 06, 2014
	0.75MG	A202206	002	Feb 06, 2014
	1.5MG	A202206	003	Feb 06, 2014
	2.25MG	A202206	004	Feb 06, 2014
	3MG	A202206	005	Feb 06, 2014
	3.75MG	A202206	006	Feb 06, 2014
	4.5MG	A202206	007	Feb 06, 2014

PRAMLINTIDE ACETATE

INJECTABLE;SUBCUTANEOUS

SYMLIN

ASTRAZENECA AB	EQ 3MG BASE/5ML (EQ 600MCG BASE/ML)	N021332	001	Mar 16, 2005

PRASUGREL HYDROCHLORIDE

TABLET;ORAL

PRASUGREL

CHARTWELL RX	EQ 5MG BASE	A205790	001	Oct 16, 2017
	EQ 10MG BASE	A205790	002	Oct 16, 2017
DR REDDYS	EQ 5MG BASE	A205926	001	Jul 07, 2020
	EQ 10MG BASE	A205926	002	Jul 07, 2020

PRAVASTATIN SODIUM

TABLET;ORAL

PRAVACHOL

+	BRISTOL MYERS SQUIBB	10MG **	N019898	002	Oct 31, 1991
+		20MG	N019898	003	Oct 31, 1991
+		40MG	N019898	004	Mar 22, 1993
+		80MG	N019898	008	Dec 18, 2001

PRAVASTATIN SODIUM

HISUN PHARM HANGZHOU	20MG	A206061	001	Nov 23, 2018
	40MG	A206061	002	Nov 23, 2018
	80MG	A206061	003	Nov 23, 2018
MYLAN	10MG	A077013	001	Oct 23, 2006
	20MG	A077013	002	Oct 23, 2006
	40MG	A077013	003	Oct 23, 2006
	80MG	A077013	004	Dec 28, 2007
MYLAN PHARMS INC	10MG	A079187	001	May 27, 2010
	20MG	A079187	002	May 27, 2010
	40MG	A079187	003	May 27, 2010
	80MG	A079187	004	May 27, 2010
PLIVA HRVATSKA DOO	10MG	A077730	001	Nov 21, 2006
	20MG	A077730	002	Nov 21, 2006
	30MG	A077730	003	Nov 21, 2006
	40MG	A077730	005	Nov 21, 2006
RANBAXY LABS LTD	10MG	A076445	001	Apr 23, 2007
	20MG	A076445	002	Apr 23, 2007
	40MG	A076445	003	Apr 23, 2007
	80MG	A076445	004	Apr 23, 2007
ZYDUS PHARMS USA	10MG	A077751	001	Apr 30, 2008

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-385(of 478)

** See List Footnote

PRAZEPAM

CAPSULE; ORAL

CENTRAX

PARKE DAVIS

5MG

N018144 001

10MG

N018144 002

20MG

N018144 003 May 10, 1982

PRAZEPAM

USL PHARMA

5MG

A070427 001 Nov 06, 1987

10MG

A070428 001 Nov 06, 1987

TABLET; ORAL

CENTRAX

PARKE DAVIS

10MG

N017415 001

PRAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

PRAZOSIN HYDROCHLORIDE

AM THERAP

EQ 1MG BASE

A072782 001 May 16, 1989

EQ 2MG BASE

A072783 001 May 16, 1989

EQ 5MG BASE

A072784 001 May 16, 1989

ANI PHARMS

EQ 1MG BASE

A072577 002 May 16, 1989

EQ 2MG BASE

A072577 001 May 16, 1989

EQ 5MG BASE

A072577 003 May 16, 1989

DAVA PHARMS INC

EQ 1MG BASE

A072705 001 May 16, 1989

EQ 2MG BASE

A072706 001 May 16, 1989

EQ 5MG BASE

A072707 001 May 16, 1989

PUREPAC PHARM

EQ 1MG BASE

A072991 001 May 16, 1989

EQ 2MG BASE

A072921 001 May 16, 1989

EQ 5MG BASE

A072992 001 May 16, 1989

WATSON LABS

EQ 1MG BASE

A072352 001 May 16, 1989

EQ 2MG BASE

A072333 001 May 16, 1989

EQ 5MG BASE

A072609 001 May 16, 1989

TABLET, EXTENDED RELEASE; ORAL

MINIPRESS XL

PFIZER

2.5MG

N019775 001 Jan 29, 1992

5MG

N019775 002 Jan 29, 1992

PREDNICARBATE

CREAM; TOPICAL

DERMATOP E EMOLLIENT

+ VALEANT BERMUDA

0.1%

N020279 001 Oct 29, 1993

PREDNICARBATE

FOUGERA PHARMS

0.1%

A077287 001 Sep 19, 2006

OINTMENT; TOPICAL

DERMATOP

+ VALEANT PHARMS NORTH

0.1% **

N019568 001 Sep 23, 1991

PREDNISOLONE

CREAM; TOPICAL

METI-DERM

SCHERING

0.5%

N010209 002

SYRUP; ORAL

PREDNISOLONE

IVAX SUB TEVA PHARMS

15MG/5ML

A040287 001 May 28, 1999

NESHER PHARMS

5MG/5ML

A040423 001 Oct 22, 2001

15MG/5ML

A040364 001 Apr 10, 2002

PHARM ASSOC

5MG/5ML

A040570 001 Aug 25, 2005

15MG/5ML

A040571 001 Aug 25, 2005

TEVA PHARMS

15MG/5ML

A040322 001 Jan 19, 2000

WE PHARMS

15MG/5ML

A040192 001 May 28, 1998

PRELONE

MURO

5MG/5ML

A089654 001 Jan 17, 1989

TABLET; ORAL

CORTALONE

HALSEY

1MG

A080304 003

2.5MG

A080304 002

5MG

A080304 001

DELTA-CORTEF

PHARMACIA AND UPJOHN

5MG

N009987 004

FERNISOLONE-P

FERNDAL LABS

5MG

A083941 001

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-386(of 478)

** See List Footnote

PREDNISOLONE

TABLET; ORAL

PREDNISOLONE

BARR	5MG	A084426	002
BUNDY	5MG	A083675	001
CHARTWELL MOLECULAR	5MG	A080531	002
CHARTWELL RX	5MG	A084542	001
ELKINS SINN	5MG	A080625	001
EVERYLIFE	1MG	A084439	001
	2.5MG	A084439	002
	5MG	A084439	003
FERRANTE	2.5MG	A080562	001
	5MG	A080562	002
FOSUN PHARMA	5MG	A080339	001
HEATHER	5MG	A080326	001
IMPAX LABS	5MG	A080780	001
INWOOD LABS	5MG	A080748	001
IVAX SUB TEVA PHARMS	5MG	A080378	001
MARSHALL PHARMA	5MG	A080307	001
PANRAY	1MG	A080351	001
	5MG	A080351	002
PHOENIX LABS NY	5MG	A080322	001
PUREPAC PHARM	5MG	A080325	001
PVT FORM	5MG	A080211	001
RISING	5MG	A084773	001
ROXANE	5MG	A080327	002
SPERTI	1MG	A080358	001
	2.5MG	A080358	002
	5MG	A080358	003
SUPERPHARM	5MG	A088892	001 Feb 26, 1985
TABLICAPS	5MG	A085170	001
TEVA	5MG	A080398	001
UDL	5MG	A087987	001 Jan 18, 1983
VALEANT PHARM INTL	5MG	A080236	001
VITARINE	5MG	A080534	001
WATSON LABS	5MG	A085085	002
	5MG	A085415	001
	5MG	A085416	001
WEST WARD	5MG	A080324	001
WHITEWORTH TOWN PLSN	5MG	A080342	001
STERANE			
PFIZER	5MG	N009996	001

PREDNISOLONE ACETATE

INJECTABLE; INJECTION

METICORTELONE

SCHERING	25MG/ML	N010255	002
PREDNISOLONE ACETATE			
AKORN	25MG/ML	A083032	001
	50MG/ML	A084492	001
BEL MAR	25MG/ML	A083738	001
	50MG/ML	A083738	002
CENT PHARMS	25MG/ML	A084717	001
	50MG/ML	A084717	002
WATSON LABS	25MG/ML	A083398	001
	25MG/ML	A083654	001
	40MG/ML	A083767	001
	50MG/ML	A083764	001
	50MG/ML	A085781	001

STERANE

PFIZER	25MG/ML	N011446	001

SUSPENSION; ORAL

FLO-PRED

TARO	EQ 5MG BASE/5ML	N022067	001 Jan 17, 2008
	EQ 15MG BASE/5ML	N022067	002 Jan 17, 2008

SUSPENSION/DROPS; OPHTHALMIC

ECONOPRED

EYEVANCE	0.125%	N017468	001

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-387(of 478)

** See List Footnote

PREDNISOLONE ACETATE; SULFACETAMIDE SODIUM

OINTMENT;OPHTHALMIC

BLEPHAMIDE S.O.P.

ALLERGAN	0.2%;10%	A087748	001	Dec 03, 1986
CETAPRED				
ALCON	0.25%;10%	A087771	001	Aug 06, 1993
METIMYD				
SCHERING	0.5%;10%	N010210	002	Sep 09, 1984
PREDSULFAIR				
PHARMAFAIR	0.5%;10%	A088032	001	Apr 15, 1983
VASOCIDIN				
NOVARTIS	0.5%;10%	A088791	001	Oct 05, 1984

SUSPENSION;OPHTHALMIC

BLEPHAMIDE

+ ALLERGAN	0.2%;10%	N012813	002	
ISOPTO CETAPRED				
ALCON	0.25%;10%	A087547	001	

SUSPENSION/DROPS;OPHTHALMIC

METIMYD

SCHERING	0.5%;10%	N010210	001	
PREDAMIDE				
AKORN	0.5%;10%	A088059	001	Jul 29, 1983
PREDSULFAIR				
PHARMAFAIR	0.5%;10%	A088007	001	Apr 19, 1983
PREDSULFAIR II				
PHARMAFAIR	0.2%;10%	A088837	001	Dec 24, 1985
SULPHRIN				
BAUSCH AND LOMB	0.5%;10%	A088089	001	Dec 28, 1982

PREDNISOLONE SODIUM PHOSPHATE

INJECTABLE;INJECTION

HYDELTRASOL

MERCK	EQ 20MG PHOSPHATE/ML	N011583	002	
PREDNISOLONE SODIUM PHOSPHATE				
WATSON LABS	EQ 20MG PHOSPHATE/ML	A080517	001	

OINTMENT;OPHTHALMIC, OTIC

HYDELTRASOL

MERCK	EQ 0.25% PHOSPHATE	N011028	001	

SOLUTION;ORAL

ORAPRED

CONCORDIA PHARMS INC	EQ 15MG BASE/5ML **	A075117	001	Dec 14, 2000
PREDNISOLONE SODIUM PHOSPHATE				
AMNEAL PHARMS	EQ 15MG BASE/5ML	A078345	001	Mar 10, 2009
BAUSCH	EQ 15MG BASE/5ML	A075250	001	Jul 12, 2002
NESHER PHARMS	EQ 5MG BASE/5ML	A076982	001	May 24, 2005
	EQ 15MG BASE/5ML	A076988	001	May 24, 2005
PHARM ASSOC	EQ 5MG BASE/5ML	A076123	001	Dec 23, 2002
VINTAGE	EQ 15MG BASE/5ML	A079010	001	May 26, 2009
VINTAGE PHARMS	EQ 5MG BASE/5ML	A078416	001	Oct 31, 2007
WE PHARMS	EQ 5MG BASE/5ML	A075181	001	Dec 23, 2002

SOLUTION/DROPS;OPHTHALMIC

INFLAMASE FORTE

+ NOVARTIS	EQ 0.9% PHOSPHATE	A080751	002	

INFLAMASE MILD

+ NOVARTIS	EQ 0.11% PHOSPHATE	A080751	001	

METRETON

SCHERING	EQ 0.5% PHOSPHATE	A083834	001	

PREDAIR

PHARMAFAIR	EQ 0.11% PHOSPHATE	A088415	001	Feb 29, 1984

PREDAIR FORTE

PHARMAFAIR	EQ 0.9% PHOSPHATE	A088165	001	Mar 28, 1983

PREDNISOLONE SODIUM PHOSPHATE

AKORN	EQ 0.11% PHOSPHATE	A083358	001	
	EQ 0.9% PHOSPHATE	A083358	002	
ALCON PHARMS LTD	EQ 0.11% PHOSPHATE	A081043	001	Oct 24, 1991
	EQ 0.9% PHOSPHATE	A081044	001	Oct 24, 1991
BAUSCH AND LOMB	EQ 0.11% PHOSPHATE	A040065	001	Jul 29, 1994
SOLA BARNES HIND	EQ 0.11% PHOSPHATE	A084171	001	
	EQ 0.9% PHOSPHATE	A084168	001	
	EQ 0.9% PHOSPHATE	A084169	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-388(of 478)

** See List Footnote

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION/DROPS;OPHTHALMIC

PREDNISOLONE SODIUM PHOSPHATE

EQ 0.9% PHOSPHATE

A084172 001

TABLET, ORALLY DISINTEGRATING;ORAL

PREDNISOLONE SODIUM PHOSPHATE

RISING

EQ 10MG BASE

A202179 001 Apr 10, 2013

EQ 15MG BASE

A202179 002 Apr 10, 2013

EQ 30MG BASE

A202179 003 Apr 10, 2013

PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM

SOLUTION/DROPS;OPHTHALMIC

SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE

SANDOZ INC

EQ 0.23% PHOSPHATE;10%

A073630 001 May 27, 1993

SULSTER

AKORN

EQ 0.23% PHOSPHATE;10%

A074511 001 Jul 30, 1996

VASOCIDIN

+ NOVARTIS

EQ 0.23% PHOSPHATE;10% **

N018988 001 Aug 26, 1988

PREDNISOLONE TEBUTATE

INJECTABLE;INJECTION

HYDELTRA-TBA

MERCK

20MG/ML

N010562 001

PREDNISOLONE TEBUTATE

WATSON LABS

20MG/ML

A083362 001 Feb 17, 1984

PREDNISONE

SOLUTION;ORAL

PREDNISONE

WOCKHARDT

5MG/5ML

A089726 001 Aug 02, 1988

SYRUP;ORAL

LIQUID PRED

MURO

5MG/5ML

A087611 002 Sep 07, 1982

TABLET;ORAL

CORTAN

HALSEY

20MG

A087480 001

DELTA-DOME

BAYER PHARMS

5MG

A080293 001

DELTASONE

+ PHARMACIA AND UPJOHN

2.5MG **

N009986 005

+

5MG **

N009986 002

+

10MG **

N009986 006

+

20MG **

N009986 007

+

50MG **

N009986 008

FERNISONE

FERNDAL LABS

5MG

A083364 001

METICORTEN

+ SCHERING

1MG **

N009766 002

+

5MG **

N009766 001

ORASONE

SOLVAY

1MG

A083009 001

5MG

A083009 002

10MG

A083009 003

20MG

A083009 004

50MG

A085999 001

PARACORT

PARKE DAVIS

5MG

N010962 002

PREDNICEN-M

SCHWARZ PHARMA

5MG

A084655 001

PREDNISONE

AM THERAP

5MG

A089387 001 Nov 06, 1986

10MG

A089388 001 Nov 06, 1986

20MG

A089389 001 Nov 06, 1986

AMNEAL PHARMS NY

5MG

A089597 001 Oct 05, 1987

10MG

A089598 001 Oct 05, 1987

20MG

A089599 001 Oct 05, 1987

BUNDY

5MG

A083676 001

CHARTWELL MOLECULAR

5MG

A080514 001

20MG

A084275 001

CHARTWELL RX

5MG

A083059 001

CONTRACT PHARMACAL

5MG

A080209 001

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-389(of 478)

** See List Footnote

PREDNISONE

TABLET;ORAL

PREDNISONE

DURAMED PHARMS BARR	5MG	A088394	001	Oct 04, 1983
	10MG	A088395	001	Oct 04, 1983
	20MG	A088396	001	Oct 04, 1983
ELKINS SINN	5MG	A080491	001	
	20MG	A085811	001	
EVERYLIFE	1MG	A084440	001	
	2.5MG	A084440	002	
	5MG	A084440	003	
FERRANTE	2.5MG	A080563	001	
	5MG	A080563	002	
HALSEY	5MG	A080300	001	
HEATHER	5MG	A080320	001	
	10MG	A084341	001	
	20MG	A084417	001	
	20MG	A085543	001	
	50MG	A086946	001	
HIKMA PHARMS	1MG	A040890	001	Nov 01, 2010
	2.5MG	A040538	001	Jan 08, 2004
	50MG	A088465	001	Jun 01, 1984
IMPAX LABS	5MG	A080782	001	
INWOOD LABS	1MG	A080328	001	
	2.5MG	A080306	001	
	5MG	A080279	001	
IVAX SUB TEVA PHARMS	5MG	A080283	001	
	10MG	A084133	001	
	20MG	A084134	001	
KV PHARM	5MG	A084236	001	
LEDERLE	5MG	A086968	001	
MARSHALL PHARMA	5MG	A080301	001	
MUTUAL PHARM	5MG	A080701	001	
	10MG	A086595	001	
	20MG	A084634	001	
NYLOS	5MG	A085115	001	
PANRAY	1MG	A080350	001	
	2.5MG	A080350	002	
	5MG	A080350	003	
PHARMAVITE	5MG	A084662	002	
PHOENIX LABS NY	5MG	A080321	001	
	20MG	A083807	001	
PUREPAC PHARM	5MG	A080353	001	
	10MG	A086062	001	
	20MG	A086061	001	
PVT FORM	20MG	A085151	001	
REXALL	5MG	A080232	001	
RISING	5MG	A084774	001	
	10MG	A089983	001	Jan 12, 1989
	20MG	A085813	001	
	50MG	A089984	001	Jan 12, 1989
ROXANE	20MG	N017109	001	
+	25MG	A087833	001	May 04, 1982
SANDOZ	5MG	A080336	002	
SCHERER LABS	5MG	A080371	001	
SPERTI	1MG	A080359	001	
	2.5MG	A080359	002	
	5MG	A080359	003	
SUN PHARM INDUSTRIES	50MG	A086596	001	
SUPERPHARM	5MG	A088865	001	Oct 25, 1984
	10MG	A088866	001	Oct 25, 1984
	20MG	A088867	001	Oct 25, 1984
TEVA	5MG	A080397	001	
UDL	5MG	A087984	001	Jan 18, 1983
	10MG	A087985	001	Jan 18, 1983
	20MG	A087986	001	Jan 18, 1983
UPSHER SMITH	5MG	A087471	001	
	20MG	A087470	001	
VALEANT PHARM INTL	5MG	A080237	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-390(of 478)

** See List Footnote

PREDNISONE

TABLET; ORAL

PREDNISONE

VANGARD	5MG	A087682	001	Jan 15, 1982
	20MG	A087701	001	Jan 15, 1982
VITARINE	5MG	A080334	001	
	5MG	A080506	001	
WATSON LABS	5MG	A085084	002	
	10MG	A087773	001	Jul 13, 1982
	20MG	A086813	001	
	50MG	A086867	001	
	50MG	A087772	001	Jul 13, 1982
WHITEWORTH TOWN PLSN	2.5MG	A084913	001	
	5MG	A080343	001	
	10MG	A089028	001	Jul 24, 1986
	20MG	A084913	002	
SERVISONE				
LEDERLE	5MG	A080223	001	

PREGABALIN

CAPSULE; ORAL

PREGABALIN

LUPIN LTD	25MG	A091040	001	May 03, 2022
	50MG	A091040	002	May 03, 2022
	75MG	A091040	003	May 03, 2022
	100MG	A091040	004	May 03, 2022
	150MG	A091040	005	May 03, 2022
	200MG	A091040	006	May 03, 2022
	225MG	A091040	007	May 03, 2022
	300MG	A091040	008	May 03, 2022
MYLAN	25MG	A091228	001	Sep 20, 2019
	50MG	A091228	002	Sep 20, 2019
	75MG	A091228	003	Sep 20, 2019
	100MG	A091228	004	Sep 20, 2019
	150MG	A091228	005	Sep 20, 2019
	200MG	A091228	006	Sep 20, 2019
	225MG	A091228	007	Sep 20, 2019
	300MG	A091228	008	Sep 20, 2019
TABLET, EXTENDED RELEASE; ORAL				
PREGABALIN				
ALVOGEN	82.5MG	A211687	001	Jul 06, 2021
	165MG	A211687	002	Jul 06, 2021
	330MG	A211687	003	Jul 06, 2021
MYLAN	82.5MG	A211948	001	Apr 13, 2021
	165MG	A211967	001	Nov 04, 2021
	330MG	A211431	001	Jul 02, 2021

PRILOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

CITANEST

+ ASTRAZENECA	1% **	N014763	004	
+	2% **	N014763	005	
+	3% **	N014763	003	
CITANEST PLAIN				
+ ASTRAZENECA	4% **	N014763	007	
CITANEST PLAIN DENTAL				
+ DENTSPLY PHARM	4%	N021382	001	

PRIMAQUINE PHOSPHATE

TABLET; ORAL

PRIMAQUINE PHOSPHATE

ALVOGEN	EQ 15MG BASE	A203924	001	Feb 03, 2014

PRIMIDONE

SUSPENSION; ORAL

MYSOLINE

+ NURO PHARMA	250MG/5ML	N010401	001	

TABLET; ORAL

PRIMIDONE

DR REDDYS LABS LTD	50MG	A040862	001	Oct 03, 2008
	250MG	A040862	002	Oct 03, 2008

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-391(of 478)

** See List Footnote

PRIMIDONE

TABLET;ORAL

PRIMIDONE

HIKMA INTL PHARMS	50MG	A040667 001	Jul 27, 2006
	250MG	A040667 002	Jul 27, 2006
IMPAX LABS	50MG	A040717 001	Feb 12, 2008
	250MG	A040717 002	Feb 12, 2008
WATSON LABS	250MG	A085052 001	

PROBENECID

TABLET;ORAL

BENEMID

+ MERCK

500MG **

N007898 004

PROBENECID

AUROBINDO PHARMA USA	500MG	A084211 002	
IVAX SUB TEVA PHARMS	500MG	A083740 001	May 09, 1984
LEDERLE	500MG	A086917 001	
WATSON LABS	500MG	A086150 002	Apr 23, 1982

PROBUCOL

TABLET;ORAL

LORELCO

SANOFI AVENTIS US	250MG	N017535 001	
	500MG	N017535 002	Jul 06, 1988

PROCAINAMIDE HYDROCHLORIDE

CAPSULE;ORAL

PROCAINAMIDE HYDROCHLORIDE

ANI PHARMS	250MG	A089219 001	Jul 01, 1986
	375MG	A089219 002	Jul 01, 1986
	500MG	A089219 003	Jul 01, 1986
ASCOT	250MG	A087542 001	Jan 08, 1982
	375MG	A087697 001	Mar 01, 1983
	500MG	A087543 001	Jan 08, 1982
IVAX SUB TEVA PHARMS	250MG	A084604 001	
	375MG	A084595 001	
	500MG	A084606 001	
LANNETT	250MG	A083693 001	
	500MG	A084696 001	
LEDERLE	250MG	A086942 001	
	375MG	A086952 001	
	500MG	A086943 001	
ROXANE	250MG	A088989 001	Apr 26, 1985
	500MG	A088990 001	Apr 26, 1985
VANGARD	250MG	A087643 001	Jun 01, 1982
	500MG	A087875 001	Jun 01, 1982
WATSON LABS	250MG	A083287 001	
	250MG	A083795 001	
	250MG	A085167 001	
	375MG	A084403 001	
	375MG	A087020 001	
	500MG	A084280 001	
	500MG	A084357 001	
	500MG	A087021 001	

PROCAN

PARKE DAVIS	250MG	A085804 001	
	375MG	A087502 001	
	500MG	A085079 001	

PROCAPAN

PANRAY	250MG	A083553 002	

PRONESTYL

+ APOTHECON	250MG **	N007335 001	
+	375MG **	N007335 004	
+	500MG **	N007335 003	

INJECTABLE;INJECTION

PROCAINAMIDE HYDROCHLORIDE

ABRAXIS PHARM	100MG/ML	A089415 001	Nov 17, 1986
	500MG/ML	A089416 001	Nov 17, 1986
HOSPIRA	500MG/ML	A089537 001	Aug 25, 1987
INTL MEDICATION	500MG/ML	A088637 001	Jul 31, 1984
PHARMAFAIR	100MG/ML	A088824 001	Nov 20, 1985

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-392(of 478)

** See List Footnote

PROCAINAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

PROCAINAMIDE HYDROCHLORIDE

	500MG/ML	A088830	001	Nov 20, 1985
SMITH AND NEPHEW	100MG/ML	A088530	001	Mar 04, 1985
	500MG/ML	A088531	001	Mar 04, 1985
SOLOPAK	500MG/ML	A088532	001	Mar 04, 1985
WARNER CHILCOTT	100MG/ML	A089528	001	May 03, 1988
	500MG/ML	A089529	001	May 03, 1988
WATSON LABS	100MG/ML	A087079	001	
	500MG/ML	A087080	001	
WEST-WARD PHARMS INT	100MG/ML	A089029	001	Apr 17, 1986
	500MG/ML	A089030	001	Apr 17, 1986

PRONESTYL

+	APOTHECON	100MG/ML	**	N007335	002
+		500MG/ML	**	N007335	005

TABLET; ORAL

PRONESTYL

APOTHECON	250MG	N017371	001	
	375MG	N017371	002	
	500MG	N017371	003	

TABLET, EXTENDED RELEASE; ORAL

PROCAINAMIDE HYDROCHLORIDE

ANI PHARMS	250MG	A088958	001	Dec 02, 1985
	250MG	A089369	001	Aug 14, 1987
	500MG	A088959	001	Dec 02, 1985
	500MG	A088974	001	Jul 22, 1985
	500MG	A089369	002	Jan 09, 1987
	750MG	A089369	003	Aug 14, 1987
	750MG	A089438	001	Mar 23, 1987
	1GM	A040111	001	Dec 13, 1996
INWOOD LABS	500MG	A089840	001	Mar 06, 1989
SANDOZ	500MG	A089284	001	Jun 23, 1986
WATSON LABS	250MG	A088533	001	Dec 03, 1984
	250MG	A089026	001	Oct 22, 1985
	500MG	A088534	001	Dec 03, 1984
	500MG	A089027	001	Oct 22, 1985
	750MG	A088535	001	Nov 03, 1984
	750MG	A089042	001	Oct 22, 1985
	1GM	A089520	001	Jan 15, 1987

PROCAN SR

+	PARKE DAVIS	250MG	A086468	001
+	PARKEDALE	500MG	A086065	001
+		750MG	A087510	001
		1GM	A088489	001

PROCANBID

KING PHARMS	500MG	N020545	001	Jan 31, 1996
	1GM	N020545	002	Jan 31, 1996

PRONESTYL-SR

APOTHECON	500MG	A087361	001	

PROCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

NOVOCAIN

HOSPIRA	1%	A085362	003	
	2%	A085362	004	
	10%	A086797	001	

PROCAINE HYDROCHLORIDE

ABRAXIS PHARM	1%	A080384	002	
	1%	A080421	001	
	2%	A080384	003	
	2%	A080421	002	
BEL MAR	1%	A080711	001	
	2%	A080756	001	
ELKINS SINN	1%	A083315	001	
	2%	A083315	002	
GD SEARLE LLC	1%	A086202	001	
	2%	A086202	002	
HOSPIRA	1%	A080416	001	
	2%	A080416	002	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-393(of 478)

** See List Footnote

PROCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

PROCAINE HYDROCHLORIDE

MILES

1%

A080415 001

2%

A080415 002

WATSON LABS

1%

A080658 001

1%

A083535 001

2%

A080658 002

2%

A083535 002

PROCAINE HYDROCHLORIDE; TETRACYCLINE HYDROCHLORIDE

INJECTABLE; INJECTION

ACHROMYCIN

LEDERLE

40MG/VIAL; 100MG/VIAL

N050276 001

40MG/VIAL; 250MG/VIAL

N050276 003

TETRACYN

PFIZER

40MG/VIAL; 100MG/VIAL

A060285 002

40MG/VIAL; 250MG/VIAL

A060285 003

PROCAINE MERETHOXYLLINE; THEOPHYLLINE

INJECTABLE; INJECTION

DICURIN PROCAINE

LILLY

100MG/ML; 50MG/ML

N008869 001

PROCHLORPERAZINE

SUPPOSITORY; RECTAL

COMPAZINE

GLAXOSMITHKLINE

2.5MG **

N011127 003

5MG **

N011127 001

25MG **

N011127 002

PROCHLORPERAZINE

ABLE

2.5MG

A040407 001 Jul 11, 2001

5MG

A040407 002 Jul 11, 2001

25MG

A040407 003 Jul 11, 2001

PROCHLORPERAZINE EDISYLATE

CONCENTRATE; ORAL

COMPAZINE

+

GLAXOSMITHKLINE

EQ 10MG BASE/ML

N011276 001

PROCHLORPERAZINE

ALPHARMA US PHARMS

EQ 10MG BASE/ML

A087153 001 Jun 08, 1982

PROCHLORPERAZINE EDISYLATE

MORTON GROVE

EQ 10MG BASE/ML

A088598 001 Oct 25, 1984

INJECTABLE; INJECTION

COMPAZINE

+

GLAXOSMITHKLINE

EQ 5MG BASE/ML **

N010742 002

PROCHLORPERAZINE

BAXTER HLTHCARE

EQ 5MG BASE/ML

A087759 001 Oct 01, 1982

PROCHLORPERAZINE EDISYLATE

HIKMA

EQ 5MG BASE/ML

A089523 001 May 03, 1988

HOSPIRA

EQ 5MG BASE/ML

A089703 001 Apr 07, 1988

MARSAM PHARMS LLC

EQ 5MG BASE/ML

A089675 001 Dec 05, 1988

SMITH AND NEPHEW

EQ 5MG BASE/ML

A089251 001 Dec 04, 1986

TEVA PARENTERAL

EQ 5MG BASE/ML

A040505 001 May 30, 2003

WATSON LABS

EQ 5MG BASE/ML

A089530 001 Jul 08, 1987

EQ 5MG BASE/ML

A089605 001 Jul 08, 1987

EQ 5MG BASE/ML

A089606 001 Jul 08, 1987

WYETH AYERST

EQ 5MG BASE/ML

A086348 001

SYRUP; ORAL

COMPAZINE

GLAXOSMITHKLINE

EQ 5MG BASE/5ML

N011188 001

PROCHLORPERAZINE EDISYLATE

ALPHARMA US PHARMS

EQ 5MG BASE/5ML

A087154 001 Sep 01, 1982

MORTON GROVE

EQ 5MG BASE/5ML

A088597 001 Oct 25, 1984

PROCHLORPERAZINE MALEATE

CAPSULE, EXTENDED RELEASE; ORAL

COMPAZINE

GLAXOSMITHKLINE

EQ 10MG BASE

N011000 001

EQ 10MG BASE

N021019 001 Oct 06, 1999

EQ 15MG BASE

N011000 002

EQ 15MG BASE

N021019 002 Oct 06, 1999

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-394(of 478)

** See List Footnote

PROCHLORPERAZINE MALEATECAPSULE, EXTENDED RELEASE;ORAL
COMPAZINEEQ 30MG BASE N011000 003
EQ 75MG BASE N011000 004

TABLET;ORAL

COMPAZINE

+ GLAXOSMITHKLINE EQ 5MG BASE ** N010571 001
+ EQ 10MG BASE ** N010571 002
+ EQ 25MG BASE ** N010571 003

PROCHLORPERAZINE

WATSON LABS

EQ 5MG BASE A085580 001
EQ 10MG BASE A085178 001
EQ 25MG BASE A085579 001

PROCHLORPERAZINE MALEATE

CHARTWELL RX

EQ 5MG BASE A040101 001 Jul 19, 1996
EQ 10MG BASE A040101 002 Jul 19, 1996
EQ 25MG BASE A040101 003 Jul 19, 1996

DURAMED PHARMS BARR

EQ 5MG BASE A040207 001 May 01, 1997
EQ 5MG BASE A089484 001 Jan 20, 1987
EQ 10MG BASE A040207 002 May 01, 1997
EQ 10MG BASE A089485 001 Jan 20, 1987
EQ 25MG BASE A089486 001 Jan 20, 1987

IVAX SUB TEVA PHARMS

EQ 5MG BASE A040162 001 Jan 20, 1998
EQ 10MG BASE A040162 002 Jan 20, 1998

MYLAN

EQ 5MG BASE A040185 002 Oct 28, 1996
EQ 10MG BASE A040185 001 Oct 28, 1996

TEVA PHARMS

EQ 5MG BASE A040120 001 Jul 11, 1996
EQ 10MG BASE A040120 002 Jul 11, 1996PROCYCLIDINE HYDROCHLORIDE

TABLET;ORAL

KEMADRIN

MONARCH PHARMS

2MG N009818 005
5MG N009818 003PROGESTERONE

CAPSULE;ORAL

PROGESTERONE

TEVA PHARMS

100MG A202121 001 Feb 29, 2012
200MG A202121 002 Feb 29, 2012

PROMETRIUM

VIRTUS PHARMS

300MG N019781 003 Oct 15, 1999

INJECTABLE;INJECTION

PROGESTERONE

+ ACTAVIS LABS UT INC

50MG/ML N017362 002

AM REGENT

50MG/ML A090845 001 Jun 22, 2009

LILLY

25MG/ML N009238 002

50MG/ML N009238 001

INSERT, EXTENDED RELEASE;INTRAUTERINE

PROGESTASERT

ALZA

38MG N017553 001

SYSTEM;VAGINAL

MILPROSA

+ FERRING PHARMS INC

1.78GM N201110 001 Apr 29, 2020

PROMAZINE HYDROCHLORIDE

CONCENTRATE;ORAL

SPARINE

WYETH AYERST

30MG/ML N010942 001

100MG/ML N010942 004

INJECTABLE;INJECTION

PROMAZINE HYDROCHLORIDE

WATSON LABS

25MG/ML A084510 001

50MG/ML A084517 001

SPARINE

HIKMA

25MG/ML N010349 008

50MG/ML N010349 006

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-395(of 478)

** See List Footnote

PROMAZINE HYDROCHLORIDE

SYRUP; ORAL

SPARINE

WYETH AYERST

10MG/5ML

N010942 003

TABLET; ORAL

SPARINE

WYETH AYERST

10MG

N010348 006

25MG

N010348 001

50MG

N010348 002

100MG

N010348 003

200MG

N010348 004

PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

PHENERGAN

WYETH AYERST

25MG/ML

N008857 002

50MG/ML

N008857 003

PROMETHAZINE HYDROCHLORIDE

ABBOTT

25MG/ML

A084223 001

50MG/ML

A084222 001

AKORN

25MG/ML

A083955 002

50MG/ML

A083955 001

AM REGENT

25MG/ML

A040515 001 Mar 19, 2003

BEDFORD LABS

25MG/ML

A040524 001 Mar 17, 2004

50MG/ML

A040524 002 Mar 17, 2004

HOSPIRA

25MG/ML

A040372 001 Jun 08, 2000

50MG/ML

A040372 002 Jun 08, 2000

50MG/ML

A083838 002

MARSAM PHARMS LLC

25MG/ML

A089463 001 May 02, 1988

50MG/ML

A089477 001 May 02, 1988

MYLAN INSTITUTIONAL

25MG/ML

A040471 001 Nov 21, 2002

SANDOZ

25MG/ML

A040593 001 Nov 08, 2006

50MG/ML

A040593 002 Nov 08, 2006

TEVA PHARMS USA

25MG/ML **

A040454 001 Aug 22, 2002

50MG/ML **

A040454 002 Aug 22, 2002

WATSON LABS

25MG/ML

A083532 001

25MG/ML

A084591 001

50MG/ML

A080629 002

50MG/ML

A083532 002

WOCKHARDT

25MG/ML

A040785 001 Sep 26, 2008

50MG/ML

A040785 002 Sep 26, 2008

ZIPAN-25

ALTANA

25MG/ML

A083997 001

ZIPAN-50

ALTANA

50MG/ML

A083997 002

SUPPOSITORY; RECTAL

PHENERGAN

+ MYLAN

12.5MG **

N010926 002

+

25MG **

N010926 001

+

50MG **

N011689 001

PROMETHACON

POLYMEDICA

25MG

A084901 001

50MG

A084902 001

PROMETHAZINE HYDROCHLORIDE

ABLE

12.5MG

A040504 001 Apr 11, 2003

25MG

A040504 002 Apr 11, 2003

50MG

A040449 001 Feb 27, 2003

WATSON LABS INC

12.5MG

A040479 001 Jun 24, 2003

25MG

A040479 002 Jun 24, 2003

SYRUP; ORAL

MYMETHAZINE FORTIS

USL PHARMA

25MG/5ML

A087996 001 Jan 18, 1983

PROMETH FORTIS

ALPHARMA US PHARMS

25MG/5ML

A084772 001

PROMETH PLAIN

ACTAVIS MID ATLANTIC

6.25MG/5ML

A085953 001

PROMETHAZINE

CENCI

6.25MG/5ML

A089013 001 Sep 20, 1985

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-396(of 478)

** See List Footnote

PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETHAZINE HYDROCHLORIDE

KV PHARM 6.25MG/5ML A085388 001

25MG/5ML A085385 001

PHARM ASSOC 6.25MG/5ML A087518 001

WHITEWORTH TOWN PLSN 6.25MG/5ML A086395 001

PROMETHAZINE HYDROCHLORIDE PLAIN

+ ANI PHARMS 6.25MG/5ML ** N008381 004 Apr 18, 1984

+ 25MG/5ML ** N008381 003

TABLET; ORAL

PHENERGAN

+ DELCOR ASSET CORP 12.5MG ** N007935 002

+ 25MG ** N007935 003

+ 50MG ** N007935 004

PROMETHAZINE HYDROCHLORIDE

ABBOTT 12.5MG A084160 001

25MG A084166 001

50MG A084539 001

ABLE 12.5MG A040558 001 Jul 01, 2004

25MG A040558 002 Jul 01, 2004

50MG A040558 003 Jul 01, 2004

CHARTWELL MOLECULAR 12.5MG A080949 001

25MG A080949 002

50MG A080949 003

IMPAX LABS 12.5MG A040791 002 Feb 12, 2008

25MG A040791 003 Feb 12, 2008

25MG A084214 002 Jul 07, 1982

50MG A040791 001 May 20, 2008

INVATECH 12.5MG A084233 001

25MG A085146 001

50MG A085146 002

IVAX SUB TEVA PHARMS 12.5MG A083604 001

25MG A083603 001

50MG A083613 001

MYLAN 12.5MG A091054 001 Aug 30, 2011

25MG A091054 002 Aug 30, 2011

50MG A091054 003 Aug 30, 2011

PVT FORM 12.5MG A083214 001

25MG A083658 001

SANDOZ 12.5MG A084176 002 May 22, 2009

SUN PHARM INDUSTRIES 12.5MG A084555 001

25MG A084554 001

50MG A084557 001

TABLICAPS 12.5MG A084080 001

25MG A084027 001

TEVA 25MG A089109 001 Sep 10, 1985

WATSON LABS 12.5MG A083401 001

12.5MG A083712 001

12.5MG A085986 001

25MG A083204 001

25MG A085684 001

50MG A083403 001

50MG A085664 001

REMSSED

BRISTOL MYERS SQUIBB 25MG A083176 002

50MG A083176 001

PROPAFENONE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

PROPAFENONE HYDROCHLORIDE

MYLAN 225MG A203803 001 Apr 29, 2016

325MG A203803 002 Apr 29, 2016

425MG A203803 003 Apr 29, 2016

TABLET; ORAL

PROPAFENONE HYDROCHLORIDE

NESHER PHARMS 150MG A076193 001 Feb 07, 2002

225MG A076193 002 Feb 07, 2002

300MG A076193 003 Feb 07, 2002

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-397(of 478)

** See List Footnote

PROPAFENONE HYDROCHLORIDE

TABLET; ORAL

RYTHMOL

+	GLAXOSMITHKLINE LLC	150MG **
+		225MG **
+		300MG **

N019151	001	Nov 27, 1989
N019151	003	Nov 20, 1992
N019151	002	Nov 27, 1989

PROPANTHELINE BROMIDE

INJECTABLE; INJECTION

PRO-BANTHINE

GD SEARLE LLC

30MG/VIAL

N008843 001

TABLET; ORAL

PRO-BANTHINE

+	SHIRE	7.5MG **
+		15MG **

N008732	003
N008732	002

PROPANTHELINE BROMIDE

ASCOT

15MG

A087663 001 Oct 25, 1982

HEATHER

15MG

A085780 001

HIKMA

7.5MG

A080927 001

15MG

A080927 002

IMPAX LABS

15MG

A084541 002

MYLAN

15MG

A083706 001

PAR PHARM

15MG

A088377 001 Dec 08, 1983

PVT FORM

15MG

A080977 001

SANDOZ

15MG

A080928 001

TABLICAPS

15MG

A084428 001

WATSON LABS

15MG

A083029 002

15MG

A083151 001

PROPARACAINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

KAINAIR

PHARMAFAIR

0.5%

A088087 001 Jun 07, 1983

OPHTHAINE

+	APOTHECON	0.5% **

N008883 001

OPHTHETIC

+	ALLERGAN	0.5% **

N012583 001

PARACAINE

OPTOPICS

0.5%

A087681 001 Aug 05, 1982

PROPARACAINE HYDROCHLORIDE

SOLA BARNES HIND

0.5%

A084144 001

0.5%

A084151 001

PROPIOLACTONE

SOLUTION; IRRIGATION

BETAPRONE

FOREST LABS

N/A

N011657 001

PROPIOMAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

LARGON

HIKMA

20MG/ML

N012382 002

PROPOFOL

INJECTABLE; INJECTION

DIPRIVAN

FRESENIUS KABI USA

10MG/ML

N019627 001 Oct 02, 1989

PROPOFOL

TEVA PARENTERAL

10MG/ML

A075392 001 Sep 19, 2000

PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL

DARVON

XANODYNE PHARM

32MG

N010997 001

65MG

N010997 003

DOLENE

HERITAGE PHARMS INC

65MG

A080530 001

KESSO-GESIC

MK LABS

65MG

A083544 001

PROPHENE 65

HALSEY

65MG

A083538 002

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-398(of 478)

** See List Footnote

PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL

PROPOXYPHENE HYDROCHLORIDE

ALRA	65MG	A083184	001	
IMPAX LABS	65MG	A083317	001	
IVAX SUB TEVA PHARMS	32MG	A083597	001	
MUTUAL PHARM	65MG	A083186	001	
MYLAN	32MG	A083528	001	
	65MG	A040569	001	Dec 16, 2004
	65MG	A083299	001	
NEXGEN PHARMA INC	65MG	A083185	001	
PAR PHARM	65MG	A080269	001	
PUREPAC PHARM	65MG	A083278	001	
PVT FORM	32MG	A083464	001	
	65MG	A083113	001	
ROXANE	32MG	A083089	001	
	65MG	A083089	002	
SANDOZ	32MG	A084014	001	
	65MG	A083125	002	
	65MG	A083688	001	
	65MG	A083870	002	
	65MG	A086495	001	
TEVA	65MG	A088615	001	Oct 22, 1984
VALEANT PHARM INTL	65MG	A080783	001	
VINTAGE PHARMS	65MG	A040908	001	Jul 17, 2009
WATSON LABS	65MG	A080908	002	
	65MG	A085190	001	
WEST WARD	65MG	A083501	001	
WHITEWORTH TOWN PLSN	65MG	A084551	001	
PROPOXYPHENE HYDROCHLORIDE	65			
WARNER CHILCOTT	65MG	A083786	001	

PROPOXYPHENE NAPSYLATE

SUSPENSION; ORAL

DARVON-N

AAIPHARMA LLC	50MG/5ML	N016861	001	

TABLET; ORAL

DARVON-N

XANODYNE PHARM	100MG	N016862	002	

PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

PROPRANOLOL HYDROCHLORIDE

INWOOD LABS	60MG	A072499	001	Apr 11, 1989
	80MG	A072500	001	Apr 11, 1989
	120MG	A072501	001	Apr 11, 1989
	160MG	A072502	001	Apr 11, 1989
MYLAN	60MG	A078022	001	Feb 15, 2007
	80MG	A078022	002	Feb 15, 2007
	120MG	A078022	003	Feb 15, 2007
	160MG	A078022	004	Feb 15, 2007
UPSHER SMITH LABS	60MG	A078311	001	Mar 06, 2009
	80MG	A078311	002	Mar 06, 2009
	120MG	A078311	003	Mar 06, 2009
	160MG	A078311	004	Mar 06, 2009

CONCENTRATE; ORAL

PROPRANOLOL HYDROCHLORIDE INTENSOL

ROXANE	80MG/ML	A071388	001	May 15, 1987

INJECTABLE; INJECTION

PROPRANOLOL HYDROCHLORIDE

+	BAXTER HLTHCARE CORP	1MG/ML **	N016419	001	
	CHARTWELL INJECTABLE	1MG/ML	A075792	001	Aug 29, 2000
	FOSUN PHARMA	1MG/ML	A076400	001	Feb 26, 2003
	SMITH AND NEPHEW	1MG/ML	A070135	001	Apr 15, 1986
		1MG/ML	A070137	001	Apr 15, 1986
	SOLOPAK	1MG/ML	A070136	001	Apr 15, 1986

SOLUTION; ORAL

PROPRANOLOL HYDROCHLORIDE

PAI HOLDINGS PHARM	20MG/5ML	A071984	001	Mar 03, 1989
	40MG/5ML	A071985	001	Mar 03, 1989

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-399(of 478)

** See List Footnote

PROPRANOLOL HYDROCHLORIDE

SUSPENSION;ORAL

INDERAL

WYETH AYERST

10MG/ML

N019536 001 Dec 12, 1986

TABLET;ORAL

INDERAL

+ WYETH PHARMS

10MG **

N016418 001

+

20MG **

N016418 003

+

40MG **

N016418 002

+

60MG **

N016418 009 Oct 18, 1982

+

80MG **

N016418 004

+

90MG **

N016418 010 Oct 18, 1982

PROPRANOLOL HYDROCHLORIDE

ANI PHARMS

60MG

A071791 001 Jul 15, 1987

90MG

A071977 001 Apr 06, 1988

CHARTWELL RX

10MG

A070663 001 Jun 13, 1986

20MG

A070664 001 Jun 13, 1986

40MG

A070665 001 Jun 13, 1986

60MG

A070666 001 Oct 10, 1986

80MG

A070667 001 Jun 13, 1986

DAVA PHARMS INC

10MG

A070125 001 Jul 30, 1985

20MG

A070126 001 Jul 30, 1985

40MG

A070127 001 Jul 30, 1985

60MG

A071495 001 Dec 31, 1987

80MG

A070128 001 Jul 30, 1985

90MG

A071496 001 Dec 31, 1987

DURAMED PHARMS BARR

10MG

A070306 001 Sep 09, 1985

20MG

A070307 001 Sep 09, 1985

40MG

A070308 001 Sep 09, 1985

60MG

A070309 001 Oct 01, 1986

80MG

A070310 001 Sep 09, 1985

90MG

A071327 001 Oct 01, 1986

INTERPHARM

10MG

A071368 001 May 05, 1987

20MG

A071369 001 May 05, 1987

40MG

A071370 001 May 05, 1987

80MG

A071371 001 May 05, 1987

IVAX SUB TEVA PHARMS

10MG

A072063 001 Jul 29, 1988

20MG

A072066 001 Jul 29, 1988

40MG

A072067 001 Jul 29, 1988

60MG

A072068 001 Jul 29, 1988

80MG

A072069 001 Jul 29, 1988

LEDERLE

10MG

A072117 001 Jun 23, 1988

20MG

A072118 001 Jun 23, 1988

40MG

A072119 001 Jun 23, 1988

80MG

A072120 001 Jun 23, 1988

MYLAN

60MG

A072275 001 Jun 09, 1989

PUREPAC PHARM

10MG

A070814 001 Nov 03, 1986

20MG

A070815 001 Nov 03, 1986

40MG

A070816 001 Nov 03, 1986

60MG

A070817 001 Nov 03, 1986

80MG

A070757 001 Nov 03, 1986

ROXANE

10MG

A070516 001 Jul 07, 1986

20MG

A070517 001 Jul 07, 1986

40MG

A070518 001 Jul 07, 1986

60MG

A070519 001 Sep 24, 1986

80MG

A070520 001 Jul 07, 1986

90MG

A070521 001 Sep 24, 1986

SANDOZ

10MG

A071658 001 Jul 05, 1988

20MG

A071687 001 Jul 05, 1988

40MG

A071688 001 Jul 05, 1988

60MG

A072197 001 Jul 05, 1988

80MG

A071689 001 Jul 05, 1988

90MG

A072198 001 Jul 05, 1988

SCHERING

10MG

A070120 001 Aug 06, 1985

20MG

A070121 001 Aug 06, 1985

40MG

A070122 001 Aug 06, 1985

60MG

A070123 001 Oct 29, 1986

80MG

A070124 001 Aug 06, 1985

STRIDES PHARMA

90MG

A071288 001 Oct 22, 1986

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-400(of 478)

** See List Footnote

PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL

PROPRANOLOL HYDROCHLORIDE

SUPERPHARM	10MG	A071515	001	Jun 08, 1988
	20MG	A071516	001	Jun 08, 1988
	40MG	A071517	001	Jun 08, 1988
	80MG	A071518	001	Jun 08, 1988
TEVA	10MG	A070232	001	Oct 07, 1987
	20MG	A070233	001	Jun 23, 1986
	40MG	A070234	001	Jun 23, 1986
WARNER CHILCOTT	10MG	A070438	001	Sep 15, 1986
	20MG	A070439	001	Sep 15, 1986
	40MG	A070440	001	Sep 15, 1986
	60MG	A070441	001	Sep 24, 1986
	80MG	A070442	001	Sep 15, 1986
WATSON LABS	10MG	A070140	001	Jul 30, 1985
	10MG	A070378	001	Mar 19, 1987
	20MG	A070141	001	Jul 30, 1985
	20MG	A070379	001	Mar 19, 1987
	40MG	A070142	001	Jul 30, 1985
	40MG	A070380	001	Mar 19, 1987
	60MG	A070143	001	Jan 15, 1987
	60MG	A070178	002	Apr 23, 2018
	60MG	A070381	001	Mar 19, 1987
	60MG	A071098	001	Oct 06, 1986
	80MG	A070144	001	Jul 30, 1985
	80MG	A070382	001	Mar 19, 1987
	80MG	A070551	001	Jul 10, 1986
	90MG	A071183	001	Oct 06, 1986
	90MG	A071792	001	Jul 15, 1987
WATSON LABS TEVA	10MG	A070548	001	Jul 10, 1986
	20MG	A070549	001	Apr 11, 1986
	40MG	A070550	001	Apr 11, 1986

PROPYLIODONE

SUSPENSION; INTRATRACHEAL

DIONOSIL AQUEOUS

GLAXOSMITHKLINE	50%	N009309	001

DIONOSIL OILY

GLAXOSMITHKLINE	60%	N009309	002

PROPYLTHIOURACIL

TABLET; ORAL

PROPYLTHIOURACIL

ABBOTT	50MG	A084075	001
ANABOLIC	50MG	A080285	001
ANI PHARMS	50MG	A080215	001
CHARTWELL MOLECULAR	50MG	A080016	001
CHARTWELL RX	50MG	A084543	001
HALSEY	50MG	A080015	001
IMPAX LABS	50MG	A080159	001
LILLY	50MG	N006213	001
SUN PHARM INDUSTRIES	50MG	A083982	001
TABLICAPS	50MG	A080840	001
WATSON LABS	50MG	A080932	001
	50MG	A085201	001

PROTAMINE SULFATE

INJECTABLE; INJECTION

PROTAMINE SULFATE

HIKMA	10MG/ML	A089474	001	Nov 05, 1986
	10MG/ML	A089475	001	Nov 05, 1986
+ LILLY	10MG/ML **	N006460	002	
PHARMACIA AND UPJOHN	50MG/VIAL	N007413	001	
	250MG/VIAL	N007413	002	Aug 02, 1984

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-401(of 478)

** See List Footnote

PROTEIN HYDROLYSATE

INJECTABLE; INJECTION

AMINOSOL 5%

ABBVIE

5%

N005932 012 Jan 31, 1985

HYPROTIGEN 5%

B BRAUN

5%

N006170 003 Jan 10, 1984

PROTIRELIN

INJECTABLE; INJECTION

THYPINONE

ABBOTT

0.5MG/ML

N017638 001

THYREL TRH

FERRING

0.5MG/ML

N018087 001

PROTOKYLOL HYDROCHLORIDE

TABLET; ORAL

VENTAIRE

SANOFI AVENTIS US

2MG

A083459 001

PROTRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

VIVACTIL

HERITAGE PHARMA AVET

5MG

A073644 001 Aug 24, 1995

10MG

A073645 001 Aug 24, 1995

TEVA WOMENS

5MG **

N016012 001

10MG **

N016012 002

PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

NOVAFED

SANOFI AVENTIS US

120MG

N017603 001

SUDAFED 12 HOUR

+

GLAXOSMITHKLINE

120MG **

N017941 002

TABLET, EXTENDED RELEASE; ORAL

SUDAFED 12 HOUR

MCNEIL CONS

120MG

A073585 001 Oct 31, 1991

PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

ACTIFED

GLAXOSMITHKLINE

120MG; 5MG

N018996 001 Jun 17, 1985

TRIPROLIDINE AND PSEUDOEPHEDRINE HYDROCHLORIDES

KV PHARM

120MG; 5MG

A071798 001 Mar 16, 1989

SYRUP; ORAL

ACTAHIST

CENCI

30MG/5ML; 1.25MG/5ML

A088344 001 Feb 09, 1984

HISTAFED

CENCI

30MG/5ML; 1.25MG/5ML

A088283 001 Apr 20, 1984

MYFED

USL PHARMA

30MG/5ML; 1.25MG/5ML

A088116 001 Mar 04, 1983

TRILITRON

NEWTRON PHARMS

30MG/5ML; 1.25MG/5ML

A088474 001 Feb 12, 1985

TABLET; ORAL

ALLERFED

PVT FORM

60MG; 2.5MG

A088860 001 Jan 31, 1985

CORPHED

FOSUN PHARMA

60MG; 2.5MG

A088602 001 Apr 11, 1985

PSEUDOEPHEDRINE HYDROCHLORIDE AND TRIPROLIDINE HYDROCHLORIDE

SANDOZ

60MG; 2.5MG

A088193 001 May 17, 1983

TRILITRON

NEWTRON PHARMS

60MG; 2.5MG

A088515 001 Jan 09, 1985

TRIPHED

TEVA

60MG; 2.5MG

A088630 001 May 17, 1984

TRIPROLIDINE AND PSEUDOEPHEDRINE

WATSON LABS

60MG; 2.5MG

A088318 002 Jan 13, 1984

WEST WARD

60MG; 2.5MG

A088117 001 Apr 19, 1983

TRIPROLIDINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

IVAX SUB TEVA PHARMS

60MG; 2.5MG

A085273 001 Dec 12, 1984

SUPERPHARM

60MG; 2.5MG

A088578 001 Feb 21, 1985

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-402(of 478)

** See List Footnote

PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

TRIPROLIDINE AND PSEUDOEPHEDRINE HYDROCHLORIDES

KV PHARM

120MG;5MG

A072758 001 Nov 25, 1991

PSEUDOEPHEDRINE POLISTIREX

SUSPENSION, EXTENDED RELEASE;ORAL

PSEUDO-12

UCB INC

EQ 60MG HYDROCHLORIDE/5ML

N019401 001 Jun 19, 1987

PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE;ORAL

AFRINOL

+

SCHERING PLOUGH

120MG

N018191 001

PYRIDOSTIGMINE BROMIDE

TABLET;ORAL

PYRIDOSTIGMINE BROMIDE

ANI PHARMS

30MG

A040512 002 Jul 20, 2005

60MG

A040512 001 Oct 08, 2003

IMPAX LABS INC

60MG

A040457 001 Dec 26, 2002

SOLVAY

30MG

A089572 001 Nov 27, 1990

US ARMY

30MG

N020414 001 Feb 05, 2003

PYRIDOXINE HYDROCHLORIDE

INJECTABLE;INJECTION

HEXA-BETALIN

LILLY

100MG/ML

A080854 001

PYRIDOXINE HYDROCHLORIDE

AKORN

100MG/ML

A087967 001 Oct 01, 1982

BEL MAR

100MG/ML

A080761 001

DELL LABS

50MG/ML

A083771 001

100MG/ML

A083772 001

DR REDDYS

100MG/ML

A080572 001

ELKINS SINN

100MG/ML

A080581 001

LUITPOLD

100MG/ML

A080669 001

MYLAN INSTITUTIONAL

100MG/ML

A204879 001 Jul 14, 2016

WATSON LABS

100MG/ML

A083760 001

PYRILAMINE MALEATE

TABLET;ORAL

PYRILAMINE MALEATE

IMPAX LABS

25MG

A080808 001

WATSON LABS

25MG

A085231 001

PYRIMETHAMINE; SULFADOXINE

TABLET;ORAL

FANSIDAR

ROCHE

25MG;500MG

N018557 001

PYRITHIONE ZINC

LOTION;TOPICAL

HEAD & SHOULDERS CONDITIONER

WARNER CHILCOTT

0.3%

N019412 002 Mar 10, 1986

PYRVINIUM PAMOATE

SUSPENSION;ORAL

POVAN

PARKE DAVIS

EQ 50MG BASE/5ML

N011964 001

TABLET;ORAL

POVAN

PARKE DAVIS

EQ 50MG BASE

N012485 002

QUAZEPAM

TABLET;ORAL

DORAL

GALT PHARMS

7.5MG

N018708 003 Feb 26, 1987

DISCONTINUED DRUG PRODUCT LIST

6-403(of 478)

** See List Footnote

QUETIAPINE FUMARATE

TABLET;ORAL

QUETIAPINE FUMARATE

ACTAVIS GRP PTC

EQ 25MG BASE

A201762 001 Feb 27, 2013

EQ 50MG BASE

A201762 002 Feb 27, 2013

EQ 100MG BASE

A201762 003 Feb 27, 2013

EQ 150MG BASE

A201762 004 Feb 27, 2013

EQ 200MG BASE

A201762 005 Feb 27, 2013

EQ 300MG BASE

A201762 006 Feb 27, 2013

EQ 400MG BASE

A201762 007 Feb 27, 2013

ALEMBIC PHARMS

EQ 25MG BASE

A203390 001 Oct 28, 2014

EQ 50MG BASE

A203390 002 Oct 28, 2014

EQ 100MG BASE

A203390 003 Oct 28, 2014

EQ 200MG BASE

A203390 004 Oct 28, 2014

EQ 300MG BASE

A203390 005 Oct 28, 2014

EQ 400MG BASE

A203390 006 Oct 28, 2014

JUBILANT GENERICS

EQ 25MG BASE

A203150 001 Nov 26, 2013

MYLAN PHARMS INC

EQ 25MG BASE

A090323 001 Mar 27, 2012

TORRENT PHARMS LTD

EQ 25MG BASE

A200363 001 Mar 27, 2012

EQ 50MG BASE

A200363 002 Mar 27, 2012

EQ 100MG BASE

A200363 003 Mar 27, 2012

EQ 200MG BASE

A200363 004 Mar 27, 2012

EQ 300MG BASE

A200363 005 Mar 27, 2012

EQ 400MG BASE

A200363 006 Mar 27, 2012

SEROQUEL

+ ASTRAZENECA

EQ 150MG BASE **

N020639 004 Dec 20, 1998

TABLET, EXTENDED RELEASE;ORAL

QUETIAPINE FUMARATE

AMNEAL PHARMS

EQ 400MG BASE

A211405 001 Oct 26, 2018

ANCHEN PHARMS

EQ 150MG BASE

A090757 001 Dec 01, 2017

EQ 200MG BASE

A090757 002 Dec 01, 2017

EQ 300MG BASE

A090757 003 Dec 01, 2017

EQ 400MG BASE

A090757 004 Dec 01, 2017

RISING

EQ 50MG BASE

A202228 001 Feb 02, 2021

EQ 150MG BASE

A202228 002 Feb 02, 2021

EQ 200MG BASE

A202228 003 Feb 02, 2021

EQ 300MG BASE

A202228 004 Feb 02, 2021

EQ 400MG BASE

A202228 005 Feb 02, 2021

QUINAPRIL HYDROCHLORIDE

TABLET;ORAL

ACCUPRIL

+ PFIZER PHARMS

EQ 5MG BASE

N019885 001 Nov 19, 1991

+

EQ 10MG BASE

N019885 002 Nov 19, 1991

+

EQ 20MG BASE

N019885 003 Nov 19, 1991

+

EQ 40MG BASE

N019885 004 Nov 19, 1991

QUINAPRIL HYDROCHLORIDE

ACTAVIS ELIZABETH

EQ 5MG BASE

A076459 001 Dec 22, 2004

EQ 10MG BASE

A076459 002 Dec 22, 2004

EQ 20MG BASE

A076459 003 Dec 22, 2004

EQ 40MG BASE

A076459 004 Dec 22, 2004

ACTAVIS LABS FL INC

EQ 5MG BASE

A076049 001 Jan 14, 2005

EQ 10MG BASE

A076049 002 Jan 14, 2005

EQ 20MG BASE

A076049 003 Jan 14, 2005

EQ 40MG BASE

A076049 004 Jan 14, 2005

ANI PHARMS

EQ 5MG BASE

A075504 001 Aug 24, 2007

EQ 10MG BASE

A075504 002 Aug 24, 2007

EQ 20MG BASE

A075504 003 Aug 24, 2007

EQ 40MG BASE

A075504 004 Aug 24, 2007

APOTEX INC

EQ 5MG BASE

A076240 001 Jan 26, 2006

EQ 10MG BASE

A076240 002 Jan 26, 2006

EQ 20MG BASE

A076240 003 Jan 26, 2006

EQ 40MG BASE

A076240 004 Jan 26, 2006

CHARTWELL RX

EQ 5MG BASE

A076803 001 Mar 02, 2005

EQ 10MG BASE

A076803 002 Mar 02, 2005

EQ 20MG BASE

A076803 003 Mar 02, 2005

EQ 40MG BASE

A076803 004 Mar 02, 2005

MYLAN

EQ 5MG BASE

A076036 001 Jan 28, 2005

EQ 5MG BASE

A076694 001 Dec 23, 2004

EQ 10MG BASE

A076036 002 Jan 28, 2005

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-404(of 478)

** See List Footnote

QUINAPRIL HYDROCHLORIDE

TABLET;ORAL

QUINAPRIL HYDROCHLORIDE

	EQ 10MG BASE	A076694 002	Dec 23, 2004
	EQ 20MG BASE	A076036 003	Jan 28, 2005
	EQ 20MG BASE	A076694 003	Dec 23, 2004
	EQ 40MG BASE	A076036 004	Jan 28, 2005
	EQ 40MG BASE	A076694 004	Dec 23, 2004
SUN PHARM INDS LTD	EQ 5MG BASE	A076607 001	Dec 15, 2004
	EQ 5MG BASE	A090800 001	Jun 18, 2009
	EQ 10MG BASE	A076607 002	Dec 15, 2004
	EQ 10MG BASE	A090800 002	Jun 18, 2009
	EQ 20MG BASE	A076607 003	Dec 15, 2004
	EQ 20MG BASE	A090800 003	Jun 18, 2009
	EQ 40MG BASE	A076607 004	Dec 15, 2004
	EQ 40MG BASE	A090800 004	Jun 18, 2009

QUINESTROL

TABLET;ORAL

ESTROVIS

PARKE DAVIS	0.1MG	N016768 002	
	0.2MG	N016768 003	

QUINETHAZONE

TABLET;ORAL

HYDROMOX

LEDERLE	50MG	N013264 001	

QUINETHAZONE; RESERPINE

TABLET;ORAL

HYDROMOX R

LEDERLE	50MG;0.125MG	N013927 001	

QUINIDINE GLUCONATE

INJECTABLE;INJECTION

QUINIDINE GLUCONATE

+ LILLY

80MG/ML

N007529 002 Feb 10, 1989

TABLET;ORAL

QUINACT

BAYER HLTHCARE	266MG	A085978 001	
	400MG	A086099 001	

TABLET, EXTENDED RELEASE;ORAL

DURAQUIN

WARNER CHILCOTT	330MG	N017917 001	

QUINAGLUTE

+ BAYER HLTHCARE

324MG **

N016647 001

QUINALAN

CHARTWELL MOLECULAR	324MG	A088081 001	Feb 10, 1986

QUINATIME

WATSON LABS	324MG	A087448 001	

QUINIDINE GLUCONATE

ANI PHARMS	324MG	A087810 001	Sep 29, 1982
ASCOT	324MG	A088582 001	Jun 17, 1985
CYCLE	324MG	A088431 001	Jan 06, 1984
HALSEY	324MG	A089476 001	Apr 10, 1987
RISING	324MG	A089894 001	Dec 15, 1988
SUPERPHARM	324MG	A089164 001	Nov 21, 1985
WATSON LABS	324MG	A087785 001	Jan 24, 1983

QUINIDINE POLYGALACTURONATE

TABLET;ORAL

CARDIOQUIN

PHARM RES ASSOC	275MG	N011642 002	

QUINIDINE SULFATE

CAPSULE;ORAL

CIN-QUIN

SOLVAY	200MG	A085296 001	
	300MG	A085297 001	

QUINIDINE SULFATE

LILLY	200MG	A085103 001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-405(of 478)

** See List Footnote

QUINIDINE SULFATE

TABLET; ORAL

CIN-QUIN

+	SOLVAY	100MG	A085299	001
+		200MG	A084932	001
		300MG	A085298	001

QUINIDINE SULFATE

BARR	200MG	A084177	001	
CHARTWELL MOLECULAR	200MG	A083743	001	
CONTRACT PHARMACAL	200MG	A083808	001	
CYCLE	200MG	A083640	001	
	300MG	A085632	001	
DAVA PHARMS INC	200MG	A087011	001	
ELKINS SINN	200MG	A083622	001	
EVERYLIFE	200MG	A083439	001	
HALSEY	200MG	A083583	001	
HIKMA	200MG	A083862	001	
IMPAX LABS	200MG	A083347	001	
IVAX SUB TEVA PHARMS	200MG	A084549	001	
KING PHARMS	200MG	A085175	001	
KV PHARM	200MG	A085276	001	
LEDERLE	200MG	A086176	001	
LILLY	200MG	A085038	001	
PERRIGO	200MG	A085322	001	
PHARMAVITE	200MG	A084627	001	
PUREPAC PHARM	200MG	A084003	001	
SANDOZ	200MG	A084631	001	
	200MG	A084914	001	
	300MG	A089839	001	Sep 29, 1988
SCHERER LABS	200MG	A085068	001	
SUN PHARM INDUSTRIES	100MG	A081029	001	Apr 14, 1989
	200MG	A081030	001	Apr 14, 1989
	300MG	A081031	001	Apr 14, 1989
SUPERPHARM	200MG	A088973	001	Apr 10, 1985
USL PHARMA	200MG	A087837	001	Apr 14, 1982
VALEANT PHARM INTL	200MG	A083393	001	
VANGARD	200MG	A087909	001	Jul 13, 1982
VINTAGE PHARMS	200MG	A083963	001	
WARNER CHILCOTT	200MG	A083879	001	
WATSON LABS	100MG	A085584	001	
	200MG	A083288	001	
	200MG	A085140	002	
	300MG	A085583	001	
WHITEWORTH TOWN PLSN	200MG	A085444	001	

QUINORA

KEY PHARMS	200MG	A083576	001	
+	SCHERING	300MG	A085222	001

TABLET, EXTENDED RELEASE; ORAL

QUINIDEX

WYETH PHARMS INC	300MG	N012796	002	

QUINIDINE SULFATE

COSETTE	300MG	A040045	001	Jun 30, 1994

QUININE SULFATE

CAPSULE; ORAL

QUININE SULFATE

MYLAN PHARMS INC	324MG	A202581	001	Dec 14, 2012

RABEPRAZOLE SODIUM

CAPSULE, DELAYED RELEASE; ORAL

ACIPHEX SPRINKLE

+	AYTU	5MG	N204736	001	Mar 26, 2013
+		10MG	N204736	002	Mar 26, 2013

TABLET, DELAYED RELEASE; ORAL

ACIPHEX

+	WOODWARD	10MG **	N020973	001	May 29, 2002

RABEPRAZOLE SODIUM

MYLAN	20MG	A076885	001	Nov 08, 2013
TEVA PHARMS USA	20MG	A076822	001	Nov 08, 2013

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-406(of 478)

** See List Footnote

RAMIPRIL

CAPSULE;ORAL

RAMIPRIL

ACTAVIS ELIZABETH	1.25MG	A077513 001	Jun 18, 2008
	2.5MG	A077513 002	Jun 18, 2008
	5MG	A077513 003	Jun 18, 2008
	10MG	A077513 004	Jun 18, 2008
CHARTWELL RX	1.25MG	A077514 001	Jun 18, 2008
	2.5MG	A077514 002	Jun 18, 2008
	5MG	A077514 003	Jun 18, 2008
	10MG	A077514 004	Jun 18, 2008
CIPLA	1.25MG	A077004 001	Aug 07, 2008
	2.5MG	A077004 002	Aug 07, 2008
	5MG	A077004 003	Aug 07, 2008
	10MG	A077004 004	Aug 07, 2008
RANBAXY LABS LTD	5MG	A078849 001	Mar 06, 2009
	10MG	A078849 002	Mar 06, 2009
TEVA PHARMS	1.25MG	A077470 001	Jun 18, 2008
	2.5MG	A077470 002	Jun 18, 2008
	5MG	A077470 003	Jun 18, 2008
	10MG	A077470 004	Jun 18, 2008
WATSON LABS	5MG	A076549 003	Oct 24, 2005

TABLET;ORAL

ALTACE

+ KING PFIZER	1.25MG **	N022021 001	Feb 27, 2007
+	2.5MG **	N022021 002	Feb 27, 2007
+	5MG **	N022021 003	Feb 27, 2007
+	10MG **	N022021 004	Feb 27, 2007

RAMIPRIL

APOTEX	1.25MG	A091069 001	Dec 02, 2015
	2.5MG	A091069 002	Dec 02, 2015
	5MG	A091069 003	Dec 02, 2015
	10MG	A091069 004	Dec 02, 2015
MYLAN PHARMS INC	1.25MG	A090650 001	Jun 30, 2011
	2.5MG	A090650 002	Jun 30, 2011
	5MG	A090650 003	Jun 30, 2011
	10MG	A090650 004	Jun 30, 2011
ZYDUS PHARMS USA INC	1.25MG	A090697 001	Sep 24, 2009
	2.5MG	A090697 002	Sep 24, 2009
	5MG	A090697 003	Sep 24, 2009
	10MG	A090697 004	Sep 24, 2009

RANITIDINE BISMUTH CITRATE

TABLET;ORAL

TRITEC

GLAXOSMITHKLINE	400MG	N020559 001	Aug 08, 1996

RANITIDINE HYDROCHLORIDE

CAPSULE;ORAL

RANITIDINE HYDROCHLORIDE

AJANTA PHARMA LTD	EQ 150MG BASE	A209859 001	Sep 27, 2018
	EQ 300MG BASE	A209859 002	Sep 27, 2018
APPCO	EQ 150MG BASE	A211893 001	Apr 05, 2019
	EQ 300MG BASE	A211893 002	Apr 05, 2019
AUROBINDO PHARMA	EQ 150MG BASE	A211058 001	Jul 16, 2018
	EQ 300MG BASE	A211058 002	Jul 16, 2018
MYLAN	EQ 150MG BASE	A075564 001	Oct 27, 2000
	EQ 300MG BASE	A075564 002	Oct 27, 2000
NOVITIUM PHARMA	EQ 150MG BASE	A210681 001	Nov 23, 2018
	EQ 300MG BASE	A210681 002	Nov 23, 2018
TEVA	EQ 150MG BASE	A075557 001	Oct 31, 2003
	EQ 300MG BASE	A075557 002	Oct 31, 2003
ZANTAC 150			
+ GLAXOSMITHKLINE	EQ 150MG BASE **	N020095 001	Mar 08, 1994
ZANTAC 300			
+ GLAXOSMITHKLINE	EQ 300MG BASE **	N020095 002	Mar 08, 1994
GRANULE, EFFERVESCENT;ORAL			
ZANTAC 150			
GLAXO GRP LTD	EQ 150MG BASE/PACKET	N020251 002	Mar 31, 1994

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-407(of 478)

** See List Footnote

RANITIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

RANITIDINE HYDROCHLORIDE

BEDFORD	EQ 25MG BASE/ML	A074764	001	Nov 19, 2004
MYLAN LABS LTD	EQ 25MG BASE/ML	A079076	001	Jun 09, 2016
ZANTAC IN PLASTIC CONTAINER				
PAI HOLDINGS PHARM	EQ 1MG BASE/ML	N019593	002	Sep 27, 1991
	EQ 50MG BASE/100ML	N019593	001	Dec 17, 1986

SYRUP; ORAL

RANITIDINE HYDROCHLORIDE

ACTAVIS MID ATLANTIC	EQ 15MG BASE/ML	A076124	001	Feb 21, 2007
AKORN	EQ 15MG BASE/ML	A091078	001	Mar 22, 2011
AMNEAL PHARMS	EQ 15MG BASE/ML	A078312	001	Sep 02, 2008
APOTEX INC	EQ 15MG BASE/ML	A077602	001	Sep 17, 2007
AUROBINDO PHARMA	EQ 15MG BASE/ML	A090623	001	Jul 28, 2010
LANNETT CO INC	EQ 15MG BASE/ML	A078890	001	Jul 01, 2010
NOSTRUM LABS INC	EQ 15MG BASE/ML	A078684	001	Aug 27, 2009
	EQ 15MG BASE/ML	A091091	001	Sep 20, 2011
RANBAXY	EQ 15MG BASE/ML	A078448	001	Dec 13, 2007
TARO	EQ 15MG BASE/ML	A077476	001	Jun 13, 2011
TOLMAR	EQ 15MG BASE/ML	A090054	001	Nov 15, 2010
TORRENT	EQ 15MG BASE/ML	A090102	001	May 26, 2009
WOCKHARDT	EQ 15MG BASE/ML	A079211	001	May 26, 2009
	EQ 15MG BASE/ML	A079212	001	Feb 23, 2009

ZANTAC

+ GLAXO GRP LTD

EQ 15MG BASE/ML N019675 001 Dec 30, 1988

TABLET; ORAL

RANITIDINE HYDROCHLORIDE

AMNEAL PHARMS NY	EQ 150MG BASE	A077824	001	Oct 13, 2006
	EQ 300MG BASE	A077824	002	Oct 13, 2006
ANI PHARMS	EQ 75MG BASE	A075212	001	Jan 14, 2000
	EQ 75MG BASE	A075296	001	Jan 14, 2000
	EQ 150MG BASE	A074488	001	Jul 31, 1997
	EQ 150MG BASE	A077426	001	Dec 19, 2005
	EQ 300MG BASE	A074488	002	Jul 31, 1997
	EQ 300MG BASE	A077426	002	Dec 19, 2005
APOTEX INC	EQ 75MG BASE	A075167	001	May 04, 2000
	EQ 150MG BASE	A200172	001	May 31, 2012
AUROBINDO PHARMA	EQ 75MG BASE	A207579	001	Nov 13, 2017
	EQ 150MG BASE	A207578	001	Nov 13, 2017
BOEHRINGER INGELHEIM	EQ 150MG BASE	A074662	001	Aug 29, 1997
	EQ 300MG BASE	A074662	002	Aug 29, 1997
CONTRACT PHARMACAL	EQ 75MG BASE	A075094	001	Jun 21, 1999
GRANULES	EQ 150MG BASE	A210243	001	Aug 20, 2018
	EQ 150MG BASE	A210243	002	Aug 20, 2018
HERITAGE PHARMA AVET	EQ 150MG BASE	A075165	001	Sep 30, 1998
	EQ 300MG BASE	A075165	002	Sep 30, 1998
MYLAN	EQ 75MG BASE	A075497	001	Jan 14, 2000
	EQ 150MG BASE	A074023	001	Aug 22, 1997
	EQ 150MG BASE	A074552	001	Jul 30, 1998
	EQ 300MG BASE	A074023	002	Aug 22, 1997
	EQ 300MG BASE	A074552	002	Jul 30, 1998
NOSTRUM LABS INC	EQ 150MG BASE	A203694	001	Nov 30, 2017
	EQ 300MG BASE	A203694	002	Nov 30, 2017
PERRIGO	EQ 75MG BASE	A076195	001	Aug 30, 2002
PERRIGO R AND D	EQ 150MG BASE	A091429	001	May 11, 2011
	EQ 150MG BASE	A091429	002	May 11, 2011
RANBAXY	EQ 75MG BASE	A075254	001	Jan 14, 2000
	EQ 150MG BASE	A075000	001	Jan 30, 1998
	EQ 300MG BASE	A075000	002	Jan 30, 1998
SANDOZ	EQ 75MG BASE	A075519	001	Sep 26, 2002
STRIDES PHARMA	EQ 75MG BASE	A201745	001	Feb 29, 2012
	EQ 75MG BASE	A209160	001	Mar 05, 2018
	EQ 150MG BASE	A200536	001	Jun 28, 2011
	EQ 150MG BASE	A205512	001	Aug 22, 2016
	EQ 150MG BASE	A209161	001	Feb 22, 2018
	EQ 150MG BASE	A210010	001	Aug 01, 2018
	EQ 300MG BASE	A205512	002	Aug 22, 2016
	EQ 300MG BASE	A210010	002	Aug 01, 2018

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-408(of 478)

** See List Footnote

RANITIDINE HYDROCHLORIDE

TABLET;ORAL

RANITIDINE HYDROCHLORIDE

SUN PHARM INDS LTD	EQ 75MG BASE	A075132 001	Jan 14, 2000
	EQ 150MG BASE	A075439 001	Apr 19, 2000
	EQ 300MG BASE	A075439 002	Apr 19, 2000
WATSON LABS	EQ 150MG BASE	A074864 001	Oct 20, 1997
	EQ 300MG BASE	A074864 002	Oct 20, 1997
WOCKHARDT	EQ 75MG BASE	A076760 001	Feb 24, 2006
	EQ 75MG BASE	A078884 001	Jul 31, 2008
	EQ 150MG BASE	A078653 001	Nov 26, 2007
	EQ 150MG BASE	A078701 001	Nov 12, 2009
	EQ 300MG BASE	A078701 002	Dec 11, 2009
WOCKHARDT LTD	EQ 150MG BASE	A075208 001	Dec 17, 1998
	EQ 300MG BASE	A075208 002	Dec 17, 1998
ZANTAC 150			
+ CHATTEM SANOFI	EQ 150MG BASE	N021698 001	Aug 31, 2004
+	EQ 150MG BASE	N021698 002	Mar 13, 2007
+ GLAXO GRP LTD	EQ 150MG BASE **	N018703 001	Jun 09, 1983
ZANTAC 300			
+ GLAXO GRP LTD	EQ 300MG BASE **	N018703 002	Dec 09, 1985
ZANTAC 75			
+ CHATTEM SANOFI	EQ 75MG BASE	N020520 001	Dec 19, 1995
TABLET, EFFERVESCENT;ORAL			
ZANTAC 150			
GLAXO GRP LTD	EQ 150MG BASE	N020251 001	Mar 31, 1994
ZANTAC 25			
GLAXO GRP LTD	EQ 25MG BASE	N020251 003	Apr 01, 2004
ZANTAC 75			
+ CHATTEM SANOFI	EQ 75MG BASE **	N020745 001	Feb 26, 1998

RANOLAZINE

TABLET, EXTENDED RELEASE;ORAL

RANOLAZINE

ACCORD HLTHCARE	500MG	A212930 001	May 18, 2021
	1GM	A212930 002	May 18, 2021
AMNEAL	500MG	A207690 001	Mar 11, 2021
	1GM	A207690 002	Mar 11, 2021
ANI PHARMS	500MG	A210482 001	Oct 29, 2019
	1GM	A210482 002	Oct 29, 2019
CIPLA	500MG	A211291 001	May 28, 2019
	1GM	A211291 002	May 28, 2019

RAPACURONIUM BROMIDE

INJECTABLE;INJECTION

RAPLON

ORGANON USA INC	100MG/VIAL	N020984 001	Aug 18, 1999
	200MG/VIAL	N020984 002	Aug 18, 1999

RASAGILINE MESYLATE

TABLET;ORAL

RASAGILINE MESYLATE

APOTEX INC	EQ 0.5MG BASE	A201950 001	Sep 12, 2013
	EQ 1MG BASE	A201950 002	Sep 12, 2013
DR REDDYS	EQ 0.5MG BASE	A201942 001	Nov 18, 2021
	EQ 1MG BASE	A201942 002	Nov 18, 2021
WATSON LABS INC	EQ 0.5MG BASE	A201823 001	Jul 01, 2013
	EQ 1MG BASE	A201823 002	Jul 01, 2013

RAUWOLFIA SERPENTINA ROOT

TABLET;ORAL

HIWOLFIA

BOWMAN PHARMS	50MG	N009276 003	
	50MG	N009276 005	
	100MG	N009276 004	
HYSERPIN			
PHYS PRODS VA	50MG	N010581 001	
KOGLUCOID			
PANRAY	50MG	N009278 001	
	100MG	N009278 002	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-409(of 478)

** See List Footnote

RAUWOLFIA SERPENTINA ROOT

TABLET;ORAL

RAUDIXIN

APOTHECON

50MG

N008842 001

100MG

N008842 002

RAUSERPIN

FERNDAL LABS

50MG

N009926 002

100MG

N009926 004

RAUVAL

PAL PAK

50MG

N009108 002

100MG

N009108 004

RAUWOLFIA SERPENTINA

BUNDY

50MG

N009477 001

100MG

N009477 002

HALSEY

50MG

A080498 001

100MG

A080498 002

IMPAX LABS

50MG

N009273 001

100MG

N009273 002

IVAX SUB TEVA PHARMS

50MG

N011521 001

100MG

N011521 002

PUREPAC PHARM

50MG

A080842 001

100MG

A080842 002

PVT FORM

50MG

A080583 001

100MG

A080583 002

SOLVAY

50MG

A080500 001

100MG

A080500 002

TABLICAPS

50MG

A083867 001

100MG

A083444 001

VALEANT PHARM INTL

50MG

N009668 001

100MG

N009668 002

WATSON LABS

50MG

A080907 001

100MG

A080914 001

WOLFINA

FOREST PHARMS

50MG

N009255 008

100MG

N009255 006

REGADENOSON

SOLUTION;INTRAVENOUS

REGADENOSON

IMS LTD

0.4MG/5ML (0.08MG/ML)

A214252 001 May 23, 2022

REPAGLINIDE

TABLET;ORAL

PRANDIN

+

GEMINI LABS LLC

0.5MG **

N020741 001 Dec 22, 1997

+

1MG **

N020741 002 Dec 22, 1997

+

2MG **

N020741 003 Dec 22, 1997

REPAGLINIDE

ACTAVIS TOTOWA

0.5MG

A090008 001 Jan 22, 2014

1MG

A090008 002 Jan 22, 2014

2MG

A090008 003 Jan 22, 2014

BOSCOGEN

0.5MG

A091517 001 Apr 24, 2015

1MG

A091517 002 Apr 24, 2015

2MG

A091517 003 Apr 24, 2015

MYLAN

0.5MG

A090252 001 Aug 23, 2013

1MG

A090252 002 Jan 22, 2014

2MG

A090252 003 Jan 22, 2014

RESCINNAMINE

CAPSULE;ORAL

CINNASIL

PANRAY

0.5MG

A084736 001

TABLET;ORAL

MODERIL

PFIZER

0.25MG

N010686 003

0.5MG

N010686 006

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-410(of 478)

** See List Footnote

RESERPINE

ELIXIR;ORAL

SERPASIL

NOVARTIS

0.2MG/4ML

N009115 005

INJECTABLE;INJECTION

SANDRIL

LILLY

2.5MG/ML

N010012 001

SERPASIL

NOVARTIS

2.5MG/ML

N009434 002

TABLET;ORAL

HISERPIA

BOWMAN PHARMS

0.1MG

N009631 002

0.25MG

N009631 004

RAU-SED

BRISTOL MYERS SQUIBB

0.1MG

N009357 001

0.25MG

N009357 004

0.5MG

N009357 006

1MG

N009357 008

RESERPINE

BARR

0.25MG

A080721 002

BELL PHARMA

0.1MG

A083058 001

0.25MG

A083058 002

BUNDY

0.1MG

N009663 001

0.25MG

N009663 003

CYCLE

0.1MG

N009859 001

0.25MG

N009859 002

ELKINS SINN

0.1MG

A083145 001

0.25MG

A083145 002

EVERYLIFE

0.1MG

N010441 001

0.25MG

N010441 002

0.5MG

N010441 003

1MG

N010441 004

HALSEY

0.1MG

A080457 002

0.25MG

A080457 001

1MG

A080457 003

HIKMA INTL PHARMS

0.1MG

A080975 001

0.25MG

A080975 002

1MG

A080975 003

IMPAX LABS

0.1MG

N009627 001

0.25MG

N009627 002

IVAX SUB TEVA PHARMS

0.1MG

N011185 001

0.25MG

N011185 002

MARSHALL PHARMA

0.1MG

A080492 001

0.25MG

A080492 002

MK LABS

0.1MG

A080525 002

0.25MG

A080525 001

MYLAN

1MG

A084974 001

PHARMAVITE

0.25MG

A084663 001

PUREPAC PHARM

0.1MG

A080753 002

0.25MG

A080753 001

PVT FORM

0.1MG

A086117 001

0.25MG

A080582 001

0.25MG

A085775 001

1MG

A080582 002

REXALL

0.25MG

A080637 001

+

SANDOZ

0.1MG

N009838 001

+

0.25MG

N009838 002

SOLVAY

0.25MG

A080446 001

TABLICAPS

0.25MG

A085207 001

TEVA

0.1MG

A089020 001

Mar 07, 1985

0.25MG

A089019 001

Mar 07, 1985

VALEANT PHARM INTL

0.1MG

N009667 001

0.25MG

N009667 002

WATSON LABS

0.1MG

A080679 001

0.25MG

A080393 001

0.25MG

A085401 001

1MG

A080749 001

WHITEWORTH TOWN PLSN

0.1MG

A080723 001

0.25MG

A080723 002

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-411(of 478)

** See List Footnote

RESERPINE

TABLET;ORAL

RESERPINE

1MG

A080723 003

SANDRIL

LILLY

0.1MG

N009376 004

0.25MG

N009376 001

SERPALAN

LANNETT

0.1MG

N010124 001

0.25MG

N010124 002

SERPANRAY

PANRAY

0.1MG

N009391 001

0.25MG

N009391 002

1MG

N009391 004

SERPASIL

NOVARTIS

0.1MG

N009115 001

0.25MG

N009115 003

1MG

N009115 004

SERPATE

VALE

0.1MG

N009453 001

0.25MG

N009453 002

SERPIVITE

VITARINE

0.25MG

N009645 002

RESERPINE; TRICHLORMETHIAZIDE

TABLET;ORAL

METATENSIN #2

SANOFI AVENTIS US

0.1MG;2MG

N012972 001

METATENSIN #4

SANOFI AVENTIS US

0.1MG;4MG

N012972 002

NAQUIVAL

SCHERING

0.1MG;4MG

N012265 003

TRICHLORMETHIAZIDE W/ RESERPINE

WATSON LABS

0.1MG;4MG

A085248 001

RIBAVIRIN

CAPSULE;ORAL

REBETOL

MERCK SHARP DOHME

200MG**Indicated for use and comarketed
with Interferon ALFA-2B, Recombinant
(INTRON A), as Rebetrone Combination
Therapy**

N020903 001 Jun 03, 1998

+

200MG

N020903 002 Jul 25, 2001

RIBASPHERE

CHARTWELL RX

200MG

A076203 001 Apr 06, 2004

RIBAVIRIN

CHARTWELL RX

200MG

A076192 001 Apr 06, 2004

TEVA

200MG

A076277 001 Oct 04, 2004

SOLUTION;ORAL

REBETOL

+

SCHERING

40MG/ML

N021546 001 Jul 29, 2003

TABLET;ORAL

COPEGUS

+

ROCHE

200MG **

N021511 001 Dec 03, 2002

+

400MG **

N021511 002 Jun 21, 2005

RIBAVIRIN

BEXIMCO PHARMS USA

200MG

A202546 001 Aug 12, 2014

400MG

A202546 002 Aug 12, 2014

500MG

A202546 003 Aug 12, 2014

600MG

A202546 004 Aug 12, 2014

CHARTWELL RX

200MG

A077456 001 Dec 05, 2005

400MG

A077456 002 Dec 05, 2005

600MG

A077456 003 Dec 05, 2005

HERITAGE PHARMA AVET

200MG

A077053 001 Dec 05, 2005

ZYDUS PHARMS USA

400MG

A077094 002 Mar 16, 2007

500MG

A077094 004 Apr 18, 2008

600MG

A077094 003 Mar 16, 2007

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-412(of 478)

** See List Footnote

RIFAMPIN

CAPSULE;ORAL

RIFADIN

SANOFI AVENTIS US

150MG

A062303 001

+

300MG

N050420 001

INJECTABLE;INJECTION

RIFAMPIN

EMCURE PHARMS LTD

600MG/VIAL

A204101 001 Aug 18, 2014

WATSON PHARMS TEVA

600MG/VIAL

A206736 001 Jan 19, 2016

RILUZOLE

TABLET;ORAL

RILUZOLE

APOTEX CORP

50MG

A091300 001 Jun 18, 2013

DAITO PHARMS CO LTD

50MG

A204430 001 Oct 16, 2018

RIMANTADINE HYDROCHLORIDE

SYRUP;ORAL

FLUMADINE

FOREST LABS

50MG/5ML

N019650 001 Sep 17, 1993

TABLET;ORAL

RIMANTADINE HYDROCHLORIDE

HERITAGE PHARMA AVET

100MG

A076375 001 Jan 14, 2003

IMPAX LABS INC

100MG

A075916 001 Nov 02, 2001

RIMEXOLONE

SUSPENSION/DROPS;OPHTHALMIC

VEXOL

EYEVANCE

1%

N020474 001 Dec 30, 1994

RISEDRONATE SODIUM

TABLET;ORAL

ACTONEL

+ APIL

5MG

N020835 002 Apr 14, 2000

+

30MG

N020835 001 Mar 27, 1998

+

75MG **

N020835 004 Apr 16, 2007

RISEDRONATE SODIUM

HANGZHOU BINJIANG

35MG

A207516 001 Feb 15, 2019

MYLAN

5MG

A200477 001 Nov 30, 2015

30MG

A200477 002 Nov 30, 2015

35MG

A200477 003 Nov 30, 2015

75MG

A200477 004 Jun 10, 2014

150MG

A200477 005 Jun 10, 2014

TABLET, DELAYED RELEASE;ORAL

RISEDRONATE SODIUM

IMPAX LABS INC

35MG

A205066 001 Jun 29, 2018

ZYDUS PHARMS

35MG

A203822 001 Sep 11, 2018

RISPERIDONE

SOLUTION;ORAL

RISPERIDONE

ANI PHARMS

1MG/ML

A076440 001 Jan 30, 2009

PRECISION DOSE

1MG/ML

A076797 001 Jun 28, 2010

TORRENT

1MG/ML

A078909 001 Jul 29, 2009

WOCKHARDT

1MG/ML

A078744 001 Oct 08, 2009

TABLET;ORAL

RISPERDAL

JANSSEN PHARMS

5MG

N020272 005 Dec 29, 1993

RISPERIDONE

HERITAGE PHARMA AVET

0.25MG

A076228 001 Jun 30, 2008

0.25MG

A077769 001 Oct 16, 2008

0.5MG

A076228 002 Jun 30, 2008

0.5MG

A077769 002 Oct 16, 2008

1MG

A076228 003 Jun 30, 2008

1MG

A077769 003 Oct 16, 2008

2MG

A076228 004 Jun 30, 2008

2MG

A077769 004 Oct 16, 2008

3MG

A076228 005 Jun 30, 2008

3MG

A077769 005 Oct 16, 2008

4MG

A076228 006 Jun 30, 2008

4MG

A077769 006 Oct 16, 2008

JUBILANT CADISTA

0.25MG

A078828 001 Mar 23, 2009

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-413(of 478)

** See List Footnote

RISPERIDONE

TABLET;ORAL

RISPERIDONE

	0.5MG	A078828 002	Mar 23, 2009
	1MG	A078828 003	Mar 23, 2009
	2MG	A078828 004	Mar 23, 2009
	3MG	A078828 005	Mar 23, 2009
	4MG	A078828 006	Mar 23, 2009
MYLAN	0.25MG	A076288 001	Sep 15, 2008
	0.5MG	A076288 002	Sep 15, 2008
	1MG	A076288 003	Sep 15, 2008
	2MG	A076288 004	Sep 15, 2008
	3MG	A076288 005	Sep 15, 2008
	4MG	A076288 006	Sep 15, 2008
RATIOPHARM	0.25MG	A077784 001	Jun 08, 2010
	0.5MG	A077784 002	Jun 08, 2010
	1MG	A077784 003	Jun 08, 2010
	2MG	A077784 004	Jun 08, 2010
	3MG	A077784 005	Jun 08, 2010
	4MG	A077784 006	Jun 08, 2010
SUN PHARM INDS INC	0.25MG	A078036 001	Mar 10, 2014
	0.5MG	A078036 002	Mar 10, 2014
	1MG	A078036 003	Mar 10, 2014
	2MG	A078036 004	Mar 10, 2014
	3MG	A078036 005	Mar 10, 2014
	4MG	A078036 006	Mar 10, 2014
SYNTHON PHARMS	0.25MG	A078187 001	Oct 22, 2009
	0.5MG	A078187 002	Oct 22, 2009
	1MG	A078187 003	Oct 22, 2009
	2MG	A078187 004	Oct 22, 2009
	3MG	A078187 005	Oct 22, 2009
	4MG	A078187 006	Oct 22, 2009
WATSON LABS	0.25MG	A077860 001	Dec 05, 2008
	0.5MG	A077860 002	Dec 05, 2008
	1MG	A077860 003	Dec 05, 2008
	2MG	A077860 004	Dec 05, 2008
	3MG	A077860 005	Dec 05, 2008
	4MG	A077860 006	Dec 05, 2008
WEST WARD PHARMS	0.25MG	A078740 001	May 29, 2009
	0.5MG	A078740 002	May 29, 2009
	1MG	A078740 003	May 29, 2009
	2MG	A078740 004	May 29, 2009
	3MG	A078740 005	May 29, 2009
	4MG	A078740 006	May 29, 2009
TABLET, ORALLY DISINTEGRATING;ORAL			
RISPERDAL			
+	JANSSEN PHARMS 0.5MG **	N021444 001	Apr 02, 2003
+	1MG **	N021444 002	Apr 02, 2003
+	2MG **	N021444 003	Apr 02, 2003
+	3MG **	N021444 004	Dec 23, 2004
+	4MG **	N021444 005	Dec 23, 2004
RISPERIDONE			
ACTAVIS LABS FL INC	0.5MG	A076996 001	Apr 19, 2011
	1MG	A076996 002	Apr 19, 2011
	2MG	A076996 003	Apr 19, 2011
	3MG	A076996 004	Apr 19, 2011
	4MG	A076996 005	Apr 19, 2011
HERITAGE PHARMA AVET	0.5MG	A076908 001	Mar 12, 2012
	1MG	A076908 002	Mar 12, 2012
	2MG	A076908 003	Mar 12, 2012
MYLAN PHARMS INC	0.25MG	A091537 006	Feb 12, 2013
	0.5MG	A091537 001	Mar 30, 2011
	1MG	A091537 002	Mar 30, 2011
	2MG	A091537 003	Mar 30, 2011
	3MG	A091537 004	Mar 30, 2011
	4MG	A091537 005	Mar 30, 2011

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-414(of 478)

** See List Footnote

RITODRINE HYDROCHLORIDE

INJECTABLE; INJECTION

RITODRINE HYDROCHLORIDE

ABRAXIS PHARM	10MG/ML	A071188	001	Jul 23, 1987
	15MG/ML	A071189	001	Jul 23, 1987
HOSPIRA	10MG/ML	A071618	001	Feb 28, 1991
	15MG/ML	A071619	001	Feb 28, 1991

RITODRINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER

HOSPIRA	30MG/100ML	A071438	001	Jan 22, 1991

YUTOPAR

ASTRAZENECA	10MG/ML	N018580	001	
	15MG/ML	N018580	002	Sep 27, 1984

TABLET; ORAL

YUTOPAR

ASTRAZENECA	10MG	N018555	001	

RITONAVIR

CAPSULE; ORAL

NORVIR

ABBOTT	100MG	N020680	001	Mar 01, 1996
+ ABBVIE	100MG **	N020945	001	Jun 29, 1999
RITONAVIR				
HIKMA	100MG	A205801	001	Dec 03, 2020

RIVASTIGMINE TARTRATE

CAPSULE; ORAL

EXELON

+ NOVARTIS	EQ 1.5MG BASE **	N020823	003	Apr 21, 2000
+	EQ 3MG BASE **	N020823	004	Apr 21, 2000
+	EQ 4.5MG BASE **	N020823	005	Apr 21, 2000
+	EQ 6MG BASE **	N020823	006	Apr 21, 2000

RIVASTIGMINE TARTRATE

APOTEX INC	EQ 1.5MG BASE	A091072	001	May 16, 2013
	EQ 3MG BASE	A091072	002	May 16, 2013
	EQ 4.5MG BASE	A091072	003	May 16, 2013
	EQ 6MG BASE	A091072	004	May 16, 2013

SOLUTION; ORAL

EXELON

NOVARTIS	EQ 2MG BASE/ML	N021025	001	Apr 21, 2000

RIZATRIPTAN BENZOATE

TABLET; ORAL

MAXALT

+ ORGANON LLC	EQ 5MG BASE **	N020864	001	Jun 29, 1998

RIZATRIPTAN BENZOATE

APOTEX INC	EQ 5MG BASE	A202244	001	Dec 31, 2012
	EQ 10MG BASE	A202244	002	Dec 31, 2012
EMCURE PHARMS LTD	EQ 5MG BASE	A204090	001	Nov 26, 2013
	EQ 10MG BASE	A204090	002	Nov 26, 2013
JUBILANT GENERICS	EQ 5MG BASE	A203252	001	Dec 31, 2014
	EQ 10MG BASE	A203252	002	Dec 31, 2014
SANDOZ	EQ 5MG BASE	A079230	001	Dec 31, 2012
	EQ 10MG BASE	A079230	002	Dec 31, 2012
UNICHEM	EQ 5MG BASE	A207836	001	Mar 07, 2017
	EQ 10MG BASE	A207836	002	Mar 07, 2017

TABLET, ORALLY DISINTEGRATING; ORAL

MAXALT-MLT

+ ORGANON	EQ 5MG BASE **	N020865	001	Jun 29, 1998

RIZATRIPTAN BENZOATE

APOTEX INC	EQ 5MG BASE	A202477	001	Jul 01, 2013
	EQ 10MG BASE	A202477	002	Jul 01, 2013
JUBILANT GENERICS	EQ 5MG BASE	A203334	001	Oct 16, 2015
	EQ 10MG BASE	A203334	002	Oct 16, 2015
MYLAN PHARMS INC	EQ 5MG BASE	A078173	001	Dec 31, 2012
	EQ 10MG BASE	A078173	002	Dec 31, 2012
SANDOZ	EQ 5MG BASE	A078739	001	Jul 01, 2013
	EQ 10MG BASE	A078739	002	Jul 01, 2013

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-415(of 478)

** See List Footnote

ROCURONIUM BROMIDE

INJECTABLE; INJECTION

ROCURONIUM BROMIDE

TEVA PHARMS

50MG/5ML (10MG/ML)

A078717 001 Nov 26, 2008

100MG/10ML (10MG/ML)

A078717 002 Nov 26, 2008

ZEMURON

+ ORGANON USA INC

50MG/5ML (10MG/ML) **

N020214 001 Mar 17, 1994

+

10MG/ML (10MG/ML) **

N020214 002 Mar 17, 1994

+

100MG/10ML (10MG/ML) **

N020214 003 Mar 17, 1994

ROFECOXIB

SUSPENSION; ORAL

VIOXX

MERCK

12.5MG/5ML

N021052 001 May 20, 1999

25MG/5ML

N021052 002 May 20, 1999

TABLET; ORAL

VIOXX

MERCK

12.5MG

N021042 001 May 20, 1999

25MG

N021042 002 May 20, 1999

50MG

N021042 003 Feb 25, 2000

ROFLUMILAST

TABLET; ORAL

ROFLUMILAST

BRECKENRIDGE

500MCG

A208236 001 Oct 03, 2018

ROLAPITANT HYDROCHLORIDE

EMULSION; INTRAVENOUS

VARUBI

+ TERSERA

EQ 166.5MG BASE/92.5ML (EQ 1.8MG
BASE/ML)

N208399 001 Oct 25, 2017

ROMIDEPSIN

SOLUTION; INTRAVENOUS

ROMIDEPSIN

+ TEVA PHARMS USA INC

10MG/2ML (5MG/ML)

N208574 001 Mar 13, 2020

+

27.5MG/5.5ML (5MG/ML)

N208574 002 Mar 13, 2020

ROPINIROLE HYDROCHLORIDE

TABLET; ORAL

REQUIP

+ GLAXOSMITHKLINE LLC

EQ 0.25MG BASE

N020658 001 Sep 19, 1997

+

EQ 0.5MG BASE

N020658 002 Sep 19, 1997

+

EQ 1MG BASE

N020658 003 Sep 19, 1997

+

EQ 2MG BASE

N020658 004 Sep 19, 1997

+

EQ 3MG BASE

N020658 006 Jan 27, 1999

+

EQ 4MG BASE

N020658 007 Jan 27, 1999

+

EQ 5MG BASE

N020658 005 Sep 19, 1997

ROPINIROLE HYDROCHLORIDE

COSETTE

EQ 0.25MG BASE

A077460 001 May 05, 2008

EQ 0.5MG BASE

A077460 002 May 05, 2008

EQ 1MG BASE

A077460 003 May 05, 2008

EQ 2MG BASE

A077460 004 May 05, 2008

EQ 3MG BASE

A077460 005 May 05, 2008

EQ 4MG BASE

A077460 006 May 05, 2008

EQ 5MG BASE

A077460 007 May 19, 2008

EPIC PHARMA LLC

EQ 0.25MG BASE

A078230 001 May 20, 2008

EQ 0.5MG BASE

A078230 002 May 20, 2008

EQ 1MG BASE

A078230 003 May 20, 2008

EQ 2MG BASE

A078230 004 May 20, 2008

EQ 3MG BASE

A078230 005 May 20, 2008

EQ 4MG BASE

A078230 006 May 20, 2008

EQ 5MG BASE

A078230 007 May 20, 2008

HIKMA

EQ 0.25MG BASE

A077852 001 May 05, 2008

EQ 0.5MG BASE

A077852 002 May 05, 2008

EQ 1MG BASE

A077852 003 May 05, 2008

EQ 2MG BASE

A077852 004 May 05, 2008

EQ 3MG BASE

A077852 005 May 05, 2008

EQ 4MG BASE

A077852 006 May 05, 2008

EQ 5MG BASE

A077852 007 May 19, 2008

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-416(of 478)

** See List Footnote

ROPINIROLE HYDROCHLORIDETABLET, EXTENDED RELEASE;ORAL
REQUIP XL

+	GLAXOSMITHKLINE LLC	EQ 2MG BASE **	N022008 001	Jun 13, 2008
+		EQ 3MG BASE **	N022008 002	Jun 13, 2008
+		EQ 4MG BASE **	N022008 003	Jun 13, 2008
+		EQ 6MG BASE **	N022008 006	Apr 10, 2009
+		EQ 8MG BASE **	N022008 004	Jun 13, 2008
+		EQ 12MG BASE **	N022008 005	Oct 31, 2008

ROPINIROLE HYDROCHLORIDE

MYLAN PHARMS INC

EQ 2MG BASE	A200462 001	Oct 15, 2012
EQ 3MG BASE	A200462 002	Oct 15, 2012
EQ 4MG BASE	A200462 003	Oct 15, 2012
EQ 6MG BASE	A200462 004	Oct 15, 2012
EQ 8MG BASE	A200462 005	Oct 15, 2012
EQ 12MG BASE	A200462 006	Oct 15, 2012

WATSON LABS INC

EQ 2MG BASE	A200431 001	Jun 06, 2012
EQ 4MG BASE	A200431 002	Jun 06, 2012
EQ 6MG BASE	A200431 003	Jun 06, 2012
EQ 8MG BASE	A200431 004	Jun 06, 2012
EQ 12MG BASE	A200431 005	Jun 06, 2012

ROPIVACAINE HYDROCHLORIDE

SOLUTION;INJECTION

NAROPIN

+	FRESENIUS KABI USA	50MG/10ML (5MG/ML)	N020533 013	May 01, 1998
+		75MG/10ML (7.5MG/ML)	N020533 012	Sep 24, 1996

ROPIVACAINE HYDROCHLORIDE

RISING

40MG/20ML (2MG/ML)	A090318 001	Sep 23, 2014
150MG/30ML (5MG/ML)	A090318 002	Sep 23, 2014
150MG/20ML (7.5MG/ML)	A090318 003	Sep 23, 2014
200MG/20ML (10MG/ML)	A090318 004	Sep 23, 2014

ROSE BENGAL SODIUM I-131

INJECTABLE;INJECTION

ROBENGATOPE

BRACCO

0.5mCi/VIAL	N016224 001
1mCi/VIAL	N016224 002
2mCi/VIAL	N016224 003

SODIUM ROSE BENGAL I 131

SORIN

0.5mCi/ML	N017318 001

ROSIGLITAZONE MALEATE

TABLET;ORAL

AVANDIA

+	WOODWARD	EQ 8MG BASE **	N021071 004	May 25, 1999

ROSIGLITAZONE MALEATE

ANI PHARMS

EQ 2MG BASE	A076747 001	Jan 25, 2013
EQ 4MG BASE	A076747 002	Jan 25, 2013
EQ 8MG BASE	A076747 003	Jan 25, 2013

ROSUVASTATIN CALCIUM

TABLET;ORAL

ROSUVASTATIN CALCIUM

AMNEAL PHARMS CO

EQ 5MG BASE	A208850 001	Oct 16, 2018
EQ 10MG BASE	A208850 002	Oct 16, 2018
EQ 20MG BASE	A208850 003	Oct 16, 2018
EQ 40MG BASE	A208850 004	Oct 16, 2018

APOTEX INC

EQ 5MG BASE	A079145 001	Jul 19, 2016
EQ 10MG BASE	A079145 002	Jul 19, 2016
EQ 20MG BASE	A079145 003	Jul 19, 2016
EQ 40MG BASE	A079145 004	Jul 19, 2016

INVENTIA

EQ 5MG BASE	A207653 001	Feb 05, 2021
EQ 10MG BASE	A207653 002	Feb 05, 2021
EQ 20MG BASE	A207653 003	Feb 05, 2021
EQ 40MG BASE	A207653 004	Feb 05, 2021

STRIDES PHARMA

EQ 5MG BASE	A079161 001	Jul 19, 2016
EQ 10MG BASE	A079161 002	Jul 19, 2016
EQ 20MG BASE	A079161 003	Jul 19, 2016
EQ 40MG BASE	A079161 004	Jul 19, 2016

SUNSHINE

EQ 5MG BASE	A210667 001	Apr 01, 2020

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-417(of 478)

** See List Footnote

ROSUVASTATIN CALCIUM

TABLET;ORAL

ROSUVASTATIN CALCIUM

	EQ 10MG BASE	A210667 002	Apr 01, 2020
	EQ 20MG BASE	A210667 003	Apr 01, 2020
	EQ 40MG BASE	A210667 004	Apr 01, 2020
TEVA PHARMS USA	EQ 5MG BASE	A079166 001	Jul 19, 2016
	EQ 10MG BASE	A079166 002	Jul 19, 2016
	EQ 20MG BASE	A079166 003	Jul 19, 2016
	EQ 40MG BASE	A079166 004	Jul 19, 2016
UMEDICA LABS PVT LTD	EQ 5MG BASE	A207626 001	Apr 09, 2019
	EQ 10MG BASE	A207626 002	Apr 09, 2019
	EQ 20MG BASE	A207626 003	Apr 09, 2019
	EQ 40MG BASE	A207626 004	Apr 09, 2019
ZHEJIANG JINGXIN	EQ 5MG BASE	A206513 001	Mar 01, 2019
	EQ 10MG BASE	A206513 002	Mar 01, 2019
	EQ 20MG BASE	A206513 003	Mar 01, 2019
	EQ 40MG BASE	A206513 004	Mar 01, 2019

RUFINAMIDE

TABLET;ORAL

BANZEL

+	EISAI INC	100MG **	N021911 001	Nov 14, 2008

SAFFLOWER OIL

INJECTABLE;INJECTION

LIPOSYN 10%

ABBOTT	10% (10GM/100ML)	N018203 001

LIPOSYN 20%

ABBOTT	20% (20GM/100ML)	N018614 001

SAFFLOWER OIL; SOYBEAN OIL

INJECTABLE;INJECTION

LIPOSYN II 10%

HOSPIRA	5%;5% (5GM/100ML)	N018997 001	Aug 27, 1984

LIPOSYN II 20%

HOSPIRA	10%;10% (10GM/100ML)	N018991 001	Aug 27, 1984

SALMETEROL XINAFOATE

AEROSOL, METERED;INHALATION

SEREVENT

GLAXOSMITHKLINE	EQ 0.021MG BASE/INH	N020236 001	Feb 04, 1994

SAMARIUM SM-153 LEXIDRONAM PENTASODIUM

INJECTABLE;INJECTION

QUADRAMET

+	LANTHEUS MEDICAL	50mCi/ML	N020570 001	Mar 28, 1997

SAQUINAVIR

CAPSULE;ORAL

FORTOVASE

+	HOFFMANN LA ROCHE	200MG **	N020828 001	Nov 07, 1997

SAQUINAVIR MESYLATE

CAPSULE;ORAL

INVIRASE

+	HOFFMANN LA ROCHE	EQ 200MG BASE	N020628 001	Dec 06, 1995

TABLET;ORAL

INVIRASE

+	HOFFMANN-LA ROCHE	EQ 500MG BASE	N021785 001	Dec 17, 2004

SARALASIN ACETATE

INJECTABLE;INJECTION

SARENIN

PROCTER AND GAMBLE	EQ 0.6MG BASE/ML	N018009 001

SECOBARBITAL SODIUM

CAPSULE;ORAL

SECOBARBITAL SODIUM

ANABOLIC	100MG	A084422 001

BARR	100MG	A084225 001

EVERYLIFE	100MG	A085895 001

HALSEY	100MG	A084676 001

IVAX PHARMS	100MG	A085869 001

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-418(of 478)

** See List Footnote

SECOBARBITAL SODIUM

CAPSULE;ORAL

SECOBARBITAL SODIUM

KV PHARM	100MG	A085285	001	
LANNETT	50MG	A085909	001	
	100MG	A085903	001	
PARKE DAVIS	100MG	A084762	001	
PERRIGO	100MG	A084561	001	
PUREPAC PHARM	100MG	A085867	001	
VALEANT PHARM INTL	100MG	A085477	001	
VITARINE	100MG	A085898	001	
	100MG	A086273	001	
WATSON LABS	100MG	A085792	001	
WEST WARD	100MG	A084926	001	
WHITEWORTH TOWN PLSN	100MG	A085798	001	
WYETH AYERST	100MG	A086390	001	

SECONAL SODIUM

VALEANT PHARMS NORTH	50MG	A086101	001	Oct 03, 1983
	100MG	A086101	002	Oct 03, 1983

INJECTABLE;INJECTION

SECOBARBITAL SODIUM

ELKINS SINN	100MG/VIAL	A083281	001	
WYETH AYERST	50MG/ML	A083262	001	

SECONAL SODIUM

LILLY	50MG/ML **	N007392	002	

SUPPOSITORY;RECTAL

SECONAL SODIUM

LILLY	30MG	A086530	001	
	60MG	A086530	002	
	120MG	A086530	003	
	200MG	A086530	004	

SECRETIN

INJECTABLE;INJECTION

SECRETIN-FERRING

FERRING	75CU/VIAL	N018290	001	

SECRETIN SYNTHETIC PORCINE

FOR SOLUTION;INTRAVENOUS

SECREFLO

CHIRHOCLIN	16MCG/VIAL	N021136	001	Apr 04, 2002

SELEGILINE HYDROCHLORIDE

CAPSULE;ORAL

ELDEPRYL

+ SOMERSET	5MG **	N020647	001	May 15, 1996

SELEGILINE HYDROCHLORIDE

LANNETT CO INC	5MG	A075145	001	Sep 15, 2003

TABLET;ORAL

SELEGILINE HYDROCHLORIDE

BOSCOGEN	5MG	A074912	001	Apr 30, 1998
CHARTWELL MOLECULES	5MG	A074565	001	Aug 02, 1996
	5MG	A074641	001	Aug 02, 1996
COSETTE	5MG	A074744	001	Jan 27, 1997
	5MG	A074756	001	Nov 25, 1998
G AND W LABS INC	5MG	A074537	001	Aug 02, 1996
MYLAN	5MG	A074866	001	Nov 26, 1997
+ SOMERSET	5MG **	N019334	001	Jun 05, 1989

SELENIUM SULFIDE

LOTION/SHAMPOO;TOPICAL

EXSEL

ALLERGAN HERBERT	2.5%	A083892	001	

SELENIUM SULFIDE

ACTAVIS MID ATLANTIC	2.5%	A084394	001	
COSETTE	2.5%	A086209	001	
IVAX PHARMS	2.5%	A085777	001	
WOCKHARDT BIO AG	2.5%	A088228	001	Sep 01, 1983

SELSUN

+ CHATTEM	2.5% **	N007936	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-419(of 478)

** See List Footnote

SELENOMETHIONINE SE-75

INJECTABLE; INJECTION

SELENOMETHIONINE SE 75

GE HEALTHCARE	250uCi/ML	N017257	001
MALLINCKRODT	100uCi/ML	N017098	001
PHARMALUCENCE	500uCi/ML	N017322	001
SETHOTOPE			
BRACCO	85-550uCi/ML	N017047	001

SERMORELIN ACETATE

INJECTABLE; INJECTION

GEREF

+	EMD SERONO	EQ 0.05MG BASE/AMP **	N019863	001	Dec 28, 1990
+	EMD SERONO INC	EQ 0.5MG BASE/VIAL **	N020443	001	Sep 26, 1997
+		EQ 1MG BASE/VIAL **	N020443	002	Sep 26, 1997

SERTRALINE HYDROCHLORIDE

CONCENTRATE; ORAL

SERTRALINE HYDROCHLORIDE

RANBAXY LABS LTD	EQ 20MG BASE/ML	A078053	001	Feb 05, 2007

TABLET; ORAL

SERTRALINE HYDROCHLORIDE

ANDA REPOSITORY	EQ 25MG BASE	A077818	001	Feb 06, 2007
	EQ 50MG BASE	A077818	002	Feb 06, 2007
	EQ 100MG BASE	A077818	003	Feb 06, 2007
CADILA	EQ 25MG BASE	A077106	001	Feb 06, 2007
	EQ 50MG BASE	A077106	002	Feb 06, 2007
	EQ 100MG BASE	A077106	003	Feb 06, 2007
CHARTWELL MOLECULAR	EQ 25MG BASE	A077162	001	Feb 06, 2007
	EQ 50MG BASE	A077162	002	Feb 06, 2007
	EQ 100MG BASE	A077162	003	Feb 06, 2007
FOSUN PHARMA	EQ 25MG BASE	A077713	001	Feb 06, 2007
	EQ 50MG BASE	A077713	002	Feb 06, 2007
	EQ 100MG BASE	A077713	003	Feb 06, 2007
HERITAGE PHARMA AVET	EQ 25MG BASE	A076465	001	Aug 11, 2006
	EQ 25MG BASE	A077299	001	Feb 06, 2007
	EQ 25MG BASE	A077345	001	Feb 06, 2007
	EQ 25MG BASE	A077663	001	Feb 06, 2007
	EQ 50MG BASE	A076465	002	Aug 11, 2006
	EQ 50MG BASE	A077299	002	Feb 06, 2007
	EQ 50MG BASE	A077345	002	Feb 06, 2007
	EQ 50MG BASE	A077663	002	Feb 06, 2007
	EQ 100MG BASE	A076465	003	Aug 11, 2006
	EQ 100MG BASE	A077299	003	Feb 06, 2007
	EQ 100MG BASE	A077345	003	Feb 06, 2007
	EQ 100MG BASE	A077663	003	Feb 06, 2007
HIKMA PHARMS	EQ 25MG BASE	A077864	001	Aug 10, 2009
	EQ 50MG BASE	A077864	002	Aug 10, 2009
	EQ 100MG BASE	A077864	003	Aug 10, 2009
IVAX SUB TEVA PHARMS	EQ 25MG BASE	A075719	003	Jun 30, 2006
	EQ 50MG BASE	A075719	001	Jun 30, 2006
	EQ 100MG BASE	A075719	002	Jun 30, 2006
MYLAN	EQ 25MG BASE	A076671	001	Feb 06, 2007
	EQ 50MG BASE	A076671	002	Feb 06, 2007
	EQ 100MG BASE	A076671	003	Feb 06, 2007
MYLAN PHARMS INC	EQ 25MG BASE	A076540	001	Mar 20, 2007
	EQ 25MG BASE	A078626	001	Jan 31, 2008
	EQ 50MG BASE	A076540	002	Mar 20, 2007
	EQ 50MG BASE	A078626	002	Jan 31, 2008
	EQ 100MG BASE	A076540	003	Mar 20, 2007
	EQ 100MG BASE	A078626	003	Jan 31, 2008
SUN PHARM INDS (IN)	EQ 25MG BASE	A078108	001	Feb 06, 2007
	EQ 50MG BASE	A078108	002	Feb 06, 2007
	EQ 100MG BASE	A078108	003	Feb 06, 2007
SUN PHARM INDS LTD	EQ 25MG BASE	A077977	001	Feb 06, 2007
	EQ 50MG BASE	A077977	002	Feb 06, 2007
	EQ 100MG BASE	A077977	003	Feb 06, 2007
	EQ 150MG BASE	A077977	004	Feb 06, 2007
	EQ 200MG BASE	A077977	005	Feb 06, 2007
TORRENT PHARMS	EQ 25MG BASE	A077765	001	Feb 06, 2007

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-420(of 478)

** See List Footnote

SERTRALINE HYDROCHLORIDE

TABLET;ORAL

SERTRALINE HYDROCHLORIDE

EQ 50MG BASE

A077765 002 Feb 06, 2007

EQ 100MG BASE

A077765 003 Feb 06, 2007

ZOLOFT

+ VIATRIS

EQ 150MG BASE **

N019839 003 Dec 30, 1991

+

EQ 200MG BASE **

N019839 004 Dec 30, 1991

SEVELAMER CARBONATE

FOR SUSPENSION;ORAL

SEVELAMER CARBONATE

LUPIN LTD

800MG/PACKET

A201513 001 Dec 23, 2021

2.4GM/PACKET

A201513 002 Dec 23, 2021

TABLET;ORAL

SEVELAMER CARBONATE

IMPAX LABS INC

800MG

A090975 001 Oct 23, 2017

LUPIN LTD

800MG

A204600 001 Jan 14, 2021

STRIDES PHARMA

800MG

A201069 001 Aug 05, 2020

SEVELAMER HYDROCHLORIDE

CAPSULE;ORAL

RENAGEL

GENZYME

403MG

N020926 001 Oct 30, 1998

TABLET;ORAL

SEVELAMER HYDROCHLORIDE

RISING

400MG

A201068 001 Dec 14, 2020

800MG

A201068 002 Dec 14, 2020

SIBUTRAMINE HYDROCHLORIDE

CAPSULE;ORAL

MERIDIA

ABBOTT

5MG

N020632 001 Nov 22, 1997

10MG

N020632 002 Nov 22, 1997

15MG

N020632 003 Nov 22, 1997

SILDENAFIL CITRATE

FOR SUSPENSION;ORAL

SILDENAFIL CITRATE

TRIS PHARMA INC

EQ 10MG BASE/ML

A212312 001 Nov 17, 2021

TABLET;ORAL

SILDENAFIL CITRATE

ACTAVIS GRP PTC

EQ 20MG BASE

A200149 001 Feb 25, 2013

APOTEX CORP

EQ 20MG BASE

A091379 001 Nov 06, 2012

PERRIGO R AND D

EQ 25MG BASE

A205791 001 Apr 23, 2020

EQ 50MG BASE

A205791 002 Apr 23, 2020

WATSON LABS INC

EQ 25MG BASE

A202506 001 Nov 25, 2020

EQ 50MG BASE

A202506 002 Nov 25, 2020

EQ 100MG BASE

A202506 003 Nov 25, 2020

SILODOSIN

CAPSULE;ORAL

SILODOSIN

ALEMBIC PHARMS

4MG

A211731 001 Nov 22, 2019

8MG

A211731 002 Nov 22, 2019

UPSHER SMITH LABS

4MG

A213230 001 Jan 03, 2022

8MG

A213230 002 Jan 03, 2022

SILVER SULFADIAZINE

CREAM;TOPICAL

SSD AF

DR REDDYS LA

1%

N018578 003 Jul 11, 1990

DRESSING;TOPICAL

SILDAFLO

FRANKLIN PHARMS

1%

N019608 001 Nov 30, 1989

SIMEPREVIR SODIUM

CAPSULE;ORAL

OLYSIO

+ JANSSEN PRODS

EQ 150MG BASE

N205123 001 Nov 22, 2013

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-421(of 478)

** See List Footnote

SIMETHICONE-CELLULOSE

SUSPENSION;ORAL

SONORX

BRACCO

7.5MG/ML

N020773 001 Oct 29, 1998

SIMVASTATIN

TABLET;ORAL

SIMVASTATIN

CHARTWELL RX

5MG

A077766 001 Dec 20, 2006

10MG

A077766 002 Dec 20, 2006

20MG

A077766 003 Dec 20, 2006

40MG

A077766 004 Dec 20, 2006

80MG

A077766 005 Dec 20, 2006

IVAX SUB TEVA PHARMS

5MG

A076052 001 Jun 23, 2006

10MG

A076052 002 Jun 23, 2006

20MG

A076052 003 Jun 23, 2006

40MG

A076052 004 Jun 23, 2006

80MG

A076052 005 Dec 20, 2006

MYLAN PHARMS INC

5MG

A090868 001 Jun 08, 2010

10MG

A090868 002 Jun 08, 2010

20MG

A090868 003 Jun 08, 2010

40MG

A090868 004 Jun 08, 2010

80MG

A090868 005 Jun 08, 2010

SUN PHARM INDS LTD

5MG

A076285 001 Dec 20, 2006

10MG

A076285 002 Dec 20, 2006

20MG

A076285 003 Dec 20, 2006

40MG

A076285 004 Dec 20, 2006

80MG

A076285 005 Jun 23, 2006

ZOCOR

+ ORGANON

80MG **

N019766 005 Jul 10, 1998

TABLET, ORALLY DISINTEGRATING;ORAL

SIMVASTATIN

+ SYNTHON PHARMS

10MG

N021961 001 Oct 09, 2007

+

20MG

N021961 002 Oct 09, 2007

+

40MG

N021961 003 Oct 09, 2007

+

80MG

N021961 004 Oct 09, 2007

SIMVASTATIN; SITAGLIPTIN PHOSPHATE

TABLET;ORAL

JUVISYNC

+ MERCK SHARP DOHME

10MG;EQ 50MG BASE **

N202343 004 Sep 18, 2012

+

10MG;EQ 100MG BASE **

N202343 001 Oct 07, 2011

+

20MG;EQ 50MG BASE **

N202343 005 Sep 18, 2012

+

20MG;EQ 100MG BASE **

N202343 002 Oct 07, 2011

+

40MG;EQ 50MG BASE **

N202343 006 Sep 18, 2012

+

40MG;EQ 100MG BASE **

N202343 003 Oct 07, 2011

SIROLIMUS

SOLUTION;ORAL

SIROLIMUS

TORRENT

1MG/ML

A215016 001 Dec 27, 2021

TABLET;ORAL

RAPAMUNE

+ PF PRISM CV

5MG **

N021110 003 Feb 23, 2004

SODIUM BENZOATE; SODIUM PHENYLACETATE

SOLUTION;ORAL

UCEPHAN

B BRAUN

100MG/ML;100MG/ML

N019530 001 Dec 23, 1987

SODIUM BICARBONATE

INJECTABLE;INJECTION

SODIUM BICARBONATE

HOSPIRA

0.9MEQ/ML

A077394 001 Nov 09, 2005

1MEQ/ML

A077394 002 Nov 09, 2005

SODIUM BICARBONATE IN PLASTIC CONTAINER

+ ABBOTT

0.9MEQ/ML **

N019443 001 Jun 03, 1986

+

1MEQ/ML **

N019443 002 Jun 03, 1986

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-422(of 478)

** See List Footnote

SODIUM BICARBONATE; TARTARIC ACID

GRANULE, EFFERVESCENT; ORAL

BAROS

MALLINCKRODT INC 460MG/GM; 420MG/GM

N018509 001 Aug 07, 1985

SODIUM CHLORIDE

AEROSOL, METERED; INHALATION

BRONCHO SALINE

+ BLAIREX 0.9%

N019912 001 Sep 03, 1992

INJECTABLE; INJECTION

BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

ABRAXIS PHARM 9MG/ML

A088909 001 Feb 07, 1985

SODIUM CHLORIDE

ABBOTT 20GM/100ML

N017013 001

B BRAUN 20GM/100ML

N017038 001

SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

B BRAUN 450MG/100ML

N018184 001

MILES 450MG/100ML

N018503 001

SODIUM CHLORIDE 0.9%

+ MEDEFIL INC 9MG/ML (9MG/ML)

N202832 001 Jan 06, 2012

+ 18MG/2ML (9MG/ML)

N202832 002 Jan 06, 2012

+ 22.5MG/2.5ML (9MG/ML)

N202832 003 Jan 06, 2012

+ 27MG/3ML (9MG/ML)

N202832 004 Jan 06, 2012

+ 45MG/5ML (9MG/ML)

N202832 005 Jan 06, 2012

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

ABBOTT 9MG/ML

N019218 001 Jul 13, 1984

+ ICU MEDICAL INC 9MG/ML

N019217 001 Jul 13, 1984

JUBILANT CADISTA 9MG/ML

A203352 001 May 18, 2016

+ LIEBEL-FLARSHEIM 405MG/50ML (9MG/ML)

N021569 001 Jul 27, 2006

MILES 900MG/100ML

N018502 001

SODIUM CHLORIDE 23.4% IN PLASTIC CONTAINER

+ ABRAXIS PHARM 234MG/ML **

N019329 001 Apr 22, 1987

SOLUTION; INTRAVENOUS

SODIUM CHLORIDE 14.6%

+ HOSPIRA 50MEQ/20ML (2.5MEQ/ML) **

N018897 001 Jul 20, 1984

SOLUTION; IRRIGATION

SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

BAXTER HLTHCARE 450MG/100ML

N017864 001

450MG/100ML

N018497 001 Feb 19, 1982

HOSPIRA 450MG/100ML

N017670 001

450MG/100ML

N018380 001

SODIUM CHLORIDE IN PLASTIC CONTAINER

MILES 900MG/100ML

N018247 001

SODIUM CHROMATE CR-51

INJECTABLE; INJECTION

CHROMITOPHE SODIUM

BRACCO 2mCi/VIAL

N013993 002

200uCi/ML

N013993 001

SODIUM CHROMATE CR 51

CURIUM 100uCi/ML

N016708 001

SODIUM FLUORIDE F-18

INJECTABLE; INTRAVENOUS

FLUORINE F-18

+ GE HEALTHCARE 2mCi/ML **

N017042 001

SODIUM FLUORIDE F 18

+ NIH NCI DCTD 10-200mCi/ML **

N022494 001 Jan 26, 2011

SODIUM FLUORIDE F-18

DECATUR 10-200mCi/ML

A204464 001 Oct 21, 2014

UCSF RODIOPHARM 10-200mCi/ML

A204437 001 Mar 13, 2014

UIHC PET IMAGING 10-200mCi/ML

A204462 001 Nov 17, 2015

UNIV TX MD ANDERSON 10-200mCi/ML

A203247 001 Dec 23, 2013

SODIUM FLUORIDE; TRICLOSAN

PASTE; DENTAL

COLGATE TOTAL

+ COLGATE PALMOLIVE 0.24%; 0.3%

N020231 001 Jul 11, 1997

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-423(of 478)

** See List Footnote

SODIUM IODIDE I-123

CAPSULE;ORAL

SODIUM IODIDE I 123

CARDINAL HEALTH 418	400uCi	N018671	003	May 27, 1982
GE HEALTHCARE	100uCi	N017630	001	
	200uCi	N017630	003	Jan 08, 1993

SOLUTION;ORAL

SODIUM IODIDE I 123

GE HEALTHCARE	2mCi/ML **	N017630	002	

SODIUM IODIDE I-131

CAPSULE;ORAL

IODOTOPE

BRACCO	1-130mCi	N010929	001	
	1-150mCi	N010929	003	

SODIUM IODIDE I 131

CIS	50uCi	N017316	001	
	100uCi	N017316	002	
CURIUM	0.8-100mCi	N016515	002	
+	0.8-100mCi	N016517	001	
	15-100uCi	N016517	002	
JUBILANT	2-200mCi	N021305	004	Nov 18, 2004

SOLUTION;ORAL

HICON

JUBILANT	1-250mCi/0.25ML	N021305	002	Jan 24, 2003
	1-500mCi/0.5ML	N021305	003	Jan 24, 2003
	1-1000mCi/ML	N021305	005	Apr 04, 2006

IODOTOPE

BRACCO	7-106mCi/BOT	N010929	002	

SODIUM IODIDE I 131

CIS	50mCi/ML	N017315	001	
+	CURIUM	3.5-150mCi/VIAL	N016515	001

SODIUM LACTATE

INJECTABLE; INJECTION

SODIUM LACTATE 0.167 MOLAR IN PLASTIC CONTAINER

B BRAUN	1.87GM/100ML	N018186	001	
BAXTER HLTHCARE	1.87GM/100ML	N016692	001	
HOSPIRA	1.87GM/100ML	N018249	001	

SODIUM LACTATE 1/6 MOLAR IN PLASTIC CONTAINER

B BRAUN	1.87GM/100ML	N020004	001	Apr 21, 1992

SODIUM LACTATE IN PLASTIC CONTAINER

+	HOSPIRA	5MEQ/ML	N018947	001	Sep 05, 1984

SODIUM MONOFLUOROPHOSPHATE

GEL; DENTAL

EXTRA-STRENGTH AIM

CHESEBROUGH PONDS	1.2%	N019518	002	Aug 06, 1986

PASTE; DENTAL

EXTRA-STRENGTH AIM

CHESEBROUGH PONDS	1.2%	N019518	001	Jun 03, 1987

SODIUM NITROPRUSSIDE

INJECTABLE; INJECTION

NIPRIDE

ROCHE	50MG/VIAL	N017546	001	

NITROPRESS

ABBOTT	50MG/VIAL	A071555	001	Nov 16, 1987
+	ABBVIE	50MG/VIAL **	N018450	001
HOSPIRA	50MG/VIAL	A070566	001	Jun 09, 1986
VPNA	25MG/ML	A071961	001	Aug 01, 1988

SODIUM NITROPRUSSIDE

ABRAXIS PHARM	50MG/VIAL	A070031	001	Jan 17, 1985	
AKORN	25MG/ML	A208635	001	May 04, 2017	
AMPHASTAR PHARMS INC	25MG/ML	A209832	001	Dec 18, 2017	
ANDA REPOSITORY	25MG/ML	A209834	001	Jun 26, 2018	
AVET LIFESCIENCES	25MG/ML	A208923	001	Nov 08, 2022	
+	BAXTER HLTHCARE	50MG/VIAL **	N018581	001	Jul 28, 1982
CIPLA	25MG/ML	A210855	001	Jul 16, 2018	
EUGIA PHARMA	25MG/ML	A211934	001	Dec 10, 2020	
SUN PHARM	25MG/ML	A210467	001	Nov 26, 2018	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-424(of 478)

** See List Footnote

SODIUM NITROPRUSSIDE

INJECTABLE; INJECTION

SODIUM NITROPRUSSIDE

TEVA PARENTERAL 25MG/ML

A073465 001 Mar 30, 1992

SOLUTION; INTRAVENOUS

NIPRIDE RTU IN SODIUM CHLORIDE 0.9%

+ EXELA PHARMA 10MG/50ML (0.2MG/ML) **

N209387 002 Dec 07, 2017

SODIUM OXYBATE

SOLUTION; ORAL

SODIUM OXYBATE

HIKMA 0.5GM/ML

A202090 001 Jan 17, 2017

SODIUM PHENYLBUTYRATE

TABLET; ORAL

SODIUM PHENYLBUTYRATE

ALVOGEN 500MG

A090910 001 Nov 18, 2011

SODIUM PHOSPHATE P-32

SOLUTION; INJECTION, ORAL

PHOSPHOTOPE

BRACCO 1-8mCi/VIAL

N010927 001

SODIUM PHOSPHATE P 32

MALLINCKRODT 0.67mCi/ML

N011777 001

1.5mCi/VIAL

N011777 002

SODIUM PHOSPHATE, DIBASIC, ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE

TABLET; ORAL

VISICOL

SALIX PHARMS 0.398GM; 1.102GM

N021097 001 Sep 21, 2000

SODIUM POLYSTYRENE SULFONATE

POWDER; ORAL, RECTAL

KAYEXALATE

+ CONCORDIA 453.6GM/BOT **

N011287 001

SODIUM POLYSTYRENE SULFONATE

CITRUSPHARMA 454GM/BOT

A040909 001 Dec 03, 2008

+ PAI HOLDINGS PHARM 453.6GM/BOT

A088786 001 Sep 11, 1984

SUSPENSION; ORAL, RECTAL

SODIUM POLYSTYRENE SULFONATE

ANI PHARMS 15GM/60ML

A090590 001 May 13, 2011

HIKMA 15GM/60ML

A089049 001 Nov 17, 1986

MORTON GROVE 15GM/60ML

A088717 001 Sep 11, 1984

ROXANE 15GM/60ML

A088453 001 Nov 17, 1983

SODIUM SUCCINATE

INJECTABLE; INJECTION

SODIUM SUCCINATE

ELKINS SINN 30%

A080516 001

SODIUM TETRADECYL SULFATE

INJECTABLE; INJECTION

SOTRADECOL

+ ELKINS SINN 1% **

N005970 004

+ 3% **

N005970 005

SODIUM THIOSULFATE

INJECTABLE; INJECTION

SODIUM THIOSULFATE

+ US ARMY 250MG/ML

N020166 001 Feb 14, 1992

SOFOSBUVIR

TABLET; ORAL

SOFOSBUVIR

TEVA PHARMS USA INC 400MG

A211353 001 Jan 27, 2022

SOLIFENACIN SUCCINATE

TABLET; ORAL

SOLIFENACIN SUCCINATE

ACCORD HLTHCARE 5MG

A207477 001 Jan 04, 2022

10MG

A207477 002 Jan 04, 2022

AJANTA PHARMA LTD 5MG

A205483 001 May 20, 2019

10MG

A205483 002 May 20, 2019

AMNEAL PHARMS CO 5MG

A209719 001 May 20, 2019

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-425(of 478)

** See List Footnote

SOLIFENACIN SUCCINATE

TABLET;ORAL

SOLIFENACIN SUCCINATE

	10MG	A209719 002	May 20, 2019
BRECKENRIDGE	5MG	A209818 001	May 20, 2019
	10MG	A209818 002	May 20, 2019
SUNSHINE	5MG	A213346 001	Apr 13, 2020
	10MG	A213346 002	Apr 13, 2020
ZYDUS PHARMS	5MG	A207721 001	Oct 19, 2020
	10MG	A207721 002	Oct 19, 2020

SORBITOL

SOLUTION;IRRIGATION

SORBITOL 3% IN PLASTIC CONTAINER

BAXTER HLTHCARE	3GM/100ML	N018512 001	May 27, 1982

SOTALOL HYDROCHLORIDE

TABLET;ORAL

BETAPACE

LEGACY PHARMA	320MG	N019865 004	Oct 30, 1992

BETAPACE AF

LEGACY PHARMA	40MG	N021151 006	Apr 02, 2003
	60MG	N021151 007	Apr 02, 2003
	100MG	N021151 005	Mar 14, 2003

SOTALOL HYDROCHLORIDE

AUROBINDO PHARMA USA	80MG	A077616 001	Feb 07, 2007
	120MG	A077616 002	Feb 07, 2007
	160MG	A077616 003	Feb 07, 2007
IMPAX PHARMS	80MG	A075663 001	Nov 07, 2000
	120MG	A075663 002	Nov 07, 2000
	160MG	A075663 003	Nov 07, 2000
	240MG	A075663 004	Nov 07, 2000
MYLAN	80MG	A075237 001	May 01, 2000
	80MG	A075725 001	Dec 19, 2000
	120MG	A075237 002	May 01, 2000
	120MG	A075725 002	Dec 19, 2000
	160MG	A075237 003	May 01, 2000
	160MG	A075725 003	Dec 19, 2000
	240MG	A075237 004	May 01, 2000
	240MG	A075725 004	Dec 19, 2000
SUN PHARM INDUSTRIES	80MG	A075515 001	Oct 15, 2001
	80MG	A076576 001	Apr 08, 2004
	120MG	A075515 004	Oct 15, 2001
	120MG	A076576 002	Apr 08, 2004
	160MG	A075515 002	Oct 15, 2001
	160MG	A076576 003	Apr 08, 2004
	240MG	A075515 003	Oct 15, 2001
TEVA	80MG	A076883 001	Jul 26, 2004
	120MG	A076883 002	Jul 26, 2004
	160MG	A076883 003	Jul 26, 2004
UPSHER SMITH LABS	80MG	A075366 001	May 01, 2000
	120MG	A075366 002	May 01, 2000
	160MG	A075366 003	May 01, 2000
	240MG	A075366 004	May 01, 2000
WATSON LABS	80MG	A075238 001	Jul 13, 2000
	120MG	A075238 002	Jul 13, 2000
	160MG	A075238 003	Jul 13, 2000
	240MG	A075238 004	Jul 13, 2000

SOYBEAN OIL

INJECTABLE;INJECTION

LIPOSYN III 10%

HOSPIRA	10%	N018969 001	Sep 24, 1984

LIPOSYN III 20%

HOSPIRA	20%	N018970 001	Sep 25, 1984

LIPOSYN III 30%

HOSPIRA	30%	N020181 001	Jan 13, 1998

SOYACAL 10%

ALPHA THERA	10%	N018465 001	Jun 29, 1983

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-426(of 478)

** See List Footnote

SOYBEAN OIL

INJECTABLE; INJECTION

SOYACAL 20%

ALPHA THERA

20%

N018786 001 Jun 29, 1983

TRAVAMULSION 10%

BAXTER HLTHCARE

10%

N018660 001 Feb 26, 1982

TRAVAMULSION 20%

BAXTER HLTHCARE

20%

N018758 001 Feb 15, 1983

SPARFLOXACIN

TABLET; ORAL

ZAGAM

MYLAN

200MG

N020677 001 Dec 19, 1996

SPECTINOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION

TROBICIN

PFIZER

EQ 2GM BASE/VIAL

N050347 001

EQ 4GM BASE/VIAL

N050347 002

SPIRAPRIL HYDROCHLORIDE

TABLET; ORAL

RENORMAX

SCHERING

3MG

N020240 001 Dec 29, 1994

6MG

N020240 002 Dec 29, 1994

12MG

N020240 003 Dec 29, 1994

24MG

N020240 004 Dec 29, 1994

SPIRONOLACTONE

TABLET; ORAL

SPIRONOLACTONE

ACTAVIS ELIZABETH

25MG

A040353 003 Mar 15, 2006

50MG

A040353 001 Jul 29, 1999

100MG

A040353 002 Jul 29, 1999

ASCOT

25MG

A087687 001 Oct 20, 1982

CHARTWELL RX

25MG

A086809 001

IVAX PHARMS

25MG

A087108 001

LEDERLE

25MG

A087634 001

MUTUAL PHARM

25MG

A087265 001

MYLAN

25MG

A087086 001

PUREPAC PHARM

25MG

A087998 001 Oct 14, 1983

25MG

A088053 001 Aug 25, 1983

SUPERPHARM

25MG

A089364 001 Nov 07, 1986

UPSHER SMITH

25MG

A087554 001

VANGARD

25MG

A087648 001 Feb 01, 1982

WARNER CHILCOTT

25MG

A087952 001 Nov 18, 1982

WATSON LABS

25MG

A086898 002 Mar 02, 1982

25MG

A087078 001

STANOZOLOL

TABLET; ORAL

WINSTROL

+ LUNDBECK INC

2MG

N012885 001 May 14, 1984

STAVUDINE

CAPSULE; ORAL

STAVUDINE

AUROBINDO PHARMA

15MG

A077672 003 Dec 29, 2008

20MG

A077672 004 Dec 29, 2008

30MG

A077672 001 Dec 29, 2008

40MG

A077672 002 Dec 29, 2008

HETERO LABS LTD III

15MG

A078957 001 Dec 29, 2008

20MG

A078957 002 Dec 29, 2008

30MG

A078957 003 Dec 29, 2008

40MG

A078957 004 Dec 29, 2008

MYLAN

15MG

A079069 001 Dec 29, 2008

20MG

A079069 002 Dec 29, 2008

30MG

A079069 003 Dec 29, 2008

40MG

A079069 004 Dec 29, 2008

MYLAN LABS LTD

30MG

A078775 001 Jan 05, 2009

40MG

A078775 002 Jan 05, 2009

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-427(of 478)

** See List Footnote

STAVUDINE

CAPSULE;ORAL

ZERIT

BRISTOL	5MG	N020412 001	Jun 24, 1994
+	15MG **	N020412 002	Jun 24, 1994
+	20MG **	N020412 003	Jun 24, 1994
+	30MG **	N020412 004	Jun 24, 1994
+	40MG **	N020412 005	Jun 24, 1994

CAPSULE, EXTENDED RELEASE;ORAL

ZERIT XR

BRISTOL MYERS SQUIBB	37.5MG	N021453 001	Dec 31, 2002
	50MG	N021453 002	Dec 31, 2002
	75MG	N021453 003	Dec 31, 2002
	100MG	N021453 004	Dec 31, 2002

FOR SOLUTION;ORAL

STAVUDINE

AUROBINDO PHARMA	1MG/ML	A077774 001	Dec 29, 2008
CIPLA LTD	1MG/ML	A078030 001	Mar 20, 2009

ZERIT

+	BRISTOL	1MG/ML **	N020413 001	Sep 06, 1996

STERILE WATER FOR INJECTION

LIQUID;N/A

BACTERIOSTATIC WATER FOR INJECTION IN PLASTIC CONTAINER

ABRAXIS PHARM	100%	A089099 001	Dec 29, 1987
	100%	A089100 001	Dec 29, 1987

STERILE WATER FOR INJECTION

HIKMA	100% (20ML)	A206369 002	Sep 02, 2015	
+	HOSPIRA	100% (1ML)	N018801 001	Oct 27, 1982

STERILE WATER FOR INJECTION IN PLASTIC CONTAINER

B BRAUN	100%	N019077 001	Mar 02, 1984

STERILE WATER FOR IRRIGATION

LIQUID;IRRIGATION

STERILE WATER IN PLASTIC CONTAINER

MILES	100%	N018246 001

STREPTOMYCIN SULFATE

INJECTABLE;INJECTION

STREPTOMYCIN SULFATE

COPANOS	EQ 500MG BASE/ML	A060684 001
LILLY	EQ 1GM BASE/VIAL	A060107 001
	EQ 1GM BASE/2ML	A060404 001
	EQ 5GM BASE/VIAL	A060107 002
PFIZER	EQ 1GM BASE/VIAL **	A060076 001
	EQ 1GM BASE/2.5ML	A060111 001
	EQ 5GM BASE/VIAL **	A060076 002

SUCCINYLCHOLINE CHLORIDE

INJECTABLE;INJECTION

ANECTINE

SANDOZ INC	50MG/ML	N008453 003
	500MG/VIAL	N008453 001
	1GM/VIAL	N008453 004

QUELICIN PRESERVATIVE FREE

+	HOSPIRA	20MG/ML **	N008845 001
+		50MG/ML **	N008845 002
+		100MG/ML **	N008845 004

SUCCINYLCHOLINE CHLORIDE

AMPHASTAR PHARMS INC	20MG/ML	A213432 001	Jun 08, 2020
BE PHARMS	20MG/ML	A216003 001	Feb 07, 2022
INTL MEDICATION	100MG/VIAL	A085400 001	Feb 04, 1982
ORGANON USA INC	20MG/ML	A080997 001	

SUCOSTRIN

+	APOTHECON	20MG/ML	N008847 001
+		100MG/ML	N008847 003

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-428(of 478)

** See List Footnote

SUFENTANIL CITRATE

INJECTABLE; INJECTION

SUFENTANIL CITRATE

WATSON LABS

EQ 0.05MG BASE/ML

A074406 001 Dec 15, 1995

SULFACETAMIDE SODIUM

OINTMENT; OPHTHALMIC

BLEPH-10

ALLERGAN

10%

A084015 001

CETAMIDE

ALCON

10%

A080021 001

SODIUM SULAMYD

+ SCHERING

10% **

N005963 002

SULFAIR 10

PHARMAFAIR

10%

A088000 001 Dec 22, 1982

SOLUTION/DROPS; OPHTHALMIC

BLEPH-30

ALLERGAN

30%

A080028 002

ISOPTO CETAMIDE

ALCON

15%

A080020 002

OCUSULF-10

MIZA PHARMS USA

10%

A080660 001

OCUSULF-30

MIZA PHARMS USA

30%

A080660 002

SODIUM SULAMYD

+ SCHERING

10% **

N005963 001

+

30% **

N005963 003

SODIUM SULFACETAMIDE

AKORN

10%

A083021 001

15%

A083021 002

30%

A083021 003

SOLA BARNES HIND

10%

A084143 001

10%

A084145 001

30%

A084146 001

30%

A084147 001

SULF-10

NOVARTIS

10%

A080025 001

SULF-15

NOVARTIS

15%

A089047 001 Oct 31, 1995

SULFACEL-15

OPTOPICS

15%

A080024 001

SULFACETAMIDE SODIUM

AKORN

30%

A040216 001 May 25, 1999

ALCON PHARMS LTD

30%

A089068 001 May 05, 1987

PHARMAFAIR

10%

A088947 001 May 17, 1985

SULFAIR 10

PHARMAFAIR

10%

A087949 001 Dec 13, 1982

SULFAIR FORTE

PHARMAFAIR

30%

A088385 001 Oct 13, 1983

SULFAIR-15

PHARMAFAIR

15%

A088186 001 May 25, 1983

SULTEN-10

BAUSCH AND LOMB

10%

A087818 001 Feb 03, 1983

SULFACYTINE

TABLET; ORAL

RENOQUID

GLENWOOD

250MG

N017569 001

SULFADIAZINE

TABLET; ORAL

SULFADIAZINE

ABBVIE

300MG

N004125 005

EVERYLIFE

500MG

A080088 001

+

IMPAX LABS

500MG

A080081 001

LANNETT

500MG

A080084 001

LEDERLE

500MG

N004054 001

+

LILLY

500MG

N004122 002

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-429(of 478)

** See List Footnote

SULFADIAZINE SODIUM

INJECTABLE; INJECTION

SULFADIAZINE SODIUM

LEDERLE

250MG/ML

N004054 002

SULFADIAZINE; SULFAMERAZINE

SUSPENSION; ORAL

SULFONAMIDES DUPLEX

LILLY

250MG/5ML; 250MG/5ML

N006317 007

SULFAMETER

TABLET; ORAL

SULLA

BAYER HLTHCARE

500MG

N016000 002

SULFAMETHIZOLE

TABLET; ORAL

MICROSUL

FOREST PHARMS

1GM

A086012 001

PROKLAR

FOREST PHARMS

500MG

A080273 001

THIOSULFIL

WYETH AYERST

250MG

N008565 001

500MG

N008565 004

SULFAMETHOXAZOLE

SUSPENSION; ORAL

GANTANOL

ROCHE

500MG/5ML

N013664 002

TABLET; ORAL

GANTANOL

ROCHE

500MG

N012715 002

GANTANOL-DS

ROCHE

1GM

N012715 003

SULFAMETHOXAZOLE

ASCOT

500MG

A087662 001

Oct 20, 1982

BARR

500MG

A087189 001

Jul 25, 1983

HEATHER

500MG

A086163 001

RISING

500MG

A085844 001

WATSON LABS

500MG

A085053 001

1GM

A086000 001

UROBAK

SHIONOGI

500MG

A087307 001

SULFAMETHOXAZOLE; TRIMETHOPRIM

INJECTABLE; INJECTION

BACTRIM

+ SUN PHARM INDS INC

80MG/ML; 16MG/ML **

N018374 001

SEPTRA

MONARCH PHARMS

80MG/ML; 16MG/ML **

N018452 001

SULFAMETHOXAZOLE AND TRIMETHOPRIM

ABRAXIS PHARM

80MG/ML; 16MG/ML

A070223 001

Dec 29, 1987

BEDFORD

80MG/ML; 16MG/ML

A072383 001

Apr 29, 1992

HIKMA

80MG/ML; 16MG/ML

A070627 001

Dec 29, 1987

80MG/ML; 16MG/ML

A070628 001

Dec 29, 1987

HOSPIRA

80MG/ML; 16MG/ML

A073199 001

Sep 11, 1992

WATSON LABS

80MG/ML; 16MG/ML

A071556 001

Dec 29, 1987

SUSPENSION; ORAL

BACTRIM

+ SUN PHARM INDUSTRIES

200MG/5ML; 40MG/5ML **

N017560 001

BACTRIM PEDIATRIC

SUN PHARM INDUSTRIES

200MG/5ML; 40MG/5ML **

N017560 002

SEPTRA

MONARCH PHARMS

200MG/5ML; 40MG/5ML **

N017598 001

SEPTRA GRAPE

MONARCH PHARMS

200MG/5ML; 40MG/5ML **

N017598 002

Feb 12, 1986

SULFAMETHOXAZOLE AND TRIMETHOPRIM

ANI PHARMS

200MG/5ML; 40MG/5ML

A070028 001

Jun 02, 1987

LUPIN LTD

200MG/5ML; 40MG/5ML

A212699 001

Jan 05, 2021

TEVA

200MG/5ML; 40MG/5ML

N018812 001

Jan 28, 1983

200MG/5ML; 40MG/5ML

N018812 002

Jun 10, 1983

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-430(of 478)

** See List Footnote

SULFAMETHOXAZOLE; TRIMETHOPRIM

SUSPENSION; ORAL

SULFATRIM

PHARM ASSOC	200MG/5ML; 40MG/5ML	N018615	002	Jan 07, 1983

SULMEPRIM

USL PHARMA	200MG/5ML; 40MG/5ML	A070063	001	Aug 01, 1986

SULMEPRIM PEDIATRIC

USL PHARMA	200MG/5ML; 40MG/5ML	A070064	001	Aug 01, 1986

TRIMETH/SULFA

ALPHARMA US PHARMS	200MG/5ML; 40MG/5ML	A072289	001	May 23, 1988

	200MG/5ML; 40MG/5ML	A072398	001	May 23, 1988

NASKA	200MG/5ML; 40MG/5ML	A072399	001	May 23, 1988

TABLET; ORAL

COTRIM

TEVA	400MG; 80MG	A070034	001	May 16, 1985

COTRIM D.S.

TEVA	800MG; 160MG	A070048	001	Mar 18, 1985

SULFAMETHOPRIM

NOVEL LABS INC	400MG; 80MG	A070022	001	Feb 15, 1985

SULFAMETHOPRIM-DS

NOVEL LABS INC	800MG; 160MG	A070032	001	Feb 15, 1985

SULFAMETHOXAZOLE AND TRIMETHOPRIM

FOSUN PHARMA	400MG; 80MG	A070889	001	Nov 13, 1986

	400MG; 80MG	N018598	003	May 19, 1982

	800MG; 160MG	A070890	001	Nov 13, 1986

HEATHER	400MG; 80MG	N018946	001	Aug 10, 1984

	800MG; 160MG	N018946	002	Aug 10, 1984

INTERPHARM	400MG; 80MG	A071299	001	Oct 27, 1987

	800MG; 160MG	A071300	001	Oct 27, 1987

MARTEC USA LLC	400MG; 80MG	A072408	001	Dec 07, 1988

MUTUAL PHARM	400MG; 80MG	A070006	001	Nov 14, 1984

PLIVA	400MG; 80MG	A070215	001	Sep 10, 1985

	800MG; 160MG	A070216	001	Sep 10, 1985

ROXANE	400MG; 80MG	A072768	001	Aug 30, 1991

TEVA	400MG; 80MG	N018242	001	

	800MG; 160MG	N018242	002	

USL PHARMA	400MG; 80MG	A070203	001	Nov 08, 1985

	800MG; 160MG	A070204	001	Nov 08, 1985

WATSON LABS	400MG; 80MG	A070002	001	Nov 07, 1984

	400MG; 80MG	N018852	001	May 09, 1983

	800MG; 160MG	A070000	001	Nov 07, 1984

SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH

FOSUN PHARMA	800MG; 160MG	N018598	004	May 19, 1982

HERITAGE PHARMA AVET	800MG; 160MG	A070037	001	Jun 02, 1987

MARTEC USA LLC	800MG; 160MG	A072417	001	Dec 07, 1988

MUTUAL PHARM	800MG; 160MG	A070007	001	Nov 14, 1984

ROXANE	800MG; 160MG	A072769	001	Aug 30, 1991

WATSON LABS	800MG; 160MG	N018854	001	May 09, 1983

SULFAMETHOXAZOLE AND TRIMETHOPRIM SINGLE STRENGTH

HERITAGE PHARMA AVET	400MG; 80MG	A070030	001	Jun 02, 1987

SULFATRIM-DS

SUPERPHARM	800MG; 160MG	A070066	001	Jun 24, 1985

SULFATRIM-SS

SUPERPHARM	400MG; 80MG	A070065	002	Jun 24, 1985

UROPLUS DS

SHIONOGI	800MG; 160MG	A071816	001	Sep 28, 1987

UROPLUS SS

SHIONOGI	400MG; 80MG	A071815	001	Sep 28, 1987

SULFANILAMIDE

CREAM; VAGINAL

AVC

+	MYLAN SPECIALITY LP	15% **	N006530	003	Jan 27, 1987

SULFANILAMIDE

COSETTE	15%	A088718	001	Sep 19, 1985

SUPPOSITORY; VAGINAL

AVC

MYLAN SPECIALITY LP	1.05GM	N006530	004	Jan 27, 1987

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-431(of 478)

** See List Footnote

SULFAPHENAZOLE

SUSPENSION;ORAL

SULFABID

PHARM RES ASSOC

500MG/5ML

N013093 001

TABLET;ORAL

SULFABID

PURDUE FREDERICK

500MG

N013092 002

SULFAPYRIDINE

TABLET;ORAL

SULFAPYRIDINE

LILLY

500MG

N000159 001

SULFASALAZINE

SUSPENSION;ORAL

AZULFIDINE

PHARMACIA AND UPJOHN

250MG/5ML

N018605 001

TABLET;ORAL

S.A.S.-500

SOLVAY

500MG

A083450 001

SULFASALAZINE

EPIC PHARMA

500MG

A086184 001

SUN PHARM INDUSTRIES

500MG

A089590 001 Oct 19, 1987

SUPERPHARM

500MG

A089339 001 Oct 26, 1987

WATSON LABS

500MG

A084964 001

500MG

A087197 001

TABLET, DELAYED RELEASE;ORAL

SULFASALAZINE

WATSON LABS

500MG

A088052 001 May 24, 1983

SULFINPYRAZONE

CAPSULE;ORAL

ANTURANE

+ NOVARTIS

200MG **

N011556 004

SULFINPYRAZONE

BARR

200MG

A087666 001 Sep 17, 1982

IVAX PHARMS

200MG

A087770 001 Nov 19, 1982

PAR PHARM

200MG

A088934 001 Sep 06, 1985

VANGARD

200MG

A088666 001 Feb 17, 1984

TABLET;ORAL

ANTURANE

NOVARTIS

100MG **

N011556 003

SULFINPYRAZONE

BARR

100MG

A087665 001 Sep 17, 1982

IVAX PHARMS

100MG

A087769 001 Jun 01, 1982

PAR PHARM

100MG

A088933 001 Sep 06, 1985

WATSON LABS

100MG

A087667 001 May 26, 1982

SULFISOXAZOLE

TABLET;ORAL

GANTRISIN

ROCHE

500MG

N006525 001

SOSOL

MK LABS

500MG

A080036 001

SOXAZOLE

ALRA

500MG

A080366 001

SULFALAR

PARKE DAVIS

500MG

A084955 001

SULFISOXAZOLE

ANI PHARMS

500MG

A080142 001

BARR

500MG

A084031 001

HEATHER

500MG

A080189 001

IMPAX LABS

500MG

A080109 001

LANNETT

500MG

A080085 001

LEDERLE

500MG

A087649 001

PHARMERAL

500MG

A084385 001

PUREPAC PHARM

500MG

A080087 001

RISING

500MG

A085628 001

ROXANE

500MG

A080082 001

VALEANT PHARM INTL

500MG

A080268 002

VITARINE

500MG

A087332 001

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-432(of 478)

** See List Footnote

SULFISOXAZOLE

TABLET; ORAL

SULFISOXAZOLE

WATSON LABS

500MG

A085534 001

WEST WARD

500MG

A080379 001

SULSOXIN

SOLVAY

500MG

A080040 001

SULFISOXAZOLE ACETYL

EMULSION; ORAL

LIPO GANTRISIN

ROCHE

EQ 1GM BASE/5ML

N009182 009

SUSPENSION; ORAL

GANTRISIN PEDIATRIC

ROCHE

EQ 500MG BASE/5ML

N009182 004

SYRUP; ORAL

GANTRISIN

ROCHE

EQ 500MG BASE/5ML

N009182 002

SULFISOXAZOLE DIOLAMINE

INJECTABLE; INJECTION

GANTRISIN

ROCHE

EQ 400MG BASE/ML

N006917 001

OINTMENT; OPHTHALMIC

GANTRISIN

ROCHE

EQ 4% BASE

N008414 002

SOLUTION/DROPS; OPHTHALMIC

GANTRISIN

ROCHE

EQ 4% BASE

N007757 002

SULFISOXAZOLE DIOLAMINE

SOLA BARNES HIND

EQ 4% BASE

A084148 001

SULFOXONE SODIUM

TABLET, DELAYED RELEASE; ORAL

DIASONE SODIUM

ABBVIE

165MG

N006044 003

SULFUR

POWDER; TOPICAL

BENSULFOID

POYTHRESS

33.32%

N002918 001

SULINDAC

TABLET; ORAL

CLINORIL

+ MERCK

150MG **

N017911 001

+

200MG **

N017911 002

SULINDAC

ANI PHARMS

150MG

A072973 002 Feb 28, 1992

200MG

A072973 001 Feb 28, 1992

EPIC PHARMA LLC

150MG

A073262 002 Sep 06, 1991

200MG

A073262 001 Sep 06, 1991

FOSUN PHARMA

150MG

A072712 001 Aug 30, 1991

200MG

A072713 001 Aug 30, 1991

RISING

150MG

A073039 002 Jun 22, 1993

200MG

A073039 001 Jun 22, 1993

SUMATRIPTAN

SPRAY; NASAL

IMITREX

GLAXOSMITHKLINE

10MG/SPRAY

N020626 002 Aug 26, 1997

SUMATRIPTAN SUCCINATE

INJECTABLE; SUBCUTANEOUS

ALSUMA

MERIDIAN MEDCL

EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)

N022377 001 Jun 29, 2010

SUMATRIPTAN SUCCINATE

FRESENIUS KABI USA

EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)

A079240 002 Sep 18, 2009

EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)

A079240 001 Sep 18, 2009

MYLAN LABS LTD

EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)

A203322 001 Apr 14, 2014

PAR STERILE PRODUCTS

EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)

A077871 001 Jul 09, 2009

SANDOZ INC

EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)

A078067 002 Feb 06, 2009

EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)

A078067 001 Feb 06, 2009

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-433(of 478)

** See List Footnote

SUMATRIPTAN SUCCINATE

INJECTABLE;SUBCUTANEOUS

SUMATRIPTAN SUCCINATE

STERISCIENCE

EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)

A090314 001 Jun 10, 2010

EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)

A090641 001 Jul 28, 2010

TEVA PARENTERAL

EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)

A078318 001 Feb 06, 2009

EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)

A078318 002 Feb 06, 2009

TEVA PHARMS USA

EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)

A077907 001 Feb 06, 2009

ZYDUS

EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)

A090310 001 Aug 11, 2010

SUMAVEL DOSEPRO

+ ENDO VENTURES LTD

EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)

N022239 002 Nov 26, 2013

+

EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)

N022239 001 Jul 15, 2009

SYSTEM;IONTOPHORESIS

ZECUITY

+ TEVA BRANDED PHARM

EQ 6.5MG BASE/4HR

N202278 001 Jan 17, 2013

TABLET;ORAL

SUMATRIPTAN SUCCINATE

FOSUN PHARMA

EQ 25MG BASE

A076976 001 Aug 10, 2009

EQ 50MG BASE

A076976 002 Aug 10, 2009

EQ 100MG BASE

A076976 003 Aug 10, 2009

HIKMA PHARMS

EQ 25MG BASE

A078298 001 May 21, 2013

EQ 50MG BASE

A078298 002 May 21, 2013

EQ 100MG BASE

A078298 003 May 21, 2013

MYLAN

EQ 25MG BASE

A077163 001 Nov 02, 2009

EQ 50MG BASE

A077163 002 Nov 02, 2009

EQ 100MG BASE

A077163 003 Nov 02, 2009

ROXANE

EQ 25MG BASE

A078241 001 Aug 10, 2009

EQ 50MG BASE

A078241 002 Aug 10, 2009

EQ 100MG BASE

A078241 003 Aug 10, 2009

TEVA

EQ 25MG BASE

A076840 001 Feb 09, 2009

EQ 50MG BASE

A076840 002 Feb 09, 2009

EQ 100MG BASE

A076840 003 Feb 09, 2009

SUPROFEN

SOLUTION/DROPS;OPHTHALMIC

PROFENAL

ALCON

1%

N019387 001 Dec 23, 1988

TACRINE HYDROCHLORIDE

CAPSULE;ORAL

COGNEX

SHIONOGI INC

EQ 10MG BASE

N020070 001 Sep 09, 1993

EQ 20MG BASE

N020070 002 Sep 09, 1993

EQ 30MG BASE

N020070 003 Sep 09, 1993

EQ 40MG BASE

N020070 004 Sep 09, 1993

TACROLIMUS

CAPSULE;ORAL

TACROLIMUS

CONCORD BIOTECH LTD

EQ 0.5MG BASE

A213112 001 Nov 10, 2020

HERITAGE PHARMA AVET

EQ 5MG BASE

A090402 001 Jul 01, 2010

INJECTABLE;INJECTION

TACROLIMUS

HOSPIRA

EQ 5MG BASE/ML

A203900 001 Aug 25, 2017

TADALAFIL

TABLET;ORAL

TADALAFIL

CHARTWELL RX

2.5MG

A210716 001 Dec 29, 2020

5MG

A210716 002 Dec 29, 2020

10MG

A210716 003 Dec 29, 2020

20MG

A210716 004 Dec 29, 2020

MYLAN

5MG

A206957 001 Apr 29, 2019

20MG

A200630 001 Aug 03, 2018

RISING

2.5MG

A206956 001 Apr 29, 2019

10MG

A206956 002 Apr 29, 2019

20MG

A206956 003 Apr 29, 2019

WATSON LABS INC

2.5MG

A205885 001 Mar 29, 2019

5MG

A205885 002 Mar 29, 2019

10MG

A205885 003 Mar 29, 2019

20MG

A205885 004 Mar 29, 2019

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-434(of 478)

** See List Footnote

TALBUTAL

TABLET; ORAL

LOTUSATE

SANOFI AVENTIS US

120MG

N009410 005

TAMOXIFEN CITRATE

TABLET; ORAL

NOLVADEX

+ ASTRAZENECA

EQ 10MG BASE **

N017970 001

+

EQ 20MG BASE **

N017970 002 Mar 21, 1994

TAMOXIFEN CITRATE

ACTAVIS LABS FL INC

EQ 10MG BASE

A076179 001 Feb 20, 2003

EQ 20MG BASE

A076179 002 Feb 20, 2003

AEGIS PHARMS

EQ 10MG BASE

A076398 001 Mar 31, 2003

EQ 20MG BASE

A076398 002 Mar 31, 2003

IVAX SUB TEVA PHARMS

EQ 10MG BASE

A075740 001 Feb 20, 2003

EQ 20MG BASE

A075740 002 Feb 20, 2003

PHARMACHEMIE

EQ 10MG BASE

A074539 001 Mar 31, 2003

ROXANE

EQ 10MG BASE

A076027 001 Feb 20, 2003

EQ 20MG BASE

A076027 002 Feb 20, 2003

TEVA

EQ 10MG BASE

A074504 001 Apr 28, 2003

EQ 20MG BASE

A074504 002 Apr 28, 2003

TAMSULOSIN HYDROCHLORIDE

CAPSULE; ORAL

TAMSULOSIN HYDROCHLORIDE

ACME LABS

0.4MG

A214730 001 May 04, 2022

ANCHEN PHARMS

0.4MG

A202010 001 Jan 04, 2013

MYLAN

0.4MG

A090408 001 Apr 27, 2010

TAPENTADOL HYDROCHLORIDE

SOLUTION; ORAL

NUCYNTA

+ COLLEGIUM PHARM INC

EQ 20MG BASE/ML

N203794 001 Oct 15, 2012

TAZAROTENE

CREAM; TOPICAL

TAZAROTENE

FOUGERA PHARMS INC

0.1%

A211175 001 Jan 28, 2019

TECHNETIUM TC-99M APCITIDE

INJECTABLE; INJECTION

ACUTECT

CIS BIO INTL SA

N/A

N020887 001 Sep 14, 1998

TECHNETIUM TC-99M DEPREOTIDE

INJECTABLE; INJECTION

NEO TECT KIT

CIS BIO INTL SA

N/A **

N021012 001 Aug 03, 1999

TECHNETIUM TC-99M DISOFENIN KIT

INJECTABLE; INJECTION

HEPATOLITE

SUN PHARM INDS INC

N/A

N018467 001 Mar 16, 1982

TECHNETIUM TC-99M ETIDRONATE KIT

INJECTABLE; INJECTION

CINTICHEM TECHNETIUM 99M HEDSPA

GE HEALTHCARE

N/A

N017653 001

MPI STANNOUS DIPHOSPHONATE

GE HEALTHCARE

N/A

N017667 001

OSTEOSCAN

MALLINCKRODT

N/A

N017454 001

TECHNETIUM TC 99M DIPHOSPHONATE-TIN KIT

GE HEALTHCARE

N/A

N017562 001

TECHNETIUM TC-99M FERMENTETATE KIT

INJECTABLE; INJECTION

RENOTEC

BRACCO

N/A

N017045 001

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-435(of 478)

** See List Footnote

TECHNETIUM TC-99M GLUCEPTATE KIT

INJECTABLE; INJECTION

GLUCOSCAN

BRISTOL MYERS SQUIBB N/A

N017907 001

TECHNESCAN GLUCEPTATE

DRAXIMAGE N/A

N018272 001 Jan 27, 1982

TECHNETIUM TC-99M LIDOFEININ KIT

INJECTABLE; INJECTION

TECHNESCAN HIDA

DRAXIMAGE N/A

N018489 001 Oct 31, 1986

TECHNETIUM TC-99M MEDRONATE

INJECTABLE; INJECTION

DRAXIMAGE MDP-10

JUBILANT N/A

N018035 001

TECHNETIUM TC-99M MEDRONATE KIT

INJECTABLE; INJECTION

AMERSCAN MDP KIT

GE HEALTHCARE N/A

N018335 001 Aug 05, 1982

OSTEOLITE

PHARMALUCENCE N/A

N017972 001

TECHNETIUM TC 99M MPI MDP

GE HEALTHCARE N/A

N018141 001

N/A

N018141 002 Jun 12, 1989

TECHNETIUM TC-99M PENTETATE KIT

INJECTABLE; INJECTION

AN-DTPA

JUBILANT DRAXIMAGE N/A

N017714 001

MPI DTPA KIT - CHELATE

GE HEALTHCARE N/A

N017255 001

TECHNETIUM TC-99M PENTETATE KIT

GE HEALTHCARE N/A

N017264 002

TECHNETIUM TC-99M POLYPHOSPHATE KIT

INJECTABLE; INJECTION

SODIUM POLYPHOSPHATE-TIN KIT

GE HEALTHCARE N/A

N017664 001

TECHNETIUM TC-99M PYRO/TRIMETA PHOSPHATES KIT

INJECTABLE; INJECTION

PYROLITE

PHARMALUCENCE N/A

N017684 001

TECHNETIUM TC-99M PYROPHOSPHATE KIT

INJECTABLE; INJECTION

PHOSPHOTEC

BRACCO N/A

N017680 001

TECHNETIUM TC-99M RED BLOOD CELL KIT

INJECTABLE; INJECTION

RBC-SCAN

CADEMA N/A

N020063 001 Jun 11, 1992

TECHNETIUM TC-99M SESTAMIBI KIT

INJECTABLE; INJECTION

MIRALUMA

LANTHEUS MEDCL N/A

N019785 003 May 23, 1997

TECHNETIUM TC-99M SODIUM PERTECHNETATE

SOLUTION; INJECTION, ORAL

SODIUM PERTECHNETATE TC 99M

+ GE HEALTHCARE 2-100mCi/ML **

N017471 001

+ MALLINCKRODT 10-60mCi/ML **

N017725 001

PHARMALUCENCE 12mCi/ML

N017321 001

24mCi/ML

N017321 002

48mCi/ML

N017321 003

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-436(of 478)

** See List Footnote

TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR

SOLUTION;INJECTION, ORAL

MINITEC

BRACCO

0.22-2.22 CI/GENERATOR

N017339 001

SOLUTION;INTRAVENOUS

TECHNELITE

LANTHEUS MEDCL

0.0083-2.7 CI/GENERATOR

N017771 001

ULTRA-TECHNEKOW FM

CURIUM

0.25-3 CI/GENERATOR

N017243 002

SOLUTION;INTRAVENOUS, ORAL

TECHNETIUM TC 99M GENERATOR

+

GE HEALTHCARE

68-2703mCi/GENERATOR

N017693 002 Dec 13, 2013

830-16600mCi/GENERATOR

N017693 001

TECHNETIUM TC-99M SUCCIMER KIT

INJECTABLE;INJECTION

MPI DMSA KIDNEY REAGENT

+

GE HEALTHCARE

N/A **

N017944 001 May 18, 1982

TECHNETIUM TC-99M SULFUR COLLOID

SOLUTION;INJECTION, ORAL

TECHNETIUM TC 99M SULFUR COLLOID

GE HEALTHCARE

4mCi/ML

N017456 001

SOLUTION;ORAL

TECHNETIUM TC 99M SULFUR COLLOID

MALLINCKRODT

3mCi/ML

N017724 001

TECHNETIUM TC-99M SULFUR COLLOID KIT

SOLUTION;INJECTION, ORAL

TECHNECOLL

MALLINCKRODT

N/A

N017059 001

TECHNETIUM TC 99M TSC

GE HEALTHCARE

N/A

N017784 001

TESULOID

BRACCO

N/A

N016923 001

TECHNETIUM TC-99M TEBOROXIME KIT

INJECTABLE;INJECTION

CARDIOTEC

BRACCO

N/A

N019928 001 Dec 19, 1990

TEGASEROD MALEATE

TABLET;ORAL

ZELNORM

+

ALFASIGMA

EQ 2MG BASE

N021200 001 Jul 24, 2002

+

EQ 6MG BASE

N021200 002 Jul 24, 2002

TELAPREVIR

TABLET;ORAL

INCIVEK

VERTEX PHARMS

375MG

N201917 001 May 23, 2011

TELAVANCIN HYDROCHLORIDE

POWDER;INTRAVENOUS

VIBATIV

+

CUMBERLAND PHARMS

EQ 250MG BASE/VIAL

N022110 001 Sep 11, 2009

TELBIVUDINE

SOLUTION;ORAL

TYZEKA

NOVARTIS

100MG/5ML

N022154 001 Apr 28, 2009

TABLET;ORAL

TYZEKA

+

NOVARTIS

600MG

N022011 001 Oct 25, 2006

TELITHROMYCIN

TABLET;ORAL

KETEK

SANOFI AVENTIS US

300MG

N021144 002 Feb 09, 2005

400MG

N021144 001 Apr 01, 2004

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-437(of 478)

** See List Footnote

TELMISARTAN

TABLET; ORAL

TELMISARTAN

HISUN PHARM HANGZHOU	20MG	A207843 001	Feb 19, 2019
	40MG	A207843 002	Feb 19, 2019
	80MG	A207843 003	Feb 19, 2019
JUBILANT GENERICS	20MG	A204164 001	Aug 22, 2016
	40MG	A204164 002	Aug 22, 2016
	80MG	A204164 003	Aug 22, 2016
TORRENT	20MG	A203171 001	Jul 07, 2014
	40MG	A203171 002	Jul 07, 2014
	80MG	A203171 003	Jul 07, 2014

TEMAZEPAM

CAPSULE; ORAL

TEMAZ

QUANTUM PHARMICS	15MG	A070564 001	Oct 15, 1985
	30MG	A070547 001	Oct 15, 1985

TEMAZEPAM

AUROBINDO PHARMA USA	7.5MG	A070920 002	May 21, 2010
	15MG	A070920 004	Jul 07, 1986
	22.5MG	A070920 003	Jun 12, 2009
	30MG	A070920 001	Jul 10, 1986
DURAMED PHARMS BARR	15MG	A071708 001	Sep 29, 1988
	30MG	A071709 001	Sep 29, 1988
SUN PHARM INDUSTRIES	15MG	A071174 001	Jul 10, 1986
	30MG	A071175 001	Jul 10, 1986
USL PHARMA	15MG	A070489 001	Jul 07, 1986
	30MG	A070490 001	Jul 07, 1986
WATSON LABS	15MG	A070383 001	Mar 23, 1987
	15MG	A071446 001	May 21, 1993
	30MG	A070384 001	Mar 23, 1987
	30MG	A071447 001	May 21, 1993

TEMOZOLOMIDE

CAPSULE; ORAL

TEMODAR

+	MERCK SHARP DOHME	5MG	N021029 001	Aug 11, 1999
+		20MG	N021029 002	Aug 11, 1999
+		100MG	N021029 003	Aug 11, 1999
+		140MG	N021029 005	Oct 19, 2006
+		180MG	N021029 006	Oct 19, 2006
+		250MG	N021029 004	Aug 11, 1999

TEMOZOLOMIDE

ANI PHARMS	5MG	A203490 001	Jul 13, 2016
	20MG	A203490 002	Jul 13, 2016
	100MG	A203490 003	Jul 13, 2016
	140MG	A203490 004	Jul 13, 2016
	180MG	A203490 005	Jul 13, 2016
	250MG	A203490 006	Jul 13, 2016
APOTEX INC	5MG	A204159 001	Jul 05, 2018
	20MG	A204159 002	Jul 05, 2018
	100MG	A204159 003	Jul 05, 2018
	140MG	A204159 004	Jul 05, 2018
	180MG	A204159 005	Jul 05, 2018
	250MG	A204159 006	Jul 05, 2018
LANNETT CO INC	5MG	A203898 001	Feb 10, 2016
	20MG	A203898 002	Feb 10, 2016
	100MG	A203898 003	Feb 10, 2016
	140MG	A203898 004	Feb 10, 2016
	180MG	A203898 005	Feb 10, 2016
	250MG	A203898 006	Feb 10, 2016
MYLAN	5MG	A205227 001	Jun 29, 2016
	20MG	A205227 002	Jun 29, 2016
	100MG	A205227 003	Jun 29, 2016
	140MG	A205227 004	Jun 29, 2016
	180MG	A205227 005	Jun 29, 2016
	250MG	A205227 006	Jun 29, 2016
WATSON LABS TEVA	5MG	A203959 001	Apr 18, 2017
	20MG	A203959 002	Apr 18, 2017

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-438(of 478)

** See List Footnote

TEMOZOLOMIDE

CAPSULE; ORAL

TEMOZOLOMIDE

100MG	A203959	003	Apr 18, 2017
140MG	A203959	004	Apr 18, 2017
250MG	A203959	005	Apr 18, 2017

TENIPOSIDE

INJECTABLE; INJECTION

VUMON

+ HQ SPECLT PHARMA 10MG/ML

N020119 001 Jul 14, 1992

TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL

TENOFOVIR DISOPROXIL FUMARATE

MYLAN 150MG	A206569	001	Nov 27, 2018
200MG	A206569	002	Nov 27, 2018
250MG	A206569	003	Nov 27, 2018
300MG	A206569	004	Nov 27, 2018

TERAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

HYTRIN

+ ABBOTT EQ 1MG BASE **	N020347	001	Dec 14, 1994
+ EQ 2MG BASE **	N020347	002	Dec 14, 1994
+ EQ 5MG BASE **	N020347	003	Dec 14, 1994
+ EQ 10MG BASE **	N020347	004	Dec 14, 1994

TERAZOSIN HYDROCHLORIDE

BEXIMCO PHARMS USA EQ 1MG BASE	A075667	001	Jul 28, 2000
EQ 2MG BASE	A075667	002	Jul 28, 2000
EQ 5MG BASE	A075667	003	Jul 28, 2000
EQ 10MG BASE	A075667	004	Jul 28, 2000
HIKMA EQ 1MG BASE	A075498	001	Apr 12, 2001
EQ 2MG BASE	A075498	002	Apr 12, 2001
EQ 5MG BASE	A075498	003	Apr 12, 2001
EQ 10MG BASE	A075498	004	Apr 12, 2001
MYLAN EQ 1MG BASE	A075140	002	Feb 11, 2000
EQ 2MG BASE	A075140	003	Feb 11, 2000
EQ 5MG BASE	A075140	001	Feb 11, 2000
EQ 10MG BASE	A075140	004	Feb 11, 2000
MYLAN TECHNOLOGIES EQ 1MG BASE	A075384	001	Dec 01, 2000
EQ 2MG BASE	A075384	002	Dec 01, 2000
EQ 5MG BASE	A075384	003	Dec 01, 2000
EQ 10MG BASE	A075384	004	Dec 01, 2000
RANBAXY LABS LTD EQ 1MG BASE	A076021	001	Aug 22, 2002
EQ 2MG BASE	A076021	002	Aug 22, 2002
EQ 5MG BASE	A076021	003	Aug 22, 2002
EQ 10MG BASE	A076021	004	Aug 22, 2002

TABLET; ORAL

HYTRIN

ABBOTT EQ 1MG BASE	N019057	001	Aug 07, 1987
EQ 2MG BASE	N019057	002	Aug 07, 1987
EQ 5MG BASE	N019057	003	Aug 07, 1987
EQ 10MG BASE	N019057	004	Aug 07, 1987

TERAZOSIN HYDROCHLORIDE

IVAX SUB TEVA PHARMS EQ 1MG BASE	A074530	001	Apr 21, 2000
EQ 2MG BASE	A074530	002	Apr 21, 2000
EQ 5MG BASE	A074530	003	Apr 21, 2000
EQ 10MG BASE	A074530	004	Apr 21, 2000
SANDOZ EQ 1MG BASE	A074315	001	Dec 31, 1998
EQ 1MG BASE	A074657	001	Apr 28, 2000
EQ 2MG BASE	A074315	002	Dec 31, 1998
EQ 2MG BASE	A074657	002	Apr 28, 2000
EQ 5MG BASE	A074315	003	Dec 31, 1998
EQ 5MG BASE	A074657	003	Apr 28, 2000
EQ 10MG BASE	A074315	004	Dec 31, 1998
EQ 10MG BASE	A074657	004	Apr 28, 2000
TEVA EQ 1MG BASE	A074446	001	May 18, 2000
EQ 2MG BASE	A074446	002	May 18, 2000
EQ 5MG BASE	A074446	003	May 18, 2000
EQ 10MG BASE	A074446	004	May 18, 2000

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-439(of 478)

** See List Footnote

TERBINAFINE

GEL; TOPICAL

LAMISIL

GLAXOSMITHKLINE CONS 1%

N020846 001 Apr 29, 1998

TERBINAFINE HYDROCHLORIDE

CREAM; TOPICAL

LAMISIL

NOVARTIS

1% **

N020192 001 Dec 30, 1992

GRANULE; ORAL

LAMISIL

+ NOVARTIS

EQ 125MG BASE/PACKET

N022071 001 Sep 28, 2007

+

EQ 187.5MG BASE/PACKET

N022071 002 Sep 28, 2007

SOLUTION; TOPICAL

LAMISIL

GLAXOSMITHKLINE CONS 1%

N020749 001 Oct 17, 1997

TABLET; ORAL

LAMISIL

+ NOVARTIS

EQ 250MG BASE **

N020539 001 May 10, 1996

TERBINAFINE HYDROCHLORIDE

GEDEON RICHTER USA

EQ 250MG BASE

A077065 001 Jul 02, 2007

HERITAGE PHARMA AVET

EQ 250MG BASE

A076377 001 Jul 02, 2007

MYLAN

EQ 250MG BASE

A077136 001 Jul 02, 2007

EQ 250MG BASE

A077195 001 Jul 02, 2007

ROXANE

EQ 250MG BASE

A077223 001 Jul 02, 2007

WOCKHARDT

EQ 250MG BASE

A078229 001 Jul 02, 2007

TERBUTALINE SULFATE

AEROSOL, METERED; INHALATION

BRETHAIRE

NOVARTIS

0.2MG/INH

N018762 001 Aug 17, 1984

BRICANYL

SANOFI AVENTIS US

0.2MG/INH

N018000 001 Mar 19, 1985

INJECTABLE; INJECTION

BRETHINE

+ PHARMACARE

1MG/ML **

N018571 001

BRICANYL

SANOFI AVENTIS US

1MG/ML

N017466 001

TERBUTALINE SULFATE

AKORN

1MG/ML

A078151 001 Jan 07, 2008

DR REDDYS

1MG/ML

A076853 001 Jul 20, 2004

TABLET; ORAL

BRICANYL

SANOFI AVENTIS US

2.5MG

N017618 001

5MG

N017618 002

TERCONAZOLE

CREAM; VAGINAL

TERAZOL 3

+ JANSSEN PHARMS

0.8% **

N019964 001 Feb 21, 1991

TERAZOL 7

+ JANSSEN PHARMS

0.4% **

N019579 001 Dec 31, 1987

SUPPOSITORY; VAGINAL

TERAZOL 3

+ JANSSEN PHARMS

80MG

N019641 001 May 24, 1988

TERCONAZOLE

FOUGERA PHARMS

80MG

A076850 001 Jul 12, 2006

TERIFLUNOMIDE

TABLET; ORAL

TERIFLUNOMIDE

AMNEAL PHARMS CO

7MG

A209613 001 Sep 28, 2018

14MG

A209613 002 Sep 28, 2018

APOTEX

7MG

A209601 001 Nov 02, 2018

14MG

A209601 002 Nov 02, 2018

AUROBINDO PHARMA

7MG

A209638 001 Oct 26, 2018

14MG

A209638 002 Oct 26, 2018

BRECKENRIDGE

7MG

A209583 001 Sep 24, 2021

14MG

A209583 002 Sep 24, 2021

MSN

7MG

A209623 001 Apr 24, 2019

14MG

A209623 002 Apr 24, 2019

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-440(of 478)

** See List Footnote

TERIFLUNOMIDE

TABLET; ORAL

TERIFLUNOMIDE

MYLAN	7MG	A209702 001	Feb 28, 2020
	14MG	A209702 002	Feb 28, 2020
SOLA PHARMS	14MG	A209677 001	Jun 17, 2020
TEVA PHARMS USA	7MG	A209700 001	Sep 04, 2018
	14MG	A209700 002	Sep 04, 2018
WATSON LABS TEVA	7MG	A209549 001	Jul 27, 2018
	14MG	A209549 002	Jul 27, 2018
ZYDUS PHARMS	7MG	A209668 001	Nov 30, 2018
	14MG	A209668 002	Nov 30, 2018

TERIPARATIDE

SOLUTION; SUBCUTANEOUS

FORTEO

LILLY	0.75MG/3ML (0.25MG/ML)	N021318 001	Nov 26, 2002

TERIPARATIDE ACETATE

INJECTABLE; INJECTION

PARATHAR

SANOFI AVENTIS US	200 UNITS/VIAL	N019498 001	Dec 23, 1987

TESTOLACTONE

INJECTABLE; INJECTION

TESLAC

BRISTOL MYERS SQUIBB	100MG/ML	N016119 001	

TABLET; ORAL

TESLAC

BRISTOL MYERS SQUIBB	50MG	N016118 001	
	250MG	N016118 002	

TESTOSTERONE

FILM, EXTENDED RELEASE; TRANSDERMAL

ANDRODERM

ALLERGAN	2.5MG/24HR	N020489 001	Sep 29, 1995
	5MG/24HR	N020489 002	May 02, 1997

TESTODERM

ALZA	4MG/24HR	N019762 001	Oct 12, 1993
	6MG/24HR	N019762 002	Oct 12, 1993

TESTODERM TTS

ALZA	5MG/24HR	N020791 001	Dec 18, 1997

GEL; TRANSDERMAL

ANDROGEL

+	ABBVIE	1.62% (20.25MG/1.25GM PACKET)	N022309 002	Sep 07, 2012
+		1.62% (40.5MG/2.5GM PACKET)	N022309 003	Sep 07, 2012
+		25MG/2.5GM PACKET	N021015 001	Feb 28, 2000
+		50MG/5GM PACKET	N021015 002	Feb 28, 2000

TESTOSTERONE

ANI PHARMS	25MG/2.5GM PACKET	N202763 001	Feb 14, 2012
	50MG/5GM PACKET	N202763 002	Feb 14, 2012
PERRIGO ISRAEL	25MG/2.5GM PACKET	N203098 002	Jan 31, 2013
	50MG/5GM PACKET	N203098 003	Jan 31, 2013

GEL, METERED; TRANSDERMAL

ANDROGEL

+	ABBVIE	12.5MG/1.25GM ACTUATION **	N021015 003	Sep 26, 2003

TESTOSTERONE

ALEOR DERMACEUTICALS	1.62% (20.25MG/1.25GM ACTUATION)	A213922 001	Mar 03, 2021
PERRIGO ISRAEL	12.5MG/1.25GM ACTUATION	N203098 001	Jan 31, 2013

INJECTABLE; INJECTION

TESTOSTERONE

DR REDDYS	100MG/ML	A086417 001	Jul 07, 1983
WATSON LABS	25MG/ML	A086420 001	May 10, 1983
	50MG/ML	A086419 001	Aug 23, 1983

SOLUTION, METERED; TRANSDERMAL

AXIRON

+	ELI LILLY AND CO	30MG/1.5ML ACTUATION **	N022504 001	Nov 23, 2010

TESTOSTERONE

ALEOR DERMACEUTICALS	30MG/1.5ML ACTUATION	A212882 001	Jun 14, 2021
APOTEX	30MG/1.5ML ACTUATION	A209181 001	Nov 25, 2020

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-441(of 478)

** See List Footnote

TESTOSTERONETABLET, EXTENDED RELEASE;BUCCAL
STRIANT

+ AUXILIUM PHARMS LLC 30MG

N021543 001 Jun 19, 2003

TESTOSTERONE CYPIONATE

INJECTABLE;INJECTION

DEPO-TESTOSTERONE

PFIZER 50MG/ML

A085635 001

TESTOSTERONE CYPIONATE

RISING 200MG/ML

A040652 001 Dec 11, 2006

WATSON LABS 100MG/ML

A084401 001

100MG/ML

A086029 001

200MG/ML

A084401 002

SOLUTION;INTRAMUSCULAR

TESTOSTERONE CYPIONATE

+ SLAYBACK PHARMA LLC 200MG/ML (200MG/ML)

N216318 001 Jun 02, 2022

TESTOSTERONE ENANTHATE

INJECTABLE;INJECTION

DELATESTRYL

ENDO PHARMS 200MG/ML

N009165 001

+ 200MG/ML

N009165 003

TESTOSTERONE ENANTHATE

RISING 200MG/ML

A040647 001 Oct 05, 2009

WATSON LABS 100MG/ML

A083667 001

100MG/ML

A085599 001

200MG/ML

A083667 002

TESTOSTERONE PROPIONATE

INJECTABLE;INJECTION

TESTOSTERONE PROPIONATE

BEL MAR 25MG/ML

A080741 001

50MG/ML

A080742 001

100MG/ML

A080743 001

ELKINS SINN 25MG/ML

A080276 001

LILLY 50MG/ML

A080254 002

WATSON LABS 25MG/ML

A080188 001

25MG/ML

A085490 001

50MG/ML

A080188 002

50MG/ML

A085490 002

100MG/ML

A080188 003

100MG/ML

A083595 003

TETRABENAZINE

TABLET;ORAL

TETRABENAZINE

AJANTA PHARMA LTD 12.5MG

A213621 001 Dec 04, 2020

25MG

A213621 002 Dec 04, 2020

HIKMA 12.5MG

A209739 001 Apr 08, 2019

25MG

A209739 002 Apr 08, 2019

TETRACYCLINE HYDROCHLORIDE

CAPSULE;ORAL

BRISTACYCLINE

BRISTOL 250MG

A061658 001

250MG

A061888 001

500MG

A061658 002

500MG

A061888 002

CYCLOPAR

WARNER CHILCOTT 250MG

A061725 001

250MG

A062175 001

250MG

A062332 001

500MG

A061725 002

500MG

A062332 002

PANMYCIN

PHARMACIA AND UPJOHN 250MG

A060347 001

RETET

SOLVAY 250MG

A061443 001

500MG

A061443 002

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-442(of 478)

** See List Footnote

TETRACYCLINE HYDROCHLORIDE

CAPSULE;ORAL

ROBITET

WYETH AYERST	250MG	A061734	001
	500MG	A061734	002

SUMYCIN

APOTHECON	100MG	A060429	002
	125MG	A060429	004
	250MG	A060429	001
	500MG	A060429	003

TETRACHEL

ANGUS	250MG	A060343	001
	500MG	A060343	003

TETRACYCLINE HYDROCHLORIDE

ABBOTT	250MG	A061802	001	
	500MG	A061802	002	
ANI PHARMS	250MG	A061471	001	
ELKINS SINN	250MG	A060059	001	
FERRANTE	125MG	A060173	001	
	250MG	A060173	002	
HEATHER	250MG	A061148	001	
	500MG	A061148	002	
HIKMA	250MG	A060768	001	
	500MG	A060768	002	
IMPAX LABS	100MG	A060469	002	
	250MG	A060469	001	
	500MG	A060469	003	
IVAX SUB TEVA PHARMS	250MG	A060704	001	
	500MG	A060704	002	
MAST MM	250MG	A062085	001	
MYLAN	250MG	A060783	001	
	500MG	A060783	002	
PUREPAC PHARM	250MG	A060290	001	
	500MG	A060290	002	
PVT FORM	250MG	A062686	001	Jul 24, 1986
	500MG	A062686	002	Jul 24, 1986
ROXANE	500MG	A061214	002	
SUN PHARM INDUSTRIES	250MG	A060736	001	
	500MG	A060736	002	
SUPERPHARM	250MG	A062540	001	Mar 21, 1985
	500MG	A062540	002	Mar 21, 1985
VALEANT PHARM INTL	250MG	A060471	001	
	500MG	A060471	002	
WARNER CHILCOTT	250MG	A062300	001	
	500MG	A062300	002	
WATSON LABS	250MG	A062103	001	
	250MG	A062343	001	
	500MG	A062103	002	
	500MG	A062343	002	
WYETH AYERST	250MG	A061685	001	
	500MG	A061685	002	

TETRACYN

PFIPHARMECS	250MG	A060082	003
	500MG	A060082	004

FIBER, EXTENDED RELEASE;PERIODONTAL

ACTISITE

SCHIFF AND CO	12.7MG/FIBER	N050653	001	Mar 25, 1994

FOR SOLUTION;TOPICAL

TOPICYCLINE

SHIRE	2.2MG/ML	N050493	001

INJECTABLE;INJECTION

ACHROMYCIN

LEDERLE	250MG/VIAL	N050273	002
	500MG/VIAL	N050273	003

TETRACYN

PFIZER	250MG/VIAL	A060096	001
	500MG/VIAL	A060096	002

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-443(of 478)

** See List Footnote

TETRACYCLINE HYDROCHLORIDE

OINTMENT;OPHTHALMIC

ACHROMYCIN

STORZ

10MG/GM

N050266 001

SUSPENSION;ORAL

ACHROMYCIN V

LEDERLE

125MG/5ML

N050263 002

SUMYCIN

PAR PHARM

125MG/5ML

A060400 001

TETRACYCLINE HYDROCHLORIDE

ALPHARMA US PHARMS

125MG/5ML

A060633 001

FERRANTE

125MG/5ML

A060174 001

PROTER

125MG/5ML

A060446 001

PUREPAC PHARM

125MG/5ML

A060291 001

TETRACYN

PFIPHARMECS

125MG/5ML

A060095 001

TETRAMED

IVAX SUB TEVA PHARMS

125MG/5ML

A061468 001

SUSPENSION/DROPS;OPHTHALMIC

ACHROMYCIN

STORZ

1%

N050268 001

TABLET;ORAL

PANMYCIN

PHARMACIA AND UPJOHN

250MG

A061705 001

500MG

A061705 002

SUMYCIN

STRIDES PHARMA

50MG

A061147 003

100MG

A061147 002

250MG

A061147 001

500MG

A061147 004

TETRACYCLINE PHOSPHATE COMPLEX

CAPSULE;ORAL

TETREX

BRISTOL

EQ 100MG HYDROCHLORIDE

A061653 001

EQ 250MG HYDROCHLORIDE

A061653 002

EQ 250MG HYDROCHLORIDE

A061889 002

EQ 250MG HYDROCHLORIDE

N050212 002

EQ 500MG HYDROCHLORIDE

A061653 003

EQ 500MG HYDROCHLORIDE

A061889 001

EQ 500MG HYDROCHLORIDE

N050212 003

THALLOUS CHLORIDE TL-201

INJECTABLE;INJECTION

THALLOUS CHLORIDE TL 201

BRACCO

1mCi/ML

N018548 001 Dec 30, 1982

+ GE HEALTHCARE

1mCi/ML

N018110 002 Feb 27, 1996

TRACE LIFE

1mCi/ML

A075569 001 Nov 21, 2001

INJECTABLE;INTRAVENOUS

THALLOUS CHLORIDE TL 201

CURIUM

2mCi/ML

A077698 001 Nov 09, 2006

+ LANTHEUS MEDCL

2mCi/ML

N017806 002 Oct 09, 1998

THEOPHYLLINE

CAPSULE;ORAL

BRONKODYL

SANOFI AVENTIS US

100MG

A085264 001

200MG

A085264 002

ELIXOPHYLLIN

FOREST LABS

100MG

A085545 001 Jul 31, 1984

200MG

A083921 001 Jul 31, 1984

SOMOPHYLLIN-T

FISONS

100MG

A087155 001 Feb 25, 1985

200MG

A087155 002 Feb 25, 1985

250MG

A087155 003 Feb 25, 1985

THEOPHYLLINE

KV PHARM

100MG

A085263 001

200MG

A085263 002

SCHERER RP

100MG

A084731 002 Nov 07, 1986

200MG

A084731 001 Nov 07, 1986

250MG

A084731 003 Nov 07, 1986

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-444(of 478)

** See List Footnote

THEOPHYLLINE

CAPSULE, EXTENDED RELEASE;ORAL

AEROLATE III

FLEMING PHARMS 65MG A085075 003 Nov 24, 1986

AEROLATE JR

FLEMING PHARMS 130MG A085075 002 Nov 24, 1986

AEROLATE SR

FLEMING PHARMS 260MG A085075 001 Nov 24, 1986

ELIXOPHYLLIN SR

FOREST LABS 125MG A086826 001 Jan 29, 1985

250MG A086826 002 Jan 29, 1985

SLO-BID

SANOFI AVENTIS US 50MG A088269 001 Jan 31, 1985

75MG A089539 001 May 10, 1989

100MG A087892 001 Jan 31, 1985

125MG A089540 001 May 10, 1989

200MG A087893 001 Jan 31, 1985

300MG A087894 001 Jan 31, 1985

SLO-PHYLLIN

SANOFI AVENTIS US 60MG A085206 001 May 24, 1982

+ 125MG A085203 001 May 24, 1982

250MG A085205 001 May 24, 1982

SOMOPHYLLIN-CRT

GRAHAM DM 50MG A087763 001 Feb 27, 1985

100MG A087194 001

200MG A088382 001 Feb 27, 1985

+ 250MG A087193 001

300MG A088383 001 Feb 27, 1985

THEO-DUR

SCHERING 50MG A088022 001 Sep 10, 1985

75MG A088015 001 Sep 10, 1985

125MG A088016 001 Sep 10, 1985

200MG A087995 001 Sep 10, 1985

THEOBID

WHITBY 260MG A085983 001 Mar 20, 1985

THEOBID JR.

WHITBY 130MG A087854 001 Mar 20, 1985

THEOCLEAR L.A.-130

SCHWARZ PHARMA 130MG A086569 001 May 27, 1982

THEOCLEAR L.A.-260

SCHWARZ PHARMA 260MG A086569 002 May 27, 1982

THEOPHYL-SR

ORTHO MCNEIL PHARM 125MG A086480 001 Feb 08, 1985

250MG A086471 001 Feb 08, 1985

THEOPHYLLINE

CENT PHARMS 125MG A088654 001 Feb 12, 1985

250MG A088689 001 Feb 12, 1985

HOSPIRA 100MG A089976 001 Jan 04, 1995

200MG A089977 001 Jan 04, 1995

300MG A089932 001 Jan 04, 1995

INWOOD LABS 100MG A040052 001 Feb 14, 1994

125MG A040052 002 Feb 14, 1994

200MG A040052 003 Feb 14, 1994

300MG A040052 004 Feb 14, 1994

260MG A087462 001 May 11, 1982

THEOPHYLLINE-SR

SCHERER RP 300MG A088255 001 Jun 12, 1986

THEOVENT

SCHERING 125MG A087010 001 Jan 31, 1985

250MG A087910 001 Jan 31, 1985

ELIXIR;ORAL

ELIXOMIN

CENCI 80MG/15ML A088303 001 Jan 25, 1984

LANOPHYLLIN

LANNETT 80MG/15ML A084578 001

THEOLIXIR

PANRAY 80MG/15ML A084559 001

THEOPHYL-225

ORTHO MCNEIL PHARM 112.5MG/15ML A086485 001

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-445(of 478)

** See List Footnote

THEOPHYLLINE

ELIXIR;ORAL

THEOPHYLLINE

ALPHARMA US PHARMS	80MG/15ML	A089223	001	May 27, 1988
CENCI	80MG/15ML	A087679	001	Apr 15, 1982
CHARTWELL RX	80MG/15ML	A085952	001	
HALSEY	80MG/15ML	A085169	001	
PHARM ASSOC	80MG/15ML	A086720	001	
+ PRECISION DOSE	80MG/15ML	A085863	001	
ROXANE	80MG/15ML	A084739	001	
TARO	80MG/15ML	A089626	001	Oct 28, 1988
WOCKHARDT	80MG/15ML	A086748	001	

INJECTABLE;INJECTION

THEOPHYLLINE 0.04% AND DEXTROSE 5% IN PLASTIC CONTAINER				
B BRAUN	40MG/100ML	N019083	001	Nov 07, 1984
THEOPHYLLINE 0.08% AND DEXTROSE 5% IN PLASTIC CONTAINER				
B BRAUN	80MG/100ML	N019083	002	Nov 07, 1984
THEOPHYLLINE 0.16% AND DEXTROSE 5% IN PLASTIC CONTAINER				
B BRAUN	160MG/100ML	N019083	003	Nov 07, 1984
THEOPHYLLINE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER				
B BRAUN	200MG/100ML	N019212	001	Nov 07, 1984
	200MG/100ML	N019826	004	Aug 14, 1992
THEOPHYLLINE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER				
B BRAUN	4MG/ML	N019212	003	Nov 07, 1984
	400MG/100ML	N019212	002	Nov 07, 1984
	400MG/100ML	N019826	005	Aug 14, 1992
THEOPHYLLINE AND DEXTROSE 5% IN PLASTIC CONTAINER				
BAXTER HLTHCARE	4MG/ML	N018649	007	Jul 26, 1982
	40MG/100ML	N018649	001	Jul 26, 1982
	80MG/100ML	N018649	002	Jul 26, 1982
	160MG/100ML	N018649	003	Jul 26, 1982
	200MG/100ML	N018649	004	Jul 26, 1982
	320MG/100ML	N018649	006	Nov 13, 1985
	400MG/100ML	N018649	005	Jul 26, 1982
THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER				
+ HOSPIRA INC	4MG/ML	N019211	007	Dec 14, 1984
+	40MG/100ML	N019211	001	Dec 14, 1984
	80MG/100ML	N019211	002	Dec 14, 1984
+	160MG/100ML	N019211	003	Dec 14, 1984
	200MG/100ML	N019211	004	Dec 14, 1984
+	320MG/100ML	N019211	006	Jan 20, 1988
	400MG/100ML	N019211	005	Dec 14, 1984

SOLUTION;ORAL

AEROLATE

FLEMING PHARMS	150MG/15ML	A089141	001	Dec 03, 1986
THEOLAIR				
3M	80MG/15ML	A086107	001	
THEOPHYLLINE				
+ ROXANE	80MG/15ML	A087449	001	Sep 15, 1983

SUSPENSION;ORAL

ELIXICON

FOREST LABS	100MG/5ML	A085502	001	

SYRUP;ORAL

ACCURBRON

SANOFI AVENTIS US	150MG/15ML	A088746	001	Nov 22, 1985

AQUAPHYLLIN

FERNDAL LABS	80MG/15ML	A087917	001	Jan 18, 1983

SLO-PHYLLIN

SANOFI AVENTIS US	80MG/15ML	A085187	001	

THEOCLEAR-80

CENT PHARMS	80MG/15ML	A087095	001	Mar 01, 1982

THEOPHYLLINE

ALPHARMA US PHARMS	80MG/15ML	A086001	001	
+	150MG/15ML	A086545	001	

TABLET;ORAL

QUIBRON-T

MONARCH PHARMS	300MG	A088656	001	Aug 22, 1985

SLO-PHYLLIN

SANOFI AVENTIS US	100MG	A085202	001	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-446(of 478)

** See List Footnote

THEOPHYLLINE

TABLET;ORAL

SLO-PHYLLIN

200MG

A085204 001

THEOCLEAR-100

CENT PHARMS

100MG

A085353 002

THEOCLEAR-200

CENT PHARMS

200MG

A085353 001

THEOLAIR

MEDICIS

125MG

A086399 001

250MG

A086399 002

THEOPHYL-225

ORTHO MCNEIL PHARM

225MG

A084726 001

TABLET, CHEWABLE;ORAL

THEOPHYL

ORTHO MCNEIL PHARM

100MG

A086506 001 Sep 12, 1985

TABLET, EXTENDED RELEASE;ORAL

DURAPHYL

FOREST LABS

100MG

A088503 001 Apr 03, 1985

200MG

A088504 001 Apr 03, 1985

300MG

A088505 001 Apr 03, 1985

LABID

WARNER CHILCOTT

250MG

A087225 001

QUIBRON-T/SR

MONARCH PHARMS

300MG

A087563 001 Jun 21, 1983

SUSTAIRE

ROERIG

100MG

A085665 001

300MG

A085665 002

T-PHYL

PHARM RES ASSOC

200MG

A088253 001 Aug 17, 1983

THEO-DUR

SCHERING

100MG **

A085328 001

+

200MG

A086998 001

+

300MG **

A085328 002

450MG

A089131 001 Jun 25, 1986

THEOCHRON

NOSTRUM PHARMS LLC

100MG

A087400 003 Feb 21, 1985

200MG

A087400 004 Feb 21, 1985

300MG

A087400 002 Jan 11, 1983

THEOLAIR-SR

3M

200MG

A088369 001 Jul 16, 1987

250MG

A086363 002 Jul 16, 1987

300MG

A088364 001 Jul 16, 1987

500MG

A089132 001 Jul 16, 1987

THEOPHYLLINE

ABLE

300MG

A040548 001 Apr 30, 2004

400MG

A040543 001 Apr 27, 2004

450MG

A040546 001 Apr 30, 2004

600MG

A040539 001 Apr 27, 2004

HERITAGE PHARMA AVET

100MG

A089807 001 Apr 30, 1990

200MG

A089808 001 Apr 30, 1990

INWOOD LABS

450MG

A040034 001 Apr 28, 1995

UNI-DUR

SCHERING

400MG

A089822 001 Jan 04, 1995

600MG

A089823 001 Jan 04, 1995

THEOPHYLLINE SODIUM GLYCINATE

ELIXIR;ORAL

SYNOPHYLATE

CENT PHARMS

EQ 165MG BASE/15ML

N006333 008

TABLET;ORAL

ASBRON

NOVARTIS

EQ 150MG BASE

A085148 001

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-447(of 478)

** See List Footnote

THIABENDAZOLE

SUSPENSION;ORAL

MINTEZOL

MERCK SHARP DOHME 500MG/5ML

N016097 001

TABLET, CHEWABLE;ORAL

MINTEZOL

MERCK SHARP DOHME 500MG

N016096 001

THIAMINE HYDROCHLORIDE

INJECTABLE;INJECTION

BETALIN S

+ LILLY

100MG/ML

A080853 001

THIAMINE HYDROCHLORIDE

ABRAXIS PHARM

100MG/ML

A080509 001

AKORN

100MG/ML

A087968 001

Oct 01, 1982

BEL MAR

100MG/ML

A080718 001

200MG/ML

A080712 001

DELL LABS

100MG/ML

A083775 001

DR REDDYS

100MG/ML

A080571 001

200MG/ML

A080571 002

HOSPIRA

100MG/ML

A040079 001

May 03, 1996

LUITPOLD

100MG/ML

A080667 001

PARKE DAVIS

100MG/ML

A080770 001

WATSON LABS

100MG/ML

A083534 001

200MG/ML

A083534 002

WYETH AYERST

100MG/ML

A080553 001

THIAMYLAL SODIUM

INJECTABLE;INJECTION

SURITAL

PARKEDALE

1GM/VIAL

N007600 003

5GM/VIAL

N007600 005

10GM/VIAL

N007600 009

THIETHYLPERAZINE MALATE

INJECTABLE;INJECTION

TORECAN

NOVARTIS

5MG/ML

N012754 002

THIETHYLPERAZINE MALEATE

SUPPOSITORY;RECTAL

TORECAN

NOVARTIS

10MG

N013247 001

TABLET;ORAL

TORECAN

NOVARTIS

10MG

N012753 001

THIOPENTAL SODIUM

SUSPENSION;RECTAL

PENTOTHAL

ABBOTT

400MG/GM

N011679 001

THIORIDAZINE

SUSPENSION;ORAL

MELLARIL-S

NOVARTIS

EQ 25MG HYDROCHLORIDE/5ML **

N017923 001

EQ 100MG HYDROCHLORIDE/5ML **

N017923 002

THIORIDAZINE HYDROCHLORIDE

CONCENTRATE;ORAL

MELLARIL

NOVARTIS

30MG/ML **

N011808 012

100MG/ML **

N011808 018

THIORIDAZINE HYDROCHLORIDE

ACTAVIS MID ATLANTIC

100MG/ML

A088229 001

Aug 23, 1983

AKORN

30MG/ML

A040125 001

Aug 16, 1996

100MG/ML

A040126 001

Aug 16, 1996

ALPHARMA US PHARMS

30MG/ML

A087766 001

Apr 26, 1983

ANI PHARMS

30MG/ML

A089602 001

Nov 09, 1987

100MG/ML

A089603 001

Nov 09, 1987

PHARM ASSOC

30MG/ML

A040187 001

Aug 28, 1997

100MG/ML

A040213 001

May 29, 1998

SANDOZ

30MG/ML

A088307 001

Nov 23, 1983

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-448(of 478)

** See List Footnote

THIORIDAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

THIORIDAZINE HYDROCHLORIDE

	100MG/ML	A088308	001	Nov 23, 1983
WOCKHARDT	30MG/ML	A088258	001	Jul 25, 1983
	100MG/ML	A088227	001	Jul 05, 1983
THIORIDAZINE HYDROCHLORIDE	INTENSOL			
ROXANE	30MG/ML	A088941	001	Dec 16, 1985
	100MG/ML	A088942	001	Dec 16, 1985

TABLET; ORAL

MELLARIL

+	NOVARTIS	10MG **	N011808	003
+		15MG **	N011808	016
+		25MG **	N011808	006
+		50MG **	N011808	011
+		100MG **	N011808	009
+		150MG **	N011808	017
+		200MG **	N011808	015

THIORIDAZINE HYDROCHLORIDE

ANI PHARMS

	10MG	A088270	001	Apr 14, 1983
	10MG	A088493	001	May 17, 1985
	15MG	A088271	001	Apr 14, 1983
	25MG	A088272	001	Apr 14, 1983
	50MG	A088194	001	Apr 14, 1983
	100MG	A088273	001	Oct 03, 1983
	100MG	A088456	001	May 17, 1985

FOSUN PHARMA

	10MG	A088131	001	Aug 30, 1983
	15MG	A088132	001	Aug 30, 1983
	25MG	A088133	001	Aug 30, 1983
	50MG	A088134	001	Aug 30, 1983
	100MG	A088135	001	Nov 20, 1984
	150MG	A088136	001	Sep 17, 1986
	200MG	A088137	001	Sep 17, 1986

HERITAGE PHARMA AVET

	10MG	A088476	001	Nov 08, 1983
	25MG	A088478	001	Nov 08, 1983
	50MG	A088479	001	Nov 08, 1983
	100MG	A088736	001	Jul 24, 1984

MUTUAL PHARM

	10MG	A088375	001	Nov 18, 1983
	25MG	A087264	001	Nov 18, 1983
	50MG	A088370	001	Nov 18, 1983
	100MG	A088379	001	Nov 16, 1983

MYLAN

	10MG	A088332	001	Jun 27, 1983
	25MG	A088333	001	Jun 27, 1983
	50MG	A088334	001	Jun 27, 1983
	100MG	A088335	001	Nov 18, 1983

PAR PHARM

	10MG	A088351	001	Dec 05, 1983
	15MG	A088352	001	Dec 05, 1983
	25MG	A088336	001	Dec 05, 1983
	50MG	A088322	001	Dec 05, 1983
	100MG	A088480	001	Dec 29, 1983
	150MG	A089764	001	Feb 09, 1988
	200MG	A089765	001	Feb 09, 1988

ROXANE

	10MG	A088663	001	Mar 15, 1984
	25MG	A088664	001	Mar 15, 1984
	50MG	A088665	001	Mar 15, 1984
	100MG	A089048	001	Feb 26, 1985

SUN PHARM INDUSTRIES

	10MG	A089953	004	Aug 01, 1986
	15MG	A088461	001	Nov 18, 1983
	25MG	A089953	003	Aug 01, 1986
	50MG	A089953	002	Aug 01, 1986
	100MG	A089953	001	Oct 07, 1988
	150MG	A088737	001	Sep 26, 1984
	200MG	A088738	001	Oct 16, 1984

SUPERPHARM

	10MG	A089103	001	Jul 02, 1985
	25MG	A089104	001	Jul 02, 1985
	50MG	A089105	001	Jul 02, 1985

WATSON LABS

	10MG	A088412	001	Sep 12, 1983
	10MG	A088561	001	May 11, 1984
	15MG	A088345	001	Jul 28, 1983

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-449(of 478)

** See List Footnote

THIORIDAZINE HYDROCHLORIDE

TABLET; ORAL

THIORIDAZINE HYDROCHLORIDE

15MG	A088562	001	May 11, 1984	
25MG	A088296	001	Jul 28, 1983	
25MG	A088755	001	Jul 24, 1984	
50MG	A088323	001	Jul 28, 1983	
50MG	A088563	001	May 11, 1984	
100MG	A088284	001	Aug 25, 1983	
100MG	A088564	001	May 11, 1984	
150MG	A088410	001	Mar 05, 1984	
150MG	A088869	001	Jun 28, 1985	
200MG	A088381	001	Mar 14, 1984	
WATSON LABS TEVA	15MG	A088477	001	Nov 08, 1983
	25MG	A088567	001	May 11, 1984
	200MG	A088872	001	Apr 26, 1985
WEST WARD	10MG	A088658	001	Mar 26, 1984
	15MG	A088659	001	Mar 26, 1984
	25MG	A088660	001	Mar 26, 1984
	50MG	A088661	001	Mar 26, 1984

THIOTEPA

INJECTABLE; INJECTION

THIOPLEX

+ IMMUNEX

15MG/VIAL **

N020058 001 Dec 22, 1994

THIOTEPA

FRESENIUS KABI USA

15MG/VIAL

A075698 001 Sep 20, 2001

IMMUNEX

15MG/VIAL

N011683 001

TEVA PARENTERAL

15MG/VIAL **

A075730 001 Apr 20, 2001

30MG/VIAL **

A075730 002 Apr 20, 2001

THIOTHIXENE

CAPSULE; ORAL

NAVANE

+ PFIZER

1MG **

N016584 001

+

2MG **

N016584 002

+

5MG **

N016584 003

+

10MG **

N016584 004

+

20MG **

N016584 005

THIOTHIXENE

AM THERAP

1MG

A071884 001 Aug 12, 1987

2MG

A071885 001 Aug 12, 1987

5MG

A071886 001 Aug 12, 1987

10MG

A071887 001 Aug 12, 1987

20MG

A072200 001 Dec 17, 1987

EPIC PHARMA

1MG

A071529 002 Jun 24, 1987

2MG

A071529 003 Jun 24, 1987

5MG

A071529 001 Jun 24, 1987

10MG

A071529 004 Jun 24, 1987

HERITAGE PHARMA AVET

1MG

A070600 001 Jun 05, 1987

2MG

A070601 001 Jun 05, 1987

5MG

A070602 001 Jun 05, 1987

10MG

A070603 001 Jun 05, 1987

WATSON LABS

2MG

A071626 001 Jun 25, 1987

5MG

A071627 001 Jun 25, 1987

10MG

A071628 001 Jun 25, 1987

THIOTHIXENE HYDROCHLORIDE

CONCENTRATE; ORAL

NAVANE

+ PFIZER

EQ 5MG BASE/ML

N016758 001

THIOTHIXENE HYDROCHLORIDE

ALPHARMA US PHARMS

EQ 5MG BASE/ML

A070969 001 Oct 16, 1987

PACO

EQ 1MG BASE/ML

A071917 001 Sep 20, 1989

EQ 5MG BASE/ML

A071939 001 Dec 16, 1988

TEVA

EQ 5MG BASE/ML

A071184 001 Jun 22, 1987

TEVA PHARMS

EQ 5MG BASE/ML

A071554 001 Oct 16, 1987

THIOTHIXENE HYDROCHLORIDE INTENSOL

HIKMA

EQ 5MG BASE/ML

A073494 001 Jun 30, 1992

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-450(of 478)

** See List Footnote

THIOTHIXENE HYDROCHLORIDE

INJECTABLE; INJECTION

NAVANE

PFIZER

EQ 2MG BASE/ML

N016904 001

EQ 10MG BASE/VIAL

N016904 002

TIAGABINE HYDROCHLORIDE

TABLET; ORAL

GABITRIL

CEPHALON

6MG

N020646 006 Nov 29, 2005

8MG

N020646 007 Nov 29, 2005

10MG

N020646 008 Nov 29, 2005

20MG

N020646 004 Sep 30, 1997

TIAGABINE HYDROCHLORIDE

AMNEAL PHARMS CO

2MG

A208181 001 Dec 08, 2017

4MG

A208181 002 Dec 08, 2017

12MG

A208181 003 Dec 08, 2017

16MG

A208181 004 Dec 08, 2017

WILSHIRE PHARMS INC

2MG

A206857 001 Oct 13, 2017

4MG

A206857 002 Oct 13, 2017

12MG

A206857 003 Oct 13, 2017

16MG

A206857 004 Oct 13, 2017

TICAGRELOR

TABLET; ORAL

TICAGRELOR

AMNEAL

90MG

A208531 001 Jan 23, 2019

MYLAN

60MG

A208597 001 Jul 09, 2021

90MG

A208597 002 Jul 09, 2021

SIGMAPHARM LABS LLC

90MG

A208596 001 Apr 07, 2020

SUNSHINE

90MG

A208508 001 Apr 06, 2020

WATSON LABS INC

60MG

A208390 001 Sep 04, 2018

90MG

A208390 002 Sep 04, 2018

TICARCILLIN DISODIUM

INJECTABLE; INJECTION

TICAR

GLAXOSMITHKLINE

EQ 1GM BASE/VIAL

N050497 001

EQ 3GM BASE/VIAL

A062690 001 Dec 19, 1986

EQ 3GM BASE/VIAL

N050497 002

EQ 6GM BASE/VIAL

N050497 003

EQ 20GM BASE/VIAL

N050497 004

EQ 30GM BASE/VIAL

N050497 005 Apr 04, 1984

TICLOPIDINE HYDROCHLORIDE

TABLET; ORAL

TICLID

ROCHE PALO

125MG

N019979 001 Mar 24, 1993

250MG

N019979 002 Oct 31, 1991

TICLOPIDINE HYDROCHLORIDE

ACTAVIS ELIZABETH

250MG

A075253 001 Aug 20, 1999

CHARTWELL RX

250MG

A075318 001 Aug 20, 1999

250MG

A075326 001 Aug 20, 1999

MYLAN

250MG

A075161 001 Sep 13, 1999

250MG

A075316 001 Nov 02, 1999

SUN PHARM INDS INC

250MG

A075526 001 Sep 26, 2002

WATSON LABS

250MG

A075309 001 Apr 26, 2000

TIGECYCLINE

POWDER; INTRAVENOUS

TIGECYCLINE

XELLIA PHARMS APS

50MG/VIAL

A205722 001 Oct 18, 2019

TILUDRONATE DISODIUM

TABLET; ORAL

SKELID

+

SANOFI AVENTIS US

EQ 200MG BASE **

N020707 001 Mar 07, 1997

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-451(of 478)

** See List Footnote

TIMOLOL MALEATE

SOLUTION/DROPS;OPHTHALMIC

TIMOLOL MALEATE

AKORN	EQ 0.25% BASE	A074465 001	Mar 25, 1997
	EQ 0.25% BASE	A074515 001	Mar 25, 1997
	EQ 0.5% BASE	A074516 001	Mar 25, 1997
	EQ 0.5% BASE	A075163 001	Sep 10, 2002
APOTEX INC	EQ 0.25% BASE	A075411 001	Sep 08, 2000
	EQ 0.5% BASE	A075412 001	Sep 08, 2000
FOUGERA	EQ 0.25% BASE	A074667 001	Mar 25, 1997
	EQ 0.5% BASE	A074668 001	Mar 25, 1997

TABLET;ORAL

BLOCADREN

+ MERCK	5MG **	N018017 001
+	10MG **	N018017 002
+	20MG **	N018017 004

TIMOLOL MALEATE

ANI PHARMS	5MG	A072917 001	Jul 31, 1991
	10MG	A072918 001	Jul 31, 1991
	20MG	A072919 001	Jul 31, 1991
CHARTWELL RX	5MG	A072550 001	Apr 13, 1989
	10MG	A072551 001	Apr 13, 1989
	20MG	A072552 001	Apr 13, 1989
QUANTUM PHARMICS	5MG	A072466 001	May 19, 1989
	10MG	A072467 001	May 19, 1989
	20MG	A072468 001	May 19, 1989
TEVA	5MG	A072648 001	Jun 16, 1993
	10MG	A072649 001	Jun 16, 1993
	20MG	A072650 001	Jun 16, 1993
USL PHARMA	5MG	A072001 001	Apr 11, 1989
	10MG	A072002 001	Apr 11, 1989
	20MG	A072003 001	Apr 11, 1989
WATSON LABS	5MG	A072269 001	Apr 11, 1989
	10MG	A072270 001	Apr 11, 1989
	20MG	A072271 001	Apr 11, 1989

TINIDAZOLE

TABLET;ORAL

TINIDAZOLE

HIKMA	250MG	A201172 001	Apr 30, 2012
	500MG	A201172 002	Apr 30, 2012

TINZAPARIN SODIUM

INJECTABLE;INJECTION

INNOHEP

LEO PHARMA AS	20,000 IU/ML	N020484 001	Jul 14, 2000

TIOCONAZOLE

CREAM;TOPICAL

TZ-3

PFIZER	1%	N018682 001	Feb 18, 1983

TIPRANAVIR

SOLUTION;ORAL

APTIVUS

+ BOEHRINGER INGELHEIM	100MG/ML	N022292 001	Jun 23, 2008

TIROFIBAN HYDROCHLORIDE

INJECTABLE;INJECTION

AGGRASTAT

MEDICURE	EQ 12.5MG BASE/50ML (EQ 0.25MG BASE/ML)	N020912 001	May 14, 1998

SOLUTION;INTRAVENOUS

AGGRASTAT

MEDICURE	EQ 25MG BASE/500ML (EQ 0.05MG BASE/ML)	N020913 001	May 14, 1998

TIZANIDINE HYDROCHLORIDE

CAPSULE;ORAL

TIZANIDINE HYDROCHLORIDE

MYLAN PHARMS INC	EQ 2MG BASE	A091502 001	Nov 09, 2012
	EQ 4MG BASE	A091502 002	Nov 09, 2012
	EQ 6MG BASE	A091502 003	Nov 09, 2012
PAR PHARM INC	EQ 2MG BASE	A207199 001	Mar 14, 2017

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-452(of 478)

** See List Footnote

TIZANIDINE HYDROCHLORIDE

CAPSULE; ORAL

TIZANIDINE HYDROCHLORIDE

EQ 4MG BASE

A207199 002 Mar 14, 2017

EQ 6MG BASE

A207199 003 Mar 14, 2017

TABLET; ORAL

TIZANIDINE HYDROCHLORIDE

ANI PHARMS

EQ 2MG BASE

A076283 001 Jul 12, 2002

EQ 2MG BASE

A076284 001 Jul 03, 2002

EQ 2MG BASE

A076321 001 Sep 30, 2004

EQ 2MG BASE

A076371 001 Apr 09, 2003

EQ 4MG BASE

A076283 002 Jul 12, 2002

EQ 4MG BASE

A076284 002 Jul 03, 2002

EQ 4MG BASE

A076321 002 Sep 30, 2004

EQ 4MG BASE

A076371 002 Apr 09, 2003

MYLAN PHARMS INC

EQ 2MG BASE

A076282 001 Dec 16, 2003

EQ 4MG BASE

A076282 002 Dec 16, 2003

PAR PHARM INC

EQ 2MG BASE

A207170 001 Jan 26, 2017

EQ 4MG BASE

A207170 002 Jan 26, 2017

RISING

EQ 2MG BASE

A076354 001 Mar 28, 2003

EQ 4MG BASE

A076354 002 Mar 28, 2003

ZANAFLEX

+ LEGACY PHARMA

EQ 2MG BASE **

N020397 002 Feb 04, 2000

TOBRAMYCIN

SOLUTION; INHALATION

TOBRAMYCIN

LUOXIN AUROVITAS

300MG/5ML

A210871 001 Jan 22, 2021

MYLAN

300MG/5ML

A209554 001 Oct 13, 2017

SOLUTION/DROPS; OPHTHALMIC

TOBRAMYCIN

ALCON PHARMS LTD

0.3%

A063176 001 May 25, 1994

APOTEX INC

0.3%

A065087 001 Feb 25, 2002

TOBRAMYCIN SULFATE

INJECTABLE; INJECTION

NEBCIN

LILLY

EQ 10MG BASE/ML

A062008 004

EQ 10MG BASE/ML

A062707 001 Apr 29, 1987

+

EQ 10MG BASE/ML **

N050477 005

EQ 40MG BASE/ML

A062008 001

+

EQ 1.2GM BASE/VIAL **

N050519 001

TOBRAMYCIN SULFATE

AKORN

EQ 40MG BASE/ML

A205179 001 Sep 16, 2014

APOTHECON

EQ 10MG BASE/ML

A064021 001 May 31, 1994

EQ 40MG BASE/ML

A064021 002 May 31, 1994

EQ 40MG BASE/ML

A064026 001 May 31, 1994

HIKMA

EQ 10MG BASE/ML

A063113 001 Apr 26, 1991

EQ 10MG BASE/ML

A063128 001 Nov 27, 1991

EQ 40MG BASE/ML

A063118 001 Jul 29, 1991

EQ 40MG BASE/ML

A063127 001 Nov 27, 1991

HOSPIRA

EQ 10MG BASE/ML

A063080 001 Apr 30, 1991

EQ 40MG BASE/ML

A063161 001 May 29, 1991

IGI LABS INC

EQ 10MG BASE/ML

A063119 001 Oct 31, 1994

EQ 40MG BASE/ML

A063120 001 Oct 31, 1994

EQ 40MG BASE/ML

A063121 001 Oct 31, 1994

EQ 40MG BASE/ML

A063122 001 Oct 31, 1994

TEVA PHARMS USA

EQ 40MG BASE/ML

A063100 001 Jan 30, 1992

WATSON LABS INC

EQ 10MG BASE/ML

A062945 001 Aug 09, 1989

EQ 40MG BASE/ML

A062945 002 Aug 09, 1989

TOBRAMYCIN SULFATE (PHARMACY BULK)

HOSPIRA

EQ 40MG BASE/ML **

A063116 001 May 18, 1992

TOCAINIDE HYDROCHLORIDE

TABLET; ORAL

TONOCARD

ASTRAZENECA

400MG

N018257 001 Nov 09, 1984

600MG

N018257 002 Nov 09, 1984

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-453(of 478)

** See List Footnote

TOFACITINIB CITRATE

TABLET;ORAL

TOFACITINIB CITRATE

AJANTA PHARMA LTD EQ 10MG BASE

A212943 001 Jun 01, 2021

TABLET, EXTENDED RELEASE;ORAL

TOFACITINIB

ZYDUS PHARMS EQ 11MG BASE

A214264 001 Aug 19, 2021

EQ 22MG BASE

A214264 002 Aug 19, 2021

TOLAZAMIDE

TABLET;ORAL

TOLAZAMIDE

BARR 100MG

A070162 001 Jan 14, 1986

250MG

A070163 001 Jan 14, 1986

500MG

A070164 001 Jan 14, 1986

CHARTWELL RX 100MG

A071633 001 Dec 09, 1987

250MG

A070289 001 Mar 13, 1986

500MG

A070290 001 Mar 13, 1986

COSETTE 100MG

N018894 001 Nov 02, 1984

250MG

N018894 002 Nov 02, 1984

500MG

N018894 003 Nov 02, 1984

DURAMED PHARMS BARR 100MG

A070165 001 Jan 10, 1986

250MG

A070166 001 Jan 10, 1986

500MG

A070167 001 Jan 10, 1986

INTERPHARM 250MG

A071270 001 Sep 23, 1986

500MG

A071271 001 Sep 23, 1986

MYLAN PHARMS INC 250MG

A070259 001 Jan 02, 1986

500MG

A070259 003 Mar 17, 1986

PAR PHARM 100MG

A070159 001 Jan 06, 1986

250MG

A070160 001 Jan 06, 1986

500MG

A070161 001 Jan 06, 1986

SUN PHARM INDUSTRIES 100MG

A071357 001 Jul 16, 1987

250MG

A071358 001 Jul 16, 1987

500MG

A071359 001 Jul 16, 1987

SUPERPHARM 250MG

A070763 001 Jun 16, 1986

500MG

A070764 001 Jun 16, 1986

USL PHARMA 100MG

A071355 001 Jan 11, 1988

250MG

A070168 001 Apr 02, 1986

500MG

A070169 001 Apr 02, 1986

WATSON LABS 100MG

A070242 001 Aug 01, 1986

100MG

A070513 001 Jan 09, 1986

250MG

A070243 001 Aug 01, 1986

250MG

A070514 001 Jan 09, 1986

500MG

A070244 001 Aug 01, 1986

500MG

A070515 001 Jan 09, 1986

TOLINASE

+ PHARMACIA AND UPJOHN 100MG **

N015500 002

+ 250MG **

N015500 004

+ 500MG **

N015500 005

TOLAZOLINE HYDROCHLORIDE

INJECTABLE;INJECTION

PRISCOLINE

NOVARTIS 25MG/ML

N006403 005 Feb 22, 1985

TOLBUTAMIDE

TABLET;ORAL

ORINASE

PHARMACIA AND UPJOHN 250MG **

N010670 002

500MG **

N010670 001

TOLBUTAMIDE

ALRA 500MG

A086141 001

ANI PHARMS 500MG

A087093 001

ASCOT 500MG

A087541 001 Mar 01, 1983

BARR 500MG

A087121 001

CHARTWELL RX 500MG

A086574 001

DAVA PHARMS INC 500MG

A086926 001

MYLAN PHARMS INC 500MG

A086445 001

PARKE DAVIS 500MG

A086047 001

PUREPAC PHARM 500MG

A088950 001 Jun 17, 1985

SANDOZ 500MG

N012678 001

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-454(of 478)

** See List Footnote

TOLBUTAMIDE

TABLET; ORAL

TOLBUTAMIDE

SUPERPHARM	500MG	A088893	001	Nov 19, 1984
VANGARD	500MG	A087876	001	Apr 20, 1982
WATSON LABS	250MG	A089110	001	May 29, 1987
	500MG	A086109	001	
	500MG	A087318	001	
	500MG	A089111	001	May 29, 1987

TOLBUTAMIDE SODIUM

INJECTABLE; INJECTION

ORINASE DIAGNOSTIC

PHARMACIA AND UPJOHN	EQ 1GM BASE/VIAL	N012095	001	

TOLCAPONE

TABLET; ORAL

TASMAR

BAUSCH	200MG	N020697	002	Jan 29, 1998

TOLCAPONE

ALVOGEN	100MG	A207729	001	Jul 29, 2020
MAYNE PHARMA	100MG	A210095	001	Aug 01, 2019

TOLMETIN SODIUM

CAPSULE; ORAL

TOLECTIN DS

+ ORTHO MCNEIL JANSSEN	EQ 400MG BASE	N018084	001	

TOLMETIN SODIUM

ANI PHARMS	EQ 400MG BASE	A073308	001	Jan 24, 1992
	EQ 400MG BASE	A073392	001	Jan 24, 1992
	EQ 400MG BASE	A073519	001	May 29, 1992
FOSUN PHARMA	EQ 400MG BASE	A073462	001	Apr 30, 1992
RISING	EQ 400MG BASE	A073393	001	May 27, 1993
SUN PHARM INDUSTRIES	EQ 400MG BASE	A073311	001	Nov 27, 1991
TEVA	EQ 400MG BASE	A073290	001	Nov 27, 1991

TABLET; ORAL

TOLECTIN

+ ORTHO MCNEIL JANSSEN	EQ 200MG BASE	N017628	001	

TOLECTIN 600

+ ORTHO MCNEIL JANSSEN	EQ 600MG BASE	N017628	002	Mar 08, 1989

TOLMETIN SODIUM

ANI PHARMS	EQ 600MG BASE	A073527	001	Jun 30, 1992
COSETTE	EQ 600MG BASE	A074399	001	Mar 28, 1996
	EQ 600MG BASE	A074729	001	Feb 27, 1997
FOSUN PHARMA	EQ 200MG BASE	A073588	001	Jul 31, 1992
	EQ 600MG BASE	A074002	001	Sep 27, 1993
RISING	EQ 600MG BASE	A074473	001	Aug 30, 1994
SUN PHARM INDUSTRIES	EQ 200MG BASE	A073310	001	Nov 27, 1991

TOLTERODINE TARTRATE

CAPSULE, EXTENDED RELEASE; ORAL

TOLTERODINE TARTRATE

AUROBINDO PHARMA USA	2MG	A201486	001	Oct 31, 2013
	4MG	A201486	002	Oct 31, 2013

TABLET; ORAL

TOLTERODINE TARTRATE

APOTEX CORP	1MG	A200164	001	Sep 25, 2012
	2MG	A200164	002	Sep 25, 2012
MYLAN PHARMS INC	1MG	A202641	001	Nov 27, 2012
	2MG	A202641	002	Nov 27, 2012

TOLVAPTAN

TABLET; ORAL

SAMSCA

+ OTSUKA	60MG **	N022275	003	May 19, 2009

DISCONTINUED DRUG PRODUCT LIST

6-455(of 478)

** See List Footnote

TOPIRAMATE

CAPSULE; ORAL

TOPAMAX SPRINKLE

JANSSEN PHARMS 50MG N020844 003 Oct 26, 1998

TOPIRAMATE

BARR 15MG A076448 001 Apr 15, 2009

25MG A076448 002 Apr 15, 2009

FOSUN PHARMA 15MG A079206 001 Oct 14, 2009

25MG A079206 002 Oct 14, 2009

STRIDES PHARMA 15MG A078418 001 Oct 14, 2009

25MG A078418 002 Oct 14, 2009

TABLET; ORAL

TOPAMAX

JANSSEN PHARMS 300MG N020505 003 Dec 24, 1996

400MG N020505 006 Dec 24, 1996

TOPIRAMATE

ACTAVIS TOTOWA 25MG A078637 001 Feb 27, 2013

50MG A078637 002 Feb 27, 2013

100MG A078637 003 Feb 27, 2013

200MG A078637 004 Feb 27, 2013

BARR 25MG A076315 001 Mar 27, 2009

100MG A076315 002 Mar 27, 2009

200MG A076315 003 Mar 27, 2009

CHARTWELL 25MG A078410 001 Sep 11, 2013

50MG A078410 002 Sep 11, 2013

100MG A078410 003 Sep 11, 2013

200MG A078410 004 Sep 11, 2013

HIKMA PHARMS 25MG A091185 001 Nov 25, 2013

50MG A091185 002 Nov 25, 2013

100MG A091185 003 Nov 25, 2013

200MG A091185 004 Nov 25, 2013

MYLAN 25MG A076314 001 Mar 27, 2009

50MG A076314 002 Mar 27, 2009

100MG A076314 003 Mar 27, 2009

200MG A076314 004 Mar 27, 2009

PLIVA HRVATSKA DOO 25MG A077905 001 Mar 30, 2009

50MG A077905 002 Mar 30, 2009

100MG A077905 003 Mar 30, 2009

200MG A077905 004 Mar 30, 2009

ROXANE 25MG A076306 001 Mar 27, 2009

50MG A076306 002 Mar 27, 2009

100MG A076306 003 Mar 27, 2009

200MG A076306 004 Mar 27, 2009

TORRENT PHARMS 25MG A079153 001 Mar 27, 2009

50MG A079153 002 Mar 27, 2009

100MG A079153 003 Mar 27, 2009

200MG A079153 004 Mar 27, 2009

UPSHER SMITH LABS 25MG A078499 001 Jan 07, 2010

50MG A078499 002 Jan 07, 2010

100MG A078499 003 Jan 07, 2010

200MG A078499 004 Jan 07, 2010

WATSON LABS 25MG A077643 001 Mar 27, 2009

50MG A077643 002 Mar 27, 2009

100MG A077643 003 Mar 27, 2009

200MG A077643 004 Mar 27, 2009

WOCKHARDT 25MG A090353 001 Sep 01, 2010

50MG A090353 002 Sep 01, 2010

100MG A090353 003 Sep 01, 2010

200MG A090353 004 Sep 01, 2010

TOPOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION

TOPOTECAN HYDROCHLORIDE

FRESENIUS KABI USA EQ 4MG BASE/VIAL A091376 001 Nov 29, 2010

MEITHEAL EQ 4MG BASE/VIAL A201166 001 Aug 08, 2012

MYLAN LABS LTD EQ 4MG BASE/VIAL A091542 001 Aug 28, 2012

SUN PHARM INDS LTD EQ 4MG BASE/VIAL A202203 001 Aug 29, 2013

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-456(of 478)

** See List Footnote

TOPOTECAN HYDROCHLORIDE

SOLUTION; INTRAVENOUS

TOPOTECAN

+	SANDOZ INC	EQ 1MG BASE/ML (EQ 1MG BASE/ML) **	N200199 001	Feb 25, 2011
+		EQ 3MG BASE/3ML (EQ 1MG BASE/ML) **	N200199 002	Feb 25, 2011
+		EQ 4MG BASE/4ML (EQ 1MG BASE/ML) **	N200199 003	Feb 25, 2011

TOPOTECAN HYDROCHLORIDE

MYLAN LABS LTD	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A206074 001	Nov 24, 2017

TORSEMIDE

INJECTABLE; INJECTION

DEMADEX

+	ROCHE	50MG/5ML (10MG/ML) **	N020137 002	Aug 23, 1993
+		20MG/2ML (10MG/ML) **	N020137 001	Aug 23, 1993

TORSEMIDE

AM REGENT	20MG/2ML (10MG/ML)	A090656 001	Apr 21, 2010
	50MG/5ML (10MG/ML)	A090656 002	Apr 21, 2010
WEST-WARD PHARMS INT	20MG/2ML (10MG/ML)	A078007 001	Jun 11, 2008
	50MG/5ML (10MG/ML)	A078007 002	Jun 11, 2008

TABLET; ORAL

DEMADEX

+	MYLAN SPECIALITY LP	5MG **	N020136 001	Aug 23, 1993
+		10MG **	N020136 002	Aug 23, 1993
+		20MG **	N020136 003	Aug 23, 1993
+		100MG **	N020136 004	Aug 23, 1993

TORSEMIDE

SUN PHARM INDS	5MG	A078478 001	Feb 26, 2008
	10MG	A078478 002	Feb 26, 2008
	20MG	A078478 003	Feb 26, 2008
	100MG	A078478 004	Feb 26, 2008

TRAMADOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

CONZIP

+	CIPHER PHARMS INC	150MG	N022370 004	Aug 01, 2011

TABLET; ORAL

TRAMADOL HYDROCHLORIDE

ACCORD HLTHCARE	50MG	A202390 001	May 16, 2013
ACTAVIS ELIZABETH	50MG	A075960 001	Jun 19, 2002
ASTA	50MG	A075974 001	Jul 12, 2002
GRAVITI PHARMS	50MG	A075968 001	Jun 25, 2002
IVAX SUB TEVA PHARMS	50MG	A075963 001	Jul 03, 2002
MACLEODS PHARMS LTD	50MG	A205702 001	Sep 25, 2015
MYLAN	50MG	A075986 001	Jun 21, 2002
MYLAN PHARMS INC	50MG	A075980 001	Nov 21, 2002
NORTHSTAR HLTHCARE	50MG	A078935 001	May 26, 2010
SPECGX LLC	50MG	A075983 001	Jun 25, 2002
SUN PHARM INDUSTRIES	50MG	A076100 001	Jun 20, 2002
WATSON LABS	50MG	A075962 001	Jun 24, 2002

ULTRAM

+	JANSSEN PHARMS	50MG	N020281 002	Mar 03, 1995
+		100MG **	N020281 001	Mar 03, 1995

TABLET, EXTENDED RELEASE; ORAL

RYZOLT

+	PURDUE PHARMA	100MG **	N021745 001	Dec 30, 2008
+		200MG **	N021745 002	Dec 30, 2008
+		300MG **	N021745 003	Dec 30, 2008

TRAMADOL HYDROCHLORIDE

ANCHEN PHARMS	100MG	A200491 001	Jun 27, 2012
	200MG	A200491 002	Jun 27, 2012
	300MG	A200491 003	Jun 27, 2012
AUROBINDO PHARMA LTD	100MG	A204421 001	Oct 20, 2015
	200MG	A204421 002	Oct 20, 2015
	300MG	A204421 003	Oct 20, 2015
MYLAN	100MG	A205257 001	Dec 22, 2015
	200MG	A205257 002	Dec 22, 2015
	300MG	A205257 003	Dec 22, 2015
STRIDES PHARMA	100MG	A078783 001	Nov 13, 2009
	200MG	A078783 002	Nov 13, 2009
	300MG	A078783 003	Sep 20, 2011

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-457(of 478)

** See List Footnote

TRAMADOL HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

ULTRAM ER

+	VALEANT PHARMS	100MG **
+		200MG **
+		300MG **

N021692	001	Sep 08, 2005
N021692	002	Sep 08, 2005
N021692	003	Sep 08, 2005

TABLET, ORALLY DISINTEGRATING;ORAL

RYBIX ODT

SHIONOGI INC 50MG

N021693 001 May 05, 2005

TRAMETINIB DIMETHYL SULFOXIDE

TABLET;ORAL

MEKINIST

+ NOVARTIS EQ 1MG

N204114 002 May 29, 2013

TRANDOLAPRIL

TABLET;ORAL

MAVIK

+	ABBVIE	1MG **
+		2MG **
+		4MG **

N020528	001	Apr 26, 1996
N020528	002	Apr 26, 1996
N020528	003	Apr 26, 1996

TRANDOLAPRIL

CHARTWELL MOLECULAR 1MG

A077307 002 Jun 12, 2007

2MG

A077307 001 Jun 12, 2007

4MG

A077307 003 Jun 12, 2007

DR REDDYS LABS LTD 1MG

A078493 001 Aug 25, 2008

2MG

A078493 002 Aug 25, 2008

4MG

A078493 003 Aug 25, 2008

EPIC PHARMA LLC 1MG

A077256 001 Jun 12, 2007

2MG

A077256 002 Jun 12, 2007

4MG

A077256 003 Jun 12, 2007

INVAGEN PHARMS 1MG

A078320 001 Jun 12, 2007

2MG

A078320 002 Jun 12, 2007

4MG

A078320 003 Jun 12, 2007

MYLAN 1MG

A078346 001 Apr 28, 2008

2MG

A078346 002 Apr 28, 2008

4MG

A078346 003 Apr 28, 2008

WATSON LABS 1MG

A077805 001 Jun 12, 2007

2MG

A077805 002 Jun 12, 2007

4MG

A077805 003 Jun 12, 2007

TRANDOLAPRIL; VERAPAMIL HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

TARKA

+	ABBVIE	1MG;240MG **
+		2MG;180MG
+		2MG;240MG
+		4MG;240MG

N020591	003	Oct 22, 1996
N020591	001	Oct 22, 1996
N020591	004	Oct 22, 1996
N020591	002	Oct 22, 1996

TRANEXAMIC ACID

INJECTABLE;INJECTION

TRANEXAMIC ACID

AKORN 100MG/ML

A206594 001 Sep 28, 2017

100MG/ML

A206634 001 Jun 09, 2016

ANDA REPOSITORY 100MG/ML

A202755 001 Feb 25, 2016

ZYDUS PHARMS 100MG/ML

A205228 001 Jul 17, 2017

TABLET;ORAL

CYKLOKAPRON

PHARMACIA AND UPJOHN 500MG

N019280 001 Dec 30, 1986

TRANEXAMIC ACID

APOTEX INC 650MG

A202286 001 Jan 27, 2014

AUROBINDO PHARMA USA 650MG

A205133 001 Sep 21, 2015

TRAVOPROST

SOLUTION/DROPS;OPHTHALMIC

IZBA

+ NOVARTIS 0.003% **

N204822 001 May 15, 2014

TRAVATAN

+ ALCON PHARMS LTD 0.004% **

N021257 001 Mar 16, 2001

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-458(of 478)

** See List Footnote

TRAZODONE HYDROCHLORIDE

TABLET; ORAL

DESYREL

+	PRAGMA	50MG **	N018207	001	
+		100MG **	N018207	002	
+		150MG **	N018207	003	Mar 25, 1985
+		300MG **	N018207	004	Nov 07, 1988

TRAZODONE HYDROCHLORIDE

ALVOGEN

50MG	A071636	001	Apr 18, 1988
100MG	A071514	001	Apr 18, 1988

AM THERAP

50MG	A071139	001	Oct 29, 1986
100MG	A071140	001	Oct 29, 1986

FOSUN PHARMA

100MG	A072483	001	Apr 30, 1990

MYLAN

50MG	A071405	001	Feb 27, 1991
100MG	A071406	001	Feb 27, 1991

MYLAN PHARMS INC

50MG	A090514	001	Jun 02, 2009
100MG	A090514	002	Jun 02, 2009

150MG	A090514	003	Jun 02, 2009

300MG	A090514	004	Jun 02, 2009

QUANTUM PHARMICS

100MG	A070921	001	Dec 01, 1986

RISING

50MG	A072484	001	Apr 30, 1990

TEVA

150MG	A074357	001	Apr 30, 1997

USL PHARMA

50MG	A070491	001	Apr 29, 1987

100MG	A070492	001	Apr 29, 1987

WATSON LABS

50MG	A070857	001	Oct 10, 1986

50MG	A071112	001	Nov 17, 1986

100MG	A070858	001	Oct 10, 1986

100MG	A071113	001	Nov 17, 1986

TRIALODINE

QUANTUM PHARMICS

50MG	A070942	001	Dec 01, 1986

TABLET, EXTENDED RELEASE; ORAL

OLEPTRO

+	ANGELINI PHARMA	150MG **	N022411	001	Feb 02, 2010

+		300MG **	N022411	002	Feb 02, 2010

TREPROSTINIL

INJECTABLE; IV (INFUSION), SUBCUTANEOUS

TREPROSTINIL

DR REDDYS

1MG/ML	A210214	001	May 22, 2020

2.5MG/ML	A210214	002	May 22, 2020

5MG/ML	A210214	003	May 22, 2020

10MG/ML	A210214	004	May 22, 2020

SOLUTION; INTRAVENOUS, SUBCUTANEOUS

REMODULIN

UNITED THERAP

20MG/20ML (1MG/ML)	N208276	001	Jul 30, 2018

50MG/20ML (2.5MG/ML)	N208276	002	Jul 30, 2018

100MG/20ML (5MG/ML)	N208276	003	Jul 30, 2018

200MG/20ML (10MG/ML)	N208276	004	Jul 30, 2018

TRETINOIN

CAPSULE; ORAL

VESANOID

+	CHEPLAPHARM	10MG **	N020438	001	Nov 22, 1995

CREAM; TOPICAL

RENOVA

+	VALEANT PHARMS NORTH	0.05%	N019963	001	Dec 29, 1995

TRETINOIN

ALLERGAN

0.0375%	A090098	001	Mar 22, 2010

0.075%	A202209	001	Oct 11, 2012

ZO SKIN HEALTH

0.05%	A076498	001	Sep 15, 2005

GEL; TOPICAL

TRETINOIN

MYLAN

0.04%	A202567	001	Jul 17, 2013

0.1%	A202026	001	Jul 17, 2013

SOLUTION; TOPICAL

RETIN-A

+	VALEANT INTL	0.05%	N016921	001	

TRETINOIN

TEVA PHARMS

0.05%	A074873	001	Jun 19, 1998

WOCKHARDT

0.05%	A075260	001	Jan 25, 1999

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-459(of 478)

** See List Footnote

TRETINOIN

SWAB; TOPICAL

RETIN-A

VALEANT INTL

0.05%

N016921 002

TRIAMCINOLONE

TABLET; ORAL

ARISTOCORT

ASTELLAS

1MG

N011161 009

2MG

N011161 004

4MG

N011161 007

8MG

N011161 011

16MG

N011161 010

KENACORT

DELCOR ASSET CORP

1MG

N011283 003

2MG

N011283 008

4MG

N011283 006

8MG

N011283 010

TRIAMCINOLONE

BARR

2MG

A084286 001

2MG

A084318 001

4MG

A084267 001

4MG

A084319 001

8MG

A084268 001

8MG

A084320 001

IMPAX LABS

4MG

A084340 001

IVAX SUB TEVA PHARMS

4MG

A083750 001

MYLAN

2MG

A084406 001

PUREPAC PHARM

2MG

A084020 002

4MG

A084020 003

ROXANE

2MG

A084708 001

4MG

A084709 001

8MG

A084707 001

SANDOZ

4MG

A085601 001

TEVA

4MG

A084775 001

WATSON LABS

4MG

A084270 001

4MG

A085834 001

TRIAMCINOLONE ACETONIDE

AEROSOL, METERED; INHALATION

AZMACORT

ABBVIE

0.1MG/INH

N018117 001 Apr 23, 1982

AEROSOL, METERED; NASAL

NASACORT

CHATTEM SANOFI

0.055MG/INH

N019798 001 Jul 11, 1991

CREAM; TOPICAL

ARISTOCORT

ASTELLAS

0.025%

A083017 003

0.1%

A083016 004

+

0.5%

A083015 002

ARISTOCORT A

ASTELLAS

0.025%

A083017 004

0.025%

A088818 001 Oct 16, 1984

0.1%

A083016 005

0.1%

A088819 001 Oct 16, 1984

0.5%

A083015 003

0.5%

A088820 001 Oct 16, 1984

FLUTEX

IVAX PHARMS

0.025%

A085539 001

0.1%

A085539 002

0.5%

A085539 003

KENALOG

+

DELCOR ASSET CORP

0.5%

A083943 001

KENALOG-H

DELCOR ASSET CORP

0.1%

A086240 001

TRIACET

TEVA

0.025%

A084908 001

0.1%

A084908 002

0.5%

A084908 003

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-460(of 478)

** See List Footnote

TRIAMCINOLONE ACETONIDE

CREAM;TOPICAL

TRIAACORT

SOLVAY	0.1%	A087113	001	

TRIAMCINOLONE ACETONIDE

ACTAVIS MID ATLANTIC	0.1%	A087798	001	Jun 04, 1982

ALPHARMA US PHARMS	0.025%	A087797	001	Jun 07, 1982

AMBIX	0.025%	A087932	001	May 09, 1983

MORTON GROVE	0.025%	A088094	001	Sep 01, 1983

	0.1%	A088095	001	Sep 01, 1983

	0.5%	A088096	001	Sep 01, 1983

+ MYLAN	0.025% **	N011601	003	

+	0.1% **	N011601	006	

PHARMADERM	0.025%	A087990	001	Jul 07, 1983

	0.1%	A087991	001	Jul 07, 1983

	0.5%	A087992	001	Jul 07, 1983

PHARMAFAIR	0.025%	A087921	001	Aug 10, 1982

	0.1%	A087912	001	Aug 10, 1982

	0.5%	A087922	001	Aug 10, 1982

TARO	0.025%	A040038	001	Oct 26, 1994

	0.025%	A086277	001	

	0.1%	A086276	001	

	0.5%	A086275	001	

TOPIDERM	0.025%	A089274	001	Feb 21, 1989

	0.1%	A089275	001	Feb 21, 1989

	0.5%	A089276	001	Feb 21, 1989

TRIADEX

IVAX PHARMS	0.025%	A087430	001	Nov 01, 1988

	0.1%	A087429	001	Nov 01, 1988

	0.5%	A087428	001	Nov 01, 1988

TRYMEX

SAVAGE LABS	0.025%	A088196	001	Mar 25, 1983

	0.1%	A088197	001	Mar 25, 1983

	0.5%	A088198	001	Mar 25, 1983

GEL;TOPICAL

ARISTOGEL

ASTELLAS	0.1%	A083380	001	

INJECTABLE;INJECTION

TRIAMCINOLONE ACETONIDE

PARNELL	3MG/ML	N019503	001	Oct 16, 1987

SANDOZ INC	10MG/ML	A090166	001	May 27, 2009

	40MG/ML	A090164	001	Jun 01, 2009

WATSON LABS	40MG/ML	A085825	001	

INJECTABLE;INTRA-ARTICULAR, INTRAMUSCULAR, INTRAVITREAL

TRIVARIS

+ ALLERGAN	8MG/0.1ML (8MG/0.1ML) **	N022220	001	Jun 16, 2008

LOTION;TOPICAL

KENALOG

DELCOR ASSET CORP	0.025% **	A084343	001	

+	0.025% **	N011602	003	

	0.1% **	A084343	002	

+	0.1% **	N011602	001	

TRIAMCINOLONE ACETONIDE

ALPHARMA US PHARMS	0.025%	A087191	001	Sep 08, 1982

	0.1%	A087192	001	Sep 08, 1982

OINTMENT;TOPICAL

ARISTOCORT

ASTELLAS	0.1%	A080750	004	

+	0.5% **	A080745	002	

ARISTOCORT A

ASTELLAS	0.1%	A080750	003	

	0.1%	A088780	001	Oct 01, 1984

+	0.5% **	A080745	003	

	0.5%	A088781	001	Oct 05, 1984

FLUTEX

IVAX PHARMS	0.025%	A087375	001	Nov 01, 1988

	0.1%	A087377	001	Nov 01, 1988

	0.5%	A087376	001	Nov 01, 1988

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-461(of 478)

** See List Footnote

TRIAMCINOLONE ACETONIDE

OINTMENT; TOPICAL

KENALOG

+ DELCOR ASSET CORP 0.5% **

A083944 001

TRIAMCINOLONE ACETONIDE

ACTAVIS MID ATLANTIC 0.1%

A087799 001 Jun 07, 1982

ALPHARMA US PHARMS 0.5%

A089913 001 Dec 23, 1988

MORTON GROVE 0.025%

A088090 001 Sep 01, 1983

0.1%

A088091 001 Sep 01, 1983

0.5%

A088092 001 Sep 01, 1983

+ MYLAN 0.025% **

N011600 003

+ 0.1% **

N011600 001

PHARMADERM 0.025%

A088692 001 Aug 02, 1984

0.1%

A088690 001 Aug 02, 1984

STRIDES PHARMA 0.1%

A211315 001 Mar 18, 2020

0.5%

A211315 002 Mar 18, 2020

TARO 0.025%

A040040 001 Sep 30, 1994

0.025%

A040374 001 Jun 05, 2001

0.1%

A087902 001 Dec 27, 1982

0.5%

A040386 001 Jun 05, 2001

TRYMEX

SAVAGE LABS 0.025%

A088693 001 Aug 02, 1984

0.1%

A088691 001 Aug 02, 1984

PASTE; DENTAL

KENALOG IN ORABASE

+ DELCOR ASSET CORP 0.1% **

N012097 001

ORALONE

TARO 0.1%

A071383 001 Jul 06, 1987

SPRAY, METERED; NASAL

ALLERNAZE

LUPIN ATLANTIS 0.05MG/SPRAY

N020120 001 Feb 04, 2000

NASACORT HFA

SANOFI AVENTIS US 0.055MG/SPRAY

N020784 001 Apr 07, 2004

TRIAMCINOLONE ACETONIDE

PERRIGO PHARMA INTL 0.055MG/SPRAY

A078104 001 Jul 30, 2009

TRIAMCINOLONE DIACETATE

INJECTABLE; INJECTION

ARISTOCORT

FOSUN PHARMA 25MG/ML

N011685 003

+ 40MG/ML **

N012802 001

TRIAMCINOLONE DIACETATE

AKORN 25MG/ML

A085122 001

40MG/ML

A086394 001

WATSON LABS 40MG/ML

A084072 001

40MG/ML

A085529 001

SYRUP; ORAL

ARISTOCORT

ASTELLAS 2MG/5ML

N011960 004

KENACORT

DELCOR ASSET CORP EQ 4MG BASE/5ML N012515 001

TRIAMCINOLONE HEXACETONIDE

INJECTABLE; INJECTION

ARISTOSPAN

+ SANDOZ INC 5MG/ML

N016466 001

+ 20MG/ML

N016466 002

TRIAZOLAM

TABLET; ORAL

HALCION

PFIZER 0.5MG

N017892 002 Nov 15, 1982

TRIAZOLAM

MYLAN PHARMS INC 0.125MG

A074031 001 Mar 25, 1994

0.25MG

A074031 002 Mar 25, 1994

WATSON LABS 0.125MG

A074445 001 Oct 20, 1995

0.25MG

A074445 002 Oct 20, 1995

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-462(of 478)

** See List Footnote

TRICHLORMETHIAZIDE

TABLET; ORAL

METAHYDRIN

SANOFI AVENTIS US

2MG

N012594 001 Jun 16, 1988

4MG

N012594 002 Jun 16, 1988

NAQUA

SCHERING

2MG

N012265 001

4MG

N012265 002

TRICHLOREX

LANNETT

4MG

A083436 001

4MG

A085630 001

TRICHLORMAS

MAST MM

4MG

A086259 001

TRICHLORMETHIAZIDE

CHARTWELL RX

4MG

A085568 001

IMPAX LABS

4MG

A083967 001

PAR PHARM

2MG

A087007 001

4MG

A087005 001

SANDOZ

4MG

A086171 001

WATSON LABS

2MG

A083847 001

2MG

A086458 001

4MG

A083462 001

4MG

A083855 001

4MG

A085962 001

TRICLOFOS SODIUM

SOLUTION; ORAL

TRICLOS

SANOFI AVENTIS US

1.5GM/15ML

N016830 001

TABLET; ORAL

TRICLOS

SANOFI AVENTIS US

750MG

N016809 002

TRIDIHEXETHYL CHLORIDE

INJECTABLE; INJECTION

PATHILON

LEDERLE

10MG/ML

N009729 001

TABLET; ORAL

PATHILON

LEDERLE

25MG

N009489 005

TRIENTINE HYDROCHLORIDE

CAPSULE; ORAL

CLOVIQUE

CHARTWELL RX

250MG

A209731 001 Oct 21, 2019

TRIENTINE HYDROCHLORIDE

ACCORD HLTHCARE

250MG

A212929 001 Aug 30, 2021

AMNEAL

250MG

A210619 001 Feb 08, 2019

CHARTWELL RX

250MG

A209415 001 Sep 16, 2019

LUPIN LTD

250MG

A211637 001 May 21, 2020

TRIFLUOPERAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

STELAZINE

+ GLAXOSMITHKLINE

EQ 10MG BASE/ML **

N011552 006

TRIFLUOPERAZINE HYDROCHLORIDE

FOSUN PHARMA

EQ 10MG BASE/ML

A085787 001 Apr 15, 1982

WOCKHARDT

EQ 10MG BASE/ML

A088143 001 Jul 26, 1983

INJECTABLE; INJECTION

STELAZINE

+ GLAXOSMITHKLINE

EQ 2MG BASE/ML **

N011552 005

TABLET; ORAL

STELAZINE

+ GLAXOSMITHKLINE

EQ 1MG BASE **

N011552 001

+

EQ 2MG BASE **

N011552 002

+

EQ 5MG BASE **

N011552 003

+

EQ 10MG BASE **

N011552 004

TRIFLUOPERAZINE HYDROCHLORIDE

ATHEM

EQ 1MG BASE

A040153 001 Oct 25, 1996

EQ 2MG BASE

A040153 002 Oct 25, 1996

EQ 5MG BASE

A040153 003 Oct 25, 1996

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-463(of 478)

** See List Footnote

TRIFLUOPERAZINE HYDROCHLORIDE

TABLET; ORAL

TRIFLUOPERAZINE HYDROCHLORIDE

	EQ 10MG BASE	A040153 004	Oct 25, 1996
DURAMED PHARMS BARR	EQ 1MG BASE	A088967 001	Apr 23, 1985
	EQ 2MG BASE	A088968 001	Apr 23, 1985
	EQ 5MG BASE	A088969 001	Apr 23, 1985
	EQ 10MG BASE	A088970 001	Apr 23, 1985
IVAX PHARMS	EQ 1MG BASE	A087612 001	Nov 19, 1982
	EQ 2MG BASE	A087613 001	Nov 19, 1982
	EQ 5MG BASE	A087328 001	Nov 19, 1982
	EQ 10MG BASE	A087614 001	Nov 19, 1982
WATSON LABS	EQ 1MG BASE	A085975 001	Jun 23, 1988
	EQ 2MG BASE	A085976 001	Jun 23, 1988
	EQ 5MG BASE	A085973 001	Jun 23, 1988
	EQ 10MG BASE	A088710 001	Jun 23, 1988

TRIFLUPROMAZINE

SUSPENSION; ORAL

VESPRIN

APOTHECON	EQ 50MG HYDROCHLORIDE/5ML	N011491 004

TRIFLUPROMAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

VESPRIN

APOTHECON	3MG/ML	N011325 005
	10MG/ML	N011325 004
	20MG/ML	N011325 001

TABLET; ORAL

VESPRIN

BRISTOL MYERS SQUIBB	10MG	N011123 001
	25MG	N011123 002
	50MG	N011123 003

TRIFLURIDINE

SOLUTION/DROPS; OPHTHALMIC

TRIFLURIDINE

AKORN	1%	A205438 001	Jul 28, 2017

TRIHEXYPHENIDYL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

ARTANE

LEDERLE	5MG	N006773 010
	5MG	N012947 001

ELIXIR; ORAL

ARTANE

LEDERLE	2MG/5ML	N006773 009

TRIHEXYPHENIDYL HYDROCHLORIDE

PHARM VENTURES	2MG/5ML	A089514 001	Apr 07, 1989

TABLET; ORAL

ARTANE

+	LEDERLE	2MG **	N006773 005
+		5MG **	N006773 003

TREMIN

SCHERING	2MG	A080381 001
	5MG	A080381 003

TRIHEXYPHENIDYL HYDROCHLORIDE

HIKMA	2MG	A040337 002	Feb 16, 2000
	5MG	A040337 001	Feb 16, 2000
NYLOS	5MG	A085622 001	
VANGARD	2MG	A088035 001	Jul 30, 1982
WATSON LABS	2MG	A040184 001	Feb 06, 1998
	2MG	A085117 001	
	5MG	A040184 002	Feb 06, 1998
	5MG	A085105 001	

DISCONTINUED DRUG PRODUCT LIST

6-464(of 478)

** See List Footnote

TRILOSTANE

CAPSULE; ORAL

MODRASTANE

BIOENVISION

30MG

N018719 002 Dec 31, 1984

60MG

N018719 001 Dec 31, 1984

TRIMEPRAZINE TARTRATE

CAPSULE, EXTENDED RELEASE; ORAL

TEMARIL

ALLERGAN HERBERT

EQ 5MG BASE

N011316 004

SYRUP; ORAL

TEMARIL

ALLERGAN HERBERT

EQ 2.5MG BASE/5ML

N011316 003

TRIMEPRAZINE TARTRATE

ALPHARMA US PHARMS

EQ 2.5MG BASE/5ML

A085015 001 Feb 18, 1982

MORTON GROVE

EQ 2.5MG BASE/5ML

A088285 001 Apr 11, 1985

TABLET; ORAL

TEMARIL

ALLERGAN HERBERT

EQ 2.5MG BASE

N011316 001

TRIMETHADIONE

CAPSULE; ORAL

TRIDIONE

ABBVIE

300MG

N005856 005

SOLUTION; ORAL

TRIDIONE

ABBVIE

200MG/5ML

N005856 002

TABLET; ORAL

TRIDIONE

+ ABBVIE

150MG

N005856 009

TRIMETHAPHAN CAMSYLATE

INJECTABLE; INJECTION

ARFONAD

ROCHE

50MG/ML

N008983 001

TRIMETHOBENZAMIDE HYDROCHLORIDE

CAPSULE; ORAL

TIGAN

+ KING PHARMS LLC

300MG **

N017531 006 Dec 13, 2001

INJECTABLE; INJECTION

TRIMETHOBENZAMIDE HYDROCHLORIDE

AM REGENT

100MG/ML

A091330 001 Mar 08, 2011

HOSPIRA

100MG/ML

A088804 001 Apr 03, 1987

SMITH AND NEPHEW

100MG/ML

A088960 001 Apr 04, 1986

100MG/ML

A089043 001 Apr 04, 1986

SOLOPAK

100MG/ML

A089094 001 Apr 04, 1986

WATSON LABS

100MG/ML

A086577 001 Oct 19, 1982

100MG/ML

A087939 001 Dec 28, 1982

TRIMETHOBENZAMIDE HYDROCHLORIDE PRESERVATIVE FREE

AM REGENT

100MG/ML

A091329 001 Mar 08, 2011

TRIMETHOPRIM

TABLET; ORAL

PROLOPRIM

MONARCH PHARMS

100MG

N017943 001

200MG

N017943 003 Jul 14, 1982

TRIMETHOPRIM

SUN PHARM INDUSTRIES

100MG

A070494 001 Jan 22, 1986

200MG

A070495 001 Sep 24, 1986

TEVA

200MG **

A071259 001 Jun 18, 1987

TRIMPEX

ROCHE

100MG

N017952 001

TRIMPEX 200

ROCHE

200MG

N017952 002 Nov 09, 1982

DISCONTINUED DRUG PRODUCT LIST

6-465(of 478)

** See List Footnote

TRIMETHOPRIM HYDROCHLORIDE

SOLUTION; ORAL

PRIMSOL

ALLEGIS

EQ 25MG BASE/5ML

N074374 001 Jun 23, 1995

+

EQ 50MG BASE/5ML

N074973 001 Jan 24, 2000

TRIMETREXATE GLUCURONATE

INJECTABLE; INJECTION

NEUTREXIN

MEDIMMUNE ONCOLOGY

EQ 25MG BASE/VIAL

N020326 001 Dec 17, 1993

EQ 200MG BASE/VIAL

N020326 002 Jul 31, 1998

TRIMIPRAMINE MALEATE

CAPSULE; ORAL

SURMONTIL

+ ODYSSEY PHARMS

EQ 25MG BASE **

N016792 001

+

EQ 50MG BASE **

N016792 002

+

EQ 100MG BASE **

N016792 003 Sep 15, 1982

TRIMIPRAMINE MALEATE

USL PHARMA

EQ 25MG BASE

A071283 001 Dec 08, 1987

EQ 50MG BASE

A071284 001 Dec 08, 1987

EQ 100MG BASE

A071285 001 Dec 08, 1987

TRIOXSALEN

TABLET; ORAL

TRISORALEN

VALEANT PHARM INTL

5MG

N012697 001

TRIPLENNAMINE CITRATE

ELIXIR; ORAL

PBZ

NOVARTIS

EQ 25MG HYDROCHLORIDE/5ML

N005914 004

TRIPLENNAMINE HYDROCHLORIDE

TABLET; ORAL

PBZ

NOVARTIS

25MG

A083149 001

50MG

N005914 002

TRIPLENNAMINE HYDROCHLORIDE

ANABOLIC

50MG

A083037 001

BARR

50MG

A080744 001

HEATHER

50MG

A083989 001

IMPAX LABS

50MG

A080785 001

LANNETT

50MG

A083557 001

NYLOS

50MG

A085412 001

PARKE DAVIS

25MG

A083625 001

50MG

A083626 001

WATSON LABS

50MG

A080713 001

50MG

A080790 001

50MG

A085188 001

TABLET, EXTENDED RELEASE; ORAL

PBZ-SR

NOVARTIS

50MG

N010533 002

100MG

N010533 001

TRIPLE SULFA (SULFABENZAMIDE; SULFACETAMIDE; SULFATHIAZOLE)

CREAM; VAGINAL

GYNE-SULF

COSETTE

3.7%; 2.86%; 3.42%

A088607 001 Jun 09, 1986

SULTRIN

ORTHO MCNEIL PHARM

3.7%; 2.86%; 3.42%

N005794 001

TRIPLE SULFA

ALPHARMA US PHARMS

3.7%; 2.86%; 3.42%

A087864 001 Sep 01, 1982

FOUGERA

3.7%; 2.86%; 3.42%

A086424 001

PADAGIS US

3.7%; 2.86%; 3.42%

A087285 001 Nov 15, 1982

TRYSUL

SAVAGE LABS

3.7%; 2.86%; 3.42%

A087887 001 Jul 23, 1982

VAGILIA

COSETTE

3.7%; 2.86%; 3.42%

A088821 001 Nov 09, 1987

TABLET; VAGINAL

SULTRIN

ORTHO MCNEIL PHARM

184MG; 143.75MG; 172.5MG

N005794 002

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-466(of 478)

** See List Footnote

TRIPLE SULFA (SULFABENZAMIDE;SULFACETAMIDE;SULFATHIAZOLE)

TABLET;VAGINAL

TRIPLE SULFA

FOUGERA 184MG;143.75MG;172.5MG

A088463 001 Jan 03, 1985

PHARMADERM 184MG;143.75MG;172.5MG

A088462 001 Jan 03, 1985

TRIPROLIDINE HYDROCHLORIDE

SYRUP;ORAL

ACTIDIL

GLAXOSMITHKLINE 1.25MG/5ML

N011496 002 Jul 01, 1983

MYIDYL

USL PHARMA 1.25MG/5ML

A087963 001 Jan 18, 1983

TRIPROLIDINE HYDROCHLORIDE

ALPHARMA US PHARMS 1.25MG/5ML

A085940 001

HALSEY 1.25MG/5ML

A088735 001 Jan 17, 1985

PHARM ASSOC 1.25MG/5ML

A087514 001 Feb 10, 1982

TABLET;ORAL

ACTIDIL

GLAXOSMITHKLINE 2.5MG

N011110 002 Jul 01, 1983

TRIPROLIDINE HYDROCHLORIDE

VITARINE 2.5MG

A085610 001

WATSON LABS 2.5MG

A085094 001

TRISULFAPYRIMIDINES (SULFADIAZINE;SULFAMERAZINE;SULFAMETHAZINE)

SUSPENSION;ORAL

LANTRISUL

LANNETT 167MG/5ML;167MG/5ML;167MG/5ML

A080123 002

NEOTRIZINE

LILLY 167MG/5ML;167MG/5ML;167MG/5ML

N006317 012

SULFALOID

FOREST PHARMS 167MG/5ML;167MG/5ML;167MG/5ML

A080100 001

SULFOSE

WYETH AYERST 167MG/5ML;167MG/5ML;167MG/5ML

A080013 002

TERFONYL

BRISTOL MYERS SQUIBB 167MG/5ML;167MG/5ML;167MG/5ML

N006904 002

TRIPLE SULFA

ALPHARMA US PHARMS 167MG/5ML;167MG/5ML;167MG/5ML

A080280 001

TRIPLE SULFAS

LEDERLE 167MG/5ML;167MG/5ML;167MG/5ML

N006920 003

TABLET;ORAL

NEOTRIZINE

LILLY 167MG;167MG;167MG

N006317 011

SULFA-TRIPLE #2

IMPAX LABS 167MG;167MG;167MG

A080079 001

SULFALOID

FOREST PHARMS 167MG;167MG;167MG

A080099 001

SULFOSE

WYETH AYERST 167MG;167MG;167MG

A080013 001

TERFONYL

BRISTOL MYERS SQUIBB 167MG;167MG;167MG

N006904 001

TRIPLE SULFA

PUREPAC PHARM 167MG;167MG;167MG

A080086 001

TRIPLE SULFAS

LEDERLE 167MG;167MG;167MG

N006920 002

TRIPLE SULFOID

PAL PAK 167MG;167MG;167MG

A080094 001

TROGLITAZONE

TABLET;ORAL

PRELAY

SANKYO 200MG

N020719 001 Jan 29, 1997

300MG

N020719 003 Aug 04, 1997

400MG

N020719 002 Jan 29, 1997

REZULIN

PFIZER PHARMS 200MG

N020720 001 Jan 29, 1997

300MG

N020720 003 Aug 04, 1997

400MG

N020720 002 Jan 29, 1997

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-467(of 478)

** See List Footnote

TROLAMINE POLYPEPTIDE OLEATE CONDENSATE

SOLUTION/DROPS;OTIC

CERUMENEX

PHARM RES ASSOC

10%

N011340 002

TROLEANDOMYCIN

CAPSULE;ORAL

TAO

PFIZER

EQ 250MG BASE

N050336 002

SUSPENSION;ORAL

TAO

PFIZER

EQ 125MG BASE/5ML

N050332 001

TROPICAMIDE

SOLUTION/DROPS;OPHTHALMIC

MYDRIACYL

ALCON

0.5% **

N012111 002

1% **

N012111 004

MYDRIAFAIR

PHARMAFAIR

0.5%

A088274 001 Sep 16, 1983

1%

A088230 001 Sep 16, 1983

TROPICAMIDE

AKORN

1%

A088447 001 Aug 28, 1985

ALCON PHARMS LTD

1%

A089172 001 Dec 28, 1990

MIZA PHARMS USA

0.5%

A087636 001 Jul 30, 1982

1%

A087637 001 Aug 09, 1982

WATSON LABS

0.5%

A089171 001 Dec 28, 1990

TROSPIMUM CHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

SANCTURA XR

+ ALLERGAN

60MG **

N022103 001 Aug 03, 2007

TROSPIMUM CHLORIDE

UPSHER SMITH LABS

60MG

A091635 001 Apr 29, 2015

TABLET;ORAL

SANCTURA

+ ALLERGAN

20MG **

N021595 001 May 28, 2004

TROVAFLOXACIN MESYLATE

TABLET;ORAL

TROVAN

PFIZER

EQ 100MG BASE

N020759 001 Dec 18, 1997

EQ 200MG BASE

N020759 002 Dec 18, 1997

TRYPAN BLUE

SOLUTION;OPHTHALMIC

MEMBRANEBLUE

+ DORC

0.15%

N022278 001 Feb 20, 2009

TUBOCURARINE CHLORIDE

INJECTABLE;INJECTION

TUBOCURARINE CHLORIDE

BRISTOL MYERS SQUIBB

3MG/ML

N005657 001

HOSPIRA

3MG/ML

N006095 001

LILLY

3MG/ML

N006325 001

TYROPANOATE SODIUM

CAPSULE;ORAL

BILOPAQUE

GE HEALTHCARE

750MG

N013731 001

UMBRALISIB TOSYLATE

TABLET;ORAL

UKONIQ

+ TG THERAPS

EQ 200MG BASE

N213176 001 Feb 05, 2021

UNOPROSTONE ISOPROPYL

SOLUTION/DROPS;OPHTHALMIC

RESCULA

+ SUCAMPO PHARMA LLC

0.15% **

N021214 001 Aug 03, 2000

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-468(of 478)

** See List Footnote

URACIL MUSTARD

CAPSULE;ORAL

URACIL MUSTARD

SHIRE

1MG

N012892 001

UREA

INJECTABLE;INJECTION

STERILE UREA

HOSPIRA

40GM/VIAL

N017698 001

UREAPHIL

HOSPIRA

40GM/VIAL

N012154 001

UREA C-13

FOR SOLUTION;ORAL

BREATHTEK UBT FOR H-PYLORI

OTSUKA AMERICA

EQ 75MG/POUCH

N020586 002 May 10, 2001

HELICOSOL

METABOLIC SOLUTIONS

125MG/VIAL

N021092 001 Dec 17, 1999

MERETEK UBT KIT (W/ PRANACTIN)

OTSUKA AMERICA

125MG/VIAL

N020586 001 Sep 17, 1996

PYLORI-CHEK BREATH TEST

DXS DEVICES

100MG/VIAL

N020900 001 Feb 04, 1999

URSODIOL

CAPSULE;ORAL

ACTIGALL

TEVA BRANDED PHARM

150MG

N019594 001 Dec 31, 1987

URSODIOL

IMPAX LABS INC

300MG

A077895 001 Jul 27, 2006

VGYAAN

300MG

A214329 001 Jul 28, 2021

TABLET;ORAL

URSODIOL

IMPAX LABS INC

250MG

A200826 001 Dec 23, 2011

500MG

A200826 002 Dec 23, 2011

TEVA PHARMS USA

250MG

A079184 001 May 13, 2009

500MG

A079184 002 May 13, 2009

VALACYCLOVIR HYDROCHLORIDE

TABLET;ORAL

VALACYCLOVIR HYDROCHLORIDE

HIKMA

EQ 500MG BASE

A078656 001 May 24, 2010

EQ 1GM BASE

A078656 002 May 24, 2010

MYLAN

EQ 500MG BASE

A078070 001 May 24, 2010

EQ 1GM BASE

A078070 002 May 24, 2010

TEVA PHARMS

EQ 500MG BASE

A077655 001 May 24, 2010

EQ 1GM BASE

A077655 002 May 24, 2010

WATSON LABS INC

EQ 500MG BASE

A090370 001 Mar 16, 2011

EQ 1GM BASE

A090370 002 Mar 16, 2011

VALDECOXIB

TABLET;ORAL

BEXTRA

GD SEARLE

10MG

N021341 002 Nov 16, 2001

20MG

N021341 003 Nov 16, 2001

VALGANCICLOVIR HYDROCHLORIDE

TABLET;ORAL

VALGANCICLOVIR HYDROCHLORIDE

MYLAN

EQ 450MG BASE

A205151 001 Mar 03, 2021

VALPROATE SODIUM

INJECTABLE;INJECTION

DEPACON

+

ABBVIE

EQ 100MG BASE/ML **

N020593 001 Dec 30, 1996

VALPROATE SODIUM

MYLAN

EQ 100MG BASE/ML

A208120 001 Dec 22, 2021

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-469(of 478)

** See List Footnote

VALPROIC ACID

CAPSULE;ORAL

DEPAKENE

+ ABBVIE 250MG **

N018081 001

VALPROIC ACID

PAR PHARM 250MG

A070431 001 Feb 28, 1986

SCHERER RP 250MG

A070195 001 Jul 02, 1987

UPSHER SMITH LABS 250MG

A070631 001 Jun 11, 1987

CAPSULE, DELAYED RELEASE;ORAL

STAVZOR

+ BIONPHARMA INC 125MG **

N022152 001 Jul 29, 2008

+ 250MG **

N022152 002 Jul 29, 2008

+ 500MG **

N022152 003 Jul 29, 2008

SYRUP;ORAL

DEPAKENE

+ ABBVIE 250MG/5ML **

N018082 001

VALPROIC ACID

ANI PHARMS 250MG/5ML

A073178 001 Aug 25, 1992

LANNETT CO INC 250MG/5ML

A077960 001 Oct 13, 2006

NOSTRUM LABS INC 250MG/5ML

A077105 001 Jul 29, 2005

WOCKHARDT BIO AG 250MG/5ML

A070868 001 Jul 01, 1986

VALSARTAN

CAPSULE;ORAL

DIOVAN

NOVARTIS 80MG

N020665 001 Dec 23, 1996

160MG

N020665 002 Dec 23, 1996

SOLUTION;ORAL

PREXXARTAN

+ CARMEL BIOSCIENCES 20MG/5ML

N209139 001 Dec 19, 2017

+ 80MG/20ML

N209139 002 Dec 19, 2017

TABLET;ORAL

VALSARTAN

TORRENT 40MG

A202728 001 Jan 05, 2015

80MG

A202728 002 Jan 05, 2015

160MG

A202728 003 Jan 05, 2015

320MG

A202728 004 Jan 05, 2015

UNICHEM 40MG

A209261 001 May 04, 2018

80MG

A209261 002 May 04, 2018

160MG

A209261 003 May 04, 2018

320MG

A209261 004 May 04, 2018

WATSON LABS INC 40MG

A090642 001 Jan 05, 2015

80MG

A090642 002 Jan 05, 2015

160MG

A090642 003 Jan 05, 2015

320MG

A090642 004 Jan 05, 2015

VANCOMYCIN HYDROCHLORIDE

CAPSULE;ORAL

VANCOMYCIN HYDROCHLORIDE

FRESENIUS KABI USA EQ 125MG BASE

A065453 001 Jun 18, 2012

EQ 250MG BASE

A065453 002 Jun 18, 2012

FOR SOLUTION;ORAL

VANCOCIN HYDROCHLORIDE

ANI PHARMS EQ 500MG BASE/6ML

A061667 001

VANCOLED

LEDERLE EQ 250MG BASE/5ML

A063321 002 Oct 15, 1993

EQ 500MG BASE/6ML

A063321 003 Oct 15, 1993

INJECTABLE;INJECTION

VANCOCIN HYDROCHLORIDE

STERISCIENCE EQ 500MG BASE/VIAL **

A060180 001

EQ 500MG BASE/VIAL

A062476 001 Mar 15, 1984

EQ 500MG BASE/VIAL

A062716 001 Mar 13, 1987

EQ 500MG BASE/VIAL **

A062812 001 Nov 17, 1987

EQ 1GM BASE/VIAL **

A060180 002 Mar 21, 1986

EQ 1GM BASE/VIAL

A062476 002 Mar 21, 1986

EQ 1GM BASE/VIAL

A062716 002 Mar 13, 1987

EQ 1GM BASE/VIAL **

A062812 002 Nov 17, 1987

EQ 10GM BASE/VIAL **

A062812 003 Nov 17, 1987

VANCOLED

HIKMA EQ 500MG BASE/VIAL **

A062682 001 Jul 22, 1986

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-470(of 478)

** See List Footnote

VANCOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION

VANCOLED

EQ 1GM BASE/VIAL **	A062682	002	Mar 30, 1988
EQ 2GM BASE/VIAL **	A062682	003	May 11, 1988
EQ 5GM BASE/VIAL **	A062682	004	May 11, 1988
EQ 10GM BASE/VIAL **	A062682	005	May 11, 1988

VANCOMYCIN HYDROCHLORIDE

EMCURE PHARMS LTD

EQ 500MG BASE/VIAL	A202275	001	Oct 31, 2013
EQ 1GM BASE/VIAL	A202275	002	Oct 31, 2013
EQ 10GM BASE/VIAL	A202464	001	Oct 09, 2013
EQ 5GM BASE/VIAL	A202274	001	Oct 31, 2013

HIKMA

EQ 1GM BASE/VIAL	A203300	002	Aug 11, 2020
EQ 500MG BASE/VIAL	A062879	001	Aug 02, 1988
EQ 500MG BASE/VIAL	A203300	001	Aug 11, 2020
EQ 1GM BASE/VIAL	A062879	002	Aug 02, 1988

KNACK

EQ 500MG BASE/VIAL	A213059	001	Feb 15, 2022
EQ 750MG BASE/VIAL	A213059	002	Feb 15, 2022
EQ 1GM BASE/VIAL	A213059	003	Feb 15, 2022

MYLAN LABS LTD

SANDOZ

EQ 10GM BASE/VIAL	A091469	001	Jul 01, 2011
EQ 500MG BASE/VIAL	A090250	001	Apr 27, 2010
EQ 1GM BASE/VIAL	A090250	002	Apr 27, 2010

TEVA PHARMS USA

EQ 500MG BASE/VIAL	A201251	001	Dec 23, 2015
EQ 1GM BASE/VIAL	A201251	002	Dec 23, 2015
EQ 5GM BASE/VIAL	A201250	001	Dec 23, 2015
EQ 10GM BASE/VIAL	A201250	002	Dec 23, 2015

XELLIA PHARMS APS

EQ 500MG BASE/VIAL	A091377	001	Sep 09, 2015
EQ 1GM BASE/VIAL	A091377	002	Sep 09, 2015
EQ 5GM BASE/VIAL	A206243	001	Dec 23, 2015
EQ 10GM BASE/VIAL	A206243	002	Dec 23, 2015

VANCOR

PHARMACIA AND UPJOHN

EQ 500MG BASE/VIAL	A062956	001	Aug 01, 1988
EQ 1GM BASE/VIAL	A062956	002	Aug 01, 1988

POWDER; INTRAVENOUS

VANCOMYCIN HYDROCHLORIDE

+ MYLAN LABS LTD EQ 250MG BASE/VIAL

N209481 001 Jul 10, 2018

VARDENAFIL HYDROCHLORIDE

TABLET; ORAL

LEVITRA

+ BAYER HLTHCARE EQ 2.5MG BASE **	N021400	003	Aug 19, 2003
+ EQ 5MG BASE	N021400	001	Aug 19, 2003
+ EQ 10MG BASE	N021400	002	Aug 19, 2003
+ EQ 20MG BASE	N021400	004	Aug 19, 2003

VARDENAFIL HYDROCHLORIDE

AMNEAL PHARMS CO

EQ 5MG BASE	A210738	001	Oct 31, 2018
EQ 10MG BASE	A210738	002	Oct 31, 2018
EQ 20MG BASE	A210738	003	Oct 31, 2018

TABLET, ORALLY DISINTEGRATING; ORAL

STAXYN

+ BAYER HLTHCARE 10MG	N200179	001	Jun 17, 2010

VARENICLINE TARTRATE

TABLET; ORAL

CHANTIX

+ PF PRISM CV EQ 0.5MG BASE	N021928	001	May 10, 2006
+ EQ 1MG BASE	N021928	002	May 10, 2006

VASOPRESSIN TANNATE

INJECTABLE; INJECTION

PITRESSIN TANNATE

+ PARKE DAVIS 5PRESSOR UNITS/ML ** N003402 001

VECURONIUM BROMIDE

INJECTABLE; INJECTION

NORCURON

+ ORGANON USA INC 10MG/VIAL **	N018776	002	Apr 30, 1984
+ 20MG/VIAL **	N018776	003	Jan 03, 1992

VECURONIUM BROMIDE

HIKMA

10MG/VIAL	A075218	001	Aug 23, 1999
20MG/VIAL	A075218	002	Aug 23, 1999

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-471(of 478)

** See List Footnote

VECURONIUM BROMIDE

INJECTABLE; INJECTION

VECURONIUM BROMIDE

HOSPIRA	4MG/VIAL
WATSON LABS	10MG/VIAL
	20MG/VIAL

A075558	001	Sep 11, 2001
A074334	001	Aug 31, 1995
A074334	002	Aug 31, 1995

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

EFFEXOR XR

UPJOHN	EQ 100MG BASE

N020699	003	Oct 20, 1997

VENLAFAXINE HYDROCHLORIDE

ANCHEN PHARMS	EQ 37.5MG BASE
	EQ 75MG BASE
	EQ 150MG BASE
MYLAN	EQ 37.5MG BASE
	EQ 75MG BASE
	EQ 150MG BASE

A078087	001	Mar 16, 2012
A078087	002	Mar 16, 2012
A078087	003	Mar 16, 2012
A078789	001	Jun 01, 2011
A078789	002	Jun 01, 2011
A078789	003	Jun 01, 2011

TABLET; ORAL

EFFEXOR

+	WYETH PHARMS INC	EQ 12.5MG BASE **
+		EQ 25MG BASE **
+		EQ 37.5MG BASE **
+		EQ 50MG BASE **
+		EQ 75MG BASE **
+		EQ 100MG BASE **

N020151	001	Dec 28, 1993
N020151	002	Dec 28, 1993
N020151	006	Dec 28, 1993
N020151	003	Dec 28, 1993
N020151	004	Dec 28, 1993
N020151	005	Dec 28, 1993

VENLAFAXINE HYDROCHLORIDE

FOSUN PHARMA	EQ 25MG BASE
	EQ 37.5MG BASE
	EQ 50MG BASE
	EQ 75MG BASE
	EQ 100MG BASE
MYLAN	EQ 25MG BASE
	EQ 37.5MG BASE
	EQ 50MG BASE
	EQ 75MG BASE
	EQ 100MG BASE
PLIVA HRVATSKA DOO	EQ 25MG BASE
	EQ 37.5MG BASE
	EQ 50MG BASE
	EQ 75MG BASE
	EQ 100MG BASE
PRINSTON INC	EQ 25MG BASE
	EQ 37.5MG BASE
	EQ 50MG BASE
	EQ 75MG BASE
	EQ 100MG BASE

A077515	001	Jun 13, 2008
A077515	002	Jun 13, 2008
A077515	003	Jun 13, 2008
A077515	004	Jun 13, 2008
A077515	005	Jun 13, 2008
A077166	001	Jun 13, 2008
A077166	002	Jun 13, 2008
A077166	003	Jun 13, 2008
A077166	004	Jun 13, 2008
A077166	005	Jun 13, 2008
A078517	001	Jun 13, 2008
A078517	002	Jun 13, 2008
A078517	003	Jun 13, 2008
A078517	004	Jun 13, 2008
A078517	005	Jun 13, 2008
A090027	001	Aug 04, 2010
A090027	002	Aug 04, 2010
A090027	003	Aug 04, 2010
A090027	004	Aug 04, 2010
A090027	005	Aug 04, 2010

TABLET, EXTENDED RELEASE; ORAL

VENLAFAXINE HYDROCHLORIDE

SUNNY	EQ 75MG BASE
	EQ 150MG BASE

A214423	001	Jan 04, 2022
A214423	002	Jan 04, 2022

VERAPAMIL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

VERAPAMIL HYDROCHLORIDE

RISING	100MG
	200MG
	300MG

A078306	001	Aug 09, 2007
A078306	002	Aug 09, 2007
A078306	003	Aug 09, 2007

INJECTABLE; INJECTION

CALAN

GD SEARLE LLC	2.5MG/ML

N019038	001	Mar 30, 1984

ISOPTIN

+	MT ADAMS	2.5MG/ML **

N018485	001	

VERAPAMIL HYDROCHLORIDE

ABRAXIS PHARM	2.5MG/ML
BEDFORD	2.5MG/ML
HOSPIRA	2.5MG/ML
	2.5MG/ML
	2.5MG/ML
INTL MEDICATION	2.5MG/ML

A070348	001	May 01, 1986
A072888	001	Jul 28, 1995
A070577	001	Feb 02, 1987
A070739	001	May 06, 1987
A070740	001	May 06, 1987
A070451	001	Dec 16, 1985

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-472(of 478)

** See List Footnote

VERAPAMIL HYDROCHLORIDE

INJECTABLE; INJECTION

VERAPAMIL HYDROCHLORIDE

LUITPOLD	2.5MG/ML	A070225	001	Nov 12, 1985
	2.5MG/ML	A070617	001	Nov 12, 1985
MARSAM PHARMS LLC	2.5MG/ML	A072233	001	Feb 26, 1993
	2.5MG/ML	A073485	001	Sep 27, 1993
SMITH AND NEPHEW	2.5MG/ML	A070696	001	Jul 31, 1987
	2.5MG/ML	A070697	001	Jul 31, 1987
SOLOPAK	2.5MG/ML	A070695	001	Jul 31, 1987

SOLUTION; INTRAVENOUS

VERAPAMIL HYDROCHLORIDE

EXELA PHARMA	10MG/4ML (2.5MG/ML)	N018925	002	Apr 05, 2018

TABLET; ORAL

CALAN

PFIZER	40MG **	N018817	003	Feb 23, 1988
+	80MG **	N018817	001	Sep 10, 1984
+	120MG **	N018817	002	Sep 10, 1984
	160MG **	N018817	004	Feb 23, 1988

ISOPTIN

MT ADAMS	40MG **	N018593	003	Nov 23, 1987
+	80MG **	N018593	001	Mar 08, 1982
+	120MG **	N018593	002	Mar 08, 1982

VERAPAMIL HYDROCHLORIDE

ACTAVIS ELIZABETH	80MG	A071019	001	Sep 24, 1986
	120MG	A070468	001	Sep 24, 1986
CHARTWELL RX	40MG	A073168	001	Jul 31, 1992
	80MG	A071423	001	May 24, 1988
	120MG	A071424	001	May 25, 1988
MUTUAL PHARM	80MG	A070482	001	Sep 24, 1986
	120MG	A070483	001	Sep 24, 1986
PLIVA	40MG	A072751	001	Feb 23, 1996
	80MG	A072124	001	Jan 26, 1989
	120MG	A072125	001	Jan 26, 1989
RISING	80MG	A071483	002	Feb 15, 1989
	120MG	A071483	001	Feb 15, 1989
SUN PHARM INDUSTRIES	80MG	A071489	002	Jan 13, 1988
	120MG	A071489	001	Jan 13, 1988
WARNER CHILCOTT	80MG	A070340	001	Sep 24, 1986
	120MG	A070341	001	Sep 24, 1986
WATSON LABS	40MG	A072799	001	Apr 28, 1989
	40MG	A072923	001	Jun 29, 1993
	80MG	A070855	001	Sep 24, 1986
	80MG	A071366	001	Oct 01, 1986
	120MG	A070856	001	Sep 24, 1986
	120MG	A071367	001	Oct 01, 1986

TABLET, EXTENDED RELEASE; ORAL

CALAN SR

PFIZER	180MG **	N019152	002	Dec 15, 1989

COVERA-HS

PFIZER	180MG	N020552	001	Feb 26, 1996
	240MG	N020552	002	Feb 26, 1996

VERAPAMIL HYDROCHLORIDE

APOTEX CORP	120MG	A200878	001	Apr 20, 2012
	180MG	A200878	002	Apr 20, 2012
	240MG	A200878	003	Apr 20, 2012
PLIVA	240MG	A072922	001	Mar 01, 1996
RISING	120MG	A074587	002	Feb 21, 1997
	180MG	A074587	003	Sep 09, 1997
	240MG	A074587	001	Mar 23, 1996

VERATRUM VIRIDE ROOT

TABLET; ORAL

VERTAVIS

MEDPOINTE PHARM HLC	130CSR UNIT	N005691	002	

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-473(of 478)

** See List Footnote

VIDARABINE

INJECTABLE; INJECTION

VIRA-A

PARKEDALE

EQ 187.4MG BASE/ML

N050523 001

OINTMENT; OPHTHALMIC

VIRA-A

PARKEDALE

3%

N050486 001

VIGABATRIN

FOR SOLUTION; ORAL

VIGABATRIN

GRANULES

500MG/PACKET

A213469 001 Apr 24, 2020

LUPIN LTD

500MG/PACKET

A211790 001 Mar 10, 2022

SPECGX LLC

500MG/PACKET

A212626 001 Jul 28, 2021

VINBLASTINE SULFATE

INJECTABLE; INJECTION

VELBAN

+ LILLY

10MG/VIAL **

N012665 001

VINBLASTINE SULFATE

ABRAXIS PHARM

10MG/VIAL

A089011 001 Nov 18, 1985

HOSPIRA

10MG/VIAL

A089565 001 Aug 18, 1987

VINCRISTINE SULFATE

INJECTABLE; INJECTION

ONCOVIN

+ LILLY

1MG/VIAL **

N014103 001

+

1MG/ML **

N014103 003 Mar 07, 1984

+

5MG/VIAL **

N014103 002

VINCASAR PFS

TEVA PARENTERAL

1MG/ML

A071426 001 Jul 17, 1987

VINCREX

BRISTOL MYERS SQUIBB

5MG/VIAL

A070867 001 Jul 12, 1988

VINCRISTINE SULFATE

ABIC

1MG/ML

A070873 001 Feb 19, 1987

ABRAXIS PHARM

1MG/ML

A070411 001 Sep 10, 1986

FRESENIUS KABI USA

1MG/ML

A076296 001 Dec 20, 2002

1MG/ML

A076401 001 Oct 28, 2003

HOSPIRA

1MG/VIAL

A071559 001 Apr 11, 1988

2MG/VIAL

A071560 001 Apr 11, 1988

5MG/VIAL

A071561 001 Apr 11, 1988

INJECTABLE, LIPOSOMAL; INTRAVENOUS

MARQIBO KIT

+ ACROTECH

5MG/5ML (1MG/ML)

N202497 001 Aug 09, 2012

VINORELBINE TARTRATE

INJECTABLE; INJECTION

NAVELBINE

+ PIERRE FABRE

EQ 10MG BASE/ML **

N020388 001 Dec 23, 1994

VINORELBINE TARTRATE

EBEWE PHARMA

EQ 10MG BASE/ML

A078408 001 Feb 13, 2008

FRESENIUS KABI USA

EQ 10MG BASE/ML

A076849 001 Apr 18, 2005

HOSPIRA

EQ 10MG BASE/ML

A076827 001 Jun 02, 2005

MYLAN LABS LTD

EQ 10MG BASE/ML

A200148 001 Aug 31, 2012

NOVAST LABS

EQ 10MG BASE/ML

A208997 001 Aug 05, 2019

TEVA PHARMS USA

EQ 10MG BASE/ML

A076028 001 Feb 03, 2003

VIOMYCIN SULFATE

INJECTABLE; INJECTION

VIOCIN SULFATE

PFIZER

EQ 1GM BASE/VIAL

A061086 001

EQ 5GM BASE/VIAL

A061086 002

VITAMIN A

CAPSULE; ORAL

AQUASOL A

ASTRAZENECA

25,000USP UNITS

A083080 002

50,000USP UNITS

A083080 001

VITAMIN A

BANNER PHARMACAPS

50,000USP UNITS

A083973 001

CHASE CHEM

50,000 IU

A083351 001

EVERYLIFE

50,000 IU

A083134 001

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-474(of 478)

** See List Footnote

VITAMIN A

CAPSULE;ORAL

VITAMIN A

IMPAX LABS	50,000USP UNITS	A080952	001
WEST WARD	50,000USP UNITS	A080985	001

VITAMIN A PALMITATE

CAPSULE;ORAL

AFAXIN

STERLING WINTHROP	EQ 50,000 UNITS BASE	A083187	001

ALPHALIN

LILLY	EQ 50,000 UNITS BASE	A080883	001

DEL-VI-A

DEL RAY LABS	EQ 50,000 UNITS BASE	A080830	001

VI-DOM-A

BAYER PHARMS	EQ 50,000 UNITS BASE	A080972	001

VITAMIN A

BANNER PHARMACAPS	EQ 50,000 UNITS BASE	A080702	001

BRISTOL MYERS SQUIBB	EQ 50,000 UNITS BASE	A080860	001

CHASE CHEM	EQ 50,000 UNITS BASE	A080746	001

	EQ 50,000 UNITS BASE	A083207	001

ELKINS SINN	EQ 50,000 UNITS BASE	A085479	001

EVERYLIFE	EQ 50,000 UNITS BASE	A080943	001

	EQ 50,000 UNITS BASE	A083114	001

IMPAX LABS	EQ 50,000 UNITS BASE	A080953	001

	EQ 50,000 UNITS BASE	A080955	001

IVAX SUB TEVA PHARMS	EQ 50,000 UNITS BASE	A083035	001

	EQ 50,000 UNITS BASE	A083190	001

MK LABS	EQ 25,000 UNITS BASE	A083457	002

	EQ 50,000 UNITS BASE	A083457	001

WEST WARD	EQ 50,000 UNITS BASE	A080967	001

WHARTON LABS	EQ 50,000 UNITS BASE	A083665	001

VITAMIN A PALMITATE

ARCUM	EQ 50,000 UNITS BASE	A083311	001

	EQ 50,000 UNITS BASE	A083321	001

BANNER PHARMACAPS	EQ 50,000 UNITS BASE	A083948	001

	EQ 50,000 UNITS BASE	A083981	001

VITAMIN A SOLUBILIZED

TEVA	EQ 50,000 UNITS BASE	A080921	001

INJECTABLE;INJECTION

VITAMIN A PALMITATE

BEL MAR	EQ 50,000 UNITS BASE/ML	A080819	001

VORICONAZOLE

FOR SUSPENSION;ORAL

VORICONAZOLE

RISING	200MG/5ML	A202361	001	May 28, 2013

INJECTABLE;INTRAVENOUS

VORICONAZOLE

MYLAN LABS LTD	200MG/VIAL	A210849	001	Oct 11, 2022

TABLET;ORAL

VORICONAZOLE

TEVA PHARMS	50MG	A091658	001	Apr 06, 2012

	200MG	A091658	002	Apr 06, 2012

VORTIOXETINE HYDROBROMIDE

TABLET;ORAL

TRINTELLIX

+ TAKEDA PHARMS USA	EQ 15MG BASE **	N204447	003	Sep 30, 2013

VORTIOXETINE HYDROBROMIDE

ZYDUS PHARMS	EQ 5MG BASE	A211146	001	Sep 17, 2021

	EQ 10MG BASE	A211146	002	Sep 17, 2021

	EQ 20MG BASE	A211146	003	Sep 17, 2021

WARFARIN POTASSIUM

TABLET;ORAL

ATHROMBIN-K

PHARM RES ASSOC	2MG	N011771	007

	5MG	N011771	004

	10MG	N011771	005

	25MG	N011771	006

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-475(of 478)

** See List Footnote

WARFARIN SODIUM

INJECTABLE; INJECTION

COUMADIN

BRISTOL MYERS SQUIBB 5MG/VIAL
 50MG/VIAL
 75MG/VIAL

N009218 024 Feb 07, 1995
 N009218 020
 N009218 012

TABLET; ORAL

ATHROMBIN

PHARM RES ASSOC 5MG
 10MG
 25MG

N011771 003
 N011771 002
 N011771 001

COUMADIN

+ BRISTOL MYERS SQUIBB 1MG **
 + 2MG
 + 2.5MG
 + 3MG
 + 4MG
 + 5MG
 + 6MG
 + 7.5MG
 + 10MG

N009218 022 Mar 01, 1990
 N009218 013
 N009218 018
 N009218 025 Nov 18, 1996
 N009218 023 Aug 24, 1993
 N009218 007
 N009218 026 Nov 18, 1996
 N009218 016
 N009218 005

PANWARFIN

ABBOTT 2MG
 2.5MG
 5MG
 7.5MG
 10MG

N017020 001
 N017020 002
 N017020 003
 N017020 004
 N017020 005

WARFARIN SODIUM

CHARTWELL RX

1MG
 2MG
 2.5MG
 3MG
 4MG
 5MG
 6MG
 7.5MG
 10MG
 1MG
 2MG
 2.5MG
 3MG
 4MG
 5MG
 6MG
 7.5MG
 10MG
 2MG
 2.5MG
 5MG
 2MG
 2.5MG
 5MG
 7.5MG
 10MG

A040196 001 Sep 30, 1997
 A040196 002 Sep 30, 1997
 A040196 003 Sep 30, 1997
 A040196 008 Jul 26, 2000
 A040196 004 Sep 30, 1997
 A040196 005 Sep 30, 1997
 A040196 009 Jul 26, 2000
 A040196 006 Sep 30, 1997
 A040196 007 Sep 30, 1997
 A040415 001 Sep 27, 2004
 A040415 002 Sep 27, 2004
 A040415 003 Sep 29, 2004
 A040415 004 Sep 27, 2004
 A040415 005 Sep 27, 2004
 A040415 006 Sep 27, 2004
 A040415 007 Sep 27, 2004
 A040415 008 Sep 27, 2004
 A040415 009 Sep 27, 2004
 A088719 001 Jun 27, 1985
 A088720 001 Aug 06, 1985
 A088721 001 Jul 02, 1985
 A086123 001 Aug 17, 1982
 A086120 001 Aug 17, 1982
 A086119 001 Aug 17, 1982
 A086118 001 Aug 17, 1982
 A086122 001 Aug 17, 1982

MYLAN

USL PHARMA

WATSON LABS

XENON XE-127

GAS; INHALATION

XENON XE 127

MALLINCKRODT 5mCi/VIAL
 10mCi/VIAL

N018536 001 Oct 01, 1982
 N018536 002 Oct 01, 1982

XENON XE-133

GAS; INHALATION

XENON XE 133

GE HEALTHCARE 1 CI/AMP
 10mCi/VIAL
 20mCi/VIAL
 GEN ELECTRIC 5-100 CI/CYLINDER
 0.25-5 CI/AMP

N017256 002
 N017687 002
 N017687 003
 N017550 001
 N017550 003

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-476(of 478)

** See List Footnote

XENON XE-133

GAS; INHALATION

XENON XE 133-V.S.S.

GE HEALTHCARE

10mCi/VIAL

N017687 001

INJECTABLE; INJECTION

XENON XE 133

GE HEALTHCARE

1.3-1.7 CI/AMP

N017256 001

LANTHEUS MEDCL

6.3mCi/ML

N017283 001

SOLUTION; INHALATION, INJECTION

XENEISOL

MALLINCKRODT

18-25mCi/AMP

N017262 002

XYLOSE

POWDER; ORAL

XYLO-PFAN

SAVAGE LABS

25GM/BOT

N017605 001

XYLOSE

LYNE

25GM/BOT

N018856 001 Mar 26, 1987

ZALCITABINE

TABLET; ORAL

HIVID

ROCHE

0.375MG

N020199 001 Jun 19, 1992

0.75MG

N020199 002 Jun 19, 1992

ZALEPLON

CAPSULE; ORAL

ZALEPLON

HIKMA PHARMS

5MG

A078147 001 Nov 25, 2008

10MG

A078147 002 Nov 25, 2008

MYLAN

5MG

A077238 001 Jun 06, 2008

10MG

A077238 002 Jun 06, 2008

TEVA PHARMS

5MG

A077239 001 Jun 06, 2008

10MG

A077239 002 Jun 06, 2008

UPSHER SMITH LABS

5MG

A078095 001 Jun 06, 2008

5MG

A078706 001 Jun 06, 2008

10MG

A078095 002 Jun 06, 2008

10MG

A078706 002 Jun 06, 2008

ZICONOTIDE ACETATE

INJECTABLE; INTRATHECAL

PRIALT

TERSERA

200MCG/2ML (100MCG/ML)

N021060 003 Dec 28, 2004

ZIDOVUDINE

INJECTABLE; INJECTION

ZIDOVUDINE

AM REGENT

10MG/ML

A091457 001 May 06, 2010

LIAONING CHENGDA

10MG/ML

A204538 001 Nov 26, 2013

TABLET; ORAL

RETROVIR

VIIV HLTHCARE

200MG

N020518 001 Dec 19, 1995

+

300MG **

N020518 002 Oct 04, 1996

ZIDOVUDINE

AUROBINDO PHARMA

60MG

N022294 001 Jul 23, 2009

HEC PHARM

300MG

A202058 001 Oct 07, 2011

HIKMA

300MG

A076844 001 Sep 19, 2005

MYLAN LABS LTD

100MG

N200732 001 Feb 23, 2011

RANBAXY LABS LTD

300MG

A077327 001 Sep 19, 2005

ZILEUTON

TABLET; ORAL

ZYFLO

CHIESI

300MG

N020471 001 Dec 09, 1996

TABLET, EXTENDED RELEASE; ORAL

ZILEUTON

TEVA PHARMS USA

600MG

A211043 001 May 03, 2022

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-477(of 478)

** See List Footnote

ZINC SULFATE

INJECTABLE; INJECTION

ZINC SULFATE

ABRAXIS PHARM

EQ 1MG ZINC/ML

N019229 002 May 05, 1987

ZIPRASIDONE HYDROCHLORIDE

CAPSULE; ORAL

ZIPRASIDONE HYDROCHLORIDE

MYLAN

EQ 20MG BASE

A202395 001 Oct 10, 2013

EQ 40MG BASE

A202395 002 Oct 10, 2013

EQ 60MG BASE

A202395 003 Oct 10, 2013

EQ 80MG BASE

A202395 004 Oct 10, 2013

SUSPENSION; ORAL

GEODON

PFIZER INC

EQ 10MG BASE/ML

N021483 001 Mar 29, 2006

ZOLEDRONIC ACID

INJECTABLE; INTRAVENOUS

ZOLEDRONIC ACID

ACTAVIS INC

EQ 4MG BASE/5ML

A202472 001 Mar 04, 2013

DR REDDYS

EQ 4MG BASE/100ML

A204344 001 Nov 19, 2018

EMCURE PHARMS LTD

EQ 4MG BASE/5ML

A201783 001 Mar 12, 2013

EQ 5MG BASE/100ML

A201801 001 Mar 29, 2013

EUGIA PHARMA

EQ 4MG BASE/5ML

A207751 001 Sep 26, 2016

EQ 5MG BASE/100ML

A209125 001 Dec 08, 2017

SHILPA

EQ 4MG BASE/5ML

A208513 001 May 15, 2019

SUN PHARMA GLOBAL

EQ 4MG BASE/VIAL

A090018 001 Mar 04, 2013

EQ 4MG BASE/5ML

A202746 001 Mar 04, 2013

ZOMETA

+ NOVARTIS

EQ 4MG BASE/VIAL **

N021223 001 Aug 20, 2001

ZOLMITRIPTAN

TABLET; ORAL

ZOLMITRIPTAN

ANI PHARMS

2.5MG

A090861 001 Mar 04, 2014

5MG

A090861 002 Mar 04, 2014

APOTEX INC

2.5MG

A202078 001 May 14, 2013

5MG

A202078 002 May 14, 2013

MACLEODS PHARMS LTD

2.5MG

A203772 001 Sep 30, 2015

5MG

A203772 002 Sep 30, 2015

MYLAN PHARMS INC

2.5MG

A203186 001 May 14, 2013

5MG

A203186 002 May 14, 2013

SUN PHARMA GLOBAL

2.5MG

A203476 001 Nov 13, 2014

5MG

A203476 002 Nov 13, 2014

TABLET, ORALLY DISINTEGRATING; ORAL

ZOLMITRIPTAN

APOTEX INC

2.5MG

A202476 001 May 14, 2013

5MG

A202476 002 May 14, 2013

MACLEODS PHARMS LTD

2.5MG

A204336 001 Oct 22, 2015

5MG

A204336 002 Oct 22, 2015

RISING

2.5MG

A202855 001 Sep 20, 2019

5MG

A202855 002 Sep 20, 2019

ZOLPIDEM TARTRATE

SPRAY, METERED; ORAL

ZOLPIMIST

+ AYTU

5MG/SPRAY

N022196 001 Dec 19, 2008

TABLET; ORAL

ZOLPIDEM TARTRATE

DR REDDYS LABS LTD

5MG

A077985 001 Apr 23, 2007

10MG

A077985 002 Apr 23, 2007

HIKMA

5MG

A078129 001 Apr 30, 2008

10MG

A078129 002 Apr 30, 2008

MYLAN PHARMS INC

5MG

A078016 001 Apr 23, 2007

10MG

A078016 002 Apr 23, 2007

RISING

5MG

A076578 001 Apr 23, 2007

10MG

A076578 002 Apr 23, 2007

STRIDES PHARMA

5MG

A076062 001 Apr 23, 2007

5MG

A078616 001 Nov 21, 2008

10MG

A076062 002 Apr 23, 2007

10MG

A078616 002 Nov 21, 2008

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

DISCONTINUED DRUG PRODUCT LIST

6-478(of 478)

** See List Footnote

ZOLPIDEM TARTRATE

TABLET;ORAL

ZOLPIDEM TARTRATE

SUN PHARM INDS INC	5MG	A077359 001	Apr 23, 2007
	10MG	A077359 002	Apr 23, 2007
SUN PHARM INDS LTD	5MG	A078055 001	Apr 23, 2007
	10MG	A078055 002	Apr 23, 2007
SUN PHARM INDUSTRIES	5MG	A077288 001	Apr 23, 2007
	10MG	A077288 002	Apr 23, 2007
SYNTHON PHARMS	5MG	A077540 001	Apr 23, 2007
	10MG	A077540 002	Apr 23, 2007
WATSON LABS	5MG	A077773 001	Apr 23, 2007
	10MG	A077773 002	Apr 23, 2007
WOCKHARDT	5MG	A078426 001	May 15, 2007
	10MG	A078426 002	May 15, 2007
YUNG SHIN PHARM	5MG	A077990 001	Apr 23, 2007
	10MG	A077990 002	Apr 23, 2007

TABLET;SUBLINGUAL

INTERMEZZO

+ PURDUE PHARMA	1.75MG	N022328 001	Nov 23, 2011
+	3.5MG	N022328 002	Nov 23, 2011

ZOLPIDEM TARTRATE

MYLAN	5MG	A202657 001	Aug 08, 2016
	10MG	A202657 002	Aug 08, 2016

TABLET, EXTENDED RELEASE;ORAL

ZOLPIDEM TARTRATE

ACTAVIS ELIZABETH	6.25MG	A078179 002	Oct 13, 2010
	12.5MG	A078179 001	Jun 06, 2011
SYNTHON PHARMS	6.25MG	A078483 001	Apr 12, 2011
	12.5MG	A078483 002	Jun 06, 2011

TABLET, ORALLY DISINTEGRATING;ORAL

TOVALT ODT

+ BIOVAIL LABS INTL	5MG	N021412 001	Apr 25, 2007
+	10MG	N021412 002	Apr 25, 2007

ZONISAMIDE

CAPSULE;ORAL

ZONEGRAN

+ CONCORDIA	50MG **	N020789 002	Aug 22, 2003

ZONISAMIDE

ANI PHARMS	25MG	A077639 001	Dec 22, 2005
	25MG	A077641 003	Dec 22, 2005
	50MG	A077639 002	Dec 22, 2005
	50MG	A077641 002	Dec 22, 2005
	100MG	A077639 003	Dec 22, 2005
	100MG	A077641 001	Dec 22, 2005
EPIC PHARMA LLC	25MG	A077876 001	Feb 21, 2007
	50MG	A077876 002	Feb 21, 2007
	100MG	A077876 003	Feb 21, 2007
HERITAGE PHARMA AVET	25MG	A077650 001	Apr 20, 2006
	50MG	A077650 002	Apr 20, 2006
	100MG	A077650 003	Apr 20, 2006
MYLAN PHARMS INC	25MG	A077647 001	Dec 22, 2005
	50MG	A077647 002	Dec 22, 2005
	100MG	A077647 003	Dec 22, 2005
RISING	25MG	A077637 001	Dec 22, 2005
	50MG	A077637 002	Dec 22, 2005
	100MG	A077637 003	Dec 22, 2005
ROXANE	25MG	A077648 001	Dec 22, 2005
	50MG	A077648 002	Dec 22, 2005
	100MG	A077648 003	Dec 22, 2005
SUN PHARM INDUSTRIES	25MG	A077635 001	Dec 22, 2005
	50MG	A077635 002	Dec 22, 2005
	100MG	A077635 003	Dec 22, 2005
UPSHER SMITH LABS	25MG	A077644 001	Dec 22, 2005
	50MG	A077644 002	Dec 22, 2005
	100MG	A077644 003	Dec 22, 2005

Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

ORPHAN PRODUCTS DESIGNATIONS AND APPROVALS LIST

The list of Orphan Designations and Approvals is available at:

<http://www.fda.gov/ForIndustry/DevelopingProductsforRareDiseasesConditions/default.htm>

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

ACETAMINOPHEN;ASPIRIN;BUTALBITAL
CAPSULE OR TABLET; ORAL
160-165MG;160-165MG;50MG
325MG;325MG;50MG

ASPIRIN;CAFFEINE;CARISOPRODOL;
CODEINE PHOSPHATE
TABLET; ORAL
160MG;32MG;200MG;16MG

ACETAMINOPHEN;ASPIRIN;BUTALBITAL;
CAFFEINE
CAPSULE OR TABLET; ORAL
160-165MG;160-165MG;50MG;40MG
325MG;325MG;50MG;40MG

ASPIRIN;CARISOPRODOL
TABLET; ORAL
325MG;200MG

ACETAMINOPHEN;BUTALBITAL
CAPSULE OR TABLET; ORAL
325MG;50MG

ASPIRIN;CARISOPRODOL;
CODEINE PHOSPHATE
TABLET; ORAL
325MG;200MG;16MG

ACETAMINOPHEN;BUTALBITAL;CAFFEINE
CAPSULE OR TABLET; ORAL
325MG;50MG;40MG

ASPIRIN;MEPROBAMATE
TABLET; ORAL
325MG;200MG

AMINOPHYLLINE
TABLET; ORAL
100MG;200MG

ASPIRIN;METHOCARBAMOL
TABLET; ORAL
325MG;400MG

ASPIRIN;BUTALBITAL
CAPSULE OR TABLET; ORAL
325MG;50MG
650MG;50MG

CHLOROTHIAZIDE
TABLET; ORAL
250MG

ASPIRIN;BUTALBITAL;CAFFEINE
CAPSULE OR TABLET; ORAL
325MG;50MG;40MG
650MG;50MG;40MG

HYDROXYZINE HYDROCHLORIDE
TABLET; ORAL
10MG;25MG;
50MG;100MG

ASPIRIN;CAFFEINE;CARISOPRODOL
TABLET; ORAL
160MG;32MG;200MG

PREDNISONE
TABLET; ORAL
1MG;2.5MG;5MG;10MG;
20MG;25MG;50MG

APPENDIX A - PRODUCT NAME INDEX**** A ****

ABACAVIR SULFATE, ABACAVIR SULFATE
ABACAVIR SULFATE AND LAMIVUDINE, ABACAVIR SULFATE
ABACAVIR SULFATE, LAMIVUDINE AND ZIDOVUDINE, ABACAVIR SULFATE
ABELCET, AMPHOTERICIN B
ABILIFY, ARIPIPRAZOLE
ABILIFY MAINTENA KIT, ARIPIPRAZOLE
ABILIFY MYCITE KIT, ARIPIPRAZOLE
ABIRATERONE ACETATE, ABIRATERONE ACETATE
ABLYSINOL, ALCOHOL
ABRAXANE, PACLITAXEL
ABREVA, DOCOSANOL (OTC)
ABSORICA, ISOTRETINOIN
ABSORICA LD, ISOTRETINOIN
ACAMPROSATE CALCIUM, ACAMPROSATE CALCIUM
ACANYA, BENZOYL PEROXIDE
ACARBOSE, ACARBOSE
ACCOLATE, ZAFIRLUKAST
ACCRUFER, FERRIC MALTOL
ACCUNEB, ALBUTEROL SULFATE
ACEBUTOLOL HYDROCHLORIDE, ACEBUTOLOL HYDROCHLORIDE
ACEPHEN, ACETAMINOPHEN (OTC)
ACETADOTE, ACETYLCYSTEINE
ACETAMINOPHEN, ACETAMINOPHEN (OTC)
ACETAMINOPHEN, ACETAMINOPHEN
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ACETAMINOPHEN, ASPIRIN AND CAFFEINE, ACETAMINOPHEN (OTC)
ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE, ACETAMINOPHEN
ACETAZOLAMIDE, ACETAZOLAMIDE
ACETAZOLAMIDE SODIUM, ACETAZOLAMIDE SODIUM
ACETIC ACID, ACETIC ACID, GLACIAL
ACETIC ACID 0.25% IN PLASTIC CONTAINER, ACETIC ACID, GLACIAL
ACETYLCYSTEINE, ACETYLCYSTEINE
ACHROMYCIN V, TETRACYCLINE HYDROCHLORIDE
ACIPHEX, RABEPRAZOLE SODIUM
ACITRETIN, ACITRETIN
ACTHAR GEL, CORTICOTROPIN
ACTICLATE, DOXYCYCLINE HYCLATE
ACTIGALL, URSODIOL
ACTIQ, FENTANYL CITRATE
ACTIVELLA, ESTRADIOL
ACTONEL, RISEDRONATE SODIUM
ACTOPLUS MET, METFORMIN HYDROCHLORIDE
ACTOS, PIOGLITAZONE HYDROCHLORIDE
ACULAR, KETOROLAC TROMETHAMINE
ACULAR LS, KETOROLAC TROMETHAMINE
ACUVAIL, KETOROLAC TROMETHAMINE
ACUVUE THERAVISION WITH KETOTIFEN, KETOTIFEN FUMARATE
ACYCLOVIR, ACYCLOVIR
ACYCLOVIR SODIUM, ACYCLOVIR SODIUM
ACZONE, DAPSONE
ADAPALENE, ADAPALENE (OTC)
ADAPALENE, ADAPALENE
ADAPALENE AND BENZOYL PEROXIDE, ADAPALENE
ADASUVE, LOXAPINE
ADCIRCA, TADALAFIL
ADDERALL XR 10, AMPHETAMINE ASPARTATE
ADDERALL XR 15, AMPHETAMINE ASPARTATE
ADDERALL XR 20, AMPHETAMINE ASPARTATE
ADDERALL XR 25, AMPHETAMINE ASPARTATE
ADDERALL XR 30, AMPHETAMINE ASPARTATE
ADDERALL XR 5, AMPHETAMINE ASPARTATE
ADDYI, FLIBANSERIN
ADEFOVIR DIPIVOXIL, ADEFOVIR DIPIVOXIL
ADEMPAS, RIOICIGUAT
ADENOSINE, ADENOSINE

APPENDIX A - PRODUCT NAME INDEX**** A ****

ADIPEX-P, PHENTERMINE HYDROCHLORIDE
ADLARITY, DONEPEZIL HYDROCHLORIDE
ADRENAClick, EPINEPHRINE
ADRENALIN, EPINEPHRINE
ADREVIEW, IOBENGUANE SULFATE I-123
ADVAIR DISKUS 100/50, FLUTICASONE PROPIONATE
ADVAIR DISKUS 250/50, FLUTICASONE PROPIONATE
ADVAIR DISKUS 500/50, FLUTICASONE PROPIONATE
ADVAIR HFA, FLUTICASONE PROPIONATE
ADVIL, IBUPROFEN (OTC)
ADVIL, IBUPROFEN SODIUM (OTC)
ADVIL ALLERGY AND CONGESTION RELIEF, CHLORPHENIRAMINE MALEATE (OTC)
ADVIL ALLERGY SINUS, CHLORPHENIRAMINE MALEATE (OTC)
ADVIL COLD AND SINUS, IBUPROFEN (OTC)
ADVIL CONGESTION RELIEF, IBUPROFEN (OTC)
ADVIL DUAL ACTION WITH ACETAMINOPHEN, ACETAMINOPHEN (OTC)
ADVIL LIQUI-GELS, IBUPROFEN (OTC)
ADVIL MIGRAINE LIQUI-GELS, IBUPROFEN (OTC)
ADVIL MULTI-SYMPTOM COLD & FLU, CHLORPHENIRAMINE MALEATE (OTC)
ADVIL PM, DIPHENHYDRAMINE CITRATE (OTC)
ADVIL PM, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
ADZENYS XR-ODT, AMPHETAMINE
AEMCOLO, RIFAMYCIN SODIUM
AFINITOR, EVEROLIMUS
AFINITOR DISPERZ, EVEROLIMUS
AFIRMELLE, ETHINYL ESTRADIOL
AGGRASTAT, TIROFIBAN HYDROCHLORIDE
AGRYLIN, ANAGRELIDE HYDROCHLORIDE
AIRDUO DIGIHALER, FLUTICASONE PROPIONATE
AIRDUO RESPIClick, FLUTICASONE PROPIONATE
AK-FLUOR 10%, FLUORESCEIN SODIUM
AK-FLUOR 25%, FLUORESCEIN SODIUM
AKLIEF, TRIFAROTENE
AKOFAZ, EPHEDRINE SULFATE
AKPENTOLATE, CYCLOPENTOLATE HYDROCHLORIDE
AKTEN, LIDOCAINE HYDROCHLORIDE
AKTOB, TOBRAMYCIN
AKYNZEO, FOSNETUPITANT CHLORIDE HYDROCHLORIDE
AKYNZEO, NETUPITANT
ALA-CORT, HYDROCORTISONE
ALA-SCALP, HYDROCORTISONE
ALAVERT, LORATADINE (OTC)
ALAWAY, KETOTIFEN FUMARATE (OTC)
ALBENDAZOLE, ALBENDAZOLE
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE, ALBUTEROL SULFATE
ALCAINE, PROPARACAINE HYDROCHLORIDE
ALCLOMETASONE DIPROPIONATE, ALCLOMETASONE DIPROPIONATE
ALDACTAZIDE, HYDROCHLOROTHIAZIDE
ALDACTONE, SPIRONOLACTONE
ALDARA, IMIQUIMOD
ALECENSA, ALECTINIB HYDROCHLORIDE
ALENDRONATE SODIUM, ALENDRONATE SODIUM
ALEVE, NAPROXEN SODIUM (OTC)
ALEVE PM, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
ALFENTA, ALFENTANIL HYDROCHLORIDE
ALFENTANIL, ALFENTANIL HYDROCHLORIDE
ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE
ALIMTA, PEMETREXED DISODIUM
ALINIA, NITAZOXANIDE
ALIQOPA, COPANLISIB DIHYDROCHLORIDE
ALISKIREN HEMIFUMARATE, ALISKIREN HEMIFUMARATE
ALKINDI SPRINKLE, HYDROCORTISONE
ALLEGRA ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
ALLEGRA HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)

APPENDIX A - PRODUCT NAME INDEX**** A ****

ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION, FEXOFENADINE HYDROCHLORIDE (OTC)
 ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION, FEXOFENADINE HYDROCHLORIDE (OTC)
 ALLI, ORLISTAT (OTC)
 ALLOPURINOL, ALLOPURINOL
 ALLOPURINOL SODIUM, ALLOPURINOL SODIUM
 ALLZITAL, ACETAMINOPHEN
 ALMOTRIPTAN MALATE, ALMOTRIPTAN MALATE
 ALOMIDE, LODOXAMIDE TROMETHAMINE
 ALOPRIM, ALLOPURINOL SODIUM
 ALOSETRON HYDROCHLORIDE, ALOSETRON HYDROCHLORIDE
 ALPHAGAN P, BRIMONIDINE TARTRATE
 ALPRAZOLAM, ALPRAZOLAM
 ALPROSTADIL, ALPROSTADIL
 ALREX, LOTEPREDNOL ETABONATE
 ALTABAX, RETAPAMULIN
 ALTACE, RAMIPRIL
 ALTAFLUOR BENOX, BENOXINATE HYDROCHLORIDE
 ALTAVERA, ETHINYL ESTRADIOL
 ALTOPREV, LOVASTATIN
 ALTRENO, TRETINOIN
 ALUNBRIG, BRIGATINIB
 ALVESCO, CICLESONIDE
 ALVIMOPAN, ALVIMOPAN
 ALYACEN 1/35, ETHINYL ESTRADIOL
 ALYACEN 7/7/7, ETHINYL ESTRADIOL
 ALYQ, TADALAFIL
 AMABELZ, ESTRADIOL
 AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
 AMARYL, GLIMEPIRIDE
 AMBIEN, ZOLPIDEM TARTRATE
 AMBIEN CR, ZOLPIDEM TARTRATE
 AMBISOME, AMPHOTERICIN B
 AMBRISENTAN, AMBRISENTAN
 AMCINONIDE, AMCINONIDE
 AMELUZ, AMINOLEVULINIC ACID HYDROCHLORIDE
 AMERGE, NARATRIPTAN HYDROCHLORIDE
 AMICAR, AMINOCAPROIC ACID
 AMIDATE, ETOMIDATE
 AMIFOSTINE, AMIFOSTINE
 AMIKACIN SULFATE, AMIKACIN SULFATE
 AMILORIDE HYDROCHLORIDE, AMILORIDE HYDROCHLORIDE
 AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, AMILORIDE HYDROCHLORIDE
 AMINO ACIDS, AMINO ACIDS
 AMINOACETIC ACID 1.5% IN PLASTIC CONTAINER, GLYCINE
 AMINOCAPROIC ACID, AMINOCAPROIC ACID
 AMINOCAPROIC ACID IN PLASTIC CONTAINER, AMINOCAPROIC ACID
 AMINOPHYLLINE, AMINOPHYLLINE
 AMINOSYN II 10% IN PLASTIC CONTAINER, AMINO ACIDS
 AMINOSYN II 15% IN PLASTIC CONTAINER, AMINO ACIDS
 AMINOSYN-PF 10%, AMINO ACIDS
 AMINOSYN-PF 7%, AMINO ACIDS
 AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
 AMITIZA, LUBIPROSTONE
 AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
 AMLODIPINE AND OLMESARTAN MEDOXOMIL, AMLODIPINE BESYLATE
 AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
 AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM, AMLODIPINE BESYLATE
 AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE
 AMLODIPINE BESYLATE AND VALSARTAN, AMLODIPINE BESYLATE
 AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE, AMLODIPINE BESYLATE
 AMMONIA N 13, AMMONIA N-13
 AMMONIUM CHLORIDE IN PLASTIC CONTAINER, AMMONIUM CHLORIDE
 AMMONIUM LACTATE, AMMONIUM LACTATE
 AMMONUL, SODIUM BENZOATE
 AMNESTEEM, ISOTRETINOIN

APPENDIX A - PRODUCT NAME INDEX**** A ****

AMONDYS 45, CASIMERSEN
AMOXAPINE, AMOXAPINE
AMOXICILLIN, AMOXICILLIN
AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
AMOXICILLIN PEDIATRIC, AMOXICILLIN
AMOXIL, AMOXICILLIN
AMPHETAMINE SULFATE, AMPHETAMINE SULFATE
AMPHOTERICIN B, AMPHOTERICIN B
AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
AMPICILLIN SODIUM, AMPICILLIN SODIUM
AMPICILLIN TRIHYDRATE, AMPICILLIN/AMPICILLIN TRIHYDRATE
AMPYRA, DALFAMPRIDINE
AMRINONE LACTATE, INAMRINONE LACTATE
AMRIX, CYCLOBENZAPRINE HYDROCHLORIDE
AMVUTTRA, VUTRISIRAN
AMYVID, FLORBETAPIR F-18
AMZEEQ, MINOCYCLINE HYDROCHLORIDE
AN-SULFUR COLLOID, TECHNETIUM TC-99M SULFUR COLLOID KIT
ANAFRANIL, CLOMIPRAMINE HYDROCHLORIDE
ANAGRELIDE HYDROCHLORIDE, ANAGRELIDE HYDROCHLORIDE
ANAPROX DS, NAPROXEN SODIUM
ANASTROZOLE, ANASTROZOLE
ANCEF IN PLASTIC CONTAINER, CEFAZOLIN SODIUM
ANCOBON, FLUCYTOSINE
ANDRODERM, TESTOSTERONE
ANDROGEL, TESTOSTERONE
ANDROID 25, METHYLTESTOSTERONE
ANECTINE, SUCCINYLCHOLINE CHLORIDE
ANEXSIA 5/325, ACETAMINOPHEN
ANEXSIA 7.5/325, ACETAMINOPHEN
ANGELIQ, DROSPIRENONE
ANGIOMAX, BIVALIRUDIN
ANGIOMAX RTU, BIVALIRUDIN
ANNOVERA, ETHINYL ESTRADIOL
ANORO ELLIPTA, UMECLIDINIUM BROMIDE
ANTARA (MICRONIZED), FENOFIBRATE
ANTHELIOS 20, AVOBENZONE (OTC)
ANTHELIOS 40, AVOBENZONE (OTC)
ANTHELIOS SX, AVOBENZONE (OTC)
ANTIVERT, MECLIZINE HYDROCHLORIDE
ANUSOL HC, HYDROCORTISONE
ANZEMET, DOLASETRON MESYLATE
APADAZ, ACETAMINOPHEN
APIXABAN, APIXABAN
APLENZIN, BUPROPION HYDROBROMIDE
APOKYN, APOMORPHINE HYDROCHLORIDE
APOMORPHINE HYDROCHLORIDE, APOMORPHINE HYDROCHLORIDE
APONVIE, APREPITANT
APRACLONIDINE HYDROCHLORIDE, APRACLONIDINE HYDROCHLORIDE
APREMILAST, APREMILAST
APREPITANT, APREPITANT
APRETUDE, CABOTEGRAVIR
APRISO, MESALAMINE
APTENSIO XR, METHYLPHENIDATE HYDROCHLORIDE
APTIOM, ESLICARBAZEPINE ACETATE
APTIVUS, TIPRANAVIR
AQUASOL A, VITAMIN A PALMITATE
ARAKODA, TAFENOQUINE SUCCINATE
ARANELLE, ETHINYL ESTRADIOL
ARAVA, LEFLUNOMIDE
ARAZLO, TAZAROTENE
ARESTIN, MINOCYCLINE HYDROCHLORIDE
ARFORMOTEROL TARTRATE, ARFORMOTEROL TARTRATE
ARGATROBAN, ARGATROBAN
ARGATROBAN IN SODIUM CHLORIDE, ARGATROBAN

APPENDIX A - PRODUCT NAME INDEX**** A ****

ARICEPT, DONEPEZIL HYDROCHLORIDE
ARIDOL KIT, MANNITOL
ARIKAYCE KIT, AMIKACIN SULFATE
ARIMIDEX, ANASTROZOLE
ARIPIPRAZOLE, ARIPIPRAZOLE
ARISTADA, ARIPIPRAZOLE LAUROXIL
ARISTADA INITIO KIT, ARIPIPRAZOLE LAUROXIL
ARIXTRA, FONDAPARINUX SODIUM
ARMODAFINIL, ARMODAFINIL
ARMONAIR DIGIHALER, FLUTICASONE PROPIONATE
ARNUITY ELLIPTA, FLUTICASONE FUROATE
AROMASIN, EXEMESTANE
ARRANON, NELARABINE
ARSENIC TRIOXIDE, ARSENIC TRIOXIDE
ARTESUNATE, ARTESUNATE
ARTHROTEC, DICLOFENAC SODIUM
ASCLERA, POLIDOCANOL
ASCOR, ASCORBIC ACID
ASENAPINE MALEATE, ASENAPINE MALEATE
ASHLYNA, ETHINYL ESTRADIOL
ASMANEX HFA, MOMETASONE FUROATE
ASMANEX TWISTHALER, MOMETASONE FUROATE
ASPIRIN AND DIPYRIDAMOLE, ASPIRIN
ASPRUZYO SPRINKLE, RANOLAZINE
ASTAGRAF XL, TACROLIMUS
ASTEPRO ALLERGY, AZELASTINE HYDROCHLORIDE (OTC)
ATACAND, CANDESARTAN CILEXETIL
ATACAND HCT, CANDESARTAN CILEXETIL
ATAZANAVIR SULFATE, ATAZANAVIR SULFATE
ATELVIA, RISEDRONATE SODIUM
ATENOLOL, ATENOLOL
ATENOLOL AND CHLORTHALIDONE, ATENOLOL
ATHENTIA NEXT, LEVONORGESTREL (OTC)
ATIVAN, LORAZEPAM
ATOMOXETINE HYDROCHLORIDE, ATOMOXETINE HYDROCHLORIDE
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
ATOVAQUONE, ATOVAQUONE
ATOVAQUONE AND PROGUANIL HYDROCHLORIDE, ATOVAQUONE
ATRACURIUM BESYLATE, ATRACURIUM BESYLATE
ATRACURIUM BESYLATE PRESERVATIVE FREE, ATRACURIUM BESYLATE
ATRALIN, TRETINOIN
ATRIPLA, EFAVIRENZ
ATROPEN, ATROPINE
ATROPINE SULFATE, ATROPINE SULFATE
ATROVENT HFA, IPRATROPIUM BROMIDE
AUBAGIO, TERIFLUNOMIDE
AUGMENTIN '125', AMOXICILLIN
AUGMENTIN '250', AMOXICILLIN
AUGMENTIN '875', AMOXICILLIN
AUGMENTIN ES-600, AMOXICILLIN
AUROVELA 1.5/30, ETHINYL ESTRADIOL
AUROVELA 1/20, ETHINYL ESTRADIOL
AUROVELA 24 FE, ETHINYL ESTRADIOL
AUROVELA FE 1.5/30, ETHINYL ESTRADIOL
AUROVELA FE 1/20, ETHINYL ESTRADIOL
AURYXIA, FERRIC CITRATE
AUSTEDO, DEUTETRABENAZINE
AUVELITY, BUPROPION HYDROCHLORIDE
AUVI-Q, EPINEPHRINE
AVAGARD, ALCOHOL (OTC)
AVAGE, TAZAROTENE
AVALIDE, HYDROCHLOROTHIAZIDE
AVANDIA, ROSIGLITAZONE MALEATE
AVAPRO, IRBESARTAN
AVEED, TESTOSTERONE UNDECANOATE

APPENDIX A - PRODUCT NAME INDEX**** A ****

AVIANE-28, ETHINYL ESTRADIOL
AVITA, TRETINOIN
AVODART, DUTASTERIDE
AVYCAZ, AVIBACTAM SODIUM
AXID AR, NIZATIDINE (OTC)
AXUMIN, FLUCICLOVINE F-18
AYUNA, ETHINYL ESTRADIOL
AYVAKIT, AVAPRITINIB
AZACITIDINE, AZACITIDINE
AZACTAM, AZTREONAM
AZASAN, AZATHIOPRINE
AZASITE, AZITHROMYCIN
AZATHIOPRINE, AZATHIOPRINE
AZATHIOPRINE SODIUM, AZATHIOPRINE SODIUM
AZEDRA, IOBENGUANE I-131
AZELAIC ACID, AZELAIC ACID
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE, AZELASTINE HYDROCHLORIDE
AZELEX, AZELAIC ACID
AZILECT, RASAGILINE MESYLATE
AZITHROMYCIN, AZITHROMYCIN
AZOPT, BRINZOLAMIDE
AZOR, AMLODIPINE BESYLATE
AZSTARYS, DEXMETHYLPHENIDATE HYDROCHLORIDE
AZTREONAM, AZTREONAM
AZULFIDINE, SULFASALAZINE
AZULFIDINE EN-TABS, SULFASALAZINE

**** B ****

BACITRACIN, BACITRACIN
BACITRACIN ZINC AND POLYMYXIN B SULFATE, BACITRACIN ZINC
BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE, BACITRACIN ZINC
BACLOFEN, BACLOFEN
BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
BACTERIOSTATIC WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION
BACTOCILL IN PLASTIC CONTAINER, OXACILLIN SODIUM
BACTRIM, SULFAMETHOXAZOLE
BACTRIM DS, SULFAMETHOXAZOLE
BAFIERTAM, MONOMETHYL FUMARATE
BAL, DIMERCAPROL
BALANCED SALT, CALCIUM CHLORIDE
BALCOLTRA, ETHINYL ESTRADIOL
BALSALAZIDE DISODIUM, BALSALAZIDE DISODIUM
BALVERSA, ERDAFITINIB
BALZIVA-28, ETHINYL ESTRADIOL
BANZEL, RUFINAMIDE
BAQSIMI, GLUCAGON
BARACLUDE, ENTECAVIR
BARHEMSYS, AMISULPRIDE
BAXDELA, DELAFLOXACIN MEGLUMINE
BECONASE AQ, BECLOMETHASONE DIPROPIONATE MONOHYDRATE
BEKYREE, DESOGESTREL
BELBUCA, BUPRENORPHINE HYDROCHLORIDE
BELEODAQ, BELINOSTAT
BELRAPZO, BENDAMUSTINE HYDROCHLORIDE
BELSOMRA, SUVOREXANT
BENZAEPRIIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
BENZAEPRIIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, BENAZEPRIL HYDROCHLORIDE
BENDAMUSTINE HYDROCHLORIDE, BENDAMUSTINE HYDROCHLORIDE
BENDEKA, BENDAMUSTINE HYDROCHLORIDE
BENICAR, OLMESARTAN MEDOXOMIL
BENICAR HCT, HYDROCHLOROTHIAZIDE
BENTYL, DICYCLOMINE HYDROCHLORIDE
BENTYL PRESERVATIVE FREE, DICYCLOMINE HYDROCHLORIDE
BENZAELIN, BENZOYL PEROXIDE

APPENDIX A - PRODUCT NAME INDEX**** B ****

BENZAMYCIN, BENZOYL PEROXIDE
BENZNIDAZOLE, BENZNIDAZOLE
BENZONATATE, BENZONATATE
BENZPHETAMINE HYDROCHLORIDE, BENZPHETAMINE HYDROCHLORIDE
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
BEPOTASTINE BESILATE, BEPOTASTINE BESILATE
BEPREVE, BEPOTASTINE BESILATE
BESIVANCE, BESIFLOXACIN HYDROCHLORIDE
BETA-VAL, BETAMETHASONE VALERATE
BETADINE, POVIDONE-IODINE
BETAGAN, LEVOBUNOLOL HYDROCHLORIDE
BETAINE, BETAINE
BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE, BETAMETHASONE ACETATE
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
BETAPACE, SOTALOL HYDROCHLORIDE
BETAPACE AF, SOTALOL HYDROCHLORIDE
BETAXOLOL HYDROCHLORIDE, BETAXOLOL HYDROCHLORIDE
BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
BETHKIS, TOBRAMYCIN
BETIMOL, TIMOLOL
BETOPTIC, BETAXOLOL HYDROCHLORIDE
BETOPTIC S, BETAXOLOL HYDROCHLORIDE
BEVESPI AEROSPHERE, FORMOTEROL FUMARATE
BEXAROTENE, BEXAROTENE
BEYAZ, DROSPIRENONE
BICALUTAMIDE, BICALUTAMIDE
BICILLIN C-R, PENICILLIN G BENZATHINE
BICILLIN C-R 900/300, PENICILLIN G BENZATHINE
BICILLIN L-A, PENICILLIN G BENZATHINE
BICNU, CARMUSTINE
BIDIL, HYDRALAZINE HYDROCHLORIDE
BIJUVA, ESTRADIOL
BIKTARVY, BICTEGRAVIR SODIUM
BILTRICIDE, PRAZIQUANTEL
BIMATOPROST, BIMATOPROST
BINOSTO, ALENDRONATE SODIUM
BIORPHEN, PHENYLEPHRINE HYDROCHLORIDE
BIOSCRUB, CHLORHEXIDINE GLUCONATE (OTC)
BISMUTH SUBSALICYLATE, METRONIDAZOLE AND TETRACYCLINE HYDROCHLORIDE, BISMUTH SUBSALICYLATE
BISOPROLOL FUMARATE, BISOPROLOL FUMARATE
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE, BISOPROLOL FUMARATE
BIVALIRUDIN, BIVALIRUDIN
BLEOMYCIN SULFATE, BLEOMYCIN SULFATE
BLEPH-10, SULFACETAMIDE SODIUM
BLISOVI 24 FE, ETHINYL ESTRADIOL
BLISOVI FE 1.5/30, ETHINYL ESTRADIOL
BLISOVI FE 1/20, ETHINYL ESTRADIOL
BLOXIVERZ, NEOSTIGMINE METHYLSULFATE
BLUDIGO, INDIGOTINDISULFONATE SODIUM
BONJESTA, DOXYLAMINE SUCCINATE
BONSITY, TERIPARATIDE
BONTRIL PDM, PHENDIMETRAZINE TARTRATE
BORTEZOMIB, BORTEZOMIB
BOSENTAN, BOSENTAN
BOSULIF, BOSUTINIB MONOHYDRATE
BRAFTOVI, ENCORAFENIB
BREO ELLIPTA, FLUTICASONE FUROATE
BRETHINE, TERBUTALINE SULFATE
BRETILIUM TOSYLATE, BRETILIUM TOSYLATE
BREVIBLOC, ESMOLOL HYDROCHLORIDE
BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER, ESMOLOL HYDROCHLORIDE
BREVIBLOC IN PLASTIC CONTAINER, ESMOLOL HYDROCHLORIDE
BREVITAL SODIUM, METHOHEXITAL SODIUM
BREXAFEMME, IBREXAFUNGERP CITRATE

APPENDIX A - PRODUCT NAME INDEX**** B ****

BREXPIRAZOLE, BREXPIRAZOLE
 BREYNA, BUDESONIDE
 BREZTRI AEROSPHERE, BUDESONIDE
 BRIDION, SUGAMMADEX SODIUM
 BRIELLYN, ETHINYL ESTRADIOL
 BRILINTA, TICAGRELOR
 BRIMONIDINE TARTRATE, BRIMONIDINE TARTRATE
 BRIMONIDINE TARTRATE AND TIMOLOL MALEATE, BRIMONIDINE TARTRATE
 BRINZOLAMIDE, BRINZOLAMIDE
 BRISDELLE, PAROXETINE MESYLATE
 BRIVARACETAM, BRIVARACETAM
 BRIVIACT, BRIVARACETAM
 BROMFED-DM, BROMPHENIRAMINE MALEATE
 BROMFENAC SODIUM, BROMFENAC SODIUM
 BROMOCRIPTINE MESYLATE, BROMOCRIPTINE MESYLATE
 BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE,
 BROMSITE, BROMFENAC SODIUM
 BRONCHITOL, MANNITOL
 BROVANA, ARFORMOTEROL TARTRATE
 BRUKINSA, ZANUBRUTINIB
 BRYHALI, HALOBETASOL PROPIONATE
 BSS, CALCIUM CHLORIDE
 BSS PLUS, CALCIUM CHLORIDE
 BUDESONIDE, BUDESONIDE (OTC)
 BUDESONIDE, BUDESONIDE
 BUMETANIDE, BUMETANIDE
 BUMEX, BUMETANIDE
 BUPHENYL, SODIUM PHENYLBUTYRATE
 BUPIVACAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE
 BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE, BUPIVACAINE HYDROCHLORIDE
 BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE
 BUPRENEX, BUPRENORPHINE HYDROCHLORIDE
 BUPRENORPHINE, BUPRENORPHINE
 BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
 BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
 BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
 BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
 BUSULFAN, BUSULFAN
 BUSULFEX, BUSULFAN
 BUTALBITAL AND ACETAMINOPHEN, ACETAMINOPHEN
 BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
 BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE, ACETAMINOPHEN
 BUTALBITAL, ASPIRIN AND CAFFEINE, ASPIRIN
 BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE, ASPIRIN
 BUTAPAP, ACETAMINOPHEN
 BUTENAFINE HYDROCHLORIDE, BUTENAFINE HYDROCHLORIDE (OTC)
 BUTORPHANOL TARTRATE, BUTORPHANOL TARTRATE
 BUTORPHANOL TARTRATE PRESERVATIVE FREE, BUTORPHANOL TARTRATE
 BUTRANS, BUPRENORPHINE
 BYDUREON BCISE, EXENATIDE SYNTHETIC
 BYETTA, EXENATIDE SYNTHETIC
 BYFAVO, REMIMAZOLAM BESYLATE
 BYLVAY, ODEVIXIBAT
 BYSTOLIC, NEBIVOLOL HYDROCHLORIDE

**** C ****

CABAZITAXEL, CABAZITAXEL
 CABENUVA KIT, CABOTEGRAVIR
 CABERGOLINE, CABERGOLINE
 CABOMETYX, CABOZANTINIB S-MALATE
 CADUET, AMLODIPINE BESYLATE
 CAFKIT, CAFFEINE CITRATE
 CAFFEINE CITRATE, CAFFEINE CITRATE
 CALAN SR, VERAPAMIL HYDROCHLORIDE
 CALCIPOTRIENE, CALCIPOTRIENE

APPENDIX A - PRODUCT NAME INDEX**** C ****

CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CALCIPOTRIENE AND BETHAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CALCITONIN-SALMON, CALCITONIN SALMON
CALCITRIOL, CALCITRIOL
CALCIUM ACETATE, CALCIUM ACETATE
CALCIUM CHLORIDE 10%, CALCIUM CHLORIDE
CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
CALCIUM DISODIUM VERSENATE, EDETATE CALCIUM DISODIUM
CALCIUM GLUCONATE, CALCIUM GLUCONATE
CALCIUM GLUCONATE IN SODIUM CHLORIDE, CALCIUM GLUCONATE
CALDOLOR, IBUPROFEN
CALQUENCE, ACALABRUTINIB
CALQUENCE, ACALABRUTINIB MALEATE
CAMBIA, DICLOFENAC POTASSIUM
CAMCEVI KIT, LEUPROLIDE MESYLATE
CAMILA, NORETHINDRONE
CAMPTOSAR, IRINOTECAN HYDROCHLORIDE
CAMZYOS, MAVACAMTEN
CANASA, MESALAMINE
CANCIDAS, CASPOFUNGIN ACETATE
CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL
CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE, CANDESARTAN CILEXETIL
CAPECITABINE, CAPECITABINE
CAPEX, FLUOCINOLONE ACETONIDE
CAPITAL SOLEIL 15, AVOBENZONE (OTC)
CAPLYTA, LUMATEPERONE TOSYLATE
CAPRELSA, VANDETANIB
CAPTOPRIL, CAPTOPRIL
CARAC, FLUOROURACIL
CARAFATE, SUCRALFATE
CARBAGLU, CARGLUMIC ACID
CARBAMAZEPINE, CARBAMAZEPINE
CARBATROL, CARBAMAZEPINE
CARBIDOPA, CARBIDOPA
CARBIDOPA AND LEVODOPA, CARBIDOPA
CARBIDOPA, LEVODOPA AND ENTACAPONE, CARBIDOPA
CARBINOXAMINE MALEATE, CARBINOXAMINE MALEATE
CARBOCAINE, MEPIVACAINE HYDROCHLORIDE
CARBOPLATIN, CARBOPLATIN
CARBOPROST TROMETHAMINE, CARBOPROST TROMETHAMINE
CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE
CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE
CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE
CARDIOGEN-82, RUBIDIUM CHLORIDE RB-82
CARDIOLITE, TECHNETIUM TC-99M SESTAMIBI KIT
CARDIOPLEGIC IN PLASTIC CONTAINER, CALCIUM CHLORIDE
CARDIZEM, DILTIAZEM HYDROCHLORIDE
CARDIZEM CD, DILTIAZEM HYDROCHLORIDE
CARDIZEM LA, DILTIAZEM HYDROCHLORIDE
CARDURA, DOXAZOSIN MESYLATE
CARDURA XL, DOXAZOSIN MESYLATE
CARFILZOMIB, CARFILZOMIB
CARGLUMIC ACID, CARGLUMIC ACID
CARISOPRODOL, CARISOPRODOL
CARMUSTINE, CARMUSTINE
CARNITOR, LEVOCARNITINE
CARNITOR SF, LEVOCARNITINE
CAROSPIR, SPIRONOLACTONE
CARTEOLOL HYDROCHLORIDE, CARTEOLOL HYDROCHLORIDE
CARTIA XT, DILTIAZEM HYDROCHLORIDE
CARVEDILOL, CARVEDILOL
CARVEDILOL PHOSPHATE, CARVEDILOL PHOSPHATE
CASODEX, BICALUTAMIDE
CASPOFUNGIN ACETATE, CASPOFUNGIN ACETATE
CASPORYN HC, HYDROCORTISONE

APPENDIX A - PRODUCT NAME INDEX**** C ****

CATAFLAM, DICLOFENAC POTASSIUM
CATAPRES-TTS-1, CLONIDINE
CATAPRES-TTS-2, CLONIDINE
CATAPRES-TTS-3, CLONIDINE
CAVERJECT, ALPROSTADIL
CAVERJECT IMPULSE, ALPROSTADIL
CAYSTON, AZTREONAM
CEFACLOR, CEFACLOR
CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
CEFAZOLIN AND DEXTROSE, CEFZOLIN SODIUM
CEFAZOLIN IN PLASTIC CONTAINER, CEFZOLIN SODIUM
CEFAZOLIN SODIUM, CEFZOLIN SODIUM
CEFDINIR, CEFdinir
CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER, CEFEPIME HYDROCHLORIDE
CEFEPIME HYDROCHLORIDE, CEFEPIME HYDROCHLORIDE
CEFEPIME HYDROCHLORIDE IN PLASTIC CONTAINER, CEFEPIME HYDROCHLORIDE
CEFEPIME IN PLASTIC CONTAINER, CEFEPIME HYDROCHLORIDE
CEFIXIME, CEFIXIME
CEFOTAN, CEFOTETAN DISODIUM
CEFOTAXIME, CEFOTAXIME SODIUM
CEFOTETAN, CEFOTETAN DISODIUM
CEFOXITIN, CEFOXITIN SODIUM
CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER, CEFOXITIN SODIUM
CEFOXITIN IN PLASTIC CONTAINER, CEFOXITIN SODIUM
CEFPODOXIME PROXETIL, CEFPODOXIME PROXETIL
CEFPROZIL, CEFPROZIL
CEFTAZIDIME, CEFTAZIDIME
CEFTRIAXONE, CEFTRIAXONE SODIUM
CEFTRIAXONE AND DEXTROSE IN DUPLEX CONTAINER, CEFTRIAXONE SODIUM
CEFTRIAXONE IN PLASTIC CONTAINER, CEFTRIAXONE SODIUM
CEFTRIAXONE SODIUM, CEFTRIAXONE SODIUM
CEFUROXIME AND DEXTROSE IN DUPLEX CONTAINER, CEFUROXIME SODIUM
CEFUROXIME AXETIL, CEFUROXIME AXETIL
CEFUROXIME SODIUM, CEFUROXIME SODIUM
CELEBREX, CELECOXIB
CELECOXIB, CELECOXIB
CELESTONE SOLUSPAN, BETAMETHASONE ACETATE
CELEXA, CITALOPRAM HYDROBROMIDE
CELLCEPT, MYCOPHENOLATE MOFETIL
CELLCEPT, MYCOPHENOLATE MOFETIL HYDROCHLORIDE
CELONTIN, METHSUXIMIDE
CENTANY, MUPIROCIN
CEPHALEXIN, CEFHALEXIN
CEQUA, CYCLOSPORINE
CERDELGA, ELIGLUSTAT TARTRATE
CEREBYX, FOSPHENYTOIN SODIUM
CERETEC, TECHNETIUM TC-99M EXAMETAZIME KIT
CERIANNA, FLUOROESTRADIOL F-18
CERUBIDINE, DAUNORUBICIN HYDROCHLORIDE
CERVIDIL, DINOPROSTONE
CESAMET, NABILONE
CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CETRAXAL, CIPROFLOXACIN HYDROCHLORIDE
CETRORELIX ACETATE, CETRORELIX ACETATE
CETROTIDE, CETRORELIX ACETATE
CEVIMELINE HYDROCHLORIDE, CEVIMELINE HYDROCHLORIDE
CHABELINA FE, ETHINYL ESTRADIOL
CHEMET, SUCCIMER
CHENODIOL, CHENODIOL
CHG SCRUB, CHLORHEXIDINE GLUCONATE (OTC)

APPENDIX A - PRODUCT NAME INDEX**** C ****

CHILDREN'S ADVIL, IBUPROFEN (OTC)
CHILDREN'S ADVIL ALLERGY SINUS, CHLORPHENIRAMINE MALEATE (OTC)
CHILDREN'S ADVIL COLD, IBUPROFEN (OTC)
CHILDREN'S ADVIL-FLAVORED, IBUPROFEN (OTC)
CHILDREN'S ALAWAY, KETOTIFEN FUMARATE (OTC)
CHILDREN'S ALLEGRA ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
CHILDREN'S ASTEPRO ALLERGY, AZELASTINE HYDROCHLORIDE (OTC)
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S CLARITIN, LORATADINE (OTC)
CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
CHILDREN'S IBUPROFEN, IBUPROFEN (OTC)
CHILDREN'S MOTRIN, IBUPROFEN (OTC)
CHILDREN'S MOTRIN COLD, IBUPROFEN (OTC)
CHILDREN'S ZYRTEC ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S ZYRTEC HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CHIRHOSTIM, SECRETIN SYNTHETIC HUMAN
CHLORAMPHENICOL SODIUM SUCCINATE, CHLORAMPHENICOL SODIUM SUCCINATE
CHLORAPREP ONE-STEP, CHLORHEXIDINE GLUCONATE (OTC)
CHLORAPREP ONE-STEP FREPP, CHLORHEXIDINE GLUCONATE (OTC)
CHLORAPREP ONE-STEP SEPP, CHLORHEXIDINE GLUCONATE (OTC)
CHLORAPREP SINGLE SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)
CHLORAPREP TRIPLE SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)
CHLORAPREP WITH TINT, CHLORHEXIDINE GLUCONATE (OTC)
CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
CHLORDIAZEPOXIDE HYDROCHLORIDE, CHLORDIAZEPOXIDE HYDROCHLORIDE
CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDE, CHLORDIAZEPOXIDE HYDROCHLORIDE
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE (OTC)
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE
CHLOROPROCAINE HYDROCHLORIDE, CHLOROPROCAINE HYDROCHLORIDE
CHLOROQUINE PHOSPHATE, CHLOROQUINE PHOSPHATE
CHLOROTHIAZIDE SODIUM, CHLOROTHIAZIDE SODIUM
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE (OTC)
CHLORPROMAZINE HYDROCHLORIDE, CHLORPROMAZINE HYDROCHLORIDE
CHLORTHALIDONE, CHLORTHALIDONE
CHLORZOXAZONE, CHLORZOXAZONE
CHOLBAM, CHOLIC ACID
CHOLESTYRAMINE, CHOLESTYRAMINE
CHOLESTYRAMINE LIGHT, CHOLESTYRAMINE
CHOLETEC, TECHNETIUM TC-99M MEBROFENIN KIT
CHOLINE C-11, CHOLINE C-11
CHROMIC CHLORIDE IN PLASTIC CONTAINER, CHROMIC CHLORIDE
CIALIS, TADALAFIL
CIBINQO, ABROCITINIB
CICLOPIROX, CICLOPIROX
CIDA-STAT, CHLORHEXIDINE GLUCONATE (OTC)
CIDOFOVIR, CIDOFOVIR
CILOSTAZOL, CILOSTAZOL
CILOXAN, CIPROFLOXACIN HYDROCHLORIDE
CIMDUO, LAMIVUDINE
CIMETIDINE, CIMETIDINE (OTC)
CIMETIDINE, CIMETIDINE
CIMETIDINE HYDROCHLORIDE, CIMETIDINE HYDROCHLORIDE
CINACALCET HYDROCHLORIDE, CINACALCET HYDROCHLORIDE
CINVANTI, APREPITANT
CIPRO, CIPROFLOXACIN
CIPRO, CIPROFLOXACIN HYDROCHLORIDE
CIPRO HC, CIPROFLOXACIN HYDROCHLORIDE
CIPRODEX, CIPROFLOXACIN
CIPROFLOXACIN, CIPROFLOXACIN
CIPROFLOXACIN AND DEXAMETHASONE, CIPROFLOXACIN
CIPROFLOXACIN EXTENDED RELEASE, CIPROFLOXACIN
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, CIPROFLOXACIN

APPENDIX A - PRODUCT NAME INDEX**** C ****

CIS-MDP, TECHNETIUM TC-99M MEDRONATE KIT
CIS-PYRO, TECHNETIUM TC-99M PYROPHOSPHATE KIT
CISATRACURIUM BESYLATE, CISATRACURIUM BESYLATE
CISATRACURIUM BESYLATE PRESERVATIVE FREE, CISATRACURIUM BESYLATE
CISPLATIN, CISPLATIN
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
CITANEST FORTE DENTAL, EPINEPHRINE BITARTRATE
CLADRIBINE, CLADRIBINE
CLARAVIS, ISOTRETINOIN
CLARINEX, DESLORATADINE
CLARINEX-D 12 HOUR, DESLORATADINE
CLARISCAN, GADOTERATE MEGLUMINE
CLARITHROMYCIN, CLARITHROMYCIN
CLARITIN, LORATADINE (OTC)
CLARITIN HIVES RELIEF, LORATADINE (OTC)
CLARITIN HIVES RELIEF REDITAB, LORATADINE (OTC)
CLARITIN REDITABS, LORATADINE (OTC)
CLARITIN-D, LORATADINE (OTC)
CLARITIN-D 24 HOUR, LORATADINE (OTC)
CLEMASTINE FUMARATE, CLEMASTINE FUMARATE
CLENPIQ, CITRIC ACID
CLEOCIN, CLINDAMYCIN PALMITATE HYDROCHLORIDE
CLEOCIN, CLINDAMYCIN PHOSPHATE
CLEOCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
CLEOCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLEOCIN T, CLINDAMYCIN PHOSPHATE
CLEVIPREX, CLEVIDIPINE
CLIMARA, ESTRADIOL
CLIMARA PRO, ESTRADIOL
CLINDA-DERM, CLINDAMYCIN PHOSPHATE
CLINDAGEL, CLINDAMYCIN PHOSPHATE
CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
CLINDAMYCIN PALMITATE HYDROCHLORIDE, CLINDAMYCIN PALMITATE HYDROCHLORIDE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
CLINDAMYCIN PHOSPHATE AND TRETINOIN, CLINDAMYCIN PHOSPHATE
CLINDAMYCIN PHOSPHATE IN 0.9% SODIUM CHLORIDE, CLINDAMYCIN PHOSPHATE
CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER, CLINDAMYCIN PHOSPHATE
CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%, CLINDAMYCIN PHOSPHATE
CLINDESSE, CLINDAMYCIN PHOSPHATE
CLINDETS, CLINDAMYCIN PHOSPHATE
CLINIMIX 2.75/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 2.75/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 2.75/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 4.25/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 4.25/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 4.25/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 4.25/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/15 SULFITE FREE IN DEXTROSE 15% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/35 SULFITE FREE IN DEXTROSE 35% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 2.75/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 2.75/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 2.75/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 4.25/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 4.25/20 SULFITE FREE W/ ELECT IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 4.25/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 4.25/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 5/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 5/15 SULFITE FREE W/ ELECT IN DEXTROSE 15% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 5/20 SULFITE FREE W/ ELECT IN 20% DEXTROSE W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 5/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 5/35 SULFITE FREE W/ ELECT IN DEXTROSE 35% W/ CALCIUM IN PLASTIC CONTAINER,

APPENDIX A - PRODUCT NAME INDEX**** C ****

CLINISOL 15% SULFITE FREE IN PLASTIC CONTAINER, AMINO ACIDS
CLINOLIPID 20%, OLIVE OIL
CLOBAZAM, CLOBAZAM
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CLOBETASOL PROPIONATE (EMOLLIENT), CLOBETASOL PROPIONATE
CLOBEX, CLOBETASOL PROPIONATE
CLOCORTOLONE PIVALATE, CLOCORTOLONE PIVALATE
CLODERM, CLOCORTOLONE PIVALATE
CLOFARABINE, CLOFARABINE
CLOLAR, CLOFARABINE
CLOMIPHENE CITRATE, CLOMIPHENE CITRATE
CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
CLONAZEPAM, CLONAZEPAM
CLONIDINE, CLONIDINE
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
CLORAZEPATE DIPOTASSIUM, CLORAZEPATE DIPOTASSIUM
CLORTEKAL, CHLOROPROCAINE HYDROCHLORIDE
CLOTTRIMAZOLE, CLOTTRIMAZOLE (OTC)
CLOTTRIMAZOLE, CLOTTRIMAZOLE
CLOTTRIMAZOLE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CLOZAPINE, CLOZAPINE
CLOZARIL, CLOZAPINE
COARTEM, ARTEMETHER
CODEINE SULFATE, CODEINE SULFATE
COL-PROBENECID, COLCHICINE
COLAZAL, BALSALAZIDE DISODIUM
COLCHICINE, COLCHICINE
COLCRYS, COLCHICINE
COLESEVELAM HYDROCHLORIDE, COLESEVELAM HYDROCHLORIDE
COLESTID, COLESTIPOL HYDROCHLORIDE
COLESTIPOL HYDROCHLORIDE, COLESTIPOL HYDROCHLORIDE
COLISTIMETHATE SODIUM, COLISTIMETHATE SODIUM
COLOCORT, HYDROCORTISONE
COLY-MYCIN M, COLISTIMETHATE SODIUM
COLY-MYCIN S, COLISTIN SULFATE
COLYTE WITH FLAVOR PACKS, POLYETHYLENE GLYCOL 3350
COMBIGAN, BRIMONIDINE TARTRATE
COMBIPATCH, ESTRADIOL
COMBIVENT RESPIMAT, ALBUTEROL SULFATE
COMBIVIR, LAMIVUDINE
COMETRIQ, CABOZANTINIB S-MALATE
COMPLERA, EMTRICITABINE
COMPRO, PROCHLORPERAZINE
COMTAN, ENTACAPONE
CONCERTA, METHYLPHENIDATE HYDROCHLORIDE
CONDYLOX, PODOFILOX
CONJUPRI, LEVAMLODIPINE MALEATE
CONRAY, IOTHALAMATE MEGLUMINE
CONTRAVE, BUPROPION HYDROCHLORIDE
CONZIP, TRAMADOL HYDROCHLORIDE
COPAXONE, GLATIRAMER ACETATE
COPIKTRA, DUVELISIB
CORDRAN, FLURANDRENOLIDE
COREG, CARVEDILOL
COREG CR, CARVEDILOL PHOSPHATE
CORGARD, NADOLOL
CORLANOR, IVABRADINE
CORLANOR, IVABRADINE HYDROCHLORIDE
CORLOPAM, FENOLDOPAM MESYLATE
CORMAX, CLOBETASOL PROPIONATE
CORPHEDRA, EPHEDRINE SULFATE
CORTEF, HYDROCORTISONE
CORTENEMA, HYDROCORTISONE
CORTIFOAM, HYDROCORTISONE ACETATE

APPENDIX A - PRODUCT NAME INDEX**** C ****

CORTISONE ACETATE, CORTISONE ACETATE
CORTROSYN, COSYNTROPIN
CORVERT, IBUTILIDE FUMARATE
COSELA, TRILACICLIB DIHYDROCHLORIDE
COSMEGEN, DACTINOMYCIN
COSOPT, DORZOLAMIDE HYDROCHLORIDE
COSOPT PF, DORZOLAMIDE HYDROCHLORIDE
COSYNTROPIN, COSYNTROPIN
COTELLIC, COBIMETINIB FUMARATE
COTEMPLA XR-ODT, METHYLPHENIDATE
COZAAR, LOSARTAN POTASSIUM
CRESEMBA, ISAVUCONAZONIUM SULFATE
CRESTOR, ROSUVASTATIN CALCIUM
CRINONE, PROGESTERONE
CROMOLYN SODIUM, CROMOLYN SODIUM (OTC)
CROMOLYN SODIUM, CROMOLYN SODIUM
CROTAN, CROTAMITON
CRYSELLE, ETHINYL ESTRADIOL
CUBICIN, DAPTOMYCIN
CUPRIC CHLORIDE, CUPRIC CHLORIDE
CUPRIC CHLORIDE IN PLASTIC CONTAINER, CUPRIC CHLORIDE
CUPRIC SULFATE, CUPRIC SULFATE
CUPRIMINE, PENICILLAMINE
CUVPOSA, GLYCOPYRROLATE
CUVRIOR, TRIENTINE TETRAHYDROCHLORIDE
CYANOCOBALAMIN, CYANOCOBALAMIN
CYANOKIT, HYDROXOCOBALAMIN
CYCLESSA, DESOGESTREL
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
CYCLOGYL, CYCLOPENTOLATE HYDROCHLORIDE
CYCLOMYDRIL, CYCLOPENTOLATE HYDROCHLORIDE
CYCLOPENTOLATE HYDROCHLORIDE, CYCLOPENTOLATE HYDROCHLORIDE
CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE
CYCLOSET, BROMOCRIPTINE MESYLATE
CYCLOSPORINE, CYCLOSPORINE
CYKLOKAPRON, TRANEXAMIC ACID
CYMBALTA, DULOXETINE HYDROCHLORIDE
CYONANZ, ETHINYL ESTRADIOL
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
CYSTADANE, BETAINE
CYSTADROPS, CYSTEAMINE HYDROCHLORIDE
CYSTAGON, CYSTEAMINE BITARTRATE
CYSTARAN, CYSTEAMINE HYDROCHLORIDE
CYSTO-CONRAY II, IOTHALAMATE MEGLUMINE
CYSTOGRAFIN, DIATRIZOATE MEGLUMINE
CYSTOGRAFIN DILUTE, DIATRIZOATE MEGLUMINE
CYSVIEW KIT, HEXAMINOLEVULINATE HYDROCHLORIDE
CYTALUX, PAFOLACIANINE SODIUM
CYTARABINE, CYTARABINE
CYTOMEL, LIOTHYRONINE SODIUM
CYTOTEC, MISOPROSTOL
CYTOXAN, CYCLOPHOSPHAMIDE
Carmustine, CARMUSTINE

**** D ****

DABIGATRAN ETEXILATE MESYLATE, DABIGATRAN ETEXILATE MESYLATE
DACARBAZINE, DACARBAZINE
DACTINOMYCIN, DACTINOMYCIN
DALFAMPRIDINE, DALFAMPRIDINE
DALIRESPI, ROFLUMILAST
DALVANCE, DALBAVANCIN HYDROCHLORIDE
DANAZOL, DANAZOL
DANTRIUM, DANTROLENE SODIUM
DANTROLENE SODIUM, DANTROLENE SODIUM
DAPSONE, DAPSONE

APPENDIX A - PRODUCT NAME INDEX**** D ****

DAPTOMYCIN, DAPTOMYCIN
DARAPRIM, PYRIMETHAMINE
DARIFENACIN, DARIFENACIN HYDROBROMIDE
DARIFENACIN HYDROBROMIDE, DARIFENACIN HYDROBROMIDE
DARTISLA ODT, GLYCOPYRROLATE
DARUNAVIR, DARUNAVIR
DASETTA 1/35, ETHINYL ESTRADIOL
DASETTA 7/7/7, ETHINYL ESTRADIOL
DATSCAN, IOFLUPANE I-123
DAUNORUBICIN HYDROCHLORIDE, DAUNORUBICIN HYDROCHLORIDE
DAURISMO, GLASDEGIB MALEATE
DAYPRO, OXAPROZIN
DAYSEE, ETHINYL ESTRADIOL
DAYTRANA, METHYLPHENIDATE
DAYVIGO, LEMBOREXANT
DDAVP, DESMOPRESSIN ACETATE
DECITABINE, DECITABINE
DEFERASIROX, DEFERASIROX
DEFERIPRONE, DEFERIPRONE
DEFEROXAMINE MESYLATE, DEFEROXAMINE MESYLATE
DEFINITY, PERFLUTREN
DEFINITY RT, PERFLUTREN
DEFITELIO, DEFIBROTIDE SODIUM
DELESTROGEN, ESTRADIOL VALERATE
DELFLEX W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELSTRIGO, DORAVIRINE
DELSYM, DEXTROMETHORPHAN POLISTIREX (OTC)
DELZICOL, MESALAMINE
DEMECLOCYCLINE HYDROCHLORIDE, DEMECLOCYCLINE HYDROCHLORIDE
DEMEROL, MEPERIDINE HYDROCHLORIDE
DEMSER, METYROSINE
DENA VIR, PENCICLOVIR
DEOXYCHOLIC ACID, DEOXYCHOLIC ACID
DEPAKOTE, DIVALPROEX SODIUM
DEPAKOTE ER, DIVALPROEX SODIUM
DEPEN, PENICILLAMINE
DEPO-ESTRADIOL, ESTRADIOL CYPIONATE
DEPO-MEDROL, METHYLPREDNISOLONE ACETATE
DEPO-PROVERA, MEDROXYPROGESTERONE ACETATE
DEPO-SUBQ PROVERA 104, MEDROXYPROGESTERONE ACETATE
DEPO-TESTOSTERONE, TESTOSTERONE CYPIONATE
DERMA-SMOOTH/FS, FLUOCINOLONE ACETONIDE
DERMABET, BETAMETHASONE VALERATE
DERMOTIC, FLUOCINOLONE ACETONIDE
DESCOVY, EMTRICITABINE
DESFERAL, DEFEROXAMINE MESYLATE
DESFLURANE, DESFLURANE
DESIPRAMINE HYDROCHLORIDE, DESIPRAMINE HYDROCHLORIDE
DESLORATADINE, DESLORATADINE
DESLORATADINE AND PSEUDOEPHEDRINE SULFATE 24 HOUR, DESLORATADINE
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION), DESMOPRESSIN ACETATE
DESOGESTREL AND ETHINYL ESTRADIOL, DESOGESTREL
DESONIDE, DESONIDE
DESOWEN, DESONIDE
DESOXIMETASONE, DESOXIMETASONE
DESODYN, METHAMPHETAMINE HYDROCHLORIDE

APPENDIX A - PRODUCT NAME INDEX**** D ****

DESVENLAFAXINE, DESVENLAFAXINE
DESVENLAFAXINE SUCCINATE, DESVENLAFAXINE SUCCINATE
DETECTNET, COPPER CU-64 DOTATATE
DETROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DETROL, TOLTERODINE TARTRATE
DETROL LA, TOLTERODINE TARTRATE
DEXAMETHASONE, DEXAMETHASONE
DEXAMETHASONE INTENSOL, DEXAMETHASONE
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
DEXAMETHASONE SODIUM PHOSPHATE PRESERVATIVE FREE, DEXAMETHASONE SODIUM PHOSPHATE
DEXASPORIN, DEXAMETHASONE
DEXCHLORPHENIRAMINE MALEATE, DEXCHLORPHENIRAMINE MALEATE
DEXEDRINE, DEXTROAMPHETAMINE SULFATE
DEXILANT, DEXLANSOPRAZOLE
DEXLANSOPRAZOLE, DEXLANSOPRAZOLE
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
DEXRAZOXANE HYDROCHLORIDE, DEXRAZOXANE HYDROCHLORIDE
DEXTENZA, DEXAMETHASONE
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
DEXTROMETHORPHAN HYDROBROMIDE AND QUINIDINE SULFATE, DEXTROMETHORPHAN HYDROBROMIDE
DEXTROMETHORPHAN POLISTIREX, DEXTROMETHORPHAN POLISTIREX (OTC)
DEXTROSE 10% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 20% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 25%, DEXTROSE
DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 30% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 40% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND ELECTROLYTE NO. 48 IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.075%, DEXTROSE
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.15%, DEXTROSE
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.225%, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.45%, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.9%, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 10MEQ, DEXTROSE

APPENDIX A - PRODUCT NAME INDEX**** D ****

DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 15MEQ (K), DEXTROSE
 DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ, DEXTROSE
 DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ (K), DEXTROSE
 DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 30MEQ, DEXTROSE
 DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 40MEQ, DEXTROSE
 DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ, DEXTROSE
 DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ (K), DEXTROSE
 DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER,
 DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 15MEQ IN PLASTIC CONTAINER,
 DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER,
 DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER,
 DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER,
 DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 5MEQ IN PLASTIC CONTAINER,
 DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 20MEQ (K) IN PLASTIC CONTAINER,
 DEXTROSE 50%, DEXTROSE
 DEXTROSE 50% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 70% IN PLASTIC CONTAINER, DEXTROSE
 DEXYCU KIT, DEXAMETHASONE
 DHIVY, CARBIDOPA
 DIABETA, GLYBURIDE
 DIACOMIT, STIRIPENTOL
 DIANEAL LOW CALCIUM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL LOW CALCIUM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL LOW CALCIUM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL LOW CALCIUM W/DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL LOW CALCIUM W/DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL LOW CALCIUM W/DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL LOW CALCIUM W/DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL PD-2 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL PD-2 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL PD-2 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIASTAT, DIAZEPAM
 DIASTAT ACUDIAL, DIAZEPAM
 DIATRIZOATE MEGLUMINE AND DIATRIZOATE SODIUM, DIATRIZOATE MEGLUMINE
 DIAZEPAM, DIAZEPAM
 DIAZEPAM INTENSOL, DIAZEPAM
 DIAZOXIDE, DIAZOXIDE
 DIBENZYLINE, PHENOXYBENZAMINE HYDROCHLORIDE
 DICHLORPHENAMIDE, DICHLORPHENAMIDE
 DICLEGIS, DOXYLAMINE SUCCINATE
 DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
 DICLOFENAC SODIUM, DICLOFENAC SODIUM (OTC)
 DICLOFENAC SODIUM, DICLOFENAC SODIUM
 DICLOFENAC SODIUM AND MISOPROSTOL, DICLOFENAC SODIUM
 DICLOXACILLIN SODIUM, DICLOXACILLIN SODIUM
 DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
 DICYCLOMINE HYDROCHLORIDE (PRESERVATIVE FREE), DICYCLOMINE HYDROCHLORIDE
 DIETHYLPROPION HYDROCHLORIDE, DIETHYLPROPION HYDROCHLORIDE
 DIFFERIN, ADAPALENE (OTC)
 DIFFERIN, ADAPALENE
 DIFICID, FIDAXOMICIN
 DIFLORASONE DIACETATE, DIFLORASONE DIACETATE
 DIFLUCAN, FLUCONAZOLE
 DIFLUNISAL, DIFLUNISAL
 DIFLUPREDNATE, DIFLUPREDNATE
 DIGOXIN, DIGOXIN
 DIHYDROERGOTAMINE MESYLATE, DIHYDROERGOTAMINE MESYLATE
 DILANTIN, PHENYTOIN
 DILANTIN, PHENYTOIN SODIUM
 DILANTIN-125, PHENYTOIN
 DILAUDID, HYDROMORPHONE HYDROCHLORIDE
 DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
 DIMENHYDRINATE, DIMENHYDRINATE
 DIMETHYL FUMARATE, DIMETHYL FUMARATE
 DIOVAN, VALSARTAN

APPENDIX A - PRODUCT NAME INDEX**** D ****

DIOVAN HCT, HYDROCHLOROTHIAZIDE
DIPENTUM, OLSALAZINE SODIUM
DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE
DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE, DIPHENHYDRAMINE HYDROCHLORIDE
DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, ATROPINE SULFATE
DIPRIVAN, PROPOFOL
DIPROLENE, BETAMETHASONE DIPROPIONATE
DIPYRIDAMOLE, DIPYRIDAMOLE
DISOPYRAMIDE PHOSPHATE, DISOPYRAMIDE PHOSPHATE
DISULFIRAM, DISULFIRAM
DITROPAN XL, OXYBUTYNIN CHLORIDE
DIURIL, CHLOROTHIAZIDE
DIURIL, CHLOROTHIAZIDE SODIUM
DIVALPROEX SODIUM, DIVALPROEX SODIUM
DIVIGEL, ESTRADIOL
DOBUTAMINE HYDROCHLORIDE, DOBUTAMINE HYDROCHLORIDE
DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER, DOBUTAMINE HYDROCHLORIDE
DOCETAXEL, DOCETAXEL
DOCOSANOL, DOCOSANOL (OTC)
DODEX, CYANOCOBALAMIN
DOFETILDE, DOFETILIDE
DOFETILIDE, DOFETILIDE
DOJOLVI, TRIHEPTANOIN
DOLISHALE, ETHINYL ESTRADIOL
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
DOPAMINE HYDROCHLORIDE, DOPAMINE HYDROCHLORIDE
DOPAMINE HYDROCHLORIDE AND DEXTROSE 5%, DOPAMINE HYDROCHLORIDE
DOPAMINE HYDROCHLORIDE AND DEXTROSE 5% IN PLASTIC CONTAINER, DOPAMINE HYDROCHLORIDE
DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER, DOPAMINE HYDROCHLORIDE
DOPRAM, DOXAPRAM HYDROCHLORIDE
DOPTelet, AVATROMBOPAG MALEATE
DORAL, QUAZEPAM
DORYX, DOXYCYCLINE HYCLATE
DORYX MPC, DOXYCYCLINE HYCLATE
DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
DOTAREM, GADOTERATE MEGLUMINE
DOVATO, DOLUTEGRAVIR SODIUM
DOVONEX, CALCIPOTRIENE
DOXAPRAM HYDROCHLORIDE, DOXAPRAM HYDROCHLORIDE
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
DOXERCALCIFEROL, DOXERCALCIFEROL
DOXIL (LIPOSOMAL), DOXORUBICIN HYDROCHLORIDE
DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL), DOXORUBICIN HYDROCHLORIDE
DOXY 100, DOXYCYCLINE HYCLATE
DOXY 200, DOXYCYCLINE HYCLATE
DOXYCYCLINE, DOXYCYCLINE
DOXYCYCLINE, DOXYCYCLINE HYCLATE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DOXYLAMINE SUCCINATE, DOXYLAMINE SUCCINATE (OTC)
DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE, DOXYLAMINE SUCCINATE
DRAX EXAMETAZIME, TECHNETIUM TC-99M EXAMETAZIME KIT
DRAXIMAGE DTPA, TECHNETIUM TC-99M PENTETATE KIT
DRAXIMAGE MDP-25, TECHNETIUM TC-99M MEDRONATE
DRISDOL, ERGOCALCIFEROL
DRIZALMA SPRINKLE, DULOXETINE HYDROCHLORIDE
DRONABINOL, DRONABINOL
DROPERIDOL, DROPERIDOL
DROSPIRENONE, DROSPIRENONE
DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE
DROSPIRENONE, ETHINYL ESTRADIOL AND LEVOMEFOLATE CALCIUM, DROSPIRENONE
DROXIA, HYDROXYUREA
DROXIDOPA, DROXIDOPA

APPENDIX A - PRODUCT NAME INDEX**** D ****

DSUVIA, SUFENTANIL CITRATE
DUAC, BENZOYL PEROXIDE
DUAKLIR PRESSAIR, ACLIDINIUM BROMIDE
DUAVEE, BAZEDOXIFENE ACETATE
DUETACT, GLIMEPIRIDE
DUEXIS, FAMOTIDINE
DULERA, FORMOTEROL FUMARATE
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
DUOBRII, HALOBETASOL PROPIONATE
DUODOTE, ATROPINE
DUOPA, CARBIDOPA
DURACLON, CLONIDINE HYDROCHLORIDE
DURAMORPH PF, MORPHINE SULFATE
DURAPREP, IODINE POVACRYLEX (OTC)
DUREZOL, DIFLUPREDNATE
DURLAZA, ASPIRIN
DURYSTA, BIMATOPROST
DUTASTERIDE, DUTASTERIDE
DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE, DUTASTERIDE
DUVOID, BETHANECHOL CHLORIDE
DYANAVAL XR, AMPHETAMINE
DYANAVAL XR 10, AMPHETAMINE
DYANAVAL XR 15, AMPHETAMINE
DYANAVAL XR 20, AMPHETAMINE
DYANAVAL XR 5, AMPHETAMINE
DYCLOPRO, DYCLONINE HYDROCHLORIDE
DYMISTA, AZELASTINE HYDROCHLORIDE
DYNACIN, MINOCYCLINE HYDROCHLORIDE
DYRENIUM, TRIAMTERENE

**** E ****

E-Z SCRUB 201, POVIDONE-IODINE (OTC)
E-Z SCRUB 241, POVIDONE-IODINE (OTC)
E-Z-HD, BARIUM SULFATE
E-Z-PAQUE, BARIUM SULFATE
E.E.S., ERYTHROMYCIN ETHYLSUCCINATE
E.E.S. 400, ERYTHROMYCIN ETHYLSUCCINATE
EC-NAPROSYN, NAPROXEN
ECONAZOLE NITRATE, ECONAZOLE NITRATE
ECOZA, ECONAZOLE NITRATE
EDARBI, AZILSARTAN KAMEDOXOMIL
EDARBYCLOR, AZILSARTAN KAMEDOXOMIL
EDECRIN, ETHACRYNATE SODIUM
EDECRIN, ETHACRYNIC ACID
EDEX, ALPROSTADIL
EDLUAR, ZOLPIDEM TARTRATE
EDURANT, RILPIVIRINE HYDROCHLORIDE
EFAVIRENZ, EFAVIRENZ
EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE, EFAVIRENZ
EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE, EFAVIRENZ
EFFEXOR XR, VENLAFAXINE HYDROCHLORIDE
EFFIENT, PRASUGREL HYDROCHLORIDE
EFINACONAZOLE, EFINACONAZOLE
EFUDEX, FLUOROURACIL
EGATEN, TRICLABENDAZOLE
ELCYS, CYSTEINE HYDROCHLORIDE
ELEPSIA XR, LEVETIRACETAM
ELESTRIN, ESTRADIOL
ELETRIPTAN HYDROBROMIDE, ELETRIPTAN HYDROBROMIDE
ELIDEL, PIMECROLIMUS
ELIGARD KIT, LEUPROLIDE ACETATE
ELIGLUSTAT TARTRATE, ELIGLUSTAT TARTRATE
ELINEST, ETHINYL ESTRADIOL
ELIQUIS, APIXABAN
ELIXOPHYLLIN, THEOPHYLLINE

APPENDIX A - PRODUCT NAME INDEX**** E ****

ELLA, ULIPRISTAL ACETATE
ELLENC, EPIRUBICIN HYDROCHLORIDE
ELLIOTTS B SOLUTION, CALCIUM CHLORIDE
ELMIRON, PENTOSAN POLYSULFATE SODIUM
ELOCON, MOMETASONE FUROATE
ELOXATIN, OXALIPLATIN
ELUCIREM, GADOPICLENOL
ELURYNG, ETHINYL ESTRADIOL
EMBELINE, CLOBETASOL PROPIONATE
EMCYT, ESTRAMUSTINE PHOSPHATE SODIUM
EMEND, APREPITANT
EMEND, FOSAPREPITANT DIMEGLUMINE
EMERPHED, EPHEDRINE SULFATE
EMFLAZA, DEFLAZACORT
EMPAGLIFLOZIN, EMPAGLIFLOZIN
EMPAVELI, PEGCETACOPLAN
EMSAM, SELEGILINE
EMTRICITABINE, EMTRICITABINE
EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE, EMTRICITABINE
EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE, EMTRICITABINE
EMTRIVA, EMTRICITABINE
EMVERM, MEBENDAZOLE
EMZAH, NORETHINDRONE
ENALAPRIL MALEATE, ENALAPRIL MALEATE
ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE, ENALAPRIL MALEATE
ENALAPRILAT, ENALAPRILAT
ENDARI, L-GLUTAMINE
ENDOMETRIN, PROGESTERONE
ENOXAPARIN SODIUM, ENOXAPARIN SODIUM
ENOXAPARIN SODIUM (PRESERVATIVE FREE), ENOXAPARIN SODIUM
ENPRESSE-28, ETHINYL ESTRADIOL
ENSKYCE, DESOGESTREL
ENSTILAR, BETAMETHASONE DIPROPIONATE
ENTACAPONE, ENTACAPONE
ENTADFI, FINASTERIDE
ENTECAVIR, ENTECAVIR
ENTEREG, ALVIMOPAN
ENTERO VU 24%, BARIUM SULFATE
ENTOCORT EC, BUDESONIDE
ENTRESTO, SACUBITRIL
ENVARUS XR, TACROLIMUS
EOVIST, GADOXETATE DISODIUM
EPANED, ENALAPRIL MALEATE
EPCLUSA, SOFOSBUVIR
EPHEDRINE SULFATE, EPHEDRINE SULFATE
EPIDIOLEX, CANNABIDIOL
EPIDUO, ADAPALENE
EPIDUO FORTE, ADAPALENE
EPIFOAM, HYDROCORTISONE ACETATE
EPINASTINE HYDROCHLORIDE, EPINASTINE HYDROCHLORIDE
EPINEPHRINE, EPINEPHRINE
EPINEPHRINE (AUTOINJECTOR), EPINEPHRINE
EPIPEN, EPINEPHRINE
EPIPEN JR., EPINEPHRINE
EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
EPITOL, CARBAMAZEPINE
EPIVIR, LAMIVUDINE
EPIVIR-HBV, LAMIVUDINE
EPLERENONE, EPLERENONE
EPOPROSTENOL SODIUM, EPOPROSTENOL SODIUM
EPRONTIA, TOPIRAMATE
EPSOLAY, BENZOYL PEROXIDE
EPTIFIBATIDE, EPTIFIBATIDE
EPZICOM, ABACAVIR SULFATE
EQUETRO, CARBAMAZEPINE

APPENDIX A - PRODUCT NAME INDEX**** E ****

ERAXIS, ANIDULAFUNGIN
ERGOCALCIFEROL, ERGOCALCIFEROL
ERGOLOID MESYLATES, ERGOLOID MESYLATES
ERGOMAR, ERGOTAMINE TARTRATE
ERGOTAMINE TARTRATE AND CAFFEINE, CAFFEINE
ERIVEDGE, VISMODEGIB
ERLEADA, APALUTAMIDE
ERLOTINIB HYDROCHLORIDE, ERLOTINIB HYDROCHLORIDE
ERMEZA, LEVOTHYROXINE SODIUM
ERRIN, NORETHINDRONE
ERTACZO, SERTACONAZOLE NITRATE
ERTAPENEM SODIUM, ERTAPENEM SODIUM
ERY-TAB, ERYTHROMYCIN
ERYC, ERYTHROMYCIN
ERYGEL, ERYTHROMYCIN
ERYPED, ERYTHROMYCIN ETHYLSUCCINATE
ERYTHRA-DERM, ERYTHROMYCIN
ERYTHROCIN, ERYTHROMYCIN LACTOBIONATE
ERYTHROCIN STEARATE, ERYTHROMYCIN STEARATE
ERYTHROMYCIN, ERYTHROMYCIN
ERYTHROMYCIN AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
ERYTHROMYCIN ETHYLSUCCINATE, ERYTHROMYCIN ETHYLSUCCINATE
ERYTHROMYCIN LACTOBIONATE, ERYTHROMYCIN LACTOBIONATE
ESBRIET, PIRFENIDONE
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
ESLICARBAZEPINE ACETATE, ESLICARBAZEPINE ACETATE
ESMOLOL HYDROCHLORIDE, ESMOLOL HYDROCHLORIDE
ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER, ESMOLOL HYDROCHLORIDE
ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER, ESMOLOL HYDROCHLORIDE
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM (OTC)
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
ESOMEPRAZOLE SODIUM, ESOMEPRAZOLE SODIUM
ESTARYLLA, ETHINYL ESTRADIOL
ESTAZOLAM, ESTAZOLAM
ESTRACE, ESTRADIOL
ESTRADIOL, ESTRADIOL
ESTRADIOL AND NORETHINDRONE ACETATE, ESTRADIOL
ESTRADIOL AND NORGESTIMATE, ESTRADIOL
ESTRADIOL VALERATE, ESTRADIOL VALERATE
ESTRING, ESTRADIOL
ESTROGEL, ESTRADIOL
ESZOPICLONE, ESZOPICLONE
ETHACRYNATE SODIUM, ETHACRYNATE SODIUM
ETHACRYNIC ACID, ETHACRYNIC ACID
ETHAMBUTOL HYDROCHLORIDE, ETHAMBUTOL HYDROCHLORIDE
ETHAMOLIN, ETHANOLAMINE OLEATE
ETHINYL ESTRADIOL AND NORELGESTROMIN, ETHINYL ESTRADIOL
ETHINYL ESTRADIOL; ETONOGESTREL, ETHINYL ESTRADIOL
ETHOSUXIMIDE, ETHOSUXIMIDE
ETHYNODIOL DIACETATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
ETHYOL, AMIFOSTINE
ETODOLAC, ETODOLAC
ETOMIDATE, ETOMIDATE
ETOPOPHOS PRESERVATIVE FREE, ETOPOSIDE PHOSPHATE
ETOPOSIDE, ETOPOSIDE
ETRAVIRINE, ETRAVIRINE
EUCRISA, CRISABOROLE
EURAX, CROTAMITON
EUTHYROX, LEVOTHYROXINE SODIUM **
EVAMIST, ESTRADIOL
EVEKEO, AMPHETAMINE SULFATE
EVEKEO ODT, AMPHETAMINE SULFATE
EVEROLIMUS, EVEROLIMUS
EVISTA, RALOXIFENE HYDROCHLORIDE
EVOCLIN, CLINDAMYCIN PHOSPHATE

APPENDIX A - PRODUCT NAME INDEX**** E ****

EVOMELA, MELPHALAN HYDROCHLORIDE
EVOTAZ, ATAZANAVIR SULFATE
EVOXAC, CEVIMELINE HYDROCHLORIDE
EVRYSI, RISDIPLAM
EXCEDRIN (MIGRAINE), ACETAMINOPHEN (OTC)
EXELDERM, SULCONAZOLE NITRATE
EXELON, RIVASTIGMINE
EXEM FOAM KIT, AIR POLYMER-TYPE A
EXEMESTANE, EXEMESTANE
EXFORGE, AMLODIPINE BESYLATE
EXFORGE HCT, AMLODIPINE BESYLATE
EXIDINE, CHLORHEXIDINE GLUCONATE (OTC)
EXJADE, DEFERASIROX
EXKIVITY, MOBOCERTINIB SUCCINATE
EXONDYS 51, ETEPLIRSEN
EXPAREL, BUPIVACAINE
EXSERVAN, RILUZOLE
EXTENDED PHENYTOIN SODIUM, PHENYTOIN SODIUM
EXTINA, KETOCONAZOLE
EXTRANEAL, ICODextrin
EYSUVIS, LOTEPREDNOL ETABONATE
EZALLOR SPRINKLE, ROSUVASTATIN CALCIUM
EZETIMIBE, EZETIMIBE
EZETIMIBE AND SIMVASTATIN, EZETIMIBE

**** F ****

FABIOR, TAZAROTENE
FALLBACK SOLO, LEVONORGESTREL (OTC)
FALMINA, ETHINYL ESTRADIOL
FAMCICLOVIR, FAMCICLOVIR
FAMOTIDINE, FAMOTIDINE (OTC)
FAMOTIDINE, FAMOTIDINE
FAMOTIDINE PRESERVATIVE FREE, FAMOTIDINE
FAMOTIDINE PRESERVATIVE FREE IN PLASTIC CONTAINER, FAMOTIDINE
FAMOTIDINE, CALCIUM CARBONATE, AND MAGNESIUM HYDROXIDE, CALCIUM CARBONATE (OTC)
FANAPT, ILOPERIDONE
FARESTON, TOREMIFENE CITRATE
FARXIGA, DAPAGLIFLOZIN
FASLODEX, FULVESTRANT
FEBUXOSTAT, FEBUXOSTAT
FELBAMATE, FELBAMATE
FELBATOL, FELBAMATE
FELDENE, PIROXICAM
FELODIPINE, FELODIPINE
FEMARA, LETROZOLE
FEMRING, ESTRADIOL ACETATE
FENOFIBRATE, FENOFIBRATE
FENOFIBRATE (MICRONIZED), FENOFIBRATE
FENOFIBRIC ACID, CHOLINE FENOFIBRATE
FENOGLIDE, FENOFIBRATE
FENOLDOPAM MESYLATE, FENOLDOPAM MESYLATE
FENOPROFEN CALCIUM, FENOPROFEN CALCIUM
FENSOLVI KIT, LEUPROLIDE ACETATE
FENTANYL CITRATE, FENTANYL CITRATE
FENTANYL CITRATE PRESERVATIVE FREE, FENTANYL CITRATE
FENTANYL-100, FENTANYL
FENTANYL-12, FENTANYL
FENTANYL-25, FENTANYL
FENTANYL-37, FENTANYL
FENTANYL-50, FENTANYL
FENTANYL-62, FENTANYL
FENTANYL-75, FENTANYL
FENTANYL-87, FENTANYL
FENTORA, FENTANYL CITRATE
FERAHEME, FERUMOXYTOL

APPENDIX A - PRODUCT NAME INDEX**** F ****

FERRIPROX, DEFERIPRONE
FERRLECIT, FERRIC OXYHYDROXIDE
FERUMOXYTOL, FERUMOXYTOL
FESOTERODINE FUMARATE, FESOTERODINE FUMARATE
FETROJA, CEFIDEROCOL SULFATE TOSYLATE
FETZIMA, LEVOMILNACIPRAN HYDROCHLORIDE
FEXINIDAZOLE, FEXINIDAZOLE
FEXOFENADINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE (OTC)
FEXOFENADINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE
FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE
FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
FINACEA, AZELAIC ACID
FINASTERIDE, FINASTERIDE
FINGOLIMOD HYDROCHLORIDE, FINGOLIMOD HYDROCHLORIDE
FINTEPLA, FENFLURAMINE HYDROCHLORIDE
FINZALA, ETHINYL ESTRADIOL
FIORICET W/ CODEINE, ACETAMINOPHEN
FIRAZYR, ICATIBANT ACETATE
FIRDAPSE, AMIFAMPRIDINE PHOSPHATE
FIRMAGON, DEGARELIX ACETATE
FIRVANQ KIT, VANCOMYCIN HYDROCHLORIDE
FLAC, FLUOCINOLONE ACETONIDE
FLAGYL, METRONIDAZOLE
FLAGYL I.V. RTU IN PLASTIC CONTAINER, METRONIDAZOLE
FLAREX, FLUOROMETHOLONE ACETATE
FLAVORED COLESTID, COLESTIPOL HYDROCHLORIDE
FLAVOXATE HYDROCHLORIDE, FLAVOXATE HYDROCHLORIDE
FLECAINIDE ACETATE, FLECAINIDE ACETATE
FLECTOR, DICLOFENAC EPOLAMINE
FLEQSUVY, BACLOFEN
FLOLAN, EPOPROSTENOL SODIUM
FLOLIPID, SIMVASTATIN
FLOMAX, TAMSULOSIN HYDROCHLORIDE
FLONASE ALLERGY RELIEF, FLUTICASONE PROPIONATE (OTC)
FLONASE SENSIMIST ALLERGY RELIEF, FLUTICASONE FUROATE (OTC)
FLOVENT DISKUS 100, FLUTICASONE PROPIONATE
FLOVENT DISKUS 250, FLUTICASONE PROPIONATE
FLOVENT DISKUS 50, FLUTICASONE PROPIONATE
FLOVENT HFA, FLUTICASONE PROPIONATE
FLOXURIDINE, FLOXURIDINE
FLUCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
FLUCONAZOLE, FLUCONAZOLE
FLUCONAZOLE IN SODIUM CHLORIDE 0.9%, FLUCONAZOLE
FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE
FLUCYTOSINE, FLUCYTOSINE
FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
FLUDROCORTISONE ACETATE, FLUDROCORTISONE ACETATE
FLUMADINE, RIMANTADINE HYDROCHLORIDE
FLUMAZENIL, FLUMAZENIL
FLUNISOLIDE, FLUNISOLIDE
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
FLUOCINONIDE, FLUOCINONIDE
FLUOCINONIDE ACETONIDE, FLUOCINOLONE ACETONIDE
FLUOCINONIDE EMULSIFIED BASE, FLUOCINONIDE
FLUORESCIN SODIUM AND BENOXINATE HYDROCHLORIDE, BENOXINATE HYDROCHLORIDE
FLUORESCITE, FLUORESCIN SODIUM
FLUORODOPA F18, FLUORODOPA F-18
FLUOROURACIL, FLUOROURACIL
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FLUPHENAZINE DECANOATE, FLUPHENAZINE DECANOATE
FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE
FLURANDRENOLIDE, FLURANDRENOLIDE
FLURAZEPAM HYDROCHLORIDE, FLURAZEPAM HYDROCHLORIDE

APPENDIX A - PRODUCT NAME INDEX**** F ****

FLURBIPROFEN, FLURBIPROFEN
 FLURBIPROFEN SODIUM, FLURBIPROFEN SODIUM
 FLUTAMIDE, FLUTAMIDE
 FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE (OTC)
 FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
 FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE, FLUTICASONE PROPIONATE
 FLUVASTATIN SODIUM, FLUVASTATIN SODIUM
 FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
 FML, FLUOROMETHOLONE
 FML FORTE, FLUOROMETHOLONE
 FOCALIN, DEXMETHYLPHENIDATE HYDROCHLORIDE
 FOCALIN XR, DEXMETHYLPHENIDATE HYDROCHLORIDE
 FOLIC ACID, FOLIC ACID
 FOLOTYN, PRALATREXATE
 FOMEPIZOLE, FOMEPIZOLE
 FONDAPARINUX SODIUM, FONDAPARINUX SODIUM
 FORANE, ISOFLURANE
 FORFIVO XL, BUPROPION HYDROCHLORIDE
 FORMOTEROL FUMARATE, FORMOTEROL FUMARATE
 FORTAMET, METFORMIN HYDROCHLORIDE
 FORTAZ, CEFTAZIDIME
 FORTEO, TERIPARATIDE
 FORTESTA, TESTOSTERONE
 FOSAMAX, ALENDRONATE SODIUM
 FOSAMAX PLUS D, ALENDRONATE SODIUM
 FOSAMPRENAVIR CALCIUM, FOSAMPRENAVIR CALCIUM
 FOSAPREPITANT DIMEGLUMINE, FOSAPREPITANT DIMEGLUMINE
 FOSCARNET SODIUM, FOSCARNET SODIUM
 FOSCAVIR, FOSCARNET SODIUM
 FOSFOMYCIN TROMETHAMINE, FOSFOMYCIN TROMETHAMINE
 FOSINOPRIL SODIUM, FOSINOPRIL SODIUM
 FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE, FOSINOPRIL SODIUM
 FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
 FOSRENOL, LANTHANUM CARBONATE
 FOTIVDA, TIVOZANIB HYDROCHLORIDE
 FRAGMIN, DALTEPARIN SODIUM
 FREAMINE HBC 6.9%, AMINO ACIDS
 FREAMINE III 10%, AMINO ACIDS
 FREAMINE III 3% W/ ELECTROLYTES, AMINO ACIDS
 FREAMINE III 8.5%, AMINO ACIDS
 FREAMINE III 8.5% W/ ELECTROLYTES, AMINO ACIDS
 FROVA, FROVATRIPTAN SUCCINATE
 FROVATRIPTAN SUCCINATE, FROVATRIPTAN SUCCINATE
 FULVESTRANT, FULVESTRANT
 FULVICIN P/G, GRISEOFULVIN, ULTRAMICROCRYSTALLINE
 FULVICIN P/G 165, GRISEOFULVIN, ULTRAMICROCRYSTALLINE
 FULVICIN P/G 330, GRISEOFULVIN, ULTRAMICROCRYSTALLINE
 FULVICIN-U/F, GRISEOFULVIN, MICROCRYSTALLINE
 FURADANTIN, NITROFURANTOIN
 FUROSCIX, FUROSEMIDE
 FUROSEMIDE, FUROSEMIDE
 FUSILEV, LEVOLEUCOVORIN CALCIUM
 FUZEON, ENFUVIRTIDE
 FYARRO, SIROLIMUS
 FYAVOLV, ETHINYL ESTRADIOL
 FYCOMPA, PERAMPANEL
 FYREMADEL, GANIRELIX ACETATE

**** G ****

GABAPENTIN, GABAPENTIN
 GABITRIL, TIAGABINE HYDROCHLORIDE
 GABLOFEN, BACLOFEN
 GADAVIST, GADOBUTROL
 GADOBUTROL, GADOBUTROL
 GADOTERATE MEGLUMINE, GADOTERATE MEGLUMINE

APPENDIX A - PRODUCT NAME INDEX**** G ****

GALAFOLD, MIGALASTAT HYDROCHLORIDE
GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
GALLIUM CITRATE GA 67, GALLIUM CITRATE GA-67
GALLIUM GA 68 DOTATOC, GALLIUM GA-68 DOTATOC
GALLIUM GA 68 GOZETOTIDE, GALLIUM GA-68 GOZETOTIDE
GALZIN, ZINC ACETATE
GANCICLOVIR SODIUM, GANCICLOVIR SODIUM
GANIRELIX ACETATE, GANIRELIX ACETATE
GANZYK-RTU, GANCICLOVIR
GASTROCROM, CROMOLYN SODIUM
GASTROGRAFIN, DIATRIZOATE MEGLUMINE
GATIFLOXACIN, GATIFLOXACIN
GATTEX KIT, TEDUGLUTIDE RECOMBINANT
GAVRETO, PRALSETINIB
GEFITINIB, GEFITINIB
GELNIQUE, OXYBUTYNIN CHLORIDE
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
GEMFIBROZIL, GEMFIBROZIL
GEMMILY, ETHINYL ESTRADIOL
GEMTESA, VIBEGRON
GENERLAC, LACTULOSE
GENGRAF, CYCLOSPORINE
GENOPTIC, GENTAMICIN SULFATE
GENOSYL, NITRIC OXIDE
GENTAK, GENTAMICIN SULFATE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, GENTAMICIN SULFATE
GENVOYA, COBICISTAT
GEODON, ZIPRASIDONE HYDROCHLORIDE
GEODON, ZIPRASIDONE MESYLATE
GIAPREZA, ANGIOTENSIN II ACETATE
GILDAGIA, ETHINYL ESTRADIOL
GILDESS 24 FE, ETHINYL ESTRADIOL
GILENYA, FINGOLIMOD HYDROCHLORIDE
GILOTRIF, AFATINIB DIMALEATE
GIMOTI, METOCLOPRAMIDE HYDROCHLORIDE
GIVLAARI, GIVOSIRAN SODIUM
GLATIRAMER ACETATE, GLATIRAMER ACETATE
GLATOPA, GLATIRAMER ACETATE
GLEEVEC, IMATINIB MESYLATE
GLEOLAN, AMINOLEVULINIC ACID HYDROCHLORIDE
GLEOSTINE, LOMUSTINE
GLIADEL, CARMUSTINE
GLIMEPIRIDE, GLIMEPIRIDE
GLIPIZIDE, GLIPIZIDE
GLIPIZIDE AND METFORMIN HYDROCHLORIDE, GLIPIZIDE
GLOFIL-125, IOTHALAMATE SODIUM I-125
GLOPERBA, COLCHICINE
GLUCAGEN, GLUCAGON HYDROCHLORIDE
GLUCAGON, GLUCAGON
GLUCAGON, GLUCAGON HYDROCHLORIDE
GLUCOTROL XL, GLIPIZIDE
GLUMETZA, METFORMIN HYDROCHLORIDE
GLYBURIDE, GLYBURIDE
GLYBURIDE (MICRONIZED), GLYBURIDE
GLYBURIDE AND METFORMIN HYDROCHLORIDE, GLYBURIDE
GLYCINE 1.5% IN PLASTIC CONTAINER, GLYCINE
GLYCOPYRROLATE, GLYCOPYRROLATE
GLYDO, LIDOCAINE HYDROCHLORIDE
GLYNASE, GLYBURIDE
GLYRX-PF, GLYCOPYRROLATE
GLYSET, MIGLITOL
GLYXAMBI, EMPAGLIFLOZIN
GOCOVRI, AMANTADINE HYDROCHLORIDE
GOLYTELY, POLYETHYLENE GLYCOL 3350

APPENDIX A - PRODUCT NAME INDEX**** G ****

GOPRELTO, COCAINE HYDROCHLORIDE
 GRALISE, GABAPENTIN
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
 GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE, GRANISETRON HYDROCHLORIDE
 GRIS-PEG, GRISEOFULVIN, ULTRAMICROSIZE
 GRISEOFULVIN, GRISEOFULVIN, MICROSIZE
 GRISEOFULVIN, ULTRAMICROSIZE, GRISEOFULVIN, ULTRAMICROSIZE
 GRISEOFULVIN, ULTRAMICROSIZE, GRISEOFULVIN, ULTRAMICROSIZE
 GUAIFENESIN, GUAIFENESIN (OTC)
 GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE, DEXTROMETHORPHAN HYDROBROMIDE (OTC)
 GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE, GUAIFENESIN (OTC)
 GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
 GVOKE HYPOPEN, GLUCAGON
 GVOKE PFS, GLUCAGON
 GYNAZOLE-1, BUTOCONAZOLE NITRATE

**** H ****

HABITROL, NICOTINE (OTC)
 HAILEY 1.5/30, ETHINYL ESTRADIOL
 HAILEY FE 1.5/30, ETHINYL ESTRADIOL
 HAILEY FE 1/20, ETHINYL ESTRADIOL
 HALAVEN, ERIBULIN MESYLATE
 HALCINONIDE, HALCINONIDE
 HALCION, TRIAZOLAM
 HALDOL, HALOPERIDOL DECANOATE
 HALOBETASOL PROPIONATE, HALOBETASOL PROPIONATE
 HALOETTE, ETHINYL ESTRADIOL
 HALOG, HALCINONIDE
 HALOPERIDOL, HALOPERIDOL
 HALOPERIDOL, HALOPERIDOL LACTATE
 HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
 HARVONI, LEDIPASVIR
 HEATHER, NORETHINDRONE
 HECTOROL, DOXERCALCIFEROL
 HEMABATE, CARBOPROST TROMETHAMINE
 HEMADY, DEXAMETHASONE
 HEMANGEOL, PROPRANOLOL HYDROCHLORIDE
 HEPARIN SODIUM, HEPARIN SODIUM
 HEPARIN SODIUM 1,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPARIN SODIUM 2,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPARIN SODIUM IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPARIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM
 HEPATAMINE 8%, AMINO ACIDS
 HEPSERA, ADEFOVIR DIPIVOXIL
 HER STYLE, LEVONORGESTREL (OTC)
 HETLIOZ, TASIMELTEON
 HETLIOZ LQ, TASIMELTEON
 HIBICLEN, CHLORHEXIDINE GLUCONATE (OTC)
 HIBISTAT, CHLORHEXIDINE GLUCONATE (OTC)
 HICON, SODIUM IODIDE I-131
 HIPREX, METHENAMINE HIPPURATE
 HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE, HOMATROPINE METHYLBROMIDE
 HORIZANT, GABAPENTIN ENACARBIL
 HYCAMTIN, TOPOTECAN HYDROCHLORIDE
 HYCODAN, HOMATROPINE METHYLBROMIDE
 HYDRA-ZIDE, HYDRALAZINE HYDROCHLORIDE
 HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE

APPENDIX A - PRODUCT NAME INDEX**** H ****

HYDREA, HYDROXYUREA
 HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 HYDROCODONE, HYDROCODONE BITARTRATE
 HYDROCODONE BITARTRATE, HYDROCODONE BITARTRATE
 HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
 HYDROCODONE BITARTRATE AND ASPIRIN, ASPIRIN
 HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE, HOMATROPINE METHYLBROMIDE
 HYDROCODONE BITARTRATE AND IBUPROFEN, HYDROCODONE BITARTRATE
 HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE,
 HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX, CHLORPHENIRAMINE POLISTIREX
 HYDROCORTISONE, HYDROCORTISONE
 HYDROCORTISONE AND ACETIC ACID, ACETIC ACID, GLACIAL
 HYDROCORTISONE BUTYRATE, HYDROCORTISONE BUTYRATE
 HYDROCORTISONE IN ABSORBASE, HYDROCORTISONE
 HYDROCORTISONE VALERATE, HYDROCORTISONE VALERATE
 HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
 HYDROXOCOBALAMIN, HYDROXOCOBALAMIN
 HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
 HYDROXYPROGESTERONE CAPROATE, HYDROXYPROGESTERONE CAPROATE
 HYDROXYUREA, HYDROXYUREA
 HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
 HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE
 HYFTOR, SIROLIMUS
 HYSINGLA ER, HYDROCODONE BITARTRATE
 HYZAAR, HYDROCHLOROTHIAZIDE

**** I ****

IBANDRONATE SODIUM, IBANDRONATE SODIUM
 IBRANCE, PALBOCICLIB
 IBSRELA, TENAPANOR HYDROCHLORIDE
 IBUPROFEN, IBUPROFEN (OTC)
 IBUPROFEN, IBUPROFEN
 IBUPROFEN AND DIPHENHYDRAMINE CITRATE, DIPHENHYDRAMINE CITRATE (OTC)
 IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
 IBUPROFEN AND FAMOTIDINE, FAMOTIDINE
 IBUPROFEN AND PHENYLEPHRINE HYDROCHLORIDE, IBUPROFEN (OTC)
 IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE, IBUPROFEN (OTC)
 IBUPROFEN LYSINE, IBUPROFEN LYSINE
 IBUPROHM COLD AND SINUS, IBUPROFEN (OTC)
 IBUTILIDE FUMARATE, IBUTILIDE FUMARATE
 IC-GREEN, INDOCYANINE GREEN
 ICATIBANT ACETATE, ICATIBANT ACETATE
 ICLEVIA, ETHINYL ESTRADIOL
 ICLUSIG, PONATINIB HYDROCHLORIDE
 ICOSAPENT ETHYL, ICOSAPENT ETHYL
 IDAMYCIN PFS, IDARUBICIN HYDROCHLORIDE
 IDARUBICIN HYDROCHLORIDE, IDARUBICIN HYDROCHLORIDE
 IDARUBICIN HYDROCHLORIDE PFS, IDARUBICIN HYDROCHLORIDE
 IDHIFA, ENASIDENIB MESYLATE
 IDKIT:HP, CITRIC ACID
 IFEX, IFOSFAMIDE
 IFOSFAMIDE, IFOSFAMIDE
 IGALMI, DEXMEDETOMIDINE HYDROCHLORIDE
 IHEEZO, CHLOROPROCAINE HYDROCHLORIDE
 ILEVRO, NEPAFENAC
 ILLUCCIX, GALLIUM GA-68 GOZETOTIDE
 ILUVIEN, FLUOCINOLONE ACETONIDE
 IMATINIB MESYLATE, IMATINIB MESYLATE
 IMBRUVICA, IBRUTINIB
 IMCIVREE, SETMELANOTIDE ACETATE
 IMIPENEM AND CILASTATIN, CILASTATIN SODIUM
 IMIPRAMINE HYDROCHLORIDE, IMIPRAMINE HYDROCHLORIDE
 IMIPRAMINE PAMOATE, IMIPRAMINE PAMOATE
 IMIQUIMOD, IMIQUIMOD
 IMITREX, SUMATRIPTAN

APPENDIX A - PRODUCT NAME INDEX**** I ****

IMITREX, SUMATRIPTAN SUCCINATE
IMITREX STATDOSE, SUMATRIPTAN SUCCINATE
IMODIUM A-D, LOPERAMIDE HYDROCHLORIDE (OTC)
IMODIUM MULTI-SYMPTOM RELIEF, LOPERAMIDE HYDROCHLORIDE (OTC)
IMPAVIDO, MILTEFOSINE
IMPEKLO, CLOBETASOL PROPIONATE
IMPOYZ, CLOBETASOL PROPIONATE
IMURAN, AZATHIOPRINE
IMVEXXY, ESTRADIOL
INAPSINE, DROPERIDOL
INBRIJA, LEVODOPA
INCASSIA, NORETHINDRONE
INCRUSE ELLIPTA, UMECLIDINIUM BROMIDE
INDAPAMIDE, INDAPAMIDE
INDERAL LA, PROPRANOLOL HYDROCHLORIDE
INDIUM IN 111 CHLORIDE, INDIUM IN-111 CHLORIDE
INDIUM IN 111 OXYQUINOLINE, INDIUM IN-111 OXYQUINOLINE
INDOCIN, INDOMETHACIN
INDOCYANINE GREEN, INDOCYANINE GREEN
INDOMETHACIN, INDOMETHACIN
INDOMETHACIN SODIUM, INDOMETHACIN SODIUM
INFANT'S ADVIL, IBUPROFEN (OTC)
INFANTS' FEVERALL, ACETAMINOPHEN (OTC)
INFED, FERRIC OXYHYDROXIDE
INFUGEM, GEMCITABINE HYDROCHLORIDE
INFUMORPH, MORPHINE SULFATE
INFUVITE ADULT, ALPHA-TOCOPHEROL ACETATE
INFUVITE PEDIATRIC, ASCORBIC ACID
INFUVITE PEDIATRIC (PHARMACY BULK PACKAGE), ASCORBIC ACID
INGREZZA, VALBENAZINE TOSYLATE
INJECTAFER, FERRIC CARBOXYMALTOSE
INLYTA, AXITINIB
INNOPRAN XL, PROPRANOLOL HYDROCHLORIDE
INOMAX, NITRIC OXIDE
INQOVI, CEDAZURIDINE
INREBIC, FEDRATINIB HYDROCHLORIDE
INSpra, EPLERENONE
INTELENCE, ETRAVIRINE
INTRALIPID 10%, SOYBEAN OIL
INTRALIPID 20%, SOYBEAN OIL
INTRALIPID 30%, SOYBEAN OIL
INTRAROSA, PRASTERONE
INTROVALE, ETHINYL ESTRADIOL
INTUNIV, GUANFACINE HYDROCHLORIDE
INVANZ, ERTAPENEM SODIUM
INVEGA, PALIPERIDONE
INVEGA HAFYERA, PALIPERIDONE PALMITATE
INVEGA SUSTENNA, PALIPERIDONE PALMITATE
INVEGA TRINZA, PALIPERIDONE PALMITATE
INVELTYS, LOTEPREDNOL ETABONATE
INVOKAMET, CANAGLIFLOZIN
INVOKAMET XR, CANAGLIFLOZIN
INVOKANA, CANAGLIFLOZIN
IODIXANOL, IODIXANOL
IOFLUPANE I-123, IOFLUPANE I-123
IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
IOPIDINE, APRACLOnidine HYDROCHLORIDE
IOSAT, POTASSIUM IODIDE (OTC)
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
IRBESARTAN, IRBESARTAN
IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IRESSA, GEFITINIB
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
ISENTRESS, RALTEGRAVIR POTASSIUM
ISENTRESS HD, RALTEGRAVIR POTASSIUM

APPENDIX A - PRODUCT NAME INDEX**** I ****

ISIBLOOM, DESOGESTREL
ISOFLURANE, ISOFLURANE
ISOLYTE P IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
ISOLYTE S IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
ISOLYTE S PH 7.4 IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
ISONIAZID, ISONIAZID
ISOPROTERENOL HYDROCHLORIDE, ISOPROTERENOL HYDROCHLORIDE
ISOPTO ATROPINE, ATROPINE SULFATE
ISOPTO CARPINE, PILOCARPINE HYDROCHLORIDE
ISORDIL, ISOSORBIDE DINITRATE
ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE
ISOSORBIDE DINITRATE AND HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
ISOSULFAN BLUE, ISOSULFAN BLUE
ISOTRETINOIN, ISOTRETINOIN
ISOVUE-200, IOPAMIDOL
ISOVUE-250, IOPAMIDOL
ISOVUE-300, IOPAMIDOL
ISOVUE-370, IOPAMIDOL
ISOVUE-M 200, IOPAMIDOL
ISOVUE-M 300, IOPAMIDOL
ISRADIPINE, ISRADIPINE
ISTALOL, TIMOLOL MALEATE
ISTODAX, ROMIDEPSIN
ISTURISA, OSILODROSTAT PHOSPHATE
ISUPREL, ISOPROTERENOL HYDROCHLORIDE
ITRACONAZOLE, ITRACONAZOLE
IVABRADINE HYDROCHLORIDE, IVABRADINE HYDROCHLORIDE
IVERMECTIN, IVERMECTIN (OTC)
IVERMECTIN, IVERMECTIN
IVY BLOCK, BENTOQUATAM (OTC)
IXEMPRA KIT, IXABEPILONE
IYUZEH, LATANOPROST

**** J ****

JADENU, DEFERASIROX
JADENU SPRINKLE, DEFERASIROX
JAIMIESS, ETHINYL ESTRADIOL
JAKAFI, RUXOLITINIB PHOSPHATE
JALYN, DUTASTERIDE
JANTOVEN, WARFARIN SODIUM
JANUMET, METFORMIN HYDROCHLORIDE
JANUMET XR, METFORMIN HYDROCHLORIDE
JANUVIA, SITAGLIPTIN PHOSPHATE
JARDIANCE, EMPAGLIFLOZIN
JATENZO, TESTOSTERONE UNDECANOATE
JELMYTO, MITOMYCIN
JENCYCLA, NORETHINDRONE
JENTADUETO, LINAGLIPTIN
JENTADUETO XR, LINAGLIPTIN
JEVTANA KIT, CABAZITAXEL
JORNAY PM, METHYLPHENIDATE HYDROCHLORIDE
JUBLIA, EFINACONAZOLE
JULUCA, DOLUTEGRAVIR SODIUM
JUNEL 1.5/30, ETHINYL ESTRADIOL
JUNEL 1/20, ETHINYL ESTRADIOL
JUNEL FE 1.5/30, ETHINYL ESTRADIOL
JUNEL FE 1/20, ETHINYL ESTRADIOL
JUNIOR STRENGTH ADVIL, IBUPROFEN (OTC)
JUNIOR STRENGTH MOTRIN, IBUPROFEN (OTC)
JUXTAPID, LOMITAPIDE MESYLATE
JYLAMVO, METHOTREXATE
JYNARQUE, TOLVAPTAN

**** K ****

APPENDIX A - PRODUCT NAME INDEX**** K ****

K-TAB, POTASSIUM CHLORIDE
KABIVEN IN PLASTIC CONTAINER, AMINO ACIDS
KAITLIB FE, ETHINYL ESTRADIOL
KALETRA, LOPINAVIR
KALEXATE, SODIUM POLYSTYRENE SULFONATE
KALLIGA, DESOGESTREL
KALYDECO, IVACAFTOR
KAPSPARGO SPRINKLE, METOPROLOL SUCCINATE
KAPVAY, CLONIDINE HYDROCHLORIDE
KARBINAL ER, CARBINOXAMINE MALEATE
KARIVA, DESOGESTREL
KATERZIA, AMLODIPINE BENZOATE
KAZANO, ALOGLIPTIN BENZOATE
KELNOR, ETHINYL ESTRADIOL
KENALOG, TRIAMCINOLONE ACETONIDE
KENALOG-10, TRIAMCINOLONE ACETONIDE
KENALOG-40, TRIAMCINOLONE ACETONIDE
KENALOG-80, TRIAMCINOLONE ACETONIDE
KENGREAL, CANGRELOR
KEPPRA, LEVETIRACETAM
KEPPRA XR, LEVETIRACETAM
KERENDIA, FINERENONE
KERYDIN, TAVABOROLE
KETALAR, KETAMINE HYDROCHLORIDE
KETAMINE HYDROCHLORIDE, KETAMINE HYDROCHLORIDE
KETOCONAZOLE, KETOCONAZOLE
KETOPROFEN, KETOPROFEN
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
KETOROLAC TROMETHAMINE AND PHENYLEPHRINE HYDROCHLORIDE, KETOROLAC TROMETHAMINE
KETOTIFEN FUMARATE, KETOTIFEN FUMARATE (OTC)
KETOZOLE, KETOCONAZOLE
KEVEYIS, DICHLORPHENAMIDE
KHAPZORY, LEVOLEUCOVORIN
KIMIDESS, DESOGESTREL
KIMYRSA, ORITAVANCIN DIPHOSPHATE
KINEVAC, SINCALIDE
KIONEX, SODIUM POLYSTYRENE SULFONATE
KISQALI, RIBOCICLIB SUCCINATE
KISQALI FEMARA CO-PACK (COPACKAGED), LETROZOLE
KITABIS PAK, TOBRAMYCIN
KLARON, SULFACETAMIDE SODIUM
KLISYRI, TIRBANIBULIN
KLONOPIN, CLONAZEPAM
KLOR-CON, POTASSIUM CHLORIDE
KLOR-CON M10, POTASSIUM CHLORIDE
KLOR-CON M15, POTASSIUM CHLORIDE
KLOR-CON M20, POTASSIUM CHLORIDE
KLOXXADO, NALOXONE HYDROCHLORIDE
KOMBIGLYZE XR, METFORMIN HYDROCHLORIDE
KONVOMEF, OMEPRAZOLE
KORLYM, MIFEPRISTONE
KORSUVA, DIFELIKEFALIN ACETATE
KOSELUGO, SELUMETINIB SULFATE
KOVANAZE, OXYMETAZOLINE HYDROCHLORIDE
KRAZATI, ADAGRASIB
KRINTAFEL, TAFENOQUINE SUCCINATE
KURVELO, ETHINYL ESTRADIOL
KUVAN, SAPROPTERIN DIHYDROCHLORIDE
KYBELLA, DEOXYCHOLIC ACID
KYLEENA, LEVONORGESTREL
KYNMOBI, APOMORPHINE HYDROCHLORIDE
KYPROLIS, CARFILZOMIB
KYZATREX, TESTOSTERONE UNDECANOATE

**** L ****

APPENDIX A - PRODUCT NAME INDEX**** L ****

LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
LABETALOL HYDROCHLORIDE IN DEXTROSE, LABETALOL HYDROCHLORIDE
LABETALOL HYDROCHLORIDE IN SODIUM CHLORIDE, LABETALOL HYDROCHLORIDE
LACOSAMIDE, LACOSAMIDE
LACRISERT, HYDROXYPROPYL CELLULOSE
LACTATED RINGER'S AND DEXTROSE 5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
LACTULOSE, LACTULOSE
LAMICTAL, LAMOTRIGINE
LAMICTAL CD, LAMOTRIGINE
LAMICTAL ODT, LAMOTRIGINE
LAMICTAL XR, LAMOTRIGINE
LAMISIL, TERBINAFINE HYDROCHLORIDE (OTC)
LAMISIL AT, TERBINAFINE (OTC)
LAMISIL AT, TERBINAFINE HYDROCHLORIDE (OTC)
LAMIVUDINE, LAMIVUDINE
LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE
LAMOTRIGINE, LAMOTRIGINE
LAMPIT, NIFURTIMOX
LANORINAL, ASPIRIN
LANOXIN, DIGOXIN
LANOXIN PEDIATRIC, DIGOXIN
LANREOTIDE ACETATE, LANREOTIDE ACETATE
LANSOPRAZOLE, LANSOPRAZOLE (OTC)
LANSOPRAZOLE, LANSOPRAZOLE
LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN (COPACKAGED), AMOXICILLIN
LANTHANUM CARBONATE, LANTHANUM CARBONATE
LAPATINIB DITOSYLATE, LAPATINIB DITOSYLATE
LARIN 1.5/30, ETHINYL ESTRADIOL
LARIN 1/20, ETHINYL ESTRADIOL
LARIN 24 FE, ETHINYL ESTRADIOL
LARIN FE 1.5/30, ETHINYL ESTRADIOL
LARIN FE 1/20, ETHINYL ESTRADIOL
LAROTID, AMOXICILLIN
LARYNG-O-JET KIT, LIDOCAINE HYDROCHLORIDE
LASIX, FUROSEMIDE
LASTACFT, ALCAFTADINE (OTC)
LATANOPROST, LATANOPROST
LATISSE, BIMATOPROST
LATUDA, LURASIDONE HYDROCHLORIDE
LEFLUNOMIDE, LEFLUNOMIDE
LENALIDOMIDE, LENALIDOMIDE
LENVIMA, LENVATINIB MESYLATE
LEQVIO, INCLISIRAN SODIUM
LERIBANE, ETHINYL ESTRADIOL
LESCOL XL, FLUVASTATIN SODIUM
LESSINA-28, ETHINYL ESTRADIOL
LETAIRIS, AMBRISENTAN
LETROZOLE, LETROZOLE
LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
LEUCOVORIN CALCIUM PRESERVATIVE FREE, LEUCOVORIN CALCIUM
LEUKERAN, CHLORAMBUCIL
LEUPROLIDE ACETATE, LEUPROLIDE ACETATE
LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE
LEVETIRACETAM, LEVETIRACETAM
LEVETIRACETAM IN SODIUM CHLORIDE, LEVETIRACETAM
LEVO-T, LEVOTHYROXINE SODIUM **
LEVOBUNOLOL HYDROCHLORIDE, LEVOBUNOLOL HYDROCHLORIDE
LEVOCARNITINE, LEVOCARNITINE
LEVOCARNITINE SF, LEVOCARNITINE
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE (OTC)
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
LEVOCETIRIZINE HYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
LEVOFLOXACIN, LEVOFLOXACIN
LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, LEVOFLOXACIN

APPENDIX A - PRODUCT NAME INDEX**** L ****

LEVOLET, LEVOTHYROXINE SODIUM **
LEVOLEUCOVORIN CALCIUM, LEVOLEUCOVORIN CALCIUM
LEVOMILNACIPRAN HYDROCHLORIDE, LEVOMILNACIPRAN HYDROCHLORIDE
LEVONEST, ETHINYL ESTRADIOL
LEVONORGESTREL, LEVONORGESTREL (OTC)
LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
LEVOPHED, NOREPINEPHRINE BITARTRATE
LEVORA 0.15/30-28, ETHINYL ESTRADIOL
LEVORPHANOL TARTRATE, LEVORPHANOL TARTRATE
LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM
LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM **
LEVOXYL, LEVOTHYROXINE SODIUM **
LEVULAN, AMINOLEVULINIC ACID HYDROCHLORIDE
LEXAPRO, ESCITALOPRAM OXALATE
LEXETTE, HALOBETASOL PROPIONATE
LEXISCAN, REGADENOSON
LEXIVA, FOSAMPRENAVIR CALCIUM
LIALDA, MESALAMINE
LIBRAX, CHLORDIAZEPOXIDE HYDROCHLORIDE
LIBRIUM, CHLORDIAZEPOXIDE HYDROCHLORIDE
LICART, DICLOFENAC EPOLAMINE
LIDEX, FLUOCINONIDE
LIDOCAINE, LIDOCAINE
LIDOCAINE AND PRILOCAINE, LIDOCAINE
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE 5% AND DEXTROSE 7.5%, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE, EPINEPHRINE
LIDOCAINE HYDROCHLORIDE IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE VISCOUS, LIDOCAINE HYDROCHLORIDE
LIDOCAINE VISCOUS, LIDOCAINE HYDROCHLORIDE
LIDODERM, LIDOCAINE
LIGNOSPAN FORTE, EPINEPHRINE BITARTRATE
LIGNOSPAN STANDARD, EPINEPHRINE BITARTRATE
LILETTA, LEVONORGESTREL
LINAGLIPTIN, LINAGLIPTIN
LINAGLIPTIN AND METFORMIN HYDROCHLORIDE, LINAGLIPTIN
LINCOCIN, LINCOMYCIN HYDROCHLORIDE
LINCOMYCIN HYDROCHLORIDE, LINCOMYCIN HYDROCHLORIDE
LINEZOLID, LINEZOLID
LINEZOLID IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, LINEZOLID
LINZESS, LINACLOTIDE
LIORESAL, BACLOFEN
LIOTHYRONINE SODIUM, LIOTHYRONINE SODIUM
LIPIODOL, ETHIODIZED OIL
LIPITOR, ATORVASTATIN CALCIUM
LIPOFEN, FENOFIBRATE
LIQUID E-Z-PAQUE, BARIUM SULFATE
LISINOPRIL, LISINOPRIL
LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LITHIUM CARBONATE, LITHIUM CARBONATE
LITHIUM CITRATE, LITHIUM CITRATE
LITHOBID, LITHIUM CARBONATE
LITHOSTAT, ACETOHYDROXAMIC ACID
LIVALO, PITAVASTATIN CALCIUM
LIVMARLI, MARALIXIBAT CHLORIDE
LIVTENCITY, MARIBAVIR
LO LOESTRIN FE, ETHINYL ESTRADIOL
LO SIMPESE, ETHINYL ESTRADIOL
LO-MALMOREDE, ETHINYL ESTRADIOL

APPENDIX A - PRODUCT NAME INDEX**** L ****

LO-ZUMANDIMINE, DROSPIRENONE
 LOCAMETZ, GALLIUM GA-68 GOZETOTIDE
 LOCHOLEST, CHOLESTYRAMINE
 LOCHOLEST LIGHT, CHOLESTYRAMINE
 LOCID, HYDROCORTISONE BUTYRATE
 LOCID LIPOCREAM, HYDROCORTISONE BUTYRATE
 LODOSYN, CARBIDOPA
 LOGILIA, ULIPRISTAL ACETATE
 LOKELMA, SODIUM ZIRCONIUM CYCLOSILICATE
 LOMAIRA, PHENTERMINE HYDROCHLORIDE
 LOMOTIL, ATROPINE SULFATE
 LONHALA MAGNAIR KIT, GLYCOPYRROLATE
 LONSURF, TIPIRACIL HYDROCHLORIDE
 LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)
 LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE
 LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE, LOPERAMIDE HYDROCHLORIDE (OTC)
 LOPID, GEMFIBROZIL
 LOPINAVIR AND RITONAVIR, LOPINAVIR
 LOPRESSOR, METOPROLOL TARTRATE
 LOPRESSOR HCT, HYDROCHLOROTHIAZIDE
 LOPROX, CICLOPIROX
 LOPURIN, ALLOPURINOL
 LORATADINE, LORATADINE (OTC)
 LORATADINE AND PSEUDOEPHEDRINE SULFATE, LORATADINE (OTC)
 LORATADINE REDIDOSE, LORATADINE (OTC)
 LORAZEPAM, LORAZEPAM
 LORAZEPAM INTENSOL, LORAZEPAM
 LORBRENA, LORLATINIB
 LOREEV XR, LORAZEPAM
 LORYNA, DROSPIRENONE
 LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
 LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 LOSEASONIQUE, ETHINYL ESTRADIOL
 LOTEMAX, LOTEPRDNOL ETABONATE
 LOTEMAX SM, LOTEPRDNOL ETABONATE
 LOTENSIN, BENAZEPRIL HYDROCHLORIDE
 LOTENSIN HCT, BENAZEPRIL HYDROCHLORIDE
 LOTEPRDNOL ETABONATE, LOTEPRDNOL ETABONATE
 LOTREL, AMLODIPINE BESYLATE
 LOTRIMIN ULTRA, BUTENAFINE HYDROCHLORIDE (OTC)
 LOTRISONE, BETAMETHASONE DIPROPIONATE
 LOTRONEX, ALOSETRON HYDROCHLORIDE
 LOVASTATIN, LOVASTATIN
 LOVAZA, OMEGA-3-ACID ETHYL ESTERS
 LOVENOX, ENOXAPARIN SODIUM
 LOVENOX (PRESERVATIVE FREE), ENOXAPARIN SODIUM
 LOW-OGESTREL-28, ETHINYL ESTRADIOL
 LOXAPINE SUCCINATE, LOXAPINE SUCCINATE
 LUBIPROSTONE, LUBIPROSTONE
 LUCEMYRA, LOFEXIDINE HYDROCHLORIDE
 LUMAKRAS, SOTORASIB
 LUMASON, SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSPHERES
 LUMI-SPORYN, BACITRACIN ZINC
 LUMIFY, BRIMONIDINE TARTRATE (OTC)
 LUMIGAN, BIMATOPROST
 LUNESTA, ESZOPICLONE
 LUPKYNIS, VOCLOSPORIN
 LUPRON DEPOT, LEUPROLIDE ACETATE
 LUPRON DEPOT-PED KIT, LEUPROLIDE ACETATE
 LURASIDONE HYDROCHLORIDE, LURASIDONE HYDROCHLORIDE
 LUTATHERA, LUTETIUM LU 177 DOTATATE
 LUTRATE DEPOT KIT, LEUPROLIDE ACETATE
 LUVOX, FLUVOXAMINE MALEATE
 LUXIQ, BETAMETHASONE VALERATE
 LUZU, LULICONAZOLE

APPENDIX A - PRODUCT NAME INDEX**** L ****

LYBALVI, OLANZAPINE
LYMPHOSEEK KIT, TECHNETIUM TC-99M TILMANOCEPT
LYNPARZA, OLAPARIB
LYPQOZET, ATORVASTATIN CALCIUM
LYRICA, PREGABALIN
LYRICA CR, PREGABALIN
LYSODREN, MITOTANE
LYSTEDA, TRANEXAMIC ACID
LYTGOBI, FUTIBATINIB
LYVISPAH, BACLOFEN

**** M ****

M-ZOLE 3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MACRILEN, MACIMORELIN ACETATE
MACROBID, NITROFURANTOIN
MACRODANTIN, NITROFURANTOIN, MACROCRYSTALLINE
MAFENIDE ACETATE, MAFENIDE ACETATE
MAGNESIUM SULFATE, MAGNESIUM SULFATE
MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MAGNESIUM SULFATE
MAGNESIUM SULFATE IN PLASTIC CONTAINER, MAGNESIUM SULFATE
MAKENA, HYDROXYPROGESTERONE CAPROATE
MAKENA (AUTOINJECTOR), HYDROXYPROGESTERONE CAPROATE
MAKENA PRESERVATIVE FREE, HYDROXYPROGESTERONE CAPROATE
MALARONE, ATOVAQUONE
MALARONE PEDIATRIC, ATOVAQUONE
MALATHION, MALATHION
MALMOREDE, ETHINYL ESTRADIOL
MANGANESE CHLORIDE IN PLASTIC CONTAINER, MANGANESE CHLORIDE
MANNITOL 10% IN PLASTIC CONTAINER, MANNITOL
MANNITOL 15% IN PLASTIC CONTAINER, MANNITOL
MANNITOL 20% IN PLASTIC CONTAINER, MANNITOL
MANNITOL 25%, MANNITOL
MANNITOL 5% IN PLASTIC CONTAINER, MANNITOL
MARAVIROC, MARAVIROC
MARCAINE, BUPIVACAINE HYDROCHLORIDE
MARCAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE
MARCAINE HYDROCHLORIDE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE
MARCAINE HYDROCHLORIDE W/ EPINEPHRINE, BUPIVACAINE HYDROCHLORIDE
MARCAINE HYDROCHLORIDE W/ EPINEPHRINE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE
MARINOL, DRONABINOL
MARLISSA, ETHINYL ESTRADIOL
MARPLAN, ISOCARBOXAZID
MATULANE, PROCARBAZINE HYDROCHLORIDE
MAVENCLAD, CLADRIBINE
MAVYRET, GLECAPREVIR
MAXALT, RIZATRIPTAN BENZOATE
MAXALT-MLT, RIZATRIPTAN BENZOATE
MAXIDEX, DEXAMETHASONE
MAXIPIME, CEFEPIME HYDROCHLORIDE
MAXITROL, DEXAMETHASONE
MAXZIDE, HYDROCHLOROTHIAZIDE
MAXZIDE-25, HYDROCHLOROTHIAZIDE
MAYZENT, SIPONIMOD FUMARIC ACID
MD-GASTROVIEW, DIATRIZOATE MEGLUMINE
MECAMYLAMINE HYDROCHLORIDE, MECAMYLAMINE HYDROCHLORIDE
MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE
MECLOFENAMATE SODIUM, MECLOFENAMATE SODIUM
MEDROL, METHYLPREDNISOLONE
MEDROXYPROGESTERONE ACETATE, MEDROXYPROGESTERONE ACETATE
MEFENAMIC ACID, MEFENAMIC ACID
MEFLOQUINE HYDROCHLORIDE, MEFLOQUINE HYDROCHLORIDE
MEGACE ES, MEGESTROL ACETATE
MEGESTROL ACETATE, MEGESTROL ACETATE
MEKINIST, TRAMETINIB DIMETHYL SULFOXIDE
MEKTOVI, BINIMETINIB

APPENDIX A - PRODUCT NAME INDEX**** M ****

MELAMISA, DROSPIRENONE
MELOXICAM, MELOXICAM
MELPHALAN, MELPHALAN
MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
MEN'S ROGAINE, MINOXIDIL (OTC)
MENEST, ESTROGENS, ESTERIFIED
MENOSTAR, ESTRADIOL
MENTAX, BUTENAFINE HYDROCHLORIDE
MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE
MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE, MEPERIDINE HYDROCHLORIDE
MEPHYTON, PHYTONADIONE
MEPROBAMATE, MEPROBAMATE
MEPRON, ATOVAQUONE
MERCAPTOPYRINE, MERCAPTOPYRINE
MEROPENEM, MEROPENEM
MEROPENEM AND SODIUM CHLORIDE IN DUPLEX CONTAINER, MEROPENEM
MERREM, MEROPENEM
MERZEE, ETHINYL ESTRADIOL
MESALAMINE, MESALAMINE
MESNA, MESNA
MESNEX, MESNA
MESTINON, PYRIDOSTIGMINE BROMIDE
METADATE CD, METHYLPHENIDATE HYDROCHLORIDE
METAPROTERENOL SULFATE, METAPROTERENOL SULFATE
METARAMINOL BITARTRATE, METARAMINOL BITARTRATE
METASTRON, STRONTIUM CHLORIDE SR-89
METAXALONE, METAXALONE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
METHADONE HYDROCHLORIDE INTENSOL, METHADONE HYDROCHLORIDE
METHADOSE, METHADONE HYDROCHLORIDE
METHAMPHETAMINE HYDROCHLORIDE, METHAMPHETAMINE HYDROCHLORIDE
METHAZOLAMIDE, METHAZOLAMIDE
METHENAMINE HIPPUATE, METHENAMINE HIPPUATE
METHERGINE, METHYLERGONOVINE MALEATE
METHIMAZOLE, METHIMAZOLE
METHOCARBAMOL, METHOCARBAMOL
METHOTREXATE PRESERVATIVE FREE, METHOTREXATE SODIUM
METHOTREXATE SODIUM, METHOTREXATE SODIUM
METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM
METHOXSALIN, METHOXSALIN
METHSCOPOLAMINE BROMIDE, METHSCOPOLAMINE BROMIDE
METHYLERGONOVINE MALEATE, METHYLERGONOVINE MALEATE
METHYLIN, METHYLPHENIDATE HYDROCHLORIDE
METHYLIN ER, METHYLPHENIDATE HYDROCHLORIDE
METHYLPHENIDATE, METHYLPHENIDATE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
METHYLPREDNISOLONE, METHYLPREDNISOLONE
METHYLPREDNISOLONE ACETATE, METHYLPREDNISOLONE ACETATE
METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE SODIUM SUCCINATE
METHYLTESTOSTERONE, METHYLTESTOSTERONE
METOCLOPRAMIDE, METOCLOPRAMIDE HYDROCHLORIDE
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
METOLAZONE, METOLAZONE
METOPIRONE, METYRAPONE
METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
METRO I.V. IN PLASTIC CONTAINER, METRONIDAZOLE
METROCREAM, METRONIDAZOLE
METROGEL, METRONIDAZOLE
METROGEL-VAGINAL, METRONIDAZOLE
METROLOTION, METRONIDAZOLE
METRONIDAZOLE, METRONIDAZOLE

APPENDIX A - PRODUCT NAME INDEX**** M ****

METRONIDAZOLE IN PLASTIC CONTAINER, METRONIDAZOLE
METYROSINE, METYROSINE
MEXILETINE HYDROCHLORIDE, MEXILETINE HYDROCHLORIDE
MIACALCIN, CALCITONIN SALMON
MIBELAS 24 FE, ETHINYL ESTRADIOL
MICAFUNGIN, MICAFUNGIN SODIUM
MICAFUNGIN SODIUM, MICAFUNGIN SODIUM
MICARDIS, TELMISARTAN
MICARDIS HCT, HYDROCHLOROTHIAZIDE
MICONAZOLE 3, MICONAZOLE NITRATE (OTC)
MICONAZOLE 3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MICONAZOLE 7, MICONAZOLE NITRATE (OTC)
MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)
MICONAZOLE NITRATE, MICONAZOLE NITRATE
MICONAZOLE NITRATE COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MICORT-HC, HYDROCORTISONE ACETATE
MICROZIDE, HYDROCHLOROTHIAZIDE
MIDAMOR, AMILORIDE HYDROCHLORIDE
MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE, MIDAZOLAM HYDROCHLORIDE
MIDAZOLAM IN 0.8% SODIUM CHLORIDE, MIDAZOLAM
MIDAZOLAM IN 0.9% SODIUM CHLORIDE, MIDAZOLAM
MIDODRINE HYDROCHLORIDE, MIDODRINE HYDROCHLORIDE
MIDOL LIQUID GELS, IBUPROFEN (OTC)
MIFEPREX, MIFEPRISTONE
MIFEPRISTONE, MIFEPRISTONE
MIGERGOT, CAFFEINE
MIGLITOL, MIGLITOL
MIGLUSTAT, MIGLUSTAT
MIGRANAL, DIHYDROERGOTAMINE MESYLATE
MILI, ETHINYL ESTRADIOL
MILRINONE LACTATE, MILRINONE LACTATE
MILRINONE LACTATE IN DEXTROSE 5%, MILRINONE LACTATE
MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MILRINONE LACTATE
MILRINONE LACTATE IN PLASTIC CONTAINER, MILRINONE LACTATE
MINASTRIN 24 FE, ETHINYL ESTRADIOL
MINIPRESS, PRAZOSIN HYDROCHLORIDE
MINIVELLE, ESTRADIOL
MINOCIN, MINOCYCLINE HYDROCHLORIDE
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
MINOLIRA, MINOCYCLINE HYDROCHLORIDE
MINOXIDIL, MINOXIDIL (OTC)
MINOXIDIL, MINOXIDIL
MINOXIDIL (FOR MEN), MINOXIDIL (OTC)
MINOXIDIL (FOR WOMEN), MINOXIDIL (OTC)
MINOXIDIL EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
MIOCHOL-E, ACETYLCHOLINE CHLORIDE
MIOSTAT, CARBACHOL
MIRABEGRON, MIRABEGRON
MIRALAX, POLYETHYLENE GLYCOL 3350 (OTC)
MIRAPEX ER, PRAMIPEXOLE DIHYDROCHLORIDE
MIRENA, LEVONORGESTREL
MIRTAZAPINE, MIRTAZAPINE
MIRVASO, BRIMONIDINE TARTRATE
MISOPROSTOL, MISOPROSTOL
MITIGARE, COLCHICINE
MITIGO, MORPHINE SULFATE
MITOMYCIN, MITOMYCIN
MITOSOL, MITOMYCIN
MITOXANTRONE HYDROCHLORIDE, MITOXANTRONE HYDROCHLORIDE
MIVACURIUM CHLORIDE, MIVACURIUM CHLORIDE
MOBIC, MELOXICAM
MODAFINIL, MODAFINIL
MOEXIPRIL HYDROCHLORIDE, MOEXIPRIL HYDROCHLORIDE
MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE

APPENDIX A - PRODUCT NAME INDEX**** M ****

MOLINDONE HYDROCHLORIDE, MOLINDONE HYDROCHLORIDE
 MOMETASONE FUROATE, MOMETASONE FUROATE
 MONISTAT 1 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
 MONISTAT 3, MICONAZOLE NITRATE (OTC)
 MONISTAT 3, MICONAZOLE NITRATE
 MONISTAT 3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
 MONISTAT 3 COMBINATION PACK (PREFILLED), MICONAZOLE NITRATE (OTC)
 MONISTAT 7, MICONAZOLE NITRATE (OTC)
 MONISTAT 7 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
 MONO-LINYAH, ETHINYL ESTRADIOL
 MONOBASIC SODIUM PHOSPHATE AND DIBASIC SODIUM PHOSPHATE, SODIUM PHOSPHATE, DIBASIC,
 MONODOX, DOXYCYCLINE
 MONOFERRIC, FERRIC DERISOMALTOSE
 MONOKET, ISOSORBIDE MONONITRATE
 MONTELUKAST SODIUM, MONTELUKAST SODIUM
 MONUROL, FOSFOMYCIN TROMETHAMINE
 MORPHINE SULFATE, MORPHINE SULFATE
 MOTEGRITY, PRUCALOPRIDE SUCCINATE
 MOTOFEN, ATROPINE SULFATE
 MOTRIN IB, IBUPROFEN (OTC)
 MOUNJARO, TIRZEPATIDE
 MOVANTIK, NALOXEGOL OXALATE
 MOVIPREP, ASCORBIC ACID
 MOXEZA, MOXIFLOXACIN HYDROCHLORIDE
 MOXIDECTIN, MOXIDECTIN
 MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
 MOXIFLOXACIN HYDROCHLORIDE IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER, MOXIFLOXACIN
 MOZOBIL, PLERIXAFOR
 MPI INDIUM DTPA IN 111, INDIUM IN-111 PENTETATE DISODIUM
 MS CONTIN, MORPHINE SULFATE
 MUCINEX, GUAIFENESIN (OTC)
 MUCINEX D, GUAIFENESIN (OTC)
 MUCINEX DM, DEXTROMETHORPHAN HYDROBROMIDE (OTC)
 MULPLETA, LUSUTROMBOPAG
 MULTAQ, DRONEDARONE HYDROCHLORIDE
 MULTIHANCE, GADOBENATE DIMEGLUMINE
 MULTIHANCE MULTIPACK, GADOBENATE DIMEGLUMINE
 MULTRYS, CUPRIC SULFATE
 MUPIROCIN, MUPIROCIN
 MUPIROCIN, MUPIROCIN CALCIUM
 MUSE, ALPROSTADIL
 MYAMBUTOL, ETHAMBUTOL HYDROCHLORIDE
 MYCAMINE, MICAFUNGIN SODIUM
 MYCAPSSA, OCTREOTIDE ACETATE
 MYCOBUTIN, RIFABUTIN
 MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
 MYCOPHENOLATE MOFETIL HYDROCHLORIDE, MYCOPHENOLATE MOFETIL HYDROCHLORIDE
 MYCOPHENOLIC SODIUM, MYCOPHENOLIC SODIUM
 MYDAYIS, AMPHETAMINE ASPARTATE
 MYDRIACYL, TROPICAMIDE
 MYFEMBREE, ESTRADIOL
 MYFORTIC, MYCOPHENOLIC SODIUM
 MYKACET, NYSTATIN
 MYLERAN, BUSULFAN
 MYORISAN, ISOTRETINOIN
 MYOVIEW, TECHNETIUM TC-99M TETROFOSMIN KIT
 MYOVIEW 30ML, TECHNETIUM TC-99M TETROFOSMIN KIT
 MYRBETRIQ, MIRABEGRON
 MYRBETRIQ GRANULES, MIRABEGRON
 MYSOLINE, PRIMIDONE
 MYTESI, CROFELEMER
 MYZILRA, ETHINYL ESTRADIOL

**** N ****

NABUMETONE, NABUMETONE

APPENDIX A - PRODUCT NAME INDEX**** N ****

NADOLOL, NADOLOL
 NAFICILLIN SODIUM, NAFICILLIN SODIUM
 NAFTIFINE HYDROCHLORIDE, NAFTIFINE HYDROCHLORIDE
 NAFTIN, NAFTIFINE HYDROCHLORIDE
 NALBUPHINE HYDROCHLORIDE, NALBUPHINE HYDROCHLORIDE
 NALFON, FENOPROFEN CALCIUM
 NALLPEN IN PLASTIC CONTAINER, NAFICILLIN SODIUM
 NALMEFENE HYDROCHLORIDE, NALMEFENE HYDROCHLORIDE
 NALOXONE, NALOXONE HYDROCHLORIDE
 NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
 NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
 NALTREXONE HYDROCHLORIDE, NALTREXONE HYDROCHLORIDE
 NAMENDA, MEMANTINE HYDROCHLORIDE
 NAMENDA XR, MEMANTINE HYDROCHLORIDE
 NAMZARIC, DONEPEZIL HYDROCHLORIDE
 NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE, NAPHAZOLINE HYDROCHLORIDE (OTC)
 NAPHCN-A, NAPHAZOLINE HYDROCHLORIDE (OTC)
 NAPRELAN, NAPROXEN SODIUM
 NAPROSYN, NAPROXEN
 NAPROXEN, NAPROXEN
 NAPROXEN AND ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
 NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
 NAPROXEN SODIUM, NAPROXEN SODIUM
 NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
 NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE, NAPROXEN SODIUM (OTC)
 NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE
 NARCAN, NALOXONE HYDROCHLORIDE
 NARDIL, PHENELZINE SULFATE
 NAROPIN, ROPIVACAINE HYDROCHLORIDE
 NASACORT ALLERGY 24 HOUR, TRIAMCINOLONE ACETONIDE (OTC)
 NASCOBAL, CYANOCOBALAMIN
 NASONEX 24HR ALLERGY, MOMETASONE FUROATE (OTC)
 NATACYN, NATAMYCIN
 NATAZIA, DIENOGEST
 NATEGLINIDE, NATEGLINIDE
 NATESTO, TESTOSTERONE
 NATROBA, SPINOSAD
 NAYZILAM, MIDAZOLAM
 NEBIVOLOL HYDROCHLORIDE, NEBIVOLOL HYDROCHLORIDE
 NEBUPENT, PENTAMIDINE ISETHIONATE
 NEFAZODONE HYDROCHLORIDE, NEFAZODONE HYDROCHLORIDE
 NELARABINE, NELARABINE
 NEMBUTAL SODIUM, PENTOBARBITAL SODIUM
 NEO-SYNALAR, FLUOCINOLONE ACETONIDE
 NEOMYCIN AND POLYMYXIN B SULFATE, NEOMYCIN SULFATE
 NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC, BACITRACIN ZINC
 NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE, DEXAMETHASONE
 NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN, GRAMICIDIN
 NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE, HYDROCORTISONE
 NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE, BACITRACIN ZINC
 NEOMYCIN SULFATE, NEOMYCIN SULFATE
 NEOPROFEN, IBUPROFEN LYSINE
 NEORAL, CYCLOSPORINE
 NEOSPORIN, GRAMICIDIN
 NEOSPORIN G.U. IRRIGANT, NEOMYCIN SULFATE
 NEOSTIGMINE METHYLSULFATE, NEOSTIGMINE METHYLSULFATE
 NEOSTIGMINE METHYLSULFATE, NEOSTIGMINE METHYLSULFATE
 NEPHROSCAN, TECHNETIUM TC-99M SUCCIMER
 NERLYNX, NERATINIB MALEATE
 NESACAINA, CHLOROPROCAINE HYDROCHLORIDE
 NESACAINA-MPF, CHLOROPROCAINE HYDROCHLORIDE
 NESINA, ALOGLIPTIN BENZOATE
 NETSPOT, GALLIUM DOTATATE GA-68
 NEUPRO, ROTIGOTINE
 NEURACEQ, FLORBETABEN F-18

APPENDIX A - PRODUCT NAME INDEX**** N ****

NEUROLITE, TECHNETIUM TC-99M BICISATE KIT
 NEURONTIN, GABAPENTIN
 NEVANAC, NEPAFENAC
 NEVIRAPINE, NEVIRAPINE
 NEXAVAR, SORAFENIB TOSYLATE
 NEXESTA FE, ETHINYL ESTRADIOL
 NEXICLON XR, CLONIDINE
 NEXIUM, ESOMEPRAZOLE MAGNESIUM
 NEXIUM 24HR, ESOMEPRAZOLE MAGNESIUM (OTC)
 NEXIUM IV, ESOMEPRAZOLE SODIUM
 NEXLETOL, BEMPEDOIC ACID
 NEXLIZET, BEMPEDOIC ACID
 NEXPLANON, ETNOGESTREL
 NEXTERONE, AMIODARONE HYDROCHLORIDE
 NEXTSTELLIS, DROSPIRENONE
 NIACIN, NIACIN
 NIACOR, NIACIN
 NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE
 NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE, NICARDIPINE HYDROCHLORIDE
 NICODERM CQ, NICOTINE (OTC)
 NICORETTE, NICOTINE POLACRILEX (OTC)
 NICORETTE (MINT), NICOTINE POLACRILEX (OTC)
 NICOTINE, NICOTINE (OTC)
 NICOTINE POLACRILEX, NICOTINE POLACRILEX (OTC)
 NICOTROL, NICOTINE
 NIFEDIPINE, NIFEDIPINE
 NIKKI, DROSPIRENONE
 NILANDRON, NILUTAMIDE
 NILUTAMIDE, NILUTAMIDE
 NIMBEX, CISATRACURIUM BESYLATE
 NIMBEX PRESERVATIVE FREE, CISATRACURIUM BESYLATE
 NIMODIPINE, NIMODIPINE
 NINLARO, IXAZOMIB CITRATE
 NIPENT, PENTOSTATIN
 NIPRIDE RTU IN SODIUM CHLORIDE 0.9%, SODIUM NITROPRUSSIDE
 NISOLDIPINE, NISOLDIPINE
 NITAZOXANIDE, NITAZOXANIDE
 NITHIODOTE, SODIUM NITRITE
 NITISINONE, NITISINONE
 NITRO-DUR, NITROGLYCERIN
 NITROFURANTOIN, NITROFURANTOIN
 NITROFURANTOIN, NITROFURANTOIN, MACROCRYSTALLINE
 NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS), NITROFURANTOIN
 NITROGLYCERIN, NITROGLYCERIN
 NITROGLYCERIN IN DEXTROSE 5%, NITROGLYCERIN
 NITROLINGUAL PUMPSPRAY, NITROGLYCERIN
 NITROMIST, NITROGLYCERIN
 NITROSTAT, NITROGLYCERIN
 NITYR, NITISINONE
 NIX, PERMETHRIN (OTC)
 NIZATIDINE, NIZATIDINE
 NIZORAL ANTI-DANDRUFF, KETOCONAZOLE (OTC)
 NOCDURNA, DESMOPRESSIN ACETATE
 NOR-QD, NORETHINDRONE
 NOREPINEPHRINE BITARTRATE, NOREPINEPHRINE BITARTRATE
 NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE, NOREPINEPHRINE BITARTRATE
 NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE, NOREPINEPHRINE BITARTRATE
 NORETHINDRONE, NORETHINDRONE
 NORETHINDRONE ACETATE, NORETHINDRONE ACETATE
 NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
 NORETHINDRONE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 NORETHINDRONE AND ETHINYL ESTRADIOL (10/11), ETHINYL ESTRADIOL
 NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
 NORGESTIMATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL

APPENDIX A - PRODUCT NAME INDEX**** N ****

NORITATE, METRONIDAZOLE
 NORLIQVA, AMLODIPINE BESYLATE
 NORMOCARB HF 25, MAGNESIUM CHLORIDE
 NORMOCARB HF 35, MAGNESIUM CHLORIDE
 NORMOSOL-M AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
 NORMOSOL-R AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
 NORMOSOL-R IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
 NORPACE, DISOPYRAMIDE PHOSPHATE
 NORPACE CR, DISOPYRAMIDE PHOSPHATE
 NORPRAMIN, DESIPRAMINE HYDROCHLORIDE
 NORTHERA, DROXIDOPA
 NORTREL 0.5/35-28, ETHINYL ESTRADIOL
 NORTREL 1/35-21, ETHINYL ESTRADIOL
 NORTREL 1/35-28, ETHINYL ESTRADIOL
 NORTREL 7/7/7, ETHINYL ESTRADIOL
 NORTRIPTYLINE HYDROCHLORIDE, NORTRIPTYLINE HYDROCHLORIDE
 NORVASC, AMLODIPINE BESYLATE
 NORVIR, RITONAVIR
 NOURIANZ, ISTRADefYLLINE
 NOXAFIL, POSACONAZOLE
 NOXAFIL POWDERMIX KIT, POSACONAZOLE
 NOXIVENT, NITRIC OXIDE
 NUBEQA, DAROLUTAMIDE
 NUCYNТА, TAPENTADOL HYDROCHLORIDE
 NUCYNТА ER, TAPENTADOL HYDROCHLORIDE
 NUEDEXTA, DEXTROMETHORPHAN HYDROBROMIDE
 NULIBRY, FOSDENOPTERIN HYDROBROMIDE
 NULYTELY, POLYETHYLENE GLYCOL 3350
 NULYTELY-FLAVORED, POLYETHYLENE GLYCOL 3350
 NUMBRINO, COCAINE HYDROCHLORIDE
 NUPLAZID, PIMAVANSERIN TARTRATE
 NURTEC ODT, RIMEGEPANT SULFATE
 NUTRILIPID 10%, SOYBEAN OIL
 NUTRILIPID 20%, SOYBEAN OIL
 NUVARING, ETHINYL ESTRADIOL
 NUVESSA, METRONIDAZOLE
 NUVIGIL, ARMODAFINIL
 NUZYRA, OMADACYCLINE TOSYLATE
 NYLIA 1/35, ETHINYL ESTRADIOL
 NYLIA 7/7/7, ETHINYL ESTRADIOL
 NYMALIZE, NIMODIPINE
 NYSTATIN, NYSTATIN
 NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
 NYSTOP, NYSTATIN

**** O ****

OCALIVA, OBETICHOLIC ACID
 OCTREOSCAN, INDIUM IN-111 PENTETREOTIDE KIT
 OCTREOTIDE ACETATE, OCTREOTIDE ACETATE
 OCTREOTIDE ACETATE (PRESERVATIVE FREE), OCTREOTIDE ACETATE
 OCUFLOX, OFLOXACIN
 ODEFSEY, EMTRICITABINE
 ODOMZO, SONIDEGIB PHOSPHATE
 OFEV, NINTEDANIB ESYLATE
 OFLOXACIN, OFLOXACIN
 OGEN 5, ESTROPIRATE
 OLANZAPINE, OLANZAPINE
 OLANZAPINE AND FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 OLINVYK, OLICERIDINE
 OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
 OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE, AMLODIPINE BESYLATE
 OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE (OTC)
 OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE
 OLPRUVA, SODIUM PHENYLBUTYRATE

APPENDIX A - PRODUCT NAME INDEX**** 0 ****

OLUMIANT, BARICITINIB
OLUX, CLOBETASOL PROPIONATE
OLUX E, CLOBETASOL PROPIONATE
OMEGA-3-ACID ETHYL ESTERS, OMEGA-3-ACID ETHYL ESTERS
OMEGAVEN, FISH OIL TRIGLYCERIDES
OMEPRazole, OMEPRazole (OTC)
OMEPRazole, OMEPRazole
OMEPRazole AND SODIUM BICARBONATE, OMEPRazole (OTC)
OMEPRazole AND SODIUM BICARBONATE, OMEPRazole
OMEPRazole MAGNESIUM, OMEPRazole MAGNESIUM (OTC)
OMIDRIA, KETOROLAC TROMETHAMINE
OMLONTI, OMIDENEPAG ISOPROPYL
OMNARIS, CICLESONIDE
OMNIPAQUE 12, IOHEXOL
OMNIPAQUE 140, IOHEXOL
OMNIPAQUE 180, IOHEXOL
OMNIPAQUE 240, IOHEXOL
OMNIPAQUE 300, IOHEXOL
OMNIPAQUE 350, IOHEXOL
OMNIPAQUE 9, IOHEXOL
OMNIPRED, PREDNISOLONE ACETATE
OMNISCAN, GADODIAMIDE
ONDANSETRON, ONDANSETRON
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
ONEXTON, BENZOYL PEROXIDE
ONFI, CLOBAZAM
ONGENTYS, OPICAPONE
ONGLYZA, SAXAGLIPTIN HYDROCHLORIDE
ONIVYDE, IRINOTECAN HYDROCHLORIDE
ONPATTRO, PATISIRAN SODIUM
ONSURA, ETHINYL ESTRADIOL
ONUREG, AZACITIDINE
ONZETRA XSAIL, SUMATRIPTAN SUCCINATE
OPCON ONE-STEP, LEVONORGESTREL (OTC)
OPCON-A, NAPHAZOLINE HYDROCHLORIDE (OTC)
OPSUMIT, MACITENTAN
OPTIRAY 300, IOVERSOL
OPTIRAY 320, IOVERSOL
OPTIRAY 350, IOVERSOL
OPTISON, ALBUMIN HUMAN
OPZELURA, RUXOLITINIB PHOSPHATE
ORABLOC, ARTICAIN HYDROCHLORIDE
ORACEA, DOXYCYCLINE
ORAPRED ODT, PREDNISOLONE SODIUM PHOSPHATE
ORAQIX, LIDOCAINE
ORAVVERSE, PHENTOLAMINE MESYLATE
ORAVIG, MICONAZOLE
ORBACTIV, ORITAVANCIN DIPHOSPHATE
ORENITRAM, TREPROSTINIL DIOLAMINE
ORFADIN, NITISINONE
ORGOVYX, RELUGOLIX
ORIAHNN (COPACKAGED), ELAGOLIX SODIUM, ESTRADIOL, NORETHINDRONE ACETATE
ORILISSA, ELAGOLIX SODIUM
ORKAMBI, IVACAFTOR
ORLADEYO, BEROTRALSTAT HYDROCHLORIDE
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
ORPHENGESIC, ASPIRIN
ORPHENGESIC FORTE, ASPIRIN
ORTIKOS, BUDESONIDE
ORVATEN, MIDODRINE HYDROCHLORIDE
OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
OSEN, ALOGLIPTIN BENZOATE
OSMITROL 10% IN WATER, MANNITOL
OSMITROL 10% IN WATER IN PLASTIC CONTAINER, MANNITOL

APPENDIX A - PRODUCT NAME INDEX**** O ****

OSMITROL 15% IN WATER, MANNITOL
 OSMITROL 15% IN WATER IN PLASTIC CONTAINER, MANNITOL
 OSMITROL 20% IN WATER, MANNITOL
 OSMITROL 20% IN WATER IN PLASTIC CONTAINER, MANNITOL
 OSMITROL 5% IN WATER, MANNITOL
 OSMITROL 5% IN WATER IN PLASTIC CONTAINER, MANNITOL
 OSMOLEX ER, AMANTADINE HYDROCHLORIDE
 OSMOPREP, SODIUM PHOSPHATE, DIBASIC, ANHYDROUS
 OSPHENA, OSPEMIFENE
 OTEZLA, APREMILAST
 OTICAIR, HYDROCORTISONE
 OTIPRIO, CIPROFLOXACIN
 OTOVEL, CIPROFLOXACIN HYDROCHLORIDE
 OTREXUP, METHOTREXATE
 OXACILLIN SODIUM, OXACILLIN SODIUM
 OXALIPLATIN, OXALIPLATIN
 OXANDROLONE, OXANDROLONE
 OXAPROZIN, OXAPROZIN
 OXAYDO, OXYCODONE HYDROCHLORIDE
 OXAZEPAM, OXAZEPAM
 OXBRYTA, VOXELTOR
 OXCARBAZEPINE, OXCARBAZEPINE
 OXICONAZOLE NITRATE, OXICONAZOLE NITRATE
 OXISTAT, OXICONAZOLE NITRATE
 OXLUMO, LUMASIRAN SODIUM
 OXSORALEN-ULTRA, METHOXSALEN
 OXTELLAR XR, OXCARBAZEPINE
 OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
 OXYCET, ACETAMINOPHEN
 OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
 OXYCODONE AND ASPIRIN, ASPIRIN
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
 OXYCONTIN, OXYCODONE HYDROCHLORIDE
 OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE
 OXYTOCIN, OXYTOCIN
 OXYTROL, OXYBUTYNIN
 OXYTROL FOR WOMEN, OXYBUTYNIN (OTC)
 OZEMPIC, SEMAGLUTIDE
 OZOBAX, BACLOFEN
 OZURDEX, DEXAMETHASONE

**** P ****

PACERONE, AMIODARONE HYDROCHLORIDE
 PACLITAXEL, PACLITAXEL
 PALIPERIDONE, PALIPERIDONE
 PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE
 PAMELOR, NORTRIPTYLINE HYDROCHLORIDE
 PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
 PANCURONIUM BROMIDE, PANCURONIUM BROMIDE
 PANDEL, HYDROCORTISONE PROBUTATE
 PANRETIN, ALITRETINOIN
 PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
 PARAGARD T 380A, COPPER
 PAREMYD, HYDROXYAMPHETAMINE HYDROBROMIDE
 PARICALCITOL, PARICALCITOL
 PARLODEL, BROMOCRIPTINE MESYLATE
 PARNATE, TRANYLCPROMINE SULFATE
 PAROMOMYCIN SULFATE, PAROMOMYCIN SULFATE
 PAROXETINE, PAROXETINE HYDROCHLORIDE
 PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
 PAROXETINE MESYLATE, PAROXETINE MESYLATE
 PARSABIV, ETELCALCETIDE
 PASER, AMINOSALICYLIC ACID
 PATADAY ONCE DAILY RELIEF, OLOPATADINE HYDROCHLORIDE (OTC)
 PATADAY TWICE DAILY RELIEF, OLOPATADINE HYDROCHLORIDE (OTC)

APPENDIX A - PRODUCT NAME INDEX**** P ****

PATANASE, OLOPATADINE HYDROCHLORIDE
PAXIL, PAROXETINE HYDROCHLORIDE
PAXIL CR, PAROXETINE HYDROCHLORIDE
PEDIAPRED, PREDNISOLONE SODIUM PHOSPHATE
PEDMARK, SODIUM THIOSULFATE
PEG 3350 AND ELECTROLYTES, POLYETHYLENE GLYCOL 3350
PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE, POLYETHYLENE GLYCOL
PEG-3350, SODIUM SULFATE, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM ASCORBATE AND
PEMAZYRE, PEMIGATINIB
PEMETREXED, PEMETREXED
PEMETREXED DISODIUM, PEMETREXED DISODIUM
PEMETREXED DITROMETHAMINE, PEMETREXED DITROMETHAMINE
PEMFEXY, PEMETREXED
PENCICLOVIR, PENCICLOVIR
PENICILLAMINE, PENICILLAMINE
PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM
PENICILLIN G POTASSIUM IN PLASTIC CONTAINER, PENICILLIN G POTASSIUM
PENICILLIN G PROCAINE, PENICILLIN G PROCAINE
PENICILLIN G SODIUM, PENICILLIN G SODIUM
PENICILLIN V POTASSIUM, PENICILLIN V POTASSIUM
PENICILLIN-VK, PENICILLIN V POTASSIUM
PENLAC, CICLOPIROX
PENNSAID, DICLOFENAC SODIUM
PENTAM, PENTAMIDINE ISETHIONATE
PENTAMIDINE ISETHIONATE, PENTAMIDINE ISETHIONATE
PENTASA, MESALAMINE
PENTOBARBITAL SODIUM, PENTOBARBITAL SODIUM
PENTOLAIR, CYCLOPENTOLATE HYDROCHLORIDE
PENTOSTATIN, PENTOSTATIN
PENTOXIFYLLINE, PENTOXIFYLLINE
PEPCID AC, FAMOTIDINE (OTC)
PEPCID COMPLETE, CALCIUM CARBONATE (OTC)
PERCOCET, ACETAMINOPHEN
PERCODAN, ASPIRIN
PERFOROMIST, FORMOTEROL FUMARATE
PERIDEX, CHLORHEXIDINE GLUCONATE
PERIKABIVEN IN PLASTIC CONTAINER, AMINO ACIDS
PERINDOPRIL ERBUMINE, PERINDOPRIL ERBUMINE
PERIOGARD, CHLORHEXIDINE GLUCONATE
PERMETHRIN, PERMETHRIN (OTC)
PERMETHRIN, PERMETHRIN
PERPHENAZINE, PERPHENAZINE
PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
PERSANTINE, DIPYRIDAMOLE
PERSERIS KIT, RISPERIDONE
PEXEVA, PAROXETINE MESYLATE
PFIZERPEN, PENICILLIN G POTASSIUM
PHEBURANE, SODIUM PHENYLBUTYRATE
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
PHENELZINE SULFATE, PHENELZINE SULFATE
PHENOXYBENZAMINE HYDROCHLORIDE, PHENOXYBENZAMINE HYDROCHLORIDE
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
PHENTOLAMINE MESYLATE, PHENTOLAMINE MESYLATE
PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
PHENYTEK, PHENYTOIN SODIUM
PHENYTOIN, PHENYTOIN
PHENYTOIN SODIUM, PHENYTOIN SODIUM
PHEXXI, CITRIC ACID
PHILITH, ETHINYL ESTRADIOL
PHOSLO GELCAPS, CALCIUM ACETATE
PHOSLYRA, CALCIUM ACETATE
PHOSPHOLINE IODIDE, ECHOTHIOPHATE IODIDE
PHOTOFRIN, PORFIMER SODIUM
PHOTREXA, RIBOFLAVIN 5'-PHOSPHATE SODIUM

APPENDIX A - PRODUCT NAME INDEX**** P ****

PHOTREXA VISCOUS IN DEXTRAN 20%, RIBOFLAVIN 5'-PHOSPHATE SODIUM
 PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 PHYSIOLYTE IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
 PHYSIOSOL IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
 PHYTONADIONE, PHYTONADIONE
 PIFELTRO, DORAVIRINE
 PILOCARPINE HYDROCHLORIDE, PILOCARPINE HYDROCHLORIDE
 PIMECROLIMUS, PIMECROLIMUS
 PIMOZIDE, PIMOZIDE
 PIMTREA, DESOGESTREL
 PINDOLOL, PINDOLOL
 PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
 PIOGLITAZONE HYDROCHLORIDE AND GLIMEPIRIDE, GLIMEPIRIDE
 PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 PIPERACILLIN, PIPERACILLIN SODIUM
 PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM
 PIQRAY, ALPELISIB
 PIRFENIDONE, PIRFENIDONE
 PIRMELLA 1/35, ETHINYL ESTRADIOL
 PIRMELLA 7/7/7, ETHINYL ESTRADIOL
 PIROXICAM, PIROXICAM
 PITAVASTATIN CALCIUM, PITAVASTATIN CALCIUM
 PITOCIN, OXYTOCIN
 PLAN B ONE-STEP, LEVONORGESTREL (OTC)
 PLAQUENIL, HYDROXYCHLOROQUINE SULFATE
 PLASMA-LYTE 148 IN WATER IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
 PLASMA-LYTE A IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
 PLAVIX, CLOPIDOGREL BISULFATE
 PLEGISOL IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 PLENVU, ASCORBIC ACID
 PLIAGLIS, LIDOCAINE
 PLUVICTO, LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN
 PODOFILOX, PODOFILOX
 POLMON, DEXCHLORPHENIRAMINE MALEATE
 POLOCAINE, MEPIVACAINE HYDROCHLORIDE
 POLOCAINE-MPF, MEPIVACAINE HYDROCHLORIDE
 POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
 POLYETHYLENE GLYCOL 3350 AND ELECTROLYTES, POLYETHYLENE GLYCOL 3350
 POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
 POLYTRIM, POLYMYXIN B SULFATE
 POMALYST, POMALIDOMIDE
 PONSTEL, MEFENAMIC ACID
 PONVORY, PONESIMOD
 PORTIA-28, ETHINYL ESTRADIOL
 POSACONAZOLE, POSACONAZOLE
 POSIMIR, BUPIVACAINE
 POTASSIUM ACETATE, POTASSIUM ACETATE
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
 POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.075% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,

**** P ****

[illegible]

APPENDIX A - PRODUCT NAME INDEX**** P ****

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 40MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CITRATE, POTASSIUM CITRATE
POTASSIUM IODIDE, POTASSIUM IODIDE (OTC)
POTASSIUM PHOSPHATES, POTASSIUM PHOSPHATE, DIBASIC
POVIDONE IODINE, POVIDONE-IODINE (OTC)
PRADAXA, DABIGATRAN ETEXILATE MESYLATE
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
PRAMOSONE, HYDROCORTISONE ACETATE
PRASUGREL, PRASUGREL HYDROCHLORIDE
PRASUGREL HYDROCHLORIDE, PRASUGREL
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
PRAZQUANTEL, PRAZQUANTEL
PRAZOSIN HYDROCHLORIDE, PRAZOSIN HYDROCHLORIDE
PRE-OP, HEXACHLOROPHENE
PRE-OP II, HEXACHLOROPHENE
PRECEDEX, DEXMEDETOMIDINE HYDROCHLORIDE
PRED FORTE, PREDNISOLONE ACETATE
PRED MILD, PREDNISOLONE ACETATE
PRED-G, GENTAMICIN SULFATE
PREDNICARBATE, PREDNICARBATE
PREDNISOLONE, PREDNISOLONE
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
PREDNISON, PREDNISON
PREDNISON INTENSOL, PREDNISON
PREGABALIN, PREGABALIN
PRELONE, PREDNISOLONE
PREMARIN, ESTROGENS, CONJUGATED
PREMASOL 10% IN PLASTIC CONTAINER, AMINO ACIDS
PREMASOL 6% IN PLASTIC CONTAINER, AMINO ACIDS
PREMPHASE 14/14, ESTROGENS, CONJUGATED
PREMPRO, ESTROGENS, CONJUGATED
PREPIDIL, DINOPROSTONE
PRESTALIA, AMLODIPINE BESYLATE
PRETOMANID, PRETOMANID
PREVACID, LANSOPRAZOLE
PREVACID 24 HR, LANSOPRAZOLE (OTC)
PREVALITE, CHOLESTYRAMINE
PREVANTICS MAXI SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)
PREVANTICS SWAB, CHLORHEXIDINE GLUCONATE (OTC)
PREVANTICS SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)
PREVIFEM, ETHINYL ESTRADIOL
PREVYMIS, LETERMIVIR
PREZCOBIX, COBICISTAT
PREZISTA, DARUNAVIR
PRIALT, ZICONOTIDE ACETATE
PRIFTIN, RIFAPENTINE
PRILOCAINE HYDROCHLORIDE, PRILOCAINE HYDROCHLORIDE
PRILOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE, EPINEPHRINE BITARTRATE
PRILOSEC, OMEPRAZOLE MAGNESIUM
PRILOSEC OTC, OMEPRAZOLE MAGNESIUM (OTC)
PRIMAQUINE, PRIMAQUINE PHOSPHATE
PRIMAQUINE PHOSPHATE, PRIMAQUINE PHOSPHATE
PRIMATENE MIST, EPINEPHRINE (OTC)
PRIMAXIN, CILASTATIN SODIUM
PRIMIDONE, PRIMIDONE
PRISMASOL B22GK 4/0 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BGK 0/2.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BGK 2/0 IN PLASTIC CONTAINER, CALCIUM CHLORIDE

APPENDIX A - PRODUCT NAME INDEX**** P ****

PRISMASOL BGK 2/3.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BGK 4/0/1.2 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BGK 4/2.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BK 0/0/1.2 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISTIQ, DESVENLAFAXINE SUCCINATE
PROAIR DIGIHALER, ALBUTEROL SULFATE
PROAIR HFA, ALBUTEROL SULFATE
PROAIR RESPICLICK, ALBUTEROL SULFATE
PROBALAN, PROBENECID
PROBENECID, PROBENECID
PROBENECID AND COLCHICINE, COLCHICINE
PROCAINAMIDE HYDROCHLORIDE, PROCAINAMIDE HYDROCHLORIDE
PROCALAMINE, AMINO ACIDS
PROCARDIA, NIFEDIPINE
PROCARDIA XL, NIFEDIPINE
PROCHLORPERAZINE, PROCHLORPERAZINE
PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE
PROCHLORPERAZINE MALEATE, PROCHLORPERAZINE MALEATE
PROCOMP, PROCHLORPERAZINE MALEATE
PROCTOFOAM HC, HYDROCORTISONE ACETATE
PROCYSBI, CYSTEAMINE BITARTRATE
PROGESTERONE, PROGESTERONE
PROGLYCEM, DIAZOXIDE
PROGRAF, TACROLIMUS
PROHANCE, GADOTERIDOL
PROHANCE MULTIPACK, GADOTERIDOL
PROLENSA, BROMFENAC SODIUM
PROMACTA, ELTROMBOPAG OLAMINE
PROMACTA KIT, ELTROMBOPAG OLAMINE
PROMETH HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE, CODEINE PHOSPHATE
PROMETHAZINE DM, DEXTROMETHORPHAN HYDROBROMIDE
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE, CODEINE PHOSPHATE
PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE, DEXTROMETHORPHAN
PROMETHAZINE HYDROCHLORIDE AND PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE, CODEINE
PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE, CODEINE
PROMETHAZINE PLAIN, PROMETHAZINE HYDROCHLORIDE
PROMETHAZINE W/ DEXTROMETHORPHAN, DEXTROMETHORPHAN HYDROBROMIDE
PROMETHAZINE WITH CODEINE, CODEINE PHOSPHATE
PROMETHEGAN, PROMETHAZINE HYDROCHLORIDE
PROMETRIUM, PROGESTERONE
PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
PROPARACAINE HYDROCHLORIDE, PROPARACAINE HYDROCHLORIDE
PROPECIA, FINASTERIDE
PROPOFOL, PROPOFOL
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
PROPYLTHIOURACIL, PROPYLTHIOURACIL
PROSCAR, FINASTERIDE
PROSOL 20% SULFITE FREE IN PLASTIC CONTAINER, AMINO ACIDS
PROSTIN VR PEDIATRIC, ALPROSTADIL
PROTAMINE SULFATE, PROTAMINE SULFATE
PROTONIX, PANTOPRAZOLE SODIUM
PROTONIX IV, PANTOPRAZOLE SODIUM
PROTOPAM CHLORIDE, PRALIDOXIME CHLORIDE
PROTOPIC, TACROLIMUS
PROTRIPTYLINE HYDROCHLORIDE, PROTRIPTYLINE HYDROCHLORIDE
PROVAYBLUE, METHYLENE BLUE
PROVENTIL-HFA, ALBUTEROL SULFATE
PROVERA, MEDROXYPROGESTERONE ACETATE
PROVIGIL, MODAFINIL
PROVOCHOLINE, METHACHOLINE CHLORIDE
PROZAC, FLUOXETINE HYDROCHLORIDE
PSEUDOEPHEDRINE HYDROCHLORIDE, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
PULMICORT FLEXHALER, BUDESONIDE

APPENDIX A - PRODUCT NAME INDEX**** P ****

PULMICORT RESPULES, BUDESONIDE
 PUR-WASH, PURIFIED WATER (OTC)
 PURIFIED CORTROPHIN GEL, CORTICOTROPIN
 PURINETHOL, MERCAPTOPURINE
 PURIXAN, MERCAPTOPURINE
 PYLARIFY, PIFLUFOLASTAT F-18
 PYLERA, BISMUTH SUBCITRATE POTASSIUM
 PYRAZINAMIDE, PYRAZINAMIDE
 PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE
 PYRIDOXINE HYDROCHLORIDE, PYRIDOXINE HYDROCHLORIDE
 PYRIMETHAMINE, PYRIMETHAMINE
 PYRUKYND, MITAPIVAT SULFATE
 PYTEST, UREA, C-14
 PYTEST KIT, UREA, C-14

**** Q ****

QBRELIS, LISINOPRIL
 QBREXZA, GLYCOPYRRONIUM TOSYLATE
 QDOLO, TRAMADOL HYDROCHLORIDE
 QELBREE, VILOXAZINE HYDROCHLORIDE
 QINLOCK, RIPRETINIB
 QNASL, BECLOMETHASONE DIPROPIONATE
 QOLIANA, BRIMONIDINE TARTRATE
 QSYMIA, PHENTERMINE HYDROCHLORIDE
 QTERN, DAPAGLIFLOZIN
 QUALAQUIN, QUININE SULFATE
 QUARTETTE, ETHINYL ESTRADIOL
 QUASENSE, ETHINYL ESTRADIOL
 QUDEXY XR, TOPIRAMATE
 QUELICIN, SUCCINYLCHOLINE CHLORIDE
 QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
 QUILLICHEW ER, METHYLPHENIDATE HYDROCHLORIDE
 QUILLIVANT XR, METHYLPHENIDATE HYDROCHLORIDE
 QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE
 QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 QUINIDINE GLUCONATE, QUINIDINE GLUCONATE
 QUINIDINE SULFATE, QUINIDINE SULFATE
 QUININE SULFATE, QUININE SULFATE
 QULIPTA, ATOGEPANT
 QUTENZA, CAPSAICIN
 QUVIVIQ, DARIDOREXANT HYDROCHLORIDE
 QUZYTIR, CETIRIZINE HYDROCHLORIDE
 QVAR REDHALER, BECLOMETHASONE DIPROPIONATE

**** R ****

R-GENE 10, ARGININE HYDROCHLORIDE
 RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM
 RADICAVA, EDARAVONE
 RADICAVA ORS, EDARAVONE
 RADIOGARDASE (PRUSSIAN BLUE), FERRIC HEXACYANOFERRATE(II)
 RADIOGENIX SYSTEM, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR
 RALOXIFENE HYDROCHLORIDE, RALOXIFENE HYDROCHLORIDE
 RAMELTEON, RAMELTEON
 RAMIPRIL, RAMIPRIL
 RANEXA, RANOLAZINE
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
 RANOLAZINE, RANOLAZINE
 RAPAFLO, SILODOSIN
 RAPAMUNE, SIROLIMUS
 RAPIVAB, PERAMIVIR
 RASAGILINE MESYLATE, RASAGILINE MESYLATE
 RASUVO, METHOTREXATE
 RAVICTI, GLYCEROL PHENYLBUTYRATE
 RAYALDEE, CALCIFEDIOL

APPENDIX A - PRODUCT NAME INDEX**** R ****

RAYOS, PREDNISONE
RAZADYNE ER, GALANTAMINE HYDROBROMIDE
READI-CAT 2, BARIUM SULFATE
READI-CAT 2 SMOOTHIE, BARIUM SULFATE
READYPREP CHG, CHLORHEXIDINE GLUCONATE (OTC)
RECARBRIO, CILASTATIN SODIUM
RECLAST, ZOLEDRONIC ACID
RECORLEV, LEVOKETOCONAZOLE
RECTIV, NITROGLYCERIN
REDITREX, METHOTREXATE
REGADENOSON, REGADENOSON
REGLAN, METOCLOPRAMIDE HYDROCHLORIDE
REGONOL, PYRIDOSTIGMINE BROMIDE
RELENZA, ZANAMIVIR
RELEXXII, METHYLPHENIDATE HYDROCHLORIDE
RELISTOR, METHYLNALTREXONE BROMIDE
RELPAK, ELETRIPTAN HYDROBROMIDE
RELYVRIO, SODIUM PHENYLBUTYRATE
REMERON, MIRTAZAPINE
REMERON SOLTAB, MIRTAZAPINE
REMIFENTANIL HYDROCHLORIDE, REMIFENTANIL HYDROCHLORIDE
REMODULIN, TREPROSTINIL
RENACIDIN, CITRIC ACID
RENAGEL, SEVELAMER HYDROCHLORIDE
RENOVA, TRETINOIN
RENVELA, SEVELAMER CARBONATE
REPAGLINIDE, REPAGLINIDE
RESTASIS, CYCLOSPORINE
RESTASIS MULTIDOSE, CYCLOSPORINE
RESTORIL, TEMAZEPAM
RETEVMO, SELPERCATINIB
RETIN-A, TRETINOIN
RETIN-A MICRO, TRETINOIN
RETIN-A-MICRO, TRETINOIN
RETISERT, FLUOCINOLONE ACETONIDE
RETROVIR, ZIDOVUDINE
REVATIO, SILDENAFIL CITRATE
REVLIMID, LENALIDOMIDE
REVONTO, DANTROLENE SODIUM
REXULTI, BREXPIRAZOLE
REYATAZ, ATAZANAVIR SULFATE
REYVOW, LASMIDITAN SUCCINATE
REZIPRES, EPHEDRINE HYDROCHLORIDE
REZLIDHIA, OLUTASIDENIB
REZUROCK, BELUMOSUDIL MESYLATE
RHINOCORT ALLERGY, BUDESONIDE (OTC)
RHOFAD, OXYMETAZOLINE HYDROCHLORIDE
RHOPRESSA, NETARSUDIL MESYLATE
RHUZDAH, ETHINYL ESTRADIOL
RIBAVIRIN, RIBAVIRIN
RIDAURA, AURANOFIN
RIFABUTIN, RIFABUTIN
RIFADIN, RIFAMPIN
RIFAMPIN, RIFAMPIN
RILUTEK, RILUZOLE
RILUZOLE, RILUZOLE
RIMACTANE, RIFAMPIN
RIMANTADINE HYDROCHLORIDE, RIMANTADINE HYDROCHLORIDE
RIMSO-50, DIMETHYL SULFOXIDE
RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
RINVOQ, UPADACITINIB
RIOCIGUAT, RIOCIQUAT
RISEDRONATE SODIUM, RISEDRONATE SODIUM
RISPERDAL, RISPERIDONE
RISPERDAL CONSTA, RISPERIDONE

APPENDIX A - PRODUCT NAME INDEX**** R ****

RISPERIDONE, RISPERIDONE
RITALIN, METHYLPHENIDATE HYDROCHLORIDE
RITALIN LA, METHYLPHENIDATE HYDROCHLORIDE
RITONAVIR, RITONAVIR
RIVASTIGMINE, RIVASTIGMINE
RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
ROBAXIN, METHOCARBAMOL
ROBINUL, GLYCOPYRROLATE
ROBINUL FORTE, GLYCOPYRROLATE
ROCALTROL, CALCITRIOL
ROCKLATAN, LATANOPROST
ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
ROFLUMILAST, ROFLUMILAST
ROGAINE (FOR MEN), MINOXIDIL (OTC)
ROGAINE (FOR WOMEN), MINOXIDIL (OTC)
ROGAINE EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
ROMIDEPSIN, ROMIDEPSIN
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
ROPIVACAINE HYDROCHLORIDE, ROPIVACAINE HYDROCHLORIDE
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
ROWASA, MESALAMINE
ROXICODONE, OXYCODONE HYDROCHLORIDE
ROXYBOND, OXYCODONE HYDROCHLORIDE
ROZEREM, RAMELTEON
ROZLYTREK, ENTRECTINIB
RUBRACA, RUCAPARIB CAMSYLATE
RUBY-FILL, RUBIDIUM CHLORIDE RB-82
RUFINAMIDE, RUFINAMIDE
RUKOBIA, FOSTEMSAVIR TROMETHAMINE
RYALTRIS, MOMETASONE FUROATE
RYANODEX, DANTROLENE SODIUM
RYBELSUS, SEMAGLUTIDE
RYDAPT, MIDOSTAURIN
RYTARY, CARBIDOPA
RYTHMOL SR, PROPAFENONE HYDROCHLORIDE

**** S ****

SABRIL, VIGABATRIN
SAFYRAL, DROSPIRENONE
SALAGEN, PILOCARPINE HYDROCHLORIDE
SALONPAS, MENTHOL (OTC)
SAMSCA, TOLVAPTAN
SANCUSO, GRANISETRON
SANDIMMUNE, CYCLOSPORINE
SANDOSTATIN, OCTREOTIDE ACETATE
SANDOSTATIN LAR, OCTREOTIDE ACETATE
SAPHRIS, ASENAPINE MALEATE
SAPROPTERIN DIHYDROCHLORIDE, SAPROPTERIN DIHYDROCHLORIDE
SAVAYSA, EDOXABAN TOSYLATE
SAVELLA, MILNACIPRAN HYDROCHLORIDE
SAXENDA, LIRAGLUTIDE RECOMBINANT
SCANDONEST L, LEVONORDEFIN
SCANDONEST PLAIN, MEPIVACAINE HYDROCHLORIDE
SCEMBLIX, ASCIMINIB HYDROCHLORIDE
SCENESSE, AFAMELANOTIDE
SCLEROSOL, TALC
SCOPOLAMINE, SCOPOLAMINE
SEASONALE, ETHINYL ESTRADIOL
SEASONIQUE, ETHINYL ESTRADIOL
SECUADO, ASENAPINE
SEGLENTIS, CELECOXIB
SEGLUROMET, ERTUGLIFLOZIN
SEIZALAM, MIDAZOLAM HYDROCHLORIDE
SELEGILINE HYDROCHLORIDE, SELEGILINE HYDROCHLORIDE

APPENDIX A - PRODUCT NAME INDEX**** S ****

SELENIOS ACID, SELENIOS ACID
 SELENIUM SULFIDE, SELENIUM SULFIDE
 SELEXIPAG, SELEXIPAG
 SELZENTRY, MARAVIROC
 SENSIPAR, CINACALCET HYDROCHLORIDE
 SENSORCAINE, BUPIVACAINE HYDROCHLORIDE
 SEPTOCAINE, ARTICAINE HYDROCHLORIDE
 SEPTRA, SULFAMETHOXAZOLE
 SEPTRA DS, SULFAMETHOXAZOLE
 SEREVENT, SALMETEROL XINAFOATE
 SERNIVO, BETAMETHASONE DIPROPIONATE
 SEROMYCIN, CYCLOSERINE
 SEROQUEL, QUETIAPINE FUMARATE
 SEROQUEL XR, QUETIAPINE FUMARATE
 SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
 SETLAKIN, ETHINYL ESTRADIOL
 SEVELAMER CARBONATE, SEVELAMER CARBONATE
 SEVELAMER HYDROCHLORIDE, SEVELAMER HYDROCHLORIDE
 SEVOFLURANE, SEVOFLURANE
 SEYSARA, SARECYCLINE HYDROCHLORIDE
 SEZABY, PHENOBARBITAL SODIUM
 SFROWASA, MESALAMINE
 SIGNIFOR, PASIREOTIDE DIASPARTATE
 SIGNIFOR LAR KIT, PASIREOTIDE PAMOATE
 SIKLOS, HYDROXYUREA
 SILDENAFIL CITRATE, SILDENAFIL CITRATE
 SILENOR, DOXEPIN HYDROCHLORIDE
 SILODOSIN, SILODOSIN
 SILVADENE, SILVER SULFADIAZINE
 SIMBRINZA, BRIMONIDINE TARTRATE
 SIMLIYA, DESOGESTREL
 SIMPESE, ETHINYL ESTRADIOL
 SIMVASTATIN, SIMVASTATIN
 SINCALIDE, SINCALIDE
 SINE-AID IB, IBUPROFEN (OTC)
 SINEMET, CARBIDOPA
 SINGULAIR, MONTELUKAST SODIUM
 SINUVA, MOMETASONE FUROATE
 SIROLIMUS, SIROLIMUS
 SIRTURO, BEDAQUILINE FUMARATE
 SITAVIG, ACYCLOVIR
 SIVEXTRO, TEDIZOLID PHOSPHATE
 SKELAXIN, METAXALONE
 SKLICE, IVERMECTIN (OTC)
 SKYLA, LEVONORGESTREL
 SLYND, DROSPIRENONE
 SMOFLIPID 20%, FISH OIL
 SOAANZ, TORSEMIDE
 SODIUM ACETATE, SODIUM ACETATE
 SODIUM BICARBONATE, SODIUM BICARBONATE
 SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, SODIUM CHLORIDE
 SODIUM CHLORIDE 0.9%, SODIUM CHLORIDE
 SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
 SODIUM CHLORIDE 0.9% IN STERILE PLASTIC CONTAINER, SODIUM CHLORIDE
 SODIUM CHLORIDE 14.6%, SODIUM CHLORIDE
 SODIUM CHLORIDE 23.4%, SODIUM CHLORIDE
 SODIUM CHLORIDE 3% IN PLASTIC CONTAINER, SODIUM CHLORIDE
 SODIUM CHLORIDE 5% IN PLASTIC CONTAINER, SODIUM CHLORIDE
 SODIUM FERRIC GLUCONATE COMPLEX IN SUCROSE, FERRIC OXYHYDROXIDE
 SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18
 SODIUM IODIDE I 123, SODIUM IODIDE I-123
 SODIUM IODIDE I 131, SODIUM IODIDE I-131
 SODIUM NITRITE, SODIUM NITRITE
 SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE
 SODIUM PHENYLACETATE AND SODIUM BENZOATE, SODIUM BENZOATE

APPENDIX A - PRODUCT NAME INDEX**** S ****

SODIUM PHENYLBUTYRATE, SODIUM PHENYLBUTYRATE
SODIUM PHOSPHATES, SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE
SODIUM PHOSPHATES IN PLASTIC CONTAINER, SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE
SODIUM PICOSULFATE, MAGNESIUM OXIDE AND ANHYDROUS CITRIC ACID, CITRIC ACID
SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE
SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE, MAGNESIUM SULFATE
SODIUM TETRADECYL SULFATE, SODIUM TETRADECYL SULFATE
SODIUM THIOSULFATE, SODIUM THIOSULFATE
SOJOURN, SEVOFLURANE
SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE
SOLODYN, MINOCYCLINE HYDROCHLORIDE
SOLOSEC, SECNIDAZOLE
SOLTAMOX, TAMOXIFEN CITRATE
SOLU-CORTEF, HYDROCORTISONE SODIUM SUCCINATE
SOLU-MEDROL, METHYLPREDNISOLONE SODIUM SUCCINATE
SOLUPREP, CHLORHEXIDINE GLUCONATE (OTC)
SOMA, CARISOPRODOL
SOMATULINE DEPOT, LANREOTIDE ACETATE
SONATA, ZALEPLON
SOOLANTRA, IVERMECTIN
SORAFENIB TOSYLATE, SORAFENIB TOSYLATE
SORBITOL 3% IN PLASTIC CONTAINER, SORBITOL
SORBITOL 3.3% IN PLASTIC CONTAINER, SORBITOL
SORBITOL-MANNITOL IN PLASTIC CONTAINER, MANNITOL
SORILUX, CALCIPOTRIENE
SORINE, SOTALOL HYDROCHLORIDE
SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE
SOTRADECOL, SODIUM TETRADECYL SULFATE
SOTYKTU, DEUCRAVACITINIB
SOTYLIZE, SOTALOL HYDROCHLORIDE
SOVALDI, SOFOSBUVIR
SPINRAZA, NUSINERSEN SODIUM
SPIRIVA, TIOTROPIUM BROMIDE
SPIRIVA RESPIMAT, TIOTROPIUM BROMIDE
SPIRONOLACTONE, SPIRONOLACTONE
SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
SPORANOX, ITRACONAZOLE
SPRAVATO, ESKETAMINE HYDROCHLORIDE
SPRINTEC, ETHINYL ESTRADIOL
SPRITAM, LEVETIRACETAM
SPRIX, KETOROLAC TROMETHAMINE
SPRYCEL, DASATINIB
SPS, SODIUM POLYSTYRENE SULFONATE
SPY AGENT GREEN KIT, INDOCYANINE GREEN
SSD, SILVER SULFADIAZINE
STALEVO 100, CARBIDOPA
STALEVO 125, CARBIDOPA
STALEVO 150, CARBIDOPA
STALEVO 200, CARBIDOPA
STALEVO 50, CARBIDOPA
STALEVO 75, CARBIDOPA
STEGLATRO, ERTUGLIFLOZIN
STEGLUJAN, ERTUGLIFLOZIN
STENDRA, AVANAFIL
STERILE WATER, STERILE WATER FOR IRRIGATION
STERILE WATER FOR INJECTION, STERILE WATER FOR INJECTION
STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION
STERILE WATER IN PLASTIC CONTAINER, STERILE WATER FOR IRRIGATION
STERITALC, TALC
STIE-CORT, HYDROCORTISONE
STIOLTO RESPIMAT, OLODATEROL HYDROCHLORIDE
STIVARGA, REGORAFENIB
STRATTERA, ATOMOXETINE HYDROCHLORIDE
STREPTOMYCIN SULFATE, STREPTOMYCIN SULFATE
STRIBILD, COBICISTAT

APPENDIX A - PRODUCT NAME INDEX**** S ****

STRIVERDI RESPIMAT, OLODATEROL HYDROCHLORIDE
 STROMEKTOL, IVERMECTIN
 STRONTIUM CHLORIDE SR-89, STRONTIUM CHLORIDE SR-89
 SUBLIMAZE PRESERVATIVE FREE, FENTANYL CITRATE
 SUBLOCADE, BUPRENORPHINE
 SUBOXONE, BUPRENORPHINE HYDROCHLORIDE
 SUCCINYLCHOLINE CHLORIDE, SUCCINYLCHOLINE CHLORIDE
 SUCRALFATE, SUCRALFATE
 SUDAFED 24 HOUR, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
 SUFENTA PRESERVATIVE FREE, SUFENTANIL CITRATE
 SUFENTANIL CITRATE, SUFENTANIL CITRATE
 SULAR, NISOLDIPINE
 SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM
 SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
 SULFADIAZINE, SULFADIAZINE
 SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
 SULFAMYLON, MAFENIDE ACETATE
 SULFASALAZINE, SULFASALAZINE
 SULFATRIM PEDIATRIC, SULFAMETHOXAZOLE
 SULINDAC, SULINDAC
 SUMATRIPTAN, SUMATRIPTAN
 SUMATRIPTAN AND NAPROXEN SODIUM, NAPROXEN SODIUM
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
 SUNITINIB MALATE, SUNITINIB MALATE
 SUNLENCA, LENACAPAVIR SODIUM
 SUNOSI, SOLRIAMFETOL HYDROCHLORIDE
 SUPPRELIN LA, HISTRELIN ACETATE
 SUPRANE, DESFLURANE
 SUPRAX, CEFIXIME
 SUPREP BOWEL PREP KIT, MAGNESIUM SULFATE
 SUSTIVA, EFAVIRENZ
 SUSTOL, GRANISETRON
 SUTAB, MAGNESIUM SULFATE
 SUTENT, SUNITINIB MALATE
 SYEDA, DROSPIRENONE
 SYMBICORT, BUDESONIDE
 SYMBYAX, FLUOXETINE HYDROCHLORIDE
 SYMDEKO (COPACKAGED), IVACAFTOR
 SYMFI, EFAVIRENZ
 SYMFI LO, EFAVIRENZ
 SYMJEPI, EPINEPHRINE
 SYMLIN, PRAMLintide ACETATE
 SYMPAZAN, CLOBAZAM
 SYMPROIC, NALDEMEDINE TOSYLATE
 SYMTUZA, COBICISTAT
 SYNALAR, FLUOCINOLONE ACETONIDE
 SYNAREL, NAFARELIN ACETATE
 SYNDROS, DRONABINOL
 SYNERCID, DALFOPRISTIN
 SYNJARDY, EMPAGLIFLOZIN
 SYNJARDY XR, EMPAGLIFLOZIN
 SYNTRIBO, OMACETAXINE MEPESUCCINATE
 SYNTHROID, LEVOTHYROXINE SODIUM **
 SYPRINE, TRIENTINE HYDROCHLORIDE

**** T ****

TABRECTA, CAPMATINIB HYDROCHLORIDE
 TACLONEX, BETAMETHASONE DIPROPIONATE
 TACROLIMUS, TACROLIMUS
 TADALAFIL, TADALAFIL
 TADLIQ, TADALAFIL
 TAFINLAR, DABRAFENIB MESYLATE
 TAFLUPROST, TAFLUPROST
 TAGAMET HB, CIMETIDINE (OTC)
 TAGITOL V, BARIUM SULFATE

APPENDIX A - PRODUCT NAME INDEX**** T ****

TAGRISSO, OSIMERTINIB MESYLATE
TALC, TALC
TALICIA, AMOXICILLIN
TALZENNA, TALAZOPARIB TOSYLATE
TAMIFLU, OSELTAMIVIR PHOSPHATE
TAMOXIFEN CITRATE, TAMOXIFEN CITRATE
TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
TARCEVA, ERLOTINIB HYDROCHLORIDE
TARGRETIN, BEXAROTENE
TARPEYO, BUDESONIDE
TASCENSO ODT, FINGOLIMOD LAURYL SULFATE
TASIGNA, NILOTINIB HYDROCHLORIDE
TASIMELTEON, TASIMELTEON
TASMAR, TOLCAPONE
TAUVID, FLORTAUCIPIR F-18
TAVABOROLE, TAVABOROLE
TAVALISSE, FOSTAMATINIB DISODIUM
TAVNEOS, AVACOPAN
TAXOTERE, DOCETAXEL
TAYTULLA, ETHINYL ESTRADIOL
TAZAROTENE, TAZAROTENE
TAZICEF, CEFTAZIDIME
TAZORAC, TAZAROTENE
TAZTIA XT, DILTIAZEM HYDROCHLORIDE
TAZVERIK, TAZEMETOSTAT HYDROBROMIDE
TECFIDERA, DIMETHYL FUMARATE
TECHNELITE, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR
TECHNESCAN, TECHNETIUM TC-99M OXIDRONATE KIT
TECHNESCAN MAG3, TECHNETIUM TC-99M MERTIATIDE KIT
TECHNESCAN PYP KIT, TECHNETIUM TC-99M PYROPHOSPHATE KIT
TECHNETIUM TC 99M SESTAMIBI, TECHNETIUM TC-99M SESTAMIBI KIT
TECHNETIUM TC-99M MEBROFENIN, TECHNETIUM TC-99M MEBROFENIN KIT
TECHNETIUM TC-99M MEDRONATE KIT, TECHNETIUM TC-99M MEDRONATE KIT
TECHNETIUM TC99M MERTIATIDE KIT, TECHNETIUM TC-99M MERTIATIDE KIT
TEFLARO, CEFTAROLINE FOSAMIL
TEGRETOL, CARBAMAZEPINE
TEGRETOL-XR, CARBAMAZEPINE
TEGSEDI, INOTERSEN SODIUM
TEKTRNA, ALISKIREN HEMIFUMARATE
TELMISARTAN, TELMISARTAN
TELMISARTAN AND AMLODIPINE, AMLODIPINE BESYLATE
TELMISARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TEMAZEPAM, TEMAZEPAM
TEMBEXA, BRINCIDOFIVIR
TEMODAR, TEMOZOLOMIDE
TEMOZOLOMIDE, TEMOZOLOMIDE
TEMSIROLIMUS, TEMSIROLIMUS
TENOFIVIR DISOPROXIL FUMARATE, TENOFIVIR DISOPROXIL FUMARATE
TENORETIC 100, ATENOLOL
TENORETIC 50, ATENOLOL
TENORMIN, ATENOLOL
TEPADINA, THIOTEPA
TEPMETKO, TEPOTINIB HYDROCHLORIDE
TERAZOSIN HYDROCHLORIDE, TERAZOSIN HYDROCHLORIDE
TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE (OTC)
TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
TERBUTALINE SULFATE, TERBUTALINE SULFATE
TERCONAZOLE, TERCONAZOLE
TERIFLUNOMIDE, TERIFLUNOMIDE
TERIL, CARBAMAZEPINE
TERLIVAZ, TERLIPRESSIN ACETATE
TESSALON, BENZONATATE
TESTIM, TESTOSTERONE
TESTOPEL, TESTOSTERONE
TESTOSTERONE, TESTOSTERONE

APPENDIX A - PRODUCT NAME INDEX**** T ****

TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
 TESTOSTERONE ENANTHATE, TESTOSTERONE ENANTHATE
 TETRABENAZINE, TETRABENAZINE
 TETRACAINE HYDROCHLORIDE, TETRACAINE HYDROCHLORIDE
 TETRACYCLINE HYDROCHLORIDE, TETRACYCLINE HYDROCHLORIDE
 TEXACORT, HYDROCORTISONE
 THALITONE, CHLORTHALIDONE
 THALLOUS CHLORIDE TL 201, THALLOUS CHLORIDE TL-201
 THALOMID, THALIDOMIDE
 THAM, TROMETHAMINE
 THEO-24, THEOPHYLLINE
 THEOPHYLLINE, THEOPHYLLINE
 THEOPHYLLINE 0.04% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
 THEOPHYLLINE 0.08% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
 THEOPHYLLINE 0.16% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
 THEOPHYLLINE 0.32% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
 THERMAZENE, SILVER SULFADIAZINE
 THEROXIDIL, MINOXIDIL (OTC)
 THIAMINE HYDROCHLORIDE, THIAMINE HYDROCHLORIDE
 THIOGUANINE, THIOGUANINE
 THIOLA, TIOPRONIN
 THIOLA EC, TIOPRONIN
 THIORIDAZINE HYDROCHLORIDE, THIORIDAZINE HYDROCHLORIDE
 THIOTEPA, THIOTEPA
 THIOTHIXENE, THIOTHIXENE
 THYQUIDITY, LEVOTHYROXINE SODIUM
 THYRO-TABS, LEVOTHYROXINE SODIUM **
 THYROSAFE, POTASSIUM IODIDE (OTC)
 TIAGABINE HYDROCHLORIDE, TIAGABINE HYDROCHLORIDE
 TIAZAC, DILTIAZEM HYDROCHLORIDE
 TIBSOVO, IVOSIDENIB
 TICAGRELOR, TICAGRELOR
 TICLOPIDINE HYDROCHLORIDE, TICLOPIDINE HYDROCHLORIDE
 TIGAN, TRIMETHOBENZAMIDE HYDROCHLORIDE
 TIGECYCLINE, TIGECYCLINE
 TIGLUTIK KIT, RILUZOLE
 TIKOSYN, DOFETILIDE
 TIMOLOL, TIMOLOL
 TIMOLOL MALEATE, TIMOLOL MALEATE
 TIMOPTIC, TIMOLOL MALEATE
 TIMOPTIC IN OCUDOSE, TIMOLOL MALEATE
 TIMOPTIC-XE, TIMOLOL MALEATE
 TINDAMAX, TINIDAZOLE
 TINIDAZOLE, TINIDAZOLE
 TIOCONAZOLE, TIOCONAZOLE (OTC)
 TIOPRONIN, TIOPRONIN
 TIROFIBAN HYDROCHLORIDE, TIROFIBAN HYDROCHLORIDE
 TIROSINT, LEVOTHYROXINE SODIUM
 TIROSINT-SOL, LEVOTHYROXINE SODIUM
 TIS-U-SOL, MAGNESIUM SULFATE
 TIS-U-SOL IN PLASTIC CONTAINER, MAGNESIUM SULFATE
 TISSUEBLUE, BRILLIANT BLUE G
 TIVICAY, DOLUTEGRAVIR SODIUM
 TIVICAY PD, DOLUTEGRAVIR SODIUM
 TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
 TLANDO, TESTOSTERONE UNDECANOATE
 TOBI, TOBRAMYCIN
 TOBI PODHALER, TOBRAMYCIN
 TOBRADEX, DEXAMETHASONE
 TOBRADEX ST, DEXAMETHASONE
 TOBRAMYCIN, TOBRAMYCIN
 TOBRAMYCIN AND DEXAMETHASONE, DEXAMETHASONE
 TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
 TOBRAMYCIN SULFATE (PHARMACY BULK), TOBRAMYCIN SULFATE
 TOBRAMYCIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, TOBRAMYCIN SULFATE

APPENDIX A - PRODUCT NAME INDEX**** T ****

TOBREX, TOBRAMYCIN
TOFRANIL, IMIPRAMINE HYDROCHLORIDE
TOLAK, FLUOROURACIL
TOLCAPONE, TOLCAPONE
TOLSURA, ITRACONAZOLE
TOLTERODINE TARTRATE, TOLTERODINE TARTRATE
TOLVAPTAN, TOLVAPTAN
TOPAMAX, TOPIRAMATE
TOPICORT, DESOXIMETASONE
TOPIRAMATE, TOPIRAMATE
TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
TOPROL-XL, METOPROLOL SUCCINATE
TOREMIFENE CITRATE, TOREMIFENE CITRATE
TORISEL, TEMSIROLIMUS
TORSEMIDE, TORSEMIDE
TOSYMRA, SUMATRIPTAN
TOVIAZ, FESOTERODINE FUMARATE
TPN ELECTROLYTES IN PLASTIC CONTAINER, CALCIUM CHLORIDE
TPOXX, TECOVIRIMAT
TRACLEER, BOSENTAN
TRADJENTA, LINAGLIPTIN
TRALEMENT, CUPRIC SULFATE
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
TRANDATE, LABETALOL HYDROCHLORIDE
TRANDOLAPRIL, TRANDOLAPRIL
TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE, TRANDOLAPRIL
TRANEXAMIC ACID, TRANEXAMIC ACID
TRANSERM SCOP, SCOPOLAMINE
TRANXENE, CLORAZEPATE DIPOTASSIUM
TRANLYCYPROMINE SULFATE, TRANLYCYPROMINE SULFATE
TRAVASOL 10% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 5.5% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 8.5% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVATAN Z, TRAVOPROST
TRAVOPROST, TRAVOPROST
TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
TREANDA, BENDAMUSTINE HYDROCHLORIDE
TRECATOR, ETHIONAMIDE
TREGGY ELLIPTA, FLUTICASONE FUROATE
TRELSTAR, TRIPTORELIN PAMOATE
TREPROSTINIL, TREPROSTINIL
TRETINOIN, TRETINOIN
Trexall, METHOTREXATE SODIUM
Treximet, NAPROXEN SODIUM
Trezix, ACETAMINOPHEN
TRI LO SPRINTEC, ETHINYL ESTRADIOL
TRI-ESTARYLLA, ETHINYL ESTRADIOL
TRI-LEGEST 21, ETHINYL ESTRADIOL
TRI-LEGEST FE, ETHINYL ESTRADIOL
TRI-LINYAH, ETHINYL ESTRADIOL
TRI-LO-ESTARYLLA, ETHINYL ESTRADIOL
TRI-LO-LINYAH, ETHINYL ESTRADIOL
TRI-LO-MILI, ETHINYL ESTRADIOL
TRI-LUMA, FLUOCINOLONE ACETONIDE
TRI-MILI, ETHINYL ESTRADIOL
TRI-NORINYL 28-DAY, ETHINYL ESTRADIOL
TRI-SPRINTEC, ETHINYL ESTRADIOL
TRIACIN-C, CODEINE PHOSPHATE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE (OTC)
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
TRIAMTERENE, TRIAMTERENE
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TRIANEX, TRIAMCINOLONE ACETONIDE
TRIAZOLAM, TRIAZOLAM

APPENDIX A - PRODUCT NAME INDEX**** T ****

TRIBENZOR, AMLODIPINE BESYLATE
 TRICOR, FENOFIBRATE
 TRIDERM, TRIAMCINOLONE ACETONIDE
 TRIENTINE HYDROCHLORIDE, TRIENTINE HYDROCHLORIDE
 TRISENCE, TRIAMCINOLONE ACETONIDE
 TRIFLUOPERAZINE HYDROCHLORIDE, TRIFLUOPERAZINE HYDROCHLORIDE
 TRIFLURIDINE, TRIFLURIDINE
 TRIGLIDE, FENOFIBRATE
 TRIHEXYPHENIDYL HYDROCHLORIDE, TRIHEXYPHENIDYL HYDROCHLORIDE
 TRIJARDY XR, EMPAGLIFLOZIN
 TRIKAFTA (COPACKAGED), ELEXACFTOR, IVACFTOR, TEZACFTOR
 TRILEPTAL, OXCARBAZEPINE
 TRILIPIX, CHOLINE FENOFIBRATE
 TRIMETHOBENZAMIDE HYDROCHLORIDE, TRIMETHOBENZAMIDE HYDROCHLORIDE
 TRIMETHOPRIM, TRIMETHOPRIM
 TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
 TRIMIPRAMINE MALEATE, TRIMIPRAMINE MALEATE
 TRINTELLIX, VORTIOXETINE HYDROBROMIDE
 TRIOSTAT, LIOTHYRONINE SODIUM
 TRIPTODUR KIT, TRIPTORELIN PAMOATE
 TRISENOX, ARSENIC TRIOXIDE
 TRIUMEQ, ABACAVIR SULFATE
 TRIUMEQ PD, ABACAVIR SULFATE
 TRIVAGIZOLE 3, CLOTRIMAZOLE (OTC)
 TRIVORA-28, ETHINYL ESTRADIOL
 TRIZIVIR, ABACAVIR SULFATE
 TROKENDI XR, TOPIRAMATE
 TROPHAMINE, AMINO ACIDS
 TROPHAMINE 10%, AMINO ACIDS
 TROPICACYL, TROPICAMIDE
 TROPICAMIDE, TROPICAMIDE
 TROSPIMUM CHLORIDE, TROSPIMUM CHLORIDE
 TRUDHESA, DIHYDROERGOTAMINE MESYLATE
 TRULANCE, PLECANATIDE
 TRUSELTIQ, INFIGRATINIB PHOSPHATE
 TRUVADA, EMTRICITABINE
 TUDORZA PRESSAIR, ACLIDINIUM BROMIDE
 TUKYSA, TUCATINIB
 TURALIO, PEXIDARTINIB HYDROCHLORIDE
 TUXARIN ER, CHLORPHENIRAMINE MALEATE
 TWIRLA, ETHINYL ESTRADIOL
 TWYNEO, BENZOYL PEROXIDE
 TYBLUME, ETHINYL ESTRADIOL
 TYBOST, COBICISTAT
 TYDEMY, DROSPIRENONE
 TYGACIL, TIGECYCLINE
 TYKERB, LAPATINIB DITOSYLATE
 TYLENOL, ACETAMINOPHEN (OTC)
 TYMLOS, ABALOPARATIDE
 TYRVAYA, VARENICLINE TARTRATE
 TYVASO, TREPROSTINIL
 TYVASO DPI, TREPROSTINIL
 TYZINE, TETRAHYDROZOLINE HYDROCHLORIDE

**** U ****

UBRELVY, UBROGEPANT
 UCERIS, BUDESONIDE
 ULORIC, FEBUXOSTAT
 ULTANE, SEVOFLURANE
 ULTIVA, REMIFENTANIL HYDROCHLORIDE
 ULTRA-TECHNEKOW FM, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR
 ULTRACET, ACETAMINOPHEN
 ULTRATAG, TECHNETIUM TC-99M RED BLOOD CELL KIT
 ULTRAVATE, HALOBETASOL PROPIONATE
 ULTRAVIST (PHARMACY BULK), IOPROMIDE

APPENDIX A - PRODUCT NAME INDEX**** U ****

ULTRAVIST 300, IOPROMIDE
ULTRAVIST 370, IOPROMIDE
UNASYN, AMPICILLIN SODIUM
UNISOM, DOXYLAMINE SUCCINATE (OTC)
UNITHROID, LEVOTHYROXINE SODIUM **
UPNEEQ, OXYMETAZOLINE HYDROCHLORIDE
UPTRAVI, SELEXIPAG
UREX, METHENAMINE HIPPURATE
UROCIT-K, POTASSIUM CITRATE
UROXATRAL, ALFUZOSIN HYDROCHLORIDE
URSO 250, URSODIOL
URSO FORTE, URSODIOL
URSODIOL, URSODIOL
UVADEX, METHOXSALEN

**** V ****

VABOMERE, MEROPENEM
VAGIFEM, ESTRADIOL
VAGISTAT-1, TIOCONAZOLE (OTC)
VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
VALCHLOR, MECHLORETHAMINE HYDROCHLORIDE
VALCYTE, VALGANCICLOVIR HYDROCHLORIDE
VALGANCICLOVIR HYDROCHLORIDE, VALGANCICLOVIR HYDROCHLORIDE
VALIUM, DIAZEPAM
VALNAC, BETAMETHASONE VALERATE
VALPROATE SODIUM, VALPROATE SODIUM
VALPROIC ACID, VALPROIC ACID
VALRUBICIN, VALRUBICIN
VALSARTAN, VALSARTAN
VALSARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
VALSTAR PRESERVATIVE FREE, VALRUBICIN
VALTOCO, DIAZEPAM
VALTREX, VALACYCLOVIR HYDROCHLORIDE
VANCOCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
VANCOCIN HYDROCHLORIDE IN PLASTIC CONTAINER, VANCOMYCIN HYDROCHLORIDE
VANCOMYCIN, VANCOMYCIN
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
VANCOMYCIN HYDROCHLORIDE IN PLASTIC CONTAINER, VANCOMYCIN HYDROCHLORIDE
VANDAZOLE, METRONIDAZOLE
VANOS, FLUOCINONIDE
VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER, CONIVAPTAN HYDROCHLORIDE
VARDENAFIL HYDROCHLORIDE, VARDENAFIL HYDROCHLORIDE
VARENICLINE TARTRATE, VARENICLINE TARTRATE
VARIBAR HONEY, BARIUM SULFATE
VARIBAR NECTAR, BARIUM SULFATE
VARIBAR PUDDING, BARIUM SULFATE
VARIBAR THIN HONEY, BARIUM SULFATE
VARIBAR THIN LIQUID, BARIUM SULFATE
VARITHENA, POLIDOCANOL
VARUBI, ROLAPITANT HYDROCHLORIDE
VASCEPA, ICOSAPENT ETHYL
VASERETIC, ENALAPRIL MALEATE
VASOPRESSIN, VASOPRESSIN
VASOSTRICT, VASOPRESSIN
VASOTEC, ENALAPRIL MALEATE
VAZALORE, ASPIRIN (OTC)
VAZCULEP, PHENYLEPHRINE HYDROCHLORIDE
VECTICAL, CALCITRIOL
VECURONIUM BROMIDE, VECURONIUM BROMIDE
VEKLURY, REMDESIVIR
VELCADE, BORTEZOMIB
VELETRI, EPOPROSTENOL SODIUM
VELIVET, DESOGESTREL
VELPHORO, FERRIC OXYHYDROXIDE
VELTASSA, PATIROMER SORBITE CALCIUM

APPENDIX A - PRODUCT NAME INDEX**** V ****

VELTIN, CLINDAMYCIN PHOSPHATE
VEMLIDY, TENOFOVIR ALAFENAMIDE FUMARATE
VENCLEXTA, VENETOCLAX
VENLAFAXINE BESYLATE, VENLAFAXINE BESYLATE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
VENOFER, FERRIC OXYHYDROXIDE
VENTAVIS, ILOPROST
VENTOLIN HFA, ALBUTEROL SULFATE
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE
VERDESO, DESONIDE
VEREGEN, SINECATECHINS
VERELAN, VERAPAMIL HYDROCHLORIDE
VERELAN PM, VERAPAMIL HYDROCHLORIDE
VERKAZIA, CYCLOSPORINE
VERQUVO, VERICIGUAT
VERSACLOZ, CLOZAPINE
VERZENIO, ABEMACICLIB
VESICARE, SOLIFENACIN SUCCINATE
VESICARE LS, SOLIFENACIN SUCCINATE
VFEND, VORICONAZOLE
VIAGRA, SILDENAFIL CITRATE
VIBATIV, TELAVANCIN HYDROCHLORIDE
VIBERZI, ELUXADOLINE
VIBISONE, CYANOCOBALAMIN
VIBRAMYCIN, DOXYCYCLINE
VIBRAMYCIN, DOXYCYCLINE CALCIUM
VIBRAMYCIN, DOXYCYCLINE HYCLATE
VICTOZA, LIRAGLUTIDE RECOMBINANT
VIDAZA, AZACITIDINE
VIENVA, ETHINYL ESTRADIOL
VIGABATRIN, VIGABATRIN
VIGADRONE, VIGABATRIN
VIGAMOX, MOXIFLOXACIN HYDROCHLORIDE
VIIBRYD, VILAZODONE HYDROCHLORIDE
VIJOICE, ALPELISIB
VILAZODONE HYDROCHLORIDE, VILAZODONE HYDROCHLORIDE
VILTEPSO, VILTOLARSEN
VIMOVO, ESOMEPRAZOLE MAGNESIUM
VIMPAT, LACOSAMIDE
VINBLASTINE SULFATE, VINBLASTINE SULFATE
VINCRISTINE SULFATE PFS, VINCRISTINE SULFATE
VINORELBINE TARTRATE, VINORELBINE TARTRATE
VIORELE, DESOGESTREL
VIRACEPT, NELFINAVIR MESYLATE
VIRAMUNE, NEVIRAPINE
VIRAMUNE XR, NEVIRAPINE
VIRAZOLE, RIBAVIRIN
VIREAD, TENOFOVIR DISOPROXIL FUMARATE
VIROPTIC, TRIFLURIDINE
VISINE, NAPHAZOLINE HYDROCHLORIDE (OTC)
VISINE L.R., OXYMETAZOLINE HYDROCHLORIDE (OTC)
VISIONBLUE, TRYPAN BLUE
VISIPAQUE 270, IODIXANOL
VISIPAQUE 320, IODIXANOL
VISTARIL, HYDROXYZINE PAMOATE
VISTOGARD, URIDINE TRIACETATE
VISUDYNE, VERTEPORFIN
VITAMIN D, ERGOCALCIFEROL
VITAMIN K1, PHYTONADIONE
VITRAKVI, LAROTRECTINIB SULFATE
VIVELLE-DOT, ESTRADIOL
VIVIMUSTA, BENDAMUSTINE HYDROCHLORIDE
VIVITROL, NALTREXONE
VIVJOA, OTESECONAZOLE
VIZAMYL, FLUTEMETAMOL F-18

APPENDIX A - PRODUCT NAME INDEX**** V ****

VIZIMPRO, DACOMITINIB
VOCABRIA, CABOTEGRAVIR SODIUM
VOGELXO, TESTOSTERONE
VOLNEA, DESOGESTREL
VOLTAREN ARTHRITIS PAIN, DICLOFENAC SODIUM (OTC)
VONJO, PACRITINIB CITRATE
VORICONAZOLE, VORICONAZOLE
VOSEVI, SOFOSBUVIR
VOSOL, ACETIC ACID, GLACIAL
VOSOL HC, ACETIC ACID, GLACIAL
VOTRIENT, PAZOPANIB HYDROCHLORIDE
VOXZOGO, VOSORITIDE
VRAYLAR, CARIPRAZINE HYDROCHLORIDE
VTAMA, TAPINAROF
VUITY, PILOCARPINE HYDROCHLORIDE
VUMERITY, DIROXIMEL FUMARATE
VUSION, MICONAZOLE NITRATE
VYDUO, NEBIVOLOL HYDROCHLORIDE
VYFEMLA, ETHINYL ESTRADIOL
VYLEESI (AUTOINJECTOR), BREMELANOTIDE ACETATE
VYNDAMAX, TAFAMIDIS
VYNDAQEL, TAFAMIDIS MEGLUMINE
VYONDYS 53, GOLODIRSEN
VYTORIN, EZETIMIBE
VYVANSE, LISDEXAMFETAMINE DIMESYLATE
VYXEOS, CYTARABINE
VYZULTA, LATANOPROSTENE BUNOD

**** W ****

WAKIX, PITOLISANT HYDROCHLORIDE
WARFARIN SODIUM, WARFARIN SODIUM
WEGOVY, SEMAGLUTIDE
WELCHOL, COLESEVELAM HYDROCHLORIDE
WELIREG, BELZUTIFAN
WELLBUTRIN SR, BUPROPION HYDROCHLORIDE
WELLBUTRIN XL, BUPROPION HYDROCHLORIDE
WERA, ETHINYL ESTRADIOL
WINLEVI, CLASCOTERONE
WIXELA INHUB, FLUTICASONE PROPIONATE
WOMEN'S ROGAINE, MINOXIDIL (OTC)
WYNZORA, BETAMETHASONE DIPROPIONATE

**** X ****

XACIATO, CLINDAMYCIN PHOSPHATE
XADAGO, SAFINAMIDE MESYLATE
XALATAN, LATANOPROST
XALKORI, CRIZOTINIB
XANAX, ALPRAZOLAM
XANAX XR, ALPRAZOLAM
XARACOLL, BUPIVACAINE HYDROCHLORIDE
XARELTO, RIVAROXABAN
XATMEP, METHOTREXATE SODIUM
XCOPRI, CENOBAMATE
XELJANZ, TOFACITINIB CITRATE
XELJANZ XR, TOFACITINIB CITRATE
XELODA, CAPECITABINE
XELPROS, LATANOPROST
XELSTRYM, DEXTROAMPHETAMINE
XENAZINE, TETRABENAZINE
XENICAL, ORLISTAT
XENLETA, LEFAMULIN ACETATE
XENON XE 133, XENON XE-133
XEPI, OZENOXACIN
XERAVA, ERAVACYCLINE DIHYDROCHLORIDE
XERESE, ACYCLOVIR

APPENDIX A - PRODUCT NAME INDEX**** X ****

XERMELO, TELOTRISTAT ETIPRATE
 XHANCE, FLUTICASONE PROPIONATE
 XIFAXAN, RIFAXIMIN
 XIGDUO XR, DAPAGLIFLOZIN
 XIIDRA, LIFITEGRAST
 XIMINO, MINOCYCLINE HYDROCHLORIDE
 XIPERE, TRIAMCINOLONE ACETONIDE
 XOFIGO, RADIUM RA-223 DICHLORIDE
 XOFLUZA, BALOXAVIR MARBOXIL
 XOPENEX, LEVALBUTEROL HYDROCHLORIDE
 XOPENEX HFA, LEVALBUTEROL TARTRATE
 XOSPATA, GILTERITINIB FUMARATE
 XPOVIO, SELINEXOR
 XTAMPZA ER, OXYCODONE
 XTANDI, ENZALUTAMIDE
 XULANE, ETHINYL ESTRADIOL
 XURIDEN, URIDINE TRIACETATE
 XYLOCAINE, LIDOCAINE HYDROCHLORIDE
 XYLOCAINE W/ EPINEPHRINE, EPINEPHRINE
 XYOSTED (AUTOINJECTOR), TESTOSTERONE ENANTHATE
 XYREM, SODIUM OXYBATE
 XYWAV, CALCIUM OXYBATE
 XYZAL ALLERGY 24HR, LEVOCETIRIZINE DIHYDROCHLORIDE (OTC)

**** Y ****

YAELA, DROSPIRENONE
 YASMIN, DROSPIRENONE
 YAZ, DROSPIRENONE
 YONDELIS, TRABECTEDIN
 YONSA, ABIRATERONE ACETATE
 YUPELRI, REVEFENACIN
 YUTIQ, FLUOCINOLONE ACETONIDE

**** Z ****

ZADITOR, KETOTIFEN FUMARATE (OTC)
 ZAFIRLUKAST, ZAFIRLUKAST
 ZALEPLON, ZALEPLON
 ZANAFLEX, TIZANIDINE HYDROCHLORIDE
 ZANOSAR, STREPTOZOCIN
 ZANTAC, RANITIDINE HYDROCHLORIDE
 ZARONTIN, ETHOSUXIMIDE
 ZAVESCA, MIGLUSTAT
 ZEGALOGUE, DASIGLUCAGON HYDROCHLORIDE
 ZEGALOGUE (AUTOINJECTOR), DASIGLUCAGON HYDROCHLORIDE
 ZEGERID, OMEPRAZOLE
 ZEGERID OTC, OMEPRAZOLE (OTC)
 ZEJULA, NIRAPARIB TOSYLATE
 ZELAPAR, SELEGILINE HYDROCHLORIDE
 ZELBORAF, VEMURAFENIB
 ZEMBRACE SYMTOUCH, SUMATRIPTAN SUCCINATE
 ZEMDRI, PLAZOMICIN SULFATE
 ZEMPLAR, PARICALCITOL
 ZENATANE, ISOTRETINOIN
 ZEPATIER, ELBASVIR
 ZEPOSIA, OZANIMOD HYDROCHLORIDE
 ZEPZELCA, LURBINECTEDIN
 ZERBAXA, CEFTOLOZANE SULFATE
 ZERVIAE, CETIRIZINE HYDROCHLORIDE
 ZESTORETIC, HYDROCHLOROTHIAZIDE
 ZESTRIL, LISINAPRIL
 ZETIA, EZETIMIBE
 ZETONNA, CICLESONIDE
 ZIAC, BISOPROLOL FUMARATE
 ZIAGEN, ABACAVIR SULFATE
 ZIANA, CLINDAMYCIN PHOSPHATE

APPENDIX A - PRODUCT NAME INDEX**** Z ****

ZIDOVUDINE, ZIDOVUDINE
ZILEUTON, ZILEUTON
ZILRETTA, TRIAMCINOLONE ACETONIDE
ZILXI, MINOCYCLINE HYDROCHLORIDE
ZIMHI, NALOXONE HYDROCHLORIDE
ZINACEF, CEFUROXIME SODIUM
ZINC CHLORIDE, ZINC CHLORIDE
ZINC CHLORIDE IN PLASTIC CONTAINER, ZINC CHLORIDE
ZINC SULFATE, ZINC SULFATE
ZINC SULFATE, ZINC SULFATE MONOHYDRATE
ZINGO, LIDOCAINE HYDROCHLORIDE
ZIOPTAN, TAFLUPROST
ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE
ZIPRASIDONE MESYLATE, ZIPRASIDONE MESYLATE
ZIPSOR, DICLOFENAC POTASSIUM
ZIRGAN, GANCICLOVIR
ZITHROMAX, AZITHROMYCIN
ZOCOR, SIMVASTATIN
ZOKINVY, LONAFARNIB
ZOLADAX, GOSERELIN ACETATE
ZOLEDRONIC, ZOLEDRONIC ACID
ZOLEDRONIC ACID, ZOLEDRONIC ACID
ZOLINZA, VORINOSTAT
ZOLMITRIPTAN, ZOLMITRIPTAN
ZOLOFT, SERTRALINE HYDROCHLORIDE
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE
ZOMETA, ZOLEDRONIC ACID
ZOMIG, ZOLMITRIPTAN
ZOMIG-ZMT, ZOLMITRIPTAN
ZONALON, DOXEPIN HYDROCHLORIDE
ZONEGRAN, ZONISAMIDE
ZONISADE, ZONISAMIDE
ZONISAMIDE, ZONISAMIDE
ZONTIVITY, VORAPAXAR SULFATE
ZORTRESS, EVEROLIMUS
ZORYVE, ROFLUMILAST
ZOSYN IN PLASTIC CONTAINER, PIPERACILLIN SODIUM
ZOVIA 1/50E-28, ETHINYL ESTRADIOL
ZOVIRAX, ACYCLOVIR
ZTALMY, GANAXOLONE
ZTLIDO, LIDOCAINE
ZUBSOLV, BUPRENORPHINE HYDROCHLORIDE
ZULRESSO, BREXANOLONE
ZUMANDIMINE, DROSPIRENONE
ZURAGARD, ISOPROPYL ALCOHOL (OTC)
ZYCLARA, IMIQUIMOD
ZYDELIG, IDELALISIB
ZYFLO, ZILEUTON
ZYFLO CR, ZILEUTON
ZYKADIA, CERITINIB
ZYLET, LOTEPREDNOL ETABONATE
ZYLOPRIM, ALLOPURINOL
ZYMAR, GATIFLOXACIN
ZYMAXID, GATIFLOXACIN
ZYNRELEF KIT, BUPIVACAINE
ZYPITAMAG, PITAVASTATIN MAGNESIUM
ZYPREXA, OLANZAPINE
ZYPREXA RELPREVV, OLANZAPINE PAMOATE
ZYPREXA ZYDIS, OLANZAPINE
ZYRTEC ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
ZYRTEC-D 12 HOUR, CETIRIZINE HYDROCHLORIDE (OTC)
ZYTIGA, ABIRATERONE ACETATE
ZYVOX, LINEZOLID

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** 3 ******3D IMAGING DRUG**

- * 3D IMAGING DRUG DESIGN AND DEVELOPMENT LLC
AMMONIA N 13, AMMONIA N-13
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

3M

- * 3M CO
PERIDEX, CHLORHEXIDINE GLUCONATE
- * 3M HEALTH CARE INC
AVAGARD, ALCOHOL (OTC)
DURAPREP, IODINE POVACRYLEX (OTC)

3M HEALTH CARE

- * 3M HEALTH CARE INFECTION PREVENTION DIV
SOLUPREP, CHLORHEXIDINE GLUCONATE (OTC)

**** 6 ******60 DEGREES PHARMS**

- * 60 DEGREES PHARMACEUTICALS INC
ARAKODA, TAFENOQUINE SUCCINATE

**** A ******AAA USA INC**

- * ADVANCED ACCELERATOR APPLICATIONS USA INC
LUTATHERA, LUTETIUM LU 177 DOTATATE
NETSPOT, GALLIUM DOTATATE GA-68

AAA USA NOVARTIS

- * ADVANCED ACCELERATOR APPLICATIONS USA INC A NOVARTIS CO
LOCAMETZ, GALLIUM GA-68 GOZETOTIDE
PLUVICTO, LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN

AACE PHARMS

- * AACE PHARMACEUTICALS INC
BUTALBITAL AND ACETAMINOPHEN, ACETAMINOPHEN
METOLAZONE, METOLAZONE

AADI

- * AADI BIOSCIENCE INC
FYARRO, SIROLIMUS

AAIPHARMA LLC

- * AAIPHARMA LLC
AZASAN, AZATHIOPRINE

ABBVIE

- * ABBVIE INC
ANDROGEL, TESTOSTERONE
CYCLOSPORINE, CYCLOSPORINE
DEPAKOTE ER, DIVALPROEX SODIUM
DEPAKOTE, DIVALPROEX SODIUM
GENGRAF, CYCLOSPORINE
K-TAB, POTASSIUM CHLORIDE
KALETRA, LOPINAVIR
NIMBEX PRESERVATIVE FREE, CISATRACURIUM BESYLATE
NIMBEX, CISATRACURIUM BESYLATE
NORVIR, RITONAVIR
SYNTHROID, LEVOTHYROXINE SODIUM **
TRICOR, FENOFIBRATE
TRILIPIX, CHOLINE FENOFIBRATE
ULTANE, SEVOFLURANE
ZEMPLAR, PARICALCITOL

ABBVIE ENDOCRINE INC

- * ABBVIE ENDOCRINE INC
LUPRON DEPOT, LEUPROLIDE ACETATE
LUPRON DEPOT-PED KIT, LEUPROLIDE ACETATE

ABBVIE INC

- * ABBVIE INC
DUOPA, CARBIDOPA
MAVYRET, GLECAPREVIR

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ****

* ABBVIE INC
 NORVIR, RITONAVIR
 ORIAHNN (COPACKAGED), ELAGOLIX SODIUM, ESTRADIOL, NORETHINDRONE ACETATE
 ORILISSA, ELAGOLIX SODIUM
 QULIPTA, ATOGEPANT
 RINVOQ, UPADACITINIB
 VENCLEXTA, VENETOCLAX
 VUITY, PILOCARPINE HYDROCHLORIDE

ABHAI INC

* ABHAI INC
 DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
 METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE

ABHAI LLC

* ABHAI LLC
 ATOVAQUONE, ATOVAQUONE
 BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
 DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
 HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
 HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE, HOMATROPINE METHYLBROMIDE
 LEFLUNOMIDE, LEFLUNOMIDE
 METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
 OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
 OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
 URSODIOL, URSODIOL

ABON PHARMS LLC

* ABON PHARMACEUTICALS LLC
 ATOVAQUONE, ATOVAQUONE
 CLOFARABINE, CLOFARABINE

ABRAXIS PHARM

* ABRAXIS PHARMACEUTICAL PRODUCTS
 CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%, CLINDAMYCIN PHOSPHATE

ACACIA

* ACACIA PHARMA LTD
 BARHEMSYS, AMISULPRIDE
 BYFAVO, REMIMAZOLAM BESYLATE

ACADIA PHARMS INC

* ACADIA PHARMACEUTICALS INC
 NUPLAZID, PIMAVANSERIN TARTRATE

ACCELRX LABS

* ACCELRX LABS LLC
 CARISOPRODOL, CARISOPRODOL

ACCORD

* ACCORD BIOPHARMA INC
 CAMCEVI KIT, LEUPROLIDE MESYLATE

ACCORD HLTHCARE

* ACCORD HEALTHCARE INC
 ACETAZOLAMIDE, ACETAZOLAMIDE
 ALLOPURINOL, ALLOPURINOL
 AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
 AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
 ANASTROZOLE, ANASTROZOLE
 APIXABAN, APIXABAN
 ARGATROBAN IN SODIUM CHLORIDE, ARGATROBAN
 ARIPIPRAZOLE, ARIPIPRAZOLE
 ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
 ATROPINE SULFATE, ATROPINE SULFATE
 AZACITIDINE, AZACITIDINE
 BENDAMUSTINE HYDROCHLORIDE, BENDAMUSTINE HYDROCHLORIDE
 BICALUTAMIDE, BICALUTAMIDE
 BIVALIRUDIN, BIVALIRUDIN
 BORTEZOMIB, BORTEZOMIB
 BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
 BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
 CABAZITAXEL, CABAZITAXEL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ****

* ACCORD HEALTHCARE INC
 CAPECITABINE, CAPECITABINE
 CARBIDOPA AND LEVODOPA, CARBIDOPA
 CARBOPLATIN, CARBOPLATIN
 CARMUSTINE, CARMUSTINE
 CINACALCET HYDROCHLORIDE, CINACALCET HYDROCHLORIDE
 CISPLATIN, CISPLATIN
 CLOBAZAM, CLOBAZAM
 CLOFARABINE, CLOFARABINE
 CLONAZEPAM, CLONAZEPAM
 CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
 CLOZAPINE, CLOZAPINE
 Carmustine, CARMUSTINE
 DALFAMPRIDINE, DALFAMPRIDINE
 DAPTOMYCIN, DAPTOMYCIN
 DECITABINE, DECITABINE
 DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
 DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
 DIMETHYL FUMARATE, DIMETHYL FUMARATE
 DOCETAXEL, DOCETAXEL
 DODEX, CYANOCOBALAMIN
 DOFETILIDE, DOFETILIDE
 DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
 EPLERENONE, EPLERENONE
 EPTIFIBATIDE, EPTIFIBATIDE
 ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
 ESOMEPRAZOLE SODIUM, ESOMEPRAZOLE SODIUM
 ETOPOSIDE, ETOPOSIDE
 EZETIMIBE, EZETIMIBE
 FESOTERODINE FUMARATE, FESOTERODINE FUMARATE
 FINASTERIDE, FINASTERIDE
 FINGOLIMOD HYDROCHLORIDE, FINGOLIMOD HYDROCHLORIDE
 FLUOROURACIL, FLUOROURACIL
 FOSAPREPITANT DIMEGLUMINE, FOSAPREPITANT DIMEGLUMINE
 FULVESTRANT, FULVESTRANT
 FUROSEMIDE, FUROSEMIDE
 GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
 GLIMEPIRIDE, GLIMEPIRIDE
 GLIPIZIDE, GLIPIZIDE
 GLYCOPYRROLATE, GLYCOPYRROLATE
 HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
 IBANDRONATE SODIUM, IBANDRONATE SODIUM
 IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
 ITRACONAZOLE, ITRACONAZOLE
 LACOSAMIDE, LACOSAMIDE
 LETROZOLE, LETROZOLE
 LEVETIRACETAM, LEVETIRACETAM
 LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM **
 LISINOPRIL, LISINOPRIL
 LURASIDONE HYDROCHLORIDE, LURASIDONE HYDROCHLORIDE
 METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM
 METHOTREXATE SODIUM, METHOTREXATE SODIUM
 METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
 METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
 MITOMYCIN, MITOMYCIN
 MONTELUKAST SODIUM, MONTELUKAST SODIUM
 MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
 MYCOPHENOLIC SODIUM, MYCOPHENOLIC SODIUM
 NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
 NALTREXONE HYDROCHLORIDE, NALTREXONE HYDROCHLORIDE
 OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
 ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ****

* ACCORD HEALTHCARE INC
OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
OXALIPLATIN, OXALIPLATIN
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
PACLITAXEL, PACLITAXEL
PARICALCITOL, PARICALCITOL
PEMETREXED DISODIUM, PEMETREXED DISODIUM
PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
PIRFENIDONE, PIRFENIDONE
PRASUGREL, PRASUGREL HYDROCHLORIDE
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
RAMIPRIL, RAMIPRIL
REGADENOSON, REGADENOSON
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
SIMVASTATIN, SIMVASTATIN
SPIRONOLACTONE, SPIRONOLACTONE
SUCCINYLCHOLINE CHLORIDE, SUCCINYLCHOLINE CHLORIDE
TACROLIMUS, TACROLIMUS
TADALAFIL, TADALAFIL
TEMOZOLOMIDE, TEMOZOLOMIDE
TEMSIROLIMUS, TEMSIROLIMUS
TERIFLUNOMIDE, TERIFLUNOMIDE
TOPIRAMATE, TOPIRAMATE
TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
VIGABATRIN, VIGABATRIN
VILAZODONE HYDROCHLORIDE, VILAZODONE HYDROCHLORIDE
ZOLEDRONIC ACID, ZOLEDRONIC ACID

ACCORD HLTHCARE INC

* ACCORD HEALTHCARE INC USA
BUSULFAN, BUSULFAN
TIGECYCLINE, TIGECYCLINE

ACELLA

* ACELLA PHARMACEUTICALS LLC
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
BENZONATATE, BENZONATATE
BETAXOLOL HYDROCHLORIDE, BETAXOLOL HYDROCHLORIDE
BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN
CICLOPIROX, CICLOPIROX
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DUTASTERIDE, DUTASTERIDE
NIFEDIPINE, NIFEDIPINE
PHENYTOIN SODIUM, PHENYTOIN SODIUM

ACELLA PHARMS LLC

* ACELLA PHARMACEUTICALS LLC
GABAPENTIN, GABAPENTIN

ACELRX PHARMS

* ACELRX PHARMACEUTICALS INC
DSUVIA, SUFENTANIL CITRATE

ACER

* ACER THERAPEUTICS INC
OLPRUVA, SODIUM PHENYLBUTYRATE

ACERUS

* ACERUS PHARMACEUTICALS CORP
NATESTO, TESTOSTERONE

ACI

* ACI HEALTHCARE LTD
AZITHROMYCIN, AZITHROMYCIN
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
GABAPENTIN, GABAPENTIN
LEVETIRACETAM, LEVETIRACETAM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ****

* ACI HEALTHCARE LTD
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE

ACIC PHARMS

* ACIC PHARMACEUTICALS INC
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
TRANEXAMIC ACID, TRANEXAMIC ACID
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE

ACORDA

* ACORDA THERAPEUTICS INC
AMPYRA, DALFAMPRIDINE
INBRIJA, LEVODOPA

ACROTECH BIOPHARMA

* ACROTECH BIOPHARMA INC
BELEODAQ, BELINOSTAT
EVOMELA, MELPHALAN HYDROCHLORIDE
FOLOTYN, PRALATREXATE
FUSILEV, LEVOLEUCOVORIN CALCIUM
KHAPZORY, LEVOLEUCOVORIN

ACS DOBFAR

* ACS DOBFAR SPA
AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
CEFAZOLIN SODIUM, CEFAZOLIN SODIUM
CEFEPIME HYDROCHLORIDE, CEFEPIME HYDROCHLORIDE
CEFOXITIN, CEFOTIXIN SODIUM
CEFTAZIDIME, CEFTAZIDIME
CEFTRIAXONE, CEFTRIAXONE SODIUM
IMIPENEM AND CILASTATIN, CILASTATIN SODIUM
MEROPENEM, MEROPENEM

ACS DOBFAR SPA

* ACS DOBFAR SPA
AMPICILLIN SODIUM, AMPICILLIN SODIUM
CEFUROXIME SODIUM, CEFUROXIME SODIUM
ERTAPENEM SODIUM, ERTAPENEM SODIUM
MEROPENEM, MEROPENEM
PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM

ACTAVIS ELIZABETH

* ACTAVIS ELIZABETH LLC
ALBENDAZOLE, ALBENDAZOLE
ALPRAZOLAM, ALPRAZOLAM
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
CARBIDOPA AND LEVODOPA, CARBIDOPA
CLONAZEPAM, CLONAZEPAM
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
DEFERASIROX, DEFERASIROX
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
DEXTROMETHORPHAN HYDROBROMIDE AND QUINIDINE SULFATE, DEXTROMETHORPHAN HYDROBROMIDE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
FENOFIBRIC ACID, CHOLINE FENOFIBRATE
FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
GABAPENTIN, GABAPENTIN
GLYBURIDE AND METFORMIN HYDROCHLORIDE, GLYBURIDE
GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
INDAPAMIDE, INDAPAMIDE
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
LAMOTRIGINE, LAMOTRIGINE
LOVASTATIN, LOVASTATIN
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ****

- * ACTAVIS ELIZABETH LLC
 - METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
 - NIFEDIPINE, NIFEDIPINE
 - OXAZEPAM, OXAZEPAM
 - OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
 - PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
 - PREGABALIN, PREGABALIN
 - PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
 - PROPYLTHIOURACIL, PROPYLTHIOURACIL
 - RANOLAZINE, RANOLAZINE
 - ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
 - TEMAZEPAM, TEMAZEPAM
 - TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
- * ACTAVIS ELIZABETH LLC AN INDIRECT WHOLLY OWNED SUB OF TEVA PHARMACEUTICALS USA INC
 - ALPRAZOLAM, ALPRAZOLAM
 - CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
 - MORPHINE SULFATE, MORPHINE SULFATE
 - PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE

ACTAVIS GROUP

- * ACTAVIS GROUP PTC EHF
 - HALOPERIDOL, HALOPERIDOL

ACTAVIS INC

- * ACTAVIS INC
 - DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
 - DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE

ACTAVIS LABS

- * ACTAVIS LABORATORIES INC AN INDIRECT WHOLLY OWNED SUB OF TEVA PHARMACEUTICALS USA INC
 - PERMETHRIN, PERMETHRIN

ACTAVIS LABS FL

- * ACTAVIS LABORATORIES FL INC AN INDIRECT WHOLLY OWNED SUB OF TEVA PHARMACEUTICALS USA INC
 - DESVENLAFAXINE SUCCINATE, DESVENLAFAXINE SUCCINATE
 - GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE, DEXTROMETHORPHAN HYDROBROMIDE (OTC)
 - GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE, GUAIFENESIN (OTC)
 - GUAIFENESIN, GUAIFENESIN (OTC)
 - ISOTRETINOIN, ISOTRETINOIN
 - MESALAMINE, MESALAMINE
 - METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE

ACTAVIS LABS FL INC

- * ACTAVIS LABORATORIES FL INC
 - BUDESONIDE, BUDESONIDE
 - BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
 - CARTIA XT, DILTIAZEM HYDROCHLORIDE
 - CLARITHROMYCIN, CLARITHROMYCIN
 - CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
 - DALFAMPRIDINE, DALFAMPRIDINE
 - DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
 - DICLOFENAC SODIUM AND MISOPROSTOL, DICLOFENAC SODIUM
 - DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
 - DIVALPROEX SODIUM, DIVALPROEX SODIUM
 - DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
 - DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE, DOXYLAMINE SUCCINATE
 - FESOTERODINE FUMARATE, FESOTERODINE FUMARATE
 - HYDROCODONE BITARTRATE AND IBUPROFEN, HYDROCODONE BITARTRATE
 - LACOSAMIDE, LACOSAMIDE
 - LEVETIRACETAM, LEVETIRACETAM
 - METAXALONE, METAXALONE
 - METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 - METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
 - METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
 - NAPROXEN AND ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
 - NAPROXEN SODIUM, NAPROXEN SODIUM
 - NITROFURANTOIN, NITROFURANTOIN, MACROCRYSTALLINE
 - OMEPRAZOLE, OMEPRAZOLE
 - PALIPERIDONE, PALIPERIDONE
 - PAROXETINE MESYLATE, PAROXETINE MESYLATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ****

* ACTAVIS LABORATORIES FL INC
 POSACONAZOLE, POSACONAZOLE
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
 PREDNISONE, PREDNISONE
 RAMELTEON, RAMELTEON
 TAMOXIFEN CITRATE, TAMOXIFEN CITRATE
 TAZTIA XT, DILTIAZEM HYDROCHLORIDE
 TETRABENAZINE, TETRABENAZINE
 TRANEXAMIC ACID, TRANEXAMIC ACID
 TROSPIMUM CHLORIDE, TROSPIMUM CHLORIDE
 VALGANCICLOVIR HYDROCHLORIDE, VALGANCICLOVIR HYDROCHLORIDE
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

ACTAVIS LABS UT INC

* ACTAVIS LABORATORIES UT INC
 AZELAIC ACID, AZELAIC ACID
 BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
 CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
 CLONIDINE, CLONIDINE
 FIORICET W/ CODEINE, ACETAMINOPHEN
 LIDOCAINE, LIDOCAINE
 SCOPOLAMINE, SCOPOLAMINE
 TESTOSTERONE, TESTOSTERONE

* ACTAVIS LABORATORIES UT INC INDIRECT WHOLLY OWNED SUB OF TEVA PHARMACEUTICALS USA INC
 ADAPALENE AND BENZOYL PEROXIDE, ADAPALENE
 PIMECROLIMUS, PIMECROLIMUS
 TESTOSTERONE, TESTOSTERONE

ACTAVIS LLC

* ACTAVIS LLC
 AZACITIDINE, AZACITIDINE
 DAPSONE, DAPSONE
 FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE
 MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE

* ACTAVIS LLC AN INDIRECT WHOLLY-OWNED SUB OF TEVA PHARMACEUTICALS USA INC
 DOCETAXEL, DOCETAXEL
 HYDROXOCOBALAMIN, HYDROXOCOBALAMIN
 OXALIPLATIN, OXALIPLATIN
 PEMETREXED, PEMETREXED

ACTAVIS MID ATLANTIC

* ACTAVIS MID ATLANTIC LLC
 ACYCLOVIR, ACYCLOVIR
 ADAPALENE, ADAPALENE
 BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
 BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
 CICLOPIROX, CICLOPIROX
 CLINDAMYCIN PHOSPHATE AND TRETINOIN, CLINDAMYCIN PHOSPHATE
 CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
 CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
 DESOXIMETASONE, DESOXIMETASONE
 DICLOFENAC SODIUM, DICLOFENAC SODIUM
 GRISEOFULVIN, GRISEOFULVIN, MICROSIZE
 HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE, HOMATROPINE METHYLBROMIDE
 HYDROCORTISONE BUTYRATE, HYDROCORTISONE BUTYRATE
 HYDROCORTISONE, HYDROCORTISONE
 LEVETIRACETAM, LEVETIRACETAM
 MESALAMINE, MESALAMINE
 NITROFURANTOIN, NITROFURANTOIN
 NYSTATIN, NYSTATIN
 PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE, CODEINE PHOSPHATE
 VALNAC, BETAMETHASONE VALERATE

* ACTAVIS MID ATLANTIC LLC AN INDIRECT WHOLLY OWNED SUB OF TEVA PHARMACEUTICALS USA INC
 IBUPROFEN, IBUPROFEN
 PERMETHRIN, PERMETHRIN (OTC)

ACTAVIS PHARMA

* ACTAVIS PHARMA INC AN INDIRECT WHOLLY OWNED SUB OF TEVA PHARMACEUTICALS USA INC
 MICONAZOLE NITRATE, MICONAZOLE NITRATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ******ACTAVIS TOTOWA**

- * ACTAVIS TOTOWA LLC
DESIPRAMINE HYDROCHLORIDE, DESIPRAMINE HYDROCHLORIDE
FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
OXALIPLATIN, OXALIPLATIN
PACLITAXEL, PACLITAXEL
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
VINORELBINE TARTRATE, VINORELBINE TARTRATE

ACTELION

- * ACTELION PHARMACEUTICALS US INC
OPSUMIT, MACITENTAN
TRACLEER, BOSENTAN
UPTRAVI, SELEXIPAG
VELETRI, EPOPROSTENOL SODIUM
VENTAVIS, ILOPROST
ZAVESCA, MIGLUSTAT

ACTIENT PHARMS

- * ACTIENT PHARMACEUTICALS LLC
THEO-24, THEOPHYLLINE

ADAMAS OPERATIONS

- * ADAMAS OPERATIONS LLC
GOCOVRI, AMANTADINE HYDROCHLORIDE
OSMOLEX ER, AMANTADINE HYDROCHLORIDE

ADAMIS PHARMS CORP

- * ADAMIS PHARMACEUTICALS CORP
SYMJEPI, EPINEPHRINE
ZIMHI, NALOXONE HYDROCHLORIDE

ADARE PHARMS INC

- * ADARE PHARMACEUTICALS INC
DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE

ADDMEDICA SAS

- * ADDMEDICA SAS
SIKLOS, HYDROXYUREA

ADHERA

- * ADHERA THERAPEUTICS INC
PRESTALIA, AMLODIPINE BESYLATE

ADIENNE SA

- * ADIENNE SA
TEPADINA, THIOTEPA

AERIE PHARMS INC

- * AERIE PHARMACEUTICALS INC
RHOPRESSA, NETARSUDIL MESYLATE
ROCKLATAN, LATANOPROST

AET PHARMA

- * AET PHARMA US INC
LEFLUNOMIDE, LEFLUNOMIDE
POSACONAZOLE, POSACONAZOLE

AFAXYS

- * AFAXYS PHARMA LLC
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE

AGILE

- * AGILE THERAPEUTICS INC
TWIRLA, ETHINYL ESTRADIOL

AGIOS PHARMS INC

- * AGIOS PHARMACEUTICALS INC
PYRUKYND, MITAPIVAT SULFATE

AGNITIO

- * AGNITIO INC
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
ETHACRYNIC ACID, ETHACRYNIC ACID

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ****

* AGNITIO INC
 TRIAMTERENE, TRIAMTERENE

AGOURON PHARMS

* AGOURON PHARMACEUTICALS LLC
 VIRACEPT, NELFINAVIR MESYLATE

AILEX PHARMS LLC

* AILEX PHARMACEUTICALS LLC
 BISMUTH SUBSALICYLATE, METRONIDAZOLE AND TETRACYCLINE HYDROCHLORIDE, BISMUTH
 CROMOLYN SODIUM, CROMOLYN SODIUM
 SODIUM PHENYLACETATE AND SODIUM BENZOATE, SODIUM BENZOATE

AIPING LIFE SCI

* AIPING LIFE SCIENCES LLC
 BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
 HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
 METHIMAZOLE, METHIMAZOLE
 SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE

AIPING PHARM INC

* AIPING PHARMACEUTICAL INC
 LEVETIRACETAM, LEVETIRACETAM

AIZANT

* AIZANT DRUG RESEARCH SOLUTIONS PRIVATE LTD
 ALBUTEROL SULFATE, ALBUTEROL SULFATE
 PIRFENIDONE, PIRFENIDONE
 * AIZANT DRUG RESEARCH SOLUTIONS PVT LTD
 ELIGLUSTAT TARTRATE, ELIGLUSTAT TARTRATE

AJANTA PHARMA LTD

* AJANTA PHARMA LTD
 ALMOTRIPTAN MALATE, ALMOTRIPTAN MALATE
 AMLODIPINE AND OLMESARTAN MEDOXOMIL, AMLODIPINE BESYLATE
 ARIPIRAZOLE, ARIPIRAZOLE
 CAPTOPRIL, CAPTOPRIL
 CHLORTHALIDONE, CHLORTHALIDONE
 CHOLESTYRAMINE, CHOLESTYRAMINE
 CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
 CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
 DIVALPROEX SODIUM, DIVALPROEX SODIUM
 DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
 DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
 DROXIDOPA, DROXIDOPA
 DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
 ELETRIPTAN HYDROBROMIDE, ELETRIPTAN HYDROBROMIDE
 ENTACAPONE, ENTACAPONE
 FENOFIBRATE (MICRONIZED), FENOFIBRATE
 FENOFIBRATE, FENOFIBRATE
 FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE
 LAMOTRIGINE, LAMOTRIGINE
 MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 MONTELUKAST SODIUM, MONTELUKAST SODIUM
 NAPROXEN AND ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
 OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE
 OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
 OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
 RANOLAZINE, RANOLAZINE
 RISPERIDONE, RISPERIDONE
 SILDENAFIL CITRATE, SILDENAFIL CITRATE
 SILODOSIN, SILODOSIN
 TADALAFIL, TADALAFIL
 TOLTERODINE TARTRATE, TOLTERODINE TARTRATE
 VALGANCICLOVIR HYDROCHLORIDE, VALGANCICLOVIR HYDROCHLORIDE
 VORICONAZOLE, VORICONAZOLE
 ZOLMITRIPTAN, ZOLMITRIPTAN

AKARX INC

* AKARX INC
 DOPTELET, AVATROMBOPAG MALEATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ******AKCEA THERAPS**

* AKCEA THERAPEUTICS INC
TEGSEDI, INOTERSEN SODIUM

AKORN

* AKORN OPERATING CO LLC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ACETYLCYSTEINE, ACETYLCYSTEINE
ACYCLOVIR, ACYCLOVIR
ADENOSINE, ADENOSINE
AK-FLUOR 10%, FLUORESCCEIN SODIUM
AK-FLUOR 25%, FLUORESCCEIN SODIUM
AKPENTOLATE, CYCLOPENTOLATE HYDROCHLORIDE
AKTOB, TOBRAMYCIN
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ALFENTA, ALFENTANIL HYDROCHLORIDE
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
AMICAR, AMINOCAPROIC ACID
APRACLONIDINE HYDROCHLORIDE, APRACLONIDINE HYDROCHLORIDE
ATROPINE SULFATE, ATROPINE SULFATE
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
BACITRACIN ZINC AND POLYMYXIN B SULFATE, BACITRACIN ZINC
BAL, DIMERCAPROL
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
BETAXOLOL HYDROCHLORIDE, BETAXOLOL HYDROCHLORIDE
BIMATOPROST, BIMATOPROST
BRIMONIDINE TARTRATE AND TIMOLOL MALEATE, BRIMONIDINE TARTRATE
BRIMONIDINE TARTRATE, BRIMONIDINE TARTRATE
BROMFENAC SODIUM, BROMFENAC SODIUM
CALCIPOTRIENE, CALCIPOTRIENE
CALCITRIOL, CALCITRIOL
CARBOPLATIN, CARBOPLATIN
CEFTRIAXONE, CEFTRIAXONE SODIUM
CETRORELIX ACETATE, CETRORELIX ACETATE
CICLOPIROX, CICLOPIROX
CIMETIDINE HYDROCHLORIDE, CIMETIDINE HYDROCHLORIDE
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER, CLINDAMYCIN PHOSPHATE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CORMAX, CLOBETASOL PROPIONATE
CROMOLYN SODIUM, CROMOLYN SODIUM
CYCLOPENTOLATE HYDROCHLORIDE, CYCLOPENTOLATE HYDROCHLORIDE
DEMECLOCYCLINE HYDROCHLORIDE, DEMECLOCYCLINE HYDROCHLORIDE
DESONIDE, DESONIDE
DESOXIMETASONE, DESOXIMETASONE
DEXMETETOMIDINE HYDROCHLORIDE, DEXMETETOMIDINE HYDROCHLORIDE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DICLOFENAC SODIUM, DICLOFENAC SODIUM (OTC)
DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DIURIL, CHLOROTHIAZIDE SODIUM
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE
DRONABINOL, DRONABINOL
EMBELINE, CLOBETASOL PROPIONATE
EPHEDRINE SULFATE, EPHEDRINE SULFATE
EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
ERYTHROMYCIN, ERYTHROMYCIN
ETHAMBUTOL HYDROCHLORIDE, ETHAMBUTOL HYDROCHLORIDE
ETHOSUXIMIDE, ETHOSUXIMIDE
FAMOTIDINE, FAMOTIDINE
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE (OTC)
GABAPENTIN, GABAPENTIN
GATIFLOXACIN, GATIFLOXACIN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ******* AKORN OPERATING CO LLC**

GENTAK, GENTAMICIN SULFATE
 GENTAMICIN SULFATE, GENTAMICIN SULFATE
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
 HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
 HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE, HOMATROPINE METHYLBROMIDE
 HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
 IC-GREEN, INDOCYANINE GREEN
 INAPSINE, DROPERIDOL
 IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
 KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
 KETOTIFEN FUMARATE, KETOTIFEN FUMARATE (OTC)
 LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
 LACTULOSE, LACTULOSE
 LATANOPROST, LATANOPROST
 LEVETIRACETAM, LEVETIRACETAM
 LEVOCARNITINE, LEVOCARNITINE
 LEVOFLOXACIN, LEVOFLOXACIN
 LIDOCAINE AND PRILOCAINE, LIDOCAINE
 LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
 LORAZEPAM, LORAZEPAM
 LOTEPREDNOL ETABONATE, LOTEPREDNOL ETABONATE
 MEGESTROL ACETATE, MEGESTROL ACETATE
 METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
 MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
 MORPHINE SULFATE, MORPHINE SULFATE
 MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
 MYCOPHENOLATE MOFETIL HYDROCHLORIDE, MYCOPHENOLATE MOFETIL HYDROCHLORIDE
 NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
 NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE, NAPHAZOLINE HYDROCHLORIDE (OTC)
 NEMBUTAL SODIUM, PENTOBARBITAL SODIUM
 NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC, BACITRACIN ZINC
 NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE, BACITRACIN ZINC
 NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
 OFLOXACIN, OFLOXACIN
 OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE
 OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE (OTC)
 ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
 OXCARBAZEPINE, OXCARBAZEPINE
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
 PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
 PAREMYD, HYDROXYAMPHETAMINE HYDROBROMIDE
 PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE
 PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
 PILOCARPINE HYDROCHLORIDE, PILOCARPINE HYDROCHLORIDE
 PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
 PREDNISOLONE, PREDNISOLONE
 PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE, CODEINE PHOSPHATE
 PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE, CODEINE
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
 PROPARACAINE HYDROCHLORIDE, PROPARACAINE HYDROCHLORIDE
 PYRAZINAMIDE, PYRAZINAMIDE
 RIFAMPIN, RIFAMPIN
 ROPIVACAINE HYDROCHLORIDE, ROPIVACAINE HYDROCHLORIDE
 SUBLIMAZE PRESERVATIVE FREE, FENTANYL CITRATE
 SUFENTA PRESERVATIVE FREE, SUFENTANIL CITRATE
 SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM
 SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
 TIMOLOL MALEATE, TIMOLOL MALEATE
 TIMOLOL, TIMOLOL
 TOBRAMYCIN, TOBRAMYCIN
 TRANEXAMIC ACID, TRANEXAMIC ACID
 TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
 TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
 TROPICACYL, TROPICAMIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ****

* AKORN OPERATING CO LLC
 VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
 VORICONAZOLE, VORICONAZOLE
 VOSOL HC, ACETIC ACID, GLACIAL
 VOSOL, ACETIC ACID, GLACIAL
 XOPENEX, LEVALBUTEROL HYDROCHLORIDE
 ZOLEDRONIC ACID, ZOLEDRONIC ACID

ALBIRO

* ALBIRO AB
 BYLVAY, ODEVIXIBAT

ALCON

* ALCON LABORATORIES INC
 BSS PLUS, CALCIUM CHLORIDE
 BSS, CALCIUM CHLORIDE
 MIOSTAT, CARBACHOL
 NAPHCN-A, NAPHAZOLINE HYDROCHLORIDE (OTC)

ALCON LABS

* ALCON LABORATORIES LTD
 TETRACAINE HYDROCHLORIDE, TETRACAINE HYDROCHLORIDE

ALCON LABS INC

* ALCON LABORATORIES INC
 ALCAINE, PROPARACAINE HYDROCHLORIDE
 CYCLOGYL, CYCLOPENTOLATE HYDROCHLORIDE
 CYCLOMYDRIL, CYCLOPENTOLATE HYDROCHLORIDE
 EYSUVIS, LOTEPREDNOL ETABONATE
 FLUORESCITE, FLUORESCIN SODIUM
 INVELTYS, LOTEPREDNOL ETABONATE
 ISOPTO ATROPINE, ATROPINE SULFATE
 MYDRIACYL, TROPICAMIDE
 PATADAY ONCE DAILY RELIEF, OLOPATADINE HYDROCHLORIDE (OTC)
 PATADAY TWICE DAILY RELIEF, OLOPATADINE HYDROCHLORIDE (OTC)
 SIMBRINZA, BRIMONIDINE TARTRATE

ALCON PHARMS LTD

* ALCON PHARMACEUTICALS LTD
 BETADINE, POVIDONE-IODINE
 ZADITOR, KETOTIFEN FUMARATE (OTC)

ALEMBIC GLOBAL

* ALEMBIC GLOBAL HOLDING SA
 TREPROSTINIL, TREPROSTINIL

ALEMBIC LABS

* ALEMBIC LABS LLC
 BENZONATATE, BENZONATATE
 BISOPROLOL FUMARATE, BISOPROLOL FUMARATE
 CLINDAMYCIN PALMITATE HYDROCHLORIDE, CLINDAMYCIN PALMITATE HYDROCHLORIDE
 CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
 ERGOCALCIFEROL, ERGOCALCIFEROL
 FENOFIBRATE, FENOFIBRATE
 GLYCOPYRROLATE, GLYCOPYRROLATE
 LEVETIRACETAM, LEVETIRACETAM
 METRONIDAZOLE, METRONIDAZOLE

ALEMBIC LTD

* ALEMBIC LTD
 LITHIUM CARBONATE, LITHIUM CARBONATE
 ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE

ALEMBIC PHARMS

* ALEMBIC PHARMACEUTICALS LTD
 ACETAZOLAMIDE, ACETAZOLAMIDE
 ACYCLOVIR, ACYCLOVIR
 AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
 AMLODIPINE AND OLMESARTAN MEDOXOMIL, AMLODIPINE BESYLATE
 AMLODIPINE BESYLATE AND VALSARTAN, AMLODIPINE BESYLATE
 ARFORMOTEROL TARTRATE, ARFORMOTEROL TARTRATE
 ARIPIIPRAZOLE, ARIPIIPRAZOLE
 ASENAPINE MALEATE, ASENAPINE MALEATE
 AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ****

* ALEMBIC PHARMACEUTICALS LTD
AZITHROMYCIN, AZITHROMYCIN
BIMATOPROST, BIMATOPROST
BROMFENAC SODIUM, BROMFENAC SODIUM
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL
CARBIDOPA AND LEVODOPA, CARBIDOPA
CELECOXIB, CELECOXIB
CHLORTHALIDONE, CHLORTHALIDONE
CLARITHROMYCIN, CLARITHROMYCIN
CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
CLONAZEPAM, CLONAZEPAM
CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE
DARIFENACIN HYDROBROMIDE, DARIFENACIN HYDROBROMIDE
DEFERASIROX, DEFERASIROX
DESIPRAMINE HYDROCHLORIDE, DESIPRAMINE HYDROCHLORIDE
DESVENLAFAXINE SUCCINATE, DESVENLAFAXINE SUCCINATE
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DOXYCYCLINE, DOXYCYCLINE
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
ENTACAPONE, ENTACAPONE
ERLOTINIB HYDROCHLORIDE, ERLOTINIB HYDROCHLORIDE
FEBUXOSTAT, FEBUXOSTAT
FENOFIBRATE (MICRONIZED), FENOFIBRATE
FENOFIBRATE, FENOFIBRATE
FENOFIBRIC ACID, CHOLINE FENOFIBRATE
FESOTERODINE FUMARATE, FESOTERODINE FUMARATE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FORMOTEROL FUMARATE, FORMOTEROL FUMARATE
FULVESTRANT, FULVESTRANT
GLYCOPYRROLATE, GLYCOPYRROLATE
IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
ITRACONAZOLE, ITRACONAZOLE
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LACOSAMIDE, LACOSAMIDE
LAMOTRIGINE, LAMOTRIGINE
LINEZOLID, LINEZOLID
LURASIDONE HYDROCHLORIDE, LURASIDONE HYDROCHLORIDE
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
MESALAMINE, MESALAMINE
METOLAZONE, METOLAZONE
METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
METRONIDAZOLE, METRONIDAZOLE
MIDODRINE HYDROCHLORIDE, MIDODRINE HYDROCHLORIDE
MODAFINIL, MODAFINIL
MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
NIFEDIPINE, NIFEDIPINE
NITROFURANTOIN, NITROFURANTOIN, MACROCRYSTALLINE
OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE (OTC)
OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
PACLITAXEL, PACLITAXEL
PIRFENIDONE, PIRFENIDONE
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
PREGABALIN, PREGABALIN
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE
TADALAFIL, TADALAFIL
TELMISARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TELMISARTAN, TELMISARTAN
TEMAZEPAM, TEMAZEPAM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ****

* ALEMBIC PHARMACEUTICALS LTD
 TERIFLUNOMIDE, TERIFLUNOMIDE
 THEOPHYLLINE, THEOPHYLLINE
 TIMOLOL MALEATE, TIMOLOL MALEATE
 TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
 TOBRAMYCIN, TOBRAMYCIN
 TRAVOPROST, TRAVOPROST
 VALSARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 VALSARTAN, VALSARTAN
 VARDENAFIL HYDROCHLORIDE, VARDENAFIL HYDROCHLORIDE
 VILAZODONE HYDROCHLORIDE, VILAZODONE HYDROCHLORIDE
 ZOLMITRIPTAN, ZOLMITRIPTAN

ALEMBIC PHARMS LTD

* ALEMBIC PHARMACEUTICALS LTD
 CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
 DESVENLAFAXINE, DESVENLAFAXINE
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
 FAMOTIDINE, FAMOTIDINE
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 IRBESARTAN, IRBESARTAN
 LAMOTRIGINE, LAMOTRIGINE
 LEFLUNOMIDE, LEFLUNOMIDE
 LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
 MEPROBAMATE, MEPROBAMATE
 METOPROLOL TARTRATE, METOPROLOL TARTRATE
 METRONIDAZOLE, METRONIDAZOLE
 RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

ALEOR DERMACEUTICALS

* ALEOR DERMACEUTICALS LTD
 ADAPALENE AND BENZOYL PEROXIDE, ADAPALENE
 ADAPALENE, ADAPALENE
 CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
 DESONIDE, DESONIDE
 DICLOFENAC SODIUM, DICLOFENAC SODIUM
 DOCOSANOL, DOCOSANOL (OTC)
 LIDOCAINE AND PRILOCAINE, LIDOCAINE
 LIDOCAINE, LIDOCAINE
 METRONIDAZOLE, METRONIDAZOLE
 MUPIROCIN, MUPIROCIN CALCIUM
 NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
 TAVABOROLE, TAVABOROLE

ALEXZA PHARMS

* ALEXZA PHARMACEUTICALS INC
 ADASUVE, LOXAPINE

ALIGNSCIENCE PHARMA

* ALIGNSCIENCE PHARMA INC
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 QUETIAPINE FUMARATE, QUETIAPINE FUMARATE

ALIMERA SCIENCES INC

* ALIMERA SCIENCES INC
 ILUVIEN, FLUOCINOLONE ACETONIDE

ALK ABELLO

* ALK-ABELLO INC
 OTIPRIO, CIPROFLOXACIN

ALKALOIDA ZRT

* ALKALOIDA CHEMICAL CO ZRT
 HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE

ALKEM

* ALKEM LABORATORIES LTD
 AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
 GABAPENTIN, GABAPENTIN
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

ALKEM LABS LTD

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ******* ALKEM LABORATORIES LTD**

AMLODIPINE AND OLMESARTAN MEDOXOMIL, AMLODIPINE BESYLATE
AMPHETAMINE SULFATE, AMPHETAMINE SULFATE
APREMILAST, APREMILAST
ARIPIRAZOLE, ARIPIRAZOLE
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
AZATHIOPRINE, AZATHIOPRINE
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
CAPECITABINE, CAPECITABINE
CEFDINIR, CEFDINIR
CEFIXIME, CEFIXIME
CEFPODOXIME PROXETIL, CEFPODOXIME PROXETIL
CEFUROXIME AXETIL, CEFUROXIME AXETIL
CEPHALEXIN, CEPHALEXIN
CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDE, CHLORDIAZEPOXIDE HYDROCHLORIDE
CHLORTHALIDONE, CHLORTHALIDONE
CHOLESTYRAMINE LIGHT, CHOLESTYRAMINE
CHOLESTYRAMINE, CHOLESTYRAMINE
CINACALCET HYDROCHLORIDE, CINACALCET HYDROCHLORIDE
CLOBAZAM, CLOBAZAM
COLCHICINE, COLCHICINE
COLESEVELAM HYDROCHLORIDE, COLESEVELAM HYDROCHLORIDE
DABIGATRAN ETEXILATE MESYLATE, DABIGATRAN ETEXILATE MESYLATE
DALFAMPRIDINE, DALFAMPRIDINE
DEFERASIROX, DEFERASIROX
DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
DIMETHYL FUMARATE, DIMETHYL FUMARATE
DROXIDOPA, DROXIDOPA
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
ENALAPRIL MALEATE, ENALAPRIL MALEATE
ERYTHROMYCIN, ERYTHROMYCIN
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
EVEROLIMUS, EVEROLIMUS
EZETIMIBE AND SIMVASTATIN, EZETIMIBE
EZETIMIBE, EZETIMIBE
FAMOTIDINE, FAMOTIDINE
FEBUXOSTAT, FEBUXOSTAT
FESOTERODINE FUMARATE, FESOTERODINE FUMARATE
FINASTERIDE, FINASTERIDE
FINGOLIMOD HYDROCHLORIDE, FINGOLIMOD HYDROCHLORIDE
FOSFOMYCIN TROMETHAMINE, FOSFOMYCIN TROMETHAMINE
GABAPENTIN, GABAPENTIN
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
IBUPROFEN AND FAMOTIDINE, FAMOTIDINE
IBUPROFEN, IBUPROFEN
ITRACONAZOLE, ITRACONAZOLE
LACOSAMIDE, LACOSAMIDE
LAMOTRIGINE, LAMOTRIGINE
LANSOPRAZOLE, LANSOPRAZOLE
LEVETIRACETAM, LEVETIRACETAM
LIDOCAINE, LIDOCAINE
LINEZOLID, LINEZOLID
LURASIDONE HYDROCHLORIDE, LURASIDONE HYDROCHLORIDE
MARINOL, DRONABINOL
MESALAMINE, MESALAMINE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
MORPHINE SULFATE, MORPHINE SULFATE
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
MYCOPHENOLIC SODIUM, MYCOPHENOLIC SODIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ****

* ALKEM LABORATORIES LTD
 NIFEDIPINE, NIFEDIPINE
 OLANZAPINE, OLANZAPINE
 OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
 PREGABALIN, PREGABALIN
 QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
 RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM
 RANOLAZINE, RANOLAZINE
 RASAGILINE MESYLATE, RASAGILINE MESYLATE
 RILUZOLE, RILUZOLE
 RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
 ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
 RUFINAMIDE, RUFINAMIDE
 SILDENAFIL CITRATE, SILDENAFIL CITRATE
 SIROLIMUS, SIROLIMUS
 SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE
 TACROLIMUS, TACROLIMUS
 TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
 TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
 TOBRAMYCIN, TOBRAMYCIN
 TOLVAPTAN, TOLVAPTAN
 TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
 TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
 VALSARTAN, VALSARTAN
 VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
 VIGABATRIN, VIGABATRIN

ALKERMES

* ALKERMES INC
 VIVITROL, NALTREXONE

ALKERMES INC

* ALKERMES INC
 ARISTADA INITIO KIT, ARIPIPRAZOLE LAUROXIL
 ARISTADA, ARIPIPRAZOLE LAUROXIL
 LYBALVI, OLANZAPINE

ALLEGIANCE HLTHCARE

* ALLEGIANCE HEALTHCARE CORP
 POVIDONE IODINE, POVIDONE-IODINE (OTC)

ALLERGAN

* ALLERGAN
 ACULAR LS, KETOROLAC TROMETHAMINE
 ALPHAGAN P, BRIMONIDINE TARTRATE
 BLEPH-10, SULFACETAMIDE SODIUM
 GENOPTIC, GENTAMICIN SULFATE
 ZYMAXID, GATIFLOXACIN

* ALLERGAN INC
 ACULAR, KETOROLAC TROMETHAMINE
 ACUVAIL, KETOROLAC TROMETHAMINE
 ACZONE, DAPSONE
 ALPHAGAN P, BRIMONIDINE TARTRATE
 AVAGE, TAZAROTENE
 COMBIGAN, BRIMONIDINE TARTRATE
 LASTACFT, ALCAFTADINE (OTC)
 LATISSE, BIMATOPROST
 LUMIGAN, BIMATOPROST
 OCUFLOX, OFLOXACIN
 OZURDEX, DEXAMETHASONE
 POLYTRIM, POLYMYXIN B SULFATE
 RESTASIS MULTIDOSE, CYCLOSPORINE
 RESTASIS, CYCLOSPORINE
 TAZORAC, TAZAROTENE
 ZYMAR, GATIFLOXACIN

* ALLERGAN PHARMACEUTICAL
 BETAGAN, LEVOBUNOLOL HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ****

* ALLERGAN PHARMACEUTICAL
 FML FORTE, FLUOROMETHOLONE
 FML, FLUOROMETHOLONE
 PRED FORTE, PREDNISOLONE ACETATE
 PRED MILD, PREDNISOLONE ACETATE
 PRED-G, GENTAMICIN SULFATE

* ALLERGAN SALES LLC
 ANDRODERM, TESTOSTERONE
 AVYCAZ, AVIBACTAM SODIUM
 BENTYL PRESERVATIVE FREE, DICYCLOMINE HYDROCHLORIDE
 BENTYL, DICYCLOMINE HYDROCHLORIDE
 BYSTOLIC, NEBIVOLOL HYDROCHLORIDE
 CANASA, MESALAMINE
 CARAFATE, SUCRALFATE
 CELEXA, CITALOPRAM HYDROBROMIDE
 CONDYLOX, PODOFILOX
 CRINONE, PROGESTERONE
 DALVANCE, DALBAVANCIN HYDROCHLORIDE
 ESTRACE, ESTRADIOL
 FETZIMA, LEVOMILNACIPRAN HYDROCHLORIDE
 GELNIQUE, OXYBUTYNIN CHLORIDE
 INFED, FERRIC OXYHYDROXIDE
 LEXAPRO, ESCITALOPRAM OXALATE
 LINZESS, LINACLOTIDE
 NAMENDA XR, MEMANTINE HYDROCHLORIDE
 NAMENDA, MEMANTINE HYDROCHLORIDE
 NAMZARIC, DONEPEZIL HYDROCHLORIDE
 OXYTROL FOR WOMEN, OXYBUTYNIN (OTC)
 OXYTROL, OXYBUTYNIN
 PYLERA, BISMUTH SUBCITRATE POTASSIUM
 RAPAFLO, SILODOSIN
 RECTIV, NITROGLYCERIN
 SAPHRIS, ASENAPINE MALEATE
 SAVELLA, MILNACIPRAN HYDROCHLORIDE
 TEFLARO, CEFTAROLINE FOSAMIL
 UBRELVY, UBROGEPANT
 URSO 250, URSODIOL
 URSO FORTE, URSODIOL
 VIIBRYD, VILAZODONE HYDROCHLORIDE
 VRAYLAR, CARIPRAZINE HYDROCHLORIDE

ALLERGAN HOLDINGS

* ALLERGAN HOLDINGS UNLTD CO
 VIBERZI, ELUXADOLINE

ALLERGAN INC

* ALLERGAN INC
 DURYSTA, BIMATOPROST

ALMAJECT

* ALMAJECT INC
 CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
 MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE
 VORICONAZOLE, VORICONAZOLE

ALMATICA

* ALMATICA PHARMA INC
 CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
 GRALISE, GABAPENTIN

* ALMATICA PHARMA LLC
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 FORFIVO XL, BUPROPION HYDROCHLORIDE
 LOREEV XR, LORAZEPAM
 MACROBID, NITROFURANTOIN
 MACRODANTIN, NITROFURANTOIN, MACROCRYSTALLINE
 NAPRELAN, NAPROXEN SODIUM
 SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
 TENORETIC 100, ATENOLOL
 TENORETIC 50, ATENOLOL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ****

* ALMATICA PHARMA LLC
 TENORMIN, ATENOLOL
 VENLAFAXINE BESYLATE, VENLAFAXINE BESYLATE
 ZESTORETIC, HYDROCHLOROTHIAZIDE
 ZESTRIL, LISINAPRIL

ALMIRALL

* ALMIRALL LLC
 ACTICLATE, DOXYCYCLINE HYCLATE
 ACZONE, DAPSONE
 ALTABAX, RETAPAMULIN
 AZELEX, AZELAIC ACID
 CORDRAN, FLURANDRENOLIDE
 KLISYRI, TIRBANIBULIN
 SEYSARA, SARECYCLINE HYDROCHLORIDE
 VELTIN, CLINDAMYCIN PHOSPHATE
 VERDESO, DESONIDE

ALNYLAM PHARMS INC

* ALNYLAM PHARMACEUTICALS INC
 AMVUTTRA, VUTRISIRAN
 GIVLAARI, GIVOSIRAN SODIUM
 ONPATTRO, PATISIRAN SODIUM
 OXLUMO, LUMASIRAN SODIUM

ALTAIRE PHARMS INC

* ALTAIRE PHARMACEUTICALS INC
 ALTAFLUOR BENOX, BENOXINATE HYDROCHLORIDE
 CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
 DICLOFENAC SODIUM, DICLOFENAC SODIUM
 NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE, NAPHAZOLINE HYDROCHLORIDE (OTC)
 OFLOXACIN, OFLOXACIN

ALTATHERA PHARMS LLC

* ALTATHERA PHARMACEUTICALS LLC
 SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE

ALVOGEN

* ALVOGEN INC
 ACETYLCYSTEINE, ACETYLCYSTEINE
 ATENOLOL AND CHLORTHALIDONE, ATENOLOL
 ATENOLOL, ATENOLOL
 BONSTY, TERIPARATIDE
 BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
 BUPRENORPHINE, BUPRENORPHINE
 BUTALBITAL AND ACETAMINOPHEN, ACETAMINOPHEN
 CARBIDOPA, CARBIDOPA
 DAPSONE, DAPSONE
 DEXAMETHASONE, DEXAMETHASONE
 DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
 DISULFIRAM, DISULFIRAM
 DYNACIN, MINOCYCLINE HYDROCHLORIDE
 ESTRADIOL, ESTRADIOL
 EXEMESTANE, EXEMESTANE
 FELBAMATE, FELBAMATE
 FLUOCINONIDE, FLUOCINONIDE
 HYDROCODONE BITARTRATE, HYDROCODONE BITARTRATE
 LIDEX, FLUOCINONIDE
 MELPHALAN, MELPHALAN
 NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS), NITROFURANTOIN
 OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
 OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
 PREGABALIN, PREGABALIN
 PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE
 PYRIMETHAMINE, PYRIMETHAMINE
 RIVASTIGMINE, RIVASTIGMINE
 THYRO-TABS, LEVOTHYROXINE SODIUM **
 TRANDATE, LABETALOL HYDROCHLORIDE
 UREX, METHENAMINE HIPPURATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ******AM REAGENT**

* AMERICAN REAGENT INC
 ACETYLCYSTEINE, ACETYLCYSTEINE
 ATROPINE SULFATE, ATROPINE SULFATE
 BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE, BETAMETHASONE ACETATE
 BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
 BUSULFAN, BUSULFAN
 CAFFEINE CITRATE, CAFFEINE CITRATE
 CALCIUM CHLORIDE 10%, CALCIUM CHLORIDE
 CHLOROTHIAZIDE SODIUM, CHLOROTHIAZIDE SODIUM
 CUPRIC SULFATE, CUPRIC SULFATE
 CYANOCOBALAMIN, CYANOCOBALAMIN
 DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
 DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
 DROPERIDOL, DROPERIDOL
 EPINEPHRINE, EPINEPHRINE
 ESTRADIOL VALERATE, ESTRADIOL VALERATE
 FOMEPIZOLE, FOMEPIZOLE
 GLYCOPYRROLATE, GLYCOPYRROLATE
 HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
 HYDROXYPROGESTERONE CAPROATE, HYDROXYPROGESTERONE CAPROATE
 HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
 INJECTAFER, FERRIC CARBOXYMALTOSE
 ISOPROTERENOL HYDROCHLORIDE, ISOPROTERENOL HYDROCHLORIDE
 LEVOCARNITINE, LEVOCARNITINE
 METHOCARBAMOL, METHOCARBAMOL
 METHYLERGONOVINE MALEATE, METHYLERGONOVINE MALEATE
 MULTRY'S, CUPRIC SULFATE
 NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE
 NITROGLYCERIN, NITROGLYCERIN
 OLANZAPINE, OLANZAPINE
 SELENIUM ACID, SELENIUM ACID
 TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
 TRALEMENT, CUPRIC SULFATE
 TRANEXAMIC ACID, TRANEXAMIC ACID
 VASOPRESSIN, VASOPRESSIN
 VENOFER, FERRIC OXYHYDROXIDE
 ZINC SULFATE, ZINC SULFATE

AMARIN PHARMS

* AMARIN PHARMACEUTICALS IRELAND LTD
 VASCEPA, ICOSAPENT ETHYL

AMGEN

* AMGEN INC
 SENSIPAR, CINACALCET HYDROCHLORIDE

AMGEN INC

* AMGEN INC
 CORLANOR, IVABRADINE
 CORLANOR, IVABRADINE HYDROCHLORIDE
 LUMAKRAS, SOTORASIB
 OTEZLA, APREMILAST

AMICI

* AMICI PHARMACEUTICALS LLC
 CATAFLAM, DICLOFENAC POTASSIUM
 DIGOXIN, DIGOXIN
 METRONIDAZOLE, METRONIDAZOLE
 PILOCARPINE HYDROCHLORIDE, PILOCARPINE HYDROCHLORIDE

AMICUS THERAP US

* AMICUS THERAPEUTICS US LLC
 GALAFOLD, MIGALASTAT HYDROCHLORIDE

AMIVAS

* AMIVAS INC
 ARTESUNATE, ARTESUNATE

AMNEAL

* AMNEAL EU LTD
 AMINOCAPROIC ACID, AMINOCAPROIC ACID

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ******* AMNEAL EU LTD**

ARSENIC TRIOXIDE, ARSENIC TRIOXIDE
 ATAZANAVIR SULFATE, ATAZANAVIR SULFATE
 ATROPINE SULFATE, ATROPINE SULFATE
 AZACITIDINE, AZACITIDINE
 BUSULFAN, BUSULFAN
 CARBOPROST TROMETHAMINE, CARBOPROST TROMETHAMINE
 CARMUSTINE, CARMUSTINE
 CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDE, CHLORDIAZEPOXIDE HYDROCHLORIDE
 CLOFARABINE, CLOFARABINE
 CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE
 DEXAMETHASONE SODIUM PHOSPHATE PRESERVATIVE FREE, DEXAMETHASONE SODIUM PHOSPHATE
 DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
 DEXAMETHASONE, DEXAMETHASONE
 DIFLUPREDNATE, DIFLUPREDNATE
 DIMETHYL FUMARATE, DIMETHYL FUMARATE
 DOCETAXEL, DOCETAXEL
 DOXERCALCIFEROL, DOXERCALCIFEROL
 DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
 EPHEDRINE SULFATE, EPHEDRINE SULFATE
 ESMOLOL HYDROCHLORIDE, ESMOLOL HYDROCHLORIDE
 ETRAVIRINE, ETRAVIRINE
 FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE
 FULVESTRANT, FULVESTRANT
 GLYCOPYRROLATE, GLYCOPYRROLATE
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
 ISOPROTERENOL HYDROCHLORIDE, ISOPROTERENOL HYDROCHLORIDE
 LEUPROLIDE ACETATE, LEUPROLIDE ACETATE
 LEVOLEUCOVORIN CALCIUM, LEVOLEUCOVORIN CALCIUM
 METHYLPREDNISOLONE ACETATE, METHYLPREDNISOLONE ACETATE
 METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE SODIUM SUCCINATE
 METYROSINE, METYROSINE
 NEOSTIGMINE METHYLSULFATE, NEOSTIGMINE METHYLSULFATE
 NOREPINEPHRINE BITARTRATE, NOREPINEPHRINE BITARTRATE
 OFLOXACIN, OFLOXACIN
 PEMETREXED DISODIUM, PEMETREXED DISODIUM
 PHENOXYBENZAMINE HYDROCHLORIDE, PHENOXYBENZAMINE HYDROCHLORIDE
 PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
 PILOCARPINE HYDROCHLORIDE, PILOCARPINE HYDROCHLORIDE
 PIRFENIDONE, PIRFENIDONE
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
 PREDNISONE, PREDNISONE
 PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE
 SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE
 SUCCINYLCHOLINE CHLORIDE, SUCCINYLCHOLINE CHLORIDE
 THIOTHIXENE, THIOTHIXENE
 TOBRAMYCIN AND DEXAMETHASONE, DEXAMETHASONE
 TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
 VASOPRESSIN, VASOPRESSIN
 VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE
 ZOLEDRONIC ACID, ZOLEDRONIC ACID

*** AMNEAL PHARMACEUTICALS LLC**

ACTIVELLA, ESTRADIOL
 ACYCLOVIR, ACYCLOVIR
 AMINOCAPROIC ACID, AMINOCAPROIC ACID
 AZATHIOPRINE, AZATHIOPRINE
 AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
 AZITHROMYCIN, AZITHROMYCIN
 BACLOFEN, BACLOFEN
 BEXAROTENE, BEXAROTENE
 BUPRENORPHINE, BUPRENORPHINE
 CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
 CLOBAZAM, CLOBAZAM
 CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
 DEXTROMETHORPHAN POLISTIREX, DEXTROMETHORPHAN POLISTIREX (OTC)

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ****

* AMNEAL PHARMACEUTICALS LLC
 DICLOFENAC SODIUM, DICLOFENAC SODIUM
 ELURYNG, ETHINYL ESTRADIOL
 ESTRADIOL, ESTRADIOL
 ETHINYL ESTRADIOL AND NORELGESTROMIN, ETHINYL ESTRADIOL
 FENOFIBRATE, FENOFIBRATE
 FLUOCINONIDE, FLUOCINONIDE
 IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
 LIDOCAINE, LIDOCAINE
 LIORESAL, BACLOFEN
 LYVISPAH, BACLOFEN
 MUPIROCIN, MUPIROCIN CALCIUM
 MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
 NAPROXEN, NAPROXEN
 NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
 OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE
 POSACONAZOLE, POSACONAZOLE
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
 PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
 PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE
 RISPERIDONE, RISPERIDONE
 RITONAVIR, RITONAVIR
 SIROLIMUS, SIROLIMUS
 SUCRALFATE, SUCRALFATE
 TAVABOROLE, TAVABOROLE
 TESTOSTERONE, TESTOSTERONE
 TIGECYCLINE, TIGECYCLINE

AMNEAL PHARM

* AMNEAL PHARMACEUTICAL
 ACEBUTOLOL HYDROCHLORIDE, ACEBUTOLOL HYDROCHLORIDE
 BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
 DEMECLOCYCLINE HYDROCHLORIDE, DEMECLOCYCLINE HYDROCHLORIDE
 FLECAINIDE ACETATE, FLECAINIDE ACETATE
 FOLIC ACID, FOLIC ACID
 GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
 HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
 PRIMIDONE, PRIMIDONE

AMNEAL PHARMS

* AMNEAL PHARMACEUTICALS
 ACYCLOVIR, ACYCLOVIR
 ALBUTEROL SULFATE, ALBUTEROL SULFATE
 ARIPIPRAZOLE, ARIPIPRAZOLE
 ATOVAQUONE, ATOVAQUONE
 CALCITRIOL, CALCITRIOL
 CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
 CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
 CLINDAMYCIN PALMITATE HYDROCHLORIDE, CLINDAMYCIN PALMITATE HYDROCHLORIDE
 CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
 COLCHICINE, COLCHICINE
 DICLOFENAC SODIUM AND MISOPROSTOL, DICLOFENAC SODIUM
 DICLOFENAC SODIUM, DICLOFENAC SODIUM
 DICLOFENAC SODIUM, DICLOFENAC SODIUM (OTC)
 DIVALPROEX SODIUM, DIVALPROEX SODIUM
 ENTECAVIR, ENTECAVIR
 ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
 ESTRADIOL, ESTRADIOL
 FELBAMATE, FELBAMATE
 GABAPENTIN, GABAPENTIN
 HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
 INDOMETHACIN, INDOMETHACIN
 ITRACONAZOLE, ITRACONAZOLE
 LEVETIRACETAM, LEVETIRACETAM
 LIDOCAINE, LIDOCAINE
 LORAZEPAM, LORAZEPAM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ******* AMNEAL PHARMACEUTICALS**

MEROPENEM, MEROPENEM
 METAXALONE, METAXALONE
 MOMETASONE FUROATE, MOMETASONE FUROATE
 MONTELUKAST SODIUM, MONTELUKAST SODIUM
 NIACIN, NIACIN
 NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS), NITROFURANTOIN
 NORETHINDRONE ACETATE, NORETHINDRONE ACETATE
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 OXCARBAZEPINE, OXCARBAZEPINE
 OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
 PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
 PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE, CODEINE PHOSPHATE
 PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE, DEXTROMETHORPHAN
 PROMETHAZINE HYDROCHLORIDE AND PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
 PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE, CODEINE
 QUININE SULFATE, QUININE SULFATE
 RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM
 RALOXIFENE HYDROCHLORIDE, RALOXIFENE HYDROCHLORIDE
 RISPERIDONE, RISPERIDONE
 SILDENAFIL CITRATE, SILDENAFIL CITRATE
 TELMISARTAN, TELMISARTAN
 TEMAZEPAM, TEMAZEPAM
 TEMOZOLOMIDE, TEMOZOLOMIDE
 TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
 VORICONAZOLE, VORICONAZOLE
 WARFARIN SODIUM, WARFARIN SODIUM

*** AMNEAL PHARMACEUTICALS HOLDINGS GMBH**

DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE

*** AMNEAL PHARMACEUTICALS OF NEW YORK LLC**

ABIRATERONE ACETATE, ABIRATERONE ACETATE
 ALOSETRON HYDROCHLORIDE, ALOSETRON HYDROCHLORIDE
 AMPHETAMINE SULFATE, AMPHETAMINE SULFATE
 ASPIRIN AND DIPYRIDAMOLE, ASPIRIN
 BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
 BUDESONIDE, BUDESONIDE
 BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
 CELECOXIB, CELECOXIB
 DUTASTERIDE, DUTASTERIDE
 ERYTHROMYCIN ETHYLSUCCINATE, ERYTHROMYCIN ETHYLSUCCINATE
 GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE, DEXTROMETHORPHAN HYDROBROMIDE (OTC)
 GUAIFENESIN, GUAIFENESIN (OTC)
 IBUPROFEN, IBUPROFEN (OTC)
 IRBESARTAN, IRBESARTAN
 LACOSAMIDE, LACOSAMIDE
 LAMOTRIGINE, LAMOTRIGINE
 LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE
 MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
 METHOTREXATE SODIUM, METHOTREXATE SODIUM
 METHYLERGONOVINE MALEATE, METHYLERGONOVINE MALEATE
 METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
 MONTELUKAST SODIUM, MONTELUKAST SODIUM
 NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
 NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
 NORGESTIMATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 OMEGA-3-ACID ETHYL ESTERS, OMEGA-3-ACID ETHYL ESTERS
 OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
 OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
 PALIPERIDONE, PALIPERIDONE
 PARICALCITOL, PARICALCITOL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ****

* AMNEAL PHARMACEUTICALS OF NEW YORK LLC
 PRASUGREL, PRASUGREL HYDROCHLORIDE
 RIVASTIGMINE, RIVASTIGMINE
 SILDENAFIL CITRATE, SILDENAFIL CITRATE
 SPIRONOLACTONE, SPIRONOLACTONE
 SUCRALFATE, SUCRALFATE
 TOBRAMYCIN, TOBRAMYCIN
 TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
 VALSARTAN, VALSARTAN
 VIGABATRIN, VIGABATRIN

AMNEAL PHARMS CO

* AMNEAL PHARMACEUTICALS CO GMBH
 ALBUTEROL SULFATE, ALBUTEROL SULFATE
 ARGATROBAN, ARGATROBAN
 BUMETANIDE, BUMETANIDE
 BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
 CHLORPROMAZINE HYDROCHLORIDE, CHLORPROMAZINE HYDROCHLORIDE
 CHLORTHALIDONE, CHLORTHALIDONE
 CLOBAZAM, CLOBAZAM
 CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
 DESIPRAMINE HYDROCHLORIDE, DESIPRAMINE HYDROCHLORIDE
 DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
 DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
 EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE, EMTRICITABINE
 ERYTHROMYCIN, ERYTHROMYCIN
 ETHACRYNIC ACID, ETHACRYNIC ACID
 ETODOLAC, ETODOLAC
 EZETIMIBE AND SIMVASTATIN, EZETIMIBE
 EZETIMIBE, EZETIMIBE
 FROVATRIPTAN SUCCINATE, FROVATRIPTAN SUCCINATE
 HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
 NADOLOL, NADOLOL
 NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE
 OXAPROZIN, OXAPROZIN
 PARICALCITOL, PARICALCITOL
 PHYTONADIONE, PHYTONADIONE
 PREGABALIN, PREGABALIN
 SEVELAMER CARBONATE, SEVELAMER CARBONATE
 SILODOSIN, SILODOSIN
 TADALAFIL, TADALAFIL
 TRANEXAMIC ACID, TRANEXAMIC ACID
 URSODIOL, URSODIOL

AMNEAL PHARMS NY

* AMNEAL PHARMACEUTICALS NY LLC
 ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
 ALPRAZOLAM, ALPRAZOLAM
 CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
 CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
 EXTENDED PHENYTOIN SODIUM, PHENYTOIN SODIUM
 GABAPENTIN, GABAPENTIN
 HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
 HYDROCODONE BITARTRATE AND IBUPROFEN, HYDROCODONE BITARTRATE
 IBUPROFEN, IBUPROFEN
 IBUPROFEN, IBUPROFEN (OTC)
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 NAPROXEN SODIUM, NAPROXEN SODIUM
 NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
 NAPROXEN, NAPROXEN
 OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
 SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE

* AMNEAL PHARMACEUTICALS OF NY LLC
 BEXAROTENE, BEXAROTENE
 CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ****

* AMNEAL PHARMACEUTICALS OF NY LLC
 ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM (OTC)
 FESOTERODINE FUMARATE, FESOTERODINE FUMARATE
 HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
 ISOTRETINOIN, ISOTRETINOIN
 OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
 PROGESTERONE, PROGESTERONE
 SILDENAFIL CITRATE, SILDENAFIL CITRATE
 TETRACYCLINE HYDROCHLORIDE, TETRACYCLINE HYDROCHLORIDE

AMNEALS PHARMS

* AMNEALS PHARMACEUTICALS LLC
 FAMOTIDINE, FAMOTIDINE

AMPHASTAR PHARM

* AMPHASTAR PHARMACEUTICAL INC
 ENOXAPARIN SODIUM (PRESERVATIVE FREE), ENOXAPARIN SODIUM

AMPHASTAR PHARMS INC

* AMPHASTAR PHARMACEUTICALS INC
 CORTROSYN, COSYNTROPIN
 ENOXAPARIN SODIUM, ENOXAPARIN SODIUM
 GANIRELIX ACETATE, GANIRELIX ACETATE
 GLUCAGON, GLUCAGON
 ISOPROTERENOL HYDROCHLORIDE, ISOPROTERENOL HYDROCHLORIDE
 MEDROXYPROGESTERONE ACETATE, MEDROXYPROGESTERONE ACETATE
 NEOSTIGMINE METHYLSULFATE, NEOSTIGMINE METHYLSULFATE
 VASOPRESSIN, VASOPRESSIN

AMRING PHARMS

* AMRING PHARMACEUTICALS INC
 ARSENIC TRIOXIDE, ARSENIC TRIOXIDE
 ISOPROTERENOL HYDROCHLORIDE, ISOPROTERENOL HYDROCHLORIDE
 LAMOTRIGINE, LAMOTRIGINE
 LATANOPROST, LATANOPROST
 LYSTEDA, TRANEXAMIC ACID
 MESALAMINE, MESALAMINE
 NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN, GRAMICIDIN
 NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE, HYDROCORTISONE
 NEOSTIGMINE METHYLSULFATE, NEOSTIGMINE METHYLSULFATE
 SUCCINYLCHOLINE CHLORIDE, SUCCINYLCHOLINE CHLORIDE
 TIMOLOL MALEATE, TIMOLOL MALEATE

AMRYT

* AMRYT PHARMACEUTICALS DAC
 JUXTAPID, LOMITAPIDE MESYLATE
 MYCAPSSA, OCTREOTIDE ACETATE

AMTA

* AMTA LABS LTD
 DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
 MYCOPHENOLIC SODIUM, MYCOPHENOLIC SODIUM
 PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
 TOLTERODINE TARTRATE, TOLTERODINE TARTRATE
 TROSPIMUM CHLORIDE, TROSPIMUM CHLORIDE

AMYLYX

* AMYLYX PHARMACEUTICALS INC
 RELYVRIO, SODIUM PHENYLBUTYRATE

ANACOR PHARMS INC

* ANACOR PHARMACEUTICALS INC
 EUCRISA, CRISABOROLE
 KERYDIN, TAVABOROLE

ANBEX

* ANBEX INC
 IOSAT, POTASSIUM IODIDE (OTC)

ANBISON LAB

* ANBISON LABORATORY CO LTD
 BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
 CARBAMAZEPINE, CARBAMAZEPINE
 MONTELUKAST SODIUM, MONTELUKAST SODIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ****

* ANBISON LABORATORY CO LTD
TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE

ANCHEN PHARMS

* ANCHEN PHARMACEUTICALS INC
ALISKIREN HEMIFUMARATE, ALISKIREN HEMIFUMARATE
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE, DUTASTERIDE
FENOFIBRIC ACID, CHOLINE FENOFIBRATE
FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
LAMOTRIGINE, LAMOTRIGINE
LEVETIRACETAM, LEVETIRACETAM
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
TRETINOIN, TRETINOIN
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

* ANCHEN PHARMACEUTICALS, INC
ALPRAZOLAM, ALPRAZOLAM
CIPROFLOXACIN EXTENDED RELEASE, CIPROFLOXACIN

ANDA REPOSITORY

* ANDA REPOSITORY LLC
AMCINONIDE, AMCINONIDE
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
FLAC, FLUOCINOLONE ACETONIDE
LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE
LEVETIRACETAM, LEVETIRACETAM
METAPROTERENOL SULFATE, METAPROTERENOL SULFATE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
PRIMIDONE, PRIMIDONE

ANDOR PHARMS

* ANDOR PHARMACEUTICALS LLC
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE

ANDRX LABS LLC

* ANDRX LABS LLC
FORTAMET, METFORMIN HYDROCHLORIDE

ANI PHARMS

* ANI PHARMACEUTICALS INC
ACEBUTOLOL HYDROCHLORIDE, ACEBUTOLOL HYDROCHLORIDE
AMINOCAPROIC ACID, AMINOCAPROIC ACID
ARIMIDEX, ANASTROZOLE
ATACAND HCT, CANDESARTAN CILEXETIL
ATACAND, CANDESARTAN CILEXETIL
BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, BENAZEPRIL HYDROCHLORIDE
BEXAROTENE, BEXAROTENE
BRETHINE, TERBUTALINE SULFATE
CASODEX, BICALUTAMIDE
CHOLESTYRAMINE, CHOLESTYRAMINE
CLOBETASOL PROPIONATE (EMOLLIENT), CLOBETASOL PROPIONATE
CORTENEMA, HYDROCORTISONE
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DIFLORASONE DIACETATE, DIFLORASONE DIACETATE
DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, ATROPINE SULFATE
DIPYRIDAMOLE, DIPYRIDAMOLE
ERYTHROMYCIN ETHYLSUCCINATE, ERYTHROMYCIN ETHYLSUCCINATE
ETODOLAC, ETODOLAC
FELBAMATE, FELBAMATE
FENOFIBRATE (MICRONIZED), FENOFIBRATE
FESOTERODINE FUMARATE, FESOTERODINE FUMARATE
FLECAINIDE ACETATE, FLECAINIDE ACETATE
FLUCONAZOLE, FLUCONAZOLE
GLIPIZIDE, GLIPIZIDE
INDAPAMIDE, INDAPAMIDE
INDERAL LA, PROPRANOLOL HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ******* ANI PHARMACEUTICALS INC**

INNOPRAN XL, PROPRANOLOL HYDROCHLORIDE
 KIONEX, SODIUM POLYSTYRENE SULFONATE
 LITHOBID, LITHIUM CARBONATE
 LUVOX, FLUVOXAMINE MALEATE
 MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE
 MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
 METHAZOLAMIDE, METHAZOLAMIDE
 METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
 MEXILETINE HYDROCHLORIDE, MEXILETINE HYDROCHLORIDE
 MIGLUSTAT, MIGLUSTAT
 MISOPROSTOL, MISOPROSTOL
 NEBIVOLOL HYDROCHLORIDE, NEBIVOLOL HYDROCHLORIDE
 NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE
 NILUTAMIDE, NILUTAMIDE
 OXISTAT, OXICONAZOLE NITRATE
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
 PANDEL, HYDROCORTISONE PROBUTATE
 PENICILLAMINE, PENICILLAMINE
 PINDOLOL, PINDOLOL
 POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
 POTASSIUM CITRATE, POTASSIUM CITRATE
 PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
 PURIFIED CORTROPHIN GEL, CORTICOTROPIN
 REGLAN, METOCLOPRAMIDE HYDROCHLORIDE
 TRANEXAMIC ACID, TRANEXAMIC ACID
 VANCOCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
 VEREGEN, SINECATECHINS

ANIMA*** ANIMA PHARMACEUTICALS PVT LTD**

BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
 CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE
 DEXAMETHASONE, DEXAMETHASONE

ANNORA*** ANNORA PHARMA PRIVATE LTD**

DROXIDOPA, DROXIDOPA
 LAMIVUDINE, LAMIVUDINE

ANNORA PHARMA*** ANNORA PHARMA PRIVATE LTD**

AMINOCAPROIC ACID, AMINOCAPROIC ACID
 BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
 CAPTOPRIL, CAPTOPRIL
 DEFERASIROX, DEFERASIROX
 DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
 ENALAPRIL MALEATE, ENALAPRIL MALEATE
 FAMOTIDINE, FAMOTIDINE
 FAMOTIDINE, FAMOTIDINE (OTC)
 GLYCOPYRROLATE, GLYCOPYRROLATE
 ITRACONAZOLE, ITRACONAZOLE
 IVABRADINE HYDROCHLORIDE, IVABRADINE HYDROCHLORIDE
 MESALAMINE, MESALAMINE
 MEXILETINE HYDROCHLORIDE, MEXILETINE HYDROCHLORIDE
 NABUMETONE, NABUMETONE
 OXCARBAZEPINE, OXCARBAZEPINE
 PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
 POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
 SAPROPTERIN DIHYDROCHLORIDE, SAPROPTERIN DIHYDROCHLORIDE
 SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
 VIGABATRIN, VIGABATRIN
 ZAFIRLUKAST, ZAFIRLUKAST
 ZILEUTON, ZILEUTON

ANTARES PHARMA INC*** ANTARES PHARMA INC**

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ****

* ANTARES PHARMA INC
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
 TLANDO, TESTOSTERONE UNDECANOATE
 XYOSTED (AUTOINJECTOR), TESTOSTERONE ENANTHATE

ANTIBIOTICE

* ANTIBIOTICE SA
 AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
 AMPICILLIN SODIUM, AMPICILLIN SODIUM
 NAFCILLIN SODIUM, NAFCILLIN SODIUM

ANXIN

* ANXIN PHARMA INC
 SEVELAMER CARBONATE, SEVELAMER CARBONATE

APELLIS PHARMS

* APELLIS PHARMACEUTICALS INC
 EMPAVELI, PEGCETACOPLAN

APGDI

* ASTELLAS PHARMA GLOBAL DEVELOPMENT INC
 MYRBETRIQ GRANULES, MIRABEGRON
 MYRBETRIQ, MIRABEGRON

APIIL

* ALLERGAN PHARMACEUTICALS INTERNATIONAL LTD
 ACTONEL, RISEDRONATE SODIUM
 ATELVIA, RISEDRONATE SODIUM
 DELZICOL, MESALAMINE
 LO LOESTRIN FE, ETHINYL ESTRADIOL
 MINASTRIN 24 FE, ETHINYL ESTRADIOL
 NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
 TAYTULLA, ETHINYL ESTRADIOL

APNAR PHARMA LP

* APNAR PHARMA LP
 BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE
 PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
 TERAZOSIN HYDROCHLORIDE, TERAZOSIN HYDROCHLORIDE

APOTEX

* APOTEX INC
 ABIRATERONE ACETATE, ABIRATERONE ACETATE
 ACYCLOVIR, ACYCLOVIR
 ADEFOVIR DIPIVOXIL, ADEFOVIR DIPIVOXIL
 ALENDRONATE SODIUM, ALENDRONATE SODIUM
 AMBRISENTAN, AMBRISENTAN
 AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM, AMLODIPINE BESYLATE
 AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE
 AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
 ATOMOXETINE HYDROCHLORIDE, ATOMOXETINE HYDROCHLORIDE
 ATOVAQUONE, ATOVAQUONE
 AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE, AZELASTINE HYDROCHLORIDE
 BENDAMUSTINE HYDROCHLORIDE, BENDAMUSTINE HYDROCHLORIDE
 BEPOTASTINE BESILATE, BEPOTASTINE BESILATE
 BORTEZOMIB, BORTEZOMIB
 BRIMONIDINE TARTRATE, BRIMONIDINE TARTRATE
 BUSULFAN, BUSULFAN
 CARBIDOPA AND LEVODOPA, CARBIDOPA
 CEFUROXIME AXETIL, CEFUROXIME AXETIL
 CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CIMETIDINE, CIMETIDINE (OTC)
 CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
 CYCLOSPORINE, CYCLOSPORINE
 DICLOFENAC SODIUM, DICLOFENAC SODIUM
 DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
 DIVALPROEX SODIUM, DIVALPROEX SODIUM
 DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
 DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
 DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ******* APOTEX INC**

EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE, EMTRICITABINE
 EPINASTINE HYDROCHLORIDE, EPINASTINE HYDROCHLORIDE
 ERLOTINIB HYDROCHLORIDE, ERLOTINIB HYDROCHLORIDE
 ETODOLAC, ETODOLAC
 FAMCICLOVIR, FAMCICLOVIR
 FAMOTIDINE, FAMOTIDINE
 FENOFIBRATE (MICRONIZED), FENOFIBRATE
 FINGOLIMOD HYDROCHLORIDE, FINGOLIMOD HYDROCHLORIDE
 FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE
 FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE (OTC)
 FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
 GEFITINIB, GEFITINIB
 GEMFIBROZIL, GEMFIBROZIL
 GLIPIZIDE, GLIPIZIDE
 GLYCOPYRROLATE, GLYCOPYRROLATE
 GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
 IBANDRONATE SODIUM, IBANDRONATE SODIUM
 ICOSAPENT ETHYL, ICOSAPENT ETHYL
 IMATINIB MESYLATE, IMATINIB MESYLATE
 LACOSAMIDE, LACOSAMIDE
 LAMIVUDINE, LAMIVUDINE
 LENALIDOMIDE, LENALIDOMIDE
 LEVETIRACETAM, LEVETIRACETAM
 LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE (OTC)
 MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 MICA FUNGIN SODIUM, MICA FUNGIN SODIUM
 MIDODRINE HYDROCHLORIDE, MIDODRINE HYDROCHLORIDE
 MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
 NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE
 OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE (OTC)
 OMEGA-3-ACID ETHYL ESTERS, OMEGA-3-ACID ETHYL ESTERS
 OMEPRAZOLE, OMEPRAZOLE
 OMEPRAZOLE, OMEPRAZOLE (OTC)
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
 PAXIL CR, PAROXETINE HYDROCHLORIDE
 PAXIL, PAROXETINE HYDROCHLORIDE
 PEMETREXED DISODIUM, PEMETREXED DISODIUM
 PENICILLAMINE, PENICILLAMINE
 PENTOXIFYLLINE, PENTOXIFYLLINE
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
 PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
 PREGABALIN, PREGABALIN
 RAMIPRIL, RAMIPRIL
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
 REGADENOSON, REGADENOSON
 SELEGILINE HYDROCHLORIDE, SELEGILINE HYDROCHLORIDE
 SIROLIMUS, SIROLIMUS
 SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE
 TAMOXIFEN CITRATE, TAMOXIFEN CITRATE
 TETRABENAZINE, TETRABENAZINE
 TICLOPIDINE HYDROCHLORIDE, TICLOPIDINE HYDROCHLORIDE
 TIGECYCLINE, TIGECYCLINE
 TIMOLOL MALEATE, TIMOLOL MALEATE
 TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
 TOLVAPTAN, TOLVAPTAN
 TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
 TRANEXAMIC ACID, TRANEXAMIC ACID
 TRAVOPROST, TRAVOPROST
 TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
 TROSPIMUM CHLORIDE, TROSPIMUM CHLORIDE
 VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
 ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ****

* APOTEX INC
 ZOLEDRONIC ACID, ZOLEDRONIC ACID

APOTEX CORP

* APOTEX CORP
 QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 TASIMELTEON, TASIMELTEON

APOTEX INC

* APOTEX INC
 ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE
 ALPRAZOLAM, ALPRAZOLAM
 ARIPIPRAZOLE, ARIPIPRAZOLE
 ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
 ATROPINE SULFATE, ATROPINE SULFATE
 AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
 BICALUTAMIDE, BICALUTAMIDE
 BIMATOPROST, BIMATOPROST
 BRIMONIDINE TARTRATE AND TIMOLOL MALEATE, BRIMONIDINE TARTRATE
 BUTORPHANOL TARTRATE, BUTORPHANOL TARTRATE
 CALCITONIN-SALMON, CALCITONIN SALMON
 CARBAMAZEPINE, CARBAMAZEPINE
 CARBIDOPA AND LEVODOPA, CARBIDOPA
 CEFPROZIL, CEFPROZIL
 CELECOXIB, CELECOXIB
 CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
 ENOXAPARIN SODIUM (PRESERVATIVE FREE), ENOXAPARIN SODIUM
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
 IBANDRONATE SODIUM, IBANDRONATE SODIUM
 IMIQUIMOD, IMIQUIMOD
 IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
 KETOTIFEN FUMARATE, KETOTIFEN FUMARATE (OTC)
 LEVETIRACETAM, LEVETIRACETAM
 LEVOFLOXACIN, LEVOFLOXACIN
 MODAFINIL, MODAFINIL
 MOEXIPRIL HYDROCHLORIDE, MOEXIPRIL HYDROCHLORIDE
 MOMETASONE FUROATE, MOMETASONE FUROATE
 MYCOPHENOLIC SODIUM, MYCOPHENOLIC SODIUM
 OFLOXACIN, OFLOXACIN
 OLANZAPINE, OLANZAPINE
 OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE
 OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE (OTC)
 RISEDRONATE SODIUM, RISEDRONATE SODIUM
 RISPERIDONE, RISPERIDONE
 TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
 TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
 TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

* APOTEX INC ETOBICOKE SITE
 ACYCLOVIR, ACYCLOVIR
 BALSALAZIDE DISODIUM, BALSALAZIDE DISODIUM
 BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
 CARBAMAZEPINE, CARBAMAZEPINE
 CILOSTAZOL, CILOSTAZOL
 CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
 DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
 ETODOLAC, ETODOLAC
 FOSINOPRIL SODIUM, FOSINOPRIL SODIUM
 GABAPENTIN, GABAPENTIN
 LEFLUNOMIDE, LEFLUNOMIDE
 LORATADINE, LORATADINE (OTC)
 MELOXICAM, MELOXICAM
 MIRTAZAPINE, MIRTAZAPINE
 SELEGILINE HYDROCHLORIDE, SELEGILINE HYDROCHLORIDE
 ZONISAMIDE, ZONISAMIDE

* APOTEX INC RICHMOND HILL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ****

* APOTEX INC RICHMOND HILL
 AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
 BUDESONIDE, BUDESONIDE (OTC)
 DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION), DESMOPRESSIN ACETATE
 FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
 KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE

APOTHECON

* APOTHECON INC DIV BRISTOL MYERS SQUIBB
 KENALOG-10, TRIAMCINOLONE ACETONIDE
 KENALOG-40, TRIAMCINOLONE ACETONIDE
 KENALOG-80, TRIAMCINOLONE ACETONIDE

APP PHARMS

* APP PHARMACEUTICALS LLC
 DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE

APPCO

* APPCO PHARMA LLC
 ACETAZOLAMIDE, ACETAZOLAMIDE
 CHLORTHALIDONE, CHLORTHALIDONE
 CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
 DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
 HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
 LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
 LORATADINE, LORATADINE (OTC)
 METAXALONE, METAXALONE
 MODAFINIL, MODAFINIL
 OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
 PERPHENAZINE, PERPHENAZINE
 PRAZOSIN HYDROCHLORIDE, PRAZOSIN HYDROCHLORIDE
 SILDENAFIL CITRATE, SILDENAFIL CITRATE
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
 ZOLMITRIPTAN, ZOLMITRIPTAN

APRECIA PHARMS

* APRECIA PHARMACEUTICALS LLC
 SPRITAM, LEVETIRACETAM

APTAPHARMA INC

* APTAPHARMA INC
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 IBUPROFEN, IBUPROFEN (OTC)
 OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
 SILDENAFIL CITRATE, SILDENAFIL CITRATE

AQUESTIVE

* AQUESTIVE THERAPEUTICS INC
 EXSERVAN, RILUZOLE

ARBOR PHARMS LLC

* ARBOR PHARMACEUTICALS LLC
 DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
 E.E.S. 400, ERYTHROMYCIN ETHYLSUCCINATE
 ERY-TAB, ERYTHROMYCIN
 ERYTHROCIN STEARATE, ERYTHROMYCIN STEARATE
 ERYTHROMYCIN ETHYLSUCCINATE, ERYTHROMYCIN ETHYLSUCCINATE
 ERYTHROMYCIN, ERYTHROMYCIN
 EVEKEO, AMPHETAMINE SULFATE
 SKLICE, IVERMECTIN (OTC)

ARCUTIS

* ARCUTIS BIOTHERAPEUTICS INC
 ZORYVE, ROFLUMILAST

ARDELYX INC

* ARDELYX INC
 IBSRELA, TENAPANOR HYDROCHLORIDE

AREVA PHARMS

* AREVA PHARMACEUTICALS INC
 FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE
 FUROSEMIDE, FUROSEMIDE
 PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ****

* AREVA PHARMACEUTICALS INC
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE

ARISE

* ARISE PHARMACEUTICALS LLC
IBUPROFEN, IBUPROFEN (OTC)

ARMSTRONG PHARMS

* ARMSTRONG PHARMACEUTICALS INC
PRIMATENE MIST, EPINEPHRINE (OTC)

ARRAY BIOPHARMA INC

* ARRAY BIOPHARMA INC
BRAFTOVI, ENCORAFENIB
MEKTOVI, BINIMETINIB

ARROW INTL

* ARROW INTERNATIONAL LTD
LENALIDOMIDE, LENALIDOMIDE

ARTHUR GRP

* ARTHUR GROUP LLC
BUSULFAN, BUSULFAN
MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE
SEVELAMER CARBONATE, SEVELAMER CARBONATE

ASCEND THERAPS US

* ASCEND THERAPEUTICS US LLC
BINOSTO, ALENDRONATE SODIUM
ESTROGEL, ESTRADIOL

ASCENT PHARMS INC

* ASCENT PHARMACEUTICALS INC
BENZONATATE, BENZONATATE
DETXOAMP SACCHARATE, AMP ASPARTATE, DETXOAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
DETXOAMP SACCHARATE, AMP ASPARTATE, DETXOAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DRONABINOL, DRONABINOL
DUTASTERIDE, DUTASTERIDE
FAMOTIDINE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE (OTC)
GABAPENTIN, GABAPENTIN
GEMFIBROZIL, GEMFIBROZIL
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
IBUPROFEN, IBUPROFEN (OTC)
LISINOPRIL, LISINOPRIL
METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
OMEGA-3-ACID ETHYL ESTERS, OMEGA-3-ACID ETHYL ESTERS
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
POTASSIUM CITRATE, POTASSIUM CITRATE
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
TOPIRAMATE, TOPIRAMATE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

ASPEN

* ASPEN PHARMA USA INC
ACETYLCYSTEINE, ACETYLCYSTEINE
GLYCOPYRROLATE, GLYCOPYRROLATE
HYDROXYPROGESTERONE CAPROATE, HYDROXYPROGESTERONE CAPROATE

ASPEN GLOBAL INC

* ASPEN GLOBAL INC
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
CYCLESSA, DESOGESTREL
HYDROXYPROGESTERONE CAPROATE, HYDROXYPROGESTERONE CAPROATE

ASPIRO

* ASPIRO PHARMA LTD
ACETAMINOPHEN, ACETAMINOPHEN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ****

- * ASPIRO PHARMA LTD
 - DAPTOMYCIN, DAPTOMYCIN
 - FOSAPREPITANT DIMEGLUMINE, FOSAPREPITANT DIMEGLUMINE
 - LACOSAMIDE, LACOSAMIDE
 - LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
 - PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
 - SUCCINYLCHOLINE CHLORIDE, SUCCINYLCHOLINE CHLORIDE
 - VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE

ASSERTIO

- * ASSERTIO THERAPEUTICS INC
 - CAMBIA, DICLOFENAC POTASSIUM
 - ZIPSOR, DICLOFENAC POTASSIUM

ASTELLAS

- * ASTELLAS PHARMA US INC
 - AMBISOME, AMPHOTERICIN B
 - ASTAGRAF XL, TACROLIMUS
 - CRESEMBA, ISAVUCONAZONIUM SULFATE
 - LEXISCAN, REGADENOSON
 - MYCAMINE, MICAFUNGIN SODIUM
 - PROGRAF, TACROLIMUS
 - VESICARE LS, SOLIFENACIN SUCCINATE
 - VESICARE, SOLIFENACIN SUCCINATE
 - XOSPATA, GILTERITINIB FUMARATE
 - XTANDI, ENZALUTAMIDE

ASTRAL

- * ASTRAL STERITECH PVT LTD
 - AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
 - CEFEPIME HYDROCHLORIDE, CEFEPIME HYDROCHLORIDE
 - CEFTRIAZONE SODIUM, CEFTRIAZONE SODIUM
 - CEFTRIAZONE, CEFTRIAZONE SODIUM
 - PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM

ASTRAZENECA

- * ASTRAZENECA LP
 - PULMICORT FLEXHALER, BUDESONIDE
 - SYMBICORT, BUDESONIDE
- * ASTRAZENECA PHARMACEUTICALS LP
 - BEVESPI AEROSPHERE, FORMOTEROL FUMARATE
 - BRILINTA, TICAGRELOR
 - DALIRESP, ROFLUMILAST
 - FASLODEX, FULVESTRANT
 - IRESSA, GEFITINIB
 - KOSELUGO, SELUMETINIB SULFATE
 - LOKELMA, SODIUM ZIRCONIUM CYCLOSILICATE
 - LYNPARZA, OLAPARIB
 - NEXIUM IV, ESOMEPRAZOLE SODIUM
 - NEXIUM, ESOMEPRAZOLE MAGNESIUM
 - PRILOSEC OTC, OMEPRAZOLE MAGNESIUM (OTC)
 - PULMICORT RESPULES, BUDESONIDE
 - SEROQUEL, QUETIAPINE FUMARATE
 - TAGRISSO, OSIMERTINIB MESYLATE
 - ZOMIG, ZOLMITRIPTAN
 - ZOMIG-ZMT, ZOLMITRIPTAN
- * ASTRAZENECA UK LTD
 - CALQUENCE, ACALABRUTINIB
 - CALQUENCE, ACALABRUTINIB MALEATE
 - SEROQUEL XR, QUETIAPINE FUMARATE

ASTRAZENECA AB

- * ASTRAZENECA AB
 - BREZTRI AEROSPHERE, BUDESONIDE
 - BYDUREON BCISE, EXENATIDE SYNTHETIC
 - BYETTA, EXENATIDE SYNTHETIC
 - FARXIGA, DAPAGLIFLOZIN
 - KOMBIGLYZE XR, METFORMIN HYDROCHLORIDE
 - ONGLYZA, SAXAGLIPTIN HYDROCHLORIDE
 - QTERN, DAPAGLIFLOZIN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ****

* ASTRAZENECA AB
SYMLIN, PRAMLINTIDE ACETATE
XIGDUO XR, DAPAGLIFLOZIN

ASTRAZENECA LP

* ASTRAZENECA LP
NEXIUM 24HR, ESOMEPRAZOLE MAGNESIUM (OTC)

ATHEM

* ATHEM HOLDINGS LLC
FOLIC ACID, FOLIC ACID
TOLTERODINE TARTRATE, TOLTERODINE TARTRATE

ATHENA

* ATHENA BIOSCIENCE LLC
NEXICLON XR, CLONIDINE
QDOLO, TRAMADOL HYDROCHLORIDE

ATHENEX

* ATHENEX PHARMACEUTICAL DIV
PENTOBARBITAL SODIUM, PENTOBARBITAL SODIUM

ATHENEX INC

* ATHENEX INC
BUMETANIDE, BUMETANIDE
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
FAMOTIDINE PRESERVATIVE FREE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE
FUROSEMIDE, FUROSEMIDE
GLYCOPYRROLATE, GLYCOPYRROLATE
PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE
VALPROATE SODIUM, VALPROATE SODIUM

ATLAS PHARMS LLC

* ATLAS PHARMACEUTICALS LLC
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

ATNAHS PHARMA US

* ATNAHS PHARMA US LTD
ANAPROX DS, NAPROXEN SODIUM
EC-NAPROSYN, NAPROXEN
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
NAPROSYN, NAPROXEN

ATON

* ATON PHARMA INC
LODOSYN, CARBIDOPA

AUCTA

* AUCTA PHARMACEUTICALS INC
DEFERASIROX, DEFERASIROX
FORMOTEROL FUMARATE, FORMOTEROL FUMARATE
MEXILETINE HYDROCHLORIDE, MEXILETINE HYDROCHLORIDE
OXCARBAZEPINE, OXCARBAZEPINE
VIGADRONE, VIGABATRIN

AURINIA

* AURINIA PHARMACEUTICALS INC
LUPKYNIS, VOCLOSPORIN

AUROBINDO

* AUROBINDO PHARMA LTD
AMOXICILLIN, AMOXICILLIN
CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
CLARITHROMYCIN, CLARITHROMYCIN
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LISINOPRIL, LISINOPRIL
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
MIRTAZAPINE, MIRTAZAPINE
NEVIRAPINE, NEVIRAPINE
ZIDOVUDINE, ZIDOVUDINE

AUROBINDO PHARMA

* AUROBINDO PHARMA LTD

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ****

* AUROBINDO PHARMA LTD
 ACETAMINOPHEN, ACETAMINOPHEN (OTC)
 AFIRMELLE, ETHINYL ESTRADIOL
 ALENDRONATE SODIUM, ALENDRONATE SODIUM
 ALPRAZOLAM, ALPRAZOLAM
 AMBRISENTAN, AMBRISENTAN
 AMINOCAPROIC ACID, AMINOCAPROIC ACID
 AMLODIPINE AND OLMESARTAN MEDOXOMIL, AMLODIPINE BESYLATE
 AMLODIPINE BESYLATE AND VALSARTAN, AMLODIPINE BESYLATE
 AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
 AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE, AMLODIPINE BESYLATE
 AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
 ARIPIPIRAZOLE, ARIPIPIRAZOLE
 ATAZANAVIR SULFATE, ATAZANAVIR SULFATE
 ATENOLOL, ATENOLOL
 ATHENTIA NEXT, LEVONORGESTREL (OTC)
 ATOMOXETINE HYDROCHLORIDE, ATOMOXETINE HYDROCHLORIDE
 AUROVELA 1.5/30, ETHINYL ESTRADIOL
 AUROVELA 1/20, ETHINYL ESTRADIOL
 AUROVELA 24 FE, ETHINYL ESTRADIOL
 AUROVELA FE 1.5/30, ETHINYL ESTRADIOL
 AUROVELA FE 1/20, ETHINYL ESTRADIOL
 AYUNA, ETHINYL ESTRADIOL
 BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
 BISOPROLOL FUMARATE, BISOPROLOL FUMARATE
 CARBIDOPA, CARBIDOPA
 CARISOPRODOL, CARISOPRODOL
 CARVEDILOL, CARVEDILOL
 CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
 CEFDINIR, CEFDINIR
 CEFPODOXIME PROXETIL, CEFPODOXIME PROXETIL
 CEFPROZIL, CEFPROZIL
 CEFUROXIME AXETIL, CEFUROXIME AXETIL
 CELECOXIB, CELECOXIB
 CEPHALEXIN, CEPHALEXIN
 CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
 CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
 CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
 CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
 CLORAZEPATE DIPOTASSIUM, CLORAZEPATE DIPOTASSIUM
 CLOZAPINE, CLOZAPINE
 CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
 CYONANZ, ETHINYL ESTRADIOL
 DALFAMPRIDINE, DALFAMPRIDINE
 DARIFENACIN HYDROBROMIDE, DARIFENACIN HYDROBROMIDE
 DICLOXACILLIN SODIUM, DICLOXACILLIN SODIUM
 DIMETHYL FUMARATE, DIMETHYL FUMARATE
 EFAVIRENZ, EFAVIRENZ
 EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE, EFAVIRENZ
 ELETRIPTAN HYDROBROMIDE, ELETRIPTAN HYDROBROMIDE
 EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE, EMTRICITABINE
 EMZAHH, NORETHINDRONE
 ENTECAVIR, ENTECAVIR
 ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM (OTC)
 ESZOPICLONE, ESZOPICLONE
 EZETIMIBE, EZETIMIBE
 FAMOTIDINE, FAMOTIDINE (OTC)
 FENOFIBRATE, FENOFIBRATE
 FESOTERODINE FUMARATE, FESOTERODINE FUMARATE
 FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, FEXOFENADINE
 FINASTERIDE, FINASTERIDE
 FLUCONAZOLE, FLUCONAZOLE
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE, FOSINOPRIL SODIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ****

* AUROBINDO PHARMA LTD
 GABAPENTIN, GABAPENTIN
 GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
 GLIPIZIDE, GLIPIZIDE
 GLYBURIDE AND METFORMIN HYDROCHLORIDE, GLYBURIDE
 GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE, DEXTROMETHORPHAN HYDROBROMIDE (OTC)
 GUAIFENESIN, GUAIFENESIN (OTC)
 HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 IBANDRONATE SODIUM, IBANDRONATE SODIUM
 IBUPROFEN AND DIPHENHYDRAMINE CITRATE, DIPHENHYDRAMINE CITRATE (OTC)
 IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE, IBUPROFEN (OTC)
 IBUPROFEN, IBUPROFEN (OTC)
 INCASSIA, NORETHINDRONE
 ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
 KALLIGA, DESOGESTREL
 LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE
 LAMIVUDINE, LAMIVUDINE
 LAMOTRIGINE, LAMOTRIGINE
 LEFLUNOMIDE, LEFLUNOMIDE
 LEVETIRACETAM, LEVETIRACETAM
 LO SIMPESSE, ETHINYL ESTRADIOL
 LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)
 LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
 MELOXICAM, MELOXICAM
 METOPROLOL TARTRATE, METOPROLOL TARTRATE
 MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
 MIRTAZAPINE, MIRTAZAPINE
 NADOLOL, NADOLOL
 NAPROXEN, NAPROXEN
 NEVIRAPINE, NEVIRAPINE
 NEXESTA FE, ETHINYL ESTRADIOL
 NICOTINE POLACRILEX, NICOTINE POLACRILEX (OTC)
 NIFEDIPINE, NIFEDIPINE
 NYLIA 1/35, ETHINYL ESTRADIOL
 NYLIA 7/7/7, ETHINYL ESTRADIOL
 OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
 OMEPRAZOLE MAGNESIUM, OMEPRAZOLE MAGNESIUM (OTC)
 OMEPRAZOLE, OMEPRAZOLE
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 ONDANSETRON, ONDANSETRON
 PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
 PENICILLIN V POTASSIUM, PENICILLIN V POTASSIUM
 PERINDOPRIL ERBUMINE, PERINDOPRIL ERBUMINE
 PHENYTOIN SODIUM, PHENYTOIN SODIUM
 PITAVASTATIN CALCIUM, PITAVASTATIN CALCIUM
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
 PRASUGREL, PRASUGREL HYDROCHLORIDE
 PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
 PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
 PSEUDOEPHEDRINE HYDROCHLORIDE, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
 QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
 QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM
 RALOXIFENE HYDROCHLORIDE, RALOXIFENE HYDROCHLORIDE
 RANOLAZINE, RANOLAZINE
 RHUZDAH, ETHINYL ESTRADIOL
 RIBAVIRIN, RIBAVIRIN
 RISEDRONATE SODIUM, RISEDRONATE SODIUM
 RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
 RUFINAMIDE, RUFINAMIDE
 SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
 SEVELAMER CARBONATE, SEVELAMER CARBONATE
 SIMLIYA, DESOGESTREL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ******* AUROBINDO PHARMA LTD**

SIMPESSE, ETHINYL ESTRADIOL
 SIMVASTATIN, SIMVASTATIN
 SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE
 SPIRONOLACTONE, SPIRONOLACTONE
 SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
 TELMISARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 TELMISARTAN, TELMISARTAN
 TENOFOVIR DISOPROXIL FUMARATE, TENOFOVIR DISOPROXIL FUMARATE
 TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
 TOPIRAMATE, TOPIRAMATE
 TORSEMIDE, TORSEMIDE
 TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
 TRANDOLAPRIL, TRANDOLAPRIL
 TRI-LO-MILI, ETHINYL ESTRADIOL
 VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
 VALGANCICLOVIR HYDROCHLORIDE, VALGANCICLOVIR HYDROCHLORIDE
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
 ZALEPLON, ZALEPLON
 ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE
 ZOLMITRIPTAN, ZOLMITRIPTAN
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

AUROBINDO PHARMA LTD*** AUROBINDO PHARMA LIMITED**

DIVALPROEX SODIUM, DIVALPROEX SODIUM
 FOSINOPRIL SODIUM, FOSINOPRIL SODIUM
 GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
 LEVOFLOXACIN, LEVOFLOXACIN
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

*** AUROBINDO PHARMA LTD**

ABACAVIR SULFATE AND LAMIVUDINE, ABACAVIR SULFATE
 ABACAVIR SULFATE, ABACAVIR SULFATE
 ACETAMINOPHEN, ASPIRIN AND CAFFEINE, ACETAMINOPHEN (OTC)
 ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE
 AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
 AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE
 AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
 AMOXICILLIN, AMOXICILLIN
 ARIPIPRAZOLE, ARIPIPRAZOLE
 ARMODAFINIL, ARMODAFINIL
 AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
 AZITHROMYCIN, AZITHROMYCIN
 BACLOFEN, BACLOFEN
 BRIVARACETAM, BRIVARACETAM
 BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
 CARBIDOPA AND LEVODOPA, CARBIDOPA
 CEFIXIME, CEFIXIME
 CEFPODOXIME PROXETIL, CEFPODOXIME PROXETIL
 CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
 CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE (OTC)
 CHLORZOXAZONE, CHLORZOXAZONE
 CINACALCET HYDROCHLORIDE, CINACALCET HYDROCHLORIDE
 CLINDAMYCIN PALMITATE HYDROCHLORIDE, CLINDAMYCIN PALMITATE HYDROCHLORIDE
 CLOBAZAM, CLOBAZAM
 CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
 CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
 COLCHICINE, COLCHICINE
 DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
 DIGOXIN, DIGOXIN
 DIVALPROEX SODIUM, DIVALPROEX SODIUM
 DOFETILDE, DOFETILDE
 DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
 DROXIDOPA, DROXIDOPA

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ****

* AUROBINDO PHARMA LTD
 DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
 DUTASTERIDE, DUTASTERIDE
 EFAVIRENZ, EFAVIRENZ
 ENTACAPONE, ENTACAPONE
 ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
 ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
 FAMCICLOVIR, FAMCICLOVIR
 FAMOTIDINE, FAMOTIDINE
 FELODIPINE, FELODIPINE
 FENOFIBRATE (MICRONIZED), FENOFIBRATE
 FENOFIBRIC ACID, CHOLINE FENOFIBRATE
 FINASTERIDE, FINASTERIDE
 FLECAINIDE ACETATE, FLECAINIDE ACETATE
 FLUCYTOSINE, FLUCYTOSINE
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 GABAPENTIN, GABAPENTIN
 GEMFIBROZIL, GEMFIBROZIL
 GLIMEPIRIDE, GLIMEPIRIDE
 GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE, GUAIFENESIN (OTC)
 HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
 IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
 IBUPROFEN, IBUPROFEN
 IBUPROFEN, IBUPROFEN (OTC)
 ICLEVIA, ETHINYL ESTRADIOL
 IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 IRBESARTAN, IRBESARTAN
 LACOSAMIDE, LACOSAMIDE
 LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE
 LEVOMILNACIPRAN HYDROCHLORIDE, LEVOMILNACIPRAN HYDROCHLORIDE
 LO-ZUMANDIMINE, DROSPIRENONE
 LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE, LOPERAMIDE HYDROCHLORIDE (OTC)
 LORATADINE, LORATADINE (OTC)
 MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 METHENAMINE HIPPURATE, METHENAMINE HIPPURATE
 METRONIDAZOLE, METRONIDAZOLE
 MIDODRINE HYDROCHLORIDE, MIDODRINE HYDROCHLORIDE
 MILI, ETHINYL ESTRADIOL
 MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
 MODAFINIL, MODAFINIL
 MONTELUKAST SODIUM, MONTELUKAST SODIUM
 MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
 NAPROXEN SODIUM, NAPROXEN SODIUM
 NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
 NEBIVOLOL HYDROCHLORIDE, NEBIVOLOL HYDROCHLORIDE
 NIACIN, NIACIN
 NICOTINE POLACRILEX, NICOTINE POLACRILEX (OTC)
 OLANZAPINE, OLANZAPINE
 PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
 PARICALCITOL, PARICALCITOL
 PILOCARPINE HYDROCHLORIDE, PILOCARPINE HYDROCHLORIDE
 PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
 POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
 PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
 PREDNISONE, PREDNISONE
 PYRIMETHAMINE, PYRIMETHAMINE
 QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
 QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE
 RAMIPRIL, RAMIPRIL
 REPAGLINIDE, REPAGLINIDE
 RISEDRONATE SODIUM, RISEDRONATE SODIUM
 RISPERIDONE, RISPERIDONE
 RITONAVIR, RITONAVIR

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ****

- * AUROBINDO PHARMA LTD
 - RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
 - ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
 - SILDENAFIL CITRATE, SILDENAFIL CITRATE
 - SILODOSIN, SILODOSIN
 - SUMATRIPTAN AND NAPROXEN SODIUM, NAPROXEN SODIUM
 - TADALAFIL, TADALAFIL
 - TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
 - TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
 - TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
 - TRI-MILI, ETHINYL ESTRADIOL
 - URSODIOL, URSODIOL
 - VALGANCICLOVIR HYDROCHLORIDE, VALGANCICLOVIR HYDROCHLORIDE
 - VALSARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 - VALSARTAN, VALSARTAN
 - VIGABATRIN, VIGABATRIN
 - VORICONAZOLE, VORICONAZOLE
 - ZONISAMIDE, ZONISAMIDE
 - ZUMANDIMINE, DROSPIRENONE
- * AUROBINDO PHARMA LTD INC
 - ZIDOVUDINE, ZIDOVUDINE

AUROBINDO PHARMA USA

- * AUROBINDO PHARMA USA INC
 - BUDESONIDE, BUDESONIDE
 - CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
 - DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
 - GLIPIZIDE, GLIPIZIDE
 - HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
 - MAXZIDE, HYDROCHLOROTHIAZIDE
 - MAXZIDE-25, HYDROCHLOROTHIAZIDE
 - PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
 - PINDOLOL, PINDOLOL
 - RASAGILINE MESYLATE, RASAGILINE MESYLATE

AUROLIFE PHARMA LLC

- * AUROLIFE PHARMA LLC
 - ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
 - AMPHETAMINE SULFATE, AMPHETAMINE SULFATE
 - BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
 - CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
 - DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
 - DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
 - DICLOFENAC SODIUM, DICLOFENAC SODIUM (OTC)
 - FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
 - GLYCOPYRROLATE, GLYCOPYRROLATE
 - HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
 - HYDROCODONE BITARTRATE AND IBUPROFEN, HYDROCODONE BITARTRATE
 - HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
 - LORAZEPAM, LORAZEPAM
 - METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
 - METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
 - OMEPRazole AND SODIUM BICARBONATE, OMEPRazole
 - OMEPRazole AND SODIUM BICARBONATE, OMEPRazole (OTC)
 - OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
 - OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
 - OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE
 - PHTERMINE HYDROCHLORIDE, PHTERMINE HYDROCHLORIDE
 - TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE

AUSTARPHARMA

- * AUSTARPHARMA LLC
 - FENOFIBRATE, FENOFIBRATE
 - SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE
 - TADALAFIL, TADALAFIL

AUSTARPHARMA LLC

- * AUSTARPHARMA LLC
 - METHOCARBAMOL, METHOCARBAMOL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ******AUXILIUM PHARMS INC**

- * AUXILIUM PHARMACEUTICALS INC
TESTOPEL, TESTOSTERONE
THEO-24, THEOPHYLLINE

AUXILIUM PHARMS LLC

- * AUXILIUM PHARMACEUTICALS LLC
EDEX, ALPROSTADIL
TESTIM, TESTOSTERONE
THEO-24, THEOPHYLLINE

AVANIR PHARMS

- * AVANIR PHARMACEUTICALS INC
NUEDEXTA, DEXTROMETHORPHAN HYDROBROMIDE

AVANTHI INC

- * AVANTHI INC
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE (OTC)
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
DIETHYLPROPION HYDROCHLORIDE, DIETHYLPROPION HYDROCHLORIDE
HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE, HOMATROPINE METHYLBROMIDE
INDOMETHACIN, INDOMETHACIN
LOMAIRA, PHENTERMINE HYDROCHLORIDE
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE

AVEMA PHARMA

- * AVEMA PHARMA SOLUTIONS
IBUPROFEN, IBUPROFEN (OTC)

AVENT

- * AVENT INC
PYTEST KIT, UREA, C-14
PYTEST, UREA, C-14

AVEO PHARMS

- * AVEO PHARMACEUTICALS INC
FOTIVDA, TIVOZANIB HYDROCHLORIDE

AVERITAS

- * AVERITAS PHARMA INC
QUTENZA, CAPSAICIN

AVET

- * AVET PHARMACEUTICALS INC
ACHROMYCIN V, TETRACYCLINE HYDROCHLORIDE
DOXERCALCIFEROL, DOXERCALCIFEROL

AVET LIFESCIENCES

- * AVET LIFESCIENCES LTD
BICNU, CARMUSTINE
ISOPROTERENOL HYDROCHLORIDE, ISOPROTERENOL HYDROCHLORIDE
- * AVET LIFESCIENCES PRIVATE LTD
NEOSTIGMINE METHYSULFATE, NEOSTIGMINE METHYSULFATE

AVEVA

- * AVEVA DRUG DELIVERY SYSTEMS INC
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
BUPRENORPHINE, BUPRENORPHINE
CLONIDINE, CLONIDINE
NICOTINE, NICOTINE (OTC)

AVID RADIOPHARMS INC

- * AVID RADIOPHARMACEUTICALS INC
AMYVID, FLORBETAPIR F-18
TAUVID, FLORTAUCIPIR F-18

AVION PHARMS

- * AVION PHARMACEUTICALS LLC
BALCOLTRA, ETHINYL ESTRADIOL
DHIVY, CARBIDOPA
PONSTEL, MEFENAMIC ACID

AVONDALE PHARMS

- * AVONDALE PHARMACEUTICALS LLC
MELOXICAM, MELOXICAM
NIACOR, NIACIN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** A ******AXSOME**

* AXSOME THERAPEUTICS INC
AUVELITY, BUPROPION HYDROCHLORIDE

AXSOME MALTA

* AXSOME MALTA LTD
SUNOSI, SOLRIAMFETOL HYDROCHLORIDE

AYANA PHARMA LTD

* AYANA PHARMA LTD
DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL), DOXORUBICIN HYDROCHLORIDE

AYTU

* AYTU BIOSCIENCE INC
KARBINAL ER, CARBINOXAMINE MALEATE

AYTU BIOPHARMA

* AYTU BIOPHARMA INC
METADATE CD, METHYLPHENIDATE HYDROCHLORIDE

AZURITY

* AZURITY PHARMACEUTICALS INC
BIDIL, HYDRALAZINE HYDROCHLORIDE
E.E.S., ERYTHROMYCIN ETHYLSUCCINATE
EDARBI, AZILSARTAN KAMEDOXOMIL
EDARBYCLOR, AZILSARTAN KAMEDOXOMIL
EPANED, ENALAPRIL MALEATE
EPRONTIA, TOPIRAMATE
ERYPED, ERYTHROMYCIN ETHYLSUCCINATE
EVEKEO ODT, AMPHETAMINE SULFATE
FIRVANQ KIT, VANCOMYCIN HYDROCHLORIDE
FLEQSUVY, BACLOFEN
GLIADEL, CARMUSTINE
HORIZANT, GABAPENTIN ENACARBIL
KATERZIA, AMLODIPINE BENZOATE
KONVOMEP, OMEPRAZOLE
NYMALIZE, NIMODIPINE
QBRELIS, LISINOPRIL
SOTYLIZE, SOTALOL HYDROCHLORIDE
THYQUIDITY, LEVOTHYROXINE SODIUM
TRIPTODUR KIT, TRIPTORELIN PAMOATE
XATMEP, METHOTREXATE SODIUM
ZONISADE, ZONISAMIDE

**** B ******B BRAUN**

* B BRAUN MEDICAL INC
ACETIC ACID 0.25% IN PLASTIC CONTAINER, ACETIC ACID, GLACIAL
AMINO ACIDS, AMINO ACIDS
BALANCED SALT, CALCIUM CHLORIDE
CEFAZOLIN AND DEXTROSE, CEFZOLIN SODIUM
CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER, CEFEPIME HYDROCHLORIDE
CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER, CEFOTAXIME SODIUM
CEFTRIAXONE AND DEXTROSE IN DUPLEX CONTAINER, CEFTRIAXONE SODIUM
CEFUROXIME AND DEXTROSE IN DUPLEX CONTAINER, CEFUROXIME SODIUM
DEXTROSE 10% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM
DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** B ******* B BRAUN MEDICAL INC**

DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% IN LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 70% IN PLASTIC CONTAINER, DEXTROSE
 DOPAMINE HYDROCHLORIDE AND DEXTROSE 5% IN PLASTIC CONTAINER, DOPAMINE HYDROCHLORIDE
 DOPAMINE HYDROCHLORIDE AND DEXTROSE 5%, DOPAMINE HYDROCHLORIDE
 FREAMINE HBC 6.9%, AMINO ACIDS
 FREAMINE III 10%, AMINO ACIDS
 FREAMINE III 3% W/ ELECTROLYTES, AMINO ACIDS
 FREAMINE III 8.5% W/ ELECTROLYTES, AMINO ACIDS
 FREAMINE III 8.5%, AMINO ACIDS
 GLYCINE 1.5% IN PLASTIC CONTAINER, GLYCINE
 HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN
 HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPATAMINE 8%, AMINO ACIDS
 ISOLYTE P IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
 ISOLYTE S IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
 ISOLYTE S PH 7.4 IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
 LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 LIDOCAINE HYDROCHLORIDE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE
 LIDOCAINE HYDROCHLORIDE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE
 LIDOCAINE HYDROCHLORIDE 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE
 MANNITOL 10% IN PLASTIC CONTAINER, MANNITOL
 MANNITOL 15% IN PLASTIC CONTAINER, MANNITOL
 MANNITOL 20% IN PLASTIC CONTAINER, MANNITOL
 MANNITOL 5% IN PLASTIC CONTAINER, MANNITOL
 METRO I.V. IN PLASTIC CONTAINER, METRONIDAZOLE
 NUTRILIPID 10%, SOYBEAN OIL
 NUTRILIPID 20%, SOYBEAN OIL
 PHYSIOLYTE IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
 POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC
 POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC
 POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC
 POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC
 POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC
 POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC
 POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC
 POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC
 POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC
 POTASSIUM CHLORIDE 0.075% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC
 POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC
 POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC
 POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC
 POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC
 POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.11% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC
 POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC
 POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.15% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC
 POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER,

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** B ******* B BRAUN MEDICAL INC**

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM
 POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC
 POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.22% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC
 POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.3% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
 PROCALAMINE, AMINO ACIDS
 RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, SODIUM CHLORIDE
 SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
 SODIUM CHLORIDE 0.9%, SODIUM CHLORIDE
 SODIUM CHLORIDE 3% IN PLASTIC CONTAINER, SODIUM CHLORIDE
 SODIUM CHLORIDE 5% IN PLASTIC CONTAINER, SODIUM CHLORIDE
 SORBITOL 3.3% IN PLASTIC CONTAINER, SORBITOL
 STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION
 STERILE WATER IN PLASTIC CONTAINER, STERILE WATER FOR IRRIGATION
 THEOPHYLLINE 0.04% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
 THEOPHYLLINE 0.08% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
 THEOPHYLLINE 0.16% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
 THEOPHYLLINE 0.32% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
 TROPHAMINE 10%, AMINO ACIDS
 TROPHAMINE, AMINO ACIDS

B BRAUN MEDICAL INC*** B BRAUN MEDICAL INC**

ACETAMINOPHEN, ACETAMINOPHEN
 BUPIVACAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE
 CLOROTEKAL, CHLOROPROCAINE HYDROCHLORIDE
 HEPARIN SODIUM, HEPARIN SODIUM
 LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE, EPINEPHRINE
 LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
 MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MAGNESIUM SULFATE
 MAGNESIUM SULFATE, MAGNESIUM SULFATE
 MEROPENEM AND SODIUM CHLORIDE IN DUPLEX CONTAINER, MEROPENEM

BAJAJ*** BAJAJ MEDICAL**

CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE

*** BAJAJ MEDICAL LLC**

CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
 CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
 CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE (OTC)

BAMF*** BAMF HEALTH INC**

SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** B ******BANNER LIFE SCIENCES**

* BANNER LIFE SCIENCES LLC
BAFIERTAM, MONOMETHYL FUMARATE

BARR

* BARR LABORATORIES INC
AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, AMILORIDE HYDROCHLORIDE
ARANELLE, ETHINYL ESTRADIOL
ASPIRIN AND DIPYRIDAMOLE, ASPIRIN
BALZIVA-28, ETHINYL ESTRADIOL
CHLORDIAZEPOXIDE HYDROCHLORIDE, CHLORDIAZEPOXIDE HYDROCHLORIDE
CLONAZEPAM, CLONAZEPAM
DANAZOL, DANAZOL
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
DIPYRIDAMOLE, DIPYRIDAMOLE
DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE
DUTASTERIDE, DUTASTERIDE
ESTRADIOL AND NORETHINDRONE ACETATE, ESTRADIOL
ESTRADIOL AND NORGESTIMATE, ESTRADIOL
FLUDROCORTISONE ACETATE, FLUDROCORTISONE ACETATE
GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
HYDROXYUREA, HYDROXYUREA
HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE
ISONIAZID, ISONIAZID
JUNEL 1.5/30, ETHINYL ESTRADIOL
JUNEL 1/20, ETHINYL ESTRADIOL
JUNEL FE 1.5/30, ETHINYL ESTRADIOL
JUNEL FE 1/20, ETHINYL ESTRADIOL
KARIVA, DESOGESTREL
KELNOR, ETHINYL ESTRADIOL
LESSINA-28, ETHINYL ESTRADIOL
MEDROXYPROGESTERONE ACETATE, MEDROXYPROGESTERONE ACETATE
MEFLOQUINE HYDROCHLORIDE, MEFLOQUINE HYDROCHLORIDE
MEGESTROL ACETATE, MEGESTROL ACETATE
METHOTREXATE SODIUM, METHOTREXATE SODIUM
NALTREXONE HYDROCHLORIDE, NALTREXONE HYDROCHLORIDE
NIACIN, NIACIN
NORETHINDRONE ACETATE, NORETHINDRONE ACETATE
NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
NORTREL 0.5/35-28, ETHINYL ESTRADIOL
NORTREL 1/35-21, ETHINYL ESTRADIOL
NORTREL 1/35-28, ETHINYL ESTRADIOL
NORTREL 7/7/7, ETHINYL ESTRADIOL
PORTIA-28, ETHINYL ESTRADIOL
SPRINTEC, ETHINYL ESTRADIOL
TREXALL, METHOTREXATE SODIUM
TRI-LEGEST 21, ETHINYL ESTRADIOL
TRI-LEGEST FE, ETHINYL ESTRADIOL
TRI-SPRINTEC, ETHINYL ESTRADIOL
WARFARIN SODIUM, WARFARIN SODIUM

* BARR LABORATORIES INC A WHOLLY OWNED SUB OF TEVA PHARMACEUTICALS USA INC
LANTHANUM CARBONATE, LANTHANUM CARBONATE

* BARR PHARMACEUTICALS
LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM

BARR LABS INC

* BARR LABORATORIES INC
ACITRETIN, ACITRETIN
CLOZAPINE, CLOZAPINE
ESTRADIOL, ESTRADIOL
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
OLANZAPINE, OLANZAPINE
OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE (OTC)
TRETINOIN, TRETINOIN
TRI LO SPRINTEC, ETHINYL ESTRADIOL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** B ******BAUSCH**

- * BAUSCH HEALTH AMERICAS INC
 - ACANYA, BENZOYL PEROXIDE
 - BENZACLIN, BENZOYL PEROXIDE
 - BRYHALI, HALOBETASOL PROPIONATE
 - DUOBRII, HALOBETASOL PROPIONATE
 - EDECRIN, ETHACRYNATE SODIUM
 - EDECRIN, ETHACRYNIC ACID
 - EFUDEX, FLUOROURACIL
 - JUBLIA, EFINACONAZOLE
 - LOCOID, HYDROCORTISONE BUTYRATE
 - MEPHYTON, PHYTONADIONE
 - ONEXTON, BENZOYL PEROXIDE
 - OXSORALEN-ULTRA, METHOXSALEN
 - SYPRINE, TRIENTINE HYDROCHLORIDE
- * BAUSCH HEALTH IRELAND LTD
 - ERTACZO, SERTACONAZOLE NITRATE
 - TARGRETIN, BEXAROTENE
- * BAUSCH HEALTH US LLC
 - ALDARA, IMIQUIMOD
 - AMMONUL, SODIUM BENZOATE
 - ANCOBON, FLUCYTOSINE
 - APLENZIN, BUPROPION HYDROBROMIDE
 - ARAZLO, TAZAROTENE
 - ATIVAN, LORAZEPAM
 - CALCIUM DISODIUM VERSENATE, EDETATE CALCIUM DISODIUM
 - CARDIZEM CD, DILTIAZEM HYDROCHLORIDE
 - CARDIZEM LA, DILTIAZEM HYDROCHLORIDE
 - CARDIZEM, DILTIAZEM HYDROCHLORIDE
 - CESAMET, NABILONE
 - CLINDAGEL, CLINDAMYCIN PHOSPHATE
 - DEMSEER, METYROSINE
 - DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
 - DIASSTAT ACUDIAL, DIAZEPAM
 - DIASSTAT, DIAZEPAM
 - ELIDEL, PIMECROLIMUS
 - FLUNISOLIDE, FLUNISOLIDE
 - GRIS-PEG, GRISEOFULVIN, ULTRAMICROSIZE
 - IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
 - ISORDIL, ISOSORBIDE DINITRATE
 - ISUPREL, ISOPROTERENOL HYDROCHLORIDE
 - KLARON, SULFACETAMIDE SODIUM
 - LIBRAX, CHLORDIAZEPOXIDE HYDROCHLORIDE
 - LIBRIUM, CHLORDIAZEPOXIDE HYDROCHLORIDE
 - LOCOID, HYDROCORTISONE BUTYRATE
 - LOPROX, CICLOPIROX
 - LUZU, LULICONAZOLE
 - MESTINON, PYRIDOSTIGMINE BROMIDE
 - METROGEL-VAGINAL, METRONIDAZOLE
 - MIGRANAL, DIHYDROERGOTAMINE MESYLATE
 - MINOCIN, MINOCYCLINE HYDROCHLORIDE
 - NORITATE, METRONIDAZOLE
 - SOLODYN, MINOCYCLINE HYDROCHLORIDE
 - TASMAR, TOLCAPONE
 - TIAZAC, DILTIAZEM HYDROCHLORIDE
 - VANOS, FLUOCINONIDE
 - VASERETIC, ENALAPRIL MALEATE
 - VASOTEC, ENALAPRIL MALEATE
 - VIRAZOLE, RIBAVIRIN
 - WELLBUTRIN XL, BUPROPION HYDROCHLORIDE
 - XENAZINE, TETRABENAZINE
 - XERESE, ACYCLOVIR
 - ZELAPAR, SELEGILINE HYDROCHLORIDE
 - ZIANA, CLINDAMYCIN PHOSPHATE
 - ZOVIRAX, ACYCLOVIR

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** B ****

* BAUSCH HEALTH US LLC
ZYCLARA, IMIQUIMOD

BAUSCH AND LOMB

* BAUSCH AND LOMB INC
ALAWAY, KETOTIFEN FUMARATE (OTC)
ALREX, LOTEPREDNOL ETABONATE
BESIVANCE, BESIFLOXACIN HYDROCHLORIDE
BRINZOLAMIDE, BRINZOLAMIDE
CHILDREN'S ALAWAY, KETOTIFEN FUMARATE (OTC)
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE
FLURBIPROFEN SODIUM, FLURBIPROFEN SODIUM
ISTALOL, TIMOLOL MALEATE
LATANOPROST, LATANOPROST
LOTEMAX, LOTEPREDNOL ETABONATE
MIOCHOL-E, ACETYLCHOLINE CHLORIDE
OFLOXACIN, OFLOXACIN
OPCON-A, NAPHAZOLINE HYDROCHLORIDE (OTC)
PROLENSA, BROMFENAC SODIUM
RETISERT, FLUOCINOLONE ACETONIDE
SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
TIMOLOL MALEATE, TIMOLOL MALEATE
TROPICAMIDE, TROPICAMIDE
VYZULTA, LATANOPROSTENE BUNOD
ZIRGAN, GANCICLOVIR
ZYLET, LOTEPREDNOL ETABONATE

* BAUSCH AND LOMB PHARMACEUTICALS INC
BACITRACIN ZINC AND POLYMYXIN B SULFATE, BACITRACIN ZINC
BRIMONIDINE TARTRATE, BRIMONIDINE TARTRATE
CROMOLYN SODIUM, CROMOLYN SODIUM (OTC)
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
DEXASPORIN, DEXAMETHASONE
ERYTHROMYCIN, ERYTHROMYCIN
GENTAMICIN SULFATE, GENTAMICIN SULFATE
LEVOBUNOLOL HYDROCHLORIDE, LEVOBUNOLOL HYDROCHLORIDE
NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC, BACITRACIN ZINC
NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE, DEXAMETHASONE
NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN, GRAMICIDIN
NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE, HYDROCORTISONE
NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE, BACITRACIN ZINC
OFLOXACIN, OFLOXACIN
OTICAIR, HYDROCORTISONE
PENTOLAIR, CYCLOPENTOLATE HYDROCHLORIDE
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
PROPARACAINE HYDROCHLORIDE, PROPARACAINE HYDROCHLORIDE
SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM
TIMOLOL MALEATE, TIMOLOL MALEATE
TOBRAMYCIN AND DEXAMETHASONE, DEXAMETHASONE
TOBRAMYCIN, TOBRAMYCIN
TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
TROPICAMIDE, TROPICAMIDE

BAUSCH AND LOMB INC

* BAUSCH AND LOMB INC
ALAWAY, KETOTIFEN FUMARATE (OTC)
ATROPINE SULFATE, ATROPINE SULFATE
BEPREVE, BEPOTASTINE BESILATE
LOTEMAX SM, LOTEPREDNOL ETABONATE
LOTEMAX, LOTEPREDNOL ETABONATE
LUMIFY, BRIMONIDINE TARTRATE (OTC)
METHAZOLAMIDE, METHAZOLAMIDE
TIMOPTIC IN OCUDOSE, TIMOLOL MALEATE
TIMOPTIC, TIMOLOL MALEATE
TIMOPTIC-XE, TIMOLOL MALEATE
XIPERE, TRIAMCINOLONE ACETONIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** B ******BAUSCH LOMB IRELAND**

* BAUSCH AND LOMB IRELAND LTD

FLUORESCHEIN SODIUM AND BENOXINATE HYDROCHLORIDE, BENOXINATE HYDROCHLORIDE
TETRACAINE HYDROCHLORIDE, TETRACAINE HYDROCHLORIDE

BAXTER HLTHCARE

* BAXTER HEALTHCARE CORP

ACETIC ACID 0.25% IN PLASTIC CONTAINER, ACETIC ACID, GLACIAL
AMINOACETIC ACID 1.5% IN PLASTIC CONTAINER, GLYCINE
ANCEF IN PLASTIC CONTAINER, CEFAZOLIN SODIUM
BACTOCILL IN PLASTIC CONTAINER, OXACILLIN SODIUM
BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER, ESMOLOL HYDROCHLORIDE
BREVIBLOC IN PLASTIC CONTAINER, ESMOLOL HYDROCHLORIDE
BREVIBLOC, ESMOLOL HYDROCHLORIDE
CARDIOPLEGIC IN PLASTIC CONTAINER, CALCIUM CHLORIDE
CEFEPIME IN PLASTIC CONTAINER, CEFEPIME HYDROCHLORIDE
CEFTRIAZONE IN PLASTIC CONTAINER, CEFTRIAZONE SODIUM
CLINIMIX 2.75/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 2.75/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 2.75/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 4.25/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 4.25/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 4.25/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 4.25/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/15 SULFITE FREE IN DEXTROSE 15% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/35 SULFITE FREE IN DEXTROSE 35% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 2.75/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC
CLINIMIX E 2.75/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC
CLINIMIX E 2.75/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 4.25/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC
CLINIMIX E 4.25/20 SULFITE FREE W/ ELECT IN DEXTROSE 20% W/ CALCIUM IN PLASTIC
CLINIMIX E 4.25/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC
CLINIMIX E 4.25/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 5/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 5/15 SULFITE FREE W/ ELECT IN DEXTROSE 15% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 5/20 SULFITE FREE W/ ELECT IN 20% DEXTROSE W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 5/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 5/35 SULFITE FREE W/ ELECT IN DEXTROSE 35% W/ CALCIUM IN PLASTIC CONTAINER,
CLINISOL 15% SULFITE FREE IN PLASTIC CONTAINER, AMINO ACIDS
CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE
CYTOXAN, CYCLOPHOSPHAMIDE
DEXTROSE 10% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND ELECTROLYTE NO. 48 IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 10MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 15MEQ (K), DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ (K), DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 30MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 40MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ (K), DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER,
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 15MEQ IN PLASTIC CONTAINER,

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** B ******* BAXTER HEALTHCARE CORP**

DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER,
 DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER,
 DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER,
 DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 5MEQ IN PLASTIC CONTAINER,
 DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 20MEQ (K) IN PLASTIC
 DEXTROSE 50% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 70% IN PLASTIC CONTAINER, DEXTROSE
 DIANEAL LOW CALCIUM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL LOW CALCIUM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL LOW CALCIUM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL LOW CALCIUM W/DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL LOW CALCIUM W/DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL LOW CALCIUM W/DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL LOW CALCIUM W/DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL PD-2 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL PD-2 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DIANEAL PD-2 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER, DOBUTAMINE HYDROCHLORIDE
 DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER, DOPAMINE HYDROCHLORIDE
 EXTRANEAL, ICODextrin
 FAMOTIDINE PRESERVATIVE FREE IN PLASTIC CONTAINER, FAMOTIDINE
 FLAGYL I.V. RTU IN PLASTIC CONTAINER, METRONIDAZOLE
 FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE
 FORANE, ISOFLURANE
 GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, GENTAMICIN SULFATE
 HEPARIN SODIUM 1,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN
 HEPARIN SODIUM 2,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN
 IFEX, IFOSFAMIDE
 LACTATED RINGER'S AND DEXTROSE 5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 LIDOCAINE HYDROCHLORIDE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE
 LIDOCAINE HYDROCHLORIDE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE
 LIDOCAINE HYDROCHLORIDE 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE
 MESNEX, MESNA
 MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MILRINONE LACTATE
 NALLPEN IN PLASTIC CONTAINER, NAFCILLIN SODIUM
 NEXTERONE, AMIODARONE HYDROCHLORIDE
 NITROGLYCERIN IN DEXTROSE 5%, NITROGLYCERIN
 OSMITROL 10% IN WATER IN PLASTIC CONTAINER, MANNITOL
 OSMITROL 10% IN WATER, MANNITOL
 OSMITROL 15% IN WATER IN PLASTIC CONTAINER, MANNITOL
 OSMITROL 15% IN WATER, MANNITOL
 OSMITROL 20% IN WATER IN PLASTIC CONTAINER, MANNITOL
 OSMITROL 20% IN WATER, MANNITOL
 OSMITROL 5% IN WATER IN PLASTIC CONTAINER, MANNITOL
 OSMITROL 5% IN WATER, MANNITOL
 PENICILLIN G POTASSIUM IN PLASTIC CONTAINER, PENICILLIN G POTASSIUM
 PLASMA-LYTE 148 IN WATER IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
 PLASMA-LYTE A IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
 POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.45%, POTASSIUM CHLORIDE
 POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.9%, POTASSIUM CHLORIDE
 POTASSIUM CHLORIDE 0.3% AND SODIUM CHLORIDE 0.9%, POTASSIUM CHLORIDE
 POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
 POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
 POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** B ******* BAXTER HEALTHCARE CORP**

POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
 POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
 POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 PREMASOL 10% IN PLASTIC CONTAINER, AMINO ACIDS
 PREMASOL 6% IN PLASTIC CONTAINER, AMINO ACIDS
 RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 SEVOFLURANE, SEVOFLURANE
 SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, SODIUM CHLORIDE
 SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
 SODIUM CHLORIDE 0.9% IN STERILE PLASTIC CONTAINER, SODIUM CHLORIDE
 SODIUM CHLORIDE 3% IN PLASTIC CONTAINER, SODIUM CHLORIDE
 SODIUM CHLORIDE 5% IN PLASTIC CONTAINER, SODIUM CHLORIDE
 SORBITOL 3% IN PLASTIC CONTAINER, SORBITOL
 STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION
 STERILE WATER IN PLASTIC CONTAINER, STERILE WATER FOR IRRIGATION
 STERILE WATER, STERILE WATER FOR IRRIGATION
 SUPRANE, DESFLURANE
 TIS-U-SOL IN PLASTIC CONTAINER, MAGNESIUM SULFATE
 TIS-U-SOL, MAGNESIUM SULFATE
 TRAVASOL 10% IN PLASTIC CONTAINER, AMINO ACIDS
 TRAVASOL 5.5% IN PLASTIC CONTAINER, AMINO ACIDS
 TRAVASOL 8.5% IN PLASTIC CONTAINER, AMINO ACIDS
 VANCOCIN HYDROCHLORIDE IN PLASTIC CONTAINER, VANCOMYCIN HYDROCHLORIDE

*** BAXTER HEALTHCARE INTERNATIONAL SPECIALTY THERAPIES DIV**
 PROSOL 20% SULFITE FREE IN PLASTIC CONTAINER, AMINO ACIDS

BAXTER HLTHCARE CORP*** BAXTER HEALTHCARE CORP**

ACETAMINOPHEN, ACETAMINOPHEN
 BENDAMUSTINE HYDROCHLORIDE, BENDAMUSTINE HYDROCHLORIDE
 BORTEZOMIB, BORTEZOMIB
 BUPIVACAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE
 CEFAZOLIN IN PLASTIC CONTAINER, CEFAZOLIN SODIUM
 CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, CIPROFLOXACIN
 CIPROFLOXACIN, CIPROFLOXACIN
 CLINDAMYCIN PHOSPHATE IN 0.9% SODIUM CHLORIDE, CLINDAMYCIN PHOSPHATE
 CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER, CLINDAMYCIN PHOSPHATE
 CLINOLIPID 20%, OLIVE OIL
 DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
 DOXIL (LIPOSOMAL), DOXORUBICIN HYDROCHLORIDE
 EPTIFIBATIDE, EPTIFIBATIDE
 FLUCONAZOLE IN SODIUM CHLORIDE 0.9%, FLUCONAZOLE
 FLUMAZENIL, FLUMAZENIL
 FOSAPREPITANT DIMEGLUMINE, FOSAPREPITANT DIMEGLUMINE
 FUROSEMIDE, FUROSEMIDE
 KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
 LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
 LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, LEVOFLOXACIN
 LEVOFLOXACIN, LEVOFLOXACIN
 MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MAGNESIUM SULFATE
 MAGNESIUM SULFATE IN PLASTIC CONTAINER, MAGNESIUM SULFATE
 METHOCARBAMOL, METHOCARBAMOL
 METOPROLOL TARTRATE, METOPROLOL TARTRATE
 METRONIDAZOLE IN PLASTIC CONTAINER, METRONIDAZOLE
 NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
 NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE, NOREPINEPHRINE BITARTRATE
 NOREPINEPHRINE BITARTRATE, NOREPINEPHRINE BITARTRATE
 ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
 PALONOSSETRON HYDROCHLORIDE, PALONOSSETRON HYDROCHLORIDE
 PEMETREXED DISODIUM, PEMETREXED DISODIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** B ****

- * BAXTER HEALTHCARE CORP
 - PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 - PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 - PRISMASOL B22GK 4/0 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 - PRISMASOL BGK 0/2.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 - PRISMASOL BGK 2/0 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 - PRISMASOL BGK 2/3.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 - PRISMASOL BGK 4/0/1.2 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 - PRISMASOL BGK 4/2.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 - PRISMASOL BK 0/0/1.2 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 - TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
 - TRANSDERM SCOP, SCOPOLAMINE
- * BAXTER HEALTHCARE CORP ANESTHESIA AND CRITICAL CARE
 - PROTOPAM CHLORIDE, PRALIDOXIME CHLORIDE

BAYER

- * BAYER HEALTHCARE LLC
 - ALEVE, NAPROXEN SODIUM (OTC)

BAYER HEALTHCARE

- * BAYER HEALTHCARE PHARMACEUTICALS INC
 - ALIQOPA, COPANLISIB DIHYDROCHLORIDE
 - LAMPIT, NIFURTIMOX
 - NUBEQA, DAROLUTAMIDE
 - VITRAKVI, LAROTRECTINIB SULFATE

BAYER HEALTHCARE LLC

- * BAYER HEALTHCARE LLC
 - CHILDREN'S CLARITIN, LORATADINE (OTC)
 - CLARITIN HIVES RELIEF REDITAB, LORATADINE (OTC)
 - CLARITIN HIVES RELIEF, LORATADINE (OTC)
 - CLARITIN REDITABS, LORATADINE (OTC)
 - CLARITIN, LORATADINE (OTC)
 - CLARITIN-D 24 HOUR, LORATADINE (OTC)
 - CLARITIN-D, LORATADINE (OTC)
 - LOTRIMIN ULTRA, BUTENAFINE HYDROCHLORIDE (OTC)
 - MIRALAX, POLYETHYLENE GLYCOL 3350 (OTC)

BAYER HLTHCARE

- * BAYER HEALTHCARE CONSUMER CARE
 - ALEVE PM, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
 - ASTEPRO ALLERGY, AZELASTINE HYDROCHLORIDE (OTC)
 - CHILDREN'S ASTEPRO ALLERGY, AZELASTINE HYDROCHLORIDE (OTC)
- * BAYER HEALTHCARE PHARMACEUTICALS INC
 - ADEMPAS, RIOCIGUAT
 - ANGELIQ, DROSPIRENONE
 - BEYAZ, DROSPIRENONE
 - BILTRICIDE, PRAZIQUANTEL
 - CIPRO, CIPROFLOXACIN
 - CIPRO, CIPROFLOXACIN HYDROCHLORIDE
 - CLIMARA PRO, ESTRADIOL
 - CLIMARA, ESTRADIOL
 - EOVIST, GADOXETATE DISODIUM
 - GADAVIST, GADOBUTROL
 - KERENDIA, FINERENONE
 - KYLEENA, LEVONORGESTREL
 - MENOSTAR, ESTRADIOL
 - MIRENA, LEVONORGESTREL
 - NATAZIA, DIENOGEST
 - NEXAVAR, SORAFENIB TOSYLATE
 - SAFYRAL, DROSPIRENONE
 - SKYLA, LEVONORGESTREL
 - STIVARGA, REGORAFENIB
 - ULTRAVIST (PHARMACY BULK), IOPROMIDE
 - ULTRAVIST 300, IOPROMIDE
 - ULTRAVIST 370, IOPROMIDE
 - VITRAKVI, LAROTRECTINIB SULFATE
 - XOFIGO, RADIUM RA-223 DICHLORIDE
 - YASMIN, DROSPIRENONE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** B ****

* BAYER HEALTHCARE PHARMACEUTICALS INC
YAZ, DROSPIRENONE

BAYSHORE PHARMS LLC

* BAYSHORE PHARMACEUTICALS LLC
DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, ATROPINE SULFATE
ETODOLAC, ETODOLAC
KETOTIFEN FUMARATE, KETOTIFEN FUMARATE (OTC)
METHSCOPOLAMINE BROMIDE, METHSCOPOLAMINE BROMIDE
METOLAZONE, METOLAZONE
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
PINDOLOL, PINDOLOL
PRIMAQUINE PHOSPHATE, PRIMAQUINE PHOSPHATE

BDSI

* BIODELIVERY SCIENCES INTERNATIONAL INC
BELBUCA, BUPRENORPHINE HYDROCHLORIDE
SYMPROIC, NALDEMEDINE TOSYLATE

BE PHARMS

* BE PHARMACEUTICALS AG
DAPTOMYCIN, DAPTOMYCIN
FOSAPREPITANT DIMEGLUMINE, FOSAPREPITANT DIMEGLUMINE
HEPARIN SODIUM, HEPARIN SODIUM
NEOSTIGMINE METHYLSULFATE, NEOSTIGMINE METHYLSULFATE
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE

BECTON DICKINSON

* BECTON DICKINSON AND CO
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE (OTC)
E-Z SCRUB 201, POVIDONE-IODINE (OTC)
E-Z SCRUB 241, POVIDONE-IODINE (OTC)

BECTON DICKINSON CO

* BECTON DICKINSON AND CO
CHLORAPREP ONE-STEP FREPP, CHLORHEXIDINE GLUCONATE (OTC)
CHLORAPREP ONE-STEP SEPP, CHLORHEXIDINE GLUCONATE (OTC)
CHLORAPREP ONE-STEP, CHLORHEXIDINE GLUCONATE (OTC)
CHLORAPREP SINGLE SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)
CHLORAPREP TRIPLE SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)
CHLORAPREP WITH TINT, CHLORHEXIDINE GLUCONATE (OTC)

BEIGENE

* BEIGENE USA INC
BRUKINSA, ZANUBRUTINIB

BEIJING

* BEIJING SCIECURE PHARMACEUTICAL CO LTD
FLUVASTATIN SODIUM, FLUVASTATIN SODIUM

BEIJING TIDE PHARM

* BEIJING TIDE PHARMACEUTICAL CO LTD
COLESEVELAM HYDROCHLORIDE, COLESEVELAM HYDROCHLORIDE

BEIJING YILING

* BEIJING YILING BIO-ENGINEERING AND TECHNOLOGY CO LTD
ANASTROZOLE, ANASTROZOLE
LETROZOLE, LETROZOLE

BELCHER

* BELCHER PHARMACEUTICALS LLC
AMINOCAPROIC ACID, AMINOCAPROIC ACID
CEFIXIME, CEFIXIME
GABAPENTIN, GABAPENTIN
LEVETIRACETAM, LEVETIRACETAM
MEFENAMIC ACID, MEFENAMIC ACID
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE
TACROLIMUS, TACROLIMUS

BELCHER PHARMS

* BELCHER PHARMACEUTICALS LLC
CEPHALEXIN, CEPHALEXIN
DESLOMATADINE, DESLOMATADINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** B ******BELOTECA INC**

- * BELOTECA INC
DIAZEPAM, DIAZEPAM
THIOTEPA, THIOTEPA

BENUVIA OPERATIONS

- * BENUVIA OPERATIONS LLC
SYNDROS, DRONABINOL

BEOWULF ASSET

- * BEOWULF ASSET MANAGEMENT LP
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
LEVETIRACETAM, LEVETIRACETAM

BEXIMCO PHARMS USA

- * BEXIMCO PHARMACEUTICALS USA INC
BACLOFEN, BACLOFEN
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
ELETRIPTAN HYDROBROMIDE, ELETRIPTAN HYDROBROMIDE
FLECAINIDE ACETATE, FLECAINIDE ACETATE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METHOCARBAMOL, METHOCARBAMOL
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
NADOLOL, NADOLOL
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE

BEXIMCO USA

- * BEXIMCO PHARMACEUTICALS USA INC
CARVEDILOL, CARVEDILOL

BIOCODEX SA

- * BIOCODEX SA
DIACOMIT, STIRIPENTOL

BIOCON PHARMA

- * BIOCON PHARMA INC
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
- * BIOCON PHARMA LTD
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
EVEROLIMUS, EVEROLIMUS
MYCOPHENOLIC SODIUM, MYCOPHENOLIC SODIUM
POSACONAZOLE, POSACONAZOLE
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
SIMVASTATIN, SIMVASTATIN
TACROLIMUS, TACROLIMUS

BIOCRYST

- * BIOCRYST PHARMACEUTICALS INC
ORLADEYO, BEROTRALSTAT HYDROCHLORIDE
RAPIVAB, PERAMIVIR

BIOFRONTERA

- * BIOFRONTERA BIOSCIENCE GMBH
AMELUZ, AMINOLEVULINIC ACID HYDROCHLORIDE

BIOGEN IDEC

- * BIOGEN IDEC INC
SPINRAZA, NUSINERSEN SODIUM

BIOGEN INC

- * BIOGEN INC
TECFIDERA, DIMETHYL FUMARATE
VUMERITY, DIROXIMEL FUMARATE

BIOHAVEN IRELAND

- * BIOHAVEN PHARMACEUTICAL IRELAND DESIGNATED ACTIVITY CO
NURTEC ODT, RIMEGEPANT SULFATE

BIOMARIN PHARM

- * BIOMARIN PHARMACEUTICAL INC
KUVAN, SAPROPTERIN DIHYDROCHLORIDE
VOXZOGO, VOSORITIDE

BIOMEDCL RES FDN

- * BIOMEDICAL RESEARCH FOUNDATION NORTHWEST LOUISIANA
AMMONIA N 13, AMMONIA N-13

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** B ****

- * BIOMEDICAL RESEARCH FOUNDATION NORTHWEST LOUISIANA
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

BIONPHARMA INC

- * BIONPHARMA INC
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
AMPHETAMINE SULFATE, AMPHETAMINE SULFATE
ATOVAQUONE, ATOVAQUONE
AZITHROMYCIN, AZITHROMYCIN
BENZONATATE, BENZONATATE
BEXAROTENE, BEXAROTENE
CALCITRIOL, CALCITRIOL
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CLOBAZAM, CLOBAZAM
COLESEVELAM HYDROCHLORIDE, COLESEVELAM HYDROCHLORIDE
DEFERASIROX, DEFERASIROX
DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
DOFETILIDE, DOFETILIDE
DROXIDOPA, DROXIDOPA
DUTASTERIDE, DUTASTERIDE
ENALAPRIL MALEATE, ENALAPRIL MALEATE
ETHOSUXIMIDE, ETHOSUXIMIDE
FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE, GRANISETRON HYDROCHLORIDE
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
IBUPROFEN, IBUPROFEN (OTC)
LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE, LOPERAMIDE HYDROCHLORIDE (OTC)
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)
LORATADINE, LORATADINE (OTC)
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
MIDOL LIQUID GELS, IBUPROFEN (OTC)
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
NIMODIPINE, NIMODIPINE
OMEGA-3-ACID ETHYL ESTERS, OMEGA-3-ACID ETHYL ESTERS
OXCARBAZEPINE, OXCARBAZEPINE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
PARICALCITOL, PARICALCITOL
POTASSIUM CITRATE, POTASSIUM CITRATE
PROGESTERONE, PROGESTERONE
RUFINAMIDE, RUFINAMIDE
SEVELAMER CARBONATE, SEVELAMER CARBONATE
TETRABENAZINE, TETRABENAZINE
VALPROIC ACID, VALPROIC ACID
VITAMIN D, ERGOCALCIFEROL
ZONISAMIDE, ZONISAMIDE

BIOXCEL

- * BIOXCEL THERAPEUTICS INC
IGALMI, DEXMEDETOMIDINE HYDROCHLORIDE

BLUE EARTH

- * BLUE EARTH DIAGNOSTICS LTD
AXUMIN, FLUCICLOVINE F-18

BLUEPRINT MEDICINES

- * BLUEPRINT MEDICINES CORP
AYVAKIT, AVAPRITINIB

BOEHRINGER INGELHEIM

- * BOEHRINGER INGELHEIM
GILOTRIF, AFATINIB DIMALEATE
GLYXAMBI, EMPAGLIFLOZIN
MICARDIS HCT, HYDROCHLOROTHIAZIDE
MICARDIS, TELMISARTAN
- * BOEHRINGER INGELHEIM PHARMACEUTICALS INC
APTIVUS, TIPRANAVIR

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** B ****

* BOEHRINGER INGELHEIM PHARMACEUTICALS INC
 ATROVENT HFA, IPRATROPIUM BROMIDE
 COMBIVENT RESPIMAT, ALBUTEROL SULFATE
 JARDIANCE, EMPAGLIFLOZIN
 JENTADUETO XR, LINAGLIPTIN
 JENTADUETO, LINAGLIPTIN
 MIRAPEX ER, PRAMIPEXOLE DIHYDROCHLORIDE
 MOBIC, MELOXICAM
 OFEV, NINTEDANIB ESYLATE
 PERSANTINE, DIPYRIDAMOLE
 PRADAXA, DABIGATRAN ETEXILATE MESYLATE
 SPIRIVA RESPIMAT, TIOTROPIUM BROMIDE
 SPIRIVA, TIOTROPIUM BROMIDE
 STIOLTO RESPIMAT, OLODATEROL HYDROCHLORIDE
 STRIVERDI RESPIMAT, OLODATEROL HYDROCHLORIDE
 SYNJARDY XR, EMPAGLIFLOZIN
 SYNJARDY, EMPAGLIFLOZIN
 TRADJENTA, LINAGLIPTIN
 TRIJARDY XR, EMPAGLIFLOZIN
 VIRAMUNE XR, NEVIRAPINE
 VIRAMUNE, NEVIRAPINE

BOSCOGEN

* BOSCOGEN INC
 ARIPIPRAZOLE, ARIPIPRAZOLE
 CAPTOPRIL, CAPTOPRIL
 CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE

BPI LABS

* BPI LABS LLC
 ABLYSINOL, ALCOHOL
 EPINEPHRINE, EPINEPHRINE
 MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE
 ZOLEDRONIC ACID, ZOLEDRONIC ACID

BRACCO

* BRACCO DIAGNOSTICS INC
 CARDIOGEN-82, RUBIDIUM CHLORIDE RB-82
 CHOLETEC, TECHNETIUM TC-99M MEBROFENIN KIT
 CYSTOGRAFIN DILUTE, DIATRIZOATE MEGLUMINE
 CYSTOGRAFIN, DIATRIZOATE MEGLUMINE
 E-Z-HD, BARIUM SULFATE
 E-Z-PAQUE, BARIUM SULFATE
 ENTERO VU 24%, BARIUM SULFATE
 GASTROGRAFIN, DIATRIZOATE MEGLUMINE
 ISOVUE-200, IOPAMIDOL
 ISOVUE-250, IOPAMIDOL
 ISOVUE-300, IOPAMIDOL
 ISOVUE-370, IOPAMIDOL
 ISOVUE-M 200, IOPAMIDOL
 ISOVUE-M 300, IOPAMIDOL
 KINEVAC, SINCALIDE
 LIQUID E-Z-PAQUE, BARIUM SULFATE
 LUMASON, SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSPHERES
 MULTIHANCE MULTIPACK, GADOBENATE DIMEGLUMINE
 MULTIHANCE, GADOBENATE DIMEGLUMINE
 PROHANCE MULTIPACK, GADOTERIDOL
 PROHANCE, GADOTERIDOL
 READI-CAT 2 SMOOTHIE, BARIUM SULFATE
 READI-CAT 2, BARIUM SULFATE
 TAGITOL V, BARIUM SULFATE
 VARIBAR HONEY, BARIUM SULFATE
 VARIBAR NECTAR, BARIUM SULFATE
 VARIBAR PUDDING, BARIUM SULFATE
 VARIBAR THIN HONEY, BARIUM SULFATE
 VARIBAR THIN LIQUID, BARIUM SULFATE

BRAINTREE

* BRAINTREE LABORATORIES INC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** B ****

* BRAINTREE LABORATORIES INC
 GOLYTELY, POLYETHYLENE GLYCOL 3350
 NULYTELY, POLYETHYLENE GLYCOL 3350
 NULYTELY-FLAVORED, POLYETHYLENE GLYCOL 3350

BRAINTREE LABS

* BRAINTREE LABORATORIES INC
 SUPREP BOWEL PREP KIT, MAGNESIUM SULFATE
 SUTAB, MAGNESIUM SULFATE

BRECKENRIDGE

* BRECKENRIDGE PHARMACEUTICAL INC
 ACETAZOLAMIDE, ACETAZOLAMIDE
 ALPRAZOLAM, ALPRAZOLAM
 ASENAPINE MALEATE, ASENAPINE MALEATE
 AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
 BRETYLIUM TOSYLATE, BRETYLIUM TOSYLATE
 BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN
 CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
 CLOBAZAM, CLOBAZAM
 DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
 ENTECAVIR, ENTECAVIR
 EPINASTINE HYDROCHLORIDE, EPINASTINE HYDROCHLORIDE
 EPLERENONE, EPLERENONE
 EVEROLIMUS, EVEROLIMUS
 EXEMESTANE, EXEMESTANE
 IMATINIB MESYLATE, IMATINIB MESYLATE
 LAMIVUDINE, LAMIVUDINE
 LEVETIRACETAM, LEVETIRACETAM
 MEGESTROL ACETATE, MEGESTROL ACETATE
 METHYLERGONOVINE MALEATE, METHYLERGONOVINE MALEATE
 METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
 MIGLUSTAT, MIGLUSTAT
 NOREPINEPHRINE BITARTRATE, NOREPINEPHRINE BITARTRATE
 OMEPRAZOLE, OMEPRAZOLE
 PENICILLAMINE, PENICILLAMINE
 RIVASTIGMINE, RIVASTIGMINE
 SUCCINYLCHOLINE CHLORIDE, SUCCINYLCHOLINE CHLORIDE
 TETRACYCLINE HYDROCHLORIDE, TETRACYCLINE HYDROCHLORIDE
 ZOLEDRONIC ACID, ZOLEDRONIC ACID
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

BRECKENRIDGE PHARM

* BRECKENRIDGE PHARMACEUTICAL INC
 ESTRADIOL AND NORETHINDRONE ACETATE, ESTRADIOL
 METHSCOPOLAMINE BROMIDE, METHSCOPOLAMINE BROMIDE
 OXCARBAZEPINE, OXCARBAZEPINE
 TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE

BRIGHAM WOMENS

* BRIGHAM AND WOMENS HOSP
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

BRIGHAM WOMENS HOSP

* BRIGHAM AND WOMENS HOSP INC
 AMMONIA N 13, AMMONIA N-13

BRIGHTGENE

* BRIGHTGENE BIO-MEDICAL TECHNOLOGY CO LTD
 ENTECAVIR, ENTECAVIR

BRISTOL

* BRISTOL MYERS SQUIBB CO
 CAMZYOS, MAVACAMTEN
 EVOTAZ, ATAZANAVIR SULFATE
 ONUREG, AZACITIDINE
 SOTYKTU, DEUCRAVACITINIB

BRISTOL MYERS SQUIBB

* BRISTOL MYERS SQUIBB
 AZACTAM, AZTREONAM
 BARACLUDE, ENTECAVIR
 IDHIFA, ENASIDENIB MESYLATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** B ****

- * BRISTOL MYERS SQUIBB CO
REYATAZ, ATAZANAVIR SULFATE
SPRYCEL, DASATINIB
SUSTIVA, EFAVIRENZ
- * BRISTOL MYERS SQUIBB CO PHARMACEUTICAL RESEARCH INSTITUTE
ELIQUIS, APIXABAN

BRISTOL-MYERS

- * BRISTOL-MYERS SQUIBB CO
ABRAXANE, PACLITAXEL
VIDAZA, AZACITIDINE

BROOKS STERISCIENCE

- * BROOKS STERISCIENCE LTD
MEROPENEM, MEROPENEM

BTG INTL

- * BTG INTERNATIONAL INC
CYANOKIT, HYDROXOCOBALAMIN
THYROSAFE, POTASSIUM IODIDE (OTC)

BWXT ITG

- * BWXT ITG CANADA INC
INDIUM IN 111 OXYQUINOLINE, INDIUM IN-111 OXYQUINOLINE

**** C ******CADILA**

- * CADILA HEALTHCARE LTD
ACETAZOLAMIDE, ACETAZOLAMIDE
ACYCLOVIR, ACYCLOVIR
BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE, BISOPROLOL FUMARATE
BISOPROLOL FUMARATE, BISOPROLOL FUMARATE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
DESONIDE, DESONIDE
DESOXIMETASONE, DESOXIMETASONE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DUTASTERIDE, DUTASTERIDE
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
FELBAMATE, FELBAMATE
FLUOCINONIDE, FLUOCINONIDE
INDOMETHACIN, INDOMETHACIN
LEVOFLOXACIN, LEVOFLOXACIN
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METRONIDAZOLE, METRONIDAZOLE
MODAFINIL, MODAFINIL
NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
NYSTATIN, NYSTATIN
PIROXICAM, PIROXICAM
RANOLAZINE, RANOLAZINE
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
VORICONAZOLE, VORICONAZOLE
ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE
ZONISAMIDE, ZONISAMIDE

CADILA PHARMS LTD

- * CADILA PHARMACEUTICALS LTD
ACYCLOVIR, ACYCLOVIR
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
CELECOXIB, CELECOXIB
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
ERYTHROMYCIN ETHYLSUCCINATE, ERYTHROMYCIN ETHYLSUCCINATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** C ****

* CADILA PHARMACEUTICALS LTD
 ERYTHROMYCIN, ERYTHROMYCIN
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 FOLIC ACID, FOLIC ACID
 GEMFIBROZIL, GEMFIBROZIL
 GLYBURIDE, GLYBURIDE
 HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
 LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
 METRONIDAZOLE, METRONIDAZOLE
 NATEGLINIDE, NATEGLINIDE
 NEBIVOLOL HYDROCHLORIDE, NEBIVOLOL HYDROCHLORIDE
 OFLOXACIN, OFLOXACIN
 PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
 RALOXIFENE HYDROCHLORIDE, RALOXIFENE HYDROCHLORIDE
 RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
 ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
 TELMISARTAN, TELMISARTAN
 TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
 VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE

CALL INC

* CALL INC DBA ROCHESTER PHARMACEUTICALS
 ADAPALENE, ADAPALENE

CALLIDITAS

* CALLIDITAS THERAPEUTICS AB
 TARPEYO, BUDESONIDE

CAPELLON PHARMS LLC

* CAPELLON PHARMACEUTICALS LLC
 POLMON, DEXCHLORPHENIRAMINE MALEATE

CAPLIN

* CAPLIN STERILES LTD
 ARGATROBAN, ARGATROBAN
 ETOMIDATE, ETOMIDATE
 GLYCOPYRROLATE, GLYCOPYRROLATE
 LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
 MILRINONE LACTATE, MILRINONE LACTATE
 NEOSTIGMINE METHYLSULFATE, NEOSTIGMINE METHYLSULFATE
 PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
 PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE
 ROPIVACAINE HYDROCHLORIDE, ROPIVACAINE HYDROCHLORIDE
 SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
 TRANEXAMIC ACID, TRANEXAMIC ACID
 VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE

CARA THERAP

* CARA THERAPEUTICS INC
 KORSUVA, DIFELIKEFALIN ACETATE

CARDINAL HEALTH 414

* CARDINAL HEALTH 414 LLC CARDINAL HEALTH NUCLEAR PHARMACY SERVICES
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
 LYMPHOSEEK KIT, TECHNETIUM TC-99M TILMANOCEPT
 SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18
 TECHNETIUM TC 99M SESTAMIBI, TECHNETIUM TC-99M SESTAMIBI KIT
 TECHNETIUM TC-99M MEDRONATE KIT, TECHNETIUM TC-99M MEDRONATE KIT

CARDINAL HEALTH 418

* CARDINAL HEALTH 418 INC
 SODIUM IODIDE I 123, SODIUM IODIDE I-123

CARDINAL HLTH 414

* CARDINAL HEALTH 414 LLC
 AMMONIA N 13, AMMONIA N-13

CARIBE HOLDINGS

* CARIBE HOLDINGS CAYMAN CO LTD DBA PURACAP CARIBE
 DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
 GEMFIBROZIL, GEMFIBROZIL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** C ******CARLSBAD**

- * CARLSBAD TECHNOLOGY INC
ACYCLOVIR, ACYCLOVIR
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
FAMOTIDINE, FAMOTIDINE
GLIMEPIRIDE, GLIMEPIRIDE
LOVASTATIN, LOVASTATIN

CARLSBAD TECHNOLOGY

- * CARLSBAD TECHNOLOGY INC
ACYCLOVIR, ACYCLOVIR

CARNEGIE

- * CARNEGIE PHARMACEUTICALS LLC
AMINOCAPROIC ACID, AMINOCAPROIC ACID
ETRAVIRINE, ETRAVIRINE

CASI PHARMS INC

- * CASI PHARMACEUTICALS INC
CILOSTAZOL, CILOSTAZOL
ENTECAVIR, ENTECAVIR
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
TENOFVIR DISOPROXIL FUMARATE, TENOFVIR DISOPROXIL FUMARATE
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE

CASPER PHARMA LLC

- * CASPER PHARMA LLC
ANTIVERT, MECLIZINE HYDROCHLORIDE
AQUASOL A, VITAMIN A PALMITATE
CASPORYN HC, HYDROCORTISONE
FURADANTIN, NITROFURANTOIN
LUMI-SPORYN, BACITRACIN ZINC
ROBINUL FORTE, GLYCOPYRROLATE
ROBINUL, GLYCOPYRROLATE
THALITONE, CHLORTHALIDONE
ZYLOPRIM, ALLOPURINOL

CATALENT

- * CATALENT PHARMA SOLUTIONS LLC
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
VALPROIC ACID, VALPROIC ACID

CATALYST PHARMS

- * CATALYST PHARMACEUTICALS INC
FIRDAPSE, AMIFAMPRIDINE PHOSPHATE

CEDIPROF INC

- * CEDIPROF INC
DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
LEVO-T, LEVOTHYROXINE SODIUM **

CELATOR PHARMS

- * CELATOR PHARMACEUTICALS INC
VYXEOS, CYTARABINE

CELERITY PHARMS

- * CELERITY PHARMACEUTICALS LLC
DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL), DOXORUBICIN HYDROCHLORIDE

CELGENE

- * CELGENE CORP
ISTODAX, ROMIDEPSIN
POMALYST, POMALIDOMIDE
REVLIMID, LENALIDOMIDE
THALOMID, THALIDOMIDE

CELGENE INTL

- * CELGENE INTERNATIONAL II SARL
ZEPOSIA, OZANIMOD HYDROCHLORIDE

CELLTRION

- * CELLTRION INC
DEFERASIROX, DEFERASIROX
DIVALPROEX SODIUM, DIVALPROEX SODIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** C ******* CELLTRION INC**

FAMOTIDINE, FAMOTIDINE
 LEVOFLOXACIN, LEVOFLOXACIN
 LINEZOLID, LINEZOLID
 MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
 PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
 PREGABALIN, PREGABALIN
 RISPERIDONE, RISPERIDONE
 RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
 ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
 SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE
 TELMISARTAN, TELMISARTAN

CEPHALON*** CEPHALON INC**

ACTIQ, FENTANYL CITRATE
 FENTORA, FENTANYL CITRATE
 GABITRIL, TIAGABINE HYDROCHLORIDE
 NUVIGIL, ARMODAFINIL
 PROVIGIL, MODAFINIL
 TREANDA, BENDAMUSTINE HYDROCHLORIDE
 TRISENOX, ARSENIC TRIOXIDE

CEROVENE INC*** CEROVENE INC**

AMPHETAMINE SULFATE, AMPHETAMINE SULFATE
 FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE
 PYRIMETHAMINE, PYRIMETHAMINE
 SEROMYCIN, CYCLOSERINE

CHANGZHOU PHARM*** CHANGZHOU PHARMACEUTICAL FACTORY**

DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
 PREGABALIN, PREGABALIN
 ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM

CHARTWELL*** CHARTWELL LIFE MOLECULES LLC**

ALLOPURINOL, ALLOPURINOL
 AMOXICILLIN, AMOXICILLIN
 CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
 CLARITHROMYCIN, CLARITHROMYCIN
 COLOCORT, HYDROCORTISONE
 FLUCONAZOLE, FLUCONAZOLE
 NALTREXONE HYDROCHLORIDE, NALTREXONE HYDROCHLORIDE
 OXAPROZIN, OXAPROZIN
 TEMOZOLOMIDE, TEMOZOLOMIDE
 TENOFOVIR DISOPROXIL FUMARATE, TENOFOVIR DISOPROXIL FUMARATE
 TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE

*** CHARTWELL PHARMA SCIENCE LLC**

SULFASALAZINE, SULFASALAZINE

*** CHARTWELL SCHEDULED LLC**

ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
 BENZPHETAMINE HYDROCHLORIDE, BENZPHETAMINE HYDROCHLORIDE
 DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
 DOXYCYCLINE, DOXYCYCLINE
 HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
 PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE

CHARTWELL INJECTABLE*** CHARTWELL INJECTABLES LLC**

DIPYRIDAMOLE, DIPYRIDAMOLE
 DOXAPRAM HYDROCHLORIDE, DOXAPRAM HYDROCHLORIDE
 ENALAPRILAT, ENALAPRILAT
 TERBUTALINE SULFATE, TERBUTALINE SULFATE

CHARTWELL MOLECULAR*** CHARTWELL MOLECULAR HOLDINGS LLC**

ACETAZOLAMIDE, ACETAZOLAMIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** C ****

* CHARTWELL MOLECULAR HOLDINGS LLC
 ALBUTEROL SULFATE, ALBUTEROL SULFATE
 BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN
 CALCIUM ACETATE, CALCIUM ACETATE
 CARVEDILOL, CARVEDILOL
 CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
 CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
 CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
 CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
 CLOBAZAM, CLOBAZAM
 CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
 DEXAMETHASONE, DEXAMETHASONE
 DIAZEPAM, DIAZEPAM
 DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
 FOLIC ACID, FOLIC ACID
 GLIMEPIRIDE, GLIMEPIRIDE
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
 IRBESARTAN, IRBESARTAN
 ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
 LANSOPRAZOLE, LANSOPRAZOLE
 LEVETIRACETAM, LEVETIRACETAM
 LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
 LEVOFLOXACIN, LEVOFLOXACIN
 MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
 MONTELUKAST SODIUM, MONTELUKAST SODIUM
 OLANZAPINE, OLANZAPINE
 RAMIPRIL, RAMIPRIL
 RIFAMPIN, RIFAMPIN
 RISPERIDONE, RISPERIDONE
 THEOPHYLLINE, THEOPHYLLINE
 ZALEPLON, ZALEPLON
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

CHARTWELL MOLECULES

* CHARTWELL MOLECULES LLC
 CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
 DISULFIRAM, DISULFIRAM
 GEMFIBROZIL, GEMFIBROZIL
 INDOMETHACIN, INDOMETHACIN
 NABUMETONE, NABUMETONE
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 ONDANSETRON, ONDANSETRON
 SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE

CHARTWELL RX

* CHARTWELL RX SCIENCES LLC
 ACYCLOVIR, ACYCLOVIR
 ALBUTEROL SULFATE, ALBUTEROL SULFATE
 AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
 AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
 ATOVAQUONE, ATOVAQUONE
 AZITHROMYCIN, AZITHROMYCIN
 BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
 BENZONATATE, BENZONATATE
 BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
 CALCIUM ACETATE, CALCIUM ACETATE
 CARISOPRODOL, CARISOPRODOL
 CEFPROZIL, CEFPROZIL
 CEFUROXIME AXETIL, CEFUROXIME AXETIL
 CEPHALEXIN, CEPHALEXIN
 CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDE, CHLORDIAZEPOXIDE HYDROCHLORIDE
 CHLORDIAZEPOXIDE HYDROCHLORIDE, CHLORDIAZEPOXIDE HYDROCHLORIDE
 CHLORTHALIDONE, CHLORTHALIDONE
 CICLOPIROX, CICLOPIROX
 CILOSTAZOL, CILOSTAZOL
 DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, ATROPINE SULFATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** C ******* CHARTWELL RX SCIENCES LLC**

DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
 DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
 DUVOID, BETHANECHOL CHLORIDE
 EPLERENONE, EPLERENONE
 FOSINOPRIL SODIUM, FOSINOPRIL SODIUM
 FULVICIN P/G 165, GRISEOFULVIN, ULTRAMICROCRYSTALLINE
 FULVICIN P/G 330, GRISEOFULVIN, ULTRAMICROCRYSTALLINE
 FULVICIN P/G, GRISEOFULVIN, ULTRAMICROCRYSTALLINE
 FULVICIN-U/F, GRISEOFULVIN, MICROCRYSTALLINE
 GRISEOFULVIN, GRISEOFULVIN, MICROSIZE
 INDOMETHACIN, INDOMETHACIN
 LACTULOSE, LACTULOSE
 LEVETIRACETAM, LEVETIRACETAM
 LISINOPRIL, LISINOPRIL
 LOCHOLEST LIGHT, CHOLESTYRAMINE
 LOCHOLEST, CHOLESTYRAMINE
 LOVASTATIN, LOVASTATIN
 METHIMAZOLE, METHIMAZOLE
 MOEXIPRIL HYDROCHLORIDE, MOEXIPRIL HYDROCHLORIDE
 MONODOX, DOXYCYCLINE
 NABUMETONE, NABUMETONE
 NADOLOL, NADOLOL
 PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
 PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
 PREDNISOLONE, PREDNISOLONE
 RASAGILINE MESYLATE, RASAGILINE MESYLATE
 REPAGLINIDE, REPAGLINIDE
 RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
 ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
 SILDENAFIL CITRATE, SILDENAFIL CITRATE
 SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE
 TAVABOROLE, TAVABOROLE
 URSODIOL, URSODIOL
 VALPROIC ACID, VALPROIC ACID
 ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE

CHARTWELL TETRA*** CHARTWELL TETRA LLC**

TETRACYCLINE HYDROCHLORIDE, TETRACYCLINE HYDROCHLORIDE

CHATTEM*** CHATTEM INC**

UNISOM, DOXYLAMINE SUCCINATE (OTC)

CHATTEM SANOFI*** CHATTEM INC DBA SANOFI CONSUMER HEALTHCARE**

ALLEGRA ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
 ALLEGRA HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
 ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION, FEXOFENADINE HYDROCHLORIDE (OTC)
 ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION, FEXOFENADINE HYDROCHLORIDE (OTC)
 CHILDREN'S ALLEGRA ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
 NASACORT ALLERGY 24 HOUR, TRIAMCINOLONE ACETONIDE (OTC)
 NICODERM CQ, NICOTINE (OTC)
 XYZAL ALLERGY 24HR, LEVOCETIRIZINE DIHYDROCHLORIDE (OTC)

CHEMI SPA*** CHEMI SPA**

DECITABINE, DECITABINE
 TEMOZOLOMIDE, TEMOZOLOMIDE

CHEMISCH FBRK KRSSLR*** CHEMISCHE FABRIK KREUSSLER & CO. GMBH**

ASCLERA, POLIDOCANOL

CHEMO RESEARCH SL*** CHEMO RESEARCH SL**

BENZNIDAZOLE, BENZNIDAZOLE
 ESTRADIOL, ESTRADIOL
 NUVESSA, METRONIDAZOLE

CHEMOCENTRYX

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** C ****

* CHEMOCENTRYX INC
TAVNEOS, AVACOPAN

CHEPLAPHARM

* CHEPLAPHARM ARZNEIMITTEL GMBH
DROXIA, HYDROXYUREA
ETOPOPHOS PRESERVATIVE FREE, ETOPOSIDE PHOSPHATE
HYDREA, HYDROXYUREA
KLONOPIN, CLONAZEPAM
XENICAL, ORLISTAT

CHIA TAI TIANQING

* CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD
FOSAPREPITANT DIMEGLUMINE, FOSAPREPITANT DIMEGLUMINE
FULVESTRANT, FULVESTRANT

CHIESI

* CHIESI USA INC
BETHKIS, TOBRAMYCIN
BRONCHITOL, MANNITOL
CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE
CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE
CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE
CLEVIPREX, CLEVIDIPINE
FERRIPROX, DEFERIPRONE
KENGREAL, CANGRELOR
ZYFLO CR, ZILEUTON
ZYFLO, ZILEUTON

CHILDRENS HOSP MI

* CHILDRENS HOSP MICHIGAN
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

CHINA RESOURCES

* CHINA RESOURCES SAIKE PHARMACEUTICAL CO LTD
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE

CHIRHOCLIN

* CHIRHOCLIN INC
CHIRHOSTIM, SECRETIN SYNTHETIC HUMAN

CINTEX SVCS

* CINTEX SERVICES LLC
DESONIDE, DESONIDE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

CIPHER PHARMS INC

* CIPHER PHARMACEUTICALS INC
CONZIP, TRAMADOL HYDROCHLORIDE
LIPOFEN, FENOFIBRATE

CIPLA

* CIPLA LTD
ABACAVIR SULFATE AND LAMIVUDINE, ABACAVIR SULFATE
ABACAVIR SULFATE, ABACAVIR SULFATE
ACYCLOVIR, ACYCLOVIR
ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE, ALBUTEROL SULFATE
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ALENDRONATE SODIUM, ALENDRONATE SODIUM
AMBRISENTAN, AMBRISENTAN
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
ANASTROZOLE, ANASTROZOLE
ARFORMOTEROL TARTRATE, ARFORMOTEROL TARTRATE
ATAZANAVIR SULFATE, ATAZANAVIR SULFATE
AZACITIDINE, AZACITIDINE
BUDESONIDE, BUDESONIDE
CELECOXIB, CELECOXIB
CINACALCET HYDROCHLORIDE, CINACALCET HYDROCHLORIDE
CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE
DARIFENACIN HYDROBROMIDE, DARIFENACIN HYDROBROMIDE
DEFERASIROX, DEFERASIROX
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DIFLUPREDNATE, DIFLUPREDNATE
DIHYDROERGOTAMINE MESYLATE, DIHYDROERGOTAMINE MESYLATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** C ******* CIPLA LTD**

DIMETHYL FUMARATE, DIMETHYL FUMARATE
 EFAVIRENZ, EFAVIRENZ
 EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE, EFAVIRENZ
 EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE, EMTRICITABINE
 EMTRICITABINE, EMTRICITABINE
 ENTECAVIR, ENTECAVIR
 ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
 EXEMESTANE, EXEMESTANE
 FENOFIBRATE, FENOFIBRATE
 FINASTERIDE, FINASTERIDE
 FOSFOMYCIN TROMETHAMINE, FOSFOMYCIN TROMETHAMINE
 GRISEOFULVIN, GRISEOFULVIN, MICROSIZE
 ICATIBANT ACETATE, ICATIBANT ACETATE
 ISOPROTERENOL HYDROCHLORIDE, ISOPROTERENOL HYDROCHLORIDE
 LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE
 LAMIVUDINE, LAMIVUDINE
 LENALIDOMIDE, LENALIDOMIDE
 LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE
 MELOXICAM, MELOXICAM
 METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
 MONTELUKAST SODIUM, MONTELUKAST SODIUM
 NEVIRAPINE, NEVIRAPINE
 PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE
 PHYTONADIONE, PHYTONADIONE
 PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
 PREGABALIN, PREGABALIN
 RITONAVIR, RITONAVIR
 SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE
 SUMATRIPTAN, SUMATRIPTAN
 TADALAFIL, TADALAFIL
 TAVABOROLE, TAVABOROLE
 TENOFOVIR DISOPROXIL FUMARATE, TENOFOVIR DISOPROXIL FUMARATE
 TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
 TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
 TESTOSTERONE, TESTOSTERONE
 VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
 VALGANCICLOVIR HYDROCHLORIDE, VALGANCICLOVIR HYDROCHLORIDE
 ZIDOVUDINE, ZIDOVUDINE

CIPLA LTD*** CIPLA LTD**

ALBENDAZOLE, ALBENDAZOLE
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
 EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
 TOPIRAMATE, TOPIRAMATE
 ZIDOVUDINE, ZIDOVUDINE

CIPLA USA*** CIPLA USA INC**

ZEMDRI, PLAZOMICIN SULFATE

CISEN*** CISEN PHARMACEUTICAL CO LTD**

ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM

CLINIGEN*** CLINIGEN INC**

ETHYOL, AMIFOSTINE

CLINIGEN HLTHCARE*** CLINIGEN HEALTHCARE LTD**

FOSCAVIR, FOSCARNET SODIUM

CLIVUNEL INC*** CLINUVEL INC**

SCENESSE, AFAMELANOTIDE

CLOVIS ONCOLOGY INC*** CLOVIS ONCOLOGY INC**

RUBRACA, RUCAPARIB CAMSYLATE

CMP DEV LLC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** C ****

- * CMP DEVELOPMENT LLC
CAROSPIR, SPIRONOLACTONE
NORLIQVA, AMLODIPINE BESYLATE
POTASSIUM PHOSPHATES, POTASSIUM PHOSPHATE, DIBASIC
TADLIQ, TADALAFIL

CMP PHARMA INC

- * CMP PHARMA INC
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
HYDROCORTISONE IN ABSORBASE, HYDROCORTISONE
ISONIAZID, ISONIAZID
SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE
SPS, SODIUM POLYSTYRENE SULFONATE
TRIANEX, TRIAMCINOLONE ACETONIDE

CODY LABS INC

- * CODY LABORATORIES INC A WHOLLY OWNED SUBSIDIARY OF LANNETT CO INC
NUMBRINO, COCAINE HYDROCHLORIDE

COLGATE-PALMOLIVE CO

- * COLGATE-PALMOLIVE CO
PERIOGARD, CHLORHEXIDINE GLUCONATE

COLLEGIUM PHARM INC

- * COLLEGIUM PHARMACEUTICAL INC
NUCYNTA ER, TAPENTADOL HYDROCHLORIDE
NUCYNTA, TAPENTADOL HYDROCHLORIDE
XTAMPZA ER, OXYCODONE

COMBE

- * COMBE INC
VAGISTAT-1, TIOCONAZOLE (OTC)

COMMAVE THERAP

- * COMMAVE THERAPEUTICS SA
AZSTARYS, DEXMETHYLPHENIDATE HYDROCHLORIDE

CONCORD BIOTECH LTD

- * CONCORD BIOTECH LTD
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
MYCOPHENOLIC SODIUM, MYCOPHENOLIC SODIUM
TACROLIMUS, TACROLIMUS

CONCORDIA

- * CONCORDIA PHARMACEUTICALS INC
DIBENZYLINE, PHENOXYBENZAMINE HYDROCHLORIDE
DYRENIUM, TRIAMTERENE
LANOXIN, DIGOXIN
NILANDRON, NILUTAMIDE
PANRETIN, ALITRETINOIN
PARNATE, TRANLYCYPROMINE SULFATE
PLAQUENIL, HYDROXYCHLOROQUINE SULFATE
SALAGEN, PILOCARPINE HYDROCHLORIDE
UROXATRAL, ALFUZOSIN HYDROCHLORIDE
ZONEGRAN, ZONISAMIDE

CONCORDIA PHARMS INC

- * CONCORDIA PHARMACEUTICALS INC
KAPVAY, CLONIDINE HYDROCHLORIDE
ORAPRED ODT, PREDNISOLONE SODIUM PHOSPHATE

CONTRACT PHARMACAL

- * CONTRACT PHARMACAL CORP
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)

COOPERSURGICAL

- * COOPERSURGICAL INC
PARAGARD T 380A, COPPER

CORCEPT THERAP

- * CORCEPT THERAPEUTICS INC
KORLYM, MIFEPRISTONE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** C ******CORDEN PHARMA**

* CORDEN PHARMA LATINA SPA
GLEOSTINE, LOMUSTINE

COREPHARMA

* COREPHARMA LLC
CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDE, CHLORDIAZEPOXIDE HYDROCHLORIDE
CHLORZOXAZONE, CHLORZOXAZONE
CLORAZEPATE DIPOTASSIUM, CLORAZEPATE DIPOTASSIUM
DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
LISINOPRIL, LISINOPRIL
LOVASTATIN, LOVASTATIN
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
TORSEMIDE, TORSEMIDE

CORIUM

* CORIUM INC
ADLARITY, DONEPEZIL HYDROCHLORIDE

COSETTE

* COSETTE PHARMACEUTICALS INC
ACEPHEN, ACETAMINOPHEN (OTC)
ACYCLOVIR, ACYCLOVIR
ALBUTEROL SULFATE, ALBUTEROL SULFATE
AZOR, AMLODIPINE BESYLATE
BENICAR HCT, HYDROCHLOROTHIAZIDE
BENICAR, OLMESARTAN MEDOXOMIL
BETA-VAL, BETAMETHASONE VALERATE
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CALCIPOTRIENE, CALCIPOTRIENE
CICLOPIROX, CICLOPIROX
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CLOMIPHENE CITRATE, CLOMIPHENE CITRATE
DAPSONE, DAPSONE
DESONIDE, DESONIDE
DESOXIMETASONE, DESOXIMETASONE
DOXYCYCLINE, DOXYCYCLINE
EFFIENT, PRASUGREL HYDROCHLORIDE
ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE, ENALAPRIL MALEATE
EVOXAC, CEVIMELINE HYDROCHLORIDE
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
FLUOCINONIDE EMULSIFIED BASE, FLUOCINONIDE
FLUOCINONIDE, FLUOCINONIDE
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
GRISEOFULVIN, GRISEOFULVIN, MICROSIZE
HALOBETASOL PROPIONATE, HALOBETASOL PROPIONATE
HYDROCORTISONE AND ACETIC ACID, ACETIC ACID, GLACIAL
HYDROCORTISONE VALERATE, HYDROCORTISONE VALERATE
INDOMETHACIN, INDOMETHACIN
LIDOCAINE, LIDOCAINE
METRONIDAZOLE, METRONIDAZOLE
MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)
MIGERGOT, CAFFEINE
MOMETASONE FUROATE, MOMETASONE FUROATE
MYKACET, NYSTATIN
NYSTATIN, NYSTATIN
PROCHLORPERAZINE, PROCHLORPERAZINE
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
PROMETHEGAN, PROMETHAZINE HYDROCHLORIDE
TAZAROTENE, TAZAROTENE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
TRIBENZOR, AMLODIPINE BESYLATE
WELCHOL, COLESEVELAM HYDROCHLORIDE

COVIS

* COVIS PHARMA GMBH

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** C ****

* COVIS PHARMA GMBH
 ALTOPREV, LOVASTATIN
 ALVESCO, CICLESONIDE
 DUAKLIR PRESSAIR, ACLIDINIUM BROMIDE
 FERAHEME, FERUMOXYTOL
 LANOXIN PEDIATRIC, DIGOXIN
 LANOXIN, DIGOXIN
 MAKENA (AUTOINJECTOR), HYDROXYPROGESTERONE CAPROATE
 MAKENA PRESERVATIVE FREE, HYDROXYPROGESTERONE CAPROATE
 MAKENA, HYDROXYPROGESTERONE CAPROATE
 OMNARIS, CICLESONIDE
 PRILOSEC, OMEPRAZOLE MAGNESIUM
 RILUTEK, RILUZOLE
 SULAR, NISOLDIPINE
 TUDORZA PRESSAIR, ACLIDINIUM BROMIDE
 ZETONNA, CICLESONIDE

CPPI CV

* CP PHARMACEUTICALS INTERNATIONAL CV
 SUTENT, SUNITINIB MALATE

CROSSMEDIKA SA

* CROSSMEDIKA SA
 MEXILETINE HYDROCHLORIDE, MEXILETINE HYDROCHLORIDE
 MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
 TRANLYCYPROMINE SULFATE, TRANLYCYPROMINE SULFATE
 TRIMIPRAMINE MALEATE, TRIMIPRAMINE MALEATE
 VARDENAFIL HYDROCHLORIDE, VARDENAFIL HYDROCHLORIDE

CROWN LABS

* CROWN LABORATORIES INC
 ALA-CORT, HYDROCORTISONE
 TRIDERM, TRIAMCINOLONE ACETONIDE

CROWN LABS INC

* CROWN LABORATORIES INC
 NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
 NYSTATIN, NYSTATIN

CSPC OUYI

* CSPC OUYI PHARMACEUTICAL CO LTD
 AZITHROMYCIN, AZITHROMYCIN
 CARBAMAZEPINE, CARBAMAZEPINE
 CELECOXIB, CELECOXIB
 CONJUPRI, LEVAMLODIPINE MALEATE
 DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
 ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
 GABAPENTIN, GABAPENTIN
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 PALIPERIDONE, PALIPERIDONE
 PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE

CSPC OUYI PHARM CO

* CSPC OUYI PHARMACEUTICAL CO LTD
 TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE

CSPC-NBP PHARM

* CSPC-NBP PHARMACEUTICAL CO LTD
 BENZONATATE, BENZONATATE
 OMEGA-3-ACID ETHYL ESTERS, OMEGA-3-ACID ETHYL ESTERS

CTI BIOPHARMA CORP

* CTI BIOPHARMA CORP
 VONJO, PACRITINIB CITRATE

CUBIST PHARMS

* CUBIST PHARMACEUTICALS INC
 ENTEREG, ALVIMOPAN

CUBIST PHARMS LLC

* CUBIST PHARMACEUTICALS LLC
 CUBICIN, DAPTOMYCIN
 DIFICID, FIDAXOMICIN
 SIVEXTRO, TEDIZOLID PHOSPHATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** C ****

* CUBIST PHARMACEUTICALS LLC
ZERBAXA, CEFTOLOZANE SULFATE

CUMBERLAND PHARMS

* CUMBERLAND PHARMACEUTICALS INC
ACETADOTE, ACETYLCYSTEINE
CALDOLOR, IBUPROFEN
LACTULOSE, LACTULOSE
VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER, CONIVAPTAN HYDROCHLORIDE
VIBATIV, TELAVANCIN HYDROCHLORIDE

CURIUM

* CURIUM US LLC
GALLIUM CITRATE GA 67, GALLIUM CITRATE GA-67
INDIUM IN 111 CHLORIDE, INDIUM IN-111 CHLORIDE
IOFLUPANE I-123, IOFLUPANE I-123
OCTREOSCAN, INDIUM IN-111 PENTETREOTIDE KIT
SODIUM IODIDE I 123, SODIUM IODIDE I-123
TECHNISCAN MAG3, TECHNETIUM TC-99M MERTIATIDE KIT
TECHNISCAN PYP KIT, TECHNETIUM TC-99M PYROPHOSPHATE KIT
TECHNISCAN, TECHNETIUM TC-99M OXIDRONATE KIT
TECHNETIUM TC 99M SESTAMIBI, TECHNETIUM TC-99M SESTAMIBI KIT
THALLOUS CHLORIDE TL 201, THALLOUS CHLORIDE TL-201
ULTRA-TECHNEKOW FM, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR
ULTRATAG, TECHNETIUM TC-99M RED BLOOD CELL KIT
XENON XE 133, XENON XE-133

CURRAX

* CURRAX PHARMACEUTICALS LLC
ONZETRA XSAIL, SUMATRIPTAN SUCCINATE
SILENOR, DOXEPIN HYDROCHLORIDE
TREXIMET, NAPROXEN SODIUM

CUSTOPHARM INC

* CUSTOPHARM INC
CALCITONIN-SALMON, CALCITONIN SALMON

CYCLE

* CYCLE PHARMACEUTICALS LTD
HALOPERIDOL, HALOPERIDOL
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
NITYR, NITISINONE

**** D ******DAEWOONG PHARM CO**

* DAEWOONG PHARMACEUTICAL CO LTD
MEROPENEM, MEROPENEM

DAIICHI SANKYO INC

* DAIICHI SANKYO INC
SAVAYSA, EDOXABAN TOSYLATE
TURALIO, PEXIDARTINIB HYDROCHLORIDE

DANCO LABS LLC

* DANCO LABORATORIES LLC
MIFEPREX, MIFEPRISTONE

DARE

* DARE BIOSCIENCE INC
XACIATO, CLINDAMYCIN PHOSPHATE

DASH PHARMS

* DASH PHARMACEUTICALS LLC
TESTOSTERONE, TESTOSTERONE
ZILEUTON, ZILEUTON

DASTECH GENERICS

* DASTECH GENERICS LLC
NYSTATIN, NYSTATIN

DAVA PHARMS INC

* DAVA PHARMACEUTICALS INC
AMOXICILLIN, AMOXICILLIN
MORPHINE SULFATE, MORPHINE SULFATE
PROPYLTHIOURACIL, PROPYLTHIOURACIL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** D ******DAVIS AND GECK**

- * DAVIS AND GECK DIV AMERICAN CYANAMID CO
PRE-OP II, HEXACHLOROPHENE
PRE-OP, HEXACHLOROPHENE

DECATUR

- * DECATUR MEMORIAL HOSP
AMMONIA N 13, AMMONIA N-13
CHOLINE C-11, CHOLINE C-11
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

DECIPHERA PHARMS

- * DECIPHERA PHARMACEUTICALS LLC
QINLOCK, RIPRETINIB

DENTSPLY PHARM

- * DENTSPLY PHARMACEUTICAL INC
CITANEST FORTE DENTAL, EPINEPHRINE BITARTRATE
ORAQIX, LIDOCAINE

DEPROCO

- * DEPROCO INC
LIGNOSPAN FORTE, EPINEPHRINE BITARTRATE
LIGNOSPAN STANDARD, EPINEPHRINE BITARTRATE
SCANDONEST L, LEVONORDEFIN
SCANDONEST PLAIN, MEPIVACAINE HYDROCHLORIDE
SEPTOCAINE, ARTICAINE HYDROCHLORIDE

DERM RX

- * DERM RX LLC
ALA-SCALP, HYDROCORTISONE

DERMAVANT SCI

- * DERMAVANT SCIENCES INC
VTAMA, TAPINAROF

DEVA HOLDING AS

- * DEVA HOLDING AS
ESOMEPRAZOLE SODIUM, ESOMEPRAZOLE SODIUM
SUCCINYLCHOLINE CHLORIDE, SUCCINYLCHOLINE CHLORIDE
TEMOZOLOMIDE, TEMOZOLOMIDE

DEXCEL

- * DEXCEL PHARMA TECHNOLOGIES LTD
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
HEMADY, DEXAMETHASONE
LANSOPRAZOLE, LANSOPRAZOLE (OTC)
OMEPRAZOLE, OMEPRAZOLE (OTC)
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
VIGABATRIN, VIGABATRIN

DEXCEL LTD

- * DEXCEL LTD
DICLOFENAC SODIUM, DICLOFENAC SODIUM
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE

DEXCEL PHARMA

- * DEXCEL PHARMA TECHNOLOGIES LTD
OMEPRAZOLE, OMEPRAZOLE (OTC)

DIALYSIS SUPS

- * DIALYSIS SUPPLIES INC
NORMOCARB HF 25, MAGNESIUM CHLORIDE
NORMOCARB HF 35, MAGNESIUM CHLORIDE

DORC

- * DORC INTERNATIONAL BV
VISIONBLUE, TRYPTAN BLUE

DOUGLAS PHARMS

- * DOUGLAS PHARMACEUTICALS AMERICA LTD
MYORISAN, ISOTRETINOIN

DOW PHARM

- * DOW PHARMACEUTICAL SCIENCES
ALTRENO, TRETINOIN
ATRALIN, TRETINOIN

DR REDDYS

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** D ****

- * DR REDDYS LABORATORIES INC
 - FENOFIBRATE, FENOFIBRATE
 - ICOSAPENT ETHYL, ICOSAPENT ETHYL
 - METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
 - NITROGLYCERIN, NITROGLYCERIN
 - PROGESTERONE, PROGESTERONE
 - PROPOFOL, PROPOFOL
 - SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
 - TESTOSTERONE, TESTOSTERONE
 - ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE
- * DR REDDYS LABORATORIES LTD
 - ABIRATERONE ACETATE, ABIRATERONE ACETATE
 - ALBENDAZOLE, ALBENDAZOLE
 - AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM, AMLODIPINE BESYLATE
 - ASPIRIN AND DIPYRIDAMOLE, ASPIRIN
 - ATOMOXETINE HYDROCHLORIDE, ATOMOXETINE HYDROCHLORIDE
 - ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
 - AZACITIDINE, AZACITIDINE
 - BENDAMUSTINE HYDROCHLORIDE, BENDAMUSTINE HYDROCHLORIDE
 - BIVALIRUDIN, BIVALIRUDIN
 - BORTEZOMIB, BORTEZOMIB
 - CAPECITABINE, CAPECITABINE
 - CARBOPROST TROMETHAMINE, CARBOPROST TROMETHAMINE
 - CARFILZOMIB, CARFILZOMIB
 - CARMUSTINE, CARMUSTINE
 - CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDE, CHLORDIAZEPOXIDE HYDROCHLORIDE
 - CINACALCET HYDROCHLORIDE, CINACALCET HYDROCHLORIDE
 - CIPROFLOXACIN AND DEXAMETHASONE, CIPROFLOXACIN
 - CLOFARABINE, CLOFARABINE
 - CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
 - COLCHICINE, COLCHICINE
 - COLESEVELAM HYDROCHLORIDE, COLESEVELAM HYDROCHLORIDE
 - DAPTOMYCIN, DAPTOMYCIN
 - DECITABINE, DECITABINE
 - DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
 - DIFLUPREDNATE, DIFLUPREDNATE
 - DOCETAXEL, DOCETAXEL
 - DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
 - DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL), DOXORUBICIN HYDROCHLORIDE
 - EPHEDRINE SULFATE, EPHEDRINE SULFATE
 - ESLICARBAZEPINE ACETATE, ESLICARBAZEPINE ACETATE
 - ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
 - ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM (OTC)
 - ESZOPICLONE, ESZOPICLONE
 - FEBUXOSTAT, FEBUXOSTAT
 - FESOTERODINE FUMARATE, FESOTERODINE FUMARATE
 - FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, FEXOFENADINE
 - FINGOLIMOD HYDROCHLORIDE, FINGOLIMOD HYDROCHLORIDE
 - FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 - FOSAPREPITANT DIMEGLUMINE, FOSAPREPITANT DIMEGLUMINE
 - FULVESTRANT, FULVESTRANT
 - GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
 - GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE, GUAIFENESIN (OTC)
 - GUAIFENESIN, GUAIFENESIN (OTC)
 - IMATINIB MESYLATE, IMATINIB MESYLATE
 - LANSOPRAZOLE, LANSOPRAZOLE
 - LENALIDOMIDE, LENALIDOMIDE
 - LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE (OTC)
 - LIDOCAINE, LIDOCAINE
 - LUBIPROSTONE, LUBIPROSTONE
 - LURASIDONE HYDROCHLORIDE, LURASIDONE HYDROCHLORIDE
 - MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE
 - MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
 - NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
 - NAPROXEN AND ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** D ******* DR REDDYS LABORATORIES LTD**

NELARABINE, NELARABINE
 NEOSTIGMINE METHYLSULFATE, NEOSTIGMINE METHYLSULFATE
 NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
 OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE
 OMEPRAZOLE, OMEPRAZOLE (OTC)
 PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE
 PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
 PANCURONIUM BROMIDE, PANCURONIUM BROMIDE
 PARICALCITOL, PARICALCITOL
 PEMETREXED DISODIUM, PEMETREXED DISODIUM
 PENICILLAMINE, PENICILLAMINE
 PHYTONADIONE, PHYTONADIONE
 POSACONAZOLE, POSACONAZOLE
 PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
 PREGABALIN, PREGABALIN
 RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM
 REGADENOSON, REGADENOSON
 SAPROPTERIN DIHYDROCHLORIDE, SAPROPTERIN DIHYDROCHLORIDE
 SEVELAMER CARBONATE, SEVELAMER CARBONATE
 SIROLIMUS, SIROLIMUS
 SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE
 SORAFENIB TOSYLATE, SORAFENIB TOSYLATE
 SUCCINYLCHOLINE CHLORIDE, SUCCINYLCHOLINE CHLORIDE
 SUNITINIB MALATE, SUNITINIB MALATE
 TADALAFIL, TADALAFIL
 TETRABENAZINE, TETRABENAZINE
 THIOTEPA, THIOTEPA
 TIMOLOL MALEATE, TIMOLOL MALEATE
 TRIENTINE HYDROCHLORIDE, TRIENTINE HYDROCHLORIDE
 VALGANCICLOVIR HYDROCHLORIDE, VALGANCICLOVIR HYDROCHLORIDE
 VALSARTAN, VALSARTAN
 VIGABATRIN, VIGABATRIN
 VINORELBINE TARTRATE, VINORELBINE TARTRATE

DR REDDYS LA*** DR REDDYS LABORATORIES LOUISIANA LLC**

IBUPROFEN, IBUPROFEN
 IBUPROFEN, IBUPROFEN (OTC)
 LOPURIN, ALLOPURINOL
 SSD, SILVER SULFADIAZINE

DR REDDYS LABS INC*** DR REDDYS LABORATORIES INC**

AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE
 FINASTERIDE, FINASTERIDE
 FLUCONAZOLE, FLUCONAZOLE
 IBUPROFEN, IBUPROFEN
 IBUPROFEN, IBUPROFEN (OTC)
 LEVOFLOXACIN, LEVOFLOXACIN
 MELOXICAM, MELOXICAM
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE, NAPROXEN SODIUM (OTC)
 NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
 PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
 RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
 SIMVASTATIN, SIMVASTATIN
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
 TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
 TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
 ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE

DR REDDYS LABS LTD*** DR REDDYS LABORATORIES LIMITED**

LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE

*** DR REDDYS LABORATORIES LTD**

ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** D ****

* DR REDDYS LABORATORIES LTD
CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE, CANDESARTAN CILEXETIL
CARVEDILOL, CARVEDILOL
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
CIPROFLOXACIN EXTENDED RELEASE, CIPROFLOXACIN
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
DESLOMATADINE AND PSEUDOEPHEDRINE SULFATE 24 HOUR, DESLOMATADINE
DESLOMATADINE, DESLOMATADINE
DIVALPROEX SODIUM, DIVALPROEX SODIUM
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE, ENALAPRIL MALEATE
FAMOTIDINE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE (OTC)
FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, FEXOFENADINE
FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
FEXOFENADINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE
FINASTERIDE, FINASTERIDE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FONDAPARINUX SODIUM, FONDAPARINUX SODIUM
GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
GLIMEPIRIDE, GLIMEPIRIDE
GLYCOPYRROLATE, GLYCOPYRROLATE
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
IBANDRONATE SODIUM, IBANDRONATE SODIUM
IBUPROFEN AND DIPHENHYDRAMINE CITRATE, DIPHENHYDRAMINE CITRATE (OTC)
IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE, IBUPROFEN (OTC)
IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LAMOTRIGINE, LAMOTRIGINE
LANSOPRAZOLE, LANSOPRAZOLE
LANSOPRAZOLE, LANSOPRAZOLE (OTC)
LATANOPROST, LATANOPROST
LETROZOLE, LETROZOLE
LEVETIRACETAM, LEVETIRACETAM
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
MONTELUKAST SODIUM, MONTELUKAST SODIUM
NAPROXEN SODIUM, NAPROXEN SODIUM
NATEGLINIDE, NATEGLINIDE
NIZATIDINE, NIZATIDINE
OFLOXACIN, OFLOXACIN
OLANZAPINE, OLANZAPINE
OMEPRazole MAGNESIUM, OMEPRazole MAGNESIUM (OTC)
OMEPRazole, OMEPRazole
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
OXAPROZIN, OXAPROZIN
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
RAMIPRIL, RAMIPRIL
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)
RISPERIDONE, RISPERIDONE
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
TACROLIMUS, TACROLIMUS
TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
ZAFIRLUKAST, ZAFIRLUKAST
ZENATANE, ISOTRETINOIN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** D ****

* DR REDDYS LABORATORIES LTD
ZOLEDRONIC ACID, ZOLEDRONIC ACID

DR REDDYS LABS SA

* DR REDDYS LABORATORIES SA
BIORPHEN, PHENYLEPHRINE HYDROCHLORIDE
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
EZETIMIBE AND SIMVASTATIN, EZETIMIBE
FENOFIBRATE (MICRONIZED), FENOFIBRATE
HABITROL, NICOTINE (OTC)
MERCAPTOPYRINE, MERCAPTOPYRINE
NICOTINE POLACRILEX, NICOTINE POLACRILEX (OTC)
RAMELTEON, RAMELTEON
REZIPRES, EPHEDRINE HYDROCHLORIDE
TOBRAMYCIN, TOBRAMYCIN

DUCHESNAY

* DUCHESNAY INC
BONJESTA, DOXYLAMINE SUCCINATE
DICLEGIS, DOXYLAMINE SUCCINATE
OSPHENA, OSPEMIFENE

DURAMED PHARMS BARR

* DURAMED PHARMACEUTICALS INC SUB BARR LABORATORIES INC
AVIANE-28, ETHINYL ESTRADIOL
CRYSSELLE, ETHINYL ESTRADIOL
DESOGESTREL AND ETHINYL ESTRADIOL, DESOGESTREL
ENPRESSE-28, ETHINYL ESTRADIOL
VELIVET, DESOGESTREL

DUSA

* DUSA PHARMACEUTICALS INC
LEVULAN, AMINOLEVULINIC ACID HYDROCHLORIDE

DUTCH OPHTHALMIC

* DUTCH OPHTHALMIC RESEARCH CENTER INTERNATIONAL BV
TISSUEBLUE, BRILLIANT BLUE G

REDDYS

* DOCTOR REDDYS LABORATORIES LTD
DESLORATADINE, DESLORATADINE
DIVALPROEX SODIUM, DIVALPROEX SODIUM
METOPROLOL SUCCINATE, METOPROLOL SUCCINATE

**** E ******E5 PHARMA INC**

* E5 PHARMA INC
DIAZOXIDE, DIAZOXIDE

EAGLE PHARMS

* EAGLE PHARMACEUTICALS INC
BELRAPZO, BENDAMUSTINE HYDROCHLORIDE
BENDEKA, BENDAMUSTINE HYDROCHLORIDE
PEMFEXY, PEMETREXED
RYANODEX, DANTROLENE SODIUM
VASOPRESSIN, VASOPRESSIN

ECI PHARMS LLC

* ECI PHARMACEUTICALS LLC
MONOKET, ISOSORBIDE MONONITRATE
TRIENTINE HYDROCHLORIDE, TRIENTINE HYDROCHLORIDE
VALPROIC ACID, VALPROIC ACID

ECOLAB

* ECOLAB INC
CHG SCRUB, CHLORHEXIDINE GLUCONATE (OTC)
CIDA-STAT, CHLORHEXIDINE GLUCONATE (OTC)

EDENBRIDGE PHARMS

* EDENBRIDGE PHARMACEUTICALS LLC
ALBENDAZOLE, ALBENDAZOLE
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE, BISOPROLOL FUMARATE
CARBIDOPA, CARBIDOPA
DARTISLA ODT, GLYCOPYRROLATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** E ******* EDENBRIDGE PHARMACEUTICALS LLC**

DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
 DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
 ETHACRYNIC ACID, ETHACRYNIC ACID
 ETODOLAC, ETODOLAC
 IVERMECTIN, IVERMECTIN
 LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE
 MIGLUSTAT, MIGLUSTAT
 PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
 TINIDAZOLE, TINIDAZOLE

EDISON THERAPS LLC

*** EDISON THERAPEUTICS LLC**
 METHERGINE, METHYLERGONOVINE MALEATE

EGALET

*** EGALET US INC**
 INDOCIN, INDOMETHACIN

EIGER BIOPHARMS

*** EIGER BIOPHARMACEUTICALS INC**
 ZOKINVY, LONAFARNIB

EIRGEN

*** EIRGEN PHARMA LTD**
 RAYALDEE, CALCIFEDIOL

EISAI INC

*** EISAI INC**
 ARICEPT, DONEPEZIL HYDROCHLORIDE
 BANZEL, RUFINAMIDE
 DAYVIGO, LEMBOREXANT
 FYCOMPA, PERAMPANEL
 HALAVEN, ERIBULIN MESYLATE
 LENVIMA, LENVATINIB MESYLATE

ELI LILLY AND CO

*** ELI LILLY AND CO**
 BAQSIMI, GLUCAGON
 MOUNJARO, TIRZEPATIDE
 OLUMIANT, BARICITINIB
 PROZAC, FLUOXETINE HYDROCHLORIDE
 REYVOW, LASMIDITAN SUCCINATE
 VERZENIO, ABEMACICLIB

ELI LILLY CO

*** ELI LILLY CO**
 ADCIRCA, TADALAFIL
 ZYPREXA RELPREVV, OLANZAPINE PAMOATE

ELITE LABS

*** ELITE LABORATORIES INC**
 NALTREXONE HYDROCHLORIDE, NALTREXONE HYDROCHLORIDE
 PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE

ELITE LABS INC

*** ELITE LABORATORIES INC**
 ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
 DANTROLENE SODIUM, DANTROLENE SODIUM
 DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
 ISRADIPINE, ISRADIPINE
 LOXAPINE SUCCINATE, LOXAPINE SUCCINATE
 PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
 PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
 TRIMIPRAMINE MALEATE, TRIMIPRAMINE MALEATE

ELITE PHARM SOLUTION

*** ELITE PHARMACEUTICAL SOLUTION INC**
 NIFEDIPINE, NIFEDIPINE

ELYSIUM

*** ELYSIUM PHARMACEUTICALS LTD**
 CALCITRIOL, CALCITRIOL
 CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
 PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** E ****

* ELYSIUM PHARMACEUTICALS LTD
TIMOLOL MALEATE, TIMOLOL MALEATE

EMCURE PHARMS LTD

* EMCURE PHARMACEUTICALS LTD
ACARBOSE, ACARBOSE
ACETAZOLAMIDE SODIUM, ACETAZOLAMIDE SODIUM
ADENOSINE, ADENOSINE
AMIKACIN SULFATE, AMIKACIN SULFATE
CIDOFOVIR, CIDOFOVIR
COLISTIMETHATE SODIUM, COLISTIMETHATE SODIUM
ETOMIDATE, ETOMIDATE
FUROSEMIDE, FUROSEMIDE
METOCLOPRAMIDE, METOCLOPRAMIDE HYDROCHLORIDE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE
PENTAMIDINE ISETHIONATE, PENTAMIDINE ISETHIONATE
PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE
PROPOFOL, PROPOFOL
TRANEXAMIC ACID, TRANEXAMIC ACID

EMD SERONO INC

* EMD SERONO INC
CETROTIDE, CETRORELIX ACETATE
MAVENCLAD, CLADRIBINE
TEPMETKO, TEPOTINIB HYDROCHLORIDE

EMED MEDCL

* EMED MEDICAL CO LLC
TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE

EMERGENT

* EMERGENT OPERATIONS IRELAND LTD
NARCAN, NALOXONE HYDROCHLORIDE

EMERGENT BIODEFENSE

* EMERGENT BIODEFENSE OPERATIONS LANSING INC
TEMBEXA, BRINCIDOFOVIR
* EMERGENT BIODEFENSE OPERATIONS LANSING LLC
TEMBEXA, BRINCIDOFOVIR

EMMAUS MEDCL

* EMMAUS MEDICAL INC
ENDARI, L-GLUTAMINE

ENALTEC

* ENALTEC LABS INC
RAMELTEON, RAMELTEON

ENCUBE

* ENCUBE ETHICALS INC
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
* ENCUBE ETHICALS PRIVATE LTD
AZELAIC ACID, AZELAIC ACID
CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
DICLOFENAC SODIUM, DICLOFENAC SODIUM (OTC)
DOCOSANOL, DOCOSANOL (OTC)
KETOCONAZOLE, KETOCONAZOLE
LIDOCAINE AND PRILOCAINE, LIDOCAINE
METRONIDAZOLE, METRONIDAZOLE
MUPIROCIN, MUPIROCIN CALCIUM
TAVABOROLE, TAVABOROLE
TESTOSTERONE, TESTOSTERONE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

ENCUBE ETHICALS

* ENCUBE ETHICALS PVT LTD
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
DESONIDE, DESONIDE
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
FLUOCINONIDE, FLUOCINONIDE
HYDROCORTISONE VALERATE, HYDROCORTISONE VALERATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** E ****

- * ENCUBE ETHICALS PVT LTD
PERMETHRIN, PERMETHRIN

ENDO PHARM

- * ENDO PHARMACEUTICAL SOLUTIONS INC
SUPPRELIN LA, HISTRELIN ACETATE
VALSTAR PRESERVATIVE FREE, VALRUBICIN

ENDO PHARMS

- * ENDO PHARMACEUTICALS INC
FORTESTA, TESTOSTERONE
FROVA, FROVATRIPTAN SUCCINATE
PERCODAN, ASPIRIN

ENDO PHARMS INC

- * ENDO PHARMACEUTICALS INC
AVEED, TESTOSTERONE UNDECANOATE
COLY-MYCIN S, COLISTIN SULFATE
MEGACE ES, MEGESTROL ACETATE
NASCOBAL, CYANOCOBALAMIN

ENDO VENTURES

- * ENDO VENTURES LTD
EPHEDRINE SULFATE, EPHEDRINE SULFATE

EPI HLTH

- * EPI HEALTH LLC
CLODERM, CLOCORTOLONE PIVALATE
MINOLIRA, MINOCYCLINE HYDROCHLORIDE
RHOFAD, OXYMETAZOLINE HYDROCHLORIDE
SITAVIG, ACYCLOVIR

EPIC PHARMA

- * EPIC PHARMA INC
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE, BISOPROLOL FUMARATE
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
CHOLESTYRAMINE LIGHT, CHOLESTYRAMINE
CHOLESTYRAMINE, CHOLESTYRAMINE
ESTRADIOL, ESTRADIOL
LOVASTATIN, LOVASTATIN
MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE
NIZATIDINE, NIZATIDINE
OLANZAPINE AND FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
OXAZEPAM, OXAZEPAM
QUINIDINE SULFATE, QUINIDINE SULFATE
RIFAMPIN, RIFAMPIN
SULFADIAZINE, SULFADIAZINE
- * EPIC PHARMA LLC
BETAXOLOL HYDROCHLORIDE, BETAXOLOL HYDROCHLORIDE
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
FLAVOXATE HYDROCHLORIDE, FLAVOXATE HYDROCHLORIDE
SULINDAC, SULINDAC
TRANDOLAPRIL, TRANDOLAPRIL
URSODIOL, URSODIOL

EPIC PHARMA INC

- * EPIC PHARMA INC
SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE

EPIC PHARMA LLC

- * EPIC PHARMA LLC
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
AMPHETAMINE SULFATE, AMPHETAMINE SULFATE
AZITHROMYCIN, AZITHROMYCIN
BENZPHETAMINE HYDROCHLORIDE, BENZPHETAMINE HYDROCHLORIDE
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
DEMECLOCYCLINE HYDROCHLORIDE, DEMECLOCYCLINE HYDROCHLORIDE
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** E ******* EPIC PHARMA LLC**

DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
 FUROSEMIDE, FUROSEMIDE
 GLIPIZIDE AND METFORMIN HYDROCHLORIDE, GLIPIZIDE
 GLYBURIDE, GLYBURIDE
 GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
 HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
 HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
 LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
 LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
 MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE
 METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
 MOLINDONE HYDROCHLORIDE, MOLINDONE HYDROCHLORIDE
 NYSTATIN, NYSTATIN
 OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
 OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
 OXYCODONE AND ASPIRIN, ASPIRIN
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
 OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE
 PHENYTOIN, PHENYTOIN
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
 PROTRIPTYLINE HYDROCHLORIDE, PROTRIPTYLINE HYDROCHLORIDE
 SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE
 TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE

EPIZYME INC*** EPIZYME INC**

TAZVERIK, TAZEMETOSTAT HYDROBROMIDE

ESKAYEF*** ESKAYEF PHARMACEUTICALS LTD**

PREGABALIN, PREGABALIN

ESPERION THERAPS INC*** ESPERION THERAPEUTICS INC**

NEXLETOL, BEMPEDOIC ACID
 NEXLIZET, BEMPEDOIC ACID

ESPERO*** ESPERO BIOPHARMA INC**

DURLAZA, ASPIRIN

ESSENTIAL ISOTOPES*** ESSENTIAL ISOTOPES LLC**

AMMONIA N 13, AMMONIA N-13
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
 SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

ETHYPHARM*** ETHYPHARM**

BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE

*** ETHYPHARM SA**

ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM

ETHYPHARM USA CORP*** ETHYPHARM USA CORP**

BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE

ETON*** ETON PHARMACEUTICALS INC**

ALKINDI SPRINKLE, HYDROCORTISONE
 BETAINE, BETAINE

EUGIA PHARMA*** EUGIA PHARMA SPECIALITIES LTD**

ACETAMINOPHEN, ACETAMINOPHEN
 ACETYLCYSTEINE, ACETYLCYSTEINE
 ACYCLOVIR SODIUM, ACYCLOVIR SODIUM
 ADENOSINE, ADENOSINE
 AMPHOTERICIN B, AMPHOTERICIN B
 ANASTROZOLE, ANASTROZOLE
 ARSENIC TRIOXIDE, ARSENIC TRIOXIDE
 ATRACURIUM BESYLATE PRESERVATIVE FREE, ATRACURIUM BESYLATE
 ATRACURIUM BESYLATE, ATRACURIUM BESYLATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** E ****

* EUGIA PHARMA SPECIALITIES LTD
 AZACITIDINE, AZACITIDINE
 AZITHROMYCIN, AZITHROMYCIN
 BIMATOPROST, BIMATOPROST
 BIVALIRUDIN, BIVALIRUDIN
 BORTEZOMIB, BORTEZOMIB
 BROMFENAC SODIUM, BROMFENAC SODIUM
 BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE
 BUPIVACAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE
 CAFFEINE CITRATE, CAFFEINE CITRATE
 CAPECITABINE, CAPECITABINE
 CARBOPLATIN, CARBOPLATIN
 CHLORPROMAZINE HYDROCHLORIDE, CHLORPROMAZINE HYDROCHLORIDE
 CISATRACURIUM BESYLATE PRESERVATIVE FREE, CISATRACURIUM BESYLATE
 CISATRACURIUM BESYLATE, CISATRACURIUM BESYLATE
 CLOFARABINE, CLOFARABINE
 CYANOCOBALAMIN, CYANOCOBALAMIN
 DACTINOMYCIN, DACTINOMYCIN
 DAPTOMYCIN, DAPTOMYCIN
 DECITABINE, DECITABINE
 DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
 DEXMETOMIDINE HYDROCHLORIDE, DEXMETOMIDINE HYDROCHLORIDE
 DEXRAZOXANE HYDROCHLORIDE, DEXRAZOXANE HYDROCHLORIDE
 DOCETAXEL, DOCETAXEL
 DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
 DOXERCALCIFEROL, DOXERCALCIFEROL
 EPHEDRINE SULFATE, EPHEDRINE SULFATE
 EPTIFIBATIDE, EPTIFIBATIDE
 ERTAPENEM SODIUM, ERTAPENEM SODIUM
 ESMOLOL HYDROCHLORIDE, ESMOLOL HYDROCHLORIDE
 ESOMEPRAZOLE SODIUM, ESOMEPRAZOLE SODIUM
 ETOMIDATE, ETOMIDATE
 EXEMESTANE, EXEMESTANE
 FLUPHENAZINE DECANOATE, FLUPHENAZINE DECANOATE
 FONDAPARINUX SODIUM, FONDAPARINUX SODIUM
 FOSAPREPITANT DIMEGLUMINE, FOSAPREPITANT DIMEGLUMINE
 FULVESTRANT, FULVESTRANT
 FUROSEMIDE, FUROSEMIDE
 HYDROXYPROGESTERONE CAPROATE, HYDROXYPROGESTERONE CAPROATE
 IBANDRONATE SODIUM, IBANDRONATE SODIUM
 IMATINIB MESYLATE, IMATINIB MESYLATE
 IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
 ISOPROTERENOL HYDROCHLORIDE, ISOPROTERENOL HYDROCHLORIDE
 KETAMINE HYDROCHLORIDE, KETAMINE HYDROCHLORIDE
 LETROZOLE, LETROZOLE
 LEUPROLIDE ACETATE, LEUPROLIDE ACETATE
 LEVETIRACETAM IN SODIUM CHLORIDE, LEVETIRACETAM
 LEVETIRACETAM, LEVETIRACETAM
 LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
 LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
 LINEZOLID, LINEZOLID
 MEDROXYPROGESTERONE ACETATE, MEDROXYPROGESTERONE ACETATE
 MEROPENEM, MEROPENEM
 METHOCARBAMOL, METHOCARBAMOL
 METHOTREXATE SODIUM, METHOTREXATE SODIUM
 MILRINONE LACTATE IN DEXTROSE 5%, MILRINONE LACTATE
 MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
 NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
 NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE
 OLANZAPINE, OLANZAPINE
 OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE (OTC)
 OXALIPLATIN, OXALIPLATIN
 PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE
 PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
 PARICALCITOL, PARICALCITOL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** E ****

* EUGIA PHARMA SPECIALITIES LTD
 PEMETREXED DISODIUM, PEMETREXED DISODIUM
 PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
 POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
 PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE
 PROGESTERONE, PROGESTERONE
 REGADENOSON, REGADENOSON
 ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
 ROPIVACAINE HYDROCHLORIDE, ROPIVACAINE HYDROCHLORIDE
 SILDENAFIL CITRATE, SILDENAFIL CITRATE
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
 TAMOXIFEN CITRATE, TAMOXIFEN CITRATE
 THIAMINE HYDROCHLORIDE, THIAMINE HYDROCHLORIDE
 TIGECYCLINE, TIGECYCLINE
 TRANEXAMIC ACID, TRANEXAMIC ACID
 TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
 VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
 VASOPRESSIN, VASOPRESSIN
 VECURONIUM BROMIDE, VECURONIUM BROMIDE
 VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE

EUGIA PHARMA SPECLTS

* EUGIA PHARMA SPECIALITIES LTD
 AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
 AMPICILLIN SODIUM, AMPICILLIN SODIUM
 ARGATROBAN IN SODIUM CHLORIDE, ARGATROBAN
 CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE
 NAFCILLIN SODIUM, NAFCILLIN SODIUM
 OXACILLIN SODIUM, OXACILLIN SODIUM
 PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM

EUROCEPT PHARMS

* EUROCEPT PHARMACEUTICALS
 PASER, AMINOSALICYLIC ACID

EUROHLTH INTL SARL

* EUROHEALTH INTERNATIONAL SARL
 AZACITIDINE, AZACITIDINE
 DROPERIDOL, DROPERIDOL
 HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
 NEOSTIGMINE METHYLSULFATE, NEOSTIGMINE METHYLSULFATE

EVEREST LIFE SCI

* EVEREST LIFE SCIENCES LLC
 DAPSONE, DAPSONE

EVOFEM INC

* EVOFEM INC
 PHEXXI, CITRIC ACID

EVOKE PHARMA INC

* EVOKE PHARMA INC
 GIMOTI, METOCLOPRAMIDE HYDROCHLORIDE

EVUS

* EVUS HEALTH SOLUTIONS LLC
 NITROMIST, NITROGLYCERIN

EXELA PHARMA

* EXELA PHARMA SCIENCES LLC
 AKOVAZ, EPHEDRINE SULFATE
 BLOXIVERZ, NEOSTIGMINE METHYLSULFATE
 CAFFEINE CITRATE, CAFFEINE CITRATE
 CUPRIC CHLORIDE, CUPRIC CHLORIDE
 ELCYS, CYSTEINE HYDROCHLORIDE
 ERYTHROMYCIN LACTOBIONATE, ERYTHROMYCIN LACTOBIONATE
 GANZYK-RTU, GANCICLOVIR
 GLYRX-PF, GLYCOPYRROLATE
 MAGNESIUM SULFATE, MAGNESIUM SULFATE
 MIDAZOLAM IN 0.8% SODIUM CHLORIDE, MIDAZOLAM
 NIPRIDE RTU IN SODIUM CHLORIDE 0.9%, SODIUM NITROPRUSSIDE
 POTASSIUM ACETATE, POTASSIUM ACETATE
 SODIUM BICARBONATE, SODIUM BICARBONATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** E ****

- * EXELA PHARMA SCIENCES LLC
TRANEXAMIC ACID, TRANEXAMIC ACID
VAZCULEP, PHENYLEPHRINE HYDROCHLORIDE
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE
ZINC CHLORIDE, ZINC CHLORIDE

EXELA PHARMA SCIENCE

- * EXELA PHARMA SCIENCES
CAFFEINE CITRATE, CAFFEINE CITRATE

EXELIXIS

- * EXELIXIS INC
COMETRIQ, CABOZANTINIB S-MALATE

EXELIXIS INC

- * EXELIXIS INC
CABOMETYX, CABOZANTINIB S-MALATE

EXELTIS USA INC

- * EXELTIS USA INC
DROSPIRENONE, DROSPIRENONE
SLYND, DROSPIRENONE
TYBLUME, ETHINYL ESTRADIOL

EYEPOINT PHARMS

- * EYEPOINT PHARMACEUTICALS INC
DEXYCU KIT, DEXAMETHASONE
YUTIQ, FLUOCINOLONE ACETONIDE

EYEVANCE

- * EYEVANCE PHARMACEUTICALS LLC
FLAREX, FLUOROMETHOLONE ACETATE
NATACYN, NATAMYCIN
TOBRADEX ST, DEXAMETHASONE
ZERVIATE, CETIRIZINE HYDROCHLORIDE

EYWA

- * EYWA PHARMA INC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
POTASSIUM CITRATE, POTASSIUM CITRATE
PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE
QUINIDINE GLUCONATE, QUINIDINE GLUCONATE
TRIAMTERENE, TRIAMTERENE
VALPROIC ACID, VALPROIC ACID

EYWA PHARMA

- * EYWA PHARMA PTE LTD
ACETAZOLAMIDE, ACETAZOLAMIDE
BACLOFEN, BACLOFEN
URSODIOL, URSODIOL

LILLY

- * ELI LILLY AND CO
ALIMTA, PEMETREXED DISODIUM
CIALIS, TADALAFIL
CYMBALTA, DULOXETINE HYDROCHLORIDE
EVISTA, RALOXIFENE HYDROCHLORIDE
FORTEO, TERIPARATIDE
GLUCAGON, GLUCAGON
STRATTERA, ATOMOXETINE HYDROCHLORIDE
SYMBYAX, FLUOXETINE HYDROCHLORIDE
ZYPREXA ZYDIS, OLANZAPINE
ZYPREXA, OLANZAPINE

**** F ******FDC LTD**

- * FDC LTD

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** F ******* FDC LTD**

CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE
LATANOPROST, LATANOPROST
OFLOXACIN, OFLOXACIN
TIMOLOL MALEATE, TIMOLOL MALEATE

FDN CONSUMER

- * FOUNDATION CONSUMER BRANDS LLC
ALAVERT, LORATADINE (OTC)
- * FOUNDATION CONSUMER HEALTHCARE LLC
PLAN B ONE-STEP, LEVONORGESTREL (OTC)

FEINSTEIN

- * FEINSTEIN INSTITUTE MEDICAL RESEARCH
AMMONIA N 13, AMMONIA N-13
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
FLUORODOPA F18, FLUORODOPA F-18

FENNEC PHARMS INC

- * FENNEC PHARMACEUTICALS INC
PEDMARK, SODIUM THIOSULFATE

FERA PHARMS

- * FERA PHARMACEUTICALS LLC
TOBRAMYCIN, TOBRAMYCIN

FERA PHARMS LLC

- * FERA PHARMACEUTICALS LLC
CROMOLYN SODIUM, CROMOLYN SODIUM
GENTAMICIN SULFATE, GENTAMICIN SULFATE
PHOSPHOLINE IODIDE, ECHOTHIOPHATE IODIDE

FERRER INTERNACIONAL

- * FERRER INTERNACIONAL SA
XEPI, OZENOXACIN

FERRING

- * FERRING PHARMACEUTICALS INC
ENDOMETRIN, PROGESTERONE
FIRMAGON, DEGARELIX ACETATE

FERRING PHARMS INC

- * FERRING PHARMACEUTICALS INC
CERVIDIL, DINOPROSTONE
CLENPIQ, CITRIC ACID
DDAVP, DESMOPRESSIN ACETATE
NOC DURNA, DESMOPRESSIN ACETATE

FERTIN PHARMA

- * FERTIN PHARMA AS
NICOTINE POLACRILEX, NICOTINE POLACRILEX (OTC)

FLAMINGO PHARMS

- * FLAMINGO PHARMACEUTICALS LTD
METRONIDAZOLE, METRONIDAZOLE
PIROXICAM, PIROXICAM

FLORIDA

- * FLORIDA PHARMACEUTICAL PRODUCTS LLC
AMINOCAPROIC ACID, AMINOCAPROIC ACID
SUMATRIPTAN, SUMATRIPTAN

FOLDRX PHARMS

- * FOLDRX PHARMACEUTICALS LLC A WHOLLY OWNED SUB OF PFIZER INC
VYNDAMAX, TAFAMIDIS
VYNDAQEL, TAFAMIDIS MEGLUMINE

FOSUN PHARMA

- * FOSUN PHARMA USA INC
DICYCLIMINE HYDROCHLORIDE, DICYCLIMINE HYDROCHLORIDE

FOUGERA PHARMS

- * FOUGERA PHARMACEUTICALS INC
ADAPALENE, ADAPALENE
ALCLOMETASONE DIPROPIONATE, ALCLOMETASONE DIPROPIONATE
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** F ****

* FOUGERA PHARMACEUTICALS INC
 CALCIPOTRIENE, CALCIPOTRIENE
 CICLOPIROX, CICLOPIROX
 CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
 CLOBETASOL PROPIONATE (EMOLLIENT), CLOBETASOL PROPIONATE
 CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
 CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
 CLOTRIMAZOLE, CLOTRIMAZOLE
 DESONIDE, DESONIDE
 DESOXIMETASONE, DESOXIMETASONE
 DIFLORASONE DIACETATE, DIFLORASONE DIACETATE
 ERYTHROMYCIN, ERYTHROMYCIN
 FLUOCINONIDE EMULSIFIED BASE, FLUOCINONIDE
 FLUOCINONIDE, FLUOCINONIDE
 FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
 HALOBETASOL PROPIONATE, HALOBETASOL PROPIONATE
 HYDROCORTISONE, HYDROCORTISONE
 IMIQUIMOD, IMIQUIMOD
 KETOCONAZOLE, KETOCONAZOLE
 LIDOCAINE AND PRILOCAINE, LIDOCAINE
 METRONIDAZOLE, METRONIDAZOLE
 MOMETASONE FUROATE, MOMETASONE FUROATE
 MUPIROCI, MUPIROCI
 NYSTATIN, NYSTATIN
 OXISTAT, OXICONAZOLE NITRATE
 PREDNICARBATE, PREDNICARBATE
 SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM
 TERCONAZOLE, TERCONAZOLE
 TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
 TYZINE, TETRAHYDROZOLINE HYDROCHLORIDE

FOUGERA PHARMS INC

* FOUGERA PHARMACEUTICALS INC
 ACYCLOVIR, ACYCLOVIR
 BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
 BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
 CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
 CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
 FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
 FLUOCINONIDE, FLUOCINONIDE
 GENTAMICIN SULFATE, GENTAMICIN SULFATE
 HYDROCORTISONE, HYDROCORTISONE
 LIDOCAINE, LIDOCAINE
 NITROGLYCERIN, NITROGLYCERIN
 NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
 NYSTATIN, NYSTATIN
 TACROLIMUS, TACROLIMUS
 TERCONAZOLE, TERCONAZOLE

FRESENIUS

* FRESENIUS KABI DEUTSCHLAND GMBH
 INTRALIPID 10%, SOYBEAN OIL
 INTRALIPID 20%, SOYBEAN OIL
 INTRALIPID 30%, SOYBEAN OIL
 * FRESENIUS KABI IPSUM SRL
 NAFCILLIN SODIUM, NAFCILLIN SODIUM

FRESENIUS KABI

* FRESENIUS KABI ANTI INFECTIVES SRL
 PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM
 * FRESENIUS KABI AUSTRIA GMBH
 LACTULOSE, LACTULOSE

FRESENIUS KABI USA

* FRESENIUS KABI USA LLC
 ACETAMINOPHEN, ACETAMINOPHEN
 ACETYLCYSTEINE, ACETYLCYSTEINE
 ACYCLOVIR SODIUM, ACYCLOVIR SODIUM
 ADENOSINE, ADENOSINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** F ****

* FRESSENIUS KABI USA LLC
 AMIKACIN SULFATE, AMIKACIN SULFATE
 AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
 ARGATROBAN, ARGATROBAN
 ARSENIC TRIOXIDE, ARSENIC TRIOXIDE
 ATROPINE SULFATE, ATROPINE SULFATE
 AZITHROMYCIN, AZITHROMYCIN
 AZTREONAM, AZTREONAM
 BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
 BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
 BIVALIRUDIN, BIVALIRUDIN
 BLEOMYCIN SULFATE, BLEOMYCIN SULFATE
 BORTEZOMIB, BORTEZOMIB
 CAFFEINE CITRATE, CAFFEINE CITRATE
 CALCIUM GLUCONATE IN SODIUM CHLORIDE, CALCIUM GLUCONATE
 CALCIUM GLUCONATE, CALCIUM GLUCONATE
 CARBOPLATIN, CARBOPLATIN
 CARDIOPLEGIC IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 CASPOFUNGIN ACETATE, CASPOFUNGIN ACETATE
 CEFOTETAN, CEFOTETAN DISODIUM
 CHLORAMPHENICOL SODIUM SUCCINATE, CHLORAMPHENICOL SODIUM SUCCINATE
 CHLOROTHIAZIDE SODIUM, CHLOROTHIAZIDE SODIUM
 CISATRACURIUM BESYLATE PRESERVATIVE FREE, CISATRACURIUM BESYLATE
 CISATRACURIUM BESYLATE, CISATRACURIUM BESYLATE
 CISPLATIN, CISPLATIN
 CLADRIBINE, CLADRIBINE
 CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
 CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
 COLISTIMETHATE SODIUM, COLISTIMETHATE SODIUM
 CYTARABINE, CYTARABINE
 DACARBAZINE, DACARBAZINE
 DAPTOMYCIN, DAPTOMYCIN
 DAUNORUBICIN HYDROCHLORIDE, DAUNORUBICIN HYDROCHLORIDE
 DEFEROXAMINE MESYLATE, DEFEROXAMINE MESYLATE
 DEXAMETHASONE SODIUM PHOSPHATE PRESERVATIVE FREE, DEXAMETHASONE SODIUM PHOSPHATE
 DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
 DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
 DEXTROSE 10% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% AND POTASSIUM CHLORIDE 0.075%, DEXTROSE
 DEXTROSE 5% AND POTASSIUM CHLORIDE 0.15%, DEXTROSE
 DEXTROSE 5% AND SODIUM CHLORIDE 0.225%, DEXTROSE
 DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 5% AND SODIUM CHLORIDE 0.45%, DEXTROSE
 DEXTROSE 5% AND SODIUM CHLORIDE 0.9%, DEXTROSE
 DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
 DIAZEPAM, DIAZEPAM
 DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
 DILAUDID, HYDROMORPHONE HYDROCHLORIDE
 DIMENHYDRINATE, DIMENHYDRINATE
 DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE, DIPHENHYDRAMINE HYDROCHLORIDE
 DIPRIVAN, PROPOFOL
 DIPYRIDAMOLE, DIPYRIDAMOLE
 DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
 DOXY 100, DOXYCYCLINE HYCLATE
 DOXY 200, DOXYCYCLINE HYCLATE
 EPHEDRINE SULFATE, EPHEDRINE SULFATE
 ESMOLOL HYDROCHLORIDE, ESMOLOL HYDROCHLORIDE
 ETOPOSIDE, ETOPOSIDE
 FAMOTIDINE PRESERVATIVE FREE, FAMOTIDINE
 FAMOTIDINE, FAMOTIDINE
 FENTANYL CITRATE PRESERVATIVE FREE, FENTANYL CITRATE
 FENTANYL CITRATE, FENTANYL CITRATE
 FLOXURIDINE, FLOXURIDINE
 FLUCONAZOLE IN SODIUM CHLORIDE 0.9%, FLUCONAZOLE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** F ****

* FRESSENIUS KABI USA LLC
 FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE
 FLUMAZENIL, FLUMAZENIL
 FLUOROURACIL, FLUOROURACIL
 FLUPHENAZINE DECANOATE, FLUPHENAZINE DECANOATE
 FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE
 FOLIC ACID, FOLIC ACID
 FOSAPREPITANT DIMEGLUMINE, FOSAPREPITANT DIMEGLUMINE
 FOSCARNET SODIUM, FOSCARNET SODIUM
 FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
 FULVESTRANT, FULVESTRANT
 FUROSEMIDE, FUROSEMIDE
 GANCICLOVIR SODIUM, GANCICLOVIR SODIUM
 GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
 GENTAMICIN SULFATE, GENTAMICIN SULFATE
 GLUCAGON, GLUCAGON HYDROCHLORIDE
 GLYCOPYRROLATE, GLYCOPYRROLATE
 GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE, GRANISETRON HYDROCHLORIDE
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
 HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
 HALOPERIDOL, HALOPERIDOL LACTATE
 HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN
 HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN
 HEPARIN SODIUM IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPARIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM
 HEPARIN SODIUM, HEPARIN SODIUM
 HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
 ICATIBANT ACETATE, ICATIBANT ACETATE
 IFOSFAMIDE, IFOSFAMIDE
 INDOMETHACIN, INDOMETHACIN
 IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
 KABIVEN IN PLASTIC CONTAINER, AMINO ACIDS
 KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
 LACOSAMIDE, LACOSAMIDE
 LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 LEUCOVORIN CALCIUM PRESERVATIVE FREE, LEUCOVORIN CALCIUM
 LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
 LEVETIRACETAM, LEVETIRACETAM
 LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, LEVOFLOXACIN
 LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM
 LIDOCAINE HYDROCHLORIDE IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
 LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
 LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
 LINEZOLID, LINEZOLID
 MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MAGNESIUM SULFATE
 MAGNESIUM SULFATE IN PLASTIC CONTAINER, MAGNESIUM SULFATE
 MAGNESIUM SULFATE, MAGNESIUM SULFATE
 MANNITOL 25%, MANNITOL
 MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE
 MESNA, MESNA
 METHOCARBAMOL, METHOCARBAMOL
 METHOTREXATE PRESERVATIVE FREE, METHOTREXATE SODIUM
 METHOTREXATE SODIUM, METHOTREXATE SODIUM
 METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE SODIUM SUCCINATE
 METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
 METOPROLOL TARTRATE, METOPROLOL TARTRATE
 MICA FUNGIN SODIUM, MICA FUNGIN SODIUM
 MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE, MIDAZOLAM HYDROCHLORIDE
 MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
 MILRINONE LACTATE, MILRINONE LACTATE
 MITOXANTRONE HYDROCHLORIDE, MITOXANTRONE HYDROCHLORIDE
 MORPHINE SULFATE, MORPHINE SULFATE
 MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
 NAROPIN, ROPIVACAINE HYDROCHLORIDE
 NEBUPENT, PENTAMIDINE ISETHIONATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** F ******* FRESSENIUS KABI USA LLC**

NEOSTIGMINE METHYLSULFATE, NEOSTIGMINE METHYLSULFATE
 NESACAINE, CHLOROPROCAINE HYDROCHLORIDE
 NESACAINE-MPF, CHLOROPROCAINE HYDROCHLORIDE
 NOREPINEPHRINE BITARTRATE, NOREPINEPHRINE BITARTRATE
 OCTREOTIDE ACETATE (PRESERVATIVE FREE), OCTREOTIDE ACETATE
 OCTREOTIDE ACETATE, OCTREOTIDE ACETATE
 OMEGAVEN, FISH OIL TRIGLYCERIDES
 ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 OXACILLIN SODIUM, OXACILLIN SODIUM
 OXALIPLATIN, OXALIPLATIN
 OXYTOCIN, OXYTOCIN
 PACLITAXEL, PACLITAXEL
 PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE
 PEMETREXED DISODIUM, PEMETREXED DISODIUM
 PENTAM, PENTAMIDINE ISETHIONATE
 PERIKABIVEN IN PLASTIC CONTAINER, AMINO ACIDS
 PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
 PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM
 POLOCAINE, MEPIVACAINE HYDROCHLORIDE
 POLOCAINE-MPF, MEPIVACAINE HYDROCHLORIDE
 POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
 POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.45%, POTASSIUM CHLORIDE
 POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.9%, POTASSIUM CHLORIDE
 POTASSIUM CHLORIDE 0.3% AND SODIUM CHLORIDE 0.9%, POTASSIUM CHLORIDE
 POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45%, DEXTROSE
 POTASSIUM CHLORIDE 10MEQ, POTASSIUM CHLORIDE
 POTASSIUM CHLORIDE 20MEQ, POTASSIUM CHLORIDE
 POTASSIUM CHLORIDE 40MEQ, POTASSIUM CHLORIDE
 POTASSIUM CHLORIDE IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
 POTASSIUM PHOSPHATES, POTASSIUM PHOSPHATE, DIBASIC
 PROGESTERONE, PROGESTERONE
 PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
 PROTAMINE SULFATE, PROTAMINE SULFATE
 PYRIDOXINE HYDROCHLORIDE, PYRIDOXINE HYDROCHLORIDE
 REMIFENTANIL HYDROCHLORIDE, REMIFENTANIL HYDROCHLORIDE
 RIFAMPIN, RIFAMPIN
 ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
 ROMIDEPSIN, ROMIDEPSIN
 SENSORCAINE, BUPIVACAINE HYDROCHLORIDE
 SENSORCAINE, BUPIVACAINE HYDROCHLORIDE
 SMOFLIPID 20%, FISH OIL
 SODIUM ACETATE, SODIUM ACETATE
 SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, SODIUM CHLORIDE
 SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
 SODIUM CHLORIDE 14.6%, SODIUM CHLORIDE
 SODIUM CHLORIDE 23.4%, SODIUM CHLORIDE
 SODIUM CHLORIDE 3% IN PLASTIC CONTAINER, SODIUM CHLORIDE
 SODIUM PHOSPHATES, SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE
 STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION
 STERILE WATER FOR INJECTION, STERILE WATER FOR INJECTION
 SUCCINYLCHOLINE CHLORIDE, SUCCINYLCHOLINE CHLORIDE
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
 TERBUTALINE SULFATE, TERBUTALINE SULFATE
 THIAMINE HYDROCHLORIDE, THIAMINE HYDROCHLORIDE
 TIGECYCLINE, TIGECYCLINE
 TOBRAMYCIN SULFATE (PHARMACY BULK), TOBRAMYCIN SULFATE
 TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
 TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
 TRANEXAMIC ACID, TRANEXAMIC ACID
 VALPROATE SODIUM, VALPROATE SODIUM
 VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
 VIBISONE, CYANOCOBALAMIN
 VINBLASTINE SULFATE, VINBLASTINE SULFATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** F ****

- * FRESENIUS KABI USA LLC
 - XYLOCAINE W/ EPINEPHRINE, EPINEPHRINE
 - XYLOCAINE, LIDOCAINE HYDROCHLORIDE
 - ZINC SULFATE, ZINC SULFATE MONOHYDRATE
 - ZOLEDRONIC ACID, ZOLEDRONIC ACID

FRESENIUS MEDCL

- * FRESENIUS MEDICAL CARE NORTH AMERICA
 - DELFLX W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 - DELFLX W/ DEXTROSE 1.5% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 - DELFLX W/ DEXTROSE 1.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM
 - DELFLX W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 - DELFLX W/ DEXTROSE 2.5% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 - DELFLX W/ DEXTROSE 2.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM
 - DELFLX W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 - DELFLX W/ DEXTROSE 4.25% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 - DELFLX W/ DEXTROSE 4.25% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM
 - PHOSLO GELCAPS, CALCIUM ACETATE
 - PHOSLYRA, CALCIUM ACETATE
 - SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE

**** G ******G1 THERAP**

- * G1 THERAPEUTICS INC
 - COSELA, TRILACICLIB DIHYDROCHLORIDE

GALDERMA LABS

- * GALDERMA LABORATORIES INC
 - CLOBEX, CLOBETASOL PROPIONATE
 - EPIDUO FORTE, ADAPALENE

GALDERMA LABS LP

- * GALDERMA LABORATORIES L P
 - CLOBEX, CLOBETASOL PROPIONATE
- * GALDERMA LABORATORIES LP
 - AKLIEF, TRIFAROTENE
 - CAPEX, FLUOCINOLONE ACETONIDE
 - CLOBEX, CLOBETASOL PROPIONATE
 - DESOWEN, DESONIDE
 - DIFFERIN, ADAPALENE
 - DIFFERIN, ADAPALENE (OTC)
 - EPIDUO, ADAPALENE
 - EPSOLAY, BENZOYL PEROXIDE
 - METROCREAM, METRONIDAZOLE
 - METROGEL, METRONIDAZOLE
 - METROLOTION, METRONIDAZOLE
 - MIRVASO, BRIMONIDINE TARTRATE
 - ORACEA, DOXYCYCLINE
 - SOOLANTRA, IVERMECTIN
 - TRI-LUMA, FLUOCINOLONE ACETONIDE
 - TWYNEO, BENZOYL PEROXIDE
 - VECTICAL, CALCITRIOL

GALT PHARMS

- * GALT PHARMACEUTICALS LLC
 - DORAL, QUAZEPAM
 - ORAVIG, MICONAZOLE
 - ORPHENGESIC FORTE, ASPIRIN
 - ORPHENGESIC, ASPIRIN

GE HEALTHCARE

- * GE HEALTHCARE
 - ADREVIEW, IOBENGUANE SULFATE I-123
 - CERETEC, TECHNETIUM TC-99M EXAMETAZIME KIT
 - CLARISCAN, GADOTERATE MEGLUMINE
 - INDIUM IN 111 OXYQUINOLINE, INDIUM IN-111 OXYQUINOLINE
 - MPI INDIUM DTPA IN 111, INDIUM IN-111 PENTETATE DISODIUM
 - MYOVUE 30ML, TECHNETIUM TC-99M TETROFOSMIN KIT
 - MYOVUE, TECHNETIUM TC-99M TETROFOSMIN KIT
 - OMNIPAQUE 12, IOHEXOL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** G ******* GE HEALTHCARE**

OMNIPAQUE 140, IOHEXOL
 OMNIPAQUE 180, IOHEXOL
 OMNIPAQUE 240, IOHEXOL
 OMNIPAQUE 300, IOHEXOL
 OMNIPAQUE 350, IOHEXOL
 OMNIPAQUE 9, IOHEXOL
 OMNISCAN, GADODIAMIDE
 OPTISON, ALBUMIN HUMAN
 VISIPAQUE 270, IODIXANOL
 VISIPAQUE 320, IODIXANOL
 VIZAMYL, FLUTEMETAMOL F-18

GE HLTHCARE INC

* GE HEALTHCARE INC
 DATSCAN, IOFLUPANE I-123

GENBIOPRO

* GENBIOPRO INC
 MIFEPRISTONE, MIFEPRISTONE

GENENTECH

* GENENTECH INC
 ERIVEDGE, VISMODEGIB

GENENTECH INC

* GENENTECH INC
 COTELLIC, COBIMETINIB FUMARATE
 ESBRIET, PIRFENIDONE
 EVRYSDI, RISDIPLAM
 GAVRETO, PRALSETINIB
 ROZLYTREK, ENTRECTINIB
 XOFLUZA, BALOXAVIR MARBOXIL

GENERICIS

* GENERICIS INTERNATIONAL VENTURES ENTERPRISES LLC
 DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE

GENEYORK PHARMS

* GENEYORK PHARMACEUTICALS GROUP LLC
 PREDNISONE, PREDNISONE

GENUS

* GENUS LIFESCIENCES INC
 CHLORPROMAZINE HYDROCHLORIDE, CHLORPROMAZINE HYDROCHLORIDE
 CLEMASTINE FUMARATE, CLEMASTINE FUMARATE
 HYCODAN, HOMATROPINE METHYLBROMIDE
 HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
 NYSTATIN, NYSTATIN

GENUS LIFESCIENCES

* GENUS LIFE SCIENCES INC
 AMCINONIDE, AMCINONIDE
 GOPRELTO, COCAINE HYDROCHLORIDE
 LEVOLET, LEVOTHYROXINE SODIUM **
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE

GENZYME

* GENZYME CORP
 CLOLAR, CLOFARABINE
 MOZOBIL, PLERIXAFOR
 RENAGEL, SEVELAMER HYDROCHLORIDE
 RENVELA, SEVELAMER CARBONATE

GENZYME CORP

* GENZYME CORP
 CAPRELSA, VANDETANIB
 CERDELGA, ELIGLUSTAT TARTRATE

GILEAD

* GILEAD SCIENCES INC
 CAYSTON, AZTREONAM
 EMTRIVA, EMTRICITABINE
 HEPSERA, ADEFOVIR DIPIVOXIL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** G ****

* GILEAD SCIENCES INC
LETAIRIS, AMBRISENTAN
RANEXA, RANOLAZINE
TRUVADA, EMTRICITABINE

GILEAD SCIENCES

* GILEAD SCIENCES LLC
ATRIPLA, EFAVIRENZ

GILEAD SCIENCES INC

* GILEAD SCIENCES INC
BIKTARVY, BICTEGRAVIR SODIUM
COMPLERA, EMTRICITABINE
DESCOVY, EMTRICITABINE
EPCLUSA, SOFOSBUVIR
GENVOYA, COBICISTAT
HARVONI, LEDIPASVIR
ODEFSEY, EMTRICITABINE
SOVALDI, SOFOSBUVIR
STRIBILD, COBICISTAT
SUNLENCA, LENACAPAVIR SODIUM
TYBOST, COBICISTAT
VEKLURY, REMDESIVIR
VEMLIDY, TENOFOVIR ALAFENAMIDE FUMARATE
VIREAD, TENOFOVIR DISOPROXIL FUMARATE
VOSEVI, SOFOSBUVIR
ZYDELIG, IDELALISIB

GISKIT

* GISKIT PHARMA BV
EXEM FOAM KIT, AIR POLYMER-TYPE A

GLAND

* GLAND PHARMA LTD
CASPOFUNGIN ACETATE, CASPOFUNGIN ACETATE
DECITABINE, DECITABINE
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
DEXRAZOXANE HYDROCHLORIDE, DEXRAZOXANE HYDROCHLORIDE
HEPARIN SODIUM, HEPARIN SODIUM
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
MEROPENEM, MEROPENEM
MESNA, MESNA
OXALIPLATIN, OXALIPLATIN
POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
TRANEXAMIC ACID, TRANEXAMIC ACID
VECURONIUM BROMIDE, VECURONIUM BROMIDE
ZOLEDRONIC ACID, ZOLEDRONIC ACID

GLAND PHARMA LTD

* GLAND PHARMA LTD
ADENOSINE, ADENOSINE
ALLOPURINOL SODIUM, ALLOPURINOL SODIUM
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
ARGATROBAN IN SODIUM CHLORIDE, ARGATROBAN
ARSENIC TRIOXIDE, ARSENIC TRIOXIDE
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
AZITHROMYCIN, AZITHROMYCIN
BIMATOPROST, BIMATOPROST
BROMFENAC SODIUM, BROMFENAC SODIUM
BUMETANIDE, BUMETANIDE
CALCITRIOL, CALCITRIOL
CARBOPLATIN, CARBOPLATIN
CISPLATIN, CISPLATIN
CLOFARABINE, CLOFARABINE
CYANOCOBALAMIN, CYANOCOBALAMIN
CYTARABINE, CYTARABINE
DEFEROXAMINE MESYLATE, DEFEROXAMINE MESYLATE
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** G ******* GLAND PHARMA LTD**

DOCETAXEL, DOCETAXEL
 DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
 DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE
 DOXERCALCIFEROL, DOXERCALCIFEROL
 DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
 EPHEDRINE SULFATE, EPHEDRINE SULFATE
 ERTAPENEM SODIUM, ERTAPENEM SODIUM
 ESMOLOL HYDROCHLORIDE, ESMOLOL HYDROCHLORIDE
 ESOMEPRAZOLE SODIUM, ESOMEPRAZOLE SODIUM
 ETOMIDATE, ETOMIDATE
 FLUOROURACIL, FLUOROURACIL
 FOSCARNET SODIUM, FOSCARNET SODIUM
 FUROSEMIDE, FUROSEMIDE
 GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
 GLYCOPYRROLATE, GLYCOPYRROLATE
 HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
 HALOPERIDOL, HALOPERIDOL LACTATE
 IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
 LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
 LACOSAMIDE, LACOSAMIDE
 LEVETIRACETAM IN SODIUM CHLORIDE, LEVETIRACETAM
 LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, LEVOFLOXACIN
 LEVOFLOXACIN, LEVOFLOXACIN
 LEVOLEUCOVORIN CALCIUM, LEVOLEUCOVORIN CALCIUM
 LINCOMYCIN HYDROCHLORIDE, LINCOMYCIN HYDROCHLORIDE
 MAGNESIUM SULFATE IN PLASTIC CONTAINER, MAGNESIUM SULFATE
 MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE
 METHOCARBAMOL, METHOCARBAMOL
 METOPROLOL TARTRATE, METOPROLOL TARTRATE
 METRONIDAZOLE IN PLASTIC CONTAINER, METRONIDAZOLE
 MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
 MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MILRINONE LACTATE
 MITOMYCIN, MITOMYCIN
 MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
 NEOSTIGMINE METHYLSULFATE, NEOSTIGMINE METHYLSULFATE
 NOREPINEPHRINE BITARTRATE, NOREPINEPHRINE BITARTRATE
 OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE (OTC)
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 OXALIPLATIN, OXALIPLATIN
 PACLITAXEL, PACLITAXEL
 PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
 PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
 PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE
 REGADENOSON, REGADENOSON
 ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
 ROPIVACAINE HYDROCHLORIDE, ROPIVACAINE HYDROCHLORIDE
 SUCCINYLCHOLINE CHLORIDE, SUCCINYLCHOLINE CHLORIDE
 TEMSIROLIMUS, TEMSIROLIMUS
 THIOTEPA, THIOTEPA
 TIMOLOL MALEATE, TIMOLOL MALEATE
 TIROFIBAN HYDROCHLORIDE, TIROFIBAN HYDROCHLORIDE
 TOBRAMYCIN SULFATE (PHARMACY BULK), TOBRAMYCIN SULFATE
 TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
 TOBRAMYCIN, TOBRAMYCIN
 VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
 VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE
 VORICONAZOLE, VORICONAZOLE
 ZINC SULFATE, ZINC SULFATE
 ZIPRASIDONE MESYLATE, ZIPRASIDONE MESYLATE
 ZOLEDRONIC ACID, ZOLEDRONIC ACID
 ZOLEDRONIC, ZOLEDRONIC ACID

GLASSHOUSE PHARMS

*** GLASSHOUSE PHARMACEUTICALS LTD CANADA**
 ARIPIPRAZOLE, ARIPIPRAZOLE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** G ****

- * GLASSHOUSE PHARMACEUTICALS LTD CANADA
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
FLUOCINONIDE, FLUOCINONIDE
HALCINONIDE, HALCINONIDE
OXCARBAZEPINE, OXCARBAZEPINE
RUFINAMIDE, RUFINAMIDE

GLAUKOS

- * GLAUKOS CORP
PHOTREXA VISCOSUS IN DEXTRAN 20%, RIBOFLAVIN 5'-PHOSPHATE SODIUM
PHOTREXA, RIBOFLAVIN 5'-PHOSPHATE SODIUM

GLAXO GRP ENGLAND

- * GLAXO GROUP LTD ENGLAND DBA GLAXOSMITHKLINE
INCRUSE ELLIPTA, UMECLIDINIUM BROMIDE

GLAXO GRP LTD

- * GLAXO GROUP LTD DBA GLAXOSMITHKLINE
FLOVENT HFA, FLUTICASONE PROPIONATE
- * GLAXO GROUP LTD ENGLAND DBA GLAXOSMITHKLINE
ADVAIR DISKUS 100/50, FLUTICASONE PROPIONATE
ADVAIR DISKUS 250/50, FLUTICASONE PROPIONATE
ADVAIR DISKUS 500/50, FLUTICASONE PROPIONATE
ADVAIR HFA, FLUTICASONE PROPIONATE
BREQ ELLIPTA, FLUTICASONE FUROATE
FLOVENT DISKUS 100, FLUTICASONE PROPIONATE
FLOVENT DISKUS 250, FLUTICASONE PROPIONATE
FLOVENT DISKUS 50, FLUTICASONE PROPIONATE

GLAXOSMITHKLINE

- * GLAXOSMITHKLINE
ABREVA, DOCOSANOL (OTC)
BECONASE AQ, BECLOMETHASONE DIPROPIONATE MONOHYDRATE
EPIVIR-HBV, LAMIVUDINE
IMITREX STATDOSE, SUMATRIPTAN SUCCINATE
IMITREX, SUMATRIPTAN
IMITREX, SUMATRIPTAN SUCCINATE
MALARONE PEDIATRIC, ATOVAQUONE
MALARONE, ATOVAQUONE
NICORETTE (MINT), NICOTINE POLACRILEX (OTC)
NICORETTE, NICOTINE POLACRILEX (OTC)
RELENZA, ZANAMIVIR
VALTREX, VALACYCLOVIR HYDROCHLORIDE
WELLBUTRIN SR, BUPROPION HYDROCHLORIDE
- * GLAXOSMITHKLINE CONSUMER HEALTHCARE HOLDINGS US LLC
ADVIL ALLERGY AND CONGESTION RELIEF, CHLORPHENIRAMINE MALEATE (OTC)
ADVIL ALLERGY SINUS, CHLORPHENIRAMINE MALEATE (OTC)
ADVIL COLD AND SINUS, IBUPROFEN (OTC)
ADVIL CONGESTION RELIEF, IBUPROFEN (OTC)
ADVIL DUAL ACTION WITH ACETAMINOPHEN, ACETAMINOPHEN (OTC)
ADVIL LIQUI-GELS, IBUPROFEN (OTC)
ADVIL MIGRAINE LIQUI-GELS, IBUPROFEN (OTC)
ADVIL MULTI-SYMPTOM COLD & FLU, CHLORPHENIRAMINE MALEATE (OTC)
ADVIL PM, DIPHENHYDRAMINE CITRATE (OTC)
ADVIL PM, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
ADVIL, IBUPROFEN (OTC)
ADVIL, IBUPROFEN SODIUM (OTC)
AXID AR, NIZATIDINE (OTC)
CHILDREN'S ADVIL ALLERGY SINUS, CHLORPHENIRAMINE MALEATE (OTC)
CHILDREN'S ADVIL COLD, IBUPROFEN (OTC)
CHILDREN'S ADVIL, IBUPROFEN (OTC)
CHILDREN'S ADVIL-FLAVORED, IBUPROFEN (OTC)
INFANT'S ADVIL, IBUPROFEN (OTC)
JUNIOR STRENGTH ADVIL, IBUPROFEN (OTC)
LAMISIL, TERBINAFINE HYDROCHLORIDE (OTC)
NICORETTE, NICOTINE POLACRILEX (OTC)
- * GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LTD ENGLAND
ANORO ELLIPTA, UMECLIDINIUM BROMIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** G ****

- * GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LTD ENGLAND
ARNUITY ELLIPTA, FLUTICASONE FUROATE
KRINTAFEL, TAFENOQUINE SUCCINATE
TRELEGY ELLIPTA, FLUTICASONE FUROATE
- * GLAXOSMITHKLINE INTELLECTUAL PROPERTY LTD ENGLAND
SEREVENT, SALMETEROL XINAFOATE
VENTOLIN HFA, ALBUTEROL SULFATE
- * GLAXOSMITHKLINE LLC
ZEJULA, NIRAPARIB TOSYLATE

GLAXOSMITHKLINE CONS

- * GLAXOSMITHKLINE CONSUMER HEALTHCARE
ALLI, ORLISTAT (OTC)
EXCEDRIN (MIGRAINE), ACETAMINOPHEN (OTC)
FLONASE ALLERGY RELIEF, FLUTICASONE PROPIONATE (OTC)
FLONASE SENSIMIST ALLERGY RELIEF, FLUTICASONE FUROATE (OTC)
LAMISIL AT, TERBINAFAINE (OTC)
LAMISIL AT, TERBINAFAINE HYDROCHLORIDE (OTC)
NICORETTE, NICOTINE POLACRILEX (OTC)
VOLTAREN ARTHRITIS PAIN, DICLOFENAC SODIUM (OTC)

GLAXOSMITHKLINE LLC

- * GLAXOSMITHKLINE LLC
AMERGE, NARATRIPTAN HYDROCHLORIDE
FLOLAN, EPOPROSTENOL SODIUM
LAMICTAL CD, LAMOTRIGINE
LAMICTAL ODT, LAMOTRIGINE
LAMICTAL XR, LAMOTRIGINE
LAMICTAL, LAMOTRIGINE
MEPRON, ATOVAQUONE
RYTHMOL SR, PROPAFENONE HYDROCHLORIDE

GLENMARK GENERICS

- * GLENMARK GENERICS INC USA
ADAPALENE, ADAPALENE (OTC)
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
IMIQUIMOD, IMIQUIMOD
MOMETASONE FUROATE, MOMETASONE FUROATE
NIZATIDINE, NIZATIDINE
ZONISAMIDE, ZONISAMIDE
- * GLENMARK GENERICS LIMITED
BRIELLYN, ETHINYL ESTRADIOL
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
- * GLENMARK GENERICS LTD
ACAMPROSATE CALCIUM, ACAMPROSATE CALCIUM
ALCLOMETASONE DIPROPIONATE, ALCLOMETASONE DIPROPIONATE
ALYACEN 1/35, ETHINYL ESTRADIOL
ALYACEN 7/7/7, ETHINYL ESTRADIOL
ASHLYNA, ETHINYL ESTRADIOL
ATOVAQUONE AND PROGUANIL HYDROCHLORIDE, ATOVAQUONE
CARVEDILOL, CARVEDILOL
CICLOPIROX, CICLOPIROX
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
DESOXIMETASONE, DESOXIMETASONE
ESZOPICLONE, ESZOPICLONE
FELODIPINE, FELODIPINE
FLUCONAZOLE, FLUCONAZOLE
FLUOCINONIDE, FLUOCINONIDE
HEATHER, NORETHINDRONE
HYDROCORTISONE BUTYRATE, HYDROCORTISONE BUTYRATE
LAMOTRIGINE, LAMOTRIGINE
LEVOFLOXACIN, LEVOFLOXACIN
LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
LITHIUM CARBONATE, LITHIUM CARBONATE
MARLISSA, ETHINYL ESTRADIOL
MELOXICAM, MELOXICAM
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** G ****

- * GLENMARK GENERICS LTD
 - MOEXIPRIL HYDROCHLORIDE, MOEXIPRIL HYDROCHLORIDE
 - MOMETASONE FUROATE, MOMETASONE FUROATE
 - MONTELUKAST SODIUM, MONTELUKAST SODIUM
 - NAPROXEN, NAPROXEN
 - NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 - NORETHINDRONE, NORETHINDRONE
 - NORGESTIMATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 - OMEPRazole, OMEPRazole
 - ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 - ONDANSETRON, ONDANSETRON
 - PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
 - RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
 - ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
 - SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
 - TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
 - THEOPHYLLINE, THEOPHYLLINE
 - TOPIRAMATE, TOPIRAMATE
 - TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE, TRANDOLAPRIL
 - TROSPIMUM CHLORIDE, TROSPIMUM CHLORIDE
 - URSODIOL, URSODIOL
 - VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE
 - VIORALE, DESOGESTREL
 - ZOLMITRIPTAN, ZOLMITRIPTAN
- * GLENMARK GENERICS LTD INDIA
 - INDOMETHACIN, INDOMETHACIN
 - NORETHINDRONE ACETATE, NORETHINDRONE ACETATE
 - PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
- GLENMARK PHARMS**
 - * GLENMARK PHARMACEUTICALS INC
 - TERIFLUNOMIDE, TERIFLUNOMIDE
 - * GLENMARK PHARMACEUTICALS INC USA
 - CICLOPIROX, CICLOPIROX
 - CLOTRIMAZOLE, CLOTRIMAZOLE
 - MUPIROcin, MUPIROcin
 - * GLENMARK PHARMACEUTICALS LTD
 - MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 - * GLENMARK PHARMACEUTICALS SA
 - ABIRATERONE ACETATE, ABIRATERONE ACETATE
 - ATOVAQUONE, ATOVAQUONE
 - AZELAIC ACID, AZELAIC ACID
 - CALCIPOTRIENE, CALCIPOTRIENE
 - CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
 - CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
 - CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
 - DESONIDE, DESONIDE
 - ESOMEPRazole MAGNESIUM, ESOMEPRazole MAGNESIUM
 - HAILEY 1.5/30, ETHINYL ESTRADIOL
 - HAILEY FE 1.5/30, ETHINYL ESTRADIOL
 - LINEZOLID, LINEZOLID
 - NORGESTIMATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 - ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
 - TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
- GLENMARK PHARMS INC**
 - * GLENMARK PHARMACEUTICALS INC USA
 - CALCIPOTRIENE, CALCIPOTRIENE
 - CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 - FAMOTIDINE, FAMOTIDINE (OTC)
 - FULVESTRANT, FULVESTRANT
 - LANSOPRAZOLE, LANSOPRAZOLE (OTC)
 - LITHIUM CARBONATE, LITHIUM CARBONATE
 - MUPIROcin, MUPIROcin CALCIUM
 - RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
 - SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE
- GLENMARK PHARMS LTD**

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** G ******* GLENMARK PHARMACEUTICALS LTD**

ADAPALENE AND BENZOYL PEROXIDE, ADAPALENE
 AMLODIPINE AND OLMESARTAN MEDOXOMIL, AMLODIPINE BESYLATE
 ATOMOXETINE HYDROCHLORIDE, ATOMOXETINE HYDROCHLORIDE
 BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE, BISOPROLOL FUMARATE
 CHLORPROMAZINE HYDROCHLORIDE, CHLORPROMAZINE HYDROCHLORIDE
 CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
 CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
 COLESEVELAM HYDROCHLORIDE, COLESEVELAM HYDROCHLORIDE
 DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
 DESONIDE, DESONIDE
 DICLOFENAC SODIUM, DICLOFENAC SODIUM
 DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
 DIMETHYL FUMARATE, DIMETHYL FUMARATE
 DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE
 ESTRADIOL, ESTRADIOL
 EZETIMIBE AND SIMVASTATIN, EZETIMIBE
 EZETIMIBE, EZETIMIBE
 FENOFIBRATE (MICRONIZED), FENOFIBRATE
 FINGOLIMOD HYDROCHLORIDE, FINGOLIMOD HYDROCHLORIDE
 FLUCINOLONE ACETONIDE, FLUCINOLONE ACETONIDE
 FLUOCINONIDE ACETONIDE, FLUOCINOLONE ACETONIDE
 FROVATRIPTAN SUCCINATE, FROVATRIPTAN SUCCINATE
 GABAPENTIN, GABAPENTIN
 HAILEY FE 1/20, ETHINYL ESTRADIOL
 HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
 HYDROCORTISONE VALERATE, HYDROCORTISONE VALERATE
 INDOMETHACIN, INDOMETHACIN
 LACOSAMIDE, LACOSAMIDE
 LAMOTRIGINE, LAMOTRIGINE
 LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 LEVONORGESTREL, LEVONORGESTREL (OTC)
 LIDOCAINE, LIDOCAINE
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 METRONIDAZOLE, METRONIDAZOLE
 NAPROXEN SODIUM, NAPROXEN SODIUM
 NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE
 NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
 NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
 OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
 OXCARBAZEPINE, OXCARBAZEPINE
 PIMECROLIMUS, PIMECROLIMUS
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
 PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
 RALOXIFENE HYDROCHLORIDE, RALOXIFENE HYDROCHLORIDE
 RANOLAZINE, RANOLAZINE
 RILUZOLE, RILUZOLE
 RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
 RUFINAMIDE, RUFINAMIDE
 SEVELAMER HYDROCHLORIDE, SEVELAMER HYDROCHLORIDE
 SIROLIMUS, SIROLIMUS
 SODIUM PHENYLBUTYRATE, SODIUM PHENYLBUTYRATE
 TACROLIMUS, TACROLIMUS
 TELMISARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 TELMISARTAN, TELMISARTAN
 THEOPHYLLINE, THEOPHYLLINE
 TOPIRAMATE, TOPIRAMATE
 TRETINOIN, TRETINOIN
 TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
 VORICONAZOLE, VORICONAZOLE

GLENMARK PHARMS SA*** GLENMARK PHARMACEUTICALS SA SWITZERLAND**

ACYCLOVIR, ACYCLOVIR
 APREPITANT, APREPITANT

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** G ****

- * GLENMARK PHARMACEUTICALS SA SWITZERLAND
ASPIRIN AND DIPYRIDAMOLE, ASPIRIN
NITROGLYCERIN, NITROGLYCERIN

GLENMARK SPECIALTY

- * GLENMARK SPECIALTY SA
RYALTRIS, MOMETASONE FUROATE

GLOBAL BLOOD THERAPY

- * GLOBAL BLOOD THERAPEUTICS INC
OXBRYTA, VOXELOTOR

GLW

- * GLW PHARMA GMBH
OMEGA-3-ACID ETHYL ESTERS, OMEGA-3-ACID ETHYL ESTERS

GRANULES

- * GRANULES INDIA LTD
ACETAMINOPHEN, ACETAMINOPHEN (OTC)
ACETAMINOPHEN, ASPIRIN AND CAFFEINE, ACETAMINOPHEN (OTC)
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
GABAPENTIN, GABAPENTIN
GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE, GUAIFENESIN (OTC)
GUAIFENESIN, GUAIFENESIN (OTC)
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE, LOPERAMIDE HYDROCHLORIDE (OTC)
LORATADINE, LORATADINE (OTC)
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METHOCARBAMOL, METHOCARBAMOL
NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE
NAPROXEN, NAPROXEN
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
ZONISAMIDE, ZONISAMIDE
- * GRANULES PHARMACEUTICALS INC
AMPHETAMINE SULFATE, AMPHETAMINE SULFATE
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
BUTALBITAL AND ACETAMINOPHEN, ACETAMINOPHEN
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
COLCHICINE, COLCHICINE
DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DOFETILIDE, DOFETILIDE
METHYLERGONOVINE MALEATE, METHYLERGONOVINE MALEATE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
PENICILLAMINE, PENICILLAMINE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PRAZOSIN HYDROCHLORIDE, PRAZOSIN HYDROCHLORIDE
RAMELTEON, RAMELTEON
TROSPIMUM CHLORIDE, TROSPIMUM CHLORIDE
VALGANCICLOVIR HYDROCHLORIDE, VALGANCICLOVIR HYDROCHLORIDE

GRANULES INDIA

- * GRANULES INDIA LTD
IBUPROFEN, IBUPROFEN (OTC)
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)

GRAVITI PHARMS

- * GRAVITI PHARMACEUTICALS INC
GABAPENTIN, GABAPENTIN
MONTELUKAST SODIUM, MONTELUKAST SODIUM
- * GRAVITI PHARMACEUTICALS PRIVATE LTD
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM (OTC)

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** G ****

- * GRAVITI PHARMACEUTICALS PRIVATE LTD
FENOFIBRATE, FENOFIBRATE
FENOFIBRIC ACID, CHOLINE FENOFIBRATE
FUROSEMIDE, FUROSEMIDE
MONTELUKAST SODIUM, MONTELUKAST SODIUM
RANOLAZINE, RANOLAZINE
SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE

GUANGZHOU NOVAKEN

- * GUANGZHOU NOVAKEN PHARMACEUTICAL CO LTD
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE

GUARDIAN DRUG

- * GUARDIAN DRUG CO
DIATRIZOATE MEGLUMINE AND DIATRIZOATE SODIUM, DIATRIZOATE MEGLUMINE
GUAIFENESIN, GUAIFENESIN (OTC)
IBUPROFEN, IBUPROFEN (OTC)
LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE, LOPERAMIDE HYDROCHLORIDE (OTC)
OMEPRazole AND SODIUM BICARBONATE, OMEPRazole
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE

GUERBET

- * GUERBET
ELUCIREM, GADOPICLENOL
- * GUERBET LLC
DOTAREM, GADOTERATE MEGLUMINE
LIPIODOL, ETHIODIZED OIL

GW RES LTD

- * GW RESEARCH LTD
EPIDIOLEX, CANNABIDIOL

**** H ******HAEMONETICS**

- * HAEMONETICS CORP
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE

HAINAN POLY

- * HAINAN POLY PHARM CO LTD
DOBUTAMINE HYDROCHLORIDE, DOBUTAMINE HYDROCHLORIDE
ESOMEPRazole SODIUM, ESOMEPRazole SODIUM
LINCOMYCIN HYDROCHLORIDE, LINCOMYCIN HYDROCHLORIDE
METHOCARBAMOL, METHOCARBAMOL
SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE

HAINAN POLY PHARM

- * HAINAN POLY PHARMACEUTICAL CO LTD
AZITHROMYCIN, AZITHROMYCIN
BIVALIRUDIN, BIVALIRUDIN
DAPTOMYCIN, DAPTOMYCIN
EPTIFIBATIDE, EPTIFIBATIDE
GANCICLOVIR SODIUM, GANCICLOVIR SODIUM
LEVETIRACETAM, LEVETIRACETAM
SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
VORICONAZOLE, VORICONAZOLE

HALOCARBON PRODS

- * HALOCARBON PRODUCTS CORP
ISOFLURANE, ISOFLURANE
SEVOFLURANE, SEVOFLURANE

HANDA

- * HANDA NEUROSCIENCE LLC
TASCENSO ODT, FINGOLIMOD LAURYL SULFATE

HANGZHOU BINJIANG

- * HANGZHOU MINSHENG BINJIANG PHARMACEUTICAL CO LTD
ALENDRONATE SODIUM, ALENDRONATE SODIUM

HANGZHOU ZHONGMEI

- * HANGZHOU ZHONGMEI HUADONG PHARMACEUTICAL CO LTD
DAPTOMYCIN, DAPTOMYCIN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** H ******HARMAN FINOCHEM**

- * HARMAN FINOCHEM LTD
ALLOPURINOL, ALLOPURINOL
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

HARMONY

- * HARMONY BIOSCIENCES LLC
WAKIX, PITOLISANT HYDROCHLORIDE

HARROW EYE

- * HARROW EYE LLC
IHEEZO, CHLOROPROCAINE HYDROCHLORIDE

HBT LABS INC

- * HBT LABS INC
FULVESTRANT, FULVESTRANT
PACLITAXEL, PACLITAXEL

HEC PHARM

- * HEC PHARM USA INC
CLARITHROMYCIN, CLARITHROMYCIN
LEVOFLOXACIN, LEVOFLOXACIN
OLANZAPINE, OLANZAPINE
PRASUGREL, PRASUGREL HYDROCHLORIDE

HEC PHARM CO LTD

- * HEC PHARM CO LTD
FINGOLIMOD HYDROCHLORIDE, FINGOLIMOD HYDROCHLORIDE

HELSINN

- * HELSINN BIREX PHARMACEUTICALS LTD
VALCHLOR, MECHLORETHAMINE HYDROCHLORIDE

HELSINN HLTHCARE

- * HELSINN HEALTHCARE SA
AKYNZEO, FOSNETUPITANT CHLORIDE HYDROCHLORIDE
AKYNZEO, NETUPITANT
TRUSELTIQ, INFIGRATINIB PHOSPHATE

HERITAGE

- * HERITAGE PHARMA LABS INC DBA AVET PHARMA LABS INC
TEMOZOLOMIDE, TEMOZOLOMIDE

HERITAGE LIFE

- * HERITAGE LIFE SCIENCES BARBADOS INC
CLOZARIL, CLOZAPINE

HERITAGE PHARMA

- * HERITAGE PHARMA LABS INC
ACETAMINOPHEN, ACETAMINOPHEN (OTC)
ACETAZOLAMIDE, ACETAZOLAMIDE
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
BUMETANIDE, BUMETANIDE
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
DIFLUNISAL, DIFLUNISAL
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
ENALAPRIL MALEATE, ENALAPRIL MALEATE
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
LITHIUM CARBONATE, LITHIUM CARBONATE
METHIMAZOLE, METHIMAZOLE
NADOLOL, NADOLOL
NIFEDIPINE, NIFEDIPINE

HERITAGE PHARMA AVET

- * HERITAGE PHARMA LABS INC DBA AVET PHARMACEUTICALS LABS INC
TERAZOSIN HYDROCHLORIDE, TERAZOSIN HYDROCHLORIDE
THEOPHYLLINE, THEOPHYLLINE

HERITAGE PHARMS

- * HERITAGE PHARMACEUTICALS INC DBA AVET PHARMACEUTICALS INC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** H ****

* HERITAGE PHARMACEUTICALS INC DBA AVET PHARMACEUTICALS INC
 ACYCLOVIR, ACYCLOVIR
 DESIPRAMINE HYDROCHLORIDE, DESIPRAMINE HYDROCHLORIDE
 DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
 DOXYCYCLINE, DOXYCYCLINE
 FELODIPINE, FELODIPINE
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 GLIPIZIDE AND METFORMIN HYDROCHLORIDE, GLIPIZIDE
 GLYBURIDE, GLYBURIDE
 HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
 HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 LEFLUNOMIDE, LEFLUNOMIDE
 NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE
 NIMODIPINE, NIMODIPINE
 NYSTATIN, NYSTATIN
 OCTREOTIDE ACETATE, OCTREOTIDE ACETATE
 PAROMOMYCIN SULFATE, PAROMOMYCIN SULFATE
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
 VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE

HERITAGE PHARMS INC

* HERITAGE PHARMACEUTICALS INC
 ACYCLOVIR, ACYCLOVIR
 CALCIUM ACETATE, CALCIUM ACETATE
 CLINDAMYCIN PALMITATE HYDROCHLORIDE, CLINDAMYCIN PALMITATE HYDROCHLORIDE
 ETHOSUXIMIDE, ETHOSUXIMIDE
 GLYCOPYRROLATE, GLYCOPYRROLATE
 METRONIDAZOLE, METRONIDAZOLE
 TROSPIMUM CHLORIDE, TROSPIMUM CHLORIDE

HERON THERAPS INC

* HERON THERAPEUTICS INC
 APONVIE, APREPITANT
 CINVANTI, APREPITANT
 SUSTOL, GRANISETRON
 ZYNRELEF KIT, BUPIVACAINE

HETERO LABS

* HETERO LABS LTD
 AMLODIPINE BESYLATE AND VALSARTAN, AMLODIPINE BESYLATE
 DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE
 LINEZOLID, LINEZOLID

HETERO LABS LTD III

* HETERO LABS LTD UNIT III
 ABACAVIR SULFATE, ABACAVIR SULFATE
 ACYCLOVIR, ACYCLOVIR
 ATAZANAVIR SULFATE, ATAZANAVIR SULFATE
 ATOVAQUONE, ATOVAQUONE
 CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
 CLOBAZAM, CLOBAZAM
 DABIGATRAN ETEXILATE MESYLATE, DABIGATRAN ETEXILATE MESYLATE
 DIMETHYL FUMARATE, DIMETHYL FUMARATE
 DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
 EFAVIREN, EFAVIREN
 EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE, EMTRICITABINE
 ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
 ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
 ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM (OTC)
 EZETIMIBE, EZETIMIBE
 FENOFIBRATE, FENOFIBRATE
 FINASTERIDE, FINASTERIDE
 HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
 HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
 INDOMETHACIN, INDOMETHACIN
 KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
 LACOSAMIDE, LACOSAMIDE
 LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** H ******* HETERO LABS LTD UNIT III**

LANSOPRAZOLE, LANSOPRAZOLE
 LEVETIRACETAM, LEVETIRACETAM
 LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
 LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE (OTC)
 LEVOCETIRIZINE HYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
 LITHIUM CARBONATE, LITHIUM CARBONATE
 LOPINAVIR AND RITONAVIR, LOPINAVIR
 LORATADINE, LORATADINE (OTC)
 MARAVIROC, MARAVIROC
 METHOCARBAMOL, METHOCARBAMOL
 METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
 NAPROXEN, NAPROXEN
 NEBIVOLOL HYDROCHLORIDE, NEBIVOLOL HYDROCHLORIDE
 NEVIRAPINE, NEVIRAPINE
 OMEPRAZOLE MAGNESIUM, OMEPRAZOLE MAGNESIUM (OTC)
 OMEPRAZOLE, OMEPRAZOLE
 OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
 POSACONAZOLE, POSACONAZOLE
 PREGABALIN, PREGABALIN
 RANOLAZINE, RANOLAZINE
 RITONAVIR, RITONAVIR
 ROFLUMILAST, ROFLUMILAST
 RUFINAMIDE, RUFINAMIDE
 SIMVASTATIN, SIMVASTATIN
 TADALAFIL, TADALAFIL
 TENOFOVIR DISOPROXIL FUMARATE, TENOFOVIR DISOPROXIL FUMARATE
 TOLTERODINE TARTRATE, TOLTERODINE TARTRATE
 TORSEMIDE, TORSEMIDE
 TRIENTINE HYDROCHLORIDE, TRIENTINE HYDROCHLORIDE
 ZIDOVUDINE, ZIDOVUDINE

HETERO LABS LTD V*** HETERO LABS LTD UNIT V**

ACYCLOVIR, ACYCLOVIR
 ARIPIRAZOLE, ARIPIRAZOLE
 ATOMOXETINE HYDROCHLORIDE, ATOMOXETINE HYDROCHLORIDE
 CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
 CINACALCET HYDROCHLORIDE, CINACALCET HYDROCHLORIDE
 COLCHICINE, COLCHICINE
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
 EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE, EFAVIRENZ
 ENTECAVIR, ENTECAVIR
 FAMCICLOVIR, FAMCICLOVIR
 FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
 FINGOLIMOD HYDROCHLORIDE, FINGOLIMOD HYDROCHLORIDE
 IRBESARTAN, IRBESARTAN
 LACOSAMIDE, LACOSAMIDE
 LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE
 LAMIVUDINE, LAMIVUDINE
 LEVOFLOXACIN, LEVOFLOXACIN
 LINEZOLID, LINEZOLID
 LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE, LOPERAMIDE HYDROCHLORIDE (OTC)
 LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
 MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
 MONTELUKAST SODIUM, MONTELUKAST SODIUM
 NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
 OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
 PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
 PIRFENIDONE, PIRFENIDONE
 QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
 ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
 SILDENAFIL CITRATE, SILDENAFIL CITRATE
 SILODOSIN, SILODOSIN
 SODIUM PICOSULFATE, MAGNESIUM OXIDE AND ANHYDROUS CITRIC ACID, CITRIC ACID
 TELMISARTAN, TELMISARTAN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** H ****

- * HETERO LABS LTD UNIT V
TETRABENAZINE, TETRABENAZINE
TOLTERODINE TARTRATE, TOLTERODINE TARTRATE
TOLVAPTAN, TOLVAPTAN
VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
VALGANCICLOVIR HYDROCHLORIDE, VALGANCICLOVIR HYDROCHLORIDE
VALSARTAN, VALSARTAN

HEYL CHEMISCH

- * HEYL CHEMISCH PHARMAZEUTISCHE FABRIK
RADIOGARDASE (PRUSSIAN BLUE), FERRIC HEXACYANOFERRATE(II)

HIGH TECH PHARMA

- * HIGH TECHNOLOGY PHARMACAL CO INC
VALPROIC ACID, VALPROIC ACID

HIKAL

- * HIKAL LTD
PREGABALIN, PREGABALIN

HIKMA

- * HIKMA FARMACEUTICA LDA
CEFOTAXIME, CEFOTAXIME SODIUM
- * HIKMA FARMACEUTICA PORTUGAL SA
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
CEFTRIAXONE SODIUM, CEFTRIAXONE SODIUM
DOCETAXEL, DOCETAXEL
ESTRADIOL VALERATE, ESTRADIOL VALERATE
ETOMIDATE, ETOMIDATE
METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE SODIUM SUCCINATE
NOREPINEPHRINE BITARTRATE, NOREPINEPHRINE BITARTRATE
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
VECURONIUM BROMIDE, VECURONIUM BROMIDE
- * HIKMA PHARMACEUTICALS
AMOXICILLIN, AMOXICILLIN
CEFACLOR, CEFACLOX
CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
CEPHALEXIN, CEPHALEXIN
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
GLYBURIDE (MICRONIZED), GLYBURIDE
- * HIKMA PHARMACEUTICALS INTERNATIONAL LTD
CODEINE SULFATE, CODEINE SULFATE
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
DIGOXIN, DIGOXIN
FUROSEMIDE, FUROSEMIDE
LINEZOLID, LINEZOLID
MICA FUNGIN SODIUM, MICA FUNGIN SODIUM
MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
MORPHINE SULFATE, MORPHINE SULFATE
NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE
RUFINAMIDE, RUFINAMIDE
SUCCINYLCHOLINE CHLORIDE, SUCCINYLCHOLINE CHLORIDE
- * HIKMA PHARMACEUTICALS LLC
ABIRATERONE ACETATE, ABIRATERONE ACETATE
DANTROLENE SODIUM, DANTROLENE SODIUM
DOXERCALCIFEROL, DOXERCALCIFEROL
FLUDROCORTISONE ACETATE, FLUDROCORTISONE ACETATE
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
PIROXICAM, PIROXICAM
- * HIKMA PHARMACEUTICALS USA INC
ACARBOSE, ACARBOSE
ACETAMINOPHEN, ACETAMINOPHEN
ACETAZOLAMIDE SODIUM, ACETAZOLAMIDE SODIUM
ADENOSINE, ADENOSINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** H ****

* HIKMA PHARMACEUTICALS USA INC
 ALENDRONATE SODIUM, ALENDRONATE SODIUM
 ALLOPURINOL SODIUM, ALLOPURINOL SODIUM
 ALOSETRON HYDROCHLORIDE, ALOSETRON HYDROCHLORIDE
 ALPRAZOLAM, ALPRAZOLAM
 ALPROSTADIL, ALPROSTADIL
 AMIKACIN SULFATE, AMIKACIN SULFATE
 AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
 AMRINONE LACTATE, INAMRINONE LACTATE
 ATIVAN, LORAZEPAM
 ATRACURIUM BESYLATE PRESERVATIVE FREE, ATRACURIUM BESYLATE
 ATRACURIUM BESYLATE, ATRACURIUM BESYLATE
 ATROPINE SULFATE, ATROPINE SULFATE
 AZATHIOPRINE SODIUM, AZATHIOPRINE SODIUM
 AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
 BALSALAZIDE DISODIUM, BALSALAZIDE DISODIUM
 BEXAROTENE, BEXAROTENE
 BLEOMYCIN SULFATE, BLEOMYCIN SULFATE
 BOSENTAN, BOSENTAN
 BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
 BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
 BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE, ACETAMINOPHEN
 BUTORPHANOL TARTRATE PRESERVATIVE FREE, BUTORPHANOL TARTRATE
 BUTORPHANOL TARTRATE, BUTORPHANOL TARTRATE
 CAFECIT, CAFFEINE CITRATE
 CALCITRIOL, CALCITRIOL
 CALCIUM ACETATE, CALCIUM ACETATE
 CAPECITABINE, CAPECITABINE
 CARBOPLATIN, CARBOPLATIN
 CEFAZOLIN SODIUM, CEFAZOLIN SODIUM
 CEFOXITIN, CEFOXITIN SODIUM
 CERUBIDINE, DAUNORUBICIN HYDROCHLORIDE
 CEVIMELINE HYDROCHLORIDE, CEVIMELINE HYDROCHLORIDE
 CHLOROPROCAINE HYDROCHLORIDE, CHLOROPROCAINE HYDROCHLORIDE
 CISATRACURIUM BESYLATE, CISATRACURIUM BESYLATE
 CISPLATIN, CISPLATIN
 CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
 CLADRIBINE, CLADRIBINE
 CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
 CLOTRIMAZOLE, CLOTRIMAZOLE
 CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE
 CYCLOSPORINE, CYCLOSPORINE
 CYTARABINE, CYTARABINE
 DACARBAZINE, DACARBAZINE
 DAUNORUBICIN HYDROCHLORIDE, DAUNORUBICIN HYDROCHLORIDE
 DEFERIPRONE, DEFERIPRONE
 DESVENLAFAXINE SUCCINATE, DESVENLAFAXINE SUCCINATE
 DEXAMETHASONE INTENSOL, DEXAMETHASONE
 DEXAMETHASONE, DEXAMETHASONE
 DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
 DEXRAZOXANE HYDROCHLORIDE, DEXRAZOXANE HYDROCHLORIDE
 DIAZEPAM INTENSOL, DIAZEPAM
 DIAZEPAM, DIAZEPAM
 DICYCLOMINE HYDROCHLORIDE (PRESERVATIVE FREE), DICYCLOMINE HYDROCHLORIDE
 DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
 DIHYDROERGOTAMINE MESYLATE, DIHYDROERGOTAMINE MESYLATE
 DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, ATROPINE SULFATE
 DIPYRIDAMOLE, DIPYRIDAMOLE
 DISULFIRAM, DISULFIRAM
 DOBUTAMINE HYDROCHLORIDE, DOBUTAMINE HYDROCHLORIDE
 DOPRAM, DOXAPRAM HYDROCHLORIDE
 DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
 DOXYCYCLINE, DOXYCYCLINE HYCLATE
 DROXIDOPA, DROXIDOPA
 DURAMORPH PF, MORPHINE SULFATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** H ****

* HIKMA PHARMACEUTICALS USA INC
 EPHEDRINE SULFATE, EPHEDRINE SULFATE
 EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
 ESMOLOL HYDROCHLORIDE, ESMOLOL HYDROCHLORIDE
 ETHACRYNIC ACID, ETHACRYNIC ACID
 ETOMIDATE, ETOMIDATE
 ETOPOSIDE, ETOPOSIDE
 EVEROLIMUS, EVEROLIMUS
 EXEMESTANE, EXEMESTANE
 FAMOTIDINE PRESERVATIVE FREE, FAMOTIDINE
 FAMOTIDINE, FAMOTIDINE
 FEBUXOSTAT, FEBUXOSTAT
 FENOLDOPAM MESYLATE, FENOLDOPAM MESYLATE
 FENTANYL CITRATE PRESERVATIVE FREE, FENTANYL CITRATE
 FLECAINIDE ACETATE, FLECAINIDE ACETATE
 FLOXURIDINE, FLOXURIDINE
 FLUCONAZOLE IN SODIUM CHLORIDE 0.9%, FLUCONAZOLE
 FLUCYTOSINE, FLUCYTOSINE
 FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE
 FLUMAZENIL, FLUMAZENIL
 FLUPHENAZINE DECANOATE, FLUPHENAZINE DECANOATE
 FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE, FLUTICASONE PROPIONATE
 FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
 FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE (OTC)
 FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
 FUROSEMIDE, FUROSEMIDE
 GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
 GANCICLOVIR SODIUM, GANCICLOVIR SODIUM
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
 HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
 HALOPERIDOL, HALOPERIDOL LACTATE
 HEPARIN SODIUM, HEPARIN SODIUM
 HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
 HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
 ICOSAPENT ETHYL, ICOSAPENT ETHYL
 IDARUBICIN HYDROCHLORIDE, IDARUBICIN HYDROCHLORIDE
 IFOSFAMIDE, IFOSFAMIDE
 IMATINIB MESYLATE, IMATINIB MESYLATE
 IMIPRAMINE PAMOATE, IMIPRAMINE PAMOATE
 INFUMORPH, MORPHINE SULFATE
 IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
 IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 KETAMINE HYDROCHLORIDE, KETAMINE HYDROCHLORIDE
 KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
 KLOXXADO, NALOXONE HYDROCHLORIDE
 LABETALOL HYDROCHLORIDE IN DEXTROSE, LABETALOL HYDROCHLORIDE
 LABETALOL HYDROCHLORIDE IN SODIUM CHLORIDE, LABETALOL HYDROCHLORIDE
 LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
 LEUCOVORIN CALCIUM PRESERVATIVE FREE, LEUCOVORIN CALCIUM
 LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
 LEVOCARNITINE, LEVOCARNITINE
 LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM
 LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
 LIDOCAINE VISCOUS, LIDOCAINE HYDROCHLORIDE
 LINEZOLID, LINEZOLID
 LITHIUM CARBONATE, LITHIUM CARBONATE
 LORAZEPAM INTENSOL, LORAZEPAM
 MEDROXYPROGESTERONE ACETATE, MEDROXYPROGESTERONE ACETATE
 MEFLOQUINE HYDROCHLORIDE, MEFLOQUINE HYDROCHLORIDE
 MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE
 MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE
 MERCAPTOPURINE, MERCAPTOPURINE
 MESNA, MESNA
 METHADONE HYDROCHLORIDE INTENSOL, METHADONE HYDROCHLORIDE
 METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** H ******* HIKMA PHARMACEUTICALS USA INC**

METHAMPHETAMINE HYDROCHLORIDE, METHAMPHETAMINE HYDROCHLORIDE
 METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM
 METHOTREXATE SODIUM, METHOTREXATE SODIUM
 METOPROLOL TARTRATE, METOPROLOL TARTRATE
 MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
 MILRINONE LACTATE, MILRINONE LACTATE
 MITOMYCIN, MITOMYCIN
 MITOXANTRONE HYDROCHLORIDE, MITOXANTRONE HYDROCHLORIDE
 MORPHINE SULFATE, MORPHINE SULFATE
 MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
 NALOXONE, NALOXONE HYDROCHLORIDE
 NAPROXEN, NAPROXEN
 NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE
 NEOSTIGMINE METHYLSULFATE, NEOSTIGMINE METHYLSULFATE
 NOREPINEPHRINE BITARTRATE, NOREPINEPHRINE BITARTRATE
 ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
 OXCARBAZEPINE, OXCARBAZEPINE
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
 OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE
 OXYTOCIN, OXYTOCIN
 PACLITAXEL, PACLITAXEL
 PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
 PENTOBARBITAL SODIUM, PENTOBARBITAL SODIUM
 PHENOXYBENZAMINE HYDROCHLORIDE, PHENOXYBENZAMINE HYDROCHLORIDE
 PHENTOLAMINE MESYLATE, PHENTOLAMINE MESYLATE
 POSACONAZOLE, POSACONAZOLE
 PREDNISONE INTENSOL, PREDNISONE
 PREDNISONE, PREDNISONE
 PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE
 PROPOFOL, PROPOFOL
 PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
 PROTRIPTYLINE HYDROCHLORIDE, PROTRIPTYLINE HYDROCHLORIDE
 QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
 RAMIPRIL, RAMIPRIL
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
 REMIFENTANIL HYDROCHLORIDE, REMIFENTANIL HYDROCHLORIDE
 RIFAMPIN, RIFAMPIN
 RISPERIDONE, RISPERIDONE
 ROBAXIN, METHOCARBAMOL
 ROPIVACAINE HYDROCHLORIDE, ROPIVACAINE HYDROCHLORIDE
 RUFINAMIDE, RUFINAMIDE
 SODIUM CHLORIDE 0.9%, SODIUM CHLORIDE
 SODIUM TETRADECYL SULFATE, SODIUM TETRADECYL SULFATE
 STERILE WATER FOR INJECTION, STERILE WATER FOR INJECTION
 SUCCINYLCHOLINE CHLORIDE, SUCCINYLCHOLINE CHLORIDE
 SUFENTANIL CITRATE, SUFENTANIL CITRATE
 TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
 TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
 TORSEMIDE, TORSEMIDE
 TRIAZOLAM, TRIAZOLAM
 VALRUBICIN, VALRUBICIN
 VECURONIUM BROMIDE, VECURONIUM BROMIDE
 VIGABATRIN, VIGABATRIN
 VINBLASTINE SULFATE, VINBLASTINE SULFATE
 VINORELBINE TARTRATE, VINORELBINE TARTRATE
 ZALEPLON, ZALEPLON

HIKMA FARMACEUTICA*** HIKMA FARMACEUTICA (PORTUGAL) SA**

AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
 BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
 BUTORPHANOL TARTRATE, BUTORPHANOL TARTRATE
 CEFOXITIN, CEFOXITIN SODIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** H ****

- * HIKMA FARMACEUTICA (PORTUGAL) SA
 - CEFTRIAZONE, CEFTRIAZONE SODIUM
 - CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, CIPROFLOXACIN
 - CIPROFLOXACIN, CIPROFLOXACIN
 - CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
 - ENALAPRILAT, ENALAPRILAT
 - FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE
 - FLUMAZENIL, FLUMAZENIL
 - FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
 - GLYCOPYRROLATE, GLYCOPYRROLATE
 - GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
 - IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
 - LEVETIRACETAM, LEVETIRACETAM
 - LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, LEVOFLOXACIN
 - METOPROLOL TARTRATE, METOPROLOL TARTRATE
 - MILRINONE LACTATE IN PLASTIC CONTAINER, MILRINONE LACTATE
 - MILRINONE LACTATE, MILRINONE LACTATE
 - ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 - PROGESTERONE, PROGESTERONE
 - PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
 - TERBUTALINE SULFATE, TERBUTALINE SULFATE
 - TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
 - VALPROATE SODIUM, VALPROATE SODIUM
- * HIKMA FARMACEUTICA PORTUGAL LDA
 - CEFAZOLIN SODIUM, CEFAZOLIN SODIUM
 - CEFUROXIME SODIUM, CEFUROXIME SODIUM
 - FLUCONAZOLE IN SODIUM CHLORIDE 0.9%, FLUCONAZOLE
- * HIKMA FARMACEUTICA PORTUGAL SA
 - DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
 - OXYTOCIN, OXYTOCIN
 - TESTOSTERONE ENANTHATE, TESTOSTERONE ENANTHATE
- * HIKMA FARMACEUTICA SA
 - ZOLEDRONIC ACID, ZOLEDRONIC ACID

HIKMA INTL PHARMS

- * HIKMA INTERNATIONAL PHARMACEUTICALS LLC
 - CAPTOPRIL, CAPTOPRIL
 - CORTISONE ACETATE, CORTISONE ACETATE
 - DIGOXIN, DIGOXIN
 - DOPAMINE HYDROCHLORIDE, DOPAMINE HYDROCHLORIDE
 - DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
 - GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
 - ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE
 - MITIGARE, COLCHICINE
 - NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE, NICARDIPINE HYDROCHLORIDE
 - NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE

HIKMA PHARM CO LTD

- * HIKMA PHARM CO LTD
 - ARGATROBAN, ARGATROBAN

HIKMA PHARMS

- * HIKMA PHARMACEUTICALS
 - AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
 - AMOXICILLIN, AMOXICILLIN
 - BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE
 - BUPIVACAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE
 - CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
 - DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
 - DIHYDROERGOTAMINE MESYLATE, DIHYDROERGOTAMINE MESYLATE
 - PENICILLIN V POTASSIUM, PENICILLIN V POTASSIUM
 - RIFAMPIN, RIFAMPIN
 - VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
- * HIKMA PHARMACEUTICALS CO LTD
 - PARICALCITOL, PARICALCITOL

HILL DERMAC

- * HILL DERMACEUTICALS INC
 - DERMA-SMOOTHIE/FS, FLUCINOLONE ACETONIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** H ****

- * HILL DERMACEUTICALS INC
DERMOTIC, FLUOCINOLONE ACETONIDE

HILL DERMACEUTICALS

- * HILL DERMACEUTICALS INC
TOLAK, FLUOROURACIL

HISAMITSU

- * HISAMITSU PHARMACEUTICAL CO INC
SECUADO, ASENAPINE

HISAMITSU PHARM CO

- * HISAMITSU PHARMACEUTICAL CO INC
SALONPAS, MENTHOL (OTC)

HISUN PHARM HANGZHOU

- * HISUN PHARMACEUTICAL (HANGZHOU) CO LTD
CLADRIBINE, CLADRIBINE
EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IRBESARTAN, IRBESARTAN
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
LEVETIRACETAM, LEVETIRACETAM
SIMVASTATIN, SIMVASTATIN
- * HISUN PHARMACEUTICAL HANGZHOU CO LTD
DACTINOMYCIN, DACTINOMYCIN
DAUNORUBICIN HYDROCHLORIDE, DAUNORUBICIN HYDROCHLORIDE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
TICAGRELOR, TICAGRELOR

HLTHCARE

- * HEALTHCARE PHARMACEUTICALS LTD
ATENOLOL, ATENOLOL
DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE

HOFFMANN LA ROCHE

- * HOFFMANN LA ROCHE INC
VALCYTE, VALGANCICLOVIR HYDROCHLORIDE
XELODA, CAPECITABINE
ZELBORAF, VEMURAFENIB

HOFFMANN-LA ROCHE

- * HOFFMANN-LA ROCHE INC
ALECENSA, ALECTINIB HYDROCHLORIDE

HONG KONG

- * HONG KONG KING FRIEND INDUSTRIAL CO LTD
PEMETREXED DISODIUM, PEMETREXED DISODIUM

HOPE PHARMS

- * HOPE PHARMACEUTICALS
NITHIODOTE, SODIUM NITRITE
SODIUM NITRITE, SODIUM NITRITE
SODIUM THIOSULFATE, SODIUM THIOSULFATE

HORIZON

- * HORIZON MEDICINES LLC
DUEXIS, FAMOTIDINE
VIMOVO, ESOMEPRAZOLE MAGNESIUM
- * HORIZON THERAPEUTICS IRELAND DAC
PENNSAID, DICLOFENAC SODIUM
- * HORIZON THERAPEUTICS USA INC
PROCYSBI, CYSTEAMINE BITARTRATE
RAYOS, PREDNISONE

HORIZON THERAP

- * HORIZON THERAPEUTICS LLC
BUPHENYL, SODIUM PHENYLBUTYRATE
RAVICTI, GLYCEROL PHENYLBUTYRATE

HOSPIRA

- * HOSPIRA INC
ACETYLCYSTEINE, ACETYLCYSTEINE
ADENOSINE, ADENOSINE
ALFENTANIL, ALFENTANIL HYDROCHLORIDE
AMIDATE, ETOMIDATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** H ******* HOSPIRA INC**

AMINOCAPROIC ACID IN PLASTIC CONTAINER, AMINOCAPROIC ACID
 AMINOPHYLLINE, AMINOPHYLLINE
 AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
 AMMONIUM CHLORIDE IN PLASTIC CONTAINER, AMMONIUM CHLORIDE
 ARGATROBAN, ARGATROBAN
 ATROPINE SULFATE, ATROPINE SULFATE
 AZITHROMYCIN, AZITHROMYCIN
 AZTREONAM, AZTREONAM
 BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
 BACTERIOSTATIC WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION
 BENDAMUSTINE HYDROCHLORIDE, BENDAMUSTINE HYDROCHLORIDE
 BIVALIRUDIN, BIVALIRUDIN
 BLEOMYCIN SULFATE, BLEOMYCIN SULFATE
 BORTEZOMIB, BORTEZOMIB
 BUMETANIDE, BUMETANIDE
 BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE, BUPIVACAINE HYDROCHLORIDE
 BUPIVACAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE
 BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
 BUSULFAN, BUSULFAN
 BUTORPHANOL TARTRATE PRESERVATIVE FREE, BUTORPHANOL TARTRATE
 CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 CARBOCAINE, MEPIVACAINE HYDROCHLORIDE
 CARBOPLATIN, CARBOPLATIN
 CHROMIC CHLORIDE IN PLASTIC CONTAINER, CHROMIC CHLORIDE
 CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, CIPROFLOXACIN
 CISATRACURIUM BESYLATE, CISATRACURIUM BESYLATE
 CORLOPAM, FENOLDOPAM MESYLATE
 CUPRIC CHLORIDE IN PLASTIC CONTAINER, CUPRIC CHLORIDE
 CYTARABINE, CYTARABINE
 DACARBAZINE, DACARBAZINE
 DAPTOMYCIN, DAPTOMYCIN
 DEFEROXAMINE MESYLATE, DEFEROXAMINE MESYLATE
 DEMEROL, MEPERIDINE HYDROCHLORIDE
 DEXTROSE 25%, DEXTROSE
 DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
 DEXTROSE 50%, DEXTROSE
 DIAZEPAM, DIAZEPAM
 DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
 DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER, DOBUTAMINE HYDROCHLORIDE
 DOBUTAMINE HYDROCHLORIDE, DOBUTAMINE HYDROCHLORIDE
 DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER, DOPAMINE HYDROCHLORIDE
 DOPAMINE HYDROCHLORIDE, DOPAMINE HYDROCHLORIDE
 DOXERCALCIFEROL, DOXERCALCIFEROL
 DROPERIDOL, DROPERIDOL
 ENALAPRILAT, ENALAPRILAT
 EPINEPHRINE, EPINEPHRINE
 ERYTHROCIN, ERYTHROMYCIN LACTOBIONATE
 FENTANYL CITRATE PRESERVATIVE FREE, FENTANYL CITRATE
 FENTANYL CITRATE, FENTANYL CITRATE
 FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE
 FUROSEMIDE, FUROSEMIDE
 GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, GENTAMICIN SULFATE
 GENTAMICIN SULFATE, GENTAMICIN SULFATE
 HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN
 HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, HEPARIN
 HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN
 HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
 HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, HEPARIN
 HEPARIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM
 HEPARIN SODIUM, HEPARIN SODIUM
 INDOMETHACIN SODIUM, INDOMETHACIN SODIUM
 IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** H ******* HOSPIRA INC**

KETAMINE HYDROCHLORIDE, KETAMINE HYDROCHLORIDE
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, LEVOFLOXACIN
LEVOPHED, NOREPINEPHRINE BITARTRATE
LIDOCAINE HYDROCHLORIDE 5% AND DEXTROSE 7.5%, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE, EPINEPHRINE
LIDOCAINE HYDROCHLORIDE IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE IN PLASTIC CONTAINER, LIDOCAINE
LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
LINEZOLID IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, LINEZOLID
LORAZEPAM, LORAZEPAM
MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MAGNESIUM SULFATE
MAGNESIUM SULFATE IN PLASTIC CONTAINER, MAGNESIUM SULFATE
MAGNESIUM SULFATE, MAGNESIUM SULFATE
MANGANESE CHLORIDE IN PLASTIC CONTAINER, MANGANESE CHLORIDE
MANNITOL 25%, MANNITOL
MARCAINE HYDROCHLORIDE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE
MARCAINE HYDROCHLORIDE W/ EPINEPHRINE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE
MARCAINE HYDROCHLORIDE W/ EPINEPHRINE, BUPIVACAINE HYDROCHLORIDE
MARCAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE
MARCAINE, BUPIVACAINE HYDROCHLORIDE
METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM
METHOTREXATE SODIUM, METHOTREXATE SODIUM
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
METRONIDAZOLE IN PLASTIC CONTAINER, METRONIDAZOLE
MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE, MIDAZOLAM HYDROCHLORIDE
MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MILRINONE LACTATE
MILRINONE LACTATE, MILRINONE LACTATE
MORPHINE SULFATE, MORPHINE SULFATE
NALBUPHINE HYDROCHLORIDE, NALBUPHINE HYDROCHLORIDE
NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
PACLITAXEL, PACLITAXEL
PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE
PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
PANCURONIUM BROMIDE, PANCURONIUM BROMIDE
PARICALCITOL, PARICALCITOL
PEMETREXED DISODIUM, PEMETREXED DISODIUM
PEMETREXED DITROMETHAMINE, PEMETREXED DITROMETHAMINE
PLEGISOL IN PLASTIC CONTAINER, CALCIUM CHLORIDE
POTASSIUM ACETATE, POTASSIUM ACETATE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PRECEDEX, DEXMEDETOMIDINE HYDROCHLORIDE
PROCAINAMIDE HYDROCHLORIDE, PROCAINAMIDE HYDROCHLORIDE
PROPOFOL, PROPOFOL
QUELICIN, SUCCINYLCHOLINE CHLORIDE
REGADENOSON, REGADENOSON
ROCURIUM BROMIDE, ROCURIUM BROMIDE
ROPIVACAINE HYDROCHLORIDE, ROPIVACAINE HYDROCHLORIDE
SODIUM ACETATE, SODIUM ACETATE
SODIUM BICARBONATE, SODIUM BICARBONATE
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 14.6%, SODIUM CHLORIDE
SODIUM CHLORIDE 23.4%, SODIUM CHLORIDE
SODIUM PHOSPHATES IN PLASTIC CONTAINER, SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE
STERILE WATER FOR INJECTION, STERILE WATER FOR INJECTION
SUFENTANIL CITRATE, SUFENTANIL CITRATE
TAZICEF, CEFTAZIDIME

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** H ****

- * HOSPIRA INC
 - THAM, TROMETHAMINE
 - TOBRAMYCIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, TOBRAMYCIN SULFATE
 - TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
 - TPN ELECTROLYTES IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 - VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
 - VECURONIUM BROMIDE, VECURONIUM BROMIDE
 - VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE
 - VITAMIN K1, PHYTONADIONE
 - ZINC CHLORIDE IN PLASTIC CONTAINER, ZINC CHLORIDE
 - ZOLEDRONIC ACID, ZOLEDRONIC ACID
- * HOSPIRA WORLDWIDE, INC
 - GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
 - MITOXANTRONE HYDROCHLORIDE, MITOXANTRONE HYDROCHLORIDE
 - TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
 - VINCRISTINE SULFATE PFS, VINCRISTINE SULFATE

HOSPIRA INC

- * HOSPIRA INC
 - ATracurium besylate preservative free, ATRACURIUM BESYLATE
 - ATracurium besylate, ATRACURIUM BESYLATE
 - DOCETAXEL, DOCETAXEL
 - GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
 - HEPARIN SODIUM, HEPARIN SODIUM
 - HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
 - LEVETIRACETAM, LEVETIRACETAM
 - MAXIPIME, CEFEPIME HYDROCHLORIDE
 - MORPHINE SULFATE, MORPHINE SULFATE
 - NIPENT, PENTOSTATIN
 - TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
 - VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
 - ZOLEDRONIC ACID, ZOLEDRONIC ACID

HOSPIRA WORLDWIDE

- * HOSPIRA WORLDWIDE PTY
 - OXALIPLATIN, OXALIPLATIN

HOT SHOTS NM LLC

- * HOT SHOTS NUCLEAR MEDICINE LLC
 - SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

HQ SPCLT PHARMA

- * HQ SPECIALTY PHARMA CORP
 - CALCIUM GLUCONATE IN SODIUM CHLORIDE, CALCIUM GLUCONATE
 - CISPLATIN, CISPLATIN
 - DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
 - ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER, ESMOLOL HYDROCHLORIDE
 - ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER, ESMOLOL HYDROCHLORIDE
 - ESMOLOL HYDROCHLORIDE, ESMOLOL HYDROCHLORIDE
 - IMIPENEM AND CILASTATIN, CILASTATIN SODIUM
 - LINEZOLID, LINEZOLID
 - MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MAGNESIUM SULFATE
 - MAGNESIUM SULFATE IN PLASTIC CONTAINER, MAGNESIUM SULFATE
 - MEROPENEM, MEROPENEM

HQ SPECIALITY PHARMA

- * HQ SPECIALITY PHARMA LLC
 - LEVETIRACETAM IN SODIUM CHLORIDE, LEVETIRACETAM

HQ SPECLT PHARMA

- * HQ SPECIALTY PHARMA CORP
 - AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
 - AMPICILLIN SODIUM, AMPICILLIN SODIUM
 - PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM

HRA PHARMA

- * HRA PHARMA RARE DISEASES
 - LYSODREN, MITOTANE
 - METOPIRONE, METYRAPONE

HUMANWELL PURACAP

- * HUMANWELL PURACAP PHARMACEUTICAL WUHAN CO LTD
 - AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** H ****

- * HUMANWELL PURACAP PHARMACEUTICAL WUHAN CO LTD
DUTASTERIDE, DUTASTERIDE
IBUPROFEN, IBUPROFEN (OTC)

HUONS

- * HUONS CO LTD
BUPIVACAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE

ROCHE

- * HOFFMANN LA ROCHE INC
FUZEON, ENFUVIRTIDE
TAMIFLU, OSELTAMIVIR PHOSPHATE

SHUANGCHENG

- * HAINAN SHUANGCHENG PHARMACEUTICALS CO LTD
BIVALIRUDIN, BIVALIRUDIN
EPTIFIBATIDE, EPTIFIBATIDE
PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
PREGABALIN, PREGABALIN

**** I ******I3 PHARMS**

- * I3 PHARMACEUTICALS LLC
CHLORZOXAZONE, CHLORZOXAZONE
RAMELTEON, RAMELTEON
RANOLAZINE, RANOLAZINE
SELEGILINE HYDROCHLORIDE, SELEGILINE HYDROCHLORIDE

IBSA INST BIO

- * IBSA INSTITUT BIOCHIMIQUE SA
LICART, DICLOFENAC EPOLAMINE

ICHNOS

- * ICHNOS SCIENCES SA
DEFERASIROX, DEFERASIROX

ICU MEDICAL INC

- * ICU MEDICAL INC
ACETIC ACID 0.25% IN PLASTIC CONTAINER, ACETIC ACID, GLACIAL
AMINOSYN II 10% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 15% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN-PF 10%, AMINO ACIDS
AMINOSYN-PF 7%, AMINO ACIDS
DEXTROSE 10% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 20% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 30% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 40% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 50% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 70% IN PLASTIC CONTAINER, DEXTROSE
GLYCINE 1.5% IN PLASTIC CONTAINER, GLYCINE
IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
MANNITOL 20% IN PLASTIC CONTAINER, MANNITOL
NORMOSOL-M AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
NORMOSOL-R AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
NORMOSOL-R IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
PHYSIOSOL IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
POTASSIUM CHLORIDE 0.149% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, POTASSIUM
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** I ******* ICU MEDICAL INC**

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
 POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
 POTASSIUM CHLORIDE 20MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM
 POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
 POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
 POTASSIUM CHLORIDE 40MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM
 RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
 SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, SODIUM CHLORIDE
 SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
 SORBITOL-MANNITOL IN PLASTIC CONTAINER, MANNITOL
 STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION
 STERILE WATER IN PLASTIC CONTAINER, STERILE WATER FOR IRRIGATION

IDORSIA*** IDORSIA PHARMACEUTICALS LTD**

QUVIVIQ, DARIDOREXANT HYDROCHLORIDE

IMPACT*** IMPACT BIOMEDICINES INC A WHOLLY OWNED SUB OF CELGENE CORP**

INREBIC, FEDRATINIB HYDROCHLORIDE

IMPAX*** IMPAX LABORATORIES LLC**

ADRENALIN, EPINEPHRINE
 BACLOFEN, BACLOFEN
 SEVELAMER CARBONATE, SEVELAMER CARBONATE

IMPAX LABS*** IMPAX LABORATORIES INC**

ACARBOSE, ACARBOSE
 ANAGRELIDE HYDROCHLORIDE, ANAGRELIDE HYDROCHLORIDE
 BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
 CARBIDOPA AND LEVODOPA, CARBIDOPA
 CHLOROQUINE PHOSPHATE, CHLOROQUINE PHOSPHATE
 CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
 COLESTIPOL HYDROCHLORIDE, COLESTIPOL HYDROCHLORIDE
 DANTROLENE SODIUM, DANTROLENE SODIUM
 DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
 DIGOXIN, DIGOXIN
 DIPYRIDAMOLE, DIPYRIDAMOLE
 FENOFIBRATE, FENOFIBRATE
 FLUDROCORTISONE ACETATE, FLUDROCORTISONE ACETATE
 METHYLTESTOSTERONE, METHYLTESTOSTERONE
 MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
 OMEPRAZOLE, OMEPRAZOLE
 OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE
 PILOCARPINE HYDROCHLORIDE, PILOCARPINE HYDROCHLORIDE
 PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE
 RILUZOLE, RILUZOLE
 RIMANTADINE HYDROCHLORIDE, RIMANTADINE HYDROCHLORIDE
 TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
 TERBUTALINE SULFATE, TERBUTALINE SULFATE

IMPAX LABS INC*** IMPAX LABORATORIES INC**

ACITRETIN, ACITRETIN
 BUDESONIDE, BUDESONIDE
 BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
 CARVEDILOL PHOSPHATE, CARVEDILOL PHOSPHATE
 COLESEVELAM HYDROCHLORIDE, COLESEVELAM HYDROCHLORIDE
 DEXEDRINE, DEXTROAMPHETAMINE SULFATE
 DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
 EMVERM, MEBENDAZOLE
 EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
 FENOFIBRIC ACID, CHOLINE FENOFIBRATE
 GLYBURIDE AND METFORMIN HYDROCHLORIDE, GLYBURIDE
 GLYBURIDE, GLYBURIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** I ******* IMPAX LABORATORIES INC**

HYDROCORTISONE, HYDROCORTISONE
HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE
LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
METHYLTESTOSTERONE, METHYLTESTOSTERONE
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
NITROFURANTOIN, NITROFURANTOIN, MACROCRYSTALLINE
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE
RYTARY, CARBIDOPA

IMPAX PHARMS*** IMPAX PHARMACEUTICALS**

GEMFIBROZIL, GEMFIBROZIL
MIDODRINE HYDROCHLORIDE, MIDODRINE HYDROCHLORIDE

IMPEL PHARMS*** IMPEL PHARMACEUTICALS INC**

TRUDHESA, DIHYDROERGOTAMINE MESYLATE

IMPRIMIS PHARMS USA*** IMPRIMIS PHARMACEUTICALS USA LLC**

IOPIDINE, APRACLOPIDINE HYDROCHLORIDE
MAXITROL, DEXAMETHASONE
MOXEZA, MOXIFLOXACIN HYDROCHLORIDE

INCYTE CORP*** INCYTE CORP**

JAKAFI, RUXOLITINIB PHOSPHATE
OPZELURA, RUXOLITINIB PHOSPHATE
PEMAZYRE, PEMIGATINIB

INDCHEMIE HEALTH*** INDCHEMIE HEALTH SPECIALTIES PVT LTD**

ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
NEBIVOLOL HYDROCHLORIDE, NEBIVOLOL HYDROCHLORIDE

INDICUS PHARMA*** INDICUS PHARMA LLC**

DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE

INDIVIOR INC*** INDIVIOR INC**

BUPRENEX, BUPRENORPHINE HYDROCHLORIDE
PERSERIS KIT, RISPERIDONE
SUBLOCADE, BUPRENORPHINE
SUBOXONE, BUPRENORPHINE HYDROCHLORIDE

INDOCO*** INDOCO REMEDIES LTD**

ACETYLCYSTEINE, ACETYLCYSTEINE
ALLOPURINOL, ALLOPURINOL
APIXABAN, APIXABAN
BRIMONIDINE TARTRATE, BRIMONIDINE TARTRATE
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE
FEBUXOSTAT, FEBUXOSTAT
LACOSAMIDE, LACOSAMIDE
MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
NEOSTIGMINE METHYLSULFATE, NEOSTIGMINE METHYLSULFATE
OLANZAPINE, OLANZAPINE
RASAGILINE MESYLATE, RASAGILINE MESYLATE
SUCCINYLCHOLINE CHLORIDE, SUCCINYLCHOLINE CHLORIDE

INDOCO REMEDIES*** INDOCO REMEDIES LTD**

GLIMEPIRIDE, GLIMEPIRIDE

INFORLIFE*** INFORLIFE SA**

CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, CIPROFLOXACIN
FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** I ******* INFORLIFE SA**

LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, LEVOFLOXACIN
 METRONIDAZOLE IN PLASTIC CONTAINER, METRONIDAZOLE
 MIDAZOLAM IN 0.9% SODIUM CHLORIDE, MIDAZOLAM
 NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE, NOREPINEPHRINE BITARTRATE
 ROPIVACAINE HYDROCHLORIDE, ROPIVACAINE HYDROCHLORIDE
 ZOLEDRONIC ACID, ZOLEDRONIC ACID

INGENUS PHARMS LLC*** INGENUS PHARMACEUTICALS LLC**

ARSENIC TRIOXIDE, ARSENIC TRIOXIDE
 CABERGOLINE, CABERGOLINE
 CARMUSTINE, CARMUSTINE
 CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE
 DOCETAXEL, DOCETAXEL
 MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE
 PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE
 PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
 TIMOLOL MALEATE, TIMOLOL MALEATE
 ZOLEDRONIC ACID, ZOLEDRONIC ACID

INNOCOLL*** INNOCOLL PHARMACEUTICALS LTD**

POSIMIR, BUPIVACAINE

INNOCOLL PHARMS*** INNOCOLL PHARMACEUTICALS**

XARACOLL, BUPIVACAINE HYDROCHLORIDE

INNOGENIX*** INNOGENIX LLC**

BACLOFEN, BACLOFEN
 HALOPERIDOL, HALOPERIDOL
 LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
 METOLAZONE, METOLAZONE
 PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE

INNOPHARMA*** INNOPHARMA LICENSING LLC A SUB OF PFIZER INC**

PROPOFOL, PROPOFOL

INSMED INC*** INSMED INC**

ARIKAYCE KIT, AMIKACIN SULFATE

INST BIOCHEM*** INSTITUT BIOCHEMIQUE SA**

FLECTOR, DICLOFENAC EPOLAMINE

INSTITUT BIOCHIMIQUE*** INSTITUT BIOCHIMIQUE SA (IBSA)**

TIROSINT, LEVOTHYROXINE SODIUM
 TIROSINT-SOL, LEVOTHYROXINE SODIUM

INTAS PHARMS USA*** INTAS PHARMACEUTICALS USA**

IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE

INTELLIPHARMACEUTICS*** INTELLIPHARMACEUTICS CORP**

DESVENLAFAXINE SUCCINATE, DESVENLAFAXINE SUCCINATE
 DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

INTERCEPT PHARMS INC*** INTERCEPT PHARMACEUTICALS INC**

OALIVA, OBETICHOLIC ACID

INTERSECT ENT INC*** INTERSECT ENT INC**

SINUVA, MOMETASONE FUROATE

INTL ISOTOPES*** INTERNATIONAL ISOTOPES INC**

SODIUM IODIDE I 131, SODIUM IODIDE I-131

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** I ******INTL MEDICATION**

- * INTERNATIONAL MEDICATION SYSTEM
 - LARYNG-O-JET KIT, LIDOCAINE HYDROCHLORIDE
 - LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
 - NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
 - PHYTONADIONE, PHYTONADIONE
 - PROCAINAMIDE HYDROCHLORIDE, PROCAINAMIDE HYDROCHLORIDE

INTL MEDICATION SYS

- * INTERNATIONAL MEDICATION SYSTEMS LTD
 - ATROPINE SULFATE, ATROPINE SULFATE
 - CALCIUM CHLORIDE 10%, CALCIUM CHLORIDE
 - DEXTROSE 50%, DEXTROSE
 - EPINEPHRINE, EPINEPHRINE
 - LORAZEPAM, LORAZEPAM
 - MORPHINE SULFATE, MORPHINE SULFATE
 - SODIUM BICARBONATE, SODIUM BICARBONATE

INTRA-CELLULAR

- * INTRA-CELLULAR THERAPIES INC
 - CAPLYTA, LUMATEPERONE TOSYLATE

INVAGEN PHARMS

- * INVAGEN PHARMACEUTICALS INC
 - ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE
 - AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
 - ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
 - BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
 - BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
 - CALCIUM ACETATE, CALCIUM ACETATE
 - CARBINOXAMINE MALEATE, CARBINOXAMINE MALEATE
 - CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
 - CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
 - ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
 - FENOFIBRATE (MICRONIZED), FENOFIBRATE
 - FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE, FOSINOPRIL SODIUM
 - FOSINOPRIL SODIUM, FOSINOPRIL SODIUM
 - GABAPENTIN, GABAPENTIN
 - GEMFIBROZIL, GEMFIBROZIL
 - HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
 - HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
 - LANREOTIDE ACETATE, LANREOTIDE ACETATE
 - LANTHANUM CARBONATE, LANTHANUM CARBONATE
 - LEVETIRACETAM, LEVETIRACETAM
 - LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 - LISINOPRIL, LISINOPRIL
 - LURASIDONE HYDROCHLORIDE, LURASIDONE HYDROCHLORIDE
 - LUTRATE DEPOT KIT, LEUPROLIDE ACETATE
 - MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE
 - MEPROBAMATE, MEPROBAMATE
 - NABUMETONE, NABUMETONE
 - NADOLOL, NADOLOL
 - NAPROXEN, NAPROXEN
 - PENICILLAMINE, PENICILLAMINE
 - PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
 - PREGABALIN, PREGABALIN
 - QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 - QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE
 - RALOXIFENE HYDROCHLORIDE, RALOXIFENE HYDROCHLORIDE
 - RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
 - SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
 - SEVELAMER CARBONATE, SEVELAMER CARBONATE
 - TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
 - TOPIRAMATE, TOPIRAMATE
 - TROSPIUM CHLORIDE, TROSPIUM CHLORIDE
 - VIGABATRIN, VIGABATRIN
 - VILAZODONE HYDROCHLORIDE, VILAZODONE HYDROCHLORIDE
 - WARFARIN SODIUM, WARFARIN SODIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** I ****

- * INVAGEN PHARMACEUTICALS INC
ZOLMITRIPTAN, ZOLMITRIPTAN
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE
ZONISAMIDE, ZONISAMIDE

INVATECH

- * INVATECH PHARMA SOLUTIONS LLC
DIVALPROEX SODIUM, DIVALPROEX SODIUM
MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE
PREGABALIN, PREGABALIN

INVENTIA

- * INVENTIA HEALTHCARE LTD
CHLORTHALIDONE, CHLORTHALIDONE
COLESEVELAM HYDROCHLORIDE, COLESEVELAM HYDROCHLORIDE
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
LANSOPRAZOLE, LANSOPRAZOLE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS), NITROFURANTOIN
PALIPERIDONE, PALIPERIDONE
TELMISARTAN, TELMISARTAN

INVENTIA HLTHCARE

- * INVENTIA HEALTHCARE PRIVATE LTD
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
TOLTERODINE TARTRATE, TOLTERODINE TARTRATE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

IONETIX

- * IONETIX CORP
AMMONIA N 13, AMMONIA N-13

IPCA LABS LTD

- * IPCA LABORATORIES LTD
ALLOPURINOL, ALLOPURINOL
ATENOLOL, ATENOLOL
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
CHLOROQUINE PHOSPHATE, CHLOROQUINE PHOSPHATE
FUROSEMIDE, FUROSEMIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
WARFARIN SODIUM, WARFARIN SODIUM

IPR

- * IPR PHARMACEUTICALS INC
CRESTOR, ROSUVASTATIN CALCIUM
ZOMIG, ZOLMITRIPTAN

IPSEN INC

- * IPSSEN BIOPHARMACEUTICALS INC
ONIVYDE, IRINOTECAN HYDROCHLORIDE

IPSEN PHARMA

- * IPSSEN PHARMA BIOTECH SAS
SOMATULINE DEPOT, LANREOTIDE ACETATE

IRONSHORE PHARMS

- * IRONSHORE PHARMACEUTICALS AND DEVELOPMENT INC
JORNAY PM, METHYLPHENIDATE HYDROCHLORIDE

ISOLOGIC INNOVATIVE

- * ISOLOGIC INNOVATIVE RADIOPHARMACEUTICALS LTD
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

ISOTEX

- * ISOTEX DIAGNOSTICS

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** I ******* ISOTEX DIAGNOSTICS**

GLOFIL-125, IOTHALAMATE SODIUM I-125

ISTITUTO BIO ITA SPA*** ISTITUTO BIOCHIMICO ITALIANO SPA**

AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
 AMPICILLIN SODIUM, AMPICILLIN SODIUM
 NAFCILLIN SODIUM, NAFCILLIN SODIUM
 PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM
 PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM
 PIPERACILLIN, PIPERACILLIN SODIUM

ITALFARMACO SA*** ITALFARMACO SA**

TIGLUTIK KIT, RILUZOLE

IVAX PHARMS*** IVAX PHARMACEUTICALS INC**

VALSARTAN, VALSARTAN

IVAX SUB TEVA PHARMS*** IVAX PHARMACEUTICALS INC SUB TEVA PHARMACEUTICALS USA**

ANAGRELIDE HYDROCHLORIDE, ANAGRELIDE HYDROCHLORIDE
 BACLOFEN, BACLOFEN
 CABERGOLINE, CABERGOLINE
 CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
 CIMETIDINE, CIMETIDINE (OTC)
 CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
 CLOZAPINE, CLOZAPINE
 CYCLOSPORINE, CYCLOSPORINE
 DIAZEPAM, DIAZEPAM
 ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
 FAMOTIDINE, FAMOTIDINE
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 GABAPENTIN, GABAPENTIN
 HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 TOLTERODINE TARTRATE, TOLTERODINE TARTRATE
 VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE

**** J ******HENGRUI PHARMA***** JIANGSU HENGRUI PHARMACEUTICALS CO LTD**

CARMUSTINE, CARMUSTINE
 CASPOFUNGIN ACETATE, CASPOFUNGIN ACETATE
 CISATRACURIUM BESYLATE PRESERVATIVE FREE, CISATRACURIUM BESYLATE
 CISATRACURIUM BESYLATE, CISATRACURIUM BESYLATE
 CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE
 DAPTOMYCIN, DAPTOMYCIN
 DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
 DOCETAXEL, DOCETAXEL
 FONDAPARINUX SODIUM, FONDAPARINUX SODIUM
 GADOBUTROL, GADOBUTROL
 GADOTERATE MEGLUMINE, GADOTERATE MEGLUMINE
 IODIXANOL, IODIXANOL
 IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
 OXALIPLATIN, OXALIPLATIN
 THIOTEPA, THIOTEPA

J AND J CONSUMER INC*** JOHNSON AND JOHNSON CONSUMER INC MCNEIL CONSUMER HEALTHCARE DIV**

CHILDREN'S MOTRIN COLD, IBUPROFEN (OTC)
 CHILDREN'S MOTRIN, IBUPROFEN (OTC)
 CHILDREN'S ZYRTEC ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CHILDREN'S ZYRTEC HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
 IMODIUM A-D, LOPERAMIDE HYDROCHLORIDE (OTC)
 IMODIUM MULTI-SYMPTOM RELIEF, LOPERAMIDE HYDROCHLORIDE (OTC)
 JUNIOR STRENGTH MOTRIN, IBUPROFEN (OTC)
 MOTRIN IB, IBUPROFEN (OTC)
 PEPCID AC, FAMOTIDINE (OTC)
 PEPCID COMPLETE, CALCIUM CARBONATE (OTC)

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** J ****

- * JOHNSON AND JOHNSON CONSUMER INC MCNEIL CONSUMER HEALTHCARE DIV
 - RHINOCORT ALLERGY, BUDESONIDE (OTC)
 - SINE-AID IB, IBUPROFEN (OTC)
 - SUDAFED 24 HOUR, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
 - TYLENOL, ACETAMINOPHEN (OTC)
 - ZYRTEC ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 - ZYRTEC-D 12 HOUR, CETIRIZINE HYDROCHLORIDE (OTC)

JANSSEN BIOTECH

- * JANSSEN BIOTECH INC
 - BALVERSA, ERDAFITINIB
 - ERLEADA, APALUTAMIDE
 - ZYTIGA, ABIRATERONE ACETATE

JANSSEN PHARMS

- * JANSSEN PHARMACEUTICALS INC
 - CONCERTA, METHYLPHENIDATE HYDROCHLORIDE
 - DITROPAN XL, OXYBUTYNIN CHLORIDE
 - ELMIRON, PENTOSAN POLYSULFATE SODIUM
 - HALDOL, HALOPERIDOL DECANOATE
 - INVEGA HAFYERA, PALIPERIDONE PALMITATE
 - INVEGA SUSTENNA, PALIPERIDONE PALMITATE
 - INVEGA TRINZA, PALIPERIDONE PALMITATE
 - INVEGA, PALIPERIDONE
 - INVOKAMET XR, CANAGLIFLOZIN
 - INVOKAMET, CANAGLIFLOZIN
 - INVOKANA, CANAGLIFLOZIN
 - PONVORY, PONESIMOD
 - RAZADYNE ER, GALANTAMINE HYDROBROMIDE
 - RISPERDAL CONSTA, RISPERIDONE
 - RISPERDAL, RISPERIDONE
 - SPORANOX, ITRACONAZOLE
 - SPRAVATO, ESKETAMINE HYDROCHLORIDE
 - TOPAMAX, TOPIRAMATE
 - ULTRACET, ACETAMINOPHEN
 - XARELTO, RIVAROXABAN

JANSSEN PRODS

- * JANSSEN PRODUCTS LP
 - EDURANT, RILPIVIRINE HYDROCHLORIDE
 - PREZCOBIX, COBICISTAT
 - PREZISTA, DARUNAVIR
 - SYM TUZA, COBICISTAT
 - YONDELIS, TRABECTEDIN

JANSSEN R AND D

- * JANSSEN RESEARCH AND DEVELOPMENT LLC
 - INTELENCE, ETRAVIRINE

JANSSEN THERAP

- * JANSSEN THERAPEUTICS DIV JANSSEN PRODUCTS LP
 - SIRTURO, BEDAQUILINE FUMARATE

JAZZ

- * JAZZ PHARMACEUTICALS IRELAND LTD
 - XYWAV, CALCIUM OXYBATE
 - ZEPZELCA, LURBINECTEDIN

JAZZ PHARMS

- * JAZZ PHARMACEUTICALS INC
 - XYREM, SODIUM OXYBATE

JAZZ PHARMS INC

- * JAZZ PHARMACEUTICALS INC
 - DEFITELIO, DEFIBROTIDE SODIUM

JDP

- * JDP THERAPEUTICS LLC
 - QUZYTIR, CETIRIZINE HYDROCHLORIDE

JIANGSU HANSON PHARM

- * JIANGSU HANSON PHARMACEUTICAL GROUP CO LTD
 - BORTEZOMIB, BORTEZOMIB
 - DECITABINE, DECITABINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** J ****

- * JIANGSU HANSON PHARMACEUTICAL GROUP CO LTD
FULVESTRANT, FULVESTRANT
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
ICATIBANT ACETATE, ICATIBANT ACETATE
MICA FUNGIN SODIUM, MICA FUNGIN SODIUM
PEMETREXED DISODIUM, PEMETREXED DISODIUM
VINORELBINE TARTRATE, VINORELBINE TARTRATE

JOHNS HOPKINS UNIV

- * JOHNS HOPKINS UNIV
AMMONIA N 13, AMMONIA N-13

JOHNSON AND JOHNSON

- * JOHNSON AND JOHNSON CONSUMER INC
VISINE L.R., OXYMETAZOLINE HYDROCHLORIDE (OTC)
VISINE, NAPHAZOLINE HYDROCHLORIDE (OTC)
- * JOHNSON AND JOHNSON GROUP CONSUMER COMPANIES
MEN'S ROGAINE, MINOXIDIL (OTC)
ROGAINE (FOR MEN), MINOXIDIL (OTC)
ROGAINE (FOR WOMEN), MINOXIDIL (OTC)
ROGAINE EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
WOMEN'S ROGAINE, MINOXIDIL (OTC)

JOHNSON JOHNSON VISN

- * JOHNSON AND JOHNSON VISION CARE INC
ACUVUE THERAVISION WITH KETOTIFEN, KETOTIFEN FUMARATE

JOURNEY

- * JOURNEY MEDICAL CORP
AMZEEQ, MINOCYCLINE HYDROCHLORIDE
EURAX, CROTAMITON
EXELDERM, SULCONAZOLE NITRATE
QBREXZA, GLYCOPYRROLONIUM TOSYLATE
XIMINO, MINOCYCLINE HYDROCHLORIDE
ZILXI, MINOCYCLINE HYDROCHLORIDE

JUBILANT

- * JUBILANT DRAXIMAGE INC DBA JUBILANT RADIOPHARMA
DRAX EXAMETAZIME, TECHNETIUM TC-99M EXAMETAZIME KIT
DRAXIMAGE DTPA, TECHNETIUM TC-99M PENTETATE KIT
DRAXIMAGE MDP-25, TECHNETIUM TC-99M MEDRONATE
HICON, SODIUM IODIDE I-131
RUBY-FILL, RUBIDIUM CHLORIDE RB-82
SODIUM IODIDE I 131, SODIUM IODIDE I-131

JUBILANT CADISTA

- * JUBILANT CADISTA PHARMACEUTICALS INC
CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LAMOTRIGINE, LAMOTRIGINE
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE
METHYLPREDNISOLONE, METHYLPREDNISOLONE
PREDNISONE, PREDNISONE
PROCOMP, PROCHLORPERAZINE MALEATE
TERAZOSIN HYDROCHLORIDE, TERAZOSIN HYDROCHLORIDE

JUBILANT DRAXIMAGE

- * JUBILANT DRAXIMAGE RADIOPHARMACIES INC
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18
- * JUBILANT DRAXIMAGE USA INC
TECHNETIUM TC 99M SESTAMIBI, TECHNETIUM TC-99M SESTAMIBI KIT

JUBILANT GENERICS

- * JUBILANT GENERICS LTD
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** J ****

* JUBILANT GENERICS LTD
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
IRBESARTAN, IRBESARTAN
OLANZAPINE, OLANZAPINE
RISPERIDONE, RISPERIDONE
SPIRONOLACTONE, SPIRONOLACTONE
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
VALSARTAN, VALSARTAN
ZOLMITRIPTAN, ZOLMITRIPTAN

STEVENS J

* JEROME STEVENS PHARMACEUTICALS INC
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE, ASPIRIN
DIGOXIN, DIGOXIN
UNITHROID, LEVOTHYROXINE SODIUM **

**** K ******GRIFFEN**

* KW GRIFFEN CO
BIOSCRUB, CHLORHEXIDINE GLUCONATE (OTC)

KADMON PHARMS LLC

* KADMON PHARMACEUTICALS LLC
REZUROCK, BELUMOSUDIL MESYLATE

KAI PHARMS INC

* KAI PHARMACEUTICALS INC A WHOLLY OWNED SUBSIDIARY OF AMGEN INC
PARSABIV, ETELCALCETIDE

KALEO INC

* KALEO INC
AUVI-Q, EPINEPHRINE

KARTHA

* KARTHA PHARMACEUTICALS INC
BACLOFEN, BACLOFEN
EPLERENONE, EPLERENONE

KARYOPHARM THERAPS

* KARYOPHARM THERAPEUTICS INC
XPOVIO, SELINEXOR

KENTON

* KENTON CHEMICALS AND PHARMACEUTICALS CORP
ACYCLOVIR, ACYCLOVIR
ANASTROZOLE, ANASTROZOLE
BICALUTAMIDE, BICALUTAMIDE
GLYCOPYRROLATE, GLYCOPYRROLATE
RILUZOLE, RILUZOLE

KERYX BIOPHARMS

* KERYX BIOPHARMACEUTICALS INC
AURYXIA, FERRIC CITRATE

KETTERING MEDCTR

* KETTERING MEDCTR
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

KEY THERAP

* KEY THERAPEUTICS LLC
DESOXYN, METHAMPHETAMINE HYDROCHLORIDE
TRANXENE, CLORAZEPATE DIPOTASSIUM

KINDEVA

* KINDEVA DRUG DELIVERY LP
FENTANYL-100, FENTANYL
FENTANYL-12, FENTANYL
FENTANYL-25, FENTANYL
FENTANYL-50, FENTANYL
FENTANYL-75, FENTANYL
PROVENTIL-HFA, ALBUTEROL SULFATE

KINDOS

* KINDOS PHARMACEUTICALS CO LTD
NELARABINE, NELARABINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** K ******KING PHARMS**

- * KING PHARMACEUTICALS INC
SYNERCID, DALFOPRISTIN
- * KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT LLC
CYTOMEL, LIOTHYRONINE SODIUM
LEVOXYL, LEVOTHYROXINE SODIUM **
- * KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT LLC A SUB OF PFIZER INC
SKELAXIN, METAXALONE

KING PHARMS LLC

- * KING PHARMACEUTICALS LLC
ALTACE, RAMIPRIL
BICILLIN C-R 900/300, PENICILLIN G BENZATHINE
BICILLIN C-R, PENICILLIN G BENZATHINE
BICILLIN L-A, PENICILLIN G BENZATHINE
PENICILLIN G PROCAINE, PENICILLIN G PROCAINE
SILVADENE, SILVER SULFADIAZINE

KNIGHT THERAPS

- * KNIGHT THERAPEUTICS USA INC
IMPAVIDO, MILTEFOSINE

KOWA CO

- * KOWA CO LTD
LIVALO, PITAVASTATIN CALCIUM

KOWA PHARMS

- * KOWA PHARMACEUTICALS AMERICA INC
SEGLENTIS, CELECOXIB

KRAMER

- * KRAMER LABORATORIES INC
NIZORAL ANTI-DANDRUFF, KETOCONAZOLE (OTC)

KREITCHMAN PET CTR

- * KREITCHMAN PET CENTER
AMMONIA N 13, AMMONIA N-13
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

KVK TECH

- * KVK TECH INC
BENZPHETAMINE HYDROCHLORIDE, BENZPHETAMINE HYDROCHLORIDE
BETAXOLOL HYDROCHLORIDE, BETAXOLOL HYDROCHLORIDE
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
KALEXATE, SODIUM POLYSTYRENE SULFONATE
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE

KVK TECH INC

- * KVK TECH INC
APADAZ, ACETAMINOPHEN
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE

KYOWA KIRIN

- * KYOWA KIRIN INC
FARESTON, TOREMIFENE CITRATE
NOURIANZ, ISTRADefYLLINE
SANCUSO, GRANISETRON

KYTHERA BIOPHARMS

- * KYTHERA BIOPHARMACEUTICALS INC
KYBELLA, DEOXYCHOLIC ACID

**** L ******L PERRIGO CO**

- * L PERRIGO CO
CIMETIDINE, CIMETIDINE (OTC)
FEXOFENADINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE (OTC)
GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE, GUAIFENESIN (OTC)
IBUPROFEN, IBUPROFEN (OTC)
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** L ******* L PERRIGO CO**

MICONAZOLE NITRATE COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MINOXIDIL (FOR MEN), MINOXIDIL (OTC)
MINOXIDIL (FOR WOMEN), MINOXIDIL (OTC)
NICOTINE POLACRILEX, NICOTINE POLACRILEX (OTC)
OMEPRazole MAGNESIUM, OMEPRazole MAGNESIUM (OTC)
PSEUDOEPHEDRINE HYDROCHLORIDE, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)

LA JOLLA PHARMA*** LA JOLLA PHARMA LLC**

GIAPREZA, ANGIOTENSIN II ACETATE

LAB HRA PHARMA*** LABORATOIRE HRA PHARMA**

ELLA, ULIPRISTAL ACETATE

LABORATOIRE HRA*** LABORATOIRE HRA PHARMA**

LEVONORGESTREL, LEVONORGESTREL (OTC)

LABORATORIOS GRIFOLS*** LABORATORIOS GRIFOLS SA**

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE

LABORATORIOS SALVAT*** LABORATORIOS SALVAT SA**

OTOVEL, CIPROFLOXACIN HYDROCHLORIDE

LANDELA PHARM*** LANDELA PHARMACEUTICAL**

FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE

LANNETT*** LANNETT CO INC**

DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, ATROPINE SULFATE
LANORINAL, ASPIRIN
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
PRIMIDONE, PRIMIDONE
PROBALAN, PROBENECID

LANNETT CO INC*** LANNETT CO INC**

ARIPIPRAZOLE, ARIPIPRAZOLE
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
BACLOFEN, BACLOFEN
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
CHLORPROMAZINE HYDROCHLORIDE, CHLORPROMAZINE HYDROCHLORIDE
CODEINE SULFATE, CODEINE SULFATE
DANAZOL, DANAZOL
DIETHYLPROPION HYDROCHLORIDE, DIETHYLPROPION HYDROCHLORIDE
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
DOXYCYCLINE, DOXYCYCLINE
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE
HALOPERIDOL, HALOPERIDOL LACTATE
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
LACTULOSE, LACTULOSE
LAMIVUDINE, LAMIVUDINE
LEVOFLOXACIN, LEVOFLOXACIN
LIDOCAINE HYDROCHLORIDE VISCOUS, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
LOPINAVIR AND RITONAVIR, LOPINAVIR
LORATADINE, LORATADINE (OTC)
LOXAPINE SUCCINATE, LOXAPINE SUCCINATE
METAXALONE, METAXALONE
METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
MONTELUKAST SODIUM, MONTELUKAST SODIUM
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** L ****

* LANNETT CO INC
 NIACIN, NIACIN
 OMEPRAZOLE, OMEPRAZOLE
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
 PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
 PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
 PILOCARPINE HYDROCHLORIDE, PILOCARPINE HYDROCHLORIDE
 PREDNISOLONE, PREDNISOLONE
 RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
 RISPERIDONE, RISPERIDONE
 SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
 SUMATRIPTAN, SUMATRIPTAN
 TERBUTALINE SULFATE, TERBUTALINE SULFATE
 TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 URSODIOL, URSODIOL

LANTHEUS MEDCL

* LANTHEUS MEDICAL IMAGING INC
 CARDIOLITE, TECHNETIUM TC-99M SESTAMIBI KIT
 DEFINITY RT, PERFLUTREN
 DEFINITY, PERFLUTREN
 GALLIUM CITRATE GA 67, GALLIUM CITRATE GA-67
 NEUROLITE, TECHNETIUM TC-99M BICISATE KIT
 TECHNELITE, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR
 THALLOUS CHLORIDE TL 201, THALLOUS CHLORIDE TL-201
 XENON XE 133, XENON XE-133

LARKEN LABS

* LARKEN LABORATORIES INC
 DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
 OFLOXACIN, OFLOXACIN

LARKEN LABS INC

* LARKEN LABORATORIES INC
 ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE, ACETAMINOPHEN
 ALLZITAL, ACETAMINOPHEN
 BUTALBITAL AND ACETAMINOPHEN, ACETAMINOPHEN
 DEXAMETHASONE, DEXAMETHASONE

LAURUS

* LAURUS LABS LTD
 ABACAVIR SULFATE AND LAMIVUDINE, ABACAVIR SULFATE
 ATAZANAVIR SULFATE, ATAZANAVIR SULFATE
 EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE, EFAVIRENZ
 EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE, EFAVIRENZ
 EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE, EMTRICITABINE
 HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
 LOPINAVIR AND RITONAVIR, LOPINAVIR
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 PIRFENIDONE, PIRFENIDONE

LAVIPHARM

* LAVIPHARM SA
 CATAPRES-TTS-1, CLONIDINE
 CATAPRES-TTS-2, CLONIDINE
 CATAPRES-TTS-3, CLONIDINE

LEADIANT BIOSCI INC

* LEADIANT BIOSCIENCES INC
 ABELCET, AMPHOTERICIN B
 CARNITOR SF, LEVOCARNITINE
 CARNITOR, LEVOCARNITINE
 CYSTARAN, CYSTEAMINE HYDROCHLORIDE
 MATULANE, PROCARBAZINE HYDROCHLORIDE

LEADING

* LEADING PHARMA LLC
 AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
 BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
 CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** L ******* LEADING PHARMA LLC**

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, ATROPINE SULFATE
 DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
 FOLIC ACID, FOLIC ACID
 FUROSEMIDE, FUROSEMIDE
 GLYCOPYRROLATE, GLYCOPYRROLATE
 HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 HYDROXYUREA, HYDROXYUREA
 IMIPRAMINE HYDROCHLORIDE, IMIPRAMINE HYDROCHLORIDE
 LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
 LORAZEPAM, LORAZEPAM
 NIFEDIPINE, NIFEDIPINE
 NYSTATIN, NYSTATIN
 OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE

LEGACY PHARMA*** LEGACY PHARMA INC**

BETAPACE AF, SOTALOL HYDROCHLORIDE
 BETAPACE, SOTALOL HYDROCHLORIDE
 ZANAFLEX, TIZANIDINE HYDROCHLORIDE

LEO PHARMA AS*** LEO PHARMA AS**

DOVONEX, CALCIPOTRIENE
 ENSTILAR, BETAMETHASONE DIPROPIONATE
 FINACEA, AZELAIC ACID
 PROTOPIC, TACROLIMUS
 TACLONEX, BETAMETHASONE DIPROPIONATE

LEPU PHARM*** LEPU PHARMACEUTICAL TECHNOLOGY CO LTD**

ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM

LGM PHARMA*** LGM PHARMA SOLUTIONS LLC**

BUTALBITAL AND ACETAMINOPHEN, ACETAMINOPHEN
 BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
 BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE, ACETAMINOPHEN
 BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE, ASPIRIN
 CHENODIOL, CHENODIOL
 GLYCOPYRROLATE, GLYCOPYRROLATE
 HYDROCODONE BITARTRATE AND ASPIRIN, ASPIRIN
 MECAMYLAMINE HYDROCHLORIDE, MECAMYLAMINE HYDROCHLORIDE
 NABUMETONE, NABUMETONE
 POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
 URSODIOL, URSODIOL

LIEBEL-FLARSHEIM*** LIEBEL-FLARSHEIM CO LLC**

CONRAY, IOTHALAMATE MEGLUMINE
 CYSTO-CONRAY II, IOTHALAMATE MEGLUMINE
 MD-GASTROVIEW, DIATRIZOATE MEGLUMINE
 OPTIRAY 300, IOVERSOL
 OPTIRAY 320, IOVERSOL
 OPTIRAY 350, IOVERSOL
 SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE

LIFE MOLECULAR*** LIFE MOLECULAR IMAGING LTD**

NEURACEQ, FLORBETABEN F-18

LINDE GAS EQUIP*** LINDE GAS AND EQUIPMENT INC**

NOXIVENT, NITRIC OXIDE

LNK*** LNK INTERNATIONAL INC**

DOXYLAMINE SUCCINATE, DOXYLAMINE SUCCINATE (OTC)
 IBUPROFEN, IBUPROFEN (OTC)
 LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)

LNK INTL INC*** LNK INTERNATIONAL INC**

NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** L ******LONG GROVE PHARMS**

- * LONG GROVE PHARMACEUTICALS LLC
CARBOPROST TROMETHAMINE, CARBOPROST TROMETHAMINE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

LOREAL USA

- * LOREAL USA PRODUCTS INC
ANTHELIOS 20, AVOBENZONE (OTC)
ANTHELIOS 40, AVOBENZONE (OTC)
ANTHELIOS SX, AVOBENZONE (OTC)
CAPITAL SOLEIL 15, AVOBENZONE (OTC)

LOTUS PHARM CO LTD

- * LOTUS PHARMACEUTICAL CO LTD NANTOU PLANT
LENALIDOMIDE, LENALIDOMIDE
METHOTREXATE SODIUM, METHOTREXATE SODIUM

LOXO ONCOL ELI LILLY

- * LOXO ONCOLOGY INC A WHOLLY OWNED SUB OF ELI LILLY AND CO
RETEVMO, SELPERCATINIB

LUITPOLD

- * LUITPOLD PHARMACEUTICALS INC
AMINOCAPROIC ACID, AMINOCAPROIC ACID

LUKARE MEDICAL LLC

- * LUKARE MEDICAL LLC
ELLIOTTS B SOLUTION, CALCIUM CHLORIDE

LUNDBECK NA LTD

- * LUNDBECK NA LTD
NORTHERA, DROXIDOPA

LUNDBECK PHARMS LLC

- * LUNDBECK PHARMACEUTICALS LLC
ONFI, CLOBAZAM
SABRIL, VIGABATRIN

LUOXIN AUROVITAS

- * LUOXIN AUROVITAS PHARMA CHENGDU CO LTD
ALBUTEROL SULFATE, ALBUTEROL SULFATE
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE

LUPIN

- * LUPIN INC
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ANTARA (MICRONIZED), FENOFIBRATE
ARFORMOTEROL TARTRATE, ARFORMOTEROL TARTRATE
BROVANA, ARFORMOTEROL TARTRATE
BUDESONIDE, BUDESONIDE
DESOXIMETASONE, DESOXIMETASONE
DIMETHYL FUMARATE, DIMETHYL FUMARATE
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
FORMOTEROL FUMARATE, FORMOTEROL FUMARATE
LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM **
MIBELAS 24 FE, ETHINYL ESTRADIOL
NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
NYSTATIN, NYSTATIN
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
SOLOSEC, SECNIDAZOLE
TESTOSTERONE, TESTOSTERONE
TOBRAMYCIN, TOBRAMYCIN
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
TRIMETHOBENZAMIDE HYDROCHLORIDE, TRIMETHOBENZAMIDE HYDROCHLORIDE
XOPENEX HFA, LEVALBUTEROL TARTRATE
- * LUPIN LTD
AMLODIPINE BESYLATE AND VALSARTAN, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
CARVEDILOL, CARVEDILOL
CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** L ******* LUPIN LTD**

CEFDINIR, CEFDINIR
 CEFPROZIL, CEFPROZIL
 CEFUROXIME AXETIL, CEFUROXIME AXETIL
 CEPHALEXIN, CEPHALEXIN
 DIVALPROEX SODIUM, DIVALPROEX SODIUM
 ETHAMBUTOL HYDROCHLORIDE, ETHAMBUTOL HYDROCHLORIDE
 LEVETIRACETAM, LEVETIRACETAM
 LEVOFLOXACIN, LEVOFLOXACIN
 LISINAPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 LISINAPRIL, LISINAPRIL
 LOVASTATIN, LOVASTATIN
 QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE
 RAMIPRIL, RAMIPRIL
 SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
 SIMVASTATIN, SIMVASTATIN
 TRANDOLAPRIL, TRANDOLAPRIL

LUPIN LTD*** LUPIN LIMITED**

LEVETIRACETAM, LEVETIRACETAM
 LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL

*** LUPIN LTD**

ABACAVIR SULFATE AND LAMIVUDINE, ABACAVIR SULFATE
 ABACAVIR SULFATE, LAMIVUDINE AND ZIDOVUDINE, ABACAVIR SULFATE
 AMABELZ, ESTRADIOL
 AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE, AMLODIPINE BESYLATE
 ARMODAFINIL, ARMODAFINIL
 ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
 ATOVAQUONE, ATOVAQUONE
 AZITHROMYCIN, AZITHROMYCIN
 BEKYREE, DESOGESTREL
 BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
 BIMATOPROST, BIMATOPROST
 BLISOVI 24 FE, ETHINYL ESTRADIOL
 BLISOVI FE 1.5/30, ETHINYL ESTRADIOL
 BLISOVI FE 1/20, ETHINYL ESTRADIOL
 BRIVARACETAM, BRIVARACETAM
 BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
 CALCIUM ACETATE, CALCIUM ACETATE
 CELECOXIB, CELECOXIB
 CLOBAZAM, CLOBAZAM
 CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
 CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
 CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
 DARUNAVIR, DARUNAVIR
 DAYSEE, ETHINYL ESTRADIOL
 DECITABINE, DECITABINE
 DESVENLAFAXINE SUCCINATE, DESVENLAFAXINE SUCCINATE
 DICLOFENAC SODIUM, DICLOFENAC SODIUM
 DIVALPROEX SODIUM, DIVALPROEX SODIUM
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
 DOXERCALCIFEROL, DOXERCALCIFEROL
 DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
 DOXYCYCLINE, DOXYCYCLINE
 DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE
 DROSPIRENONE, ETHINYL ESTRADIOL AND LEVOMEFOLATE CALCIUM, DROSPIRENONE
 DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
 EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE, EMTRICITABINE
 ENSKYCE, DESOGESTREL
 ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
 ESZOPICLONE, ESZOPICLONE
 ETHACRYNIC ACID, ETHACRYNIC ACID
 FALLBACK SOLO, LEVONORGESTREL (OTC)
 FAMOTIDINE, FAMOTIDINE
 FENOFIBRATE, FENOFIBRATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** L ******* LUPIN LTD**

FENOFIBRIC ACID, CHOLINE FENOFIBRATE
 FESOTERODINE FUMARATE, FESOTERODINE FUMARATE
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 FOSAPREPITANT DIMEGLUMINE, FOSAPREPITANT DIMEGLUMINE
 FYAVOLV, ETHINYL ESTRADIOL
 GATIFLOXACIN, GATIFLOXACIN
 HYDROCORTISONE BUTYRATE, HYDROCORTISONE BUTYRATE
 HYDROCORTISONE VALERATE, HYDROCORTISONE VALERATE
 HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
 IMIPRAMINE PAMOATE, IMIPRAMINE PAMOATE
 IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 IRBESARTAN, IRBESARTAN
 JENCYCLA, NORETHINDRONE
 KAITLIB FE, ETHINYL ESTRADIOL
 KETOROLAC TROMETHAMINE AND PHENYLEPHRINE HYDROCHLORIDE, KETOROLAC TROMETHAMINE
 KURVELO, ETHINYL ESTRADIOL
 LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE
 LAMIVUDINE, LAMIVUDINE
 LAMOTRIGINE, LAMOTRIGINE
 LEFLUNOMIDE, LEFLUNOMIDE
 LEVETIRACETAM, LEVETIRACETAM
 LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 LORAZEPAM, LORAZEPAM
 LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
 MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE
 MEFENAMIC ACID, MEFENAMIC ACID
 MELOXICAM, MELOXICAM
 MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 METRONIDAZOLE, METRONIDAZOLE
 MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
 MIRABEGRON, MIRABEGRON
 MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
 NIACIN, NIACIN
 NIKKI, DROSPIRENONE
 NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
 NORETHINDRONE, NORETHINDRONE
 NORGESTIMATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
 PALIPERIDONE, PALIPERIDONE
 PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
 PENICILLAMINE, PENICILLAMINE
 PIRMELLA 1/35, ETHINYL ESTRADIOL
 PIRMELLA 7/7/7, ETHINYL ESTRADIOL
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
 PRASUGREL HYDROCHLORIDE, PRASUGREL
 QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
 QUININE SULFATE, QUININE SULFATE
 RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM
 RANOLAZINE, RANOLAZINE
 RIFABUTIN, RIFABUTIN
 RUFINAMIDE, RUFINAMIDE
 SEVELAMER HYDROCHLORIDE, SEVELAMER HYDROCHLORIDE
 SILDENAFIL CITRATE, SILDENAFIL CITRATE
 SILODOSIN, SILODOSIN
 SUPRAX, CEFIXIME
 TADALAFIL, TADALAFIL
 TAVABOROLE, TAVABOROLE
 TELMISARTAN AND AMLODIPINE, AMLODIPINE BESYLATE
 TELMISARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 TESTOSTERONE, TESTOSTERONE
 TETRABENAZINE, TETRABENAZINE
 TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** L ****

* LUPIN LTD
 TYDEMY, DROSPIRENONE
 VALSARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 VALSARTAN, VALSARTAN
 VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
 VYFEMLA, ETHINYL ESTRADIOL
 ZILEUTON, ZILEUTON
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

LUPIN PHARMS

* LUPIN PHARMACEUTICALS INC
 AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE
 DESLORATADINE, DESLORATADINE
 DICLOFENAC SODIUM, DICLOFENAC SODIUM
 DROXIDOPA, DROXIDOPA
 MELOXICAM, MELOXICAM
 NORGESTIMATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
 RIFAMPIN, RIFAMPIN
 SUPRAX, CEFIXIME
 ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE

LYNE

* LYNE LABORATORIES INC
 CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE
 CLINDAMYCIN PALMITATE HYDROCHLORIDE, CLINDAMYCIN PALMITATE HYDROCHLORIDE
 CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
 DEXAMETHASONE, DEXAMETHASONE
 ERYTHROMYCIN AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
 FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
 LEVOCARNITINE, LEVOCARNITINE
 NYSTATIN, NYSTATIN
 TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

PERRIGO

* L PERRIGO CO
 ACETAMINOPHEN, ACETAMINOPHEN (OTC)
 ACETAMINOPHEN, ASPIRIN AND CAFFEINE, ACETAMINOPHEN (OTC)
 CHILDREN'S IBUPROFEN, IBUPROFEN (OTC)
 DOXYLAMINE SUCCINATE, DOXYLAMINE SUCCINATE (OTC)
 FAMOTIDINE, FAMOTIDINE (OTC)
 IBUPROFEN, IBUPROFEN (OTC)
 LORATADINE, LORATADINE (OTC)
 MICONAZOLE 3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
 MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)
 MINOXIDIL EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
 NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE, NAPROXEN SODIUM (OTC)
 NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
 TIOCONAZOLE, TIOCONAZOLE (OTC)

**** M ******MA GENERAL HOSP**

* MASSACHUSETTS GENERAL HOSP
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

MACLEODS PHARMS LTD

* MACLEODS PHARMACEUTICALS LTD
 ACYCLOVIR, ACYCLOVIR
 AMLODIPINE AND OLMESARTAN MEDOXOMIL, AMLODIPINE BESYLATE
 ARIPIRAZOLE, ARIPIRAZOLE
 CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE, CANDESARTAN CILEXETIL
 CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL
 CELECOXIB, CELECOXIB
 CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
 CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
 DARIFENACIN, DARIFENACIN HYDROBROMIDE
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
 DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
 EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE, EFAVIRENZ

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** M ****

* MACLEODS PHARMACEUTICALS LTD
 EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE, EMTRICITABINE
 ENTACAPONE, ENTACAPONE
 ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
 ESZOPICLONE, ESZOPICLONE
 FAMCICLOVIR, FAMCICLOVIR
 FLUOCINONIDE, FLUOCINONIDE
 IBANDRONATE SODIUM, IBANDRONATE SODIUM
 IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 IRBESARTAN, IRBESARTAN
 LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE
 LAMIVUDINE, LAMIVUDINE
 LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
 LEVOFLOXACIN, LEVOFLOXACIN
 LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM **
 LIDOCAINE, LIDOCAINE
 LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
 MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 MONTELUKAST SODIUM, MONTELUKAST SODIUM
 NEVIRAPINE, NEVIRAPINE
 NIACIN, NIACIN
 NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
 NYSTATIN, NYSTATIN
 OLANZAPINE, OLANZAPINE
 OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
 OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
 PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
 PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
 PYRAZINAMIDE, PYRAZINAMIDE
 QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
 RISEDRONATE SODIUM, RISEDRONATE SODIUM
 RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
 RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
 SILDENAFIL CITRATE, SILDENAFIL CITRATE
 SILODOSIN, SILODOSIN
 TADALAFIL, TADALAFIL
 TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
 TENOFOVIR DISOPROXIL FUMARATE, TENOFOVIR DISOPROXIL FUMARATE
 TOLTERODINE TARTRATE, TOLTERODINE TARTRATE
 TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
 VALSARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 VALSARTAN, VALSARTAN
 VARDENAFIL HYDROCHLORIDE, VARDENAFIL HYDROCHLORIDE
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
 ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE

MAIA PHARMS INC

* MAIA PHARMACEUTICALS INC
 ANGIOMAX RTU, BIVALIRUDIN
 BACLOFEN, BACLOFEN
 BORTEZOMIB, BORTEZOMIB
 LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM
 SINCALIDE, SINCALIDE
 SODIUM PHENYLACETATE AND SODIUM BENZOATE, SODIUM BENZOATE

MAINPOINTE

* MAINPOINTE PHARMACEUTICALS LLC
 TUXARIN ER, CHLORPHENIRAMINE MALEATE

MALLINCKRODT ARD

* MALLINCKRODT ARD INC
 ACTHAR GEL, CORTICOTROPIN

MALLINCKRODT HOSP

* MALLINCKRODT HOSP PRODUCTS IP LTD
 INOMAX, NITRIC OXIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** M ****

- * MALLINCKRODT HOSP PRODUCTS IP LTD
UVADEX, METHOXSALEN

MALLINCKRODT IRELAND

- * MALLINCKRODT PHARMACEUTICALS IRELAND LTD
TERLIVAZ, TERLIPRESSIN ACETATE

MANKIND PHARMA

- * MANKIND PHARMA LTD
ACETAZOLAMIDE, ACETAZOLAMIDE
ALOSETRON HYDROCHLORIDE, ALOSETRON HYDROCHLORIDE
AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
ARFORMOTEROL TARTRATE, ARFORMOTEROL TARTRATE
BACLOFEN, BACLOFEN
CHLORTHALIDONE, CHLORTHALIDONE
CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
EPHEDRINE SULFATE, EPHEDRINE SULFATE
FENOFIBRATE, FENOFIBRATE
FUROSEMIDE, FUROSEMIDE
NEBIVOLOL HYDROCHLORIDE, NEBIVOLOL HYDROCHLORIDE
OFLOXACIN, OFLOXACIN
OMEGA-3-ACID ETHYL ESTERS, OMEGA-3-ACID ETHYL ESTERS
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
PRAZOSIN HYDROCHLORIDE, PRAZOSIN HYDROCHLORIDE
RANOLAZINE, RANOLAZINE
TIMOLOL MALEATE, TIMOLOL MALEATE
TOBRAMYCIN, TOBRAMYCIN
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE

MARINUS

- * MARINUS PHARMACEUTICALS INC
ZTALMY, GANAXOLONE

MARIUS PHARMS LLC

- * MARIUS PHARMACEUTICALS LLC
KYZATREX, TESTOSTERONE UNDECANOATE

MARKSANS PHARMA

- * MARKSANS PHARMA LTD
ACETAMINOPHEN, ACETAMINOPHEN (OTC)
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
DUTASTERIDE, DUTASTERIDE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
GABAPENTIN, GABAPENTIN
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
LORATADINE, LORATADINE (OTC)
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
NAPROXEN, NAPROXEN
PARICALCITOL, PARICALCITOL
PREGABALIN, PREGABALIN

MARNEL PHARMS

- * MARNEL PHARMACEUTICALS LLC
CROTAN, CROTAMITON

MAYNE PHARMA

- * MAYNE PHARMA INTERNATIONAL PTY LTD
DORYX MPC, DOXYCYCLINE HYCLATE
DORYX, DOXYCYCLINE HYCLATE
ERYC, ERYTHROMYCIN
TOLSURA, ITRACONAZOLE
- * MAYNE PHARMA LLC
BIJUVA, ESTRADIOL
BUDESONIDE, BUDESONIDE
CAMILA, NORETHINDRONE
CARBIDOPA AND LEVODOPA, CARBIDOPA

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** M ****

* MAYNE PHARMA LLC
 CHLORZOXAZONE, CHLORZOXAZONE
 CLARITHROMYCIN, CLARITHROMYCIN
 CLONIDINE, CLONIDINE
 CLOZAPINE, CLOZAPINE
 CYCLOSPORINE, CYCLOSPORINE
 DIAZEPAM, DIAZEPAM
 DISOPYRAMIDE PHOSPHATE, DISOPYRAMIDE PHOSPHATE
 DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE
 ERRIN, NORETHINDRONE
 ESTAZOLAM, ESTAZOLAM
 FABIOR, TAZAROTENE
 FLUOROURACIL, FLUOROURACIL
 HALOETTE, ETHINYL ESTRADIOL
 LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 LEVORA 0.15/30-28, ETHINYL ESTRADIOL
 LEXETTE, HALOBETASOL PROPIONATE
 LOW-OGESTREL-28, ETHINYL ESTRADIOL
 METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
 NEXTSTELLIS, DROSPIRENONE
 NORTRIPTYLINE HYDROCHLORIDE, NORTRIPTYLINE HYDROCHLORIDE
 SORILUX, CALCIPOTRIENE
 TAMOXIFEN CITRATE, TAMOXIFEN CITRATE
 TRI-NORINYL 28-DAY, ETHINYL ESTRADIOL
 TRIMETHOPRIM, TRIMETHOPRIM
 TRIVORA-28, ETHINYL ESTRADIOL

MAYNE PHARMA INC

* MAYNE PHARMA INC
 AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
 BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN
 BUTALBITAL AND ACETAMINOPHEN, ACETAMINOPHEN
 BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
 DOFETILIDE, DOFETILIDE
 DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
 DOXYCYCLINE, DOXYCYCLINE
 LIOTHYRONINE SODIUM, LIOTHYRONINE SODIUM
 METHAMPHETAMINE HYDROCHLORIDE, METHAMPHETAMINE HYDROCHLORIDE
 MORPHINE SULFATE, MORPHINE SULFATE
 NYSTATIN, NYSTATIN
 OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
 SOLTAMOX, TAMOXIFEN CITRATE

MAYNE PHARMA INTL

* MAYNE PHARMA INTERNATIONAL PTY LTD
 DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE

MC2

* MC2 THERAPEUTICS LTD
 WYNZORA, BETAMETHASONE DIPROPIONATE

MCGUFF

* MCGUFF PHARMACEUTICALS INC
 ASCOR, ASCORBIC ACID

MCNEIL

* MCNEIL CONSUMER PRODUCTS CO DIV MCNEILAB INC
 IBUPROFEN, IBUPROFEN (OTC)

MCPRE

* MAYO CLINIC PET RADIOCHEMISTRY FACILITY
 AMMONIA N-13, AMMONIA N-13
 CHOLINE C-11, CHOLINE C-11
 FLUDEOXYGLUCOSE F-18, FLUDEOXYGLUCOSE F-18
 SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

MDD US

* MDD US OPERATIONS LLC
 APOKYN, APOMORPHINE HYDROCHLORIDE
 XADAGO, SAFINAMIDE MESYLATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** M ******MDGH**

- * MEDICINES DEVELOPMENT FOR GLOBAL HEALTH
MOXIDECTIN, MOXIDECTIN

MEDEFIL INC

- * MEDEFIL INC
ATROPINE SULFATE, ATROPINE SULFATE
CALCIUM CHLORIDE 10%, CALCIUM CHLORIDE
SODIUM CHLORIDE 0.9%, SODIUM CHLORIDE
STERILE WATER FOR INJECTION, STERILE WATER FOR INJECTION

MEDEXUS

- * MEDEXUS PHARMA INC
RASUVO, METHOTREXATE

MEDI-RADIOPHARMA

- * MEDI-RADIOPHARMA LTD
TECHNETIUM TC99M MERTIATIDE KIT, TECHNETIUM TC-99M MERTIATIDE KIT

MEDICINES360

- * MEDICINES360
LILETTA, LEVONORGESTREL

MEDICURE

- * MEDICURE INTERNATIONAL INC
AGGRASTAT, TIROFIBAN HYDROCHLORIDE
SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE
ZYPITAMAG, PITAVASTATIN MAGNESIUM

MEDIMETRIKS PHARMS

- * MEDIMETRIKS PHARMACEUTICALS INC
BETAXOLOL HYDROCHLORIDE, BETAXOLOL HYDROCHLORIDE
LOPROX, CICLOPIROX
NEO-SYNALAR, FLUOCINOLONE ACETONIDE
SYNALAR, FLUOCINOLONE ACETONIDE

MEDLINE INDUSTRIES

- * MEDLINE INDUSTRIES INC
READYPREP CHG, CHLORHEXIDINE GLUCONATE (OTC)

MEDTECH PRODUCTS

- * MEDTECH PRODUCTS INC
MONISTAT 1 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MONISTAT 3 COMBINATION PACK (PREFILLED), MICONAZOLE NITRATE (OTC)
MONISTAT 3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MONISTAT 3, MICONAZOLE NITRATE
MONISTAT 3, MICONAZOLE NITRATE (OTC)
MONISTAT 7 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MONISTAT 7, MICONAZOLE NITRATE (OTC)
NIX, PERMETHRIN (OTC)
TAGAMET HB, CIMETIDINE (OTC)

MEDUNIK

- * MEDUNIK CANADA INC
NITISINONE, NITISINONE
PHEBURANE, SODIUM PHENYLBUTYRATE

MEITHEAL

- * MEITHEAL PHARMACEUTICALS INC
ATRACURIUM BESYLATE PRESERVATIVE FREE, ATRACURIUM BESYLATE
ATRACURIUM BESYLATE, ATRACURIUM BESYLATE
AZACITIDINE, AZACITIDINE
BIVALIRUDIN, BIVALIRUDIN
BLEOMYCIN SULFATE, BLEOMYCIN SULFATE
BORTEZOMIB, BORTEZOMIB
BUSULFAN, BUSULFAN
CARMUSTINE, CARMUSTINE
CISATRACURIUM BESYLATE, CISATRACURIUM BESYLATE
CLOFARABINE, CLOFARABINE
CYTARABINE, CYTARABINE
DACTINOMYCIN, DACTINOMYCIN
DAPTOMYCIN, DAPTOMYCIN
DECITABINE, DECITABINE
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** M ****

* MEITHEAL PHARMACEUTICALS INC
DOCETAXEL, DOCETAXEL
DOXERCALCIFEROL, DOXERCALCIFEROL
FUROSEMIDE, FUROSEMIDE
GANIRELIX ACETATE, GANIRELIX ACETATE
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
GLYCOPYRROLATE, GLYCOPYRROLATE
HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
ISOSULFAN BLUE, ISOSULFAN BLUE
LEVOLEUCOVORIN CALCIUM, LEVOLEUCOVORIN CALCIUM
MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE
MICA FUNGIN SODIUM, MICA FUNGIN SODIUM
MILRINONE LACTATE, MILRINONE LACTATE
MITOMYCIN, MITOMYCIN
MYCOPHENOLATE MOFETIL HYDROCHLORIDE, MYCOPHENOLATE MOFETIL HYDROCHLORIDE
NEOSTIGMINE METHYLSULFATE, NEOSTIGMINE METHYLSULFATE
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
REGADENOSON, REGADENOSON
SUCCINYLCHOLINE CHLORIDE, SUCCINYLCHOLINE CHLORIDE
TIGECYCLINE, TIGECYCLINE
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
VORICONAZOLE, VORICONAZOLE

MELINTA

* MELINTA SUBSIDIARY CORP
BAXDELA, DELAFLOXACIN MEGLUMINE

MELINTA THERAP

* MELINTA THERAPEUTICS LLC
KIMYRSA, ORITAVANCIN DIPHOSPHATE
ORBACTIV, ORITAVANCIN DIPHOSPHATE

MEM SLOAN-KETTERING

* MEMORIAL SLOAN-KETTERING CANCER CENTER
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

MERCK

* MERCK AND CO INC
CANCIDAS, CASPOFUNGIN ACETATE
EMEND, APREPITANT
PRIMAXIN, CILASTATIN SODIUM

MERCK AND CO INC

* MERCK AND CO INC
EMEND, FOSAPREPITANT DIMEGLUMINE

MERCK SHARP DOHME

* MERCK SHARP AND DOHME CORP
BELSOMRA, SUVOREXANT
JANUMET XR, METFORMIN HYDROCHLORIDE
JANUMET, METFORMIN HYDROCHLORIDE
JANUVIA, SITAGLIPTIN PHOSPHATE
NOXAFIL, POSACONAZOLE
PREVYMIS, LETERMIVIR
STROMECTOL, IVERMECTIN
TEMODAR, TEMOZOLOMIDE
VERQUVO, VERICIGUAT
* MERCK SHARP AND DOHME CORP A SUB OF MERCK AND CO INC
WELIREG, BELZUTIFAN

MERIDIAN BIOSCIENCE

* MERIDIAN BIOSCIENCE ISRAEL LTD
IDKIT:HP, CITRIC ACID

MERIDIAN LABS

* MERIDIAN LABORATORIES INC
DOCETAXEL, DOCETAXEL

MERRO PHARM USA

* MERRO PHARMACEUTICAL USA INC
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** M ******MERZ PHARMS**

* MERZ PHARMACEUTICALS LLC
CUVPOSA, GLYCOPYRROLATE

METACEL PHARMS LLC

* METACEL PHARMACEUTICALS LLC
OZOBAX, BACLOFEN

METHAPHARM

* METHAPHARM INC
PROVOCHOLINE, METHACHOLINE CHLORIDE

METUCHEN PHARMS

* METUCHEN PHARMACEUTICALS LLC
STENDRA, AVANAFIL

MICRO LABS

* MICRO LABS LTD
AMLODIPINE AND OLMESARTAN MEDOXOMIL, AMLODIPINE BESYLATE
AMOXICILLIN, AMOXICILLIN
ASPIRIN AND DIPYRIDAMOLE, ASPIRIN
BIMATOPROST, BIMATOPROST
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
CAFFEINE CITRATE, CAFFEINE CITRATE
CELECOXIB, CELECOXIB
CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDE, CHLORDIAZEPOXIDE HYDROCHLORIDE
CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
CLOBAZAM, CLOBAZAM
CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
CROMOLYN SODIUM, CROMOLYN SODIUM
DALFAMPRIDINE, DALFAMPRIDINE
DICLOFENAC SODIUM AND MISOPROSTOL, DICLOFENAC SODIUM
DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE
ERYTHRA-DERM, ERYTHROMYCIN
FENOFIBRIC ACID, CHOLINE FENOFIBRATE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
GLIMEPIRIDE, GLIMEPIRIDE
ISOPROTERENOL HYDROCHLORIDE, ISOPROTERENOL HYDROCHLORIDE
LEVETIRACETAM, LEVETIRACETAM
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE (OTC)
LINCOMYCIN HYDROCHLORIDE, LINCOMYCIN HYDROCHLORIDE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
MEFENAMIC ACID, MEFENAMIC ACID
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METHENAMINE HIPPURATE, METHENAMINE HIPPURATE
MISOPROSTOL, MISOPROSTOL
OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
PIRFENIDONE, PIRFENIDONE
PIROXICAM, PIROXICAM
RANOLAZINE, RANOLAZINE
RASAGILINE MESYLATE, RASAGILINE MESYLATE
ROFLUMILAST, ROFLUMILAST
SEVELAMER CARBONATE, SEVELAMER CARBONATE
SIMVASTATIN, SIMVASTATIN
SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE
SUCCINYLCHOLINE CHLORIDE, SUCCINYLCHOLINE CHLORIDE
TAFLUPROST, TAFLUPROST
TELMISARTAN, TELMISARTAN
TIMOLOL MALEATE, TIMOLOL MALEATE
TRANEXAMIC ACID, TRANEXAMIC ACID
TRAVOPROST, TRAVOPROST
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE

MICRO LABS LTD

* MICRO LABS LTD
NEVIRAPINE, NEVIRAPINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** M ******MICRO LABS LTD INDIA**

- * MICRO LABS LTD INDIA
 - ACETAZOLAMIDE, ACETAZOLAMIDE
 - AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
 - ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
 - CROMOLYN SODIUM, CROMOLYN SODIUM
 - KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
 - LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
 - LEVOFLOXACIN, LEVOFLOXACIN
 - TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN

MIDWEST MEDCL

- * MIDWEST MEDICAL ISOTOPES LLC CYCLOTRON DIV
 - AMMONIA N 13, AMMONIA N-13
 - SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

MIKART

- * MIKART LLC
 - BUTALBITAL AND ACETAMINOPHEN, ACETAMINOPHEN
 - BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
 - BUTAPAP, ACETAMINOPHEN
 - CARBINOXAMINE MALEATE, CARBINOXAMINE MALEATE
 - CHLORZOXAZONE, CHLORZOXAZONE
 - ERGOTAMINE TARTRATE AND CAFFEINE, CAFFEINE
 - ETHOSUXIMIDE, ETHOSUXIMIDE
 - HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
 - ISONIAZID, ISONIAZID
 - METHAZOLAMIDE, METHAZOLAMIDE
 - OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
 - TRIHENYPHENIDYL HYDROCHLORIDE, TRIHENYPHENIDYL HYDROCHLORIDE

MILLA PHARMS

- * MILLA PHARMACEUTICALS INC
 - MAGNESIUM SULFATE IN PLASTIC CONTAINER, MAGNESIUM SULFATE
 - PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE
 - SODIUM ACETATE, SODIUM ACETATE

MILLICENT

- * MILLICENT HOLDINGS LTD
 - FEMRING, ESTRADIOL ACETATE
- * MILLICENT PHARMA LTD
 - INTRAROSA, PRASTERONE

MIPS CRE

- * MIPS CYCLOTRON AND RADIOCHEMISTRY FACILITY
 - AMMONIA N 13, AMMONIA N-13
 - FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
 - SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

MIRATI THERAPS

- * MIRATI THERAPEUTICS INC
 - KRAZATI, ADAGRASIB

MIRUM

- * MIRUM PHARMACEUTICALS INC
 - LIVMARLI, MARALIXIBAT CHLORIDE

MISEMER

- * MISEMER PHARMACEUTICALS INC
 - CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDE, CHLORDIAZEPOXIDE HYDROCHLORIDE
 - KETOPROFEN, KETOPROFEN

MISSION PHARMA

- * MISSION PHARMACAL CO
 - LITHOSTAT, ACETOHYDROXAMIC ACID
 - PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
 - TEXACORT, HYDROCORTISONE
 - THIOLA, TIOPRONIN
 - TINDAMAX, TINIDAZOLE
 - UROCIT-K, POTASSIUM CITRATE

MISSION PHARMACAL CO

- * MISSION PHARMACAL CO
 - CARBINOXAMINE MALEATE, CARBINOXAMINE MALEATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** M ****

- * MISSION PHARMACAL CO
POTASSIUM IODIDE, POTASSIUM IODIDE (OTC)
THIOLA EC, TIOPRONIN

MITSUBISHI TANABE

- * MITSUBISHI TANABE PHARMA CORP
RADICAVA ORS, EDARAVONE
RADICAVA, EDARAVONE

MLV

- * MLV PHARMA LLC
CARISOPRODOL, CARISOPRODOL
METHOCARBAMOL, METHOCARBAMOL
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE

MMT

- * MERIDIAN MEDICAL TECHNOLOGIES LLC
ATROPEN, ATROPINE
DUODOTE, ATROPINE
SEIZALAM, MIDAZOLAM HYDROCHLORIDE

MOBIUS THERAP

- * MOBIUS THERAPEUTICS LLC
MITOSOL, MITOMYCIN

MOLNLYCKE HLTH

- * MOLNLYCKE HEALTH CARE
HIBICLENS, CHLORHEXIDINE GLUCONATE (OTC)
HIBISTAT, CHLORHEXIDINE GLUCONATE (OTC)

MONARCH PHARMS

- * MONARCH PHARMACEUTICALS LLC
MENEST, ESTROGENS, ESTERIFIED
NEOSPORIN G.U. IRRIGANT, NEOMYCIN SULFATE
NEOSPORIN, GRAMICIDIN
SEPTRA DS, SULFAMETHOXAZOLE
SEPTRA, SULFAMETHOXAZOLE
VIROPTIC, TRIFLURIDINE

MONTEREY PHARMS LLC

- * MONTEREY PHARMACEUTICALS LLC
METHOCARBAMOL, METHOCARBAMOL

MOUNTAIN

- * MOUNTAIN LLC
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
GRISEOFULVIN, ULTRAMICROSIZED, GRISEOFULVIN, ULTRAMICROSIZED
METAXALONE, METAXALONE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE

MSD MERCK CO

- * MERCK SHARP AND DOHME CORP A SUB OF MERCK AND CO INC
DELSTRIGO, DORAVIRINE
EMEND, APREPITANT
NOXAFIL POWDERMIX KIT, POSACONAZOLE
PIFELTRO, DORAVIRINE
RECARBRIO, CILASTATIN SODIUM

MSD SUB MERCK

- * MERCK SHARP AND DOHME LLC A SUB OF MERCK AND CO INC
INVANZ, ERTAPENEM SODIUM
ISENTRESS HD, RALTEGRAVIR POTASSIUM
ISENTRESS, RALTEGRAVIR POTASSIUM
SEGLUROMET, ERTUGLIFLOZIN
STEGLATRO, ERTUGLIFLOZIN
STEGLUJAN, ERTUGLIFLOZIN
ZEPATIER, ELBASVIR
ZOLINZA, VORINOSTAT

MSN

- * MSN LABORATORIES PRIVATE LTD
ABIRATERONE ACETATE, ABIRATERONE ACETATE
ALBENDAZOLE, ALBENDAZOLE
AMINOCAPROIC ACID, AMINOCAPROIC ACID
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** M ****

* MSN LABORATORIES PRIVATE LTD
 BORTEZOMIB, BORTEZOMIB
 BUMETANIDE, BUMETANIDE
 CAPECITABINE, CAPECITABINE
 CHLORPROMAZINE HYDROCHLORIDE, CHLORPROMAZINE HYDROCHLORIDE
 CLOBAZAM, CLOBAZAM
 CLOFARABINE, CLOFARABINE
 DECITABINE, DECITABINE
 DEFERASIROX, DEFERASIROX
 DIMETHYL FUMARATE, DIMETHYL FUMARATE
 DOFETILIDE, DOFETILIDE
 DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
 ERLOTINIB HYDROCHLORIDE, ERLOTINIB HYDROCHLORIDE
 FEBUXOSTAT, FEBUXOSTAT
 FOSAPREPITANT DIMEGLUMINE, FOSAPREPITANT DIMEGLUMINE
 HALOPERIDOL, HALOPERIDOL
 ISOSULFAN BLUE, ISOSULFAN BLUE
 LEVETIRACETAM, LEVETIRACETAM
 LURASIDONE HYDROCHLORIDE, LURASIDONE HYDROCHLORIDE
 MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
 OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
 PACLITAXEL, PACLITAXEL
 PIRFENIDONE, PIRFENIDONE
 PREGABALIN, PREGABALIN
 RIOCIQUAT, RIOCIQUAT
 ROFLUMILAST, ROFLUMILAST
 ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
 SILDENAFIL CITRATE, SILDENAFIL CITRATE
 SILODOSIN, SILODOSIN
 SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE
 THIOTEPA, THIOTEPA
 TIAGABINE HYDROCHLORIDE, TIAGABINE HYDROCHLORIDE
 TOREMIFENE CITRATE, TOREMIFENE CITRATE
 TRIENTINE HYDROCHLORIDE, TRIENTINE HYDROCHLORIDE
 VALGANCICLOVIR HYDROCHLORIDE, VALGANCICLOVIR HYDROCHLORIDE
 VIGABATRIN, VIGABATRIN
 ZIPRASIDONE MESYLATE, ZIPRASIDONE MESYLATE

MSN LABS PVT LTD

* MSN LABORATORIES PRIVATE LTD
 LACOSAMIDE, LACOSAMIDE

MSN PHARMS INC

* MSN PHARMACEUTICALS INC
 DROXIDOPA, DROXIDOPA

MURTY PHARMS

* MURTY PHARMACEUTICALS INC
 AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
 DIPYRIDAMOLE, DIPYRIDAMOLE

MYCOVIA PHARMS

* MYCOVIA PHARMACEUTICALS INC
 VIVJOA, OTESECONAZOLE

MYLAN

* MYLAN INSTITUTIONAL LLC A VIATRIS CO
 ALOPRIM, ALLOPURINOL SODIUM
 * MYLAN LABORATORIES LTD A VIATRIS CO
 NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 * MYLAN PHARMACEUTICALS
 METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 * MYLAN PHARMACEUTICALS INC
 ABIRATERONE ACETATE, ABIRATERONE ACETATE
 ACAMPROSATE CALCIUM, ACAMPROSATE CALCIUM
 ACETAMINOPHEN, ACETAMINOPHEN
 ACITRETIN, ACITRETIN
 ALBUTEROL SULFATE, ALBUTEROL SULFATE
 ALLOPURINOL, ALLOPURINOL
 ALMOTRIPTAN MALATE, ALMOTRIPTAN MALATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** M ****

* MYLAN PHARMACEUTICALS INC
 AMBRISENTAN, AMBRISENTAN
 AMLODIPINE BESYLATE AND VALSARTAN, AMLODIPINE BESYLATE
 ATENOLOL, ATENOLOL
 ATOVAQUONE AND PROGUANIL HYDROCHLORIDE, ATOVAQUONE
 AVITA, TRETINOIN
 BEPOTASTINE BESILATE, BEPOTASTINE BESILATE
 BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE, BISOPROLOL FUMARATE
 BREYNA, BUDESONIDE
 BROMOCRIPTINE MESYLATE, BROMOCRIPTINE MESYLATE
 BUDESONIDE, BUDESONIDE
 BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
 CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE, CANDESARTAN CILEXETIL
 CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL
 CARBIDOPA AND LEVODOPA, CARBIDOPA
 CARVEDILOL, CARVEDILOL
 CELECOXIB, CELECOXIB
 CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
 CHLORTHALIDONE, CHLORTHALIDONE
 CIMETIDINE, CIMETIDINE
 CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
 CLOBAZAM, CLOBAZAM
 CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
 CLOZAPINE, CLOZAPINE
 COLCHICINE, COLCHICINE
 CYCLOSPORINE, CYCLOSPORINE
 CYSTAGON, CYSTEAMINE BITARTRATE
 DAPSONE, DAPSONE
 DENAVIR, PENCICLOVIR
 DIAZEPAM, DIAZEPAM
 DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
 DIMETHYL FUMARATE, DIMETHYL FUMARATE
 DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, ATROPINE SULFATE
 DIVALPROEX SODIUM, DIVALPROEX SODIUM
 ELETRIPTAN HYDROBROMIDE, ELETRIPTAN HYDROBROMIDE
 EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE, EMTRICITABINE
 ERYGEL, ERYTHROMYCIN
 ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
 ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM (OTC)
 ESTRADIOL, ESTRADIOL
 ETOPOSIDE, ETOPOSIDE
 EVEROLIMUS, EVEROLIMUS
 EVOCLIN, CLINDAMYCIN PHOSPHATE
 EXTENDED PHENYTOIN SODIUM, PHENYTOIN SODIUM
 EXTINA, KETOCONAZOLE
 FEBUXOSTAT, FEBUXOSTAT
 FENOFIBRATE, FENOFIBRATE
 FOSAMPRENAVIR CALCIUM, FOSAMPRENAVIR CALCIUM
 FROVATRIPTAN SUCCINATE, FROVATRIPTAN SUCCINATE
 FUROSEMIDE, FUROSEMIDE
 GLATIRAMER ACETATE, GLATIRAMER ACETATE
 HALCINONIDE, HALCINONIDE
 HALOPERIDOL, HALOPERIDOL
 IMATINIB MESYLATE, IMATINIB MESYLATE
 IMPEKLO, CLOBETASOL PROPIONATE
 KETOPROFEN, KETOPROFEN
 KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
 LANSOPRAZOLE, LANSOPRAZOLE
 LANSOPRAZOLE, LANSOPRAZOLE (OTC)
 LENALIDOMIDE, LENALIDOMIDE
 LEVETIRACETAM, LEVETIRACETAM
 LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM **
 LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE
 LORATADINE, LORATADINE (OTC)

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** M ****

- * MYLAN PHARMACEUTICALS INC
 LUXIQ, BETAMETHASONE VALERATE
 MECLOFENAMATE SODIUM, MECLOFENAMATE SODIUM
 MENTAX, BUTENAFINE HYDROCHLORIDE
 MERCAPTOPURINE, MERCAPTOPURINE
 MESALAMINE, MESALAMINE
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 METHIMAZOLE, METHIMAZOLE
 METHOTREXATE SODIUM, METHOTREXATE SODIUM
 METOLAZONE, METOLAZONE
 METOPROLOL TARTRATE, METOPROLOL TARTRATE
 MIRTAZAPINE, MIRTAZAPINE
 MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
 MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
 NAPROXEN AND ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
 NEVIRAPINE, NEVIRAPINE
 NISOLDIPINE, NISOLDIPINE
 OLANZAPINE, OLANZAPINE
 OLUX E, CLOBETASOL PROPIONATE
 OLUX, CLOBETASOL PROPIONATE
 ONDANSETRON, ONDANSETRON
 PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
 PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
 PHENYTEK, PHENYTOIN SODIUM
 POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
 PRASUGREL, PRASUGREL HYDROCHLORIDE
 PRAZOSIN HYDROCHLORIDE, PRAZOSIN HYDROCHLORIDE
 PREDNISONE, PREDNISONE
 PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
 ROFLUMILAST, ROFLUMILAST
 ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
 RUFINAMIDE, RUFINAMIDE
 SILDENAFIL CITRATE, SILDENAFIL CITRATE
 SORAFENIB TOSYLATE, SORAFENIB TOSYLATE
 SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 SPIRONOLACTONE, SPIRONOLACTONE
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
 SUNITINIB MALATE, SUNITINIB MALATE
 SYMFI LO, EFAVIRENZ
 TACROLIMUS, TACROLIMUS
 TAMOXIFEN CITRATE, TAMOXIFEN CITRATE
 TELMISARTAN AND AMLODIPINE, AMLODIPINE BESYLATE
 TETRABENAZINE, TETRABENAZINE
 THIORIDAZINE HYDROCHLORIDE, THIORIDAZINE HYDROCHLORIDE
 THIOTHIXENE, THIOTHIXENE
 TIMOLOL MALEATE, TIMOLOL MALEATE
 TRAVOPROST, TRAVOPROST
 TRETINOIN, TRETINOIN
 TRIFLUOPERAZINE HYDROCHLORIDE, TRIFLUOPERAZINE HYDROCHLORIDE
 URSODIOL, URSODIOL
 VALSARTAN, VALSARTAN
 VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE
 VUSION, MICONAZOLE NITRATE
 WIXELA INHUB, FLUTICASONE PROPIONATE
 ZONALON, DOXEPIN HYDROCHLORIDE
 ZOVIRAX, ACYCLOVIR
- * MYLAN PHARMACEUTICALS INC A VIATRIS CO
 AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM, AMLODIPINE BESYLATE
 ERMEZA, LEVOTHYROXINE SODIUM
 FINGOLIMOD HYDROCHLORIDE, FINGOLIMOD HYDROCHLORIDE
 PREDNISONE, PREDNISONE
 SUCRALFATE, SUCRALFATE
 TELMISARTAN, TELMISARTAN

MYLAN ASI

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** M ****

* MYLAN ASI LLC
 ACETAZOLAMIDE SODIUM, ACETAZOLAMIDE SODIUM
 ADENOSINE, ADENOSINE
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE

MYLAN INSTITUTIONAL

* MYLAN INSTITUTIONAL INC
 BUSULFAN, BUSULFAN

* MYLAN INSTITUTIONAL LLC
 AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
 ARGATROBAN, ARGATROBAN
 BIVALIRUDIN, BIVALIRUDIN
 CIDOFOVIR, CIDOFOVIR
 COSYNTROPIN, COSYNTROPIN
 DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
 DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE
 DURACLON, CLONIDINE HYDROCHLORIDE
 ESMOLOL HYDROCHLORIDE, ESMOLOL HYDROCHLORIDE
 ETHACRYNATE SODIUM, ETHACRYNATE SODIUM
 FOMEPIZOLE, FOMEPIZOLE
 HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
 IBUTILIDE FUMARATE, IBUTILIDE FUMARATE
 ISOSULFAN BLUE, ISOSULFAN BLUE
 MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE
 METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
 NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
 OCTREOTIDE ACETATE (PRESERVATIVE FREE), OCTREOTIDE ACETATE
 PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE
 RIMSO-50, DIMETHYL SULFOXIDE
 ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
 SOTRADECOL, SODIUM TETRADECYL SULFATE
 THIAMINE HYDROCHLORIDE, THIAMINE HYDROCHLORIDE
 TRANEXAMIC ACID, TRANEXAMIC ACID
 ULTIVA, REMIFENTANIL HYDROCHLORIDE

MYLAN IRELAND LTD

* MYLAN IRELAND LTD
 ARIXTRA, FONDAPARINUX SODIUM
 MIACALCIN, CALCITONIN SALMON
 PRETOMANID, PRETOMANID
 YUPELRI, REVEFENACIN

MYLAN LABS LTD

* MYLAN LABORATORIES LTD
 ADENOSINE, ADENOSINE
 AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
 AMPICILLIN SODIUM, AMPICILLIN SODIUM
 BACLOFEN, BACLOFEN
 CIMDUO, LAMIVUDINE
 CLOFARABINE, CLOFARABINE
 CYANOCOBALAMIN, CYANOCOBALAMIN
 DAPTOMYCIN, DAPTOMYCIN
 DESOGESTREL AND ETHINYL ESTRADIOL, DESOGESTREL
 DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
 DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
 DOCETAXEL, DOCETAXEL
 DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
 DOXYCYCLINE, DOXYCYCLINE HYCLATE
 DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE
 EPTIFIBATIDE, EPTIFIBATIDE
 ESMOLOL HYDROCHLORIDE, ESMOLOL HYDROCHLORIDE
 ESTRADIOL AND NORETHINDRONE ACETATE, ESTRADIOL
 ETHYNODIOL DIACETATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 ETOMIDATE, ETOMIDATE
 FAMOTIDINE PRESERVATIVE FREE, FAMOTIDINE
 FAMOTIDINE, FAMOTIDINE
 FLUPHENAZINE DECANOATE, FLUPHENAZINE DECANOATE
 FOSAPREPITANT DIMEGLUMINE, FOSAPREPITANT DIMEGLUMINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** M ******* MYLAN LABORATORIES LTD**

FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
 GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
 HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
 HALOPERIDOL, HALOPERIDOL LACTATE
 HEPARIN SODIUM, HEPARIN SODIUM
 IBANDRONATE SODIUM, IBANDRONATE SODIUM
 ISOPROTERENOL HYDROCHLORIDE, ISOPROTERENOL HYDROCHLORIDE
 LAMIVUDINE, LAMIVUDINE
 LEUCOVORIN CALCIUM PRESERVATIVE FREE, LEUCOVORIN CALCIUM
 LEVETIRACETAM, LEVETIRACETAM
 LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 LEVONORGESTREL, LEVONORGESTREL (OTC)
 LINEZOLID, LINEZOLID
 MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MAGNESIUM SULFATE
 MAGNESIUM SULFATE IN PLASTIC CONTAINER, MAGNESIUM SULFATE
 MEDROXYPROGESTERONE ACETATE, MEDROXYPROGESTERONE ACETATE
 MOXIFLOXACIN HYDROCHLORIDE IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER, MOXIFLOXACIN
 MYCOPHENOLATE MOFETIL HYDROCHLORIDE, MYCOPHENOLATE MOFETIL HYDROCHLORIDE
 NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
 NOREPINEPHRINE BITARTRATE, NOREPINEPHRINE BITARTRATE
 NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 NORETHINDRONE ACETATE, NORETHINDRONE ACETATE
 NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
 NORETHINDRONE, NORETHINDRONE
 OXALIPLATIN, OXALIPLATIN
 PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
 PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE
 RIFAMPIN, RIFAMPIN
 SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE
 SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
 SYMFI, EFAVIRENZ
 TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
 TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
 VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
 VECURONIUM BROMIDE, VECURONIUM BROMIDE
 ZOLEDRONIC ACID, ZOLEDRONIC ACID

MYLAN PHARMS INC*** MYLAN PHARMACEUTICALS INC**

ABACAVIR SULFATE, ABACAVIR SULFATE
 ACYCLOVIR, ACYCLOVIR
 AMNESTEEM, ISOTRETINOIN
 ARMODAFINIL, ARMODAFINIL
 ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
 AVITA, TRETINOIN
 CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
 CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
 DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
 DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE, DOXYLAMINE SUCCINATE
 ESZOPICLONE, ESZOPICLONE
 FENOFIBRATE, FENOFIBRATE
 LANSOPRAZOLE, LANSOPRAZOLE
 LITHIUM CARBONATE, LITHIUM CARBONATE
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
 MIDODRINE HYDROCHLORIDE, MIDODRINE HYDROCHLORIDE
 NEVIRAPINE, NEVIRAPINE
 PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
 RILUZOLE, RILUZOLE
 RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
 SILDENAFIL CITRATE, SILDENAFIL CITRATE
 VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
 VALSARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 VORICONAZOLE, VORICONAZOLE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** M ****

- * MYLAN PHARMACEUTICALS INC
ZIDOVUDINE, ZIDOVUDINE
- * MYLAN PHARMACEUTICALS INC.
FLUVASTATIN SODIUM, FLUVASTATIN SODIUM

MYLAN SPCLT VIATRIS

- * MYLAN SPECIALTY LP A VIATRIS CO
DIPENTUM, OLSALAZINE SODIUM

MYLAN SPECIALITY LP

- * MYLAN SPECIALTY LP
ACCUNEB, ALBUTEROL SULFATE
COLYTE WITH FLAVOR PACKS, POLYETHYLENE GLYCOL 3350
CORTIFOAM, HYDROCORTISONE ACETATE
DEPEN, PENICILLAMINE
DYMISTA, AZELASTINE HYDROCHLORIDE
EDLUAR, ZOLPIDEM TARTRATE
ELESTRIN, ESTRADIOL
EPIFOAM, HYDROCORTISONE ACETATE
EPIPEN JR., EPINEPHRINE
EPIPEN, EPINEPHRINE
FELBATOL, FELBAMATE
GASTROCROM, CROMOLYN SODIUM
LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE
MUSE, ALPROSTADIL
PROCTOFOAM HC, HYDROCORTISONE ACETATE
ROWASA, MESALAMINE
SFROWASA, MESALAMINE
SOMA, CARISOPRODOL
TOBI PODHALER, TOBRAMYCIN
TOBI, TOBRAMYCIN

MYLAN SPECLT

- * MYLAN SPECIALTY LP
PERFORMIST, FORMOTEROL FUMARATE

MYLAN TECH VIATRIS

- * MYLAN TECHNOLOGIES INC A VIATRIS CO
METHYLPHENIDATE, METHYLPHENIDATE

MYLAN TECHNOLOGIES

- * MYLAN TECHNOLOGIES INC
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
CLONIDINE, CLONIDINE
ESTRADIOL, ESTRADIOL
FENTANYL-100, FENTANYL
FENTANYL-12, FENTANYL
FENTANYL-25, FENTANYL
FENTANYL-37, FENTANYL
FENTANYL-50, FENTANYL
FENTANYL-62, FENTANYL
FENTANYL-75, FENTANYL
FENTANYL-87, FENTANYL
LIDOCAINE, LIDOCAINE
NITROGLYCERIN, NITROGLYCERIN
RIVASTIGMINE, RIVASTIGMINE
SCOPOLAMINE, SCOPOLAMINE
XULANE, ETHINYL ESTRADIOL

MYOVANT SCIENCES

- * MYOVANT SCIENCES GMBH
MYFEMBREE, ESTRADIOL
ORGOVYX, RELUGOLIX

**** N ******NAARI PTE LTD**

- * NAARI PTE LTD
DESOGESTREL AND ETHINYL ESTRADIOL, DESOGESTREL
DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE
LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
LEVONORGESTREL, LEVONORGESTREL (OTC)

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** N ****

- * NAARI PTE LTD
NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
NORETHINDRONE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
NORETHINDRONE, NORETHINDRONE
NORGESTIMATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL

NABRIVA

- * NABRIVA THERAPEUTICS IRELAND DAC
XENLETA, LEFAMULIN ACETATE

NAL PHARM

- * NAL PHARMACEUTICAL GROUP LTD
LIDOCAINE, LIDOCAINE

NALPROPION

- * NALPROPION PHARMACEUTICALS LLC
CONTRAVE, BUPROPION HYDROCHLORIDE

NANG KUANG PHARM CO

- * NANG KUANG PHARMACEUTICAL CO LTD
ICATIBANT ACETATE, ICATIBANT ACETATE
LINEZOLID, LINEZOLID
PEMETREXED DISODIUM, PEMETREXED DISODIUM

NANJING

- * NANJING SIMCERE DONGYUAN PHARMACEUTICAL CO LTD
CELECOXIB, CELECOXIB

NANJING KING-FRIEND

- * NANJING KING-FRIEND BIOCHEMICAL PHARMACEUTICAL CO LTD
ENOXAPARIN SODIUM (PRESERVATIVE FREE), ENOXAPARIN SODIUM
ENOXAPARIN SODIUM, ENOXAPARIN SODIUM
HEPARIN SODIUM, HEPARIN SODIUM

NAPO PHARMS INC

- * NAPO PHARMACEUTICALS INC
MYTESI, CROFELEMER

NATCO

- * NATCO PHARMA LTD
ALPRAZOLAM, ALPRAZOLAM
CARISOPRODOL, CARISOPRODOL
GLYCOPYRROLATE, GLYCOPYRROLATE
LANSOPRAZOLE, LANSOPRAZOLE (OTC)
NITROGLYCERIN, NITROGLYCERIN
OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE

NATCO PHARMA

- * NATCO PHARMA LTD
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE

NATCO PHARMA LTD

- * NATCO PHARMA LIMITED
CHLOROQUINE PHOSPHATE, CHLOROQUINE PHOSPHATE
- * NATCO PHARMA LTD
ANASTROZOLE, ANASTROZOLE
ARMODAFINIL, ARMODAFINIL
AZACITIDINE, AZACITIDINE
CHLOROQUINE PHOSPHATE, CHLOROQUINE PHOSPHATE
ERLOTINIB HYDROCHLORIDE, ERLOTINIB HYDROCHLORIDE
IMATINIB MESYLATE, IMATINIB MESYLATE
LANSOPRAZOLE, LANSOPRAZOLE
LANTHANUM CARBONATE, LANTHANUM CARBONATE
LAPATINIB DITOSYLATE, LAPATINIB DITOSYLATE
LETROZOLE, LETROZOLE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
TRIHENYPHENIDYL HYDROCHLORIDE, TRIHENYPHENIDYL HYDROCHLORIDE

NAVINTA LLC

- * NAVINTA LLC
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
CARGLUMIC ACID, CARGLUMIC ACID
CARMUSTINE, CARMUSTINE
FAMOTIDINE, FAMOTIDINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** N ******* NAVINTA LLC**

FOMEPIZOLE, FOMEPIZOLE
 FOSAPREPITANT DIMEGLUMINE, FOSAPREPITANT DIMEGLUMINE
 HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
 INDOMETHACIN SODIUM, INDOMETHACIN SODIUM
 METHOCARBAMOL, METHOCARBAMOL
 PENICILLAMINE, PENICILLAMINE
 RIBAVIRIN, RIBAVIRIN
 ROPIVACAINE HYDROCHLORIDE, ROPIVACAINE HYDROCHLORIDE
 SODIUM PHENYLACETATE AND SODIUM BENZOATE, SODIUM BENZOATE
 TRIENTINE HYDROCHLORIDE, TRIENTINE HYDROCHLORIDE

NCM USA BRONX LLC*** NCM USA BRONX LLC**

AMMONIA N 13, AMMONIA N-13
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
 SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

NEOS THERAPS*** NEOS THERAPEUTICS**

ADZENYS XR-ODT, AMPHETAMINE

NEOS THERAPS INC*** NEOS THERAPEUTICS INC**

COTEMPLA XR-ODT, METHYLPHENIDATE

NEPHRON*** NEPHRON CORP**

ALBUTEROL SULFATE, ALBUTEROL SULFATE
 IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE

*** NEPHRON PHARMACEUTICALS CORP**

ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE, ALBUTEROL SULFATE
 ALBUTEROL SULFATE, ALBUTEROL SULFATE
 BUDESONIDE, BUDESONIDE
 KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
 SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
 STERILE WATER FOR INJECTION, STERILE WATER FOR INJECTION

NEURELIS INC*** NEURELIS INC**

VALTOCO, DIAZEPAM

NEUROCRINE*** NEUROCRINE BIOSCIENCES INC**

INGREZZA, VALBENAZINE TOSYLATE
 ONGENTYS, OPICAPONE

NEVAKAR INJECTABLES*** NEVAKAR INJECTABLES INC**

NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE, NOREPINEPHRINE BITARTRATE

NEXTWAVE*** NEXTWAVE PHARMACEUTICALS INC A SUB OF TRIS PHARMA INC**

QUILLIVANT XR, METHYLPHENIDATE HYDROCHLORIDE

NEXTWAVE PHARMS*** NEXTWAVE PHARMACEUTICALS INC**

QUILLICHEW ER, METHYLPHENIDATE HYDROCHLORIDE

NEXUS PHARMS*** NEXUS PHARMACEUTICALS INC**

ARSENIC TRIOXIDE, ARSENIC TRIOXIDE
 BUSULFAN, BUSULFAN
 COLISTIMETHATE SODIUM, COLISTIMETHATE SODIUM
 DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
 EMERPHED, EPHEDRINE SULFATE
 ERYTHROMYCIN LACTOBIONATE, ERYTHROMYCIN LACTOBIONATE
 ISOPROTERENOL HYDROCHLORIDE, ISOPROTERENOL HYDROCHLORIDE
 LEVETIRACETAM IN SODIUM CHLORIDE, LEVETIRACETAM
 MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
 POTASSIUM CHLORIDE 10MEQ, POTASSIUM CHLORIDE
 POTASSIUM CHLORIDE 20MEQ, POTASSIUM CHLORIDE
 POTASSIUM CHLORIDE 40MEQ, POTASSIUM CHLORIDE
 PROCAINAMIDE HYDROCHLORIDE, PROCAINAMIDE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** N ****

- * NEXUS PHARMACEUTICALS INC
PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE
SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE
SUCCINYLCHOLINE CHLORIDE, SUCCINYLCHOLINE CHLORIDE
TESTOSTERONE ENANTHATE, TESTOSTERONE ENANTHATE

NIAGARA PHARMS

- * NIAGARA PHARMACEUTICALS INC
PUR-WASH, PURIFIED WATER (OTC)

NIPPON SHINYAKU

- * NIPPON SHINYAKU CO LTD
VILTEPSO, VILTOLARSEN

NIVAGEN PHARMS INC

- * NIVAGEN PHARMACEUTICALS INC
CALCIUM GLUCONATE, CALCIUM GLUCONATE
DECITABINE, DECITABINE
EFINACONAZOLE, EFINACONAZOLE
GLYCOPYRROLATE, GLYCOPYRROLATE
NEOSTIGMINE METHYLSULFATE, NEOSTIGMINE METHYLSULFATE
SUCCINYLCHOLINE CHLORIDE, SUCCINYLCHOLINE CHLORIDE
TEMOZOLOMIDE, TEMOZOLOMIDE

NOBELPHARMA

- * NOBELPHARMA CO LTD
HYFTOR, SIROLIMUS

NODEN PHARMA

- * NODEN PHARMA DAC
TEKTURN, ALISKIREN HEMIFUMARATE

NORDIC GRP

- * NORDIC GROUP BV
REDITREX, METHOTREXATE

NORTEC DEV ASSOC

- * NORTEC DEVELOPMENT ASSOC INC
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE

NORTHLAND

- * NORTHLAND NUCLEAR MEDICINE LLC
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

NORTHSTAR HLTHCARE

- * NORTHSTAR HEALTHCARE HOLDINGS LTD
ALLOPURINOL, ALLOPURINOL
BACLOFEN, BACLOFEN
GEMFIBROZIL, GEMFIBROZIL
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE

NORTHSTAR MEDICAL

- * NORTHSTAR MEDICAL RADIOISOTOPES LLC
RADIOGENIX SYSTEM, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR

NORTON WATERFORD

- * NORTON WATERFORD LTD
QVAR REDIHALER, BECLOMETHASONE DIPROPIONATE

NOSTRUM LABS INC

- * NOSTRUM LABORATORIES INC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ACETAZOLAMIDE, ACETAZOLAMIDE
BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE, ACETAMINOPHEN
BUTALBITAL, ASPIRIN AND CAFFEINE, ASPIRIN
CALCIUM ACETATE, CALCIUM ACETATE
CARBAMAZEPINE, CARBAMAZEPINE
CARISOPRODOL, CARISOPRODOL
DAPSONE, DAPSONE
ELIXOPHYLLIN, THEOPHYLLINE
HYDROCODONE BITARTRATE AND IBUPROFEN, HYDROCODONE BITARTRATE
HYDROCODONE, HYDROCODONE BITARTRATE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
NITROFURANTOIN, NITROFURANTOIN
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** N ****

* NOSTRUM LABORATORIES INC
PINDOLOL, PINDOLOL
PIROXICAM, PIROXICAM
PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE, CODEINE PHOSPHATE
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
SUCRALFATE, SUCRALFATE
THEOPHYLLINE, THEOPHYLLINE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

NOSTRUM PHARMS LLC

* NOSTRUM PHARMACEUTICALS LLC
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

NOVA LABS LTD

* NOVA LABORATORIES LTD
PURIXAN, MERCAPTOPYRINE

NOVADAQ TECH

* NOVADAQ TECHNOLOGIES ULC
SPY AGENT GREEN KIT, INDOCYANINE GREEN

NOVARTIS

* NOVARTIS PHARMACEUTICALS CORP
AFINITOR, EVEROLIMUS
ALOMIDE, LODOXAMIDE TROMETHAMINE
ARGATROBAN, ARGATROBAN
ARRANON, NELARABINE
AZOPT, BRINZOLAMIDE
BETOPTIC S, BETAXOLOL HYDROCHLORIDE
CILOXAN, CIPROFLOXACIN HYDROCHLORIDE
CIPRO HC, CIPROFLOXACIN HYDROCHLORIDE
CIPRODEX, CIPROFLOXACIN
COARTEM, ARTEMETHER
DESFERAL, DEFEROXAMINE MESYLATE
DIOVAN HCT, HYDROCHLOROTHIAZIDE
DIOVAN, VALSARTAN
DUREZOL, DIFLUPREDNATE
EGATEN, TRICLABENDAZOLE
EXELON, RIVASTIGMINE
EXFORGE HCT, AMLODIPINE BESYLATE
EXFORGE, AMLODIPINE BESYLATE
EXJADE, DEFERASIROX
FOCALIN XR, DEXMETHYLPHENIDATE HYDROCHLORIDE
FOCALIN, DEXMETHYLPHENIDATE HYDROCHLORIDE
GILENYA, FINGOLIMOD HYDROCHLORIDE
GLEEVEC, IMATINIB MESYLATE
HYCANTIN, TOPOTECAN HYDROCHLORIDE
ILEVRO, NEPAFENAC
ISOPTO CARPINE, PILOCARPINE HYDROCHLORIDE
JADENU SPRINKLE, DEFERASIROX
KISQALI FEMARA CO-PACK (COPACKAGED), LETROZOLE
KISQALI, RIBOCICLIB SUCCINATE
LEQVIO, INCLISIRAN SODIUM
LESCOL XL, FLUVASTATIN SODIUM
LOTREL, AMLODIPINE BESYLATE
MAXIDEX, DEXAMETHASONE
MAXITROL, DEXAMETHASONE
MAYZENT, SIPONIMOD FUMARIC ACID
MEKINIST, TRAMETINIB DIMETHYL SULFOXIDE
MYFORTIC, MYCOPHENOLIC SODIUM
NEORAL, CYCLOSPORINE
NEVANAC, NEPAFENAC
OMNIPRED, PREDNISOLONE ACETATE
PATANASE, OLOPATADINE HYDROCHLORIDE
PIQRAY, ALPELISIB
PROMACTA KIT, ELTROMBOPAG OLAMINE
PROMACTA, ELTROMBOPAG OLAMINE
RECLAST, ZOLEDRONIC ACID
RITALIN LA, METHYLPHENIDATE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** N ****

* NOVARTIS PHARMACEUTICALS CORP
 RITALIN, METHYLPHENIDATE HYDROCHLORIDE
 RYDAPT, MIDOSTAURIN
 SANDIMMUNE, CYCLOSPORINE
 SANDOSTATIN LAR, OCTREOTIDE ACETATE
 SANDOSTATIN, OCTREOTIDE ACETATE
 SCEMBLIX, ASCIMINIB HYDROCHLORIDE
 TAFINLAR, DABRAFENIB MESYLATE
 TASIGNA, NILOTINIB HYDROCHLORIDE
 TEGRETOL, CARBAMAZEPINE
 TEGRETOL-XR, CARBAMAZEPINE
 TOBRADEX, DEXAMETHASONE
 TOBREX, TOBRAMYCIN
 TRAVATAN Z, TRAVOPROST
 TRIESENCE, TRIAMCINOLONE ACETONIDE
 TRILEPTAL, OXCARBAZEPINE
 TYKERB, LAPATINIB DITOSYLATE
 VIGAMOX, MOXIFLOXACIN HYDROCHLORIDE
 VIJOICE, ALPELISIB
 VIVELLE-DOT, ESTRADIOL
 VOTRIENT, PAZOPANIB HYDROCHLORIDE
 XIIDRA, LIFITEGRAST
 ZOMETA, ZOLEDRONIC ACID
 ZORTRESS, EVEROLIMUS
 ZYKADIA, CERITINIB

NOVARTIS PHARM

* NOVARTIS PHARMACEUTICAL CORP
 AFINITOR DISPERZ, EVEROLIMUS
 TABRECTA, CAPMATINIB HYDROCHLORIDE

NOVARTIS PHARMS

* NOVARTIS PHARMACEUTICALS CORP
 FEMARA, LETROZOLE

NOVARTIS PHARMS CORP

* NOVARTIS PHARMACEUTICALS CORP
 ENTRESTO, SACUBITRIL
 JADENU, DEFERASIROX

NOVAST LABS

* NOVAST LABORATORIES CHINA LTD
 NORETHINDRONE, NORETHINDRONE

* NOVAST LABORATORIES LTD
 ACETAZOLAMIDE, ACETAZOLAMIDE
 BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
 CARBOPLATIN, CARBOPLATIN
 CARISOPRODOL, CARISOPRODOL
 CHABELINA FE, ETHINYL ESTRADIOL
 CHLORTHALIDONE, CHLORTHALIDONE
 CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
 CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
 DECITABINE, DECITABINE
 DESIPRAMINE HYDROCHLORIDE, DESIPRAMINE HYDROCHLORIDE
 DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
 DESOGESTREL AND ETHINYL ESTRADIOL, DESOGESTREL
 DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
 DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
 DOLISHALE, ETHINYL ESTRADIOL
 ESTRADIOL AND NORETHINDRONE ACETATE, ESTRADIOL
 HER STYLE, LEVONORGESTREL (OTC)
 INDOMETHACIN, INDOMETHACIN
 IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
 LARIN 1.5/30, ETHINYL ESTRADIOL
 LARIN 1/20, ETHINYL ESTRADIOL
 LARIN 24 FE, ETHINYL ESTRADIOL
 LARIN FE 1.5/30, ETHINYL ESTRADIOL
 LARIN FE 1/20, ETHINYL ESTRADIOL
 LERIBANE, ETHINYL ESTRADIOL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** N ******* NOVAST LABORATORIES LTD**

LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
 LO-MALMOREDE, ETHINYL ESTRADIOL
 MAFENIDE ACETATE, MAFENIDE ACETATE
 MALMOREDE, ETHINYL ESTRADIOL
 MELAMISA, DROSPIRENONE
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 METHENAMINE HIPPURATE, METHENAMINE HIPPURATE
 METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
 MEXILETINE HYDROCHLORIDE, MEXILETINE HYDROCHLORIDE
 NIFEDIPINE, NIFEDIPINE
 NORETHINDRONE ACETATE, NORETHINDRONE ACETATE
 NORETHINDRONE, NORETHINDRONE
 OXALIPLATIN, OXALIPLATIN
 OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
 PIMTREA, DESOGESTREL
 PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
 PRIMAQUINE PHOSPHATE, PRIMAQUINE PHOSPHATE
 PROBENECID AND COLCHICINE, COLCHICINE
 QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
 QUININE SULFATE, QUININE SULFATE
 SETLAKIN, ETHINYL ESTRADIOL
 TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
 TOLCAPONE, TOLCAPONE
 TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
 TRI-LO-LINYAH, ETHINYL ESTRADIOL
 TRIAZOLAM, TRIAZOLAM
 YAELA, DROSPIRENONE

NOVAST LABS LTD*** NOVAST LABORATORIES LTD**

DASETTA 1/35, ETHINYL ESTRADIOL
 DASETTA 7/7/7, ETHINYL ESTRADIOL
 ELINEST, ETHINYL ESTRADIOL
 FALMINA, ETHINYL ESTRADIOL
 LEVONEST, ETHINYL ESTRADIOL
 MONO-LINYAH, ETHINYL ESTRADIOL
 PHILITH, ETHINYL ESTRADIOL
 TRI-LINYAH, ETHINYL ESTRADIOL
 WERA, ETHINYL ESTRADIOL

NOVATECH SA*** NOVATECH SA**

STERITALC, TALC

NOVEL LABS INC*** NOVEL LABORATORIES INC**

AMLODIPINE BESYLATE AND VALSARTAN, AMLODIPINE BESYLATE
 CALCIPOTRIENE, CALCIPOTRIENE
 CARBIDOPA, CARBIDOPA
 CEVIMELINE HYDROCHLORIDE, CEVIMELINE HYDROCHLORIDE
 CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
 DESOXIMETASONE, DESOXIMETASONE
 DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
 DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
 DICLOFENAC SODIUM, DICLOFENAC SODIUM
 DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
 FAMOTIDINE, FAMOTIDINE
 FLUCYTOSINE, FLUCYTOSINE
 FLUOCINONIDE, FLUOCINONIDE
 HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
 HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE, HOMATROPINE METHYLBROMIDE
 LEVONORGESTREL, LEVONORGESTREL (OTC)
 LINEZOLID, LINEZOLID
 METHYLERGONOVINE MALEATE, METHYLERGONOVINE MALEATE
 METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
 METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** N ******* NOVEL LABORATORIES INC**

MISOPROSTOL, MISOPROSTOL
 MONOBASIC SODIUM PHOSPHATE AND DIBASIC SODIUM PHOSPHATE, SODIUM PHOSPHATE, DIBASIC,
 MORPHINE SULFATE, MORPHINE SULFATE
 MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
 NITROFURANTOIN, NITROFURANTOIN
 NITROFURANTOIN, NITROFURANTOIN, MACROCRYSTALLINE
 OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
 PEG 3350 AND ELECTROLYTES, POLYETHYLENE GLYCOL 3350
 PEG-3350, SODIUM SULFATE, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM ASCORBATE AND
 PHENELZINE SULFATE, PHENELZINE SULFATE
 POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
 SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE, MAGNESIUM SULFATE
 TEMAZEPAM, TEMAZEPAM
 TINIDAZOLE, TINIDAZOLE
 TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
 TRIMETHOPRIM, TRIMETHOPRIM
 VORICONAZOLE, VORICONAZOLE
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

NOVELGENIX THERAPS*** NOVELGENIX THERAPEUTICS PVT LTD**

AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
 NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
 POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)

NOVEN*** NOVEN PHARMACEUTICALS INC**

MINIVELLE, ESTRADIOL

NOVEN PHARMS INC*** NOVEN PHARMACEUTICALS INC**

COMBIPATCH, ESTRADIOL
 DAYTRANA, METHYLPHENIDATE
 XELSTRYM, DEXTROAMPHETAMINE

NOVITIUM PHARMA*** NOVITIUM PHARMA LLC**

ACETAZOLAMIDE, ACETAZOLAMIDE
 ACYCLOVIR, ACYCLOVIR
 ALPRAZOLAM, ALPRAZOLAM
 ATENOLOL AND CHLORTHALIDONE, ATENOLOL
 BETAINE, BETAINE
 BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE, BISOPROLOL FUMARATE
 BISOPROLOL FUMARATE, BISOPROLOL FUMARATE
 CARBAMAZEPINE, CARBAMAZEPINE
 CARGLUMIC ACID, CARGLUMIC ACID
 CHLORZOXAZONE, CHLORZOXAZONE
 CLORAZEPATE DIPOTASSIUM, CLORAZEPATE DIPOTASSIUM
 CLOTRIMAZOLE, CLOTRIMAZOLE
 DAPSONE, DAPSONE
 DEXAMETHASONE, DEXAMETHASONE
 DIAZOXIDE, DIAZOXIDE
 DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
 DIGOXIN, DIGOXIN
 ESTAZOLAM, ESTAZOLAM
 FAMOTIDINE, FAMOTIDINE
 FELBAMATE, FELBAMATE
 FLUDROCORTISONE ACETATE, FLUDROCORTISONE ACETATE
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE
 HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
 LACOSAMIDE, LACOSAMIDE
 LEVOCARNITINE SF, LEVOCARNITINE
 LEVOCARNITINE, LEVOCARNITINE
 LEVORPHANOL TARTRATE, LEVORPHANOL TARTRATE
 LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** N ******* NOVITIUM PHARMA LLC**

MELOXICAM, MELOXICAM
 METHYLTESTOSTERONE, METHYLTESTOSTERONE
 NAPROXEN, NAPROXEN
 NITISINONE, NITISINONE
 OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
 PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
 PHENOXYBENZAMINE HYDROCHLORIDE, PHENOXYBENZAMINE HYDROCHLORIDE
 PRAZOSIN HYDROCHLORIDE, PRAZOSIN HYDROCHLORIDE
 PREDNISONE, PREDNISONE
 PROCHLORPERAZINE MALEATE, PROCHLORPERAZINE MALEATE
 PYRAZINAMIDE, PYRAZINAMIDE
 PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE
 RIFABUTIN, RIFABUTIN
 SELEGILINE HYDROCHLORIDE, SELEGILINE HYDROCHLORIDE
 SILDENAFIL CITRATE, SILDENAFIL CITRATE
 SIROLIMUS, SIROLIMUS
 SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
 THIOTHIXENE, THIOTHIXENE
 TRANLYCYPROMINE SULFATE, TRANLYCYPROMINE SULFATE
 TRIHEXYPHENIDYL HYDROCHLORIDE, TRIHEXYPHENIDYL HYDROCHLORIDE
 TRIMETHOPRIM, TRIMETHOPRIM
 VALSARTAN, VALSARTAN

NOVO*** NOVO NORDISK INC**

MACRILEN, MACIMORELIN ACETATE
 OZEMPIC, SEMAGLUTIDE
 RYBELSUS, SEMAGLUTIDE
 SAXENDA, LIRAGLUTIDE RECOMBINANT
 WEGOVY, SEMAGLUTIDE

NOVO NORDISK

*** NOVO NORDISK PHARMACEUTICALS INC**
 GLUCAGEN, GLUCAGON HYDROCHLORIDE

NOVO NORDISK INC

*** NOVO NORDISK INC**
 VAGIFEM, ESTRADIOL
 VICTOZA, LIRAGLUTIDE RECOMBINANT

NOVOCOL INC

*** NOVOCOL INC**
 DYCLOPRO, DYCLONINE HYDROCHLORIDE

NOVUGEN

*** NOVUGEN ONCOLOGY SDN BHD**
 ABIRATERONE ACETATE, ABIRATERONE ACETATE

NUKEMED

*** NUKEMED INC DBA SPECTRONRX**
 AMMONIA N 13, AMMONIA N-13
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
 SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

NUVO PHARM

*** NUVO PHARMACEUTICAL INC**
 DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
 DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
 PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE

NUVO PHARMS INC

*** NUVO PHARMACEUTICALS INC**
 BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
 CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDE, CHLORDIAZEPOXIDE HYDROCHLORIDE
 FOLIC ACID, FOLIC ACID
 HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
 NAPROXEN, NAPROXEN
 POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
 SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE
 SULFASALAZINE, SULFASALAZINE

NXDC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** N ****

* NX DEVELOPMENT CORP
GLEOLAN, AMINOLEVULINIC ACID HYDROCHLORIDE

**** O ******OCULAR THERAPEUTIX**

* OCULAR THERAPEUTIX INC
DEXTENZA, DEXAMETHASONE

OHM

* OHM CORP
IBUPROFEN, IBUPROFEN (OTC)

OHM LABS

* OHM LABORATORIES INC
ACETAMINOPHEN, ACETAMINOPHEN (OTC)
IBUPROHM COLD AND SINUS, IBUPROFEN (OTC)
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)

OHM LABS INC

* OHM LABORATORIES INC
EZETIMIBE, EZETIMIBE
GUAIFENESIN, GUAIFENESIN (OTC)
VALSARTAN, VALSARTAN

ON TARGET LABS

* ON TARGET LABORATORIES INC
CYTALUX, PAFOLACIANINE SODIUM

ONYX THERAP

* ONYX THERAPEUTICS INC A WHOLLY OWNED SUB OF AMGEN INC
KYPROLIS, CARFILZOMIB

OPTIMUS

* OPTIMUS PHARMA PRIVATE LTD
AMINOCAPROIC ACID, AMINOCAPROIC ACID

OPTINOSE US INC

* OPTINOSE US INC
XHANCE, FLUTICASONE PROPIONATE

ORAPHARMA

* ORAPHARMA INC
ARESTIN, MINOCYCLINE HYDROCHLORIDE

ORBION PHARMS

* ORBION PHARMACEUTICALS PRIVATE LTD
AMLODIPINE BESYLATE, AMLDIPINE BESYLATE
ARIPIPRAZOLE, ARIPIPRAZOLE
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
DESLORATADINE, DESLORATADINE
DIVALPROEX SODIUM, DIVALPROEX SODIUM
ESZOPICLONE, ESZOPICLONE
FELODIPINE, FELODIPINE
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
IBANDRONATE SODIUM, IBANDRONATE SODIUM
LEVETIRACETAM, LEVETIRACETAM
LEVOFLOXACIN, LEVOFLOXACIN
MODAFINIL, MODAFINIL
NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE
OLANZAPINE, OLANZAPINE
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
RASAGILINE MESYLATE, RASAGILINE MESYLATE
RISEDRONATE SODIUM, RISEDRONATE SODIUM
RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
ZALEPLON, ZALEPLON
ZOLMITRIPTAN, ZOLMITRIPTAN

ORCHID HLTHCARE

* ORCHID HEALTHCARE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** 0 ****

* ORCHID HEALTHCARE
CEFDINIR, CEFdinir
CEFPodoxime Proxetil, Cefpodoxime Proxetil
CEfuroxime Axetil, Cefuroxime Axetil
CEPHalexin, Cephalixin

OREXO US INC

* OREXO US INC
ZUBSOLV, BUPRENORPHINE HYDROCHLORIDE

ORGANON

* ORGANON LLC A SUB OF ORGANON AND CO
CELESTONE SOLUSPAN, BETAMETHASONE ACETATE
CLARINEX, DESLORATADINE
COZAAR, LOSARTAN POTASSIUM
DIPROLENE, BETAMETHASONE DIPROPIONATE
ELOCON, MOMETASONE FUROATE
FOSAMAX, ALENDRONATE SODIUM
HYZAAR, HYDROCHLOROTHIAZIDE
LOTRISONE, BETAMETHASONE DIPROPIONATE
MAXALT-MLT, RIZATRIPTAN BENZOATE
PROPECIA, FINASTERIDE
PROSCAR, FINASTERIDE
SINEMET, CARBIDOPA
SINGULAIR, MONTELUKAST SODIUM
VYTORIN, EZETIMIBE
ZETIA, EZETIMIBE
ZOCOR, SIMVASTATIN

* ORGANON USA LLC
NEXPLANON, ETNOGESTREL

ORGANON LLC

* ORGANON LLC
ASMANEX HFA, MOMETASONE FUROATE
ASMANEX TWISTHALER, MOMETASONE FUROATE
CLARINEX-D 12 HOUR, DESLORATADINE
DULERA, FORMOTEROL FUMARATE
FOSAMAX PLUS D, ALENDRONATE SODIUM
MAXALT, RIZATRIPTAN BENZOATE

ORGANON SUB MERCK

* ORGANON USA INC A SUB OF MERCK AND CO INC
BRIDION, SUGAMMADEX SODIUM

ORGANON USA INC

* ORGANON USA INC
GANIRELIX ACETATE, GANIRELIX ACETATE
REMERON SOLTAB, MIRTAZAPINE
REMERON, MIRTAZAPINE

ORGANON USA ORGANON

* ORGANON USA LLC A SUB OF ORGANON AND CO
NUVARING, ETHINYL ESTRADIOL

ORIENT PHARMA

* ORIENT PHARMA CO LTD
EZETIMIBE, EZETIMIBE

ORIENT PHARMA CO LTD

* ORIENT PHARMA CO LTD
CARISOPRODOL, CARISOPRODOL
GLYBURIDE, GLYBURIDE
PITAVASTATIN CALCIUM, PITAVASTATIN CALCIUM
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE

ORION PHARMA

* ORION PHARMA
COMTAN, ENTACAPONE
STALEVO 100, CARBIDOPA
STALEVO 125, CARBIDOPA
STALEVO 150, CARBIDOPA
STALEVO 200, CARBIDOPA
STALEVO 50, CARBIDOPA
STALEVO 75, CARBIDOPA

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** 0 ******ORPHALAN**

- * ORPHALAN SA
CUVRIOR, TRIENTINE TETRAHYDROCHLORIDE

OSI PHARMS

- * OSI PHARMACEUTICALS LLC
TARCEVA, ERLOTINIB HYDROCHLORIDE

OSMOTICA

- * OSMOTICA KERESKEDELMI ES SZOLGALTATO KFT
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE

OSMOTICA PHARM

- * OSMOTICA PHARMACEUTICAL CORP
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

OSMOTICA PHARM US

- * OSMOTICA PHARMACEUTICAL US LLC
HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
NIFEDIPINE, NIFEDIPINE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
RELEXXII, METHYLPHENIDATE HYDROCHLORIDE

OTSUKA

- * OTSUKA PHARMACEUTICAL CO LTD
ABILIFY MYCITE KIT, ARIPIPRAZOLE
ABILIFY, ARIPIPRAZOLE
INQOVI, CEDAZURIDINE
JYNARQUE, TOLVAPTAN
REXULTI, BREXPIPRAZOLE
SAMSCA, TOLVAPTAN

OTSUKA PHARM

- * OTSUKA PHARMACEUTICAL CO LTD
BUSULFEX, BUSULFAN

OTSUKA PHARM CO LTD

- * OTSUKA PHARMACEUTICAL CO LTD
ABILIFY MAINTENA KIT, ARIPIPRAZOLE

OTTER PHARMS

- * OTTER PHARMACEUTICALS LLC
OTREXUP, METHOTREXATE
SYMPAZAN, CLOBAZAM

OUTLOOK PHARMS

- * OUTLOOK PHARMACEUTICALS INC
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE

OVERSEAS

- * OVERSEAS PHARMACEUTICALS LTD
LEVETIRACETAM, LEVETIRACETAM

OXFORD PHARMS

- * OXFORD PHARMACEUTICALS LLC
AMLODIPINE BESYLATE, AMLDIPINE BESYLATE
BACLOFEN, BACLOFEN
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
CARISOPRODOL, CARISOPRODOL
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
DIPYRIDAMOLE, DIPYRIDAMOLE
GLYCOPYRROLATE, GLYCOPYRROLATE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IMIPRAMINE HYDROCHLORIDE, IMIPRAMINE HYDROCHLORIDE
LEVETIRACETAM, LEVETIRACETAM
LORAZEPAM, LORAZEPAM
METHOCARBAMOL, METHOCARBAMOL
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
PRIMIDONE, PRIMIDONE
RIMACTANE, RIFAMPIN
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
SIMVASTATIN, SIMVASTATIN
SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE
SPIRONOLACTONE, SPIRONOLACTONE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** O ****

- * OXFORD PHARMACEUTICALS LLC
 - TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
 - TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE

OYSTER POINT PHARMA

- * OYSTER POINT PHARMA INC
 - TYRVAYA, VARENICLINE TARTRATE

**** P ******P AND L**

- * P AND L DEVELOPMENT LLC
 - ADAPALENE, ADAPALENE (OTC)
 - CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
 - CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
 - CLOTRIMAZOLE, CLOTRIMAZOLE (OTC)
 - DOCOSANOL, DOCOSANOL (OTC)
 - FAMOTIDINE, FAMOTIDINE (OTC)
 - IBUPROFEN, IBUPROFEN (OTC)
 - LORATADINE AND PSEUDOEPHEDRINE SULFATE, LORATADINE (OTC)
 - M-ZOLE 3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
 - MICONAZOLE 7, MICONAZOLE NITRATE (OTC)
 - MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)
 - MINOXIDIL (FOR MEN), MINOXIDIL (OTC)
 - MINOXIDIL (FOR WOMEN), MINOXIDIL (OTC)
 - MINOXIDIL EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
 - NICOTINE POLACRILEX, NICOTINE POLACRILEX (OTC)
 - OMEPRazole MAGNESIUM, OMEPRazole MAGNESIUM (OTC)

P AND L DEV LLC

- * P AND L DEVELOPMENT LLC DBA PLD DEVELOPMENTS LLC
 - IBUPROFEN, IBUPROFEN (OTC)

PACIFIC PHARMA

- * PACIFIC PHARMA
 - TIMOLOL MALEATE, TIMOLOL MALEATE
- * PACIFIC PHARMA INC
 - TIMOLOL MALEATE, TIMOLOL MALEATE

PACIRA PHARMS INC

- * PACIRA PHARMACEUTICALS INC
 - EXPAREL, BUPIVACAINE
 - ZILRETTA, TRIAMCINOLONE ACETONIDE

PADAGIS ISRAEL

- * PADAGIS ISRAEL PHARMACEUTICALS LTD
 - ACYCLOVIR, ACYCLOVIR
 - ADAPALENE AND BENZOYL PEROXIDE, ADAPALENE
 - AMMONIUM LACTATE, AMMONIUM LACTATE
 - AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE, AZELASTINE HYDROCHLORIDE
 - AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
 - BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
 - BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
 - BRIMONIDINE TARTRATE, BRIMONIDINE TARTRATE
 - CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
 - CALCIPOTRIENE AND BETHAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
 - CICLOPIROX, CICLOPIROX
 - CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
 - CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
 - CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
 - DESOXIMETASONE, DESOXIMETASONE
 - DICLOFENAC SODIUM, DICLOFENAC SODIUM
 - ECONAZOLE NITRATE, ECONAZOLE NITRATE
 - ESTRADIOL, ESTRADIOL
 - FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
 - FLUOCINONIDE, FLUOCINONIDE
 - FLURANDRENOLIDE, FLURANDRENOLIDE
 - FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
 - GYNAZOLE-1, BUTOCONAZOLE NITRATE
 - HALOBETASOL PROPIONATE, HALOBETASOL PROPIONATE
 - HYDROCORTISONE VALERATE, HYDROCORTISONE VALERATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** P ****

* PADAGIS ISRAEL PHARMACEUTICALS LTD
 IMIQUIMOD, IMIQUIMOD
 KETOCONAZOLE, KETOCONAZOLE
 MESALAMINE, MESALAMINE
 METRONIDAZOLE, METRONIDAZOLE
 MOMETASONE FUROATE, MOMETASONE FUROATE
 MUPIROCIN, MUPIROCIN
 MUPIROCIN, MUPIROCIN CALCIUM
 NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
 NITROGLYCERIN, NITROGLYCERIN
 NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
 OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE
 PERMETHRIN, PERMETHRIN
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
 SUMATRIPTAN, SUMATRIPTAN
 TERCONAZOLE, TERCONAZOLE
 TESTOSTERONE, TESTOSTERONE
 TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
 ZOLMITRIPTAN, ZOLMITRIPTAN

PADAGIS US

* PADAGIS US LLC
 BACITRACIN ZINC AND POLYMYXIN B SULFATE, BACITRACIN ZINC
 BACITRACIN, BACITRACIN
 BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE, BACITRACIN ZINC
 BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
 BROMOCRIPTINE MESYLATE, BROMOCRIPTINE MESYLATE
 BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN
 CALCIUM ACETATE, CALCIUM ACETATE
 CENTANY, MUPIROCIN
 CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
 CICLOPIROX, CICLOPIROX
 CLINDA-DERM, CLINDAMYCIN PHOSPHATE
 CLINDAMYCIN PALMITATE HYDROCHLORIDE, CLINDAMYCIN PALMITATE HYDROCHLORIDE
 CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
 CLINDESSE, CLINDAMYCIN PHOSPHATE
 CLINDETS, CLINDAMYCIN PHOSPHATE
 CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
 CLOTRIMAZOLE, CLOTRIMAZOLE
 COMPRO, PROCHLORPERAZINE
 CYCLOSPORINE, CYCLOSPORINE
 DESONIDE, DESONIDE
 DESOXIMETASONE, DESOXIMETASONE
 DIHYDROERGOTAMINE MESYLATE, DIHYDROERGOTAMINE MESYLATE
 ENTOCORT EC, BUDESONIDE
 ERYTHROMYCIN, ERYTHROMYCIN
 EVAMIST, ESTRADIOL
 FLAVOXATE HYDROCHLORIDE, FLAVOXATE HYDROCHLORIDE
 GENTAMICIN SULFATE, GENTAMICIN SULFATE
 HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE, HOMATROPINE METHYLBROMIDE
 HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE,
 HYDROCORTISONE, HYDROCORTISONE
 HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
 IBUPROFEN, IBUPROFEN
 LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
 LIDOCAINE AND PRILOCAINE, LIDOCAINE
 MIDAMOR, AMILORIDE HYDROCHLORIDE
 MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
 MOMETASONE FUROATE, MOMETASONE FUROATE
 MORPHINE SULFATE, MORPHINE SULFATE
 NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE
 NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC, BACITRACIN ZINC
 NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE, DEXAMETHASONE
 NYSTATIN, NYSTATIN
 NYSTOP, NYSTATIN
 PILOCARPINE HYDROCHLORIDE, PILOCARPINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** P ****

* PADAGIS US LLC
 PODOFILOX, PODOFILOX
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
 REPAGLINIDE, REPAGLINIDE
 SCOPOLAMINE, SCOPOLAMINE
 SELENIUM SULFIDE, SELENIUM SULFIDE
 STIE-CORT, HYDROCORTISONE
 SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM
 TAVABOROLE, TAVABOROLE
 TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
 TOBRAMYCIN AND DEXAMETHASONE, DEXAMETHASONE
 TRETINOIN, TRETINOIN
 TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
 TROSPIMUM CHLORIDE, TROSPIMUM CHLORIDE

PAI HOLDINGS PHARM

* PAI HOLDINGS LLC DBA PHARMACEUTICAL ASSOCIATES INC
 BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
 CEFOTAN, CEFOTETAN DISODIUM
 CICLOPIROX, CICLOPIROX
 CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
 CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
 CLOBETASOL PROPIONATE (EMOLLIENT), CLOBETASOL PROPIONATE
 CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
 DESONIDE, DESONIDE
 DESOXIMETASONE, DESOXIMETASONE
 DEXCHLORPHENIRAMINE MALEATE, DEXCHLORPHENIRAMINE MALEATE
 DICLOFENAC SODIUM, DICLOFENAC SODIUM
 ECONAZOLE NITRATE, ECONAZOLE NITRATE
 ERYTHROMYCIN, ERYTHROMYCIN
 FLUOCINONIDE, FLUOCINONIDE
 FORTAZ, CEFTAZIDIME
 GENTAMICIN SULFATE, GENTAMICIN SULFATE
 HALOBETASOL PROPIONATE, HALOBETASOL PROPIONATE
 LIDOCAINE AND PRILOCAINE, LIDOCAINE
 LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
 LIDOCAINE, LIDOCAINE
 LITHIUM CITRATE, LITHIUM CITRATE
 NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
 PHENYTOIN, PHENYTOIN
 TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
 ZANTAC, RANITIDINE HYDROCHLORIDE
 ZINACEF, CEFUROXIME SODIUM

PALATIN TECHNOLOGIES

* PALATIN TECHNOLOGIES INC
 VYLEESI (AUTOINJECTOR), BREMELANOTIDE ACETATE

PANACEA

* PANACEA BIOTEC PHARMA LTD
 PRASUGREL, PRASUGREL HYDROCHLORIDE
 RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
 TACROLIMUS, TACROLIMUS

PAR FORM

* PAR FORMULATIONS PRIVATE LTD
 DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

PAR PHARM

* PAR PHARMACEUTICAL
 EVEROLIMUS, EVEROLIMUS
 * PAR PHARMACEUTICAL INC
 ALPRAZOLAM, ALPRAZOLAM
 AMILORIDE HYDROCHLORIDE, AMILORIDE HYDROCHLORIDE
 CHOLESTYRAMINE LIGHT, CHOLESTYRAMINE
 CHOLESTYRAMINE, CHOLESTYRAMINE
 CLONAZEPAM, CLONAZEPAM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** P ******* PAR PHARMACEUTICAL INC**

DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
 DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
 GLYCOPYRROLATE, GLYCOPYRROLATE
 HYDROXYUREA, HYDROXYUREA
 ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE
 LAMOTRIGINE, LAMOTRIGINE
 MINOXIDIL, MINOXIDIL
 OLANZAPINE AND FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 OXANDROLONE, OXANDROLONE
 PIMOZIDE, PIMOZIDE
 QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
 RISPERIDONE, RISPERIDONE
 SODIUM PHENYLBUTYRATE, SODIUM PHENYLBUTYRATE
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
 URSODIOL, URSODIOL

PAR PHARM INC*** PAR PHARMACEUTICAL INC**

AMBRISENTAN, AMBRISENTAN
 ASPIRIN AND DIPYRIDAMOLE, ASPIRIN
 BOSENTAN, BOSENTAN
 CHLORZOXAZONE, CHLORZOXAZONE
 COLCHICINE, COLCHICINE
 DEXLANSOPRAZOLE, DEXLANSOPRAZOLE
 DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
 DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE, DOXYLAMINE SUCCINATE
 ETHACRYNIC ACID, ETHACRYNIC ACID
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 GLYCOPYRROLATE, GLYCOPYRROLATE
 ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE
 ITRACONAZOLE, ITRACONAZOLE
 MIDODRINE HYDROCHLORIDE, MIDODRINE HYDROCHLORIDE
 OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE, AMLODIPINE BESYLATE
 PENICILLAMINE, PENICILLAMINE
 PHENOXYBENZAMINE HYDROCHLORIDE, PHENOXYBENZAMINE HYDROCHLORIDE
 PRAZIQUANTEL, PRAZIQUANTEL
 SAPROTERIN DIHYDROCHLORIDE, SAPROTERIN DIHYDROCHLORIDE
 TIOPRONIN, TIOPRONIN
 TOLCAPONE, TOLCAPONE
 TOLVAPTAN, TOLVAPTAN
 TRIENTINE HYDROCHLORIDE, TRIENTINE HYDROCHLORIDE
 VARENICLINE TARTRATE, VARENICLINE TARTRATE
 VIGABATRIN, VIGABATRIN
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

PAR STERILE PRODUCTS*** PAR STERILE PRODUCTS LLC**

ADRENALIN, EPINEPHRINE
 ARGATROBAN, ARGATROBAN
 BREVITAL SODIUM, METHOHEXITAL SODIUM
 BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
 CALCITONIN-SALMON, CALCITONIN SALMON
 COLY-MYCIN M, COLISTIMETHATE SODIUM
 CORPHEDRA, EPHEDRINE SULFATE
 DANTRIUM, DANTROLENE SODIUM
 DELESTROGEN, ESTRADIOL VALERATE
 DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
 DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
 ETHACRYNATE SODIUM, ETHACRYNATE SODIUM
 FLUPHENAZINE DECANOATE, FLUPHENAZINE DECANOATE
 GANCICLOVIR SODIUM, GANCICLOVIR SODIUM
 KETALAR, KETAMINE HYDROCHLORIDE
 METHYLPREDNISOLONE ACETATE, METHYLPREDNISOLONE ACETATE
 MICA FUNGIN, MICA FUNGIN SODIUM
 MYCOPHENOLATE MOFETIL HYDROCHLORIDE, MYCOPHENOLATE MOFETIL HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** P ******* PAR STERILE PRODUCTS LLC**

NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
 NEOSTIGMINE METHYLSULFATE, NEOSTIGMINE METHYLSULFATE
 PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
 PITOCIN, OXYTOCIN
 POSACONAZOLE, POSACONAZOLE
 TIGAN, TRIMETHOBENZAMIDE HYDROCHLORIDE
 TREPROSTINIL, TREPROSTINIL
 TRIOSTAT, LIOTHYRONINE SODIUM
 VASOSTRICT, VASOPRESSIN

PARAGON BIOTECK*** PARAGON BIOTECK INC**

PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE

PARAPRO LLC*** PARAPRO LLC**

NATROBA, SPINOSAD

PARATEK PHARMS INC*** PARATEK PHARMACEUTICALS INC**

NUZYRA, OMADACYCLINE TOSYLATE

PARKE DAVIS*** PARKE DAVIS DIV WARNER LAMBERT CO**

CELONTIN, METHSUXIMIDE
 CEREBYX, FOSPHENYTOIN SODIUM
 NARDIL, PHENELZINE SULFATE
 ZARONTIN, ETHOSUXIMIDE

PARKE-DAVIS*** PARKE-DAVIS DIVISION OF PFIZER INC**

ZARONTIN, ETHOSUXIMIDE

PATHEON SOFTGELS*** PATHEON SOFTGELS BV**

NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)

PERRIGO NEW YORK*** PERRIGO NEW YORK INC**

ACETAMINOPHEN, ACETAMINOPHEN (OTC)
 PERMETHRIN, PERMETHRIN (OTC)

PERRIGO PHARMA INTL*** PERRIGO PHARMA INTERNATIONAL DAC**

DICLOFENAC SODIUM, DICLOFENAC SODIUM (OTC)
 LORATADINE AND PSEUDOEPHEDRINE SULFATE, LORATADINE (OTC)
 LORATADINE, LORATADINE (OTC)
 MINOXIDIL, MINOXIDIL (OTC)
 NASONEX 24HR ALLERGY, MOMETASONE FUROATE (OTC)
 TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE (OTC)

*** PERRIGO PHARMA INTERNATIONAL DESIGNATED ACTIVITY CO**

LORATADINE, LORATADINE (OTC)
 PREVACID 24 HR, LANSOPRAZOLE (OTC)

PERRIGO R AND D*** PERRIGO R AND D CO**

CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
 CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
 CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
 ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM (OTC)
 FAMOTIDINE, CALCIUM CARBONATE, AND MAGNESIUM HYDROXIDE, CALCIUM CARBONATE (OTC)
 FAMOTIDINE, FAMOTIDINE (OTC)
 GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE, DEXTROMETHORPHAN HYDROBROMIDE (OTC)
 GUAIFENESIN, GUAIFENESIN (OTC)
 IBUPROFEN AND DIPHENHYDRAMINE CITRATE, DIPHENHYDRAMINE CITRATE (OTC)
 IBUPROFEN AND PHENYLEPHRINE HYDROCHLORIDE, IBUPROFEN (OTC)
 IBUPROFEN, IBUPROFEN (OTC)
 LANSOPRAZOLE, LANSOPRAZOLE (OTC)
 LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE (OTC)
 LEVONORGESTREL, LEVONORGESTREL (OTC)
 LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE, LOPERAMIDE HYDROCHLORIDE (OTC)

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** P ****

- * PERRIGO R AND D CO
 - LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)
 - MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)
 - NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE
 - NICOTINE POLACRILEX, NICOTINE POLACRILEX (OTC)
 - OMEPRazole AND SODIUM BICARBONATE, OMEPRazole (OTC)
 - POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)

PETNET

- * PETNET SOLUTIONS INC
 - AMMONIA N 13, AMMONIA N-13
 - FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
 - SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

PF PRISM CV

- * PF PRISM CV
 - BOSULIF, BOSUTINIB MONOHYDRATE
 - INLYTA, AXITINIB
 - PRISTIQ, DESVENLAFAXINE SUCCINATE
 - RAPAMUNE, SIROLIMUS
 - TORISEL, TEMSIROLIMUS
 - TYGACIL, TIGECYCLINE
 - VFEND, VORICONAZOLE
 - XALKORI, CRIZOTINIB
 - XELJANZ, TOFACITINIB CITRATE

PFIZER

- * PFIZER CENTRAL RESEARCH
 - DIFLUCAN, FLUCONAZOLE
 - ZITHROMAX, AZITHROMYCIN
- * PFIZER CHEMICALS DIV PFIZER INC
 - DIFLUCAN, FLUCONAZOLE
 - ZITHROMAX, AZITHROMYCIN
- * PFIZER INC
 - ALDACTAZIDE, HYDROCHLOROTHIAZIDE
 - ALDACTONE, SPIRONOLACTONE
 - AROMASIN, EXEMESTANE
 - ARTHROTEC, DICLOFENAC SODIUM
 - AZULFIDINE EN-TABS, SULFASALAZINE
 - AZULFIDINE, SULFASALAZINE
 - CALAN SR, VERAPAMIL HYDROCHLORIDE
 - CAVERJECT IMPULSE, ALPROSTADIL
 - CAVERJECT, ALPROSTADIL
 - CIBINQO, ABROCITINIB
 - CLEOCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
 - CLEOCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
 - CLEOCIN T, CLINDAMYCIN PHOSPHATE
 - CLEOCIN, CLINDAMYCIN PALMITATE HYDROCHLORIDE
 - CLEOCIN, CLINDAMYCIN PHOSPHATE
 - COLESTID, COLESTIPOL HYDROCHLORIDE
 - CORVERT, IBUTILIDE FUMARATE
 - CYKLOKAPRON, TRANEXAMIC ACID
 - CYTOTEC, MISOPROSTOL
 - DAURISMO, GLASDEGIB MALEATE
 - DAYPRO, OXAPROZIN
 - DEPO-ESTRADIOL, ESTRADIOL CYPIONATE
 - DEPO-MEDROL, METHYLPREDNISOLONE ACETATE
 - DEPO-PROVERA, MEDROXYPROGESTERONE ACETATE
 - DEPO-SUBQ PROVERA 104, MEDROXYPROGESTERONE ACETATE
 - DEPO-TESTOSTERONE, TESTOSTERONE CYPIONATE
 - DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
 - ESTRING, ESTRADIOL
 - FLAGYL, METRONIDAZOLE
 - FLAVORED COLESTID, COLESTIPOL HYDROCHLORIDE
 - FRAGMIN, DALTEPARIN SODIUM
 - GLUCOTROL XL, GLIPIZIDE
 - GLYNASE, GLYBURIDE
 - GLYSET, MIGLITOL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** P ****

* PFIZER INC
 HALCION, TRIAZOLAM
 HEMABATE, CARBOPROST TROMETHAMINE
 HEPARIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM
 HEPARIN SODIUM, HEPARIN SODIUM
 IBRANCE, PALBOCICLIB
 IDAMYCIN PFS, IDARUBICIN HYDROCHLORIDE
 LINCOCIN, LINCOMYCIN HYDROCHLORIDE
 LOMOTIL, ATROPINE SULFATE
 LORBRENA, LORLATINIB
 MEDROL, METHYLPREDNISOLONE
 MERREM, MEROPENEM
 MYCOBUTIN, RIFABUTIN
 NICOTROL, NICOTINE
 NORPACE CR, DISOPYRAMIDE PHOSPHATE
 NORPACE, DISOPYRAMIDE PHOSPHATE
 OGEN 5, ESTROPIRATE
 PREPIDIL, DINOPROSTONE
 PROCARDIA, NIFEDIPINE
 PROSTIN VR PEDIATRIC, ALPROSTADIL
 PROVERA, MEDROXYPROGESTERONE ACETATE
 SONATA, ZALEPLON
 SYNAREL, NAFARELIN ACETATE
 TALZENNA, TALAZOPARIB TOSYLATE
 TESSALON, BENZONATATE
 TOVIAZ, FESOTERODINE FUMARATE
 UNASYN, AMPICILLIN SODIUM
 VIZIMPRO, DACOMITINIB
 XELJANZ XR, TOFACITINIB CITRATE
 XELJANZ, TOFACITINIB CITRATE
 ZITHROMAX, AZITHROMYCIN
 ZYVOX, LINEZOLID

* PFIZER LABORATORIES DIV PFIZER INC
 FELDENE, PIROXICAM
 MINIPRESS, PRAZOSIN HYDROCHLORIDE
 PFIZERPEN, PENICILLIN G POTASSIUM
 PROCARDIA XL, NIFEDIPINE
 UNASYN, AMPICILLIN SODIUM
 VIBRAMYCIN, DOXYCYCLINE
 VIBRAMYCIN, DOXYCYCLINE CALCIUM
 VIBRAMYCIN, DOXYCYCLINE HYCLATE
 VISTARIL, HYDROXYZINE PAMOATE

* PFIZER PHARMACEUTICALS PRODUCTION CORP LTD
 TIKOSYN, DOFETILIDE

PFIZER INC

* PFIZER INC
 CAMPTOSAR, IRINOTECAN HYDROCHLORIDE
 ELLENCE, EPIRUBICIN HYDROCHLORIDE
 NICOTROL, NICOTINE

PFIZER PHARMS

* PFIZER PHARMACEUTICALS LTD
 LOPID, GEMFIBROZIL

PHARM ASSOC

* PHARMACEUTICAL ASSOC INC
 CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
 HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
 LORAZEPAM, LORAZEPAM
 PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE

* PHARMACEUTICAL ASSOCIATES INC
 ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
 AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
 BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN
 CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE
 CIMETIDINE HYDROCHLORIDE, CIMETIDINE HYDROCHLORIDE
 DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** P ****

* PHARMACEUTICAL ASSOCIATES INC
 ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
 ETHOSUXIMIDE, ETHOSUXIMIDE
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE
 HALOPERIDOL, HALOPERIDOL LACTATE
 HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
 LACTULOSE, LACTULOSE
 LEVETIRACETAM, LEVETIRACETAM
 METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
 MORPHINE SULFATE, MORPHINE SULFATE
 NORTRIPTYLINE HYDROCHLORIDE, NORTRIPTYLINE HYDROCHLORIDE
 NYSTATIN, NYSTATIN
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
 PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
 PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
 PREDNISOLONE, PREDNISOLONE
 PROMETH HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE, CODEINE
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
 PROMETHAZINE WITH CODEINE, CODEINE PHOSPHATE
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
 RISPERIDONE, RISPERIDONE
 SULFATRIM PEDIATRIC, SULFAMETHOXAZOLE
 THEOPHYLLINE, THEOPHYLLINE
 TRIHEXYPHENIDYL HYDROCHLORIDE, TRIHEXYPHENIDYL HYDROCHLORIDE
 VALPROIC ACID, VALPROIC ACID
 VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE

PHARM SOURCING

* PHARMACEUTICAL SOURCING PARTNERS INC
 MESALAMINE, MESALAMINE

PHARMA RES SOFTWARE

* PHARMA RESEARCH SOFTWARE SOLUTION LLC
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE

PHARMACHEMIE BV

* PHARMACHEMIE BV
 CARBOPLATIN, CARBOPLATIN
 CISPLATIN, CISPLATIN
 DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
 METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM

PHARMACIA

* PHARMACIA AND UPJOHN CO LLC
 CADUET, AMLODIPINE BESYLATE
 DILANTIN, PHENYTOIN

PHARMACIA AND UPJOHN

* PHARMACIA AND UPJOHN CO
 CORTEF, HYDROCORTISONE
 EMCYT, ESTRAMUSTINE PHOSPHATE SODIUM
 R-GENE 10, ARGININE HYDROCHLORIDE
 SOLU-CORTEF, HYDROCORTISONE SODIUM SUCCINATE
 SOLU-MEDROL, METHYLPREDNISOLONE SODIUM SUCCINATE

PHARMACOSMOS AS

* PHARMACOSMOS AS
 MONOFERRIC, FERRIC DERISOMALTOSE

PHARMACYCLICS INC

* PHARMACYCLICS INC
 IMBRUVICA, IBRUTINIB

PHARMADAX INC

* PHARMADAX INC
 ENTECAVIR, ENTECAVIR
 LEVETIRACETAM, LEVETIRACETAM
 METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
 NIFEDIPINE, NIFEDIPINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** P ****

* PHARMADAX INC
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE

PHARMALOGIC HLDGS

* PHARMALOGIC HOLDINGS CORP
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

PHARMASCIENCE INC

* PHARMASCIENCE INC
BORTEZOMIB, BORTEZOMIB
BUSULFAN, BUSULFAN
DECITABINE, DECITABINE
GANCICLOVIR SODIUM, GANCICLOVIR SODIUM

PHARMAXIS LTD

* PHARMAXIS LTD
ARIDOL KIT, MANNITOL

PHARMGEN

* PHARMGEN LLC
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE

PHOTOCURE ASA

* PHOTOCURE ASA
CYSVIEW KIT, HEXAMINOLEVULINATE HYDROCHLORIDE

PIERRE FABRE DERMA

* PIERRE FABRE DERMATOLOGIE
HEMANGEOL, PROPRANOLOL HYDROCHLORIDE

PIERREL

* PIERREL S.P.A.
ORABLOC, ARTICAIN HYDROCHLORIDE

PINNACLE BIOLOGS

* PINNACLE BIOLOGICS INC
PHOTOFRIN, PORFIMER SODIUM

PIRAMAL CRITICAL

* PIRAMAL CRITICAL CARE INC
CISATRACURIUM BESYLATE, CISATRACURIUM BESYLATE
GABLOFEN, BACLOFEN
GLYCOPYRROLATE, GLYCOPYRROLATE
ISOFLURANE, ISOFLURANE
MITIGO, MORPHINE SULFATE
OXACILLIN SODIUM, OXACILLIN SODIUM
ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
SOJOURN, SEVOFLURANE
* PIRAMAL CRITICAL CARE LTD
LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM

PIRAMAL HLTHCARE UK

* PIRAMAL HEALTHCARE UK LTD
CINACALCET HYDROCHLORIDE, CINACALCET HYDROCHLORIDE
CLOBAZAM, CLOBAZAM
DEFERASIROX, DEFERASIROX
EPLERENONE, EPLERENONE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
TETRABENAZINE, TETRABENAZINE

PIRAMAL PHARMA

* PIRAMAL PHARMA LTD
ISOFLURANE, ISOFLURANE

PLD ACQUISITIONS

* PLD ACQUISITIONS LLC DBA AVEMA PHARMA SOLUTIONS
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
NICOTINE POLACRILEX, NICOTINE POLACRILEX (OTC)

PLD ACQUISITIONS LLC

* PLD ACQUISITIONS LLC
LORATADINE, LORATADINE (OTC)
ZOLMITRIPTAN, ZOLMITRIPTAN

PLIVA

* PLIVA INC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** P ******* PLIVA INC**

AZITHROMYCIN, AZITHROMYCIN
 BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
 CIMETIDINE, CIMETIDINE
 DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
 HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
 HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
 METRONIDAZOLE, METRONIDAZOLE
 TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
 TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
 WARFARIN SODIUM, WARFARIN SODIUM

PLIVA PHARM IND

*** PLIVA PHARMACEUTICAL INDUSTRY INC**
 TORSEMIDE, TORSEMIDE

PLX PHARMA

*** PLX PHARMA INC**
 VAZALORE, ASPIRIN (OTC)

POHL BOSKAMP

*** POHL BOSKAMP**
 NITROLINGUAL PUMPSPRAY, NITROGLYCERIN

POLYGEN PHARMS

*** POLYGEN PHARMACEUTICALS INC**
 AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
 CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
 DARIFENACIN HYDROBROMIDE, DARIFENACIN HYDROBROMIDE
 MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE

POWDER PHARMS

*** POWDER PHARMACEUTICALS INC**
 ZINGO, LIDOCAINE HYDROCHLORIDE

PRASCO

*** PRASCO LLC DBA PRASCO LABORATORIES**
 DEXAMETHASONE, DEXAMETHASONE
 EPLERENONE, EPLERENONE
 FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE
 SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE

PRASCO LABS LLC

*** PRASCO LABORATORIES LLC**
 ESTRADIOL, ESTRADIOL

PRAXGEN

*** PRAXGEN PHARMACEUTICALS LLC**
 METHYLPREDNISOLONE, METHYLPREDNISOLONE
 RANOLAZINE, RANOLAZINE

PRECISION DERMAT

*** PRECISION DERMATOLOGY INC**
 LOCOID LIPOCREAM, HYDROCORTISONE BUTYRATE
 LOCOID, HYDROCORTISONE BUTYRATE

PRECISION DOSE INC

*** PRECISION DOSE INC**
 PHENTOLAMINE MESYLATE, PHENTOLAMINE MESYLATE

PRECISION NUCLEAR

*** PRECISION NUCLEAR LLC**
 AMMONIA N 13, AMMONIA N-13
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
 SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

PRIMUS PHARMS

*** PRIMUS PHARMACEUTICALS INC**
 IMPOYZ, CLOBETASOL PROPIONATE
 SERNIVO, BETAMETHASONE DIPROPIONATE

PRINSTON INC

*** PRINSTON PHARMACEUTICAL INC**
 AMPHETAMINE SULFATE, AMPHETAMINE SULFATE
 ARIPIPRAZOLE, ARIPIPRAZOLE
 BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
 BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** P ******* PRINSTON PHARMACEUTICAL INC**

CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE, CANDESARTAN CILEXETIL
 CAPTOPRIL, CAPTOPRIL
 CLONAZEPAM, CLONAZEPAM
 CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
 CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
 CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
 DIMETHYL FUMARATE, DIMETHYL FUMARATE
 DIVALPROEX SODIUM, DIVALPROEX SODIUM
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
 DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
 DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
 ENALAPRIL MALEATE, ENALAPRIL MALEATE
 ENTECAVIR, ENTECAVIR
 ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
 FEBUXOSTAT, FEBUXOSTAT
 FENOFIBRATE, FENOFIBRATE
 FINGOLIMOD HYDROCHLORIDE, FINGOLIMOD HYDROCHLORIDE
 FOSINOPRIL SODIUM, FOSINOPRIL SODIUM
 FUROSEMIDE, FUROSEMIDE
 GLIMEPIRIDE, GLIMEPIRIDE
 GLYCOPYRROLATE, GLYCOPYRROLATE
 HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
 HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
 IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 IRBESARTAN, IRBESARTAN
 LEVETIRACETAM, LEVETIRACETAM
 LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 LISINOPRIL, LISINOPRIL
 LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 METHOCARBAMOL, METHOCARBAMOL
 METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
 NEBIVOLOL HYDROCHLORIDE, NEBIVOLOL HYDROCHLORIDE
 OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
 PAROXETINE MESYLATE, PAROXETINE MESYLATE
 PAROXETINE, PAROXETINE HYDROCHLORIDE
 PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
 PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
 PREGABALIN, PREGABALIN
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
 QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
 QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE
 RISPERIDONE, RISPERIDONE
 ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
 ROFLUMILAST, ROFLUMILAST
 ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
 SILODOSIN, SILODOSIN
 TADALAFIL, TADALAFIL
 TELMISARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 TELMISARTAN, TELMISARTAN
 TEMAZEPAM, TEMAZEPAM
 VALSARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 VALSARTAN, VALSARTAN
 VORICONAZOLE, VORICONAZOLE
 VYDUO, NEBIVOLOL HYDROCHLORIDE

PROF DSPLS*** PROFESSIONAL DISPOSABLES INC**

PREVANTICS MAXI SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)
 PREVANTICS SWAB, CHLORHEXIDINE GLUCONATE (OTC)
 PREVANTICS SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** P ******PROGENICS PHARMS INC**

- * PROGENICS PHARMACEUTICALS INC
AZEDRA, IOBENGUANE I-131
PYLARIFY, PIFLUFOLASTAT F-18

PROPEL PHARMA

- * PROPEL PHARMA CORP
VIGABATRIN, VIGABATRIN

PROTEGA PHARMS

- * PROTEGA PHARMACEUTICALS LLC
ROXYBOND, OXYCODONE HYDROCHLORIDE

PROVELL

- * PROVELL PHARMACEUTICALS LLC
EUTHYROX, LEVOTHYROXINE SODIUM **

PROVENSIS

- * PROVENSIS LTD
VARITHENA, POLIDOCANOL

PROVEPHARM SAS

- * PROVEPHARM SAS
BLUDIGO, INDIGOTINDISULFONATE SODIUM
DIHYDROERGOTAMINE MESYLATE, DIHYDROERGOTAMINE MESYLATE
PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM
PROVAYBLUE, METHYLENE BLUE
TRANEXAMIC ACID, TRANEXAMIC ACID

PTC THERAP

- * PTC THERAPEUTICS INC
EMFLAZA, DEFLAZACORT

PULMOFLOW INC

- * PULMOFLOW INC
KITABIS PAK, TOBRAMYCIN

PUMA BIOTECH

- * PUMA BIOTECHNOLOGY INC
NERLYNX, NERATINIB MALEATE

PURACAP PHARM

- * PURACAP PHARMACEUTICAL LLC
MELOXICAM, MELOXICAM

PURACAP PHARM LLC

- * PURACAP PHARMACEUTICAL LLC
BENZONATATE, BENZONATATE
ERGOCALCIFEROL, ERGOCALCIFEROL
ETHOSUXIMIDE, ETHOSUXIMIDE
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
OMEGA-3-ACID ETHYL ESTERS, OMEGA-3-ACID ETHYL ESTERS
PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE

PURDUE PHARMA LP

- * PURDUE PHARMA LP
BUTRANS, BUPRENORPHINE
HYSINGLA ER, HYDROCODONE BITARTRATE
MS CONTIN, MORPHINE SULFATE
NALMEFENE HYDROCHLORIDE, NALMEFENE HYDROCHLORIDE
OXYCONTIN, OXYCODONE HYDROCHLORIDE

PURE SOURCE

- * PURE SOURCE LLC
THEROXIDIL, MINOXIDIL (OTC)

PYROS PHARMS

- * PYROS PHARMACEUTICALS INC
VIGABATRIN, VIGABATRIN

**** Q ******Q BIOMED**

- * Q BIOMED INC
METASTRON, STRONTIUM CHLORIDE SR-89
STRONTIUM CHLORIDE SR-89, STRONTIUM CHLORIDE SR-89

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** Q ******QILU**

* QILU PHARMACEUTICAL CO LTD
 ABIRATERONE ACETATE, ABIRATERONE ACETATE
 CEFAZOLIN SODIUM, CEFAZOLIN SODIUM
 CEFEPIME HYDROCHLORIDE, CEFEPIME HYDROCHLORIDE
 CEFTRIAXONE, CEFTRIAXONE SODIUM
 EXEMESTANE, EXEMESTANE
 OLANZAPINE, OLANZAPINE
 OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
 PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM
 SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE
 TENOFOVIR DISOPROXIL FUMARATE, TENOFOVIR DISOPROXIL FUMARATE

QILU PHARM HAINAN

* QILU PHARMACEUTICAL HAINAN CO LTD
 BORTEZOMIB, BORTEZOMIB
 DAPTOMYCIN, DAPTOMYCIN
 DECITABINE, DECITABINE
 FOSAPREPITANT DIMEGLUMINE, FOSAPREPITANT DIMEGLUMINE
 IMATINIB MESYLATE, IMATINIB MESYLATE
 IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 OXALIPLATIN, OXALIPLATIN
 PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE
 PEMETREXED DISODIUM, PEMETREXED DISODIUM
 TADALAFIL, TADALAFIL

QINGDAO BAHEAL PHARM

* QINGDAO BAHEAL PHARMACEUTICAL CO LTD
 CELECOXIB, CELECOXIB
 DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
 FOLIC ACID, FOLIC ACID
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

QOL MEDCL

* QOL MEDICAL LLC
 ETHAMOLIN, ETHANOLAMINE OLEATE

QUAGEN

* QUAGEN PHARMACEUTICALS LLC
 ALBUTEROL SULFATE, ALBUTEROL SULFATE
 CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
 CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
 FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
 HALOBETASOL PROPIONATE, HALOBETASOL PROPIONATE
 LIDOCAINE, LIDOCAINE
 METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
 PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE, CODEINE PHOSPHATE
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
 PROPYLTHIOURACIL, PROPYLTHIOURACIL
 TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

QUEEN HAMAMATSU PET

* QUEEN HAMAMATSU PET IMAGING CENTER
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

**** R ******R-PHARM US LLC**

* R-PHARM US LLC
 IXEMPRA KIT, IXABEPILONE

RADIOMEDIX

* RADIOMEDIX INC
 DETECTNET, COPPER CU-64 DOTATATE

RADIUS HEALTH INC

* RADIUS HEALTH INC
 TYMLOS, ABALOPARATIDE

RAYNER SURGICAL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** R ****

* RAYNER SURGICAL INC
OMIDRIA, KETOROLAC TROMETHAMINE

RB HLTH

* RB HEALTH US LLC
DELSYM, DEXTROMETHORPHAN POLISTIREX (OTC)
MUCINEX D, GUAIFENESIN (OTC)
MUCINEX DM, DEXTROMETHORPHAN HYDROBROMIDE (OTC)
MUCINEX, GUAIFENESIN (OTC)

RECORDATI RARE

* RECORDATI RARE DISEASES INC
CARBAGLU, CARGLUMIC ACID
CHEMET, SUCCIMER
COSMEGEN, DACTINOMYCIN
CYSTADANE, BETAINE
CYSTADROPS, CYSTEAMINE HYDROCHLORIDE
ISTURISA, OSILODROSTAT PHOSPHATE
NEOPROFEN, IBUPROFEN LYSINE
SIGNIFOR LAR KIT, PASIREOTIDE PAMOATE
SIGNIFOR, PASIREOTIDE DIASPARTATE

REDHILL

* REDHILL BIOPHARMA INC
AEMCOLO, RIFAMYCIN SODIUM
MOVANTIK, NALOXEGOL OXALATE
* REDHILL BIOPHARMA LTD
TALICIA, AMOXICILLIN

RELIANCE LIFE

* RELIANCE LIFE SCIENCES PVT LTD
CAPECITABINE, CAPECITABINE

REMPEX

* REMPEX PHARMACEUTICALS INC A WHOLLY OWNED SUB OF MELINTA THERAPEUTICS LLC
MINOCIN, MINOCYCLINE HYDROCHLORIDE
VABOMERE, MEROPENEM

RENATA

* RENATA LTD
FROVATRIPTAN SUCCINATE, FROVATRIPTAN SUCCINATE
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
METOLAZONE, METOLAZONE
PREGABALIN, PREGABALIN
RISPERIDONE, RISPERIDONE
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM

RENEW PHARMS

* RENEW PHARMACEUTICALS LTD
INDOCYANINE GREEN, INDOCYANINE GREEN

RESILIA PHARMS

* RESILIA PHARMACEUTICALS INC
ECOZA, ECONAZOLE NITRATE

REYOUNG

* REYOUNG CORPORATION
FENOFIBRATE (MICRONIZED), FENOFIBRATE
NEBIVOLOL HYDROCHLORIDE, NEBIVOLOL HYDROCHLORIDE
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
SILDENAFIL CITRATE, SILDENAFIL CITRATE

RHODES PHARMS

* RHODES PHARMACEUTICALS LP
AMPHETAMINE SULFATE, AMPHETAMINE SULFATE
APTENSIO XR, METHYLPHENIDATE HYDROCHLORIDE
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DILAUDID, HYDROMORPHONE HYDROCHLORIDE
FENOFIBRATE (MICRONIZED), FENOFIBRATE
FENOFIBRATE, FENOFIBRATE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** R ****

- * RHODES PHARMACEUTICALS LP
 - LIDOCAINE, LIDOCAINE
 - MORPHINE SULFATE, MORPHINE SULFATE
 - OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
 - OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
 - THEOPHYLLINE, THEOPHYLLINE

RHYTHM

- * RHYTHM PHARMACEUTICALS INC
 - IMCIVREE, SETMELANOTIDE ACETATE

RICONPHARMA LLC

- * RICONPHARMA LLC
 - DICLOFENAC SODIUM, DICLOFENAC SODIUM
 - FLUNISOLIDE, FLUNISOLIDE
 - ISOSORBIDE DINITRATE AND HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
 - ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
 - SCOPOLAMINE, SCOPOLAMINE

RIGEL PHARMS INC

- * RIGEL PHARMACEUTICALS INC
 - REZLIDHIA, OLUTASIDENIB
 - TAVALISSE, FOSTAMATINIB DISODIUM

RILEY CONSUMER

- * RILEY CONSUMER CARE LLC DBA CARLIN CONSUMER HEALTH
 - ZEGERID OTC, OMEPRAZOLE (OTC)

RISE PHARMA

- * RISE PHARMA LLC
 - AMPHETAMINE SULFATE, AMPHETAMINE SULFATE
 - BUTALBITAL AND ACETAMINOPHEN, ACETAMINOPHEN
 - HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE

RISING

- * RISING PHARMA HOLDING INC
 - AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, AMILORIDE HYDROCHLORIDE
 - BUTORPHANOL TARTRATE, BUTORPHANOL TARTRATE
 - CAPECITABINE, CAPECITABINE
 - CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
 - CYTARABINE, CYTARABINE
 - DIGOXIN, DIGOXIN
 - DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
 - FLUMAZENIL, FLUMAZENIL
 - FLUNISOLIDE, FLUNISOLIDE
 - PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
 - TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
- * RISING PHARMA HOLDINGS INC
 - ABIRATERONE ACETATE, ABIRATERONE ACETATE
 - ACETIC ACID, ACETIC ACID, GLACIAL
 - ALBUTEROL SULFATE, ALBUTEROL SULFATE
 - ALOSETRON HYDROCHLORIDE, ALOSETRON HYDROCHLORIDE
 - AZATHIOPRINE, AZATHIOPRINE
 - BUDESONIDE, BUDESONIDE
 - BUMETANIDE, BUMETANIDE
 - CARBIDOPA, LEVODOPA AND ENTACAPONE, CARBIDOPA
 - CEVIMELINE HYDROCHLORIDE, CEVIMELINE HYDROCHLORIDE
 - CHLORZOXAZONE, CHLORZOXAZONE
 - CICLOPIROX, CICLOPIROX
 - CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
 - CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
 - CROMOLYN SODIUM, CROMOLYN SODIUM
 - CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
 - DAPSONE, DAPSONE
 - DESOXIMETASONE, DESOXIMETASONE
 - DICLOFENAC SODIUM, DICLOFENAC SODIUM
 - DIFLORASONE DIACETATE, DIFLORASONE DIACETATE
 - DOXERCALCIFEROL, DOXERCALCIFEROL
 - ERLOTINIB HYDROCHLORIDE, ERLOTINIB HYDROCHLORIDE
 - EXEMESTANE, EXEMESTANE
 - FENOPROFEN CALCIUM, FENOPROFEN CALCIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** R ****

- * RISING PHARMA HOLDINGS INC
 - FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
 - FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
 - FEXOFENADINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE
 - FLURAZEPAM HYDROCHLORIDE, FLURAZEPAM HYDROCHLORIDE
 - GLYCOPYRROLATE, GLYCOPYRROLATE
 - HYDROCORTISONE, HYDROCORTISONE
 - LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN (COPACKAGED), AMOXICILLIN
 - LEVOCARNITINE, LEVOCARNITINE
 - LEVOFLOXACIN, LEVOFLOXACIN
 - METHIMAZOLE, METHIMAZOLE
 - METHYLERGONOVINE MALEATE, METHYLERGONOVINE MALEATE
 - METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
 - NADOLOL, NADOLOL
 - NATEGLINIDE, NATEGLINIDE
 - NITAZOXANIDE, NITAZOXANIDE
 - NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
 - PARICALCITOL, PARICALCITOL
 - PERPHENAZINE, PERPHENAZINE
 - PHENYTOIN, PHENYTOIN
 - POTASSIUM CITRATE, POTASSIUM CITRATE
 - PREGABALIN, PREGABALIN
 - PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
 - PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE
 - RISPERIDONE, RISPERIDONE
 - SELEGILINE HYDROCHLORIDE, SELEGILINE HYDROCHLORIDE
 - SEVELAMER CARBONATE, SEVELAMER CARBONATE
 - SULFAMYLON, MAFENIDE ACETATE
 - SUMATRIPTAN AND NAPROXEN SODIUM, NAPROXEN SODIUM
 - TEMOZOLOMIDE, TEMOZOLOMIDE
 - TOREMIFENE CITRATE, TOREMIFENE CITRATE
 - TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
 - TRIENTINE HYDROCHLORIDE, TRIENTINE HYDROCHLORIDE
 - VORICONAZOLE, VORICONAZOLE
 - ZILEUTON, ZILEUTON
- * RISING PHARMACEUTICALS
 - URSODIOL, URSODIOL

RISING PHARMS

- * RISING PHARMACEUTICALS INC
 - ZAFIRLUKAST, ZAFIRLUKAST

RK PHARMA

- * RK PHARMA INC
 - CHLOROTHIAZIDE SODIUM, CHLOROTHIAZIDE SODIUM
 - DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
 - DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
 - MITOMYCIN, MITOMYCIN
 - MYCOPHENOLIC SODIUM, MYCOPHENOLIC SODIUM
 - PALIPERIDONE, PALIPERIDONE

ROCHE PALO

- * ROCHE PALO ALTO LLC
 - CELLCEPT, MYCOPHENOLATE MOFETIL
 - CELLCEPT, MYCOPHENOLATE MOFETIL HYDROCHLORIDE

ROMARK

- * ROMARK LABORATORIES
 - ALINIA, NITAZOXANIDE

ROXANE

- * ROXANE LABORATORIES INC
 - METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE

RUBICON

- * RUBICON RESEARCH PRIVATE LTD
 - ACETAZOLAMIDE, ACETAZOLAMIDE
 - ACYCLOVIR, ACYCLOVIR
 - AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
 - AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
 - ARIPIRAZOLE, ARIPIRAZOLE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** R ******* RUBICON RESEARCH PRIVATE LTD**

BACLOFEN, BACLOFEN
 BISOPROLOL FUMARATE, BISOPROLOL FUMARATE
 BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
 BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
 CARBIDOPA AND LEVODOPA, CARBIDOPA
 CARVEDILOL, CARVEDILOL
 CLONAZEPAM, CLONAZEPAM
 CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
 DESVENLAFAXINE SUCCINATE, DESVENLAFAXINE SUCCINATE
 DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
 DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
 GABAPENTIN, GABAPENTIN
 ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE
 LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
 LAMOTRIGINE, LAMOTRIGINE
 LORATADINE, LORATADINE (OTC)
 METOLAZONE, METOLAZONE
 METOPROLOL TARTRATE, METOPROLOL TARTRATE
 MIDODRINE HYDROCHLORIDE, MIDODRINE HYDROCHLORIDE
 NITROGLYCERIN, NITROGLYCERIN
 OXCARBAZEPINE, OXCARBAZEPINE
 OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
 PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
 PREGABALIN, PREGABALIN
 PRIMIDONE, PRIMIDONE
 RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM
 SILDENAFIL CITRATE, SILDENAFIL CITRATE
 TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
 TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
 TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE

RVL PHARMS

*** RVL PHARMACEUTICALS INC**
 UPNEEQ, OXYMETAZOLINE HYDROCHLORIDE

**** S ******SAGE CHEMS**

*** SAGE CHEMICALS INC**
 APOMORPHINE HYDROCHLORIDE, APOMORPHINE HYDROCHLORIDE

SAGE PRODS

*** SAGE PRODUCTS INC**
 CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE (OTC)

SAGE THERAP

*** SAGE THERAPEUTICS INC**
 ZULRESSO, BREXANOLONE

SAGENT PHARMS

*** SAGENT PHARMACEUTICALS INC**
 CAFFEINE CITRATE, CAFFEINE CITRATE
 DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
 FLUMAZENIL, FLUMAZENIL
 HALOPERIDOL, HALOPERIDOL LACTATE
 HEPARIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM
 HEPARIN SODIUM, HEPARIN SODIUM
 LEUCOVORIN CALCIUM PRESERVATIVE FREE, LEUCOVORIN CALCIUM
 LEVETIRACETAM, LEVETIRACETAM
 NAFCILLIN SODIUM, NAFCILLIN SODIUM
 ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
 OXACILLIN SODIUM, OXACILLIN SODIUM
 TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
 VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE

SAGENT PHARMS INC

*** SAGENT PHARMACEUTICALS INC**
 ACETYLCYSTEINE, ACETYLCYSTEINE
 AMIKACIN SULFATE, AMIKACIN SULFATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** S ******* SAGENT PHARMACEUTICALS INC**

AMPICILLIN SODIUM, AMPICILLIN SODIUM
 CEFEPIME HYDROCHLORIDE, CEFEPIME HYDROCHLORIDE
 CHLOROTHIAZIDE SODIUM, CHLOROTHIAZIDE SODIUM
 CISATRACURIUM BESYLATE, CISATRACURIUM BESYLATE
 CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
 COLISTIMETHATE SODIUM, COLISTIMETHATE SODIUM
 CYANOCOBALAMIN, CYANOCOBALAMIN
 DAPTOMYCIN, DAPTOMYCIN
 DECITABINE, DECITABINE
 DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
 DIHYDROERGOTAMINE MESYLATE, DIHYDROERGOTAMINE MESYLATE
 EPTIFIBATIDE, EPTIFIBATIDE
 ESMOLOL HYDROCHLORIDE, ESMOLOL HYDROCHLORIDE
 FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE
 FLUOROURACIL, FLUOROURACIL
 FULVESTRANT, FULVESTRANT
 GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
 GLYDO, LIDOCAINE HYDROCHLORIDE
 IBANDRONATE SODIUM, IBANDRONATE SODIUM
 KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
 LEUCOVORIN CALCIUM PRESERVATIVE FREE, LEUCOVORIN CALCIUM
 LINEZOLID, LINEZOLID
 MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE
 MESNA, MESNA
 METHOCARBAMOL, METHOCARBAMOL
 METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM
 METHYLPREDNISOLONE ACETATE, METHYLPREDNISOLONE ACETATE
 METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE SODIUM SUCCINATE
 OCTREOTIDE ACETATE (PRESERVATIVE FREE), OCTREOTIDE ACETATE
 OCTREOTIDE ACETATE, OCTREOTIDE ACETATE
 OXYTOCIN, OXYTOCIN
 PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE
 PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
 PENTOBARBITAL SODIUM, PENTOBARBITAL SODIUM
 PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
 PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM
 PROPOFOL, PROPOFOL
 ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
 SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE
 SUCCINYLCHOLINE CHLORIDE, SUCCINYLCHOLINE CHLORIDE
 THIAMINE HYDROCHLORIDE, THIAMINE HYDROCHLORIDE
 VECURONIUM BROMIDE, VECURONIUM BROMIDE
 ZOLEDRONIC ACID, ZOLEDRONIC ACID

SALIX*** SALIX PHARMACEUTICALS INC**

FENOGLIDE, FENOFIBRATE
 PLENVU, ASCORBIC ACID
 RELISTOR, METHYLNALTREXONE BROMIDE
 TRULANCE, PLECANATIDE
 UCERIS, BUDESONIDE
 ZEGERID, OMEPRAZOLE

SALIX PHARMS*** SALIX PHARMACEUTICALS INC**

ANUSOL HC, HYDROCORTISONE
 DIURIL, CHLOROTHIAZIDE
 MOVIPREP, ASCORBIC ACID
 OSMOPREP, SODIUM PHOSPHATE, DIBASIC, ANHYDROUS
 RELISTOR, METHYLNALTREXONE BROMIDE
 XIFAXAN, RIFAXIMIN

SAMSON MEDCL*** SAMSON MEDICAL TECHNOLOGIES LLC**

CEFAZOLIN SODIUM, CEFAZOLIN SODIUM
 CEFEPIME HYDROCHLORIDE IN PLASTIC CONTAINER, CEFEPIME HYDROCHLORIDE
 CEFOXITIN IN PLASTIC CONTAINER, CEFOXITIN SODIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** S ****

* SAMSON MEDICAL TECHNOLOGIES LLC
 CEFTRIAXONE, CEFTRIAXONE SODIUM
 VANCOMYCIN HYDROCHLORIDE IN PLASTIC CONTAINER, VANCOMYCIN HYDROCHLORIDE

SANDOZ

* SANDOZ
 DOCETAXEL, DOCETAXEL

* SANDOZ INC
 ALPRAZOLAM, ALPRAZOLAM
 AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
 AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
 AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
 AMOXICILLIN, AMOXICILLIN
 AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
 AMPICILLIN SODIUM, AMPICILLIN SODIUM
 AMPICILLIN TRIHYDRATE, AMPICILLIN/AMPICILLIN TRIHYDRATE
 APREPITANT, APREPITANT
 ARGATROBAN IN SODIUM CHLORIDE, ARGATROBAN
 AZITHROMYCIN, AZITHROMYCIN
 BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, BENAZEPRIL HYDROCHLORIDE
 BICALUTAMIDE, BICALUTAMIDE
 BUMETANIDE, BUMETANIDE
 CARVEDILOL, CARVEDILOL
 CEFAZOLIN SODIUM, CEFAZOLIN SODIUM
 CEFDINIR, CEFDINIR
 CEFPODOXIME PROXETIL, CEFPODOXIME PROXETIL
 CEFTRIAXONE, CEFTRIAXONE SODIUM
 CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CLARITHROMYCIN, CLARITHROMYCIN
 CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
 CLONAZEPAM, CLONAZEPAM
 COSYNTROPIN, COSYNTROPIN
 CYCLOSPORINE, CYCLOSPORINE
 DESIPRAMINE HYDROCHLORIDE, DESIPRAMINE HYDROCHLORIDE
 DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
 DICLOFENAC SODIUM AND MISOPROSTOL, DICLOFENAC SODIUM
 DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
 DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
 ENOXAPARIN SODIUM (PRESERVATIVE FREE), ENOXAPARIN SODIUM
 EPLERENONE, EPLERENONE
 ETODOLAC, ETODOLAC
 FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE
 FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE, FOSINOPRIL SODIUM
 GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
 GLIPIZIDE, GLIPIZIDE
 HALOPERIDOL, HALOPERIDOL
 HEPARIN SODIUM, HEPARIN SODIUM
 HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
 HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE
 IMIPRAMINE HYDROCHLORIDE, IMIPRAMINE HYDROCHLORIDE
 INDOMETHACIN, INDOMETHACIN
 IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 IRBESARTAN, IRBESARTAN
 ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE
 ITRACONAZOLE, ITRACONAZOLE
 LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
 LANSOPRAZOLE, LANSOPRAZOLE
 LEUPROLIDE ACETATE, LEUPROLIDE ACETATE
 LEVOFLOXACIN, LEVOFLOXACIN
 LISINAPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 LORAZEPAM, LORAZEPAM
 LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
 MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE
 METAXALONE, METAXALONE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** S ******* SANDOZ INC**

METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 METHAZOLAMIDE, METHAZOLAMIDE
 METHYLPREDNISOLONE, METHYLPREDNISOLONE
 METOLAZONE, METOLAZONE
 MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
 MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
 NADOLOL, NADOLOL
 NAFCILLIN SODIUM, NAFCILLIN SODIUM
 NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS), NITROFURANTOIN
 OMEPRAZOLE, OMEPRAZOLE
 ONDANSETRON, ONDANSETRON
 ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
 OXALIPLATIN, OXALIPLATIN
 OXAPROZIN, OXAPROZIN
 PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM
 PENICILLIN G SODIUM, PENICILLIN G SODIUM
 PENICILLIN V POTASSIUM, PENICILLIN V POTASSIUM
 PERPHENAZINE, PERPHENAZINE
 PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
 PIOGLITAZONE HYDROCHLORIDE AND GLIMEPIRIDE, GLIMEPIRIDE
 PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
 PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
 QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
 RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
 RIBAVIRIN, RIBAVIRIN
 RISPERIDONE, RISPERIDONE
 TACROLIMUS, TACROLIMUS
 TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
 TEMAZEPAM, TEMAZEPAM
 TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 TRIFLUOPERAZINE HYDROCHLORIDE, TRIFLUOPERAZINE HYDROCHLORIDE
 VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

SANDOZ CANADA INC*** SANDOZ CANADA INC**

INFUVITE ADULT, ALPHA-TOCOPHEROL ACETATE
 INFUVITE PEDIATRIC (PHARMACY BULK PACKAGE), ASCORBIC ACID
 INFUVITE PEDIATRIC, ASCORBIC ACID

SANDOZ INC*** SANDOZ INC**

ACETAMINOPHEN, ACETAMINOPHEN
 ALBUTEROL SULFATE, ALBUTEROL SULFATE
 AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
 ANECTINE, SUCCINYLCHOLINE CHLORIDE
 ANGIOMAX, BIVALIRUDIN
 ARSENIC TRIOXIDE, ARSENIC TRIOXIDE
 ASPIRIN AND DIPYRIDAMOLE, ASPIRIN
 ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
 AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
 BETOPTIC, BETAXOLOL HYDROCHLORIDE
 BIMATOPROST, BIMATOPROST
 BORTEZOMIB, BORTEZOMIB
 BRIMONIDINE TARTRATE AND TIMOLOL MALEATE, BRIMONIDINE TARTRATE
 BRIMONIDINE TARTRATE, BRIMONIDINE TARTRATE
 BROMOCRIPTINE MESYLATE, BROMOCRIPTINE MESYLATE
 BUDESONIDE, BUDESONIDE
 BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
 CARBOPLATIN, CARBOPLATIN
 CARTEOLOL HYDROCHLORIDE, CARTEOLOL HYDROCHLORIDE
 CEFTRIAXONE, CEFTRIAXONE SODIUM
 CISATRACURIUM BESYLATE PRESERVATIVE FREE, CISATRACURIUM BESYLATE
 CISATRACURIUM BESYLATE, CISATRACURIUM BESYLATE
 CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER, CLINDAMYCIN PHOSPHATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** S ****

* SANDOZ INC
 CROMOLYN SODIUM, CROMOLYN SODIUM
 CYANOCOBALAMIN, CYANOCOBALAMIN
 DECITABINE, DECITABINE
 DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
 DICLOFENAC SODIUM, DICLOFENAC SODIUM
 DIGOXIN, DIGOXIN
 DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
 DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE
 DOXERCALCIFEROL, DOXERCALCIFEROL
 ENALAPRIL MALEATE, ENALAPRIL MALEATE
 ENOXAPARIN SODIUM, ENOXAPARIN SODIUM
 EPHEDRINE SULFATE, EPHEDRINE SULFATE
 EZETIMIBE, EZETIMIBE
 FENOLDOPAM MESYLATE, FENOLDOPAM MESYLATE
 FERUMOXYTOL, FERUMOXYTOL
 FLUMAZENIL, FLUMAZENIL
 FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE
 FULVESTRANT, FULVESTRANT
 GATIFLOXACIN, GATIFLOXACIN
 GENTAMICIN SULFATE, GENTAMICIN SULFATE
 GLATOPA, GLATIRAMER ACETATE
 GLYCOPYRROLATE, GLYCOPYRROLATE
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
 GRISEOFULVIN, GRISEOFULVIN, MICROSIZE
 GRISEOFULVIN, ULTRAMICROSIZE, GRISEOFULVIN, ULTRAMICROSIZE
 GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
 ISONIAZID, ISONIAZID
 KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
 LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN (COPACKAGED), AMOXICILLIN
 LATANOPROST, LATANOPROST
 LEVOLEUCOVORIN CALCIUM, LEVOLEUCOVORIN CALCIUM
 LINEZOLID, LINEZOLID
 MAXITROL, DEXAMETHASONE
 MESALAMINE, MESALAMINE
 METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM
 METHYLPREDNISOLONE ACETATE, METHYLPREDNISOLONE ACETATE
 METOPROLOL TARTRATE, METOPROLOL TARTRATE
 MONTELUKAST SODIUM, MONTELUKAST SODIUM
 MYDRIACYL, TROPICAMIDE
 NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE, HYDROCORTISONE
 NEVIRAPINE, NEVIRAPINE
 NOREPINEPHRINE BITARTRATE, NOREPINEPHRINE BITARTRATE
 OLANZAPINE, OLANZAPINE
 ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE
 PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
 PARICALCITOL, PARICALCITOL
 PEMETREXED DISODIUM, PEMETREXED DISODIUM
 PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
 PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM
 PIRFENIDONE, PIRFENIDONE
 PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
 QOLIANA, BRIMONIDINE TARTRATE
 REGONOL, PYRIDOSTIGMINE BROMIDE
 ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
 ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
 ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
 SILODOSIN, SILODOSIN
 SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM
 TAFLUPROST, TAFLUPROST
 TELMISARTAN, TELMISARTAN
 TERIFLUNOMIDE, TERIFLUNOMIDE
 TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** S ****

* SANDOZ INC
 TIGECYCLINE, TIGECYCLINE
 TIMOLOL MALEATE, TIMOLOL MALEATE
 TOBREX, TOBRAMYCIN
 TREPROSTINIL, TREPROSTINIL
 TRIAZOLAM, TRIAZOLAM
 TRIFLURIDINE, TRIFLURIDINE
 TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
 VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
 VORICONAZOLE, VORICONAZOLE
 ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

SANOFI

* SANOFI AVENTIS US LLC
 FEXINIDAZOLE, FEXINIDAZOLE
 FLOMAX, TAMSULOSIN HYDROCHLORIDE
 * SANOFI GENZYME
 HECTOROL, DOXERCALCIFEROL
 RENVELA, SEVELAMER CARBONATE

SANOFI AVENTIS US

* SANOFI AVENTIS US INC
 JEVTANA KIT, CABAZITAXEL
 * SANOFI AVENTIS US LLC
 AMARYL, GLIMEPIRIDE
 AMBIEN CR, ZOLPIDEM TARTRATE
 AMBIEN, ZOLPIDEM TARTRATE
 ARAVA, LEFLUNOMIDE
 AUBAGIO, TERIFLUNOMIDE
 AVALIDE, HYDROCHLOROTHIAZIDE
 AVAPRO, IRBESARTAN
 DIABETA, GLYBURIDE
 ELOXATIN, OXALIPLATIN
 FERRLECIT, FERRIC OXYHYDROXIDE
 LOVENOX (PRESERVATIVE FREE), ENOXAPARIN SODIUM
 LOVENOX, ENOXAPARIN SODIUM
 MULTAQ, DRONEDARONE HYDROCHLORIDE
 PLAVIX, CLOPIDOGREL BISULFATE
 PRIFTIN, RIFAPENTINE
 PRIMAQUINE, PRIMAQUINE PHOSPHATE
 RIFADIN, RIFAMPIN
 TAXOTERE, DOCETAXEL

SANTARUS INC

* SANTARUS INC
 GLUMETZA, METFORMIN HYDROCHLORIDE

SANTEN

* SANTEN INC
 OMLONTI, OMIDENEPAG ISOPROPYL
 VERKAZIA, CYCLOSPORINE

SAPTALIS PHARMS

* SAPTALIS PHARMACEUTICALS LLC
 ACETIC ACID, ACETIC ACID, GLACIAL
 CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
 LEVOCARNITINE, LEVOCARNITINE
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE

SAREPTA THERAPS INC

* SAREPTA THERAPEUTICS INC
 AMONDYS 45, CASIMERSSEN
 EXONDYS 51, ETEPLIRSEN
 VYONDYS 53, GOLODIRSEN

SARFE PHARMS

* SARFEZ PHARMACEUTICALS INC
 SOAANZ, TORSEMED

SAVIOR LIFETEC CORP

* SAVIOR LIFETEC CORP

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** S ****

* SAVIOR LIFETEC CORP
ERTAPENEM SODIUM, ERTAPENEM SODIUM
MEROPENEM, MEROPENEM

SAWAI USA

* SAWAI USA INC
PITAVASTATIN CALCIUM, PITAVASTATIN CALCIUM

SCHERING

* SCHERING CORP
NOXAFIL, POSACONAZOLE

SCIARRA LABS

* SCIARRA LABORATORIES INC
SCLEROSOL, TALC
TALC, TALC

SCIECURE PHARMA INC

* SCIECURE PHARMA INC
PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE

SCIEGEN PHARMS INC

* SCIEGEN PHARMACEUTICALS INC
ARIPIRAZOLE, ARIPIRAZOLE
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
CARBIDOPA AND LEVODOPA, CARBIDOPA
CARISOPRODOL, CARISOPRODOL
CELECOXIB, CELECOXIB
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
DROXIDOPA, DROXIDOPA
ETHACRYNIC ACID, ETHACRYNIC ACID
EZETIMIBE, EZETIMIBE
FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
GABAPENTIN, GABAPENTIN
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IRBESARTAN, IRBESARTAN
LACOSAMIDE, LACOSAMIDE
LAMOTRIGINE, LAMOTRIGINE
LEVETIRACETAM, LEVETIRACETAM
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
METAXALONE, METAXALONE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
NABUMETONE, NABUMETONE
NAPROXEN SODIUM, NAPROXEN SODIUM
NAPROXEN, NAPROXEN
OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
OMEPRazole AND SODIUM BICARBONATE, OMEPRazole
PIRFENIDONE, PIRFENIDONE
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
PREGABALIN, PREGABALIN
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
RALOXIFENE HYDROCHLORIDE, RALOXIFENE HYDROCHLORIDE
RANOLAZINE, RANOLAZINE
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE
VALSARTAN, VALSARTAN

SCILEX PHARMS

* SCILEX PHARMACEUTICALS INC
GLOPERBA, COLCHICINE
ZTLIDO, LIDOCAINE

SCINOPHARM TAIWAN

* SCINOPHARM TAIWAN LTD
FONDAPARINUX SODIUM, FONDAPARINUX SODIUM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** S ******SCOV3**

- * SCOV3 LLC
LYPQOZET, ATORVASTATIN CALCIUM

SCPHARMACEUTICALS

- * SCPHARMACEUTICALS INC
FUROSCIX, FUROSEMIDE

SCYNEXIS

- * SCYNEXIS INC
BREXAFEMME, IBREXAFUNGERP CITRATE

SEAGEN

- * SEAGEN INC
TUKYSA, TUCATINIB

SEBELA IRELAND LTD

- * SEBELA IRELAND LTD
BRISDELLE, PAROXETINE MESYLATE
IMURAN, AZATHIOPRINE
LOTRONEX, ALOSETRON HYDROCHLORIDE
MICORT-HC, HYDROCORTISONE ACETATE
MOTOFEN, ATROPINE SULFATE
NAFTIN, NAFTIFINE HYDROCHLORIDE
PEXEVA, PAROXETINE MESYLATE
PRAMOSONE, HYDROCORTISONE ACETATE
RIDAURA, AURANOFIN

SECURA

- * SECURA BIO INC
COPIKTRA, DUVELISIB

SENORES PHARMS

- * SENORES PHARMACEUTICALS INC
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
CHLORZOXAZONE, CHLORZOXAZONE
KETOCONAZOLE, KETOCONAZOLE
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
MEXILETINE HYDROCHLORIDE, MEXILETINE HYDROCHLORIDE

SENTYNL THERAPS INC

- * SENTYNL THERAPEUTICS INC
NULIBRY, FOSDENOPTERIN HYDROBROMIDE

SEPTODONT

- * SEPTODONT INC
BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE, BUPIVACAINE HYDROCHLORIDE

SEPTODONT HOLDING

- * SEPTODONT HOLDING SAS
ORAVSE, PHENTOLAMINE MESYLATE

SEPTODONT INC

- * SEPTODONT INC
LIDOCAINE, LIDOCAINE
PRILOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE, EPINEPHRINE BITARTRATE
PRILOCAINE HYDROCHLORIDE, PRILOCAINE HYDROCHLORIDE

SERVIER

- * SERVIER PHARMACEUTICALS LLC
TIBSOVO, IVOSIDENIB

SETON PHARM

- * SETON PHARMACEUTICAL LLC
PEDIAPRED, PREDNISOLONE SODIUM PHOSPHATE

SETON PHARMS

- * SETON PHARMACEUTICALS LLC
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
PENTAMIDINE ISETHIONATE, PENTAMIDINE ISETHIONATE

SHANDONG

- * SHANDONG NEW TIME PHARMACEUTICAL CO LTD
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM

SHANDONG XINHUA

- * SHANDONG XINHUA PHARMACEUTICAL CO LTD
IBUPROFEN, IBUPROFEN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** S ****

- * SHANDONG XINHUA PHARMACEUTICAL CO LTD
IBUPROFEN, IBUPROFEN (OTC)

SHANGHAI HENGRUI

- * SHANGHAI HENGRUI PHARMACEUTICAL CO LTD
DESFLURANE, DESFLURANE
SEVOFLURANE, SEVOFLURANE

SHENZHEN TECHDOW

- * SHENZHEN TECHDOW PHARMACEUTICAL CO LTD
HEPARIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM
HEPARIN SODIUM, HEPARIN SODIUM

SHERTECH LABS LLC

- * SHERTECH LABORATORIES LLC
AMMONIA N 13, AMMONIA N-13
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

SHIELD TX

- * SHIELD TX UK LTD
ACCRUFER, FERRIC MALTOL

SHILPA

- * SHILPA MEDICARE LTD
BUSULFAN, BUSULFAN
CAPECITABINE, CAPECITABINE
DOCETAXEL, DOCETAXEL
ERLOTINIB HYDROCHLORIDE, ERLOTINIB HYDROCHLORIDE
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
IMATINIB MESYLATE, IMATINIB MESYLATE
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE

SHILPA MEDICARE

- * SHILPA MEDICARE LTD
AZACITIDINE, AZACITIDINE

SHIONOGI INC

- * SHIONOGI INC
FETROJA, CEFIDEROCOL SULFATE TOSYLATE
MULPLETA, LUSUTROMBOPAG

SIDMAK LABS INDIA

- * SIDMAK LABORATORIES INDIA PVT LTD
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE

SIGA TECHNOLOGIES

- * SIGA TECHNOLOGIES INC
TPOXX, TECOVIRIMAT

SIGMAPHARM LABS LLC

- * SIGMAPHARM LABORATORIES LLC
ACITRETIN, ACITRETIN
ADEFOVIR DIPIVOXIL, ADEFOVIR DIPIVOXIL
AMBRISANTAN, AMBRISANTAN
AMILORIDE HYDROCHLORIDE, AMILORIDE HYDROCHLORIDE
ASENAPINE MALEATE, ASENAPINE MALEATE
DISULFIRAM, DISULFIRAM
DOFETILIDE, DOFETILIDE
FLUCYTOSINE, FLUCYTOSINE
GRISEOFULVIN, GRISEOFULVIN, MICROSIZE
GRISEOFULVIN, ULTRAMICROSIZE, GRISEOFULVIN, ULTRAMICROSIZE
LIOETHYRONINE SODIUM, LIOETHYRONINE SODIUM
PROTRIPTYLINE HYDROCHLORIDE, PROTRIPTYLINE HYDROCHLORIDE
SODIUM PHENYLBUTYRATE, SODIUM PHENYLBUTYRATE

SINOTHERAPEUTICS INC

- * SINOTHERAPEUTICS INC
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
POSACONAZOLE, POSACONAZOLE
PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE

SINTETICA US

- * SINTETICA US LLC
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE

SK LIFE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** S ****

- * SK LIFE SCIENCE INC
XCOPRI, CENOBAMATE

SKYEPHARMA AG

- * SKYEPHARMA AG
TRIGLIDE, FENOFIBRATE

SLATE RUN PHARMA

- * SLATE RUN PHARMACEUTICALS LLC
ARFORMOTEROL TARTRATE, ARFORMOTEROL TARTRATE
CILOSTAZOL, CILOSTAZOL
DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
DROXIDOPA, DROXIDOPA
PROMETHAZINE DM, DEXTROMETHORPHAN HYDROBROMIDE

SLAYBACK PHARMA LLC

- * SLAYBACK PHARMA LLC
ARFORMOTEROL TARTRATE, ARFORMOTEROL TARTRATE
DEOXYCHOLIC ACID, DEOXYCHOLIC ACID
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
FORMOTEROL FUMARATE, FORMOTEROL FUMARATE
HYDROXYPROGESTERONE CAPROATE, HYDROXYPROGESTERONE CAPROATE
ICATIBANT ACETATE, ICATIBANT ACETATE
MERZEE, ETHINYL ESTRADIOL
METARAMINOL BITARTRATE, METARAMINOL BITARTRATE
METHYLPREDNISOLONE ACETATE, METHYLPREDNISOLONE ACETATE
VIVIMUSTA, BENDAMUSTINE HYDROCHLORIDE

SOCIETAL CDMO

- * SOCIETAL CDMO GAINESVILLE LLC
VERELAN PM, VERAPAMIL HYDROCHLORIDE
VERELAN, VERAPAMIL HYDROCHLORIDE

SOFGEN PHARMS

- * SOFGEN PHARMACEUTICALS LLC
IBUPROFEN, IBUPROFEN (OTC)
OMEGA-3-ACID ETHYL ESTERS, OMEGA-3-ACID ETHYL ESTERS
PROGESTERONE, PROGESTERONE

SOFIE

- * SOFIE CO DBA SOFIE
AMMONIA N 13, AMMONIA N-13
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18
- * SOFIE CO DBA SOFIE (FKA ZEVACOR PHARMA INC)
AMMONIA N 13, AMMONIA N-13
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

SOLA PHARMS

- * SOLA PHARMACEUTICALS
CYANOCOBALAMIN, CYANOCOBALAMIN

SOLARIS PHARMA CORP

- * SOLARIS PHARMA CORP
CLINDAMYCIN PHOSPHATE AND TRETINOIN, CLINDAMYCIN PHOSPHATE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
METRONIDAZOLE, METRONIDAZOLE

SOMERSET

- * SOMERSET PHARMACEUTICALS INC
EMSAM, SELEGILINE
- * SOMERSET THERAPEUTICS LLC
CISATRACURIUM BESYLATE, CISATRACURIUM BESYLATE
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
LATANOPROST, LATANOPROST
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE

SOMERSET THERAPS LLC

- * SOMERSET THERAPEUTICS LLC
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
BIMATOPROST, BIMATOPROST

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** S ******* SOMERSET THERAPEUTICS LLC**

BRIMONIDINE TARTRATE, BRIMONIDINE TARTRATE
 CISATRACURIUM BESYLATE PRESERVATIVE FREE, CISATRACURIUM BESYLATE
 CYANOCOBALAMIN, CYANOCOBALAMIN
 DEXAMETHASONE SODIUM PHOSPHATE PRESERVATIVE FREE, DEXAMETHASONE SODIUM PHOSPHATE
 DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
 EPINASTINE HYDROCHLORIDE, EPINASTINE HYDROCHLORIDE
 GLYCOPYRROLATE, GLYCOPYRROLATE
 HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
 METHOCARBAMOL, METHOCARBAMOL
 NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
 OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE
 PILOCARPINE HYDROCHLORIDE, PILOCARPINE HYDROCHLORIDE
 ROPIVACAINE HYDROCHLORIDE, ROPIVACAINE HYDROCHLORIDE
 SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE
 SUCCINYLCHOLINE CHLORIDE, SUCCINYLCHOLINE CHLORIDE
 TOBRAMYCIN, TOBRAMYCIN
 TROPICAMIDE, TROPICAMIDE
 VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE

SPECGX LLC*** SPECGX LLC**

ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
 AMPHETAMINE SULFATE, AMPHETAMINE SULFATE
 ANAFRANIL, CLOMIPRAMINE HYDROCHLORIDE
 ANEXSIA 5/325, ACETAMINOPHEN
 ANEXSIA 7.5/325, ACETAMINOPHEN
 BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
 DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
 DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
 DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, ATROPINE SULFATE
 FENTANYL CITRATE, FENTANYL CITRATE
 FENTANYL-100, FENTANYL
 FENTANYL-12, FENTANYL
 FENTANYL-25, FENTANYL
 FENTANYL-37, FENTANYL
 FENTANYL-50, FENTANYL
 FENTANYL-62, FENTANYL
 FENTANYL-75, FENTANYL
 HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
 HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
 IMIPRAMINE HYDROCHLORIDE, IMIPRAMINE HYDROCHLORIDE
 LEVORPHANOL TARTRATE, LEVORPHANOL TARTRATE
 METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
 METHADOSE, METHADONE HYDROCHLORIDE
 METHYLIN ER, METHYLPHENIDATE HYDROCHLORIDE
 METHYLIN, METHYLPHENIDATE HYDROCHLORIDE
 METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
 MORPHINE SULFATE, MORPHINE SULFATE
 NALTREXONE HYDROCHLORIDE, NALTREXONE HYDROCHLORIDE
 OXYCET, ACETAMINOPHEN
 OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
 OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE
 PAMELOR, NORTRIPTYLINE HYDROCHLORIDE
 POSACONAZOLE, POSACONAZOLE
 RESTORIL, TEMAZEPAM
 ROXICODONE, OXYCODONE HYDROCHLORIDE
 TOFRANIL, IMIPRAMINE HYDROCHLORIDE

SPECTRA MDCL DEVICES*** SPECTRA MEDICAL DEVICES INC**

LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
 SODIUM CHLORIDE 0.9%, SODIUM CHLORIDE

SPH*** SPH PHILILAB INC**

COLESEVELAM HYDROCHLORIDE, COLESEVELAM HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** S ******SPIIL**

- * SUN PHARMA INDUSTRIES LTD
AMPHOTERICIN B, AMPHOTERICIN B
ASPRUZYO SPRINKLE, RANOLAZINE
KAPSPARGO SPRINKLE, METOPROLOL SUCCINATE
NIFEDIPINE, NIFEDIPINE
OMEPRazole MAGNESIUM, OMEPRazole MAGNESIUM (OTC)

SPROUT PHARMS

- * SPROUT PHARMACEUTICALS INC
ADDYI, FLIBANSERIN

SQUARE PHARMS

- * SQUARE PHARMACEUTICALS LTD
ACYCLOVIR, ACYCLOVIR
ARIPIPRazole, ARIPIPRazole
MIRTAZAPINE, MIRTAZAPINE
VALSARTAN, VALSARTAN

ST RENATUS

- * ST RENATUS LLC
KOVANAZE, OXYMETAZOLINE HYDROCHLORIDE

STALLION LABS

- * STALLION LABORATORIES PRIVATE LTD
LEVETIRACETAM, LEVETIRACETAM

STAND HOMEOPATH

- * STANDARD HOMEOPATHIC CO
IVY BLOCK, BENTOQUATAM (OTC)

STASON PHARMS

- * STASON PHARMACEUTICALS INC
PURINETHOL, MERCAPTOPURINE

STERISCIENCE

- * STERISCIENCE PTE LTD
MYCOPHENOLATE MOFETIL HYDROCHLORIDE, MYCOPHENOLATE MOFETIL HYDROCHLORIDE
OXACILLIN SODIUM, OXACILLIN SODIUM
PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM

STI PHARMA LLC

- * STI PHARMA LLC
ARSENIC TRIOXIDE, ARSENIC TRIOXIDE
CARMUSTINE, CARMUSTINE
ISOPROTERENOL HYDROCHLORIDE, ISOPROTERENOL HYDROCHLORIDE
MYAMBUTOL, ETHAMBUTOL HYDROCHLORIDE
THIOTEPA, THIOTEPA
TRIACIN-C, CODEINE PHOSPHATE

STIEFEL

- * STIEFEL LABORATORIES INC
DUAC, BENZOYL PEROXIDE

STRIDES PHARMA

- * STRIDES PHARMA GLOBAL PTE LTD
ABACAVIR SULFATE, ABACAVIR SULFATE
ACARBOSE, ACARBOSE
ACCOLATE, ZAFIRLUKAST
ACETAZOLAMIDE, ACETAZOLAMIDE
ACYCLOVIR, ACYCLOVIR
ALBENDAZOLE, ALBENDAZOLE
ALPRAZOLAM, ALPRAZOLAM
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
AMLODIPINE BESYLATE AND VALSARTAN, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE, AMLODIPINE BESYLATE
BENZONATATE, BENZONATATE
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE, ACETAMINOPHEN
BUTALBITAL, ASPIRIN AND CAFFEINE, ASPIRIN
CABERGOLINE, CABERGOLINE
CALCITRIOL, CALCITRIOL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** S ****

* STRIDES PHARMA GLOBAL PTE LTD
 CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CINACALCET HYDROCHLORIDE, CINACALCET HYDROCHLORIDE
 CLARITHROMYCIN, CLARITHROMYCIN
 COLCHICINE, COLCHICINE
 CYCLOSPORINE, CYCLOSPORINE
 CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
 DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
 DIAZEPAM, DIAZEPAM
 DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
 DOFETILIDE, DOFETILIDE
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
 DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
 DOXYCYCLINE, DOXYCYCLINE
 DUTASTERIDE, DUTASTERIDE
 EFAVIRENZ, EFAVIRENZ
 EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE, EMTRICITABINE
 ERGOCALCIFEROL, ERGOCALCIFEROL
 ETHACRYNIC ACID, ETHACRYNIC ACID
 ETHOSUXIMIDE, ETHOSUXIMIDE
 FLUCYTOSINE, FLUCYTOSINE
 GABAPENTIN, GABAPENTIN
 HYDRA-ZIDE, HYDRALAZINE HYDROCHLORIDE
 HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
 HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
 HYDROCORTISONE, HYDROCORTISONE
 IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
 IBUPROFEN, IBUPROFEN
 IBUPROFEN, IBUPROFEN (OTC)
 IMIPRAMINE HYDROCHLORIDE, IMIPRAMINE HYDROCHLORIDE
 KETOCONAZOLE, KETOCONAZOLE
 LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE
 LAMIVUDINE, LAMIVUDINE
 LIDOCAINE, LIDOCAINE
 LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)
 LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
 MEGESTROL ACETATE, MEGESTROL ACETATE
 MELOXICAM, MELOXICAM
 MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
 METHOXSALEN, METHOXSALEN
 METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
 METRONIDAZOLE, METRONIDAZOLE
 MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
 MORPHINE SULFATE, MORPHINE SULFATE
 MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
 NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
 NATEGLINIDE, NATEGLINIDE
 NEVIRAPINE, NEVIRAPINE
 NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
 OLANZAPINE, OLANZAPINE
 OMEGA-3-ACID ETHYL ESTERS, OMEGA-3-ACID ETHYL ESTERS
 OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE
 OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
 OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
 PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE, POLYETHYLENE GLYCOL
 PENICILLIN V POTASSIUM, PENICILLIN V POTASSIUM
 PIROXICAM, PIROXICAM
 POLYETHYLENE GLYCOL 3350 AND ELECTROLYTES, POLYETHYLENE GLYCOL 3350
 POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
 POTASSIUM CITRATE, POTASSIUM CITRATE
 PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
 PREDNISONE, PREDNISONE
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
 PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** S ******* STRIDES PHARMA GLOBAL PTE LTD**

ROFLUMILAST, ROFLUMILAST
 SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE
 TACROLIMUS, TACROLIMUS
 TENOFOVIR DISOPROXIL FUMARATE, TENOFOVIR DISOPROXIL FUMARATE
 TESTOSTERONE, TESTOSTERONE
 TETRACYCLINE HYDROCHLORIDE, TETRACYCLINE HYDROCHLORIDE
 TORSEMIDE, TORSEMIDE
 TRANYLCYPROMINE SULFATE, TRANYLCYPROMINE SULFATE
 TRAVOPROST, TRAVOPROST
 TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
 URSODIOL, URSODIOL
 VALGANCICLOVIR HYDROCHLORIDE, VALGANCICLOVIR HYDROCHLORIDE
 VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
 VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE
 ZILEUTON, ZILEUTON

STRONGBRIDGE

*** STRONGBRIDGE DUBLIN LTD**
 RECORLEV, LEVOKETOCONAZOLE

SUCAMPO PHARMA LLC

*** SUCAMPO PHARMA AMERICAS LLC**
 AMITIZA, LUBIPROSTONE

SUN PHARM

*** SUN PHARMACEUTICAL INDUSTRIES LTD**
 ABSORICA LD, ISOTRETINOIN
 ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE, ALBUTEROL SULFATE
 ALBUTEROL SULFATE, ALBUTEROL SULFATE
 ALENDRONATE SODIUM, ALENDRONATE SODIUM
 ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE
 ALPRAZOLAM, ALPRAZOLAM
 AMBRISENTAN, AMBRISENTAN
 AMIFOSTINE, AMIFOSTINE
 ARFORMOTEROL TARTRATE, ARFORMOTEROL TARTRATE
 AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
 BICALUTAMIDE, BICALUTAMIDE
 BOSENTAN, BOSENTAN
 BROMSITE, BROMFENAC SODIUM
 BUDESONIDE, BUDESONIDE
 BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
 BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
 BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
 CAFFEINE CITRATE, CAFFEINE CITRATE
 CALCITRIOL, CALCITRIOL
 CAPECITABINE, CAPECITABINE
 CARBIDOPA AND LEVODOPA, CARBIDOPA
 CARBIDOPA, LEVODOPA AND ENTACAPONE, CARBIDOPA
 CARBOPLATIN, CARBOPLATIN
 CEQUA, CYCLOSPORINE
 CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
 CHLOROTHIAZIDE SODIUM, CHLOROTHIAZIDE SODIUM
 CHLORPROMAZINE HYDROCHLORIDE, CHLORPROMAZINE HYDROCHLORIDE
 CINACALCET HYDROCHLORIDE, CINACALCET HYDROCHLORIDE
 CIPROFLOXACIN AND DEXAMETHASONE, CIPROFLOXACIN
 CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
 DALFAMPRIDINE, DALFAMPRIDINE
 DECITABINE, DECITABINE
 DEFERASIROX, DEFERASIROX
 DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION), DESMOPRESSIN ACETATE
 DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
 DOCETAXEL, DOCETAXEL
 DOFETILIDE, DOFETILIDE
 DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL), DOXORUBICIN HYDROCHLORIDE
 DRIZALMA SPRINKLE, DULOXETINE HYDROCHLORIDE
 DROXIDOPA, DROXIDOPA

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** S ******* SUN PHARMACEUTICAL INDUSTRIES LTD**

DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
 ENTACAPONE, ENTACAPONE
 EPOPROSTENOL SODIUM, EPOPROSTENOL SODIUM
 ERLOTINIB HYDROCHLORIDE, ERLOTINIB HYDROCHLORIDE
 ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
 ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM (OTC)
 ESOMEPRAZOLE SODIUM, ESOMEPRAZOLE SODIUM
 ESZOPICLONE, ESZOPICLONE
 EZALLOR SPRINKLE, ROSUVASTATIN CALCIUM
 FEBUXOSTAT, FEBUXOSTAT
 FENOFIBRATE, FENOFIBRATE
 FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, FEXOFENADINE
 FINASTERIDE, FINASTERIDE
 FINGOLIMOD HYDROCHLORIDE, FINGOLIMOD HYDROCHLORIDE
 FOSAMPRENAVIR CALCIUM, FOSAMPRENAVIR CALCIUM
 FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
 FYREMADEL, GANIRELIX ACETATE
 GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
 GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
 GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE, DEXTROMETHORPHAN HYDROBROMIDE (OTC)
 GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
 HYDROXYPROGESTERONE CAPROATE, HYDROXYPROGESTERONE CAPROATE
 IBANDRONATE SODIUM, IBANDRONATE SODIUM
 IMATINIB MESYLATE, IMATINIB MESYLATE
 INFUGEM, GEMCITABINE HYDROCHLORIDE
 IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
 KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
 LACOSAMIDE, LACOSAMIDE
 LANSOPRAZOLE, LANSOPRAZOLE
 LEUPROLIDE ACETATE, LEUPROLIDE ACETATE
 LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE
 LEVETIRACETAM, LEVETIRACETAM
 LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
 LIOTHYRONINE SODIUM, LIOTHYRONINE SODIUM
 LORATADINE, LORATADINE (OTC)
 LOTE Prednol ETABONATE, LOTE Prednol ETABONATE
 LURASIDONE HYDROCHLORIDE, LURASIDONE HYDROCHLORIDE
 MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
 MESALAMINE, MESALAMINE
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 METHOTREXATE SODIUM, METHOTREXATE SODIUM
 NALTREXONE HYDROCHLORIDE, NALTREXONE HYDROCHLORIDE
 NIACIN, NIACIN
 NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE
 NOREPINEPHRINE BITARTRATE, NOREPINEPHRINE BITARTRATE
 ODOMZO, SONIDEGIB PHOSPHATE
 OMEGA-3-ACID ETHYL ESTERS, OMEGA-3-ACID ETHYL ESTERS
 OMEPRAZOLE, OMEPRAZOLE (OTC)
 OPCICON ONE-STEP, LEVONORGESTREL (OTC)
 PALIPERIDONE, PALIPERIDONE
 PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
 PREGABALIN, PREGABALIN
 QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
 RANOLAZINE, RANOLAZINE
 RISEDRONATE SODIUM, RISEDRONATE SODIUM
 RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
 ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
 SUMATRIPTAN AND NAPROXEN SODIUM, NAPROXEN SODIUM
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
 SUNITINIB MALATE, SUNITINIB MALATE
 TADALAFIL, TADALAFIL
 TEMOZOLOMIDE, TEMOZOLOMIDE
 TETRABENAZINE, TETRABENAZINE
 TOBRAMYCIN, TOBRAMYCIN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** S ******* SUN PHARMACEUTICAL INDUSTRIES LTD**

TOPIRAMATE, TOPIRAMATE
 TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
 VECURONIUM BROMIDE, VECURONIUM BROMIDE
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
 WINLEVI, CLASCOTERONE
 XELPROS, LATANOPROST
 YONSA, ABIRATERONE ACETATE
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

SUN PHARM INDS*** SUN PHARMACEUTICAL INDUSTRIES LTD**

CARBIDOPA AND LEVODOPA, CARBIDOPA
 DIVALPROEX SODIUM, DIVALPROEX SODIUM
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
 DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
 EXTENDED PHENYTOIN SODIUM, PHENYTOIN SODIUM
 FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
 FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
 METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 OLANZAPINE, OLANZAPINE
 ONDANSETRON, ONDANSETRON
 OXCARBAZEPINE, OXCARBAZEPINE
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
 TIAGABINE HYDROCHLORIDE, TIAGABINE HYDROCHLORIDE

SUN PHARM INDS (IN)*** SUN PHARMACEUTICAL INDUSTRIES LTD**

METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 ZONISAMIDE, ZONISAMIDE

SUN PHARM INDS INC*** SUN PHARMACEUTICAL INDUSTRIES INC**

ABSORICA, ISOTRETINOIN
 AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
 AMPHETAMINE SULFATE, AMPHETAMINE SULFATE
 AN-SULFUR COLLOID, TECHNETIUM TC-99M SULFUR COLLOID KIT
 CIS-MDP, TECHNETIUM TC-99M MEDRONATE KIT
 CIS-PYRO, TECHNETIUM TC-99M PYROPHOSPHATE KIT
 CLONAZEPAM, CLONAZEPAM
 CLOZAPINE, CLOZAPINE
 DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
 DIGOXIN, DIGOXIN
 ERGOCALCIFEROL, ERGOCALCIFEROL
 FLUMADINE, RIMANTADINE HYDROCHLORIDE
 GLIPIZIDE, GLIPIZIDE
 GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE, GUAIFENESIN (OTC)
 HALOG, HALCINONIDE
 HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
 ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE
 KENALOG, TRIAMCINOLONE ACETONIDE
 LEVORPHANOL TARTRATE, LEVORPHANOL TARTRATE
 LITHIUM CARBONATE, LITHIUM CARBONATE
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
 METOPROLOL TARTRATE, METOPROLOL TARTRATE
 MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
 MIRTAZAPINE, MIRTAZAPINE
 ORTIKOS, BUDESONIDE
 OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
 OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
 PAROMOMYCIN SULFATE, PAROMOMYCIN SULFATE
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
 REPAGLINIDE, REPAGLINIDE
 SEZABY, PHENOBARBITAL SODIUM
 TECHNETIUM TC 99M SESTAMIBI, TECHNETIUM TC-99M SESTAMIBI KIT

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** S ******* SUN PHARMACEUTICAL INDUSTRIES INC**

TECHNETIUM TC-99M MEBROFENIN, TECHNETIUM TC-99M MEBROFENIN KIT
 TECHNETIUM TC99M MERTIATIDE KIT, TECHNETIUM TC-99M MERTIATIDE KIT
 TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
 TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
 TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
 VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE

SUN PHARM INDS LTD*** SUN PHARMACEUTICAL INDUSTRIES LTD**

ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
 ACETAMINOPHEN, ACETAMINOPHEN (OTC)
 AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
 ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
 AZITHROMYCIN, AZITHROMYCIN
 BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
 CARVEDILOL, CARVEDILOL
 CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
 CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
 CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
 CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
 DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
 DOXYCYCLINE, DOXYCYCLINE
 FAMOTIDINE, FAMOTIDINE (OTC)
 FELODIPINE, FELODIPINE
 FENOFIBRATE, FENOFIBRATE
 FLECAINIDE ACETATE, FLECAINIDE ACETATE
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 GABAPENTIN, GABAPENTIN
 GLYCOPYRROLATE, GLYCOPYRROLATE
 LEVETIRACETAM, LEVETIRACETAM
 LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 LISINOPRIL, LISINOPRIL
 LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE, LOPERAMIDE HYDROCHLORIDE (OTC)
 LORATADINE AND PSEUDOEPHEDRINE SULFATE, LORATADINE (OTC)
 LORATADINE REDIDOSE, LORATADINE (OTC)
 LORATADINE, LORATADINE (OTC)
 MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
 MORPHINE SULFATE, MORPHINE SULFATE
 NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
 NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
 NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE
 ONDANSETRON, ONDANSETRON
 OXCARBAZEPINE, OXCARBAZEPINE
 PSEUDOEPHEDRINE HYDROCHLORIDE, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
 RILUZOLE, RILUZOLE
 RISPERIDONE, RISPERIDONE
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
 TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
 TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
 TOPIRAMATE, TOPIRAMATE
 VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
 VALPROIC ACID, VALPROIC ACID

SUN PHARM INDUSTRIES*** SUN PHARMACEUTICAL INDUSTRIES INC**

ALBUTEROL SULFATE, ALBUTEROL SULFATE
 ALLOPURINOL, ALLOPURINOL
 BACTRIM DS, SULFAMETHOXAZOLE
 BACTRIM, SULFAMETHOXAZOLE
 CARVEDILOL PHOSPHATE, CARVEDILOL PHOSPHATE
 CHLORTHALIDONE, CHLORTHALIDONE
 DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
 DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
 DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** S ****

* SUN PHARMACEUTICAL INDUSTRIES INC
ERGOLOID MESYLATES, ERGOLOID MESYLATES
FELODIPINE, FELODIPINE
IMIPRAMINE HYDROCHLORIDE, IMIPRAMINE HYDROCHLORIDE
METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
MINOXIDIL, MINOXIDIL
NITROFURANTOIN, NITROFURANTOIN, MACROCRYSTALLINE
NYSTATIN, NYSTATIN
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
PINDOLOL, PINDOLOL
PREDNISONE, PREDNISONE
PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
QUALAQUIN, QUININE SULFATE
QUINIDINE GLUCONATE, QUINIDINE GLUCONATE
SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
SPIRONOLACTONE, SPIRONOLACTONE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
SULINDAC, SULINDAC
TEMAZEPAM, TEMAZEPAM
TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
TRIMETHOBENZAMIDE HYDROCHLORIDE, TRIMETHOBENZAMIDE HYDROCHLORIDE
ULTRAVATE, HALOBETASOL PROPIONATE

SUNNY

* SUNNY PHARMTECH INC
AMINOCAPROIC ACID, AMINOCAPROIC ACID
CARBOPROST TROMETHAMINE, CARBOPROST TROMETHAMINE
NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS), NITROFURANTOIN

SUNOVION PHARMS INC

* SUNOVION PHARMACEUTICALS INC
APTOM, ESlicARBAZEPINE ACETATE
KYNMOBI, APOMORPHINE HYDROCHLORIDE
LATUDA, LURASIDONE HYDROCHLORIDE

SUNOVION RESP

* SUNOVION RESPIRATORY DEVELOPMENT INC
LONHALA MAGNAIR KIT, GLYCOPYRROLATE

SUNSHINE

* SUNSHINE LAKE PHARMA CO LTD
AZITHROMYCIN, AZITHROMYCIN
CLARITHROMYCIN, CLARITHROMYCIN
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
ENTACAPONE, ENTACAPONE
FEBUXOSTAT, FEBUXOSTAT
LINAGLIPTIN AND METFORMIN HYDROCHLORIDE, LINAGLIPTIN
LINAGLIPTIN, LINAGLIPTIN
METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
RANOLAZINE, RANOLAZINE
SILDENAFIL CITRATE, SILDENAFIL CITRATE
TADALAFIL, TADALAFIL

SUPERNUS PHARMS

* SUPERNUS PHARMACEUTICALS INC
OXTELLAR XR, OXCARBAZEPINE
QELBREE, VILOXAZINE HYDROCHLORIDE
TROKENDI XR, TOPIRAMATE

SUVEN PHARMS

* SUVEN PHARMACEUTICALS LTD
CALCIUM ACETATE, CALCIUM ACETATE
CHLOROQUINE PHOSPHATE, CHLOROQUINE PHOSPHATE
GLYCOPYRROLATE, GLYCOPYRROLATE
MALATHION, MALATHION

SVC PHARMA

* SVC PHARMA LP
DRONABINOL, DRONABINOL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** S ******SWEDISH ORPHAN**

- * SWEDISH ORPHAN BIOVITRUM AB PUBL
ORFADIN, NITISINONE

SYNTHON PHARMS

- * SYNTHON PHARMACEUTICALS INC
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE

**** T ******ACME LABS**

- * THE ACME LABORATORIES LTD
CINACALCET HYDROCHLORIDE, CINACALCET HYDROCHLORIDE
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
METHOCARBAMOL, METHOCARBAMOL
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

GEN HOSP

- * THE GENERAL HOSPITAL CORP
AMMONIA N 13, AMMONIA N-13

METHODIST

- * THE METHODIST HOSP RESEARCH INSTITUTE
AMMONIA N 13, AMMONIA N-13

METHODIST HOSP RES

- * THE METHODIST HOSP RESEARCH INSTITUTE
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

RTEDOSE CORP

- * THE RTEDOSE CORP
ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE, ALBUTEROL SULFATE
ALBUTEROL SULFATE, ALBUTEROL SULFATE
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE

TAGI

- * TAGI PHARMA INC
CHLORTHALIDONE, CHLORTHALIDONE
CHOLESTYRAMINE LIGHT, CHOLESTYRAMINE
CHOLESTYRAMINE, CHOLESTYRAMINE
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
METHAZOLAMIDE, METHAZOLAMIDE

TAIHO ONCOLOGY

- * TAIHO ONCOLOGY INC
LONSURF, TIPIRACIL HYDROCHLORIDE
LYTGOBI, FUTIBATINIB

TAKEDA PHARMS USA

- * TAKEDA PHARMACEUTICALS USA INC
ACTOPLUS MET, METFORMIN HYDROCHLORIDE
ACTOS, PIOGLITAZONE HYDROCHLORIDE
ADDERALL XR 10, AMPHETAMINE ASPARTATE
ADDERALL XR 15, AMPHETAMINE ASPARTATE
ADDERALL XR 20, AMPHETAMINE ASPARTATE
ADDERALL XR 25, AMPHETAMINE ASPARTATE
ADDERALL XR 30, AMPHETAMINE ASPARTATE
ADDERALL XR 5, AMPHETAMINE ASPARTATE
AGRYLIN, ANAGRELIDE HYDROCHLORIDE
ALUNBRIG, BRIGATINIB
CARBATROL, CARBAMAZEPINE
COLCRYS, COLCHICINE
DEXILANT, DEXLANSOPRAZOLE
DUETACT, GLIMEPIRIDE
EXKIVITY, MOBOCERTINIB SUCCINATE
FIRAZYR, ICATIBANT ACETATE
FOSRENOL, LANTHANUM CARBONATE
GATTEX KIT, TEDUGLUTIDE RECOMBINANT
ICLUSIG, PONATINIB HYDROCHLORIDE
INTUNIV, GUANFACINE HYDROCHLORIDE
KAZANO, ALOGLIPTIN BENZOATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** T ****

* TAKEDA PHARMACEUTICALS USA INC
 LIALDA, MESALAMINE
 LIVTENCITY, MARIBAVIR
 MOTEGRITY, PRUCALOPRIDE SUCCINATE
 MYDAYIS, AMPHETAMINE ASPARTATE
 NESINA, ALOGLIPTIN BENZOATE
 NINLARO, IXAZOMIB CITRATE
 OSENI, ALOGLIPTIN BENZOATE
 PENTASA, MESALAMINE
 PREVACID, LANSOPRAZOLE
 ROZEREM, RAMELTEON
 TRINTELLIX, VORTIOXETINE HYDROBROMIDE
 ULORIC, FEBUXOSTAT
 VELCADE, BORTEZOMIB
 VYVANSE, LISDEXAMFETAMINE DIMESYLATE

TAMARANG

* TAMARANG SA
 ROCURONIUM BROMIDE, ROCURONIUM BROMIDE

TARO

* TARO PHARMACEUTICAL INDUSTRIES LTD
 ACETAZOLAMIDE, ACETAZOLAMIDE
 AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
 BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
 BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN
 CARBAMAZEPINE, CARBAMAZEPINE
 CARVEDILOL, CARVEDILOL
 CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
 CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
 CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
 CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
 CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
 CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
 CLOBAZAM, CLOBAZAM
 CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
 CLOCORTOLONE PIVALATE, CLOCORTOLONE PIVALATE
 CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
 CLORAZEPATE DIPOTASSIUM, CLORAZEPATE DIPOTASSIUM
 DESONIDE, DESONIDE
 ENALAPRIL MALEATE, ENALAPRIL MALEATE
 ETODOLAC, ETODOLAC
 EXTENDED PHENYTOIN SODIUM, PHENYTOIN SODIUM
 FELBAMATE, FELBAMATE
 FLUCONAZOLE, FLUCONAZOLE
 FLUOROURACIL, FLUOROURACIL
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 GABAPENTIN, GABAPENTIN
 GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
 HYDROCORTISONE BUTYRATE, HYDROCORTISONE BUTYRATE
 IMIQUIMOD, IMIQUIMOD
 IVERMECTIN, IVERMECTIN (OTC)
 KETOCONAZOLE, KETOCONAZOLE
 LAMOTRIGINE, LAMOTRIGINE
 LEVETIRACETAM, LEVETIRACETAM
 LORATADINE, LORATADINE (OTC)
 MELOXICAM, MELOXICAM
 METRONIDAZOLE, METRONIDAZOLE
 MINOXIDIL (FOR MEN), MINOXIDIL (OTC)
 MINOXIDIL (FOR WOMEN), MINOXIDIL (OTC)
 NORTRIPTYLINE HYDROCHLORIDE, NORTRIPTYLINE HYDROCHLORIDE
 NYSTATIN, NYSTATIN
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 OXCARBAZEPINE, OXCARBAZEPINE
 PHENYTOIN, PHENYTOIN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** T ****

* TARO PHARMACEUTICAL INDUSTRIES LTD
 TERIL, CARBAMAZEPINE
 WARFARIN SODIUM, WARFARIN SODIUM

* TARO PHARMACEUTICALS USA INC
 ACETIC ACID, ACETIC ACID, GLACIAL
 ACYCLOVIR, ACYCLOVIR
 ADAPALENE AND BENZOYL PEROXIDE, ADAPALENE
 ADAPALENE, ADAPALENE
 ALCLOMETASONE DIPROPIONATE, ALCLOMETASONE DIPROPIONATE
 AMMONIUM LACTATE, AMMONIUM LACTATE
 AZELAIC ACID, AZELAIC ACID
 BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
 CICLOPIROX, CICLOPIROX
 CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
 CLOBETASOL PROPIONATE (EMOLLIENT), CLOBETASOL PROPIONATE
 CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
 CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
 CLOTRIMAZOLE, CLOTRIMAZOLE
 CLOTRIMAZOLE, CLOTRIMAZOLE (OTC)
 DAPSONE, DAPSONE
 DERMABET, BETAMETHASONE VALERATE
 DESONIDE, DESONIDE
 DICLOFENAC SODIUM, DICLOFENAC SODIUM
 DIFLORASONE DIACETATE, DIFLORASONE DIACETATE
 ECONAZOLE NITRATE, ECONAZOLE NITRATE
 ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
 FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
 FLUOCINONIDE, FLUOCINONIDE
 GENTAMICIN SULFATE, GENTAMICIN SULFATE
 HALOBETASOL PROPIONATE, HALOBETASOL PROPIONATE
 HYDROCORTISONE VALERATE, HYDROCORTISONE VALERATE
 HYDROCORTISONE, HYDROCORTISONE
 IBUPROFEN, IBUPROFEN
 IBUPROFEN, IBUPROFEN (OTC)
 KETOZOLE, KETOCONAZOLE
 LIDOCAINE, LIDOCAINE
 LORATADINE, LORATADINE (OTC)
 MICONAZOLE 3, MICONAZOLE NITRATE (OTC)
 MOMETASONE FUROATE, MOMETASONE FUROATE
 MUPIROCIN, MUPIROCIN
 MUPIROCIN, MUPIROCIN CALCIUM
 NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
 NYSTATIN, NYSTATIN
 PHENYTOIN, PHENYTOIN
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
 RISPERIDONE, RISPERIDONE
 SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
 STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION
 SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM
 TERBINAFFINE HYDROCHLORIDE, TERBINAFFINE HYDROCHLORIDE (OTC)
 TERCONAZOLE, TERCONAZOLE
 TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
 TRIVAGIZOLE 3, CLOTRIMAZOLE (OTC)

TARO PHARM INDS

* TARO PHARMACEUTICAL INDUSTRIES LTD
 AMCINONIDE, AMCINONIDE
 CARBAMAZEPINE, CARBAMAZEPINE
 CICLOPIROX, CICLOPIROX
 CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
 ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE, ENALAPRIL MALEATE
 ETODOLAC, ETODOLAC
 HYDROCORTISONE BUTYRATE, HYDROCORTISONE BUTYRATE
 LAMOTRIGINE, LAMOTRIGINE

TARO PHARM INDS LTD

* TARO PHARMACEUTICAL INDUSTRIES LTD

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** T ****

* TARO PHARMACEUTICAL INDUSTRIES LTD
 ACETAMINOPHEN, ACETAMINOPHEN (OTC)
 BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
 CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
 DEFERIPRONE, DEFERIPRONE
 DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
 FLUOCINONIDE EMULSIFIED BASE, FLUOCINONIDE
 FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE
 HYDROCORTISONE AND ACETIC ACID, ACETIC ACID, GLACIAL
 HYDROCORTISONE, HYDROCORTISONE
 INFANTS' FEVERALL, ACETAMINOPHEN (OTC)
 LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
 SILDENAFIL CITRATE, SILDENAFIL CITRATE
 TOPICORT, DESOXIMETASONE
 TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

TARO PHARMS

* TARO PHARMACEUTICALS INC
 ADAPALENE, ADAPALENE (OTC)
 BUTENAFINE HYDROCHLORIDE, BUTENAFINE HYDROCHLORIDE (OTC)
 CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
 CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
 CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
 CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
 DAPSONE, DAPSONE
 MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)
 NAFTIFINE HYDROCHLORIDE, NAFTIFINE HYDROCHLORIDE
 OXICONAZOLE NITRATE, OXICONAZOLE NITRATE
 PLIAGLIS, LIDOCAINE
 TAVABOROLE, TAVABOROLE
 TAZAROTENE, TAZAROTENE
 TOPICORT, DESOXIMETASONE
 TRETINOIN, TRETINOIN

TASMAN PHARMA

* TASMAN PHARMA INC
 BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
 CLOTRIMAZOLE, CLOTRIMAZOLE
 FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
 KETOCONAZOLE, KETOCONAZOLE
 VERSACLOZ, CLOZAPINE

TCG FLUENT PHARMA

* TCG FLUENT PHARMA INVESTORS LP
 FLOLIPID, SIMVASTATIN

TEIKOKU PHARMA USA

* TEIKOKU PHARMA USA INC
 LIDODERM, LIDOCAINE

TELIGENT

* TELIGENT PHARMA INC
 FLURANDRENOLIDE, FLURANDRENOLIDE

TELIX

* TELIX PHARMACEUTICALS US INC
 ILLUCCIX, GALLIUM GA-68 GOZETOTIDE

TENSHI

* TENSHI KAIZEN PVT LTD
 LORATADINE, LORATADINE (OTC)

TERSERA

* TERSERA THERAPEUTICS LLC
 ERGOMAR, ERGOTAMINE TARTRATE
 PRIALT, ZICONOTIDE ACETATE
 VARUBI, ROLAPITANT HYDROCHLORIDE
 XERMELO, TELOTRISTAT ETIPRATE
 ZOLADEX, GOSERELIN ACETATE

TETRAPHASE PHARMS

* TETRAPHASE PHARMACEUTICALS INC
 XERAVA, ERAVACYCLINE DIHYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** T ******TEVA**

* TEVA NEUROSCIENCE INC
AZILECT, RASAGILINE MESYLATE

* TEVA PHARMACEUTICALS USA INC
ACYCLOVIR, ACYCLOVIR
ADIPEX-P, PHENTERMINE HYDROCHLORIDE
ALBUTEROL SULFATE, ALBUTEROL SULFATE
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
AMOXICILLIN PEDIATRIC, AMOXICILLIN
AMOXICILLIN, AMOXICILLIN
ATENOLOL, ATENOLOL
AZITHROMYCIN, AZITHROMYCIN
BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
CALCITRIOL, CALCITRIOL
CARVEDILOL, CARVEDILOL
CEFACLOR, CEFACLOL
CEFPROZIL, CEFPROZIL
CELECOXIB, CELECOXIB
CEPHALEXIN, CEPHALEXIN
CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
CILOSTAZOL, CILOSTAZOL
CIMETIDINE, CIMETIDINE
CLARITHROMYCIN, CLARITHROMYCIN
CLEMASTINE FUMARATE, CLEMASTINE FUMARATE
CLONAZEPAM, CLONAZEPAM
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
CLOTRIMAZOLE, CLOTRIMAZOLE
DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
DICLOXACILLIN SODIUM, DICLOXACILLIN SODIUM
DIFLUNISAL, DIFLUNISAL
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DISOPYRAMIDE PHOSPHATE, DISOPYRAMIDE PHOSPHATE
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
EPITOL, CARBAMAZEPINE
ESZOPICLONE, ESZOPICLONE
ETODOLAC, ETODOLAC
FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
FEXOFENADINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE
FINASTERIDE, FINASTERIDE
FLUOCINONIDE EMULSIFIED BASE, FLUOCINONIDE
FLUOCINONIDE, FLUOCINONIDE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FLURBIPROFEN, FLURBIPROFEN
FOSINOPRIL SODIUM, FOSINOPRIL SODIUM
GALZIN, ZINC ACETATE
GLYBURIDE (MICRONIZED), GLYBURIDE
GLYBURIDE, GLYBURIDE
IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
KETOCONAZOLE, KETOCONAZOLE
KETOPROFEN, KETOPROFEN
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LEVOFLOXACIN, LEVOFLOXACIN
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE
LOVASTATIN, LOVASTATIN
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
MEXILETINE HYDROCHLORIDE, MEXILETINE HYDROCHLORIDE
MIRTAPAZINE, MIRTAPAZINE
MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
MOEXIPRIL HYDROCHLORIDE, MOEXIPRIL HYDROCHLORIDE
MUPIROCIN, MUPIROCIN

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** T ****

* TEVA PHARMACEUTICALS USA INC
 NAPROXEN, NAPROXEN
 NEFAZODONE HYDROCHLORIDE, NEFAZODONE HYDROCHLORIDE
 NEOMYCIN SULFATE, NEOMYCIN SULFATE
 NORTRIPTYLINE HYDROCHLORIDE, NORTRIPTYLINE HYDROCHLORIDE
 NYSTATIN, NYSTATIN
 OFLOXACIN, OFLOXACIN
 OXAPROZIN, OXAPROZIN
 OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE
 PENICILLIN-VK, PENICILLIN V POTASSIUM
 PIROXICAM, PIROXICAM
 PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
 PRELONE, PREDNISOLONE
 SILDENAFIL CITRATE, SILDENAFIL CITRATE
 SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE
 SUCRALFATE, SUCRALFATE
 TICLOPIDINE HYDROCHLORIDE, TICLOPIDINE HYDROCHLORIDE
 TOPIRAMATE, TOPIRAMATE
 TORSEMIDE, TORSEMIDE
 TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

TEVA BRANDED PHARM

* TEVA BRANDED PHARMACEUTICAL PRODUCTS R AND D INC
 ACTIGALL, URSODIOL
 AUSTEDO, DEUTETRABENAZINE
 CONDYLOX, PODOFILOX
 LOSEASONIQUE, ETHINYL ESTRADIOL
 MICROZIDE, HYDROCHLOROTHIAZIDE
 NOR-QD, NORETHINDRONE
 PROAIR DIGIHALER, ALBUTEROL SULFATE
 PROAIR HFA, ALBUTEROL SULFATE
 PROAIR RESPICLICK, ALBUTEROL SULFATE
 PROGLYCEM, DIAZOXIDE
 QNASL, BECLOMETHASONE DIPROPIONATE
 QUARTETTE, ETHINYL ESTRADIOL
 SEASONALE, ETHINYL ESTRADIOL
 SEASONIQUE, ETHINYL ESTRADIOL
 ZIAC, BISOPROLOL FUMARATE

TEVA PARENTERAL

* TEVA PARENTERAL MEDICINES INC
 LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE

TEVA PHARM

* TEVA PHARMACEUTICAL INDUSTRIES LTD
 AIRDUO DIGIHALER, FLUTICASONE PROPIONATE
 AIRDUO RESPICLICK, FLUTICASONE PROPIONATE
 ARMONAIR DIGIHALER, FLUTICASONE PROPIONATE

TEVA PHARMS

* TEVA PHARMACEUTICALS DEVELOPMENT INC
 CHLORPROMAZINE HYDROCHLORIDE, CHLORPROMAZINE HYDROCHLORIDE
 PYRIMETHAMINE, PYRIMETHAMINE

* TEVA PHARMACEUTICALS USA
 AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
 ANASTROZOLE, ANASTROZOLE
 BUDESONIDE, BUDESONIDE
 CARBAMAZEPINE, CARBAMAZEPINE
 CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
 CEFDINIR, CEFDINIR
 CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
 CROMOLYN SODIUM, CROMOLYN SODIUM
 DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
 FAMCICLOVIR, FAMCICLOVIR
 FLUVASTATIN SODIUM, FLUVASTATIN SODIUM
 GLIPIZIDE AND METFORMIN HYDROCHLORIDE, GLIPIZIDE
 HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** T ****

* TEVA PHARMACEUTICALS USA
 IRBESARTAN, IRBESARTAN
 LANSOPRAZOLE, LANSOPRAZOLE
 LETROZOLE, LETROZOLE
 LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
 LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
 MONTELUKAST SODIUM, MONTELUKAST SODIUM
 MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
 OLANZAPINE AND FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 OXALIPLATIN, OXALIPLATIN
 PACLITAXEL, PACLITAXEL
 PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
 PRAZOSIN HYDROCHLORIDE, PRAZOSIN HYDROCHLORIDE
 PREGABALIN, PREGABALIN
 QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
 QUININE SULFATE, QUININE SULFATE
 RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
 SILDENAFIL CITRATE, SILDENAFIL CITRATE
 TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
 TRANDOLAPRIL, TRANDOLAPRIL
 URSODIOL, URSODIOL
 VANDAZOLE, METRONIDAZOLE
 VARDENAFIL HYDROCHLORIDE, VARDENAFIL HYDROCHLORIDE

TEVA PHARMS INC

* TEVA PHARMACEUTICALS INC
 ALYQ, TADALAFIL
 THEOPHYLLINE, THEOPHYLLINE

TEVA PHARMS INTL

* TEVA PHARMACEUTICALS INTERNATIONAL GMBH
 AMRIX, CYCLOBENZAPRINE HYDROCHLORIDE
 SYNTRIBO, OMACETAXINE MEPESSUCINATE

TEVA PHARMS USA

* TEVA PHARMACEUTICALS USA
 ACITRETIN, ACITRETIN
 ADENOSINE, ADENOSINE
 ALMOTRIPTAN MALATE, ALMOTRIPTAN MALATE
 ALPROSTADIL, ALPROSTADIL
 AMIKACIN SULFATE, AMIKACIN SULFATE
 ARFORMOTEROL TARTRATE, ARFORMOTEROL TARTRATE
 ATAZANAVIR SULFATE, ATAZANAVIR SULFATE
 ATOMOXETINE HYDROCHLORIDE, ATOMOXETINE HYDROCHLORIDE
 ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
 BEXAROTENE, BEXAROTENE
 BLEOMYCIN SULFATE, BLEOMYCIN SULFATE
 BUDESONIDE, BUDESONIDE
 CLARAVIS, ISOTRETINOIN
 CLOZAPINE, CLOZAPINE
 COPAXONE, GLATIRAMER ACETATE
 DACARBAZINE, DACARBAZINE
 DAUNORUBICIN HYDROCHLORIDE, DAUNORUBICIN HYDROCHLORIDE
 DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
 DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
 DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
 EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE, EFAVIRENZ
 EPOPROSTENOL SODIUM, EPOPROSTENOL SODIUM
 EPTIFIBATIDE, EPTIFIBATIDE
 ESTRADIOL, ESTRADIOL
 ETOPOSIDE, ETOPOSIDE
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 FLUVASTATIN SODIUM, FLUVASTATIN SODIUM
 FOSAPREPITANT DIMEGLUMINE, FOSAPREPITANT DIMEGLUMINE
 GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
 HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
 IBUPROFEN AND FAMOTIDINE, FAMOTIDINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** T ****

- * TEVA PHARMACEUTICALS USA
 - ICOSAPENT ETHYL, ICOSAPENT ETHYL
 - IDARUBICIN HYDROCHLORIDE PFS, IDARUBICIN HYDROCHLORIDE
 - IFOSFAMIDE, IFOSFAMIDE
 - IMATINIB MESYLATE, IMATINIB MESYLATE
 - IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
 - LANSOPRAZOLE, LANSOPRAZOLE
 - LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
 - LEUPROLIDE ACETATE, LEUPROLIDE ACETATE
 - LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE
 - LOGILIA, ULIPRISTAL ACETATE
 - METHYLPREDNISOLONE ACETATE, METHYLPREDNISOLONE ACETATE
 - METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
 - MITOXANTRONE HYDROCHLORIDE, MITOXANTRONE HYDROCHLORIDE
 - MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
 - NOREPINEPHRINE BITARTRATE, NOREPINEPHRINE BITARTRATE
 - OCTREOTIDE ACETATE, OCTREOTIDE ACETATE
 - OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE, AMLODIPINE BESYLATE
 - OMEPRazole, OMEPRazole
 - PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE
 - PARICALCITOL, PARICALCITOL
 - PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 - PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
 - RALOXIFENE HYDROCHLORIDE, RALOXIFENE HYDROCHLORIDE
 - RISEDRONATE SODIUM, RISEDRONATE SODIUM
 - SILDENAFIL CITRATE, SILDENAFIL CITRATE
 - SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE
 - SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
 - SUNITINIB MALATE, SUNITINIB MALATE
 - TADALAFIL, TADALAFIL
 - TENOFOVIR DISOPROXIL FUMARATE, TENOFOVIR DISOPROXIL FUMARATE
 - TOBRAMYCIN, TOBRAMYCIN
 - TOLTERODINE TARTRATE, TOLTERODINE TARTRATE
 - TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
 - TREPROSTINIL, TREPROSTINIL
 - VECURONIUM BROMIDE, VECURONIUM BROMIDE
 - VIGABATRIN, VIGABATRIN
 - VILAZODONE HYDROCHLORIDE, VILAZODONE HYDROCHLORIDE
 - VINCRISTINE SULFATE PFS, VINCRISTINE SULFATE
 - ZANOSAR, STREPTOZOCIN
- * TEVA PHARMACEUTICALS USA INC
 - ABIRATERONE ACETATE, ABIRATERONE ACETATE
 - ALYQ, TADALAFIL
 - AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
 - CAPECITABINE, CAPECITABINE
 - DAPTOMYCIN, DAPTOMYCIN
 - DARUNAVIR, DARUNAVIR
 - DEFERASIROX, DEFERASIROX
 - EFINACONAZOLE, EFINACONAZOLE
 - ELETRIPTAN HYDROBROMIDE, ELETRIPTAN HYDROBROMIDE
 - EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE, EMTRICITABINE
 - EPINEPHRINE (AUTOINJECTOR), EPINEPHRINE
 - ESTRADIOL, ESTRADIOL
 - EVEROLIMUS, EVEROLIMUS
 - FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE, FLUTICASONE PROPIONATE
 - ICATIBANT ACETATE, ICATIBANT ACETATE
 - IVERMECTIN, IVERMECTIN
 - LIOTHYRONINE SODIUM, LIOTHYRONINE SODIUM
 - MEDROXYPROGESTERONE ACETATE, MEDROXYPROGESTERONE ACETATE
 - MESALAMINE, MESALAMINE
 - METHYLERGONOVINE MALEATE, METHYLERGONOVINE MALEATE
 - METRONIDAZOLE, METRONIDAZOLE
 - MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
 - NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
 - OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** T ****

* TEVA PHARMACEUTICALS USA INC
ONSURA, ETHINYL ESTRADIOL
OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
PENCICLOVIR, PENCICLOVIR
PIRFENIDONE, PIRFENIDONE
TOBRAMYCIN, TOBRAMYCIN
TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

TEVA PHARMS USA INC

* TEVA PHARMACEUTICALS USA INC
APREMILAST, APREMILAST
BREXPIRAZOLE, BREXPIRAZOLE
CHLORZOXAZONE, CHLORZOXAZONE
ERLOTINIB HYDROCHLORIDE, ERLOTINIB HYDROCHLORIDE
ERYTHROMYCIN, ERYTHROMYCIN
ETHINYL ESTRADIOL; ETONOGESTREL, ETHINYL ESTRADIOL
FINZALA, ETHINYL ESTRADIOL
FORMOTEROL FUMARATE, FORMOTEROL FUMARATE
FULVESTRANT, FULVESTRANT
LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM
LUBIPROSTONE, LUBIPROSTONE
MIFEPRISTONE, MIFEPRISTONE
POTASSIUM CITRATE, POTASSIUM CITRATE
SORAFENIB TOSYLATE, SORAFENIB TOSYLATE
TASIMELTEON, TASIMELTEON
TIOPRONIN, TIOPRONIN

TEYRO LABS

* TEYRO LABS PRIVATE LTD
CARBOPLATIN, CARBOPLATIN
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE

THE FEINSTEIN INST

* THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

THE J MOLNER

* THE J MOLNER CO OU
DESOXIMETASONE, DESOXIMETASONE
DIFLORASONE DIACETATE, DIFLORASONE DIACETATE
HYDROCORTISONE BUTYRATE, HYDROCORTISONE BUTYRATE

THEA PHARMA

* THEA PHARMA INC
AKTEN, LIDOCAINE HYDROCHLORIDE
AZASITE, AZITHROMYCIN
BETIMOL, TIMOLOL
COSOPT PF, DORZOLAMIDE HYDROCHLORIDE
COSOPT, DORZOLAMIDE HYDROCHLORIDE
IYUZEH, LATANOPROST
ZIOPTAN, TAFLUPROST

THEPHARMANETWORK LLC

* THEPHARMANETWORK LLC
BENZONATATE, BENZONATATE
ISONIAZID, ISONIAZID
METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
NIMODIPINE, NIMODIPINE
THERMAZENE, SILVER SULFADIAZINE

THERAGNOSTICS

* THERAGNOSTICS INC
NEPHROSCAN, TECHNETIUM TC-99M SUCCIMER

THERAKIND

* THERAKIND LTD
JYLAMVO, METHOTREXATE

THERAPEUTICSMD INC

* THERAPEUTICSMD INC
ANNOVERA, ETHINYL ESTRADIOL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** T ****

* THERAPEUTICSMD INC
IMVEXXY, ESTRADIOL

THINQ PHARM-CRO PVT

* THINQ PHARMA-CRO PRIVATE LTD
FLUCONAZOLE, FLUCONAZOLE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)

TIANJIN KINGYORK

* TIANJIN KINGYORK PHARMACEUTICALS CO LTD
METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE SODIUM SUCCINATE

TIANJIN TIANYAO

* TIANJIN TIANYAO PHARMACEUTICALS CO LTD
CELECOXIB, CELECOXIB
METHYLPREDNISOLONE, METHYLPREDNISOLONE

TIME-CAP LABS INC

* TIME-CAP LABORATORIES INC
VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE

TOLMAR

* TOLMAR INC
CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CALCIPOTRIENE, CALCIPOTRIENE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
JATENZO, TESTOSTERONE UNDECANOATE
KETOCONAZOLE, KETOCONAZOLE
METRONIDAZOLE, METRONIDAZOLE
NAFTIFINE HYDROCHLORIDE, NAFTIFINE HYDROCHLORIDE
* TOLMAR INTERNATIONAL LTD
FENSOLVI KIT, LEUPROLIDE ACETATE

TOLMAR THERAP

* TOLMAR THERAPEUTICS INC
ELIGARD KIT, LEUPROLIDE ACETATE

TOPROL

* TOPROL ACQUISITION LLC
TOPROL-XL, METOPROLOL SUCCINATE

TORPHARM

* TORPHARM INC
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE

TORRENT

* TORRENT PHARMA INC
APREPITANT, APREPITANT
DICHLORPHENAMIDE, DICHLORPHENAMIDE
ERYTHROMYCIN, ERYTHROMYCIN
NITISINONE, NITISINONE
* TORRENT PHARMACEUTICALS LTD
ACYCLOVIR, ACYCLOVIR
ANAGRELIDE HYDROCHLORIDE, ANAGRELIDE HYDROCHLORIDE
ARIPIRAZOLE, ARIPIRAZOLE
CELECOXIB, CELECOXIB
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
DAPSONE, DAPSONE
DARIFENACIN HYDROBROMIDE, DARIFENACIN HYDROBROMIDE
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
FENOFIBRATE (MICRONIZED), FENOFIBRATE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
ITRACONAZOLE, ITRACONAZOLE
LAMOTRIGINE, LAMOTRIGINE
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
MONTELUKAST SODIUM, MONTELUKAST SODIUM
MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
NEBIVOLOL HYDROCHLORIDE, NEBIVOLOL HYDROCHLORIDE
NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
NYSTATIN, NYSTATIN
OLANZAPINE, OLANZAPINE
OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE, AMLODIPINE BESYLATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** T ****

* TORRENT PHARMACEUTICALS LTD
 OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
 RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM
 ROFLUMILAST, ROFLUMILAST
 ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
 SILDENAFIL CITRATE, SILDENAFIL CITRATE
 TADALAFIL, TADALAFIL
 TOLTERODINE TARTRATE, TOLTERODINE TARTRATE
 TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

TORRENT PHARMS

* TORRENT PHARMACEUTICALS LTD
 CARBAMAZEPINE, CARBAMAZEPINE
 CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
 DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
 ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
 LAMOTRIGINE, LAMOTRIGINE
 LEVETIRACETAM, LEVETIRACETAM
 PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
 PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
 RISPERIDONE, RISPERIDONE
 ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

TORRENT PHARMS LTD

* TORRENT PHARMACEUTICALS LTD
 CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
 ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
 FELODIPINE, FELODIPINE
 MONTELUKAST SODIUM, MONTELUKAST SODIUM
 SILDENAFIL CITRATE, SILDENAFIL CITRATE

TRAVERE

* TRAVERE THERAPEUTICS INC
 CHOLBAM, CHOLIC ACID

TREVENA

* TREVENA INC
 OLINVYK, OLICERIDINE

TRIPPOINT

* TRIPPOINT THERAPEUTICS
 ELEPSIA XR, LEVETIRACETAM

TRIS PHARMA INC

* TRIS PHARMA INC
 DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
 DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
 DEXTROMETHORPHAN POLISTIREX, DEXTROMETHORPHAN POLISTIREX (OTC)
 DROXIDOPA, DROXIDOPA
 DYANAVEL XR 10, AMPHETAMINE
 DYANAVEL XR 15, AMPHETAMINE
 DYANAVEL XR 20, AMPHETAMINE
 DYANAVEL XR 5, AMPHETAMINE
 DYANAVEL XR, AMPHETAMINE
 HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
 HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX, CHLORPHENIRAMINE POLISTIREX
 IBUPROFEN, IBUPROFEN (OTC)
 METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
 MORPHINE SULFATE, MORPHINE SULFATE
 PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE, CODEINE PHOSPHATE
 PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE, DEXTROMETHORPHAN
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
 RISPERIDONE, RISPERIDONE
 THEOPHYLLINE, THEOPHYLLINE

TRUSTEES UNIV PA

* TRUSTEES OF THE UNIV OF PENNSYLVANIA
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

TULEX PHARMS INC

* TULEX PHARMACEUTICALS INC
 AMINOCAPROIC ACID, AMINOCAPROIC ACID

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** T ****

- * TULEX PHARMACEUTICALS INC
CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
METHYLERGONOVINE MALEATE, METHYLERGONOVINE MALEATE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE

TWI PHARMS

- * TWI PHARMACEUTICALS INC
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
DEXLANSOPRAZOLE, DEXLANSOPRAZOLE
DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DIMETHYL FUMARATE, DIMETHYL FUMARATE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
FENOFIBRIC ACID, CHOLINE FENOFIBRATE
FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE
GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
MEGESTROL ACETATE, MEGESTROL ACETATE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
MYCOPHENOLIC SODIUM, MYCOPHENOLIC SODIUM
NIFEDIPINE, NIFEDIPINE
PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
TERBUTALINE SULFATE, TERBUTALINE SULFATE
TESTOSTERONE, TESTOSTERONE

TWI PHARMS INC

- * TWI PHARMACEUTICALS INC
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE

**** U ******UBI**

- * UBI PHARMA INC
CASPOFUNGIN ACETATE, CASPOFUNGIN ACETATE
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE

UCB INC

- * UCB INC
BRIVIACT, BRIVARACETAM
KEPPRA XR, LEVETIRACETAM
KEPPRA, LEVETIRACETAM
NAYZILAM, MIDAZOLAM
NEUPRO, ROTIGOTINE
VIMPAT, LACOSAMIDE

UCLA BIOMEDICAL

- * UCLA BIOMEDICAL CYCLOTRON
AMMONIA N 13, AMMONIA N-13
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

UCSF RODIOPHARM

- * UCSF RODIOPHARMACEUTICAL FACILITY
AMMONIA N 13, AMMONIA N-13
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

UIHC PET IMAGING

- * UNIV IOWA HOSPS AND CLINICS PET IMAGING CENTER
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
GALLIUM GA 68 DOTATOC, GALLIUM GA-68 DOTATOC

ULTRAGENYX PHARM INC

- * ULTRAGENYX PHARMACEUTICAL INC
DOJOLVI, TRIHEPTANOIN

UMEDICA LABS PVT LTD

- * UMEDICA LABORATORIES PRIVATE LTD
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
CARBAMAZEPINE, CARBAMAZEPINE
CELECOXIB, CELECOXIB
CHLORTHALIDONE, CHLORTHALIDONE
DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
SILDENAFIL CITRATE, SILDENAFIL CITRATE
TADALAFIL, TADALAFIL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** U ******UNICHEM**

* UNICHEM LABORATORIES LTD
 ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE
 ALLOPURINOL, ALLOPURINOL
 AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
 AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
 AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
 ARIPIPRAZOLE, ARIPIPRAZOLE
 ATENOLOL AND CHLORTHALIDONE, ATENOLOL
 ATENOLOL, ATENOLOL
 BACLOFEN, BACLOFEN
 BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE, BISOPROLOL FUMARATE
 BISOPROLOL FUMARATE, BISOPROLOL FUMARATE
 BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
 CARBAMAZEPINE, CARBAMAZEPINE
 CHLORTHALIDONE, CHLORTHALIDONE
 CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
 CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
 DIVALPROEX SODIUM, DIVALPROEX SODIUM
 EXTENDED PHENYTOIN SODIUM, PHENYTOIN SODIUM
 GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
 HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
 MELOXICAM, MELOXICAM
 MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 METRONIDAZOLE, METRONIDAZOLE
 MONTELUKAST SODIUM, MONTELUKAST SODIUM
 PIROXICAM, PIROXICAM
 QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
 RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
 SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE
 TADALAFIL, TADALAFIL
 TOLTERODINE TARTRATE, TOLTERODINE TARTRATE
 TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
 ZALEPLON, ZALEPLON
 ZONISAMIDE, ZONISAMIDE

UNICHEM LABS LTD

* UNICHEM LABORATORIES LIMITED
 DIVALPROEX SODIUM, DIVALPROEX SODIUM
 * UNICHEM LABORATORIES LTD
 LAMOTRIGINE, LAMOTRIGINE
 TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
 TOPIRAMATE, TOPIRAMATE

UNIMARK REMEDIES LTD

* UNIMARK REMEDIES LTD
 MONTELUKAST SODIUM, MONTELUKAST SODIUM

UNIQUE

* UNIQUE PHARMACEUTICAL LABORATORIES A DIV OF JB CHEMICALS AND PHARMACEUTICALS LTD
 ATENOLOL, ATENOLOL
 CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
 CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
 CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
 CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
 DICLOFENAC SODIUM, DICLOFENAC SODIUM
 FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
 GLIPIZIDE, GLIPIZIDE
 LITHIUM CARBONATE, LITHIUM CARBONATE
 MIDODRINE HYDROCHLORIDE, MIDODRINE HYDROCHLORIDE
 OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
 TINIDAZOLE, TINIDAZOLE
 TOLTERODINE TARTRATE, TOLTERODINE TARTRATE
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

UNIQUE PHARM

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** U ****

- * UNIQUE PHARMACEUTICAL LABORATORIES
CARBAMAZEPINE, CARBAMAZEPINE
LORATADINE, LORATADINE (OTC)

UNITED BIOMEDCL

- * UNITED BIOMEDICAL INC
TERBUTALINE SULFATE, TERBUTALINE SULFATE

UNITED GUARDIAN

- * UNITED GUARDIAN INC
RENACIDIN, CITRIC ACID

UNITED RES LABS

- * UNITED RESEARCH LABORATORIES LLC
BISOPROLOL FUMARATE, BISOPROLOL FUMARATE
OXAZEPAM, OXAZEPAM

UNITED THERAP

- * UNITED THERAPEUTICS CORP
ORENITRAM, TREPROSTINIL DIOLAMINE
REMODULIN, TREPROSTINIL
TYVASO DPI, TREPROSTINIL
TYVASO, TREPROSTINIL

UNIV ALAHAMA BIRM

- * UNIV ALABAMA AT BIRMINGHAM
AMMONIA N 13, AMMONIA N-13

UNIV CA LOS ANGELES

- * UNIV CALIFORNIA LOS ANGELES
GALLIUM GA 68 GOZETOTIDE, GALLIUM GA-68 GOZETOTIDE

UNIV MICHIGAN

- * UNIV MICHIGAN PET RADIOPHARMACEUTICAL PRODUCTION PROGRAM
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

UNIV OF CA SAN FRAN

- * UNIV OF CALIFORNIA SAN FRANCISCO
GALLIUM GA 68 GOZETOTIDE, GALLIUM GA-68 GOZETOTIDE

UNIV SOUTHERN CA

- * UNIV SOUTHERN CALIFORNIA DBA USC MOLECULAR IMAGING CENTER
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

UNIV TX MD ANDERSON

- * UNIV TEXAS MD ANDERSON CANCER CENTER
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

UNIV TX SW MEDCTR

- * UNIV TEXAS SOUTHWESTERN MEDCTR
AMMONIA N 13, AMMONIA N-13

UNIV UTAH CYCLOTRON

- * UNIV UTAH CYCLOTRON RADIOCHEMISTRY LAB
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

UNIV WISCONSIN

- * UNIV WISCONSIN SYSTEM
AMMONIA N 13, AMMONIA N-13

UPJOHN

- * UPJOHN MANUFACTURING IRELAND UNLTD
LIPITOR, ATORVASTATIN CALCIUM
RELPA, ELETRIPTAN HYDROBROMIDE
- * UPJOHN US 2 LLC
CELEBREX, CELECOXIB
DETROL LA, TOLTERODINE TARTRATE
DETROL, TOLTERODINE TARTRATE
EFFEXOR XR, VENLAFAXINE HYDROCHLORIDE
INSPIRA, EPLERENONE
LYRICA CR, PREGABALIN
LYRICA, PREGABALIN
XALATAN, LATANOPROST
XANAX XR, ALPRAZOLAM
XANAX, ALPRAZOLAM

UPSHER SMITH LABS

- * UPSHER SMITH LABORATORIES LLC

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** U ******* UPSHER SMITH LABORATORIES LLC**

AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
BACLOFEN, BACLOFEN
BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
BEXAROTENE, BEXAROTENE
BRIMONIDINE TARTRATE AND TIMOLOL MALEATE, BRIMONIDINE TARTRATE
BUMETANIDE, BUMETANIDE
CHLORPROMAZINE HYDROCHLORIDE, CHLORPROMAZINE HYDROCHLORIDE
CLOBAZAM, CLOBAZAM
DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, ATROPINE SULFATE
DIVALPROEX SODIUM, DIVALPROEX SODIUM
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
DROXIDOPA, DROXIDOPA
ETHACRYNIC ACID, ETHACRYNIC ACID
EXEMESTANE, EXEMESTANE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE
FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
HALOPERIDOL, HALOPERIDOL
ISOTRETINOIN, ISOTRETINOIN
JANTOVEN, WARFARIN SODIUM
KLOR-CON M10, POTASSIUM CHLORIDE
KLOR-CON M15, POTASSIUM CHLORIDE
KLOR-CON M20, POTASSIUM CHLORIDE
KLOR-CON, POTASSIUM CHLORIDE
LAMIVUDINE, LAMIVUDINE
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
MIRTAZAPINE, MIRTAZAPINE
MORPHINE SULFATE, MORPHINE SULFATE
MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
NYSTATIN, NYSTATIN
ORVATEN, MIDODRINE HYDROCHLORIDE
OXANDROLONE, OXANDROLONE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
PACERONE, AMIODARONE HYDROCHLORIDE
PREVALITE, CHOLESTYRAMINE
PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
QUDEXY XR, TOPIRAMATE
RAMELTEON, RAMELTEON
SORINE, SOTALOL HYDROCHLORIDE
TOSYMRA, SUMATRIPTAN
VOGELXO, TESTOSTERONE
ZEMBRACE SYMTOUCH, SUMATRIPTAN SUCCINATE

URL LABS*** URL LABORATORIES LLC**

CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE

UROGEN PHARMA*** UROGEN PHARMA LTD**

JELMYTO, MITOMYCIN

UROVANT*** UROVANT SCIENCES GMBH**

GEMTESA, VIBEGRON

US ANTIBIOTICS*** US ANTIBIOTICS LLC**

AMOXIL, AMOXICILLIN
AUGMENTIN '125', AMOXICILLIN
AUGMENTIN '250', AMOXICILLIN
AUGMENTIN '875', AMOXICILLIN
AUGMENTIN ES-600, AMOXICILLIN
LAROTID, AMOXICILLIN

USPHARMA*** USPHARMA LTD**

NITRO-DUR, NITROGLYCERIN

USPHARMA WINDLAS

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** U ****

- * USPHARMA WINDLAS LLC
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE

USV

- * USV PRIVATE LTD
OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE (OTC)
ZOLEDRONIC ACID, ZOLEDRONIC ACID

USWM

- * USWM LLC
CORCARD, NADOLOL
LUCEMYRA, LOFEXIDINE HYDROCHLORIDE
REVONTO, DANTROLENE SODIUM

**** V ******VALEANT**

- * VALEANT PHARMACEUTICALS INTERNATIONAL
BONTRIL PDM, PHENDIMETRAZINE TARTRATE
MYSOLINE, PRIMIDONE

VALEANT BERMUDA

- * VALEANT INTERNATIONAL BERMUDA
PENLAC, CICLOPIROX
RETIN-A, TRETINOIN

VALEANT INTL

- * VALEANT INTERNATIONAL BARBADOS SRL
RETIN-A MICRO, TRETINOIN
RETIN-A, TRETINOIN
RETIN-A-MICRO, TRETINOIN
- * VALEANT INTERNATIONAL SRL
BENZAMYCIN, BENZOYL PEROXIDE

VALEANT LUXEMBOURG

- * VALEANT PHARMACEUTICALS LUXEMBOURG SARL
TARGRETIN, BEXAROTENE
VISUDYNE, VERTEPORFIN

VALEANT PHARM INTL

- * VALEANT PHARMACEUTICALS INTERNATIONAL
ANDROID 25, METHYLTESTOSTERONE
LIBRIUM, CHLORDIAZEPOXIDE HYDROCHLORIDE

VALEANT PHARMS

- * VALEANT PHARMACEUTICALS NORTH AMERICA LLC
PENTOXIFYLLINE, PENTOXIFYLLINE

VALEANT PHARMS INTL

- * VALEANT PHARMACEUTICALS INTERNATIONAL
APRISO, MESALAMINE
COLAZAL, BALSALAZIDE DISODIUM
CUPRIMINE, PENICILLAMINE
LACRISERT, HYDROXYPROPYL CELLULOSE

VALEANT PHARMS NORTH

- * VALEANT PHARMACEUTICALS NORTH AMERICA LLC
CARAC, FLUOROURACIL
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
FENOFIBRATE, FENOFIBRATE
NIFEDIPINE, NIFEDIPINE
RENOVA, TRETINOIN
RETIN-A, TRETINOIN
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

VALIDUS PHARMS

- * VALIDUS PHARMACEUTICALS LLC
ANZEMET, DOLASETRON MESYLATE
BUMEX, BUMETANIDE
DRISDOL, ERGOCALCIFEROL
EQUETRO, CARBAMAZEPINE
HIPREX, METHENAMINE HIPPURATE
LASIX, FUROSEMIDE
LOPRESSOR HCT, HYDROCHLOROTHIAZIDE
LOPRESSOR, METOPROLOL TARTRATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** V ****

* VALIDUS PHARMACEUTICALS LLC
LOTENSIN HCT, BENAZEPRIL HYDROCHLORIDE
LOTENSIN, BENAZEPRIL HYDROCHLORIDE
NORPRAMIN, DESIPRAMINE HYDROCHLORIDE
PARLODEL, BROMOCRIPTINE MESYLATE
ROCALTROL, CALCITRIOL

VALIDUS PHARMS INC

* VALIDUS PHARMACEUTICALS INC
MARPLAN, ISOCARBOXAZID

VANDA PHARMS INC

* VANDA PHARMACEUTICALS INC
FANAPT, ILOPERIDONE
HETLIOZ LQ, TASIMELTEON
HETLIOZ, TASIMELTEON

VELOXIS PHARMS INC

* VELOXIS PHARMACEUTICALS INC
ENVARUS XR, TACROLIMUS

VERITY

* VERITY PHARMACEUTICALS INC
TRELSTAR, TRIPTORELIN PAMOATE

VERO BIOTECH

* VERO BIOTECH
GENOSYL, NITRIC OXIDE

VEROSCIENCE

* VEROSCIENCE LLC
CYCLOSET, BROMOCRIPTINE MESYLATE

VERTEX PHARMS

* VERTEX PHARMACEUTICALS INC
KALYDECO, IVACAFTOR

VERTEX PHARMS INC

* VERTEX PHARMACEUTICALS INC
KALYDECO, IVACAFTOR
ORKAMBI, IVACAFTOR
SYMDEKO (COPACKAGED), IVACAFTOR
TRIKAFTA (COPACKAGED), ELEXACAFTOR, IVACAFTOR, TEZACAFTOR

VERTICAL PHARMS LLC

* VERTICAL PHARMACEUTICALS LLC
DIVIGEL, ESTRADIOL

VERU

* VERU INC
ENTADFI, FINASTERIDE

VGYAAN

* VGYAAN PHARMACEUTICALS LLC
CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
LEUPROLIDE ACETATE, LEUPROLIDE ACETATE
NADOLOL, NADOLOL

VIATRIS

* VIATRIS SPECIALTY LLC
CARDURA XL, DOXAZOSIN MESYLATE
CARDURA, DOXAZOSIN MESYLATE
DILANTIN, PHENYTOIN SODIUM
DILANTIN-125, PHENYTOIN
GEODON, ZIPRASIDONE HYDROCHLORIDE
GEODON, ZIPRASIDONE MESYLATE
NEURONTIN, GABAPENTIN
NITROSTAT, NITROGLYCERIN
NORVASC, AMLODIPINE BESYLATE
REVATIO, SILDENAFIL CITRATE
VIAGRA, SILDENAFIL CITRATE
ZOLOFT, SERTRALINE HYDROCHLORIDE

VICURON HOLDINGS

* VICURON HOLDINGS LLC
ERAXIS, ANIDULAFUNGIN

VIFOR FRESENIUS

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** V ****

- * VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA FRANCE
VELPHORO, FERRIC OXYHYDROXIDE

VIFOR PHARMA

- * VIFOR PHARMA INC
VELTASSA, PATIROMER SORBITE X CALCIUM

VIIV HLTHCARE

- * VIIV HEALTHCARE CO
APRETUDE, CABOTEGRAVIR
CABENUVA KIT, CABOTEGRAVIR
COMBIVIR, LAMIVUDINE
DOVATO, DOLUTEGRAVIR SODIUM
EPIVIR, LAMIVUDINE
EPZICOM, ABACAVIR SULFATE
JULUCA, DOLUTEGRAVIR SODIUM
LEXIVA, FOSAMPRENAVIR CALCIUM
RETROVIR, ZIDOVUDINE
RUKOBIA, FOSTEMSAVIR TROMETHAMINE
SELZENTRY, MARAVIROC
TIVICAY PD, DOLUTEGRAVIR SODIUM
TIVICAY, DOLUTEGRAVIR SODIUM
TRIUMEQ PD, ABACAVIR SULFATE
TRIUMEQ, ABACAVIR SULFATE
TRIZIVIR, ABACAVIR SULFATE
VOCABRIA, CABOTEGRAVIR SODIUM
ZIAGEN, ABACAVIR SULFATE

VINTAGE

- * VINTAGE PHARMACEUTICALS LLC
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
DUTASTERIDE, DUTASTERIDE

VINTAGE PHARMS

- * VINTAGE PHARMACEUTICALS
GILDAGIA, ETHINYL ESTRADIOL
GILDESS 24 FE, ETHINYL ESTRADIOL
KIMIDESS, DESOGESTREL
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
- * VINTAGE PHARMACEUTICALS INC
ALLOPURINOL, ALLOPURINOL
BACLOFEN, BACLOFEN
IBUPROFEN, IBUPROFEN (OTC)
METHYLPREDNISOLONE, METHYLPREDNISOLONE
PERPHENAZINE, PERPHENAZINE
PREDNISONE, PREDNISONE

VINTAGE PHARMS LLC

- * VINTAGE PHARMACEUTICALS LLC
FELODIPINE, FELODIPINE
MYZILRA, ETHINYL ESTRADIOL
PERCOCET, ACETAMINOPHEN
PREVIFEM, ETHINYL ESTRADIOL

VIRTUS PHARM

- * VIRTUS PHARMACEUTICAL INC
ACARBOSE, ACARBOSE
ALBUTEROL SULFATE, ALBUTEROL SULFATE
PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE

VIRTUS PHARMS

- * VIRTUS PHARMACEUTICALS LLC
LEVORPHANOL TARTRATE, LEVORPHANOL TARTRATE
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
PROMETRIUM, PROGESTERONE

VISTA PHARMS

- * VISTA PHARMACEUTICALS INC
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE

VISTAPHARM

- * VISTAPHARM INC
ACYCLOVIR, ACYCLOVIR
AMINOCAPROIC ACID, AMINOCAPROIC ACID

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** V ****

* VISTAPHARM INC
ARIPIPIRAZOLE, ARIPIPIRAZOLE
CLOBAZAM, CLOBAZAM
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
LACTULOSE, LACTULOSE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
NYSTATIN, NYSTATIN
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
PHENYTOIN, PHENYTOIN
SUCRALFATE, SUCRALFATE

VISUM PHARM

* VISUM PHARMACEUTICAL CO LTD
METOPROLOL SUCCINATE, METOPROLOL SUCCINATE

VITRUVIAS THERAP

* VITRUVIAS THERAPEUTICS
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
* VITRUVIAS THERAPEUTICS LLC
CYANOCOBALAMIN, CYANOCOBALAMIN
LIDOCAINE, LIDOCAINE

VIVUS

* VIVUS INC
QSYMIA, PHENTERMINE HYDROCHLORIDE

VIWIT PHARM

* VIWIT PHARMACEUTICAL CO LTD
LEVETIRACETAM, LEVETIRACETAM
PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
TOPIRAMATE, TOPIRAMATE

VKT PHARMA

* VKT PHARMA PRIVATE LTD
FAMOTIDINE, FAMOTIDINE (OTC)
LEVETIRACETAM, LEVETIRACETAM
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
RANOLAZINE, RANOLAZINE
TADALAFIL, TADALAFIL

VPI PHARMS INC

* VPI PHARMACEUTICALS INC
ETHACRYNATE SODIUM, ETHACRYNATE SODIUM

VPNA

* VALEANT PHARMACEUTICALS NORTH AMERICA
DICLOFENAC SODIUM, DICLOFENAC SODIUM

VYERA PHARMS LLC

* VYERA PHARMACEUTICALS LLC
DARAPRIM, PYRIMETHAMINE

**** W ******WA UNIV SCH MED**

* WASHINGTON UNIV SCHOOL MEDICINE
AMMONIA N 13, AMMONIA N-13
CHOLINE C-11, CHOLINE C-11

WANBANG BIOPHARMS

* WANBANG BIOPHARMACEUTICALS
CARISOPRODOL, CARISOPRODOL
LEFLUNOMIDE, LEFLUNOMIDE

WATSON LABS

* WATSON LABORATORIES
FOLIC ACID, FOLIC ACID
PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
* WATSON LABORATORIES INC
ACARBOSE, ACARBOSE
ALBUTEROL SULFATE, ALBUTEROL SULFATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** W ******* WATSON LABORATORIES INC**

ALENDRONATE SODIUM, ALENDRONATE SODIUM
ALLOPURINOL, ALLOPURINOL
AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE
AMOXAPINE, AMOXAPINE
ATENOLOL AND CHLORTHALIDONE, ATENOLOL
CARISOPRODOL, CARISOPRODOL
CHLORZOXAZONE, CHLORZOXAZONE
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
COL-PROBENECID, COLCHICINE
DESOGESTREL AND ETHINYL ESTRADIOL, DESOGESTREL
DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE
ESTAZOLAM, ESTAZOLAM
GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
GLIPIZIDE, GLIPIZIDE
GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
LAMOTRIGINE, LAMOTRIGINE
LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
LISINOPRIL, LISINOPRIL
LORAZEPAM, LORAZEPAM
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
LOXAPINE SUCCINATE, LOXAPINE SUCCINATE
METHYLPREDNISOLONE, METHYLPREDNISOLONE
METRONIDAZOLE, METRONIDAZOLE
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
MINOXIDIL, MINOXIDIL
NABUMETONE, NABUMETONE
NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
NATEGLINIDE, NATEGLINIDE
NEOMYCIN AND POLYMYXIN B SULFATE, NEOMYCIN SULFATE
NIZATIDINE, NIZATIDINE
NORETHINDRONE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
PREDNISOLONE, PREDNISOLONE
PREDNISONE, PREDNISONE
PRIMIDONE, PRIMIDONE
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
QUASENSE, ETHINYL ESTRADIOL
RAMIPRIL, RAMIPRIL
RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
SULFASALAZINE, SULFASALAZINE
SULINDAC, SULINDAC
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
TETRACYCLINE HYDROCHLORIDE, TETRACYCLINE HYDROCHLORIDE
TOPIRAMATE, TOPIRAMATE
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TRIHEXYPHENIDYL HYDROCHLORIDE, TRIHEXYPHENIDYL HYDROCHLORIDE
TRIMETHOPRIM, TRIMETHOPRIM
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE
ZOVIA 1/50E-28, ETHINYL ESTRADIOL

*** WATSON LABS INC**

LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE

WATSON LABS INC*** WATSON LABORATORIES INC**

AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
AMBRISENTAN, AMBRISENTAN
AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE
BOSENTAN, BOSENTAN
BRINZOLAMIDE, BRINZOLAMIDE
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** W ****

* WATSON LABORATORIES INC
 CELECOXIB, CELECOXIB
 CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
 COLCHICINE, COLCHICINE
 DICLOFENAC SODIUM, DICLOFENAC SODIUM
 DROSPIRENONE, ETHINYL ESTRADIOL AND LEVOMEFOLATE CALCIUM, DROSPIRENONE
 EZETIMIBE AND SIMVASTATIN, EZETIMIBE
 EZETIMIBE, EZETIMIBE
 METRONIDAZOLE, METRONIDAZOLE
 MODAFINIL, MODAFINIL
 NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS), NITROFURANTOIN
 PENICILLAMINE, PENICILLAMINE
 PERPHENAZINE, PERPHENAZINE
 PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
 PROPOFOL, PROPOFOL
 RALOXIFENE HYDROCHLORIDE, RALOXIFENE HYDROCHLORIDE
 ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
 SILDENAFIL CITRATE, SILDENAFIL CITRATE
 SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE

WATSON LABS TEVA

* WATSON LABORATORIES INC AN INDIRECT WHOLLY OWNED SUB OF TEVA PHARMACEUTICALS USA INC
 ALVIMOPAN, ALVIMOPAN
 BICALUTAMIDE, BICALUTAMIDE
 BRIMONIDINE TARTRATE AND TIMOLOL MALEATE, BRIMONIDINE TARTRATE
 BUPRENORPHINE, BUPRENORPHINE
 CINACALCET HYDROCHLORIDE, CINACALCET HYDROCHLORIDE
 GLIPIZIDE, GLIPIZIDE
 IBANDRONATE SODIUM, IBANDRONATE SODIUM
 ISRADIPINE, ISRADIPINE
 LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM **
 MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
 NORETHINDRONE AND ETHINYL ESTRADIOL (10/11), ETHINYL ESTRADIOL
 NORETHINDRONE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 PROBENECID, PROBENECID
 SIMVASTATIN, SIMVASTATIN
 TRIENTINE HYDROCHLORIDE, TRIENTINE HYDROCHLORIDE

WATSON PHARMS INC

* WATSON PHARMACEUTICALS INC
 TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
 TESTOSTERONE ENANTHATE, TESTOSTERONE ENANTHATE

WAVERLEY PHARMA INC

* WAVERLEY PHARMA INC
 BORTEZOMIB, BORTEZOMIB
 PEMETREXED DISODIUM, PEMETREXED DISODIUM

WAYLIS THERAP

* WAYLIS THERAPEUTICS LLC
 FLUTAMIDE, FLUTAMIDE
 VALIUM, DIAZEPAM

WELLSTAT THERAP

* WELLSTAT THERAPEUTICS CORP
 VISTOGARD, URIDINE TRIACETATE
 XURIDEN, URIDINE TRIACETATE

WES PHARMA INC

* WES PHARMA INC
 BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
 HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
 OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE

WEST WARD

* WEST WARD PHARMACEUTICAL CORP
 DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE

WEST WARD PHARM CORP

* WEST WARD PHARMACEUTICAL CORP
 ROCURONIUM BROMIDE, ROCURONIUM BROMIDE

WEST-WARD PHARMS INT

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** W ******* WEST-WARD PHARMACEUTICALS INTERNATIONAL LTD**

BUMETANIDE, BUMETANIDE
 CHLORPROMAZINE HYDROCHLORIDE, CHLORPROMAZINE HYDROCHLORIDE
 CYANOCOBALAMIN, CYANOCOBALAMIN
 CYTARABINE, CYTARABINE
 DEFEROXAMINE MESYLATE, DEFEROXAMINE MESYLATE
 DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
 DIGOXIN, DIGOXIN
 DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
 DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE
 DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
 FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE
 INDOMETHACIN SODIUM, INDOMETHACIN SODIUM
 IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
 LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
 LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
 MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE, MEPERIDINE HYDROCHLORIDE
 MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE
 MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MILRINONE LACTATE
 OCTREOTIDE ACETATE (PRESERVATIVE FREE), OCTREOTIDE ACETATE
 OCTREOTIDE ACETATE, OCTREOTIDE ACETATE
 PENTOSTATIN, PENTOSTATIN
 PHENYTOIN SODIUM, PHENYTOIN SODIUM
 PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
 SODIUM FERRIC GLUCONATE COMPLEX IN SUCROSE, FERRIC OXYHYDROXIDE
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
 THIAMINE HYDROCHLORIDE, THIAMINE HYDROCHLORIDE
 THIOTEPA, THIOTEPA

WESTMINSTER PHARMS*** WESTMINSTER PHARMACEUTICALS LLC**

EPLERENONE, EPLERENONE
 MIGLITOL, MIGLITOL

WILSHIRE PHARMS INC*** WILSHIRE PHARMACEUTICALS INC**

CARISOPRODOL, CARISOPRODOL
 PERPHENAZINE, PERPHENAZINE
 TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE

WINDER LABS LLC*** WINDER LABORATOIRES LLC**

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, ATROPINE SULFATE

WISCONSIN*** WISCONSIN MEDICAL RADIOPHARMACY LLC**

AMMONIA N 13, AMMONIA N-13
 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

WOCKHARDT*** WOCKHARDT LTD**

CAPTOPRIL, CAPTOPRIL
 CEFTRIAXONE, CEFTRIAXONE SODIUM
 CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
 CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
 DIVALPROEX SODIUM, DIVALPROEX SODIUM
 FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
 FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
 FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
 FUROSEMIDE, FUROSEMIDE
 KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
 LANSOPRAZOLE, LANSOPRAZOLE
 METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
 ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
 ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
 SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
 TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE

WOCKHARDT BIO AG*** WOCKHARDT BIO AG**

ABIRATERONE ACETATE, ABIRATERONE ACETATE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** W ******* WOCKHARDT BIO AG**

AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
 AMOXICILLIN, AMOXICILLIN
 BROMFED-DM, BROMPHENIRAMINE MALEATE
 CARBAMAZEPINE, CARBAMAZEPINE
 CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE
 CIMETIDINE HYDROCHLORIDE, CIMETIDINE HYDROCHLORIDE
 CROMOLYN SODIUM, CROMOLYN SODIUM
 CYCLOSPORINE, CYCLOSPORINE
 DECITABINE, DECITABINE
 ENTACAPONE, ENTACAPONE
 FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
 FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
 GENERLAC, LACTULOSE
 HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE, HOMATROPINE METHYLBROMIDE
 HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
 IMATINIB MESYLATE, IMATINIB MESYLATE
 LACTULOSE, LACTULOSE
 LAMOTRIGINE, LAMOTRIGINE
 LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
 LISINAPRIL, LISINAPRIL
 LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)
 LORATADINE, LORATADINE (OTC)
 MEGESTROL ACETATE, MEGESTROL ACETATE
 METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
 MINOXIDIL (FOR MEN), MINOXIDIL (OTC)
 MINOXIDIL EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
 NYSTATIN, NYSTATIN
 OXACILLIN SODIUM, OXACILLIN SODIUM
 PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
 PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM
 PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
 PREDNISOLONE, PREDNISOLONE
 PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE, CODEINE PHOSPHATE
 PROMETHAZINE PLAIN, PROMETHAZINE HYDROCHLORIDE
 PROMETHAZINE W/ DEXTROMETHORPHAN, DEXTROMETHORPHAN HYDROBROMIDE
 TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
 VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

WOCKHARDT LTD*** WOCKHARDT LTD**

BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
 ENALAPRIL MALEATE, ENALAPRIL MALEATE

WOODWARD*** WOODWARD PHARMA SERVICES LLC**

ACIPHEX, RABEPRAZOLE SODIUM
 AVANDIA, ROSIGLITAZONE MALEATE
 AVODART, DUTASTERIDE
 COREG CR, CARVEDILOL PHOSPHATE
 COREG, CARVEDILOL
 FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE
 JALYN, DUTASTERIDE
 LOVAZA, OMEGA-3-ACID ETHYL ESTERS
 LUNESTA, ESZOPICLONE
 MILRINONE LACTATE IN DEXTROSE 5%, MILRINONE LACTATE
 MIVACURIUM CHLORIDE, MIVACURIUM CHLORIDE

WOODWARD SPECIALTY*** WOODWARD SPECIALTY LLC**

LEUKERAN, CHLORAMBUCIL
 MYLERAN, BUSULFAN
 THIOGUANINE, THIOGUANINE

WRASER PHARMS*** WRASER PHARMACEUTICALS LLC**

CETRAXAL, CIPROFLOXACIN HYDROCHLORIDE

WUSM CYCLOTRON

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** W ****

- * WASHINGTON UNIV SCH MEDICINE CYCLOTRON FACILITY
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

WYETH PHARMS

- * WYETH PHARMACEUTICALS LLC
DUAVEE, BAZEDOXIFENE ACETATE
PREMARIN, ESTROGENS, CONJUGATED
PREMPHASE 14/14, ESTROGENS, CONJUGATED
PREMPRO, ESTROGENS, CONJUGATED
PROTONIX IV, PANTOPRAZOLE SODIUM
PROTONIX, PANTOPRAZOLE SODIUM
TRECATOR, ETHIONAMIDE
ZOSYN IN PLASTIC CONTAINER, PIPERACILLIN SODIUM

**** X ******XELLIA PHARMS APS**

- * XELLIA PHARMACEUTICALS APS
COLISTIMETHATE SODIUM, COLISTIMETHATE SODIUM
CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE
DAPTOMYCIN, DAPTOMYCIN
MICA FUNGIN SODIUM, MICA FUNGIN SODIUM
POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
VANCOMYCIN, VANCOMYCIN
VORICONAZOLE, VORICONAZOLE

XERIS

- * XERIS PHARMACEUTICALS INC
GVOKE HYPOPEN, GLUCAGON
GVOKE PFS, GLUCAGON
KEVEYIS, DICHLORPHENAMIDE

XGEN PHARMS

- * XGEN PHARMACEUTICALS DJB INC
ACETAZOLAMIDE SODIUM, ACETAZOLAMIDE SODIUM
AMPHOTERICIN B, AMPHOTERICIN B
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
COLISTIMETHATE SODIUM, COLISTIMETHATE SODIUM
DACTINOMYCIN, DACTINOMYCIN
FOLIC ACID, FOLIC ACID
IBUPROFEN LYSINE, IBUPROFEN LYSINE
LINCOMYCIN HYDROCHLORIDE, LINCOMYCIN HYDROCHLORIDE
LIOETHYRONINE SODIUM, LIOETHYRONINE SODIUM
NEOMYCIN AND POLYMYXIN B SULFATE, NEOMYCIN SULFATE
NEOMYCIN SULFATE, NEOMYCIN SULFATE
NYSTATIN, NYSTATIN
PENTAMIDINE ISETHIONATE, PENTAMIDINE ISETHIONATE
POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
STREPTOMYCIN SULFATE, STREPTOMYCIN SULFATE
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
TRANEXAMIC ACID, TRANEXAMIC ACID

XIAMEN LP PHARM CO

- * XIAMEN LP PHARMACEUTICAL CO LTD
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE

XIROMED

- * XIROMED PHARMA ESPANA SL
ACYCLOVIR, ACYCLOVIR
ALTAVERA, ETHINYL ESTRADIOL
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
EPHEDRINE SULFATE, EPHEDRINE SULFATE
ESTARYLLA, ETHINYL ESTRADIOL
FLUOCINONIDE, FLUOCINONIDE
FOSFOMYCIN TROMETHAMINE, FOSFOMYCIN TROMETHAMINE
FULVESTRANT, FULVESTRANT

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** X ****

* XIROMED PHARMA ESPANA SL
 GEMMILY, ETHINYL ESTRADIOL
 GLYCOPYRROLATE, GLYCOPYRROLATE
 INTROVALE, ETHINYL ESTRADIOL
 ISIBLOOM, DESOGESTREL
 JAIMIESS, ETHINYL ESTRADIOL
 KETOCONAZOLE, KETOCONAZOLE
 LANSOPRAZOLE, LANSOPRAZOLE
 LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
 LEVONORGESTREL, LEVONORGESTREL (OTC)
 LORYNA, DROSPIRENONE
 MIDODRINE HYDROCHLORIDE, MIDODRINE HYDROCHLORIDE
 NAFTIFINE HYDROCHLORIDE, NAFTIFINE HYDROCHLORIDE
 NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
 OMEPRAZOLE, OMEPRAZOLE
 PROGESTERONE, PROGESTERONE
 RAMELTEON, RAMELTEON
 SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE
 SYEDA, DROSPIRENONE
 TESTOSTERONE, TESTOSTERONE
 TRI-ESTARYLLA, ETHINYL ESTRADIOL
 TRI-LO-ESTARYLLA, ETHINYL ESTRADIOL
 VIENVA, ETHINYL ESTRADIOL
 VOLNEA, DESOGESTREL

XSPIRE PHARMA

* XSPIRE PHARMA
 BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
 NALFON, FENOPROFEN CALCIUM
 TREZIX, ACETAMINOPHEN
 ZONTIVITY, VORAPAXAR SULFATE

* XSPIRE PHARMA LLC
 DEXAMETHASONE, DEXAMETHASONE
 FENOPROFEN CALCIUM, FENOPROFEN CALCIUM

XTTRIUM

* XTTRIUM LABORATORIES INC
 CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE
 EXIDINE, CHLORHEXIDINE GLUCONATE (OTC)

XTTRIUM LABS INC

* XTTRIUM LABORATORIES INC
 DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
 ERYTHROMYCIN, ERYTHROMYCIN

**** Y ******YABAO PHARM**

* YABAO PHARMACEUTICAL CO LTD BEIJING
 GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
 SORAFENIB TOSYLATE, SORAFENIB TOSYLATE

YAOPHARMA CO LTD

* YAOPHARMA CO LTD
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

YICHANG HUMANWELL

* YICHANG HUMANWELL PHARMACEUTICAL CO LTD
 BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
 DESVENLAFAXINE SUCCINATE, DESVENLAFAXINE SUCCINATE
 FENOFIBRIC ACID, CHOLINE FENOFIBRATE
 FLECAINIDE ACETATE, FLECAINIDE ACETATE
 GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
 IBUPROFEN, IBUPROFEN
 MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
 METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
 METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
 NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

YILING

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** Y ****

* YILING PHARMACEUTICAL LTD
 ACYCLOVIR, ACYCLOVIR
 BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
 CELECOXIB, CELECOXIB
 CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
 FELODIPINE, FELODIPINE
 LAMOTRIGINE, LAMOTRIGINE
 LISINOPRIL, LISINOPRIL
 PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
 VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE

YOUNGTECH PHARMS INC

* YOUNGTECH PHARMACEUTICALS INC
 METOPROLOL TARTRATE, METOPROLOL TARTRATE

YUNG SHIN PHARM

* YUNG SHIN PHARMACEUTICAL INDUSTRIAL CO LTD
 AZITHROMYCIN, AZITHROMYCIN
 CEFACLOL, CEFACLOL
 CEPHALEXIN, CEPHALEXIN
 CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
 DICLOFENAC SODIUM AND MISOPROSTOL, DICLOFENAC SODIUM
 FELODIPINE, FELODIPINE
 MELOXICAM, MELOXICAM

**** Z ******ZAMBON SPA**

* ZAMBON SPA ITALY
 MONUROL, FOSFOMYCIN TROMETHAMINE

ZAMEER PHARMS

* ZAMEER PHARMACEUTICALS LLC
 CHLORPROMAZINE HYDROCHLORIDE, CHLORPROMAZINE HYDROCHLORIDE
 FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE
 TROSPIMUM CHLORIDE, TROSPIMUM CHLORIDE

ZEALAND PHARMA

* ZEALAND PHARMA US INC
 ZEGALOGUE (AUTOINJECTOR), DASIGLUCAGON HYDROCHLORIDE
 ZEGALOGUE, DASIGLUCAGON HYDROCHLORIDE

ZENNOVA

* ZENNOVA PHARMACEUTICALS CHENGDU CO LTD
 IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
 PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
 QUETIAPINE FUMARATE, QUETIAPINE FUMARATE

ZHEJIANG HISUN PHARM

* ZHEJIANG HISUN PHARMACEUTICAL CO LTD
 MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL

ZHEJIANG JINGXIN

* ZHEJIANG JINGXIN PHARMACEUTICAL CO LTD
 COLESEVELAM HYDROCHLORIDE, COLESEVELAM HYDROCHLORIDE
 LEVETIRACETAM, LEVETIRACETAM

ZHEJIANG JIUZHOU

* ZHEJIANG JIUZHOU BIOPHARMA CO LTD
 CARBAMAZEPINE, CARBAMAZEPINE

ZHEJIANG JUTAI PHARM

* ZHEJIANG JUTAI PHARMACEUTICAL CO LTD
 BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE

ZHEJIANG YONGTAI

* ZHEJIANG YONGTAI PHARMACEUTICAL CO LTD
 GABAPENTIN, GABAPENTIN
 ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM

ZIONEXA

* ZIONEXA US CORP
 CERIENNA, FLUOROESTRADIOL F-18

ZOGENIX INC

* ZOGENIX INC
 FINTEPLA, FENFLURAMINE HYDROCHLORIDE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** Z ******ZUREX PHARMA**

* ZUREX PHARMA
ZURAGARD, ISOPROPYL ALCOHOL (OTC)

ZYDUS

* ZYDUS WORLDWIDE DMCC
AZITHROMYCIN, AZITHROMYCIN
BACLOFEN, BACLOFEN
CHLORPROMAZINE HYDROCHLORIDE, CHLORPROMAZINE HYDROCHLORIDE
DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL), DOXORUBICIN HYDROCHLORIDE
FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE
ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE
IVERMECTIN, IVERMECTIN
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LEFLUNOMIDE, LEFLUNOMIDE
LIOTHYRONINE SODIUM, LIOTHYRONINE SODIUM
MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE
MIDODRINE HYDROCHLORIDE, MIDODRINE HYDROCHLORIDE
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
PHYTONADIONE, PHYTONADIONE
PROCHLORPERAZINE MALEATE, PROCHLORPERAZINE MALEATE
PROPAPENONE HYDROCHLORIDE, PROPAPENONE HYDROCHLORIDE
SELEXIPAG, SELEXIPAG
SILDENAFIL CITRATE, SILDENAFIL CITRATE
URSODIOL, URSODIOL
VIGABATRIN, VIGABATRIN

ZYDUS HLTHCARE

* ZYDUS HEALTHCARE USA LLC
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
LANSOPRAZOLE, LANSOPRAZOLE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

ZYDUS NOVELTECH INC

* ZYDUS NOVELTECH INC
ESTRADIOL, ESTRADIOL

ZYDUS PHARMS

* ZYDUS PHARMACEUTICALS USA INC
ACAMPROSATE CALCIUM, ACAMPROSATE CALCIUM
ACETAMINOPHEN, ACETAMINOPHEN
ACETAZOLAMIDE SODIUM, ACETAZOLAMIDE SODIUM
ACETYLCYSTEINE, ACETYLCYSTEINE
ACYCLOVIR SODIUM, ACYCLOVIR SODIUM
ACYCLOVIR, ACYCLOVIR
ADAPALENE AND BENZOYL PEROXIDE, ADAPALENE
ALBENDAZOLE, ALBENDAZOLE
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ALLOPURINOL, ALLOPURINOL
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
AMBRISANTAN, AMBRISANTAN
AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
AMLODIPINE AND OLMESARTAN MEDOXOMIL, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM, AMLODIPINE BESYLATE
ARSENIC TRIOXIDE, ARSENIC TRIOXIDE
ASPIRIN AND DIPYRIDAMOLE, ASPIRIN
ATENOLOL AND CHLORTHALIDONE, ATENOLOL
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
BORTEZOMIB, BORTEZOMIB
BOSENTAN, BOSENTAN
BREXPIPRAZOLE, BREXPIPRAZOLE
BUDESONIDE, BUDESONIDE
BUMETANIDE, BUMETANIDE
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE, CANDESARTAN CILEXETIL

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** Z ****

* ZYDUS PHARMACEUTICALS USA INC
CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL
CARBAMAZEPINE, CARBAMAZEPINE
CARBIDOPA, CARBIDOPA
CHLORTHALIDONE, CHLORTHALIDONE
CHOLESTYRAMINE LIGHT, CHOLESTYRAMINE
CHOLESTYRAMINE, CHOLESTYRAMINE
CISATRACURIUM BESYLATE, CISATRACURIUM BESYLATE
CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
CLOBAZAM, CLOBAZAM
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
COLCHICINE, COLCHICINE
COLESEVELAM HYDROCHLORIDE, COLESEVELAM HYDROCHLORIDE
COLESTIPOL HYDROCHLORIDE, COLESTIPOL HYDROCHLORIDE
CYANOCOBALAMIN, CYANOCOBALAMIN
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
DECITABINE, DECITABINE
DEFERASIROX, DEFERASIROX
DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION), DESMOPRESSIN ACETATE
DESVENLAFAXINE SUCCINATE, DESVENLAFAXINE SUCCINATE
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DIFLUNISAL, DIFLUNISAL
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
DOXYCYCLINE, DOXYCYCLINE
DOXYCYCLINE, DOXYCYCLINE HYCLATE
DROXIDOPA, DROXIDOPA
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE, DUTASTERIDE
ELETRIPTAN HYDROBROMIDE, ELETRIPTAN HYDROBROMIDE
EMPAGLIFLOZIN, EMPAGLIFLOZIN
EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE, EMTRICITABINE
ENOXAPARIN SODIUM (PRESERVATIVE FREE), ENOXAPARIN SODIUM
ENTECAVIR, ENTECAVIR
ERLOTINIB HYDROCHLORIDE, ERLOTINIB HYDROCHLORIDE
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
ETHACRYNATE SODIUM, ETHACRYNATE SODIUM
ETODOLAC, ETODOLAC
ETOMIDATE, ETOMIDATE
EXEMESTANE, EXEMESTANE
EZETIMIBE, EZETIMIBE
FAMOTIDINE, FAMOTIDINE
FEBUXOSTAT, FEBUXOSTAT
FESOTERODINE FUMARATE, FESOTERODINE FUMARATE
FINGOLIMOD HYDROCHLORIDE, FINGOLIMOD HYDROCHLORIDE
FLUCONAZOLE, FLUCONAZOLE
FLUOCINONIDE, FLUOCINONIDE
FULVESTRANT, FULVESTRANT
GLIPIZIDE, GLIPIZIDE
GLYBURIDE AND METFORMIN HYDROCHLORIDE, GLYBURIDE
GLYBURIDE, GLYBURIDE
HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
IMATINIB MESYLATE, IMATINIB MESYLATE
INDOMETHACIN, INDOMETHACIN
ITRACONAZOLE, ITRACONAZOLE
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
LACOSAMIDE, LACOSAMIDE
LAMOTRIGINE, LAMOTRIGINE
LANSOPRAZOLE, LANSOPRAZOLE
LENALIDOMIDE, LENALIDOMIDE
LINEZOLID, LINEZOLID

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** Z ****

* ZYDUS PHARMACEUTICALS USA INC
 LURASIDONE HYDROCHLORIDE, LURASIDONE HYDROCHLORIDE
 MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
 MESALAMINE, MESALAMINE
 METHOTREXATE SODIUM, METHOTREXATE SODIUM
 METHYLPREDNISOLONE, METHYLPREDNISOLONE
 METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
 MICAFUNGIN SODIUM, MICAFUNGIN SODIUM
 MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
 MIRABEGRON, MIRABEGRON
 MYCOPHENOLATE MOFETIL HYDROCHLORIDE, MYCOPHENOLATE MOFETIL HYDROCHLORIDE
 NADOLOL, NADOLOL
 NATEGLINIDE, NATEGLINIDE
 NELARABINE, NELARABINE
 NIFEDIPINE, NIFEDIPINE
 NITROFURANTOIN, NITROFURANTOIN, MACROCRYSTALLINE
 NITROGLYCERIN, NITROGLYCERIN
 NYSTATIN, NYSTATIN
 OLANZAPINE, OLANZAPINE
 OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
 OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE
 OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE (OTC)
 OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
 OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
 PEMETREXED DISODIUM, PEMETREXED DISODIUM
 PERPHENAZINE, PERPHENAZINE
 PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
 POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
 POTASSIUM CITRATE, POTASSIUM CITRATE
 PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
 PREGABALIN, PREGABALIN
 PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE
 RAMELTEON, RAMELTEON
 RIVASTIGMINE, RIVASTIGMINE
 ROFLUMILAST, ROFLUMILAST
 SEVELAMER CARBONATE, SEVELAMER CARBONATE
 SILODOSIN, SILODOSIN
 SIROLIMUS, SIROLIMUS
 SPIRONOLACTONE, SPIRONOLACTONE
 SUCCINYLCHOLINE CHLORIDE, SUCCINYLCHOLINE CHLORIDE
 TADALAFIL, TADALAFIL
 TAMOXIFEN CITRATE, TAMOXIFEN CITRATE
 TELMISARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 TELMISARTAN, TELMISARTAN
 TEMOZOLOMIDE, TEMOZOLOMIDE
 TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
 TOPIRAMATE, TOPIRAMATE
 TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
 TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
 TRIAZOLAM, TRIAZOLAM
 TRIENTINE HYDROCHLORIDE, TRIENTINE HYDROCHLORIDE
 VARDENAFIL HYDROCHLORIDE, VARDENAFIL HYDROCHLORIDE
 VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
 VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE
 VORICONAZOLE, VORICONAZOLE
 ZOLMITRIPTAN, ZOLMITRIPTAN

ZYDUS PHARMS USA

* ZYDUS PHARMACEUTICALS USA INC
 AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
 ATENOLOL, ATENOLOL
 AZATHIOPRINE, AZATHIOPRINE
 BENZONATATE, BENZONATATE
 CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
 HALOPERIDOL, HALOPERIDOL
 LAMOTRIGINE, LAMOTRIGINE

APPENDIX B - PRODUCT NAME SORTED BY APPLICANT**** Z ******* ZYDUS PHARMACEUTICALS USA INC**

MELOXICAM, MELOXICAM
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
NAPROXEN, NAPROXEN
PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
RAMIPRIL, RAMIPRIL
RIBAVIRIN, RIBAVIRIN
RISPERIDONE, RISPERIDONE
SIMVASTATIN, SIMVASTATIN
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
WARFARIN SODIUM, WARFARIN SODIUM

ZYDUS PHARMS USA INC*** ZYDUS PHARMACEUTICALS USA INC**

AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
ANASTROZOLE, ANASTROZOLE
ATOMOXETINE HYDROCHLORIDE, ATOMOXETINE HYDROCHLORIDE
BICALUTAMIDE, BICALUTAMIDE
BROMOCRIPTINE MESYLATE, BROMOCRIPTINE MESYLATE
CARVEDILOL, CARVEDILOL
DIPYRIDAMOLE, DIPYRIDAMOLE
DIVALPROEX SODIUM, DIVALPROEX SODIUM
FINASTERIDE, FINASTERIDE
GABAPENTIN, GABAPENTIN
GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
GLIPIZIDE AND METFORMIN HYDROCHLORIDE, GLIPIZIDE
HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
IRBESARTAN, IRBESARTAN
LAMOTRIGINE, LAMOTRIGINE
LEVETIRACETAM, LEVETIRACETAM
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
OMEPRazole, OMEPRazole
PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
RISPERIDONE, RISPERIDONE
TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
TOPIRAMATE, TOPIRAMATE
TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
ZOLMITRIPTAN, ZOLMITRIPTAN

ZYLA*** ZYLA LIFE SCIENCES US INC**

OXAYDO, OXYCODONE HYDROCHLORIDE
SPRIX, KETOROLAC TROMETHAMINE

APPENDIX C
UNIFORM TERMS

DOSAGE FORMS

AEROSOL, FOAM	LOTION, AUGMENTED
AEROSOL, METERED	LOTION/SHAMPOO
CAPSULE	OIL
CAPSULE, DELAYED REL PELLETS	OIL/DROPS
CAPSULE, DELAYED RELEASE	OINTMENT
CAPSULE, EXTENDED RELEASE	OINTMENT, AUGMENTED
CAPSULE, PELLETS	PASTE
CAPSULE, TABLET	PATCH
CAPSULE, TABLET, TABLET	PELLET
CLOTH	PELLETS
CONCENTRATE	POWDER
CREAM	POWDER, EXTENDED RELEASE
CREAM, AUGMENTED	POWDER, METERED
CREAM, INSERT	RING
DRUG-ELUTING CONTACT LENS	SHAMPOO
ELIXIR	SOLUTION
EMULSION	SOLUTION FOR SLUSH
ENEMA	SOLUTION, EXTENDED RELEASE
FILM	SOLUTION, GEL FORMING/DROPS
FILM, EXTENDED RELEASE	SOLUTION, METERED
FOAM	SOLUTION/DROPS
FOR SOLUTION	SPONGE
FOR SUSPENSION	SPRAY
FOR SUSPENSION, DELAYED RELEASE	SPRAY, METERED
FOR SUSPENSION, EXTENDED RELEASE	SUPPOSITORY
GAS	SUSPENSION
GEL	SUSPENSION, EXTENDED RELEASE
GEL, AUGMENTED	SUSPENSION, LIPOSOMAL
GEL, METERED	SUSPENSION/DROPS
GRANULE	SWAB
GRANULE, DELAYED RELEASE	SYRUP
GRANULES	SYSTEM
GRANULES, EXTENDED RELEASE	TABLET
GUM, CHEWING	TABLET, CHEWABLE
IMPLANT	TABLET, DELAYED RELEASE
INHALANT	TABLET, EFFERVESCENT
INJECTABLE	TABLET, EXTENDED RELEASE
INJECTABLE, LIPID COMPLEX	TABLET, EXTENDED RELEASE, CHEWABLE
INJECTABLE, LIPOSOMAL	TABLET, FOR SUSPENSION
INJECTION, EXTENDED RELEASE	TABLET, ORALLY DISINTEGRATING
INSERT	TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE
INSERT, EXTENDED RELEASE	TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE
INTRAUTERINE DEVICE	TAPE
JELLY	TROCHE/LOZENGE
LIQUID	
LOTION	

Note: Terms comprise currently marketed products

43RD EDITION 2023 - APPROVED DRUG PRODUCTS LIST

APPENDIX C**UNIFORM TERMS*****ROUTES OF ADMINISTRATION***

BUCCAL	INTRAVESICAL
DENTAL	INTRAVESICULAR
ENDOCERVICAL	INTRAVITREAL
ENDOTRACHEAL	IRRIGATION
ENTERAL	IV (INFUSION)
EPIDURAL	N/A
IMPLANTATION	NASAL
INFILTRATION	OPHTHALMIC
INHALATION	ORAL
INJECTION	ORAL-21
INTERSTITIAL	ORAL-28
INTRA-ANAL	OTIC
INTRA-ARTERIAL	PERFUSION, CARDIAC
INTRA-ARTICULAR	PERIARTICULAR
INTRACAVITARY	PERIODONTAL
INTRACRANIAL	PYELOCALYCEAL
INTRADERMAL	RECTAL
INTRAMUSCULAR	SPINAL
INTRAOCULAR	SUBCUTANEOUS
INTRAOSSEOUS	SUBLINGUAL
INTRAPERITONEAL	TOPICAL
INTRAPLEURAL	TRANSDERMAL
INTRATHECAL	TRANSMUCOSAL
INTRATRACHEAL	URETHRAL
INTRAUTERINE	VAGINAL
INTRAVENOUS	

Note: Terms comprise currently marketed products

APPENDIX C**UNIFORM TERMS*****ABBREVIATIONS***

AMP	AMPULE
AMPICIL	AMPICILLIN
APPROX	APPROXIMATELY
BOT	BOTTLE
CI	CURIE
CSR	CAROTID SINUS REFLEX
CU	CLINICAL UNITS
DIPROP	DIPROPIONATE
ELECT	ELECTROLYTE
EQ	EQUIVALENT TO
ER	EXTENDED RELEASE
GM	GRAM
HBR	HYDROBROMIDE
HCL	HYDROCHLORIDE
HR	HOUR
IM	INTRAMUSCULAR
INH	INHALATION
IU	INTERNATIONAL UNITS
IV	INTRAVENOUS
KIU	KALLIKREIN INHIBITOR UNITS
MCG	MICROGRAM
mCi	MILLICURIE
MEQ	MILLIEQUIVALENT
MG	MILLIGRAM
ML	MILLILITER
N/A	NOT APPLICABLE
PPM	PARTS PER MILLION
REL	RELEASE
SC	SUBCUTANEOUS
SQ CM	SQUARE CENTIMETER
U	UNITS
uCi	MICROCURIE
UMOLAR	MICROMOLAR
USP	UNITED STATES PHARMACOPEIA

PATENT AND EXCLUSIVITY INFORMATION ADDENDUM

This *Addendum* identifies drugs that qualify under the Federal Food, Drug, and Cosmetic Act (the FD&C Act) for periods of exclusivity and provides patent information that has been submitted to the Food and Drug Administration (FDA) concerning the listed drug products.

Exclusivity

This *Addendum* identifies:

- Drugs approved under section 505(c) of the FD&C Act that have qualified under the Drug Price Competition and Patent Term Restoration Act of 1984 (Hatch-Waxman Amendments) for five-year and three-year periods of exclusivity pursuant to Section 505(c)(3)(E) and Section 505(j)(5)(F) of the FD&C Act
- Drugs that have qualified for Orphan Drug Exclusivity pursuant to Section 527 of the FD&C Act
- Drugs that have qualified for Pediatric Exclusivity pursuant to Section 505A of the FD&C Act
- Drugs that have qualified for Generating Antibiotics Incentives Now (GAIN) exclusivity pursuant to Section 505E of the FD&C Act
- Generic drugs approved under section 505(j) of the FD&C Act that have qualified for 180-day exclusivity pursuant to Section 505(j)(5)(B)(iv) of the FD&C Act
- Generic drugs approved under section 505(j) of the FD&C Act that have qualified for Competitive Generic Therapy (CGT) exclusivity pursuant to Section 505(j)(5)(B)(v) of the FD&C Act

This section is arranged in alphabetical order by established name of the active ingredient, followed by the proprietary name (brand name or trade name) of the drug product. Active ingredient headings for multiple active ingredient, fixed-combination drug products are arranged alphabetically.

Individual descriptions of the protected use have been added to each Orphan Drug Exclusivity entry listed in the Orange Book. Such descriptions of Orphan Drug Exclusivity were included beginning with the 38th edition of the Orange Book. The ODE* code means that the timing of approval of certain follow-on applications may be subject to delay due to ODE for another drug that has the same active moiety.

For an explanation of the codes used in the *Addendum*, see the *Patent and Exclusivity Terms* Section. The exclusivity codes are general shorthand descriptions and do not necessarily identify, with specificity, the actual scope of exclusivity.

Patent Information

The FD&C Act requires that patent information be filed with all newly submitted Section 505(b) drug applications. In addition, patent information must be filed on Form FDA 3542 within 30 days of the date of approval of a Section 505(b) drug application.¹ FDA publishes certain information from Form FDA 3542 in the Orange Book after approval of the new drug application (NDA) or supplement.

The Orange Book includes the patent submission date (i.e., the date on which the FDA receives patent information from the NDA holder on Form FDA 3542) for each newly listed patent to facilitate assessments of whether patent information is untimely filed with respect to a pending 505(b)(2) application or abbreviated new drug application (ANDA).²

The patents that FDA regards as covered by the statutory provisions for submission of patent information for listing in the Orange Book are:

- Patents that claim the drug for which the applicant submitted the application and are drug substance (active ingredient) patents or drug product (formulation or composition) patents; or
- Patents that claim a method of using such drug for which approval has been granted in the application.

This information, as provided by the NDA holder on Form FDA 3542, will be published as described above. An NDA holder submitting information on a patent that claims both the drug substance and the drug product (and is eligible for listing on either basis) is required only to specify that the patent claims either the drug substance or the drug product.

The Addendum lists patent and exclusivity information up to January of the Edition year. The monthly Cumulative Supplements to the Annual Edition list patent and exclusivity information changes since the Annual Edition Addendum. Since all parts of this publication are subject to changes, additions, or deletions, the [Orange Book](#), updated regularly, should be consulted for the most recent patent and exclusivity information.

¹ Please note that the date of approval for an NDA for a drug for which FDA intends to recommend controls under the Controlled Substances Act is the later of the date on the approval letter for the NDA or the date of issuance of the interim final rule controlling the drug (see Section 505(x)(1) and (2) of the FD&C Act).

² See 21 CFR 314.50(i)(4) and 314.94(a)(12)(vi). The submission date for patent information is determined in accordance with 21 CFR 314.53(d)(5).

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE - TRIUMEO</u>						
N 205551 001	8129385	Oct 05, 2027	DS DP			
	9242986	Dec 08, 2029	DS DP			
<u>ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE - TRIUMEO PD</u>						
N 215413 001	8129385	Oct 05, 2027	DS DP			
	9242986	Dec 08, 2029	DS DP			
<u>ABALOPARATIDE - TYMLOS</u>						
N 208743 001	10996208	Apr 30, 2038	DP		M-270	Sep 20, 2024
	11255842	Jan 10, 2040	U-3322			
	7803770	Apr 28, 2031	U-2009			
	8148333	Nov 08, 2027	DP			
	8748382	Oct 03, 2027	U-2009			
<u>ABAMETAPIR - XEGLYZE</u>						
N 206966 001	10292389	Dec 17, 2034	DP U-2863		NCE	Jul 24, 2025
	7812163	Oct 28, 2026	DP U-2863			
	8212038	Jul 16, 2024	DP U-2863			
	9357783	Jul 16, 2024	DP			
	9839631	Jul 16, 2024	DS DP U-2863			
<u>ABEMACICLIB - VERZENIO</u>						
N 208716 001	7855211	Dec 15, 2029	DS DP U-2132		I-877	Oct 12, 2024
	7855211	Dec 15, 2029	DS DP U-2135		NPP	Oct 12, 2024
	7855211	Dec 15, 2029	DS DP U-2251			
	7855211	Dec 15, 2029	DS DP U-3241			
	7855211	Dec 15, 2029	DS DP U-3242			
	7855211	Dec 15, 2029	DS DP U-3243			
<u>ABEMACICLIB - VERZENIO</u>						
N 208716 002	7855211	Dec 15, 2029	DS DP U-2132		I-877	Oct 12, 2024
	7855211	Dec 15, 2029	DS DP U-2135		NPP	Oct 12, 2024
	7855211	Dec 15, 2029	DS DP U-2251			
	7855211	Dec 15, 2029	DS DP U-3241			
	7855211	Dec 15, 2029	DS DP U-3242			
	7855211	Dec 15, 2029	DS DP U-3243			
<u>ABEMACICLIB - VERZENIO</u>						
N 208716 003	7855211	Dec 15, 2029	DS DP U-2132		I-877	Oct 12, 2024
	7855211	Dec 15, 2029	DS DP U-2135		NPP	Oct 12, 2024
	7855211	Dec 15, 2029	DS DP U-2251			
	7855211	Dec 15, 2029	DS DP U-3241			
	7855211	Dec 15, 2029	DS DP U-3242			
	7855211	Dec 15, 2029	DS DP U-3243			
<u>ABEMACICLIB - VERZENIO</u>						
N 208716 004	7855211	Dec 15, 2029	DS DP U-1981		I-877	Oct 12, 2024
	7855211	Dec 15, 2029	DS DP U-2132		NPP	Oct 12, 2024
	7855211	Dec 15, 2029	DS DP U-2135			
	7855211	Dec 15, 2029	DS DP U-2251			
<u>ABIRATERONE ACETATE - YONSA</u>						
N 210308 001	10292990	May 20, 2034	U-2535			
	9889144	Mar 17, 2034	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ABROCITINIB - CIBINQO</u>						
N 213871 001	9035074	Feb 19, 2034	DS DP		NCE	Jan 14, 2027
	9545405	Feb 19, 2034	DS DP			
	9549929	Feb 19, 2034	U-3195			
<u>ABROCITINIB - CIBINQO</u>						
N 213871 002	9035074	Feb 19, 2034	DS DP		NCE	Jan 14, 2027
	9545405	Feb 19, 2034	DS DP			
	9549929	Feb 19, 2034	U-3195			
<u>ABROCITINIB - CIBINQO</u>						
N 213871 003	9035074	Feb 19, 2034	DS DP		NCE	Jan 14, 2027
	9545405	Feb 19, 2034	DS DP			
	9549929	Feb 19, 2034	U-3195			
<u>ACALABRUTINIB - CALQUENCE</u>						
N 210259 001	10167291	Jul 01, 2036	DP U-2145		ODE-175	Oct 31, 2024
	10167291	Jul 01, 2036	DP U-2666		ODE-274	Nov 21, 2026
	10167291	Jul 01, 2036	DP U-2667			
	10167291	Jul 01, 2036	DP U-2668			
	10167291	Jul 01, 2036	DP U-2669			
	10167291	Jul 01, 2036	DP U-2670			
	10167291	Jul 01, 2036	DP U-2671			
	10239883	Jul 11, 2032	U-2666			
	10239883	Jul 11, 2032	U-2668			
	10272083	Jan 21, 2035	U-2519			
	10272083	Jan 21, 2035	U-2682			
	10272083	Jan 21, 2035	U-2683			
	10272083	Jan 21, 2035	U-2684			
	10272083	Jan 21, 2035	U-2685			
	10272083	Jan 21, 2035	U-2686			
	10272083	Jan 21, 2035	U-2687			
	7459554	Nov 24, 2026	DS			
	9290504	Jul 11, 2032	DS DP			
	9758524	Jul 11, 2032	U-2145			
	9796721	Jul 01, 2036	DS DP U-2145			
	9796721	Jul 01, 2036	DS DP U-2666			
	9796721	Jul 01, 2036	DS DP U-2667			
	9796721	Jul 01, 2036	DS DP U-2668			
	9796721	Jul 01, 2036	DS DP U-2669			
	9796721	Jul 01, 2036	DS DP U-2670			
	9796721	Jul 01, 2036	DS DP U-2671			
<u>ACALABRUTINIB MALEATE - CALQUENCE</u>						
N 216387 001	10239883	Jul 11, 2032	U-2666			
	10239883	Jul 11, 2032	U-2668			
	10272083	Jan 21, 2035	U-2519			
	10272083	Jan 21, 2035	U-2682			
	10272083	Jan 21, 2035	U-2683			
	10272083	Jan 21, 2035	U-2684			
	10272083	Jan 21, 2035	U-2685			
	10272083	Jan 21, 2035	U-2686			
	10272083	Jan 21, 2035	U-2687			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ACALABRUTINIB MALEATE - CALQUENCE</u>						
N 216387 001	11059829	Jul 01, 2036	DS DP U-2145			
	11059829	Jul 01, 2036	DS DP U-2666			
	11059829	Jul 01, 2036	DS DP U-2667			
	11059829	Jul 01, 2036	DS DP U-2668			
	11059829	Jul 01, 2036	DS DP U-2669			
	11059829	Jul 01, 2036	DS DP U-2670			
	11059829	Jul 01, 2036	DS DP U-2671			
	7459554	Nov 24, 2026	DS			
	9290504	Jul 11, 2032	DS DP			
	9758524	Jul 11, 2032	U-2145			
<u>ACETAMINOPHEN - OFIRMEV</u>						
N 022450 001	10383834	Nov 13, 2028	U-2262			
	10383834	Nov 13, 2028	U-2621			
	9399012	Sep 11, 2031	U-2261			
	9399012	Sep 11, 2031	U-2262			
	9399012*PED	Mar 11, 2032				
	9610265	Nov 13, 2028	U-2263			
	9610265*PED	May 13, 2029				
	9987238	Nov 13, 2028	U-2261			
	9987238*PED	May 13, 2029				
<u>ACETAMINOPHEN - ACETAMINOPHEN</u>						
N 204767 001	8741959	Apr 19, 2030	DP			
<u>ACETAMINOPHEN; BENZHYDROCODONE HYDROCHLORIDE - APADAZ</u>						
N 208653 001	8461137	Feb 22, 2031	DS DP			
	8748413	Jul 01, 2030	DS DP			
	8828978	Jul 01, 2030	DP			
	9132125	Jul 01, 2030	DS DP U-2249			
	9549923	Jul 01, 2030	DS DP			
<u>ACETAMINOPHEN; BENZHYDROCODONE HYDROCHLORIDE - APADAZ</u>						
N 208653 002	8461137	Feb 22, 2031	DS DP			
	8748413	Jul 10, 2030	DS DP			
	8828978	Jul 01, 2030	DP			
	9132125	Jul 01, 2030	DS DP U-2249			
	9549923	Jul 01, 2030	DS DP			
<u>ACETAMINOPHEN; BENZHYDROCODONE HYDROCHLORIDE - APADAZ</u>						
N 208653 003	8461137	Feb 22, 2031	DS DP			
	8748413	Jul 10, 2030	DS DP			
	8828978	Jul 01, 2030	DP			
	9132125	Jul 01, 2030	DS DP U-2249			
	9549923	Jul 01, 2030	DS DP			
<u>ACETAMINOPHEN; IBUPROFEN - ADVIL DUAL ACTION WITH ACETAMINOPHEN</u>						
N 211733 001					NP	Feb 28, 2023
<u>ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE - XARTEMIS XR</u>						
N 204031 001	7976870	Jun 01, 2027	U-1498			
	8372432	Mar 11, 2029	DP U-1499			
	8377453	Nov 19, 2029	DP U-1499			
	8394408	Mar 11, 2029	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE - XARTEMIS XR</u>						
N 204031 001	8597681	Dec 21, 2030	DP			
	8658631	May 16, 2032	DP			
	8668929	Mar 11, 2029		U-1499		
	8741885	May 16, 2032	DP	U-1499		
	8980319	Dec 21, 2030	DP			
	8992975	May 16, 2032	DP			
	9050335	May 16, 2032	DP			
	9468636	May 16, 2032		U-1499		
<u>ACETYLCYSTEINE - ACETADOTE</u>						
N 021539 001	8148356	May 21, 2026	DP			
	8399445	Aug 24, 2025		U-1373		
	8653061	Aug 24, 2025		U-1373		
	8722738	Apr 06, 2032		U-1373		
	9327028	Jul 21, 2031		U-1839		
<u>ACETYLCYSTEINE - CETYLEV</u>						
N 207916 001	8747894	May 08, 2032	DP	U-1373		
	9427421	May 08, 2032	DP			
	9561204	May 08, 2032		U-1373		
<u>ACETYLCYSTEINE - CETYLEV</u>						
N 207916 002	8747894	May 08, 2032	DP	U-1373		
	9427421	May 08, 2032	DP			
	9561204	May 08, 2032		U-1373		
<u>ACLIDINIUM BROMIDE - TUDORZA PRESSAIR</u>						
N 202450 001	10085974	Mar 13, 2029	DP	U-2513		
	11000517	Mar 13, 2029	DP	U-2513		
	8051851	Apr 22, 2027	DP			
	RE46417	Feb 10, 2025	DS DP	U-2513		
<u>ACLIDINIUM BROMIDE; FORMOTEROL FUMARATE - DUAKLIR PRESSAIR</u>						
N 210595 001	10085974	Mar 13, 2029	DP	U-2513		
	11000517	Mar 13, 2029	DP	U-2513		
	8051851	Apr 22, 2027	DP			
	RE46417	Feb 10, 2025	DS DP	U-2513		
<u>ACYCLOVIR - AVACLYR</u>						
N 202408 001					ODE-235	Mar 29, 2026
<u>ACYCLOVIR - SITAVIG</u>						
N 203791 001	8592434	Jun 16, 2030	DP	U-1460		
	8747896	Jun 03, 2027	DP	U-1460		
	8791127	Mar 23, 2027	DP	U-1460		
<u>ADAGRASIB - KRAZATI</u>						
N 216340 001	10689377	May 17, 2037	DS DP	U-3490		
<u>ADAPALENE - DIFFERIN</u>						
N 021753 001	7579377	Feb 23, 2025		U-818		
	7737181	Aug 29, 2024	DP			
	7834060	Mar 12, 2023		U-1078		
	7838558	Mar 12, 2023	DP			
	7868044	Mar 12, 2023		U-1078		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ADAPALENE - DIFFERIN</u>						
N 021753 001	8703820	Mar 12, 2023	U-1078			
<u>ADAPALENE - DIFFERIN</u>						
N 022502 001	7998467	May 31, 2028	DP U-1078			
	8435502	Sep 15, 2026	DP U-1078			
	8709392	Sep 15, 2026	DP U-1078			
<u>ADAPALENE; BENZOYL PEROXIDE - EPIDUO</u>						
N 022320 001	7820186	Nov 23, 2025	DP			
	7964202	Sep 01, 2024	DP U-1078			
	8071644	Jul 18, 2027	DP U-1078			
	8080537	Jul 18, 2027	U-1078			
	8129362	Jul 18, 2027	U-1078			
	8445543	Jul 12, 2027	U-1078			
<u>ADAPALENE; BENZOYL PEROXIDE - EPIDUO FORTE</u>						
N 207917 001	8703820	Mar 12, 2023	U-1078			
	8729127	Mar 12, 2023	U-1078			
	9381179	Mar 12, 2023	U-1078			
	9387187	Mar 12, 2023	U-1078			
<u>AFAMELANOTIDE - SCENESSE</u>						
N 210797 001	10076555	Feb 11, 2025	U-2638		NCE	Oct 08, 2024
	8334265	Mar 11, 2029	U-2638		ODE-270	Oct 08, 2026
<u>AFATINIB DIMALEATE - GILOTRIF</u>						
N 201292 001	10004743	Jul 05, 2030	DP		M-276	Apr 07, 2025
	10004743*PED	Jan 05, 2031			ODE-115	Apr 15, 2023
	8426586	Oct 10, 2029	DS		ODE-230	Jan 12, 2025
	8426586*PED	Apr 10, 2030			PED	Oct 15, 2023
	8545884	Dec 19, 2029	DP		PED	Jul 12, 2025
	8545884*PED	Jun 19, 2030			PED	Oct 07, 2025
	9539258	Nov 09, 2026	U-1950			
	9539258*PED	May 09, 2027				
	RE43431	Jan 13, 2026	DS			
	RE43431*PED	Jul 13, 2026				
<u>AFATINIB DIMALEATE - GILOTRIF</u>						
N 201292 002	10004743	Jul 05, 2030	DP		M-276	Apr 07, 2025
	10004743*PED	Jan 05, 2031			ODE-115	Apr 15, 2023
	8426586	Oct 10, 2029	DS		ODE-230	Jan 12, 2025
	8426586*PED	Apr 10, 2030			PED	Oct 15, 2023
	8545884	Dec 19, 2029	DP		PED	Jul 12, 2025
	8545884*PED	Jun 19, 2030			PED	Oct 07, 2025
	9539258	Nov 09, 2026	U-1950			
	9539258*PED	May 09, 2027				
	RE43431	Jan 13, 2026	DS			
	RE43431*PED	Jul 13, 2026				
<u>AFATINIB DIMALEATE - GILOTRIF</u>						
N 201292 003	10004743	Jul 05, 2030	DP		M-276	Apr 07, 2025
	10004743*PED	Jan 05, 2031			ODE-115	Apr 15, 2023
	8426586	Oct 10, 2029	DS		ODE-230	Jan 12, 2025
	8426586*PED	Apr 10, 2030			PED	Oct 15, 2023

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>AFATINIB DIMALEATE - GILOTTRIF</u>						
N 201292 003	8545884	Dec 19, 2029	DP		PED	Jul 12, 2025
	8545884*PED	Jun 19, 2030			PED	Oct 07, 2025
	9539258	Nov 09, 2026	U-1950			
	9539258*PED	May 09, 2027				
	RE43431	Jan 13, 2026	DS			
	RE43431*PED	Jul 13, 2026				
<u>AIR POLYMER-TYPE A - EXEM FOAM KIT</u>						
N 212279 001	9034300	Oct 15, 2030	DP U-2663		NCE	Nov 07, 2024
	9259494	May 04, 2035	DP U-2663			
	9849199	Feb 11, 2036	DP			
<u>ALBUTEROL SULFATE - VENTOLIN HFA</u>						
N 020983 001	7500444	Feb 26, 2026	DP			
	7500444*PED	Aug 26, 2026				
	7832351	Jun 19, 2023	DP			
<u>ALBUTEROL SULFATE - PROAIR HFA</u>						
N 021457 001	10022509	May 18, 2031	DP			
	10022510	May 18, 2031	DP			
	10086156	May 18, 2031	DP			
	10561808	Jan 01, 2032	DP			
	10695512	May 18, 2031	DP			
	11395889	May 18, 2031	DP			
	7105152	Sep 12, 2023	DP			
	8132712	Sep 07, 2028	DP			
	9463289	May 18, 2031	DP			
	9808587	May 18, 2031	DP			
<u>ALBUTEROL SULFATE - PROAIR RESPICLICK</u>						
N 205636 001	10022510	May 18, 2031	DP			
	10124131	May 18, 2031	DP			
	10561808	Jan 01, 2032	DP			
	10765820	May 19, 2025	DP			
	7540282	May 06, 2023	DP			
	8651103	Mar 26, 2028	DP			
	8978966	Jan 13, 2032	DP			
	9216260	Jun 28, 2031	DP			
	9463288	May 19, 2025	DP			
	9731087	May 18, 2031	DP			
<u>ALBUTEROL SULFATE - PROAIR DIGIHALER</u>						
N 205636 002	10022510	May 18, 2031	DP			
	10124131	May 18, 2031	DP			
	10561808	Jan 01, 2032	DP			
	10569034	Aug 16, 2036	DP			
	10765820	May 19, 2025	DP			
	10918816	Dec 14, 2035	DP			
	11000653	Dec 18, 2038	DP			
	11173259	Jul 06, 2040	DP			
	11266796	Feb 22, 2041	DP			
	11344685	Sep 26, 2039	DP			
	11351317	Feb 10, 2038	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ALBUTEROL SULFATE - PROAIR DIGIHALER</u>						
N 205636 002	11357935	Sep 24, 2038	DP			
	11439777	May 24, 2040	DP			
	11464923	Jun 19, 2040	DP			
	7540282	May 06, 2023	DP			
	8651103	Mar 26, 2028	DP			
	8978966	Jan 13, 2032	DP			
	9216260	Jun 28, 2031	DP			
	9463288	May 19, 2025	DP			
	9731087	May 18, 2031	DP			
	9782550	Aug 28, 2035	DP			
	9782551	Aug 28, 2035	DP			
<u>ALBUTEROL SULFATE; IPRATROPIUM BROMIDE - COMBIVENT RESPIMAT</u>						
N 021747 001	7284474	Aug 26, 2024	DP			
	7396341	Oct 10, 2026	DP			
	7837235	Mar 13, 2028	DP			
	7896264	May 26, 2025	DP			
	8733341	Oct 16, 2030	DP			
	9027967	Mar 31, 2027	DP			
<u>ALCAFTADINE - LASTACFT</u>						
N 022134 001	10617695	Mar 19, 2027	DP U-3267			
	8664215	Dec 23, 2027	U-3267			
<u>ALCOHOL - ABLYSINOL</u>						
N 207987 001					ODE-192	Jun 21, 2025
<u>ALCOHOL - ABLYSINOL</u>						
N 207987 002					ODE-192	Jun 21, 2025
<u>ALECTINIB HYDROCHLORIDE - ALECENSA</u>						
N 208434 001	10350214	Apr 24, 2035	DP		ODE-159	Nov 06, 2024
	11433076	Apr 24, 2035	DP			
	9126931	May 29, 2031	DS			
	9365514	Mar 04, 2032	DP			
	9440922	Jun 09, 2030	DP			
<u>ALENDRONATE SODIUM - BINOSTO</u>						
N 202344 001	7488496	Aug 11, 2023	DS DP			
	7964212	Mar 06, 2023	DS DP			
	9592195	Dec 05, 2031	DP			
<u>ALISKIREN HEMIFUMARATE - TEKTRUNA</u>						
N 021985 001	8617595	Feb 19, 2026	DP			
	8617595*PED	Aug 19, 2026				
<u>ALISKIREN HEMIFUMARATE - TEKTRUNA</u>						
N 021985 002	8617595	Feb 19, 2026	DP			
	8617595*PED	Aug 19, 2026				
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO</u>						
N 022545 001	8613949	Dec 21, 2029	DP			
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO</u>						
N 022545 002	8613949	Dec 21, 2029	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO</u>						
N 022545	003 8613949	Dec 21, 2029	DP			
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO</u>						
N 022545	004 8613949	Dec 21, 2029	DP			
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N 200045	001 8183295	May 16, 2023	DP			
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N 200045	002 8183295	May 16, 2023	DP			
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N 200045	003 8183295	May 16, 2023	DP			
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N 200045	004 8183295	May 16, 2023	DP			
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N 200045	005 8183295	May 16, 2023	DP			
<u>ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTURN HCT</u>						
N 022107	001 8618172	Jul 13, 2028	DP			
<u>ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTURN HCT</u>						
N 022107	002 8618172	Jul 13, 2028	DP			
<u>ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTURN HCT</u>						
N 022107	003 8618172	Jul 13, 2028	DP			
<u>ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTURN HCT</u>						
N 022107	004 8618172	Jul 13, 2028	DP			
<u>ALISKIREN HEMIFUMARATE; VALSARTAN - VALTURN</u>						
N 022217	001 8168616	Jul 03, 2026	DP			
<u>ALISKIREN HEMIFUMARATE; VALSARTAN - VALTURN</u>						
N 022217	002 8168616	Jul 03, 2026	DP			
<u>ALLOPURINOL; LESINURAD - DUZALLO</u>						
N 209203	001 10183012	Nov 26, 2028				U-2104
	8003681	Aug 25, 2025	DS			
	8084483	Aug 17, 2029				U-2104
	8283369	Nov 26, 2028				U-2104
	8357713	Dec 22, 2029				DP U-2104
	8546436	Feb 29, 2032	DS			
	8546437	Apr 29, 2029				U-2104
	9216179	Aug 01, 2031				U-2104
	9956205	Dec 28, 2031				U-2104
<u>ALLOPURINOL; LESINURAD - DUZALLO</u>						
N 209203	002 10183012	Nov 26, 2028				U-2104
	8003681	Aug 25, 2025	DS			
	8084483	Aug 17, 2029				U-2104
	8283369	Nov 26, 2028				U-2104
	8357713	Dec 22, 2029				DP U-2104
	8546436	Feb 29, 2032	DS			
	8546437	Apr 29, 2029				U-2104
	9216179	Aug 01, 2031				U-2104

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ALLOPURINOL; LESINURAD - DUZALLO</u>						
N 209203	002 9956205	Dec 28, 2031	U-2104			
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271	001 7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Dec 02, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
	8697125	Jun 16, 2029	DP			
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271	002 7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Dec 02, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
	8697125	Jun 16, 2029	DP			
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271	003 7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Dec 02, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
	8697125	Jun 16, 2029	DP			
<u>ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE - KAZANO</u>						
N 203414	001 7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Jun 24, 2025	DS			
	8900638	May 24, 2029	DP			
<u>ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE - KAZANO</u>						
N 203414	002 7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Jun 24, 2025	DS			
	8900638	May 24, 2029	DP			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426	001 7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
	8637079	Jun 04, 2029	DP			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426	002 7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
	8637079	Jun 04, 2029	DP			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426	003 7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
	8637079	Jun 04, 2029	DP			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426	004 7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
	8637079	Jun 04, 2029	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 005	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
	8637079	Jun 04, 2029	DP			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 006	7807689	Jun 27, 2028	DS DP U-1337			
	8173663	Mar 15, 2025	U-1338			
	8288539	Mar 15, 2025	DS			
	8637079	Jun 04, 2029	DP			
<u>ALPELISIB - PIQRAY</u>						
N 212526 001	8227462	Sep 28, 2030	DS DP U-2539		NCE	May 24, 2024
	8476268	Sep 10, 2029	DS DP			
<u>ALPELISIB - PIQRAY</u>						
N 212526 002	8227462	Sep 28, 2030	DS DP U-2539		NCE	May 24, 2024
	8476268	Sep 10, 2029	DS DP			
<u>ALPELISIB - PIQRAY</u>						
N 212526 003	8227462	Sep 28, 2030	DS DP U-2539		NCE	May 24, 2024
	8476268	Sep 10, 2029	DS DP			
<u>ALPELISIB - VIJOICE</u>						
N 215039 001	8227462	Sep 28, 2030	DS DP		NCE	May 24, 2024
	8476268	Sep 10, 2029	DS DP			
<u>ALPELISIB - VIJOICE</u>						
N 215039 002	8227462	Sep 28, 2030	DS DP		NCE	May 24, 2024
	8476268	Sep 10, 2029	DS DP			
<u>ALPELISIB - VIJOICE</u>						
N 215039 003	8227462	Sep 28, 2030	DS DP		NCE	May 24, 2024
	8476268	Sep 10, 2029	DS DP			
<u>ALVIMOPAN - ENTEREG</u>						
N 021775 001	8946262	Feb 12, 2030	U-1655			
<u>AMANTADINE HYDROCHLORIDE - GOCOVRI</u>						
N 208944 001	10154971	Dec 04, 2034	U-2459		ODE-153	Aug 24, 2024
	10646456	Jun 17, 2034	U-2808			
	11065213	Aug 23, 2038	DP			
	11077073	Aug 23, 2038	U-2106			
	11077073	Aug 23, 2038	U-2224			
	11077073	Aug 23, 2038	U-3180			
	11197835	Dec 02, 2030	U-2106			
	8389578	Jan 22, 2028	U-2105			
	8741343	Dec 02, 2030	U-2106			
	8796337	Nov 23, 2025	U-2106			
	8889740	Nov 23, 2025	DP			
	8895614	Nov 23, 2025	DP			
	8895615	Nov 23, 2025	U-2106			
	8895616	Nov 23, 2025	U-2106			
	8895617	Nov 23, 2025	U-2106			
	8895618	Nov 23, 2025	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>AMANTADINE HYDROCHLORIDE - GOCOVRI</u>						
N 208944 001	9867791	Dec 02, 2030	U-2106			
	9867792	Dec 02, 2030	U-2106			
	9867793	Dec 02, 2030	U-2106			
	9877933	Dec 02, 2030	U-2224			
<u>AMANTADINE HYDROCHLORIDE - GOCOVRI</u>						
N 208944 002	10154971	Dec 04, 2034	U-2459		ODE-153	Aug 24, 2024
	10646456	Jun 17, 2034	U-2808			
	11065213	Aug 23, 2038	DP			
	11077073	Aug 23, 2038	U-2106			
	11077073	Aug 23, 2038	U-2224			
	11077073	Aug 23, 2038	U-3180			
	11197835	Dec 02, 2030	U-2106			
	8389578	Jan 22, 2028	U-2105			
	8741343	Dec 02, 2030	U-2106			
	8796337	Nov 23, 2025	U-2106			
	8889740	Nov 23, 2025	DP			
	8895614	Nov 23, 2025	DP			
	8895615	Nov 23, 2025	U-2106			
	8895616	Nov 23, 2025	U-2106			
	8895617	Nov 23, 2025	U-2106			
	8895618	Nov 23, 2025	DP			
	9867791	Dec 02, 2030	U-2106			
	9867792	Dec 02, 2030	U-2106			
	9867793	Dec 02, 2030	U-2106			
	9877933	Dec 02, 2030	U-2224			
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410 001	10213393	Feb 15, 2038	U-20			
	10213394	Feb 15, 2038	U-2497			
	10500170	Feb 15, 2038	U-20			
	10500171	Feb 15, 2038	U-2497			
	10500172	Feb 15, 2038	U-2497			
	10512617	Feb 15, 2038	U-2497			
	8252331	Mar 13, 2030	DP			
	8389578	Jan 22, 2028	U-219			
	8389578	Jan 22, 2028	U-3054			
	8574626	Nov 28, 2025	DP U-20			
	8796337	Nov 23, 2025	U-219			
	8796337	Nov 23, 2025	U-2497			
	8796337	Nov 23, 2025	U-3054			
	8889740	Nov 23, 2025	DP			
	8895614	Nov 23, 2025	DP			
	8895615	Nov 23, 2025	U-219			
	8895615	Nov 23, 2025	U-3054			
	8895616	Nov 23, 2025	U-219			
	8895616	Nov 23, 2025	U-3054			
	8895617	Nov 23, 2025	U-219			
	8895617	Nov 23, 2025	U-3054			
	8895618	Nov 23, 2025	DP			
	8987333	Nov 23, 2025	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410	001	9072697	Nov 23, 2025	U-219		
		9072697	Nov 23, 2025	U-3054		
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410	002	10213393	Feb 15, 2038	U-20		
		10213394	Feb 15, 2038	U-2497		
		10500170	Feb 15, 2038	U-20		
		10500171	Feb 15, 2038	U-2497		
		10500172	Feb 15, 2038	U-2497		
		10512617	Feb 15, 2038	U-2497		
		8252331	Mar 13, 2030	DP		
		8389578	Jan 22, 2028	U-219		
		8389578	Jan 22, 2028	U-3054		
		8574626	Nov 28, 2025	DP U-20		
		8796337	Nov 23, 2025	U-219		
		8796337	Nov 23, 2025	U-2497		
		8796337	Nov 23, 2025	U-3054		
		8889740	Nov 23, 2025	DP		
		8895614	Nov 23, 2025	DP		
		8895615	Nov 23, 2025	U-219		
		8895615	Nov 23, 2025	U-3054		
		8895616	Nov 23, 2025	U-219		
		8895616	Nov 23, 2025	U-3054		
		8895617	Nov 23, 2025	U-219		
		8895617	Nov 23, 2025	U-3054		
		8895618	Nov 23, 2025	DP		
		8987333	Nov 23, 2025	DP		
		9072697	Nov 23, 2025	U-219		
		9072697	Nov 23, 2025	U-3054		
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410	003	10213393	Feb 15, 2038	U-20		
		10213394	Feb 15, 2038	U-2497		
		10500170	Feb 15, 2038	U-20		
		10500171	Feb 15, 2038	U-2497		
		10500172	Feb 15, 2038	U-2497		
		10512617	Feb 15, 2038	U-2497		
		8252331	Mar 13, 2030	DP		
		8389578	Jan 22, 2028	U-219		
		8389578	Jan 22, 2028	U-3054		
		8574626	Nov 28, 2025	DP U-20		
		8796337	Nov 23, 2025	U-219		
		8796337	Nov 23, 2025	U-2497		
		8796337	Nov 23, 2025	U-3054		
		8889740	Nov 23, 2025	DP		
		8895614	Nov 23, 2025	DP		
		8895615	Nov 23, 2025	U-219		
		8895615	Nov 23, 2025	U-3054		
		8895616	Nov 23, 2025	U-219		
		8895616	Nov 23, 2025	U-3054		
		8895617	Nov 23, 2025	U-219		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410 003	8895617	Nov 23, 2025	U-3054			
	8895618	Nov 23, 2025	DP			
	8987333	Nov 23, 2025	DP			
	9072697	Nov 23, 2025	U-219			
	9072697	Nov 23, 2025	U-3054			
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410 004	10213393	Feb 15, 2038	U-20			
	10213394	Feb 15, 2038	U-2497			
	10500170	Feb 15, 2038	U-20			
	10500171	Feb 15, 2038	U-2497			
	10500172	Feb 15, 2038	U-2497			
	10512617	Feb 15, 2038	U-2497			
	8252331	Mar 13, 2030	DP			
	8389578	Jan 22, 2028	U-219			
	8389578	Jan 22, 2028	U-3054			
	8574626	Nov 28, 2025	DP U-20			
	8796337	Nov 23, 2025	U-219			
	8796337	Nov 23, 2025	U-2497			
	8796337	Nov 23, 2025	U-3054			
	8889740	Nov 23, 2025	DP			
	8895614	Nov 23, 2025	DP			
	8895615	Nov 23, 2025	U-219			
	8895615	Nov 23, 2025	U-3054			
	8895616	Nov 23, 2025	U-219			
	8895616	Nov 23, 2025	U-3054			
	8895617	Nov 23, 2025	U-219			
	8895617	Nov 23, 2025	U-3054			
	8895618	Nov 23, 2025	DP			
	8987333	Nov 23, 2025	DP			
	9072697	Nov 23, 2025	U-219			
	9072697	Nov 23, 2025	U-3054			
<u>AMBRISANTAN - LETAIRIS</u>						
N 022081 001	8377933	Dec 11, 2027	U-1754			
	9474752	Dec 11, 2027	U-1754			
	9549926	Oct 14, 2031	U-1965			
<u>AMBRISANTAN - LETAIRIS</u>						
N 022081 002	8377933	Dec 11, 2027	U-1754			
	9474752	Dec 11, 2027	U-1754			
	9549926	Oct 14, 2031	U-1965			
<u>AMIFAMPRIDINE PHOSPHATE - FIRDAPSE</u>						
N 208078 001	10626088	Feb 25, 2037	DP		NCE	Nov 28, 2023
	10793893	May 26, 2034	U-2956		NPP	Sep 29, 2025
	11060128	Jun 29, 2032	U-2956		ODE-223	Nov 28, 2025
	11268128	Jun 29, 2032	U-2956			
	11274331	Jun 29, 2032	U-2956			
	11274332	Jun 29, 2032	U-2956			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>AMIKACIN SULFATE - ARIKAYCE KIT</u>						
N 207356 001	10251900	May 15, 2035	U-2414		ODE-214	Sep 28, 2025
	10751355	May 15, 2035	U-2414		GAIN	Sep 28, 2030
	11446318	May 15, 2035	U-2414			
	7718189	Jun 06, 2025	DP U-2415			
	8226975	Aug 15, 2028	DP			
	8632804	Dec 05, 2026	U-2416			
	8642075	Dec 05, 2026	DP			
	8679532	Dec 05, 2026	U-2415			
	8802137	Apr 08, 2024	DP U-2414			
	9566234	Jan 18, 2034	DP U-2415			
	9827317	Apr 08, 2024	DP U-2415			
	9895385	May 15, 2035	U-2417			
<u>AMINOLEVULINIC ACID HYDROCHLORIDE - LEVULAN</u>						
N 020965 001	10357567	Jan 12, 2038	U-3163			
	11077192	Jan 12, 2038	U-3163			
	11135293	Jan 12, 2038	U-3163			
<u>AMINOLEVULINIC ACID HYDROCHLORIDE - AMELUZ</u>						
N 208081 001	11235169	Oct 15, 2040	U-3303			
<u>AMINOLEVULINIC ACID HYDROCHLORIDE - GLEOLAN</u>						
N 208630 001					ODE-146	Jun 06, 2024
<u>AMIODARONE HYDROCHLORIDE - NEXTERONE</u>						
N 022325 001	7635773	Mar 13, 2029	DP			
<u>AMIODARONE HYDROCHLORIDE - NEXTERONE</u>						
N 022325 002	7635773	Mar 13, 2029	DP			
<u>AMIODARONE HYDROCHLORIDE - NEXTERONE</u>						
N 022325 003	7635773	Mar 13, 2029	DP			
<u>AMISULPRIDE - BARHEMSYS</u>						
N 209510 001	10525033	Mar 10, 2031	DP		NCE	Feb 26, 2025
	11357753	Feb 09, 2038	U-2754			
	9084765	Feb 26, 2034	U-1744			
	9084765	Feb 26, 2034	U-2754			
	9084765	Feb 26, 2034	U-3467			
	9545426	Mar 10, 2031	U-1744			
	9545426	Mar 10, 2031	U-2754			
	9889118	Mar 10, 2031	U-1744			
	9889118	Mar 10, 2031	U-2754			
<u>AMISULPRIDE - BARHEMSYS</u>						
N 209510 002	10525033	Mar 10, 2031	DP		NCE	Feb 26, 2025
	11357753	Feb 09, 2038	U-2754			
	9084765	Feb 26, 2034	U-1744			
	9084765	Feb 26, 2034	U-2754			
	9084765	Feb 26, 2034	U-3467			
	9545426	Mar 10, 2031	U-1744			
	9545426	Mar 10, 2031	U-2754			
	9889118	Mar 10, 2031	U-1744			
	9889118	Mar 10, 2031	U-2754			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>AMLODIPINE BENZOATE - KATERZIA</u>						
N 211340	001	10695329	Oct 16, 2037	DP		
		10799453	Apr 11, 2039	DP		
		10894039	Oct 06, 2037	U-185		
		10894039	Oct 06, 2037	U-3		
		10952998	Oct 06, 2037	DP		
		10959991	Oct 06, 2037	U-158		
		10959991	Oct 06, 2037	U-39		
		11364230	Oct 06, 2037	DP		
		11471409	Oct 06, 2037	U-3447		
		11471409	Oct 06, 2037	U-3448		
		11484498	Oct 06, 2037	DP		
<u>AMLODIPINE BESYLATE - NORLIOVA</u>						
N 214439	001	11253474	Feb 24, 2041	DP U-3309		
		11253474	Feb 24, 2041	DP U-3310		
		11253474	Feb 24, 2041	DP U-3311		
		11458095	Feb 24, 2041	DP U-3309		
		11458095	Feb 24, 2041	DP U-3310		
		11458095	Feb 24, 2041	DP U-3311		
<u>AMLODIPINE BESYLATE; CELECOXIB - CONSENSI</u>						
N 210045	001	10350171	Jun 14, 2038	DP		
		10925835	Jun 14, 2038	U-2410		
		10945960	Jun 14, 2038	DP		
		9408837	Feb 28, 2030	U-2410		
		9662315	May 22, 2029	DP U-2410		
<u>AMLODIPINE BESYLATE; CELECOXIB - CONSENSI</u>						
N 210045	002	10350171	Jun 14, 2038	DP		
		10925835	Jun 14, 2038	U-2410		
		10945960	Jun 14, 2038	DP		
		9408837	Feb 28, 2030	U-2410		
		9662315	May 22, 2029	DP U-2410		
<u>AMLODIPINE BESYLATE; CELECOXIB - CONSENSI</u>						
N 210045	003	10350171	Jun 14, 2038	DP		
		10925835	Jun 14, 2038	U-2410		
		10945960	Jun 14, 2038	DP		
		9408837	Feb 28, 2030	U-2410		
		9662315	May 22, 2029	DP U-2410		
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N 022314	001	8101599	May 16, 2023	DP		
		8475839	May 16, 2023	DP		
		8475839*PED	Nov 16, 2023			
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N 022314	002	8101599	May 16, 2023	DP		
		8475839	May 16, 2023	DP		
		8475839*PED	Nov 16, 2023			
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N 022314	003	8101599	May 16, 2023	DP		
		8475839	May 16, 2023	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N 022314	003	8475839*PED	Nov 16, 2023			
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N 022314	004	8101599	May 16, 2023	DP		
		8475839	May 16, 2023	DP		
		8475839*PED	Nov 16, 2023			
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N 022314	005	8101599	May 16, 2023	DP		
		8475839	May 16, 2023	DP		
		8475839*PED	Nov 16, 2023			
<u>AMLODIPINE BESYLATE; PERINDOPRIL ARGININE - PRESTALIA</u>						
N 205003	001	6696481	Apr 15, 2023	DS DP U-3		
		7846961	Oct 05, 2029	DS DP U-3		
<u>AMLODIPINE BESYLATE; PERINDOPRIL ARGININE - PRESTALIA</u>						
N 205003	002	6696481	Apr 15, 2023	DS DP U-3		
		7846961	Oct 05, 2029	DS DP U-3		
<u>AMLODIPINE BESYLATE; PERINDOPRIL ARGININE - PRESTALIA</u>						
N 205003	003	6696481	Apr 15, 2023	DS DP U-3		
		7846961	Oct 05, 2029	DS DP U-3		
<u>AMOXICILLIN - MOXATAG</u>						
N 050813	001	8299052	May 07, 2027	U-1304		
		8357394	Dec 08, 2026	DP		
		8778924	Dec 08, 2026	DS DP U-897		
<u>AMOXICILLIN; CLARITHROMYCIN; VONOPRAZAN FUMARATE - VOQUEZNA TRIPLE PAK</u>						
N 215152	001	7977488	Aug 11, 2028	DS	NCE	May 03, 2027
		9186411	Aug 11, 2030	DP	GAIN	May 03, 2032
<u>AMOXICILLIN; OMEPRAZOLE MAGNESIUM; RIFABUTIN - TALICIA</u>						
N 213004	001	10238606	Feb 12, 2034	DP		
		11135172	Feb 12, 2034	DP U-2660		
		9050263	Feb 12, 2034	DP U-2660		
		9498445	Feb 12, 2034	DP U-2660		
		9603806	Feb 12, 2034	DP U-2660		
<u>AMOXICILLIN; VONOPRAZAN FUMARATE - VOQUEZNA DUAL PAK</u>						
N 215153	001	7977488	Aug 11, 2028	DS	NCE	May 03, 2027
		9186411	Aug 11, 2030	DP	GAIN	May 03, 2032
<u>AMPHETAMINE - ADZENYS ER</u>						
N 204325	001	8709491	Jun 28, 2032	DP		
		9017731	Jun 28, 2032	DP		
		9265737	Jun 28, 2032	DP		
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326	001	8709491	Jun 28, 2032	DP		
		8840924	Apr 09, 2026	DP		
		9017731	Jun 28, 2032	DP		
		9265737	Jun 28, 2032	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 002	8709491	Jun 28, 2032	DP			
	8840924	Apr 09, 2026	DP			
	9017731	Jun 28, 2032	DP			
	9265737	Jun 28, 2032	DP			
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 003	8709491	Jun 28, 2032	DP			
	8840924	Apr 09, 2026	DP			
	9017731	Jun 28, 2032	DP			
	9265737	Jun 28, 2032	DP			
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 004	8709491	Jun 28, 2032	DP			
	8840924	Apr 09, 2026	DP			
	9017731	Jun 28, 2032	DP			
	9265737	Jun 28, 2032	DP			
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 005	8709491	Jun 28, 2032	DP			
	8840924	Apr 09, 2026	DP			
	9017731	Jun 28, 2032	DP			
	9265737	Jun 28, 2032	DP			
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 006	8709491	Jun 28, 2032	DP			
	8840924	Apr 09, 2026	DP			
	9017731	Jun 28, 2032	DP			
	9265737	Jun 28, 2032	DP			
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - MYDAYIS</u>						
N 022063 001	6913768	May 24, 2023	DP U-2025			
	8846100	Aug 24, 2029	DP			
	9173857	May 12, 2026	U-2025			
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - MYDAYIS</u>						
N 022063 002	6913768	May 24, 2023	DP U-2025			
	8846100	Aug 24, 2029	DP			
	9173857	May 12, 2026	U-2025			
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - MYDAYIS</u>						
N 022063 003	6913768	May 24, 2023	DP U-2025			
	8846100	Aug 24, 2029	DP			
	9173857	May 12, 2026	U-2025			
<u>AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - MYDAYIS</u>						
N 022063 004	6913768	May 24, 2023	DP U-2025			
	8846100	Aug 24, 2029	DP			
	9173857	May 12, 2026	U-2025			
<u>AMPHETAMINE SULFATE - EVEKEO ODT</u>						
N 209905 001	10130580	Apr 19, 2024	DP			
	10441554	Mar 10, 2037	DP			
	11160772	Mar 10, 2037	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>AMPHETAMINE SULFATE - EVEKEO ODT</u>						
N 209905 001	10130580	Apr 19, 2024	DP			
	10441554	Mar 10, 2037	DP			
	11160772	Mar 10, 2037	DP			
<u>AMPHETAMINE SULFATE - EVEKEO ODT</u>						
N 209905 002	10130580	Apr 19, 2024	DP			
	10441554	Mar 10, 2037	DP			
	11160772	Mar 10, 2037	DP			
<u>AMPHETAMINE SULFATE - EVEKEO ODT</u>						
N 209905 003	10130580	Apr 19, 2024	DP			
	10441554	Mar 10, 2037	DP			
	11160772	Mar 10, 2037	DP			
<u>AMPHETAMINE SULFATE - EVEKEO ODT</u>						
N 209905 004	10130580	Apr 19, 2024	DP			
	10441554	Mar 10, 2037	DP			
	11160772	Mar 10, 2037	DP			
<u>AMPHETAMINE SULFATE - EVEKEO ODT</u>						
N 209905 005	10130580	Apr 19, 2024	DP			
	10441554	Mar 10, 2037	DP			
	11160772	Mar 10, 2037	DP			
<u>AMPHETAMINE; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE - DYANA VEL XR</u>						
N 208147 001	10086087	Mar 15, 2027	DP			
	8062667	Mar 29, 2029	DP			
	8597684	Mar 15, 2027	DP			
	8747902	Mar 15, 2027	DP			
	8883217	Mar 15, 2027	DP			
	9675703	Mar 15, 2027	DP			
<u>AMPHETAMINE; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE - DYANA VEL XR 5</u>						
N 210526 001	8337890	Mar 15, 2027	DP			
	8747902	Mar 15, 2027	DP			
	9675704	Mar 15, 2027	DP			
<u>AMPHETAMINE; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE - DYANA VEL XR 10</u>						
N 210526 002	8337890	Mar 15, 2027	DP			
	8747902	Mar 15, 2027	DP			
	9675704	Mar 15, 2027	DP			
<u>AMPHETAMINE; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE - DYANA VEL XR 15</u>						
N 210526 003	8337890	Mar 15, 2027	DP			
	8747902	Mar 15, 2027	DP			
	9675704	Mar 15, 2027	DP			
<u>AMPHETAMINE; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE - DYANA VEL XR 20</u>						
N 210526 004	8337890	Mar 15, 2027	DP			
	8747902	Mar 15, 2027	DP			
	9675704	Mar 15, 2027	DP			
<u>ANGIOTENSIN II ACETATE - GIAPREZA</u>						
N 209360 001	10028995	Dec 18, 2034	U-2338			
	10335451	Dec 16, 2029	U-2581			
	10493124	Dec 18, 2034	U-2679			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ANGIOTENSIN II ACETATE - GIAPREZA</u>						
N 209360 001	10500247	Dec 16, 2029	U-2680			
	10500247	Dec 16, 2029	U-2681			
	10548943	Dec 16, 2029	U-2739			
	10548943	Dec 16, 2029	U-2740			
	11096983	Dec 18, 2034	U-3211			
	11096983	Dec 18, 2034	U-3212			
	11219662	Jan 06, 2037	U-3262			
	9220745	Dec 18, 2034	U-2217			
	9220745	Dec 18, 2034	U-2218			
	9572856	Jul 18, 2031	U-2221			
	9867863	Dec 16, 2029	U-2231			
<u>ANGIOTENSIN II ACETATE - GIAPREZA</u>						
N 209360 002	10028995	Dec 18, 2034	U-2338			
	10335451	Dec 16, 2029	U-2581			
	10493124	Dec 18, 2034	U-2679			
	10500247	Dec 16, 2029	U-2680			
	10500247	Dec 16, 2029	U-2681			
	10548943	Dec 16, 2029	U-2739			
	10548943	Dec 16, 2029	U-2740			
	11096983	Dec 18, 2034	U-3211			
	11096983	Dec 18, 2034	U-3212			
	11219662	Jan 06, 2037	U-3262			
	9220745	Dec 18, 2034	U-2217			
	9220745	Dec 18, 2034	U-2218			
	9572856	Nov 20, 2030	U-2221			
	9867863	Dec 16, 2029	U-2231			
<u>ANGIOTENSIN II ACETATE - GIAPREZA</u>						
N 209360 003	10028995	Dec 18, 2034	U-2338			
	10335451	Dec 16, 2029	U-2581			
	10493124	Dec 18, 2034	U-2679			
	10500247	Dec 16, 2029	U-2680			
	10500247	Dec 16, 2029	U-2681			
	10548943	Dec 16, 2029	U-2739			
	10548943	Dec 16, 2029	U-2740			
	11096983	Dec 18, 2034	U-3211			
	11096983	Dec 18, 2034	U-3212			
	11219662	Jan 06, 2037	U-3262			
	9220745	Dec 18, 2034	U-2217			
	9220745	Dec 18, 2034	U-2218			
	9572856	Jul 18, 2031	U-2221			
	9867863	Dec 16, 2029	U-2231			
<u>ANIDULAFUNGIN - ERAXIS</u>						
N 021632 001					NPP	Sep 22, 2023
<u>ANIDULAFUNGIN - ERAXIS</u>						
N 021632 002					NPP	Sep 22, 2023
<u>APALUTAMIDE - ERLEADA</u>						
N 210951 001	10052314	Sep 23, 2033	U-2381		NCE	Feb 14, 2023
	10052314	Sep 23, 2033	U-2382			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>APALUTAMIDE - ERLEADA</u>						
N 210951 001	10702508	Apr 30, 2038	U-3012			
	10849888	Sep 23, 2033	U-3013			
	8445507	Sep 15, 2030	DS DP U-2237			
	8445507	Sep 15, 2030	DS DP U-2624			
	8802689	Mar 27, 2027	U-2237			
	8802689	Mar 27, 2027	U-2624			
	9388159	Mar 27, 2027	DS DP			
	9481663	Jun 04, 2033	DS			
	9884054	Sep 23, 2033	U-2237			
	9987261	Mar 27, 2027	DP			
<u>APIXABAN - ELIQUIS</u>						
N 202155 001	6967208	Nov 21, 2026	DS DP U-1167			
	6967208	Nov 21, 2026	DS DP U-1200			
	6967208	Nov 21, 2026	DS DP U-1301			
	6967208	Nov 21, 2026	DS DP U-1302			
	6967208	Nov 21, 2026	DS DP U-1323			
	6967208	Nov 21, 2026	DS DP U-1501			
	6967208	Nov 21, 2026	DS DP U-1502			
	6967208	Nov 21, 2026	DS DP U-1729			
	6967208	Nov 21, 2026	DS DP U-1730			
	9326945	Feb 24, 2031	DP			
<u>APIXABAN - ELIQUIS</u>						
N 202155 002	6967208	Nov 21, 2026	DS DP U-1200			
	6967208	Nov 21, 2026	DS DP U-1301			
	6967208	Nov 21, 2026	DS DP U-1302			
	6967208	Nov 21, 2026	DS DP U-1323			
	9326945	Feb 24, 2031	DP			
<u>APOMORPHINE HYDROCHLORIDE - KYNMOBI</u>						
N 210875 001	10420763	Jun 11, 2030	DP U-2825		NP	May 21, 2023
	10449146	Apr 19, 2036	U-2825			
	10821074	Aug 07, 2029	DP			
	10959943	Apr 19, 2036	U-2825			
	11419769	Dec 16, 2031	DP U-2825			
	8414922	Dec 16, 2031	DP U-2825			
	8603514	Apr 03, 2024	DP			
	8663687	Feb 02, 2023	DP			
	8765167	Feb 20, 2024	DP			
	8846074	Dec 16, 2031	DP U-2825			
	9044475	Jun 11, 2030	DP			
	9283219	Jun 11, 2030	DP U-2825			
	9326981	Jun 11, 2030	U-2825			
	9669019	Jun 11, 2030	DP U-2825			
	9669021	Jun 11, 2030	U-2825			
<u>APOMORPHINE HYDROCHLORIDE - KYNMOBI</u>						
N 210875 002	10420763	Jun 11, 2030	DP U-2825		NP	May 21, 2023
	10449146	Apr 19, 2036	U-2825			
	10821074	Aug 07, 2029	DP			
	10959943	Apr 19, 2036	U-2825			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>APOMORPHINE HYDROCHLORIDE - KYNMOBI</u>						
N 210875 002	11419769	Dec 16, 2031	DP U-2825			
	8414922	Dec 16, 2031	DP U-2825			
	8603514	Apr 03, 2024	DP			
	8663687	Feb 02, 2023	DP			
	8765167	Feb 20, 2024	DP			
	8846074	Dec 16, 2031	DP U-2825			
	9044475	Jun 11, 2030	DP			
	9283219	Jun 11, 2030	DP U-2825			
	9326981	Jun 11, 2030	U-2825			
	9669019	Jun 11, 2030	DP U-2825			
	9669021	Jun 11, 2030	U-2825			
<u>APOMORPHINE HYDROCHLORIDE - KYNMOBI</u>						
N 210875 003	10420763	Jun 11, 2030	DP U-2825		NP	May 21, 2023
	10449146	Apr 19, 2036	U-2825			
	10821074	Aug 07, 2029	DP			
	10959943	Apr 19, 2036	U-2825			
	11419769	Dec 16, 2031	DP U-2825			
	8414922	Dec 16, 2031	DP U-2825			
	8603514	Apr 03, 2024	DP			
	8663687	Feb 02, 2023	DP			
	8765167	Feb 20, 2024	DP			
	8846074	Dec 16, 2031	DP U-2825			
	9044475	Jun 11, 2030	DP			
	9283219	Jun 11, 2030	DP U-2825			
	9326981	Jun 11, 2030	U-2825			
	9669019	Jun 11, 2030	DP U-2825			
	9669021	Jun 11, 2030	U-2825			
<u>APOMORPHINE HYDROCHLORIDE - KYNMOBI</u>						
N 210875 004	10420763	Jun 11, 2030	DP U-2825		NP	May 21, 2023
	10449146	Apr 19, 2036	U-2825			
	10821074	Aug 07, 2029	DP			
	10959943	Apr 19, 2036	U-2825			
	11419769	Dec 16, 2031	DP U-2825			
	8414922	Dec 16, 2031	DP U-2825			
	8603514	Apr 03, 2024	DP			
	8663687	Feb 02, 2023	DP			
	8765167	Feb 20, 2024	DP			
	8846074	Dec 16, 2031	DP U-2825			
	9044475	Jun 11, 2030	DP			
	9283219	Jun 11, 2030	DP U-2825			
	9326981	Jun 11, 2030	U-2825			
	9669019	Jun 11, 2030	DP U-2825			
	9669021	Jun 11, 2030	U-2825			
<u>APOMORPHINE HYDROCHLORIDE - KYNMOBI</u>						
N 210875 005	10420763	Jun 11, 2030	DP U-2825		NP	May 21, 2023
	10449146	Apr 19, 2036	U-2825			
	10821074	Aug 07, 2029	DP			
	10959943	Apr 19, 2036	U-2825			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>APOMORPHINE HYDROCHLORIDE - KYNMOBI</u>						
N 210875 005	11419769	Dec 16, 2031	DP U-2825			
	8414922	Dec 16, 2031	DP U-2825			
	8603514	Apr 03, 2024	DP			
	8663687	Feb 02, 2023	DP			
	8765167	Feb 20, 2024	DP			
	8846074	Dec 16, 2031	DP U-2825			
	9044475	Jun 11, 2030	DP			
	9283219	Jun 11, 2030	DP U-2825			
	9326981	Jun 11, 2030	U-2825			
	9669019	Jun 11, 2030	DP U-2825			
	9669021	Jun 11, 2030	U-2825			
<u>APREMILAST - OTEZLA</u>						
N 205437 001	10092541	May 29, 2034	U-2403		I-884	Dec 20, 2024
	10092541	May 29, 2034	U-2659		M-257	Apr 10, 2023
	6962940	Mar 19, 2023	U-1504		ODE-248	Jul 19, 2026
	6962940	Mar 19, 2023	U-2656			
	6962940	Mar 19, 2023	U-2658			
	6962940	Mar 19, 2023	U-3276			
	7208516	Mar 19, 2023	U-1505			
	7427638	Feb 16, 2028	DS DP			
	7659302	Mar 19, 2023	U-1505			
	7659302	Mar 19, 2023	U-1595			
	7659302	Mar 19, 2023	U-2658			
	7659302	Mar 19, 2023	U-3276			
	7893101	Dec 09, 2023	DS DP			
	8455536	Mar 19, 2023	U-1505			
	8455536	Mar 19, 2023	U-1595			
	8455536	Mar 19, 2023	U-2658			
	8455536	Mar 19, 2023	U-3276			
	8802717	Mar 19, 2023	U-1561			
	9018243	Mar 19, 2023	U-1505			
	9018243	Mar 19, 2023	U-1595			
	9018243	Mar 19, 2023	U-2656			
	9018243	Mar 19, 2023	U-2658			
	9018243	Mar 19, 2023	U-3276			
	9724330	Mar 19, 2023	U-1561			
	9724330	Mar 19, 2023	U-1595			
	9724330	Mar 19, 2023	U-2656			
	9724330	Mar 19, 2023	U-2658			
	9724330	Mar 19, 2023	U-3276			
	9872854	May 29, 2034	U-2232			
	9872854	May 29, 2034	U-2233			
<u>APREMILAST - OTEZLA</u>						
N 205437 002	10092541	May 29, 2034	U-2403		I-884	Dec 20, 2024
	10092541	May 29, 2034	U-2659		M-257	Apr 10, 2023
	6962940	Mar 19, 2023	U-1504		ODE-248	Jul 19, 2026
	6962940	Mar 19, 2023	U-2656			
	6962940	Mar 19, 2023	U-2658			
	6962940	Mar 19, 2023	U-3276			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>APREMILAST - OTEZLA</u>						
N 205437 002	7208516	Mar 19, 2023	U-1505			
	7427638	Feb 16, 2028	DS DP			
	7659302	Mar 19, 2023	U-1505			
	7659302	Mar 19, 2023	U-1595			
	7659302	Mar 19, 2023	U-2658			
	7659302	Mar 19, 2023	U-3276			
	7893101	Dec 09, 2023	DS DP			
	8455536	Mar 19, 2023	U-1505			
	8455536	Mar 19, 2023	U-1595			
	8455536	Mar 19, 2023	U-2658			
	8455536	Mar 19, 2023	U-3276			
	8802717	Mar 19, 2023	U-1561			
	9018243	Mar 19, 2023	U-1505			
	9018243	Mar 19, 2023	U-1595			
	9018243	Mar 19, 2023	U-2656			
	9018243	Mar 19, 2023	U-2658			
	9018243	Mar 19, 2023	U-3276			
	9724330	Mar 19, 2023	U-1561			
	9724330	Mar 19, 2023	U-1595			
	9724330	Mar 19, 2023	U-2656			
	9724330	Mar 19, 2023	U-2658			
	9724330	Mar 19, 2023	U-3276			
	9872854	May 29, 2034	U-2232			
	9872854	May 29, 2034	U-2233			
<u>APREMILAST - OTEZLA</u>						
N 205437 003	10092541	May 29, 2034	U-2403		I-884	Dec 20, 2024
	10092541	May 29, 2034	U-2659		M-257	Apr 10, 2023
	6962940	Mar 19, 2023	U-1504		ODE-248	Jul 19, 2026
	6962940	Mar 19, 2023	U-2656			
	6962940	Mar 19, 2023	U-2658			
	6962940	Mar 19, 2023	U-3276			
	7208516	Mar 19, 2023	U-1505			
	7427638	Feb 16, 2028	DS DP			
	7659302	Mar 19, 2023	U-1505			
	7659302	Mar 19, 2023	U-1595			
	7659302	Mar 19, 2023	U-2658			
	7659302	Mar 19, 2023	U-3276			
	7893101	Dec 09, 2023	DS DP			
	8455536	Mar 19, 2023	U-1505			
	8455536	Mar 19, 2023	U-1595			
	8455536	Mar 19, 2023	U-2658			
	8455536	Mar 19, 2023	U-3276			
	8802717	Mar 19, 2023	U-1561			
	9018243	Mar 19, 2023	U-1505			
	9018243	Mar 19, 2023	U-1595			
	9018243	Mar 19, 2023	U-2656			
	9018243	Mar 19, 2023	U-2658			
	9018243	Mar 19, 2023	U-3276			
	9724330	Mar 19, 2023	U-1561			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>APREMILAST - OTEZLA</u>						
N 205437	003 9724330	Mar 19, 2023	U-1595			
	9724330	Mar 19, 2023	U-2656			
	9724330	Mar 19, 2023	U-2658			
	9724330	Mar 19, 2023	U-3276			
	9872854	May 29, 2034	U-2232			
	9872854	May 29, 2034	U-2233			
<u>APREPITANT - EMEND</u>						
N 021549	001 8258132	Sep 26, 2027	DP U-1743			
	8258132	Sep 26, 2027	DP U-901			
<u>APREPITANT - EMEND</u>						
N 021549	002 8258132	Sep 26, 2027	DP U-1743			
	8258132	Sep 26, 2027	DP U-901			
<u>APREPITANT - EMEND</u>						
N 021549	003 8258132	Sep 26, 2027	DP U-1743			
	8258132	Sep 26, 2027	DP U-901			
<u>APREPITANT - EMEND</u>						
N 207865	001 8258132	Sep 26, 2027	DP U-1916			
<u>APREPITANT - CINVANTI</u>						
N 209296	001 10500208	Sep 18, 2035	DP			
	10624850	Sep 18, 2035	U-2161			
	10953018	Sep 18, 2035	U-2161			
	11173118	Sep 18, 2035	DP			
	9561229	Sep 18, 2035	DP U-2161			
	9808465	Sep 18, 2035	U-2161			
	9974742	Sep 18, 2035	DP			
	9974793	Sep 18, 2035	DP			
	9974794	Sep 18, 2035	DP U-2161			
<u>APREPITANT - APONVIE</u>						
N 216457	001 10500208	Sep 18, 2035	DP			
	10624850	Sep 18, 2035	U-3440			
	10953018	Sep 18, 2035	U-3440			
	11173118	Sep 18, 2035	DP			
	9561229	Sep 18, 2035	DP U-3440			
	9808465	Sep 18, 2035	U-3440			
	9974742	Sep 18, 2035	DP			
	9974793	Sep 18, 2035	DP			
	9974794	Sep 18, 2035	DP U-3440			
<u>ARGATROBAN - ARGATROBAN IN SODIUM CHLORIDE</u>						
N 022434	001 7589106	Sep 26, 2027	DP U-1163			
	7687516	Sep 26, 2027	DP U-1164			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436	001 8017615	Jun 16, 2024	DP			
	8017615*PED	Dec 16, 2024				
	8580796*PED	Mar 25, 2023				
	8642760*PED	Mar 25, 2023				
	8759350	Mar 02, 2027	U-1529			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ARIPIRAZOLE - ABILIFY</u>						
N 021436 001	9125939	Jul 28, 2026	U-1749			
	9387182	Dec 25, 2023	U-1529			
<u>ARIPIRAZOLE - ABILIFY</u>						
N 021436 002	8017615	Jun 16, 2024	DP			
	8017615*PED	Dec 16, 2024				
	8580796*PED	Mar 25, 2023				
	8642760*PED	Mar 25, 2023				
	8759350	Mar 02, 2027	U-1529			
	9125939	Jul 28, 2026	U-1749			
	9387182	Dec 25, 2023	U-1529			
<u>ARIPIRAZOLE - ABILIFY</u>						
N 021436 003	8017615	Jun 16, 2024	DP			
	8017615*PED	Dec 16, 2024				
	8580796*PED	Mar 25, 2023				
	8642760*PED	Mar 25, 2023				
	8759350	Mar 02, 2027	U-1529			
	9125939	Jul 28, 2026	U-1749			
	9387182	Dec 25, 2023	U-1529			
<u>ARIPIRAZOLE - ABILIFY</u>						
N 021436 004	8017615	Jun 16, 2024	DP			
	8017615*PED	Dec 16, 2024				
	8580796*PED	Mar 25, 2023				
	8642760*PED	Mar 25, 2023				
	8759350	Mar 02, 2027	U-1529			
	9125939	Jul 28, 2026	U-1749			
	9387182	Dec 25, 2023	U-1529			
<u>ARIPIRAZOLE - ABILIFY</u>						
N 021436 005	8017615	Jun 16, 2024	DP			
	8017615*PED	Dec 16, 2024				
	8580796*PED	Mar 25, 2023				
	8642760*PED	Mar 25, 2023				
	8759350	Mar 02, 2027	U-1529			
	9125939	Jul 28, 2026	U-1749			
	9387182	Dec 25, 2023	U-1529			
<u>ARIPIRAZOLE - ABILIFY</u>						
N 021436 006	8017615	Jun 16, 2024	DP			
	8017615*PED	Dec 16, 2024				
	8580796*PED	Mar 25, 2023				
	8642760*PED	Mar 25, 2023				
	8759350	Mar 02, 2027	U-1529			
	9125939	Jul 28, 2026	U-1749			
	9387182	Dec 25, 2023	U-1529			
<u>ARIPIRAZOLE - ABILIFY</u>						
N 021713 001	8759350	Mar 02, 2027	U-1529			
	9387182	Dec 25, 2023	U-1529			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ARIPIRAZOLE - ABILIFY</u>						
N 021729 002	8017615	Jun 16, 2024	DP			
	8017615*PED	Dec 16, 2024				
	8580796*PED	Mar 25, 2023				
	8642760*PED	Mar 25, 2023				
	8759350	Mar 02, 2027	U-1529			
	9125939	Jul 28, 2026	U-1749			
	9387182	Dec 25, 2023	U-1529			
<u>ARIPIRAZOLE - ABILIFY</u>						
N 021729 003	8017615	Jun 16, 2024	DP			
	8017615*PED	Dec 16, 2024				
	8580796*PED	Mar 25, 2023				
	8642760*PED	Mar 25, 2023				
	8759350	Mar 02, 2027	U-1529			
	9125939	Jul 28, 2026	U-1749			
	9387182	Dec 25, 2023	U-1529			
<u>ARIPIRAZOLE - ABILIFY</u>						
N 021729 004	8017615	Jun 16, 2024	DP			
	8017615*PED	Dec 16, 2024				
	8580796*PED	Mar 25, 2023				
	8642760*PED	Mar 25, 2023				
	9387182	Dec 25, 2023	U-1529			
<u>ARIPIRAZOLE - ABILIFY</u>						
N 021729 005	8017615	Jun 16, 2024	DP			
	8017615*PED	Dec 16, 2024				
	8580796*PED	Mar 25, 2023				
	8642760*PED	Mar 25, 2023				
	9387182	Dec 25, 2023	U-1529			
<u>ARIPIRAZOLE - ABILIFY</u>						
N 021866 001	7115587	Jul 21, 2024	DP U-764			
	7115587*PED	Jan 21, 2025				
	7550445	Jul 21, 2024	DP			
<u>ARIPIRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 001	10525057	Mar 08, 2034	U-1632			
	10525057	Mar 08, 2034	U-2723			
	10525057	Mar 08, 2034	U-543			
	10980803	Sep 24, 2033	U-1632			
	10980803	Sep 24, 2033	U-543			
	11154553	Sep 24, 2033	U-1632			
	11154553	Sep 24, 2033	U-3245			
	11154553	Sep 24, 2033	U-814			
	11344547	Sep 24, 2033	U-1632			
	11344547	Sep 24, 2033	U-3245			
	11344547	Sep 24, 2033	U-814			
	11400087	Sep 24, 2033	U-1632			
	11400087	Sep 24, 2033	U-3245			
	11400087	Sep 24, 2033	U-814			
	7807680	Oct 19, 2024	DP			
	8030313	Oct 19, 2024	U-1632			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ARIPIRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 001	8030313	Oct 19, 2024	U-543			
	8338427	Mar 15, 2025	DP U-1633			
	8338427	Mar 15, 2025	DP U-543			
	8338428	Aug 06, 2023	DP U-1633			
	8338428	Aug 06, 2023	DP U-543			
	8399469	Jun 29, 2025	DS			
	8722679	Oct 19, 2024	DP			
	8759351	Aug 06, 2023	DP U-1530			
	8759351	Aug 06, 2023	DP U-1633			
<u>ARIPIRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 002	10525057	Mar 08, 2034	U-1632			
	10525057	Mar 08, 2034	U-2723			
	10525057	Mar 08, 2034	U-543			
	10980803	Sep 24, 2033	U-1632			
	10980803	Sep 24, 2033	U-543			
	11154553	Sep 24, 2033	U-1632			
	11154553	Sep 24, 2033	U-3245			
	11154553	Sep 24, 2033	U-814			
	11344547	Sep 24, 2033	U-1632			
	11344547	Sep 24, 2033	U-3245			
	11344547	Sep 24, 2033	U-814			
	11400087	Sep 24, 2033	U-1632			
	11400087	Sep 24, 2033	U-3245			
	11400087	Sep 24, 2033	U-814			
	7807680	Oct 19, 2024	DP			
	8030313	Oct 19, 2024	U-1632			
	8030313	Oct 19, 2024	U-543			
	8338427	Mar 15, 2025	DP U-1633			
	8338427	Mar 15, 2025	DP U-543			
	8338428	Aug 06, 2023	DP U-1633			
	8338428	Aug 06, 2023	DP U-543			
	8399469	Jun 29, 2025	DS			
	8722679	Oct 19, 2024	DP			
	8759351	Aug 06, 2023	DP U-1530			
	8759351	Aug 06, 2023	DP U-1633			
<u>ARIPIRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 003	10525057	Mar 08, 2034	U-1632			
	10525057	Mar 08, 2034	U-2723			
	10525057	Mar 08, 2034	U-543			
	10980803	Sep 24, 2033	U-1632			
	10980803	Sep 24, 2033	U-543			
	11154553	Sep 24, 2033	U-1632			
	11154553	Sep 24, 2033	U-3245			
	11154553	Sep 24, 2033	U-814			
	11344547	Sep 24, 2033	U-1632			
	11344547	Sep 24, 2033	U-3245			
	11344547	Sep 24, 2033	U-814			
	11400087	Sep 24, 2033	U-1632			
	11400087	Sep 24, 2033	U-3245			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ARIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 003	11400087	Sep 24, 2033	U-814			
	7807680	Oct 19, 2024	DP			
	8030313	Oct 19, 2024	U-1632			
	8030313	Oct 19, 2024	U-543			
	8338427	Mar 15, 2025	DP U-1633			
	8338427	Mar 15, 2025	DP U-543			
	8338428	Aug 06, 2023	DP U-1633			
	8338428	Aug 06, 2023	DP U-543			
	8399469	Jun 29, 2025	DS			
	8722679	Oct 19, 2024	DP			
	8759351	Aug 06, 2023	DP U-1530			
	8759351	Aug 06, 2023	DP U-1633			
<u>ARIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 004	10525057	Mar 08, 2034	U-1632			
	10525057	Mar 08, 2034	U-2723			
	10525057	Mar 08, 2034	U-543			
	10980803	Sep 24, 2033	U-1632			
	10980803	Sep 24, 2033	U-543			
	11154553	Sep 24, 2033	U-1632			
	11154553	Sep 24, 2033	U-3245			
	11154553	Sep 24, 2033	U-814			
	11344547	Sep 24, 2033	U-1632			
	11344547	Sep 24, 2033	U-3245			
	11344547	Sep 24, 2033	U-814			
	11400087	Sep 24, 2033	U-1632			
	11400087	Sep 24, 2033	U-3245			
	11400087	Sep 24, 2033	U-814			
	7807680	Oct 19, 2024	DP			
	8030313	Oct 19, 2024	U-1632			
	8030313	Oct 19, 2024	U-543			
	8338427	Mar 15, 2025	DP U-1633			
	8338427	Mar 15, 2025	DP U-543			
	8338428	Aug 06, 2023	DP U-1633			
	8338428	Aug 06, 2023	DP U-543			
	8399469	Jun 29, 2025	DS			
	8722679	Oct 19, 2024	DP			
	8759351	Aug 06, 2023	DP U-1530			
	8759351	Aug 06, 2023	DP U-1633			
<u>ARIPRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 001	10441194	Jul 26, 2029	DP			
	10517507	Jun 13, 2032	DP			
	11229378	Jul 11, 2031	DP			
	11464423	Sep 15, 2030	DP			
	11476952	Apr 28, 2026	DP			
	7978064	Sep 14, 2026	DP			
	8017615	Jun 16, 2024	DP			
	8114021	Jun 21, 2030	DP			
	8258962	Nov 25, 2030	DP			
	8545402	Apr 27, 2030	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ARIPIRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 001	8547248	Dec 18, 2030	DP U-2167			
	8674825	Apr 09, 2029	DP U-2170			
	8718193	Dec 05, 2029	DP			
	8759350	Mar 02, 2027	U-1529			
	8847766	Mar 29, 2030	DP U-2167			
	8945005	Aug 19, 2029	DP U-2167			
	8956288	Jul 06, 2029	DP U-2167			
	8961412	Nov 17, 2030	DP			
	9060708	Mar 05, 2029	DP			
	9119554	Dec 16, 2028	DP			
	9125939	Jul 28, 2026	U-1749			
	9149577	Dec 15, 2029	DP			
	9258035	Mar 05, 2029	DP			
	9268909	Oct 15, 2033	DP U-2168			
	9320455	Dec 15, 2031	DP			
	9387182	Dec 25, 2023	U-1529			
	9433371	Sep 15, 2029	DP			
	9444503	Nov 19, 2027	DP U-2169			
	9941931	Nov 04, 2030	DP			
<u>ARIPIRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 002	10441194	Jul 26, 2029	DP			
	10517507	Jun 13, 2032	DP			
	11229378	Jul 11, 2031	DP			
	11464423	Sep 15, 2030	DP			
	11476952	Apr 28, 2026	DP			
	7978064	Sep 14, 2026	DP			
	8017615	Jun 16, 2024	DP			
	8114021	Jun 21, 2030	DP			
	8258962	Nov 25, 2030	DP			
	8545402	Apr 27, 2030	DP			
	8547248	Dec 18, 2030	DP U-2167			
	8674825	Apr 09, 2029	DP U-2170			
	8718193	Dec 05, 2029	DP			
	8759350	Mar 02, 2027	U-1529			
	8847766	Mar 29, 2030	DP U-2167			
	8945005	Aug 19, 2029	DP U-2167			
	8956288	Jul 06, 2029	DP U-2167			
	8961412	Nov 17, 2030	DP			
	9060708	Mar 05, 2029	DP			
	9119554	Dec 16, 2028	DP			
	9125939	Jul 28, 2026	U-1749			
	9149577	Dec 15, 2029	DP			
	9258035	Mar 05, 2029	DP			
	9268909	Oct 15, 2033	DP U-2168			
	9320455	Dec 15, 2031	DP			
	9387182	Dec 25, 2023	U-1529			
	9433371	Sep 15, 2029	DP			
	9444503	Nov 19, 2027	DP U-2169			
	9941931	Nov 04, 2030	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ARIPRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 002	10441194	Jul 26, 2029	DP			
	10517507	Jun 13, 2032	DP			
	11229378	Jul 11, 2031	DP			
	11464423	Sep 15, 2030	DP			
	11476952	Apr 28, 2026	DP			
	7978064	Sep 14, 2026	DP			
	8017615	Jun 16, 2024	DP			
	8114021	Jun 21, 2030	DP			
	8258962	Nov 25, 2030	DP			
	8545402	Apr 27, 2030	DP			
	8547248	Dec 18, 2030	DP U-2167			
	8674825	Apr 09, 2029	DP U-2170			
	8718193	Dec 05, 2029	DP			
	8759350	Mar 02, 2027	U-1529			
	8847766	Mar 29, 2030	DP U-2167			
	8945005	Aug 19, 2029	DP U-2167			
	8956288	Jul 06, 2029	DP U-2167			
	8961412	Nov 17, 2030	DP			
	9060708	Mar 05, 2029	DP			
	9119554	Dec 16, 2028	DP			
	9125939	Jul 28, 2026	U-1749			
	9149577	Dec 15, 2029	DP			
	9258035	Mar 05, 2029	DP			
	9268909	Oct 15, 2033	DP U-2168			
	9320455	Dec 15, 2031	DP			
	9387182	Dec 25, 2023	U-1529			
	9433371	Sep 15, 2029	DP			
	9444503	Nov 19, 2027	DP U-2169			
	9941931	Nov 04, 2030	DP			
<u>ARIPRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 003	10441194	Jul 26, 2029	DP			
	10517507	Jun 13, 2032	DP			
	11229378	Jul 11, 2031	DP			
	11464423	Sep 15, 2030	DP			
	11476952	Apr 28, 2026	DP			
	7978064	Sep 14, 2026	DP			
	8017615	Jun 16, 2024	DP			
	8114021	Jun 21, 2030	DP			
	8258962	Nov 25, 2030	DP			
	8545402	Apr 27, 2030	DP			
	8547248	Dec 18, 2030	DP U-2167			
	8674825	Apr 09, 2029	DP U-2170			
	8718193	Dec 05, 2029	DP			
	8759350	Mar 02, 2027	U-1529			
	8847766	Mar 29, 2030	DP U-2167			
	8945005	Aug 19, 2029	DP U-2167			
	8956288	Jul 06, 2029	DP U-2167			
	8961412	Nov 17, 2030	DP			
	9060708	Mar 05, 2029	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ARIPIRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 003	9119554	Dec 16, 2028	DP			
	9125939	Jul 28, 2026	U-1749			
	9149577	Dec 15, 2029	DP			
	9258035	Mar 05, 2029	DP			
	9268909	Oct 15, 2033	DP U-2168			
	9320455	Dec 15, 2031	DP			
	9387182	Dec 25, 2023	U-1529			
	9433371	Sep 15, 2029	DP			
	9444503	Nov 19, 2027	DP U-2169			
	9941931	Nov 04, 2030	DP			
<u>ARIPIRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 004	10441194	Jul 26, 2029	DP			
	10517507	Jun 13, 2032	DP			
	11229378	Jul 11, 2031	DP			
	11464423	Sep 15, 2030	DP			
	11476952	Apr 28, 2026	DP			
	7978064	Sep 14, 2026	DP			
	8017615	Jun 16, 2024	DP			
	8114021	Jun 21, 2030	DP			
	8258962	Nov 25, 2030	DP			
	8545402	Apr 27, 2030	DP			
	8547248	Dec 18, 2030	DP U-2167			
	8674825	Apr 09, 2029	DP U-2170			
	8718193	Dec 05, 2029	DP			
	8759350	Mar 02, 2027	U-1529			
	8847766	Mar 29, 2030	DP U-2167			
	8945005	Aug 19, 2029	DP U-2167			
	8956288	Jul 06, 2029	DP U-2167			
	8961412	Nov 17, 2030	DP			
	9060708	Mar 05, 2029	DP			
	9119554	Dec 16, 2028	DP			
	9125939	Jul 28, 2026	U-1749			
	9149577	Dec 15, 2029	DP			
	9258035	Mar 05, 2029	DP			
	9268909	Oct 15, 2033	DP U-2168			
	9320455	Dec 15, 2031	DP			
	9387182	Dec 25, 2023	U-1529			
	9433371	Sep 15, 2029	DP			
	9444503	Nov 19, 2027	DP U-2169			
	9941931	Nov 04, 2030	DP			
<u>ARIPIRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 005	10441194	Jul 26, 2029	DP			
	10517507	Jun 13, 2032	DP			
	11229378	Jul 11, 2031	DP			
	11464423	Sep 15, 2030	DP			
	11476952	Apr 28, 2026	DP			
	7978064	Sep 14, 2026	DP			
	8017615	Jun 16, 2024	DP			
	8114021	Jun 21, 2030	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ARIPIRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 005	8258962	Nov 25, 2030	DP			
	8545402	Apr 27, 2030	DP			
	8547248	Dec 18, 2030	DP U-2167			
	8674825	Apr 09, 2029	DP U-2170			
	8718193	Dec 05, 2029	DP			
	8759350	Mar 02, 2027	U-1529			
	8847766	Mar 29, 2030	DP U-2167			
	8945005	Aug 19, 2029	DP U-2167			
	8956288	Jul 06, 2029	DP U-2167			
	8961412	Nov 17, 2030	DP			
	9060708	Mar 05, 2029	DP			
	9119554	Dec 16, 2028	DP			
	9125939	Jul 28, 2026	U-1749			
	9149577	Dec 15, 2029	DP			
	9258035	Mar 05, 2029	DP			
	9268909	Oct 15, 2033	DP U-2168			
	9320455	Dec 15, 2031	DP			
	9387182	Dec 25, 2023	U-1529			
	9433371	Sep 15, 2029	DP			
	9444503	Nov 19, 2027	DP U-2169			
	9941931	Nov 04, 2030	DP			
<u>ARIPIRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 006	10441194	Jul 26, 2029	DP			
	10517507	Jun 13, 2032	DP			
	11229378	Jul 11, 2031	DP			
	11464423	Sep 15, 2030	DP			
	11476952	Apr 28, 2026	DP			
	7978064	Sep 14, 2026	DP			
	8017615	Jun 16, 2024	DP			
	8114021	Jun 21, 2030	DP			
	8258962	Nov 25, 2030	DP			
	8545402	Apr 27, 2030	DP			
	8547248	Dec 18, 2030	DP U-2167			
	8674825	Apr 09, 2029	DP U-2170			
	8718193	Dec 05, 2029	DP			
	8759350	Mar 02, 2027	U-1529			
	8847766	Mar 29, 2030	DP U-2167			
	8945005	Aug 19, 2029	DP U-2167			
	8956288	Jul 06, 2029	DP U-2167			
	8961412	Nov 17, 2030	DP			
	9060708	Mar 05, 2029	DP			
	9119554	Dec 16, 2028	DP			
	9125939	Jul 28, 2026	U-1749			
	9149577	Dec 15, 2029	DP			
	9258035	Mar 05, 2029	DP			
	9268909	Oct 15, 2033	DP U-2168			
	9320455	Dec 15, 2031	DP			
	9387182	Dec 25, 2023	U-1529			
	9433371	Sep 15, 2029	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ARIPIRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202 006	9444503	Nov 19, 2027	DP U-2169			
	9941931	Nov 04, 2030	DP			
<u>ARIPIRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 001	10112903	Jun 24, 2030	DS U-543			
	10226458	Mar 19, 2032	U-543			
	10238651	Mar 19, 2035	U-2402			
	10813928	Mar 19, 2035	U-2983			
	11097006	Oct 24, 2033	DP U-764			
	11273158	Apr 06, 2039	U-543			
	11406632	Mar 19, 2035	U-2402			
	8431576	Oct 26, 2030	DS			
	8796276	Jun 24, 2030	U-543			
	9034867	Nov 07, 2032	DP U-543			
	9193685	Oct 24, 2033	DP U-543			
	9452131	Mar 19, 2035	U-2402			
<u>ARIPIRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 002	10112903	Jun 24, 2030	DS U-543			
	10226458	Mar 19, 2032	U-543			
	10238651	Mar 19, 2035	U-2402			
	10813928	Mar 19, 2035	U-2983			
	11097006	Oct 24, 2033	DP U-764			
	11273158	Apr 06, 2039	U-543			
	11406632	Mar 19, 2035	U-2402			
	8431576	Oct 26, 2030	DS			
	8796276	Jun 24, 2030	U-543			
	9034867	Nov 07, 2032	DP U-543			
	9193685	Oct 24, 2033	DP U-543			
	9452131	Mar 19, 2035	U-2402			
	9526726	Mar 19, 2035	DP			
<u>ARIPIRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 003	10112903	Jun 24, 2030	DS U-543			
	10226458	Mar 19, 2032	U-543			
	10238651	Mar 19, 2035	U-2402			
	10813928	Mar 19, 2035	U-2402			
	11097006	Oct 24, 2033	DP U-764			
	11273158	Apr 06, 2039	U-543			
	11406632	Mar 19, 2035	U-2402			
	8431576	Oct 26, 2030	DS			
	8796276	Jun 24, 2030	U-543			
	9034867	Nov 07, 2032	DP U-543			
	9193685	Oct 24, 2033	DP U-543			
	9452131	Mar 19, 2035	U-2402			
	9526726	Mar 19, 2035	DP			
<u>ARIPIRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 004	10112903	Jun 24, 2030	DS U-543			
	10226458	Mar 19, 2032	U-543			
	10238651	Mar 19, 2035	U-2402			
	10813928	Mar 19, 2035	U-2983			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ARIPIRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 004	11097006	Oct 24, 2033	DP U-764			
	11273158	Apr 06, 2039	U-543			
	11406632	Mar 19, 2035	U-2402			
	8431576	Oct 26, 2030	DS			
	8796276	Jun 24, 2030	U-543			
	9034867	Nov 07, 2032	DP U-543			
	9193685	Oct 24, 2033	DP U-543			
	9452131	Mar 19, 2035	U-2402			
<u>ARIPIRAZOLE LAUROXIL - ARISTADA INITIO KIT</u>						
N 209830 001	10016415	Sep 08, 2035	DP			
	10112903	Jun 24, 2030	DS U-543			
	10688091	Aug 17, 2035	DP			
	10849894	Aug 17, 2035	U-543			
	11154552	Aug 17, 2035	DP			
	11273158	Apr 06, 2039	U-543			
	8431576	Oct 26, 2030	DS			
	8796276	Jun 24, 2030	U-543			
<u>ARMODAFINIL - NUVIGIL</u>						
N 021875 001	7132570	Dec 18, 2023	DS DP			
	7297346	Nov 29, 2023	DP			
<u>ARMODAFINIL - NUVIGIL</u>						
N 021875 002	7132570	Dec 18, 2023	DS DP			
	7297346	Nov 29, 2023	DP			
<u>ARMODAFINIL - NUVIGIL</u>						
N 021875 003	7132570	Dec 18, 2023	DS DP			
	7297346	Nov 29, 2023	DP			
<u>ARMODAFINIL - NUVIGIL</u>						
N 021875 004	7132570	Dec 18, 2023	DS DP			
	7297346	Nov 29, 2023	DP			
<u>ARMODAFINIL - NUVIGIL</u>						
N 021875 005	7132570	Dec 18, 2023	DS DP			
	7297346	Nov 29, 2023	DP			
<u>ARSENIC TRIOXIDE - TRISENOX</u>						
N 021248 001					ODE-167	Jan 12, 2025
<u>ARSENIC TRIOXIDE - TRISENOX</u>						
N 021248 002					ODE-167	Jan 12, 2025
<u>ARTESUNATE - ARTESUNATE</u>						
N 213036 001					NCE	May 26, 2025
					ODE-290	May 26, 2027
<u>ASCIMINIB HYDROCHLORIDE - SCEMBLIX</u>						
N 215358 001	11407735	May 14, 2040	DS		NCE	Oct 29, 2026
	8829195	May 13, 2033	DS U-1374		ODE-381	Oct 29, 2028
					ODE-382	Oct 29, 2028
<u>ASCIMINIB HYDROCHLORIDE - SCEMBLIX</u>						
N 215358 002	11407735	May 14, 2040	DS		NCE	Oct 29, 2026

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ASCIMINIB HYDROCHLORIDE - SCEMBLIX</u>						
N 215358 002	8829195	May 13, 2033	DS U-1374		ODE-381	Oct 29, 2028
					ODE-382	Oct 29, 2028
<u>ASCORBIC ACID - ASCOR</u>						
N 209112 001					ODE-160	Oct 02, 2024
<u>ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE - MOVIPREP</u>						
N 021881 001	7169381	Sep 01, 2024	DS DP			
	7658914	Sep 01, 2024	DS DP			
<u>ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE - PLENVU</u>						
N 209381 001	10016504	Sep 10, 2033	DP			
	10646512	Mar 25, 2032	DP			
	10780112	Mar 09, 2032	DP			
	10792306	Mar 09, 2032	DP U-2310			
	10918723	Sep 10, 2033	U-2310			
	11529368	Mar 09, 2032	DP U-2310			
	8999313	Sep 10, 2033	DP			
	9326969	Sep 10, 2033	U-2310			
	9592252	Aug 11, 2032	DP U-2310			
	9707297	Sep 10, 2033	DP			
<u>ASENAPINE - SECUADO</u>						
N 212268 001	10022445	Jul 25, 2033	DP			
	10583121	Jul 25, 2033	DP U-2763			
	10814002	Jul 25, 2033	DP U-2763			
	11123305	Jul 25, 2033	DP			
	9687474	Jul 25, 2033	DP			
<u>ASENAPINE - SECUADO</u>						
N 212268 002	10022445	Jul 25, 2033	DP			
	10583121	Jul 25, 2033	DP U-2763			
	10814002	Jul 25, 2033	DP U-2763			
	11123305	Jul 25, 2033	DP			
	9687474	Jul 25, 2033	DP			
<u>ASENAPINE - SECUADO</u>						
N 212268 003	10022445	Jul 25, 2033	DP			
	10583121	Jul 25, 2033	DP U-2763			
	10814002	Jul 25, 2033	DP U-2763			
	11123305	Jul 25, 2033	DP			
	9687474	Jul 25, 2033	DP			
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N 022117 001	7741358	Apr 06, 2026	DS DP U-1064			
	7741358	Apr 06, 2026	DS DP U-1960			
	7741358	Apr 06, 2026	DS DP U-1961			
	7741358	Apr 06, 2026	DS DP U-1962			
	7741358	Apr 06, 2026	DS DP U-1963			
	7741358*PED	Oct 06, 2026				
	8022228	Apr 06, 2026	DS DP			
	8022228*PED	Oct 06, 2026				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N 022117 002	7741358	Apr 06, 2026	DS DP U-1064			
	7741358	Apr 06, 2026	DS DP U-1960			
	7741358	Apr 06, 2026	DS DP U-1961			
	7741358	Apr 06, 2026	DS DP U-1962			
	7741358	Apr 06, 2026	DS DP U-1963			
	7741358*PED	Oct 06, 2026				
	8022228	Apr 06, 2026	DS DP			
	8022228*PED	Oct 06, 2026				
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N 022117 003	7741358	Apr 06, 2026	DS DP U-1893			
	7741358	Apr 06, 2026	DS DP U-1966			
	7741358*PED	Oct 06, 2026				
	8022228	Apr 06, 2026	DS DP			
	8022228*PED	Oct 06, 2026				
<u>ASPIRIN - VAZALORE</u>						
N 203697 001	9216150	Sep 29, 2032	DP			
	9226892	Sep 29, 2032	U-1731			
	9226892	Sep 29, 2032	U-1732			
	9226892	Sep 29, 2032	U-1733			
<u>ASPIRIN; OMEPRAZOLE - YOSPRALA</u>						
N 205103 001	6926907	Feb 28, 2023	DP U-1902			
	8206741	Feb 28, 2023	DP U-1902			
	9539214	Mar 13, 2033	U-1902			
	9987231	Jan 02, 2033	U-2324			
<u>ASPIRIN; OMEPRAZOLE - YOSPRALA</u>						
N 205103 002	6926907	Feb 28, 2023	DP U-1902			
	8206741	Feb 28, 2023	DP U-1902			
	9539214	Mar 13, 2033	U-1902			
	9987231	Jan 02, 2033	U-2324			
<u>ATAZANAVIR SULFATE; COBICISTAT - EVOTAZ</u>						
N 206353 001	10039718	Oct 06, 2032	DP			
	8148374	Sep 03, 2029	DS DP U-1279			
<u>ATOGEFANT - OULIPTA</u>						
N 215206 001	10117836	Jan 30, 2035	DP		NCE	Sep 28, 2026
	8754096	Jul 19, 2032	DS DP U-3142			
	9499545	Nov 10, 2031	DS DP U-3142			
	9850246	Mar 13, 2033	DS			
<u>ATOGEFANT - OULIPTA</u>						
N 215206 002	10117836	Jan 30, 2035	DP		NCE	Sep 28, 2026
	8754096	Jul 19, 2032	DS DP U-3142			
	9499545	Nov 10, 2031	DS DP U-3142			
	9850246	Mar 13, 2033	DS			
<u>ATOGEFANT - OULIPTA</u>						
N 215206 003	10117836	Jan 30, 2035	DP		NCE	Sep 28, 2026
	8754096	Jul 19, 2032	DS DP U-3142			
	9499545	Nov 10, 2031	DS DP U-3142			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ATOGEFANT - QULIPTA</u>						
N 215206 003	9850246	Mar 13, 2033	DS			
<u>ATROPINE SULFATE - ATROPINE SULFATE</u>						
A 216120 001					CGT	Jan 29, 2023
<u>ATROPINE SULFATE - ATROPINE SULFATE</u>						
A 216120 002					CGT	Jan 29, 2023
<u>AVACOPAN - TAVNEOS</u>						
N 214487 001	8445515	Feb 03, 2031	DS DP		NCE	Oct 07, 2026
	8906938	Dec 21, 2029	DS DP		ODE-377	Oct 07, 2028
<u>AVANAFIL - STENDRA</u>						
N 202276 001	6656935	Apr 27, 2025	DS DP U-155		M-282	Oct 18, 2025
	7501409	May 05, 2023	DP			
<u>AVANAFIL - STENDRA</u>						
N 202276 002	6656935	Apr 27, 2025	DS DP U-155		M-282	Oct 18, 2025
	7501409	May 05, 2023	DP			
<u>AVANAFIL - STENDRA</u>						
N 202276 003	6656935	Apr 27, 2025	DS DP U-155		M-282	Oct 18, 2025
	7501409	May 05, 2023	DP			
<u>AVAPRITINIB - AYWAKIT</u>						
N 212608 001	9200002	Oct 15, 2034	DS DP U-2726		I-863	Jun 16, 2024
	9200002	Oct 15, 2034	DS DP U-3168		I-864	Jun 16, 2024
	9944651	Oct 15, 2034	DS DP U-2726		NCE	Jan 09, 2025
	9944651	Oct 15, 2034	DS DP U-3168		ODE-356	Jun 16, 2028
	9994575	Oct 15, 2034	DS DP U-2726		ODE-366	Jan 09, 2027
	9994575	Oct 15, 2034	DS DP U-3168			
<u>AVAPRITINIB - AYWAKIT</u>						
N 212608 002	9200002	Oct 15, 2034	DS DP U-2726		I-863	Jun 16, 2024
	9200002	Oct 15, 2034	DS DP U-3168		I-864	Jun 16, 2024
	9944651	Oct 15, 2034	DS DP U-2726		NCE	Jan 09, 2025
	9944651	Oct 15, 2034	DS DP U-3168		ODE-356	Jun 16, 2028
	9994575	Oct 15, 2034	DS DP U-2726		ODE-366	Jan 09, 2027
	9994575	Oct 15, 2034	DS DP U-3168			
<u>AVAPRITINIB - AYWAKIT</u>						
N 212608 003	9200002	Oct 15, 2034	DS DP U-2726		NCE	Jan 09, 2025
	9944651	Oct 15, 2034	DS DP U-2726		ODE-356	Jun 16, 2028
	9994575	Oct 15, 2034	DS DP U-2726		ODE-366	Jan 09, 2027
<u>AVAPRITINIB - AYWAKIT</u>						
N 212608 004	9200002	Oct 15, 2034	DS DP U-3168		I-863	Jun 16, 2024
	9944651	Oct 15, 2034	DS DP U-3168		I-864	Jun 16, 2024
	9994575	Oct 15, 2034	DS DP U-3168		NCE	Jan 09, 2025
					ODE-356	Jun 16, 2028
					ODE-366	Jan 09, 2027
<u>AVAPRITINIB - AYWAKIT</u>						
N 212608 005	9200002	Oct 15, 2034	DS DP U-3168		I-863	Jun 16, 2024
	9944651	Oct 15, 2034	DS DP U-3168		I-864	Jun 16, 2024
	9994575	Oct 15, 2034	DS DP U-3168		NCE	Jan 09, 2025

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>AVAPRITINIB - AYVAKIT</u>						
N 212608	005				ODE-356	Jun 16, 2028
					ODE-366	Jan 09, 2027
<u>AVATROMBOPAG MALEATE - DOPTELET</u>						
N 210238	001	7638536	May 05, 2025	DS DP	NCE	May 21, 2023
		8338429	Jun 30, 2023	U-2577	ODE-246	Jun 26, 2026
		8765764	Jan 15, 2023	U-2314		
		8765764	Jan 15, 2023	U-2578		
<u>AVIBACTAM SODIUM; CEFTAZIDIME - AVYCAZ</u>						
N 206494	001	7112592	Jan 07, 2026	DS DP U-2244	NCE	Feb 25, 2020
		7112592	Jan 07, 2026	DS DP U-2508	GAIN	Feb 25, 2025
		7112592	Jan 07, 2026	DS DP U-282		
		7612087	Nov 12, 2026	DP		
		8471025	Aug 12, 2031	DS		
		8835455	Oct 08, 2030	DP		
		8969566	Jun 15, 2032	DS		
		9284314	Jun 15, 2032	DS		
		9695122	Jun 15, 2032	DS		
<u>AXITINIB - INLYTA</u>						
N 202324	001	10570202	Feb 03, 2035	U-2844		
		10869924	Jan 12, 2037	U-3044		
		6534524	Apr 29, 2025	DS DP		
		8791140	Dec 14, 2030	DS		
<u>AXITINIB - INLYTA</u>						
N 202324	002	10570202	Feb 03, 2035	U-2844		
		10869924	Jan 12, 2037	U-3044		
		6534524	Apr 29, 2025	DS DP		
		8791140	Dec 14, 2030	DS		
<u>AZACITIDINE - VIDAZA</u>						
N 050794	001				I-889	May 20, 2025
<u>AZACITIDINE - ONUREG</u>						
N 214120	001	8846628	Jun 03, 2030	DP U-2950	NP	Sep 01, 2023
					ODE-320	Sep 01, 2027
<u>AZACITIDINE - ONUREG</u>						
N 214120	002	8846628	Jun 03, 2030	DP U-2950	NP	Sep 01, 2023
					ODE-320	Sep 01, 2027
<u>AZELAIC ACID - FINACEA</u>						
N 207071	001	10117812	Oct 18, 2027	DP U-1796		
		10322085	Oct 24, 2023	DP		
		7700076	Sep 18, 2027	DP		
		8435498	Mar 01, 2024	U-1727		
		8722021	Oct 24, 2023	DP		
		8900554	Oct 24, 2023	DP		
		9211259	Feb 28, 2029	U-1796		
		9265725	Dec 08, 2027	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AZELASTINE HYDROCHLORIDE - ASTEPRO</u>						
N 022203	001 8071073	Jun 04, 2028	DP			
	8518919	Nov 22, 2025	U-1430			
<u>AZELASTINE HYDROCHLORIDE - ASTEPRO</u>						
N 022203	002 8071073	Jun 04, 2028	DP			
	8518919	Nov 22, 2025	U-1430			
	9919050	Nov 22, 2025	DP			
<u>AZELASTINE HYDROCHLORIDE - ASTEPRO ALLERGY</u>						
N 213872	001 8071073	Jun 04, 2028	DP			
	8518919	Nov 22, 2025	U-3166			
	9919050	Nov 22, 2025	DP			
<u>AZELASTINE HYDROCHLORIDE - CHILDREN'S ASTEPRO ALLERGY</u>						
N 213872	002 8071073	Jun 04, 2028	DP			
	8518919	Nov 22, 2025	U-3166			
	9919050	Nov 22, 2025	DP			
<u>AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE - DYMISTA</u>						
N 202236	001 8163723	Aug 29, 2023	U-1667			
	8163723	Aug 29, 2023	U-644			
	8163723	Aug 29, 2023	U-707			
	8163723	Aug 29, 2023	U-77			
	8163723	Aug 29, 2023	U-81			
	8163723*PED	Feb 29, 2024				
	8168620	Feb 24, 2026	DP			
	9259428	Jun 13, 2023	U-644			
	9259428*PED	Dec 13, 2023				
	9901585	Jun 13, 2023	DP			
<u>AZILSARTAN KAMEDOXOMIL - EDARBI</u>						
N 200796	001 7157584	May 22, 2025	DS			
	7572920	Jan 07, 2025	DP U-3			
	9066936	Mar 26, 2028	DP			
<u>AZILSARTAN KAMEDOXOMIL - EDARBI</u>						
N 200796	002 7157584	May 22, 2025	DS			
	7572920	Jan 07, 2025	DP U-3			
	9066936	Mar 26, 2028	DP			
<u>AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR</u>						
N 202331	001 7157584	May 22, 2025	DS			
	7572920	Jan 07, 2025	DP U-3			
	9066936	Mar 26, 2028	DP			
	9169238	Feb 04, 2030	DP			
	9387249	Jul 01, 2031	U-3			
<u>AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR</u>						
N 202331	002 7157584	May 22, 2025	DS			
	7572920	Jan 07, 2025	DP U-3			
	9066936	Mar 26, 2028	DP			
	9169238	Feb 04, 2030	DP			
	9387249	Jul 01, 2031	U-3			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>AZITHROMYCIN - ZMAX</u>						
N 050797 001	6984403	Feb 14, 2024	DP U-282			
	7887844	Feb 14, 2024	DP			
<u>BACLOFEN - OZOBAX</u>						
N 208193 001	10610502	Aug 30, 2039	U-2779			
<u>BACLOFEN - LYVISPAH</u>						
N 215422 001	10792262	Jul 29, 2039	DP U-3263			
	11491125	Sep 29, 2041	DP U-3488			
	11491125	Sep 29, 2041	DP U-3489			
<u>BACLOFEN - LYVISPAH</u>						
N 215422 002	10792262	Jul 29, 2039	DP U-3263			
	11491125	Sep 29, 2041	DP U-3488			
	11491125	Sep 29, 2041	DP U-3489			
<u>BACLOFEN - LYVISPAH</u>						
N 215422 003	10792262	Jul 29, 2039	DP U-3263			
	11491125	Sep 29, 2041	DP U-3488			
	11491125	Sep 29, 2041	DP U-3489			
<u>BACLOFEN - FLEQSUVY</u>						
N 215602 001	11324696	Sep 29, 2037	DP			
	11446246	Sep 08, 2037	U-3433			
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 210854 001	10392406	Apr 27, 2036	DS		NCE	Oct 24, 2023
	10633397	Apr 27, 2036	U-2816			
	10633397	Apr 27, 2036	U-3000			
	10759814	Aug 09, 2037	DS DP			
	11261198	Sep 25, 2038	DP			
	11306106	Aug 09, 2037	U-2816			
	11306106	Aug 09, 2037	U-3000			
	8927710	May 05, 2031	DP			
	8987441	Sep 21, 2031	DS DP			
	9815835	Jun 14, 2030	DP			
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 210854 002	10392406	Apr 27, 2036	DS		NCE	Oct 24, 2023
	10633397	Apr 27, 2036	U-2816			
	10633397	Apr 27, 2036	U-3000			
	10759814	Aug 09, 2037	DS DP			
	11261198	Sep 25, 2038	DP			
	11306106	Aug 09, 2037	U-2816			
	11306106	Aug 09, 2037	U-3000			
	8927710	May 05, 2031	DP			
	8987441	Sep 21, 2031	DS DP			
	9815835	Jun 14, 2030	DP			
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 210854 003	10392406	Apr 27, 2036	DS		NCE	Oct 24, 2023
	10633397	Apr 27, 2036	U-2816			
	10633397	Apr 27, 2036	U-3000			
	10759814	Aug 09, 2037	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 210854 003	11261198	Sep 25, 2038	DP			
	11306106	Aug 09, 2037	U-2816			
	11306106	Aug 09, 2037	U-3000			
	8927710	May 05, 2031	DP			
	8987441	Sep 21, 2031	DS DP			
	9815835	Jun 14, 2030	DP			
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 214410 001	10392406	Apr 27, 2036	DS		NCE	Oct 24, 2023
	10633397	Apr 27, 2036	U-2816			
	10633397	Apr 27, 2036	U-3000			
	10759814	Aug 09, 2037	DS DP			
	11261198	Sep 25, 2038	DP			
	11306106	Aug 09, 2037	U-2816			
	11306106	Aug 09, 2037	U-3000			
	8927710	May 05, 2031	DP			
	8987441	Sep 21, 2031	DS DP			
	9815835	Jun 14, 2030	DP			
<u>BALSALAZIDE DISODIUM - COLAZAL</u>						
N 020610 001	7452872	Aug 24, 2026	U-141			
	7625884	Aug 24, 2026	U-141			
<u>BALSALAZIDE DISODIUM - GIAZO</u>						
N 022205 001	7452872	Aug 24, 2026	U-1229			
	7625884	Aug 24, 2026	U-1229			
	8497256	Jun 23, 2031	U-1229			
	9192616	Aug 02, 2026	U-1229			
<u>BARICITINIB - OLUMIANT</u>						
N 207924 001	11045474	Nov 30, 2032	U-3372		I-890	Jun 13, 2025
	8158616	Jun 08, 2030	DS DP		I-891	May 10, 2025
	8420629	Mar 10, 2029	U-247		NCE	May 31, 2023
	9089574	Nov 30, 2032	U-3372			
	9737469	Mar 29, 2033	U-3500			
<u>BARICITINIB - OLUMIANT</u>						
N 207924 002	11045474	Nov 30, 2032	U-3372		I-890	Jun 13, 2025
	8158616	Jun 08, 2030	DS DP		I-891	May 10, 2025
	8420629	Mar 10, 2029	U-247		NCE	May 31, 2023
	9089574	Nov 30, 2032	U-3372			
	9737469	Mar 29, 2033	U-3500			
<u>BARICITINIB - OLUMIANT</u>						
N 207924 003	11045474	Nov 30, 2032	U-3372		I-890	Jun 13, 2025
	8158616	Jun 08, 2030	DS DP		I-891	May 10, 2025
	9089574	Nov 30, 2032	U-3372		NCE	May 31, 2023
	9737469	Mar 29, 2033	U-3500			
<u>BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED - DUAVEE</u>						
N 022247 001	6479535	May 06, 2024	DP U-594			
	6479535	May 06, 2024	DP U-904			
	7683051	Mar 10, 2027	DS DP U-594			
	7683051	Mar 10, 2027	DS DP U-904			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED - DUAVEE</u>						
N 022247 001	6479535	May 06, 2024	DP U-594			
	6479535	May 06, 2024	DP U-904			
	7683051	Mar 10, 2027	DS DP U-594			
	7683051	Mar 10, 2027	DS DP U-904			
<u>BECLOMETHASONE DIPROPIONATE - QVAR 80</u>						
N 020911 001	10022509	May 18, 2031	DP			
	10022510	May 18, 2031	DP			
	10086156	May 18, 2031	DP			
	10561808	Jan 01, 2032	DP			
	10695512	May 18, 2031	DP			
	11395889	May 18, 2031	DP			
	9463289	May 18, 2031	DP			
	9808587	May 18, 2031	DP			
<u>BECLOMETHASONE DIPROPIONATE - QVAR 40</u>						
N 020911 002	10022509	May 18, 2031	DP			
	10022510	May 18, 2031	DP			
	10086156	May 18, 2031	DP			
	10561808	Jan 01, 2032	DP			
	10695512	May 18, 2031	DP			
	11395889	May 18, 2031	DP			
	9463289	May 18, 2031	DP			
	9808587	May 18, 2031	DP			
<u>BECLOMETHASONE DIPROPIONATE - QNASL</u>						
N 202813 001	10188811	Oct 21, 2031	DP			
	7780038	Jan 24, 2027	DP			
<u>BECLOMETHASONE DIPROPIONATE - QNASL</u>						
N 202813 002	10188811	Oct 21, 2031	DP			
	7780038	Jan 24, 2027	DP			
<u>BECLOMETHASONE DIPROPIONATE - QVAR REDHALER</u>						
N 207921 001	10022509	May 18, 2031	DP			
	10022510	May 18, 2031	DP			
	10086156	May 18, 2031	DP			
	10561808	Jan 01, 2032	DP			
	10695512	May 18, 2031	DP			
	10792447	Jan 25, 2039	DP			
	11395888	Jan 26, 2038	DP			
	11395889	May 18, 2031	DP			
	8132712	Sep 07, 2028	DP			
	8931476	Jul 17, 2031	DP			
<u>BECLOMETHASONE DIPROPIONATE - QVAR REDHALER</u>						
N 207921 002	10022509	May 18, 2031	DP			
	10022510	May 18, 2031	DP			
	10086156	May 18, 2031	DP			
	10561808	Jan 01, 2032	DP			
	10695512	May 18, 2031	DP			
	10792447	Jan 25, 2039	DP			
	11395888	Jan 26, 2038	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BECLOMETHASONE DIPROPIONATE - QVAR REDHALER</u>						
N 207921 002	11395889	May 18, 2031	DP			
	8132712	Sep 07, 2028	DP			
	8931476	Jul 17, 2031	DP			
<u>BEDAQUILINE FUMARATE - SIRTURO</u>						
N 204384 001	7498343	Dec 01, 2026	DS DP U-1321		ODE-251	Aug 09, 2026
	8546428	Mar 19, 2029	DS DP U-1321		ODE-307	May 27, 2027
<u>BEDAQUILINE FUMARATE - SIRTURO</u>						
N 204384 002	7498343	Dec 01, 2026	DS DP U-1321		ODE-307	May 27, 2027
	8546428	Mar 19, 2029	DS DP U-1321			
<u>BELINOSTAT - BELEODAO</u>						
N 206256 001	6888027	Aug 10, 2026	DS DP U-1544			
	8835501	Oct 27, 2027	DP			
<u>BELUMOSUDIL MESYLATE - REZUROCK</u>						
N 214783 001	10183931	Oct 07, 2033	U-3246		NCE	Jul 16, 2026
	10696660	Oct 07, 2033	U-3246		ODE-362	Jul 16, 2028
	11311541	Apr 09, 2035	U-3369			
	8357693	Oct 30, 2029	DS DP U-3247			
	9815820	Oct 07, 2033	U-3247			
<u>BELZUTIFAN - WELIREG</u>						
N 215383 001	9908845	Sep 05, 2034	DS DP U-3201		NCE	Aug 13, 2026
	9969689	Sep 05, 2034	DS DP U-3201		ODE-364	Aug 13, 2028
<u>BEMPEDOIC ACID - NEXLETOL</u>						
N 211616 001	10118881	Dec 23, 2023	U-2747		NCE	Feb 21, 2025
	10941095	Dec 23, 2023	U-2747			
	7335799	Dec 03, 2025	DS			
	8497301	Dec 23, 2023	U-2747			
	9000041	Dec 23, 2023	U-2747			
	9624152	Dec 23, 2023	U-2748			
<u>BEMPEDOIC ACID; EZETIMIBE - NEXLIZET</u>						
N 211617 001	10118881	Dec 23, 2023	U-2746		NCE	Feb 21, 2025
	10912751	Mar 14, 2036	U-3224		NP	Feb 26, 2023
	10941095	Dec 23, 2023	U-2746			
	7335799	Dec 03, 2025	DS			
	8497301	Dec 23, 2023	U-2746			
	9000041	Dec 23, 2023	U-2746			
	9624152	Dec 23, 2023	U-2749			
<u>BENDAMUSTINE HYDROCHLORIDE - BENDAMUSTINE HYDROCHLORIDE</u>						
A 205574 001					PC	Jun 05, 2023
<u>BENDAMUSTINE HYDROCHLORIDE - BENDAMUSTINE HYDROCHLORIDE</u>						
A 205574 002					PC	Jun 05, 2023
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N 022249 001	8436190	Oct 26, 2030	DP			
	8436190*PED	Apr 26, 2031				
	8445524	Mar 26, 2029	DS DP U-1402			
	8445524*PED	Sep 26, 2029				
	8609863	Jan 12, 2026	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N 022249 001	8609863*PED	Jul 12, 2026				
	8669279	Mar 26, 2029	DP U-1402			
	8669279*PED	Sep 26, 2029				
	8791270	Jan 12, 2026	DP U-1542			
	8791270*PED	Jul 12, 2026				
	8883836	Mar 26, 2029	DP U-1402			
	8883836*PED	Sep 26, 2029				
	8895756	Jan 12, 2026	DP			
	8895756*PED	Jul 12, 2026				
	9533955	Mar 26, 2029	DP U-1949			
	9533955	Mar 26, 2029	DP U-1952			
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N 022249 002	8436190	Oct 26, 2030	DP			
	8436190*PED	Apr 26, 2031				
	8445524	Mar 26, 2029	DS DP U-1402			
	8445524*PED	Sep 26, 2029				
	8609863	Jan 12, 2026	DP			
	8609863*PED	Jul 12, 2026				
	8669279	Mar 26, 2029	DP U-1402			
	8669279*PED	Sep 26, 2029				
	8791270	Jan 12, 2026	DP U-1542			
	8791270*PED	Jul 12, 2026				
	8883836	Mar 26, 2029	DP U-1402			
	8883836*PED	Sep 26, 2029				
	8895756	Jan 12, 2026	DP			
	8895756*PED	Jul 12, 2026				
	9533955	Mar 26, 2029	DP U-1949			
	9533955	Mar 26, 2029	DP U-1952			
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N 022249 003	8344006	Sep 23, 2029	DP U-1402			
	8344006*PED	Mar 23, 2030				
	8445524	Mar 26, 2029	DS			
	8445524*PED	Sep 26, 2029				
	8791270	Jan 12, 2026	DP U-1542			
	8791270*PED	Jul 12, 2026				
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N 022249 004	8344006	Sep 23, 2029	DP U-1402			
	8344006*PED	Mar 23, 2030				
	8445524	Mar 26, 2029	DS			
	8445524*PED	Sep 26, 2029				
	8791270	Jan 12, 2026	DP U-1542			
	8791270*PED	Jul 12, 2026				
<u>BENDAMUSTINE HYDROCHLORIDE - BELRAPZO</u>						
N 205580 001	10010533	Jan 28, 2031	DP			
	11103483	Jan 28, 2031	DP U-1971			
	11103483	Jan 28, 2031	DP U-1972			
	8609707	Aug 11, 2031	DP U-1971			
	8609707	Aug 11, 2031	DP U-1972			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BENDAMUSTINE HYDROCHLORIDE - BELRAPZO</u>						
N 205580 001	8791270	Jan 12, 2026	DP U-1971			
	8791270	Jan 12, 2026	DP U-1972			
	9265831	Jan 28, 2031	DP			
	9572796	Jan 28, 2031	DP U-1971			
	9572796	Jan 28, 2031	DP U-1972			
	9572797	Jan 28, 2031	U-1971			
	9572797	Jan 28, 2031	U-1972			
<u>BENDAMUSTINE HYDROCHLORIDE - BENDEKA</u>						
N 208194 001	10010533	Jan 28, 2031	DP			
	10052385	Mar 15, 2033	U-1971			
	10052385	Mar 15, 2033	U-1972			
	11103483	Jan 28, 2031	DP U-1971			
	11103483	Jan 28, 2031	DP U-1972			
	8609707	Aug 11, 2031	DP U-1542			
	8791270	Jan 12, 2026	DP U-1790			
	9000021	Mar 15, 2033	U-1542			
	9034908	Mar 15, 2033	U-1542			
	9144568	Mar 15, 2033	U-1542			
	9265831	Jan 28, 2031	DP			
	9572796	Jan 28, 2031	DP U-1971			
	9572796	Jan 28, 2031	DP U-1972			
	9572797	Jan 28, 2031	U-1971			
	9572797	Jan 28, 2031	U-1972			
	9572887	Mar 15, 2033	U-1971			
	9572887	Mar 15, 2033	U-1972			
	9579384	Mar 15, 2033	U-1971			
	9579384	Mar 15, 2033	U-1972			
	9597397	Mar 15, 2033	U-1971			
	9597397	Mar 15, 2033	U-1972			
	9597398	Mar 15, 2033	U-1971			
	9597399	Mar 15, 2033	U-1971			
	9597399	Mar 15, 2033	U-1972			
<u>BENOXINATE HYDROCHLORIDE; FLUORESCCEIN SODIUM - FLUORESCCEIN SODIUM AND BENOXINATE HYDROCHLORIDE</u>						
N 211039 001	10293047	Nov 15, 2037	DP U-2755			
	10632197	Nov 15, 2037	DP U-2755			
	10842872	Nov 15, 2037	U-3001			
<u>BENZNIDAZOLE - BENZNIDAZOLE</u>						
N 209570 001					ODE-154	Aug 29, 2024
<u>BENZNIDAZOLE - BENZNIDAZOLE</u>						
N 209570 002					ODE-154	Aug 29, 2024
<u>BENZOYL PEROXIDE - EPSOLAY</u>						
N 214510 001	10933046	Feb 19, 2040	DP U-3357		NP	Apr 22, 2025
	10945987	Feb 19, 2040	U-3356			
	11426378	Aug 18, 2040	U-3356			
	9687465	Nov 27, 2032	DP U-3356			
	9868103	Aug 08, 2028	DP U-3356			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE</u>						
A 212433	001				CGT	Mar 13, 2023
<u>BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - ACANYA</u>						
N 050819	001	10220049	Jun 03, 2029	DP U-916		
		10624918	Jun 03, 2029	U-916		
		8288434	Aug 05, 2029	DP U-124		
		8663699	Jun 03, 2029	U-124		
		8895070	Jun 03, 2029	U-124		
		9078870	Jun 03, 2029	DP		
<u>BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - ONEXTON</u>						
N 050819	002	10137142	Jun 03, 2029	DP U-916		
		10220049	Jun 03, 2029	DP U-916		
		8288434	Aug 05, 2029	DP U-1033		
		8288434	Aug 05, 2029	DP U-124		
		8288434	Aug 05, 2029	DP U-134		
		8288434	Aug 05, 2029	DP U-818		
		8288434	Aug 05, 2029	DP U-916		
		8288434	Aug 05, 2029	DP U-921		
		9504704	Jun 03, 2029	DP U-124		
		9504704	Jun 03, 2029	DP U-134		
		9504704	Jun 03, 2029	DP U-818		
		9504704	Jun 03, 2029	DP U-916		
		9561208	Jun 03, 2029	DP U-916		
<u>BENZOYL PEROXIDE; TRETINOIN - TWYNEO</u>						
N 214902	001	10420743	Jul 12, 2038	U-3194	NC	Jul 26, 2024
		10653899	Dec 30, 2030	DP U-3194		
		11071878	Dec 30, 2030	DP		
		8617580	Feb 03, 2028	DP		
		9868103	Aug 08, 2028	DP U-3194		
<u>BENZYL ALCOHOL - ULESFIA</u>						
N 022129	001	7294342	May 19, 2024	U-970		
<u>BEPOTASTINE BESILATE - BEPREVE</u>						
N 022288	001	8784789	Jan 13, 2025	DP		
		8877168	Jul 30, 2023	DP		
<u>BEROTRALSTAT HYDROCHLORIDE - ORLADEYO</u>						
N 214094	001	10125102	Apr 07, 2035	DS U-3010	NCE	Dec 03, 2025
		10329260	Mar 09, 2035	DS	ODE-333	Dec 03, 2027
		10662160	Nov 01, 2039	DS U-3010		
		10689346	Mar 09, 2035	U-3010		
		11117867	Nov 01, 2039	DP U-3010		
		11230530	Mar 09, 2035	U-3300		
<u>BEROTRALSTAT HYDROCHLORIDE - ORLADEYO</u>						
N 214094	002	10125102	Apr 07, 2035	DS U-3010	NCE	Dec 03, 2025
		10329260	Mar 09, 2035	DS	ODE-333	Dec 03, 2027
		10662160	Nov 01, 2039	DS U-3010		
		10689346	Mar 09, 2035	U-3010		
		11117867	Nov 01, 2039	DP U-3010		
		11230530	Mar 09, 2035	U-3300		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BEROTRALSTAT HYDROCHLORIDE - ORLADEYO</u>						
N 214094 002	10125102	Apr 07, 2035	DS U-3010		NCE	Dec 03, 2025
	10329260	Mar 09, 2035	DS		ODE-333	Dec 03, 2027
	10662160	Nov 01, 2039	DS U-3010			
	10689346	Mar 09, 2035	U-3010			
	11117867	Nov 01, 2039	DP U-3010			
	11230530	Mar 09, 2035	U-3300			
<u>BESIFLOXACIN HYDROCHLORIDE - BESIVANCE</u>						
N 022308 001	8415342	Nov 07, 2030	U-80			
	8481526	Jan 09, 2031	DS			
	8604020	Mar 12, 2030	DP			
	8937062	Nov 13, 2029	U-80			
<u>BETAMETHASONE DIPROPIONATE - SERNIVO</u>						
N 208079 001	10179137	Aug 31, 2030	DP U-1858			
	9364485	Aug 31, 2030	DP U-1858			
	9433630	Aug 31, 2030	DP U-1858			
	9439911	Aug 31, 2030	DP U-1858			
	9655907	Aug 31, 2030	DP U-1858			
	9775851	Aug 31, 2030	DP U-1858			
	9877974	Aug 31, 2030	DP U-1858			
<u>BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE - ENSTILAR</u>						
N 207589 001	10130640	Jun 10, 2031	DP			
	10130640*PED	Dec 10, 2031				
	10617698	Jun 10, 2031	DP			
	10660908	Jun 10, 2031	DP U-2627			
	10682364	Jun 10, 2031	DP			
	10688108	Jun 10, 2031	U-2627			
	10716799	Jun 10, 2031	DP			
	9119781	Jun 10, 2031	DP U-1761			
	9119781	Jun 10, 2031	DP U-2627			
	9119781*PED	Dec 10, 2031				
	9566286	Jun 10, 2031	DP			
<u>BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE - WYNZORA</u>						
N 213422 001	10265265	Sep 27, 2027	DP		NDF	Jul 20, 2023
<u>BETRIXABAN - BEVYXXA</u>						
N 208383 001	7598276	Nov 08, 2026	DS			
	8404724	Mar 29, 2031	DP U-2034			
	8557852	Sep 08, 2028	U-1167			
	8557852	Sep 08, 2028	U-2030			
	8987463	Dec 28, 2030	DP			
	9555023	Nov 07, 2026	U-1502			
<u>BETRIXABAN - BEVYXXA</u>						
N 208383 002	7598276	Nov 08, 2026	DS			
	8404724	Mar 29, 2031	DP U-2034			
	8557852	Sep 08, 2028	U-1167			
	8557852	Sep 08, 2028	U-2030			
	8987463	Dec 28, 2030	DP			
	9555023	Nov 07, 2026	U-1502			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - BIKTARVY</u>						
N 210251 001	10385067	Jun 19, 2035	U-257		M-82	Feb 24, 2024
	10548846	Nov 08, 2036	DP		NCE	Feb 07, 2023
	7390791	Apr 17, 2025	DS DP		ODE-256	Jun 18, 2026
	7390791*PED	Oct 17, 2025				
	8754065	Aug 15, 2032	DS DP U-257			
	8754065*PED	Feb 15, 2033				
	9216996	Dec 19, 2033	DS DP			
	9296769	Aug 15, 2032	DS DP U-257			
	9296769*PED	Feb 15, 2033				
	9708342	Jun 19, 2035	DS DP			
	9732092	Dec 19, 2033	DS DP			
<u>BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - BIKTARVY</u>						
N 210251 002	10385067	Jun 19, 2035	U-257		NCE	Feb 07, 2023
	7390791	Apr 17, 2025	DS DP		ODE-378	Oct 07, 2028
	8754065	Aug 15, 2032	DS DP U-257			
	9216996	Dec 19, 2033	DS DP			
	9296769	Aug 15, 2032	DS DP U-257			
	9708342	Jun 19, 2035	DS DP			
	9732092	Dec 19, 2033	DS DP			
<u>BIMATOPROST - LUMIGAN</u>						
N 022184 001	7851504	Jun 13, 2027	DS DP			
	8278353	Mar 16, 2025	DP			
	8299118	Mar 16, 2025	U-1295			
	8309605	Mar 16, 2025	U-1293			
	8309605	Mar 16, 2025	U-1294			
	8338479	Mar 16, 2025	DP U-1295			
	8524777	Mar 16, 2025	U-1235			
	8586630	Mar 16, 2025	U-1458			
	8772338	Mar 16, 2025	DP U-1528			
	8933120	Mar 16, 2025	DP			
	8933127	Mar 16, 2025	DP			
	9155716	Mar 16, 2025	DP U-1528			
	9241918	Mar 16, 2025	DP U-1814			
<u>BIMATOPROST - LATISSE</u>						
N 022369 001	8038988	Aug 25, 2023	DS DP U-1208			
	8101161	May 25, 2024	U-1217			
	8101161	May 25, 2024	U-1218			
	8263054	Jan 15, 2023	U-1277			
	8632760	Jan 15, 2023	U-1487			
	8758733	Jan 15, 2023	U-1487			
	8986715	Jan 15, 2023	U-1217			
	9216183	Jan 15, 2023	U-1487			
	9226931	Jan 15, 2023	U-1799			
<u>BIMATOPROST - DURYSTA</u>						
N 211911 001	10398707	Apr 30, 2024	U-2759		NP	Mar 04, 2023
	10441543	Dec 19, 2026	DP			
	7799336	Apr 24, 2029	DP			
	8206737	Apr 07, 2027	U-2759			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BIMATOPROST - DURYSTA</u>						
N 211911 001	8629185	Jul 15, 2031	DS DP			
	8673341	Feb 19, 2025	U-2759			
	9149428	Dec 19, 2026	DP			
	9492316	Oct 31, 2034	DP			
	9980974	Oct 31, 2034	U-2759			
<u>BINIMETINIB - MEKTOVI</u>						
N 210498 001	10005761	Aug 27, 2030	U-2331		NCE	Jun 27, 2023
	7777050	Mar 13, 2023	DS DP		ODE-194	Jun 27, 2025
	8178693	Mar 13, 2023	DS DP			
	8193229	Mar 13, 2023	U-2330			
	8513293	Mar 13, 2023	U-2331			
	9314464	Jul 04, 2031	U-2332			
	9562016	Oct 18, 2033	DS DP			
	9598376	Oct 18, 2033	U-2330			
	9850229	Aug 27, 2030	U-2333			
	9980944	Oct 18, 2033	U-2334			
<u>BIVALIRUDIN - ANGIOMAX</u>						
N 020873 001	7582727	Jul 27, 2028	DP			
	7598343	Jul 27, 2028	DP			
<u>BOCEPREVIR - VICTRELIS</u>						
N 202258 001	7772178	Nov 11, 2027	DP U-1128			
	8119602	Mar 17, 2027	U-1233			
	RE43298	Dec 22, 2024	DS DP U-1128			
<u>BORTEZOMIB - BORTEZOMIB</u>						
N 205004 001	8962572	Nov 03, 2032	DP			
<u>ROSENTAN - TRACLEER</u>						
N 021290 001					ODE*	Sep 05, 2024
<u>ROSENTAN - TRACLEER</u>						
N 021290 002					ODE*	Sep 05, 2024
<u>ROSENTAN - TRACLEER</u>						
N 209279 001	7959945	Dec 28, 2027	DP		ODE-161	Sep 05, 2024
	8309126	May 15, 2026	DP			
<u>BOSUTINIB MONOHYDRATE - BOSULIF</u>						
N 203341 001	11103497	Feb 28, 2034	U-3216		ODE-163	Dec 19, 2024
	11103497	Feb 28, 2034	U-3217			
	7417148	Dec 11, 2025	U-1283			
	7767678	Nov 23, 2026	DS DP			
	7919625	Dec 11, 2025	DP			
	RE42376	Apr 13, 2024	DS			
<u>BOSUTINIB MONOHYDRATE - BOSULIF</u>						
N 203341 002	11103497	Feb 28, 2034	U-3216		ODE-163	Dec 19, 2024
	11103497	Feb 28, 2034	U-3217			
	7417148	Dec 11, 2025	U-1283			
	7767678	Nov 23, 2026	DS DP			
	7919625	Dec 11, 2025	DP			
	RE42376	Apr 13, 2024	DS			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BOSUTINIB MONOHYDRATE - BOSULIF</u>						
N 203341 003	11103497	Feb 28, 2034	U-3216		ODE-163	Dec 19, 2024
	11103497	Feb 28, 2034	U-3217			
	7417148	Dec 11, 2025	U-1283			
	7767678	Nov 23, 2026	DS DP			
	7919625	Dec 11, 2025	DP			
	RE42376	Apr 13, 2024	DS			
<u>BREMELANOTIDE ACETATE - VYLEESI (AUTOINJECTOR)</u>						
N 210557 001	10286034	Nov 05, 2033	U-2568		NCE	Jun 21, 2024
	6794489	Jun 28, 2025	DS DP			
	9352013	Nov 05, 2033	U-2568			
	9700592	Nov 05, 2033	U-2568			
<u>BREXANOLONE - ZULRESSO</u>						
N 211371 001	10117951	Mar 13, 2029	DP		NCE	Jun 17, 2024
	10251894	Nov 27, 2033	U-2552		NPP	Jun 16, 2025
	10322139	Jan 23, 2033	DP			
	10940156	Mar 08, 2037	U-2552			
	7635773	Mar 13, 2029	DP			
	8410077	Mar 13, 2029	DP			
	9200088	Mar 13, 2029	DP			
	9750822	Mar 13, 2029	DP			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 001	10307419	Oct 12, 2032	DP		NPP	Dec 27, 2024
	7888362	Apr 12, 2026	DS	Y		
	8349840	Apr 12, 2026	DP U-1529			
	8618109	Apr 12, 2026	U-3281			
	8618109	Apr 12, 2026	U-543			
	9839637	Apr 12, 2026	DP U-1529			
	9839637	Apr 12, 2026	DP U-3281			
	9839637	Apr 12, 2026	DP U-543			
	RE48059	Dec 23, 2028	DS			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 002	10307419	Oct 12, 2032	DP		NPP	Dec 27, 2024
	7888362	Apr 12, 2026	DS	Y		
	8349840	Apr 12, 2026	DP U-1529			
	8618109	Apr 12, 2026	U-3281			
	8618109	Apr 12, 2026	U-543			
	9839637	Apr 12, 2026	DP U-1529			
	9839637	Apr 12, 2026	DP U-3281			
	9839637	Apr 12, 2026	DP U-543			
	RE48059	Dec 23, 2028	DS			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 003	10307419	Oct 12, 2032	DP		NPP	Dec 27, 2024
	7888362	Apr 12, 2026	DS	Y		
	8349840	Apr 12, 2026	DP U-1529			
	8618109	Apr 12, 2026	U-3281			
	8618109	Apr 12, 2026	U-543			
	9839637	Apr 12, 2026	DP U-1529			
	9839637	Apr 12, 2026	DP U-3281			
	9839637	Apr 12, 2026	DP U-543			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 003	9839637	Apr 12, 2026	DP U-543			
	RE48059	Dec 23, 2028	DS			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 004	10307419	Oct 12, 2032	DP		NPP	Dec 27, 2024
	7888362	Apr 12, 2026	DS	Y		
	8349840	Apr 12, 2026	DP U-1529			
	8618109	Apr 12, 2026	U-3281			
	8618109	Apr 12, 2026	U-543			
	9839637	Apr 12, 2026	DP U-1529			
	9839637	Apr 12, 2026	DP U-3281			
	9839637	Apr 12, 2026	DP U-543			
	RE48059	Dec 23, 2028	DS			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 005	10307419	Oct 12, 2032	DP		NPP	Dec 27, 2024
	7888362	Apr 12, 2026	DS	Y		
	8349840	Apr 12, 2026	DP U-1529			
	8618109	Apr 12, 2026	U-3281			
	8618109	Apr 12, 2026	U-543			
	9839637	Apr 12, 2026	DP U-1529			
	9839637	Apr 12, 2026	DP U-3281			
	9839637	Apr 12, 2026	DP U-543			
	RE48059	Dec 23, 2028	DS			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 006	7888362	Apr 12, 2026	DS	Y	NPP	Dec 27, 2024
	8349840	Apr 12, 2026	DP U-1529			
	8618109	Apr 12, 2026	U-3281			
	8618109	Apr 12, 2026	U-543			
	9839637	Apr 12, 2026	DP U-1529			
	9839637	Apr 12, 2026	DP U-3281			
	9839637	Apr 12, 2026	DP U-543			
	RE48059	Dec 23, 2028	DS			
<u>BRIGATINIB - ALUNBRIG</u>						
N 208772 001	10385078	Nov 10, 2035	DS DP U-2837		I-847	May 22, 2023
	9012462	Apr 28, 2031	DS		ODE-142	Apr 28, 2024
	9273077	May 21, 2029	U-2837		ODE-300	May 22, 2027
	9611283	Apr 10, 2034	U-2837			
<u>BRIGATINIB - ALUNBRIG</u>						
N 208772 002	10385078	Nov 10, 2035	DS DP U-2837		I-847	May 22, 2023
	9012462	Apr 28, 2031	DS		ODE-142	Apr 28, 2024
	9273077	May 21, 2029	U-2837		ODE-300	May 22, 2027
	9611283	Apr 10, 2034	U-2837			
<u>BRIGATINIB - ALUNBRIG</u>						
N 208772 003	10385078	Nov 10, 2035	DS DP U-2837		I-847	May 22, 2023
	9012462	Apr 28, 2031	DS		ODE-142	Apr 28, 2024
	9273077	May 21, 2029	U-2837		ODE-300	May 22, 2027
	9611283	Apr 10, 2034	U-2837			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BRILLIANT BLUE G - TISSUEBLUE</u>						
N 209569	001				NCE	Dec 20, 2024
					ODE-282	Dec 20, 2026
<u>BRIMONIDINE TARTRATE - OOLIANA</u>						
N 021764	001 7265117	Aug 19, 2025	DP			
<u>BRIMONIDINE TARTRATE - ALPHAGAN P</u>						
N 021770	001 8858961	Sep 02, 2023	DP			
	8858961*PED	Mar 02, 2024				
<u>BRIMONIDINE TARTRATE - MIRVASO</u>						
N 204708	001 10201517	Jun 13, 2031	DP			
	7439241	Aug 25, 2025	U-1428			
	8053427	Jun 13, 2031	DP U-1428			
	8163725	Jun 13, 2031	DP			
	8231885	May 24, 2025	DP			
	8410102	May 24, 2025	U-1428			
	8426410	May 24, 2025	U-1428			
	8513247	Mar 25, 2031	DP U-1428			
	8513249	Mar 25, 2031	DP U-1428			
	8859551	May 25, 2024	U-1428			
	9861631	Mar 25, 2031	U-1428			
	9861632	Mar 25, 2031	U-1428			
<u>BRIMONIDINE TARTRATE - LUMIFY</u>						
N 208144	001 8293742	Jul 14, 2030	U-2222			
	9259425	Jul 14, 2030	U-2222			
<u>BRIMONIDINE TARTRATE; BRINZOLAMIDE - SIMBRINZA</u>						
N 204251	001 9044484	Oct 30, 2030	DP			
	9421265	Jun 17, 2030	DP			
<u>BRINCIDOFOVIR - TEMBEXA</u>						
N 214460	001 9303051	Aug 31, 2031	DS DP U-3165		NP	Jun 04, 2024
					ODE-354	Jun 04, 2028
<u>BRINCIDOFOVIR - TEMBEXA</u>						
N 214461	001 10112909	Oct 10, 2034	U-3165		NP	Jun 04, 2024
	10487061	Oct 10, 2034	DP U-3165		ODE-354	Jun 04, 2028
	8962829	Oct 10, 2034	DS DP			
	9303051	Aug 31, 2031	DS DP U-3165			
	9371344	Oct 10, 2034	DP			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836	001 10729653	Apr 09, 2030	DP		NPP	Aug 27, 2024
	6911461	Feb 21, 2026	DS DP U-2295			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836	002 10729653	Apr 09, 2030	DP		NPP	Aug 27, 2024
	6911461	Feb 21, 2026	DS DP U-2295			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836	003 10729653	Apr 09, 2030	DP		NPP	Aug 27, 2024
	6911461	Feb 21, 2026	DS DP U-2295			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 004	10729653	Apr 09, 2030	DP		NPP	Aug 27, 2024
	6911461	Feb 21, 2026	DS DP U-2295			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 005	10729653	Apr 09, 2030	DP		NPP	Aug 27, 2024
	6911461	Feb 21, 2026	DS DP U-2295			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205837 001	6911461	Feb 21, 2026	DS DP U-1815		NPP	Aug 27, 2024
	6911461	Feb 21, 2026	DS DP U-2130			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205838 001	6911461	Feb 21, 2026	DS DP U-2295		NPP	Aug 27, 2024
<u>BROMFENAC SODIUM - PROLENSA</u>						
N 203168 001	10085958	Nov 19, 2032	DP			
	8129431	Sep 11, 2025	DS DP			
	8669290	Jan 16, 2024	DP			
	8754131	Jan 16, 2024	DP			
	8871813	Jan 16, 2024	DP			
	8927606	Jan 16, 2024	U-100			
	8927606	Jan 16, 2024	U-1095			
	8927606	Jan 16, 2024	U-810			
	9144609	Jan 16, 2024	DP			
	9517220	Nov 11, 2033	U-1933			
	9561277	Jan 16, 2024	U-1933			
<u>BROMFENAC SODIUM - BROMSITE</u>						
N 206911 001	8778999	Aug 07, 2029	DP U-1834			
<u>BROMOCRIPTINE MESYLATE - CYCLOSET</u>						
N 020866 001	10688094	Apr 30, 2032	U-2870			
	10688094	Apr 30, 2032	U-2871			
	10688094	Apr 30, 2032	U-2872			
	10688094	Apr 30, 2032	U-2873			
	10688094	Apr 30, 2032	U-2874			
	10688094	Apr 30, 2032	U-2875			
	10688094	Apr 30, 2032	U-2876			
	10688094	Apr 30, 2032	U-2877			
	10688094	Apr 30, 2032	U-2878			
	10688094	Apr 30, 2032	U-2879			
	10688094	Apr 30, 2032	U-2880			
	10688094	Apr 30, 2032	U-2881			
	10688094	Apr 30, 2032	U-2882			
	10688094	Apr 30, 2032	U-2883			
	10688094	Apr 30, 2032	U-2884			
	10688094	Apr 30, 2032	U-2885			
	10688094	Apr 30, 2032	U-2886			
	10688094	Apr 30, 2032	U-2887			
	10688094	Apr 30, 2032	U-2888			
	10688155	Jun 07, 2030	U-2281			
	10688155	Jun 07, 2030	U-2890			
	10688155	Jun 07, 2030	U-2891			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BROMOCRIPTINE MESYLATE - CYCLOSET</u>						
N 020866 001	10688155	Jun 07, 2030	U-2892			
	10688155	Jun 07, 2030	U-2893			
	10688155	Jun 07, 2030	U-2894			
	10688155	Jun 07, 2030	U-2895			
	10688155	Jun 07, 2030	U-2896			
	10688155	Jun 07, 2030	U-2897			
	10688155	Jun 07, 2030	U-2898			
	10688155	Jun 07, 2030	U-2899			
	10688155	Jun 07, 2030	U-2900			
	10688155	Jun 07, 2030	U-2901			
	10688155	Jun 07, 2030	U-2902			
	10688155	Jun 07, 2030	U-2903			
	10688155	Jun 07, 2030	U-2904			
	10688155	Jun 07, 2030	U-2905			
	10688155	Jun 07, 2030	U-2906			
	10688155	Jun 07, 2030	U-2907			
	10688155	Jun 07, 2030	U-2908			
	10688155	Jun 07, 2030	U-2909			
	10688155	Jun 07, 2030	U-2910			
	10688155	Jun 07, 2030	U-2911			
	10688155	Jun 07, 2030	U-2912			
	10688155	Jun 07, 2030	U-2913			
	10688155	Jun 07, 2030	U-2914			
	10688155	Jun 07, 2030	U-2915			
	10688155	Jun 07, 2030	U-2916			
	10688155	Jun 07, 2030	U-2917			
	10688155	Jun 07, 2030	U-2918			
	10688155	Jun 07, 2030	U-2919			
	10688155	Jun 07, 2030	U-2920			
	10688155	Jun 07, 2030	U-2921			
	10688155	Jun 07, 2030	U-2922			
	10688155	Jun 07, 2030	U-2923			
	10688155	Jun 07, 2030	U-2924			
	10688155	Jun 07, 2030	U-2925			
	10688155	Jun 07, 2030	U-2926			
	10688155	Jun 07, 2030	U-2927			
	10688155	Jun 07, 2030	U-2928			
	10688155	Jun 07, 2030	U-2929			
	10688155	Jun 07, 2030	U-2930			
	10688155	Jun 07, 2030	U-2931			
	10688155	Jun 07, 2030	U-2932			
	10688155	Jun 07, 2030	U-2933			
	10688155	Jun 07, 2030	U-2934			
	10688155	Jun 07, 2030	U-2935			
	10688155	Jun 07, 2030	U-2936			
	10688155	Jun 07, 2030	U-2937			
	11000522	Apr 30, 2032	U-3119			
	11000522	Apr 30, 2032	U-3120			
	11000522	Apr 30, 2032	U-3121			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BROMOCRIPTINE MESYLATE - CYCLOSET</u>						
N 020866 001	11000522	Apr 30, 2032	U-3122			
	7888310	Jul 25, 2023	U-1433			
	8137992	Jul 25, 2023	U-1433			
	8137993	Jul 25, 2023	U-1433			
	8137994	Jul 25, 2023	U-1433			
	8431155	Apr 30, 2032	DP U-976			
	8613947	Apr 30, 2032	DP U-976			
	8877708	Jun 07, 2030	DP U-1706			
	9192576	Apr 30, 2032	DP U-976			
	9352025	Jun 07, 2030	U-2111			
	9352025	Jun 07, 2030	U-2112			
	9352025	Jun 07, 2030	U-2113			
	9352025	Jun 07, 2030	U-2114			
	9352025	Jun 07, 2030	U-2115			
	9352025	Jun 07, 2030	U-2116			
	9352025	Jun 07, 2030	U-2117			
	9352025	Jun 07, 2030	U-2118			
	9352025	Jun 07, 2030	U-2119			
	9522117	Apr 30, 2032	DP U-1939			
	9522117	Apr 30, 2032	DP U-976			
	9700555	Apr 30, 2032	DP U-2183			
	9700555	Apr 30, 2032	DP U-2184			
	9700555	Apr 30, 2032	DP U-2185			
	9700555	Apr 30, 2032	DP U-2186			
	9700555	Apr 30, 2032	DP U-2187			
	9700555	Apr 30, 2032	DP U-2188			
	9700555	Apr 30, 2032	DP U-2189			
	9700555	Apr 30, 2032	DP U-2190			
	9700555	Apr 30, 2032	DP U-2191			
	9700555	Apr 30, 2032	DP U-2192			
	9700555	Apr 30, 2032	DP U-2193			
	9700555	Apr 30, 2032	DP U-2194			
	9700555	Apr 30, 2032	DP U-2195			
	9700555	Apr 30, 2032	DP U-2196			
	9700555	Apr 30, 2032	DP U-2197			
	9700555	Apr 30, 2032	DP U-2198			
	9895422	Jun 07, 2030	U-2114			
	9895422	Jun 07, 2030	U-2116			
	9895422	Jun 07, 2030	U-2281			
	9895422	Jun 07, 2030	U-2282			
	9895422	Jun 07, 2030	U-2283			
	9895422	Jun 07, 2030	U-2284			
	9895422	Jun 07, 2030	U-2285			
	9895422	Jun 07, 2030	U-2286			
	9895422	Jun 07, 2030	U-2287			
	9993474	Apr 30, 2032	U-2384			
	9993474	Apr 30, 2032	U-2385			
	9993474	Apr 30, 2032	U-2386			
	9993474	Apr 30, 2032	U-2387			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BROMOCRIPTINE MESYLATE - CYCLOSET</u>						
N 020866 001	9993474	Apr 30, 2032	U-2388			
	9993474	Apr 30, 2032	U-2389			
	9993474	Apr 30, 2032	U-2390			
	9993474	Apr 30, 2032	U-2391			
	9993474	Apr 30, 2032	U-2392			
	9993474	Apr 30, 2032	U-2393			
<u>BUDESONIDE - UCERIS</u>						
N 203634 001	10307375	Sep 07, 2031	DP			
	10660858	Sep 07, 2031	DP			
	8895064	Sep 07, 2031	DP			
	9132093	Sep 07, 2031	DP			
	9192581	Sep 07, 2031	DP U-1325			
<u>BUDESONIDE - ORTIKOS</u>						
N 211929 001	10172802	Sep 09, 2036	U-2554			
	9707182	Sep 09, 2036	DP U-2554			
<u>BUDESONIDE - ORTIKOS</u>						
N 211929 002	10172802	Sep 09, 2036	U-2554			
	9707182	Sep 09, 2036	DP U-2554			
<u>BUDESONIDE - TARPEYO</u>						
N 215935 001	8491932	May 07, 2029	DP U-3269		NP	Dec 15, 2024
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N 021929 001	10166247	Jan 29, 2023	DP U-2001			
	10166247	Jan 29, 2023	DP U-2002			
	10166247	Jan 29, 2023	DP U-2122			
	10166247*PED	Jul 29, 2023				
	11311558	Jan 29, 2023	DP			
	11311558*PED	Jul 29, 2023				
	7587988	Apr 10, 2026	DP			
	7587988*PED	Oct 10, 2026				
	7759328	Jan 29, 2023	DP U-2001			
	7759328	Jan 29, 2023	DP U-2002			
	7759328	Jan 29, 2023	DP U-2122			
	7759328*PED	Jul 29, 2023				
	8143239	Jan 29, 2023	DP U-2001			
	8143239	Jan 29, 2023	DP U-2002			
	8143239	Jan 29, 2023	DP U-2122			
	8143239*PED	Jul 29, 2023				
	8387615	Mar 26, 2027	DP			
	8387615*PED	Sep 26, 2027				
	8528545	Oct 16, 2028	DP			
	8528545*PED	Apr 16, 2029				
	8575137	Jan 29, 2023	DP U-2001			
	8575137	Jan 29, 2023	DP U-2002			
	8575137	Jan 29, 2023	DP U-2122			
	8575137*PED	Jul 29, 2023				
	8616196	Apr 07, 2029	DP			
	8616196*PED	Oct 07, 2029				
	8875699	Nov 10, 2024	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N 021929	001	8875699*PED	May 10, 2025			
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N 021929	002	10166247	Jan 29, 2023	DP U-2001		
		10166247	Jan 29, 2023	DP U-2002		
		10166247	Jan 29, 2023	DP U-2122		
		10166247*PED	Jul 29, 2023			
		11311558	Jan 29, 2023	DP		
		11311558*PED	Jul 29, 2023			
		7587988	Apr 10, 2026	DP		
		7587988*PED	Oct 10, 2026			
		7759328	Jan 29, 2023	DP U-2001		
		7759328	Jan 29, 2023	DP U-2002		
		7759328	Jan 29, 2023	DP U-2122		
		7759328*PED	Jul 29, 2023			
		8143239	Jan 29, 2023	DP U-2001		
		8143239	Jan 29, 2023	DP U-2002		
		8143239	Jan 29, 2023	DP U-2122		
		8143239*PED	Jul 29, 2023			
		8387615	Mar 26, 2027	DP		
		8387615*PED	Sep 26, 2027			
		8528545	Oct 16, 2028	DP		
		8528545*PED	Apr 16, 2029			
		8575137	Jan 29, 2023	DP U-2001		
		8575137	Jan 29, 2023	DP U-2002		
		8575137	Jan 29, 2023	DP U-2122		
		8575137*PED	Jul 29, 2023			
		8616196	Apr 07, 2029	DP		
		8616196*PED	Oct 07, 2029			
		8875699	Nov 10, 2024	DP		
		8875699*PED	May 10, 2025			
<u>BUDESONIDE; FORMOTEROL FUMARATE; GLYCOPYRROLATE - BREZTRI AEROSPHERE</u>						
N 212122	001	10716753	May 28, 2030	DP U-2889	NC	Jul 23, 2023
		11331442	May 10, 2038	DP		
		8324266	May 28, 2030	U-2889		
		8703806	May 28, 2030	U-2889		
		8808713	May 28, 2030	DP U-2889		
		8815258	Mar 17, 2031	U-2889		
		9415009	May 28, 2030	U-2889		
		9463161	May 28, 2030	DP U-2889		
<u>BUPIVACAINE - EXPAREL</u>						
N 022496	001	11033495	Jan 22, 2041	DP U-3182	NPP	Mar 22, 2024
		11179336	Jan 22, 2041	DP U-3250		
		11278494	Jan 22, 2041	DP U-3250		
		11304904	Jan 22, 2041	DP U-3346		
		11311486	Jan 22, 2041	DP U-3250		
		11357727	Jan 22, 2041	DP U-3380		
		11426348	Jan 22, 2041	DP U-3380		
		11452691	Jan 22, 2041	DP U-3439		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BUPIVACAINE - EXPAREL</u>						
N 022496 002	11033495	Jan 22, 2041	DP U-3182		NPP	Mar 22, 2024
	11179336	Jan 22, 2041	DP U-3250			
	11278494	Jan 22, 2041	DP U-3250			
	11304904	Jan 22, 2041	DP U-3346			
	11311486	Jan 22, 2041	DP U-3250			
	11357727	Jan 22, 2041	DP U-3380			
	11426348	Jan 22, 2041	DP U-3380			
	11452691	Jan 22, 2041	DP U-3439			
<u>BUPIVACAINE - POSIMIR</u>						
N 204803 001	11400019	Jan 12, 2041	DP		NP	Feb 01, 2024
	8153149	Sep 15, 2025	DP			
	8153661	Sep 15, 2025	U-3074			
	8753665	Sep 15, 2025	DP U-3074			
	8846072	Sep 15, 2025	DP U-3074			
<u>BUPIVACAINE HYDROCHLORIDE - XARACOLL</u>						
N 209511 001	RE47826	May 20, 2029	U-2949		NP	Aug 28, 2023
<u>BUPIVACAINE; MELOXICAM - ZYNRELEF KIT</u>						
N 211988 001	10098957	Apr 20, 2035	U-3118		NP	May 12, 2024
	10213510	Apr 20, 2035	DP U-3118			
	10398686	Mar 13, 2034	DP			
	10632199	Apr 20, 2035	DP U-3118			
	10898575	Apr 20, 2035	DP U-3118			
	10980886	Apr 20, 2035	DP			
	11083730	Apr 20, 2035	DP U-3118			
	11083797	Apr 20, 2035	DP U-3118			
	11253504	Mar 13, 2034	U-3118			
	11413350	Apr 20, 2035	U-3417			
	9592227	Mar 13, 2034	DP U-3118			
	9694079	Apr 20, 2035	DP U-3118			
	9744163	Mar 13, 2034	DP			
	9801945	Apr 20, 2035	DP U-3118			
	9913909	Mar 13, 2034	U-3118			
<u>BUPIVACAINE; MELOXICAM - ZYNRELEF KIT</u>						
N 211988 002	10098957	Apr 20, 2035	U-3118		NP	May 12, 2024
	10213510	Apr 20, 2035	DP U-3118			
	10398686	Mar 13, 2034	DP			
	10632199	Apr 20, 2035	DP U-3118			
	10898575	Apr 20, 2035	DP U-3118			
	10980886	Apr 20, 2035	DP			
	11083730	Apr 20, 2035	DP U-3118			
	11083797	Apr 20, 2035	DP U-3118			
	11253504	Mar 13, 2034	U-3118			
	11413350	Apr 20, 2035	U-3417			
	9592227	Mar 13, 2034	DP U-3118			
	9694079	Apr 20, 2035	DP U-3118			
	9744163	Mar 13, 2034	DP			
	9801945	Apr 20, 2035	DP U-3118			
	9913909	Mar 13, 2034	U-3118			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BUPIVACAINE; MELOXICAM - ZYNRELEF KIT</u>						
N 211988 002	10098957	Apr 20, 2035	U-3118		NP	May 12, 2024
	10213510	Apr 20, 2035	DP U-3118			
	10398686	Mar 13, 2034	DP			
	10632199	Apr 20, 2035	DP U-3118			
	10898575	Apr 20, 2035	DP U-3118			
	10980886	Apr 20, 2035	DP			
	11083730	Apr 20, 2035	DP U-3118			
	11083797	Apr 20, 2035	DP U-3118			
	11253504	Mar 13, 2034	U-3118			
	11413350	Apr 20, 2035	U-3417			
	9592227	Mar 13, 2034	DP U-3118			
	9694079	Apr 20, 2035	DP U-3118			
	9744163	Mar 13, 2034	DP			
	9801945	Apr 20, 2035	DP U-3118			
	9913909	Mar 13, 2034	U-3118			
<u>BUPIVACAINE; MELOXICAM - ZYNRELEF KIT</u>						
N 211988 003	10098957	Apr 20, 2035	U-3118		NP	May 12, 2024
	10213510	Apr 20, 2035	DP U-3118			
	10398686	Mar 13, 2034	DP			
	10632199	Apr 20, 2035	DP U-3118			
	10898575	Apr 20, 2035	DP U-3118			
	10980886	Apr 20, 2035	DP			
	11083730	Apr 20, 2035	DP U-3118			
	11083797	Apr 20, 2035	DP U-3118			
	11253504	Mar 13, 2034	U-3118			
	11413350	Apr 20, 2035	U-3417			
	9592227	Mar 13, 2034	DP U-3118			
	9694079	Apr 20, 2035	DP U-3118			
	9744163	Mar 13, 2034	DP			
	9801945	Apr 20, 2035	DP U-3118			
	9913909	Mar 13, 2034	U-3118			
<u>BUPIVACAINE; MELOXICAM - ZYNRELEF KIT</u>						
N 211988 004	10098957	Apr 20, 2035	U-3118		NP	May 12, 2024
	10213510	Apr 20, 2035	DP U-3118			
	10398686	Mar 13, 2034	DP			
	10632199	Apr 20, 2035	DP U-3118			
	10898575	Apr 20, 2035	DP U-3118			
	10980886	Apr 20, 2035	DP			
	11083730	Apr 20, 2035	DP U-3118			
	11083797	Apr 20, 2035	DP U-3118			
	11253504	Mar 13, 2034	U-3118			
	11413350	Apr 20, 2035	U-3417			
	9592227	Mar 13, 2034	DP U-3118			
	9694079	Apr 20, 2035	DP U-3118			
	9744163	Mar 13, 2034	DP			
	9801945	Apr 20, 2035	DP U-3118			
	9913909	Mar 13, 2034	U-3118			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BUPRENORPHINE - SUBLOCADE</u>						
N 209819 001	10198218	Jun 06, 2031	U-2489			
	10558394	Jun 25, 2031	DP			
	10592168	Jun 06, 2031	U-2489			
	11000520	Nov 06, 2035	U-3111			
	8921387	Jan 06, 2032	DP U-2173			
	8921387	Jan 06, 2032	DP U-2174			
	8975270	Sep 05, 2031	DP U-2175			
	8975270	Sep 05, 2031	DP U-2206			
	9272044	Jun 06, 2031	U-2176			
	9272044	Jun 06, 2031	U-2177			
	9272044	Jun 06, 2031	U-2178			
	9272044	Jun 06, 2031	U-2209			
	9498432	Jun 06, 2031	DP U-2179			
	9782402	Jun 06, 2031	DP U-2176			
	9782402	Jun 06, 2031	DP U-2180			
	9782402	Jun 06, 2031	DP U-2207			
	9782402	Jun 06, 2031	DP U-2208			
	9827241	Jun 06, 2031	DP U-2174			
	9827241	Jun 06, 2031	DP U-2181			
	9827241	Jun 06, 2031	DP U-2206			
	9827241	Jun 06, 2031	DP U-2210			
	9827241	Jun 06, 2031	DP U-2211			
<u>BUPRENORPHINE - SUBLOCADE</u>						
N 209819 002	10198218	Jun 06, 2031	U-2489			
	10558394	Jun 25, 2031	DP			
	10592168	Jun 06, 2031	U-2489			
	10646484	Jun 22, 2038	U-2489			
	11000520	Nov 06, 2035	U-3111			
	8921387	Jan 06, 2032	DP U-2173			
	8921387	Jan 06, 2032	DP U-2174			
	8975270	Sep 05, 2031	DP U-2175			
	8975270	Sep 05, 2031	DP U-2206			
	9272044	Jun 06, 2031	U-2176			
	9272044	Jun 06, 2031	U-2177			
	9272044	Jun 06, 2031	U-2178			
	9272044	Jun 06, 2031	U-2209			
	9498432	Jun 06, 2031	DP U-2179			
	9782402	Jun 06, 2031	DP U-2176			
	9782402	Jun 06, 2031	DP U-2180			
	9782402	Jun 06, 2031	DP U-2207			
	9782402	Jun 06, 2031	DP U-2208			
	9827241	Jun 06, 2031	DP U-2174			
	9827241	Jun 06, 2031	DP U-2181			
	9827241	Jun 06, 2031	DP U-2206			
	9827241	Jun 06, 2031	DP U-2210			
	9827241	Jun 06, 2031	DP U-2211			
<u>BUPRENORPHINE HYDROCHLORIDE - PROBUPHINE</u>						
N 204442 001	7736665	Apr 25, 2024	U-1878			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 001	8147866	Jul 23, 2027	DP U-1769			
	9655843	Jul 23, 2027	DP U-1556			
	9901539	Dec 21, 2032	U-1556			
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 002	8147866	Jul 23, 2027	DP U-1769			
	9655843	Jul 23, 2027	DP U-1556			
	9901539	Dec 21, 2032	U-1556			
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 003	8147866	Jul 23, 2027	DP U-1769			
	9655843	Jul 23, 2027	DP U-1556			
	9901539	Dec 21, 2032	U-1556			
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 004	8147866	Jul 23, 2027	DP U-1769			
	9655843	Jul 23, 2027	DP U-1556			
	9901539	Dec 21, 2032	U-1556			
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 005	8147866	Jul 23, 2027	DP U-1769			
	9655843	Jul 23, 2027	DP U-1556			
	9901539	Dec 21, 2032	U-1556			
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 006	8147866	Jul 23, 2027	DP U-1769			
	9655843	Jul 23, 2027	DP U-1556			
	9901539	Dec 21, 2032	U-1556			
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 007	8147866	Jul 23, 2027	DP U-1769			
	9655843	Jul 23, 2027	DP U-1556			
	9901539	Dec 21, 2032	U-1556			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 001	11135216	Aug 07, 2029	DP U-3111			
	8017150	Feb 13, 2023	DP			
	8475832	Mar 26, 2030	DP U-1411			
	8603514	Apr 03, 2024	DP U-1464			
	9687454	Aug 07, 2029	DP U-1464			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 002	11135216	Aug 07, 2029	DP U-3111			
	8017150	Feb 13, 2023	DP			
	8475832	Mar 26, 2030	DP U-1411			
	8603514	Apr 03, 2024	DP U-1464			
	9687454	Aug 07, 2029	DP U-1464			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 003	11135216	Aug 07, 2029	DP U-3111			
	8017150	Feb 13, 2023	DP			
	8475832	Mar 26, 2030	DP U-1411			
	8603514	Apr 03, 2024	DP U-1464			
	9687454	Aug 07, 2029	DP U-1464			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 004	11135216	Aug 07, 2029	DP U-3111			
	8017150	Feb 13, 2023	DP			
	8475832	Mar 26, 2030	DP U-1411			
	8603514	Apr 03, 2024	DP U-1464			
	9687454	Aug 07, 2029	DP U-1464			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 001	10946010	Sep 18, 2032	DP			
	11020388	Sep 18, 2032	DP U-3131			
	11433066	Sep 18, 2032	U-3131			
	8470361	May 22, 2030	DP U-1425			
	8658198	Dec 03, 2027	DP U-1494			
	8940330	Sep 18, 2032	DP			
	9259421	Sep 18, 2032	DP			
	9439900	Sep 18, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 002	10874661	Sep 18, 2032	DP			
	10946010	Sep 18, 2032	DP			
	11020387	Sep 18, 2032	DP U-3131			
	11020388	Sep 18, 2032	DP U-3131			
	11433066	Sep 18, 2032	U-3131			
	8470361	May 22, 2030	DP U-1425			
	8658198	Dec 03, 2027	DP U-1494			
	8940330	Sep 18, 2032	DP			
	9259421	Sep 18, 2032	DP			
	9439900	Sep 18, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 003	10946010	Sep 18, 2032	DP			
	11020387	Sep 18, 2032	DP U-3131			
	11020388	Sep 18, 2032	DP U-3131			
	11433066	Sep 18, 2032	U-3131			
	8470361	May 22, 2030	DP U-1425			
	8658198	Dec 03, 2027	DP U-1494			
	8940330	Sep 18, 2032	DP			
	9259421	Sep 18, 2032	DP			
	9439900	Sep 18, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 004	10946010	Sep 18, 2032	DP			
	11020387	Sep 18, 2032	DP U-3131			
	11020388	Sep 18, 2032	DP U-3131			
	11433066	Sep 18, 2032	U-3131			
	8470361	May 22, 2030	DP U-1425			
	8658198	Dec 03, 2027	DP U-1494			
	8940330	Sep 18, 2032	DP			
	9259421	Sep 18, 2032	DP			
	9439900	Sep 18, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 005	10946010	Sep 18, 2032	DP			
	11020387	Sep 18, 2032	DP U-3131			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 005	11020388	Sep 18, 2032	DP U-3131			
	11433066	Sep 18, 2032	U-3131			
	8470361	May 22, 2030	DP U-1425			
	8658198	Dec 03, 2027	DP U-1494			
	8940330	Sep 18, 2032	DP			
	9259421	Sep 18, 2032	DP			
	9439900	Sep 18, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 006	10946010	Sep 18, 2032	DP			
	11020388	Sep 18, 2032	DP U-3131			
	8470361	May 22, 2030	DP U-1425			
	8658198	Dec 03, 2027	DP U-1494			
	8940330	Sep 18, 2032	DP			
	9259421	Sep 18, 2032	DP			
	9439900	Sep 18, 2032	DP	Y		
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - BUNAVAIL</u>						
N 205637 001	8147866	Jul 23, 2027	DP U-1521			
	8703177	Aug 20, 2032	DP			
	9522188	Apr 24, 2035	DP			
	9655843	Jul 23, 2027	DP U-2017			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - BUNAVAIL</u>						
N 205637 002	8147866	Jul 23, 2027	DP U-1521			
	8703177	Aug 20, 2032	DP			
	9522188	Apr 24, 2035	DP			
	9655843	Jul 23, 2027	DP U-2017			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - BUNAVAIL</u>						
N 205637 003	8147866	Jul 23, 2027	DP U-1521			
	8703177	Aug 20, 2032	DP			
	9522188	Apr 24, 2035	DP			
	9655843	Jul 23, 2027	DP U-2017			
<u>BUPROPION HYDROBROMIDE - APLENZIN</u>						
N 022108 001	7241805	Jun 27, 2026	DP			
	7569610	Jun 27, 2026	U-997			
	7572935	Jun 27, 2026	DP			
	7585897	Jun 27, 2026	DP			
	7645802	Jun 27, 2026	DP			
	7649019	Jun 27, 2026	DP			
	7662407	Jun 27, 2026	DP			
	7671094	Jun 27, 2026	DP			
<u>BUPROPION HYDROBROMIDE - APLENZIN</u>						
N 022108 002	7241805	Jun 27, 2026	DP			
	7569610	Jun 27, 2026	U-997			
	7572935	Jun 27, 2026	DP			
	7585897	Jun 27, 2026	DP			
	7645802	Jun 27, 2026	DP			
	7649019	Jun 27, 2026	DP			
	7662407	Jun 27, 2026	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BUPROPION HYDROBROMIDE - APLENZIN</u>						
N 022108 002	7671094	Jun 27, 2026	DP			
<u>BUPROPION HYDROBROMIDE - APLENZIN</u>						
N 022108 003	7241805	Jun 27, 2026	DP			
	7569610	Jun 27, 2026	U-997			
	7572935	Jun 27, 2026	DP			
	7585897	Jun 27, 2026	DP			
	7645802	Jun 27, 2026	DP			
	7649019	Jun 27, 2026	DP			
	7662407	Jun 27, 2026	DP			
	7671094	Jun 27, 2026	DP			
<u>BUPROPION HYDROCHLORIDE - FORFIVO XL</u>						
N 022497 001	7674479	Jun 25, 2027	DP			
<u>BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE - AUVELITY</u>						
N 215430 001	10058518	Nov 05, 2034	U-3419		NP	Aug 18, 2025
	10064857	Nov 05, 2034	U-3419			
	10080727	Nov 05, 2034	U-3419			
	10092560	Nov 05, 2034	U-3419			
	10092561	Nov 05, 2034	U-3419			
	10105327	Nov 05, 2034	U-3419			
	10105361	Nov 05, 2034	U-3419			
	10251879	Nov 05, 2034	U-3419			
	10463634	Nov 05, 2034	U-3419			
	10512643	Nov 05, 2034	U-3419			
	10548857	Nov 05, 2034	U-3419			
	10596167	Nov 05, 2034	U-3419			
	10772850	Nov 05, 2034	U-3419			
	10780064	Jan 07, 2040	U-3419			
	10780066	Nov 09, 2034	U-3419			
	10786469	Nov 05, 2034	U-3419			
	10786496	Nov 05, 2034	U-3419			
	10799497	Nov 05, 2034	U-3419			
	10806710	Nov 05, 2034	U-3419			
	10864209	Nov 05, 2034	U-3419			
	10874663	Nov 05, 2034	U-3419			
	10874664	Nov 05, 2034	U-3419			
	10874665	Nov 05, 2034	U-3419			
	10881624	Nov 05, 2034	U-3419			
	10881657	Nov 05, 2034	U-3419			
	10894046	Nov 05, 2034	U-3419			
	10894047	Nov 05, 2034	U-3419			
	10898453	Nov 05, 2034	U-3419			
	10925842	Jan 07, 2040	U-3419			
	10933034	Nov 05, 2034	U-3419			
	10940124	Jan 07, 2040	U-3419			
	10945973	Nov 05, 2034	U-3419			
	10966941	Nov 05, 2034	U-3419			
	10966942	Jan 07, 2040	U-3419			
	10966974	Nov 05, 2034	U-3419			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE - AUVELITY</u>						
N 215430 001	11020389	Nov 05, 2034	U-3419			
	11058648	Nov 05, 2034	U-3419			
	11090300	Nov 05, 2034	U-3419			
	11096937	Nov 05, 2034	U-3419			
	11123343	Nov 05, 2034	U-3419			
	11129826	Nov 05, 2034	U-3419			
	11141388	Nov 05, 2034	U-3419			
	11141416	Nov 05, 2034	U-3419			
	11147808	Nov 05, 2034	U-3419			
	11185515	Nov 05, 2034	U-3419			
	11191739	Nov 05, 2034	DP U-3419			
	11197839	Nov 05, 2034	DP U-3419			
	11207281	Nov 05, 2034	U-3419			
	11213521	Nov 05, 2034	U-3419			
	11229640	Nov 05, 2034	U-3419			
	11234946	Nov 05, 2034	U-3419			
	11253491	Nov 05, 2034	U-3419			
	11253492	Nov 05, 2034	U-3419			
	11273133	Nov 05, 2034	U-3419			
	11273134	Nov 05, 2034	U-3419			
	11285118	Nov 05, 2034	U-3419			
	11285146	Nov 05, 2034	U-3419			
	11291638	Nov 05, 2034	U-3419			
	11291665	Nov 05, 2034	U-3419			
	11298351	Nov 05, 2034	U-3419			
	11298352	Nov 05, 2034	U-3419			
	11311534	Nov 05, 2034	U-3419			
	11344544	Nov 05, 2034	U-3419			
	11357744	Nov 05, 2034	U-3419			
	11364233	Nov 05, 2034	U-3419			
	11382874	Nov 05, 2034	U-3419			
	11419867	Nov 05, 2034	U-3419			
	11426370	Nov 05, 2034	U-3419			
	11426401	Nov 05, 2034	U-3419			
	11433067	Nov 05, 2034	DP U-3419			
	11439636	Nov 05, 2034	U-3419			
	11478468	Nov 05, 2034	U-3419			
	11497721	Nov 05, 2034	U-3419			
	11510918	Nov 05, 2034	U-3419			
	11517542	Nov 05, 2034	U-3419			
	11517543	Nov 05, 2034	U-3419			
	11524007	Nov 05, 2034	U-3419			
	11524008	Nov 05, 2034	U-3419			
	8569328	Oct 29, 2033	DP U-3419			
	9168234	Nov 05, 2034	U-3419			
	9198905	Nov 05, 2034	U-3419			
	9205083	Nov 05, 2034	U-3419			
	9238032	Nov 05, 2034	U-3419			
	9278095	Nov 05, 2034	U-3419			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE - AUVELITY</u>						
N 215430 001	9314462	Nov 05, 2034	U-3419			
	9370513	Nov 05, 2034	U-3419			
	9375429	Nov 05, 2034	U-3419			
	9408815	Nov 05, 2034	U-3419			
	9421176	Nov 05, 2034	U-3419			
	9457023	Nov 05, 2034	U-3419			
	9457025	Nov 05, 2034	U-3419			
	9474731	Nov 05, 2034	U-3419			
	9486450	Nov 05, 2034	U-3419			
	9700528	Nov 05, 2034	U-3419			
	9700553	Nov 05, 2034	U-3419			
	9707191	Nov 05, 2034	U-3419			
	9763932	Nov 05, 2034	U-3419			
	9861595	Nov 05, 2034	U-3419			
	9867819	Nov 05, 2034	U-3419			
	9968568	Nov 05, 2034	U-3419			
<u>BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE - CONTRAVE</u>						
N 200063 001	10231964	Jul 02, 2034	U-1583			
	10307376	Nov 08, 2027	U-1585			
	10403170	Jun 05, 2033	U-1583			
	10828294	Jul 02, 2034	U-1583			
	10835527	Jul 02, 2034	U-1583			
	11033543	Jan 10, 2031	U-1583			
	11139056	Jun 05, 2033	U-1583			
	11278544	Apr 21, 2024	U-1583			
	11324741	May 29, 2029	U-1583			
	7375111	Mar 26, 2025	DP			
	7462626	Jul 20, 2024	U-1583			
	8088786	Feb 03, 2029	DP			
	8318788	Nov 08, 2027	U-1584			
	8722085	Nov 08, 2027	U-1585			
	8815889	Jul 20, 2024	U-1586			
	8916195	Feb 02, 2030	U-1639			
	9107837	Jun 04, 2027	U-1639			
	9125868	Nov 08, 2027	U-1585			
	9248123	Jan 13, 2032	U-1808			
	9633575	Jun 25, 2033	U-1583			
<u>CABAZITAXEL - JEVTANA KIT</u>						
N 201023 001	10583110	Oct 27, 2030	U-2753		M-128	Dec 18, 2023
	10716777	Oct 27, 2030	U-2856			
	7241907	Dec 10, 2025	DS			
	7241907*PED	Jun 10, 2026				
	8927592	Oct 27, 2030	U-3200			
	8927592*PED	Apr 27, 2031				
<u>CABOTEGRAVIR - APRETEUDE</u>						
N 215499 001	10927129	Apr 28, 2026	DS DP		NCE	Jan 21, 2026
	11224597	Sep 15, 2031	DP			
	8410103	Apr 28, 2026	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CABOTEGRAVIR SODIUM - VOCABRIA</u>						
N 212887 001	10927129	Apr 28, 2026	DS DP		M-273	Jan 31, 2025
	8410103	Apr 28, 2026	DS DP U-3061		NCE	Jan 21, 2026
	8410103	Apr 28, 2026	DS DP U-3348		NPP	Mar 29, 2025
<u>CABOTEGRAVIR; RILPIVIRINE - CABENUVA KIT</u>						
N 212888 001	10927129	Apr 28, 2026	DS DP		D-184	Jan 31, 2025
	11224597	Sep 15, 2031	DP U-3348		NCE	Jan 21, 2026
	11389447	Jun 30, 2027	U-3405		NPP	Mar 29, 2025
	7125879	Apr 21, 2025	DS DP U-3348			
	8080551	Apr 11, 2023	DS DP			
	8410103	Apr 28, 2026	DS DP U-3348			
<u>CABOTEGRAVIR; RILPIVIRINE - CABENUVA KIT</u>						
N 212888 002	10927129	Apr 28, 2026	DS DP		D-184	Jan 31, 2025
	11224597	Sep 15, 2031	DP U-3348		NCE	Jan 21, 2026
	11389447	Jun 30, 2027	U-3405		NPP	Mar 29, 2025
	7125879	Apr 21, 2025	DS DP U-3348			
	8080551	Apr 11, 2023	DS DP			
	8410103	Apr 28, 2026	DS DP U-3348			
<u>CABOZANTINIB S-MALATE - COMETRIQ</u>						
N 203756 001	11091439	Jan 15, 2030	DS			
	11091440	Jan 15, 2030	DP			
	11098015	Jan 15, 2030	U-1617			
	11298349	Feb 10, 2032	DP			
	7579473	Aug 14, 2026	DS DP			
	8877776	Oct 08, 2030	DS DP U-1617			
	9717720	Feb 10, 2032	DP			
<u>CABOZANTINIB S-MALATE - COMETRIQ</u>						
N 203756 002	11091439	Jan 15, 2030	DS			
	11091440	Jan 15, 2030	DP			
	11098015	Jan 15, 2030	U-1617			
	11298349	Feb 10, 2032	DP			
	7579473	Aug 14, 2026	DS DP			
	8877776	Oct 08, 2030	DS DP U-1617			
	9717720	Feb 10, 2032	DP			
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 001	10034873	Jul 18, 2031	U-2488		I-854	Jan 22, 2024
	10039757	Jul 18, 2031	U-1480		I-873	Sep 17, 2024
	11091439	Jan 15, 2030	DS		ODE-227	Jan 14, 2026
	11091440	Jan 15, 2030	DP		ODE-375	Sep 17, 2028
	11098015	Jan 15, 2030	U-1220			
	11098015	Jan 15, 2030	U-1480			
	11098015	Jan 15, 2030	U-2488			
	11098015	Jan 15, 2030	U-3225			
	11298349	Feb 10, 2032	DP			
	7579473	Aug 14, 2026	DS DP			
	8497284	Sep 24, 2024	U-1220			
	8497284	Sep 24, 2024	U-1480			
	8497284	Sep 24, 2024	U-2488			
	8877776	Oct 08, 2030	DS DP U-3225			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 001	9724342	Jul 09, 2033	DP			
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 002	10034873	Jul 18, 2031	U-2488		I-854	Jan 22, 2024
	10039757	Jul 18, 2031	U-1480		I-873	Sep 17, 2024
	11091439	Jan 15, 2030	DS		ODE-227	Jan 14, 2026
	11091440	Jan 15, 2030	DP		ODE-375	Sep 17, 2028
	11098015	Jan 15, 2030	U-1220			
	11098015	Jan 15, 2030	U-1480			
	11098015	Jan 15, 2030	U-2488			
	11098015	Jan 15, 2030	U-3225			
	11298349	Feb 10, 2032	DP			
	7579473	Aug 14, 2026	DS DP			
	8497284	Sep 24, 2024	U-1220			
	8497284	Sep 24, 2024	U-1480			
	8497284	Sep 24, 2024	U-2488			
	8877776	Oct 08, 2030	DS DP U-3225			
	9724342	Jul 09, 2033	DP			
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 003	10034873	Jul 18, 2031	U-2488		I-854	Jan 22, 2024
	10039757	Jul 18, 2031	U-1480		I-873	Sep 17, 2024
	11091439	Jan 15, 2030	DS		ODE-227	Jan 14, 2026
	11091440	Jan 15, 2030	DP		ODE-375	Sep 17, 2028
	11098015	Jan 15, 2030	U-1220			
	11098015	Jan 15, 2030	U-1480			
	11098015	Jan 15, 2030	U-2488			
	11098015	Jan 15, 2030	U-3225			
	11298349	Feb 10, 2032	DP			
	7579473	Aug 14, 2026	DS DP			
	8497284	Sep 24, 2024	U-1220			
	8497284	Sep 24, 2024	U-1480			
	8497284	Sep 24, 2024	U-2488			
	8877776	Oct 08, 2030	DS DP U-3225			
	9724342	Jul 09, 2033	DP			
<u>CALCIFEDIOL - RAYALDEE</u>						
N 208010 001	10213442	Feb 02, 2027	DP			
	10300078	Mar 14, 2034	DP			
	10357502	Mar 14, 2034	DP			
	11154509	Apr 25, 2028	U-3248			
	11253528	Mar 14, 2034	DP			
	8207149	Apr 25, 2028	U-1871			
	8361488	Jul 19, 2028	DP			
	8426391	Aug 27, 2028	U-1872			
	8778373	Apr 25, 2028	U-1873			
	8906410	Feb 02, 2027	DP			
	9408858	Apr 25, 2028	U-1888			
	9498486	Apr 25, 2028	U-1920			
	9861644	Mar 14, 2034	DP			
	9925147	Apr 25, 2028	DP U-2255			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CALCIFEDIOL - RAYALDEE</u>						
N 208010 001	9925147	Apr 25, 2028	DP U-2256			
	9925147	Apr 25, 2028	DP U-2257			
	9925147	Apr 25, 2028	DP U-2258			
	9925147	Apr 25, 2028	DP U-2259			
	9943530	Feb 02, 2027	U-2274			
<u>CALCIPOTRIENE - SORILUX</u>						
N 022563 001	8263580	May 07, 2028	DP U-1280			
	8263580	May 07, 2028	DP U-2662			
	8629128	May 26, 2026	DP U-1280			
	8629128	May 26, 2026	DP U-1767			
	8629128	May 26, 2026	DP U-2662			
<u>CALCITRIOL - VECTICAL</u>						
N 022087 001					NPP	Jul 17, 2023
<u>CALCIUM ACETATE - PHOSLYRA</u>						
N 022581 001	8591938	Feb 23, 2030	DP U-1469			
	8592480	Jul 20, 2027	U-1469			
	9089528	Jul 20, 2027	U-1469			
<u>CALCIUM GLUCONATE - CALCIUM GLUCONATE</u>						
A 213071 001					CGT	May 05, 2023
<u>CALCIUM GLUCONATE - CALCIUM GLUCONATE IN SODIUM CHLORIDE</u>						
N 210906 001	10130646	Jul 25, 2037	DP			
	10342813	Jul 25, 2037	DP			
<u>CALCIUM GLUCONATE - CALCIUM GLUCONATE IN SODIUM CHLORIDE</u>						
N 210906 002	10130646	Jul 25, 2037	DP			
	10342813	Jul 25, 2037	DP			
<u>CALCIUM GLUCONATE - CALCIUM GLUCONATE IN SODIUM CHLORIDE</u>						
N 210906 003	10130646	Jul 25, 2037	DP			
	10342813	Jul 25, 2037	DP			
<u>CALCIUM OXYBATE; MAGNESIUM OXYBATE; POTASSIUM OXYBATE; SODIUM OXYBATE - XYWAV</u>						
N 212690 001	10195168	Jan 11, 2033	DP		I-870	Aug 12, 2024
	10213400	Mar 15, 2033	U-2499		NP	Jul 21, 2023
	10213400*PED	Sep 15, 2033			ODE-361	Jul 21, 2027
	10675258	Jan 11, 2033	U-2938		ODE-369	Aug 12, 2028
	10864181	Mar 15, 2033	U-3017			
	10864181*PED	Sep 15, 2033				
	11253494	Mar 15, 2033	U-3323			
	11253494	Mar 15, 2033	U-3324			
	11253494*PED	Sep 15, 2033				
	11426373	Sep 19, 2037	U-3432			
	8591922	Jan 11, 2033	DP			
	8731963*PED	Jun 17, 2023				
	8772306	Mar 15, 2033	U-1532			
	8772306	Mar 15, 2033	U-3198			
	8772306*PED	Sep 15, 2033				
	8901173	Jan 11, 2033	DP			
	9050302	Mar 15, 2033	U-1532			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CALCIUM OXYBATE; MAGNESIUM OXYBATE; POTASSIUM OXYBATE; SODIUM OXYBATE - XYWAV</u>						
N 212690 001	9050302*PED	Sep 15, 2033				
	9132107	Jan 11, 2033	DP			
	9486426	Mar 15, 2033	U-1532			
	9486426*PED	Sep 15, 2033				
<u>CANAGLIFLOZIN - INVOKANA</u>						
N 204042 001	10617668	May 11, 2031	DP U-2441			
	10617668	May 11, 2031	DP U-2632			
	10617668	May 11, 2031	DP U-2794			
	10617668	May 11, 2031	DP U-2795			
	10617668	May 11, 2031	DP U-2796			
	10617668	May 11, 2031	DP U-2797			
	10617668	May 11, 2031	DP U-2798			
	10617668	May 11, 2031	DP U-2799			
	10617668	May 11, 2031	DP U-493			
	7943582	Feb 26, 2029	DS DP U-2441			
	7943582	Feb 26, 2029	DS DP U-2632			
	7943582	Feb 26, 2029	DS DP U-493			
	7943788	Jul 14, 2027	DS DP			
	8222219	Apr 11, 2025	U-2441			
	8222219	Apr 11, 2025	U-2632			
	8222219	Apr 11, 2025	U-493			
	8513202	Dec 03, 2027	DS DP U-2441			
	8513202	Dec 03, 2027	DS DP U-2632			
	8513202	Dec 03, 2027	DS DP U-493			
<u>CANAGLIFLOZIN - INVOKANA</u>						
N 204042 002	10617668	May 11, 2031	DP U-2441			
	10617668	May 11, 2031	DP U-2632			
	10617668	May 11, 2031	DP U-2794			
	10617668	May 11, 2031	DP U-2795			
	10617668	May 11, 2031	DP U-2796			
	10617668	May 11, 2031	DP U-2797			
	10617668	May 11, 2031	DP U-2798			
	10617668	May 11, 2031	DP U-2799			
	10617668	May 11, 2031	DP U-493			
	7943582	Feb 26, 2029	DS DP U-2441			
	7943582	Feb 26, 2029	DS DP U-2632			
	7943582	Feb 26, 2029	DS DP U-493			
	7943788	Jul 14, 2027	DS DP			
	8222219	Apr 11, 2025	U-2441			
	8222219	Apr 11, 2025	U-2632			
	8222219	Apr 11, 2025	U-493			
	8513202	Dec 03, 2027	DS DP U-2441			
	8513202	Dec 03, 2027	DS DP U-2632			
	8513202	Dec 03, 2027	DS DP U-493			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 001	7943582	Feb 26, 2029	DS DP U-2441			
	7943582	Feb 26, 2029	DS DP U-2632			
	7943582	Feb 26, 2029	DS DP U-493			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 001	7943788	Jul 14, 2027	DS DP			
	8222219	Apr 11, 2025			U-2441	
	8222219	Apr 11, 2025			U-2632	
	8222219	Apr 11, 2025			U-493	
	8513202	Dec 03, 2027	DS DP		U-2441	
	8513202	Dec 03, 2027	DS DP		U-2632	
	8513202	Dec 03, 2027	DS DP		U-493	
	8785403	Jul 30, 2024	DP			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 002	7943582	Feb 26, 2029	DS DP		U-2441	
	7943582	Feb 26, 2029	DS DP		U-2632	
	7943582	Feb 26, 2029	DS DP		U-493	
	7943788	Jul 14, 2027	DS DP			
	8222219	Apr 11, 2025			U-2441	
	8222219	Apr 11, 2025			U-2632	
	8222219	Apr 11, 2025			U-493	
	8513202	Dec 03, 2027	DS DP		U-2441	
	8513202	Dec 03, 2027	DS DP		U-2632	
	8513202	Dec 03, 2027	DS DP		U-493	
	8785403	Jul 30, 2024	DP			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 003	7943582	Feb 26, 2029	DS DP		U-2441	
	7943582	Feb 26, 2029	DS DP		U-2632	
	7943582	Feb 26, 2029	DS DP		U-493	
	7943788	Jul 14, 2027	DS DP			
	8222219	Apr 11, 2025			U-2441	
	8222219	Apr 11, 2025			U-2632	
	8222219	Apr 11, 2025			U-493	
	8513202	Dec 03, 2027	DS DP		U-2441	
	8513202	Dec 03, 2027	DS DP		U-2632	
	8513202	Dec 03, 2027	DS DP		U-493	
	8785403	Jul 30, 2024	DP			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 004	7943582	Feb 26, 2029	DS DP		U-2441	
	7943582	Feb 26, 2029	DS DP		U-2632	
	7943582	Feb 26, 2029	DS DP		U-493	
	7943788	Jul 14, 2027	DS DP			
	8222219	Apr 11, 2025			U-2441	
	8222219	Apr 11, 2025			U-2632	
	8222219	Apr 11, 2025			U-493	
	8513202	Dec 03, 2027	DS DP		U-2441	
	8513202	Dec 03, 2027	DS DP		U-2632	
	8513202	Dec 03, 2027	DS DP		U-493	
	8785403	Jul 30, 2024	DP			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR</u>						
N 205879 001	7943582	Feb 26, 2029	DS DP		U-2441	
	7943582	Feb 26, 2029	DS DP		U-2632	
	7943582	Feb 26, 2029	DS DP		U-493	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR</u>						
N 205879 001	7943788	Jul 14, 2027	DS DP			
	8222219	Apr 11, 2025			U-2441	
	8222219	Apr 11, 2025			U-2632	
	8222219	Apr 11, 2025			U-493	
	8513202	Dec 03, 2027	DS DP		U-2441	
	8513202	Dec 03, 2027	DS DP		U-2632	
	8513202	Dec 03, 2027	DS DP		U-493	
	8785403	Jul 30, 2024	DP			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR</u>						
N 205879 002	7943582	Feb 26, 2029	DS DP		U-2441	
	7943582	Feb 26, 2029	DS DP		U-2632	
	7943582	Feb 26, 2029	DS DP		U-493	
	7943788	Jul 14, 2027	DS DP			
	8222219	Apr 11, 2025			U-2441	
	8222219	Apr 11, 2025			U-2632	
	8222219	Apr 11, 2025			U-493	
	8513202	Dec 03, 2027	DS DP		U-2441	
	8513202	Dec 03, 2027	DS DP		U-2632	
	8513202	Dec 03, 2027	DS DP		U-493	
	8785403	Jul 30, 2024	DP			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR</u>						
N 205879 003	7943582	Feb 26, 2029	DS DP		U-2441	
	7943582	Feb 26, 2029	DS DP		U-2632	
	7943582	Feb 26, 2029	DS DP		U-493	
	7943788	Jul 14, 2027	DS DP			
	8222219	Apr 11, 2025			U-2441	
	8222219	Apr 11, 2025			U-2632	
	8222219	Apr 11, 2025			U-493	
	8513202	Dec 03, 2027	DS DP		U-2441	
	8513202	Dec 03, 2027	DS DP		U-2632	
	8513202	Dec 03, 2027	DS DP		U-493	
	8785403	Jul 30, 2024	DP			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR</u>						
N 205879 004	7943582	Feb 26, 2029	DS DP		U-2441	
	7943582	Feb 26, 2029	DS DP		U-2632	
	7943582	Feb 26, 2029	DS DP		U-493	
	7943788	Jul 14, 2027	DS DP			
	8222219	Apr 11, 2025			U-2441	
	8222219	Apr 11, 2025			U-2632	
	8222219	Apr 11, 2025			U-493	
	8513202	Dec 03, 2027	DS DP		U-2441	
	8513202	Dec 03, 2027	DS DP		U-2632	
	8513202	Dec 03, 2027	DS DP		U-493	
	8785403	Jul 30, 2024	DP			
<u>CANGRELOR - KENGREAL</u>						
N 204958 001	10039780	Jul 10, 2035			U-2260	
	6130208	Jun 29, 2023	DP		U-1715	
	8680052	Mar 09, 2033			U-2979	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CANGRELOR - KENGREAL</u>						
N 204958 001	9295687	Jul 10, 2035	DP			
	9427448	Nov 10, 2030	U-1926			
	9439921	Jul 10, 2035	DP			
	9700575	Jul 10, 2035	DP			
	9925265	May 13, 2029	U-2260			
<u>CANNABIDIOL - EPIDIOLEX</u>						
N 210365 001	10092525	Jun 17, 2035	U-2427		NCE	Sep 28, 2023
	10111840	Jun 17, 2035	U-2442		NPP	Jul 31, 2023
	10111840	Jun 17, 2035	U-2443		ODE-216	Sep 28, 2025
	10137095	Jun 17, 2035	U-2454		ODE-326	Jul 31, 2027
	10137095	Jun 17, 2035	U-2455		ODE-332	Jul 31, 2027
	10603288	Jun 17, 2035	U-2780			
	10603288	Jun 17, 2035	U-2781			
	10603288	Jun 17, 2035	U-2782			
	10603288	Jun 17, 2035	U-2783			
	10709671	Jun 17, 2035	U-2862			
	10709673	Jun 17, 2035	DP			
	10709674	Jun 17, 2035	U-2780			
	10709674	Jun 17, 2035	U-2781			
	10849860	Jun 17, 2035	U-2427			
	10849860	Jun 17, 2035	U-2454			
	10918608	Oct 13, 2035	U-3071			
	10918608	Oct 13, 2035	U-3072			
	10918608	Oct 13, 2035	U-3073			
	10966939	Jun 17, 2035	DP U-2780			
	10966939	Jun 17, 2035	DP U-2781			
	11065209	Oct 13, 2035	U-3071			
	11096905	Oct 13, 2035	DS DP U-2780			
	11096905	Oct 13, 2035	DS DP U-2781			
	11154516	Jun 17, 2035	U-3235			
	11154516	Jun 17, 2035	U-3236			
	11160795	Mar 01, 2041	U-3233			
	11207292	Apr 26, 2039	DS U-3235			
	11207292	Apr 26, 2039	DS U-3236			
	11207292	Apr 26, 2039	DS U-3277			
	11311498	Jun 17, 2035	U-3375			
	11311498	Jun 17, 2035	U-3376			
	11357741	Jun 17, 2035	U-2862			
	11400055	Oct 13, 2035	U-3071			
	11406623	Mar 01, 2041	U-3233			
	11446258	Jun 17, 2035	U-2780			
	11446258	Jun 17, 2035	U-2781			
	11446258	Jun 17, 2035	U-3071			
	9949937	Jun 17, 2035	U-2421			
	9956183	Jun 17, 2035	U-2422			
	9956183	Jun 17, 2035	U-2423			
	9956184	Jun 17, 2035	U-2424			
	9956185	Jun 17, 2035	U-2425			
	9956186	Jun 17, 2035	U-2426			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CANNABIDIOL - EPIDIOLEX</u>						
N 210365 001	10092525	Jun 17, 2035	U-2427		NCE	Sep 28, 2023
	10111840	Jun 17, 2035	U-2442		NPP	Jul 31, 2023
	10111840	Jun 17, 2035	U-2443		ODE-216	Sep 28, 2025
	10137095	Jun 17, 2035	U-2454		ODE-326	Jul 31, 2027
	10137095	Jun 17, 2035	U-2455		ODE-332	Jul 31, 2027
	10603288	Jun 17, 2035	U-2780			
	10603288	Jun 17, 2035	U-2781			
	10603288	Jun 17, 2035	U-2782			
	10603288	Jun 17, 2035	U-2783			
	10709671	Jun 17, 2035	U-2862			
	10709673	Jun 17, 2035	DP			
	10709674	Jun 17, 2035	U-2780			
	10709674	Jun 17, 2035	U-2781			
	10849860	Jun 17, 2035	U-2427			
	10849860	Jun 17, 2035	U-2454			
	10918608	Oct 13, 2035	U-3071			
	10918608	Oct 13, 2035	U-3072			
	10918608	Oct 13, 2035	U-3073			
	10966939	Jun 17, 2035	DP U-2780			
	10966939	Jun 17, 2035	DP U-2781			
	11065209	Oct 13, 2035	U-3071			
	11096905	Oct 13, 2035	DS DP U-2780			
	11096905	Oct 13, 2035	DS DP U-2781			
	11154516	Jun 17, 2035	U-3235			
	11154516	Jun 17, 2035	U-3236			
	11160795	Mar 01, 2041	U-3233			
	11207292	Apr 26, 2039	DS U-3235			
	11207292	Apr 26, 2039	DS U-3236			
	11207292	Apr 26, 2039	DS U-3277			
	11311498	Jun 17, 2035	U-3375			
	11311498	Jun 17, 2035	U-3376			
	11357741	Jun 17, 2035	U-2862			
	11400055	Oct 13, 2035	U-3071			
	11406623	Mar 01, 2041	U-3233			
	11446258	Jun 17, 2035	U-2780			
	11446258	Jun 17, 2035	U-2781			
	11446258	Jun 17, 2035	U-3071			
	9949937	Jun 17, 2035	U-2421			
	9956183	Jun 17, 2035	U-2422			
	9956183	Jun 17, 2035	U-2423			
	9956184	Jun 17, 2035	U-2424			
	9956185	Jun 17, 2035	U-2425			
	9956186	Jun 17, 2035	U-2426			
<u>CAPMATINIB HYDROCHLORIDE - TABRECTA</u>						
N 213591 001	10596178	Jul 22, 2035	DS DP		NCE	May 06, 2025
	7767675	Nov 19, 2027	DS DP		ODE-291	May 06, 2027
	8420645	Jun 05, 2031	DS DP			
	8461330	Nov 19, 2027	DS DP			
	8901123	May 20, 2029	U-2813			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CAPMATINIB HYDROCHLORIDE - TABRECTA</u>						
N 213591 001	10596178	Jul 22, 2035	DS DP		NCE	May 06, 2025
	7767675	Nov 19, 2027	DS DP		ODE-291	May 06, 2027
	8420645	Jun 05, 2031	DS DP			
	8461330	Nov 19, 2027	DS DP			
	8901123	May 20, 2029	U-2813			
<u>CAPMATINIB HYDROCHLORIDE - TABRECTA</u>						
N 213591 002	10596178	Jul 22, 2035	DS DP		NCE	May 06, 2025
	7767675	Nov 19, 2027	DS DP		ODE-291	May 06, 2027
	8420645	Jun 05, 2031	DS DP			
	8461330	Nov 19, 2027	DS DP			
	8901123	May 20, 2029	U-2813			
<u>CAPSAICIN - OUTENZA</u>						
N 022395 001	10034841	Sep 06, 2025	DP		I-838	Jul 17, 2023
	10463598	Sep 05, 2023	DP			
	10869827	Sep 05, 2023	DP			
	8263059	Sep 05, 2023	U-2705			
	8821920	Mar 26, 2030	DP			
	8889113	Sep 05, 2023	U-2705			
	9226903	Dec 15, 2028	DP			
<u>CARBAMAZEPINE - EQUETRO</u>						
N 021710 001	6977253	May 19, 2024	U-693			
<u>CARBAMAZEPINE - EQUETRO</u>						
N 021710 002	6977253	May 19, 2024	U-693			
<u>CARBAMAZEPINE - EQUETRO</u>						
N 021710 003	6977253	May 19, 2024	U-693			
<u>CARBAMAZEPINE - CARNEXIV</u>						
N 206030 001	7635773	Mar 13, 2029	DP		ODE-124	Oct 07, 2023
	8410077	Mar 13, 2029	DP			
	9493582	Feb 27, 2033	DP			
	9629797	Nov 10, 2028	U-2004			
	9629797	Nov 10, 2028	U-2005			
	9629797	Nov 10, 2028	U-2006			
	9750822	Mar 13, 2029	DP			
	9770407	Nov 10, 2028	DP			
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312 001	8377474	Dec 26, 2028	DP U-1645			
	8377474	Dec 26, 2028	DP U-219			
	8454998	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-1646			
	8454998	Dec 26, 2028	DP U-1647			
	8454998	Dec 26, 2028	DP U-1649			
	8454998	Dec 26, 2028	DP U-219			
	8557283	Dec 26, 2028	DP U-1645			
	8557283	Dec 26, 2028	DP U-219			
	9089607	Dec 26, 2028	DP U-1645			
	9089607	Dec 26, 2028	DP U-1720			
	9089608	Dec 26, 2028	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312 001	9463246	Dec 26, 2028	DP U-219			
	9533046	Dec 26, 2028	DP U-219			
	9901640	Dec 26, 2028	DP U-219			
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312 002	8377474	Dec 26, 2028	DP U-1645			
	8377474	Dec 26, 2028	DP U-219			
	8454998	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-1646			
	8454998	Dec 26, 2028	DP U-1647			
	8454998	Dec 26, 2028	DP U-1649			
	8454998	Dec 26, 2028	DP U-219			
	8557283	Dec 26, 2028	DP U-1645			
	8557283	Dec 26, 2028	DP U-219			
	9089607	Dec 26, 2028	DP U-1645			
	9089607	Dec 26, 2028	DP U-1720			
	9089608	Dec 26, 2028	DP			
	9463246	Dec 26, 2028	DP U-219			
	9533046	Dec 26, 2028	DP U-219			
	9901640	Dec 26, 2028	DP U-219			
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312 003	8377474	Dec 26, 2028	DP U-1645			
	8377474	Dec 26, 2028	DP U-219			
	8454998	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-1646			
	8454998	Dec 26, 2028	DP U-1647			
	8454998	Dec 26, 2028	DP U-1649			
	8454998	Dec 26, 2028	DP U-219			
	8557283	Dec 26, 2028	DP U-1645			
	8557283	Dec 26, 2028	DP U-219			
	9089607	Dec 26, 2028	DP U-1645			
	9089607	Dec 26, 2028	DP U-1720			
	9089608	Dec 26, 2028	DP			
	9463246	Dec 26, 2028	DP U-219			
	9533046	Dec 26, 2028	DP U-219			
	9901640	Dec 26, 2028	DP U-219			
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312 004	8377474	Dec 26, 2028	DP U-1645			
	8377474	Dec 26, 2028	DP U-219			
	8454998	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-1646			
	8454998	Dec 26, 2028	DP U-1647			
	8454998	Dec 26, 2028	DP U-1649			
	8454998	Dec 26, 2028	DP U-219			
	8557283	Dec 26, 2028	DP U-1645			
	8557283	Dec 26, 2028	DP U-219			
	9089607	Dec 26, 2028	DP U-1645			
	9089607	Dec 26, 2028	DP U-1720			
	9089608	Dec 26, 2028	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312 004	9463246	Dec 26, 2028	DP U-219			
	9533046	Dec 26, 2028	DP U-219			
	9901640	Dec 26, 2028	DP U-219			
<u>CARBIDOPA; LEVODOPA - DHIVY</u>						
N 214869 001	11033521	Mar 28, 2039	DP U-219			
	11033521	Mar 28, 2039	DP U-3304			
	11033521	Mar 28, 2039	DP U-3305			
<u>CARBINOXAMINE MALEATE - KARBINAL ER</u>						
N 022556 001	8062667	Mar 29, 2029	DP			
	9522191	Jun 15, 2027	DP			
<u>CAREFILZOMIB - KYPROLIS</u>						
N 202714 001	7232818	Apr 14, 2025	DS DP		I-842	Aug 20, 2023
	7417042	Jul 20, 2026	DS DP			
	7491704	Apr 14, 2025	U-1260			
	7491704	Apr 14, 2025	U-2319			
	7491704	Apr 14, 2025	U-2320			
	7491704	Apr 14, 2025	U-2947			
	7737112	Dec 07, 2027	DP			
	8129346	Apr 14, 2025	U-1260			
	8129346	Apr 14, 2025	U-2319			
	8129346	Apr 14, 2025	U-2320			
	8129346	Apr 14, 2025	U-2947			
	8207125	Apr 14, 2025	DS DP			
	8207126	Apr 14, 2025	DP			
	8207127	Apr 14, 2025	U-1260			
	8207127	Apr 14, 2025	U-2319			
	8207127	Apr 14, 2025	U-2320			
	8207127	Apr 14, 2025	U-2947			
	8207297	Apr 14, 2025	DS DP			
	9493582	Feb 27, 2033	DP			
	9511109	Oct 21, 2029	U-1924			
	RE47954	Oct 21, 2029	U-3449			
<u>CAREFILZOMIB - KYPROLIS</u>						
N 202714 002	7232818	Apr 14, 2025	DS DP		I-842	Aug 20, 2023
	7417042	Jul 20, 2026	DS DP			
	7491704	Apr 14, 2025	U-1260			
	7491704	Apr 14, 2025	U-2319			
	7491704	Apr 14, 2025	U-2320			
	7491704	Apr 14, 2025	U-2947			
	7737112	Dec 07, 2027	DP			
	8129346	Apr 14, 2025	U-1260			
	8129346	Apr 14, 2025	U-2319			
	8129346	Apr 14, 2025	U-2320			
	8129346	Apr 14, 2025	U-2947			
	8207125	Apr 14, 2025	DS DP			
	8207126	Apr 14, 2025	DP			
	8207127	Apr 14, 2025	U-1260			
	8207127	Apr 14, 2025	U-2319			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CARFILZOMIB - KYPROLIS</u>						
N 202714 002	8207127	Apr 14, 2025	U-2320			
	8207127	Apr 14, 2025	U-2947			
	8207297	Apr 14, 2025	DS DP			
	9493582	Feb 27, 2033	DP			
	9511109	Oct 21, 2029	U-1924			
	RE47954	Oct 21, 2029	U-3449			
<u>CARFILZOMIB - KYPROLIS</u>						
N 202714 003	7232818	Apr 14, 2025	DS DP		I-842	Aug 20, 2023
	7417042	Jul 20, 2026	DS DP			
	7491704	Apr 14, 2025	U-2319			
	7491704	Apr 14, 2025	U-2320			
	7491704	Apr 14, 2025	U-2947			
	7737112	Dec 07, 2027	DP			
	8129346	Apr 14, 2025	U-2319			
	8129346	Apr 14, 2025	U-2320			
	8129346	Apr 14, 2025	U-2947			
	8207125	Apr 14, 2025	DS DP			
	8207126	Apr 14, 2025	DP			
	8207127	Apr 14, 2025	U-2319			
	8207127	Apr 14, 2025	U-2320			
	8207127	Apr 14, 2025	U-2947			
	8207297	Apr 14, 2025	DS DP			
	9493582	Feb 27, 2033	DP			
	9511109	Oct 21, 2029	U-1924			
	RE47954	Oct 21, 2029	U-3449			
<u>CARGLUMIC ACID - CARBAGLU</u>						
N 022562 001					ODE-345	Jan 22, 2028
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 001	7737142	Sep 17, 2029	DS DP U-1750			
	7737142	Sep 17, 2029	DS DP U-2543			
	7737142	Sep 17, 2029	DS DP U-2544			
	7737142	Sep 17, 2029	DS DP U-2545			
	7943621	Dec 16, 2028	DS DP			
	RE47350	Jul 16, 2029	U-1750			
	RE47350	Jul 16, 2029	U-2543			
	RE47350	Jul 16, 2029	U-2544			
	RE47350	Jul 16, 2029	U-2545			
	RE49110	Jul 16, 2029	U-2543			
	RE49110	Jul 16, 2029	U-2544			
	RE49110	Jul 16, 2029	U-2545			
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 002	7737142	Sep 17, 2029	DS DP U-1750			
	7737142	Sep 17, 2029	DS DP U-2543			
	7737142	Sep 17, 2029	DS DP U-2544			
	7737142	Sep 17, 2029	DS DP U-2545			
	7943621	Dec 16, 2028	DS DP			
	RE49110	Jul 16, 2029	U-2543			
	RE49110	Jul 16, 2029	U-2544			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 002	RE49110	Jul 16, 2029	U-2545			
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 003	7737142	Sep 17, 2029	DS DP U-1750			
	7737142	Sep 17, 2029	DS DP U-2543			
	7737142	Sep 17, 2029	DS DP U-2544			
	7943621	Dec 16, 2028	DS DP			
	RE49110	Jul 16, 2029	U-2543			
	RE49110	Jul 16, 2029	U-2544			
	RE49110	Jul 16, 2029	U-2545			
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 004	7737142	Sep 17, 2029	DS DP U-1750			
	7737142	Sep 17, 2029	DS DP U-2543			
	7737142	Sep 17, 2029	DS DP U-2544			
	7943621	Dec 16, 2028	DS DP			
	RE49110	Jul 16, 2029	U-2543			
	RE49110	Jul 16, 2029	U-2544			
	RE49110	Jul 16, 2029	U-2545			
<u>CARVEDILOL PHOSPHATE - COREG CR</u>						
N 022012 001	7268156	Jun 27, 2023	DS DP U-3			
	7268156	Jun 27, 2023	DS DP U-313			
	8101209	Sep 11, 2025	DP			
<u>CARVEDILOL PHOSPHATE - COREG CR</u>						
N 022012 002	7268156	Jun 27, 2023	DS DP U-3			
	7268156	Jun 27, 2023	DS DP U-313			
	8101209	Sep 11, 2025	DP			
<u>CARVEDILOL PHOSPHATE - COREG CR</u>						
N 022012 003	7268156	Jun 27, 2023	DS DP U-3			
	7268156	Jun 27, 2023	DS DP U-313			
	8101209	Sep 11, 2025	DP			
<u>CARVEDILOL PHOSPHATE - COREG CR</u>						
N 022012 004	7268156	Jun 27, 2023	DS DP U-3			
	7268156	Jun 27, 2023	DS DP U-313			
	8101209	Sep 11, 2025	DP			
<u>CASIMERSEN - AMONDYS 45</u>						
N 213026 001	10287586	Nov 12, 2030	DS DP		NCE	Feb 25, 2026
	10781450	Nov 12, 2030	U-3089		ODE-347	Feb 25, 2028
	9228187	Nov 12, 2030	DS DP			
	9447415	Jun 28, 2025	DS DP			
	9758783	Nov 12, 2030	U-3088			
	9758783	Nov 12, 2030	U-3089			
	RE48960	Jun 28, 2025	DS DP U-3087			
	RE48960	Jun 28, 2025	DS DP U-3088			
<u>CASPOFUNGIN ACETATE - CASPOFUNGIN ACETATE</u>						
N 206110 001	9636407	Dec 21, 2032	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CASPOFUNGIN ACETATE - CASPOFUNGIN ACETATE</u>						
N 206110 002	9636407	Dec 21, 2032	DP			
<u>CEDAZURIDINE; DECITABINE - INQOVI</u>						
N 212576 001	8268800	Aug 22, 2030	DS	U-2864	NCE	Jul 07, 2025
	8268800	Aug 22, 2030	DS	U-2865	ODE-316	Jul 07, 2027
	8268800	Aug 22, 2030	DS	U-2866		
	8268800	Aug 22, 2030	DS	U-2867		
	8618075	Oct 16, 2028		U-2864		
	8618075	Oct 16, 2028		U-2867		
	9567363	Oct 16, 2028	DS			
<u>CEFAZOLIN SODIUM - CEFAZOLIN AND DEXTROSE</u>						
N 050779 001					NPP	Nov 23, 2023
<u>CEFAZOLIN SODIUM - CEFAZOLIN AND DEXTROSE</u>						
N 050779 002					NPP	Nov 23, 2023
<u>CEFAZOLIN SODIUM - CEFAZOLIN AND DEXTROSE</u>						
N 050779 003					NPP	Nov 23, 2023
<u>CEFIDEROCOL SULFATE TOSYLATE - FETROJA</u>						
N 209445 001	10004750	Sep 03, 2035	DS DP		I-844	Sep 25, 2023
	9238657	Nov 14, 2033	DS DP U-282		NCE	Nov 14, 2024
	9238657	Nov 14, 2033	DS DP U-3470		GAIN	Nov 14, 2029
	9238657	Nov 14, 2033	DS DP U-3471			
	9949982	Sep 03, 2035	DP			
<u>CEFIXIME - SUPRAX</u>						
N 202091 001	9233112	Dec 14, 2028	DP U-1676			
<u>CEFTAROLINE FOSAMIL - TEFLARO</u>						
N 200327 001	8247400	Feb 10, 2031	DP U-282			
	9629861	Sep 21, 2030	DP			
<u>CEFTAROLINE FOSAMIL - TEFLARO</u>						
N 200327 002	8247400	Feb 10, 2031	DP U-282			
	9629861	Sep 21, 2030	DP			
<u>CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM - ZERBAXA</u>						
N 206829 001	10028963	Sep 07, 2032	U-2565		NCE	Dec 19, 2019
	10028963	Sep 07, 2032	U-2566		NPP	Apr 21, 2025
	10125149	Aug 14, 2035	DP		GAIN	Dec 19, 2024
	10376496	Sep 09, 2034	U-2610			
	10376496	Sep 09, 2034	U-2611			
	10420841	Mar 14, 2034	U-1672			
	10420841	Mar 14, 2034	U-2631			
	10420841	Mar 14, 2034	U-3360			
	10420841	Mar 14, 2034	U-3361			
	10933053	Sep 09, 2034	U-3090			
	10933053	Sep 09, 2034	U-3091			
	11278622	Mar 14, 2034	U-3335			
	11278622	Mar 14, 2034	U-3336			
	7129232	May 15, 2028	DS DP U-1676			
	7129232	May 15, 2028	DS DP U-3360			
	7129232	May 15, 2028	DS DP U-3361			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM - ZERBAXA</u>						
N 206829 001	7129232	May 15, 2028	DS DP U-36			
	8476425	Sep 27, 2032	DS			
	8685957	Sep 27, 2032	DS U-36			
	8906898	May 28, 2034	DS DP			
	8968753	Mar 14, 2034	U-1672			
	8968753	Mar 14, 2034	U-1673			
	8968753	Mar 14, 2034	U-3360			
	8968753	Mar 14, 2034	U-3361			
	9320740	Mar 14, 2034	DP			
	9724353	Sep 07, 2032	U-2565			
	9724353	Sep 07, 2032	U-2566			
	9872906	Mar 14, 2034	DP			
<u>CELECOXIB - ELYXYB</u>						
N 212157 001	10376527	May 27, 2036	DP U-2718		NP	May 05, 2023
	10722456	May 27, 2036	DP U-2718			
	10799517	May 27, 2036	DP U-2718			
	9572819	May 27, 2036	DP U-2718			
	9795620	May 27, 2036	DP U-2718			
	9949990	May 27, 2036	DP U-2718			
<u>CELECOXIB; TRAMADOL HYDROCHLORIDE - SEGLENTIS</u>						
N 213426 001	10238668	Apr 19, 2030	DS DP U-3244		NP	Oct 15, 2024
	10245276	Apr 19, 2030	DS DP			
	10548909	Apr 19, 2030	U-3244			
	11478488	Apr 19, 2030	U-3244			
	8598152	Apr 19, 2030	DS DP			
	8846744	Jun 03, 2031	DP			
	9012440	Apr 19, 2030	DS DP			
<u>CENOBAMATE - XCOPRI</u>						
N 212839 001	7598279	Oct 30, 2027	DS		NCE	Mar 10, 2025
<u>CENOBAMATE - XCOPRI</u>						
N 212839 002	7598279	Oct 30, 2027	DS		NCE	Mar 10, 2025
<u>CENOBAMATE - XCOPRI</u>						
N 212839 003	7598279	Oct 30, 2027	DS		NCE	Mar 10, 2025
<u>CENOBAMATE - XCOPRI</u>						
N 212839 004	7598279	Oct 30, 2027	DS		NCE	Mar 10, 2025
<u>CENOBAMATE - XCOPRI</u>						
N 212839 005	7598279	Oct 30, 2027	DS		NCE	Mar 10, 2025
<u>CENOBAMATE - XCOPRI</u>						
N 212839 006	7598279	Oct 30, 2027	DS		NCE	Mar 10, 2025
<u>CERITINIB - ZYKADIA</u>						
N 205755 001	7893074	Apr 25, 2026	DS DP		ODE-145	May 26, 2024
	7964592	Apr 29, 2028	DS DP			
	8039479	Jun 29, 2030	DS DP			
	8188276	Jan 31, 2023	DS DP			
	8377921	Nov 20, 2027	U-1179			
	8399450	Nov 20, 2027	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CERITINIB - ZYKADIA</u>						
N 205755 001	8703787	Feb 02, 2032	U-1179			
	8835430	Jan 31, 2023	DS DP			
	9018204	Jan 31, 2023	DS DP			
	9309229	Jan 18, 2032	DS DP			
	9416112	Jan 31, 2023	DS DP			
<u>CERITINIB - ZYKADIA</u>						
N 211225 001	7893074	Apr 25, 2026	DS DP		ODE*	May 26, 2024
	7964592	Apr 29, 2028	DS DP			
	8039479	Jun 29, 2030	DS DP			
	8188276	Jan 31, 2023	DS DP			
	8377921	Nov 20, 2027	U-1179			
	8399450	Nov 20, 2027	DS DP			
	8703787	Feb 02, 2032	U-1179			
	8835430	Jan 31, 2023	DS DP			
	9018204	Jan 31, 2023	DS DP			
	9309229	Jan 18, 2032	DS DP			
	9416112	Jan 31, 2023	DS DP			
<u>CETIRIZINE HYDROCHLORIDE - ZERVIAE</u>						
N 208694 001	8829005	Mar 15, 2030	U-1680			
	8829005*PED	Sep 15, 2030				
	9254286	Jul 09, 2032	DP			
	9254286*PED	Jan 09, 2033				
	9750684	Mar 15, 2030	DP			
	9993471	Mar 15, 2030	U-1680			
<u>CETIRIZINE HYDROCHLORIDE - OUZYTTIR</u>						
N 211415 001	8263581	Feb 28, 2030	U-2635			
	8314083	Feb 28, 2030	U-2634			
	8513259	Feb 11, 2030	U-2636			
	9119771	Feb 11, 2030	U-2635			
	9180090	Feb 11, 2030	U-2635			
<u>CETRORELIX ACETATE - CETRORELIX ACETATE</u>						
A 215737 001					CGT	Apr 22, 2023
<u>CHLORHEXIDINE GLUCONATE - CHLORHEXIDINE GLUCONATE</u>						
N 021669 001	7066916	Feb 17, 2024	U-737			
	7427574	Apr 25, 2026	DP			
	7595021	May 12, 2023	DP U-1022			
	7717889	Feb 27, 2025	DP U-1022			
	7935093	Oct 02, 2027	DP U-1022			
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP WITH TINT</u>						
N 020832 002	6729786	Mar 14, 2023	DP			
	6991394	Jan 31, 2024	DP			
	7182536	Dec 30, 2023	DP			
	7241065	Mar 14, 2023	DP			
	7422388	Apr 25, 2027	DP U-1397			
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP WITH TINT</u>						
N 020832 005	6729786	Mar 14, 2023	DP			
	7241065	Mar 14, 2023	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP WITH TINT</u>						
N 020832 005	7422388	Apr 25, 2027	DP U-1397			
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP ONE-STEP</u>						
N 020832 006	6991394	Jan 31, 2024	DP			
	7182536	Dec 30, 2023	DP			
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP WITH TINT</u>						
N 020832 007	6729786	Mar 14, 2023	DP			
	7241065	Mar 14, 2023	DP			
	7422388	Apr 25, 2027	DP U-1397			
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - SOLUPREP</u>						
N 208288 001	8623935	Jul 26, 2029	DP U-1022			
<u>CHLOROPROCAINE HYDROCHLORIDE - CLOROTEKAL</u>						
N 208791 001	8969412	Sep 05, 2026	DP U-2609			
	9504666	Dec 11, 2033	DP			
<u>CHLOROPROCAINE HYDROCHLORIDE - IHEEZO</u>						
N 216227 001	10792271	Sep 15, 2038	DP U-3457			
<u>CHLORPHENIRAMINE MALEATE; CODEINE PHOSPHATE - TUXARIN ER</u>						
N 206323 001	9066942	Jan 03, 2032	U-1716			
	9107921	Jan 03, 2032	DP			
<u>CHLORPHENIRAMINE MALEATE; IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE - ADVIL ALLERGY SINUS</u>						
N 021441 001	7863287	Feb 28, 2027	DP			
<u>CHLORPHENIRAMINE MALEATE; IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE - CHILDREN'S ADVIL ALLERGY SINUS</u>						
N 021587 001	10238640	May 25, 2024	DP			
<u>CHLORPHENIRAMINE POLISTIREX; CODEINE POLISTIREX - TUZISTRA XR</u>						
N 207768 001	8062667	Mar 29, 2029	DP			
	8790700	Mar 15, 2027	DP			
<u>CHOLINE FENOFIBRATE - TRILIPIX</u>						
N 022224 001	7259186	Jan 07, 2025	DS			
<u>CHOLINE FENOFIBRATE - TRILIPIX</u>						
N 022224 002	7259186	Jan 07, 2025	DS			
<u>CICLESONIDE - ALVESCO</u>						
N 021658 002	8371292	Feb 01, 2028	U-1355			
<u>CICLESONIDE - ALVESCO</u>						
N 021658 003	8371292	Feb 01, 2028	U-1355			
<u>CICLESONIDE - OMNARIS</u>						
N 022004 001	8371292	Feb 01, 2028	U-1356			
<u>CICLESONIDE - ZETONNA</u>						
N 202129 001	8371292	Feb 01, 2028	U-1357			
<u>CILASTATIN SODIUM; IMIPENEM; RELEBACTAM - RECARBRIQ</u>						
N 212819 001	8487093	Nov 19, 2029	DS DP U-2586		NCE	Jul 16, 2024
	8487093	Nov 19, 2029	DS DP U-2587		GAIN	Jul 16, 2029
	8487093	Nov 19, 2029	DS DP U-2840			
<u>CINACALCET HYDROCHLORIDE - SENSIPAR</u>						
N 021688 001	7829595	Sep 22, 2026	DP U-1098			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CINACALCET HYDROCHLORIDE - SENSIPAR</u>						
N 021688 001	9375405	Sep 22, 2026	DP			
<u>CINACALCET HYDROCHLORIDE - SENSIPAR</u>						
N 021688 002	7829595	Sep 22, 2026	DP U-1098			
	9375405	Sep 22, 2026	DP			
<u>CINACALCET HYDROCHLORIDE - SENSIPAR</u>						
N 021688 003	7829595	Sep 22, 2026	DP U-1098			
	9375405	Sep 22, 2026	DP			
<u>CIPROFLOXACIN - OTIPRIO</u>						
N 207986 001	11040004	Nov 12, 2037	U-2252			
	11246863	Nov 27, 2038	DP			
	11369566	Apr 21, 2029	DP			
	8318817	Apr 27, 2030	U-1792			
	9205048	Apr 21, 2029	U-1793			
	9220796	Jul 01, 2035	DP			
	9233068	Dec 11, 2029	DP			
	9603796	Apr 21, 2029	DS DP U-2252			
<u>CIPROFLOXACIN HYDROCHLORIDE; FLUOCINOLONE ACETONIDE - OTOVEL</u>						
N 208251 001	8932610	Mar 24, 2030	DP U-1578			
<u>CIPROFLOXACIN; DEXAMETHASONE - CIPRODEX</u>						
N 021537 001	8846650	Jun 04, 2025	DP U-1578			
<u>CITRIC ACID; LACTIC ACID; POTASSIUM BITARTRATE - PHEXXI</u>						
N 208352 001	10568855	Mar 15, 2033	U-1		NP	May 22, 2023
	11337989	Mar 15, 2033	U-1			
	11439610	Mar 15, 2033	DS DP			
	6706276	Mar 06, 2023	DP			
<u>CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE - PREPOPIK</u>						
N 202535 001	8450338	Oct 10, 2028	DP			
	8481083	Oct 10, 2028	DP			
<u>CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE - CLENPIO</u>						
N 209589 001	10624879	Jun 23, 2034	DP			
	11191753	Jun 23, 2034	U-3261			
	9827231	Jun 26, 2034	DP U-2162			
<u>CLADRIBINE - MAVENCLAD</u>						
N 022561 001	10849919	Nov 23, 2038	U-3411			
	7713947	Oct 16, 2026	U-2520			
	7888328	Apr 11, 2024	DP U-2521			
	8377903	May 31, 2026	U-2522			
	8785415	Apr 11, 2024	DP U-2523			
<u>CLASCOTERONE - WINLEVI</u>						
N 213433 001	10159682	Aug 14, 2028	U-2942		NCE	Aug 26, 2025
	11207332	Nov 20, 2028	DP U-3280			
	8143240	Jan 12, 2023	U-2942			
	8785427	Jul 25, 2030	DP			
	8865690	Jul 24, 2023	U-2942			
	9211295	Jul 24, 2023	DP			
	9433628	Feb 28, 2029	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CLASCOTERONE - WINLEVI</u>						
N 213433	001 9486458	Jul 24, 2028	U-2942			
<u>CLEVIDIPINE - CLEVIPREX</u>						
N 022156	001 10010537	Oct 10, 2031	DP			
	11103490	Oct 10, 2031	DP			
	8658676	Oct 10, 2031	DP			
<u>CLEVIDIPINE - CLEVIPREX</u>						
N 022156	002 10010537	Oct 10, 2031	DP			
	11103490	Oct 10, 2031	DP			
	8658676	Oct 10, 2031	DP			
<u>CLEVIDIPINE - CLEVIPREX</u>						
N 022156	003 10010537	Oct 10, 2031	DP			
	11103490	Oct 10, 2031	DP			
	8658676	Oct 10, 2031	DP			
<u>CLINDAMYCIN PHOSPHATE - CLINDAMYCIN PHOSPHATE</u>						
A 214668	001				CGT	Feb 01, 2023
<u>CLINDAMYCIN PHOSPHATE - CLINDESSE</u>						
N 050793	001 6899890	Apr 27, 2023	DP U-137			
	9789057	Dec 02, 2026	DP U-137			
<u>CLINDAMYCIN PHOSPHATE - EVOCLIN</u>						
N 050801	001 7141237	Feb 03, 2024	DP			
	7374747	Jan 23, 2024	DP U-921			
<u>CLINDAMYCIN PHOSPHATE - XACIATO</u>						
N 215650	001 11129896	Sep 22, 2036	U-3293		NP	Dec 07, 2024
					GAIN	Dec 07, 2029
<u>CLOBAZAM - SYMPAZAN</u>						
N 210833	001 11541002	Sep 05, 2039	DP U-724			
	8603514	Apr 03, 2024	DP			
	8765167	Feb 20, 2024	DP			
<u>CLOBAZAM - SYMPAZAN</u>						
N 210833	002 11541002	Sep 05, 2039	DP U-724			
	8603514	Apr 03, 2024	DP			
	8765167	Feb 20, 2024	DP			
<u>CLOBAZAM - SYMPAZAN</u>						
N 210833	003 11541002	Sep 05, 2039	DP U-724			
	8603514	Apr 03, 2024	DP			
	8765167	Feb 20, 2024	DP			
<u>CLOBETASOL PROPIONATE - OLUX E</u>						
N 022013	001 8460641	Nov 05, 2028	DP U-1410			
	8962000	Aug 31, 2025	DP U-1410			
<u>CLOBETASOL PROPIONATE - IMPOYZ</u>						
N 209483	001 10064875	Aug 31, 2030	DP U-1408			
	10064875	Aug 31, 2030	DP U-1858			
	10064875	Aug 31, 2030	DP U-193			
	10064875	Aug 31, 2030	DP U-742			
	10064875	Aug 31, 2030	DP U-88			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CLOBETASOL PROPIONATE - IMPOYZ</u>						
N 209483 001	10588914	Aug 31, 2030	DP U-2771			
	9855334	Mar 11, 2035	DP			
	9956231	Aug 31, 2030	DP U-1408			
	9956231	Aug 31, 2030	DP U-1761			
	9956231	Aug 31, 2030	DP U-1858			
	9956231	Aug 31, 2030	DP U-193			
	9956231	Aug 31, 2030	DP U-742			
	9956231	Aug 31, 2030	DP U-88			
<u>CLONIDINE - NEXICLON XR</u>						
N 022500 001	8337890	Apr 17, 2027	DP			
	8623409	Sep 08, 2031	DP			
<u>CLONIDINE - NEXICLON XR</u>						
N 022500 002	8337890	Apr 17, 2027	DP			
	8623409	Sep 08, 2031	DP			
<u>CLOZAPINE - VERSACLOZ</u>						
N 203479 001	8057811	May 01, 2028	DP			
<u>COBICISTAT - TYBOST</u>						
N 203094 001	10039718	Oct 06, 2032	DP		ODE-260	Aug 22, 2026
	10039718*PED	Apr 06, 2033				
	8148374	Sep 03, 2029	DS DP U-1279			
	8148374*PED	Mar 03, 2030				
<u>COBICISTAT; DARUNAVIR - PREZCOBIX</u>						
N 205395 001	10039718	Oct 06, 2032	DP			
	7700645	Dec 26, 2026	DS DP			
	7700645*PED	Jun 26, 2027				
	8148374	Sep 03, 2029	DS DP U-1279			
	8148374	Sep 03, 2029	DS DP U-2939			
	8518987	Feb 16, 2024	DS DP			
	8518987*PED	Aug 16, 2024				
<u>COBICISTAT; DARUNAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - SYMTUZA</u>						
N 210455 001	10039718	Oct 06, 2032	DP			
	10786518	Jul 19, 2038	U-2978			
	7390791	Apr 17, 2025	DS DP			
	7700645	Dec 26, 2026	DS DP			
	8148374	Sep 03, 2029	DS DP U-2353			
	8148374	Sep 03, 2029	DS DP U-2364			
	8148374	Sep 03, 2029	DS DP U-2365			
	8148374	Sep 03, 2029	DS DP U-2766			
	8148374	Sep 03, 2029	DS DP U-2767			
	8148374	Sep 03, 2029	DS DP U-2768			
	8518987	Feb 16, 2024	DS DP			
	8754065	Aug 15, 2032	DS DP U-2352			
	8754065	Aug 15, 2032	DS DP U-2765			
	9296769	Aug 15, 2032	DS DP U-2352			
	9296769	Aug 15, 2032	DS DP U-2765			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - GENVOYA</u>						
N 207561 001	10039718	Oct 06, 2032	DP			
	10039718*PED	Apr 06, 2033				
	7176220	Aug 27, 2026	DS DP U-257			
	7176220*PED	Feb 27, 2027				
	7390791	Apr 17, 2025	DS DP			
	7390791*PED	Oct 17, 2025				
	7635704	Oct 26, 2026	DS DP U-257			
	7635704*PED	Apr 26, 2027				
	8148374	Sep 03, 2029	DS DP U-1279			
	8148374*PED	Mar 03, 2030				
	8633219	Apr 30, 2030	DP U-257			
	8633219*PED	Oct 30, 2030				
	8754065	Aug 15, 2032	DS DP U-257			
	8754065*PED	Feb 15, 2033				
	8981103	Oct 26, 2026	DS DP			
	8981103*PED	Apr 26, 2027				
	9296769	Aug 15, 2032	DS DP U-257			
	9296769*PED	Feb 15, 2033				
	9891239	Sep 03, 2029	DP U-257			
	9891239*PED	Mar 03, 2030				
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - STRIBILD</u>						
N 203100 001	10039718	Oct 06, 2032	DP			
	10039718*PED	Apr 06, 2033				
	7176220	Aug 27, 2026	DS DP U-257			
	7176220*PED	Feb 27, 2027				
	7635704	Oct 26, 2026	DS DP U-257			
	7635704*PED	Apr 26, 2027				
	8148374	Sep 03, 2029	DS DP U-1279			
	8592397	Jan 13, 2024	DP U-257			
	8633219	Apr 30, 2030	DP U-257			
	8633219*PED	Oct 30, 2030				
	8716264	Jan 13, 2024	DP U-257			
	8981103	Oct 26, 2026	DS DP			
	8981103*PED	Apr 26, 2027				
	9457036	Jan 13, 2024	DP U-257			
	9744181	Jan 13, 2024	DP U-257			
	9891239	Sep 03, 2029	DP U-257			
	9891239*PED	Mar 03, 2030				
<u>COBIMETINIB FUMARATE - COTELLIC</u>						
N 206192 001	10478400	Jun 29, 2036	DS DP U-1776		I-902	Oct 28, 2025
	10478400*PED	Dec 29, 2036			M-278	Jul 28, 2025
	10590102	Jun 30, 2036	DS DP U-1776		PED	Jan 28, 2026
	10590102*PED	Dec 30, 2036				
	11087354	Jun 22, 2034	U-1776			
	11087354*PED	Dec 22, 2034				
	11254649	Jun 30, 2036	DS DP U-1776			
	11254649*PED	Dec 30, 2036				
	7803839	Nov 10, 2029	DS DP			
	7803839*PED	May 10, 2030				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>COBIMETINIB FUMARATE - COTELLIC</u>						
N 206192 001	8362002	Oct 05, 2026	U-1776			
	8362002*PED	Apr 05, 2027				
<u>COCAINE HYDROCHLORIDE - NUMBRINO</u>						
N 209575 001					NP	Jan 10, 2023
<u>COCAINE HYDROCHLORIDE - GOPRELTO</u>						
N 209963 001	10016407	Feb 07, 2037	U-2329			
	10149843	Feb 07, 2037	U-2478			
	10149843	Feb 07, 2037	U-2479			
	10231961	Feb 07, 2037	DP			
	10413505	Feb 07, 2037	U-2479			
	10420760	Feb 07, 2037	U-2478			
	10857095	Feb 07, 2037	U-3014			
	10894012	Feb 07, 2037	U-3014			
	10933060	Feb 07, 2037	U-3014			
	10973811	Feb 07, 2037	U-2226			
	10987347	Feb 07, 2037	U-2225			
	11040032	Feb 07, 2037	DP			
	9867815	Feb 07, 2037	U-2225			
	9867815	Feb 07, 2037	U-2226			
	9867815	Feb 07, 2037	U-2227			
<u>COLCHICINE - COLCRYS</u>						
N 022352 001	7601758	Feb 10, 2029	U-1007			
	7619004	Dec 03, 2028	U-1020			
	7820681	Feb 17, 2029	U-1020			
	7906519	Feb 17, 2029	U-1116			
	7915269	Feb 17, 2029	U-1007			
	7935731	Dec 03, 2028	U-1116			
	7964647	Oct 06, 2028	U-1007			
	7964648	Oct 06, 2028	U-1161			
	7981938	Oct 06, 2028	U-1166			
	8093296	Oct 06, 2028	U-1007			
	8093297	Oct 06, 2028	U-1161			
	8093298	Oct 06, 2028	U-1116			
	8097655	Oct 06, 2028	U-1020			
	8415395	Oct 06, 2028	U-1007			
	8415396	Oct 06, 2028	U-1007			
	8440721	Feb 17, 2029	U-1007			
	8440722	Feb 17, 2029	U-1020			
<u>COLCHICINE - MITIGARE</u>						
N 204820 001	8927607	Aug 22, 2033	U-1020			
	9399036	Aug 22, 2033	U-1020			
	9555029	Aug 22, 2033	U-1020			
	9675613	Aug 22, 2033	U-1020			
	9789108	Aug 22, 2033	U-1020			
<u>COLCHICINE - GLOPERBA</u>						
N 210942 001	10226423	Dec 20, 2037	DP			
	10383820	Nov 22, 2036	DP U-2814			
	10383821	Nov 22, 2036	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>COLCHICINE - GLOPERBA</u>						
N 210942 001	9907751	Nov 22, 2036	DP			
<u>COLESEVELAM HYDROCHLORIDE - WELCHOL</u>						
N 022362 001					M-232	Oct 20, 2024
<u>COLESEVELAM HYDROCHLORIDE - WELCHOL</u>						
N 022362 002					M-232	Oct 20, 2024
<u>COPANLISIB DIHYDROCHLORIDE - ALIQOPA</u>						
N 209936 001	10383876	Mar 29, 2032	DS DP		ODE-155	Sep 14, 2024
	7511041	May 13, 2024	DS DP			
	9636344	Mar 29, 2032		U-2124		
	RE46856	Oct 22, 2029	DS DP	U-2124		
<u>COPPER CU-64 DOTATATE - DETECTNET</u>						
N 213227 001	10159759	Aug 23, 2032		U-2951	NCE	Sep 03, 2025
	10383961	Aug 23, 2032		U-2951	ODE-317	Sep 03, 2027
	11160888	Aug 23, 2032		U-2951		
<u>CRISABOROLE - EUCRISA</u>						
N 207695 001	8039451	Jun 29, 2029	DS DP		NPP	Mar 23, 2023
	8039451*PED	Dec 29, 2029			PED	Sep 23, 2023
	8168614	Jan 20, 2030		U-1932		
	8168614*PED	Jul 20, 2030				
	8501712	Feb 16, 2027		U-1932		
	8501712*PED	Aug 16, 2027				
	9682092	Feb 16, 2027		U-1932		
	9682092*PED	Aug 16, 2027				
<u>CRIZOTINIB - XALKORI</u>						
N 202570 001	7230098	Aug 26, 2025	DS		I-852	Jan 14, 2024
	7825137	May 12, 2027		U-3057	I-897	Jul 14, 2025
	7825137	May 12, 2027		U-3058	ODE-111	Mar 11, 2023
	7825137	May 12, 2027		U-3403	ODE-328	Jan 14, 2028
	7858643	Oct 08, 2029	DS DP			
	8217057	Nov 06, 2029	DS DP			
	8785632	Mar 01, 2025	DS			
<u>CRIZOTINIB - XALKORI</u>						
N 202570 002	7230098	Aug 26, 2025	DS		I-852	Jan 14, 2024
	7825137	May 12, 2027		U-3057	I-897	Jul 14, 2025
	7825137	May 12, 2027		U-3058	ODE-111	Mar 11, 2023
	7825137	May 12, 2027		U-3403	ODE-328	Jan 14, 2028
	7858643	Oct 08, 2029	DS DP			
	8217057	Nov 06, 2029	DS DP			
	8785632	Mar 01, 2025	DS			
<u>CROFELEMER - MYTESI</u>						
N 202292 001	8962680	Oct 31, 2031		U-1319		
	9585868	Oct 31, 2031		U-1319		
<u>CUPRIC SULFATE; MANGANESE SULFATE; SELENIOUS ACID; ZINC SULFATE - TRALEMENT</u>						
N 209376 001					NCE	Apr 30, 2024

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CUPRIC SULFATE; MANGANESE SULFATE; SELENIOUS ACID; ZINC SULFATE - TRALEMENT</u>						
N 209376	002				NCE	Apr 30, 2024
<u>CUPRIC SULFATE; MANGANESE SULFATE; SELENIOUS ACID; ZINC SULFATE - MULTRYS</u>						
N 209376	003				NCE	Apr 30, 2024
<u>CYANOCOBALAMIN - NASCOBAL</u>						
N 021642	001	7229636	Aug 01, 2024	DP U-817		
		7404489	Mar 12, 2024	DP		
		7879349	Aug 01, 2024	DP U-1152		
		8003353	Aug 01, 2024	U-817		
		8940714	Feb 26, 2024	U-1152		
		9415007	Jul 28, 2024	U-1896		
<u>CYCLOBENZAPRINE HYDROCHLORIDE - AMRIX</u>						
N 021777	001	7387793	Feb 26, 2025	DP		
		7544372	Nov 14, 2023	U-979		
		7790199	Nov 14, 2023	DP		
		7820203	Nov 14, 2023	DP		
		7829121	Nov 14, 2023	U-1088		
		8877245	Nov 14, 2023	U-979		
		9375410	Nov 14, 2023	U-1088		
		9399025	Nov 14, 2023	DP U-979		
<u>CYCLOBENZAPRINE HYDROCHLORIDE - AMRIX</u>						
N 021777	002	7387793	Feb 26, 2025	DP		
		7544372	Nov 14, 2023	U-979		
		7790199	Nov 14, 2023	DP		
		7820203	Nov 14, 2023	DP		
		7829121	Nov 14, 2023	U-1088		
		8877245	Nov 14, 2023	U-979		
		9375410	Nov 14, 2023	U-1088		
		9399025	Nov 14, 2023	DP U-979		
<u>CYCLOPHOSPHAMIDE - CYCLOPHOSPHAMIDE</u>						
N 210735	001	9662342	Jun 26, 2035	DP		
<u>CYCLOPHOSPHAMIDE - CYCLOPHOSPHAMIDE</u>						
N 210735	002	9662342	Jun 26, 2035	DP		
<u>CYCLOPHOSPHAMIDE - CYCLOPHOSPHAMIDE</u>						
N 212501	001	10993952	Feb 15, 2036	DP		
<u>CYCLOPHOSPHAMIDE - CYCLOPHOSPHAMIDE</u>						
N 212501	002	10993952	Feb 15, 2036	DP		
<u>CYCLOPHOSPHAMIDE - CYCLOPHOSPHAMIDE</u>						
N 212501	003	10993952	Feb 15, 2036	DP		
<u>CYCLOSPORINE - RESTASIS MULTIDOSE</u>						
N 050790	002	8292129	Feb 25, 2031	DP		
		8561859	Apr 16, 2032	DP		
		8629111	Aug 27, 2024	DP		
		8633162	Aug 27, 2024	U-1479		
		8642556	Aug 27, 2024	DP		
		8648048	Aug 27, 2024	U-1483		
		8685930	Aug 27, 2024	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CYCLOSPORINE - RESTASIS MULTIDOSE</u>						
N 050790 002	9248191	Aug 27, 2024	U-1479			
	9669974	May 11, 2034	DP			
	9676525	Feb 07, 2034	DP			
<u>CYCLOSPORINE - CEQUA</u>						
N 210913 001	10441630	Aug 23, 2033	DP			
	10918694	Feb 28, 2037	DP			
	8980839	Aug 23, 2033	DP U-1483			
	9937225	Aug 23, 2033	DP U-1483			
<u>CYCLOSPORINE - VERKAZIA</u>						
N 214965 001	7973081	Jan 27, 2026	DP		NP	Jun 23, 2023
	8298568	Nov 03, 2027	DP		ODE-358	Jun 23, 2028
	8524779	Jan 27, 2026	DP			
	9132071	Jun 02, 2029	DP			
	9220694	Jan 27, 2026	DP			
	9956289	Jan 27, 2026	DP			
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 001	10143665	Aug 16, 2036	U-1399		ODE-162	Dec 22, 2024
	10143665*PED	Feb 16, 2037			PED	Jun 22, 2025
	10328037	Aug 16, 2036	U-1399			
	10328037*PED	Feb 16, 2037				
	10548859	Aug 16, 2036	U-1399			
	10548859*PED	Feb 16, 2037				
	10905662	Aug 16, 2036	U-1399			
	10905662*PED	Feb 16, 2037				
	8026284	Sep 22, 2027	U-1399			
	8026284*PED	Mar 22, 2028				
	9173851	Jun 17, 2034	DP			
	9173851*PED	Dec 17, 2034				
	9192590	Jan 26, 2027	U-1399			
	9192590*PED	Jul 26, 2027				
	9198882	Jan 26, 2027	U-1399			
	9198882*PED	Jul 26, 2027				
	9233077	Jun 17, 2034	DP			
	9233077*PED	Dec 17, 2034				
	9925156	Jan 26, 2027	DS DP U-1399			
	9925156*PED	Jul 26, 2027				
	9925157	Jan 26, 2027	DS DP U-1399			
	9925157*PED	Jul 26, 2027				
	9925158	Jan 26, 2027	DS DP U-1399			
	9925158*PED	Jul 26, 2027				
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 002	10143665	Aug 16, 2036	U-1399		ODE-162	Dec 22, 2024
	10143665*PED	Feb 16, 2037			PED	Jun 22, 2025
	10328037	Aug 16, 2036	U-1399			
	10328037*PED	Feb 16, 2037				
	10548859	Aug 16, 2036	U-1399			
	10548859*PED	Feb 16, 2037				
	10905662	Aug 16, 2036	U-1399			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 002	10905662*PED	Feb 16, 2037				
	8026284	Sep 22, 2027	U-1399			
	8026284*PED	Mar 22, 2028				
	9173851	Jun 17, 2034	DP			
	9173851*PED	Dec 17, 2034				
	9192590	Jan 26, 2027	U-1399			
	9192590*PED	Jul 26, 2027				
	9198882	Jan 26, 2027	U-1399			
	9198882*PED	Jul 26, 2027				
	9233077	Jun 17, 2034	DP			
	9233077*PED	Dec 17, 2034				
	9925156	Jan 26, 2027	DS DP U-1399			
	9925156*PED	Jul 26, 2027				
	9925157	Jan 26, 2027	DS DP U-1399			
	9925157*PED	Jul 26, 2027				
	9925158	Jan 26, 2027	DS DP U-1399			
	9925158*PED	Jul 26, 2027				
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 213491 001	10143665	Aug 16, 2036	U-1399		ODE*	Dec 22, 2024
	10143665*PED	Feb 16, 2037			ODE*	Dec 22, 2024
	10328037	Aug 16, 2036	U-1399		PED	Jun 22, 2025
	10328037*PED	Feb 16, 2037			PED	Jun 22, 2025
	10548859	Aug 16, 2036	U-1399			
	10548859*PED	Feb 16, 2037				
	10905662	Aug 16, 2036	U-1399			
	10905662*PED	Feb 16, 2037				
	8026284	Sep 22, 2027	U-1399			
	8026284*PED	Mar 22, 2028				
	9173851	Jun 17, 2034	DP			
	9173851*PED	Dec 17, 2034				
	9192590	Jan 26, 2027	U-1399			
	9192590*PED	Jul 26, 2027				
	9198882	Jan 26, 2027	U-1399			
	9198882*PED	Jul 26, 2027				
	9233077	Jun 17, 2034	DP			
	9233077*PED	Dec 17, 2034				
	9925156	Jan 26, 2027	DP U-1399			
	9925156*PED	Jul 26, 2027				
	9925157	Jan 26, 2027	DP U-1399			
	9925157*PED	Jul 26, 2027				
	9925158	Jan 26, 2027	DP U-1399			
	9925158*PED	Jul 26, 2027				
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 213491 002	10143665	Aug 16, 2036	U-1399		ODE*	Dec 22, 2024
	10143665*PED	Feb 16, 2037			ODE*	Dec 22, 2024
	10328037	Aug 16, 2036	U-1399		PED	Jun 22, 2025
	10328037*PED	Feb 16, 2037			PED	Jun 22, 2025
	10548859	Aug 16, 2036	U-1399			
	10548859*PED	Feb 16, 2037				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 213491 002	10905662	Aug 16, 2036	U-1399			
	10905662*PED	Feb 16, 2037				
	8026284	Sep 22, 2027	U-1399			
	8026284*PED	Mar 22, 2028				
	9173851	Jun 17, 2034	DP			
	9173851*PED	Dec 17, 2034				
	9192590	Jan 26, 2027	U-1399			
	9192590*PED	Jul 26, 2027				
	9198882	Jan 26, 2027	U-1399			
	9198882*PED	Jul 26, 2027				
	9233077	Jun 17, 2034	DP			
	9233077*PED	Dec 17, 2034				
	9925156	Jan 26, 2027	DP U-1399			
	9925156*PED	Jul 26, 2027				
	9925157	Jan 26, 2027	DP U-1399			
	9925157*PED	Jul 26, 2027				
	9925158	Jan 26, 2027	DP U-1399			
	9925158*PED	Jul 26, 2027				
<u>CYSTEAMINE HYDROCHLORIDE - CYSTADROPS</u>						
N 211302 001					NP	Aug 19, 2023
<u>CYSTEINE HYDROCHLORIDE - ELCYS</u>						
N 210660 001	10478453	Jan 15, 2039	DP U-2752			
	10583155	Jan 15, 2039	DP U-2752			
	10653719	Jan 15, 2039	DP			
	10905713	Jan 15, 2039	DP			
	10905714	Jan 15, 2039	DP			
	10912795	Jan 15, 2039	DP			
	10918662	Jan 15, 2039	DP			
	10933089	Jan 15, 2039	DP			
	11510941	Jan 15, 2039	DP			
	11510942	Jan 15, 2039	DP U-2752			
<u>CYSTEINE HYDROCHLORIDE - NOURESS</u>						
N 212535 001	10478453	Jan 15, 2039	DP U-2752			
	10493051	Mar 15, 2039	DP			
	10543186	Mar 15, 2039	U-2722			
	10583155	Jan 15, 2039	DP U-2752			
	10653719	Jan 15, 2039	DP			
	10702490	Mar 15, 2039	DP			
	10905713	Jan 15, 2039	DP			
	10905714	Jan 15, 2039	DP			
	10912795	Jan 15, 2039	DP			
	10918662	Jan 15, 2039	DP			
	10933089	Jan 15, 2039	DP			
	11045438	Mar 15, 2039	DP			
<u>CYTARABINE; DAUNORUBICIN - VYXEOS</u>						
N 209401 001	10028912	Sep 29, 2034	DP U-3149		NPP	Mar 30, 2024
	10028912	Sep 29, 2034	DP U-3150		ODE-287	Aug 03, 2024
	10166184	Oct 15, 2032	DP U-3149		ODE-350	Mar 30, 2028

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CYTARABINE; DAUNORUBICIN - VYXEOS</u>						
N 209401 001	10835492	Oct 15, 2032	U-3150			
	7850990	Jan 23, 2027	DP U-3147			
	8022279	Sep 14, 2027	DP U-3147			
	8092828	Apr 01, 2029	U-3147			
	8431806	Apr 22, 2025	DP U-3147			
	8518437	Jun 07, 2026	DP			
	9271931	Jan 23, 2027	DP			
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 022512 001	7866474	Aug 31, 2027	DP	Y	I-862	Jun 21, 2024
	7932273	Sep 07, 2025	DS DP		PED	Dec 21, 2024
	9034822	Jan 20, 2031	U-1759			
	9034822*PED	Jul 20, 2031				
	9925174	Jun 14, 2023	DP			
	9925174*PED	Dec 14, 2023				
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 022512 002	7866474	Aug 31, 2027	DP	Y	I-862	Jun 21, 2024
	7932273	Sep 07, 2025	DS DP		PED	Dec 21, 2024
	9034822	Jan 20, 2031	U-1759			
	9034822*PED	Jul 20, 2031				
	9925174	Jun 14, 2023	DP			
	9925174*PED	Dec 14, 2023				
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 022512 003	7866474	Aug 31, 2027	DP	Y	I-862	Jun 21, 2024
	7866474*PED	Mar 02, 2028			PED	Dec 21, 2024
	7932273	Sep 07, 2025	DS DP			
	7932273*PED	Mar 07, 2026				
	9034822	Jan 20, 2031	U-1759			
	9034822*PED	Jul 20, 2031				
	9925174	Jun 14, 2023	DP			
	9925174*PED	Dec 14, 2023				
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 214358 001	7932273	Sep 07, 2025	DS DP		NP	Jun 21, 2024
	7932273*PED	Mar 07, 2026			PED	Dec 21, 2024
	9925174	Jun 14, 2023	DP			
	9925174*PED	Dec 14, 2023				
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 214358 002	7932273	Sep 07, 2025	DS DP		NP	Jun 21, 2024
	7932273*PED	Mar 07, 2026			PED	Dec 21, 2024
	9925174	Jun 14, 2023	DP			
	9925174*PED	Dec 14, 2023				
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 214358 003	7932273	Sep 07, 2025	DS DP		NP	Jun 21, 2024
	7932273*PED	Mar 07, 2026			PED	Dec 21, 2024
	9925174	Jun 14, 2023	DP			
	9925174*PED	Dec 14, 2023				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 214358 004	7932273	Sep 07, 2025	DS DP		NP	Jun 21, 2024
	7932273*PED	Mar 07, 2026			PED	Dec 21, 2024
	9925174	Jun 14, 2023	DP			
	9925174*PED	Dec 14, 2023				
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 214358 005	7932273	Sep 07, 2025	DS DP		NP	Jun 21, 2024
	7932273*PED	Mar 07, 2026			PED	Dec 21, 2024
	9925174	Jun 14, 2023	DP			
	9925174*PED	Dec 14, 2023				
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 214358 006	7932273	Sep 07, 2025	DS DP		NP	Jun 21, 2024
	7932273*PED	Mar 07, 2026			PED	Dec 21, 2024
	9925174	Jun 14, 2023	DP			
	9925174*PED	Dec 14, 2023				
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 001	10869869	Aug 30, 2033	U-3185		I-894	Jun 22, 2025
	7994185	Jan 20, 2030	DS DP U-1406		ODE-147	Jun 22, 2024
	7994185	Jan 20, 2030	DS DP U-2031		ODE-182	Apr 30, 2025
	7994185	Jan 20, 2030	DS DP U-2032		ODE-183	May 04, 2025
	7994185	Jan 20, 2030	DS DP U-2296			
	8415345	Jan 20, 2030	DS DP U-1406			
	8415345	Jan 20, 2030	DS DP U-2031			
	8415345	Jan 20, 2030	DS DP U-2032			
	8415345	Jan 20, 2030	DS DP U-2296			
	8703781	Oct 15, 2030	DS DP U-1713			
	8703781	Oct 15, 2030	DS DP U-2032			
	8703781	Oct 15, 2030	DS DP U-2296			
	8703781	Oct 15, 2030	DS DP U-2298			
	8835443	Jun 10, 2025	U-2026			
	8835443	Jun 10, 2025	U-2027			
	8835443	Jun 10, 2025	U-2296			
	8835443	Jun 10, 2025	U-2298			
	8952018	Oct 15, 2030	U-2027			
	9233956	May 04, 2029	U-1811			
	9233956	May 04, 2029	U-2031			
	9233956	May 04, 2029	U-2032			
	9233956	May 04, 2029	U-2296			
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 002	10869869	Aug 30, 2033	U-3185		I-894	Jun 22, 2025
	7994185	Jan 20, 2030	DS DP U-1406		ODE-147	Jun 22, 2024
	7994185	Jan 20, 2030	DS DP U-2031		ODE-182	Apr 30, 2025
	7994185	Jan 20, 2030	DS DP U-2032		ODE-183	May 04, 2025
	7994185	Jan 20, 2030	DS DP U-2296			
	8415345	Jan 20, 2030	DS DP U-1406			
	8415345	Jan 20, 2030	DS DP U-2031			
	8415345	Jan 20, 2030	DS DP U-2032			
	8415345	Jan 20, 2030	DS DP U-2296			
	8703781	Oct 15, 2030	DS DP U-1713			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 002	8703781	Oct 15, 2030	DS DP U-2032			
	8703781	Oct 15, 2030	DS DP U-2296			
	8703781	Oct 15, 2030	DS DP U-2298			
	8835443	Jun 10, 2025	U-2026			
	8835443	Jun 10, 2025	U-2027			
	8835443	Jun 10, 2025	U-2296			
	8835443	Jun 10, 2025	U-2298			
	8952018	Oct 15, 2030	U-2027			
	9233956	May 04, 2029	U-1811			
	9233956	May 04, 2029	U-2031			
	9233956	May 04, 2029	U-2032			
	9233956	May 04, 2029	U-2296			
<u>DACLATASVIR DIHYDROCHLORIDE - DAKLINZA</u>						
N 206843 001	8329159	Jul 24, 2029	DS			
	8629171	Jun 13, 2031	DS DP U-1724			
	8642025	Aug 11, 2027	DS DP U-1724			
	8642025	Aug 11, 2027	DS DP U-1725			
	8900566	Aug 08, 2027	U-1724			
	8900566	Aug 08, 2027	U-1725			
	9421192	Aug 08, 2027	DS U-1724			
	9421192	Aug 08, 2027	DS U-1725			
<u>DACLATASVIR DIHYDROCHLORIDE - DAKLINZA</u>						
N 206843 002	8329159	Jul 24, 2029	DS			
	8629171	Jun 13, 2031	DS DP U-1724			
	8642025	Aug 11, 2027	DS DP U-1724			
	8642025	Aug 11, 2027	DS DP U-1725			
	8900566	Aug 08, 2027	U-1724			
	8900566	Aug 08, 2027	U-1725			
	9421192	Aug 08, 2027	DS U-1724			
	9421192	Aug 08, 2027	DS U-1725			
<u>DACLATASVIR DIHYDROCHLORIDE - DAKLINZA</u>						
N 206843 003	9421192	Aug 08, 2027	DS U-1724			
	9421192	Aug 08, 2027	DS U-1725			
<u>DACOMITINIB - VIZIMPRO</u>						
N 211288 001	10596162	Feb 02, 2026	U-3338		NCE	Sep 27, 2023
	10603314	Feb 02, 2026	U-3337		ODE-206	Sep 27, 2025
	7772243	Aug 26, 2028	DS DP		ODE-213	Sep 27, 2025
	8623883	May 05, 2025	U-1403			
<u>DACOMITINIB - VIZIMPRO</u>						
N 211288 002	10596162	Feb 02, 2026	U-3338		NCE	Sep 27, 2023
	10603314	Feb 02, 2026	U-3337		ODE-206	Sep 27, 2025
	7772243	Aug 26, 2028	DS DP		ODE-213	Sep 27, 2025
	8623883	May 05, 2025	U-1403			
<u>DACOMITINIB - VIZIMPRO</u>						
N 211288 003	10596162	Feb 02, 2026	U-3338		NCE	Sep 27, 2023
	10603314	Feb 02, 2026	U-3337		ODE-206	Sep 27, 2025
	7772243	Aug 26, 2028	DS DP		ODE-213	Sep 27, 2025

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DACOMITINIB - VIZIMPRO</u>						
N 211288 003	8623883	May 05, 2025	U-1403			
<u>DALBAVANCIN HYDROCHLORIDE - DALVANCE</u>						
N 021883 001	6900175	Dec 25, 2023	U-1517		NCE	May 23, 2019
	7115564	Nov 14, 2023	DP		NPP	Jul 22, 2024
	7119061	Nov 14, 2023	DP		GAIN	May 23, 2024
	8143212	Nov 14, 2023	U-1517			
<u>DANTROLENE SODIUM - RYANODEX</u>						
N 205579 001	7758890	Jun 30, 2025	DP			
	8685460	Feb 15, 2023	U-1546			
<u>DAPAGLIFLOZIN - FARXIGA</u>						
N 202293 001	6515117	Oct 04, 2025	DS DP U-2139		I-834	May 05, 2023
	6515117	Oct 04, 2025	DS DP U-493		I-857	Apr 30, 2024
	7456254	Jun 30, 2025	DP U-2139			
	7851502	Aug 19, 2028	DP			
	7919598	Dec 16, 2029	DS			
	8221786	Mar 21, 2028	DP			
	8329648	Aug 18, 2026	U-2139			
	8329648	Aug 18, 2026	U-2212			
	8329648	Aug 18, 2026	U-2213			
	8361972	Mar 21, 2028	U-2139			
	8361972	Mar 21, 2028	U-493			
	8431685	Apr 13, 2025	DP U-2139			
	8461105	Apr 13, 2025	DP U-2139			
	8501698	Jun 20, 2027	DP U-493			
	8685934	May 26, 2030	U-1522			
	8716251	Mar 21, 2028	DP			
	8721615	Jan 18, 2030	DP	Y		
	8906851	Aug 18, 2026	U-2139			
	9238076	Apr 15, 2024	DP U-2139			
<u>DAPAGLIFLOZIN - FARXIGA</u>						
N 202293 002	10973836	Mar 09, 2040	U-3127		I-834	May 05, 2023
	6515117	Oct 04, 2025	DS DP U-2139		I-857	Apr 30, 2024
	6515117	Oct 04, 2025	DS DP U-493			
	7456254	Jun 30, 2025	DP U-2139			
	7851502	Aug 19, 2028	DP			
	7919598	Dec 16, 2029	DS			
	8221786	Mar 21, 2028	DP			
	8329648	Aug 18, 2026	U-2139			
	8329648	Aug 18, 2026	U-2212			
	8329648	Aug 18, 2026	U-2213			
	8361972	Mar 21, 2028	U-2139			
	8361972	Mar 21, 2028	U-493			
	8431685	Apr 13, 2025	DP U-2139			
	8461105	Apr 13, 2025	DP U-2139			
	8501698	Jun 20, 2027	DP U-493			
	8685934	May 26, 2030	U-1522			
	8716251	Mar 21, 2028	DP			
	8721615	Jan 18, 2030	DP	Y		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DAPAGLIFLOZIN - FARXIGA</u>						
N 202293 002	8906851	Aug 18, 2026	U-2139			
	9238076	Apr 15, 2024	DP U-2139			
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 001	6515117	Oct 04, 2025	DS DP U-493			
	7919598	Dec 16, 2029	DS			
	8501698	Jun 20, 2027	DP U-493			
	8685934	May 26, 2030	U-1522			
	9616028	Nov 12, 2030	DP			
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 002	6515117	Oct 04, 2025	DS DP U-493			
	7919598	Dec 16, 2029	DS			
	8501698	Jun 20, 2027	DP U-493			
	8685934	May 26, 2030	U-1522			
	9616028	Nov 12, 2030	DP			
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 003	6515117	Oct 04, 2025	DS DP U-493			
	7919598	Dec 16, 2029	DS			
	8501698	Jun 20, 2027	DP U-493			
	8685934	May 26, 2030	U-1522			
	9616028	Nov 12, 2030	DP			
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 004	6515117	Oct 04, 2025	DS DP U-493			
	7919598	Dec 16, 2029	DS			
	8501698	Jun 20, 2027	DP U-493			
	8685934	May 26, 2030	U-1522			
	9616028	Nov 12, 2030	DP			
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 005	6515117	Oct 04, 2025	DS DP U-493			
	7919598	Dec 16, 2029	DS			
	8501698	Jun 20, 2027	DP U-493			
	8685934	May 26, 2030	U-1522			
	9616028	Nov 12, 2030	DP			
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - QTERNMET XR</u>						
N 210874 001	6515117	Oct 04, 2025	DS DP U-493			
	7919598	Dec 16, 2029	DS			
	8501698	Jun 20, 2027	DP U-493			
	8628799	Jul 13, 2025	DP			
	8716251	Mar 21, 2028	DP			
	9616028	Nov 12, 2030	DP			
	RE44186	Jul 31, 2023	DS DP U-493			
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - QTERNMET XR</u>						
N 210874 002	6515117	Oct 04, 2025	DS DP U-493			
	7919598	Dec 16, 2029	DS			
	8501698	Jun 20, 2027	DP U-493			
	8628799	Jul 13, 2025	DP			
	8716251	Mar 21, 2028	DP			
	9616028	Nov 12, 2030	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - QTERNMET XR</u>						
N 210874 002	RE44186	Jul 31, 2023	DS DP U-493			
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - QTERNMET XR</u>						
N 210874 003	6515117	Oct 04, 2025	DS DP U-493			
	7919598	Dec 16, 2029	DS			
	8501698	Jun 20, 2027	DP U-493			
	8628799	Jul 13, 2025	DP			
	8716251	Mar 21, 2028	DP			
	9616028	Nov 12, 2030	DP			
	RE44186	Jul 31, 2023	DS DP U-493			
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - QTERNMET XR</u>						
N 210874 004	6515117	Oct 04, 2025	DS DP U-493			
	7919598	Dec 16, 2029	DS			
	8501698	Jun 20, 2027	DP U-493			
	8628799	Jul 13, 2025	DP			
	8716251	Mar 21, 2028	DP			
	9616028	Nov 12, 2030	DP			
	RE44186	Jul 31, 2023	DS DP U-493			
<u>DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE - QTERN</u>						
N 209091 001	6515117	Oct 04, 2025	DS DP U-493			
	7919598	Dec 16, 2029	DS			
	8221786	Mar 21, 2028	DP			
	8361972	Mar 21, 2028	U-1976			
	8361972	Mar 21, 2028	U-1977			
	8361972	Mar 21, 2028	U-493			
	8501698	Jun 20, 2027	DP U-1976			
	8501698	Jun 20, 2027	DP U-1977			
	8501698	Jun 20, 2027	DP U-493			
	8628799	Jul 13, 2025	DP			
	8716251	Mar 21, 2028	DP			
	RE44186	Jul 31, 2023	DS DP U-493			
<u>DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE - QTERN</u>						
N 209091 002	6515117	Oct 04, 2025	DS DP U-493			
	7919598	Dec 16, 2029	DS			
	8221786	Mar 21, 2028	DP			
	8361972	Mar 21, 2028	U-493			
	8501698	Jun 20, 2027	DP U-493			
	8628799	Jul 13, 2025	DP			
	8716251	Mar 21, 2028	DP			
	RE44186	Jul 31, 2023	DS DP U-493			
<u>DAPSONE - ACZONE</u>						
N 207154 001	11273132	Nov 18, 2033	DP			
	9161926	Nov 18, 2033	DP			
	9517219	Nov 18, 2033	U-1033			
<u>DAPTOMYCIN - CUBICIN</u>						
N 021572 002	8003673	Sep 04, 2028	U-1180			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DAPTOMYCIN - CUBICIN RF</u>						
N 021572	003 9138456	Nov 23, 2030	DP			
<u>DAPTOMYCIN - DAPTOMYCIN</u>						
N 210282	001 10357535	Sep 11, 2033	DP U-3176			
	9655946	Sep 11, 2033	DP U-3175			
<u>DAPTOMYCIN - DAPTOMYCIN</u>						
N 210282	002 10357535	Sep 11, 2033	DP U-3176			
	9655946	Sep 11, 2033	DP U-3175			
<u>DAPTOMYCIN - DAPZURA RT</u>						
N 213645	001 11173189	Mar 11, 2041	DP U-3294			
<u>DARIDOREXANT HYDROCHLORIDE - QUVIVIQ</u>						
N 214985	001 10023560	Dec 02, 2034	U-620		NCE	Apr 07, 2027
	9732075	Jun 12, 2033	DS DP U-620			
	9790208	Dec 02, 2034	DS DP			
<u>DARIDOREXANT HYDROCHLORIDE - QUVIVIQ</u>						
N 214985	002 10023560	Dec 02, 2034	U-620		NCE	Apr 07, 2027
	9732075	Jun 12, 2033	DS DP U-620			
	9790208	Dec 02, 2034	DS DP			
<u>DAROLUTAMIDE - NUBEQA</u>						
N 212099	001 10010530	Jan 28, 2036	DS		I-900	Aug 05, 2025
	10383853	Jan 28, 2036	DS		NCE	Jul 30, 2024
	10711013	Oct 27, 2030	DS DP			
	10835515	Jan 28, 2036	DP U-2605			
	11046713	Oct 27, 2030	DS			
	11168058	Feb 27, 2038	DS DP			
	8975254	Oct 27, 2030	DS DP U-2605			
	9657003	Oct 27, 2030	DS DP U-2605			
<u>DARUNAVIR - PREZISTA</u>						
N 021976	001 7700645	Dec 26, 2026	DS DP			
	8518987	Feb 16, 2024	DS DP			
	8518987*PED	Aug 16, 2024				
<u>DARUNAVIR - PREZISTA</u>						
N 021976	002 7700645	Dec 26, 2026	DS DP			
	8518987	Feb 16, 2024	DS DP			
	8518987*PED	Aug 16, 2024				
<u>DARUNAVIR - PREZISTA</u>						
N 021976	003 7700645	Dec 26, 2026	DS DP			
	8518987	Feb 16, 2024	DS DP			
	8518987*PED	Aug 16, 2024				
<u>DARUNAVIR - PREZISTA</u>						
N 021976	004 7700645	Dec 26, 2026	DS DP			
	8518987	Feb 16, 2024	DS DP			
	8518987*PED	Aug 16, 2024				
<u>DARUNAVIR - PREZISTA</u>						
N 021976	005 7700645	Dec 26, 2026	DS DP			
	8518987	Feb 16, 2024	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DARUNAVIR - PREZISTA</u>						
N 021976	005 8518987*PED	Aug 16, 2024				
<u>DARUNAVIR - PREZISTA</u>						
N 021976	006 7700645	Dec 26, 2026	DS DP			
	8518987	Feb 16, 2024	DS DP			
	8518987*PED	Aug 16, 2024				
<u>DARUNAVIR - PREZISTA</u>						
N 202895	001 7700645	Dec 26, 2026	DS DP			
	8518987	Feb 16, 2024	DS DP			
	8518987*PED	Aug 16, 2024				
<u>DASABUVIR SODIUM; OMBITASVIR, PARITAPREVIR, RITONAVIR - VIEKIRA PAK (COPACKAGED)</u>						
N 206619	001 10201542	Oct 18, 2033	DP U-1753			
	8188104	May 17, 2029	DS DP U-1636			
	8268349	Aug 25, 2024	DP			
	8399015	Aug 25, 2024	DP			
	8420596	Apr 10, 2031	DS DP			
	8466159	Sep 04, 2032	U-1637			
	8492386	Sep 04, 2032	U-1840			
	8501238	Dec 19, 2028	DS DP U-1636			
	8642538	Sep 10, 2029	DS DP U-1638			
	8680106	Sep 04, 2032	U-1637			
	8685984	Sep 04, 2032	U-1840			
	8686026	Jun 09, 2031	DP			
	8691938	Apr 13, 2032	DS DP			
	9006387	Jun 10, 2030	U-1687			
	9044480	Apr 10, 2031	U-1638			
	9139536	Nov 09, 2028	U-1753			
	9629841	Oct 18, 2033	DP U-1753			
<u>DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR - VIEKIRA XR</u>						
N 208624	001 10105365	Jan 02, 2035	DP U-1889			
	10201541	May 17, 2032	DP			
	10201584	May 17, 2032	U-1889			
	8188104	May 17, 2029	DS DP U-1636			
	8268349	Aug 25, 2024	DP			
	8399015	Aug 25, 2024	DP			
	8420596	Apr 10, 2031	DS DP			
	8466159	Sep 04, 2032	U-1637			
	8492386	Sep 04, 2032	U-1840			
	8501238	Sep 17, 2028	DS DP U-1636			
	8642538	Sep 10, 2029	DS DP U-1638			
	8680106	Sep 04, 2032	U-1637			
	8685984	Sep 04, 2032	U-1840			
	8686026	Jun 09, 2031	DP			
	8691938	Apr 13, 2032	DS DP			
	9006387	Jun 10, 2030	U-1687			
	9044480	Apr 10, 2031	U-1638			
	9139536	Nov 09, 2028	U-1753			
	9333204	Jan 02, 2035	DP U-1889			
	9744170	Jan 02, 2035	DP U-1889			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR - VIEKIRA XR</u>						
N 208624 001	10105365	Jan 02, 2035	DP U-1889			
	10201541	May 17, 2032	DP			
	10201584	May 17, 2032	U-1889			
	8188104	May 17, 2029	DS DP U-1636			
	8268349	Aug 25, 2024	DP			
	8399015	Aug 25, 2024	DP			
	8420596	Apr 10, 2031	DS DP			
	8466159	Sep 04, 2032	U-1637			
	8492386	Sep 04, 2032	U-1840			
	8501238	Sep 17, 2028	DS DP U-1636			
	8642538	Sep 10, 2029	DS DP U-1638			
	8680106	Sep 04, 2032	U-1637			
	8685984	Sep 04, 2032	U-1840			
	8686026	Jun 09, 2031	DP			
	8691938	Apr 13, 2032	DS DP			
	9006387	Jun 10, 2030	U-1687			
	9044480	Apr 10, 2031	U-1638			
	9139536	Nov 09, 2028	U-1753			
	9333204	Jan 02, 2035	DP U-1889			
	9744170	Jan 02, 2035	DP U-1889			
<u>DASATINIB - SPRYCEL</u>						
N 021986 001	7491725	Mar 28, 2026	DS DP		ODE-164	Nov 09, 2024
	7491725*PED	Sep 28, 2026			ODE-225	Dec 21, 2025
	8680103	Feb 04, 2025	DP		PED	May 09, 2025
	8680103*PED	Aug 04, 2025			PED	Jun 21, 2026
<u>DASATINIB - SPRYCEL</u>						
N 021986 002	7491725	Mar 28, 2026	DS DP		ODE-164	Nov 09, 2024
	7491725*PED	Sep 28, 2026			ODE-225	Dec 21, 2025
	8680103	Feb 04, 2025	DP		PED	May 09, 2025
	8680103*PED	Aug 04, 2025			PED	Jun 21, 2026
<u>DASATINIB - SPRYCEL</u>						
N 021986 003	7491725	Mar 28, 2026	DS DP		ODE-164	Nov 09, 2024
	7491725*PED	Sep 28, 2026			ODE-225	Dec 21, 2025
	8680103	Feb 04, 2025	DP		PED	May 09, 2025
	8680103*PED	Aug 04, 2025			PED	Jun 21, 2026
<u>DASATINIB - SPRYCEL</u>						
N 021986 004	7491725	Mar 28, 2026	DS DP		ODE-164	Nov 09, 2024
	7491725*PED	Sep 28, 2026			ODE-225	Dec 21, 2025
	8680103	Feb 04, 2025	DP		PED	May 09, 2025
	8680103*PED	Aug 04, 2025			PED	Jun 21, 2026
<u>DASATINIB - SPRYCEL</u>						
N 021986 005	7491725	Mar 28, 2026	DS DP		ODE-164	Nov 09, 2024
	7491725*PED	Sep 28, 2026			ODE-225	Dec 21, 2025
	8680103	Feb 04, 2025	DP		PED	May 09, 2025
	8680103*PED	Aug 04, 2025			PED	Jun 21, 2026

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DASATINIB - SPRYCEL</u>						
N 021986 006	7491725	Mar 28, 2026	DS DP		ODE-164	Nov 09, 2024
	7491725*PED	Sep 28, 2026			ODE-225	Dec 21, 2025
	8680103	Feb 04, 2025	DP		PED	May 09, 2025
	8680103*PED	Aug 04, 2025			PED	Jun 21, 2026
<u>DASIGLUCAGON HYDROCHLORIDE - ZEGALOGUE</u>						
N 214231 001	10442847	Feb 03, 2035	DS DP		NCE	Mar 22, 2026
<u>DASIGLUCAGON HYDROCHLORIDE - ZEGALOGUE (AUTOINJECTOR)</u>						
N 214231 002	10442847	Feb 03, 2035	DS DP		NCE	Mar 22, 2026
<u>DEFERASIROX - EXJADE</u>						
N 021882 001					M-263	Jul 23, 2023
<u>DEFERASIROX - EXJADE</u>						
N 021882 002					M-263	Jul 23, 2023
<u>DEFERASIROX - EXJADE</u>						
N 021882 003					M-263	Jul 23, 2023
<u>DEFERASIROX - JADENU</u>						
N 206910 001	9283209	Nov 21, 2034	DS DP		M-263	Jul 23, 2023
<u>DEFERASIROX - JADENU</u>						
N 206910 002	9283209	Nov 21, 2034	DS DP		M-263	Jul 23, 2023
<u>DEFERASIROX - JADENU</u>						
N 206910 003	9283209	Nov 21, 2034	DS DP		M-263	Jul 23, 2023
<u>DEFERASIROX - JADENU SPRINKLE</u>						
N 207968 001					M-263	Jul 23, 2023
<u>DEFERASIROX - JADENU SPRINKLE</u>						
N 207968 002					M-263	Jul 23, 2023
<u>DEFERASIROX - JADENU SPRINKLE</u>						
N 207968 003					M-263	Jul 23, 2023
<u>DEFERIPRONE - FERRIPROX</u>						
N 021825 001					I-859	Apr 30, 2024
<u>DEFERIPRONE - FERRIPROX</u>						
N 021825 002					I-859	Apr 30, 2024
<u>DEFERIPRONE - FERRIPROX</u>						
N 208030 001	8703156	Oct 26, 2029	DP U-3083		I-859	Apr 30, 2024
<u>DEFERIPRONE - FERRIPROX</u>						
N 208030 002	8703156	Oct 26, 2029	DP U-3083		I-859	Apr 30, 2024
<u>DEFERIPRONE - FERRIPROX</u>						
N 212269 001	10780055	Oct 25, 2038	DP U-3083		I-859	Apr 30, 2024
	10940115	Oct 25, 2038	DP U-3083			
	10940116	Oct 25, 2038	DP			
	11357731	Oct 25, 2038	U-3083			
	11458103	Oct 25, 2038	DP			
<u>DEFIBROTIDE SODIUM - DEFITELIO</u>						
N 208114 001	11085043	Jun 22, 2032	DP		ODE-112	Mar 30, 2023
	11236328	Jun 22, 2032	U-3301			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEFLAZACORT - EMFLAZA</u>						
N 208684 001					ODE-130	Feb 09, 2024
					ODE-252	Jun 07, 2026
<u>DEFLAZACORT - EMFLAZA</u>						
N 208684 002					ODE-130	Feb 09, 2024
					ODE-252	Jun 07, 2026
<u>DEFLAZACORT - EMFLAZA</u>						
N 208684 003					ODE-130	Feb 09, 2024
					ODE-252	Jun 07, 2026
<u>DEFLAZACORT - EMFLAZA</u>						
N 208684 004					ODE-130	Feb 09, 2024
					ODE-252	Jun 07, 2026
<u>DEFLAZACORT - EMFLAZA</u>						
N 208685 001					ODE-130	Feb 09, 2024
					ODE-252	Jun 07, 2026
<u>DEGARELIX ACETATE - FIRMAGON</u>						
N 022201 001	10695398	Apr 27, 2032	U-1895			
	10729739	Feb 10, 2029	U-1978			
	10973870	Feb 10, 2029	U-1978			
	9415085	Apr 27, 2032	U-1895			
	9579359	Feb 10, 2029	U-1978			
<u>DEGARELIX ACETATE - FIRMAGON</u>						
N 022201 002	10695398	Apr 27, 2032	U-1895			
	10729739	Feb 10, 2029	U-1978			
	10973870	Feb 10, 2029	U-1978			
	9415085	Apr 27, 2032	U-1895			
	9579359	Feb 10, 2029	U-1978			
<u>DELAFLUXACIN MEGLUMINE - BAXDELA</u>						
N 208610 001	7728143	Jun 19, 2031	DS		NCE	Jun 19, 2022
	8252813	Oct 02, 2026	DP U-2028		GAIN	Jun 19, 2027
	8273892	Aug 06, 2026	DS			
	8648093	Oct 07, 2025	DP U-2028			
	8871938	Sep 23, 2029	DS			
	8969569	Oct 07, 2025	DP U-2028			
	9539250	Oct 07, 2025	DS DP U-2028			
	RE46617	Dec 28, 2029	DS			
<u>DELAFLUXACIN MEGLUMINE - BAXDELA</u>						
N 208611 001	7635773	Mar 13, 2029	DP		NCE	Jun 19, 2022
	7728143	Jun 19, 2031	DS		GAIN	Jun 19, 2027
	8252813	Oct 02, 2026	DP U-2028			
	8273892	Aug 06, 2026	DS			
	8410077	Mar 13, 2029	DP			
	8648093	Oct 07, 2025	DP U-2028			
	8871938	Sep 23, 2029	DS			
	9200088	Mar 13, 2029	DP			
	9493582	Feb 27, 2033	DP			
	9539250	Oct 07, 2025	DS DP U-2028			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DELAFLORACIN MEGLUMINE - BAXDELA</u>						
N 208611 001	9750822	Mar 13, 2029	DP			
	RE46617	Dec 28, 2029	DS			
<u>DEOXYCHOLIC ACID - KYBELLA</u>						
N 206333 001	10500214	Mar 02, 2030	DP			
	7622130	Dec 10, 2027	U-1690			
	7754230	Dec 10, 2027	U-1690			
	8101593	Mar 02, 2030	DP			
	8242294	May 16, 2028	DS			
	8298556	Aug 03, 2025	U-1690			
	8367649	Mar 02, 2030	DP			
	8461140	Feb 21, 2028	DP			
	8546367	Feb 21, 2028	DP U-1690			
	8653058	Mar 02, 2030	DP			
	8846066	Feb 08, 2025	U-1690			
	8883770	Feb 21, 2028	DP			
	9522155	Feb 21, 2028	DP U-1940			
	9636349	Feb 21, 2028	U-1940			
	9949986	Feb 21, 2028	U-1940			
<u>DESMOPRESSIN ACETATE - NOCDURNA</u>						
N 022517 001	10307459	May 07, 2023	DP			
	11020448	May 21, 2029	U-2327			
	7560429	Feb 02, 2024	DP U-2326			
	7947654	Dec 29, 2023	DP			
	8802624	Dec 29, 2023	U-2326			
	9220747	May 07, 2023	U-2326			
	9504647	May 07, 2023	DP U-2326			
	9919025	May 07, 2023	U-2326			
	9974826	Apr 13, 2030	U-2326			
<u>DESMOPRESSIN ACETATE - NOCDURNA</u>						
N 022517 002	10137167	May 21, 2029	U-2327			
	10307459	May 07, 2023	DP			
	7560429	Feb 02, 2024	DP U-2326			
	7947654	Dec 29, 2023	DP			
	8802624	Dec 29, 2023	U-2326			
	9220747	May 07, 2023	U-2326			
	9504647	May 07, 2023	DP U-2326			
	9919025	May 07, 2023	U-2326			
	9974826	Apr 13, 2030	U-2327			
<u>DESMOPRESSIN ACETATE - NOCTIVA</u>						
N 201656 001	11419914	Jun 15, 2030	U-3431			
	7799761	Sep 26, 2024	DP			
	9539302	Jun 15, 2030	DP			
<u>DESMOPRESSIN ACETATE - NOCTIVA</u>						
N 201656 002	11419914	Jun 15, 2030	U-3431			
	9539302	Jun 15, 2030	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DESONIDE - VERDESO</u>						
N 021978 001	8460641	Aug 13, 2027	DP U-1412			
	8962000	Aug 31, 2025	DP U-1412			
	9492384	Aug 31, 2025	DP U-1412			
<u>DESOXIMETASONE - TOPICORT</u>						
N 204141 001	8277780	Sep 01, 2028	DP U-1408			
	8715624	May 26, 2026	DP U-1408			
<u>DESVENLAFAXINE SUCCINATE - PRISTIO</u>						
N 021992 001	8269040	Jul 05, 2027	DS			
<u>DESVENLAFAXINE SUCCINATE - PRISTIO</u>						
N 021992 002	8269040	Jul 05, 2027	DS			
<u>DESVENLAFAXINE SUCCINATE - PRISTIO</u>						
N 021992 003	8269040	Jul 05, 2027	DS			
<u>DEUCRAVACITINIB - SOTYKTU</u>						
N 214958 001	10000480	Nov 07, 2033	DS DP		NCE	Sep 09, 2027
	11021475	Nov 07, 2033	U-3434			
	RE47929	Nov 07, 2033	DS DP U-3434			
<u>DEUTETRABENAZINE - AUSTEDO</u>						
N 208082 001	10959996	Mar 07, 2036	U-3055		M-54	Jun 24, 2024
	10959996*PED	Sep 07, 2036			ODE-134	Apr 03, 2024
	11179386	Mar 15, 2038	DP U-1995		PED	Oct 03, 2024
	11179386	Mar 15, 2038	DP U-3055		PED	Dec 24, 2024
	11179386*PED	Sep 15, 2038				
	11357772	Mar 07, 2036	U-1995			
	11357772	Mar 07, 2036	U-3055			
	11357772*PED	Sep 07, 2036				
	11446291	Mar 07, 2036	U-1995			
	8524733	Apr 03, 2031	DS DP			
	8524733*PED	Oct 03, 2031				
	9233959	Sep 18, 2033	DP			
	9233959*PED	Mar 18, 2034				
	9296739	Sep 18, 2033	DP			
	9296739*PED	Mar 18, 2034				
	9550780	Sep 18, 2033	DS DP U-1995			
	9550780	Sep 18, 2033	DS DP U-3055			
	9550780*PED	Mar 18, 2034				
	9814708	Sep 18, 2033	DP			
	9814708*PED	Mar 18, 2034				
<u>DEUTETRABENAZINE - AUSTEDO</u>						
N 208082 002	10959996	Mar 07, 2036	U-3055		M-54	Jun 24, 2024
	10959996*PED	Sep 07, 2036			ODE-134	Apr 03, 2024
	11179386	Mar 15, 2038	DP U-1995		PED	Oct 03, 2024
	11179386	Mar 15, 2038	DP U-3055		PED	Dec 24, 2024
	11179386*PED	Sep 15, 2038				
	11357772	Mar 07, 2036	U-1995			
	11357772	Mar 07, 2036	U-3055			
	11357772*PED	Sep 07, 2036				
	11446291	Mar 07, 2036	U-1995			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DEUTETRABENAZINE - AUSTEDO</u>						
N 208082 002	8524733	Apr 03, 2031	DS DP			
	8524733*PED	Oct 03, 2031				
	9233959	Sep 18, 2033	DP			
	9233959*PED	Mar 18, 2034				
	9296739	Sep 18, 2033	DP			
	9296739*PED	Mar 18, 2034				
	9550780	Sep 18, 2033	DS DP U-1995			
	9550780	Sep 18, 2033	DS DP U-3055			
	9550780*PED	Mar 18, 2034				
	9814708	Sep 18, 2033	DP			
	9814708*PED	Mar 18, 2034				
<u>DEUTETRABENAZINE - AUSTEDO</u>						
N 208082 003	10959996	Mar 07, 2036	U-3055		M-54	Jun 24, 2024
	10959996*PED	Sep 07, 2036			ODE-134	Apr 03, 2024
	11179386	Mar 15, 2038	DP U-1995		PED	Oct 03, 2024
	11179386	Mar 15, 2038	DP U-3055		PED	Dec 24, 2024
	11179386*PED	Sep 15, 2038				
	11357772	Mar 07, 2036	U-1995			
	11357772	Mar 07, 2036	U-3055			
	11357772*PED	Sep 07, 2036				
	11446291	Mar 07, 2036	U-1995			
	8524733	Apr 03, 2031	DS DP			
	8524733*PED	Oct 03, 2031				
	9233959	Sep 18, 2033	DP			
	9233959*PED	Mar 18, 2034				
	9296739	Sep 18, 2033	DP			
	9296739*PED	Mar 18, 2034				
	9550780	Sep 18, 2033	DS DP U-1995			
	9550780	Sep 18, 2033	DS DP U-3055			
	9550780*PED	Mar 18, 2034				
	9814708	Sep 18, 2033	DP			
	9814708*PED	Mar 18, 2034				
<u>DEXAMETHASONE - DEXAMETHASONE</u>						
A 216295 001					CGT	Mar 08, 2023
<u>DEXAMETHASONE - OZURDEX</u>						
N 022315 001	10076526	Jan 09, 2023	DP			
	10702539	Jan 09, 2023	U-1597			
	10702539	Jan 09, 2023	U-2868			
	10702539	Jan 09, 2023	U-985			
	6899717	Nov 01, 2023	U-1206			
	8034366	Jan 09, 2023	DP U-1204			
	8034366	Jan 09, 2023	DP U-1205			
	8034370	Jan 09, 2023	DP			
	8506987	Jan 09, 2023	U-1204			
	8506987	Jan 09, 2023	U-1205			
	9192511	Jan 09, 2023	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DEXAMETHASONE - DEXTENZA</u>						
N 208742 001	11458041	Nov 16, 2037	U-1680		I-876	Oct 07, 2024
	11458041	Nov 16, 2037	U-3455			
	8409606	May 14, 2030	DP			
	8563027	Feb 12, 2030	U-2487			
	9254267	Sep 11, 2024	DP			
<u>DEXAMETHASONE - DEXYCU KIT</u>						
N 208912 001	10022502	Jun 22, 2034	U-2340			
	10028965	May 23, 2034	U-2340			
	10159683	May 23, 2034	DP			
	10799642	May 11, 2032	DP			
	11097061	Jun 23, 2039	DP U-3418			
	6960346	Jul 03, 2023	DP			
<u>DEXAMETHASONE - HEMADY</u>						
N 211379 001	10537585	Dec 18, 2037	DP		ODE-271	Oct 03, 2026
	11304961	Dec 18, 2037	DP U-3344			
<u>DEXAMETHASONE; TOBRAMYCIN - TOBRADEX ST</u>						
N 050818 001	7795316	Aug 03, 2028	DP U-1082			
	8101582	Dec 19, 2027	DP U-1082			
	8450287	Dec 19, 2027	DP			
<u>DEXLANSOPRAZOLE - DEXILANT</u>						
N 022287 001	6664276	Jan 30, 2023	DS DP U-1507			
	6664276	Jan 30, 2023	DS DP U-949			
	6664276	Jan 30, 2023	DS DP U-950			
	6664276	Jan 30, 2023	DS DP U-951			
	6664276*PED	Jul 30, 2023				
	7790755	Aug 02, 2026	DP			
	8105626	Sep 27, 2026	DP			
	8173158	Mar 17, 2030	U-949			
	8173158	Mar 17, 2030	U-950			
	8173158	Mar 17, 2030	U-951			
	8461187	Jan 17, 2026	DP			
	8461187*PED	Jul 17, 2026				
	8722084	Oct 15, 2023	DP			
	8722084*PED	Apr 15, 2024				
	8784885	Oct 15, 2023	DP U-1552			
	8784885	Oct 15, 2023	DP U-1553			
	8784885	Oct 15, 2023	DP U-1554			
	8784885*PED	Apr 15, 2024				
	8871273	Jan 11, 2028	DP			
	9011926	Feb 24, 2026	DP			
	9233103	Mar 05, 2032	U-1805			
	9238029	Jan 17, 2026	DP			
<u>DEXLANSOPRAZOLE - DEXILANT</u>						
N 022287 002	6664276	Jan 30, 2023	DS DP U-1507			
	6664276	Jan 30, 2023	DS DP U-949			
	6664276	Jan 30, 2023	DS DP U-950			
	6664276	Jan 30, 2023	DS DP U-951			
	6664276*PED	Jul 30, 2023				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DEXLANSOPRAZOLE - DEXILANT</u>						
N 022287 002	7790755	Aug 02, 2026	DP			
	8105626	Sep 27, 2026	DP			
	8173158	Mar 17, 2030	U-949			
	8173158	Mar 17, 2030	U-950			
	8173158	Mar 17, 2030	U-951			
	8461187	Jan 17, 2026	DP			
	8461187*PED	Jul 17, 2026				
	8722084	Oct 15, 2023	DP			
	8722084*PED	Apr 15, 2024				
	8784885	Oct 15, 2023	DP U-1552			
	8784885	Oct 15, 2023	DP U-1553			
	8784885	Oct 15, 2023	DP U-1554			
	8784885*PED	Apr 15, 2024				
	8871273	Jan 11, 2028	DP			
	9011926	Feb 24, 2026	DP			
	9233103	Mar 05, 2032	U-1805			
	9238029	Jan 17, 2026	DP			
<u>DEXLANSOPRAZOLE - DEXILANT SOLUTAB</u>						
N 208056 001	6664276	Jan 30, 2023	DS DP U-950			
	6664276	Jan 30, 2023	DS DP U-951			
	6664276*PED	Jul 30, 2023				
	8461187	Jan 17, 2026	DP			
	8461187*PED	Jul 17, 2026				
	8784885	Oct 15, 2023	DP			
	8784885*PED	Apr 15, 2024				
	8871273	Jan 11, 2028	DP			
	8871273*PED	Jul 11, 2028				
	9011926	Feb 24, 2026	DP			
	9238029	Jan 17, 2026	DP			
	9241910	Mar 10, 2029	DP			
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 002	10016396	Jan 04, 2032	DP			
	8242158	Jan 04, 2032	DP			
	8242158*PED	Jul 04, 2032				
	8338470	Jan 04, 2032	DP			
	8338470*PED	Jul 04, 2032				
	8455527	Jan 04, 2032	U-421			
	8455527*PED	Jul 04, 2032				
	8648106	Jan 04, 2032	DP			
	8648106*PED	Jul 04, 2032				
	9320712	Jan 04, 2032	DP			
	9320712*PED	Jul 04, 2032				
	9616049	Jan 04, 2032	DP			
	9616049*PED	Jul 04, 2032				
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 003	10016396	Jan 04, 2032	DP			
	8242158	Jan 04, 2032	DP			
	8242158*PED	Jul 04, 2032				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 003	8338470	Jan 04, 2032	DP			
	8338470*PED	Jul 04, 2032				
	8455527	Jan 04, 2032	U-421			
	8455527*PED	Jul 04, 2032				
	8648106	Jan 04, 2032	DP			
	8648106*PED	Jul 04, 2032				
	9320712	Jan 04, 2032	DP			
	9320712*PED	Jul 04, 2032				
	9616049	Jan 04, 2032	DP			
	9616049*PED	Jul 04, 2032				
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 004	8242158	Jan 04, 2032	DP			
	8242158*PED	Jul 04, 2032				
	8338470	Jan 04, 2032	DP			
	8338470*PED	Jul 04, 2032				
	8455527	Jan 04, 2032	U-421			
	8455527*PED	Jul 04, 2032				
	8648106	Jan 04, 2032	DP			
	8648106*PED	Jul 04, 2032				
	9320712	Jan 04, 2032	DP			
	9320712*PED	Jul 04, 2032				
	9616049	Jan 04, 2032	DP			
	9616049*PED	Jul 04, 2032				
<u>DEXMEDETOMIDINE HYDROCHLORIDE - DEXMEDETOMIDINE HYDROCHLORIDE</u>						
N 206628 003	9649296	Apr 20, 2036	DP			
	9717796	Apr 20, 2036	DP			
<u>DEXMEDETOMIDINE HYDROCHLORIDE - DEXMEDETOMIDINE HYDROCHLORIDE</u>						
N 206628 004	9649296	Apr 20, 2036	DP			
	9717796	Apr 20, 2036	DP			
<u>DEXMEDETOMIDINE HYDROCHLORIDE - IGALMI</u>						
N 215390 001	10792246	Jun 26, 2039	DP U-3350		NP	Apr 05, 2025
	11478422	Jun 26, 2039	DP			
	11497711	Jun 26, 2039	DP			
	11517524	Jun 26, 2039	DP			
<u>DEXMEDETOMIDINE HYDROCHLORIDE - IGALMI</u>						
N 215390 002	10792246	Jun 26, 2039	DP U-3350		NP	Apr 05, 2025
	11478422	Jun 26, 2039	DP			
	11497711	Jun 26, 2039	DP			
	11517524	Jun 26, 2039	DP			
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE; SERDEXMETHYLPHENIDATE CHLORIDE - AZSTARYS</u>						
N 212994 001	10584112	Dec 09, 2037	DS DP		NCE	May 07, 2026
	10584113	Dec 09, 2037	DP			
	10759778	Dec 09, 2037	DP			
	10858341	Dec 09, 2037	U-3094			
	10954213	Dec 09, 2037	U-3094			
	9079928	Jul 27, 2032	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE; SERDEXMETHYLPHENIDATE CHLORIDE - AZSTARYS</u>						
N 212994 002	10584112	Dec 09, 2037	DS DP		NCE	May 07, 2026
	10584113	Dec 09, 2037	DP			
	10759778	Dec 09, 2037	DP			
	10858341	Dec 09, 2037	U-3094			
	10954213	Dec 09, 2037	U-3094			
	9079928	Jul 27, 2032	DP			
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE; SERDEXMETHYLPHENIDATE CHLORIDE - AZSTARYS</u>						
N 212994 003	10584112	Dec 09, 2037	DS DP		NCE	May 07, 2026
	10584113	Dec 09, 2037	DP			
	10759778	Dec 09, 2037	DP			
	10858341	Dec 09, 2037	U-3094			
	10954213	Dec 09, 2037	U-3094			
	9079928	Jul 27, 2032	DP			
<u>DEXTROAMPHETAMINE - XELSTRYM</u>						
N 215401 001	8591941	Oct 07, 2025	DP		NP	Mar 22, 2025
	8632802	Oct 07, 2025	DP			
	9034370	Oct 07, 2025	DP			
	9456993	Oct 24, 2033	DP U-3340			
	9474722	Oct 24, 2033	DP			
<u>DEXTROAMPHETAMINE - XELSTRYM</u>						
N 215401 002	8591941	Oct 07, 2025	DP		NP	Mar 22, 2025
	8632802	Oct 07, 2025	DP			
	9034370	Oct 07, 2025	DP			
	9456993	Oct 24, 2033	DP U-3340			
	9474722	Oct 24, 2033	DP			
<u>DEXTROAMPHETAMINE - XELSTRYM</u>						
N 215401 003	8591941	Oct 07, 2025	DP		NP	Mar 22, 2025
	8632802	Oct 07, 2025	DP			
	9034370	Oct 07, 2025	DP			
	9456993	Oct 24, 2033	DP U-3340			
	9474722	Oct 24, 2033	DP			
<u>DEXTROAMPHETAMINE - XELSTRYM</u>						
N 215401 004	8591941	Oct 07, 2025	DP		NP	Mar 22, 2025
	8632802	Oct 07, 2025	DP			
	9034370	Oct 07, 2025	DP			
	9456993	Oct 24, 2033	DP U-3340			
	9474722	Oct 24, 2033	DP			
<u>DEXTROMETHORPHAN HYDROBROMIDE; QUINIDINE SULFATE - NUEDEXTA</u>						
N 021879 001	7659282	Aug 13, 2026	U-1093			
	8227484	Jul 17, 2023	U-1093			
<u>DIAZEPAM - VALTOCO</u>						
N 211635 001	10265402	May 11, 2025	DP		NP	Jan 10, 2023
	11241414	Mar 27, 2029	DP		ODE-279	Jan 10, 2027
	8895546	Mar 27, 2029	DP			
	8927497	Jul 21, 2025	DP U-2727			
	9642913	May 11, 2025	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DIAZEPAM - VALTOCO</u>						
N 211635	002	10265402	May 11, 2025	DP	NP	Jan 10, 2023
		11241414	Mar 27, 2029	DP	ODE-279	Jan 10, 2027
		8895546	Mar 27, 2029	DP		
		8927497	Jul 21, 2025	DP U-2727		
		9642913	May 11, 2025	DP		
<u>DIAZEPAM - VALTOCO</u>						
N 211635	003	10265402	May 11, 2025	DP	NP	Jan 10, 2023
		11241414	Mar 27, 2029	DP	ODE-279	Jan 10, 2027
		8895546	Mar 27, 2029	DP		
		8927497	Jul 21, 2025	DP U-2727		
		9642913	May 11, 2025	DP		
<u>DICLOFENAC - ZORVOLEX</u>						
N 204592	001	8679544	Apr 23, 2030	DP		
		8999387	Apr 23, 2030	U-55		
		9017721	Apr 23, 2030	DP		
		9173854	Apr 23, 2030	DP		
		9180095	Apr 23, 2030	U-55		
		9180096	Apr 23, 2030	DP		
		9186328	Apr 23, 2030	U-55		
<u>DICLOFENAC - ZORVOLEX</u>						
N 204592	002	8679544	Apr 23, 2030	DP		
		8999387	Apr 23, 2030	U-55		
		9017721	Apr 23, 2030	DP		
		9173854	Apr 23, 2030	DP		
		9180095	Apr 23, 2030	U-55		
		9180096	Apr 23, 2030	DP		
		9186328	Apr 23, 2030	U-55		
<u>DICLOFENAC EPOLAMINE - LICART</u>						
N 206976	001	11344520	Feb 20, 2035	U-3393		
		11351133	Feb 20, 2035	U-3393		
<u>DICLOFENAC POTASSIUM - CAMBIA</u>						
N 022165	001	7759394	Jun 16, 2026	DS DP U-436		
		8097651	Jun 16, 2026	DS DP U-436		
		8927604	Jun 16, 2026	U-436		
		9827197	Jun 16, 2026	DP		
<u>DICLOFENAC POTASSIUM - ZIPSOR</u>						
N 022202	001	7662858	Feb 24, 2029	U-1035	NPP	May 25, 2024
		7884095	Feb 24, 2029	U-1111		
		7939518	Feb 24, 2029	U-980		
		8110606	Feb 24, 2029	U-980		
		8623920	Feb 24, 2029	U-1482		
		9561200	Feb 24, 2029	U-1482		
<u>DICLOFENAC SODIUM - PENNSAID</u>						
N 020947	001	8217078	Jul 10, 2029	U-1248		
		8546450	Aug 09, 2030	U-1435		
		8546450	Aug 09, 2030	U-1436		
		8618164	Jul 10, 2029	U-1477		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DICLOFENAC SODIUM - PENNSAID</u>						
N 020947 001	8741956	Jul 10, 2029	U-1435			
<u>DICLOFENAC SODIUM - DYLOJECT</u>						
N 022396 001	8946292	Mar 22, 2027	U-1659			
<u>DICLOFENAC SODIUM - PENNSAID</u>						
N 204623 001	8217078	Jul 10, 2029	U-1477			
	8252838	Apr 21, 2028	DP U-1489			
	8546450	Aug 09, 2030	U-1435			
	8546450	Aug 09, 2030	U-1436			
	8563613	Oct 17, 2027	DP U-1488			
	8618164	Jul 10, 2029	U-1477			
	8741956	Jul 10, 2029	U-1435			
	8871809	Oct 17, 2027	U-1614			
	9066913	Oct 17, 2027	DP U-1488			
	9101591	Oct 17, 2027	DP U-1488			
	9132110	Oct 17, 2027	U-1488			
	9168304	Oct 17, 2027	DP			
	9168305	Oct 17, 2027	U-1488			
	9220784	Oct 17, 2027	U-1488			
	9339551	Oct 17, 2027	U-1488			
	9339552	Oct 17, 2027	DP U-1488			
	9370501	Jul 10, 2029	U-1614			
	9375412	Jul 10, 2029	U-1614			
	9415029	Jul 10, 2029	U-1614			
	9539335	Oct 17, 2027	U-1614			
<u>DICLOXACILLIN SODIUM - DICLOXACILLIN SODIUM</u>						
A 216845 001					CGT	Mar 29, 2023
<u>DICLOXACILLIN SODIUM - DICLOXACILLIN SODIUM</u>						
A 216845 002					CGT	Mar 29, 2023
<u>DIENOGEST; DIENOGEST; DIENOGEST; ESTRADIOL VALERATE; ESTRADIOL VALERATE; ESTRADIOL VALERATE; ESTRADIOL VALERATE; ESTRADIOL VALERATE - NATAZIA</u>						
N 022252 001	8071577	May 13, 2026	DP U-1			
	8153616	Jan 30, 2028	U-1240			
<u>DIFELIKEFALIN ACETATE - KORSUVA</u>						
N 214916 001	10017536	Nov 12, 2027	DS U-3204		NCE	Aug 23, 2026
	10138270	Nov 12, 2027	U-3204			
	10793596	Nov 12, 2027	DS DP U-3204			
	7402564	Nov 12, 2027	DS DP U-3204			
	7713937	Nov 12, 2027	DS DP U-3204			
	7727963	Nov 12, 2027	DS DP U-3204			
	8217007	Nov 12, 2027	U-3204			
	8236766	Nov 12, 2027	U-3204			
	8486894	Nov 12, 2027	U-3204			
	8536131	Nov 12, 2027	DS DP U-3204			
	9334305	Nov 12, 2027	U-3204			
	9359399	Nov 12, 2027	U-3204			
<u>DIHYDROERGOTAMINE MESYLATE - TRUDHESA</u>						
N 213436 001	10507295	Dec 25, 2032	DP		NP	Sep 02, 2024

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DIHYDROERGOTAMINE MESYLATE - TRUDHESA</u>						
N 213436 001	10940278	Jan 23, 2033	DP			
	11185497	Jan 04, 2039	U-3218			
	11266799	Nov 05, 2036	DP			
	9550036	Sep 05, 2032	DP			
	9919117	Mar 17, 2033	DP U-3218			
<u>DIMETHYL FUMARATE - TECFIDERA</u>						
N 204063 001	10391160	Mar 13, 2035	U-3148		M-260	Feb 05, 2023
	10555993	Mar 13, 2035	U-3148			
	10959972	Nov 16, 2035	U-1384			
	10994003	Mar 13, 2035	U-3148			
	11007166	Nov 16, 2035	U-1384			
	11007167	Nov 16, 2035	U-1384			
	11129806	Nov 16, 2035	U-1384			
	11246850	Nov 16, 2035	U-1384			
	8399514	Feb 07, 2028	U-1384			
<u>DIMETHYL FUMARATE - TECFIDERA</u>						
N 204063 002	10391160	Mar 13, 2035	U-3148		M-260	Feb 05, 2023
	10555993	Mar 13, 2035	U-3148			
	10959972	Nov 16, 2035	U-1384			
	10994003	Mar 13, 2035	U-3148			
	11007166	Nov 16, 2035	U-1384			
	11007167	Nov 16, 2035	U-1384			
	11129806	Nov 16, 2035	U-1384			
	11246850	Nov 16, 2035	U-1384			
	8399514	Feb 07, 2028	U-1384			
<u>DIROXIMEL FUMARATE - VUMERITY</u>						
N 211855 001	10080733	Sep 20, 2033	DS DP U-1384			
	8669281	Sep 20, 2033	DS DP			
	9090558	Sep 20, 2033	U-1384			
<u>DOCETAXEL - DOCETAXEL</u>						
N 205934 001	10842770	Aug 07, 2031	DP U-2998			
	8940786	Sep 30, 2033	DP U-1789			
	9308195	Sep 30, 2033	DP			
	9763880	Sep 30, 2033	U-2558			
	9763880	Sep 30, 2033	U-2559			
	9763880	Sep 30, 2033	U-2560			
	9763880	Sep 30, 2033	U-2561			
	9763880	Sep 30, 2033	U-2562			
	9763880	Sep 30, 2033	U-2563			
	9763880	Sep 30, 2033	U-2564			
<u>DOCETAXEL - DOCETAXEL</u>						
N 205934 002	10842770	Aug 07, 2031	DP U-2998			
	8940786	Sep 30, 2033	DP U-1789			
	9308195	Sep 30, 2033	DP			
	9763880	Sep 30, 2033	U-2558			
	9763880	Sep 30, 2033	U-2559			
	9763880	Sep 30, 2033	U-2560			
	9763880	Sep 30, 2033	U-2561			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DOCETAXEL - DOCETAXEL</u>						
N 205934 002	9763880	Sep 30, 2033	U-2562			
	9763880	Sep 30, 2033	U-2563			
	9763880	Sep 30, 2033	U-2564			
<u>DOCETAXEL - DOCETAXEL</u>						
N 205934 003	10842770	Aug 07, 2031	DP U-2998			
	8940786	Sep 30, 2033	DP U-1789			
	9308195	Sep 30, 2033	DP			
	9763880	Sep 30, 2033	U-2558			
	9763880	Sep 30, 2033	U-2559			
	9763880	Sep 30, 2033	U-2560			
	9763880	Sep 30, 2033	U-2561			
	9763880	Sep 30, 2033	U-2562			
	9763880	Sep 30, 2033	U-2563			
	9763880	Sep 30, 2033	U-2564			
<u>DOLUTEGRAVIR SODIUM - TIVICAY</u>						
N 204790 001	8129385	Oct 05, 2027	DS DP			
	9242986	Dec 08, 2029	DS DP			
<u>DOLUTEGRAVIR SODIUM - TIVICAY</u>						
N 204790 002	8129385	Oct 05, 2027	DS DP			
	9242986	Dec 08, 2029	DS DP			
<u>DOLUTEGRAVIR SODIUM - TIVICAY</u>						
N 204790 003	8129385	Oct 05, 2027	DS DP			
	9242986	Dec 08, 2029	DS DP			
<u>DOLUTEGRAVIR SODIUM - TIVICAY PD</u>						
N 213983 001	8129385	Oct 05, 2027	DS DP			
	9242986	Dec 08, 2029	DS DP			
<u>DOLUTEGRAVIR SODIUM; LAMIVUDINE - DOVATO</u>						
N 211994 001	11234985	Jan 24, 2031	DP U-257		I-839	Aug 06, 2023
	8129385	Oct 05, 2027	DS DP			
	9242986	Dec 08, 2029	DS DP			
<u>DOLUTEGRAVIR SODIUM; RILPIVIRINE HYDROCHLORIDE - JULUCA</u>						
N 210192 001	10426780	Jan 24, 2031	DS DP U-257			
	7125879	Apr 21, 2025	DS DP U-257			
	8080551	Apr 11, 2023	DS DP			
	8129385	Oct 05, 2027	DS DP			
	9242986	Dec 08, 2029	DS DP			
<u>DONEPEZIL HYDROCHLORIDE - ARICEPT</u>						
N 022568 001	8481565	Oct 04, 2026	DP			
<u>DONEPEZIL HYDROCHLORIDE - ADLARITY</u>						
N 212304 001	10016372	Jul 26, 2037	U-3334		NP	Mar 11, 2025
	10300025	Jul 26, 2037	DP			
	10307379	Jul 26, 2037	DP			
	10835499	May 20, 2038	DP U-3334			
	10966936	Aug 11, 2038	DP U-3334			
	11103463	Jul 26, 2037	U-3334			
	9993466	Jul 26, 2037	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DONEPEZIL HYDROCHLORIDE - ADLARITY</u>						
N 212304 002	10016372	Jul 26, 2037	U-3334		NP	Mar 11, 2025
	10300025	Jul 26, 2037	DP			
	10307379	Jul 26, 2037	DP			
	10835499	May 20, 2038	DP U-3334			
	10966936	Aug 11, 2038	DP U-3334			
	11103463	Jul 26, 2037	U-3334			
	9993466	Jul 26, 2037	DP			
<u>DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC</u>						
N 206439 001	8039009	Mar 24, 2029	U-1641			
	8039009*PED	Sep 24, 2029				
	8058291	Dec 05, 2029	U-1641			
	8168209	Nov 22, 2025	DP			
	8168209*PED	May 22, 2026				
	8173708	Nov 22, 2025	U-1641			
	8173708*PED	May 22, 2026				
	8283379	Nov 22, 2025	U-1641			
	8283379*PED	May 22, 2026				
	8293794	Nov 22, 2025	DP			
	8329752	Nov 22, 2025	DP			
	8329752*PED	May 22, 2026				
	8338485	Nov 22, 2025	DP			
	8338486	Nov 22, 2025	U-1641			
	8362085	Nov 22, 2025	U-1641			
	8362085*PED	May 22, 2026				
	8580858	Nov 22, 2025	U-1641			
	8598233	Nov 22, 2025	DP			
	8598233*PED	May 22, 2026				
<u>DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC</u>						
N 206439 002	8039009	Mar 24, 2029	U-1641			
	8039009*PED	Sep 24, 2029				
	8058291	Dec 05, 2029	U-1641			
	8168209	Nov 22, 2025	DP			
	8168209*PED	May 22, 2026				
	8173708	Nov 22, 2025	U-1641			
	8173708*PED	May 22, 2026				
	8283379	Nov 22, 2025	U-1641			
	8283379*PED	May 22, 2026				
	8293794	Nov 22, 2025	DP			
	8329752	Nov 22, 2025	DP			
	8329752*PED	May 22, 2026				
	8338485	Nov 22, 2025	DP			
	8338486	Nov 22, 2025	U-1641			
	8362085	Nov 22, 2025	U-1641			
	8362085*PED	May 22, 2026				
	8580858	Nov 22, 2025	U-1641			
	8598233	Nov 22, 2025	DP			
	8598233*PED	May 22, 2026				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC</u>						
N 206439 003	8039009	Mar 24, 2029	U-1641			
	8039009*PED	Sep 24, 2029				
	8058291	Dec 05, 2029	U-1641			
	8168209	Nov 22, 2025	DP			
	8168209*PED	May 22, 2026				
	8173708	Nov 22, 2025	U-1641			
	8173708*PED	May 22, 2026				
	8283379	Nov 22, 2025	U-1641			
	8283379*PED	May 22, 2026				
	8293794	Nov 22, 2025	DP			
	8329752	Nov 22, 2025	DP			
	8329752*PED	May 22, 2026				
	8338485	Nov 22, 2025	DP			
	8338486	Nov 22, 2025	U-1641			
	8362085	Nov 22, 2025	U-1641			
	8362085*PED	May 22, 2026				
	8580858	Nov 22, 2025	U-1641			
	8598233	Nov 22, 2025	DP			
	8598233*PED	May 22, 2026				
<u>DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC</u>						
N 206439 004	8039009	Mar 24, 2029	U-1641			
	8039009*PED	Sep 24, 2029				
	8058291	Dec 05, 2029	U-1641			
	8168209	Nov 22, 2025	DP			
	8168209*PED	May 22, 2026				
	8173708	Nov 22, 2025	U-1641			
	8173708*PED	May 22, 2026				
	8283379	Nov 22, 2025	U-1641			
	8283379*PED	May 22, 2026				
	8293794	Nov 22, 2025	DP			
	8329752	Nov 22, 2025	DP			
	8329752*PED	May 22, 2026				
	8338485	Nov 22, 2025	DP			
	8338486	Nov 22, 2025	U-1641			
	8362085	Nov 22, 2025	U-1641			
	8362085*PED	May 22, 2026				
	8580858	Nov 22, 2025	U-1641			
	8598233	Nov 22, 2025	DP			
	8598233*PED	May 22, 2026				
<u>DORAVIRINE - PIFELTRO</u>						
N 210806 001	8486975	Oct 07, 2031	DS DP U-2394		NCE	Aug 30, 2023
	8486975	Oct 07, 2031	DS DP U-2630		NPP	Jan 27, 2025
	8486975	Oct 07, 2031	DS DP U-3308			
<u>DORAVIRINE; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE - DELSTRIGO</u>						
N 210807 001	10603282	Nov 29, 2036	DP		NCE	Aug 30, 2023
	10842751	Nov 29, 2036	DP		NPP	Jan 27, 2025
	8486975	Oct 07, 2031	DS DP U-2395			
	8486975	Oct 07, 2031	DS DP U-2629			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DORAVIRINE; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE - DELSTRIGO</u>						
N 210807	001 8486975	Oct 07, 2031	DS DP U-3307			
<u>DOXEPIN HYDROCHLORIDE - SILENOR</u>						
N 022036	001 10238620	May 18, 2027	U-620			
	10548871	Apr 11, 2028	U-620			
	10653660	Jul 20, 2027	U-620			
	10653662	May 18, 2027	U-620			
	11096920	Apr 11, 2028	U-620			
	11110074	Jul 20, 2027	U-620			
	11234954	Jan 18, 2028	U-620			
	7915307	Aug 24, 2027	U-620			
	8513299	Sep 07, 2030	U-620			
	9107898	May 01, 2028	U-620			
	9486437	May 18, 2027	U-620			
	9532971	Jun 01, 2029	DP			
	9572814	Jul 20, 2027	U-620			
	9861607	May 18, 2027	U-620			
	9907780	Apr 11, 2028	DP			
<u>DOXEPIN HYDROCHLORIDE - SILENOR</u>						
N 022036	002 10238620	May 18, 2027	U-620			
	10548871	Apr 11, 2028	U-620			
	10653660	Jul 20, 2027	U-620			
	10653662	May 18, 2027	U-620			
	11096920	Apr 11, 2028	U-620			
	11110074	Jul 20, 2027	U-620			
	11234954	Jan 18, 2028	U-620			
	7915307	Aug 24, 2027	U-620			
	8513299	Sep 07, 2030	U-620			
	9107898	May 01, 2028	U-620			
	9486437	May 18, 2027	U-620			
	9532971	Jun 01, 2029	DP			
	9572814	Jul 20, 2027	U-620			
	9861607	May 18, 2027	U-620			
	9907780	Apr 11, 2028	DP			
<u>DOXYCYCLINE - ORACEA</u>						
N 050805	001 7749532	Dec 19, 2027	DP U-1063			
	8206740	Dec 24, 2025	DP U-925			
	8394405	Apr 07, 2024	DP U-925			
	8394406	Apr 07, 2024	DP U-925			
	8470364	Apr 07, 2024	DP U-925			
	8709478	Apr 07, 2024	U-1063			
<u>DOXYCYCLINE HYCLATE - DORYX</u>						
N 050795	001 8715724	Feb 03, 2028	DP			
<u>DOXYCYCLINE HYCLATE - DORYX</u>						
N 050795	002 8715724	Feb 03, 2028	DP			
<u>DOXYCYCLINE HYCLATE - DORYX</u>						
N 050795	003 8715724	Feb 03, 2028	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DOXYCYCLINE HYCLATE - DORYX</u>						
N 050795 004	8715724	Feb 03, 2028	DP			
<u>DOXYCYCLINE HYCLATE - DORYX</u>						
N 050795 005	8715724	Feb 03, 2028	DP			
<u>DOXYCYCLINE HYCLATE - DORYX</u>						
N 050795 006	8715724	Feb 03, 2028	DP			
<u>DOXYCYCLINE HYCLATE - DORYX MPC</u>						
N 050795 007	8715724	Feb 03, 2028	DP			
	9295652	Oct 23, 2034	DP U-918			
	9446057	Dec 23, 2034	DP U-918			
	9511031	Oct 23, 2034	DP			
<u>DOXYCYCLINE HYCLATE - DORYX MPC</u>						
N 050795 008	8715724	Feb 03, 2028	DP			
	9295652	Oct 23, 2034	DP U-918			
	9446057	Dec 23, 2034	DP U-918			
	9511031	Oct 23, 2034	DP			
<u>DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE - BONJESTA</u>						
N 209661 001	9089489	Feb 18, 2033	DP U-1382			
	9375404	Feb 18, 2033	DP U-1382			
	9526703	Feb 18, 2033	DP U-1382			
	9937132	Feb 18, 2033	DP U-1382			
<u>DRONABINOL - SYNDROS</u>						
N 205525 001	10265293	Aug 06, 2028	DS DP			
	11253472	Aug 06, 2028	DS DP			
	8222292	Aug 06, 2028	DS DP			
	9345771	Aug 06, 2028	DS DP			
<u>DRONEDARONE HYDROCHLORIDE - MULTAQ</u>						
N 022425 001	8410167	Apr 16, 2029	U-1387			
	8410167	Apr 16, 2029	U-1388			
	8602215	Jun 30, 2031	U-1473			
	9107900	Apr 16, 2029	U-1726			
	9107900	Apr 16, 2029	U-1728			
<u>DROSPIRENONE - SLYND</u>						
N 211367 001	10179140	Jun 28, 2031	U-2553			
	10603281	Jun 28, 2031	U-2553			
	10849857	Jun 28, 2031	DP U-2553			
	10987364	Jun 28, 2031	DP			
	11123299	Jun 28, 2031	DP			
	11291632	Jun 28, 2031	DP			
	11291633	Jun 28, 2031	DP			
	11351122	Jun 28, 2031	DP			
	11413249	Jun 28, 2031	U-2553			
	11439598	Jun 28, 2031	DP			
	11478487	Jun 28, 2031	DP			
	11504334	Jun 28, 2031	DP			
	9603860	Jun 28, 2031	U-2553			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DROSPIRENONE - DROSPIRENONE</u>						
N 216285 001	10179140	Jun 28, 2031	U-2553		NP	Jun 29, 2025
	10603281	Jun 28, 2031	U-2553			
	10849857	Jun 28, 2031	DP U-2553			
	10987364	Jun 28, 2031	DP			
	11123299	Jun 28, 2031	DP			
	11291632	Jun 28, 2031	DP			
	11291633	Jun 28, 2031	DP			
	11351122	Jun 28, 2031	DP			
	11413249	Jun 28, 2031	U-2553			
	11439598	Jun 28, 2031	DP			
	11478487	Jun 28, 2031	DP			
	11504334	Jun 28, 2031	DP			
	9603860	Jun 28, 2031	U-2553			
<u>DROSPIRENONE; ESTETROL - NEXTSTELLIS</u>						
N 214154 001	7732430	Mar 02, 2025	DP U-3152		NCE	Apr 15, 2026
<u>DROSPIRENONE; ESTRADIOL - ANGELIO</u>						
N 021355 001	8906890	Oct 22, 2031	DP			
<u>DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM - BEYAZ</u>						
N 022532 001	8617597	Feb 08, 2030	DP			
<u>DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM - SAFYRAL</u>						
N 022574 001	8617597	Feb 08, 2030	DP			
<u>DULOXETINE HYDROCHLORIDE - CYMBALTA</u>						
N 021427 001					NPP	Apr 20, 2023
<u>DULOXETINE HYDROCHLORIDE - CYMBALTA</u>						
N 021427 002					NPP	Apr 20, 2023
<u>DULOXETINE HYDROCHLORIDE - CYMBALTA</u>						
N 021427 004					NPP	Apr 20, 2023
<u>DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE</u>						
N 212516 001	10413525	Apr 13, 2037	DP			
	10959982	Apr 13, 2037	DP			
	11202772	Apr 13, 2037	DP			
	9839626	Apr 13, 2037	DP			
<u>DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE</u>						
N 212516 002	10413525	Apr 13, 2037	DP			
	10959982	Apr 13, 2037	DP			
	11202772	Apr 13, 2037	DP			
	9839626	Apr 13, 2037	DP			
<u>DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE</u>						
N 212516 003	10413525	Apr 13, 2037	DP			
	10959982	Apr 13, 2037	DP			
	11202772	Apr 13, 2037	DP			
	9839626	Apr 13, 2037	DP			
<u>DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE</u>						
N 212516 004	10413525	Apr 13, 2037	DP			
	10959982	Apr 13, 2037	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE</u>						
N 212516 004	11202772	Apr 13, 2037	DP			
	9839626	Apr 13, 2037	DP			
<u>DUVELISIB - COPIKTRA</u>						
N 211155 001	11312718	Jan 10, 2032	DP		NCE	Sep 24, 2023
	8193182	Feb 13, 2030	DS		ODE-208	Sep 24, 2025
	9216982	Jan 05, 2029	U-2412			
	9216982	Jan 05, 2029	U-2413			
	9840505	Jan 10, 2032	U-2412			
	9840505	Jan 10, 2032	U-2413			
	RE46621	May 17, 2032	DS DP			
<u>DUVELISIB - COPIKTRA</u>						
N 211155 002	11312718	Jan 10, 2032	DP		NCE	Sep 24, 2023
	8193182	Feb 13, 2030	DS		ODE-208	Sep 24, 2025
	9216982	Jan 05, 2029	U-2412			
	9216982	Jan 05, 2029	U-2413			
	9840505	Jan 10, 2032	U-2412			
	9840505	Jan 10, 2032	U-2413			
	RE46621	May 17, 2032	DS DP			
<u>ECONAZOLE NITRATE - ECOZA</u>						
N 205175 001	10071054	Aug 08, 2031	DP			
<u>EDARAVONE - RADICAVA</u>						
N 209176 001					ODE-144	May 05, 2024
<u>EDARAVONE - RADICAVA</u>						
N 209176 002					ODE*	May 05, 2024
<u>EDARAVONE - RADICAVA ORS</u>						
N 215446 001	10987341	Nov 01, 2039	DP		NP	May 12, 2025
	11241416	Nov 01, 2039	DP			
	11478450	Nov 01, 2039	U-3468			
<u>EDOXABAN TOSYLATE - SAVAYSA</u>						
N 206316 001	7365205	Apr 18, 2027	DS			
	9149532	Mar 28, 2028	DP			
<u>EDOXABAN TOSYLATE - SAVAYSA</u>						
N 206316 002	7365205	Apr 18, 2027	DS			
	9149532	Mar 28, 2028	DP			
<u>EDOXABAN TOSYLATE - SAVAYSA</u>						
N 206316 003	7365205	Apr 18, 2027	DS			
	9149532	Mar 28, 2028	DP			
<u>EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - ATRIPLA</u>						
N 021937 001	8592397	Jan 13, 2024	DP U-1170			
	8592397	Jan 13, 2024	DP U-750			
	8598185	Apr 28, 2029	DP			
	8716264	Jan 13, 2024	DP U-257			
	9018192	Jun 13, 2026	U-1170			
	9018192	Jun 13, 2026	U-750			
	9457036	Jan 13, 2024	DP U-257			
	9545414	Jun 13, 2026	DP U-1170			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EFFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - ATRIPLA</u>						
N 021937	001 9545414	Jun 13, 2026	DP U-750			
	9744181	Jan 13, 2024	DP U-257			
<u>EFINACONAZOLE - JUBLIA</u>						
N 203567	001 10105444	Jul 08, 2030	DP		NPP	Apr 27, 2023
	10342875	Oct 02, 2034	DP U-2720			
	10478601	Apr 25, 2035	DP U-2721			
	10512640	Jan 03, 2028	U-1969			
	10828293	Oct 02, 2034	U-2720			
	10828369	Jan 03, 2028	DP			
	10864274	Oct 02, 2034	U-2720			
	11213519	Jan 03, 2028	U-2720			
	7214506	Feb 22, 2026	U-281			
	8039494	Jul 08, 2030	U-281			
	8486978	Oct 24, 2030	DP			
	9302009	Oct 24, 2030	DP			
	9566272	Jan 03, 2028	U-1969			
	9662394	Oct 02, 2034	DP			
	9861698	Jul 08, 2030	DP			
	9877955	Jan 03, 2028	U-1969			
<u>ELAGOLIX SODIUM - ORILISSA</u>						
N 210450	001 10537572	Sep 01, 2036	U-2735		NCE	Jul 23, 2023
	10682351	Sep 01, 2036	U-2850			
	7056927	Sep 10, 2024	DS DP			
	7176211	Jul 06, 2024	U-2360			
	7419983	Jul 06, 2024	DS DP U-2360			
<u>ELAGOLIX SODIUM - ORILISSA</u>						
N 210450	002 11344551	Mar 14, 2034	U-3388		NCE	Jul 23, 2023
	11344551	Mar 14, 2034	U-3389			
	7056927	Sep 10, 2024	DS DP			
	7176211	Jul 06, 2024	U-2360			
	7419983	Jul 06, 2024	DS DP U-2360			
<u>ELAGOLIX SODIUM, ESTRADIOL, NORETHINDRONE ACETATE; ELAGOLIX SODIUM - ORIAHNN (COPACKAGED)</u>						
N 213388	001 10881659	Mar 14, 2034	U-2842		NCE	Jul 23, 2023
	11045470	Mar 14, 2034	U-2842		NP	May 29, 2023
	11459305	Nov 07, 2028	DP U-2842			
	7056927	Sep 10, 2024	DS DP			
	7419983	Jul 06, 2024	DS DP			
<u>ELBASVIR; GRAZOPREVRIL - ZEPATIER</u>						
N 208261	001 7973040	Jul 24, 2029	DS DP U-1813		NPP	Dec 09, 2024
	8871759	May 04, 2031	DS DP U-1813			
<u>ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)</u>						
N 212273	001 10022352	Apr 09, 2027	DP U-2651		NCE	Feb 12, 2023
	10022352	Apr 09, 2027	DP U-3156		NCE	Oct 21, 2024
	10081621	Mar 25, 2031	DP U-2652		NPP	Jun 08, 2024
	10081621	Mar 25, 2031	DP U-3032		ODE-275	Oct 21, 2026
	10081621	Mar 25, 2031	DP U-3157		ODE-323	Dec 21, 2027
	10239867	Apr 09, 2027	DS DP U-2653		ODE-357	Jun 08, 2028

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ELEXACAFITOR, IVACAFITOR, TEZACAFITOR; IVACAFITOR - TRIKAFTA (COPACKAGED)</u>						
N 212273 001	10239867	Apr 09, 2027	DS DP U-3033			
	10239867	Apr 09, 2027	DS DP U-3158			
	10646481	Aug 13, 2029	DP			
	10758534	Oct 06, 2035	DS DP U-2645			
	10758534	Oct 06, 2035	DS DP U-3028			
	10758534	Oct 06, 2035	DS DP U-3144			
	10793547	Dec 08, 2037	DS DP U-2645			
	10793547	Dec 08, 2037	DS DP U-3028			
	10793547	Dec 08, 2037	DS DP U-3144			
	11179367	Dec 08, 2037	DP U-3253			
	11426407	Oct 06, 2035	DS DP U-3425			
	11453655	Dec 08, 2037	DS DP			
	11517564	Dec 08, 2037	DP U-3498			
	7495103	May 20, 2027	DS DP			
	7645789	May 01, 2027	DS DP			
	7776905	Jun 03, 2027	DS DP			
	8324242	Aug 05, 2027	U-2645			
	8324242	Aug 05, 2027	U-3028			
	8324242	Aug 05, 2027	U-3144			
	8354427	Jul 06, 2026	U-2646			
	8354427	Jul 06, 2026	U-3029			
	8354427	Jul 06, 2026	U-3145			
	8410274	Dec 28, 2026	DP			
	8415387	Nov 12, 2027	U-2645			
	8415387	Nov 12, 2027	U-3028			
	8415387	Nov 12, 2027	U-3144			
	8598181	May 01, 2027	U-2645			
	8598181	May 01, 2027	U-3028			
	8598181	May 01, 2027	U-3144			
	8623905	May 01, 2027	DS DP			
	8629162	Jun 24, 2025	U-2648			
	8629162	Jun 24, 2025	U-3030			
	8629162	Jun 24, 2025	U-3146			
	8754224	Dec 28, 2026	DS DP			
	9012496	Jul 15, 2033	U-2649			
	9012496	Jul 15, 2033	U-3154			
	9670163	Dec 28, 2026	DP U-2650			
	9670163	Dec 28, 2026	DP U-3031			
	9670163	Dec 28, 2026	DP U-3155			
	9931334	Dec 28, 2026	DP U-2650			
	9931334	Dec 28, 2026	DP U-3031			
	9931334	Dec 28, 2026	DP U-3155			
	9974781	Apr 09, 2027	DP U-2645			
	9974781	Apr 09, 2027	DP U-3028			
	9974781	Apr 09, 2027	DP U-3144			
<u>ELEXACAFITOR, IVACAFITOR, TEZACAFITOR; IVACAFITOR - TRIKAFTA (COPACKAGED)</u>						
N 212273 002	10022352	Apr 09, 2027	DP U-3156		NCE	Feb 12, 2023
	10081621	Mar 25, 2031	DP U-3157		NCE	Oct 21, 2024
	10239867	Apr 09, 2027	DS DP U-3158		NPP	Jun 08, 2024

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ELEXACAFITOR, IVACAFITOR, TEZACAFITOR; IVACAFITOR - TRIKAFTA (COPACKAGED)</u>						
N 212273 002	10646481	Aug 13, 2029	DP		ODE-357	Jun 08, 2028
	10758534	Oct 06, 2035	DS DP U-3144			
	10793547	Dec 08, 2037	DS DP U-3144			
	11179367	Dec 08, 2037	DP U-3253			
	11426407	Oct 06, 2035	DS DP U-3425			
	11453655	Dec 08, 2037	DS DP			
	11517564	Dec 08, 2037	DP U-3498			
	7495103	May 20, 2027	DS DP			
	7645789	May 01, 2027	DS DP			
	7776905	Jun 03, 2027	DS DP			
	8324242	Aug 05, 2027	U-3144			
	8354427	Jul 06, 2026	U-3145			
	8410274	Dec 28, 2026	DP			
	8415387	Nov 12, 2027	U-3144			
	8598181	May 01, 2027	U-3144			
	8623905	May 01, 2027	DS DP			
	8629162	Jun 24, 2025	U-3146			
	8754224	Dec 28, 2026	DS DP			
	9012496	Jul 15, 2033	U-3154			
	9670163	Dec 28, 2026	DP U-3155			
	9931334	Dec 28, 2026	DP U-3155			
	9974781	Apr 09, 2027	DP U-3144			
<u>ELIGLUSTAT TARTRATE - CERDELGA</u>						
N 205494 001	10888544	Dec 13, 2038	U-3040			
	10888544	Dec 13, 2038	U-3041			
	10888547	Jan 31, 2031	U-3042			
	10888547	Jan 31, 2031	U-3043			
	11458119	Nov 24, 2030	DS DP			
	7196205	Jun 26, 2026	DS			
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 001	7160870*PED	May 20, 2023			ODE-210	Nov 16, 2025
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-2451			
	7547719	Jul 13, 2025	DS DP U-2452			
	7547719*PED	Jan 13, 2026				
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-2451			
	7795293*PED	Nov 21, 2023				
	8052993	Aug 01, 2027	DP U-1306			
	8052993	Aug 01, 2027	DP U-1575			
	8052993	Aug 01, 2027	DP U-2451			
	8052993	Aug 01, 2027	DP U-930			
	8052993*PED	Feb 01, 2028				
	8052994	Aug 01, 2027	DP U-1714			
	8052994*PED	Feb 01, 2028				
	8062665	Aug 01, 2027	DP U-1714			
	8062665*PED	Feb 01, 2028				
	8071129	Aug 01, 2027	DP U-1714			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 001	8071129*PED	Feb 01, 2028				
	8828430	Aug 01, 2027	DP U-1306			
	8828430	Aug 01, 2027	DP U-2451			
	8828430*PED	Feb 01, 2028				
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 002	7160870*PED	May 20, 2023			ODE-210	Nov 16, 2025
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-2451			
	7547719	Jul 13, 2025	DS DP U-2452			
	7547719	Jul 13, 2025	DS DP U-930			
	7547719*PED	Jan 13, 2026				
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-2451			
	7795293	May 21, 2023	U-930			
	7795293*PED	Nov 21, 2023				
	8052993	Aug 01, 2027	DP U-1714			
	8052993*PED	Feb 01, 2028				
	8052994	Aug 01, 2027	DP U-1306			
	8052994	Aug 01, 2027	DP U-2451			
	8052994	Aug 01, 2027	DP U-930			
	8052994*PED	Feb 01, 2028				
	8062665	Aug 01, 2027	DP U-1714			
	8062665*PED	Feb 01, 2028				
	8071129	Aug 01, 2027	DP U-1714			
	8071129*PED	Feb 01, 2028				
	8828430	Aug 01, 2027	DP U-1306			
	8828430	Aug 01, 2027	DP U-2451			
	8828430*PED	Feb 01, 2028				
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 003	7160870*PED	May 20, 2023			ODE-210	Nov 16, 2025
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-2451			
	7547719	Jul 13, 2025	DS DP U-2452			
	7547719	Jul 13, 2025	DS DP U-930			
	7547719*PED	Jan 13, 2026				
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-2451			
	7795293	May 21, 2023	U-930			
	7795293*PED	Nov 21, 2023				
	8052993	Aug 01, 2027	DP U-1714			
	8052993*PED	Feb 01, 2028				
	8052994	Aug 01, 2027	DP U-1714			
	8052994*PED	Feb 01, 2028				
	8062665	Aug 01, 2027	DP U-1306			
	8062665	Aug 01, 2027	DP U-2451			
	8062665	Aug 01, 2027	DP U-930			
	8062665*PED	Feb 01, 2028				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 003	8071129	Aug 01, 2027	DP U-1714			
	8071129*PED	Feb 01, 2028				
	8828430	Aug 01, 2027	DP U-1306			
	8828430	Aug 01, 2027	DP U-2451			
	8828430*PED	Feb 01, 2028				
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 004	7160870*PED	May 20, 2023			ODE-210	Nov 16, 2025
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-2451			
	7547719	Jul 13, 2025	DS DP U-2452			
	7547719*PED	Jan 13, 2026				
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-2451			
	7795293*PED	Nov 21, 2023				
	8052993	Aug 01, 2027	DP U-1714			
	8052993*PED	Feb 01, 2028				
	8052994	Aug 01, 2027	DP U-1714			
	8052994*PED	Feb 01, 2028				
	8062665	Aug 01, 2027	DP U-1714			
	8062665*PED	Feb 01, 2028				
	8071129	Aug 01, 2027	DP U-1306			
	8071129	Aug 01, 2027	DP U-2451			
	8071129	Aug 01, 2027	DP U-930			
	8071129*PED	Feb 01, 2028				
	8828430	Aug 01, 2027	DP U-1306			
	8828430	Aug 01, 2027	DP U-2451			
	8828430*PED	Feb 01, 2028				
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 005	7160870*PED	May 20, 2023			ODE-210	Nov 16, 2025
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-930			
	7547719*PED	Jan 13, 2026				
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-1575			
	7795293	May 21, 2023	U-930			
	7795293*PED	Nov 21, 2023				
<u>ELTROMBOPAG OLAMINE - PROMACTA KIT</u>						
N 207027 001	7160870*PED	May 20, 2023			ODE*	Nov 16, 2025
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-1736			
	7547719	Jul 13, 2025	DS DP U-2452			
	7547719*PED	Jan 13, 2026				
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-1736			
	7795293*PED	Nov 21, 2023				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ELTROMBOPAG OLAMINE - PROMACTA KIT</u>						
N 207027 002	7160870*PED	May 20, 2023			ODE*	Nov 16, 2025
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-1736			
	7547719	Jul 13, 2025	DS DP U-2452			
	7547719*PED	Jan 13, 2026				
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-1736			
	7795293*PED	Nov 21, 2023				
<u>ELUXADOLINE - VIBERZI</u>						
N 206940 001	10188632	Mar 14, 2033	DP			
	10213415	Mar 14, 2025	DS U-2152			
	11007179	Mar 14, 2033	DP			
	11090291	Mar 14, 2033	DP			
	11160792	Mar 14, 2033	DP			
	11229627	Mar 14, 2033	DP			
	11311516	Mar 14, 2033	DP			
	7741356	May 27, 2029	DS DP			
	7786158	Mar 14, 2025	DS			
	8344011	Mar 14, 2025	U-1709			
	8609709	Mar 14, 2025	DS			
	8691860	Jul 07, 2028	DS U-1709			
	8772325	Mar 14, 2025	U-1709			
	9115091	Jul 07, 2028	DS DP U-1738			
	9205076	Mar 14, 2025	U-1709			
	9364489	Jul 07, 2028	U-1709			
	9675587	Mar 14, 2033	DP			
	9700542	Mar 14, 2025	DP			
	9789125	Jul 07, 2028	DP U-1709			
	9789125	Jul 07, 2028	DP U-2152			
<u>ELUXADOLINE - VIBERZI</u>						
N 206940 002	10188632	Mar 14, 2033	DP			
	10213415	Mar 14, 2025	DS U-2152			
	11007179	Mar 14, 2033	DP			
	11090291	Mar 14, 2033	DP			
	11160792	Mar 14, 2033	DP			
	11229627	Mar 14, 2033	DP			
	11311516	Mar 14, 2033	DP			
	11484527	Mar 14, 2033	U-3475			
	7741356	May 27, 2029	DS DP			
	7786158	Mar 14, 2025	DS			
	8344011	Mar 14, 2025	U-1709			
	8609709	Mar 14, 2025	DS			
	8691860	Jul 07, 2028	DS U-1709			
	8772325	Mar 14, 2025	U-1709			
	9115091	Jul 07, 2028	DS DP U-1738			
	9205076	Mar 14, 2025	U-1709			
	9364489	Jul 07, 2028	U-1709			
	9675587	Mar 14, 2033	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ELUXADOLINE - VIBERZI</u>						
N 206940 002	9700542	Mar 14, 2025	DP			
	9789125	Jul 07, 2028	DP U-1709			
	9789125	Jul 07, 2028	DP U-2152			
<u>ELVITEGRAVIR - VITEKTA</u>						
N 203093 001	7176220	Aug 27, 2026	DS DP U-257			
	7176220*PED	Feb 27, 2027				
	7635704	Oct 26, 2026	DS DP U-257			
	7635704*PED	Apr 26, 2027				
	8981103	Oct 26, 2026	DS DP			
	8981103*PED	Apr 26, 2027				
<u>ELVITEGRAVIR - VITEKTA</u>						
N 203093 002	7176220	Aug 27, 2026	DS DP U-257			
	7176220*PED	Feb 27, 2027				
	7635704	Oct 26, 2026	DS DP U-257			
	7635704*PED	Apr 26, 2027				
	8981103	Oct 26, 2026	DS DP			
	8981103*PED	Apr 26, 2027				
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 001	10258637	Apr 03, 2034	U-2290		I-869	Aug 18, 2024
	11090323	Apr 03, 2034	U-3191		M-82	Feb 24, 2025
	7579449	Aug 01, 2028	DS			
	7713938	Apr 15, 2027	DS DP			
	8551957	Oct 14, 2029	U-1651			
	9949997	May 17, 2034	U-2292			
	9949997	May 17, 2034	U-3199			
	9949997	May 17, 2034	U-3325			
	9949998	Jun 11, 2034	U-2290			
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 002	10258637	Apr 03, 2034	U-2290			
	11090323	Apr 03, 2034	U-3191			
	7579449	Aug 01, 2028	DS			
	7713938	Apr 15, 2027	DS DP			
	8551957	Oct 14, 2029	U-1651			
	9949997	May 17, 2034	U-2292			
	9949998	Jun 11, 2034	U-2290			
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 001	10258637	Apr 03, 2034	U-2290		M-252	Mar 30, 2023
	11033552	May 04, 2027	DP			
	11090323	Apr 03, 2034	U-3191			
	7407955	May 02, 2025	DS DP			
	7579449	Aug 01, 2028	DS			
	7713938	Apr 15, 2027	DS DP			
	8119648	Aug 12, 2023	U-1651			
	8178541	Aug 12, 2023	DP U-1653			
	8178541	Aug 12, 2023	DP U-1654			
	8551957	Oct 14, 2029	DP U-1651			
	8673927	May 04, 2027	U-1652	Y		
	8883805	Nov 26, 2025	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 001	9173859	May 04, 2027	DP U-1772	Y		
	9949998	Jun 11, 2034	U-2290			
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 002	10258637	Apr 03, 2034	U-2290		M-252	Mar 30, 2023
	11033552	May 04, 2027	DP			
	11090323	Apr 03, 2034	U-3191			
	7407955	May 02, 2025	DS DP			
	7579449	Aug 01, 2028	DS			
	7713938	Apr 15, 2027	DS DP			
	8119648	Aug 12, 2023	U-1651			
	8178541	Aug 12, 2023	DP U-1653			
	8178541	Aug 12, 2023	DP U-1654			
	8551957	Oct 14, 2029	DP U-1651			
	8673927	May 04, 2027	U-1652	Y		
	8883805	Nov 26, 2025	DP			
	9173859	May 04, 2027	DP U-1772	Y		
	9949998	Jun 11, 2034	U-2290			
<u>EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR</u>						
N 212614 001	10022379	Apr 02, 2029	DP U-2732			
	10258637	Apr 03, 2034	U-2731			
	10406172	Jun 15, 2030	DP U-2733			
	10596120	Mar 07, 2032	DP U-2776			
	10596120	Mar 07, 2032	DP U-2790			
	11090323	Apr 03, 2034	U-3192			
	7407955	May 02, 2025	DS DP			
	7579449	Aug 01, 2028	DS			
	7713938	Apr 15, 2027	DS DP			
	8119648	Aug 12, 2023	U-1652			
	8178541	Aug 12, 2023	DP U-1652			
	8551957	Oct 14, 2029	DP U-2730			
	8883805	Nov 26, 2025	DP			
	9155705	May 21, 2030	DP			
	9415016	Apr 02, 2029	DP			
	9949998	Jun 11, 2034	U-2731			
<u>EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR</u>						
N 212614 002	10022379	Apr 02, 2029	DP U-2732			
	10258637	Apr 03, 2034	U-2731			
	10406172	Jun 15, 2030	DP U-2733			
	10596120	Mar 07, 2032	DP U-2776			
	10596120	Mar 07, 2032	DP U-2790			
	11090323	Apr 03, 2034	U-3192			
	7407955	May 02, 2025	DS DP			
	7579449	Aug 01, 2028	DS			
	7713938	Apr 15, 2027	DS DP			
	8119648	Aug 12, 2023	U-1652			
	8178541	Aug 12, 2023	DP U-1652			
	8551957	Oct 14, 2029	DP U-2730			
	8883805	Nov 26, 2025	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR</u>						
N 212614 002	9155705	May 21, 2030	DP			
	9415016	Apr 02, 2029	DP			
	9949998	Jun 11, 2034	U-2731			
<u>EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR</u>						
N 212614 003	10022379	Apr 02, 2029	DP	U-2732		
	10258637	Apr 03, 2034	U-2731			
	10406172	Jun 15, 2030	DP	U-2733		
	10596120	Mar 07, 2032	DP	U-2776		
	10596120	Mar 07, 2032	DP	U-2790		
	11090323	Apr 03, 2034	U-3192			
	7407955	May 02, 2025	DS DP			
	7579449	Aug 01, 2028	DS			
	7713938	Apr 15, 2027	DS DP			
	8119648	Aug 12, 2023	U-1652			
	8178541	Aug 12, 2023	DP	U-1652		
	8551957	Oct 14, 2029	DP	U-2730		
	8883805	Nov 26, 2025	DP			
	9155705	May 21, 2030	DP			
	9415016	Apr 02, 2029	DP			
	9949998	Jun 11, 2034	U-2731			
<u>EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR</u>						
N 212614 004	10022379	Apr 02, 2029	DP	U-2732		
	10258637	Apr 03, 2034	U-2731			
	10406172	Jun 15, 2030	DP	U-2733		
	10596120	Mar 07, 2032	DP	U-2776		
	10596120	Mar 07, 2032	DP	U-2790		
	11090323	Apr 03, 2034	U-3192			
	7407955	May 02, 2025	DS DP			
	7579449	Aug 01, 2028	DS			
	7713938	Apr 15, 2027	DS DP			
	8119648	Aug 12, 2023	U-1652			
	8178541	Aug 12, 2023	DP	U-1652		
	8551957	Oct 14, 2029	DP	U-2730		
	8883805	Nov 26, 2025	DP			
	9155705	May 21, 2030	DP			
	9415016	Apr 02, 2029	DP			
	9949998	Jun 11, 2034	U-2731			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 001	10258637	Apr 03, 2034	U-2290			
	10610489	Sep 30, 2030	DP			
	11090323	Apr 03, 2034	U-3193			
	7579449	Aug 01, 2028	DS			
	7713938	Apr 15, 2027	DS DP			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 002	10258637	Apr 03, 2034	U-2290			
	10610489	Sep 30, 2030	DP			
	11090323	Apr 03, 2034	U-3193			
	7579449	Aug 01, 2028	DS			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 002	7713938	Apr 15, 2027	DS DP			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 003	10258637	Apr 03, 2034	U-2290			
	10610489	Sep 30, 2030	DP			
	11090323	Apr 03, 2034	U-3193			
	7579449	Aug 01, 2028	DS			
	7713938	Apr 15, 2027	DS DP			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 004	10258637	Apr 03, 2034	U-2290			
	10610489	Sep 30, 2030	DP			
	11090323	Apr 03, 2034	U-3193			
	7579449	Aug 01, 2028	DS			
	7713938	Apr 15, 2027	DS DP			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 001	10258637	Apr 03, 2034	U-2290			
	10596120	Mar 07, 2032	DP U-2775			
	10596120	Mar 07, 2032	DP U-2792			
	11090323	Apr 03, 2034	U-3193			
	7579449	Aug 01, 2028	DS			
	7713938	Apr 15, 2027	DS DP			
	9949998	Jun 11, 2034	U-2290			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 002	10258637	Apr 03, 2034	U-2290			
	10596120	Mar 07, 2032	DP U-2775			
	10596120	Mar 07, 2032	DP U-2792			
	11090323	Apr 03, 2034	U-3193			
	7579449	Aug 01, 2028	DS			
	7713938	Apr 15, 2027	DS DP			
	9949998	Jun 11, 2034	U-2290			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 003	10258637	Apr 03, 2034	U-2290			
	10596120	Mar 07, 2032	DP U-2775			
	10596120	Mar 07, 2032	DP U-2792			
	11090323	Apr 03, 2034	U-3193			
	7579449	Aug 01, 2028	DS			
	7713938	Apr 15, 2027	DS DP			
	9949998	Jun 11, 2034	U-2290			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 004	10258637	Apr 03, 2034	U-2290			
	10596120	Mar 07, 2032	DP U-2775			
	10596120	Mar 07, 2032	DP U-2792			
	11090323	Apr 03, 2034	U-3193			
	7579449	Aug 01, 2028	DS			
	7713938	Apr 15, 2027	DS DP			
	9949998	Jun 11, 2034	U-2290			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE - ODEFSEY</u>						
N 208351 001	7125879	Apr 21, 2025	DS DP U-257			
	7390791	Apr 17, 2025	DS DP			
	7390791*PED	Oct 17, 2025				
	8080551	Apr 11, 2023	DS DP			
	8754065	Aug 15, 2032	DS DP U-257			
	8754065*PED	Feb 15, 2033				
	9296769	Aug 15, 2032	DS DP U-257			
	9296769*PED	Feb 15, 2033				
<u>EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE - COMPLERA</u>						
N 202123 001	10857102	Jan 14, 2033	DP			
	7125879	Apr 21, 2025	DS DP U-257			
	8080551	Apr 11, 2023	DS DP			
	8592397	Jan 13, 2024	DP U-257			
	8716264	Jan 13, 2024	DP U-257			
	8841310	Dec 09, 2025	DP U-257			
	9457036	Jan 13, 2024	DP U-257			
	9744181	Jan 13, 2024	DP U-257			
<u>EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - DESCOVY</u>						
N 208215 001	7390791	Apr 17, 2025	DS DP		ODE-284	Sep 28, 2024
	7390791*PED	Oct 17, 2025			ODE-285	Sep 28, 2024
	8754065	Aug 15, 2032	DS DP U-1259			
	8754065	Aug 15, 2032	DS DP U-1663			
	8754065	Aug 15, 2032	DS DP U-257			
	8754065*PED	Feb 15, 2033				
	9296769	Aug 15, 2032	DS DP U-1259			
	9296769	Aug 15, 2032	DS DP U-1663			
	9296769	Aug 15, 2032	DS DP U-257			
	9296769*PED	Feb 15, 2033				
<u>EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - DESCOVY</u>						
N 208215 002	7390791	Apr 17, 2025	DS DP			
	7390791*PED	Oct 17, 2025				
	8754065	Aug 15, 2032	DS DP U-1663			
	8754065*PED	Feb 15, 2033				
	9296769	Aug 15, 2032	DS DP U-1663			
	9296769*PED	Feb 15, 2033				
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 001	8592397	Jan 13, 2024	DP U-1170			
	8592397	Jan 13, 2024	DP U-248			
	8592397	Jan 13, 2024	DP U-541			
	8716264	Jan 13, 2024	DP U-257			
	9457036	Jan 13, 2024	DP U-257			
	9744181	Jan 13, 2024	DP U-257			
<u>ENALAPRIL MALEATE - EPANED KIT</u>						
N 204308 001	8568747	Nov 06, 2032	DP			
	8778366	Nov 06, 2032	U-1723			
	8778366	Nov 06, 2032	U-185			
	8778366	Nov 06, 2032	U-1892			
	8778366	Nov 06, 2032	U-3			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ENALAPRIL MALEATE - EPANED KIT</u>						
N 204308 001	8778366	Nov 06, 2032	U-71			
	9855214	Nov 06, 2032	DP			
	9968553	Nov 06, 2032	U-1723			
	9968553	Nov 06, 2032	U-185			
	9968553	Nov 06, 2032	U-1892			
	9968553	Nov 06, 2032	U-3			
	9968553	Nov 06, 2032	U-71			
<u>ENALAPRIL MALEATE - EPANED</u>						
N 208686 001	10039745	Mar 25, 2036	DP			
	10154987	Mar 25, 2036	U-1723			
	10154987	Mar 25, 2036	U-185			
	10154987	Mar 25, 2036	U-1892			
	10154987	Mar 25, 2036	U-3			
	10154987	Mar 25, 2036	U-71			
	10772868	Mar 25, 2036	DP			
	10786482	Mar 25, 2036	DP			
	11040023	Mar 25, 2036	DP			
	11141405	Mar 25, 2036	DP			
	11173141	Mar 25, 2036	DP			
	9669008	Mar 25, 2036	DP			
	9808442	Mar 25, 2036	U-1723			
	9808442	Mar 25, 2036	U-185			
	9808442	Mar 25, 2036	U-1892			
	9808442	Mar 25, 2036	U-3			
	9808442	Mar 25, 2036	U-71			
<u>ENASIDENIB MESYLATE - IDHIFA</u>						
N 209606 001	10093654	Aug 01, 2034	DS DP U-2087		ODE-151	Aug 01, 2024
	10294215	Jan 07, 2033	DP U-2087			
	10610125	Jun 21, 2030	U-2087			
	9512107	Jan 07, 2033	DS DP U-2087			
	9732062	Sep 16, 2034	DS			
	9738625	Aug 01, 2034	DS			
<u>ENASIDENIB MESYLATE - IDHIFA</u>						
N 209606 002	10093654	Aug 01, 2034	DS DP U-2087		ODE-151	Aug 01, 2024
	10294215	Jan 07, 2033	DP U-2087			
	10610125	Jun 21, 2030	U-2087			
	9512107	Jan 07, 2033	DS DP U-2087			
	9732062	Sep 16, 2034	DS			
	9738625	Aug 01, 2034	DS			
<u>ENCORAFENIB - BRAFTOVI</u>						
N 210496 001	10005761	Aug 27, 2030	U-2335		I-826	Apr 08, 2023
	8501758	Mar 04, 2031	DS DP		NCE	Jun 27, 2023
	8541575	Feb 26, 2030	DS DP U-2335		ODE-194	Jun 27, 2025
	8946250	Jul 23, 2029	DS DP			
	9314464	Jul 04, 2031	U-2336			
	9387208	Nov 21, 2032	DP			
	9593099	Aug 27, 2030	DS			
	9593100	Aug 27, 2030	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ENCORAFENIB - BRAFTOVI</u>						
N 210496 001	9763941	Nov 21, 2032	U-2335			
	9850229	Aug 27, 2030	U-2337			
	9850230	Aug 27, 2030	U-2334			
<u>ENCORAFENIB - BRAFTOVI</u>						
N 210496 002	10005761	Aug 27, 2030	U-2335		I-826	Apr 08, 2023
	10005761	Aug 27, 2030	U-2802		NCE	Jun 27, 2023
	10005761	Aug 27, 2030	U-2803		ODE-194	Jun 27, 2025
	10258622	Nov 21, 2032	U-2802			
	8501758	Mar 04, 2031	DS DP			
	8541575	Feb 26, 2030	DS DP U-2335			
	8541575	Feb 26, 2030	DS DP U-2802			
	8541575	Feb 26, 2030	DS DP U-2803			
	8946250	Jul 23, 2029	DS DP			
	9314464	Jul 04, 2031	U-2336			
	9314464	Jul 04, 2031	U-2802			
	9314464	Jul 04, 2031	U-2803			
	9387208	Nov 21, 2032	DP			
	9474754	Aug 05, 2033	U-2802			
	9593099	Aug 27, 2030	DS			
	9593100	Aug 27, 2030	DP			
	9763941	Nov 21, 2032	U-2335			
	9850229	Aug 27, 2030	U-2337			
	9850230	Aug 27, 2030	U-2334			
	9850230	Aug 27, 2030	U-2802			
	9850230	Aug 27, 2030	U-2803			
<u>ENTRECTINIB - ROZLYTREK</u>						
N 212725 001	10231965	Feb 17, 2035	U-2617		NCE	Aug 15, 2024
	10231965	Feb 17, 2035	U-2618		ODE-265	Aug 15, 2026
	10398693	Jul 18, 2038	DP		ODE-313	Aug 15, 2026
	10561651	Feb 19, 2035	U-2745			
	10738037	May 18, 2037	DS DP U-2946			
	11091469	May 18, 2037	U-2617			
	11091469	May 18, 2037	U-2618			
	11253515	Jul 18, 2038	DP			
	8299057	Mar 01, 2029	DS DP			
	8673893	Jul 08, 2028	U-2617			
	8673893	Jul 08, 2028	U-2618			
	9029356	Jul 08, 2028	DS DP			
	9085558	Jul 08, 2028	DP			
	9085565	May 22, 2033	DS DP			
	9255087	Jul 08, 2028	U-2617			
	9255087	Jul 08, 2028	U-2618			
	9616059	Jul 08, 2028	U-2618			
	9649306	May 22, 2033	U-2617			
	9649306	May 22, 2033	U-2618			
<u>ENTRECTINIB - ROZLYTREK</u>						
N 212725 002	10231965	Feb 17, 2035	U-2617		NCE	Aug 15, 2024
	10231965	Feb 17, 2035	U-2618		ODE-265	Aug 15, 2026

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ENTRECTINIB - ROZLYTREK</u>						
N 212725 002	10398693	Jul 18, 2038	DP		ODE-313	Aug 15, 2026
	10561651	Feb 19, 2035	U-2745			
	10738037	May 18, 2037	DS DP U-2946			
	11091469	May 18, 2037	U-2617			
	11091469	May 18, 2037	U-2618			
	11253515	Jul 18, 2038	DP			
	8299057	Mar 01, 2029	DS DP			
	8673893	Jul 08, 2028	U-2617			
	8673893	Jul 08, 2028	U-2618			
	9029356	Jul 08, 2028	DS DP			
	9085558	Jul 08, 2028	DP			
	9085565	May 22, 2033	DS DP			
	9255087	Jul 08, 2028	U-2617			
	9255087	Jul 08, 2028	U-2618			
	9616059	Jul 08, 2028	U-2618			
	9649306	May 22, 2033	U-2617			
	9649306	May 22, 2033	U-2618			
<u>ENZALUTAMIDE - XTANDI</u>						
N 203415 001	7709517	Aug 13, 2027	DS DP			
	8183274	Aug 24, 2026	U-1281			
	8183274	Aug 24, 2026	U-1588			
	8183274	Aug 24, 2026	U-2345			
	8183274	Aug 24, 2026	U-2708			
	9126941	May 15, 2026	U-1588			
	9126941	May 15, 2026	U-2345			
	9126941	May 15, 2026	U-2708			
<u>ENZALUTAMIDE - XTANDI</u>						
N 213674 001	7709517	Aug 13, 2027	DS DP			
	8183274	Aug 24, 2026	U-2345			
	8183274	Aug 24, 2026	U-2708			
	9126941	May 15, 2026	U-2345			
	9126941	May 15, 2026	U-2708			
<u>ENZALUTAMIDE - XTANDI</u>						
N 213674 002	7709517	Aug 13, 2027	DS DP			
	8183274	Aug 24, 2026	U-2345			
	8183274	Aug 24, 2026	U-2708			
	9126941	May 15, 2026	U-2345			
	9126941	May 15, 2026	U-2708			
<u>EPHEDRINE SULFATE - EMERPHED</u>						
N 213407 001	11090278	May 16, 2040	U-3183			
	11241400	May 16, 2040	U-3183			
	11464752	May 16, 2040	DP			
	11478436	May 16, 2040	U-3183			
<u>EPHEDRINE SULFATE - EPHEDRINE SULFATE</u>						
N 213994 001	10869845	Jan 22, 2040	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EPHEDRINE SULFATE - EPHEDRINE SULFATE</u>						
N 213994 002	10869845	Jan 22, 2040	DP			
<u>EPINEPHRINE - EPIPEN</u>						
N 019430 001	7449012	Sep 11, 2025	DP			
	7794432	Sep 11, 2025	DP			
	8048035	Sep 11, 2025	DP			
	8870827	Sep 11, 2025	DP			
	9586010	Sep 11, 2025	DP			
<u>EPINEPHRINE - EPIPEN JR.</u>						
N 019430 002	7449012	Sep 11, 2025	DP			
	7794432	Sep 11, 2025	DP			
	8048035	Sep 11, 2025	DP			
	8870827	Sep 11, 2025	DP			
	9586010	Sep 11, 2025	DP			
<u>EPINEPHRINE - TWINJECT 0.3</u>						
N 020800 001	7297136	Jan 18, 2025	DP			
	7621891	Feb 04, 2025	DP			
<u>EPINEPHRINE - TWINJECT 0.15</u>						
N 020800 002	7297136	Jan 18, 2025	DP			
	7621891	Feb 04, 2025	DP			
<u>EPINEPHRINE - ADRENALINE</u>						
N 020800 003	10166334	Jan 21, 2025	DP			
	7905352	Apr 12, 2027	DP			
<u>EPINEPHRINE - ADRENALINE</u>						
N 020800 004	10166334	Jan 21, 2025	DP			
	7905352	Apr 12, 2027	DP			
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739 001	10314977	Nov 23, 2024	DP			
	10335549	Apr 30, 2025	DP			
	10737028	Nov 23, 2024	DP			
	10960155	Jun 25, 2026	DP			
	7731686	Jun 01, 2026	DP			
	7731690	Jan 15, 2025	DP			
	7749194	Oct 30, 2028	DP			
	7918823	Nov 23, 2024	DP			
	7947017	Mar 12, 2028	DP			
	8016788	Mar 21, 2025	DP			
	8021344	Nov 02, 2029	DP			
	8206360	Feb 27, 2027	DP			
	8226610	Apr 10, 2029	DP			
	8231573	Nov 25, 2028	DP			
	8313466	Nov 23, 2024	DP			
	8361029	Nov 23, 2024	DP			
	8425462	Nov 23, 2024	DP			
	8608698	Nov 23, 2024	DP			
	8920377	Nov 23, 2024	DP			
	8926594	Mar 31, 2026	DP			
	9056170	Nov 23, 2024	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739 001	9149579	Jul 19, 2025	U-1758			
	9238108	Feb 20, 2027	DP			
	9259539	Feb 01, 2026	DP			
	9278182	Feb 01, 2026	DP			
	9724471	May 23, 2027	DP U-2092			
	9737669	Nov 23, 2024	DP			
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739 002	10314977	Nov 23, 2024	DP			
	10335549	Apr 30, 2025	DP			
	10688244	Dec 21, 2037	DP U-2980			
	10737028	Nov 23, 2024	DP			
	10842938	Dec 21, 2037	DP U-2980			
	10960155	Jun 25, 2026	DP			
	7731686	Jun 01, 2026	DP			
	7731690	Jan 15, 2025	DP			
	7749194	Oct 30, 2028	DP			
	7918823	Nov 23, 2024	DP			
	7947017	Mar 12, 2028	DP			
	8016788	Mar 21, 2025	DP			
	8021344	Nov 02, 2029	DP			
	8206360	Feb 27, 2027	DP			
	8226610	Apr 10, 2029	DP			
	8231573	Nov 25, 2028	DP			
	8313466	Nov 23, 2024	DP			
	8361029	Nov 23, 2024	DP			
	8425462	Nov 23, 2024	DP			
	8608698	Nov 23, 2024	DP			
	8920377	Nov 23, 2024	DP			
	8926594	Mar 31, 2026	DP			
	9056170	Nov 23, 2024	DP			
	9149579	Jul 19, 2025	U-1758			
	9238108	Feb 20, 2027	DP			
	9259539	Feb 01, 2026	DP			
	9278182	Feb 01, 2026	DP			
	9724471	May 23, 2027	DP U-2092			
	9737669	Nov 23, 2024	DP			
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739 003	10314977	Nov 23, 2024	DP			
	10335549	Apr 30, 2025	DP			
	10688244	Dec 21, 2037	DP U-2980			
	10737028	Nov 23, 2024	DP			
	10842938	Dec 21, 2037	DP U-2980			
	10960155	Jun 25, 2026	DP			
	7731686	Jun 01, 2026	DP			
	7731690	Jan 15, 2025	DP			
	7749194	Oct 30, 2028	DP			
	7918823	Nov 23, 2024	DP			
	7947017	Mar 12, 2028	DP			
	8016788	Mar 21, 2025	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739 003	8021344	Nov 02, 2029	DP			
	8206360	Feb 27, 2027	DP			
	8226610	Apr 10, 2029	DP			
	8231573	Nov 25, 2028	DP			
	8313466	Nov 23, 2024	DP			
	8361029	Nov 23, 2024	DP			
	8425462	Nov 23, 2024	DP			
	8608698	Nov 23, 2024	DP			
	8920377	Nov 23, 2024	DP			
	8926594	Mar 31, 2026	DP			
	9056170	Nov 23, 2024	DP			
	9149579	Jul 19, 2025	U-1758			
	9238108	Feb 20, 2027	DP			
	9259539	Feb 01, 2026	DP			
	9278182	Feb 01, 2026	DP			
	9724471	May 23, 2027	DP U-2092			
	9737669	Nov 23, 2024	DP			
	9833573	Nov 23, 2024	U-2172			
<u>EPINEPHRINE - ADRENALIN</u>						
N 204200 001	9119876	Mar 13, 2035	DP			
	9295657	Mar 13, 2035	U-1829			
<u>EPINEPHRINE - ADRENALIN</u>						
N 204640 001	10130592	Mar 13, 2035	DP			
	9119876	Mar 13, 2035	DP			
	9295657	Mar 13, 2035	U-1829			
<u>EPINEPHRINE - EPINEPHRINE</u>						
N 205029 001	10004700	Aug 14, 2034	DP U-2325	Y		
	10039728	Aug 14, 2034	U-1828	Y		
	9283197	Aug 15, 2034	DP U-1828	Y		
	9283197	Aug 15, 2034	DP U-1829	Y		
	9283197	Aug 15, 2034	DP U-1830	Y		
<u>EPINEPHRINE - PRIMATENE MIST</u>						
N 205920 001	8367734	Jan 26, 2026	DP			
<u>EPINEPHRINE - SYMJEPI</u>						
N 207534 001	11141540	Oct 20, 2036	DP U-3379			
<u>EPINEPHRINE - SYMJEPI</u>						
N 207534 002	11141540	Oct 20, 2036	DP U-3379			
<u>EPOPROSTENOL SODIUM - VELETRI</u>						
N 022260 001	8318802	Mar 15, 2027	DP			
	8598227	Feb 02, 2027				
<u>EPOPROSTENOL SODIUM - VELETRI</u>						
N 022260 002	8318802	Mar 15, 2027	DP			
	8598227	Feb 02, 2027				
<u>ERAVACYCLINE DIHYDROCHLORIDE - XERAVA</u>						
N 211109 001	10961190	Oct 19, 2037	DS		NCE	Aug 27, 2023
	8796245	Aug 07, 2029	U-2380		GAIN	Aug 27, 2028

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ERAVACYCLINE DIHYDROCHLORIDE - XERAVA</u>						
N 211109 001	8906887	Dec 28, 2030	DP			
<u>ERAVACYCLINE DIHYDROCHLORIDE - XERAVA</u>						
N 211109 002	10961190	Oct 19, 2037	DS		NCE	Aug 27, 2023
	8796245	Aug 07, 2029	U-2380		GAIN	Aug 27, 2028
	8906887	Dec 28, 2030	DP			
<u>ERDAFITINIB - BALVERSA</u>						
N 212018 001	10898482	Feb 09, 2036	DP U-2518		NCE	Apr 12, 2024
	10898482	Feb 09, 2036	DP U-3065			
	10898482	Feb 09, 2036	DP U-3066			
	10898482	Feb 09, 2036	DP U-3067			
	11077106	Feb 02, 2038	U-3196			
	8895601	May 22, 2031	DS DP			
	9464071	Apr 28, 2031	U-2518			
	9902714	Mar 26, 2035	DP			
<u>ERDAFITINIB - BALVERSA</u>						
N 212018 002	10898482	Feb 09, 2036	DP U-2518		NCE	Apr 12, 2024
	10898482	Feb 09, 2036	DP U-3065			
	10898482	Feb 09, 2036	DP U-3066			
	10898482	Feb 09, 2036	DP U-3067			
	11077106	Feb 02, 2038	U-3196			
	8895601	May 22, 2031	DS DP			
	9464071	Apr 28, 2031	U-2518			
	9902714	Mar 26, 2035	DP			
<u>ERDAFITINIB - BALVERSA</u>						
N 212018 003	10898482	Feb 09, 2036	DP U-2518		NCE	Apr 12, 2024
	10898482	Feb 09, 2036	DP U-3065			
	10898482	Feb 09, 2036	DP U-3066			
	10898482	Feb 09, 2036	DP U-3067			
	11077106	Feb 02, 2038	U-3196			
	8895601	May 22, 2031	DS DP			
	9464071	Apr 28, 2031	U-2518			
	9902714	Mar 26, 2035	DP			
<u>ERIBULIN MESYLATE - HALAVEN</u>						
N 201532 001	6214865	Jul 20, 2023	DS		M-280	Sep 13, 2025
	6214865*PED	Jan 20, 2024			ODE-107	Jan 28, 2023
	RE46965	Jan 08, 2027	DP		PED	Mar 13, 2026
	RE46965*PED	Jul 08, 2027				
<u>ERTUGLIFLOZIN - STEGLATRO</u>						
N 209803 001	8080580	Jul 13, 2030	DS DP U-2214		M-275	Sep 17, 2024
<u>ERTUGLIFLOZIN - STEGLATRO</u>						
N 209803 002	8080580	Jul 13, 2030	DS DP U-2214		M-275	Sep 17, 2024
<u>ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE - SEGLUROMET</u>						
N 209806 001	8080580	Jul 13, 2030	DS DP U-2214		M-275	Sep 17, 2024
	9308204	Oct 21, 2030	DP			
	9439902	Oct 21, 2030	U-2214			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE - SEGLUROMET</u>						
N 209806 002	8080580	Jul 13, 2030	DS DP U-2214		M-275	Sep 17, 2024
	9308204	Oct 21, 2030	DP			
	9439902	Oct 21, 2030	U-2214			
<u>ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE - SEGLUROMET</u>						
N 209806 003	8080580	Jul 13, 2030	DS DP U-2214		M-275	Sep 17, 2024
	9308204	Oct 21, 2030	DP			
	9439902	Oct 21, 2030	U-2214			
<u>ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE - SEGLUROMET</u>						
N 209806 004	8080580	Jul 13, 2030	DS DP U-2214		M-275	Sep 17, 2024
	9308204	Oct 21, 2030	DP			
	9439902	Oct 21, 2030	U-2214			
<u>ERTUGLIFLOZIN; SITAGLIPTIN PHOSPHATE - STEGLUJAN</u>						
N 209805 001	6699871*PED	Jan 26, 2023			M-275	Sep 17, 2024
	7326708	Nov 24, 2026	DS DP U-2214			
	7326708*PED	May 24, 2027				
	8080580	Jul 13, 2030	DS DP U-2214			
	9308204	Oct 21, 2030	DP			
	9439901	Oct 21, 2030	U-2214			
<u>ERTUGLIFLOZIN; SITAGLIPTIN PHOSPHATE - STEGLUJAN</u>						
N 209805 002	6699871*PED	Jan 26, 2023			M-275	Sep 17, 2024
	7326708	Nov 24, 2026	DS DP U-2214			
	7326708*PED	May 24, 2027				
	8080580	Jul 13, 2030	DS DP U-2214			
	9308204	Oct 21, 2030	DP			
	9439901	Oct 21, 2030	U-2214			
<u>ESKETAMINE HYDROCHLORIDE - SPRAVATO</u>						
N 211243 001	10869844	Sep 10, 2035	U-3034		I-840	Jul 31, 2023
	10869844	Sep 10, 2035	U-3035		NCE*	Mar 05, 2024
	10869844	Sep 10, 2035	U-3036			
	11173134	Sep 14, 2035	U-3257			
	11311500	Sep 10, 2035	U-3034			
	11311500	Sep 10, 2035	U-3035			
	11311500	Sep 10, 2035	U-3036			
	11446260	Mar 14, 2034	U-3444			
	11446260	Mar 14, 2034	U-3445			
	11446260	Mar 14, 2034	U-3446			
	8785500	Mar 05, 2033	U-2502			
	9592207	Mar 20, 2027	U-2502			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 001	10675287	May 06, 2025	U-2041			
	10675287	May 06, 2025	U-2831			
	10695354	May 06, 2025	U-2501			
	10695354	May 06, 2025	U-2831			
	10702536	May 06, 2025	U-2501			
	10912781	Oct 23, 2028	DP			
	11364247	May 06, 2025	U-2501			
	11364247	May 06, 2025	U-2831			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 001	8372431	Apr 17, 2030	DP			
	9206135	Apr 21, 2026	DS			
	9566244	Oct 23, 2028	DP			
	9643929	Apr 21, 2026	DP			
	9750747	Aug 24, 2032	U-2041			
	9750747	Aug 24, 2032	U-2121			
	9763954	Sep 13, 2028	U-2123			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 002	10675287	May 06, 2025	U-2041			
	10675287	May 06, 2025	U-2831			
	10695354	May 06, 2025	U-2501			
	10695354	May 06, 2025	U-2831			
	10702536	May 06, 2025	U-2501			
	10912781	Oct 23, 2028	DP			
	11364247	May 06, 2025	U-2501			
	11364247	May 06, 2025	U-2831			
	8372431	Apr 17, 2030	DP			
	9206135	Apr 21, 2026	DS			
	9566244	Oct 23, 2028	DP			
	9643929	Apr 21, 2026	DP			
	9750747	Aug 24, 2032	U-2041			
	9750747	Aug 24, 2032	U-2121			
	9763954	Sep 13, 2028	U-2123			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 003	10675287	May 06, 2025	U-2041			
	10675287	May 06, 2025	U-2831			
	10695354	May 06, 2025	U-2501			
	10695354	May 06, 2025	U-2831			
	10702536	May 06, 2025	U-2501			
	10912781	Oct 23, 2028	DP			
	11364247	May 06, 2025	U-2501			
	11364247	May 06, 2025	U-2831			
	8372431	Apr 17, 2030	DP			
	9206135	Apr 21, 2026	DS			
	9566244	Oct 23, 2028	DP			
	9643929	Apr 21, 2026	DP			
	9750747	Aug 24, 2032	U-2041			
	9750747	Aug 24, 2032	U-2121			
	9763954	Sep 13, 2028	U-2123			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 004	10675287	May 06, 2025	U-2041			
	10675287	May 06, 2025	U-2831			
	10695354	May 06, 2025	U-2501			
	10695354	May 06, 2025	U-2831			
	10702536	May 06, 2025	U-2501			
	10912781	Oct 23, 2028	DP			
	11364247	May 06, 2025	U-2501			
	11364247	May 06, 2025	U-2831			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 004	8372431	Apr 17, 2030	DP			
	9206135	Apr 21, 2026	DS			
	9566244	Oct 23, 2028	DP			
	9643929	Apr 21, 2026	DP			
	9750747	Aug 24, 2032	U-2041			
	9750747	Aug 24, 2032	U-2121			
	9763954	Sep 13, 2028	U-2123			
<u>ESMOLOL HYDROCHLORIDE - ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER</u>						
N 205703 001	8829054	Mar 15, 2033	DP			
	8835505	Mar 15, 2033	DP			
<u>ESMOLOL HYDROCHLORIDE - ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER</u>						
N 205703 002	8829054	Mar 15, 2033	DP			
	8835505	Mar 15, 2033	DP			
<u>ESOMEPRAZOLE MAGNESIUM - ESOMEPRAZOLE MAGNESIUM</u>						
N 214278 001	10076494	Dec 08, 2036	DP			
	10835488	Dec 08, 2036	DP			
<u>ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO</u>						
N 022511 001	8945621	Oct 17, 2031	U-1661			
	9220698	Mar 10, 2031	U-1781			
	9393208	Sep 03, 2029	U-1781			
<u>ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO</u>						
N 022511 002	8945621	Oct 17, 2031	U-1661			
	9393208	Sep 03, 2029	U-1781			
<u>ESTRADIOL - ESTRADIOL</u>						
A 211783 001					CGT	Apr 08, 2023
<u>ESTRADIOL - MINIVELLE</u>						
N 203752 001	8231906	Jul 04, 2030	DS DP			
	9730900	Jul 10, 2028	U-2086			
	9833419	Jul 10, 2028	DP			
<u>ESTRADIOL - MINIVELLE</u>						
N 203752 002	8231906	Jul 04, 2030	DS DP			
	9730900	Jul 10, 2028	U-2086			
	9833419	Jul 10, 2028	DP			
<u>ESTRADIOL - MINIVELLE</u>						
N 203752 003	8231906	Jul 04, 2030	DS DP			
	9730900	Jul 10, 2028	U-2086			
	9833419	Jul 10, 2028	DP			
<u>ESTRADIOL - MINIVELLE</u>						
N 203752 004	8231906	Jul 04, 2030	DS DP			
	9730900	Jul 10, 2028	U-2086			
	9833419	Jul 10, 2028	DP			
<u>ESTRADIOL - MINIVELLE</u>						
N 203752 005	8231906	Jul 04, 2030	DS DP			
	9724310	Jul 10, 2028	DS DP			
	9730900	Jul 10, 2028	DP U-2086			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ESTRADIOL - MINIVELLE</u>						
N 203752	005 9833419	Jul 10, 2028	DP			
<u>ESTRADIOL - IMVEXXY</u>						
N 208564	001 10258630	Dec 20, 2033	U-2316			
	10258630	Dec 20, 2033	U-2317			
	10398708	Dec 20, 2033	U-2317			
	10398708	Dec 20, 2033	U-2614			
	10471072	Jun 18, 2033	U-2316			
	10471072	Jun 18, 2033	U-2317			
	10537581	Nov 21, 2032	DP U-2316			
	10537581	Nov 21, 2032	DP U-2317			
	10568891	Jun 18, 2033	U-2316			
	10568891	Jun 18, 2033	U-2317			
	10668082	Jun 18, 2033	U-2316			
	10668082	Jun 18, 2033	U-2317			
	10806697	Nov 21, 2032	DP			
	10835487	Nov 21, 2032	U-2316			
	10835487	Nov 21, 2032	U-2317			
	10888516	Jun 18, 2033	U-2316			
	10888516	Jun 18, 2033	U-2317			
	11065197	Jun 18, 2033	DP			
	11116717	Jun 18, 2033	DP			
	11123283	Jun 18, 2033	DP			
	11241445	Nov 21, 2032	U-2316			
	11241445	Nov 21, 2032	U-2317			
	11246875	Nov 21, 2032	U-2316			
	11246875	Nov 21, 2032	U-2317			
	11266661	Feb 02, 2034	U-2316			
	11266661	Feb 02, 2034	U-2317			
	11304959	Nov 21, 2032	DP			
	11351182	Nov 21, 2032	U-2316			
	11351182	Nov 21, 2032	U-2317			
	11497709	Nov 21, 2032	U-2316			
	11497709	Nov 21, 2032	U-2317			
	9180091	Dec 20, 2033	DP U-2316			
	9180091	Dec 20, 2033	DP U-2317			
	9289382	Nov 21, 2032	DP			
<u>ESTRADIOL - IMVEXXY</u>						
N 208564	002 10258630	Dec 20, 2033	U-2316			
	10258630	Dec 20, 2033	U-2317			
	10398708	Dec 20, 2033	U-2317			
	10398708	Dec 20, 2033	U-2614			
	10471072	Jun 18, 2033	U-2316			
	10471072	Jun 18, 2033	U-2317			
	10537581	Nov 21, 2032	DP U-2316			
	10537581	Nov 21, 2032	DP U-2317			
	10568891	Jun 18, 2033	U-2316			
	10568891	Jun 18, 2033	U-2317			
	10668082	Jun 18, 2033	U-2316			
	10668082	Jun 18, 2033	U-2317			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ESTRADIOL - IMVEXXY</u>						
N 208564 002	10806697	Nov 21, 2032	DP			
	10835487	Nov 21, 2032	U-2316			
	10835487	Nov 21, 2032	U-2317			
	10888516	Jun 18, 2033	U-2316			
	10888516	Jun 18, 2033	U-2317			
	11065197	Jun 18, 2033	DP			
	11116717	Jun 18, 2033	DP			
	11123283	Jun 18, 2033	DP			
	11241445	Nov 21, 2032	U-2316			
	11241445	Nov 21, 2032	U-2317			
	11246875	Nov 21, 2032	U-2316			
	11246875	Nov 21, 2032	U-2317			
	11266661	Feb 02, 2034	U-2316			
	11266661	Feb 02, 2034	U-2317			
	11304959	Nov 21, 2032	DP			
	11351182	Nov 21, 2032	U-2316			
	11351182	Nov 21, 2032	U-2317			
	11497709	Nov 21, 2032	U-2316			
	11497709	Nov 21, 2032	U-2317			
	9180091	Dec 20, 2033	DP U-2316			
	9180091	Dec 20, 2033	DP U-2317			
	9289382	Nov 21, 2032	DP			
<u>ESTRADIOL ACETATE - FEMTRACE</u>						
N 021633 001	7572779	Oct 02, 2025	U-904			
<u>ESTRADIOL ACETATE - FEMTRACE</u>						
N 021633 002	7572779	Oct 02, 2025	U-904			
<u>ESTRADIOL ACETATE - FEMTRACE</u>						
N 021633 003	7572779	Oct 02, 2025	U-904			
<u>ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX - MYFEMBREE</u>						
N 214846 001	11033551	Sep 29, 2037	U-3129		I-898	Aug 05, 2025
	7300935	Jan 28, 2024	DS		NCE	Dec 18, 2025
	8058280	Jan 28, 2024	DS		NP	May 26, 2024
	9346822	Feb 17, 2024	U-3129			
<u>ESTRADIOL; PROGESTERONE - BIJUVA</u>						
N 210132 001	10052386	Nov 21, 2032	DP			
	10206932	Nov 21, 2032	U-2439			
	10639375	Nov 21, 2032	DP			
	10675288	Nov 21, 2032	U-2439			
	10806740	Nov 21, 2032	DP U-2439			
	11033626	Nov 21, 2032	DP U-2439			
	11103513	Nov 21, 2032	U-2439			
	11103516	Nov 21, 2032	DP			
	11110099	Nov 21, 2032	DP			
	11529360	Nov 21, 2032	DP			
	8633178	Nov 21, 2032	DP			
	8846648	Nov 21, 2032	U-2439			
	8846649	Nov 21, 2032	DP U-2439			
	8987237	Nov 21, 2032	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ESTRADIOL; PROGESTERONE - BIJUVA</u>						
N 210132 001	8993548	Nov 21, 2032	DP			
	8993549	Nov 21, 2032	DP			
	9006222	Nov 21, 2032	DP U-2439			
	9114145	Nov 21, 2032	U-2439			
	9114146	Nov 21, 2032	DP U-2439			
	9301920	Nov 21, 2032	DP U-2439			
<u>ESTRADIOL; PROGESTERONE - BIJUVA</u>						
N 210132 002	10052386	Nov 21, 2032	DP			
	10206932	Nov 21, 2032	U-2439			
	10675288	Nov 21, 2032	U-2439			
	11033626	Nov 21, 2032	DP U-2439			
	11166963	Nov 21, 2032	DP			
	8633178	Nov 21, 2032	DP			
	8846648	Nov 21, 2032	U-2439			
	8846649	Nov 21, 2032	DP U-2439			
	8933059	Nov 21, 2032	DP U-2439			
	8987237	Nov 21, 2032	DP			
	8993548	Nov 21, 2032	DP			
	8993549	Nov 21, 2032	DP			
	9114145	Nov 21, 2032	U-2439			
	9114146	Nov 21, 2032	DP U-2439			
	9301920	Nov 21, 2032	DP U-2439			
<u>ETELCALCETIDE - PARSABIV</u>						
N 208325 001	10344765	Jun 27, 2034	DP			
	11162500	Jun 27, 2034	DP			
	8377880	Jul 29, 2030	DS DP			
	8999932	Feb 07, 2031	DS DP U-2014			
	9278995	Jul 29, 2030	DS			
	9701712	Jul 29, 2030	DS DP U-2014			
	9820938	Jun 27, 2034	DP			
<u>ETELCALCETIDE - PARSABIV</u>						
N 208325 002	10344765	Jun 27, 2034	DP			
	11162500	Jun 27, 2034	DP			
	8377880	Jul 29, 2030	DS DP			
	8999932	Feb 07, 2031	DS DP U-2014			
	9278995	Jul 29, 2030	DS			
	9701712	Jul 29, 2030	DS DP U-2014			
	9820938	Jun 27, 2034	DP			
<u>ETELCALCETIDE - PARSABIV</u>						
N 208325 003	10344765	Jun 27, 2034	DP			
	11162500	Jun 27, 2034	DP			
	8377880	Jul 29, 2030	DS DP			
	8999932	Feb 07, 2031	DS DP U-2014			
	9278995	Jul 29, 2030	DS			
	9701712	Jul 29, 2030	DS DP U-2014			
	9820938	Jun 27, 2034	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ETEPLIRSEN - EXONDYS 51</u>						
N 206488 001	10337003	Mar 14, 2034	U-1918		ODE-122	Sep 19, 2023
	10364431	Mar 14, 2034	U-1918			
	10364431	Mar 14, 2034	U-1919			
	10781451	Jun 28, 2025	DS DP			
	9018368	Jun 28, 2025	DS DP			
	9243245	Oct 27, 2028	DS U-2097			
	9243245	Oct 27, 2028	DS U-2098			
	9506058	Mar 14, 2034	U-1918			
	9506058	Mar 14, 2034	U-1919			
	RE47751	Jun 28, 2025	U-1918			
	RE47751	Jun 28, 2025	U-2664			
	RE47751	Jun 28, 2025	U-2673			
	RE47751	Jun 28, 2025	U-2674			
	RE47769	Feb 02, 2029	DP			
	RE48468	Oct 27, 2028	U-2097			
<u>ETEPLIRSEN - EXONDYS 51</u>						
N 206488 002	10337003	Mar 14, 2034	U-1918		ODE-122	Sep 19, 2023
	10364431	Mar 14, 2034	U-1918			
	10364431	Mar 14, 2034	U-1919			
	10781451	Jun 28, 2025	DS DP			
	9018368	Jun 28, 2025	DS DP			
	9243245	Oct 27, 2028	DS U-2097			
	9243245	Oct 27, 2028	DS U-2098			
	9506058	Mar 14, 2034	U-1918			
	9506058	Mar 14, 2034	U-1919			
	RE47751	Jun 28, 2025	U-1918			
	RE47751	Jun 28, 2025	U-2664			
	RE47751	Jun 28, 2025	U-2673			
	RE47751	Jun 28, 2025	U-2674			
	RE47769	Feb 02, 2029	DP			
	RE48468	Oct 27, 2028	U-2097			
<u>ETHINYL ESTRADIOL; ETHINYL ESTRADIOL; LEVONORGESTREL - SEASONIQUE</u>						
N 021840 001	7320969	Jan 30, 2024	U-828			
	7615545	Jun 15, 2023	U-1			
	7855190	Dec 05, 2028	U-1			
	7858605	Jun 23, 2023	DP			
<u>ETHINYL ESTRADIOL; LEVONORGESTREL - LOSEASONIQUE</u>						
N 022262 001	7615545	Jun 15, 2023	U-1			
	7855190	Dec 05, 2028	U-1			
	7858605	Jun 23, 2023	DP			
<u>ETHINYL ESTRADIOL; LEVONORGESTREL - TWIRLA</u>						
N 204017 001	8246978	Aug 26, 2028	DP		NP	Feb 14, 2023
	8747888	Jul 10, 2028	DP			
	9050348	Jul 10, 2028	DP			
<u>ETHINYL ESTRADIOL; LEVONORGESTREL - QUARTETTE</u>						
N 204061 001	8415332	Mar 11, 2029	DP			
	8450299	Oct 07, 2025	U-1			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ETHINYL ESTRADIOL; LEVONORGESTREL - BALCOLTRA</u>						
N 208612 001	7838042	Jun 01, 2027	DS U-3251			
<u>ETHINYL ESTRADIOL; LEVONORGESTREL - TYBLUME</u>						
N 209405 001					NDF	Mar 30, 2023
<u>ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - LO LOESTRIN FE</u>						
N 022501 001	7704984	Feb 02, 2029	U-1090			
<u>ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - LO MINASTRIN FE</u>						
N 204654 001	7704984	Feb 02, 2029	U-1			
<u>ETHINYL ESTRADIOL; SEGESTERONE ACETATE - ANNOVERA</u>						
N 209627 001	10632066	Feb 01, 2039	U-2786		NCE	Aug 10, 2023
	10632066	Feb 01, 2039	U-2787			
	10765628	Feb 01, 2039	U-2786			
	10765628	Feb 01, 2039	U-2787			
	10780047	Feb 01, 2039	U-2786			
	10780047	Feb 01, 2039	U-2787			
	10918649	Jun 21, 2039	DP			
	10925882	Jun 21, 2039	DP			
	10940157	Jun 21, 2039	DP			
	11529308	Jun 21, 2039	DP			
<u>ETONOGESTREL - IMPLANON</u>						
N 021529 001	9757552	Jul 28, 2030	DP U-1			
<u>ETONOGESTREL - NEXPLANON</u>						
N 021529 002	10821277	May 31, 2027	DP			
	8722037	Sep 28, 2027	DP			
	8888745	Aug 28, 2026	DP			
	9757552	Jul 28, 2030	DP U-1			
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 001	8410131	Nov 01, 2025	U-1368		ODE-108	Feb 26, 2023
	8410131*PED	May 01, 2026				
	9006224	Jul 01, 2028	U-1681			
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 002	8410131	Nov 01, 2025	U-1368		ODE-108	Feb 26, 2023
	8410131*PED	May 01, 2026				
	9006224	Jul 01, 2028	U-1681			
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 003	8410131	Nov 01, 2025	U-1368		ODE-108	Feb 26, 2023
	8410131*PED	May 01, 2026				
	9006224	Jul 01, 2028	U-1681			
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 004	8410131	Nov 01, 2025	U-1368		ODE-108	Feb 26, 2023
	8410131*PED	May 01, 2026				
	9006224	Jul 01, 2028	U-1681			
<u>EVEROLIMUS - AFINITOR DISPERZ</u>						
N 203985 001	8617598*PED	Mar 27, 2023			ODE-169	Apr 10, 2025

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EVEROLIMUS - AFINITOR DISPERZ</u>						
N 203985 002	8617598*PED	Mar 27, 2023			ODE-169	Apr 10, 2025
<u>EVEROLIMUS - AFINITOR DISPERZ</u>						
N 203985 003	8617598*PED	Mar 27, 2023			ODE-169	Apr 10, 2025
<u>EXENATIDE SYNTHETIC - BYETTA</u>						
N 021773 001					M-232	Nov 04, 2024
<u>EXENATIDE SYNTHETIC - BYETTA</u>						
N 021773 002					M-232	Nov 04, 2024
<u>EXENATIDE SYNTHETIC - BYDUREON</u>						
N 022200 001	6515117	Oct 04, 2025	DS DP U-2588		NPP	Jul 22, 2024
	6515117*PED	Apr 04, 2026			PED	Jan 22, 2025
	7456254	Jun 30, 2025	DP U-2588			
	7456254	Jun 30, 2025	DP U-2589			
	7456254	Jun 30, 2025	DP U-2590			
	7456254	Jun 30, 2025	DP U-3188			
	7456254	Jun 30, 2025	DP U-3189			
	7456254	Jun 30, 2025	DP U-3190			
	7456254*PED	Dec 30, 2025				
	7563871	Apr 15, 2024	DP			
	7612176	Apr 13, 2025	DP U-2588			
	7612176	Apr 13, 2025	DP U-2589			
	7612176	Apr 13, 2025	DP U-2590			
	7612176	Apr 13, 2025	DP U-3188			
	7612176	Apr 13, 2025	DP U-3189			
	7612176	Apr 13, 2025	DP U-3190			
	7612176*PED	Oct 13, 2025				
	8329648	Aug 18, 2026	U-2588			
	8329648	Aug 18, 2026	U-2589			
	8329648	Aug 18, 2026	U-2590			
	8329648	Aug 18, 2026	U-2593			
	8329648	Aug 18, 2026	U-2594			
	8329648	Aug 18, 2026	U-2595			
	8329648	Aug 18, 2026	U-2596			
	8329648	Aug 18, 2026	U-3188			
	8329648	Aug 18, 2026	U-3189			
	8329648	Aug 18, 2026	U-3190			
	8329648*PED	Feb 18, 2027				
	8361972	Mar 21, 2028	U-2588			
	8361972*PED	Sep 21, 2028				
	8431685	Apr 13, 2025	DP U-2588			
	8431685	Apr 13, 2025	DP U-2589			
	8431685	Apr 13, 2025	DP U-2590			
	8431685	Apr 13, 2025	DP U-3188			
	8431685	Apr 13, 2025	DP U-3189			
	8431685	Apr 13, 2025	DP U-3190			
	8431685*PED	Oct 13, 2025				
	8461105	Apr 13, 2025	DP U-2588			
	8461105	Apr 13, 2025	DP U-2589			
	8461105	Apr 13, 2025	DP U-2590			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EXENATIDE SYNTHETIC - BYDUREON</u>						
N 022200 001	8461105	Apr 13, 2025	DP U-3188			
	8461105	Apr 13, 2025	DP U-3189			
	8461105	Apr 13, 2025	DP U-3190			
	8461105*PED	Oct 13, 2025				
	8501698	Jun 20, 2027	DP U-2588			
	8501698*PED	Dec 20, 2027				
	8906851	Aug 18, 2026	U-2588			
	8906851	Aug 18, 2026	U-2589			
	8906851	Aug 18, 2026	U-2590			
	8906851	Aug 18, 2026	U-2593			
	8906851	Aug 18, 2026	U-3188			
	8906851	Aug 18, 2026	U-3189			
	8906851	Aug 18, 2026	U-3190			
	8906851*PED	Feb 18, 2027				
	9238076	Apr 15, 2024	DP U-2588			
	9238076	Apr 15, 2024	DP U-2589			
	9238076	Apr 15, 2024	DP U-2590			
	9238076	Apr 15, 2024	DP U-2599			
	9238076	Apr 15, 2024	DP U-3188			
	9238076	Apr 15, 2024	DP U-3189			
	9238076	Apr 15, 2024	DP U-3190			
	9238076*PED	Oct 15, 2024				
	9884092	Aug 18, 2026	U-2588			
	9884092	Aug 18, 2026	U-2589			
	9884092	Aug 18, 2026	U-2590			
	9884092	Aug 18, 2026	U-2593			
	9884092	Aug 18, 2026	U-2594			
	9884092	Aug 18, 2026	U-2595			
	9884092	Aug 18, 2026	U-2596			
	9884092	Aug 18, 2026	U-3188			
	9884092	Aug 18, 2026	U-3189			
	9884092	Aug 18, 2026	U-3190			
	9884092*PED	Feb 18, 2027				
<u>EXENATIDE SYNTHETIC - BYDUREON PEN</u>						
N 022200 002	6515117	Oct 04, 2025	DS DP U-2588		NPP	Jul 22, 2024
	6515117*PED	Apr 04, 2026			PED	Jan 22, 2025
	6824822*PED	Apr 09, 2023				
	7456254	Jun 30, 2025	DP U-2588			
	7456254	Jun 30, 2025	DP U-2589			
	7456254	Jun 30, 2025	DP U-2590			
	7456254	Jun 30, 2025	DP U-3188			
	7456254	Jun 30, 2025	DP U-3189			
	7456254	Jun 30, 2025	DP U-3190			
	7456254*PED	Dec 30, 2025				
	7563871	Apr 15, 2024	DP			
	7563871*PED	Oct 15, 2024				
	7612176	Apr 13, 2025	DP U-2588			
	7612176	Apr 13, 2025	DP U-2589			
	7612176	Apr 13, 2025	DP U-2590			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EXENATIDE SYNTHETIC - BYDUREON PEN</u>						
N 022200 002	7612176	Apr 13, 2025	DP U-3188			
	7612176	Apr 13, 2025	DP U-3189			
	7612176	Apr 13, 2025	DP U-3190			
	7612176*PED	Oct 13, 2025				
	8216180	Jan 12, 2028	DP			
	8216180*PED	Jul 12, 2028				
	8329648	Aug 18, 2026	U-2588			
	8329648	Aug 18, 2026	U-2589			
	8329648	Aug 18, 2026	U-2590			
	8329648	Aug 18, 2026	U-2593			
	8329648	Aug 18, 2026	U-2594			
	8329648	Aug 18, 2026	U-2595			
	8329648	Aug 18, 2026	U-2596			
	8329648	Aug 18, 2026	U-3188			
	8329648	Aug 18, 2026	U-3189			
	8329648	Aug 18, 2026	U-3190			
	8329648*PED	Feb 18, 2027				
	8361972	Mar 21, 2028	U-2588			
	8361972*PED	Sep 21, 2028				
	8431685	Apr 13, 2025	DP U-2588			
	8431685	Apr 13, 2025	DP U-2589			
	8431685	Apr 13, 2025	DP U-2590			
	8431685	Apr 13, 2025	DP U-3188			
	8431685	Apr 13, 2025	DP U-3189			
	8431685	Apr 13, 2025	DP U-3190			
	8431685*PED	Oct 13, 2025				
	8439864	Mar 25, 2028	DP			
	8439864*PED	Sep 25, 2028				
	8461105	Apr 13, 2025	DP U-2588			
	8461105	Apr 13, 2025	DP U-2589			
	8461105	Apr 13, 2025	DP U-2590			
	8461105	Apr 13, 2025	DP U-3188			
	8461105	Apr 13, 2025	DP U-3189			
	8461105	Apr 13, 2025	DP U-3190			
	8461105*PED	Oct 13, 2025				
	8501698	Jun 20, 2027	DP U-2588			
	8501698*PED	Dec 20, 2027				
	8690837	May 19, 2029	DP			
	8690837*PED	Nov 19, 2029				
	8721615	Jan 18, 2030	DP			
	8721615*PED	Jul 18, 2030				
	8758292	Nov 12, 2027	DP			
	8758292*PED	May 12, 2028				
	8827963	Feb 04, 2029	DP			
	8827963*PED	Aug 04, 2029				
	8906851	Aug 18, 2026	U-2588			
	8906851	Aug 18, 2026	U-2589			
	8906851	Aug 18, 2026	U-2590			
	8906851	Aug 18, 2026	U-2593			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EXENATIDE SYNTHETIC - BYDUREON PEN</u>						
N 022200 002	8906851	Aug 18, 2026	U-3188			
	8906851	Aug 18, 2026	U-3189			
	8906851	Aug 18, 2026	U-3190			
	8906851*PED	Feb 18, 2027				
	8998876	Jan 07, 2030	DP			
	8998876*PED	Jul 07, 2030				
	9238076	Apr 15, 2024	DP U-2588			
	9238076	Apr 15, 2024	DP U-2589			
	9238076	Apr 15, 2024	DP U-2590			
	9238076	Apr 15, 2024	DP U-2599			
	9238076	Apr 15, 2024	DP U-3188			
	9238076	Apr 15, 2024	DP U-3189			
	9238076	Apr 15, 2024	DP U-3190			
	9238076*PED	Oct 15, 2024				
	9320853	Mar 25, 2028	DP			
	9320853*PED	Sep 25, 2028				
	9884092	Aug 18, 2026	U-2588			
	9884092	Aug 18, 2026	U-2589			
	9884092	Aug 18, 2026	U-2590			
	9884092	Aug 18, 2026	U-2593			
	9884092	Aug 18, 2026	U-2594			
	9884092	Aug 18, 2026	U-2595			
	9884092	Aug 18, 2026	U-2596			
	9884092	Aug 18, 2026	U-3188			
	9884092	Aug 18, 2026	U-3189			
	9884092	Aug 18, 2026	U-3190			
	9884092*PED	Feb 18, 2027				
<u>EXENATIDE SYNTHETIC - BYDUREON BCISE</u>						
N 209210 001	6515117	Oct 04, 2025	DS DP U-2588		NPP	Jul 22, 2024
	6515117*PED	Apr 04, 2026			PED	Jan 22, 2025
	6824822*PED	Apr 09, 2023				
	7456254	Jun 30, 2025	DP U-2588			
	7456254	Jun 30, 2025	DP U-2589			
	7456254	Jun 30, 2025	DP U-2590			
	7456254	Jun 30, 2025	DP U-3188			
	7456254	Jun 30, 2025	DP U-3189			
	7456254	Jun 30, 2025	DP U-3190			
	7456254*PED	Dec 30, 2025				
	7563871	Apr 15, 2024	DP			
	7563871*PED	Oct 15, 2024				
	7612176	Apr 13, 2025	DP U-2589			
	7612176	Apr 13, 2025	DP U-2590			
	7612176	Apr 13, 2025	DP U-3188			
	7612176	Apr 13, 2025	DP U-3189			
	7612176	Apr 13, 2025	DP U-3190			
	7612176*PED	Oct 13, 2025				
	8329648	Aug 18, 2026	U-2588			
	8329648	Aug 18, 2026	U-2589			
	8329648	Aug 18, 2026	U-2590			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EXENATIDE SYNTHETIC - BYDUREON BCISE</u>						
N 209210 001	8329648	Aug 18, 2026	U-2593			
	8329648	Aug 18, 2026	U-2594			
	8329648	Aug 18, 2026	U-2595			
	8329648	Aug 18, 2026	U-2596			
	8329648	Aug 18, 2026	U-3188			
	8329648	Aug 18, 2026	U-3189			
	8329648	Aug 18, 2026	U-3190			
	8329648*PED	Feb 18, 2027				
	8361972	Mar 21, 2028	U-2588			
	8361972*PED	Sep 21, 2028				
	8431685	Apr 13, 2025	DP U-2588			
	8431685	Apr 13, 2025	DP U-2589			
	8431685	Apr 13, 2025	DP U-2590			
	8431685	Apr 13, 2025	DP U-2597			
	8431685	Apr 13, 2025	DP U-3188			
	8431685	Apr 13, 2025	DP U-3189			
	8431685	Apr 13, 2025	DP U-3190			
	8431685*PED	Oct 13, 2025				
	8461105	Apr 13, 2025	DP U-2588			
	8461105	Apr 13, 2025	DP U-2589			
	8461105	Apr 13, 2025	DP U-2590			
	8461105	Apr 13, 2025	DP U-2597			
	8461105	Apr 13, 2025	DP U-3188			
	8461105	Apr 13, 2025	DP U-3189			
	8461105	Apr 13, 2025	DP U-3190			
	8461105*PED	Oct 13, 2025				
	8501698	Jun 20, 2027	U-2588			
	8501698*PED	Dec 20, 2027				
	8895033	Oct 04, 2030	DP U-2589			
	8895033	Oct 04, 2030	DP U-2590			
	8895033	Oct 04, 2030	DP U-2597			
	8895033	Oct 04, 2030	DP U-2601			
	8895033	Oct 04, 2030	DP U-2602			
	8895033	Oct 04, 2030	DP U-3188			
	8895033	Oct 04, 2030	DP U-3189			
	8895033	Oct 04, 2030	DP U-3190			
	8895033*PED	Apr 04, 2031				
	8906851	Aug 18, 2026	U-2588			
	8906851	Aug 18, 2026	U-2589			
	8906851	Aug 18, 2026	U-2590			
	8906851	Aug 18, 2026	U-2593			
	8906851	Aug 18, 2026	U-2597			
	8906851	Aug 18, 2026	U-3188			
	8906851	Aug 18, 2026	U-3189			
	8906851	Aug 18, 2026	U-3190			
	8906851*PED	Feb 18, 2027				
	9238076	Apr 15, 2024	DP U-2588			
	9238076	Apr 15, 2024	DP U-2589			
	9238076	Apr 15, 2024	DP U-2590			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EXENATIDE SYNTHETIC - BYDUREON BCISE</u>						
N 209210 001	9238076	Apr 15, 2024	DP U-2597			
	9238076	Apr 15, 2024	DP U-2599			
	9238076	Apr 15, 2024	DP U-3188			
	9238076	Apr 15, 2024	DP U-3189			
	9238076	Apr 15, 2024	DP U-3190			
	9238076*PED	Oct 15, 2024				
	9884092	Aug 18, 2026	U-2588			
	9884092	Aug 18, 2026	U-2589			
	9884092	Aug 18, 2026	U-2590			
	9884092	Aug 18, 2026	U-2593			
	9884092	Aug 18, 2026	U-2594			
	9884092	Aug 18, 2026	U-2595			
	9884092	Aug 18, 2026	U-2596			
	9884092	Aug 18, 2026	U-2597			
	9884092	Aug 18, 2026	U-3188			
	9884092	Aug 18, 2026	U-3189			
	9884092	Aug 18, 2026	U-3190			
	9884092*PED	Feb 18, 2027				
<u>EZETIMIBE - ZETIA</u>						
N 021445 001	7612058	Oct 30, 2025	U-1027			
	7612058	Oct 30, 2025	U-1173			
	7612058*PED	Apr 30, 2026				
<u>EZETIMIBE; ROSUVASTATIN CALCIUM - ROSZET</u>						
N 213072 001	10376470	May 01, 2033	DP U-3095			
	9763885	May 01, 2033	DP U-3095			
<u>EZETIMIBE; ROSUVASTATIN CALCIUM - ROSZET</u>						
N 213072 002	10376470	May 01, 2033	DP U-3095			
	9763885	May 01, 2033	DP U-3095			
<u>EZETIMIBE; ROSUVASTATIN CALCIUM - ROSZET</u>						
N 213072 003	10376470	May 01, 2033	DP U-3095			
	9763885	May 01, 2033	DP U-3095			
<u>EZETIMIBE; ROSUVASTATIN CALCIUM - ROSZET</u>						
N 213072 004	10376470	May 01, 2033	DP U-3095			
	9763885	May 01, 2033	DP U-3095			
<u>FAMOTIDINE; IBUPROFEN - DUEXIS</u>						
N 022519 001	8067451	Jul 18, 2026	DP U-1196			
	8309127	Jul 18, 2026	DP			
	8318202	Jul 18, 2026	DP			
	8449910	Jul 18, 2026	DP			
	8501228	Jul 18, 2026	U-1196			
<u>FEBUXOSTAT - ULORIC</u>						
N 021856 001	7361676	Mar 08, 2024	DP			
	8372872	Sep 08, 2031	U-1346			
	9107912	Sep 08, 2031	U-1346			
<u>FEBUXOSTAT - ULORIC</u>						
N 021856 002	7361676	Mar 08, 2024	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FEBUXOSTAT - ULORIC</u>						
N 021856 002	8372872	Sep 08, 2031	U-1346			
	9107912	Sep 08, 2031	U-1346			
<u>FEDRATINIB HYDROCHLORIDE - INREBIC</u>						
N 212327 001	10391094	Jun 04, 2032	DP U-2607		NCE	Aug 16, 2024
	11400092	Sep 24, 2039	U-3409		ODE-259	Aug 16, 2026
	7528143	Dec 16, 2026	DS			
	7825246	Dec 16, 2026	DS			
	8138199	Jun 30, 2028	U-2607			
<u>FENFLURAMINE HYDROCHLORIDE - FINTEPLA</u>						
N 212102 001	10452815	Jun 29, 2038	U-2859	Y	I-887	Mar 25, 2025
	10452815*PED	Dec 29, 2038			NP	Jun 25, 2023
	10478441	May 03, 2033	U-2860		ODE-312	Jun 25, 2027
	10478441*PED	Nov 03, 2033			PED	Dec 25, 2023
	10478442	May 03, 2033	U-2860		PED	Sep 25, 2025
	10478442*PED	Nov 03, 2033			PED	Dec 25, 2027
	10603290	Aug 02, 2037	U-2861			
	10603290	Aug 02, 2037	U-3347			
	10603290*PED	Feb 02, 2038				
	10947183	Dec 20, 2036	DS DP			
	10947183*PED	Jun 20, 2037				
	11040018	Aug 02, 2037	U-2861			
	11040018	Aug 02, 2037	U-3347			
	11040018*PED	Feb 02, 2038				
	11406606	Aug 02, 2037	U-3406			
	11406606	Aug 02, 2037	U-3407			
	11406606*PED	Feb 02, 2038				
	9549909	May 03, 2033	U-2858			
	9549909*PED	Nov 03, 2033				
	9603814	May 03, 2033	U-2858			
	9603814*PED	Nov 03, 2033				
	9603815	May 03, 2033	U-2858			
	9603815*PED	Nov 03, 2033				
	9610260	May 03, 2033	U-2858			
	9610260*PED	Nov 03, 2033				
<u>FENOFIBRATE - TRICOR</u>						
N 021656 001	7276249	Feb 21, 2023	DP			
	7320802	Feb 21, 2023	U-847			
<u>FENOFIBRATE - TRICOR</u>						
N 021656 002	7276249	Feb 21, 2023	DP			
	7320802	Feb 21, 2023	U-847			
<u>FENOFIBRATE - ANTARA (MICRONIZED)</u>						
N 021695 004	8026281	Apr 22, 2025	U-1447			
	8026281	Apr 22, 2025	U-1448			
<u>FENOFIBRATE - ANTARA (MICRONIZED)</u>						
N 021695 005	8026281	Apr 22, 2025	U-1447			
	8026281	Apr 22, 2025	U-1448			
	9314447	May 31, 2033	DP U-1447			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FENOFIBRATE - ANTARA (MICRONIZED)</u>						
N 021695 005	9314447	May 31, 2033	DP U-1448			
<u>FENOFIBRATE - FENOGLIDE</u>						
N 022118 001	7658944	Dec 09, 2024	DP			
	8124125	Oct 01, 2024	DP U-1234			
	8481078	Oct 01, 2024	DP U-1416			
	9173847	Oct 01, 2024	DP			
<u>FENOFIBRATE - FENOGLIDE</u>						
N 022118 002	7658944	Dec 09, 2024	DP			
	8124125	Oct 01, 2024	DP U-1234			
	8481078	Oct 01, 2024	DP U-1416			
	9173847	Oct 01, 2024	DP			
<u>FENOFIBRIC ACID - FIBRICOR</u>						
N 022418 001	7569612	Aug 20, 2027	U-1000			
	7741373	Aug 20, 2027	U-1059			
	7741374	Aug 20, 2027	U-1060			
	7741374	Aug 20, 2027	U-1061			
	7915247	Aug 20, 2027	U-1000			
	7915247	Aug 20, 2027	U-1059			
	7915247	Aug 20, 2027	U-1061			
<u>FENOFIBRIC ACID - FIBRICOR</u>						
N 022418 002	7569612	Aug 20, 2027	U-1000			
	7741373	Aug 20, 2027	U-1059			
	7741374	Aug 20, 2027	U-1060			
	7741374	Aug 20, 2027	U-1061			
	7915247	Aug 20, 2027	U-1000			
	7915247	Aug 20, 2027	U-1059			
	7915247	Aug 20, 2027	U-1061			
<u>FENOPROFEN CALCIUM - FENOPROFEN CALCIUM</u>						
A 214475 001					CGT	Feb 11, 2023
<u>FENTANYL - SUBSYS</u>						
N 202788 001	10016403	Jan 25, 2027	DP			
	10610523	Jan 25, 2027	DP			
	8486972	Apr 27, 2030	DP			
	8486973	Apr 27, 2030	U-55			
	8835459	Jan 25, 2027	DP			
	8835460	Jan 25, 2027	DP U-55			
	9241935	Jan 25, 2027	DP			
	9289387	Jan 25, 2027	DP U-55			
	9642797	Jan 25, 2027	DP U-55			
	9642844	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 002	10016403	Jan 25, 2027	DP			
	10610523	Jan 25, 2027	DP			
	8486972	Apr 27, 2030	DP			
	8486973	Apr 27, 2030	U-55			
	8835460	Jan 25, 2027	DP U-55			
	9241935	Jan 25, 2027	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FENTANYL - SUBSYS</u>						
N 202788 002	9289387	Jan 25, 2027	DP U-55			
	9642797	Jan 25, 2027	DP U-55			
	9642844	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 003	10016403	Jan 25, 2027	DP			
	10610523	Jan 25, 2027	DP			
	8486972	Apr 27, 2030	DP			
	8486973	Apr 27, 2030	U-55			
	8835459	Jan 25, 2027	DP			
	8835460	Jan 25, 2027	DP U-55			
	9241935	Jan 25, 2027	DP			
	9289387	Jan 25, 2027	DP U-55			
	9642797	Jan 25, 2027	DP U-55			
	9642844	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 004	10016403	Jan 25, 2027	DP			
	10610523	Jan 25, 2027	DP			
	8486972	Apr 27, 2030	DP			
	8486973	Apr 27, 2030	U-55			
	8835459	Jan 25, 2027	DP			
	8835460	Jan 25, 2027	DP U-55			
	9241935	Jan 25, 2027	DP			
	9289387	Jan 25, 2027	DP U-55			
	9642797	Jan 25, 2027	DP U-55			
	9642844	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 005	10016403	Jan 25, 2027	DP			
	10610523	Jan 25, 2027	DP			
	8486972	Apr 27, 2030	DP			
	8486973	Apr 27, 2030	U-55			
	8835460	Jan 25, 2027	DP U-55			
	9241935	Jan 25, 2027	DP			
	9289387	Jan 25, 2027	DP U-55			
	9642797	Jan 25, 2027	DP U-55			
	9642844	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 006	10016403	Jan 25, 2027	DP			
	10610523	Jan 25, 2027	DP			
	8486972	Apr 27, 2030	DP			
	8486973	Apr 27, 2030	U-55			
	8835459	Jan 25, 2027	DP			
	8835460	Jan 25, 2027	DP U-55			
	9241935	Jan 25, 2027	DP			
	9289387	Jan 25, 2027	DP U-55			
	9642797	Jan 25, 2027	DP U-55			
	9642844	Jan 25, 2027	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FENTANYL - SUBSYS</u>						
N 202788 007	10016403	Jan 25, 2027	DP			
	10610523	Jan 25, 2027	DP			
	8486972	Apr 27, 2030	DP			
	8486973	Apr 27, 2030	U-55			
	8835459	Jan 25, 2027	DP			
	8835460	Jan 25, 2027	DP U-55			
	9241935	Jan 25, 2027	DP			
	9289387	Jan 25, 2027	DP U-55			
	9642797	Jan 25, 2027	DP U-55			
	9642844	Jan 25, 2027	DP			
<u>FENTANYL CITRATE - FENTORA</u>						
N 021947 001	7862832	Jun 15, 2028	DP			
	7862833	Jun 15, 2028	DP			
	8092832	Dec 30, 2024	DP			
<u>FENTANYL CITRATE - FENTORA</u>						
N 021947 002	7862832	Jun 15, 2028	DP			
	7862833	Jun 15, 2028	DP			
	8092832	Dec 30, 2024	DP			
	8119158	Dec 30, 2024	DP			
<u>FENTANYL CITRATE - FENTORA</u>						
N 021947 003	7862832	Jun 15, 2028	DP			
	7862833	Jun 15, 2028	DP			
	8092832	Dec 30, 2024	DP			
	8119158	Dec 30, 2024	DP			
<u>FENTANYL CITRATE - FENTORA</u>						
N 021947 004	7862832	Jun 15, 2028	DP			
	7862833	Jun 15, 2028	DP			
	8092832	Dec 30, 2024	DP			
	8119158	Dec 30, 2024	DP			
<u>FENTANYL CITRATE - FENTORA</u>						
N 021947 005	7862832	Jun 15, 2028	DP			
	7862833	Jun 15, 2028	DP			
	8092832	Dec 30, 2024	DP			
	8119158	Dec 30, 2024	DP			
<u>FENTANYL CITRATE - ONSOLIS</u>						
N 022266 001	9597288	Jul 23, 2027	DP U-767			
<u>FENTANYL CITRATE - ONSOLIS</u>						
N 022266 002	9597288	Jul 23, 2027	DP U-767			
<u>FENTANYL CITRATE - ONSOLIS</u>						
N 022266 003	9597288	Jul 23, 2027	DP U-767			
<u>FENTANYL CITRATE - ONSOLIS</u>						
N 022266 004	9597288	Jul 23, 2027	DP U-767			
<u>FENTANYL CITRATE - ONSOLIS</u>						
N 022266 005	9597288	Jul 23, 2027	DP U-767			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FENTANYL CITRATE - LAZANDA</u>						
N 022569 001	8216604	Oct 03, 2024	U-767			
	8889176	Jan 16, 2024	U-767			
	9078814	Jan 08, 2024	DP			
	9731869	Jan 26, 2032	DP			
	9814705	Jan 08, 2024	DP			
<u>FENTANYL CITRATE - LAZANDA</u>						
N 022569 002	8216604	Oct 03, 2024	U-767			
	8889176	Jan 16, 2024	U-767			
	9078814	Jan 08, 2024	DP			
	9731869	Jan 26, 2032	DP			
	9814705	Jan 08, 2024	DP			
<u>FENTANYL CITRATE - LAZANDA</u>						
N 022569 003	9731869	Jan 26, 2032	DP			
	9814705	Jan 08, 2024	DP			
<u>FENTANYL HYDROCHLORIDE - IONSYS</u>						
N 021338 001	6975902	Apr 01, 2024	DP			
	8301238	Sep 30, 2031	DP			
	8428708	May 21, 2032	U-736			
	8428709	Jun 11, 2032	DP U-736			
	8781571	Mar 31, 2032	DP U-736			
	9095706	Feb 03, 2033	DP			
	9364656	Sep 30, 2031	U-736			
	9731121	Oct 17, 2031	DP			
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 001	11123321	Oct 20, 2023	DS DP U-2555		NPP	Nov 19, 2024
	11123321	Oct 20, 2023	DS DP U-2557			
	11123321	Oct 20, 2023	DS DP U-3312			
	11123321	Oct 20, 2023	DS DP U-3313			
	11291645	Oct 20, 2023	DS DP U-3351			
	11291645	Oct 20, 2023	DS DP U-3352			
	11433091	Jan 08, 2027	U-3435			
	11433091	Jan 08, 2027	U-3436			
	11433091	Jan 08, 2027	U-3437			
	11433091	Jan 08, 2027	U-3438			
	11478502	Jan 08, 2027	U-3472			
	11478502	Jan 08, 2027	U-3473			
	11478502	Jan 08, 2027	U-3474			
	7612109	Feb 05, 2024	DS DP			
	7754702	Feb 15, 2028	U-1432			
	7754702	Feb 15, 2028	U-2555			
	7754702	Feb 15, 2028	U-2556			
	7754702	Feb 15, 2028	U-2557			
	7754702	Feb 15, 2028	U-3312			
	7754702	Feb 15, 2028	U-3313			
	7754702	Feb 15, 2028	U-3314			
	8895612	Jan 08, 2027	U-1620			
	8895612	Jan 08, 2027	U-3050			
	8895612	Jan 08, 2027	U-3051			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FERRIC CARBOXYMALTOSATE - INJECTAFER</u>						
N 203565 001	8895612	Jan 08, 2027	U-3115			
	8895612	Jan 08, 2027	U-3116			
	8895612	Jan 08, 2027	U-3315			
	8895612	Jan 08, 2027	U-3316			
	9376505	Oct 20, 2023	DS DP			
<u>FERRIC CARBOXYMALTOSATE - INJECTAFER</u>						
N 203565 002	11123321	Oct 20, 2023	DS DP U-2555		NPP	Nov 19, 2024
	11123321	Oct 20, 2023	DS DP U-2557			
	11123321	Oct 20, 2023	DS DP U-3312			
	11123321	Oct 20, 2023	DS DP U-3313			
	11291645	Oct 20, 2023	DS DP U-3351			
	11291645	Oct 20, 2023	DS DP U-3352			
	11433091	Jan 08, 2027	U-3435			
	11433091	Jan 08, 2027	U-3436			
	11433091	Jan 08, 2027	U-3437			
	11433091	Jan 08, 2027	U-3438			
	11478502	Jan 08, 2027	U-3472			
	11478502	Jan 08, 2027	U-3473			
	11478502	Jan 08, 2027	U-3474			
	7612109	Feb 05, 2024	DS DP			
	7754702	Feb 15, 2028	U-2555			
	7754702	Feb 15, 2028	U-2556			
	7754702	Feb 15, 2028	U-2557			
	7754702	Feb 15, 2028	U-3312			
	7754702	Feb 15, 2028	U-3313			
	7754702	Feb 15, 2028	U-3314			
	8895612	Jan 08, 2027	U-1620			
	8895612	Jan 08, 2027	U-3050			
	8895612	Jan 08, 2027	U-3051			
	8895612	Jan 08, 2027	U-3115			
	8895612	Jan 08, 2027	U-3116			
	8895612	Jan 08, 2027	U-3315			
	8895612	Jan 08, 2027	U-3316			
	9376505	Oct 20, 2023	DS DP			
<u>FERRIC CARBOXYMALTOSATE - INJECTAFER</u>						
N 203565 003	11123321	Oct 20, 2023	DS DP U-2555		NPP	Nov 19, 2024
	11123321	Oct 20, 2023	DS DP U-2557		NS	Apr 28, 2024
	11123321	Oct 20, 2023	DS DP U-3312			
	11123321	Oct 20, 2023	DS DP U-3313			
	11291645	Oct 20, 2023	DS DP U-3351			
	11291645	Oct 20, 2023	DS DP U-3352			
	11433091	Jan 08, 2027	U-3435			
	11433091	Jan 08, 2027	U-3436			
	11433091	Jan 08, 2027	U-3437			
	11433091	Jan 08, 2027	U-3438			
	11478502	Jan 08, 2027	U-3472			
	11478502	Jan 08, 2027	U-3473			
	11478502	Jan 08, 2027	U-3474			
	7612109	Feb 05, 2024	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 003	7754702	Feb 15, 2028	U-2555			
	7754702	Feb 15, 2028	U-2556			
	7754702	Feb 15, 2028	U-2557			
	7754702	Feb 15, 2028	U-3312			
	7754702	Feb 15, 2028	U-3313			
	7754702	Feb 15, 2028	U-3314			
	8895612	Jan 08, 2027	U-1620			
	8895612	Jan 08, 2027	U-3050			
	8895612	Jan 08, 2027	U-3051			
	8895612	Jan 08, 2027	U-3115			
	8895612	Jan 08, 2027	U-3116			
	8895612	Jan 08, 2027	U-3315			
	8895612	Jan 08, 2027	U-3316			
	9376505	Oct 20, 2023	DS DP			
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 004	11123321	Oct 20, 2023	DS DP U-3312			
	11123321	Oct 20, 2023	DS DP U-3313			
	11291645	Oct 20, 2023	DS DP U-3351			
	11291645	Oct 20, 2023	DS DP U-3352			
	11433091	Jan 08, 2027	U-3435			
	11433091	Jan 08, 2027	U-3436			
	11433091	Jan 08, 2027	U-3437			
	11433091	Jan 08, 2027	U-3438			
	11478502	Jan 08, 2027	U-3472			
	11478502	Jan 08, 2027	U-3473			
	11478502	Jan 08, 2027	U-3474			
	7612109	Feb 05, 2024	DS DP			
	7754702	Feb 15, 2028	U-3312			
	7754702	Feb 15, 2028	U-3313			
	7754702	Feb 15, 2028	U-3314			
	8895612	Jan 08, 2027	U-3115			
	8895612	Jan 08, 2027	U-3116			
	8895612	Jan 08, 2027	U-3315			
	8895612	Jan 08, 2027	U-3316			
	9376505	Oct 20, 2023	DS DP			
<u>FERRIC CITRATE - AURYXIA</u>						
N 205874 001	10300039	Jul 21, 2030	U-2549			
	7767851	Feb 18, 2024	DS DP			
	8093423	Apr 21, 2026	U-1577			
	8299298	Feb 18, 2024	DP			
	8338642	Feb 18, 2024	DS DP U-1577			
	8609896	Feb 18, 2024	DP			
	8754257	Feb 18, 2024	DP			
	8754258	Feb 18, 2024	DP			
	8846976	Feb 18, 2024	U-1577			
	8901349	Feb 18, 2024	U-1577			
	9050316	Feb 18, 2024	U-1577			
	9328133	Feb 18, 2024	DS DP U-1577			
	9387191	Jul 21, 2030	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FERRIC CITRATE - AURYXIA</u>						
N 205874 001	9757416	Feb 18, 2024	DS DP U-1577			
<u>FERRIC DERISOMALTOSE - MONOFERRIC</u>						
N 208171 001	10414831	Mar 25, 2029	DS DP			
	8815301	Aug 14, 2029	DS DP U-2734			
<u>FERRIC DERISOMALTOSE - MONOFERRIC</u>						
N 208171 002	10414831	Mar 25, 2029	DS DP			
	8815301	Aug 14, 2029	DS DP U-2734			
<u>FERRIC DERISOMALTOSE - MONOFERRIC</u>						
N 208171 003	10414831	Mar 25, 2029	DS DP			
	8815301	Aug 14, 2029	DS DP U-2734			
<u>FERRIC MALTOL - ACCRUFER</u>						
N 212320 001	10179120	Jan 06, 2035	U-2603		NCE	Jul 25, 2024
	9248148	Mar 29, 2031	U-2603			
	9802973	Oct 23, 2035	DS DP U-2603			
<u>FERRIC OXYHYDROXIDE - VELPHORO</u>						
N 205109 001	10624855	Nov 26, 2034	DP			
	10624855*PED	May 26, 2035				
	10682376	Nov 13, 2028	DP			
	10682376*PED	May 13, 2029				
	10695367	Nov 13, 2028	DP			
	10695367*PED	May 13, 2029				
	10925896	Nov 13, 2028	DP			
	10925896*PED	May 13, 2029				
	10925897	Nov 13, 2028	DP			
	10925897*PED	May 13, 2029				
	10933090	Nov 13, 2028	DP			
	10933090*PED	May 13, 2029				
	11013761	Nov 13, 2028	DP			
	11013761*PED	May 13, 2029				
	11013762	Nov 13, 2028	DP			
	11013762*PED	May 13, 2029				
	11234938	Nov 26, 2034	DP			
	11234938*PED	May 26, 2035				
	11446252	Nov 26, 2034	DP			
	11446252*PED	May 26, 2035				
	9561251	Jan 23, 2030	DP U-1468			
	9561251*PED	Jul 23, 2030				
<u>FERRIC PYROPHOSPHATE CITRATE - TRIFERIC</u>						
N 206317 001	7816404	Apr 17, 2029	DP U-1656			
<u>FERRIC PYROPHOSPHATE CITRATE - TRIFERIC</u>						
N 208551 001	7816404	Apr 17, 2029	U-1656			
	7857977	Sep 08, 2027	U-1656			
<u>FERRIC PYROPHOSPHATE CITRATE - TRIFERIC AVNU</u>						
N 212860 001	7816404	Apr 17, 2029	DS U-2801			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FERUMOXYTOL - FERAHME</u>						
N 022180	001 6599498	Jun 30, 2023	DS DP			
<u>FESOTERODINE FUMARATE - TOVIAZ</u>						
N 022030	001 7807715	Jun 07, 2027	DP U-913		I-861	Jun 17, 2024
	8088398	Jun 07, 2027	DP U-913		PED	Dec 17, 2024
	8501723	Jun 07, 2027	DP			
	8501723*PED	Dec 07, 2027				
<u>FESOTERODINE FUMARATE - TOVIAZ</u>						
N 022030	002 7807715	Jun 07, 2027	DP U-913		I-861	Jun 17, 2024
	8088398	Jun 07, 2027	DP U-913		PED	Dec 17, 2024
	8501723	Jun 07, 2027	DP			
	8501723*PED	Dec 07, 2027				
<u>FEXINIDAZOLE - FEXINIDAZOLE</u>						
N 214429	001				NCE	Jul 16, 2026
					ODE-359	Jul 16, 2028
<u>FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA ALLERGY</u>						
N 201373	001 8933097	Aug 02, 2030	DP			
<u>FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA HIVES</u>						
N 201373	002 8933097	Aug 02, 2030	DP			
<u>FIDAXOMICIN - DIFICID</u>						
N 201699	001 7378508	Jul 31, 2027	DS DP		NPP	Jan 24, 2023
	7863249	Jul 31, 2027	DS DP		ODE-367	Jan 24, 2027
	7906489	Mar 04, 2027	U-2741		PED	Jul 24, 2023
	7906489	Mar 04, 2027	U-319			
	7906489*PED	Sep 04, 2027				
	8586551	Jul 15, 2023	DS DP			
	8586551*PED	Jan 15, 2024				
	8859510	Jul 31, 2027	U-2741			
	8859510	Jul 31, 2027	U-319			
	8859510*PED	Jan 31, 2028				
<u>FIDAXOMICIN - DIFICID</u>						
N 213138	001 7378508	Jul 31, 2027	DS DP		NP	Jan 24, 2023
	7378508*PED	Jan 31, 2028			ODE-367	Jan 24, 2027
	7863249	Jul 31, 2027	DP		PED	Jul 24, 2023
	7863249*PED	Jan 31, 2028				
	7906489	Mar 04, 2027	U-2741			
	7906489*PED	Sep 04, 2027				
	8586551	Jul 23, 2023	DS DP			
	8586551*PED	Jan 23, 2024				
	8859510	Jul 31, 2027	U-2741			
	8859510*PED	Jan 31, 2028				
	9808530	May 28, 2034	DP			
	9808530*PED	Nov 28, 2034				
<u>FINAFLOXACIN - XTORO</u>						
N 206307	001 8536167	Aug 08, 2031	U-1679			
	9119859	Jul 02, 2030	U-1679			
	9504691	Nov 21, 2033	DP U-1679			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FINAFLOXACIN - XTORO</u>						
N 206307	001 9993483	Jul 02, 2030	DP			
<u>FINERENONE - KERENDIA</u>						
N 215341	001 8436180	Apr 12, 2029	DS DP		M-279 NCE	Sep 01, 2025 Jul 09, 2026
<u>FINERENONE - KERENDIA</u>						
N 215341	002 8436180	Apr 12, 2029	DS DP		M-279 NCE	Sep 01, 2025 Jul 09, 2026
<u>FINGOLIMOD HYDROCHLORIDE - FINGOLIMOD HYDROCHLORIDE</u>						
A 207971	001				PC	Mar 20, 2023
<u>FINGOLIMOD HYDROCHLORIDE - FINGOLIMOD HYDROCHLORIDE</u>						
A 207985	001				PC	Mar 20, 2023
<u>FINGOLIMOD HYDROCHLORIDE - FINGOLIMOD HYDROCHLORIDE</u>						
A 207991	001				PC	Mar 20, 2023
<u>FINGOLIMOD HYDROCHLORIDE - FINGOLIMOD HYDROCHLORIDE</u>						
A 208008	001				PC	Mar 20, 2023
<u>FINGOLIMOD HYDROCHLORIDE - GILENYA</u>						
N 022527	001 10543179	Dec 25, 2027		U-2719		
	8324283	Mar 29, 2026	DP			
	8324283*PED	Sep 29, 2026				
	9187405	Jun 25, 2027		U-2613		
	9187405*PED	Dec 25, 2027				
<u>FINGOLIMOD HYDROCHLORIDE - GILENYA</u>						
N 022527	002 9592208	Mar 30, 2032		DP U-2315		
	9592208*PED	Sep 30, 2032				
<u>FINGOLIMOD LAURYL SULFATE - TASCENSO ODT</u>						
N 214962	001 10555902	Jan 19, 2036		U-3268		
	10925829	Jan 19, 2036	DP			
	9925138	Jan 19, 2036	DP			
<u>FINGOLIMOD LAURYL SULFATE - TASCENSO ODT</u>						
N 214962	002 10555902	Jan 19, 2036		U-3493		
	10925829	Jan 19, 2036	DP			
	9925138	Jan 19, 2036	DP			
<u>FISH OIL TRIGLYCERIDES - OMEGAVEN</u>						
N 210589	001 10350186	Nov 05, 2024		U-2585	NCE	Jul 27, 2023
	9566260	Jul 11, 2025	DP U-2366		ODE-202	Jul 27, 2025
	9629821	Jul 11, 2025	DP U-2367			
<u>FISH OIL TRIGLYCERIDES - OMEGAVEN</u>						
N 210589	002 10350186	Nov 05, 2024		U-2585	NCE	Jul 27, 2023
	9566260	Jul 11, 2025	DP U-2366		ODE-202	Jul 27, 2025
	9629821	Jul 11, 2025	DP U-2367			
<u>FISH OIL; MEDIUM CHAIN TRIGLYCERIDES; OLIVE OIL; SOYBEAN OIL - SMOFLIPID 20%</u>						
N 207648	001				NPP	Mar 22, 2025
<u>FISH OIL; MEDIUM CHAIN TRIGLYCERIDES; OLIVE OIL; SOYBEAN OIL - SMOFLIPID 20%</u>						
N 207648	002				NPP	Mar 22, 2025

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FISH OIL; MEDIUM CHAIN TRIGLYCERIDES; OLIVE OIL; SOYBEAN OIL - SMOFLIPID 20%</u>						
N 207648	003				NPP	Mar 22, 2025
<u>FISH OIL; MEDIUM CHAIN TRIGLYCERIDES; OLIVE OIL; SOYBEAN OIL - SMOFLIPID 20%</u>						
N 207648	004				NPP	Mar 22, 2025
<u>FLIBANSERIN - ADDYI</u>						
N 022526	001	7151103	May 09, 2028	U-1734		
		8227471	May 09, 2023	U-1734		
<u>FLORBETABEN F-18 - NEURACEQ</u>						
N 204677	001	7807135	Mar 18, 2029	DS DP U-1497		
<u>FLORBETAPIR F-18 - AMYVID</u>						
N 202008	001	7687052	Apr 30, 2027	DS DP		
		8506929	Apr 30, 2027	DS DP U-1423		
<u>FLORBETAPIR F-18 - AMYVID</u>						
N 202008	002	7687052	Apr 30, 2027	DS DP		
		8506929	Apr 30, 2027	DS DP U-1423		
<u>FLORBETAPIR F-18 - AMYVID</u>						
N 202008	003	7687052	Apr 30, 2027	DS DP		
		8506929	Apr 30, 2027	DS DP U-1423		
<u>FLORTAUCIPIR F-18 - TAUVID</u>						
N 212123	001	8932557	May 19, 2029	DS	NCE	May 28, 2025
<u>FLORTAUCIPIR F-18 - TAUVID</u>						
N 212123	002	8932557	May 19, 2029	DS	NCE	May 28, 2025
<u>FLORTAUCIPIR F-18 - TAUVID</u>						
N 212123	003	8932557	May 19, 2029	DS		
<u>FLORTAUCIPIR F-18 - TAUVID</u>						
N 212123	004	8932557	May 19, 2029	DS		
<u>FLUCICLOVINE F-18 - AXUMIN</u>						
N 208054	001	10010632	Nov 28, 2026	DP		
		10124079	Dec 30, 2035	U-2450		
		10716868	Dec 30, 2035	U-2450		
		10933147	Dec 30, 2035	U-2450		
		10953112	Nov 28, 2026	U-1879		
		10967077	Dec 30, 2035	U-2450		
		9387266	Nov 28, 2026	U-1879		
<u>FLUOCINOLONE ACETONIDE - ILUVIEN</u>						
N 201923	001	8871241	Aug 12, 2027	DP		
<u>FLUOCINOLONE ACETONIDE - YUTIQ</u>						
N 210331	001	7998108	Jan 12, 2028	DP U-3410		
		8871241	Aug 12, 2027	DP		
<u>FLUOCINOLONE ACETONIDE; HYDROQUINONE; TRETINOIN - TRI-LUMA</u>						
N 021112	001	7915243	Sep 08, 2023	DP		
		7939516	Sep 08, 2023	DP		
<u>FLUOCINONIDE - VANOS</u>						
N 021758	001	7220424	Jan 07, 2023	U-861		
		8232264	Mar 09, 2023	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUOCINONIDE - VANOS</u>						
N 021758 001	7220424	Jan 07, 2023	U-861			
	8232264	Mar 09, 2023	DP			
<u>FLUORODOPA F-18 - FLUORODOPA F18</u>						
N 200655 001					NCE	Oct 10, 2024
					W	Oct 10, 2024
<u>FLUOROESTRADIOL F-18 - CERIANNA</u>						
N 212155 001					NCE	May 20, 2025
<u>FLUOROURACIL - TOLAK</u>						
N 022259 001	7169401	Jul 18, 2023	DP			
<u>FLUTEMETAMOL F-18 - VIZAMYL</u>						
N 203137 001	7270800	Sep 03, 2025	DS DP U-336			
	7351401	Jan 24, 2023	DS DP U-336			
	8236282	May 21, 2024	DS DP			
	8691185	Jan 24, 2023	U-336			
	8916131	Sep 16, 2028	DP			
<u>FLUTEMETAMOL F-18 - VIZAMYL</u>						
N 203137 002	7270800	Sep 03, 2025	DS DP U-336			
	7351401	Jan 24, 2023	DS DP U-336			
	8236282	May 21, 2024	DS DP			
	8691185	Jan 24, 2023	U-336			
	8916131	Sep 16, 2028	DP			
<u>FLUTICASONE FUROATE - FLONASE SENSIMIST ALLERGY RELIEF</u>						
N 022051 002	8062264	Apr 05, 2026	DP			
	8147461	Oct 15, 2028	DP			
	8347879	Jul 15, 2028	DP			
	8752543	Apr 05, 2026	DP			
	9320862	Nov 06, 2024	DP			
<u>FLUTICASONE FUROATE - ARNUITY ELLIPTA</u>						
N 205625 001	8113199	Oct 23, 2027	DP			
	8161968	Feb 05, 2028	DP			
	8201556	Feb 05, 2029	DP			
	8534281	Mar 08, 2030	DP			
	8746242	Oct 11, 2030	DP			
	9333310	Oct 02, 2027	DP			
<u>FLUTICASONE FUROATE - ARNUITY ELLIPTA</u>						
N 205625 002	8113199	Oct 23, 2027	DP			
	8161968	Feb 05, 2028	DP			
	8201556	Feb 05, 2029	DP			
	8534281	Mar 08, 2030	DP			
	8746242	Oct 11, 2030	DP			
	9333310	Oct 02, 2027	DP			
<u>FLUTICASONE FUROATE - ARNUITY ELLIPTA</u>						
N 205625 003	8113199	Oct 23, 2027	DP			
	8161968	Feb 05, 2028	DP			
	8201556	Feb 05, 2029	DP			
	8534281	Mar 08, 2030	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE FUROATE - ARNUITY ELLIPTA</u>						
N 205625 003	8746242	Oct 11, 2030	DP			
	9333310	Oct 02, 2027	DP			
<u>FLUTICASONE FUROATE; UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - TRELEGY ELLIPTA</u>						
N 209482 001	11090294	Nov 29, 2030	U-3202		I-843	Sep 09, 2023
	7439393	May 21, 2025	DS DP U-2127			
	7439393	May 21, 2025	DS DP U-2957			
	7488827	Dec 18, 2027	DS DP			
	7498440	Apr 27, 2025	DS DP			
	8113199	Oct 23, 2027	DP			
	8161968	Feb 05, 2028	DP			
	8183257	Jul 27, 2025	U-2128			
	8183257	Jul 27, 2025	U-2129			
	8309572	Apr 27, 2025	U-2129			
	8511304	Jun 14, 2027	DP U-2954			
	8534281	Mar 08, 2030	DP			
	8746242	Oct 11, 2030	DP			
	9333310	Oct 02, 2027	DP			
	9750726	Nov 29, 2030	DP			
	RE44874	Mar 23, 2023	DS DP U-2127			
	RE44874	Mar 23, 2023	DS DP U-2955			
<u>FLUTICASONE FUROATE; UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - TRELEGY ELLIPTA</u>						
N 209482 002	7439393	May 21, 2025	DS DP U-2957		NS	Sep 09, 2023
	7488827	Dec 18, 2027	DS DP			
	7498440	Apr 27, 2025	DS DP			
	8113199	Oct 23, 2027	DP			
	8161968	Feb 05, 2028	DP			
	8183257	Jul 27, 2025	U-2129			
	8309572	Apr 27, 2025	U-2129			
	8511304	Jun 14, 2027	DP U-2954			
	8534281	Mar 08, 2030	DP			
	8746242	Oct 11, 2030	DP			
	9333310	Oct 02, 2027	DP			
	9750726	Nov 29, 2030	DP			
	RE44874	Mar 23, 2023	DS DP U-2955			
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275 001	11116721	Feb 26, 2029	DP U-1401			
	11116721	Feb 26, 2029	DP U-1691			
	7439393	May 21, 2025	DS DP U-1401			
	7439393	May 21, 2025	DS DP U-1691			
	7439393	May 21, 2025	DS DP U-2099			
	7439393	May 21, 2025	DS DP U-2100			
	8113199	Oct 23, 2027	DP			
	8161968	Feb 05, 2028	DP			
	8511304	Jun 14, 2027	DP U-1424			
	8511304	Jun 14, 2027	DP U-1691			
	8534281	Mar 08, 2030	DP			
	8746242	Oct 11, 2030	DP			
	9333310	Oct 02, 2027	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275 001	RE44874	Mar 23, 2023	DS DP U-1548			
	RE44874	Mar 23, 2023	DS DP U-1691			
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275 002	11116721	Feb 26, 2029	DP U-1691			
	7439393	May 21, 2025	DS DP U-1691			
	7439393	May 21, 2025	DS DP U-2099			
	7439393	May 21, 2025	DS DP U-2100			
	8113199	Oct 23, 2027	DP			
	8161968	Feb 05, 2028	DP			
	8511304	Jun 14, 2027	DP U-1691			
	8534281	Mar 08, 2030	DP			
	8746242	Oct 11, 2030	DP			
	9333310	Oct 02, 2027	DP			
	RE44874	Mar 23, 2023	DS DP U-1691			
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
N 021433 001	7500444	Feb 26, 2026	DP			
	7500444*PED	Aug 26, 2026				
	7832351	Jun 19, 2023	DP			
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
N 021433 002	7500444	Feb 26, 2026	DP			
	7500444*PED	Aug 26, 2026				
	7832351	Jun 19, 2023	DP			
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
N 021433 003	7500444	Feb 26, 2026	DP			
	7500444*PED	Aug 26, 2026				
	7832351	Jun 19, 2023	DP			
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 001	10022510	May 18, 2031	DP		NPP	Jul 09, 2024
	10022510*PED	Nov 18, 2031			PED	Jan 09, 2025
	10124131	May 18, 2031	DP			
	10124131*PED	Nov 18, 2031				
	10195375	Feb 14, 2031	DP			
	10195375*PED	Aug 14, 2031				
	10561808	Jan 01, 2032	DP			
	10561808*PED	Jul 01, 2032				
	10765820	May 19, 2025	DP			
	10765820*PED	Nov 19, 2025				
	7540282	May 06, 2023	DP			
	7540282*PED	Nov 06, 2023				
	8651103	Mar 26, 2028	DP			
	8651103*PED	Sep 26, 2028				
	8714149	Feb 25, 2032	DP			
	8714149*PED	Aug 25, 2032				
	8978966	Jan 13, 2032	DP			
	8978966*PED	Jul 13, 2032				
	9216260	Jun 28, 2031	DP			
	9216260*PED	Dec 28, 2031				
	9463288	May 19, 2025	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 001	9463288*PED	Nov 19, 2025				
	9616024	Sep 01, 2024	DP			
	9616024*PED	Mar 01, 2025				
	9731087	May 18, 2031	DP			
	9731087*PED	Nov 18, 2031				
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 002	10022510	May 18, 2031	DP			
	10022510*PED	Nov 18, 2031				
	10124131	May 18, 2031	DP			
	10124131*PED	Nov 18, 2031				
	10195375	Feb 14, 2031	DP			
	10195375*PED	Aug 14, 2031				
	10561808	Jan 01, 2032	DP			
	10561808*PED	Jul 01, 2032				
	10765820	May 19, 2025	DP			
	10765820*PED	Nov 19, 2025				
	7540282	May 06, 2023	DP			
	7540282*PED	Nov 06, 2023				
	8651103	Mar 26, 2028	DP			
	8651103*PED	Sep 26, 2028				
	8714149	Feb 25, 2032	DP			
	8714149*PED	Aug 25, 2032				
	8978966	Jan 13, 2032	DP			
	8978966*PED	Jul 13, 2032				
	9216260	Jun 28, 2031	DP			
	9216260*PED	Dec 28, 2031				
	9463288	May 19, 2025	DP			
	9463288*PED	Nov 19, 2025				
	9616024	Sep 01, 2024	DP			
	9616024*PED	Mar 01, 2025				
	9731087	May 18, 2031	DP			
	9731087*PED	Nov 18, 2031				
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 003	10022510	May 18, 2031	DP			
	10022510*PED	Nov 18, 2031				
	10124131	May 18, 2031	DP			
	10124131*PED	Nov 18, 2031				
	10195375	Feb 14, 2031	DP			
	10195375*PED	Aug 14, 2031				
	10561808	Jan 01, 2032	DP			
	10561808*PED	Jul 01, 2032				
	10765820	May 19, 2025	DP			
	10765820*PED	Nov 19, 2025				
	7540282	May 06, 2023	DP			
	7540282*PED	Nov 06, 2023				
	8651103	Mar 26, 2028	DP			
	8651103*PED	Sep 26, 2028				
	8714149	Feb 25, 2032	DP			
	8714149*PED	Aug 25, 2032				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 003	8978966	Jan 13, 2032	DP			
	8978966*PED	Jul 13, 2032				
	9216260	Jun 28, 2031	DP			
	9216260*PED	Dec 28, 2031				
	9463288	May 19, 2025	DP			
	9463288*PED	Nov 19, 2025				
	9616024	Sep 01, 2024	DP			
	9616024*PED	Mar 01, 2025				
	9731087	May 18, 2031	DP			
	9731087*PED	Nov 18, 2031				
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 004	10022510	May 18, 2031	DP		NPP	Jul 09, 2024
	10022510*PED	Nov 18, 2031			PED	Jan 09, 2025
	10124131	May 18, 2031	DP			
	10124131*PED	Nov 18, 2031				
	10195375	Feb 14, 2031	DP			
	10195375*PED	Aug 14, 2031				
	10561808	Jan 01, 2032	DP			
	10561808*PED	Jul 01, 2032				
	10569034	Aug 16, 2036	DP			
	10569034*PED	Feb 16, 2037				
	10765820	May 19, 2025	DP			
	10765820*PED	Nov 19, 2025				
	10918816	Dec 14, 2035	DP			
	10918816*PED	Jun 14, 2036				
	11000653	Dec 18, 2038	DP			
	11000653*PED	Jun 18, 2039				
	11173259	Jul 06, 2040	DP			
	11173259*PED	Jan 06, 2041				
	11266796	Feb 22, 2041	DP			
	11266796*PED	Aug 22, 2041				
	11344685	Sep 26, 2039	DP			
	11344685*PED	Mar 26, 2040				
	11351317	Feb 10, 2038	DP			
	11351317*PED	Aug 10, 2038				
	11357935	Sep 24, 2038	DP			
	11439777	May 24, 2040	DP			
	11464923	Jun 19, 2040	DP			
	7540282	May 06, 2023	DP			
	7540282*PED	Nov 06, 2023				
	8651103	Mar 26, 2028	DP			
	8651103*PED	Sep 26, 2028				
	8714149	Feb 25, 2032	DP			
	8714149*PED	Aug 25, 2032				
	8978966	Jan 13, 2032	DP			
	8978966*PED	Jul 13, 2032				
	9216260	Jun 28, 2031	DP			
	9216260*PED	Dec 28, 2031				
	9463288	May 19, 2025	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 004	9463288*PED	Nov 19, 2025				
	9616024	Sep 01, 2024	DP			
	9616024*PED	Mar 01, 2025				
	9731087	May 18, 2031	DP			
	9731087*PED	Nov 18, 2031				
	9782550	Aug 28, 2035	DP			
	9782550*PED	Feb 28, 2036				
	9782551	Aug 28, 2035	DP			
	9782551*PED	Feb 28, 2036				
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 005	10022510	May 18, 2031	DP			
	10022510*PED	Nov 18, 2031				
	10124131	May 18, 2031	DP			
	10124131*PED	Nov 18, 2031				
	10195375	Feb 14, 2031	DP			
	10195375*PED	Aug 14, 2031				
	10561808	Jan 01, 2032	DP			
	10561808*PED	Jul 01, 2032				
	10569034	Aug 16, 2036	DP			
	10569034*PED	Feb 16, 2037				
	10765820	May 19, 2025	DP			
	10765820*PED	Nov 19, 2025				
	10918816	Dec 14, 2035	DP			
	10918816*PED	Jun 14, 2036				
	11000653	Dec 18, 2038	DP			
	11000653*PED	Jun 18, 2039				
	11173259	Jul 06, 2040	DP			
	11173259*PED	Jan 06, 2041				
	11266796	Feb 22, 2041	DP			
	11266796*PED	Aug 22, 2041				
	11344685	Sep 26, 2039	DP			
	11344685*PED	Mar 26, 2040				
	11351317	Feb 10, 2038	DP			
	11351317*PED	Aug 10, 2038				
	11357935	Sep 24, 2038	DP			
	11439777	May 24, 2040	DP			
	11464923	Jun 19, 2040	DP			
	7540282	May 06, 2023	DP			
	7540282*PED	Nov 06, 2023				
	8651103	Mar 26, 2028	DP			
	8651103*PED	Sep 26, 2028				
	8714149	Feb 25, 2032	DP			
	8714149*PED	Aug 25, 2032				
	8978966	Jan 13, 2032	DP			
	8978966*PED	Jul 13, 2032				
	9216260	Jun 28, 2031	DP			
	9216260*PED	Dec 28, 2031				
	9463288	May 19, 2025	DP			
	9463288*PED	Nov 19, 2025				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 005	9616024	Sep 01, 2024	DP			
	9616024*PED	Mar 01, 2025				
	9731087	May 18, 2031	DP			
	9731087*PED	Nov 18, 2031				
	9782550	Aug 28, 2035	DP			
	9782550*PED	Feb 28, 2036				
	9782551	Aug 28, 2035	DP			
	9782551*PED	Feb 28, 2036				
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 006	10022510	May 18, 2031	DP			
	10022510*PED	Nov 18, 2031				
	10124131	May 18, 2031	DP			
	10124131*PED	Nov 18, 2031				
	10195375	Feb 14, 2031	DP			
	10195375*PED	Aug 14, 2031				
	10561808	Jan 01, 2032	DP			
	10561808*PED	Jul 01, 2032				
	10569034	Aug 16, 2036	DP			
	10569034*PED	Feb 16, 2037				
	10765820	May 19, 2025	DP			
	10765820*PED	Nov 19, 2025				
	10918816	Dec 14, 2035	DP			
	10918816*PED	Jun 14, 2036				
	11000653	Dec 18, 2038	DP			
	11000653*PED	Jun 18, 2039				
	11173259	Jul 06, 2040	DP			
	11173259*PED	Jan 06, 2041				
	11266796	Feb 22, 2041	DP			
	11266796*PED	Aug 22, 2041				
	11344685	Sep 26, 2039	DP			
	11344685*PED	Mar 26, 2040				
	11351317	Feb 10, 2038	DP			
	11351317*PED	Aug 10, 2038				
	11357935	Sep 24, 2038	DP			
	11439777	May 24, 2040	DP			
	11464923	Jun 19, 2040	DP			
	7540282	May 06, 2023	DP			
	7540282*PED	Nov 06, 2023				
	8651103	Mar 26, 2028	DP			
	8651103*PED	Sep 26, 2028				
	8714149	Feb 25, 2032	DP			
	8714149*PED	Aug 25, 2032				
	8978966	Jan 13, 2032	DP			
	8978966*PED	Jul 13, 2032				
	9216260	Jun 28, 2031	DP			
	9216260*PED	Dec 28, 2031				
	9463288	May 19, 2025	DP			
	9463288*PED	Nov 19, 2025				
	9616024	Sep 01, 2024	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 006	9616024*PED	Mar 01, 2025				
	9731087	May 18, 2031	DP			
	9731087*PED	Nov 18, 2031				
	9782550	Aug 28, 2035	DP			
	9782550*PED	Feb 28, 2036				
	9782551	Aug 28, 2035	DP			
	9782551*PED	Feb 28, 2036				
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 007	10022510	May 18, 2031	DP		NS	Jul 09, 2024
	10022510*PED	Nov 18, 2031			PED	Jan 09, 2025
	10124131	May 18, 2031	DP			
	10124131*PED	Nov 18, 2031				
	10195375	Feb 14, 2031	DP			
	10195375*PED	Aug 14, 2031				
	10561808	Jan 01, 2032	DP			
	10561808*PED	Jul 01, 2032				
	10765820	May 19, 2025	DP			
	10765820*PED	Nov 19, 2025				
	7540282	May 06, 2023	DP			
	7540282*PED	Nov 06, 2023				
	8651103	Mar 26, 2028	DP			
	8651103*PED	Sep 26, 2028				
	8714149	Feb 25, 2032	DP			
	8714149*PED	Aug 25, 2032				
	8978966	Jan 13, 2032	DP			
	8978966*PED	Jul 13, 2032				
	9216260	Jun 28, 2031	DP			
	9216260*PED	Dec 28, 2031				
	9463288	May 19, 2025	DP			
	9463288*PED	Nov 19, 2025				
	9616024	Sep 01, 2024	DP			
	9616024*PED	Mar 01, 2025				
	9731087	May 18, 2031	DP			
	9731087*PED	Nov 18, 2031				
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 008	10022510	May 18, 2031	DP			
	10022510*PED	Nov 18, 2031				
	10124131	May 18, 2031	DP			
	10124131*PED	Nov 18, 2031				
	10195375	Feb 14, 2031	DP			
	10195375*PED	Aug 14, 2031				
	10561808	Jan 01, 2032	DP			
	10561808*PED	Jul 01, 2032				
	10569034	Aug 16, 2036	DP			
	10569034*PED	Feb 16, 2037				
	10765820	May 19, 2025	DP			
	10765820*PED	Nov 19, 2025				
	10918816	Dec 14, 2035	DP			
	10918816*PED	Jun 14, 2036				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 008	11000653	Dec 18, 2038	DP			
	11000653*PED	Jun 18, 2039				
	11173259	Jul 06, 2040	DP			
	11173259*PED	Jan 06, 2041				
	11266796	Feb 22, 2041	DP			
	11266796*PED	Aug 22, 2041				
	11344685	Sep 26, 2039	DP			
	11344685*PED	Mar 26, 2040				
	11351317	Feb 10, 2038	DP			
	11351317*PED	Aug 10, 2038				
	11357935	Sep 24, 2038	DP			
	11439777	May 24, 2040	DP			
	11464923	Jun 19, 2040	DP			
	7540282	May 06, 2023	DP			
	7540282*PED	Nov 06, 2023				
	8651103	Mar 26, 2028	DP			
	8651103*PED	Sep 26, 2028				
	8714149	Nov 08, 2030	DP			
	8714149*PED	May 08, 2031				
	8978966	Jan 13, 2032	DP			
	8978966*PED	Jul 13, 2032				
	9216260	Jun 28, 2031	DP			
	9216260*PED	Dec 28, 2031				
	9463288	May 19, 2025	DP			
	9463288*PED	Nov 19, 2025				
	9616024	Sep 01, 2024	DP			
	9616024*PED	Mar 01, 2025				
	9731087	May 18, 2031	DP			
	9731087*PED	Nov 18, 2031				
	9782550	Aug 28, 2035	DP			
	9782550*PED	Feb 28, 2036				
	9782551	Aug 28, 2035	DP			
	9782551*PED	Feb 28, 2036				
<u>FLUTICASONE PROPIONATE - XHANCE</u>						
N 209022 001	10076614	Oct 20, 2034	DP			
	10076615	Jul 30, 2029	U-2133			
	10124132	Mar 06, 2027	DP U-2133			
	10179216	Jul 08, 2033	DP U-2133			
	10252010	Feb 07, 2031	DP			
	10300229	Jul 07, 2035	DP U-2133			
	10478574	Nov 04, 2033	U-2133			
	11033696	May 20, 2033	DP			
	7975690	Dec 29, 2025	U-2133			
	8327844	Oct 08, 2023	U-2133			
	8550073	Oct 22, 2029	DP			
	8978647	Dec 06, 2030	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR HFA</u>						
N 021254 001	7500444	Feb 26, 2026	DP			
	7500444*PED	Aug 26, 2026				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR HFA</u>						
N 021254 001	7832351	Jun 19, 2023	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR HFA</u>						
N 021254 002	7500444	Feb 26, 2026	DP			
	7500444*PED	Aug 26, 2026				
	7832351	Jun 19, 2023	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR HFA</u>						
N 021254 003	7500444	Feb 26, 2026	DP			
	7500444*PED	Aug 26, 2026				
	7832351	Jun 19, 2023	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 001	10022510	May 18, 2031	DP		M-61	Jul 09, 2024
	10022510*PED	Nov 18, 2031			PED	Jan 09, 2025
	10124131	May 18, 2031	DP			
	10124131*PED	Nov 18, 2031				
	10195375	Feb 14, 2031	DP			
	10195375*PED	Aug 14, 2031				
	10561808	Jan 01, 2032	DP			
	10561808*PED	Jul 01, 2032				
	10765820	May 19, 2025	DP			
	10765820*PED	Nov 19, 2025				
	7540282	May 06, 2023	DP			
	7540282*PED	Nov 06, 2023				
	8651103	Mar 26, 2028	DP			
	8651103*PED	Sep 26, 2028				
	8714149	Feb 25, 2032	DP			
	8714149*PED	Aug 25, 2032				
	8978966	Jan 13, 2032	DP			
	8978966*PED	Jul 13, 2032				
	9066957	Oct 06, 2034	DP U-645			
	9066957*PED	Apr 06, 2035				
	9216260	Jun 28, 2031	DP			
	9216260*PED	Dec 28, 2031				
	9415008	Oct 06, 2034	DP U-645			
	9415008*PED	Apr 06, 2035				
	9463288	May 19, 2025	DP			
	9463288*PED	Nov 19, 2025				
	9616024	Sep 01, 2024	DP			
	9616024*PED	Mar 01, 2025				
	9731087	May 18, 2031	DP			
	9731087*PED	Nov 18, 2031				
	9987229	Sep 01, 2024	DP			
	9987229*PED	Mar 01, 2025				
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 002	10022510	May 18, 2031	DP			
	10022510*PED	Nov 18, 2031				
	10124131	May 18, 2031	DP			
	10124131*PED	Nov 18, 2031				
	10195375	Feb 14, 2031	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 002	10195375*PED	Aug 14, 2031				
	10561808	Jan 01, 2032	DP			
	10561808*PED	Jul 01, 2032				
	10765820	May 19, 2025	DP			
	10765820*PED	Nov 19, 2025				
	7540282	May 06, 2023	DP			
	7540282*PED	Nov 06, 2023				
	8651103	Mar 26, 2028	DP			
	8651103*PED	Sep 26, 2028				
	8714149	Feb 25, 2032	DP			
	8714149*PED	Aug 25, 2032				
	8978966	Jan 13, 2032	DP			
	8978966*PED	Jul 13, 2032				
	9066957	Oct 06, 2034	DP U-645			
	9066957*PED	Apr 06, 2035				
	9216260	Jun 28, 2031	DP			
	9216260*PED	Dec 28, 2031				
	9463288	May 19, 2025	DP			
	9463288*PED	Nov 19, 2025				
	9616024	Sep 01, 2024	DP			
	9616024*PED	Mar 01, 2025				
	9731087	May 18, 2031	DP			
	9731087*PED	Nov 18, 2031				
	9987229	Sep 01, 2024	DP			
	9987229*PED	Mar 01, 2025				
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 003	10022510	May 18, 2031	DP			
	10022510*PED	Nov 18, 2031				
	10124131	May 18, 2031	DP			
	10124131*PED	Nov 18, 2031				
	10195375	Feb 14, 2031	DP			
	10195375*PED	Aug 14, 2031				
	10561808	Jan 01, 2032	DP			
	10561808*PED	Jul 01, 2032				
	10765820	May 19, 2025	DP			
	10765820*PED	Nov 19, 2025				
	7540282	May 06, 2023	DP			
	7540282*PED	Nov 06, 2023				
	8651103	Mar 26, 2028	DP			
	8651103*PED	Sep 26, 2028				
	8714149	Feb 25, 2032	DP			
	8714149*PED	Aug 25, 2032				
	8978966	Jan 13, 2032	DP			
	8978966*PED	Jul 13, 2032				
	9066957	Oct 06, 2034	DP U-645			
	9066957*PED	Apr 06, 2035				
	9216260	Jun 28, 2031	DP			
	9216260*PED	Dec 28, 2031				
	9463288	May 19, 2025	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 003	9463288*PED	Nov 19, 2025				
	9616024	Sep 01, 2024	DP			
	9616024*PED	Mar 01, 2025				
	9731087	May 18, 2031	DP			
	9731087*PED	Nov 18, 2031				
	9987229	Sep 01, 2024	DP			
	9987229*PED	Mar 01, 2025				
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER</u>						
N 208799 004	10022510	May 18, 2031	DP		M-61	Jul 09, 2024
	10022510*PED	Nov 18, 2031			PED	Jan 09, 2025
	10124131	May 18, 2031	DP			
	10124131*PED	Nov 18, 2031				
	10195375	Feb 14, 2031	DP			
	10195375*PED	Aug 14, 2031				
	10561808	Jan 01, 2032	DP			
	10561808*PED	Jul 01, 2032				
	10569034	Aug 16, 2036	DP			
	10569034*PED	Feb 16, 2037				
	10765820	May 19, 2025	DP			
	10765820*PED	Nov 19, 2025				
	10918816	Dec 14, 2035	DP			
	10918816*PED	Jun 14, 2036				
	11000653	Dec 18, 2038	DP			
	11000653*PED	Jun 18, 2039				
	11173259	Jul 06, 2040	DP			
	11173259*PED	Jan 06, 2041				
	11266796	Feb 22, 2041	DP			
	11266796*PED	Aug 22, 2041				
	11344685	Sep 26, 2039	DP			
	11344685*PED	Mar 26, 2040				
	11351317	Feb 10, 2038	DP			
	11351317*PED	Aug 10, 2038				
	11357935	Sep 24, 2038	DP			
	11439777	May 24, 2040	DP			
	11464923	Jun 19, 2040	DP			
	7540282	May 06, 2023	DP			
	7540282*PED	Nov 06, 2023				
	8651103	Mar 26, 2028	DP			
	8651103*PED	Sep 26, 2028				
	8714149	Feb 25, 2032	DP			
	8714149*PED	Aug 25, 2032				
	8978966	Jan 13, 2032	DP			
	8978966*PED	Jul 13, 2032				
	9066957	Oct 06, 2034	DP U-645			
	9066957*PED	Apr 06, 2035				
	9216260	Jun 28, 2031	DP			
	9216260*PED	Dec 28, 2031				
	9415008	Oct 06, 2034	DP U-645			
	9415008*PED	Apr 06, 2035				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER</u>						
N 208799 004	9463288	May 19, 2025	DP			
	9463288*PED	Nov 19, 2025				
	9616024	Sep 01, 2024	DP			
	9616024*PED	Mar 01, 2025				
	9731087	May 18, 2031	DP			
	9731087*PED	Nov 18, 2031				
	9782550	Aug 28, 2035	DP			
	9782550*PED	Feb 28, 2036				
	9782551	Aug 28, 2035	DP			
	9782551*PED	Feb 28, 2036				
	9987229	Sep 01, 2024	DP			
	9987229*PED	Mar 01, 2025				
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER</u>						
N 208799 005	10022510	May 18, 2031	DP			
	10022510*PED	Nov 18, 2031				
	10124131	May 18, 2031	DP			
	10124131*PED	Nov 18, 2031				
	10195375	Feb 14, 2031	DP			
	10195375*PED	Aug 14, 2031				
	10561808	Jan 01, 2032	DP			
	10561808*PED	Jul 01, 2032				
	10569034	Aug 16, 2036	DP			
	10569034*PED	Feb 16, 2037				
	10765820	May 19, 2025	DP			
	10765820*PED	Nov 19, 2025				
	10918816	Dec 14, 2035	DP			
	10918816*PED	Jun 14, 2036				
	11000653	Dec 18, 2038	DP			
	11000653*PED	Jun 18, 2039				
	11173259	Jul 06, 2040	DP			
	11173259*PED	Jan 06, 2041				
	11266796	Feb 22, 2041	DP			
	11266796*PED	Aug 22, 2041				
	11344685	Sep 26, 2039	DP			
	11344685*PED	Mar 26, 2040				
	11351317	Feb 10, 2038	DP			
	11351317*PED	Aug 10, 2038				
	11357935	Sep 24, 2038	DP			
	11439777	May 24, 2040	DP			
	11464923	Jun 19, 2040	DP			
	7540282	May 06, 2023	DP			
	7540282*PED	Nov 06, 2023				
	8651103	Mar 26, 2028	DP			
	8651103*PED	Sep 26, 2028				
	8714149	Feb 25, 2032	DP			
	8714149*PED	Aug 25, 2032				
	8978966	Jan 13, 2032	DP			
	8978966*PED	Jul 13, 2032				
	9066957	Oct 06, 2034	DP U-645			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER</u>						
N 208799 005	9066957*PED	Apr 06, 2035				
	9216260	Jun 28, 2031	DP			
	9216260*PED	Dec 28, 2031				
	9463288	May 19, 2025	DP			
	9463288*PED	Nov 19, 2025				
	9616024	Sep 01, 2024	DP			
	9616024*PED	Mar 01, 2025				
	9731087	May 18, 2031	DP			
	9731087*PED	Nov 18, 2031				
	9782550	Aug 28, 2035	DP			
	9782550*PED	Feb 28, 2036				
	9782551	Aug 28, 2035	DP			
	9782551*PED	Feb 28, 2036				
	9987229	Sep 01, 2024	DP			
	9987229*PED	Mar 01, 2025				
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER</u>						
N 208799 006	10022510	May 18, 2031	DP			
	10022510*PED	Nov 18, 2031				
	10124131	May 18, 2031	DP			
	10124131*PED	Nov 18, 2031				
	10195375	Feb 14, 2031	DP			
	10195375*PED	Aug 14, 2031				
	10561808	Jan 01, 2032	DP			
	10561808*PED	Jul 01, 2032				
	10569034	Aug 16, 2036	DP			
	10569034*PED	Feb 16, 2037				
	10765820	May 19, 2025	DP			
	10765820*PED	Nov 19, 2025				
	10918816	Dec 14, 2035	DP			
	10918816*PED	Jun 14, 2036				
	11000653	Dec 18, 2038	DP			
	11000653*PED	Jun 18, 2039				
	11173259	Jul 06, 2040	DP			
	11173259*PED	Jan 06, 2041				
	11266796	Feb 22, 2041	DP			
	11266796*PED	Aug 22, 2041				
	11344685	Sep 26, 2039	DP			
	11344685*PED	Mar 26, 2040				
	11351317	Feb 10, 2038	DP			
	11351317*PED	Aug 10, 2038				
	11357935	Sep 24, 2038	DP			
	11439777	May 24, 2040	DP			
	11464923	Jun 19, 2040	DP			
	7540282	May 06, 2023	DP			
	7540282*PED	Nov 06, 2023				
	8651103	Mar 26, 2028	DP			
	8651103*PED	Sep 26, 2028				
	8714149	Feb 25, 2032	DP			
	8714149*PED	Aug 25, 2032				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER</u>						
N 208799 006	8978966	Jan 13, 2032	DP			
	8978966*PED	Jul 13, 2032				
	9066957	Oct 06, 2034	DP U-645			
	9066957*PED	Apr 06, 2035				
	9216260	Jun 28, 2031	DP			
	9216260*PED	Dec 28, 2031				
	9463288	May 19, 2025	DP			
	9463288*PED	Nov 19, 2025				
	9616024	Sep 01, 2024	DP			
	9616024*PED	Mar 01, 2025				
	9731087	May 18, 2031	DP			
	9731087*PED	Nov 18, 2031				
	9782550	Aug 28, 2035	DP			
	9782550*PED	Feb 28, 2036				
	9782551	Aug 28, 2035	DP			
	9782551*PED	Feb 28, 2036				
	9987229	Sep 01, 2024	DP			
	9987229*PED	Mar 01, 2025				
<u>FOMEPIZOLE - ANTIZOL</u>						
N 020696 001	7553863	Jun 30, 2027	DS DP			
<u>FORMOTEROL FUMARATE; GLYCOPYRROLATE - BEVESPI AEROSPHERE</u>						
N 208294 001	10716753	May 28, 2030	DP U-2889			
	8324266	May 28, 2030	U-2889			
	8703806	May 28, 2030	U-2889			
	8808713	May 28, 2030	DP U-2889			
	8815258	Mar 17, 2031	U-2889			
	9415009	May 28, 2030	U-2889			
	9463161	May 28, 2030	DP U-2889			
<u>FOSAPREPITANT DIMEGLUMINE - EMEND</u>						
N 022023 001					D-186	May 02, 2025
<u>FOSAPREPITANT DIMEGLUMINE - EMEND</u>						
N 022023 002					D-186	May 02, 2025
<u>FOSDENOPTERIN HYDROBROMIDE - NULIBRY</u>						
N 214018 001	7504095	Jan 31, 2025	DP U-3092		NCE	Feb 26, 2026
					ODE-342	Feb 26, 2028
<u>FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 210493 001	10208073	May 23, 2032	U-2301		NCE	Apr 19, 2023
	10624911	Jun 02, 2037	DP			
	10717721	May 23, 2032	DS			
	10828297	Dec 17, 2030	U-2301			
	11312698	May 23, 2032	DS DP			
	8426450	May 23, 2032	DS DP			
	8895586	May 23, 2032	U-2301			
	9186357	Nov 18, 2030	U-2301			
	9403772	May 23, 2032	DS U-2301			
	9908907	May 23, 2032	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 210493 002	10208073	May 23, 2032	U-2301		NCE	Apr 19, 2023
	10624911	Jun 02, 2037	DP			
	10717721	May 23, 2032	DS			
	10828297	Dec 17, 2030	U-2301			
	11312698	May 23, 2032	DS DP			
	8426450	May 23, 2032	DS DP			
	8895586	May 23, 2032	U-2301			
	9186357	Nov 18, 2030	U-2301			
	9403772	May 23, 2032	DS U-2301			
	9908907	May 23, 2032	DS DP			
<u>FOSPHENYTOIN SODIUM - SESQUIENT</u>						
N 210864 001	7635773	Mar 13, 2029	DP			
	8410077	Mar 13, 2029	DP			
	9200088	Mar 13, 2029	DP			
	9493582	Feb 27, 2033	DP			
	9750822	Mar 13, 2029	DP			
<u>FOSPHENYTOIN SODIUM - SESQUIENT</u>						
N 210864 002	7635773	Mar 13, 2029	DP			
	8410077	Mar 13, 2029	DP			
	9200088	Mar 13, 2029	DP			
	9493582	Feb 27, 2033	DP			
	9750822	Mar 13, 2029	DP			
<u>FOSTAMATINIB DISODIUM - TAVALISSE</u>						
N 209299 001	7449458	Sep 04, 2026	DS		NCE	Apr 17, 2023
	7538108	Mar 28, 2026	DS U-2294		ODE-174	Apr 17, 2025
	7989448	Jun 12, 2026	DS U-2294			
	8163902	Jun 17, 2026	DS U-2294			
	8211889	Jan 19, 2026	DS			
	8263122	Nov 24, 2030	DP			
	8445485	Jun 17, 2026	DP			
	8652492	Nov 06, 2028	DP			
	8771648	Jul 27, 2032	DP			
	8912170	Jun 17, 2026	U-2294			
	8951504	Jul 27, 2032	U-2294			
	9266912	Jan 19, 2026	U-2294			
	9283238	Jun 17, 2026	U-2294			
	RE48898	Jan 19, 2026	DP			
<u>FOSTAMATINIB DISODIUM - TAVALISSE</u>						
N 209299 002	7449458	Sep 04, 2026	DS		NCE	Apr 17, 2023
	7538108	Mar 28, 2026	DS U-2294		ODE-174	Apr 17, 2025
	7989448	Jun 12, 2026	DS U-2294			
	8163902	Jun 17, 2026	DS U-2294			
	8211889	Jan 19, 2026	DS			
	8263122	Nov 24, 2030	DP			
	8445485	Jun 17, 2026	DP			
	8652492	Nov 06, 2028	DP			
	8771648	Jul 27, 2032	DP			
	8912170	Jun 17, 2026	U-2294			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FOSTAMATINIB DISODIUM - TAVALISSE</u>						
N 209299 002	8951504	Jul 27, 2032	U-2294			
	9266912	Jan 19, 2026	U-2294			
	9283238	Jun 17, 2026	U-2294			
	RE48898	Jan 19, 2026	DP			
<u>FOSTEMSAVIR TROMETHAMINE - RUKOBIA</u>						
N 212950 001	7745625	Nov 19, 2027	DS		NCE	Jul 02, 2025
	8168615	Feb 25, 2025	DP			
	8461333	Feb 25, 2025	DS			
<u>FULVESTRANT - FULVESTRANT</u>						
N 210326 001	10188663	Feb 14, 2034	DP U-2540			
	9271990	May 17, 2034	DP U-2540			
	9833459	Feb 14, 2034	DP U-2540			
<u>FUROSEMIDE - FUROSCIX</u>						
N 209988 001	10272064	Apr 03, 2034	DP			
	11433044	Apr 03, 2034	U-3462			
	9884039	Apr 03, 2034	U-3462			
<u>FUTIBATINIB - LYTGOBI</u>						
N 214801 001	10434103	Mar 31, 2036	DS DP		NCE	Sep 30, 2027
	9108973	Feb 23, 2033	DS DP U-3456			
<u>GABAPENTIN - GRALISE</u>						
N 022544 001	7438927	Feb 26, 2024	U-1114			
<u>GABAPENTIN - GRALISE</u>						
N 022544 002	7438927	Feb 26, 2024	U-1114			
<u>GABAPENTIN ENACARBIL - HORIZANT</u>						
N 022399 001	6818787	Apr 06, 2025	DS DP			
	8026279	Nov 10, 2026	DS DP			
	8114909	Apr 11, 2026	U-1231			
	8686034	Jan 24, 2025	U-1231			
	8686034	Jan 24, 2025	U-1247			
	8795725	Jun 10, 2029	DP U-1231			
	8795725	Jun 10, 2029	DP U-1247			
<u>GABAPENTIN ENACARBIL - HORIZANT</u>						
N 022399 002	6818787	Apr 06, 2025	DS DP			
	8026279	Nov 10, 2026	DS DP			
	8114909	Apr 11, 2026	U-1231			
	8686034	Jan 24, 2025	U-1231			
	8686034	Jan 24, 2025	U-1247			
	8795725	Jun 10, 2029	DP U-1231			
	8795725	Jun 10, 2029	DP U-1247			
<u>GADOPICLENOL - ELUCIREM</u>						
N 216986 001	10973934	Aug 06, 2039	DS		NCE	Sep 21, 2027
	8114863	Sep 19, 2028	DS			
<u>GADOPICLENOL - ELUCIREM</u>						
N 216986 002	10973934	Aug 06, 2039	DS		NCE	Sep 21, 2027
	8114863	Sep 19, 2028	DS			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>GADOPICLENOL - ELUCIREM</u>						
N 216986 003	10973934	Aug 06, 2039	DS		NCE	Sep 21, 2027
	8114863	Sep 19, 2028	DS			
<u>GADOPICLENOL - ELUCIREM</u>						
N 216986 004	10973934	Aug 06, 2039	DS		NCE	Sep 21, 2027
	8114863	Sep 19, 2028	DS			
<u>GADOPICLENOL - ELUCIREM</u>						
N 216986 005	10973934	Aug 06, 2039	DS		NCE	Sep 21, 2027
	8114863	Sep 19, 2028	DS			
<u>GADOPICLENOL - ELUCIREM</u>						
N 216986 006	10973934	Aug 06, 2039	DS		NCE	Sep 21, 2027
	8114863	Sep 19, 2028	DS			
<u>GADOPICLENOL - ELUCIREM</u>						
N 216986 007	10973934	Aug 06, 2039	DS		NCE	Sep 21, 2027
	8114863	Sep 19, 2028	DS			
<u>GALLIUM DOTATATE GA-68 - NETSPOT</u>						
N 208547 001	9375498	Aug 10, 2032	DP		ODE-120	Jun 01, 2023
<u>GALLIUM GA-68 DOTATOC - GALLIUM GA 68 DOTATOC</u>						
N 210828 001					NCE	Aug 21, 2024
					ODE-383	Aug 21, 2026
					W	Aug 21, 2024
					W	Aug 21, 2026
<u>GALLIUM GA-68 GOZETOTIDE - GALLIUM GA 68 GOZETOTIDE</u>						
N 212642 001					NCE	Dec 01, 2025
					W	Dec 01, 2025
<u>GALLIUM GA-68 GOZETOTIDE - GALLIUM GA 68 GOZETOTIDE</u>						
N 212643 001					NCE	Dec 01, 2025
					W	Dec 01, 2025
<u>GALLIUM GA-68 GOZETOTIDE - ILLUCCIIX</u>						
N 214032 001	11027031	Jul 28, 2035		U-3317		
<u>GALLIUM GA-68 GOZETOTIDE - LOCAMETZ</u>						
N 215841 001	11369590	Aug 15, 2028	DS DP	U-3400	NP	Mar 23, 2025
<u>GANAXOLONE - ZTALMY</u>						
N 215904 001	10603308	Aug 10, 2037		U-3374	NCE	Jun 01, 2027
	7858609	Nov 28, 2026	DP			
	8022054	Nov 28, 2026	DP			
	8318714	Nov 28, 2026	DP			
	8367651	Nov 28, 2026	DP			
	8618087	Nov 28, 2026		U-3374		
	9029355	Nov 28, 2026	DP			
	9056116	Nov 28, 2026		U-3374		
<u>GANCICLOVIR - GANZYK-RTU</u>						
N 209347 001	9486530	Sep 02, 2034	DP			
<u>GEMCITABINE HYDROCHLORIDE - INFUGEM</u>						
N 208313 001	9241948	Jul 01, 2033	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>GEMCITABINE HYDROCHLORIDE - INFUGEM</u>						
N 208313 002	9241948	Jul 01, 2033	DP			
<u>GEMCITABINE HYDROCHLORIDE - INFUGEM</u>						
N 208313 003	9241948	Jul 01, 2033	DP			
<u>GEMCITABINE HYDROCHLORIDE - INFUGEM</u>						
N 208313 004	9241948	Jul 01, 2033	DP			
<u>GEMCITABINE HYDROCHLORIDE - INFUGEM</u>						
N 208313 005	9241948	Jul 01, 2033	DP			
<u>GEMCITABINE HYDROCHLORIDE - INFUGEM</u>						
N 208313 006	9241948	Jul 01, 2033	DP			
<u>GEMCITABINE HYDROCHLORIDE - INFUGEM</u>						
N 208313 007	9241948	Jul 01, 2033	DP			
<u>GEMCITABINE HYDROCHLORIDE - INFUGEM</u>						
N 208313 008	9241948	Jul 01, 2033	DP			
<u>GEMCITABINE HYDROCHLORIDE - INFUGEM</u>						
N 208313 009	9241948	Jul 01, 2033	DP			
<u>GEMCITABINE HYDROCHLORIDE - INFUGEM</u>						
N 208313 010	9241948	Jul 01, 2033	DP			
<u>GILTERITINIB FUMARATE - XOSPATA</u>						
N 211349 001	10786500	Jul 01, 2036	DP		NCE	Nov 28, 2023
	8969336	Jan 27, 2031	DS DP		ODE-222	Nov 28, 2025
	9487491	Jul 28, 2030		U-2456		
<u>GIVOSIRAN SODIUM - GIVLAARI</u>						
N 212194 001	10119143	Oct 03, 2034	DS DP U-2672		NCE	Nov 20, 2024
	10125364	Mar 15, 2033	DS DP U-2672		ODE-273	Nov 20, 2026
	10131907	Aug 24, 2028	DS DP U-2672			
	10273477	Mar 08, 2024	DS			
	11028392	Oct 03, 2034	DS DP U-2672			
	11530408	May 18, 2024	DS DP			
	8106022	Dec 12, 2029	DS DP U-2672			
	8828956	Dec 04, 2028	DS DP U-2672			
	9133461	May 14, 2033	DS DP U-2672			
	9150605	Aug 28, 2025	DS DP			
	9631193	Mar 15, 2033		U-2672		
	9708610	Jan 01, 2024	DS DP U-2672			
	9708615	Mar 08, 2024	DS			
<u>GLASDEGIB MALEATE - DAURISMO</u>						
N 210656 001	10414748	Apr 13, 2036	DS DP		NCE	Nov 21, 2023
	11168066	Apr 13, 2036		U-3254	ODE-224	Nov 21, 2025
	8148401	Jan 30, 2031	DS DP			
	8431597	Jun 29, 2028	DP			
<u>GLASDEGIB MALEATE - DAURISMO</u>						
N 210656 002	10414748	Apr 13, 2036	DS DP		NCE	Nov 21, 2023
	11168066	Apr 13, 2036		U-3254	ODE-224	Nov 21, 2025
	8148401	Jan 30, 2031	DS DP			
	8431597	Jun 29, 2028	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>GLASDEGIB MALEATE - DAURISMO</u>						
N 210656 002	10414748	Apr 13, 2036	DS DP		NCE	Nov 21, 2023
	11168066	Apr 13, 2036	U-3254		ODE-224	Nov 21, 2025
	8148401	Jan 30, 2031	DS DP			
	8431597	Jun 29, 2028	DP			
<u>GLECAPREVIR; PIBRENTASVIR - MAVYRET</u>						
N 209394 001	10028937	Jun 10, 2030	U-2141		M-259	Apr 10, 2023
	10028937	Jun 10, 2030	U-3237		ODE-232	Apr 30, 2026
	10028937*PED	Dec 10, 2030			ODE-233	Apr 30, 2026
	10039754	Jun 10, 2030	U-2141		ODE-372	Jun 10, 2028
	10039754	Jun 10, 2030	U-3237		PED	Oct 10, 2023
	10039754*PED	Dec 10, 2030			PED	Oct 30, 2026
	10286029	Mar 14, 2034	U-3237		PED	Oct 30, 2026
	10286029*PED	Sep 14, 2034			PED	Dec 10, 2028
	11246866	Jun 24, 2036	DP			
	11246866*PED	Dec 24, 2036				
	11484534	Mar 14, 2034	U-3237			
	11484534*PED	Sep 14, 2034				
	8648037	Jan 19, 2032	DS DP U-2141			
	8648037	Jan 19, 2032	DS DP U-3237			
	8648037*PED	Jul 19, 2032				
	8937150	May 18, 2032	DS DP			
	8937150*PED	Nov 18, 2032				
	9321807	Jun 05, 2035	DS			
	9321807*PED	Dec 05, 2035				
	9586978	Nov 06, 2030	U-2141			
	9586978	Nov 06, 2030	U-3237			
	9586978*PED	May 06, 2031				
	RE48923	May 08, 2035	DS			
	RE48923*PED	Nov 08, 2035				
<u>GLECAPREVIR; PIBRENTASVIR - MAVYRET</u>						
N 215110 001	10028937	Jun 10, 2030	U-3238		M-259	Apr 10, 2023
	10028937*PED	Dec 10, 2030			ODE-372	Jun 10, 2028
	10039754	Jun 10, 2030	U-3238		PED	Oct 10, 2023
	10039754*PED	Dec 10, 2030			PED	Dec 10, 2028
	10286029	Mar 14, 2034	U-3238			
	10286029*PED	Sep 14, 2034				
	8648037	Jan 19, 2032	DS DP U-3238			
	8648037*PED	Jul 19, 2032				
	8937150	May 18, 2032	DS DP			
	8937150*PED	Nov 18, 2032				
	9321807	Jun 05, 2035	DS DP			
	9321807*PED	Dec 05, 2035				
	9586978	Nov 06, 2030	U-3238			
	9586978*PED	May 06, 2031				
	RE48923	May 08, 2035	DS			
	RE48923*PED	Nov 08, 2035				
<u>GLIMEPIRIDE; PIOGLITAZONE HYDROCHLORIDE - DUECTACT</u>						
N 021925 001	7700128	Jan 30, 2027	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>GLIMEPIRIDE; PIOGLITAZONE HYDROCHLORIDE - DUETACT</u>						
N 021925 001	8071130	Jun 08, 2028	DP			
<u>GLIMEPIRIDE; PIOGLITAZONE HYDROCHLORIDE - DUETACT</u>						
N 021925 002	7700128	Jan 30, 2027	DP			
	8071130	Jun 08, 2028	DP			
<u>GLUCAGON - BAQSIMI</u>						
N 210134 001	10213487	Feb 16, 2036	DP U-2604			
	10765602	Sep 23, 2039	DP			
	10894133	Jan 03, 2038	DP			
<u>GLUCAGON - GVOKE PFS</u>						
N 212097 001	9649364	Apr 22, 2036	DP U-2742			
<u>GLUCAGON - GVOKE PFS</u>						
N 212097 002	9649364	Apr 22, 2036	DP U-2742			
<u>GLUCAGON - GVOKE HYPOPEN</u>						
N 212097 003	9649364	Apr 22, 2036	DP U-2742			
<u>GLUCAGON - GVOKE HYPOPEN</u>						
N 212097 004	9649364	Apr 22, 2036	DP U-2742			
<u>GLYCEROL PHENYLBUTYRATE - RAVICTI</u>						
N 203284 001	10045958	Sep 22, 2030	U-1816		ODE-157	Apr 28, 2024
	10045959	Sep 22, 2030	U-1816			
	10183002	Sep 22, 2030	U-1816			
	10183003	Sep 22, 2030	U-1816			
	10183004	Sep 22, 2030	U-1816			
	10183005	Sep 22, 2030	U-1816			
	10183006	Sep 22, 2030	U-1816			
	10668040	Sep 22, 2030	U-1816			
	8404215	Mar 09, 2032	U-1383			
	8642012	Sep 22, 2030	U-1383			
	9095559	Mar 09, 2032	U-1383			
	9254278	Mar 09, 2032	U-1816			
	9326966	Mar 09, 2032	U-1816			
	9561197	Sep 22, 2030	U-1383			
	9962359	Sep 22, 2030	U-1816			
	9999608	Sep 22, 2030	U-1816			
<u>GLYCOPYRROLATE - CUVPOSA</u>						
N 022571 001	7638552	Aug 20, 2023	U-1076			
	7816396	Aug 20, 2023	U-1076			
<u>GLYCOPYRROLATE - SEEBRI</u>						
N 207923 001	8182838	Oct 20, 2028	DP			
	8479730	Oct 11, 2028	DP			
<u>GLYCOPYRROLATE - LONHALA MAGNAIR KIT</u>						
N 208437 001	10376661	Sep 14, 2035	DP			
	10688518	Nov 12, 2036	DP			
	10744277	Dec 07, 2036	DP U-2941			
	10940110	Feb 26, 2029	DP U-1773			
	11278683	Aug 16, 2026	DP			
	7458372	Nov 18, 2024	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>GLYCOPYRROLATE - LONHALA MAGNAIR KIT</u>						
N 208437 001	7931212	Nov 25, 2025	DP			
	8511581	Nov 08, 2023	DP			
	9168556	Sep 01, 2032	DP			
	9265900	Dec 07, 2028	DP			
	9604018	May 16, 2033	DP			
	9789270	Oct 30, 2030	DP			
<u>GLYCOPYRROLATE; INDACATEROL MALEATE - UTIBRON</u>						
N 207930 001	6878721	Feb 25, 2025	DS DP U-1773			
	8182838	Oct 20, 2028	DP			
	8479730	Oct 11, 2028	DP			
<u>GLYCOPYRRONIUM TOSYLATE - OBREXZA</u>						
N 210361 001	10004717	Feb 28, 2033	DP U-2398			
	10052267	Oct 17, 2028	DP U-2398			
	10543192	Feb 28, 2033	DP			
	10548875	Feb 28, 2033	DS DP U-2398			
	8618160	Dec 10, 2029	DP U-2398			
	8859610	Feb 28, 2033	DP U-2398			
	9259414	Feb 28, 2033	U-2398			
	9744105	Jul 18, 2030	DP U-2398			
<u>GOLODIRSEN - VYONDYS 53</u>						
N 211970 001	10227590	Jun 28, 2025	DS DP		NCE	Dec 12, 2024
	10266827	Jun 28, 2025	U-2675		ODE-280	Dec 12, 2026
	10421966	Jun 28, 2025	DS DP			
	10968450	Jun 28, 2025	DS DP			
	10995337	Jun 28, 2025	DP U-2675			
	9024007	Jun 28, 2025	DS DP			
	9994851	Jun 28, 2025	DS DP			
	RE47691	Jun 28, 2025	DP			
<u>GRANISETRON - SANCUSO</u>						
N 022198 001	7608282	Jan 22, 2025	DP U-1011			
<u>GRANISETRON - SUSTOL</u>						
N 022445 001	10357570	Sep 28, 2024	U-2253			
	8252304	Sep 28, 2024	DP			
	8252305	Sep 28, 2024	U-1891			
	8715710	Sep 28, 2024	DP			
	9913910	Sep 28, 2024	U-2253			
<u>GUAIFENESIN; HYDROCODONE BITARTRATE - OBREDON</u>						
N 205474 001	10105324	Nov 13, 2035	DS DP U-2023			
	9549907	Nov 13, 2035	DS DP U-2023			
	9808431	Nov 13, 2035	DS DP U-2023			
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N 022037 001	6811794*PED	Jan 04, 2023				
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N 022037 002	6811794*PED	Jan 04, 2023				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N 022037	003 6811794*PED	Jan 04, 2023				
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N 022037	004 6811794*PED	Jan 04, 2023				
<u>HALOBETASOL PROPIONATE - ULTRAVATE</u>						
N 208183	001 8962028	Jun 19, 2033	DP U-1775		NPP	Aug 31, 2023
<u>HALOBETASOL PROPIONATE - BRYHALI</u>						
N 209355	001 10478502	Nov 02, 2031	DP U-2625			
	8809307	Nov 02, 2031	DP			
<u>HALOBETASOL PROPIONATE - LEXETTE</u>						
N 210566	001 10857159	Nov 30, 2036	DP		NPP	Aug 18, 2024
	10857159*PED	May 30, 2037				
	11020407	Nov 30, 2036	DP U-3143			
<u>HALOBETASOL PROPIONATE; TAZAROTENE - DUOBRII</u>						
N 209354	001 10251895	Jun 06, 2036	DP			
	10426787	Jun 06, 2036	U-2625			
	10478502	Nov 02, 2031	DP U-2625			
	8809307	Nov 02, 2031	DP			
<u>HEXAMINOLEVULINATE HYDROCHLORIDE - CYSVIEW KIT</u>						
N 022555	001 10556010	Dec 19, 2036	U-2250			
	11235168	Jan 04, 2038	U-2250			
	11311620	Dec 19, 2036	U-2250			
<u>HISTRELIN ACETATE - SUPPRELIN LA</u>						
N 022058	001 8062652	Jun 16, 2026	U-1197			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880	001 10028946	Jul 25, 2033	U-1810			
	10092559	Sep 12, 2034	U-55			
	10322120	Jul 25, 2033	DP			
	10456393	Jul 25, 2033	U-1810			
	10722511	Jul 25, 2033	U-1810			
	9132096	Sep 12, 2034	DP			
	9265760	Jul 25, 2033	U-1810			
	9326982	Jul 25, 2033	U-1810			
	9333201	Jul 25, 2033	U-1810			
	9339499	Jul 25, 2033	U-1810			
	9421200	Jul 25, 2033	U-1810			
	9433619	Jul 25, 2033	U-1810			
	9452163	Sep 12, 2034	U-55			
	9486451	Sep 12, 2034	U-55			
	9610286	Jul 25, 2033	U-1810			
	9713611	Sep 12, 2034	DP U-55			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880	002 10028946	Jul 25, 2033	U-1810			
	10092559	Sep 12, 2034	U-55			
	10322120	Jul 25, 2033	DP			
	10456393	Jul 25, 2033	U-1810			
	10722511	Jul 25, 2033	U-1810			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 002	9132096	Sep 12, 2034	DP			
	9265760	Jul 25, 2033	U-1810			
	9326982	Jul 25, 2033	U-1810			
	9333201	Jul 25, 2033	U-1810			
	9339499	Jul 25, 2033	U-1810			
	9421200	Jul 25, 2033	U-1810			
	9433619	Jul 25, 2033	U-1810			
	9452163	Sep 12, 2034	U-55			
	9486451	Sep 12, 2034	U-55			
	9610286	Jul 25, 2033	U-1810			
	9713611	Sep 12, 2034	DP U-55			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 003	10028946	Jul 25, 2033	U-1810			
	10092559	Sep 12, 2034	U-55			
	10322120	Jul 25, 2033	DP			
	10456393	Jul 25, 2033	U-1810			
	10722511	Jul 25, 2033	U-1810			
	9132096	Sep 12, 2034	DP			
	9265760	Jul 25, 2033	U-1810			
	9326982	Jul 25, 2033	U-1810			
	9333201	Jul 25, 2033	U-1810			
	9339499	Jul 25, 2033	U-1810			
	9421200	Jul 25, 2033	U-1810			
	9433619	Jul 25, 2033	U-1810			
	9452163	Sep 12, 2034	U-55			
	9486451	Sep 12, 2034	U-55			
	9610286	Jul 25, 2033	U-1810			
	9713611	Sep 12, 2034	DP U-55			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 004	10028946	Jul 25, 2033	U-1810			
	10092559	Sep 12, 2034	U-55			
	10322120	Jul 25, 2033	DP			
	10456393	Jul 25, 2033	U-1810			
	10722511	Jul 25, 2033	U-1810			
	9132096	Sep 12, 2034	DP			
	9265760	Jul 25, 2033	U-1810			
	9326982	Jul 25, 2033	U-1810			
	9333201	Jul 25, 2033	U-1810			
	9339499	Jul 25, 2033	U-1810			
	9421200	Jul 25, 2033	U-1810			
	9433619	Jul 25, 2033	U-1810			
	9452163	Sep 12, 2034	U-55			
	9486451	Sep 12, 2034	U-55			
	9610286	Jul 25, 2033	U-1810			
	9713611	Sep 12, 2034	DP U-55			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 005	10028946	Jul 25, 2033	U-1810			
	10092559	Sep 12, 2034	U-55			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 005	10322120	Jul 25, 2033	DP			
	10456393	Jul 25, 2033	U-1810			
	10722511	Jul 25, 2033	U-1810			
	9132096	Sep 12, 2034	DP			
	9265760	Jul 25, 2033	U-1810			
	9326982	Jul 25, 2033	U-1810			
	9333201	Jul 25, 2033	U-1810			
	9339499	Jul 25, 2033	U-1810			
	9421200	Jul 25, 2033	U-1810			
	9433619	Jul 25, 2033	U-1810			
	9452163	Sep 12, 2034	U-55			
	9486451	Sep 12, 2034	U-55			
	9610286	Jul 25, 2033	U-1810			
	9713611	Sep 12, 2034	DP U-55			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 006	10028946	Jul 25, 2033	U-1810			
	10092559	Sep 12, 2034	U-55			
	10322120	Jul 25, 2033	DP			
	10456393	Jul 25, 2033	U-1810			
	10722511	Jul 25, 2033	U-1810			
	9132096	Sep 12, 2034	DP			
	9265760	Jul 25, 2033	U-1810			
	9326982	Jul 25, 2033	U-1810			
	9333201	Jul 25, 2033	U-1810			
	9339499	Jul 25, 2033	U-1810			
	9421200	Jul 25, 2033	U-1810			
	9433619	Jul 25, 2033	U-1810			
	9452163	Sep 12, 2034	U-55			
	9486451	Sep 12, 2034	U-55			
	9610286	Jul 25, 2033	U-1810			
	9713611	Sep 12, 2034	DP U-55			
<u>HYDROCODONE BITARTRATE - HYSINGLA ER</u>						
N 206627 001	10130591	Nov 20, 2023	DP U-1819			
	10369109	Jun 16, 2023	DP			
	11304908	Aug 24, 2027	DP			
	11304909	Aug 24, 2027	U-1556			
	8309060	Nov 20, 2023	DP U-1556			
	8808740	Dec 21, 2031	DP U-1556			
	9084816	Aug 24, 2027	DP			
	9095614	Aug 24, 2027	U-1556			
	9095615	Aug 24, 2027	DP			
	9486412	Aug 24, 2027	DP			
	9486413	Aug 24, 2027	DP			
	9492389	Aug 24, 2027	DP			
	9492390	Aug 24, 2027	U-1556			
	9492391	Aug 24, 2027	U-1556			
	9545380	Aug 24, 2027	U-1556			
	9572779	Dec 21, 2031	DP			
	9675610	Jun 16, 2023	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROCODONE BITARTRATE - HYSINGLA ER</u>						
N 206627 001	9750703	Dec 21, 2031	DP			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775809	Aug 24, 2027	DP			
	9861584	Dec 21, 2031	DP			
	9872837	Dec 21, 2031	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA ER</u>						
N 206627 002	10130591	Nov 20, 2023	DP U-1819			
	10369109	Jun 16, 2023	DP			
	11304908	Aug 24, 2027	DP			
	11304909	Aug 24, 2027	U-1556			
	8309060	Nov 20, 2023	DP U-1556			
	8808740	Dec 21, 2031	DP U-1556			
	9084816	Aug 24, 2027	DP			
	9095614	Aug 24, 2027	U-1556			
	9095615	Aug 24, 2027	DP			
	9486412	Aug 24, 2027	DP			
	9486413	Aug 24, 2027	DP			
	9492389	Aug 24, 2027	DP			
	9492390	Aug 24, 2027	U-1556			
	9492391	Aug 24, 2027	U-1556			
	9545380	Aug 24, 2027	U-1556			
	9572779	Dec 21, 2031	DP			
	9675610	Jun 16, 2023	DP			
	9750703	Dec 21, 2031	DP			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775809	Aug 24, 2027	DP			
	9861584	Dec 21, 2031	DP			
	9872837	Dec 21, 2031	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA ER</u>						
N 206627 003	10130591	Nov 20, 2023	DP U-1819			
	10369109	Jun 16, 2023	DP			
	11304908	Aug 24, 2027	DP			
	11304909	Aug 24, 2027	U-1556			
	8309060	Nov 20, 2023	DP U-1556			
	8808740	Dec 21, 2031	DP U-1556			
	9084816	Aug 24, 2027	DP			
	9095614	Aug 24, 2027	U-1556			
	9095615	Aug 24, 2027	DP			
	9486412	Aug 24, 2027	DP			
	9486413	Aug 24, 2027	DP			
	9492389	Aug 24, 2027	DP			
	9492390	Aug 24, 2027	U-1556			
	9492391	Aug 24, 2027	U-1556			
	9545380	Aug 24, 2027	U-1556			
	9572779	Dec 21, 2031	DP			
	9675610	Jun 16, 2023	DP			
	9750703	Dec 21, 2031	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROCODONE BITARTRATE - HYSINGLA ER</u>						
N 206627 003	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775809	Aug 24, 2027	DP			
	9861584	Dec 21, 2031	DP			
	9872837	Dec 21, 2031	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA ER</u>						
N 206627 004	10130591	Nov 20, 2023	DP U-1819			
	10369109	Jun 16, 2023	DP			
	11304908	Aug 24, 2027	DP			
	11304909	Aug 24, 2027	U-1556			
	8309060	Nov 20, 2023	DP U-1556			
	8808740	Dec 21, 2031	DP U-1556			
	9084816	Aug 24, 2027	DP			
	9095614	Aug 24, 2027	U-1556			
	9095615	Aug 24, 2027	DP			
	9486412	Aug 24, 2027	DP			
	9486413	Aug 24, 2027	DP			
	9492389	Aug 24, 2027	DP			
	9492390	Aug 24, 2027	U-1556			
	9492391	Aug 24, 2027	U-1556			
	9545380	Aug 24, 2027	U-1556			
	9572779	Dec 21, 2031	DP			
	9675610	Jun 16, 2023	DP			
	9750703	Dec 21, 2031	DP			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775809	Aug 24, 2027	DP			
	9861584	Dec 21, 2031	DP			
	9872837	Dec 21, 2031	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA ER</u>						
N 206627 005	10130591	Nov 20, 2023	DP U-1819			
	10369109	Jun 16, 2023	DP			
	11304908	Aug 24, 2027	DP			
	11304909	Aug 24, 2027	U-1556			
	8309060	Nov 20, 2023	DP U-1556			
	8808740	Dec 21, 2031	DP U-1556			
	9084816	Aug 24, 2027	DP			
	9095614	Aug 24, 2027	U-1556			
	9095615	Aug 24, 2027	DP			
	9486412	Aug 24, 2027	DP			
	9486413	Aug 24, 2027	DP			
	9492389	Aug 24, 2027	DP			
	9492390	Aug 24, 2027	U-1556			
	9492391	Aug 24, 2027	U-1556			
	9545380	Aug 24, 2027	U-1556			
	9572779	Dec 21, 2031	DP			
	9675610	Jun 16, 2023	DP			
	9750703	Dec 21, 2031	DP			
	9763933	Aug 24, 2027	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROCODONE BITARTRATE - HYSINGLA ER</u>						
N 206627 005	9770416	Aug 24, 2027	DP			
	9775809	Aug 24, 2027	DP			
	9861584	Dec 21, 2031	DP			
	9872837	Dec 21, 2031	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA ER</u>						
N 206627 006	10130591	Nov 20, 2023	DP U-1819			
	10369109	Jun 16, 2023	DP			
	11304908	Aug 24, 2027	DP			
	11304909	Aug 24, 2027	U-1556			
	8309060	Nov 20, 2023	DP U-1556			
	8808740	Dec 21, 2031	DP U-1556			
	9084816	Aug 24, 2027	DP			
	9095614	Aug 24, 2027	U-1556			
	9095615	Aug 24, 2027	DP			
	9486412	Aug 24, 2027	DP			
	9486413	Aug 24, 2027	DP			
	9492389	Aug 24, 2027	DP			
	9492390	Aug 24, 2027	U-1556			
	9492391	Aug 24, 2027	U-1556			
	9545380	Aug 24, 2027	U-1556			
	9572779	Dec 21, 2031	DP			
	9675610	Jun 16, 2023	DP			
	9750703	Dec 21, 2031	DP			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775809	Aug 24, 2027	DP			
	9861584	Dec 21, 2031	DP			
	9872837	Dec 21, 2031	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA ER</u>						
N 206627 007	10130591	Nov 20, 2023	DP U-1819			
	10369109	Jun 16, 2023	DP			
	11304908	Aug 24, 2027	DP			
	11304909	Aug 24, 2027	U-1556			
	8309060	Nov 20, 2023	DP U-1556			
	8808740	Dec 21, 2031	DP U-1556			
	9084816	Aug 24, 2027	DP			
	9095614	Aug 24, 2027	U-1556			
	9095615	Aug 24, 2027	DP			
	9486412	Aug 24, 2027	DP			
	9486413	Aug 24, 2027	DP			
	9492389	Aug 24, 2027	DP			
	9492390	Aug 24, 2027	U-1556			
	9492391	Aug 24, 2027	U-1556			
	9545380	Aug 24, 2027	U-1556			
	9572779	Dec 21, 2031	DP			
	9675610	Jun 16, 2023	DP			
	9750703	Dec 21, 2031	DP			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROCODONE BITARTRATE - HYSINGLA ER</u>						
N 206627 007	9775809	Aug 24, 2027	DP			
	9861584	Dec 21, 2031	DP			
	9872837	Dec 21, 2031	DP			
<u>HYDROCODONE BITARTRATE - VANTRELA ER</u>						
N 207975 001	8445018	Jul 31, 2029	DP			
	9216176	Sep 13, 2027	DP			
	9572803	Sep 13, 2027	DP			
<u>HYDROCODONE BITARTRATE - VANTRELA ER</u>						
N 207975 002	8445018	Jul 31, 2029	DP			
	9216176	Sep 13, 2027	DP			
	9572803	Sep 13, 2027	DP			
<u>HYDROCODONE BITARTRATE - VANTRELA ER</u>						
N 207975 003	8445018	Jul 31, 2029	DP			
	9216176	Sep 13, 2027	DP			
	9572803	Sep 13, 2027	DP			
<u>HYDROCODONE BITARTRATE - VANTRELA ER</u>						
N 207975 004	8445018	Jul 31, 2029	DP			
	9216176	Sep 13, 2027	DP			
	9572803	Sep 13, 2027	DP			
<u>HYDROCODONE BITARTRATE - VANTRELA ER</u>						
N 207975 005	8445018	Jul 31, 2029	DP			
	9216176	Sep 13, 2027	DP			
	9572803	Sep 13, 2027	DP			
<u>HYDROCORTISONE - ALKINDI SPRINKLE</u>						
N 213876 001	9649280	May 12, 2034	DP U-3075			
	9675559	Jan 10, 2033	U-3075			
	9717740	Nov 19, 2032	U-3075			
<u>HYDROCORTISONE - ALKINDI SPRINKLE</u>						
N 213876 002	9649280	May 12, 2034	DP U-3075			
	9675559	Jan 10, 2033	U-3075			
	9717740	Nov 19, 2032	U-3075			
<u>HYDROCORTISONE - ALKINDI SPRINKLE</u>						
N 213876 003	9649280	May 12, 2034	DP U-3075			
	9675559	Jan 10, 2033	U-3075			
	9717740	Nov 19, 2032	U-3075			
<u>HYDROCORTISONE - ALKINDI SPRINKLE</u>						
N 213876 004	9649280	May 12, 2034	DP U-3075			
	9675559	Jan 10, 2033	U-3075			
	9717740	Nov 19, 2032	U-3075			
<u>HYDROCORTISONE BUTYRATE - LOCOID</u>						
N 022076 001	7378405	Dec 19, 2026	DP			
	7981877	Jan 23, 2025	DP			
<u>HYDROGEN PEROXIDE - ESKATA</u>						
N 209305 001	10098910	Apr 21, 2035	DP U-2205			
	10493103	Apr 21, 2035	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROGEN PEROXIDE - ESKATA</u>						
N 209305 001	10729720	Apr 21, 2035	DP			
	9675639	Jul 04, 2035	DP U-2205			
	9980983	Apr 21, 2035	U-2205			
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID-HP</u>						
N 019034 001	9248229	Mar 12, 2034	DP			
	9731082	Apr 23, 2032	DP			
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID-HP</u>						
N 019034 002	9248229	Mar 12, 2034	DP			
	9731082	Apr 23, 2032	DP			
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID</u>						
N 019034 003	9248229	Mar 12, 2034	DP			
	9731082	Apr 23, 2032	DP			
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID</u>						
N 019034 004	9248229	Mar 12, 2034	DP			
	9731082	Apr 23, 2032	DP			
<u>HYDROMORPHONE HYDROCHLORIDE - DILAUDID</u>						
N 019034 005	9248229	Mar 12, 2034	DP			
	9731082	Apr 23, 2032	DP			
<u>HYDROXYPROGESTERONE CAPROATE - MAKENA (AUTOINJECTOR)</u>						
N 021945 004	10471075	May 02, 2036	U-2236			
	11154562	May 02, 2036	U-2236			
	11304962	May 02, 2036	U-2236			
	11446440	Aug 21, 2031	DP			
	11446441	Jan 24, 2026	DP			
	8021335	Oct 04, 2026	DP			
	8562564	Jan 24, 2026	DP			
	9180259	Jan 24, 2026	DP			
	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
	9789257	Feb 11, 2034	DP			
	9844558	May 02, 2036	U-2236			
<u>HYDROXYUREA - SIKLOS</u>						
N 208843 001					ODE-177	Dec 21, 2024
<u>HYDROXYUREA - SIKLOS</u>						
N 208843 002					ODE-177	Dec 21, 2024
<u>IBANDRONATE SODIUM - BONIVA</u>						
N 021455 002	7192938	May 06, 2023	U-798			
	7410957	May 06, 2023	U-887			
	7718634	May 06, 2023	U-642			
<u>IBREXAFUNGERP CITRATE - BREXAFEMME</u>						
N 214900 001	10174074	Jan 19, 2035	DS DP		NCE	Jun 01, 2026
	10370406	Jan 19, 2035	U-3159		GAIN	Jun 01, 2031
	10927142	Jan 19, 2035	DS			
	8188085	Aug 28, 2030	DS DP U-3159			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 001	10004746	Jun 03, 2031	U-1684		NPP	Aug 24, 2025
	10004746	Jun 03, 2031	U-1946		ODE-109	Mar 04, 2023
	10004746	Jun 03, 2031	U-2241		ODE-117	May 06, 2023
	10004746	Jun 03, 2031	U-2242		ODE-128	Jan 18, 2024
	10004746*PED	Dec 03, 2031			ODE-152	Aug 02, 2024
	10016435	Jun 03, 2031	U-1650		PED	Feb 24, 2026
	10016435*PED	Dec 03, 2031				
	10106548	Jun 03, 2033	DS DP			
	10106548*PED	Dec 03, 2033				
	10125140	Jun 03, 2033	DS DP			
	10125140*PED	Dec 03, 2033				
	10294231	Jun 03, 2033	DP			
	10294231*PED	Dec 03, 2033				
	10294232	Jun 03, 2033	DP			
	10294232*PED	Dec 03, 2033				
	10463668	Oct 24, 2034	U-2654			
	10463668*PED	Apr 24, 2035				
	10478439	Jun 03, 2031	U-1456			
	10478439	Jun 03, 2031	U-1650			
	10478439	Jun 03, 2031	U-1684			
	10478439	Jun 03, 2031	U-1946			
	10478439	Jun 03, 2031	U-1947			
	10478439	Jun 03, 2031	U-2241			
	10478439	Jun 03, 2031	U-2242			
	10478439	Jun 03, 2031	U-2665			
	10478439	Jun 03, 2031	U-3422			
	10478439*PED	Dec 03, 2031				
	10653696	Jun 03, 2031	U-1456			
	10653696*PED	Dec 03, 2031				
	10695350	Oct 24, 2034	U-2846			
	10695350*PED	Apr 24, 2035				
	10751342	Jun 03, 2031	U-1491			
	10751342	Jun 03, 2031	U-1946			
	10751342	Jun 03, 2031	U-2943			
	10751342	Jun 03, 2031	U-2944			
	10751342*PED	Dec 03, 2031				
	10752634	Jun 03, 2033	DP			
	10752634*PED	Dec 03, 2033				
	10961251	Jun 03, 2033	DP			
	10961251*PED	Dec 03, 2033				
	7514444	Dec 28, 2026	DS DP			
	7514444*PED	Jun 28, 2027				
	8008309	Nov 13, 2027	DS DP			
	8008309*PED	May 13, 2028				
	8476284	Dec 28, 2026	U-1456			
	8476284	Dec 28, 2026	U-1650			
	8476284	Dec 28, 2026	U-1946			
	8476284	Dec 28, 2026	U-1947			
	8476284*PED	Jun 28, 2027				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 001	8497277	Dec 28, 2026	U-1456			
	8497277	Dec 28, 2026	U-1491			
	8497277	Dec 28, 2026	U-1650			
	8497277	Dec 28, 2026	U-1946			
	8497277	Dec 28, 2026	U-1947			
	8497277*PED	Jun 28, 2027				
	8563563	Apr 26, 2027	U-1491			
	8563563	Apr 26, 2027	U-1650			
	8563563	Apr 26, 2027	U-1946			
	8563563	Apr 26, 2027	U-2219			
	8563563*PED	Oct 26, 2027				
	8697711	Dec 28, 2026	DS DP			
	8697711*PED	Jun 28, 2027				
	8703780	Dec 28, 2026	U-1491			
	8703780*PED	Jun 28, 2027				
	8735403	Dec 28, 2026	DS DP			
	8735403*PED	Jun 28, 2027				
	8754090	Jun 03, 2031	U-1456			
	8754090*PED	Dec 03, 2031				
	8754091	Dec 28, 2026	DP			
	8754091*PED	Jun 28, 2027				
	8952015	Dec 28, 2026	U-1456			
	8952015	Dec 28, 2026	U-1491			
	8952015	Dec 28, 2026	U-1650			
	8952015	Dec 28, 2026	U-1946			
	8952015	Dec 28, 2026	U-1947			
	8952015*PED	Jun 28, 2027				
	8957079	Dec 28, 2026	DS DP			
	8957079*PED	Jun 28, 2027				
	8999999	Jun 03, 2031	U-1683			
	8999999	Jun 03, 2031	U-1684			
	8999999*PED	Dec 03, 2031				
	9125889	Jun 03, 2031	U-1745			
	9125889*PED	Dec 03, 2031				
	9181257	Dec 28, 2026	DS DP			
	9181257*PED	Jun 28, 2027				
	9296753	Oct 30, 2033	DS DP			
	9296753*PED	Apr 30, 2034				
	9540382	Aug 18, 2033	U-1456			
	9540382	Aug 18, 2033	U-1650			
	9540382	Aug 18, 2033	U-1684			
	9540382	Aug 18, 2033	U-1946			
	9540382	Aug 18, 2033	U-1947			
	9540382*PED	Feb 18, 2034				
	9713617	Jun 03, 2033	DP			
	9713617*PED	Dec 03, 2033				
	9725455	Jun 03, 2033	DS			
	9725455*PED	Dec 03, 2033				
	9795604	Oct 24, 2034	U-2150			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 001	9795604	Oct 24, 2034	U-2969			
	9795604	Oct 24, 2034	U-2970			
	9795604*PED	Apr 24, 2035				
	9801881	Jun 03, 2031	U-1491			
	9801881*PED	Dec 03, 2031				
	9801883	Jun 03, 2031	U-2159			
	9801883*PED	Dec 03, 2031				
	9814721	Jun 03, 2031	U-1947			
	9814721*PED	Dec 03, 2031				
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 002	10004746	Jun 03, 2031	U-1684		NPP	Aug 24, 2025
	10004746	Jun 03, 2031	U-1946		PED	Feb 24, 2026
	10004746	Jun 03, 2031	U-2241			
	10004746	Jun 03, 2031	U-2242			
	10004746*PED	Dec 03, 2031				
	10016435	Jun 03, 2031	U-1650			
	10016435*PED	Dec 03, 2031				
	10106548	Jun 03, 2033	DS DP			
	10106548*PED	Dec 03, 2033				
	10125140	Jun 03, 2033	DS DP			
	10125140*PED	Dec 03, 2033				
	10294231	Jun 03, 2033	DP			
	10294231*PED	Dec 03, 2033				
	10294232	Jun 03, 2033	DP			
	10294232*PED	Dec 03, 2033				
	10463668	Oct 24, 2034	U-2654			
	10463668*PED	Apr 24, 2035				
	10478439	Jun 03, 2031	U-1456			
	10478439	Jun 03, 2031	U-1650			
	10478439	Jun 03, 2031	U-1684			
	10478439	Jun 03, 2031	U-1946			
	10478439	Jun 03, 2031	U-1947			
	10478439	Jun 03, 2031	U-2241			
	10478439	Jun 03, 2031	U-2242			
	10478439	Jun 03, 2031	U-2665			
	10478439	Jun 03, 2031	U-3422			
	10478439*PED	Dec 03, 2031				
	10653696	Jun 03, 2031	U-1456			
	10653696*PED	Dec 03, 2031				
	10695350	Oct 24, 2034	U-2846			
	10695350*PED	Apr 24, 2035				
	10751342	Jun 03, 2031	U-1491			
	10751342	Jun 03, 2031	U-1946			
	10751342	Jun 03, 2031	U-2943			
	10751342	Jun 03, 2031	U-2944			
	10751342*PED	Dec 03, 2031				
	10961251	Jun 03, 2033	DP			
	10961251*PED	Dec 03, 2033				
	7514444	Dec 28, 2026	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 002	7514444*PED	Jun 28, 2027				
	8008309	Nov 13, 2027	DS DP			
	8008309*PED	May 13, 2028				
	8476284	Dec 28, 2026			U-1456	
	8476284	Dec 28, 2026			U-1650	
	8476284	Dec 28, 2026			U-1946	
	8476284	Dec 28, 2026			U-1947	
	8476284*PED	Jun 28, 2027				
	8497277	Dec 28, 2026			U-1456	
	8497277	Dec 28, 2026			U-1491	
	8497277	Dec 28, 2026			U-1650	
	8497277	Dec 28, 2026			U-1946	
	8497277	Dec 28, 2026			U-1947	
	8497277*PED	Jun 28, 2027				
	8563563	Apr 26, 2027			U-1491	
	8563563	Apr 26, 2027			U-1650	
	8563563	Apr 26, 2027			U-1946	
	8563563	Apr 26, 2027			U-2219	
	8563563*PED	Oct 26, 2027				
	8697711	Dec 28, 2026	DS DP			
	8697711*PED	Jun 28, 2027				
	8703780	Dec 28, 2026			U-1491	
	8703780*PED	Jun 28, 2027				
	8735403	Dec 28, 2026	DS DP			
	8735403*PED	Jun 28, 2027				
	8754090	Jun 03, 2031			U-1456	
	8754090*PED	Dec 03, 2031				
	8754091	Dec 28, 2026	DP			
	8754091*PED	Jun 28, 2027				
	8952015	Dec 28, 2026			U-1456	
	8952015	Dec 28, 2026			U-1491	
	8952015	Dec 28, 2026			U-1650	
	8952015	Dec 28, 2026			U-1946	
	8952015	Dec 28, 2026			U-1947	
	8952015*PED	Jun 28, 2027				
	8957079	Dec 28, 2026	DS DP			
	8957079*PED	Jun 28, 2027				
	8999999	Jun 03, 2031			U-1491	
	8999999	Jun 03, 2031			U-1946	
	8999999	Jun 03, 2031			U-2228	
	8999999*PED	Dec 03, 2031				
	9125889	Jun 03, 2031			U-1650	
	9125889*PED	Dec 03, 2031				
	9181257	Dec 28, 2026	DS			
	9181257*PED	Jun 28, 2027				
	9296753	Oct 30, 2033	DS			
	9296753*PED	Apr 30, 2034				
	9540382	Aug 18, 2033			U-1456	
	9540382	Aug 18, 2033			U-1491	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 002	9540382	Aug 18, 2033	U-1650			
	9540382	Aug 18, 2033	U-1946			
	9540382	Aug 18, 2033	U-1947			
	9540382*PED	Feb 18, 2034				
	9713617	Jun 03, 2033	DP			
	9713617*PED	Dec 03, 2033				
	9725455	Jun 03, 2033	DS			
	9725455*PED	Dec 03, 2033				
	9795604	Oct 24, 2034	U-2969			
	9795604	Oct 24, 2034	U-2970			
	9795604*PED	Apr 24, 2035				
	9801881	Jun 03, 2031	U-1491			
	9801881*PED	Dec 03, 2031				
	9801883	Jun 03, 2031	U-2159			
	9801883*PED	Dec 03, 2031				
	9814721	Jun 03, 2031	U-1947			
	9814721*PED	Dec 03, 2031				
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 001	10004746	Jun 03, 2031	U-1684		NPP	Aug 24, 2025
	10004746	Jun 03, 2031	U-1946		PED	Feb 24, 2026
	10004746	Jun 03, 2031	U-2241			
	10004746	Jun 03, 2031	U-2242			
	10004746*PED	Dec 03, 2031				
	10010507	Mar 03, 2036	DP			
	10010507*PED	Sep 03, 2036				
	10016435	Jun 03, 2031	U-1650			
	10016435*PED	Dec 03, 2031				
	10106548	Jun 03, 2033	DS DP			
	10106548*PED	Dec 03, 2033				
	10125140	Jun 03, 2033	DS DP			
	10125140*PED	Dec 03, 2033				
	10213386	Mar 03, 2036	DP			
	10213386*PED	Sep 03, 2036				
	10463668	Oct 24, 2034	U-2654			
	10463668*PED	Apr 24, 2035				
	10478439	Jun 03, 2031	U-1456			
	10478439	Jun 03, 2031	U-1650			
	10478439	Jun 03, 2031	U-1684			
	10478439	Jun 03, 2031	U-1946			
	10478439	Jun 03, 2031	U-1947			
	10478439	Jun 03, 2031	U-2241			
	10478439	Jun 03, 2031	U-2242			
	10478439	Jun 03, 2031	U-2665			
	10478439	Jun 03, 2031	U-3422			
	10478439*PED	Dec 03, 2031				
	10653696	Jun 03, 2031	U-1456			
	10653696*PED	Dec 03, 2031				
	10695350	Oct 24, 2034	U-2846			
	10695350*PED	Apr 24, 2035				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 001	10751342	Jun 03, 2031	U-1491			
	10751342	Jun 03, 2031	U-1946			
	10751342	Jun 03, 2031	U-2943			
	10751342	Jun 03, 2031	U-2944			
	10751342*PED	Dec 03, 2031				
	10752634	Jun 03, 2033	DP			
	10752634*PED	Dec 03, 2033				
	10828259	Mar 03, 2036	DP			
	10828259*PED	Sep 03, 2036				
	10961251	Jun 03, 2033	DP			
	10961251*PED	Dec 03, 2033				
	7514444	Dec 28, 2026	DS DP			
	7514444*PED	Jun 28, 2027				
	8008309	Nov 13, 2027	DS DP			
	8008309*PED	May 13, 2028				
	8476284	Dec 28, 2026	U-1456			
	8476284	Dec 28, 2026	U-1650			
	8476284	Dec 28, 2026	U-1946			
	8476284	Dec 28, 2026	U-1947			
	8476284	Dec 28, 2026	U-2241			
	8476284*PED	Jun 28, 2027				
	8497277	Dec 28, 2026	U-1456			
	8497277	Dec 28, 2026	U-1491			
	8497277	Dec 28, 2026	U-1650			
	8497277	Dec 28, 2026	U-1946			
	8497277	Dec 28, 2026	U-1947			
	8497277	Dec 28, 2026	U-2241			
	8497277	Dec 28, 2026	U-2242			
	8497277*PED	Jun 28, 2027				
	8563563	Apr 26, 2027	U-1491			
	8563563	Apr 26, 2027	U-1650			
	8563563	Apr 26, 2027	U-1946			
	8563563	Apr 26, 2027	U-2241			
	8563563	Apr 26, 2027	U-2242			
	8563563*PED	Oct 26, 2027				
	8697711	Dec 28, 2026	DS DP			
	8697711*PED	Jun 28, 2027				
	8703780	Dec 28, 2026	U-1491			
	8703780	Dec 28, 2026	U-2242			
	8703780*PED	Jun 28, 2027				
	8735403	Dec 28, 2026	DS DP			
	8735403*PED	Jun 28, 2027				
	8754090	Jun 03, 2031	U-1456			
	8754090*PED	Dec 03, 2031				
	8754091	Dec 28, 2026	DP			
	8754091*PED	Jun 28, 2027				
	8952015	Dec 28, 2026	U-1456			
	8952015	Dec 28, 2026	U-1491			
	8952015	Dec 28, 2026	U-1650			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 001	8952015	Dec 28, 2026	U-1946			
	8952015	Dec 28, 2026	U-1947			
	8952015	Dec 28, 2026	U-2241			
	8952015	Dec 28, 2026	U-2242			
	8952015*PED	Jun 28, 2027				
	8957079	Dec 28, 2026	DS DP			
	8957079*PED	Jun 28, 2027				
	8999999	Jun 03, 2031	U-1491			
	8999999	Jun 03, 2031	U-1946			
	8999999	Jun 03, 2031	U-2241			
	8999999	Jun 03, 2031	U-2242			
	8999999*PED	Dec 03, 2031				
	9125889	Jun 03, 2031	U-1650			
	9125889*PED	Dec 03, 2031				
	9181257	Dec 28, 2026	DS			
	9181257*PED	Jun 28, 2027				
	9296753	Oct 30, 2033	DS			
	9296753*PED	Apr 30, 2034				
	9655857	Mar 03, 2036	DP			
	9655857*PED	Sep 03, 2036				
	9725455	Jun 03, 2033	DS			
	9725455*PED	Dec 03, 2033				
	9795604	Oct 24, 2034	U-2969			
	9795604	Oct 24, 2034	U-2970			
	9795604*PED	Apr 24, 2035				
	9801881	Jun 03, 2031	U-1491			
	9801881	Jun 03, 2031	U-2242			
	9801881*PED	Dec 03, 2031				
	9801883	Jun 03, 2031	U-2159			
	9801883	Jun 03, 2031	U-2243			
	9801883*PED	Dec 03, 2031				
	9814721	Jun 03, 2031	U-1947			
	9814721*PED	Dec 03, 2031				
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 002	10004746	Jun 03, 2031	U-1684		NPP	Aug 24, 2025
	10004746	Jun 03, 2031	U-1946		PED	Feb 24, 2026
	10004746	Jun 03, 2031	U-2241			
	10004746	Jun 03, 2031	U-2242			
	10004746*PED	Dec 03, 2031				
	10010507	Mar 03, 2036	DP			
	10010507*PED	Sep 03, 2036				
	10016435	Jun 03, 2031	U-1650			
	10016435*PED	Dec 03, 2031				
	10106548	Jun 03, 2033	DS DP			
	10106548*PED	Dec 03, 2033				
	10125140	Jun 03, 2033	DS DP			
	10125140*PED	Dec 03, 2033				
	10213386	Mar 03, 2036	DP			
	10213386*PED	Sep 03, 2036				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 002	10463668	Oct 24, 2034	U-2654			
	10463668*PED	Apr 24, 2035				
	10478439	Jun 03, 2031	U-1456			
	10478439	Jun 03, 2031	U-1650			
	10478439	Jun 03, 2031	U-1684			
	10478439	Jun 03, 2031	U-1946			
	10478439	Jun 03, 2031	U-1947			
	10478439	Jun 03, 2031	U-2241			
	10478439	Jun 03, 2031	U-2242			
	10478439	Jun 03, 2031	U-2665			
	10478439	Jun 03, 2031	U-3422			
	10478439*PED	Dec 03, 2031				
	10653696	Jun 03, 2031	U-1456			
	10653696*PED	Dec 03, 2031				
	10695350	Oct 24, 2034	U-2846			
	10695350*PED	Apr 24, 2035				
	10751342	Jun 03, 2031	U-1491			
	10751342	Jun 03, 2031	U-1946			
	10751342	Jun 03, 2031	U-2943			
	10751342	Jun 03, 2031	U-2944			
	10751342*PED	Dec 03, 2031				
	10828259	Mar 03, 2036	DP			
	10828259*PED	Sep 03, 2036				
	10961251	Jun 03, 2033	DP			
	10961251*PED	Dec 03, 2033				
	7514444	Dec 28, 2026	DS DP			
	7514444*PED	Jun 28, 2027				
	8008309	Nov 13, 2027	DS DP			
	8008309*PED	May 13, 2028				
	8476284	Dec 28, 2026	U-1456			
	8476284	Dec 28, 2026	U-1650			
	8476284	Dec 28, 2026	U-1946			
	8476284	Dec 28, 2026	U-1947			
	8476284	Dec 28, 2026	U-2241			
	8476284*PED	Jun 28, 2027				
	8497277	Dec 28, 2026	U-1456			
	8497277	Dec 28, 2026	U-1491			
	8497277	Dec 28, 2026	U-1650			
	8497277	Dec 28, 2026	U-1946			
	8497277	Dec 28, 2026	U-1947			
	8497277	Dec 28, 2026	U-2241			
	8497277	Dec 28, 2026	U-2242			
	8497277*PED	Jun 28, 2027				
	8563563	Apr 26, 2027	U-1491			
	8563563	Apr 26, 2027	U-1650			
	8563563	Apr 26, 2027	U-1946			
	8563563	Apr 26, 2027	U-2241			
	8563563	Apr 26, 2027	U-2242			
	8563563*PED	Oct 26, 2027				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 002	8697711	Dec 28, 2026	DS DP			
	8697711*PED	Jun 28, 2027				
	8703780	Dec 28, 2026			U-1491	
	8703780	Dec 28, 2026			U-2242	
	8703780*PED	Jun 28, 2027				
	8735403	Dec 28, 2026	DS DP			
	8735403*PED	Jun 28, 2027				
	8754090	Jun 03, 2031			U-1456	
	8754090*PED	Dec 03, 2031				
	8754091	Dec 28, 2026	DP			
	8754091*PED	Jun 28, 2027				
	8952015	Dec 28, 2026			U-1456	
	8952015	Dec 28, 2026			U-1491	
	8952015	Dec 28, 2026			U-1650	
	8952015	Dec 28, 2026			U-1946	
	8952015	Dec 28, 2026			U-1947	
	8952015	Dec 28, 2026			U-2241	
	8952015	Dec 28, 2026			U-2242	
	8952015*PED	Jun 28, 2027				
	8957079	Dec 28, 2026	DS DP			
	8957079*PED	Jun 28, 2027				
	8999999	Jun 03, 2031			U-1491	
	8999999	Jun 03, 2031			U-1946	
	8999999	Jun 03, 2031			U-2241	
	8999999	Jun 03, 2031			U-2242	
	8999999*PED	Dec 03, 2031				
	9125889	Jun 03, 2031			U-1650	
	9125889*PED	Dec 03, 2031				
	9181257	Dec 28, 2026	DS			
	9181257*PED	Jun 28, 2027				
	9296753	Oct 30, 2033	DS			
	9296753*PED	Apr 30, 2034				
	9655857	Mar 03, 2036			DP	
	9655857*PED	Sep 03, 2036				
	9725455	Jun 03, 2033	DS			
	9725455*PED	Dec 03, 2033				
	9795604	Oct 24, 2034			U-2969	
	9795604	Oct 24, 2034			U-2970	
	9795604*PED	Apr 24, 2035				
	9801881	Jun 03, 2031			U-1491	
	9801881	Jun 03, 2031			U-2242	
	9801881*PED	Dec 03, 2031				
	9801883	Jun 03, 2031			U-2159	
	9801883	Jun 03, 2031			U-2243	
	9801883*PED	Dec 03, 2031				
	9814721	Jun 03, 2031			U-1947	
	9814721*PED	Dec 03, 2031				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 003	10004746	Jun 03, 2031	U-1684		NPP	Aug 24, 2025
	10004746	Jun 03, 2031	U-1946		PED	Feb 24, 2026
	10004746	Jun 03, 2031	U-2241			
	10004746	Jun 03, 2031	U-2242			
	10004746*PED	Dec 03, 2031				
	10010507	Mar 03, 2036	DP			
	10010507*PED	Sep 03, 2036				
	10016435	Jun 03, 2031	U-1650			
	10016435*PED	Dec 03, 2031				
	10106548	Jun 03, 2033	DS DP			
	10106548*PED	Dec 03, 2033				
	10125140	Jun 03, 2033	DS DP			
	10125140*PED	Dec 03, 2033				
	10213386	Mar 03, 2036	DP			
	10213386*PED	Sep 03, 2036				
	10463668	Oct 24, 2034	U-2654			
	10463668*PED	Apr 24, 2035				
	10478439	Jun 03, 2031	U-1456			
	10478439	Jun 03, 2031	U-1650			
	10478439	Jun 03, 2031	U-1684			
	10478439	Jun 03, 2031	U-1946			
	10478439	Jun 03, 2031	U-1947			
	10478439	Jun 03, 2031	U-2241			
	10478439	Jun 03, 2031	U-2242			
	10478439	Jun 03, 2031	U-2665			
	10478439	Jun 03, 2031	U-3422			
	10478439*PED	Dec 03, 2031				
	10653696	Jun 03, 2031	U-1456			
	10653696*PED	Dec 03, 2031				
	10695350	Oct 24, 2034	U-2846			
	10695350*PED	Apr 24, 2035				
	10751342	Jun 03, 2031	U-1491			
	10751342	Jun 03, 2031	U-1946			
	10751342	Jun 03, 2031	U-2943			
	10751342	Jun 03, 2031	U-2944			
	10751342*PED	Dec 03, 2031				
	10828259	Mar 03, 2036	DP			
	10828259*PED	Sep 03, 2036				
	10961251	Jun 03, 2033	DP			
	10961251*PED	Dec 03, 2033				
	7514444	Dec 28, 2026	DS DP			
	7514444*PED	Jun 28, 2027				
	8008309	Nov 13, 2027	DS DP			
	8008309*PED	May 13, 2028				
	8476284	Dec 28, 2026	U-1456			
	8476284	Dec 28, 2026	U-1650			
	8476284	Dec 28, 2026	U-1946			
	8476284	Dec 28, 2026	U-1947			
	8476284	Dec 28, 2026	U-2241			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 003	8476284*PED	Jun 28, 2027				
	8497277	Dec 28, 2026	U-1456			
	8497277	Dec 28, 2026	U-1491			
	8497277	Dec 28, 2026	U-1650			
	8497277	Dec 28, 2026	U-1946			
	8497277	Dec 28, 2026	U-1947			
	8497277	Dec 28, 2026	U-2241			
	8497277	Dec 28, 2026	U-2242			
	8497277*PED	Jun 28, 2027				
	8563563	Apr 26, 2027	U-1491			
	8563563	Apr 26, 2027	U-1650			
	8563563	Apr 26, 2027	U-1946			
	8563563	Apr 26, 2027	U-2241			
	8563563	Apr 26, 2027	U-2242			
	8563563*PED	Oct 26, 2027				
	8697711	Dec 28, 2026	DS DP			
	8697711*PED	Jun 28, 2027				
	8703780	Dec 28, 2026	U-1491			
	8703780	Dec 28, 2026	U-2242			
	8703780*PED	Jun 28, 2027				
	8735403	Dec 28, 2026	DS DP			
	8735403*PED	Jun 28, 2027				
	8754090	Jun 03, 2031	U-1456			
	8754090*PED	Dec 03, 2031				
	8754091	Dec 28, 2026	DP			
	8754091*PED	Jun 28, 2027				
	8952015	Dec 28, 2026	U-1456			
	8952015	Dec 28, 2026	U-1491			
	8952015	Dec 28, 2026	U-1650			
	8952015	Dec 28, 2026	U-1946			
	8952015	Dec 28, 2026	U-1947			
	8952015	Dec 28, 2026	U-2241			
	8952015	Dec 28, 2026	U-2242			
	8952015*PED	Jun 28, 2027				
	8957079	Dec 28, 2026	DS DP			
	8957079*PED	Jun 28, 2027				
	8999999	Jun 03, 2031	U-1491			
	8999999	Jun 03, 2031	U-1946			
	8999999	Jun 03, 2031	U-2241			
	8999999	Jun 03, 2031	U-2242			
	8999999*PED	Dec 03, 2031				
	9125889	Jun 03, 2031	U-1650			
	9125889*PED	Dec 03, 2031				
	9181257	Dec 28, 2026	DS			
	9181257*PED	Jun 28, 2027				
	9296753	Oct 30, 2033	DS			
	9296753*PED	Apr 30, 2034				
	9655857	Mar 03, 2036	DP			
	9655857*PED	Sep 03, 2036				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 003	9725455	Jun 03, 2033	DS			
	9725455*PED	Dec 03, 2033				
	9795604	Oct 24, 2034		U-2969		
	9795604	Oct 24, 2034		U-2970		
	9795604*PED	Apr 24, 2035				
	9801881	Jun 03, 2031		U-1491		
	9801881	Jun 03, 2031		U-2242		
	9801881*PED	Dec 03, 2031				
	9801883	Jun 03, 2031		U-2159		
	9801883	Jun 03, 2031		U-2243		
	9801883*PED	Dec 03, 2031				
	9814721	Jun 03, 2031		U-1947		
	9814721*PED	Dec 03, 2031				
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 004	10004746	Jun 03, 2031		U-1684	NPP	Aug 24, 2025
	10004746	Jun 03, 2031		U-1946	PED	Feb 24, 2026
	10004746	Jun 03, 2031		U-2241		
	10004746	Jun 03, 2031		U-2242		
	10004746*PED	Dec 03, 2031				
	10010507	Mar 03, 2036	DP			
	10010507*PED	Sep 03, 2036				
	10016435	Jun 03, 2031		U-1650		
	10016435*PED	Dec 03, 2031				
	10106548	Jun 03, 2033	DS DP			
	10106548*PED	Dec 03, 2033				
	10125140	Jun 03, 2033	DS DP			
	10125140*PED	Dec 03, 2033				
	10213386	Mar 03, 2036	DP			
	10213386*PED	Sep 03, 2036				
	10463668	Oct 24, 2034		U-2654		
	10463668*PED	Apr 24, 2035				
	10478439	Jun 03, 2031		U-1456		
	10478439	Jun 03, 2031		U-1650		
	10478439	Jun 03, 2031		U-1684		
	10478439	Jun 03, 2031		U-1946		
	10478439	Jun 03, 2031		U-1947		
	10478439	Jun 03, 2031		U-2241		
	10478439	Jun 03, 2031		U-2242		
	10478439	Jun 03, 2031		U-2665		
	10478439*PED	Dec 03, 2031				
	10653696	Jun 03, 2031		U-1456		
	10653696*PED	Dec 03, 2031				
	10695350	Oct 24, 2034		U-2846		
	10695350*PED	Apr 24, 2035				
	10751342	Jun 03, 2031		U-1491		
	10751342	Jun 03, 2031		U-1946		
	10751342	Jun 03, 2031		U-2943		
	10751342	Jun 03, 2031		U-2944		
	10751342*PED	Dec 03, 2031				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 004	10828259	Mar 03, 2036	DP			
	10828259*PED	Sep 03, 2036				
	10961251	Jun 03, 2033	DP			
	10961251*PED	Dec 03, 2033				
	7514444	Dec 28, 2026	DS DP			
	7514444*PED	Jun 28, 2027				
	8008309	Nov 13, 2027	DS DP			
	8008309*PED	May 13, 2028				
	8476284	Dec 28, 2026	U-1456			
	8476284	Dec 28, 2026	U-1650			
	8476284	Dec 28, 2026	U-1946			
	8476284	Dec 28, 2026	U-1947			
	8476284	Dec 28, 2026	U-2241			
	8476284*PED	Jun 28, 2027				
	8497277	Dec 28, 2026	U-1456			
	8497277	Dec 28, 2026	U-1491			
	8497277	Dec 28, 2026	U-1650			
	8497277	Dec 28, 2026	U-1946			
	8497277	Dec 28, 2026	U-1947			
	8497277	Dec 28, 2026	U-2241			
	8497277	Dec 28, 2026	U-2242			
	8497277*PED	Jun 28, 2027				
	8563563	Apr 26, 2027	U-1491			
	8563563	Apr 26, 2027	U-1650			
	8563563	Apr 26, 2027	U-1946			
	8563563	Apr 26, 2027	U-2241			
	8563563	Apr 26, 2027	U-2242			
	8563563*PED	Oct 26, 2027				
	8697711	Dec 28, 2026	DS DP			
	8697711*PED	Jun 28, 2027				
	8703780	Dec 28, 2026	U-1491			
	8703780	Dec 28, 2026	U-2242			
	8703780*PED	Jun 28, 2027				
	8735403	Dec 28, 2026	DS DP			
	8735403*PED	Jun 28, 2027				
	8754090	Jun 03, 2031	U-1456			
	8754090*PED	Dec 03, 2031				
	8754091	Dec 28, 2026	DP			
	8754091*PED	Jun 28, 2027				
	8952015	Dec 28, 2026	U-1456			
	8952015	Dec 28, 2026	U-1491			
	8952015	Dec 28, 2026	U-1650			
	8952015	Dec 28, 2026	U-1946			
	8952015	Dec 28, 2026	U-1947			
	8952015	Dec 28, 2026	U-2241			
	8952015	Dec 28, 2026	U-2242			
	8952015*PED	Jun 28, 2027				
	8957079	Dec 28, 2026	DS DP			
	8957079*PED	Jun 28, 2027				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 004	8999999	Jun 03, 2031	U-1491			
	8999999	Jun 03, 2031	U-1946			
	8999999	Jun 03, 2031	U-2241			
	8999999	Jun 03, 2031	U-2242			
	8999999*PED	Dec 03, 2031				
	9125889	Jun 03, 2031	U-1650			
	9125889*PED	Dec 03, 2031				
	9181257	Dec 28, 2026	DS			
	9181257*PED	Jun 28, 2027				
	9296753	Oct 30, 2033	DS			
	9296753*PED	Apr 30, 2034				
	9655857	Mar 03, 2036	DP			
	9655857*PED	Sep 03, 2036				
	9725455	Jun 03, 2033	DS			
	9725455*PED	Dec 03, 2033				
	9795604	Oct 24, 2034	U-2969			
	9795604	Oct 24, 2034	U-2970			
	9795604*PED	Apr 24, 2035				
	9801881	Jun 03, 2031	U-1491			
	9801881	Jun 03, 2031	U-2242			
	9801881*PED	Dec 03, 2031				
	9801883	Jun 03, 2031	U-2159			
	9801883	Jun 03, 2031	U-2243			
	9801883*PED	Dec 03, 2031				
	9814721	Jun 03, 2031	U-1947			
	9814721*PED	Dec 03, 2031				
<u>IBRUTINIB - IMBRUVICA</u>						
N 217003 001	10106548	Jun 03, 2033	DS DP		NP	Aug 24, 2025
	10125140	Jun 03, 2033	DS DP		PED	Feb 24, 2026
	10478439	Jun 03, 2031	U-3422			
	10961251	Jun 03, 2033	DP			
	7514444	Dec 28, 2026	DS DP			
	8008309	Nov 13, 2027	DS DP			
	8497277	Dec 28, 2026	U-3422			
	8697711	Dec 28, 2026	DS DP			
	8735403	Dec 28, 2026	DS DP			
	8754091	Dec 28, 2026	DP			
	8957079	Dec 28, 2026	DS DP			
	9181257	Dec 28, 2026	DS			
	9296753	Oct 30, 2033	DS			
	9725455	Jun 03, 2033	DS			
	9795604	Oct 24, 2034	U-3422			
<u>IBUPROFEN - CHILDREN'S ADVIL-FLAVORED</u>						
N 020589 002	10238640	May 25, 2024	DP			
<u>IBUPROFEN - CALDOLOR</u>						
N 022348 001					M-128	Nov 19, 2024

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>IBUPROFEN - CALDOLOR</u>						
N 022348 002	8735452	Sep 30, 2029	U-981		M-128	Nov 19, 2024
	8871810	Sep 30, 2029	U-981			
	9012508	Sep 14, 2030	U-981			
	9114068	Sep 30, 2029	U-1735			
	9138404	Sep 30, 2029	U-1756			
	9295639	Sep 30, 2029	U-1756			
	9649284	Sep 30, 2029	U-2018			
<u>IBUPROFEN - CALDOLOR</u>						
N 022348 003	8735452	Sep 30, 2029	U-981		M-128	Nov 19, 2024
	8871810	Sep 30, 2029	U-981			
	9012508	Sep 14, 2030	U-981			
	9072661	Mar 16, 2032	U-2264			
	9072710	Mar 16, 2032	U-2266			
<u>IBUPROFEN LYSINE - NEOPROFEN</u>						
N 021903 001	8415337	Mar 02, 2032	DS DP			
<u>ICOSAPENT ETHYL - ICOSAPENT ETHYL</u>						
A 209525 001					PC	Mar 08, 2023
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N 202057 001	10010517	Apr 29, 2030	U-2690			
	10265287	Apr 29, 2030	U-2700			
	10278935	Jun 28, 2033	U-2701			
	10278936	Jun 28, 2033	U-2702			
	10278937	Jun 28, 2033	U-2703			
	10383840	Jun 28, 2033	U-2704			
	10555924	Jun 28, 2033	U-2743			
	10555925	Jun 28, 2033	U-2744			
	10568861	Jun 28, 2033	U-2756			
	10576054	Jun 28, 2033	U-2762			
	10668042	Jun 28, 2033	U-2841			
	10786478	Jun 28, 2033	U-2959			
	10786478	Jun 28, 2033	U-2960			
	10792267	Apr 29, 2030	U-2961			
	10792270	Jun 28, 2033	U-2962			
	10842766	Apr 29, 2030	U-2997			
	10842768	Jun 15, 2030	U-2688			
	10881632	Apr 29, 2030	U-3052			
	10894028	Jun 28, 2033	U-3053			
	11000499	Jun 28, 2033	U-3126			
	11103477	Apr 29, 2030	U-3209			
	11116742	Jun 28, 2033	U-3221			
	11154526	Apr 29, 2030	U-3240			
	11213504	Apr 29, 2030	U-3292			
	11298333	Jun 28, 2033	U-3358			
	11369582	Jun 28, 2033	U-2841			
	8293727	Feb 09, 2030	U-1287			
	8293728	Feb 09, 2030	U-1287			
	8298554	Apr 29, 2030	DP			
	8314086	Feb 09, 2030	U-1287			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N 202057 001	8318715	Feb 09, 2030	U-1287			
	8357677	Feb 09, 2030	U-1287			
	8367652	Feb 09, 2030	U-1287			
	8377920	Feb 09, 2030	U-1287			
	8399446	Feb 09, 2030	U-1287			
	8410086	Jun 15, 2030	U-2688			
	8415335	Feb 09, 2030	U-1287			
	8426399	Feb 09, 2030	U-1287			
	8431560	Feb 09, 2030	U-1287			
	8440650	Feb 09, 2030	U-1287			
	8445003	Apr 29, 2030	U-1287			
	8445013	Apr 29, 2030	U-1287			
	8454994	Apr 29, 2030	U-2689			
	8455472	Jun 15, 2030	U-2690			
	8501225	Apr 29, 2030	U-1287			
	8518929	Feb 09, 2030	U-1287			
	8524698	Feb 09, 2030	U-1287			
	8546372	Feb 09, 2030	U-1287			
	8551521	Apr 29, 2030	U-1287			
	8563608	Apr 29, 2030	U-1287			
	8617593	Apr 29, 2030	U-1478			
	8617593	Apr 29, 2030	U-2691			
	8617594	Apr 29, 2030	U-1287			
	8618166	Apr 29, 2030	U-2689			
	8623406	Apr 29, 2030	U-1478			
	8623406	Apr 29, 2030	U-2692			
	8642077	Apr 29, 2030	U-2693			
	8669245	Jun 15, 2030	U-2694			
	8680144	Feb 09, 2030	U-2695			
	8691871	Apr 29, 2030	U-2689			
	8703185	Apr 29, 2030	U-2691			
	8709475	Apr 29, 2030	U-2689			
	8710041	Jun 15, 2030	U-2690			
	9198892	Sep 25, 2027	U-2706			
	9603826	Jun 28, 2033	U-2696			
	9610272	Jun 28, 2033	U-2697			
	9623001	Jun 28, 2033	U-2698			
	9693984	Jun 28, 2033	U-2697			
	9693985	Jun 28, 2033	U-2696			
	9693986	Jun 28, 2033	U-2698			
	9700537	May 31, 2027	U-2707			
	9918954	Jun 28, 2033	U-2699			
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N 202057 002	10010517	Apr 29, 2030	U-2690			
	10265287	Apr 29, 2030	U-2700			
	10278935	Jun 28, 2033	U-2701			
	10278936	Jun 28, 2033	U-2702			
	10278937	Jun 28, 2033	U-2703			
	10383840	Jun 28, 2033	U-2704			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N 202057 002	10555924	Jun 28, 2033	U-2743			
	10555925	Jun 28, 2033	U-2744			
	10568861	Jun 28, 2033	U-2756			
	10576054	Jun 28, 2033	U-2762			
	10668042	Jun 28, 2033	U-2841			
	10786478	Jun 28, 2033	U-2959			
	10786478	Jun 28, 2033	U-2960			
	10792267	Apr 29, 2030	U-2961			
	10792270	Jun 28, 2033	U-2962			
	10842766	Apr 29, 2030	U-2997			
	10842768	Jun 15, 2030	U-2688			
	10881632	Apr 29, 2030	U-3052			
	10894028	Jun 28, 2033	U-3053			
	11000499	Jun 28, 2033	U-3126			
	11103477	Apr 29, 2030	U-3209			
	11116742	Jun 28, 2033	U-3221			
	11154526	Apr 29, 2030	U-3240			
	11213504	Apr 29, 2030	U-3292			
	11298333	Jun 28, 2033	U-3358			
	11369582	Jun 28, 2033	U-2841			
	8293727	Feb 09, 2030	U-1287			
	8293728	Feb 09, 2030	U-1287			
	8298554	Apr 29, 2030	DP			
	8314086	Feb 09, 2030	U-1287			
	8318715	Feb 09, 2030	U-1287			
	8357677	Feb 09, 2030	U-1287			
	8367652	Feb 09, 2030	U-1287			
	8377920	Feb 09, 2030	U-1287			
	8399446	Feb 09, 2030	U-1287			
	8410086	Jun 15, 2030	U-2688			
	8415335	Feb 09, 2030	U-1287			
	8426399	Feb 09, 2030	U-1287			
	8440650	Feb 09, 2030	U-1287			
	8445003	Apr 29, 2030	U-1287			
	8445013	Apr 29, 2030	U-1287			
	8454994	Apr 29, 2030	U-2689			
	8501225	Apr 29, 2030	U-1287			
	8518929	Feb 09, 2030	U-1287			
	8524698	Feb 09, 2030	U-1287			
	8546372	Feb 09, 2030	U-1287			
	8551521	Apr 29, 2030	U-1287			
	8563608	Apr 29, 2030	U-1287			
	8617593	Apr 29, 2030	U-1287			
	8617593	Apr 29, 2030	U-2691			
	8617594	Apr 29, 2030	U-1287			
	8623406	Apr 29, 2030	U-1287			
	8623406	Apr 29, 2030	U-2692			
	8642077	Apr 29, 2030	U-2693			
	8669245	Jun 15, 2030	U-2694			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N 202057 002	8680144	Feb 09, 2030	U-2695			
	8691871	Apr 29, 2030	U-2689			
	8703185	Apr 29, 2030	U-2691			
	8709475	Apr 29, 2030	U-2689			
	8710041	Jun 15, 2030	U-2690			
	9198892	Sep 25, 2027	U-2706			
	9603826	Jun 28, 2033	U-2696			
	9610272	Jun 28, 2033	U-2697			
	9623001	Jun 28, 2033	U-2698			
	9693984	Jun 28, 2033	U-2697			
	9693985	Jun 28, 2033	U-2696			
	9693986	Jun 28, 2033	U-2698			
	9700537	May 31, 2027	U-2707			
	9918954	Jun 28, 2033	U-2699			
<u>IDELALISIB - ZYDELIG</u>						
N 205858 001	10730879	Mar 05, 2033	DS DP			
	8865730	Mar 05, 2033	DS DP	U-1615		
	8980901	May 12, 2025		U-1678		
	9149477	May 12, 2025		U-1757		
	9469643	Sep 02, 2033	DS			
	9492449	Mar 11, 2030		U-1914		
	RE44599	Jul 21, 2025		U-1558		
	RE44599	Jul 21, 2025		U-1615		
	RE44638	Aug 05, 2025	DS DP			
<u>IDELALISIB - ZYDELIG</u>						
N 205858 002	10730879	Mar 05, 2033	DS DP			
	8865730	Mar 05, 2033	DS DP	U-1615		
	8980901	May 12, 2025		U-1678		
	9149477	May 12, 2025		U-1757		
	9469643	Sep 02, 2033	DS			
	9492449	Mar 11, 2030		U-1914		
	RE44599	Jul 21, 2025		U-1558		
	RE44599	Jul 21, 2025		U-1615		
	RE44638	Aug 05, 2025	DS DP			
<u>ILOPERIDONE - FANAPT</u>						
N 022192 001	8586610	Nov 02, 2027	U-1625			
	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
	9072742	Jan 16, 2031	U-1674			
	9074254	Dec 28, 2031	U-1674			
	9074255	Dec 17, 2030	U-1674			
	9074256	Feb 10, 2031	U-1674			
	9138432	Sep 30, 2025	U-1737			
	9157121	Apr 05, 2030	U-1674			
<u>ILOPERIDONE - FANAPT</u>						
N 022192 002	8586610	Nov 02, 2027	U-1625			
	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ILOPERIDONE - FANAPT</u>						
N 022192 002	9072742	Jan 16, 2031	U-1674			
	9074254	Dec 28, 2031	U-1674			
	9074255	Dec 17, 2030	U-1674			
	9074256	Feb 10, 2031	U-1674			
	9138432	Sep 30, 2025	U-1737			
	9157121	Apr 05, 2030	U-1674			
<u>ILOPERIDONE - FANAPT</u>						
N 022192 003	8586610	Nov 02, 2027	U-1625			
	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
	9072742	Jan 16, 2031	U-1674			
	9074254	Dec 28, 2031	U-1674			
	9074255	Dec 17, 2030	U-1674			
	9074256	Feb 10, 2031	U-1674			
	9138432	Sep 30, 2025	U-1737			
	9157121	Apr 05, 2030	U-1674			
<u>ILOPERIDONE - FANAPT</u>						
N 022192 004	8586610	Nov 02, 2027	U-1625			
	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
	9072742	Jan 16, 2031	U-1674			
	9074254	Dec 28, 2031	U-1674			
	9074255	Dec 17, 2030	U-1674			
	9074256	Feb 10, 2031	U-1674			
	9138432	Sep 30, 2025	U-1737			
	9157121	Apr 05, 2030	U-1674			
<u>ILOPERIDONE - FANAPT</u>						
N 022192 005	8586610	Nov 02, 2027	U-1625			
	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
	9072742	Jan 16, 2031	U-1674			
	9074254	Dec 28, 2031	U-1674			
	9074255	Dec 17, 2030	U-1674			
	9074256	Feb 10, 2031	U-1674			
	9138432	Sep 30, 2025	U-1737			
	9157121	Apr 05, 2030	U-1674			
<u>ILOPERIDONE - FANAPT</u>						
N 022192 006	8586610	Nov 02, 2027	U-1625			
	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
	9072742	Jan 16, 2031	U-1674			
	9074254	Dec 28, 2031	U-1674			
	9074255	Dec 17, 2030	U-1674			
	9074256	Feb 10, 2031	U-1674			
	9138432	Sep 30, 2025	U-1737			
	9157121	Apr 05, 2030	U-1674			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ILOPERIDONE - FANAPT</u>						
N 022192 007	8586610	Nov 02, 2027	U-1625			
	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
	9072742	Jan 16, 2031	U-1674			
	9074254	Dec 28, 2031	U-1674			
	9074255	Dec 17, 2030	U-1674			
	9074256	Feb 10, 2031	U-1674			
	9138432	Sep 30, 2025	U-1737			
	9157121	Apr 05, 2030	U-1674			
<u>IMIQUIMOD - ALDARA</u>						
N 020723 001	7696159	Apr 01, 2024	DS U-1047			
	7696159	Apr 01, 2024	DS U-1048			
<u>IMIQUIMOD - ZYCLARA</u>						
N 022483 001	10238644	Dec 11, 2029	U-68			
	10238645	Aug 18, 2029	U-1455			
	10238645	Aug 18, 2029	U-172			
	10918635	Apr 30, 2030	U-1455			
	10918635	Apr 30, 2030	U-172			
	11202752	Apr 30, 2030	U-1455			
	11202752	Apr 30, 2030	U-172			
	8236816	Dec 11, 2029	U-68			
	8299109	Dec 11, 2029	U-68			
	8598196	Aug 18, 2029	U-1455			
	8598196	Aug 18, 2029	U-172			
<u>IMIQUIMOD - ZYCLARA</u>						
N 022483 002	11318130	Dec 11, 2029	U-68			
	8222270	Dec 11, 2029	U-68			
<u>INCLISIRAN SODIUM - LEOVIO</u>						
N 214012 001	10125369	Aug 18, 2034	DS DP U-3272		NCE	Dec 22, 2026
	10131907	Aug 24, 2028	DS DP U-3272			
	10266825	Nov 04, 2023	U-3272			
	10273477	Mar 08, 2024	DS			
	10669544	Mar 08, 2024	DS			
	10806791	Dec 04, 2028	DS			
	10851377	Aug 25, 2036	U-3272			
	11078485	Nov 04, 2023	DS U-3272			
	11530408	May 18, 2024	DS			
	8106022	Dec 12, 2029	DS DP U-3272			
	8222222	Dec 29, 2027	U-3272			
	8232383	Feb 20, 2023	DS DP			
	8809292	May 10, 2027	DS DP U-3272			
	8828956	Dec 04, 2028	DS DP U-3272			
	9370582	Dec 04, 2028	DS DP U-3272			
	9708610	Jan 01, 2024	DS DP U-3272			
	9708615	Mar 08, 2024	DS			
<u>INDACATEROL MALEATE - ARCAPTA NEOHALER</u>						
N 022383 001	6878721	Feb 25, 2025	DS DP U-1168			
	8479730	Oct 11, 2028	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>INDACATEROL MALEATE - ARCAPTA NEOHALER</u>						
N 022383 001	6878721	Feb 25, 2025	DS DP U-1168			
	8479730	Oct 11, 2028	DP			
<u>INDIGOTINDISULFONATE SODIUM - BLUDIGO</u>						
N 216264 001	10927258	Dec 23, 2037	DS		NCE	Jul 08, 2027
	11499050	Dec 23, 2037	DS			
<u>INDOCYANINE GREEN - SPY AGENT GREEN KIT</u>						
N 211580 001	10631746	Aug 04, 2035	DP U-2815			
	8185176	Jun 04, 2028	U-2462			
	8406860	Apr 09, 2029	U-2463			
	8647605	Feb 11, 2029	U-2464			
	8647605	Feb 11, 2029	U-2468			
	9421280	Nov 24, 2025	U-2466			
	9421280	Nov 24, 2025	U-2467			
<u>INDOMETHACIN - TIVORBEX</u>						
N 204768 001	8734847	Apr 23, 2030	DP			
	8992982	Apr 23, 2030	DP			
	9089471	Apr 23, 2030	U-55			
<u>INDOMETHACIN - TIVORBEX</u>						
N 204768 002	8734847	Apr 23, 2030	DP			
	8992982	Apr 23, 2030	DP			
	9089471	Apr 23, 2030	U-55			
<u>INFIGRATINIB PHOSPHATE - TRUSELTIQ</u>						
N 214622 001	10278969	Dec 11, 2034	DP		NCE	May 28, 2026
	11160804	Dec 11, 2034	DP		ODE-353	May 28, 2028
	8552002	Aug 25, 2029	DS DP			
	9067896	Aug 06, 2028	DS			
<u>INFIGRATINIB PHOSPHATE - TRUSELTIQ</u>						
N 214622 002	10278969	Dec 11, 2034	DP		NCE	May 28, 2026
	11160804	Dec 11, 2034	DP		ODE-353	May 28, 2028
	8552002	Aug 25, 2029	DS DP			
	9067896	Aug 06, 2028	DS			
<u>INGENOL MEBUTATE - PICATO</u>						
N 202833 001	8278292	Jul 06, 2027	DP			
	8372827	Dec 18, 2026	DP			
	8372828	Dec 18, 2026	DP			
	8377919	Dec 18, 2026	DP			
	8536163	Dec 18, 2026	U-1440			
	8716271	Dec 18, 2026	U-1440			
	8735375	Dec 18, 2026	U-1440			
	9789078	May 15, 2033	U-2138			
	9820959	Dec 18, 2026	DP U-1440			
	9833428	Dec 18, 2026	DP			
	9833429	Dec 18, 2026	DP			
	9861603	Dec 18, 2026	U-1440			
<u>INGENOL MEBUTATE - PICATO</u>						
N 202833 002	8278292	Jul 06, 2027	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>INGENOL MEBUTATE - PICATO</u>						
N 202833 002	8372827	Dec 18, 2026	DP			
	8372828	Dec 18, 2026	DP			
	8377919	Dec 18, 2026	DP			
	8536163	Dec 18, 2026	U-1440			
	8716271	Dec 18, 2026	U-1440			
	8735375	Dec 18, 2026	U-1440			
	9820959	Dec 18, 2026	DP U-1440			
	9833428	Dec 18, 2026	DP			
	9833429	Dec 18, 2026	DP			
	9861603	Dec 18, 2026	U-1440			
<u>INOTERSEN SODIUM - TEGSEDI</u>						
N 211172 001	7015315	Mar 21, 2023	DS		NCE	Oct 05, 2023
	7101993	Sep 05, 2023	DS		ODE-212	Oct 05, 2025
	8101743	Apr 01, 2025	DS DP			
	8697860	Apr 29, 2031	DP			
	9061044	Apr 29, 2031	DS			
	9399774	Apr 29, 2031	U-2430			
<u>IOBENGUANE I-131 - AZEDRA</u>						
N 209607 001					ODE-204	Jul 30, 2025
<u>IODIXANOL - IODIXANOL</u>						
A 214271 001					CGT	Jan 09, 2023
<u>IODIXANOL - IODIXANOL</u>						
A 214271 002					CGT	Jan 09, 2023
<u>IPRATROPIUM BROMIDE - ATROVENT HFA</u>						
N 021527 001	8474447	Jan 17, 2030	DP			
<u>IRINOTECAN HYDROCHLORIDE - ONIVYDE</u>						
N 207793 001	10456360	Oct 15, 2036	DP			
	10722508	May 02, 2025	DS DP			
	10980795	Jun 12, 2033	U-1848			
	10993914	Oct 15, 2036	DP			
	11369597	Jun 12, 2033	U-1848			
	8147867	Aug 29, 2028	DS DP			
	8329213	Jan 06, 2027	DS DP			
	8703181	May 02, 2025	U-1434			
	8992970	May 02, 2025	DS DP			
	9339497	Jun 12, 2033	U-1848			
	9364473	Jun 12, 2033	U-1856			
	9452162	Jun 12, 2033	U-1899			
	9492442	Jun 12, 2033	U-1848			
	9492442	Jun 12, 2033	U-1899			
	9492442	Jun 12, 2033	U-1917			
	9717724	Jun 12, 2033	U-1848			
	9717724	Jun 12, 2033	U-2091			
	9724303	May 02, 2025	DS DP			
	9730891	May 02, 2025	U-1848			
	9782349	May 02, 2025	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ISAVUCONAZONIUM SULFATE - CRESEMBA</u>						
N 207500 001	10206879	Sep 14, 2027	DP		NCE	Mar 06, 2020
	10603280	Sep 14, 2027	DP		ODE-305	Mar 06, 2022
	6812238	Oct 31, 2025	DS		ODE-90	Mar 06, 2022
					GAIN	Mar 06, 2025
					GAIN	Mar 06, 2027
					GAIN	Mar 06, 2027
<u>ISAVUCONAZONIUM SULFATE - CRESEMBA</u>						
N 207500 002	10206879	Sep 14, 2027	DP		NCE	Mar 06, 2020
	10603280	Sep 14, 2027	DP		ODE*	Mar 06, 2022
	10812238	Oct 31, 2025	DS		GAIN	Mar 06, 2025
					GAIN	Mar 06, 2027
<u>ISAVUCONAZONIUM SULFATE - CRESEMBA</u>						
N 207501 001	6812238	Oct 31, 2025	DS		NCE	Mar 06, 2020
					ODE-305	Mar 06, 2022
					ODE-90	Mar 06, 2022
					GAIN	Mar 06, 2025
					GAIN	Mar 06, 2027
					GAIN	Mar 06, 2027
<u>ISOPROPYL ALCOHOL - ZURAGARD</u>						
N 210872 001	10688291	Dec 20, 2034	DP U-1397		M-268	Jun 24, 2024
	8226971	May 06, 2025	DP			
	8389583	Aug 09, 2029	U-1397			
	8703828	May 23, 2028	DP			
	9011897	Feb 08, 2025	DP			
	9629368	May 23, 2028	U-1397			
	9844654	Apr 24, 2036	DP U-1397			
<u>ISOTRETINOIN - ABSORICA LD</u>						
N 211913 001	9700535	Aug 04, 2035	DP			
	9750711	May 29, 2035	DP			
<u>ISOTRETINOIN - ABSORICA LD</u>						
N 211913 002	9700535	Aug 04, 2035	DP			
	9750711	May 29, 2035	DP			
<u>ISOTRETINOIN - ABSORICA LD</u>						
N 211913 003	9700535	Aug 04, 2035	DP			
	9750711	May 29, 2035	DP			
<u>ISOTRETINOIN - ABSORICA LD</u>						
N 211913 004	9700535	Aug 04, 2035	DP			
	9750711	May 29, 2035	DP			
<u>ISOTRETINOIN - ABSORICA LD</u>						
N 211913 005	9700535	Aug 04, 2035	DP			
	9750711	May 29, 2035	DP			
<u>ISOTRETINOIN - ABSORICA LD</u>						
N 211913 006	9700535	Aug 04, 2035	DP			
	9750711	May 29, 2035	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ISTRADefylline - NOURIANZ</u>						
N 022075 001	7541363	Nov 13, 2024	DS DP		NCE	Aug 27, 2024
	7727993	Jan 28, 2023	U-2623			
	7727994	Jan 18, 2023	U-2623			
	8318201	Sep 05, 2027	DP			
<u>ISTRADefylline - NOURIANZ</u>						
N 022075 002	7541363	Nov 13, 2024	DS DP		NCE	Aug 27, 2024
	7727993	Jan 28, 2023	U-2623			
	7727994	Jan 18, 2023	U-2623			
	8318201	Sep 05, 2027	DP			
<u>ITRAConazole - ONMEL</u>						
N 022484 001	8486456	Oct 03, 2028	DP U-1054			
<u>ITRAConazole - TOLSURA</u>						
N 208901 001	10463740	Jun 21, 2033	DP U-2453			
	10806792	Jun 21, 2033	DP			
	8771739	Jul 25, 2023	DP			
	8921374	Jun 21, 2033	DP			
	9272046	Jun 21, 2033	DP			
	9713642	Jun 21, 2033	U-2453			
<u>IVABRADINE - CORLANOR</u>						
N 209964 001	7361649	Feb 22, 2026	DS DP U-1694		ODE-234	Apr 22, 2026
	7361650	Feb 22, 2026	DS DP U-1694		PED	Oct 22, 2026
	7867996	Dec 12, 2026	DS DP U-1694			
	7879842	Feb 22, 2026	DS DP U-1694			
<u>IVABRADINE HYDROCHLORIDE - CORLANOR</u>						
N 206143 001	7361649	Feb 22, 2026	DS DP U-1694			
	7361649*PED	Aug 22, 2026				
	7361650	Feb 22, 2026	DS DP U-1694			
	7361650*PED	Aug 22, 2026				
	7867996	Dec 12, 2026	DS DP U-1694			
	7867996*PED	Jun 12, 2027				
	7879842	Feb 22, 2026	DS DP U-1694			
	7879842*PED	Aug 22, 2026				
<u>IVABRADINE HYDROCHLORIDE - CORLANOR</u>						
N 206143 002	7361649	Feb 22, 2026	DS DP U-1694			
	7361649*PED	Aug 22, 2026				
	7361650	Feb 22, 2026	DS DP U-1694			
	7361650*PED	Aug 22, 2026				
	7867996	Dec 12, 2026	DS DP U-1694			
	7867996*PED	Jun 12, 2027				
	7879842	Feb 22, 2026	DS DP U-1694			
	7879842*PED	Aug 22, 2026				
<u>IVACaFTOR - KALYDECO</u>						
N 203188 001	10646481	Aug 13, 2029	DP		ODE-189	Jul 31, 2024
	7495103	May 20, 2027	DS DP		ODE-190	May 17, 2024
	8324242	Aug 05, 2027	U-1311		ODE-199	Aug 15, 2025
	8324242	Aug 05, 2027	U-1906		ODE-338	Dec 21, 2027
	8354427	Jul 06, 2026	U-1311			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>IVACAFITOR - KALYDECO</u>						
N 203188 001	8354427	Jul 06, 2026	U-1905			
	8410274	Dec 28, 2026	DP			
	8629162	Jun 24, 2025	U-2234			
	8754224	Dec 28, 2026	DS DP			
	9670163	Dec 28, 2026	DP U-1311			
<u>IVACAFITOR - KALYDECO</u>						
N 207925 001	10272046	Feb 27, 2033	DP U-2531		ODE-189	Jul 31, 2024
	10646481	Aug 13, 2029	DP		ODE-190	May 17, 2024
	11147770	Feb 27, 2033	DP U-3339		ODE-199	Aug 15, 2025
	7495103	May 20, 2027	DS DP		ODE-236	Apr 29, 2026
	8324242	Aug 05, 2027	U-1311		ODE-338	Dec 21, 2027
	8324242	Aug 05, 2027	U-1906			
	8324242	Aug 05, 2027	U-2527			
	8354427	Jul 06, 2026	U-1311			
	8354427	Jul 06, 2026	U-1905			
	8354427	Jul 06, 2026	U-2528			
	8410274	Dec 28, 2026	DP			
	8629162	Jun 24, 2025	U-2234			
	8629162	Jun 24, 2025	U-2529			
	8754224	Dec 28, 2026	DS DP			
	8883206	Feb 27, 2033	DP			
	9670163	Dec 28, 2026	DP U-1311			
	9670163	Dec 28, 2026	DP U-2530			
<u>IVACAFITOR - KALYDECO</u>						
N 207925 002	10272046	Feb 27, 2033	DP U-2531		ODE-189	Jul 31, 2024
	10646481	Aug 13, 2029	DP		ODE-190	May 17, 2024
	11147770	Feb 27, 2033	DP U-3339		ODE-199	Aug 15, 2025
	7495103	May 20, 2027	DS DP		ODE-236	Apr 29, 2026
	8324242	Aug 05, 2027	U-1311		ODE-338	Dec 21, 2027
	8324242	Aug 05, 2027	U-1906			
	8324242	Aug 05, 2027	U-2527			
	8354427	Jul 06, 2026	U-1311			
	8354427	Jul 06, 2026	U-1905			
	8354427	Jul 06, 2026	U-2528			
	8410274	Dec 28, 2026	DP			
	8629162	Jun 24, 2025	U-2234			
	8629162	Jun 24, 2025	U-2529			
	8754224	Dec 28, 2026	DS DP			
	8883206	Feb 27, 2033	DP			
	9670163	Dec 28, 2026	DP U-1311			
	9670163	Dec 28, 2026	DP U-2530			
<u>IVACAFITOR - KALYDECO</u>						
N 207925 003	10272046	Feb 27, 2033	DP U-2967		ODE-189	Jul 31, 2024
	10646481	Aug 13, 2029	DP		ODE-190	May 17, 2024
	11147770	Feb 27, 2033	DP U-3339		ODE-199	Aug 15, 2025
	7495103	May 20, 2027	DS DP		ODE-236	Apr 29, 2026
	8324242	Aug 05, 2027	U-1311		ODE-338	Dec 21, 2027
	8324242	Aug 05, 2027	U-1906			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>IVACAFITOR - KALYDECO</u>						
N 207925 003	8324242	Aug 05, 2027	U-2963			
	8354427	Jul 06, 2026	U-1311			
	8354427	Jul 06, 2026	U-1905			
	8354427	Jul 06, 2026	U-2964			
	8410274	Dec 28, 2026	DP			
	8629162	Jun 24, 2025	U-2234			
	8629162	Jun 24, 2025	U-2965			
	8754224	Dec 28, 2026	DS DP			
	8883206	Feb 27, 2033	DP			
	9670163	Dec 28, 2026	DP U-1311			
	9670163	Dec 28, 2026	DP U-2966			
<u>IVACAFITOR; IVACAFITOR, TEZACAFITOR - SYMDEKO (COPACKAGED)</u>						
N 210491 001	10022352	Apr 09, 2027	DP U-2343		NCE	Feb 12, 2023
	10022352	Apr 09, 2027	DP U-2573		ODE-173	Feb 12, 2025
	10058546	Jul 15, 2033	U-2399		ODE-247	Jun 21, 2026
	10058546	Jul 15, 2033	U-2572		ODE-335	Dec 21, 2027
	10058546	Jul 15, 2033	U-3022			
	10058546	Jul 15, 2033	U-3023			
	10081621	Mar 25, 2031	DP U-2420			
	10081621	Mar 25, 2031	DP U-2571			
	10081621	Mar 25, 2031	DP U-3024			
	10081621	Mar 25, 2031	DP U-3025			
	10206877	Apr 14, 2035	DP U-2498			
	10206877	Apr 14, 2035	DP U-2570			
	10206877	Apr 14, 2035	DP U-3026			
	10206877	Apr 14, 2035	DP U-3027			
	10239867	Apr 09, 2027	DS DP U-2512			
	10239867	Apr 09, 2027	DS DP U-2569			
	10646481	Aug 13, 2029	DP			
	7495103	May 20, 2027	DS DP			
	7645789	May 01, 2027	DS DP			
	7776905	Jun 03, 2027	DS DP			
	8324242	Aug 05, 2027	U-2246			
	8354427	Jul 06, 2026	U-3021			
	8410274	Dec 28, 2026	DP			
	8415387	Nov 12, 2027	U-2246			
	8598181	May 01, 2027	U-2246			
	8623905	May 01, 2027	DS DP			
	8629162	Jun 24, 2025	U-2247			
	8754224	Dec 28, 2026	DS DP			
	9012496	Jul 15, 2033	U-2248			
	9670163	Dec 28, 2026	DP U-2246			
	9931334	Dec 28, 2026	DP U-2275			
	9931334	Dec 28, 2026	DP U-2575			
	9974781	Apr 09, 2027	DP U-2318			
	9974781	Apr 09, 2027	DP U-2574			
<u>IVACAFITOR; IVACAFITOR, TEZACAFITOR - SYMDEKO (COPACKAGED)</u>						
N 210491 002	10022352	Apr 09, 2027	DP U-2343		NCE	Feb 12, 2023
	10022352	Apr 09, 2027	DP U-2573		ODE-173	Feb 12, 2025

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>IVACAFTOR; IVACAFTOR, TEZACAFTOR - SYMDEKO (COPACKAGED)</u>						
N 210491 002	10058546	Jul 15, 2033	U-2399		ODE-247	Jun 21, 2026
	10058546	Jul 15, 2033	U-2572		ODE-335	Dec 21, 2027
	10058546	Jul 15, 2033	U-3022			
	10058546	Jul 15, 2033	U-3023			
	10081621	Mar 25, 2031	DP U-2420			
	10081621	Mar 25, 2031	DP U-2571			
	10081621	Mar 25, 2031	DP U-3024			
	10081621	Mar 25, 2031	DP U-3025			
	10206877	Apr 14, 2035	DP U-2498			
	10206877	Apr 14, 2035	DP U-2570			
	10206877	Apr 14, 2035	DP U-3026			
	10206877	Apr 14, 2035	DP U-3027			
	10239867	Apr 09, 2027	DS DP U-2512			
	10239867	Apr 09, 2027	DS DP U-2569			
	10646481	Aug 13, 2029	DP			
	7495103	May 20, 2027	DS DP			
	7645789	May 01, 2027	DS DP			
	7776905	Jun 03, 2027	DS DP			
	8324242	Aug 05, 2027	U-2246			
	8354427	Jul 06, 2026	U-3021			
	8410274	Dec 28, 2026	DP			
	8415387	Nov 12, 2027	U-2246			
	8598181	May 01, 2027	U-2246			
	8623905	May 01, 2027	DS DP			
	8629162	Jun 24, 2025	U-2247			
	8754224	Dec 28, 2026	DS DP			
	9012496	Jul 15, 2033	U-2248			
	9670163	Dec 28, 2026	DP U-2246			
	9931334	Dec 28, 2026	DP U-2275			
	9931334	Dec 28, 2026	DP U-2575			
	9974781	Apr 09, 2027	DP U-2318			
	9974781	Apr 09, 2027	DP U-2574			
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038 001	10076513	Dec 04, 2028	DP U-2411		ODE-123	Sep 28, 2023
	10597384	Dec 04, 2028	DS DP U-2777			
	10646481	Aug 13, 2029	DP			
	11052075	Dec 04, 2028	DP U-3181			
	7495103	May 20, 2027	DS DP			
	7973038	Nov 08, 2026	U-1973			
	8324242	Aug 05, 2027	U-1311			
	8324242	Aug 05, 2027	U-1911			
	8410274	Dec 28, 2026	DP			
	8507534	Sep 20, 2030	DS DP			
	8653103	Dec 04, 2028	DP			
	8716338	Sep 20, 2030	DP U-1718			
	8716338	Sep 20, 2030	DP U-1910			
	8741933	Nov 08, 2026	U-1717			
	8741933	Nov 08, 2026	U-1909			
	8754224	Dec 28, 2026	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038 001	8846718	Jul 02, 2029	U-1717			
	8846718	Jul 02, 2029	U-1908			
	8993600	Dec 11, 2030	DP			
	9150552	Dec 04, 2028	U-1908			
	9192606	Sep 29, 2029	DP U-1912			
	9216969	Nov 08, 2026	DS DP			
	9670163	Dec 28, 2026	DP U-1911			
	9931334	Dec 28, 2026	DP U-2276			
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038 002	10597384	Dec 04, 2028	DS DP U-2777		ODE-123	Sep 28, 2023
	10646481	Aug 13, 2029	DP			
	11052075	Dec 04, 2028	DP U-3181			
	7495103	May 20, 2027	DS DP			
	7973038	Nov 08, 2026	U-1973			
	8324242	Aug 05, 2027	U-1911			
	8410274	Dec 28, 2026	DP			
	8507534	Sep 20, 2030	DS DP			
	8653103	Dec 04, 2028	DP			
	8716338	Sep 20, 2030	DP U-1910			
	8741933	Nov 08, 2026	U-1909			
	8754224	Dec 28, 2026	DS DP			
	8846718	Jul 02, 2029	U-1908			
	8993600	Dec 11, 2030	DP			
	9150552	Dec 04, 2028	U-1908			
	9192606	Sep 29, 2029	DP U-1912			
	9216969	Nov 08, 2026	DP			
	9670163	Dec 28, 2026	DP U-1911			
	9931334	Dec 28, 2026	DP U-2276			
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 211358 001	10597384	Dec 04, 2028	DS DP U-2778		NPP	Sep 02, 2025
	10646481	Aug 13, 2029	DP		ODE-195	Aug 07, 2025
	7495103	May 20, 2027	DS DP			
	7973038	Nov 08, 2026	U-2374			
	8324242	Aug 05, 2027	U-2374			
	8410274	Dec 28, 2026	DP			
	8507534	Sep 20, 2030	DS DP			
	8653103	Dec 04, 2028	DP			
	8716338	Sep 20, 2030	DP U-2396			
	8741933	Nov 08, 2026	U-2374			
	8754224	Dec 28, 2026	DS DP			
	8846718	Jul 02, 2029	U-2375			
	8993600	Dec 11, 2030	DP			
	9150552	Dec 04, 2028	U-2375			
	9192606	Sep 29, 2029	DP U-2397			
	9216969	Nov 08, 2026	DP			
	9670163	Dec 28, 2026	DP U-2376			
	9931334	Dec 28, 2026	DP U-2376			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 211358 002	10597384	Dec 04, 2028	DS DP U-2778		NPP	Sep 02, 2025
	10646481	Aug 13, 2029	DP		ODE-195	Aug 07, 2025
	7495103	May 20, 2027	DS DP			
	7973038	Nov 08, 2026	U-2374			
	8324242	Aug 05, 2027	U-2374			
	8410274	Dec 28, 2026	DP			
	8507534	Sep 20, 2030	DS DP			
	8653103	Dec 04, 2028	DP			
	8716338	Sep 20, 2030	DP U-2396			
	8741933	Nov 08, 2026	U-2374			
	8754224	Dec 28, 2026	DS DP			
	8846718	Jul 02, 2029	U-2375			
	8993600	Dec 11, 2030	DP			
	9150552	Dec 04, 2028	U-2375			
	9192606	Sep 29, 2029	DP U-2397			
	9216969	Nov 08, 2026	DP			
	9670163	Dec 28, 2026	DP U-2376			
	9931334	Dec 28, 2026	DP U-2376			
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 211358 003	10597384	Dec 04, 2028	DS DP U-3430		NS	Sep 02, 2025
	10646481	Aug 13, 2029	DP			
	7495103	May 20, 2027	DS DP			
	7973038	Nov 08, 2026	U-3424			
	8324242	Aug 05, 2027	U-3424			
	8410274	Dec 28, 2026	DP			
	8507534	Sep 20, 2030	DS DP			
	8653103	Dec 04, 2028	DP			
	8716338	Sep 20, 2030	DP U-3426			
	8741933	Nov 08, 2026	U-3424			
	8754224	Dec 28, 2026	DS DP			
	8846718	Jul 02, 2029	U-3427			
	8993600	Dec 11, 2030	DP			
	9150552	Dec 04, 2028	U-3427			
	9192606	Sep 29, 2029	DP U-3428			
	9216969	Nov 08, 2026	DP			
	9670163	Dec 28, 2026	DP U-3429			
	9931334	Dec 28, 2026	DP U-3429			
<u>IVERMECTIN - SOOLANTRA</u>						
N 206255 001	10206939	Mar 13, 2034	U-1631			
	11033565	Apr 22, 2024	DP			
	7550440	Apr 22, 2024	DP U-1631			
	8080530	Apr 22, 2024	DP U-1631			
	8093219	Apr 22, 2024	DP U-1631			
	8415311	Apr 22, 2024	DP U-1631			
	8470788	Apr 22, 2024	DP U-1631			
	8815816	Apr 22, 2024	DP U-1631			
	9089587	Mar 13, 2034	U-1631			
	9233117	Mar 13, 2034	U-1631			
	9233118	Mar 13, 2034	U-1631			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>IVERMECTIN - SOOLANTRA</u>						
N 206255 001	9782425	Mar 13, 2034	U-1631			
<u>IVOSIDENIB - TIBSOVO</u>						
N 211192 001	10449184	Mar 13, 2035	DP		I-875	Aug 25, 2024
	10610125	Jun 21, 2030	U-2784		I-893	May 25, 2025
	10610125	Jun 21, 2030	U-2785		NCE	Jul 20, 2023
	10610125	Jun 21, 2030	U-3385		ODE-203	Jul 20, 2025
	10653710	Oct 18, 2036	U-3387		ODE-242	May 02, 2026
	10717764	Jan 18, 2033	U-3215		ODE-368	Aug 25, 2028
	10799490	Mar 13, 2035	DP U-2981			
	10799490	Mar 13, 2035	DP U-2982			
	10799490	Mar 13, 2035	DP U-3384			
	10980788	Jun 07, 2039	U-3112			
	10980788	Jun 07, 2039	U-3113			
	10980788	Jun 07, 2039	U-3214			
	10980788	Jun 07, 2039	U-3383			
	9474779	Aug 19, 2033	DS DP U-2350			
	9474779	Aug 19, 2033	DS DP U-2533			
	9474779	Aug 19, 2033	DS DP U-2534			
	9474779	Aug 19, 2033	DS DP U-3213			
	9474779	Aug 19, 2033	DS DP U-3386			
	9850277	Jan 18, 2033	DS DP U-2350			
	9850277	Jan 18, 2033	DS DP U-2533			
	9850277	Jan 18, 2033	DS DP U-2534			
	9850277	Jan 18, 2033	DS DP U-3213			
	9850277	Jan 18, 2033	DS DP U-3386			
	9968595	Mar 13, 2035	DP U-2351			
	9968595	Mar 13, 2035	DP U-2533			
	9968595	Mar 13, 2035	DP U-2534			
	9968595	Mar 13, 2035	DP U-3384			
<u>IXABEPILONE - IXEMPRA KIT</u>						
N 022065 001	7312237	Aug 21, 2024	U-965			
<u>IXABEPILONE - IXEMPRA KIT</u>						
N 022065 002	7312237	Aug 21, 2024	U-965			
<u>IXAZOMIB CITRATE - NINLARO</u>						
N 208462 001	7442830	Nov 20, 2029	DS DP U-2434			
	7687662	Aug 06, 2027	DS DP			
	8003819	Aug 06, 2027	DS DP U-2434			
	8530694	Aug 06, 2027	DS DP U-2434			
	8546608	Aug 12, 2024	DS			
	8859504	Jun 16, 2029	DS DP			
	8871745	Aug 06, 2027	U-2434			
	9175017	Jun 16, 2029	U-2434			
	9233115	Aug 12, 2024	U-2434			
<u>IXAZOMIB CITRATE - NINLARO</u>						
N 208462 002	7442830	Nov 20, 2029	DS DP U-2434			
	7687662	Aug 06, 2027	DS DP			
	8003819	Aug 06, 2027	DS DP U-2434			
	8530694	Aug 06, 2027	DS DP U-2434			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>IXAZOMIB CITRATE - NINLARO</u>						
N 208462 002	8546608	Aug 12, 2024	DS			
	8859504	Jun 16, 2029	DS DP			
	8871745	Aug 06, 2027	U-2434			
	9175017	Jun 16, 2029	U-2434			
	9233115	Aug 12, 2024	U-2434			
<u>IXAZOMIB CITRATE - NINLARO</u>						
N 208462 003	7442830	Nov 20, 2029	DS DP U-2434			
	7687662	Aug 06, 2027	DS DP			
	8003819	Aug 06, 2027	DS DP U-2434			
	8530694	Aug 06, 2027	DS DP U-2434			
	8546608	Aug 12, 2024	DS			
	8859504	Jun 16, 2029	DS DP			
	8871745	Aug 06, 2027	U-2434			
	9175017	Jun 16, 2029	U-2434			
	9233115	Aug 12, 2024	U-2434			
<u>KETOROLAC TROMETHAMINE - ACULAR LS</u>						
N 021528 001	8008338	May 24, 2027	DS DP U-1181			
	8207215	May 28, 2024	U-1251			
	8377982	May 28, 2024	U-1363			
	8377982*PED	Nov 28, 2024				
	8541463	May 28, 2024	U-1441			
	8541463*PED	Nov 28, 2024				
	8648107	May 28, 2024	DP			
	8906950	May 28, 2024	U-1626			
	8946281	May 28, 2024	U-1662			
	9216167	May 28, 2024	U-1800			
<u>KETOROLAC TROMETHAMINE - ACUVAIL</u>						
N 022427 001	7842714	Aug 15, 2029	DS DP			
	8512717	Mar 07, 2028	DP			
	8992952	Aug 05, 2024	DP			
	9192571	Mar 07, 2028	DP			
<u>KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE - Omidria</u>						
N 205388 001	8173707	Jul 30, 2023	U-1518			
	8173707*PED	Jan 30, 2024				
	8586633	Jul 30, 2023	DP			
	8586633*PED	Jan 30, 2024				
	9066856	Oct 23, 2033	DP			
	9066856*PED	Apr 23, 2034				
	9278101	Jul 30, 2023	U-1518			
	9278101*PED	Jan 30, 2024				
	9399040	Jul 30, 2023	DP			
	9399040*PED	Jan 30, 2024				
	9486406	Oct 23, 2033	DP			
	9486406*PED	Apr 23, 2034				
	9855246	Oct 23, 2033	DP			
<u>KETOTIFEN FUMARATE - ACUVUE THERAVISION WITH KETOTIFEN</u>						
N 022388 001	9474746	Mar 27, 2028	DP		NP	Feb 25, 2025
	9962376	Jun 27, 2030	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>KETOTIFEN FUMARATE - ACUVUE THERAVISION WITH KETOTIFEN</u>						
N 022388 001	9474746	Mar 27, 2028	DP		NP	Feb 25, 2025
	9962376	Jun 27, 2030	DP			
<u>L-GLUTAMINE - ENDARI</u>						
N 208587 001					ODE-150	Jul 07, 2024
<u>LACOSAMIDE - VIMPAT</u>						
N 022253 001					I-878	Nov 16, 2023
					NPP	Oct 14, 2024
<u>LACOSAMIDE - VIMPAT</u>						
N 022253 002					I-878	Nov 16, 2023
					NPP	Oct 14, 2024
<u>LACOSAMIDE - VIMPAT</u>						
N 022253 003					I-878	Nov 16, 2023
					NPP	Oct 14, 2024
<u>LACOSAMIDE - VIMPAT</u>						
N 022253 004					I-878	Nov 16, 2023
					NPP	Oct 14, 2024
<u>LACOSAMIDE - VIMPAT</u>						
N 022254 001					I-878	Nov 16, 2023
					NPP	Nov 16, 2023
					NPP	Oct 14, 2024
<u>LACOSAMIDE - VIMPAT</u>						
N 022255 001					I-878	Nov 16, 2023
					NPP	Oct 14, 2024
<u>LACTITOL - PIZENSY</u>						
N 211281 001	10806743	May 12, 2037		U-1516	NCE	Feb 12, 2025
<u>LAMIVUDINE; RALTEGRAVIR POTASSIUM - DUTREBIS</u>						
N 206510 001	7169780	Oct 03, 2023	DS DP			
	7169780*PED	Apr 03, 2024				
	7217713*PED	Apr 21, 2023				
	7435734*PED	Apr 21, 2023				
	7754731	Mar 11, 2029	DS DP U-1663			
	7754731*PED	Sep 11, 2029				
	7820660	Apr 25, 2023	DS			
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115 001	8637512	Jun 14, 2028	DP			
	9144547	Sep 22, 2023	DP			
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115 002	8637512	Jun 14, 2028	DP			
	9144547	Sep 22, 2023	DP			
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115 003	8637512	Jun 14, 2028	DP			
	9144547	Sep 22, 2023	DP			
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115 004	8637512	Jun 14, 2028	DP			
	9144547	Sep 22, 2023	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115 004	8637512	Jun 14, 2028	DP			
	9144547	Sep 22, 2023	DP			
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115 005	8637512	Jun 14, 2028	DP			
	9144547	Sep 22, 2023	DP			
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115 006	8637512	Jun 14, 2028	DP			
	9144547	Sep 22, 2023	DP			
<u>LANREOTIDE ACETATE - SOMATULINE DEPOT</u>						
N 022074 001					ODE-156	Sep 15, 2024
<u>LANREOTIDE ACETATE - SOMATULINE DEPOT</u>						
N 022074 002					ODE-156	Sep 15, 2024
<u>LANREOTIDE ACETATE - SOMATULINE DEPOT</u>						
N 022074 003					ODE-156	Sep 15, 2024
<u>LANSOPRAZOLE - LANSOPRAZOLE</u>						
N 208025 001	11077055	Apr 21, 2036	DP			
<u>LANTHANUM CARBONATE - FOSRENOL</u>						
N 021468 001	7381428	Aug 26, 2024	U-890			
	7465465	Aug 26, 2024	DP			
<u>LANTHANUM CARBONATE - FOSRENOL</u>						
N 021468 002	7381428	Aug 26, 2024	U-890			
	7465465	Aug 26, 2024	DP			
<u>LANTHANUM CARBONATE - FOSRENOL</u>						
N 021468 003	7381428	Aug 26, 2024	U-890			
	7465465	Aug 26, 2024	DP			
<u>LANTHANUM CARBONATE - FOSRENOL</u>						
N 021468 004	7381428	Aug 26, 2024	U-890			
	7465465	Aug 26, 2024	DP			
<u>LANTHANUM CARBONATE - FOSRENOL</u>						
N 204734 001	7465465	Aug 26, 2024	DP			
	8980327	Dec 01, 2030	DP			
	9023397	Dec 01, 2030	DP			
<u>LANTHANUM CARBONATE - FOSRENOL</u>						
N 204734 002	7465465	Aug 26, 2024	DP			
	8980327	Dec 01, 2030	DP			
	9023397	Dec 01, 2030	DP			
<u>LAPATINIB DITOSYLATE - TYKERB</u>						
N 022059 001	8821927	Sep 18, 2029	DS DP			
<u>LAROTRECTINIB SULFATE - VITRAKVI</u>						
N 210861 001	10005783	Oct 21, 2029	U-2472		NCE	Nov 26, 2023
	10047097	Oct 21, 2029	U-2474		ODE-215	Nov 26, 2025
	10172861	Nov 16, 2035	DS DP		ODE-220	Nov 26, 2025
	10285993	Nov 16, 2035	U-2470		ODE-221	Nov 26, 2025
	10774085	Oct 21, 2029	U-2470			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LAROTRECTINIB SULFATE - VITRAKVI</u>						
N 210861 001	10799505	Aug 15, 2036	DS DP			
	10813936	Nov 16, 2035	U-2987			
	8513263	Dec 23, 2029	DS DP			
	8865698	Oct 21, 2029	U-2469			
	9127013	Oct 21, 2029	DS DP			
	9447104	Oct 21, 2029	U-2470			
	9676783	Oct 21, 2029	U-2469			
	9782414	Nov 16, 2035	U-2475			
<u>LAROTRECTINIB SULFATE - VITRAKVI</u>						
N 210861 002	10005783	Oct 21, 2029	U-2472		NCE	Nov 26, 2023
	10047097	Oct 21, 2029	U-2474		ODE-215	Nov 26, 2025
	10172861	Nov 16, 2035	DS DP		ODE-220	Nov 26, 2025
	10285993	Nov 16, 2035	U-2470		ODE-221	Nov 26, 2025
	10774085	Oct 21, 2029	U-2470			
	10799505	Aug 15, 2036	DS DP			
	10813936	Nov 16, 2035	U-2987			
	8513263	Dec 23, 2029	DS DP			
	8865698	Oct 21, 2029	U-2469			
	9127013	Oct 21, 2029	DS DP			
	9447104	Oct 21, 2029	U-2470			
	9676783	Oct 21, 2029	U-2469			
	9782414	Nov 16, 2035	U-2475			
<u>LAROTRECTINIB SULFATE - VITRAKVI</u>						
N 211710 001	10005783	Oct 21, 2029	U-2472		NCE	Nov 26, 2023
	10045991	Apr 04, 2037	U-2473		ODE-215	Nov 26, 2025
	10047097	Oct 21, 2029	U-2474		ODE-220	Nov 26, 2025
	10137127	Apr 04, 2037	DP		ODE-221	Nov 26, 2025
	10172861	Nov 16, 2035	DS			
	10668072	Apr 04, 2037	DP			
	10774085	Oct 21, 2029	U-2470			
	10799505	Aug 15, 2036	DS			
	8513263	Dec 23, 2029	DS DP			
	8865698	Oct 21, 2029	U-2469			
	9127013	Oct 21, 2029	DS DP			
	9447104	Oct 21, 2029	U-2470			
	9676783	Oct 21, 2029	U-2469			
	9782414	Nov 16, 2035	U-2471			
<u>LASMITIDAN SUCCINATE - REYVOW</u>						
N 211280 001	11053214	Dec 05, 2037	DS DP U-1719		NCE	Jan 31, 2025
	7423050	Apr 06, 2025	DS DP U-1719			
	8748459	Mar 27, 2023	U-1719			
<u>LASMITIDAN SUCCINATE - REYVOW</u>						
N 211280 002	11053214	Dec 05, 2037	DS DP U-1719		NCE	Jan 31, 2025
	7423050	Apr 06, 2025	DS DP U-1719			
	8748459	Mar 27, 2023	U-1719			
<u>LASMITIDAN SUCCINATE - REYVOW</u>						
N 211280 003	11053214	Dec 05, 2037	DS DP U-1719		NCE	Jan 31, 2025
	7423050	Apr 06, 2025	DS DP U-1719			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LASMIDITAN SUCCINATE - REYVOW</u>						
N 211280 003	8748459	Mar 27, 2023	U-1719			
<u>LATANOPROST - XELPROS</u>						
N 206185 001	9539262	Oct 15, 2028	U-2400			
	9629852	Sep 12, 2029	DP			
<u>LATANOPROST; NETARSUDIL DIMESYLATE - ROCKLATAN</u>						
N 208259 001	10174017	Jan 27, 2030	DS DP U-1524			
	10532993	Jul 11, 2026	U-1524			
	10588901	Mar 14, 2034	DS DP U-1524			
	10654844	Jan 27, 2030	DS DP U-1524			
	10882840	Jul 11, 2026	U-1524			
	11021456	Jul 11, 2026	U-1524			
	11028081	Jan 27, 2030	U-1524			
	11185538	Mar 14, 2034	DP			
	11197853	Mar 14, 2034	DP			
	8394826	Nov 10, 2030	DS DP U-1524			
	8450344	Jul 11, 2026	DS DP U-1524			
	9096569	Jul 11, 2026	DS DP U-1524			
	9415043	Mar 14, 2034	DS			
	9931336	Mar 14, 2034	DS DP U-1524			
	9993470	Mar 14, 2034	DS DP U-1524			
<u>LATANOPROSTENE BUNOD - VYZULTA</u>						
N 207795 001	7273946	Oct 03, 2025	DS DP U-2144			
	7629345	Jan 05, 2025	DP U-2144			
	7910767	Jan 05, 2025	DS DP U-2144			
	8058467	Jan 05, 2025	DS U-2144			
<u>LEDIPASVIR; SOFOSBUVIR - HARVONI</u>						
N 205834 001	10039779	Jan 30, 2034	DS DP U-2369		ODE*	Aug 28, 2026
	10039779	Jan 30, 2034	DS DP U-2370		ODE*	Aug 28, 2026
	10039779*PED	Jul 30, 2034			ODE*	Aug 28, 2026
	10456414	Sep 14, 2032	DP		ODE-136	Apr 07, 2024
	7964580	Mar 26, 2029	DS DP U-1470		PED	Oct 07, 2024
	7964580*PED	Sep 26, 2029				
	8088368	May 12, 2030	DS DP			
	8088368*PED	Nov 12, 2030				
	8273341	May 12, 2030	U-1470			
	8273341*PED	Nov 12, 2030				
	8334270	Mar 21, 2028	DS DP U-1470			
	8334270*PED	Sep 21, 2028				
	8580765	Mar 21, 2028	DS DP U-1470			
	8580765*PED	Sep 21, 2028				
	8618076	Dec 11, 2030	DS DP U-1470			
	8618076*PED	Jun 11, 2031				
	8633309	Mar 26, 2029	DS DP U-1470			
	8633309*PED	Sep 26, 2029				
	8735372	Mar 21, 2028	U-1470			
	8735372*PED	Sep 21, 2028				
	8822430	May 12, 2030	DS DP U-1470			
	8822430*PED	Nov 12, 2030				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LEDIPASVIR; SOFOSBUVIR - HARVONI</u>						
N 205834 001	8841278	May 12, 2030	DP U-1470			
	8841278*PED	Nov 12, 2030				
	8889159	Mar 26, 2029	DP U-1470			
	8889159*PED	Sep 26, 2029				
	9085573	Mar 21, 2028	DS DP U-1470			
	9085573*PED	Sep 21, 2028				
	9284342	Sep 13, 2030	DS DP U-1470			
	9284342*PED	Mar 13, 2031				
	9393256	Sep 14, 2032	U-1470			
	9393256*PED	Mar 14, 2033				
	9511056	May 12, 2030	DP U-1470			
	9511056*PED	Nov 12, 2030				
<u>LEDIPASVIR; SOFOSBUVIR - HARVONI</u>						
N 205834 002	10039779	Jan 30, 2034	DS DP U-1470		ODE*	Apr 07, 2024
	10039779*PED	Jul 30, 2034			ODE*	Aug 28, 2026
	10456414	Sep 14, 2032	DP		ODE*	Aug 28, 2026
	7964580	Mar 26, 2029	DS DP U-1470		ODE*	Aug 28, 2026
	7964580*PED	Sep 26, 2029			PED	Oct 07, 2024
	8088368	May 12, 2030	DS DP			
	8088368*PED	Nov 12, 2030				
	8273341	May 12, 2030	U-1470			
	8273341*PED	Nov 12, 2030				
	8334270	Mar 21, 2028	DS DP U-1470			
	8334270*PED	Sep 21, 2028				
	8580765	Mar 21, 2028	DS DP U-1470			
	8580765*PED	Sep 21, 2028				
	8618076	Dec 11, 2030	DS DP U-1470			
	8618076*PED	Jun 11, 2031				
	8633309	Mar 26, 2029	DS DP U-1470			
	8633309*PED	Sep 26, 2029				
	8735372	Mar 21, 2028	U-1470			
	8735372*PED	Sep 21, 2028				
	8822430	May 12, 2030	DS DP U-1470			
	8822430*PED	Nov 12, 2030				
	8841278	May 12, 2030	DP U-1470			
	8841278*PED	Nov 12, 2030				
	8889159	Mar 26, 2029	DP U-1470			
	8889159*PED	Sep 26, 2029				
	9085573	Mar 21, 2028	DS DP U-1470			
	9085573*PED	Sep 21, 2028				
	9284342	Sep 13, 2030	DS DP U-1470			
	9284342*PED	Mar 13, 2031				
	9393256	Sep 14, 2032	U-1470			
	9393256*PED	Mar 14, 2033				
	9511056	May 12, 2030	U-1470			
	9511056*PED	Nov 12, 2030				
<u>LEDIPASVIR; SOFOSBUVIR - HARVONI</u>						
N 212477 001	10456414	Sep 14, 2032	DP		ODE-262	Aug 28, 2026
	7964580	Mar 26, 2029	DS DP U-1470		ODE-263	Aug 28, 2026

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LEDIPASVIR; SOFOSBUVIR - HARVONI</u>						
N 212477 001	7964580*PED	Sep 26, 2029			ODE-264	Aug 28, 2026
	8088368	May 12, 2030	DS DP			
	8088368*PED	Nov 12, 2030				
	8273341	May 12, 2030		U-1470		
	8273341*PED	Nov 12, 2030				
	8334270	Mar 21, 2028	DS DP U-1470			
	8334270*PED	Sep 21, 2028				
	8580765	Mar 21, 2028	DS DP U-1470			
	8580765*PED	Sep 21, 2028				
	8618076	Dec 11, 2030	DS DP U-1470			
	8618076*PED	Jun 11, 2031				
	8633309	Mar 26, 2029	DS DP U-1470			
	8633309*PED	Sep 26, 2029				
	8735372	Mar 21, 2028		U-1470		
	8735372*PED	Sep 21, 2028				
	8822430	May 12, 2030	DS DP U-1470			
	8822430*PED	Nov 12, 2030				
	8841278	May 12, 2030	DP U-1470			
	8841278*PED	Nov 12, 2030				
	8889159	Mar 26, 2029	DP U-1470			
	8889159*PED	Sep 26, 2029				
	9085573	Mar 21, 2028	DS DP U-1470			
	9085573*PED	Sep 21, 2028				
	9284342	Sep 13, 2030	DS DP U-1470			
	9284342*PED	Mar 13, 2031				
	9393256	Sep 14, 2032		U-1470		
	9393256*PED	Mar 14, 2033				
	9511056	May 12, 2030		U-1470		
	9511056*PED	Nov 12, 2030				
<u>LEDIPASVIR; SOFOSBUVIR - HARVONI</u>						
N 212477 002	10456414	Sep 14, 2032	DP		ODE-262	Aug 28, 2026
	7964580	Mar 26, 2029	DS DP U-1470		ODE-263	Aug 28, 2026
	7964580*PED	Sep 26, 2029			ODE-264	Aug 28, 2026
	8088368	May 12, 2030	DS DP			
	8088368*PED	Nov 12, 2030				
	8273341	May 12, 2030		U-1470		
	8273341*PED	Nov 12, 2030				
	8334270	Mar 21, 2028	DS DP U-1470			
	8334270*PED	Sep 21, 2028				
	8580765	Mar 21, 2028	DS DP U-1470			
	8580765*PED	Sep 21, 2028				
	8618076	Dec 11, 2030	DS DP U-1470			
	8618076*PED	Jun 11, 2031				
	8633309	Mar 26, 2029	DS DP U-1470			
	8633309*PED	Sep 26, 2029				
	8735372	Mar 21, 2028		U-1470		
	8735372*PED	Sep 21, 2028				
	8822430	May 12, 2030	DS DP U-1470			
	8822430*PED	Nov 12, 2030				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LEDIPASVIR; SOFOSBUVIR - HARVONI</u>						
N 212477 002	8841278	May 12, 2030	DP U-1470			
	8841278*PED	Nov 12, 2030				
	8889159	Mar 26, 2029	DP U-1470			
	8889159*PED	Sep 26, 2029				
	9085573	Mar 21, 2028	DS DP U-1470			
	9085573*PED	Sep 21, 2028				
	9284342	Sep 13, 2030	DS DP U-1470			
	9284342*PED	Mar 13, 2031				
	9393256	Sep 14, 2032	U-1470			
	9393256*PED	Mar 14, 2033				
	9511056	May 12, 2030	U-1470			
	9511056*PED	Nov 12, 2030				
<u>LEFAMULIN ACETATE - XENLETA</u>						
N 211672 001	8071643	Jan 16, 2029	DS DP		NCE	Aug 19, 2024
	8153689	Mar 19, 2028	DS DP		GAIN	Aug 19, 2029
	9120727	May 23, 2031	DS DP			
<u>LEFAMULIN ACETATE - XENLETA</u>						
N 211673 001	8071643	Jan 16, 2029	DS DP		NCE	Aug 19, 2024
	8153689	Mar 19, 2028	DS DP		GAIN	Aug 19, 2029
<u>LEMBOREXANT - DAYVIGO</u>						
N 212028 001	10188652	Oct 21, 2035	DP U-2791		NCE	Apr 07, 2025
	8268848	Sep 20, 2031	DS DP U-2791			
<u>LEMBOREXANT - DAYVIGO</u>						
N 212028 002	10188652	Oct 21, 2035	DP U-2791		NCE	Apr 07, 2025
	8268848	Sep 20, 2031	DS DP U-2791			
<u>LENALIDOMIDE - LENALIDOMIDE</u>						
A 209348 001					PC	Mar 06, 2023
<u>LENALIDOMIDE - LENALIDOMIDE</u>						
A 209348 002					PC	Mar 06, 2023
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 001	7189740	Apr 11, 2023	U-1982		ODE-131	Feb 22, 2024
	7465800	Apr 27, 2027	DS DP		ODE-241	May 28, 2026
	7468363	Oct 07, 2023	U-1983		ODE-245	May 28, 2026
	7468363	Oct 07, 2023	U-2550			
	7468363	Oct 07, 2023	U-2551			
	7855217	Nov 24, 2024	DS DP			
	7968569	Oct 07, 2023	U-1984			
	8404717	Apr 11, 2023	U-1982			
	8492406	Oct 07, 2023	U-2550			
	8530498	May 15, 2023	U-1984			
	8648095	May 15, 2023	U-1984			
	8741929	Mar 08, 2028	U-1983			
	9056120	Apr 11, 2023	U-1982			
	9101621	May 15, 2023	U-1985			
	9101622	May 15, 2023	U-1986			
	9155730	May 15, 2023	U-2550			
	9393238	May 15, 2023	U-2550			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 001	7189740	Apr 11, 2023	U-1982		ODE-131	Feb 22, 2024
	7465800	Apr 27, 2027	DS DP		ODE-241	May 28, 2026
	7468363	Oct 07, 2023	U-1983		ODE-245	May 28, 2026
	7468363	Oct 07, 2023	U-2550			
	7468363	Oct 07, 2023	U-2551			
	7855217	Nov 24, 2024	DS DP			
	7968569	Oct 07, 2023	U-1984			
	8404717	Apr 11, 2023	U-1982			
	8492406	Oct 07, 2023	U-2550			
	8530498	May 15, 2023	U-1984			
	8648095	May 15, 2023	U-1984			
	8741929	Mar 08, 2028	U-1983			
	9056120	Apr 11, 2023	U-1982			
	9101621	May 15, 2023	U-1985			
	9101622	May 15, 2023	U-1986			
	9155730	May 15, 2023	U-2550			
	9393238	May 15, 2023	U-2550			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 002	7189740	Apr 11, 2023	U-1982		ODE-131	Feb 22, 2024
	7465800	Apr 27, 2027	DS DP		ODE-241	May 28, 2026
	7468363	Oct 07, 2023	U-1983		ODE-245	May 28, 2026
	7468363	Oct 07, 2023	U-2550			
	7468363	Oct 07, 2023	U-2551			
	7855217	Nov 24, 2024	DS DP			
	7968569	Oct 07, 2023	U-1984			
	8404717	Apr 11, 2023	U-1982			
	8492406	Oct 07, 2023	U-2550			
	8530498	May 15, 2023	U-1984			
	8648095	May 15, 2023	U-1984			
	8741929	Mar 08, 2028	U-1983			
	9056120	Apr 11, 2023	U-1982			
	9101621	May 15, 2023	U-1985			
	9101622	May 15, 2023	U-1986			
	9155730	May 15, 2023	U-2550			
	9393238	May 15, 2023	U-2550			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 003	7189740	Apr 11, 2023	U-1982		ODE-131	Feb 22, 2024
	7465800	Apr 27, 2027	DS DP		ODE-241	May 28, 2026
	7468363	Oct 07, 2023	U-1983		ODE-245	May 28, 2026
	7468363	Oct 07, 2023	U-2550			
	7468363	Oct 07, 2023	U-2551			
	7855217	Nov 24, 2024	DS DP			
	7968569	Oct 07, 2023	U-1984			
	8404717	Apr 11, 2023	U-1982			
	8492406	Oct 07, 2023	U-2550			
	8530498	May 15, 2023	U-1984			
	8648095	May 15, 2023	U-1984			
	8741929	Mar 08, 2028	U-1983			
	9056120	Apr 11, 2023	U-1982			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 003	9101621	May 15, 2023	U-1985			
	9101622	May 15, 2023	U-1986			
	9155730	May 15, 2023	U-2550			
	9393238	May 15, 2023	U-2550			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 004	7189740	Apr 11, 2023	U-1982		ODE-131	Feb 22, 2024
	7465800	Apr 27, 2027	DS DP		ODE-241	May 28, 2026
	7468363	Oct 07, 2023	U-1983		ODE-245	May 28, 2026
	7468363	Oct 07, 2023	U-2550			
	7468363	Oct 07, 2023	U-2551			
	7855217	Nov 24, 2024	DS DP			
	7968569	Oct 07, 2023	U-1984			
	8404717	Apr 11, 2023	U-1982			
	8492406	Oct 07, 2023	U-2550			
	8530498	May 15, 2023	U-1984			
	8648095	May 15, 2023	U-1984			
	8741929	Mar 08, 2028	U-1983			
	9056120	Apr 11, 2023	U-1982			
	9101621	May 15, 2023	U-1985			
	9101622	May 15, 2023	U-1986			
	9155730	May 15, 2023	U-2550			
	9393238	May 15, 2023	U-2550			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 005	7189740	Apr 11, 2023	U-1982		ODE-131	Feb 22, 2024
	7465800	Apr 27, 2027	DS DP		ODE-241	May 28, 2026
	7468363	Oct 07, 2023	U-1983		ODE-245	May 28, 2026
	7468363	Oct 07, 2023	U-2550			
	7468363	Oct 07, 2023	U-2551			
	7855217	Nov 24, 2024	DS DP			
	7968569	Oct 07, 2023	U-1984			
	8404717	Apr 11, 2023	U-1982			
	8492406	Oct 07, 2023	U-2550			
	8530498	May 15, 2023	U-1984			
	8648095	May 15, 2023	U-1984			
	8741929	Mar 08, 2028	U-1983			
	9056120	Apr 11, 2023	U-1982			
	9101621	May 15, 2023	U-1985			
	9101622	May 15, 2023	U-1986			
	9155730	May 15, 2023	U-2550			
	9393238	May 15, 2023	U-2550			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 006	7189740	Apr 11, 2023	U-1982		ODE-131	Feb 22, 2024
	7465800	Apr 27, 2027	DS DP		ODE-241	May 28, 2026
	7468363	Oct 07, 2023	U-1983		ODE-245	May 28, 2026
	7468363	Oct 07, 2023	U-2550			
	7468363	Oct 07, 2023	U-2551			
	7855217	Nov 24, 2024	DS DP			
	7968569	Oct 07, 2023	U-1984			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 006	8404717	Apr 11, 2023	U-1982			
	8492406	Oct 07, 2023	U-2550			
	8530498	May 15, 2023	U-1984			
	8648095	May 15, 2023	U-1984			
	8741929	Mar 08, 2028	U-1983			
	9056120	Apr 11, 2023	U-1982			
	9101621	May 15, 2023	U-1985			
	9101622	May 15, 2023	U-1986			
	9155730	May 15, 2023	U-2550			
	9393238	May 15, 2023	U-2550			
<u>LENVATINIB MESYLATE - LENVIMA</u>						
N 206947 001	10259791	Aug 26, 2035	DS		I-868	Aug 10, 2024
	10407393	Aug 26, 2035	DS		M-269	Jul 21, 2024
	11186547	Aug 26, 2035	DS		M-272	Dec 19, 2024
	7253286	Oct 24, 2025	DS DP		ODE-196	Aug 15, 2025
	7612208	Sep 19, 2026	DS DP			
	9006256	Jul 27, 2027	U-1695			
<u>LENVATINIB MESYLATE - LENVIMA</u>						
N 206947 002	10259791	Aug 26, 2035	DS		I-868	Aug 10, 2024
	10407393	Aug 26, 2035	DS		M-269	Jul 21, 2024
	11186547	Aug 26, 2035	DS		M-272	Dec 19, 2024
	7253286	Oct 24, 2025	DS DP		ODE-196	Aug 15, 2025
	7612208	Sep 19, 2026	DS DP			
	9006256	Jul 27, 2027	U-1695			
<u>LESINURAD - ZURAMPIC</u>						
N 207988 001	10183012	Nov 26, 2028	U-2311			
	8003681	Aug 25, 2025	DS			
	8084483	Aug 17, 2029	U-1801			
	8283369	Nov 26, 2028	U-1802			
	8283369	Nov 26, 2028	U-1804			
	8357713	Dec 22, 2029	DP U-1801			
	8357713	Dec 22, 2029	DP U-1802			
	8357713	Dec 22, 2029	DP U-1803			
	8546436	Feb 29, 2032	DS DP			
	8546437	Apr 29, 2029	U-1803			
	9216179	Aug 01, 2031	U-1806			
	9956205	Dec 28, 2031	U-2311			
<u>LETERMOVIR - PREVYMIS</u>						
N 209939 001	8513255	May 22, 2024	DS DP		ODE-165	Nov 08, 2024
	RE46791	May 22, 2024	DS DP			
<u>LETERMOVIR - PREVYMIS</u>						
N 209939 002	8513255	May 22, 2024	DS DP		ODE-165	Nov 08, 2024
	RE46791	May 22, 2024	DS DP			
<u>LETERMOVIR - PREVYMIS</u>						
N 209940 001	10603384	Feb 28, 2033	DP		ODE-165	Nov 08, 2024
	8513255	May 22, 2024	DS DP			
	RE46791	May 22, 2024	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LETERMOVIR - PREVYMIS</u>						
N 209940 002	10603384	Feb 28, 2033	DP		ODE-165	Nov 08, 2024
	8513255	May 22, 2024	DS DP			
	RE46791	May 22, 2024	DS DP			
<u>LETROZOLE; RIBOCICLIB SUCCINATE - KISOALI FEMARA CO-PACK (COPACKAGED)</u>						
N 209935 001	10799506	Apr 14, 2036	DP		NPP	Dec 10, 2024
	8324225	Jun 17, 2028	DS DP			
	8415355	Mar 13, 2031	DS DP			
	8685980	May 25, 2030	DS DP			
	8962630	Dec 09, 2029	U-2505			
	8962630	Dec 09, 2029	U-3264			
	9193732	Nov 09, 2031	DS DP			
	9416136	Aug 20, 2029	U-2505			
	9416136	Aug 20, 2029	U-3264			
	9868739	Nov 09, 2031	U-2505			
	9868739	Nov 09, 2031	U-3264			
<u>LEUPROLIDE ACETATE - LUPRON DEPOT</u>						
N 020517 003	8921326	Feb 05, 2031	DP U-1666			
<u>LEUPROLIDE ACETATE - ELIGARD KIT</u>						
N 021379 001	8470359	Oct 15, 2023	DS DP U-621			
<u>LEUPROLIDE ACETATE - ELIGARD KIT</u>						
N 021488 001	8470359	Oct 15, 2023	DS DP U-621			
<u>LEUPROLIDE ACETATE - ELIGARD KIT</u>						
N 021731 001	8470359	Oct 15, 2023	DS DP U-621			
<u>LEUPROLIDE ACETATE - FENSOLVI KIT</u>						
N 213150 001	8470359	Oct 15, 2023	DS DP U-2940		I-829	May 01, 2023
<u>LEUPROLIDE MESYLATE - CAMCEVI KIT</u>						
N 211488 001	10646572	Jan 16, 2027	DP		NP	May 25, 2024
	9572857	Jan 16, 2027	DP			
	9744207	Jan 16, 2027	DP			
<u>LEVALBUTEROL TARTRATE - XOPENEX HFA</u>						
N 021730 001	7256310	Oct 08, 2024	DS DP U-636			
	8765153	Dec 08, 2023	DP			
<u>LEVETIRACETAM - KEPPRA</u>						
N 021035 001	8802142	Jun 07, 2031	DP			
	8802142*PED	Dec 07, 2031				
<u>LEVETIRACETAM - KEPPRA</u>						
N 021035 002	8802142	Jun 07, 2031	DP			
	8802142*PED	Dec 07, 2031				
<u>LEVETIRACETAM - KEPPRA</u>						
N 021035 003	8802142	Jun 07, 2031	DP			
	8802142*PED	Dec 07, 2031				
<u>LEVETIRACETAM - KEPPRA</u>						
N 021035 004	8802142	Jun 07, 2031	DP			
	8802142*PED	Dec 07, 2031				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LEVETIRACETAM - KEPPRA XR</u>						
N 022285 001	7858122	Sep 17, 2028	DP			
<u>LEVETIRACETAM - KEPPRA XR</u>						
N 022285 002	7858122	Sep 17, 2028	DP			
<u>LEVETIRACETAM - ELEPSIA XR</u>						
N 204417 001	8163306	Sep 03, 2027	DP			
	8425938	Feb 22, 2026	DP			
	8431156	Oct 31, 2027	DP			
	8470367	Oct 31, 2027	DP			
	8535717	Feb 22, 2026	DP			
<u>LEVETIRACETAM - ELEPSIA XR</u>						
N 204417 002	8163306	Sep 03, 2027	DP			
	8425938	Feb 22, 2026	DP			
	8431156	Oct 31, 2027	DP			
	8470367	Oct 31, 2027	DP			
	8535717	Feb 22, 2026	DP			
<u>LEVETIRACETAM - SPRITAM</u>						
N 207958 001	11160786	Mar 14, 2034	DP			
	9339489	Mar 14, 2034	DP U-1850			
	9669009	Mar 14, 2034	U-1850			
	9669009	Mar 14, 2034	U-2021			
	9669009	Mar 14, 2034	U-2022			
<u>LEVETIRACETAM - SPRITAM</u>						
N 207958 002	11160786	Mar 14, 2034	DP			
	9339489	Mar 14, 2034	DP U-1850			
	9669009	Mar 14, 2034	U-1850			
	9669009	Mar 14, 2034	U-2021			
	9669009	Mar 14, 2034	U-2022			
<u>LEVETIRACETAM - SPRITAM</u>						
N 207958 003	11160786	Mar 14, 2034	DP			
	9339489	Mar 14, 2034	DP U-1850			
	9669009	Mar 14, 2034	U-1850			
	9669009	Mar 14, 2034	U-2021			
	9669009	Mar 14, 2034	U-2022			
<u>LEVETIRACETAM - SPRITAM</u>						
N 207958 004	11160786	Mar 14, 2034	DP			
	9339489	Mar 14, 2034	DP U-1850			
	9669009	Mar 14, 2034	U-1850			
	9669009	Mar 14, 2034	U-2021			
	9669009	Mar 14, 2034	U-2022			
<u>LEVOCETIRIZINE DIHYDROCHLORIDE - XYZAL ALLERGY 24HR</u>						
N 209090 001	8633194	Oct 16, 2027	DP			
<u>LEVODOPA - INBRIJA</u>						
N 209184 001	7182961	Feb 22, 2024	DP			
	8404276	Mar 19, 2023	U-2484			
	8545878	Nov 16, 2032	DP			
	8586093	Mar 19, 2023	U-2484			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LEVODOPA - INBRIJA</u>						
N 209184 001	8685442	Nov 16, 2032	DP			
	8945612	Nov 16, 2032	DP			
	9155699	Mar 19, 2023	DP			
	9393210	Nov 16, 2032	DP			
	RE43711	Feb 03, 2029	U-2484			
<u>LEVOKETOCONAZOLE - RECORLEV</u>						
N 214133 001	10098877	Jan 10, 2026	U-3283			
	10517868	Jan 10, 2026	U-3283			
	10835530	Jan 10, 2026	U-3283			
	11020393	Mar 02, 2040	U-3282			
	11278547	Mar 02, 2040	U-3282			
	11478471	Jan 10, 2026	U-3283			
	9918984	Jan 10, 2026	U-3283			
<u>LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA</u>						
N 204168 001	8481598	Mar 02, 2031	U-839			
	8865937	May 23, 2032	DS DP			
	RE43879	Jan 11, 2026	U-839			
<u>LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA</u>						
N 204168 002	8481598	Mar 02, 2031	U-839			
	8865937	May 23, 2032	DS DP			
	RE43879	Jan 11, 2026	U-839			
<u>LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA</u>						
N 204168 003	8481598	Mar 02, 2031	U-839			
	8865937	May 23, 2032	DS DP			
	RE43879	Jan 11, 2026	U-839			
<u>LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA</u>						
N 204168 004	8481598	Mar 02, 2031	U-839			
	8865937	May 23, 2032	DS DP			
	RE43879	Jan 11, 2026	U-839			
<u>LEVONORGESTREL - MIRENA</u>						
N 021225 001	10561524	Sep 16, 2029	U-2948		D-181	Aug 20, 2023
	10987244	Apr 01, 2031	DP			
	9615965	Sep 16, 2029	DP U-2003			
	9668912	Apr 01, 2031	DP			
<u>LEVONORGESTREL - SKYLA</u>						
N 203159 001	10561524	Sep 16, 2029	U-2948			
	10987244	Apr 01, 2031	DP			
	7252839	Nov 13, 2023	DP			
	9615965	Sep 16, 2029	DP U-2003			
	9668912	Apr 01, 2031	DP			
<u>LEVONORGESTREL - LILETTA</u>						
N 206229 001	10028858	Mar 22, 2034	DP U-2348			
	11090186	Oct 24, 2033	U-2348			
<u>LEVONORGESTREL - KYLEENA</u>						
N 208224 001	10561524	Sep 16, 2029	U-2948			
	10987244	Apr 01, 2031	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LEVONORGESTREL - KYLEENA</u>						
N 208224 001	7252839	Nov 13, 2023	DP			
	9615965	Sep 16, 2029	DP U-2003			
	9668912	Apr 01, 2031	DP			
<u>LEVOTHYROXINE SODIUM - LEVOLET</u>						
N 021137 003	10231931	Mar 23, 2038	DP			
	10406108	Mar 23, 2038	DP			
<u>LEVOTHYROXINE SODIUM - LEVOLET</u>						
N 021137 004	10231931	Mar 23, 2038	DP			
	10406108	Mar 23, 2038	DP			
<u>LEVOTHYROXINE SODIUM - LEVOLET</u>						
N 021137 005	10231931	Mar 23, 2038	DP			
	10406108	Mar 23, 2038	DP			
<u>LEVOTHYROXINE SODIUM - LEVOLET</u>						
N 021137 006	10231931	Mar 23, 2038	DP			
	10406108	Mar 23, 2038	DP			
<u>LEVOTHYROXINE SODIUM - LEVOLET</u>						
N 021137 007	10231931	Mar 23, 2038	DP			
	10406108	Mar 23, 2038	DP			
<u>LEVOTHYROXINE SODIUM - LEVOLET</u>						
N 021137 008	10231931	Mar 23, 2038	DP			
	10406108	Mar 23, 2038	DP			
<u>LEVOTHYROXINE SODIUM - LEVOLET</u>						
N 021137 009	10231931	Mar 23, 2038	DP			
	10406108	Mar 23, 2038	DP			
<u>LEVOTHYROXINE SODIUM - LEVOLET</u>						
N 021137 010	10231931	Mar 23, 2038	DP			
	10406108	Mar 23, 2038	DP			
<u>LEVOTHYROXINE SODIUM - LEVOLET</u>						
N 021137 011	10231931	Mar 23, 2038	DP			
	10406108	Mar 23, 2038	DP			
<u>LEVOTHYROXINE SODIUM - LEVOLET</u>						
N 021137 012	10231931	Mar 23, 2038	DP			
	10406108	Mar 23, 2038	DP			
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 001	7101569	Oct 02, 2023	U-759			
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 002	7101569	Oct 02, 2023	U-759			
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 003	7101569	Oct 02, 2023	U-759			
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 004	7101569	Oct 02, 2023	U-759			
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 005	7101569	Oct 02, 2023	U-759			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 006	7101569	Oct 02, 2023	U-759			
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 007	7101569	Oct 02, 2023	U-759			
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 008	7101569	Oct 02, 2023	U-759			
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 009	7101569	Oct 02, 2023	U-759			
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 010	7101569	Oct 02, 2023	U-759			
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 011	7101569	Oct 02, 2023	U-759			
<u>LEVOTHYROXINE SODIUM - LEVOXYL</u>						
N 021301 012	7101569	Oct 02, 2023	U-759			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 002	7691411	Mar 14, 2024	DP			
	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 003	7691411	Mar 14, 2024	DP			
	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 004	7691411	Mar 14, 2024	DP			
	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 005	7691411	Mar 14, 2024	DP			
	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 006	7691411	Mar 14, 2024	DP			
	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 007	7691411	Mar 14, 2024	DP			
	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 008	7691411	Mar 14, 2024	DP			
	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 009	7691411	Mar 14, 2024	DP			
	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 010	7691411	Mar 14, 2024	DP			
	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 011	7691411	Mar 14, 2024	DP			
	7723390	Mar 14, 2024	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 012	7691411	Mar 14, 2024	DP			
	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 013	7691411	Mar 14, 2024	DP			
	7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM</u>						
N 202231 001	9006289	Oct 03, 2032	DP			
	9168238	Aug 29, 2032	DP			
	9168239	Aug 29, 2032	DP			
<u>LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM</u>						
N 202231 002	9006289	Oct 03, 2032	DP			
	9168238	Aug 29, 2032	DP			
	9168239	Aug 29, 2032	DP			
<u>LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM</u>						
N 202231 003	9006289	Oct 03, 2032	DP			
	9168238	Aug 29, 2032	DP			
	9168239	Aug 29, 2032	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 001	10537538	Feb 28, 2037	DP			
	11096913	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 002	10537538	Feb 28, 2037	DP			
	11096913	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 003	10537538	Feb 28, 2037	DP			
	11096913	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 004	10537538	Feb 28, 2037	DP			
	11096913	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 005	10537538	Feb 28, 2037	DP			
	11096913	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 006	10537538	Feb 28, 2037	DP			
	11096913	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 007	10537538	Feb 28, 2037	DP			
	11096913	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 008	10537538	Feb 28, 2037	DP			
	11096913	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 009	10537538	Feb 28, 2037	DP			
	11096913	Feb 28, 2037	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 010	10537538	Feb 28, 2037	DP			
	11096913	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 011	10537538	Feb 28, 2037	DP			
	11096913	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 012	10537538	Feb 28, 2037	DP			
	11096913	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 013	10537538	Feb 28, 2037	DP			
	11096913	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 014	10537538	Feb 28, 2037	DP			
	11096913	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT-SOL</u>						
N 206977 015	10537538	Feb 28, 2037	DP			
	11096913	Feb 28, 2037	DP			
<u>LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM</u>						
N 210632 001	10398669	Dec 01, 2036	DP			
	11135190	Dec 01, 2036	DP			
	9782376	Dec 01, 2036	DP			
<u>LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM</u>						
N 210632 002	10398669	Dec 01, 2036	DP			
	11135190	Dec 01, 2036	DP			
	9782376	Dec 01, 2036	DP			
<u>LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM</u>						
N 210632 003	10398669	Dec 01, 2036	DP			
	11135190	Dec 01, 2036	DP			
	9782376	Dec 01, 2036	DP			
<u>LEVOTHYROXINE SODIUM - THYQUIDITY</u>						
N 214047 001	9050307	Aug 06, 2031	DP			
<u>LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM</u>						
N 214253 001	11154498	Jul 20, 2036	DP			
<u>LEVOTHYROXINE SODIUM - ERMEZA</u>						
N 215809 001	9345772	Feb 27, 2035	DP			
<u>LIDOCAINE - ZTLIDO</u>						
N 207962 001	10765640	May 10, 2031	DP			
	10765749	May 10, 2031	DP			
	11278623	May 10, 2031	DP			
	9283174	May 10, 2031	DP			
	9925264	May 10, 2031	DP		U-2267	
	9931403	May 10, 2031	DP			
<u>LIDOCAINE HYDROCHLORIDE - ZINGO</u>						
N 022114 001	8540665	Oct 22, 2029		U-1438		
	9358338	Apr 27, 2035		U-1870		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LIDOCAINE HYDROCHLORIDE - ZINGO</u>						
N 022114	001 9370622	Sep 28, 2035	U-1870			
<u>LIDOCAINE HYDROCHLORIDE - AKTEN</u>						
N 022221	001 8759401	Jul 24, 2026	DP U-1523			
<u>LIDOCAINE; TETRACAINE - PLIAGLIS</u>						
N 021717	001 10350180	Jan 14, 2031	DP			
	10603293	Jan 14, 2031	DP			
	10751305	Jan 14, 2031	DP			
<u>LIFITEGRAST - XIIDRA</u>						
N 208073	001 10124000	Nov 05, 2024	U-1900			
	11058677	Dec 18, 2033	DP			
	7314938	Mar 10, 2025	DS DP			
	7745460	Nov 05, 2024	DS DP U-1880			
	7790743	Nov 05, 2024	U-1880			
	7928122	Nov 05, 2024	DS DP			
	8084047	May 17, 2026	DS DP			
	8168655	May 09, 2029	U-1880			
	8367701	Apr 15, 2029	DP U-1880			
	8592450	May 17, 2026	U-1880			
	8927574	Nov 12, 2030	DP			
	9085553	Jul 25, 2033	DP			
	9216174	Nov 05, 2024	DP			
	9353088	Oct 21, 2030	DP			
	9447077	Apr 15, 2029	U-1900			
	9890141	Oct 21, 2030	DS			
<u>LINACLOTIDE - LINZESS</u>						
N 202811	001 7304036	Aug 30, 2026	DS DP U-1278			
	7304036	Aug 30, 2026	DS DP U-1516			
	7371727	Jan 28, 2024	DS			
	7704947	Jan 28, 2024	DS DP			
	7745409	Jan 28, 2024	DS DP			
	8080526	Jan 28, 2024	DS DP			
	8110553	Jan 28, 2024	U-1278			
	8748573	Oct 30, 2031	U-1515			
	8748573	Oct 30, 2031	U-1516			
	8802628	Oct 30, 2031	DP			
	8933030	Feb 17, 2031	DP			
	9708371	Aug 16, 2033	DP U-1515			
	9708371	Aug 16, 2033	DP U-1516			
<u>LINACLOTIDE - LINZESS</u>						
N 202811	002 7304036	Aug 30, 2026	DS DP U-1278			
	7304036	Aug 30, 2026	DS DP U-1516			
	7371727	Jan 28, 2024	DS			
	7704947	Jan 28, 2024	DS DP			
	7745409	Jan 28, 2024	DS DP			
	8080526	Jan 28, 2024	DS DP			
	8110553	Jan 28, 2024	U-1278			
	8748573	Oct 30, 2031	U-1515			
	8748573	Oct 30, 2031	U-1516			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LINACLOTIDE - LINZESS</u>						
N 202811 002	8802628	Oct 30, 2031	DP			
	8933030	Feb 17, 2031	DP			
	9708371	Aug 16, 2033	DP U-1515			
<u>LINACLOTIDE - LINZESS</u>						
N 202811 003	10675325	Aug 11, 2031	DP			
	10702576	Aug 11, 2031	U-1516			
	7304036	Aug 30, 2026	DS DP U-1516			
	7371727	Jan 28, 2024	DS			
	7704947	Jan 28, 2024	DS DP			
	7745409	Jan 28, 2024	DS DP			
	8080526	Jan 28, 2024	DS DP			
	8110553	Jan 28, 2024	U-1516			
	8933030	Feb 17, 2031	DP U-1516			
	9708371	Aug 16, 2033	DP U-1516			
<u>LINAGLIPTIN - TRADJENTA</u>						
N 201280 001	10034877	Aug 05, 2029	U-2347		M-252	Mar 30, 2023
	11033552	May 04, 2027	DP			
	7407955	May 02, 2025	DS DP			
	8119648	Aug 12, 2023	U-1270			
	8119648	Aug 12, 2023	U-774			
	8178541	Aug 12, 2023	U-1244			
	8178541	Aug 12, 2023	U-1245			
	8178541	Aug 12, 2023	U-1270			
	8178541	Aug 12, 2023	U-775			
	8673927	May 04, 2027	U-1503	Y		
	8846695	Jun 04, 2030	U-1503	Y		
	8853156	Mar 05, 2031	U-1642			
	8883805	Nov 26, 2025	DP			
	9486526	Aug 05, 2029	U-1915			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 001	10022379	Apr 02, 2029	U-2339		M-252	Mar 30, 2023
	10973827	Apr 02, 2029	DP			
	7407955	May 02, 2025	DS DP			
	8119648	Aug 12, 2023	U-802			
	8178541	Aug 12, 2023	DP U-775			
	8673927	May 04, 2027	U-1503	Y		
	8846695	Jun 04, 2030	U-1503			
	8883805	Nov 26, 2025	DP			
	9155705	May 21, 2030	DP			
	9415016	Apr 02, 2029	DP			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 002	10022379	Apr 02, 2029	U-2339		M-252	Mar 30, 2023
	10973827	Apr 02, 2029	DP			
	7407955	May 02, 2025	DS DP			
	8119648	Aug 12, 2023	U-802			
	8178541	Aug 12, 2023	DP U-775			
	8673927	May 04, 2027	U-1503	Y		
	8846695	Jun 04, 2030	U-1503			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 002	8883805	Nov 26, 2025	DP			
	9155705	May 21, 2030	DP			
	9415016	Apr 02, 2029	DP			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 003	10022379	Apr 02, 2029	U-2339		M-252	Mar 30, 2023
	10973827	Apr 02, 2029	DP			
	7407955	May 02, 2025	DS DP			
	8119648	Aug 12, 2023	U-802			
	8178541	Aug 12, 2023	DP U-775			
	8673927	May 04, 2027	U-1503	Y		
	8846695	Jun 04, 2030	U-1503	Y		
	8883805	Nov 26, 2025	DP			
	9155705	May 21, 2030	DP			
	9415016	Apr 02, 2029	DP			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR</u>						
N 208026 001	10022379	Apr 02, 2029	U-2339		M-252	Mar 30, 2023
	7407955	May 02, 2025	DS DP			
	8119648	Aug 12, 2023	U-802			
	8178541	Aug 12, 2023	DP U-1853			
	8673927	May 04, 2027	U-1503	Y		
	8883805	Nov 26, 2025	DP			
	9155705	May 21, 2030	DP			
	9173859	May 04, 2027	DP U-1503	Y		
	9415016	Apr 02, 2029	DP			
	9555001	Mar 06, 2033	DP U-1967			
	9555001	Mar 06, 2033	DP U-1968			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR</u>						
N 208026 002	10022379	Apr 02, 2029	U-2339		M-252	Mar 30, 2023
	7407955	May 02, 2025	DS DP			
	8119648	Aug 12, 2023	U-802			
	8178541	Aug 12, 2023	DP U-1853			
	8673927	May 04, 2027	U-1503	Y		
	8883805	Nov 26, 2025	DP			
	9155705	May 21, 2030	DP			
	9173859	May 04, 2027	DP U-1503	Y		
	9415016	Apr 02, 2029	DP			
	9555001	Mar 06, 2033	DP U-1967			
	9555001	Mar 06, 2033	DP U-1968			
<u>LIRAGLUTIDE RECOMBINANT - VICTOZA</u>						
N 022341 001	6268343*PED	Feb 22, 2023				
	7762994	May 23, 2024	DP			
	7762994*PED	Nov 23, 2024				
	8114833	Aug 13, 2025	DS DP			
	8114833*PED	Feb 13, 2026				
	8579869	Jun 30, 2023	DP			
	8579869*PED	Dec 30, 2023				
	9265893	Sep 23, 2032	DP			
	9265893*PED	Mar 23, 2033				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LIRAGLUTIDE RECOMBINANT - VICTOZA</u>						
N 022341 001	9968659	Jan 09, 2037	U-2313			
	9968659*PED	Jul 09, 2037				
<u>LIRAGLUTIDE RECOMBINANT - SAXENDA</u>						
N 206321 001	10220155	Jul 17, 2026	DP		NPP	Dec 04, 2023
	10220155*PED	Jan 17, 2027				
	10357616	Jan 20, 2026	DP			
	10376652	Jan 20, 2026	DP			
	11097063	Jul 17, 2026	DP			
	11311679	Jan 20, 2026	DP			
	11446443	Oct 20, 2025	DP			
	6268343*PED	Feb 22, 2023				
	7762994	May 23, 2024	DP			
	7762994*PED	Nov 23, 2024				
	8114833	Aug 13, 2025	DP			
	8114833*PED	Feb 13, 2026				
	8579869	Jun 30, 2023	DP			
	8579869*PED	Dec 30, 2023				
	8684969	Oct 20, 2025	DP			
	8684969*PED	Apr 20, 2026				
	8920383	Jul 17, 2026	DP			
	8920383*PED	Jan 17, 2027				
	9108002	Jan 26, 2026	DP			
	9108002*PED	Jul 26, 2026				
	9132239	Feb 01, 2032	DP			
	9132239*PED	Aug 01, 2032				
	9457154	Sep 27, 2027	DP			
	9457154*PED	Mar 27, 2028				
	9616180	Jan 20, 2026	DP			
	9616180*PED	Jul 20, 2026				
	9687611	Feb 27, 2027	DP			
	9687611*PED	Aug 27, 2027				
	9775953	Jul 17, 2026	DP			
	9775953*PED	Jan 17, 2027				
	9861757	Jan 20, 2026	DP			
	9861757*PED	Jul 20, 2026				
	9968659	Jan 09, 2037	U-2438			
	9968659*PED	Jul 09, 2037				
	RE46363	Aug 03, 2026	DP			
	RE46363*PED	Feb 03, 2027				
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 001	7105486	Feb 24, 2023	U-727			
	7105486*PED	Aug 24, 2023				
	7223735	Feb 24, 2023	DP			
	7223735*PED	Aug 24, 2023				
	7655630	Feb 24, 2023	DS			
	7659253	Feb 24, 2023	DS DP	U-727		
	7659254	Feb 24, 2023			U-1034	
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023		U-727		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 001	7671030	Feb 24, 2023	DP U-727			
	7671031	Feb 24, 2023	U-727			
	7671031*PED	Aug 24, 2023				
	7674774	Feb 24, 2023	DP U-842			
	7674774*PED	Aug 24, 2023				
	7678770	Feb 24, 2023	U-842			
	7678770*PED	Aug 24, 2023				
	7678771	Feb 24, 2023	DP U-842			
	7678771*PED	Aug 24, 2023				
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP U-842			
	7687467*PED	Aug 24, 2023				
	7700561	Feb 24, 2023	DP			
	7700561*PED	Aug 24, 2023				
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-842			
	7723305	Feb 24, 2023	DP U-842			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 002	7105486	Feb 24, 2023	U-727			
	7105486*PED	Aug 24, 2023				
	7223735	Feb 24, 2023	DP			
	7223735*PED	Aug 24, 2023				
	7655630	Feb 24, 2023	DS			
	7659253	Feb 24, 2023	DS DP U-727			
	7659254	Feb 24, 2023	U-1034			
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023	U-727			
	7671030	Feb 24, 2023	DP U-727			
	7671031	Feb 24, 2023	U-727			
	7671031*PED	Aug 24, 2023				
	7674774	Feb 24, 2023	DP U-842			
	7674774*PED	Aug 24, 2023				
	7678770	Feb 24, 2023	U-842			
	7678770*PED	Aug 24, 2023				
	7678771	Feb 24, 2023	DP U-842			
	7678771*PED	Aug 24, 2023				
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP U-842			
	7687467*PED	Aug 24, 2023				
	7700561	Feb 24, 2023	DP			
	7700561*PED	Aug 24, 2023				
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-842			
	7723305	Feb 24, 2023	DP U-842			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 003	7105486	Feb 24, 2023	U-727			
	7105486*PED	Aug 24, 2023				
	7223735	Feb 24, 2023	DP			
	7223735*PED	Aug 24, 2023				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 003	7655630	Feb 24, 2023	DS			
	7659253	Feb 24, 2023	DS DP U-727			
	7659254	Feb 24, 2023	U-1034			
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023	U-727			
	7671030	Feb 24, 2023	DP U-727			
	7671031	Feb 24, 2023	U-727			
	7671031*PED	Aug 24, 2023				
	7674774	Feb 24, 2023	DP U-842			
	7674774*PED	Aug 24, 2023				
	7678770	Feb 24, 2023	U-842			
	7678770*PED	Aug 24, 2023				
	7678771	Feb 24, 2023	DP U-842			
	7678771*PED	Aug 24, 2023				
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP U-842			
	7687467*PED	Aug 24, 2023				
	7700561	Feb 24, 2023	DP			
	7700561*PED	Aug 24, 2023				
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-842			
	7723305	Feb 24, 2023	DP U-842			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 004	7105486	Feb 24, 2023	U-727			
	7105486	Feb 24, 2023	U-842			
	7105486*PED	Aug 24, 2023				
	7223735	Feb 24, 2023	DP			
	7223735*PED	Aug 24, 2023				
	7655630	Feb 24, 2023	DS			
	7659253	Feb 24, 2023	DS DP U-727			
	7659254	Feb 24, 2023	U-1034			
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023	U-727			
	7671030	Feb 24, 2023	DP U-727			
	7671031	Feb 24, 2023	U-727			
	7671031*PED	Aug 24, 2023				
	7674774	Feb 24, 2023	DP U-842			
	7674774*PED	Aug 24, 2023				
	7678770	Feb 24, 2023	U-842			
	7678770*PED	Aug 24, 2023				
	7678771	Feb 24, 2023	DP U-842			
	7678771*PED	Aug 24, 2023				
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP U-842			
	7687467*PED	Aug 24, 2023				
	7700561	Feb 24, 2023	DP			
	7700561*PED	Aug 24, 2023				
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-842			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 004	7723305	Feb 24, 2023	DP U-842			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 005	7105486	Feb 24, 2023	U-842			
	7105486*PED	Aug 24, 2023				
	7223735	Feb 24, 2023	DP			
	7655630	Feb 24, 2023	DS			
	7659253	Feb 24, 2023	DS DP U-727			
	7659254	Feb 24, 2023	U-1034			
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023	U-727			
	7671030	Feb 24, 2023	DP U-727			
	7671031	Feb 24, 2023	U-727			
	7671031*PED	Aug 24, 2023				
	7674774	Feb 24, 2023	DP U-842			
	7674774*PED	Aug 24, 2023				
	7678770	Feb 24, 2023	U-842			
	7678770*PED	Aug 24, 2023				
	7678771	Feb 24, 2023	DP U-842			
	7678771*PED	Aug 24, 2023				
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP U-842			
	7687467*PED	Aug 24, 2023				
	7700561	Feb 24, 2023	DP			
	7700561*PED	Aug 24, 2023				
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-842			
	7723305	Feb 24, 2023	DP U-842			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 006	7105486	Feb 24, 2023	U-727			
	7105486	Feb 24, 2023	U-842			
	7105486*PED	Aug 24, 2023				
	7223735	Feb 24, 2023	DP			
	7223735*PED	Aug 24, 2023				
	7655630	Feb 24, 2023	DS			
	7659253	Feb 24, 2023	DS DP U-727			
	7659254	Feb 24, 2023	U-1034			
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023	U-727			
	7671030	Feb 24, 2023	DP U-727			
	7671031	Feb 24, 2023	U-727			
	7671031*PED	Aug 24, 2023				
	7674774	Feb 24, 2023	DP U-842			
	7674774*PED	Aug 24, 2023				
	7678770	Feb 24, 2023	U-842			
	7678770*PED	Aug 24, 2023				
	7678771	Feb 24, 2023	DP U-842			
	7678771*PED	Aug 24, 2023				
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP U-842			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 006	7687467*PED	Aug 24, 2023				
	7700561	Feb 24, 2023	DP			
	7700561*PED	Aug 24, 2023				
	7713936	Feb 24, 2023			U-727	
	7718619	Feb 24, 2023	DP U-842			
	7723305	Feb 24, 2023	DP U-842			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 007	7223735	Feb 24, 2023	DP			
	7223735*PED	Aug 24, 2023				
	7655630	Feb 24, 2023	DS			
	7655630*PED	Aug 24, 2023				
	7659253	Feb 24, 2023	DS DP U-727			
	7659253*PED	Aug 24, 2023				
	7659254	Feb 24, 2023			U-1034	
	7659254*PED	Aug 24, 2023				
	7662787	Feb 24, 2023	DS			
	7662787*PED	Aug 24, 2023				
	7662788	Feb 24, 2023			U-727	
	7662788*PED	Aug 24, 2023				
	7671030	Feb 24, 2023	DP U-727			
	7671030*PED	Aug 24, 2023				
	7671031	Feb 24, 2023			U-727	
	7671031*PED	Aug 24, 2023				
	7674774	Feb 24, 2023	DP U-842			
	7674774*PED	Aug 24, 2023				
	7678770	Feb 24, 2023			U-842	
	7678770*PED	Aug 24, 2023				
	7678771	Feb 24, 2023	DP			
	7678771*PED	Aug 24, 2023				
	7687466	Feb 24, 2023	DP			
	7687466*PED	Aug 24, 2023				
	7687467	Feb 24, 2023	DP U-842			
	7687467*PED	Aug 24, 2023				
	7700561	Feb 24, 2023	DP			
	7700561*PED	Aug 24, 2023				
	7713936	Feb 24, 2023			U-727	
	7713936*PED	Aug 24, 2023				
	7718619	Feb 24, 2023	DP U-842			
	7718619*PED	Aug 24, 2023				
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 001	7105486	Feb 24, 2023			U-727	
	7105486*PED	Aug 24, 2023				
	7223735	Feb 24, 2023	DP			
	7223735*PED	Aug 24, 2023				
	7655630	Feb 24, 2023	DS DP			
	7655630*PED	Aug 24, 2023				
	7659253	Feb 24, 2023	DS DP U-727			
	7659253*PED	Aug 24, 2023				
	7659254	Feb 24, 2023			U-727	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 001	7659254*PED	Aug 24, 2023				
	7662787	Feb 24, 2023	DS			
	7662787*PED	Aug 24, 2023				
	7662788	Feb 24, 2023			U-727	
	7662788*PED	Aug 24, 2023				
	7671030	Feb 24, 2023	DP		U-727	
	7671030*PED	Aug 24, 2023				
	7671031	Feb 24, 2023			U-727	
	7671031*PED	Aug 24, 2023				
	7674774	Feb 24, 2023	DP		U-727	
	7674774*PED	Aug 24, 2023				
	7678770	Feb 24, 2023			U-727	
	7678770*PED	Aug 24, 2023				
	7678771	Feb 24, 2023	DP		U-727	
	7678771*PED	Aug 24, 2023				
	7687466	Feb 24, 2023	DP			
	7687466*PED	Aug 24, 2023				
	7687467	Feb 24, 2023	DP		U-727	
	7687467*PED	Aug 24, 2023				
	7713936	Feb 24, 2023			U-727	
	7713936*PED	Aug 24, 2023				
	7718619	Feb 24, 2023	DP		U-727	
	7718619*PED	Aug 24, 2023				
	7723305	Feb 24, 2023	DP		U-727	
	7723305*PED	Aug 24, 2023				
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 002	7105486	Feb 24, 2023			U-727	
	7105486*PED	Aug 24, 2023				
	7223735	Feb 24, 2023	DP			
	7223735*PED	Aug 24, 2023				
	7655630	Feb 24, 2023	DS	DP		
	7655630*PED	Aug 24, 2023				
	7659253	Feb 24, 2023	DS	DP	U-727	
	7659253*PED	Aug 24, 2023				
	7659254	Feb 24, 2023			U-727	
	7659254*PED	Aug 24, 2023				
	7662787	Feb 24, 2023	DS			
	7662787*PED	Aug 24, 2023				
	7662788	Feb 24, 2023			U-727	
	7662788*PED	Aug 24, 2023				
	7671030	Feb 24, 2023	DP		U-727	
	7671030*PED	Aug 24, 2023				
	7671031	Feb 24, 2023			U-727	
	7671031*PED	Aug 24, 2023				
	7674774	Feb 24, 2023	DP		U-727	
	7674774*PED	Aug 24, 2023				
	7678770	Feb 24, 2023			U-727	
	7678770*PED	Aug 24, 2023				
	7678771	Feb 24, 2023	DP		U-727	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 002	7678771*PED	Aug 24, 2023				
	7687466	Feb 24, 2023	DP			
	7687466*PED	Aug 24, 2023				
	7687467	Feb 24, 2023	DP U-727			
	7687467*PED	Aug 24, 2023				
	7713936	Feb 24, 2023	U-727			
	7713936*PED	Aug 24, 2023				
	7718619	Feb 24, 2023	DP U-727			
	7718619*PED	Aug 24, 2023				
	7723305	Feb 24, 2023	DP U-727			
	7723305*PED	Aug 24, 2023				
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 003	7105486	Feb 24, 2023	U-727			
	7105486*PED	Aug 24, 2023				
	7223735	Feb 24, 2023	DP			
	7223735*PED	Aug 24, 2023				
	7655630	Feb 24, 2023	DS DP			
	7655630*PED	Aug 24, 2023				
	7659253	Feb 24, 2023	DS DP U-727			
	7659253*PED	Aug 24, 2023				
	7659254	Feb 24, 2023	U-727			
	7659254*PED	Aug 24, 2023				
	7662787	Feb 24, 2023	DS			
	7662787*PED	Aug 24, 2023				
	7662788	Feb 24, 2023	U-727			
	7662788*PED	Aug 24, 2023				
	7671030	Feb 24, 2023	DP U-727			
	7671030*PED	Aug 24, 2023				
	7671031	Feb 24, 2023	U-727			
	7671031*PED	Aug 24, 2023				
	7674774	Feb 24, 2023	DP U-727			
	7674774*PED	Aug 24, 2023				
	7678770	Feb 24, 2023	U-727			
	7678770*PED	Aug 24, 2023				
	7678771	Feb 24, 2023	DP U-727			
	7678771*PED	Aug 24, 2023				
	7687466	Feb 24, 2023	DP			
	7687466*PED	Aug 24, 2023				
	7687467	Feb 24, 2023	DP U-727			
	7687467*PED	Aug 24, 2023				
	7713936	Feb 24, 2023	U-727			
	7713936*PED	Aug 24, 2023				
	7718619	Feb 24, 2023	DP U-727			
	7718619*PED	Aug 24, 2023				
	7723305	Feb 24, 2023	DP U-727			
	7723305*PED	Aug 24, 2023				
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 004	7105486	Feb 24, 2023	U-727			
	7105486*PED	Aug 24, 2023				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 004	7223735	Feb 24, 2023	DP			
	7223735*PED	Aug 24, 2023				
	7655630	Feb 24, 2023	DS DP			
	7655630*PED	Aug 24, 2023				
	7659253	Feb 24, 2023	DS DP U-727			
	7659253*PED	Aug 24, 2023				
	7659254	Feb 24, 2023	U-727			
	7659254*PED	Aug 24, 2023				
	7662787	Feb 24, 2023	DS			
	7662787*PED	Aug 24, 2023				
	7662788	Feb 24, 2023	U-727			
	7662788*PED	Aug 24, 2023				
	7671030	Feb 24, 2023	DP U-727			
	7671030*PED	Aug 24, 2023				
	7671031	Feb 24, 2023	U-727			
	7671031*PED	Aug 24, 2023				
	7674774	Feb 24, 2023	DP U-727			
	7674774*PED	Aug 24, 2023				
	7678770	Feb 24, 2023	U-727			
	7678770*PED	Aug 24, 2023				
	7678771	Feb 24, 2023	DP U-727			
	7678771*PED	Aug 24, 2023				
	7687466	Feb 24, 2023	DP			
	7687466*PED	Aug 24, 2023				
	7687467	Feb 24, 2023	DP U-727			
	7687467*PED	Aug 24, 2023				
	7713936	Feb 24, 2023	U-727			
	7713936*PED	Aug 24, 2023				
	7718619	Feb 24, 2023	DP U-727			
	7718619*PED	Aug 24, 2023				
	7723305	Feb 24, 2023	DP U-727			
	7723305*PED	Aug 24, 2023				
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 005	7105486	Feb 24, 2023	U-727			
	7105486*PED	Aug 24, 2023				
	7223735	Feb 24, 2023	DP			
	7223735*PED	Aug 24, 2023				
	7655630	Feb 24, 2023	DS DP			
	7655630*PED	Aug 24, 2023				
	7659253	Feb 24, 2023	DS DP U-727			
	7659253*PED	Aug 24, 2023				
	7659254	Feb 24, 2023	U-727			
	7659254*PED	Aug 24, 2023				
	7662787	Feb 24, 2023	DS			
	7662787*PED	Aug 24, 2023				
	7662788	Feb 24, 2023	U-727			
	7662788*PED	Aug 24, 2023				
	7671030	Feb 24, 2023	DP U-727			
	7671030*PED	Aug 24, 2023				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 005	7671031	Feb 24, 2023	U-727			
	7671031*PED	Aug 24, 2023				
	7674774	Feb 24, 2023	DP U-727			
	7674774*PED	Aug 24, 2023				
	7678770	Feb 24, 2023	U-727			
	7678770*PED	Aug 24, 2023				
	7678771	Feb 24, 2023	DP U-727			
	7678771*PED	Aug 24, 2023				
	7687466	Feb 24, 2023	DP			
	7687466*PED	Aug 24, 2023				
	7687467	Feb 24, 2023	DP U-727			
	7687467*PED	Aug 24, 2023				
	7713936	Feb 24, 2023	U-727			
	7713936*PED	Aug 24, 2023				
	7718619	Feb 24, 2023	DP U-727			
	7718619*PED	Aug 24, 2023				
	7723305	Feb 24, 2023	DP U-727			
	7723305*PED	Aug 24, 2023				
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 006	7105486	Feb 24, 2023	U-727			
	7105486*PED	Aug 24, 2023				
	7223735	Feb 24, 2023	DP			
	7223735*PED	Aug 24, 2023				
	7655630	Feb 24, 2023	DS DP			
	7655630*PED	Aug 24, 2023				
	7659253	Feb 24, 2023	DS DP U-727			
	7659253*PED	Aug 24, 2023				
	7659254	Feb 24, 2023	U-727			
	7659254*PED	Aug 24, 2023				
	7662787	Feb 24, 2023	DS			
	7662787*PED	Aug 24, 2023				
	7662788	Feb 24, 2023	U-727			
	7662788*PED	Aug 24, 2023				
	7671030	Feb 24, 2023	DP U-727			
	7671030*PED	Aug 24, 2023				
	7671031	Feb 24, 2023	U-727			
	7671031*PED	Aug 24, 2023				
	7674774	Feb 24, 2023	DP U-727			
	7674774*PED	Aug 24, 2023				
	7678770	Feb 24, 2023	U-727			
	7678770*PED	Aug 24, 2023				
	7678771	Feb 24, 2023	DP U-727			
	7678771*PED	Aug 24, 2023				
	7687466	Feb 24, 2023	DP			
	7687466*PED	Aug 24, 2023				
	7687467	Feb 24, 2023	DP U-727			
	7687467*PED	Aug 24, 2023				
	7713936	Feb 24, 2023	U-727			
	7713936*PED	Aug 24, 2023				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 208510 006	7718619	Feb 24, 2023	DP U-727			
	7718619*PED	Aug 24, 2023				
	7723305	Feb 24, 2023	DP U-727			
	7723305*PED	Aug 24, 2023				
<u>LISINOPRIL - OBRELIS</u>						
N 208401 001	10039800	Nov 06, 2035	U-1723			
	10039800	Nov 06, 2035	U-185			
	10039800	Nov 06, 2035	U-1864			
	10039800	Nov 06, 2035	U-1991			
	10039800	Nov 06, 2035	U-3			
	10039800	Nov 06, 2035	U-71			
	10039800	Nov 06, 2035	U-8			
	10265370	Nov 06, 2035	DP			
	10406199	Nov 06, 2035	U-1723			
	10406199	Nov 06, 2035	U-185			
	10406199	Nov 06, 2035	U-1864			
	10406199	Nov 06, 2035	U-1991			
	10406199	Nov 06, 2035	U-3			
	10406199	Nov 06, 2035	U-71			
	10406199	Nov 06, 2035	U-8			
	10940177	Nov 06, 2035	DP			
	11179434	Nov 06, 2035	DP			
	9463183	Nov 06, 2035	DP			
	9616096	Nov 06, 2035	U-1723			
	9616096	Nov 06, 2035	U-185			
	9616096	Nov 06, 2035	U-1864			
	9616096	Nov 06, 2035	U-1991			
	9616096	Nov 06, 2035	U-3			
	9616096	Nov 06, 2035	U-71			
	9616096	Nov 06, 2035	U-8			
	9814751	Nov 06, 2035	DP			
<u>LOFEXIDINE HYDROCHLORIDE - LUCEMYRA</u>						
N 209229 001					NCE	May 16, 2023
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 001	10016404	Mar 07, 2025	U-1316			
	10555938	Mar 07, 2025	U-1316			
	7932268	Aug 19, 2027	U-1316			
	8618135	Mar 07, 2025	U-1316			
	9265758	Mar 07, 2025	U-1316			
	9364470	Mar 07, 2025	U-1851			
	9433617	Mar 07, 2025	U-1316			
	9861622	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 002	10016404	Mar 07, 2025	U-1316			
	10555938	Mar 07, 2025	U-1316			
	7932268	Aug 19, 2027	U-1316			
	8618135	Mar 07, 2025	U-1316			
	9265758	Mar 07, 2025	U-1316			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 002	9364470	Mar 07, 2025	U-1851			
	9433617	Mar 07, 2025	U-1316			
	9861622	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 003	10016404	Mar 07, 2025	U-1316			
	10555938	Mar 07, 2025	U-1316			
	7932268	Aug 19, 2027	U-1316			
	8618135	Mar 07, 2025	U-1316			
	9265758	Mar 07, 2025	U-1316			
	9364470	Mar 07, 2025	U-1851			
	9433617	Mar 07, 2025	U-1316			
	9861622	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 004	10016404	Mar 07, 2025	U-1316			
	10555938	Mar 07, 2025	U-1316			
	7932268	Aug 19, 2027	U-1316			
	8618135	Mar 07, 2025	U-1316			
	9265758	Mar 07, 2025	U-1316			
	9364470	Mar 07, 2025	U-1851			
	9433617	Mar 07, 2025	U-1316			
	9861622	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 005	10016404	Mar 07, 2025	U-1316			
	10555938	Mar 07, 2025	U-1316			
	7932268	Aug 19, 2027	U-1316			
	8618135	Mar 07, 2025	U-1316			
	9265758	Mar 07, 2025	U-1316			
	9364470	Mar 07, 2025	U-1851			
	9433617	Mar 07, 2025	U-1316			
	9861622	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 006	10016404	Mar 07, 2025	U-1316			
	10555938	Mar 07, 2025	U-1316			
	7932268	Aug 19, 2027	U-1316			
	8618135	Mar 07, 2025	U-1316			
	9265758	Mar 07, 2025	U-1316			
	9364470	Mar 07, 2025	U-1851			
	9433617	Mar 07, 2025	U-1316			
	9861622	Mar 07, 2025	U-1316			
<u>LONAFARNIB - ZOKINVY</u>						
N 213969 001	7838531	Jul 26, 2024	U-3070		NCE	Nov 20, 2025
	8828356	Oct 17, 2023	U-3070		ODE-324	Nov 20, 2027
<u>LONAFARNIB - ZOKINVY</u>						
N 213969 002	7838531	Jul 26, 2024	U-3070		NCE	Nov 20, 2025
	8828356	Oct 17, 2023	U-3070		ODE-324	Nov 20, 2027

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LORAZEPAM - LOREEV XR</u>						
N 214826	001 8999393	Jan 08, 2034	DP U-3210			
<u>LORAZEPAM - LOREEV XR</u>						
N 214826	002 8999393	Jan 08, 2034	DP U-3210			
<u>LORAZEPAM - LOREEV XR</u>						
N 214826	003 8999393	Jan 08, 2034	DP U-3210			
<u>LORAZEPAM - LOREEV XR</u>						
N 214826	004 8999393	Jan 08, 2034	DP U-3210			
<u>LORLATINIB - LORBRENA</u>						
N 210868	001 10420749	Jul 27, 2036	DS DP U-2633		I-847	Mar 03, 2024
	10420749	Jul 27, 2036	DS DP U-3096		NCE	Nov 02, 2023
	11020376	Jul 27, 2036	DP		ODE-217	Nov 02, 2025
	11299500	Oct 04, 2038	DS		ODE-218	Nov 02, 2025
	8680111	Mar 05, 2033	DS DP		ODE-219	Nov 02, 2025
					ODE-349	Mar 03, 2028
<u>LORLATINIB - LORBRENA</u>						
N 210868	002 10420749	Jul 27, 2036	DS DP U-2633		I-847	Mar 03, 2024
	10420749	Jul 27, 2036	DS DP U-3096		NCE	Nov 02, 2023
	11020376	Jul 27, 2036	DP		ODE-217	Nov 02, 2025
	11299500	Oct 04, 2038	DS		ODE-218	Nov 02, 2025
	8680111	Mar 05, 2033	DS DP		ODE-219	Nov 02, 2025
					ODE-349	Mar 03, 2028
<u>LOTEPREDNOL ETABONATE - LOTEMAX SM</u>						
N 208219	001 10596107	Dec 23, 2036	DP U-2764			
<u>LOTEPREDNOL ETABONATE - INVELTYS</u>						
N 210565	001 10058511	May 03, 2033	DP U-2492			
	10646437	May 03, 2033	DP			
	10688045	May 03, 2033	DP			
	10864219	May 03, 2033	U-3011			
	11219597	May 03, 2033	U-3278			
	11219597	May 03, 2033	U-3279			
	9056057	May 03, 2033	DP U-2491			
	9393213	May 03, 2033	DP			
	9532955	May 03, 2033	U-2491			
	9737491	May 03, 2033	U-2492			
	9827191	May 03, 2033	DP U-2493			
<u>LOTEPREDNOL ETABONATE - EYSUVIS</u>						
N 210933	001 10058511	May 03, 2033	DP U-2492		NP	Oct 26, 2023
	10646436	May 03, 2033	DP			
	10688045	May 03, 2033	DP			
	10857096	May 03, 2033	U-2985			
	10940108	May 03, 2033	U-2985			
	10945948	May 03, 2033	U-2985			
	10993908	May 03, 2033	U-3117			
	11219596	May 03, 2033	U-2985			
	9056057	May 03, 2033	DP U-2491			
	9393213	May 03, 2033	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LOTEPREDNOL ETABONATE - EYSUVIS</u>						
N 210933 001	9532955	May 03, 2033	U-2491			
	9737491	May 03, 2033	U-2492			
	9827191	May 03, 2033	DP U-2985			
<u>LOXAPINE - ADASUVE</u>						
N 022549 001	7458374	Aug 18, 2024	DP			
	7537009	Oct 28, 2024	DP			
	8387612	Oct 23, 2026	DP			
	8991387	May 21, 2024	DP			
	9370629	May 20, 2024	DP			
<u>LUBIPROSTONE - AMITIZA</u>						
N 021908 001	8026393	Oct 25, 2027	DP			
	8338639	Jan 23, 2027	DP			
	8748481	Sep 01, 2025	U-1520			
	8779187	Jan 23, 2027	DP			
<u>LUBIPROSTONE - AMITIZA</u>						
N 021908 002	7795312	Sep 17, 2024	U-1085			
	8026393	Oct 25, 2027	DP			
	8338639	Jan 23, 2027	DP			
	8748481	Sep 01, 2025	U-1519			
	8779187	Jan 23, 2027	DP			
<u>LULICONAZOLE - LUZU</u>						
N 204153 001	8980931	Apr 28, 2034	DP			
	9012484	Sep 06, 2033	DS DP U-540			
	9199977	Sep 06, 2033	DS DP			
	9453006	Sep 06, 2033	DS			
<u>LUMASIRAN SODIUM - OXLUMO</u>						
N 214103 001	10131907	Aug 24, 2028	DS DP U-2995		I-901	Oct 06, 2025
	10435692	Dec 26, 2034	U-2995		NCE	Nov 23, 2025
	10465195	Dec 26, 2034	DS DP U-2995		ODE-339	Nov 23, 2027
	10478500	Oct 09, 2035	DS DP U-2995			
	10487330	Dec 26, 2034	DS DP U-2995			
	10612024	Aug 14, 2035	DS DP U-2995			
	10612027	Aug 14, 2035	DS DP U-2995			
	11060093	Dec 26, 2034	DS DP U-2995			
	11261447	Nov 20, 2038	DS DP U-2995			
	11401517	Aug 14, 2035	DS DP U-2995			
	11446380	Oct 09, 2035	DS DP			
	8106022	Dec 12, 2029	DS DP U-2995			
	8828956	Dec 04, 2028	DS DP U-2995			
	9828606	Dec 26, 2034	DS DP			
<u>LUMATEPERONE TOSYLATE - CAPLYTA</u>						
N 209500 001	10117867	May 27, 2029	U-3271		I-882	Dec 17, 2024
	10464938	Mar 12, 2028	DP		NCE	Dec 20, 2024
	10695345	Aug 30, 2039	DP U-543			
	10960009	Dec 03, 2034	U-814			
	11026951	Dec 03, 2034	U-3274			
	8598119	Dec 28, 2029	U-543			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LUMATEPERONE TOSYLATE - CAPLYTA</u>						
N 209500 001	8648077	Dec 01, 2029	DS DP			
	9199995	Mar 12, 2029	U-2713			
	9586960	Mar 12, 2029	DS DP			
	9616061	May 27, 2029	DP			
	9956227	Dec 03, 2034	U-2714			
	RE48825	Mar 12, 2029	DS DP			
	RE48839	Dec 28, 2029	U-3271			
	RE48839	Dec 28, 2029	U-814			
<u>LUMATEPERONE TOSYLATE - CAPLYTA</u>						
N 209500 002	10117867	May 27, 2029	U-3271		NCE	Dec 20, 2024
	10464938	Mar 12, 2028	DP			
	10695345	Aug 30, 2039	DP U-814			
	11026951	Dec 03, 2034	U-3364			
	11052084	Aug 30, 2039	DP U-3362			
	11052084	Aug 30, 2039	DP U-3363			
	8648077	Dec 01, 2029	DS DP			
	9199995	Mar 12, 2029	U-2713			
	9616061	May 27, 2029	DP			
	9956227	Dec 03, 2034	U-2714			
	RE48825	Feb 12, 2029	DS			
	RE48839	Dec 28, 2029	U-3271			
	RE48839	Dec 28, 2029	U-814			
<u>LUMATEPERONE TOSYLATE - CAPLYTA</u>						
N 209500 003	10117867	May 27, 2029	U-3271		NCE	Dec 20, 2024
	10464938	Mar 12, 2028	DP			
	10695345	Aug 30, 2039	DP U-814			
	11026951	Dec 03, 2034	U-3364			
	11052084	Aug 30, 2039	DP U-3362			
	11052084	Aug 30, 2039	DP U-3363			
	8648077	Dec 01, 2029	DS DP			
	9199995	Mar 12, 2029	U-2713			
	9616061	May 27, 2029	DP			
	9956227	Dec 03, 2034	U-2714			
	RE48825	Feb 12, 2029	DS			
	RE48839	Dec 28, 2029	U-3271			
	RE48839	Dec 28, 2029	U-814			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 001	8729085	May 26, 2026	DP			
	8729085*PED	Nov 26, 2026				
	8883794	May 26, 2026	DP			
	8883794*PED	Nov 26, 2026				
	9174975	Feb 20, 2024	U-1770			
	9174975*PED	Aug 20, 2024				
	9259423	May 23, 2031	U-1822			
	9259423*PED	Nov 23, 2031				
	9555027	May 26, 2026	DP U-543			
	9815827	Feb 20, 2024	U-2166			
	9815827	Feb 20, 2024	U-543			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 001	9827242	May 23, 2031	U-2199			
	9827242	May 23, 2031	U-2201			
	9907794	May 26, 2026	DP			
	RE45573	Jun 23, 2025	DS			
	RE45573*PED	Dec 23, 2025				
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 002	8729085	May 26, 2026	DP			
	8729085*PED	Nov 26, 2026				
	8883794	May 26, 2026	DP			
	8883794*PED	Nov 26, 2026				
	9174975	Feb 20, 2024	U-1770			
	9174975*PED	Aug 20, 2024				
	9259423	May 23, 2031	U-1822			
	9259423*PED	Nov 23, 2031				
	9555027	May 26, 2026	DP U-543			
	9815827	Feb 20, 2024	U-2166			
	9815827	Feb 20, 2024	U-543			
	9827242	May 23, 2031	U-2199			
	9827242	May 23, 2031	U-2201			
	9907794	May 26, 2026	DP			
	RE45573	Jun 23, 2025	DS			
	RE45573*PED	Dec 23, 2025				
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 003	8729085	May 26, 2026	DP			
	8729085*PED	Nov 26, 2026				
	8883794	May 26, 2026	DP			
	8883794*PED	Nov 26, 2026				
	9174975	Feb 20, 2024	U-1770			
	9174975*PED	Aug 20, 2024				
	9259423	May 23, 2031	U-1822			
	9259423*PED	Nov 23, 2031				
	9555027	May 26, 2026	DP U-543			
	9815827	Feb 20, 2024	U-2166			
	9815827	Feb 20, 2024	U-543			
	9827242	May 23, 2031	U-2199			
	9827242	May 23, 2031	U-2201			
	9907794	May 26, 2026	DP			
	RE45573	Jun 23, 2025	DS			
	RE45573*PED	Dec 23, 2025				
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 004	8729085	May 26, 2026	DP			
	8729085*PED	Nov 26, 2026				
	8883794	May 26, 2026	DP			
	8883794*PED	Nov 26, 2026				
	9174975	Feb 20, 2024	U-1770			
	9174975*PED	Aug 20, 2024				
	9259423	May 23, 2031	U-1822			
	9259423*PED	Nov 23, 2031				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 004	9555027	May 26, 2026	DP U-543			
	9815827	Feb 20, 2024	U-2166			
	9815827	Feb 20, 2024	U-543			
	9827242	May 23, 2031	U-2199			
	9827242	May 23, 2031	U-2201			
	9907794	May 26, 2026	DP			
	RE45573	Jun 23, 2025	DS			
	RE45573*PED	Dec 23, 2025				
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 005	8729085	May 26, 2026	DP			
	8729085*PED	Nov 26, 2026				
	8883794	May 26, 2026	DP			
	8883794*PED	Nov 26, 2026				
	9174975	Feb 20, 2024	U-1770			
	9174975*PED	Aug 20, 2024				
	9259423	May 23, 2031	U-1822			
	9259423*PED	Nov 23, 2031				
	9555027	May 26, 2026	DP U-543			
	9815827	Feb 20, 2024	U-2166			
	9815827	Feb 20, 2024	U-543			
	9827242	May 23, 2031	U-2199			
	9827242	May 23, 2031	U-2201			
	9907794	May 26, 2026	DP			
	RE45573	Jun 23, 2025	DS			
	RE45573*PED	Dec 23, 2025				
<u>LURBINECTEDIN - ZEPZELCA</u>						
N 213702 001	7763615	Dec 13, 2024	DS DP U-2836		NCE ODE-304	Jun 15, 2025 Jun 15, 2027
<u>LUSUTROMBOPAG - MULPLETA</u>						
N 210923 001	7601746	Sep 05, 2024	DS DP U-2344		NCE	Jul 31, 2023
	8530668	Jan 21, 2030	DS DP			
	8889722	Jul 29, 2028	DS DP			
	9427402	Sep 29, 2031	DP			
<u>LUTETIUM LU 177 DOTATATE - LUTATHERA</u>						
N 208700 001	10596276	Jul 25, 2038	DP		NCE	Jan 26, 2023
	10596278	Jul 25, 2038	DP		ODE-166	Jan 26, 2025
<u>LUTETIUM LU-177 VIPIVOTIDE TETRAKETAN - PLUVICTO</u>						
N 215833 001	10398791	Oct 17, 2034	DS DP		NCE	Mar 23, 2027
	10406240	Aug 15, 2028	DS DP U-3345			
	11318121	Aug 15, 2028	DS DP U-3345			
<u>MACIMORELIN ACETATE - MACRILEN</u>						
N 205598 001	8192719	Oct 12, 2027	U-2220		ODE-170	Dec 20, 2024
<u>MACITENTAN - ORSUMIT</u>						
N 204410 001	10946015	Sep 11, 2026	DP U-1445			
	7094781	Dec 05, 2025	DS DP			
	8268847	Apr 18, 2029	U-1446			
	8367685	Oct 04, 2028	DP U-1445			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>MACITENTAN - OPSUMIT</u>						
N 204410	001 9265762	May 29, 2027	DP U-1820			
<u>MAGNESIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE - NORMOCARB HF 25</u>						
N 021910	001 7300674	Mar 04, 2023	DP U-785			
<u>MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM SULFATE - SUTAB</u>						
N 213135	001 10143656	Aug 04, 2037	DP		NP	Nov 10, 2023
	11033498	Aug 04, 2037	U-3164			
	11382864	Aug 04, 2037	U-3164			
<u>MAGNESIUM SULFATE; POTASSIUM SULFATE; SODIUM SULFATE - SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE</u>						
A 202511	001				PC	Mar 06, 2023
<u>MAGNESIUM SULFATE; POTASSIUM SULFATE; SODIUM SULFATE - SUPREP BOWEL PREP KIT</u>						
N 022372	001 6946149	Mar 07, 2023	DP U-837		ODE-315	Aug 05, 2027
<u>MALATHION - OVIDE</u>						
N 018613	001 7560445	Feb 01, 2027	DS DP U-986			
	7977324	Aug 14, 2026	DP			
<u>MANNITOL - BRONCHITOL</u>						
N 202049	001				NP	Oct 30, 2023
					ODE-327	Oct 30, 2027
<u>MARALIXIBAT CHLORIDE - LIVMARLI</u>						
N 214662	001 11229647	Feb 12, 2040	U-3290		NCE	Sep 29, 2026
	11260053	May 26, 2031	U-3290		ODE-379	Sep 29, 2028
	11376251	Oct 26, 2032	U-3290			
	11497745	Feb 12, 2040	U-3290			
<u>MARAVIROC - SELZENTRY</u>						
N 022128	001 7368460*PED	May 25, 2023				
<u>MARAVIROC - SELZENTRY</u>						
N 022128	002 7368460*PED	May 25, 2023				
<u>MARAVIROC - SELZENTRY</u>						
N 022128	003 7368460*PED	May 25, 2023				
<u>MARAVIROC - SELZENTRY</u>						
N 022128	004 7368460*PED	May 25, 2023				
<u>MARAVIROC - SELZENTRY</u>						
N 208984	001 7368460*PED	May 25, 2023			NPP	Oct 30, 2023
					PED	Apr 30, 2024
<u>MARIBAVIR - LIVTENCITY</u>						
N 215596	001				NCE	Nov 23, 2026
<u>MAVACAMTEN - CAMZYOS</u>						
N 214998	001 9181200	Jun 19, 2034	DS DP		NCE	Apr 28, 2027
	9585883	Jun 19, 2034	U-3373			
<u>MAVACAMTEN - CAMZYOS</u>						
N 214998	002 9181200	Jun 19, 2034	DS DP		NCE	Apr 28, 2027
	9585883	Jun 19, 2034	U-3373			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>MAVACAMTEN - CAMZYOS</u>						
N 214998 003	9181200	Jun 19, 2034	DS DP		NCE	Apr 28, 2027
	9585883	Jun 19, 2034	U-3373			
<u>MAVACAMTEN - CAMZYOS</u>						
N 214998 004	9181200	Jun 19, 2034	DS DP		NCE	Apr 28, 2027
	9585883	Jun 19, 2034	U-3373			
<u>MECHLORETHAMINE HYDROCHLORIDE - VALCHLOR</u>						
N 202317 001	7838564	Mar 07, 2026	DP			
	7872050	Jul 08, 2029	U-1427			
	8450375	Mar 07, 2026	DP			
	8501818	Mar 07, 2026	DP			
	8501819	Mar 07, 2026	U-1427			
	9382191	Mar 07, 2026	DP			
<u>MEGESTROL ACETATE - MEGACE ES</u>						
N 021778 001	7101576	Apr 22, 2024	U-755			
	9040088	Apr 22, 2024	U-755			
	9101540	Apr 22, 2024	DP U-755			
	9101549	Apr 22, 2024	U-755			
	9107827	Apr 22, 2024	U-755			
<u>MELOXICAM - VIVLODEX</u>						
N 207233 001	9526734	Mar 31, 2033	DP			
	9649318	Mar 31, 2035	DP			
	9808468	Mar 31, 2035	U-2160			
	9808468	Mar 31, 2035	U-2165			
<u>MELOXICAM - VIVLODEX</u>						
N 207233 002	9526734	Mar 31, 2033	DP			
	9649318	Mar 31, 2035	DP			
	9808468	Mar 31, 2035	U-2160			
	9808468	Mar 31, 2035	U-2165			
<u>MELOXICAM - ANJESO</u>						
N 210583 001	10463673	Feb 24, 2024	DP U-2750		NP	Feb 20, 2023
	10471067	Feb 24, 2024	DP U-2750			
	10709713	May 26, 2030	U-2750			
	10881663	Mar 08, 2039	U-3038			
	11253478	May 26, 2030	DP U-3318			
	11458145	Mar 08, 2039	U-3318			
	9974746	May 26, 2030	DP			
<u>MELOXICAM - OMIIZ ODT</u>						
N 211210 001	8545879	Aug 31, 2030	DP			
<u>MELOXICAM - OMIIZ ODT</u>						
N 211210 002	8545879	Aug 31, 2030	DP			
<u>MELPHALAN FLUFENAMIDE HYDROCHLORIDE - PEPAXTO</u>						
N 214383 001	10285946	Apr 25, 2032	DP		NCE	Feb 26, 2026
	10322182	Apr 25, 2032	DP		ODE-348	Feb 26, 2028
	10543274	Apr 25, 2032	U-3093			
	10869928	Apr 25, 2032	DP			
	11344622	Apr 25, 2032	U-3093			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>MELPHALAN FLUFENAMIDE HYDROCHLORIDE - PEPAXTO</u>						
N 214383 001	6992207	Jun 25, 2023	DS DP U-3093			
<u>MELPHALAN HYDROCHLORIDE - EVOMELA</u>						
N 207155 001	10040872	Jan 30, 2034	DP		ODE-110	Mar 10, 2023
	10864183	May 28, 2030	DP			
	10940128	Jun 14, 2030	DP U-3086			
	11020363	May 28, 2030	DP			
	8410077	Mar 13, 2029	DP			
	9200088	Mar 13, 2029	DP			
	9493582	Feb 27, 2033	DP			
<u>MEMANTINE HYDROCHLORIDE - NAMENDA XR</u>						
N 022525 001	8039009	Mar 24, 2029	U-539			
	8039009*PED	Sep 24, 2029				
<u>MEMANTINE HYDROCHLORIDE - NAMENDA XR</u>						
N 022525 002	8039009	Mar 24, 2029	U-539			
	8039009*PED	Sep 24, 2029				
<u>MEMANTINE HYDROCHLORIDE - NAMENDA XR</u>						
N 022525 003	8039009	Mar 24, 2029	U-539			
	8039009*PED	Sep 24, 2029				
<u>MEMANTINE HYDROCHLORIDE - NAMENDA XR</u>						
N 022525 004	8039009	Mar 24, 2029	U-539			
	8039009*PED	Sep 24, 2029				
<u>MENTHOL; METHYL SALICYLATE - SALONPAS</u>						
N 022029 001	8809615	Jan 03, 2030	DP			
	9233184	Aug 01, 2027	DP			
<u>MENTHOL; METHYL SALICYLATE - SALONPAS</u>						
N 022029 002	8809615	Jan 03, 2030	DP			
	9233184	Aug 01, 2027	DP			
<u>MEROPENEM; VABORBACTAM - VABOMERE</u>						
N 209776 001	10172874	Aug 08, 2031	DP		NCE	Aug 29, 2022
	10183034	Aug 08, 2031	U-2490		GAIN	Aug 29, 2027
	10561675	Aug 08, 2031	U-2490			
	11007206	Aug 08, 2031	U-3128			
	11376237	Apr 06, 2039	U-3421			
	8680136	Aug 29, 2031	DS DP			
	9694025	Aug 08, 2031	U-2120			
<u>MESALAMINE - SFROWASA</u>						
N 019618 002	7645801	Jul 24, 2027	DS DP			
<u>MESALAMINE - CANASA</u>						
N 021252 002	8217083	Jun 06, 2028	DP			
	8436051	Jun 06, 2028	DP			
<u>MESALAMINE - LIALDA</u>						
N 022000 001					NPP	Jun 26, 2023
<u>MESALAMINE - APRISO</u>						
N 022301 001	8865688	May 01, 2030	U-1310			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>METAXALONE - SKELAXIN</u>						
N 013217	003 7122566	Feb 06, 2026	U-915			
<u>METFORMIN HYDROCHLORIDE - GLUMETZA</u>						
N 021748	002 7780987	Mar 23, 2025	DS DP			
	8323692	Mar 30, 2023	DP			
<u>METFORMIN HYDROCHLORIDE - RIOMET ER</u>						
N 212595	001 9962336	May 01, 2035	DP			
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET</u>						
N 021842	001 9101660	Jan 22, 2027	DP			
	9320714	Feb 03, 2029	DP			
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET</u>						
N 021842	002 9101660	Jan 22, 2027	DP			
	9320714	Feb 03, 2029	DP			
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET XR</u>						
N 022024	001 7785627	Jul 31, 2026	DP			
	7959946	Jul 31, 2026	DP			
	8470368	Sep 19, 2023	DP			
	8668931	Sep 19, 2023	DP			
	9060941	Sep 19, 2023	DP			
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET XR</u>						
N 022024	002 7785627	Jul 31, 2026	DP			
	7959946	Jul 31, 2026	DP			
	8470368	Sep 19, 2023	DP			
	8668931	Sep 19, 2023	DP			
	9060941	Sep 19, 2023	DP			
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678	001 8628799	Jul 13, 2025	DP			
	9339472	Jul 13, 2025	DP			
	RE44186	Jul 31, 2023	DS DP U-1097			
	RE44186	Jul 31, 2023	DS DP U-1838			
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678	002 8628799	Jul 13, 2025	DP			
	9339472	Jul 13, 2025	DP			
	RE44186	Jul 31, 2023	DS DP U-1097			
	RE44186	Jul 31, 2023	DS DP U-1838			
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678	003 8628799	Jul 13, 2025	DP			
	9339472	Jul 13, 2025	DP			
	RE44186	Jul 31, 2023	DS DP U-1097			
	RE44186	Jul 31, 2023	DS DP U-1838			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET</u>						
N 022044	001 6699871*PED	Jan 26, 2023			M-187	Dec 04, 2023
	7125873*PED	Jan 26, 2023			PED	Jun 04, 2024
	7326708	Nov 24, 2026	DS DP U-802			
	7326708*PED	May 24, 2027				
	8414921	Jul 21, 2028	DP U-1036			
	8414921*PED	Jan 21, 2029				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET</u>						
N 022044 001	6699871*PED	Jan 26, 2023			M-187	Dec 04, 2023
	7125873*PED	Jan 26, 2023			PED	Jun 04, 2024
	7326708	Nov 24, 2026	DS DP U-802			
	7326708*PED	May 24, 2027				
	8414921	Jul 21, 2028	DP U-1036			
	8414921*PED	Jan 21, 2029				
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET</u>						
N 022044 002	6699871*PED	Jan 26, 2023			M-187	Dec 04, 2023
	7125873*PED	Jan 26, 2023			PED	Jun 04, 2024
	7326708	Nov 24, 2026	DS DP U-802			
	7326708*PED	May 24, 2027				
	8414921	Jul 21, 2028	DP U-1036			
	8414921*PED	Jan 21, 2029				
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270 001	6699871*PED	Jan 26, 2023			M-187	Dec 04, 2023
	7125873*PED	Jan 26, 2023			PED	Jun 04, 2024
	7326708	Nov 24, 2026	DS DP U-1227			
	7326708*PED	May 24, 2027				
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270 002	6699871*PED	Jan 26, 2023			M-187	Dec 04, 2023
	7125873*PED	Jan 26, 2023			PED	Jun 04, 2024
	7326708	Nov 24, 2026	DS DP U-1227			
	7326708*PED	May 24, 2027				
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270 003	6699871*PED	Jan 26, 2023				
	7125873*PED	Jan 26, 2023				
	7326708	Nov 24, 2026	DS DP U-1227			
	7326708*PED	May 24, 2027				
<u>METHOTREXATE - OTREXUP</u>						
N 204824 001	10709844	Mar 10, 2029	DP			
	11446441	Jan 24, 2026	DP			
	11497753	Mar 19, 2030	DP			
	8021335	Oct 04, 2026	DP			
	8480631	Mar 19, 2030	DP U-1442			
	8562564	Jan 24, 2026	DP			
	8579865	Mar 19, 2030	DP U-1442			
	8814834	May 27, 2031	DP			
	8945063	Mar 19, 2030	DP U-1442			
	9421333	Mar 19, 2030	DP U-1442			
	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
	9867949	Mar 10, 2029	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 002	10709844	Mar 10, 2029	DP			
	11446441	Jan 24, 2026	DP			
	11497753	Mar 19, 2030	DP			
	8021335	Oct 04, 2026	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>METHOTREXATE - OTREXUP</u>						
N 204824 002	8480631	Mar 19, 2030	DP U-1442			
	8562564	Jan 24, 2026	DP			
	8579865	Mar 19, 2030	DP U-1442			
	8814834	May 27, 2031	DP			
	8945063	Mar 19, 2030	DP U-1442			
	9421333	Mar 19, 2030	DP U-1442			
	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
	9867949	Mar 10, 2029	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 003	10709844	Mar 10, 2029	DP			
	11446441	Jan 24, 2026	DP			
	11497753	Mar 19, 2030	DP			
	8021335	Oct 04, 2026	DP			
	8480631	Mar 19, 2030	DP U-1442			
	8562564	Jan 24, 2026	DP			
	8579865	Mar 19, 2030	DP U-1442			
	8814834	May 27, 2031	DP			
	8945063	Mar 19, 2030	DP U-1442			
	9421333	Mar 19, 2030	DP U-1442			
	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
	9867949	Mar 10, 2029	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 004	10709844	Mar 10, 2029	DP			
	11446441	Jan 24, 2026	DP			
	11497753	Mar 19, 2030	DP			
	8021335	Oct 04, 2026	DP			
	8480631	Mar 19, 2030	DP U-1442			
	8562564	Jan 24, 2026	DP			
	8579865	Mar 19, 2030	DP U-1442			
	8814834	May 27, 2031	DP			
	8945063	Mar 19, 2030	DP U-1442			
	9421333	Mar 19, 2030	DP U-1442			
	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
	9867949	Mar 10, 2029	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 005	10709844	Mar 10, 2029	DP			
	11446441	Jan 24, 2026	DP			
	11497753	Mar 19, 2030	DP			
	8021335	Oct 04, 2026	DP			
	8480631	Mar 19, 2030	DP U-1442			
	8562564	Jan 24, 2026	DP			
	8579865	Mar 19, 2030	DP U-1442			
	8814834	May 27, 2031	DP			
	8945063	Mar 19, 2030	DP U-1442			
	9421333	Mar 19, 2030	DP U-1442			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METHOTREXATE - OTREXUP</u>						
N 204824 005	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
	9867949	Mar 10, 2029	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 006	10709844	Mar 10, 2029	DP			
	11446441	Jan 24, 2026	DP			
	11497753	Mar 19, 2030	DP			
	8021335	Oct 04, 2026	DP			
	8480631	Mar 19, 2030	DP U-1442			
	8562564	Jan 24, 2026	DP			
	8579865	Mar 19, 2030	DP U-1442			
	8814834	May 27, 2031	DP			
	8945063	Mar 19, 2030	DP U-1442			
	9421333	Mar 19, 2030	DP U-1442			
	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
	9867949	Mar 10, 2029	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 007	10709844	Mar 10, 2029	DP			
	11446441	Jan 24, 2026	DP			
	11497753	Mar 19, 2030	DP			
	8021335	Oct 04, 2026	DP			
	8480631	Mar 19, 2030	DP U-1442			
	8562564	Jan 24, 2026	DP			
	8579865	Mar 19, 2030	DP U-1442			
	8814834	May 27, 2031	DP			
	8945063	Mar 19, 2030	DP U-1442			
	9421333	Mar 19, 2030	DP U-1442			
	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
	9867949	Mar 10, 2029	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 008	10709844	Mar 10, 2029	DP			
	11446441	Jan 24, 2026	DP			
	11497753	Mar 19, 2030	DP			
	8021335	Oct 04, 2026	DP			
	8480631	Mar 19, 2030	DP U-1442			
	8562564	Jan 24, 2026	DP			
	8579865	Mar 19, 2030	DP U-1442			
	8814834	May 27, 2031	DP			
	8945063	Mar 19, 2030	DP U-1442			
	9421333	Mar 19, 2030	DP U-1442			
	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
	9867949	Mar 10, 2029	DP			
<u>METHOTREXATE - RASUVO</u>						
N 205776 001	8664231	Jun 01, 2029	U-1442			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>METHOTREXATE - RASUVO</u>						
N 205776 002	8664231	Jun 01, 2029	U-1442			
<u>METHOTREXATE - RASUVO</u>						
N 205776 003	8664231	Jun 01, 2029	U-1442			
<u>METHOTREXATE - RASUVO</u>						
N 205776 004	8664231	Jun 01, 2029	U-1442			
<u>METHOTREXATE - RASUVO</u>						
N 205776 005	8664231	Jun 01, 2029	U-1442			
<u>METHOTREXATE - RASUVO</u>						
N 205776 006	8664231	Jun 01, 2029	U-1442			
<u>METHOTREXATE - RASUVO</u>						
N 205776 007	8664231	Jun 01, 2029	U-1442			
<u>METHOTREXATE - RASUVO</u>						
N 205776 008	8664231	Jun 01, 2029	U-1442			
<u>METHOTREXATE - RASUVO</u>						
N 205776 009	8664231	Jun 01, 2029	U-1442			
<u>METHOTREXATE - RASUVO</u>						
N 205776 010	8664231	Jun 01, 2029	U-1442			
<u>METHOTREXATE SODIUM - XATMEP</u>						
N 208400 001	10231927	Jan 02, 2033	U-1349		ODE-137	Apr 25, 2024
	10231927	Jan 02, 2033	U-1699		ODE-138	Apr 25, 2024
	10610485	Jan 02, 2033	DP			
	11116724	Jan 02, 2033	U-1349			
	11116724	Jan 02, 2033	U-1699			
	9259427	Jan 02, 2033	DP			
	9855215	Jan 02, 2033	DP			
<u>METHYLENE BLUE - PROVAYBLUE</u>						
N 204630 001					ODE-113	Apr 08, 2023
<u>METHYLENE BLUE - PROVAYBLUE</u>						
N 204630 002					ODE*	Apr 08, 2023
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 021964 001	10376584	Apr 08, 2024	DP U-1185			
	8247425	Dec 31, 2030	U-1185			
	8420663	Sep 30, 2029	U-1185			
	8552025	Apr 08, 2024	DP			
	8822490	Sep 30, 2029	DP U-1185			
	9180125	Sep 30, 2029	DP U-1185			
	9492445	Sep 30, 2029	DP U-1185			
	9669096	Apr 08, 2024	DP			
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 021964 002	10376584	Apr 08, 2024	DP U-1185			
	8247425	Dec 31, 2030	U-1185			
	8420663	Sep 30, 2029	U-1185			
	8552025	Apr 08, 2024	DP			
	8822490	Sep 30, 2029	DP U-1185			
	9180125	Sep 30, 2029	DP U-1185			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 021964 002	9492445	Sep 30, 2029	DP U-1185			
	9669096	Apr 08, 2024	DP			
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 021964 003	10376584	Apr 08, 2024	DP U-1185			
	8247425	Dec 31, 2030	U-1185			
	8420663	Sep 30, 2029	U-1185			
	8552025	Apr 08, 2024	DP			
	8822490	Sep 30, 2029	DP U-1185			
	9180125	Sep 30, 2029	DP U-1185			
	9492445	Sep 30, 2029	DP U-1185			
	9669096	Apr 08, 2024	DP			
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 208271 001	10307417	Mar 10, 2031	DP			
	10376505	Mar 10, 2031	DP			
	8420663	Sep 30, 2029	U-1185			
	8524276	Mar 10, 2031	DP			
	8956651	Mar 10, 2031	DP			
	9180125	Sep 30, 2029	DP U-1185			
	9314461	Mar 10, 2031	DP			
	9492445	Sep 30, 2029	DP U-1185			
	9724343	Sep 30, 2029	DP U-1185			
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514 001	8632802	Oct 07, 2025	DP			
	9034370	Oct 07, 2025	DP			
	9668981	Oct 07, 2025	U-2024			
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514 002	8632802	Oct 07, 2025	DP			
	9034370	Oct 07, 2025	DP			
	9668981	Oct 07, 2025	U-2024			
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514 003	8632802	Oct 07, 2025	DP			
	9034370	Oct 07, 2025	DP			
	9668981	Oct 07, 2025	U-2024			
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514 004	8632802	Oct 07, 2025	DP			
	9034370	Oct 07, 2025	DP			
	9668981	Oct 07, 2025	U-2024			
<u>METHYLPHENIDATE - COTEMPLA XR-ODT</u>						
N 205489 001	11166947	Jan 25, 2038	U-3299			
	8840924	Jun 05, 2026	DP			
	9072680	Jun 28, 2032	DP			
	9089496	Jun 28, 2032	DP			
<u>METHYLPHENIDATE - COTEMPLA XR-ODT</u>						
N 205489 002	11166947	Jan 25, 2038	U-3299			
	8840924	Jun 05, 2026	DP			
	9072680	Jun 28, 2032	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLPHENIDATE - COTEMPLA XR-ODT</u>						
N 205489 002	9089496	Jun 28, 2032	DP			
<u>METHYLPHENIDATE - COTEMPLA XR-ODT</u>						
N 205489 003	11166947	Jan 25, 2038	U-3299			
	8840924	Jun 05, 2026	DP			
	9072680	Jun 28, 2032	DP			
	9089496	Jun 28, 2032	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - METHYLIN</u>						
N 021419 001	7691880	Oct 07, 2024	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - METHYLIN</u>						
N 021419 002	7691880	Oct 07, 2024	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLIVANT XR</u>						
N 202100 001	8062667	Mar 29, 2029	DP			
	8287903	Feb 15, 2031	DP			
	8465765	Feb 15, 2031	DP U-1415			
	8563033	Feb 15, 2031	DP U-1415			
	8778390	Feb 15, 2031	DP U-1543			
	8956649	Feb 15, 2031	DP U-1665			
	9040083	Feb 15, 2031	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER</u>						
N 207960 001	10857143	Aug 14, 2033	DP U-2993			
	11103494	Aug 14, 2033	DP			
	11103495	Aug 14, 2033	DP U-2993			
	8202537	Mar 15, 2027	DP			
	8287903	Feb 15, 2031	DP			
	8999386	Aug 14, 2033	DP			
	9295642	Aug 14, 2033	DP U-1827			
	9545399	Aug 14, 2033	DP U-1827			
	9844544	Aug 14, 2033	DP U-2203			
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER</u>						
N 207960 002	10857143	Aug 14, 2033	DP U-2993			
	11103494	Aug 14, 2033	DP			
	11103495	Aug 14, 2033	DP U-2993			
	8202537	Mar 15, 2027	DP			
	8287903	Feb 15, 2031	DP			
	8999386	Aug 14, 2033	DP			
	9295642	Aug 14, 2033	DP U-1827			
	9545399	Aug 14, 2033	DP U-1827			
	9844544	Aug 14, 2033	DP U-2203			
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER</u>						
N 207960 003	10857143	Aug 14, 2033	DP U-2993			
	11103494	Aug 14, 2033	DP			
	11103495	Aug 14, 2033	DP U-2993			
	8202537	Mar 15, 2027	DP			
	8287903	Feb 15, 2031	DP			
	8999386	Aug 14, 2033	DP			
	9295642	Aug 14, 2033	DP U-1827			
	9545399	Aug 14, 2033	DP U-1827			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER</u>						
N 207960 003	9844544	Aug 14, 2033	DP U-2203			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 001	10182995	Mar 23, 2032	DP			
	10292937	Mar 23, 2032	U-2357			
	10617651	Mar 23, 2032	U-2357			
	10881618	Mar 23, 2032	U-2357			
	10905652	Mar 23, 2032	DP			
	11241391	Mar 23, 2032	U-2357			
	11241392	Mar 23, 2032	DP			
	8916588	Mar 23, 2032	U-2357			
	8927010	Mar 23, 2032	DP			
	9023389	Mar 23, 2032	DP			
	9028868	Mar 23, 2032	U-2357			
	9034902	Mar 23, 2032	U-2357			
	9283214	Mar 23, 2032	DP			
	9498447	Mar 23, 2032	DP			
	9603809	Mar 23, 2032	U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 002	10182995	Mar 23, 2032	DP			
	10292937	Mar 23, 2032	U-2357			
	10617651	Mar 23, 2032	U-2357			
	10881618	Mar 23, 2032	U-2357			
	10905652	Mar 23, 2032	DP			
	11241391	Mar 23, 2032	U-2357			
	11241392	Mar 23, 2032	DP			
	8916588	Mar 23, 2032	U-2357			
	8927010	Mar 23, 2032	DP			
	9023389	Mar 23, 2032	DP			
	9028868	Mar 23, 2032	U-2357			
	9034902	Mar 23, 2032	U-2357			
	9283214	Mar 23, 2032	DP			
	9498447	Mar 23, 2032	DP			
	9603809	Mar 23, 2032	U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 003	10182995	Mar 23, 2032	DP			
	10292937	Mar 23, 2032	U-2357			
	10617651	Mar 23, 2032	U-2357			
	10881618	Mar 23, 2032	U-2357			
	10905652	Mar 23, 2032	DP			
	11241391	Mar 23, 2032	U-2357			
	11241392	Mar 23, 2032	DP			
	8916588	Mar 23, 2032	U-2357			
	8927010	Mar 23, 2032	DP			
	9023389	Mar 23, 2032	DP			
	9028868	Mar 23, 2032	U-2357			
	9034902	Mar 23, 2032	U-2357			
	9283214	Mar 23, 2032	DP			
	9498447	Mar 23, 2032	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 003	9603809	Mar 23, 2032	U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 004	10182995	Mar 23, 2032	DP			
	10292937	Mar 23, 2032	U-2357			
	10617651	Mar 23, 2032	U-2357			
	10881618	Mar 23, 2032	U-2357			
	10905652	Mar 23, 2032	DP			
	11241391	Mar 23, 2032	U-2357			
	11241392	Mar 23, 2032	DP			
	8916588	Mar 23, 2032	U-2357			
	8927010	Mar 23, 2032	DP			
	9023389	Mar 23, 2032	DP			
	9028868	Mar 23, 2032	U-2357			
	9034902	Mar 23, 2032	U-2357			
	9283214	Mar 23, 2032	DP			
	9498447	Mar 23, 2032	DP			
	9603809	Mar 23, 2032	U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 005	10182995	Mar 23, 2032	DP			
	10292937	Mar 23, 2032	U-2357			
	10617651	Mar 23, 2032	U-2357			
	10881618	Mar 23, 2032	U-2357			
	10905652	Mar 23, 2032	DP			
	11241391	Mar 23, 2032	U-2357			
	11241392	Mar 23, 2032	DP			
	8916588	Mar 23, 2032	U-2357			
	8927010	Mar 23, 2032	DP			
	9023389	Mar 23, 2032	DP			
	9028868	Mar 23, 2032	U-2357			
	9034902	Mar 23, 2032	U-2357			
	9283214	Mar 23, 2032	DP			
	9498447	Mar 23, 2032	DP			
	9603809	Mar 23, 2032	U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 001	10111839	Oct 30, 2035	U-2357		M-82	Jun 28, 2024
	10292938	Oct 30, 2035	DP			
	10292939	Oct 30, 2035	DP U-2357			
	10449159	Oct 30, 2035	U-2357			
	10500162	Oct 30, 2035	U-2357			
	10507186	Oct 30, 2035	DP			
	10512612	Oct 30, 2035	DP			
	10512613	Oct 30, 2035	U-2357			
	10568841	Oct 30, 2035	DP U-2357			
	10688060	Oct 30, 2035	DP			
	10722473	Nov 19, 2038	U-2357			
	9974752	Oct 30, 2035	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 002	10111839	Oct 30, 2035	U-2357		M-82	Jun 28, 2024
	10292938	Oct 30, 2035	DP			
	10292939	Oct 30, 2035	DP U-2357			
	10449159	Oct 30, 2035	U-2357			
	10500162	Oct 30, 2035	U-2357			
	10507186	Oct 30, 2035	DP			
	10512612	Oct 30, 2035	DP			
	10512613	Oct 30, 2035	U-2357			
	10568841	Oct 30, 2035	DP U-2357			
	10688060	Oct 30, 2035	DP			
	10722473	Nov 19, 2038	U-2357			
	9974752	Oct 30, 2035	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 003	10111839	Oct 30, 2035	U-2357		M-82	Jun 28, 2024
	10292938	Oct 30, 2035	DP			
	10292939	Oct 30, 2035	DP U-2357			
	10449159	Oct 30, 2035	U-2357			
	10500162	Oct 30, 2035	U-2357			
	10507186	Oct 30, 2035	DP			
	10512612	Oct 30, 2035	DP			
	10512613	Oct 30, 2035	U-2357			
	10568841	Oct 30, 2035	DP U-2357			
	10688060	Oct 30, 2035	DP			
	10722473	Nov 19, 2038	U-2357			
	9974752	Oct 30, 2035	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 004	10111839	Oct 30, 2035	U-2357		M-82	Jun 28, 2024
	10292938	Oct 30, 2035	DP			
	10292939	Oct 30, 2035	DP U-2357			
	10449159	Oct 30, 2035	U-2357			
	10500162	Oct 30, 2035	U-2357			
	10507186	Oct 30, 2035	DP			
	10512612	Oct 30, 2035	DP			
	10512613	Oct 30, 2035	U-2357			
	10568841	Oct 30, 2035	DP U-2357			
	10688060	Oct 30, 2035	DP			
	10722473	Nov 19, 2038	U-2357			
	9974752	Oct 30, 2035	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 005	10111839	Oct 30, 2035	U-2357		M-82	Jun 28, 2024
	10292938	Oct 30, 2035	DP			
	10292939	Oct 30, 2035	DP U-2357			
	10449159	Oct 30, 2035	U-2357			
	10500162	Oct 30, 2035	U-2357			
	10507186	Oct 30, 2035	DP			
	10512612	Oct 30, 2035	DP			
	10512613	Oct 30, 2035	U-2357			
	10568841	Oct 30, 2035	DP U-2357			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 005	10688060	Oct 30, 2035	DP			
	10722473	Nov 19, 2038	U-2357			
	9974752	Oct 30, 2035	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 006	10111839	Oct 30, 2035	U-2357		M-82	Jun 28, 2024
	10292938	Oct 30, 2035	DP			
	10292939	Oct 30, 2035	DP U-2357			
	10449159	Oct 30, 2035	U-2357			
	10500162	Oct 30, 2035	U-2357			
	10507186	Oct 30, 2035	DP			
	10512612	Oct 30, 2035	DP			
	10512613	Oct 30, 2035	U-2357			
	10568841	Oct 30, 2035	DP U-2357			
	10688060	Oct 30, 2035	DP			
	10722473	Nov 19, 2038	U-2357			
	9974752	Oct 30, 2035	DP			
<u>METOCLOPRAMIDE HYDROCHLORIDE - GIMOTI</u>						
N 209388 001	11020361	Dec 22, 2029	U-2843		NP	Jun 19, 2023
	8334281	May 16, 2030	DP U-2843			
<u>METOPROLOL SUCCINATE - KAPSPARGO SPRINKLE</u>						
N 210428 001	9504655	Jul 09, 2035	DP			
	9700530	Jul 09, 2035	DP			
<u>METOPROLOL SUCCINATE - KAPSPARGO SPRINKLE</u>						
N 210428 002	9504655	Jul 09, 2035	DP			
	9700530	Jul 09, 2035	DP			
<u>METOPROLOL SUCCINATE - KAPSPARGO SPRINKLE</u>						
N 210428 003	9504655	Jul 09, 2035	DP			
	9700530	Jul 09, 2035	DP			
<u>METOPROLOL SUCCINATE - KAPSPARGO SPRINKLE</u>						
N 210428 004	9504655	Jul 09, 2035	DP			
	9700530	Jul 09, 2035	DP			
<u>METRONIDAZOLE - VANDAZOLE</u>						
N 021806 001	7456207	Sep 22, 2024	DP			
<u>METRONIDAZOLE - NUVESSA</u>						
N 205223 001	10238634	Jun 28, 2032	DP			
	10596155	Jun 28, 2032	DP			
	7893097	Feb 19, 2028	DP			
	8658678	Jun 27, 2028	U-1682			
	8877792	Feb 02, 2028	DP			
	8946276	Jun 28, 2032	U-1664			
	9198858	Jun 28, 2032	U-1664			
<u>MICONAZOLE NITRATE; WHITE PETROLATUM; ZINC OXIDE - VUSION</u>						
N 021026 001	8147852	Mar 30, 2028	U-1426			
<u>MIDAZOLAM - NAYZILAM</u>						
N 211321 001	8217033	Jan 18, 2028	DP U-2526		ODE-243	May 17, 2026
	8809322	Jan 18, 2028	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>MIDAZOLAM - NAYZILAM</u>						
N 211321	001 9289432	Jan 18, 2028	DP U-2526			
	9687495	Jan 18, 2028	DP U-2526			
<u>MIDAZOLAM - MIDAZOLAM IN 0.9% SODIUM CHLORIDE</u>						
N 211844	001 10966990	Jun 20, 2038	DP			
<u>MIDAZOLAM - MIDAZOLAM IN 0.9% SODIUM CHLORIDE</u>						
N 211844	002 10966990	Jun 20, 2038	DP			
<u>MIDAZOLAM HYDROCHLORIDE - SEIZALAM</u>						
N 209566	001				ODE-207	Sep 14, 2025
<u>MIDOSTAURIN - RYDAPT</u>						
N 207997	001 7973031	Oct 09, 2028	U-2007		ODE-140	Apr 28, 2024
	8575146	Dec 02, 2030	U-2008		ODE-141	Apr 28, 2024
<u>MIFEPRISTONE - KORLYM</u>						
N 202107	001 10006924	Aug 12, 2036	U-1643			
	10151763	Jan 18, 2037	U-1643			
	10166242	Apr 20, 2036	U-1643			
	10166243	Apr 20, 2036	U-1643			
	10195214	Jun 19, 2037	U-1643			
	10231983	Aug 22, 2038	U-1643			
	10314850	Aug 22, 2038	U-1643			
	10495650	Aug 12, 2036	U-1643			
	10500216	Mar 05, 2033	U-1643			
	10660904	Apr 20, 2036	U-1643			
	10780097	Aug 22, 2038	U-1643			
	10842800	Jun 19, 2037	U-1643			
	10842801	Nov 15, 2032	U-1643			
	8921348	Aug 27, 2028	U-1643			
	9829495	Aug 15, 2036	U-1643			
	9943526	Apr 20, 2036	U-1643			
<u>MIGALASTAT HYDROCHLORIDE - GALAFOLD</u>						
N 208623	001 10076514	Mar 15, 2037	U-2371		NCE	Aug 10, 2023
	10251873	May 30, 2038	U-2371		ODE-205	Aug 10, 2025
	10383864	May 16, 2027	U-2371			
	10406143	May 16, 2027	U-2371			
	10471053	May 30, 2038	U-2371			
	10525045	Apr 28, 2028	U-2371			
	10792278	May 30, 2038	U-2371			
	10792279	May 30, 2038	U-2371			
	10799491	May 30, 2038	U-2371			
	10806727	May 30, 2038	U-2371			
	10813921	Feb 12, 2029	U-2371			
	10849889	May 30, 2038	U-2371			
	10849890	May 30, 2038	U-2371			
	10857141	May 30, 2038	U-2371			
	10857142	May 30, 2038	U-2371			
	10874655	May 30, 2038	U-2371			
	10874656	May 30, 2038	U-2371			
	10874657	May 30, 2038	U-2371			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>MIGALASTAT HYDROCHLORIDE - GALAFOLD</u>						
N 208623 001	10925866	Apr 28, 2028	U-2371			
	11033538	Apr 28, 2028	U-2371			
	11234972	Mar 15, 2037	U-2371			
	11241422	May 16, 2027	U-2371			
	11278536	May 30, 2038	U-2371			
	11278537	May 30, 2038	U-2371			
	11278538	May 30, 2038	U-2371			
	11278539	May 30, 2038	U-2371			
	11278540	May 30, 2038	U-2371			
	11304940	May 30, 2038	DS			
	11357761	May 30, 2038	U-2371			
	11357762	May 30, 2038	U-2371			
	11357763	May 30, 2038	U-2371			
	11357764	May 30, 2038	DS			
	11357765	May 30, 2038	DS			
	11357784	Feb 06, 2039	U-2371			
	11376244	May 30, 2038	DS			
	11389436	May 30, 2038	U-2371			
	11389437	May 30, 2038	U-2371			
	11426396	May 30, 2038	DS			
	11458128	May 30, 2038	U-2371			
	8592362	Feb 12, 2029	U-2371	Y		
	9000011	May 16, 2027	U-2371			
	9095584	Feb 12, 2029	U-2371			
	9480682	May 16, 2027	U-2371			
	9987263	May 16, 2027	U-2371			
	9999618	Apr 28, 2028	U-2372			
	9999618	Apr 28, 2028	U-2373			
	RE48608	Feb 12, 2029	U-2371			
<u>MILNACIPRAN HYDROCHLORIDE - SAVELLA</u>						
N 022256 001	6602911	Jan 14, 2023	U-882			
	7994220	Sep 19, 2029	U-819			
<u>MILNACIPRAN HYDROCHLORIDE - SAVELLA</u>						
N 022256 002	6602911	Jan 14, 2023	U-882			
	7994220	Sep 19, 2029	U-819			
<u>MILNACIPRAN HYDROCHLORIDE - SAVELLA</u>						
N 022256 003	6602911	Jan 14, 2023	U-882			
	7994220	Sep 19, 2029	U-819			
<u>MILNACIPRAN HYDROCHLORIDE - SAVELLA</u>						
N 022256 004	6602911	Jan 14, 2023	U-882			
	7994220	Sep 19, 2029	U-819			
<u>MINOCYCLINE HYDROCHLORIDE - MINOCIN</u>						
N 050444 001	9084802	May 12, 2031	U-282			
	9278105	May 12, 2031	U-282			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N 050808 001	7790705	Jun 24, 2025	U-1078			
	7919483	Mar 07, 2027	U-1078			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N 050808 001	8252776	Jun 24, 2025	U-124			
	8268804	Jun 24, 2025	U-1078			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N 050808 002	7541347	Apr 02, 2027	U-917			
	7544373	Apr 02, 2027	DP			
	7790705	Jun 24, 2025	U-1078			
	7919483	Mar 07, 2027	U-1078			
	8252776	Jun 24, 2025	U-124			
	8268804	Jun 24, 2025	U-1078			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N 050808 003	7790705	Jun 24, 2025	U-1078			
	7919483	Mar 07, 2027	U-1078			
	8252776	Jun 24, 2025	U-124			
	8268804	Jun 24, 2025	U-1078			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N 050808 004	7790705	Jun 24, 2025	U-1078			
	7919483	Mar 07, 2027	U-1078			
	8252776	Jun 24, 2025	U-124			
	8268804	Jun 24, 2025	U-1078			
	9192615	Nov 17, 2031	DP			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N 050808 005	7790705	Jun 24, 2025	U-1078			
	7919483	Mar 07, 2027	U-1078			
	8252776	Jun 24, 2025	U-124			
	8268804	Jun 24, 2025	U-1078			
	9192615	Nov 17, 2031	DP			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N 050808 006	7790705	Jun 24, 2025	U-1078			
	7919483	Mar 07, 2027	U-1078			
	8252776	Jun 24, 2025	U-124			
	8268804	Jun 24, 2025	U-1078			
	8722650	Jun 24, 2025	U-1078			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N 050808 007	7790705	Jun 24, 2025	U-1078			
	7919483	Mar 07, 2027	U-1078			
	8252776	Jun 24, 2025	U-124			
	8268804	Jun 24, 2025	U-1078			
	8722650	Jun 24, 2025	U-1078			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N 050808 008	7790705	Jun 24, 2025	U-1078			
	7919483	Mar 07, 2027	U-1078			
	8252776	Jun 24, 2025	U-124			
	8268804	Jun 24, 2025	U-1078			
	8722650	Jun 24, 2025	U-1078			
<u>MINOCYCLINE HYDROCHLORIDE - XIMINO</u>						
N 201922 001	7541347	Apr 02, 2027	U-917			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>MINOCYCLINE HYDROCHLORIDE - XIMINO</u>						
N 201922 001	7544373	Apr 02, 2027	DP			
	7790705	Jun 24, 2025	U-124			
	7919483	Mar 07, 2027	U-124			
	8252776	Jun 24, 2025	U-124			
	8268804	Jun 24, 2025	U-124			
<u>MINOCYCLINE HYDROCHLORIDE - XIMINO</u>						
N 201922 003	7541347	Apr 02, 2027	U-917			
	7544373	Apr 02, 2027	DP			
	7790705	Jun 24, 2025	U-124			
	7919483	Mar 07, 2027	U-124			
	8252776	Jun 24, 2025	U-124			
	8268804	Jun 24, 2025	U-124			
<u>MINOCYCLINE HYDROCHLORIDE - XIMINO</u>						
N 201922 005	7541347	Apr 02, 2027	U-917			
	7544373	Apr 02, 2027	DP			
	7790705	Jun 24, 2025	U-124			
	7919483	Mar 07, 2027	U-124			
	8252776	Jun 24, 2025	U-124			
	8268804	Jun 24, 2025	U-124			
<u>MINOCYCLINE HYDROCHLORIDE - MINOLIRA</u>						
N 209269 001	11103517	Apr 07, 2036	DP			
<u>MINOCYCLINE HYDROCHLORIDE - MINOLIRA</u>						
N 209269 002	11103517	Apr 07, 2036	DP			
<u>MINOCYCLINE HYDROCHLORIDE - AMZEEQ</u>						
N 212379 001	10086080	Oct 01, 2030	U-2647			
	10137200	Oct 01, 2030	U-2647			
	10213512	Oct 01, 2030	DP U-2647			
	10265404	Oct 01, 2030	DP			
	10398641	Sep 08, 2037	U-2647			
	10517882	Oct 01, 2030	U-2647			
	10821187	Oct 01, 2030	U-2647			
	10849847	Sep 08, 2037	U-2647			
	8865139	Oct 01, 2030	DP U-2647			
	8945516	Oct 01, 2030	DP			
	8992896	Oct 01, 2030	DP U-2647			
	9675700	Oct 01, 2030	DP U-2647			
<u>MINOCYCLINE HYDROCHLORIDE - ZILXI</u>						
N 213690 001	10213512	Oct 01, 2030	DP U-1631			
	10265404	Oct 01, 2030	DP			
	10322186	Oct 01, 2030	U-1631			
	10946101	Oct 01, 2030	U-1631			
	8865139	Oct 01, 2030	DP U-1631			
	8945516	Oct 01, 2030	DP			
	8992896	Oct 01, 2030	DP U-1631			
	9675700	Oct 01, 2030	DP U-1631			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>MIPOMERSEN SODIUM - KYNAMRO</u>						
N 203568 001	7015315	Mar 21, 2023	DS			
	7101993	Sep 05, 2023	DS			
	7511131	Jan 29, 2027	DS			
<u>MIRABEGRON - MYRBETRIQ</u>						
N 202611 001	10842780	Sep 28, 2029	DP U-2996		I-855	Mar 25, 2024
	10842780*PED	Mar 28, 2030			PED	Sep 25, 2024
	7342117	Nov 04, 2023	DS			
	7982049	Nov 04, 2023	DP			
	8772315	Oct 30, 2028	U-2300			
	8772315*PED	Apr 30, 2029				
	8835474	Nov 04, 2023	U-1527			
	8835474*PED	May 04, 2024				
	RE44872	Nov 04, 2023	U-1527			
	RE44872*PED	May 04, 2024				
<u>MIRABEGRON - MYRBETRIQ</u>						
N 202611 002	10842780	Sep 28, 2029	DP U-2996		I-855	Mar 25, 2024
	10842780*PED	Mar 28, 2030			PED	Sep 25, 2024
	7342117	Nov 04, 2023	DS			
	7982049	Nov 04, 2023	DP			
	8772315	Oct 30, 2028	U-2300			
	8772315*PED	Apr 30, 2029				
	8835474	Nov 04, 2023	U-1527			
	8835474*PED	May 04, 2024				
	RE44872	Nov 04, 2023	U-1527			
	RE44872*PED	May 04, 2024				
<u>MIRABEGRON - MYRBETRIQ GRANULES</u>						
N 213801 001	10058536	Mar 31, 2036	DP U-3108		NP	Mar 25, 2024
	10058536*PED	Oct 01, 2036			PED	Sep 25, 2024
	7342117	Nov 04, 2023	DS			
	7342117*PED	May 04, 2024				
	7982049	Nov 04, 2023	DP			
	7982049*PED	May 04, 2024				
<u>MITAPIVAT SULFATE - PYRUKYND</u>						
N 216196 001	10632114	May 03, 2032	U-3320		NCE	Feb 17, 2027
	11234976	Oct 11, 2038	U-3321			
	11254652	Nov 21, 2038	DS DP			
	8785450	Feb 24, 2031	DS DP			
	9193701	Oct 26, 2032	U-3319			
	9682080	May 03, 2032	U-3319			
	9980961	May 03, 2032	U-3319			
<u>MITAPIVAT SULFATE - PYRUKYND</u>						
N 216196 002	10632114	May 03, 2032	U-3320		NCE	Feb 17, 2027
	11234976	Oct 11, 2038	U-3321			
	11254652	Nov 21, 2038	DS DP			
	8785450	Feb 24, 2031	DS DP			
	9193701	Oct 26, 2032	U-3319			
	9682080	May 03, 2032	U-3319			
	9980961	May 03, 2032	U-3319			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>MITAPIVAT SULFATE - PYRUKYND</u>						
N 216196 002	10632114	May 03, 2032	U-3320		NCE	Feb 17, 2027
	11234976	Oct 11, 2038	U-3321			
	11254652	Nov 21, 2038	DS DP			
	8785450	Feb 24, 2031	DS DP			
	9193701	Oct 26, 2032	U-3319			
	9682080	May 03, 2032	U-3319			
	9980961	May 03, 2032	U-3319			
<u>MITAPIVAT SULFATE - PYRUKYND</u>						
N 216196 003	10632114	May 03, 2032	U-3320		NCE	Feb 17, 2027
	11234976	Oct 11, 2038	U-3321			
	11254652	Nov 21, 2038	DS DP			
	8785450	Feb 24, 2031	DS DP			
	9193701	Oct 26, 2032	U-3319			
	9682080	May 03, 2032	U-3319			
	9980961	May 03, 2032	U-3319			
<u>MITOMYCIN - MITOSOL</u>						
N 022572 001	7806265	Feb 01, 2029	DP			
	8186511	Jul 19, 2026	DP			
	9205075	Jul 19, 2026	DP			
	9539241	Jan 02, 2028	DS DP U-2095			
	9649428	May 21, 2029	U-2095			
<u>MITOMYCIN - JELMYTO</u>						
N 211728 001	9040074	Jan 20, 2031	DP		NP	Apr 15, 2023
	9950069	Jan 20, 2031	DP		ODE-289	Apr 15, 2027
<u>MOBOCERTINIB SUCCINATE - EXKIVITY</u>						
N 215310 001	10227342	May 13, 2035	DS DP U-3220		NCE	Sep 15, 2026
	9796712	May 13, 2035	DS DP		ODE-374	Sep 15, 2028
<u>MODAFINIL - PROVIGIL</u>						
N 020717 001	7297346	Nov 29, 2023	DP			
<u>MODAFINIL - PROVIGIL</u>						
N 020717 002	7297346	Nov 29, 2023	DP			
<u>MOMETASONE FUROATE - SINUVA</u>						
N 209310 001	10232152	Nov 24, 2034	DP U-2272			
	10357640	Oct 03, 2031	U-2272			
	10406332	Mar 13, 2034	DP			
	7544192	Nov 29, 2026	U-2272			
	7662141	Mar 12, 2024	U-2272			
	7713255	Mar 12, 2024	U-2272			
	7951130	Mar 12, 2024	U-2272			
	7951131	Mar 12, 2024	U-2272			
	7951133	Mar 12, 2024	U-2272			
	8025635	Jun 12, 2027	DP U-2272			
	8109918	Mar 12, 2024	U-2272			
	8763222	Feb 08, 2032	DP			
	9585681	Apr 04, 2026	U-2272			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>MOMETASONE FUROATE; OLOPATADINE HYDROCHLORIDE - RYALTRIS</u>						
N 211746 001	10016443	Sep 04, 2034	U-3297		NP	Jan 13, 2025
	10376526	Sep 04, 2034	DP			
	10517880	Sep 04, 2034	DP U-3297			
	10548907	Sep 04, 2034	U-3297			
	10561672	Sep 04, 2034	DP			
	10646500	Sep 04, 2034	U-3297			
	10758550	Sep 04, 2034	U-3296			
	10765686	Sep 04, 2034	U-3295			
	11400101	Sep 04, 2034	U-3297			
	9078923	Sep 04, 2034	DP U-3297			
	9370483	Sep 04, 2034	DP			
	9750754	Sep 04, 2034	DP U-3297			
	9937189	Sep 04, 2034	DP			
<u>MONOMETHYL FUMARATE - BAFIERTAM</u>						
N 210296 001	10098863	Feb 27, 2035	DP U-1384			
	10105335	Feb 27, 2035	DP			
	10105336	Feb 27, 2035	DP U-1384			
	10105337	Feb 27, 2035	DP			
	10918615	Aug 12, 2035	DP U-1384			
	10918616	Jun 03, 2035	U-1384			
	10918617	Aug 10, 2035	DP			
	10945985	Aug 14, 2035	DP			
	9326947	Feb 27, 2035	DP			
	9326965	Feb 27, 2035	U-1384			
	9511043	Feb 27, 2035	U-1384			
	9517209	Feb 27, 2035	DP			
	9566259	Feb 27, 2035	DP			
	9636318	Feb 27, 2035	U-1384			
	9636319	Feb 27, 2035	DP			
	9814691	Feb 27, 2035	U-1384			
	9814692	Feb 27, 2035	U-1384			
	9820960	Feb 27, 2035	DP			
	9820961	Feb 27, 2035	DP U-1384			
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 022195 001					NPP	Jun 02, 2024
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 022195 002					NPP	Jun 02, 2024
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 022207 001					NPP	Jun 02, 2024
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 022207 002					NPP	Jun 02, 2024
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223 001	9072781	Mar 12, 2034	DP			
	9192608	Mar 12, 2034	U-43			
	9192608	Mar 12, 2034	U-55			
	9248229	Mar 12, 2034	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223 002	9072781	Mar 12, 2034	DP			
	9192608	Mar 12, 2034	U-43			
	9192608	Mar 12, 2034	U-55			
	9248229	Mar 12, 2034	DP			
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223 003	9072781	Mar 12, 2034	DP			
	9192608	Mar 12, 2034	U-43			
	9192608	Mar 12, 2034	U-55			
	9248229	Mar 12, 2034	DP			
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223 004	9072781	Mar 12, 2034	DP			
	9192608	Mar 12, 2034	U-43			
	9192608	Mar 12, 2034	U-55			
	9248229	Mar 12, 2034	DP			
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223 005	9072781	Mar 12, 2034	DP			
	9192608	Mar 12, 2034	U-43			
	9192608	Mar 12, 2034	U-55			
	9248229	Mar 12, 2034	DP			
<u>MORPHINE SULFATE - MORPHABOND ER</u>						
N 206544 001	10314788	Aug 12, 2028	DP			
	7955619	Aug 12, 2028	DP			
<u>MORPHINE SULFATE - MORPHABOND ER</u>						
N 206544 002	10314788	Aug 12, 2028	DP			
	7955619	Aug 12, 2028	DP			
<u>MORPHINE SULFATE - MORPHABOND ER</u>						
N 206544 003	10314788	Aug 12, 2028	DP			
	7955619	Aug 12, 2028	DP			
<u>MORPHINE SULFATE - MORPHABOND ER</u>						
N 206544 004	10314788	Aug 12, 2028	DP			
	7955619	Aug 12, 2028	DP			
<u>MORPHINE SULFATE - ARYMO ER</u>						
N 208603 001	9044402	Jul 01, 2033	DP U-1556			
	9549899	Jul 01, 2033	DP U-1556			
<u>MORPHINE SULFATE - ARYMO ER</u>						
N 208603 002	9044402	Jul 01, 2033	DP U-1556			
	9549899	Jul 01, 2033	DP U-1556			
<u>MORPHINE SULFATE - ARYMO ER</u>						
N 208603 003	9044402	Jul 01, 2033	DP U-1556			
	9549899	Jul 01, 2033	DP U-1556			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 001	7682633	Jun 19, 2027	U-1510			
	7682634	Jun 19, 2027	DP			
	7815934	Dec 12, 2027	DP			
	8158156	Jun 19, 2027	U-1510			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 001	8623418	Nov 07, 2029	U-1640			
	8685443	Jul 03, 2025	U-1508			
	8685444	Jul 03, 2025	DP			
	8846104	Jun 19, 2027	DP			
	8877247	Jun 19, 2027	DP			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 002	7682633	Jun 19, 2027	U-1510			
	7682634	Jun 19, 2027	DP			
	7815934	Dec 12, 2027	DP			
	8158156	Jun 19, 2027	U-1510			
	8623418	Nov 07, 2029	U-1640			
	8685443	Jul 03, 2025	U-1508			
	8685444	Jul 03, 2025	DP			
	8846104	Jun 19, 2027	DP			
	8877247	Jun 19, 2027	DP			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 003	7682633	Jun 19, 2027	U-1510			
	7682634	Jun 19, 2027	DP			
	7815934	Dec 12, 2027	DP			
	8158156	Jun 19, 2027	U-1510			
	8623418	Nov 07, 2029	U-1640			
	8685443	Jul 03, 2025	U-1508			
	8685444	Jul 03, 2025	DP			
	8846104	Jun 19, 2027	DP			
	8877247	Jun 19, 2027	DP			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 004	7682633	Jun 19, 2027	U-1510			
	7682634	Jun 19, 2027	DP			
	7815934	Dec 12, 2027	DP			
	8158156	Jun 19, 2027	U-1510			
	8623418	Nov 07, 2029	U-1640			
	8685443	Jul 03, 2025	U-1508			
	8685444	Jul 03, 2025	DP			
	8846104	Jun 19, 2027	DP			
	8877247	Jun 19, 2027	DP			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 005	7682633	Jun 19, 2027	U-1510			
	7682634	Jun 19, 2027	DP			
	7815934	Dec 12, 2027	DP			
	8158156	Jun 19, 2027	U-1510			
	8623418	Nov 07, 2029	U-1640			
	8685443	Jul 03, 2025	U-1508			
	8685444	Jul 03, 2025	DP			
	8846104	Jun 19, 2027	DP			
	8877247	Jun 19, 2027	DP			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 006	7682633	Jun 19, 2027	U-1510			
	7682634	Jun 19, 2027	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 006	7815934	Dec 12, 2027	DP			
	8158156	Jun 19, 2027	U-1510			
	8623418	Nov 07, 2029	U-1640			
	8685443	Jul 03, 2025	U-1508			
	8685444	Jul 03, 2025	DP			
	8846104	Jun 19, 2027	DP			
	8877247	Jun 19, 2027	DP			
<u>MOXIDECTIN - MOXIDECTIN</u>						
N 210867 001					NCE	Jun 13, 2023
					ODE-193	Jun 13, 2025
<u>MOXIFLOXACIN HYDROCHLORIDE - MOXEZA</u>						
N 022428 001	8450311	May 29, 2029	DP			
	9114168	May 29, 2029	DP			
<u>NAFTIFINE HYDROCHLORIDE - NAFTIN</u>						
N 204286 001	10166205	Jan 31, 2033	DP			
	10166206	Jan 31, 2033	DP			
	10695303	Jan 31, 2033	DP			
	10729667	Jan 31, 2033	DP			
	8778365	Jan 31, 2033	DP			
	9161914	Jan 31, 2033	U-540			
<u>NALDEMEDINE TOSYLATE - SYMPROIC</u>						
N 208854 001	10952968	May 13, 2033	DS DP			
	9108975	Nov 11, 2031	DS DP			
	RE46365	Jan 11, 2028	DS DP			
	RE46375	Oct 05, 2026	DS DP U-1185			
<u>NALOXEGOL OXALATE - MOVANTIK</u>						
N 204760 001	7056500	Jun 29, 2024	DP U-1185			
	7786133	Sep 16, 2028	DS DP			
	8067431	Dec 16, 2024	U-1185			
	9012469	Apr 02, 2032	DS DP			
<u>NALOXEGOL OXALATE - MOVANTIK</u>						
N 204760 002	7056500	Jun 29, 2024	DP U-1185			
	7786133	Sep 16, 2028	DS DP			
	8067431	Dec 16, 2024	U-1185			
	9012469	Apr 02, 2032	DS DP			
<u>NALOXONE HYDROCHLORIDE - EVZIO</u>						
N 205787 001	10143972	May 24, 2031	U-2476			
	10220158	Mar 20, 2035	DP U-2500			
	10314977	Nov 23, 2024	DP			
	10322239	Feb 28, 2031	U-1907			
	10335549	Apr 30, 2025	DP			
	10737028	Nov 23, 2024	DP			
	10960155	Jun 25, 2026	DP			
	7731686	Jun 10, 2026	DP			
	7731690	Jan 15, 2025	DP			
	7749194	Oct 30, 2028	DP			
	7918823	Nov 23, 2024	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NALOXONE HYDROCHLORIDE - EVZIO</u>						
N 205787 001	7947017	Mar 12, 2028	DP			
	8016788	Mar 21, 2025	DP			
	8021344	Nov 02, 2029	DP			
	8206360	Feb 27, 2027	DP			
	8226610	Apr 10, 2029	DP			
	8231573	Nov 25, 2028	DP			
	8313466	Nov 23, 2024	DP			
	8361029	Nov 23, 2024	DP			
	8425462	Nov 23, 2024	DP			
	8608698	Nov 23, 2024	DP			
	8627816	Feb 04, 2032	DP			
	8926594	Mar 31, 2026	DP			
	8939943	Feb 28, 2031	DP			
	9022022	Feb 28, 2031	DP			
	9056170	Nov 23, 2024	DP			
	9238108	Feb 20, 2027	DP			
	9278182	Feb 01, 2026	DP			
	9474869	Feb 28, 2031	DP U-1907			
	9517307	Jul 18, 2034	DP U-1925			
	9724471	May 23, 2027	DP U-2092			
	9737669	Nov 23, 2024	DP			
<u>NALOXONE HYDROCHLORIDE - NARCAN</u>						
N 208411 002	9480644	Mar 16, 2035	DP U-1903	Y		
	9707226	Mar 16, 2035	DP U-1903	Y		
<u>NALOXONE HYDROCHLORIDE - EVZIO (AUTOINJECTOR)</u>						
N 209862 001	10143792	May 24, 2031	U-2476			
	10220158	Mar 20, 2035	DP U-2500			
	10314977	Nov 23, 2024	DP			
	10322239	Feb 28, 2031	U-1907			
	10335549	Apr 30, 2025	DP			
	10737028	Nov 23, 2024	DP			
	10960155	Jun 25, 2026	DP			
	7731686	Jun 01, 2026	DP			
	7731690	Jan 15, 2025	DP			
	7749194	Oct 30, 2028	DP			
	7918823	Nov 23, 2024	DP			
	7947017	Mar 12, 2028	DP			
	8016788	Mar 21, 2025	DP			
	8021344	Nov 02, 2029	DP			
	8206360	Feb 27, 2027	DP			
	8226610	Apr 10, 2029	DP			
	8231573	Nov 25, 2028	DP			
	8313466	Nov 23, 2024	DP			
	8361029	Nov 23, 2024	DP			
	8425462	Nov 23, 2024	DP			
	8608698	Nov 23, 2024	DP			
	8627816	Feb 04, 2032	DP			
	8926594	Mar 31, 2026	DP			
	8939943	Feb 28, 2031	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>NALOXONE HYDROCHLORIDE - EVZIO (AUTOINJECTOR)</u>						
N 209862 001	9022022	Feb 28, 2031	DP			
	9056170	Nov 23, 2024	DP			
	9238108	Feb 20, 2027	DP			
	9278182	Feb 01, 2026	DP			
	9474869	Feb 28, 2031	DP U-1907			
	9517307	Jul 18, 2034	DP U-1925			
	9724471	May 23, 2027	DP U-2092			
	9737669	Nov 23, 2024	DP			
<u>NALOXONE HYDROCHLORIDE - KLOXXADO</u>						
N 212045 001	10722510	Aug 26, 2034	DP U-3110			
	10973814	Aug 26, 2034	DP U-3110			
	11135155	Aug 26, 2034	DP			
<u>NALOXONE HYDROCHLORIDE - ZIMHI</u>						
N 212854 001	11027072	May 24, 2039	DP			
<u>NALOXONE HYDROCHLORIDE - NALOXONE HYDROCHLORIDE (AUTOINJECTOR)</u>						
N 215457 001	10143792	May 24, 2031	U-2476			
	10314977	Nov 23, 2024	DP			
	10322239	Feb 28, 2031	U-1907			
	10335549	Apr 30, 2025	DP			
	10737028	Nov 23, 2024	DP			
	7731690	Jan 15, 2025	DP			
	7918823	Nov 23, 2024	DP			
	7947017	Mar 12, 2028	DP			
	8016788	Mar 21, 2025	DP			
	8313466	Nov 23, 2024	DP			
	8361029	Nov 23, 2024	DP			
	8425462	Nov 23, 2024	DP			
	8608698	Nov 23, 2024	DP			
	8939943	Feb 28, 2031	DP			
	9022022	Feb 28, 2031	DP			
	9056170	Nov 23, 2024	DP			
	9474869	Feb 28, 2031	DP U-1907			
	9737669	Nov 23, 2024	DP			
	9814838	Feb 28, 2031	DP			
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ</u>						
N 205777 001	8846090	Apr 04, 2023	DP			
	8846091	Apr 04, 2023	DP			
	9073933	Mar 30, 2025	DS			
	9522919	Mar 30, 2025	DS DP			
	9555000	Apr 04, 2023	DP U-1556			
	9907793	Apr 04, 2023	DP U-1556			
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ</u>						
N 205777 002	8846090	Apr 04, 2023	DP			
	8846091	Apr 04, 2023	DP			
	9073933	Mar 30, 2025	DS			
	9522919	Mar 30, 2025	DS DP			
	9555000	Apr 04, 2023	DP U-1556			
	9907793	Apr 04, 2023	DP U-1556			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ</u>						
N 205777 002	8846090	Apr 04, 2023	DP			
	8846091	Apr 04, 2023	DP			
	9073933	Mar 30, 2025	DS			
	9522919	Mar 30, 2025	DS DP			
	9555000	Apr 04, 2023	DP U-1556			
	9907793	Apr 04, 2023	DP U-1556			
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ</u>						
N 205777 003	8846090	Apr 04, 2023	DP			
	8846091	Apr 04, 2023	DP			
	9073933	Mar 30, 2025	DS			
	9522919	Mar 30, 2025	DS DP			
<u>NALTREXONE - VIVITROL</u>						
N 021897 001	7919499	Oct 15, 2029	U-1123			
	7919499	Oct 15, 2029	U-1124			
<u>NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TROXYCA ER</u>						
N 207621 001	7815934	Dec 12, 2027	DP			
	8685443	Jul 03, 2025	U-1508			
<u>NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TROXYCA ER</u>						
N 207621 002	7815934	Dec 12, 2027	DP			
	8685443	Jul 03, 2025	U-1508			
<u>NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TROXYCA ER</u>						
N 207621 003	7815934	Dec 12, 2027	DP			
	8685443	Jul 03, 2025	U-1508			
<u>NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TROXYCA ER</u>						
N 207621 004	7815934	Dec 12, 2027	DP			
	8685443	Jul 03, 2025	U-1508			
<u>NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TROXYCA ER</u>						
N 207621 005	7815934	Dec 12, 2027	DP			
	8685443	Jul 03, 2025	U-1508			
<u>NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TROXYCA ER</u>						
N 207621 006	7815934	Dec 12, 2027	DP			
	8685443	Jul 03, 2025	U-1508			
<u>NAPROXEN SODIUM - NAPROXEN SODIUM</u>						
N 021920 001	10022344	Mar 03, 2026	DP U-1731			
	10022344	Mar 03, 2026	DP U-1732			
	10028925	Mar 03, 2026	DP U-1731			
	10028925	Mar 03, 2026	DP U-1732			
	11090280	Mar 03, 2026	DP U-1731			
	11090280	Mar 03, 2026	DP U-1732			
	9693978	Mar 03, 2026	DP			
	9693979	Mar 03, 2026	DP			
<u>NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE - TREXIMET</u>						
N 021926 001	7332183	Oct 02, 2025	DP U-867			
	7332183*PED	Apr 02, 2026				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE - TREXIMET</u>						
N 021926 002	7332183	Oct 02, 2025	DP U-1719			
	7332183*PED	Apr 02, 2026				
<u>NEBIVOLOL HYDROCHLORIDE; VALSARTAN - BYVALSON</u>						
N 206302 001	7803838	Aug 29, 2026	DP			
	7838552	Oct 04, 2027	U-185			
<u>NEOSTIGMINE METHYLSULFATE - NEOSTIGMINE METHYLSULFATE</u>						
A 216291 001					CGT	Jan 21, 2023
<u>NEPAFENAC - NEVANAC</u>						
N 021862 001	7834059	Jan 31, 2027	U-1095			
	8071648	Dec 02, 2025	DP			
	8324281	Dec 02, 2025	DP			
<u>NEPAFENAC - ILEVRO</u>						
N 203491 001	7947295	Jun 08, 2024	DP			
	8921337	Mar 31, 2032	DP			
	9662398	Dec 01, 2030	DP			
<u>NERATINIB MALEATE - NERLYNX</u>						
N 208051 001	10035788	Oct 15, 2028	U-2043		D-182	Jun 28, 2024
	10035788	Oct 15, 2028	U-3047		I-823	Feb 25, 2023
	10035788	Oct 15, 2028	U-3097			
	7399865	Dec 29, 2030	DS DP			
	7982043	Oct 08, 2025	U-2043			
	7982043	Oct 08, 2025	U-3047			
	7982043	Oct 08, 2025	U-3097			
	8518446	Nov 20, 2030	DP U-2043			
	8518446	Nov 20, 2030	DP U-3047			
	8518446	Nov 20, 2030	DP U-3097			
	8669273	Jul 18, 2031	U-3047			
	8790708	Nov 05, 2030	DP U-2043			
	8790708	Nov 05, 2030	DP U-3047			
	8790708	Nov 05, 2030	DP U-3097			
	9139558	Oct 15, 2028	U-2043			
	9139558	Oct 15, 2028	U-3047			
	9139558	Oct 15, 2028	U-3097			
	9211291	Mar 24, 2030	U-2043			
	9211291	Mar 24, 2030	U-3097			
	9265784	Aug 04, 2029	U-3047			
	9630946	Oct 15, 2028	U-2043			
	9630946	Oct 15, 2028	U-3047			
	9630946	Oct 15, 2028	U-3097			
<u>NETARSUDIL MESYLATE - RHOPRESSA</u>						
N 208254 001	10174017	Jan 27, 2030	DS DP U-1524			
	10532993	Jul 11, 2026	U-1524			
	10588901	Mar 14, 2034	DS DP U-1524			
	10654844	Jan 27, 2030	DS DP U-1524			
	10882840	Jul 11, 2026	U-1524			
	11021456	Jul 11, 2026	U-1524			
	11028081	Jan 27, 2030	U-1524			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>NETARSUDIL MESYLATE - RHOPRESSA</u>						
N 208254 001	11185538	Mar 14, 2034	DP			
	8394826	Nov 10, 2030	DS DP U-1524			
	8450344	Jul 11, 2026	DS DP U-1524			
	9096569	Jul 11, 2026	DS DP U-1524			
	9415043	Mar 14, 2034	DS			
	9931336	Mar 14, 2034	DS DP U-1524			
<u>NETUPITANT; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 205718 001	10233154	Sep 25, 2035	DS			
	10676440	Sep 25, 2035	DS DP			
	10828297	Dec 17, 2030	U-2293			
	10961195	Sep 25, 2035	DS DP			
	6297375	Mar 17, 2023	DS			
	8623826	Nov 18, 2030	U-2293			
	8951969	Nov 18, 2030	DP			
	9186357	Nov 18, 2030	U-2293			
	9271975	Sep 09, 2031	U-2293			
	9943515	Nov 18, 2030	U-2293			
	9951016	Sep 25, 2035	DS DP			
<u>NEVIRAPINE - VIRAMUNE XR</u>						
N 201152 001	8460704	Mar 12, 2029	U-1409			
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER</u>						
N 019734 002	10758616	Apr 18, 2027	DP			
	7612102	Dec 26, 2027	DP			
	7659291	Apr 18, 2027	U-1029			
	8455524	Apr 18, 2027	U-1029			
	9364564	Dec 26, 2027	DP			
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER</u>						
N 019734 003	10758616	Apr 18, 2027	DP			
	7612102	Dec 26, 2027	DP			
	7659291	Apr 18, 2027	U-1029			
	8455524	Apr 18, 2027	U-1029			
	9364564	Dec 26, 2027	DP			
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER</u>						
N 019734 004	10758616	Apr 18, 2027	DP			
	7612102	Dec 26, 2027	DP			
	7659291	Apr 18, 2027	U-1029			
	8455524	Apr 18, 2027	U-1029			
	9364564	Dec 26, 2027	DP			
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER</u>						
N 019734 005	7612102	Dec 26, 2027	DP			
	7659291	Apr 18, 2027	U-1029			
	8455524	Apr 18, 2027	U-1029			
	9364564	Dec 26, 2027	DP			
<u>NICOTINE POLACRILEX - NICORETTE</u>						
N 018612 002	8323683	Apr 30, 2028				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>NICOTINE POLACRILEX - NICORETTE</u>						
N 020066 002	8323683	Apr 30, 2028	DP			
<u>NICOTINE POLACRILEX - NICORETTE</u>						
N 022360 001	8501164	Jun 14, 2029	DP			
	8940772	Apr 30, 2029	DP			
<u>NICOTINE POLACRILEX - NICORETTE</u>						
N 022360 002	8501164	Jun 14, 2029	DP			
	8940772	Apr 30, 2029	DP			
<u>NIFURTIMOX - LAMPIT</u>						
N 213464 001					NCE	Aug 06, 2025
					ODE-319	Aug 06, 2027
<u>NIFURTIMOX - LAMPIT</u>						
N 213464 002					NCE	Aug 06, 2025
					ODE-319	Aug 06, 2027
<u>NILOTINIB HYDROCHLORIDE - TASIGNA</u>						
N 022068 001	7169791	Jul 04, 2023	DS DP U-836		ODE-171	Mar 22, 2025
	7169791*PED	Jan 04, 2024			ODE-172	Mar 22, 2025
	8163904	Aug 23, 2028	DS DP		ODE-380	Sep 23, 2028
	8163904*PED	Feb 23, 2029			PED	Sep 22, 2025
	8293756	Sep 25, 2027	DP		PED	Sep 22, 2025
	8293756*PED	Mar 25, 2028			PED	Mar 23, 2029
	8389537	Jul 18, 2026	U-1374			
	8389537*PED	Jan 18, 2027				
	8415363	Jul 18, 2026	DS DP U-1374			
	8415363	Jul 18, 2026	DS DP U-1407			
	8415363*PED	Jan 18, 2027				
	8501760	Jul 18, 2026	DP			
	8501760*PED	Jan 18, 2027				
	9061029	Apr 07, 2032	DS U-1374			
	9061029	Apr 07, 2032	DS U-3231			
	9061029*PED	Oct 07, 2032				
<u>NILOTINIB HYDROCHLORIDE - TASIGNA</u>						
N 022068 002	7169791	Jul 04, 2023	DS DP U-836		ODE-171	Mar 22, 2025
	7169791*PED	Jan 04, 2024			ODE-172	Mar 22, 2025
	8163904	Aug 23, 2028	DS DP		ODE-380	Sep 23, 2028
	8163904*PED	Feb 23, 2029			PED	Sep 22, 2025
	8293756	Sep 25, 2027	DP		PED	Sep 22, 2025
	8293756*PED	Mar 25, 2028			PED	Mar 23, 2029
	8389537	Jul 18, 2026	U-1374			
	8389537*PED	Jan 18, 2027				
	8415363	Jul 18, 2026	DS DP U-1374			
	8415363	Jul 18, 2026	DS DP U-1407			
	8415363*PED	Jan 18, 2027				
	8501760	Jul 18, 2026	DP			
	8501760*PED	Jan 18, 2027				
	9061029	Apr 07, 2032	DS U-1374			
	9061029	Apr 07, 2032	DS U-3231			
	9061029*PED	Oct 07, 2032				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>NILOTINIB HYDROCHLORIDE - TASIGNA</u>						
N 022068 003	7169791	Jul 04, 2023	DS DP U-836		ODE-171	Mar 22, 2025
	7169791*PED	Jan 04, 2024			ODE-172	Mar 22, 2025
	8163904	Aug 23, 2028	DS DP		ODE-380	Sep 23, 2028
	8163904*PED	Feb 23, 2029			PED	Sep 22, 2025
	8293756	Sep 25, 2027	DP		PED	Sep 22, 2025
	8293756*PED	Mar 25, 2028			PED	Mar 23, 2029
	8389537	Jul 18, 2026	U-1374			
	8389537*PED	Jan 18, 2027				
	8415363	Jul 18, 2026	DS DP U-1374			
	8415363	Jul 18, 2026	DS DP U-1407			
	8415363*PED	Jan 18, 2027				
	8501760	Jul 18, 2026	DP			
	8501760*PED	Jan 18, 2027				
	9061029	Apr 07, 2032	DS U-1374			
	9061029	Apr 07, 2032	DS U-3231			
	9061029*PED	Oct 07, 2032				
<u>NIMODIPINE - NYMALIZE</u>						
N 203340 002	10342787	Apr 16, 2038	DP U-2804			
	10576070	Apr 16, 2038	DP U-2804			
	11207306	Apr 16, 2038	U-2804			
	11413277	Apr 16, 2038	DP U-2804			
	11517563	Apr 16, 2038	DP			
	7070581	Jun 23, 2023	DP			
	8517997	May 14, 2024	DP			
<u>NINTEDANIB ESYLATE - OFEV</u>						
N 205832 001	10105323	Jun 04, 2029	DP		I-825	Mar 09, 2023
	10154990	Dec 20, 2025	U-2620		ODE-261	Sep 06, 2026
	6762180	Oct 01, 2025	DS DP			
	7119093	Feb 21, 2024	DS DP			
	9907756	Jun 07, 2029	DP			
<u>NINTEDANIB ESYLATE - OFEV</u>						
N 205832 002	10105323	Jun 04, 2029	DP		I-825	Mar 09, 2023
	10154990	Dec 20, 2025	U-2620		ODE-261	Sep 06, 2026
	6762180	Oct 01, 2025	DS DP			
	7119093	Feb 21, 2024	DS DP			
	9907756	Jun 07, 2029	DP			
<u>NIRAPARIB TOSYLATE - ZEJULA</u>						
N 208447 001	11091459	Mar 27, 2038	DP		I-833	Apr 29, 2023
	8071579	Aug 12, 2027	U-2655		ODE-133	Mar 27, 2024
	8071623	Mar 27, 2031	DS DP		ODE-277	Oct 23, 2026
	8143241	Aug 12, 2027	U-2655		ODE-278	Oct 23, 2026
	8436185	Apr 24, 2029	DS		ODE-295	Apr 29, 2027
	8859562	Aug 04, 2031	U-2655			
<u>NITISINONE - ORFADIN</u>						
N 206356 001	9301932	Feb 28, 2033	DP U-1836			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>NITISINONE - NITYR</u>						
N 209449 001	10328029	Jan 05, 2035	DP U-1836			
<u>NITISINONE - NITYR</u>						
N 209449 002	10328029	Jan 05, 2035	DP U-1836			
<u>NITISINONE - NITYR</u>						
N 209449 003	10328029	Jan 05, 2035	DP U-1836			
<u>NITRIC OXIDE - INOMAX</u>						
N 020845 002	8282966	Jun 30, 2029	U-1286			
	8291904	Jan 06, 2031	DP U-1226			
	8293284	Jun 30, 2029	U-1286			
	8431163	Jun 30, 2029	U-1286			
	8431163*PED	Dec 30, 2029				
	8573209	Jan 06, 2031	DP			
	8573209*PED	Jul 06, 2031				
	8573210	Jan 06, 2031	DP U-1453			
	8573210*PED	Jul 06, 2031				
	8776794	Jan 06, 2031	DP U-1226			
	8776794*PED	Jul 06, 2031				
	8776795	Jan 06, 2031	DP U-1226			
	8776795*PED	Jul 06, 2031				
	8795741	Jun 30, 2029	U-1286			
	8795741*PED	Dec 30, 2029				
	8846112	Jun 30, 2029	U-1286			
	8846112*PED	Dec 30, 2029				
<u>NITRIC OXIDE - INOMAX</u>						
N 020845 003	8282966	Jun 30, 2029	U-1286			
	8291904	Jan 06, 2031	DP U-1226			
	8293284	Jun 30, 2029	U-1286			
	8431163	Jun 30, 2029	U-1286			
	8431163*PED	Dec 30, 2029				
	8573209	Jan 06, 2031	DP			
	8573209*PED	Jul 06, 2031				
	8573210	Jan 06, 2031	DP U-1453			
	8573210*PED	Jul 06, 2031				
	8776794	Jan 06, 2031	DP U-1226			
	8776794*PED	Jul 06, 2031				
	8776795	Jan 06, 2031	DP U-1226			
	8776795*PED	Jul 06, 2031				
	8795741	Jun 30, 2029	U-1286			
	8795741*PED	Dec 30, 2029				
	8846112	Jun 30, 2029	U-1286			
	8846112*PED	Dec 30, 2029				
	9265911	Jan 06, 2031	DP U-1824			
	9265911*PED	Jul 06, 2031				
	9279794	Feb 19, 2034	DP U-1823			
	9279794*PED	Aug 19, 2034				
	9295802	Jan 06, 2031	DP U-1226			
	9295802*PED	Jul 06, 2031				
	9408993	Jan 06, 2031	DP U-1824			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>NITRIC OXIDE - INOMAX</u>						
N 020845 003	9408993*PED	Jul 06, 2031				
	9770570	May 03, 2036	U-2148			
	9770570*PED	Nov 03, 2036				
<u>NITRIC OXIDE - GENOSYL</u>						
N 202860 001	10124142	Aug 18, 2025	U-3037			
	10213572	Feb 12, 2036	DP			
	10737051	Oct 20, 2035	DP			
	10814092	Oct 17, 2025	U-3037			
	10926054	Aug 13, 2029	DP			
	11103669	Jun 21, 2030	DP			
	11291793	Aug 18, 2025	DP			
	11383059	Aug 18, 2025	U-3037			
	7560076	Apr 21, 2027	DP			
	7618594	Oct 17, 2026	DP			
	7947227	Oct 17, 2026	U-3037			
	8057742	Jan 18, 2026	U-3037			
	8226916	Aug 18, 2025	U-3037			
	8607785	Jul 14, 2030	DP			
	8609028	Aug 18, 2025	U-3037			
	8821801	Aug 18, 2025	DP			
	8944049	Aug 13, 2029	DP			
	9522249	Aug 18, 2025	DP			
	9604028	Aug 13, 2029	U-2793			
	9701538	Jan 28, 2029	DP			
	9956373	Aug 18, 2025	U-3037			
<u>NITROGLYCERIN - NITROLINGUAL PUMPSPRAY</u>						
N 018705 002	7872049	Mar 12, 2029	DP U-2223			
<u>NITROGLYCERIN - GONITRO</u>						
N 208424 001	9101592	Mar 11, 2032	DP			
<u>NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE</u>						
N 214628 001	10159657	Jan 30, 2038	DP			
	10226436	Jan 30, 2038	DP U-3461			
	10420735	Jan 30, 2038	DP U-3461			
	10568850	Jan 30, 2038	DP			
	11413259	Jan 30, 2038	DP U-3461			
<u>NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE</u>						
N 214628 002	10159657	Jan 30, 2038	DP			
	10226436	Jan 30, 2038	DP U-3461			
	10420735	Jan 30, 2038	DP U-3461			
	10568850	Jan 30, 2038	DP			
	11413259	Jan 30, 2038	DP U-3461			
<u>NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE</u>						
N 214628 003	10159657	Jan 30, 2038	DP			
	10226436	Jan 30, 2038	DP U-3461			
	10420735	Jan 30, 2038	DP U-3461			
	10568850	Jan 30, 2038	DP			
	11413259	Jan 30, 2038	DP U-3461			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE</u>						
N 215700 001	10888534	Apr 26, 2039	DP			
<u>NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE</u>						
N 215700 002	10888534	Apr 26, 2039	DP			
<u>NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE</u>						
N 215700 003	10888534	Apr 26, 2039	DP			
<u>NUSINERSEN SODIUM - SPINRAZA</u>						
N 209531 001	10266822	Dec 05, 2025	U-1942		ODE-127	Dec 23, 2023
	10266822	Dec 05, 2025	U-1943			
	10266822	Dec 05, 2025	U-1944			
	10436802	Sep 11, 2035	U-1941			
	10436802	Sep 11, 2035	U-1942			
	10436802	Sep 11, 2035	U-1943			
	10436802	Sep 11, 2035	U-1944			
	10436802	Sep 11, 2035	U-2093			
	10436802	Sep 11, 2035	U-2094			
	7101993	Sep 05, 2023	DS			
	7838657	Jul 11, 2027	DS			
	8110560	Dec 05, 2025	U-1942			
	8110560	Dec 05, 2025	U-1943			
	8110560	Dec 05, 2025	U-1944			
	8361977	May 27, 2030	DS DP			
	8980853	Nov 24, 2030	U-1941			
	9717750	Jun 17, 2030	U-1942			
	9717750	Jun 17, 2030	U-1943			
	9717750	Jun 17, 2030	U-2093			
	9717750	Jun 17, 2030	U-2094			
	9926559	Jan 09, 2034	U-1943			
<u>OBETICHOLIC ACID - OCALIVA</u>						
N 207999 001	10047117	Sep 06, 2033	U-1854		ODE-119	May 27, 2023
	10052337	Apr 26, 2036	DP			
	10174073	Jun 17, 2033	DS			
	10751349	Apr 26, 2036	DP			
	10758549	Apr 26, 2036	U-2945			
	9238673	Jun 17, 2033	DP			
	RE48286	Feb 21, 2027	DS DP			
<u>OBETICHOLIC ACID - OCALIVA</u>						
N 207999 002	10047117	Sep 06, 2033	U-1854		ODE-119	May 27, 2023
	10052337	Apr 26, 2036	DP			
	10174073	Jun 17, 2033	DS			
	10751349	Apr 26, 2036	DP			
	10758549	Apr 26, 2036	U-2945			
	9238673	Jun 17, 2033	DP			
	RE48286	Feb 21, 2027	DS DP			
<u>OCTREOTIDE ACETATE - MYCAPSSA</u>						
N 208232 001	10238709	Feb 03, 2036	U-2857		NP	Jun 26, 2023
	10695397	Feb 03, 2036	U-2857			
	11052126	Feb 03, 2036	U-2857			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OCTREOTIDE ACETATE - MYCAPSSA</u>						
N 208232 001	11141457	Dec 28, 2040	U-3232			
	11338011	Feb 03, 2036	U-2857			
	11510963	Feb 03, 2036	U-2857			
	8329198	Sep 17, 2029	DP			
	8535695	Sep 17, 2029	U-2857			
	9265812	Sep 17, 2029	DP			
	9566246	Sep 17, 2029	DP			
<u>ODEVIXIBAT - BYLVAY</u>						
N 215498 001	10011633	Nov 08, 2031	U-3186		NCE	Jul 20, 2026
	10093697	Nov 08, 2031	U-3186		ODE-363	Jul 20, 2028
	10487111	Nov 08, 2031	U-3186			
	10487111	Nov 08, 2031	U-3187			
	10975046	Jun 20, 2039	DS			
	10981952	Nov 08, 2031	U-3186			
	10981952	Nov 08, 2031	U-3187			
	11365182	Jun 20, 2039	U-3186			
	11365182	Jun 20, 2039	U-3187			
	9694018	Nov 08, 2031	U-3186			
<u>ODEVIXIBAT - BYLVAY</u>						
N 215498 002	10011633	Nov 08, 2031	U-3186		NCE	Jul 20, 2026
	10093697	Nov 08, 2031	U-3186		ODE-363	Jul 20, 2028
	10487111	Nov 08, 2031	U-3186			
	10487111	Nov 08, 2031	U-3187			
	10975046	Jun 20, 2039	DS			
	10981952	Nov 08, 2031	U-3186			
	10981952	Nov 08, 2031	U-3187			
	11365182	Jun 20, 2039	U-3186			
	11365182	Jun 20, 2039	U-3187			
	9694018	Nov 08, 2031	U-3186			
<u>ODEVIXIBAT - BYLVAY</u>						
N 215498 003	10011633	Nov 08, 2031	U-3186		NCE	Jul 20, 2026
	10093697	Nov 08, 2031	U-3186		ODE-363	Jul 20, 2028
	10487111	Nov 08, 2031	U-3186			
	10487111	Nov 08, 2031	U-3187			
	10975046	Jun 20, 2039	DS			
	10981952	Nov 08, 2031	U-3186			
	10981952	Nov 08, 2031	U-3187			
	11365182	Jun 20, 2039	U-3186			
	11365182	Jun 20, 2039	U-3187			
	9694018	Nov 08, 2031	U-3186			
<u>ODEVIXIBAT - BYLVAY</u>						
N 215498 004	10011633	Nov 08, 2031	U-3186		NCE	Jul 20, 2026
	10093697	Nov 08, 2031	U-3186		ODE-363	Jul 20, 2028
	10487111	Nov 08, 2031	U-3186			
	10487111	Nov 08, 2031	U-3187			
	10975046	Jun 20, 2039	DS			
	10981952	Nov 08, 2031	U-3186			
	10981952	Nov 08, 2031	U-3187			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ODEVIXIBAT - BYLVAY</u>						
N 215498 004	11365182	Jun 20, 2039	U-3186			
	11365182	Jun 20, 2039	U-3187			
	9694018	Nov 08, 2031	U-3186			
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 001	10300054	Aug 23, 2031	DP U-3140		NCE	May 28, 2026
	10300054	Aug 23, 2031	DP U-3141			
	10716785	Aug 23, 2031	U-3136			
	10716785	Aug 23, 2031	U-3137			
	11185541	Aug 23, 2031	U-3140			
	11241425	Aug 23, 2031	U-3137			
	11351166	Aug 23, 2031	U-3140			
	11351166	Aug 23, 2031	U-3141			
	7262298	Nov 23, 2025	DS			
	8778960	Feb 13, 2032	U-3136			
	8778960	Feb 13, 2032	U-3137			
	9119848	Aug 30, 2031	DS			
	9126977	Aug 23, 2031	DP U-3136			
	9126977	Aug 23, 2031	DP U-3137			
	9517235	Aug 23, 2031	U-3138			
	9517235	Aug 23, 2031	U-3139			
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 002	10300054	Aug 23, 2031	DP U-3140		NCE	May 28, 2026
	10300054	Aug 23, 2031	DP U-3141			
	10716785	Aug 23, 2031	U-3136			
	10716785	Aug 23, 2031	U-3137			
	11185541	Aug 23, 2031	U-3140			
	11241425	Aug 23, 2031	U-3137			
	11351166	Aug 23, 2031	U-3140			
	11351166	Aug 23, 2031	U-3141			
	7262298	Nov 23, 2025	DS			
	8778960	Feb 13, 2032	U-3136			
	8778960	Feb 13, 2032	U-3137			
	9119848	Aug 30, 2031	DS			
	9126977	Aug 23, 2031	DP U-3136			
	9126977	Aug 23, 2031	DP U-3137			
	9517235	Aug 23, 2031	U-3138			
	9517235	Aug 23, 2031	U-3139			
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 003	10300054	Aug 23, 2031	DP U-3140		NCE	May 28, 2026
	10300054	Aug 23, 2031	DP U-3141			
	10716785	Aug 23, 2031	U-3136			
	10716785	Aug 23, 2031	U-3137			
	11185541	Aug 23, 2031	U-3140			
	11241425	Aug 23, 2031	U-3137			
	11351166	Aug 23, 2031	U-3140			
	11351166	Aug 23, 2031	U-3141			
	7262298	Nov 23, 2025	DS			
	8778960	Feb 13, 2032	U-3136			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 003	8778960	Feb 13, 2032	U-3137			
	9119848	Aug 30, 2031	DS			
	9126977	Aug 23, 2031	DP U-3136			
	9126977	Aug 23, 2031	DP U-3137			
	9517235	Aug 23, 2031	U-3138			
	9517235	Aug 23, 2031	U-3139			
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 004	10300054	Aug 23, 2031	DP U-3140		NCE	May 28, 2026
	10300054	Aug 23, 2031	DP U-3141			
	10716785	Aug 23, 2031	U-3136			
	10716785	Aug 23, 2031	U-3137			
	11185541	Aug 23, 2031	U-3140			
	11241425	Aug 23, 2031	U-3137			
	11351166	Aug 23, 2031	U-3140			
	11351166	Aug 23, 2031	U-3141			
	7262298	Nov 23, 2025	DS			
	8778960	Feb 13, 2032	U-3136			
	8778960	Feb 13, 2032	U-3137			
	9119848	Aug 30, 2031	DS			
	9126977	Aug 23, 2031	DP U-3136			
	9126977	Aug 23, 2031	DP U-3137			
	9517235	Aug 23, 2031	U-3138			
	9517235	Aug 23, 2031	U-3139			
<u>OLAPARIB - LYNPARZA</u>						
N 206162 001	7449464	Oct 11, 2024	DS DP			
	7981889	Oct 11, 2024	DS DP			
	8143241	Aug 12, 2027	U-1634			
	8247416	Sep 24, 2028	DS			
	8859562	Aug 04, 2031	U-1634			
	8912187	Mar 12, 2024	U-1634			
<u>OLAPARIB - LYNPARZA</u>						
N 208558 001	7449464	Oct 11, 2024	DS DP		I-831	May 08, 2023
	7981889	Oct 11, 2024	DS DP		I-832	May 19, 2023
	8071579	Aug 12, 2027	U-2101		I-885	Mar 11, 2025
	8071579	Aug 12, 2027	U-2103		ODE-180	Aug 17, 2024
	8071579	Aug 12, 2027	U-2480		ODE-181	Aug 17, 2024
	8071579	Aug 12, 2027	U-2482		ODE-226	Dec 19, 2025
	8071579	Aug 12, 2027	U-2483		ODE-283	Dec 27, 2026
	8071579	Aug 12, 2027	U-2716		ODE-306	May 08, 2027
	8071579	Aug 12, 2027	U-2819			
	8071579	Aug 12, 2027	U-2820			
	8071579	Aug 12, 2027	U-2821			
	8071579	Aug 12, 2027	U-2822			
	8071579	Aug 12, 2027	U-2823			
	8071579	Aug 12, 2027	U-2824			
	8071579	Aug 12, 2027	U-2832			
	8071579	Aug 12, 2027	U-2833			
	8071579	Aug 12, 2027	U-3333			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OLAPARIB - LYNPARZA</u>						
N 208558 001	8143241	Aug 12, 2027	U-2101			
	8143241	Aug 12, 2027	U-2103			
	8143241	Aug 12, 2027	U-2480			
	8143241	Aug 12, 2027	U-2482			
	8143241	Aug 12, 2027	U-2483			
	8143241	Aug 12, 2027	U-2716			
	8143241	Aug 12, 2027	U-2819			
	8143241	Aug 12, 2027	U-2820			
	8143241	Aug 12, 2027	U-2821			
	8143241	Aug 12, 2027	U-2822			
	8143241	Aug 12, 2027	U-2823			
	8143241	Aug 12, 2027	U-2824			
	8143241	Aug 12, 2027	U-2832			
	8143241	Aug 12, 2027	U-2833			
	8143241	Aug 12, 2027	U-3333			
	8475842	Dec 31, 2029	DP			
	8859562	Aug 04, 2031	U-2101			
	8859562	Aug 04, 2031	U-2103			
	8859562	Aug 04, 2031	U-2480			
	8859562	Aug 04, 2031	U-2482			
	8859562	Aug 04, 2031	U-2483			
	8859562	Aug 04, 2031	U-2716			
	8859562	Aug 04, 2031	U-2819			
	8859562	Aug 04, 2031	U-2820			
	8859562	Aug 04, 2031	U-2821			
	8859562	Aug 04, 2031	U-2822			
	8859562	Aug 04, 2031	U-2823			
	8859562	Aug 04, 2031	U-2824			
	8859562	Aug 04, 2031	U-2832			
	8859562	Aug 04, 2031	U-2833			
	8859562	Aug 04, 2031	U-3333			
	8912187	Mar 12, 2024	U-2101			
	8912187	Mar 12, 2024	U-2480			
	8912187	Mar 12, 2024	U-2482			
	8912187	Mar 12, 2024	U-2483			
	8912187	Mar 12, 2024	U-2819			
	8912187	Mar 12, 2024	U-2820			
	8912187	Mar 12, 2024	U-2821			
	8912187	Mar 12, 2024	U-2822			
	8912187	Mar 12, 2024	U-2823			
	8912187	Mar 12, 2024	U-2824			
	8912187	Mar 12, 2024	U-3333			
	9169235	Mar 12, 2024	U-2832			
	9169235	Mar 12, 2024	U-2833			
	9566276	Mar 12, 2024	U-2716			
<u>OLAPARIB - LYNPARZA</u>						
N 208558 002	7449464	Oct 11, 2024	DS DP		I-831	May 08, 2023
	7981889	Oct 11, 2024	DS DP		I-832	May 19, 2023
	8071579	Aug 12, 2027	U-2101		I-885	Mar 11, 2025

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OLAPARIB - LYNPARZA</u>						
N 208558 002	8071579	Aug 12, 2027	U-2103		ODE-180	Aug 17, 2024
	8071579	Aug 12, 2027	U-2480		ODE-181	Aug 17, 2024
	8071579	Aug 12, 2027	U-2482		ODE-226	Dec 19, 2025
	8071579	Aug 12, 2027	U-2483		ODE-283	Dec 27, 2026
	8071579	Aug 12, 2027	U-2716		ODE-306	May 08, 2027
	8071579	Aug 12, 2027	U-2819			
	8071579	Aug 12, 2027	U-2820			
	8071579	Aug 12, 2027	U-2821			
	8071579	Aug 12, 2027	U-2822			
	8071579	Aug 12, 2027	U-2823			
	8071579	Aug 12, 2027	U-2824			
	8071579	Aug 12, 2027	U-2832			
	8071579	Aug 12, 2027	U-2833			
	8071579	Aug 12, 2027	U-3333			
	8143241	Aug 12, 2027	U-2101			
	8143241	Aug 12, 2027	U-2103			
	8143241	Aug 12, 2027	U-2480			
	8143241	Aug 12, 2027	U-2482			
	8143241	Aug 12, 2027	U-2483			
	8143241	Aug 12, 2027	U-2716			
	8143241	Aug 12, 2027	U-2819			
	8143241	Aug 12, 2027	U-2820			
	8143241	Aug 12, 2027	U-2821			
	8143241	Aug 12, 2027	U-2822			
	8143241	Aug 12, 2027	U-2823			
	8143241	Aug 12, 2027	U-2824			
	8143241	Aug 12, 2027	U-2832			
	8143241	Aug 12, 2027	U-2833			
	8143241	Aug 12, 2027	U-3333			
	8475842	Dec 31, 2029	DP			
	8859562	Aug 04, 2031	U-2101			
	8859562	Aug 04, 2031	U-2103			
	8859562	Aug 04, 2031	U-2480			
	8859562	Aug 04, 2031	U-2482			
	8859562	Aug 04, 2031	U-2483			
	8859562	Aug 04, 2031	U-2716			
	8859562	Aug 04, 2031	U-2819			
	8859562	Aug 04, 2031	U-2820			
	8859562	Aug 04, 2031	U-2821			
	8859562	Aug 04, 2031	U-2822			
	8859562	Aug 04, 2031	U-2823			
	8859562	Aug 04, 2031	U-2824			
	8859562	Aug 04, 2031	U-2832			
	8859562	Aug 04, 2031	U-2833			
	8859562	Aug 04, 2031	U-3333			
	8912187	Mar 12, 2024	U-2101			
	8912187	Mar 12, 2024	U-2480			
	8912187	Mar 12, 2024	U-2482			
	8912187	Mar 12, 2024	U-2483			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OLAPARIB - LYNPARZA</u>						
N 208558 002	8912187	Mar 12, 2024	U-2819			
	8912187	Mar 12, 2024	U-2820			
	8912187	Mar 12, 2024	U-2821			
	8912187	Mar 12, 2024	U-2822			
	8912187	Mar 12, 2024	U-2823			
	8912187	Mar 12, 2024	U-2824			
	8912187	Mar 12, 2024	U-3333			
	9169235	Mar 12, 2024	U-2832			
	9169235	Mar 12, 2024	U-2833			
	9566276	Mar 12, 2024	U-2716			
<u>OLICERIDINE - OLINVYK</u>						
N 210730 001	11077098	Mar 23, 2032	DS DP U-2986		NCE	Oct 30, 2025
	8835488	Mar 23, 2032	DS DP U-2986			
	9309234	Mar 23, 2032	DS DP U-2986			
	9642842	Mar 23, 2032	DP U-2986			
<u>OLICERIDINE - OLINVYK</u>						
N 210730 002	11077098	Mar 23, 2032	DS DP U-2986		NCE	Oct 30, 2025
	8835488	Mar 23, 2032	DS DP U-2986			
	9309234	Mar 23, 2032	DS DP U-2986			
	9642842	Mar 23, 2032	DP U-2986			
<u>OLICERIDINE - OLINVYK</u>						
N 210730 003	11077098	Mar 23, 2032	DS DP U-2986		NCE	Oct 30, 2025
	8835488	Mar 23, 2032	DS DP U-2986			
	9309234	Mar 23, 2032	DS DP U-2986			
	9642842	Mar 23, 2032	DP U-2986			
<u>OLODATEROL HYDROCHLORIDE - STRIVERDI RESPIMAT</u>						
N 203108 001	7056916	Dec 07, 2023	DS DP			
	7220742	May 12, 2025	DS DP U-1547			
	7284474	Aug 26, 2024	DP			
	7396341	Oct 10, 2026	DP U-1547			
	7491719	Nov 10, 2023	DS DP			
	7727984	Jan 19, 2027	DS			
	7786111	Nov 10, 2023	DP			
	7837235	Mar 13, 2028	DP			
	7896264	May 26, 2025	DP			
	8034809	May 12, 2025	U-1547			
	8044046	Nov 10, 2023	U-1547			
	8733341	Oct 16, 2030	DP			
	9027967	Mar 31, 2027	DP			
<u>OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE - STIOLTO RESPIMAT</u>						
N 206756 001	7056916	Dec 07, 2023	DS DP			
	7220742	May 12, 2025	DS DP U-1703			
	7284474	Aug 26, 2024	DP			
	7284474*PED	Feb 26, 2025				
	7396341	Oct 10, 2026	DP			
	7396341*PED	Apr 10, 2027				
	7491719	Nov 10, 2023	DS DP			
	7727984	Jan 19, 2027	DS			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE - STIOLTO RESPIMAT</u>						
N 206756 001	7786111	Nov 10, 2023	DP			
	7837235	Mar 13, 2028	DP			
	7837235*PED	Sep 13, 2028				
	7896264	May 26, 2025	DP			
	8034809	May 12, 2025	U-1702			
	8044046	Nov 10, 2023	U-1702			
	8733341	Oct 16, 2030	DP			
	9027967	Mar 31, 2027	DP			
<u>OLOPATADINE HYDROCHLORIDE - PATANASE</u>						
N 021861 001	7977376	Feb 02, 2023	DP			
	8399508*PED	Mar 17, 2023				
<u>OLOPATADINE HYDROCHLORIDE - PATADAY ONCE DAILY RELIEF</u>						
N 206276 001	8791154	May 19, 2032	DP	U-1680		
	9533053	May 19, 2032	DP			
<u>OLUTASIDENIB - REZLIDHIA</u>						
N 215814 001	10414752	Sep 18, 2035	DP			
	10532047	May 16, 2039	DS			
	10550098	Sep 18, 2035	DP			
	10959994	May 16, 2039	DP			
	11013733	May 16, 2039	U-3496			
	11013734	May 16, 2039	U-3495			
	11376246	May 16, 2039	U-3495			
	11497743	May 16, 2039	U-3495			
	11498913	Sep 18, 2035	DP			
	9834539	Sep 18, 2035	DS DP	U-3497		
<u>OMACETAXINE MEPESUCCINATE - SYNRIBO</u>						
N 203585 001	6987103	Oct 26, 2026	U-1300			
<u>OMADACYCLINE TOSYLATE - NUZYRA</u>						
N 209816 001	10111890	Aug 03, 2037	U-2444		NCE	Oct 02, 2023
	10124014	Mar 05, 2029	U-2449		GAIN	Oct 02, 2028
	10383884	Oct 31, 2037	U-2576			
	10835542	Oct 31, 2037	U-2576			
	7326696	Sep 24, 2023	DS			
	7553828	Jun 02, 2023	DS			
	8383610	Sep 23, 2030	DS			
	9265740	Mar 05, 2029	U-1569			
	9314475	Mar 18, 2031	DP			
	9724358	Mar 05, 2029	U-1569			
<u>OMADACYCLINE TOSYLATE - NUZYRA</u>						
N 209817 001	10124014	Mar 05, 2029	U-2449		NCE	Oct 02, 2023
	10383884	Oct 31, 2037	U-2576		GAIN	Oct 02, 2028
	10835542	Oct 31, 2037	U-2576			
	7326696	Sep 24, 2023	DS			
	7553828	Jun 02, 2023	DS			
	9265740	Mar 05, 2029	DP			
	9724358	Mar 05, 2029	U-1569			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OMBITASVIR; PARITAPREVIR; RITONAVIR - TECHNIVIE</u>						
N 207931 001	8268349	Aug 25, 2024	DP			
	8268349*PED	Feb 25, 2025				
	8399015	Aug 25, 2024	DP			
	8399015*PED	Feb 25, 2025				
	8420596	Apr 10, 2031	DS DP			
	8420596*PED	Oct 10, 2031				
	8642538	Sep 10, 2029	DS DP U-1638			
	8686026	Jun 09, 2031	DP			
	8691938	Apr 13, 2032	DS DP			
	9006387	Jun 10, 2030	U-1687			
	9044480	Apr 10, 2031	U-1638			
<u>OMEGA-3-CARBOXYLIC ACIDS - EPANOVA</u>						
N 205060 001	10117844	Jan 04, 2033	U-2447			
	7960370	Dec 20, 2026	DP			
	8383678	Feb 07, 2025	DP U-1511			
	9012501	Feb 07, 2025	DP U-1511			
	9050308	Jan 04, 2033	U-1511			
	9050309	Jan 04, 2033	DS			
	9132112	Feb 07, 2025	DP U-1511			
<u>OMEPRAZOLE - OMEPRAZOLE</u>						
N 022032 001	9023391	Aug 16, 2025	DP			
<u>OMEPRAZOLE - OMEPRAZOLE</u>						
N 209400 001	10076494	Dec 08, 2036	DP			
	10835488	Dec 08, 2036	DP			
<u>OMEPRAZOLE; SODIUM BICARBONATE - KONVOMEF</u>						
N 213593 001	10751333	Jul 16, 2039	DP			
	11103492	Jul 16, 2039	DP			
<u>OMIDENEPAG ISOPROPYL - OMLONTI</u>						
N 215092 001	10179127	Jan 08, 2035	DP U-3454		NCE	Sep 22, 2027
	10702511	Jan 08, 2035	DP U-3454			
	10765750	Jan 08, 2035	DP			
	10774072	Jun 10, 2035	DS			
	11197849	Jan 08, 2035	DP U-3454			
	8648097	Oct 13, 2029	DS DP			
	8685986	Oct 13, 2029	DP			
	9415038	Jan 08, 2035	DP U-3454			
	RE48183	Jan 08, 2035	DP U-3454			
<u>ONDANSETRON - ZUPLENZ</u>						
N 022524 001	8580830	Nov 23, 2029	DP			
	9095577	Jul 13, 2030	DP			
<u>ONDANSETRON - ZUPLENZ</u>						
N 022524 002	8580830	Nov 23, 2029	DP			
	9095577	Jul 13, 2030	DP			
<u>OPICAPONE - ONGENTYS</u>						
N 212489 001	10071085	Mar 31, 2030	DP		NCE	Apr 24, 2025
	10357468	May 27, 2035	U-2812			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OPICAPONE - ONGENTYS</u>						
N 212489 001	10583130	Mar 31, 2030	U-2811			
	8168793	Apr 02, 2029	DS DP U-2811			
	8524746	Jul 14, 2029	U-2811			
	8907099	May 12, 2027	DS			
	9550759	Jul 26, 2026	U-2811			
	9550759	Jul 26, 2026	U-2817			
	9550759	Jul 26, 2026	U-2818			
	9630955	Dec 12, 2032	DS DP U-2811			
	9745290	Oct 10, 2027	DP U-2811			
<u>OPICAPONE - ONGENTYS</u>						
N 212489 002	10071085	Mar 31, 2030	DP		NCE	Apr 24, 2025
	10357468	May 27, 2035	U-2812			
	10583130	Mar 31, 2030	U-2811			
	8168793	Apr 02, 2029	DS DP U-2811			
	8524746	Jul 14, 2029	U-2811			
	8907099	May 12, 2027	DS			
	9550759	Jul 26, 2026	U-2811			
	9550759	Jul 26, 2026	U-2817			
	9550759	Jul 26, 2026	U-2818			
	9630955	Dec 12, 2032	DS DP U-2811			
	9745290	Oct 10, 2027	DP U-2811			
<u>ORITAVANCIN DIPHOSPHATE - ORBACTIV</u>						
N 206334 001	8420592	Aug 29, 2029	U-1570		NCE	Aug 06, 2019
	9649352	Jul 16, 2035	DP		GAIN	Aug 06, 2024
	9682061	Apr 26, 2030	U-1569			
<u>ORITAVANCIN DIPHOSPHATE - KIMYRSA</u>						
N 214155 001	8420592	Aug 29, 2029	U-3101		NCE	Aug 06, 2019
	9649352	Jul 16, 2035	DS DP		NP	Mar 12, 2024
	9682061	Apr 26, 2030	U-3101		GAIN	Aug 06, 2024
<u>OSILODROSTAT PHOSPHATE - ISTURISA</u>						
N 212801 001	10143680	Jul 06, 2035	DP		NCE	Mar 06, 2025
	10709691	Oct 12, 2035	U-2770		ODE-286	Mar 06, 2027
	8314097	Mar 27, 2029	DS DP			
	8609862	Jan 13, 2031	U-2770			
	8835646	Aug 23, 2026	DS DP			
	9434754	Jan 13, 2031	DS			
<u>OSILODROSTAT PHOSPHATE - ISTURISA</u>						
N 212801 002	10143680	Jul 06, 2035	DP		NCE	Mar 06, 2025
	10709691	Oct 12, 2035	U-2770		ODE-286	Mar 06, 2027
	8314097	Mar 27, 2029	DS DP			
	8609862	Jan 13, 2031	U-2770			
	8835646	Aug 23, 2026	DS DP			
	9434754	Jan 13, 2031	DS			
<u>OSILODROSTAT PHOSPHATE - ISTURISA</u>						
N 212801 003	10143680	Jul 06, 2035	DP		NCE	Mar 06, 2025
	10709691	Oct 12, 2035	U-2770		ODE-286	Mar 06, 2027
	8314097	Mar 27, 2029	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OSILODROSTAT PHOSPHATE - ISTURISA</u>						
N 212801 003	8609862	Jan 13, 2031	U-2770			
	8835646	Aug 23, 2026	DS DP			
	9434754	Jan 13, 2031	DS			
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065 001	10183020	Jan 02, 2035	DP U-1777		I-853	Dec 18, 2023
	10183020	Jan 02, 2035	DP U-2289		ODE-176	Apr 18, 2025
	10183020	Jan 02, 2035	DP U-3016		ODE-337	Dec 18, 2027
	11524951	Jul 25, 2032	DS DP			
	8946235	Aug 08, 2032	DS DP U-1777			
	8946235	Aug 08, 2032	DS DP U-2289			
	8946235	Aug 08, 2032	DS DP U-3016			
	9732058	Jul 25, 2032	DS DP U-1777			
	9732058	Jul 25, 2032	DS DP U-2289			
	9732058	Jul 25, 2032	DS DP U-3016			
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065 002	10183020	Jan 02, 2035	DP U-1777		I-853	Dec 18, 2023
	10183020	Jan 02, 2035	DP U-2289		ODE-176	Apr 18, 2025
	10183020	Jan 02, 2035	DP U-3016		ODE-337	Dec 18, 2027
	11524951	Jul 25, 2032	DS DP			
	8946235	Aug 08, 2032	DS DP U-1777			
	8946235	Aug 08, 2032	DS DP U-2289			
	8946235	Aug 08, 2032	DS DP U-3016			
	9732058	Jul 25, 2032	DS DP U-1777			
	9732058	Jul 25, 2032	DS DP U-2289			
	9732058	Jul 25, 2032	DS DP U-3016			
<u>OSPHEMIFENE - OSPHENA</u>						
N 203505 001	6245819	Jul 21, 2025	U-1370			
	6245819	Jul 21, 2025	U-905			
	8236861	Aug 11, 2026	U-1369			
	8236861	Aug 11, 2026	U-1370			
	8236861	Aug 11, 2026	U-905			
	8470890	Feb 13, 2024	U-1369			
	8470890	Feb 13, 2024	U-1370			
	8470890	Feb 13, 2024	U-905			
	8642079	Jul 09, 2028	DP			
	8772353	Feb 13, 2024	U-1369			
	8772353	Feb 13, 2024	U-1370			
	8772353	Feb 13, 2024	U-905			
	9241915	Feb 13, 2024	U-1369			
	9241915	Feb 13, 2024	U-1370			
	9241915	Feb 13, 2024	U-905			
	9855224	Feb 13, 2024	U-1369			
	9855224	Feb 13, 2024	U-1370			
	9855224	Feb 13, 2024	U-905			
<u>OTEESECONAZOLE - VIVJOA</u>						
N 215888 001	10414751	Mar 17, 2036	DS DP		NCE	Apr 26, 2027
	11247981	May 09, 2033	U-3366		GAIN	Apr 26, 2032
	8236962	Apr 22, 2031	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OTECSECONAZOLE - VIVJOA</u>						
N 215888	001 8754227	Apr 22, 2031			U-3366	
	9840492	Mar 17, 2036	DS DP			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810	001 10220042	Apr 13, 2027			U-2501	
	11166960	Apr 13, 2027	DP			
	7722898	Apr 13, 2027	DP			
	7910131	Apr 13, 2027			U-2041	
	8617600	Apr 13, 2027	DP			
	8821930	Apr 13, 2027	DP			
	9119791	Apr 13, 2027			U-2041	
	9351975	Apr 13, 2027	DP			
	9370525	Apr 13, 2027	DP			
	9855278	Apr 13, 2027	DP			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810	002 10220042	Apr 13, 2027			U-2501	
	11166960	Apr 13, 2027	DP			
	7722898	Apr 13, 2027	DP			
	7910131	Apr 13, 2027			U-2041	
	8617600	Apr 13, 2027	DP			
	8821930	Apr 13, 2027	DP			
	9119791	Apr 13, 2027			U-2041	
	9351975	Apr 13, 2027	DP			
	9370525	Apr 13, 2027	DP			
	9855278	Apr 13, 2027	DP			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810	003 10220042	Apr 13, 2027			U-2501	
	11166960	Apr 13, 2027	DP			
	7722898	Apr 13, 2027	DP			
	7910131	Apr 13, 2027			U-2041	
	8617600	Apr 13, 2027	DP			
	8821930	Apr 13, 2027	DP			
	9119791	Apr 13, 2027			U-2041	
	9351975	Apr 13, 2027	DP			
	9370525	Apr 13, 2027	DP			
	9855278	Apr 13, 2027	DP			
<u>OXYBUTYNIN CHLORIDE - GELNIQUE</u>						
N 022204	001 10449173	Nov 06, 2029	DP		U-2637	
	8920392	Mar 26, 2031			U-1644	
	9259388	Nov 06, 2029			U-1644	
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090	001 10004729	Dec 10, 2030	DP		U-1556	
	10188644	Sep 02, 2036	DP		U-1556	
	10525052	Jul 07, 2023	DP		U-1556	
	10525053	Jul 07, 2023	DP			
	10646485	Sep 02, 2036	DP		U-1556	
	10668060	Dec 10, 2030	DP		U-1556	
	7399488	Mar 24, 2025	DP			
	7771707	Mar 24, 2025	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 001	8449909	Mar 24, 2025	DP			
	8557291	Mar 21, 2025	DP			
	8758813	Jun 10, 2025	U-1556			
	8840928	Jul 07, 2023	DP U-1556			
	9044398	Jul 07, 2023	DP			
	9248195	Jul 07, 2023	U-1556			
	9592200	Jul 07, 2023	DP			
	9682075	Dec 10, 2030	DP U-1556			
	9737530	Sep 02, 2036	DP U-1556			
	9763883	Jul 07, 2023	DP			
	9968598	Sep 02, 2036	DP U-1556			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 002	10004729	Dec 10, 2030	DP U-1556			
	10188644	Sep 02, 2036	DP U-1556			
	10525052	Jul 07, 2023	DP U-1556			
	10525053	Jul 07, 2023	DP			
	10646485	Sep 02, 2036	DP U-1556			
	10668060	Dec 10, 2030	DP U-1556			
	7399488	Mar 24, 2025	DP			
	7771707	Mar 24, 2025	DP			
	8449909	Mar 24, 2025	DP			
	8557291	Mar 21, 2025	DP			
	8758813	Jun 10, 2025	U-1556			
	8840928	Jul 07, 2023	DP U-1556			
	9044398	Jul 07, 2023	DP			
	9248195	Jul 07, 2023	U-1556			
	9592200	Jul 07, 2023	DP			
	9682075	Dec 10, 2030	DP U-1556			
	9737530	Sep 02, 2036	DP U-1556			
	9763883	Jul 07, 2023	DP			
	9968598	Sep 02, 2036	DP U-1556			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 003	10004729	Dec 10, 2030	DP U-1556			
	10188644	Sep 02, 2036	DP U-1556			
	10525052	Jul 07, 2023	DP U-1556			
	10525053	Jul 07, 2023	DP			
	10646485	Sep 02, 2036	DP U-1556			
	10668060	Dec 10, 2030	DP U-1556			
	7399488	Mar 24, 2025	DP			
	7771707	Mar 24, 2025	DP			
	8449909	Mar 24, 2025	DP			
	8557291	Mar 21, 2025	DP			
	8758813	Jun 10, 2025	U-1556			
	8840928	Jul 07, 2023	DP U-1556			
	9044398	Jul 07, 2023	DP			
	9248195	Jul 07, 2023	U-1556			
	9592200	Jul 07, 2023	DP			
	9682075	Dec 10, 2030	DP U-1556			
	9737530	Sep 02, 2036	DP U-1556			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090	003	9763883	Jul 07, 2023	DP		
	9968598	Sep 02, 2036	DP U-1556			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090	004	10004729	Dec 10, 2030	DP U-1556		
	10188644	Sep 02, 2036	DP U-1556			
	10525052	Jul 07, 2023	DP U-1556			
	10525053	Jul 07, 2023	DP			
	10646485	Sep 02, 2036	DP U-1556			
	10668060	Dec 10, 2030	DP U-1556			
	7399488	Mar 24, 2025	DP			
	7771707	Mar 24, 2025	DP			
	8449909	Mar 24, 2025	DP			
	8557291	Mar 21, 2025	DP			
	8758813	Jun 10, 2025	U-1556			
	8840928	Jul 07, 2023	DP U-1556			
	9044398	Jul 07, 2023	DP			
	9248195	Jul 07, 2023	U-1556			
	9592200	Jul 07, 2023	DP			
	9682075	Dec 10, 2030	DP U-1556			
	9737530	Sep 02, 2036	DP U-1556			
	9763883	Jul 07, 2023	DP			
	9968598	Sep 02, 2036	DP U-1556			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090	005	10004729	Dec 10, 2030	DP U-1556		
	10188644	Sep 02, 2036	DP U-1556			
	10525052	Jul 07, 2023	DP U-1556			
	10525053	Jul 07, 2023	DP			
	10646485	Sep 02, 2036	DP U-1556			
	10668060	Dec 10, 2030	DP U-1556			
	7399488	Mar 24, 2025	DP			
	7771707	Mar 24, 2025	DP			
	8449909	Mar 24, 2025	DP			
	8557291	Mar 21, 2025	DP			
	8758813	Jun 10, 2025	U-1556			
	8840928	Jul 07, 2023	DP U-1556			
	9044398	Jul 07, 2023	DP			
	9248195	Jul 07, 2023	U-1556			
	9592200	Jul 07, 2023	DP			
	9682075	Dec 10, 2030	DP U-1556			
	9737530	Sep 02, 2036	DP U-1556			
	9763883	Jul 07, 2023	DP			
	9968598	Sep 02, 2036	DP U-1556			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272	001	10130591	Nov 20, 2023	DP U-1819		
	10369109	Jun 16, 2023	DP			
	10407434	Mar 30, 2025	DS			
	10675278	Nov 20, 2023	DP			
	10696684	Mar 30, 2025	DS			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 001	11304908	Aug 24, 2027	DP			
	11304909	Aug 24, 2027	U-1556			
	8309060	Nov 20, 2023	DP U-1556			
	8808741	Aug 24, 2027	U-1556			
	8894987	Mar 29, 2030	DP			
	8894988	Aug 24, 2027	DP			
	9073933	Mar 30, 2025	DS			
	9492389	Aug 24, 2027	DP			
	9492391	Aug 24, 2027	U-1556			
	9492392	Aug 24, 2027	DP			
	9492393	Aug 24, 2027	U-1556			
	9522919	Mar 30, 2025	DS DP			
	9675610	Jun 16, 2023	DP			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775808	Aug 24, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 002	10130591	Nov 20, 2023	DP U-1819			
	10369109	Jun 16, 2023	DP			
	10407434	Mar 30, 2025	DS			
	10675278	Nov 20, 2023	DP			
	10696684	Mar 30, 2025	DS			
	11304908	Aug 24, 2027	DP			
	11304909	Aug 24, 2027	U-1556			
	8309060	Nov 20, 2023	DP U-1556			
	8808741	Aug 24, 2027	U-1556			
	8894987	Mar 29, 2030	DP			
	8894988	Aug 24, 2027	DP			
	9073933	Mar 30, 2025	DS			
	9492389	Aug 24, 2027	DP			
	9492391	Aug 24, 2027	U-1556			
	9492392	Aug 24, 2027	DP			
	9492393	Aug 24, 2027	U-1556			
	9522919	Mar 30, 2025	DS DP			
	9675610	Jun 16, 2023	DP			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775808	Aug 24, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 003	10130591	Nov 20, 2023	DP U-1819			
	10369109	Jun 16, 2023	DP			
	10407434	Mar 30, 2025	DS			
	10675278	Nov 20, 2023	DP			
	10696684	Mar 30, 2025	DS			
	11304908	Aug 24, 2027	DP			
	11304909	Aug 24, 2027	U-1556			
	8309060	Nov 20, 2023	DP U-1556			
	8808741	Aug 24, 2027	U-1556			
	8894987	Mar 29, 2030	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 003	8894988	Aug 24, 2027	DP			
	9073933	Mar 30, 2025	DS			
	9492389	Aug 24, 2027	DP			
	9492391	Aug 24, 2027			U-1556	
	9492392	Aug 24, 2027	DP			
	9492393	Aug 24, 2027			U-1556	
	9522919	Mar 30, 2025	DS DP			
	9675610	Jun 16, 2023	DP			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775808	Aug 24, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 004	10130591	Nov 20, 2023	DP	U-1819		
	10369109	Jun 16, 2023	DP			
	10407434	Mar 30, 2025	DS			
	10675278	Nov 20, 2023	DP			
	10696684	Mar 30, 2025	DS			
	11304908	Aug 24, 2027	DP			
	11304909	Aug 24, 2027			U-1556	
	8309060	Nov 20, 2023	DP	U-1556		
	8808741	Aug 24, 2027			U-1556	
	8894987	Mar 29, 2030	DP			
	8894988	Aug 24, 2027	DP			
	9073933	Mar 30, 2025	DS			
	9492389	Aug 24, 2027	DP			
	9492391	Aug 24, 2027			U-1556	
	9492392	Aug 24, 2027	DP			
	9492393	Aug 24, 2027			U-1556	
	9522919	Mar 30, 2025	DS DP			
	9675610	Jun 16, 2023	DP			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775808	Aug 24, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 005	10130591	Nov 20, 2023	DP	U-1819		
	10369109	Jun 16, 2023	DP			
	10407434	Mar 30, 2025	DS			
	10675278	Nov 20, 2023	DP			
	10696684	Mar 30, 2025	DS			
	11304908	Aug 24, 2027	DP			
	11304909	Aug 24, 2027			U-1556	
	8309060	Nov 20, 2023	DP	U-1556		
	8808741	Aug 24, 2027			U-1556	
	8894988	Aug 24, 2027	DP			
	9073933	Mar 30, 2025	DS			
	9492389	Aug 24, 2027	DP			
	9492391	Aug 24, 2027			U-1556	
	9492392	Aug 24, 2027	DP			
	9492393	Aug 24, 2027			U-1556	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 005	9522919	Mar 30, 2025	DS DP			
	9675610	Jun 16, 2023	DP			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775808	Aug 24, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 006	10130591	Nov 20, 2023	DP U-1819			
	10369109	Jun 16, 2023	DP			
	10407434	Mar 30, 2025	DS			
	10675278	Nov 20, 2023	DP			
	10696684	Mar 30, 2025	DS			
	11304908	Aug 24, 2027	DP			
	11304909	Aug 24, 2027	U-1556			
	8309060	Nov 20, 2023	DP U-1556			
	8808741	Aug 24, 2027	U-1556			
	8894988	Aug 24, 2027	DP			
	9073933	Mar 30, 2025	DS			
	9492389	Aug 24, 2027	DP			
	9492391	Aug 24, 2027	U-1556			
	9492392	Aug 24, 2027	DP			
	9492393	Aug 24, 2027	U-1556			
	9522919	Mar 30, 2025	DS DP			
	9675610	Jun 16, 2023	DP			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775808	Aug 24, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 007	10130591	Nov 20, 2023	DP U-1819			
	10369109	Jun 16, 2023	DP			
	10407434	Mar 30, 2025	DS			
	10675278	Nov 20, 2023	DP			
	10696684	Mar 30, 2025	DS			
	11304908	Aug 24, 2027	DP			
	11304909	Aug 24, 2027	U-1556			
	8309060	Nov 20, 2023	DP U-1556			
	8808741	Aug 24, 2027	U-1556			
	8894988	Aug 24, 2027	DP			
	9073933	Mar 30, 2025	DS			
	9492389	Aug 24, 2027	DP			
	9492391	Aug 24, 2027	U-1556			
	9492392	Aug 24, 2027	DP			
	9492393	Aug 24, 2027	U-1556			
	9522919	Mar 30, 2025	DS DP			
	9675610	Jun 16, 2023	DP			
	9763933	Aug 24, 2027	DP			
	9770416	Aug 24, 2027	DP			
	9775808	Aug 24, 2027	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYCODONE HYDROCHLORIDE - OXAYDO</u>						
N 202080 001	7201920	Mar 16, 2025	DP			
	7510726	Nov 26, 2023	DP			
	7981439	Nov 26, 2023	DP			
	8409616	Nov 26, 2023	DP			
	8637540	Nov 26, 2023	DP			
	9492443	May 26, 2024	DP			
<u>OXYCODONE HYDROCHLORIDE - OXAYDO</u>						
N 202080 002	7201920	Mar 16, 2025	DP			
	7510726	Nov 26, 2023	DP			
	7981439	Nov 26, 2023	DP			
	8409616	Nov 26, 2023	DP			
	8637540	Nov 26, 2023	DP			
	9492443	May 26, 2024	DP			
<u>OXYCODONE HYDROCHLORIDE - ROXYBOND</u>						
N 209777 001	10314788	Aug 12, 2028	DP			
	7955619	Aug 12, 2028	DP			
<u>OXYCODONE HYDROCHLORIDE - ROXYBOND</u>						
N 209777 002	10314788	Aug 12, 2028	DP			
	7955619	Aug 12, 2028	DP			
<u>OXYCODONE HYDROCHLORIDE - ROXYBOND</u>						
N 209777 003	10314788	Aug 12, 2028	DP			
	7955619	Aug 12, 2028	DP			
<u>OXYMETAZOLINE HYDROCHLORIDE - RHOFAD</u>						
N 208552 001	10335391	Jun 11, 2035	U-2567			
	10751325	Jun 11, 2035	U-2921			
	11517560	Jun 11, 2035	U-3494			
	7812049	May 02, 2028	U-1959			
	8420688	Aug 02, 2024	U-1959			
	8815929	Jan 22, 2024	U-1959			
	8883838	Dec 01, 2031	DP			
	9974773	Jun 11, 2035	U-2306			
<u>OXYMETAZOLINE HYDROCHLORIDE - UPNEEQ</u>						
N 212520 001	10799481	Dec 16, 2039	U-2849		NP	Jul 08, 2023
	10814001	Dec 16, 2039	DP			
	10898573	Dec 16, 2039	DP			
	10912765	Aug 26, 2031	U-2849			
	10940138	Dec 16, 2039	U-2849			
	11103482	Dec 16, 2039	DP			
	11311515	Dec 16, 2039	DP			
	11324722	Dec 16, 2039	U-2849			
	11541036	Dec 16, 2039	DP			
	8357714	Aug 26, 2031	U-2849			
	9867808	Aug 26, 2031	U-2849			
<u>OXYMETAZOLINE HYDROCHLORIDE; TETRACAINE HYDROCHLORIDE - KOVANAZE</u>						
N 208032 001	8580282	Apr 02, 2030	DP U-1876			
	9308191	Apr 02, 2030	DP U-1876			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 021610 001	7276250	Feb 04, 2023	DP U-826			
	8309112	Feb 04, 2023	DP			
	8329216	Feb 04, 2023	DP			
	8808737	Jun 21, 2027	U-3085			
	8871779	Nov 22, 2029	DS			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 021610 002	7276250	Feb 04, 2023	DP U-826			
	8309112	Feb 04, 2023	DP			
	8329216	Feb 04, 2023	DP			
	8808737	Jun 21, 2027	U-3085			
	8871779	Nov 22, 2029	DS			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 021610 003	7276250	Feb 04, 2023	DP U-826			
	8309112	Feb 04, 2023	DP			
	8329216	Feb 04, 2023	DP			
	8808737	Jun 21, 2027	U-3085			
	8871779	Nov 22, 2029	DS			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 021610 004	7276250	Feb 04, 2023	DP U-826			
	8309112	Feb 04, 2023	DP			
	8329216	Feb 04, 2023	DP			
	8808737	Jun 21, 2027	U-3085			
	8871779	Nov 22, 2029	DS			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 021610 005	7276250	Feb 04, 2023	DP U-826			
	8309112	Feb 04, 2023	DP			
	8329216	Feb 04, 2023	DP			
	8808737	Jun 21, 2027	U-3085			
	8871779	Nov 22, 2029	DS			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 021610 006	7276250	Feb 04, 2023	DP U-826			
	8309112	Feb 04, 2023	DP			
	8329216	Feb 04, 2023	DP			
	8808737	Jun 21, 2027	U-3085			
	8871779	Nov 22, 2029	DS			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 021610 007	7276250	Feb 04, 2023	DP U-826			
	8309112	Feb 04, 2023	DP			
	8329216	Feb 04, 2023	DP			
	8808737	Jun 21, 2027	U-3085			
	8871779	Nov 22, 2029	DS			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 201655 001	7851482	Jul 10, 2029	DS			
	8075872	Nov 20, 2023	DP			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
	8309060	Nov 20, 2023	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 201655 001	8309122	Feb 04, 2023	DP			
	8329216	Feb 04, 2023	DP			
	8808737	Jun 21, 2027			U-1598	
	8871779	Nov 22, 2029	DS			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 201655 002	7851482	Jul 10, 2029	DS			
	8075872	Nov 20, 2023	DP			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
	8309060	Nov 20, 2023	DP			
	8309122	Feb 04, 2023	DP			
	8329216	Feb 04, 2023	DP			
	8808737	Jun 21, 2027			U-1598	
	8871779	Nov 22, 2029	DS			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 201655 003	7851482	Jul 10, 2029	DS			
	8075872	Nov 20, 2023	DP			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
	8309060	Nov 20, 2023	DP			
	8309122	Feb 04, 2023	DP			
	8329216	Feb 04, 2023	DP			
	8808737	Jun 21, 2027			U-1598	
	8871779	Nov 22, 2029	DS			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 201655 004	7851482	Jul 10, 2029	DS			
	8075872	Nov 20, 2023	DP			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
	8309060	Nov 20, 2023	DP			
	8309122	Feb 04, 2023	DP			
	8329216	Feb 04, 2023	DP			
	8808737	Jun 21, 2027			U-1598	
	8871779	Nov 22, 2029	DS			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 201655 005	7851482	Jul 10, 2029	DS			
	8075872	Nov 20, 2023	DP			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
	8309060	Nov 20, 2023	DP			
	8309122	Feb 04, 2023	DP			
	8329216	Feb 04, 2023	DP			
	8808737	Jun 21, 2027			U-1598	
	8871779	Nov 22, 2029	DS			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 201655 006	7851482	Jul 10, 2029	DS			
	8075872	Nov 20, 2023	DP			
	8114383	Aug 08, 2024	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 201655 006	8192722	Sep 15, 2025	DP			
	8309060	Nov 20, 2023	DP			
	8309122	Feb 04, 2023	DP			
	8329216	Feb 04, 2023	DP			
	8808737	Jun 21, 2027	U-1598			
	8871779	Nov 22, 2029	DS			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 201655 007	7851482	Jul 10, 2029	DS			
	8075872	Nov 20, 2023	DP			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
	8309060	Nov 20, 2023	DP			
	8309122	Feb 04, 2023	DP			
	8329216	Feb 04, 2023	DP			
	8808737	Jun 21, 2027	U-1598			
	8871779	Nov 22, 2029	DS			
<u>OZANIMOD HYDROCHLORIDE - ZEPOSIA</u>						
N 209899 001	10239846	Nov 15, 2030	U-3132		I-860	May 27, 2024
	8481573	May 14, 2029	DS DP U-2774		NCE	Mar 25, 2025
	8796318	May 14, 2029	DS DP			
	9382217	May 14, 2029	U-2774			
<u>OZANIMOD HYDROCHLORIDE - ZEPOSIA</u>						
N 209899 002	10239846	Nov 15, 2030	U-3132		I-860	May 27, 2024
	8481573	May 14, 2029	DS DP U-2774		NCE	Mar 25, 2025
	8796318	May 14, 2029	DS DP			
	9382217	May 14, 2029	U-2774			
<u>OZANIMOD HYDROCHLORIDE - ZEPOSIA</u>						
N 209899 003	10239846	Nov 15, 2030	U-3132		I-860	May 27, 2024
	8481573	May 14, 2029	DS DP U-2774		NCE	Mar 25, 2025
	8796318	May 14, 2029	DS DP			
	9382217	May 14, 2029	U-2774			
<u>OZENOXACIN - XEPI</u>						
N 208945 001	6335447	Nov 09, 2023	DS			
	9180200	Jan 29, 2032	DP U-805			
	9399014	Dec 15, 2029	U-805			
<u>PACLITAXEL - ABRAXANE</u>						
N 021660 001	7758891	Feb 21, 2026	U-1434			
	7758891*PED	Aug 21, 2026				
	7820788	Oct 27, 2024	DP U-1092			
	7820788	Oct 27, 2024	DP U-1290			
	7820788	Oct 27, 2024	DP U-1434			
	7820788*PED	Apr 27, 2025				
	7923536	Dec 09, 2023	U-1117			
	7923536	Dec 09, 2023	U-1290			
	7923536	Dec 09, 2023	U-1434			
	7923536*PED	Jun 09, 2024				
	8034375	Aug 13, 2026	U-1290			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PACLITAXEL - ABRAXANE</u>						
N 021660 001	8138229	Dec 09, 2023	DP U-1092			
	8138229	Dec 09, 2023	DP U-1290			
	8138229	Dec 09, 2023	DP U-1434			
	8138229*PED	Jun 09, 2024				
	8268348	Feb 21, 2026	U-1290			
	8314156	Dec 09, 2023	U-1290			
	8314156	Dec 09, 2023	U-1434			
	8314156*PED	Jun 09, 2024				
	9101543	Feb 21, 2026	U-1434			
	9101543*PED	Aug 21, 2026				
	9393318	Mar 04, 2032	U-1290			
	9393318*PED	Sep 04, 2032				
	9511046	Jan 12, 2034	U-1434			
	9511046*PED	Jul 12, 2034				
	9597409	Mar 04, 2032	U-1290			
	9597409*PED	Sep 04, 2032				
<u>PACRITINIB CITRATE - VONJO</u>						
N 208712 001	8153632	Jan 17, 2029	DS DP U-3331		NCE	Feb 28, 2027
	8153632	Jan 17, 2029	DS DP U-3332			
	8980873	Mar 25, 2030	DS DP U-3331			
	8980873	Mar 25, 2030	DS DP U-3332			
	9573964	May 05, 2028	U-3331			
	9573964	May 05, 2028	U-3332			
<u>PAFOLACIANINE SODIUM - CYTALUX</u>						
N 214907 001	10881747	Aug 26, 2033	DS DP U-3291		NCE	Nov 29, 2026
	9061057	Aug 26, 2033	DS DP U-3291			
	9254341	Oct 04, 2033	DS DP			
	9333270	Aug 26, 2033	DS DP U-3291			
	9341629	Aug 26, 2033	DS DP			
	9789208	Aug 26, 2033	DS DP U-3291			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 001	10723730	Feb 08, 2034	DS DP			
	6936612	Jan 16, 2023	DS DP			
	7208489	Jan 16, 2023	DS DP	Y		
	7456168	Jan 16, 2023	U-1998			
	7456168	Jan 16, 2023	U-2515			
	7456168	Jan 16, 2023	U-3501			
	RE47739	Mar 05, 2027	DS DP			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 002	10723730	Feb 08, 2034	DS DP			
	6936612	Jan 16, 2023	DS DP			
	7208489	Jan 16, 2023	DS DP	Y		
	7456168	Jan 16, 2023	U-1998			
	7456168	Jan 16, 2023	U-2515			
	7456168	Jan 16, 2023	U-3501			
	RE47739	Mar 05, 2027	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 003	10723730	Feb 08, 2034	DS DP			
	6936612	Jan 16, 2023	DS DP			
	7208489	Jan 16, 2023	DS DP	Y		
	7456168	Jan 16, 2023	U-1998			
	7456168	Jan 16, 2023	U-2515			
	7456168	Jan 16, 2023	U-3501			
	RE47739	Mar 05, 2027	DS DP			
<u>PALBOCICLIB - IBRANCE</u>						
N 212436 001	10723730	Feb 08, 2034	DS DP			
	11065250	May 24, 2036	DP			
	6936612	Jan 16, 2023	DS DP			
	7456168	Jan 16, 2023	U-2515			
	7456168	Jan 16, 2023	U-3501			
	RE47739	Mar 05, 2027	DS DP			
<u>PALBOCICLIB - IBRANCE</u>						
N 212436 002	10723730	Feb 08, 2034	DS DP			
	11065250	May 24, 2036	DP			
	6936612	Jan 16, 2023	DS DP			
	7456168	Jan 16, 2023	U-2515			
	7456168	Jan 16, 2023	U-3501			
	RE47739	Mar 05, 2027	DS DP			
<u>PALBOCICLIB - IBRANCE</u>						
N 212436 003	10723730	Feb 08, 2034	DS DP			
	11065250	May 24, 2036	DP			
	6936612	Jan 16, 2023	DS DP			
	7456168	Jan 16, 2023	U-2515			
	7456168	Jan 16, 2023	U-3501			
	RE47739	Mar 05, 2027	DS DP			
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264 001	9439906	Jan 26, 2031	U-1901			
	9439906	Jan 26, 2031	U-2757			
	9439906	Jan 26, 2031	U-2758			
	9439906	Jan 26, 2031	U-543			
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264 002	9439906	Jan 26, 2031	U-1901			
	9439906	Jan 26, 2031	U-2757			
	9439906	Jan 26, 2031	U-2758			
	9439906	Jan 26, 2031	U-543			
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264 003	9439906	Jan 26, 2031	U-1901			
	9439906	Jan 26, 2031	U-2757			
	9439906	Jan 26, 2031	U-2758			
	9439906	Jan 26, 2031	U-543			
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264 004	9439906	Jan 26, 2031	U-1901			
	9439906	Jan 26, 2031	U-2757			
	9439906	Jan 26, 2031	U-2758			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264 004	9439906	Jan 26, 2031	U-543			
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264 005	9439906	Jan 26, 2031	U-1901			
	9439906	Jan 26, 2031	U-2757			
	9439906	Jan 26, 2031	U-2758			
	9439906	Jan 26, 2031	U-543			
<u>PALIPERIDONE PALMITATE - INVEGA TRINZA</u>						
N 207946 001	10143693	Apr 05, 2036	U-2457			
	10143693	Apr 05, 2036	U-2458			
<u>PALIPERIDONE PALMITATE - INVEGA TRINZA</u>						
N 207946 002	10143693	Apr 05, 2036	U-2457			
	10143693	Apr 05, 2036	U-2458			
<u>PALIPERIDONE PALMITATE - INVEGA TRINZA</u>						
N 207946 003	10143693	Apr 05, 2036	U-2457			
	10143693	Apr 05, 2036	U-2458			
<u>PALIPERIDONE PALMITATE - INVEGA TRINZA</u>						
N 207946 004	10143693	Apr 05, 2036	U-2457			
	10143693	Apr 05, 2036	U-2458			
<u>PALIPERIDONE PALMITATE - INVEGA HAFYERA</u>						
N 207946 005	11304951	May 07, 2041	U-3349		NS	Aug 30, 2024
	11324751	May 07, 2041	U-3359			
<u>PALIPERIDONE PALMITATE - INVEGA HAFYERA</u>						
N 207946 006	11304951	May 07, 2041	U-3349		NS	Aug 30, 2024
	11324751	May 07, 2041	U-3359			
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N 021372 001	7947724	Jan 30, 2024	DP			
	7947724*PED	Jul 30, 2024				
	7947725	Jan 30, 2024	DP			
	7947725*PED	Jul 30, 2024				
	7960424	Jan 30, 2024	DP			
	7960424*PED	Jul 30, 2024				
	8518981	Jan 30, 2024	DP			
	8518981*PED	Jul 30, 2024				
	8598218	Jan 30, 2024	DP			
	8598218*PED	Jul 30, 2024				
	8598219	Jan 30, 2024	DP			
	8598219*PED	Jul 30, 2024				
	8729094	Jan 30, 2024	DP U-528			
	8729094*PED	Jul 30, 2024				
	9066980	Jan 30, 2024	DP U-528			
	9066980*PED	Jul 30, 2024				
	9125905	Jan 30, 2024	DP			
	9125905*PED	Jul 30, 2024				
	9173942	Jan 30, 2024	DP			
	9173942*PED	Jul 30, 2024				
	9439854	Jan 30, 2024	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N 021372 001	9439854*PED	Jul 30, 2024				
	9457020	Jan 30, 2024	DP			
	9457020*PED	Jul 30, 2024				
	9457021	Jan 30, 2024	DP			
	9457021*PED	Jul 30, 2024				
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N 021372 002	7947724	Jan 30, 2024	DP			
	7947724*PED	Jul 30, 2024				
	7947725	Jan 30, 2024	DP			
	7947725*PED	Jul 30, 2024				
	7960424	Jan 30, 2024	DP			
	7960424*PED	Jul 30, 2024				
	8518981	Jan 30, 2024	DP			
	8518981*PED	Jul 30, 2024				
	8598218	Jan 30, 2024	DP			
	8598218*PED	Jul 30, 2024				
	9173942	Jan 30, 2024	DP			
	9173942*PED	Jul 30, 2024				
	9439854	Jan 30, 2024	DP			
	9439854*PED	Jul 30, 2024				
	9457020	Jan 30, 2024	DP			
	9457020*PED	Jul 30, 2024				
<u>PANOBINOSTAT LACTATE - FARYDAK</u>						
N 205353 001	7989494	Jan 17, 2028	DS DP			
	8883842	Jun 13, 2028			U-1669	
<u>PANOBINOSTAT LACTATE - FARYDAK</u>						
N 205353 002	7989494	Jan 17, 2028	DS DP			
	8883842	Jun 13, 2028			U-1669	
<u>PANOBINOSTAT LACTATE - FARYDAK</u>						
N 205353 003	7989494	Jan 17, 2028	DS DP			
	8883842	Jun 13, 2028			U-1669	
<u>PANTOPRAZOLE SODIUM - PROTONIX</u>						
N 022020 001	7544370	Jun 07, 2026	DP			
	7550153	Sep 30, 2024	U-859			
	7553498	Sep 30, 2024	U-859			
	7838027	Sep 30, 2024	DP U-859			
<u>PARICALCITOL - ZEMPLAR</u>						
N 020819 001					ODE*	Oct 18, 2023
<u>PARICALCITOL - ZEMPLAR</u>						
N 020819 002					ODE*	Oct 18, 2023
<u>PARICALCITOL - ZEMPLAR</u>						
N 020819 003					ODE*	Oct 18, 2023
<u>PARICALCITOL - ZEMPLAR</u>						
N 021606 001					ODE-125	Oct 18, 2023

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PARICALCITOL - ZEMPLAR</u>						
N 021606	002				ODE-125	Oct 18, 2023
<u>PARICALCITOL - ZEMPLAR</u>						
N 021606	003				ODE-125	Oct 18, 2023
<u>PAROXETINE MESYLATE - PEXEVA</u>						
N 021299	001	7598271	May 04, 2025	DS		
<u>PAROXETINE MESYLATE - PEXEVA</u>						
N 021299	002	7598271	May 04, 2025	DS		
<u>PAROXETINE MESYLATE - PEXEVA</u>						
N 021299	003	7598271	May 04, 2025	DS		
<u>PAROXETINE MESYLATE - PEXEVA</u>						
N 021299	004	7598271	May 04, 2025	DS		
<u>PAROXETINE MESYLATE - BRISDELLE</u>						
N 204516	001	7598271	May 04, 2025	DS		
		8658663	Apr 06, 2029	DS DP	U-904	
		8946251	Aug 04, 2026	DS DP	U-904	
		9393237	Aug 04, 2026		U-904	
<u>PASIREOTIDE DIASPARTATE - SIGNIFOR</u>						
N 200677	001	7473761	Dec 14, 2026	DS DP		
		8299209	Dec 27, 2025	DS DP		
<u>PASIREOTIDE DIASPARTATE - SIGNIFOR</u>						
N 200677	002	7473761	Dec 14, 2026	DS DP		
		8299209	Dec 27, 2025	DS DP		
<u>PASIREOTIDE DIASPARTATE - SIGNIFOR</u>						
N 200677	003	7473761	Dec 14, 2026	DS DP		
		8299209	Dec 27, 2025	DS DP		
<u>PASIREOTIDE PAMOATE - SIGNIFOR LAR KIT</u>						
N 203255	001	7473761	Dec 14, 2026	DS DP	ODE-268	Jun 29, 2025
		7759308	Oct 25, 2026	DP		
		8822637	Aug 06, 2023		U-1629	
		9351923	May 23, 2028	DP		
<u>PASIREOTIDE PAMOATE - SIGNIFOR LAR KIT</u>						
N 203255	002	7473761	Dec 14, 2026	DS DP	ODE-268	Jun 29, 2025
		7759308	Oct 25, 2026	DP		
		8822637	Aug 06, 2023		U-1629	
		9351923	May 23, 2028	DP		
<u>PASIREOTIDE PAMOATE - SIGNIFOR LAR KIT</u>						
N 203255	003	7473761	Dec 14, 2026	DS DP	ODE-268	Jun 29, 2025
		7759308	Oct 25, 2026	DP		
		8822637	Aug 06, 2023		U-1629	
		9351923	May 23, 2028	DP		
<u>PASIREOTIDE PAMOATE - SIGNIFOR LAR KIT</u>						
N 203255	004	7473761	Dec 14, 2026	DS DP	ODE-268	Jun 29, 2025
		7759308	Oct 25, 2026	DP		
		9351923	May 23, 2028	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PASIREOTIDE PAMOATE - SIGNIFOR LAR KIT</u>						
N 203255 005	7473761	Dec 14, 2026	DS DP		ODE-268	Jun 29, 2025
	7759308	Oct 25, 2026	DP			
	9351923	May 23, 2028	DP			
<u>PATIROMER SORBITE X CALCIUM - VELTASSA</u>						
N 205739 001	10485821	Mar 30, 2024		U-1766		
	11123363	Oct 08, 2033		U-1766		
	7556799	Feb 27, 2025		U-1766		
	8147873	Jun 20, 2028	DP			
	8216560	Mar 14, 2027		U-1766		
	8282913	May 29, 2027	DP			
	8287847	Mar 30, 2024		U-1766		
	8337824	May 29, 2030	DS	U-1766		
	8475780	Mar 30, 2024		U-1766		
	8778324	Mar 30, 2024		U-1766		
	8889115	Mar 30, 2024		U-1766		
	9492476	Oct 08, 2033		U-1766		
	9925212	Oct 08, 2033		U-1766		
<u>PATIROMER SORBITE X CALCIUM - VELTASSA</u>						
N 205739 002	10485821	Mar 30, 2024		U-1766		
	11123363	Oct 08, 2033		U-1766		
	7556799	Feb 27, 2025		U-1766		
	8147873	Jun 20, 2028	DP			
	8216560	Mar 14, 2027		U-1766		
	8282913	May 29, 2027	DP			
	8287847	Mar 30, 2024		U-1766		
	8337824	May 29, 2030	DS	U-1766		
	8475780	Mar 30, 2024		U-1766		
	8778324	Mar 30, 2024		U-1766		
	8889115	Mar 30, 2024		U-1766		
	9492476	Oct 08, 2033		U-1766		
	9925212	Oct 08, 2033		U-1766		
<u>PATIROMER SORBITE X CALCIUM - VELTASSA</u>						
N 205739 003	10485821	Mar 30, 2024		U-1766		
	11123363	Oct 08, 2033		U-1766		
	7556799	Feb 27, 2025		U-1766		
	8147873	Jun 20, 2028	DP			
	8216560	Mar 14, 2027		U-1766		
	8282913	May 29, 2027	DP			
	8287847	Mar 30, 2024		U-1766		
	8337824	May 29, 2030	DS	U-1766		
	8475780	Mar 30, 2024		U-1766		
	8778324	Mar 30, 2024		U-1766		
	8889115	Mar 30, 2024		U-1766		
	9492476	Oct 08, 2033		U-1766		
	9925212	Oct 08, 2033		U-1766		
<u>PATISIRAN SODIUM - ONPATRO</u>						
N 210922 001	10240152	Oct 20, 2029	DS DP U-2378		NCE	Aug 10, 2023
	11079379	Aug 27, 2035	DS DP U-2378		ODE-197	Aug 10, 2025

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PATISIRAN SODIUM - ONPATRO</u>						
N 210922 001	11141378	Apr 15, 2029	DP			
	8058069	Apr 15, 2029	DP			
	8158601	Nov 10, 2030	DP U-2378			
	8168775	Oct 20, 2029	DS DP U-2378			
	8334373	May 27, 2025	DS DP			
	8492359	Apr 15, 2029	DP			
	8642076	Oct 03, 2027	DP			
	8741866	Oct 20, 2029	U-2378			
	8802644	Oct 21, 2030	DP U-2378			
	8822668	Apr 15, 2029	DP U-2378			
	9234196	Oct 20, 2029	DP U-2378			
	9364435	Apr 15, 2029	DP U-2378			
	9943538	Nov 04, 2023	DP			
	9943539	Nov 04, 2023	DP			
<u>PAZOPANIB HYDROCHLORIDE - VOTRIENT</u>						
N 022465 001	7105530	Oct 19, 2023	DS DP			
<u>PAZOPANIB HYDROCHLORIDE - VOTRIENT</u>						
N 022465 002	7105530	Oct 19, 2023	DS DP			
<u>PEGCETACOPLAN - EMPAVELI</u>						
N 215014 001	10035822	Nov 15, 2033	DS		NCE	May 14, 2026
	10125171	Aug 02, 2033	DS		ODE-351	May 14, 2028
	10875893	Nov 15, 2033	DS U-3124			
	11040107	Apr 09, 2038	DP U-3172			
	11040107	Apr 09, 2038	DP U-3173			
	11040107	Apr 09, 2038	DP U-3174			
	11292815	Nov 15, 2033	DS DP U-3124			
	11292815	Nov 15, 2033	DS DP U-3354			
	7888323	Dec 04, 2027	DS			
	7989589	Dec 04, 2027	DS			
	9169307	Nov 18, 2027	DS U-3123			
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N 202799 001	7084245	May 12, 2024	DS DP U-1238			
	7414105	May 12, 2024	DS DP U-1238			
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026	U-1238			
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026	U-1238			
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N 202799 002	7084245	May 12, 2024	DS DP U-1238			
	7414105	May 12, 2024	DS DP U-1238			
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026	U-1238			
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026	U-1238			
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N 202799 003	7084245	May 12, 2024	DS DP U-1238			
	7414105	May 12, 2024	DS DP U-1238			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N 202799 003	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026			U-1238	
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026			U-1238	
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N 202799 004	7084245	May 12, 2024	DS DP		U-1238	
	7414105	May 12, 2024	DS DP		U-1238	
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026			U-1238	
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026			U-1238	
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N 202799 005	7084245	May 12, 2024	DS DP		U-1238	
	7414105	May 12, 2024	DS DP		U-1238	
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026			U-1238	
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026			U-1238	
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N 202799 006	7084245	May 12, 2024	DS DP		U-1238	
	7414105	May 12, 2024	DS DP		U-1238	
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026			U-1238	
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026			U-1238	
<u>PEGINESATIDE ACETATE - OMONTYS</u>						
N 202799 007	7084245	May 12, 2024	DS DP		U-1238	
	7414105	May 12, 2024	DS DP		U-1238	
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026			U-1238	
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026			U-1238	
<u>PEGINESATIDE ACETATE - OMONTYS</u>						
N 202799 008	7084245	May 12, 2024	DS DP		U-1238	
	7414105	May 12, 2024	DS DP		U-1238	
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026			U-1238	
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026			U-1238	
<u>PEMETREXED - PEMFEXY</u>						
N 209472 001	9604990	Oct 28, 2035	DS			
<u>PEMIGATINIB - PEMAZYRE</u>						
N 213736 001	10131667	Jun 12, 2033		U-2809	I-899	Aug 26, 2025
	11466004	May 03, 2039		U-3464	NCE	Apr 17, 2025
	11466004	May 03, 2039		U-3465	ODE-292	Apr 17, 2027
	11466004	May 03, 2039		U-3466		
	9611267	Jan 30, 2035	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PEMIGATINIB - PEMAZYRE</u>						
N 213736 001	10131667	Jun 12, 2033	U-2809		I-899	Aug 26, 2025
	11466004	May 03, 2039	U-3464		NCE	Apr 17, 2025
	11466004	May 03, 2039	U-3465		ODE-292	Apr 17, 2027
	11466004	May 03, 2039	U-3466			
	9611267	Jan 30, 2035	DS DP			
<u>PEMIGATINIB - PEMAZYRE</u>						
N 213736 002	10131667	Jun 12, 2033	U-2809		I-899	Aug 26, 2025
	11466004	May 03, 2039	U-3464		NCE	Apr 17, 2025
	11466004	May 03, 2039	U-3465		ODE-292	Apr 17, 2027
	11466004	May 03, 2039	U-3466			
	9611267	Jan 30, 2035	DS DP			
<u>PEMIGATINIB - PEMAZYRE</u>						
N 213736 003	10131667	Jun 12, 2033	U-2809		I-899	Aug 26, 2025
	11466004	May 03, 2039	U-3464		NCE	Apr 17, 2025
	11466004	May 03, 2039	U-3465		ODE-292	Apr 17, 2027
	11466004	May 03, 2039	U-3466			
	9611267	Jan 30, 2035	DS DP			
<u>PERAMIVIR - RAPIVAB</u>						
N 206426 001	10391075	Feb 12, 2027	U-2622			
	10391075	Feb 12, 2027	U-3069			
	6562861	Dec 16, 2023	DS			
	8778997	May 07, 2027	U-1627			
	8778997	May 07, 2027	U-2622			
	8778997	May 07, 2027	U-3069			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 001	6949571	Jun 08, 2023	DS DP U-106			
	6949571	Jun 08, 2023	DS DP U-2088			
	6949571	Jun 08, 2023	DS DP U-2089			
	6949571	Jun 08, 2023	DS DP U-2428			
	6949571	Jun 08, 2023	DS DP U-2429			
	8772497	Jul 01, 2026	DS			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 002	6949571	Jun 08, 2023	DS DP U-106			
	6949571	Jun 08, 2023	DS DP U-2088			
	6949571	Jun 08, 2023	DS DP U-2089			
	6949571	Jun 08, 2023	DS DP U-2428			
	6949571	Jun 08, 2023	DS DP U-2429			
	8772497	Jul 01, 2026	DS			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 003	6949571	Jun 08, 2023	DS DP U-106			
	6949571	Jun 08, 2023	DS DP U-2088			
	6949571	Jun 08, 2023	DS DP U-2089			
	6949571	Jun 08, 2023	DS DP U-2428			
	6949571	Jun 08, 2023	DS DP U-2429			
	8772497	Jul 01, 2026	DS			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 004	6949571	Jun 08, 2023	DS DP U-106			
	6949571	Jun 08, 2023	DS DP U-2088			
	6949571	Jun 08, 2023	DS DP U-2089			
	6949571	Jun 08, 2023	DS DP U-2428			
	6949571	Jun 08, 2023	DS DP U-2429			
	8772497	Jul 01, 2026	DS			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 005	6949571	Jun 08, 2023	DS DP U-106			
	6949571	Jun 08, 2023	DS DP U-2088			
	6949571	Jun 08, 2023	DS DP U-2089			
	6949571	Jun 08, 2023	DS DP U-2428			
	6949571	Jun 08, 2023	DS DP U-2429			
	8772497	Jul 01, 2026	DS			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 006	6949571	Jun 08, 2023	DS DP U-106			
	6949571	Jun 08, 2023	DS DP U-2088			
	6949571	Jun 08, 2023	DS DP U-2089			
	6949571	Jun 08, 2023	DS DP U-2428			
	6949571	Jun 08, 2023	DS DP U-2429			
	8772497	Jul 01, 2026	DS			
<u>PERAMPANEL - FYCOMPA</u>						
N 208277 001	6949571	Jun 08, 2023	DS DP U-106			
	6949571	Jun 08, 2023	DS DP U-2088			
	6949571	Jun 08, 2023	DS DP U-2089			
	6949571	Jun 08, 2023	DS DP U-2428			
	6949571	Jun 08, 2023	DS DP U-2429			
	8772497	Jul 01, 2026	DS			
<u>PERFLUTREN - DEFINITY</u>						
N 021064 001	10583207	Dec 28, 2035	U-665			
	10583208	Mar 16, 2037	U-665			
	10588988	May 04, 2037	U-665			
	11266750	Mar 16, 2037	U-665			
	11529431	Mar 16, 2037	U-665			
	9789210	Mar 16, 2037	U-665			
<u>PERFLUTREN - DEFINITY RT</u>						
N 021064 002	10022460	Dec 28, 2035	DS DP			
	10583207	Dec 28, 2035	U-665			
	10583208	Mar 16, 2037	U-665			
	10588988	May 04, 2037	U-665			
	11266750	Mar 16, 2037	U-665			
	11395856	Dec 28, 2035	DS DP U-665			
	11529431	Mar 16, 2037	U-665			
	9789210	Mar 16, 2037	U-665			
<u>PEXIDARTINIB HYDROCHLORIDE - TURALIO</u>						
N 211810 001	10189833	May 05, 2036	U-2606		NCE	Aug 02, 2024
	10435404	Jul 24, 2038	DP		ODE-250	Aug 02, 2026
	10730876	May 05, 2036	DS			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PEXIDARTINIB HYDROCHLORIDE - TURALIO</u>						
N 211810 001	10941142	Jul 24, 2038	DP			
	10961240	Jul 24, 2038	U-2606			
	7893075	May 04, 2033	DS			
	8404700	Nov 21, 2027	DS			
	8461169	Apr 19, 2028	U-2606			
	8722702	Nov 21, 2027	DS			
	9169250	Nov 21, 2027	DS			
	9358235	Jun 08, 2033	U-2606			
	9802932	May 05, 2036	DS			
<u>PEXIDARTINIB HYDROCHLORIDE - TURALIO</u>						
N 211810 002	10189833	May 05, 2036	U-2606		NCE	Aug 02, 2024
	10435404	Jul 24, 2038	DP		ODE*	Aug 02, 2026
	10730876	May 05, 2036	DS			
	10941142	Jul 24, 2038	DP			
	10961240	Jul 24, 2038	U-2606			
	7893075	May 04, 2033	DS			
	8404700	Nov 21, 2027	DS			
	8461169	Apr 19, 2028	U-2606			
	8722702	Nov 21, 2027	DS			
	9169250	Nov 21, 2027	DS			
	9358235	Jun 08, 2033	U-2606			
	9802932	May 05, 2036	DS			
<u>PHENTERMINE HYDROCHLORIDE - SUPRENZA</u>						
N 202088 001	8440170	Mar 14, 2029	DP			
<u>PHENTERMINE HYDROCHLORIDE - SUPRENZA</u>						
N 202088 002	8440170	Mar 14, 2029	DP			
<u>PHENTERMINE HYDROCHLORIDE - SUPRENZA</u>						
N 202088 003	8440170	Mar 14, 2029	DP			
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA</u>						
N 022580 001	8580298	May 15, 2029	DP		NPP	Jun 24, 2025
	8580299	Jun 14, 2029	U-3399			
	8895057	Jun 09, 2028	U-3398			
	8895058	Jun 09, 2028	DP			
	9011905	Jun 09, 2028	DP			
	9011906	Jun 09, 2028	U-3398			
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA</u>						
N 022580 002	8580298	May 15, 2029	DP		NPP	Jun 24, 2025
	8580299	Jun 14, 2029	U-3399			
	8895057	Jun 09, 2028	U-3398			
	8895058	Jun 09, 2028	DP			
	9011905	Jun 09, 2028	DP			
	9011906	Jun 09, 2028	U-3398			
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA</u>						
N 022580 003	8580298	May 15, 2029	DP		NPP	Jun 24, 2025
	8580299	Jun 14, 2029	U-3399			
	8895057	Jun 09, 2028	U-3398			
	8895058	Jun 09, 2028	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA</u>						
N 022580 003	9011905	Jun 09, 2028	DP			
	9011906	Jun 09, 2028	U-3398			
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA</u>						
N 022580 004	8580298	May 15, 2029	DP		NPP	Jun 24, 2025
	8580299	Jun 14, 2029	U-3399			
	8895057	Jun 09, 2028	U-3398			
	8895058	Jun 09, 2028	DP			
	9011905	Jun 09, 2028	DP			
	9011906	Jun 09, 2028	U-3398			
<u>PHENTOLAMINE MESYLATE - ORAVERSE</u>						
N 022159 001	7229630	Jun 20, 2023	DP			
	7569230	Oct 17, 2023	U-967			
	7575757	Apr 21, 2025	DP			
<u>PHENYLEPHRINE HYDROCHLORIDE - PHENYLEPHRINE HYDROCHLORIDE</u>						
A 216859 001					CGT	Apr 05, 2023
<u>PHENYLEPHRINE HYDROCHLORIDE - PHENYLEPHRINE HYDROCHLORIDE</u>						
N 203510 001	8859623	Nov 14, 2033	U-1594			
<u>PHENYLEPHRINE HYDROCHLORIDE - PHENYLEPHRINE HYDROCHLORIDE</u>						
N 203510 002	8859623	Nov 14, 2033	U-1594			
<u>PIFLUFOLASTAT F-18 - PYLARIFY</u>						
N 214793 001	10947197	Jun 09, 2037	DS DP U-3130		NCE	May 26, 2026
	8487129	Nov 07, 2027	DS DP			
	8778305	Sep 21, 2030	DS DP U-3130			
	9861713	Jul 31, 2029	DS DP U-3130			
<u>PILOCARPINE HYDROCHLORIDE - VUITY</u>						
N 214028 001	10610518	Apr 24, 2039	U-3252		NP	Oct 28, 2024
	11285134	Apr 24, 2039	U-3252			
<u>PIMAVANSERIN TARTRATE - NUPLAZID</u>						
N 207318 001	10028944	Jan 15, 2024	U-1974			
	7601740	Apr 29, 2030	DS DP			
	7659285	Aug 24, 2026	U-1844			
	7732615	Jun 03, 2028	DS DP			
	7923564	Sep 26, 2025	DS DP			
	8618130	Jan 15, 2024	U-1845			
	8921393	Jan 15, 2024	U-1846			
	9566271	Jan 15, 2024	U-1974			
<u>PIMAVANSERIN TARTRATE - NUPLAZID</u>						
N 207318 002	10028944	Jan 15, 2024	U-1974			
	10517860	Mar 23, 2037	U-1974			
	10953000	Mar 23, 2037	U-1974			
	7601740	Apr 29, 2030	DS DP			
	7659285	Aug 24, 2026	U-1844			
	7732615	Jun 03, 2028	DS DP			
	7923564	Sep 26, 2025	DS DP			
	8618130	Jan 15, 2024	U-1845			
	8921393	Jan 15, 2024	U-1846			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PIMAVANSERIN TARTRATE - NUPLAZID</u>						
N 207318 002	9566271	Jan 15, 2024	U-1974			
<u>PIMAVANSERIN TARTRATE - NUPLAZID</u>						
N 210793 001	10028944	Jan 15, 2024	U-1974			
	10449185	Aug 27, 2038	DP			
	10646480	Aug 27, 2038	DP			
	10849891	Aug 27, 2038	DP U-1974			
	11452721	Aug 27, 2038	DP			
	7601740	Apr 29, 2030	DS DP			
	7659285	Aug 24, 2026	U-1844			
	7732615	Jun 03, 2028	DS DP			
	7923564	Sep 26, 2025	DS DP			
	8618130	Jan 15, 2024	U-1845			
	8921393	Jan 15, 2024	U-1846			
	9566271	Jan 15, 2024	U-1974			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN</u>						
N 050684 001	6900184	Apr 14, 2023	DP U-282			
	7915229	Apr 14, 2023	DP			
	8133883	Apr 14, 2023	DP U-282			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN</u>						
N 050684 002	6900184	Apr 14, 2023	DP U-282			
	7915229	Apr 14, 2023	DP			
	8133883	Apr 14, 2023	DP U-282			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN</u>						
N 050684 003	6900184	Apr 14, 2023	DP U-282			
	7915229	Apr 14, 2023	DP			
	8133883	Apr 14, 2023	DP U-282			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN</u>						
N 050684 004	6900184	Apr 14, 2023	DP U-282			
	7915229	Apr 14, 2023	DP			
	8133883	Apr 14, 2023	DP U-282			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER</u>						
N 050750 001	6900184	Apr 14, 2023	DP U-282			
	7915229	Apr 14, 2023	DP			
	8133883	Apr 14, 2023	DP U-282			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER</u>						
N 050750 002	6900184	Apr 14, 2023	DP U-282			
	7915229	Apr 14, 2023	DP			
	8133883	Apr 14, 2023	DP U-282			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER</u>						
N 050750 003	6900184	Apr 14, 2023	DP U-282			
	7915229	Apr 14, 2023	DP			
	8133883	Apr 14, 2023	DP U-282			
<u>PIRFENIDONE - ESBRIET</u>						
N 022535 001	7566729	Apr 22, 2029	U-1600			
	7635707	Apr 22, 2029	U-1609			
	7696236	Dec 18, 2027	U-1601			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PIRFENIDONE - ESBRIET</u>						
N 022535 001	7767225	Sep 22, 2026	DP U-1602			
	7767700	Dec 18, 2027	U-1601			
	7816383	Jan 08, 2030	U-1603			
	7910610	Jan 08, 2030	U-1604			
	7988994	Sep 22, 2026	DP U-1602			
	8013002	Jan 08, 2030	U-1603			
	8084475	Jan 08, 2030	U-1605			
	8318780	Jan 08, 2030	U-1606			
	8383150	May 10, 2028	DP U-2361			
	8420674	Dec 18, 2027	DP U-1608			
	8592462	Apr 22, 2029	U-1609			
	8609701	Apr 22, 2029	U-1610			
	8648098	Jan 08, 2030	U-1611			
	8753679	Sep 22, 2026	DP U-1602			
	8754109	Jan 08, 2030	U-1612			
	8778947	Aug 30, 2033	U-1613			
<u>PIRFENIDONE - ESBRIET</u>						
N 208780 001	10188637	Mar 28, 2037	DP			
	7566729	Apr 22, 2029	U-2077			
	7566729	Apr 22, 2029	U-2078			
	7635707	Apr 22, 2029	U-2072			
	7635707	Apr 22, 2029	U-2073			
	7635707	Apr 22, 2029	U-2074			
	7635707	Apr 22, 2029	U-2075			
	7635707	Apr 22, 2029	U-2076			
	7635707	Apr 22, 2029	U-2083			
	7767700	Dec 18, 2027	U-2080			
	7816383	Jan 08, 2030	U-2042			
	7816383	Jan 08, 2030	U-2050			
	7910610	Jan 08, 2030	U-2048			
	7910610	Jan 08, 2030	U-2049			
	8013002	Jan 08, 2030	U-2047			
	8013002	Jan 08, 2030	U-2082			
	8084475	Jan 08, 2030	U-2052			
	8084475	Jan 08, 2030	U-2054			
	8318780	Jan 08, 2030	U-2046			
	8318780	Jan 08, 2030	U-2081			
	8383150	May 10, 2028	DP U-2361			
	8420674	Dec 18, 2027	U-2079			
	8592462	Apr 22, 2029	U-2055			
	8592462	Apr 22, 2029	U-2056			
	8592462	Apr 22, 2029	U-2057			
	8592462	Apr 22, 2029	U-2058			
	8592462	Apr 22, 2029	U-2059			
	8592462	Apr 22, 2029	U-2060			
	8592462	Apr 22, 2029	U-2061			
	8592462	Apr 22, 2029	U-2062			
	8592462	Apr 22, 2029	U-2063			
	8609701	Apr 22, 2029	U-2064			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PIRFENIDONE - ESBRIET</u>						
N 208780 001	8609701	Apr 22, 2029	U-2065			
	8609701	Apr 22, 2029	U-2066			
	8609701	Apr 22, 2029	U-2067			
	8609701	Apr 22, 2029	U-2068			
	8609701	Apr 22, 2029	U-2069			
	8609701	Apr 22, 2029	U-2070			
	8648098	Jan 08, 2030	U-2051			
	8648098	Jan 08, 2030	U-2052			
	8754109	Jan 08, 2030	U-2053			
	8778947	Aug 30, 2033	U-2044			
	8778947	Aug 30, 2033	U-2045			
<u>PIRFENIDONE - ESBRIET</u>						
N 208780 002	10188637	Mar 28, 2037	DP			
	7566729	Apr 22, 2029	U-2269			
	7566729	Apr 22, 2029	U-2270			
	7635707	Apr 22, 2029	U-2072			
	7635707	Apr 22, 2029	U-2073			
	7635707	Apr 22, 2029	U-2074			
	7635707	Apr 22, 2029	U-2075			
	7635707	Apr 22, 2029	U-2076			
	7635707	Apr 22, 2029	U-2083			
	7767700	Dec 18, 2027	U-2080			
	7816383	Jan 08, 2030	U-2042			
	7816383	Jan 08, 2030	U-2050			
	7910610	Jan 08, 2030	U-2048			
	7910610	Jan 08, 2030	U-2049			
	8013002	Jan 08, 2030	U-2047			
	8013002	Jan 08, 2030	U-2082			
	8084475	Jan 08, 2030	U-2054			
	8084475	Jan 08, 2030	U-2268			
	8318780	Jan 08, 2030	U-2046			
	8318780	Jan 08, 2030	U-2081			
	8383150	May 10, 2028	DP U-2361			
	8420674	Dec 18, 2027	U-2079			
	8592462	Apr 22, 2029	U-2055			
	8592462	Apr 22, 2029	U-2056			
	8592462	Apr 22, 2029	U-2057			
	8592462	Apr 22, 2029	U-2058			
	8592462	Apr 22, 2029	U-2059			
	8592462	Apr 22, 2029	U-2060			
	8592462	Apr 22, 2029	U-2061			
	8592462	Apr 22, 2029	U-2062			
	8592462	Apr 22, 2029	U-2063			
	8609701	Apr 22, 2029	U-2064			
	8609701	Apr 22, 2029	U-2065			
	8609701	Apr 22, 2029	U-2066			
	8609701	Apr 22, 2029	U-2067			
	8609701	Apr 22, 2029	U-2068			
	8609701	Apr 22, 2029	U-2069			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PIRFENIDONE - ESBRIET</u>						
N 208780 002	8609701	Apr 22, 2029	U-2070			
	8648098	Jan 08, 2030	U-2051			
	8648098	Jan 08, 2030	U-2052			
	8754109	Jan 08, 2030	U-2053			
	8778947	Aug 30, 2033	U-2044			
	8778947	Aug 30, 2033	U-2045			
<u>PIRFENIDONE - ESBRIET</u>						
N 208780 003	10188637	Mar 28, 2037	DP			
	7566729	Apr 22, 2029	U-2077			
	7566729	Apr 22, 2029	U-2078			
	7635707	Apr 22, 2029	U-2072			
	7635707	Apr 22, 2029	U-2073			
	7635707	Apr 22, 2029	U-2074			
	7635707	Apr 22, 2029	U-2075			
	7635707	Apr 22, 2029	U-2076			
	7635707	Apr 22, 2029	U-2083			
	7767700	Dec 18, 2027	U-2080			
	7816383	Jan 08, 2030	U-2042			
	7816383	Jan 08, 2030	U-2050			
	7910610	Jan 08, 2030	U-2048			
	7910610	Jan 08, 2030	U-2049			
	8013002	Jan 08, 2030	U-2047			
	8013002	Jan 08, 2030	U-2082			
	8084475	Jan 08, 2030	U-2052			
	8084475	Jan 08, 2030	U-2054			
	8318780	Jan 08, 2030	U-2046			
	8318780	Jan 08, 2030	U-2081			
	8383150	May 10, 2028	DP U-2361			
	8420674	Dec 18, 2027	U-2079			
	8592462	Apr 22, 2029	U-2055			
	8592462	Apr 22, 2029	U-2056			
	8592462	Apr 22, 2029	U-2057			
	8592462	Apr 22, 2029	U-2058			
	8592462	Apr 22, 2029	U-2059			
	8592462	Apr 22, 2029	U-2060			
	8592462	Apr 22, 2029	U-2061			
	8592462	Apr 22, 2029	U-2062			
	8592462	Apr 22, 2029	U-2063			
	8609701	Apr 22, 2029	U-2064			
	8609701	Apr 22, 2029	U-2065			
	8609701	Apr 22, 2029	U-2066			
	8609701	Apr 22, 2029	U-2067			
	8609701	Apr 22, 2029	U-2068			
	8609701	Apr 22, 2029	U-2069			
	8609701	Apr 22, 2029	U-2070			
	8648098	Jan 08, 2030	U-2051			
	8648098	Jan 08, 2030	U-2052			
	8754109	Jan 08, 2030	U-2053			
	8778947	Aug 30, 2033	U-2044			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PIRFENIDONE - ESBRIET</u>						
N 208780 003	8778947	Aug 30, 2033	U-2045			
<u>PITAVASTATIN CALCIUM - LIVALO</u>						
N 022363 001	7022713	Feb 19, 2024	U-998			
	7022713*PED	Aug 19, 2024				
	8557993	Feb 02, 2024	DP			
	8557993*PED	Aug 02, 2024				
<u>PITAVASTATIN CALCIUM - LIVALO</u>						
N 022363 002	7022713	Feb 19, 2024	U-998			
	7022713*PED	Aug 19, 2024				
	8557993	Feb 02, 2024	DP			
	8557993*PED	Aug 02, 2024				
<u>PITAVASTATIN CALCIUM - LIVALO</u>						
N 022363 003	7022713	Feb 19, 2024	U-998			
	7022713*PED	Aug 19, 2024				
	8557993	Feb 02, 2024	DP			
	8557993*PED	Aug 02, 2024				
<u>PITAVASTATIN MAGNESIUM - ZYPITAMAG</u>						
N 208379 001	8829186	Jan 19, 2031	DS DP			
<u>PITAVASTATIN MAGNESIUM - ZYPITAMAG</u>						
N 208379 002	8829186	Jan 19, 2031	DS DP			
<u>PITAVASTATIN MAGNESIUM - ZYPITAMAG</u>						
N 208379 003	8829186	Jan 19, 2031	DS DP			
<u>PITOLISANT HYDROCHLORIDE - WAKIX</u>						
N 211150 001	8207197	Mar 07, 2030	DS DP		I-846	Oct 13, 2023
	8354430	Feb 06, 2026	U-1101		NCE	Aug 14, 2024
	8354430	Feb 06, 2026	U-1102		ODE-255	Aug 14, 2026
	8486947	Sep 26, 2029	U-1101		ODE-331	Oct 13, 2027
	8486947	Sep 26, 2029	U-1102			
<u>PITOLISANT HYDROCHLORIDE - WAKIX</u>						
N 211150 002	8207197	Mar 07, 2030	DS DP		I-846	Oct 13, 2023
	8354430	Feb 06, 2026	U-1101		NCE	Aug 14, 2024
	8354430	Feb 06, 2026	U-1102		ODE-255	Aug 14, 2026
	8486947	Sep 26, 2029	U-1101		ODE-331	Oct 13, 2027
	8486947	Sep 26, 2029	U-1102			
<u>PLAZOMICIN SULFATE - ZEMDRI</u>						
N 210303 001	8383596	Jun 02, 2031	DS U-2328		NCE	Jun 25, 2023
	8822424	Nov 21, 2028	DP		GAIN	Jun 25, 2028
	9266919	Nov 21, 2028	U-2328			
	9688711	Nov 21, 2028	DS U-2328			
<u>PLECANATIDE - TRULANCE</u>						
N 208745 001	10011637	Jun 05, 2034	DS			
	11142549	Jun 05, 2034	DP			
	11319346	Mar 01, 2032	DP			
	7041786	Jan 30, 2028	DS			
	9610321	Sep 15, 2031	U-1999			
	9610321	Sep 15, 2031	U-2230			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PLECANATIDE - TRULANCE</u>						
N 208745 001	9616097	Aug 20, 2032	DP			
	9919024	Sep 15, 2031	U-1999			
	9919024	Sep 15, 2031	U-2230			
	9925231	Sep 15, 2031	DP			
<u>PLERIXAFOR - MOZOBIL</u>						
N 022311 001	6987102	Jul 22, 2023	U-936			
	7897590	Jul 22, 2023	U-936			
<u>POLIDOCANOL - VARITHENA</u>						
N 205098 001	7731986	Nov 17, 2024	DS DP U-1463			
	7814943	Nov 19, 2027	DP U-1461			
	8122917	Sep 09, 2024	DP			
	9480652	May 12, 2032	DP			
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 001	10555939	May 19, 2030	DP		M-14	Nov 20, 2023
	10555939*PED	Nov 19, 2030			ODE-296	May 14, 2027
	8198262	Jun 17, 2025	U-1360		ODE-297	May 14, 2027
	8198262	Jun 17, 2025	U-2254		PED	May 20, 2024
	8198262*PED	Dec 17, 2025			PED	Nov 14, 2027
	8673939	May 15, 2023	U-1360		PED	Nov 14, 2027
	8673939	May 15, 2023	U-2254			
	8673939*PED	Nov 15, 2023				
	8735428	May 15, 2023	U-1360			
	8735428	May 15, 2023	U-2254			
	8735428*PED	Nov 15, 2023				
	8828427	Jun 21, 2031	DS DP			
	8828427*PED	Dec 21, 2031				
	9993467	May 19, 2030	DP			
	9993467*PED	Nov 19, 2030				
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 002	10555939	May 19, 2030	DP		M-14	Nov 20, 2023
	10555939*PED	Nov 19, 2030			ODE-296	May 14, 2027
	8198262	Jun 17, 2025	U-1360		ODE-297	May 14, 2027
	8198262	Jun 17, 2025	U-2254		PED	May 20, 2024
	8198262*PED	Dec 17, 2025			PED	Nov 14, 2027
	8673939	May 15, 2023	U-1360		PED	Nov 14, 2027
	8673939	May 15, 2023	U-2254			
	8673939*PED	Nov 15, 2023				
	8735428	May 15, 2023	U-1360			
	8735428	May 15, 2023	U-2254			
	8735428*PED	Nov 15, 2023				
	8828427	Jun 21, 2031	DS DP			
	8828427*PED	Dec 21, 2031				
	9993467	May 19, 2030	DP			
	9993467*PED	Nov 19, 2030				
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 003	10555939	May 19, 2030	DP		M-14	Nov 20, 2023
	10555939*PED	Nov 19, 2030			ODE-296	May 14, 2027
	8198262	Jun 17, 2025	U-1360		ODE-297	May 14, 2027

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 003	8198262	Jun 17, 2025	U-2254		PED	May 20, 2024
	8198262*PED	Dec 17, 2025			PED	Nov 14, 2027
	8673939	May 15, 2023	U-1360		PED	Nov 14, 2027
	8673939	May 15, 2023	U-2254			
	8673939*PED	Nov 15, 2023				
	8735428	May 15, 2023	U-1360			
	8735428	May 15, 2023	U-2254			
	8735428*PED	Nov 15, 2023				
	8828427	Jun 21, 2031	DS DP			
	8828427*PED	Dec 21, 2031				
	9993467	May 19, 2030	DP			
	9993467*PED	Nov 19, 2030				
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 004	10555939	May 19, 2030	DP		M-14	Nov 20, 2023
	10555939*PED	Nov 19, 2030			ODE-296	May 14, 2027
	8198262	Jun 17, 2025	U-1360		ODE-297	May 14, 2027
	8198262	Jun 17, 2025	U-2254		PED	May 20, 2024
	8198262*PED	Dec 17, 2025			PED	Nov 14, 2027
	8673939	May 15, 2023	U-1360		PED	Nov 14, 2027
	8673939	May 15, 2023	U-2254			
	8673939*PED	Nov 15, 2023				
	8735428	May 15, 2023	U-1360			
	8735428	May 15, 2023	U-2254			
	8735428*PED	Nov 15, 2023				
	8828427	Jun 21, 2031	DS DP			
	8828427*PED	Dec 21, 2031				
	9993467	May 19, 2030	DP			
	9993467*PED	Nov 19, 2030				
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 001	11192895	Dec 12, 2033	U-1700		I-849	Dec 18, 2023
	11192895	Dec 12, 2033	U-1701			
	11192895	Dec 12, 2033	U-1948			
	11192897	Dec 12, 2033	DS U-1700			
	11192897	Dec 12, 2033	DS U-1701			
	11192897	Dec 12, 2033	DS U-1948			
	11384086	Dec 12, 2033	DS DP U-1700			
	11384086	Dec 12, 2033	DS DP U-1701			
	11384086	Dec 12, 2033	DS DP U-1948			
	8114874	Jan 24, 2027	DS DP			
	9029533	Dec 22, 2026	U-1283			
	9029533	Dec 22, 2026	U-1699			
	9029533	Dec 22, 2026	U-1700			
	9029533	Dec 22, 2026	U-1701			
	9029533	Dec 22, 2026	U-836			
	9493470	Dec 12, 2033	DS DP U-1700			
	9493470	Dec 12, 2033	DS DP U-1948			
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 002	11192895	Dec 12, 2033	U-1700		I-849	Dec 18, 2023

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 002	11192895	Dec 12, 2033	U-1701			
	11192895	Dec 12, 2033	U-1948			
	11192897	Dec 12, 2033	DS U-1700			
	11192897	Dec 12, 2033	DS U-1701			
	11192897	Dec 12, 2033	DS U-1948			
	11384086	Dec 12, 2033	DS DP U-1700			
	11384086	Dec 12, 2033	DS DP U-1701			
	11384086	Dec 12, 2033	DS DP U-1948			
	8114874	Jan 24, 2027	DS DP			
	9029533	Dec 22, 2026	U-1283			
	9029533	Dec 22, 2026	U-1699			
	9029533	Dec 22, 2026	U-1700			
	9029533	Dec 22, 2026	U-1701			
	9029533	Dec 22, 2026	U-836			
	9493470	Dec 12, 2033	DS DP U-1700			
	9493470	Dec 12, 2033	DS DP U-1948			
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 003	11192895	Dec 12, 2033	U-1700		I-849	Dec 18, 2023
	11192895	Dec 12, 2033	U-1701			
	11192895	Dec 12, 2033	U-1948			
	11192897	Dec 12, 2033	DS U-1700			
	11192897	Dec 12, 2033	DS U-1701			
	11192897	Dec 12, 2033	DS U-1948			
	11384086	Dec 12, 2033	DS DP U-1700			
	11384086	Dec 12, 2033	DS DP U-1701			
	11384086	Dec 12, 2033	DS DP U-1948			
	8114874	Jan 24, 2027	DS DP			
	9029533	Dec 22, 2026	U-1283			
	9029533	Dec 22, 2026	U-1699			
	9029533	Dec 22, 2026	U-1700			
	9029533	Dec 22, 2026	U-1701			
	9029533	Dec 22, 2026	U-836			
	9493470	Dec 12, 2033	DS DP U-1700			
	9493470	Dec 12, 2033	DS DP U-1948			
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 004	11192895	Dec 12, 2033	U-1700		I-849	Dec 18, 2023
	11192895	Dec 12, 2033	U-1701			
	11192895	Dec 12, 2033	U-1948			
	11192897	Dec 12, 2033	DS U-1700			
	11192897	Dec 12, 2033	DS U-1701			
	11192897	Dec 12, 2033	DS U-1948			
	11384086	Dec 12, 2033	DS DP U-1700			
	11384086	Dec 12, 2033	DS DP U-1701			
	11384086	Dec 12, 2033	DS DP U-1948			
	8114874	Jan 24, 2027	DS DP			
	9029533	Dec 22, 2026	U-1283			
	9029533	Dec 22, 2026	U-1699			
	9029533	Dec 22, 2026	U-1700			
	9029533	Dec 22, 2026	U-1701			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 004	9029533	Dec 22, 2026	U-836			
	9493470	Dec 12, 2033	DS DP U-1700			
	9493470	Dec 12, 2033	DS DP U-1948			
<u>PONESIMOD - PONVORY</u>						
N 213498 001	10220023	Dec 10, 2035	U-3103		NCE	Mar 18, 2026
	8273779	Dec 17, 2025	U-2774			
	9000018	Nov 16, 2024	U-3102			
	9062014	May 06, 2032	DS DP U-2774			
	RE43728	Nov 16, 2024	DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 002	10220023	Dec 10, 2035	U-3103		NCE	Mar 18, 2026
	8273779	Dec 17, 2025	U-2774			
	9000018	Nov 16, 2024	U-3102			
	9062014	May 06, 2032	DS DP U-2774			
	RE43728	Nov 16, 2024	DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 003	10220023	Dec 10, 2035	U-3103		NCE	Mar 18, 2026
	8273779	Dec 17, 2025	U-2774			
	9000018	Nov 16, 2024	U-3102			
	9062014	May 06, 2032	DS DP U-2774			
	RE43728	Nov 16, 2024	DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 004	10220023	Dec 10, 2035	U-3103		NCE	Mar 18, 2026
	8273779	Dec 17, 2025	U-2774			
	9000018	Nov 16, 2024	U-3102			
	9062014	May 06, 2032	DS DP U-2774			
	RE43728	Nov 16, 2024	DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 005	10220023	Dec 10, 2035	U-3103		NCE	Mar 18, 2026
	8273779	Dec 17, 2025	U-2774			
	9000018	Nov 16, 2024	U-3102			
	9062014	May 06, 2032	DS DP U-2774			
	RE43728	Nov 16, 2024	DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 006	10220023	Dec 10, 2035	U-3103		NCE	Mar 18, 2026
	8273779	Dec 17, 2025	U-2774			
	9000018	Nov 16, 2024	U-3102			
	9062014	May 06, 2032	DS DP U-2774			
	RE43728	Nov 16, 2024	DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 007	10220023	Dec 10, 2035	U-3103		NCE	Mar 18, 2026
	8273779	Dec 17, 2025	U-2774			
	9000018	Nov 16, 2024	U-3102			
	9062014	May 06, 2032	DS DP U-2774			
	RE43728	Nov 16, 2024	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PONESIMOD - PONVORY</u>						
N 213498 008	10220023	Dec 10, 2035	U-3103		NCE	Mar 18, 2026
	8273779	Dec 17, 2025	U-2774			
	9000018	Nov 16, 2024	U-3102			
	9062014	May 06, 2032	DS DP U-2774			
	RE43728	Nov 16, 2024	DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 009	10220023	Dec 10, 2035	U-3103		NCE	Mar 18, 2026
	8273779	Dec 17, 2025	U-2774			
	9000018	Nov 16, 2024	U-3102			
	9062014	May 06, 2032	DS DP U-2774			
	RE43728	Nov 16, 2024	DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 010	10220023	Dec 10, 2035	U-3103		NCE	Mar 18, 2026
	8273779	Dec 17, 2025	U-2774			
	9000018	Nov 16, 2024	U-3102			
	9062014	May 06, 2032	DS DP U-2774			
	RE43728	Nov 16, 2024	DS DP			
<u>POSACONAZOLE - NOXAFIL</u>						
N 205053 001					I-881	Jun 17, 2024
					NPP	May 31, 2024
					ODE-355	Jun 17, 2028
<u>POSACONAZOLE - NOXAFIL</u>						
N 205596 001	10117951	Mar 13, 2029	DP		I-881	Jun 17, 2024
	8410077	Mar 13, 2029	DP		NPP	May 31, 2024
	9023790	Jul 04, 2031	DP U-1698		ODE-355	Jun 17, 2028
	9023790	Jul 04, 2031	DP U-3160			
	9023790	Jul 04, 2031	DP U-3171			
	9358297	Jun 24, 2031	DP U-3160			
	9358297	Jun 24, 2031	DP U-3171			
	9493582	Feb 27, 2033	DP			
	9750822	Mar 13, 2029	DP			
<u>POSACONAZOLE - NOXAFIL POWDERMIX KIT</u>						
N 214770 001					NP	May 31, 2024
<u>POTASSIUM PHOSPHATE, DIBASIC; POTASSIUM PHOSPHATE, MONOBASIC - POTASSIUM PHOSPHATES</u>						
N 212121 001	10632150	Apr 19, 2039	DP U-2789			
<u>PRALATREXATE - FOLOTYN</u>						
N 022468 001	7622470	May 31, 2025	U-1015			
	8299078	May 31, 2025	U-1004			
<u>PRALATREXATE - FOLOTYN</u>						
N 022468 002	7622470	May 31, 2025	U-1015			
	8299078	May 31, 2025	U-1004			
<u>PRALSETINIB - GAVRETO</u>						
N 213721 001	10030005	Nov 01, 2036	DS DP U-2827		NCE	Sep 04, 2025
	10030005	Nov 01, 2036	DS DP U-2952		ODE-318	Sep 04, 2027
	10030005	Nov 01, 2036	DS DP U-3002		ODE-340	Dec 01, 2027
	11273160	Apr 03, 2039	U-2952		ODE-341	Dec 01, 2027

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N 022421 001	7695734	Apr 26, 2028	DP			
	8679533	Sep 08, 2029	DP U-219			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N 022421 002	7695734	Apr 26, 2028	DP			
	8679533	Sep 08, 2029	DP U-219			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N 022421 003	7695734	Apr 26, 2028	DP			
	8679533	Sep 08, 2029	DP U-219			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N 022421 004	7695734	Apr 26, 2028	DP			
	8679533	Sep 08, 2029	DP U-219			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N 022421 005	7695734	Apr 26, 2028	DP			
	8679533	Sep 08, 2029	DP U-219			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N 022421 006	7695734	Apr 26, 2028	DP			
	8679533	Sep 08, 2029	DP U-219			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N 022421 007	7695734	Apr 26, 2028	DP			
	8679533	Sep 08, 2029	DP U-219			
<u>PRASTERONE - INTRAROSA</u>						
N 208470 001	8268806	Mar 19, 2031	DP			
	8629129	Aug 07, 2028	DP			
	8957054	Jan 08, 2030	U-1922			
<u>PREDNISOLONE ACETATE - FLO-PRED</u>						
N 022067 001	7799331	Oct 11, 2028	DP U-1068			
	7799331	Oct 11, 2028	DP U-139			
<u>PREDNISOLONE ACETATE - FLO-PRED</u>						
N 022067 002	7799331	Oct 11, 2028	DP U-1068			
	7799331	Oct 11, 2028	DP U-139			
<u>PREDNISONE - RAYOS</u>						
N 202020 001	8309124	Apr 23, 2024	U-1292			
	8394407	Apr 23, 2024	DP U-1362			
	9040085	Apr 23, 2024	U-1362			
	9186332	Apr 23, 2024	U-1362			
	9504699	Aug 03, 2027	U-1362			
<u>PREDNISONE - RAYOS</u>						
N 202020 002	8309124	Apr 23, 2024				
	8394407	Apr 23, 2024	DP U-1362			
	9040085	Apr 23, 2024	U-1362			
	9186332	Apr 23, 2024	U-1362			
	9504699	Aug 03, 2027	U-1362			
<u>PREDNISONE - RAYOS</u>						
N 202020 003	8168218	Jan 07, 2028	DP U-1269			
	8309124	Apr 23, 2024	U-1292			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PREDNISONE - RAYOS</u>						
N 202020 003	8394407	Apr 23, 2024	DP U-1362			
	9040085	Apr 23, 2024	U-1362			
	9186332	Apr 23, 2024	U-1362			
	9504699	Aug 03, 2027	U-1362			
<u>PREGABALIN - LYRICA CR</u>						
N 209501 001	10022447	Nov 02, 2026	U-2136			
	10022447	Nov 02, 2026	U-2137			
	10022447*PED	May 02, 2027				
	8945620	Nov 02, 2026	DP U-2136			
	8945620	Nov 02, 2026	DP U-2137			
	8945620*PED	May 02, 2027				
	9144559	Nov 02, 2026	DP			
	9144559*PED	May 02, 2027				
<u>PREGABALIN - LYRICA CR</u>						
N 209501 002	10022447	Nov 02, 2026	U-2136			
	10022447	Nov 02, 2026	U-2137			
	10022447*PED	May 02, 2027				
	8945620	Nov 02, 2026	DP U-2136			
	8945620	Nov 02, 2026	DP U-2137			
	8945620*PED	May 02, 2027				
	9144559	Nov 02, 2026	DP			
	9144559*PED	May 02, 2027				
<u>PREGABALIN - LYRICA CR</u>						
N 209501 003	10022447	Nov 02, 2026	U-2136			
	10022447	Nov 02, 2026	U-2137			
	10022447*PED	May 02, 2027				
	8945620	Nov 02, 2026	DP U-2136			
	8945620	Nov 02, 2026	DP U-2137			
	8945620*PED	May 02, 2027				
	9144559	Nov 02, 2026	DP			
	9144559*PED	May 02, 2027				
<u>PRETOMANID - PRETOMANID</u>						
N 212862 001					NCE	Aug 14, 2024
					ODE-253	Aug 14, 2026
					GAIN	Aug 14, 2029
<u>PROGESTERONE - MILPROSA</u>						
N 201110 001	10537584	Feb 03, 2029	DP		NP	Apr 29, 2023
	10548904	Feb 03, 2029	U-2810			
	8580293	Jan 21, 2030	U-2810			
<u>PROPOFOL - DIPRIVAN</u>						
N 019627 002	8476010	Dec 01, 2024	DS DP			
	8476010*PED	Jun 01, 2025				
<u>PROPRANOLOL HYDROCHLORIDE - HEMANGEOL</u>						
N 205410 001	8338489	Oct 16, 2028	U-1496			
	8987262	Oct 16, 2028	U-1988			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PRUCALOPRIDE SUCCINATE - MOTEGRITY</u>						
N 210166	001				NCE	Dec 14, 2023
<u>PRUCALOPRIDE SUCCINATE - MOTEGRITY</u>						
N 210166	002				NCE	Dec 14, 2023
<u>QUAZEPAM - DORAL</u>						
N 018708	001	7608616	Jun 03, 2028	U-1012		
<u>QUAZEPAM - DORAL</u>						
N 018708	003	7608616	Jun 03, 2028	U-1012		
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N 022145	001	7169780	Oct 03, 2023	DS DP		
		7169780*PED	Apr 03, 2024			
		7217713*PED	Apr 21, 2023			
		7435734*PED	Apr 21, 2023			
		7754731	Mar 11, 2029	DS DP U-257		
		7754731*PED	Sep 11, 2029			
<u>RALTEGRAVIR POTASSIUM - ISENTRESS HD</u>						
N 022145	002	10772888	Mar 30, 2032	U-1663		
		7169780	Oct 03, 2023	DS DP		
		7169780*PED	Apr 03, 2024			
		7217713*PED	Apr 21, 2023			
		7435734*PED	Apr 21, 2023			
		7754731	Mar 11, 2029	DS DP U-257		
		7754731*PED	Sep 11, 2029			
		9649311	Oct 21, 2030	DP		
		9649311*PED	Apr 21, 2031			
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N 203045	001	7169780	Oct 03, 2023	DS DP		
		7169780*PED	Apr 03, 2024			
		7217713*PED	Apr 21, 2023			
		7435734*PED	Apr 21, 2023			
		7754731	Mar 11, 2029	DS DP U-257		
		7754731*PED	Sep 11, 2029			
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N 203045	002	7169780	Oct 03, 2023	DS DP		
		7169780*PED	Apr 03, 2024			
		7217713*PED	Apr 21, 2023			
		7435734*PED	Apr 21, 2023			
		7754731	Mar 11, 2029	DS DP U-257		
		7754731*PED	Sep 11, 2029			
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N 205786	001	7169780	Oct 03, 2023	DS DP		
		7169780*PED	Apr 03, 2024			
		7217713*PED	Apr 21, 2023			
		7435734*PED	Apr 21, 2023			
		7754731	Mar 11, 2029	DS DP U-257		
		7754731*PED	Sep 11, 2029			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>RANOLAZINE - ASPRUZYO SPRINKLE</u>						
N 216018	001 11510878	Jan 24, 2038	DP			
<u>RANOLAZINE - ASPRUZYO SPRINKLE</u>						
N 216018	002 10898444	Jan 24, 2038	DP			
	11510878	Jan 24, 2038	DP			
<u>RASAGILINE MESYLATE - AZILECT</u>						
N 021641	001 7572834	Dec 05, 2026	DP			
	7815942	Aug 27, 2027	DS DP U-219			
<u>RASAGILINE MESYLATE - AZILECT</u>						
N 021641	002 7572834	Dec 05, 2026	DP			
	7815942	Aug 27, 2027	DS DP U-219			
<u>REGADENOSON - LEXISCAN</u>						
N 022161	001 8106183	Feb 02, 2027	DS			
	RE47301	Feb 02, 2027	DP			
<u>REGORAFENIB - STIVARGA</u>						
N 203085	001 8637553	Feb 16, 2031	DS DP		ODE-139	Apr 27, 2024
	8680124	Jun 02, 2030	U-1506			
	9458107	Apr 08, 2031	DP			
	9957232	Jul 09, 2032	DS			
<u>RELUGOLIX - ORGOVYX</u>						
N 214621	001 10350170	Feb 25, 2036	DP		NCE	Dec 18, 2025
	10449191	Sep 29, 2037	U-3020			
	10786501	Sep 29, 2037	U-3020			
	7300935	Jan 28, 2024	DS			
	8058280	Jan 28, 2024	DS DP			
	8735401	Feb 04, 2024	U-3019			
<u>REMDESIVIR - VEKLURY</u>						
N 214787	001 10065958	Sep 16, 2031	DS		D-183	Jan 21, 2025
	10675296	Jul 10, 2038	DP		NCE	Oct 22, 2025
	10695361	Sep 16, 2036	U-2984		NPP	Apr 25, 2025
	10695361	Sep 16, 2036	U-3249			
	10695361	Sep 16, 2036	U-3367			
	10695361	Sep 16, 2036	U-3368			
	11007208	Sep 16, 2036	U-2984			
	11007208	Sep 16, 2036	U-3249			
	11007208	Sep 16, 2036	U-3367			
	11007208	Sep 16, 2036	U-3368			
	11266681	Jul 10, 2038	U-2984			
	11266681	Jul 10, 2038	U-3249			
	11266681	Jul 10, 2038	U-3367			
	11266681	Jul 10, 2038	U-3368			
	11382926	Sep 16, 2036	U-3367			
	11382926	Sep 16, 2036	U-3368			
	11491169	May 28, 2041	U-3484			
	11491169	May 28, 2041	U-3485			
	11492353	Dec 08, 2031	DS			
	8008264	Sep 06, 2029	DS DP			
	8318682	Apr 22, 2029	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>REMDESIVIR - VEKLURY</u>						
N 214787 001	9724360	Oct 29, 2035	DS DP			
	9949994	Oct 29, 2035	DS			
	RE46762	Apr 22, 2029	DS DP			
<u>REMDESIVIR - VEKLURY</u>						
N 214787 002	10065958	Sep 16, 2031	DS		D-183	Jan 21, 2025
	10675296	Jul 10, 2038	DP		NCE	Oct 22, 2025
	10695361	Sep 16, 2036	U-2984		NPP	Apr 25, 2025
	10695361	Sep 16, 2036	U-3249			
	10695361	Sep 16, 2036	U-3367			
	10695361	Sep 16, 2036	U-3368			
	11007208	Sep 16, 2036	U-2984			
	11007208	Sep 16, 2036	U-3249			
	11007208	Sep 16, 2036	U-3367			
	11007208	Sep 16, 2036	U-3368			
	11266681	Jul 10, 2038	U-2984			
	11266681	Jul 10, 2038	U-3249			
	11266681	Jul 10, 2038	U-3367			
	11266681	Jul 10, 2038	U-3368			
	11382926	Sep 16, 2036	U-3367			
	11382926	Sep 16, 2036	U-3368			
	11491169	May 28, 2041	U-3484			
	11491169	May 28, 2041	U-3485			
	11492353	Dec 08, 2031	DS			
	8008264	Sep 06, 2029	DS DP			
	8318682	Apr 22, 2029	DS DP			
	9724360	Oct 29, 2035	DS DP			
	9949994	Oct 29, 2035	DS			
	RE46762	Apr 22, 2029	DS DP			
<u>REMIMAZOLAM BESYLATE - BYFAVO</u>						
N 212295 001	10052334	Nov 07, 2031	U-2968		NCE	Oct 06, 2025
	10195210	Nov 07, 2031	U-2968			
	10342800	Nov 07, 2031	U-2968			
	10472365	Jul 10, 2027	U-2968			
	10722522	Nov 07, 2031	U-2968			
	10961250	Jul 10, 2027	DP U-2968			
	9561236	Apr 30, 2033	U-2968			
	9737547	Nov 07, 2031	U-2968			
	9777007	Jul 10, 2027	DP			
	9827251	Nov 07, 2031	U-2968			
	9914738	Jul 10, 2027	DP			
<u>RETAPAMULIN - ALTABAX</u>						
N 022055 001	7875630	Feb 14, 2027	DS			
	8207191	Aug 30, 2024	U-805			
<u>REVEFENACIN - YUPELRI</u>						
N 210598 001	10106503	Mar 10, 2025	U-2440		NCE	Nov 09, 2023
	10343995	Mar 10, 2025	U-2440			
	10550081	Jul 14, 2030	DS			
	11008289	Jul 14, 2030	U-2440			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>REVEFENACIN - YUPELRI</u>						
N 210598 001	11247969	Mar 10, 2025	DP			
	11484531	Oct 23, 2039	U-2440			
	7288657	Dec 23, 2025	DS			
	7491736	Mar 10, 2025	U-2440			
	7521041	Mar 10, 2025	U-2440			
	7550595	Mar 10, 2025	DP			
	7585879	Mar 10, 2025	DS DP	U-2440		
	7910608	Mar 10, 2025	DS DP			
	8034946	Mar 10, 2025	DP			
	8053448	Mar 10, 2025	U-2440			
	8273894	Mar 10, 2025	DP			
	8541451	Aug 25, 2031	DS			
	9765028	Jul 14, 2030	DS			
<u>RIBAVIRIN - REBETOL</u>						
N 021546 001	6790837	Apr 05, 2023	DP			
<u>RIBOCICLIB SUCCINATE - KISOALI</u>						
N 209092 001	10799506	Apr 14, 2036	DP		NPP	Dec 10, 2024
	8324225	Jun 17, 2028	DS DP			
	8415355	Mar 13, 2031	DS DP			
	8685980	May 25, 2030	DS DP			
	8962630	Dec 09, 2029	U-1981			
	8962630	Dec 09, 2029	U-2355			
	8962630	Dec 09, 2029	U-2356			
	8962630	Dec 09, 2029	U-3265			
	8962630	Dec 09, 2029	U-3266			
	9193732	Nov 09, 2031	DS DP			
	9416136	Aug 20, 2029	U-1981			
	9416136	Aug 20, 2029	U-2355			
	9416136	Aug 20, 2029	U-2356			
	9416136	Aug 20, 2029	U-3265			
	9416136	Aug 20, 2029	U-3266			
	9868739	Nov 09, 2031	U-1981			
	9868739	Nov 09, 2031	U-2355			
	9868739	Nov 09, 2031	U-2356			
	9868739	Nov 09, 2031	U-3265			
	9868739	Nov 09, 2031	U-3266			
<u>RIBOFLAVIN 5'-PHOSPHATE SODIUM - PHOTREXA</u>						
N 203324 001					ODE-116	Apr 15, 2023
					ODE-121	Jul 15, 2023
<u>RIBOFLAVIN 5'-PHOSPHATE SODIUM - PHOTREXA VISCOUS IN DEXTRAN 20%</u>						
N 203324 002					ODE-116	Apr 15, 2023
					ODE-121	Jul 15, 2023
<u>RIFAMYCIN SODIUM - AEMCOLO</u>						
N 210910 001	8263120	May 03, 2025	DP		NCE	Nov 16, 2023
	8486446	May 03, 2025	DP		GAIN	Nov 16, 2028
	8529945	May 03, 2025	DP			
	8741948	May 03, 2025	DP U-2448			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>RIFAXIMIN - XIFAXAN</u>						
N 021361 001	10703763	Feb 27, 2026	U-1708			
	10703763	Feb 27, 2026	U-2847			
	10703763	Feb 27, 2026	U-2848			
	7045620	Jun 19, 2024	DS DP			
	7612199	Jun 19, 2024	DS DP			
	7902206	Jun 19, 2024	DS DP			
	7906542	Jun 01, 2025	DS DP			
	7928115	Jul 24, 2029	U-1121			
	8158644	Jun 19, 2024	DP			
	8158781	Jun 19, 2024	DS			
	8193196	Sep 02, 2027	DS DP			
	8518949	Feb 27, 2026	DP			
	8741904	Feb 27, 2026	DS U-1526			
	8835452	Jun 19, 2024	DS DP			
	8853231	Jun 19, 2024	DP			
	9271968	Feb 27, 2026	DP			
<u>RIFAXIMIN - XIFAXAN</u>						
N 021361 002	10314828	Jul 24, 2029	U-1481			
	10335397	Jul 24, 2029	U-2579			
	10456384	Feb 26, 2029	U-2643			
	10456384	Feb 26, 2029	U-2644			
	10703763	Feb 27, 2026	U-1708			
	10703763	Feb 27, 2026	U-2847			
	10703763	Feb 27, 2026	U-2848			
	10709694	Jul 24, 2029	U-2579			
	10765667	Feb 26, 2029	U-2643			
	10765667	Feb 26, 2029	U-2644			
	7045620	Jun 19, 2024	DS			
	7612199	Jun 19, 2024	DS DP			
	7902206	Jun 19, 2024	DS DP			
	7906542	Jun 01, 2025	DS DP			
	7915275	Feb 23, 2025	U-1707			
	7915275	Feb 23, 2025	U-1708			
	8158644	Jun 19, 2024	DP			
	8158781	Jun 19, 2024	DS			
	8193196	Sep 02, 2027	DS DP U-1707			
	8193196	Sep 02, 2027	DS DP U-1708			
	8309569	Jul 18, 2029	U-1707			
	8309569	Jul 18, 2029	U-1708			
	8518949	Feb 27, 2026	DP			
	8642573	Oct 02, 2029	U-1481			
	8741904	Feb 27, 2026	DS U-1526			
	8741904	Feb 27, 2026	DS U-1707			
	8741904	Feb 27, 2026	DS U-1708			
	8829017	Jul 24, 2029	U-1562			
	8835452	Jun 19, 2024	DS DP			
	8853231	Jun 19, 2024	DP			
	8946252	Jul 24, 2029	U-1481			
	8969398	Oct 02, 2029	U-1481			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>RIFAXIMIN - XIFAXAN</u>						
N 021361 002	9271968	Feb 27, 2026	DP			
	9421195	Jul 24, 2029	U-1481			
	9629828	Jul 24, 2029	U-1994			
<u>RILPIVIRINE HYDROCHLORIDE - EDURANT</u>						
N 202022 001	7125879	Apr 21, 2025	DS DP U-1153			
	7125879	Apr 21, 2025	DS DP U-1307			
	7125879	Apr 21, 2025	DS DP U-1740			
	7125879	Apr 21, 2025	DS DP U-3353			
	7638522	Apr 14, 2023	DP			
	8080551	Apr 11, 2023	DS DP			
<u>RILUZOLE - TIGLUTIK KIT</u>						
N 209080 001	8765150	Mar 12, 2029	DP U-2401			
<u>RILUZOLE - EXSERVAN</u>						
N 212640 001	8603514	Apr 03, 2024	DP			
	8765167	Feb 20, 2024	DP			
<u>RIMEGEPANT SULFATE - NURTEC ODT</u>						
N 212728 001	11083724	Mar 25, 2039	DP U-2718		I-865	May 27, 2024
	11083724	Mar 25, 2039	DP U-3142		NCE	Feb 27, 2025
	8314117	Feb 22, 2031	DS DP U-2718			
	8314117	Feb 22, 2031	DS DP U-3142			
	8759372	Feb 25, 2033	DS DP			
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819 001	10662188	Feb 18, 2034	DS DP U-2834			
	10662188	Feb 18, 2034	DS DP U-2835			
	11203593	Feb 18, 2034	DS DP U-2834			
	11203593	Feb 18, 2034	DS DP U-2835			
	7173037	Dec 04, 2026	DS DP			
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819 002	10662188	Feb 18, 2034	DS DP U-2834			
	10662188	Feb 18, 2034	DS DP U-2835			
	11203593	Feb 18, 2034	DS DP U-2834			
	11203593	Feb 18, 2034	DS DP U-2835			
	7173037	Dec 04, 2026	DS DP			
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819 003	10662188	Feb 18, 2034	DS DP U-2834			
	10662188	Feb 18, 2034	DS DP U-2835			
	11203593	Feb 18, 2034	DS DP U-2834			
	11203593	Feb 18, 2034	DS DP U-2835			
	7173037	Dec 04, 2026	DS DP			
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819 004	10662188	Feb 18, 2034	DS DP U-2834			
	10662188	Feb 18, 2034	DS DP U-2835			
	11203593	Feb 18, 2034	DS DP U-2834			
	11203593	Feb 18, 2034	DS DP U-2835			
	7173037	Dec 04, 2026	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>RIOCIGUAT - ADEMPAS</u>						
N 204819 005	10662188	Feb 18, 2034	DS DP U-2834			
	10662188	Feb 18, 2034	DS DP U-2835			
	11203593	Feb 18, 2034	DS DP U-2834			
	11203593	Feb 18, 2034	DS DP U-2835			
	7173037	Dec 04, 2026	DS DP			
<u>RIPRETINIB - QINLOCK</u>						
N 213973 001	10966966	Aug 12, 2040	U-3153		NCE	May 15, 2025
	11185535	Dec 30, 2040	DP		ODE-298	May 15, 2027
	11266635	Aug 12, 2040	U-3330			
	11344536	Aug 12, 2040	U-3381			
	11395818	Dec 30, 2040	DP			
	11426390	Aug 12, 2040	U-3416			
	11433056	Aug 12, 2040	U-3423			
	8188113	Jul 27, 2030	DS DP			
	8461179	Jun 07, 2032	DS DP			
	RE48731	Jun 07, 2032	U-3219			
<u>RISDIPLAM - EVRYSOI</u>						
N 213535 001	9586955	Feb 08, 2033	DS DP		NCE	Aug 07, 2025
	9969754	May 11, 2035	DS DP U-1943		NPP	May 27, 2025
					ODE-334	Aug 07, 2027
<u>RISEDRONATE SODIUM - ACTONEL</u>						
N 020835 005	7192938	May 06, 2023	U-353			
	7718634	May 06, 2023	U-662			
<u>RISEDRONATE SODIUM - ATELVIA</u>						
N 022560 001	7645459	Jan 09, 2028	DP U-662			
	7645460	Jan 09, 2028	DP U-662			
	8246989	Jan 16, 2026	DP			
<u>RISPERIDONE - PERSERIS KIT</u>						
N 210655 001	10010612	Feb 13, 2028	DP			
	10058554	Sep 26, 2026	U-2363			
	10376590	Feb 13, 2028	U-2608			
	10406160	Jun 26, 2026	DP U-2608			
	11013809	Feb 13, 2028	DP U-3135			
	11110093	Nov 05, 2026	DP U-3135			
	9180197	Feb 13, 2028	DP			
	9186413	Feb 13, 2028	U-543			
	9597402	Sep 26, 2026	DP			
<u>RISPERIDONE - PERSERIS KIT</u>						
N 210655 002	10010612	Feb 13, 2028	DP			
	10058554	Sep 26, 2026	U-2363			
	10376590	Feb 13, 2028	U-2608			
	10406160	Jun 26, 2026	DP U-2608			
	11013809	Feb 13, 2028	DP U-3135			
	11110093	Nov 05, 2026	DP U-3135			
	9180197	Feb 13, 2028	DP			
	9186413	Feb 13, 2028	U-543			
	9597402	Sep 26, 2026	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>RIVAROXABAN - XARELTO</u>						
N 022406 001	7157456	Aug 28, 2024	DS DP U-1301		I-867	Aug 23, 2024
	7157456	Aug 28, 2024	DS DP U-1302		M-284	Mar 10, 2023
	7157456*PED	Feb 28, 2025			PED	Sep 10, 2023
	9415053	Nov 13, 2024	DP U-1167		PED	Feb 23, 2025
	9415053	Nov 13, 2024	DP U-2142			
	9415053	Nov 13, 2024	DP U-2640			
	9415053	Nov 13, 2024	DP U-3284			
	9415053*PED	May 13, 2025				
	9539218	Feb 17, 2034	U-1957			
	9539218	Feb 17, 2034	U-2143			
	9539218	Feb 17, 2034	U-2641			
	9539218	Feb 17, 2034	U-3288			
	9539218*PED	Aug 17, 2034				
<u>RIVAROXABAN - XARELTO</u>						
N 022406 002	7157456	Aug 28, 2024	DS DP U-1301		I-867	Aug 23, 2024
	7157456	Aug 28, 2024	DS DP U-1302		M-284	Mar 10, 2023
	7157456*PED	Feb 28, 2025			PED	Sep 10, 2023
	9415053	Nov 13, 2024	DP U-1200		PED	Feb 23, 2025
	9415053	Nov 13, 2024	DP U-1301			
	9415053	Nov 13, 2024	DP U-1302			
	9415053	Nov 13, 2024	DP U-3286			
	9415053*PED	May 13, 2025				
	9539218	Feb 17, 2034	U-1953			
	9539218	Feb 17, 2034	U-3289			
	9539218*PED	Aug 17, 2034				
<u>RIVAROXABAN - XARELTO</u>						
N 022406 003	7157456	Aug 28, 2024	DS DP U-1301		I-867	Aug 23, 2024
	7157456	Aug 28, 2024	DS DP U-1302		M-284	Mar 10, 2023
	7157456*PED	Feb 28, 2025			PED	Sep 10, 2023
	9415053	Nov 13, 2024	DP U-1200		PED	Feb 23, 2025
	9415053	Nov 13, 2024	DP U-1301			
	9415053	Nov 13, 2024	DP U-1302			
	9415053	Nov 13, 2024	DP U-3287			
	9415053*PED	May 13, 2025				
	9539218	Feb 17, 2034	U-1953			
	9539218	Feb 17, 2034	U-1954			
	9539218	Feb 17, 2034	U-1955			
	9539218	Feb 17, 2034	U-3285			
	9539218*PED	Aug 17, 2034				
<u>RIVAROXABAN - XARELTO</u>						
N 022406 004	10828310	Jan 31, 2039	U-3207		I-867	Aug 23, 2024
	10828310	Jan 31, 2039	U-3208		M-284	Mar 10, 2023
	10828310*PED	Jul 31, 2039			PED	Sep 10, 2023
	7157456	Aug 28, 2024	DS DP		PED	Feb 23, 2025
	7157456*PED	Feb 28, 2025				
	9415053	Nov 13, 2024	DP U-2435			
	9415053	Nov 13, 2024	DP U-3205			
	9415053	Nov 13, 2024	DP U-3206			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>RIVAROXABAN - XARELTO</u>						
N 022406	004 9415053*PED	May 13, 2025				
<u>RIVAROXABAN - XARELTO</u>						
N 215859	001 7157456	Aug 28, 2024	DS DP		NP PED	Dec 20, 2024 Jun 20, 2025
<u>ROFLUMILAST - ROFLUMILAST</u>						
A 208213	001				PC	Apr 17, 2023
<u>ROFLUMILAST - ROFLUMILAST</u>						
A 208247	001				PC	Apr 17, 2023
<u>ROFLUMILAST - ROFLUMILAST</u>						
A 208256	001				PC	Apr 18, 2023
<u>ROFLUMILAST - ROFLUMILAST</u>						
A 208257	001				PC	Apr 17, 2023
<u>ROFLUMILAST - DALIRESP</u>						
N 022522	001 8431154	Feb 19, 2023	DP			
	8536206	Mar 08, 2024	U-1115			
	8604064	Mar 08, 2024	U-1115			
	8618142	Mar 08, 2024	DP			
	9468598	Feb 19, 2023	DP			
<u>ROFLUMILAST - DALIRESP</u>						
N 022522	002 8431154	Feb 19, 2023	DP			
	8536206	Mar 08, 2024	U-1115			
	8604064	Mar 08, 2024	U-1115			
	8618142	Mar 08, 2024	DP			
	9468598	Feb 19, 2023	DP			
<u>ROFLUMILAST - ZORYVE</u>						
N 215985	001 10940142	Jun 07, 2037	DP		NP	Jul 29, 2025
	11129818	Aug 25, 2037	DP U-3408			
	9884050	Jun 07, 2037	DP			
	9907788	Jun 07, 2037	DP U-3408			
<u>ROLAPITANT HYDROCHLORIDE - VARUBI</u>						
N 206500	001 7049320	Aug 19, 2028	DS DP U-1741			
	7563801	Apr 04, 2027	DP			
	7981905	Apr 04, 2027	U-1741			
	8178550	Apr 04, 2027	DS DP			
	8361500	Oct 09, 2029	DP			
	8404702	Apr 04, 2027	U-1741			
	8470842	Jan 18, 2029	U-1741			
<u>ROLAPITANT HYDROCHLORIDE - VARUBI</u>						
N 208399	001 7049320	Aug 19, 2028	DS DP U-1741			
	7981905	Apr 04, 2027	U-1741			
	8178550	Apr 04, 2027	DS DP			
	8404702	Apr 04, 2027	U-1741			
	8470842	Jan 18, 2029	U-1741			
	9101615	Jul 14, 2032	U-1741			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ROPIVACAINE HYDROCHLORIDE - NAROPIN</u>						
N 020533 006	7828787	Oct 18, 2025	DP			
	7857802	Nov 28, 2026	DP			
	8118802	May 18, 2023	DP			
	8162915	May 23, 2024	DP			
<u>ROPIVACAINE HYDROCHLORIDE - NAROPIN</u>						
N 020533 007	7828787	Oct 18, 2025	DP			
	7857802	Nov 28, 2026	DP			
	8118802	May 18, 2023	DP			
	8162915	May 23, 2024	DP			
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>						
N 021366 002					ODE-118	May 27, 2023
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>						
N 021366 003					ODE-118	May 27, 2023
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>						
N 021366 004					ODE-118	May 27, 2023
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>						
N 021366 005					ODE-118	May 27, 2023
<u>ROSUVASTATIN CALCIUM - EZALLOR SPRINKLE</u>						
N 208647 001	10413543	Feb 12, 2036	DP			
<u>ROSUVASTATIN CALCIUM - EZALLOR SPRINKLE</u>						
N 208647 002	10413543	Feb 12, 2036	DP			
<u>ROSUVASTATIN CALCIUM - EZALLOR SPRINKLE</u>						
N 208647 003	10413543	Feb 12, 2036	DP			
<u>ROSUVASTATIN CALCIUM - EZALLOR SPRINKLE</u>						
N 208647 004	10413543	Feb 12, 2036	DP			
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 001	10130589	Dec 22, 2030	DP			
	10350174	Dec 22, 2030	DP			
	8246979	Sep 01, 2027	DP U-1272			
	8246979	Sep 01, 2027	DP U-1273			
	8246980	Nov 27, 2025	DP			
	8617591	Jul 22, 2023	DP U-1474			
	9925150	Mar 01, 2032	DP			
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 002	10130589	Dec 22, 2030	DP			
	10350174	Dec 22, 2030	DP			
	8246979	Sep 01, 2027	DP U-1272			
	8246979	Sep 01, 2027	DP U-1273			
	8246980	Nov 27, 2025	DP			
	8617591	Jul 22, 2023	DP U-1474			
	9925150	Mar 01, 2032	DP			
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 003	10130589	Dec 22, 2030	DP			
	10350174	Dec 22, 2030	DP			
	8246979	Sep 01, 2027	DP U-1272			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 003	8246979	Sep 01, 2027	DP U-1273			
	8246980	Nov 27, 2025	DP			
	8617591	Jul 22, 2023	DP U-1474			
	9925150	Mar 01, 2032	DP			
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 004	10130589	Dec 22, 2030	DP			
	10350174	Dec 22, 2030	DP			
	8246979	Sep 01, 2027	DP U-1272			
	8246979	Sep 01, 2027	DP U-1273			
	8246980	Nov 27, 2025	DP			
	8617591	Jul 22, 2023	DP U-1474			
	9925150	Mar 01, 2032	DP			
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 005	10130589	Dec 22, 2030	DP			
	10350174	Dec 22, 2030	DP			
	8246979	Sep 01, 2027	DP U-1272			
	8246979	Sep 01, 2027	DP U-1273			
	8246980	Nov 27, 2025	DP			
	8617591	Jul 22, 2023	DP U-1474			
	9925150	Mar 01, 2032	DP			
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 006	10130589	Dec 22, 2030	DP			
	10350174	Dec 22, 2030	DP			
	8246979	Sep 01, 2027	DP U-1272			
	8246979	Sep 01, 2027	DP U-1273			
	8246980	Nov 27, 2025	DP			
	8617591	Jul 22, 2023	DP U-1474			
	9925150	Mar 01, 2032	DP			
<u>RUCAPARIB CAMSYLATE - RUBRACA</u>						
N 209115 001	10130636	Aug 17, 2035	U-2012		I-830	May 15, 2023
	10130636	Aug 17, 2035	U-2101		ODE-126	Dec 19, 2023
	10130636	Aug 17, 2035	U-2273		ODE-168	Apr 06, 2025
	10130636	Aug 17, 2035	U-2830			
	10278974	Feb 10, 2031	DP			
	6495541	Nov 22, 2023	DS DP			
	7351701	Jul 23, 2024	U-2012			
	7351701	Jul 23, 2024	U-2273			
	7351701	Jul 23, 2024	U-2830			
	7531530	Jul 23, 2024	U-2012			
	7531530	Jul 23, 2024	U-2273			
	7531530	Jul 23, 2024	U-2830			
	8071579	Aug 12, 2027	U-2012			
	8071579	Aug 12, 2027	U-2273			
	8071579	Aug 12, 2027	U-2830			
	8143241	Aug 12, 2027	U-2012			
	8143241	Aug 12, 2027	U-2273			
	8143241	Aug 12, 2027	U-2830			
	8754072	Feb 10, 2031	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>RUCAPARIB CAMSYLATE - RUBRACA</u>						
N 209115 001	8859562	Aug 04, 2031	U-2012			
	8859562	Aug 04, 2031	U-2273			
	8859562	Aug 04, 2031	U-2830			
	9045487	Feb 10, 2031	DS DP			
	9861638	Feb 10, 2031	U-2012			
	9861638	Feb 10, 2031	U-2273			
	9987285	Aug 17, 2035	DP			
<u>RUCAPARIB CAMSYLATE - RUBRACA</u>						
N 209115 002	10130636	Aug 17, 2035	U-2012		I-830	May 15, 2023
	10130636	Aug 17, 2035	U-2101		ODE-126	Dec 19, 2023
	10130636	Aug 17, 2035	U-2273		ODE-168	Apr 06, 2025
	10130636	Aug 17, 2035	U-2830			
	10278974	Feb 10, 2031	DP			
	6495541	Nov 22, 2023	DS DP			
	7351701	Jul 23, 2024	U-2012			
	7351701	Jul 23, 2024	U-2273			
	7351701	Jul 23, 2024	U-2830			
	7531530	Jul 23, 2024	U-2012			
	7531530	Jul 23, 2024	U-2273			
	7531530	Jul 23, 2024	U-2830			
	8071579	Aug 12, 2027	U-2012			
	8071579	Aug 12, 2027	U-2273			
	8071579	Aug 12, 2027	U-2830			
	8143241	Aug 12, 2027	U-2012			
	8143241	Aug 12, 2027	U-2273			
	8143241	Aug 12, 2027	U-2830			
	8754072	Feb 10, 2031	DS DP			
	8859562	Aug 04, 2031	U-2012			
	8859562	Aug 04, 2031	U-2273			
	8859562	Aug 04, 2031	U-2830			
	9045487	Feb 10, 2031	DS DP			
	9861638	Feb 10, 2031	U-2012			
	9861638	Feb 10, 2031	U-2273			
	9987285	Aug 17, 2035	DP			
<u>RUCAPARIB CAMSYLATE - RUBRACA</u>						
N 209115 003	10130636	Aug 17, 2035	U-2012		I-830	May 15, 2023
	10130636	Aug 17, 2035	U-2101		ODE-126	Dec 19, 2023
	10130636	Aug 17, 2035	U-2273		ODE-168	Apr 06, 2025
	10130636	Aug 17, 2035	U-2830			
	10278974	Feb 10, 2031	DP			
	6495541	Nov 22, 2023	DS DP			
	7351701	Jul 23, 2024	U-2012			
	7351701	Jul 23, 2024	U-2273			
	7351701	Jul 23, 2024	U-2830			
	7531530	Jul 23, 2024	U-2012			
	7531530	Jul 23, 2024	U-2273			
	7531530	Jul 23, 2024	U-2830			
	8071579	Aug 12, 2027	U-2012			
	8071579	Aug 12, 2027	U-2273			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>RUCAPARIB CAMSYLATE - RUBRACA</u>						
N 209115 003	8071579	Aug 12, 2027	U-2830			
	8143241	Aug 12, 2027	U-2012			
	8143241	Aug 12, 2027	U-2273			
	8143241	Aug 12, 2027	U-2830			
	8754072	Feb 10, 2031	DS DP			
	8859562	Aug 04, 2031	U-2012			
	8859562	Aug 04, 2031	U-2273			
	8859562	Aug 04, 2031	U-2830			
	9045487	Feb 10, 2031	DS DP			
	9861638	Feb 10, 2031	U-2012			
	9861638	Feb 10, 2031	U-2273			
	9987285	Aug 17, 2035	DP			
<u>RUFINAMIDE - BANZEL</u>						
N 021911 001	6740669*PED	May 14, 2023				
<u>RUFINAMIDE - BANZEL</u>						
N 021911 002	6740669*PED	May 14, 2023				
<u>RUFINAMIDE - BANZEL</u>						
N 021911 003	6740669*PED	May 14, 2023				
<u>RUFINAMIDE - BANZEL</u>						
N 201367 001	6740669*PED	May 14, 2023				
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 001	10016429	Jun 12, 2028	U-3226		I-872	Sep 22, 2024
	10016429	Jun 12, 2028	U-3230		ODE-238	May 24, 2026
	10016429*PED	Dec 12, 2028			ODE-373	Sep 22, 2028
	7598257	Dec 24, 2027	DS DP U-3227		PED	Mar 22, 2025
	7598257	Dec 24, 2027	DS DP U-3228		PED	Nov 24, 2026
	7598257*PED	Jun 24, 2028			PED	Mar 22, 2029
	8415362	Dec 24, 2027	DS DP			
	8415362*PED	Jun 24, 2028				
	8722693	Jun 12, 2028	DS DP			
	8722693*PED	Dec 12, 2028				
	8822481	Jun 12, 2028	U-1573			
	8822481	Jun 12, 2028	U-3226			
	8822481	Jun 12, 2028	U-3227			
	8822481	Jun 12, 2028	U-3228			
	8822481	Jun 12, 2028	U-3230			
	8822481*PED	Dec 12, 2028				
	8829013	Jun 12, 2028	U-1201			
	8829013	Jun 12, 2028	U-1622			
	8829013	Jun 12, 2028	U-3227			
	8829013	Jun 12, 2028	U-3228			
	8829013*PED	Dec 12, 2028				
	9079912	Dec 12, 2026	U-3226			
	9079912	Dec 12, 2026	U-3227			
	9079912	Dec 12, 2026	U-3228			
	9079912	Dec 12, 2026	U-3230			
	9079912*PED	Jun 12, 2027				
	9814722	Dec 12, 2026	U-3226			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 001	9814722	Dec 12, 2026	U-3230			
	9814722*PED	Jun 12, 2027				
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 002	10016429	Jun 12, 2028	U-3226		I-872	Sep 22, 2024
	10016429	Jun 12, 2028	U-3230		ODE-238	May 24, 2026
	10016429*PED	Dec 12, 2028			ODE-373	Sep 22, 2028
	7598257	Dec 24, 2027	DS DP U-3227		PED	Mar 22, 2025
	7598257	Dec 24, 2027	DS DP U-3228		PED	Nov 24, 2026
	7598257*PED	Jun 24, 2028			PED	Mar 22, 2029
	8415362	Dec 24, 2027	DS DP			
	8415362*PED	Jun 24, 2028				
	8722693	Jun 12, 2028	DS DP			
	8722693*PED	Dec 12, 2028				
	8822481	Jun 12, 2028	U-1573			
	8822481	Jun 12, 2028	U-3226			
	8822481	Jun 12, 2028	U-3227			
	8822481	Jun 12, 2028	U-3228			
	8822481	Jun 12, 2028	U-3230			
	8822481*PED	Dec 12, 2028				
	8829013	Jun 12, 2028	U-1201			
	8829013	Jun 12, 2028	U-1622			
	8829013	Jun 12, 2028	U-3227			
	8829013	Jun 12, 2028	U-3228			
	8829013*PED	Dec 12, 2028				
	9079912	Dec 12, 2026	U-3226			
	9079912	Dec 12, 2026	U-3227			
	9079912	Dec 12, 2026	U-3228			
	9079912	Dec 12, 2026	U-3230			
	9079912*PED	Jun 12, 2027				
	9814722	Dec 12, 2026	U-3226			
	9814722	Dec 12, 2026	U-3230			
	9814722*PED	Jun 12, 2027				
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 003	10016429	Jun 12, 2028	U-3226		ODE-238	May 24, 2026
	10016429	Jun 12, 2028	U-3230		ODE-373	Sep 22, 2028
	10016429*PED	Dec 12, 2028			PED	Nov 24, 2026
	7598257	Dec 24, 2027	DS DP U-3227		PED	Mar 22, 2029
	7598257	Dec 24, 2027	DS DP U-3228			
	7598257*PED	Jun 24, 2028				
	8415362	Dec 24, 2027	DS DP			
	8415362*PED	Jun 24, 2028				
	8722693	Jun 12, 2028	DS DP			
	8722693*PED	Dec 12, 2028				
	8822481	Jun 12, 2028	U-1573			
	8822481	Jun 12, 2028	U-3226			
	8822481	Jun 12, 2028	U-3227			
	8822481	Jun 12, 2028	U-3228			
	8822481	Jun 12, 2028	U-3230			
	8822481*PED	Dec 12, 2028				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 003	8829013	Jun 12, 2028	U-1201			
	8829013	Jun 12, 2028	U-1622			
	8829013	Jun 12, 2028	U-3227			
	8829013	Jun 12, 2028	U-3228			
	8829013*PED	Dec 12, 2028				
	9079912	Dec 12, 2026	U-3226			
	9079912	Dec 12, 2026	U-3227			
	9079912	Dec 12, 2026	U-3228			
	9079912	Dec 12, 2026	U-3230			
	9079912*PED	Jun 12, 2027				
	9814722	Dec 12, 2026	U-3226			
	9814722	Dec 12, 2026	U-3230			
	9814722*PED	Jun 12, 2027				
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 004	10016429	Jun 12, 2028	U-3226		ODE-238	May 24, 2026
	10016429	Jun 12, 2028	U-3230		ODE-373	Sep 22, 2028
	10016429*PED	Dec 12, 2028			PED	Nov 24, 2026
	7598257	Dec 24, 2027	DS DP U-3227		PED	Mar 22, 2029
	7598257	Dec 24, 2027	DS DP U-3228			
	7598257*PED	Jun 24, 2028				
	8415362	Dec 24, 2027	DS DP			
	8415362*PED	Jun 24, 2028				
	8722693	Jun 12, 2028	DS DP			
	8722693*PED	Dec 12, 2028				
	8822481	Jun 12, 2028	U-1573			
	8822481	Jun 12, 2028	U-3226			
	8822481	Jun 12, 2028	U-3227			
	8822481	Jun 12, 2028	U-3228			
	8822481	Jun 12, 2028	U-3230			
	8822481*PED	Dec 12, 2028				
	8829013	Jun 12, 2028	U-1201			
	8829013	Jun 12, 2028	U-1622			
	8829013	Jun 12, 2028	U-3227			
	8829013	Jun 12, 2028	U-3228			
	8829013*PED	Dec 12, 2028				
	9079912	Dec 12, 2026	U-3226			
	9079912	Dec 12, 2026	U-3227			
	9079912	Dec 12, 2026	U-3228			
	9079912	Dec 12, 2026	U-3230			
	9079912*PED	Jun 12, 2027				
	9814722	Dec 12, 2026	U-3226			
	9814722	Dec 12, 2026	U-3230			
	9814722*PED	Jun 12, 2027				
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 005	10016429	Jun 12, 2028	U-3226		ODE-238	May 24, 2026
	10016429	Jun 12, 2028	U-3230		ODE-373	Sep 22, 2028
	10016429*PED	Dec 12, 2028			PED	Nov 24, 2026
	7598257	Dec 24, 2027	DS DP U-3227		PED	Mar 22, 2029
	7598257	Dec 24, 2027	DS DP U-3228			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 005	7598257*PED	Jun 24, 2028				
	8415362	Dec 24, 2027	DS DP			
	8415362*PED	Jun 24, 2028				
	8722693	Jun 12, 2028	DS DP			
	8722693*PED	Dec 12, 2028				
	8822481	Jun 12, 2028	U-1573			
	8822481	Jun 12, 2028	U-3226			
	8822481	Jun 12, 2028	U-3227			
	8822481	Jun 12, 2028	U-3228			
	8822481	Jun 12, 2028	U-3230			
	8822481*PED	Dec 12, 2028				
	8829013	Jun 12, 2028	U-1201			
	8829013	Jun 12, 2028	U-1622			
	8829013	Jun 12, 2028	U-3227			
	8829013	Jun 12, 2028	U-3228			
	8829013*PED	Dec 12, 2028				
	9079912	Dec 12, 2026	U-3226			
	9079912	Dec 12, 2026	U-3227			
	9079912	Dec 12, 2026	U-3228			
	9079912	Dec 12, 2026	U-3230			
	9079912*PED	Jun 12, 2027				
	9814722	Dec 12, 2026	U-3226			
	9814722	Dec 12, 2026	U-3230			
	9814722*PED	Jun 12, 2027				
<u>RUXOLITINIB PHOSPHATE - OPZELURA</u>						
N 215309 001	10610530	Jun 12, 2028	U-3229		I-896	Jul 18, 2025
	10610530	Jun 12, 2028	U-3404		NP	Sep 21, 2024
	10610530*PED	Dec 12, 2028			PED	Mar 21, 2025
	10639310	Dec 12, 2026	U-3229		PED	Jan 18, 2026
	10639310*PED	Jun 12, 2027				
	10758543	May 20, 2031	DP			
	10758543*PED	Nov 20, 2031				
	10869870	May 20, 2031	U-3229			
	10869870	May 20, 2031	U-3404			
	10869870*PED	Nov 20, 2031				
	11219624	May 20, 2031	DP U-3229			
	11219624*PED	Nov 20, 2031				
	7598257	Dec 24, 2027	DS DP			
	7598257*PED	Jun 24, 2028				
	8415362	Dec 24, 2027	DS DP			
	8415362*PED	Jun 24, 2028				
	8722693	Jun 12, 2028	DS DP			
	8722693*PED	Dec 12, 2028				
	8822481	Jun 12, 2028	U-3229			
	8822481	Jun 12, 2028	U-3404			
	8822481*PED	Dec 12, 2028				
	9079912	Dec 12, 2026	U-3229			
	9079912	Dec 12, 2026	U-3404			
	9079912*PED	Jun 12, 2027				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>RUXOLITINIB PHOSPHATE - OPZELURA</u>						
N 215309 001	9974790	Dec 12, 2026	U-3229			
	9974790	Dec 12, 2026	U-3404			
	9974790*PED	Jun 12, 2027				
<u>SACUBITRIL; VALSARTAN - ENTRESTO</u>						
N 207620 001	11058667	May 09, 2036	U-3170		M-82	Feb 16, 2024
	11135192	Aug 22, 2033	U-3084			
	7468390	Nov 27, 2023	DP			
	7468390*PED	May 27, 2024				
	8101659	Jan 15, 2025	DP			
	8101659*PED	Jul 15, 2025				
	8404744	Jan 14, 2023	DP			
	8404744*PED	Jul 14, 2023				
	8796331	Jan 14, 2023	U-1723			
	8796331*PED	Jul 14, 2023				
	8877938	May 27, 2027	DS DP			
	8877938*PED	Nov 27, 2027				
	9388134	Nov 08, 2026	U-1723			
	9388134*PED	May 08, 2027				
	9517226	Aug 22, 2033	U-3084			
	9937143	Aug 22, 2033	U-3084			
<u>SACUBITRIL; VALSARTAN - ENTRESTO</u>						
N 207620 002	11058667	May 09, 2036	U-3170		M-82	Feb 16, 2024
	11135192	Aug 22, 2033	U-3084			
	7468390	Nov 27, 2023	DP			
	7468390*PED	May 27, 2024				
	8101659	Jan 15, 2025	DP			
	8101659*PED	Jul 15, 2025				
	8404744	Jan 14, 2023	DP			
	8404744*PED	Jul 14, 2023				
	8796331	Jan 14, 2023	U-1723			
	8796331*PED	Jul 14, 2023				
	8877938	May 27, 2027	DS DP			
	8877938*PED	Nov 27, 2027				
	9388134	Nov 08, 2026	U-1723			
	9388134*PED	May 08, 2027				
	9517226	Aug 22, 2033	U-3084			
	9937143	Aug 22, 2033	U-3084			
<u>SACUBITRIL; VALSARTAN - ENTRESTO</u>						
N 207620 003	11058667	May 09, 2036	U-3170		M-82	Feb 16, 2024
	11135192	Aug 22, 2033	U-3084			
	7468390	Nov 27, 2023	DP			
	7468390*PED	May 27, 2024				
	8101659	Jan 15, 2025	DP			
	8101659*PED	Jul 15, 2025				
	8404744	Jan 14, 2023	DP			
	8404744*PED	Jul 14, 2023				
	8796331	Jan 14, 2023	U-1723			
	8796331*PED	Jul 14, 2023				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SACUBITRIL; VALSARTAN - ENTRESTO</u>						
N 207620 003	8877938	May 27, 2027	DS DP			
	8877938*PED	Nov 27, 2027				
	9388134	Nov 08, 2026	U-1723			
	9388134*PED	May 08, 2027				
	9517226	Aug 22, 2033	U-3084			
	9937143	Aug 22, 2033	U-3084			
<u>SAFINAMIDE MESYLATE - XADAGO</u>						
N 207145 001	8076515	Dec 10, 2028	DS DP U-1993			
	8278485	Jun 08, 2027	DS U-1993			
	8283380	Mar 21, 2031	U-1993			
<u>SAFINAMIDE MESYLATE - XADAGO</u>						
N 207145 002	8076515	Dec 10, 2028	DS DP U-1993			
	8278485	Jun 08, 2027	DS U-1993			
	8283380	Mar 21, 2031	U-1993			
<u>SAPROPTERIN DIHYDROCHLORIDE - KUVAN</u>						
N 022181 001	7566462	Nov 16, 2025	DP			
	7566462*PED	May 16, 2026				
	7566714	Nov 17, 2024	U-989			
	7566714*PED	May 17, 2025				
	7612073	Nov 17, 2024	U-1010			
	7612073*PED	May 17, 2025				
	7727987	Nov 17, 2024	DP			
	7727987*PED	May 17, 2025				
	8003126	Nov 16, 2025				
	8003126*PED	May 16, 2026				
	8067416	Nov 17, 2024	U-989			
	8067416*PED	May 17, 2025				
	8318745	Nov 17, 2024	DP			
	8318745*PED	May 17, 2025				
	9433624	Nov 17, 2024	U-1589			
	9433624*PED	May 17, 2025				
	RE43797	Nov 17, 2024	U-1156			
	RE43797*PED	May 17, 2025				
<u>SAPROPTERIN DIHYDROCHLORIDE - KUVAN</u>						
N 205065 001	7566714	Nov 17, 2024	U-1589			
	7566714*PED	May 17, 2025				
	7612073	Nov 17, 2024	U-1010			
	7612073*PED	May 17, 2025				
	8067416	Nov 17, 2024	U-1589			
	8067416*PED	May 17, 2025				
	9216178	Nov 01, 2032	DP			
	9216178*PED	May 01, 2033				
	9433624	Nov 17, 2024	U-1589			
	9433624*PED	May 17, 2025				
	RE43797	Nov 17, 2024	U-1590			
	RE43797*PED	May 17, 2025				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SAPROPTERIN DIHYDROCHLORIDE - KUVAN</u>						
N 205065 002	7566714	Nov 17, 2024	U-1589			
	7566714*PED	May 17, 2025				
	7612073	Nov 17, 2024	U-1010			
	7612073*PED	May 17, 2025				
	8067416	Nov 17, 2024	U-1589			
	8067416*PED	May 17, 2025				
	9216178	Nov 01, 2032	DP			
	9216178*PED	May 01, 2033				
	9433624	Nov 17, 2024	U-1589			
	9433624*PED	May 17, 2025				
	RE43797	Nov 17, 2024	U-1590			
	RE43797*PED	May 17, 2025				
<u>SARECYCLINE HYDROCHLORIDE - SEYSARA</u>						
N 209521 001	8318706	May 01, 2031	DS DP U-2405		NCE	Oct 01, 2023
	8513223	Dec 07, 2029	U-2406			
	9255068	Feb 09, 2033	DS DP U-2407			
	9255068	Feb 09, 2033	DS DP U-2408			
	9481639	Aug 10, 2028	U-2409			
<u>SARECYCLINE HYDROCHLORIDE - SEYSARA</u>						
N 209521 002	8318706	May 01, 2031	DS DP U-2405		NCE	Oct 01, 2023
	8513223	Dec 07, 2029	U-2406			
	9255068	Feb 09, 2033	DS DP U-2407			
	9255068	Feb 09, 2033	DS DP U-2408			
	9481639	Aug 10, 2028	U-2409			
<u>SARECYCLINE HYDROCHLORIDE - SEYSARA</u>						
N 209521 003	8318706	May 01, 2031	DS DP U-2405		NCE	Oct 01, 2023
	8513223	Dec 07, 2029	U-2406			
	9255068	Feb 09, 2033	DS DP U-2407			
	9255068	Feb 09, 2033	DS DP U-2408			
	9481639	Aug 10, 2028	U-2409			
<u>SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA</u>						
N 022350 001	7951400	Nov 30, 2028	DP			
	RE44186	Jul 31, 2023	DS DP U-1837			
	RE44186	Jul 31, 2023	DS DP U-995			
<u>SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA</u>						
N 022350 002	7951400	Nov 30, 2028	DP			
	RE44186	Jul 31, 2023	DS DP U-1837			
	RE44186	Jul 31, 2023	DS DP U-995			
<u>SECNIDAZOLE - SOLOSEC</u>						
N 209363 001	10335390	Sep 04, 2035	DP U-2583		I-866	Jun 30, 2024
	10335390	Sep 04, 2035	DP U-3270		NCE	Sep 15, 2022
	10682338	Sep 04, 2035	DP U-2583		NPP	Jan 26, 2025
	10682338	Sep 04, 2035	DP U-3270		GAIN	Sep 15, 2027
	10849884	Sep 04, 2035	DP U-2583			
	10849884	Sep 04, 2035	DP U-3169			
	10849884	Sep 04, 2035	DP U-3270			
	10849884	Sep 04, 2035	DP U-3302			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SECNIDAZOLE - SOLOSEC</u>						
N 209363 001	10857133	Sep 04, 2035	DP U-2583			
	10857133	Sep 04, 2035	DP U-3270			
	11000507	Sep 04, 2035	DP U-2583			
	11000507	Sep 04, 2035	DP U-3169			
	11000507	Sep 04, 2035	DP U-3270			
	11000507	Sep 04, 2035	DP U-3302			
	11000508	Sep 04, 2035	DP U-2583			
	11000508	Sep 04, 2035	DP U-3169			
	11000508	Sep 04, 2035	DP U-3270			
	11000508	Sep 04, 2035	DP U-3302			
	11020377	Sep 04, 2035	DP U-2583			
	11020377	Sep 04, 2035	DP U-3169			
	11020377	Sep 04, 2035	DP U-3270			
	11020377	Sep 04, 2035	DP U-3302			
	11324721	Sep 04, 2035	DP U-2583			
	11324721	Sep 04, 2035	DP U-3169			
	11324721	Sep 04, 2035	DP U-3270			
	11324721	Sep 04, 2035	DP U-3302			
<u>SELENIOS ACID - SELENIOS ACID</u>						
N 209379 001					NCE	Apr 30, 2024
<u>SELENIOS ACID - SELENIOS ACID</u>						
N 209379 002					NCE	Apr 30, 2024
<u>SELENIOS ACID - SELENIOS ACID</u>						
N 209379 003					NCE	Apr 30, 2024
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 001	10821108	Dec 01, 2036	DP U-2992			
	10828298	Dec 01, 2036	DP U-2991			
	7205302	Oct 31, 2026	DS DP U-1797			
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 002	10821108	Dec 01, 2036	DP U-2992			
	10828298	Dec 01, 2036	DP U-2991			
	7205302	Oct 31, 2026	DS DP U-1797			
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 003	10821108	Dec 01, 2036	DP U-2992			
	10828298	Dec 01, 2036	DP U-2991			
	7205302	Oct 31, 2026	DS DP U-1797			
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 004	10821108	Dec 01, 2036	DP U-2992			
	10828298	Dec 01, 2036	DP U-2991			
	7205302	Oct 31, 2026	DS DP U-1797			
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 005	10821108	Dec 01, 2036	DP U-2992			
	10828298	Dec 01, 2036	DP U-2991			
	7205302	Oct 31, 2026	DS DP U-1797			
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 006	10821108	Dec 01, 2036	DP U-2992			
	10828298	Dec 01, 2036	DP U-2991			
	7205302	Oct 31, 2026	DS DP U-1797			
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 007	10821108	Dec 01, 2036	DP U-2992			
	10828298	Dec 01, 2036	DP U-2991			
	7205302	Oct 31, 2026	DS DP U-1797			
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 008	10821108	Dec 01, 2036	DP U-2992			
	10828298	Dec 01, 2036	DP U-2991			
	7205302	Oct 31, 2026	DS DP U-1797			
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
<u>SELEXIPAG - UPTRAVI</u>						
N 214275 001	7205302	Oct 31, 2026	DS DP U-1797			
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
<u>SELINEXOR - XPOVIO</u>						
N 212306 001	10519139	Aug 14, 2035	DS DP U-2584		I-837	Jun 22, 2023
	10519139	Aug 14, 2035	DS DP U-2855		NCE	Jul 03, 2024
	10519139	Aug 14, 2035	DS DP U-3018		ODE-257	Jul 03, 2026
	10544108	Jul 26, 2032	U-2584		ODE-310	Jun 22, 2027
	10544108	Jul 26, 2032	U-3018		ODE-346	Dec 18, 2027
	11034660	Jul 26, 2032	U-2584			
	11034660	Jul 26, 2032	U-3018			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SELINEXOR - XPOVIO</u>						
N 212306 001	8999996	Sep 15, 2032	DS DP			
	9079865	Jul 26, 2032	U-2584			
	9079865	Jul 26, 2032	U-2855			
	9079865	Jul 26, 2032	U-3018			
	9714226	Jul 26, 2032	DS DP			
<u>SELINEXOR - XPOVIO</u>						
N 212306 002	10519139	Aug 14, 2035	DS DP U-2584		ODE*	Jul 03, 2026
	10519139	Aug 14, 2035	DS DP U-2855		ODE*	Jun 22, 2027
	10519139	Aug 14, 2035	DS DP U-3018		ODE*	Dec 18, 2027
	10544108	Jul 26, 2032	U-2584			
	10544108	Jul 26, 2032	U-3018			
	11034660	Jul 26, 2032	U-2584			
	11034660	Jul 26, 2032	U-3018			
	8999996	Sep 15, 2032	DS DP			
	9079865	Jul 26, 2032	U-2584			
	9079865	Jul 26, 2032	U-2855			
	9079865	Jul 26, 2032	U-3018			
	9714226	Jul 26, 2032	DS DP			
<u>SELINEXOR - XPOVIO</u>						
N 212306 003	10519139	Aug 14, 2035	DS DP U-2584		ODE*	Jul 03, 2026
	10519139	Aug 14, 2035	DS DP U-2855		ODE*	Jun 22, 2027
	10519139	Aug 14, 2035	DS DP U-3018		ODE*	Dec 18, 2027
	10544108	Jul 26, 2032	U-2584			
	10544108	Jul 26, 2032	U-3018			
	11034660	Jul 26, 2032	U-2584			
	11034660	Jul 26, 2032	U-3018			
	8999996	Sep 15, 2032	DS DP			
	9079865	Jul 26, 2032	U-2584			
	9079865	Jul 26, 2032	U-2855			
	9079865	Jul 26, 2032	U-3018			
	9714226	Jul 26, 2032	DS DP			
<u>SELINEXOR - XPOVIO</u>						
N 212306 004	10519139	Aug 14, 2035	DS DP U-2584		ODE*	Jul 03, 2026
	10519139	Aug 14, 2035	DS DP U-2855		ODE*	Jun 22, 2027
	10519139	Aug 14, 2035	DS DP U-3018		ODE*	Dec 18, 2027
	10544108	Jul 26, 2032	U-2584			
	10544108	Jul 26, 2032	U-3018			
	11034660	Jul 26, 2032	U-2584			
	11034660	Jul 26, 2032	U-3018			
	8999996	Sep 15, 2032	DS DP			
	9079865	Jul 26, 2032	U-2584			
	9079865	Jul 26, 2032	U-2855			
	9079865	Jul 26, 2032	U-3018			
	9714226	Jul 26, 2032	DS DP			
<u>SELPERCATINIB - RETEVMO</u>						
N 213246 001	10112942	Oct 10, 2037	DS DP		NCE	May 08, 2025
	10137124	Oct 10, 2037	U-2826		ODE-301	May 08, 2027
	10137124	Oct 10, 2037	U-2827		ODE-302	May 08, 2027

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SELPERCATINIB - RETEVMO</u>						
N 213246 001	10137124	Oct 10, 2037	U-2828		ODE-303	May 08, 2027
	10137124	Oct 10, 2037	U-3450			
	10137124	Oct 10, 2037	U-3451			
	10137124	Oct 10, 2037	U-3452			
	10137124	Oct 10, 2037	U-3453			
	10172851	Oct 10, 2037	U-2826			
	10172851	Oct 10, 2037	U-2827			
	10172851	Oct 10, 2037	U-2828			
	10172851	Oct 10, 2037	U-3450			
	10172851	Oct 10, 2037	U-3451			
	10172851	Oct 10, 2037	U-3452			
	10172851	Oct 10, 2037	U-3453			
	10584124	Oct 10, 2038	DS U-2826			
	10584124	Oct 10, 2038	DS U-2827			
	10584124	Oct 10, 2038	DS U-2828			
	10584124	Oct 10, 2038	DS U-3450			
	10584124	Oct 10, 2038	DS U-3451			
	10584124	Oct 10, 2038	DS U-3452			
	10584124	Oct 10, 2038	DS U-3453			
	10786489	Oct 10, 2038	DP U-2971			
	10786489	Oct 10, 2038	DP U-2972			
	10786489	Oct 10, 2038	DP U-2973			
	10786489	Oct 10, 2038	DP U-2974			
	10786489	Oct 10, 2038	DP U-2975			
	10786489	Oct 10, 2038	DP U-2976			
	10786489	Oct 10, 2038	DP U-2977			
	10786489	Oct 10, 2038	DP U-3450			
	10786489	Oct 10, 2038	DP U-3451			
	10786489	Oct 10, 2038	DP U-3452			
	10786489	Oct 10, 2038	DP U-3453			
<u>SELPERCATINIB - RETEVMO</u>						
N 213246 002	10112942	Oct 10, 2037	DS DP		NCE	May 08, 2025
	10137124	Oct 10, 2037	U-2826		ODE-301	May 08, 2027
	10137124	Oct 10, 2037	U-2827		ODE-302	May 08, 2027
	10137124	Oct 10, 2037	U-2828		ODE-303	May 08, 2027
	10137124	Oct 10, 2037	U-3450			
	10137124	Oct 10, 2037	U-3451			
	10137124	Oct 10, 2037	U-3452			
	10137124	Oct 10, 2037	U-3453			
	10172851	Oct 10, 2037	U-2826			
	10172851	Oct 10, 2037	U-2827			
	10172851	Oct 10, 2037	U-2828			
	10584124	Oct 10, 2038	DS U-2826			
	10584124	Oct 10, 2038	DS U-2827			
	10584124	Oct 10, 2038	DS U-2828			
	10584124	Oct 10, 2038	DS U-3450			
	10584124	Oct 10, 2038	DS U-3451			
	10584124	Oct 10, 2038	DS U-3452			
	10584124	Oct 10, 2038	DS U-3453			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SEPERCATINIB - RETEVMO</u>						
N 213246 002	10786489	Oct 10, 2038	DP U-2971			
	10786489	Oct 10, 2038	DP U-2972			
	10786489	Oct 10, 2038	DP U-2973			
	10786489	Oct 10, 2038	DP U-2974			
	10786489	Oct 10, 2038	DP U-2975			
	10786489	Oct 10, 2038	DP U-2976			
	10786489	Oct 10, 2038	DP U-2977			
	10786489	Oct 10, 2038	DP U-3450			
	10786489	Oct 10, 2038	DP U-3451			
	10786489	Oct 10, 2038	DP U-3452			
	10786489	Oct 10, 2038	DP U-3453			
<u>SELUMETINIB SULFATE - KOSELUGO</u>						
N 213756 001	7425637	Apr 11, 2024	DS		NCE	Apr 10, 2025
	8178693	Mar 13, 2023	DS DP		ODE-288	Apr 10, 2027
	9156795	Dec 12, 2026	DS DP			
	9562017	Dec 12, 2026	DS U-2800			
<u>SELUMETINIB SULFATE - KOSELUGO</u>						
N 213756 002	7425637	Apr 11, 2024	DS		NCE	Apr 10, 2025
	8178693	Mar 13, 2023	DS DP		ODE-288	Apr 10, 2027
	9156795	Dec 12, 2026	DS DP			
	9562017	Dec 12, 2026	DS U-2800			
<u>SEMAGLUTIDE - OZEMPIC</u>						
N 209637 001	10220155	Jul 17, 2026	DP		I-822	Jan 16, 2023
	10335462	Jun 21, 2033	U-2580			
	10357616	Jan 20, 2026	DP			
	10376652	Jan 20, 2026	DP			
	11097063	Jul 17, 2026	DP			
	11311679	Jan 20, 2026	DP			
	11446443	Oct 20, 2025	DP			
	7762994	May 23, 2024	DP			
	8114833	Aug 13, 2025	DP			
	8129343	Dec 05, 2031	DS DP U-2202			
	8536122	Mar 20, 2026	DS DP U-2202			
	8579869	Jun 30, 2023	DP			
	8684969	Oct 20, 2025	DP			
	8920383	Jul 17, 2026	DP			
	9108002	Jan 20, 2026	DP			
	9132239	Feb 01, 2032	DP			
	9457154	Sep 27, 2027	DP			
	9616180	Jan 20, 2026	DP			
	9687611	Feb 27, 2027	DP			
	9775953	Jul 17, 2026	DP			
	9861757	Jan 20, 2026	DP			
	RE46363	Aug 03, 2026	DP			
<u>SEMAGLUTIDE - OZEMPIC</u>						
N 209637 002	10220155	Jul 17, 2026	DP		I-822	Jan 16, 2023
	10335462	Jun 21, 2033	U-2580			
	10357616	Jan 20, 2026	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SEMAGLUTIDE - OZEMPIC</u>						
N 209637 002	10376652	Jan 20, 2026	DP			
	11097063	Jul 17, 2026	DP			
	11311679	Jan 20, 2026	DP			
	11446443	Oct 20, 2025	DP			
	7762994	May 23, 2024	DP			
	8114833	Aug 13, 2025	DP			
	8129343	Dec 05, 2031	DS DP U-2202			
	8536122	Mar 20, 2026	DS DP U-2202			
	8579869	Jun 30, 2023	DP			
	8684969	Oct 20, 2025	DP			
	8920383	Jul 17, 2026	DP			
	9108002	Jan 20, 2026	DP			
	9132239	Feb 01, 2032	DP			
	9457154	Sep 29, 2027	DP			
	9616180	Jan 20, 2026	DP			
	9687611	Feb 27, 2027	DP			
	9775953	Jul 17, 2026	DP			
	9861757	Jan 20, 2026	DP			
	RE46363	Aug 03, 2026	DP			
<u>SEMAGLUTIDE - OZEMPIC</u>						
N 209637 003	10220155	Jul 17, 2026	DP		D-185	Mar 28, 2025
	10357616	Jan 20, 2026	DP			
	10376652	Jan 20, 2026	DP			
	11097063	Jul 17, 2026	DP			
	11311679	Jan 20, 2026	DP			
	11446443	Oct 20, 2025	DP			
	7762994	May 23, 2024	DP			
	8114833	Aug 13, 2025	DP			
	8129343	Dec 05, 2031	DS DP U-3355			
	8536122	Mar 20, 2026	DS DP U-3355			
	8579869	Jun 30, 2023	DP			
	8684969	Oct 20, 2025	DP			
	8920383	Jul 17, 2026	DP			
	9108002	Jan 20, 2026	DP			
	9132239	Feb 01, 2032	DP			
	9457154	Sep 29, 2027	DP			
	9616180	Jan 20, 2026	DP			
	9687611	Feb 27, 2027	DP			
	9775953	Jul 17, 2026	DP			
	9861757	Jan 20, 2026	DP			
	RE46363	Aug 03, 2026	DP			
<u>SEMAGLUTIDE - OZEMPIC</u>						
N 209637 004	10220155	Jul 17, 2026	DP			
	10335462	Jun 21, 2033	DP U-2580			
	10357616	Jan 20, 2026	DP			
	10376652	Jan 20, 2026	DP			
	11097063	Jul 17, 2026	DP			
	11311679	Jan 20, 2026	DP			
	11446443	Oct 20, 2025	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SEMAGLUTIDE - OZEMPIC</u>						
N 209637 004	7762994	May 23, 2024	DP			
	8114833	Aug 13, 2025	DP			
	8129343	Dec 05, 2031	DS DP U-3469			
	8536122	Mar 20, 2026	DS DP U-3469			
	8579869	Jun 30, 2023	DP			
	8684969	Oct 20, 2025	DP			
	8920383	Jul 17, 2026	DP			
	9108002	Jan 20, 2026	DP			
	9132239	Feb 01, 2032	DP			
	9457154	Sep 29, 2027	DP			
	9616180	Jan 20, 2026	DP			
	9687611	Feb 27, 2027	DP			
	9775953	Jul 17, 2026	DP			
	9861757	Jan 20, 2026	DP			
	RE46363	Aug 03, 2026	DP			
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051 001	10086047	Dec 16, 2031	DP		M-252	Jan 16, 2023
	10278923	May 02, 2034	U-2628			
	10933120	Mar 15, 2033	DP			
	10960052	Dec 16, 2031	DP			
	11382957	Dec 16, 2031	DP			
	8129343	Dec 05, 2031	DS DP U-2628			
	8536122	Mar 20, 2026	DS DP U-2628			
	9278123	Dec 16, 2031	DP U-2628			
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051 002	10086047	Dec 16, 2031	DP		M-252	Jan 16, 2023
	10278923	May 02, 2034	U-2628			
	10933120	Mar 15, 2033	DP			
	10960052	Dec 16, 2031	DP			
	11382957	Dec 16, 2031	DP			
	8129343	Dec 05, 2031	DS DP U-2628			
	8536122	Mar 20, 2026	DS DP U-2628			
	9278123	Dec 16, 2031	DP U-2628			
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051 003	10086047	Dec 16, 2031	DP		M-252	Jan 16, 2023
	10278923	May 02, 2034	U-2628			
	10933120	Mar 15, 2033	DP			
	10960052	Dec 16, 2031	DP			
	11382957	Dec 16, 2031	DP			
	8129343	Dec 05, 2031	DS DP U-2628			
	8536122	Mar 20, 2026	DS DP U-2628			
	9278123	Dec 16, 2031	DP U-2628			
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 001	10888605	Aug 24, 2038	DP U-3162		NP	Jun 04, 2024
	11318191	Feb 17, 2041	DP U-3162			
	8129343	Dec 05, 2031	DS DP			
	8536122	Mar 20, 2026	DS DP			
	9764003	Jun 21, 2033	U-3161			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 001	10888605	Aug 24, 2038	DP U-3162		NP	Jun 04, 2024
	11318191	Feb 17, 2041	DP U-3162			
	8129343	Dec 05, 2031	DS DP			
	8536122	Mar 20, 2026	DS DP			
	9764003	Jun 21, 2033	U-3161			
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 002	10888605	Aug 24, 2038	DP U-3162		NP	Jun 04, 2024
	11318191	Feb 17, 2041	DP U-3162			
	8129343	Dec 05, 2031	DS DP			
	8536122	Mar 20, 2026	DS DP			
	9764003	Jun 21, 2033	U-3161			
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 003	10888605	Aug 24, 2038	DP U-3162		NP	Jun 04, 2024
	11318191	Feb 17, 2041	DP U-3162			
	8129343	Dec 05, 2031	DS DP			
	8536122	Mar 20, 2026	DS DP			
	9764003	Jun 21, 2033	U-3161			
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 004	10888605	Aug 24, 2038	DP U-3162		NP	Jun 04, 2024
	11318191	Feb 17, 2041	DP U-3162			
	8129343	Dec 05, 2031	DS DP			
	8536122	Mar 20, 2026	DS DP			
	9764003	Jun 21, 2033	U-3161			
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 005	10888605	Aug 24, 2038	DP U-3162		NP	Jun 04, 2024
	11318191	Feb 17, 2041	DP U-3162			
	8129343	Dec 05, 2031	DS DP			
	8536122	Mar 20, 2026	DS DP			
	9764003	Jun 21, 2033	U-3161			
<u>SETMELANOTIDE ACETATE - IMCIVREE</u>						
N 213793 001	11129869	Jul 04, 2034	DP		I-892	Jun 16, 2025
	8039435	Oct 13, 2027	DS DP		NCE	Nov 25, 2025
	9458195	Oct 13, 2027	DS DP		ODE-336	Nov 25, 2027
<u>SEVELAMER CARBONATE - RENVELA</u>						
N 022127 001	7985418	Oct 27, 2025	DP			
<u>SEVELAMER CARBONATE - RENVELA</u>						
N 022318 001	9095509	Dec 06, 2030	DP			
<u>SEVELAMER CARBONATE - RENVELA</u>						
N 022318 002	9095509	Dec 06, 2030	DP			
<u>SIMEPREVIR SODIUM - OLYSIO</u>						
N 205123 001	7671032	May 19, 2025	DS DP			
	8148399	Sep 05, 2029	DS DP U-1467			
	8349869	Jul 28, 2026	DS DP U-1467			
	8741926	Jul 28, 2026	DS U-1467			
	8754106	Jul 28, 2026	DS U-1467			
	9040562	Jul 28, 2026	DS DP U-1467			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SIMEPREVIR SODIUM - OLYSIO</u>						
N 205123	001 9353103	Jul 28, 2026	U-1467			
	9623022	Jul 28, 2026	U-1467			
	9856265	Jul 28, 2026	DS DP U-1467			
<u>SIMVASTATIN - FLOLIPID</u>						
N 206679	001 10300041	Apr 26, 2027	DP			
	9597289	Feb 23, 2030	DP			
<u>SIMVASTATIN - FLOLIPID</u>						
N 206679	002 10300041	Apr 26, 2027	DP			
	9597289	Feb 23, 2030	DP			
<u>SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC</u>						
N 202343	001 6699871*PED	Jan 26, 2023				
	7125873*PED	Jan 26, 2023				
	7326708	Apr 11, 2026	DS DP U-1188			
	7326708*PED	Oct 11, 2026				
<u>SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC</u>						
N 202343	002 6699871*PED	Jan 26, 2023				
	7125873*PED	Jan 26, 2023				
	7326708	Apr 11, 2026	DS DP U-1188			
	7326708*PED	Oct 11, 2026				
<u>SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC</u>						
N 202343	003 6699871*PED	Jan 26, 2023				
	7125873*PED	Jan 26, 2023				
	7326708	Apr 11, 2026	DS DP U-1188			
	7326708*PED	Oct 11, 2026				
<u>SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC</u>						
N 202343	004 6699871*PED	Jan 26, 2023				
	7125873*PED	Jan 26, 2023				
	7326708	Apr 11, 2026	DS DP U-1188			
	7326708*PED	Oct 11, 2026				
<u>SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC</u>						
N 202343	005 6699871*PED	Jan 26, 2023				
	7125873*PED	Jan 26, 2023				
	7326708	Apr 11, 2026	DS DP U-1188			
	7326708*PED	Oct 11, 2026				
<u>SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC</u>						
N 202343	006 6699871*PED	Jan 26, 2023				
	7125873*PED	Jan 26, 2023				
	7326708	Apr 11, 2026	DS DP U-1188			
	7326708*PED	Oct 11, 2026				
<u>SINCALIDE - SINCALIDE</u>						
N 210850	001 11110063	Apr 20, 2038	DP U-3481			
	11110063	Apr 20, 2038	DP U-3482			
	11110063	Apr 20, 2038	DP U-3483			
	11318100	Apr 20, 2038	DP U-3477			
	11318100	Apr 20, 2038	DP U-3478			
	11318100	Apr 20, 2038	DP U-3479			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SINCALIDE - SINCALIDE</u>						
N 210850 001	11318100	Apr 20, 2038	DP U-3480			
<u>SINECATECHINS - VEREGEN</u>						
N 021902 001	7858662	Oct 02, 2026	DP U-172			
	9770406	Jul 12, 2025	DP U-172			
<u>SIPONIMOD FUMARIC ACID - MAYZENT</u>						
N 209884 001	7939519	Aug 27, 2028	DS DP		M-274	Mar 01, 2025
	8492441	Nov 30, 2030	U-2511		NCE	Mar 26, 2024
<u>SIPONIMOD FUMARIC ACID - MAYZENT</u>						
N 209884 002	7939519	Aug 27, 2028	DS DP		M-274	Mar 01, 2025
	8492441	Nov 30, 2030	U-2511		NCE	Mar 26, 2024
<u>SIPONIMOD FUMARIC ACID - MAYZENT</u>						
N 209884 003	7939519	Aug 27, 2028	DS DP		M-274	Mar 01, 2025
	8492441	Nov 30, 2030	U-2511		NCE	Mar 26, 2024
<u>SIROLIMUS - FYARRO</u>						
N 213312 001	10206887	Apr 15, 2030	DP		NP	Nov 22, 2024
	10705070	Mar 05, 2036	DP			
	10973806	Jun 29, 2036	U-3258			
	11497737	Oct 28, 2040	DP			
	8911786	Feb 14, 2029	DP U-3259			
<u>SIROLIMUS - HYFTOR</u>						
N 213478 001					NP	Mar 22, 2025
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 001	7326708	Nov 24, 2026	DS DP U-802		M-187	Dec 04, 2023
	7326708*PED	May 24, 2027			PED	Jun 04, 2024
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 002	7326708	Nov 24, 2026	DS DP U-802		M-187	Dec 04, 2023
	7326708*PED	May 24, 2027			PED	Jun 04, 2024
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 003	7326708	Nov 24, 2026	DS DP U-802		M-187	Dec 04, 2023
	7326708*PED	May 24, 2027			PED	Jun 04, 2024
<u>SODIUM NITRITE - SODIUM NITRITE</u>						
N 203922 001	8568793	Dec 24, 2031	DS DP			
	9687506	Feb 10, 2030	DP U-3394			
	9687506	Feb 10, 2030	DP U-3395			
<u>SODIUM NITRITE; SODIUM THIOSULFATE - NITHIODOTE</u>						
N 201444 001	10479686	Jul 07, 2030	DP U-3390			
	8496973	Mar 29, 2031	DS DP U-1419			
	8568793	Dec 24, 2031	DS DP			
	9345724	Jul 07, 2030	DS DP U-2015			
	9585912	Jul 07, 2030	DS DP			
	9687506	Feb 10, 2030	DP U-3394			
	9687506	Feb 10, 2030	DP U-3395			
<u>SODIUM OXYBATE - XYREM</u>						
N 021196 001	10213400	Mar 15, 2033	U-2499		ODE-231	Oct 26, 2025
	10213400*PED	Sep 15, 2033			PED	Apr 26, 2026

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SODIUM OXYBATE - XYREM</u>						
N 021196 001	10864181	Mar 15, 2033	U-1532			
	10864181*PED	Sep 15, 2033				
	11253494	Mar 15, 2033	U-3323			
	11253494	Mar 15, 2033	U-3324			
	11253494*PED	Sep 15, 2033				
	7668730	Jun 16, 2024	U-1110	Y		
	7668730*PED	Dec 16, 2024				
	8731963*PED	Jun 17, 2023				
	8772306	Mar 15, 2033	U-1532			
	8772306*PED	Sep 15, 2033				
	9050302	Mar 15, 2033	U-1532			
	9050302*PED	Sep 15, 2033				
	9486426	Mar 15, 2033	U-1532			
	9486426*PED	Sep 15, 2033				
<u>SODIUM PHENYLBUTYRATE; TAURURSODIOL - RELYVRIO</u>						
N 216660 001	10251896	Dec 24, 2033	U-3460		NCE	Sep 29, 2027
	10857162	Dec 24, 2033	U-3460			
	11071742	Dec 24, 2033	DP			
	9872865	Dec 24, 2033	U-3460			
<u>SODIUM PHOSPHATE, DIBASIC, ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE - OSMOPREP</u>						
N 021892 001	7687075	Jun 22, 2028	DS DP			
<u>SODIUM THIOSULFATE - SODIUM THIOSULFATE</u>						
N 203923 001	10479686	Jul 07, 2030	DP U-3390			
	8496973	Mar 29, 2031	DS DP U-1419			
	9345724	Jul 07, 2030	DS DP U-2015			
	9585912	Jul 07, 2030	DS DP			
<u>SODIUM THIOSULFATE - PEDMARK</u>						
N 212937 001	10596190	Jan 05, 2038	U-3443		NP	Sep 20, 2025
	11291728	Jul 01, 2039	DP			
	11510984	Jul 01, 2039	DP			
<u>SODIUM ZIRCONIUM CYCLOSILICATE - LOKELMA</u>						
N 207078 001	10300087	Oct 14, 2035	DS U-2312		M-261	Apr 24, 2023
	10335432	Feb 10, 2032	U-2312		NCE	May 18, 2023
	10398730	Feb 10, 2032	U-2312			
	10413569	Feb 10, 2032	DS			
	10695365	Oct 22, 2033	DS			
	11406662	Feb 10, 2032	DS			
	8802152	Apr 19, 2032	DS			
	8808750	Feb 10, 2032	U-2312			
	8877255	Oct 22, 2033	DS			
	9592253	Oct 14, 2035	DS U-2312			
	9844567	Feb 10, 2032	U-2312			
	9861658	Feb 10, 2032	U-2312			
	9913860	Oct 22, 2033	DS U-2312			
<u>SODIUM ZIRCONIUM CYCLOSILICATE - LOKELMA</u>						
N 207078 002	10300087	Oct 14, 2035	DS U-2312		M-261	Apr 24, 2023
	10398730	Feb 10, 2032	U-2312		NCE	May 18, 2023

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SODIUM ZIRCONIUM CYCLOSILICATE - LOKELMA</u>						
N 207078 002	10413569	Feb 10, 2032	DS			
	10695365	Oct 22, 2033	DS			
	11406662	Feb 10, 2032	DS			
	8802152	Apr 19, 2032	DS			
	8808750	Feb 10, 2032	U-2312			
	8877255	Oct 22, 2033	DS			
	9592253	Oct 14, 2035	DS U-2312			
	9844567	Feb 10, 2032	U-2312			
	9861658	Feb 10, 2032	U-2312			
	9913860	Oct 22, 2033	DS U-2312			
<u>SOFOSEBUVIR - SOVALDI</u>						
N 204671 001	7964580	Mar 26, 2029	DS DP U-1470		ODE*	Aug 28, 2026
	7964580*PED	Sep 26, 2029			ODE-135	Apr 07, 2024
	8334270	Mar 21, 2028	DS DP U-1470		PED	Oct 07, 2024
	8334270*PED	Sep 21, 2028				
	8580765	Mar 21, 2028	DS DP U-1470			
	8580765*PED	Sep 21, 2028				
	8618076	Dec 11, 2030	DS DP U-1470			
	8618076*PED	Jun 11, 2031				
	8633309	Mar 26, 2029	DS DP U-1470			
	8633309*PED	Sep 26, 2029				
	8889159	Mar 26, 2029	DP U-1470			
	8889159*PED	Sep 26, 2029				
	9085573	Mar 21, 2028	DS DP U-1470			
	9085573*PED	Sep 21, 2028				
	9284342	Sep 13, 2030	DS DP U-1470			
	9284342*PED	Mar 13, 2031				
	9549941	Mar 26, 2029	U-1958			
	9549941*PED	Sep 26, 2029				
<u>SOFOSEBUVIR - SOVALDI</u>						
N 204671 002	7964580	Mar 26, 2029	DS DP U-1470		ODE*	Apr 07, 2024
	7964580*PED	Sep 26, 2029			ODE*	Aug 28, 2026
	8334270	Mar 21, 2028	DS DP U-1470		PED	Oct 07, 2024
	8334270*PED	Sep 21, 2028				
	8580765	Mar 21, 2028	DS DP U-1470			
	8580765*PED	Sep 21, 2028				
	8618076	Dec 11, 2030	DS DP U-1470			
	8618076*PED	Jun 11, 2031				
	8633309	Mar 26, 2029	DS DP U-1470			
	8633309*PED	Sep 26, 2029				
	8889159	Mar 26, 2029	DP U-1470			
	8889159*PED	Sep 26, 2029				
	9085573	Mar 21, 2028	DS DP U-1470			
	9085573*PED	Sep 21, 2028				
	9284342	Sep 13, 2030	DS DP U-1470			
	9284342*PED	Mar 13, 2031				
<u>SOFOSEBUVIR - SOVALDI</u>						
N 212480 001	7964580	Mar 26, 2029	DS DP U-1470		ODE*	Apr 07, 2024

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SOFOSBUVIR - SOVALDI</u>						
N 212480 001	7964580*PED	Sep 26, 2029			ODE-258	Aug 28, 2026
	8334270	Mar 21, 2028	DS DP U-1470		PED	Oct 07, 2024
	8334270*PED	Sep 21, 2028				
	8580765	Mar 21, 2028	DS DP U-1470			
	8580765*PED	Sep 21, 2028				
	8618076	Dec 11, 2030	DS DP U-1470			
	8618076*PED	Jun 11, 2031				
	8633309	Mar 26, 2029	DS DP U-1470			
	8633309*PED	Sep 26, 2029				
	8889159	Mar 26, 2029	DP U-1470			
	8889159*PED	Sep 26, 2029				
	9085573	Mar 21, 2028	DS DP U-1470			
	9085573*PED	Sep 21, 2028				
	9284342	Sep 13, 2030	DS DP U-1470			
	9284342*PED	Mar 13, 2031				
<u>SOFOSBUVIR - SOVALDI</u>						
N 212480 002	7964580	Mar 26, 2029	DS DP U-1470		ODE*	Apr 07, 2024
	7964580*PED	Sep 26, 2029			ODE-258	Aug 28, 2026
	8334270	Mar 21, 2028	DS DP U-1470		PED	Oct 07, 2024
	8334270*PED	Sep 21, 2028				
	8580765	Mar 21, 2028	DS DP U-1470			
	8580765*PED	Sep 21, 2028				
	8618076	Dec 11, 2030	DS DP U-1470			
	8618076*PED	Jun 11, 2031				
	8633309	Mar 26, 2029	DS DP U-1470			
	8633309*PED	Sep 26, 2029				
	8889159	Mar 26, 2029	DP U-1470			
	8889159*PED	Sep 26, 2029				
	9085573	Mar 21, 2028	DS DP U-1470			
	9085573*PED	Sep 21, 2028				
	9284342	Sep 13, 2030	DS DP U-1470			
	9284342*PED	Mar 13, 2031				
<u>SOFOSBUVIR; VELPATASVIR - EPCLUSA</u>						
N 208341 001	10086011	Jan 30, 2034	U-1470		M-264	Jul 14, 2023
	10086011*PED	Jul 30, 2034			M-277	Apr 27, 2025
	11116783	Jan 30, 2034	DP U-1470		NPP	Mar 19, 2023
	11116783*PED	Jul 30, 2034			ODE-293	Mar 19, 2027
	7964580	Mar 26, 2029	DS DP U-1470		ODE-376	Jun 10, 2028
	7964580*PED	Sep 26, 2029			PED	Sep 19, 2023
	8334270	Mar 21, 2028	DS DP U-1470		PED	Jan 14, 2024
	8334270*PED	Sep 21, 2028			PED	Sep 19, 2027
	8575135	Nov 16, 2032	DS DP U-1470		PED	Dec 10, 2028
	8575135*PED	May 16, 2033				
	8580765	Mar 21, 2028	DS DP U-1470			
	8580765*PED	Sep 21, 2028				
	8618076	Dec 11, 2030	DS DP U-1470			
	8618076*PED	Jun 11, 2031				
	8633309	Mar 26, 2029	DS DP U-1470			
	8633309*PED	Sep 26, 2029				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SOFOSBUVIR; VELPATASVIR - EPCLUSA</u>						
N 208341 001	8735372	Mar 21, 2028	U-1470			
	8735372*PED	Sep 21, 2028				
	8889159	Mar 26, 2029	DP U-1470			
	8889159*PED	Sep 26, 2029				
	8921341	Nov 16, 2032	DS DP U-1470			
	8921341*PED	May 16, 2033				
	8940718	Nov 16, 2032	DS DP U-1470			
	8940718*PED	May 16, 2033				
	9085573	Mar 21, 2028	DS DP U-1470			
	9085573*PED	Sep 21, 2028				
	9284342	Sep 13, 2030	DS DP U-1470			
	9284342*PED	Mar 13, 2031				
	9757406	Jan 30, 2034	DP			
	9757406*PED	Jul 30, 2034				
<u>SOFOSBUVIR; VELPATASVIR - EPCLUSA</u>						
N 208341 002	10086011	Jan 30, 2034	U-1470		M-264	Jul 14, 2023
	10086011*PED	Jul 30, 2034			M-277	Apr 27, 2025
	11116783	Jan 30, 2034	DP U-1470		NS	Mar 19, 2023
	11116783*PED	Jul 30, 2034			ODE-293	Mar 19, 2027
	7964580	Mar 26, 2029	DS DP U-1470		ODE-376	Jun 10, 2028
	7964580*PED	Sep 26, 2029			PED	Sep 19, 2023
	8334270	Mar 21, 2028	DS DP U-1470		PED	Jan 14, 2024
	8334270*PED	Sep 21, 2028			PED	Sep 19, 2027
	8575135	Nov 16, 2032	DS DP U-1470		PED	Dec 10, 2028
	8575135*PED	May 16, 2033				
	8580765	Mar 21, 2028	DS DP U-1470			
	8580765*PED	Sep 21, 2028				
	8618076	Dec 11, 2030	DS DP U-1470			
	8618076*PED	Jun 11, 2031				
	8633309	Mar 26, 2029	DS DP U-1470			
	8633309*PED	Sep 26, 2029				
	8735372	Mar 21, 2028	U-1470			
	8735372*PED	Sep 21, 2028				
	8889159	Mar 26, 2029	DP U-1470			
	8889159*PED	Sep 26, 2029				
	8921341	Nov 16, 2032	DS DP U-1470			
	8921341*PED	May 16, 2033				
	8940718	Nov 16, 2032	DS DP U-1470			
	8940718*PED	May 16, 2033				
	9085573	Mar 21, 2028	DS DP U-1470			
	9085573*PED	Sep 21, 2028				
	9284342	Sep 13, 2030	DS DP U-1470			
	9284342*PED	Mar 13, 2031				
	9757406	Jan 30, 2034	DP			
	9757406*PED	Jul 30, 2034				
<u>SOFOSBUVIR; VELPATASVIR - EPCLUSA</u>						
N 214187 001	11116783	Jan 30, 2034	DP U-1470		M-277	Apr 27, 2025
	11116783*PED	Jul 30, 2034			ODE-376	Jun 10, 2028
	7964580	Mar 26, 2029	DS DP U-1470		PED	Dec 10, 2028

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SOFOSBUVIR; VELPATASVIR - EPCLUSA</u>						
N 214187 001	7964580*PED	Sep 26, 2029				
	8334270	Mar 21, 2028	DS DP U-1470			
	8334270*PED	Sep 21, 2028				
	8575135	Nov 16, 2032	DS DP U-1470			
	8575135*PED	May 16, 2033				
	8580765	Mar 21, 2028	DS DP U-1470			
	8580765*PED	Sep 21, 2028				
	8618076	Dec 11, 2030	DS DP U-1470			
	8618076*PED	Jun 11, 2031				
	8633309	Mar 26, 2029	DS DP U-1470			
	8633309*PED	Sep 26, 2029				
	8735372	Mar 21, 2028	U-1470			
	8735372*PED	Sep 21, 2028				
	8889159	Mar 26, 2029	DP U-1470			
	8889159*PED	Sep 26, 2029				
	8921341	Nov 16, 2032	DS DP U-1470			
	8921341*PED	May 16, 2033				
	8940718	Nov 16, 2032	DS DP U-1470			
	8940718*PED	May 16, 2033				
	9085573	Mar 21, 2028	DS DP U-1470			
	9085573*PED	Sep 21, 2028				
	9284342	Sep 13, 2030	DS DP U-1470			
	9284342*PED	Mar 13, 2031				
<u>SOFOSBUVIR; VELPATASVIR - EPCLUSA</u>						
N 214187 002	11116783	Jan 30, 2034	DP U-1470		M-277	Apr 27, 2025
	11116783*PED	Jul 30, 2034			ODE-376	Jun 10, 2028
	7964580	Mar 26, 2029	DS DP U-1470		PED	Dec 10, 2028
	7964580*PED	Sep 26, 2029				
	8334270	Mar 21, 2028	DS DP U-1470			
	8334270*PED	Sep 21, 2028				
	8575135	Nov 16, 2032	DS DP U-1470			
	8575135*PED	May 16, 2033				
	8580765	Mar 21, 2028	DS DP U-1470			
	8580765*PED	Sep 21, 2028				
	8618076	Dec 11, 2030	DS DP U-1470			
	8618076*PED	Jun 11, 2031				
	8633309	Mar 26, 2029	DS DP U-1470			
	8633309*PED	Sep 26, 2029				
	8735372	Mar 21, 2028	U-1470			
	8735372*PED	Sep 21, 2028				
	8889159	Mar 26, 2029	DP U-1470			
	8889159*PED	Sep 26, 2029				
	8921341	Nov 16, 2032	DS DP U-1470			
	8921341*PED	May 16, 2033				
	8940718	Nov 16, 2032	DS DP U-1470			
	8940718*PED	May 16, 2033				
	9085573	Mar 21, 2028	DS DP U-1470			
	9085573*PED	Sep 21, 2028				
	9284342	Sep 13, 2030	DS DP U-1470			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SOFOSEBUVIR; VELPATASVIR - EPCLUSA</u>						
N 214187 002	9284342*PED	Mar 13, 2031				
<u>SOFOSEBUVIR; VELPATASVIR; VOXILAPREVIR - VOSEVI</u>						
N 209195 001	10912814	Jun 01, 2037	DP			
	11116783	Jan 30, 2034	DP U-2039			
	11116783	Jan 30, 2034	DP U-2040			
	11116783*PED	Jul 30, 2034				
	11338007	Jun 01, 2037	DP U-2039			
	11338007	Jun 01, 2037	DP U-2040			
	11338007*PED	Dec 01, 2037				
	7964580	Mar 26, 2029	DS DP U-2039			
	7964580	Mar 26, 2029	DS DP U-2040			
	7964580*PED	Sep 26, 2029				
	8334270	Mar 21, 2028	DS DP U-2039			
	8334270	Mar 21, 2028	DS DP U-2040			
	8334270*PED	Sep 21, 2028				
	8575135	Nov 16, 2032	DS DP U-2039			
	8575135	Nov 16, 2032	DS DP U-2040			
	8575135*PED	May 16, 2033				
	8580765	Mar 21, 2028	DS DP U-2039			
	8580765	Mar 21, 2028	DS DP U-2040			
	8580765*PED	Sep 21, 2028				
	8618076	Dec 11, 2030	DS DP U-2039			
	8618076	Dec 11, 2030	DS DP U-2040			
	8618076*PED	Jun 11, 2031				
	8633309	Mar 26, 2029	DS DP U-2039			
	8633309	Mar 26, 2029	DS DP U-2040			
	8633309*PED	Sep 26, 2029				
	8735372	Mar 21, 2028	DS DP U-2039			
	8735372	Mar 21, 2028	DS DP U-2040			
	8735372*PED	Sep 21, 2028				
	8889159	Mar 26, 2029	DS DP U-2039			
	8889159	Mar 26, 2029	DS DP U-2040			
	8889159*PED	Sep 26, 2029				
	8921341	Nov 16, 2032	DS DP U-2039			
	8921341	Nov 16, 2032	DS DP U-2040			
	8921341*PED	May 16, 2033				
	8940718	Nov 16, 2032	DS DP U-2039			
	8940718	Nov 16, 2032	DS DP U-2040			
	8940718*PED	May 16, 2033				
	8957046	Mar 21, 2028	U-2039			
	8957046	Mar 21, 2028	U-2040			
	9085573	Mar 21, 2028	DS DP U-2039			
	9085573	Mar 21, 2028	DS DP U-2040			
	9085573*PED	Sep 21, 2028				
	9284342	Sep 13, 2030	DS DP U-2039			
	9284342	Sep 13, 2030	DS DP U-2040			
	9284342*PED	Mar 13, 2031				
	9296782	Jul 17, 2034	DS DP			
	9585906	Mar 21, 2028	DS DP U-2039			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR - VOSEVI</u>						
N 209195 001	9585906	Mar 21, 2028	DS DP U-2040			
	9868745	Nov 16, 2032	DS DP			
<u>SOLIFENACIN SUCCINATE - VESICARE LS</u>						
N 209529 001	9918970	May 18, 2031	DP		NP	May 26, 2023
					PED	Nov 26, 2023
<u>SOLRIAMFETOL HYDROCHLORIDE - SUNOSI</u>						
N 211230 001	10195151	Sep 05, 2037	DP		NCE	Jun 17, 2024
	10351517	Jun 07, 2026	U-2548		ODE-254	Jun 17, 2026
	10512609	Sep 05, 2037	U-2548			
	10912754	Jun 01, 2038	U-3082			
	10940133	Mar 19, 2040	U-3099			
	10959976	Jun 01, 2038	U-3151			
	11439597	Nov 05, 2034	DP			
	8440715	Aug 25, 2027	U-2548			
	8877806	Jun 07, 2026	U-2548			
	9604917	Jun 07, 2026	U-2548			
<u>SOLRIAMFETOL HYDROCHLORIDE - SUNOSI</u>						
N 211230 002	10195151	Sep 05, 2037	DP		NCE	Jun 17, 2024
	10351517	Jun 07, 2026	U-2548		ODE-254	Jun 17, 2026
	10512609	Sep 05, 2037	U-2548			
	10912754	Jun 01, 2038	U-3082			
	10959976	Jun 01, 2038	U-3151			
	11439597	Nov 05, 2034	DP			
	8440715	Aug 25, 2027	U-2548			
	8877806	Jun 07, 2026	U-2548			
	9604917	Jun 07, 2026	U-2548			
<u>SONIDEGIB PHOSPHATE - ODOMZO</u>						
N 205266 001	10266523	Mar 30, 2036	DS DP			
	8063043	Sep 15, 2029	DS DP			
	8178563	Jul 24, 2029	DS U-1722			
<u>SORAFENIB TOSYLATE - NEXAVAR</u>						
N 021923 001	8618141	Feb 11, 2023	U-1480			
	8877933	Dec 24, 2027	DS DP U-1624			
	9737488	Sep 10, 2028	DP U-1480			
	9737488	Sep 10, 2028	DP U-1696			
	9737488	Sep 10, 2028	DP U-2107			
<u>SOTALOL HYDROCHLORIDE - SOTALOL HYDROCHLORIDE</u>						
N 022306 001	10512620	Aug 18, 2038	U-2769			
	10799138	Apr 05, 2039	U-3125			
<u>SOTALOL HYDROCHLORIDE - SOTYLIZE</u>						
N 205108 001	10206895	Apr 01, 2034	DP U-2096			
	10206895	Apr 01, 2034	DP U-2494			
	11013703	Apr 01, 2034	DP			
	9724297	Aug 31, 2035	DP U-2096			
<u>SOTORASIB - LUMAKRAS</u>						
N 214665 001	10519146	May 21, 2038	DS DP		NCE	May 28, 2026

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SOTORASIB - LUMAKRAS</u>						
N 214665	001 11236091	May 20, 2040	DS DP U-3306		ODE-352	May 28, 2028
	11426404	Aug 11, 2040	U-3306			
<u>SPINOSAD - NATROBA</u>						
N 022408	001 6063771	Jul 25, 2023	DP U-1670		I-858	Apr 28, 2024
	9895388	Nov 25, 2033	U-3365			
<u>SPIRONOLACTONE - CAROSPIR</u>						
N 209478	001 10493083	Oct 28, 2036	DP			
	10624906	Oct 28, 2036	DP			
	10660907	Oct 28, 2036	DP			
	10888570	Oct 28, 2036	DP			
	11389461	Oct 28, 2036	DP			
	11395828	Oct 28, 2036	U-2109			
	11395828	Oct 28, 2036	U-3401			
	11395828	Oct 28, 2036	U-3402			
	11491166	Oct 28, 2036	DP			
	9757394	Oct 28, 2036	DP U-2109			
<u>STAVUDINE - ZERIT XR</u>						
N 021453	001 7135465	Feb 18, 2023	DP U-167			
<u>STAVUDINE - ZERIT XR</u>						
N 021453	002 7135465	Feb 18, 2023	DP U-167			
<u>STAVUDINE - ZERIT XR</u>						
N 021453	003 7135465	Feb 18, 2023	DP U-167			
<u>STAVUDINE - ZERIT XR</u>						
N 021453	004 7135465	Feb 18, 2023	DP U-167			
<u>STIRIPENTOL - DIACOMIT</u>						
N 206709	001				M-281	Jul 14, 2025
					NCE	Aug 20, 2023
					ODE-198	Aug 20, 2025
<u>STIRIPENTOL - DIACOMIT</u>						
N 206709	002				M-281	Jul 14, 2025
					NCE	Aug 20, 2023
					ODE-198	Aug 20, 2025
<u>STIRIPENTOL - DIACOMIT</u>						
N 207223	001				NCE	Aug 20, 2023
					NPP	Jul 14, 2025
					ODE-198	Aug 20, 2025
<u>STIRIPENTOL - DIACOMIT</u>						
N 207223	002				NCE	Aug 20, 2023
					NPP	Jul 14, 2025
					ODE-198	Aug 20, 2025
<u>SUFENTANIL CITRATE - DSUVIA</u>						
N 209128	001 10245228	Jan 05, 2027	DP U-1351			
	10342762	Jan 05, 2027	DP			
	10507180	Jan 05, 2027	DP U-1351			
	10896751	Mar 16, 2030	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SUFENTANIL CITRATE - DSUVIA</u>						
N 209128 001	8202535	Oct 22, 2030	U-1351			
	8226978	Jan 05, 2027	DP U-1351			
	8231900	Jan 05, 2027	DP			
	8252328	Jan 05, 2027	DP			
	8252329	Jan 05, 2027	DP			
	8535714	Jan 05, 2027	DP U-1351			
	8574189	Mar 16, 2030	DP			
	8778393	Jan 05, 2027	U-1351			
	8778394	Jan 05, 2027	U-1351			
	8865211	Jan 05, 2027	U-1351			
	8865743	Oct 22, 2030	U-1351			
	8945592	Jul 29, 2031	DP			
	9320710	Jan 05, 2027	U-1351			
	9744129	Jan 05, 2027	DP			
<u>SUGAMMADEX SODIUM - BRIDION</u>						
N 022225 001	RE44733	Jan 27, 2026	DS DP U-1794		M-262	Jun 09, 2023
					NPP	Jun 25, 2024
<u>SUGAMMADEX SODIUM - BRIDION</u>						
N 022225 002	RE44733	Jan 27, 2026	DS DP U-1794		M-262	Jun 09, 2023
					NPP	Jun 25, 2024
<u>SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSPHERES - LUMASON</u>						
N 203684 001	10232061	Jul 06, 2038	DP			
	10335502	Jul 06, 2038	DP			
<u>SUMATRIPTAN - TOSYMRA</u>						
N 210884 001	10603305	Jun 16, 2030	DP U-1719			
	11337962	Jun 16, 2030	DP U-1719			
	8268791	May 09, 2026	DP			
	8440631	May 09, 2026	DP U-1719			
	9211282	Jul 19, 2031	DP U-1719			
	9283280	May 09, 2026	DP			
	9610280	Jun 16, 2030	DP U-1719			
	9974770	Jun 16, 2030	DP U-1719			
<u>SUMATRIPTAN SUCCINATE - SUMAVEL DOSEPRO</u>						
N 022239 001	7776007	Nov 22, 2026	DP			
	7901385	Jul 31, 2026	DP			
	8118771	Aug 10, 2023	DP			
	8241243	Aug 10, 2023	DP			
	8267903	Mar 18, 2023	DP			
	8287489	Dec 06, 2024	DP			
<u>SUMATRIPTAN SUCCINATE - ALSUMA</u>						
N 022377 001	7811254	Aug 26, 2027	DP U-1083			
<u>SUMATRIPTAN SUCCINATE - ZECUITY</u>						
N 202278 001	6745071	Feb 21, 2023	DP			
	7973058	Apr 12, 2027	U-1328			
	8155737	Apr 12, 2027	U-1328			
	8366600	Apr 21, 2029	U-1327			
	8470853	Apr 12, 2027	U-1328			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SUMATRIPTAN SUCCINATE - ZECUITY</u>						
N 202278 001	8597272	Apr 12, 2027	DP			
	8983594	Nov 19, 2030	DP U-1328			
	9272137	Sep 07, 2027	DP			
	9327114	Oct 08, 2032	DP U-1328			
	9427578	Apr 12, 2027	DP U-1328			
<u>SUMATRIPTAN SUCCINATE - ONZETRA XSAIL</u>						
N 206099 001	10076614	Oct 20, 2034	DP			
	10076615	Jul 30, 2029	U-2010			
	10076615	Jul 30, 2029	U-2011			
	10076615	Jul 30, 2029	U-2404			
	10124132	Mar 06, 2027	DP U-1719			
	10124132	Mar 06, 2027	DP U-2010			
	10124132	Mar 06, 2027	DP U-2011			
	10398859	Dec 19, 2027	DP			
	10478574	Nov 04, 2033	U-2404			
	10722667	Dec 30, 2028	DP			
	7975690	Aug 18, 2025	DP U-1809			
	8047202	Jul 02, 2023	DP			
	8327844	Oct 03, 2023	U-1809			
	8550073	Oct 22, 2029	DP			
	8590530	Sep 15, 2025	DP U-1809			
	8875704	Apr 07, 2028	DP U-1809			
	8899229	Aug 18, 2030	DP			
	8978647	Dec 06, 2030	DP			
	9108015	Sep 15, 2025	DP			
	9119932	Apr 23, 2024	DP			
	9649456	Oct 21, 2030	DP U-1719			
	9649456	Oct 21, 2030	DP U-2010			
	9649456	Oct 21, 2030	DP U-2011			
<u>SUMATRIPTAN SUCCINATE - ZEMBRACE SYMTOUCH</u>						
N 208223 001	10537554	Jan 29, 2036	U-72			
	11364224	Jan 29, 2036	U-72			
<u>SUVOREXANT - BELSOMRA</u>						
N 204569 001	10098892	May 29, 2033	DP		M-253	Jan 29, 2023
	7951797	Nov 20, 2029	DS DP U-620			
<u>SUVOREXANT - BELSOMRA</u>						
N 204569 002	10098892	May 29, 2033	DP		M-253	Jan 29, 2023
	7951797	Nov 20, 2029	DS DP U-620			
<u>SUVOREXANT - BELSOMRA</u>						
N 204569 003	10098892	May 29, 2033	DP		M-253	Jan 29, 2023
	7951797	Nov 20, 2029	DS DP U-620			
<u>SUVOREXANT - BELSOMRA</u>						
N 204569 004	10098892	May 29, 2033	DP		M-253	Jan 29, 2023
	7951797	Nov 20, 2029	DS DP U-620			
<u>TACROLIMUS - PROGRAF</u>						
N 050708 001					ODE-294	May 24, 2025
					ODE-360	Jul 16, 2028

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TACROLIMUS - PROGRAF</u>						
N 050708	001				ODE-294	May 24, 2025
					ODE-360	Jul 16, 2028
<u>TACROLIMUS - PROGRAF</u>						
N 050708	002				ODE-294	May 24, 2025
					ODE-360	Jul 16, 2028
<u>TACROLIMUS - PROGRAF</u>						
N 050708	003				ODE-294	May 24, 2025
					ODE-360	Jul 16, 2028
<u>TACROLIMUS - PROGRAF</u>						
N 050709	001				ODE-294	May 24, 2025
					ODE-360	Jul 16, 2028
<u>TACROLIMUS - ASTAGRAF XL</u>						
N 204096	001				ODE*	May 24, 2025
<u>TACROLIMUS - ASTAGRAF XL</u>						
N 204096	002				ODE*	May 24, 2025
<u>TACROLIMUS - ASTAGRAF XL</u>						
N 204096	003				ODE*	May 24, 2025
<u>TACROLIMUS - ENVARSUS XR</u>						
N 206406	001	10166190	May 30, 2028	DP		
		10548880	Aug 30, 2024	U-2677		
		10548880	Aug 30, 2024	U-2678		
		10864199	May 30, 2028	U-2677		
		10864199	May 30, 2028	U-2678		
		11077096	Aug 30, 2024	DP		
		11110081	May 30, 2028	U-2678		
		11123331	May 30, 2028	U-2677		
		11419823	May 30, 2028	DP		
		7994214	Aug 30, 2024	DP		
		8486993	Aug 30, 2024	DP U-1752		
		8586084	Aug 30, 2024	U-1752		
		8591946	Aug 30, 2024	DP		
		8617599	Aug 30, 2024	DP		
		8623410	Aug 30, 2024	DP		
		8623411	Aug 30, 2024	U-1752		
		8664239	Aug 30, 2028	U-1752		
		8664239	Aug 30, 2028	U-2677		
		8664239	Aug 30, 2028	U-2678		
		8685998	Aug 30, 2028	DP U-1752		
		8685998	Aug 30, 2028	DP U-2677		
		8685998	Aug 30, 2028	DP U-2678		
		8889185	Aug 30, 2024	U-1752		
		8889186	Aug 30, 2024	U-1752		
		9161907	Aug 30, 2024	DP U-1752		
		9549918	May 30, 2028	DP		
		9757362	Aug 30, 2024	DP		
		9763920	Aug 30, 2024	DP		

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TACROLIMUS - ENVARUSUS XR</u>						
N 206406 002	10166190	May 30, 2028	DP			
	10548880	Aug 30, 2024	U-2677			
	10548880	Aug 30, 2024	U-2678			
	10864199	May 30, 2028	U-2677			
	10864199	May 30, 2028	U-2678			
	11077096	Aug 30, 2024	DP			
	11110081	May 30, 2028	U-2678			
	11123331	May 30, 2028	U-2677			
	11419823	May 30, 2028	DP			
	7994214	Aug 30, 2024	DP			
	8486993	Aug 30, 2024	DP U-1752			
	8586084	Aug 30, 2024	U-1752			
	8591946	Aug 30, 2024	DP			
	8617599	Aug 30, 2024	DP			
	8623410	Aug 30, 2024	DP			
	8623411	Aug 30, 2024	U-1752			
	8664239	Aug 30, 2028	U-1752			
	8664239	Aug 30, 2028	U-2677			
	8664239	Aug 30, 2028	U-2678			
	8685998	Aug 30, 2028	DP U-1752			
	8685998	Aug 30, 2028	DP U-2677			
	8685998	Aug 30, 2028	DP U-2678			
	8889185	Aug 30, 2024	U-1752			
	8889186	Aug 30, 2024	U-1752			
	9161907	Aug 30, 2024	DP U-1752			
	9549918	May 30, 2028	DP			
	9757362	Aug 30, 2024	DP			
	9763920	Aug 30, 2024	DP			
<u>TACROLIMUS - ENVARUSUS XR</u>						
N 206406 003	10166190	May 30, 2028	DP			
	10548880	Aug 30, 2024	U-2677			
	10548880	Aug 30, 2024	U-2678			
	10864199	May 30, 2028	U-2677			
	10864199	May 30, 2028	U-2678			
	11077096	Aug 30, 2024	DP			
	11110081	May 30, 2028	U-2678			
	11123331	May 30, 2028	U-2677			
	11419823	May 30, 2028	DP			
	7994214	Aug 30, 2024	DP			
	8486993	Aug 30, 2024	DP U-1752			
	8586084	Aug 30, 2024	U-1752			
	8591946	Aug 30, 2024	DP			
	8617599	Aug 30, 2024	DP			
	8623410	Aug 30, 2024	DP			
	8623411	Aug 30, 2024	U-1752			
	8664239	Aug 30, 2028	U-1752			
	8664239	Aug 30, 2028	U-2677			
	8664239	Aug 30, 2028	U-2678			
	8685998	Aug 30, 2028	DP U-1752			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TACROLIMUS - ENVARSUS XR</u>						
N 206406 003	8685998	Aug 30, 2028	DP U-2677			
	8685998	Aug 30, 2028	DP U-2678			
	8889185	Aug 30, 2024	U-1752			
	8889186	Aug 30, 2024	U-1752			
	9161907	Aug 30, 2024	DP U-1752			
	9549918	May 30, 2028	DP			
	9757362	Aug 30, 2024	DP			
	9763920	Aug 30, 2024	DP			
<u>TACROLIMUS - PROGRAF</u>						
N 210115 001					ODE-269	May 24, 2025
					ODE-360	Jul 16, 2028
<u>TACROLIMUS - PROGRAF</u>						
N 210115 002					ODE-269	May 24, 2025
					ODE-360	Jul 16, 2028
<u>TADALAFIL - TADLIO</u>						
N 214522 001	11382917	Dec 24, 2038	DP U-3397			
<u>TAFAMIDIS - VYNDAMAX</u>						
N 212161 001	7214695	Apr 27, 2024	DS DP		NCE	May 03, 2024
	7214696	Dec 19, 2023	U-2524		ODE-237	May 03, 2026
	9770441	Aug 31, 2035	DS DP U-2524			
<u>TAFAMIDIS MEGLUMINE - VYNDAQEL</u>						
N 211996 001	7214695	Apr 27, 2024	DS DP		NCE	May 03, 2024
	7214696	Dec 19, 2023	U-2524		ODE-237	May 03, 2026
	8168663	Dec 19, 2023	DS DP			
	8653119	Jan 28, 2024	U-2524			
<u>TAFENOQUINE SUCCINATE - ARAKODA</u>						
N 210607 001	10342791	Dec 02, 2035	U-2582		NCE	Jul 20, 2023
	10888558	Dec 02, 2035	U-2582			
<u>TAFENOQUINE SUCCINATE - KRINTAFEL</u>						
N 210795 001					NCE	Jul 20, 2023
					ODE-201	Jul 20, 2025
<u>TAFLUPROST - ZIOPTAN</u>						
N 202514 001	10864159	May 28, 2029	DP U-778			
	9999593	May 28, 2029	DP			
<u>TALAZOPARIB TOSYLATE - TALZENNA</u>						
N 211651 001	10189837	Oct 20, 2031	DS DP		NCE	Oct 16, 2023
	8012976	Oct 19, 2029	DS DP			
	8420650	Jul 27, 2029	DS DP			
	8735392	Oct 20, 2031	DS DP			
	9820985	Jul 27, 2029	U-2437			
<u>TALAZOPARIB TOSYLATE - TALZENNA</u>						
N 211651 002	10189837	Oct 20, 2031	DS DP		NCE	Oct 16, 2023
	8012976	Oct 19, 2029	DS DP			
	8420650	Jul 27, 2029	DS DP			
	8735392	Oct 20, 2031	DS DP			
	9820985	Jul 27, 2029	U-2437			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TALAZOPARIB TOSYLATE - TALZENNA</u>						
N 211651 002	10189837	Oct 20, 2031	DS DP		NCE	Oct 16, 2023
	8012976	Oct 19, 2029	DS DP			
	8420650	Jul 27, 2029	DS DP			
	8735392	Oct 20, 2031	DS DP			
	9820985	Jul 27, 2029	U-2437			
<u>TALAZOPARIB TOSYLATE - TALZENNA</u>						
N 211651 003	10189837	Oct 20, 2031	DS DP		NCE	Oct 16, 2023
	8012976	Oct 19, 2029	DS DP			
	8420650	Jul 27, 2029	DS DP			
	8735392	Oct 20, 2031	DS DP			
	9820985	Jul 27, 2029	U-2437			
<u>TALAZOPARIB TOSYLATE - TALZENNA</u>						
N 211651 004	10189837	Oct 20, 2031	DS DP		NCE	Oct 16, 2023
	8012976	Oct 19, 2029	DS DP			
	8420650	Jul 27, 2029	DS DP			
	8735392	Oct 20, 2031	DS DP			
	9820985	Jul 27, 2029	U-2437			
<u>TALC - STERITALC</u>						
N 205555 001					ODE-143	May 01, 2024
					ODE-191	May 01, 2024
<u>TALC - STERITALC</u>						
N 205555 002					ODE-143	May 01, 2024
					ODE-191	May 01, 2024
<u>TALC - STERITALC</u>						
N 205555 003					ODE-143	May 01, 2024
					ODE-191	May 01, 2024
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA</u>						
N 022304 001	7994364	Jun 27, 2025	DS DP U-931			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA</u>						
N 022304 002	7994364	Jun 27, 2025	DS DP U-931			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA</u>						
N 022304 003	7994364	Jun 27, 2025	DS DP U-931			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N 200533 001	11344512	Apr 21, 2028	U-3391			
	11344512	Apr 21, 2028	U-3392			
	7994364	Jun 27, 2025	DS DP U-1178			
	7994364	Jun 27, 2025	DS DP U-1276			
	8075872	Nov 20, 2023	DP			
	8114383	Oct 10, 2024	DP	Y		
	8309060	Nov 20, 2023	DP U-1178			
	8309060	Nov 20, 2023	DP U-1276			
	8420056	Nov 20, 2023	DP			
	8536130	Sep 22, 2028	U-1276			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N 200533 002	11344512	Apr 21, 2028	U-3391			
	11344512	Apr 21, 2028	U-3392			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TAPENTADOL HYDROCHLORIDE - NUCYNТА ER</u>						
N 200533 002	7994364	Jun 27, 2025	DS DP U-1178			
	7994364	Jun 27, 2025	DS DP U-1276			
	8075872	Nov 20, 2023	DP			
	8114383	Oct 10, 2024	DP	Y		
	8309060	Nov 20, 2023	DP U-1178			
	8309060	Nov 20, 2023	DP U-1276			
	8420056	Nov 20, 2023	DP			
	8536130	Sep 22, 2028	U-1276			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNТА ER</u>						
N 200533 003	11344512	Apr 21, 2028	U-3391			
	11344512	Apr 21, 2028	U-3392			
	7994364	Jun 27, 2025	DS DP U-1178			
	7994364	Jun 27, 2025	DS DP U-1276			
	8075872	Nov 20, 2023	DP			
	8114383	Oct 10, 2024	DP	Y		
	8309060	Nov 20, 2023	DP U-1178			
	8309060	Nov 20, 2023	DP U-1276			
	8420056	Nov 20, 2023	DP			
	8536130	Sep 22, 2028	U-1276			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNТА ER</u>						
N 200533 004	11344512	Apr 21, 2028	U-3391			
	11344512	Apr 21, 2028	U-3392			
	7994364	Jun 27, 2025	DS DP U-1178			
	7994364	Jun 27, 2025	DS DP U-1276			
	8075872	Nov 20, 2023	DP			
	8114383	Oct 10, 2024	DP	Y		
	8309060	Nov 20, 2023	DP U-1178			
	8309060	Nov 20, 2023	DP U-1276			
	8420056	Nov 20, 2023	DP			
	8536130	Sep 22, 2028	U-1276			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNТА ER</u>						
N 200533 005	11344512	Apr 21, 2028	U-3391			
	11344512	Apr 21, 2028	U-3392			
	7994364	Jun 27, 2025	DS DP U-1178			
	7994364	Jun 27, 2025	DS DP U-1276			
	8075872	Nov 20, 2023	DP			
	8114383	Oct 10, 2024	DP	Y		
	8309060	Nov 20, 2023	DP U-1178			
	8309060	Nov 20, 2023	DP U-1276			
	8420056	Nov 20, 2023	DP			
	8536130	Sep 22, 2028	U-1276			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNТА</u>						
N 203794 001	7994364	Jun 27, 2025	DS DP U-1289			
<u>TAPINAROF - VTAMA</u>						
N 215272 001	10195160	May 19, 2036	DP		NCE	May 23, 2027
	10426743	May 19, 2036	U-2625			
	10647649	Nov 13, 2038	DS			
	11458108	May 19, 2036	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TAPINAROF - VTAMA</u>						
N 215272 001	10195160	May 19, 2036	DP		NCE	May 23, 2027
	10426743	May 19, 2036	U-2625			
	10647649	Nov 13, 2038	DS			
	11458108	May 19, 2036	DP			
<u>TASIMELTEON - TASIMELTEON</u>						
A 211607 001					PC	Jun 27, 2023
<u>TASIMELTEON - HETLIOZ</u>						
N 205677 001	10071977	Feb 12, 2035	DS DP		I-850	Dec 01, 2023
	10149829	Jan 25, 2033	U-2477		ODE-330	Dec 01, 2027
	10149829	Jan 25, 2033	U-3006			
	10179119	Aug 29, 2035	U-3003			
	10376487	Jul 27, 2035	U-2615			
	10376487	Jul 27, 2035	U-3007			
	10449176	Jan 25, 2033	U-2149			
	10610510	Jan 25, 2033	U-2805			
	10610510	Jan 25, 2033	U-3009			
	10610511	Oct 10, 2034	U-2615			
	10610511	Oct 10, 2034	U-3007			
	10829465	Feb 12, 2035	DS DP			
	10945988	Jan 25, 2033	U-2149			
	10980770	Jan 25, 2033	U-3106			
	10980770	Jan 25, 2033	U-3107			
	11141400	Oct 10, 2034	U-2615			
	11141400	Oct 10, 2034	U-3007			
	11266622	Aug 29, 2035	U-3003			
	11285129	Jan 25, 2033	U-3342			
	11285129	Jan 25, 2033	U-3343			
	9060995	Jan 25, 2033	U-1710			
	9539234	Jan 25, 2033	U-1934			
	9539234	Jan 25, 2033	U-3004			
	9549913	Jan 25, 2033	U-1486			
	9730910	May 17, 2034	U-2085			
	9730910	May 17, 2034	U-3005			
	9855241	Jan 25, 2033	U-2149			
	RE46604	Jan 25, 2033	U-2147			
<u>TASIMELTEON - HETLIOZ LQ</u>						
N 214517 001	10071977	Feb 12, 2035	DS DP		NP	Dec 01, 2023
	10149829	Jan 25, 2033	U-3006		ODE-329	Dec 01, 2027
	10179119	Aug 29, 2035	U-3003			
	10376487	Jul 27, 2035	U-3007			
	10610510	Jan 25, 2033	U-3009			
	10610511	Oct 10, 2034	U-3007			
	10829465	Feb 12, 2035	DS DP			
	10980770	Jan 25, 2033	U-3106			
	11141400	Oct 10, 2034	U-3007			
	11202770	Dec 11, 2040	DP			
	11266622	Aug 29, 2035	U-3003			
	11285129	Jan 25, 2033	U-3342			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TASIMELTEON - HETLIOZ LO</u>						
N 214517 001	9539234	Jan 25, 2033	U-3004			
	9730910	May 17, 2034	U-3005			
<u>TAZAROTENE - TAZAROTENE</u>						
A 214136 001					CGT	Mar 13, 2023
<u>TAZAROTENE - FABIOR</u>						
N 202428 001	10568859	Feb 24, 2030	DP U-2760			
	10688071	Feb 24, 2030	DP U-2760			
	8808716	Feb 24, 2030	DP			
<u>TAZAROTENE - ARAZLO</u>						
N 211882 001	11311482	May 11, 2038	U-2368			
<u>TAZEMETOSTAT HYDROBROMIDE - TAZVERIK</u>						
N 211723 001	10155002	Apr 13, 2032	U-2736		I-835	Jun 18, 2023
	10245269	Apr 11, 2033	U-2737		I-836	Jun 18, 2023
	10245269	Apr 11, 2033	U-2851		NCE	Jan 23, 2025
	10245269	Apr 11, 2033	U-2854		ODE-299	Jan 23, 2027
	10369155	Oct 16, 2035	U-2736		ODE-314	Jun 18, 2027
	10369155	Oct 16, 2035	U-2852			
	10369155	Oct 16, 2035	U-2853			
	10420775	Apr 13, 2032	U-2736			
	10420775	Apr 13, 2032	U-2852			
	10420775	Apr 13, 2032	U-2853			
	10786511	Dec 19, 2035	DP			
	10821113	Apr 11, 2033	DS DP			
	11052093	Apr 13, 2032	DS DP U-2736			
	11052093	Apr 13, 2032	DS DP U-3179			
	11491163	Apr 11, 2033	U-3491			
	11491163	Apr 11, 2033	U-3492			
	8410088	Aug 25, 2034	DS DP			
	8691507	Sep 12, 2031	U-2852			
	8765732	Apr 13, 2032	U-2852			
	8765732	Apr 13, 2032	U-2853			
	8895245	Sep 12, 2031	U-2852			
	9090562	Apr 13, 2032	DS DP			
	9175331	Sep 12, 2031	U-2852			
	9333217	Sep 12, 2031	U-2852			
	9334527	Sep 12, 2031	U-2852			
	9394283	Apr 11, 2033	DS DP U-2852			
	9394283	Apr 11, 2033	DS DP U-2853			
	9522152	Apr 13, 2032	U-2738			
	9549931	Apr 13, 2032	U-2736			
	9549931	Apr 13, 2032	U-2852			
	9549931	Apr 13, 2032	U-2853			
	9688665	Aug 22, 2034	U-2736			
	9855275	Apr 13, 2032	U-2736			
	9872862	Apr 11, 2033	U-2738			
	9889138	Oct 16, 2035	U-2736			
	9889138	Oct 16, 2035	U-2852			
	9889138	Oct 16, 2035	U-2853			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TAZEMETOSTAT HYDROBROMIDE - TAZVERIK</u>						
N 211723	001 9949999	Sep 12, 2031	U-2851			
<u>TECHNETIUM TC-99M TETROFOSMIN KIT - MYOVUE 30ML</u>						
N 020372	002 9549999	Mar 10, 2030	DP			
<u>TECHNETIUM TC-99M TILMANOCEPT - LYMPHOSEEK KIT</u>						
N 202207	001 6409990	May 12, 2025	DS		NPP	May 19, 2024
	9439985	Jan 30, 2029	DP			
<u>TECOVIRIMAT - TPOXX</u>						
N 208627	001 7737168	Sep 04, 2031	U-2346		NCE	Jul 13, 2023
	8039504	Jul 23, 2027	DP		ODE-200	Jul 13, 2025
	8124643	Jun 18, 2024	DS DP			
	8530509	Jun 18, 2024	DP			
	8802714	Jun 18, 2024	U-2346			
	9339466	Mar 23, 2031	DS DP			
<u>TECOVIRIMAT - TPOXX</u>						
N 214518	001 10576165	Aug 02, 2031	DP		NCE	Jul 13, 2023
	7737168	Sep 04, 2031	U-3377			
	8039504	Jul 23, 2027	DP			
	8124643	Jun 18, 2024	DS DP			
	8530509	Jun 18, 2024	DP			
	8802714	Jun 18, 2024	U-3377			
	9233097	Aug 02, 2031	DP			
	9907859	Aug 02, 2031	U-3377			
<u>TEDIZOLID PHOSPHATE - SIVEXTRO</u>						
N 205435	001 10065947	Feb 03, 2030	DP		NCE	Jun 20, 2019
	10442829	Feb 03, 2030	DS		NPP	Jun 19, 2023
	7816379	Jun 20, 2028	DS DP U-2507		GAIN	Jun 20, 2024
	8420676	Feb 23, 2028	DS DP U-282			
	8426389	Dec 31, 2030	DS DP U-282			
	9624250	Feb 03, 2030	DS DP U-2507			
	9988406	Feb 03, 2030	DP			
<u>TEDIZOLID PHOSPHATE - SIVEXTRO</u>						
N 205436	001 10065947	Feb 03, 2030	DP		NCE	Jun 20, 2019
	10442829	Feb 03, 2030	DS		NPP	Jun 19, 2023
	7816379	Jun 20, 2028	DS DP U-2507		GAIN	Jun 20, 2024
	8420676	Feb 23, 2028	DS DP U-282			
	8426389	Dec 31, 2030	DS DP U-282			
	9624250	Feb 03, 2030	DS DP U-2507			
	9988406	Feb 03, 2030	DP			
<u>TEDUGLUTIDE RECOMBINANT - GATTEX KIT</u>						
N 203441	001 7056886*PED	Mar 18, 2023			ODE-240	May 16, 2026
	7847061	Nov 01, 2025	U-1320	Y		
	7847061*PED	May 01, 2026				
	9060992	Nov 01, 2025	U-1320	Y		
	9060992*PED	May 01, 2026				
<u>TELAPREVIR - INCIVEK</u>						
N 201917	001 7820671	Feb 25, 2025	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TELAPREVIR - INCIVEK</u>						
N 201917	001 8431615	May 30, 2028	U-1398			
<u>TELAVANCIN HYDROCHLORIDE - VIBATIV</u>						
N 022110	001 6635618	Sep 11, 2023	DS DP U-728			
	7531623	Jan 01, 2027	DS			
<u>TELAVANCIN HYDROCHLORIDE - VIBATIV</u>						
N 022110	002 6635618	Sep 11, 2023	DS DP U-728			
	7531623	Jan 01, 2027	DS			
<u>TELBIVUDINE - TYZEKA</u>						
N 022011	001 7589079	Sep 11, 2023	DS DP U-999			
	7858594	Sep 11, 2023	DS DP U-999			
<u>TELBIVUDINE - TYZEKA</u>						
N 022154	001 7858594	Sep 11, 2023	DS DP U-999			
<u>TELOTRISTAT ETIPRATE - XERMELO</u>						
N 208794	001 7553840	Dec 11, 2027	DS		ODE-132	Feb 28, 2024
	7709493	Feb 28, 2031	DS	U-1979		
	7968559	Dec 11, 2027		U-1979		
	8193204	Feb 27, 2031	DS			
	8653094	Dec 19, 2028		U-1979		
<u>TEMOZOLOMIDE - TEMODAR</u>						
N 022277	001 6987108	Sep 08, 2023	DP			
	7786118	Feb 21, 2023	DP			
	8623868	Feb 21, 2023	DP			
<u>TEMSIROLIMUS - TORISEL</u>						
N 022088	001 8026276	Jan 20, 2026	DP			
	8299116	Jul 25, 2023	DP			
	8455539	Jul 25, 2023	DP			
	8455539*PED	Jan 25, 2024				
	8722700	Jul 25, 2023	DP			
	8722700*PED	Jan 25, 2024				
	8791097	May 10, 2032		U-1550		
	8791097	May 10, 2032		U-1551		
	8791097*PED	Nov 10, 2032				
<u>TENAPANOR HYDROCHLORIDE - IBSRELA</u>						
N 211801	001 8541448	Aug 01, 2033	DS DP		NCE	Sep 12, 2024
	8969377	Dec 30, 2029	DS DP			
	9006281	May 02, 2030		U-2626		
	9408840	Dec 30, 2029		U-2626		
<u>TENOFOVIR ALAFENAMIDE FUMARATE - VEMPLIDY</u>						
N 208464	001 7390791	Apr 17, 2025	DS DP		M-255	Feb 04, 2023
	7390791*PED	Oct 17, 2025			M-266	Aug 22, 2023
	8754065	Aug 15, 2032	DS DP U-1275		NPP	Oct 17, 2025
	8754065	Aug 15, 2032	DS DP U-999			
	8754065*PED	Feb 15, 2033				
	9296769	Aug 15, 2032	DS DP U-1275			
	9296769	Aug 15, 2032	DS DP U-999			
	9296769*PED	Feb 15, 2033				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TEPOTINIB HYDROCHLORIDE - TEPMETKO</u>						
N 214096 001	8329692	Oct 30, 2029	DS DP		NCE	Feb 03, 2026
	8580781	Mar 19, 2030	DS DP		ODE-325	Feb 03, 2028
	8658643	Jul 04, 2028		U-3077		
	8921357	May 30, 2028	DS DP			
	8927540	Jul 21, 2028		U-3078		
	9062029	Jul 04, 2028	DP			
	9284300	Apr 29, 2028	DP			
	9403799	Jul 04, 2028		U-3077		
<u>TERIFLUNOMIDE - AUBAGIO</u>						
N 202992 001	6794410	Sep 12, 2026		U-1285	M-61	Apr 30, 2024
	6794410*PED	Mar 12, 2027			PED	Oct 30, 2024
	8802735	Sep 14, 2030	DP			
	8802735*PED	Mar 14, 2031				
	9186346	Feb 04, 2034		U-1786		
	9186346*PED	Aug 04, 2034				
<u>TERIFLUNOMIDE - AUBAGIO</u>						
N 202992 002	6794410	Sep 12, 2026		U-1285	M-61	Apr 30, 2024
	6794410*PED	Mar 12, 2027			PED	Oct 30, 2024
	8802735	Sep 14, 2030	DP			
	8802735*PED	Mar 14, 2031				
	9186346	Feb 04, 2034		U-1786		
	9186346*PED	Aug 04, 2034				
<u>TERIPARATIDE - FORTEO</u>						
N 021318 001	7517334	Mar 25, 2025	DP			
<u>TERIPARATIDE - FORTEO</u>						
N 021318 002	7517334	Mar 25, 2025	DP			
<u>TERLIPRESSIN ACETATE - TERLIVAZ</u>						
N 022231 001					NCE	Sep 14, 2027
<u>TESTOSTERONE - TESTIM</u>						
N 021454 001	7320968	Jan 18, 2025		U-843		
	7608605	Apr 21, 2023		U-1009		
	7608606	Apr 21, 2023		U-1009		
	7608607	Apr 21, 2023		U-1009		
	7608608	Apr 21, 2023		U-1009		
	7608609	Apr 21, 2023		U-1009		
	7608610	Apr 21, 2023		U-1009		
	7935690	Apr 21, 2023		U-1009		
	8063029	Apr 21, 2023		U-843		
	8178518	Apr 21, 2023	DP			
<u>TESTOSTERONE - ANDROGEL</u>						
N 022309 001	8466136	Oct 12, 2026	DP			
	8466137	Oct 12, 2026		U-1103		
	8466138	Oct 12, 2026		U-1103		
	8486925	Oct 12, 2026	DP			
	8729057	Oct 12, 2026	DP			
	8741881	Oct 12, 2026		U-1103		
	8754070	Oct 12, 2026	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TESTOSTERONE - ANDROGEL</u>						
N 022309	001 8759329	Oct 12, 2026	DP			
<u>TESTOSTERONE - ANDROGEL</u>						
N 022309	002 8466136	Oct 12, 2026	DP			
	8466137	Oct 12, 2026	U-1103			
	8466138	Oct 12, 2026	U-1103			
	8486925	Oct 12, 2026	DP			
	8729057	Oct 12, 2026	DP			
	8741881	Oct 12, 2026	U-1103			
	8754070	Oct 12, 2026	DP			
	8759329	Oct 12, 2026	DP			
<u>TESTOSTERONE - ANDROGEL</u>						
N 022309	003 8466136	Oct 12, 2026	DP			
	8466137	Oct 12, 2026	U-1103			
	8466138	Oct 12, 2026	U-1103			
	8486925	Oct 12, 2026	DP			
	8729057	Oct 12, 2026	DP			
	8741881	Oct 12, 2026	U-1103			
	8754070	Oct 12, 2026	DP			
	8759329	Oct 12, 2026	DP			
<u>TESTOSTERONE - AXIRON</u>						
N 022504	001 8419307	Feb 26, 2027	U-1386			
	8435944	Sep 27, 2027	U-1390			
	8784878	Jul 13, 2023	DP U-1545			
	8807861	Feb 26, 2027	DP U-1563			
	8993520	Jun 02, 2026	U-1390			
	9180194	Jun 02, 2026	U-1390			
	9289586	Feb 26, 2027	U-1390			
<u>TESTOSTERONE - VOGELXO</u>						
N 024399	002 8785426	Feb 11, 2034	DP U-1531			
	9295675	Feb 11, 2034	DP U-1531			
	9662340	Feb 11, 2034	DP U-1531			
<u>TESTOSTERONE - VOGELXO</u>						
N 024399	003 8785426	Feb 11, 2034	DP U-1531			
	9295675	Feb 11, 2034	DP U-1531			
	9662340	Feb 11, 2034	DP U-1531			
<u>TESTOSTERONE - NATESTO</u>						
N 205488	001 11090312	Mar 17, 2034	U-1616			
	8574622	Feb 04, 2024	DP			
	8784869	Feb 04, 2024	DP			
	8784882	Feb 04, 2024	DP U-1557			
	8877230	Feb 04, 2024	U-1616			
<u>TESTOSTERONE CYPIONATE - TESTOSTERONE CYPIONATE</u>						
N 216318	001 11311554	Mar 25, 2039	DP			
<u>TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR)</u>						
N 209863	001 10238662	Feb 19, 2035	DP U-2418			
	10279131	Jul 31, 2031	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR)</u>						
N 209863 001	10357609	Aug 21, 2031	DP			
	10478560	Jan 24, 2026	DP			
	10646495	Aug 30, 2038	DP			
	10821072	Jun 04, 2033	DP U-2418			
	10881798	Feb 11, 2034	DP			
	10905827	Aug 21, 2031	DP			
	10912782	Feb 19, 2035	DP U-2418			
	11160751	Oct 07, 2034	DP U-2418			
	11191908	Oct 18, 2035	DP			
	11446440	Aug 21, 2031	DP			
	11446441	Jan 24, 2026	DP			
	11497753	Mar 19, 2030	DP			
	8021335	Oct 04, 2026	DP			
	8562564	Jan 24, 2026	DP			
	9180259	Jan 24, 2026	DP			
	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
	9744302	Nov 19, 2035	DP			
	9950125	Sep 04, 2036	DP U-2418			
<u>TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR)</u>						
N 209863 002	10238662	Feb 19, 2035	DP U-2418			
	10279131	Jul 31, 2031	DP			
	10357609	Aug 21, 2031	DP			
	10478560	Jan 24, 2026	DP			
	10646495	Aug 30, 2038	DP			
	10821072	Jun 04, 2033	DP U-2418			
	10881798	Feb 11, 2034	DP			
	10905827	Aug 21, 2031	DP			
	10912782	Feb 19, 2035	DP U-2418			
	11160751	Oct 07, 2034	DP U-2418			
	11191908	Oct 18, 2035	DP			
	11446440	Aug 21, 2031	DP			
	11446441	Jan 24, 2026	DP			
	11497753	Mar 19, 2030	DP			
	8021335	Oct 04, 2026	DP			
	8562564	Jan 24, 2026	DP			
	9180259	Jan 24, 2026	DP			
	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
	9744302	Nov 19, 2035	DP			
	9950125	Sep 04, 2036	DP U-2418			
<u>TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR)</u>						
N 209863 003	10238662	Feb 19, 2035	DP U-2418			
	10279131	Jul 31, 2031	DP			
	10357609	Aug 21, 2031	DP			
	10478560	Jan 24, 2026	DP			
	10646495	Aug 30, 2038	DP			
	10821072	Jun 04, 2033	DP U-2418			
	10881798	Feb 11, 2034	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR)</u>						
N 209863 003	10905827	Aug 21, 2031	DP			
	10912782	Feb 19, 2035	DP U-2418			
	11160751	Oct 07, 2034	DP U-2418			
	11191908	Oct 18, 2035	DP			
	11446440	Aug 21, 2031	DP			
	11446441	Jan 24, 2026	DP			
	11497753	Mar 19, 2030	DP			
	8021335	Oct 04, 2026	DP			
	8562564	Jan 24, 2026	DP			
	9180259	Jan 24, 2026	DP			
	9533102	Jan 24, 2026	DP			
	9629959	Jan 24, 2026	DP			
	9744302	Nov 19, 2035	DP			
	9950125	Sep 04, 2036	DP U-2418			
<u>TESTOSTERONE UNDECANOATE - AVEED</u>						
N 022219 001	7718640	Mar 14, 2027	DP			
	8338395	May 08, 2027	U-1500			
<u>TESTOSTERONE UNDECANOATE - JATENZO</u>						
N 206089 001	10543219	Apr 12, 2030	U-2506			
	10617696	Apr 12, 2030	DS DP			
	11179402	Apr 14, 2026	DS DP			
	11179403	Apr 12, 2030	U-2506			
	11331325	Jan 06, 2027	U-2506			
	11426416	Apr 12, 2030	U-3420			
	8241664	Mar 29, 2029	DP U-2506			
	8492369	Dec 20, 2030	DP U-2506			
	8778916	Apr 12, 2030	DP			
<u>TESTOSTERONE UNDECANOATE - JATENZO</u>						
N 206089 002	10543219	Apr 12, 2030	U-2506			
	10617696	Apr 12, 2030	DS DP			
	11179402	Apr 14, 2026	DS DP			
	11179403	Apr 12, 2030	U-2506			
	11331325	Jan 06, 2027	U-2506			
	11426416	Apr 12, 2030	U-3420			
	8241664	Mar 29, 2029	DP U-2506			
	8492369	Dec 20, 2030	DP U-2506			
	8778916	Apr 12, 2030	DP			
<u>TESTOSTERONE UNDECANOATE - JATENZO</u>						
N 206089 003	10543219	Apr 12, 2030	U-2506			
	10617696	Apr 12, 2030	DS DP			
	11179402	Apr 14, 2026	DS DP			
	11179403	Apr 12, 2030	U-2506			
	11331325	Jan 06, 2027	U-2506			
	11426416	Apr 12, 2030	U-3420			
	8241664	Mar 29, 2029	DP U-2506			
	8492369	Dec 20, 2030	DP U-2506			
	8778916	Apr 12, 2030	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TESTOSTERONE UNDECANOATE - TLANDO</u>						
N 208088 001	10226473	Nov 30, 2030	U-1500		NP	Mar 28, 2025
	10716794	Nov 30, 2030	U-1500			
	11304960	Jan 08, 2029	DP U-1500			
	11311555	Nov 30, 2030	U-1500			
	11364249	Nov 30, 2030	U-1500			
	11433083	Nov 30, 2030	U-1500			
	11464735	Apr 28, 2041	DP U-1500			
	8778922	Jan 08, 2029	DP U-1500			
	8865695	Jan 08, 2029	U-1500			
	9943527	Nov 30, 2030	U-1500			
	9949985	Nov 30, 2030	U-1500			
<u>TESTOSTERONE UNDECANOATE - KYZATREX</u>						
N 213953 001	10576089	Dec 31, 2030	DP U-2506		NP	Jul 27, 2025
	10576090	Dec 31, 2030	DP			
<u>TESTOSTERONE UNDECANOATE - KYZATREX</u>						
N 213953 002	10576089	Dec 31, 2030	DP U-2506		NP	Jul 27, 2025
	10576090	Dec 31, 2030	DP			
<u>TESTOSTERONE UNDECANOATE - KYZATREX</u>						
N 213953 003	10576089	Dec 31, 2030	DP U-2506		NP	Jul 27, 2025
	10576090	Dec 31, 2030	DP			
<u>THALIDOMIDE - THALOMID</u>						
N 020785 001	7230012	Dec 09, 2023	DP			
<u>THALIDOMIDE - THALOMID</u>						
N 020785 002	7230012	Dec 09, 2023	DP			
<u>THALIDOMIDE - THALOMID</u>						
N 020785 003	7230012	Dec 09, 2023	DP			
<u>THIOTEPA - TEPADINA</u>						
N 208264 001					ODE-129	Jan 26, 2024
<u>THIOTEPA - TEPADINA</u>						
N 208264 002					ODE-129	Jan 26, 2024
<u>TICAGRELOR - BRILINTA</u>						
N 022433 001	10300065	Jan 27, 2036	U-2541		I-848	Nov 05, 2023
	10300065	Jan 27, 2036	U-2542		I-851	May 28, 2023
	10300065*PED	Jul 27, 2036			M-283	May 09, 2025
	8425934	Apr 17, 2030	DP		PED	Nov 28, 2023
	8425934*PED	Oct 17, 2030			PED	May 05, 2024
	RE46276	Oct 30, 2024	DS DP U-1935		PED	Nov 09, 2025
	RE46276	Oct 30, 2024	DS DP U-1936			
	RE46276	Oct 30, 2024	DS DP U-1937			
	RE46276	Oct 30, 2024	DS DP U-1938			
	RE46276	Oct 30, 2024	DS DP U-2838			
	RE46276	Oct 30, 2024	DS DP U-2839			
	RE46276	Oct 30, 2024	DS DP U-2988			
	RE46276*PED	Apr 30, 2025				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TICAGRELOR - BRILINTA</u>						
N 022433 002	10300065	Jan 27, 2036	U-2541		I-848	Nov 05, 2023
	10300065	Jan 27, 2036	U-2542		I-851	May 28, 2023
	10300065*PED	Jul 27, 2036			M-283	May 09, 2025
	8425934	Apr 17, 2030	DP		PED	Nov 28, 2023
	8425934*PED	Oct 17, 2030			PED	May 05, 2024
	RE46276	Oct 30, 2024	DS DP U-1935		PED	Nov 09, 2025
	RE46276	Oct 30, 2024	DS DP U-1936			
	RE46276	Oct 30, 2024	DS DP U-1937			
	RE46276	Oct 30, 2024	DS DP U-1938			
	RE46276	Oct 30, 2024	DS DP U-2838			
	RE46276	Oct 30, 2024	DS DP U-2839			
	RE46276	Oct 30, 2024	DS DP U-2988			
	RE46276*PED	Apr 30, 2025				
<u>TIGECYCLINE - TYGACIL</u>						
N 021821 001	10588975	Mar 13, 2026	DP			
	7879828	Feb 05, 2029	DP			
	8372995	Oct 08, 2030	DP			
	8975242	Oct 24, 2028	DP			
	9254328	Mar 13, 2026	DP			
	9694078	Mar 13, 2026	DP			
<u>TIGECYCLINE - TIGECYCLINE</u>						
N 211158 001	9855335	Apr 07, 2033	DP			
<u>TIOPRONIN - THIOLA</u>						
N 019569 001					ODE-267	Jun 28, 2026
<u>TIOPRONIN - THIOLA EC</u>						
N 211843 001	11458104	Nov 14, 2038	U-3441		ODE*	Jun 28, 2026
<u>TIOPRONIN - THIOLA EC</u>						
N 211843 002	11458104	Nov 14, 2038	U-3441		ODE*	Jun 28, 2026
<u>TIOTROPIUM BROMIDE - SPIRIVA</u>						
N 021395 001	7694676	Mar 12, 2027	DP			
	7694676*PED	Sep 12, 2027				
	8022082	Jan 19, 2026	DP U-1186			
	8022082*PED	Jul 19, 2026				
	9010323	Apr 19, 2030	DP			
<u>TIOTROPIUM BROMIDE - SPIRIVA RESPIMAT</u>						
N 021936 001	7284474	Aug 26, 2024	DP			
	7284474*PED	Feb 26, 2025				
	7396341	Oct 10, 2026	DP			
	7396341*PED	Apr 10, 2027				
	7837235	Mar 13, 2028	DP			
	7837235*PED	Sep 13, 2028				
	7896264	May 26, 2025	DP			
	7896264*PED	Nov 26, 2025				
	8733341	Oct 16, 2030	DP			
	8733341*PED	Apr 16, 2031				
	9027967	Mar 31, 2027	DP			
	9027967*PED	Oct 01, 2027				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TIOTROPIUM BROMIDE - SPIRIVA RESPIMAT</u>						
N 021936 001	7284474	Aug 26, 2024	DP			
	7284474*PED	Feb 26, 2025				
	7396341	Oct 10, 2026	DP			
	7396341*PED	Apr 10, 2027				
	7837235	Mar 13, 2028	DP			
	7837235*PED	Sep 13, 2028				
	7896264	May 26, 2025	DP			
	7896264*PED	Nov 26, 2025				
	8733341	Oct 16, 2030	DP			
	8733341*PED	Apr 16, 2031				
	9027967	Mar 31, 2027	DP			
	9027967*PED	Oct 01, 2027				
<u>TIOTROPIUM BROMIDE - SPIRIVA RESPIMAT</u>						
N 021936 002	7284474	Aug 26, 2024	DP			
	7284474*PED	Feb 26, 2025				
	7396341	Oct 10, 2026	DP			
	7396341*PED	Apr 10, 2027				
	7837235	Mar 13, 2028	DP			
	7837235*PED	Sep 13, 2028				
	7896264	May 26, 2025	DP			
	7896264*PED	Nov 26, 2025				
	8733341	Oct 16, 2030	DP			
	8733341*PED	Apr 16, 2031				
	9027967	Mar 31, 2027	DP			
	9027967*PED	Oct 01, 2027				
<u>TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE - LONSURE</u>						
N 207981 001	10456399	Feb 03, 2037	U-2642		ODE-229	Feb 22, 2026
	10457666	Jun 17, 2034	DS DP			
	10960004	Feb 03, 2037	U-2642			
	9527833	Jun 17, 2034	DS DP			
	RE46284	Sep 22, 2029	U-1751			
	RE46284	Sep 22, 2029	U-2503			
<u>TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE - LONSURE</u>						
N 207981 002	10456399	Feb 03, 2037	U-2642		ODE-229	Feb 22, 2026
	10457666	Jun 17, 2034	DS DP			
	10960004	Feb 03, 2037	U-2642			
	9527833	Jun 17, 2034	DS DP			
	RE46284	Sep 22, 2029	U-1751			
	RE46284	Sep 22, 2029	U-2503			
<u>TIRBANIBULIN - KLISYRI</u>						
N 213189 001	10323001	Dec 28, 2027	DP		NCE	Dec 14, 2025
	10617693	Mar 12, 2038	U-3015			
	10669236	Sep 07, 2038	DS DP			
	11497750	Mar 12, 2038	U-3015			
	7300931	Feb 06, 2026	DS DP			
	7851470	Feb 02, 2029	DS DP U-3015			
	8236799	Dec 28, 2025	DS DP			
	8980890	Dec 28, 2025	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TIRBANIBULIN - KLISYRI</u>						
N 213189 001	10323001	Dec 28, 2027	DP		NCE	Dec 14, 2025
	10617693	Mar 12, 2038	U-3015			
	10669236	Sep 07, 2038	DS DP			
	11497750	Mar 12, 2038	U-3015			
	7300931	Feb 06, 2026	DS DP			
	7851470	Feb 02, 2029	DS DP U-3015			
	8236799	Dec 28, 2025	DS DP			
	8980890	Dec 28, 2025	DS DP			
<u>TIROFIBAN HYDROCHLORIDE - AGGRASTAT</u>						
N 020912 001	6770660	May 01, 2023	U-1444			
<u>TIROFIBAN HYDROCHLORIDE - AGGRASTAT</u>						
N 020912 002	6770660	May 01, 2023	U-1444			
<u>TIROFIBAN HYDROCHLORIDE - AGGRASTAT</u>						
N 020913 001	6770660	May 01, 2023	U-1444			
<u>TIROFIBAN HYDROCHLORIDE - AGGRASTAT</u>						
N 020913 002	6770660	May 01, 2023	U-1444			
<u>TIROFIBAN HYDROCHLORIDE - AGGRASTAT</u>						
N 020913 003	6770660	May 01, 2023	U-1444			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 001	11357820	Jun 14, 2039	DP		NCE	May 13, 2027
	8734394	Feb 24, 2031	DP			
	9402957	Jun 29, 2031	DP			
	9474780	Jan 05, 2036	DS DP U-3378			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 002	11357820	Jun 14, 2039	DP		NCE	May 13, 2027
	8734394	Feb 24, 2031	DP			
	9402957	Jun 29, 2031	DP			
	9474780	Jan 05, 2036	DS DP U-3378			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 003	11357820	Jun 14, 2039	DP		NCE	May 13, 2027
	8734394	Feb 24, 2031	DP			
	9402957	Jun 29, 2031	DP			
	9474780	Jan 05, 2036	DS DP U-3378			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 004	11357820	Jun 14, 2039	DP		NCE	May 13, 2027
	8734394	Feb 24, 2031	DP			
	9402957	Jun 29, 2031	DP			
	9474780	Jan 05, 2036	DS DP U-3378			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 005	11357820	Jun 14, 2039	DP		NCE	May 13, 2027
	8734394	Feb 24, 2031	DP			
	9402957	Jun 29, 2031	DP			
	9474780	Jan 05, 2036	DS DP U-3378			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 006	11357820	Jun 14, 2039	DP		NCE	May 13, 2027

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 006	8734394	Feb 24, 2031	DP			
	9402957	Jun 29, 2031	DP			
	9474780	Jan 05, 2036	DS DP U-3378			
<u>TIVOZANIB HYDROCHLORIDE - FOTIVDA</u>						
N 212904 001	11504365	Nov 05, 2039	U-3476		NCE	Mar 10, 2026
	6821987	Apr 26, 2023	DS DP U-3100			
	7166722	Nov 16, 2023	DS			
<u>TIVOZANIB HYDROCHLORIDE - FOTIVDA</u>						
N 212904 002	11504365	Nov 05, 2039	U-3476		NCE	Mar 10, 2026
	6821987	Apr 26, 2023	DS DP U-3100			
	7166722	Nov 16, 2023	DS			
<u>TOBRAMYCIN - TOBI PODHALER</u>						
N 201688 001	10207066	Nov 04, 2030	DP U-909			
	11484671	Nov 07, 2024	DP U-909			
	7516741	Jan 11, 2024	DP			
	7559325	Oct 27, 2025	DP			
	8069851	Sep 24, 2024	DP			
	8664187	Jun 20, 2025	U-909			
	8869794	Sep 12, 2028	DP U-909			
	RE47526	Apr 09, 2024	DP			
<u>TOFACITINIB CITRATE - XELJANZ</u>						
N 203214 001	6965027	Mar 25, 2023	DS		I-879	Dec 14, 2024
	RE41783	Dec 08, 2025	DS		NPP	Sep 25, 2023
<u>TOFACITINIB CITRATE - XELJANZ</u>						
N 203214 002	6965027	Mar 25, 2023	DS		I-879	Dec 14, 2024
	RE41783	Dec 08, 2025	DS			
<u>TOFACITINIB CITRATE - XELJANZ XR</u>						
N 208246 001	11253523	Mar 14, 2034	U-3326		I-879	Dec 14, 2024
	11253523	Mar 14, 2034	U-3327			
	11253523	Mar 14, 2034	U-3328			
	11253523	Mar 14, 2034	U-3329			
	6965027	Mar 25, 2023	DS			
	9937181	Mar 14, 2034	DP			
	RE41783	Dec 08, 2025	DS			
<u>TOFACITINIB CITRATE - XELJANZ XR</u>						
N 208246 002	10639309	Mar 14, 2034	DP			
	11253523	Mar 14, 2034	U-3326			
	11253523	Mar 14, 2034	U-3327			
	11253523	Mar 14, 2034	U-3328			
	11253523	Mar 14, 2034	U-3329			
	6965027	Mar 25, 2023	DS			
	RE41783	Dec 08, 2025	DS			
<u>TOFACITINIB CITRATE - XELJANZ</u>						
N 213082 001	RE41783	Dec 08, 2025	DS		NP	Sep 25, 2023

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TOLVAPTAN - SAMSCA</u>						
N 022275	001 10905694	Apr 07, 2030	DP			
	8501730	Sep 01, 2026	DS			
<u>TOLVAPTAN - SAMSCA</u>						
N 022275	002 10905694	Apr 07, 2030	DP			
	8501730	Sep 01, 2026	DS			
<u>TOLVAPTAN - SAMSCA</u>						
N 022275	003 10905694	Apr 07, 2030	DP			
	8501730	Sep 01, 2026	DS			
<u>TOLVAPTAN - JYNARQUE</u>						
N 204441	001 10905694	Apr 07, 2030	DP		ODE-178	Apr 23, 2025
	8501730	Sep 01, 2026	DS			
<u>TOLVAPTAN - JYNARQUE</u>						
N 204441	002 10905694	Apr 07, 2030	DP		ODE-178	Apr 23, 2025
	8501730	Sep 01, 2026	DS			
<u>TOLVAPTAN - JYNARQUE</u>						
N 204441	003 10905694	Apr 07, 2030	DP		ODE-178	Apr 23, 2025
	8501730	Sep 01, 2026	DS			
<u>TOLVAPTAN - JYNARQUE</u>						
N 204441	004 10905694	Apr 07, 2030	DP		ODE-178	Apr 23, 2025
	8501730	Sep 01, 2026	DS			
<u>TOLVAPTAN - JYNARQUE</u>						
N 204441	005 10905694	Apr 07, 2030	DP		ODE-178	Apr 23, 2025
	8501730	Sep 01, 2026	DS			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635	001 10314790	Nov 16, 2027	DP U-1675			
	10314790	Nov 16, 2027	DP U-1992			
	8298576	Apr 04, 2028	DP U-106			
	8298576	Apr 04, 2028	DP U-1992			
	8298580	Nov 16, 2027	DP U-106			
	8298580	Nov 16, 2027	DP U-1992			
	8663683	Nov 16, 2027	DP U-106			
	8663683	Nov 16, 2027	DP U-1992			
	8877248	Nov 16, 2027	DP U-106			
	8877248	Nov 16, 2027	DP U-1992			
	8889191	Nov 16, 2027	U-106			
	8889191	Nov 16, 2027	U-1992			
	8992989	Nov 16, 2027	DP U-1675			
	8992989	Nov 16, 2027	DP U-1992			
	9549940	Nov 16, 2027	DP U-1675			
	9549940	Nov 16, 2027	DP U-1992			
	9555004	Nov 16, 2027	DP U-1675			
	9555004	Nov 16, 2027	DP U-1992			
	9622983	Nov 16, 2027	DP U-1675			
	9622983	Nov 16, 2027	DP U-1992			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 002	10314790	Nov 16, 2027	DP U-1675			
	10314790	Nov 16, 2027	DP U-1992			
	8298576	Apr 04, 2028	DP U-106			
	8298576	Apr 04, 2028	DP U-1992			
	8298580	Nov 16, 2027	DP U-106			
	8298580	Nov 16, 2027	DP U-1992			
	8663683	Nov 16, 2027	DP U-106			
	8663683	Nov 16, 2027	DP U-1992			
	8877248	Nov 16, 2027	DP U-106			
	8877248	Nov 16, 2027	DP U-1992			
	8889191	Nov 16, 2027	U-106			
	8889191	Nov 16, 2027	U-1992			
	8992989	Nov 16, 2027	DP U-1675			
	8992989	Nov 16, 2027	DP U-1992			
	9549940	Nov 16, 2027	DP U-1675			
	9549940	Nov 16, 2027	DP U-1992			
	9555004	Nov 16, 2027	DP U-1675			
	9555004	Nov 16, 2027	DP U-1992			
	9622983	Nov 16, 2027	DP U-1675			
	9622983	Nov 16, 2027	DP U-1992			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 003	10314790	Nov 16, 2027	DP U-1675			
	10314790	Nov 16, 2027	DP U-1992			
	8298576	Apr 04, 2028	DP U-106			
	8298576	Apr 04, 2028	DP U-1992			
	8298580	Nov 16, 2027	DP U-106			
	8298580	Nov 16, 2027	DP U-1992			
	8663683	Nov 16, 2027	DP U-106			
	8663683	Nov 16, 2027	DP U-1992			
	8877248	Nov 16, 2027	DP U-106			
	8877248	Nov 16, 2027	DP U-1992			
	8889191	Nov 16, 2027	U-106			
	8889191	Nov 16, 2027	U-1992			
	8992989	Nov 16, 2027	DP U-1675			
	8992989	Nov 16, 2027	DP U-1992			
	9549940	Nov 16, 2027	DP U-1675			
	9549940	Nov 16, 2027	DP U-1992			
	9555004	Nov 16, 2027	DP U-1675			
	9555004	Nov 16, 2027	DP U-1992			
	9622983	Nov 16, 2027	DP U-1675			
	9622983	Nov 16, 2027	DP U-1992			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 004	10314790	Nov 16, 2027	DP U-1675			
	10314790	Nov 16, 2027	DP U-1992			
	8298576	Apr 04, 2028	DP U-106			
	8298576	Apr 04, 2028	DP U-1992			
	8298580	Nov 16, 2027	DP U-106			
	8298580	Nov 16, 2027	DP U-1992			
	8663683	Nov 16, 2027	DP U-106			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 004	8663683	Nov 16, 2027	DP U-1992			
	8877248	Nov 16, 2027	DP U-106			
	8877248	Nov 16, 2027	DP U-1992			
	8889191	Nov 16, 2027	U-106			
	8889191	Nov 16, 2027	U-1992			
	8992989	Nov 16, 2027	DP U-1675			
	8992989	Nov 16, 2027	DP U-1992			
	9549940	Nov 16, 2027	DP U-1675			
	9549940	Nov 16, 2027	DP U-1992			
	9555004	Nov 16, 2027	DP U-1675			
	9555004	Nov 16, 2027	DP U-1992			
	9622983	Nov 16, 2027	DP U-1675			
	9622983	Nov 16, 2027	DP U-1992			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 001	10363224	Mar 19, 2033	U-766			
	8652527	Mar 19, 2033	DP			
	8889190	Mar 19, 2033	DP			
	9101545	Mar 19, 2033	DP			
	9555005	Mar 19, 2033	DP			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 002	10363224	Mar 19, 2033	U-766			
	8652527	Mar 19, 2033	DP			
	8889190	Mar 19, 2033	DP			
	9101545	Mar 19, 2033	DP			
	9555005	Mar 19, 2033	DP			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 003	10363224	Mar 19, 2033	U-766			
	8652527	Mar 19, 2033	DP			
	8889190	Mar 19, 2033	DP			
	9101545	Mar 19, 2033	DP			
	9555005	Mar 19, 2033	DP			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 004	10363224	Mar 19, 2033	U-766			
	8652527	Mar 19, 2033	DP			
	8889190	Mar 19, 2033	DP			
	9101545	Mar 19, 2033	DP			
	9555005	Mar 19, 2033	DP			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 005	10363224	Mar 19, 2033	U-766			
	8652527	Mar 19, 2033	DP			
	8889190	Mar 19, 2033	DP			
	9101545	Mar 19, 2033	DP			
	9555005	Mar 19, 2033	DP			
<u>TOPIRAMATE - EPRONTIA</u>						
N 214679 001	11433046	Aug 21, 2040	U-3413			
	11433046	Aug 21, 2040	U-3414			
	11433046	Aug 21, 2040	U-3415			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TOPOTECAN HYDROCHLORIDE - HYCAMTIN</u>						
N 020981 001	8158645	Dec 10, 2024	DP			
<u>TOPOTECAN HYDROCHLORIDE - HYCAMTIN</u>						
N 020981 002	8158645	Dec 10, 2024	DP			
<u>TORSEMIDE - SOAANZ</u>						
N 213218 001	10154963	Oct 06, 2033	DP			
<u>TORSEMIDE - SOAANZ</u>						
N 213218 002	10154963	Oct 06, 2033	DP			
<u>TRABECTEDIN - YONDELIS</u>						
N 207953 001	8895557	Jan 07, 2028	DP			
	8895557*PED	Jul 07, 2028				
<u>TRAMADOL HYDROCHLORIDE - RYZOLT</u>						
N 021745 001	7988998	Oct 27, 2023	DP			
<u>TRAMADOL HYDROCHLORIDE - RYZOLT</u>						
N 021745 002	7988998	Oct 27, 2023	DP			
<u>TRAMADOL HYDROCHLORIDE - RYZOLT</u>						
N 021745 003	7988998	Oct 27, 2023	DP			
<u>TRAMADOL HYDROCHLORIDE - QDOLO</u>						
N 214044 001	11103452	Sep 01, 2040	DP U-3197			
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 001	10869869	Aug 30, 2033	U-3184		I-895	Jun 22, 2025
	7378423	May 29, 2027	DS DP		ODE-148	Jun 22, 2024
	8580304	Jan 28, 2032	DP		ODE-182	Apr 30, 2025
	8703781	Oct 15, 2030	DS DP U-1712		ODE-183	May 04, 2025
	8703781	Oct 15, 2030	DS DP U-2020			
	8703781	Oct 15, 2030	DS DP U-2037			
	8703781	Oct 15, 2030	DS DP U-2302			
	8703781	Oct 15, 2030	DS DP U-2305			
	8835443	Jun 10, 2025	U-1581			
	8835443	Jun 10, 2025	U-1582			
	8835443	Jun 10, 2025	U-2020			
	8835443	Jun 10, 2025	U-2037			
	8835443	Jun 10, 2025	U-2302			
	8835443	Jun 10, 2025	U-2305			
	8952018	Oct 15, 2030	U-2020			
	9155706	Jan 28, 2032	DP			
	9271941	Jan 28, 2032	DP			
	9399021	Jan 28, 2032	DP			
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 002	10869869	Aug 30, 2033	U-3184		I-895	Jun 22, 2025
	7378423	May 29, 2027	DS DP		ODE-148	Jun 22, 2024
	8580304	Jan 28, 2032	DP		ODE-182	Apr 30, 2025
	8703781	Oct 15, 2030	DS DP U-1712		ODE-183	May 04, 2025
	8703781	Oct 15, 2030	DS DP U-2020			
	8703781	Oct 15, 2030	DS DP U-2037			
	8703781	Oct 15, 2030	DS DP U-2302			
	8703781	Oct 15, 2030	DS DP U-2305			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114	002 8835443	Jun 10, 2025	U-1581			
	8835443	Jun 10, 2025	U-1582			
	8835443	Jun 10, 2025	U-2020			
	8835443	Jun 10, 2025	U-2037			
	8835443	Jun 10, 2025	U-2302			
	8835443	Jun 10, 2025	U-2305			
	8952018	Oct 15, 2030	U-2020			
	9155706	Jan 28, 2032	DP			
	9271941	Jan 28, 2032	DP			
	9399021	Jan 28, 2032	DP			
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114	003 10869869	Aug 30, 2033	U-3184		I-895	Jun 22, 2025
	7378423	May 29, 2027	DS DP		ODE-148	Jun 22, 2024
	8580304	Jan 28, 2032	DP		ODE-182	Apr 30, 2025
	8703781	Oct 15, 2030	DS DP U-1712		ODE-183	May 04, 2025
	8703781	Oct 15, 2030	DS DP U-2020			
	8703781	Oct 15, 2030	DS DP U-2037			
	8703781	Oct 15, 2030	DS DP U-2302			
	8703781	Oct 15, 2030	DS DP U-2305			
	8835443	Jun 10, 2025	U-1581			
	8835443	Jun 10, 2025	U-1582			
	8835443	Jun 10, 2025	U-2020			
	8835443	Jun 10, 2025	U-2037			
	8835443	Jun 10, 2025	U-2302			
	8835443	Jun 10, 2025	U-2305			
	8952018	Oct 15, 2030	U-2020			
	9155706	Jan 28, 2032	DP			
	9271941	Jan 28, 2032	DP			
	9399021	Jan 28, 2032	DP			
<u>TRANEXAMIC ACID - LYSTEDA</u>						
N 022430	001 7947739	Mar 04, 2025	DP			
	8022106	Mar 04, 2025	U-1182			
	8273795	Mar 04, 2025	U-1182			
	8487005	Mar 04, 2025	DP U-1182			
	8791160	Mar 04, 2025	DP U-1182			
	8809394	Mar 04, 2025	DP U-1182			
	8957113	Mar 04, 2025	DP U-1182			
	9060939	Mar 04, 2025	DP			
<u>TRAVOPROST - TRAVATAN Z</u>						
N 021994	001 8268299	Oct 13, 2029	DP			
	8323630	Sep 20, 2027	DP			
	8388941	Sep 20, 2027	DP			
<u>TRAVOPROST - IZBA</u>						
N 204822	001 8178582	Oct 10, 2029	DP			
	8722735	Oct 10, 2029	DP			
	8754123	May 19, 2029	DP			
	9144561	Mar 13, 2029	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TRAZODONE HYDROCHLORIDE - DESYREL</u>						
N 018207 001	8133893	Mar 13, 2029	DS DP			
<u>TRAZODONE HYDROCHLORIDE - DESYREL</u>						
N 018207 002	8133893	Mar 13, 2029	DS DP			
<u>TRAZODONE HYDROCHLORIDE - DESYREL</u>						
N 018207 003	8133893	Mar 13, 2029	DS DP			
<u>TRAZODONE HYDROCHLORIDE - DESYREL</u>						
N 018207 004	8133893	Mar 13, 2029	DS DP			
<u>TRAZODONE HYDROCHLORIDE - OLEPTRO</u>						
N 022411 001	7829120	Mar 27, 2027	DP U-796			
	8133893	Mar 13, 2029	DS DP			
<u>TRAZODONE HYDROCHLORIDE - OLEPTRO</u>						
N 022411 002	7829120	Mar 27, 2027	DP U-796			
	8133893	Mar 13, 2029	DS DP			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 001	10076505	Dec 16, 2024	DP			
	10695308	Dec 16, 2024	U-2845			
	7999007	Mar 29, 2029	DP U-1437			
	8653137	Sep 05, 2028	U-1437			
	8658694	Sep 05, 2028	U-1437			
	9199908	May 24, 2024	U-1771			
	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
	9713599	Dec 16, 2024	U-2036			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 002	10076505	Dec 16, 2024	DP			
	10695308	Dec 16, 2024	U-2845			
	7999007	Mar 29, 2029	DP U-1437			
	8653137	Sep 05, 2028	U-1437			
	8658694	Sep 05, 2028	U-1437			
	9199908	May 24, 2024	U-1771			
	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
	9713599	Dec 16, 2024	U-2036			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 003	10076505	Dec 16, 2024	DP			
	10695308	Dec 16, 2024	U-2845			
	7999007	Mar 29, 2029	DP U-1437			
	8653137	Sep 05, 2028	U-1437			
	8658694	Sep 05, 2028	U-1437			
	9199908	May 24, 2024	U-1771			
	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
	9713599	Dec 16, 2024	U-2036			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 004	10076505	Dec 16, 2024	DP			
	10695308	Dec 16, 2024	U-2845			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 004	7999007	Mar 29, 2029	DP U-1437			
	8653137	Sep 05, 2028	U-1437			
	8658694	Sep 05, 2028	U-1437			
	9199908	May 24, 2024	U-1771			
	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
	9713599	Dec 16, 2024	U-2036			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 005	10076505	Dec 16, 2024	DP			
	10695308	Dec 16, 2024	U-2845			
	7999007	Mar 29, 2029	DP U-1437			
	8653137	Sep 05, 2028	U-1437			
	8658694	Sep 05, 2028	U-1437			
	9199908	May 24, 2024	U-1771			
	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
	9713599	Dec 16, 2024	U-2036			
<u>TREPROSTINIL - TYVASO</u>						
N 022387 001	10376525	May 14, 2027	U-1849		I-856	Mar 31, 2024
	10716793	May 14, 2027	U-1849			
	9339507	Mar 10, 2028	DP			
	9358240	May 05, 2028	U-1849			
	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
<u>TREPROSTINIL - REMODULIN</u>						
N 208276 001	10076505	Dec 16, 2024	DP			
	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
	9713599	Dec 16, 2024	U-2036			
<u>TREPROSTINIL - REMODULIN</u>						
N 208276 002	10076505	Dec 16, 2024	DP			
	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
	9713599	Dec 16, 2024	U-2036			
<u>TREPROSTINIL - REMODULIN</u>						
N 208276 003	10076505	Dec 16, 2024	DP			
	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
	9713599	Dec 16, 2024	U-2036			
<u>TREPROSTINIL - REMODULIN</u>						
N 208276 004	10076505	Dec 16, 2024	DP			
	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
	9713599	Dec 16, 2024	U-2036			
<u>TREPROSTINIL - TYVASO DPI</u>						
N 214324 001	10130685	Aug 23, 2025	DP			
	10421729	Apr 01, 2035	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TREPROSTINIL - TYVASO DPI</u>						
N 214324 001	10716793	May 14, 2027	U-1849			
	10772883	Jun 11, 2030	DP			
	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
<u>TREPROSTINIL - TYVASO DPI</u>						
N 214324 002	10130685	Aug 23, 2025	DP			
	10421729	Apr 01, 2035	DP			
	10716793	May 14, 2027	U-1849			
	10772883	Jun 11, 2030	DP			
	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
<u>TREPROSTINIL - TYVASO DPI</u>						
N 214324 003	10130685	Aug 23, 2025	DP			
	10421729	Apr 01, 2035	DP			
	10716793	May 14, 2027	U-1849			
	10772883	Jun 11, 2030	DP			
	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
<u>TREPROSTINIL - TYVASO DPI</u>						
N 214324 004	10130685	Aug 23, 2025	DP			
	10421729	Apr 01, 2035	DP			
	10716793	May 14, 2027	U-1849			
	10772883	Jun 11, 2030	DP			
	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 001	7417070	Jul 30, 2026	DS		ODE-272	Oct 18, 2026
	7544713	Jul 14, 2024	U-1475			
	8252839	May 24, 2024	DP			
	8349892	Jan 22, 2031	DP			
	8410169	Feb 13, 2030	DP			
	8747897	Aug 11, 2031	DP U-2724			
	8747897	Aug 11, 2031	DP U-2725			
	9050311	May 24, 2024	DS DP			
	9278901	May 24, 2024	U-1475			
	9393203	Apr 27, 2026	DP U-1877			
	9422223	May 24, 2024	DP			
	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 002	7417070	Jul 30, 2026	DS		ODE-272	Oct 18, 2026
	7544713	Jul 14, 2024	U-1475			
	8252839	May 24, 2024	DP			
	8349892	Jan 22, 2031	DP			
	8410169	Feb 13, 2030	DP			
	8497393	Dec 15, 2028	DS	Y		
	8747897	Aug 11, 2031	DP U-2724			
	8747897	Aug 11, 2031	DP U-2725			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 002	9050311	May 24, 2024	DS DP			
	9278901	May 24, 2024	U-1475			
	9393203	Apr 27, 2026	DP U-1877			
	9422223	May 24, 2024	DP			
	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 003	7417070	Jul 30, 2026	DS		ODE-272	Oct 18, 2026
	7544713	Jul 14, 2024	U-1475			
	8252839	May 24, 2024	DP			
	8349892	Jan 22, 2031	DP			
	8410169	Feb 13, 2030	DP			
	8497393	Dec 15, 2028	DS	Y		
	8747897	Aug 11, 2031	DP U-2724			
	8747897	Aug 11, 2031	DP U-2725			
	9050311	May 24, 2024	DS DP			
	9278901	May 24, 2024	U-1475			
	9393203	Apr 27, 2026	DP U-1877			
	9422223	May 24, 2024	DP			
	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 004	7417070	Jul 30, 2026	DS		ODE-272	Oct 18, 2026
	7544713	Jul 14, 2024	U-1475			
	8252839	May 24, 2024	DP			
	8349892	Jan 22, 2031	DP			
	8410169	Feb 13, 2030	DP			
	8497393	Dec 15, 2028	DS	Y		
	8747897	Aug 11, 2031	DP U-2724			
	8747897	Aug 11, 2031	DP U-2725			
	9050311	May 24, 2024	DS DP			
	9278901	May 24, 2024	U-1475			
	9393203	Apr 27, 2026	DP U-1877			
	9422223	May 24, 2024	DP			
	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 005	7417070	Jul 30, 2026	DS		ODE-272	Oct 18, 2026
	7544713	Jul 14, 2024	U-1475			
	8252839	May 24, 2024	DP			
	8349892	Jan 22, 2031	DP			
	8410169	Feb 13, 2030	DP			
	8747897	Aug 11, 2031	DP U-2724			
	8747897	Aug 11, 2031	DP U-2725			
	9050311	May 24, 2024	DS DP			
	9278901	May 24, 2024	U-1475			
	9393203	Apr 27, 2026	DP U-1877			
	9422223	May 24, 2024	DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 005	9593066	Dec 15, 2028	DS			
	9604901	Dec 15, 2028	DS			
<u>TRETINOIN - ALTRENO</u>						
N 209353 001	10653656	Aug 22, 2038	DP U-2368			
	11324710	Aug 22, 2038	U-2368			
<u>TRIAMCINOLONE ACETONIDE - TRIESENCE</u>						
N 022048 001	8128960	Dec 17, 2029	DP			
	8211880	Mar 10, 2029	U-1257			
	8211880	Mar 10, 2029	U-1258			
<u>TRIAMCINOLONE ACETONIDE - ZILRETTA</u>						
N 208845 001	8828440	Aug 04, 2031	DP			
	9555048	Aug 04, 2031	U-2151			
<u>TRIAMCINOLONE ACETONIDE - XIPERE</u>						
N 211950 001	8636713	May 02, 2027	U-3234		NP	Oct 22, 2024
	9636332	Nov 08, 2033	U-3234			
	9937075	May 02, 2034	DP			
<u>TRICLABENDAZOLE - EGATEN</u>						
N 208711 001					NCE	Feb 13, 2024
					ODE-228	Feb 13, 2026
<u>TRIENTINE TETRAHYDROCHLORIDE - CUVRIOR</u>						
N 215760 001	10988436	May 03, 2039	DS		NP	Apr 28, 2025
	11072577	May 03, 2039	U-3370			
<u>TRIFAROTENE - AKLIEF</u>						
N 211527 001	7807708	Oct 01, 2026	DS DP		NCE	Oct 04, 2024
	8227507	Dec 21, 2025	U-818			
	8470871	Dec 21, 2025	U-2639			
	9084778	May 30, 2033	DP U-134			
	9498465	May 30, 2033	DP U-1033			
<u>TRIEPTANOLIN - DOJOLVI</u>						
N 213687 001	8697748	Oct 03, 2025	DP		NCE	Jun 30, 2025
	9186344	Jul 01, 2025	DP		ODE-311	Jun 30, 2027
<u>TRILACICLIB DIHYDROCHLORIDE - COSELA</u>						
N 214200 001	10085992	Mar 14, 2034	U-3081		NCE	Feb 12, 2026
	10189849	Oct 25, 2031	DS			
	10189850	Oct 25, 2031	DP			
	10927120	Oct 25, 2031	DP			
	10966984	Mar 14, 2034	U-3079			
	10966984	Mar 14, 2034	U-3080			
	11040042	Mar 14, 2034	DP			
	8598186	Oct 25, 2031	DS DP			
	8598197	Oct 25, 2031	DS DP			
	9487530	Mar 14, 2034	U-3079			
	9487530	Mar 14, 2034	U-3080			
	9957276	Oct 25, 2031	DS			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TRIPTORELIN PAMOATE - TRELSTAR</u>						
N 022437 001	10166181	Jun 30, 2029	DP			
<u>TRIPTORELIN PAMOATE - TRIPTODUR KIT</u>						
N 208956 001	10166181	Jun 30, 2029	DP		ODE-149	Jun 29, 2024
<u>TUCATINIB - TUKYSA</u>						
N 213411 001	11504370	Mar 25, 2033	U-2788		NCE	Apr 17, 2025
	7452895	Nov 16, 2024	DS DP U-2788		ODE-309	Apr 17, 2027
	8648087	Apr 12, 2031	DS DP			
	9457093	Oct 12, 2032	DP U-2788			
	9693989	May 09, 2027	DP U-2788			
<u>TUCATINIB - TUKYSA</u>						
N 213411 002	11504370	Mar 25, 2033	U-2788		NCE	Apr 17, 2025
	7452895	Nov 16, 2024	DS DP U-2788		ODE-309	Apr 17, 2027
	8648087	Apr 12, 2031	DS DP			
	9457093	Oct 12, 2032	DP U-2788			
	9693989	May 09, 2027	DP U-2788			
<u>UBROGEPANT - UBRELVY</u>						
N 211765 001	10117836	Jan 30, 2035	DP		NCE	Dec 23, 2024
	8754096	Jul 19, 2032	DS DP U-2717			
	8912210	Nov 10, 2031	DS DP			
	9499545	Nov 10, 2031	DS DP U-2718			
	9833448	Nov 10, 2031	U-2718			
<u>UBROGEPANT - UBRELVY</u>						
N 211765 002	10117836	Jan 30, 2035	DP		NCE	Dec 23, 2024
	8754096	Jul 19, 2032	DS DP U-2717			
	8912210	Nov 10, 2031	DS DP			
	9499545	Nov 10, 2031	DS DP U-2718			
	9833448	Nov 10, 2031	U-2718			
<u>ULIPRISTAL ACETATE - ELLA</u>						
N 022474 001	10159681	Apr 13, 2030	U-2510		M-271	Jun 24, 2024
	10772897	Apr 13, 2030	U-2958			
	8426392	Jun 12, 2030	U-1389			
	8512745	Jun 02, 2030	DP			
	8735380	Feb 20, 2029	DP			
	8962603	Jun 12, 2030	U-1657			
	9283233	Apr 13, 2030	U-1821			
	9844510	Dec 08, 2028	DP			
<u>UMBRALISIB TOSYLATE - UKONIO</u>						
N 213176 001	10072013	Jul 02, 2033	U-3063		NCE	Feb 05, 2026
	10072013	Jul 02, 2033	U-3064			
	10414773	May 26, 2035	DS DP U-3063			
	10414773	May 26, 2035	DS DP U-3064			
	10570142	Jul 02, 2033	DS DP U-3063			
	10570142	Jul 02, 2033	DS DP U-3064			
	10947244	May 26, 2035	U-3063			
	10947244	May 26, 2035	U-3064			
	10981919	Jul 02, 2033	U-3063			
	10981919	Jul 02, 2033	U-3064			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>UMBRALISIB TOSYLATE - UKONIO</u>						
N 213176 001	9150579	Jul 02, 2033	DS DP			
	9669033	Jul 02, 2033	U-3063			
	9669033	Jul 02, 2033	U-3064			
	9969740	May 26, 2035	DS DP U-3063			
	9969740	May 26, 2035	DS DP U-3064			
<u>UMECLIDINIUM BROMIDE - INCRUSE ELLIPTA</u>						
N 205382 001	7488827	Dec 18, 2027	DS DP			
	7498440	Apr 27, 2025	DS DP			
	8113199	Oct 23, 2027	DP			
	8161968	Feb 05, 2028	DP			
	8183257	Jul 27, 2025	U-1476			
	8201556	Feb 05, 2029	DP			
	8309572	Apr 27, 2025	U-1476			
	8534281	Mar 08, 2030	DP			
	8746242	Oct 11, 2030	DP			
	9333310	Oct 02, 2027	DP			
<u>UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - ANORO ELLIPTA</u>						
N 203975 001	11090294	Nov 29, 2030	U-3203			
	7439393	May 21, 2025	DS DP U-1476			
	7488827	Dec 18, 2027	DS DP			
	7498440	Apr 27, 2025	DS DP			
	8113199	Oct 23, 2027	DP			
	8161968	Feb 05, 2028	DP			
	8183257	Jul 27, 2025	U-1476			
	8309572	Apr 27, 2025	U-1476			
	8511304	Jun 14, 2027	DP U-1476			
	8534281	Mar 08, 2030	DP			
	8746242	Oct 11, 2030	DP			
	9333310	Oct 02, 2027	DP			
	9750726	Nov 29, 2030	DP			
	RE44874	Mar 23, 2023	DS DP U-1476			
<u>UPADACITINIB - RINVOQ</u>						
N 211675 001	10519164	Oct 17, 2036	DP		I-880	Dec 14, 2024
	10597400	Oct 17, 2036	U-3255		I-883	Jan 14, 2025
	10981923	Oct 17, 2036	DS		I-886	Mar 16, 2025
	10981924	Oct 17, 2036	DP		I-888	Apr 29, 2025
	10995095	Oct 17, 2036	U-3298		NCE	Aug 16, 2024
	11186584	Oct 17, 2036	DS			
	11198697	Oct 17, 2036	DP			
	11365198	Oct 17, 2036	U-3275			
	11512092	Oct 17, 2036	U-3275			
	11512092	Oct 17, 2036	U-3371			
	11512092	Oct 17, 2036	U-3487			
	8962629	Jan 15, 2031	DS U-3255			
	8962629	Jan 15, 2031	DS U-3275			
	8962629	Jan 15, 2031	DS U-3341			
	8962629	Jan 15, 2031	DS U-3371			
	9951080	Oct 17, 2036	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>UPADACITINIB - RINVOQ</u>						
N 211675 001	9963459	Oct 17, 2036	DP			
	RE47221	Dec 01, 2030	DS			
<u>UPADACITINIB - RINVOQ</u>						
N 211675 002	10344036	Oct 17, 2036	DP		I-883	Jan 14, 2025
	10550126	Oct 17, 2036	U-3298		I-886	Mar 16, 2025
	10730883	Oct 17, 2036	DP		NCE	Aug 16, 2024
	10981923	Oct 17, 2036	DS			
	10981924	Oct 17, 2036	DP			
	11186584	Oct 17, 2036	DS			
	11198697	Oct 17, 2036	DP			
	8962629	Jan 15, 2031	DS U-3341			
	9951080	Oct 17, 2036	DS DP			
	RE47221	Dec 01, 2030	DS			
<u>UPADACITINIB - RINVOQ</u>						
N 211675 003	10202393	Oct 17, 2036	DP		I-886	Mar 16, 2025
	10981923	Oct 17, 2036	DS		NCE	Aug 16, 2024
	11186584	Oct 17, 2036	DS			
	11198697	Oct 17, 2036	DP			
	8962629	Jan 15, 2031	DS U-3341			
	9951080	Oct 17, 2036	DS DP			
	RE47221	Dec 01, 2030	DS			
<u>URIDINE TRIACETATE - VISTOGARD</u>						
N 208159 001	6258795	Jul 10, 2023	DP			
	7776838	Aug 17, 2027	U-1791			
<u>URIDINE TRIACETATE - XURIDEN</u>						
N 208169 001	6258795	Jul 10, 2023	DP			
<u>VALBENAZINE TOSYLATE - INGREZZA</u>						
N 209241 001	10065952	Oct 28, 2036	DS DP U-1995			
	10844058	Oct 28, 2036	DS DP U-1995			
	10851103	Oct 28, 2036	DS DP U-1995			
	10851104	Oct 28, 2036	DS U-1995			
	10857137	Oct 10, 2037	U-1995			
	10857148	Oct 10, 2037	U-1995			
	10874648	Oct 10, 2037	U-1995			
	10874648	Oct 10, 2037	U-3046			
	10906902	Dec 22, 2036	DS DP			
	10906903	Dec 22, 2036	DS DP			
	10912771	Oct 10, 2037	U-1995			
	10912771	Oct 10, 2037	U-3076			
	10919892	Dec 22, 2036	DS DP			
	10940141	Aug 10, 2040	U-1995			
	10952997	Oct 10, 2037	U-1995			
	10993941	Oct 10, 2037	U-1995			
	11026931	Aug 14, 2039	U-1995			
	11026939	Sep 18, 2038	DP U-1995			
	11040029	Oct 10, 2037	U-1995			
	11311532	Sep 18, 2038	DP U-1995			
	8039627	Apr 11, 2031	DS DP			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>VALBENAZINE TOSYLATE - INGREZZA</u>						
N 209241 001	8357697	Nov 08, 2027	U-1995			
<u>VALBENAZINE TOSYLATE - INGREZZA</u>						
N 209241 002	10065952	Oct 28, 2036	DS DP U-1995			
	10844058	Oct 28, 2036	DS DP U-1995			
	10851103	Oct 28, 2036	DS DP U-1995			
	10851104	Oct 28, 2036	DS U-1995			
	10857137	Oct 10, 2037	U-1995			
	10857148	Oct 10, 2037	U-1995			
	10874648	Oct 10, 2037	U-1995			
	10874648	Oct 10, 2037	U-3046			
	10906902	Dec 22, 2036	DS DP			
	10906903	Dec 22, 2036	DS DP			
	10912771	Oct 10, 2037	U-1995			
	10912771	Oct 10, 2037	U-3076			
	10919892	Dec 22, 2036	DS DP			
	10940141	Aug 10, 2040	U-1995			
	10952997	Oct 10, 2037	U-1995			
	10993941	Oct 10, 2037	U-1995			
	11026931	Aug 14, 2039	U-1995			
	11026939	Sep 18, 2038	DP U-1995			
	11040029	Oct 10, 2037	U-1995			
	11311532	Sep 18, 2038	DP U-1995			
	8039627	Apr 11, 2031	DS DP			
	8357697	Nov 08, 2027	U-1995			
<u>VALBENAZINE TOSYLATE - INGREZZA</u>						
N 209241 003	10065952	Oct 28, 2036	DS DP U-1995			
	10844058	Oct 28, 2036	DS DP U-1995			
	10851103	Oct 28, 2036	DS DP U-1995			
	10851104	Oct 28, 2036	DS U-1995			
	10857137	Oct 10, 2037	U-1995			
	10857148	Oct 10, 2037	U-1995			
	10874648	Oct 10, 2037	U-1995			
	10874648	Oct 10, 2037	U-3046			
	10906902	Dec 22, 2036	DS DP			
	10906903	Dec 22, 2036	DS DP			
	10912771	Oct 10, 2037	U-1995			
	10912771	Oct 10, 2037	U-3076			
	10919892	Dec 22, 2036	DS DP			
	10940141	Aug 10, 2040	U-1995			
	10952997	Oct 10, 2037	U-1995			
	10993941	Oct 10, 2037	U-1995			
	11026931	Aug 14, 2039	U-1995			
	11026939	Sep 18, 2038	DP U-1995			
	11040029	Oct 10, 2037	U-1995			
	11311532	Sep 18, 2038	DP U-1995			
	8039627	Apr 11, 2031	DS DP			
	8357697	Nov 08, 2027	U-1995			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>VALGANCICLOVIR HYDROCHLORIDE - VALCYTE</u>						
N 022257 001	8889109	Dec 11, 2027	DP			
	9642911	Dec 11, 2027	DP			
<u>VALSARTAN - DIOVAN</u>						
N 021283 001					NPP	Apr 19, 2024
<u>VALSARTAN - DIOVAN</u>						
N 021283 002					NPP	Apr 19, 2024
<u>VALSARTAN - DIOVAN</u>						
N 021283 004					NPP	Apr 19, 2024
<u>VANCOMYCIN - VANCOMYCIN</u>						
N 213895 001	10039804	Nov 06, 2035	DP U-282			
	10188697	Nov 06, 2035	DP U-282			
	10849956	Nov 06, 2035	DP			
	11000567	Nov 06, 2035	DP			
<u>VANCOMYCIN HYDROCHLORIDE - FIRVANO KIT</u>						
N 208910 001	10493028	Mar 13, 2035	DP			
	10688046	Mar 13, 2035	DP			
	10959946	Mar 13, 2035	DP			
	10959947	Mar 13, 2035	DP U-3104			
	10959947	Mar 13, 2035	DP U-3105			
	10959948	Mar 13, 2035	DP U-3104			
	10959948	Mar 13, 2035	DP U-3105			
	10959949	Mar 13, 2035	DP U-3104			
	10959949	Mar 13, 2035	DP U-3105			
<u>VANCOMYCIN HYDROCHLORIDE - FIRVANO KIT</u>						
N 208910 002	10493028	Mar 13, 2035	DP			
	10688046	Mar 13, 2035	DP			
	10959946	Mar 13, 2035	DP			
	10959947	Mar 13, 2035	DP U-3104			
	10959947	Mar 13, 2035	DP U-3105			
	10959948	Mar 13, 2035	DP U-3104			
	10959948	Mar 13, 2035	DP U-3105			
	10959949	Mar 13, 2035	DP U-3104			
	10959949	Mar 13, 2035	DP U-3105			
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962 001	10039804	Nov 06, 2035	DP U-282			
	10188697	Nov 06, 2035	DP U-282			
	10849956	Nov 06, 2035	DP			
	11517609	Nov 06, 2035	U-282			
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962 002	10039804	Nov 06, 2035	DP U-282			
	10188697	Nov 06, 2035	DP U-282			
	10849956	Nov 06, 2035	DP			
	11517609	Nov 06, 2035	U-282			
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962 003	10039804	Nov 06, 2035	DP U-282			
	10188697	Nov 06, 2035	DP U-282			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962 003	10849956	Nov 06, 2035	DP			
	11517609	Nov 06, 2035	U-282			
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962 004	10039804	Nov 06, 2035	DP U-282			
	10188697	Nov 06, 2035	DP U-282			
	10849956	Nov 06, 2035	DP			
	11517609	Nov 06, 2035	U-282			
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962 005	10039804	Nov 06, 2035	DP U-282			
	10188697	Nov 06, 2035	DP U-282			
	10849956	Nov 06, 2035	DP			
	11517609	Nov 06, 2035	U-282			
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962 006	10039804	Nov 06, 2035	DP U-282			
	10188697	Nov 06, 2035	DP U-282			
	10849956	Nov 06, 2035	DP			
	11517609	Nov 06, 2035	U-282			
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962 007	10039804	Nov 06, 2035	DP U-282			
	10188697	Nov 06, 2035	DP U-282			
	10849956	Nov 06, 2035	DP			
	11517609	Nov 06, 2035	U-282			
<u>VANDETANIB - CAPRELSA</u>						
N 022405 001	8067427	Aug 08, 2028	DP			
<u>VANDETANIB - CAPRELSA</u>						
N 022405 002	8067427	Aug 08, 2028	DP			
<u>VARDENAFIL HYDROCHLORIDE - LEVITRA</u>						
N 021400 001	8273876	Jul 23, 2027	U-1288			
	8841446	Jul 03, 2023	DP			
<u>VARDENAFIL HYDROCHLORIDE - LEVITRA</u>						
N 021400 002	8273876	Jul 23, 2027	U-1288			
	8841446	Jul 03, 2023	DP			
<u>VARDENAFIL HYDROCHLORIDE - LEVITRA</u>						
N 021400 003	8273876	Jul 23, 2027	U-1288			
	8841446	Jul 03, 2023	DP			
<u>VARDENAFIL HYDROCHLORIDE - LEVITRA</u>						
N 021400 004	8273876	Jul 23, 2027	U-1288			
	8841446	Jul 03, 2023	DP			
<u>VARDENAFIL HYDROCHLORIDE - STAXYN</u>						
N 200179 001	8613950	Dec 23, 2028	DP			
<u>VARENICLINE TARTRATE - CHANTIX</u>						
N 021928 001	7265119*PED	Feb 03, 2023				
<u>VARENICLINE TARTRATE - CHANTIX</u>						
N 021928 002	7265119*PED	Feb 03, 2023				

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>VARENICLINE TARTRATE - TYRVAYA</u>						
N 213978 001	10456396	Oct 19, 2035	DP U-1900		NP	Oct 15, 2024
	11224598	Oct 19, 2035	U-1900			
	9504644	Oct 19, 2035	U-1900			
	9504645	Oct 19, 2035	DP			
	9532944	Oct 19, 2035	U-1900			
	9597284	Oct 19, 2035	U-1900			
<u>VASOPRESSIN - VASOSTRICT</u>						
N 204485 001	9375478	Jan 30, 2035	U-1857			
	9687526	Jan 30, 2035	U-1857			
	9744209	Jan 30, 2035	U-1857			
	9744239	Jan 30, 2035	U-1857			
	9750785	Jan 30, 2035	DP			
<u>VASOPRESSIN - VASOSTRICT</u>						
N 204485 002	9375478	Jan 30, 2035	U-1857			
	9687526	Jan 30, 2035	U-1857			
	9744209	Jan 30, 2035	U-1857			
	9744239	Jan 30, 2035	U-1857			
	9750785	Jan 30, 2035	DP			
	9937223	Jan 30, 2035	U-1857			
<u>VASOPRESSIN - VASOSTRICT</u>						
N 204485 003	10010575	Jan 30, 2035	U-1857			
	9919026	Jan 30, 2035	DP			
	9925233	Jan 30, 2035	U-1857			
	9925234	Jan 30, 2035	U-1857			
	9962422	Jan 30, 2035	U-1857			
	9968649	Jan 30, 2035	U-1857			
	9974827	Jan 30, 2035	U-1857			
	9981006	Jan 30, 2035	U-1857			
<u>VASOPRESSIN - VASOSTRICT</u>						
N 204485 004	10010575	Jan 30, 2035	U-1857			
	9919026	Jan 30, 2035	DP			
	9925233	Jan 30, 2035	U-1857			
	9925234	Jan 30, 2035	U-1857			
	9962422	Jan 30, 2035	U-1857			
	9968649	Jan 30, 2035	U-1857			
	9974827	Jan 30, 2035	U-1857			
	9981006	Jan 30, 2035	U-1857			
<u>VASOPRESSIN - VASOSTRICT</u>						
N 204485 005	10010575	Jan 30, 2035	U-1857			
	9919026	Jan 30, 2035	DP			
	9925233	Jan 30, 2035	U-1857			
	9925234	Jan 30, 2035	U-1857			
	9962422	Jan 30, 2035	U-1857			
	9968649	Jan 30, 2035	U-1857			
	9974827	Jan 30, 2035	U-1857			
	9981006	Jan 30, 2035	U-1857			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>VENURAFENIB - ZELBORAF</u>						
N 202429 001	7504509	Oct 22, 2026	DS DP		ODE-158	Nov 06, 2024
	7863288	Jun 20, 2029	DS DP			
	8143271	Jun 21, 2026	DS DP			
	8470818	Aug 02, 2026	U-1418			
	8470818	Aug 02, 2026	U-2164			
	8741920	Jul 27, 2030	DS DP			
	9447089	Jun 06, 2032	DP			
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 001	10730873	Nov 21, 2031	DS		M-265	Oct 16, 2023
	10993942	Sep 06, 2033	U-3114		ODE-114	Apr 11, 2023
	11110087	Sep 06, 2033	U-3222		ODE-185	Jun 08, 2025
	11110087	Sep 06, 2033	U-3223		ODE-211	Nov 21, 2025
	11369599	May 23, 2032	DP		ODE-239	May 15, 2026
	11413282	Sep 06, 2033	U-3412			
	8546399	Jun 27, 2031	DS DP			
	8722657	Jan 29, 2032	DS			
	9174982	May 26, 2030	U-2323			
	9174982	May 26, 2030	U-2445			
	9174982	May 26, 2030	U-2446			
	9174982	May 26, 2030	U-2537			
	9539251	Sep 06, 2033	U-2538			
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 002	10730873	Nov 21, 2031	DS		M-265	Oct 16, 2023
	10993942	Sep 06, 2033	U-3114		ODE-114	Apr 11, 2023
	11110087	Sep 06, 2033	U-3222		ODE-185	Jun 08, 2025
	11110087	Sep 06, 2033	U-3223		ODE-211	Nov 21, 2025
	11369599	May 23, 2032	DP		ODE-239	May 15, 2026
	11413282	Sep 06, 2033	U-3412			
	8546399	Jun 27, 2031	DS DP			
	8722657	Jan 29, 2032	DS			
	9174982	May 26, 2030	U-2323			
	9174982	May 26, 2030	U-2445			
	9174982	May 26, 2030	U-2446			
	9174982	May 26, 2030	U-2537			
	9539251	Sep 06, 2033	U-2538			
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 003	10730873	Nov 21, 2031	DS		M-265	Oct 16, 2023
	10993942	Sep 06, 2033	U-3114		ODE-114	Apr 11, 2023
	11110087	Sep 06, 2033	U-3222		ODE-185	Jun 08, 2025
	11110087	Sep 06, 2033	U-3223		ODE-211	Nov 21, 2025
	11369599	May 23, 2032	DP		ODE-239	May 15, 2026
	11413282	Sep 06, 2033	U-3412			
	8546399	Jun 27, 2031	DS DP			
	8722657	Jan 29, 2032	DS			
	9174982	May 26, 2030	U-2323			
	9174982	May 26, 2030	U-2445			
	9174982	May 26, 2030	U-2446			
	9174982	May 26, 2030	U-2537			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 003	9539251	Sep 06, 2033	U-2538			
<u>VENLAFAXINE BESYLATE - VENLAFAXINE BESYLATE</u>						
N 215429 001	6717015	Mar 27, 2023	DS DP U-451			
	7776358	May 16, 2028	DP			
<u>VERICIGUAT - VEROUVO</u>						
N 214377 001	10736896	May 19, 2031	DS DP		NCE	Jan 19, 2026
	11439642	May 19, 2031	U-3062			
	8420656	May 19, 2031	DS DP			
	8921377	May 19, 2031	U-3062			
	9604948	Nov 26, 2032	DS DP U-3062			
	9993476	May 19, 2031	U-3062			
<u>VERICIGUAT - VEROUVO</u>						
N 214377 002	10736896	May 19, 2031	DS DP		NCE	Jan 19, 2026
	11439642	May 19, 2031	U-3062			
	8420656	May 19, 2031	DS DP			
	8921377	May 19, 2031	U-3062			
	9604948	Nov 26, 2032	DS DP U-3062			
	9993476	May 19, 2031	U-3062			
<u>VERICIGUAT - VEROUVO</u>						
N 214377 003	10736896	May 19, 2031	DS DP		NCE	Jan 19, 2026
	11439642	May 19, 2031	U-3062			
	8420656	May 19, 2031	DS DP			
	8921377	May 19, 2031	U-3062			
	9604948	Nov 26, 2032	DS DP U-3062			
	9993476	May 19, 2031	U-3062			
<u>VIBEGRON - GEMTESA</u>						
N 213006 001	8247415	Dec 01, 2030	DS DP U-3045		NCE	Dec 23, 2025
	8653260	Apr 02, 2029	DS			
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N 022567 001					M-254	Jan 31, 2023
					PED	Jul 31, 2023
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N 022567 002					M-254	Jan 31, 2023
					PED	Jul 31, 2023
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N 022567 003					M-254	Jan 31, 2023
					PED	Jul 31, 2023
<u>VILOXAZINE HYDROCHLORIDE - OELBREE</u>						
N 211964 001	11324753	Sep 04, 2029	U-727		NCE	Apr 02, 2026
	11458143	Sep 04, 2029	U-727		NPP	Apr 29, 2025
	9358204	Feb 07, 2033	DP			
	9603853	Feb 07, 2033	U-727			
	9662338	Feb 07, 2033	DP			
<u>VILOXAZINE HYDROCHLORIDE - OELBREE</u>						
N 211964 002	11324753	Sep 04, 2029	U-727		NCE	Apr 02, 2026
	11458143	Sep 04, 2029	U-727		NPP	Apr 29, 2025

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>VILOXAZINE HYDROCHLORIDE - QELBREE</u>						
N 211964 002	9358204	Feb 07, 2033	DP			
	9603853	Feb 07, 2033	U-727			
	9662338	Feb 07, 2033	DP			
<u>VILOXAZINE HYDROCHLORIDE - QELBREE</u>						
N 211964 003	11324753	Sep 04, 2029	U-727		NCE	Apr 02, 2026
	11458143	Sep 04, 2029	U-727		NPP	Apr 29, 2025
	9358204	Feb 07, 2033	DP			
	9603853	Feb 07, 2033	U-727			
	9662338	Feb 07, 2033	DP			
<u>VILTOLARSEN - VILTEPSO</u>						
N 212154 001	10870676	Aug 31, 2031	DS DP U-3039		NCE	Aug 12, 2025
	9079934	Aug 31, 2031	DS DP		ODE-280	Aug 12, 2027
<u>VISMODEGIB - ERIVEDGE</u>						
N 203388 001	7888364	Nov 11, 2028	DS DP			
	9278961	Dec 15, 2028	U-1825			
	9790183	Sep 02, 2025	U-3109			
<u>VOCLOSPORIN - LUPKYNIS</u>						
N 213716 001	10286036	Dec 07, 2037	U-3056		NCE	Jan 22, 2026
	7332472	Oct 17, 2023	DS DP U-3056			
<u>VORAPAXAR SULFATE - ZONTIVITY</u>						
N 204886 001	7304078	Dec 23, 2027	DS DP U-1512			
	7713999	May 30, 2024	DS DP U-2291			
<u>VORINOSTAT - ZOLINZA</u>						
N 021991 001	7399787	Feb 09, 2025	U-892			
	7456219	Mar 11, 2027	DS			
	7652069	Mar 04, 2023	DP			
	7732490	Mar 04, 2023	U-892			
	7851509	Feb 21, 2024	DP U-892			
	8067472	Mar 04, 2023	U-892			
	8093295	May 16, 2026	DP			
	8101663	Mar 04, 2023	U-892			
	8450372	Mar 18, 2028	U-892			
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 001	11458134	Jun 15, 2027	DP U-3463		M-187	Jan 22, 2024
	7144884	Jun 17, 2026	DS DP U-1439		M-267	Nov 13, 2023
	8722684	Jun 30, 2031	DS DP			
	8969355	Jun 15, 2027	U-1668			
	9125908	Jun 15, 2027	U-2309			
	9125909	Jun 15, 2027	U-2309			
	9125910	Jun 15, 2027	U-2309			
	9227946	Jun 15, 2027	U-1668			
	9278096	Mar 21, 2032	U-2436			
	9861630	Jun 15, 2027	U-1668			
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 002	11458134	Jun 15, 2027	DP U-3463		M-187	Jan 22, 2024
	7144884	Jun 17, 2026	DS DP U-1439		M-267	Nov 13, 2023

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 002	8722684	Jun 30, 2031	DS DP			
	8969355	Jun 15, 2027	U-1668			
	9125908	Jun 15, 2027	U-2309			
	9125909	Jun 15, 2027	U-2309			
	9125910	Jun 15, 2027	U-2309			
	9227946	Jun 15, 2027	U-1668			
	9278096	Mar 21, 2032	U-2436			
	9861630	Jun 15, 2027	U-1668			
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 003	11458134	Jun 15, 2027	DP U-3463		M-187	Jan 22, 2024
	7144884	Jun 17, 2026	DS DP U-1439		M-267	Nov 13, 2023
	8722684	Jun 30, 2031	DS DP			
	8969355	Jun 15, 2027	U-1668			
	9125908	Jun 15, 2027	U-2309			
	9125909	Jun 15, 2027	U-2309			
	9125910	Jun 15, 2027	U-2309			
	9227946	Jun 15, 2027	U-1668			
	9278096	Mar 21, 2032	U-2436			
	9861630	Jun 15, 2027	U-1668			
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 004	11458134	Jun 15, 2027	DP U-3463		M-187	Jan 22, 2024
	7144884	Jun 17, 2026	DS DP U-1439		M-267	Nov 13, 2023
	8722684	Jun 30, 2031	DS DP			
	8969355	Jun 15, 2027	U-1668			
	9125908	Jun 15, 2027	U-2309			
	9125909	Jun 15, 2027	U-2309			
	9125910	Jun 15, 2027	U-2309			
	9227946	Jun 15, 2027	U-1668			
	9278096	Mar 21, 2032	U-2436			
	9861630	Jun 15, 2027	U-1668			
<u>VOSORITIDE - VOXZOGO</u>						
N 214938 001	10646550	Aug 01, 2036	DP U-3256		NCE	Nov 19, 2026
	8198242	Jun 11, 2030	DS DP U-3256			
	9907834	Aug 01, 2036	DP			
	RE48267	May 20, 2030	U-3256			
<u>VOSORITIDE - VOXZOGO</u>						
N 214938 002	10646550	Aug 01, 2036	DP U-3256		NCE	Nov 19, 2026
	8198242	Jun 11, 2030	DS DP U-3256			
	9907834	Aug 01, 2036	DP			
	RE48267	May 20, 2030	U-3256			
<u>VOSORITIDE - VOXZOGO</u>						
N 214938 003	10646550	Aug 01, 2036	DP U-3256		NCE	Nov 19, 2026
	8198242	Jun 11, 2030	DS DP U-3256			
	9907834	Aug 01, 2036	DP			
	RE48267	May 20, 2030	U-3256			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>VOXELOTOR - OXBRYTA</u>						
N 213137 001	10017491	Dec 28, 2032	DP		NCE	Nov 25, 2024
	10034879	Dec 28, 2032	DS DP		ODE-281	Nov 25, 2026
	10493035	Oct 12, 2037	DP			
	10722502	Feb 06, 2035	DP			
	10806733	Dec 28, 2032	DS			
	11020382	Dec 02, 2036	U-3133			
	11020382	Dec 02, 2036	U-3134			
	11452720	Feb 06, 2035	U-3459			
	9018210	Nov 25, 2033	DS DP			
	9248199	Jan 29, 2034	U-2676			
	9248199	Jan 29, 2034	U-2715			
	9447071	Feb 06, 2035	DS DP			
<u>VOXELOTOR - OXBRYTA</u>						
N 213137 002	10017491	Dec 28, 2032	DP			
	10034879	Dec 28, 2032	DS DP			
	10493035	Oct 12, 2037	DP			
	10722502	Feb 06, 2035	DP			
	10806733	Dec 28, 2032	DS			
	11020382	Dec 02, 2036	U-3133			
	11020382	Dec 02, 2036	U-3134			
	11452720	Feb 06, 2035	U-3459			
	9018210	Nov 25, 2033	DS DP			
	9248199	Jan 29, 2034	U-2676			
	9248199	Jan 29, 2034	U-2715			
	9447071	Feb 06, 2035	DS DP			
<u>VOXELOTOR - OXBRYTA</u>						
N 216157 001	10017491	Dec 28, 2032	DP		NCE	Nov 25, 2024
	10034879	Dec 28, 2032	DS DP			
	10722502	Feb 06, 2035	DP			
	10806733	Dec 28, 2032	DS			
	11020382	Dec 02, 2036	U-3133			
	11020382	Dec 02, 2036	U-3134			
	11452720	Feb 06, 2035	U-3459			
	9018210	Nov 25, 2033	DS DP			
	9248199	Jan 29, 2034	U-2676			
	9248199	Jan 29, 2034	U-2715			
	9447071	Feb 06, 2035	DS DP			
<u>VUTRISIRAN - AMVUTTRA</u>						
N 215515 001	10131907	Aug 24, 2028	DS DP U-3396		NCE	Jun 13, 2027
	10208307	Jul 28, 2036	DS DP U-3396			
	10570391	Nov 16, 2032	DS DP U-3396			
	10612024	Aug 14, 2035	DS DP U-3396			
	10683501	Jul 28, 2036	DS DP U-3396			
	10806791	Dec 04, 2028	DS			
	11286486	Jul 28, 2036	DS DP U-3396			
	11401517	Aug 14, 2035	DS DP U-3396			
	8106022	Dec 12, 2029	DS DP U-3396			
	8828956	Dec 04, 2028	DS DP U-3396			

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>VUTRISIRAN - AMVUTTRA</u>						
N 215515 001	9370581	Dec 04, 2028	DS DP U-3396			
	9399775	Nov 16, 2032	DS DP U-3396			
<u>ZANUBRUTINIB - BRUKINSA</u>						
N 213217 001	10570139	Apr 22, 2034	U-1745		I-871	Aug 31, 2024
	10570139	Apr 22, 2034	U-2145		I-874	Sep 14, 2024
	10570139	Apr 22, 2034	U-3063		NCE	Nov 14, 2024
	10927117	Aug 15, 2037	DS DP		ODE-276	Nov 14, 2026
	11142528	Apr 22, 2034	DP U-1745		ODE-370	Sep 14, 2028
	11142528	Apr 22, 2034	DP U-2145		ODE-371	Aug 31, 2028
	11142528	Apr 22, 2034	DP U-3063			
	9447106	Apr 22, 2034	DS DP U-1745			
	9447106	Apr 22, 2034	DS DP U-2145			
	9447106	Apr 22, 2034	DS DP U-3063			
<u>ZICONOTIDE ACETATE - PRIALT</u>						
N 021060 001	8653033	Oct 01, 2024	U-48			
	8653033	Oct 01, 2024	U-55			
	8765680	Oct 01, 2024	U-48			
	8765680	Oct 01, 2024	U-55			
	9707270	Oct 01, 2024	U-2084			
<u>ZICONOTIDE ACETATE - PRIALT</u>						
N 021060 002	8653033	Oct 01, 2024	U-48			
	8653033	Oct 01, 2024	U-55			
	8765680	Oct 01, 2024	U-48			
	8765680	Oct 01, 2024	U-55			
	9707270	Oct 01, 2024	U-2084			
<u>ZICONOTIDE ACETATE - PRIALT</u>						
N 021060 003	8653033	Oct 01, 2024	U-48			
	8653033	Oct 01, 2024	U-55			
	8765680	Oct 01, 2024	U-48			
	8765680	Oct 01, 2024	U-55			
	9707270	Oct 01, 2024	U-2084			
<u>ZICONOTIDE ACETATE - PRIALT</u>						
N 021060 004	8653033	Oct 01, 2024	U-48			
	8653033	Oct 01, 2024	U-55			
	8765680	Oct 01, 2024	U-48			
	8765680	Oct 01, 2024	U-55			
	9707270	Oct 01, 2024	U-2084			
<u>ZIPRASIDONE HYDROCHLORIDE - GEODON</u>						
N 020825 001					M-232	Jan 28, 2025
<u>ZIPRASIDONE HYDROCHLORIDE - GEODON</u>						
N 020825 002					M-232	Jan 28, 2025
<u>ZIPRASIDONE HYDROCHLORIDE - GEODON</u>						
N 020825 003					M-232	Jan 28, 2025
<u>ZIPRASIDONE HYDROCHLORIDE - GEODON</u>						
N 020825 004					M-232	Jan 28, 2025

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ZOLEDRONIC ACID - ZOMETA</u>						
N 021223	002 8324189	May 29, 2025	U-1308			
	8324189	May 29, 2025	U-1309			
	8324189	May 29, 2025	U-53			
<u>ZOLEDRONIC ACID - ZOMETA</u>						
N 021223	003 7932241	Feb 05, 2028	DP			
	8324189	May 29, 2025	U-1308			
	8324189	May 29, 2025	U-1309			
	8324189	May 29, 2025	U-53			
<u>ZOLEDRONIC ACID - RECLAST</u>						
N 021817	001 7932241	Feb 05, 2028	DP			
	8052987	Oct 27, 2023	U-1199			
<u>ZOLPIDEM TARTRATE - EDLUAR</u>						
N 021997	001 9265720	Feb 25, 2031	U-674			
	9597281	Apr 06, 2027	U-674			
<u>ZOLPIDEM TARTRATE - EDLUAR</u>						
N 021997	002 9265720	Feb 25, 2031	U-674			
	9597281	Apr 06, 2027	U-674			
<u>ZOLPIDEM TARTRATE - ZOLPIMIST</u>						
N 022196	001 8236285	Aug 07, 2032	DS DP U-70			
<u>ZOLPIDEM TARTRATE - INTERMEZZO</u>						
N 022328	001 7658945	Apr 15, 2027	DP U-1194			
	7682628	Feb 16, 2025	U-1194			
	8242131	Aug 20, 2029	U-1266			
	8252809	Feb 16, 2025	DP			
<u>ZOLPIDEM TARTRATE - INTERMEZZO</u>						
N 022328	002 7658945	Apr 15, 2027	DP U-1194			
	7682628	Feb 16, 2025	U-1194			
	8242131	Aug 20, 2029	U-1266			
	8252809	Feb 16, 2025	DP			
<u>ZONISAMIDE - ZONISADE</u>						
N 214273	001 11478456	Aug 18, 2038	U-3458			
	11529333	Aug 18, 2038	DP			

PATENT AND EXCLUSIVITY TERMS

ADB 1 of 191

PATENT & EXCLUSIVITY ABBREVIATIONS

CGT	COMPETITIVE GENERIC THERAPY
D	NEW DOSING SCHEDULE (SEE INDIVIDUAL REFERENCES)
GAIN	GAIN EXCLUSIVITY
I	NEW INDICATION (SEE INDIVIDUAL REFERENCES)
M	MISCELLANEOUS EXCLUSIVITY CODES (SEE INDIVIDUAL REFERENCES)
NC	NEW COMBINATION
NCE	NEW CHEMICAL ENTITY
NCE*	NEW CHEMICAL ENTITY (AN ENANTIOMER OF PREVIOUSLY APPROVED RACEMIC MIXTURE. SEE SECTION 505(U) OF THE FEDERAL FOOD AND DRUG COSMETIC ACT).
NDF	NEW DOSAGE FORM
NE	NEW ESTER OR SALT OF AN ACTIVE INGREDIENT
NP	NEW PRODUCT
NP*	NEW PRODUCT (MINT FLAVORED)
NPP	NEW PATIENT POPULATION
NR	NEW ROUTE
NS	NEW STRENGTH
ODE	ORPHAN DRUG EXCLUSIVITY (SEE INDIVIDUAL REFERENCES)
ODE*	FDA has not recognized Orphan-Drug Exclusivity (ODE) for this drug, but it contains the same active moiety or moieties as another drug(s) that was eligible for ODE, and also shares ODE-protected use(s) or indication(s) with that drug(s). An application seeking approval for the same active moiety or moieties, including an ANDA that cites this NDA as its basis of submission, may not be approved for such ODE-protected use(s) and indication(s)
PC	PATENT CHALLENGE
PED	PEDIATRIC EXCLUSIVITY
RTO	RX TO OTC SWITCH OR OTC USE
RTO*	OTC USE FOR WOMEN AGES 15 AND 16
RTO**	OTC USE FOR WOMEN 14 AND BELOW
U	PATENT USE CODE (SEE INDIVIDUAL REFERENCES)
W	EXCLUSIVITY ON THIS APPLICATION EXPIRING ON THIS DATE HAS BEEN WAIVED BY SPONSOR - SEE SECTION 1.8 OF ORANGE BOOK PREFACE WAIVED EXCLUSIVITY

EXCLUSIVITY DOSING SCHEDULE

D-1	ONCE A DAY APPLICATION
D-2	ONCE DAILY DOSING
D-3	SEVEN DAYS/SEVEN DAYS/SEVEN DAYS DOSING SCHEDULE
D-4	SEVEN DAYS/FOURTEEN DAYS DOSING SCHEDULE
D-5	TEN DAYS/ELEVEN DAYS DOSING SCHEDULE
D-6	SEVEN DAYS/NINE DAYS/FIVE DAYS DOSING SCHEDULE
D-7	BID DOSING
D-8	INTRAVENOUS, EPIDURAL AND INTRATHECAL DOSING
D-9	NARCOTIC OVERDOSE IN ADULTS
D-10	NARCOTIC OVERDOSE IN CHILDREN
D-11	POSTOPERATIVE NARCOTIC DEPRESSION IN CHILDREN
D-12	BEDTIME DOSING OF 800MG FOR TREATMENT OF ACTIVE DUODENAL ULCER
D-13	INCREASED MAXIMUM DAILY DOSAGE RECOMMENDATION
D-14	BEDTIME DOSING OF 800MG FOR TREATMENT OF ACTIVE BENIGN GASTRIC ULCER
D-15	SINGLE DAILY DOSE OF 25MG/37.5MG
D-16	CONTINUOUS INTRAVENOUS INFUSION
D-17	400MG EVERY 12 HOURS FOR THREE DAYS FOR UNCOMPLICATED URINARY TRACT INFECTIONS
D-18	LOWER RECOMMENDED STARTING DOSE GUIDELINES
D-19	BOLUS DOSING GUIDELINES
D-20	SINGLE 32MG DOSE
D-21	ALTERNATIVE DOSAGE OF 300MG ONCE DAILY AFTER THE EVENING MEAL

PATENT AND EXCLUSIVITY TERMS

ADB 2 of 191

EXCLUSIVITY DOSING SCHEDULE

D-22	REDUCTION IN INFUSION TIME FROM 24 TO 4 HOURS FOR THE 60MG DOSE
D-23	INCREASE MAXIMUM DOSE AND VARIATIONS IN THE DOSING REGIMEN
D-24	FOR OVARIAN CANCER THE RECOMMENDED REGIMEN IS 135MG/M2 OR 175MG/M2 INTRAVENOUSLY OVER THREE HOURS EVERY THREE WEEKS
D-25	ADDITIONAL DOSAGE REGIMEN EQUAL TO HALF THE ORIGINAL DOSING REGIMEN
D-26	ONCE WEEKLY APPLICATION
D-27	BID DOSING IN PATIENTS 12 YEARS OF AGE AND OLDER FOR PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH MODERATE EMETOGENIC CANCER CHEMOTHERAPY
D-28	USE OF ISOVUE-370 IN EXCRETORY UROGRAPHY AT EQUIVALENT GRAMS OF IODINE TO THE CURRENTLY APPROVED ISOVUE-250 AND ISOVUE-300
D-29	INCREASE OF CUMULATIVE DOSE TO 0.3MMOL/KG FOR MRI OF CNS IN ADULTS
D-30	5000 IU DOSE FOR PROPHYLAXIS AGAINST DEEP VEIN THROMBOSIS
D-31	CHANGE IN RECOMMENDED TOTAL DAILY DOSE TO 80MG (40MG BID)
D-32	REMOVAL OF THE RESTRICTIONS LIMITING TREATMENT TO TWO CONSECUTIVE WEEKS AND TO SMALL AREAS
D-33	ONCE DAILY DOSING FOR PLAQUE PSORIASIS
D-34	EVERY FOUR MONTHS DOSAGE REGIMEN
D-35	FOR A ONE WEEK DOSING OF INTERDIGITAL TINEA PEDIS
D-36	FOR A SINGLE 2MG DOSE AS AN ALTERNATIVE TO THE 1MG DOSE GIVEN TWICE DAILY
D-37	DOSING REGIMEN FOR ADMINISTRATION EITHER ONCE DAILY (QD) OR TWICE DAILY (BID)
D-38	CONTINUOUS INFUSION AS AN ALTERNATE METHOD OF ADMINISTRATION
D-39	CHANGE IN TIME TO TAKE THE DRUG PRIOR TO A MEAL TO PREVENT MEAL-INDUCED HEARTBURN SYMPTOMS FROM "...1/2 TO 1 HOUR BEFORE EATING" TO "... RIGHT BEFORE EATING OR UP TO 60MIN BEFORE CONSUMING..."
D-40	ONCE-A-DAY DOSING REGIMEN
D-41	DRUG MAY BE DOSED RIGHT BEFORE A MEAL OR ANY TIME UP TO 30MIN BEFORE EATING OR DRINKING FOOD AND BEVERAGES THAT WOULD BE EXPECTED TO CAUSE SYMPTOMS
D-42	TEN DAY DOSING REGIMEN FOR TRIPLE THERAPY, PREVACID IN COMBINATION WITH CLARITHROMYCIN AND AMOXICILLIN, FOR THE ERADICATION OF H.PYLORI IN PATIENTS WITH DUODENAL ULCER DISEASE
D-43	INITIATION OF TREATMENT WITH 900MG/DAY BY DELETION OF THE REQUIREMENT TO TITRATE TO 900MG/DAY OVER A 3-DAY PERIOD
D-44	IN A CLINICAL TRIAL, FEWER DISCONTINUATIONS DUE TO ADVERSE EVENTS, ESPECIALLY DIZZINESS AND VERTIGO, WERE OBSERVED WHEN TITRATING THE DOSE IN INCREMENTS OF 50MG/DAY EVERY 3 DAYS UNTIL AN EFFECTIVE DOSE (NOT EXCEEDING 400MG/DAY) WAS REACHED
D-45	ONCE DAILY DOSING FOR MAINTENANCE ONLY
D-46	NEW DOSING REGIMEN OF 80MG DAILY
D-47	PREVENTION OF HEARTBURN SYMPTOMS WHEN ADMINISTERED FROM 15 MINUTES UP TO, BUT NOT INCLUDING, 1 HOUR PRIOR TO A PROVOCATIVE MEAL
D-48	ADMINISTRATION OF CISATRACURIUM A NEUROMUSCULAR BLOCKING AGENT AT DOSES OF 3 AND 4X THE ED95 OF CISATRACURIUM FOLLOWING INDUCTION WITH THIOPENTAL
D-49	PEDIATRIC DOSING GUIDELINES
D-50	INFORMATION FOR USE OF CORVERT IN POST-CARDIAC SURGERY PATIENTS
D-51	OPTIONAL STARTING DOSE OF 40MG/DAY
D-52	ALTERNATE DOSING REGIMEN OF 1250MG TWICE DAILY
D-53	USE IN PEDIATRIC PATIENTS FROM 1 MONTH TO 16 YEARS OF AGE
D-54	USE OF ZYBAN FOR MAINTENANCE THERAPY. TREATMENT UP TO 6 MONTHS WAS SHOWN EFFICACIOUS
D-55	ADDITION OF A HIGHER DOSE OF NUTROPIN FOR PUBERTAL PATIENTS (PUBERTAL DOSE LESS THAN OR EQUAL TO 0.7MG/KG/WEEK)
D-56	ADDITION OF POSTPRANDIAL DOSING

PATENT AND EXCLUSIVITY TERMS

ADB 3 of 191

EXCLUSIVITY DOSING SCHEDULE

D-57	3-HOUR INFUSION OF TAXOL GIVEN EVERY THREE WEEKS AT A DOSE OF 175MG/M2 FOLLOWED BY CISPLATIN AT A DOSE OF 75MG/M2 FOR THE FIRST-LINE TREATMENT OF ADVANCED OVARIAN CANCER
D-58	CHANGE IN DOSING INTERVAL TO ONCE-DAILY ADMINISTRATION
D-59	REDUCTION OF ELEVATED LDL-C IN A NEW, HIGHER STRENGTH TABLET, 0.8MG, AND FOR EXTENSION OF THE DOSAGE RANGE TO 0.8MG DAILY
D-60	ADDITION OF A POST-OPERATIVE DOSING REGIMEN
D-61	ONCE WEEKLY DOSING FOR THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
D-62	ONCE WEEKLY DOSING FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
D-63	TO ALLOW A TITRATION DOSING REGIMEN USING A 25MG DOSE
D-64	INCREASING DOSAGE FOR NERVE BLOCK ANESTHESIA USING NAROPIN 7.5MG/ML AND FOR EXTENDING THE DURATION OF TREATMENT FOR POSTOPERATIVE ANALGESIA USING NAROPIN 2MG/ML
D-65	CHANGE DOSING AND ADMINISTRATION TO INDICATE MAINTENANCE OF WEIGHT LOSS OVER AN 18 MONTH PERIOD THUS EXTENDING THE USE OF THIS DRUG FROM ONE TO TWO YEARS
D-66	DOSING RECOMMENDATIONS FOR PATIENTS UNDERGOING PCI
D-67	SHORTER TREATMENT COURSE OF THREE DAYS IN THE TREATMENT OF RECURRENT EPISODES OF GENITAL HERPES
D-68	CHANGE OF ADMIN RATE FOR INFUSION OF AREDIA FOR TREATMENT OF MODERATE AND SEVERE HYPERCALCEMIA OF MALIGNANCY FROM 24 HOURS TO 2 HOURS UP TO BUT NOT INCLUDING 24 HOURS
D-69	SHORTENED DOSING REGIMEN TO 5 DAYS FOR THE TREATMENT OF ACUTE EXACERBATION OF CHRONIC BRONCHITIS
D-70	80MG ONCE DAILY DOSING REGIMEN
D-71	EIGHT WEEK DOSING REGIMEN
D-72	INFORMATION REGARDING INCREASED RATE OF INFUSION FOR DEPAACON
D-73	ONCE A WEEK DOSING FOR THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
D-74	ONCE A WEEK DOSING FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
D-75	INTERMITTENT DOSING REGIMEN, STARTING DAILY DOSE 14 DAYS PRIOR TO THE ANTICIPATED ONSET OF MENSTRUATION THROUGH THE FIRST FULL DAY OF MENSES AND REPEATING WITH EACH NEW CYCLE
D-76	FOR USE ON AN "AS NEEDED" OR PRN BASIS FOR THE MANAGEMENT OF NASAL SYMPTOMS IN PATIENTS FOR WHOM THE DRUG IS INDICATED
D-77	ADDITION OF 20MG AND 40MG DAILY AS OPTIONAL STARTING DOSES WITH 40MG INTENDED FOR PATIENTS WHO REQUIRE A LARGE REDUCTION IN LDL-C (MORE THAN 45%)
D-78	USE OF FLEXERIL 5MG FOR THE RELIEF OF MUSCLE SPASM ASSOCIATED WITH ACUTE, PAINFUL, MUSCULOSKELETAL CONDITIONS
D-79	NEW LOWER STARTING DOSE FOR TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS AND/OR MODERATE TO SEVERE SYMPTOMS OF VULVAR AND VAGINAL ATROPHY ASSOCIATED W/ THE MENOPAUSE
D-80	CHANGE OF DOSING SCHEDULE FOR LANTUS FROM ONCE DAILY AT BEDTIME TO FLEXIBLE DAILY DOSING
D-81	NEW LOWER STARTING DOSE FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPORSIS
D-82	USE OF PREMARIN 0.3 MG AND 0.45 MG FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
D-83	750 MG, ONCE DAILY FOR 5 DAYS FOR COMMUNITY ACQUIRED PNEUMONIA (CAP)
D-84	ONCE-A-DAY DOSING OF FLOXACIN OTIC FOR THE TREATMENT OF ADULTS AND PEDIATRIC PATIENTS(AGES 6 MO & OLDER) W/ OTITIS EXTERNA CAUSED BY SUSCEPTIBLE STRAINS OF E.COLI, P.AERUGINOSA AND S.AUREUS
D-85	LOWER RECOMMENDED STARTING DOSE GUIDELINES FOR TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH THE MENOPAUSE
D-86	FOR USE IN SELECT EXTERNAL INSULIN PUMPS
D-87	ADDITION OF ONCE-WEEKLY DOSING FOR THE TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS

PATENT AND EXCLUSIVITY TERMS

ADB 4 of 191

EXCLUSIVITY DOSING SCHEDULE

D-88	NEW DOSING RANGE OF 200-400MG PER DAY IN TWO DIVIDED DOSES FOR ADULTS WITH PARTIAL SEIZURES
D-89	USE OF REYATAZ 300 MG/RITONAVIR 100 MG ONCE DAILY FOR TREATMENT IN HIV-INFECTED ANTIRETROVIRAL-EXPERIENCED PATIENTS
D-90	ADDITION OF DAYTIME ADMINISTRATION TO TREAT VULVOVAGINAL CANDIDIASIS
D-91	ALTERNATE INTERMITTENT DOSING REGIMEN
D-92	ALTERNATIVE DOSAGE OF 1000MG ONCE DAILY AT BEDTIME
D-93	ALTERNATE TWO OR THREE TIMES DAILY DOSING REGIMENS
D-94	NEW MAXIMUM DOSAGE OF 72 MG/DAY IN ADOLESCENTS 13-17 YEARS OF AGE WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
D-95	BROADENED INITIAL STARTING DOSE FOR HYPERTENSION FROM 50 MG TO 100 MG TO 25 MG TO 100 MG DOSE RANGE
D-96	ONCE-MONTHLY TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS WITH BONIVA (IBANDRONATE SODIUM) 150 MG TABLETS
D-97	PED CANCER PT POPULATION EXPANDED TO INCLUDE PTS 6 MOS UP TO BUT NOT INCLUDING 4 YRS AND DOSING INSTRUCTIONS TO ADMIN 30 MIN BEFORE CHEMO WITH SECOND AND THIRD DOSES 4 & 8 HOURS AFTER FIRST DOSE
D-98	DOSING FOR PED SURGICAL PTS EXPANDED TO INCLUDE PTS 1 MONTH UP TO BUT NOT INCLUDING 2 YEARS OF AGE
D-99	ONCE DAILY ADMINISTRATION FOR THE TREATMENT OF HIV INFECTION IN THERAPY NAIVE ADULT PATIENTS
D-100	750 MG ONCE DAILY FOR FIVE DAYS FOR THE TREATMENT OF ACUTE BACTERIAL SINUSITIS
D-101	ONCE DAILY IN CHRONIC IDIOPATHIC URTICARIA FOR ADULTS AND CHILDREN 12 YEARS OF AGE AND OLDER
D-102	NEW DOSING REGIMEN OF ONE SPRAY TWICE DAILY FOR SEASONAL ALLERGIC RHINITIS IN PATIENTS 12 YRS OF AGE AND OLDER
D-103	NEW DOSING RECOMMENDATION FOR THE TREATMENT OF RECURRENT GENITAL HERPES IN IMMUNOCOMPETENT PATIENTS, SPECIFICALLY A REDUCTION IN COURSE OF THERAPY FROM FAMCICLOVIR 125 MG TWICE-A-DAY FOR 5 DAYS TO 1000 MG TWICE-A-DAY FOR 1 DAY.
D-104	0.5MG/0.1MG FOR THE TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE IN WOMEN WHO HAVE A UTERUS
D-105	USE OF ACTONEL 75MG TWO CONSECUTIVE DAYS PER MONTH FOR THE PREVENTION AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
D-106	FIVE DAY TREATMENT OF SELECTED SUSCEPTIBLE STRAINS OF STREPTOCOCCUS PNEUMONIAE, HAEMOPHILUS INFLUENZA, MYCOPLASMA PNEUMONIAE, AND CHLAMYDIA PNEUMONIAE FOR COMMUNITY-ACQUIRED PNEUMONIA
D-107	PROVIDES FOR THE COMBINATION TABLET OF 70MG ALENDRONATE AND 5600 IU OF VITAMIN D3 FOR THE TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN AND TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS
D-108	TREATMENT OF COMPLICATED URINARY TRACT INFECTION AND ACUTE PYELONEPHRITIS WITH LEVAQUIN 750MG ONCE DAILY FOR FIVE DAYS
D-109	PROVIDE FOR THE USE OF A LOWER DOSE FOR THE TREATMENT OF ADULTS WITH CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (CML) WITH RESISTANCE OR INTOLERANCE TO PRIOR THERAPY INCLUDING IMATINIB MESYLATE
D-110	TREATMENT OF SCHIZOPHRENIA IN ADOLESCENTS AGED 13-17
D-111	PROVIDES FOR ONCE DAILY USE OF CIALIS, 2.5 MG AND 5 MG, FOR THE TREATMENT OF ERECTILE DYSFUNCTION
D-112	PROVIDES FOR PEDIATRIC PUMP USE
D-113	ONCE DAILY DOSING REGIMEN FOR PATIENTS WHO BECOME CONSTIPATED ON TWICE DAILY REGIMEN
D-114	NEW DOSING RECOMMENDATIONS FOR USE OF SIROLIMUS IN COMBINATION WITH CYCLOSPORINE FOR THE PROPHYLAXIS OF REJECTION IN HIGH-RISK RENAL TRANSPLANT RECIPIENTS
D-115	STARTING DOSE OF 15MG/DAY FOR MONOTHERAPY IN ACUTE TREATMENT OF BIPOLAR DISORDER, MANIC OR MIXED
D-116	ALTERNATIVE DOSING REGIMEN ATAZANAVIR SULATE CO-ADMINISTERED WITH RITONAVIR FOR THE TREATMENT OF HIV-1 INFECTION IN TREATMENT NAIVE PATIENTS

PATENT AND EXCLUSIVITY TERMS

ADB 5 of 191

EXCLUSIVITY DOSING SCHEDULE

D-117	50 MG TABLET FOR INITIATION OF DOSE TITRATION FOR BIPOLAR DISORDER
D-118	TWO 400MG TABLETS ONCE DAILY, CO-ADMINISTERED WITH 100MG RITONAVIR
D-119	DOSING RECOMMENDATIONS FOR HIV INFECTED PEDIATRIC PATIENTS 6 TO LESS THAN 18 YEARS OF AGE
D-120	DOSING REGIMEN ADJUSTMENTS
D-121	CHANGE TO REMOVE 20 MG MAXIMUM DOSAGE RESTRICTION
D-122	USE OF VAGIFEM 10 MCG FOR THE TREATMENT OF ATROPHIC VAGINITIS DUE TO MENOPAUSE
D-123	ALTERNATIVE DOSING REGIMEN DOSE OF 20 MG/METER SQUARE BY CONTINUOUS INTRAVENOUS INFUSION OVER 1 HOUR REPEATED DAILY FOR 5 DAYS
D-124	ONCE DAILY DOSING REGIMEN IN ADULT PATIENTS WITH LESS THAN THREE LOPINAVIR RESISTANCE-ASSOCIATED SUBSTITUTIONS
D-125	EXTEND CURRENT DOSING REGIMEN TO 900MG (2-450MG TABLETS) ONCE A DAY WITHIN 10 DAYS OF TRANSPLANTATION UNTIL 200 DAYS POST-TRANSPLANTATION FOR THE PREVENTION OF CYTOMEGALOVIRUS (CMV) DISEASE IN ADULT KIDNEY TRANSPLANT PATIENTS AT HIGH RISK.
D-126	CHANGE DOSAGE REGIMEN FROM 250MG TO 500MG
D-127	DOSING REGIMEN FOR ADULT PATIENTS WITH CHRONIC HEPATITIS B (CHB) AND DECOMPENSATED LIVER DISEASE
D-128	SINGLE IV DOSE OF FOSAPREPITANT 150MG, DOSED CONCOMITANTLY WITH 5HT3 RECEPTOR ANTAGONIST & CORTICOSTEROID, FOR PREVENTION OF ACUTE & DELAYED NAUSEA & VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF HIGHLY EMETOGENIC CANCER CHEMO
D-129	800/100 MG DARUNAVIR/RITONAVIR, ONCE DAILY, IN TREATMENT-EXPERIENCED HIV-1 INFECTED PATIENTS WITH NO DARUNAVIR RESISTANCE ASSOCIATED SUBSTITUTIONS
D-130	DOSING RECOMMENDATIONS FOR TREATMENT OF HIV-1 INFECTION DURING PREGNANCY BASED ON DATA FROM STUDY AI424-182, A STUDY OF ATAZANAVIR/RITONAVIR IN COMBINATION WITH ZIDOVUDINE/LAMIVUDINE IN HIV INFECTED PREGNANT WOMEN
D-131	EVERY 6 TO 8 WEEKS FOR THE 120MG STRENGTH FOR PATIENTS WHO ARE CONTROLLED ON SOMATULINE DEPOT 60MG OR 90MG
D-132	45MG FOR 6 MONTH ADMINISTRATION
D-133	NEW EFFICACY DATA AND DOSING REGIMEN FOR PREGNANCY IN NORMAL OVULATORY WOMEN UNDERGOING CONTROLLED OVARIAN STIMULATION AS PART OF AN IVF OR INTRACYTOPLASMIC SPERM INJECTION (ICSI) CYCLE
D-134	INCREASING MAXIMUM DOSING OF PATIENTS WITH SCHIZOPHRENIA TO 160 MG/DAY
D-135	UPDATE LABELING WITH ONCE DAILY DOSING IN HIV-1 INFECTED, TREATMENT-NAIVE PEDIATRIC PATIENTS 12 TO LESS THAN 18 YEARS OF AGE
D-136	ALTERNATE DOSING REGIMEN FOR UNCOMPLICATED URETHRAL OR ENDOCERVICAL INFECTION CAUSED BY CHLAMYDIA TRACHOMATIS, ADMINISTER 200 MG BY MOUTH ONCE-A-DAY FOR 7 DAYS
D-137	NEW LOWER DOSING REGIMEN FOR REVATIO IN THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (WHO GROUP 1) IN ADULTS
D-138	80 MG DOSING REGIMEN FOR THE RISK REDUCTION OF REBLEEDING OF GASTRIC AND DUODENAL ULCERS IN THE FIRST 72 HOURS FOLLOWING THERAPEUTIC ENDOSCOPY IN ADULTS
D-139	ADDITIONAL INFORMATION ADDED TO THE DOSING AND ADMINISTRATION SECTION OF THE LABELING REGARDING THE ADMINISTRATION OF BRAVELLE AND MENOPUR IN THE SAME SYRINGE TO OVULATORY WOMEN AS PART OF AN ART CYCLE
D-140	REVISED DOSING SCHEDULE TO ADMINISTER AVANAFIL 15 MINUTES PRIOR TO SEXUAL ACTIVITY
D-141	DOSING INFORMATION IN PREVIOUSLY UNTREATED MANTLE CELL LYMPHOMA
D-142	DOSE MODIFICATION GUIDELINES FOR BORTEZOMIB WHEN GIVEN IN COMBINATION WITH RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, AND PREDNISONE
D-143	INITIATION OF VIMPAT THERAPY WITH A LOADING DOSE OF 200MG
D-144	LOWER LIMIT OF 15 MINUTES FOR THE INFUSION DURATION
D-145	UPDATES TO THE DOSAGE AND ADMINISTRATION SECTION OF THE LABELING TO REFLECT THE RESULTS OF TWO SHORT TERM STUDIES EVALUATING THE SAFETY AND EFFICACY OF INTUNIV IN CHILDREN AND ADOLESCENTS AGES 6 TO 17 WITH ADHD.

PATENT AND EXCLUSIVITY TERMS

ADB 6 of 191

EXCLUSIVITY DOSING SCHEDULE

D-146	CHANGE IN TARGET DOSING TO 20MG TO 40MG ORALLY ONCE DAILY
D-147	ONCE DAILY DOSING IN PEDIATRIC PATIENTS 3 MONTHS OF AGE AND OLDER IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS FOR THE TREATMENT OF HIV-1 INFECTION
D-148	EXTENDED THE DURATION OF THE DOSING REGIMEN FROM 100 DAYS TO 200 DAYS POST-TRANSPLANTATION FOR THE PREVENTION OF CMV DISEASE IN PEDIATRIC KIDNEY TRANSPLANT
D-149	DOSING INFORMATION ADDED TO THE LABELING REGARDING PEDIATRIC PATIENTS 6 YEARS AND OLDER WITH ITP
D-150	1600MG DAILY FOR PATIENTS ON ADJUNCTIVE THERAPY WHO DID NOT ACHIEVE A SATISFACTORY RESPONSE ON 1200MG DAILY DOSE
D-151	DOSING RECOMMENDATIONS FOR THE TREATMENT OF CHRONIC HEPATITIS C IN PATIENTS CO-INFECTED WITH HIV-1
D-152	DOSING RECOMMENDATIONS AS NECESSARY FOR FEVER AND PAIN FOR AGES 6MO TO LESS THAN 12 YEARS AND 12 TO 17 YEARS.
D-153	IN COMBINATION WITH RIBAVIRIN FOR 12 WEEKS, FOR THE TREATMENT OF GENOTYPE 1, CHRONIC HEPATITIS C TREATMENT EXPERIENCED PATIENTS WITH COMPENSATED CIRRHOSIS BASED UPON THE RESULTS OF THE SIRIUS STUDY
D-154	ADDITION OF A 1500MG-SINGLE-DOSE REGIMEN FOR THE TREATMENT OF ADULT PATIENTS WITH ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS (ABSSI)
D-155	SINGLE IV DOSE OF FOSAPREPITANT 150MG DOSED CONCOMITANTLY WITH 5HT3 RECEPTOR ANTAGONIST & CORTICOSTEROID FOR PREVENTION OF DELAYED NAUSEA AND VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF MODERATELY EMETOGENIC CANCER CHEMOTHERAPY
D-156	DOSING INFORMATION ADDED TO THE LABELING PROVIDING INFORMATION ON TRANSITIONING FROM SUBCUTANEOUS OR INTRAVENOUS ROUTES OF ADMINISTRATION OF TREPROSTINIL
D-157	UPDATED INFORMATION ADDED TO THE DOSAGE AND ADMINISTRATION SECTION OF THE LABELING PROVIDING DOSAGE RECOMMENDATIONS FOR INTERRUPTIONS AND DISCONTINUATION OF THERAPY
D-158	REVISED DOSING TO EXPAND PATIENT POPULATION TO INCLUDE LIVER TRANSPLANT RECIPIENTS WITH GENOTYPE 1 HCV INFECTION
D-159	REVISED DOSING TO EXPAND PATIENT POPULATION TO INCLUDE LIVER TRANSPLANT RECIPIENTS WITH GENOTYPE 4 HCV INFECTION
D-160	REVISED DOSING TO EXPAND PATIENT POPULATION TO INCLUDE PATIENTS WITH DECOMPENSATED CIRRHOSIS WITH GENOTYPE 1 HCV INFECTION
D-161	DOSAGE RECOMMENDATIONS ADDED TO INCLUDE TREATMENT OF HCV GENOTYPE 3 SUBJECTS CO-INFECTED WITH HIV-1
D-162	DOSING TO INCLUDE PATIENTS WITH CHRONIC HCV GENOTYPE 1 INFECTION WITH COMPENSATED (CHILD-PUGH A) OR DECOMPENSATED (CHILD-PUGH B OR C) CIRRHOSIS AND TREATMENT OF CHRONIC HCV GENOTYPE 3 INFECTION IN SUBJECTS WITH DECOMPENSATED (CHILD-PUGH B OR C) CIRRHOSIS
D-163	DOSING TO INCLUDE PATIENTS WITH CHRONIC HCV GENOTYPE 1A INFECTION WITH COMPENSATED (CHILD-PUGH A) CIRRHOSIS AND GENOTYPE 1B WITH OR WITHOUT COMPENSATED (CHILD-PUGH A) CIRRHOSIS
D-164	UPDATES TO THE DOSAGE AND ADMINISTRATION, DOSE MODIFICATIONS SECTION OF THE LABELING
D-165	DOSING RECOMMENDATION ADDED TO THE LABELING FOR IMBRUVICA USE IN COMBINATION WITH BENDAMUSTINE AND RITUXIMAB FOR THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LEUKEMIA (SLL)
D-166	BROADEN INITIAL STARTING DOSE FOR BIPOLAR I DISORDER TO 5-10MG TWICE DAILY
D-167	ADDITION OF 1200 MG ONCE DAILY DOSING FOR TREATMENT-NAIVE PATIENTS OR PATIENTS WHO ARE VIROLOGICALLY SUPPRESSED ON AN INITIAL REGIMEN OF RALTEGRAVIR FILM-COATED TABLETS 400 MG TWICE DAILY
D-168	NEW DOSING REGIMEN OF 10 MG ONCE DAILY FOR THE REDUCTION IN THE RISK OF RECURRENCE OF DEEP VEIN THROMBOSIS (DVT) AND/OR PULMONARY EMBOLISM (PE) IN PATIENTS AT CONTINUED RISK FOR DVT AND/OR PE AFTER COMPLETION OF INITIAL TREATMENT LASTING AT LEAST 6 MONTHS
D-169	ONCE-DAILY DOSING FOR PATIENTS 5 YEARS OF AGE AND OLDER WHO HAVE UNDETECTABLE SERUM AND URINE SUCCINYLACETONE CONCENTRATIONS AFTER A MINIMUM OF 4 WEEKS ON A STABLE DOSAGE OF NITISINONE

PATENT AND EXCLUSIVITY TERMS

ADB 7 of 191

EXCLUSIVITY DOSING SCHEDULE

D-170	TO ALLOW WITHDRAWAL THERAPY OF PATIENTS WITH PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE WHO HAVE ACHIEVED A SUSTAINED MOLECULAR RESPONSE ON NILOTINIB THERAPY FOR A MINIMUM OF ONE YEAR PRIOR TO DISCONTINUATION
D-171	REVISED DOSING TO INCLUDE UP-TITRATION AS A STRATEGY TO IMPROVE TOLERABILITY AND THEREBY REDUCE TREATMENT DISCONTINUATION FOR ROFLUMILAST MAINTENANCE DOSAGE OF 500 MCG DAILY
D-172	ADDITION OF A ONCE WEEKLY DOSING REGIMEN FOR CARFILZOMIB IN COMBINATION WITH DEXAMETHASONE FOR PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED ONE TO THREE LINES OF THERAPY
D-173	DOSING RECOMMENDATION FOR THE USE OF ELVITEGRAVIR/COBICISTAT/EMTRICITABINE/TENOFOVIR ALAFENAMIDE FIXED DOSE COMBINATION IN HIV-1 INFECTED ADULT PATIENTS WITH END-STAGE-RENAL DISEASE WHO ARE RECEIVING CHRONIC HEMODIALYSIS
D-174	MODIFICATIONS TO THE EXISTING DOSING REGIMEN TO ALLOW FOR TREATMENT INTERRUPTIONS OF UP TO 8 WEEKS FOR INTOLERABLE ADVERSE REACTIONS
D-175	EIGHT-WEEK DOSING REGIMEN FOR THE TREATMENT OF GENOTYPES 1, 2, 3, 4, 5, AND 6, CHRONIC HEPATITIS C VIRUS INFECTION IN TREATMENT-NAIVE SUBJECTS WITH COMPENSATED CIRRHOSIS BASED ON THE RESULTS FROM THE EXPEDITION-8 STUDY
D-176	IBRUTINIB IN COMBINATION WITH RITUXIMAB
D-177	INFORMATION ADDED TO THE DOSING SECTION IN REGARD TO THE TREATMENT OF CHRONIC HEPATITIS C VIRUS INFECTION IN PATIENTS WITH SEVERE RENAL IMPAIRMENT INCLUDING PATIENTS WITH END STAGE RENAL DISEASE ON DIALYSIS
D-181	DOSING REGIMEN EXTENDING THE CONTRACEPTION USE FROM 5 YEARS TO UP TO 6 YEARS
D-182	NEW DOSING REGIMEN FOR THE PREVENTION AND MANAGEMENT OF NERATINIB ASSOCIATED DIARRHEA
D-183	3-DAY DOSING REGIMEN FOR THE TREATMENT OF COVID-19 IN ADULTS AND PEDIATRIC PATIENTS (>12 YEARS AND WEIGHING AT LEAST 40 KG) WITH POSITIVE RESULTS OF DIRECT SARS-COV-2 VIRAL TESTING, WHO ARE NOT HOSPITALIZED AND HAVE MILD-TO-MODERATE COVID-19, AND ARE AT HIGH RISK FOR PROGRESSION TO SEVERE COVID-19, INCLUDING HOSPITALIZATION OR DEATH
D-184	NEW DOSING SCHEDULE FOR CABOTEGRAVIR/RILPIVRINE INJECTION EVERY 2 MONTHS
D-185	ADDITION OF A 3RD MAINTENANCE DOSE OF SEMAGLUTIDE
D-186	ADDITION OF A 3-DAY FOSAPREPITANT FOR INJECTION INTRAVENOUS DOSING REGIMEN IN PEDIATRIC PATIENTS FOR THE CURRENTLY APPROVED PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING

EXCLUSIVITY INDICATION

I-1	DYSMENORRHEA
I-2	CHOLANGIOPANCREATOGRAPHY
I-3	INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY
I-4	PERIPHERAL VENOGRAPHY (PHLEBOGRAPHY)
I-5	HYSTEOSALPINGOGRAPHY
I-6	TREATMENT OF JUVENILE ARTHRITIS
I-7	BIOPSY PROVEN MINIMAL CHANGE NEPHROTIC SYNDROME IN CHILDREN
I-8	ADULT INTRAVENOUS CONTRAST-ENHANCED COMPUTED TOMOGRAPHY OF THE HEAD AND BODY
I-9	PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING
I-10	PREVENTION OF POSTOPERATIVE DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM IN TOTAL HIP REPLACEMENT SURGERY
I-11	RELIEF OF MILD TO MODERATE PAIN
I-12	TREATMENT OF CUTANEOUS CANDIDIASIS
I-13	URINARY TRACT INFECTION (UTI) PREVENTION FOR PERIODS UP TO FIVE MONTHS IN WOMEN WITH A HISTORY OF RECURRENT UTI
I-14	SEBORRHEIC DERMATITIS

PATENT AND EXCLUSIVITY TERMS

ADB 8 of 191

EXCLUSIVITY INDICATION

I-15	PHOTOPHERESIS IN THE PALLIATIVE TREATMENT OF SKIN MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PERSONS NOT RESPONSIVE TO OTHER TREATMENT
I-16	STIMULATE THE DEVELOPMENT OF MULTIPLE FOLLICLES/OOCYTES IN OVULATORY PATIENTS PARTICIPATING IN AN IN VITRO FERTILIZATION PROGRAM
I-17	MANAGEMENT OF CONGESTIVE HEART FAILURE
I-18	ENDOSCOPIC RETROGRADE PANCREATOGRAPHY
I-19	HERNIOGRAPHY
I-20	KNEE ARTHROGRAPHY
I-21	HIGH DOSE METHOTREXATE WITH LEUCOVORIN RESCUE IN COMBINATION WITH OTHER CHEMOTHERAPEUTIC AGENTS TO DELAY RECURRENCE IN PATIENTS WITH NONMETASTATIC OSTEOSARCOMA WHO HAVE UNDERGONE SURGICAL RESECTION OR AMPUTATION FOR THE PRIMARY TUMOR
I-22	RESCUE AFTER HIGH-DOSE METHOTREXATE THERAPY IN OSTEOSARCOMA
I-23	SHORT-TERM TREATMENT OF ACTIVE BENIGN GASTRIC ULCER
I-24	TREATMENT OF RHEUMATOID ARTHRITIS
I-25	ADULT INTRA-ARTERIAL DIGITAL SUBTRACTION ANGIOGRAPHY OF THE HEAD, NECK, ABDOMINAL, RENAL AND PERIPHERAL VESSELS
I-26	TREATMENT OF LIVER FLUKES
I-27	ADJUNCTIVE THERAPY TO DIET TO REDUCE THE RISK OF CORONARY ARTERY DISEASE
I-28	SELECTIVE ADULT VISCERAL ARTERIOGRAPHY
I-29	METASTATIC BREAST CANCER IN PREMENOPAUSAL WOMEN AS AN ALTERNATIVE TO OOPHORECTOMY OR OVARIAN IRRADIATION
I-30	TREATMENT OF TINEA PEDIS
I-31	CONTRAST ENHANCEMENT AGENT TO FACILITATE VISUALIZATION OF LESIONS IN THE SPINE AND ASSOCIATED TISSUES
I-32	PEDIATRIC MYELOGRAPHY
I-33	ORAL USE OF DILUTED OMNIPAQUE INJECTION IN ADULTS FOR CONTRAST ENHANCED COMPUTED TOMOGRAPHY OF THE ABDOMEN
I-34	ORAL USE IN ADULTS FOR PASS-THROUGH EXAMINATION OF THE GASTROINTESTINAL TRACT
I-35	PEDIATRIC CONTRAST ENHANCEMENT OF COMPUTED TOMOGRAPHIC HEAD IMAGING
I-36	ARTHROGRAPHY OF THE SHOULDER JOINTS IN ADULTS
I-37	RADIOGRAPHY OF THE TEMPOROMANDIBULAR JOINT IN ADULTS
I-38	CONTRAST ENHANCEMENT AGENT TO FACILITATE VISUALIZATION OF LESIONS OF THE CENTRAL NERVOUS SYSTEM IN CHILDREN (2 YEARS OF AGE AND OLDER)
I-39	TREATMENT OF ACUTE MYOCARDIAL INFARCTION
I-40	PRIMARY NOCTURNAL ENURESIS
I-41	MIGRAINE HEADACHE PROPHYLAXIS
I-42	HERPES ZOSTER
I-43	HERPES SIMPLEX ENCEPHALITIS
I-44	MAINTENANCE THERAPY IN HEALED DUODENAL ULCER PATIENTS AT DOSE OF 1 GRAM TWICE DAILY
I-45	ACUTE TREATMENT OF VARICELLA ZOSTER VIRUS
I-46	USE IN PEDIATRIC COMPUTED TOMOGRAPHIC HEAD AND BODY IMAGING
I-47	TREATMENT OF PEDIATRIC PATIENTS WITH SYMPTOMATIC HUMAN IMMUNODEFICIENCY VIRUS (HIV) DISEASE
I-48	PEDIATRIC ANGIOCARDIOGRAPHY
I-49	TREATMENT OF TRAVELERS' DIARRHEA DUE TO SUSCEPTIBLE STRAINS OF ENTEROTOXIGENIC ESCHERICHIA COLI
I-50	FOR USE IN WOMEN WITH AXILLARY NODE-NEGATIVE BREAST CANCER
I-51	TREATMENT OF PRIMARY DYSMENORRHEA AND FOR THE TREATMENT OF IDIOPATHIC HEAVY MENSTRUAL BLOOD LOSS

PATENT AND EXCLUSIVITY TERMS

ADB 9 of 191

EXCLUSIVITY INDICATION

I-52	PEDIATRIC EXCRETORY UROGRAPHY
I-53	TREATMENT OF PANIC DISORDER, WITH OR WITHOUT AGORAPHOBIA
I-54	RENAL CONCENTRATION CAPACITY TEST
I-55	HYPERTENSION
I-56	EROSIVE GASTROESOPHAGEAL REFLUX DISEASE
I-57	SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER
I-58	INITIAL TREATMENT OF ADVANCED OVARIAN CARCINOMA IN COMBINATION WITH OTHER APPROVED CHEMOTHERAPEUTIC AGENTS
I-59	ENDOSCOPICALLY DIAGNOSED ESOPHAGITIS, INCLUDING EROSION AND ULCERATIVE ESOPHAGITIS, AND ASSOCIATED HEARTBURN DUE TO GASTROESOPHAGEAL REFLUX DISEASE
I-60	SINGLE APPLICATION TREATMENT OF HEAD LICE IN CHILDREN TWO MONTHS TO TWO YEARS IN AGE
I-61	FEMALE ANDROGENETIC ALOPECIA
I-62	PREVENTION AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
I-63	ONCE DAILY TREATMENT AS INITIAL THERAPY IN THE TREATMENT OF HYPERTENSION
I-64	PREVENTION OF SUPRAVENTRICULAR TACHYCARDIAS
I-65	PREVENTION OF UPPER GASTROINTESTINAL BLEEDING IN CRITICALLY ILL PATIENTS
I-66	UNCOMPLICATED GONORRHEA
I-67	TREATMENT OF ACUTE ASTHMATIC ATTACKS IN CHILDREN SIX YEARS OF AGE AND OLDER
I-68	CENTRAL PRECOCIOUS PUBERTY
I-69	SHORT TERM TREATMENT OF PATIENTS WITH SYMPTOMS OF GASTROESOPHAGEAL REFLUX DISEASE (GERD), AND FOR THE SHORT TERM TREATMENT OF ESOPHAGITIS DUE TO GERD INCLUDING ULCERATIVE DISEASE DIAGNOSED BY ENDOSCOPY
I-70	USE IN COMBINATION WITH 5-FLUOROURACIL TO PROLONG SURVIVAL IN THE PALLIATIVE TREATMENT OF PATIENTS WITH ADVANCED COLORECTAL CANCER
I-71	VARICELLA INFECTIONS (CHICKENPOX)
I-72	PREVENTION OF CMV DISEASE IN TRANSPLANT PATIENTS AT RISK FOR CMV DISEASE
I-73	INITIATE AND MAINTAIN MONITORED ANESTHESIA CARE (MAC) SEDATION DURING DIAGNOSTIC PROCEDURES
I-74	INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY
I-75	TREATMENT OF ENDOSCOPICALLY DIAGNOSED EROSION ESOPHAGITIS
I-76	PREVENTION OF OSTEOPOROSIS
I-77	DERMAL INFECTIONS-TINEA PEDIS, TINEA CORPORIS, TINEA CRURIS DUE TO EPIDERMOPHYTON FLOCCOSUM
I-78	CONTRAST ENHANCED COMPUTED TOMOGRAPHIC IMAGING OF THE HEAD AND BODY AND INTRAVENOUS EXCRETORY UROGRAPHY
I-79	MANAGEMENT OF CHRONIC STABLE ANGINA AND ANGINA DUE TO CORONARY ARTERY SPASM
I-80	DIAGNOSIS AND LOCALIZATION OF ISCHEMIA AND CORONARY HEART DISEASE
I-81	PROPHYLAXIS IN DESIGNATED IMMUNOCOMPROMISED CONDITIONS TO REDUCE THE INCIDENCE OF OROPHARYNGEAL CANDIDIASIS
I-82	TREATMENT OF TRAVELERS' DIARRHEA
I-83	ANGIOCARDIOGRAPHY, CONTRAST ENHANCED COMPUTED TOMOGRAPHIC IMAGING OF THE HEAD AND BODY, AND INTRAVENOUS EXCRETORY UROGRAPHY IN CHILDREN
I-84	INTRAOPERATIVE AND POSTOPERATIVE TACHYCARDIA AND/OR HYPERTENSION
I-85	TREATMENT OF ANOREXIA ASSOCIATED WITH WEIGHT LOSS IN PATIENTS WITH AIDS
I-86	TREATMENT OF SECONDARY CARNITINE DEFICIENCY
I-87	RENAL IMAGING AGENT FOR USE IN CHILDREN
I-88	MANAGEMENT OF ENDOMETRIOSIS
I-89	EPIDURAL USE IN LABOR AND DELIVERY AS AN ANALGESIC ADJUNCT TO BUPIVACAINE
I-90	INTENSIVE CARE UNIT SEDATION

PATENT AND EXCLUSIVITY TERMS

ADB 10 of 191

EXCLUSIVITY INDICATION

I-91	MONOTHERAPY USE FOR HYPERTENSION
I-92	ADJUNCTIVE THERAPY IN THE MANAGEMENT OF HEART FAILURE
I-93	PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN CHILDREN AGES 4-11 YEARS
I-94	USE WITH MRI IN ADULTS TO PROVIDE CONTRAST ENHANCEMENT AND FACILITATE VISUALIZATION OF LESIONS IN THE BODY [EXCLUDING THE HEART]
I-95	TREATMENT OF LEFT VENTRICULAR DYSFUNCTION FOLLOWING MYOCARDIAL INFARCTION
I-96	TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA
I-97	ORAL OR RECTAL USE IN CHILDREN FOR THE EXAMINATION OF THE GASTROINTESTINAL TRACT
I-98	TREATMENT OF CHILDREN WHO HAVE GROWTH FAILURE ASSOCIATED WITH CHRONIC RENAL INSUFFICIENCY
I-99	PEDIATRIC ANESTHESIA IN CHILDREN 3 YEARS AND OLDER
I-100	TO DECREASE THE INCIDENCE OF CANDIDIASIS IN PATIENTS UNDERGOING BONE MARROW TRANSPLANTATION WHO RECEIVE CYTOTOXIC CHEMOTHERAPY AND/OR RADIATION THERAPY
I-101	TREATMENT OF DIABETIC NEPHROPATHY IN PATIENTS WITH TYPE I INSULIN-DEPENDENT DIABETES MELLITUS AND RETINOPATHY
I-102	TREATMENT OF OBSESSIVE-COMPULSIVE DISORDER
I-103	PROPHYLAXIS AGAINST PNEUMOCYSTIS CARINII PNEUMONIA IN INDIVIDUALS WHO ARE IMMUNOCOMPROMISED AND CONSIDERED TO BE AT RISK OF DEVELOPING PNEUMOCYSTIS CARINII PNEUMONIA
I-104	TREATMENT OF PULMONARY AND EXTRAPULMONARY ASPERGILLOSIS IN PATIENTS WHO ARE INTOLERANT OF OR WHO ARE REFRACTORY TO AMPHOTERICIN B THERAPY
I-105	TREATMENT OF METASTATIC CARCINOMA OF THE BREAST AFTER FAILURE OF FIRST-LINE OR SUBSEQUENT CHEMOTHERAPY
I-106	TREATMENT OF ACROMEGALY
I-107	VAGINAL CANDIDIASIS
I-108	EXPANDED USE-FOR ICU PATIENTS UNDERGOING LONG-TERM INFUSION DURING MECHANICAL VENTILATION
I-109	TYPHOID FEVER
I-110	PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH RADIOTHERAPY
I-111	TREATMENT OF PAGET'S DISEASE OF BONE
I-112	MANAGEMENT OF MODERATE TO SEVERE PAIN
I-113	TREATMENT OF PROSTATITIS
I-114	USE IN CHILDREN TO VISUALIZE LESIONS WITH ABNORMAL VASCULARITY IN THE BRAIN (INTRACRANIAL LESIONS), SPINE, AND ASSOCIATED TISSUE
I-115	USE IN MRI IN ADULTS TO VISUALIZE LESIONS IN THE HEAD AND NECK
I-116	MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS
I-117	TO SLOW THE PROGRESSION OF CORONARY ATHEROSCLEROSIS IN PATIENTS WITH CORONARY HEART DISEASE
I-118	PREVENTION OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM FOLLOWING KNEE REPLACEMENT SURGERY
I-119	TREATMENT OF ANEMIA CAUSED BY UTERINE LEIOMYOMATA IN WOMEN WHO FAIL IRON THERAPY
I-120	MAINTENANCE THERAPY FOR GASTRIC ULCER PATIENTS AT REDUCED DOSAGE AFTER HEALING ACUTE ULCERS
I-121	EXPANDED PATIENT POPULATION -- USE IN ICU PATIENTS
I-122	PSORIASIS OF THE SCALP
I-123	RELIEF OF MILD TO MODERATE PAIN IN PATIENTS AGED 6 MONTHS AND OLDER
I-124	LEUKOCYTE LABELED SCINTIGRAPHY AS AN ADJUNCT IN THE LOCALIZATION OF INTRA-ABDOMINAL INFECTION AND INFLAMMATORY BOWEL DISEASE
I-125	EXPANSION OF CONSCIOUS SEDATION INDICATION TO INCLUDE SHORT THERAPEUTIC PROCEDURES
I-126	ADJUNCT TO THALLIUM- 201 MYOCARDIAL PERFUSION IN PATIENTS UNABLE TO EXERCISE ADEQUATELY

PATENT AND EXCLUSIVITY TERMS

ADB 11 of 191

EXCLUSIVITY INDICATION

I-127	TREATMENT OF ACYCLOVIR-RESISTANT HERPES IN IMMUNOCOMPROMISED PATIENTS
I-128	IN PT W/ CH DISEASE AND HYPERCHOLESTEROLEMIA; REDUCE RISK TOTAL MORTALITY BY REDUCING CORONARY DEATH; REDUCE RISK NON-FATAL MI; REDUCE RISK UNDERGOING MYOCARDIAL REVASCULARIZATION PROCEDURES; REDUCTION ELEVATED TOTAL AND LDL CHOL LEVELS...
I-129	TREATMENT OF ALCOHOL DEPENDENCE
I-130	MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS
I-131	PERIPHERAL ARTERIOGRAPHY
I-132	TREATMENT OF MANIC PHASE OF BIPOLAR DISORDER
I-133	MANAGEMENT OF CHRONIC STABLE ANGINA
I-134	HEART FAILURE POST MYOCARDIAL INFARCTION
I-135	BONE METASTASES ASSOCIATED WITH MULTIPLE MYELOMA
I-136	IDIOPATHIC CHRONIC URTICARIA
I-137	PREVENTION OF METAL-INDUCED HEART BURN, ACID INDIGESTION, AND SOUR STOMACH WHEN TAKEN 30 MINUTES PRIOR TO CONSUMING FOOD OR BEVERAGES
I-138	TREATMENT OF ACUTE RECURRENT GENITAL HERPES
I-139	PALLIATIVE TREATMENT OF ADVANCED BREAST CANCER IN PRE- AND PERIMENOPAUSAL WOMEN
I-140	PREVENTION OF CYTOMEGALOVIRUS (CMV) DISEASE IN INDIVIDUALS WITH HIV INFECTION AT RISK FOR DEVELOPING CMV DISEASE
I-141	TREATMENT OF HEMODYNAMICALLY STABLE PATIENTS WITHIN 24 HOURS OF ACUTE MYOCARDIAL INFARCTION TO IMPROVE SURVIVAL
I-142	LOCALIZE MYOCARDIAL ISCHEMIA(REVERSIBLE DEFECT) AND INFARCTION (NON-REVERSIBLE DEFECTS) IN EVALUATING MYOCARDIAL FUNCTION
I-143	EPISODIC TREATMENT OF RECURRENT GENITAL HERPES IN IMMUNOCOMPETENT ADULTS
I-144	ENHANCEMENT OF MRI OF THE ADULT BODY INTERNAL ORGANS
I-145	0.1MMOL/KG AS A SINGLE INTRAVENOUS BOLUS FOR MRI OF THE CNS IN CHILDREN
I-146	CONTRAST ENHANCEMENT AND FACILITATION OF VISUALIZATION OF EXTRACRANIAL HEAD AND NECK LESIONS
I-147	PREVENTION OF GALLSTONE FORMATION IN OBESE PATIENTS EXPERIENCING RAPID WEIGHT LOSS
I-148	TREATMENT OF ACUTE PNEUMOCYSTIS CARINI PNEUMONIA (PCP) IN HIV-INFECTED PATIENTS WHOSE ALVEOLAR-ARTERIAL OXYGEN DIFFERENCE (AaDO ₂) IS LESS THAN OR EQUAL TO 55 TORR
I-149	TREATMENT OF PATIENTS WITH NON-SMALL CELL LUNG CANCER
I-150	TREATMENT OF OBSESSIVE COMPULSIVE DISORDER AND PANIC DISORDER
I-151	PREVENTION OF AND PREVENTION OF FURTHER POSTOPERATIVE NAUSEA AND VOMITING IN PEDIATRIC PATIENTS RECEIVING GENERAL ANESTHESIA
I-152	SLOWING THE PROGRESSION OF CORONARY ATHEROSCLEROSIS AND REDUCING THE RISK OF ACUTE CORONARY EVENTS
I-153	MANAGEMENT OF SEVERE SPASTICITY [ENCOMPASSES SPINAL AND CEREBRAL ORIGIN]
I-154	PATIENT POPULATION ALTERED TO INCLUDE PEDIATRIC USE
I-155	TREATMENT OF ONYCHOMYCOSIS DUE TO DERMATOPHYTES (TINEA UNGUIUM) OF THE TOENAIL WITH OR WITHOUT FINGERNAIL INVOLVEMENT
I-156	ADDITIONAL DATA REGARDING THE SAFE USE OF NORVASC IN PATIENTS WITH HEART FAILURE
I-157	TREATMENT OF ACUTE UNCOMPLICATED CYSTITIS IN FEMALES
I-158	TREATMENT OF OSTEOLYTIC BONE METASTASES OF BREAST CANCER
I-159	FOR HYPERCHOLESTEROLEMIC PATIENTS WITHOUT CLINICALLY EVIDENT HEART DISEASE REDUCE THE RISK OF MYOCARDIAL INFARCTION, REVASCULARIZATION, AND DEATH DUE TO CARDIOVASCULAR CAUSES WITH NO INCREASE IN DEATH FROM NON-CARDIOVASCULAR CAUSES
I-160	TREATMENT OF BACTERIAL CORNEAL ULCERS
I-161	TREATMENT OF ADULT-ONSET OR CHILDHOOD-ONSET ADULT GROWTH HORMONE DEFICIENCY
I-162	FOR USE IN PATIENTS 6-11 YEARS OF AGE

PATENT AND EXCLUSIVITY TERMS

ADB 12 of 191

EXCLUSIVITY INDICATION

I-163	TREATMENT OF PHOTOPHOBIA
I-164	CHRONIC BACTERIAL PROSTATITIS
I-165	MANAGEMENT OF ADULTS WITH ACTIVE, CLASSIC AND DEFINITIVE RHEUMATOID ARTHRITIS WHO HAVE HAD INSUFFICIENT THERAPEUTIC RESPONSE TO OR ARE INTOLERANT OF AN ADEQUATE TRIAL OF FULL DOSES OF ONE OR MORE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS
I-166	TREATMENT OF BULIMIA
I-167	COMPLICATED INTRA-ABDOMINAL INFECTIONS (USED IN COMBINATION WITH METRONIDAZOLE) CAUSED BY MIXED AEROBIC/ANAEROBIC PATHOGENS
I-168	MANAGEMENT OF LOCALLY CONFINED STAGE B2-C METASTATIC CARCINOMA OF THE PROSTATE (IN COMBINATION WITH LHRH AGONISTS)
I-169	USE IN COMBINATION WITH CORTICOSTEROIDS AS INITIAL CHEMOTHERAPY FOR THE TREATMENT OF PATIENTS WITH PAIN RELATED TO ADVANCED HORMONE-REFRACTORY PROSTATE CANCER
I-170	PROPHYLACTIC USE DURING HEAD LICE EPIDEMICS
I-171	RELIEF OF SYMPTOMS OF THE COMMON COLD
I-172	TREATMENT OF INITIAL EPISODE OF GENITAL HERPES
I-173	PREOPERATIVELY FOR THE PREVENTION OF INFECTION IN TRANSRECTAL PROSTATE BIOPSY
I-174	PELVIC INFLAMMATORY DISEASE
I-175	TREATMENT OF TINEA CORPORIS AND TINEA CRURIS
I-176	TREATMENT OF POSTOPERATIVE INFLAMMATION IN PATIENTS WHO HAVE UNDERGONE CATARACT EXTRACTION
I-177	TX OF MODERATE ACNE VULGARIS IN FEMALES, GREATER OR EQUAL TO 15YRS OF AGE, WHO HAVE NO KNOWN CONTRAINDICATIONS TO ORAL CONTRACEPTIVE THERAPY, DESIRE CONTRACEPTION, HAVE ACHIEVED MENARCHE AND ARE UNRESPONSIVE TO TOPICAL ANTI-ACNE MEDICATIONS
I-178	TREATMENT OF ONYCHOMYCOSIS OF THE FINGERNAIL WITHOUT CONCOMITANT ONCHOMYCOSIS OF THE TOENAIL WITH A PULSE DOSING REGIMEN
I-179	NOSOCOMIAL PNEUMONIA-MILD TO MODERATE AND SEVERE CAUSED BY HAEMOPHILUS INFLUENZAE OR KLEBSIELLA PNEUMONIAE
I-180	TREATMENT OF PLANTAR TINEA PEDIS (MOCCASIN TYPE)
I-181	TREATMENT OF PATIENTS WITH COMPLEX PARTIAL SEIZURES WITH AND WITHOUT SECONDARY GENERALIZATION
I-182	TREATMENT OF GROWTH FAILURE ASSOCIATED WITH TURNER SYNDROME
I-183	MAINTENANCE THERAPY IN THE MANAGEMENT OF MILD TO MODERATE ASTHMA IN PEDIATRIC PATIENTS AGES 6-11
I-184	TREATMENT OF PANIC DISORDER AT A RECOMMENDED DOSE RANGE OF 1 TO 2MG/DAY (MAXIMUM OF 4MG)
I-185	PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
I-186	TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR CAUSED BY OR PRESUMED TO BE CAUSED BY PITYROSPORUM ORBICULARE (ALSO KNOWN AS MALASSEZIA FURFUR OR M. ORBICULARE)
I-187	PREVENTION OF FRACTURES IN THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
I-188	TREATMENT OF ACUTE SINUSITIS AND ACUTE EXACERBATION OF CHRONIC SINUSITIS
I-189	TREATMENT OF ACUTE OTITIS MEDIA IN PEDIATRIC PATIENTS
I-190	PLANAR IMAGING AS A SECOND LINE DIAGNOSTIC DRUG AFTER MAMMOGRAPHY TO ASSIST IN THE EVALUATION OF BREAST LESIONS IN PATIENTS WITH AN ABNORMAL MAMMOGRAM OR A PALPABLE BREAST MASS
I-191	ENDOMETRIAL THINNING AGENT PRIOR TO ENDOMETRIAL ABLATION FOR DYSFUNCTIONAL UTERINE BLEEDING
I-192	THE PREVENTION OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING ABDOMINAL SURGERY WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS AND A NEW DOSAGE REGIMEN, 40MG ONCE DAILY, FOR THIS INDICATION
I-193	TREATMENT OF PANIC DISORDER IN A RECOMMENDED DOSE RANGE OF 50 TO 200MG/DAY
I-194	CONGESTIVE HEART FAILURE

PATENT AND EXCLUSIVITY TERMS

ADB 13 of 191

EXCLUSIVITY INDICATION

I-195	FOR USE OF LANSOPRAZOLE IN COMBINATION WITH CLARITHROMYCIN AND AMOXICILLIN FOR THE ERADICATION OF HELICOBACTER PYLORI IN PATIENTS WITH ACTIVE DUODENAL ULCER DISEASE OR A ONE-YEAR HISTORY OF DUODENAL ULCER
I-196	ACUTE TREATMENT OF ACTIVE BENIGN GASTRIC ULCER
I-197	MAINTENANCE OF HEALING OF DUODENAL ULCER
I-198	FOR THE USE OF LANSOPRAZOLE IN COMBINATION WITH AMOXICILLIN FOR THE ERADICATION OF HELICOBACTER PYLORI IN PATIENTS WITH ACTIVE DUODENAL ULCER DISEASE OR A ONE-YEAR HISTORY OF A DUODENAL ULCER
I-199	MONOTHERAPY AND COMBINATION THERAPY WITH SULFONYLUREA IN THE TREATMENT OF TYPE II DIABETES
I-200	TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR
I-201	EMPIRICAL THERAPY FOR FEBRILE NEUTROPENIC PATIENTS
I-202	SECOND-LINE TREATMENT OF AIDS-RELATED KAPOSI'S SARCOMA
I-203	MAINTENANCE OF REMISSION OF ULCERATIVE COLITIS
I-204	USE IN PEDIATRIC PATIENTS BETWEEN THE AGES OF 6 AND 11 FOR THE TREATMENT OF THE NASAL SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS
I-205	INITIAL ANTICONVULSANT TREATMENT OF STATUS EPILEPTICUS
I-206	TREATMENT OF EDEMA ASSOCIATED WITH CHRONIC RENAL FAILURE
I-207	FOR THE SUPPRESSION OF RECURRENT EPISODES OF GENITAL HERPES IN IMMUNOCOMPETENT ADULTS
I-208	TREATMENT OF OBSESSIVE COMPULSIVE DISORDER IN THE PEDIATRIC POPULATION
I-209	PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA (PSVT)
I-210	TO SLOW THE PROGRESSION OF CORONARY ATHEROSCLEROSIS IN PATIENTS WITH CORONARY HEART DISEASE AS PART OF A TREATMENT STRATEGY TO LOWER TOTAL AND LDL CHOLESTEROL TO TARGET LEVELS
I-211	FOR USE IN PEDIATRIC POPULATION
I-212	TREATMENT OF SYMPTOMS OF DRY MOUTH IN PATIENTS WITH SJOGREN'S SYNDROME
I-213	TEMPORARY RELIEF OF PAIN AND PHOTOPHOBIA IN PATIENTS UNDERGOING CORNEAL REFRACTIVE SURGERY
I-214	TREATMENT OF OSTEOPOROSIS
I-215	PRE-PROCEDURAL APPLICATION TO ADULT MALE GENITAL SKIN PRIOR TO SITE-SPECIFIC SUBCUTANEOUS INFILTRATION WITH LIDOCAINE FOR THE REMOVAL OF GENITAL WARTS
I-216	FOR THE LONG-TERM TWICE-DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD, INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA
I-217	PREVENTION (DURING AND FOLLOWING HOSPITALIZATION) OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING HIP REPLACEMENT SURGERY
I-218	USE OF LIPITOR AS AN ADJUNCTIVE THERAPY TO DIET FOR THE TREATMENT OF PATIENTS WITH ELEVATED SERUM TRIGLYCERIDE LEVELS (FREDERICKSON TYPE IV)
I-219	USE OF LIPITOR BY PATIENTS WITH PRIMARY DYSBETALIPOPROTEINEMIA (FREDERICKSON TYPE III) WHO DO NOT RESPOND ADEQUATELY TO DIET
I-220	TREATMENT OF EPISODIC- HEARTBURN, ACID INDIGESTION AND SOUR STOMACH
I-221	TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH) IN MEN WITH AN ENLARGED PROSTATE TO IMPROVE SYMPTOMS, REDUCE THE RISK OF ACUTE URINARY RETENTION AND REDUCE THE RISK OF THE NEED OF SURGERY
I-222	PREVENTION OF ISCHEMIC COMPLICATIONS OF UNSTABLE ANGINA AND NON-Q-WAVE MYOCARDIAL INFARCTION, WHEN CONCURRENTLY ADMINISTERED WITH ASPIRIN
I-223	USE IN THE SYMPTOMATIC RELIEF OF RHINORRHEA ASSOCIATED WITH ALLERGIC AND NONALLERGIC-PERENNIAL RHINITIS IN CHILDREN AGE 6-11 YEARS
I-224	FOR THE USE IN PEDIATRIC PATIENTS 4 TO 11 YEARS OF AGE FOR THE MANAGEMENT OF THE NASAL SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS
I-225	USE IN PATIENTS WITH PREVIOUS MI AND NORMAL CHOLESTEROL LEVELS, TO REDUCE RISK OF RECURRENT MI, MYOCARDIAL REVASCULARIZATION, AND CEREBROVASCULAR DISEASE EVENTS

PATENT AND EXCLUSIVITY TERMS

ADB 14 of 191

EXCLUSIVITY INDICATION

I-226	FIRST-LINE THERAPY FOR THE TREATMENT OF ADVANCED CARCINOMA OF THE OVARY IN COMBINATION WITH CISPLATIN
I-227	SHORT-TERM TREATMENT OF SYMPTOMATIC GASTROESOPHAGEAL REFLUX DISEASE (GERD)
I-228	PREVENTION OF MEAL INDUCED HEARTBURN AT A DOSE OF 75MG TAKEN 30-60MIN PRIOR TO A MEAL
I-229	PRILOSEC (OMEPRAZOLE), AMOXICILLIN, AND CLARITHROMYCIN FOR THE ERADICATION OF H. PYLORI IN PATIENTS WITH DUODENAL ULCER DISEASE
I-230	IN COMBINATION WITH CIS-PLATIN, FOR THE FIRST LINE TREATMENT OF NON-SMALL CELL LUNG CANCER IN PATIENTS WHO ARE NOT CANDIDATES FOR POTENTIALLY CURATIVE SURGERY AND/OR RADIATION
I-231	TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC BREAST CANCER AFTER FAILURE OF PRIOR CHEMOTHERAPY
I-232	TREATMENT OF RECURRENT MUCOCUTANEOUS HERPES SIMPLEX INFECTIONS IN HIV-AFFECTED PATIENTS AT A DOSE OF 500MG TWICE DAILY
I-233	PROPHYLACTIC USE TO REDUCE PERIOPERATIVE BLOOD LOSS AND THE NEED FOR BLOOD TRANSFUSION IN PATIENTS UNDERGOING CARDIOPULMONARY BYPASS IN THE COURSE OF CORONARY ARTERY BYPASS GRAFT SURGERY
I-234	FOR USE IN COMBINATION WITH CISPLATIN FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH INOPERABLE LOCALLY ADVANCED (STAGE IIIA OR IIIB) OR METASTATIC (STAGE IV) NON-SMALL CELL LUNG CANCER
I-235	PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN PATIENTS 12 YEARS OF AGE AND OLDER
I-236	PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN PATIENTS 4 YEARS OF AGE AND OLDER
I-237	MAINTENANCE TREATMENT OF ASTHMA AND PREVENTION OF BRONCHOSPASM IN PATIENTS 4 YEARS OF AGE AND OLDER
I-238	ADJUNCTIVE TREATMENT OF LENNOX-GASTAUT SYNDROME IN PEDIATRIC AND ADULT PATIENTS
I-239	TREATMENT OF PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
I-240	MANAGEMENT OF SECONDARY HYPERPARATHYROIDISM AND RESULTANT METABOLIC BONE DISEASE IN PATIENTS WITH MODERATE TO SEVERE CHRONIC RENAL FAILURE (CCR 15 TO 55ML/MIN) NOT YET ON DIALYSIS
I-241	USE IN PHOTODYNAMIC THERAPY (PDT) FOR REDUCTION OF OBSTRUCTION AND PALLIATION OF SYMPTOMS IN PATIENTS WITH COMPLETELY OR PARTIALLY OBSTRUCTING ENDOBRONCHIAL NONSMALL CELL LUNG CANCER
I-242	TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH THE MENOPAUSE AND IN THE TREATMENT OF VULVAR AND VAGINAL ATROPHY IN WOMEN WITH AN INTACT UTERUS
I-243	USE IN THE SYMPTOMATIC RELIEF OF RHINORRHEA ASSOCIATED WITH THE COMMON COLD IN CHILDREN AGE 5 TO 11 YEARS
I-244	REDUCE THE INCIDENCE OF BREAST CANCER IN WOMEN AT HIGH RISK FOR BREAST CANCER
I-245	TREATMENT OF ACUTE SINUSITIS
I-246	TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTIONS
I-247	USE IN CONVERSION TO MONOTHERAPY IN ADULTS WITH PARTIAL SEIZURES WHO ARE RECEIVING TREATMENT WITH A SINGLE ENZYME-INDUCING ANTIEPILEPTIC DRUG
I-248	INPATIENT TREATMENT OF ACUTE DEEP VEIN THROMBOSIS WITH/WITHOUT PULMONARY EMBOLISM WHEN ADMIN WITH WARFARIN SODIUM AND OUTPATIENT TREATMENT OF ACUTE DEEP VEIN THROMBOSIS WITHOUT PULMONARY EMBOLISM WHEN ADMIN WITH WARFARIN SODIUM
I-249	TREATMENT OF CHRONIC HEPATITIS C IN PATIENTS WITH COMPENSATED LIVER DISEASE PREVIOUSLY UNTREATED WITH ALPHA INTERFERON THERAPY
I-250	PRIMARY PREVENTION OF CORONARY HEART DISEASE IN PATIENTS WITHOUT SYMPATOMATIC CARDIOVASCULAR DISEASE WHO HAVE AVERAGE TO MODERATELY ELEVATED TOTAL-C AND LDL-C AND BELOW AVERAGE HDL-C
I-251	TREATMENT OF GENERALIZED ANXIETY DISORDER
I-252	NEW COMBINATION USE OF PRECOSE FOR PATIENTS WITH TYPE 2 DIABETES TREATED WITH DIET PLUS METFORMIN
I-253	COMBINATION USE OF PRECOSE FOR PATIENTS WITH TYPE 2 DIABETES TREATED WITH DIET PLUS INSULIN

PATENT AND EXCLUSIVITY TERMS

ADB 15 of 191

EXCLUSIVITY INDICATION

I-254	PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS (LOSS OF BONE MASS)
I-255	PREVENTION OF PNEUMOCYSTIS CARINII PNEUMONIA (PCP)
I-256	USE IN TREATMENT OF SMALL CELL LUNG CANCER SENSITIVE DISEASE AFTER FAILURE OF FIRST-LINE CHEMOTHERAPY
I-257	TREATMENT OF CHRONIC HEPATITIS B ASSOCIATED WITH EVIDENCE OF HEPATITIS B VIRAL REPLICATION AND ACTIVE LIVER INFLAMMATION
I-258	FOR PERENNIAL NONALLERGIC RHINITIS FOR AGES 4 AND ABOVE
I-259	PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT), WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING HIP REPLACEMENT SURGERY
I-260	EXPANDED PEDIATRIC USE IN CHILDREN YOUNGER THAN ONE MONTH OF AGE TO BIRTH (WITH A GESTATIONAL AGE OF 37 WEEKS OR GREATER)
I-261	TREATMENT OF SOCIAL ANXIETY DISORDER
I-262	TREATMENT OR PREVENTION OF BRONCHOSPASM WITH REVERSIBLE OBSTRUCTIVE AIRWAY DISEASE AND FOR THE PREVENTION OF EXERCISE INDUCED BRONCHOSPASM IN CHILDREN AGES 4-12
I-263	TREATMENT OF UNSTABLE ANGINA AND NON-Q-WAVE MYOCARDIAL INFARCTION FOR THE PREVENTION OF ISCHEMIC COMPLICATIONS IN PATIENTS ON CONCURRENT ASPIRIN THERAPY
I-264	PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH RADIATION, INCLUDING TOTAL BODY IRRADIATION (TBI) AND FRACTIONATED ABDOMINAL RADIATION
I-265	TREATMENT OF ATOPIC DERMATITIS IN PEDIATRIC PATIENTS 6 YEARS AND OLDER
I-266	USE OF TOPAMAX AS ADJUNCTIVE THERAPY IN PEDIATRIC PATIENTS AGES 2-16 YEARS WITH PARTIAL ONSET SEIZURES
I-267	USE IN PEDIATRIC PATIENTS 3 MONTHS OLD AND OLDER - FOR CORTICOSTEROID-RESPONSIVE DERMATOSES
I-268	PROPHYLAXIS AND CHRONIC TREATMENT OF ASTHMA IN PATIENTS 7-11 YEARS OF AGE
I-269	PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH HIGHLY EMETOGENIC CANCER CHEMOTHERAPY, INCLUDING CISPLATIN
I-270	ADJUVANT TREATMENT OF NODE-POSITIVE BREAST CANCER ADMINISTERED SEQUENTIALLY TO STANDARD DOXORUBICIN-CONTAINING COMBINATION CHEMOTHERAPY
I-271	TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
I-272	TREATMENT OF GLUCOCORTICOID-INDUCED OSTEOPOROSIS IN MEN AND WOMEN RECEIVING GLUCOCORTICOID IN A DAILY DOSE EQUIVALENT TO 7.5MG OR GREATER OF PREDNISONE AND WHO HAVE LOW BONE MINERAL DENSITY
I-273	ADJUNCT TO DIET TO INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA (HETEROZYGOUS FAMILIAL AND NON FAMILIAL) AND MIXED DYSLIPIDEMIA (FREDERICKSON TYPES IIA AND IIB)
I-274	USE OF TOPAMAX AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES
I-275	USE IN COMBINATION WITH METFORMIN AND SULFONYLUREA IN PATIENTS WITH TYPE 2 DIABETES
I-276	USE OF REZULIN IN COMBINATION WITH METFORMIN AND SULFONYLUREAS IN PATIENTS WITH TYPE 2 DIABETES
I-277	TREATMENT OF TYPE III HYPERLIPOPROTEINEMIA
I-278	TREATMENT OF PATIENTS WITH ISOLATED HYPERTRIGLYCERIDEMIA (FREDERICKSON TYPE IV)
I-279	TREATMENT OF POST-TRAUMATIC STRESS DISORDER
I-280	USE OF CARNITOR INJECTION FOR THE PREVENTION AND TREATMENT OF CARNITINE DEFICIENCY IN PATIENTS WITH END STAGE RENAL DISEASE WHO ARE UNDERGOING DIALYSIS
I-281	INCREASING HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA (HETEROZYGOUS FAMILIAL AND NONFAMILIAL) AND MIXED DYSLIPIDEMIA (FREDERICKSON TYPES IIA AND IIB)
I-282	TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER AFTER FAILURE OF PRIOR PLATINUM-BASED CHEMOTHERAPY
I-283	TO REDUCE THE INCIDENCE OF MODERATE TO SEVERE XEROSTOMIA IN PATIENTS UNDERGOING POST-OPERATIVE RADIATION TREATMENT FOR HEAD AND NECK CANCER, WHERE THE RADIATION PORT INCLUDES A SUBSTANTIAL PORTION OF THE PAROTID GLANDS

PATENT AND EXCLUSIVITY TERMS

ADB 16 of 191

EXCLUSIVITY INDICATION

I-284	TO REDUCE THE NUMBER OF ADENOMATOUS COLORECTAL POLYPS IN FAMILIAL ADENOMATOUS POLYPOSIS PATIENTS AS AN ADJUNCT TO USUAL CARE
I-285	TREATMENT OF NASAL SYMPTOMS OF SEASONAL AND PERENNIAL RHINITIS IN ADULTS AND CHILDREN 3 YEARS OF AGE AND OLDER
I-286	TREATMENT OF PATIENTS WITH FREDERICKSON TYPE III
I-287	USE OF PRAVASTATIN IN PATIENTS WITH EVIDENT CORONARY HEART DISEASE TO REDUCE THE RISK OF TOTAL MORTALITY BY REDUCING CORONARY DEATH
I-288	CHANGES IN SEVERAL SECTIONS OF THE INSERT TO INCORPORATE STATEMENTS CONCERNING THE USE OF HIGH DOSES OF LISINAPRIL TO REDUCE THE RISK OF THE COMBINED OUTCOMES OF MORTALITY AND HOSPITALIZATION IN PATIENTS WITH CONGESTIVE HEART FAILURE
I-289	USE OF AVANDIA IN COMBINATION WITH A SULFONYLUREA IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WHEN DIET AND EXERCISE WITH EITHER SINGLE AGENT DOES NOT ACHIEVE ADEQUATE GLYCEMIC CONTROL
I-290	PREVENTION OF CORTICOSTEROID-INDUCED OSTEOPOROSIS
I-291	PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
I-292	TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS
I-293	TREATMENT OF CORTICOSTEROID-INDUCED OSTEOPOROSIS
I-294	TREATMENT OF UNCOMPLICATED ACUTE ILLNESS DUE TO INFLUENZA A AND B IN PEDIATRIC PATIENTS 7 YEARS AND OLDER WHO HAVE BEEN SYMPTOMATIC FOR NO MORE THAN 2 DAYS
I-295	PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS FOR WOMEN WITH AN INTACT UTERUS
I-296	LONG-TERM INTRAVENOUS TREATMENT OF PULMONARY HYPERTENSION ASSOCIATED WITH THE SCLERODERMA SPECTRUM OF DISEASE IN NYHA CLASS III AND CLASS IV PATIENTS WHO DO NOT RESPOND TO CONVENTIONAL THERAPY
I-297	SHORT-TERM TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
I-298	TREATMENT OF PATIENTS WITH FREDERICKSON TYPE IIA AND IIB HYPERLIPOPROTEINEMIA
I-299	USE OF CAMPTOSAR AS A COMPONENT OF FIRST-LINE THERAPY IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN FOR PATIENTS WITH METASTATIC CARCINOMA OF THE COLON OR RECTUM
I-300	PROPHYLAXIS FOR ASTHMA IN CHILDREN 2-5 YEARS OF AGE
I-301	TREATMENT OF SIGNS AND SYMPTOMS OF ALLERGIC CONJUNCTIVITIS
I-302	TREATMENT OF PEDIATRIC PATIENTS WITH PRADER-WILLI SYNDROME
I-303	INCREASING HDL-CHOLESTEROL IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA AND MIXED DYSLIPIDEMIAS
I-304	TREATMENT OF PATIENTS WITH FREDERICKSON TYPE IV
I-305	TREATMENT OF LEVOFLOXACIN SUSCEPTIBLE STRAINS OF PENICILLIN-RESISTANT STREPTOCOCCUS PNEUMONIAE IN PATIENTS WITH COMMUNITY ACQUIRED PNEUMONIA
I-306	INDUCTION OF SPERMATOGENESIS IN MEN WITH PRIMARY AND SECONDARY HYPOGONADOTROPIC HYPOGONADISM IN WHOM THE CAUSE OF INFERTILITY IS NOT DUE TO PRIMARY TESTICULAR FAILURE
I-307	NEW COMBINATION USE OF METFORMIN AND INSULIN IN TYPE 2 DIABETES
I-308	TREATMENT OF PEDIATRIC PATIENTS WITH POLYARTICULAR COURSE JUVENILE RHEUMATOID ARTHRITIS WHO RESPONDED INADEQUATELY TO SALICYLATES OR OTHER NSAIDS
I-309	USE OF ACTONEL 35MG ONCE A WEEK TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS
I-310	REDUCTION IN RISK OF MYOCARDIAL INFARCTION, STROKE, AND DEATH FROM CARDIOVASCULAR CAUSES
I-311	ADJUNCTIVE THERAPY IN THE TREATMENT OF PARTIAL SEIZURES IN PEDIATRIC PATIENTS AGE 3 TO 12 YEARS
I-312	FIRST LINE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE OR HORMONE RECEPTOR UNKNOWN LOCALLY ADVANCED OR METASTATIC BREAST CANCER
I-313	EXTENSION OF INDICATION TO PROVIDE FOR MAINTENANCE OF RESPONSE
I-314	TOPICAL ANESTHETIC FOR SUPERFICIAL MINOR SURGERY OF GENITAL MUCOUS MEMBRANES AND AS AN ADJUNCT FOR LOCAL INFILTRATION ANESTHESIA IN GENITAL MUCOUS MEMBRANES
I-315	THROMBOPROPHYLAXIS OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM, IN MEDICAL PATIENTS WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS DUE TO SEVERELY RESTRICTED MOBILITY DURING ACUTE ILLNESS

PATENT AND EXCLUSIVITY TERMS

ADB 17 of 191

EXCLUSIVITY INDICATION

I-316	TREATMENT OF NSAID-ASSOCIATED GASTRIC ULCER PATIENTS WHO CONTINUE NSAID USE AND REDUCING RISK OF NSAID-ASSOCIATED GASTRIC ULCERS IN PATIENTS WITH HISTORY OF DOCUMENTED GASTRIC ULCER WHO REQUIRE USE OF AN NSAID
I-317	PROPHYLAXIS OF INFLUENZA IN ADULTS AND ADOLESCENTS 13 YEARS AND OLDER
I-318	FIRSTLINE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE OR HORMONE RECEPTOR UNKNOWN LOCALLY ADVANCED OR METASTATIC BREAST CANCER
I-319	USE FOR SUSPECTED OR CONFIRMED METHANOL POISONING, EITHER ALONE OR IN COMBINATION WITH HEMODIALYSIS
I-320	TREATMENT OF TYPE 2 DIABETES IN PEDIATRIC PATIENTS (AGES 10-16 YEARS)
I-321	JUVENILE RHEUMATOID ARTHRITIS
I-322	USE OF DIPRIVAN IN PATIENTS 3 MONTHS TO 16 YEARS
I-323	COLORECTAL CANCER
I-324	REDUCING NEUROLOGIC DISABILITY AND/OR FREQUENCY OF CLINICAL RELAPSES IN PATIENTS WITH SECONDARY (CHRONIC) PROGRESSIVE, PROGRESSIVE RELAPSING, OR WORSENING RELAPSING-REMITTING MULTIPLE SCLEROSIS
I-325	PREVENTION OF RELAPSE AND RECURRENCE OF DEPRESSION
I-326	GENERALIZED ANXIETY DISORDER
I-327	SYMPTOMATIC RELIEF OF RHINORRHEA ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN PATIENTS 5 YEARS AND OLDER
I-328	PROPHYLAXIS AND CHRONIC TREATMENT OF ASTHMA IN PATIENTS 5-6 YEARS OF AGE
I-329	UNCOMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS
I-330	MAINTENANCE OF HEALING OF EROSIIVE ESOPHAGITIS AND CONTROL OF DAYTIME AND NIGHTTIME HEARTBURN SYMPTOMS IN PATIENTS WITH GERD
I-331	TREATMENT OF MODERATE ACNE VULGARIS
I-332	EMPIRIC THERAPY IN FEBRILE NEUTROPENIC PATIENTS WITH SUSPECTED FUNGAL INFECTIONS (EFTN)
I-333	TOPICAL TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR DUE TO MALASSEZIA FURFUR (FORMERLY PITYROSPORUM ORBICULARE)
I-334	LONG-TERM TREATMENT OF GROWTH FAILURE IN CHILDREN BORN SMALL FOR GESTATIONAL AGE WHO FAIL TO MANIFEST CATCH-UP GROWTH BY TWO YEARS OF AGE
I-335	ADJUNCTIVE THERAPY IN PATIENTS TWO YEARS AND OLDER WITH SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME
I-336	EXPANSION OF INDICATION TO INCLUDE THE TREATMENT OF PATIENTS WITH PREDOMINATELY CLASSIC SUBFOVEAL CHOROIDAL NEOVASCULARIZATION DUE TO PATHOLOGIC MYOPIA OR PRESUMED OCULAR HISTOPLASMOSIS
I-337	PATHOLOGICAL HYPERSECRETION ASSOCIATED WITH ZOLLINGER-ELLISON SYNDROME
I-338	MANAGEMENT OF ACUTE PAIN IN ADULTS AND TREATMENT OF PRIMARY DYSMENORRHEA
I-339	TREATMENT OF HEPATITIS B IN PEDIATRIC PATIENTS AGES 2-17 YEARS
I-340	ATOPIC DERMATITIS IN PEDIATRIC PATIENTS AGES 2-5
I-341	BREAST CANCER COMBINATION THERAPY
I-342	USE OF FORADIL FOR LONG-TERM, TWICE DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHO-CONSTRICTION IN PATIENTS WITH COPD INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA
I-343	USE OF COREG FOR SEVERE HEART FAILURE
I-344	ACNE VULGARIS
I-345	TREATMENT OF POSTTRAUMATIC STRESS DISORDER
I-346	TREATMENT OF SYMPTOMATIC GASTRO ESOPHAGEAL REFLUX DISEASE (GERD)
I-347	TREATMENT OR PREVENTION OF BRONCHOSPASM IN CHILDREN 6 YEARS OF AGE AND OLDER WITH OBSTRUCTIVE AIRWAY DISEASE
I-348	LONG-TERM, TWICE-DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD (INCLUDING EMPHYSEMA AND CHRONIC BRONCHITIS)
I-349	ACUTE CORONARY SYNDROME

PATENT AND EXCLUSIVITY TERMS

ADB 18 of 191

EXCLUSIVITY INDICATION

I-350	TREATMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN ADOLESCENT BOYS AND GIRLS AT LEAST ONE YEAR POSTMENARCHAL, AGES 10 TO 17 YEARS, WITH A RECOMMENDED DOSING RANGE OF 10 TO 40MG ONCE DAILY
I-351	PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS FOR ALL STRENGTHS
I-352	ANTICOAGULANT IN PATIENTS WITH OR AT RISK FOR HEPARIN-INDUCED THROMBOCYTOPENIA UNDERGOING PERCUTANEOUS CORONARY INTERVENTIONS (PCI)
I-353	TREATMENT OF SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS
I-354	MANAGEMENT OF POST HERPETIC NEURALGIA
I-355	PREMENSTRUAL DYSPHORIC DISORDER
I-356	TREATMENT OF PATHOLOGICAL HYPERSECRETORY CONDITIONS, INCLUDING ZOLLINGER-ELLISON SYNDROME
I-357	TREATMENT OF COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS
I-358	TREATMENT OF PANIC DISORDER
I-359	TREATMENT OF VULVAR AND VAGINAL ATROPHY ASSOCIATED WITH MENOPAUSE
I-360	TREATMENT OF NASAL SYMPTOMS OF SEASONAL AND PERENNIAL RHINITIS IN CHILDREN AGES TWO UP TO AGE THREE
I-361	TREATMENT OF MULTIPLE MYELOMA AND DOCUMENTED BONE METASTASES FROM SOLID TUMORS, IN CONJUNCTION WITH STANDARD ANTINEOPLASTIC THERAPY. PROSTATE CANCER SHOULD HAVE PROGRESSED AFTER TREATMENT WITH AT LEAST ONE HORMONAL THERAPY
I-362	TREATMENT OF PANIC DISORDER, WITH OR WITHOUT AGORAPHOBIA
I-363	ADJUVANT TREATMENT OF POST MENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE EARLY BREAST CANCER
I-364	TREATMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN ADULTS
I-365	TREATMENT OF HEART FAILURE (NYHA CLASS II-IV) IN PATIENTS WHO ARE INTOLERANT TO AN ACE INHIBITOR
I-366	PREVENTION OF RELAPSE FOLLOWING LONG-TERM TREATMENT OF MAJOR DEPRESSIVE DISORDER
I-367	COMBINATION THERAPY WITH THIAZOLIDINEDIONE TO LOWER BLOOD GLUCOSE IN PTS WHOSE HYPERGLYCEMIA CANNOT BE CONTROLLED BY DIET/EXERCISE PLUS MONOTHERAPY WITH ANY OF THE FOLLOWING AGENTS: METFORMIN, SULFONYLUREAS, REPAGLINIDE, OR THIAZOLIDINEDIONES
I-368	USE OF GLUCOVANCE WITH A THIAZOLIDINEDIONE WHEN GLYCEMIC CONTROL IS NOT OBTAINED WITH GLUCOVANCE ALONE
I-369	PREVENTION AND TREATMENT OF POSTOPERATIVE NAUSEA AND VOMITING
I-370	TREATMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN CHILDREN, AGES 8-13 YEARS, WITH RECOMMENDED DOSE OF 20MG ONCE DAILY AND IN ADOLESCENTS, AGES 14-18 WITH A RECOMMENDED DOSE OF 40MG ONCE DAILY
I-371	HELICOBACTER PYLORI ERADICATION TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE
I-372	NOSOCOMIAL PNEUMONIA
I-373	TREATMENT OF TYPE 2 DIABETIC NEPHROPATHY
I-374	SHORT TERM TOPICAL TREATMENT OF MILD TO MODERATE PLAQUE-TYPE PSORIASIS OF NON SCALP REGIONS
I-375	FIRST LINE THERAPY FOR THE REDUCTION OF INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION
I-376	TREATMENT OF NEWLY DIAGNOSED ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (CML)
I-377	USE OF BRAVELLE FOR MULTIPLE FOLLICULAR DEVELOPMENT (CONTROLLED OVARIAN STIMULATION) DURING ASSISTED REPRODUCTIVE TECHNOLOGY CYCLES IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED PITUITARY SUPPRESSION
I-378	RELIEF OF SYMPTOMS OF SEASONAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER
I-379	USE TAXOTERE IN COMBINATION WITH CISPLATIN FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WHO HAVE NOT PREVIOUSLY RECEIVED CHEMOTHERAPY FOR THIS CONDITION
I-380	TO TREAT PATIENTS WITH SCHIZOPHRENIA OR SCHIZOAFFECTIVE DISORDER AT RISK FOR EMERGENT SUICIDAL BEHAVIOR

PATENT AND EXCLUSIVITY TERMS

ADB 19 of 191

EXCLUSIVITY INDICATION

I-381	TREATMENT OF COLD SORES (HERPES LABIALIS) IN ADULT AND ADOLESCENT PATIENTS 12 YEARS OF AGE AND OLDER
I-382	FOR NEWLY-DIAGNOSED HIGH GRADE MALIGNANT GLIOMA PATIENTS AS AN ADJUNCT TO SURGERY AND RADIATION
I-383	TREATMENT OF TYPE 2 DIABETIC NEPHROPATHY
I-384	USE IN COMBINATION WITH INSULIN FOR THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES MELLITUS
I-385	MODIFICATION OF THE INDICATION FOR COMMUNITY ACQUIRED PNEUMONIA TO ADD "INCLUDING PENICILLIN-RESISTANT STRAINS, MIC PENICILLIN>=2MCG/ML" TO STREPTOCOCCUS PNEUMONIAE
I-386	RAPAMUNE (SIROLIMUS) WITHIN AN IMMUNOSUPPRESSIVE REGIMEN THAT WOULD ALLOW FOR THE WITHDRAWAL OF CYCLOSPORINE 2 TO 4 MONTHS AFTER RENAL TRANSPLANTATION IN PATIENTS CONSIDERED AT LOW TO MODERATE IMMUNOLOGIC RISK FOR RENAL TRANSPLANT REJECTION
I-387	ADJUNCTIVE THERAPY OF PARTIAL SEIZURES IN PEDIATRIC PATIENTS GREATER THAN OR EQUAL TO 2 YEARS OF AGE
I-388	TREATMENT OF PATIENTS WITH LEFT VENTRICULAR DYSFUNCTION FOLLOWING MYOCARDIAL INFARCTION
I-389	SUPPRESSION OF RECURRENT GENITAL HERPES IN HIV-INFECTED INDIVIDUALS
I-390	USE IN PTS AT HIGH RISK CORONARY EVENTS DUE TO EXISTING CORONARY HEART DISEASE, DIABETES, PERIPHERAL VESSEL DISEASE, STROKE HISTORY, OTHER CV DISEASE TO REDUCE RISK TOTAL MORTALITY BY REDUCING CORONARY DEATH, REDUCE NONFATAL MI & STROKE.....
I-391	ABLATION OF HIGH-GRADE DYSPLASIA IN BARRETT'S ESOPHAGUS PATIENTS WHO DO NOT UNDERGO ESOPHAGECTOMY
I-392	TX OF PED PATIENTS W/PH+ CHRONIC PHASE CML DISEASE RECURRENCE AFTER STEM CELL TRANSPLANT OR RESISTANCE TO INTERFERON ALPHA THERAPY. NO CONTROLLED TRIALS DEMONSTRATING A CLINICAL BENEFIT SUCH AS IMPROVEMENT IN DISEASE RELATED SX OR INCREASED SURVIVAL
I-393	CHRONIC BACTERIAL PROSTATITIS
I-394	USE IN PATIENTS WITH CORONARY HEART DISEASE TO REDUCE THE RISK OF UNDERGOING CORONARY REVASCULARIZATION PROCEDURES
I-395	TO IMPROVE PHYSICAL FUNCTION
I-396	EXPANDED INDICATION TO INCLUDE THE ASSESSMENT OF VENTRICULAR FUNCTION IN SUBJECTS BEING EVALUATED FOR HEART DISEASE AND/OR VENTRICULAR FUNCTION
I-397	EXTENDED PROPHYLAXIS IN PATIENTS UNDERGOING HIP FRACTURE SURGERY
I-398	IDIOPATHIC SHORT STATURE
I-399	TREATMENT OF CANDIDEMIA AND THE FOLLOWING CANDIDA INFECTIONS: INTRA-ABDOMINAL ABSCESES, PERITONITIS AND PLEURAL SPACE INFECTIONS
I-400	USE OF OLANZAPINE IN COMBINATION WITH LITHIUM OR VALPROATE FOR THE TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR DISORDER
I-401	LONGER-TERM EFFICACY OF ARIPIPRAZOLE IN THE TREATMENT OF SCHIZOPHRENIA
I-402	DIABETIC FOOT INFECTIONS WITHOUT CONCOMITANT OSTEOMYELITIS
I-403	USE OF VALTREX IN COMBINATION WITH SAFER SEX PRACTICES FOR THE REDUCTION OF THE RISK OF TRANSMISSION OF GENITAL HERPES DURING SUPPRESSIVE THERAPY OF THE SOURCE PARTNER IN A HETEROSEXUAL COUPLE
I-404	MAINTENANCE TREATMENT OF BIPOLAR I DISORDER TO DELAY THE TIME TO OCCURRENCE OF MOOD EPISODES (DEPRESSION, MANIA, HYPOMANIA, MIXED EPISODES) IN PATIENTS TREATED FOR ACUTE MOOD EPISODES WITH STANDARD THERAPY
I-405	TREATMENT OF PREMENSTRUAL DYSPHORIC DISORDER (PMDD) USING AN INTERMITTENT DOSING REGIMEN
I-406	PREVENTION OF CYTOMEGALOVIRUS DISEASE IN KIDNEY, HEART, AND KIDNEY-PANCREAS TRANSPLANT PATIENTS AT HIGH RISK (DONOR CMV SEROPOSITIVE/RECIPIENT CMV SERONEGATIVE)
I-407	IMPROVE SURVIVAL OF STABLE PATIENTS WITH LEFT VENTRICULAR SYSTOLIC DYSFUNCTION (EJECTION FRACTION<=40%) AND CLINICAL EVIDENCE OF CONGESTIVE HEART FAILURE AFTER AN ACUTE MYOCARDIAL INFARCTION

PATENT AND EXCLUSIVITY TERMS

ADB 20 of 191

EXCLUSIVITY INDICATION

I-408	STIMULATION OF PANCREATIC SECRETIONS TO FACILITATE THE IDENTIFICATION OF THE AMPULLA OF VATER AND ACCESSORY PAPILLA DURING ENDOSCOPIC RETROGRADE CHOLANGIO-PANCREATOGRAPHY (ERCP)
I-409	ESOPHAGEAL CANDIDIASIS
I-410	USE OF ADVAIR DISKUS 250/50 FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) ASSOCIATED WITH CHRONIC BRONCHITIS
I-411	EXPANDED INDICATION FOR USE IN COMBINATION WITH ANTIDIABETIC DRUGS IN THE THIAZOLIDINEDIONE CLASS
I-412	MONOTHERAPY FOR THE SHORT TERM TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
I-413	ADJUNCTIVE THERAPY FOR THE SHORT TERM TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
I-414	PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT), WHICH MAY LEAD TO PULMONARY EMBOLISM (PE) IN MEDICAL PATIENTS WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS DUE TO SEVERELY RESTRICTED MOBILITY DURING ACUTE ILLNESS
I-415	SEVERE HYPERTENSION WHEN THE VALUE OF ACHIEVING PROMPT BLOOD PRESSURE CONTROL EXCEEDS THE RISK OF INITIATING COMBINATION THERAPY
I-416	THE USE OF CIPRO XR FOR COMPLICATED URINARY TRACT INFECTIONS AND ACUTE UNCOMPLICATED PYELONEPHRITIS
I-417	USE IN THE LONG TERM TREATMENT OF BIPOLAR I DISORDER
I-418	ADJUNCTIVE THERAPY W/ MOOD STABILIZERS (LITHIUM OR DIVALPROEX) IN THE TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDERS
I-419	MONOTHERAPY IN THE TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
I-420	TOPICAL TREATMENT OF CLINICALLY TYPICAL, NONHYPERKERATOTIC, NONHYPERTROPHIC ACTINIC KERATOSES ON THE FACE OR SCALP IN IMMUNOCOMPETENT ADULTS
I-421	TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS AND PYELONEPHRITIS DUE TO E.COLI FOR PED PATIENTS (1-17) NOT AS FIRST CHOICE
I-422	INDICATED FOR THE IN-HOSPITAL SHORT-TERM (UP TO 4 HOURS) REDUCTION IN BLOOD PRESSURE IN PEDIATRIC PATIENTS
I-423	ACUTE TREATMENT OF MIGRAINE ATTACKS WITH OR WITHOUT AURA IN ADULTS
I-424	MANAGEMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH MODERATE TO SEVERE CHRONIC RENAL INSUFFICIENCY NOT YET ON DIALYSIS
I-425	ELOXATIN IN COMBINATION WITH INFUSIONAL 5-FLUOROURACIL (5-FU) AND LEUCOVORIN (LV) FOR THE TREATMENT OF PATIENTS PREVIOUSLY UNTREATED FOR ADVANCED COLORECTAL CANCER
I-426	TREATMENT OF ACUTE PULMONARY EMBOLISM WHEN ADMINISTERED IN CONJUNCTION WITH WARFARIN SODIUM
I-427	TREATMENT OF ACUTE DEEP VEIN THROMBOSIS WITHOUT PULMONARY EMBOLISM WHEN ADMINISTERED IN CONJUNCTION WITH WARFARIN SODIUM
I-428	FOR USE IN COMBINATION WITH PACLITAXEL FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC BREAST CANCER AFTER FAILURE OF PRIOR ANTHRACYCLINE CONTAINING ADJUVANT CHEMOTHERAPY UNLESS ANTHRACYCLINES WERE CLINICALLY CONTRAINDICATED
I-429	FOR USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH ANDROGEN INDEPENDENT (HORMONE REFRACTORY) METASTATIC PROSTATE CANCER
I-430	FOR USE IN THE RELIEF OF THE SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS IN ADULTS
I-431	NOSOCOMIAL PNEUMONIA AND COMMUNITY-ACQUIRED PNEUMONIA CAUSED BY STREPTOCOCCUS PNEUMONIAE INDICATION EXPANDED TO INCLUDE MULTI-DRUG RESISTANT STRAINS
I-432	TREATMENT OF COMMUNITY ACQUIRED PNEUMONIA CAUSED BY MULTI-DRUG RESISTANT STREPTOCOCCUS PNEUMONIAE
I-433	TREATMENT OF BIOPSY-CONFIRMED, PRIMARY SUPERFICIAL BASAL CELL CARCINOMA IN IMMUNOCOMPETENT ADULTS, WITH A MAXIMUM TUMOR DIAMETER OF 2.0CM, LOCATED ON THE TRUNK (EXCLUDING ANOGENITAL SKIN), NECK, OR EXTREMITIES (EXCLUDING HANDS AND FEET)
I-434	PREVENTION OF CARDIOVASCULAR DISEASE IN ADULT PATIENTS WITHOUT CLINICALLY EVIDENT HEART DISEASE, BUT WITH MULTIPLE RISK FACTORS FOR CORONARY HEART DISEASE TO REDUCE RISK OF MI AND RISK FOR REVASCULARIZATION PROCEDURES AND ANGINA

PATENT AND EXCLUSIVITY TERMS

ADB 21 of 191

EXCLUSIVITY INDICATION

I-435	CHRONIC IDIOPATHIC CONSTIPATION
I-436	FOR USE IN COMBINATION WITH DOXORUBICIN AND CYCLOPHOSPHAMIDE FOR THE ADJUVANT TREATMENT OF PATIENTS WITH OPERABLE NODE-POSITIVE BREAST CANCER
I-437	TREATMENT OF ACUTE MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR DISORDER
I-438	EMPIRICAL THERAPY FOR PRESUMED FUNGAL INFECTIONS IN FEBRILE, NEUTROPENIC PATIENTS
I-439	USED TO TREAT ADULTS WITH GROWTH HORMONE DEFICIENCY
I-440	FOR THE REPLACEMENT OF ENDOGENOUS GROWTH HORMONE IN ADULTS WITH GROWTH HORMONE DEFICIENCY
I-441	USE COMBINATION WITH INFUSIONAL 5-FU/LV FOR ADJUVANT TREATMENT STAGE III COLON CANCER PTS WHO HAVE UNDERGONE COMPLETE RESECTION PRIMARY TUMOR-BASED ON IMPROVEMENT IN DISEASE FREE SURVIVAL, NO DEMONSTRATED BENEFIT OVERALL SURVIVAL AFTER 4YRS
I-442	USED FOR CANDIDEMIA IN NONNEUTROPENIC PATIENTS AND THE FOLLOWING CANDIDA INFECTIONS: DISSEMINATED INFECTIONS IN SKIN & INFECTIONS IN ABDOMEN, KIDNEY, BLADDER WALL, AND WOUNDS
I-443	TREATMENT OF NASAL POLYPS IN PATIENTS 18 YEARS OF AGE AND OLDER
I-444	USE OF PROTONIX IV FOR INJECTION AS STAND ALONE THERAPY FOR THE SHORT-TERM TREATMENT OF PATIENTS HAVING GASTROESOPHAGEAL REFLUX (GERD) WITH A HISTORY OF EROSIIVE ESOPHAGITIS
I-445	TO IMPROVE (COMPARED TO 4.25% DEXTROSE) LONG-DWELL ULTRAFILTRATION AND CLEARANCE OF CREATININE AND UREA NITROGEN IN PATIENTS WITH HIGH AVERAGE OR GREATER TRANSPORT CHARACTERISTICS, AS DEFINED USING THE PERITONEAL EQUILIBRATION TEST (PET)
I-446	EXTENDED ADJUVANT TREATMENT OF EARLY BREAST CANCER IN POSTMENOPAUSAL WOMEN WHO HAVE RECEIVED 5 YRS ADJUVANT TAMOXIFEN THERAPY-EFFECTIVENESS BASED ON AN ANALYSIS OF DISEASE FREE SURVIVAL IN PATIENTS TREATED FOR A MEDIAN 24 MONTHS
I-447	USE OF COPEGUS (RIBAVIRIN) FOR TREATMENT OF CHRONIC HEPATITIS C IN ADULT PATIENTS COINFECTED WITH HIV IN COMBINATION WITH PEGASYS (PEGINTERFERON ALFA-2A)
I-448	TREATMENT OF HEART FAILURE (NYHA CLASS II-IV AND EJECTION FRACTION <=40%) TO REDUCE THE RISK OF DEATH FROM CARDIOVASCULAR CAUSES AND TO REDUCE HOSPITALIZATIONS FOR HEART FAILURE
I-449	TO IMPROVE WAKEFULNESS IN TWO NEW PATIENT POPULATIONS WITH EXCESSIVE SLEEPINESS: THOSE WITH OBSTRUCTIVE SLEEP APNEA/HYPOPNEA SYNDROME AND THOSE WITH SHIFT WORK SLEEP DISORDER
I-450	TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED HIGH GRADE GLIOMAS CONCOMITANTLY WITH RADIOTHERAPY AND THEN AS ADJUVANT TREATMENT
I-451	MANAGEMENT OF ENDOMETRIOSIS ASSOCIATED PAIN
I-452	EXPANDED INDICATION TO INCLUDE TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEAST 1 PRIOR THERAPY
I-453	USE IN COMBINATION WITH A SULFONYLUREA PLUS METFORMIN WHEN DIET, EXERCISE AND BOTH AGENTS DO NOT RESULT IN ADEQUATE GLYCEMIC CONTROL (TRIPLE THERAPY)
I-454	MAINTENANCE OF CLINICAL REMISSION OF MILD TO MODERATE CROHN'S DISEASE INVOLVING THE ILEUM AND/OR THE ASCENDING COLON FOR UP TO 3 MONTHS
I-455	MODIFIED HEART FAILURE INDICATION TO INCLUDE TREATMENT OF HEART FAILURE IN PATIENTS WITH LEFT VENTRICULAR SYSTOLIC DYSFUNCTION (NYHA CLASS II-IV; EJECTION FRACTION LESS THAN OR EQUAL TO 40%)
I-456	TO REDUCE CARDIOVASCULAR DEATH AND TO REDUCE HEART FAILURE HOSPITALIZATIONS. INCLUDES ADDITIONAL INFORMATION ON THE ADDED EFFECT ON THESE OUTCOMES WHEN USED WITH AN ACE INHIBITOR
I-457	TREATMENT OF PATIENTS UNDERGOING ABDOMINAL SURGERY WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS
I-458	USE OF BIVALIRUDIN FOR INJECTION WITH PROVISIONAL USE OF GLYCOPROTEIN IIB/IIIA INHIBITOR (GPI) AS LISTED IN THE CLINICAL TRIALS REPLACE-2 SECTION FOR USE AS AN ANTICOAGULANT IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION (PCI)
I-459	NON-DIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) PATIENTS RECEIVING OR NOT RECEIVING AN ERYTHROPOIETIN
I-460	TREATMENT OF DIARRHEA CAUSED BY CRYPTOSPORIDIUM PARVUM IN NON-HIV INFECTED

PATENT AND EXCLUSIVITY TERMS

ADB 22 of 191

EXCLUSIVITY INDICATION

PATIENTS 12 YEARS OF AGE AND OLDER

- I-461 USE AS A SINGLE AGENT FOR ADJUVANT TREATMENT IN PATIENTS WITH DUKES' C COLON CANCER WHO HAVE UNDERGONE COMPLETE RESECTION OF THE PRIMARY TUMOR WHEN TREATMENT WITH FLUOROPYRIMIDINE THERAPY ALONE IS PREFERRED
- I-462 LONG TERM TREATMENT OF IDIOPATHIC SHORT STATURE
- I-463 TREATMENT OF PATIENTS POST MYOCARDIAL INFARCTION
- I-464 TREATMENT OF MODERATE TO SEVERE PRIMARY RESTLESS LEGS SYNDROME
- I-465 PERENNIAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC PATIENTS 6 MONTHS OF AGE AND OLDER
- I-466 FOR RELIEF OF THE SIGNS AND SYMPTOMS OF ANKYLOSING SPONDYLITIS
- I-467 USE OF TOPIRAMATE AS INITIAL MONOTHERAPY IN PATIENTS 10 YEARS OF AGE AND OLDER WITH PARTIAL ONSET OR PRIMARY GENERALIZED TONIC CLONIC SEIZURES
- I-468 USE IN PATIENTS WITH STABLE CORONARY ARTERY DISEASE TO REDUCE THE RISK OF CARDIOVASCULAR MORTALITY OR NON-FATAL MYOCARDIAL INFARCTION
- I-469 RELIEF OF THE SIGNS AND SYMPTOMS OF PAUCIARTICULAR OR POLYARTICULAR COURSE JUVENILE RHEUMATOID ARTHRITIS IN PATIENTS 2 YEARS OF AGE AND OLDER
- I-470 DIABETIC PERIPHERAL NEUROPATHIC PAIN
- I-471 INDICATED TO REDUCE THE RISK OF MYOCARDIAL INFARCTION AND STROKE IN PATIENTS WITH TYPE 2 DIABETES AND WITHOUT CLINICALLY EVIDENT CORONARY HEART DISEASE BUT WITH MULTIPLE RISK FACTORS FOR CORONARY HEART DISEASE
- I-472 USE IN PATIENTS WITH ANGIOGRAPHICALLY DOCUMENTED CORONARY ARTERY DISEASE
- I-473 USE IN COMBINATION WITH GEMCITABINE FOR THE FIRST LINE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE OR METASTATIC PANCREATIC CANCER
- I-474 TREATMENT OF IRON DEFICIENCY ANEMIA IN PERITONEAL DIALYSIS DEPENDANT CHRONIC KIDNEY DISEASE IN PATIENTS RECEIVING AN ERYTHROPOIETIN
- I-475 PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF MODERATELY EMETOGENIC CANCER CHEMOTHERAPY
- I-476 TREATMENT OF DIABETIC FOOT INFECTIONS WITHOUT OSTEOMYELITIS
- I-477 TREATMENT OF COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS CAUSED BY METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS, ESCHERICHIA COLI, KLEBSIELLA PNEUMONIAE, OR ENTEROBACTER CLOACAE
- I-478 FOR USE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PARTIAL SEIZURES IN CHILDREN WITH EPILEPSY AGED 2-4 YEARS
- I-479 TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS CAUSED BY E.COLI, B. FRAGILIS, S.ANGINOSUS, S.CONSTELLATUS, E. FAECALIS, P. MIRABILIS, C. PERFRINGENS, B. THETAIOAOMICRON OR PEPTOSTREPTOCOCCUS SPECIES
- I-480 PROPHYLAXIS OF INFLUENZA FOR PATIENTS BETWEEN 1-12 YEARS OF AGE
- I-481 INDICATED FOR THE ADJUVANT TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE EARLY BREAST CANCER
- I-482 TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER WITH OR WITHOUT PSYCHOTIC FEATURES
- I-483 PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
- I-484 FOR THE RISK REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCERS
- I-485 TREATMENT OF POSTOPERATIVE INFLAMMATION AND REDUCTION OF OCULAR PAIN IN PATIENTS WHO HAVE UNDERGONE CATARACT EXTRACTION
- I-486 ANGIOMAX IS INDICATED FOR PATIENTS WITH, OR AT RISK OF, HIT/HITTS UNDERGOING PCI
- I-487 INDICATED FOR THE RELIEF OF THE INFLAMMATORY AND PRURITIC MANIFESTATIONS OF CORTICOSTEROID RESPONSIVE DERMATOSES IN PATIENTS 12 YRS OF AGE OR OLDER
- I-488 MAINTENANCE THERAPY IN BIPOLAR I DISORDER
- I-489 FOR USE IN PEDIATRIC PATIENTS WITH TYPE I DIABETES
- I-490 FOR USE IN COMBINATION WITH CISPLATIN AND FLUOROURACIL FOR THE TREATMENT OF PATIENTS WITH ADVANCED GASTRIC ADENOCARCINOMA, INCLUDING ADENOCARCINOMA OF GASTROESOPHAGEAL JUNCTION, WHO HAVE NOT RECEIVED PRIOR CHEMOTHERAPY FOR ADVANCED DISEASE

PATENT AND EXCLUSIVITY TERMS

ADB 23 of 191

EXCLUSIVITY INDICATION

I-491	INFLUENZA PROPHYLAXIS
I-492	MONOTHERAPY IN THE TREATMENT OF ACUTE MANIC OR MIXED EPISODES IN BIPOLAR I DISORDER, WITH OR WITHOUT PSYCHOTIC FEATURES
I-493	ADMINISTERED IN COMBINATION WITH FENOFIBRATE, AS ADJUNCTIVE THERAPY TO DIET FOR THE REDUCTION OF ELEVATED TOTAL-C, LDL-C, APO B, AND NON-HDL-C IN PATIENTS WITH MIXED HYPERLIPIDEMIA
I-494	CLINICAL DATA IN SUPPORT OF AVANDAMET AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WHEN TREATMENT WITH DUAL ROSIGLITAZONE AND METFORMIN THERAPY IS APPROPRIATE
I-495	ADJUVANT TX OF POSTMENOPAUSAL WOMEN WITH ESTROGEN-RECEPTOR POSITIVE EARLY BREAST CANCER WHO HAVE RECEIVED 2 TO 3 YRS OF TAMOXIFEN AND ARE SWITCHED TO AROMASIN FOR COMPLETION OF A TOTAL OF 5 CONSECUTIVE YRS OF ADJUVANT HORMONAL THERAPY
I-496	LONG TERM TREATMENT OF GROWTH FAILURE ASSOCIATED WITH TURNER SYNDROME IN PATIENTS WHO HAVE OPEN EPIPHYSES
I-497	PREVENTION OF SEASONAL MAJOR DEPRESSIVE EPISODES IN PATIENTS WITH SEASONAL AFFECTIVE DISORDER
I-498	PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING
I-499	USE OF GEMZAR IN COMBINATION WITH CARBOPLATIN FOR THE TREATMENT OF PATIENTS WITH ADVANCED OVARIAN CANCER THAT HAS RELAPSED AT LEAST 6 MONTHS AFTER COMPLETION OF PLATINUM-BASED THERAPY
I-500	FOR USE IN COMBINATION WITH DEXAMETHASONE FOR THE TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
I-501	TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) IN IMMUNOCOMPETENT PATIENTS WITH A SINGLE DOSE OF FAMCICLOVIR 1500 MG.
I-502	FOR PTS WITH ST-SEGMENT ELEVATION ACUTE MYOCARDIAL INFARCTION, PLAVIX TO REDUCE RATE OF DEATH FROM ANY CAUSE AND THE RATE OF A COMBINED ENDPOINT OF DEATH, REINFARCTION OR STROKE. NOT KNOWN TO PERTAIN TO PTS WHO RECEIVE PRIMARY ANGIOPLASTY
I-503	TREATMENT OF MAJOR DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR DISORDER
I-504	TREATMENT OF PATHOLOGICAL HYPERSECRETORY CONDITIONS INCLUDING ZOLLINGER-ELLISON SYNDROME
I-505	TREATMENT OF STAPHYLOCOCCUS AUREUS BLOODSTREAM INFECTIONS (BACTEREMIA), INCLUDING THOSE WITH RIGHT SIDED INFECTIVE ENDOCARDITIS, CAUSED BY METHICILLIN-SUSCEPTIBLE AND METHICILLIN-RESISTANT ISOLATES
I-506	ADJUNCTIVE THERAPY OF MYOCLONIC SEIZURES IN ADULTS AND ADOLESCENTS AGE 12 AND OVER WITH JUVENILE MYOCLONIC EPILEPSY
I-507	ADJUNCT TO DIET TO REDUCE TOTAL-C, LDL-C AND APO B LEVELS IN ADOLESCENT BOYS AND GIRLS WHO ARE AT LEAST ONE YEAR POST-MENARCHE, 10-16 YEARS OF AGE, WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
I-508	PREMENSTRUAL DYSPHONIC DISORDER
I-509	TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER
I-510	ADULT DERMATOFIBROSARCOMA PROTUBERANS (DFSP)
I-511	ADULT MYELODYSPLASTIC SYNDROME/MYELOPROLIFERATIVE DISEASES (MDS/MDP)
I-512	ADULT PH+ ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) MONOTHERAPY
I-513	ADULT AGGRESSIVE SYSTEMIC MASTOCYTOSIS (ASM)
I-514	ADULT HYPEREOSINOPHILIC SYNDROME/CHRONIC EOSINOPHILIC LEUKEMIA (HES/CEL)
I-515	PROPHYLAXIS OF SURGICAL SITE INFECTION FOLLOWING ELECTIVE COLORECTAL SURGERY
I-516	PRIMARY GENERALIZED TONIC CLONIC SEIZURES IN ADULTS AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER
I-517	TREATMENT OF MODERATE TO SEVERE PRIMARY RESTLESS LEG SYNDROME (RLS)
I-518	TREATMENT OF SHORT STATURE OR GROWTH FAILURE IN CHILDREN WITH SHOX (SHORT STATURE HOMEBOX CONTAINING GENE) DEFICIENCY WHOSE EPIPHYSES ARE NOT CLOSED
I-519	USE OF TAXOTERE (DOCETAXEL) INJECTION CONCENTRATE IN COMBINATION WITH CISPLATIN AND FLUOROURACIL FOR THE INDUCTION OF PATIENTS WITH INOPERABLE LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN)

PATENT AND EXCLUSIVITY TERMS

ADB 24 of 191

EXCLUSIVITY INDICATION

I-520	USE OF EXENATIDE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WHO ARE USING A THIAZOLIDINEDIONE ALONE OR IN COMBINATION WITH METFORMIN BUT HAVE NOT ACHIEVED ADEQUATE GLYCEMIC CONTROL
I-521	TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA WHO HAVE RECEIVED AT LEAST 1 YEAR PRIOR THERAPY
I-522	TREATMENT OF MODERATE ACNE VULGARIS IN WOMEN AT LEAST 14 YRS OF AGE, WHO HAVE NO KNOWN CONTRAINDICATIONS TO ORAL CONTRACEPTIVE THERAPY, AND HAVE ACHIEVED MENARCHE, IF THE PATIENT DESIRES AN ORAL CONTRACEPTIVE FOR BIRTH CONTROL.
I-523	USE IN ADULT PATIENTS WITH CLINICALLY EVIDENT CORONARY HEART DISEASE TO REDUCE THE RISK OF NONFATAL MYOCARDIAL INFARCTION, FATAL AND NONFATAL STROKE, ANGINA, REVASCULARIZATION PROCEDURES AND HOSPITALIZATION FOR CONGESTIVE HEART FAILURE
I-524	GENERALIZED ANXIETY DISORDER (GAD)
I-525	USE OF 0.5MG/0.1MG FOR PREVENTION OF POST-MENOPAUSAL OSTEOPOROSIS
I-526	TREATMENT OF HYPONATREMIA IN HOSPITALIZED PATIENTS
I-527	ADJUNCTIVE THERAPY IN THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER WITH IDIOPATHIC GENERALIZED EPILEPSY
I-528	TREATMENT OF MODERATE TO SEVERE VAGINAL DRYNESS AND PAIN WITH INTERCOURSE, SYMPTOMS OF VULVAR AND VAGINAL ATROPHY ASSOCIATED WITH MENOPAUSE
I-529	TREATMENT OF DEMENTIA OF THE ALZHEIMER'S TYPE IN PATIENTS WITH SEVERE ALZHEIMER'S DISEASE
I-530	PREVENTION OF EXERCISE-INDUCED BRONCHOCONSTRICTION IN PATIENTS 15 YEARS OF AGE AND OLDER
I-531	MAINTENANCE TREATMENT OF SCHIZOPHRENIA
I-532	TREATMENT OF BACTERIAL VAGINOSIS IN NON-PREGNANT FEMALES
I-533	ACUTE ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION (STEMI)
I-534	EXTENDED TREATMENT OF SYMPTOMATIC VENOUS THROMBOEMBOLISM (VTE) AND/OR PULMONARY EMBOLISM TO REDUCE THE RECURRENCE OF VTE IN PATIENTS WITH CANCER
I-535	MANAGEMENT OF FIBROMYALGIA
I-536	FOR THE TREATMENT OF SHORT STATURE IN CHILDREN WITH NOONAN SYNDROME
I-537	LONG TERM TREATMENT OF PANIC DISORDER
I-538	SHORT TERM TREATMENT OF PANIC DISORDER
I-539	REDUCTION IN RISK OF INVASIVE BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS OR AT HIGH RISK FOR INVASIVE BREAST CANCER
I-540	TREATMENT OF SCHIZOPHRENIA IN ADOLESCENTS AGES 13-17
I-541	TREATMENT OF BIPOLAR I DISORDER IN CHILDREN AGES 10-12 AND ADOLESCENTS AGES 13-17
I-542	EXPANSION OF PATIENT POPULATION FOR HEAD AND NECK CANCER FROM "INOPERABLE" PATIENTS TO ALL PATIENTS
I-543	USE IN COMBINATION WITH CISPLATIN AND FLUOROURACIL FOR THE INDUCTION TREATMENT OF PATIENTS WITH LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN)
I-544	ADJUNCTIVE THERAPY OF MYOCLONIC SEIZURES IN ADULTS AND ADOLESCENTS AGE 16 AND OVER WITH JUVENILE MYOCLONIC EPILEPSY
I-545	ADJUNCTIVE TREATMENT TO TREAT PATIENTS WITH MAJOR DEPRESSIVE DISORDER
I-546	TREATMENT OF UNRESECTABLE HEPATOCELLULAR CARCINOMA
I-547	ADJUNCTIVE THERAPY TO DIET TO SLOW THE PROGRESSION OF ARTEROSCLEROSIS IN ADULT PATIENTS AS PART OF A TREATMENT STRATEGY TO LOWER TOTAL-C AND LDL-C TO TARGET LEVELS
I-548	SEASONAL ALLERGIC RHINITIS IN PATIENTS 6 THROUGH LESS THAN 12 YEARS OF AGE
I-549	USE OF AVALIDE TABLETS AS INITIAL THERAPY IN PATIENTS WHO ARE LIKELY TO NEED MULTIPLE DRUGS TO ACHIEVE THEIR BLOOD PRESSURE GOALS
I-550	TREATMENT OF HYPERTENSION IN PEDIATRIC PATIENTS 6-16 YEARS OF AGE
I-551	TREATMENT OF SHORT STATURE IN CHILDREN WITH TURNER'S SYNDROME

PATENT AND EXCLUSIVITY TERMS

ADB 25 of 191

EXCLUSIVITY INDICATION

I-552	ADJUNCTIVE TREATMENT FOR RADIOIODINE ABLATION OF THYROID TISSUE REMNANTS IN PATIENTS WHO HAVE UNDERGONE THYROIDECTOMY FOR WELL-DIFFERENTIATED THYROID CANCER AND WHO DO NOT HAVE EVIDENCE OF METASTATIC THYROID CANCER
I-553	FOR USE AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
I-554	TREATMENT OF PATIENTS WITH CANDIDEMIA, ACUTE DISSEMINATED CANDIDIASIS, CANDIDA PERITONITIS AND ABSCESES
I-555	TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER IN PEDIATRIC PATIENTS AGED 10-17 YEARS
I-556	PREVENTION OF POST OPERATIVE NAUSEA AND VOMITING FOR UP TO 24 HOURS FOLLOWING SURGERY
I-557	USE OF AMITIZA (LUBIPROSTONE) 8 MCG TWICE DAILY FOR TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION IN WOMEN GREATER THAN OR EQUAL TO 18 YEARS OLD
I-558	MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION AND REDUCING EXACERBATIONS IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA
I-559	ADJUNCTIVE THERAPY ADDED TO LITHIUM OR VALPROATE IN SHORT TERM TREATMENT OF BIPOLAR DISORDER, MANIC OR MIXED
I-560	MAINTENANCE TREATMENT FOR BIPOLAR I DISORDER, AS ADJUNCTIVE THERAPY TO LITHIUM OR DIVALPROEX
I-561	LONG-TERM TREATMENT OF SOCIAL ANXIETY DISORDER
I-562	MAINTENANCE TREATMENT OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER (ADHD) IN CHILDREN AND ADOLESCENTS
I-563	ADJUNCTIVE THERAPY IN THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SIEZURES IN ADULTS AND CHILDREN 16 YEARS OF AGE AND OLDER WITH IDIOPATHIC GENERALIZED EPILEPSY
I-564	TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA
I-565	USE OF DUTASTERIDE IN COMBINATION WITH TAMSULOSIN FOR THE TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA (BPH)
I-566	MANAGEMENT OF FIBROMYALGIA
I-567	INITIAL THERAPY IN PATIENTS LIKELY TO NEED MULTIPLE DRUGS TO ACHIEVE THEIR BLOOD PRESSURE GOALS
I-568	USE OF APTIVUS, CO-ADMINISTERED W/RITONAVIR, FOR COMBINATION ANTIRETROVIRAL TREATMENT OF HIV-1 INFECTED PED (AGE 2-18 YRS) PATIENTS WHO ARE TREATMENT-EXPERIENCED AND INFECTED W/HIV-1 STRAINS RESISTANT TO MORE THAN ONE PROTEASE INHIBITOR
I-569	TREATMENT OF CHRONIC HEPATITIS B
I-570	TREATMENT OF CHICKEN POX IN IMMUNOCOMPETENT PEDIATRIC PATIENTS 2 TO <18 YEARS OF AGE
I-571	NON-SMALL CELL LUNG CANCER IN COMBINATION WITH CISPLATIN AND AS SINGLE AGENT FOR NONSQAUMOUS NON-SMALL CELL LUNG CANCER
I-572	TREATMENT OF GROWTH FAILURE IN CHILDREN BORN SMALL FOR GESTATIONAL AGE (SGA) WITH NO CATCH-UP BY AGE 2-4 YRS.
I-573	TO TREAT PATIENTS WITH PRIMARY DYSBETALIPOPROTEINEMIA (FREDRICKSON TYPE III HYPERLIPOPROTEINEMIA) AS AN ADJUNCT TO DIET
I-574	MONOTHERAPY IN THE TREATMENT OF BIPOLAR DEPRESSION
I-575	MONOTHERAPY IN THE TREATMENT OF BIPOLAR MANIA
I-576	ADJUNCTIVE THERAPY IN THE TREATMENT OF BIPOLAR MANIA
I-577	SEDATION OF NON-INTUBATED PATIENTS PRIOR TO AND/OR DURING SURGICAL AND OTHER PROCEDURES
I-578	EXPANSION OF INDICATION TO INCLUDE TREATMENT OF HIV IN TREATMENT NAIVE ADULTS
I-579	TREATMENT OF MODERATE TO SEVERE DYSPAREUNIA, A SYMPTOM OF VULVAR AND VAGINAL ATROPHY, DUE TO MENOPAUSE AND NEW TWICE WEEKLY DOSING REGIMEN FOR THIS INDICATION
I-580	INDOLENT B-CELL NON-HODGKINS LYMPHOMA (NHL) THAT HAS PROGRESSED DURING OR WITHIN SIX MONTHS OF TREATMENT WITH RITUXIMAB OR A RITUXIMAB CONTAINING REGIMEN

PATENT AND EXCLUSIVITY TERMS

ADB 26 of 191

EXCLUSIVITY INDICATION

I-581	TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS
I-582	TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
I-583	ADJUVANT TREATMENT OF ADULT PATIENTS FOLLOWING COMPLETE GROSS RESECTION OF KIT (CD117) POSITIVE GASTROINTESTINAL STROMAL TUMORS (GIST)
I-584	TREATMENT AND PREVENTION OF GLUCOCORTICOID-INDUCED OSTEOPOROSIS IN PATIENTS EXPECTED TO BE ON GLUCOCORTICIDS FOR AT LEAST 12 MONTHS
I-585	TREATMENT OF SHORT STATURE IN PEDIATRIC PATIENTS SMALL FOR GESTATIONAL AGE WHO DO NOT MANIFEST CATCH UP GROWTH BY AGE 2 TO 4 YEARS
I-586	COMMUNITY ACQUIRED BACTERIAL PNEUMONIA
I-587	ADDITIONAL PATHOGENS TO COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS INDICATION
I-588	ADDITIONAL PATHOGENS TO COMPLICATED INTRA-ABDOMINAL INFECTIONS INDICATION
I-589	TREATMENT OF TREATMENT RESISTANT DEPRESSION (TRD) IN COMBINATION WITH OLANZAPINE
I-590	ACUTE TREATMENT OF DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR DISORDER (IN COMBINATION WITH OLANZAPINE)
I-591	TREATMENT OF TREATMENT RESISTANT DEPRESSION (TRD) IN COMBINATION WITH FLUOXETINE
I-592	ACUTE TREATMENT OF DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR DISORDER (IN COMBINATION WITH FLUOXETINE)
I-593	TREATMENT OF TREATMENT RESISTANT DEPRESSION (TRD)
I-594	INDICATION EXPANDED TO INCLUDE PATIENTS WHO HAVE EXPERIENCED A FIRST CLINICAL EPISODE AND HAVE MRI FEATURES CONSISTENT WITH MULTIPLE SCLEROSIS
I-595	PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
I-596	USE AS ADJUNCTIVE THERAPY WITH LITHIUM OR VALPROATE FOR THE MAINTENANCE TREATMENT OF BIPOLAR I DISORDER
I-597	MONOTHERAPY FOR THE MAINTENANCE TREATMENT OF BIPOLAR I DISORDER
I-598	TREATMENT OF PULMONARY ARTERIAL HYPERTENSION INDICATION EXPANDED TO INCLUDE DELAY IN CLINICAL WORSENING
I-599	PREVENTION AND TREATMENT OF SECONDARY HYPERPARATHYROIDISM ASSOCIATED WITH CHRONIC KIDNEY DISEASE (CKD) STAGE 5 IN PATIENTS ON HEMODIALYSIS OR PERITONEAL DIALYSIS
I-600	FOR USE AS INITIAL THERAPY IN PATIENTS WHO ARE LIKELY TO NEED MULTIPLE DRUGS TO ACHIEVE THEIR BLOOD PRESSURE GOALS
I-601	MAINTENANCE TREATMENT IN PATIENTS WITH ADVANCED OR METASTATIC NONSQUAMOUS NON-SMALL CELL LUNG CANCER WHOSE DISEASE HAS NOT PROGRESSED AFTER FOUR CYCLES OF PLATINUM-BASED FIRST LINE CHEMOTHERAPY
I-602	TREATMENT OF MEN AND WOMEN WITH OSTEOPOROSIS ASSOCIATED WITH SUSTAINED SYSTEMIC GLUCOCORTICOID THERAPY AT HIGH RISK FOR FRACTURE
I-603	GOUT FLARES
I-604	PREVENTION OF CMV DISEASE IN KIDNEY AND HEART TRANSPLANT PATIENTS 4 MONTHS TO 16 YEARS AT HIGH RISK
I-605	ADJUNCT TO MOOD STABILIZERS AND/OR ANTIDEPRESSANTS FOR SCHIZOAFFECTIVE DISORDER
I-606	TREATMENT OF SCHIZOAFFECTIVE DISORDER AS MONOTHERAPY
I-607	INDICATION EXPANDED TO INCLUDE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (WHO GROUP I) IN PATIENTS WITH CLASS II SYMPTOMS
I-608	REDUCE LDL-C LEVELS IN BOYS AND POSTMENARCHAL GIRLS, 10 TO 17 YEARS OF AGE, WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA AS MONOTHERAPY OR IN COMBINATION WITH A STATIN AFTER FAILING AN ADEQUATE TRIAL OF DIET THERAPY
I-610	TREATMENT OF HEAVY MENSTRUAL BLEEDING FOR WOMEN WHO CHOOSE TO USE INTRAUTERINE CONTRACEPTION AS THEIR METHOD OF CONTRACEPTION
I-611	TREATMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN ADOLESCENT BOYS AND POSTMENARCHAL GIRLS, AGES 10 TO 17 YEARS, WITH A RECOMMENDATION DOSING RANGE OF 5 TO 20 MG ONCE DAILY
I-612	MICARDIS 80 MG FOR REDUCTION OF THE RISK OF MYOCARDIAL INFARCTION, STROKE, OR DEATH FROM CARDIOVASCULAR CAUSES IN PATIENTS 55 YEARS OF AGE OR OLDER AT HIGH RISK OF DEVELOPING MAJOR CARDIOVASCULAR EVENTS WHO ARE UNABLE TO TAKE ACE

PATENT AND EXCLUSIVITY TERMS

ADB 27 of 191

EXCLUSIVITY INDICATION

INHIBITORS

I-613	MILD TO MODERATE ATOPIC DERMATITIS IN PATIENTS 3 MONTHS OF AGE TO LESS THAN 18 YEARS OF AGE
I-614	SHORT TERM TREATMENT OF EROSIIVE ESOPHAGITIS ASSOCIATED WITH GERD IN PEDIATRIC PATIENTS AGES FIVE YEARS AND OLDER
I-615	MAINTENANCE TREATMENT OF BIPOLAR DISORDER AS AN ADJUNCT TO LITHIUM OR VALPROATE
I-616	TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER IN PEDIATRIC PATIENTS AGES 6-17 YEARS OF AGE
I-617	MAINTENANCE OF GENERALIZED ANXIETY DISORDER (GAD)
I-618	ADJUNCTIVE THERAPY IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
I-619	INTRAVENOUS CONTRAST ENHANCED COMPUTER TOMOGRAPHY OF THE HEAD AND BODY
I-620	FOR USE IN COMBINATION WITH LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE METASTATIC BREAST CANCER THAT OVEREXPRESSES THE HER2 RECEPTOR FOR WHOM HORMONAL THERAPY IS INDICATED
I-621	PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE, BASED ON THE RESULTS OF JUSTIFICATION FOR THE USE OF STATINS IN PRIMARY PREVENTION; AN INTERVENTION TRIAL EVALUATING ROSUVASTATIN (JUPITER)
I-622	ADJUNCTIVE THERAPY FOR PRIMARY GENERALIZED TONIC-CLONIC SEIZURES IN PATIENTS THIRTEEN YEARS OF AGE AND OLDER
I-623	TREATMENT OF SIGNS AND SYMPTOMS OF ADVANCED IDIOPATHIC PARKINSON'S DISEASE
I-624	MAINTENANCE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WHOSE DISEASE HAS NOT PROGRESSED AFTER FOUR CYCLES OF PLATINUM-BASED FIRST-LINE CHEMOTHERAPY
I-625	PANCREATIC INSUFFICIENCY DUE TO CHRONIC PANCREATITIS AND PANCREATECTOMY
I-626	RELIEF OF NASAL CONGESTION ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER
I-627	TREATMENT OF NEWLY DIAGNOSED ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (PH & CML) IN CHRONIC PHASE.
I-628	MAINTENANCE TREATMENT OF SCHIZOPHRENIA IN ADULTS
I-629	ADJUNCTIVE THERAPY WITH EITHER LITHIUM OR VALPROATE FOR THE ACUTE TREATMENT OF MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
I-630	TREATMENT OF PATIENTS WITH SUBEPENDYMAL GIANT CELL ASTROCYTOMA (SEGA) ASSOCIATED WITH TUBEROUS SCLEROSIS (TS) WHO REQUIRE THERAPEUTIC INTERVENTION BUT ARE NOT CANDIDATES FOR CURATIVE SURGICAL RESECTION.
I-631	PREVENTION OF RELAPSE TO OPIOID DEPENDENCE FOLLOWING OPIOID DETOXIFICATION
I-632	MANAGEMENT OF CHRONIC MUSCULOSKELETAL PAIN
I-633	MAINTENANCE TREATMENT OF BIPOLAR I DISORDER AS AN ADJUNCT TO LITHIUM OR VALPROATE
I-634	TREATMENT OF SEVERE HYPERCALCEMIA IN PATIENTS WITH PRIMARY HYPERPARATHYROIDISM WHO ARE UNABLE TO UNDERGO PARATHYROIDECTOMY
I-635	ADJUNCTIVE TREATMENT WITH LONG-ACTING ORAL PSYCHOSTIMULANTS FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
I-636	TREATMENT OF EXTERNAL GENITAL AND PERIANAL WARTS/CONDYLOMA ACUMINATA IN PATIENTS 12 YEARS OR OLDER
I-637	USE IN COMBINATION CHEMOTHERAPY WITH 5-FLUOROURACIL IN THE PALLIATIVE TREATMENT OF PATIENTS WITH ADVANCED METASTATIC COLORECTAL CANCER
I-638	FOR PATIENTS WITH PROGRESSIVE NEUROENDOCRINE TUMORS OF PANCREATIC ORIGIN (PNET) THAT ARE UNRESECTABLE, LOCALLY ADVANCED, OR METASTATIC.
I-639	TREATMENT OF PROGRESSIVE, WELL-DIFFERENTIATED PANCREATIC NEUROENDOCRINE TUMORS IN PATIENTS WITH UNRESECTABLE, LOCALLY ADVANCED, OR METASTATIC DISEASE
I-640	MAINTENANCE OF REMISSION OF ULCERATIVE COLITIS
I-641	TREATMENT OF THE SIGNS AND SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA (BPH)
I-642	TREATMENT OF ERECTILE DYSFUNCTION (ED) AND THE SIGNS AND SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA (BPH)
I-643	REDUCE THE RISK OF STROKE AND SYSTEMIC EMBOLISM IN PATIENTS WITH NONVALVULAR

PATENT AND EXCLUSIVITY TERMS

ADB 28 of 191

EXCLUSIVITY INDICATION

ATRIAL FIBRILLATION.

I-644	MONOTHERAPY IN PATIENTS 13 YEARS OF AGE AND OLDER WITH PARTIAL SEIZURES WHO ARE RECEIVING THERAPY WITH A SINGLE ANTIEPILEPTIC DRUG (AED)
I-645	MAINTENANCE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN ADULTS
I-646	SIGNS AND SYMPTOMS OF ADVANCED PARKINSON'S DISEASE (APD)
I-647	SIGNS AND SYMPTOMS OF MODERATE TO SEVERE PRIMARY RESTLESS LEGS SYNDROME (RLS)
I-648	TREATMENT OF HEAVY MENSTRUAL BLEEDING IN WOMEN WITHOUT ORGANIC PATHOLOGY WHO CHOOSE TO USE AN ORAL CONTRACEPTIVE AS THEIR METHOD OF CONTRACEPTION
I-649	TREATMENT OF PATIENTS WITH ADVANCED SOFT TISSUE SARCOMA (STS) WHO HAVE RECEIVED PRIOR CHEMOTHERAPY
I-650	TREATMENT OF ADULTS WITH RENAL ANGIOMYOLIPOMA AND TUBEROUS SCLEROSIS COMPLEX (TSC), NOT REQUIRING IMMEDIATE SURGERY
I-651	MANAGEMENT OF NEUROPATHIC PAIN ASSOCIATED WITH SPINAL CORD INJURY
I-652	MANAGEMENT OF POSTHERPETIC NEURALGIA
I-653	TREATMENT OF ENDOGENOUS ANTERIOR UVEITIS
I-654	MAGNETIC RESONANCE ANGIOGRAPHY (MRA) TO EVALUATE ADULTS WITH KNOWN OR SUSPECTED RENAL OR AORTO-ILIO-FEMORAL OCCLUSIVE VASCULAR DISEASE
I-655	TREATMENT OF POSTMENOPAUSAL WOMEN WITH ADVANCED HORMONE RECEPTOR-POSITIVE,HER2-NEGATIVE BREAST CANCER (ADVANCED HR+BC) IN COMBINATION WITH EXEMESTANE, AFTER FAILURE OF TREATMENT WITH LETROZOLE OR ANASTROZOLE
I-656	MANAGEMENT OF NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY (DPN) IN ADULTS WHEN A CONTINUOUS, AROUND-THE-CLOCK OPIOID ANALGESIC IS NEEDED FOR AN EXTENDED PERIOD OF TIME
I-657	PLAQUE PSORIASIS OF THE SCALP
I-658	FIRST-LINE TREATMENT OF LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER, IN COMBINATION WITH CARBOPLATIN, IN PATIENTS WHO ARE NOT CANDIDATES FOR CURATIVE SURGERY OR RADIATION THERAPY
I-659	PLAQUE PSORIASIS OF THE BODY
I-660	TREATMENT OF DEEP VEIN THROMBOSIS
I-661	TREATMENT OF PULMONARY EMBOLISM
I-662	REDUCTION IN RISK FOR DEEP VEIN THROMBOSIS AND THE REDUCTION IN RISK FOR PULMONARY EMBOLISM
I-663	IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
I-664	TREATMENT OF THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC HEPATITIS C TO ALLOW THE INITIATION AND MAINTENANCE OF INTERFERON-BASED THERAPY
I-665	TREATMENT OF CHRONIC IRON OVERLOAD IN PATIENTS 10 YRS OF AGE AND OLDER WITH (NTDT)SYNDROMES AND WITH A (LIC) OF AT LEAST 5 MG OF IRON PER GRAM OF LIVER DRY WEIGHT (MG FE/G DW) AND SERUM FERRITIN GREATER THAN 300MCG/L
I-666	TREATMENT OF PEDIATRIC PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (PH+ALL) IN COMBINATION WITH CHEMOTHERAPY
I-667	TREATMENT OF PATIENTS WITH LOCALLY ADVANCED, UNRESECTABLE OR METASTATIC GASTROINTESTINAL STROMAL TUMOR (GIST) WHO HAVE BEEN PREVIOUSLY TREATED WITH IMATINIB MESYLATE AND SUNITINIB MALATE
I-668	PROPHYLAXIS OF ALLOGRAFT REJECTION IN ADULT PATIENTS RECEIVING A LIVER TRANSPLANT
I-669	SCINTIGRAPHIC ASSESSMENT OF SYMPATHETIC INNERVATION OF THE MYOCARDIUM BY MEASUREMENT OF THE HEART TO MEDIASTINUM (H/M) RATIO OF RADIOACTIVITY UPTAKE IN PATIENTS WITH NYHA CLASS II OR CLASS III HEART FAILURE AND LVEF LESS THAN 35%
I-670	TREATMENT OF OPIOID-INDUCED CONSTIPATION (OIC) IN ADULTS WITH CHRONIC, NON-CANCER PAIN
I-671	FIRSTLINE TREATMENT OF PATIENTS WITH METASTATIC NON- SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS HAVE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 19 DELETIONS OR EXON 21(L858R) SUBSTITUTION MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST

PATENT AND EXCLUSIVITY TERMS

ADB 29 of 191

EXCLUSIVITY INDICATION

I-672	USE IN PATIENTS WITH MANTLE CELL LYMPHOMA WHOSE DISEASE HAS RELAPSED OR PROGRESSED AFTER TWO PRIOR THERAPIES, ONE OF WHICH INCLUDED BORTEZOMIB
I-673	TREATMENT OF HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA/VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA (HABP/VABP) CAUSED BY SUSCEPTIBLE ISOLATES OF S. AUREUS (INCLUDING METHICILLIN-SUSCEPTIBLE AND RESISTANT ISOLATES) WHEN ALTERNATIVE TREATMENTS ARE NOT SUITABLE
I-674	TREATMENT OF PATIENTS WITH DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR I DISORDER (BIPOLAR DEPRESSION) AS MONOTHERAPY AND AS ADJUNCTIVE THERAPY WITH LITHIUM OR VALPROATE
I-675	MAINTENANCE TREATMENT OF MAJOR DEPRESSIVE DISORDER
I-676	FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC ADENOCARCINOMA OF THE PANCREAS, IN COMBINATION WITH GEMCITABINE
I-677	TREATMENT OF PATIENTS WITH LOCALLY RECURRENT OR METASTATIC, PROGRESSIVE, DIFFERENTIATED THYROID CARCINOMA (DTC) THAT IS REFRACTORY TO RADIOACTIVE IODINE TREATMENT
I-678	TRAMETINIB, IN COMBINATION WITH DABRAFENIB, FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E OR V600K MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST
I-679	RISK REDUCTION OF REBLEEDING OF GASTRIC OR DUODENAL ULCERS FOLLOWING THERAPEUTIC ENDOSCOPY IN ADULTS
I-680	TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
I-681	PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT) WHICH MAY LEAD TO PULMONARY EMBOLISM (PE), IN ADULT PATIENTS WHO HAVE UNDERGONE HIP OR KNEE REPLACEMENT
I-682	TREATMENT OF DEEP VEIN THROMBOSIS (DVT) AND PULMONARY EMBOLISM (PE) IN PATIENTS WHO HAVE BEEN TREATED WITH A PARENTERAL ANTICOAGULANT FOR 5-10 DAYS
I-683	TO REDUCE THE RISK OF RECURRENCE OF DVT AND PE IN PATIENTS WHO HAVE BEEN PREVIOUSLY TREATED
I-684	PREVENTION OF ACUTE NAUSEA AND VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF EMETOGENIC CANCER CHEMOTHERAPY, INCLUDING HIGHLY EMETOGENIC CANCER CHEMOTHERAPY IN PEDIATRIC PATIENTS AGED 1 MONTH TO LESS THAN 17 YEARS
I-685	EXPANDED INDICATION OF RASAGILINE AS AN ADD-ON THERAPY TO STABLE DOSES OF DOPAMINE AGONISTS IN THE TREATMENT OF EARLY PARKINSON'S DISEASE
I-686	INDICATED FOR THE TREATMENT OF DIABETIC MACULAR EDEMA IN PATIENTS WHO ARE PSEUDOPHAKIC OR ARE PHAKIC AND SCHEDULED FOR CATARACT SURGERY
I-687	GUIDING SENTINEL LYMPH NODE BIOPSY, USING A HAND-HELD GAMMA COUNTER IN PATIENTS WITH CLINICALLY NODE NEGATIVE SQUAMOUS CELL CARCINOMA OF THE ORAL CAVITY
I-688	GADAVIST IS INDICATED WITH MRI TO DETECT THE PRESENCE AND EXTENT OF MALIGNANT BREAST DISEASE
I-689	TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH 17P DELETION
I-690	INDICATED FOR THE TREATMENT OF DEEP VEIN THROMBOSIS (DVT)
I-691	INDICATED TO REDUCE THE RISK OF RECURRENT DEEP VEIN THROMBOSIS (DVT) AND PULMONARY EMBOLISM (PE) FOLLOWING INITIAL THERAPY
I-692	INDICATED FOR MANAGEMENT OF OSTEOARTHRITIS PAIN.
I-693	TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (CRPC)
I-694	TREATMENT OF PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS WHO ARE CANDIDATES FOR PHOTOTHERAPY OR SYSTEMIC THERAPY
I-695	REVISED INDICATION FOR BORTEZOMIB IN THE TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA
I-696	USE AS MONOTHERAPY IN THE TREATMENT OF PARTIAL-ONSET SEIZURES IN PATIENTS WITH EPILEPSY AGE 17 YEARS AND OLDER
I-697	FOR USE IN COMBINATION WITH SOFOSBUVIR FOR THE TREATMENT OF PATIENTS WITH CHRONIC HEPATITIS C VIRUS GENOTYPE 1 INFECTION
I-698	SCHIZOAFFECTIVE DISORDER AS MONOTHERAPY AND AS AN ADJUNCT TO MOOD STABILIZERS OR ANTIDEPRESSANTS
I-699	FOR TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA WHO HAVE HAD AN INADEQUATE

PATENT AND EXCLUSIVITY TERMS

ADB 30 of 191

EXCLUSIVITY INDICATION

	RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA
I-700	TREATMENT OF PEDIATRIC PATIENTS WITH TOURETTE'S DISORDER (6-18 YEARS)
I-701	FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE, WELL-OR MODERATELY-DIFFERENTIATED, LOCALLY ADVANCED OR METASTATIC GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS (GEP-NETS) TO IMPROVE PROGRESSION FREE SURVIVAL
I-702	FOR THE TREATMENT OF PATIENTS WITH WALDENSTROM MACROGLOBULINEMIA
I-703	MODERATE TO SEVERE BINGE EATING DISORDER (BED)
I-704	EXPANDED INDICATION TO INCLUDE PATIENTS WHO ARE VIROLOGICALLY-SUPPRESSED (HIV-1 RNA <50 COPIES/ML) ON A STABLE ANTIRETROVIRAL REGIMEN FOR AT LEAST 6 MONTHS WITH NO HISTORY OF TREATMENT FAILURE IN ORDER TO REPLACE THEIR CURRENT REGIMEN
I-705	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS 6 YEARS AND OLDER WHO HAVE AN R117H MUTATION IN THE CFTR GENE
I-706	EXPANDED INDICATION FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA
I-707	POMALYST, IN COMBINATION WITH DEXAMETHASONE, IS INDICATED FOR PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST 2 PRIOR THERAPIES AND HAVE DEMONSTRATED DISEASE PROGRESSION ON OR WITHIN 60 DAYS OF COMPLETION OF THE LAST THERAPY
I-708	DAILY TREATMENT OF ASTHMA IN PATIENTS AGED 18 YEARS AND OLDER
I-709	TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) IN ADULTS
I-710	ADJUNCTIVE THERAPY FOR THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC (PG TC) SEIZURES IN PATIENTS WITH EPILEPSY 12 YEARS OF AGE OR OLDER.
I-711	INCLUSION OF PEDIATRIC PATIENTS AGES 6 YRS AND OLDER FOR THE TREATMENT OF THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC ITP WHO HAVE HAD AN INSUFFICIENT RESPONSE TO CORTICOSTEROIDS, IMMUNOGLOBULINS, OR SPLENECTOMY.
I-712	EXPANDED INDICATION FOR USE IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH RELAPSED MULTIPLE MYELOMA WHO HAVE RECEIVED ONE TO THREE PRIOR LINES OF THERAPY
I-713	REVISIONS TO THE LABELING TO PERMIT THE USE OF ZUBSOLV AS INITIAL ("INDUCTION") TREATMENT OF OPIOID DEPENDENCE
I-714	EXTENDS THE 2011 APPROVAL OF BRILINTA FOR USE BEGINNING WITH ACS TO USE BEGINNING MORE REMOTE FROM MYOCARDIAL INFARCTION
I-715	FOR THE ADDITION OF THE INDICATION FOR MONOTHERAPY TREATMENT IN PARTIAL-ONSET SEIZURES IN ADULTS.
I-716	REVISED INDICATION TO INCLUDE LANGUAGE ABOUT THE BENEFITS OF USING LETAIRIS IN COMBINATION WITH TADALAFIL TO REDUCE THE RISK OF DISEASE PROGRESSION AND HOSPITALIZATION FOR WORSENING PAH AND TO IMPROVE EXERCISE ABILITY, BASED ON THE AMBITION STUDY
I-717	EXPANDED INDICATION TO INCLUDE THE TREATMENT OF CHRONIC HEPATITIS C GENOTYPE 4
I-718	EXPANDED INDICATION TO INCLUDE SUBJECTS INFECTED WITH CHRONIC HEPATITIS C, GENOTYPE 6 VIRUS INFECTION BASED UPON THE RESULTS OF THE ELECTRON- 2 STUDY
I-719	EXPANDED INDICATION TO INCLUDE THE TREATMENT OF SUBJECTS WITH GENOTYPE 5 CHRONIC HEPATITIS C VIRUS INFECTION BASED ON THE RESULTS FROM STUDY GS-US-337-119.
I-720	EXPANDED INDICATION TO INCLUDE TREATMENT OF GENOTYPE 4, CHRONIC HEPATITIS C VIRUS INFECTION BASED UPON THE RESULTS FROM STUDIES ION-4 AND GS-US-337-119.
I-721	TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC LIPOSARCOMA WHO HAVE RECEIVED A PRIOR ANTHRACYCLINE-CONTAINING REGIMEN.
I-722	REVISED INDICATION FOR USE IN COMBINATION WITH DEXAMETHASONE OR WITH LENALIDOMIDE PLUS DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED ONE TO THREE LINES OF THERAPY.
I-723	AS A SINGLE AGENT FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED ONE OR MORE LINES OF THERAPY
I-724	TREATMENT OF ADULT PATIENTS WITH PROGRESSIVE, WELL DIFFERENTIATED, NON-FUNCTIONAL NEUROENDOCRINE TUMORS (NET) OF GI OR LUNG ORIGIN WITH UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC DISEASE
I-725	TREATMENT OF HORMONE RECEPTOR (HR)-POSITIVE, HER2-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER IN COMBINATION THERAPY WITH PALBOCICLIB AND FULVESTRANT IN WOMEN WITH DISEASE PROGRESSION FOLLOWING ENDOCRINE THERAPY.

PATENT AND EXCLUSIVITY TERMS

ADB 31 of 191

EXCLUSIVITY INDICATION

I-726	EXPANSION OF THE PATIENT POPULATION TO INCLUDE PATIENTS WITH RECURRENCE OF HEPATITIS C VIRUS (HCV) GENOTYPE 1 OR 3 AFTER LIVER TRANSPLANTATION
I-727	EXPANSION OF THE INDICATION TO INCLUDE TREATMENT OF SUBJECTS WITH GENOTYPE-1 CHRONIC HEPATITIS C VIRUS INFECTION, INCLUDING SUBJECTS WHO ARE CO-INFECTED WITH THE HUMAN IMMUNODEFICIENCY VIRUS (HIV-1) BASED ON THE RESULTS FROM THE ALLY-2 CLINICAL TRIAL
I-728	EXPANDED INDICATION FOR USE IN ULTRASONOGRAPHY OF THE LIVER FOR CHARACTERIZATION OF FOCAL LIVER LESIONS IN ADULT AND PEDIATRIC PATIENTS
I-729	PROVIDES FOR THE FRONTLINE INDICATION FOR THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
I-730	NEW INDICATION FOR THE TREATMENT OF PATIENTS WITH METASTATIC, SQUAMOUS, NON-SMALL CELL LUNG CANCER PROGRESSING AFTER PLATINUM-BASED CHEMOTHERAPY
I-731	FOR USE IN MAGNETIC RESONANCE ANGIOGRAPHY IN ADULT AND PEDIATRIC PATIENTS (INCLUDING TERM NEONATES) TO EVALUATE KNOWN OR SUSPECTED SUPRA-AORTIC OR RENAL ARTERY DISEASE
I-732	TREATMENT OF PEDIATRIC PATIENTS 7 TO 17 YEARS OF AGE WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA TO REDUCE LDL-C, TOTAL C, NONHDL-C AND APOB AS AN ADJUNCT TO DIET, EITHER ALONE OR WITH OTHER LIPID-LOWERING TREATMENTS
I-733	USE OF CANAGLIFLOZIN FOR INITIAL THERAPY IN COMBINATION WITH METFORMIN
I-734	EXPANDED INDICATION FOR THE USE OF LENVIMA IN COMBINATION WITH EVEROLIMUS FOR THE TREATMENT OF PATIENTS WITH ADVANCED RCC FOLLOWING ONE PRIOR ANTI-ANGIOGENIC THERAPY.
I-735	AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHEN TREATMENT WITH BOTH CANAGLIFLOZIN AND METFORMIN IS APPROPRIATE
I-736	REVISED INDICATION TO INCLUDE THE TREATMENT OF PATIENTS WITH SMALL LYMPHOCYTIC LEUKEMIA (SLL)
I-737	REVISED INDICATION TO INCLUDE THE TREATMENT OF PATIENTS WITH SMALL LYMPHOCYTIC LEUKEMIA (SLL) WITH 17P DELETION
I-738	REVISIONS TO THE INDICATIONS AND USAGE SECTION WITH RESPECT TO COMPLICATED INTRA-ABDOMINAL INFECTIONS
I-739	TO REDUCE THE RISK OF CARDIOVASCULAR DEATH IN ADULT PATIENTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED CARDIOVASCULAR DISEASE
I-740	EXPANDED INDICATION FOR THE TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGE 6 YEARS AND OLDER TO INCLUDE THE G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, OR S549R MUTATION IN THE CFTR GENE
I-741	TREATMENT OF PATIENTS WITH MARGINAL ZONE LYMPHOMA (MZL) WHO REQUIRE SYSTEMIC THERAPY AND HAVE RECEIVED AT LEAST ONE PRIOR ANTI-CD20-BASED THERAPY
I-742	TREATMENT OF NODAL MARGINAL ZONE LYMPHOMA
I-743	INFORMATION ADDED TO THE LABELING FOR THE ADDITION OF THE TREATMENT OF CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 4 (GT4) INFECTED PATIENTS WITH COMPENSATED CIRRHOSIS BASED ON RESULTS FROM STUDY M11-665
I-744	TREATMENT OF PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC) WHO HAVE BEEN PREVIOUSLY TREATED WITH SORAFENIB
I-745	MEKINIST, IN COMBINATION WITH DABRAFENIB, FOR THE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH BRAF V600E MUTATION AS DETECTED BY AN FDA-APPROVED TEST.
I-746	NEW INDICATION OF MAINTENANCE MONOTHERAPY TREATMENT OF BIPOLAR I DISORDER IN ADULTS
I-747	FOR REDUCING THE RISK OF GRAFT REJECTION WHEN USED WITH HIGH-DOSE BUSULFAN AND CYCLOPHOSPHAMIDE AS A PREPARATIVE REGIMEN FOR ALLOGENEIC HEMATOPOIETIC PROGENITOR (STEM) CELL TRANSPLANTATION FOR PEDIATRIC PATIENTS WITH CLASS 3 BETA-THALASSEMIA
I-748	TO REDUCE THE ACUTE COMPLICATIONS OF SICKLE CELL DISEASE IN ADULT AND PEDIATRIC PATIENTS FIVE YEARS OF AGE AND OLDER
I-749	MONOTHERAPY FOR THE TREATMENT OF HORMONE RECEPTOR (HR) POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE, ADVANCED BREAST CANCER IN POSTMENOPAUSAL WOMEN NOT PREVIOUSLY TREATED WITH ENDOCRINE THERAPY

PATENT AND EXCLUSIVITY TERMS

ADB 32 of 191

EXCLUSIVITY INDICATION

I-750	REDUCE THE RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED CARDIOVASCULAR DISEASE
I-751	TREATMENT OF TARDIVE DYSKINESIA
I-752	CORONARY COMPUTED TOMOGRAPHY ANGIOGRAPHY (CCTA) TO ASSIST DIAGNOSTIC EVALUATION OF PATIENTS WITH SUSPECTED CORONARY ARTERY DISEASE
I-753	TREATMENT OF ADULT PATIENTS WITH CHRONIC GRAFT VERSUS HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR MORE LINES OF SYSTEMIC THERAPY
I-754	TO REDUCE THE FREQUENCY OF SHORT-ACTING SOMATOSTATIN ANALOG RESCUE THERAPY WHEN USED FOR THE TREATMENT OF ADULTS WITH CARCINOID SYNDROME
I-755	ADJUVANT TREATMENT OF ADULT PATIENTS AT HIGH RISK OF RECURRENT RENAL CELL CARCINOMA (RCC) FOLLOWING NEPHRECTOMY
I-756	EXPANDED THE APPROVED INDICATION BY REMOVING THE RESTRICTION FOR USE ONLY IN PATIENTS WHO HAVE PROGRESSED ON OR ARE INTOLERANT TO CRIZOTINIB
I-757	TREATMENT OF PATIENTS WITH ERDHEIM-CHESTER DISEASE WITH BRAF V600 MUTATION
I-758	FOR USE WITH RILPIVIRINE AS A COMPLETE REGIMEN TO REPLACE THE CURRENT ARV REGIMEN IN VIROLOGICALLY SUPPRESSED PATIENTS ON A STABLE ARV REGIMEN FOR AT LEAST 6 MONTHS WITH NO HISTORY OF TX FAILURE OR KNOWN SUBSTITUTIONS ASSOC. WITH RESISTANCE TO EITHER ARV
I-759	TREATMENT OF ADULT PATIENTS WITH NEWLY-DIAGNOSED CHRONIC PHASE (CP) PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOGENOUS LEUKEMIA (PH+CML)
I-760	FOR THE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA
I-761	TREATMENT OF ADULT PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO METHOTREXATE OR OTHER NON-BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS
I-762	TREATMENT OF DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINE BRCA-MUTATED, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE METASTATIC BREAST CANCER WHO HAVE BEEN TREATED WITH CHEMOTHERAPY IN THE NEOADJUVANT, ADJUVANT OR METASTATIC SETTING
I-763	TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER WHOSE TUMORS HAVE NON-RESISTANT EPIDERMAL GROWTH FACTOR RECEPTOR MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST
I-764	TREATMENT IN ADULT PATIENTS FOR IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C)
I-765	ABIRATERONE ACETATE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH METASTATIC HIGH-RISK CASTRATION-SENSITIVE PROSTATE CANCER
I-766	TREATMENT OF MINIMALLY TO MODERATELY THICK ACTINIC KERATOSIS OF THE UPPER EXTREMITIES IN CONJUNCTION WITH A BLUE LIGHT PHOTODYNAMIC THERAPY ILLUMINATOR
I-767	TREATMENT OF IRON DEFICIENCY ANEMIA IN ADULT PATIENTS WHO HAVE INTOLERANCE TO ORAL IRON OR HAVE HAD UNSATISFACTORY RESPONSE TO ORAL IRON
I-768	IN COMBINATION WITH AN AROMATASE INHIBITOR AS INITIAL ENDOCRINE-BASED THERAPY FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER
I-769	TREATMENT OF DYSKINESIA IN PATIENTS WITH PARKINSON'S DISEASE RECEIVING LEVODOPA-BASED THERAPY, WITH OR WITHOUT CONCOMITANT DOPAMINERGIC MEDICATIONS
I-770	TREATMENT OF ACUTE OTITIS EXTERNA IN PATIENTS 6 MONTHS OF AGE AND OLDER DUE TO PSEUDOMONAS AERUGINOSA AND STAPHYLOCOCCUS AUREUS
I-771	REVISION OF THE INDICATION SECTION OF THE PACKAGE INSERT REGARDING AN INTERSCALENE BRACHIAL PLEXUS NERVE BLOCK TO PRODUCE POSTSURGICAL REGIONAL ANALGESIA
I-772	FOR THE MAINTENANCE TREATMENT OF ADULT PATIENTS WITH RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER WHO ARE IN A COMPLETE OR PARTIAL RESPONSE TO PLATINUM-BASED CHEMOTHERAPY
I-773	FOR THE ADJUNCTIVE TREATMENT OF ADULT AND PEDIATRIC PATIENTS AGE 2 YEARS AND OLDER WITH TUBEROUS SCLEROSIS COMPLEX (TSC)-ASSOCIATED PARTIAL-ONSET SEIZURES
I-774	TO ALLOW FOR FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS HAVE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 19 DELETIONS OR EXON 21 (L858R) SUBSTITUTION MUTATIONS, AS DETECTED BY AN FDA APPROVED TEST

PATENT AND EXCLUSIVITY TERMS

ADB 33 of 191

EXCLUSIVITY INDICATION

I-775	REVISED INDICATION FOR FIXED-DOSE COMBINATION OF FLUTICASONE FUROATE, UMECLIDINIUM, AND VILANTEROL TO TREAT AIRFLOW OBSTRUCTION IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) AND TO REDUCE COPD EXACERBATIONS IN PTS WITH HISTORY OF EXACERBATIONS
I-776	FIRSTLINE MAINTENANCE TX IN PTS W/ DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINE, SOMATIC BRCA-MUTATED ADVANCED EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CA WHO ARE IN COMPLETE OR PARTIAL RESPONSE TO FIRSTLINE PLATINUM-BASED CHEMOTHERAPY
I-777	CO-ADMINISTRATION THERAPY OF MIRABEGRON WITH SOLIFENACIN SUCCINATE FOR TREATMENT OF OVERACTIVE BLADDER WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND URINARY FREQUENCY
I-778	DABRAFENIB IN COMBINATION WITH TRAMETINIB FOR THE ADJUVANT TREATMENT OF PATIENTS WITH MELANOMA WITH BRAF V600E OR V600K MUTATIONS, AS DETECTED BY AN FDA-APPROVED TEST, AND INVOLVEMENT OF LYMPH NODE(S), FOLLOWING COMPLETE RESECTION
I-779	USE OF TOLVAPTAN TO SLOW KIDNEY FUNCTION DECLINE IN ADULTS AT RISK OF RAPIDLY PROGRESSING AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD)
I-780	TREATMENT OF ADULT PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (UC)
I-781	DABRAFENIB IN COMBINATION WITH TRAMETINIB FOR THE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC ANAPLASTIC THYROID CANCER (ATC) WITH BRAF V600E MUTATION AND WITH NO SATISFACTORY LOCOREGIONAL TREATMENT OPTIONS
I-782	REVISIONS TO INDICATION FOR THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL), WITH OR WITHOUT 17P DELETION, WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
I-783	EXPANDED INDICATION TO INCLUDE RIBOCICLIB WITH AN AROMATASE INHIBITOR IN PRE/PERIMENOPAUSAL WOMEN WITH HORMONE RECEPTOR-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER, AS INITIAL ENDOCRINE-BASED THERAPY
I-784	RIBOCICLIB WITH FULVESTRANT FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HR-POSITIVE, HER2-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER, AS INITIAL ENDOCRINE BASED THERAPY OR FOLLOWING DISEASE PROGRESSION ON ENDOCRINE THERAPY
I-785	TREATMENT OF PATIENTS WITH CUSHING'S DISEASE FOR WHOM PITUITARY SURGERY IS NOT AN OPTION OR HAS NOT BEEN CURATIVE
I-786	TREATMENT OF PATIENTS WITH NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
I-787	FIRST-LINE TREATMENT OF PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA (HCC)
I-788	NEW INDICATION FOR CANAGLIFLOZIN TO REDUCE THE RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS (CARDIOVASCULAR DEATH, NONFATAL MYOCARDIAL INFARCTION AND NONFATAL STROKE) IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED CARDIOVASCULAR DISEASE (CVD)
I-789	VENETOCLAX IN COMBO WITH AZACITIDINE OR DECITABINE OR LOW-DOSE CYTARABINE FOR THE TX OF NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA IN ADULTS WHO ARE AGE 75 YEARS OR OLDER, OR WHO HAVE COMORBIDITIES THAT PRECLUDE USE OF INTENSIVE INDUCTION CHEMOTHERAPY
I-790	USE OF FERRIC CITRATE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN ADULT PATIENTS WITH CKD NOT ON DIALYSIS
I-791	TREATMENT OF PEDIATRIC PATIENTS ONE YEAR OF AGE AND OLDER WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE (PH+) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN COMBINATION WITH CHEMOTHERAPY
I-792	TREATMENT OF PATIENTS WITH HEPATOCELLULAR CARCINOMA WHO HAVE BEEN PREVIOUSLY TREATED WITH SORAFENIB
I-793	TREATMENT OF MODERATE TO SEVERE VAGINAL DRYNESS, A SYMPTOM OF VULVAR AND VAGINAL ATROPHY, DUE TO MENOPAUSE
I-794	TREATMENT OF ADULT PATIENTS WITH METASTATIC GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA PREVIOUSLY TREATED WITH AT LEAST TWO PRIOR LINES OF CHEMOTHERAPY, AND IF APPROPRIATE, HER2/NEU-TARGETED THERAPY
I-795	VENETOCLAX IN COMBINATION WITH OBINUTUZUMAB IN PREVIOUSLY UNTREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LYMPHOMA
I-796	USED IN COMBINATION WITH A RITUXIMAB PRODUCT, ARE INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY TREATED FOLLICULAR LYMPHOMA (FL)

PATENT AND EXCLUSIVITY TERMS

ADB 34 of 191

EXCLUSIVITY INDICATION

I-797	USED IN COMBINATION WITH A RITUXIMAB PRODUCT, ARE INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY TREATED MARGINAL ZONE LYMPHOMA (MZL)
I-798	TREATMENT OF DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR I DISORDER (BIPOLAR DEPRESSION)
I-799	TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (GVHD) IN ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER
I-800	TREATMENT OF OCULAR INFLAMMATION FOLLOWING OPHTHALMIC SURGERY
I-801	USE IN CARDIAC MRI TO ASSESS MYOCARDIAL PERFUSION (STRESS, REST) AND LATE GADOLINIUM ENHANCEMENT IN ADULT PATIENTS WITH KNOWN OR SUSPECTED CORONARY ARTERY DISEASE (CAD)
I-802	TREATMENT OF THROMBOCYTOPENIA IN ADULT PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA WHO HAVE HAD AN INSUFFICIENT RESPONSE TO A PREVIOUS TREATMENT
I-803	TREATMENT OF ADULT PATIENTS WITH ORAL ULCERS ASSOCIATED WITH BEHCETS DISEASE
I-804	EXPANDED INDICATION FOR USE AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
I-805	SLOW THE RATE OF DECLINE IN PULMONARY FUNCTION IN PATIENTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE
I-806	EXPANDED INDICATION FOR PTS WHO ARE VIROLOGICALLY SUPPRESSED (HIV-1 RNA LESS THAN 50 COPIES/ML) ON A STABLE ARV REGIMEN WITH NO HX OF TX FAILURE AND NO KNOWN SUBSTITUTIONS ASSOCIATED W RESISTANCE TO DORAVIRINE, LAMIVUDINE OR TENOFOVIR DISOPROXIL FUMARATE
I-807	TREATMENT OF ADVANCED ENDOMETRIAL CARCINOMA THAT IS NOT MICROSATELLITE INSTABILITY-HIGH OR MISMATCH REPAIR DEFICIENT, WHO HAVE DISEASE PROGRESSION FOLLOWING PRIOR SYSTEMIC THERAPY AND ARE NOT CANDIDATES FOR CURATIVE SURGERY OR RADIATION
I-808	TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (MCSPC)
I-809	TO REDUCE THE RISK OF END-STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND DIABETIC NEPHROPATHY WITH ALBUMINURIA > 300 MG/DAY
I-810	PROPHYLAXIS OF VENOUS THROMBOEMBOLISM IN ACUTELY ILL MEDICAL PATIENTS AT RISK FOR THROMBOEMBOLIC COMPLICATIONS NOT AT HIGH RISK OF BLEEDING
I-811	TREATMENT OF ACUTE UNCOMPLICATED INFLUENZA IN PATIENTS 12 YEARS OF AGE OR OLDER, WHO HAVE BEEN SYMPTOMATIC FOR NO MORE THAN 48 HOURS AND ARE AT HIGH RISK OF DEVELOPING INFLUENZA-RELATED COMPLICATIONS
I-812	FOR USE IN AT RISK ADULTS AND ADOLESCENTS WEIGHING AT LEAST 35 KG FOR PRE-EXPOSURE PROPHYLAXIS TO REDUCE THE RISK OF HIV-1 INFECTION FROM SEXUAL ACQUISITION, EXCLUDING INDIVIDUALS AT RISK FROM RECEPTIVE VAGINAL SEX
I-813	TX OF ADULT PTS W/ ADV OVARIAN FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER TREATED W/ >=3 PRIOR CHEMO REGIMENS & ASSOCIATED W/ HRD DEFICIENCY POSITIVE STATUS DEFINED BY A DELETERIOUS OR SUSPECTED DELETERIOUS BRCA MUTATION
I-814	TX OF ADV OVARIAN FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER TREATED W/ >=3 PRIOR CHEMO REGIMENS & ASSOCIATED W/ HRD DEFICIENCY DEFINED BY POSITIVE STATUS GENOMIC INSTABILITY & WHO HAVE PROGRESSED >6MO AFTER RESPONSE TO LAST PLATINUM-BASED CHEMO
I-815	TREATMENT OF COMMUNITY ACQUIRED BACTERIAL PNEUMONIA (CABP) CAUSED BY DESIGNATED SUSCEPTIBLE BACTERIA IN ADULTS
I-816	TREATMENT OF ADULT PATIENTS WITH NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) WHO ARE >= 75 YEARS OLD OR WHO HAVE COMORBIDITIES THAT PRECLUDE USE OF INTENSIVE INDUCTION CHEMOTHERAPY
I-817	TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL)
I-818	MAINTENANCE TREATMENT OF ADULT PATIENTS WITH DELETERIOUS OR SUSPECTED DELETERIOUS GBRCA METASTATIC PANCREATIC ADENOCARCINOMA WHOSE DISEASE HAS NOT PROGRESSED ON AT LEAST 16 WEEKS OF A FIRST-LINE PLATINUM-BASED CHEMOTHERAPY REGIMEN
I-819	ADJUNCT TO MAX TOLERATED STATIN TX TO REDUCE RISK OF MI, STROKE, CORONARY REVASCULARIZATION, & UNSTABLE ANGINA REQUIRING HOSPITALIZATION IN ADULTS W/ ELEVATED TG LEVELS & ESTABLISHED CV DISEASE OR DIABETES MELLITUS & 2+ RISK FACTORS FOR CV DISEASE

PATENT AND EXCLUSIVITY TERMS

ADB 35 of 191

EXCLUSIVITY INDICATION

I-820	INDICATED FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) (WHO GROUP 1) TO DELAY DISEASE PROGRESSION
I-821	TREATMENT OF CANDIDEMIA, ACUTE DISSEMINATED CANDIDIASIS, CANDIDA PERITONITIS AND ABSCESSSES WITHOUT MENINGOENCEPHALITIS AND/OR OCULAR DISSEMINATION IN PEDIATRIC PATIENTS YOUNGER THAN 4 MONTHS OF AGE
I-822	REDUCE THE RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS (CARDIOVASCULAR DEATH, NON-FATAL MYOCARDIAL INFARCTION OR NON-FATAL STROKE) IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED CARDIOVASCULAR DISEASE
I-823	USE IN COMBINATION WITH CAPECITABINE, FOR THE TREATMENT OF ADULT PATIENTS WITH ADVANCED OR METASTATIC HER2-POSITIVE BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR ANTI-HER2 BASED REGIMENS IN THE METASTATIC SETTING
I-824	RIVAROXABAN IN COMBINATION WITH ASPIRIN, IS INDICATED TO REDUCE THE RISK OF MAJOR CV EVENTS (CV DEATH, MI, AND STROKE) IN PATIENTS WITH CHRONIC CORONARY ARTERY DISEASE (CAD) OR PERIPHERAL ARTERY DISEASE (PAD)
I-825	TREATMENT FOR CHRONIC FIBROSING INTERSTITIAL LUNG DISEASES WITH A PROGRESSIVE PHENOTYPE
I-826	ENCORAFENIB, IN COMBINATION WITH CETUXIMAB, FOR THE TREATMENT OF ADULT PATIENTS WITH METASTATIC COLORECTAL CANCER WITH A BRAF V600E MUTATION, AS DETECTED BY AN FDA-APPROVED TEST, AFTER PRIOR THERAPY
I-827	EXPANDED INDICATION FOR PATIENTS WHO ARE VIROLOGICALLY SUPPRESSED (HIV-1 RNA LESS THAN 50 COPIES/ML) ON A STABLE ARV REGIMEN WITH NO HISTORY OF TREATMENT FAILURE AND NO KNOWN SUBSTITUTIONS ASSOCIATED WITH RESISTANCE TO DORAVIRINE
I-828	INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH CUSHING'S DISEASE FOR WHOM PITUITARY SURGERY IS NOT AN OPTION OR HAS NOT BEEN CURATIVE
I-829	TREATMENT OF PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH CENTRAL PRECOCIOUS PUBERTY (CPP)
I-830	TREATMENT OF ADULT PATIENTS WITH A DELETERIOUS BRCA MUTATION (GERMLINE AND/OR SOMATIC)-ASSOCIATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER WHO HAVE BEEN TREATED WITH ANDROGEN RECEPTOR-DIRECTED THERAPY AND A TAXANE-BASED CHEMOTHERAPY
I-831	W/BEVACIZUMAB FOR MAINTENANCE TX OF ADULTS W/ADV. EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CA IN COMPLETE OR PARTIAL RESPONSE TO FIRST-LINE PLATINUM-BASED CHEMO & CA ASSOCIATED W/ HOMOLOGOUS RECOMBINATION DEFICIENCY POSITIVE STATUS
I-832	TX OF ADULT PTS WITH DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINE OR SOMATIC HOMOLOGOUS RECOMBINATION REPAIR GENE-MUTATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER WHO HAVE PROGRESSED FOLLOWING PRIOR TREATMENT WITH ENZALUTAMIDE OR ABIRATERONE
I-833	MAINTENANCE TREATMENT OF ADULT PATIENTS WITH ADVANCED EPITHELIAL OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER WHO ARE IN A COMPLETE OR PARTIAL RESPONSE TO FIRST-LINE PLATINUM-BASED CHEMOTHERAPY
I-834	TO REDUCE THE RISK OF CARDIOVASCULAR DEATH AND HOSPITALIZATION FOR HEART FAILURE IN ADULTS WITH HEART FAILURE (NYHA CLASS II-IV) WITH REDUCED EJECTION FRACTION
I-835	TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL) WHOSE TUMORS ARE POSITIVE FOR AN EZH2 MUTATION AS DETECTED BY AN FDA-APPROVED TEST AND WHO HAVE RECEIVED AT LEAST 2 PRIOR SYSTEMIC THERAPIES
I-836	TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL) WHO HAVE NO SATISFACTORY ALTERNATIVE TREATMENT OPTIONS
I-837	TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL), NOT OTHERWISE SPECIFIED, INCLUDING DLBCL ARISING FROM FOLLICULAR LYMPHOMA, AFTER AT LEAST 2 LINES OF SYSTEMIC THERAPY
I-838	TREATMENT OF NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY (DPN) OF THE FEET
I-839	TO REPLACE THE CURRENT ANTIRETROVIRAL REGIMEN IN THOSE WHO ARE VIROLOGICALLY SUPPRESSED (HIV-1 RNA LESS THAN 50 COPIES PER ML) ON A STABLE ANTIRETROVIRAL REGIMEN WITH NO HISTORY OF TREATMENT FAILURE
I-840	TREATMENT OF SYMPTOMS IN ADULTS WITH MAJOR DEPRESSIVE DISORDER (MDD) WITH ACUTE SUICIDAL IDEATION OR BEHAVIOR.
I-841	TO REDUCE THE RISK OF HOSPITALIZATION FOR HEART FAILURE IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED CARDIOVASCULAR DISEASE OR MULTIPLE

PATENT AND EXCLUSIVITY TERMS

ADB 36 of 191

EXCLUSIVITY INDICATION

CARDIOVASCULAR RISK FACTORS

I-842	TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED ONE TO THREE LINES OF THERAPY IN COMBINATION WITH DARATUMUMAB AND DEXAMETHASONE
I-843	MAINTENANCE TREATMENT OF ASTHMA IN PATIENTS AGED 18 YEARS AND OLDER
I-844	INDICATED IN PATIENTS 18 YEARS OF AGE AND OLDER FOR THE TREATMENT OF HOSPITAL ACQUIRED BACTERIAL PNEUMONIA AND VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA (HABP/VABP) CAUSED BY THE FOLLOWING SUSCEPTIBLE GRAM-NEGATIVE MICROORGANISMS: ACINETOBACTER BAUMANNII COMPLEX, ESCHERICHIA COLI, ENTEROBACTER CLOACAE COMPLEX, KLEBSIELLA PNEUMONIAE, PSEUDOMONAS AERUGINOSA, AND SERRATIA MARCESCENS
I-845	TREATMENT OF ADULT PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) AS DETECTED BY AN FDA-APPROVED TEST
I-846	TREATMENT OF CATAPLEXY IN ADULT PATIENTS WITH NACROLEPSY
I-847	EXPANDED INDICATION OF THE TREATMENT OF ADULT PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) AS DETECTED BY AN FDA-APPROVED TEST
I-848	REDUCE THE RISK OF STROKE IN PATIENTS WITH ACUTE ISCHEMIC STROKE (NIH STROKE SCALE SCORE <=5) OR HIGH-RISK TRANSIENT ISCHEMIC ATTACK (TIA)
I-849	CHRONIC PHASE (CP) CHRONIC MYELOID LEUKEMIA (CML) WITH RESISTANCE OR INTOLERANCE TO AT LEAST TWO PRIOR KINASE INHIBITORS
I-850	TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME (SMS) IN PATIENTS 16 YEARS OF AGE AND OLDER
I-851	TO REDUCE THE RISK OF A FIRST MYOCARDIAL INFARCTION (MI) OR STROKE IN PATIENTS WITH CORONARY ARTERY DISEASE (CAD) AT HIGH RISK FOR SUCH EVENTS
I-852	TREATMENT OF PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER AND YOUNG ADULTS WITH RELAPSED OR REFRACTORY, SYSTEMIC ANAPLASTIC LARGE CELL LYMPHOMA (ALCL) THAT IS ALK-POSITIVE
I-853	INDICATION OF OSIMERTINIB AS ADJUVANT THERAPY AFTER TUMOR RESECTION IN ADULT PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS HAVE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 19 DELETIONS OR EXON 21 L858R MUTATIONS, AS DETECTED BY AN FDA-APPROVED TEST
I-854	FOR THE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA, AS A FIRST-LINE TREATMENT IN COMBINATION WITH NIVOLUMAB
I-855	TREATMENT OF NEUROGENIC DETRUSOR OVERACTIVITY (NDO) IN PEDIATRIC PATIENTS 3 YEARS AND OLDER AND WEIGHING 35 KILOGRAMS OR MORE
I-856	INDICATION FOR THE TREATMENT OF PULMONARY HYPERTENSION ASSOCIATED WITH INTERSTITIAL LUNG DISEASE TO IMPROVE EXERCISE ABILITY
I-857	TO REDUCE THE RISK OF SUSTAINED EGFR DECLINE, END-STAGE KIDNEY DISEASE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN ADULTS WITH CHRONIC KIDNEY DISEASE AT RISK OF PROGRESSION
I-858	FOR THE TOPICAL TREATMENT OF SCABIES INFESTATIONS IN ADULT AND PEDIATRIC PATIENTS 4 YEARS OF AGE AND OLDER
I-859	TREATMENT OF PATIENTS WITH TRANSFUSIONAL IRON OVERLOAD DUE TO SICKLE CELL DISEASE OR OTHER ANEMIAS
I-860	FOR THE TREATMENT OF MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN ADULT PATIENTS
I-861	TREATMENT OF NEUROGENIC DETRUSOR OVERACTIVITY (NDO) IN PEDIATRIC PATIENTS 6 YEARS OF AGE AND OLDER AND WEIGHING GREATER THAN 25 KG
I-862	TREATMENT OF VENOUS THROMBOEMBOLIC EVENTS (VTE) IN PEDIATRIC PATIENTS 8 TO LESS THAN 18 YEARS OF AGE WHO HAVE BEEN TREATED WITH A PARENTERAL ANTICOAGULANT FOR AT LEAST 5 DAYS AND TO REDUCE THE RISK OF RECURRENCE OF VTE IN PEDIATRIC PATIENTS 8 TO LESS THAN 18 YEARS OF AGE WHO HAVE BEEN PREVIOUSLY TREATED
I-863	TREATMENT OF ADULT PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS (ADVSM), INCLUDING PATIENTS WITH AGGRESSIVE SYSTEMIC MASTOCYTOSIS (ASM) AND SYSTEMIC MASTOCYTOSIS WITH AN ASSOCIATED HEMATOLOGICAL NEOPLASM (SM-AHN)
I-864	TREATMENT OF ADULT PATIENTS WITH MAST CELL LEUKEMIA (MCL)
I-865	FOR THE PREVENTIVE TREATMENT OF EPISODIC MIGRAINE IN ADULTS

PATENT AND EXCLUSIVITY TERMS

ADB 37 of 191

EXCLUSIVITY INDICATION

I-866	FOR THE TREATMENT OF TRICHOMONIASIS CAUSED BY TRICHOMONAS VAGINALIS IN ADULTS
I-867	INDICATED TO REDUCE THE RISK OF MAJOR THROMBOTIC VASCULAR EVENTS (MYOCARDIAL INFARCTION, ISCHEMIC STROKE, ACUTE LIMB ISCHEMIA, AND MAJOR AMPUTATION OF VASCULAR ETIOLOGY) IN PATIENTS WITH PAD, INCLUDING PATIENTS WHO HAVE RECENTLY UNDERGONE A LOWER EXTREMITY REVASCLARIZATION PROCEDURE DUE TO SYMPTOMATIC PAD
I-868	LENVATINIB IN COMBINATION WITH PEMBROLIZUMAB, IS INDICATED FOR THE FIRST-LINE TREATMENT OF ADULT PATIENTS WITH ADVANCED RENAL CELL CARCINOMA (RCC)
I-869	REDUCE THE RISK OF CARDIOVASCULAR DEATH AND HOSPITALIZATION FOR HEART FAILURE IN ADULTS WITH HEART FAILURE AND REDUCED EJECTION FRACTION
I-870	INDICATED FOR THE TREATMENT OF IDIOPATHIC HYPERSONNIA (IH) IN ADULTS
I-871	TREATMENT OF ADULT PATIENTS WITH WALDENSTROM'S MACROGLOBULINEMIA (WM)
I-872	ADDITION OF THE INDICATION OF TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR TWO LINES OF SYSTEMIC THERAPY IN ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER
I-873	TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH LOCALLY ADVANCED OR METASTATIC DIFFERENTIATED THYROID CANCER (DTC) THAT HAS PROGRESSED FOLLOWING PRIOR VEGFR-TARGETED THERAPY AND WHO ARE RADIOACTIVE IODINE-REFRACTORY OR INELIGIBLE
I-874	TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY MARGINAL ZONE LYMPHOMA (MZL) WHO HAVE RECEIVED AT LEAST ONE ANTI-CD20-BASED REGIMEN
I-875	FOR THE TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY TREATED, LOCALLY ADVANCED OR METASTATIC CHOLANGIOCARCINOMA WITH AN IDH1 MUTATION AS DETECTED BY AN FDA-APPROVED TEST
I-876	TREATMENT OF OCULAR ITCHING ASSOCIATED WITH ALLERGIC CONJUNCTIVITIS
I-877	INDICATION FOR THE USE OF ABEMACICLIB IN COMBINATION WITH ENDOCRINE THERAPY (TAMOXIFEN OR AN AROMATASE INHIBITOR) FOR THE ADJUVANT TREATMENT OF ADULT PATIENTS WITH HORMONE RECEPTOR (HR)-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE, NODE-POSITIVE, EARLY CANCER (EBC) AT HIGH RISK OF RECURRENCE AND A KI-67 SCORE>20% AS DETERMINED BY AN FDA APPROVED TEST
I-878	ADDITION OF A NEW INDICATION FOR ADJUNCTIVE THERAPY IN THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES IN PATIENTS 4 YEARS OF AGE AND OLDER
I-879	TREATMENT OF ADULT PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS, TO THE PRESCRIBING INFORMATION
I-880	TREATMENT OF ADULTS WITH ACTIVE PSORIATIC ARTHRITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS
I-881	FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS IN PATIENTS 13 YEARS OF AGE AND OLDER
I-882	INDICATED FOR DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR I OR II DISORDER (BIPOLAR DEPRESSION) IN ADULTS, AS MONOTHERAPY AND AS ADJUNCTIVE THERAPY WITH LITHIUM OR VALPROATE
I-883	TREATMENT OF ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH REFRACTORY, MODERATE-TO-SEVERE ATOPIC DERMATITIS WHOSE DISEASE IS NOT ADEQUATELY CONTROLLED WITH OTHER SYSTEMIC DRUG PRODUCTS, INCLUDING BIOLOGICS, OR WHEN USE OF THOSE THERAPIES ARE INADVISABLE
I-884	REVISIONS TO THE LABELING TO INCLUDE DATA FOR SUBJECTS WITH MILD TO MODERATE PLAQUE PSORIASIS, AND TO ALLOW FOR AN EXPANSION OF THE INDICATION
I-885	FOR THE ADJUVANT TREATMENT OF ADULT PATIENTS WITH DELETERIOUS OR SUSPECTED DELETERIOUS GBRCA MUTATED HER2-NEGATIVE HIGH-RISK EARLY BREAST CANCER WHO HAVE PREVIOUSLY BEEN TREATED WITH NEOADJUVANT OR ADJUVANT CHEMOTHERAPY
I-886	TREATMENT OF ADULT PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS
I-887	INDICATION FOR THE TREATMENT OF SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME (LGS) IN PATIENTS WHO ARE 2 YEARS OF AGE AND OLDER
I-888	TREATMENT OF ADULTS WITH ACTIVE ANKYLOSING SPONDYLITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS
I-889	TREATMENT OF PEDIATRIC PATIENTS AGED ONE MONTH AND OLDER WITH NEWLY DIAGNOSED JUVENILE MYELOMONOCYTIC LEUKEMIA (JMML)

PATENT AND EXCLUSIVITY TERMS

ADB 38 of 191

EXCLUSIVITY INDICATION

I-890	TREATMENT OF ADULT PATIENTS WITH SEVERE ALOPECIA AREATA
I-891	TREATMENT OF COVID-19 IN HOSPITALIZED ADULTS REQUIRING SUPPLEMENTAL OXYGEN, NONINVASIVE OR INVASIVE MECHANICAL VENTILATION, OR EXTRACORPOREAL MEMBRANE OXYGENATION (ECMO)
I-892	CHRONIC WEIGHT MANAGEMENT IN ADULT AND PEDIATRIC PATIENTS 6 YEARS OF AGE AND OLDER WITH BARDET-BIEDL SYNDROME (BBS)
I-893	IN COMBINATION WITH AZACITIDINE OR AS MONOTHERAPY FOR THE TREATMENT OF NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) WITH A SUSCEPTIBLE ISOCITRATE DEHYDROGENASE-1 (IDH1) MUTATION AS DETECTED BY AN FDA-APPROVED TEST IN ADULTS 75 YEARS OR OLDER, OR WHO HAVE COMORBIDITIES THAT PRECLUDE USE OF INTENSIVE INDUCTION CHEMOTHERAPY
I-894	DABRAFENIB IS INDICATED IN COMBINATION WITH TRAMETINIB, FOR THE TREATMENT OF ADULT AND PEDIATRIC PATIENTS 6 YEARS OF AGE AND OLDER WITH UNRESECTABLE OR METASTATIC SOLID TUMORS WITH BRAF V600E MUTATION WHO HAVE PROGRESSED FOLLOWING PRIOR TREATMENT AND HAVE NO SATISFACTORY ALTERNATIVE TREATMENT OPTIONS
I-895	TRAMETINIB IS INDICATED IN COMBINATION WITH DABRAFENIB, FOR THE TREATMENT OF ADULT AND PEDIATRIC PATIENTS 6 YEARS OF AGE AND OLDER WITH UNRESECTABLE OR METASTATIC SOLID TUMORS WITH BRAF V600E MUTATION WHO HAVE PROGRESSED FOLLOWING PRIOR TREATMENT AND HAVE NO SATISFACTORY ALTERNATIVE TREATMENT OPTIONS
I-896	INDICATED FOR THE TOPICAL TREATMENT OF NONSEGMENTAL VITILIGO IN ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER
I-897	TREATMENT OF ADULT AND PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER WITH UNRESECTABLE, RECURRENT OR REFRACTORY INFLAMMATORY MYOFIBROBLASTIC TUMOR (IMT) THAT IS ANAPLASTIC LYMPHOMA KINASE (ALK) POSITIVE
I-898	FOR THE MANAGEMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH ENDOMETRIOSIS
I-899	TREATMENT OF ADULTS WITH RELAPSED OR REFRACTORY MYELOID/LYMPHOID NEOPLASMS (MLNS) WITH FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FGFR1) REARRANGEMENT
I-900	TREATMENT OF ADULT PATIENTS WITH METASTATIC HORMONESENSITIVE PROSTATE CANCER (MHSPEC) IN COMBINATION WITH DOCETAXEL
I-901	EXPANDED INDICATION TO INCLUDE LOWERING OF PLASMA OXALATE LEVELS IN ADULT AND PEDIATRIC PATIENTS WITH PRIMARY HYPEROXALURIA TYPE 1 (PH1)
I-902	TREATMENT OF ADULT PATIENTS WITH HISTIOCYTIC NEOPLASMS

EXCLUSIVITY MISCELLANEOUS

M-1	INFORMATION REGARDING SUPERIORITY CLAIM OVER RANITIDINE FOR DAY AND NIGHT HEARTBURN ADDED TO CLINICAL STUDIES SECTION
M-2	APPROVAL FOR ADDITION TO CLINICAL PHARMACOLOGY SECTION OF THE LABEL REGARDING (1) IMPROVEMENT IN BONE MINERAL DENSITY IN CHILDHOOD-ONSET ADULT GROWTH HORMONE DEFICIENT PATIENTS AND (2) INCREASES IN SERUM ALKALINE PHOSPHATASE
M-3	ADDITION OF EFFICACY AND SAFETY INFORMATION IN WHICH FOSAMAX WAS USED CONCOMITANTLY WITH ESTROGEN ALONE OR WITH ESTROGEN PLUS PROGESTIN
M-4	CHANGES TO PEDIATRIC USE SECTION TO PROVIDE INFORMATION REGARDING SAFETY AND EFFICACY IN PEDIATRIC PATIENTS AS YOUNG AS 2 YEARS OLD
M-5	INFORMATION REGARDING EFFECTS IN PATIENTS WITH ASTHMA ON CONCOMITANT INHALED CORTICOSTEROIDS IN CLINICAL PHARMACOLOGY SECTION
M-6	ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES DONE WITH GLUCOPHAGE/GLYBURIDE COMBINATION ADDED TO CLINICAL PHARMACOLOGY AND DOSING AND ADMINISTRATION
M-7	CLINICAL PHARMACOLOGY IN PEDIATRIC PATIENTS; DOSAGE AND ADMINISTRATION INFORMATION
M-8	ADDITIONAL INFORMATION FOR THE USE OF SONATA CAPSULES FOR UP TO 5 WEEKS (35 NIGHTS) OF TREATMENT IN A CONTROLLED TRIAL SETTING
M-9	ADDITION TO THE CLINICAL STUDIES SECTION OF THE LABELING OF TEXT AND TWO TABLES CONTAINING INFORMATION FOR THE PRESCRIBING PHYSICIAN ON BLOOD PRESSURE, HEART RATE, AND HEART RATE VARIABILITY
M-10	INFORMATION REGARDING MAINTENANCE OF AN ANTIDEPRESSANT EFFECT UP TO 1 YEAR OF DOSING
M-11	USE FOR LONG-TERM TREATMENT OF POSTTRAUMATIC STRESS DISORDER

PATENT AND EXCLUSIVITY TERMS

ADB 39 of 191

EXCLUSIVITY MISCELLANEOUS

M-12	NEW LANGUAGE FOR PEDIATRIC USE
M-13	INFORMATION FROM PEDIATRIC STUDIES ADDED TO CLINICAL PHARMACOLOGY, PRECAUTIONS, AND DOSAGE AND ADMINISTRATION
M-14	ADDITIONAL CLINICAL TRIAL INFORMATION ADDED TO PEDIATRIC USE SUBSECTION
M-15	LONGER TERM EFFICACY INFORMATION FOR RISPERIDONE IN THE TREATMENT OF SCHIZOPHRENIA
M-16	CHANGE IN WORDING OF THE PEDIATRIC SECTION OF THE PACKAGE INSERT
M-17	INFORMATION REGARDING USE OF ULTANE IN PEDIATRIC PATIENTS WITH CONGENITAL HEART DISEASE
M-18	INFORMATION DENOTING THE EFFICACY OF REMERON IN MAINTAINING A RESPONSE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER (MDD)
M-19	INFORMATION REGARDING USE IN PEDIATRIC PATIENTS TWO YEARS OF AGE AND OLDER
M-20	LABELING REVISIONS RELATED TO MCCUNE ALBRIGHT SYNDROME
M-21	COMPARISON DATA ON THE ANTIHYPERTENSIVE EFFECTS OF ATACAND AND COZAAR
M-22	CHANGE IN TIME TO ONSET OF ACTION
M-23	INFORMATION REGARDING ELIMINATION ADDED TO CLINICAL PHARMACOLOGY, STUDY RESULTS IN PATIENTS WITH HEPATIC AND RENAL IMPAIRMENT
M-24	INFORMATION ON RESULTS OF A LONG TERM LONGITUDINAL GROWTH STUDY AND PEDIATRIC SAFETY INFORMATION
M-25	ADDITIONAL SAFETY AND PHARMACOKINETICS INFORMATION IN CHILDREN 6 MONTHS TO LESS THAN 6 YEARS OF AGE ADDED TO PACKAGE INSERT
M-26	INCORPORATION OF INFORMATION CONTAINED IN THE PEG-INTRON PACKAGE INSERT INTO THE REBETOL PACKAGE INSERT AND MEDGUIDE-PEG-INTRON WAS APPROVED FOR USE IN COMBINATION WITH REBETOL FOR TREATMENT OF CHRONIC HEPATITIS C VIRUS INFECTION ON 8/7/01
M-27	INFORMATION DESCRIBING ASPIRIN ENDOSCOPY STUDY AND THE MAXIMUM RECOMMENDED DOSE FOR PATIENTS WITH MODERATE HEPATIC INSUFFICIENCY
M-28	INFORMATION FROM A STUDY IN PEDIATRIC PATIENTS IN ASSOCIATION WITH A NEUROLOGICAL CONDITION
M-29	LABELING CHANGES TO PROVIDE INFORMATION IN THE MANAGEMENT OF OBESITY IN ADOLESCENTS AGED 12 TO 16 YEARS
M-30	CHANGES TO CLINICAL PHARMACOLOGY, PRECAUTIONS, AND DOSAGE AND ADMINISTRATION SECTIONS OF LABELING CONCERNING USE OF LOTENSIN IN PEDIATRIC PATIENTS WITH HYPERTENSION
M-31	INFORMATION FOR USE IN PEDIATRIC PATIENTS WITH CHRONIC KIDNEY DISEASE STAGE 5 (END-STAGE RENAL DISEASE)
M-32	ADDITIONAL LANGUAGE TO CLINICAL PHARMACOLOGY AND CLINICAL STUDIES
M-33	INFORMATION FOR USE OF ADVAIR DISKUS 100/50 IN CHILDREN 4 TO 11 YEARS OF AGE WITH ASTHMA
M-34	EXPANDED INFORMATION TO PEDIATRIC USE SUBSECTION OF LABELING IN RESPONSE TO PEDIATRIC WRITTEN REQUEST
M-35	ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES DONE WITH ACTOS IN COMBINATION WITH METFORMIN, A SULFONYLUREA, OR INSULIN ADDED TO CLINICAL PHARMACOLOGY
M-36	ADDITION OF INFORMATION TO CLINICAL STUDIES REGARDING PREVENTION OF CARDIOVASCULAR DISEASE
M-37	INFORMATION ADDED TO THE LABELING THAT DETAILS INFORMATION RELATIVE TO STUDIES DONE IN PEDIATRIC POPULATIONS IN THE CLINICAL PHARMACOLOGY AND PEDIATRIC USE SUBSECTIONS
M-38	SAFETY AND IOP-LOWERING EFFECTS OF TRUSOPT HAVE BEEN DEMONSTRATED IN PEDIATRIC PATIENTS IN A 3 MONTH, MULTI-CENTER DOUBLE MASKED ACTIVE-TREATMENT-CONTROLLED TRIAL
M-39	FOR LABELING CHANGES BASED ON RESULTS OF THE SPD422-202 CLINICAL STUDY REPORT (CSR) SUBMITTED IN RESPONSE TO THE WRITTEN REQUEST
M-40	ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES PERFORMED IN PEDIATRIC PATIENTS WITH LEUKEMIA ADDED TO PRECAUTIONS
M-41	REVISION TO THE PEDIATRIC USE PRECAUTIONS OF THE PRESCRIBING INFORMATION TO

PATENT AND EXCLUSIVITY TERMS

ADB 40 of 191

EXCLUSIVITY MISCELLANEOUS

	INCORPORATE THE RESULTS FROM THE CAPPS-169 STUDY ENTITLED "THE EFFECT OF ORTHO TRICYCLEN ON BONE MINERAL DENSITY IN PEDIATRIC SUBJECTS WITH ANOREXIA NERVOSA"
M-42	ADDITION OF A GERIATRIC USE SUBSECTION TO THE PRECAUTIONS SECTION OF THE PACKAGE INSERT AND GERIATRIC DOSING INFORMATION
M-43	INCLUSION OF RESULTS OF STUDY "PLACEBO-CONTROLLED STUDY TO EVALUATE SAFETY AND PILOT EFFICACY OF ILOPROST AS ADD ON THERAPY WITH BOSENTAN IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION"
M-44	CLINICAL INFORMATION ADDED TO THE PEDIATRIC USE SUBSECTION OF PRECAUTIONS REGARDING THE USE OF NOVOLOG IN ADOLESCENTS WITH TYPE I DIABETES AGE 6 TO 18
M-45	INFORMATION ADDED TO CLINICAL TRIALS SECTION OF LABELING, "EFFECTS OF HUMATROPE TREATMENT IN ADULTS WITH GROWTH HORMONE DEFICIENCY"
M-46	PROVISION OF RESULTS OF STUDY AND PROPOSED REVISIONS TO PACKAGE INSERT SEE SECTION ON CARDIAC ELECTROPHYSIOLOGY
M-47	PROVIDES FOR USE OF ANTARA WITHOUT REGARD TO MEALS
M-48	CHANGES TO THE LABELING DESCRIBING THE RESULTS OF A STUDY OF THE USE OF NOVOLOG MIX 70/30 WITH ORAL ANTIDIABETIC AGENTS IN PATIENTS WITH TYPE 2 DIABETES
M-49	CLINICAL DATA ADDED TO THE CLINICAL PHARMACOLOGY SECTION REGARDING EFFECT OF SINGULAIR ON GROWTH RATES IN PREPUBERTAL CHILDREN
M-50	NEW INFO TO THE CLINICAL STUDIES, ADULT GROWTH HORMONE DEFICIENCY (GHD) SUBSECTION OF THE NUTROPIN AQ PACKAGE INSERT DESCRIBING THE EFFECTS OF SOMATROPIN ON VISCERAL ADIPOSE TISSUE IN THE ADULT GROWTH HORMONE DEFICIENT PATIENT POPULATION
M-51	INFORMATION ADDED TO LABELING REGARDING OSTEOGENESIS IMPERFECTA STUDY
M-52	INFORMATION ADDED TO THE CLINICAL PHARMACOLOGY/CLINICAL STUDIES SECTION REGARDING THE USE OF RISEDRONATE ADMINISTERED ONCE A WEEK IN THE PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
M-53	FOR LABELING CHANGES TO THE QUALITY OF LIFE (QOL) STATEMENT IN THE APPROVED PACKAGE INSERT
M-54	INFORMATION FROM PEDIATRIC STUDIES ADDED TO LABEL
M-55	INFORMATION ON RESULTS OF A STUDY OF THE USE OF SANDOSTATIN LAR DEPOT IN PEDIATRIC PATIENTS WITH HYPOTHALAMIC OBESITY.
M-56	INFORMATION ADDED TO CLINICAL TRIAL SECTION WITH INFORMATION ON "GEMINI" TRIAL
M-57	CLINICAL DATA ADDED TO THE CLINICAL PHARMACOLOGY SECTION REGARDING THE PHARMACOKINETICS OF EZETIMIBE IN ASIAN SUBJECTS
M-58	CHANGES TO THE CLINICAL STUDIES, PRIMARY HYPERCHOLESTEROLEMIA, VYTORIN SUBSECTION OF THE PACKAGE INSERT TO ADD EFFICACY DATA FOR THE EZETIMIBE/SIMVASTATIN COMBINATION PRODUCT AND FOR AN ATORVASTATIN PRODUCT ON LDL-C AND OTHER LIPID PRMTRS
M-59	RESULTS OF THE T20-310 STUDY WHICH EVALUATED THE PHARMACOKINETICS, SAFETY, AND ANTIVIRAL ACTIVITY OF FUZEON IN TREATMENT EXPERIENCED PEDIATRIC SUBJECTS AND ADOLESCENTS WAS ADDED TO THE PEDIATRIC SUBSECTION OF PRECAUTIONS
M-60	CHANGES TO CLINICAL STUDIES, PRIMARY HYPERCHOLESTEROLEMIA, TO ADD EFFICACY DATA FOR THE EZETIMIBE/SIMVASTATIN COMBINATION PRODUCT AND FOR A ROSUVASTATIN PRODUCT ON LDL-C AND OTHER LIPID PARAMETERS IN PATIENTS WTH HYPERCHOLESTEROLEMIA
M-61	REVISIONS TO LABELING BASED ON DATA SUBMITTED IN RESPONSE TO PEDIATRIC WRITTEN REQUEST
M-62	CLINICAL INFORMATION FROM ONE CLINICAL STUDY INVESTIGATING THE USE OF AVANDAMET PLUS INSULIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE NOT ACHIEVED ADEQUATE GLYCEMIC CONTROL WITH PREVIOUS ANTI-DIABETIC THERAPIES
M-63	DETAILED INFORMATION ON AN INCONCLUSIVE PEDIATRIC STUDY
M-64	CHANGES TO CLINICAL PHARMACOLOGY DETAILING STUDY RESULTS
M-65	ADDITION OF INFORMATION TO LABEL TO INCLUDE INFORMATION REGARDING USE IN PATIENTS WITH HIV-ASSOCIATED ADIPOSE REDISTRIBUTION SYNDROME (HARS)
M-66	USE IN SPECIFIC POPULATIONS - PATIENTS WITH CONCOMITANT ILLNESS SUBSECTION OF THE LABELING REGARDING USE OF STRATTERA IN PATIENTS WITH ADHD WHO HAVE COMORBID TIC DISORDER
M-67	INDICATION EXPANDED TO INCLUDE PATIENTS ON PERITONEAL DIALYSIS

PATENT AND EXCLUSIVITY TERMS

ADB 41 of 191

EXCLUSIVITY MISCELLANEOUS

M-68	DESCRIPTION OF RESULTS OF STUDY OF INITIAL THERAPY IN COMBINATION WITH METFORMIN WHEN DIET AND EXERCISE DO NOT PROVIDE GLYCEMIC CONTROL
M-69	RESULTS OF STUDY OF COMBINATION THERAPY AND NON-INFERIORITY STUDY
M-70	PROVISION OF INFORMATION OF THE RESULTS OF A PHASE 2 RANDOMIZED TRIAL OF SPRYCEL 70MG TWICE DAILY OR IMATINIB 800MG DAILY
M-71	REVISIONS TO PROVIDE FOR RESULTS OF MAINTENANCE DATA IN ADULT PATIENTS WITH MAJOR DEPRESSIVE DISORDER
M-72	INFORMATION ABOUT USE OF INSPRA (EPLERENONE) FOR HYPERTENSION IN PEDIATRIC PATIENTS
M-73	NEW INFORMATION ADDED REGARDING THE TUMOR SHRINKING POTENTIAL OF SANDOSTATIN LAR DEPOT INJECTION ON GH - SECRETING PITUITARY ADENOMAS
M-74	REVISIONS TO CLINICAL STUDIES - CHILDREN AND ADOLESCENTS BASED ON CLINICAL TRIAL DATA TO SUPPORT A DURATION OF ACTION CLAIM UP TO 12 HOURS
M-75	PROVISION FOR USE OF ARGATROBAN IN CERTAIN PEDIATRIC PATIENTS WITH HEPARIN-INDUCED THROMBOCYTOPENIA (HIT) OR HEPARIN-INDUCED THROMBOCYTOPENIA WITH THROMBOSIS (HITS)
M-76	REMOVAL OF SCREEN REQUIREMENT IN PTS WITH G6PD DEFICIENCY PRIOR TO INITIATING ACZONE TREATMENT; REMOVAL OF BLOOD COUNT & RETICULOCYTE MONITORING DURING TREATMENT IN G6PD DEFICIENT PTS AND IN PATIENTS WITH HISTORY OF ANEMIA
M-77	USE IN COMBINATION WITH THE NEW AKTILITE CL128 LAMP FOR THE TREATMENT OF THIN AND MODERATELY THICK, NON-HYPERKERATOTIC, NON-PIGMENTED ACTINIC KERATOSES OF THE FACE AND SCALP IN IMMUNOCOMPETENT PATIENTS
M-78	CLINICAL TRIAL INFO ON USE OF STRATTERA IN PATIENTS WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) AND COMORBID ANXIETY DISORDER WITHOUT CAUSING WORSENING OF ANXIETY
M-79	LABELING REVISIONS RELATED TO SMOKING AND ERLOTINIB EXPOSURE
M-80	ADDITIONAL TIME POINT OF 30 MINUTES (0.5 HOUR) IN CHILDREN AGED 6-12 YEARS WITH A DIAGNOSIS OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER (ADHD)
M-81	ADDITIONAL INFO FOR PEDIATRIC USE FOR CASODEX (STUDIED IN COMBINATION WITH ARIMIDEX) IN THE PEDIATRIC POPULATION, SPECIFICALLY BOYS WITH FAMILIAL MALE-LIMITED PRECOCIOUS PUBERTY (TESTOTOXICOSIS)
M-82	LABELING REVISIONS RELATED TO CLINICAL STUDIES
M-83	ADDITIONAL INFORMATION ADDED TO LABELING REGARDING ESTABLISHMENT OF EFFICACY IN ADDITIONAL CLINICAL TRIALS AND ONE MAINTENANCE TRIAL
M-84	STUDY INFORMATION ADDED TO LABEL REGARDING BONE MINERAL DENSITY
M-85	INFORMATION ADDED TO LABELING REGARDING USE OF PREVACID IN PATIENTS LESS THAN 1 YEAR WITH SYMPTOMATIC GERD
M-86	LABELING CHANGES SUBMITTED IN RESPONSE TO PEDIATRIC WRITTEN REQUEST FOR INFANTS AGES BIRTH TO 11 MONTH INCLUSIVE REFLECTING LACK OF EFFICACY FOR GERD INDICATION FOR THIS PATIENT POPULATION
M-87	INCLUSION OF RESULTS FROM TWO DRUG INTERACTION STUDIES WITH LIPITOR AND CRESTOR IN CLINICAL PHARMACOLOGY SECTION
M-88	ADDITION OF INFORMATION REGARDING ABUSE POTENTIAL OF CONCERTA VERSUS IMMEDIATE-RELEASE METHYLPHENIDATE
M-89	PROVIDES FOR REVISIONS TO MULTIPLE SECTIONS OF THE PACKAGE INSERT TO REFLECT RESULTS OF CLINICAL TRIALS 205.235 (UPLIFT) AND 205.266 (VA STUDY) IN SUPPORT OF EXACERBATION CLAIM
M-90	LABELING CHANGES BASED ON DATA FROM CLINICAL STUDIES NV20235 AND NV20236 STUDIES OF SEASONAL PROPHYLAXIS OF INFLUENZA IN IMMUNOCOMPROMISED PATIENTS AND CHILDREN AGES 1-12
M-91	UPDATED LABELING BASED UPON STUDY: A SINGLE-DOSE, SINGLE-BLIND, PLACEBO-AND MOXIFLOXACIN-CONTROLLED 2-PERIOD, RANDOMIZED, CROSSOVER, 3RD PERIOD SEQUENTIAL STUDY OF SIDE EFFECTS OF TEMSIROLIMUS ON CARDIAC REPOLARIZATION IN HEALTHY SUBJECTS
M-92	UPDATES TO THE PACKAGE INSERT BASED UPON THE TRIAL ENTITLED "A PHASE I PHARMACOKINETIC AND PHARMACODYNAMIC STUDY OF TEMSIROLIMUS IN PATIENTS WITH ADVANCED MALIGNANCIES AND NORMAL AND IMPAIRED LIVER FUNCTION"
M-93	EXPANSION OF LABELING TO INCLUDE INFORMATION ON SAFETY AND EFFICACY OF CREON IN

PATENT AND EXCLUSIVITY TERMS

ADB 42 of 191

EXCLUSIVITY MISCELLANEOUS

	PATIENTS AGES 7 YEARS THROUGH 11 YEARS WITH PANCREATIC EXOCRINE INSUFFICIENCY DUE TO CYSTIC FIBROSIS
M-94	INFO ADDED TO LABEL RELATED TO NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME POSITIVE (PH+) CHRONIC MYELOID LEUKEMIA IC CHRONIC PHASE
M-95	INFORMATION FOR TREATMENT OF CHRONIC HEPATITIS B (CHB) IN ADULT PATIENTS WITH DECOMPENSATED LIVER DISEASE BASED ON DATA FROM CLINICAL TRIAL GS-US-174-0108
M-96	UPDATED INFORMATION IN THE CLINICAL STUDIES SECTION RELATED TO THE LOSS AND RECOVERY OF BONE MINERAL DENSITY IN ADOLESCENT GIRLS DURING AND FOLLOWING THE USE OF DEPO-PROVERA CONTRACEPTIVE INJECTION
M-97	LABELING CHANGES IN RESPONSE TO PEDIATRIC STUDIES - NOT INDICATED FOR USE IN PEDIATRIC POPULATION
M-98	NEW INFORMATION FROM A STUDY WHICH EVALUATED THE SAFETY AND EFFICACY OF FAMVIR IN TREATING RECURRENT GENITAL HERPES IN IMMUNOCOMPETENT BLACK/AFRICAN AMERICAN SUBJECTS.
M-99	ADDITION OF FINDINGS FROM A SINGLE PEDIATRIC CLINICAL TRIAL (P04292) OF NASONEX NASAL SPRAY IN THE TREATMENT OF NASAL POLYPS IN PATIENTS 6 TO <18 YEARS OF AGE TO THE PACKAGE INSERT.
M-100	INFORMATION ADDED TO LABEL BASED UPON COMPLETED CLINICAL TRIAL REPORTS
M-101	INCLUSION OF DATA FROM AN ADDITIONAL 19 SUBJECTS WITH HYPERCALCEMIA FROM PARATHYROID CARCINOMA TO THE INFORMATION CURRENTLY PRESENTED IN THE LABEL
M-102	INFORMATION FROM PEDIATRIC STUDY REPORT ML16633, "INTRAVENOUS GRANISETRON (KYTRIL) IN THE PREVENTION OF POST-OPERATIVE NAUSEA AND VOMITING (PONV) IN PEDIATRIC SUBJECTS UNDERGOING TONSILLECTOMY OR ADENOTONSILLECTOMY."
M-103	SAFETY, EFFICACY AND PHARMACOKINETIC INFO FOR FASLODEX IN THE PEDIATRIC POPULATION, SPECIFICALLY FOR GIRLS WITH PROGRESSIVE PRECOCIOUS PUBERTY ASSOCIATED WITH MCCUNE-ALBRIGHT SYNDROME ADDED TO THE PEDIATRIC USE SECTION OF THE LABELING
M-104	INFORMATION ADDED TO DOSING AND ADMINISTRATION REGARDING A 26 WEEK STUDY
M-105	NEW LANGUAGE ADDED TO CLINICAL STUDIES REGARDING USE IN SMOKERS WITH CARDIOVASCULAR DISEASE, CHRONIC OBSTRUCTIVE PULMONARY DISEASE, AND USE ACCORDING TO AN ALTERNATIVE SET OF DIRECTIONS FOR SETTING A QUIT DATE
M-106	ADDITION OF THE T1-WEIGHTED GD-ENHANCED LESION EFFICACY VARIABLE IN THE CLINICAL STUDIES SECTION 14 OF THE PACKAGE INSERT
M-107	INFORMATION TO THE CLINICAL STUDIES SECTION OF THE LUPRON DEPOT-PED 1-MONTH BASED UPON THE PHASE 3/4 COMPLETED CLINICAL STUDY REPORT FOR STUDY M90-516 ENTITLED "STUDY OF LUPRON DEPOT IN THE TREATMENT OF CENTRAL PRECOCIOUS PUBERTY".
M-108	CHANGES ARE BASED ON RESULTS FROM STUDY CV181057
M-109	CHANGES TO THE PACKAGE INSERT TO REFLECT THE RESULTS OF THE STUDY OF HEART AND RENAL PROTECTION (SHARP) TRIAL
M-110	CHANGES TO THE PACKAGE INSERT TO REFLECT THE RESULTS OF THE STUDY OF HEART AND RENAL PROTECTION (SHARP) TRIAL
M-111	LABELING CHANGES BASED ON STUDY HW80-EW-GWCI ENTITLED A PLACEBO AND POSITIVE CONTROLLED STUDY OF THE ELECTROPHYSIOLOGICAL EFFECTS OF A SINGLE 10 MCG DOSE OF EXENATIDE ON THE 12 LEAD ELECTROCARDIOGRAM QT INTERVAL IN HEALTHY SUBJECTS
M-112	REVISIONS TO THE PEDIATRIC USE SECTION OF THE PACKAGE INSERT TO ADD INFORMATION FROM A PEDIATRIC STUDY IN PATIENTS AGED 12 YEARS TO LESS THAN 18 YEARS OF AGE WITH RECURRENT HERPES LABIALIS
M-113	LABELING CHANGES BASED ON STUDY H80-US-GWCO ENTITLED A RANDOMIZED TRIAL COMPARING EXENATIDE WITH PLACEBO IN SUBJECTS WITH TYPE 2 DIABETES ON INSULIN GLARGINE WITH OR WITHOUT ORAL ANTIHYPERGLYCEMIC MEDICATIONS
M-114	CHANGES IN SECTION 14 OF THE PACKAGE INSERT TO INCLUDE DATA FROM THE SWITCHMRK STUDIES (SWITCH OF SUPPRESSED SUBJECTS FROM LOPINAVIR/RITONAVIR TO RALTEGRAVIR)
M-115	REVISIONS TO THE PI BASED ON RESULTS FROM STUDY NN2211-1842, ENTITLED THE EFFECT OF INSULIN DETEMIR IN COMBINATION WITH LIRAGLUTIDE AND METFORMIN COMPARED TO LIRAGLUTIDE AND METFORMIN IN SUBJECTS WITH TYPE 2 DIABETES
M-116	LABELING CHANGES BASED ON RESULTS FROM CLINICAL STUDY 01-06-TL-OPIMET-008
M-117	ADDITION OF RESULTS OF PEDIATRIC TRIAL TO LABEL
M-118	LABELING CHANGES BASED UPON SAFETY AND EFFICACY RESULTS FROM TRIAL 1218.36

PATENT AND EXCLUSIVITY TERMS

ADB 43 of 191

EXCLUSIVITY MISCELLANEOUS

M-119	LABELING CHANGES REGARDING MISSED DOSES
M-120	CHANGES TO CLINICAL TRIALS DETAILING STUDY RESULTS
M-121	LABELING CHANGES BASED UPON SAFETY AND EFFICACY RESULTS FROM TRIAL 1218.43
M-122	LABELING CHANGES TO INCLUDE THE RESULTS OF THE PARAMOUNT TRIAL
M-123	UPDATED RESULTS OF OVERALL SURVIVAL FROM 'CONFIRM' STUDY
M-124	LONG TERM SAFETY AND EFFICACY DATA FROM STUDY CLDT600A2303 FOR SUBJECTS PREVIOUSLY ENROLLED IN THE ORIGINAL TWO YEAR GLOBE (NV-02B-007/CLDT600A2302) AND NV02B-015 STUDIES WHO CONTINUED TELBIVUDINE TREATMENT FOR UP TO 208 WEEKS
M-125	LABELING CHANGES TO INCLUDE LACK OF EFFICACY IN CHILDREN 6 MONTHS TO 4 YEARS OF AGE
M-126	UPDATES TO THE CLINICAL STUDIES SECTION 14, OF THE PACKAGE INSERT (PI), WITH THE RESULTS OF CLINICAL TRIAL P06086
M-127	REVISIONS TO THE PEDIATRIC USE SECTION OF THE PACKAGE INSERT TO REFLECT THE RESULTS FROM CLINICAL STUDY C-10-004
M-128	CLINICAL TRIAL STUDY RESULTS
M-129	RESULTS OF A CLINICAL STUDY REPORT WHICH ASSESSES THE SAFETY AND EFFICACY IN CHILDREN AGES 6 TO 12 YEARS OF AGE
M-130	ADDITION OF INFORMATION ON LONG-TERM TREATMENT WITH VPRIV IN THE CLINICAL TRIALS SECTION OF THE PACKAGE INSERT
M-131	INFORMATION FROM STUDIES CONDUCTED IN PEDIATRIC PATIENTS WITH NEWLY DIAGNOSED NON-DISSEMINATED DIFFUSED INTRINSIC BRAINSTEM GLIOMAS
M-132	REVISIONS TO THE CLINICAL TRIALS SECTION IN THE INOMAX LABEL TO REFLECT RESULTS FROM THE PEDIATRIC STUDY REPORTS
M-133	INFORMATION ADDED TO THE LABELING REGARDING THE ADDITION OF SILDENAFIL TO BOSENTAN THERAPY
M-134	ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES PERFORMED WITH SAXAGLIPTIN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA ADDED TO THE LABELING
M-135	ADDITION OF INFORMATION TO THE CLINICAL STUDIES - RADIOGRAPHIC RESPONSE SECTION OF THE PACKAGE INSERT
M-136	ADDITIONAL INFORMATION ADDED TO THE USE IN SPECIFIC POPULATIONS SECTION OF THE LABELING REGARDING POST-OPERATIVE NAUSEA AND VOMITING STUDIES IN PEDIATRIC PATIENTS
M-137	LABELING REVISIONS RESULTING FROM A MAINTENANCE TRIAL IN PEDIATRIC PATIENTS WITH IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER
M-138	INFORMATION ADDED TO THE 8.4 PEDIATRIC USE SECTION ON THE USE OF MEMANTINE IN CHILDREN AGES 6-12 YEARS WITH AUTISM SPECTRUM DISORDER
M-139	INFORMATION ADDED TO THE DOSING AND ADMINISTRATION SECTION OF THE PACKAGE INSERT REGARDING RETREATMENT WITH VELCADE FOR PATIENTS WITH MULTIPLE MYELOMA
M-140	INFORMATION ADDED TO THE PEDIATRIC USE SECTION OF THE LABELING REGARDING USE OF LATISSE IN PATIENTS WHO WERE POST-CHEMOTHERAPY OR HAD ALOPECIA AREATA, AND ADOLESCENTS WHO HAD HYPERTRICHOSIS WITH NO ASSOCIATED MEDICAL CONDITION
M-141	REVISIONS TO THE PEDIATRIC USE SECTION OF THE LABELING TO INCORPORATE STUDY RESULTS FOR TREATMENT OF MAJOR DEPRESSIVE DISORDER IN ADOLESCENTS (AGES 12-17)
M-142	ADDITIONS TO THE LABELING DESCRIBING RESULTS FROM STUDY H6P-MC-HDAY
M-143	INFORMATION ADDED TO THE LABELING REGARDING THE SAFETY AND EFFICACY OF VARENICLINE FOR SMOKING CESSATION IN PATIENTS WITH CURRENT OR PAST HISTORY OF MAJOR DEPRESSIVE DISORDER
M-144	INFORMATION ADDED TO THE LABELING REGARDING THE SAFETY AND EFFICACY OF VARENICLINE FOR SMOKING CESSATION IN PATIENTS WHO HAD BEEN PREVIOUSLY TREATED WITH VARENICLINE
M-145	ADDITION OF INFORMATION ABOUT LONG-TERM TREATMENT OF PULMONARY ARTERIAL HYPERTENSION TO THE CLINICAL STUDIES SECTION OF THE LABELING
M-146	INFORMATION ADDED TO THE CLINICAL STUDIES SECTION ON INITIAL COMBINATION THERAPY WITH LINAGLIPTIN AND METFORMIN VS. LINAGLIPTIN MONOTHERAPY IN TREATMENT NAIVE PATIENTS
M-147	OTC USE FOR TEMPORARY RELIEF OF OCULAR SYMPTOMS DUE TO HAY FEVER OR OTHER UPPER RESPIRATORY ALLERGIES

PATENT AND EXCLUSIVITY TERMS

ADB 44 of 191

EXCLUSIVITY MISCELLANEOUS

M-148	LABELING CHANGES BASED ON STUDY H80-EW-GWDM
M-149	INFORMATION ADDED TO THE LABELING REGARDING MAINTENANCE MONOTHERAPY FOR ADHD
M-150	ADDITION OF THE RESULTS OF A CONTROLLED CLINICAL STUDY TREATING ADULT PATIENTS WITH SCHIZOPHRENIA EXPERIENCING AN ACUTE RELAPSE
M-151	REVISIONS TO THE LABELING BASED ON THE OUTCOMES OF PEDIATRIC STUDIES CONDUCTED TO ASSESS THE SAFETY AND EFFICACY OF XOPENEX IN SUBJECTS LESS THAN 6 YEARS OF AGE
M-152	INFORMATION ADDED TO THE CLINICAL PHARMACOLOGY SECTION OF THE LABELING REGARDING A SAFETY STUDY IN PEDIATRIC SUBJECTS AGES 6 MONTHS TO 4 YEARS OF AGE WITH AN ACTIVE HEAD LICE INFESTATION
M-153	ADDITION OF INFORMATION REGARDING THE INTRANASAL ABUSE POTENTIAL OF OXYCONTIN
M-154	UPDATE TO THE LABELING TO REFLECT THE RESULTS OF A LONG-TERM MAINTENANCE TREATMENT STUDY OF ADHD IN CHILDREN AND ADOLESCENTS AGES 6-17.
M-155	ADDITION OF CLINICAL FINDINGS FROM AN OBSERVATIONAL STUDY IN A PEDIATRIC AGE GROUP GREATER THAN 2 MONTHS TO 18 YEARS IN SECTION 8.4 PEDIATRIC USE OF THE PACKAGE INSERT
M-156	UPDATE TO THE LABELING WITH INFORMATION REGARDING A CLINICAL TRIAL IN CHILDREN LESS THAN 4 YEARS OF AGE.
M-157	INFORMATION ADDED TO THE LABELING REGARDING THE SAFETY AND EFFICACY OF DAPAGLIFLOZIN 10MG ONCE DAILY IN PATIENTS WITH TYPE 2 DIABETES WHO HAVE INADEQUATE GLYCEMIC CONTROL ON A BACKGROUND COMBINATION OF METFORMIN AND SULFONYLUREA
M-158	UPDATES TO THE LABELING TO REFLECT SAFETY RESULTS FROM CLINICAL TRIALS IN SCHIZOPHRENIA ADOLESCENT PATIENTS AGED 12 TO 17 YEARS
M-159	ADDITION OF PED SAFETY INFORMATION DERIVED FROM A MAINTENANCE TREATMENT STUDY OF BIPOLAR 1 DISORDER TO DELAY THE TIME TO OCCURRENCE OF MOOD EPISODES IN PATIENTS (> THAN OR = TO 13 YRS OF AGE) TREATED FOR ACUTE MOOD EPISODES WITH STANDARD THERAPY
M-160	UPDATED LABELING WITH DATA FROM A RANDOMIZED, DOUBLE-BLIND ACTIVE-CONTROLLED STUDY COMPARING EMPAGLIFLOZIN TO GLIMEPIRIDE IN PATIENTS WITH TYPE 2 DIABETES AND INSUFFICIENT GLYCEMIC CONTROL DESPITE METFORMIN TREATMENT
M-161	UPDATED LABELING WITH DATA FROM A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF EMPAGLIFLOZIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND INSUFFICIENT GLYCEMIC CONTROL ON A MULTIPLE DAILY INJECTION INSULIN REGIMEN ALONE OR WITH METFORMIN
M-162	INCLUSION OF EFFICACY AND SAFETY DATA TO THE PRESCRIBING INFORMATION OF BYDUREON BASED ON STUDY GWDE
M-163	INFORMATION ADDED TO THE LABELING REGARDING PREVIOUSLY UNTREATED ALK-POSITIVE METASTATIC NON SMALL CELL LUNG CANCER (NSCLC)
M-164	REVISES THE CLINICAL TRIALS SECTION OF THE PRESCRIBING INFORMATION TO INCORPORATE THE RESULTS FROM STUDY E7273-G000-401 ENTITLED "PHASE IV RANDOMIZED STUDY OF TWO DOSE LEVELS OF TARGRETIN CAPSULES IN SUBJECTS WITH REFRACTORY CUTANEOUS T-CELL LYMPHOMA"
M-165	PROVIDES FOR UPDATES TO THE PEDIATRIC USE SECTION BASED ON THE PEDIATRIC STUDY REPORT ENTITLED, "A PHASE II PILOT TRIAL OF BORTEZOMIB IN COMBINATION WITH INTENSIVE RE-INDUCTION THERAPY IN CHILDREN WITH RELAPSED ACUTE LYMPHOBLASTIC LYMPHOMA (LL) "
M-166	UPDATE TO LABELING WITH WEEK 48 RESULTS FROM VIKING-4 IN ANTIRETROVIRAL THERAPY (ART) - EXPERIENCED INTEGRASE STRAND TRANSFER INHIBITOR (INSTI) - RESISTANT SUBJECTS
M-167	APPROVED FOR REVISIONS TO THE LABELING BASED ON THE CLINICAL STUDY ENTITLED "BRONCHOPULMONARY DYSPLASIA (BPD) IN PRETERM INFANTS REQUIRING MECHANICAL VENTILATION OR POSITIVE PRESSURE SUPPORT ON DAYS 5 TO 14 AFTER BIRTH".
M-168	INFORMATION ADDED TO THE CLINICAL STUDIES SECTION OF THE LABELING REGARDING THE RE-NOVATE AND RE-NOVATE LL STUDIES (PROPHYLAXIS OF DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM FOLLOWING HIP REPLACEMENT SURGERY)
M-169	UPDATES TO LABELING DESCRIBING RESPONSE TO A REPEAT COURSE OF PICATO GEL 0.015% ON THE FACE OR SCALP IF AN INCOMPLETE RESPONSE IS OBSERVED AT A FOLLOW-UP EXAMINATION.

PATENT AND EXCLUSIVITY TERMS

ADB 45 of 191

EXCLUSIVITY MISCELLANEOUS

M-170	INFORMATION ADDED TO THE CLINICAL STUDIES SECTION REGARDING USE FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E OR V600K MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST
M-171	UPDATES TO LABELING WITH RESULTS TO THE TIGER CLINICAL TRIAL
M-172	UPDATES TO THE CLINICAL TRIALS SECTION OF THE LABELING TO INCLUDE RESULTS OF STUDIES PERFORMED TO EVALUATE THE BENEFIT OF ADDING INCRUSE ELLIPTA TO PATIENTS WHO ARE ON BACKGROUND THERAPY WITH BREO ELLIPTA AND ADVAIR DISKUS
M-173	INFORMATION ADDED TO THE CLINICAL STUDIES SECTION OF THE LABELING DESCRIBING THE EFFECTS OF STIOLTO RESPIMAT ON COPD PATIENTS
M-174	INFORMATION ADDED TO CLINICAL STUDIES SECTION OF THE LABELING REGARDING INITIAL COMBINATION THERAPY OF EMPAGLIFLOZIN WITH METFORMIN
M-175	INFORMATION ADDED TO THE LABELING DESCRIBING SAVOR, A PHASE IV TRIAL EVALUATING THE EFFECT OF SAXAGLIPTIN ON THE INCIDENCE OF CARDIOVASCULAR DEATH, MYOCARDIAL INFARCTION OR ISCHAEMIC STROKE IN PATIENTS WITH TYPE 2 DIABETES
M-176	INFORMATION ADDED TO THE LABELING DESCRIBING TRIAL NN2211-3916, A TRIAL EVALUATING THE SAFETY AND EFFICACY OF LIRAGLUTIDE IN SUBJECTS WITH TYPE 2 DIABETES AND MODERATE RENAL IMPAIRMENT
M-177	INFORMATION ADDED TO THE LABELING DESCRIBING EXAMINE, A TRIAL EVALUATING CARDIOVASCULAR ISCHEMIC RISKS ASSOCIATED WITH ALOGLIPTIN USE IN PATIENTS WITH TYPE 2 DIABETES AT HIGH RISK OF ISCHEMIC CARDIOVASCULAR DISEASE
M-178	INFORMATION ADDED TO THE LABELING REGARDING MAINTENANCE OF REMISSION IN CROHN'S DISEASE IN PEDIATRIC PATIENTS
M-179	UPDATES TO THE PRODUCT LABELING WITH STUDY REPORTS FROM THE OPTIMIST-1 AND OPTIMIST-2 CLINICAL TRIALS
M-180	INFORMATION ADDED TO THE LABELING REGARDING THE ADDITION OF MAINTENANCE TREATMENT IN PATIENTS WITH SCHIZOPHRENIA
M-181	UPDATE TO THE DOSAGE AND ADMINISTRATION, PATIENT SELECTION (2.1), SECTION OF THE PACKAGE INSERT TO INCLUDE THE USE OF AN FDA-APPROVED PLASMA TEST FOR THE IDENTIFICATION OF EGFR EXON 19 DELETION OR EXON 21 (L858R) SUBSTITUTION MUTATIONS
M-182	UPDATES TO THE PRODUCT LABELING BASED ON THE RESULTS OF STUDY H7T-MC-TADO TITLED, "A PHASE 3 DOUBLE-BLIND, RANDOMIZED, MULTICENTER, EFFICACY AND SAFETY STUDY OF PRASUGREL COMPARED TO PLACEBO IN PEDIATRIC PATIENTS WITH SICKLE CELL DISEASE"
M-183	CHANGES TO THE DOSAGE AND ADMINISTRATION AND CLINICAL STUDIES SECTIONS OF THE LABELING TO SUPPORT THE REDUCE-TO-QUIT PARADIGM
M-184	UPDATES MADE TO THE LABELING TO INCLUDE INFORMATION FROM STUDY MO25743 ON THE ANTI-TUMOR ACTIVITY OF VEMURAFENIB IN THE TREATMENT OF PATIENTS WITH BRAF V600E MUTATION-POSITIVE MELANOMA WITH BRAIN METASTASES
M-185	UPDATES TO THE LABELING TO INCLUDE RESULTS OF A TRIAL TO EVALUATE THE SAFETY OF MOXIFLOXACIN IN PEDIATRIC PATIENTS WITH COMPLICATED INTRA-ABDOMINAL INFECTIONS
M-186	UPDATES TO THE PRODUCT INFORMATION REGARDING MAINTENANCE TREATMENT OF SCHIZOPHRENIA IN ADULTS BASED UPON THE RESULTS FROM STUDY 331-10-232
M-187	ADDITION OF CLINICAL INFORMATION OBTAINED FROM A PEDIATRIC TRIAL TO SECTION 8.4 OF THE LABELING
M-188	PROVIDES FOR DATA SUPPORTING THE SAFETY AND EFFECTIVENESS FOR THE MAINTENANCE TREATMENT OF MODERATE TO SEVERE BINGE EATING DISORDER (BED)
M-189	LABELING DESCRIBING THE EXPECTED REDUCTION OF ABUSE OF SINGLE-ENTITY MORPHINE BY THE INTRANASAL ROUTE OF ADMINISTRATION DUE TO PHYSICOCHEMICAL PROPERTIES
M-190	INFORMATION ADDED TO THE CLINICAL STUDIES SECTION OF THE LABELING REGARDING THE LACK OF EFFICACY OF TARCEVA IN MAINTENANCE TREATMENT OF PATIENTS WITHOUT EGFR MUTATIONS
M-191	ADDITION OF DATA BASED ON PEDIATRIC STUDIES TO FULFILL THE POSTMARKETING REQUIREMENT 1857-2
M-192	PROVIDES FOR DATA EVALUATING THE NEUROPSYCHIATRIC SAFETY AND EFFICACY OF VARENICLINE FOR SMOKING CESSATION IN SUBJECTS WITH AND WITHOUT A HISTORY OF PSYCHIATRIC DISORDERS
M-193	INFORMATION ADDED TO THE LABELING REGARDING A 15-WEEK, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED FLEXIBLE-DOSE SAFETY AND EFFICACY STUDY OF

PATENT AND EXCLUSIVITY TERMS

ADB 46 of 191

EXCLUSIVITY MISCELLANEOUS

	PREGABALIN IN ADOLESCENTS (12 THROUGH 17 YEARS OLD) WITH FIBROMYALGIA
M-194	INFORMATION ADDED TO THE LABELING REGARDING USE OF REGADENOSON ADMINISTRATION FOLLOWING AN INADEQUATE EXERCISE STRESS TEST AS COMPARED TO REGADENOSON ALONE
M-195	REVISIONS TO THE PEDIATRIC USE SECTION OF THE LABELING REFLECTING LACK OF EFFICACY FOR IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER IN PEDIATRIC PATIENTS AGES 6-17
M-196	REVISIONS TO THE PACKAGE INSERT BASED ON DATA FROM A RANDOMIZED, PLACEBO CONTROLLED, MULTICENTER STUDY OF INTRAVENOUS ACETAMINOPHEN FOR THE TREATMENT OF ACUTE PAIN IN PEDIATRIC PATIENTS TO FULFILL THE POST-MARKETING REQUIREMENT 1704-1
M-197	NEW CLINICAL DATA ADDED TO THE PRESCRIBING INFORMATION REGARDING CANAGLIFLOZIN ADD-ON COMBINATION THERAPY WITH METFORMIN AND A DIPEPTIDYL-PEPTIDASE-4 INHIBITOR
M-198	PACKAGE INSERT UPDATED WITH RESULTS FROM STUDY CV181168, A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, PHASE 3 TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF SAXAGLIPTIN ADDED TO DAPAGLIFLOZIN AND METFORMIN
M-199	INFORMATION ADDED TO LABELING REGARDING THE TREATMENT OF PATIENTS WITH ALK-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC) WHO HAD NOT RECEIVED PRIOR SYSTEMIC THERAPY FOR METASTATIC DISEASE.
M-200	CLINICAL INFORMATION ADDED TO THE USE IN SPECIFIC POPULATIONS SECTION OF THE LABELING.
M-201	REVISIONS TO THE PACKAGE INSERT BASED ON DATA FROM AN OPEN LABEL, MULTI-CENTER STUDY OF CABAZITAXEL IN PEDIATRIC PATIENTS WITH REFRACTORY SOLID TUMORS INCLUDING TUMORS OF THE CENTRAL NERVOUS SYSTEM.
M-202	INCLUSION OF DATA FROM THE SUMMIT STUDY FOR BREO ELLIPTA (FLUTICASONE FUROATE/VILANTEROL TRIFENATATE) INHALATION POWDER IN THE PACKAGE INSERT.
M-203	PROVIDES FOR REVISIONS TO THE PACKAGE INSERT TO REFLECT RESULTS OF TWO POSTMARKETING REQUIREMENT STUDIES ROP111662 AND ROP111569
M-204	CLINICAL INFORMATION ADDED TO THE PACKAGE INSERT REGARDING USE OF ATORVASTATIN IN CHILDREN AND ADOLESCENTS AGES 10-17 WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HEFH)
M-205	INFORMATION ADDED TO THE LABELING REGARDING RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDIES ON PATIENTS WITH SEVERE RENAL IMPAIRMENT
M-206	INFORMATION ADDED TO LABELING REGARDING 48 WEEK EFFICACY, RESISTANCE AND SAFETY DATA ON VIROLOGICALLY SUPPRESSED HIV-1 INFECTED ADULTS SWITCHING FROM COMPLERA TO ODEFSEY
M-207	INFORMATION ADDED TO LABELING REGARDING 48 WEEK EFFICACY, RESISTANCE AND SAFETY DATA ON VIROLOGICALLY SUPPRESSED HIV-1 INFECTED ADULTS SWITCHING FROM ATRIPLA TO ODEFSEY
M-208	INFORMATION ADDED TO THE LABELING TO INCLUDE RESULTS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY IN PATIENTS WITH SEVERE COPD ASSOCIATED WITH CHRONIC BRONCHITIS AND A HISTORY OF EXACERBATIONS
M-209	INFORMATION ADDED TO THE LABELING REGARDING CABAZITAXEL AT 20 MG/M2 BASED ON THE RESULTS OF THE PROSELICA STUDY
M-210	INFORMATION ADDED TO LABELING TO SUPPORT THE USE OF SYMBICORT TO REDUCE EXACERBATIONS IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
M-211	PROVIDES FOR LABELING CHANGES REGARDING THE USE OF DAPTOMYCIN IN THE PEDIATRIC POPULATION FOR STAPHYLOCOCCUS AUREUS BACTEREMIA (SAB) BASED ON RESULTS OF A TRIAL IN PEDIATRIC PATIENTS 1 TO 17 YEARS OF AGE
M-212	INFORMATION ADDED TO THE LABELING REGARDING THE SAFETY AND EFFICACY OF DAPAGLIFLOZIN IN PATIENTS WITH TYPE 2 DIABETES WHO HAVE INADEQUATE GLYCEMIC CONTROL ON A BACKGROUND COMBINATION OF METFORMIN AND EXENATIDE EXTENDED RELEASE
M-213	INFORMATION ADDED TO THE LABELING TO INCLUDE THE EFFICACY AND SAFETY OF CARIPRAZINE RELATIVE TO PLACEBO IN THE PREVENTION OF RELAPSE OF SYMPTOMS IN PATIENTS WITH SCHIZOPHRENIA
M-214	INFORMATION ADDED TO THE CLINICAL TRIALS SECTION OF THE LABELING REGARDING A POSTMARKETING SAFETY AND EFFICACY STUDY EVALUATING THE RISK OF SERIOUS ASTHMA-RELATED EVENTS
M-215	INFORMATION ADDED TO THE LABELING REGARDING THE COMPARISON OF PALIPERIDONE PALMITATE COMPARED WITH ORAL ANTIPSYCHOTIC TREATMENT IN DELAYING TIME TO

PATENT AND EXCLUSIVITY TERMS

ADB 47 of 191

EXCLUSIVITY MISCELLANEOUS

	TREATMENT FAILURE IN ADULTS WITH SCHIZOPHRENIA WHO HAVE BEEN INCARCERATED
M-216	UPDATE THE PRESCRIBING INFORMATION AND PATIENT LABELING WITH FINDINGS FROM STUDY RP103-08 CONDUCTED IN TREATMENT-NAIVE NEPHROPATHIC CYSTINOSIS PATIENTS TO EXPAND THE INDICATED POPULATION TO PATIENTS 1 YEAR AND OLDER
M-217	INCORPORATION OF THE LABELING REVISIONS PROVIDED FOR IN NDA 022253/S-039 AND NDA 022255/S-022 INTO THE LACOSAMIDE INJECTION LABELING
M-218	ADDITIONAL INFORMATION ADDED TO THE PEDIATRIC USE SECTION OF THE LABELING REGARDING A NEW CLINICAL TRIAL IN PATIENTS AGED 6 THROUGH 11 YEARS (TRIAL 4)
M-219	INFORMATION ADDED TO THE PEDIATRIC USE SECTION OF THE LABELING REGARDING A NEW CLINICAL TRIAL IN PATIENTS 7 TO 14 YEARS OF AGE WITH DUCHENNE MUSCULAR DYSTROPHY
M-220	ADDITIONAL INFORMATION ADDED TO THE LABELING FROM STUDY PC B308/13 REGARDING THE USE OF BLUE LIGHT CYSTOSCOPY WITH CYSVIEW AS AN ADJUNCT TO WHITE LIGHT CYSTOSCOPY
M-221	DRUG FACTS LABELING CHANGES UNDER THE DIRECTIONS HEADING TO REVISE THE STATED PREPARATION TIME OF A DRY SITE FROM 120 SECONDS SCRUBBING AND 90 SECONDS DRYING TO 30 SECONDS SCRUBBING AND 30 SECONDS DRYING
M-222	ADDITION OF DATA BASED ON THE ASSESSMENT OF SAFETY AND EFFICACY IN PEDIATRIC PATIENTS WITH MAJOR DEPRESSIVE DISORDER TO FULFILL POSTMARKETING STUDY REQUIREMENT 1229-1
M-223	INFORMATION ADDED TO SECTION 8.1 OF THE LABELING REGARDING PREGNANT PATIENTS WHO ARE ALREADY ON A STABLE RILPIVIRINE REGIMEN PRIOR TO PREGNANCY AND WHO ARE VIROLOGICALLY SUPPRESSED (HIV-1 RNA LESS THAN 50 COPIES/ML)
M-224	INFORMATION ADDED TO THE LABELING REGARDING THE SAFETY AND EFFICACY OF EXENATIDE EXTENDED RELEASE AS ADD-ON IN PATIENTS WITH TYPE 2 DIABETES WHO HAVE INADEQUATE GLYCEMIC CONTROL ON BASAL INSULIN GLARGINE WITH OR WITHOUT METFORMIN
M-225	REVISIONS TO SECTION 8.4 OF THE PRESCRIBING INFORMATION TO INCLUDE A SAFETY AND EFFICACY STUDY IN PEDIATRIC PATIENTS AGES ≥ 6 YEARS TO < 18 YEARS WITH CHRONIC IDIOPATHIC CONSTIPATION
M-226	CHANGES TO THE LABELING BASED ON RESULTS FROM A CONTROLLED CLINICAL TRIAL IN PATIENTS WITH LATER-ONSET SPINAL MUSCULAR ATROPHY
M-227	ADDITION TO THE CLINICAL STUDIES SECTION OF THE LABELING WITH THE SUBSECTION ENTITLED DIGIT SYMBOL SUBSTITUTION TEST IN MAJOR DEPRESSIVE DISORDER
M-228	INFORMATION ADDED TO THE PACKAGE INSERT REGARDING THE REVISION OF THE MONOTHERAPY INDICATION OF VENETOCLAX
M-229	REVISED LABELING TO INCORPORATE THE PEDIATRIC USE OF LOTEPREDNOL ETABONATE GEL IN PATIENTS FOR THE TREATMENT OF POSTOPERATIVE INFLAMMATION FOLLOWING OCULAR SURGERY
M-230	REVISIONS TO THE GLECAPREVIR/PIBRENTASVIR COMBINATION PRODUCT PRESCRIBING INFORMATION TO INCLUDE SAFETY AND EFFICACY DATA FROM THE HCV/HIV-1 COINFECTION STUDY M14-730 AND FROM THE LIVER AND RENAL TRANSPLANT STUDY M13-596
M-231	REVISIONS TO THE USE IN SPECIFIC POPULATIONS SECTION (SECTION 8.3) OF THE PACKAGE INSERT WITH THE RESULTS OF CLINICAL TRIAL WV25651, CONDUCTED TO EVALUATE THE EFFECT OF VALGANCYCLOVIR ON SPERMATOGENESIS AND TO FULFILL PMR 1670-3
M-232	INFORMATION ADDED TO SECTION 8.4 OF THE LABELING TO DESCRIBE THE RESULTS FROM PEDIATRIC STUDIES
M-233	INFORMATION ADDED TO THE LABELING TO DESCRIBE FIXED-DOSE COMBINATION OF TIOTROPIUM BROMIDE AND OLODATEROL TO INCLUDE REDUCTION OF COPD EXACERBATIONS
M-234	UPDATE TO THE PRESCRIBING INFORMATION FOR VORTIOXETINE ON TREATMENT-EMERGENT SEXUAL DYSFUNCTION COMPARING VORTIOXETINE AND SSRIS
M-235	INFORMATION ADDED TO SECTION 14 OF THE LABELING TO DESCRIBE STUDY LAP016A2307 TO FULFILL POSTMARKETING STUDY REQUIREMENT 1586-1
M-236	INFORMATION ADDED TO THE PRESCRIBING INFORMATION TO INCLUDE EFFICACY AND SAFETY DATA FROM A STUDY IN PATIENTS WITH TREATMENT NAIVE CLL/SLL TREATED WITH IBRUTINIB IN COMBINATION WITH OBINUTUZUMAB OR CHLORAMBUCIL IN COMBINATION WITH OBINUTUZUMAB
M-237	INFORMATION ADDED TO LABELING TO DESCRIBE A STUDY TO EVALUATE THE SAFETY AND EFFICACY OF VARENICLINE FOR SMOKING CESSATION IN ADOLESCENT SMOKERS
M-238	INFORMATION ADDED TO THE PRESCRIBING INFORMATION TO REFLECT THAT NO DOSE ADJUSTMENT IS NEEDED FOR PATIENTS WITH AN ESTIMATED GLOMERULAR FILTRATION RATE

PATENT AND EXCLUSIVITY TERMS

ADB 48 of 191

EXCLUSIVITY MISCELLANEOUS

	(EGFR) OF 45 ML/MIN/1.73 M2 OR GREATER AS SUPPORTED BY CLINICAL STUDY REPORT
M-239	INFORMATION ADDED TO THE PEDIATRIC USE SECTION OF THE LABELING REGARDING A TRIAL CONDUCTED IN TREATMENT NAIVE PEDIATRIC PATIENTS, AGES 2 YEARS TO < 18 YEARS WITH TRANSFUSIONAL IRON OVERLOAD
M-240	INFORMATION ADDED TO LABELING REGARDING A RANDOMIZED, PLACEBO-CONTROLLED CLINICAL TRIAL TO EVALUATE CARDIOVASCULAR OUTCOMES AFTER TREATMENT WITH EXENATIDE ONCE WEEKLY IN PATIENTS WITH TYPE 2 DIABETES MELLITES
M-241	INFORMATION ADDED TO THE LABELING FOR SAFETY & EFFICACY STUDY ENTITLED, A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED CLINICAL TRIAL OF DEFERASIROX IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (LOW/INT-1 RISK) & TRANSFUSIONAL IRON OVERLOAD
M-242	INFORMATION ADDED TO THE LABELING REGARDING THE EFFICACY AND SAFETY OF INSULIN DEGLUDEC/LIRAGLUTIDE VS INSULIN GLARGINE IN PTS W/ TYPE 2 DIABETES INADEQUATELY CONTROLLED ON SGLT2I WITH OR WITHOUT ORAL ANTIDIABETIC THERAPIES
M-243	INFORMATION ADDED TO LABELING FROM PROSPECTIVE, RANDOMIZED, OPEN-LABEL, BLIND EVALUATOR (PROBE) STUDY EVALUATING THE EFFICACY AND SAFETY OF LOW MOLECULAR WEIGHT HEPARIN/EDOXABAN VERSUS DALTEPARIN IN VENOUS THROMBOEMBOLISM ASSOCIATED WITH CANCER
M-244	INFORMATION ADDED TO THE LABELING REGARDING EFFICACY AND SAFETY OF THE CONTINUATION OF SITAGLIPTIN COMPARED WITH THE WITHDRAWAL OF SITAGLIPTIN DURING INITIATION AND TITRATION OF INSULIN GLARGINE IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS
M-245	ADDITIONAL INFORMATION ADDED TO THE LABELING BASED ON SAFETY AND EFFICACY DATA FROM THE IMPACT TRIAL
M-246	ADDITION OF STUDY BRf117277, A NON-RANDOMIZED, OPEN-LABEL, MULTI-CENTER, MULTI-COHORT TRIAL OF DABRAFENIB PLUS TRAMETINIB IN SUBJECTS WITH BRAF MUTATION-POSITIVE MELANOMA THAT HAS METASTASIZED TO THE BRAIN
M-247	REVISIONS TO THE LABELING REGARDING CONTINUOUS SUBCUTANEOUS INSULIN INFUSION AS A CONDITION OF USE FOR INSULIN ASPART
M-248	INFORMATION ADDED TO THE LABELING TO DESCRIBE A TRIAL EVALUATING A LOWER DOSE THAN THOSE APPROVED FOR PEDIATRIC PATIENTS 13 TO 17 YEARS OF AGE
M-249	INFORMATION ADDED TO THE LABELING TO DESCRIBE STUDY LVM-MD-15 TO FULFILL POSTMARKETING COMMITMENT 1943-4
M-250	REVISIONS TO THE PEDIATRIC USE SECTION TO INCLUDE AN OPEN-LABEL CLINICAL TRIAL TO FULFILL PMR 1655-1
M-251	INFORMATION ADDED TO THE CLINICAL PHARMACOLOGY SECTION REGARDING INFLUENZA VIRUS RESISTANCE TO OSELTAMIVIR IN IMMUNOCOMPROMISED PATIENTS
M-252	ADDITION OF INFORMATION TO CLINICAL STUDIES SECTION REGARDING CARDIOVASCULAR OUTCOME
M-253	INFORMATION ADDED TO THE LABELING TO DESCRIBE STUDY P061, A RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTI-SITE, DOUBLE-BLIND STUDY TO EVALUATE SAFETY AND EFFICACY OF SUVOREXANT FOR THE TREATMENT OF INSOMNIA IN SUBJECTS WITH ALZHEIMERS DISEASE
M-254	INFORMATION ADDED TO THE LABELING REGARDING PEDIATRIC PATIENTS AGES 7 TO 17 YEARS OF AGE WITH MAJOR DEPRESSIVE DISORDER
M-255	INFORMATION ADDED TO THE LABELING TO DESCRIBE STUDY GS-US-320-4018 IN VIROLOGICALLY SUPPRESSED ADULTS W/ CHRONIC HEP B INFECTION WHO SWITCHED FROM TENOFOVIR DISOPROXIL FUMARATE TO TENOFOVIR ALAFENAMIDE
M-256	INFORMATION ADDED TO THE CLINICAL STUDIES SECTION TO FULFILL A POST-MARKETING REQUIREMENT
M-257	INFORMATION ADDED TO THE CLINICAL STUDIES SECTION OF THE LABELING REGARDING THE USE OF PLAQUE PSORIASIS OF THE SCALP
M-258	INFORMATION ADDED TO THE LABELING TO DESCRIBE CARMELINA TRIAL TO FULFILL POSTMARKETING COMMITMENT 1766-4
M-259	INFORMATION ADDED TO THE LABELING REGARDING SAFETY AND EFFICACY IN SUBJECTS WITH HCV SUBTYPE 3B INFECTION
M-260	INFORMATION ADDED TO THE LABELING DESCRIBING A RANDOMIZED, OPEN-LABEL STUDY THAT EXAMINED THE CONCOMITANT USE OF DIMETHYL FUMARATE AND SEVERAL NON-LIVE VACCINES IN ADULTS 27-55 YEARS OF AGE WITH RELAPSING FORMS OF MULTIPLE SCLEROSIS

PATENT AND EXCLUSIVITY TERMS

ADB 49 of 191

EXCLUSIVITY MISCELLANEOUS

M-261	ADDITIONAL INFORMATION ADDED TO THE LABELING REGARDING THE USE IN PATIENTS ON CHRONIC HEMODIALYSIS
M-262	REVISIONS TO THE USE IN SPECIFIC POPULATIONS SECTION OF THE PACKAGE INSERT TO INCLUDE THE RESULT OF STUDY P146 TO FULFILL THE REQUIREMENTS OF PMR 3003-4
M-263	REVISIONS TO THE LABELING TO INCLUDE RESULTS FROM CLINICAL STUDY ICL670E2419 (THETIS TRIAL) TO SUPPORT PMR 3342-2 AND 3342-3
M-264	INFORMATION ADDED TO THE LABELING DESCRIBING A PHASE 2, MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE SAFETY/EFFICACY OF SOFOSBUVIR/VELPATASVIR IN SUBJECTS WITH CHRONIC HCV INFECTION WHO HAVE RECEIVED A LIVER TRANSPLANT
M-265	REVISIONS TO THE LABELING TO INCLUDE RESULTS FROM CLINICAL STUDY M15-656 (VIALE-A) AND M16-043 (VIALE-C) TO SUPPORT PMR 3545-1 AND PMR 3545-2
M-266	INFORMATION ADDED TO THE LABELING TO DESCRIBE STUDY GS-US-320-4035 IN VIROLOGICALLY SUPPRESSED ADULTS W/ CHRONIC HEP B INFECTION WHO SWITCHED FROM TENOFOVIR DISOPROXIL FUMARATE TO TENOFOVIR ALFAENAMIDE
M-267	INFORMATION ADDED TO THE LABELING REGARDING THE RESULT OF STUDY LUAA21004-402
M-268	ADDITION OF INFORMATION TO THE LABEL REGARDING A CLEAR PRODUCT PRESENTATION AND 26 ML VOLUME PRODUCTS
M-269	REVISIONS TO THE LABELING TO INCLUDE RESULTS FROM CLINICAL STUDY 309/KEYNOTE-775 TO SUPPORT PMR 3696-1 AND 3700-1
M-270	INFORMATION ADDED TO CLINICAL PHARMACOLOGY SECTION
M-271	REVISIONS TO THE LABELING TO INCLUDE RESULTS FROM CLINICAL STUDY HRA2914-5016
M-272	REVISIONS TO THE LABELING TO INCLUDE RESULTS FROM CLINICAL STUDY E7080-G000-211 TO SUPPORT PMR 2865-1
M-273	REVISION TO THE LABELING TO INCLUDE RESULTS FROM CLINICAL STUDY 207966 ATLAS-2M
M-274	REVISIONS TO THE LABELING TO INCLUDE RESULTS FROM CLINICAL STUDY CBAF312A2130
M-275	REVISION TO THE LABELING TO INCLUDE RESULTS FROM CLINICAL STUDY, MK-8835-004/B1521021, VERTIS CV
M-276	REVISIONS TO THE PEDIATRIC USE SUBSECTION OF LABELING TO INCLUDE THE RESULTS FROM CLINICAL STUDY 1200.120, CONDUCTED TO FULFILL A PEDIATRIC WRITTEN REQUEST
M-277	UPDATES THE US PRESCRIBING INFORMATION WITH CLINICAL DATA REGARDING THE USE OF SOFOSBUVIR AND VELPATASVIR FOR THE TREATMENT OF CHRONIC HCV GENOTYPE 1, 2, 3, 4, 5, OR 6 INFECTION IN PEOPLE WHO INJECT DRUGS (PWID), INCLUDING THOSE ON MEDICATION-ASSISTED TREATMENT (MAT) FOR OPIOID USE DISORDER
M-278	INFORMATION ADDED TO SECTION 8.4 OF THE LABELING TO INCLUDE THE RESULT OF STUDY GO29665
M-279	INFORMATION ADDED TO THE LABELING TO DESCRIBE THE RESULTS OF FIGARO-DKD STUDY
M-280	REVISIONS TO THE PEDIATRIC USE SUBSECTION OF LABELING TO INCLUDE THE RESULTS FROM CLINICAL STUDIES E7389-G000-223 AND E7389-G000-213, CONDUCTED TO FULFILL A PEDIATRIC WRITTEN REQUEST
M-281	REVISIONS TO THE LABELING TO PROVIDE FOR THE EXPANSION OF THE USE OF STIRIPENTOL FOR THE TREATMENT OF SEIZURES ASSOCIATED WITH DRAVET SYNDROME IN PATIENTS TAKING CLOBAZAM TO INCLUDE PEDIATRIC PATIENTS WHO ARE 6 MONTHS TO LESS THAN 2 YEARS OF AGE AND WEIGHING 7 KG OR MORE
M-282	REVISIONS TO THE LABELING TO ADD THE RESULTS OF A CLINICAL STUDY (TA-303) IN PATIENTS WITH ED FOLLOWING BILATERAL NERVE-SPARING RADICAL PROSTATECTOMY
M-283	INFORMATION ADDED TO SECTION 8.4 OF THE LABELING TO INCLUDE THE RESULT OF STUDY HESTIA3
M-284	REVISIONS TO THE LABELING TO INCLUDE RESULTS FROM GALILEO TRIAL

ORPHAN DRUG EXCLUSIVITY

ODE-1	TO REDUCE CHRONIC DROOLING IN PATIENTS AGED 3 - 16 WITH NEUROLOGIC CONDITIONS ASSOCIATED WITH PROBLEM DROOLING (E.G. CEREBRAL PALSY)
ODE-2	FOR TREATMENT OF NON-INFECTIOUS UVEITIS AFFECTING THE POSTERIOR SEGMENT OF THE EYE

PATENT AND EXCLUSIVITY TERMS

ADB 50 of 191

ORPHAN DRUG EXCLUSIVITY

ODE-3	TO TREAT INFANTILE SPASMS
ODE-4	TREATMENT OF PATIENTS WITH SUBEPENDYMAL GIANT CELL ASTROCYTOMA (SEGA) ASSOCIATED WITH TUBEROUS SCLEROSIS WHO REQUIRE THERAPEUTIC INTERVENTION BUT ARE NOT CANDIDATES FOR CURATIVE SURGICAL RESECTION
ODE-5	FOR SEQUENTIAL USE FOR THE TREATMENT OF CYANIDE POISONING THAT IS JUDGED TO BE LIFE-THREATENING
ODE-6	FOR THE MANAGEMENT OF POSTHERPETIC NEURALGIA
ODE-7	TO REDUCE THE RISK OF PRETERM BIRTH IN WOMEN WITH SINGLETON PREGNANCY WHO HAVE A HISTORY OF SINGLETON SPONTANEOUS PRETERM BIRTH
ODE-8	TREATMENT OF SEVERE HYPERCALCEMIA IN PATIENTS WITH PRIMARY HYPERPARATHYROIDISM WHO ARE UNABLE TO UNDERGO PARATHYROIDECTOMY
ODE-9	TREATMENT OF ASYMPTOMATIC OR PROGRESSIVE MEDULLARY THYROID CANCER IN PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC DISEASE
ODE-10	FOR USE IN COMBINATION CHEMOTHERAPY WITH 5-FLUOROURACIL IN THE PALLIATIVE TREATMENT OF PATIENTS WITH ADVANCED METASTATIC COLORECTAL CANCER
ODE-11	TREATMENT OF PROGRESSIVE NEUROENDOCRINE TUMORS OF PANCREATIC ORIGIN (PNET) IN PATIENTS WITH UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC DISEASE
ODE-12	TREATMENT OF PERIPHERAL T-CELL LYMPHOMA (PTCL) IN PATIENTS WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
ODE-13	TREATMENT OF UNRESECTABLE OR METASTATIC MELANOMA WITH THE BRAF V600E MUTATION AS DETECTED BY AN FDA-APPROVED TEST
ODE-14	TREATMENT OF ACUTE ATTACKS OF HEREDITARY ANGIOEDEMA IN ADULTS 18 YEARS OF AGE AND OLDER
ODE-15	TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) THAT IS ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE AS DETECTED BY AN FDA APPROVED TEST
ODE-16	TREATMENT OF PATIENTS WITH TRANSFUSIONAL IRON OVERLOAD DUE TO THALASSEMIA SYNDROMES WHEN CURRENT CHELATION THERAPY IS INADEQUATE
ODE-17	ADJUNCTIVE TREATMENT OF SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME IN PATIENTS 2 YEARS OF AGE OR OLDER
ODE-18	ADJUNCTIVE TREATMENT OF SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME INPATIENTS 2 YEARS OF AGE OR OLDER
ODE-19	TREATMENT OF PATIENTS WITH INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS, INCLUDING PRIMARY MYELOFIBROSIS, POST-POLYCYTHEMIA VERA MYELOFIBROSIS AND POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS
ODE-20	TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS AGE 6 YEARS AND OLDER WHO HAVE A G551D MUTATION IN THE CFTR GENE.
ODE-21	AN ADJUNCT TO AB EXTERNO GLAUCOMA SURGERY
ODE-22	FOR THE CONTROL OF HYPERGLYCEMIA SECONDARY TO HYPERCORTISOLISM IN ADULT PATIENTS WITH ENDOGENOUS CUSHING'S SYNDROME WHO HAVE TYPE 2 DIABETES MELLITUS OR GLUCOSE INTOLERANCE AND HAVE FAILED SURGERY OR ARE NOT CANDIDATES FOR SURGERY
ODE-23	ADVANCED SOFT TISSUE SARCOMA (STS) WHO HAVE RECEIVED PRIOR CHEMOTHERAPY
ODE-24	TREATMENT OF ADULTS WITH RENAL ANGIOMYOLIPOMA AND TUBEROUS SCLEROSIS COMPLEX (TSC) NOT REQUIRING IMMEDIATE SURGERY
ODE-25	MANAGEMENT OF POSTHERPETIC NEURALGIA IN ADULTS.
ODE-26	TREATMENT OF ENDOGENOUS ANTERIOR UVEITIS
ODE-27	TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST TWO PRIOR THERAPIES INCLUDING BORTEZOMIB AND AN IMMUNOMODULATORY AGENT AND HAVE DEMONSTRATED DISEASE PROGRESSION ON OR WITHIN 60 DAYS OF COMPLETION OF THE LAST THERAPY
ODE-28	TREATMENT OF ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME-NEGATIVE (PH-) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN SECOND OR GREATER RELAPSE OR WHOSE DISEASE HAS PROGRESSED FOLLOWING TWO OR MORE ANTI-LEUKEMIA THERAPIES
ODE-29	LOCALIZATION OF LYMPH NODES DRAINING A PRIMARY TUMOR IN PATIENTS WITH MELANOMA WHEN USED WITH A HAND-HELD GAMMA COUNTER
ODE-30	TREATMENT OF ADULT PATIENTS WITH CHRONIC, ACCELERATED OR BLAST PHASE PHILADELPHIA CHROMOSOME-POSITIVE (PH+) CHRONIC MYELOGENOUS LEUKEMIA (CML) WITH

PATENT AND EXCLUSIVITY TERMS

ADB 51 of 191

ORPHAN DRUG EXCLUSIVITY

RESISTANCE, OR INTOLERANCE TO PRIOR THERAPY

- ODE-31 TREATMENT OF CORNEAL CYSTINE CRYSTAL ACCUMULATION IN PATIENTS WITH CYSTINOSIS
- ODE-32 TREATMENT OF ADULT PATIENTS WITH CHRONIC OR ACCELERATED PHASE CHRONIC MYELOID LEUKEMIA (CML) WITH RESISTANCE AND/OR INTOLERANCE TO TWO OR MORE TYROSINE KINASE INHIBITORS (TKI)
- ODE-33 TREATMENT OF PROGRESSIVE, METASTATIC MEDULLARY THYROID CANCER (MTC)
- ODE-34 TREATMENT OF ADULT PATIENTS WITH CUSHING'S DISEASE FOR WHOM PITUITARY SURGERY IS NOT AN OPTION OR HAS NOT BEEN CURATIVE
- ODE-35 TREATMENT OF ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (PH+ALL) THAT IS RESISTANT OR INTOLERANT TO PRIOR TYROSINE KINASE INHIBITOR THERAPY.
- ODE-36 ADJUNCT TO A LOW-FAT DIET AND OTHER LIPID-LOWERING TREATMENTS, INCLUDING LDL APHERESIS WHERE AVAILABLE, TO REDUCE LDL-C, TC, APOLIPOPROTEIN B, & NON-HDL-C IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
- ODE-37 TREATMENT OF ADULT PATIENTS WITH SHORT BOWEL SYNDROME (SBS) WHO ARE DEPENDENT ON PARENTERAL SUPPORT
- ODE-38 PART OF COMBINATION THERAPY IN ADULTS (GREATER THAN OR EQUAL TO 18 YEARS) WITH PULMONARY MULTI-DRUG RESISTANT TUBERCULOSIS (MDR-TB)
- ODE-39 TREATMENT OF CHRONIC IRON OVERLOAD IN PATIENTS 10 YRS. & OLDER WITH NON-TRANSFUSION DEPENDENT THALASSEMIA (NTDT) SYNDROMES AND WITH A LIVER IRON CONCENTRATION OF AT LEAST 5 MG OF IRON PER GRAM OF LIVER DRY WEIGHT & SERUM FERRITIN GREATER THAN 300 MCG/L.
- ODE-40 TREATMENT OF PEDIATRIC PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (PH+ ALL) IN COMBINATION WITH CHEMOTHERAPY, APPROVED UNDER NDA #21588/S-037
- ODE-41 ADJUNCT TO LIPID-LOWERING MEDICATIONS AND DIET TO REDUCE LDL-C, APOLIPOPROTEIN B (APO B), TOTAL CHOLESTEROL (TC), AND NON-HIGH DENSITY LIPOPROTEIN-CHOLESTEROL (NON-HDL-C) IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH)
- ODE-42 USE AS A NITROGEN-BINDING ADJUNCTIVE THERAPY FOR CHRONIC MGMT OF ADULT AND PEDIATRIC PATIENTS AT LEAST 2 YRS WITH UREA CYCLE DISORDERS THAT CANNOT BE MANAGED BY DIETARY PROTEIN RESTRICTION AND/OR AMINO ACID SUPPLEMENTATION ALONE
- ODE-43 TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST TWO PRIOR THERAPIES INCLUDING LENALIDOMIDE AND BORTEZOMIB AND HAVE DEMONSTRATED DISEASE PROGRESSION ON OR WITHIN 60 DAYS OF COMPLETION OF THE LAST THERAPY.
- ODE-44 TREATMENT OF PATIENTS WITH LOCALLY ADVANCED, UNRESECTABLE OR METASTATIC GASTROINTESTINAL STROMAL TUMOR (GIST) WHO HAVE BEEN PREVIOUSLY TREATED WITH IMATINIB MESYLATE AND SUNITINIB MALATE.
- ODE-45 MANAGEMENT OF NEPHROPATHIC CYSTINOSIS IN ADULTS AND CHILDREN AGES 6 YEARS AND OLDER.
- ODE-46 IMPROVEMENT OF NEUROLOGICAL OUTCOME BY REDUCING THE INCIDENCE AND SEVERITY OF ISCHEMIC DEFICITS IN ADULT PATIENTS WITH SUBARACHNOID HEMORRHAGE FROM RUPTURED INTRACRANIAL BERRY ANEURYSMS REGARDLESS OF THEIR POST-ICTUS NEUROLOGICAL CONDITION
- ODE-47 TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E MUTATION AS DETECTED BY AN FDA APPROVED TEST.
- ODE-48 TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E OR V600K MUTATIONS AS DETECTED BY AN FDA APPROVED TEST
- ODE-49 TREATMENT OF MANTLE CELL LYMPHOMA WHOSE DISEASE HAS RELAPSED OR PROGRESSED AFTER TWO PRIOR THERAPIES, ONE OF WHICH INCLUDED BORTEZOMIB
- ODE-50 FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS HAVE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 19 DELETIONS OR EXON 21 (L858R) SUBSTITUTION MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST.
- ODE-51 TOPICAL TREATMENT OF STAGE 1A AND 1B MYCOSIS FUNGOIDES-TYPE CUTANEOUS T-CELL LYMPHOMA IN PATIENTS WHO HAVE RECEIVED PRIOR SKIN-DIRECTED THERAPY
- ODE-52 TREATMENT OF METASTATIC ADENOCARCINOMA OF THE PANCREAS AS FIRST-LINE TREATMENT, IN COMBINATION WITH GEMCITABINE.
- ODE-53 TREATMENT OF ADULTS WITH PULMONARY ARTERIAL HYPERTENSION (PAH) WHO GROUP 1, TO IMPROVE EXERCISE CAPACITY, WHO FUNCTIONAL CLASS AND TO DELAY CLINICAL WORSENING.

PATENT AND EXCLUSIVITY TERMS

ADB 52 of 191

ORPHAN DRUG EXCLUSIVITY

ODE-54	TX OF PAH TO DELAY DISEASE PROGRESSION. DISEASE PROGRESSION INCLUDED: DEATH, INITIATION OF IV OR SC PROSTANOIDS, OR CLINICAL WORSENING OF PAH (DECREASED 6-MINUTE WALK DISTANCE, WORSENER PAH SYMPTOMS AND NEED FOR ADDITIONAL PAH TREATMENT).
ODE-55	TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA (MCL) WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
ODE-56	TREATMENT OF PATIENTS WITH LOCALLY RECURRENT OR METASTATIC, PROGRESSIVE, DIFFERENTIATED THYROID CARCINOMA (DCT) THAT IS REFRACTORY TO RADIOACTIVE IODINE TREATMENT.
ODE-57	TRAMETINIB IN COMBO WITH DABRAFENIB FOR TX. OF PTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E OR V600K MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST. THIS INDICATION IS BASED ON THE DEMONSTRATION OF DURABLE RESPONSE RATE
ODE-58	DABRAFENIB IN COMBO WITH TRAMETINIB FOR TX. OF PTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E OR V600K MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST. THIS INDICATION IS BASED ON THE DEMONSTRATION OF DURABLE RESPONSE RATE
ODE-59	TREATMENT OF NON-24-HOUR SLEEP-WAKE DISORDER
ODE-60	TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
ODE-61	TREATMENT OF NEUROGENIC SYMPTOMATIC ORTHOSTATIC HYPOTENSION IN PATIENTS WITH PRIMARY AUTONOMIC FAILURE, DOPAMINE-BETA-HYDROXYLASE DEFICIENCY, AND NONDIABETIC AUTONOMIC NEUROPATHY
ODE-62	TREATMENT OF PROLIFERATING INFANTILE HEMANGIOMA REQUIRING SYSTEMIC THERAPY.
ODE-63	TREATMENT OF VISCERAL LEISHMANIASIS DUE TO LEISHMANIA DONOVANI; CUTANEOUS LEISHMANIASIS DUE TO LEISHMANIA BRAZILIENSIS, LEISHMANIA GUYANENSIS, AND LEISHMANIA PANAMENSIS; AND MUCOSAL LEISHMANIASIS DUE TO LEISHMANIA BRAZILIENSIS.
ODE-64	SELECTIVE HEPATIC INTRA-ARTERIAL USE FOR IMAGING TUMORS IN ADULTS WITH KNOWN HEPATOCELLULAR CARCINOMA (HCC)
ODE-65	TREATMENT OF PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA AS PART OF A COMBINATION REGIMEN.
ODE-66	TREATMENT OF PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHO HAVE PROGRESSED ON OR ARE INTOLERANT TO CRIZOTINIB.
ODE-67	GUIDING SENTINEL LYMPH NODE BIOPSY, USING A HAND-HELD GAMMA COUNTER IN PATIENTS WITH CLINICALLY NODE NEGATIVE SQUAMOUS CELL CARCINOMA OF THE ORAL CAVITY
ODE-68	TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA
ODE-69	TREATMENT OF MALIGNANT HYPERTHERMIA IN CONJUNCTION WITH APPROPRIATE SUPPORTIVE MEASURES AND FOR THE PREVENTION OF MALIGNANT HYPERTHERMIA IN PATIENTS AT HIGH RISK
ODE-70	RELAPSED CLL, IN COMBO. WITH RITUXIMAB, IN PATIENTS FOR WHOM RITUXIMAB ALONE WOULD BE CONSIDERED APPROPRIATE THERAPY DUE TO OTHER CO-MORBIDITIES; AND RELAPSED SLL IN PATIENTS WHO HAVE RECEIVED AT LEAST 2 PRIOR SYSTEMIC THERAPIES
ODE-71	RELAPSED FOLLICULAR B-CELL NON-HODGKIN LYMPHOMA (FL) IN PATIENTS WHO HAVE RECEIVED AT LEAST TWO PRIOR SYSTEMIC THERAPIES
ODE-72	TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA WITH 17P DELETION WHO HAVE NOT RECEIVED AT LEAST ONE PRIOR THERAPY
ODE-73	LONG-TERM TREATMENT OF ADULT PATIENTS WITH GAUCHER DISEASE TYPE 1 WHO ARE CYP2D6 EXTENSIVE METABOLIZERS (EMS), INTERMEDIATE METABOLIZERS (IMS), OR POOR METABOLIZERS (PMS) AS DETECTED BY AN FDA-CLEARED TEST.
ODE-74	TREATMENT OF PATIENTS WITH SEVERE APLASTIC ANEMIA WHO HAVE HAD AN INSUFFICIENT RESPONSE TO IMMUNOSUPPRESSIVE THERAPY
ODE-75	TREATMENT OF PATIENTS WITH SEVERE APLASTIC ANEMIA WHO HAVE HAD AN INSUFFICIENT RESPONSE TO IMMUNOSUPPRESSIVE THERAPY.
ODE-76	TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA WHO HAVE NOT RECEIVED AT LEAST 1 PRIOR THERAPY
ODE-77	TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS
ODE-78	TREATMENT OF HYPERCALCEMIA IN ADULT PATIENTS WITH PRIMARY HYPERPARATHYROIDISM FOR WHOM PARATHYROIDECTOMY WOULD BE INDICATED ON THE BASIS OF SERUM CALCIUM

PATENT AND EXCLUSIVITY TERMS

ADB 53 of 191

ORPHAN DRUG EXCLUSIVITY

LEVELS, BUT WHO ARE UNABLE TO UNDERGO PARATHYROIDECTOMY.

ODE-79	TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA WHO HAVE HAD AN INADEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA
ODE-80	TREATMENT OF PEDIATRIC PATIENTS WITH TOURETTE'S
ODE-81	TREATMENT OF PATIENTS WITH ACROMEGALY WHO HAVE HAD AN INADEQUATE RESPONSE TO SURGERY AND/OR FOR WHOM SURGERY IS NOT AN OPTION
ODE-82	TREATMENT OF PATIENTS WITH UNRESECTABLE, WELL- OR MODERATELY-DIFFERENTIATED LOCALLY ADVANCED OR METASTATIC GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS TO IMPROVE PROGRESSION-FREE SURVIVAL
ODE-83	USE OF AS MONOTHERAPY FOR PATIENTS WITH DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINE BRCA MUTATED (AS DETECTED BY AN FDA-APPROVED TEST) ADVANCED OVARIAN CANCER WHO HAVE BEEN TREATED WITH THREE OR MORE PRIOR LINES OF CHEMOTHERAPY
ODE-84	TREATMENT OF MOTOR FLUCTUATIONS IN PATIENTS WITH ADVANCED PARKINSON'S DISEASE
ODE-85	AS A REPLACEMENT SOLUTION IN CONTINUOUS RENAL REPLACEMENT THERAPY (CRRT) AND IN CASE OF DRUG POISONING WHEN CRRT IS USED TO REMOVE DIALYZABLE SUBSTANCES
ODE-86	TREATMENT OF PATIENTS WITH WALDENSTROM'S MACROGLOBULINEMIA
ODE-87	TREATMENT OF PATIENTS WITH LOCALLY RECURRENT OR METASTATIC, PROGRESSIVE, RADIOACTIVE IODINE REFRACTORY DIFFERENTIATED THYROID CANCER
ODE-88	FOR USE IN COMBINATION WITH DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE NOT RECEIVED AT LEAST ONE PRIOR THERAPY (FIRST LINE TREATMENT)
ODE-89	TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST 2 PRIOR REGIMENS, INCLUDING BORTEZOMIB AND AN IMMUNOMODULATORY AGENT
ODE-90	TREATMENT OF INVASIVE MUCORMYCOSIS IN PATIENTS 18 YEARS OF AGE AND OLDER
ODE-91	TREATMENT OF BILE ACID SYNTHESIS DISORDERS DUE TO SINGLE ENZYME DEFECTS
ODE-92	TREATMENT OF LYMPHANGIOLEIOMYOMATOSIS (LAM)
ODE-93	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGE 12 YEARS AND OLDER WHO ARE HOMOZYGOUS FOR F508DEL MUTATION IN THE CFTR GENE
ODE-94	PROPHYLAXIS OF ORGAN REJECTION IN KIDNEY TRANSPLANT PATIENTS CONVERTED FROM TACROLIMUS IMMEDIATE-RELEASE FORMULATIONS IN COMBINATION WITH OTHER IMMUNOSUPPRESSANTS
ODE-95	FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS HAVE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 19 DELETIONS OR EXON 21 (L858R) SUBSTITUTION MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST
ODE-96	TREATMENT OF PRIMARY HYPERKALEMIC PERIODIC PARALYSIS, PRIMARY HYPOKALEMIC PERIODIC PARALYSIS, AND RELATED VARIANTS
ODE-97	TO EXPAND THE INDICATION TO PEDIATRIC PATIENTS 2-6 YEARS OF AGE WITH NEPHROPATHIC CYSTINOSIS
ODE-98	TREATMENT OF HEREDITARY OROTIC ACIDURIA
ODE-99	FOR USE IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN, FOR THE TREATMENT OF PATIENTS WITH METASTATIC ADENOCARCINOMA OF THE PANCREAS THAT HAS PROGRESSED FOLLOWING GEMCITABINE-BASED THERAPY
ODE-100	FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC LIPOSARCOMA OR LEIOMYOSARCOMA WHO RECEIVED A PRIOR ANTHRACYCLINE-CONTAINING REGIMEN
ODE-101	FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E OR V600K MUTATION, IN COMBINATION WITH VEMURAFENIB. COTELLIC IS NOT INDICATED FOR TREATMENT OF PATIENTS WITH WILD-TYPE BRAF MELANOMA
ODE-102	FOR TREATMENT OF PATIENTS WITH METASTATIC EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) T790M MUTATION-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC), AS DETECTED BY AN FDA-APPROVED TEST, WHO HAVE PROGRESSED ON OR AFTER EGFR TKI THERAPY
ODE-103	USE IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
ODE-104	EMERGENCY TX OF PTS FOLLOWING A FU OR CAPECITABINE OD, OR WHO EXHIBIT EARLY-ONSET, SEVERE OR LIFE-THREATENING TOXICITY AFFECTING THE CARDIAC SYSTEM OR CNS, AND/OR EARLY-ONSET, UNUSUALLY SEVERE AR W/IN 96 HRS FOLLOWING THE END OF FU OR CAPECITABINE ADMIN.

PATENT AND EXCLUSIVITY TERMS

ADB 54 of 191

ORPHAN DRUG EXCLUSIVITY

ODE-105	TREATMENT OF PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC), WHO HAVE PROGRESSED ON OR ARE INTOLERANT TO CRIZOTINIB
ODE-106	FOR USE OF UPTRAVI (SELEXIPAG) TABLETS, 200, 400, 600, 800, 1000, 1200, 1400, AND 1600 MCG FOR TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH, WHO GROUP I) TO REDUCE THE RISKS OF DISEASE PROGRESSION AND HOSPITALIZATION FOR PAH
ODE-107	TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC LIPOSARCOMA WHO HAVE RECEIVED A PRIOR ANTHRACYCLINE-CONTAINING REGIMEN
ODE-108	TREATMENT OF ADULT PATIENTS WITH PROGRESSIVE, WELL-DIFFERENTIATED, NON-FUNCTIONAL, NEUROENDOCRINE TUMORS (NET) OF GASTROINTESTINAL (GI) OR LUNG ORIGIN, (EXCLUDING PANCREATIC) WITH UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC DISEASE
ODE-109	INDICATED FOR THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA WITHOUT 17P DELETION WHO HAVE NOT RECEIVED AT LEAST ONE PRIOR THERAPY (FIRST LINE THERAPY)
ODE-110	FOR HIGH-DOSE CONDITIONING TREATMENT PRIOR TO HEMATOPOIETIC PROGENITOR (STEM) CELL TRANSPLANTATION IN PATIENTS WITH MULTIPLE MYELOMA
ODE-111	TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER WHOSE TUMORS ARE ROS-1 POSITIVE.
ODE-112	FOR THE TREATMENT OF ADULT AND PEDIATRIC PATIENTS WITH HEPATIC VENO-OCCLUSIVE DISEASE (VOD), ALSO KNOWN AS SINUSOIDAL OBSTRUCTION SYNDROME (SOS), WITH RENAL OR PULMONARY DYSFUNCTION FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT).
ODE-113	FOR TREATMENT OF PEDIATRIC AND ADULT PATIENTS WITH ACQUIRED METHEMOGLOBINEMIA.
ODE-114	TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH 17P DELETION, AS DETECTED BY AN FDA APPROVED TEST, WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
ODE-115	TREATMENT OF PATIENTS WITH METASTATIC, SQUAMOUS, NON-SMALL CELL LUNG CANCER PROGRESSING AFTER PLATINUM-BASED CHEMOTHERAPY
ODE-116	TREATMENT OF PROGRESSIVE KERATOCONUS
ODE-117	FOR TREATMENT OF PATIENTS WITH SMALL LYMPHOCYTIC LYMPHOMA (SLL)
ODE-118	AN ADJUNCT TO DIET TO REDUCE LDL-C, TOTAL-C, NONHDL-C AND APOB IN CHILDREN AND ADOLESCENTS 7 TO 17 YEARS OF AGE WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA, EITHER ALONE OR WITH OTHER LIPID-LOWERING TREATMENTS (E.G., LDL APHERESIS)
ODE-119	TREATMENT OF PRIMARY BILIARY CHOLANGITIS (PBC) IN COMBINATION WITH URSODEOXYCHOLIC ACID (UDCA) IN ADULTS WITH AN INADEQUATE RESPONSE TO UDCA, OR AS MONOTHERAPY IN ADULTS UNABLE TO TOLERATE UDCA
ODE-120	FOR USE AFTER RADIOLABELING WITH GA 68, WITH POSITRON EMISSION TOMOGRAPHY (PET) FOR LOCALIZATION OF SOMATOSTATIN RECEPTOR POSITIVE NEUROENDOCRINE TUMORS (NETS) IN ADULT AND PEDIATRIC PATIENTS.
ODE-121	TREATMENT OF CORNEAL ECTASIA FOLLOWING REFRACTIVE SURGERY
ODE-122	TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) IN PATIENTS WHO HAVE A CONFIRMED MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 51 SKIPPING
ODE-123	TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS AGE 6-11 YEAR OLD WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE
ODE-124	REPLACEMENT THERAPY FOR ORAL CARBAMAZEPINE FORMULATIONS, WHEN ORAL ADMINISTRATION IS TEMPORARILY NOT FEASIBLE, IN ADULTS WITH THE FOLLOWING SEIZURE TYPES: PARTIAL WITH COMPLEX SYMPTOMOLOGY, GENERALIZED CLONIC-TONIC, AND MIXED
ODE-125	INDICATED IN PEDIATRIC PATIENTS 10 YEARS AND OLDER FOR THE PREVENTION AND TREATMENT OF SECONDARY HYPERPARATHYROIDISM ASSOCIATED WITH CHRONIC KIDNEY DISEASE (CKD) STAGES 3 AND 4 AND CKD STAGE 5 IN PATIENTS ON HEMODIALYSIS OR PERITONEAL DIALYSIS
ODE-126	AS MONOTHERAPY FOR THE TREATMENT OF PATIENTS WITH DELETERIOUS BRCA MUTATION (GERMLINE AND/OR SOMATIC) ASSOCIATED ADVANCED OVARIAN CANCER WHO HAVE BEEN TREATED WITH TWO OR MORE CHEMOTHERAPIES
ODE-127	TREATMENT OF SPINAL MUSCULAR ATROPHY IN PEDIATRIC AND ADULT PATIENTS
ODE-128	TREATMENT OF PATIENTS WITH MARGINAL ZONE LYMPHOMA (MZL) WHO REQUIRE SYSTEMIC THERAPY AND HAVE RECEIVED AT LEAST ONE PRIOR ANTI-CD20-BASED THERAPY
ODE-129	INDICATED FOR REDUCING THE RISK OF GRAFT REJECTION WHEN USED IN CONJUNCTION WITH HIGH-DOSE BUSULFAN & CYCLOPHOSPHAMIDE AS A PREPARATIVE REGIMEN FOR ALLOGENIC

PATENT AND EXCLUSIVITY TERMS

ADB 55 of 191

ORPHAN DRUG EXCLUSIVITY

	HEMATOPOIETIC PROGENITOR CELL TRANSPLANTATION FOR PEDS. PATIENTS WITH CLASS 3 BETA-THALASSEMIA
ODE-130	TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY IN PATIENTS 5 YEARS OF AGE AND OLDER
ODE-131	TREATMENT OF MULTIPLE MYELOMA (MM), AS MAINTENANCE FOLLOWING AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION (AUTO-HSCT)
ODE-132	TREATMENT OF CARCINOID SYNDROME DIARRHEA IN COMBINATION WITH SOMATOSTATIN ANALOG (SSA) THERAPY IN ADULTS INADEQUATELY CONTROLLED BY SSA THERAPY
ODE-133	INDICATED FOR MAINTENANCE TREATMENT OF ADULT PATIENTS WITH RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER WHO ARE IN A COMPLETE OR PARTIAL RESPONSE TO PLATINUM-BASED CHEMOTHERAPY
ODE-134	TREATMENT OF CHOREA ASSOCIATED WITH HUNTINGTON'S DISEASE
ODE-135	TREATMENT OF CHRONIC HCV GENOTYPE 2 OR 3 INFECTION IN PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER OR WEIGHING AT LEAST 35 KG WITHOUT CIRRHOSIS OR WITH COMPENSATED CIRRHOSIS FOR USE IN COMBINATION WITH RIBAVIRIN
ODE-136	TREATMENT OF PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER OR WEIGHING AT LEAST 35 KG WITH CHRONIC HEPATITIS C VIRUS GENOTYPE 1, 4, 5, OR 6 INFECTION WITHOUT CIRRHOSIS OR WITH COMPENSATED CIRRHOSIS
ODE-137	TREATMENT OF OLIGOARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PERSISTENT OLIGOARTHRITIS, PSORIATIC JUVENILE IDIOPATHIC ARTHRITIS, ENTHESITIS-RELATED ARTHRITIS, OR UNDIFFERENTIATED ARTHRITIS) & POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS IN CHILDREN 0-16 YRS
ODE-138	TREATMENT OF PEDIATRIC PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA AS A COMPONENT OF A COMBINATION CHEMOTHERAPY MAINTENANCE REGIMEN
ODE-139	TREATMENT OF PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC OR LIVER CANCER) WHO HAVE BEEN PREVIOUSLY TREATED WITH THE DRUG SORAFENIB.
ODE-140	TREATMENT OF ADULT PATIENTS WITH AGGRESSIVE SYSTEMIC MASTOCYTOSIS (ASM), SYSTEMIC MASTOCYTOSIS WITH ASSOCIATED HEMATOLOGICAL NEOPLASM (SM-AHN), OR MAST CELL LEUKEMIA (MCL)
ODE-141	TREATMENT OF ADULT PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) THAT IS FLT3 MUTATION-POSITIVE AS DETECTED BY AN FDA APPROVED TEST, IN COMBINATION WITH STANDARD CYTARABINE AND DAUNORUBICIN INDUCTION AND CYTARABINE CONSOLIDATION
ODE-142	TREATMENT OF PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHO HAVE PROGRESSED ON OR ARE INTOLERANT TO CRIZOTINIB
ODE-143	TO DECREASE THE RECURRENCE OF PNEUMOTHORAX IN ADULTS
ODE-144	TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
ODE-145	TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS ARE ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE AS DETECTED BY AN FDA-APPROVED TEST
ODE-146	OPTICAL IMAGING AGENT INDICATED IN PATIENTS WITH GLIOMA (SUSPECTED WORLD HEALTH ORGANIZATION GRADES III OR IV ON PREOPERATIVE IMAGING) AS AN ADJUNCT FOR THE VISUALIZATION OF MALIGNANT TISSUE DURING SURGERY
ODE-147	DABRAFENIB IN COMBINATION WITH TRAMETINIB, FOR THE TX. OF PTS WITH METASTATIC NON-SMALL CELL LUNG CANCER WITH BRAF V600E MUTATION AS DETECTED BY AN FDA-APPROVED TEST
ODE-148	TRAMETINIB IN COMBINATION WITH DABRAFENIB, FOR THE TX. OF PTS WITH METASTATIC NON-SMALL CELL LUNG CANCER WITH BRAF V600E MUTATION AS DETECTED BY AN FDA-APPROVED TEST
ODE-149	TREATMENT OF PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH CENTRAL PRECOCIOUS PUBERTY
ODE-150	TO REDUCE THE ACUTE COMPLICATIONS OF SICKLE CELL DISEASE IN ADULT AND PEDIATRIC PATIENTS 5 YEARS OF AGE AND OLDER.
ODE-151	TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA WITH AN ISOCITRATE DEHYDROGENASE-2 (IDH2) MUTATION AS DETECTED BY AN FDA-APPROVED TEST
ODE-152	TREATMENT OF ADULT PATIENTS WITH CHRONIC GRAFT VERSUS HOST DISEASE (CGVHD)
ODE-153	TREATMENT OF DYSKINESIA IN PATIENTS WITH PARKINSON'S DISEASE RECEIVING LEVODOPA-BASED THERAPY WITH OR WITHOUT CONCOMITANT DOPAMINERGIC MEDICATIONS

PATENT AND EXCLUSIVITY TERMS

ADB 56 of 191

ORPHAN DRUG EXCLUSIVITY

ODE-154	FOR USE IN CHILDREN AGES 2 TO 12 YEARS OLD WITH CHAGAS DISEASE
ODE-155	TREATMENT OF ADULT PATIENTS WITH RELAPSED FOLLICULAR LYMPHOMA WHO HAVE RECEIVED AT LEAST TWO PRIOR SYSTEMIC THERAPIES
ODE-156	TREATMENT OF ADULTS WITH CARCINOID SYNDROME; WHEN USED, IT REDUCES THE FREQUENCY OF SHORT-ACTING SOMATOSTATIN ANALOG RESCUE THERAPY
ODE-157	FOR USE AS A NITROGEN-BINDING AGENT FOR CHRONIC MANAGEMENT OF PEDIATRIC PATIENTS $\geq$ 2 MONTHS AND $<$ 2 YEARS OF AGE WITH UREA CYCLE DISORDERS (UCDS) WHO CANNOT BE MANAGED BY DIETARY PROTEIN RESTRICTION AND/OR AMINO ACID SUPPLEMENTATION ALONE
ODE-158	TREATMENT OF PATIENTS WITH ERDHEIM-CHESTER DISEASE WITH BRAF V600 MUTATION
ODE-159	FOR TREATMENT OF PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE (ALK) POSITIVE, METASTATIC NON-SMALL-CELL LUNG CANCER (NSCLC) AS DETECTED BY AN FDA APPROVED TEST, EXCLUDING PATIENTS WHO HAVE PROGRESSED ON OR ARE INTOLERANT TO CRIZOTINIB
ODE-160	FOR TREATMENT OF SCURVY IN ADULT AND PEDIATRIC PATIENTS AGE 5 MONTHS AND OLDER FOR WHOM ORAL ADMINISTRATION IS NOT POSSIBLE, INSUFFICIENT OR CONTRAINDICATED
ODE-161	TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) (WHO GROUP 1) IN PEDIATRIC PATIENTS AGED 3 YRS AND OLDER WITH IDIOPATHIC OR CONGENITAL PAH TO IMPROVE PULMONARY VASCULAR RESISTANCE (PVR), WHICH IS EXPECTED TO RESULT IN AN IMPROVEMENT IN EXERCISE ABILITY
ODE-162	TREATMENT OF NEPHROPATHIC CYSTINOSIS IN PEDIATRIC PATIENTS 1 YEAR OF AGE TO LESS THAN 2 YEARS OF AGE
ODE-163	TREATMENT OF ADULT PATIENTS WITH NEWLY-DIAGNOSED CHRONIC PHASE (CP) PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOGENOUS LEUKEMIA (PH+ CML)
ODE-164	TREATMENT OF PEDIATRIC PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE (PH+) CHRONIC MYELOID LEUKEMIA (CML) IN CHRONIC PHASE
ODE-165	PROPHYLAXIS OF CYTOMEGALOVIRUS (CMV) INFECTION AND DISEASE IN ADULT CMV-SEROPOSITIVE RECIPIENTS [R+] OF AN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT)
ODE-166	TREATMENT OF SOMATOSTATIN RECEPTOR-POSITIVE GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS (GEP-NETS) INCLUDING FOREGUT, MIDGUT, AND HINDGUT NEUROENDOCRINE TUMORS IN ADULTS
ODE-167	ARSENIC TRIOXIDE FOR USE IN COMBINATION WITH TRETINOIN FOR TREATMENT OF ADULTS WITH NEWLY-DIAGNOSED LOW-RISK ACUTE PROMYELOCYTIC LEUKEMIA (APL) WHOSE APL IS CHARACTERIZED BY THE PRESENCE OF THE T(15;17) TRANSLOCATION OR PML/RAR-ALPHA GENE EXPRESSION
ODE-168	FOR THE MAINTENANCE TREATMENT OF ADULT PATIENTS WITH RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER WHO ARE IN A COMPLETE OR PARTIAL RESPONSE TO PLATINUM-BASED CHEMOTHERAPY
ODE-169	FOR THE ADJUNCTIVE TREATMENT OF ADULT AND PEDIATRIC PATIENTS AGED 2 YEARS AND OLDER WITH TUBEROUS SCLEROSIS COMPLEX (TSC)-ASSOCIATED PARTIAL-ONSET SEIZURES
ODE-170	FOR THE DIAGNOSIS OF ADULT GROWTH HORMONE DEFICIENCY (AGHD)
ODE-171	TREATMENT OF PEDIATRIC PATIENTS GREATER THAN OR EQUAL TO 1 YEAR OF AGE WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (PH+CML) IN CHRONIC PHASE
ODE-172	TREATMENT OF PEDIATRIC PATIENTS GREATER THAN OR EQUAL TO 1 YEAR OF AGE WITH CHRONIC PHASE PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA WITH RESISTANCE OR INTOLERANCE TO PRIOR TYROSINE-KINASE INHIBITOR THERAPY
ODE-173	TREATMENT OF PATIENTS WITH CYSTIC FIBROSIS AGED 12 YEARS AND OLDER WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION OR WHO HAVE AT LEAST ONE MUTATION IN THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR GENE RESPONSIVE TO TEZACAFTOR/IVACAFTOR
ODE-174	FOR THE TREATMENT OF THROMBOCYTOPENIA IN ADULT PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA (ITP) WHO HAVE HAD AN INSUFFICIENT RESPONSE TO A PREVIOUS TREATMENT
ODE-175	TREATMENT OF ADULT PATIENTS WITH MANTLE CELL LYMPHOMA (MCL) WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
ODE-176	INDICATED FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS HAVE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 19 DELETIONS OR EXON 21 L858R MUTATIONS, AS DETECTED BY AN FDA-APPROVED TEST

PATENT AND EXCLUSIVITY TERMS

ADB 57 of 191

ORPHAN DRUG EXCLUSIVITY

ODE-177	TO REDUCE THE FREQUENCY OF PAINFUL CRISES AND TO REDUCE THE NEED FOR BLOOD TRANSFUSIONS IN PEDIATRIC PATIENTS, 2 YEARS OF AGE AND OLDER, WITH SICKLE CELL ANEMIA WITH RECURRENT MODERATE TO SEVERE PAINFUL CRISIS
ODE-178	INDICATED TO SLOW KIDNEY FUNCTION DECLINE IN ADULTS AT RISK OF RAPIDLY PROGRESSING AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD)
ODE-179	TREATMENT OF PATIENTS WITH CLL AND TREATMENT OF PATIENTS WITH INDOLENT B-CELL NHL THAT HAS PROGRESSED DURING OR WITHIN SIX MONTHS OF TREATMENT WITH RITUXIMAB OR A RITUXIMAB CONTAINING REGIMEN
ODE-180	MAINTENANCE TREATMENT OF ADULT PATIENTS WITH RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER, WHO ARE IN A COMPLETE OR PARTIAL RESPONSE TO PLATINUM-BASED CHEMOTHERAPY
ODE-181	TREATMENT OF ADULT PATIENTS WITH DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINE BRCA-MUTATED ADVANCED OVARIAN CANCER WHO HAVE BEEN TREATED WITH THREE OR MORE PRIOR LINES OF CHEMOTHERAPY
ODE-182	TRAMETINIB IS INDICATED, IN COMBINATION WITH DABRAFENIB, FOR THE ADJUVANT TREATMENT OF PATIENTS WITH MELANOMA WITH BRAF V600E OR V600K MUTATIONS, AS DETECTED BY AN FDA-APPROVED TEST, AND INVOLVEMENT OF LYMPH NODE(S), FOLLOWING COMPLETE RESECTION
ODE-183	TRAMETINIB AND DABRAFENIB IN COMBINATION, FOR THE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC ANAPLASTIC THYROID CANCER (ATC) WITH BRAF V600E MUTATION AND WITH NO SATISFACTORY LOCOREGIONAL TREATMENT OPTIONS
ODE-184	INDICATED IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS FOR THE TREATMENT OF PEDIATRIC PATIENTS WITH HIV-1 INFECTION
ODE-185	INDICATED FOR THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL), WITH OR WITHOUT 17P DELETION, WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
ODE-186	TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS AGE 6 YEARS AND OLDER WHO HAVE ONE OF THE FOLLOWING MUTATIONS IN THE CFTR GENE: G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, OR S549R
ODE-187	TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS AGE 6 YEARS AND OLDER WHO HAVE AN R117H MUTATION IN THE CFTR GENE
ODE-188	TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS AGES 2 TO LESS THAN 6 YEARS WHO HAVE ONE OF THE FOLLOWING MUTATIONS IN THE CFTR GENE: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, S549R, AND R117H
ODE-189	TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS AGE 2 YEARS AND OLDER WHO HAVE ONE OF THE FOLLOWING MUTATIONS IN THE CFTR GENE: 711+3A-G, E831X, 2789+5G-A, 3272-26A-G, AND 3849+10KBC-T
ODE-190	TX OF CF IN PTS 2 YRS AND OLDER WHO HAVE ONE OF THE FOLLOWING MUTATIONS IN THE CFTR GENE: E56K, P67L, R74W, D110E, D110H, R117C, E193K, L206W, R347H, R352Q, A455E, D579G, S945L, S977F, F1052V, K1060T, A1067T, G1069R, R1070Q, R1070W, F1074L, D1152H, D1270N
ODE-191	TO DECREASE THE RECURRENCE OF MALIGNANT PLEURAL EFFUSIONS IN SYMPTOMATIC PATIENTS FOLLOWING MAXIMAL DRAINAGE OF THE PLEURAL EFFUSION
ODE-192	INDICATED TO INDUCE CONTROLLED CARDIAC SEPTAL INFRACTION TO IMPROVE EXERCISE CAPACITY IN ADULTS WITH SYMPTOMATIC HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY WHO ARE NOT CANDIDATES FOR SURGICAL MYECTOMY
ODE-193	INDICATED FOR THE TREATMENT OF ONCHOCERCIASIS DUE TO ONCHOCERCA VOLVULUS IN PATIENTS AGED 12 YEARS AND OLDER
ODE-194	ENCORAFENIB IS INDICATED IN COMBINATION WITH BINIMETINIB, FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH A BRAF V600E OR V600K MUTATION, AS DETECTED BY AN FDA-APPROVED TEST
ODE-195	FOR THE TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS AGE 2 THROUGH 5 YEARS OLD WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE
ODE-196	INDICATED FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA (HCC)
ODE-197	INDICATED FOR THE TREATMENT OF THE POLYNEUROPATHY OF HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS IN ADULTS
ODE-198	INDICATED FOR THE TREATMENT OF SEIZURES ASSOCIATED WITH DRAVET SYNDROME (DS) IN PATIENTS 2 YEARS OF AGE AND OLDER TAKING CLOBAZAM

PATENT AND EXCLUSIVITY TERMS

ADB 58 of 191

ORPHAN DRUG EXCLUSIVITY

ODE-199	THE TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS AGE 12 MONTHS AND OLDER WHO HAVE ONE MUTATION IN THE CFTR GENE THAT IS RESPONSIVE TO IVACAFTOR POTENTIATION BASED ON CLINICAL AND/OR IN VITRO ASSAY DATA
ODE-200	INDICATED FOR THE TREATMENT OF HUMAN SMALLPOX DISEASE CAUSED BY VARIOLA VIRUS IN ADULTS AND PEDIATRIC PATIENTS WEIGHING AT LEAST 13 KG
ODE-201	INDICATED FOR THE RADICAL CURE (PREVENTION OF RELAPSE) OF PLASMODIUM VIVAX MALARIA IN PATIENTS AGED 16 YEARS AND OLDER WHO ARE RECEIVING APPROPRIATE ANTIMALARIAL THERAPY FOR ACUTE P. VIVAX INFECTION
ODE-202	INDICATED AS A SOURCE OF CALORIES AND FATTY ACIDS IN PEDIATRIC PATIENTS WITH PARENTERAL NUTRITION-ASSOCIATED CHOLESTASIS (PNAC)
ODE-203	INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (AML) WITH A SUSCEPTIBLE ISOCITRATE DEHYDROGENASE-1 (IDH1) MUTATION AS DETECTED BY AN FDA-APPROVED TEST
ODE-204	TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER WITH IOBENGUANE SCAN POSITIVE, UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC PHEOCHROMOCYTOMA OR PARAGANGLIOMA WHO REQUIRE SYSTEMIC ANTICANCER THERAPY
ODE-205	INDICATED FOR THE TREATMENT OF ADULTS WITH A CONFIRMED DIAGNOSIS OF FABRY DISEASE AND AN AMENABLE GALACTOSIDASE ALPHA GENE (GLA) VARIANT BASED ON IN VITRO ASSAY DATA
ODE-206	FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 19 DELETION OR EXON 21 L858R SUBSTITUTION MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST
ODE-207	TREATMENT OF STATUS EPILEPTICUS IN ADULTS
ODE-208	TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL) AFTER AT LEAST TWO PRIOR THERAPIES
ODE-209	TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA (FL) AFTER AT LEAST TWO PRIOR SYSTEMIC THERAPIES
ODE-210	INDICATED IN COMBINATION WITH STANDARD IMMUNOSUPPRESSIVE THERAPY FOR THE FIRST-LINE TREATMENT OF ADULT AND PEDIATRIC PATIENTS 2 YEARS AND OLDER WITH SEVERE APLASTIC ANEMIA
ODE-211	INDICATED IN COMBO WITH AZACITIDINE, OR DECITABINE, OR LOW-DOSE CYTARABINE FOR THE TX OF NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA IN ADULTS WHO ARE AGE 75 YEARS OR OLDER, OR WHO HAVE COMORBIDITIES THAT PRECLUDE USE OF INTENSIVE INDUCTION CHEMOTHERAPY
ODE-212	INDICATED FOR THE TREATMENT OF THE POLYNEUROPATHY OF HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS IN ADULTS
ODE-213	INDICATED FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH EPIDERMAL GROWTH FACTOR (EGFR) EXON 19 DELETION OR EXON 21 L858R SUBSTITUTION MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST
ODE-214	TX OF MAC LUNG DISEASE IN ADULTS WITH LIMITED OR NO ALTERNATIVE TX OPTIONS AS PART OF A COMBO ANTIBACTERIAL DRUG REGIMEN WHO DO NOT ACHIEVE NEGATIVE SPUTUM CULTURES AFTER A MINIMUM OF 6 CONSECUTIVE MONTHS OF A MULTIDRUG BACKGROUND REGIMEN THERAPY
ODE-215	INDICATED FOR THE TREATMENT OF ADULT AND PEDIATRIC PATIENTS WITH SOLID TUMORS THAT HAVE A NEUROTROPHIC RECEPTOR TYROSINE KINASE (NTRK) GENE FUSION WITHOUT A KNOWN ACQUIRED RESISTANCE MUTATION
ODE-216	INDICATED FOR THE TREATMENT OF SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME (LGS) OR DRAVET SYNDROME (DS) IN PATIENTS 2 YEARS OF AGE AND OLDER
ODE-217	INDICATED FOR THE TREATMENT OF PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE (ALK)- POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE DISEASE HAS PROGRESSED ON CRIZOTINIB AND AT LEAST ONE OTHER ALK INHIBITOR FOR METASTATIC DISEASE
ODE-218	INDICATED FOR THE TREATMENT OF PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE (ALK)- POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE DISEASE HAS PROGRESSED ON ALECTINIB AS THE FIRST ALK INHIBITOR THERAPY FOR METASTATIC DISEASE
ODE-219	INDICATED FOR THE TREATMENT OF PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE (ALK)- POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE DISEASE HAS PROGRESSED ON CERITINIB AS THE FIRST ALK INHIBITOR THERAPY FOR METASTATIC DISEASE

PATENT AND EXCLUSIVITY TERMS

ADB 59 of 191

ORPHAN DRUG EXCLUSIVITY

ODE-220	INDICATED FOR THE TREATMENT OF ADULT AND PEDIATRIC PATIENTS WITH SOLID TUMORS THAT ARE METASTATIC OR WHERE SURGICAL RESECTION IS LIKELY TO RESULT IN SEVERE MORBIDITY
ODE-221	INDICATED FOR THE TREATMENT OF ADULT AND PEDIATRIC PATIENTS WITH SOLID TUMORS THAT HAVE NO SATISFACTORY ALTERNATIVE TREATMENTS OR THAT HAVE PROGRESSED FOLLOWING TREATMENT
ODE-222	INDICATED FOR THE TREATMENT OF ADULT PATIENTS WHO HAVE RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (AML) WITH A FMS-LIKE TYROSINE KINASE 3 (FLT3) MUTATION AS DETECTED BY AN FDA-APPROVED TEST
ODE-223	TREATMENT OF LAMBERT-EATON MYASTHENIC SYNDROME (LEMS)
ODE-224	INDICATED, IN COMBINATION WITH LOW-DOSE CYTARABINE, FOR THE TREATMENT OF NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) IN ADULT PATIENTS WHO ARE ≥75 YEARS OLD OR WHO HAVE COMORBIDITIES THAT PRECLUDE USE OF INTENSIVE INDUCTION CHEMOTHERAPY
ODE-225	INDICATED FOR THE TREATMENT OF PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN COMBINATION WITH CHEMOTHERAPY
ODE-226	MAINTENANCE TREATMENT OF ADULTS WITH DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINE OR SOMATIC BRCA-MUTATED ADVANCED EPITHELIAL OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER IN COMPLETE OR PARTIAL RESPONSE TO FIRST-LINE PLATINUM-BASED CHEMOTHERAPY
ODE-227	INDICATED FOR TREATMENT OF PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC) WHO HAVE BEEN PREVIOUSLY TREATED WITH SORAFENIB
ODE-228	INDICATED FOR THE TREATMENT OF FASCIOLIASIS IN PATIENTS 6 YEARS OF AGE AND OLDER
ODE-229	TREATMENT OF ADULT PATIENTS WITH METASTATIC GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA PREVIOUSLY TREATED WITH AT LEAST TWO PRIOR LINES OF CHEMOTHERAPY, AND IF APPROPRIATE, HER2/NEU-TARGETED THERAPY
ODE-230	FIRST-LINE TREATMENT OF METASTATIC NON-SMALL CELL LUNG CANCER WHOSE TUMORS HAVE NON-RESISTANT EPIDERMAL GROWTH FACTOR (EGFR) MUTATIONS OTHER THAN EXON 19 DELETIONS OR EXON 21 (L858R) SUBSTITUTION MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST
ODE-231	INDICATED FOR THE TREATMENT OF CATAPLEXY OR EXCESSIVE DAYTIME SLEEPINESS (EDS) IN PEDIATRIC PATIENTS 7 YEARS OF AGE AND OLDER WITH NARCOLEPSY
ODE-232	TREATMENT OF PEDIATRIC PATIENTS 12 YEARS AND OLDER OR WEIGHING AT LEAST 45 KG WITH CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1,2,3,4,5 OR 6 INFECTION WITHOUT CIRRHOSIS OR WITH COMPENSATED CIRRHOSIS (CHILD-PUGH A)
ODE-233	TREATMENT OF PEDIATRIC PATIENTS 12 YEARS AND OLDER OR WEIGHING AT LEAST 45 KG WITH HCV GENOTYPE 1 INFECTION, WHO PREVIOUSLY HAVE BEEN TREATED WITH A REGIMEN CONTAINING AN HCV NS5A INHIBITOR OR AN NS3/4A PROTEASE INHIBITOR (PI), BUT NOT BOTH
ODE-234	INDICATED FOR THE TREATMENT OF STABLE SYMPTOMATIC HEART FAILURE DUE TO DILATED CARDIOMYOPATHY (DCM) IN PEDIATRIC PATIENTS AGED 6 MONTHS AND OLDER, WHO ARE IN SINUS RHYTHM WITH AN ELEVATED HEART RATE
ODE-235	INDICATED FOR THE TREATMENT OF ACUTE HERPETIC KERATITIS (DENDRITIC ULCERS) IN PATIENTS WITH HERPES SIMPLEX (HSV-1 AND HSV-2) VIRUS
ODE-236	TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS AGE 6 MONTHS TO LESS THAN 12 MONTHS WHO HAVE ONE MUTATION IN THE CFTR GENE THAT IS RESPONSIVE TO IVACAFTOR POTENTIATION BASED ON CLINICAL AND/OR IN VITRO ASSAY DATA
ODE-237	TREATMENT OF THE CARDIOMYOPATHY OF WILD TYPE OR HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS (ATTR-CM) IN ADULTS TO REDUCE CARDIOVASCULAR MORTALITY AND CARDIOVASCULAR-RELATED HOSPITALIZATION
ODE-238	TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (GVHD) IN ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER
ODE-239	TREATMENT OF PREVIOUSLY UNTREATED ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL)
ODE-240	TREATMENT OF PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER WITH SHORT BOWEL SYNDROME (SBS) WHO ARE DEPENDENT ON PARENTERAL SUPPORT
ODE-241	INDICATED IN COMBINATION WITH A RITUXIMAB PRODUCT FOR THE TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY TREATED FOLLICULAR LYMPHOMA (FL)
ODE-242	TX OF NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA WITH A SUSCEPTIBLE ISOCITRATE DEHYDROGENASE-1 MUTATION AS DETECTED BY AN FDA-APPROVED TEST IN ADULT PTS WHO

PATENT AND EXCLUSIVITY TERMS

ADB 60 of 191

ORPHAN DRUG EXCLUSIVITY

ARE ≥75 YRS OLD OR WHO HAVE COMORBIDITIES THAT PRECLUDE USE OF INTENSIVE INDUCTION CHEMOTHERAPY

- ODE-243 ACUTE TREATMENT OF INTERMITTENT, STEREOTYPIC EPISODES OF FREQUENT SEIZURE ACTIVITY (I.E., SEIZURE CLUSTERS, ACUTE REPETITIVE SEIZURES) THAT ARE DISTINCT FROM A PATIENT'S USUAL SEIZURE PATTERN IN PATIENTS WITH EPILEPSY 12 YEARS OF AGE AND OLDER
- ODE-244 TREATMENT OF LAMBERT-EATON MYASTHENIC SYNDROME (LEMS) IN PATIENTS 6 TO LESS THAN 17 YEARS OF AGE
- ODE-245 INDICATED IN COMBINATION WITH A RITUXIMAB PRODUCT FOR THE TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY TREATED MARGINAL ZONE LYMPHOMA (MZL)
- ODE-246 TREATMENT OF THROMBOCYTOPENIA IN ADULT PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA WHO HAVE HAD AN INSUFFICIENT RESPONSE TO A PREVIOUS TREATMENT
- ODE-247 TX OF PTS W/ CYSTIC FIBROSIS (CF) AGE 6 TO <12 YRS WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION OR W/ AT LEAST 1 MUTATION IN CF TRANSMEMBRANE CONDUCTANCE REGULATORY GENE RESPONSIVE TO TEZACAFTOR/IVACAFTOR BASED ON IN VITRO DATA AND/OR CLINICAL EVIDENCE
- ODE-248 TREATMENT OF ADULT PATIENTS WITH ORAL ULCERS ASSOCIATED WITH BEHCETS DISEASE
- ODE-249 TREATMENT OF PATIENTS WITH CYSTIC FIBROSIS (CF) AGE 6 YEARS TO LESS THAN 12 YEARS WHO ARE HOMOZYGOUS FOR F508DEL MUTATION OR WHO HAVE AT LEAST ONE MUTATION IN THE CF TRANSMEMBRANE CONDUCTANCE REGULATOR GENE THAT IS RESPONSIVE TO TEZACAFTOR/IVACAFTOR
- ODE-250 INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH SYMPTOMATIC TENOSYNOVIAL GIANT CELL TUMOR (TGCT) ASSOCIATED WITH SEVERE MORBIDITY OR FUNCTIONAL LIMITATIONS AND NOT AMENABLE TO IMPROVEMENT WITH SURGERY
- ODE-251 INDICATED AS PART OF COMBINATION THERAPY IN THE TREATMENT OF PEDIATRIC PATIENTS (12 TO LESS THAN 18 YEARS OF AGE AND WEIGHING AT LEAST 30 KG) WITH PULMONARY MULTI-DRUG RESISTANT TUBERCULOSIS
- ODE-252 TREATMENT OF DUCHENE MUSCULAR DYSTROPHY IN PATIENTS 2 YEARS OF AGE TO LESS THAN 5 YEARS OF AGE
- ODE-253 INDICATED AS PART OF A COMBINATION REGIMEN WITH BEDAQUILINE AND LINEZOLID FOR THE TREATMENT OF ADULTS WITH PULMONARY EXTENSIVELY DRUG RESISTANT (XDR) OR TREATMENT-INTOLERANT OR NONRESPONSIVE MULTIDRUG-RESISTANT (MDR) TUBERCULOSIS (TB)
- ODE-254 INDICATED TO IMPROVE WAKEFULNESS IN ADULT PATIENTS WITH EXCESSIVE DAYTIME SLEEPINESS ASSOCIATED WITH NARCOLEPSY
- ODE-255 INDICATED FOR THE TREATMENT OF EXCESSIVE DAYTIME SLEEPINESS (EDS) IN ADULT PATIENTS WITH NARCOLEPSY
- ODE-256 FOR HIV-1 INFECTION IN PEDIATRIC PTS AT LEAST 25 KG W/ NO ANTIRETROVIRAL (ARV) TX HX OR TO REPLACE CURRENT ARV REGIMEN FOR VIROLOGICALLY-SUPPRESSED ON STABLE ARV W/ NO HX TX FAILURE AND NO KNOWN SUBSTITUTIONS ASSOCIATED W/ RESISTANCE TO BIC, FTC, OR TAF
- ODE-257 IN COMBO W/ DEXAMETHASONE FOR ADULTS W/ RELAPSED OR REFRACTORY MULTIPLE MYELOMA WHO RECEIVED AT LEAST 4 PRIOR THERAPIES AND REFRACTORY TO AT LEAST 2 PROTEASOME INHIBITORS, AT LEAST 2 IMMUNOMODULATORY AGENTS, AND AN ANTI-CD38 MONOCLONAL ANTIBODY
- ODE-258 FOR THE TREATMENT OF CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 2 OR 3 INFECTION IN PEDIATRIC PATIENTS BETWEEN 3 YEARS OF AGE AND 12 YEARS OF AGE OR WEIGHING 35 KG WITHOUT CIRRHOSIS OR WITH COMPENSATED CIRRHOSIS FOR USE IN COMBINATION WITH RIBAVIRIN
- ODE-259 INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH INTERMEDIATE-2 OR HIGH-RISK PRIMARY OR SECONDARY (POST-POLYCYTHEMIA VERA OR POST-ESSENTIAL THROMBOCYTHEMIA) MYELOFIBROSIS (MF)
- ODE-260 INDICATED TO INCREASE SYSTEMIC EXPOSURE OF ATAZANAVIR IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS IN THE TREATMENT OF HIV-1 INFECTION IN PEDIATRIC PATIENTS WEIGHING AT LEAST 35 KG
- ODE-261 INDICATED TO SLOW THE RATE OF DECLINE IN PULMONARY FUNCTION IN PATIENTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE (SSC-ILD)
- ODE-262 TREATMENT OF PEDIATRIC PATIENTS BETWEEN 3 YEARS OF AGE AND 12 YEARS OF AGE OR WEIGHING 35 KG WITH CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1, 4, 5, OR 6 INFECTION WITHOUT CIRRHOSIS OR WITH COMPENSATED CIRRHOSIS

PATENT AND EXCLUSIVITY TERMS

ADB 61 of 191

ORPHAN DRUG EXCLUSIVITY

ODE-263	TREATMENT OF PEDIATRIC PATIENTS 3 YEARS OF AGE AND OLDER WITH CHRONIC HCV GENOTYPE 1 INFECTION WITH DECOMPENSATED CIRRHOSIS, FOR USE IN COMBINATION WITH RIBAVIRIN
ODE-264	TREATMENT OF PEDIATRIC PATIENTS 3 YEARS OF AGE AND OLDER WITH CHRONIC HCV GENOTYPE 1 OR 4 INFECTION WHO ARE LIVER TRANSPLANT RECIPIENTS WITHOUT CIRRHOSIS OR WITH COMPENSATED CIRRHOSIS, FOR USE IN COMBINATION WITH RIBAVIRIN
ODE-265	INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS ARE ROS1-POSITIVE
ODE-266	ADULT & PED >=12YRS OLD W/ SOLID TUMORS THAT HAVE NTRK W/O KNOWN ACQUIRED RESISTANCE MUTATION, ARE METASTATIC OR WHERE SURGICAL RESECTION IS LIKELY TO RESULT IN SEVERE MORBIDITY & HAVE EITHER PROGRESSED FOLLOWING TX OR HAVE NO SATISFACTORY ALTERNATIVE TX
ODE-267	INDICATED IN COMBINATION WITH HIGH FLUID INTAKE, ALKALI, AND DIET MODIFICATION, FOR THE PREVENTION OF CYSTINE STONE FORMATION IN PEDIATRIC PATIENTS 20KG TO 9 YEARS OF AGE W/SEVERE HOMOZYGOUS CYSTINURIA, WHO ARE NOT RESPONSIVE TO THESE MEASURES ALONE
ODE-268	INDICATED FOR TREATMENT OF PATIENTS WITH CUSHING'S DISEASE FOR WHOM PITUITARY SURGERY IS NOT AN OPTION OR HAS NOT BEEN CURATIVE
ODE-269	PROPHYLAXIS OF ORGAN REJECTION IN PEDIATRIC PATIENTS RECEIVING ALLOGENEIC KIDNEY TRANSPLANT, LIVER TRANSPLANTS, AND HEART TRANSPLANT, IN COMBINATION WITH OTHER IMMUNOSUPPRESSANTS
ODE-270	INDICATED TO INCREASE PAIN FREE LIGHT EXPOSURE IN ADULT PATIENTS WITH A HISTORY OF PHOTOTOXIC REACTIONS FROM ERYTHROPOIETIC PROTOPORPHYRIA (EPP)
ODE-271	INDICATED IN COMBINATION WITH OTHER ANTI-MYELOMA PRODUCTS FOR THE TREATMENT OF ADULTS WITH MULTIPLE MYELOMA (MM)
ODE-272	INDICATED FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) (WHO GROUP 1) TO DELAY DISEASE PROGRESSION
ODE-273	INDICATED FOR THE TREATMENT OF ADULTS WITH ACUTE HEPATIC PORPHYRIA (AHP)
ODE-274	INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL)
ODE-275	INDICATED FOR THE TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS AGED 12 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) GENE
ODE-276	INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH MANTLE CELL LYMPHOMA (MCL) WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
ODE-277	TX OF ADULTS W/ ADV OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER TREATED W/ >=3 PRIOR CHEMO REGIMENS & CANCER ASSOCIATED W/ HRD+ STATUS DEFINED BY A DELETERIOUS OR SUSPECTED DELETERIOUS BRCA MUTATION
ODE-278	TX OF ADULTS W/ ADV OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER TREATED W/ >=3 PRIOR CHEMO REGIMENS & CANCER ASSOCIATED W/ HRD+ STATUS DEFINED BY GENOMIC INSTABILITY & PROGRESSED >6 MONTHS AFTER RESPONSE TO THE LAST PLATINUM-BASED CHEMOTHERAPY
ODE-279	INDICATED FOR THE ACUTE TX OF INTERMITTENT, STEREOTYPIC EPISODES OF FREQUENT SEIZURE ACTIVITY (I.E. SEIZURE CLUSTERS, ACUTE REPETITIVE SEIZURES) THAT ARE DISTINCT FROM A PATIENT'S USUAL SEIZURE PATTERN IN PATIENTS WITH EPILEPSY 6 YEARS OF AGE AND OLDER
ODE-280	INDICATED FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) IN PATIENTS WHO HAVE A CONFIRMED MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 53 SKIPPING
ODE-281	INDICATED FOR THE TREATMENT OF SICKLE CELL DISEASE (SCD) IN ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER
ODE-282	INDICATED TO SELECTIVELY STAIN THE INTERNAL LIMITING MEMBRANE (ILM)
ODE-283	MAINTENANCE TX OF ADULTS W/ DELETERIOUS OR SUSPECTED DELETERIOUS GBRCA METASTATIC PANCREATIC ADENOCARCINOMA WHOSE DZ HAS NOT PROGRESSED ON >=16WKS OF 1ST LINE PLATINUM BASED CHEMO REGIMEN. SELECT PTS FOR THERAPY BASED ON APPROVED COMPANION DIAGNOSTIC
ODE-284	IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS, FOR THE TREATMENT OF HIV-1 INFECTION IN PEDIATRIC PATIENTS UNDER 12 YEARS OF AGE WEIGHING AT LEAST 35KG
ODE-285	IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS OTHER THAN PROTEASE INHIBITORS THAT REQUIRE A CYP3A INHIBITOR, FOR THE TREATMENT OF HIV-1 INFECTION IN PEDIATRIC PATIENTS UNDER 12 YEARS OF AGE WEIGHING AT LEAST 25KG AND LESS THAN

PATENT AND EXCLUSIVITY TERMS

ADB 62 of 191

ORPHAN DRUG EXCLUSIVITY

35KG

ODE-286	INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH CUSHING'S DISEASE FOR WHOM PITUITARY SURGERY IS NOT AN OPTION OR HAS NOT BEEN CURATIVE
ODE-287	TREATMENT OF ADULTS WITH NEWLY DIAGNOSED THERAPY-RELATED ACUTE MYELOID LEUKEMIA (T-AML) OR AML WITH MYELODYSPLASIA-RELATED CHANGES (AML-MRC)
ODE-288	INDICATED FOR THE TREATMENT OF PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH NEUROFIBROMATOSIS TYPE 1 (NF1) WHO HAVE SYMPTOMATIC, INOPERABLE PLEXIFORM NEUROFIBROMAS (PN)
ODE-289	INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH LOW-GRADE UPPER TRACT UROTHELIAL CANCER (LG-UTUC)
ODE-290	INDICATED FOR THE INITIAL TREATMENT OF SEVERE MALARIA IN ADULT AND PEDIATRIC PATIENTS TO ALWAYS BE FOLLOWED BY A COMPLETE TREATMENT COURSE OF AN APPROPRIATE ORAL ANTIMALARIAL REGIMEN
ODE-291	INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS HAVE A MUTATION THAT LEADS TO MESENCHYMAL-EPITHELIAL TRANSITION (MET) EXON 14 SKIPPING AS DETECTED BY AN FDA-APPROVED TEST
ODE-292	INDICATED FOR THE TREATMENT OF ADULTS WITH PREVIOUSLY TREATED, UNRESECTABLE LOCALLY ADVANCED OR METASTATIC CHOLANGIOCARCINOMA WITH A FIBROBLAST GROWTH FACTOR RECEPTOR 2 (FGFR2) FUSION OR OTHER REARRANGEMENT AS DETECTED BY AN FDA-APPROVED TEST
ODE-293	TX OF PED PTS 6 YRS OF AGE & OLDER OR WEIGHING AT LEAST 17 KG WITH CHRONIC HEPATITIS C VIRUS GENOTYPE 1, 2, 3, 4, 5, OR 6 INFECTION: WITHOUT CIRRHOSIS OR WITH COMPENSATED CIRRHOSIS; OR WITH DECOMPENSATED CIRRHOSIS FOR USE IN COMBINATION WITH RIBAVIRIN
ODE-294	PROPHYLAXIS OF ORGAN REJECTION IN PEDIATRIC PATIENTS RECEIVING ALLOGENEIC KIDNEY OR HEART TRANSPLANTS, IN COMBINATION WITH OTHER IMMUNOSUPPRESSANTS
ODE-295	INDICATED FOR THE MAINTENANCE TREATMENT OF ADULT PATIENTS WITH ADVANCED EPITHELIAL OVARIAN CANCER WHO ARE IN A COMPLETE OR PARTIAL RESPONSE TO FIRST-LINE PLATINUM-BASED CHEMOTHERAPY
ODE-296	INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH AIDS-RELATED KAPOSI SARCOMA (KS) AFTER FAILURE OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART)
ODE-297	FOR THE TREATMENT OF KAPOSI SARCOMA (KS) IN ADULT PATIENTS WHO ARE HIV-NEGATIVE
ODE-298	INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMOR (GIST) WHO HAVE RECEIVED PRIOR TREATMENT WITH 3 OR MORE KINASE INHIBITORS, INCLUDING IMATINIB
ODE-299	INDICATED FOR THE TREATMENT OF ADULTS AND PEDIATRIC PATIENTS AGED 16 YEARS AND OLDER WITH METASTATIC OR LOCALLY ADVANCED EPITHELIOID SARCOMA NOT ELIGIBLE FOR COMPLETE RESECTION
ODE-300	FOR THE TREATMENT OF ADULT PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) AS DETECTED BY AN FDA-APPROVED TEST, NOT INCLUDING PATIENTS WHO HAVE PROGRESSED ON OR ARE INTOLERANT TO CRIZOTINIB
ODE-301	INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH METASTATIC RET FUSION-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC)
ODE-302	INDICATED FOR THE TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC RET-MUTANT MEDULLARY THYROID CANCER (MTC) WHO REQUIRE SYSTEMIC THERAPY
ODE-303	ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC RET FUSION-POSITIVE THYROID CANCER WHO REQUIRE SYSTEMIC THERAPY AND WHO ARE RADIOACTIVE IODINE-REFRACTORY (IF RADIOACTIVE IODINE IS APPROPRIATE)
ODE-304	INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH METASTATIC SMALL CELL LUNG CANCER (SCLC) WITH DISEASE PROGRESSION ON OR AFTER PLATINUM-BASED CHEMOTHERAPY
ODE-305	TREATMENT OF INVASIVE ASPERGILLOSIS
ODE-306	W/ BEVACIZUMAB FOR MAINT TX OF ADULTS W/ ADV EPITHELIAL OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CA IN COMPLETE OR PARTIAL RESPONSE TO 1ST LINE PT BASED CHEMO & WHOSE CA IS ASSOC W/ HOMOLOGOUS RECOMB DEF + STATUS DEFINED BY GENOMIC INSTABILITY
ODE-307	INDICATED AS PART OF COMBINATION THERAPY IN THE TREATMENT OF PEDIATRIC PATIENTS 5 YEARS AND OLDER TO LESS THAN 12 YEARS OF AGE AND WEIGHING AT LEAST 15 KG WITH PULMONARY MULTI-DRUG RESISTANT TUBERCULOSIS (MDR-TB)

PATENT AND EXCLUSIVITY TERMS

ADB 63 of 191

ORPHAN DRUG EXCLUSIVITY

ODE-308	TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) (WHO GROUP 1) TO IMPROVE EXERCISE CAPACITY
ODE-309	INDICATED FOR USE IN COMBINATION WITH TRASTUZUMAB AND CAPECITABINE FOR TREATMENT OF ADULT PATIENTS WITH METASTATIC HER2-POSITIVE BREAST CANCER AND BRAIN METASTASES, WHO HAVE RECEIVED ONE OR MORE PRIOR ANTI-HER2-BASED REGIMENS IN THE METASTATIC SETTING
ODE-310	INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL), NOT OTHERWISE SPECIFIED, INCLUDING DLBCL ARISING FROM FOLLICULAR LYMPHOMA, AFTER AT LEAST 2 LINES OF SYSTEMIC THERAPY
ODE-311	INDICATED AS A SOURCE OF CALORIES AND FATTY ACIDS FOR THE TREATMENT OF PEDIATRIC AND ADULT PATIENTS WITH MOLECULARLY CONFIRMED LONG-CHAIN FATTY ACID OXIDATION DISORDERS (LC-FAOD)
ODE-312	INDICATED FOR THE TREATMENT OF SEIZURES ASSOCIATED WITH DRAVET SYNDROME IN PATIENTS 2 YEARS OF AGE AND OLDER
ODE-313	INDICATED FOR THE TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH SOLID TUMORS THAT HAVE A NEUROTROPHIC TYROSINE RECEPTOR KINASE (NTRK) GENE FUSION WITHOUT A KNOWN ACQUIRED RESISTENCE MUTATION, ARE METASTATIC OR WHERE SURGICAL RESECTION IS LIKELY TO RESULT IN SEVERE MORBIDITY, AND HAVE EITHER PROGRESSED FOLLOWING TREATMENT OR HAVE NO SATISFACTORY ALTERNATIVE THERAPY
ODE-314	INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA WHOSE TUMORS ARE POSITIVE FOR AN EZH2 MUTATION AS DETECTED BY AN FDA-APPROVED TEST AND WHO HAVE RECEIVED AT LEAST 2 PRIOR SYSTEMIC THERAPIES, AND FOR THE TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA WHO HAVE NO SATISFACTORY ALTERNATIVE TREATMENT OPTIONS
ODE-315	FOR CLEANSING OF THE COLON AS A PREPARATION FOR COLONOSCOPY IN PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER
ODE-316	TREATMENT OF ADULT PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS), INCLUDING PREVIOUSLY TREATED AND UNTREATED, DE NOVO AND SECONDARY MDS WITH THE FOLLOWING FRENCH-AMERICAN-BRITISH SUBTYPES (REFRACTORY ANEMIA, REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS, REFRACTORY ANEMIA WITH EXCESS BLASTS, AND CHRONIC MYELOMONOCYTIC LEUKEMIA [CMML]) AND INTERMEDIATE-1, INTERMEDIATE-2, AND HIGH-RISK INTERNATIONAL PROGNOSTIC SCORING SYSTEM GROUPS.
ODE-317	FOR USE WITH POSITRON EMISSION TOMOGRAPHY (PET) FOR LOCALIZATION OF SOMATOSTATIN RECEPTOR POSITIVE NEUROENDOCRINE TUMORS (NETS) IN ADULT PATIENTS
ODE-318	TREATMENT OF ADULT PATIENTS WITH METASTATIC RET FUSION-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC) AS DETECTED BY AN FDA APPROVED TEST
ODE-319	INDICATED IN PEDIATRIC PATIENTS (BIRTH TO LESS THAN 18 YEARS OF AGE AND WEIGHING AT LEAST 2.5 KG) FOR THE TREATMENT OF CHAGAS DISEASE (AMERICAN TRYPANOSOMIASIS) CAUSED BY TRYPANOSOMA CRUZI
ODE-320	INDICATED FOR CONTINUED TREATMENT OF ADULT PATIENTS WITH ACUTE MYELOID LEUKEMIA WHO ACHIEVED FIRST COMPLETE REMISSION (CR) OR COMPLETE REMISSION WITH INCOMPLETE BLOOD COUNT RECOVERY (CRI) FOLLOWING INTENSIVE INDUCTION CHEMOTHERAPY AND ARE NOT ABLE TO COMPLETE INTENSIVE CURATIVE THERAPY
ODE-321	TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS AGE 4 MONTHS TO LESS THAN 6 MONTHS WHO HAVE ONE MUTATION IN THE CFTR GENE THAT IS RESPONSIVE TO IVACAFTOR POTENTIATION BASED ON CLINICAL AND/OR IN VITRO ASSAY DATA
ODE-322	TREATMENT OF NARCOLEPSY
ODE-323	TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS AGED 12 YEARS AND OLDER WHO HAVE A MUTATION IN THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) GENE THAT IS RESPONSIVE BASED ON IN VITRO DATA
ODE-324	TREATMENT OF HUTCHINSON-GILFORD PROGERIA SYNDROME (HGPS) AND PROGEROID LAMINOPATHIES
ODE-325	TREATMENT OF ADULT PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) HARBORING MESENCHYMAL-EPITHELIAL TRANSITION (MET) EXON 14 SKIPPING ALTERATIONS
ODE-326	TREATMENT OF SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME (LGS) OR DRAVET SYNDROME (DS) IN PATIENTS BETWEEN 1 AND 2 YEARS OF AGE
ODE-327	ADD-ON MAINTENANCE THERAPY TO IMPROVE PULMONARY FUNCTION IN ADULT PATIENTS 18 YEARS OF AGE AND OLDER WITH CYSTIC FIBROSIS AND WHO HAVE PASSED THE BRONCHITOL TOLERANCE TEST

PATENT AND EXCLUSIVITY TERMS

ADB 64 of 191

ORPHAN DRUG EXCLUSIVITY

ODE-328	TREATMENT OF PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER AND YOUNG ADULTS WITH RELAPSED OR REFRACTORY, SYSTEMIC ANAPLASTIC LARGE CELL LYMPHOMA (ALCL) THAT IS ALK-POSITIVE
ODE-329	FOR THE TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME (SMS) IN PEDIATRIC PATIENTS 3 TO 15 YEARS OF AGE
ODE-330	THE TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME (SMS) IN PATIENTS 16 YEARS OF AGE AND OLDER
ODE-331	TREATMENT OF CATAPLEXY IN ADULT PATIENTS WITH NACROLEPSY
ODE-332	TREATMENT OF SEIZURES ASSOCIATED WITH TUBEROUS SCLEROSIS COMPLEX (TSC) IN PATIENTS 1 YEAR OF AGE AND OLDER
ODE-333	PROPHYLAXIS TO PREVENT ATTACKS OF HEREDITARY ANGIOEDEMA (HAE) IN ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER
ODE-334	TREATMENT OF SPINAL MUSCULAR ATROPHY (SMA) IN PATIENTS 2 MONTHS OF AGE AND OLDER
ODE-335	FOR TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS AGE 6 YEARS AND OLDER WHO HAVE AT LEAST ONE OF THE ADDITIONAL MUTATIONS IN THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) GENE THAT HAVE BEEN IDENTIFIED AS RESPONSIVE TO TEZACAFTOR/IVACAFTOR BASED ON IN VITRO DATA AND IDENTIFIED IN THE APPROVAL ON DECEMBER 21, 2020
ODE-336	INDICATED FOR CHRONIC WEIGHT MANAGEMENT IN ADULT AND PEDIATRIC PATIENTS 6 YEARS OF AGE AND OLDER WITH OBESITY DUE TO PROOPOMELANOCORTIN (POMC), PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 1 (PCSK1), OR LEPTIN RECEPTOR (LEPR) DEFICIENCY CONFIRMED BY GENETIC TESTING DEMONSTRATING VARIANTS IN POMC, PCSK1, OR LEPR GENES THAT ARE INTERPRETED AS PATHOGENIC, LIKELY PATHOGENIC, OR OF UNCERTAIN SIGNIFICANCE (VUS)
ODE-337	FOR ADJUVANT THERAPY AFTER TUMOR RESECTION IN ADULT PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS HAVE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 19 DELETIONS OR EXON 21 L858R MUTATIONS, AS DETECTED BY AN FDA-APPROVED TEST
ODE-338	FOR THE TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS AGE 4 MONTHS AND OLDER WHO HAVE ONE OF THE ADDITIONAL MUTATIONS IN THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) GENE THAT HAVE BEEN IDENTIFIED AS RESPONSIVE TO IVACAFTOR POTENTIATION BASED ON IN VITRO DATA AND IDENTIFIED IN THE APPROVAL ON DECEMBER 21, 2020
ODE-339	TREATMENT OF PRIMARY HYPEROXALURIA TYPE 1 (PH1) TO LOWER URINARY OXALATE LEVELS IN PEDIATRIC AND ADULT PATIENTS
ODE-340	TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC RET-MUTANT MEDULLARY THYROID CANCER (MTC) WHO REQUIRE SYSTEMIC THERAPY
ODE-341	TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC RET FUSION-POSITIVE THYROID CANCER WHO REQUIRE SYSTEMIC THERAPY AND WHO ARE RADIOACTIVE IODINE-REFRACTORY (IF RADIOACTIVE IODINE IS APPROPRIATE)
ODE-342	INDICATED TO REDUCE THE RISK OF MORTALITY IN PATIENTS WITH MOLYBDENUM COFACTOR DEFICIENCY (MOCDF) TYPE A
ODE-343	FOR TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY MARGINAL ZONE LYMPHOMA (MZL) WHO HAVE RECEIVED AT LEAST ONE PRIOR ANTI-CD20-BASED REGIMEN
ODE-344	FOR TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA (FL) WHO HAVE RECEIVED AT LEAST THREE PRIOR LINES OF SYSTEMIC THERAPY
ODE-345	IN PEDIATRIC AND ADULT PATIENTS AS ADJUNCTIVE THERAPY TO STANDARD OF CARE FOR THE TREATMENT OF ACUTE HYPERAMMONEMIA DUE TO PROPIONIC ACIDEMIA (PA) OR METHYLMALONIC ACIDEMIA (MMA)
ODE-346	FOR THE TREATMENT OF ADULT PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY, EXCLUDING ADULT PATIENTS COVERED BY XPOVIO'S PREVIOUS INDICATION FOR MULTIPLE MYELOMA APPROVED ON JULY 3, 2019
ODE-347	TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) IN PATIENTS WHO HAVE A CONFIRMED MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 45 SKIPPING
ODE-348	TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST FOUR PRIOR LINES OF THERAPY AND WHOSE DISEASE IS REFRACTORY TO AT LEAST ONE PROTEASOME INHIBITOR, ONE IMMUNOMODULATORY AGENT, AND ONE CD-38 DIRECTED MONOCLONAL ANTIBODY

PATENT AND EXCLUSIVITY TERMS

ADB 65 of 191

ORPHAN DRUG EXCLUSIVITY

ODE-349	TREATMENT OF ADULT PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS ARE ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE AS DETECTED BY AN FDA-APPROVED TEST, EXCLUDING PATIENTS WHOSE DISEASE HAS PROGRESSED ON CRIZOTINIB AND AT LEAST ONE OTHER ALK INHIBITOR FOR METASTATIC DISEASE; OR ALECTINIB OR CERITINIB AS THE FIRST ALK INHIBITOR THERAPY FOR METASTATIC DISEASE
ODE-350	TREATMENT OF NEWLY-DIAGNOSED THERAPY-RELATED ACUTE MYELOID LEUKEMIA (T-AML) OR AML WITH MYELODYSPLASIA-RELATED CHANGES (AML-MRC) IN PEDIATRIC PATIENTS AGES 1 YEAR AND OLDER
ODE-351	TREATMENT OF ADULT PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
ODE-352	TREATMENT OF ADULT PATIENTS WITH KRAS G12C-MUTATED LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC), AS DETERMINED BY AN FDA-APPROVED TEST, WHO HAVE RECEIVED AT LEAST ONE PRIOR SYSTEMIC THERAPY
ODE-353	FOR TREATMENT OF ADULTS WITH PREVIOUSLY TREATED, UNRESECTABLE LOCALLY ADVANCED OR METASTATIC CHOLANGIOCARCINOMA WITH A FIBROBLAST GROWTH FACTOR RECEPTOR 2 (FGFR2) FUSION OR OTHER REARRANGEMENT AS DETECTED BY AN FDA-APPROVED TEST
ODE-354	TREATMENT OF HUMAN SMALLPOX DISEASE CAUSED BY VARIOLA VIRUS IN ADULT AND PEDIATRIC PATIENTS, INCLUDING NEONATES
ODE-355	FOR THE TREATMENT OF INVASIVE ASPERGILLOSIS IN ADULTS AND PEDIATRIC PATIENTS 13 YEARS OF AGE AND OLDER
ODE-356	FOR THE TREATMENT OF ADULT PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS (ADVSM). ADVSM INCLUDES PATIENTS WITH AGGRESSIVE SYSTEMIC MASTOCYTOSIS (ASM), SYSTEMIC MASTOCYTOSIS WITH AN ASSOCIATED HEMATOLOGICAL NEOPLASM (SM-AHN), AND MAST CELL LEUKEMIA (MCL)
ODE-357	FOR THE TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS AGED 6 THROUGH 11 YEARS OLD WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) GENE OR A MUTATION IN THE CFTR GENE THAT IS RESPONSIVE BASED ON IN VITRO DATA
ODE-358	FOR THE TREATMENT OF VERNAL KERATOCONJUNCTIVITIS (VKC) IN CHILDREN AND ADULTS
ODE-359	FOR THE TREATMENT OF BOTH THE FIRST-STAGE (HEMOLYMPHATIC) AND SECOND-STAGE (MENINGOENCEPHALITIC) HUMAN AFRICAN TRYPAOSOMIASIS (HAT) DUE TO TRYPAOSOMA BRUCEI GAMBIENSE IN PATIENTS 6 YEARS OF AGE AND OLDER AND WEIGHING AT LEAST 20 KG
ODE-360	FOR PROPHYLAXIS OF ORGAN REJECTION IN ADULT AND PEDIATRIC PATIENTS RECEIVING ALLOGENEIC LUNG TRANSPLANT
ODE-361	INDICATED FOR THE TREATMENT OF CATAPLEXY OR EXCESSIVE DAYTIME SLEEPINESS (EDS) IN PATIENTS 7 YEARS OF AGE AND OLDER WITH NARCOLEPSY
ODE-362	TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER WITH CHRONIC GRAFT-VERSUS-HOST DISEASE (CHRONIC GVHD) AFTER FAILURE OF AT LEAST TWO PRIOR LINES OF SYSTEMIC THERAPY
ODE-363	TREATMENT OF PRURITUS IN PATIENTS 3 MONTHS OF AGE AND OLDER WITH PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS (PFIC)
ODE-364	TREATMENT OF ADULT PATIENTS WITH VON HIPPEL-LINDAU (VHL) DISEASE WHO REQUIRE THERAPY FOR ASSOCIATED RENAL CELL CARCINOMA (RCC), CENTRAL NERVOUS SYSTEM (CNS) HEMANGIOBLASTOMAS, OR PANCREATIC NEUROENDOCRINE TUMORS (PNET), NOT REQUIRING IMMEDIATE SURGERY
ODE-365	TREATMENT OF ADULT PATIENTS WITH VON HIPPEL-LINDAU (VHL) DISEASE WHO REQUIRE THERAPY FOR ASSOCIATED RENAL CELL CARCINOMA (RCC), CENTRAL NERVOUS SYSTEM (CNS) HEMANGIOBLASTOMAS, OR PANCREATIC NEUROENDOCRINE TUMORS (PNET), NOT REQUIRING IMMEDIATE SURGERY
ODE-366	INDICATED FOR THE TREATMENT OF ADULTS WITH UNRESECTABLE OR METASTATIC GIST HARBORING A PLATELET-DERIVED GROWTH FACTOR RECEPTOR ALPHA (PDGFRA) EXON 18 MUTATION, INCLUDING PDGFRA D842V MUTATIONS
ODE-367	PEDIATRIC PATIENTS AGED 6 MONTHS AND OLDER FOR THE TREATMENT OF C. DIFFICILE-ASSOCIATED DIARRHEA (CDAD)
ODE-368	TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY TREATED, LOCALLY ADVANCED OR METASTATIC CHOLANGIOCARCINOMA WITH AN ISOCITRATE DEHYDROGENASE-1 (IDH1) MUTATION AS DETECTED BY AN FDA-APPROVED TEST
ODE-369	THE TREATMENT OF IDIOPATHIC HYPERSOMNIA (IH) IN ADULTS
ODE-370	TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY MARGINAL ZONE LYMPHOMA (MZL) WHO HAVE RECEIVED AT LEAST ONE ANTI-CD20-BASED REGIMEN

PATENT AND EXCLUSIVITY TERMS

ADB 66 of 191

ORPHAN DRUG EXCLUSIVITY

ODE-371	TREATMENT OF ADULT PATIENTS WITH WALDENSTRM'S MACROGLOBULINEMIA (WM)
ODE-372	FOR TREATMENT OF PEDIATRIC PATIENTS 3 YEARS OF AGE TO LESS THAN 12 YEARS OF AGE WEIGHING LESS THAN 45 KG WITH CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1, 2, 3, 4, 5 OR 6 INFECTION WITHOUT CIRRHOSIS OR WITH COMPENSATED CIRRHOSIS (CHILD-PUGH A); AND TREATMENT OF PEDIATRIC PATIENTS 3 YEARS OF AGE TO LESS THAN 12 YEARS OF AGE WEIGHING LESS THAN 45 KG WITH HCV GENOTYPE 1 INFECTION, WHO PREVIOUSLY HAVE BEEN TREATED WITH A REGIMEN CONTAINING AN HCV NS5A INHIBITOR OR AN NS3/4A PROTEASE INHIBITOR (PI), BUT NOT BOTH
ODE-373	TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR TWO LINES OF SYSTEMIC THERAPY IN ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER
ODE-374	TREATMENT OF ADULT PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 20 INSERTION MUTATIONS, AS DETECTED BY AN FDA-APPROVED TEST, WHOSE DISEASE HAS PROGRESSED ON OR AFTER PLATINUM-BASED CHEMOTHERAPY
ODE-375	THE TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH LOCALLY ADVANCED OR METASTATIC DIFFERENTIATED THYROID CANCER (DTC) THAT HAS PROGRESSED FOLLOWING PRIOR VEGFR-TARGETED THERAPY AND WHO ARE RADIOACTIVE IODINE-REFRACTORY OR INELIGIBLE
ODE-376	FOR TREATMENT OF PEDIATRIC PATIENTS 3 YEARS OF AGE TO LESS THAN 6 YEARS OF AGE WEIGHING LESS THAN 17 KG WITH CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1, 2, 3, 4, 5, OR 6 INFECTION: WITHOUT CIRRHOSIS OR WITH COMPENSATED CIRRHOSIS; OR WITH DECOMPENSATED CIRRHOSIS FOR USE IN COMBINATION WITH RIBAVIRIN
ODE-377	AS AN ADJUNCTIVE TREATMENT OF ADULT PATIENTS WITH SEVERE ACTIVE ANTI-NEUTROPHIL CYTOPLASMIC AUTOANTIBODY (ANCA)-ASSOCIATED VASCULITIS (GRANULOMATOSIS WITH POLYANGIITIS [GPA] AND MICROSCOPIC POLYANGIITIS [MPA])
ODE-378	A COMPLETE REGIMEN FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) INFECTION IN PEDIATRIC PATIENTS WEIGHING 14 KG TO LESS THAN 25 KG WHO HAVE NO ANTIRETROVIRAL TREATMENT HISTORY OR TO REPLACE THE CURRENT ANTIRETROVIRAL REGIMEN IN THOSE WHO ARE VIROLOGICALLY-SUPPRESSED (HIV-1 RNA LESS THAN 50 COPIES PER ML) ON A STABLE ANTIRETROVIRAL REGIMEN WITH NO HISTORY OF TREATMENT FAILURE AND NO KNOWN SUBSTITUTIONS ASSOCIATED WITH RESISTANCE TO THE INDIVIDUAL COMPONENTS OF BIKTARVY
ODE-379	FOR TREATMENT OF CHOLESTATIC PRURITUS IN PATIENTS WITH ALAGILLE SYNDROME (ALGS) 1 YEAR OF AGE AND OLDER
ODE-380	TREATMENT OF PEDIATRIC PATIENTS GREATER THAN OR EQUAL TO 1 YEAR OF AGE WITH ACCELERATED PHASE PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (PH+ CML) WITH RESISTANCE OR INTOLERANCE TO PRIOR TYROSINE-KINASE INHIBITOR (TKI) THERAPY
ODE-381	TREATMENT OF ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOID LEUKEMIA (PH+ CML) IN CHRONIC PHASE (CP) WITH THE T315I MUTATION
ODE-382	TREATMENT OF ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOID LEUKEMIA (PH+ CML) IN CHRONIC PHASE (CP), PREVIOUSLY TREATED WITH TWO OR MORE TYROSINE KINASE INHIBITORS (TKIS)
ODE-383	FOR USE WITH POSITRON EMISSION TOMOGRAPHY (PET) FOR THE LOCALIZATION OF KNOWN SOMATOSTATIN RECEPTOR POSITIVE NEUROENDOCRINE TUMORS (NETS) IN ADULT AND PEDIATRIC PATIENTS

PATENT USE

U-1	PREVENTION OF PREGNANCY
U-2	TREATMENT OR PROPHYLAXIS OF ANGINA PECTORIS AND ARRHYTHMIA
U-3	TREATMENT OF HYPERTENSION
U-4	PROVIDING PREVENTION AND TREATMENT OF EMESIS AND NAUSEA IN MAMMALS
U-5	METHOD OF PRODUCING BRONCHODILATION
U-6	METHOD OF PRODUCING SYMPATHOMIMETIC EFFECTS
U-7	INCREASING CARDIAC CONTRACTILITY
U-8	ACUTE MYOCARDIAL INFARCTION
U-9	CONTROL OF EMESIS ASSOCIATED WITH ANY CANCER CHEMOTHERAPY AGENT

PATENT AND EXCLUSIVITY TERMS

ADB 67 of 191

PATENT USE

U-10	DIAGNOSTIC METHOD FOR DISTINGUISHING BETWEEN HYPOTHALAMIC MALFUNCTIONS OR LESIONS IN HUMANS
U-11	TREATMENT OR PROPHYLAXIS OF CARDIAC DISORDERS
U-12	METHOD OF TREATING [A] HUMAN SUFFERING FROM DEPRESSION
U-13	A METHOD FOR TREATING ANXIETY IN A HUMAN SUBJECT IN NEED OF SUCH TREATMENT
U-14	ADJUNCTIVE THERAPY FOR THE PREVENTION AND TREATMENT OF HYPERAMMONEMIA IN THE CHRONIC MANAGEMENT OF PATIENTS WITH UREA CYCLE ENZYMOPATHIES
U-15	METHOD OF LOWERING INTRAOCULAR PRESSURE
U-16	USE IN LUNG SCANNING PROCEDURES
U-17	TREATMENT OF VENTRICULAR AND SUPRAVENTRICULAR ARRHYTHMIAS
U-18	METHOD FOR INHIBITING GASTRIC SECRETION IN MAMMALS
U-19	TREATMENT OF INFLAMMATION
U-20	A PROCESS FOR TREATING A PATIENT SUFFERING FROM PARKINSON'S SYNDROME AND IN NEED OF TREATMENT
U-21	TREATMENT OF HUMANS SUFFERING UNDESIRE UROTOXIC SIDE EFFECTS CAUSED BY CYTOSTATICALLY ACTIVE ALKYLATING AGENTS
U-22	METHOD OF COMBATTING PATHOLOGICALLY REDUCED CEREBRAL FUNCTIONS AND PERFORMANCE WEAKNESSES, CEREBRAL INSUFFICIENCY AND DISORDERS IN CEREBRAL CIRCULATION AND METABOLISM IN WARM-BLOODED ANIMALS
U-23	METHOD FOR TREATING PROSTATIC CARCINOMA COMPRISING ADMINISTERING FLUTAMIDE
U-24	METHOD FOR TREATING PROSTATE ADENOCARCINOMA COMPRISING ADMINISTERING AN ANTIANDROGEN INCLUDING FLUTAMIDE AND AN LHRH AGONIST
U-25	REDUCING CHOLESTEROL IN CHOLELITHIASIS PATIENTS
U-26	REDUCING CHOLESTEROL GALLSTONES AND/OR FRAGMENTS THEREOF
U-27	DISSOLVING CHOLESTEROL GALLSTONES AND/OR FRAGMENTS THEREOF
U-28	CEREBRAL, CORONARY, PERIPHERAL, VISCERAL AND RENAL ARTERIOGRAPHY, AORTOGRAPHY AND LEFT VENTRICULOGRAPHY
U-29	CT IMAGING OF THE HEAD AND BODY, AND INTRAVENOUS EXCRETORY UROGRAPHY
U-30	CEREBRAL ANGIOGRAPHY, AND VENOGRAPHY
U-31	INTRA-ARTERIAL DIGITAL SUBTRACTION ANGIOGRAPHY
U-32	PALLIATIVE TREATMENT OF PATIENTS WITH OVARIAN CARCINOMA RECURRENT AFTER PRIOR CHEMOTHERAPY, INCLUDING PATIENTS WHO HAVE BEEN PREVIOUSLY TREATED WITH CISPLATIN
U-33	TREATING VIRAL INFECTIONS IN A MAMMAL
U-34	TREATING VIRAL INFECTIONS IN A WARM-BLOODED ANIMAL
U-35	TREATING CYTOMEGALOVIRUS IN A HUMAN WITH AN INJECTABLE COMPOSITION
U-36	METHODS OF TREATING BACTERIAL ILLNESSES
U-37	METHOD OF TREATING GASTROINTESTINAL DISEASE
U-38	TREATMENT OF PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA
U-39	ANGINA PECTORIS
U-40	METHOD OF TREATMENT OF BURNS
U-41	METHOD OF TREATING CARDIAC ARRHYTHMIAS
U-42	ADJUVANT TREATMENT IN COMBINATION WITH FLUOROURACIL AFTER SURGICAL RESECTION IN PATIENTS WITH DUKES' STAGE C COLON CANCER
U-43	MANAGEMENT OF CHRONIC PAIN IN PATIENTS REQUIRING OPIOID ANALGESIA
U-44	RELIEF OF NAUSEA AND VOMITING
U-45	TREATMENT OF INFLAMMATION AND ANALGESIA
U-46	TREATMENT OF PANIC DISORDER
U-47	STIMULATION OF THE RELEASE OF GROWTH HORMONE
U-48	ANALGESIA
U-49	SYMPTOMATIC CANCER-RELATED HYPERCALCEMIA

PATENT AND EXCLUSIVITY TERMS

ADB 68 of 191

PATENT USE

U-50	USE IN TREATING INFLAMMATORY DERMATOSES
U-51	BLOOD POOL IMAGING, INCLUDING CARDIAC FIRST PASS AND GATED EQUILIBRIUM IMAGING AND FOR DETECTION OF SITES OF GASTROINTESTINAL BLEEDING
U-52	TREATMENT OF ADULT AND PEDIATRIC PATIENTS (OVER SIX MONTHS OF AGE) WITH ADVANCED HIV INFECTION
U-53	HYPERCALCEMIA OF MALIGNANCY
U-54	REVERSAL AGENT OR ANTAGONIST OF NONDEPOLARIZING NEUROMUSCULAR BLOCKING AGENTS
U-55	TREATMENT OF PAIN
U-56	AID TO SMOKING CESSATION
U-57	OPHTHALMIC USE OF NORFLOXACIN
U-58	METHOD OF TREATING INFLAMMATORY INTESTINAL DISEASES
U-59	METHOD OF TREATING HYPERCHOLESTEROLEMIA
U-60	NASAL ADMINISTRATION OF BUTORPHANOL
U-61	CEREBRAL AND PERIPHERAL ARTERIOGRAPHY AND CT IMAGING OF THE HEAD
U-62	CORONARY ARTERIOGRAPHY, LEFT VENTRICULOGRAPHY, CT IMAGING OF THE BODY, INTRAVENOUS EXCRETORY UROGRAPHY, INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY AND VENOGRAPHY
U-63	ISOPRENALINE ANTAGONISM ON THE HEART RATE OR BLOOD PRESSURE
U-64	TREATMENT OF VIRAL INFECTIONS
U-65	METHOD OF TREATMENT OF A PATIENT INFECTED WITH HIV
U-66	TRIPHASIC REGIMEN
U-67	METHOD OF INDUCING ANESTHESIA IN A WARM BLOODED ANIMAL
U-68	TREATMENT OF ACTINIC KERATOSIS
U-69	TREATMENT OF PNEUMOCYSTIS CARINII INFECTIONS
U-70	TREATMENT OF TRANSIENT INSOMNIA
U-71	METHOD OF TREATMENT OF HEART FAILURE
U-72	TREATMENT OF MIGRAINE
U-73	METHOD OF TREATING DISEASES OR INFECTIONS CAUSED BY MYCETES
U-74	METHOD OF PROVIDING HYPNOTIC EFFECT
U-75	RELIEF OF OCULAR ITCHING DUE TO SEASONAL ALLERGIC CONJUNCTIVITIS
U-76	USE TO IMAGE A SUBJECT WITH A MAGNETIC RESONANCE IMAGING SYSTEM
U-77	TREATMENT OF SYMPTOMS OF SEASONAL ALLERGIC RHINITIS
U-78	ULCERATIVE COLITIS
U-79	SYMPTOMATIC TREATMENT OF PATIENTS WITH NOCTURNAL HEARTBURN DUE TO GERD
U-80	METHOD OF TREATING OCULAR BACTERIAL INFECTIONS
U-81	RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS
U-82	TREATMENT FOR DEMENTIA IN PATIENTS WITH ALZHEIMER'S DISEASE
U-83	TREATMENT OF SEIZURES
U-84	A METHOD OF BLOCKING THE UPTAKE OF MONOAMINES BY BRAIN NEURONS IN ANIMALS
U-85	NASAL TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS
U-86	METHOD OF TREATING CERTAIN FORMS OF EPILEPSY
U-87	METHOD FOR NONINVASIVE ADMINISTRATION OF SEDATIVES, ANALGESICS, AND ANESTHETICS
U-88	TREATMENT OF MODERATE PLAQUE PSORIASIS
U-89	TREATMENT OR PROPHYLAXIS OF EMESIS
U-90	TREATMENT OF PSYCHOTIC DISORDERS
U-91	ALTERNATIVE THERAPY TO TRIMETHOPRIM-SULFAMETHOXAZOLE FOR TREATMENT OF MODERATE-TO-SEVERE PNEUMOCYSTIS CARINII PNEUMONIA IN IMMUNOCOMPROMISED AND AIDS PATIENTS
U-92	TREATMENT OF DIABETIC NEPHROPATHY IN PATIENTS WITH TYPE I INSULIN DEPENDENT

PATENT AND EXCLUSIVITY TERMS

ADB 69 of 191

PATENT USE

DIABETES MELLITUS AND RETINOPATHY

U-93 USE AS AN ANTIHISTAMINE/DECONGESTANT

U-94 TREATMENT-ADULTS W/ ADVANCED HIV,INTOLERANT OF APPROVED THERAPIES,INTOLERANT OF APPROVED THERAPIES W/PROVEN BENEFIT OR HAVE EXPERIENCED CLINICAL/IMMUNOLOGICAL DETERIORATION WHILE RECEIVING..OR FOR WHOM SUCH THERAPIES-CONTRAINDICATED

U-95 SHORT TERM MANAGEMENT OF MODERATE PRURITIS IN ADULTS WITH ATOPIC DERMATITIS AND LICHEN SIMPLEX CHRONICUS

U-96 METHOD OF TREATING VARICELLA ZOSTER (SHINGLES) INFECTIONS

U-97 A METHOD OF TREATING A PATIENT IN NEED OF MEMORY ENHANCEMENT

U-98 A METHOD OF INDUCING REGRESSION OF LEUKEMIA CELL GROWTH IN A MAMMAL

U-99 METHOD OF PROVIDING POTASSIUM TO A SUBJECT IN NEED OF POTASSIUM

U-100 METHOD OF TREATING OCULAR INFLAMMATION

U-101 ADJUNCT TO CONVENTIONAL CT OR MRI IMAGING IN THE LOCALIZATION OF STROKE IN PATIENTS IN WHOM STROKE HAS ALREADY BEEN DIAGNOSED

U-102 METHOD OF HORMONALLY TREATING MENOPAUSAL OR POST-MENOPAUSAL DISORDERS IN WOMEN

U-103 TREATMENT OF OCULAR HYPERTENSION

U-104 TREATMENT OF AQUEOUS HUMOR FORMATION AND INTRAOCULAR PRESSURE

U-105 EMESIS

U-106 TREATMENT OF EPILEPSY

U-107 TREATMENT OF HYPERTENSION AND ANGINA PECTORIS

U-108 SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER, GASTROESOPHAGEAL REFLUX DISEASE (GERD), SEVERE EROSIIVE ESOPHAGITIS, POORLY RESPONSIVE SYMPTOMATIC GERD AND PATHOLOGICAL HYPERSECRETORY CONDITIONS AND MAINTENANCE HEALING OF EROSIIVE ESOPHAGITIS

U-109 ADJUNCT DIET IN THE TX OF ELEVATED TOTAL CHOLESTEROL AND LDL-C LEVELS IN PTS W/PRIMARY HYPERCHOLESTEROLEMIA WHOSE RESPONSE TO DIETARY RESTRICTION OF SAT FAT AND CHOLESTEROL AND OTHER NONPHARMACOLOGICAL MEASURES HAS NOT BEEN ADEQUATE

U-110 USE AS A RETRIEVABLE PESSARY

U-111 DIABETES

U-112 CONTRACEPTION

U-113 METHOD OF CONDUCTING RADIOLOGICAL EXAMINATION OF A PATIENT BY ADMINISTERING TO SAID PATIENT A RADIOPAQUE AMOUNT OF IOPROMIDE

U-114 USE FOR INHIBITING BONE RESORPTION

U-115 USE OF VASODILATORS TO EFFECT AND ENHANCE AN ERECTION (AND THUS TREAT ERECTILE DYSFUNCTION), BY INJECTION INTO THE PENIS

U-116 METHOD OF MYOCARDIAL IMAGING

U-117 TREATMENT OF OCULAR ALLERGIC RESPONSE IN HUMAN EYES

U-118 METHOD OF LOWERING BLOOD SUGAR LEVEL

U-119 TREATMENT OF NASAL HYPERSECRETION

U-120 CONTROLLING OR PREVENTING POST-OPERATIVE INTRAOCULAR PRESSURE RISES ASSOCIATED WITH OPHTHALMIC LASER SURGICAL PROCEDURES

U-121 METHOD OF TREATING CONDITIONS MEDIATED THROUGH HISTAMINE H2-RECEPTORS

U-122 A THERAPEUTIC METHOD FOR CONTROLLING THROMBOSIS

U-123 METHOD FOR CONTROLLING THROMBOSIS AND DECREASING BLOOD HYPERCOAGULATION AND HEMORRHAGING RISKS

U-124 TREATMENT OF ACNE

U-125 TREATMENT NEUROGENERATIVE DISEASES

U-126 TREATMENT OF GASTRITIS

U-127 METHOD OF PRODUCING NEUROMUSCULAR BLOCKADE

U-128 METHOD FOR TREATMENT OF TUMORS

U-129 METHOD TO DESTROY OR IMPAIR TARGET CELLS

PATENT AND EXCLUSIVITY TERMS

ADB 70 of 191

PATENT USE

U-130	MANAGEMENT OF PATIENTS WITH MASTOCYTOSIS
U-131	PHOTODAMAGED SKIN
U-132	INHIBITING HIV PROTEASE
U-133	MANAGEMENT OF OBESITY INCLUDING WEIGHT LOSS AND MAINTENANCE IN PATIENTS ON A REDUCED-CALORIE DIET
U-134	TREATMENT OF ACNE VULGARIS
U-135	ANTITUMOR AGENT
U-136	PROCESS FOR WASTE NITROGEN REMOVAL
U-137	METHOD OF TREATING BACTERIAL VAGINOSIS
U-138	TREATMENT OF ALLERGIC RHINITIS
U-139	TREATMENT OF ALLERGIC REACTIONS
U-140	USE OF NORVIR TO INHIBIT HIV PROTEASE OR TO INHIBIT AN HIV INFECTION
U-141	TREATMENT OF ULCERATIVE COLITIS
U-142	METHOD OF TREATING ALLERGIC REACTIONS IN A MAMMAL BY USING THIS ACTIVE METABOLITE
U-143	BIODEGRADABLE SUPERPARAMAGNETIC METAL OXIDES AS CONTRAST AGENTS FOR MR IMAGING
U-144	BIOLOGICALLY DEGRADABLE SUPERPARAMAGNETIC MATERIALS FOR USE IN CLINICAL APPLICATIONS
U-145	BIOLOGICALLY DEGRADABLE SUPERPARAMAGNETIC PARTICLES FOR USE AS NUCLEAR MAGNETIC RESONANCE IMAGING AGENTS
U-146	METHOD OF TREATING SUSCEPTIBLE NEOPLASMS IN MAMMALS
U-147	DETECTION OF GASTROINTESTINAL DISORDERS AND THE SUBSEQUENT BREATH COLLECTION AND MEASUREMENT OF $^{13}\text{CO}_2$
U-148	DEVICE FOR COLLECTING A BREATH SAMPLE
U-149	METHOD OF TREATING AN ANIMAL, INCLUDING A HUMAN SUFFERING FROM OR SUSCEPTIBLE TO PSYCHOSIS, ACUTE MANIA OR MILD ANXIETY STATES
U-150	METHOD OF USE FOR CONTROLLING HYPERGLYCEMIA BY ADMINISTRATION OF THIS SUSTAINED RELEASE DOSAGE FORM OF GLIPIZIDE
U-151	RELIEF OF SYMPTOMS OF THE COMMON COLD
U-152	METHOD OF TREATING ANXIETY RELATED DISORDERS INCLUDING OBSESSIVE COMPULSIVE DISORDER
U-153	TREATMENT OF INITIAL EPISODE GENITAL HERPES
U-154	METHOD OF TREATING ANIMALS SUFFERING FROM AN APPETITE DISORDER
U-155	TREATMENT OF ERECTILE DYSFUNCTION
U-156	METHOD OF PROVIDING ANESTHESIA
U-157	TREATMENT OF A HUMAN SUFFERING FROM VITAMIN B12 DEFICIENCY
U-158	ANGINA
U-159	TREATMENT OF INTERSTITIAL CYSTITIS
U-160	TREATMENT OF BACTERIAL INFECTIOUS DISEASE
U-161	METHOD OF INHIBITING CHOLESTEROL BIOSYNTHESIS IN A PATIENT
U-162	METHOD OF USE TO INHIBIT CHOLESTEROL SYNTHESIS IN A HUMAN SUFFERING FROM HYPERCHOLESTEROLEMIA
U-163	METHOD OF USING TROGLITAZONE TO TREAT IMPAIRED GLUCOSE TOLERANCE TO PREVENT OR DELAY THE ONSET OF NONINSULIN-DEPENDENT DIABETES MELLITUS
U-164	METHOD OF USING TROGLITAZONE TO PREVENT OR DELAY THE ONSET OF NONINSULIN-DEPENDENT DIABETES MELLITUS IN A DEFINED POPULATION OF PATIENTS
U-165	TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA
U-166	TREATMENT OF H.PYLORI-ASSOCIATED DUODENAL ULCER
U-167	METHOD FOR TREATING HIV-1 INFECTION
U-168	METHOD OF INHIBITING LIPOXYGENASE ACTIVITY IN A MAMMAL WHICH IS THE MODE OF ACTION IN THE TREATMENT OF ASTHMA

PATENT AND EXCLUSIVITY TERMS

ADB 71 of 191

PATENT USE

U-169	METHODS OF USING THE COMPOUND/DRUG PRODUCT AS A CONTRAST AGENT IN MAGNETIC RESONANCE IMAGING
U-170	METHOD OF OBTAINING AN MR IMAGE USING THE COMPOSITION/DRUG PRODUCT AS A CONTRAST AGENT
U-171	METHODS OF USING THE COMPOUND/DRUG PRODUCT AS AN ORAL CONTRAST AGENT IN MAGNETIC RESONANCE IMAGING OF THE GASTROINTESTINAL TRACT
U-172	TREATMENT OF GENITAL WARTS
U-173	ADMINISTRATION TO A HOST SUFFERING FROM GESTATIONAL DIABETES
U-174	USE AS AN ANTIHISTAMINE AGENT
U-175	METHOD OF TREATING MALIGNANT TUMORS
U-176	METHOD OF TREATING A PATIENT SUFFERING FROM LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOSES
U-177	FUNGICIDE
U-178	FACILITATED ADHERENCE OF AGENTS TO SKIN
U-179	ENHANCED CUTANEOUS PENETRATION OF A DERMALLY-APPLIED PHARMACOLOGICALLY ACTIVE AGENT
U-180	TREATMENT OF ADULT AND PEDIATRIC PATIENTS (OVER 6 MONTHS OF AGE) WITH ADVANCED HIV INFECTION
U-181	PRODUCING ALPHA ADRENERGIC ANTAGONISTIC ACTION IN A HOST
U-182	USE OF SALMETEROL IN PATIENTS WITH REVERSIBLE AIRWAY OBSTRUCTION
U-183	TREATMENT OF CONDITIONS CAUSED BY DISTURBANCE OF NEURONAL 5HT FUNCTION
U-184	TREATING ALLERGIC EYE DISEASES IN HUMANS
U-185	METHOD OF TREATING HYPERTENSION
U-186	METHOD FOR TREATING GI DISORDERS CAUSED BY H. PYLORI WHICH COMPRISES ADMINISTRATION OF RANITIDINE BISMUTH CITRATE AND CLARITHROMYCIN FOR A GREATER THAN ADDITIVE EFFECT
U-187	THERAPEUTIC TREATMENT OF CALCIFIC TUMORS
U-188	TREATMENT OF H.PYLORI ASSOCIATED DUODENAL ULCER
U-189	ENHANCEMENT OF THE BIOAVAILABILITY OF THE DRUG SUBSTANCE
U-190	USE OF RITONAVIR IN COMBINATION WITH ANY REVERSE TRANSCRIPTASE INHIBITOR
U-191	METHOD OF TREATMENT FOR CONTROLLING AND LOWERING INTRAOCULAR PRESSURE IN A HUMAN
U-192	USE IN TREATING ALLERGIC REACTIONS
U-193	PSORIASIS
U-194	TREATING ANGINA PECTORIS AND HIGH BLOOD PRESSURE
U-195	METHOD FOR THE DIAGNOSIS OF GASTROINTESTINAL DISORDERS BY UREA ISOTOPE OR NITROGEN LABELED CARBON
U-196	TREATMENT OF METASTATIC BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH ESTROGEN RECEPTOR POSITIVE TUMORS
U-197	USE IN COMBINATION WITH CERTAIN LHRH ANALOGUES FOR THE TREATMENT OF ADVANCED PROSTATE CANCER
U-198	TREATMENT METASTATIC CARCINOMA OF OVARY AFTER 1ST LINE FAILURE OR SUBSEQUENT CHEMOTHERAPY, TREATMENT OF BREAST CANCER AFTER FAILURE OF COMBINATION CHEMOTHERAPY FOR METASTATIC DISEASE AND 2ND LINE TREATMENT OF AIDS RELATED KAPOSI'S SARCOMA
U-199	METHOD OF TREATING INFECTIOUS UPPER GI TRACT DISORDERS CAUSED BY CAMPYLOBACTER PYLORIDIS INFECTION COMPRISING ADMINISTRATION OF A BISMUTH AGENT AND AN ANTIMICROBIAL AGENT
U-200	METHOD OF TREATING GI DISORDERS COMPRISING ADMINISTRATION OF A BISMUTH-CONTAINING AGENT AND H2 RECEPTOR BLOCKING ANTI-SECRETORY AGENT
U-201	METHOD OF TREATING GI DISORDERS COMPRISING ADMINISTRATION OF CAMPYLOBACTER-INHIBITING ANTIMICROBIAL AGENT AND H2 RECEPTOR BLOCKING ANTI-SECRETORY AGENT
U-202	METHOD OF TREATING PEPTIC ULCER DISEASE CAUSED BY CAMPYLOBACTER PYLORIDIS COMPRISING ORAL ADMINISTRATION OF 50 TO 5,000MG BISMUTH DAILY FOR 3-56 DAYS

PATENT AND EXCLUSIVITY TERMS

ADB 72 of 191

PATENT USE

U-203	TREATMENT OF ADVANCED BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH DISEASE PROGRESSION FOLLOWING ANTIESTROGEN THERAPY
U-204	USE OF TAXOL IN COMBINATION WITH G-CSF FOR TREATMENT OF PATIENTS WITH AIDS-RELATED KAPOSI'S SARCOMA
U-205	METHOD FOR TREATING HEARTBURN
U-206	METHOD OF USING FSH ALONE, WITHOUT THE PRESENCE OF EXOGENEOUS LH, IN IN VITRO FERTILIZATION
U-207	USE AS NASAL SPRAY
U-208	VAGINAL ADMINISTRATION USING SPECIFIED FORMULATION
U-209	VAGINAL ADMINISTRATION OF PROGESTERONE USING SPECIFIED FORMULATION
U-210	METHOD OF TREATING CONGESTIVE HEART FAILURE
U-211	USE IN PATIENTS WITH REVERSIBLE AIRWAY OBSTRUCTION
U-212	METHOD OF TREATMENT OF PARKINSON'S DISEASE
U-213	METHOD OF INHIBITING CHOLESTEROL BIOSYNTHESIS AND TREATING HYPERCHOLESTEROLEMIA AND METHOD FOR TREATING HYPERLIPIDEMIA
U-214	USE AS A BLOOD GLUCOSE-LOWERING AGENT
U-215	TREATMENT OF EPILEPSY TWICE DAILY. TREATING A PATIENT BY ADMINISTERING CARBAMAZEPINE IN A DOSAGE FORM CAPABLE OF MAINTAINING BLOOD CONCENTRATION FROM 4-12MCG/ML OVER 12 HOURS
U-216	TREATMENT OF ADENOCARCINOMA, INCLUDING STAGE B2-C BY ADMINISTERING AN AGONIST OF LH-RH AND FLUTAMIDE
U-217	METHOD OF PRODUCING ANESTHESIA
U-218	METHOD FOR LIMITING THE POTENTIAL FOR MICROBIAL GROWTH IN THE DRUG PRODUCT
U-219	TREATMENT OF PARKINSON'S DISEASE
U-220	METHOD OF DIAGNOSIS
U-221	SELECTIVE VASODILATION BY CONTINUOUS ADENOSINE INFUSION
U-222	METHOD OF TREATING PAGET'S DISEASE USING ACTONEL
U-223	TREATMENT OF BACTERIAL CONJUNCTIVITIS CAUSED BY SUSCEPTIBLE STRAINS OF MICROORGANISMS
U-224	CONTROLLING INTRAOCULAR PRESSURE
U-225	METHOD FOR DELIVERY
U-226	METHOD OF ENHANCING THE DISSOLUTION PROFILE OF A PHARMACEUTICAL FROM A SOLID DOSAGE FORM CONTAINING THE PHARMACEUTICAL AND SIMETHICONE
U-227	NASAL ADMINISTRATION
U-228	ASTHMA
U-229	CARDIAC INSUFFICIENCY (CONGESTIVE HEART FAILURE)
U-230	PREVENTION OF ACUTE CARDIAC ISCHEMIC EVENTS
U-231	USE IN PARKINSON'S DISEASE
U-232	METHOD OF TREATING MIGRAINE
U-233	DECREASING MORTALITY CAUSED BY CONGESTIVE HEART FAILURE
U-234	METHOD OF USING RIBAVIRIN TO TREAT VIRAL INFECTIONS IN MAMMALS
U-235	METHOD OF MODULATING TH1 AND TH2 RESPONSE IN ACTIVATED T CELLS OF A HUMAN COMPRISING ADMINISTERING RIBAVIRIN TO THE T CELLS IN A DOSAGE WHICH PROMOTES THE TH1 RESPONSE AND SUPPRESSES THE TH2 RESPONSE
U-236	TREATING MALE PATTERN BALDNESS WITH 0.05 TO 3.0MG/DAY
U-237	METHOD OF PERFORMING NMR IMAGING WITH A PATIENT COMPRISING ADMINISTERING TO THE PATIENT AN EFFECTIVE AMOUNT OF CONTRAST AGENT DISCLOSED IN THE CLAIMS
U-238	IMAGING A BODY TISSUE AND SUBJECTING TO NMR TOMOGRAPHY, ADMINISTERING AN AMOUNT OF PHARMACEUTICAL AGENT FOR AFFECTING THE RELAXATION TIMES OF ATOMS IN BODY TISSUES UNDERGOING NMR DIAGNOSIS, WHEREBY THE IMAGE CONTRAST IS ENHANCED....
U-239	TREATING OR CONTROLLING OCULAR INFLAMMATION WHICH COMPRISES TOPICALLY ADMINISTERING TO AFFECTED EYE A COMPOSITION COMPRISING AN NSAID, A POLYMERIC

PATENT AND EXCLUSIVITY TERMS

ADB 73 of 191

PATENT USE

	QUATERNARY AMMONIUM COMPOUND AND BORIC ACID
U-240	TREATMENT OF ACUTE MIGRAINE ATTACKS
U-241	FOR SHORT-TERM TREATMENT ACTIVE DUODENAL ULCER, MAINTENANCE THERAPY FOR DUODENAL ULCER PATIENTS AT REDUCED DOSAGE AFTER HEALING OF ACTIVE ULCER, SHORT-TERM TREATMENT ACTIVE BENIGN GASTRIC ULCER & GERD, PATHOLOGICAL HYPERSECRETORY CONDITIONS
U-242	USE OF FOLLITROPIN ALPHA ALONE IN IN-VITRO FERTILIZATION
U-243	TOPICAL ADMINISTRATION
U-244	PLATELET AGGREGATION INHIBITORS
U-245	TREATMENT OF SEBORRHEA DERMATITIS IN HUMANS
U-246	PHOSPHATE BINDING
U-247	TREATMENT OF RHEUMATOID ARTHRITIS
U-248	TREATMENT OF HIV
U-249	METHOD OF TREATING ALLERGIC OR NON-ALLERGIC RHINITIS IN PATIENTS BY ADMINISTERING AEROSOLIZED PARTICLES OF MOMETASONE FUROATE
U-250	TREATMENT OF HEPATITIS B INFECTION
U-251	USE OF TROGLITAZONE IN COMBINATION WITH SULFONYLUREAS IN THE TREATMENT OF TYPE II DIABETES
U-252	METHOD OF TREATING A HUMAN SUBJECT HAVING GAUCHER'S DISEASE
U-253	ORAL TRANSMUCOSAL USE
U-254	USE OF AGGRASTAT IN COMBINATION WITH HEPARIN
U-255	IMPROVED WAKEFULNESS IN PATIENTS WITH EXCESSIVE DAYTIME SLEEPINESS ASSOCIATED WITH NARCOLEPSY
U-256	TREATMENT OF HIV INFECTION IN COMBINATION WITH ONE OR MORE ADDITIONAL HIV ANTIVIRAL AGENTS
U-257	TREATMENT OF HIV INFECTION
U-258	TREATMENT OF NEURODEGENERATIVE DISEASES
U-259	TREATMENT OF ANDROGENIC ALOPECIA BY ORAL ADMINISTRATION DRUG SUBSTANCE
U-260	REDUCTION OF INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA AND OCULAR HYPERTENSION WHO ARE INTOLERANT OF OTHER IOP LOWERING MEDICATIONS OR INSUFFICIENTLY RESPONSIVE TO ANOTHER IOP LOWERING MEDICATION
U-261	TREATING BENIGN PROSTATIC HYPERPLASIA WITH A GENUS OF COMPOUNDS, INCLUDING FINASTERIDE
U-262	TREATING BENIGN PROSTATIC HYPERTROPHY WITH FINASTERIDE
U-263	METHOD OF TREATING A MALIGNANT CONDITION THROUGH INTRAVASCULAR ADMINISTRATION OF BUSULFAN. METHOD FOR TREATING LEUKEMIA OR LYMPHOMA IN A PATIENT UNDERGOING A BONE MARROW TRANSPLANT THROUGH INTRAVENOUS ADMINISTRATION OF BUSULFAN
U-264	METHOD OF TREATING A MALIGNANT DISEASE THROUGH PARENTERAL ADMINISTRATION OF BUSULFAN. METHOD FOR TREATING A PATIENT UNDERGOING A BONE MARROW TRANSPLANT THROUGH INTRAVASCULAR ADMINISTRATION OF BUSULFAN
U-265	USE AS LAXATIVE
U-266	RELIEF OF THE SIGNS AND SYMPTOMS OF OSTEOARTHRITIS; RELIEF OF THE SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS IN ADULTS; MANAGEMENT OF ACUTE PAIN IN ADULTS; TREATMENT OF PRIMARY DYSMENORRHEA; ACUTE TREATMENT OF MIGRAINE ATTACKS IN ADULTS
U-267	PREVENTING HEARTBURN EPISODES FOLLOWING INGESTION OF HEARTBURN-INDUCING FOOD/BEVERAGE, COMPRISING ADMIN TO PT, 30 MIN PRIOR TO CONSUMPTION BY THE PT THE FOOD/BEVERAGE, A COMPOSITION COMPRISING 10MG FAMOTIDINE
U-268	ACROMEGALY
U-269	EXCESS GH-SECRETION OR GASTRO-INTESTINAL DISORDERS
U-270	METHOD OF IMPROVING THE TIME FOR ADMINISTRATION OR THE TIME BETWEEN CHANGES OF GIVING SETS FOR THE DRUG PRODUCT
U-271	METHOD OF TREATING TUMORS
U-272	METHOD OF TREATING CARCINOMA

PATENT AND EXCLUSIVITY TERMS

ADB 74 of 191

PATENT USE

U-273	CUTANEOUS T-CELL LYMPHOMA
U-274	ZANAMIVIR FOR INHALATION
U-275	METHOD OF USE OF THE DRUG SUBSTANCE
U-276	METHOD OF USE OF LEVOBUPIVACAINE
U-277	NEUROLOGICAL AND OTHER DISORDERS (TREATMENT OF EPILEPSY, BID ORAL DOSING)
U-278	METHOD OF USE OF THE INDICATION OF THE DRUG PRODUCT
U-279	METHOD OF USE OF THE APPROVED PRODUCT
U-280	TREATING PRECIPITATED ACUTE URINARY RETENTION WITH FINASTERIDE
U-281	ANTIMYCOTIC USES, SPECIFICALLY TREATMENT OF ONYCHOMYCOSIS
U-282	METHOD OF TREATING BACTERIAL INFECTIONS
U-283	METHOD FOR TREATING MENOPAUSAL SYMPTOMS IN A POSTMENOPAUSAL FEMALE
U-284	MENOPAUSAL AND POSTMENOPAUSAL DISORDERS (INCLUDING VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE, AND VULVAR AND VAGINAL ATROPHY) AND OSTEOPOROSIS
U-285	DEPRESSION AND SOCIAL ANXIETY DISORDER/SOCIAL PHOBIA
U-286	DEPRESSION
U-287	TREATMENT OR PREVENTION OF OSTEOPOROSIS
U-288	THERAPY OF INFLUENZA
U-289	TREATMENT OF NON-HYPERKERATOTIC ACTINIC KERATOSES OF FACE AND SCALP
U-290	INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS)
U-291	INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH CYCLOSPORIN
U-292	INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH AZATHIOPRINE
U-293	INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH A CORTICOSTEROID
U-294	TREATMENT OF HYPERPIGMENTARY DISORDERS
U-295	TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS
U-296	TREATING MIGRAINE PAIN AND ONE OR MORE OF A CLUSTER OF SYMPTOMS CHARACTERISTIC OF A MIGRAINE ATTACK SYMPTOMS BEING SELECTED FROM PHOTOPHOBIA, PHONOPHOBIA NAUSEA AND FUNCTIONAL DISABILITY
U-297	PREVENTION OR TREATMENT OF REVERSIBLE VASOCONSTRICTION BY THE INHALATION OF NITRIC OXIDE WITH AN OXYGEN CONTAINING GAS
U-298	METHOD OF COMBATING BACTERIA IN A PATIENT
U-299	TREATMENT OF ADENOMATOUS POLYPS
U-300	INDICATED FOR THE REDUCTION OF ELEVATED TOTAL AND LDL CHOLESTEROL LEVELS IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA
U-301	USE OF TROGLITAZONE IN COMBINATION WITH SULFONYLUREAS AND BIGUANIDES IN THE TREATMENT OF TYPE II DIABETES
U-302	TO REDUCE THE RISK OF STROKE IN PATIENTS WHO HAVE HAD TRANSIENT ISCHEMIA OF THE BRAIN OR COMPLETED ISCHEMIC STROKE DUE TO THROMBOSIS
U-303	METHOD OF USE PATENT-PRODUCT APPROVED FOR TREATMENT OF OSTEOPOROSIS, PAGET'S DISEASE, PREVENTION AND TREATMENT OF GLUCOCORTICOID INDUCED OSTEOPOROSIS
U-304	A METHOD OF TREATMENT OF A CONDITION INVOLVING AN ANTIBODY ANTIGEN REACTION
U-305	METHODS FOR USING THE DRUG PRODUCT
U-306	TREATMENT OF POST-MENOPAUSAL UROGENITAL SYMPTOMS ASSOCIATED WITH ESTROGEN DEFICIENCY
U-307	CLAIMS AN OLANZAPINE POLYMORPH USEFUL FOR TREATING ANY NUMBER OF LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOSES, EMPLOYING OLANZAPINE AS PER THE INDICATION OF THIS NDA
U-308	CLAIMS A SOLID ORAL FORMULATION INCLUDING TABLETS AND GRANULES OF OLANZAPINE USEFUL FOR TREATING ANY NUMBER OF LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOSES, EMPLOYING OLANZAPINE AS PER THE INDICATIONS OF THIS NDA

PATENT AND EXCLUSIVITY TERMS

ADB 75 of 191

PATENT USE

U-309	TREATING SJOEGREN SYNDROME
U-310	TREATMENT OF XEROSTOMIA
U-311	HORMONE REPLACEMENT
U-312	PANIC DISORDER, OBSESSIVE-COMPULSIVE DISORDER, POSTTRAUMATIC STRESS DISORDER
U-313	TREATMENT OF CONGESTIVE HEART FAILURE
U-314	METHOD FOR TREATING HYPERPARATHYROIDISM WHICH COMPRISES SUPPRESSING PARATHYROID ACTIVITY
U-315	METHOD FOR ADMINISTERING DRUG TO GASTROINTESTINAL TRACT
U-316	METHOD OF TREATING A SUBJECT SUFFERING FROM PROSTATE CANCER
U-317	METHOD OF USING TROGLITAZONE TO TREAT PATIENTS HAVING INSULIN RESISTANCE
U-318	TREATMENT OF PATIENTS WITH AN OVERACTIVE BLADDER WITH SYMPTOMS OF URINARY FREQUENCY, URGENCY, OR URGE INCONTINENCE
U-319	TREATMENT OF MICROBIAL INFECTIONS
U-320	INHIBITING OR ELIMINATING ACUTE MYELOID LEUKEMIA
U-321	REDUCTION OF ELEVATED IPTH LEVELS IN THE MGT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS UNDERGONG CHRONIC RENAL DIALYSIS
U-322	TREATMENT OF ALZHEIMER'S DEMENTIA
U-323	USE AS A BILE ACID SEQUESTRANT
U-324	METHOD OF TREATING AN ANIMAL, INCLUDING A HUMAN, SUFFERING FROM OR SUSCEPTIBLE TO PSYCHOSIS OR ACUTE MANIA EMPLOYING OLANZAPINE
U-325	METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED CONDITIONS, INCLUDING "BIPOLAR DISORDER NOS" EMPLOYING OLANZAPINE
U-326	METHOD OF TREATING SCHIZOPHRENIA AND BIPOLAR DISORDER
U-327	METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED PSYCHOTIC CONDITONS EMPLOYING OLANZAPINE
U-328	METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED CONDITIONS INCLUDING "A PSYCHOTIC CONDITION" EMPLOYING AN OLANZAPINE POLYMORPH
U-329	USE OF AVANDIA AS MONOTHERAPY, IN COMBINATION WITH METFORMIN, AND IN COMBINATION WITH SULFONYLUREAS TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
U-330	TREATMENT OF NAUSEA AND VOMITING
U-331	METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
U-332	TREATMENT OR PREVENTION OF BRONCHOSPASM
U-333	METHOD OF TREATING OCULAR HYPERTENSION
U-334	TREATMENT OF EXCESSIVE FEMALE FACIAL HAIR
U-335	USE OF PRAVASTATIN SODIUM FOR SECONDARY PREVENTION OF CORONARY EVENTS IN MEN AND WOMEN WHO HAVE HAD A MYOCARDIAL INFARCTION AND HAVE NORMAL CHOLESTEROL LEVELS
U-336	DIAGNOSTIC RADIOIMAGING
U-337	USE OF CARDIOLITE/MIRALUMA KIT FOR THE PREPARATION OF TC99M SESTAMIBI
U-338	METHODS FOR TREATING DISTURBANCES OF MOOD, DISTURBANCES OF APPETITE, DEPRESSED MOOD, OR CARBOHYDRATE CRAVING ALL ASSOCIATED WITH PREMENSTRUAL SYNDROME
U-339	PREVENTION OF CARDIO-TOXICITY CAUSED BY THE ADMINISTRATION OF DOXORUBICIN
U-340	THE LONG TERM TREATMENT OF GROWTH FAILURE DUE TO LACK OF ADEQUATE ENDOGENOUS GROWTH HORMONE SECRETION IN CHILDREN
U-341	METHOD FOR ENHANCING THE TREATMENT OF ... LATE LUTEAL PHASE DYSPHORIC DISORDER
U-342	METHOD FOR TREATMENT OF LATE LUTEAL PHASE DYSPHORIC DISORDER
U-343	REDUCTION OF INTESTINAL GAS, CRAMPING AND ANORECTAL IRRITATION
U-344	METHOD FOR INHIBITING HIV INFECTION BY ADMINISTERING RITONAVIR IN COMBINATION WITH ANOTHER HIV PROTEASE INHIBITOR
U-345	RITONAVIR AND ANOTHER HIV PROTEASE INHIBITOR FOR CONCOMITANT ADMINISTRATION FOR THE TREATMENT OF AN HIV INFECTION

PATENT AND EXCLUSIVITY TERMS

ADB 76 of 191

PATENT USE

U-346	METHOD FOR INHIBITING CYTOCHROME P450 MONOOXYGENASE WITH RITONAVIR AND A METHOD FOR IMPROVING THE PHARMACOKINETICS OF A DRUG THAT IS METABOLIZED BY CYTOCHROME P450 MONOOXYGENASE BY ADMIN THE DRUG AND RITONAVIR
U-347	METHOD OF USE IN COMBINATION WITH REVERSE TRANSCRIPTASE INHIBITORS
U-348	METHOD OF USE FOR INHIBITING HIV INFECTION
U-349	METHOD OF USE WHICH IS SUBJECT OF THE APPLICATION
U-350	PREPARATION OF A PHARMACEUTICAL COMPOSITION FOR CONCOMITANT ADMIN WITH A REVERSE TRANSCRIPTASE INHIBITOR
U-351	INHIBITING PROTEASE WITH LOPINAVIR AND INHIBITING AN HIV INFECTION WITH LOPINAVIR
U-352	INHIBITING HIV INFECTION BY ADMINISTERING RITONAVIR IN COMBINATION WITH A REVERSE TRANSCRIPTASE INHIBITOR
U-353	PREVENTION AND TREATMENT OF OSTEOPOROSIS
U-354	METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID WITHOUT CAUSING TREATMENT-LIMITING ELEVATIONS IN URIC ACID OR GLUCOSE LEVELS OR CAUSING LIVER DAMAGE, BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
U-355	METHOD OF ASSISTING PERSON TO QUIT SMOKING...TRANSDERMALLY ADMIN NICOTINE VIA..PATCH ADHERED TO SKIN AT DOSING RATE APPROX SAME AS ABSORBED FROM SMOKING
U-356	DELIVERING A MEDICINAL AEROSOL FORMULATION USING CFC-FREE PROPELLANT 134A.
U-357	USE OF THE DRUG PRODUCT IN PHOTODYNAMIC THERAPEUTIC PROTOCOLS FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND RELATED CONDITIONS INVOLVING UNWANTED NEOVASCULATURE IN THE EYE
U-358	DEPRESSION, OBSESSIVE COMPULSIVE DISORDER, PANIC DISORDER AND SOCIAL ANXIETY DISORDER
U-359	METHOD OF USE OF VISICOL
U-360	METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF PATHOLOGICAL PSYCHOLOGICAL CONDITIONS INCLUDING MENTAL DISORDERS EMPLOYING OLANZAPINE AS PER THE INDICATION WHICH IS THE SUBJECT MATTER OF THIS SNDA-011
U-361	MANAGEMENT OF ANXIETY DISORDERS AND THE SHORT-TERM RELIEF OF THE SYMPTOMS OF ANXIETY
U-362	USE OF APPROVED FORMULATIONS TO TREAT ALL APPROVED DISEASE INDICATIONS
U-363	METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF PATHOLOGICAL PSYCHOLOGICAL CONDITIONS THAT RELATE TO THE USE OF A PSYCHOACTIVE SUBSTANCE EMPLOYING OLANZAPINE AS PER THE INDICATION THE SUBJECT MATTER OF SUPPLEMENT 011
U-364	TREATING A PATIENT SUFFERING FROM OR SUSCEPTIBLE TO ANY NUMBER OF LISTED CONDITIONS INCLUDING PSYCHOSIS, EMPLOYING OLANZAPINE AS PER THE INDICATION WHICH IS THE SUBJECT MATTER OF THIS SNDA-011
U-365	METHOD FOR THE TREATMENT OF CARDIOVASCULAR DISEASE THROUGH THE ADMINISTRATION OF A CALCIUM BLOCKING VASODILATOR IN OUR EXTENDED, CONTROLLED RELEASE FORMULATION
U-366	METHOD FOR THE TREATMENT OF CARDIOVASCULAR DISEASE THROUGH THE ADMINISTRATION OF A CALCIUM BLOCKING VASODILATOR IN A DELAYED RELEASE FORMULATION
U-367	TREATMENT OF CARDIOVASCULAR DISORDERS
U-368	HEARTBURN
U-369	METHOD OF CONTROLLING AND LOWERING INTRAOCULAR PRESSURE
U-370	INTRAVAGINAL TREATMENT OF VAGINAL INFECTIONS WITH BUFFERED METRONIDAZOLE COMPOSITIONS
U-371	APPROVAL FOR MARKETING ONLY UNDER A SPECIAL RESTRICTION PROGRAM APPROVED BY FDA CALLED "SYSTEM FOR THALIDOMIDE EDUCATION AND PRESCRIBING SAFETY" (S.T.E.P.S.)
U-372	METHOD FOR ADMINISTERING A BENEFICIAL DRUG TO THE GI TRACT OF AN ANIMAL, WHICH METHOD COMPRISES ADMITTING AN OSMOTIC DEVICE ORALLY INTO THE ANIMAL...
U-373	GENERAL USE CLAIM SUBMITTED FOR 12 NEXIUM PATIENTS STATING "PERTINENT TO THE CAPSULE FORMULATION FOR NEXIUM AND ITS INDICATIONS FOR THE TREATMENT OF GERD AND ERADICATION OF H.PYLORI TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE
U-374	KIT ADAPTED AND DESIGNED TO PROVIDE BOTH DATA ON THE CURRENT REPRODUCTIVE STATUS OF A PATIENT AND CONTRACEPTION FOR THOSE WHO ARE NOT PREGNANT, BUT RECENTLY ENGAGED IN UNPROTECTED SEX

PATENT AND EXCLUSIVITY TERMS

ADB 77 of 191

PATENT USE

U-375	METHOD OF USING RIBAVIRIN FOR TREATING A DISEASE RESPONSIVE TO RIBAVIRIN, E.G. HEPATITIS C
U-376	TREATMENT OF INFLUENZA
U-377	METHOD OF TREATING PT WITH CHRONIC HEPATITIS C HAVING HCV GENOTYPE 1 AND VIRAL LOAD GREATER THAN 2 MILLION COPIES/ML TO ERADICATE DETECTABLE HCV-RNA BY ADMIN COMBINATION OF RIBAVIRIN AND INTERFERON ALFA-2B FOR A LEAST 24 WEEKS
U-378	METHOD FOR TREATING INCONTINENCE
U-379	METHOD OF TREATING ONYCHOMYCOSIS
U-380	COMBINATIONS OF TAXOL (PACLITAXEL) AND CISPLATIN WHICH ARE SUITABLE FOR THE TREATMENT OF OVARIAN AND NON-SMALL CELL LUNG CARCINOMAS
U-381	TREATMENT OF HYPERPHOSPHATEMIA
U-382	METHOD OF STABILIZING PROSTAGLANDIN
U-383	METHOD FOR TREATING GLAUCOMA AND OCULAR HYPERTENSION
U-384	TREATMENT OF CMV RETINITIS
U-385	TREATMENT OF PEPTIC ULCERS
U-386	TREATMENT OF PATIENTS SUFFERING FROM A LATE ASTHMATIC REACTION OR LATE PHASE ASTHMA
U-387	TREATMENT OF PATIENTS WITH RESPIRATORY DISORDERS
U-388	SMOKING CESSATION AID APPLIED TO THE SKIN
U-389	SMOKING CESSATION AID APPLIED TO THE SKIN ON WAKING AND REMOVED PRIOR TO SLEEP AFTER ABOUT 16 HOURS
U-390	METHOD OF USING THE DRUG TO TREAT NEUROIMMUNOLOGIC DISEASES (INCLUDING MULTIPLE SCLEROSIS)
U-391	USE OF CASODEX IN COMBINATION WITH LHRH AGONISTS FOR THE TREATMENT OF PROSTATE CANCER
U-392	TREATMENT OF PATIENTS FOR INFLAMMATION
U-393	MANAGEMENT OF INCONTINENCE, MGT OF HORMONE REPLACEMENT THERAPY, TREATMENT OF INVOLUNTARY INCONTINENCE, MGT OVERACTIVE BLADDER AND INCREASING COMPLIANCE IN SUCH PT
U-394	METHOD OF USE OF ALPHAGAN
U-395	METHOD OF USE OF ALPHAGAN P
U-396	METHOD OF TREATING PEOPLE SUFFERING FROM DEPRESSION
U-397	METHOD OF TREATING PEOPLE SUFFERING FROM DEPRESSION WITHOUT AN INCREASE IN NAUSEA
U-398	TREATMENT OF GENERALIZED ANXIETY DISORDER
U-399	IN-THE-EYE USE OF CHLORINE DIOXIDE CONTAINING COMPOSITIONS
U-400	USE OF RIBAVIRIN TO INCREASE TYPE 1 CYTOKINE RESPONSE AND SUPPRESS TYPE 2 CYTOKINE RESPONSE TO LYMPHOCYTES, INCLUDING METHODS THAT TAKE ADVANTAGE OF SUCH MODULATION TO TREAT INFECTIONS AND INFESTATIONS
U-401	USE OF LOPINAVIR IN COMBINATION WITH REVERSE TRANSCRIPTASE INHIBITORS FOR TREATING HIV INFECTION AND IN COMBO WITH OTHER HIV PROTEASE INHIBITORS
U-402	TREATMENT OF ACTINIC KERATOSES
U-403	ANTI-ALLERGIC FOR VARIOUS ALLERGIC DISEASES
U-404	TREATMENT OF ALLERGIC CONJUNCTIVITIS
U-405	FOR WOMEN WITH SEVERE DIARRHEA-PREDOMINANT IRRITABLE BOWEL SYNDROME (IBS)
U-406	METHOD OF USE OF ATOVAQUONE AND PROGUANIL
U-407	METHOD OF TREATING OTOPATHY
U-408	FOR INDUCING OVULATION IN CONJUNCTION WITH A GONADOTROPIN RELEASING FACTOR ANTAGONIST AND RECRUITING OOCYTES FOR IN-VITRO FERTILIZATION
U-409	METHOD OF TREATING INFLAMMATION USING DRUG SUBSTANCE
U-410	METHOD OF REDUCING AMOUNT OF RESPECTIVE ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR

PATENT AND EXCLUSIVITY TERMS

ADB 78 of 191

PATENT USE

FORMULA (INCLUDING PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER

- U-411 METHOD OF REDUCING THE SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (WHICH INCLUDES PIOGLITAZONE) IN COMBINATION WITH AN INSULIN PREPARATION
- U-412 TREATMENT OF TYPE 2 DIABETES
- U-413 USE OF THE ACTIVE INGREDIENT FOR INHIBITING THE BIOSYNTHESIS OF CHOLESTEROL AND TREATMENT OF ATHEROSCLEROSIS
- U-414 A METHOD OF TREATING GLYCOMETABOLISM DISORDERS BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE
- U-415 A METHOD FOR REDUCING THE AMOUNT OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE AS SAID ACTIVE COMPONENTS
- U-416 A METHOD FOR REDUCING SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE AS SAID ACTIVE COMPONENTS
- U-417 COMBINATION USE OF AD-4833 WITH A BIGUANIDE
- U-418 A METHOD OF TREATING LIPID METABOLISM DISORDERS BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (WHICH INCLUDES PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER
- U-419 A METHOD OF TREATING LIPID METABOLISM DISORDERS BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE
- U-420 METHOD OF TREATMENT OF TYPE II DIABETES
- U-421 USE FOR SEDATION
- U-422 METHOD OF TREATING AT LEAST ONE OF ATTENTION DEFICIT DISORDER AND ATTENTION DEFICIT HYPERACTIVITY DISORDER
- U-423 METHOD OF TREATING AT LEAST ONE OF ATTENTION DEFICIT DISORDER, ATTENTION DEFICIT HYPERACTIVITY DISORDER, OR AIDS RELATED DEMENTIA
- U-424 FOR ONCE DAILY, BOLUS ADMINISTRATION TO A PATIENT IN ORDER TO ENGENDER TREATMENT FOR A NERVOUS DISORDER FOR SUBSTANTIALLY AN ENTIRE DAY ON A CHRONIC BASIS
- U-425 METHOD OF REDUCING SIDE EFFECTS OF ACTIVE COMPONENTS ADMIN TO A DIABETIC BY ADMIN A CHEMICAL COMPOUND HAVING FORMULA (INCL PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER
- U-426 PREVENTION OF PREMATURE LH SURGES IN WOMEN UNDERGOING CONTROLLED OVARIAN STIMULATION
- U-427 METHOD OF TREATING ALLERGIC REACTIONS IN MAMMALS
- U-428 METHOD OF TREATING ALLERGY IN A MAMMAL USING THIS ACTIVE METABOLITE
- U-429 METHOD OF USING DESLORATADINE TO TREAT ALLERGIC RHINITIS
- U-430 METHOD OF TREATING A DIABETIC BY ADMINISTERING AN INSULIN SENSITIZER IN COMBINATION WITH AN INSULIN SECRETION ENHANCER, AND A DRUG PRODUCT COMPRISING AN INSULIN SENSITIZER AND AN INSULIN SECRETION ENHANCER
- U-431 POSTTRAUMATIC STRESS DISORDER
- U-432 REDUCTION OF ATHEROSCLEROTIC EVENTS (MYOCARDIAL INFARCTION, STROKE, AND VASCULAR DEATH) IN PATIENTS WITH ATHEROSCLEROSIS DOCUMENTED BY RECENT STROKE, RECENT MYOCARDIAL INFARCTION OR ESTABLISHED PERIPHERAL ARTERIAL DISEASE
- U-433 USE OF LEVOCARNITINE IN PREVENTION AND TREATMENT OF CARNITINE DEFICIENCY IN PATIENTS WITH END STAGE RENAL DISEASE WHO ARE UNDERGOING DIALYSIS
- U-434 CONTROLLED SYMPTOMS OF DIARRHEA, BLOATING PRESSURE AND CRAMPS, COMMONLY REFERRED TO AS GAS
- U-435 A TITRATION DOSING REGIMEN FOR THE TREATMENT OF PAIN USING AN INITIAL DOSE OF ABOUT 25MG
- U-436 ACUTE TREATMENT OF MIGRAINE ATTACKS WITH OR WITHOUT AURA IN ADULTS
- U-437 METHOD OF USE EQUAL TO PROCESS OF PREPARATION
- U-438 TREATMENT/PREVENTION OF NEURODEGENERATIVE DISEASE
- U-439 TREATMENT OF OBESITY

PATENT AND EXCLUSIVITY TERMS

ADB 79 of 191

PATENT USE

U-440	METHOD FOR TRANSDERMAL ADMINISTRATION OF A DRUG THROUGH NON-SCROTAL SKIN USING A TRANSDERMAL DRUG DELIVERY DEVICE CONTAINING THE DRUG AND HAVING AN ADHESIVE SURFACE
U-441	METHOD OF TREATING MS BY ADMINISTERING COPAXONE
U-442	METHOD FOR DELIVERING A DRUG TO A PATIENT IN NEED OF THE DRUG, WHILE AVOIDING THE OCCURRENCE OF AN ADVERSE SIDE EFFECT KNOWN OR SUSPECTED OF BEING CAUSED BY SAID DRUG
U-443	MANAGEMENT OF MODERATE TO SEVERE PAIN WHEN A CONTINUOUS, AROUND-THE-CLOCK ANALGESIC IS NEEDED FOR AN EXTENDED PERIOD OF TIME
U-444	TREATMENT OF MIGRAINE
U-445	USE AS AN ANTIMYCOTIC AGENT
U-446	TOPICAL TREATMENT OF OCULAR HYPERTENSION AND GLAUCOMA
U-447	METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
U-448	METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID WITHOUT CAUSING TREATMENT-LIMITING ELEVATIONS IN URIC ACID OR GLUCOSE LEVELS OR CAUSING LIVER DAMAGE, BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
U-449	USE IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER WHERE THE DOSE OF LEUCOVORIN IS AT LEAST 200MG PER SQUARE METER
U-450	INTERMEDIATE REL NICOTINIC ACID FORMULATIONS HAVING UNIQUE URINARY METAB PROFILES RESULTING FROM ABSORPTION PROFILES OF NICOTINIC ACID FROM THE INTERMEDIATE NICOTINIC ACID FORMULATIONS,SUITABLE FOR TX HYPERLIPIDEMIA FOLLOWING QD DOSING
U-451	TREATMENT OF DEPRESSION AND GENERALIZED ANXIETY DISORDER
U-452	USE OF LANSOPRAZOLE FOR COMBATTING DISEASES CAUSED BY THE GENUS CAMPYLOBACTER (C.PYLORI=H.PYLORI)
U-453	TREATMENT OF PLATELET ASSOCIATED ISCHEMIC DISORDERS
U-454	METHOD OF TX A PT SUSPECTED OF HAVING HEPATITIS C BY ADMIN, IN COMBINATION, A CONJUGATE COMPRISING PEG 12000 & INTERFERON ALFA-2B IN AN AMT OF FROM 0.5MCG/KG TO 2MCG/KG, ONCE WEEKLY, AND RIBAVIRIN
U-455	TREATMENT OF PULMONARY HYPERTENSION WITH UT-15
U-456	METHOD OF DECREASING THE PRODUCTION OF A-BETA USING A COMPOSITION WHICH DECREASES BLOOD CHOLESTEROL IN PATIENTS AT RISK OF OR EXHIBITING SYMPTOMS OF ALZHEIMER'S DISEASE
U-457	METHOD OF TREATING A VAGINAL FUNGAL INFECTION IN A FEMALE HUMAN
U-458	METHOD OF USE OF IMAGENT
U-459	TREATMENT OF DEPRESSION AND GENERALIZED ANXIETY DISORDER
U-460	METHOD OF TREATING PSYCHIATRIC SYMPTOMS ASSOCIATED WITH PREMENSTRUAL DISORDERS USING SERTRALINE
U-461	METHOD OF TREATMENT OF LATE LUTEAL PHASE DYSPHORIC DISORDER (PMDD) USING SERTRALINE
U-462	SIGNS AND SYMPTOMS OF OSTEOARTHRITIS AND ADULT RHEUMATOID ARTHRITIS AND TREATMENT OF PRIMARY DYSMENORRHEA
U-463	VENOGRAPHY
U-464	PERIPHERAL ARTERIOGRAPHY
U-465	CT IMAGING OF THE HEAD
U-466	TREATMENT OF IRRITABLE BOWEL SYNDROME
U-467	USE OF EPLERENONE IN COMBINATION WITH AN ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITOR FOR TREATING HYPERTENSION
U-468	METHOD OF USING FEXOFENADINE HCL IN TREATING ALLERGIC RHINITIS
U-469	TREATMENT OF GASTROESOPHAGEAL REFLEX DISEASE (GERD) AND ERADICATION OF H.PYLORI TO REDUCE RISK OF DUODENAL ULCER RECURRENCE
U-470	THERAPY IN CHRONIC HEPATITIS B VIRUS INFECTION

PATENT AND EXCLUSIVITY TERMS

ADB 80 of 191

PATENT USE

U-471	METHOD OF TREATING A PATIENT SUFFERING FROM DIABETES MELLITUS
U-472	TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER USING METHYLPHENIDATE BI-MODAL RELEASE PROFILE EXTENDED-RELEASE CAPSULES
U-473	TO REDUCE PLASMA CHOLESTEROL LEVELS IN A MAMMAL
U-474	TO REDUCE PLASMA CHOLESTEROL LEVELS BY ADMIN EZETIMIBE IN COMBO WITH CHOLESTEROL BIOSYNTHESIS INHIB SELECTED FROM GROUP CONSISTING OF HMG COA REDUCTASE INHIBITORS INCL SIMVASTATIN
U-475	TREATMENT OF CUTANEOUS MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PATIENTS WHO ARE REFRACTORY TO AT LEAST ONE PRIOR SYSTEMIC THERAPY
U-476	METHOD OF TREATING ANDROGEN RESPONSIVE/MEDIATED CONDITION IN MAMMAL BY ADMIN A SAFE, EFFECTIVE AMOUNT OF DUTASTERIDE OR PHARMACEUTICALLY ACCEPTABLE DERIVATIVE THEREOF..CONDITIONS INCLUDE BENIGN PROSTATIC HYPERTROPHY
U-477	METHOD OF INHIBITING 5 ALPHA TESTOSTERONE REDUCTASE ENZYME WITH DUTASTERIDE OR ITS DERIVATIVE AND TREATING ANDROGEN RESPONSIVE/MEDIATED DISEASE INCLUDING BENIGN PROSTATIC HYPERPLASIA
U-478	METHOD OF TREATING HEPATITIS C VIRAL INFECTION BY CONTINUOUS PARENTERAL ADMIN INTERFERON ALPHA 2-10 MILLION IU WEEKLY, SUBCUTANEOUSLY, INJECTION OF POLYMER-INTERFERON ALPHA CONJUGATE-POLYMER IS PEG-INTERFERON IS ALPHA 2B
U-479	METHOD OF USING PEG-INTRON/REBETOL COMBINATION THERAPY AND INTRON/REBETOL COMBINATION THERAPY
U-480	CONTRAST AGENT FOR MRI
U-481	DISUBSTITUTED ACETYLENES BEARING HETEROAROMATIC AND HETEROBICYCLIC GROUPS HAVING RETINOID-LIKE ACTIVITY
U-482	METHOD OF IN VITRO FERTILIZATION THERAPY INCLUDING MEANS FOR INDUCING OVULATION....
U-483	METHOD FOR THE ADMINISTRATION OF DRUGS USING THAT COMPOUND
U-484	METHOD OF TREATING A SKIN DISEASE WITH A CORTICOSTEROID-CONTAINING PHARMACEUTICAL COMPOSITION
U-485	METHOD AND COMPOSITION FOR REDUCING NERVE INJURY PAIN ASSOCIATED WITH SHINGLES (HERPES ZOSTER AND POST-HERPETIC NEURALGIA)
U-486	EXTERNAL PREPARATION FOR APPLICATION TO THE SKIN CONTAINING LIDOCAINE-DRUG RETAINING LAYER PLACED ON SUPPORT AND COMPRISES ADHESIVE GEL BASE 1-10% BY WEIGHT OF LIDOCAINE
U-487	METHOD AND COMPOSITION FOR REDUCING NERVE INJURY PAIN ASSOCIATED WITH SHINGLES (HERPES ZOSTER AND POST-HERPETIC NEURALGIA)
U-488	METHOD FOR REDUCING THE PAIN ASSOCIATED WITH HERPES-ZOSTER AND POST-HERPETIC NEURALGIA
U-489	EXPECTORANT
U-490	TESTOSTERONE REPLACEMENT THERAPY IN MALES FOR CONDITIONS ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE
U-491	METHOD OF DELIVERING A DRUG TO THE LUNG
U-492	METHOD FOR THE TREATMENT OF SKIN, SUFFERING FROM A CONDITION SELECTED FROM A GROUP CONSISTING OF NONACNE INFLAMMATORY DERMATOSES... COMPRISING APPLYING TO AFFECTED AREA. A THERAPEUTICALLY EFFECTIVE AMT AZELAIC ACID
U-493	TREATMENT OF TYPE 2 DIABETES MELLITUS
U-494	TREATMENT OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER
U-495	PERITONEAL DIALYSIS SOLUTION
U-496	METHOD FOR TREATING CHRONIC RENAL FAILURE
U-497	RELIEF OF THE SIGNS AND SYMPTOMS OF OSTEOARTHRITIS AND RHEUMATOID ARTHRITIS
U-498	INTRA-ARTERIAL AND INTRAVENOUS USES OF ULTRAVIST
U-499	METHOD OF USING REBETOL CAPSULES IN COMBINATION WITH A CONJUGATE COMPRISING POLYETHYLENE GLYCOL(PEG) AND AN ALPHA INTERFERON, INCLUDING, FOR EXAMPLE, PEG-INTRON POWDER FOR INJECTION
U-500	USE AS AN ANTIHYPERTENSIVE AGENT
U-501	TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) IN ADULTS

PATENT AND EXCLUSIVITY TERMS

ADB 81 of 191

PATENT USE

U-502 PITYRIASIS VERSICOLOR

U-503 GENERATOR MUST BE USED WITH INFUSION SYSTEM SPECIFICALLY LABELED FOR USE WITH GENERATOR

U-504 TINEA PEDIS, TINEA CRURIS, TINEA CORPORIS

U-505 ULTRASOUND CONTRAST AGENT

U-506 PHARM PRODUCT CONTAINER 1ST CHAMBER IS DISPOSED AQUEOUS DILUENT SOL 2ND CHAMBER PHARM ACTIVE AGENT COMPRISING ACETYLCHOLINE, BUFFER IN 1ST CHAM IS SUFFICIENT TO BUFFER PH OF MIXED SOL RESULTING MIXTURE OF AQUEOUS DILUENT SOL & PHARM ACTIVE..

U-507 ACROMEGALY IN PATIENTS W/INADEQUATE RESPONSE TO SURGERY AND/OR RADIATION THERAPY AND/OR MEDICAL THERAPIES, OR FOR WHOM THESE THERAPIES ARE NOT APPROPRIATE

U-508 METHOD OF RELEASING 17-BETA OESTRADIOL PRECURSOR IN A SUBSTANTIALLY ZERO ORDER PATTERN FOR AT LEAST THREE WEEKS

U-509 TREATMENT OF CUTANEOUS MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PATIENTS WHO ARE REFRACTORY TO AT LEAST ONE PRIOR SYSTEMIC THERAPY

U-510 TOPICAL TREATMENT OF CUTANEOUS LESIONS IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA (STAGE IA AND IB) WHO HAVE REFRACTORY OR PERSISTENT DISEASE AFTER OTHER THERAPIES OR WHO HAVE NOT TOLERATED OTHER THERAPIES

U-511 USE OF QUINOLONE COMPOUNDS AGAINST ANAEROBIC PATHOGENIC BACTERIA

U-512 USE OF QUINOLONE COMPOUNDS AGAINST ATYPICAL UPPER RESPIRATORY PATHOGENIC BACTERIA

U-513 METHODS OF USE OF ANTIMICROBIAL COMPOUNDS AGAINST PATHOGENIC MYCOPLASMA BACTERIA

U-514 PREVENTION OF OVULATION IN A WOMAN

U-515 TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEAST TWO PRIOR THERAPIES AND HAVE DEMONSTRATED DISEASE PROGRESSION ON THE LAST THERAPY

U-516 METHOD OF TREATING A PSYCHOTIC DISEASE

U-517 STABLE GEL FORMULATION FOR TOPICAL TREATMENT OF SKIN CONDITIONS

U-518 OBSESSIVE COMPULSIVE DISORDER

U-519 POST OPERATIVE NAUSEA AND VOMITING

U-520 PREMENOPAUSAL OSTEOPOROSIS

U-521 METHOD OF USING RIBAVIRIN IN COMBINATION WITH INTRON A (INTERFERON ALPHA-2 B RECOMBINANT) INJECTION TO TREAT PATIENTS WITH CHRONIC HEPATITIS C

U-522 TREATMENT OF CMV RETINITIS BY INTRAVITREAL ADMIN OF A PHOSPHOROTHIOATE OLIGONUCLEOTIDE CAPABLE OF HYBRIDIZING WITH CMV MRNA

U-523 METHOD OF TREATING INFECTION BY CRYPTOSPORIDIUM PARVUM IN AN IMMUNOCOMPROMISED MAMMAL

U-524 METHOD OF TREATING DIARRHEA

U-525 METHOD OF TREATING PARASITIC INFECTIONS

U-526 METHOD OF PROVIDING CONTROLLED RELEASE OF A TREATING AGENT USING A CONTROLLED RELEASE COMPOSITION

U-527 METHOD OF DELIVERING AN ACTIVE INGREDIENT USING A PROGRESSIVE HYDRATION BIOADHESIVE

U-528 PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING

U-529 ONCE DAILY TREATMENT OF ASTHMA WITH NEBULIZED BUDESONIDE

U-530 TREATMENT OF HERPES ZOSTER, TREATMENT OF GENITAL HERPES, TREATMENT OF COLD SORES, SUPPRESSION OF GENITAL HERPES IN IMMUNOCOMPETENT AND HIV-INFECTED INDIVIDUALS, REDUCTION OF RISK OF HETEROSEXUAL TRANSMISSION OF GENITAL HERPES

U-531 TREATMENT OF PATIENTS WITH ESSENTIAL HYPERTENSION. MAY BE USED ALONE OR GIVEN WITH OTHER CLASSES OF ANTIHYPERTENSIVES, ESPECIALLY THIAZIDE DERIVATIVES

U-532 TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD IN PATIENTS REQUIRING MORE THAN ONE BRONCHO DILATOR

U-533 ERECTILE DYSFUNCTION

U-534 HUMALOG IS AN INSULIN ANALOG THAT IS INDICATED IN THE TREATMENT OF PATIENTS WITH DIABETES MELLITUS FOR THE CONTROL OF HYPERGLYCEMIA

PATENT AND EXCLUSIVITY TERMS

ADB 82 of 191

PATENT USE

U-535	TREATMENT OF SOCIAL ANXIETY DISORDER
U-536	CONTRAST AGENT FOR MAGNETIC RESONANCE IMAGING
U-537	TREATMENT OF CONDITIONS RELATED TO HYPERALDOSTERONISM SUCH AS HYPERTENSION AND CARDIAC INSUFFICIENCY, WITH EPLERENONE
U-538	FIRST LINE TREATMENT OF SEVERE HYPERTENSION, IN PATIENTS WITH HYPERTENSION SEVERE ENOUGH THAT THE VALUE OF ACHIEVING PROMPT BLOOD PRESSURE CONTROL EXCEEDS THE RISK OF INITIATING COMBINATION THERAPY IN THESE PATIENTS
U-539	TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE
U-540	TREATMENT OF FUNGAL INFECTIONS
U-541	METHOD OF TREATMENT OF ADULTS INFECTED WITH HIV-1
U-542	METHOD OF TREATING PATIENT WITH TYPE 2 DIABETES BY ONCE DAILY ADMINISTRATION
U-543	TREATMENT OF SCHIZOPHRENIA
U-544	TREATMENT OF OVERACTIVE BLADDER. TREATMENT OF URINARY INCONTINENCE.
U-545	METHOD FOR THE PREVENTION AND/OR TREATMENT OF THROMBOTIC EPISODES, SUCH AS MYOCARDIAL INFARCTION, IN A HUMAN PATIENT AND METHOD FOR THE PREVENTION OF VENOUS THROMBOSIS IN A POSTOPERATIVE HUMAN PATIENT
U-546	USE OF REPAGLINIDE IN COMBINATION WITH METFORMIN TO LOWER BLOOD GLUCOSE
U-547	MAINTENANCE MONOTHERAPY FOR BIPOLAR DISORDER
U-548	A METHOD OF REDUCING FLUSH IN AN INDIVIDUAL BEING TREATED FOR A LIPIDEMIC DISORDER AND EFFECTIVELY TREATING THE LIPIDEMIC DISORDER
U-549	USE IN THE TREATMENT OF MEN WITH ADVANCED SYMPTOMATIC PROSTATE CANCER
U-550	TREATMENT OF BIPOLAR DISORDER AND SCHIZOPHRENIA
U-551	METHOD FOR REDUCING TOXICITY OF ALIMTA TREATED PATIENTS BY ADMINISTERING FOLIC ACID
U-552	TREATMENT OF HYPERTENSION AND HYPERLIPIDEMIA WITH A SINGLE COMPOSITION
U-553	MANAGEMENT OF PAIN AND DISCOMFORT ASSOCIATED WITH PERIDONTAL SCALING AND ROOT PLANNING PROCEDURES BY APPLICATION OF AN EUTECTIC MIXTURE OF LOCAL ANESTHETICS TO PERIDONTAL POCKETS
U-554	TREATING HIV INFECTION WITH INDINAVIR SULFATE IN COMBINATION WITH ANTIRETROVIRAL AGENTS
U-555	TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS AND ACUTE UNCOMPLICATED PYELONEPHRITIS
U-556	USE AS ADJUNCT DIAGNOSTIC FOR SERUM THYROGLOBULIN (TG) TESTING
U-557	NASAL TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS
U-558	INDICATED FOR THE RELIEF OF BRONCHOSPASM IN PATIENTS 2-12 YEARS OF AGE WITH ASTHMA (REVERSIBLE OBSTRUCTIVE AIRWAY DISEASE)
U-559	METHOD OF DECREASING OR REDUCING PARATHYROID HORMONE LEVEL; METHOD OF MODULATING PARATHYROID HORMONE SECRETION;METHOD OF TREATING HYPERPARATHYROIDISM; METHOD OF REDUCING SERUM IONIZED CALCIUM LEVEL
U-560	METHOD OF DECREASING PARATHYROID HORMONE LEVEL;METHOD OF TREATING HYPERPARATHYROIDISM
U-561	COSOPT IS INDICATED FOR THE REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION WHO ARE INSUFFICIENTLY RESPONSIVE TO BETA BLOCKERS
U-562	TOPICAL TREATMENT OF CUTANEOUS LESIONS IN PATIENTS WITH AIDS-RELATED KAPOSI'S SARCOMA
U-563	MARINOL IS INDICATED FOR, INTER ALIA, ANOREXIA ASSOCIATED WITH WEIGHT LOSS IN PATIENTS WITH AIDS
U-564	TREATMENT OF HIV IN CONCOMITANT THERAPY
U-565	TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS, AND CHRONIC URTICARIA
U-566	FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA

PATENT AND EXCLUSIVITY TERMS

ADB 83 of 191

PATENT USE

U-567	METHOD OF TREATING INFERTILITY
U-568	METHOD OF USING FSH ALONE (WITHOUT EXOGENOUS LH) IN IN VITRO FERTILIZATION
U-569	METHOD OF USING FSH ALONE (WITHOUT EXOGENOUS LH) IN IN VITRO FERTILIZATION AND WHEREIN THEREAFTER AN OVULATORY INDUCING AMOUNT OF HCG IS ADMINISTERED
U-570	METHOD OF USING FSH ALONE (WITHOUT EXOGENOUS LH) IN IN VITRO FERTILIZATION AND WHEREIN THE DAILY AMOUNT OF FSH IS ABOUT 5-10 IU/KG
U-571	TREATMENT OF AGITATION ASSOCIATED WITH SCHIZOPHRENIA AND BIPOLAR I MANIA
U-572	INTENSIVE CARE UNIT SEDATION
U-573	TREATMENT OF ACUTE PROMYELOGENOUS LEUKEMIA (APL)
U-574	PROPHYLAXIS AND TREATMENT OF THE NASAL SYMPTOMS OF SEASONAL ALLERGIC RHINITIS AND TREATMENT OF THE NASAL SYMPTOMS OF PERENNIAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER
U-575	LOTEMAX OPHTHALMIC SUSPENSION IS INDICATED FOR THE TREATMENT OF STEROID RESPONSIVE CONDITIONS OF THE PALPEBRAL BULBAR CONJUNCTIVA, CORNEA AND ANTERIOR SEGMENT OF THE GLOBE.
U-576	ALREX OPHTHALMIC SUSPENSION IS INDICATED FOR THE TEMPORARY RELIEF OF THE SIGNS AND SYMPTOMS OF SEASONAL ALLERGIC CONJUNCTIVITIS.
U-577	TREATMENT OF BENIGN PROSTATIC HYPERPLASIA WITH FINASTERIDE IN COMBINATION WITH DOXAZOSIN
U-578	TREATMENT OF COMMUNITY ACQUIRED PNEUMONIA, ACUTE EXACERBATION OF CHRONIC BRONCHITIS, AND ACUTE BACTERIAL SINUSITIS CAUSED BY SUSCEPTIBLE STRAINS OF DESIGNATED MICROORGANISMS IN PATIENTS 18 YEARS AND OLDER.
U-579	TREATMENT OF EPILEPSY AND/OR MIGRAINE.
U-580	TREATMENT OF DISORDERS OF THE SEROTONERGIC SYSTEM SUCH AS DEPRESSION AND ANXIETY-RELATED DISORDERS
U-581	METHOD OF TREATING A CONDITION CAPABLE OF TREATMENT BY INHALATION, E.G. ASTHMA, COMPRISING ADMINISTRATION OF A FORMULATION CLAIMED IN US PATENT NO. 6743413
U-582	METHOD FOR THE TREATMENT OF A RESPIRATORY DISORDER, E.G. ASTHMA, COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF AN AEROSOL COMPOSITION TO A PATIENT FROM A METERED DOSE INHALER SYSTEM AS CLAIMED IN US PATENT NO. 6253762
U-583	METHOD FOR THE TREATMENT OF A RESPIRATORY DISORDER, E.G. ASTHMA, COMPRISING ADMINISTERING TO A PATIENT BY INHALATION, A METERED AEROSOL DOSE OF A DRUG FORMULATION FROM THE METERED DOSE INHALER SYSTEM CLAIMED IN US 6546928
U-584	SINGLE-DOSE ADMINISTRATION BY THE EPIDURAL ROUTE, AT THE LUMBAR LEVEL, FOR THE TREATMENT OF PAIN FOLLOWING MAJOR SURGERY
U-585	TO PROMOTE WEIGHT GAIN AFTER WEIGHT LOSS IN CERTAIN TYPES OF PATIENTS
U-586	AN INTERMEDIATE RELEASE NICOTINIC ACID FORMULATION SUITABLE FOR ORAL ADMINISTRATION ONCE-A-DAY AS A SINGLE DOSE FOR TREATING HYPERLIPIDEMIA WITHOUT CAUSING DRUG-INDUCED HEPATOTOXICITY OR ELEVATIONS IN URIC ACID OR GLUCOSE OR BOTH
U-587	USE OF EPLERENONE IN COMBINATION WITH AN ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITOR (AND OPTIONALLY A DIURETIC) FOR TREATING CONGESTIVE HEART FAILURE AND HYPERTENSION
U-588	SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER; TREATMENT OF HEARTBURN AND OTHER SYMPTOMS ASSOCIATED WITH GERD; SHORT-TERM TREATMENT OF EROSIIVE ESOPHAGITIS; MAINTENANCE OF HEALING OF EROSIIVE ESOPHAGITIS
U-589	METHOD FOR TREATMENT OF A RESPIRATORY DISORDER, E.G., BRONCHOSPASM, COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF AN AEROSOL COMPOSITION TO A PATIENT FROM A METERED DOSE INHALER SYSTEM AS CLAIMED IN U.S. PATENT NO. 6131966
U-590	METHOD FOR TREATMENT OF A RESPIRATORY DISORDER, E.G., BRONCHOSPASM, COMPRISING ADMINISTERING TO A PATIENT BY ORAL OR NASAL INHALATION A DRUG FORMULATION BY USING THE METERED DOSE INHALER SYSTEM AS CLAIMED IN US PATENT NO. 6532955
U-591	TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER USING A DOSAGE FORM WHICH PROVIDES ONCE-DAILY ORAL ADMINISTRATION OF A PHENIDATE DRUG
U-592	TREATMENT OF PRIMARY HYPERCHOLESTEROLEMIA, MIXED HYPERLIPIDEMIA AND/OR HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH)
U-593	TREATMENT OF PRIMARY HYPERCHOLESTEROLEMIA, MIXED HYPERLIPIDEMIA AND/OR HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH)

PATENT AND EXCLUSIVITY TERMS

ADB 84 of 191

PATENT USE

U-594	PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
U-595	35 MG ORALLY ONCE A WEEK FOR PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN; 35 MG ORALLY ONCE A WEEK FOR TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
U-596	TREATMENT OF HORMONE RECEPTOR POSITIVE METASTATIC BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH DISEASE PROGRESSION FOLLOWING ANTIESTROGEN THERAPY
U-597	FORTEO IS INDICATED FOR THE TREATMENT OF POST MENOPAUSAL WOMEN WITH OSTEOPOROSIS WHO ARE AT HIGH RISK FOR FRACTURE
U-598	PROPHYLACTIC TREATMENT OF MIGRAINE
U-599	METHOD FOR TREATING ALLERGIC CONJUNCTIVITIS
U-600	A METHOD OF TREATING A PATIENT IN NEED OF OPHTHALMIC ANTIMICROBIAL THERAPY WITH LEVOFLOXACIN
U-601	TREATMENT OF BIPOLAR DISORDER
U-602	SIGNS AND SYMPTOMS OF OSTEOARTHRITIS, RHEUMATOID ARTHRITIS IN ADULTS, AND/OR PAUCIARTICULAR OR POLYARTICULAR COURSE JUVENILE RHEUMATOID ARTHRITIS, ACUTE PAIN IN ADULTS; PRIMARY DYSMENORRHEA; AND/OR ACUTE MIGRAINE ATTACKS IN ADULTS
U-603	METHOD OF TREATING INFECTIONS COMPRISING ORALLY ADMINISTERING AN EFFECTIVE AMOUNT OF THE FDA APPROVED ORAL SUSPENSION
U-604	METHOD OF LOWERING BLOOD GLUCOSE BY ONCE DAILY ADMINISTRATION
U-605	TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD); ALTHOUGH THE MECHANISM OF THE ANTIDEPRESSANT ACTION OF DULOXETINE IN HUMANS IS UNKNOWN, IT IS BELIEVED TO BE RELATED TO ITS POTENTIATION OF SERATONERGIC AND NORADRENERGIC ACTIVITY IN THE CNS
U-606	USE OF IRINOTECAN IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER
U-607	CANCIDAS IS INDICATED FOR EMPIRICAL THERAPY FOR PRESUMED FUNGAL INFECTIONS IN FEBRILE, NEUTROPENIC PATIENTS.
U-608	USE OF QUINOLONE COMPOUNDS AGAINST PNEUMOCOCCAL PATHOGENIC BACTERIA
U-609	USE OF QUINOLONE COMPOUNDS AGAINST QUINOLONE-RESISTANT PNEUMOCOCCAL PATHOGENIC BACTERIA
U-610	ATROVENT HFA (IPRATROPIUM BROMIDE HFA) INHALATION AEROSOL IS INDICATED AS A BRONCHODILATOR FOR MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE, INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA.
U-611	METHOD OF USING DESLORATADINE TO TREAT SEASONAL AND PERENNIAL ALLERGIC RHINITIS, PRURITIS, AND CHRONIC IDIOPATHIC URTICARIA IN PATIENTS 2 YEARS OF AGE AND OLDER
U-612	TREATMENT OF SEASONAL ALLERGY SYMPTOMS WITH NASAL CONGESTION IN ADULTS AND CHILDREN 12 YEARS OF AGE AND OLDER
U-613	REDUCTION OF SERUM PHOSPHATE
U-614	TREATMENT OF SEXUAL DYSFUNCTION
U-615	ADJUNCTIVE THERAPY TO DIET IN ADULTS TO REDUCE LDL-C, TOTAL-C, TRIGLYCERIDES AND APO B, AND INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA OR MIXED DYSLIPIDEMIA (TYPES IIA, IIB) AND TO TREAT HYPERTRIGLYCERIDEMIA (TYPES IV, V)
U-616	MANAGEMENT OF PERSISTENT, MODERATE TO SEVERE PAIN IN PATIENTS REQUIRING CONTINUOUS, AROUND-THE-CLOCK ANALGESIA WITH A HIGH POTENCY OPIOID FOR AN EXTENDED PERIOD OF TIME GENERALLY WEEKS TO MONTHS OR LONGER
U-617	TREATMENT OF ACUTE PROMYELOGENOUS LEUKEMIA (APL)
U-618	USE OF ROSUVASTATIN CALCIUM TO REDUCE ELEVATED TOTAL-C, LDL-C, APOB, NONHDL-C OR TG LEVELS; TO INCREASE HDL-C IN ADULT PATIENTS WITH PRIMARY HYPERLIPIDEMIA OR MIXED DYSLIPIDEMIA; AND TO SLOW THE PROGRESSION OF ATHEROSCLEROSIS.
U-619	TREATMENT OF MALIGNANT NEOPLASM
U-620	TREATMENT OF INSOMNIA
U-621	METHOD OF TREATING CANCER
U-622	TREATMENT OF VEGF MEDIATED OCULAR DISEASE.
U-623	SHORT TERM TREATMENT OF ACTIVE BENIGN GASTRIC ULCER
U-624	REDUCTION OF RISK OF UPPER GASTROINTESTINAL BLEEDING IN CRITICALLY ILL PATIENTS

PATENT AND EXCLUSIVITY TERMS

ADB 85 of 191

PATENT USE

U-625	ALLERGIC RHINITIS OR NASAL POLYPS
U-626	CLOLAR IS INDICATED FOR THE TREATMENT OF PEDIATRIC PATIENTS 1 TO 21 YEARS OLD WITH RELAPSED OR REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA AFTER AT LEAST TWO PRIOR REGIMENS
U-627	TREATMENT OF PATIENTS USING EXTENDED-RELEASE CARBAMAZEPINE
U-628	USE OF AVANDIA IN COMBINATION WITH A SULFONYLUREA, AND IN COMBINATION WITH METFORMIN AND A SULFONYLUREA TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
U-629	METHOD OF INDUCING A HYPNOTIC OR SEDATIVE EFFECT IN A HUMAN BY ADMINISTERING ESZOPICLONE
U-630	TREATING URINARY INCONTINENCE BY ADMINISTERING AN EXTENDED-RELEASE FORM OF DARIFENACIN
U-631	TREATING A DISEASE OF ALTERED MOTILITY OR TONE OF SMOOTH MUSCLE BY ADMINISTERING A MUSCARINIC RECEPTOR ANTAGONIZING AMOUNT OF DARIFENACIN
U-632	METHOD OF TREATMENT OF CANCER BY ADMINISTERING PARTICLES OF PACLITAXEL THAT HAVE A PROTEIN COATING
U-633	METHOD FOR TREATMENT OF TUMORS BY ADMINISTERING PACLITAXEL AT A DOSE IN THE RANGE OF ABOUT 30MG/METER SQUARE TO ABOUT 100MG/METER SQUARE IN A PHARMACEUTICALLY ACCEPTABLE FORMULATION THAT DOES NOT CONTAIN CREMOPHOR
U-634	METHOD FOR DELIVERY OF A BIOLOGIC (INCLUDING ANTINEOPLASTIC AGENTS) BY ADMINISTERING TO A PATIENT AN EFFECTIVE AMOUNT OF A BIOLOGIC AS A SOLID OR LIQUID WITH A POLYMERIC BIOCOMPATIBLE MATERIAL
U-635	TREATMENT OF GERD, MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS AND RISK REDUCTION OF NSAID ASSOCIATED GASTRIC ULCERS
U-636	TREATMENT OR PREVENTION OF BRONCHOSPASM OR ASTHMATIC SYMPTOMS
U-637	TREATMENT OF DIABETES WITH AN AMYLIN AGONIST
U-638	TREATMENT OF DIABETES WITH AN AMYLIN AGONIST, INCLUDING WITH INSULIN
U-639	TREATMENT OF A MAMMAL HAVING A NEED OF OR REDUCED ABILITY TO PRODUCE INSULIN WITH AN INSULIN AND AN AMYLIN SUCH AS PRAMLINTIDE
U-640	USE OF AN AMYLIN AGONIST TO REDUCE GASTRIC MOTILITY AND TREAT POST PRANDIAL HYPERGLCEMIA
U-641	USE OF AN AMYLIN AGONIST HAVING SPECIFIED BINDING ACTIVITY TO REDUCE GASTRIC MOTILITY, INCLUDING USE THROUGH PARENTERAL ADMINISTRATION
U-642	TREATMENT AND PREVENTION OF OSTEOPOROSIS
U-643	THE SHORT TERM TREATMENT (UP TO 10 DAYS) IN PTS HAVING GASTROESOPHAGEAL REFLUX DISEASE (GERD) AS AN ALTERNATIVE TO ORAL THERAPY IN PTS WHEN THERAPY WITH NEXIUM CAPSULES IS NOT POSSIBLE OR APPROPRIATE
U-644	TREATMENT OF SEASONAL ALLERGIC RHINITIS
U-645	TREATMENT OF ASTHMA
U-646	METHOD OF TREATING OTITIS
U-647	TREATMENT OF OSTEOPOROSIS IN POST MENOPAUSAL WOMEN AND/OR THE TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS
U-648	THE TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN AND/OR THE TREATMENT TO INCREASE BONE MASS IN MEN
U-649	A METHOD FOR TREATING A TUMOR DISEASE
U-650	TREATMENT OF ESOPHAGEAL CANDIDIASIS AND PROPHYLAXIS OF CANDIDA INFECTIONS IN HSCT PATIENTS
U-651	TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA (APL)
U-652	TREATMENT OF CARDIAC ARRHYTHMIA
U-653	STIMULATING INSULIN RELEASE BY ADMINISTERING EXENATIDE
U-654	LOWERING PLASMA GLUCAGON IN A SUBJECT IN NEED THEREOF, INCLUDING ONE WITH TYPE 2 DIABETES, BY ADMINISTERING AN EXENDIN OR ANALOG, SUCH AS EXENDIN-4
U-655	TREATMENT OF MILD TO MODERATE ACTIVE CHROHN'S DISEASE INVOLVING THE ILEUM AND/OR THE ASCENDING COLON AND THE MAINTENANCE OF CLINICAL REMISSION OF MILD TO MODERATE CROHN'S DISEASE INVOLVING THE ILEUM AND/OR ASCENDING COLON FOR UP TO 3

PATENT AND EXCLUSIVITY TERMS

ADB 86 of 191

PATENT USE

MONTHS

U-656	REDUCING GASTRIC MOTILITY OR DELAYING GASTRIC EMPTYING BY ADMINISTERING AN EXENDIN, SUCH AS EXENDIN-4
U-657	PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
U-658	TREATMENT OF ADVANCED HORMONE-DEPENDENT BREAST CANCER
U-659	TREATMENT OF LOCALLY ADVANCED OR METASTATIC NON SMALL-CELL LUNG CANCER (NSCLC) AFTER FAILURE OF AT LEAST ONE PRIOR CHEMOTHERAPY REGIMEN
U-660	TREATMENT OF HYPERTENSION AND TREATMENT OF HEART FAILURE
U-661	TREATMENT OF SEIZURE DISORDER
U-662	TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
U-663	THE TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTIONS
U-664	TREATMENT OF CONDITIONS FOR WHICH AN ALDOSTERONE RECEPTOR BLOCKER IS INDICATED, SUCH AS HYPERTENSION, HEART FAILURE, AND POST-MYOCARDIAL INFARCTION
U-665	METHOD OF USING THE DRUG SUBSTANCE/DRUG PRODUCT FOR ULTRASOUND IMAGING
U-666	METHOD OF TREATING ADHD
U-667	MANAGEMENT OF INCONTINENCE; METHOD FOR TREATING INCONTINENCE
U-668	LEVEMIR IS A LONG-ACTING BASAL INSULIN ANALOG THAT IS INDICATED IN THE TREATMENT OF PATIENTS WITH DIABETES MELLITUS
U-669	INDICATION OF TYPE II DIABETES
U-670	TREATMENT OF HIV-1 INFECTION BY THE CO-ADMINISTRATION OF TIPRANAVIR AND RITONAVIR.
U-671	PREVENTION AND TREATMENT OF SECONDARY HYPERPARATHYROIDISM ASSOCIATED WITH CHRONIC KIDNEY DISEASE (CKD) STAGE 3 AND 4
U-672	TREATMENT OF INFLAMMATION OR AN INFLAMMATION-ASSOCIATED DISORDER
U-673	METHOD OF TREATMENT WITH ONCE-DAILY DOSES OF 625MG/5ML
U-674	METHOD OF TREATING INSOMNIA CHARACTERIZED BY DIFFICULTY WITH SLEEP ONSET
U-675	PROPHYLAXIS AND CHRONIC TREATMENT OF ASTHMA; RELIEF OF SYMPTOMS OF ALLERGIC RHINITIS
U-676	METHOD OF TREATING ATTENTION DEFICIT DISORDER USING ORAL ADMINISTRATION OF A BI-MODAL OR PULSATILE RELEASE COMPOSITION
U-677	A METHOD OF TREATING DISEASE AMENABLE TO TREATMENT WITH A PHENIDATE DRUG BY ONCE DAILY ORAL ADMINISTRATION OF AN EXTENDED RELEASE DOSAGE FORM
U-678	METHOD OF TREATING ATTENTION DEFICIT DISORDER AND/OR ATTENTION DEFICIT HYPERACTIVITY DISORDER
U-679	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES WHO ARE ALREADY TREATED WITH A PIOGLITAZONE AND METFORMIN
U-680	A METHOD OF TREATING DYSLIPIDEMIA AND DYSLIPOPROTEINEMIA USING A DOSAGE FORM THAT CAN PROVIDE AN EFFECTIVE AMOUNT OF FENOFIBRATE TO A PATIENT IN A FASTED STATE WHICH IS AT LEAST 90% OF THE AUC AMOUNT PROVIDED BY THE DOSAGE FORM
U-681	TREATMENT OF PRIMARY IGF-1 DEFICIENCY
U-682	NON-BENZODIAZEPINE HYPNOTIC AGENT INDICATED FOR TREATMENT OF INSOMNIA, CHARACTERIZED BY DIFFICULTIES WITH SLEEP ONSET AND/OR SLEEP MAINTENANCE
U-683	PREVENTION OR TREATMENT OF ISCHEMIC HEART DISEASE
U-684	TREATMENT OF UNCOMPLICATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER
U-685	EXPECTORANT AND COUGH SUPPRESSANT
U-686	EXPECTORANT AND NASAL DECONGESTANT
U-687	REDUCING FOOD INTAKE IN A SUBJECT WITH TYPE 2 DIABETES BY ADMINISTERING AN EXENDIN, SUCH AS EXENDIN-4
U-688	TREATMENT OF HIV-INFECTION IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS
U-689	TREATMENT OF PATIENTS WITH T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA WHOSE DISEASE HAS NOT RESPONDED TO OR HAS RELAPSED FOLLOWING TREATMENT WITH AT LEAST TWO CHEMOTHERAPY REGIMENS

PATENT AND EXCLUSIVITY TERMS

ADB 87 of 191

PATENT USE

U-690	TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
U-691	USE AS A MONOTHERAPY, IN COMBINATION WITH A SULFONYLUREA, METFORMIN OR INSULIN OR IN COMBINATION WITH A SULFONYLUREA PLUS METFORMIN TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
U-692	USE OF VALSARTAN TO REDUCE CARDIOVASCULAR MORTALITY IN CLINICALLY STABLE PATIENTS WITH LEFT VENTRICULAR FAILURE OR LEFT VENTRICULAR DYSFUNCTION FOLLOWING MYOCARDIAL INFARCTION
U-693	THE RECOMMENDED INITIAL DOSE OF EQUETRO IS 400MG/DAY GIVEN IN DIVIDED DOSES, TWICE DAILY. THE DOSE SHOULD BE ADJUSTED IN 200MG DAILY INCREMENTS TO ACHIEVE OPTIMAL CLINICAL RESPONSE.
U-694	LENALIDOMIDE IS AN ANALOGUE OF THALIDOMIDE. THALIDOMIDE IS A KNOWN HUMAN TERATOGEN THAT CAUSES SEVERE LIFE-THREATENING HUMAN BIRTH DEFECTS. IF LENALIDOMIDE IS TAKEN DURING PREGNANCY, IT MAY CAUSE BIRTH DEFECTS OR DEATH TO AN UNBORN BABY.
U-695	TREATMENT OF PATIENTS WITH T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA AND T-CELL LYMPHOBLASTIC LYMPHOMA WHOSE DISEASE HAS NOT RESPONDED TO OR HAS RELAPSED FOLLOWING TREATMENT WITH AT LEAST TWO CHEMOTHERAPY REGIMENS
U-696	TREATMENT OF PATIENTS WITH T-CELL LYMPHOBLASTIC LYMPHOMA WHOSE DISEASE HAS NOT RESPONDED TO OR HAS RELAPSED FOLLOWING TREATMENT WITH AT LEAST TWO CHEMOTHERAPY REGIMENS
U-697	A METHOD OF USING RINFABATE RECOMBINANT (RHIGFBP-3) WITH MECASERMIN RECOMBINANT (RHIGF-1) TO PROMOTE LINEAR GROWTH IN THE TREATMENT OF PRIMARY IGF-1 DEFICIENCY
U-698	METHOD OF USING ANTAGONIST OF ARGININE VASOPRESSIN (AVA) V1A AND V2 RECEPTORS FOR INTRAVENOUS TREATMENT OF PATIENTS WITH EUVOLEMIC HYPONATREMIA
U-699	NASAL TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS
U-700	TREATMENT AND PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
U-701	TREATMENT OF HYPERCHOLESTEROLEMIA AND/OR HYPERTRIGLYCERIDEMIA
U-702	TOPICAL AEROSOL HAIR REGROWTH TREATMENT
U-703	TREATMENT OF PROTEIN KINASE RELATED DISORDERS, SUCH AS GASTROINTESTINAL STROMAL TUMOR AND RENAL CELL CARCINOMA WITH SUNITINIB
U-704	METHOD OF ADMINISTERING INSULIN VIA INHALATION
U-705	TREATING CHRONIC ANGINA BY ADMINISTERING AN EXTENDED RELEASE FORM OF RANOLAZINE
U-706	TREATMENT OF BENIGN PROSTATIC HYPERPLASIA
U-707	ALLERGIC RHINITIS
U-708	TREATMENT OF CHRONIC NON-INFECTIOUS UVEITIS AFFECTING THE POSTERIOR SEGMENT OF THE EYE
U-709	METHOD OF COMBATING BACTERIA IN A PATIENT
U-710	A METHOD OF TREATING RESPIRATORY DISORDERS, E.G., ASTHMA, WHICH COMPRISES ADMINISTRATION BY INHALATION OF AN EFFECTIVE AMOUNT OF A PHARMACEUTICAL FORMULATION AS CLAIMED IN US PATENT NO. 5658549
U-711	ACUTE AND LONGER-TERM TREATMENT OF MAJOR DEPRESSIVE DISORDER
U-712	A METHOD OF USING A NICOTINIC ACID FORMULATION TO REDUCE ELEVATED TC, LDL-C AND TG LEVELS, AND RAISE HDL-C LEVELS IN PATIENTS WITH HYPERLIPIDEMIA
U-713	TREATMENT OF MILD TO MODERATE DEMENTIA OF THE ALZHEIMER'S TYPE
U-714	TOPICAL TREATMENT OF INTERDIGITAL TINEA PEDIS AND TINEA CORPORIS DUE TO TRICHOPHYTON RUBRUM, TRICHOPHYTON MENTAGROPHYTES OR EPIDERMOPHYTON FLOCCOSUM
U-715	FOR CLEANSING THE BOWEL IN PREPARATION FOR COLONOSCOPY, IN ADULTS 18 YEARS OF AGE OR OLDER
U-716	THE TREATMENT OR PREVENTION OF BRONCHOSPASM IN ADULTS AND CHILDREN 4 YEARS OF AGE AND OLDER WITH REVERSIBLE OBSTRUCTIVE AIRWAYS DISEASE AND THE PREVENTION OF EXERCISED-INDUCED BRONCHOSPASM IN PATIENTS 4 YEARS OF AGE AND OLDER
U-717	METHOD OF RELIEVING OR PREVENTING CONSTIPATION IN A HUMAN CONSTIPATED PATIENT
U-718	TREATMENT OF FUNGAL INFECTIONS
U-719	TREATMENT OF PSYCHOSIS
U-720	TREATMENT OF NEUROLEPTIC DISEASES

PATENT AND EXCLUSIVITY TERMS

ADB 88 of 191

PATENT USE

U-721	TREATMENT OF INFLUENZA
U-722	PROPHYLAXIS OF INFLUENZA
U-723	PROPHYLACTIC TREATMENT OF MIGRAINE
U-724	METHOD OF TREATING SEIZURES
U-725	ALLERGIC RHINITIS AND URTICARIA
U-726	ALLERGIC RHINITIS
U-727	FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
U-728	METHOD FOR TREATING BACTERIAL INFECTION
U-729	TREATMENT OF GASTROESOPHAGEAL REFLUX DISEASE (GERD), RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER, H. PYLORI ERADICATION TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE
U-730	USE AS A NASAL SPRAY FOR TREATMENT OF THE SYMPTOMS OF SEASONAL ALLERGIC RHINITIS AND VASOMOTOR RHINITIS
U-731	USE IN COMBINATION WITH DEXAMETHASONE IS INDICATED FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
U-732	ACUTE TREATMENT OF THE CUTANEOUS MANIFESTATIONS OF MODERATE TO SEVERE ERYTHEMA NODOSUM LEPROSUM (ENL)
U-733	MAINTENANCE THERAPY FOR PREVENTION AND SUPPRESSION OF THE CUTANEOUS MANIFESTATIONS OF ENL RECURRENCE
U-734	FIRST LINE THERAPY FOR TYPE 2 DIABETES MELLITUS
U-735	METHOD OF TREATING CHRONIC IRON OVERLOAD
U-736	METHOD FOR IONTOPHORETIC TRANSDERMAL DELIVERY OF FENTANYL HYDROCHLORIDE
U-737	DISINFECTION OF PATIENT SKIN PRIOR TO AN INVASIVE PROCEDURE
U-738	INDICATED FOR THE LONG-TERM, TWICE-DAILY MAINTENANCE TREATMENT OF ASTHMA IN PATIENTS 12 YEARS OF AGE OR OLDER
U-739	METHOD FOR TREATING CONSTIPATION BY OPENING CIC CHANNELS IN A MAMMALIAN SUBJECT
U-740	FOR THE TREATMENT OF PATIENTS WITH PRIMARY BILIARY CIRRHOSIS
U-741	COMBINATION THERAPY WITH CISPLATIN FOR THE TREATMENT OF LATE STAGE CERVICAL CANCER
U-742	TWICE DAILY TOPICAL TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS.
U-743	ONCE A DAY TOPICAL TREATMENT OF THE INFLAMMATORY LESIONS OF ROSACEA
U-744	TREATMENT OF HIV INFECTION IN ANTIRETROVIRAL TREATMENT-EXPERIENCED ADULT PATIENTS
U-745	TREATMENT OR PREVENTION OF EMESIS
U-746	PREVENTION OR TREATMENT OF NAUSEA OR EMESIS INDUCED BY A CANCER CHEMOTHERAPEUTIC AGENT
U-747	PREVENTION OR TREATMENT OF POST-OPERATIVE NAUSEA AND VOMITING
U-748	A METHOD FOR THE TREATMENT OF A PROTEIN TYROSINE KINASE-ASSOCIATED DISORDER
U-749	METHOD OF CONTRACEPTION
U-750	TREATMENT OF HIV-1 INFECTION IN ADULTS
U-751	ONCE DAILY DOSING OF BUDESONIDE VIA NEBULIZER FOR THE TREATMENT OF ASTHMA
U-752	SUNSCREEN
U-753	AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES
U-754	USE FOR THE LONG-TERM MAINTENANCE TREATMENT OF ASTHMA
U-755	TREATMENT OF ANOREXIA, CACHEXIA, OR AN UNEXPLAINED, SIGNIFICANT WEIGHT LOSS IN PATIENTS WITH A DIAGNOSIS OF ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)
U-756	ADDITION OF ONCE-WEEKLY DOSING FOR THE TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS
U-757	USE AS A BILE ACID SEQUESTRANT FOR LOWERING CHOLESTEROL
U-758	TREATMENT OF SYMPTOMS OF PREMENSTRUAL DYSPHORIC DISORDER

PATENT AND EXCLUSIVITY TERMS

ADB 89 of 191

PATENT USE

U-759	METHOD OF USE OF ADMINISTERING LEVOTHYROXINE
U-760	PROPHYLAXIS OF INVASIVE ASPERGILLUS AND CANDIDA INFECTIONS AND TREATMENT OF OROPHARYNGEAL CANDIDIASIS
U-761	TREATMENT OF SCHIZOPHRENIA INCLUDING MAINTAINING STABILITY IN PATIENTS WITH SCHIZOPHRENIA
U-762	TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
U-763	ADMINISTRATION OF ARIPIPRAZOLE BY INJECTION
U-764	TREATMENT OF SCHIZOPHRENIA
U-765	METHOD OF TREATING ALLERGIC CONJUNCTIVITIS
U-766	TREATMENT OF SEIZURES
U-767	MANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER
U-768	A METHOD OF REDUCING THE CAPACITY OF EXTENDED RELEASE NICOTINIC ACID TO PROVOKE A FLUSHING REACTION BY PRETREATING AN INDIVIDUAL WITH A FLUSH INHIBITING AGENT PRIOR TO THE ADMINISTRATION OF THE EXTENDED RELEASE NICOTINIC ACID
U-769	REVLIMID (LENALIDOMIDE) IN COMBINATION WITH DEXAMETHASONE IS INDICATED FOR THE TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
U-770	LONG-TERM TREATMENT OF PATHOLOGICAL HYPERSECRETORY CONDITIONS
U-771	METHOD FOR THE TREATMENT OF DIABETES MELLITUS, SUCH AS TYPE 1 DIABETES MELLITUS OR TYPE 2 DIABETES MELLITUS, IN A HUMAN PATIENT
U-772	RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN CHILDREN 2 TO 11 YEARS AND FOR THE RELIEF OF SYMPTOMS ASSOCIATED WITH UNCOMPLICATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA IN CHILDREN 6 MONTHS TO 11 YEARS
U-773	PATHOLOGICAL HYPERSECRETORY CONDITIONS
U-774	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR
U-775	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN AND/OR A SULFONYLUREA
U-776	TREATMENT OF CUTANEOUS MANIFESTATION IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA (CTCL) WHO HAVE PROGRESSIVE, PERSISTENT OR RECURRENT DISEASE ON OR FOLLOWING TWO SYSTEMIC THERAPIES.
U-777	DECREASING MORTALITY CAUSED BY CONGESTIVE HEART FAILURE
U-778	REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION
U-779	A METHOD FOR TREATMENT OF A CANCER, WHEREIN THE CANCER IS CHRONIC MYELOGENOUS LEUKEMIA
U-780	A METHOD FOR THE TREATMENT OF CANCER
U-781	FOR TREATMENT OF ADULT PATIENTS WITH TYPE 2 DIABETES MELLITUS WHO ARE NAIVE TO PHARMACOLOGIC THERAPY
U-782	TREATMENT OF CHRONIC HEPATITIS B IN ADULT PATIENTS WITH EVIDENCE OF VIRAL REPLICATION AND EITHER EVIDENCE OF PERSISTANT ELEVATIONS IN SERUM AMINOTRANSFERASES (ALT OR AST) OR HISTOLOGICALLY ACTIVE DISEASE
U-783	DESONATE GEL IS INDICATED FOR THE TREATMENT OF MILD TO MODERATE ATOPIC DERMATITIS IN PATIENTS 3 MONTHS OF AGE AND OLDER
U-784	TREATMENT OF MODERATE TO SEVERE PRIMARY RESTLESS LEGS SYNDROME (RLS)
U-785	USE AS REPLACEMENT SOLUTION, HEMOFILTRATION SOLUTION OR HEMODIAFILTRATION SOLUTION IN CONTINUOUS RENAL REPLACEMENT THERAPY
U-786	PRODUCT IS APPROVED FOR THE TOPICAL TREATMENT OF TINEA PEDIS
U-787	MAINTENANCE TREATMENT OF ASTHMA AS PROPHYLACTIC THERAPY IN ADULT AND PEDIATRIC PATIENTS SIX YEARS OF AGE OR OLDER, INCLUDING PATIENTS REQUIRING ORAL CORTICOSTEROID THERAPY FOR ASTHMA
U-788	METHOD OF TREATING PSYCHIATRIC SYMPTOMS ASSOCIATED WITH PREMENSTRUAL DISORDERS USING PAROXETINE
U-789	TREATMENT OF KNOWN OR SUSPECTED CYANIDE POISONING

PATENT AND EXCLUSIVITY TERMS

ADB 90 of 191

PATENT USE

U-790	FORTEO IS INDICATED FOR THE TREATMENT OF POST MENOPAUSAL WOMEN WITH OSTEOPOROSIS WHO ARE AT RISK FOR FRACTURE. FORTEO CAN BE USED BY PEOPLE WHO HAVE HAD A FRACTURE RELATED TO OSTEOPOROSIS
U-791	GLEEVEC IS ALSO INDICATED FOR THE TREATMENT OF PATIENTS WITH KIT (CD117) POSITIVE UNRESECTABLE AND/OR METASTATIC MALIGNANT GASTROINTESTINAL STROMAL TUMORS (GIST)
U-792	TREATMENT OF SEBORRHEA DERMATITIS IN HUMANS
U-793	FOR THE LONG TERM TREATMENT, TWICE DAILY (MORNING AND EVENING) MAINTENANCE TREATMENT OF BRONCHOCONSTRICTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA
U-794	CLOSURE OF A CLINICALLY SIGNIFICANT PATENT DUCTUS ARTERIOSUS IN PREMATURE INFANTS WEIGHING BETWEEN 500 AND 1500G, WHO ARE NO MORE THAN 32 WEEKS GESTATIONAL AGE WHEN USUAL MEDICAL MANAGEMENT IS INEFFECTIVE
U-795	METHOD FOR INHIBITING NOREPINEPHRINE UPTAKE
U-796	METHOD OF TREATING DEPRESSION
U-797	METHOD OF TREATING ANXIETY
U-798	TREATMENT AND PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN BY ONCE-MONTHLY ORAL ADMINISTRATION OF IBANDRONATE SODIUM MONOHYDRATE EQUIVALENT TO 150MG OF IBANDRONIC ACID
U-799	METHOD FOR INHIBITING SEROTONIN UPTAKE
U-800	TREATMENT OF PATIENTS WITH ADVANCED OR METASTATIC BREAST CANCER WHOSE TUMORS OVEREXPRESS HER2 AND WHO HAVE RECEIVED PRIOR THERAPY INCLUDING ANTHRACYCLINE, A TAXANE AND TRASTUZUMAB
U-801	METHOD OF TREATING CANCER
U-802	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR
U-803	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN
U-804	TREATMENT OF ACTINIC KERATOSES BY PHOTODYNAMIC THERAPY
U-805	TREATMENT OF IMPETIGO DUE TO STAPHYLOCOCCUS AUREUS OR STREPTOCOCCUS PYOGENES
U-806	INTRATHECAL TREATMENT OF LYMPHOMATOUS MENINGITIS
U-807	PREVENTION OF EXERCISE-INDUCED BRONCHOCONSTRICTION
U-808	THE TREATMENT OF THE SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS IN PATIENTS 2 YEARS OF AGE AND OLDER
U-809	TREATMENT OF CHRONIC IDIOPATHIC URTICARIA
U-810	METHOD OF TREATMENT TO ALLEVIATE INFLAMMATION OF THE EYE
U-811	RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL AND PERENNIAL ALLERGIC RHINITIS AND TREATMENT OF THE UNCOMPLICATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA
U-812	RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL AND PERENNIAL ALLERGIC RHINITIS
U-813	MAINTENANCE TREATMENT OF BRONCHOCONSTRICTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
U-814	TREATMENT OF SCHIZOPHRENIA
U-815	TREATS COLD SORES/FEVER BLISTERS ON THE FACE OR LIPS. SHORTENS HEALING TIME AND DURATION OF SYMPTOMS: TINGLING, PAIN, BURNING AND/OR ITCHING
U-816	DEPRESSION, PANIC DISORDER, PREMENSTRUAL DISORDERS AND SOCIAL ANXIETY DISORDER
U-817	NASAL ADMINISTRATION OF CYANOCOBALAMIN
U-818	TOPICAL TREATMENT OF ACNE VULGARIS
U-819	MANAGEMENT OF FIBROMYALGIA
U-820	IMPROVED WAKEFULNESS IN PATIENTS WITH EXCESSIVE SLEEPINESS ASSOCIATED WITH NARCOLEPSY, OBSTRUCTIVE SLEEP APNEA/HYPOPNEA SYNDROME, AND SHIFT WORK SLEEP DISORDER
U-821	METHOD OF INHIBITING ENTHOTHELIN RECEPTORS BY ADMINISTERING AMBRISENTAN TO A PATIENT TO TREAT PULMONARY ARTERIAL HYPERTENSION.

PATENT AND EXCLUSIVITY TERMS

ADB 91 of 191

PATENT USE

U-822	USE IN LIPID MANAGEMENT
U-823	RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS AND FOR THE TREATMENT OF UNCOMPLICATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA IN CHILDREN 6 TO 11 YEARS OF AGE
U-824	METHOD OF TREATING PATIENTS INFECTED WITH CCR5-TROPIC HIV-1
U-825	USE FOR PREVENTION OF BREAST CANCER
U-826	RELIEF OF MODERATE TO SEVERE PAIN
U-827	USE FOR TREATMENT OF DIABETES, PARTICULARLY TYPE 2 DIABETES
U-828	PREVENTION OF PREGNANCY IN WOMEN WHO ELECT TO USE ORAL CONTRACEPTIVES AS A METHOD OF CONTRACEPTION
U-829	TREATMENT OF EXTRAVASATION RESULTING FROM IV ANTHRACYCLINE CHEMOTHERAPY
U-830	TREATMENT OF RELAPSED SMALL CELL LUNG CANCER
U-831	METHOD OF ADMINISTERING LANREOTIDE ACETATE
U-832	ZINGO IS INDICATED FOR THE USE ON INTACT SKIN TO PROVIDE LOCAL ANALGESIA PRIOR TO VENIPUNCTURE OR INTRAVENOUS CANNULATION.
U-833	METHOD OF TREATING PAIN USING A PHARMACEUTICALLY ACCEPTABLE SALT OF ROPIVACAINE AND ADMINISTERING A COMPOSITION CONTAINING LESS THAN 0.25% BY WEIGHT OF ROPIVACAINE
U-834	INVIRASE IN COMBINATION WITH RITONAVIR AND OTHER ANTIRETROVIRAL AGENTS IS INDICATED FOR THE TREATMENT OF HIV INFECTION
U-835	RELIEF OF THE INFLAMMATORY AND PRURITIC MANIFESTATIONS OF ATOPIC DERMATITIS IN PATIENTS ONE YEAR OF AGE OR OLDER
U-836	A METHOD FOR THE TREATMENT OF LEUKEMIAS
U-837	GASTROINTESTINAL LAVAGE INDICATED FOR CLEANSING OF THE COLON AS A PREPARATION FOR COLONOSCOPY IN ADULTS
U-838	METHOD OF TREATING PAIN USING A PHARMACEUTICALLY ACCEPTABLE SALT OF ROPIVACAINE AND ADMINISTERING A COMPOSITION CONTAINING LESS THAN 0.5% BY WEIGHT OF ROPIVACAINE
U-839	TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
U-840	TREATMENT FOR TYPE 2 DIABETES MELLITUS
U-841	INDICATED FOR THE LONG-TERM, MAINTENANCE TREATMENT OF ASTHMA IN PATIENTS 12 YEARS OF AGE AND OLDER
U-842	INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)
U-843	METHOD FOR ADMINISTRATION OF TESTOSTERONE
U-844	PREFEST IS INDICATED IN WOMEN WHO HAVE A UTERUS FOR THE TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE; TREATMENT OF VULVAR AND VAGINAL ATROPHY; PREVENTION OF OSTEOPOROSIS
U-845	TREATMENT OF PATIENTS WITH CANDIDEMIA, ACUTE DISSEMINATED CANDIDIASIS, CANDIDA PERITONITIS AND ABSCESES
U-846	USE FOR DELINEATION (VISUALIZATION) DURING A VITRECTOMY SURGICAL PROCEDURE
U-847	ADJUNCTIVE THERAPY TO DIET IN ADULTS TO REDUCE LDL-C, TRIGLYCERIDES AND APO B, AND INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA OR MIXED DYSLIPIDEMIA (TYPES IIA, IIB) AND TO TREAT HYPERTRIGLYCERIDEMIA (TYPES IV, V)
U-848	ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA
U-849	REDUCTION OF ELEVATED INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION WHO REQUIRE ADJUNCTIVE OR REPLACEMENT THERAPY DUE TO INADEQUATELY CONTROLLED IOP. DOSE IS ONE DROP OF COMBIGAN IN THE AFFECTED EYE TWICE DAILY
U-850	PREVENTION OR TREATMENT OF NAUSEA OR EMESIS INDUCED BY A CANCER CHEMOTHERAPEUTIC AGENT
U-851	TREATMENT OF TYPE 2 DIABETES MELLITUS
U-852	RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL AND PERENNIAL ALLERGIC RHINITIS
U-853	TREATMENT OR PREVENTION OF EMESIS
U-854	PREVENTION OF CMV DISEASE IN KIDNEY, HEART, AND KIDNEY-PANCREAS TRANSPLANT

PATENT AND EXCLUSIVITY TERMS

ADB 92 of 191

PATENT USE

	PATIENTS AT HIGH RISK (DONOR CMV SEROPOSITIVE/RECIPIENT CMV SERONEGATIVE)
U-855	METHOD TO INDUCE NATRIURESIS, DIURESIS AND/OR VASODILATION
U-856	SUPPORT EMBRYO IMPLANTATION AND EARLY PREGNANCY BY SUPPLEMENTATION OF CORPUS LUTEAL FUNCTION AS PART OF AN ASSISTED REPRODUCTIVE TECHNOLOGY (ART) TREATMENT PROGRAM FOR INFERTILE WOMEN
U-857	INHIBITION OF TRANSPLANT REJECTION
U-858	PEDIATRIC USE AGED 1-11 YEARS, GERD AND EROSION ESOPHAGITIS
U-859	EROSIVE ESOPHAGITIS, HYPERSECRETORY CONDITIONS INCLUDING ZOLLINGER-ELLISON SYNDROME, MAINTENANCE OF HEALING OF EROSION ESOPHAGITIS AND REDUCTION OF SYMPTOMS IN PATIENTS WITH GERD
U-860	FOR THE APPROVED USES AND CONDITIONS OF USE, INCLUDING DEPRESSION
U-861	RELIEF OF THE INFLAMMATORY AND PRURITIC MANIFESTATIONS OF CORTICOSTEROID RESPONSIVE DERMATOSES IN PATIENTS 12 YEARS OF AGE OR OLDER
U-862	ADJUNCT TO DIET TO REDUCE ELEVATED TOTAL-C, LDL-C, NON-HDL-C, APO B, TG, AND LP(A) LEVELS AND TO INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA, MIXED DYSLIPIDEMIA, AND HYPERTRIGLYCERIDEMIA
U-863	TAKING ASPIRIN OR NON-STEROIDAL ANTI-INFLAMMATORY MEDICATIONS APPROXIMATELY 30 MINUTES BEFORE DOSING CAN MINIMIZE FLUSHING, A COMMON SIDE EFFECT OF NIACIN THERAPY
U-864	PEDIATRIC USE AGES 1-2 YEARS, GERD AND EROSION ESOPHAGITIS
U-865	TREATMENT OF A WOMAN WITH OSTEOPOROSIS AND A HIGH RISK FOR BONE FRACTURE BY REDUCING THE RISK OF VERTEBRAL AND NONVERTEBRAL BONE FRACTURE
U-866	THE LABEL REFERENCES THE EFFECTS OF THE ACTIVE INGREDIENT OF REVLIMID UPON CYTOKINES
U-867	TREATMENT OF MIGRAINE
U-868	METHOD OF USING ANTAGONIST OF ARGININE VASOPRESSIN (AVA) V1A AND V2 RECEPTORS FOR INTRAVENOUS TREATMENT OF PATIENTS WITH HYPERVOLEMIC HYPONATREMIA
U-869	METHOD FOR STIMULATING CORONARY VASODILATION FOR PURPOSES OF IMAGING THE HEART
U-870	METHOD OF PRODUCING CORONARY VASODILATION WITHOUT PERIPHERAL VASODILATION
U-871	METHOD OF REDUCING RISK OF MYOCARDIAL INFARCTION, STROKE AND DEATH
U-872	TWICE DAILY MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA. TO REDUCE EXACERBATIONS OF COPD IN PATIENTS WITH A HISTORY OF EXACERBATIONS
U-873	METHOD OF TREATING CONSTIPATION IN A PATIENT WITH IRRITABLE BOWEL SYNDROME BY OPENING CHLORIDE CHANNELS (CIC)
U-874	METHOD OF TREATING CONSTIPATION IN A PATIENT WITH IRRITABLE BOWEL SYNDROME
U-875	FIRST-LINE TREATMENT OF LOCALLY ADVANCED UNRESECTABLE OR METASTATIC PANCREATIC CANCER, IN COMBINATION WITH GEMCITABINE
U-876	TREATMENT OF MIGRAINE WITH OR WITHOUT AURA
U-877	FOR USE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PEPTIC ULCER
U-878	A METHOD FOR BINDING A PERIPHERAL OPIOID RECEPTOR
U-879	A METHOD OF TREATING OR PREVENTING ILEUS
U-880	ENDOMETRIN IS A PROGESTERONE INDICATED TO SUPPORT EMBRYO IMPLANTATION AND EARLY PREGNANCY BY SUPPLEMENTATION OF CORPUS LUTEAL FUNCTION AS PART OF AN ASSISTED REPRODUCTIVE TECHNOLOGY (ART) TREATMENT PROGRAM FOR INFERTILE WOMEN
U-881	TREATMENT OF NON-SMALL CELL LUNG CANCER
U-882	MANAGEMENT OF FIBROMYALGIA (FM)
U-883	TREATMENT OF GASTROINTESTINAL STROMAL TUMOR WITH SUNITINIB
U-884	TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA
U-885	TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA WHO HAVE RECEIVED AT LEAST 1 PRIOR THERAPY
U-886	ADMINISTERING DESLORATADINE TO TREAT THE SYMPTOMS OF PERENNIAL ALLERGIC RHINITIS, SEASONAL ALLERGIC RHINITIS, OR CHRONIC IDIOPATHIC URTICARIA

PATENT AND EXCLUSIVITY TERMS

ADB 93 of 191

PATENT USE

U-887	TREATMENT AND PREVENTION OF OSTEOPOROSIS
U-888	FEMALE HORMONE REPLACEMENT THERAPY FOR POSTMENOPAUSAL WOMEN
U-889	MENOPAUSAL AND POSTMENOPAUSAL DISORDERS (INCLUDING VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE)
U-890	REDUCTION OF SERUM PHOSPHATE IN PATIENTS WITH END STAGE RENAL DISEASE
U-891	USE AS AN INTRAOCULAR IRRIGATING SOLUTION DURING SURGICAL PROCEDURES INVOLVING PERFUSION OF THE EYE
U-892	TREATMENT OF CUTANEOUS MANIFESTATIONS IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA (CTCL)
U-893	CLEVIPREX IS A DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKER INDICATED FOR THE REDUCTION OF BLOOD PRESSURE WHEN ORAL THERAPY IS NOT FEASIBLE OR NOT DESIRABLE
U-894	TREATMENT OF COLD SORES IN PEDIATRIC PATIENTS TWELVE YEARS OF AGE AND OLDER
U-895	TREATMENT OF HIV INFECTION IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS
U-896	TREATMENT OF NASAL SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS IN ADULTS AND CHILDREN TWO YEARS OF AGE AND OLDER
U-897	METHOD OF TREATING TONSILLITIS AND/OR PHARYNGITIS SECONDARY TO STREPTOCOCCUS PYOGENES IN A ONCE-A-DAY AMOXICILLIN PRODUCT
U-898	USE OF GLUTAMINE TOGETHER WITH GROWTH HORMONE FOR THE TREATMENT OF PATIENTS WITH SHORT BOWEL SYNDROME
U-899	USE OF THALIDOMIDE IN COMBINATION WITH DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
U-900	INTEGRASE INHIBITION FOR THE TREATMENT OF HIV INFECTION
U-901	PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING
U-902	USE IN THE TREATMENT OF THE SIGNS AND SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA (BPH)
U-903	TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ADULT PATIENTS
U-904	TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE
U-905	TREATMENT OF MODERATE TO SEVERE VAGINAL DRYNESS AND PAIN WITH INTERCOURSE, SYMPTOMS OF VULVAR AND VAGINAL ATROPHY, ASSOCIATED WITH MENOPAUSE
U-906	PROPHYLAXIS OF ORGAN REJECTION IN KIDNEY, LIVER AND HEART ALLOGENIC TRANSPLANTS; TREATMENT OF PATIENTS WITH SEVERE ACTIVE, RHEUMATOID ARTHRITIS; TREATMENT OF ADULT, NONIMMUNOCOMPROMISED PATIENTS WITH SEVERE, RECALCITRANT, PLAQUE PSORIASIS
U-907	FOR THE MAINTENANCE OF REMISSION OF ULCERATIVE COLITIS IN SUBJECTS 18 YEARS OF AGE AND OLDER
U-908	PROPHYLAXIS OF ORGAN REJECTION IN PATIENTS RECEIVING ALLOGENEIC RENAL TRANSPLANTS
U-909	TREATMENT OF CYSTIC FIBROSIS PATIENTS WITH PSEUDOMONAS AERUGINOSA
U-910	TREATMENT OF METASTATIC CARCINOMA OF THE OVARY AFTER FAILURE OF INITIAL OR SUBSEQUENT CHEMOTHERAPY
U-911	METHOD OF TREATING, AS ADJUNCTIVE THERAPY, PARTIAL-ONSET SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS AND OLDER WHEN ORAL TREATMENT IS TEMPORARILY NOT FEASIBLE
U-912	SEDATION OF NON-INTUBATED PATIENTS PRIOR TO AND/OR DURING SURGICAL AND OTHER PROCEDURES
U-913	TREATMENT OF OVERACTIVE BLADDER WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND FREQUENCY
U-914	METHOD OF TREATING, AS ADJUNCTIVE THERAPY, PARTIAL-ONSET SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS AND OLDER
U-915	TREATMENT OF MUSCULOSKELETAL CONDITIONS
U-916	TOPICAL TREATMENT OF ACNE VULGARIS IN PATIENTS 12 YEARS OR OLDER
U-917	TREATMENT OF INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS
U-918	TO TREAT OR PREVENT INFECTIONS CAUSED BY SUSCEPTIBLE BACTERIA USING DELAYED-RELEASE TABLETS CONSISTING OF DOXYCYCLINE HYCLATE COATED PELLETS IN A TABLET

PATENT AND EXCLUSIVITY TERMS

ADB 94 of 191

PATENT USE

U-919 FOR THE TREATMENT OF DERMATITIS

U-920 STEROID-RESPONSIVE INFLAMMATORY OCULAR CONDITIONS FOR WHICH A CORTICOSTEROID IS INDICATED AND WHERE SUPERFICIAL BACTERIAL OCULAR INFECTION OR A RISK OF BACTERIAL OCULAR INFECTION EXISTS

U-921 TREATMENT OF ACNE VULGARIS

U-922 FOR THE TREATMENT OF FUNGAL INFECTIONS

U-923 METHOD OF TREATING OPHTHALMIC INFLAMMATION AND INFECTION

U-924 TREATMENT OF MILD TO MODERATE INFECTION CAUSED BY SUSCEPTIBLE STRAINS

U-925 TREATMENT OF ONLY INFLAMMATORY LESIONS (PAPULES AND PUSTULES) OF ROSACEA

U-926 MGT SPECIFIC BACTERIAL INFECTIONS. TREATMENT PTS W/ COMMUNITY ACQUIRED PNEUMONIA OR BACTERIAL SINUSITIS DUE TO CONFIRMED, OR SUSPECTED B-LACTAMASE PRODUCING PATHOGENS & S. PNEUMONIAE WITH REDUCED SUSCEPTIBILITY TO PENICILLIN (MIC=2MC/ML)

U-927 METHOD FOR INCREASING TEAR PRODUCTION

U-928 TREATMENT OF BACTERIAL INFECTIOUS DISEASE

U-929 TREATMENT OF OBSESSIVE COMPULSIVE DISORDER TREATABLE WITH AN SSRI

U-930 TREATMENT OF IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP)

U-931 RELIEF OF MODERATE TO SEVERE ACUTE PAIN

U-932 PYLERA CAPSULES, IN COMBINATION WITH OMEPRAZOLE ARE INDICATED FOR THE TREATMENT OF PATIENTS WITH HELICOBACTER PYLORI INFECTION AND DUODENAL ULCER DISEASE TO ERADICATE H. PYLORI

U-933 FOR THE TREATMENT OF PATIENTS WITH HELICOBACTER PYLORI INFECTION AND DUODENAL ULCER DISEASE TO ERADICATE H. PYLORI. THE ERADICATION OF HELICOBACTER PYLORI HAS BEEN SHOWN TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE

U-934 IN COMBINATION WITH GRANULOCYTE-COLONY STIMULATING FACTOR (G-CSF) TO MOBILIZE HEMATOPOIETIC STEM CELL TO THE PERIPHERAL BLOOD FOR COLLECTION AND SUBSEQUENT AUTOLOGOUS TRANSPLANTATION WITH NON-HODGKINS LYMPHOMA AND MULTIPLE MYELOMA

U-935 TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION IN ADULT PATIENTS, AND TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN PEDIATRIC PATIENTS 6 YEARS OF AGE AND OLDER

U-936 USE IN COMBINATION WITH GRANULOCYTE-COLONY STIMULATING FACTOR (G-CSF) TO MOBILIZE HEMATOPOIETIC STEM CELLS TO PERIPHERAL BLOOD FOR COLLECTION & SUBSEQUENT AUTOLOGOUS TRANSPLANTATION IN PATIENTS WITH NON-HODGKIN'S LYMPHOMA & MULTIPLE MYELOMA

U-937 TREATMENT OF PROSTATE CANCER

U-938 TREATMENT OF HAIR LOSS AND HYPOTRICHOSIS OF THE EYELASHES BY INCREASING THEIR GROWTH INCLUDING LENGTH, THICKNESS AND DARKNESS

U-939 TREATMENT OF HYPOTRICHOSIS OF THE EYELASHES BY INCREASING AND STIMULATING THEIR GROWTH INCLUDING LENGTH, THICKNESS AND DARKNESS

U-940 METHOD TO TREAT AIDS-RELATED KAPOSI'S SARCOMA

U-941 METHOD TO TREAT OVARIAN CANCER

U-942 METHOD TO TREAT MULTIPLE MYELOMA

U-943 GNRH ANTAGONIST INDICATED FOR TREATMENT OF PATIENTS WITH ADVANCED PROSTATE CANCER

U-944 TREATMENT OF PATIENTS WITH B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

U-945 SEDATIVE-HYPNOTIC AGENT INDICATED FOR MONITORED ANESTHESIA CARE (MAC) SEDATION

U-946 TREATMENT OF BREAST CANCER

U-947 WHEN PATIENTS ARE UNABLE TO TAKE THE ORAL FORMULATIONS, PREVACID IV, FOR INJECTION IS INDICATED AS AN ALTERNATIVE FOR THE SHORT-TERM TREATMENT (UP TO 7 DAYS) OF ALL GRADES OF EROSIIVE ESOPHAGITIS

U-948 TREATMENT OF DIABETES MELLITUS

U-949 HEALING OF ALL GRADES OF EROSIIVE ESOPHAGITIS (EE) FOR UP TO 8 WEEKS

U-950 MAINTAIN HEALING OF EROSIIVE ESOPHAGITIS (EE) FOR UP TO 6 MONTHS

U-951 TREATMENT OF HEARTBURN ASSOCIATED WITH NON-EROSIVE GASTROESOPHAGEAL REFLUX DISEASE (GERD) FOR 4 WEEKS

PATENT AND EXCLUSIVITY TERMS

ADB 95 of 191

PATENT USE

U-952	USE AS AN ANALGESIC
U-953	METHOD OF TREATING OPHTHALMIC INFLAMMATION AND INFECTION
U-954	CHRONIC MANAGEMENT OF HYPERURICEMIA IN PATIENTS WITH GOUT. NOT RECOMMENDED FOR THE TREATMENT OF ASYMPTOMATIC HYPERURICEMIA
U-955	PROPHYLACTIC TREATMENT OF MIGRAINE
U-956	TREATMENT OF PATIENTS WITH H. PYLORI INFECTION AND DUODENAL ULCER DISEASE
U-957	A METHOD OF TREATING CANCER IN A PATIENT COMPRISING ADMINISTERING IXABEPILONE OR PHARMACEUTICAL COMPOSITIONS COMPRISING IXABEPILONE
U-958	METHOD OF TREATING PATIENT COMPRISING MIXING FIRST AND SECOND VIALS OF PRODUCT COMPRISING LYOPHILIZED IXABEPILONE TO PROVIDE AN EPOTHILONE ANALOG SOLUTION, DILUTING SOLUTION WITH A SUITABLE DILUENT TO PREPARE INTRAVENOUS FORMULATION FOR PT
U-959	METHOD OF TREATING CANCER, IV ADMIN, LYOPHILIZED IXABEPILONE DILUTED, EVERY WEEK OR 3 WEEKS; LYOPHILIZED IXABEPILONE WITH SOLVENT(DEHYDRATED ETHANOL) DILUTED TO CONCENTRATION OF 0.1MG/ML TO 0.9MG/ML
U-960	METHOD OF TREATING CANCER IN A PATIENT COMPRISING INTRAVENOUSLY ADMINISTERING TO THE PATIENT IXABEPILONE DILUTED IN A PARENTERAL DILUENT
U-961	METHOD OF TREATING BREAST CANCER BY ADMINISTERING IXABEPILONE; A METHOD OF TREATING A CANCER RESPONSIBLE TO MICROTUBULE STABILIZATION BY ADMINISTERING IXABEPILONE
U-962	SYMBYAX IS INDICATED FOR THE ACUTE TREATMENT OF TREATMENT RESISTANT DEPRESSION IN ADULTS
U-963	PROZAC AND OLANZAPINE IN COMBINATION FOR THE ACUTE TREATMENT OF TREATMENT RESISTANT DEPRESSION IN ADULTS
U-964	ZYPREXA ZYDIS AND FLUOXETINE IN COMBINATION FOR THE ACUTE TREATMENT OF TREATMENT RESISTANT DEPRESSION IN ADULTS
U-965	USE OF IXABEPILONE IN COMBINATION WITH CAPECITABINE IN TREATMENT OF METASTASIS BREAST CANCER
U-966	TREATMENT OF ASTHMA (MAINTENANCE AND PROPHYLACTIC THERAPY)
U-967	A METHOD OF REVERSING SOFT-TISSUE ANESTHESIA I.E. ANESTHESIA OF THE LIP AND TONGUE, AND THE ASSOCIATED FUNCTIONAL DEFICITS RESULTING FROM AN INTRAORAL SUBMUCOSAL INJECTION OF A LOCAL ANESTHETIC
U-968	A METHOD FOR IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
U-969	TREATMENT OF MIGRAINE
U-970	TOPICAL TREATMENT OF LICE INFESTATIONS
U-971	INDICATED FOR THE ACUTE TREATMENT OF ADULTS WITH SCHIZOPHRENIA
U-972	MONOTHERAPY OR AS ADJUNCTIVE THERAPY TO LITHIUM OR VALPROATE FOR THE MAINTENANCE TREATMENT OF BIPOLAR I DISORDER
U-973	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHO ARE ALREADY TREATED WITH PIOGLITAZONE AND METFORMIN OR WHO HAVE INADEQUATE GLYCEMIC CONTROL ON PIOGLITAZONE OR METFORMIN ALONE
U-974	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES WHO ARE ALREADY TREATED WITH A PIOGLITAZONE AND METFORMIN
U-975	TREATMENT OF PULMONARY HYPERTENSION
U-976	IMPROVEMENT OF GLYCEMIC CONTROL IN INDIVIDUALS WITH TYPE 2 DIABETES
U-977	TREATMENT OF ACUTE, UNCOMPLICATED MALARIA INFECTION DUE TO PLASMODIUM FALCIPARUM IN PATIENTS OF 5KG BODYWEIGHT AND ABOVE
U-978	METHOD OF TREATING HYPONATREMIA
U-979	RELIEF OF MUSCLE SPASM
U-980	NONSTEROIDAL ANTI-INFLAMMATORY DRUG INDICATED FOR RELIEF OF MILD TO MODERATE ACUTE PAIN
U-981	MANAGEMENT OF MILD TO MODERATE PAIN, MANAGEMENT OF MODERATE TO SEVERE PAIN AS AN ADJUNCT TO OPIOID ANALGESICS, REDUCTION IN FEVER THROUGH ANTI-INFLAMMATORY, ANALGESIC, AND ANTIPYRETIC ACTIVITY
U-982	A METHOD OF TREATING OSTEOPOROSIS

PATENT AND EXCLUSIVITY TERMS

ADB 96 of 191

PATENT USE

U-983	METHOD OF TREATING OSTEOPOROSIS IN A POST-MENOPAUSAL WOMAN AT RISK FOR FRACTURE
U-984	METHOD FOR THE TREATMENT OF A WOMAN WITH OSTEOPOROSIS AND AT RISK FOR BONE FRACTURE
U-985	TREATMENT OF MACULAR EDEMA FOLLOWING BRANCH RETINAL VEIN OCCLUSION (BRVO) OR CENTRAL RETINAL VEIN OCCLUSION (CRVO)
U-986	TREATMENT OF PATIENTS INFECTED WITH PEDICULUS HUMANUS CAPITIS (HEAD LICE AND THEIR OVA) OF THE SCALP HAIR
U-987	TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH CHRONIC KIDNEY DISEASE ON DIALYSIS
U-988	TREATMENT OF RHINITIS COMPRISING THE NASAL APPLICATION OF A PHARMACEUTICAL FORMULATION AS CLAIMED IN US PATENT 7541350
U-989	FOR REDUCING BLOOD PHENYLALANINE LEVELS IN A HUMAN SUFFERING FROM HYPERPHENYLALANINEMIA
U-990	TREATMENT OF PROTOZOAL INFECTION
U-991	TREATMENT OR PROPHYLAXIS OF THROMBOSIS OR EMBOLISMS
U-992	REDUCTION OF THE RISK OF CARDIOVASCULAR HOSPITALIZATION
U-993	METHOD OF TREATING INFERTILITY
U-994	METHOD OF TREATMENT OF OSTEOPOROSIS WHEREIN THE OSTEOPOROSIS IS STEROID-INDUCED
U-995	METHOD FOR TREATING TYPE II DIABETES BY ADMINISTERING SAXAGLIPTIN
U-996	AN ADJUNCTIVE THERAPY TO DIET TO REDUCE ELEVATED TOTAL CHOLESTEROL (TC), LOW-DENSITY LIPOPROTEIN CHOLESTEROL, APOLIPOPROTEIN B, TRIGLYCERIDES, AND TO INCREASE HDL-C IN ADULT PATIENTS WITH PRIMARY HYPERLIPIDEMIA OR MIX DYSLIPIDEMIA
U-997	TREATMENT OF MAJOR DEPRESSIVE DISORDER BY DOSING AT INTERVALS OF 24 HOURS
U-998	ADJUNCTIVE THERAPY TO DIET TO REDUCE ELEVATED TOTAL CHOLESTEROL, LOW-DENSITY LIPOPROTEIN CHOLESTEROL, APOLIPOPROTEIN B, TRIGLYCERIDES AND TO INCREASE HDL-C IN ADULT PATIENTS WITH PRIMARY HYPERLIPIDEMIA OR MIXED DYSLIPIDEMIA
U-999	TREATMENT OF CHRONIC HEPATITIS B IN ADULT PATIENTS
U-1000	ADJUNCTIVE THERAPY TO DIET IN PATIENTS WITH HYPERLIPIDEMIAS
U-1001	METHOD FOR DELIVERING DRUG TO LUNG OF MAMMAL, COMPRISING ADMINISTERING DRUG PRODUCT BY INHALATION. TREATING A MAMMAL HAVING A CONDITION CAPABLE OF TREATMENT BY INHALATION, COMPRISING ADMINISTERING TO THE LUNG THE DRUG PRODUCT BY INHALATION
U-1002	METHOD OF TREATING INFLAMMATORY CONDITIONS
U-1003	A METHOD OF MYOCARDIAL PERFUSION IMAGING AND INCREASING CORONARY BLOOD FLOW
U-1004	TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA
U-1005	METHOD OF TREATING A STAPHYLOCOCCAL INFECTION
U-1006	NEW COMBINATION PRODUCT FOR THE EARLY TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) TO REDUCE THE LIKELIHOOD OF ULCERATIVE COLD SORES AND TO SHORTEN THE LESION HEALING TIME IN ADULTS AND ADOLESCENTS (12 YEARS OF AGE AND OLDER)
U-1007	METHOD OF TREATING GOUT FLARES
U-1008	APPLICATION OF ANTISEPTIC WITH MOISTURIZERS FOR SURGICAL AND HEALTHCARE PERSONNEL SKIN DISINFECTION
U-1009	METHOD FOR ADMINISTRATION OF TESTOSTERONE
U-1010	TO REDUCE BLOOD PHENYLALANINE LEVELS IN PATIENTS WITH HYPERPHENYLALANINEMIA DUE TO TETRA HYDROBIOPTERIN RESPONSIVE PHENYLKETONURIA. KUVAN SHOULD BE TAKEN ORALLY WITH FOOD TO INCREASE ABSORPTION
U-1011	USE OF GRANISETRON TRANSDERMAL SYSTEM TO TREAT/PREVENT CHEMOTHERAPY INDUCED NAUSEA AND VOMITING
U-1012	METHOD FOR TREATING INSOMNIA WHILE REDUCING THE RISK OF AN ADVERSE DRUG INTERACTION
U-1013	METHOD OF USING RIBAVIRIN IN COMBINATION WITH PEGYLATED INTERFERON ALPHA-2B TO TREAT PATIENTS WITH CHRONIC HEPATITIS C
U-1014	METHOD OF USING RIBAVIRIN IN COMBINATION WITH INTERFERON ALPHA-2B (PEGYLATED AND NONPEGYLATED) TO TREAT PATIENTS WITH CHRONIC HEPATITIS C

PATENT AND EXCLUSIVITY TERMS

ADB 97 of 191

PATENT USE

U-1015	TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA
U-1016	IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS FOR THE TREATMENT OF HIV-1 INFECTION IN TREATMENT-EXPERIENCED ADULT PATIENTS, WHO HAVE EVIDENCE OF VIRAL REPLICATION AND HIV-1 STRAINS RESISTANT TO AN NNRTI AND OTHER ANTIRETROVIRAL AGENTS
U-1017	A METHOD OF TREATING NASAL AND NON-NASAL SYMPTOMS OF SEASONAL ALLERGIC RHINITIS
U-1018	TREATMENT OF PULMONARY HYPERTENSION BY INHALATION
U-1019	TREATMENT OF PULMONARY HYPERTENSION
U-1020	METHOD OF USING COLCHICINE FOR THE PROPHYLAXIS OF GOUT FLARES
U-1021	SHORT-TERM TREATMENT (4-8 WEEKS) OF ACTIVE BENIGN GASTRIC ULCER
U-1022	FOR THE PREPARATION OF SKIN PRIOR TO SURGERY; HELPS REDUCE BACTERIA THAT CAN POTENTIALLY CAUSE SKIN INFECTION
U-1023	TREATMENT OF ATROPHIC VAGINITIS DUE TO MENOPAUSE
U-1024	REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION WHO REQUIRE ADJUNCTIVE OR REPLACEMENT THERAPY DUE TO INADEQUATELY CONTROLLED IOP
U-1025	TREATING FREQUENT HEARTBURN
U-1026	A METHOD OF TREATING HUMAN SUFFERING FROM OR SUSCEPTIBLE TO PSYCHOSIS.
U-1027	REDUCTION OF ELEVATED PLASMA STEROL AND/OR STANOL LEVELS IN A MAMMAL
U-1028	A METHOD OF DISTRIBUTING SODIUM OXYBATE UNDER CONTROL OF A CENTRAL PHARMACY
U-1029	METHOD FOR TREATING ACUTE ELEVATIONS OF BLOOD PRESSURE IN HUMAN SUBJECT IN NEED THEREOF
U-1030	IMPROVEMENT OF WALKING IN PATIENTS WITH MULTIPLE SCLEROSIS (MS)
U-1031	IMPROVE RESPIRATORY SYMPTOMS IN CYSTIC FIBROSIS IN PATIENTS WITH PSEUDOMONAS AERUGINOSA
U-1032	USE OF ROSUVASTATIN CALCIUM FOR THE PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE IN INDIVIDUALS WITHOUT CLINICALLY EVIDENT CORONARY HEART DISEASE BUT WITH INCREASED RISK FACTORS
U-1033	TOPICAL TREATMENT OF ACNE VULGARIS
U-1034	TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN ADULTS
U-1035	NONSTEROIDAL ANTI-INFLAMMATORY DRUG INDICATED FOR RELIEF OF MILD TO MODERATE ACUTE PAIN
U-1036	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH INSULIN
U-1037	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH A PPAR-GAMMA AGONIST
U-1038	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH METFORMIN AND A PPAR-GAMMA AGONIST
U-1039	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH METFORMIN
U-1040	INHIBITION OF THROMBIN IN A PATIENT
U-1041	TREATMENT OF DISORDERS RESPONSIVE TO GROWTH HORMONE
U-1042	METHOD FOR STIMULATING CORONARY VASODILATION FOR PURPOSES OF IMAGING THE HEART
U-1043	MANAGEMENT OF MODERATE TO SEVERE PAIN
U-1044	TOPICAL TREATMENT OF SCALP PSORIASIS
U-1045	MAINTENANCE TREATMENT IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NSCLC WHO HAVE NOT PROGRESSED ON 1ST-LINE TREATMENT WITH PLATINUM-BASED CHEMOTHERAPY
U-1046	MAINTENANCE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NSCLC WHOSE DISEASE HAS NOT PROGRESSED AFTER FOUR CYCLES PLATINUM-BASED CHEMOTHERAPY
U-1047	TREATMENT OF BIOPSY-CONFIRMED, PRIMARY SUPERFICIAL BASAL CELL CARCINOMA (SBCC)
U-1048	WORKS THROUGH THE INDUCTION OF INTERFERON AND OTHER CYTOKINES
U-1049	PROPHYLAXIS OF ORGAN REJECTION IN ADULT PATIENTS AT LOW-MODERATE IMMUNOLOGIC RISK RECEIVING A RENAL TRANSPLANT

PATENT AND EXCLUSIVITY TERMS

ADB 98 of 191

PATENT USE

U-1050 USE OF METAXALONE FOR TREATMENT OF MUSCULOSKELETAL CONDITIONS

U-1051 TREATMENT OF OROPHARYNGEAL CANDIDIASIS

U-1052 RELIEF OF SIGNS AND SYMPTOMS OF ARTHRITIS AND RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER

U-1053 RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER

U-1054 ONYCHOMYCOSIS OF THE TOENAIL CAUSED BY TRICOPHYTON RUBRUM OR TRICHOPHYTON MENTAGROPHYTES, ONCE DAILY USE FOR 12 CONSECUTIVE WEEKS

U-1055 AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHO ARE ALREADY TREATED WITH A THIAZOLIDINEDIONE (TZD) AND METFORMIN OR WHO HAVE INADEQUATE GLYCEMIC CONTROL ON A TZD OR METFORMIN ALONE

U-1056 TREATMENT OF PAIN USING A NASAL SPRAY OF KETOROLAC TROMETHAMINE

U-1057 TREATMENT OF INFLAMMATION AND PAIN USING A NASAL SPRAY OF KETOROLAC TROMETHAMINE

U-1058 USE OF THALIDOMIDE IN COMBINATION WITH DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA

U-1059 ADJUNCTIVE THERAPY TO DIET TO PATIENTS WITH HYPERTRIGLYCERIDEMIA

U-1060 ADJUNCTIVE THERAPY TO DIET IN PATIENTS WITH ELEVATED CHOLESTEROL AND/OR LIPID LEVELS

U-1061 ADJUNCTIVE THERAPY TO DIET IN PATIENTS WITH MIXED DYSLIPIDEMIA

U-1062 ADMINISTRATION OF APPROVED PRODUCT FOR TREATMENT OF ALZHEIMER'S DISEASE

U-1063 TREATMENT OF ONLY INFLAMMATORY LESIONS (PAPULES AND PUSTULES) OF ROSACEA

U-1064 TREATMENT OF BIPOLAR DISORDER AND SCHIZOPHRENIA

U-1065 METHOD OF TREATING ANDROGEN RESPONSIVE OR MEDICATED CONDITION IN A MAMMAL BY ADMINISTERING A SAFE & EFFECTIVE AMOUNT OF DUTASTERIDE OR A PHARMACEUTICALLY ACCEPTABLE SOLVATE THEREOF.. CONDITIONS INCLUDE BENIGN PROSTATIC HYPERTROPHY

U-1066 METHOD OF TREATING AN ANDROGEN RESPONSE OR MEDIATED DISEASE IN A MAMMAL BY ADMINISTERING AN EFFECTIVE ANDROGEN RESPONSIVE OR MEDICATED DISEASE AMOUNT OF DUTASTERIDE..CONDITIONS INCLUDE BENIGN PROSTATIC HYPERPLASIA

U-1067 TREATMENT OF CANCER

U-1068 TREATMENT OF ASTHMA

U-1069 A METHOD OF TREATING A PATIENT WITH A PRESCRIPTION DRUG USING AN EXCLUSIVE COMPUTER DATABASE IN A COMPUTER SYSTEM FOR DISTRIBUTION

U-1070 A METHOD TO CONTROL ABUSE OF A SENSITIVE DRUG BY CONTROLLING WITH A COMPUTER PROCESSOR THE DISTRIBUTION OF THE SENSITIVE DRUG VIA AN EXCLUSIVITY CENTRAL PHARMACY THAT MAINTAINS A CENTRAL DATABASE

U-1071 METHOD OF TREATING BLADDER DYSFUNCTION WITH ONCE A DAY TROSPIMUM SALT FORMULATION

U-1072 THE MANAGEMENT OF MODERATE TO SEVERE CHRONIC PAIN IN PATIENTS REQUIRING A CONTINUOUS, AROUND-THE-CLOCK OPIOID ANALGESIC FOR AN EXTENDED PERIOD OF TIME

U-1073 USE FOR THE TREATMENT OF ASTHMA AND COPD

U-1074 USE OF EXENATIDE MAY RESULT IN REDUCTION IN BODY WEIGHT

U-1075 USE FOR THE TREATMENT OF ASTHMA

U-1076 REDUCE CHRONIC SEVERE DROOLING (I.E., SIALORRHEA) IN PATIENTS WITH NEUROLOGIC CONDITIONS ASSOCIATED WITH PROBLEM DROOLING

U-1077 PRETREATMENT OF PATIENTS WITH VITAMIN B12 AND FOLIC ACID PRIOR TO PEMETREXED DISODIUM ADMINISTRATION

U-1078 TREATMENT OF ACNE

U-1079 REVLIMID (LENALIDOMIDE) IS INDICATED FOR THE TREATMENT OF PATIENTS WITH TRANSFUSION-DEPENDENT ANEMIA IN MYELODYSPLASTIC SYNDROMES (MDS)

U-1080 METHOD TO TREAT PULMONARY HYPERTENSION BY ADMINISTERING AMBRISENTAN TO A PATIENT

U-1081 LUMIGAN IS A PROSTAGLANDIN ANALOG INDICATED FOR THE REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION

U-1082 USE OF A COMBINATION OF TOBRAMYCIN AND DEXAMETHASONE TO TREAT OCULAR INFLAMMATION WHERE AN INFECTION OR RISK OF INFECTION EXISTS

U-1083 ACUTE TREATMENT OF MIGRAINE ATTACKS, WITH OR WITHOUT AURA, AND THE TREATMENT OF CLUSTER HEADACHE EPISODES

PATENT AND EXCLUSIVITY TERMS

ADB 99 of 191

PATENT USE

U-1084	RELIEF OF THE INFLAMMATORY AND PRURITIC MANIFESTATIONS OF CORTICOSTEROID RESPONSIVE DERMATOSES IN PATIENTS 12 YEARS OF AGE OR OLDER
U-1085	METHOD FOR TREATING IRRITABLE BOWEL SYNDROME AND METHOD FOR TREATING ABDOMINAL DISCOMFORT ASSOCIATED WITH IRRITABLE BOWEL SYNDROME
U-1086	TREATMENT OF AUTOIMMUNE DISEASE
U-1087	DETECTION OF NON-MUSCLE INVASIVE PAPILLARY CANCER OF THE BLADDER BY PHOTODYNAMIC CYSTOSCOPY
U-1088	RELIEF OF MUSCLE SPASM
U-1089	INHIBITION OF THROMBIN
U-1090	LO LOESTRIN FE IS INDICATED FOR THE PREVENTION OF PREGNANCY IN WOMEN WHO ELECT TO USE ORAL CONTRACEPTIVES AS A METHOD OF CONTRACEPTION
U-1091	ASSESSMENT OF BRONCHIAL HYPERRESPONSIVENESS IN PATIENTS 6 YEARS OF AGE OR OLDER WHO DO NOT HAVE CLINICALLY APPARENT ASTHMA
U-1092	TREATMENT OF BREAST CANCER
U-1093	TREATMENT OF PSEUDOBULBAR AFFECT
U-1094	MANAGEMENT OF CHRONIC MUSCULOSKELETAL PAIN
U-1095	METHOD OF TREATING OCULAR INFLAMMATION
U-1096	TREATMENT OF PATIENTS WITH METASTATIC BREAST CANCER
U-1097	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHEN TREATMENT WITH BOTH SAXAGLIPTIN AND METFORMIN IS APPROPRIATE
U-1098	METHOD OF TREATING HYPERPARATHYROIDISM; METHOD OF TREATING HYPERCALCEMIA
U-1099	TREATMENT OF PAIN, INCLUDING NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY, POSTHERPETIC NEURALGIA, AND FIBROMYALGIA
U-1100	REDUCTION OF EXCESS ABDOMINAL FAT IN HIV-INFECTED PATIENTS WITH LIPODYSTROPHY
U-1101	METHOD OF TREATING EXCESSIVE DAYTIME SLEEPINESS IN PATIENTS WITH NARCOLEPSY
U-1102	METHOD OF TREATING CATAPLEXY IN PATIENTS WITH NARCOLEPSY
U-1103	TESTOSTERONE REPLACEMENT THERAPY IN MALES FOR CONDITIONS ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE
U-1104	USE OF TRAMADOL FOR THE MANAGEMENT OF MODERATE TO MODERATELY SEVERE CHRONIC PAIN
U-1105	TOPICAL TREATMENT OF HEAD LICE INFESTATION IN PATIENTS FOUR (4) YEARS OF AGE AND OLDER
U-1106	TREATING HYPERTRIGLYCERIDEMIAS WITH REDUCTION OF FOOD EFFECT
U-1107	TREATING HYPERCHOLESTEROLEMIAS WITH REDUCTION OF FOOD EFFECT
U-1108	TREATING TYPE 2 DIABETES MELLITUS WITH EXENATIDE BY STIMULATING INSULIN RELEASE
U-1109	TREATMENT OF CUTANEOUS MANIFESTATIONS OF ERYTHEMA NODOSUM LEPROSUM (ENL) IN CONNECTION WITH A SPECIAL PROGRAM APPROVED BY FDA CALLED "SYSTEM FOR THALIDOMIDE EDUCATION AND PRESCRIBING SAFETY" (S.T.E.P.S.)
U-1110	METHOD OF TREATING A PATIENT WITH A PRESCRIPTION DRUG USING A COMPUTER DATABASE IN A COMPUTER SYSTEM FOR DISTRIBUTION
U-1111	NONSTEROIDAL ANTI-INFLAMMATORY DRUG INDICATED FOR RELIEF OF MILD TO MODERATE ACUTE PAIN
U-1112	METHOD OF MR IMAGING OF A MAMMAL
U-1113	TREATMENT AND PROPHYLAXIS OF INFLUENZA
U-1114	TREATMENT WITH GABAPENTIN, INCLUDING TREATMENT OF NEUROPATHIC PAIN, INCLUDING NEUROPATHIC PAIN ASSOCIATED WITH POSTHERPETIC NEURALGIA
U-1115	TREATMENT TO REDUCE THE RISK OF COPD EXACERBATIONS IN PATIENTS WITH SEVERE COPD ASSOCIATED WITH CHRONIC BRONCHITIS AND A HISTORY OF EXACERBATIONS
U-1116	METHOD OF ADMINISTERING COLCHICINE TO FAMILIAL MEDITERRANEAN FEVER PATIENTS
U-1117	TREATMENT OF BREAST CANCER
U-1118	USE FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA

PATENT AND EXCLUSIVITY TERMS

ADB 100 of 191

PATENT USE

U-1119	CONTRAST AGENT FOR MAGNETIC RESONANCE IMAGING
U-1120	TO REDUCE GASTROINTESTINAL SIDE EFFECTS ADMINISTER WITH A MEAL; AS STARTING DOSE ADMINISTER ONCE DAILY WITH EVENING MEAL
U-1121	METHOD OF TREATING TRAVELERS' DIARRHEA
U-1122	TREATMENT OF SECONDARILY INFECTED TRAUMATIC SKIN LESIONS DUE TO S. AUREUS AND S. PYOGENES
U-1123	TREATMENT OF ALCOHOL DEPENDENCE
U-1124	PREVENTION OF RELAPSE TO OPIOID DEPENDENCE, FOLLOWING OPIOID DETOXIFICATION
U-1125	METHOD FOR THE DETECTION OF NEUROENDOCRINE TUMORS
U-1126	USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER WHO HAVE RECEIVED PRIOR CHEMOTHERAPY CONTAINING DOCETAXEL
U-1127	TREATMENT OF PATENT DUCTUS ARTERIOSUS
U-1128	TREATMENT OF CHRONIC HEPATITIS C (CHC) GENOTYPE 1 INFECTION IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN IN ADULT PATIENTS (>=18 YEARS OF AGE) WITH COMPENSATED LIVER DISEASE
U-1129	TREATMENT OF HYPERCHOLESTEROLEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITING AGENT SUCH AS ASPIRIN
U-1130	SECONDARY PREVENTION OF CARDIOVASCULAR EVENTS BY DOSING ONCE PER DAY IN THE EVENING OR A NIGHT WITH PRETREATMENT WITH A FLUSH INHIBITING AGENT SUCH AS ASPIRIN
U-1131	TREATMENT OF HYPERTRIGLYCERIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITING AGENT SUCH AS ASPIRIN
U-1132	TREATMENT OF HYPERCHOLESTEROLEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
U-1133	SECONDARY PREVENTION OF CARDIOVASCULAR EVENTS BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
U-1134	TREATMENT OF HYPERTRIGLYCERIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
U-1135	TREATMENT OF HYPERCHOLESTEROLEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION OF LDL-C, TC, TG, LP(A) AND INCREASE OF HDL-C
U-1136	SECONDARY PREVENTION OF CARDIOVASCULAR EVENTS BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION OF LDL-C, TC, TG, LP(A), AND INCREASE OF HDL-C
U-1137	TREATMENT OF HYPERTRIGLYCERIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION OF LDL-C, TC, TG, LP(A), AND INCREASE OF HDL-C
U-1138	TREATMENT OF PRIMARY AND MIXED DYSLIPIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
U-1139	REDUCTION IN RISK OF RECURRENT NONFATAL MYOCARDIAL INFARCTION BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
U-1140	REDUCTION IN ELEVATED TC AND LDL-C BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
U-1141	REDUCTION IN TG BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
U-1142	TREATMENT OF PRIMARY AND MIXED DYSLIPIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITING AGENT SUCH AS ASPIRIN
U-1143	REDUCTION IN RISK OF RECURRENT NONFATAL MYOCARDIAL INFARCTION BY DOSING ONCE PER DAY IN THE EVENING OR A T NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITING AGENT SUCH AS ASPIRIN
U-1144	REDUCTION IN ELEVATED TC AND LDL-C BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITING AGENT SUCH AS ASPIRIN
U-1145	REDUCTION IN TG BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITING AGENT SUCH AS ASPIRIN
U-1146	REDUCTION IN TG WITH REDUCED FLUSHING BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT
U-1147	TREATMENT OF PRIMARY AND MIXED DYSLIPIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION OF LDL-C, TC, TG, LP(A), AND INCREASE OF

PATENT AND EXCLUSIVITY TERMS

ADB 101 of 191

PATENT USE

HDL-C

- U-1148 REDUCTION IN RISK OF RECURRENT NONFATAL MYOCARDIAL INFARCTION BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION OF LDL-C, TC, TG, LP(A), AND INCREASE OF HDL-C
- U-1149 TREATMENT OF HYPERTRIGLYCERIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITING AGENT SUCH AS ASPIRIN
- U-1150 TRETMENT OF HYPERCHOLESTEROLEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION IN TOTAL-C, LDL-C, TG, LP(A), AND INCREASE OF HDL-C
- U-1151 TREATMENT OF HYPERTRIGLYCIDERIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION IN TOTAL-C, LDL-C, LP(A), AND INCREASE OF HDL-C
- U-1152 CYANOCOBALAMIN ADMINISTRATION THROUGH NASAL INFUSION
- U-1153 IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS, IS INDICATED FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) INFECTION IN ANTIRETROVIRAL TREATMENT-NAIVE ADULT PATIENTS, AS SET FORTH IN THE LABELING, INCLUDING I&U SECTION
- U-1154 TREATMENT OF PROTEIN KINASE RELATED DISORDERS, SUCH AS GASTROINTESTINAL STROMAL TUMORS, RENAL CELL CARCINOMA AND ADVANCED PANCREATIC NEUROENDOCRINE TUMORS, WITH SUNITINIB
- U-1155 USE OF THALIDOMIDE IN TREATMENT OF CUTANEOUS MANIFESTATIONS OF ERYTHEMA NODOSUM LEPROSUM (ENL)
- U-1156 TO REDUCE BLOOD PHENYLALANINE (PHE) LEVELS IN PATIENTS WITH HYPERPHENYLALANINEMIA (HPA)
- U-1157 RELIEF OF SYMPTOMS ASSOCIATED WITH RESPIRATORY ALLERGIES IN ADULTS AND CHILDREN 2 YEARS OF AGE AND OLDER AND FOR THE RELIEF OF SYMPTOMS ASSOCIATED WITH HIVES (URTICARIA) IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER
- U-1158 RELIEF OF SYMPTOMS ASSOCIATED WITH RESPIRATORY ALLERGIES AND FOR THE RELIEF OF SYMPTOMS ASSOCIATED WITH HIVES (URTICARIA) IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER
- U-1159 RELIEF OF SYMPTOMS ASSOCIATED WITH RESPIRATORY ALLERGIES, SWELLING OF THE NASAL PASSAGES AND SINUS CONGESTION AND PRESSURE IN ADULTS AND CHILDREN 12 YEARS OF AGE AND OLDER
- U-1160 RELIEF OF SYMPTOMS ASSOCIATED WITH RESPIRATORY ALLERGIES AND FOR THE RELIEF OF SYMPTOMS ASSOCIATED WITH HIVES (URTICARIA) IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER AND 12 YEARS OF AGE AND OLDER
- U-1161 FOR THE TREATMENT AND PROPHYLAXIS OF GOUT FLARES & THE TREATMENT OF FAMILIAL MEDITERRANEAN FEVER
- U-1162 TREATMENT OF SEBORRHEIC DERMATITIS OF THE SCALP
- U-1163 METHOD OF TREATING THROMBOSIS
- U-1164 METHOD OF TREATING AN ARGATROBAN TREATABLE CONDITION
- U-1165 USE FOR THE TREATMENT OF MULTIPLE MYELOMA
- U-1166 A METHOD FOR TREATMENT OF GOUT FLARES DURING PROPHYLAXIS
- U-1167 PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT)
- U-1168 THE LONG TERM, ONCE-DAILY MAINTENANCE BRONCHODILATOR TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA
- U-1169 MANAGEMENT OF BREAKTHROUGH PAIN IN CANCER PATIENTS 18 YEARS OF AGE AND OLDER WHO ARE RECEIVING AND TOLERANT TO OPIOID THERAPY FOR THEIR UNDERLYING PERSISTENT CANCER PAIN
- U-1170 TREATMENT OF HIV-1 INFECTION IN PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER
- U-1171 REDUCTION OF THE RATE OF THROMBOTIC EVENTS IN PATIENTS WITH ACUTE CORONARY SYNDROME
- U-1172 TO REDUCE ELEVATED TOTAL-C, APO B, AND NON-HDL-C IN PATIENTS WITH PRIMARY HYPERLIPIDEMIA BY ADMINISTRATION OF EZETIMIBE IN COMBINATION WITH A STATIN
- U-1173 TO REDUCE ELEVATED TOTAL-C, LDL-C, APO B AND NON-HDL-C IN PATIENTS WITH PRIMARY HYPERLIPIDEMIA BY ADMINISTRATION OF EZETIMIBE ALONE OR IN COMBINATION WITH A STATIN OR WITH FENOFIBRATE
- U-1174 ADMINISTRATION OF REMODULIN DILUTED FOR INTRAVENOUS INFUSION WITH STERILE WATER

PATENT AND EXCLUSIVITY TERMS

ADB 102 of 191

PATENT USE

	FOR INJECTION, 0.9% SODIUM CHLORIDE INJECTION, OR FLOLAN STERILE DILUENT FOR INJECTION PRIOR TO ADMINISTRATION
U-1175	REDUCTION OF CARDIAC TISSUE DAMAGE ASSOCIATED WITH MYOCARDIAL INFARCTION
U-1176	TREATMENT OR PREVENTION OF STROKE
U-1177	REDUCTION OF CARDIAC TISSUE DAMAGE ASSOCIATED WITH MYOCARDIAL INFARCTION
U-1178	RELIEF OF MODERATE TO SEVERE CHRONIC PAIN
U-1179	TREATMENT OF A CANCER MEDIATED BY AN ANAPLASTIC LYMPHOMA KINASE (ALK)
U-1180	TREATMENT OF THE FOLLOWING INFECTIONS: COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS AND STAPHYLOCOCCUS AUREUS BLOODSTREAM INFECTIONS (BACTEREMIA) INCLUDING THOSE WITH RIGHT-SIDED INFECTIVE ENDOCARDITIS
U-1181	A METHOD OF TREATING OR PREVENTING OCULAR PAIN IN A PATIENT
U-1182	TREATMENT OF CYCLIC HEAVY MENSTRUAL BLEEDING
U-1183	A METHOD FOR ADMINISTERING FOLLICLE STIMULATING HORMONE (FSH) FOR OVARIAN FOLLICLE OR TESTICULAR STIMULATION IN THE HUMAN
U-1184	TREATMENT OF ERECTILE DYSFUNCTION AND THE SIGNS AND SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA
U-1185	TREATMENT OF OPIOID-INDUCED CONSTIPATION
U-1186	ADMINISTRATION OF AN INHALABLE POWDER COMPRISING TIOTROPIUM VIA DEVICE
U-1187	TREATMENT OF PATHOLOGICAL STATE BY ANTAGONIZING BRADYKININ RECEPTOR INCLUDING TREATMENT OF ACUTE ATTACKS OF HEREDITARY ANGIOEDEMA (HAE)
U-1188	METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE
U-1189	METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE, IN COMBINATION WITH METFORMIN
U-1190	METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE, IN COMBINATION WITH INSULIN
U-1191	METHOD OF TX TYPE 2 DM IN PTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE, IN COMBO WITH AN AGENT ACTING ON AN ATP-DEPENDENT CHANNEL IN BETA CELLS SUCH AS A SULFONYLUREA (INCL GLIPIZIDE, GLIMEPIRIDE & GLYBURIDE)
U-1192	METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE, IN COMBINATION WITH A SULFONYLUREA (SUCH AS GLIPIZIDE, GLIMEPIRIDE AND GLYBURIDE)
U-1193	METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE, IN COMBINATION WITH A PPAR-GAMMA AGONIST (SUCH AS PIOGLITAZONE AND ROSIGLITAZONE)
U-1194	METHOD FOR TREATING INSOMNIA
U-1195	PREVENTION AND TREATMENT OF SECONDARY HYPERPARATHYROIDISM ASSOCIATED WITH CHRONIC KIDNEY DISEASE (CKD) STAGE 5, WHICH MAY RESULT IN RENAL OSTEODYSTROPHY, WHILE AVOIDING HYPERPHOSPHATEMIA
U-1196	RELIEF OF SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS AND OSTEOARTHRITIS AND TO DECREASE RISK OF DEVELOPING UPPER GASTROINTESTINAL ULCERS IN PATIENTS WHO ARE TAKING IBUPROFEN FOR THOSE INDICATIONS
U-1197	METHOD OF TREATMENT OF CHILDREN WITH CENTRAL PRECOCIOUS PUBERTY
U-1198	RECTIV IS A NITRATE VASODILATOR INDICATED FOR THE TREATMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH CHRONIC ANAL FISSURE
U-1199	TREATMENT AND PREVENTION OF POSTMENOPAUSAL OR GLUCOCORTICOID-INDUCED OSTEOPOROSIS AND TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS
U-1200	REDUCING THE RISK OF STROKE AND SYSTEMIC EMBOLISM
U-1201	FOR THE TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS
U-1202	METHOD FOR RELIEVING OR TREATING CONSTIPATION IN A PATIENT WITH IRRITABLE BOWEL SYNDROME
U-1203	METHOD FOR RELIEVING OR TREATING CONSTIPATION IN A HUMAN CONSTIPATED PATIENT
U-1204	TREATMENT OF UVEITIS

PATENT AND EXCLUSIVITY TERMS

ADB 103 of 191

PATENT USE

U-1205	TREATMENT OF MACULAR EDEMA
U-1206	DELIVERING AN OCULAR IMPLANT AS DESCRIBED IN THE DOSAGE AND ADMINISTRATION SECTION OF THE APPROVED LABELING OF OZURDEX
U-1207	INFANT USE AGED 1 MONTH TO LESS THAN ONE YEAR, GERD AND EROSION ESOPHAGITIS
U-1208	TREATMENT OF HYPOTRICHOSIS OF THE EYELASHES BY INCREASING THEIR GROWTH INCLUDING LENGTH, THICKNESS AND DARKNESS
U-1209	TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION IN ADULT PATIENTS, AND TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION IN PEDIATRIC PATIENTS 3 YEARS OF AGE AND OLDER
U-1210	USE OF REVLIMID (LENALIDOMIDE) WHILE PREVENTING THE EXPOSURE OF A FETUS OR OTHER CONTRAINDICATED INDIVIDUAL TO REVLIMID (LENALIDOMIDE)
U-1211	USE OF REVLIMID (LENALIDOMIDE) TO INHIBIT THE SECRETION OF PRO-INFLAMMATORY CYTOKINES, INCLUDING TUMOR NECROSIS FACTOR ALPHA
U-1212	USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF MULTIPLE MYELOMA AND TRANSFUSION-DEPENDENT ANEMIA IN MYELODYSPLASTIC SYNDROMES (MDS)
U-1213	TOPICAL TREATMENT OF SEBORRHEIC DERMATITIS IN IMMUNOCOMPETENT PATIENTS 12 YEARS OF AGE AND OLDER
U-1214	METHOD FOR RELIEVING CONSTIPATION IN A HUMAN PATIENT THAT COMPRISES ADMINISTERING TO THE PATIENT A DOSAGE UNIT COMPRISING (I) 24MCG+/- 10% OF A DRUG SUBSTANCE AND (II) A PHARMACEUTICALLY SUITABLE EXCIPIENT
U-1215	USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF TRANSFUSION-DEPENDENT ANEMIA IN MYELODYSPLASTIC SYNDROMES (MDS)
U-1216	USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF MULTIPLE MYELOMA
U-1217	METHOD OF INCREASING HAIR GROWTH
U-1218	METHOD OF STIMULATING HAIR GROWTH
U-1219	METHOD OF INCREASING THE NUMBER OF HAIRS
U-1220	TREATMENT OF RENAL CELL CARCINOMA
U-1221	TO STIMULATE THE IMMUNE SYSTEM TO INDUCE T CELL PROLIFERATION
U-1222	TO INHIBIT THE PROLIFERATIVE ACTIVITY OF NEOPLASTIC CELLS
U-1223	METHOD FOR TREATING TYPE 2 DIABETES USING A SUSTAINED-RELEASE COMPOSITION CONTAINING EXENATIDE
U-1224	REDUCTIONS IN BODY WEIGHT ARE OBSERVED WITH EXENATIDE
U-1225	ACCELERATING THE TIME TO UPPER AND LOWER GASTROINTESTINAL RECOVERY FOLLOWING PARTIAL LARGE OR SMALL BOWEL RESECTION SURGERY WITH PRIMARY ANASTOMOSIS
U-1226	A METHOD OF PROVIDING A PREDETERMINED CONCENTRATION OF NITRIC OXIDE TO A PATIENT
U-1227	METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND METFORMIN HCL EXTENDED RELEASE IS APPROPRIATE
U-1228	METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND METFORMIN HCL EXTENDED RELEASE IS APPROPRIATE ALONE OR IN COMBINATION WITH INSULIN
U-1229	TREATMENT OF MILDLY TO MODERATELY ACTIVE ULCERATIVE COLITIS IN MALE PATIENTS
U-1230	A METHOD OF PROVIDING NITRIC OXIDE THERAPY TO A PATIENT
U-1231	TREATMENT OF MODERATE-TO-SEVERE PRIMARY RESTLESS LEG SYNDROME IN ADULTS
U-1232	USE AS ANTICOAGULANT IN PTS W/ UNSTABLE ANGINA UNDERGOING PTCA; W/ PROVISIONAL USE OF GLYCOPROTEIN IIB/IIIA INHIBITOR, AS ANTICOAGULANT IN PTS UNDERGOING PCI AND FOR PTS W/, OR AT RISK OF, HIT/HITTS UNDERGOING PCI. INTENDED FOR USE W/ASPIRIN
U-1233	TREATMENT OF CHRONIC HEPATITIS C (CHC) GENOTYPE 1 INFECTION, ADMINISTERED WITH FOOD
U-1234	FOR REDUCING TOTAL CHOLESTEROL (TOTAL-C), LDL-C, APO-LIPOPROTEIN B, OR TOTAL TRIGLYCERIDES, AND TREATING HYPERTRIGLYCERIDEMIA
U-1235	REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION
U-1236	USE OF THALOMID (THALIDOMIDE) FOR THE TREATMENT OF MULTIPLE MYELOMA

PATENT AND EXCLUSIVITY TERMS

ADB 104 of 191

PATENT USE

U-1237	COMBO W/ OTHER ANTIRETROVIRALS FOR TX OF HIV-1 IN ANTIRETROVIRAL TX-EXPERIENCED PT 6 YEARS UP, WHO HAVE EVIDENCE OF VIRAL REPLICATION AND HIV-1 STRAINS RESISTANT TO NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR AND OTHER ANTIRETROVIRALS
U-1238	TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE
U-1239	MAGNETIC RESONANCE IMAGING OF THE LIVER
U-1240	TREATMENT OF HEAVY MENSTRUAL BLEEDING IN WOMEN WITHOUT ORGANIC PATHOLOGY WHO CHOOSE TO USE AN ORAL CONTRACEPTIVE AS THEIR METHOD OF CONTRACEPTION
U-1241	MANAGEMENT OF MODERATE TO SEVERE PAIN BY ORALLY ADMINISTERING AN INTACT COMPOSITION AS CLAIMED
U-1242	PREVENTION OF RESPIRATORY DISTRESS (RDS) IN PREMATURE INFANTS
U-1243	WITH DRY HANDS, GENTLY REMOVE THE SUPRENZA (PHENTERMINE HYDROCHLORIDE ODT) TABLET FROM THE BOTTLE. IMMEDIATELY PLACE THE SUPRENZA TABLET ON TOP OF THE TONGUE WHERE IT WILL DISSOLVE, THEN SWALLOW WITH OR WITHOUT WATER
U-1244	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH SULFONYUREA
U-1245	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH PIOGLITAZONE
U-1246	SINGLE DOSE ADMINISTRATION INTO THE SURGICAL SITE TO PRODUCE POSTSURGICAL ANALGESIA
U-1247	MANAGEMENT OF POSTHERPETIC NEURALGIA (PHN) IN ADULTS
U-1248	USE OF TOPICAL DICLOFENAC ON THE KNEE AND A SECOND TOPICAL MEDICATION ON THE SAME KNEE
U-1249	TREATMENT OF MALE PATIENT HAVING A DISEASE OR CONDITION RESPONSIVE TO A TERATOGENIC DRUG
U-1250	TREATMENT OF PAIN, INCLUDING NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY OR SPINAL CORD INJURY, POSTHERPETIC NEURALGIA, AND FIBROMYALGIA
U-1251	A METHOD OF CONTROLLING POSTOPERATIVE OCULAR PAIN AND BURNING/STINGING IN A PATIENT
U-1252	METHOD FOR CHRONIC WEIGHT MANAGEMENT BY DECREASING FOOD INTAKE
U-1253	METHOD FOR CHRONIC WEIGHT MANAGEMENT BY INDUCING SATIETY
U-1254	METHOD FOR CHRONIC WEIGHT MANAGEMENT BY CONTROLLING WEIGHT GAIN
U-1255	METHOD FOR CHRONIC WEIGHT MANAGEMENT BY TREATING OBESITY
U-1256	TREATMENT OF SEBORRHEIC DERMATITIS
U-1257	TREATMENT OF OPHTHALMIC DISORDERS
U-1258	VISUALIZATION DURING VITRECTOMY PROCEDURES
U-1259	PROPHYLAXIS OF HIV-1 INFECTION
U-1260	TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST TWO PRIOR THERAPIES INCLUDING BORTEZOMIB AND AN IMMUNOMODULATORY AGENT AND HAVE DEMONSTRATED DISEASE PROGRESSION ON OR WITHIN 60 DAYS OF COMPLETION OF THE LAST THERAPY
U-1261	REDUCTION OF THE RISK OF HOSPITALIZATION FOR ATRIAL FIBRILLATION
U-1262	USE OF QSYMIA (PHENTERMINE AND TOPIRAMATE) FOR WEIGHT MANAGEMENT, INCLUDING, BUT NOT LIMITED TO EFFECTING WEIGHT LOSS, TREATING OBESITY, AND/OR TREATING OVERWEIGHT
U-1263	TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) OR CHRONIC BRONCHITIS
U-1264	TREATMENT OF A RESPIRATORY DISEASE
U-1265	PATENTED METHOD OF USING REPAGLINIDE IN COMBINATION WITH METFORMIN AS INDICATED FOR IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
U-1266	METHOD OF TREATING MIDDLE-OF-THE-NIGHT INSOMNIA
U-1267	TREATMENT OF RHEUMATOID ARTHRITIS BY DELAYED RELEASE FORMULATION OF 1MG OR 2MG OF PREDNISONE
U-1268	TREATMENT OF PULMONARY, GASTROINTESTINAL AND/OR RHEUMATOLOGICAL DISEASES OR CONDITIONS BY USE OF DELAYED RELEASE FORMULATIONS OF 1MG OR 2MG PREDNISONE

PATENT AND EXCLUSIVITY TERMS

ADB 105 of 191

PATENT USE

U-1269	TREATMENT OF RHEUMATOLOGIC, ALLERGIC, PULMONARY, GASTROINTESTINAL, DERMATOLOGIC DISEASES OR CONDITIONS BY THE USE OF A DELAYED RELEASE 5MG PREDNISONE TABLET
U-1270	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH INSULIN (WITH OR WITHOUT METFORMIN AND/OR PIOGLITAZONE)
U-1271	TREATMENT OF ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME-NEGATIVE (PH-) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN SECOND OR GREATER RELAPSE OR WHOSE DISEASE HAS PROGRESSED FOLLOWING TWO OR MORE ANTI-LEUKEMIA THERAPIES
U-1272	TREATMENT OF SIGNS AND SYMPTOMS OF PARKINSON'S DISEASE BY APPLICATION OF CLAIMED TRANSDERMAL SYSTEM
U-1273	TREATMENT OF RESTLESS LEGS SYNDROME BY APPLICATION OF CLAIMED TRANSDERMAL DELIVERY SYSTEM
U-1274	TREATMENT OF EXOCRINE PANCREATIC INSUFFICIENCY DUE TO CYSTIC FIBROSIS OR OTHER CONDITIONS
U-1275	TREATMENT OF CHRONIC HEPATITIS B IN ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER
U-1276	MANAGEMENT OF NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY
U-1277	METHOD OF INCREASING EYELASH GROWTH INCLUDING LENGTH, THICKNESS, DARKNESS AND/OR NUMBER OF EYELASHES BY ADMINISTERING BIMATOPROST TO AN EYELID MARGIN
U-1278	METHOD OF TREATING IRRITABLE BOWEL SYNDROME WITH CONSTIPATION IN ADULTS
U-1279	TREATMENT OF HIV INFECTION USING A COMPOSITION CONTAINING A PHARMACOKINETIC ENHANCER THAT INHIBITS CYTOCHROME P450 MONOOXYGENASE
U-1280	USE OF A CALCIPOTRIENE CONTAINING FOAM FOR THE TREATMENT OF PSORIASIS
U-1281	THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER WHO HAVE PREVIOUSLY RECEIVED DOCETAXEL
U-1282	PREVENTION OF ACUTE AND DELAYED NAUSEA AND VOMITING
U-1283	A METHOD OF TREATING CHRONIC MYELOGENOUS LEUKEMIA
U-1284	A METHOD OF TREATING A NEOPLASM
U-1285	TREATMENT OF PATIENTS WITH RELAPSING FORMS OF MULTIPLE SCLEROSIS
U-1286	A METHOD OF REDUCING THE RISK OF PULMONARY EDEMA IN PATIENTS IN NEED OF TREATMENT WITH INHALED NITRIC OXIDE
U-1287	METHOD OF REDUCING TG LEVELS IN PATIENT SUFFERING FROM SEVERE HYPERTRIGLYCERIDEMIA
U-1288	TREATMENT OF ERECTILE DYSFUNCTION BY ADMINISTERING A FILM-COATED TABLET
U-1289	MANAGEMENT OF MODERATE TO SEVERE ACUTE PAIN
U-1290	TREATMENT OF LUNG CANCER
U-1291	TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA (APL) IN PATIENTS WHOSE APL IS CHARACTERIZED BY THE PRESENCE OF THE (15;17) TRANSLOCATION OR PML/RAR-ALPHA GENE EXPRESSION
U-1292	TREATMENT OF DISEASES OR CONDITIONS BY THE USE OF A DELAYED RELEASE 1, 2, OR 5 MG PREDNISONE TABLET
U-1293	A METHOD OF LOWERING INTRAOCULAR PRESSURE IN A PATIENT WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION
U-1294	METHOD OF TREATING GLAUCOMA IN A PATIENT
U-1295	A METHOD OF TREATING A PATIENT WITH GLAUCOMA OR OCULAR HYPERTENSION
U-1296	USE OF PEMETREXED WITH PRIOR AND/OR REPEATED VITAMIN B12 AND FOLIC ACID ADMINISTRATION
U-1297	TREATMENT OF PULMONARY ARTERIAL HYPERTENSION BY INHIBITING ENDOTHELIN RECEPTORS
U-1298	ADJUNCTIVE THERAPY IN THE TREATMENT OF PARTIAL SEIZURES
U-1299	TREATMENT OF PATIENTS WITH LEUKEMIA INCLUDING CHRONIC MYELOID/MYELOGENOUS LEUKEMIA (CML)
U-1300	TREATMENT OF PATIENTS WITH TYROSINE KINASE INHIBITOR (TKI) RESISTANT OR INTOLERANT CHRONIC MYELOID/MYELOGENOUS LEUKEMIA (CML)
U-1301	TREATMENT OF DEEP VEIN THROMBOSIS (DVT)

PATENT AND EXCLUSIVITY TERMS

ADB 106 of 191

PATENT USE

U-1302	TREATMENT OF PULMONARY EMBOLISM (PE)
U-1303	REDUCTION IN THE RISK OF RECURRENCE OF DEEP VEIN THROMBOSIS (DVT) AND PULMONARY EMBOLISM
U-1304	USE OF ONCE-A-DAY AMOXICILLIN PRODUCT TO TREAT TONSILLITIS AND/OR PHARYNGITIS SECONDARY TO STREPTOCOCCUS PYOGENES
U-1305	TREATMENT OF HIV-1 INFECTION IN ADULT PATIENTS, AND TREATMENT OF HIV-1 INFECTION IN PEDIATRIC PATIENTS 3 YEARS OF AGE AND OLDER, CO-ADMINISTERED WITH RITONAVIR (PREZISTA/RITONAVIR) AND WITH OTHER ANTIRETROVIRAL AGENTS
U-1306	TREATMENT OF THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC HEPATITIS C TO ALLOW THE INITIATION AND MAINTENANCE OF INTERFERON-BASED THERAPY
U-1307	IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS FOR THE TREATMENT OF HIV-1 INFECTION IN TREATMENT-NAIVE ADULT PATIENTS WITH HIV-1 RNA LESS THAN OR EQUAL TO 100,000 AT THE START OF THERAPY
U-1308	MULTIPLE MYELOMA
U-1309	BONE METASTASES
U-1310	FOR THE MAINTENANCE OF REMISSION OF ULCERATIVE COLITIS
U-1311	METHOD OF TREATING CYSTIC FIBROSIS
U-1312	USE FOR THE TREATMENT OF HYPERGLYCEMIA
U-1313	AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
U-1314	USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
U-1315	THE LONG TERM TREATMENT OF PROPHYLACTIC MANAGEMENT OF OCULAR HYPERTENSION AND GLAUCOMA
U-1316	A DOSING REGIMEN FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA AND HYPERLIPIDEMIA IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA USING AT LEAST THREE STEP-WISE INCREASING DOSES
U-1317	TREATMENT OF HYPERCHOLESTEROLEMIA, HYPERLIPIDEMIA AND HYPERLIPOPROTEINEMIA IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
U-1318	TREATMENT OF HYPERCHOLESTEROLEMIA BY DECREASING THE AMOUNT OR ACTIVITY OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
U-1319	SYMPTOMATIC RELIEF OF NON-INFECTIOUS DIARRHEA
U-1320	TREATMENT OF ADULT PATIENTS WITH SHORT BOWEL SYNDROME WHO ARE DEPENDENT ON PARENTERAL SUPPORT
U-1321	TREATMENT OF PULMONARY MULTI-DRUG RESISTANT TUBERCULOSIS
U-1322	METHOD OF REDUCING OCULAR HYPERTENSION
U-1323	REDUCING THE RISK OF STROKE
U-1324	MANAGEMENT OF CYSTIC FIBROSIS PATIENTS
U-1325	INDUCTION OF REMISSION IN PATIENTS WITH ACTIVE, MILD TO MODERATE ULCERATIVE COLITIS
U-1326	METHOD OF INDUCING CONTRACEPTION IN A FEMALE OF REPRODUCTIVE AGE WHO HAS NOT YET REACHED PREMENOPAUSE
U-1327	METHOD FOR TREATING ACUTE MIGRAINE IN ADULTS, WITH OR WITHOUT AURA, COMPRISING IONTOPHORETIC TRANSDERMAL DELIVERY OF SUMATRIPTAN OR A SALT THEREOF, USING A FLOWABLE HYDROGEL FORMULATION
U-1328	METHOD FOR TREATING ACUTE MIGRAINE IN ADULTS, WITH OR WITHOUT AURA, COMPRISING IONTOPHORETIC TRANSDERMAL DELIVERY OF SUMATRIPTAN OR A SALT THEREOF
U-1329	TREATMENT OF PATIENTS WITH AN OVERACTIVE BLADDER
U-1330	METHODS OF TREATING LIPID METABOLISM AND GLYCOMETABOLISM DISORDERS COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH AN INSULIN SECRETION ENHANCER
U-1331	METHODS OF REDUCING THE AMOUNT OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH AN INSULIN SECRETION ENHANCER

PATENT AND EXCLUSIVITY TERMS

ADB 107 of 191

PATENT USE

U-1332	METHODS OF REDUCING THE SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH AN INSULIN SECRETION ENHANCER
U-1333	METHODS OF LOWERING ELEVATED POST PRANDIAL BLOOD GLUCOSE LEVELS COMPRISING ADMINISTERING A DIPEPTIDYL PEPTIDASE INHIBITOR
U-1334	METHODS OF TREATING DIABETES COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH AN INSULIN SECRETION ENHANCER
U-1335	METHODS OF MODIFYING GLUCOSE METABOLISM AND TREATING DIABETES COMPRISING ADMINISTERING A DIPEPTIDYL PEPTIDASE INHIBITOR AND ONE OR MORE OTHER THERAPEUTIC AGENTS SUCH AS METFORMIN
U-1336	METHODS OF TREATING DIABETES COMPRISING ADMINISTERING A DIPEPTIDYL PEPTIDASE INHIBITOR AND METFORMIN
U-1337	METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN
U-1338	METHOD OF TREATING DIABETES COMPRISING ADMINISTERING A COMPOUND SUCH AS ALOGLIPTIN
U-1339	METHODS OF TREATING DIABETES COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH A BIGUANIDE SUCH AS METFORMIN
U-1340	METHODS OF TREATING LIPID METABOLISM DISORDERS COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH A BIGUANIDE SUCH AS METFORMIN
U-1341	METHODS OF TREATING GLYCOMETABOLISM DISORDERS COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH A BIGUANIDE SUCH AS METFORMIN
U-1342	METHODS OF REDUCING THE AMOUNT OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH A BIGUANIDE SUCH AS METFORMIN
U-1343	METHODS OF REDUCING THE SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH A BIGUANIDE SUCH AS METFORMIN
U-1344	METHODS OF REDUCING THE SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH AN INSULIN PREPARATION
U-1345	USE IN RELIEVING OR PREVENTING CONSTIPATION IN A HUMAN PATIENT WITH A DOSAGE UNIT COMPRISING 24MICROG+/- 10% OF A DRUG SUBSTANCE AND A PHARMACEUTICALLY SUITABLE EXCIPIENT
U-1346	USE OF FEBUXOSTAT FOR THE MANAGEMENT OF HYPERURICEMIA IN PATIENTS SUFFERING FROM GOUT AND, WHEN USED WITH THEOPHYLLINE WITHOUT THE NEED FOR DOSE ADJUSTMENT OF THEOPHYLLINE
U-1347	TREATMENT OF A SKIN DISORDER
U-1348	TREATMENT OF OSTEOARTHRITIS
U-1349	TREATMENT OF JUVENILE RHEUMATOID ARTHRITIS
U-1350	TREATMENT OF ANKYLOSING SPONDYLITIS
U-1351	TREATMENT OF ACUTE PAIN
U-1352	TREATMENT OF PRIMARY DYSMENORRHEA
U-1353	ADJUNCTIVE THERAPY TO LIPID-LOWERING MEDICATIONS AND DIET TO REDUCE LOW DENSITY LIPOPROTEIN-CHOLESTEROL, APOLIPOPROTEIN B, TOTAL CHOLESTEROL, AND NON-HIGH DENSITY LIPOPROTEIN CHOLESTEROL IN PTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
U-1354	INHIBITION OF PREMATURE LH SURGES IN WOMEN UNDERGOING CONTROLLED OVARIAN HYPERSTIMULATION WITH FSH
U-1355	MAINTENANCE TREATMENT OF ASTHMA AS PROPHYLACTIC THERAPY IN ADULT AND ADOLESCENT PATIENTS 12 YEARS OF AGE AND OLDER. PATENT CLAIMS METHOD FOR TREATING A RESPIRATORY DISEASE IN A CHILD
U-1356	TREATMENT OF NASAL SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER. TREATMENT OF NASAL SYMPTOMS ASSOCIATED W PERENNIAL ALLERGIC RHINITIS IN ADULTS AND ADOLESCENTS 12 YEARS OF AGE AND OLDER
U-1357	TREATMENT OF SYMPTOMS ASSOCIATED WITH SEASONAL AND PERENNIAL ALLERGIC RHINITIS IN ADULTS AND ADOLESCENTS 12 YEARS OF AGE AND OLDER. PATENT CLAIMS METHODS FOR

PATENT AND EXCLUSIVITY TERMS

ADB 108 of 191

PATENT USE

	TREATING A RESPIRATORY DISEASE IN A CHILD
U-1358	TREATMENT OF BACTERIAL INFECTIONS IN THE NASAL PASSAGE OF ADULT PATIENTS AND HEALTH CARE WORKERS WITH METHICILLIN RESISTANT S. AUREUS
U-1359	USE OF POMALIDOMIDE TO INHIBIT THE SECRETION OF PRO-INFLAMMATION CYTOKINES, INCLUDING TUMOR NECROSIS FACTOR ALPHA
U-1360	USE OF POMALIDOMIDE FOR THE TREATMENT OF MULTIPLE MYELOMA
U-1361	USE OF POMALIDOMIDE WHILE PREVENTING THE EXPOSURE OF A FETUS OR OTHER CONTRAINDICATED INDIVIDUAL TO POMALIDOMIDE
U-1362	TREATMENT OF DISEASES OR CONDITIONS BY THE USE OF A DELAYED-RELEASE 1,2, OR 5MG PREDNISONE TABLET
U-1363	A METHOD OF TREATING OR PREVENTING OCULAR PAIN AND BURNING/STINGING FOLLOWING CORNEAL SURGERY
U-1364	MAINTENANCE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
U-1365	PROPHYLAXIS OF ALLOGRAFT REJECTION IN ADULT PATIENTS RECEIVING A LIVER TRANSPLANT
U-1366	TREATMENT OF INFERTILITY THROUGH INDUCTION OF OVULATION AND PREGNANCY TO ANOVULATORY INFERTILE WOMEN
U-1367	METHOD OF ADMINISTERING FSH FOR THE TREATMENT OF INFERTILITY THROUGH INDUCTION OF OVULATION AND PREGNANCY IN ANOVULATORY INFERTILE WOMEN
U-1368	TREATMENT OF SOLID EXCRETORY SYSTEM TUMORS; ADVANCED RENAL CELL CARCINOMA (RCC), AFTER FAILURE OF TREATMENT WITH SUNITINIB OR SORAFENIB
U-1369	TREATMENT OF VAGINAL SYMPTOMS OF UROGENITAL ATROPHY BY ORALLY ADMINISTERING OSPEMIFENE WITH FOOD TO ENHANCE BIOAVAILABILITY OF OSPEMIFENE
U-1370	TREATMENT OF DYSPAREUNIA ASSOCIATED WITH MENOPAUSE
U-1371	REDUCTION OF INTRAOCULAR PRESSURE IN PATIENTS WITH ELEVATED INTRAOCULAR PRESSURE OR GLAUCOMA
U-1372	ADMINISTRATION WITHOUT FOOD FOR TREATMENT OF HIV-1 INFECTION
U-1373	METHOD OF TREATING ACETAMINOPHEN OVERDOSE WITH ACETYLCYSTEINE SOLUTIONS
U-1374	TREATMENT OF PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (PH+CML)
U-1375	ADASUVE IS A TYPICAL ANTIPSYCHOTIC INDICATED FOR THE ACUTE TREATMENT OF AGITATION ASSOCIATED WITH SCHIZOPHRENIA OR BIPOLAR I DISORDER IN ADULTS
U-1376	TREATMENT OF INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS
U-1377	IMPROVE RESPIRATORY SYMPTOMS IN CYSTIC FIBROSIS IN PATIENTS WITH PSEUDOMONAS AERUGINOSA
U-1378	TREATMENT OF A NITROGEN METABOLISM DISORDER
U-1379	IMPROVEMENT OF GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE ONE OR MORE SPECIFIED CARDIOVASCULAR RISK FACTORS
U-1380	IMPROVEMENT OF GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE ONE OR MORE SPECIFIED CARDIOVASCULAR RISK FACTORS WHEREIN THE PATIENT HAS CARDIOVASCULAR DISEASE
U-1381	USE OF PRASUGREL AND ASPIRIN IN PATIENTS REQUIRING THE REDUCTION OF THROMBOTIC CARDIOVASCULAR EVENTS
U-1382	TREATMENT OF NAUSEA AND VOMITING OF PREGNANCY IN WOMEN WHO DO NOT RESPOND TO CONSERVATIVE MANAGEMENT
U-1383	DOSAGE ADJUSTMENT OF A NITROGEN SCAVENGING DRUG IN THE TREATMENT OF A UREA CYCLE DISORDER
U-1384	METHOD OF TREATING MULTIPLE SCLEROSIS
U-1385	METHOD OF TREATING AN AUTOIMMUNE DISEASE SELECTED FROM AUTOIMMUNE POLYARTHRITIS AND MULTIPLE SCLEROSIS BUT NOT TREATING PSORIATIC ARTHRITIS
U-1386	A METHOD OF INCREASING THE TESTOSTERONE BLOOD LEVEL OF A PERSON IN NEED THEREOF
U-1387	REDUCTION IN RISK OF HOSPITALIZATION IN PATIENTS WITH A HISTORY OF PAROXYSMAL OR PERSISTENT AF WITHOUT SEVERE HEART FAILURE AND WITH ONE OR MORE RISK FACTORS BY ADMINISTRATION TWICE A DAY WITH MORNING AND EVENING MEALS
U-1388	TREATMENT OF PATIENTS WITH A HISTORY OF PAROXYSMAL OR PERSISTENT AF WITHOUT

PATENT AND EXCLUSIVITY TERMS

ADB 109 of 191

PATENT USE

	SEVERE HEART FAILURE AND WITH ONE OR MORE RISK FACTORS BY ADMINISTRATION TWICE A DAY WITH MORNING AND EVENING MEALS
U-1389	ELLA IS A PROGESTERONE AGONIST/ANTAGONIST EMERGENCY CONTRACEPTION INDICATED FOR THE PREVENTION OF PREGNANCY FOLLOWING UNPROTECTED INTERCOURSE OR A KNOWN OR SUSPECTED CONTRACEPTIVE FAILURE. ELLA CAN BE TAKEN WITH OR WITHOUT FOOD
U-1390	A METHOD OF INCREASING THE TESTOSTERONE BLOOD LEVEL OF AN ADULT MALE SUBJECT IN NEED THEREOF
U-1391	METHOD FOR TREATING OPIOID-INDUCED CONSTIPATION
U-1392	METHOD OF RELIEVING OR PREVENTING CONSTIPATION IN A HUMAN PATIENT WITH OPIOID-INDUCED CONSTIPATION
U-1393	METHOD FOR RELIEVING OR TREATING CONSTIPATION IN A PATIENT WITH OPIOID-INDUCED CONSTIPATION
U-1394	METHOD FOR RELIEVING CONSTIPATION IN A PATIENT WITH OPIOID-INDUCED CONSTIPATION THAT COMPRISES ADMINISTERING TO THE PATIENT A DOSAGE UNIT COMPRISING (I) 24MICROG +/- 10% OF A DRUG SUBSTANCE AND (II) A PHARMACEUTICALLY SUITABLE EXCIPIENT
U-1395	USE IN RELIEVING OR PREVENTING CONSTIPATION IN A PATIENT WITH OPIOID-INDUCED CONSTIPATION WITH A DOSAGE UNIT COMPRISING 24MICROG +/- 10% OF A DRUG SUBSTANCE AND A PHARMACEUTICALLY SUITABLE EXCIPIENT
U-1396	TREATMENT OF ADVANCED HORMONE RECEPTOR POSITIVE, HER2-NEGATIVE BREAST CANCER IN COMBINATION WITH EXEMESTANE AFTER FAILURE OF TREATMENT WITH LETROZOLE OR ANASTROZOLE
U-1397	USE AS AN ANTISEPTIC FOR THE PREPARATION OF A PATIENT'S SKIN PRIOR TO SURGERY
U-1398	METHOD OF TREATING CHRONIC HEPATITIS C
U-1399	MANAGEMENT OF NEPHROPATHIC CYSTINOSIS BY ADMINISTERING A TOTAL DAILY DOSE IN TWO DIVIDED DOSES
U-1400	FOR THE TREATMENT OF PRIMARY HYPERLIPIDEMIA, MIXED HYPERLIPIDEMIA OR HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
U-1401	INDICATED FOR LONG-TERM, ONCE-DAILY MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PTS WITH COPD, INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA, ALSO TO REDUCE EXACERBATIONS OF COPD IN PTS WITH A HISTORY OF EXACERBATIONS
U-1402	FOR USE IN THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND/OR INDOLENT B-CELL NON-HODGKIN LYMPHOMA (NHL)
U-1403	FIRST-LINE TREATMENT OF METASTATIC NON SMALL-CELL LUNG CANCER (NSCLC) WITH EGFR EXON 19 DELETIONS OR EXON 21 (L858R) SUBSTITUTION MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST
U-1404	METHOD FOR TREATING CONSTIPATION IN A PATIENT WITH OPIOID-INDUCED CONSTIPATION BY OPENING CIC CHANNELS
U-1405	THERAPEUTIC TREATMENT OF BONE METASTASES
U-1406	TREATMENT OF MELANOMA
U-1407	TREATMENT OF NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (PH + CML)
U-1408	TREATMENT OF PLAQUE PSORIASIS IN PATIENTS 18 YEARS OF AGE OR OLDER
U-1409	TREATMENT OF HIV-1 BY ONCE DAILY ADMINISTRATION
U-1410	TREATMENT OF CORTICOSTEROID-RESPONSIVE DERMATOSES
U-1411	THIS DRUG IS ADMINISTERED BY SUBLINGUAL ROUTE TO HUMANS FOR MAINTENANCE TREATMENT OF OPIOID DEPENDENCE
U-1412	TREATMENT OF ATOPIC DERMATITIS
U-1413	ADMINISTRATION OF REMODULIN DILUTED FOR INTRAVENOUS INFUSION WITH FLOLAN STERILE DILUENT FOR INJECTION PRIOR TO INFUSION
U-1414	USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF MANTLE CELL LYMPHOMA (MCL)
U-1415	TREATING A PATIENT HAVING A CONDITION SUSCEPTIBLE TO TREATMENT WITH METHYLPHENIDATE, SUCH AS ADHD, BY ADMINISTERING THE FORMULATION RECITED IN CLAIMS 1 OR 2
U-1416	USE OF FENOFIBRATE FOR REDUCING ELEVATED TOTAL CHOLESTEROL (TOTAL-C), LDL-C, APO-LIPOPROTEIN B, OR TOTAL TRIGLYCERIDES

PATENT AND EXCLUSIVITY TERMS

ADB 110 of 191

PATENT USE

U-1417	USE FOR TREATMENT OF HELICOBACTER INFECTIONS
U-1418	TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAFV600E MUTATION AS DETECTED BY AN FDA APPROVED TEST
U-1419	TREATMENT OF ACUTE CYANIDE POISONING THAT IS JUDGED TO BE LIFE THREATENING
U-1420	METHOD OF ONCE A DAY ADMINISTRATION
U-1421	SUBLINGUAL ADMINISTRATION OF A PHARMACEUTICAL COMPOSITION COMPRISING BUPRENORPHINE
U-1422	METHOD OF TREATING PATIENTS NEEDING AN IRON SUPPLEMENT
U-1423	AMYVID IS A RADIOACTIVE DIAGNOSTIC AGENT FOR POSITRON EMISSION TOMOGRAPHY (PET) IMAGING OF THE BRAIN TO ESTIMATE BETA-AMYLOID NEURITIC PLAQUE DENSITY IN ADULT PATIENTS WITH COGNITIVE IMPAIRMENT
U-1424	LONG-TERM, ONCE DAILY MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PTS WITH COPD, INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA, ALSO TO REDUCE EXACERBATIONS OF COPD IN PATIENTS WITH A HISTORY OF EXACERBATIONS
U-1425	SUBLINGUAL ADMINISTRATION OF A PHARMACEUTICAL COMPOSITION COMPRISING BUPRENORPHINE AND NALOXONE
U-1426	USE FOR TREATMENT OF DIAPER DERMATITIS COMPLICATED BY CANDIDIASIS
U-1427	ALKYLATING DRUG INDICATED FOR THE TOPICAL TREATMENT OF STAGE IA AND IB MYCOSIS FUNGOIDES-TYPE CUTANEOUS T-CELL LYMPHOMA IN PATIENTS WHO HAVE RECEIVED PRIOR SKIN DIRECTED THERAPY
U-1428	TOPICAL TREATMENT OF FACIAL ERYTHEMA OF ROSACEA
U-1429	TREATMENT OF PATIENTS WITH BREAST CANCER WHOSE TUMORS OVEREXPRESS THE HER2 RECEPTOR
U-1430	TREATMENT OF ALLERGIC RHINITIS, INCLUDING SEASONAL AND PERENNIAL ALLERGIC RHINITIS
U-1431	METHOD OF TREATING HYPERGLYCEMIA TO IMPROVE GLYCEMIC CONTROL IN A PATIENT BY ORAL ADMIN OF ONCE A DAY OSMOTIC DOSAGE FORM OF GLIPIZIDE WITH POLYETHYLENE OXIDE, HYDROXYPROPYLMETHYLCELLULOSE, CELLULOSE ACETATE, AND SODIUM CHLORIDE
U-1432	METHOD OF TREATMENT OF IRON-RELATED CONDITIONS WITH AT LEAST 0.6 GRAMS OF ELEMENTAL IRON VIA AN IRON CARBOHYDRATE COMPLEX
U-1433	IMPROVEMENTS OF GLYCEMIC CONTROL IN INDIVIDUALS WITH TYPE 2 DIABETES WHO HAVE ONE OR MORE SPECIFIED CARDIOVASCULAR RISK FACTORS
U-1434	TREATMENT OF PANCREATIC CANCER
U-1435	COMBINATION USE OF TOPICAL DICLOFENAC ON THE KNEE AND ADMINISTRATION OF AN ORAL NSAID.
U-1436	USE OF TOPICAL DICLOFENAC ON THE KNEE AND A SECOND TOPICAL AGENT SELECTED FROM SUNSCREEN AND INSECT REPELLANT
U-1437	ADMINISTRATION OF REMODULIN DILUTED FOR INTRAVENOUS INFUSION WITH STERILE DILUENT FOR FLOLAN OR STERILE DILUENT FOR EPOPROSTENOL SODIUM PRIOR TO ADMINISTRATION
U-1438	ZINGO INTRADERMAL INJECTION SYSTEM IS A DRUG DELIVERY SYSTEM THAT IS CAPABLE OF DELIVERING FINE DRY POWDERED LIDOCAINE HYDROCHLORIDE MONOHYDRATE FOR LOCAL ANESTHETIC ACTION
U-1439	METHOD OF TREATING AN AFFECTIVE DISORDER SUCH AS DEPRESSION
U-1440	USE OF INGENOL MEBUTATE TO TREAT ACTINIC KERATOSIS
U-1441	A METHOD OF TREATING OR REDUCING OCULAR PAIN AND BURNING/STINGING
U-1442	SUBCUTANEOUS INJECTION OF METHOTREXATE
U-1443	ACCELERATING THE TIME TO UPPER AND LOWER GASTROINTESTINAL RECOVERY FOLLOWING SURGERIES THAT INCLUDE PARTIAL BOWEL RESECTION WITH PRIMARY ANASTOMOSIS
U-1444	A DOSING REGIMEN OF AGGRASTAT (TIROFIBAN HYDROCHLORIDE) (25MCG/KG FOLLOWED BY 0.15MCG/KG/MIN INFUSION) TO REDUCE THE RATE OF THROMBOTIC CORONARY EVENTS ASSOCIATED WITH ACUTE CORONARY SYNDROME (ACS) IN PATIENTS WITH NON-ST ELEVATION ACS
U-1445	METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION BY ADMINISTERING A PHARMACEUTICAL COMPOSITION COMPRISING MACITENTAN AND A POLYSORBATE, WHEREIN THE POLYSORBATE REPRESENTS 0.1 TO 1% OF THE WEIGHT OF SAID PHARMACEUTICAL

PATENT AND EXCLUSIVITY TERMS

ADB 111 of 191

PATENT USE

COMPOSITION

U-1446	METHOD OF TREATING PULMONARY HYPERTENSION COMPRISING ADMINISTERING MACITENTAN IN COMBINATION WITH A COMPOUND HAVING PHOSPHODIESTERASE-5 INHIBITORY PROPERTIES
U-1447	TREATING PRIMARY HYPERCHOLESTEROLEMIA AND MIXED DYSLIPIDEMIA
U-1448	TREATING SEVERE HYPERTRIGLYCERIDEMIA
U-1449	METHOD OF ALLEVIATING A SKIN CONDITION
U-1450	TREATMENT OF ALLERGIC RHINITIS SYMPTOMS
U-1451	APPROVED INDICATIONS: APTIOM (ESLICARBAZEPINE ACETATE) IS INDICATED AS ADJUNCTIVE TREATMENT OF PARTIAL-ONSET SEIZURES AND APPROVED IN PATIENTS WITH EPILEPSY. PATENT CLAIMS: IN A METHOD OF TREATING A SUBJECT AFFLICTED WITH EPILEPSY
U-1452	METHOD FOR CHRONIC WEIGHT MANAGEMENT
U-1453	A METHOD OF TREATING HYPOXIC RESPIRATORY FAILURE BY VERIFYING GAS INFORMATION OF NITRIC OXIDE PRIOR TO DELIVERY TO PATIENT
U-1454	PROPHYLAXIS OF INVASIVE ASPERGILLUS AND CANDIDA INFECTIONS
U-1455	TREATMENT OF PERIANAL WARTS
U-1456	TREATMENT OF MANTLE CELL LYMPHOMA
U-1457	A METHOD OF PURGING A NITRIC OXIDE DELIVERY SYSTEM
U-1458	A METHOD OF REDUCING INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION
U-1459	TREATMENT OF CARCINOMA OF THE THYROID
U-1460	TREATMENT OF HERPES LABIALIS
U-1461	A METHOD OF GENERATING AN INJECTABLE FOAM OF CONTROLLED DENSITY AND BUBBLE SIZE
U-1462	A METHOD OF USING A SCLEROSING AGENT FOR THE TREATMENT OF INCOMPETENT GREAT SAPHENOUS VEINS, ACCESSORY SAPHENOUS VEINS AND VISIBLE VARICOSITIES OF THE GREAT SAPHENOUS (GSV) SYSTEM ABOVE AND BELOW THE KNEE
U-1463	A METHOD OF INTRAVENOUS INJECTION USING ULTRASOUND GUIDANCE, ADMINISTERED VIA A SINGLE CANNULA INTO THE LUMEN OF THE TARGET INCOMPETENT TRUNK VEINS OR BY DIRECT INJECTION INTO VARICOSITIES
U-1464	TREATMENT OF OPIOID DEPENDENCE/SUBLINGUAL OR BUCCAL APPLICATION
U-1465	USE OF THALIDOMIDE WHILE PREVENTING THE EXPOSURE OF A FETUS OR OTHER CONTRAINDICATED INDIVIDUAL TO THALIDOMIDE
U-1466	RELIEF OF SYMPTOMS ASSOCIATED WITH RESPIRATORY ALLERGIES ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER
U-1467	METHOD OF TREATING HEPATITIS C
U-1468	CONTROL OF PHOSPHOROUS LEVELS IN PATIENTS
U-1469	USE OF PHOSLYRA FOR REDUCTION OF SERUM PHOSPHOROUS IN PATIENTS
U-1470	FOR THE TREATMENT OF HEPATITIS C
U-1471	A METHOD FOR TREATING CARDIOVASCULAR DISEASE COMPRISING ADMINISTERING A RECONSTITUTED LYOPHILIZED PHARMACEUTICAL COMPOSITION COMPRISING EPOPROSTENOL, ARGININE AND SODIUM HYDROXIDE.
U-1472	INTENSIVE CARE UNIT SEDATION, INCLUDING SEDATION OF NON-INTUBATED PATIENTS PRIOR TO AND/OR DURING SURGICAL AND OTHER PROCEDURES
U-1473	MANAGEMENT OF RISK OF DRONEDARONE/BETA-BLOCKER INTERACTION IN PATIENTS IN SINUS RYTHM WITH A HISTORY OF PAROXYSMAL OR PERSISTENT AF
U-1474	A METHOD FOR THE TREATMENT OF A PATIENT SUFFERING FROM A DISEASE TREATABLE WITH ROTIGOTINE, COMPRISING APPLYING THE CLAIMED TRANSDERMAL DELIVERY SYSTEM (TDS) TO THE SKIN OF THE PATIENT
U-1475	USE OF ORENITRAM FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) (WHO GROUP 1).
U-1476	INDICATED FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA.
U-1477	USE OF TOPICAL DICLOFENAC ON THE KNEE AND A SECOND TOPICAL PRESCRIPTION

PATENT AND EXCLUSIVITY TERMS

ADB 112 of 191

PATENT USE

MEDICATION ON THE SAME KNEE

U-1478	METHOD OF REDUCING TG LEVELS IN PATIENT ON STATIN THERAPY SUFFERING FROM SEVERE HYPERTRIGLYCERIDEMIA
U-1479	INCREASE TEAR PRODUCTION TO TREAT PATIENTS WITH KERATOCONJUNCTIVITIS SICCA (DRY EYE).
U-1480	TREATMENT OF ADVANCED RENAL CELL CARCINOMA
U-1481	REDUCTION IN RISK OF OVERT HEPATIC ENCEPHALOPATHY (HE) RECURRENCE
U-1482	DICLOFENAC POTASSIUM FOR RELIEF OF MILD TO MODERATE ACUTE PAIN
U-1483	INCREASE TEAR PRODUCTION IN PATIENTS WITH KERATOCONJUNCTIVITIS SICCA (DRY EYE).
U-1484	COMBINATION PRODUCT FOR THE EARLY TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) TO REDUCE THE LIKELIHOOD OF ULCERATIVE COLD SORES AND TO SHORTEN THE LESION HEALING TIME IN ADULTS AND CHILDREN (6 YEARS OF AGE AND OLDER)
U-1485	TREATING A SUBJECT UNDERGOING ABDOMINAL SURGERY BY ADMINISTERING ALVIMOPAN TO ACCELERATE THE TIME TO UPPER AND LOWER GASTROINTESTINAL RECOVERY FOLLOWING SURGERIES THAT INCLUDE PARTIAL BOWEL RESECTION WITH PRIMARY ANASTOMOSIS
U-1486	TREATMENT OF NON-24-HOUR SLEEP-WAKE DISORDER
U-1487	METHOD OF INCREASING EYELASH GROWTH
U-1488	USE OF TOPICAL DICLOFENAC FOR TREATING PAIN
U-1489	USE OF TOPICAL DICLOFENAC ON A JOINT FOR TREATING OSTEOARTHRITIS
U-1490	FOR USE IN PATIENTS HAVING SYMPTOMATIC OR PROGRESSIVE MEDULLARY THYROID CANCER, WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC DISEASE
U-1491	TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
U-1492	TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER
U-1493	METHOD FOR PREVENTING ITCHING ASSOCIATED WITH ALLERGIC CONJUNCTIVITIS
U-1494	SUBLINGUAL OR BUCCAL ADMINISTRATION OF A PHARMACEUTICAL COMPOSITION COMPRISING BUPRENORPHINE AND NALOXONE
U-1495	RISK REDUCTION OF REBLEEDING IN PTS FOLLOWING THERAPEUTIC ENDOSCOPY FOR ACUTE BLEEDING GASTRIC OR DUODENAL ULCERS IN ADULTS.
U-1496	METHOD TO TREAT HEMANGIOMA.
U-1497	NEURACEQ IS A RADIOACTIVE DIAGNOSTIC AGENT FOR POSITRON EMISSION TOMOGRAPHY (PET) IMAGING OF THE BRAIN TO ESTIMATE P-AMYLOID NEURITIC PLAQUE DENSITY IN ADULT PATIENTS WITH COGNITIVE IMPAIRMENT
U-1498	METHOD OF TREATING PATIENTS WITH GASTRIC RETENTIVE DOSAGE FORM
U-1499	MANAGEMENT OF ACUTE PAIN IN PATIENTS REQUIRING OPIOID ANALGESIA
U-1500	TESTOSTERONE REPLACEMENT THERAPY IN ADULT MALES FOR CONDITIONS ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE; PRIMARY HYPOGONADISM (CONGENITAL OR ACQUIRED); HYPOGONADOTROPIC HYPOGONADISM (CONGENITAL OR ACQUIRED).
U-1501	PROPHYLAXIS OF DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM
U-1502	PROPHYLAXIS OF PULMONARY EMBOLISM
U-1503	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
U-1504	USE OF OTEZLA (APREMILAST) FOR INHIBITING PDE4
U-1505	USE OF OTEZLA (APREMILAST) FOR THE TREATMENT OF PSORIATIC ARTHRITIS
U-1506	TREATMENT OF PATIENTS WITH GASTROINTESTINAL STROMAL TUMOR (GIST), INCLUDING BUT NOT LIMITED TO PATIENTS PREVIOUSLY TREATED WITH IMATINIB AND PATIENTS WITH GIST HAVING RESISTANCE TO A KIT TYROSINE KINASE INHIBITOR
U-1507	TO MAINTAIN HEALING OF EE AND RELIEF OF HEARTBURN
U-1508	MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG TERM OPIOID TREATMENT BY ORALLY ADMINISTERING A PLURALITY OF COMPOSITE SUBUNITS AS CLAIMED
U-1509	TREATMENT OF FREQUENT HEARTBURN BY ADMINISTERING A GASTRIC ACID REDUCER
U-1510	MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG TERM

PATENT AND EXCLUSIVITY TERMS

ADB 113 of 191

PATENT USE

OPIOID TREATMENT BY ORALLY ADMINISTERING AN INTACT COMPOSITION AS CLAIMED.

U-1511 TREATMENT OF HYPERTRIGLYCERIDEMIA

U-1512 REDUCTION OF THROMBOTIC CARDIOVASCULAR EVENTS

U-1513 TREATMENT OF HIV-1 INFECTION IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS

U-1514 MANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER BY BUCCAL OR SUBLINGUAL ADMINISTRATION OF FENTANYL

U-1515 METHOD OF TREATING IRRITABLE BOWEL SYNDROME WITH CONSTIPATION IN ADULT PATIENTS.

U-1516 METHOD OF TREATING CHRONIC IDIOPATHIC CONSTIPATION IN ADULT PATIENTS.

U-1517 TREATMENT OF BACTERIAL INFECTIONS USING A TWO-DOSE REGIMEN OF DALBAVANCIN.

U-1518 MAINTAINING PUPIL SIZE BY PREVENTING INTRAOPERATIVE MIOSIS AND REDUCING POSTOPERATIVE OCULAR PAIN

U-1519 METHOD FOR THE LONG TERM TREATMENT OF CHRONIC CONSTIPATION IN A HUMAN SUBJECT WITH IRRITABLE BOWEL SYNDROME

U-1520 METHOD FOR THE LONG TERM TREATMENT OF CHRONIC CONSTIPATION IN A HUMAN SUBJECT

U-1521 MAINTENANCE TREATMENT OF OPIOID DEPENDENCE

U-1522 TREATMENT OF TYPE 2 DIABETES MELLITUS IN A PATIENT, WHEREIN GLYCEMIC CONTROL (HBA1C < 7.0%) IS NOT ACHIEVABLE USING ONE OR MORE OF INSULIN, METFORMIN, PIOGLITAZONE, OR ROSIGLITAZONE

U-1523 METHOD OF INDUCING TOPICAL ANESTHESIA IN THE EYE

U-1524 REDUCTION OF ELEVATED INTRAOCULAR PRESSURE

U-1525 METHOD OF TREATING EXCESSIVE DAYTIME SLEEPINESS IN PATIENTS WITH NARCOLEPSY

U-1526 THE TREATMENT OF PATIENTS WITH TRAVELERS' DIARRHEA (TD) OR THE REDUCTION IN RISK OF OVERT HEPATIC ENCEPHALOPATHY (HE) RECURRENCE

U-1527 FOR THE TREATMENT OF OVERACTIVE BLADDER (OAB) WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND URINARY FREQUENCY

U-1528 A METHOD OF LOWERING INTRAOCULAR PRESSURE

U-1529 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)

U-1530 USE OF ARIPIPRAZOLE IN EXTENDED RELEASE INJECTABLE SUSPENSION

U-1531 METHOD FOR TRANSDERMAL DELIVERY OF TESTOSTERONE

U-1532 METHOD OF TREATING EXCESSIVE DAYTIME SLEEPINESS AND/OR CATAPLEXY IN NARCOLEPSY PATIENTS WITH SODIUM OXYBATE WHEN DIVALPROEX SODIUM IS CONCOMITANTLY ADMINISTERED.

U-1533 PULMONARY ADMINISTRATION OF PARTICLES COMPRISING A DIKETOPIPERAZINE AND INSULIN.

U-1534 ADMINISTRATION OF A COMPOSITION COMPRISING INSULIN COMPLEXED WITH A DIKETOPIPERAZINE.

U-1535 ADMINISTRATION OF A COMPOSITION COMPRISING INSULIN COMPLEXED WITH MICROPARTICLES OF A DIKETOPIPERAZINE.

U-1536 ADMINISTRATION OF A COMPOSITION COMPRISING A DIKETOPIPERAZINE AND INSULIN.

U-1537 TREATMENT OF A PATIENT HAVING DIABETES MELLITUS WITH A PRANDIAL RAPID ACTING INSULIN.

U-1538 ADMINISTRATION OF FDKP MICROPARTICLES COMPRISING INSULIN.

U-1539 PULMONARY ADMINISTRATION OF AN INSULIN COMPOSITION COMPRISING FDKP AT THE BEGINNING OF A MEAL TO A PATIENT ALSO BEING TREATED WITH A LONG-ACTING INSULIN.

U-1540 BUTRANS IS A PARTIAL OPIOID AGONIST PRODUCT INDICATED FOR THE MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG TERM OPIOID TREATMENT FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE.

U-1541 TREATMENT OF PATIENTS WITH TUBEROUS SCLEROSIS COMPLEX (TSC) WHO HAVE SUBEPENDYMAL GIANT CELL ASTROCYTOMA (SEGA) THAT REQUIRES THERAPEUTIC INTERVENTION BUT CANNOT BE CURATIVELY RESECTED.

U-1542 FOR USE IN THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA AND/OR NON-HODGKINS LYMPHOMA

U-1543 TREATMENT OF A PATIENT BY ADMINISTERING THE FORMULATION RECITED IN CLAIM 1 OR CLAIM 23

PATENT AND EXCLUSIVITY TERMS

ADB 114 of 191

PATENT USE

U-1544	TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA (PTCL).
U-1545	A METHOD OF TRANSDERMALLY DELIVERING TESTOSTERONE
U-1546	FOR USE IN THE TREATMENT OF MALIGNANT HYPERTHERMIA IN CONJUNCTION WITH APPROPRIATE SUPPORTIVE MEASURES AND FOR THE PREVENTION OF MALIGNANT HYPERTHERMIA IN PATIENTS AT HIGH RISK.
U-1547	TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), CHRONIC BRONCHITIS OR EMPHYSEMA
U-1548	FOR THE LONG-TERM, ONCE-DAILY MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH COPD, INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA, ALSO TO REDUCE EXACERBATIONS OF COPD IN PATIENTS WITH A HISTORY OF EXACERBATIONS
U-1549	FOR THE TREATMENT OF PATIENTS WITH RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA
U-1550	METHOD OF TREATING METASTATIC PAPILLARY RENAL CELL CARCINOMA WITH TEMSIROLIMUS.
U-1551	METHOD OF TREATING PAPILLARY RENAL CELL CARCINOMA WITH TEMSIROLIMUS, IN THE ABSENCE OF INTERFERON ALPHA.
U-1552	FOR HEALING OF ALL GRADES OF EROSION ESOPHAGITIS (EE)
U-1553	TO MAINTAIN HEALING OF EE AND RELIEF OF HEARTBURN
U-1554	FOR THE TREATMENT OF HEARTBURN ASSOCIATED WITH SYMPTOMATIC NON-EROSIVE GASTROESOPHAGEAL DISEASE (GERD)
U-1555	MANAGEMENT OF MODERATE TO SEVERE PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE.
U-1556	MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
U-1557	A METHOD OF TESTOSTERONE REPLACEMENT THERAPY COMPRISING THE STEP OF NASALLY ADMINISTERING TO A PATIENT IN NEED OF SUCH TREATMENT AN EFFECTIVE AMOUNT OF TESTOSTERONE GEL FORMULATION.
U-1558	FOR THE TREATMENT OF PATIENTS WITH RELAPSED FOLLICULAR B-CELL NON-HODGKIN LYMPHOMA OR [RELAPSED] SMALL LYMPHOCYTIC LYMPHOMA
U-1559	INDICATED FOR THE ONCE-DAILY MAINTENANCE TREATMENT OF ASTHMA AS PROPHYLACTIC THERAPY IN PATIENTS AGED 12 YEARS OF AGE AND OLDER
U-1560	A METHOD OF DISRUPTING LEUKOCYTE FUNCTION, INCLUDING AS AN INHIBITOR OF PI3KDELTA KINASE
U-1561	USE OF OTEZLA (APREMILAST) FOR THE TREATMENT OF PSORIATIC ARTHRITIS
U-1562	TREATMENT OF PATIENTS WITH HEPATIC ENCEPHALOPATHY (HE)
U-1563	A METHOD OF TRANSDERMAL ADMINISTRATION OF A PHYSIOLOGICALLY ACTIVE AGENT TO A SUBJECT.
U-1564	A METHOD OF TREATING GAUCHER'S DISEASE
U-1565	METHOD OF TREATING, AS INITIAL LOADING DOSE FOR MONOTHERAPY OR ADJUNCTIVE THERAPY, PARTIAL ONSET-SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS OR OLDER WHEN ORAL ADMINISTRATION IS TEMPORARILY NOT FEASIBLE
U-1566	METHOD OF TREATING, AS MONOTHERAPY OR ADJUNCTIVE THERAPY, PARTIAL-ONSET SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS AND OLDER
U-1567	METHOD OF TREATING, AS INITIAL LOADING DOSE FOR MONOTHERAPY OR ADJUNCTIVE THERAPY, PARTIAL ONSET-SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS OR OLDER
U-1568	METHOD OF TREATING, AS MONOTHERAPY OR ADJUNCTIVE THERAPY, PARTIAL-ONSET SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS AND OLDER WHEN ORAL ADMINISTRATION IS TEMPORARILY NOT FEASIBLE
U-1569	TREATMENT OF BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS
U-1570	TREATMENT OF BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS USING A SINGLE DOSE
U-1571	TREATMENT OF GAUCHER DISEASE TYPE 1
U-1572	TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION.
U-1573	USE OF RUXOLITINIB (JAKAFI) FOR INHIBITING JANUS ASSOCIATED KINASES (JAKS) JAK1 AND/OR JAK2.

PATENT AND EXCLUSIVITY TERMS

ADB 115 of 191

PATENT USE

U-1574	A METHOD OF CATALYZING THE HYDROLYSIS OF GLUCOCEREBROSIDE TO GLUCOSE AND CERAMIDE.
U-1575	PATIENTS WITH SEVERE APLASTIC ANEMIA WHO HAVE HAD AN INSUFFICIENT RESPONSE TO IMMUNOSUPPRESSIVE THERAPY
U-1576	TREATMENT OF LEUKEMIA
U-1577	CONTROL OF SERUM PHOSPHOROUS LEVELS
U-1578	TREATMENT OF ACUTE OTITIS MEDIA
U-1579	USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
U-1580	USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER WHO HAD RECEIVED PRIOR DOCETAXEL CHEMOTHERAPY
U-1581	IN COMBINATION WITH DABRAFENIB FOR THE TREATMENT OF UNRESECTABLE OR METASTATIC MELANOMA.
U-1582	TREATMENT OF UNRESECTABLE OR METASTATIC MELANOMA
U-1583	FOR CHRONIC WEIGHT MANAGEMENT FOR TREATING OVERWEIGHT OR OBESITY
U-1584	USE OF NALTREXONE AND BUPROPION IN A LAYERED FORMULATION FOR CHRONIC WEIGHT MANAGEMENT FOR AFFECTING WEIGHT LOSS
U-1585	USE OF NALTREXONE AND BUPROPION BASED ON AN ESCALATING DOSE SCHEDULE
U-1586	FOR EFFECT ON BLOOD GLUCOSE PARAMETERS IN PATIENTS WITH INSULIN RESISTANCE
U-1587	SINGLE-DOSE INFILTRATION INTO THE SURGICAL SITE TO PRODUCE POSTSURGICAL ANALGESIA.
U-1588	THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (CRPC).
U-1589	METHOD OF USE FOR REDUCING BLOOD PHENYLALANINE LEVELS IN A HUMAN SUFFERING FROM HYPERPHENYLALANINEMIA
U-1590	KUVAN IS INDICATED TO REDUCE BLOOD PHENYLALANINE LEVELS IN PATIENTS WITH HYPERPHENYLALANINEMIA
U-1591	TREATMENT OF ASTHMA IN PATIENTS AGED 12 YEARS AND OLDER
U-1592	TO REDUCE SERUM PHOSPHATE IN PATIENTS WITH END STAGE RENAL DISEASE
U-1593	MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD, INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA, AND REDUCTION OF EXACERBATIONS IN COPD PATIENTS.
U-1594	DILATION OF THE PUPIL
U-1595	USE OF OTEZLA (APREMILAST) FOR THE TREATMENT OF PSORIASIS
U-1596	LAMICTAL IS AN ANTIEPILEPTIC DRUG (AED) INDICATED FOR: EPILEPSY-ADJUNCTIVE THERAPY IN PATIENTS GREATER THAN OR EQUAL TO 2 YEARS OF AGE: (1.1) PARTIAL SEIZURES PRIMARY GENERALIZED TONIC-CLONIC SEIZURES
U-1597	TREATMENT OF DIABETIC MACULAR EDEMA
U-1598	METHOD OF ADMINISTRATION OF CONTROLLED RELEASE OXYMORPHONE
U-1599	MANAGEMENT OF MILD TO MODERATE PAIN, MANAGEMENT OF MODERATE TO SEVERE PAIN AS AN ADJUNCT TO OPIOID ANALGESICS, REDUCTION IN FEVER THROUGH ANTI-INFLAMMATORY, ANALGESIC, AND ANTIPYRETIC ACTIVITY
U-1600	DOSAGE MODIFICATION FOLLOWING ELEVATED LIVER ENZYMES IN TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS
U-1601	DOSE ESCALATION OVER 14 DAYS FOR TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS
U-1602	METHOD OF ADMINISTERING PIRFENIDONE CAPSULES TO TREAT A FIBROTIC CONDITION
U-1603	METHOD FOR ADMINISTERING PIRFENIDONE TO REDUCE DRUG INTERACTIONS WITH FLUVOXAMINE
U-1604	METHOD FOR ADMINISTERING PIRFENIDONE TO REDUCE DRUG INTERACTIONS WITH A STRONG INHIBITOR OF CYP1A2
U-1605	METHOD FOR ADMINISTERING PIRFENIDONE TO AVOID REDUCED EFFICACY BY DISCONTINUING SMOKING OR BY DISCONTINUING OR AVOIDING ANOTHER STRONG CYP1A2 INDUCER
U-1606	METHOD FOR ADMINISTERING PIRFENIDONE WHILE AVOIDING OR DISCONTINUING CONCOMITANT USE OF A MODERATE TO STRONG INHIBITOR OF BOTH CYP1A2 AND ANOTHER CYP ENZYME

PATENT AND EXCLUSIVITY TERMS

ADB 116 of 191

PATENT USE

INVOLVED IN PIRFENIDONE METABOLISM

- U-1607 METHOD OF ADMINISTERING A DOSAGE FORM THAT INCLUDES A GRANULATE FORMULATION OF PIRFENIDONE TO TREAT A FIBROTIC CONDITION
- U-1608 DOSE ESCALATION OVER 14 DAYS FOR TREATMENT OF A FIBROSIS CONDITION
- U-1609 CONTINUED DOSING OR DOSAGE MODIFICATION FOLLOWING ELEVATED LIVER ENZYMES IN TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS
- U-1610 CONTINUED DOSING OR DOSAGE MODIFICATION FOLLOWING ELVATED LIVER ENZYMES IN USE OF PIRFENIDONE
- U-1611 METHOD FOR ADMINISTERING PIRFENIDONE TO AVOID REDUCED EFFICACY BY DISCONTINUING SMOKING OR BY DISCONTINUING A STRONG CYP1A2 INDUCER
- U-1612 METHOD FOR ADMINISTERING PIRFENIDONE TO AVOID REDUCED EFFICACY BY AVOIDING SMOKING OR BY AVOIDING ANOTHER STRONG CYP1A2 INDUCER
- U-1613 DOSAGE MODIFICATION IN TREATMENT WITH PIRFENIDONE TO REDUCE DRUG INTERACTIONS WITH CIPROFLOXACIN
- U-1614 USE OF TOPICAL DICLOFENAC SODIUM FOR TREATING PAIN
- U-1615 FOR THE TREATMENT OF PATIENTS WITH CLL, FL, OR SLL
- U-1616 NASAL ADMINISTRATION OF A TESTOSTERONE GEL TO A PATIENT TO TREAT THE PATIENT FOR A CONDITION ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE
- U-1617 METHOD OF TREATING MEDULLARY THYROID CANCER
- U-1618 A METHOD OF TREATING A PATIENT SUFFERING FROM A PAIN ASSOCIATED SLEEP DISTURBANCE COMPRISING ADMINISTERING A LIQUID COMPOSITION FORMULATED INSIDE A SOFT GEL CAPSULE, AS CLAIMED, TO THE PATIENT
- U-1619 TREATMENT OF IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP)
- U-1620 METHOD OF TREATMENT OF IRON-RELATED CONDITIONS WITH AT LEAST 0.6 GRAMS OF ELEMENTAL IRON VIA AN IRON CARBOHYDRATE COMPLEX, WITH A SUBSTANTIALLY NON-IMMUNOGENIC CARBOHYDRATE COMPONENT, IN ABOUT 15 MINUTES OR LESS.
- U-1621 PULMONARY ADMINISTRATION OF A COMPOSITION COMPRISING INSULIN BOUND TO A COMPLEXING AGENT.
- U-1622 FOR THE TREATMENT OF POLYCYTHEMIA VERA
- U-1623 USE OF EXENATIDE MAY RESULT IN REDUCTION IN APPETITE.
- U-1624 TREATMENT OF UNRESECTABLE HEPATOCELLULAR CARCINOMA, ADVANCED RENAL CELL CARCINOMA, OR DIFFERENTIATED THYROID CARCINOMA.
- U-1625 METHOD OF TREATING SCHIZOPHRENIA BY ADMINISTERING ILOPERIDONE TO A PATIENT BY REDUCING THE DOSE IN PATIENTS WHO ARE POOR METABOLIZERS OF CYP2D6
- U-1626 A METHOD OF TREATING OR PREVENTING OCULAR PAIN AND BURNING
- U-1627 TREATMENT OF ACUTE UNCOMPLICATED INFLUENZA IN ADULTS
- U-1628 METHOD OF TREATING DISORDERS WITH AN ETIOLOGY COMPRISING OR ASSOCIATED WITH EXCESS GH-SECRETION
- U-1629 METHOD OF TREATING ACROMEGALY
- U-1630 TREATMENT IN COMBINATION WITH A CORTICOID SUCH AS PREDNISONE OF PROSTATE CANCER PREVIOUSLY TREATED WITH DOCETAXEL
- U-1631 TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA.
- U-1632 TREATMENT OF SCHIZOPHRENIA, WITH EFFICACY IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA
- U-1633 USE OF ARIPIRAZOLE IN EXTENDED RELEASE INJECTABLE SUSPENSION IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA
- U-1634 TREATMENT OF BRCA MUTATED OVARIAN CANCER USING PARP INHIBITOR
- U-1635 USE OF RITONAVIR AS A POTENT CYP3A INHIBITOR TO INCREASE PLASMA DRUG CONCENTRATION OF PARITAPREXIR AND OVERALL DRUG EXPOSURE FOR TREATMENT OF HCV INFECTION
- U-1636 USE OF DASABUVIR TO INHIBIT VIRAL REPLICATION FOR THE TREATMENT OF HCV INFECTION.
- U-1637 TREATMENT OF HCV INFECTION USING PARITAPREXIR, OMBITASVIR, RITONAVIR, AND DASABUVIR WITH RIBAVIRIN.

PATENT AND EXCLUSIVITY TERMS

ADB 117 of 191

PATENT USE

U-1638	TREATMENT OF HCV INFECTION USING PARITAPREVIR
U-1639	USE OF NALTREXONE AND BUPROPION IN EXTENDED-RELEASE FORM FOR CHRONIC WEIGHT MANAGEMENT FOR TREATING OVERWEIGHT OR OBESITY
U-1640	TREATMENT OF MODERATE TO SEVERE CHRONIC PAIN BY ADMINISTERING AN INTACT COMPOSITION AS CLAIMED
U-1641	MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE
U-1642	METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS WITH SEVERE CHRONIC RENAL IMPAIRMENT AND FOR WHOM METFORMIN THERAPY IS INAPPROPRIATE BY ADMINISTERING LINAGLIPTIN
U-1643	TREATING CUSHING'S SYNDROME
U-1644	TREATMENT OF OVERACTIVE BLADDER BY APPLICATION OF OXYBUTYNIN CHLORIDE GEL TO SKIN
U-1645	TREATMENT OF PARKINSON'S DISEASE, POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION
U-1646	TREATMENT OF POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION
U-1647	TREATMENT OF PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION
U-1648	TREATMENT OF PATIENTS WITH PARKINSON'S DISEASE, POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION
U-1649	TREATMENT OF POST-ENCEPHALITIC PARKINSONISM
U-1650	TREATMENT OF WALDENSTROM'S MACROGLOBULINEMIA
U-1651	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN
U-1652	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN AND METFORMIN
U-1653	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN (WITH OR WITHOUT METFORMIN)
U-1654	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN (WITH OR WITHOUT INSULIN OR A SULFONYLUREA)
U-1655	A METHOD TO ACCELERATE THE TIME TO GASTROINTESTINAL RECOVERY BY ADMINISTERING ABOUT 12 MG OF ALVIMOPAN TO THE PATIENT FROM ABOUT 30 TO 60 MINUTES PRIOR TO SURGERY
U-1656	METHOD OF IRON ADMINISTRATION TO TREAT PATIENTS IN NEED OF IRON REPLACEMENT
U-1657	METHOD FOR PROVIDING POST COITAL CONTRACEPTION TO A WOMAN BY ADMINISTERING ABOUT 30 MG OF ULIPRISTAL ACETATE WITHIN ABOUT 120 HOURS AFTER INTERCOURSE, WHEREIN THE WOMAN IS OVERWEIGHT HAVING A BMI OF 25 TO 29.99
U-1658	TREATMENT OF ER-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER IN COMBINATION WITH LETROZOLE AS INITIAL ENDOCRINE-BASED THERAPY FOR METASTATIC DISEASE IN POSTMENOPAUSAL WOMEN
U-1659	MANAGEMENT OF PAIN
U-1660	TREATMENT OF HIV-1 INFECTION IN ADULTS WITH NO DARUNAVIR RESISTANCE-ASSOCIATED SUBSTITUTIONS
U-1661	RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCERS IN PATIENTS ALSO TAKING LOW DOSE ASPIRIN
U-1662	A METHOD OF TREATING OCULAR PAIN
U-1663	TREATMENT OF HIV-1 INFECTION
U-1664	TREATMENT OF BACTERIAL VAGINOSIS WITH METRONIDAZOLE GEL
U-1665	METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER BY ADMINISTERING THE COMPOSITION OF CLAIM 1
U-1666	PALLIATIVE TREATMENT OF PROSTATE CANCER
U-1667	TREATMENT OF ALLERGIC RHINITIS, INCLUDING SEASONAL ALLERGIC RHINITIS

PATENT AND EXCLUSIVITY TERMS

ADB 118 of 191

PATENT USE

U-1668	METHOD OF TREATING DEPRESSION OR MAJOR DEPRESSIVE DISORDER
U-1669	TREATMENT OF MULTIPLE MYELOMA, IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE
U-1670	NATROBA TOPICAL SUSPENSION IS A PEDICULICIDE INDICATED FOR THE TOPICAL TREATMENT OF HEAD LICE INFESTATION IN PATIENTS SIX (6) MONTHS OF AGE AND OLDER.
U-1671	TREATMENT OF OCULAR ITCHING ASSOCIATED WITH CONJUNCTIVITIS
U-1672	TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTION
U-1673	TREATMENT OF COMPLICATED URINARY TRACT INFECTION, INCLUDING PYELONEPHRITIS
U-1674	DOSAGE MODIFICATION TO REDUCE RISKS ASSOCIATED WITH QT PROLONGATION NOT INDUCED BY OTHER DRUGS DURING TREATMENT WITH ILOPERIDONE
U-1675	USE OF TROKENDI XR FOR THE TREATMENT OF EPILEPSY
U-1676	METHODS FOR TREATING BACTERIAL INFECTIONS
U-1677	TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS (IPF)
U-1678	FOR THE TREATMENT OF PATIENTS WITH CLL, FL, OR SLL
U-1679	TREATMENT OF ACUTE OTITIS EXTERNA
U-1680	TREATMENT OF OCULAR ITCHING ASSOCIATED WITH ALLERGIC CONJUNCTIVITIS
U-1681	TREATMENT OF PATIENTS WITH PROGRESSIVE NEUROENDOCRINE TUMORS OF PANCREATIC ORIGIN (PNET) THAT ARE UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC
U-1682	TREATMENT OF BACTERIAL VAGINOSIS
U-1683	TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA WITH 17P DELETION
U-1684	TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
U-1685	DOSAGE MODIFICATION TO REDUCE THE RISK ASSOCIATED WITH QT PROLONGATION NOT INDUCED BY OTHER DRUGS DURING TREATMENT WITH ILOPERIDONE
U-1686	A METHOD TO REDUCE WITHDRAWAL SYMPTOMS, INCLUDING NICOTINE CRAVING, ASSOCIATED WITH SMOKING CESSATION
U-1687	TREATMENT OF HCV INFECTION USING OMBITASVIR
U-1688	METHOD FOR CHRONIC WEIGHT MANAGEMENT BY TREATING OBESITY IN AN INDIVIDUAL WHO DOES NOT HAVE SEVERE RENAL IMPAIRMENT OR ESRD
U-1689	METHOD FOR CHRONIC WEIGHT MANAGEMENT BY INDUCING SATIETY IN AN INDIVIDUAL WHO DOES NOT HAVE SEVERE RENAL IMPAIRMENT OR ESRD
U-1690	METHOD FOR REDUCTION OF SUBMENTAL FAT
U-1691	INDICATED FOR THE ONCE-DAILY INHALED TREATMENT FOR ASTHMA IN ADULTS AGED 18 YEARS AND OLDER
U-1692	METHOD FOR CHRONIC WEIGHT MANAGEMENT BY DECREASING FOOD INTAKE IN AN INDIVIDUAL WHO DOES NOT HAVE SEVERE RENAL IMPAIRMENT OR ESRD
U-1693	METHOD OF TREATING ADHD IN CHILDREN 6 YEARS OF AGE AND OLDER AND ADOLESCENTS
U-1694	A METHOD FOR TREATING HEART FAILURE IN A HUMAN USING A CRYSTALLINE FORM OF IVABRADINE HYDROCHLORIDE
U-1695	METHOD FOR TREATING THYROID CARCINOMA INCLUDING DIFFERENTIATED THYROID CANCER
U-1696	TREATMENT OF UNRESECTABLE HEPATOCELLULAR CARCINOMA
U-1697	PULMONARY ADMINISTRATION OF A COMPOSITION COMPRISING INSULIN BOUND TO A DIKETOPIPERAZINE.
U-1698	PROPHYLAXIS OF INVASIVE ASPERGILLUS AND CANDIDA INFECTIONS
U-1699	A METHOD FOR TREATING ACUTE LYMPHOBLASTIC LEUKEMIA
U-1700	A METHOD FOR TREATING PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA
U-1701	A METHOD FOR TREATING LEUKEMIA RESULTING FROM A MUTATION IN THE BCR-ABL KINASE DOMAIN
U-1702	TREATMENT OF COPD
U-1703	TREATMENT OF RESPIRATORY COMPLAINTS
U-1704	USE FOR TREATMENT IN PATIENTS WITH DIABETES
U-1705	USE FOR TREATMENT IN PATIENTS WITH HYPERGLYCEMIA

PATENT AND EXCLUSIVITY TERMS

ADB 119 of 191

PATENT USE

U-1706	TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE WHEREIN THE COMBINED THERAPEUTIC EFFECT IS GREATER THAN THE ADDITIVE EFFECT OF ADMINISTERING EACH AGENT ALONE
U-1707	TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) IN ADULTS AND SYMPTOMS THEREOF.
U-1708	TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) IN ADULTS.
U-1709	TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) WITH VIBERZI (ELUXADOLINE).
U-1710	TREATMENT OF NON-24-HOUR SLEEP-WAKE DISORDER BY AVOIDING THE USE OF TASIMELTEON IN COMBINATION WITH FLUVOXAMINE
U-1711	FOR THE TREATMENT OF PATIENTS WITH CLL, FL OR SLL
U-1712	MEKINIST IN COMBINATION WITH DABRAFENIB FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA
U-1713	TAFINLAR IN COMBINATION WITH TRAMETINIB FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA
U-1714	TREATMENT OF THROMBOCYTOPENIA IN ADULT AND PEDIATRIC PATIENTS 6 YEARS AND OLDER WITH CHRONIC IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP)
U-1715	P2Y12 PLATELET INHIBITOR FOR USE AS ADJUNCT TO PERCUTANEOUS CORONARY INTERVENTION TO REDUCE RISK OF VARIOUS DISEASES/CONDITIONS IN PATIENTS NOT TREATED WITH A P2Y12 PLATELET INHIBITOR AND NOT GIVEN A GLYCOPROTEIN IIB/IIIA INHIBITOR
U-1716	TREATMENT OF COUGH AND SYMPTOMS ASSOCIATED WITH UPPER RESPIRATORY ALLERGIES OR A COMMON COLD WITH CODEINE PHOSPHATE AND CHLORPHENIRAMINE MALEATE ORALLY ADMINISTERED EXTENDED RELEASE TABLETS
U-1717	METHOD OF TREATING CYSTIC FIBROSIS IN PATIENTS WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) GENE
U-1718	METHOD OF TREATING CYSTIC FIBROSIS IN PATIENTS WHO HAVE THE F508DEL MUTATION IN THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) GENE.
U-1719	ACUTE TREATMENT OF MIGRAINE
U-1720	METHOD OF PROVIDING A THERAPEUTICALLY EFFECTIVE AND STABLE MEDIAN BLOOD PLASMA LEVEL OF LEVODOPA
U-1721	USE OF RUXOLITINIB (JAKAFI) FOR BLOCKING SIGNAL TRANSDUCTION OF JANUS ASSOCIATED KINASES (JAKS) JAK1 AND/OR JAK2
U-1722	TREATMENT OF BASAL CELL CARCINOMA
U-1723	TREATMENT OF HEART FAILURE
U-1724	METHOD OF INHIBITING HEPATITIS C VIRUS
U-1725	METHOD OF INHIBITING HEPATITIS C VIRUS WITH DAKLINZA AND AT LEAST ONE ADDITIONAL COMPOUND HAVING ANTI-HCV ACTIVITY
U-1726	REDUCTION IN RISK OF HOSPITALIZATION IN PATIENTS WITH CORONARY HEART DISEASE AND A HISTORY OF PAROXYSMAL OR PERSISTENT AF AND WITH ONE OR MORE RISK FACTORS BY ADMINISTRATION TWICE A DAY WITH MORNING AND EVENING MEALS
U-1727	TOPICAL TREATMENT OF INFLAMMATORY PAPULES AND PUSTULES OF MILD TO MODERATE ROSACEA
U-1728	REDUCTION IN RISK OF HOSPITALIZATION IN PATIENTS WITH STABLE NYHA CLASS III HEART FAILURE AND A HISTORY OF PAROXYSMAL OR PERSISTENT AF AND WITH ONE OR MORE RISK FACTORS BY ADMINISTRATION TWICE A DAY WITH MORNING AND EVENING MEALS
U-1729	REDUCE THE RISK OF RECURRENT DEEP VEIN THROMBOSIS (DVT)
U-1730	REDUCE THE RISK OF RECURRENT PULMONARY EMBOLISM
U-1731	TEMPORARY RELIEF OF MINOR ACHES AND PAINS
U-1732	TEMPORARY REDUCTION OF FEVER
U-1733	TREATMENT/PREVENTION OF CARDIOVASCULAR DISEASE
U-1734	USE OF FLIBANSERIN OR A PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF TO TREAT HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD)
U-1735	METHODS OF TREATING PAIN, INFLAMMATION AND/OR FEVER WITH INTRAVENOUS IBUPROFEN SUCH THAT MEAN ARTERIAL BLOOD PRESSURE DOES NOT INCREASE THE DOSAGE INTERVAL

PATENT AND EXCLUSIVITY TERMS

ADB 120 of 191

PATENT USE

U-1736	TREATMENT OF THROMBOCYTOPENIA IN ADULT AND PEDIATRIC PATIENTS 1 YEAR AND OLDER WITH CHRONIC IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP)
U-1737	METHOD OF TREATING SCHIZOPHRENIA BY ADMINISTERING ILOPERIDONE TO A PATIENT BY REDUCING THE DOSE IN PATIENTS WHO ARE BEING TREATED WITH FLUOXETINE
U-1738	TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) WITH VIBERZI (ELUXADOLINE)
U-1739	MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND -THE-CLOCK, LONG-TERM OPIOID TREATMENT, INCLUDING NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY
U-1740	IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS FOR THE TREATMENT OF HIV-1 INFECTION IN TREATMENT-NAIVE PATIENTS WITH HIV-1 RNA LESS THAN OR EQUAL TO 100,000 AT THE START OF THERAPY
U-1741	PREVENTION OF DELAYED NAUSEA AND VOMITING ASSOCIATED WITH EMETOGENIC CANCER CHEMOTHERAPY
U-1742	ROLAPITANT IS APPROVED FOR THE PREVENTION OF DELAYED NAUSEA AND VOMITING (I.E., EMESIS) ASSOCIATED WITH EMETOGENIC CANCER CHEMOTHERAPY
U-1743	FOR THE PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH CHEMOTHERAPY
U-1744	PREVENTION OF POST-OPERATIVE NAUSEA AND VOMITING
U-1745	FOR THE TREATMENT OF PATIENTS WITH WALDENSTROM'S MACROGLOBULINEMIA
U-1746	MONOTHERAPY OR ADJUNCTIVE THERAPY FOR TREATMENT OF PARTIAL-ONSET SEIZURES AND APPROVED IN PATIENTS WITH EPILEPSY
U-1747	FOR CLAIMS 1-3,6-13,16-24 AND 26-32: METHOD OF TREATING ADHD
U-1748	FOR CLAIMS 1-4,6-14,16-24 AND 26-32: METHOD OF TREATING ADHD IN CHILDREN 6 YEARS OF AGE AND OLDER AND ADOLESCENTS
U-1749	ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
U-1750	TREATMENT OF SCHIZOPHRENIA AND/OR ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER WITH CARIPRAZINE
U-1751	TREATMENT OF PATIENTS WITH METASTATIC COLORECTAL CANCER WHO HAVE BEEN PREVIOUSLY TREATED WITH FLUOROPYRIMIDINE-, OXALIPLATIN- AND IRINOTECAN-BASED CHEMOTHERAPY, AN ANTI-VEGF BIOLOGICAL THERAPY, AND IF RAS WILD-TYPE, AN ANTI-EGFR THERAPY
U-1752	PROPHYLAXIS OF ORGAN REJECTION
U-1753	TREATMENT OF HCV INFECTION USING DASABUVIR
U-1754	FOR THE TREATMENT OF PULMONARY HYPERTENSION (PAH) IN COMBINATION WITH TADALAFIL
U-1755	FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS HAVE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 19 DELETIONS OR EXON 21 (L858R) SUBSTITUTION MUTATIONS
U-1756	METHODS OF TREATING PAIN, INFLAMMATION AND/OR FEVER IN A CRITICALLY ILL PATIENT WITH INTRAVENOUS IBUPROFEN IN NEED THEREOF
U-1757	INHIBITION ON PI3K KINASE
U-1758	METHOD OF TREATING ALLERGIC REACTION VIA INJECTION
U-1759	METHOD OF REVERSING THE ANTICOAGULANT EFFECT OF DABIGATRAN USING IDARUCIZUMAB
U-1760	RISK-REDUCTION OF NSAID GASTRIC ULCER IN PATIENTS REQUIRING CHRONIC NSAID TREATMENT
U-1761	PLAQUE PSORIASIS
U-1762	USE OF BELVIQ (LORCASERIN HYDROCHLORIDE) FOR CHRONIC WEIGHT MANAGEMENT IN PATIENTS ON A REDUCED-CALORIE DIET AND WHO HAVE ACHIEVED A GREATER THAN OR EQUAL TO 5% WEIGHT LOSS BY WEEK 12 OF TREATMENT
U-1763	USE OF BELVIQ (LORCASERIN HYDROCHLORIDE) FOR CHRONIC WEIGHT MANAGEMENT BY DECREASING FOOD INTAKE IN PATIENTS ON A REDUCED-CALORIE DIET AND WHO HAVE ACHIEVED GREATER THAN OR EQUAL TO 5% WEIGHT LOSS BY WEEK 12 OF TREATMENT
U-1764	USE OF BELVIQ (LORCASERIN HYDROCHLORIDE) FOR CHRONIC WEIGHT MANAGEMENT BY INDUCING SATIETY IN PATIENTS ON A REDUCED-CALORIE DIET AND WHO HAVE ACHIEVED A GREATER THAN OR EQUAL TO 5% WEIGHT LOSS BY WEEK 12 OF TREATMENT
U-1765	USE OF BELVIQ (LORCASERIN HYDROCHLORIDE) FOR CHRONIC WEIGHT MANAGEMENT BY TREATING OBESITY IN PATIENTS ON A REDUCED-CALORIE DIET AND WHO HAVE ACHIEVED A GREATER THAN OR EQUAL TO 5% WEIGHT LOSS BY WEEK 12 OF TREATMENT

PATENT AND EXCLUSIVITY TERMS

ADB 121 of 191

PATENT USE

U-1766	TREATMENT OF HYPERKALEMIA
U-1767	USE OF CALCIPOTRIENE FOAM FOR THE TOPICAL TREATMENT OF PLAQUE PSORIASIS IN PATIENTS AGED 18 YEARS AND OLDER
U-1768	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN
U-1769	TREATMENT OF PAIN BY TRANSMUCOSAL DELIVERY OF BUPRENORPHINE
U-1770	TREATMENT OF SCHIZOPHRENIA WITH IMPROVEMENT IN NEGATIVE SYMPTOMS AND/OR COGNITIVE DYSFUNCTION OF SCHIZOPHRENIA
U-1771	ADMINISTRATION OF REMODULIN DILUTED FOR INTRAVENOUS INFUSION WITH STERILE WATER FOR INJECTION OR 0.9% SODIUM CHLORIDE INJECTION PRIOR TO ADMINISTRATION
U-1772	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN
U-1773	LONG-TERM MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
U-1774	USE OF A LOTION CONTAINING HALOBETASOL PROPIONATE FOR THE TREATMENT OF CORTICOSTEROID-RESPONSIVE
U-1775	USE OF A LOTION CONTAINING HALOBETASOL PROPIONATE FOR THE TREATMENT OF CORTICOSTEROID-RESPONSIVE DERMATOSES INCLUDING PSORIASIS
U-1776	METHOD OF USING COBIMETINIB FOR THE TREATMENT OF MELANOMA
U-1777	TREATMENT OF PATIENTS WITH METASTATIC EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) T790M MUTATION-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC), WHO HAVE PROGRESSED ON OR AFTER EGFR TKI THERAPY
U-1778	METHOD FOR TREATING MULTIPLE MYELOMA
U-1779	METHOD FOR TREATING MULTIPLE MYELOMA WITH ONE OR MORE OTHER THERAPEUTIC AGENTS
U-1780	METHOD FOR TREATING CANCER, INCLUDING MULTIPLE MYELOMA
U-1781	RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER IN PATIENTS REQUIRING NSAID TREATMENT
U-1782	FOR HEAD LICE INFESTATIONS
U-1783	METHOD OF TREATING FREQUENT HEARTBURN BY ADMINISTERING AN ESOMEPRAZOLE MAGNESIUM AS CLAIMED
U-1784	METHOD OF TREATING FREQUENT HEARTBURN BY ADMINISTERING AN ESOMEPRAZOLE MAGNESIUM TRIHYDRATE AS CLAIMED
U-1785	METHOD OF TREATING FREQUENT HEARTBURN BY ADMINISTERING AN ESOMEPRAZOLE MAGNESIUM FORMULATION AS CLAIMED
U-1786	TREATMENT OF PATIENTS WITH RELAPSING FORMS OF MULTIPLE SCLEROSIS WHILE MANAGING THE RISK OF TERIFLUNOMIDE AND ROSUVASTATIN INTERACTION BY LIMITING THE ROSUVASTATIN DOSE TO NO MORE THAN 10MG AND/OR ADMINISTERING ABOUT HALF THE NORMAL DOSE
U-1787	TREATMENT OF EXOCRINE PANCREATIC INSUFFICIENCY
U-1788	TREATMENT OF PATIENT HAVING DIABETES MELLITUS VIA ORAL INHALATION OF FDKP MICROPARTICLES COMPRISING INSULIN
U-1789	METHOD OF ADMINISTERING AN ETHANOL-FREE TAXANE LIQUID NANODISPERSION FORMULATION TO A SUBJECT COMBINING THE FORMULATION WITH AN AQUEOUS MEDIUM TO PROVIDE AN ETHANOL-FREE TAXANE DILUTED SOLUTION
U-1790	FOR USE IN TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND/OR NON-HODGKIN'S LYMPHOMA
U-1791	EMERGENCY TREATMENT OF ADULT & PEDIATRIC PATIENTS FOLLOWING FLUOROURACIL OR CAPECITABINE OVERDOSE, OR WHO EXHIBIT EARLY-ONSET, SEVERE OR LIFE-THREATENING CARDIAC OR CNS TOXICITY OR UNUSUALLY SEVERE ADVERSE REACTIONS WITHIN 96 HOURS
U-1792	TREATMENT OF OTIC INFECTION OR INFLAMMATION
U-1793	TREATMENT OF PEDIATRIC PATIENTS WITH OTITIS MEDIA WITH EFFUSION UNDERGOING TYMPANOSTOMY TUBE PLACEMENT
U-1794	REVERSAL OF DRUG-INDUCED NEUROMUSCULAR BLOCK
U-1795	REVERSAL OF NEUROMUSCULAR BLOCKAGE INDUCED BY ROCURONIUM BROMIDE OR VECURONIUM BROMIDE
U-1796	TOPICAL TREATMENT OF INFLAMMATORY PAPULES AND PUSTULES OF MILD TO MODERATE ROSACEA

PATENT AND EXCLUSIVITY TERMS

ADB 122 of 191

PATENT USE

U-1797	METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING A PHARMACEUTICAL COMPOSITION COMPRISING SELEXIPAG
U-1798	METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING SELEXIPAG IN COMBINATION WITH THE ENDOTHELIN RECEPTOR ANTAGONIST MACITENTAN
U-1799	METHOD OF INCREASING GROWTH OF HAIR INCLUDING EYELASHES
U-1800	A METHOD OF TREATING OCULAR PAIN AND/OR ENHANCING OCULAR COMFORT
U-1801	REDUCTION OF SERUM URIC ACID LEVELS
U-1802	TREATMENT OF GOUT
U-1803	TREATMENT OF HYPERURICEMIA
U-1804	ACHIEVING A THERAPEUTIC BENEFIT IN A SUBJECT WITH GOUT
U-1805	USE OF DEXLANSOPRAZOLE IN PATIENTS TAKING CLOPIDOGREL WITHOUT MEANINGFUL CYP2C19 INTERACTIONS
U-1806	COADMINISTERING WITH ALLOPURINOL TO REDUCE SERUM URIC ACID (SUA) BELOW 4 MG/DL; BELOW 6MG/DL IN PATIENTS HAVING URIC ACID DEPOSITS; AND/OR BELOW 6MG/DL WITH SUA INTRADAY CHANGE MORE THAN 50% AND/OR ADVERSE EVENT RATE LESS THAN 15%
U-1807	TREATMENT OF PEDIATRIC PATIENTS 8 TO 17 YEARS OF AGE WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HEFH)
U-1808	USE OF NALTREXONE AND BUPROPION FOR CHRONIC WEIGHT MANAGEMENT FOR TREATING OVERWEIGHT OR OBESITY IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER
U-1809	METHOD OF DRUG DELIVERY VIA THE NASAL CAVITY
U-1810	TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
U-1811	TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E MUTATIONS AFTER CONFIRMING THE PRESENCE OF BRAF V600E MUTATION
U-1812	TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC LIPOSARCOMA
U-1813	TREATMENT OF PATIENTS INFECTED WITH HEPATITIS C VIRUS
U-1814	METHOD OF TREATING GLAUCOMA OR ELEVATED INTRAOCULAR PRESSURE
U-1815	TREATMENT OF PARTIAL-ONSET SEIZURES AS ADJUNCTIVE THERAPY IN PATIENTS WITH EPILEPSY AGED 16 YEARS AND OLDER WITH EPILEPSY
U-1816	TREATMENT OF A UREA CYCLE DISORDER
U-1817	PEDIATRIC USE AGES 1 MONTH TO 2 YEARS, GERD AND EROSION ESOPHAGITIS
U-1818	TREATING HR-POS., HER2-NEG. ADVANCED OR METASTATIC BREAST CANCER WITH PALBOCICLIB IN COMBO WITH LETROZOLE AS INITIAL ENDOCRINE BASED THERAPY IN POSTMENOPAUSAL WOMEN, OR FULVESTRANT IN WOMEN WITH DISEASE PROGRESSION AFTER ENDOCRINE THERAPY
U-1819	MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
U-1820	METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION BY ADMINISTERING A PHARMACEUTICAL COMPOSITION COMPRISING MACITENTAN AND A POLYSORBATE, WHEREIN THE POLYSORBATE REPRESENTS 0.1 TO 3% OF THE WEIGHT OF SAID PHARMACEUTICAL COMPOSITION
U-1821	METHOD FOR CONTRACEPTION TO A WOMAN COMPRISING ADMINISTERING TO THE WOMAN 30MG OF ULIPRISTAL ACETATE MORE THAN 72 HOURS AND UP TO 120 HOURS AFTER AN UNPROTECTED INTERCOURSE
U-1822	TREATMENT OF SCHIZOPHRENIA OR BIPOLAR DEPRESSION WITH IMPROVEMENT IN ATTENTION FUNCTION IN SCHIZOPHRENIA AND/OR BIPOLAR DISORDER
U-1823	A METHOD OF PROVIDING NITRIC OXIDE THERAPY TO A PATIENT BY COMPENSATING LONG-TERM SENSITIVITY DRIFT OF ELECTROCHEMICAL GAS SENSORS USED IN SYSTEMS FOR DELIVERING THERAPEUTIC NITRIC OXIDE TO A PATIENT
U-1824	A METHOD OF PROVIDING NITRIC OXIDE THERAPY TO A PATIENT BY VERIFYING GAS INFORMATION OF NITRIC OXIDE PRIOR TO DELIVERY TO PATIENT
U-1825	METHOD OF USING VISMODEGIB TO TREAT CANCER IN A MAMMAL
U-1826	TREATMENT OF HR-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER IN COMBINATION WITH PALBOCICLIB IN WOMEN WITH DISEASE PROGRESSION AFTER ENDOCRINE THERAPY
U-1827	A METHOD OF PROVIDING A SUBJECT WITH THERAPEUTICALLY EFFECTIVE AMOUNT OF RACEMIC

PATENT AND EXCLUSIVITY TERMS

ADB 123 of 191

PATENT USE

	METHYLPHENIDATE BY ORALLY ADMINISTERING TO SAID SUBJECT A SINGLE METHYLPHENIDATE EXTENDED RELEASE CHEWABLE TABLET ACCORDING TO CLAIM 1
U-1828	INCREASING MEAN ARTERIAL BLOOD PRESSURE IN ADULT PATIENTS WITH HYPOTENSION ASSOCIATED WITH SEPTIC SHOCK
U-1829	EMERGENCY TREATMENT OF ALLERGIC REACTIONS (TYPE I), INCLUDING ANAPHYLAXIS
U-1830	INDUCTION AND MAINTENANCE OF MYDRIASIS DURING INTRAOCULAR SURGERY
U-1831	METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING A CRYSTALLINE FORM OF SELEXIPAG
U-1832	IMPROVEMENT IN GLYCEMIC CONTROL IN DIABETES MELLITUS PATIENTS BY USE OF A PEN INJECTOR WITH A THREADED DRIVE SLEEVE
U-1833	REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION
U-1834	TREATMENT OF POSTOPERATIVE INFLAMMATION AND PREVENTION OF OCULAR PAIN IN PATIENTS UNDERGOING CATARACT SURGERY
U-1835	TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH 17P DELETION, AS DETECTED BY AN FDA APPROVED TEST, WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
U-1836	TREATMENT OF HEREDITARY TYROSINEMIA TYPE 1 (HT-1) IN COMBINATION WITH DIETARY RESTRICTION OF TYROSINE AND PHENYLALANINE
U-1837	METHOD FOR TREATING TYPE II DIABETES MELLITUS BY ADMINISTERING SAXAGLIPTIN ALONE OR IN COMBINATION WITH INSULIN, METFORMIN, A THIAZOLIDINEDIONE, GLYBURIDE OR METFORMIN PLUS A SULFONYLUREA
U-1838	METHOD FOR TREATING TYPE II DIABETES MELLITUS BY ADMINISTERING SAXAGLIPTIN IN COMBINATION WITH METFORMIN
U-1839	COMPOSITION AND METHOD FOR PROVIDING A REDUCTION IN SIDE EFFECTS FOR HUMAN PATIENTS IN NEED OF ACETYLCYSTEINE THERAPY
U-1840	TREATMENT OF HCV INFECTION USING PARITAPREVR, OMBITASVIR, RITONAVIR, AND DASABUVIR, WITHOUT RIBAVIRIN
U-1841	USE IN THE LONG-TERM, MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
U-1842	METHOD OF TREATING EPILEPSY
U-1843	TREATMENT OF PSYCHOSIS
U-1844	TREATMENT OF PARKINSON'S DISEASE PSYCHOSIS
U-1845	TREATMENT OF PSYCHOSIS OR A SYMPTOM THEREOF
U-1846	TREATMENT OF A NEURODEGENERATIVE DISEASE OR A SYMPTOM THEREOF
U-1847	METHOD OF TREATING A BACTERIAL INFECTION
U-1848	TREATMENT OF METASTATIC ADENOCARCINOMA OF THE PANCREAS THAT HAS PROGRESSED ON GEMCITABINE-BASED THERAPY, IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN
U-1849	METHOD OF TREATING PULMONARY HYPERTENSION BY ADMINISTERING TREPROSTINIL OR A SALT THEREOF BY INHALATION USING A DEVICE
U-1850	METHOD OF ADMINISTERING LEVETIRACETAM
U-1851	A DOSING REGIMEN FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA AND HYPERLIPIDEMIA IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA USING AT LEAST THREE STEP-WISE INCREASING DOSES
U-1852	METHOD OF TREATING TYPE 2 DIABETES
U-1853	METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN AND, OPTIONALLY, A SULFONYLUREA
U-1854	TREATMENT OF PRIMARY BILIARY CHOLANGITIS (PBC)
U-1855	IMPROVEMENT IN GLYCEMIC CONTROL IN DIABETES MELLITUS PATIENTS
U-1856	TREATMENT OF METASTATIC ADENOCARCINOMA OF THE PANCREAS THAT HAS PROGRESSED ON GEMCITABINE-BASED THERAPY, IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN, IN A PATIENT HOMOZYGOUS FOR THE UGT1A1*28 ALLELE
U-1857	TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES

PATENT AND EXCLUSIVITY TERMS

ADB 124 of 191

PATENT USE

U-1858	TREATMENT OF PLAQUE PSORIASIS
U-1859	TREATMENT OF SCHIZOPHRENIA, ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER, ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER, AND TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER
U-1860	REDUCTION OF THE RATE OF CARDIOVASCULAR DEATH, MYOCARDIAL INFARCTION, AND STROKE IN PATIENTS WITH ACUTE CORONARY SYNDROME OR A HISTORY OF MYOCARDIAL INFARCTION
U-1861	USE OF AN INHALER TO ADMINISTER DRY POWDER MEDICAMENT
U-1862	TREATMENT OF POST-MYOCARDIAL INFARCTION
U-1863	TREATMENT OF STROKE
U-1864	TREATMENT OF MYOCARDIAL INFARCTION
U-1865	TREATMENT OF THROMBOTIC STROKE
U-1866	TREATMENT OF STABLE AND UNSTABLE ANGINA
U-1867	METHOD OF INHIBITING PLATELET AGGREGATION
U-1868	TREATMENT OF ARTERIAL THROMBOTIC COMPLICATIONS SELECTED FROM THE GROUP CONSISTING OF UNSTABLE ANGINA, THROMBOTIC OR EMBOLIC STROKE, TRANSIENT ISCHAEMIC ATTACKS, PERIPHERAL VASCULAR DISEASE AND MYOCARDIAL INFARCTION
U-1869	TREATMENT OF AN ARTERIAL THROMBOTIC COMPLICATION IN A PATIENT WITH CORONARY ARTERY, CEREBROVASCULAR OR PERIPHERAL VASCULAR DISEASE
U-1870	ZINGO IS A POWDER INTRADERMAL SYSTEM THAT IS CAPABLE OF DELIVERING FINE DRY POWDERED LIDOCAINE HYDROCHLORIDE MONOHYDRATE FOR LOCAL ANESTHETIC ACTION
U-1871	TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH STAGE 3 OR 4 CHRONIC KIDNEY DISEASE USING CONTROLLED RELEASE, ORAL 25-HYDROXYVITAMIN D
U-1872	USE OF SUSTAINED RELEASE 25-HYDROXYVITAMIN D IN TREATING PATIENTS HAVING 25-HYDROXYVITAMIN D INSUFFICIENCY OR DEFICIENCY
U-1873	ADMINISTRATION OF 25-HYDROXYVITAMIN D3 BY CONTROLLED RELEASE
U-1874	TREATMENT OF FREQUENT HEARTBURN BY ADMINISTERING OMEPRAZOLE ACCORDING TO CLAIMS 1-8
U-1875	TREATMENT OF FREQUENT HEARTBURN BY ADMINISTERING S-OMEPRAZOLE TRIHYDRATE ACCORDING TO CLAIMS 1-3
U-1876	METHOD OF ANESTHETIZING AT LEAST A PORTION OF THE MAXILLARY DENTAL ARCH
U-1877	METHOD OF TREATING PULMONARY HYPERTENSION BY ORALLY ADMINISTERING A FORMULATION OF A PHARMACEUTICALLY ACCEPTABLE SALT OF TREPROSTINIL
U-1878	FOR OPIOID DEPENDENCE
U-1879	METHOD OF DIAGNOSING TUMORS USING POSITRON EMISSION TOMOGRAPHY
U-1880	TREATMENT OF SIGNS AND SYMPTOMS OF DRY EYE DISEASE (DED)
U-1881	IMPROVEMENT IN GLYCEMIC CONTROL IN TYPE 2 DIABETES MELLITUS PATIENTS BY USE OF A PEN INJECTOR
U-1882	MANAGEMENT OF MILD TO MODERATE PAIN, MANAGEMENT OF MODERATE TO SEVERE PAIN AS AN ADJUNCT TO OPIOID ANALGESICS, REDUCTION IN FEVER THROUGH ANALGESIC AND ANTIPYRETIC ACTIVITY
U-1883	TREATMENT OF GASTROINTESTINAL STROMAL TUMORS (GIST)
U-1884	USE OF LORCASERIN HYDROCHLORIDE FOR CHRONIC WEIGHT MANAGEMENT IN PATIENTS ON A REDUCED-CALORIE DIET AND WHO HAVE ACHIEVED A GREATER THAN OR EQUAL TO 5% WEIGHT LOSS BY WEEK 12 OF TREATMENT
U-1885	USE OF LORCASERIN HYDROCHLORIDE FOR CHRONIC WEIGHT MANAGEMENT BY DECREASING FOOD INTAKE IN PATIENTS ON A REDUCED-CALORIE DIET AND WHO HAVE ACHIEVED A GREATER THAN OR EQUAL TO 5% WEIGHT LOSS BY WEEK 12 OF TREATMENT
U-1886	USE OF LORCASERIN HYDROCHLORIDE FOR CHRONIC WEIGHT MANAGEMENT BY INDUCING SATIETY IN PATIENTS ON A REDUCED-CALORIE DIET AND WHO HAVE ACHIEVED A GREATER THAN OR EQUAL TO 5% WEIGHT LOSS BY WEEK 12 OF TREATMENT
U-1887	USE OF LORCASERIN HYDROCHLORIDE FOR CHRONIC WEIGHT MANAGEMENT BY TREATING OBESITY IN PATIENTS ON A REDUCED-CALORIE DIET AND WHO HAVE ACHIEVED A GREATER THAN OR EQUAL TO 5% WEIGHT LOSS BY WEEK 12 OF TREATMENT
U-1888	USE OF CONTROLLED RELEASE 25-HYDROXYVITAMIN D IN TREATING SECONDARY HYPERPARATHYROIDISM IN PATIENTS HAVING CHRONIC KIDNEY DISEASE

PATENT AND EXCLUSIVITY TERMS

ADB 125 of 191

PATENT USE

U-1889	TREATMENT OF HCV INFECTION USING DASABUVIR/OMBITASVIR/PARITAPREVIR/RITONAVIR FIXED DOSE COMBINATION
U-1890	OTC USE: ALLERGY SYMPTOM RELIEVER; TEMPORARILY RELIEVES THESE SYMPTOMS DUE TO HAY FEVER OR OTHER UPPER RESPIRATORY ALLERGIES; NASAL CONGESTION, RUNNY NOSE, SNEEZING, ITCHY NOSE, AND (ITCHY WATER EYES (AGES 12 AND UP))
U-1891	TREATMENT OR PREVENTION OF NAUSEA AND VOMITING
U-1892	METHOD OF TREATING LEFT VENTRICULAR DYSFUNCTION
U-1893	METHOD OF TREATING MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR DISORDER IN PEDIATRIC PATIENTS
U-1894	COMBINATION TREATMENT WITH A GLITAZONE FOR IMPROVEMENT OF GLYCEMIC CONTROL IN TYPE 2 DIABETES MELLITUS PATIENTS
U-1895	METHOD OF TREATING PROSTATE CANCER
U-1896	SUPPLEMENT FOR VITAMIN B12 DEFICIENCIES
U-1897	METHOD OF TREATING ACS USING ANGIOPLASTY WITH AGGRASTAT (TIROFIBAN HYDROCHLORIDE)
U-1898	METHOD OF INHIBITING PLATELET AGGREGATION WITH AGGRASTAT (TIROFIBAN HYDROCHLORIDE)
U-1899	TREATMENT OF PANCREATIC CANCER THAT HAS PROGRESSED ON GEMCITABINE-BASED THERAPY, IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN
U-1900	TREATMENT OF THE SIGNS AND SYMPTOMS OF DRY EYE DISEASE (DED)
U-1901	TREATMENT OF SCHIZOAFFECTIVE DISORDER AS A MONOTHERAPY AND AS AN ADJUNCT TO MOOD STABILIZERS OR ANTIDEPRESSANTS
U-1902	TREATMENT OR SECONDARY PREVENTION OF CARDIOVASCULAR DISEASE, CARDIOVASCULAR EVENTS, OR CEREBROVASCULAR EVENTS AND RISK-REDUCTION OF ASPIRIN-ASSOCIATED GASTRIC ULCERS
U-1903	USE OF NALOXONE HYDROCHLORIDE FOR EMERGENCY TREATMENT OF KNOWN OR SUSPECTED OPIOID OVERDOSE, AS MANIFESTED BY RESPIRATORY AND/OR CENTRAL NERVOUS SYSTEM DEPRESSION.
U-1904	(I)TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY; (II)RESTORING/INCREASING FUNCTIONAL DYSTROPHIN PROTEIN; OR (III) INDUCING SKIPPING; EACH OF (I)-(III) IN PATIENTS HAVING A CONFIRMED MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 51 SKIPPING
U-1905	METHOD OF TREATING A PATIENT HAVING CYSTIC FIBROSIS, THE PATIENT HAVING A R117H MUTATION IN CFTR, USING N-(5-HYDROXY-2,4-DI-TERT-BUTYL-PHENYL)-4-OXO-1H-QUINOLINE-3-CARBOXAMIDE
U-1906	METHOD OF TREATING A PATIENT HAVING CYSTIC FIBROSIS, SUCH AS A PATIENT HAVING A G551D MUTATION IN CFTR, USING N-(5-HYDROXY-2,4-DI-TERT-BUTYL-PHENYL)-4-OXO-1H-QUINOLINE-3-CARBOXAMIDE
U-1907	USE OF A DELIVERY DEVICE TO ADMINISTER A DOSE OF NALOXONE
U-1908	METHOD OF TREATING CYSTIC FIBROSIS IN A PATIENT, THE PATIENT HAVING THE F508DEL MUTATION IN CFTR, USING IVACAFTOR AND FORM I LUMACAFTOR
U-1909	METHOD OF TREATING CYSTIC FIBROSIS IN A PATIENT, THE PATIENT HAVING THE F508DEL MUTATION IN CFTR, USING IVACAFTOR AND LUMACAFTOR
U-1910	METHOD OF TREATING CYSTIC FIBROSIS IN A PATIENT, THE PATIENT HAVING THE F508DEL MUTATION IN CFTR, USING THE DOSAGE UNIT OF CLAIM 1 OF U.S. PATENT NO. 8,716,338
U-1911	METHOD OF TREATING A PATIENT HAVING CYSTIC FIBROSIS USING IVACAFTOR AND LUMACAFTOR
U-1912	METHOD OF TREATING CYSTIC FIBROSIS IN A PATIENT, THE PATIENT HAVING THE F508DEL MUTATION IN CFTR, USING A DOSAGE UNIT AS DEFINED IN CLAIM 1 OF U.S. PATENT NO. 9,192,606
U-1913	TREATMENT OF PEDIATRIC PATIENTS WITH BILATERAL OTITIS MEDIA WITH EFFUSION UNDERGOING TYMPANOSTOMY TUBE PLACEMENT
U-1914	IN COMBINATION WITH RITUXIMAB, FOR THE TREATMENT OF PATIENTS WITH RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
U-1915	METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS WITH SEVERE CHRONIC RENAL IMPAIRMENT AND WHO ARE INELIGIBLE FOR METFORMIN THERAPY BY ADMINISTERING LINAGLIPTIN
U-1916	PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH CHEMOTHERAPY (CINV)

PATENT AND EXCLUSIVITY TERMS

ADB 126 of 191

PATENT USE

U-1917	TREATMENT OF EXOCRINE PANCREATIC CANCER THAT HAS PROGRESSED ON GEMCITABINE-BASED THERAPY, IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN
U-1918	TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY IN PATIENTS HAVING A MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 51 SKIPPING
U-1919	RESTORING AN MRNA READING FRAME TO INDUCE DYSTROPHIN PROTEIN PRODUCTION IN PATIENTS HAVING A MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 51 SKIPPING
U-1920	USE OF EXTENDED RELEASE ORAL 25-HYDROXYVITAMIN D3 IN TREATING SECONDARY HYPERPARATHYROIDISM IN ADULT PATIENTS HAVING CHRONIC KIDNEY DISEASE STAGE 3 OR STAGE 4
U-1921	MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE BY PROVIDING AN ABUSE-DETERRENT ORAL CONTROLLED RELEASE COMBINATION DRUG PRODUCT
U-1922	INTRAVAGINAL PRASTERONE (DEHYDROEPIANDROSTERONE) AT A DAILY DOSE OF 6.5MG FOR THE TREATMENT OF DYSPAREUNIA, A SYMPTOM OF VULVAR AND VAGINAL ATROPHY, DUE TO MENOPAUSE
U-1923	IMPROVEMENT IN GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED BY BASAL INSULIN OR LIXISENATIDE BY USE OF A PEN INJECTOR WITH A THREADED DRIVE SLEEVE
U-1924	KYPROLIS IS INDICATED IN COMBINATION WITH LENALIDOMIDE PLUS DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED ONE TO THREE LINES OF THERAPY
U-1925	USE OF AN AUTO INJECTOR TO ADMINISTER NALOXONE HCL
U-1926	METHOD OF TREATING, REDUCING THE INCIDENCE OF, OR PREVENTING AN ISCHEMIC EVENT IN A PATIENT UNDERGOING PCI BY ADMINISTERING INTRAVENOUSLY 30 UG/KG BOLUS BEFORE PCI AND CONTINUOUS INFUSION OF 4 UG/KG/MIN FOR AT LEAST 2 HOURS OR THE DURATION OF THE PCI
U-1927	TREATMENT OF PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHO HAVE PROGRESSED ON OR ARE INTOLERANT TO CRIZOTINIB
U-1928	RUBRACA IS INDICATED AS MONOTHERAPY FOR THE TREATMENT OF PATIENTS WITH DELETERIOUS BRCA MUTATION (GERMLINE AND/OR SOMATIC) ASSOCIATED ADVANCED OVARIAN CANCER WHO HAVE BEEN TREATED WITH TWO OR MORE CHEMOTHERAPIES.
U-1929	TREATMENT OF DIABETES MELLITUS WITH AN INHALED INSULIN TO IMPROVE GLYCEMIC CONTROL USING A DRY POWDER INHALATION SYSTEM COMPRISING AN INHALER, A CARTRIDGE AND A DRY POWDER MEDICAMENT COMPRISING INSULIN IN A SINGLE INHALATION
U-1930	METHOD OF AEROSOLIZING/DEAGGLOMERATING AN INSULIN DRY POWDER FOR USE IN TREATING DIABETES MELLITUS VIA ORAL INHALATION USING AN INHALER WITH A CARTRIDGE CONTAINING THE INSULIN DRY POWDER.
U-1931	PROPHYLAXIS OR TREATMENT OF VENOUS AND ARTERIAL THROMBOTIC DISEASE
U-1932	METHOD OF TREATING MILD TO MODERATE ATOPIC DERMATITIS.
U-1933	TREATMENT OF POSTOPERATIVE INFLAMMATION AND REDUCTION OF OCULAR PAIN IN PATIENTS WHO HAVE UNDERGONE CATARACT SURGERY
U-1934	TREATMENT OF NON-24-HOUR SLEEP-WAKE DISORDER BY AVOIDING THE USE OF TASIMELTEON IN COMBINATION WITH A STRONG CYP1A2 INHIBITOR
U-1935	REDUCTION OF THE RATE OF CARDIOVASCULAR DEATH, MYOCARDIAL INFARCTION, AND STROKE IN PATIENTS WITH A HISTORY OF MYOCARDIAL INFARCTION
U-1936	TREATMENT OF MYOCARDIAL INFARCTION AND STROKE IN PATIENTS WITH ACUTE CORONARY SYNDROME OR A HISTORY OF MYOCARDIAL INFARCTION
U-1937	TREATMENT OF MYOCARDIAL INFARCTION IN PATIENTS WITH ACUTE CORONARY SYNDROME OR A HISTORY OF MYOCARDIAL INFARCTION
U-1938	TREATMENT OF STROKE IN PATIENTS WITH ACUTE CORONARY SYNDROME OR A HISTORY OF MYOCARDIAL INFARCTION
U-1939	ADMINISTRATION ONCE DAILY WITHIN TWO HOURS AFTER WAKING IN THE MORNING FOR IMPROVEMENT OF GLYCEMIC CONTROL IN A TYPE 2 DIABETES PATIENT
U-1940	IMPROVEMENT IN THE APPEARANCE OF MODERATE TO SEVERE CONVEXITY OR FULLNESS ASSOCIATED WITH SUBMENTAL FAT IN ADULTS BY MEANS OF REDUCING SUBMENTAL FAT VOLUME AS DESCRIBED IN THE APPROVED LABELING
U-1941	TREATMENT OF INFANTILE-ONSET SPINAL MUSCULAR ATROPHY

PATENT AND EXCLUSIVITY TERMS

ADB 127 of 191

PATENT USE

U-1942	TREATMENT OF SPINAL MUSCULAR ATROPHY BY INCREASING EXON-7 INCLUSION IN SMN2 MRNA
U-1943	TREATMENT OF SPINAL MUSCULAR ATROPHY
U-1944	TREATMENT OF SPINAL MUSCULAR ATROPHY BY INHIBITING AN SMN2 PRE-MRNA INTRONIC SPLICING SILENCER SITE
U-1945	IMPROVEMENT OF GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN.
U-1946	TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA
U-1947	TREATMENT OF MARGINAL ZONE LYMPHOMA
U-1948	A METHOD FOR TREATING CHRONIC MYELOID LEUKEMIA
U-1949	FOR USE IN THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
U-1950	TREATMENT OF PATIENTS WITH ADVANCED (METASTATIC) NON-SMALL CELL LUNG CANCER WHOSE DISEASE PROGRESSED DURING OR AFTER PLATINUM-BASED CHEMOTHERAPY
U-1951	TREATMENT OF ONYCHOMYCOSIS OF A TOENAIL
U-1952	FOR USE IN THE TREATMENT OF PATIENTS WITH INDOLENT B-CELL NON-HODGKIN LYMPHOMA
U-1953	REDUCE THE RISK OF STROKE IN PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION WITH ONCE DAILY, RAPID-RELEASE TABLET ADMINISTERED FOR AT LEAST FIVE CONSECUTIVE DAYS
U-1954	TREATMENT OF DEEP VEIN THROMBOSIS WITH ONCE DAILY, RAPID-RELEASE TABLET ADMINISTERED FOR AT LEAST FIVE CONSECUTIVE DAYS
U-1955	TREATMENT OF PULMONARY EMBOLISM WITH ONCE DAILY, RAPID-RELEASE TABLET ADMINISTERED FOR AT LEAST FIVE CONSECUTIVE DAYS
U-1956	FOLLOWING INITIAL 6 MONTHS TREATMENT FOR DEEP VEIN THROMBOSIS (DVT) AND/OR PULMONARY EMBOLISM (PE), REDUCTION IN THE RISK OF RECURRENCE OF DVT AND OF PE WITH ONCE DAILY, RAPID-RELEASE TABLET ADMINISTERED FOR AT LEAST FIVE CONSECUTIVE DAYS
U-1957	PROPHYLAXIS OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM IN PATIENTS UNDERGOING KNEE OR HIP REPLACEMENT SURGERY, WITH ONCE DAILY, RAPID-RELEASE TABLET ADMINISTERED FOR AT LEAST FIVE CONSECUTIVE DAYS
U-1958	FOR THE TREATMENT OF GENOTYPE 1, 2, 3 OR 4 CHRONIC HEPATITIS C VIRUS (HCV) INFECTION AS A COMPONENT OF A COMBINATION ANTIVIRAL TREATMENT REGIMEN WITH RIBAVIRIN
U-1959	TOPICAL TREATMENT OF PERSISTENT FACIAL ERYTHEMA ASSOCIATED WITH ROSACEA IN ADULTS WITH 1% OXYMETAZOLINE HYDROCHLORIDE CREAM
U-1960	USE OF THE ATYPICAL ANTIPSYCHOTIC ASENAPINE FOR TREATMENT OF SCHIZOPHRENIA IN ADULTS
U-1961	USE OF THE ATYPICAL ANTIPSYCHOTIC ASENAPINE FOR TREATMENT OF MANIC OR MIXED EPISODES OF BIPOLAR I DISORDER: ACUTE MONOTHERAPY OF MANIC OR MIXED EPISODES (AGES 10 TO ADULT)
U-1962	USE OF THE ATYPICAL ANTIPSYCHOTIC ASENAPINE FOR TREATMENT OF MANIC OR MIXED EPISODES OF BIPOLAR I DISORDER: MAINTENANCE MONOTHERAPY IN ADULTS
U-1963	USE OF THE ATYPICAL ANTIPSYCHOTIC ASENAPINE FOR TREATMENT OF MANIC OR MIXED EPISODES OF BIPOLAR I DISORDER: AS ADJUNCTIVE TREATMENT TO LITHIUM OR VALPROATE IN ADULTS
U-1964	ELEVATION OF INTRACELLULAR CGMP RESULTING IN INCREASED INTESTINAL FLUID AND ACCELERATED TRANSIT
U-1965	FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) IN COMBINATION WITH TADALAFIL, WHEREIN THE WEIGHT RATIO OF AMBRISENTAN TO TADALAFIL IS ABOUT 1:2 TO ABOUT 1:3
U-1966	USE OF THE ATYPICAL ANTIPSYCHOTIC ASENAPINE FOR TREATMENT OF MANIC OR MIXED EPISODES OF BIPOLAR I DISORDER: ACUTE MONOTHERAPY OF MANIC OR MIXED EPISODES IN PEDIATRIC PATIENTS AGE 10-17
U-1967	METHOD OF TREATING TYPE 2 DIABETES IN PATIENTS WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE THERAPY WITH ONE OR MORE CONVENTIONAL ANTIHYPERGLYCEMIC AGENTS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
U-1968	METHOD OF TREATING TYPE 2 DIABETES IN PATIENTS WHO HAVE NOT BEEN PREVIOUSLY TREATED WITH AN ANTIHYPERGLYCEMIC AGENT BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
U-1969	TOPICAL TREATMENT OF ONYCHOMYCOSIS OF THE TOENAIL(S) DUE TO TRICHOPHYTON RUBRUM

PATENT AND EXCLUSIVITY TERMS

ADB 128 of 191

PATENT USE

AND TRICHOPHYTON MENTAGROPHYTES

U-1970	TREATMENT OF ONYCHOMYCHOSIS OF A TOENAIL CAUSED BY TRICHOPHYTON RUBRUM OR TRICHOPHYTON MENTAGROPHYTES
U-1971	FOR THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
U-1972	FOR THE TREATMENT OF PATIENTS WITH INDOLENT B-CELL NON-HODGKIN LYMPHOMA
U-1973	METHOD OF TREATING CYSTIC FIBROSIS USING N-(5-HYDROXY-2,4-DITERT-BUTYL-PHENYL)-4-OXO-1H-QUINOLINE-3-CARBOXAMIDE AND 3-(6-(1-2,2-DIFLUOROBENZO[D][1,3]DIOXOL-5-YL) CYCLOPROPANECARBOXAMIDO)-3-METHYLPYRIDIN-2-YL) BENZOIC ACID
U-1974	TREATMENT OF HALLUCINATIONS AND DELUSIONS ASSOCIATED WITH PARKINSON'S DISEASE PSYCHOSIS
U-1975	METHOD OF INCREASING EYELASH GROWTH WITH BIMATOPROST
U-1976	METHOD FOR TREATING TYPE 2 DIABETES MELLITUS (T2DM) IN PATIENTS WHO HAVE INADEQUATE CONTROL WITH DAPAGLIFLOZIN
U-1977	METHOD FOR TREATING TYPE 2 DIABETES MELLITUS (T2DM) IN PATIENTS WHO ARE ALREADY TREATED WITH DAPAGLIFLOZIN AND SAXAGLIPTIN
U-1978	TREATMENT OF ADVANCED PROSTATE CANCER WITH A REDUCED LIKELIHOOD OF CAUSING A GONADOTROPHIN RELEASING HORMONE AGONIST SIDE-EFFECT
U-1979	THE TREATMENT OF CARCINOID SYNDROME DIARRHEA IN COMBINATION WITH SOMATOSTATIN ANALOG (SSA) THERAPY IN ADULTS INADEQUATELY CONTROLLED BY SSA THERAPY
U-1980	A METHOD OF TREATING NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS
U-1981	IN COMBINATION WITH AN AROMATASE INHIBITOR AS INITIAL ENDOCRINE-BASED THERAPY FOR TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR (HR)-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER-2)-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER
U-1982	USE OF REVLIMID (LENALIDOMIDE) FOR TREATMENT OF PATIENTS WITH TRANSFUSION-DEPENDENT ANEMIA DUE TO LOW-OR INTERMEDIATE-1-RISK MYELODYSPLASTIC SYNDROMES ASSOCIATED WITH A DELETION 5Q ABNORMALITY WITH OR WITHOUT ADDITIONAL CYTOGENETIC ABNORMALITIES
U-1983	USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA WHOSE DISEASE HAS RELAPSED OR PROGRESSED AFTER TWO PRIOR THERAPIES, ONE OF WHICH INCLUDED BORTEZOMIB
U-1984	USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA, IN COMBINATION WITH DEXAMETHASONE
U-1985	USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA, AS MAINTENANCE FOLLOWING AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION (AUTO-HSCT)
U-1986	USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA, IN COMBINATION WITH DEXAMETHASONE, WHEREIN THOSE PATIENTS HAVE NOT RECEIVED PREVIOUS TREATMENT FOR MULTIPLE MYELOMA
U-1987	METHOD OF CONTROLLING GLYCEMIA IN DIABETICS BY ADMINISTERING AN INITIAL DOSE OF INSULIN-FDKP WITH A MEAL; DETERMINING BLOOD GLUCOSE LEVEL 1-2 HRS AFTER AND ADMINISTERING A SUPPLEMENTAL DOSE OF INSULIN-FDKP IF POSTPRANDIAL GLUCOSE LEVEL IS >140 MG/DL
U-1988	METHOD TO TREAT INFANTILE HEMANGIOMA
U-1989	INTRAVITREAL TREATMENT OF MACULAR EDEMA FOLLOWING BRANCH RETINAL VEIN OCCLUSION (BRVO) OR CENTRAL RETINAL VEIN OCCLUSION (CRVO)
U-1990	INTRAVITREAL TREATMENT OF DIABETIC MACULAR EDEMA
U-1991	REDUCTION OF MORTALITY IN ACUTE MYOCARDIAL INFARCTION
U-1992	USE OF TROKENDI XR FOR PROPHYLACTIC TREATMENT OF MIGRAINE
U-1993	ADJUNCTIVE TREATMENT TO LEVODOPA/CARBIDOPA IN PATIENTS WITH PARKINSON'S DISEASE EXPERIENCING "OFF" EPISODES
U-1994	REDUCTION IN RISK OF OVERT HEPATIC ENCEPHALOPATHY (HE) IN ADULTS
U-1995	TREATMENT OF TARDIVE DYSKINESIA
U-1996	IMPROVEMENT OF GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
U-1997	IMPROVEMENT OF GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN AND/OR A PPAR-GAMMA AGONIST AND/OR SULFONYLUREA

PATENT AND EXCLUSIVITY TERMS

ADB 129 of 191

PATENT USE

AND/OR INSULIN

U-1998	TREATING HR-POS., HER2-NEG. ADVANCED OR METASTATIC BREAST CANCER WITH PALBOCICLIB IN COMBO WITH AN AROMATASE INHIBITOR AS INITIAL ENDOCRINE BASED THERAPY IN POSTMENOPAUSAL WOMEN OR FULVESTRANT IN WOMEN WITH DISEASE PROGRESSION AFTER ENDOCRINE THERAPY
U-1999	CHRONIC IDIOPATHIC CONSTIPATION
U-2000	MANAGEMENT OF MODERATE TO SEVERE PAIN AS AN ADJUNCT TO OPIOID ANALGESICS
U-2001	USE FOR THE TREATMENT OF ASTHMA IN PATIENTS 6 YEARS OF AGE AND OLDER
U-2002	USE FOR MAINTENANCE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
U-2003	A METHOD OF POSITIONING AN INTRAUTERINE SYSTEM BY HOLDING AN INSERTER HANDLE WITH ONE HAND, ADVANCING THE INSERTER THROUGH THE CERVIX AND INTO THE UTERUS, AND RETRACTING A SLIDER ON THE HANDLE TO RELEASE THE INTRAUTERINE SYSTEM
U-2004	REPLACEMENT THERAPY FOR ORAL CARBAMAZEPINE IN ADULTS WITH PARTIAL SEIZURES WITH COMPLEX SYMPTOMATOLOGY
U-2005	REPLACEMENT THERAPY FOR ORAL CARBAMAZEPINE IN ADULTS WITH GENERALIZED TONIC-CLONIC SEIZURES
U-2006	REPLACEMENT THERAPY FOR ORAL CARBAMAZEPINE IN ADULTS WITH MIXED SEIZURE PATTERNS THAT INCLUDE PARTIAL SEIZURES WITH COMPLEX SYMPTOMATOLOGY, GENERALIZED TONIC-CLONIC SEIZURES, OR OTHER PARTIAL OR GENERALIZED SEIZURES
U-2007	TREATMENT OF ADULT PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) WHO ARE FLT3 MUTATION-POSITIVE, IN COMBINATION WITH STANDARD CYTARABINE AND DAUNORUBICIN INDUCTION AND CYTARABINE CONSOLIDATION CHEMOTHERAPY
U-2008	TREATMENT OF ADULT PATIENTS WITH AGGRESSIVE SYSTEMIC MASTOCYTOSIS (ASM), SYSTEMIC MASTOCYTOSIS WITH ASSOCIATED HEMATOLOGICAL NEOPLASM (SM-AHN), OR MAST CELL LEUKEMIA (MCL)
U-2009	METHOD OF TREATING POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS AT HIGH RISK FOR FRACTURE.
U-2010	ACUTE TREATMENT OF MIGRAINE BY DELIVERING A POWDERED SUBSTANCE COMPRISING SUMATRIPTAN VIA A BREATH-POWERED DELIVERY DEVICE
U-2011	TREATMENT OF MIGRAINE VIA DELIVERY OF SUMATRIPTAN VIA THE NASAL CAVITY
U-2012	A METHOD FOR TREATING OVARIAN CANCER BY ADMINISTERING RUCAPARIB, WHEREIN THE CANCER IS ASSOCIATED WITH A DELETERIOUS BRCA MUTATION
U-2013	TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
U-2014	A METHOD OF TREATING SECONDARY HYPERPARATHYROIDISM (SHPT)
U-2015	SODIUM THIOSULFATE INJECTION IS INDICATED FOR SEQUENTIAL USE WITH SODIUM NITRITE FOR THE TREATMENT OF ACUTE CYANIDE POISONING
U-2016	TREATMENT FOR ONYCHOMYCOSIS THAT IS TINEA UNGUIUM
U-2017	TREATMENT OF OPIOID DEPENDENCE
U-2018	MANAGEMENT OF MILD TO MODERATE PAIN, MANAGEMENT OF MODERATE TO SEVERE PAIN AS AN ADJUNCT TO OPIOID ANALGESICS IN A CRITICALLY ILL PATIENT WITH INTRAVENOUS IBUPROFEN IN NEED THEREOF
U-2019	METHOD OF DELIVERING TO A PATIENT WITH DIABETES MELLITUS IN A SINGLE INHALATION, GREATER THAN 75% OF A DRY POWDER DOSE COMPRISING INSULIN AND FUMARYL DIKETOPIPERAZINE USING A HIGH RESISTANCE TO FLOW DRY POWDER INHALER.
U-2020	MEKINIST IS INDICATED, IN COMBINATION WITH DABRAFENIB, FOR THE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH BRAF V600E MUTATION AS DETECTED BY AN FDA-APPROVED TEST
U-2021	METHOD OF ADMINISTERING LEVETIRACETAM UNDER FASTED CONDITIONS
U-2022	METHOD OF ADMINISTERING LEVETIRACETAM UNDER FED CONDITIONS
U-2023	A METHOD OF INCREASING THE BIOAVAILABILITY OF GUAIFENESIN IN A SOLUTION CONTAINING 54% TO 66% BY WEIGHT OF PROPYLENE GLYCOL AND GLYCEROL, WHEREIN THE METHOD INCREASES THE CMAX BY AT LEAST 1.5 AND/OR INCREASES THE AUC (0-INF) BY AT LEAST 1.4
U-2024	METHOD FOR TRANSDERMALLY DELIVERING A DRUG TO A USER IN NEED THEREOF
U-2025	TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER

PATENT AND EXCLUSIVITY TERMS

ADB 130 of 191

PATENT USE

U-2026	TAFINLAR(R) IS INDICATED, IN COMBINATION WITH TRAMETINIB, FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E OR V600K MUTATIONS, AS DETECTED BY AN FDA-APPROVED TEST.
U-2027	TAFINLAR(R) IS INDICATED, IN COMBINATION WITH TRAMETINIB, FOR THE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH BRAF V600E MUTATION AS DETECTED BY AN FDA-APPROVED TEST.
U-2028	TREATMENT OF ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS CAUSED BY DESIGNATED SUSCEPTIBLE BACTERIA IN ADULTS
U-2029	PREVENTING CONDITION CHARACTERIZED BY UNDESIRED THROMBOSIS
U-2030	PROPHYLAXIS OF VENOUS THROMBOSIS
U-2031	TAFINLAR IS INDICATED AS A SINGLE AGENT FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E MUTATION AS DETECTED BY AN FDA-APPROVED TEST
U-2032	TAFINLAR IS INDICATED, IN COMBINATION WITH TRAMETINIB, FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E OR V600K MUTATIONS, AS DETECTED BY AN FDA-APPROVED TEST.
U-2033	MEKINIST IS INDICATED, AS A SINGLE AGENT OR IN COMBINATION WITH DABRAFENIB, FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E OR V600K MUTATIONS
U-2034	INHIBITING COAGULATION
U-2035	PROPHYLAXIS OF VENOUS THROMBOEMBOLISM
U-2036	A METHOD OF TREATING PULMONARY HYPERTENSION COMPRISING PARENTERALLY ADMINISTERING A FORMULATION COMPRISING A) 0.1 TO 5% W/V OF TREPROSTINIL OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND B) A CITRATE BUFFER
U-2037	MEKINIST IS INDICATED, AS A SINGLE AGENT OR IN COMBINATION WITH DABRAFENIB, FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E OR V600K MUTATIONS, AS DETECTED BY AN FDA-APPROVED TEST
U-2038	MEKINIST IS INDICATED, IN COMBINATION WITH DABRAFENIB, FOR THE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH BRAF V600E MUTATION AS DETECTED BY AN FDA-APPROVED TEST
U-2039	TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1, 2, 3, 4, 5, OR 6 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING AN NS5A INHIBITOR
U-2040	TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1A OR 3 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING SOFOSBUVIR WITHOUT AN NS5A INHIBITOR
U-2041	TREATMENT OF PARTIAL-ONSET SEIZURES
U-2042	DISCONTINUING ADMINISTRATION OF FLUVOXAMINE TO AVOID DRUG INTERACTIONS WITH PIRFENIDONE AND THEN ADMINISTERING PIRFENIDONE
U-2043	EXTENDED ADJUVANT TREATMENT OF ADULT PATIENTS WITH EARLY STAGE HER2-OVEREXPRESSED/AMPLIFIED BREAST CANCER, TO FOLLOW ADJUVANT TRASTUZUMAB BASE THERAPY
U-2044	DOSE REDUCTION OF PIRFENIDONE BY ABOUT ONE HALF DURING CONCURRENT ADMINISTRATION OF CIPROFLOXACIN AT A DOSE OF 750 MG TWICE DAILY (1500 MG/DAY) TO REDUCE DRUG INTERACTIONS IN TREATMENT OF A FIBROTIC, INFLAMMATORY, OR AUTOIMMUNE DISORDER
U-2045	ADMINISTRATION OF PIRFENIDONE AND AVOIDING CONCURRENT ADMINISTRATION OF CIPROFLOXACIN AT A DOSE OF 750 MG TO REDUCE DRUG INTERACTIONS IN TREATMENT OF A FIBROTIC, INFLAMMATORY, OR AUTOIMMUNE DISORDER
U-2046	ADMINISTERING PIRFENIDONE WHILE AVOIDING CONCOMITANT USE OF A CYP1A2 INHIBITOR THAT IS A MODERATE TO STRONG INHIBITOR OF BOTH CYP1A2 AND ANOTHER CYP ENZYME SELECTED FROM CYP2C9, CYP2C19, AND CYP2D6
U-2047	ADMINISTERING PIRFENIDONE CONCURRENTLY WITH FLUVOXAMINE, THE PIRFENIDONE AT A DOSE OF ABOUT 801 MG/DAY TO REDUCE DRUG INTERACTIONS WITH FLUVOXAMINE
U-2048	ADMINISTERING PIRFENIDONE WHILE AVOIDING CO-ADMINISTRATION OF A STRONG CYP1A2 INHIBITOR TO AVOID DRUG INTERACTIONS WITH PIRFENIDONE
U-2049	DISCONTINUING ADMINISTRATION OF A STRONG CYP1A2 INHIBITOR TO AVOID DRUG INTERACTIONS WITH PIRFENIDONE AND THEN ADMINISTERING PIRFENIDONE
U-2050	ADMINISTERING PIRFENIDONE WHILE AVOIDING CO-ADMINISTRATION OF FLUVOXAMINE TO AVOID DRUG INTERACTIONS WITH PIRFENIDONE

PATENT AND EXCLUSIVITY TERMS

ADB 131 of 191

PATENT USE

U-2051	DISCONTINUING SMOKING TO AVOID REDUCED PIRFENIDONE EFFICACY AND THEN ADMINISTERING PIRFENIDONE
U-2052	DISCONTINUING ADMINISTRATION OF A STRONG CYP1A2 INDUCER TO AVOID REDUCED PIRFENIDONE EFFICACY AND THEN ADMINISTERING PIRFENIDONE
U-2053	ADMINISTERING PIRFENIDONE WHILE AVOIDING CONCOMITANT ADMINISTRATION OF A STRONG INDUCER OF CYP1A2, INCLUDING CIGARETTE SMOKE, TO AVOID REDUCED PIRFENIDONE EFFICACY
U-2054	ADMINISTERING PIRFENIDONE WHILE AVOIDING CONCOMITANT ADMINISTRATION OF A STRONG INDUCER OF CYP1A2 TO AVOID REDUCED PIRFENIDONE EFFICACY
U-2055	DOSING OF AT LEAST 1600 MG/DAY FOLLOWING GRADE 2 LIVER ABNORMALITY IN BIOMARKER AST AND/OR ALT AFTER PIRFENIDONE ADMINISTRATION IN TREATMENT OF IPF
U-2056	DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN BIOMARKER AST AND/OR ALT AFTER PIRFENIDONE ADMINISTRATION, BY ADMINISTERING SUB-1600 MG/DAY, FOLLOWING BY ADMINISTERING AT LEAST 1600 MG/DAY IN TREATMENT OF IPF
U-2057	DOSING 2403 MG/DAY PIRFENIDONE FOLLOWING GRADE 2 ABNORMALITY IN BIOMARKER AST AND/OR ALT AFTER PIRFENIDONE ADMINISTRATION IN TREATMENT OF IPF
U-2058	DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN BIOMARKER AST AND/OR ALT AFTER PIRFENIDONE ADMINISTRATION, BY ADMINISTERING SUB-2400MG/DAY DOSE, FOLLOWED BY ADMINISTERING 2403MG/DAY IN TREATMENT OF IPF
U-2059	DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN BIOMARKER AST AND/OR ALT AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE UNTIL BIOMARKERS OF LIVER FUNCTION ARE WITHIN NORMAL LIMITS, FOLLOWED BY FULL DAILY DOSE IN TREATMENT OF IPF
U-2060	DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN BIOMARKER AST AND/OR ALT AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE UNTIL BIOMARKERS OF LIVER FUNCTION ARE WITHIN NORMAL LIMITS, THEN AT LEAST 1600MG/DAY IN TREATMENT OF IPF
U-2061	DOSING OF AT LEAST 1600 MG/DAY FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION IN TREATMENT OF IPF
U-2062	DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION, BY ADMINISTERING SUB-1600 MG/DAY DOSE, FOLLOWED BY ADMINISTERING AT LEAST 1600 MG/DAY DOSE IN TREATMENT OF IPF
U-2063	DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE UNTIL BIOMARKERS ARE WITHIN NORMAL LIMITS, FOLLOWED BY ADMINISTERING AT LEAST 1600 MG/DAY IN TREATMENT OF IPF
U-2064	DOSING AT LEAST 1602 MG/DAY FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER ALT OR AST AFTER PIRFENIDONE ADMINISTRATION
U-2065	FULL DAILY DOSING FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER ALT OR AST AFTER PIRFENIDONE ADMINISTRATION
U-2066	DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER ALT OR AST AFTER PIRFENIDONE ADMINISTRATION, BY ADMINISTERING SUB-2400 MG/DAY DOSE, FOLLOWED BY FULL DAILY DOSE
U-2067	DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER ALT OR AST AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE, FOLLOWED BY ADMINISTERING AT LEAST 1602 MG/DAY
U-2068	DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER ALT OR AST AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE UNTIL BIOMARKERS OF LIVER FUNCTION ARE WITHIN NORMAL LIMITS, FOLLOWED BY FULL DAILY DOSE
U-2069	DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER ALT OR AST AFTER PIRFENIDONE ADMINISTRATION, BY ADMINISTERING A SUB-1600 MG/DAY DOSE, FOLLOWED BY ADMINISTERING AT LEAST 1602 MG/DAY
U-2070	DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN BIOMARKER ALT OR AST AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE UNTIL BIOMARKERS OF LIVER FUNCTION ARE WITHIN NORMAL LIMITS, THEN SUB-1600 MG/DAY, THEN AT LEAST 1602 MG/DAY
U-2071	FULL DAILY DOSING FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION IN TREATMENT OF IPF
U-2072	FULL DAILY DOSING FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER

PATENT AND EXCLUSIVITY TERMS

ADB 132 of 191

PATENT USE

AFTER PIRFENIDONE ADMINISTRATION IN TREATMENT OF IPF

- U-2073 DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE UNTIL BIOMARKERS ARE WITHIN NORMAL LIMITS, FOLLOWED BY ADMINISTERING FULL DAILY DOSE IN TREATMENT OF IPF
- U-2074 DOSING 1602 MG/DAY PIRFENIDONE FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION IN TREATMENT OF IPF
- U-2075 DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE UNTIL BIOMARKERS ARE WITHIN NORMAL LIMITS FOLLOWED BY ADMINISTERING 1602 MG/DAY IN TREATMENT OF IPF
- U-2076 DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION, BY ADMINISTERING 801 MG/DAY FOLLOWED BY ADMINISTERING 1602 MG/DAY IN TREATMENT OF IPF
- U-2077 DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION, BY ADMINISTERING SUB-2400 MG/DAY DOSE THEN FULL DAY DAILY DOSE IN TREATMENT OF IPF
- U-2078 DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE UNTIL BIOMARKERS ARE WITHIN LIMITS, THEN SUB-2400MG/DAY DOSE, THEN FULL DAILY DOSE IN TREATMENT OF IPF
- U-2079 PIRFENIDONE DOSE ESCALATION REGIMEN FOR TREATMENT OF FIBROSIS AS 801 MG/DAY FOR DAYS 1-7 OF THE REGIMEN, 1602 MG/DAY FOR DAYS 8-14 OF THE REGIMEN, AND 2403 MG/DAY FOR AT LEAST DAY 15 OF THE REGIMEN
- U-2080 PIRFENIDONE DOSE ESCALATION REGIMEN FOR TREATMENT OF IPF AS 801 MG/DAY FOR DAYS 1-7 OF THE REGIMEN, 1602 MG/DAY FOR DAYS 8-14 OF THE REGIMEN, AND 2403 MG/DAY FOR AT LEAST DAY 15 OF THE REGIMEN
- U-2081 DISCONTINUING USE OF A CYP1A2 INHIBITOR THAT IS A MODERATE TO STRONG INHIBITOR OF BOTH CYP1A2 AND ANOTHER CYP ENZYME SELECTED FROM CYP2C9, CYP2C19, AND CYP2D6 AND THEN ADMINISTERING PIRFENIDONE
- U-2082 MODIFYING PIRFENIDONE ADMINISTRATION FROM A DOSE OF ABOUT 2400 MG/DAY DOWNWARD BY ABOUT 1600 MG/DAY WHILE CO-ADMINISTERING FLUVOXAMINE TO REDUCE DRUG INTERACTIONS WITH FLUVOXAMINE
- U-2083 DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE UNTIL BIOMARKERS ARE WITHIN NORMAL LIMITS, FOLLOWED BY 801 MG/DAY, DOSE, THEN 1602 MG/DAY IN TREATMENT OF IPF
- U-2084 TREATMENT OF SEVERE CHRONIC PAIN VIA INTRATHECAL INFUSION OF ZICONOTIDE IN PATIENTS ALSO RECEIVING MORPHINE
- U-2085 TREATMENT OF NON-24-HOUR SLEEP-WAKE DISORDER BY AVOIDING THE USE OF TASIMELTEON IN COMBINATION WITH RIFAMPIN
- U-2086 A METHOD FOR ADMINISTERING ESTRADIOL COMPRISING A MONOLITHIC TRANSDERMAL DRUG DELIVERY SYSTEM CONSISTING OF (I) A BACKING LAYER AND (II) A SINGLE ADHESIVE POLYMER MATRIX LAYER AS CLAIMED IN US PATENT NO. 9730900
- U-2087 TREATMENT OF RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (AML) WITH AN ISOCITRATE DEHYDROGENASE-2 (IDH2) MUTATION
- U-2088 TREATMENT OF PARTIAL-ONSET SEIZURES WITH OR WITHOUT SECONDARILY GENERALIZED SEIZURES IN PATIENTS WITH EPILEPSY
- U-2089 TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES AS ADJUNCTIVE THERAPY IN PATIENTS WITH EPILEPSY
- U-2090 FOR THE TREATMENT OF ADULTS WITH NEWLY-DIAGNOSED THERAPY-RELATED ACUTE MYELOID LEUKEMIA (T-AML) OR AML WITH MYELODYSPLASIA-RELATED CHANGES (AML-MRC)
- U-2091 TREATMENT OF METASTATIC ADENOCARCINOMA OF THE PANCREAS THAT HAS PROGRESSED ON GEMCITABINE-BASED THERAPY, IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN, IN A PATIENT NOT HOMOZYGOUS FOR THE UGT1A1*28 ALLELE
- U-2092 METHOD FOR CONFIRMING DOSE DELIVERY
- U-2093 TREATMENT OF TYPE II SPINAL MUSCULAR ATROPHY
- U-2094 TREATMENT OF TYPE III SPINAL MUSCULAR ATROPHY
- U-2095 MITOSOL IS AN ANTIMETABOLITE INDICATED AS AN ADJUNCT TO AB EXTERNO GLAUCOMA

PATENT AND EXCLUSIVITY TERMS

ADB 133 of 191

PATENT USE

SURGERY. IT IS INTENDED FOR TOPICAL APPLICATION TO THE SITE OF GLAUCOMA FILTRATION SURGERY

- U-2096 SOTYLIZE IS INDICATED FOR THE MAINTENANCE OF NORMAL SINUS RHYTHM [DELAY IN TIME TO RECURRENCE OF ATRIAL FIBRILLATION/ATRIAL FLUTTER (AFIB/AFL)] IN PATIENTS WITH SYMPTOMATIC AFIB/AFL WHO ARE CURRENTLY IN SINUS RHYTHM
- U-2097 TREATMENT OF DMD IN PATIENTS HAVING A MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 51 SKIPPING
- U-2098 INCREASING PRODUCTION OF FUNCTIONAL DYSTROPHIN PROTEIN IN DMD PATIENTS HAVING A MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 51 SKIPPING
- U-2099 INDICATED FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING BRONCHITIS AND/OR EMPHYSEMA
- U-2100 INDICATED FOR THE ONCE-DAILY TREATMENT OF ASTHMA IN PATIENTS 18 YEARS AND OLDER
- U-2101 MAINTENANCE TREATMENT OF RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER, WHO ARE IN A COMPLETE OR PARTIAL RESPONSE TO PLATINUM-BASED CHEMOTHERAPY
- U-2102 TREATMENT OF DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINE BRCA-MUTATED ADVANCED OVARIAN CANCER WHO HAVE BEEN TREATED WITH THREE OR MORE PRIOR LINES OF CHEMOTHERAPY BASED ON AN FDA-APPROVED COMPANION DIAGNOSTIC FOR LYNPARZA
- U-2103 MAINTENANCE TREATMENT OF BRCA-MUTATED RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER, WHO ARE IN A COMPLETE OR PARTIAL RESPONSE TO PLATINUM-BASED CHEMOTHERAPY
- U-2104 TREATMENT OF HYPERURICEMIA ASSOCIATED WITH GOUT IN PATIENTS WHO HAVE NOT ACHIEVED TARGET SERUM URIC ACID LEVELS WITH A MEDICALLY APPROPRIATE DAILY DOSE OF ALLOPURINOL ALONE
- U-2105 TREATMENT OF DYSKINESIA IN PATIENTS WITH PARKINSON'S DISEASE RECEIVING IMMEDIATE RELEASE LEVODOPA-BASED THERAPY, WITH OR WITHOUT CONCOMITANT DOPAMINERGIC MEDICATIONS
- U-2106 TREATMENT OF DYSKINESIA IN PATIENTS WITH PARKINSON'S DISEASE RECEIVING LEVODOPA-BASED THERAPY, WITH OR WITHOUT CONCOMITANT DOPAMINERGIC MEDICATIONS
- U-2107 TREATMENT OF LOCALLY RECURRENT OR METASTATIC, PROGRESSIVE, DIFFERENTIATED THYROID CARCINOMA REFRACTORY TO RADIOACTIVE IODINE TREATMENT
- U-2108 TREATMENT OF HORMONE RECEPTOR POSITIVE HER2-NEGATIVE ADVANCED BREAST CANCER IN POSTMENOPAUSAL WOMEN NOT PREVIOUSLY TREATED WITH ENDOCRINE THERAPY
- U-2109 CAROSPIR IS INDICATED FOR TREATMENT OF NYHA CLASS III-IV HEART FAILURE AND REDUCED EJECTION FRACTION TO INCREASE SURVIVAL, MANAGE EDEMA, AND TO REDUCE THE NEED FOR HOSPITALIZATION FOR HEART FAILURE
- U-2110 METHOD FOR CHRONIC WEIGHT MANAGEMENT IN PATIENTS WITH MODERATE RENAL IMPAIRMENT WHO ARE OBESE, OR OVERWEIGHT AND HAVE AT LEAST ONE WEIGHT RELATED COMORBID CONDITION
- U-2111 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 1-5 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIMS 1-5
- U-2112 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 6 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 6
- U-2113 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 7 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 7
- U-2114 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 9 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 9
- U-2115 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 10 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 10

PATENT AND EXCLUSIVITY TERMS

ADB 134 of 191

PATENT USE

U-2116	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 12 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 12
U-2117	ADJUNCT TO DIET AND EXERCISE TO TREAT GLUCOSE INTOLERANCE IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 14-15 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIMS 14-15
U-2118	ADJUNCT TO DIET AND EXERCISE TO TREAT GLUCOSE INTOLERANCE IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 16-18 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIMS 16-18
U-2119	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 19 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 19
U-2120	TREATMENT OF PATIENTS 18 YEARS OF AGE AND OLDER WITH COMPLICATED URINARY TRACT INFECTIONS CAUSED BY SUSCEPTIBLE MICROORGANISMS
U-2121	TREATMENT OF PARTIAL-ONSET SEIZURES IN A PATIENT SUFFERING FROM OR SUSCEPTIBLE TO ABSENCE SEIZURES
U-2122	USE FOR REDUCING EXACERBATIONS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
U-2123	TREATMENT OF PARTIAL-ONSET SEIZURES IN PATIENTS WITH EPILEPSY WHO HAVE BEEN PREVIOUSLY TREATED WITH OXCARBAZEPINE
U-2124	TREATMENT OF ADULT PATIENTS WITH RELAPSED FOLLICULAR LYMPHOMA WHO HAVE RECEIVED AT LEAST TWO PRIOR SYSTEMIC THERAPIES
U-2125	THE TREATMENT OF AN INFLAMMATORY DISORDER OF THE RESPIRATORY TRACT BY ONCE-PER-DAY ADMINISTRATION OF A PHARMACEUTICAL FORMULATION COMPRISING FLUTICASONE FUROATE AND A LONG-ACTING BETA2 ADRENORECEPTOR AGONIST
U-2126	USE OF FLUTICASONE FUROATE FOR THE TREATMENT OF AN INFLAMMATORY OR ALLERGIC CONDITIONS, INCLUDING CHRONIC OBSTRUCTIVE PULMONARY DISEASE
U-2127	INDICATED FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA
U-2128	METHOD OF INHIBITING THE BINDING OF ACETYLCHOLINE TO AN ACETYLCHOLINE RECEPTOR IN THE RESPIRATORY TRACT OF A HUMAN, COMPRISING CONTACTING THE RECEPTOR WITH AN EFFECTIVE AMOUNT OF UMECLIDINIUM, VIA INHALATION
U-2129	METHOD OF INHIBITING THE BINDING OF ACETYLCHOLINE TO AN ACETYLCHOLINE RECEPTOR IN THE RESPIRATORY TRACT OF A HUMAN, COMPRISING CONTACTING THE RECEPTOR WITH AN EFFECTIVE AMOUNT OF UMECLIDINIUM, VIA TOPICAL APPLICATION
U-2130	TREATMENT OF PARTIAL ONSET SEIZURES IN PATIENTS WITH EPILEPSY AGED 16 YEARS AND OLDER WITH EPILEPSY
U-2131	REDUCTION OF ELEVATED INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION, WITH COMPARABLE EFFICACY, AND A REDUCTION IN SPECIFIED ADVERSE EVENTS, COMPARED TO BRIMONIDINE 0.2% TID
U-2132	IN COMBINATION WITH FULVESTRANT FOR THE TREATMENT OF WOMEN WITH HORMONE RECEPTOR (HR)-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER WITH DISEASE PROGRESSION FOLLOWING ENDOCRINE THERAPY
U-2133	METHOD OF DELIVERING FLUTICASONE PROPIONATE TO A NASAL AIRWAY
U-2134	THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY ONCE-PER-DAY ADMINISTRATION OF A PHARMACEUTICAL FORMULATION COMPRISING FLUTICASONE FUROATE AND A LONG-ACTING BETA2 ADRENORECEPTOR
U-2135	AS MONOTHERAPY FOR THE TREATMENT OF ADULT PATIENTS WITH HR-POSITIVE, HER2-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER WITH DISEASE PROGRESSION FOLLOWING ENDOCRINE THERAPY AND PRIOR CHEMOTHERAPY IN THE METASTATIC SETTING
U-2136	TREATMENT OF NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY
U-2137	TREATMENT OF POSTHERPETIC NEURALGIA
U-2138	TOPICAL TREATMENT OF ACTINIC KERATOSIS OF THE FACE OR SCALP USING MORE THAN ONE TREATMENT COURSE OF INGENOL MEBUTATE
U-2139	TREATMENT OF TYPE 2 DIABETES MELLITUS IN COMBINATION WITH EXENATIDE

PATENT AND EXCLUSIVITY TERMS

ADB 135 of 191

PATENT USE

U-2140	METHOD OF TREATING PARTIAL ONSET SEIZURES IN PATIENTS 4 YEARS OF AGE AND OLDER
U-2141	TREATMENT OF CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1, 2, 3, 4, 5, OR 6
U-2142	REDUCTION IN THE RISK OF RECURRENCE OF DEEP VEIN THROMBOSIS (DVT) AND/OR PULMONARY EMBOLISM (PE) IN PATIENTS AT CONTINUED RISK FOR RECURRENT DVT AND/OR AFTER COMPLETION OF INITIAL TREATMENT LASTING AT LEAST 6 MONTHS
U-2143	AFTER COMPLETION OF INITIAL TREATMENT LASTING AT LEAST 6 MONTHS, TO REDUCE THE RISK OF RECURRENCE OF DEEP VEIN THROMBOSIS AND/OR PULMONARY EMBOLISM IN CERTAIN PATIENTS WITH ONCE DAILY, RAPID-RELEASE TABLET ADMINISTERED FOR AT LEAST 5 CONSECUTIVE DAYS
U-2144	REDUCTION OF INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION
U-2145	TREATMENT OF ADULT PATIENTS WITH MANTLE CELL LYMPHOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
U-2146	IMPROVEMENT IN GLYCEMIC CONTROL IN DIABETES MELLITUS PATIENTS BY USE OF A PEN INJECTOR WITH A ROTATING DRIVE SLEEVE
U-2147	TREATMENT OF NON-24 HOUR SLEEP-WAKE DISORDER BY ORALLY ADMINISTERING 20MG OF TASIMELTEON ONCE DAILY BEFORE BEDTIME
U-2148	A METHOD OF PROVIDING NITRIC OXIDE THERAPY TO A PATIENT BY MEASURING AND DISPLAYING AN INDICATION OF THE CALCULATED DELIVERY CONCENTRATION OF NITRIC OXIDE AS COMPARED TO THE DESIRED DELIVERY CONCENTRATION OF NITRIC OXIDE
U-2149	TREATMENT OF NON-24 HOUR SLEEP-WAKE DISORDER BY ADMINISTERING TASIMELTEON
U-2150	TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE
U-2151	METHOD OF TREATING PAIN OR INFLAMMATION WITH AN INJECTABLE CONTROLLED OR SUSTAINED RELEASE FORMULATION OF TRIAMCINOLONE ACETONIDE
U-2152	TREATMENT OF PAIN ASSOCIATED WITH IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) WITH VIBERZI (ELUXADOLINE)
U-2153	REDUCING FASTING PLASMA GLUCOSE IN A HUMAN IN NEED THEREOF USING A SUSTAINED-RELEASE COMPOSITION CONTAINING EXENDIN-4
U-2154	REDUCING FASTING PLASMA GLUCOSE IN A HUMAN IN NEED THEREOF USING A SUSTAINED-RELEASE COMPOSITION CONTAINING EXENDIN-4
U-2155	REDUCING BODY WEIGHT IN A HUMAN IN NEED THEREOF USING A SUSTAINED-RELEASE COMPOSITION CONTAINING EXENDIN-4
U-2156	REDUCING HBA1C IN A HUMAN IN NEED THEREOF USING A SUSTAINED-RELEASE COMPOSITION CONTAINING EXENDIN-4
U-2157	TREATING TYPE 2 DIABETES MELLITUS BY STIMULATING INSULIN RELEASE
U-2158	DECREASING GASTRIC MOTILITY OR DELAYING GASTRIC EMPTYING BY USING A SUSTAINED-RELEASE COMPOSITION
U-2159	TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA
U-2160	MANAGEMENT OF OSTEOARTHRITIS PAIN BY ADMINISTERING 5 MG OF MELOXICAM
U-2161	TREATMENT OF NAUSEA AND VOMITING, INCLUDING THE PREVENTION OF ACUTE AND DELAYED NAUSEA AND VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF HIGHLY OR MODERATELY EMETOGENIC CANCER CHEMOTHERAPY
U-2162	FOR CLEANSING THE LARGE INTESTINE AS A PREPARATION FOR COLONOSCOPY
U-2163	TREATMENT OF HR-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER-2)-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER IN COMBINATION WITH PALBOCICLIB OR ABEMACICLIB IN WOMEN WITH DISEASE PROGRESSION AFTER ENDOCRINE THERAPY
U-2164	ZELBORAF IS INDICATED FOR THE TREATMENT OF PATIENTS WITH ERDHEIM-CHESTER DISEASE WITH BRAF V600 MUTATION
U-2165	MANAGEMENT OF OSTEOARTHRITIS PAIN BY ADMINISTERING 10 MG OF MELOXICAM
U-2166	TREATMENT OF MAJOR DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
U-2167	METHOD OF USING A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
U-2168	METHOD OF USING A LOGIC CIRCUIT TO STABILIZE BATTERY VOLTAGE SUPPLIED TO A SENSOR EMBEDDED WITH A TABLET AND THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
U-2169	METHOD OF USING A RECEIVER TO IDENTIFY A SIGNAL FROM A TABLET EMBEDDED WITH A

PATENT AND EXCLUSIVITY TERMS

ADB 136 of 191

PATENT USE

	SENSOR THAT COMMUNICATES INFORMATION THROUGH THE BODY OF A PATIENT
U-2170	METHOD OF USING A RECEIVER TO RECEIVE A SIGNAL FROM A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION THROUGH THE BODY OF A PATIENT
U-2171	ADJUVANT TREATMENT OF ADULT PATIENTS AT HIGH RISK OF RECURRENT RCC FOLLOWING NEPHRECTOMY
U-2172	METHOD TO TREAT SEVERE ALLERGIC EMERGENCIES IN PATIENTS WEIGHING 7.5 TO 15 KG (16.5 TO 33 LBS)
U-2173	TREATING OPIOID DEPENDENCE BY ADMINISTERING BUPRENORPHINE
U-2174	TREATING OPIOID DEPENDENCY BY ADMINISTERING BUPRENORPHINE ONCE PER MONTH
U-2175	TREATING OPIOID DEPENDENCY BY ADMINISTERING BUPRENORPHINE ONCE MONTHLY
U-2176	TREATING OPIOID ADDICTION BY ADMINISTERING BUPRENORPHINE
U-2177	TREATING OPIOID ADDICTION BY SUBCUTANEOUS INJECTION OF BUPRENORPHINE
U-2178	TREATING OPIOID ADDICTION BY ADMINISTERING BUPRENORPHINE COMPOSITION WITH 28 DAY DOSE DURATION
U-2179	IN SITU FORMATION OF SOLID BUPRENORPHINE COMPOSITION
U-2180	TREATING ADDICTION WITH 100 MG OR 300 MG DOSE OF BUPRENORPHINE
U-2181	TREATING OPIOID DEPENDENCY BY SUBCUTANEOUSLY ADMINISTERING BUPRENORPHINE
U-2182	IMPROVEMENT OF GLYCEMIC CONTROL IN TYPE 2 DIABETES MELLITUS PATIENTS
U-2183	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 1 AND 13
U-2184	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 1, 13, AND 14
U-2185	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 15 AND 27
U-2186	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 15, 27, AND 28
U-2187	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 29 AND 39
U-2188	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 29, 39, AND 40
U-2189	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 41 AND 52
U-2190	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 41, 52, AND 53
U-2191	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 54 AND 64
U-2192	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 54, 64, AND 65
U-2193	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 66 AND 75
U-2194	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 66, 75, AND 76
U-2195	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 77 AND 87

PATENT AND EXCLUSIVITY TERMS

ADB 137 of 191

PATENT USE

U-2196 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 77, 87, AND 88

U-2197 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 89 AND 99

U-2198 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 89, 99, AND 100

U-2199 TREATMENT OF SCHIZOPHRENIA WITH IMPROVEMENT IN ATTENTION FUNCTION IN SCHIZOPHRENIA

U-2200 COMBINATION TREATMENT WITH INSULIN GLARGINE WITH OR WITHOUT METFORMIN FOR IMPROVEMENT OF GLYCEMIC CONTROL IN TYPE 2 DIABETES MELLITUS PATIENTS

U-2201 TREATMENT OF BIPOLAR DEPRESSION WITH IMPROVEMENT IN ATTENTION FUNCTION IN BIPOLAR DISORDER

U-2202 OZEMPIC IS INDICATED AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS

U-2203 A METHOD OF PROVIDING A SUBJECT WITH A THERAPEUTICALLY EFFECTIVE AMOUNT OF RACEMIC METHYLPHENIDATE BY ORALLY ADMINISTERING TO SAID SUBJECT A SINGLE METHYLPHENIDATE EXTENDED RELEASE CHEWABLE TABLET AS CLAIMED

U-2204 TREATING PATIENTS WITH ACUTE PROMYELOCYTIC LEUKEMIA (APL) WHO ARE REFRACTORY TO, OR HAVE RELAPSED FROM, RETINOID AND ANTHRACYCLINE CHEMOTHERAPY, AND WHOSE APL IS CHARACTERIZED BY THE PRESENCE OF THE T(15;17) TRANSLOCATION OR PML/RAR-ALPHA GENE EXPRESSION

U-2205 TREATMENT OF SEBORRHEIC KERATOSES THAT ARE RAISED

U-2206 TREATING OPIOID DEPENDENCY BY ADMINISTERING BUPRENORPHINE

U-2207 TREATING ADDICTION BY SUBCUTANEOUS INJECTION OF BUPRENORPHINE

U-2208 TREATING ADDICTION BY ONCE PER MONTH ADMINISTRATION OF BUPRENORPHINE

U-2209 TREATING OPIOID ADDICTION BY ADMINISTERING BUPRENORPHINE ONCE PER MONTH

U-2210 TREATING OPIOID ADDICTION BY 100 MG OR 300 MG DOSE BUPRENORPHINE

U-2211 TREATING OPIOID ADDICTION BY ADMINISTRATION OF BUPRENORPHINE

U-2212 REDUCING FASTING PLASMA GLUCOSE IN A HUMAN IN NEED THEREOF IN COMBINATION WITH A SUSTAINED-RELEASE COMPOSITION CONTAINING EXENDIN-4

U-2213 REDUCING HBA1C IN A HUMAN IN NEED THEREOF IN COMBINATION WITH A SUSTAINED-RELEASE COMPOSITION CONTAINING EXENDIN-4

U-2214 AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES

U-2215 ERTUGLIFLOZIN IN COMBINATION WITH SITAGLIPTIN AND IN FURTHER COMBINATION WITH METFORMIN AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS

U-2216 ERTUGLIFLOZIN AND SITAGLIPTIN IN COMBINATION AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS

U-2217 TREATING HIGH OUTPUT SHOCK WITH ANGIOTENSIN II BY INCREASING MEAN ARTERIAL PRESSURE IN PATIENTS TREATED WITH CATECHOLAMINES AND REDUCING CATECHOLAMINE USE

U-2218 MAINTAINING MEAN ARTERIAL PRESSURE OF ABOUT 65 MMHG OR HIGHER WITH ANGIOTENSIN II IN SHOCK PATIENTS TREATED WITH CATECHOLAMINES AND REDUCING CATECHOLAMINE USE

U-2219 TREATMENT OF CHRONIC SMALL LYMPHOCYTIC LEUKEMIA

U-2220 A METHOD FOR THE DIAGNOSIS OF ADULT GROWTH HORMONE DEFICIENCY BY MEASURING THE LEVEL OF GROWTH HORMONE AFTER ORAL ADMINISTRATION OF MACIMORELIN

U-2221 TREATING REFRACTORY HYPOTENSION WITH ABOUT 20 NG/KG/MIN ANGIOTENSIN II IN A PATIENT RECEIVING VASOPRESSOR

U-2222 RELIEVES REDNESS OF THE EYE DUE TO MINOR EYE IRRITATIONS

U-2223 METHOD OF TREATING ANGINA PECTORIS

U-2224 TREATMENT OF DYSKINESIA AND INCREASING ON TIME WITHOUT TROUBLESOME DYSKINESIA IN PATIENTS WITH PARKINSON'S DISEASE RECEIVING LEVODOPA-BASED THERAPY, WITH OR WITHOUT CONCOMITANT DOPAMINERGIC MEDICATIONS

PATENT AND EXCLUSIVITY TERMS

ADB 138 of 191

PATENT USE

U-2225	METHOD OF ADMINISTERING A LOCAL ANESTHETIC TO THE MUCOUS MEMBRANES IN PATIENTS WITH HEPATIC IMPAIRMENT
U-2226	METHOD OF ADMINISTERING A LOCAL ANESTHETIC TO THE MUCOUS MEMBRANES IN PATIENTS WITH RENAL IMPAIRMENT
U-2227	METHOD OF ADMINISTERING A LOCAL ANESTHETIC TO THE MUCOUS MEMBRANES IN GERIATRIC PATIENTS
U-2228	TREATMENT OF SMALL LYMPHOCYTIC LEUKEMIA
U-2229	IN COMBINATION WITH TRETINOIN, TREATING ADULTS AND PEDIATRIC PATIENTS 1 YEAR AND OLDER WITH NEWLY-DIAGNOSED LOW-RISK ACUTE PROMYELOCYTIC LEUKEMIA (APL) CHARACTERIZED BY THE PRESENCE OF THE T(15;17) TRANSLOCATION OR PML/RAR-A GENE EXPRESSION
U-2230	IRRITABLE BOWEL SYNDROME WITH CONSTIPATION
U-2231	TREATING REFRACTORY HYPOTENSION WITH ABOUT 5 NG/KG/MIN TO ABOUT 20 NG/KG/MIN ANGIOTENSIN II IN A PATIENT RECEIVING VASOPRESSOR
U-2232	TREATMENT OF PSORIATIC ARTHRITIS USING A DOSAGE TITRATION SCHEDULE
U-2233	TREATMENT OF PSORIATIC ARTHRITIS WITH APREMILAST USING A DOSAGE TITRATION SCHEDULE AND A SECOND ACTIVE AGENT
U-2234	USE OF IVACAFTOR FOR TREATING CYSTIC FIBROSIS IN A PATIENT WITH A MILD TO MODERATE CF PHENOTYPE WITH AT LEAST ONE MUTATION IN THE CFTR GENE THAT IS RESPONSIVE TO IVACAFTOR BASED ON CLINICAL AND/OR IN VITRO ASSAY DATA
U-2235	USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH METASTATIC HIGH-RISK CASTRATION-SENSITIVE PROSTATE CANCER
U-2236	REDUCING THE RISK OF PRETERM BIRTH IN WOMEN WITH A SINGLETON PREGNANCY WHO HAVE A HISTORY OF SINGLETON SPONTANEOUS PRETERM BIRTH
U-2237	TREATMENT OF NON-METASTATIC, CASTRATION-RESISTANT PROSTATE CANCER (NM-CRPC)
U-2238	METHOD OF IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH DIABETES MELLITUS BY ADMINISTERING A MIXTURE OF INSULIN DEGLUDEC AND INSULIN ASPART DURING OR AROUND THE TIME OF THE LARGEST MEAL OF THE DAY
U-2239	REDUCTION OF ELEVATED INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION, WITH A REDUCTION IN SPECIFIED ADVERSE EVENTS, COMPARED TO BRIMONIDINE 0.2% TID
U-2240	REDUCTION OF ELEVATED INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION, WITH COMPARABLE EFFICACY TO BRIMONIDINE 0.2% TID
U-2241	TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA WITH 17P DELETION
U-2242	TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA WITH 17P DELETION
U-2243	TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA WITH 17P DELETION
U-2244	A METHOD OF TREATING BACTERIAL INFECTIONS IN HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA AND VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA (HABP/VABP) PATIENTS COMPRISING ADMINISTERING A BACTERICIDALLY EFFECTIVE AMOUNT OF AVIBACTAM SODIUM
U-2245	A METHOD OF TREATING A BACTERIAL INFECTION IN HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA AND VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA (HABP/VABP) PATIENTS COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF AVIBACTAM SODIUM
U-2246	TEZACAFTOR AND IVACAFTOR FOR THE TREATMENT OF CYSTIC FIBROSIS IN PATIENTS WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION OR HAVING AT LEAST ONE CFTR GENE MUTATION THAT IS RESPONSIVE TO TEZACAFTOR/IVACAFTOR BASED ON IN VITRO DATA AND/OR CLINICAL EVIDENCE
U-2247	TEZACAFTOR AND IVACAFTOR FOR THE TREATMENT OF PATIENTS WITH A MILD TO MODERATE CLINICAL PHENOTYPE OF CYSTIC FIBROSIS HAVING AT LEAST ONE CFTR GENE MUTATION THAT IS RESPONSIVE TO TEZACAFTOR/IVACAFTOR BASED ON IN VITRO DATA AND/OR CLINICAL EVIDENCE
U-2248	TEZACAFTOR AND IVACAFTOR FOR THE TREATMENT OF CYSTIC FIBROSIS IN PATIENTS WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION OR HETEROZYGOUS FOR THE F508DEL MUTATION AND A SECOND MUTATION THAT IS RESPONSIVE TO TEZACAFTOR/IVACAFTOR
U-2249	MANAGEMENT OF ACUTE PAIN SEVERE ENOUGH TO REQUIRE AN OPIOID ANALGESIC AND FOR WHICH ALTERNATIVE TREATMENTS ARE INADEQUATE
U-2250	DETECTION OF CARCINOMA IN THE BLADDER BY PHOTODYNAMIC CYSTOSCOPY

PATENT AND EXCLUSIVITY TERMS

ADB 139 of 191

PATENT USE

U-2251	IN COMBINATION WITH AN AROMATASE INHIBITOR AS INITIAL ENDOCRINE-BASED THERAPY FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR (HR)-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER
U-2252	THE TREATMENT OF ACUTE OTITIS EXTERNA IN PATIENTS 6 MONTHS OF AGE AND OLDER DUE TO PSEUDOMONAS AERUGINOSA AND STAPHYLOCOCCUS AUREUS
U-2253	PROPHYLACTIC TREATMENT OF NAUSEA AND VOMITING, INCLUDING PREVENTION OF ACUTE AND DELAYED NAUSEA AND VOMITING ASSOCIATED CHEMOTHERAPY
U-2254	USE OF POMALIDOMIDE WITH DEXAMETHASONE FOR PATIENTS WITH MULTIPLE MYELOMA AFTER AT LEAST TWO PRIOR THERAPIES INCLUDING LENALIDOMIDE AND A PROTEASOME INHIBITOR AND DEMONSTRATED DISEASE PROGRESSION ON OR WITHIN 60 DAYS OF COMPLETING THE LAST THERAPY
U-2255	TREATING SECONDARY HYPERPARATHYROIDISM IN CHRONIC KIDNEY DISEASE WITH SUSTAINED RELEASE 25-HYDROXYVITAMIN D TO REDUCE THE PATIENT'S SERUM PARATHYROID HORMONE LEVEL AND THE SUSTAINED RELEASE IS OVER AT LEAST 10 HOURS
U-2256	TREATING SECONDARY HYPERPARATHYROIDISM IN CHRONIC KIDNEY DISEASE WITH SUSTAINED RELEASE 25-HYDROXYVITAMIN D TO REDUCE THE PATIENT'S SERUM PARATHYROID HORMONE LEVEL AND CMAX IS REDUCED COMPARED TO BOLUS IV INJECTION AND IMMEDIATE-RELEASE, ORAL DOSING
U-2257	TREATING SHPT IN CKD WITH SUSTAINED RELEASE CALCIFEDIOL TO REDUCE SERUM PARATHYROID HORMONE LEVEL AND CHANGE IN SERUM CONCENTRATION OF CALCIFEDIOL IN DOSE INTERVAL IS REDUCED COMPARED TO BOLUS IV INJECTION AND IMMEDIATE-RELEASE, ORAL DOSING
U-2258	TREATING SECONDARY HYPERPARATHYROIDISM IN CKD WITH SUSTAINED RELEASE CALCIFEDIOL TO REDUCE THE PATIENT'S SERUM PARATHYROID HORMONE LEVEL AND CMAX24HR/C24HR IS REDUCED COMPARED TO BOLUS IV INJECTION AND IMMEDIATE-RELEASE, ORAL DOSING
U-2259	TREATING SECONDARY HYPERPARATHYROIDISM IN CKD WITH SUSTAINED RELEASE CALCIFEDIOL TO REDUCE THE PATIENT'S SERUM PARATHYROID HORMONE LEVEL AND TMAX IS INCREASED COMPARED TO BOLUS IV INJECTION AND IMMEDIATE-RELEASE, ORAL DOSING
U-2260	METHOD OF REDUCING THE RISK OF PERIPROCEDURAL MYOCARDIAL INFARCTION, AND STENT THROMBOSIS IN A PATIENT UNDERGOING PCI BY ADMINISTERING INTRAVENOUSLY 30 UG/KG BOLUS BEFORE PCI AND THEN A CONTINUOUS INFUSION
U-2261	MODIFIED DOSING REGIMEN FOR THE MANAGEMENT OF MILD TO MODERATE PAIN OR MANAGEMENT OF MODERATE TO SEVERE PAIN AS AN ADJUNCT TO OPIOID ANALGESICS
U-2262	MODIFIED DOSING REGIMEN FOR THE REDUCTION OF FEVER
U-2263	MODIFIED DOSING REGIMEN FOR THE MANAGEMENT OF MODERATE TO SEVERE PAIN WITH ADJUNCTIVE OPIOID ANALGESICS
U-2264	METHODS OF TREATING PAIN, INFLAMMATION, FEVER, PATENT DUCTUS ARTERIOSIS WITH AQUEOUS COMPOSITION
U-2265	PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH HEC AND MEC IN ADULT AND PEDIATRIC PATIENTS
U-2266	METHODS OF MAKING AQUEOUS COMPOSITION AND TREATING PAIN, INFLAMMATION, FEVER, PATENT DUCTUS ARTERIOSIS WITH AQUEOUS COMPOSITION
U-2267	METHOD FOR RELIEVING THE PAIN ASSOCIATED WITH POST-HERPETIC NEURALGIA
U-2268	DISCONTINUING A STRONG CYP1A2 INDUCER TO AVOID REDUCED PIRFENIDONE EFFICACY AND THEN ADMINISTERING PIRFENIDONE
U-2269	DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION, BY ADMINISTERING SUB-2400MG/DAY DOSE THEN FULL DAILY DOSE IN TREATMENT OF IPF
U-2270	DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE UNTIL BIOMARKERS ARE WITHIN NORMAL LIMITS, THEN SUB-2400MG/DAY DOSE, THEN FULL DAILY DOSE IN TREATMENT OF IPF
U-2271	THERAPEUTIC TREATMENT OF PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER, SYMPTOMATIC BONE METASTASES AND NO KNOWN VISCERAL METASTATIC DISEASE
U-2272	TREATMENT OF NASAL POLYPS IN PATIENTS ≥18 YEARS OF AGE WHO HAVE HAD ETHMOID SINUS SURGERY USING A CORTICOSTEROID-ELUTING (MOMETASONE FUROATE) IMPLANT
U-2273	A METHOD FOR TREATING EPITHELIAL OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER, WHEREIN THE CANCER IS ASSOCIATED WITH A DELETERIOUS BRCA MUTATION

PATENT AND EXCLUSIVITY TERMS

ADB 140 of 191

PATENT USE

U-2274	MAINTAINING SERUM 25-HYDROXYVITAMIN D AT A LEVEL OF AT LEAST 30 NG/ML WITH ORAL, SUSTAINED RELEASE 25-HYDROXYVITAMIN D
U-2275	TREATING CYSTIC FIBROSIS PATIENTS AGES 12 AND OLDER, WHO ARE HOMOZYGOUS FOR F508DEL OR HAVE AT LEAST 1 CFTR GENE MUTATION RESPONSIVE TO TEZACAFTOR/IVACAFTOR, WITH TEZACAFTOR AND A SOLID COMPOSITION COMPRISING AMORPHOUS (<30% CRYSTALLINE) IVACAFTOR
U-2276	METHOD OF TREATING CYSTIC FIBROSIS IN A PATIENT AGE 6 OR OLDER HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE USING LUMACAFTOR AND A SOLID COMPOSITION COMPRISING AMORPHOUS (LESS THAN ABOUT 30% CRYSTALLINE) IVACAFTOR
U-2277	IMPROVEMENT IN GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED BY LIXISENATIDE
U-2278	IMPROVEMENT IN GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED BY LIXISENATIDE IN COMBINATION WITH METFORMIN
U-2279	IMPROVEMENT IN GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED BY LIXISENATIDE IN COMBINATION WITH METFORMIN AND A SECOND ORAL ANTIDIABETIC DRUG
U-2280	ADJUNCTIVE TREATMENT OF PATIENTS WITH TSC-ASSOCIATED PARTIAL-ONSET SEIZURES
U-2281	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 1 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 1
U-2282	ADJUNCT TO DIET AND EXERCISE TO TREAT GLUCOSE INTOLERANCE IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 2 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 2
U-2283	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 3-7 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIMS 3-7
U-2284	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 8 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 8
U-2285	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 11 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 11
U-2286	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 14 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 14
U-2287	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 16-19 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIMS 16-19
U-2288	TREATMENT OF TYPE 2 DIABETES MELLITUS WITH EXENATIDE AS AN ADD-ON TO BASIL INSULIN OR BASAL INSULIN PLUS METFORMIN THERAPY
U-2289	TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS HAVE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 19 DELETIONS OR EXON 21L858R MUTATIONS
U-2290	METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
U-2291	REDUCTION OF THROMBOTIC CARDIOVASCULAR EVENTS IN PATIENTS WITH A HISTORY OF MYOCARDIAL INFARCTION (MI) OR WITH PERIPHERAL ARTERIAL DISEASE (PAD)
U-2292	METHOD OF REDUCING THE RISK OF CARDIOVASCULAR DEATH IN ADULT PATIENTS WITH TYPE 2 DIABETES MELLITUS AND CARDIOVASCULAR DISEASE BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
U-2293	USE IN COMBINATION WITH DEXAMETHASONE IN ADULTS FOR THE PREVENTION OF ACUTE AND DELAYED NAUSEA AND VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF CANCER CHEMOTHERAPY, INCLUDING, BUT NOT LIMITED TO, HIGHLY EMETOGENIC CHEMOTHERAPY

PATENT AND EXCLUSIVITY TERMS

ADB 141 of 191

PATENT USE

U-2294	TREATMENT OF THROMBOCYTOPENIA IN ADULT PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA (ITP) WHO HAVE HAD AN INSUFFICIENT RESPONSE TO A PREVIOUS TREATMENT
U-2295	TREATMENT OF PARTIAL-ONSET SEIZURES IN PATIENTS 4 YEARS OF AGE AND OLDER
U-2296	TAFINLAR IS INDICATED, IN COMBINATION WITH TRAMETINIB, FOR THE ADJUVANT TREATMENT OF PATIENTS WITH MELANOMA WITH BRAF V600E OR V600K MUTATIONS, AS DETECTED BY AN FDA-APPROVED TEST, AND INVOLVEMENT OF LYMPH NODE(S), FOLLOWING COMPLETE RESECTION
U-2297	IMPROVEMENT OF GLYCEMIC CONTROL IN TYPE 2 DIABETES PATIENTS BY ADMINISTERING A STARTING DOSE OF 10 MCG FOR 14 DAYS AND INCREASING TO A MAINTENANCE DOSE OF 20 MCG ON DAY 15
U-2298	TAFINLAR IS INDICATED, IN COMBINATION WITH TRAMETINIB, FOR THE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC ANAPLASTIC THYROID CANCER (ATC) WITH BRAF V600E MUTATION AND WITH NO SATISFACTORY LOCOREGIONAL TREATMENT OPTIONS
U-2299	TAFINLAR IS INDICATED AS A SINGLE AGENT FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E MUTATION
U-2300	USE IN COMBINATION WITH THE MUSCARINIC ANTAGONIST SOLIFENACIN SUCCINATE FOR THE TREATMENT OF OVERACTIVE BLADDER (OAB) WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND URINARY FREQUENCY
U-2301	USE IN COMBINATION WITH DEXAMETHASONE IN ADULTS FOR THE PREVENTION OF ACUTE AND DELAYED NAUSEA AND VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF HIGHLY EMETOGENIC CANCER CHEMOTHERAPY
U-2302	MEKINIST IS INDICATED, IN COMBINATION WITH DABRAFENIB, FOR THE ADJUVANT TREATMENT OF PATIENTS WITH MELANOMA WITH BRAF V600E OR V600K MUTATIONS, AS DETECTED BY AN FDA-APPROVED TEST, AND INVOLVEMENT OF LYMPH NODE(S), FOLLOWING COMPLETE RESECTION
U-2303	MEKINIST IS INDICATED, IN COMBINATION WITH DABRAFENIB, FOR THE ADJUVANT TREATMENT OF PATIENTS WITH MELANOMA WITH BRAF V600E OR V600K MUTATIONS AND INVOLVEMENT OF LYMPH NODE(S), FOLLOWING COMPLETE RESECTION
U-2304	MEKINIST IS INDICATED, IN COMBINATION WITH DABRAFENIB, FOR THE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH BRAF V600E MUTATION
U-2305	MEKINIST IS INDICATED, IN COMBINATION WITH DABRAFENIB, FOR THE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC ANAPLASTIC THYROID CANCER (ATC) WITH BRAF V600E MUTATION AND WITH NO SATISFACTORY LOCOREGIONAL TREATMENT OPTIONS
U-2306	ONCE DAILY TOPICAL TREATMENT OF PERSISTENT FACIAL ERYTHEMA ASSOCIATED WITH ROSACEA IN ADULTS WITH 1% OXYMETAZOLINE HYDROCHLORIDE CREAM
U-2307	TREATMENT OF AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE
U-2308	TREATMENT OF ADULT PATIENTS WITH SHORT BOWEL SYNDROME WHO ARE DEPENDENT ON PARENTERAL SUPPORT
U-2309	USE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER TO IMPROVE PROCESSING SPEED, AN ASPECT OF COGNITIVE FUNCTION
U-2310	FOR CLEANSING OF THE COLON IN PREPARATION FOR COLONOSCOPY IN ADULTS
U-2311	TREATMENT OF HYPERURICEMIA ASSOCIATED WITH GOUT IN PATIENTS WHO HAVE NOT ACHIEVED TARGET SERUM URIC ACID LEVELS WITH A XANTHINE OXIDASE INHIBITOR ALONE
U-2312	TREATMENT OF HYPERKALEMIA IN ADULTS
U-2313	METHOD OF REDUCING THE RISK OF CARDIOVASCULAR DEATH, NON-FATAL MYOCARDIAL INFARCTION, AND/OR NON-FATAL STROKE IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED CARDIOVASCULAR DISEASE BY ADMINISTERING LIRAGLUTIDE
U-2314	TREATMENT OF THROMBOCYTOPENIA IN AN ADULT PATIENT WITH CHRONIC LIVER DISEASE WHO IS SCHEDULED TO UNDERGO A PROCEDURE USING DOPTELET
U-2315	TREATMENT OF MULTIPLE SCLEROSIS IN THE PEDIATRIC PATIENT POPULATION WITH 0.25 MG FINGOLIMOD
U-2316	TREATMENT OF DYSPAREUNIA
U-2317	TREATMENT OF A SYMPTOM OF VULVAR AND VAGINAL ATROPHY
U-2318	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 12 AND OLDER, WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION OR HAVE AT LEAST ONE CFTR GENE MUTATION THAT IS RESPONSIVE TO TEZACAFTOR/IVACAFTOR, WITH TEZACAFTOR AND IVACAFTOR

PATENT AND EXCLUSIVITY TERMS

ADB 142 of 191

PATENT USE

U-2319	KYPROLIS IS INDICATED IN COMBINATION WITH DEXAMETHASONE OR WITH LENALIDOMIDE PLUS DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED ONE TO THREE LINES OF THERAPY
U-2320	KYPROLIS IS INDICATED AS A SINGLE AGENT FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED ONE OR MORE LINES OF THERAPY
U-2321	A METHOD OF APPLYING TRYPAN BLUE ONTO AN OUTER SURFACE OF THE ANTERIOR LENS CAPSULE TO FACILITATE REMOVAL OF THE LENS SUBSTANCE
U-2322	TREATMENT OF ADULT PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (UC)
U-2323	TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL), WITH OR WITHOUT 17P DELETION, WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
U-2324	FOR SECONDARY PREVENTION OF CARDIOVASCULAR AND CEREBROVASCULAR EVENTS IN PATIENTS AT RISK OF DEVELOPING ASPIRIN-ASSOCIATED GASTRIC ULCERS
U-2325	EMERGENCY TREATMENT OF ALLERGIC REACTIONS (TYPE 1), INCLUDING ANAPHYLAXIS; A METHOD OF TREATING ALLERGIC REACTION, ANAPHYLAXIS, ANAPHYLACTIC SHOCK, OR COMBINATION THEREOF BY AN INJECTION OF AT LEAST ONE DOSAGE OF THE INJECTABLE LIQUID PHARMACEUTICAL
U-2326	TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS
U-2327	TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS, COMPRISING MONITORING A PATIENT'S SERUM SODIUM CONCENTRATION
U-2328	METHOD OF USING PLAZOMICIN TO TREAT BACTERIAL INFECTIONS
U-2329	METHOD OF ADMINISTERING A LOCAL ANESTHETIC PRIOR TO PERFORMING A DIAGNOSTIC OR SURGICAL PROCEDURE ON A SUBJECT WITH HEPATIC OR RENAL IMPAIRMENT
U-2330	METHOD OF TREATING MELANOMA
U-2331	INDICATED IN COMBINATION WITH ENCORAFENIB FOR THE TREATMENT OF MELANOMA
U-2332	INDICATED IN COMBINATION WITH ENCORAFENIB FOR THE TREATMENT OF MELANOMA MEDIATED BY A B-RAF PROTEIN KINASE
U-2333	INDICATED IN COMBINATION WITH ENCORAFENIB FOR THE TREATMENT OF MELANOMA WITH A BRAF MUTATION
U-2334	TREATMENT OF MELANOMA WITH A BRAF MUTATION
U-2335	TREATMENT OF MELANOMA
U-2336	TREATMENT OF MELANOMA MEDIATED BY A B-RAF PROTEIN KINASE
U-2337	INDICATED IN COMBINATION WITH BINIMETINIB FOR THE TREATMENT OF MELANOMA WITH A BRAF MUTATION
U-2338	MAINTAINING MEAN ARTERIAL PRESSURE OF ABOUT 65 MMHG OR ABOVE WITH ABOUT 1 NG/KG/MIN TO ABOUT 40 NG/KG/MIN ANGIOTENSIN II IN HYPOTENSIVE PATIENTS TREATED WITH VASOPRESSIN OR A VASOPRESSIN ANALOGUE AND REDUCING VASOPRESSIN OR VASOPRESSIN ANALOGUE USE
U-2339	USE OF A PHARMACEUTICAL COMPOSITION COMPRISING LINAGLIPTIN, METFORMIN AND A BASIC AMINO ACID TO TREAT TYPE 2 DIABETES MELLITUS
U-2340	TREATMENT OF POSTOPERATIVE INFLAMMATION
U-2341	METHOD OF RECONSTITUTING A LYOPHILIZED LIPOSOMAL COMPOSITION FOR ADMINISTERING CYTARABINE AND DAUNORUBICIN TO TREAT ADULTS WITH NEWLY-DIAGNOSED THERAPY-RELATED ACUTE MYELOID LEUKEMIA (T-AML) OR AML WITH MYELOYDYSPLASIA-RELATED CHANGES (AML-MRC)
U-2342	METHOD OF ADMINISTERING A RECONSTITUTED LIPOSOMAL COMPOSITION CONTAINING CYTARABINE AND DAUNORUBICIN TO TREAT ADULTS WITH NEWLY-DIAGNOSED THERAPY-RELATED ACUTE MYELOID LEUKEMIA (T-AML) OR AML WITH MYELOYDYSPLASIA-RELATED CHANGES (AML-MRC)
U-2343	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 12 YEARS AND OLDER, WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION OR HETEROZYGOUS FOR F508DEL AND A SECOND CFTR MUTATION PREDICTED TO BE RESPONSIVE TO TEZACAFTOR/IVACAFTOR, WITH TEZACAFTOR AND IVACAFTOR
U-2344	TREATMENT OF THROMBOCYTOPENIA IN ADULT PATIENTS WITH CHRONIC LIVER DISEASE WHO ARE SCHEDULED TO UNDERGO A PROCEDURE

PATENT AND EXCLUSIVITY TERMS

ADB 143 of 191

PATENT USE

U-2345	TREATMENT OF PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER (CRPC)
U-2346	TREATMENT OF HUMAN SMALLPOX DISEASE CAUSED BY VARIOLA VIRUS IN ADULTS AND PEDIATRIC PATIENTS WEIGHING AT LEAST 13 KG
U-2347	TREATMENT OF TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT AND FOR WHOM METFORMIN THERAPY IS INAPPROPRIATE BY ADMINISTERING LINAGLIPTIN WITHOUT DOSE ADJUSTMENT
U-2348	A METHOD FOR PREVENTION OF PREGNANCY
U-2349	FOR ONCE-DAILY MAINTENANCE TREATMENT OF ASTHMA AS PROPHYLACTIC THERAPY IN PATIENTS AGED 5 YEARS AND OLDER
U-2350	A METHOD OF TREATING A CANCER CHARACTERIZED BY AN IDH1 MUTATION WHERE THE CANCER IS ACUTE MYELOGENOUS LEUKEMIA (AML)
U-2351	TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) WITH AN IDH1 MUTATION
U-2352	TREATMENT OF HIV-1 INFECTION IN ADULTS WHO HAVE NO PRIOR ANTIRETROVIRAL TREATMENT HISTORY OR ARE VIROLOGICALLY SUPPRESSED ON A STABLE ANTIRETROVIRAL REGIMEN FOR AT LEAST 6 MONTHS
U-2353	TX OF HIV-1 INFECTION USING A COMPOSITION CONTAINING A PK ENHANCER THAT INHIBITS CYTOCHROME P450 MONOOXYGENATES IN ADULTS WHO HAVE NO PRIOR ANTIRETROVIRAL TX HISTORY OR ARE VIROLOGICALLY SUPPRESSED ON A STABLE ANTIRETROVIRAL REGIMEN FOR AT LEAST 6 MONTHS
U-2354	COMBINATION WITH OTHER ANTIRETROVIRALS (ATV) FOR TREATMENT OF HIV-1 IN ATV TREATMENT-EXPERIENCED PATIENTS 2 YEARS AND OLDER WITH EVIDENCE OF VIRAL REPLICATION AND HIV-1 STRAINS RESISTANT TO NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR AND OTHER ATV
U-2355	IN COMBINATION WITH AN AROMATASE INHIBITOR FOR THE TREATMENT OF PRE/PERIMENOPAUSAL OR POSTMENOPAUSAL WOMEN WITH HR-POSITIVE, HER2-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER, AS INITIAL ENDOCRINE-BASED THERAPY
U-2356	IN COMBINATION WITH FULVESTRANT FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HR-POSITIVE, HER2-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER, AS INITIAL ENDOCRINE BASED THERAPY OR FOLLOWING DISEASE PROGRESSION ON ENDOCRINE THERAPY
U-2357	METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
U-2358	TREATMENT OF PATIENTS WITH HORMONE RECEPTOR (HR)-NEGATIVE BREAST CANCER WITH DELETERIOUS OR SUSPECTED DELETERIOUS GBRCA, HER2-NEGATIVE METASTATIC BREAST CANCER, WHO HAVE BEEN TREATED WITH CHEMOTHERAPY IN NEOADJUVANT, ADJUVANT, OR METASTATIC SETTING
U-2359	TREATMENT OF PATIENTS WITH HORMONE RECEPTOR (HR)-POSITIVE BREAST CANCER WHO SHOULD HAVE BEEN TREATED WITH PRIOR ENDOCRINE THERAPY OR BE CONSIDERED INAPPROPRIATE FOR ENDOCRINE THERAPY
U-2360	MANAGEMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH ENDOMETRIOSIS
U-2361	METHOD OF ADMINISTERING A GRANULATE FORMULATION OF 5-METHYL-1-PHENYL-2-(1H)-PYRIDONE AS RECITED IN CLAIM 1, TO TREAT IDIOPATHIC PULMONARY FIBROSIS
U-2362	TREATMENT OF HEPATITIS C VIRUS (HCV) GENOTYPE 1, 2, 3, 4, 5, OR 6
U-2363	ADMINISTRATION OF RISPERIDONE
U-2364	TREATMENT OF HIV-1 INFECTION USING A COMPOSITION CONTAINING A PHARMACOKINETIC ENHANCER THAT INHIBITS CYTOCHROME P450 MONOOXYGENASE IN ADULTS WHO HAVE NO PRIOR ANTIRETROVIRAL TREATMENT HISTORY
U-2365	TREATMENT OF HIV-1 INFECTION USING A COMPOSITION CONTAINING A PHARMACOKINETIC ENHANCER THAT INIBITS CYTOCHROME P450 MONOOXYGENASE IN ADULTS WHO ARE VIROLOGICALLY SUPPRESSED ON A STABLE ANTIRETROVIRAL REGIMEN FOR AT LEAST 6 MONTHS
U-2366	TREATMENT OF LIVER DISEASE THROUGH NUTRITION FOR PATIENTS UNDER THE AGE OF 12
U-2367	USE FOR PATIENTS WITH PARENTERAL NUTRITION ASSOCIATED CHOLESTASIS OR PARENTERAL NUTRITION ASSOCIATED LIVER DISEASE
U-2368	TOPICAL TREATMENT OF ACNE VULGARIS IN PATIENTS 9 YEARS OF AGE AND OLDER
U-2369	FOR THE TREATMENT OF GENOTYPE 1, 4, 5 OR 6 CHRONIC HEPATITIS C VIRUS (HCV) INFECTION
U-2370	FOR TREATMENT-NAIVE GENOTYPE 1 PATIENTS WITH CHRONIC HEPATITIS C VIRUS (HCV) INFECTION FOR A DURATION OF 8-WEEKS

PATENT AND EXCLUSIVITY TERMS

ADB 144 of 191

PATENT USE

U-2371	THE TREATMENT OF FABRY PATIENTS
U-2372	A METHOD OF REDUCING LEFT VENTRICULAR MASS INDEX (LVMI) IN A FABRY PATIENT BY ADMINISTERING MIGALASTAT
U-2373	A METHOD OF REDUCING PODOCYTE GLOBOTRIAOSYL CERAMIDE (GL-3) IN A FABRY PATIENT BY ADMINISTERING MIGALASTAT
U-2374	TREATMENT OF CYSTIC FIBROSIS IN A PATIENT AGE 2-5 YEARS WHO IS HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE USING LUMACAFOR AND IVACAFOR
U-2375	TREATMENT OF CYSTIC FIBROSIS IN A PATIENT AGE 2-5 YEARS WHO IS HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE USING LUMACAFOR FORM I AND IVACAFOR
U-2376	TREATMENT OF CYSTIC FIBROSIS IN A PATIENT AGE 2-5 YEARS WHO IS HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE USING LUMACAFOR AND A SOLID COMPOSITION COMPRISING AMORPHOUS AND LESS THAN ABOUT 30% CRYSTALLINE IVACAFOR
U-2377	USE OF VITAL DYE FOR FACILITATING SURGICAL PROCEDURES FOR VITREO-RETINAL SURGERY
U-2378	TREATMENT OF POLYNEUROPATHY OF HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS
U-2379	USE IN IDENTIFICATION OF INTRAOCULAR MEMBRANES TO FACILITATE REMOVAL DURING OPHTHALMIC SURGERY
U-2380	TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS IN PATIENTS 18 YEARS OF AGE AND OLDER
U-2381	TREATMENT IN COMBINATION WITH A GNRH AGONIST OF NON-METASTATIC, CASTRATION-RESISTANT PROSTATE CANCER (NM-CRPC)
U-2382	TREATMENT IN COMBINATION WITH A GNRH AGONIST OF HIGH RISK NON-METASTATIC, CASTRATION-RESISTANT PROSTATE CANCER (NM-CRPC)
U-2383	METHOD OF CONTROLLING GLYCEMIA IN A DIABETIC PATIENT WITH DELAYED OR PROLONGED FOOD ABSORPTION BY ADMINISTERING 50 TO 75% OF A PREDETERMINED DOSE OF INSULIN-FDKP AT MEALTIME, AND ADMINISTERING REMAINDER OF DOSE 30-120 MINUTES AFTER BEGINNING OF MEAL
U-2384	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 1 AND 10
U-2385	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 1,10 AND 11
U-2386	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 12 AND 19
U-2387	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 12, 19 AND 20
U-2388	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 21 AND 28
U-2389	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 21, 28, AND 29
U-2390	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 30 AND 41
U-2391	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 30, 41, AND 42
U-2392	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 43 AND 50
U-2393	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 43, 50 AND 51
U-2394	FOR USE IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS FOR THE TREATMENT OF HIV-1 INFECTION IN ADULT PATIENTS WITH NO PRIOR ANTIRETROVIRAL TREATMENT HISTORY

PATENT AND EXCLUSIVITY TERMS

ADB 145 of 191

PATENT USE

U-2395	FOR THE TREATMENT OF HIV-1 INFECTION IN ADULT PATIENTS WITH NO PRIOR ANTIRETROVIRAL TREATMENT HISTORY
U-2396	TREATMENT OF CYSTIC FIBROSIS IN A PATIENT AGE 2-5 YEARS WHO IS HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE USING THE DOSAGE UNIT COMPRISING LUMACAFTOR AS RECITED IN CLAIM 1 OF US PATENT 8716338 AND IVACAFTOR
U-2397	TREATMENT OF CYSTIC FIBROSIS IN A PATIENT AGE 2-5 YEARS WHO IS HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE USING THE DOSAGE UNIT COMPRISING LUMACAFTOR AND IVACAFTOR AS RECITED IN CLAIM 1 OF US PATENT 9192606
U-2398	TOPICAL TREATMENT OF PRIMARY AXILLARY HYPERHIDROSIS IN ADULTS AND PEDIATRIC PATIENTS 9 YEARS OF AGE AND OLDER
U-2399	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS 12 YEARS AND OLDER, WITH A F508DEL OR G551D CFTR GENE MUTATION AND A A455E, 2789+5G->A, OR 3849+10KBC->T MUTATION, COMPRISING CONCURRENT COADMINISTRATION OF THE COMPOSITIONS OF CLAIM 1 OF U.S. PATENT 10058546
U-2400	REDUCING ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION
U-2401	A METHOD OF TREATING AMYOTROPHIC LATERAL SCLEROSIS IN A PATIENT IN NEED OF SUCH TREATMENT, SAID METHOD COMPRISING ADMINISTERING TO SAID PATIENT AN EFFECTIVE AMOUNT OF A SUSPENSION ACCORDING TO CLAIM 1
U-2402	TREATMENT OF SCHIZOPHRENIA BY RAPID AND CONTINUOUS INTRAMUSCULAR INJECTION
U-2403	TREATMENT OF PSORIASIS USING A DOSAGE TITRATION SCHEDULE
U-2404	METHOD OF DELIVERING SUMATRIPTAN TO A NASAL CAVITY
U-2405	A METHOD FOR TREATING A BACTERIAL INFECTION IN INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS PATIENTS 9 YEARS OF AGE AND OLDER COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF SARECYCLINE HYDROCHLORIDE
U-2406	A METHOD FOR TREATING A PATIENT 9 YEARS OF AGE AND OLDER SUFFERING FROM AN INFLAMMATORY SKIN DISORDER OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF SARECYCLINE HYDROCHLORIDE
U-2407	A METHOD FOR TREATING ACNE IN INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS PATIENTS 9 YEARS OF AGE AND OLDER COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF SARECYCLINE HYDROCHLORIDE CRYSTALLINE SALT
U-2408	A METHOD FOR TREATING A BACTERIAL INFECTION IN INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS PATIENTS 9 YEARS OF AGE AND OLDER COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF SARECYCLINE HYDROCHLORIDE CRYSTALLINE SALT
U-2409	A METHOD FOR TREATING ACNE IN INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS PATIENTS 9 YEARS OF AGE AND OLDER COMPRISING ADMINISTERING SARECYCLINE HYDROCHLORIDE IN 60 MG, 100 MG OR 150 MG EQUIVALENT DOSES
U-2410	TREATMENT OF ADULT PATIENTS FOR WHOM TREATMENT WITH BOTH AMLODIPINE FOR HYPERTENSION AND CELECOXIB FOR OSTEOARTHRITIS ARE APPROPRIATE
U-2411	TREATMENT OF CYSTIC FIBROSIS IN A PATIENT AGE 12 YEARS OR OLDER WHO IS HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE USING THE TABLET COMPRISING LUMACAFTOR AS RECITED IN CLAIM 1, 19, OR 21 OF U.S. PATENT NO. 10,076,513 AND IVACAFTOR
U-2412	FOR THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND/OR SMALL LYMPHOCYTIC LEUKEMIA (SLL)
U-2413	FOR THE TREATMENT OF PATIENTS WITH FOLLICULAR LYMPHOMA (FL)
U-2414	TREATING MYCOBACTERIUM AVIUM COMPLEX (MAC) LUNG DISEASE IN ADULTS AS PART OF A COMBINATION DRUG REGIMEN
U-2415	TREATING MYCOBACTERIUM AVIUM COMPLEX (MAC) LUNG DISEASE IN ADULTS AS PART OF A COMBINATION ANTIBACTERIAL DRUG REGIMEN
U-2416	TREATING MYCOBACTERIUM AVIUM COMPLEX (MAC) LUNG DISEASE IN ADULTS WITH CYSTIC FIBROSIS AS PART OF A COMBINATION DRUG REGIMEN
U-2417	TREATING MYCOBACTERIUM AVIUM COMPLEX (MAC) LUNG DISEASE IN NON-CYSTIC FIBROSIS ADULTS AS PART OF A COMBINATION ANTIBACTERIAL DRUG REGIMEN
U-2418	METHOD OF ADMINISTERING TESTOSTERONE ENANTHATE SUBCUTANEOUSLY
U-2419	METHOD OF OPERATING AN INJECTION DEVICE
U-2420	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGES 12 AND OLDER, WHO HAVE TWO COPIES

PATENT AND EXCLUSIVITY TERMS

ADB 146 of 191

PATENT USE

OF THE F508DEL MUTATION OR ONE F508DEL MUTATION AND A CFTR MUTATION PREDICTED TO BE RESPONSIVE TO TEZACAFTOR/IVACAFTOR, WITH THE COMPOSITION OF CLAIM 1 OF US 10,081,621

U-2421	USE IN COMBINATION WITH CLOBAZAM FOR THE TREATMENT OF SEIZURES IN PATIENTS WITH DRAVET SYNDROME
U-2422	USE IN COMBINATION WITH CLOBAZAM FOR THE TREATMENT OF SEIZURES IN PATIENTS WITH LENNOX GASTAUT SYNDROME WHO HAVE BEEN PREVIOUSLY TREATED WITH CLOBAZAM
U-2423	USE IN COMBINATION WITH CLOBAZAM FOR THE TREATMENT OF SEIZURES IN PATIENTS WITH DRAVET SYNDROME WHO HAVE BEEN PREVIOUSLY TREATED WITH CLOBAZAM
U-2424	USE IN COMBINATION WITH CLOBAZAM FOR TREATMENT OF SEIZURES IN PATIENTS WITH LENNOX GASTAUT SYNDROME
U-2425	USE FOR THE TREATMENT OF CONVULSIVE SEIZURES IN PATIENTS WITH DRAVET SYNDROME
U-2426	USE FOR THE TREATMENT OF CONVULSIVE SEIZURES IN PATIENTS WITH LENNOX GASTAUT SYNDROME
U-2427	USE FOR THE TREATMENT OF DROP SEIZURES IN PATIENTS WITH DRAVET SYNDROME
U-2428	TREATMENT OF PARTIAL-ONSET SEIZURES WITH OR WITHOUT SECONDARILY GENERALIZED SEIZURES IN PATIENTS WITH EPILEPSY 4 YEARS OF AGE AND OLDER
U-2429	TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES AS ADJUNCTIVE THERAPY IN PATIENTS WITH EPILEPSY 12 YEARS OF AGE AND OLDER
U-2430	TREATMENT OF POLYNEUROPATHY OF HEREDITARY TRANSTHYRETIN AMYLOIDOSIS
U-2431	TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS
U-2432	LONG-TERM, MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
U-2433	METHOD OF TREATING A BIOLOGICAL RHYTHM DISORDER, SUCH AS INSOMNIA
U-2434	USE IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
U-2435	REDUCTION OF RISK OF MAJOR CARDIOVASCULAR EVENTS (CV DEATH, MI, AND STROKE) IN CHRONIC CAD OR PAD
U-2436	USE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER TO IMPROVE TREATMENT EMERGENT SEXUAL DYSFUNCTION (TESD) INDUCED BY PRIOR SEROTONIN REUPTAKE INHIBITOR TREATMENT
U-2437	TREATMENT OF ADULT PATIENTS WITH DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINE BREAST CANCER SUSCEPTIBILITY GENE (BRCA)-MUTATED (GBRCAM) HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER
U-2438	CARDIOVASCULAR OUTCOMES TRIAL OF LIRAGLUTIDE 1.8 MG IN PATIENTS WITH TYPE 2 DIABETES AND CARDIOVASCULAR DISEASE
U-2439	TREATMENT OF MENOPAUSE SYMPTOMS, INCLUDING VASOMOTOR SYMPTOMS
U-2440	FOR THE MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
U-2441	REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
U-2442	USE FOR THE TREATMENT OF ATONIC SEIZURES IN PATIENTS WITH LENNOX-GASTAUT SYNDROME
U-2443	USE FOR THE TREATMENT OF ATONIC SEIZURES IN PATIENTS WITH DRAVET SYNDROME
U-2444	TREATMENT OF SUBJECTS HAVING BACTERIAL SKIN OR SKIN STRUCTURE INFECTION
U-2445	TREATMENT IN COMBINATION WITH AZACITIDINE OR DECITABINE OR LOW-DOSE CYTARABINE OF NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) IN ADULTS WHO ARE AGE 75 YEARS OR OLDER, OR WHO HAVE COMORBIDITIES THAT PRECLUDE USE OF INTENSIVE INDUCTION CHEMOTHERAPY
U-2446	TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL), WITH OR WITHOUT 17P DELETION, WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
U-2447	TREATMENT OF SEVERE HYPERTRIGLYCERIDEMIA (500 MG/DL) IN ADULT PATIENTS AS AN ADJUNCT TO DIET
U-2448	TREATMENT OF TRAVELERS' DIARRHEA CAUSED BY NON-INVASIVE STRAINS OF ESCHERICHIA COLI IN ADULTS

PATENT AND EXCLUSIVITY TERMS

ADB 147 of 191

PATENT USE

U-2449	TREATMENT OF BACTERIAL SKIN AND SKIN STRUCTURE INFECTION
U-2450	POSITRON EMISSION TOMOGRAPHY DIAGNOSTIC AGENT IN ADULTS WITH SUSPECTED PROSTATE CANCER RECURRENCE BASED ON ELEVATED BLOOD PROSTATE SPECIFIC ANTIGEN LEVELS FOLLOWING PRIOR TREATMENT
U-2451	TREATMENT OF THROMBOCYTOPENIA IN ADULT AND PEDIATRIC PATIENTS 1 YEAR AND OLDER WITH CHRONIC IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP)
U-2452	COMBINATION WITH IMMUNOSUPPRESSIVE THERAPY FOR FIRST-LINE TREATMENT OF ADULT AND PEDIATRIC PATIENTS 2 YEARS AND OLDER WITH SEVERE APLASTIC ANEMIA
U-2453	TREATMENT OF FUNGAL INFECTIONS, INCLUDING BLASTOMYCOSIS, HISTOPLASMOSIS, AND ASPERGILLOSIS
U-2454	USE FOR THE TREATMENT OF DROP SEIZURES IN PATIENTS WITH LENNOX-GASTAUT SYNDROME
U-2455	USE IN COMBINATION WITH CLOBAZAM FOR TREATMENT OF DROP SEIZURES IN PATIENTS WITH LENNOX GASTAUT SYNDROME
U-2456	TREATMENT OF ACUTE MYELOID LEUKEMIA (AML)
U-2457	REINITIATION OF SCHIZOPHRENIA TREATMENT FOLLOWING A MISSED DOSE MORE THAN 9 MONTHS AGO
U-2458	REINITIATION OF SCHIZOPHRENIA TREATMENT FOLLOWING A MISSED DOSE 4-9 MONTHS AGO
U-2459	TREATMENT OF DYSKINESIA AND DECREASING OFF TIME IN PATIENTS WITH PARKINSON'S DISEASE RECEIVING LEVODOPA-BASED THERAPY, WITH OR WITHOUT CONCOMITANT DOPAMINERGIC MEDICATIONS
U-2460	VISUALIZATION OF VESSELS, BLOOD FLOW AND TISSUE PERFUSION OF CORONARY ARTERY BYPASS GRAFT IN VASCULAR, GASTROINTESTINAL, ORGAN TRANSPLANT, AND PLASTIC, MICRO- AND RECONSTRUCTIVE, INCLUDING MINIMALLY INVASIVE, SURGERY
U-2461	VISUALIZATION OF VESSELS, BLOOD FLOW AND TISSUE PERFUSION OF CARDIOVASCULAR BYPASS GRAFT AND VASCULATURE IN VASCULAR, GASTROINTESTINAL, ORGAN TRANSPLANT, AND PLASTIC, MICRO- AND RECONSTRUCTIVE, INCLUDING MINIMALLY INVASIVE, SURGERY
U-2462	VISUALIZATION OF VESSELS, BLOOD FLOW AND TISSUE PERFUSION OF VESSEL WITH ARTERIOVENOUS MALFORMATION IN VASCULAR, GASTROINTESTINAL, ORGAN TRANSPLANT, AND PLASTIC, MICRO- AND RECONSTRUCTIVE, INCLUDING MINIMALLY INVASIVE, SURGERY
U-2463	VISUALIZATION OF VESSELS, BLOOD FLOW AND TISSUE PERFUSION IN SURGICAL FLAPS IN VASCULAR, GASTROINTESTINAL, ORGAN TRANSPLANT, AND PLASTIC, MICRO- AND RECONSTRUCTIVE, INCLUDING MINIMALLY INVASIVE, SURGERY
U-2464	VISUALIZATION OF VESSELS, BLOOD FLOW AND TISSUE PERFUSION OF TRANSPLANTED ORGAN OR ATTACHED VESSEL IN VASCULAR, GASTROINTESTINAL, ORGAN TRANSPLANT, AND PLASTIC, MICRO- AND RECONSTRUCTIVE, INCLUDING MINIMALLY INVASIVE, SURGERY
U-2465	VISUALIZATION OF VESSELS, BLOOD FLOW AND TISSUE PERFUSION OF VESSEL GRAFT IN VASCULAR, GASTROINTESTINAL, ORGAN TRANSPLANT, AND PLASTIC, MICRO- AND RECONSTRUCTIVE, INCLUDING MINIMALLY INVASIVE, SURGERY
U-2466	VISUALIZATION OF VESSELS, BLOOD FLOW AND TISSUE PERFUSION OF DONOR ORGAN OR ATTACHED VESSEL IN VASCULAR, GASTROINTESTINAL, ORGAN TRANSPLANT, AND PLASTIC, MICRO- AND RECONSTRUCTIVE, INCLUDING MINIMALLY INVASIVE, SURGERY
U-2467	VISUALIZATION OF EXTRAHEPATIC BILIARY DUCT ATTACHED TO DONOR ORGAN IN PATIENTS 12 YEARS AND OLDER
U-2468	VISUALIZATION OF EXTRAHEPATIC BILIARY DUCT ATTACHED TO TRANSPLANTED ORGAN IN PATIENTS 12 YEARS AND OLDER
U-2469	METHOD OF TREATING CANCEROUS SOLID TUMORS
U-2470	METHOD OF TREATING SOLID TUMORS THAT EXHIBIT AN NTRK GENE FUSION
U-2471	METHOD OF TREATING SOLID TUMORS THAT EXHIBIT AN NTRK FUSION GENE IN A PEDIATRIC PATIENT
U-2472	METHOD OF TREATING NEUROBLASTOMA, GLIOMA, THYROID, AND BREAST CANCER SOLID TUMORS THAT EXHIBIT AN NTRK GENE FUSION
U-2473	METHOD OF TREATING CMN, IFS, HGG, DIPGS, PTC, SOFT TISSUE SARCOMA, AND SPINDLE CELL SARCOMA SOLID TUMORS EXHIBITING AN NTRK GENE FUSION IN A PEDIATRIC PATIENT WITH AN ORAL SOLUTION
U-2474	METHOD OF TREATING SOLID TUMORS THAT EXHIBIT AN NTRK GENE FUSION AFTER SURGICAL RESECTION
U-2475	METHOD OF TREATING SOLID TUMORS THAT EXHIBIT AN NTRK GENE FUSION IN A PEDIATRIC PATIENT

PATENT AND EXCLUSIVITY TERMS

ADB 148 of 191

PATENT USE

U-2476	USE OF A DELIVERY DEVICE TO DELIVER A DOSE OF NALOXONE
U-2477	TREATMENT OF NON-24 HOUR SLEEP-WAKE DISORDER BY AVOIDING THE USE OF TASIMELTEON IN COMBINATION WITH CYP1A2 STRONG INHIBITORS
U-2478	METHOD FOR THE INDUCTION OF LOCAL ANESTHESIA PRIOR TO PERFORMING A PROCEDURE ON, THROUGH, OR ADJACENT TO THE MUCOUS MEMBRANES
U-2479	METHOD OF ADMINISTERING A LOCAL ANESTHETIC TO THE MUCOUS MEMBRANES
U-2480	MAINTENANCE TREATMENT OF GBRCA- OR SBRCA-MUTATED ADVANCED EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER WHO ARE IN A COMPLETE OR PARTIAL RESPONSE TO FIRST-LINE PLATINUM-BASED CHEMOTHERAPY
U-2481	TREATMENT OF DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINE BRCA-MUTATED ADVANCED OVARIAN CANCER WHO HAVE BEEN TREATED WITH THREE OR MORE PRIOR LINES OF CHEMOTHERAPY
U-2482	TREATMENT OF HR-NEGATIVE, HER-2 NEGATIVE, GBRCA-MUTATED METASTATIC BREAST CANCER, WHO HAVE BEEN TREATED WITH CHEMOTHERAPY IN THE NEOADJUVANT, ADJUVANT, OR METASTATIC SETTING
U-2483	TREATMENT OF HR-POSITIVE, HER-2 NEGATIVE, GBRCA-MUTATED METASTATIC BREAST CANCER, WHO HAVE BEEN TREATED WITH CHEMOTHERAPY IN THE NEOADJUVANT, ADJUVANT, OR METASTATIC SETTING, AND WITH ENDOCRINE THERAPY OR ARE INAPPROPRIATE FOR ENDOCRINE THERAPY
U-2484	INTERMITTENT TREATMENT OF OFF EPISODES IN PATIENTS WITH PARKINSON'S DISEASE TREATED WITH CARBIDOPA/LEVODOPA BY INHALATION OF LEVODOPA POWDER PARTICLES
U-2485	INTERMITTENT TREATMENT OF OFF EPISODES IN PATIENTS WITH PARKINSON'S DISEASE TREATED WITH CARBIDOPA/LEVODOPA BY INHALATION OF LEVODOPA POWDER PARTICLES THROUGH A SINGLE BREATH ACTIVATED STEP
U-2486	INTERMITTENT TREATMENT OF OFF EPISODES IN PATIENTS WITH PARKINSON'S DISEASE WITH A POWDER INHALER
U-2487	DEXTENZA IS APPROVED FOR THE TREATMENT OF OCULAR PAIN FOLLOWING OPHTHALMIC SURGERY
U-2488	TREATMENT OF PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC) WHO HAVE BEEN PREVIOUSLY TREATED WITH SORAFENIB
U-2489	TREATMENT OF MODERATE TO SEVERE OPIOID USE DISORDER
U-2490	TREATMENT OF COMPLICATED URINARY TRACT INFECTION (UTI) INCLUDING PYELONEPHRITIS CAUSED BY THE FOLLOWING SUSCEPTIBLE MICROORGANISMS: ESCHERICHIA COLI, KLEBSIELLA PNEUMONIA, AND ENTEROBACTER CLOACAE SPECIES COMPLEX
U-2491	A METHOD FOR DELIVERING A COMPOSITION TO A MUCUS MEMBRANE
U-2492	A METHOD FOR DELIVERING A PHARMACEUTICAL AGENT ACROSS A MUCOSAL BARRIER
U-2493	A METHOD FOR TREATING INFLAMMATION AND/OR OTHER DISORDERS IN AN EYE OF A PATIENT
U-2494	INDICATED FOR THE TREATMENT OF VENTRICULAR ARRHYTHMIAS, SUCH AS SUSTAINED VENTRICULAR TACHYCARDIA, THAT IN THE JUDGEMENT OF THE PHYSICIAN ARE LIFE-THREATENING
U-2495	VENTRICULAR FIBRILLATION
U-2496	IMPROVEMENT IN GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY USE OF A PEN INJECTOR WITH A THREADED DRIVE SLEEVE
U-2497	TREATMENT OF DRUG-INDUCED EXTRAPYRAMIDAL REACTION IN ADULT PATIENTS
U-2498	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGES 12 AND OLDER, WHO HAVE TWO COPIES OF THE F508DEL MUTATION OR ONE F508DEL MUTATION AND A CFTR MUTATION PREDICTED TO BE RESPONSIVE TO TEZACAFTOR/IVACAFTOR, WITH THE COMPOSITION OF CLAIM 1 OF US 10,206,877
U-2499	METHOD OF REDUCING ADVERSE EFFECTS IN PATIENTS SUFFERING FROM EXCESSIVE DAYTIME SLEEPINESS AND/OR CATAPLEXY IN NARCOLEPSY WHO ARE CONCOMITANTLY ADMINISTERED SODIUM OXYBATE AND DIVALPROEX SODIUM
U-2500	USE OF A DELIVERY DEVICE TO DELIVER A BIOEQUIVALENT DOSE OF A NALOXONE COMPOSITION VIA A NEEDLE
U-2501	TREATMENT OF PARTIAL-ONSET SEIZURES
U-2502	TREATMENT OF TREATMENT-RESISTANT DEPRESSION IN ADULT IN CONJUNCTION WITH AN ORAL ANTIDEPRESSANT
U-2503	TREATMENT OF ADULTS WITH METASTATIC GASTRIC OR GJA PREVIOUSLY TREATED WITH AT

PATENT AND EXCLUSIVITY TERMS

ADB 149 of 191

PATENT USE

LEAST TWO PRIOR LINES OF CHEMOTHERAPY THAT INCLUDED A FLUOROPYRIMIDINE, A PLATINUM, EITHER A TAXANE OR IRINOTECAN, AND IF APPROPRIATE, HER2/NEU-TARGETED THERAPY

- U-2504 TREATMENT OF HR-POSITIVE, HER2-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER IN POSTMENOPAUSAL WOMEN IN COMBINATION WITH RIBOCICLIB AS INITIAL ENDOCRINE BASED THERAPY OR FOLLOWING DISEASE PROGRESSION ON ENDOCRINE THERAPY
- U-2505 TREATMENT OF PRE/PERIMENOPAUSAL WOMEN WITH HORMONE RECEPTOR (HR)-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER
- U-2506 METHOD OF TREATING TESTOSTERONE DEFICIENCY
- U-2507 METHOD OF TREATING ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS (ABSSSI) CAUSED BY DESIGNATED SUSCEPTIBLE BACTERIA
- U-2508 A METHOD OF TREATING BACTERIAL INFECTIONS IN COMPLICATED INTRA-ABDOMINAL INFECTION AND COMPLICATED URINARY TRACT INFECTION, INCLUDING PYELONEPHRITIS, PATIENTS COMPRISING ADMINISTERING A BACTERICIDALLY EFFECTIVE AMOUNT OF AVIBACTAM SODIUM
- U-2509 A METHOD OF TREATING A BACTERIAL INFECTION IN COMPLICATED INTRA-ABDOMINAL INFECTION (CIAI) AND COMPLICATED URINARY TRACT INFECTION (CUTI), INCLUDING PYELONEPHRITIS, PATIENTS COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF AVIBACTAM SODIUM
- U-2510 A METHOD FOR CONTRACEPTION COMPRISING THE STEP OF ORAL ADMINISTRATION A DOSAGE OF 20 MG TO 30 MG OF ULIPRISTAL ACETATE TO A WOMAN WITHIN 72 HOURS AND UP TO 120 HOURS AFTER AN UNPROTECTED INTERCOURSE
- U-2511 A METHOD OF TREATING MULTIPLE SCLEROSIS BY ADMINISTERING SIPONIMOD USING A TITRATION SCHEME TO REACH A MAINTENANCE DOSE
- U-2512 TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 12 YEARS AND OLDER, WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION OR HAVE AT LEAST ONE CFTR MUTATION THAT IS RESPONSIVE TO TEZACAFTOR/IVACAFTOR, WITH AN EFFECTIVE AMOUNT OF TEZACAFTOR AND IVACAFTOR
- U-2513 MAINTENANCE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
- U-2514 MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
- U-2515 PALBOCICLIB FOR HR-POS. HER2-NEG. ADVANCED OR METASTATIC BREAST CANCER IN COMBO WITH AN AROMATASE INHIBITOR AS INITIAL ENDOCRINE-BASED THERAPY IN POSTMENOPAUSAL WOMEN OR MEN, OR WITH FULVESTRANT IN PTS WITH DISEASE PROGRESSION AFTER ENDOCRINE THERAPY
- U-2516 A METHOD FOR REDUCING SERUM GLUCOSE LEVELS IN ADULTS WITH TYPE 2 DIABETES MELLITUS
- U-2517 A METHOD FOR REDUCING SERUM GLUCOSE LEVELS IN ADULTS WITH TYPE 2 DIABETES MELLITUS
- U-2518 TREATMENT OF ADULTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA THAT HAS SUSCEPTIBLE FGFR3 OR FGFR2 GENETIC ALTERATIONS AND PROGRESSED DURING OR FOLLOWING PRIOR PLATINUM-CONTAINING CHEMOTHERAPY
- U-2519 TREATMENT OF ADULT PATIENTS WITH MANTLE CELL LYMPHOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY BY ADMINISTERING 100 MG OF ACALABRUTINIB TWICE DAILY
- U-2520 TREATING MS WITH ORAL CLADRIBINE ACC. TO THE STEPS (I) INDUCTION PERIOD WITH ABOUT 1.7 MG/KG-3.5 MG/KG CLADRIBINE; (II) CLADRIBINE-FREE PERIOD OF ABOUT 8-10 MONTHS; (III) MAINTENANCE PERIOD WITH ABOUT 1.7 MG/KG CLADRIBINE; (IV) CLADRIBINE-FREE PERIOD
- U-2521 TREATMENT OF MS WITH A TABLET WITH AN ADMIXTURE OF (A) AN AMORPHOUS INCLUSION COMPLEX OF CLADRIBINE AND HYDROXYPROPYL-B-CYCLODEXTRIN AND (B) AMORPHOUS FREE CLADRIBINE AND CYCLODEXTRIN AS A NON-INCLUSION COMPLEX, CLADRIBINE/CYCLODEXTRIN 1:10-1:16 W/W
- U-2522 TREATING RMS OR SPMS WITH ORAL CLADRIBINE: (I) 2-4 MONTHS INDUCTION WITH 1.7 MG/KG - 3.5 MG/KG CLADRIBINE; (II) CLADRIBINE-FREE PERIOD OF ABOUT 8-10 MONTHS; (III) 2-4 MONTHS MAINTENANCE WITH ABOUT 1.7 MG/KG CLADRIBINE; (IV) CLADRIBINE-FREE PERIOD
- U-2523 TREATMENT OF MS WITH AN ADMIXTURE OF (A) AN AMORPHOUS INCLUSION COMPLEX OF CLADRIBINE (2CDA) AND CYCLODEXTRIN AND (B) AMORPHOUS FREE 2CDA AND CYCLODEXTRIN AS A NON-INCLUSION COMPLEX, FORMULATED AS A SOLID ORAL FORM, W/O SIGN. AMOUNTS

PATENT AND EXCLUSIVITY TERMS

ADB 150 of 191

PATENT USE

OF CRYST. 2CDA

- U-2524 TREATMENT OF THE CARDIOMYOPATHY OF WILD TYPE OR HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS (ATTR-CM)
- U-2525 TREATMENT OF PATIENTS WITH AN OVERACTIVE BLADDER WITH SYMPTOMS OF URINARY FREQUENCY, URGENCY OR URGE INCONTINENCE
- U-2526 ACUTE TREATMENT OF INTERMITTENT, STEREOTYPIC EPISODES OF FREQUENT SEIZURE ACTIVITY (I.E., SEIZURE CLUSTERS, ACUTE REPETITIVE SEIZURES) THAT ARE DISTINCT FROM A PATIENT'S USUAL SEIZURE PATTERN IN PATIENTS WITH EPILEPSY 12 YEARS OF AGE AND OLDER
- U-2527 TREATMENT OF CYSTIC FIBROSIS USING IVACAFTOR IN A PATIENT AGE 6 MONTHS TO <6 YEARS WHO HAS ONE MUTATION IN THE CFTR GENE THAT IS RESPONSIVE TO IVACAFTOR BASED ON CLINICAL AND/OR IN VITRO ASSAY DATA
- U-2528 TREATMENT OF CYSTIC FIBROSIS USING IVACAFTOR IN A PATIENT AGE 6 MONTHS TO <6 YEARS WHO HAS A R117H MUTATION IN THE CFTR GENE
- U-2529 TREATMENT OF A MODERATE MILD CLINICAL PHENOTYPE OF CF USING IVACAFTOR IN A PATIENT AGE 6 MONTHS TO <6 YEARS WHO HAS ONE CFTR MUTATION REPSONSIVE TO IVACAFTOR BASED ON CLINICAL AND/OR IN VITRO ASSAY DATA
- U-2530 TREATMENT OF CF IN A PATIENT AGE 6 MONTHS TO < 6 YEARS WHO HAS ONE CFTR MUTATION RESPONSIVE TO IVACAFTOR BASED ON CLINICAL AND/OR IN VITRO ASSAY DATA USING A SOLID COMPOSITION COMPRISING AMORPHOUS (LESS THAN ABOUT 30% CRYSTALLINE) IVACAFTOR
- U-2531 TREATMENT OF CF IN A PATIENT AGE 6 MONTHS TO <6 YEARS WHO HAS ONE MUTATION IN THE CFTR GENE THAT IS RESPONSIVE TO IVACAFTOR BASED ON CLINICAL AND/OR IN VITRO ASSAY DATA USING THE COMPOSITION RECITED IN CLAIM 1 OF US 10272046
- U-2532 TREATMENT OF CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1, 2, 3, 4, OR 6 IN ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER OR WEIGHING AT LEAST 45 KG
- U-2533 A METHOD OF TREATING A CANCER CHARACTERIZED BY AN IDH1 MUTATION WHERE THE CANCER IS RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (AML)
- U-2534 A METHOD OF TREATING A CANCER CHARACTERIZED BY AN IDH1 MUTATION WHERE THE CANCER IS NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML)
- U-2535 USE IN COMBINATION WITH METHYLPREDNISOLONE FOR THE TREATMENT OF PATIENTS WITH PROSTATE CANCER
- U-2536 FOR TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE
- U-2537 TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL)
- U-2538 TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LEUKEMIA (SLL) IN COMBINATION WITH A GA101 ANTIBODY SUCH AS OBINUTUZUMAB FOR ONE OR MORE DOSING PERIODS, WHEREIN THE CLL OR SLL IS A CD20-EXPRESSING CANCER
- U-2539 IN COMBINATION WITH FULVESTRANT FOR TREATMENT OF POSTMENOPAUSAL WOMEN, AND MEN, WITH HR-POSITIVE, HER-2-NEGATIVE, PIK3CA-MUTATED, ADVANCED OR METASTATIC BREAST CANCER
- U-2540 TREATMENT OF HORMONE RECEPTOR POSITIVE ADVANCED BREAST CANCER IN POSTMENOPAUSAL WOMEN
- U-2541 REDUCING THE RATE OF CARDIOVASCULAR DEATH, MYOCARDIAL INFARCTION (MI), AND STROKE IN A PATIENT RECEIVING 75-100 MG ASPIRIN DAILY WITH A HISTORY OF MI BY ADMINISTERING 60 MG TICAGRELOR TWICE DAILY
- U-2542 REDUCING THE RATE OF CARDIOVASCULAR DEATH, MYOCARDIAL INFARCTION, AND STROKE IN A PATIENT RECEIVING 75-100 MG ASPIRIN DAILY AND HAVING OR WHO HAD ACUTE CORONARY SYNDROME BY ADMINISTERING 60 MG TICAGRELOR TWICE DAILY
- U-2543 TREATMENT OF SCHIZOPHRENIA WITH CARIPRAZINE
- U-2544 TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER WITH CARIPRAZINE
- U-2545 TREATMENT OF DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR I DISORDER (BIPOLAR DEPRESSION) WITH CARIPRAZINE
- U-2546 USE FOR THE MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA
- U-2547 METHOD OF PROVIDING CONTRACEPTION IN A WOMAN HAVING A BMI OF 25 KG/M2 OR MORE WITH RESULTANT LIMITED BLEEDING EVENTS PER TREATMENT CYCLE

PATENT AND EXCLUSIVITY TERMS

ADB 151 of 191

PATENT USE

U-2548	TO IMPROVE WAKEFULNESS IN ADULT PATIENTS WITH EXCESSIVE DAYTIME SLEEPINESS ASSOCIATED WITH NARCOLEPSY OR OBSTRUCTIVE SLEEP APNEA (OSA)
U-2549	CONTROL OF SERUM PHOSPHORUS LEVELS
U-2550	USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PREVIOUSLY TREATED FOLLICULAR LYMPHOMA IN COMBINATION WITH A RITUXIMAB PRODUCT
U-2551	USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PREVIOUSLY TREATED MARGINAL ZONE LYMPHOMA IN COMBINATION WITH A RITUXIMAB PRODUCT
U-2552	METHOD OF TREATING POSTPARTUM DEPRESSION
U-2553	PREVENTION OF PREGNANCY IN FEMALES OF REPRODUCTIVE AGE
U-2554	TREATMENT OF MILD TO MODERATE ACTIVE CROHN'S DISEASE INVOLVING THE ILEUM AND/OR THE ASCENDING COLON
U-2555	A METHOD OF TREATING IRON DEFICIENCY ANEMIA IN ADULT PATIENTS WHO HAVE INTOLERANCE TO ORAL IRON OR HAVE HAD UNSATISFACTORY RESPONSE TO ORAL IRON BY INTRAVENOUSLY ADMINISTERING FERRIC CARBOXYMALTOSE TO PROVIDE AT LEAST ABOUT 0.6 G OF ELEMENTAL IRON
U-2556	METHOD OF TREATING IRON DEFICIENCY ANEMIA IN ADULTS WHO HAVE INTOLERANCE TO OR HAVE HAD UNSATISFACTORY RESPONSE TO ORAL IRON ASSOCIATED WITH HEAVY UTERINE BLEEDING OR A GASTROINTESTINAL DISORDER BY INTRAVENOUSLY ADMINISTERING FERRIC CARBOXYMALTOSE
U-2557	A METHOD OF TREATING IRON DEFICIENCY ANEMIA IN ADULT PATIENTS WHO HAVE NON-DIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE BY INTRAVENOUSLY ADMINISTERING FERRIC CARBOXYMALTOSE TO PROVIDE AT LEAST ABOUT 0.6 GRAMS OF ELEMENTAL IRON
U-2558	TREATMENT OF PATIENTS WITH LOCALLY ADVANCED METASTATIC BREAST CANCER AFTER FAILURE OF PRIOR CHEMOTHERAPY
U-2559	USE IN COMBINATION WITH DOXORUBICIN AND CYCLOPHOSPHAMIDE FOR ADJUVANT TREATMENT OF PATIENTS WITH OPERABLE NODE-POSITIVE BREAST CANCER
U-2560	TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER AFTER FAILURE OF PRIOR PLATINUM-BASED CHEMOTHERAPY
U-2561	USE IN COMBINATION WITH CISPLATIN FOR TREATMENT OF UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WITHOUT PRIOR CHEMOTHERAPY TREATMENT
U-2562	TREATMENT OF PATIENTS WITH ANDROGEN INDEPENDENT (HORMONE REFRACTORY) METASTATIC PROSTATE CANCER IN COMBINATION WITH PREDNISONE
U-2563	TREATMENT OF ADVANCED GASTRIC ADENOCARCINOMA IN COMBINATION WITH CISPLATIN AND FLUOROURACIL IN PATIENTS THAT HAVE NOT RECEIVED PRIOR CHEMOTHERAPY
U-2564	TREATMENT OF PATIENTS WITH LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK IN COMBINATION WITH CISPLATIN AND FLUOROURACIL
U-2565	TREATMENT OF HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA
U-2566	TREATMENT OF VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA
U-2567	ONCE DAILY TOPICAL TREATMENT OF PERSISTENT FACIAL ERYTHEMA ASSOCIATED WITH ROSACEA IN ADULTS WITH 1% OXYMETAZOLINE HYDROCHLORIDE CREAM, WHERE THE PATIENT EXPERIENCES NO REBOUND OR WORSENING OF FACIAL ERYTHEMA POST-TREATMENT
U-2568	TREATMENT OF HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD)
U-2569	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 6 YEARS AND OLDER, WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION OR HAVE AT LEAST ONE CFTR MUTATION THAT IS RESPONSIVE TO TEZACAFTOR/IVACAFTOR, WITH AN EFFECTIVE AMOUNT OF TEZACAFTOR AND IVACAFTOR
U-2570	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGES 6 AND OLDER, WHO HAVE TWO COPIES OF THE F508DEL MUTATION OR ONE F508DEL MUTATION AND A CFTR MUTATION PREDICTED TO BE RESPONSIVE TO TEZACAFTOR/IVACAFTOR, WITH THE COMPOSITION OF CLAIM 1 OF US 10,206,877
U-2571	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGES 6 AND OLDER, WHO HAVE TWO COPIES OF THE F508DEL MUTATION OR ONE F508DEL MUTATION AND A CFTR MUTATION PREDICTED TO BE RESPONSIVE TO TEZACAFTOR/IVACAFTOR, WITH THE COMPOSITION OF CLAIM 1 OF US 10,081,621
U-2572	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS 6 YEARS AND OLDER, WITH A F508DEL OR G551D CFTR GENE MUTATION AND A A455E, 2789+5G->, OR 3849+10KBC->T MUTATION, COMPRISING CONCURRENT COADMINISTRATION OF THE COMPOSITIONS OF CLAIM 1 OF U.S.

PATENT AND EXCLUSIVITY TERMS

ADB 152 of 191

PATENT USE

PATENT 10058546

- U-2573 TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 6 YEARS AND OLDER, WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION OR HETEROZYGOUS FOR F508DEL AND A SECOND CFTR MUTATION PREDICTED TO BE RESPONSIVE TO TEZACAFTOR/IVACAFTOR, WITH TEZACAFTOR AND IVACAFTOR
- U-2574 TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 6 AND OLDER, WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION OR HAVE AT LEAST ONE CFTR GENE MUTATION THAT IS RESPONSIVE TO TEZACAFTOR/IVACAFTOR, WITH TEZACAFTOR AND IVACAFTOR
- U-2575 TREATING CYSTIC FIBROSIS PATIENTS AGES 6 AND OLDER, WHO ARE HOMOZYGOUS FOR F508DEL OR HAVE AT LEAST 1 CFTR GENE MUTATION RESPONSIVE TO TEZACAFTOR/IVACAFTOR, WITH TEZACAFTOR AND A SOLID COMPOSITION COMPRISING AMORPHOUS (<30% CRYSTALLINE) IVACAFTOR
- U-2576 TREATMENT OF COMMUNITY ACQUIRED BACTERIAL PNEUMONIA
- U-2577 TREATMENT OF THROMBOCYTOPENIA IN AN ADULT PATIENT WITH CHRONIC IMMUNE THROMBOCYTOPENIA WHO HAS HAD AN INSUFFICIENT RESPONSE TO A PREVIOUS TREATMENT
- U-2578 TREATMENT OF THROMBOCYTOPENIA IN AN ADULT PATIENT WITH CHRONIC LIVER DISEASE WHO IS SCHEDULED TO UNDERGO A PROCEDURE
- U-2579 REDUCTION IN A SUBJECT'S RISK OF EXPERIENCING A BREAKTHROUGH OVERT HEPATIC ENCEPHALOPATHY (HE) EPISODE
- U-2580 A METHOD OF TREATING TYPE 2 DIABETES COMPRISING ADMINISTERING SEMAGLUTIDE ONCE WEEKLY IN A AMOUNT OF 1.0 MG TO A SUBJECT IN NEED THEREOF
- U-2581 TREATING HYPOTENSION WITH ABOUT 20 NG/KG/MIN TO ABOUT 40 NG/KG/MIN ANGIOTENSIN II IN A HUMAN SUBJECT HAVING SEPTIC SHOCK
- U-2582 FOR THE ORAL PREVENTION/PROPHYLAXIS OF MALARIA IN ADULTS, COMPRISING A THREE-PHASE DOSING REGIMEN CONSISTING OF A LOADING/INITIAL DOSE, A MAINTENANCE/EXPOSURE DOSE, AND A TERMINAL/POST-EXPOSURE DOSE
- U-2583 TREATMENT OF BACTERIAL VAGINOSIS IN ADULT WOMEN
- U-2584 XPOVIO IS INDICATED IN COMBINATION WITH DEXAMETHASONE TO TREAT RELAPSED OR REFRACTORY MULTIPLE MYELOMA (REFRACTORY TO AT LEAST AN ANTI-CD38 MAB, 2 PROTEASOME INHIBITORS AND 2 IMMUNOMODULATORY AGENTS) IN ADULTS WHO RECEIVED AT LEAST 4 PRIOR THERAPIES
- U-2585 TREATMENT OF PARENTERAL NUTRITION-ASSOCIATED CHOLESTASIS IN PATIENTS UNDER THE AGE OF 12
- U-2586 TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS, INCLUDING PYELONEPHRITIS (CUTI)
- U-2587 TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS (CIAI)
- U-2588 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH DAPAGLIFLOZIN AND METFORMIN
- U-2589 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH BASAL INSULIN OR BASAL INSULIN PLUS METFORMIN
- U-2590 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN, A SULFONYLUREA, A THIAZOLIDINEDIONE, OR COMBINATION OF ANY TWO OF THESE THERAPIES
- U-2591 LOWERING PLASMA GLUCAGON IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING EXENATIDE AS AN ADJUNCT TO DIET AND EXERCISE
- U-2592 IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING A SUSTAINED-RELEASE EXENATIDE FORMULATION AS AN ADJUNCT TO DIET AND EXERCISE
- U-2593 IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN EXENATIDE FORMULATION ONCE WEEKLY AS AN ADJUNCT TO DIET AND EXERCISE TO ACHIEVE A MEAN STEADY STATE PLASMA CONCENTRATION OF EXENATIDE AT LEAST 170 PG/ML
- U-2594 REDUCING FASTING PLASMA GLUCOSE IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN EXENATIDE FORMULATION ONCE WEEKLY AS AN ADJUNCT TO DIET AND EXERCISE TO ACHIEVE A MEAN STEADY STATE PLASMA CONCENTRATION OF EXENATIDE AT LEAST 170 PG/ML
- U-2595 REDUCING BODY WEIGHT IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN EXENATIDE FORMULATION ONCE WEEKLY AS AN ADJUNCT TO DIET AND EXERCISE TO ACHIEVE

PATENT AND EXCLUSIVITY TERMS

ADB 153 of 191

PATENT USE

	A MEAN STEADY STATE PLASMA CONCENTRATION OF EXENATIDE AT LEAST 170 PG/ML
U-2596	REDUCING HBA1C IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN EXENATIDE FORMULATION ONCE WEEKLY AS AN ADJUNCT TO DIET AND EXERCISE TO ACHIEVE A MEAN STEADY STATE PLASMA CONCENTRATION OF EXENATIDE AT LEAST 170 PG/ML
U-2597	AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH DAPAGLIFLOZIN AS ADD-ON TO METFORMIN
U-2598	IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN INJECTABLE SUSTAINED RELEASE FORMULATION OF EXENATIDE AS AN ADJUNCT TO DIET AND EXERCISE
U-2599	IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN EXENATIDE FORMULATION AS AN ADJUNCT TO DIET AND EXERCISE TO PROVIDE A RELEASE PROFILE HAVING A RATIO OF C-MAX TO C-AVG OF ABOUT 3 OR LESS
U-2600	IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING A PRE-MIXED EXENATIDE FORMULATION AS AN ADJUNCT TO DIET AND EXERCISE
U-2601	STIMULATING INSULIN RELEASE IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING A PRE-MIXED EXENATIDE FORMULATION AS AN ADJUNCT TO DIET AND EXERCISE
U-2602	DELAYING GASTRIC EMPTYING IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING A PRE-MIXED EXENATIDE FORMULATION AS AN ADJUNCT TO DIET AND EXERCISE
U-2603	METHOD OF TREATING IRON DEFICIENCY
U-2604	TREATMENT OF SEVERE HYPOGLYCEMIA IN PATIENTS WITH DIABETES
U-2605	TREATMENT OF PATIENTS WITH NON-METASTATIC CASTRATION RESISTANT PROSTATE CANCER
U-2606	TREATMENT OF ADULT PATIENTS WITH SYMPTOMATIC TENOSYNOVIAL GIANT CELL TUMOR (TGCT) ASSOCIATED WITH SEVERE MORBIDITY OR FUNCTIONAL LIMITATIONS AND NOT AMENABLE TO IMPROVEMENT WITH SURGERY
U-2607	TREATMENT OF ADULT PATIENTS WITH INTERMEDIATE-2 OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS
U-2608	METHOD OF TREATING SCHIZOPHRENIA
U-2609	A METHOD FOR INDUCING A REGIONAL ANAESTHESIA VIA INTRATHECAL ADMINISTRATION OF A PATENTED PRESERVATIVE FREE SOLUTION FOR INJECTION (WITH A SPECIFIC COMPOSITION, PH, OSMOLALITY AND DENSITY) CONTAINING 9-11 MG/ML CHLOROPROCAINE HCL
U-2610	TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTION IN PATIENTS WITH END-STAGE RENAL DISEASE ON HEMODIALYSIS
U-2611	TREATMENT OF COMPLICATED URINARY TRACT INFECTION IN PATIENTS WITH END-STAGE RENAL DISEASE ON HEMODIALYSIS
U-2612	TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN PATIENTS 10 YEARS OF AGE AND OLDER
U-2613	TREATMENT OF RELAPSING-REMITTING SCLEROSIS (MS)
U-2614	TREATMENT OF MODERATE TO SEVERE DYSpareunia
U-2615	TREATMENT OF NON-24 HOUR SLEEP-WAKE DISORDER BY AVOIDING THE ADMINISTRATION OF TASIMELTEON WITH FOOD
U-2616	TREATMENT OF ADULTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO METHOTREXATE
U-2617	TREATMENT OF ROS1-POSITIVE NON-SMALL CELL LUNG CANCER
U-2618	TREATMENT OF SOLID TUMORS THAT HAVE A NEUROTROPHIC TYROSINE RECEPTOR KINASE (NTRK) GENE FUSION
U-2619	TREATMENT OF ADULTS WITH COMMUNITY-ACQUIRED BACTERIAL PNEUMONIA CAUSED BY SUSCEPTIBLE MICROORGANISMS
U-2620	USE OF NINTEDANIB FOR SLOWING THE RATE OF DECLINE IN PULMONARY FUNCTION IN PATIENTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE (SSC-ILD)
U-2621	MODIFIED DOSING REGIMEN FOR THE MANAGEMENT OF MILD TO MODERATE PAIN
U-2622	TREATMENT OF ACUTE UNCOMPLICATED INFLUENZA IN PATIENTS 2 YEARS AND OLDER

PATENT AND EXCLUSIVITY TERMS

ADB 154 of 191

PATENT USE

U-2623	A METHOD OF REDUCING OFF TIME FROM L-DOPA THERAPY, COMPRISING ADMINISTERING, TO A HUMAN PATIENT WITH PARKINSON'S DISEASE, AN EFFECTIVE AMOUNT OF ISTRADEFYLLINE, WHEREIN THE PATIENT CURRENTLY RECEIVES SAID L-DOPA THERAPY
U-2624	TREATMENT OF METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (MCSPC)
U-2625	TOPICAL TREATMENT OF PLAQUE PSORIASIS IN ADULTS
U-2626	METHOD OF TREATING IRRITABLE BOWEL SYNDROME WITH CONSTIPATION BY ADMINISTERING TENAPANOR
U-2627	TOPICAL TREATMENT OF PLAQUE PSORIASIS IN PATIENTS 12 YEARS AND OLDER
U-2628	METHOD OF TREATING TYPE 2 DIABETES MELLITUS
U-2629	TREATMENT OF HIV-1 INFECTION IN ADULT PATIENTS AS A REPLACEMENT THERAPY IN VIROLOGICALLY SUPPRESSED ADULTS WITH NO HISTORY OF TREATMENT FAILURE AND NO KNOWN SUBSTITUTIONS ASSOCIATED WITH RESISTANCE TO THE INDIVIDUAL COMPONENTS OF DELSTRIGO
U-2630	FOR USE IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS FOR THE TREATMENT OF HIV-1 AS A REPLACEMENT THERAPY IN VIROLOGICALLY SUPPRESSED ADULTS WITH NO HISTORY OF TREATMENT FAILURE AND NO KNOWN SUBSTITUTIONS ASSOCIATED WITH RESISTANCE TO DORAVIRINE
U-2631	TREATMENT OF COMPLICATED URINARY TRACT INFECTION
U-2632	REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
U-2633	TREATMENT OF ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER, PROGRESSED ON: CRIZOTINIB + AT LEAST 1 OTHER ALK INHIBITOR FOR METASTATIC DISEASE; OR ALECTINIB, OR CERITINIB AS FIRST ALK INHIBITOR FOR METASTATIC DISEASE.
U-2634	METHOD OF TREATMENT IN PATIENTS WITH CONCOMITANT ANGIOEDEMA
U-2635	TREATMENT OF ACUTE URTICARIA
U-2636	METHOD OF INCREASING PEAK PLASMA OR ONSET OF PLASMA CONCENTRATION BY INTRAVENOUS INJECTION IN INDIVIDUALS IN NEED OF TREATMENT FOR ACUTE URTICARIA
U-2637	TREATMENT OF PATIENTS WITH AN OVERACTIVE BLADDER WITH SYMPTOMS OF URINARY FREQUENCY, URGENCY, OR URGE INCONTINENCE WITH A SINGLE UNIT DOSE OF 10% OXYBUTYNIN CHLORIDE GEL
U-2638	INCREASE PAIN-FREE LIGHT EXPOSURE IN ADULT PATIENTS WITH A HISTORY OF PHOTOTOXIC REACTIONS FROM ERYTHROPOIETIC PROTOPORPHYRIA (EPP)
U-2639	METHOD OF ACTIVATING RARGAMMA RECEPTOR
U-2640	PROPHYLAXIS OF VENOUS THROMBOEMBOLISM IN ACUTELY ILL MEDICAL PATIENTS AT RISK FOR THROMBOEMBOLIC COMPLICATIONS NOT AT HIGH RISK OF BLEEDING
U-2641	PROPHYLAXIS OF VENOUS THROMBOEMBOLISM IN ACUTELY ILL MEDICAL PATIENTS AT RISK FOR THROMBOEMBOLIC COMPLICATIONS NOT AT HIGH RISK OF BLEEDING WITH ONCE DAILY, RAPID-RELEASE TABLET ADMINISTERED FOR AT LEAST 5 CONSECUTIVE DAYS
U-2642	METHOD OF TREATING CANCER BY DETECTING A CREATININE CLEARANCE OF A PATIENT AND ADMINISTERING LONSURF
U-2643	TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) IN ADULTS 65 YEARS OF AGE OR OLDER AND SYMPTOMS THEREOF
U-2644	TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) IN ADULTS 65 YEARS OF AGE OR OLDER
U-2645	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 12 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE WITH ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR
U-2646	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 12 YEARS AND OLDER WHO HAVE ONE F508DEL MUTATION AND ONE R117H MUTATION IN THE CFTR GENE WITH ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR
U-2647	TREATMENT OF NON-NODULAR ACNE VULGARIS
U-2648	TREATMENT OF A MODERATE TO MILD CLINICAL PHENOTYPE OF CF IN PATIENTS AGED 12 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE WITH ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR
U-2649	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 12 YEARS AND OLDER WHO HAVE AT

PATENT AND EXCLUSIVITY TERMS

ADB 155 of 191

PATENT USE

LEAST ONE F508DEL MUTATION IN THE CFTR GENE WITH A COMPOSITION COMPRISING ELEXACFTOR, TEZACFTOR, AND IVACFTOR; AND ANOTHER COMPOSITION COMPRISING IVACFTOR

- U-2650 TREATMENT OF CF IN PATIENTS AGED 12 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE USING A SOLID COMPOSITION COMPRISING ELEXACFTOR, TEZACFTOR, AMORPHOUS IVACFTOR, AND LESS THAN ABOUT 30% CRYSTALLINE IVACFTOR
- U-2651 TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 12 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE WITH AN EFFECTIVE AMOUNT OF A PHARMACEUTICAL COMPOSITION COMPRISING ELEXACFTOR, TEZACFTOR, AND IVACFTOR
- U-2652 TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 12 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE WITH A COMPOSITION ACCORDING TO CLAIM 1 OF US 10081621
- U-2653 TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 12 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE WITH AN EFFECTIVE AMOUNT OF ELEXACFTOR, TEZACFTOR, AND IVACFTOR
- U-2654 TREATMENT OF REFRACTORY CHRONIC GRAFT-VERSUS-HOST DISEASE
- U-2655 A METHOD OF TREATMENT OF ADVANCED OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER ASSOCIATED WITH HOMOLOGOUS RECOMBINATION DEFICIENCY (HRD) POSITIVE STATUS
- U-2656 TREATMENT OF ADULT PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS
- U-2657 TREATMENT OF PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS WHO ARE CANDIDATES FOR PHOTOTHERAPY OR SYSTEMIC THERAPY
- U-2658 TREATMENT OF ADULT PATIENTS WITH ORAL ULCERS ASSOCIATED WITH BEHCET'S DISEASE
- U-2659 TREATMENT OF ADULT PATIENTS WITH ORAL ULCERS ASSOCIATED WITH BEHCET'S DISEASE USING A DOSAGE TITRATION SCHEDULE
- U-2660 TREATMENT OF H. PYLORI INFECTION IN ADULTS
- U-2661 CHRONIC WEIGHT MANAGEMENT IN ADULT PATIENTS USING AN EXTENDED RELEASE TABLET CONTAINING LORCARSERIN HYDROCHLORIDE HEMIHYDRATE
- U-2662 USE OF CALCIPOTRIENE FOAM FOR THE TOPICAL TREATMENT OF PLAQUE PSORIASIS IN PATIENTS AGED 4 YEARS AND OLDER
- U-2663 USE IN SONOHYSTEROSALPINOGRAPHY TO ASSESS FALLOPIAN TUBE PATENCY
- U-2664 TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) IN PATIENTS HAVING A MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 51 SKIPPING BY INDUCING SKIPPING OF EXON 51
- U-2665 TREATMENT OF CHRONIC GRAFT VERSUS HOST DISEASE AFTER FAILURE OF ONE OR MORE LINES OF SYSTEMIC THERAPY
- U-2666 TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
- U-2667 TREATMENT OF ADULT PATIENTS WITH SMALL LYMPHOCYTIC LEUKEMIA
- U-2668 TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA IN COMBINATION WITH OBINUTUZUMAB
- U-2669 TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY UNTREATED SMALL LYMPHOCYTIC LEUKEMIA IN COMBINATION WITH OBINUTUZUMAB
- U-2670 TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LEUKEMIA
- U-2671 TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LEUKEMIA IN COMBINATION WITH OBINUTUZUMAB
- U-2672 TREATMENT OF ACUTE HEPATIC PORPHYRIA
- U-2673 TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) IN PATIENTS HAVING A MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 51 SKIPPING BY CORRECTING A DEFECTIVE GENE FOR DYSTROPHIN
- U-2674 TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) IN PATIENTS HAVING A MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 51 SKIPPING BY RESTORING OR INCREASING FUNCTIONAL DYSTROPHIN PROTEIN PRODUCTION
- U-2675 TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) IN PATIENTS HAVING A CONFIRMED MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 53 SKIPPING
- U-2676 TREATMENT OF SICKLE CELL DISEASE BY ADMINISTERING VOXELOTOR, AS RECITED IN CLAIM 1

PATENT AND EXCLUSIVITY TERMS

ADB 156 of 191

PATENT USE

U-2677	PROPHYLAXIS OF ORGAN REJECTION IN PATIENTS CONVERTED FROM TACROLIMUS IMMEDIATE-RELEASE FORMULATIONS
U-2678	PROPHYLAXIS OF ORGAN REJECTION IN DE NOVO TRANSPLANT PATIENT
U-2679	TREATING LOW BLOOD PRESSURE WITH ANGIOTENSIN II AT AN INITIAL RATE OF ABOUT 20 NG/KG/MIN AND TITRATING DOWN TO ACHIEVE AND/OR MAINTAIN A MAP OF ABOUT 65 MM HG OR ABOVE
U-2680	TREATING LOW BLOOD PRESSURE WITH ANGIOTENSIN II WITH AN INITIAL RATE OF ABOUT 5 NG/KG/MIN TO ABOUT 20 NG/KG/MIN IN A SUBJECT HAVING REFRACTORY HYPOTENSION OR SEVERE HYPOTENSION
U-2681	TREATING LOW BLOOD PRESSURE WITH ANGIOTENSIN II WITH AN INITIAL RATE OF ABOUT 5 NG/KG/MIN TO ABOUT 20 NG/KG/MIN IN A SUBJECT HAVING REFRACTORY HYPOTENSION OR SEVERE HYPOTENSION, AND TITRATING THE RATE UP
U-2682	TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA BY ADMINISTERING 100MG OF ACALABRUTINIB TWICE DAILY
U-2683	TREATMENT OF ADULT PATIENTS WITH SMALL LYMPHOCYTIC LEUKEMIA BY ADMINISTERING 100MG OF ACALABRUTINIB TWICE DAILY
U-2684	TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA BY ADMINISTERING 100 MG OF ACALABRUTINIB TWICE DAILY IN COMBINATION WITH OBINUTUZUMAB
U-2685	TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY UNTREATED SMALL LYMPHOCYTIC LEUKEMIA BY ADMINISTERING 100 MG OF ACALABRUTINIB TWICE DAILY IN COMBINATION WITH OBINUTUZUMAB
U-2686	TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LEUKEMIA BY ADMINISTERING 100 MG OF ACALABRUTINIB TWICE DAILY
U-2687	TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LEUKEMIA IN COMBINATION WITH OBINUTUZUMAB BY ADMINISTERING 100 MG OF ACALABRUTINIB TWICE DAILY
U-2688	USE OF VASCEPA TO LOWER TRIGLYCERIDES AND LDL-C IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE (TG) LEVELS (ABOUT 200 MG/DL TO LESS THAN ABOUT 500 MG/DL) AND ON STATIN THERAPY
U-2689	USE OF VASCEPA TO TREAT MIXED DYSLIPIDEMIA IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE (TG) LEVELS ($\geq$ 150 MG/DL) AND ON STATIN THERAPY
U-2690	USE OF VASCEPA TO LOWER TRIGLYCERIDES IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE (TG) LEVELS (ABOUT 200 MG/DL TO LESS THAN ABOUT 500 MG/DL) AND ON STATIN THERAPY
U-2691	USE OF VASCEPA TO TREAT HYPERTRIGLYCERIDEMIA IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE (TG) LEVELS ($\geq$ 150 MG/DL) AND ON STATIN THERAPY
U-2692	USE OF VASCEPA TO REDUCE TRIGLYCERIDES IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE (TG) LEVELS ($\geq$ 150 MG/DL) AND ON STATIN THERAPY
U-2693	USE OF VASCEPA TO REDUCE TRIGLYCERIDES IN A MIXED DYSLIPIDEMIA ADULT PATIENT WITH ELEVATED TRIGLYCERIDE (TG) LEVELS ($\geq$ 150 MG/DL) AND ON STATIN THERAPY
U-2694	USE OF VASCEPA TO LOWER TRIGLYCERIDES IN A MIXED DYSLIPIDEMIA ADULT PATIENT WITH ELEVATED TRIGLYCERIDE (TG) LEVELS (ABOUT 200 MG/DL TO LESS THAN ABOUT 500 MG/DL) AND ON STATIN THERAPY
U-2695	USE OF VASCEPA TO TREAT MIXED HYPERTRIGLYCERIDEMIA IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE (TG) LEVELS ($\geq$ 150 MG/DL) AND ON STATIN THERAPY
U-2696	USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF CARDIOVASCULAR DEATH, CORONARY REVASCULARIZATION, AND UNSTABLE ANGINA IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE LEVELS (TG $\geq$ 150 MG/DL TO ABOUT 500 MG/DL)
U-2697	USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF CARDIOVASCULAR DEATH AND/OR UNSTABLE ANGINA IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE LEVELS (TG $\geq$ 150 MG/DL TO ABOUT 500 MG/DL)
U-2698	USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF CARDIOVASCULAR DEATH AND/OR CORONARY REVASCULARIZATION IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE LEVELS (TG $\geq$ 150 MG/DL TO ABOUT 500 MG/DL)
U-2699	USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF A CARDIOVASCULAR EVENT (CORONARY REVASCULARIZATION, UNSTABLE ANGINA, STROKE AND/OR MYOCARDIAL INFARCTION) IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE LEVELS

PATENT AND EXCLUSIVITY TERMS

ADB 157 of 191

PATENT USE

U-2700	USE OF VASCEPA TO REDUCE TRIGLYCERIDES IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE (TG) LEVELS (ABOUT 200 MG/DL TO LESS THAN ABOUT 500 MG/DL) AND ON ROSUVASTATIN THERAPY
U-2701	USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF CORONARY REVASCULARIZATION AND/OR UNSTABLE ANGINA IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE LEVELS (TG >= 150 MG/DL TO ABOUT 500 MG/DL)
U-2702	USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF A CARDIOVASCULAR EVENT (CARDIOVASCULAR DEATH, CORONARY REVASCULARIZATION AND/OR UNSTABLE ANGINA) IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE LEVELS
U-2703	USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF A CV EVENT (CV DEATH, CORONARY REVASCULARIZATION, UNSTABLE ANGINA, STROKE AND/OR MYOCARDIAL INFARCTION) IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE LEVELS AND DIABETES MELLITUS
U-2704	USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF A CARDIOVASCULAR EVENT IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE LEVELS AND AT LEAST ONE RISK FACTOR FOR CARDIOVASCULAR DISEASE
U-2705	METHOD OF USING CAPSAICIN IN COMBINATION WITH A GEL COMPOSITION FOR REMOVAL OF CAPSAICIN FROM A TREATMENT AREA OR UNINTENDED AREA
U-2706	USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF ONSET AND/OR RECURRENCE OF CARDIOVASCULAR EVENTS IN A PATIENT WHO HAS ESCAPED THE UNSTABLE PERIOD AFTER CARDIOVASCULAR ANGIOPLASTY
U-2707	USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE OCCURRENCE OF A CARDIOVASCULAR EVENT IN AN ADULT PATIENT WITH HYPERCHOLESTEROLEMIA
U-2708	THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER
U-2709	A METHOD OF TREATING IRON DEFICIENCY ANEMIA IN ADULT PATIENTS WHO HAVE INTOLERANCE TO ORAL IRON OR HAVE HAD UNSATISFACTORY RESPONSE TO ORAL IRON BY INTRAVENOUSLY ADMINISTERING FERRIC CARBOXYMALTOSE
U-2710	A METHOD OF TREATING IRON DEFICIENCY ANEMIA IN ADULT PATIENTS WHO HAVE NON-DIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE BY INTRAVENOUSLY ADMINISTERING FERRIC CARBOXYMALTOSE
U-2711	A METHOD OF TREATING IRON DEFICIENCY ANEMIA IN ADULT PATIENTS WHO HAVE INTOLERANCE TO ORAL IRON OR HAVE HAD UNSATISFACTORY RESPONSE TO ORAL IRON BY INTRAVENOUSLY ADMINISTERING FERRIC CARBOXYMALTOSE TO PROVIDE 750 MG OF ELEMENTAL IRON
U-2712	A METHOD OF TREATING IRON DEFICIENCY ANEMIA IN ADULT PATIENTS WHO HAVE NON-DIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE BY INTRAVENOUSLY ADMINISTERING FERRIC CARBOXYMALTOSE TO PROVIDE 750 MG OF ELEMENTAL IRON
U-2713	MODULATION OF 5-HYDROXYTRYPTAMINE 2 RECEPTOR ACTIVITY IN SCHIZOPHRENIA
U-2714	TREATMENT OF SCHIZOPHRENIA WITH IMPROVEMENT IN RESIDUAL SYMPTOMS OF SCHIZOPHRENIA
U-2715	TREATMENT OF SICKLE CELL DISEASE BY ADMINISTERING VOXELOTOR, AS RECITED IN CLAIM 2
U-2716	MAINTENANCE TREATMENT OF DELETERIOUS OR SUSPECTED DELETERIOUS GBRCA-MUTATED METASTATIC PANCREATIC ADENOCARCINOMA WHOSE DISEASE HAS NOT PROGRESSED ON AT LEAST 16 WEEKS OF A FIRST-LINE PLATINUM-BASED CHEMOTHERAPY REGIMEN
U-2717	ACUTE TREATMENT OF MIGRAINE WITH HEADACHE, WITH OR WITHOUT AURA IN ADULTS
U-2718	ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN ADULTS
U-2719	TREATMENT OF RELAPSING REMITTING MULTIPLE SCLEROSIS BY DETERMINING VARICELLA ZOSTER VIRUS (VZV) STATUS AND VACCINATING PRIOR TO COMMENCING TREATMENT
U-2720	ANTIMYCOTIC USES, SPECIFICALLY TREATMENT OF ONYCHOMYCOSIS; TOPICAL TREATMENT OF THE TOENAIL(S) DUE TO TRICHOPHYTON RUBRUM AND TRICHOPHYTON MENTAGROPHYTES
U-2721	TOPICAL TREATMENT OF TINEA UNGUIUM BY USING AN APPLICATOR FOR APPLYING A SOLUTION FOR TREATING TINEA UNGUIUM TO AN AFFECTED PART OF A PATIENT
U-2722	METHOD OF INTRAVENOUSLY ADMINISTERING A DILUTED CYSTEINE HYDROCHLORIDE SOLUTION TO A NEONATE IN NEED THEREOF
U-2723	MAINTENANCE MONOTHERAPY TREATMENT OF BIPOLAR 1 DISORDER
U-2724	A METHOD OF ORAL DELIVERY OF TREPROSTINIL COMPRISING ADMINISTERING AN ORAL OSMOTIC PHARMACEUTICAL DOSAGE FORM

PATENT AND EXCLUSIVITY TERMS

ADB 158 of 191

PATENT USE

U-2725	A METHOD OF TREATING PULMONARY HYPERTENSION AND PULMONARY ARTERIAL HYPERTENSION BY ADMINISTERING AN ORAL OSMOTIC PHARMACEUTICAL DOSAGE FORM
U-2726	TREATMENT OF UNRESECTABLE OR METASTATIC GASTROINTESTINAL STROMAL TUMOR (GIST) HARBORING A PLATELET-DERIVED GROWTH FACTOR RECEPTOR ALPHA (PDGFRA) EXON 18 MUTATION
U-2727	NASAL ADMINISTRATION OF DIAZEPAM FOR TREATMENT OF INTERMITTENT, STEREOTYPIC EPISODES OF FREQUENT SEIZURE ACTIVITY IN PATIENTS 6 YEARS OF AGE AND OLDER
U-2728	USE OF PEMETREXED WITH PRIOR AND/OR REPEATED VITAMIN B12 AND FOLIC ACID ADMINISTRATION IN PATIENTS WITH NON-SQUAMOUS NON-SMALL CELL LUNG CANCER
U-2729	USE OF PEMETREXED WITH PRIOR AND/OR REPEATED VITAMIN B12 AND FOLIC ACID ADMINISTRATION IN PATIENTS WITH MESOTHELIOMA
U-2730	METHOD OF TREATING TYPE 2 DIABETES MELLITUS USING A PHARMACEUTICAL COMPOSITION COMPRISING EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN
U-2731	METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN IN COMBINATION WITH LINAGLIPTIN AND METFORMIN
U-2732	METHOD OF TREATING TYPE 2 DIABETES USING A PHARMACEUTICAL COMPOSITION COMPRISING LINAGLIPTIN, METFORMIN, EMPAGLIFLOZIN AND A BASIC AMINO ACID
U-2733	METHOD OF TREATING A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE THERAPY WITH METFORMIN USING A PHARMACEUTICAL COMPOSITION COMPRISING EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN
U-2734	METHOD OF TREATMENT OF IRON DEFICIENCY ANEMIA IN ADULT PATIENTS WHO HAVE INTOLERANCE TO ORAL IRON OR HAVE HAD UNSATISFACTORY RESPONSE TO ORAL IRON, WHO HAVE NON-HEMODIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE, BY ADMINISTERING FERRIC DERISOMALTOSE
U-2735	MANAGEMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH ENDOMETRIOSIS USING 150MG ELAGOLIX WHILE CO-ADMINISTERING RIFAMPIN
U-2736	METHOD OF TREATING EPITHELIOID SARCOMA
U-2737	METHOD OF TREATING EPITHELIOID SARCOMA BY INHIBITING ENHANCER OF ZESTE HOMOLOG 2 (EZH2)
U-2738	METHOD OF TREATING A LUNG METASTASIS OF EPITHELIOID SARCOMA
U-2739	INCREASING BLOOD PRESSURE WITH AN INITIAL RATE OF ABOUT 20 NG/KG/MIN ANGIOTENSIN II IN A HUMAN SUBJECT HAVING SEPTIC SHOCK, AND TITRATING THE RATE UP.
U-2740	INCREASING BLOOD PRESSURE WITH A RATE OF ABOUT 20 NG/KG/MIN TO ABOUT 40 NG/KG/MIN ANGIOTENSIN II IN A HUMAN SUBJECT HAVING SEPTIC SHOCK
U-2741	TREATMENT OF CLOSTRIDIODES DIFFICILE-ASSOCIATED DIARRHEA (CDAD) IN PATIENTS FROM 6 MONTHS OF AGE AND OLDER
U-2742	TREATMENT OF SEVERE HYPOGLYCEMIA
U-2743	USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF UNSTABLE ANGINA IN AN ADULT PATIENT WITH ESTABLISHED CARDIOVASCULAR DISEASE
U-2744	USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF STROKE IN AN ADULT PATIENT WITH ESTABLISHED CARDIOVASCULAR DISEASE
U-2745	TREATMENT OF NEUROBLASTOMAS THAT HAVE A NEUROTROPHIC TYROSINE RECEPTOR KINASE (NTRK) GENE FUSION
U-2746	USE OF NEXLIZET AS AN ADJUNCT TO DIET AND MAXIMALLY TOLERATED STATIN THERAPY TO LOWER LDL-C IN ADULTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA OR ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE
U-2747	USE OF NEXLETOL AS AN ADJUNCT TO DIET AND MAXIMALLY TOLERATED STATIN THERAPY TO LOWER LDL-C IN ADULTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA OR ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE
U-2748	USE OF NEXLETOL AS AN ADJUNCT TO DIET AND MAXIMALLY TOLERATED STATIN THERAPY FOR INHIBITING CHOLESTEROL SYNTHESIS TO LOWER LDL-C IN ADULTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA OR ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE
U-2749	USE OF NEXLIZET AS AN ADJUNCT TO DIET AND MAXIMALLY TOLERATED STATIN THERAPY FOR INHIBITING CHOLESTEROL SYNTHESIS TO LOWER LDL-C IN ADULTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA OR ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE

PATENT AND EXCLUSIVITY TERMS

ADB 159 of 191

PATENT USE

U-2750 MANAGEMENT OF MODERATE-TO-SEVERE PAIN BY INTRAVENOUS INJECTION

U-2751 A TRANSDERMAL METHOD OF CONTRACEPTION

U-2752 METHOD OF USING L-CYSTEINE IN AN ADMIXTURE FOR TREATING PATIENTS NEEDING PARENTERAL NUTRITION

U-2753 INCREASING SURVIVAL IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS PREVIOUSLY TREATED WITH DOCETAXEL BY ADMINISTERING AS A 3 WEEK CYCLE CABAZITAXEL AFTER 5 MG DEXCHLORPHENIRAMINE, 8 MG DEXAMETHASONE, AND AN H2-AGONIST

U-2754 TREATMENT OF POST-OPERATIVE NAUSEA AND VOMITING

U-2755 OCULAR EXAMINATION, INTRAOCULAR PRESSURE MEASUREMENT, OR REMOVAL OF FOREIGN BODIES OR SUTURES, IN ADULT AND PEDIATRIC PATIENTS REQUIRING A DISCLOSING AGENT IN COMBINATION WITH A TOPICAL OPHTHALMIC ANESTHETIC

U-2756 USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF CARDIOVASCULAR DEATH IN AN ADULT PATIENT WITH ESTABLISHED CARDIOVASCULAR DISEASE

U-2757 DOSING REGIMEN FOR THE TREATMENT OF SCHIZOPHRENIA IN ADULTS BY ADMINISTERING TWO LOADING DOSES OF PALIPERIDONE PALMITATE FOLLOWED BY MAINTENANCE DOSE(S)

U-2758 DOSING REGIMEN FOR THE TREATMENT OF SCHIZOAFFECTIVE DISORDER IN ADULTS AS A MONOTHERAPY AND AS AN ADJUNCT TO MOOD STABILIZERS OR ANTIDEPRESSANTS BY ADMINISTERING TWO LOADING DOSES OF PALIPERIDONE PALMITATE FOLLOWED BY MAINTENANCE DOSE(S)

U-2759 REDUCTION OF INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH OPEN ANGLE GLAUCOMA(OAG) OR OCULAR HYPERTENSION (OHT) WITH A BIODEGRADABLE BIMATOPROST IMPLANT

U-2760 TOPICAL TREATMENT OF ACNE VULGARIS IN PATIENTS 12 YEARS OF AGE OR OLDER

U-2761 INTRAVENOUS SOTALOL DOSING REGIMEN FOR ACHIEVING STEADY STATE CONCENTRATION (EXPOSURE) FASTER COMPARED TO THE CONVENTIONAL ORAL DOSING IN A FACILITY THAT CAN PROVIDE ELECTROCARDIOGRAPHIC MONITORING

U-2762 USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF A MAJOR CARDIOVASCULAR EVENT IN AN ADULT PATIENT WITH DIABETES MELLITUS AND TWO OR MORE ADDITIONAL RISK FACTORS FOR CARDIOVASCULAR DISEASE

U-2763 METHOD OF TREATING ADULTS WITH SCHIZOPHRENIA COMPRISING ADMINISTERING ASENAPINE VIA A TRANSDERMAL PATCH

U-2764 TREATMENT OF POST-OPERATIVE INFLAMMATION AND PAIN FOLLOWING OCULAR SURGERY

U-2765 TREATMENT OF HIV-1 INFECTION IN ADULTS AND PEDIATRIC PATIENTS WEIGHING AT LEAST 40 KG WHO HAVE NO PRIOR ANTIRETROVIRAL TREATMENT HISTORY OR ARE VIROLOGICALLY SUPPRESSED ON A STABLE ANTIRETROVIRAL REGIMEN FOR AT LEAST 6 MONTHS

U-2766 TX OF HIV1 INFECTION USING A COMPOSITION CONTAINING A PK ENHANCER THAT INHIBITS CY P450 MONOOXYGENASE IN ADULTS & PEDIATRIC PATIENTS AT LEAST 40KG HAVING NO PRIOR ARV TX HISTORY OR ARE VIROLOGICALLY SUPPRESSED ON A STABLE ARV REGIMEN FOR AT LEAST 6 MO

U-2767 TREATMENT OF HIV-1 INFECTION USING A COMPOSITION CONTAINING A PK ENHANCER THAT INHIBITS CY P450 MONOOXYGENASE IN ADULTS AND PEDIATRIC PATIENTS WEIGHING AT LEAST 40KG WHO HAVE NO PRIOR ARV TREATMENT HISTORY

U-2768 TREATMENT OF HIV-1 INFECTION USING A COMPOSITION CONTAINING A PK ENHANCER THAT INHIBITS CY P450 MONOOXYGENASE IN ADULTS AND PEDIATRIC PATIENTS WEIGHING AT LEAST 40KG WHO ARE VIROLOGICALLY SUPPRESSED ON A STABLE ARV REGIMEN FOR AT LEAST 6 MONTHS

U-2769 DOSING REGIMEN FOR INTRAVENOUS SOTALOL FOR ADMINISTRATION IN A FACILITY THAT CAN PROVIDE CONTINUOUS ELECTROCARDIOGRAPHIC MONITORING AND CARDIAC RESUSCITATION.

U-2770 CUSHING'S DISEASE

U-2771 TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS IN PATIENTS 18 YEARS OF AGE OR OLDER

U-2772 MAINTENANCE TREATMENT OF CHRONIC PULMONARY DISEASE (COPD)

U-2774 TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN ADULTS

U-2775 TREATMENT OF A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE METFORMIN THERAPY USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN

PATENT AND EXCLUSIVITY TERMS

ADB 160 of 191

PATENT USE

U-2776	TREATMENT OF A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE METFORMIN THERAPY USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN AND LINAGLIPTIN
U-2777	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS 6 YEARS AND OLDER WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE USING A PHARMACEUTICAL COMPOSITION ACCORDING TO CLAIM 2 OF U.S. PATENT NO. 10,597,384, FURTHER COMPRISING IVACAFTOR
U-2778	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS 2 TO 5 YEARS OLD WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE USING A PHARMACEUTICAL COMPOSITION ACCORDING TO CLAIM 2 OF U.S. PATENT NO. 10,597,384, FURTHER COMPRISING IVACAFTOR
U-2779	TREATMENT OF SPASTICITY
U-2780	USE FOR THE TREATMENT OF SEIZURES IN PATIENTS WITH LENNOX-GASTAUT SYNDROME
U-2781	USE FOR THE TREATMENT OF SEIZURES IN PATIENTS WITH DRAVET SYNDROME
U-2782	USE FOR REDUCING CONVULSIVE SEIZURE FREQUENCY IN PATIENTS WITH LENNOX GASTAUT SYNDROME
U-2783	USE FOR REDUCING CONVULSIVE SEIZURE FREQUENCY IN PATIENTS WITH DRAVET SYNDROME
U-2784	A METHOD OF TREATING A CANCER CHARACTERIZED BY AN IDH1 MUTATION WHERE THE CANCER IS RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (AML) AND WHERE THE MUTANT IDH1 HAS THE ABILITY TO CONVERT ALPHA-KETOGLUTARATE INTO 2-HYDROXYGLUTARATE (2-HG)
U-2785	A METHOD OF TREATING A CANCER CHARACTERIZED BY AN IDH1 MUTATION WHERE THE CANCER IS NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) AND WHERE THE MUTANT IDH1 HAS THE ABILITY TO CONVERT ALPHA-KETOGLUTARATE INTO 2-HYDROXYGLUTARATE (2-HG)
U-2786	METHOD OF PREVENTING PREGNANCY BY INSERTING A VAGINAL SYSTEM CONTAINING 103 MG OF SEGESTERONE ACETATE AND 17.4 MG ETHINYL ESTRADIOL INTO A VAGINA FOR UP TO THIRTEEN 21/7-DAY (IN/OUT) CYCLES
U-2787	METHOD OF CONTRACEPTION BY INSERTING A VAGINAL SYSTEM FOR UP TO 13 21/7-DAY (IN/OUT) CYCLES, WHEREIN EFFICACY REQUIRES THE SYSTEM CANNOT BE OUT OF THE VAGINA FOR MORE THAN 2 CUMULATIVE HOURS IN ANY SUCH CYCLE WITHOUT USING ALTERNATIVE CONTRACEPTION
U-2788	TREATMENT OF BREAST CANCER INCLUDING HER2 (ERBB2)-POSITIVE OR -OVEREXPRESSING BREAST CANCER
U-2789	POTASSIUM PHOSPHATES INJECTION IS INDICATED AS A SOURCE OF PHOSPHORUS IN INTRAVENOUS FLUIDS TO CORRECT HYPOPHOSPHATEMIA IN ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER
U-2790	TREATMENT OF A TREATMENT-NAIVE PATIENT WITH INADEQUATELY CONTROLLED TYPE 2 DIABETES USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN AND LINAGLIPTIN
U-2791	TREATMENT OF ADULT PATIENTS WITH INSOMNIA, CHARACTERIZED BY DIFFICULTIES WITH SLEEP ONSET AND/OR SLEEP MAINTENANCE
U-2792	TREATMENT OF A TREATMENT-NAIVE PATIENT WITH INADEQUATELY CONTROLLED TYPE 2 DIABETES USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN
U-2793	A METHOD FOR DELIVERING NITRIC OXIDE TO A PATIENT WITH PULMONARY HYPERTENSION OR HYPOXIA
U-2794	TREATMENT OF TYPE 2 DIABETES MELLITUS WITH 100 MG CANAGLIFLOZIN PER DAY
U-2795	TREATMENT OF TYPE 2 DIABETES MELLITUS WITH 300 MG CANAGLIFLOZIN PER DAY
U-2796	REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS WITH 100 MG CANAGLIFLOZIN PER DAY
U-2797	REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS WITH 300 MG CANAGLIFLOZIN PER DAY
U-2798	REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS WITH 100 MG CANAGLIFLOZIN PER DAY
U-2799	REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS WITH 300 MG CANAGLIFLOZIN PER DAY
U-2800	TREATMENT OF PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH NEUROFIBROMATOSIS TYPE 1 (NF1) WHO HAVE SYMPTOMATIC, INOPERABLE PLEXIFORM NEUROFIBROMAS (PN)

PATENT AND EXCLUSIVITY TERMS

ADB 161 of 191

PATENT USE

U-2801	METHOD OF IRON ADMINISTRATION TO TREAT PATIENTS IN NEED OF IRON REPLACEMENT THERAPY
U-2802	BRAFTOVI IS A KINASE INHIBITOR INDICATED IN COMBINATION WITH CETUXIMAB, FOR THE TREATMENT OF ADULT PATIENTS WITH METASTATIC COLORECTAL CANCER (CRC) WITH A BRAF V600E MUTATION, AS DETECTED BY AN FDA-APPROVED TEST, AFTER PRIOR THERAPY
U-2803	BRAFTOVI IS A KINASE INHIBITOR INDICATED IN COMBINATION WITH BINIMETINIB, FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH A BRAF V600E OR V600K MUTATION, AS DETECTED BY AN FDA- APPROVED TEST
U-2804	A METHOD FOR THE IMPROVEMENT OF NEUROLOGICAL OUTCOME BY REDUCING THE INCIDENCE AND SEVERITY OF ISCHEMIC DEFICITS IN ADULT PATIENTS WITH SUBARACHNOID HEMORRHAGE (SAH) FROM RUPTURED INTRACRANIAL BERRY ANEURYSMS
U-2805	TREATMENT OF NON-24 HOUR SLEEP-WAKE DISORDER BY ADMINISTERING TASIMELTEON TO PATIENTS WITH A SMOKING HISTORY
U-2806	TREATMENT OF NON-24 HOUR SLEEP-WAKE DISORDER BY AVOIDING THE ADMINISTRATION OF FOOD
U-2807	TREATMENT OF MODERATE TO SEVERE MIGRAINE PAIN WITH PAIN FREE AT 2 HOURS POST ADMINISTRATION
U-2808	TREATMENT OF DYSKINESIA, DECREASING OFF TIME, AND INCREASING ON TIME WITHOUT TROUBLESOME DYSKINESIA IN PATIENTS WITH PARKINSON'S DISEASE RECEIVING LEVODOPA-BASED THERAPY, WITH OR WITHOUT CONCOMITANT DOPAMINERGIC MEDICATIONS
U-2809	FOR THE TREATMENT OF PREVIOUSLY TREATED, UNRESECTABLE LOCALLY ADVANCED OR METASTATIC CHOLANGIOCARCINOMA WITH A FIBROBLAST GROWTH FACTOR RECEPTOR 2 (FGFR2) FUSION OR OTHER REARRANGEMENT
U-2810	METHOD OF SUPPORTING EMBRYO IMPLANTATION AND EARLY PREGNANCY BY SUPPLEMENTATION OF CORPUS LUTEAL FUNCTION AS PART OF AN ASSISTED REPRODUCTIVE TECHNOLOGY (ART) TREATMENT PROGRAM FOR INFERTILE WOMEN
U-2811	METHOD OF TREATING PARKINSON'S DISEASE
U-2812	ADJUNCTIVE TREATMENT TO LEVODOPA/CARBIDOPA IN PATIENTS WITH PARKINSON'S DISEASE
U-2813	USE FOR THE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH A MESENCHYMAL-EPITHELIAL TRANSITION (MET) EXON 14 SKIPPING MUTATION
U-2814	A METHOD OF PROPHYLACTIC TREATMENT OF GOUT FLARES IN ADULTS COMPRISES ADMINISTERING TO A PATIENT A LIQUID COLCHICINE ORAL SOLUTION
U-2815	MEASURING TIME-VARYING CHANGE IN BLOOD IN A TISSUE VOLUME USING MODIFIED BEER-LAMBERT LAW IN VASCULAR, GASTROINTESTINAL, ORGAN TRANSPLANT, AND PLASTIC, MICRO-AND RECONSTRUCTIVE, INCLUDING MINIMALLY INVASIVE, SURGERY
U-2816	METHOD FOR TREATING INFLUENZA
U-2817	METHOD OF INHIBITING COMT IN THE PERIPHERY
U-2818	METHOD OF REDUCING O-METHYLATION OF L-DOPA
U-2819	MAINTENANCE TREATMENT WITH BEVACIZUMAB OF ADV. EPITHELIAL OVARIAN CANCER IN COMPLETE OR PARTIAL RESPONSE TO FIRST-LINE PLATINUM CHEMOTHERAPY AND HOMOLOGOUS RECOMBINATION DEFICIENCY-POSITIVE WITH A DELETERIOUS OR SUSPECTED DELETERIOUS BRCA MUTATION
U-2820	MAINTENANCE TREATMENT WITH BEVACIZUMAB OF ADV. EPITHELIAL OVARIAN CANCER IN COMPLETE OR PARTIAL RESPONSE TO FIRST-LINE PLATINUM CHEMOTHERAPY AND HOMOLOGOUS RECOMBINATION DEFICIENCY-POSITIVE WITH GENOMIC INSTABILITY
U-2821	MAINTENANCE TREATMENT WITH BEVACIZUMAB OF FALLOPIAN TUBE CANCER IN COMPLETE OR PARTIAL RESPONSE TO FIRST-LINE PLATINUM CHEMOTHERAPY AND HOMOLOGOUS RECOMBINATION DEFICIENCY-POSITIVE WITH A DELETERIOUS OR SUSPECTED DELETERIOUS BRCA MUTATION
U-2822	MAINTENANCE TREATMENT WITH BEVACIZUMAB OF FALLOPIAN TUBE CANCER IN COMPLETE OR PARTIAL RESPONSE TO FIRST-LINE PLATINUM CHEMOTHERAPY AND HOMOLOGOUS RECOMBINATION DEFICIENCY-POSITIVE WITH GENOMIC INSTABILITY
U-2823	MAINTENANCE TREATMENT WITH BEVACIZUMAB OF PRIMARY PERITONEAL CANCER IN COMPLETE OR PARTIAL RESPONSE TO FIRST-LINE PLATINUM CHEMOTHERAPY AND HOMOLOGOUS RECOMBINATION DEFICIENCY-POSITIVE WITH A DELETERIOUS OR SUSPECTED DELETERIOUS BRCA MUTATION
U-2824	MAINTENANCE TREATMENT WITH BEVACIZUMAB OF PRIMARY PERITONEAL CANCER IN COMPLETE OR PARTIAL RESPONSE TO FIRST-LINE PLATINUM CHEMOTHERAPY AND HOMOLOGOUS RECOMBINATION DEFICIENCY-POSITIVE WITH GENOMIC INSTABILITY

PATENT AND EXCLUSIVITY TERMS

ADB 162 of 191

PATENT USE

U-2825	TREATMENT OF "OFF" EPISODES IN PATIENTS WITH PARKINSON'S DISEASE
U-2826	TREATMENT OF ADULT PATIENTS WITH METASTATIC RET FUSION-POSITIVE NON-SMALL CELL LUNG CANCER
U-2827	TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC RET-MUTANT MEDULLARY THYROID CANCER (MTC) WHO REQUIRE SYSTEMIC THERAPY
U-2828	TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC RET FUSION-POSITIVE THYROID CANCER WHO REQUIRE SYSTEMIC THERAPY AND WHO ARE RADIOACTIVE IODINE REFRACTORY (IF RADIOACTIVE IODINE IS APPROPRIATE)
U-2829	TREATMENT OF GASTROINTESTINAL STROMAL TUMORS
U-2830	A METHOD FOR TREATING METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC), WHEREIN THE CANCER IS ASSOCIATED WITH A DELETERIOUS BRCA-MUTATION
U-2831	TREATMENT OF PARTIAL-ONSET SEIZURES IN A PATIENT WITH REFRACTORY PARTIAL-ONSET SEIZURES
U-2832	TREATMENT OF DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINE OR SOMATIC HOMOLOGOUS RECOMBINATION REPAIR GENE-MUTATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER, WHICH HAS PROGRESSED FOLLOWING PRIOR TREATMENT WITH ENZALUTAMIDE OR ABIRATERONE
U-2833	TREATMENT OF DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINE OR SOMATIC BRCA-MUTATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER, WHICH HAS PROGRESSED FOLLOWING PRIOR TREATMENT WITH ENZALUTAMIDE OR ABIRATERONE
U-2834	TREATMENT OF ADULTS WITH PERSISTENT/RECURRENT CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION (CTEPH), (WHO GROUP 4) AFTER SURGICAL TREATMENT, OR INOPERABLE CTEPH, TO IMPROVE EXERCISE CAPACITY AND WHO FUNCTIONAL CLASS
U-2835	TREATMENT OF ADULTS WITH PULMONARY HYPERTENSION (PAH), (WHO GROUP 1), TO IMPROVE EXERCISE CAPACITY, WHO FUNCTIONAL CLASS AND TO DELAY CLINICAL WORSENING
U-2836	TREATMENT OF ADULT PATIENTS WITH SMALL CELL LUNG CANCER (SCLC) WITH DISEASE PROGRESSION ON OR AFTER PLATINUM-BASED CHEMOTHERAPY.
U-2837	TREATMENT OF ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC)
U-2838	REDUCTION OF THE RATE OF A FIRST MYOCARDIAL INFARCTION OR STROKE IN PATIENTS WITH CORONARY ARTERY DISEASE AT HIGH RISK FOR SUCH EVENTS
U-2839	TREATMENT OF MYOCARDIAL INFARCTION OR STROKE IN PATIENTS WITH CORONARY ARTERY DISEASE AT HIGH RISK FOR SUCH EVENTS
U-2840	TREATMENT OF HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA AND VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA (HABP/VABP)
U-2841	USE OF VASCEPA WITH HIGH INTENSITY STATIN THERAPY TO REDUCE THE RISK OF A CV EVENT IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE LEVELS AND (1) ESTABLISHED CV DISEASE, OR (2) DIABETES MELLITUS AND TWO OR MORE ADDITIONAL RISK FACTORS FOR CV DISEASE
U-2842	MANAGEMENT OF HEAVY MENSTRUAL BLEEDING ASSOCIATED WITH UTERINE LEIOMYOMAS (FIBROIDS)
U-2843	NASAL ADMINISTRATION OF METOCLOPRAMIDE FOR TREATMENT OF DIABETIC GASTROPARESIS
U-2844	IN COMBINATION WITH PEMBROLIZUMAB FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA
U-2845	A METHOD OF TREATING A HUMAN PATIENT SUFFERING FROM PULMONARY HYPERTENSION
U-2846	TREATMENT OF CHRONIC GRAFT VERSUS HOST DISEASE REFRACTORY TO SYSTEMIC THERAPY
U-2847	REDUCTION IN RISK OF OVERT HEPATIC ENCEPHALOPATHY (HE) RECURRENCE IN ADULTS
U-2848	TREATMENT OF TRAVELERS' DIARRHEA (TD) CAUSED BY NONINVASIVE STRAINS OF ESCHERIA COLI IN ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER
U-2849	METHOD OF TREATING BLEPHAROPTOSIS
U-2850	MANAGEMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH ENDOMETRIOSIS USING 150 MG ELAGOLIX WHILE CO-ADMINISTERING KETOCONAZOLE
U-2851	METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION BY INHIBITING EZH2
U-2852	METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN

PATENT AND EXCLUSIVITY TERMS

ADB 163 of 191

PATENT USE

	ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION
U-2853	METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA
U-2854	METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA BY INHIBITING EZH2
U-2855	XPOVIO IS INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL), NOT OTHERWISE SPECIFIED, INCLUDING DLBCL ARISING FROM FOLLICULAR LYMPHOMA, AFTER AT LEAST 2 LINES OF SYSTEMIC THERAPY
U-2856	INCREASING SURVIVAL IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS PREVIOUSLY TREATED WITH DOCETAXEL BY ADMINISTERING 20 TO 25 MG/M2 CABAZITAXEL AFTER A PREMEDICATION REGIMEN THAT INCLUDES AN H2-ANTAGONIST
U-2857	USE OF ORAL OCTREOTIDE FOR LONG-TERM MAINTENANCE TREATMENT IN ACROMEGALY PATIENTS WHO HAVE RESPONDED TO AND TOLERATED TREATMENT WITH OCTREOTIDE OR LANREOTIDE
U-2858	USE IN COMBINATION WITH STIRIPENTOL, VALPROATE, AND CLOBAZAM FOR THE TREATMENT OF SEIZURES ASSOCIATED WITH DRAVET SYNDROME
U-2859	USE OF CARDIAC MONITORING AND RESTRICTED DISTRIBUTION OF FENFLURAMINE TO MITIGATE RISK OF CARDIOVASCULAR TOXICITY IN THE TREATMENT OF SEIZURES ASSOCIATED WITH DRAVET SYNDROME
U-2860	USE IN COMBINATION WITH STIRIPENTOL FOR THE TREATMENT OF SEIZURES ASSOCIATED WITH DRAVET SYNDROME
U-2861	USE IN COMBINATION WITH CANNABIDIOL FOR THE TREATMENT OF SEIZURES ASSOCIATED WITH DRAVET SYNDROME
U-2862	USE FOR THE TREATMENT OF FOCAL SEIZURES IN PATIENTS WITH DRAVET SYNDROME
U-2863	TOPICAL TREATMENT OF HEAD LICE INFESTATION IN PATIENTS 6 MONTHS OF AGE AND OLDER
U-2864	METHOD FOR INHIBITING CYTIDINE DEAMINASE BY ADMINISTERING CEDAZURIDINE
U-2865	TREATMENT OF MYELODYSPLASTIC SYNDROME
U-2866	TREATMENT OF CHRONIC MYELOMONOCYTIC LEUKEMIA
U-2867	METHOD FOR INHIBITING DEGRADATION OF A CDA SUBSTRATE BY ADMINISTERING CEDAZURIDINE
U-2868	TREATMENT OF NON-INFECTIOUS UVEITIS AFFECTING THE POSTERIOR SEGMENT OF THE EYE
U-2869	IV ADMINISTRATION OF CANGRELOR BEFORE PCI AND CONTINUOUS INFUSION FOR AT LEAST 2 HOURS OR THE DURATION OF THE PCI AND, DURING OR AFTER THE CONTINUOUS INFUSION, ADMINISTRATION OF A LOADING DOSE OF TICAGRELOR OR AN EQUIVALENT THERAPY (PER LABELING)
U-2870	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 1 AND 2
U-2871	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 1 AND 2 AND 3
U-2872	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 4 AND 5
U-2873	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 4, 5, AND 6
U-2874	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 7 AND 8
U-2875	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 7, 8, AND 9
U-2876	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 10 AND 11
U-2877	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 10, 11, AND 12

PATENT AND EXCLUSIVITY TERMS

ADB 164 of 191

PATENT USE

U-2878	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 13 AND 14
U-2879	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 13, 14, AND 15
U-2880	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 16 AND 17
U-2881	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 16, 17, AND 18
U-2882	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 19 AND 20
U-2883	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 19, 20, AND 21
U-2884	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 22, 23, AND 24
U-2885	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 25 AND 26
U-2886	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 25, 26, AND 27
U-2887	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 28 AND 29
U-2888	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 28, 29, AND 30
U-2889	USE FOR THE MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
U-2890	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 1 AND 2 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 1
U-2891	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MEYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 1 AND 3 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 1
U-2892	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 1 AND 4 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 1
U-2893	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 1 AND 5 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 1
U-2894	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 1 AND 6 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 1
U-2895	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 1 AND 7 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 1
U-2896	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN

PATENT AND EXCLUSIVITY TERMS

ADB 165 of 191

PATENT USE

	SECRETAGOGUE AS RECITED IN CLAIMS 1 AND 8 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 1
U-2897	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 1 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIMS 1 AND 9
U-2898	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 1 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIMS 1 AND 10
U-2899	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 1 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIMS 1 AND 11
U-2900	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 1 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIMS 1 AND 13
U-2901	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 1 AND 15 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 1
U-2902	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 1 AND 16 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 1
U-2903	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 1 AND 17 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 1
U-2904	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 1, 17 AND 18 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 1
U-2905	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 1 AND 19 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 1
U-2906	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 22 WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 22
U-2907	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 22 AND 23 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 22
U-2908	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 22 AND 24 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 22
U-2909	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 22 AND 25 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 22
U-2910	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 26 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 26
U-2911	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 26 AND 27 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 26

PATENT AND EXCLUSIVITY TERMS

ADB 166 of 191

PATENT USE

U-2912	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 26 AND 28 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 26
U-2913	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 26 AND 29 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 26
U-2914	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 26 AND 30 WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 26
U-2915	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 26 AND 31 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 26
U-2916	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 26 AND 32 WHEREIN THE EFFECTS ARE AS RECITED IN SAID CLAIMS
U-2917	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 26 AND 33 WHEREIN THE EFFECTS ARE AS RECITED IN CLAIMS
U-2918	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 26 AND 34 WHEREIN THE EFFECTS ARE AS RECITED IN SAID CLAIMS
U-2919	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 26 AND 36 WHEREIN THE EFFECTS ARE AS RECITED IN SAID CLAIMS
U-2920	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 26 AND 38 AND WHEREIN THE EFFECTS ARE AS RECITED CLAIM 26
U-2921	ONCE DAILY TOPICAL TREATMENT OF PERSISTENT FACIAL ERYTHEMA ASSOCIATED WITH ROSACEA IN ADULTS
U-2922	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 26 AND 39 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 26
U-2923	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 26 AND 40 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 26
U-2924	ADJUNCT TO DIET AND EXERCISE TO TREAT GLUCOSE INTOLERANCE IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 42 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 42
U-2925	ADJUNCT TO DIET AND EXERCISE TO TREAT GLUCOSE INTOLERANCE IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 42 AND 43 WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 42
U-2926	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 44 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 44
U-2927	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 44 AND 45 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 44

PATENT AND EXCLUSIVITY TERMS

ADB 167 of 191

PATENT USE

U-2928	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 44 AND 46 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 44
U-2929	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 44 AND 47 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 44
U-2930	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 44 AND 48 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 44
U-2931	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 44 AND 49 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 44
U-2932	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 44 AND 50 WHEREIN THE EFFECTS ARE AS RECITED IN SAID CLAIMS
U-2933	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 44 AND 51 WHEREIN THE EFFECTS ARE AS RECITED IN SAID CLAIMS
U-2934	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 44 AND 52 WHEREIN THE EFFECTS ARE AS RECITED IN SAID CLAIMS
U-2935	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 44 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIMS 44 AND 54
U-2936	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 44 AND 56 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 44
U-2937	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 44 AND 57 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 44
U-2938	TREATMENT OF CATAPLEXY OR EXCESSIVE DAYTIME SLEEPINESS (EDS) IN PATIENTS 7 YEARS OF AGE AND OLDER WITH NARCOLEPSY WITH A MIXTURE OF SODIUM, POTASSIUM, MAGNESIUM, AND CALCIUM SALTS OF GHB
U-2939	TREATMENT OF HIV INFECTION IN ADULTS AND PEDIATRIC PATIENTS WEIGHING AT LEAST 40KG USING A COMPOSITION CONTAINING A PHARMACOKINETIC ENHANCER THAT INHIBITS CYTOCHROME P450 MONOOXYGENASE
U-2940	METHOD OF TREATING PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH CENTRAL PRECOCIOUS PUBERTY
U-2941	A METHOD OF USING AN AEROSOL DELIVERY DEVICE TO AEROSOLIZE GLYCOPYRROLATE FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
U-2942	METHOD OF TREATING ACNE VULGARIS WITH TOPICALLY APPLIED CORTEXOLONE 17A-PROPIONATE
U-2943	TREATMENT OF RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA
U-2944	TREATMENT OF RELAPSED OR REFRACTORY SMALL LYMPHOCYTIC LYMPHOMA
U-2945	TREATMENT OF PRIMARY BILIARY CHOLANGITIS (PBC) IN COMBINATION WITH URSODEOXYCHOLIC ACID (UDCA) IN ADULTS WITH AN INADEQUATE RESPONSE TO UDCA, OR AS MONOTHERAPY IN ADULTS UNABLE TO TOLERATE UDCA
U-2946	TREATMENT OF COLORECTAL CANCER THAT HAS A NEUROTROPHIC TYROSINE RECEPTOR KINASE (NTRK) GENE FUSION
U-2947	KYPROLIS IS INDICATED IN COMBINATION WITH DARATUMUMAB PLUS DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA WHO HAVE

PATENT AND EXCLUSIVITY TERMS

ADB 168 of 191

PATENT USE

RECEIVED ONE TO THREE LINES OF THERAPY

- U-2948 A METHOD OF POSITIONING AN INTRAUTERINE SYSTEM (IUS) BY DETERMINING A DEPTH OF THE UTERUS, HOLDING AN INSERTER HANDLE WITH ONE HAND, INSERTING THE IUS INTO THE UTERUS, AND RETRACTING A SLIDER ON THE HANDLE TO RELEASE THE IUS INTO THE UTERUS
- U-2949 A METHOD FOR INDUCING A POST-SURGICAL ANALGESIA SPARING EFFECT BY IMPLANTING AT THE SURGICAL SITE A COLLAGEN SPONGE CONTAINING BUPIVACAINE HCL WHICH PROVIDES LOCAL ANESTHESIA FOR UP TO 24 HOURS FOLLOWING IMPLANTATION
- U-2950 CONTINUED TREATMENT OF ADULTS WITH ACUTE MYELOID LEUKEMIA WHO ACHIEVED FIRST COMPLETE REMISSION (CR) OR CR WITH INCOMPLETE BLOOD COUNT RECOVERY FOLLOWING INTENSIVE INDUCTION CHEMOTHERAPY AND ARE NOT ABLE TO COMPLETE INTENSIVE CURATIVE THERAPY
- U-2951 USE OF CU-64 DOTATATE WITH POSITRON EMISSION TOMOGRAPHY (PET) FOR LOCALIZATION OF SOMATOSTATIN RECEPTOR POSITIVE NEUROENDOCRINE TUMORS (NETS) IN ADULT PATIENTS
- U-2952 TREATMENT OF ADULT PATIENTS WITH METASTATIC REARRANGED DURING TRANSFECTION (RET) FUSION-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC) AS DETECTED BY AN FDA APPROVED TEST
- U-2953 USE OF FLUTICASONE FUROATE FOR THE TREATMENT OF AN INFLAMMATORY OR ALLERGIC CONDITIONS, INCLUDING CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND ASTHMA
- U-2954 METHOD OF DISPENSING A COMBINATION MEDICAMENT PRODUCT FROM CLAIMED DELIVERY DEVICE, FOR EXAMPLE FOR THE TREATMENT OF ASTHMA OR COPD
- U-2955 INDICATED FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA; AND ASTHMA
- U-2956 METHOD OF TREATING LAMBERT-EATON MYASTHENIC SYNDROME WITH AMIFAMPRIDINE
- U-2957 MAINTENANCE TREATMENT OF ASTHMA IN PATIENTS 18 YRS AND OLDER, OR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA
- U-2958 A METHOD FOR CONTRACEPTION, THE METHOD COMPRISING ADMINISTERING A TABLET COMPRISING 20 MG TO 30 MG OF ULIPRISTAL ACETATE TO A WOMAN WITHIN 120 HOURS AFTER AN UNPROTECTED INTERCOURSE
- U-2959 USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF A THIRD AND FURTHER CARDIOVASCULAR EVENT IN AN ADULT PATIENT WITH ELEVATED TG LEVELS (≥ 150 MG/DL) AND ESTABLISHED CARDIOVASCULAR DISEASE
- U-2960 USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF A SECOND OR FURTHER CARDIOVASCULAR (CV) EVENT IN AN ADULT PATIENT WITH ELEVATED TG LEVELS (≥ 150 MG/DL) AND DIABETES MELLITUS AND 2 OR MORE ADDITIONAL RISK FACTORS FOR CV DISEASE
- U-2961 USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF MYOCARDIAL INFARCTION, STROKE, BOTH IN AN ADULT PATIENT WITH TYPE 2 DIABETES MELLITUS
- U-2962 USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF CORONARY REVASCULARIZATION IN AN ADULT PATIENT WITH ESTABLISHED CARDIOVASCULAR DISEASE
- U-2963 TREATMENT OF CYSTIC FIBROSIS USING IVACAFTOR IN A PATIENT AGE 4 MONTHS TO <6 YEARS WHO HAS ONE MUTATION IN THE CFTR GENE THAT IS RESPONSIVE TO IVACAFTOR BASED ON CLINICAL AND/OR IN VITRO ASSAY DATA
- U-2964 TREATMENT OF CYSTIC FIBROSIS USING IVACAFTOR IN A PATIENT AGE 4 MONTHS TO <6 YEARS WHO HAS A R117H MUTATION IN THE CFTR GENE
- U-2965 TREATMENT OF A MODERATE TO MILD CLINICAL PHENOTYPE OF CF USING IVACAFTOR IN A PATIENT AGE 4 MONTHS TO <6 YEARS WHO HAS ONE CFTR MUTATION RESPONSIVE TO IVACAFTOR BASED ON CLINICAL AND/OR IN VITRO ASSAY DATA
- U-2966 TREATMENT OF CF IN A PATIENT AGE 4 MONTHS TO <6 YEARS WHO HAS ONE CFTR MUTATION RESPONSIVE TO IVACAFTOR BASED ON CLINICAL AND/OR IN VITRO ASSAY DATA USING A SOLID COMPOSITION COMPRISING AMORPHOUS (LESS THAN ABOUT 30% CRYSTALLINE) IVACAFTOR
- U-2967 TREATMENT OF CF IN A PATIENT AGE 4 MONTHS TO <6 YEARS WHO HAS ONE MUTATION IN THE CFTR GENE THAT IS RESPONSIVE TO IVACAFTOR BASED ON CLINICAL AND/OR IN VITRO ASSAY DATA USING THE COMPOSITION RECITED IN CLAIM 1 OF US 10272046
- U-2968 USE OF REMIMAZOLAM FOR INDUCTION AND MAINTENANCE OF PROCEDURAL SEDATION IN ADULTS UNDERGOING PROCEDURES LASTING 30 MINUTES OR LESS
- U-2969 TREATMENT OF ADULT PATIENTS WITH CYCLOSPORIN-RESISTANT, STEROID-DEPENDENT/REFRACTORY, OR STEROID RESISTANT CHRONIC GRAFT-VERSUS-HOST DISEASE

PATENT AND EXCLUSIVITY TERMS

ADB 169 of 191

PATENT USE

	(CGVHD) AFTER FAILURE OF ONE OR MORE LINES OF SYSTEMIC THERAPY
U-2970	TREATMENT OF ADULT PATIENTS WITH CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR MORE LINES OF SYSTEMIC THERAPY
U-2971	THE TREATMENT OF ADULT PATIENTS WITH METASTATIC RET FUSION-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC)
U-2972	THE TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC RET-MUTANT MEDULLARY THYROID CANCER (MTC) WHO REQUIRE SYSTEMIC THERAPY
U-2973	TREATING ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC RET FUSION-POSITIVE THYROID CANCER WHO REQUIRE SYSTEMIC THERAPY AND WHO ARE RADIOACTIVE IODINE-REFRACTORY, WHEREIN THE CANCER IS PAPILLARY THYROID CANCER
U-2974	TREATING ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC RET FUSION-POSITIVE THYROID CANCER WHO REQUIRE SYSTEMIC THERAPY AND WHO ARE RADIOACTIVE IODINE-REFRACTORY, WHEREIN THE CANCER IS MEDULLARY THYROID CANCER
U-2975	TREATING ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC RET FUSION-POSITIVE THYROID CANCER WHO REQUIRE SYSTEMIC THERAPY AND WHO ARE RADIOACTIVE IODINE-REFRACTORY, WHEREIN THE CANCER IS DIFFERENTIATED THYROID CANCER
U-2976	TREATING ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC RET FUSION-POSITIVE THYROID CANCER WHO REQUIRE SYSTEMIC THERAPY AND WHO ARE RADIOACTIVE IODINE-REFRACTORY, WHEREIN THE CANCER IS RECURRENT THYROID CANCER
U-2977	TREATING ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC RET FUSION-POSITIVE REFRACTORY DIFFERENTIATED THYROID CANCER WHO REQUIRE SYSTEMIC THERAPY AND ARE RADIOACTIVE IODINE-REFRACTORY
U-2978	TREATMENT OF HIV-1 INFECTION IN ADULT OR PEDIATRIC PATIENTS (≥ 40 KG) WITH < 50 COPIES/ML HIV-1 RNA AFTER ≥ 6 MONTHS ON PRIOR ANTIRETROVIRAL REGIMEN AND NO KNOWN DARUNAVIR OR TENOFOVIR RESISTANCE-ASSOCIATED SUBSTITUTIONS
U-2979	METHOD COMPRISING IV ADMINISTRATION OF CANGRELOR BEFORE PCI THEN CONTINUOUS INFUSION FOR AT LEAST 2 HOURS OR THE DURATION OF PCI AND, DURING OR AFTER CONTINUOUS INFUSION, ADMINISTRATION OF A LOADING DOSE OF TICAGRELOR, OR AN EQUIVALENT METHOD
U-2980	METHOD OF TREATING AN ALLERGIC REACTION USING AN AUTO-INJECTOR
U-2981	A METHOD OF TREATING ACUTE MYELOGENOUS LEUKEMIA (AML) IN A SUBJECT BY ADMINISTERING A PHARMACEUTICAL COMPOSITION WHERE THE AML IS CHARACTERIZED BY THE PRESENCE OF A MUTANT ALLELE OF IDH1 AND THE AML IS NEWLY DIAGNOSED
U-2982	A METHOD OF TREATING ACUTE MYELOGENOUS LEUKEMIA (AML) IN A SUBJECT BY ADMINISTERING A PHARMACEUTICAL COMPOSITION WHERE THE AML IS CHARACTERIZED BY THE PRESENCE OF A MUTANT ALLELE OF IDH1 AND WHERE THE AML IS RELAPSED/REFRACTORY
U-2983	TREATMENT OF SCHIZOPHRENIA BY RAPID AND CONTINUOUS INJECTION
U-2984	TREATMENT OF CORONAVIRUS DISEASE 2019 (COVID-19) IN ADULTS AND PEDIATRIC PATIENTS (AT LEAST 12 YEARS OF AGE AND 40 KG) REQUIRING HOSPITALIZATION
U-2985	A METHOD FOR TREATING DRY EYE IN A PATIENT
U-2986	MANAGEMENT OF ACUTE PAIN BY INTRAVENOUS INJECTION
U-2987	METHOD OF TREATING LUNG CANCER, UNDIFFERENTIATED SARCOMA, OR COLORECTAL CANCER THAT EXHIBITS AN NTRK GENE FUSION
U-2988	REDUCTION OF THE RISK OF STROKE IN PATIENTS WITH ACUTE ISCHEMIC STROKE OR HIGH-RISK TRANSIENT ISCHEMIC ATTACK
U-2989	METHOD OF USE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES IN PATIENTS 4 YEARS OF AGE AND OLDER
U-2990	METHOD OF USE FOR TREATMENT OF PARTIAL-ONSET SEIZURES IN PATIENTS 4 YEARS OF AGE AND OLDER
U-2991	METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING A TABLET CONTAINING SELEXIPAG
U-2992	METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING A SOLID PREPARATION CONTAINING SELEXIPAG

PATENT AND EXCLUSIVITY TERMS

ADB 170 of 191

PATENT USE

U-2993	A METHOD FOR TREATING A SUBJECT HAVING ADHD, SAID METHOD COMPRISING ORALLY ADMINISTERING TO SAID SUBJECT A RACEMIC METHYLPHENIDATE CHEWABLE TABLET AS CLAIMED
U-2994	REDUCTION OF RISK OF MYOCARDIAL INFARCTION, STROKE OR CARDIOVASCULAR DEATH IN A PATIENT WITH CHRONIC CAD OR PAD BY ADMINISTERING CLINICALLY PROVEN EFFECTIVE AMOUNTS THAT ARE 2.5 MG RIVAROXABAN TWICE DAILY AND 75-100 MG ASPIRIN DAILY
U-2995	TREATMENT OF PRIMARY HYPEROXALURIA TYPE 1 (PH1)
U-2996	ADMINISTRATION OF AN EXTENDED RELEASE TABLET FOR THE TREATMENT OF OVERACTIVE BLADDER (OAB) WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND URINARY FREQUENCY
U-2997	USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF STROKE IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDES AND ATRIAL FIBRILLATION
U-2998	METHOD OF ADMINISTERING DOCETAXEL TO A SUBJECT COMBINING THE DOCETAXEL PRO-EMULSION FORMULATION WITH AN AQUEOUS MEDIUM TO PRODUCE DOCETAXEL EMULSION
U-2999	METHOD OF USE OF TREATING, AS AN INITIAL LOADING DOSE FOR MONOTHERAPY OR ADJUNCTIVE THERAPY IN PARTIAL ONSET SEIZURE PATIENTS WITH EPILEPSY AGED 17 YEARS OR OLDER
U-3000	METHOD FOR POST-EXPOSURE PROPHYLAXIS OF INFLUENZA
U-3001	PROCEDURES IN ADULT AND PEDIATRIC PATIENTS REQUIRING A DISCLOSING AGENT IN COMBINATION WITH A TOPICAL OPHTHALMIC ANESTHETIC.
U-3002	TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC RET FUSION-POSITIVE THYROID CANCER WHO REQUIRE SYSTEMIC THERAPY AND WHO ARE RADIOACTIVE IODINE-REFRACTORY (IF RADIOACTIVE IODINE IS APPROPRIATE)
U-3003	TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME BY ADMINISTERING TASIMELTEON
U-3004	TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME BY AVOIDING THE AVOIDING THE USE OF TASIMELTEON IN COMBINATION WITH A STRONG CYP1A2 INHIBITOR
U-3005	TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME BY AVOIDING THE USE OF TASIMELTEON WITH RIFAMPIN
U-3006	TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME NON-24 HOUR SLEEP-WAKE DISORDER BY AVOIDING THE USE OF TASIMELTEON IN COMBINATION WITH CYP1A2 STRONG INHIBITORS
U-3007	TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME BY AVOIDING THE ADMINISTRATION OF TASIMELTEON WITH FOOD
U-3008	TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME BY ADMINISTERING TASIMELTEON TO PATIENTS WITH A SMOKING HISTORY
U-3009	TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME BY ADMINISTERING TASIMELTEON TO PATIENTS WITH A SMOKING HISTORY
U-3010	PROPHYLAXIS TO PREVENT ATTACKS OF HEREDITARY ANGIOEDEMA (HAE) IN ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER
U-3011	A METHOD FOR TREATING OCULAR INFLAMMATION
U-3012	TREATMENT IN COMBINATION WITH ANDROGEN DEPRIVATION THERAPY OF NON-METASTATIC, CASTRATION-RESISTANT PROSTATE CANCER (NMCRPC) THAT IMPROVES METASTASIS FREE SURVIVAL
U-3013	TREATMENT IN COMBINATION WITH ORCHIECTOMY OF NON-METASTATIC, CASTRATION-RESISTANT PROSTATE CANCER (NMCRPC)
U-3014	METHOD FOR THE INDUCTION OF LOCAL ANESTHESIA OF THE MUCOUS MEMBRANES
U-3015	TOPICAL TREATMENT OF ACTINIC KERATOSIS OF THE FACE OR SCALP
U-3016	ADJUVANT THERAPY AFTER TUMOR RESECTION IN PATIENTS WITH NON-SMALL CELL LUNG CANCER(NSCLC) WHOSE TUMORS HAVE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 19 DELETIONS OR EXON 21 L858R MUTATIONS
U-3017	METHOD OF TREATING EXCESSIVE DAYTIME SLEEPINESS AND/OR CATAPLEXY IN NARCOLEPSY PATIENTS WITH A SALT OF GAMMA-HYDROXYBUTYRATE WHEN DIVALPROEX SODIUM IS CONCOMITANTLY ADMINISTERED
U-3018	XPOVIO IS INDICATED IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE FOR THE

PATENT AND EXCLUSIVITY TERMS

ADB 171 of 191

PATENT USE

	TREATMENT OF ADULT PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
U-3019	TREATMENT OF ADULT PATIENTS WITH ADVANCED PROSTATE CANCER THAT IS SEX-HORMONE-DEPENDENT
U-3020	TREATMENT OF ADULT PATIENTS WITH ADVANCED PROSTATE CANCER
U-3021	TEZACAFTOR AND IVACAFTOR FOR THE TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGE 6 YEARS AND OLDER WHO HAVE A R117H MUTATION IN THE CFTR GENE
U-3022	TREATMENT OF CF IN PATIENTS 12 YEARS AND OLDER WHO HAVE A F508DEL OR G551D CFTR MUTATION AND A 2ND MUTATION SELECTED FROM R117H, A455E, 2789+5G->A, & 3849+10KBC->T, COMPRISING CONCURRENT COADMINISTRATION OF THE COMPOSITIONS OF CLAIM 1 OF US 10058546
U-3023	TREATMENT OF CF IN PATIENTS 6 YEARS AND OLDER WHO HAVE A F508DEL OR G551D CFTR MUTATION AND A 2ND MUTATION SELECTED FROM R117H, A455E, 2789+5G->A, AND 3849+10KBC->T, COMPRISING CONCURRENT COADMINISTRATION OF THE COMPOSITIONS OF CLAIM 1 OF US 10058546
U-3024	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGE 12 AND OLDER, WHO HAVE TWO COPIES OF THE F508DEL MUTATION OR WHO HAVE AT LEAST ONE CFTR MUTATION THAT IS RESPONSIVE TO TEZACAFTOR/IVACAFTOR, WITH THE COMPOSITION OF CLAIM 1 OF US 10,081,621
U-3025	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGE 6 AND OLDER, WHO HAVE TWO COPIES OF THE F508DEL MUTATION OR WHO HAVE AT LEAST ONE CFTR MUTATION THAT IS RESPONSIVE TO TEZACAFTOR/IVACAFTOR, WITH THE COMPOSITION OF CLAIM 1 OF US 10,081,621
U-3026	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGE 12 AND OLDER, WHO HAVE TWO COPIES OF THE F508DEL MUTATION OR AT LEAST ONE CFTR MUTATION THAT IS RESPONSIVE TO TEZACAFTOR/IVACAFTOR, WITH THE COMPOSITION OF CLAIM 1 OF US 10,206,877
U-3027	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGE 6 AND OLDER, WHO HAVE TWO COPIES OF THE F508DEL MUTATION OR AT LEAST ONE CFTR MUTATION THAT IS RESPONSIVE TO TEZACAFTOR/IVACAFTOR, WITH THE COMPOSITION OF CLAIM 1 OF US 10,206,877
U-3028	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 12 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE OR A MUTATION IN THE CFTR GENE THAT IS RESPONSIVE BASED ON IN VITRO DATA WITH ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR
U-3029	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 12 YEARS AND OLDER WHO HAVE A R117H MUTATION IN THE CFTR GENE WITH ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR
U-3030	TREATMENT OF A MODERATE TO MILD CLINICAL PHENOTYPE OF CF IN PATIENTS AGED 12 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE OR A MUTATION IN THE CFTR GENE THAT IS RESPONSIVE BASED ON IN VITRO DATA WITH ELX, TEZ, AND IVA
U-3031	TREATMENT OF CF IN PATIENTS 12 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION OR A MUTATION IN THE CFTR GENE THAT IS RESPONSIVE BASED ON IN VITRO DATA USING A SOLID COMPOSITION COMPRISING ELX, TEZ, AMORPHOUS IVA, AND < ~30% CRYSTALLINE IVA
U-3032	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 12 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE OR A MUTATION IN THE CFTR GENE THAT IS RESPONSIVE BASED ON IN VITRO DATA WITH A COMPOSITION ACCORDING TO CLAIM 1 OF US 10081621
U-3033	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 12 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE OR A MUTATION IN THE CFTR GENE THAT IS RESPONSIVE BASED ON IN VITRO DATA WITH AN EFFECTIVE AMOUNT OF ELX, TEZ, AND IVA
U-3034	TREATMENT OF TRD IN ADULTS BY NASALLY ADMINISTERING 56MG OR 84MG OF ESKETAMINE 2X WEEKLY FOR 4 WEEKS DURING THE INDUCTION PHASE IN CONJUNCTION WITH AN ORAL ANTIDEPRESSANT
U-3035	TREATMENT OF DEPRESSIVE SYMPTOMS IN ADULTS WITH MDD WITH ACUTE SUICIDAL IDEATION OR BEHAVIOR BY NASALLY ADMINISTERING 56MG OR 84 MG OF ESKETAMINE 2X WEEKLY FOR 4 WEEKS IN CONJUNCTION WITH AN ORAL ANTIDEPRESSANT
U-3036	TREATMENT OF TRD IN ADULTS BY NASALLY ADMINISTERING 56MG OR 84MG OF ESKETAMINE 2X WEEKLY FOR 4 WEEKS DURING THE INDUCTION PHASE FOLLOWED BY A MAINTENANCE PHASE OF 56MG OR 84 MG WEEKLY OR 1X EVERY TWO WEEKS IN CONJUNCTION WITH AN ORAL ANTIDEPRESSANT
U-3037	A METHOD OF DELIVERING NITRIC OXIDE TO A PATIENT

PATENT AND EXCLUSIVITY TERMS

ADB 172 of 191

PATENT USE

U-3038	MANAGEMENT OF MODERATE-TO-SEVERE PAIN BY INTRAVENOUS INJECTION IN PATIENTS WITH MILD RENAL IMPAIRMENT
U-3039	TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) IN PATIENTS WHO HAVE A CONFIRMED MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 53 SKIPPING
U-3040	LONG-TERM TREATMENT OF ADULTS WITH GAUCHER DISEASE TYPE 1 WHO ARE CYP2D6 EXTENSIVE METABOLIZERS WITH MILD HEPATIC IMPAIRMENT AND ARE CONCURRENTLY TAKING A STRONG OR MODERATE CYP3A INHIBITOR
U-3041	LONG-TERM TREATMENT OF ADULTS WITH GAUCHER DISEASE TYPE 1 WHO ARE CYP2D6 EXTENSIVE METABOLIZERS WITH MODERATE TO SEVERE RENAL IMPAIRMENT
U-3042	LONG-TERM TREATMENT OF ADULTS WITH GAUCHER DISEASE TYPE 1 WHO ARE CYP2D6 POOR METABOLIZERS WITH 84 MG ONCE DAILY OF ELIGLUSTAT (EQUIVALENT TO 100 MG OF ELIGLUSTAT TARTRATE)
U-3043	LONG-TERM TREATMENT OF ADULTS WITH GAUCHER DISEASE TYPE 1 WHO ARE CYP2D6 EXTENSIVE OR INTERMEDIATE METABOLIZERS WITH 84 MG TWICE PER DAY OF ELIGLUSTAT (EQUIVALENT TO 100 MG OF ELIGLUSTAT TARTRATE TWICE PER DAY)
U-3044	AXITINIB IN COMBINATION WITH AVELUMAB FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA
U-3045	TREATMENT OF OVERACTIVE BLADDER (OAB) WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND URINARY FREQUENCY
U-3046	METHOD OF ADMINISTERING VALBENAZINE WHILE AVOIDING CONCOMITANT USE OF A STRONG CYP3A4 INDUCER
U-3047	USE IN COMBINATION WITH CAPECITABINE, FOR THE TREATMENT OF ADULT PATIENTS WITH ADVANCED OR METASTATIC HER2-POSITIVE BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR ANTI-HER2 BASED REGIMENS IN THE METASTATIC SETTING
U-3048	A METHOD OF TREATING IRON DEFICIENCY ANEMIA IN ADULT PATIENTS WHO HAVE INTOLERANCE TO ORAL IRON OR HAVE HAD UNSATISFACTORY RESPONSE TO ORAL IRON BY INTRAVENOUSLY ADMINISTERING FERRIC CARBOXYMALTOSE TO PROVIDE 500 TO 750 MG OF ELEMENTAL IRON
U-3049	A METHOD OF TREATING IRON DEFICIENCY ANEMIA IN ADULT PATIENTS WHO HAVE NON-DIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE BY INTRAVENOUSLY ADMINISTERING FERRIC CARBOXYMALTOSE TO PROVIDE 500 TO 750 MG OF ELEMENTAL IRON
U-3050	METHOD OF TREATING IRON DEFICIENCY ANEMIA IN ADULT PATIENTS WHO HAVE INTOLERANCE TO ORAL IRON OR HAVE HAD UNSATISFACTORY RESPONSE TO ORAL IRON BY INTRAVENOUSLY ADMINISTERING AT LEAST ABOUT 0.6G OF IRON AS FERRIC CARBOXYMALTOSE IN ABOUT 15 MIN OR LESS
U-3051	METHOD OF TREATING IRON DEFICIENCY ANEMIA IN ADULT PATIENTS WHO HAVE NON-DIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE BY INTRAVENOUSLY ADMINISTERING AT LEAST ABOUT 0.6G OF IRON AS FERRIC CARBOXYMALTOSE IN ABOUT 15 MIN OR LESS
U-3052	USE OF VASCEPA TO REDUCE TRIGLYCERIDE LEVELS IN AN ADULT PATIENT ON STATIN THERAPY AND HAVING ATRIAL FIBRILLATION AND TRIGLYCERIDE LEVELS OF GREATER THAN 500 MG/DL
U-3053	USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF MYOCARDIAL INFARCTION IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE LEVELS AND ESTABLISHED CV DISEASE OR DIABETES MELLITUS AND TWO OR MORE ADDITIONAL RISK FACTORS FOR CV DISEASE
U-3054	TREATMENT OF DRUG-INDUCED EXTRAPYRAMIDAL REACTIONS IN ADULT PATIENTS WITH PARKINSON'S DISEASE
U-3055	A METHOD OF TREATING HUNTINGTON'S CHOREA
U-3056	TREATMENT OF PATIENTS WITH ACTIVE LUPUS NEPHRITIS
U-3057	TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) THAT IS ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE
U-3058	TREATMENT OF PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER AND YOUNG ADULTS WITH RELAPSED OR REFRACTORY, SYSTEMIC ANAPLASTIC LARGE CELL LYMPHOMA (ALCL) THAT IS ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE
U-3059	TREATMENT OF HIV-1 INFECTION IN ADULTS TO REPLACE THE CURRENT ANTIRETROVIRAL REGIMEN IN THOSE WHO ARE VIROLOGICALLY SUPPRESSED ON A STABLE ANTIRETROVIRAL REGIMEN WITH NO HISTORY OF TREATMENT FAILURE
U-3060	TREATMENT OF HIV INFECTION IN ADULTS
U-3061	TREATMENT OF HIV-1 IN AN ADULT IN COMBINATION WITH RILPIVIRINE

PATENT AND EXCLUSIVITY TERMS

ADB 173 of 191

PATENT USE

U-3062	REDUCING THE RISK OF CARDIOVASCULAR DEATH AND HEART FAILURE (HF) HOSPITALIZATION FOLLOWING A HOSPITALIZATION FOR HF OR NEED FOR OUTPATIENT IV DIURETICS, IN ADULTS WITH SYMPTOMATIC CHRONIC HF AND EJECTION FRACTION LESS THAN 45%
U-3063	RELAPSED OR REFRACTORY MARGINAL ZONE LYMPHOMA (MZL) WHO HAVE RECEIVED AT LEAST ONE PRIOR ANTI-CD20-BASED REGIMEN
U-3064	RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA (FL) WHO HAVE RECEIVED AT LEAST THREE PRIOR LINES OF SYSTEMIC THERAPY
U-3065	TREATMENT OF ADULTS WITH METASTATIC UROTHELIAL CARCINOMA THAT HAS SUSCEPTIBLE FGFR3 OR FGFR2 GENETIC ALTERATIONS AND PROGRESSED DURING OR FOLLOWING PRIOR PLATINUM-CONTAINING CHEMOTHERAPY
U-3066	TREATMENT OF ADULTS WITH LOCALLY ADVANCED OR METASTATIC, SURGICALLY UNRESECTABLE UROTHELIAL CARCINOMA THAT HAS SUSCEPTIBLE FGFR3 OR FGFR2 GENETIC ALTERATIONS AND PROGRESSED DURING OR FOLLOWING PRIOR PLATINUM-CONTAINING CHEMOTHERAPY
U-3067	TREATMENT OF ADULTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA THAT HAS SUSCEPTIBLE FGFR3 GENETIC ALTERATIONS AND PROGRESSED DURING OR FOLLOWING PRIOR PLATINUM-CONTAINING CHEMOTHERAPY
U-3068	TREATMENT IN COMBINATION WITH CABOTEGRAVIR OF HIV-1 INFECTION IN ADULTS TO REPLACE THE CURRENT ANTIRETROVIRAL REGIMEN IN THOSE WHO ARE VIROLOGICALLY SUPPRESSED ON A STABLE ANTIRETROVIRAL REGIMEN WITH NO HISTORY OF TREATMENT FAILURE
U-3069	TREATMENT OF ACUTE UNCOMPLICATED INFLUENZA IN PATIENTS 6 MONTHS AND OLDER
U-3070	REDUCING THE RISK OF MORTALITY IN HUTCHINSON-GILFORD PROGERIA SYNDROME (HGPS)
U-3071	USE FOR THE TREATMENT OF SEIZURES IN PATIENTS WITH TUBEROUS SCLEROSIS COMPLEX
U-3072	USE FOR THE TREATMENT OF GENERALIZED SEIZURES OR FOCAL SEIZURES WITH IMPAIRMENT IN PATIENTS WITH TUBEROUS SCLEROSIS COMPLEX
U-3073	USE FOR REDUCING SEIZURE FREQUENCY IN PATIENTS WITH TUBEROUS SCLEROSIS COMPLEX
U-3074	METHOD FOR PROVIDING SUSTAINED LOCAL ANESTHESIA FOR AT LEAST 24 HOURS
U-3075	TREATMENT OF ADRENAL INSUFFICIENCY
U-3076	METHOD OF TREATING TARDIVE DYSKINESIA WHILE AVOIDING CONCOMITANT USE OF A STRONG CYP3A4 INDUCER
U-3077	TREATING A SOLID TUMOR, INCLUDING LUNG CANCER, WITH A MET ALTERATION(S), OR STABILIZING OR IMPROVING SYMPTOMS ASSOCIATED WITH HAVING A SOLID TUMOR, INCLUDING LUNG CANCER, WITH A MET ALTERATION(S), BY ADMINISTERING AN EFFECTIVE AMOUNT OF TEPOTINIB
U-3078	TREATING A SOLID TUMOR, INCLUDING LUNG CANCER, HAVING A MET KINASE ALTERATION(S) BY ADMINISTERING AN EFFECTIVE AMOUNT OF TEPOTINIB
U-3079	A METHOD TO DECREASE THE INCIDENCE OF CHEMOTHERAPY-INDUCED MYELOSUPPRESSION IN ADULT PATIENTS WHEN ADMINISTERED PRIOR TO A PLATINUM/ETOPOSIDE-CONTAINING REGIMEN FOR EXTENSIVE-STAGE SMALL CELL LUNG CANCER
U-3080	A METHOD TO DECREASE THE INCIDENCE OF CHEMOTHERAPY-INDUCED MYELOSUPPRESSION IN ADULT PATIENTS WHEN ADMINISTERED PRIOR TO A TOPOTECAN-CONTAINING REGIMEN FOR EXTENSIVE- STAGE SMALL CELL LUNG CANCER
U-3081	A METHOD TO DECREASE THE INCIDENCE OF CHEMOTHERAPY-INDUCED MYELOSUPPRESSION IN ADULT PATIENTS WHEN ADMINISTERED PRIOR TO A CARBOPLATIN AND ETOPOSIDE-CONTAINING REGIMEN FOR EXTENSIVE-STAGE SMALL CELL LUNG CANCER
U-3082	TREATMENT OF EXCESSIVE DAYTIME SLEEPINESS ASSOCIATED WITH OBSTRUCTIVE SLEEP APNEA (OSA) IN AN ADULT THROUGH A DOSING REGIMEN THAT INCLUDES ORAL ADMINISTRATION OF 75 MG ONCE DAILY FOR AT LEAST 3 DAYS FOLLOWED BY 150 MG ONCE DAILY
U-3083	METHOD OF TREATING TRANSFUSIONAL IRON OVERLOAD
U-3084	TREATMENT OF HEART FAILURE WITH PRESERVED EJECTION FRACTION
U-3085	DOSE MODIFICATION FOR RENAL IMPAIRMENT
U-3086	FOR HIGH-DOSE CONDITIONING TREATMENT PRIOR TO HEMATOPOIETIC PROGENITOR (STEM) CELL TRANSPLANTATION IN PATIENTS WITH MULTIPLE MYELOMA
U-3087	TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) IN PATIENTS WHO HAVE A MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 45 SKIPPING BY INDUCING EXON-SKIPPING OF EXON 45

PATENT AND EXCLUSIVITY TERMS

ADB 174 of 191

PATENT USE

U-3088	TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) IN PATIENTS WHO HAVE A MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 45 SKIPPING
U-3089	TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) IN PATIENTS WHO HAVE A MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 45 SKIPPING BY RESTORING AN MRNA READING FRAME TO INDUCE DYSTROPHIN PROTEIN PRODUCTION
U-3090	TREATMENT OF HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA IN PATIENTS WITH END-STAGE RENAL DISEASE ON HEMODIALYSIS
U-3091	TREATMENT OF VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA IN PATIENTS WITH END-STAGE RENAL DISEASE ON HEMODIALYSIS
U-3092	METHOD OF TREATING MOLYBDENUM COFACTOR DEFICIENCY TYPE A
U-3093	IN COMBINATION WITH DEXAMETHASONE TO TREAT RELAPSED OR REFRACTORY MULTIPLE MYELOMA (REFRACTORY TO AT LEAST 1 PROTEASOME INHIBITOR, 1 IMMUNOMODULATORY AGENT, AND 1 ANTI-CD38 MAB) IN ADULTS WHO RECEIVED AT LEAST 4 PRIOR LINES OF THERAPY
U-3094	TREATMENT OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER (ADHD) WITH SERDEXMETHYLPHENIDATE AND DEXMETHYLPHENIDATE
U-3095	TREATMENT OF HYPERLIPIDEMIA
U-3096	TREATMENT OF ADULT PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS ARE ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE AS DETECTED BY AN FDA-APPROVED TEST
U-3097	EXTENDED ADJUVANT TREATMENT OF ADULT PATIENTS WITH EARLY-STAGE HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-POSITIVE BREAST CANCER, TO FOLLOW ADJUVANT TRASTUZUMAB BASED THERAPY
U-3098	TREATMENT OF REFRACTORY EPILEPSY PATIENTS WITH FENFLURAMINE THAT REDUCES THE RISK OF CARDIOVASCULAR TOXICITY BY USING CARDIAC MONITORING AND RESTRICTED DISTRIBUTION
U-3099	TREATMENT OF EXCESSIVE DAYTIME SLEEPINESS ASSOCIATED WITH OBSTRUCTIVE SLEEP APNEA (OSA) IN A PATIENT WITH MODERATE RENAL IMPAIRMENT
U-3100	A METHOD OF TREATING ADULTS WITH RELAPSED OR REFRACTORY ADVANCED RENAL CELL CARCINOMA FOLLOWING TWO OR MORE PRIOR SYSTEMIC THERAPIES BY INHIBITING THE ANGIOGENESIS OF BLOOD VESSELS WITH A VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITOR
U-3101	TREATMENT OF ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS WITH A SINGLE DOSE OF 1200MG ORITAVANCIN OR ITS SINGLE DOSE EQUIVALENT
U-3102	REDUCTION OF CIRCULATING LYMPHOCYTES IN TREATING RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN ADULTS
U-3103	TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN ADULTS USING A DOSE TITRATION SCHEDULE FOLLOWED BY A MAINTENANCE DOSE
U-3104	TREATMENT OF C. DIFFICILE-ASSOCIATED DIARRHEA
U-3105	TREATMENT OF STAPHYLOCOCCAL ENTEROCOLITIS
U-3106	TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME BY AVOIDING THE ADMINISTRATION OF TASIMELTEON TO SMOKERS OR TO PATIENTS BEING TREATED WITH A CYP1A2 INHIBITOR
U-3107	TREATMENT OF NON-24 HOUR SLEEP-WAKE DISORDER BY AVOIDING THE ADMINISTRATION OF TASIMELTEON TO SMOKERS OR TO PATIENTS BEING TREATED WITH A CYP1A2 INHIBITOR
U-3108	TREATMENT OF NEUROGENIC DETRUSOR OVERACTIVITY (NDO) IN PEDIATRIC PATIENTS AGED 3 YEARS AND OLDER BY ADMINISTRATION OF AN EXTENDED-RELEASE SUSPENSION FORMULATION OF MIRABEGRON
U-3109	METHOD OF USING VISMODEGIB TO TREAT BASAL CELL CARCINOMA
U-3110	USE OF NALOXONE FOR THE EMERGENCY TREATMENT OF KNOWN OR SUSPECTED OPIOID OVERDOSE, AS MANIFESTED BY RESPIRATORY AND/OR CENTRAL NERVOUS SYSTEM DEPRESSION, FOR ADULT AND PEDIATRIC PATIENTS
U-3111	TREATING OPIOID USE DISORDER
U-3112	TREATING NEWLY DIAGNOSED ACUTE MYELOGENOUS LEUKEMIA (AML) CHARACTERIZED BY THE PRESENCE OF A MUTANT ALLELE OF IDH1 BY ADMINISTERING A ONCE DAILY 500 MG ORAL DOSE TO A SUBJECT THAT HAS NOT INGESTED A HIGH-FAT MEAL

PATENT AND EXCLUSIVITY TERMS

ADB 175 of 191

PATENT USE

U-3113	TREATING RELAPSED/REFRACTORY ACUTE MYELOGENOUS LEUKEMIA (AML) CHARACTERIZED BY THE PRESENCE OF A MUTANT ALLELE OF IDH1 BY ADMINISTERING A ONCE DAILY 500 MG ORAL DOSE TO A SUBJECT THAT HAS NOT INGESTED A HIGH-FAT MEAL
U-3114	TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL) BY ORALLY ADMINISTERING VENETOCLAX TO AN ADULT ACCORDING TO A DOSE RAMP-UP THAT INCLUDES A DOSE OF 50 MG PER DAY FOR 1 WEEK FOLLOWED BY 100 MG PER DAY FOR 1 WEEK
U-3115	METHOD OF TREATING IRON DEFICIENCY ANEMIA IN ADULT PATIENTS WHO HAVE INTOLERANCE TO ORAL IRON OR HAVE HAD UNSATISFACTORY RESPONSE TO ORAL IRON BY INTRAVENOUSLY ADMINISTERING ABOUT 1 G OF IRON AS FERRIC CARBOXYMALTOSE IN ABOUT 15 MINUTES OR LESS
U-3116	METHOD OF TREATING IRON DEFICIENCY ANEMIA IN ADULT PATIENTS WHO HAVE NON-DIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE BY INTRAVENOUSLY ADMINISTERING ABOUT 1 G OF IRON AS FERRIC CARBOXYMALTOSE IN ABOUT 15 MINUTES OR LESS
U-3117	ADMINISTRATION TO THE EYE OF A PATIENT FOR TREATMENT OF DRY EYE CONDITION
U-3118	TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION
U-3119	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 1 AND 11
U-3120	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 1, 11, AND 12
U-3121	ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 13 AND 23
U-3122	ADJUNCT TO DIET EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 13, 23, AND 24
U-3123	TREATMENT OF ADULT PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) BY ADMINISTRATION OF COMPLEMENT INHIBITOR PEGCETACOPLAN
U-3124	TREATMENT OF ADULT PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) BY ADMINISTRATION OF PEGCETACOPLAN
U-3125	USE FOR LOADING DOSE IN PATIENTS WITH SYMPTOMATIC AFIB/AFL WHO ARE CURRENTLY IN SINUS RHYTHM OR FOR THE TREATMENT OF LIFE-THREATENING VENTRICULAR TACHYCARDIA
U-3126	USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF A SECOND AND FURTHER CARDIOVASCULAR EVENT IN AN ADULT PATIENT WITH ESTABLISHED CARDIOVASCULAR DISEASE
U-3127	REDUCTION OF THE RISK OF CARDIOVASCULAR DEATH AND HOSPITALIZATION FOR HEART FAILURE IN ADULTS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION AND WITHOUT TYPE II DIABETES
U-3128	TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS (CUTI) INCLUDING PYELONEPHRITIS CAUSED BY THE FOLLOWING SUSCEPTIBLE MICROORGANISMS: ESCHERICHIA COLI, KLEBSIELLA PNEUMONIA, ENTEROBACTER CLOACAE SPECIES COMPLEX WITH MEROPENEM & VABORBACTAM AS SPECIFIED
U-3129	MANAGEMENT OF HEAVY MENSTRUAL BLEEDING ASSOCIATED WITH UTERINE LEIOMYOMAS (FIBROIDS) IN PREMENOPAUSAL WOMEN
U-3130	METHOD OF POSITRON EMISSION TOMOGRAPHY (PET) IN MEN WITH PROSTATE CANCER
U-3131	USE OF ZUBSOLV FOR TREATMENT OF OPIOID DEPENDENCE
U-3132	INDICATED FOR THE TREATMENT OF MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
U-3133	TREATING SICKLE CELL DISEASE BY ADMINISTERING 1500 MG OF VOXELOTOR ORALLY ONCE DAILY
U-3134	INCREASING HEMOGLOBIN TO TREAT SICKLE CELL DISEASE BY ADMINISTERING 1500 MG OF VOXELOTOR ORALLY ONCE DAILY
U-3135	TREATING SCHIZOPHRENIA
U-3136	METHOD OF TREATING SCHIZOPHRENIA BY ADMINISTERING THE ATYPICAL ANTIPSYCHOTIC OLANZAPINE AND SAMIDORPHAN, WITH REDUCED ANTIPSYCHOTIC INDUCED WEIGHT GAIN

PATENT AND EXCLUSIVITY TERMS

ADB 176 of 191

PATENT USE

U-3137	METHOD OF TREATING BIPOLAR DISORDER BY ADMINISTERING THE ATYPICAL ANTIPSYCHOTIC OLANZAPINE AND SAMIDORPHAN, WITH REDUCED ANTIPSYCHOTIC INDUCED WEIGHT GAIN
U-3138	METHOD OF TREATING SCHIZOPHRENIA BY ADMINISTERING THE ATYPICAL ANTIPSYCHOTIC OLANZAPINE AND SAMIDORPHAN, WITH REDUCTION OF THE ADVERSE METABOLIC PROFILE
U-3139	METHOD OF TREATING BIPOLAR DISORDER BY ADMINISTERING THE ATYPICAL ANTIPSYCHOTIC OLANZAPINE AND SAMIDORPHAN, WITH REDUCTION OF THE ADVERSE METABOLIC PROFILE
U-3140	METHOD OF TREATING SCHIZOPHRENIA BY ADMINISTERING THE ATYPICAL ANTIPSYCHOTIC OLANZAPINE AND SAMIDORPHAN
U-3141	METHOD OF TREATING BIPOLAR DISORDER BY ADMINISTERING THE ATYPICAL ANTIPSYCHOTIC OLANZAPINE AND SAMIDORPHAN
U-3142	PREVENTIVE TREATMENT OF EPISODIC MIGRAINE IN ADULTS
U-3143	FOR THE TOPICAL TREATMENT OF PLAQUE PSORIASIS IN PATIENTS 18 YEARS OF AGE AND OLDER
U-3144	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE OR A MUTATION IN THE CFTR GENE THAT IS RESPONSIVE BASED ON IN VITRO DATA WITH ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR
U-3145	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE A R117H MUTATION IN THE CFTR GENE WITH ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR
U-3146	TREATMENT OF A MODERATE TO MILD CLINICAL PHENOTYPE OF CF IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE OR A MUTATION IN THE CFTR GENE THAT IS RESPONSIVE BASED ON IN VITRO DATA WITH ELX, TEZ, AND IVA
U-3147	FOR THE TREATMENT OF NEWLY-DIAGNOSED THERAPY-RELATED ACUTE MYELOID LEUKEMIA (T-AML) OR AML WITH MYELODYSPLASIA-RELATED CHANGES (AML-MRC) IN ADULTS AND PEDIATRIC PATIENTS 1 YEAR AND OLDER
U-3148	METHOD OF TREATING RELAPSING FORMS OF MULTIPLE SCLEROSIS BEFORE AND AFTER ADMINISTERING AN INACTIVE VACCINE
U-3149	METHOD OF RECONSTITUTING A LYOPHILIZED LIPOSOMAL COMPOSITION FOR ADMINISTERING CYTARABINE AND DAUNORUBICIN TO TREAT NEWLY-DIAGNOSED THERAPY-RELATED AML (T-AML) OR AML WITH MYELODYSPLASIA-RELATED CHANGES (AML-MRC) IN PATIENTS 1 YEAR AND OLDER
U-3150	METHOD OF ADMINISTERING A RECONSTITUTED LIPOSOMAL COMPOSITION CONTAINING CYTARABINE AND DAUNORUBICIN TO TREAT NEWLY-DIAGNOSED THERAPY-RELATED AML (T-AML) OR AML WITH MYELODYSPLASIA-RELATED CHANGES (AML-MRC) IN PATIENTS 1 YEAR AND OLDER
U-3151	TO IMPROVE WAKEFULNESS IN ADULT PATIENTS WITH EXCESSIVE DAYTIME SLEEPINESS ASSOCIATED WITH NARCOLEPSY OR OBSTRUCTIVE SLEEP APNEA (OSA) WITH A DOSING REGIMEN THAT INCLUDES A DOSE OF 75 MG ONCE DAILY FOR AT LEAST 3 DAYS FOLLOWED BY 150 MG ONCE DAILY
U-3152	USE BY FEMALES OF REPRODUCTIVE POTENTIAL TO PREVENT PREGNANCY
U-3153	TREATMENT OF ADVANCED GASTROINTESTINAL STROMAL TUMOR IN PATIENTS HAVING PROGRESSED FROM A FIRST LINE ADMINISTRATION OF IMATINIB, A SECOND LINE ADMINISTRATION OF SUNITINIB, AND A THIRD LINE ADMINISTRATION OF REGORAFENIB
U-3154	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE WITH A COMPOSITION COMPRISING ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR; AND ANOTHER COMPOSITION COMPRISING IVACAFTOR
U-3155	TREATMENT OF CF IN PATIENTS 6 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION OR A MUTATION IN THE CFTR GENE THAT IS RESPONSIVE BASED ON IN VITRO DATA USING A SOLID COMPOSITION COMPRISING ELX, TEZ, AMORPHOUS IVA, AND < ~30% CRYSTALLINE IVA
U-3156	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE WITH AN EFFECTIVE AMOUNT OF A PHARMACEUTICAL COMPOSITION COMPRISING ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR
U-3157	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE OR A MUTATION IN THE CFTR GENE THAT IS RESPONSIVE BASED ON IN VITRO DATA WITH A COMPOSITION ACCORDING TO CLAIM 1 OF US 10081621
U-3158	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE OR A MUTATION IN THE CFTR GENE THAT

PATENT AND EXCLUSIVITY TERMS

ADB 177 of 191

PATENT USE

	IS RESPONSIVE BASED ON IN VITRO DATA WITH AN EFFECTIVE AMOUNT OF ELX, TEZ, AND IVA
U-3159	TREATMENT OF ADULT AND POST-MENARCHAL PEDIATRIC FEMALES WITH VULVOVAGINAL CANDIDIASIS (VVC)
U-3160	PROPHYLAXIS OF INVASIVE ASPERGILLUS AND CANDIDA INFECTIONS IN ADULTS AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WHO ARE SEVERELY IMMUNOCOMPROMISED
U-3161	METHOD FOR WEIGHT MANAGEMENT ACCORDING TO A DOSE ESCALATION SCHEDULE
U-3162	METHOD FOR WEIGHT MANAGEMENT
U-3163	TREATMENT OF ACTINIC KERATOSES OF UPPER EXTREMITIES BY PHOTODYNAMIC THERAPY
U-3164	GASTROINTESTINAL TABLETS INDICATED FOR CLEANSING THE COLON IN PREPARATION FOR COLONOSCOPY
U-3165	METHOD OF TREATING HUMAN SMALLPOX DISEASE
U-3166	OTC USE: ALLERGY SYMPTOM RELIEVER; TEMPORARY RELIEF OF THESE SYMPTOMS DUE TO HAY FEVER OR OTHER UPPER RESPIRATORY ALLERGIES: NASAL CONGESTION, RUNNY NOSE, SNEEZING AND ITCHY NOSE
U-3167	TREATMENT OF CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1, 2, 3, 4, OR 6 IN PEDIATRIC PATIENTS 3 TO LESS THAN 12 YEARS OF AGE OR WEIGHING LESS THAN 45 KG
U-3168	TREATMENT OF ADVANCED SYSTEMIC MASTOCYTOSIS, INCLUDING PATIENTS WITH AGGRESSIVE SYSTEMIC MASTOCYTOSIS (ASM), SYSTEMIC MASTOCYTOSIS WITH AN ASSOCIATED HEMATOLOGICAL NEOPLASM (SM-AHN), AND MAST CELL LEUKEMIA (MCL)
U-3169	TREATMENT OF TRICHOMONIASIS IN ADULTS
U-3170	TREATING CHRONIC HEART FAILURE WITH REDUCED EJECTION FRACTION IN PATIENTS NOT TAKING AN ACE INHIBITOR OR AN ARB OR PREVIOUSLY TAKING LOW DOSES OF THESE AGENTS, BY TITRATING UP FROM HALF THE USUALLY RECOMMENDED STARTING DOSE
U-3171	TREATMENT OF INVASIVE ASPERGILLOSIS IN ADULTS AND PEDIATRIC PATIENTS 13 YEARS OF AGE AND OLDER
U-3172	TREATMENT OF ADULT PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) BY ADMINISTRATION OF 1080 MG OF PEGCETACOPLAN
U-3173	TREATMENT OF ADULT PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) BY ADMINISTRATION OF 1080 MG OF PEGCETACOPLAN TWICE WEEKLY
U-3174	TREATMENT OF ADULT PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) BY ADMINISTRATION OF 1080 MG OF PEGCETACOPLAN EVERY THREE DAYS
U-3175	TREATMENT OF COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS AND STAPHYLOCOCCUS AUREUS BLOODSTREAM INFECTIONS (BACTEREMIA) INCLUDING THOSE WITH RIGHT-SIDED INFECTIVE ENDOCARDITIS BY ADMINISTERING THE FORMULATION OF DAPTOMYCIN AS RECITED IN CLAIM 18
U-3176	TREATMENT OF COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS AND S. AUREUS BLOODSTREAM INFECTIONS (BACTEREMIA) INCLUDING THOSE WITH RIGHT-SIDED INFECTIVE ENDOCARDITIS BY RECONSTITUTING AND ADMINISTERING THE FORMULATION AS RECITED IN CLAIM 12
U-3177	TREATMENT OF VENOUS THROMBOTIC DISEASE
U-3178	REDUCE THE RISK OF RECURRENCE OF VENOUS THROMBOTIC DISEASE
U-3179	METHOD OF TREATING FOLLICULAR LYMPHOMA
U-3180	DECREASING OFF TIME IN PATIENTS WITH PARKINSON'S DISEASE RECEIVING LEVODOPA-BASED THERAPY, WITH OR WITHOUT CONCOMITANT DOPAMINERGIC MEDICATIONS
U-3181	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS 6 YEARS AND OLDER WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE USING THE TABLET ACCORDING TO CLAIM 1 OF U.S. PATENT NO. 11,052,075, WHERE THE TABLET FURTHER COMPRISES IVACAFTOR
U-3182	METHOD OF PROVIDING POSTSURGICAL PAIN MANAGEMENT, FOR EXAMPLE, VIA INFILTRATION FOR LOCAL ANALGESIA OR VIA INTERSCALENE BRACHIAL PLEXUS NERVE BLOCK FOR REGIONAL ANALGESIA
U-3183	USE OF EPHEDRINE SULFATE FOR TREATING HYPOTENSION
U-3184	MEKINIST(R) IS INDICATED, IN COMBINATION WITH DABRAFENIB, FOR THE ADJUVANT TREATMENT OF PATIENTS WITH MELANOMA WITH BRAF V600E OR V600K MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST, AND INVOLVEMENT OF LYMPH NODE(S), FOLLOWING COMPLETE RESECTION
U-3185	TAFINLAR(R) IS INDICATED, IN COMBINATION WITH TRAMETINIB, FOR THE ADJUVANT

PATENT AND EXCLUSIVITY TERMS

ADB 178 of 191

PATENT USE

TREATMENT OF PATIENTS WITH MELANOMA WITH BRAF V600E OR V600K MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST, AND INVOLVEMENT OF LYMPH NODE(S), FOLLOWING COMPLETE RESECTION

- U-3186 METHOD OF TREATING PRURITUS IN PATIENTS 3 MONTHS OR OLDER SUFFERING FROM PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS (PFIC)
- U-3187 METHOD OF REDUCING SERUM BILE ACIDS IN PATIENTS 3 MONTHS OR OLDER SUFFERING FROM PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS (PFIC)
- U-3188 IMPROVING GLYCEMIC CONTROL IN PATIENTS 10 YEARS OF AGE AND OLDER WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING A SUSTAINED-RELEASE EXENATIDE FORMULATION AS AN ADJUNCT TO DIET AND EXERCISE
- U-3189 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH INSULIN ALONE OR INSULIN PLUS ONE OTHER ORAL ANTIDIABETIC MEDICATION
- U-3190 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN AND/OR SULFONYLUREA
- U-3191 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (30 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
- U-3192 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (EGFR<60 ML/MIN/1.73 M2) BY INITIATION OF EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN HCL IF EGFR>=45 ML/MIN/1.73 M2 AND DISCONTINUATION IF EGFR <30 ML/MIN/1.73 M2
- U-3193 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATENT WITH RENAL IMPAIRMENT (EGFR<60 ML/MIN/1.73 M2) BY INITIATION OF EMPAGLIFLOZIN AND METFORMIN HCL IF EGFR>=45 ML/MIN/1.73 M2 AND DISCONTINUATION IF EGFR<30 ML/MIN/1.73 M2
- U-3194 TOPICAL TREATMENT OF ACNE VULGARIS IN ADULTS AND PEDIATRIC PATIENTS 9 YEARS OF AGE AND OLDER
- U-3195 TREATMENT OF ADULTS WITH REFRACTORY, MODERATE-TO-SEVERE ATOPIC DERMATITIS NOT ADEQUATELY CONTROLLED WITH OTHER SYSTEMIC DRUG PRODUCTS OR WHEN USE OF THOSE THERAPIES IS INADVISABLE
- U-3196 TREATMENT OF ADULTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA WITH SUSCEPTIBLE FGFR3 OR FGFR2 GENETIC ALTERATIONS, AND PROGRESSED DURING OR FOLLOWING PRIOR PLATINUM-CONTAINING CHEMOTHERAPY, WITH DOSING BASED ON SERUM PHOSPHATE LEVELS
- U-3197 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE AN OPIOID ANALGESIC AND FOR WHICH ALTERNATIVE TREATMENTS ARE INADEQUATE
- U-3198 METHOD OF TREATING PATIENTS WITH IDIOPATHIC HYPERSOMNIA WITH SODIUM OXYBATE WHEN DIVALPROEX SODIUM IS CONCOMITANTLY ADMINISTERED
- U-3199 METHOD FOR REDUCING THE RISK OF CARDIOVASCULAR DEATH PLUS HOSPITALIZATION FOR HEART FAILURE IN ADULTS WITH TYPE 2 DIABETES MELLITUS, HEART FAILURE AND REDUCED EJECTION FRACTION BY ONCE DAILY ADMINISTRATION OF EMPAGLIFLOZIN
- U-3200 INCREASING SURVIVAL IN MCRPC PATIENTS PREVIOUSLY TREATED WITH DOCETAXEL BY ADMINISTERING CABAZITAXEL IN COMBINATION WITH PREDNISONE OR PREDNISOLONE AFTER A PREMEDICATION REGIMEN THAT INCLUDES AN ANTIHISTAMINE, A CORTICOSTEROID, AND AN H2-ANTAGONIST
- U-3201 TREATMENT OF ADULT PATIENTS WITH VON HIPPEL-LINDAU DISEASE WHO REQUIRE THERAPY FOR ASSOCIATED RENAL CELL CARCINOMA, CENTRAL NERVOUS SYSTEM HEMANGIOBLASTOMAS, OR PANCREATIC NEUROENDOCRINE TUMORS, NOT REQUIRING IMMEDIATE SURGERY
- U-3202 MAINTENANCE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) COMPRISING THE ONCE PER DAY ADMINISTRATION OF TRELEGY ELLIPTA, 100 MCG FLUTICASONE FUROATE/62.5 MCG UMECLIDINIUM/25 MCG VILANTEROL
- U-3203 MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
- U-3204 TREATMENT OF MODERATE-TO-SEVERE PRURITUS ASSOCIATED WITH CHRONIC KIDNEY DISEASE (CKD-AP) IN ADULTS UNDERGOING HEMODIALYSIS (HD)
- U-3205 REDUCTION OF RISK OF MAJOR CARDIOVASCULAR EVENTS (CARDIOVASCULAR DEATH, MYOCARDIAL INFARCTION AND STROKE) IN PATIENTS WITH CAD
- U-3206 REDUCTION OF RISK OF MAJOR THROMBOTIC VASCULAR EVENTS (MYOCARDIAL INFARCTION, ISCHEMIC STROKE, ACUTE LIMB ISCHEMIA, AND MAJOR AMPUTATION OF VASCULAR ETIOLOGY)

PATENT AND EXCLUSIVITY TERMS

ADB 179 of 191

PATENT USE

IN PATIENTS WITH PAD

- U-3207 REDUCTION OF RISK OF CARDIOVASCULAR DEATH, MYOCARDIAL INFARCTION, AND STROKE IN PATIENTS WITH CAD BY ADMINISTERING CLINICALLY PROVEN EFFECTIVE AMOUNTS THAT ARE 2.5 MG RIVAROXABAN TWICE DAILY AND 75-100 MG ASPIRIN DAILY
- U-3208 REDUCTION OF RISK OF MYOCARDIAL INFARCTION AND ISCHEMIC STROKE IN PATIENTS WITH PAD BY ADMINISTERING CLINICALLY PROVEN EFFECTIVE AMOUNTS THAT ARE 2.5 MG RIVAROXABAN TWICE DAILY AND 75-100 MG ASPIRIN DAILY
- U-3209 USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK MYOCARDIAL INFARCTION IN AN ADULT PATIENT HAVING ATRIAL FIBRILLATION OR ATRIAL FLUTTER AND ELEVATED TRIGLYCERIDE LEVELS
- U-3210 ONCE DAILY TREATMENT OF ANXIETY DISORDER IN ADULTS
- U-3211 TREATING DISTRIBUTIVE SHOCK WITH ANGIOTENSIN II
- U-3212 TREATING SEPTIC SHOCK WITH ANGIOTENSIN II
- U-3213 A METHOD OF TREATING A CANCER CHARACTERIZED BY AN IDH1 MUTATION WHEREIN THE CANCER IS PREVIOUSLY TREATED, LOCALLY ADVANCED OR METASTATIC CHOLANGIOCARCINOMA
- U-3214 A METHOD OF TREATING PREVIOUSLY TREATED, LOCALLY ADVANCED OR METASTATIC CHOLANGIOCARCINOMA CHARACTERIZED BY THE PRESENCE OF A MUTANT ALLELE OF IDH1 BY ADMINISTERING A ONCE DAILY 500 MG ORAL DOSE TO A SUBJECT THAT HAS NOT INGESTED A HIGH-FAT MEAL
- U-3215 A METHOD OF TREATING PREVIOUSLY TREATED, LOCALLY ADVANCED OR METASTATIC CHOLANGIOCARCINOMA CHARACTERIZED BY AN IDH1 MUTATION
- U-3216 A METHOD FOR TREATING A BCRABL POSITIVE LEUKEMIA IN A SUBJECT THAT IS RESISTANT TO IMATINIB COMPRISING ADMINISTERING TO THE SUBJECT A THERAPEUTICALLY EFFECTIVE AMOUNT OF BOSUTINIB, WHEREIN THE SUBJECT HAS A MUTATION IN THE BCRABL PROTEIN AT 949T>C
- U-3217 A METHOD FOR TREATING A BCRABL POSITIVE LEUKEMIA IN A SUBJECT THAT IS RESISTANT TO IMATINIB COMPRISING ADMINISTERING TO THE SUBJECT A THERAPEUTICALLY EFFECTIVE AMOUNT OF BOSUTINIB, WHEREIN THE SUBJECT HAS A MUTATION IN THE BCRABL PROTEIN AT F317L
- U-3218 NASAL ADMINISTRATION OF DIHYDROERGOTAMINE MESYLATE BY METERED SPRAY FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA
- U-3219 TREATMENT OF GASTROINTESTINAL STROMAL TUMOR
- U-3220 TREATMENT OF PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC) WITH EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 20 EXON INSERTION MUTATIONS WHOSE DISEASE HAS PROGRESSED ON OR AFTER PLATINUM-BASED CHEMOTHERAPY
- U-3221 USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF A CARDIOVASCULAR EVENT IN A PATIENT WITH PRIOR PERCUTANEOUS CORONARY INTERVENTION
- U-3222 TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) BY ORALLY ADMINISTERING VENETOCLAX WITH AZACITIDINE OR DECITABINE OR LOW-DOSE CYTARABINE IN ADULTS 75 YEARS OR OLDER OR HAVING CERTAIN COMORBIDITIES ACCORDING TO A DOSE RAMP-UP INCLUDING A 100 MG PER DAY DOSE
- U-3223 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL) BY ORALLY ADMINISTERING VENETOCLAX TO AN ADULT ACCORDING TO A DOSE RAMP-UP INCLUDING A 100 MG PER DAY DOSE
- U-3224 A METHOD OF TREATING HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA OR ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE BY DECREASING THE LEVEL OF LDL-C USING A FIXED DOSE COMBINATION OF 180 MG BEMPEDOIC ACID AND 10 MG EZETIMIBE
- U-3225 TREATMENT OF DIFFERENTIATED THYROID CANCER THAT HAS PROGRESSED FOLLOWING PRIOR VEGFR-TARGETED THERAPY
- U-3226 FOR TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR TWO LINES OF SYSTEMIC THERAPY
- U-3227 FOR TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS (MF), INCLUDING PRIMARY MF, POST-POLYCYTHEMIA VERA MF AND POST-ESSENTIAL THROMBOCYTHEMIA MF
- U-3228 FOR TREATMENT OF POLYCYTHEMIA VERA (PV) IN PATIENTS WHO HAVE HAD AN INADEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA
- U-3229 FOR TOPICAL SHORT-TERM, NON-CONTINUOUS CHRONIC TREATMENT OF MILD TO MODERATE ATOPIC DERMATITIS IN NON-IMMUNOCOMPROMISED PATIENTS WHOSE DISEASE IS NOT ADEQUATELY CONTROLLED WITH TOPICAL PRESCRIPTION THERAPIES OR WHEN THOSE THERAPIES ARE NOT ADVISABLE

PATENT AND EXCLUSIVITY TERMS

ADB 180 of 191

PATENT USE

U-3230 FOR TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD)

U-3231 TREATMENT OF PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (PH+CML) BY ADMINISTERING NILOTINIB DISPERSED IN A FRUIT PREPARATION

U-3232 USE OF ORAL OCTREOTIDE FOR LONG-TERM MAINTENANCE TREATMENT IN ACROMEGALY PATIENTS WHILE AVOIDING CONCOMITANT ADMINISTRATION OF LEVONORGESTREL

U-3233 USE FOR THE TREATMENT OF SEIZURES ASSOCIATED WITH TUBEROUS SCLEROSIS COMPLEX IN PATIENTS TAKING EVEROLIMUS

U-3234 TREATMENT OF MACULAR EDEMA ASSOCIATED WITH UVEITIS

U-3235 USE FOR THE TREATMENT OF SEIZURES ASSOCIATED WITH DRAVET SYNDROME

U-3236 USE FOR THE TREATMENT OF SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME

U-3237 TREATMENT OF CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1, 2, 3, 4, 5, OR 6 IN ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER OR WEIGHING AT LEAST 45 KG

U-3238 TREATMENT OF CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1, 2, 3, 4, 5, OR 6 IN PEDIATRIC PATIENTS 3 TO LESS THAN 12 YEARS OF AGE OR WEIGHING LESS THAN 45 KG

U-3239 TREATMENT OF ADVANCED RENAL CELL CARCINOMA (RCC) IN PATIENTS WHO HAVE RECEIVED PRIOR ANTI-ANGIOGENIC THERAPY

U-3240 USE OF VASCEPA TO REDUCE TRIGLYCERIDE LEVELS IN AN ADULT PATIENT HAVING TRIGLYCERIDE LEVELS OF AT LEAST ABOUT 500 MG/DL, ON ANTICOAGULANT/ANTIPLATELET/THROMBOLYTIC THERAPY, AND HAVING ATRIAL FIBRILLATION AND/OR ATRIAL FLUTTER

U-3241 IN COMBINATION WITH ENDOCRINE THERAPY (TAMOXIFEN OR AN AROMATASE INHIBITOR) FOR THE ADJUVANT TREATMENT OF ADULT PATIENTS WITH HR-POSITIVE, HER2-NEGATIVE, NODE-POSITIVE, EARLY BREAST CANCER AT HIGH RISK OF RECURRENCE AND A KI-67 SCORE $\geq 20\%$

U-3242 IN COMBINATION WITH FULVESTRANT FOR THE TREATMENT OF ADULT PATIENTS WITH HR-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER WITH DISEASE PROGRESSION FOLLOWING ENDOCRINE THERAPY

U-3243 IN COMBINATION WITH AN AROMATASE INHIBITOR AS INITIAL ENDOCRINE-BASED THERAPY FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN, AND MEN WITH HR-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER

U-3244 A METHOD FOR TREATMENT OF PAIN IN ADULTS USING TRAMADOL HYDROCHLORIDE AND CELECOXIB

U-3245 MAINTENANCE MONOTHERAPY TREATMENT OF BIPOLAR I DISORDER

U-3246 FOR THE TREATMENT OF CHRONIC GRAFT VERSUS HOST DISEASE

U-3247 FOR THE TREATMENT OF CHRONIC GRAFT VERSUS HOLD DISEASE

U-3248 TREATING SECONDARY HYPERPARATHYROIDISM IN STAGE 3/4 CHRONIC KIDNEY DISEASE WITH SUSTAINED RELEASE 25-HYDROXYVITAMIN D TO REDUCE THE PATIENT'S SERUM PARATHYROID HORMONE LEVEL WHILE AVOIDING PTH OVERSUPPRESSION

U-3249 TREATMENT OF CORONAVIRUS DISEASE 2019 (COVID-19) IN NON-HOSPITALIZED ADULTS AND PEDIATRIC PATIENTS (AT LEAST 12 YEARS OF AGE AND 40 KG)

U-3250 METHOD OF TREATING PAIN, FOR EXAMPLE, TREATING POSTSURGICAL PAIN VIA INFILTRATION FOR LOCAL ANALGESIA OR VIA INTERSCALENE BRACHIAL PLEXUS NERVE BLOCK FOR REGIONAL ANALGESIA

U-3251 ADMINISTRATION OF FERROUS BISGLYCINATE TABLETS

U-3252 USE OF VUITY FOR THE TREATMENT OF PRESBYOPIA IN ADULTS

U-3253 TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE IN THE CFTR GENE AT LEAST ONE F508DEL MUTATION OR A MUTATION THAT IS RESPONSIVE BASED ON IN VITRO DATA WITH A COMPOSITION ACCORDING TO AT LEAST ONE OF CLAIMS 1-9 OF US11179367

U-3254 USE, IN COMBINATION WITH LOW-DOSE CYTARABINE, FOR THE TREATMENT OF NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) IN ADULT PATIENTS WHO ARE ≥ 75 YEARS OLD OR WHO HAVE COMORBIDITIES THAT PRECLUDE USE OF INTENSIVE INDUCTION CHEMOTHERAPY

U-3255 TREATMENT OF ADULTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS

U-3256 USE TO INCREASE LINEAR GROWTH IN PEDIATRIC PATIENTS WITH ACHONDROPLASIA WHO ARE 5 YEARS OF AGE AND OLDER WITH OPEN EPIPHYSES

U-3257 TREATMENT OF TRD IN CONJUNCTION WITH AN ORAL ANTIDEPRESSANT BY NASALLY

PATENT AND EXCLUSIVITY TERMS

ADB 181 of 191

PATENT USE

	ADMINISTERING 56MG OR 84MG OF ESKETAMINE IN A MAINTENANCE PHASE WEEKLY OR 1X EVERY TWO WEEKS TO ADULTS WHO HAVE BEEN ADMINISTERED ESKETAMINE IN A INDUCTION PHASE FOR ABOUT 4 WEEKS
U-3258	TREATMENT OF ADULT PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE OR METASTATIC MALIGNANT PERIVASCULAR EPITHELIOID CELL TUMOR (PECOMA) WITH A DOSE BETWEEN ABOUT 56 MG/M2 AND ABOUT 100 MG/M2 ADMINISTERED ON DAYS 1 AND 8 OF A 21-DAY CYCLE
U-3259	TREATMENT OF ADULT PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE OR METASTATIC MALIGNANT PERIVASCULAR EPITHELIOID CELL TUMOR (PECOMA)
U-3260	METHOD OF TREATING SPASTICITY
U-3261	FOR CLEANSING OF THE COLON AS A PREPARATION FOR COLONOSCOPY
U-3262	TREATING HYPOTENSION WITH ANGIOTENSIN II IN A PATIENT RECEIVING AN ANGIOTENSIN CONVERTING ENZYME INHIBITOR
U-3263	METHOD FOR TREATING SPASTICITY
U-3264	AS INITIAL ENDOCRINE-BASED THERAPY FOR THE TREATMENT OF ADULT PATIENTS WITH HORMONE RECEPTOR (HR)-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER
U-3265	IN COMBINATION WITH AN AROMATASE INHIBITOR AS INITIAL ENDOCRINE-BASED THERAPY FOR THE TREATMENT OF ADULT PATIENTS WITH HORMONE RECEPTOR (HR)-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER
U-3266	IN COMBINATION WITH FULVESTRANT AS INITIAL ENDOCRINE-BASED THERAPY OR FOLLOWING DISEASE PROGRESSION ON ENDOCRINE THERAPY IN POSTMENOPAUSAL WOMEN OR IN MEN, FOR THE TREATMENT OF HR-POSITIVE, HER2-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER
U-3267	USE OF LASTACFT TO TEMPORARY RELIEVE ITCHY EYES DUE TO POLLEN, RAGWEED, GRASS, ANIMAL HAIR AND DANDER
U-3268	TREATMENT OF MULTIPLE SCLEROSIS IN PEDIATRIC PATIENTS 10 YEARS OF AGE AND OLDER AND WEIGHING LESS THAN OR EQUAL TO 40 KG
U-3269	TREATMENT OF PRIMARY IMMUNOGLOBULIN A NEPHROPATHY (IGAN) IN ADULTS AT RISK OF RAPID DISEASE PROGRESSION
U-3270	TREATMENT OF BACTERIAL VAGINOSIS IN FEMALE PATIENTS 12 YEARS OF AGE AND OLDER
U-3271	TREATMENT OF BIPOLAR DEPRESSION
U-3272	AS AN ADJUNCT TO DIET AND MAXIMALLY TOLERATED STATIN THERAPY FOR THE TREATMENT OF ADULTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HEFH) OR CLINICAL ATHEROSCLEROTIC CARDIOVASCULAR DISEASE (ASCVD), BY INHIBITING EXPRESSION OF THE PCSK9 GENE
U-3273	AS AN ADJUNCT TO DIET AND MAXIMALLY TOLERATED STATIN THERAPY FOR THE TREATMENT OF ADULTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HEFH) OR CLINICAL ATHEROSCLEROTIC CARDIOVASCULAR DISEASE (ASCVD), BY INHIBITING EXPRESSION OF THE PCSK9 GEN
U-3274	TREATMENT OF BIPOLAR I DISORDER, BIPOLAR II DISORDER, OR BIPOLAR DEPRESSION
U-3275	TREATMENT OF ADULTS WITH ACTIVE PSORIATIC ARTHRITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS
U-3276	TREATMENT OF PATIENTS WITH PLAQUE PSORIASIS WHO ARE CANDIDATES FOR PHOTOTHERAPY OR SYSTEMIC THERAPY
U-3277	USE FOR THE TREATMENT OF SEIZURES ASSOCIATED WITH TUBEROUS SCLEROSIS COMPLEX
U-3278	A METHOD OF REDUCING POST-SURGICAL PAIN FOLLOWING OCULAR SURGERY
U-3279	A METHOD OF TREATING POSTOPERATIVE INFLAMMATION FOLLOWING OCULAR SURGERY
U-3280	METHOD OF TREATING ACNE VULGARIS WITH TOPICALLY APPLIED CORTEXOLONE 17ALPHA-PROPIONATE
U-3281	TREATMENT OF SCHIZOPHRENIA IN ADULTS AND PEDIATRIC PATIENTS AGES 13 YEARS AND OLDER
U-3282	DURING LEVOKETOCONAZOLE DOSAGE TITRATION FOR THE TREATMENT OF CUSHING'S SYNDROME IN PATIENTS WHO CONCOMITANTLY USE METFORMIN, MONITORING GLYCEMIA, KIDNEY FUNCTION AND VITAMIN B-12 AND ADJUSTING DOSAGE OF METFORMIN AS NEEDED
U-3283	TREATMENT OF ENDOGENOUS HYPERCORTISOLEMIA IN PATIENTS WITH CUSHING'S SYNDROME FOR WHOM SURGERY IS NOT AN OPTION OR HAS NOT BEEN CURATIVE
U-3284	PROPHYLAXIS OF THROMBOEMBOLIC DISEASES IN PEDIATRIC PATIENTS AGED 2 YEARS AND

PATENT AND EXCLUSIVITY TERMS

ADB 182 of 191

PATENT USE

	OLDER WITH CONGENITAL HEART DISEASE WHO HAVE UNDERGONE THE FONTAN PROCEDURE AND A BODY WEIGHT OF ≥ 50 KG
U-3285	TREATMENT OF DVT AND/OR PE AND REDUCTION IN THE RISK OF RECURRENT DVT AND/OR PE IN PEDIATRIC PATIENTS (≥ 50 KG) ONCE DAILY WITH RAPID-RELEASE TABLET ADMINISTERED FOR AT LEAST 5 CONSECUTIVE DAYS AFTER AT LEAST 5 DAYS PARENTERAL ANTICOAGULANT TREATMENT
U-3286	TREATMENT OF VENOUS THROMBOEMBOLISM (VTE) AND THE REDUCTION IN THE RISK OF RECURRENT VTE IN PEDIATRIC PATIENTS FROM BIRTH TO LESS THAN 18 YEARS WITH A BODY WEIGHT OF 30 KG TO 49.9 KG AFTER AT LEAST 5 DAYS OF INITIAL PARENTERAL ANTICOAGULANT TREATMENT
U-3287	TREATMENT OF VENOUS THROMBOEMBOLISM (VTE) AND THE REDUCTION IN THE RISK OF RECURRENT VTE IN PEDIATRIC PATIENTS FROM BIRTH TO LESS THAN 18 YEARS WITH A BODY WEIGHT OF ≥ 50 KG AFTER AT LEAST 5 DAYS OF INITIAL PARENTERAL ANTICOAGULANT TREATMENT
U-3288	PROPHYLAXIS OF PE, DVT AND/OR STROKE IN PEDIATRIC PATIENTS (≥ 50 KG) AGED 2 YEARS AND OLDER WITH CONGENITAL HEART DISEASE AFTER FONTAN PROCEDURE WITH ONCE DAILY, RAPID-RELEASE TABLET ADMINISTERED FOR AT LEAST 5 CONSECUTIVE DAYS
U-3289	TREATMENT OF DVT AND/OR PE AND REDUCTION IN RISK OF RECURRENT DVT AND/OR PE IN PEDIATRIC PATIENTS (30-49.9 KG) ONCE DAILY WITH RAPID-RELEASE TABLET ADMINISTERED FOR AT LEAST 5 CONSECUTIVE DAYS AFTER AT LEAST 5 DAYS PARENTERAL ANTICOAGULANT TREATMENT
U-3290	TREATMENT OF CHOLESTATIC PRURITUS IN PATIENTS WITH ALAGILLE SYNDROME (ALGS)
U-3291	CYTALUX IS AN OPTICAL IMAGING AGENT INDICATED IN ADULT PATIENTS WITH OVARIAN CANCER AS AN ADJUNCT FOR INTRAOPERATIVE IDENTIFICATION OF MALIGNANT LESIONS
U-3292	USE OF VASCEPA TO REDUCE TRIGLYCERIDE LEVELS IN AN ADULT PATIENT ON STATIN THERAPY AND HAVING ATRIAL FIBRILLATION OR ATRIAL FLUTTER AND TRIGLYCERIDE LEVELS OF ABOUT 500 MG/DL TO ABOUT 2,000 MG/DL
U-3293	METHOD OF TREATING BACTERIAL VAGINOSIS BY SINGLE DOSE ADMINISTRATION OF A CLINDAMYCIN PHARMACEUTICAL GEL FORMULATION
U-3294	METHOD OF TREATING A BACTERIAL INFECTION BY ADMINISTERING A RECONSTITUTED SOLID FORMULATION OF DAPTOMYCIN CONTAINING 31.0 TO 59.4% WT TOTAL MANNITOL AND SORBITOL
U-3295	METHOD OF DELIVERING A COMBINATION OF OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE TO A NASAL AIRWAY
U-3296	TREATMENT OF SEASONAL ALLERGIC RHINITIS BY NASALY ADMINISTERING A COMBINATION OF OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE TO A PEDIATRIC PATIENT
U-3297	TREATMENT OF SEASONAL ALLERGIC RHINITIS BY NASALY ADMINISTERING A COMBINATION OF OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE
U-3298	TREATMENT OF ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH REFRACTORY, MODERATE TO SEVERE ATOPIC DERMATITIS WHOSE DISEASE IS NOT ADEQUATELY CONTROLLED WITH OTHER SYSTEMIC DRUG PRODUCTS, OR WHEN USE OF THOSE THERAPIES ARE INADVISABLE
U-3299	TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN PEDIATRIC PATIENTS
U-3300	PROPHYLAXIS TO PREVENT ATTACKS OF HEREDITARY ANGIOEDEMA (HAE) IN ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER
U-3301	TREATMENT OF ADULT AND PEDIATRIC PATIENTS WITH HEPATIC VENO-OCCLUSIVE DISEASE (VOD), ALSO KNOWN AS SINUSOIDAL OBSTRUCTION SYNDROME (SOS), WITH RENAL OR PULMONARY DYSFUNCTION FOLLOWING HEMATOPOIETIC STEM-CELL TRANSPLANTATION (HSCT)
U-3302	TREATMENT OF TRICHOMONIASIS IN PATIENTS 12 YEARS OF AGE AND OLDER
U-3303	TOPICAL LESION-DIRECTED AND FIELD-DIRECTED TREATMENT OF ACTINIC KERATOSIS OF THE FACE AND SCALP WITH PHOTODYNAMIC THERAPY BY POSITIONING AN ILLUMINATION DEVICE IN AN APPROPRIATE DISTANCE AND ILLUMINATING THE TREATMENT AREA WITH NARROWBAND RED LIGHT
U-3304	METHOD OF TREATING PARKINSON'S DISEASE BY ORALLY ADMINISTERING SEGMENTS OF A FUNCTIONALLY MULTISCORED, BILAYERED TABLET HAVING CARBIDOPA-25 MG/LEVODOPA-100 MG, EACH SEGMENT HAVING CARBIDOPA-6.25 MG/LEVODOPA-25 MG
U-3305	METHOD OF TREATING PARKINSON'S DISEASE BY ORALLY ADMINISTERING A FUNCTIONALLY MULTISCORED, BILAYERED TABLET HAVING CARBIDOPA-25 MG/LEVODOPA-100 MG

PATENT AND EXCLUSIVITY TERMS

ADB 183 of 191

PATENT USE

U-3306	TREATMENT OF ADULT PATIENTS WITH KRAS G12C-MUTATED LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC), AS DETERMINED BY AN FDA-APPROVED TEST, WHO HAVE RECEIVED AT LEAST ONE PRIOR SYSTEMIC THERAPY
U-3307	TREATMENT OF HIV-1 INFECTION IN PEDIATRIC PATIENTS WEIGHING AT LEAST 35KG WITH NO PRIOR ANTIRETROVIRAL TREATMENT HISTORY OR TO REPLACE THE CURRENT ANTIRETROVIRAL REGIMEN IN THOSE WHO ARE VIROLOGICALLY SUPPRESSED
U-3308	FOR USE IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS TO TREAT HIV-1 INFECTION IN PEDIATRIC PATIENTS WEIGHING AT LEAST 35KG WITH NO PRIOR ANTIRETROVIRAL TREATMENT HISTORY OR TO REPLACE THE CURRENT ANTIRETROVIRAL REGIMEN IF VIROLOGICALLY SUPPRESSED
U-3309	NORLIQVA IS INDICATED FOR THE TREATMENT OF HYPERTENSION, TO LOWER BLOOD PRESSURE IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER
U-3310	NORLIQVA IS INDICATED FOR THE SYMPTOMATIC TREATMENT OF CHRONIC STABLE ANGINA
U-3311	NORLIQVA IS INDICATED FOR THE TREATMENT OF CONFIRMED OR SUSPECTED VASOSPASTIC ANGINA
U-3312	METHOD TO TREAT IDA IN ADULTS & PEDIATRIC PATIENTS 1 YR & OLDER WITH INTOLERANCE OR UNSATISFACTORY RESPONSE TO ORAL IRON & WEIGHING AT LEAST 40 KG BY INTRAVENOUSLY ADMINISTERING FERRIC CARBOXYMALTOSE TO PROVIDE AT LEAST ABOUT 0.6 G OF ELEMENTAL IRON
U-3313	METHOD OF TREATING IDA IN ADULT PATIENTS WITH NON-DIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE & WEIGHING AT LEAST 40 KG BY INTRAVENOUSLY ADMINISTERING FERRIC CARBOXYMALTOSE TO PROVIDE AT LEAST ABOUT 0.6 GRAMS OF ELEMENTAL IRON
U-3314	METHOD OF TREATING IDA IN ADULTS & PEDIATRIC PATIENTS 1 YR & OLDER HAVING INTOLERANCE OR UNSATISFACTORY RESPONSE TO ORAL IRON ASSOCIATED WITH HEAVY UTERINE BLEEDING OR GASTROINTESTINAL DISORDER BY INTRAVENOUSLY ADMINISTERING FERRIC CARBOXYMALTOSE
U-3315	METHOD TO TREAT IDA IN ADULTS & PEDIATRIC PATIENTS 1 YR & OLDER WITH INTOLERANCE OR UNSATISFACTORY RESPONSE TO ORAL IRON & WEIGHING AT LEAST 40 KG BY ADMINISTERING IV AT LEAST ABOUT 0.6 G OF IRON AS FERRIC CARBOXYMALTOSE IN ABOUT 15 MIN OR LESS
U-3316	METHOD OF TREATING IDA IN ADULT PATIENTS WITH NON-DIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE & WEIGHING AT LEAST 40 KG BY INTRAVENOUSLY ADMINISTERING AT LEAST ABOUT 0.6 GRAMS OF IRON AS FERRIC CARBOXYMALTOSE IN ABOUT 15 MINUTES OR LESS
U-3317	POSITRON EMISSION TOMOGRAPHY (PET) OF PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) POSITIVE LESIONS IN MEN WITH PROSTATE CANCER
U-3318	MANAGEMENT OF MODERATE-TO-SEVERE PAIN BY INJECTION
U-3319	METHOD OF USING A PYRUVATE KINASE ACTIVATOR FOR THE TREATMENT OF HEMOLYTIC ANEMIA IN ADULTS WITH PYRUVATE KINASE (PK) DEFICIENCY
U-3320	METHOD FOR INCREASING THE LIFETIME OF RED BLOOD CELLS (RBCS) FOR THE TREATMENT OF HEMOLYTIC ANEMIA IN ADULTS WITH PYRUVATE KINASE (PK) DEFICIENCY
U-3321	METHOD OF USING A PYRUVATE KINASE ACTIVATOR FOR THE TREATMENT OF HEMOLYTIC ANEMIA IN ADULTS WITH PYRUVATE KINASE (PK) DEFICIENCY BY ADMINISTERING A DAILY DOSE OF 10MG TO 100MG
U-3322	USE FOR DETECTING NEUTRALIZING ANTIBODIES
U-3323	METHOD OF REDUCING ADVERSE EFFECTS IN PATIENTS WHO ARE CONCOMITANTLY ADMINISTERED A SALT OF GAMMA-HYDROXYBUTYRATE AND DIVALPROEX SODIUM
U-3324	METHOD OF TREATING PATIENTS WITH A SALT OF GAMMA-HYDROXYBUTYRATE WHEN DIVALPROEX SODIUM IS CONCOMITANTLY ADMINISTERED
U-3325	METHOD FOR REDUCING THE RISK OF CARDIOVASCULAR DEATH AND HOSPITALIZATION FOR HEART FAILURE IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND HEART FAILURE BY ONCE DAILY ADMINISTRATION OF EMPAGLIFLOZIN
U-3326	A METHOD OF TREATING ANKYLOSING SPONDYLITIS BY ADMINISTERING THE FORMULATION OF TOFACITINIB OF CLAIMS 1, 8, 15-20, 27-31, 34-43, 45, 47, 49, 50, 54, 59, 63, 68-71, 73, 77, 82-84, AND 87-98
U-3327	A METHOD OF TREATING PSORIATIC ARTHRITIS BY ADMINISTERING THE FORMULATION OF TOFACITINIB OF CLAIMS 1, 8, 15-20, 27-31, 34-44, 46, 48, 50, 53, 59, 62, 68-71, 73, 76, 82-84, AND 87-98
U-3328	A METHOD OF TREATING RHEUMATOID ARTHRITIS BY ADMINISTERING THE FORMULATION OF TOFACITINIB OF CLAIMS 1, 2, 8, 9, 15-21, 27-31, 34-43, 50, 51, 59, 60, 68-71, 73, 74, 82-84 AND 87-98

PATENT AND EXCLUSIVITY TERMS

ADB 184 of 191

PATENT USE

U-3329	A METHOD OF TREATING ULCERATIVE COLITIS, BY ADMINISTERING THE FORMULATION OF TOFACITINIB OF CLAIMS 1, 3, 8, 10, 15-20, 22, 27-31, 34-43, 50, 52, 59, 61, 68-71, 73, 75, 82-84 AND 87-98
U-3330	TREATMENT OF GASTROINTESTINAL STROMAL TUMORS IN PATIENTS SUFFERING FROM PALMER-PLANTER ERYTHRODYSESTHESIA SYNDROME
U-3331	TREATMENT OF MYELOFIBROSIS WITH PACRITINIB
U-3332	USE OF PACRITINIB FOR INHIBITING JANUS ASSOCIATED KINASE 2 (JAK2)
U-3333	ADJUVANT TREATMENT OF PATIENTS WITH GBRCA-MUTATED HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE HIGH RISK EARLY BREAST CANCER WHO HAVE BEEN TREATED WITH NEOADJUVANT OR ADJUVANT CHEMOTHERAPY
U-3334	A METHOD OF TRANSDERMAL DELIVERY OF DONEPEZIL FOR TREATING MILD, MODERATE AND SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE
U-3335	TREATMENT OF HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA (HABP)
U-3336	TREATMENT OF VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA (VABP)
U-3337	ADMINISTERING DAILY A UNIT DOSAGE OF AN IRREVERSIBLE EGFR INHIBITOR COVALENTLY BINDING AS CLAIMED FOR 1ST LINE TREATMENT OF GEFITINIB OF ERLOTINIB RESISTANT METASTATIC NSCLC WITH EGFR EXON 19 DELETION OR EXON 21 L858R SUBSTITUTION
U-3338	ADMINISTERING DAILY A UNIT DOSAGE OF AN IRREVERSIBLE EGFR INHIBITOR COVALENTLY BINDING AS CLAIMED FOR 1ST LINE TREATMENT OF GEFITINIB OR ERLOTINIB RESISTANT METASTATIC NSCLC WITH EGFR EXON 19 DELETION OR EXON 21 L858R SUBSTITUTION WITH T790M MUTATION
U-3339	TREATMENT OF CF IN A PATIENT AGE 4 MONTHS TO <6 YEARS WHO HAS ONE MUTATION IN THE CFTR GENE THAT IS RESPONSIVE TO IVACAFTOR BASED ON CLINICAL AND/OR IN VITRO ASSAY DATA USING THE COMPOSITION RECITED IN CLAIM 1 OF US 11147770
U-3340	A METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER BY ADMINISTERING A TRANSDERMAL COMPOSITION CONTAINING AMPHETAMINE
U-3341	TREATMENT OF ADULTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS
U-3342	TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME BY AVOIDING THE ADMINISTRATION OF TASIMELTEON WITH BETA-ADRENERGIC RECEPTOR ANTAGONISTS
U-3343	TREATMENT OF NON-24-HOUR SLEEP-WAKE DISORDER BY AVOIDING THE ADMINISTRATION OF TASIMELTEON WITH BETA-ADRENERGIC RECEPTOR ANTAGONISTS
U-3344	A METHOD OF TREATING ADULTS WITH MULTIPLE MYELOMA USING DEXAMETHASONE IN COMBINATION WITH AN ANTI-MYELOMA PRODUCT
U-3345	FOR TREATMENT OF ADULT PATIENTS WITH PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA)-POSITIVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) WHO HAVE BEEN TREATED WITH ANDROGEN RECEPTOR (AR) PATHWAY INHIBITION AND TAXANE-BASED CHEMOTHERAPY
U-3346	METHOD OF PROVIDING LOCAL OR REGIONAL ANALGESIA VIA INFILTRATION FOR LOCAL ANALGESIA OR VIA INTERSCALENE BRACHIAL PLEXUS NERVE BLOCK OR FEMORAL NERVE BLOCK FOR REGIONAL ANALGESIA
U-3347	USE IN COMBINATION WITH CANNABIDIOL FOR THE TREATMENT OF SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME
U-3348	TREATMENT OF HIV-1 INFECTION IN ADULTS AND ADOLESCENTS 12 YEARS OF AGE AND OLDER AND WEIGHING AT LEAST 35 KG
U-3349	REINITIATION OF SCHIZOPHRENIA TREATMENT WHEREIN MORE THAN 6 MONTHS 3 WEEKS BUT LESS THAN 8 MONTHS HAVE ELAPSED SINCE THE LAST DOSE
U-3350	ACUTE TREATMENT OF AGITATION ASSOCIATED WITH SCHIZOPHRENIA OR BIPOLAR I OR II DISORDER BY SUBLINGUAL ADMINISTRATION
U-3351	METHOD OF TREATING IRON DEFICIENCY ANEMIA IN ADULT PATIENTS WITH NON-DIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE BY INTRAVENOUSLY ADMINISTERING FERRIC CARBOXYMALTOSE
U-3352	METHOD TO TREAT IRON DEFICIENCY ANEMIA IN ADULTS & PEDIATRIC PATIENTS 1 YEAR AND OLDER WITH INTOLERANCE OR UNSATISFACTORY RESPONSE TO ORAL IRON BY INTRAVENOUSLY ADMINISTERING FERRIC CARBOXYMALTOSE
U-3353	TREATMENT IN COMBINATION WITH CABOTEGRAVIR OF HIV-1 INFECTION IN ADULTS AND ADOLESCENTS 12 AND OLDER TO REPLACE CURRENT REGIMEN IN THOSE WHO ARE VIROLOGICALLY SUPPRESSED ON A STABLE ANTIRETROVIRAL REGIMEN WITH NO HISTORY OF TREATMENT FAILURE

PATENT AND EXCLUSIVITY TERMS

ADB 185 of 191

PATENT USE

U-3354	TREATMENT OF ADULT PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) BY ADMINISTRATION OF PEGCETACOPLAN SO AS TO REDUCE THE SENSITIVITY OF CELLS TO COMPLEMENT-DEPENDENT DAMAGE
U-3355	AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
U-3356	TOPICAL TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA IN ADULTS 18 YEARS OF AGE AND OLDER
U-3357	TOPICAL TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA IN ADULTS 65 YEARS OF AGE AND OLDER
U-3358	USE OF VASCEPA TO REDUCE THE INCIDENCE OF MI IN AN ADULT PATIENT ON STATIN THERAPY AND WITH ELEVATED TRIGLYCERIDE LEVELS (>150 MG/DL), WHEREIN THE PATIENT EXPERIENCES ATRIAL FIBRILLATION AND/OR FLUTTER INSTEAD OF AN INCIDENCE OF MI
U-3359	TREATMENT OF SCHIZOPHRENIA BY ADMINISTERING A DOSE UP TO TWO WEEKS BEFORE OR THREE WEEKS AFTER THE SCHEDULED SIX-MONTH DOSE
U-3360	COMPLICATED INTRA-ABDOMINAL INFECTIONS (CIAI), USED IN COMBINATION WITH METRONIDAZOLE, IN ADULT AND PEDIATRIC PATIENTS (BIRTH TO LESS THAN 18 YEARS OF AGE)
U-3361	COMPLICATED URINARY TRACT INFECTIONS (CUTI), INCLUDING PYELONEPHRITIS, IN ADULT AND PEDIATRIC PATIENTS (BIRTH TO LESS THAN 18 YEARS OLD)
U-3362	TREATMENT OF BIPOLAR DEPRESSION MEDIATED BY THE 5-HT _{2A} RECEPTOR, SEROTONIN TRANSPORTER, AND/OR DOPAMINE D ₁ /D ₂ SIGNALING PATHWAYS
U-3363	TREATMENT OF SCHIZOPHRENIA MEDIATED BY THE 5-HT _{2A} RECEPTOR, SEROTONIN TRANSPORTER, AND/OR DOPAMINE D ₁ /D ₂ SIGNALING PATHWAYS
U-3364	TREATMENT OF BIPOLAR DISORDER I, BIPOLAR DISORDER II, OR BIPOLAR DEPRESSION
U-3365	THE PRODUCT COMPOSITION (NATROBA) IS FOR THE TOPICAL TREATMENT OF HUMAN SCABIES MITE INFESTATIONS BY MELTING AND DELIVERING THE ACTIVE INGREDIENT, SPINOSAD, TO THE STRATUM CORNEUM WHERE SCABIES MITES LIVE AND BREED
U-3366	VIVJOA IS INDICATED TO REDUCE THE INCIDENCE OF RECURRENT VULVOVAGINAL CANDIDIASIS (RVVC) IN FEMALES WITH A HISTORY OF RVVC WHO ARE NOT OF REPRODUCTIVE POTENTIAL
U-3367	TREATMENT OF CORONAVIRUS DISEASE 2019 (COVID-19) IN ADULTS AND PEDIATRIC PATIENTS (AT LEAST 28 DAYS OF AGE AND 3 KG) REQUIRING HOSPITALIZATION
U-3368	TREATMENT OF CORONAVIRUS DISEASE 2019 (COVID-19) IN NON-HOSPITALIZED ADULTS AND PEDIATRIC PATIENTS (AT LEAST 28 DAYS OF AGE AND 3 KG)
U-3369	TREATMENT OF ADULTS AND PEDIATRIC PATIENTS 12 AND OLDER WITH SCLERODERMATOUS FORM OF CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF AT LEAST TWO PRIOR LINES OF SYSTEMIC THERAPY
U-3370	A METHOD FOR THE TREATMENT OF ADULT PATIENTS WITH STABLE WILSON'S DISEASE WHO ARE DE-COPPERED AND TOLERANT TO PENICILLAMINE
U-3371	TREATMENT OF ADULTS WITH ACTIVE ANKYLOSING SPONDYLITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS
U-3372	TREATMENT OF CORONAVIRUS DISEASE 2019 (COVID-19) IN HOSPITALIZED ADULTS REQUIRING SUPPLEMENTAL OXYGEN, NON-INVASIVE OR INVASIVE MECHANICAL VENTILATION, OR EXTRACORPOREAL MEMBRANE OXYGENATION (ECMO)
U-3373	TREATMENT OF ADULTS WITH SYMPTOMATIC NEW YORK HEART ASSOCIATION (NYHA) CLASS II-III OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (HCM) TO IMPROVE FUNCTIONAL CAPACITY AND SYMPTOMS
U-3374	TREATMENT OF SEIZURES ASSOCIATED WITH CYCLIN-DEPENDENT KINASE-LIKE 5 (CDKL5) DEFICIENCY DISORDER (CDD) IN PATIENTS 2 YEARS OF AGE AND OLDER
U-3375	USE FOR THE TREATMENT OF ABSENCE SEIZURES IN PATIENTS WITH DRAVET SYNDROME
U-3376	USE FOR THE TREATMENT OF ABSENCE SEIZURES IN PATIENTS WITH LENNOX-GASTAUT SYNDROME
U-3377	TPOXX IS INDICATED FOR THE TREATMENT OF HUMAN SMALLPOX DISEASE IN ADULTS AND PEDIATRIC PATIENTS WEIGHING AT LEAST 3 KG
U-3378	MOUNJARO IS INDICATED AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
U-3379	A METHOD FOR ADMINISTERING A THERAPEUTIC DOSE OF EPINEPHRINE
U-3380	METHOD OF TREATING PAIN, FOR EXAMPLE, VIA INFILTRATION FOR LOCAL ANALGESIA OR

PATENT AND EXCLUSIVITY TERMS

ADB 186 of 191

PATENT USE

	VIA INTERSCALENE BRACHIAL PLEXUS NERVE BLOCK FOR REGIONAL ANALGESIA
U-3381	TREATMENT OF GASTROINTESTINAL STROMAL TUMORS IN PATIENTS SUFFERING FROM HYPERTENSION
U-3383	TREATING NEWLY DIAGNOSED AML CHARACTERIZED BY THE PRESENCE OF A MUTANT ALLELE OF IDH1 BY ADMINISTERING A ONCE DAILY 500 MG ORAL DOSE OF IVOSIDENIB TO A SUBJECT THAT HAS NOT INGESTED A HIGH-FAT MEAL, IN COMBINATION WITH AZACITIDINE
U-3384	A METHOD FOR TREATING AML BY ADMINISTERING A PHARMACEUTICAL COMPOSITION COMPRISING IVOSIDENIB WHEREIN THE AML IS NEWLY DIAGNOSED AND CHARACTERIZED BY A MUTANT IDH1 AND THE COMPOSITION IS ADMINISTERED IN COMBINATION WITH AZACITIDINE
U-3385	A METHOD FOR TREATING NEWLY DIAGNOSED AML WITH IVOSIDENIB AND AZACITIDINE WHEREIN THE AML HAS AN IDH1 MUTATION CAPABLE OF CONVERTING ALPHA-KETOGLUTARATE TO 2-HYDROXYGLUTARATE (2HG)
U-3386	A METHOD FOR TREATING A CANCER CHARACTERIZED BY AN IDH1 MUTATION WITH IVOSIDENIB IN COMBINATION WITH AZACITIDINE WHEREIN THE CANCER IS NEWLY DIAGNOSED AML
U-3387	A METHOD FOR TREATING NEWLY DIAGNOSED AML CHARACTERIZED BY THE PRESENCE OF A MUTANT ALLELE OF IDH1 SELECTED FROM R132H, R132C, R132L, R132V, R132S AND R132GF BY ADMINISTERING IVOSIDENIB AND AZACITIDINE
U-3388	USE OF ELAGOLIX 200 MG BID FOR 6 MONTHS TO MANAGE MODERATE TO SEVERE PAIN ASSOCIATED WITH ENDOMETRIOSIS IN PREMENOPAUSAL WOMEN TO REDUCE DYSPMENORRHEA AND NON-MENSTRUAL PELVIC PAIN
U-3389	USE OF ELAGOLIX 200 MG BID FOR 6 MONTHS TO MANAGE MODERATE TO SEVERE PAIN ASSOCIATED WITH ENDOMETRIOSIS IN PREMENOPAUSAL WOMEN HAVING DYSpareunia ASSOCIATED WITH ENDOMETRIOSIS
U-3390	SODIUM THIOSULFATE INJECTION IS ADMINISTERED BY INTRAVENOUS INJECTION
U-3391	A METHOD OF TITRATING AN OPIOID TO MANAGE PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENTS ARE INADEQUATE
U-3392	A METHOD OF TITRATING AN OPIOID TO MANAGE NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
U-3393	METHOD OF TREATING ACUTE PAIN DUE TO MINOR STRAINS, SPRAINS, AND CONTUSIONS USING A DICLOFENAC PATCH CONTAINING HEPARIN FOR ONCE DAILY ADMINISTRATION WHERE HEPARIN IS NOT RELEASED
U-3394	SODIUM NITRITE INJECTION IS ADMINISTERED BY INTRAVENOUS INJECTION
U-3395	SODIUM NITRITE INJECTION IS INDICATED FOR SEQUENTIAL USE WITH SODIUM THIOSULFATE FOR THE TREATMENT OF ACUTE CYANIDE POISONING
U-3396	AMVUTTRA IS INDICATED FOR THE TREATMENT OF THE POLYNEUROPATHY OF HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS IN ADULTS
U-3397	TADLIQ IS INDICATED FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) (WHO GROUP 1) TO IMPROVE EXERCISE ABILITY
U-3398	FOR CHRONIC WEIGHT MANAGEMENT IN ADULTS WITH BMI ≥ 30 KG/M ² OR BMI ≥ 27 KG/M ² WITH A WEIGHT-RELATED COMORBIDITY, AND PATIENTS AGE 12-17 WITH BMI ≥ 25 KG/M ² IN THE 95TH PERCENTILE OR GREATER (STANDARDIZED FOR AGE AND SEX)
U-3399	FOR CHRONIC WEIGHT MANAGEMENT IN ADULTS WITH BMI ≥ 30 KG/M ² , AND PATIENTS AGE 12-17 WITH BMI ≥ 30 KG/M ² AND IN THE 95TH PERCENTILE OR GREATER (STANDARDIZED FOR AGE AND SEX), EACH HAVING A WEIGHT-RELATED COMORBIDITY
U-3400	FOR USE AFTER RADIOLABELING WITH GALLIUM-68, FOR POSITRON EMISSION TOMOGRAPHY OF PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA)-POSITIVE LESIONS IN MEN WITH PROSTATE CANCER
U-3401	CAROSPIR IS INDICATED AS AN ADD-ON THERAPY FOR THE TREATMENT OF HYPERTENSION, TO LOWER BLOOD PRESSURE IN ADULT PATIENTS WHO ARE NOT ADEQUATELY CONTROLLED ON OTHER AGENTS
U-3402	CAROSPIR IS INDICATED FOR THE MANAGEMENT OF EDEMA IN ADULT CIRRHOTIC PATIENTS WHEN EDEMA IS NOT RESPONSIVE TO FLUID AND SODIUM RESTRICTION
U-3403	METHOD OF REVERSING OR INHIBITING THE PROGRESS OF UNRESECTABLE, RECURRENT, OR REFRACTORY INFLAMMATORY MYOFIBROBLASTIC TUMOR (IMT) THAT IS ALK-POSITIVE IN ADULT AND PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER
U-3404	FOR THE TOPICAL TREATMENT OF NONSEGMENTAL VITILIGO IN ADULT AND PEDIATRIC

PATENT AND EXCLUSIVITY TERMS

ADB 187 of 191

PATENT USE

PATIENTS 12 YEARS OF AGE AND OLDER

- U-3405 TREATMENT OF HIV-1 INFECTION IN ADULTS AND ADOLESCENTS 12 YEARS OF AGE AND OLDER AND WEIGHING AT LEAST 35 KG BY MONTHLY ADMINISTRATION OF RILPIVIRINE SUSPENSION AS PART OF COMBINATION THERAPY
- U-3406 USE OF FENFLURAMINE AT REDUCED AMOUNTS WITH STIRIPENTOL FOR THE TREATMENT OF SEIZURES ASSOCIATED WITH DRAVET SYNDROME
- U-3407 USE OF FENFLURAMINE AT REDUCED AMOUNTS WITH STIRIPENTOL FOR THE TREATMENT OF SEIZURES ASSOCIATED WITH LENNOX GASTAUT SYNDROME
- U-3408 TOPICAL TREATMENT OF PLAQUE PSORIASIS, INCLUDING INTERTRIGINOUS AREAS, IN PATIENTS 12 YEARS OF AGE AND OLDER. (1)
- U-3409 TREATING ADULT PATIENTS WITH INTERMEDIATE-2 OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS, MONITORING THIAMINE LEVELS AND ADMINISTERING THIAMINE OR A THIAMINE EQUIVALENT
- U-3410 A METHOD OF INJECTING AN IMPLANT
- U-3411 TREATING NON-EARLY SPMS BY ADMINISTERING ORAL CLADRIBINE AT A FIXED DOSE PER PATIENT, PER BODY WEIGHT AND PER TREATMENT YEAR, WHICH FIXED DOSE IS 1.75 +/- 0.2 MG/KG, TO BE ADMINISTERED WITHIN MONTHS 1 AND 2 IN EACH OF 2 ADJACENT TREATMENT YEARS
- U-3412 TREATMENT OF ADULTS WITH RELAPSED, REFRACTORY OR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA INCLUDING A DOSE RAMP-UP AND IN COMBINATION WITH OBINUTUZUMAB IN MULTIPLE 28-DAY DOSING CYCLES FOLLOWED BY ADMINISTRATION IN ABSENCE OF OBINUTUZUMAB
- U-3413 INDICATED AS ADJUNCTIVE THERAPY FOR THE TREATMENT OF PARTIAL-ONSET SEIZURES, PRIMARY GENERALIZED TONIC-CLONIC SEIZURES, AND SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME IN PATIENTS 2 YEARS OF AGE AND OLDER
- U-3414 INDICATED AS INITIAL MONOTHERAPY FOR THE TREATMENT OF PARTIAL-ONSET OR PRIMARY GENERALIZED TONIC-CLONIC SEIZURES IN PATIENTS 2 YEARS OF AGE AND OLDER
- U-3415 INDICATED FOR THE PREVENTIVE TREATMENT OF MIGRAINE IN PATIENTS 12 YEARS AND OLDER
- U-3416 TREATMENT OF GASTROINTESTINAL STROMAL TUMORS IN PATIENTS BEING TREATED CONCURRENTLY WITH A CYP3A4 INHIBITOR
- U-3417 TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER FOOT AND ANKLE, SMALL-TO-MEDIUM OPEN ABDOMINAL, AND LOWER EXTREMITY TOTAL JOINT ARTHROPLASTY SURGICAL PROCEDURES VIA INSTILLATION
- U-3418 A METHOD OF LOADING MEDICATION INTO A SYRINGE AND DELIVERING THE MEDICATION TO A TREATMENT SITE
- U-3419 DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER
- U-3420 A METHOD OF TREATING TESTOSTERONE DEFICIENCY IN MEN
- U-3421 TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS (CUTI) INCLUDING PYELONEPHRITIS CAUSED BY THE FOLLOWING SUSCEPTIBLE MICROORGANISMS: ESCHERICHIA COLI, KLEBSIELLA PNEUMONIA, ENTEROBACTER CLOACAE SPECIES COMPLEX WITH MEROPENEM & VABORBACTAM AS SPECIFIED
- U-3422 TREATMENT OF PEDIATRIC PATIENTS AGE 1 YEAR AND OLDER WITH CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR MORE LINES OF SYSTEMIC THERAPY
- U-3423 METHOD OF TREATING GASTROINTESTINAL STROMAL TUMORS IN PATIENTS SUFFERING FROM GRADE 2 OR GRADE 3 MYALGIA WHILE BEING ADMINISTERED RIPRETINIB DAILY
- U-3424 TREATMENT OF CYSTIC FIBROSIS IN A PATIENT AGE 1-5 YEARS WHO IS HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE USING LUMACAFOR AND IVACAFOR
- U-3425 TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE IN THE CFTR GENE AT LEAST ONE F508DEL MUTATION OR A MUTATION THAT IS RESPONSIVE BASED ON IN VITRO DATA WITH A COMPOUND OF CLAIM 1 OR COMPOSITION OF CLAIM 29 OF US11426407
- U-3426 TREATMENT OF CYSTIC FIBROSIS IN A PATIENT AGE 1-5 YEARS WHO IS HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE USING THE DOSAGE UNIT COMPRISING LUMACAFOR AS RECITED IN CLAIM 1 OF US PATENT 8716338 AND IVACAFOR
- U-3427 TREATMENT OF CYSTIC FIBROSIS IN A PATIENT AGE 1-5 YEARS WHO IS HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE USING LUMACAFOR FORM I AND IVACAFOR
- U-3428 TREATMENT OF CYSTIC FIBROSIS IN A PATIENT AGE 1-5 YEARS WHO IS HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE USING THE DOSAGE UNIT COMPRISING

PATENT AND EXCLUSIVITY TERMS

ADB 188 of 191

PATENT USE

LUMACAFITOR AND IVACAFITOR AS RECITED IN CLAIM 1 OF US PATENT 9192606

- U-3429 TREATMENT OF CYSTIC FIBROSIS IN A PATIENT AGE 1-5 YEARS WHO IS HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE USING LUMACAFITOR AND A SOLID COMPOSITION COMPRISING AMORPHOUS AND LESS THAN ABOUT 30% CRYSTALLINE IVACAFITOR
- U-3430 TREATMENT OF CYSTIC FIBROSIS IN A PATIENT AGE 1-5 YEARS WHO IS HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE USING A PHARMACEUTICAL COMPOSITION ACCORDING TO CLAIM 2 OF U.S. PATENT NO. 10,597,384, FURTHER COMPRISING IVACAFITOR
- U-3431 TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS WHO AWAKEN AT LEAST 2 TIMES PER NIGHT TO VOID BY INDUCING AN ANTIDIURETIC EFFECT BY INTRANASALLY ADMINISTERING A PLUME OF DROPLETS COMPRISING A DOSE OF ABOUT 0.05-5 MCG DESMOPRESSIN
- U-3432 TREATMENT OF CATAPLEXY OR EXCESSIVE DAYTIME SLEEPINESS (EDS) IN PATIENTS 7 YEARS OF AGE AND OLDER WITH NARCOLEPSY WITH A MIXTURE OF SODIUM, POTASSIUM, MAGNESIUM, AND CALCIUM SALTS OF GHB ADMINISTERED BETWEEN 2 AND 4 HOURS AFTER EATING
- U-3433 INDICATED FOR THE TREATMENT OF SPASTICITY RESULTING FROM MULTIPLE SCLEROSIS
- U-3434 TREATMENT OF MODERATE-TO-SEVERE PLAQUE PSORIASIS IN ADULTS WHO ARE CANDIDATES FOR SYSTEMIC THERAPY OR PHOTOTHERAPY
- U-3435 METHOD OF TREATING IDA IN ADULT PATIENTS WITH NON-DIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE & WEIGHING AT LEAST 46.7 KG BY INTRAVENOUSLY ADMINISTERING FERRIC CARBOXYMALTOSE TO PROVIDE AT LEAST 0.7 G OF ELEMENTAL IRON IN 15 MINUTES
- U-3436 METHOD OF TREATING IDA IN ADULT PATIENTS WITH NON-DIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE & WEIGHING AT LEAST 46.7 KG BY INTRAVENOUSLY ADMINISTERING FERRIC CARBOXYMALTOSE TO PROVIDE AT LEAST 0.7 G OF ELEMENTAL IRON IN LESS THAN 15 MINUTES
- U-3437 METHOD TO TREAT IDA IN ADULTS & PEDIATRIC PATIENTS 1 YEAR & OLDER WITH INTOLERANCE OR UNSATISFACTORY RESPONSE TO ORAL IRON & HEAVY UTERINE BLEEDING OR GI DISORDER BY ADMINISTERING IV FERRIC CARBOXYMALTOSE TO GIVE AT LEAST 0.7 G OF IRON IN 15 MINUTES
- U-3438 METHOD TO TREAT IDA IN ADULTS & PEDIATRIC PATIENTS 1 YR & OLDER WITH INTOLERANCE OR UNSATISFACTORY RESPONSE TO ORAL IRON & WEIGHING AT LEAST 46.7 KG BY ADMINISTERING IV FERRIC CARBOXYMALTOSE TO PROVIDE AT LEAST 0.7 G OF ELEMENTAL IRON IN < 15 MINUTES
- U-3439 METHOD OF TREATING PAIN, FOR EXAMPLE, VIA INFILTRATION FOR LOCAL ANALGESIA OR VIA NERVE BLOCK, FOR EXAMPLE, NTERSCALENE BRACHIAL PLEXUS FOR REGIONAL ANALGESIA
- U-3440 A METHOD OF ADMINISTERING APREPITANT FOR PREVENTION OF POST-OPERATIVE NAUSEA AND VOMITING
- U-3441 A METHOD OF TREATING CYSTINURIA BY ORALLY ADMINISTERING TIOPRONIN WITH FOOD TO PREVENT CYSTINE STONE FORMATION IN ADULTS AND PEDIATRIC PATIENTS WITH SEVERE HOMOZYGOUS CYSTINURIA
- U-3443 A METHOD OF REDUCING OTOTOXICITY IN A HUMAN PEDIATRIC PATIENT ABOUT 5 YEARS OF AGE OR UNDER WITH LOCALIZED MEDULLOBLASTOMA COMPRISING ADMINISTERING SODIUM THIOSULFATE ABOUT SIX HOURS AFTER ADMINISTRATION OF CISPLATIN
- U-3444 TREATMENT OF DEPRESSIVE SYMPTOMS IN ADULTS WITH MDD WITH ACUTE SUICIDAL IDEATION OR BEHAVIOR BY NASALLY ADMINISTERING 56MG OR 84MG OF ESKETAMINE AS A PHARMACEUTICAL COMPOSITION TWICE PER WEEK IN CONJUNCTION WITH AN ORAL ANTIDEPRESSANT
- U-3445 TREATMENT OF TREATMENT-RESISTANT DEPRESSION IN ADULTS BY NASALLY ADMINISTERING 56MG OR 84MG OF ESKETAMINE TWICE PER WEEK AS A PHARMACEUTICAL COMPOSITION IN CONJUNCTION WITH AN ORAL ANTIDEPRESSANT
- U-3446 TREATMENT OF TREATMENT-RESISTANT DEPRESSION IN ADULTS BY NASALLY ADMINISTERING 56MG OR 84MG OF ESKETAMINE AS A PHARMACEUTICAL COMPOSITION IN CONJUNCTION WITH AN ORAL ANTIDEPRESSANT
- U-3447 A METHOD OF TREATING CORONARY ARTERY DISEASE
- U-3448 A METHOD OF TREATING HYPERTENSION
- U-3449 USE IN COMBINATION WITH LENALIDOMIDE PLUS DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED ONE TO THREE LINES OF THERAPY
- U-3450 TREATMENT OF ADULT PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH A REARRANGED DURING TRANSFECTION (RET) GENE FUSION, AS DETECTED BY AN FDA-APPROVED TEST

PATENT AND EXCLUSIVITY TERMS

ADB 189 of 191

PATENT USE

U-3451	TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC MEDULLARY THYROID CANCER (MTC) WITH A RET MUTATION, AS DETECTED BY AN FDA-APPROVED TEST, WHO REQUIRE SYSTEMIC THERAPY
U-3452	TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC THYROID CANCER WITH A RET GENE FUSION, AS DETECTED BY AN FDA-APPROVED TEST, WHO REQUIRE SYSTEMIC THERAPY AND WHO ARE RADIOACTIVE IODINE-REFRACTORY
U-3453	TREATMENT OF ADULT PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS WITH A RET GENE FUSION THAT HAVE PROGRESSED ON OR FOLLOWING PRIOR SYSTEMIC TREATMENT OR WHO HAVE NO SATISFACTORY ALTERNATIVE TREATMENT OPTIONS
U-3454	METHOD OF TREATING OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION IN PATIENTS
U-3455	TREATMENT OF OCULAR INFLAMMATION AND PAIN FOLLOWING OPHTHALMIC SURGERY
U-3456	METHOD OF TREATING INTRAHEPATIC CHOLANGIOCARCINOMA
U-3457	METHOD OF INDUCING OCULAR ANESTHESIA
U-3458	A METHOD OF TREATING SEIZURES
U-3459	TREATING SICKLE CELL DISEASE BY ADMINISTERING VOXELOTOR AND ANOTHER ACTIVE AGENT
U-3460	TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) IN ADULTS
U-3461	INDICATED TO RAISE BLOOD PRESSURE IN ADULT PATIENTS WITH SEVERE, ACUTE HYPOTENSION
U-3462	USE OF A LIQUID FORMULATION COMPRISING FUROSEMIDE TO TREAT CONGESTION DUE TO FLUID OVERLOAD (EDEMA) IN ADULTS WITH NYHA CLASS II/III CHRONIC HEART FAILURE
U-3463	USE OF TRINTELLIX FOR THE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD) IN ADULTS
U-3464	TREATMENT OF PREVIOUSLY TREATED, UNRESECTABLE LOCALLY ADVANCED OR METASTATIC CHOLANGIOCARCINOMA WITH A FGFR2 FUSION OR OTHER REARRANGEMENT BY ADMINISTERING ONCE DAILY A TABLET CONTAINING ABOUT 0.5 MG TO ABOUT 10 MG OF PEMIGATINIB
U-3465	TREATMENT OF PREVIOUSLY TREATED, UNRESECTABLE LOCALLY ADVANCED OR METASTATIC CHOLANGIOCARCINOMA WITH A FGFR2 FUSION OR OTHER REARRANGEMENT BY ADMINISTERING PEMIGATINIB QD FOR 14 DAYS THEN NOT ADMINISTERING PEMIGATINIB FOR 7 DAYS IN A 21-DAY CYCLE
U-3466	TREATMENT OF PREVIOUSLY TREATED, UNRESECTABLE LOCALLY ADVANCED OR METASTATIC CHOLANGIOCARCINOMA WITH A FGFR2 FUSION OR OTHER REARRANGEMENT BY ADMINISTERING PEMIGATINIB IN A DAILY DOSE OF ABOUT 5 MG TO ABOUT 20 MG
U-3467	PREVENTION AND TREATMENT OF POST-OPERATIVE NAUSEA AND VOMITING
U-3468	TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS
U-3469	AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
U-3470	METHOD OF TREATING COMPLICATED URINARY TRACT INFECTIONS (CUTI), INCLUDING PYELONEPHRITIS, COMPRISING ADMINISTERING CEFIDEROCOL SULFATE TOSYLATE
U-3471	METHOD OF TREATING HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA AND VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA (HABP/VABP) COMPRISING ADMINISTERING CEFIDEROCOL SULFATE TOSYLATE
U-3472	METHOD TO TREAT IDA IN ADULTS WITH INTOLERANCE OR UNSATISFACTORY RESPONSE TO ORAL IRON & HEAVY UTERINE BLEEDING OR GI DISORDER WEIGHING AT LEAST 40 KG BY ADMINISTERING IV FERRIC CARBOXYMALTOSE TO GIVE AT LEAST 0.6 G OF IRON IN 15 MINUTES OR LESS
U-3473	METHOD TO TREAT IRON DEFICIENCY ANEMIA IN ADULTS WITH INTOLERANCE OR UNSATISFACTORY RESPONSE TO ORAL IRON & WEIGHING AT LEAST 40 KG BY INTRAVENOUSLY ADMINISTERING FERRIC CARBOXYMALTOSE TO PROVIDE AT LEAST 0.6 G OF ELEMENTAL IRON IN 15 MINUTES OR LESS
U-3474	METHOD TO TREAT IRON DEFICIENCY ANEMIA IN ADULTS WITH NON-DIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE & WEIGHING AT LEAST 40 KG BY INTRAVENOUSLY ADMINISTERING FERRIC CARBOXYMALTOSE TO PROVIDE AT LEAST 0.6 G OF ELEMENTAL IRON IN 15 MINUTES OR LESS
U-3475	REDUCTION OF THE FREQUENCY OF ABDOMINAL PAIN AND DIARRHEA, IN AN INFLAMMATORY BOWEL DISEASE WITH DIARRHEA (IBS-D) PATIENT, WITH ELUXADOLINE TWICE DAILY WITH FOOD
U-3476	TREATMENT OF ADULTS WITH MODERATE HEPATIC IMPAIRMENT AND RELAPSED OR REFRACTORY ADVANCED RENAL CELL CARCINOMA FOLLOWING TWO OR MORE PRIOR SYSTEMIC ANTI-CANCER

PATENT AND EXCLUSIVITY TERMS

ADB 190 of 191

PATENT USE

	THERAPIES WITH 1MG TIVOZANIB HCL ORALLY FOR 21 DAYS FOLLOWED BY NO DRUG FOR 7 DAYS
U-3477	ACCELERATE THE TRANSIT OF A BARIUM MEAL THROUGH THE SMALL BOWEL, THEREBY DECREASING THE TIME AND EXTENT OF RADIATION ASSOCIATED WITH FLUOROSCOPY AND X-RAY EXAMINATION OF THE INTESTINAL TRACT
U-3478	STIMULATE GALLBLADDER CONTRACTION, AS MAY BE ASSESSED BY VARIOUS METHODS OF DIAGNOSTIC IMAGING, OR TO OBTAIN BY DUODENAL ASPIRATION A SAMPLE OF CONCENTRATED BILE FOR ANALYSIS
U-3479	STIMULATE PANCREATIC SECRETION IN COMBINATION WITH SECRETIN PRIOR TO OBTAINING A DUODENAL ASPIRATE FOR ANALYSIS
U-3480	STIMULATE GALLBLADDER CONTRACTION. AS MAY BE ASSESSED BY VARIOUS METHODS OF DIAGNOSTIC IMAGING, OR TO OBTAIN BY DUODENAL ASPIRATION A SAMPLE OF CONCENTRATED BILE FOR ANALYSIS
U-3481	DIAGNOSIS OF GALL BLADDER DISORDERS OR OTHER DIAGNOSTIC IMAGING BY STIMULATING GALLBLADDER CONTRACTION, AS MAY BE ASSESSED BY VARIOUS METHODS OF DIAGNOSTIC IMAGING, OR TO OBTAIN BY DUODENAL ASPIRATION A SAMPLE OF CONCENTRATED BILE FOR ANALYSIS
U-3482	DIAGNOSIS OF PANCREATIC DISORDERS BY STIMULATING PANCREATIC SECRETION IN COMBINATION WITH SECRETIN PRIOR TO OBTAINING A DUODENAL ASPIRATE FOR ANALYSIS
U-3483	DIAGNOSTIC IMAGING BY ACCELERATING THE TRANSIT OF A BARIUM MEAL THROUGH THE SMALL BOWEL, THEREBY DECREASING THE TIME AND EXTENT OF RADIATION ASSOCIATED WITH FLUOROSCOPY AND X-RAY EXAMINATION OF THE INTESTINAL TRACT
U-3484	TREATMENT OF CORONAVIRUS DISEASE 2019 (COVID-19) IN ADULTS AND PEDIATRIC PATIENTS (AT LEAST 28 DAYS OF AGE AND 3 KG) REQUIRING HOSPITALIZATION AND FOR WHOM CONCOMITANT USE OF CHLOROQUINE, OR AN ANALOG OR SALT THEREOF, IS NOT RECOMMENDED
U-3485	TREATMENT OF CORONAVIRUS DISEASE 2019 (COVID-19) IN NON-HOSPITALIZED ADULTS AND PEDIATRIC PATIENTS (AT LEAST 28 DAYS OF AGE AND 3 KG) AND FOR WHOM CONCOMITANT USE OF CHLOROQUINE, OR AN ANALOG OR SALT THEREOF, IS NOT RECOMMENDED
U-3487	TREATMENT OF ADULTS WITH ACTIVE NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS WITH OBJECTIVE SIGNS OF INFLAMMATION WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS
U-3488	TREATMENT OF SPASTICITY RESULTING FROM MULTIPLE SCLEROSIS, PARTICULARLY FOR THE RELIEF OF FLEXOR SPASMS AND CONCOMITANT PAIN, CLONUS, AND MUSCULAR RIGIDITY
U-3489	TREATMENT OF SPASTICITY RESULTING FROM SPINAL CORD INJURIES AND OTHER SPINAL CORD DISEASES
U-3490	TREATMENT OF ADULT PATIENTS WITH KRAS G12C-MUTATED LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC), AS DETERMINED BY AN FDA APPROVED TEST, WHO HAVE RECEIVED AT LEAST ONE PRIOR SYSTEMIC THERAPY
U-3491	METHOD OF TREATING LYMPHOMA
U-3492	METHOD OF TREATING SARCOMA
U-3493	THE TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS) IN PATIENTS 10 YEARS OF AGE AND OLDER
U-3494	ONCE DAILY TOPICAL TREATMENT OF PERSISTENT FACIAL ERYTHEMA ASSOCIATED WITH ROSACEA IN FEMALE ADULTS
U-3495	A METHOD OF TREATING ACUTE MYELOID LEUKEMIA (AML) IN PATIENTS WITH AN ISOCITRATE DEHYDROGENASE-1 (IDH1) MUTATION
U-3496	A METHOD OF TREATING A CANCER CHARACTERIZED BY AN IDH1 MUTATION WHERE THE CANCER IS ACUTE MYELOID LEUKEMIA (AML)
U-3497	A METHOD OF TREATING A CANCER WHERE THE CANCER IS ACUTE MYELOID LEUKEMIA (AML)
U-3498	TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE IN THE CFTR GENE AT LEAST ONE F508DEL MUTATION OR A MUTATION THAT IS RESPONSIVE BASED ON IN VITRO DATA BY ADMINISTERING DAILY ELX (200 MG OR 100 MG); TEZ; AND IVA
U-3500	TREATMENT OF ADULT PATIENTS WITH SEVERE ALOPECIA AREATA
U-3501	PALBOCICLIB FOR HR-POS. HER2-NEG. ADVANCED OR METASTATIC BREAST CANCER IN COMBO WITH AN AROMATASE INHIBITOR IN PTS AS INITIAL ENDOCRINE-BASED THERAPY OR WITH FULVESTRANT WITH DISEASE PROGRESSION AFTER ENDOCRINE THERAPY
U-3502	TREATMENT OF A UREA CYCLE DISORDER INVOLVING DEFICIENCIES OF CARBAMYLPHOSPHATE SYNTHETASE, ORNITHINE TRANS-CARBAMYLASE, OR ARGININOSUCCINIC ACID SYNTHETASE

PATENT AND EXCLUSIVITY TERMS

ADB 191 of 191

PATENT USE

U-3503	ADJUNCTIVE THERAPY TO ANTIDEPRESSANTS FOR THE TREATMENT OF MAJOR DEPRESSIVE DISORDER
U-3504	A METHOD TO DECREASE THE INCIDENCE OF CHEMOTHERAPY-INDUCED MYELOSUPPRESSION IN ADULT PATIENTS WHEN ADMINISTERED PRIOR TO A PLATINUM/ETOPOSIDE-CONTAINING REGIMEN THAT INCLUDES AN IMMUNE CHECKPOINT INHIBITOR FOR EXTENSIVE-STAGE SMALL CELL CANCER
U-3505	FOR TOPICAL TREATMENT OF MODERATE AD IN NON-IMMUNOCOMPROMISED PATIENTS, WITH BASELINE BSA OF 3-20% AND ITCH NRS SCORE OF ≥ 4 , WHOSE DISEASE IS NOT ADEQUATELY CONTROLLED WITH TOPICAL PRESCRIPTION THERAPIES OR WHEN THOSE THERAPIES ARE NOT ADVISABLE